<SEC-DOCUMENT>0000950123-13-005262.txt : 20130904
<SEC-HEADER>0000950123-13-005262.hdr.sgml : 20130904
<ACCEPTANCE-DATETIME>20130801213402
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-13-005262
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		59
FILED AS OF DATE:		20130802
<PUBLIC-REL-DATE>20130904
DATE AS OF CHANGE:		20130829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-00268
		FILM NUMBER:		131004491

	BUSINESS ADDRESS:	
		STREET 1:		1500 East Gude Drive
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		1500 EAST GUDE DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>As confidentially submitted to the Securities and Exchange Commission on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Statement
No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Washington, D.C. 20549
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM S-1 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>REGISTRATION STATEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B><I>UNDER </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B><I>THE SECURITIES ACT OF 1933 </I></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact Name of Registrant as Specified in Its Charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Delaware<BR></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2834</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>06-1591613</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>incorporation or organization)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Primary Standard Industrial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Classification Code Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9640 Medical Center Drive </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Rockville, MD 20850 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(301) 251-5172 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address, including zip code and telephone number, including area code, of registrant&#146;s principal executive offices)
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Scott Koenig, M.D., Ph.D. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>President and Chief Executive Officer </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9640 Medical Center Drive
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Rockville, MD 20850 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(301) 251-5172 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Name, address, including zip code, and telephone number,
including area code, of agent for service) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Copies to:
</I></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Richard E. Baltz</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Arnold &amp; Porter LLP</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>555 12<FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Street NW</FONT></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Washington, DC 20004-1206</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(202) 942-5000</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Steven D. Singer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Lisa Firenze</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7 World Trade Center<BR>New York, NY 10007</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(212) 230-8000</B></FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Approximate date of commencement of proposed sale to the public: </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">As soon as practicable after this Registration Statement becomes effective. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px;page-break-before:always"></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check
the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Check one): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Large&nbsp;accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accelerated filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Smaller&nbsp;reporting&nbsp;company</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CALCULATION OF REGISTRATION FEE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD></TR>


<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title of each class of</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>securities to be registered</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Proposed&nbsp;maximum&nbsp;&nbsp;&nbsp;&nbsp;<BR>aggregate
offering&nbsp;&nbsp;&nbsp;&nbsp;<BR>price(1)&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount of&nbsp;&nbsp;&nbsp;&nbsp;<BR>Registration&nbsp;Fee(2)&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common Stock, $0.01 par value per share</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated solely for the purpose of computing the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Calculated pursuant to Rule 457(o) based on an estimate of the proposed maximum aggregate offering price. </FONT></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically
states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant
to said Section&nbsp;8(a), may determine. </B></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Arial Narrow" SIZE="2" COLOR="#de1a1e"><B>The information in this prospectus is not complete and may be changed. We cannot sell these
securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the
offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>Subject to completion </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>Preliminary Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>P R O S P E C T U S</U> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754311new.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This is MacroGenics, Inc.&#146;s initial public offering. We are selling &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect the public offering price to be between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. Currently, no public market exists for the shares. After pricing of the offering, we expect that the shares will trade on the NASDAQ Global Market under the symbol &#147;MGNX&#148;.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our common stock involves risks that are described in the &#147;<A HREF="#cov575431_1">Risk Factors</A>&#148; section
beginning on page 9 of this prospectus. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds before expenses, to us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters may also exercise their option to purchase up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us, at the public offering price, less the underwriting discount, for 30 days after the date of this prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares
will be ready for delivery on or about &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>BofA Merrill Lynch</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Leerink Swann</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Stifel</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Lazard Capital Markets</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Wedbush PacGrow Life Sciences</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of this prospectus is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2013. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_2">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_3">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_4">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_5">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_6">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_7">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_8">Selected Consolidated Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of
Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_10">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_11">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_12">Certain Relationships and Related Party Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_13">Principal Stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_14">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_15">Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">122</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_16">Material U.S. Federal Tax Consequences for Non-U.S. Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_17">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">128</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_18">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_19">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_20">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#rom575431_21">Index to Consolidated Financial Statements </A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have not authorized anyone to provide you with information other than that contained in this
prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give to you. We
are offering to sell shares of our common stock, and seeking offers to buy shares of our common stock, only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or any sale of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither we nor any of the
underwriters have taken any action to permit a public offering of the shares of our common stock or the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. You
are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed
information and consolidated financial statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you. You should read and carefully consider the following summary together with
the entire prospectus, including our consolidated financial statements and the notes thereto appearing elsewhere in this prospectus and the matters discussed in the sections in this prospectus entitled &#147;Risk Factors,&#148; &#147;Selected
Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; before deciding to invest in our common stock. Some of the statements in this prospectus constitute
forward-looking statements that involve risks and uncertainties. See &#147;Special Note Regarding Forward-Looking Statements.&#148; Our actual results could differ materially from those anticipated in such forward-looking statements as a result of
certain factors, including those discussed in the &#147;Risk Factors&#148; and other sections of this prospectus. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus to &#147;MacroGenics&#148;
&#147;the company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to MacroGenics, Inc. and its consolidated subsidiaries. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. We create both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148;
which are drugs designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with
global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance the development of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have three versatile, proprietary technology platforms that can be applied in combination with one another to custom design an
antibody or antibody-derived molecule that is optimized to treat a specific disease. These technologies are described below. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our <I>Dual Affinity Re-Targeting, or DART, platform</I> enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure,
and also includes the ability to recruit any T cell in a patient&#146;s body to destroy targeted cancer cells. We have created over 100 DART-based molecules, or DARTs, which we believe improve upon the human immune system and have more potent immune
properties than the parent antibody molecules from which they are derived. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our<I> Fc Optimization platform</I> enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular
cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells. To date, we have successfully incorporated our Fc Optimization technology into our two lead oncology product candidates and have
pre-clinical data demonstrating that these antibodies have substantially greater ability to kill cancer cells than similar antibodies that have not been Fc-optimized. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our<I> Cancer Stem-like Cell, or CSLC, platform</I> provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the
differentiated cancer cells derived from them. Using this platform, we can create antibodies or antibody-derived molecules that specifically target and destroy CSLCs, potentially enabling us to address the large, unmet medical needs of many cancers
that are difficult to treat. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We utilize one or more of our technology platforms for engineering and optimizing
our antibody and antibody-derived product candidates. Many of our cancer product candidates are derived from our library of over 1,900 purified antibodies. We believe our approach allows us to take advantage of the enhanced properties of an
engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune disorders </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
more effectively than a wild type, or non-engineered, monoclonal antibody. Our methods for improving the effectiveness of antibodies include the following: enhancing the body&#146;s immune
system; targeting multiple antigens on the surface of the same target cell; increasing the strength of the binding of an antibody to its antigen targets; and reducing the likelihood of an unwanted immune response to the antibody or antibody-derived
molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases and to improve clinical outcomes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into strategic collaborations with Les Laboratoires Servier and Institut de Recherches Servier, or collectively, Servier,
Gilead Sciences, Inc., or Gilead, Boehringer Ingelheim International GmbH, or Boehringer, and Pfizer, Inc., or Pfizer, among others. Under our current strategic collaborations, we have received approximately $101 million in non-equity funding during
the three year period ended March&nbsp;31, 2013. Under these agreements we are entitled to receive substantial milestone and other payments, including over $100 million of potential payments that we believe are likely to be received by the end of
2015, assuming all of our collaboration programs advance as currently contemplated. As of March&nbsp;31, 2013, we had $43.5&nbsp;million in cash and cash equivalents. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Product Candidates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates
in clinical development. Additionally, we have several proprietary product candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. We believe the profile of our compounds
provides us with the flexibility to pursue either monotherapy or combination therapy, depending on disease characteristics, current standards of care, and overall safety, tolerability and efficacy of specific regimens. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below depicts the current status of our product candidates: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754312new.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the
antibody&#146;s ability to kill tumor cells expressing lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed
margetuximab to benefit a large sub-group of patients, which represents 80% or more of the overall population whose Fc receptors, or Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, expressed on immune cells bind less effectively to currently
available antibodies that have not been optimized by our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2 positive, or HER2+, patient populations than those treated with current HER2 therapies, as
well as improve the outcomes for patients who would be eligible for other </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American Society of Clinical
Oncology, or ASCO, demonstrated that anti-tumor activity had been observed at a range of doses tested, including the lowest dose level, even in patients who were heavily pre-treated (frequently including with other anti-HER2 agents). We currently
are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase 2/3 potential registration clinical trial in advanced gastroesophageal cancer in 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. MGA271 represents one of the few novel molecules that may provide relief from immune checkpoint inhibition by releasing a restraint, or brake, on the anti-tumor immune
response. Inhibition of immune checkpoints has been shown to have powerful anti-tumor effects in several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine,</I> complete
or partial tumor regression was observed in patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on T cells.
We have engineered MGA271 to utilize the same Fc Optimization enhancements that we incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumor cells and CSLCs, as well as on the supporting tumor vasculature and
underlying tissues. MGA271 is designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells. We have initiated a Phase 1 clinical trial that we expect to complete by the end of 2014. We plan
to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor, or IL3R, alpha chain is expressed on
leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and
expand T cell populations to eliminate leukemia cells. We expect to commence a Phase 1 clinical trial in the first half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors,
including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial in
the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Collaborations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations for our product candidates and technology platforms, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option grant fee and may be eligible to receive up to approximately $420
million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for, and successfully commercializes MGA271. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to
develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We
received a $20 million option grant fee and may be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its options
and successfully develops, obtains regulatory approval for and commercializes a product under each license. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally,
under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its territories. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We
are further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and sales milestone payments if Gilead exercises all four
of the options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered royalties on the net
sales at percentages ranging from the high single digits to the low double digits, subject to reductions in specified circumstances. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a
third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to $210 million for each of the DART programs under this agreement. Boehringer
provides funding for our internal and external research costs under the agreement and is required to pay us mid-single digit royalties on product sales. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical,
development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is
required to pay us mid-single digit to low double digit royalties on product sales. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this program in October 2013.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our goal is to be a leader in the discovery, development and commercialization of antibody-based therapeutics for the treatment of patients with cancer, autoimmune disorders and other complex diseases.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key elements of our strategy to achieve this goal are to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types. </I>We intend to pursue the fastest feasible
pathways to approval and to address large, underserved markets. We are developing product candidates that we believe could address disease specific challenges which are not currently being met by existing therapies. We are currently enrolling a
Phase 2a clinical trial of margetuximab in metastatic breast cancer for which we expect to have results in 2014. We anticipate commencing a Phase 2/3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in 2014.
We are currently enrolling the dose-expansion portion of a Phase 1 clinical trial of MGA271 as a single-agent in the treatment of 45 patients with solid tumors. In addition, we are currently optimizing multiple DART therapeutics as candidates for
clinical development. We anticipate that we will begin Phase 1 clinical trials of MGD006, our first DART candidate, in the first half of 2014, and MGD007, our second DART candidate, in the second half of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leverage collaborative relationships. </I>We have multiple programs in development under our collaborations and are working closely with our
collaborators to advance these programs. We believe that these collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and
access to the development and commercial expertise of our collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to enter into additional collaboration agreements with
biopharmaceutical companies. We anticipate that we would structure these collaborations in ways that would allow us to retain development and commercialization rights in key markets. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Create new product candidates that combine the potency and target selectivity of our DART and Fc Optimization technologies with small molecule and
toxin conjugation technologies</I>. We are working with several companies to combine their proprietary linkers and drug conjugates with our monoclonal antibodies and our DART molecules. Our goal is to identify and further develop new clinical
product candidates, either antibody-drug conjugates, or ADCs, or DART-drug conjugates, through these research efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for
our clinical stage programs as well as the three DART programs that we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product
candidates that receive regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities. </I>We have built a powerful and fully
integrated set of capabilities that are critical to our ability to discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We currently manufacture the drug substance for all of our product
candidates at our manufacturing facility. We intend to build on our technology platforms, methods and know-how that together comprise our capabilities in order to expand our product pipeline. Our goal is to file one or more new investigational new
drug applications, or INDs, annually for the next several years. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_2"></A><A NAME="cov575431_1"></A>Risk Factors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves substantial risk. You should carefully consider all of the information in this prospectus prior to investing in our common stock. There are numerous risk factors
related to our business that are described under &#147;Risk Factors&#148; and elsewhere in this prospectus. Among these important risks are the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our clinical trials may not be successful, and clinical results may not reflect results seen in previously conducted pre-clinical studies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we do not have adequate funding to complete development in some areas, and may be unable to access additional capital on reasonable terms or at all to
complete development and begin commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our current or future collaborators may not adequately support development in designated areas, or they may elect to change their strategic or business
priorities, and these changes may have an adverse impact on us, our development plans, or our business; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter unexpected regulatory changes that delay or impede our development and commercialization efforts; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be able to obtain adequate protection for the intellectual property covering our product candidates or develop and commercialize our product
candidates without infringing on the intellectual property rights of third parties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product reimbursement may be challenging for us due to recent and proposed changes in healthcare law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may encounter manufacturing and distribution challenges; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be unable to recruit or retain well qualified personnel who are necessary for us to conduct our business. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Corporate Information </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated under the laws of the state of Delaware in 2000 under the name MacroGenics, Inc. Our principal executive offices are
located at 9640 Medical Center Drive, Rockville, Maryland 20850 and our telephone number is (301)&nbsp;251-5172. Our website address is www.macrogenics.com. The information contained on, or that can be accessed through, our website is not a part of
this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">DART<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and the MacroGenics logo are our registered trademarks. The
other trademarks, trade names and service marks appearing in this prospectus are the property of their respective owners. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THE OFFERING</B> </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over-allotment option</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock to be outstanding after this offering</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to use $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the net proceeds of this offering to fund clinical development expenses for margetuximab and MGA271;
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to fund research and development expenses to advance our remaining product candidates, including MGD006, MGD007 and MGD010, as well as other earlier stage programs; and the remainder for working
capital and general corporate purposes, which may include in-licensing or acquiring other products or technologies. See &#147;Use of Proceeds.&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">See &#147;Risk Factors&#148; and the other information included in this prospectus for a discussion of factors you should consider carefully before investing in shares of our
common stock.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed NASDAQ Global Market symbol</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;MGNX&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock to be outstanding after this offering is based on 36,836,099
shares of our common stock outstanding as of June&nbsp;30, 2013 and excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,879,146 shares of common stock issuable upon the exercise of outstanding options to issue common stock, as of June&nbsp;30, 2013, at a weighted
average exercise price of $0.05 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,342,394 shares of common stock reserved for future grant or issuance under our stock option plans, as of June&nbsp;30, 2013.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise indicated, all information in this prospectus reflects and assumes: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the automatic conversion of all outstanding shares of our convertible preferred stock into 318,327,547 shares of common stock upon the closing of this
offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exercise of outstanding warrants, as of June&nbsp;30, 2013 to purchase
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our Series D-2 preferred stock, at a weighted average exercise price of $0.6521 per share and the subsequent conversion of these shares of our Series D-2 preferred
stock into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise by the underwriters of their option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a &nbsp;&nbsp;&nbsp;&nbsp;for &nbsp;&nbsp;&nbsp;&nbsp;reverse split of our common stock effected on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the filing of our amended and restated certificate of incorporation immediately after the completion of this offering. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUMMARY CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following tables summarize our consolidated financial data for the periods presented and should be read together with
&#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our consolidated financial statements and related notes appearing elsewhere in this prospectus. The consolidated statements of operations and
comprehensive income (loss) data for the years ended December&nbsp;31, 2011 and 2012 included in this prospectus have been derived from our audited consolidated financial statements and footnotes included elsewhere in this prospectus. The following
summary consolidated statements of operations and comprehensive income (loss) data for the three months ended March&nbsp;31, 2012 and 2013 and the balance sheet data as of March&nbsp;31, 2013 have been derived from our unaudited consolidated
financial statements and footnotes included elsewhere in this prospectus. We have prepared the unaudited consolidated financial statements on the same basis as the audited consolidated financial statements and have included all adjustments,
consisting only of normal recurring adjustments, which in our opinion are necessary to state fairly the financial information set forth in those statements. Our historical results are not necessarily indicative of the results we expect in the
future, and our interim results should not necessarily be considered indicative of results we expect for the full year. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statements of Operations and Comprehensive Income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,906,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,565,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">398,917,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,565,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share(1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,665,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,893,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">399,750,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,893,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,&nbsp;2013</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Forma(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma&nbsp;As<BR>Adjusted(3)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited) </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,898</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pro forma basic and diluted net income (loss) per share reflects the issuance of common stock upon the automatic conversion of all outstanding shares of our
preferred stock upon the closing of this offering, assuming all such shares of preferred stock had been converted to common stock for all periods in which such shares of preferred stock were outstanding. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma consolidated balance sheet data give effect to the automatic conversion of all outstanding shares of preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock upon the closing of this offering. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma as adjusted consolidated balance sheet data give additional effect to the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock at an initial offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, after deducting the
estimated underwriting discounts and commissions and estimated offering expenses payable by us. A $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
per share, the midpoint of the estimated price range set forth on the cover page of this prospectus, would increase or decrease total stockholders&#146; equity (deficit) and total capitalization on a pro forma as adjusted basis by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
</div></div>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RISK FACTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the following risk factors, as well as the other information in this prospectus, before you decide to
purchase our common stock. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our common stock could decline and you may lose all or part of
your investment.</I> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Business and the Development and Commercialization of our Product Candidates. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>All of our product candidates are in pre-clinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and
we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and
non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application, or BLA,
from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not
submitted an application for or received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA.
Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative
or judicially imposed sanctions, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">restrictions on the products, manufacturers or manufacturing process; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">warning letters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">civil and criminal penalties; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injunctions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">suspension or withdrawal of regulatory approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product seizures, detentions or import bans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">voluntary or mandatory product recalls and publicity requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">total or partial suspension of production; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">imposition of restrictions on operations, including costly new manufacturing requirements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">refusal to approve pending BLAs or supplements to approved BLAs. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of pre-clinical
studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug
candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a product candidate may not be deemed safe or effective; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the results may not confirm the positive results from earlier pre-clinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory agencies may change their approval policies or adopt new regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the
particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses
for which we may market the product. These limitations may limit the size of the market for the product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to
obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently enrolling a Phase 2a clinical trial of margetuximab in patients with metastatic breast cancer and anticipate commencing
a Phase 2/3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in 2014. We have initiated a Phase 1 clinical trial of MGA271 that we expect to complete by the end of 2014. We expect to commence a Phase 1
clinical trial of MGD006 in the first half of 2014 and expect to commence a Phase 1 clinical trial of MGD007 in the second half of 2014. The commencement of these planned clinical trials could be substantially delayed or prevented by several
factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial
programs, including some that may be for the same indication as our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to obtain sufficient funds required for a clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical
research organizations, or CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The completion of our clinical trials could also be substantially delayed or prevented by several factors,
including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">slower than expected rates of patient recruitment and enrollment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of patients to complete the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of efficacy during clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of our clinical trials by one or more clinical trial sites; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">inability to monitor patients adequately during or after treatment by us and/or our CROs; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend
clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing
or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to
that site, or us, due to a number of factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for
the clinical development of any of our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any failure or significant delay in completing
clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not
satisfy the requirements of the FDA or non-U.S. regulatory authorities. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no products approved for
sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future
collaborators may decide, or regulators may require us, to conduct additional clinical or pre-clinical testing. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe
and effective for use in a diverse population before we can seek regulatory approvals for their commercial sale. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product
candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. Product candidates that
have shown promising results in early clinical trials may still suffer significant setbacks in subsequent registration clinical trials. Similarly, the outcome of pre-clinical testing and early clinical trials may not be predictive of the success of
later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant
setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. For example, although early stage trials of our product candidate teplizumab were promising, it did not meet its primary efficacy endpoint in a
Phase 3 clinical trial and our collaboration with Eli Lilly &amp; Co., or Eli Lilly, was subsequently terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
addition, the design of a clinical trial can determine whether its results will support approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design
and execute a clinical trial to support regulatory approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some instances, there can be significant variability in
safety and/or efficacy results between different trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other
trial protocols and the rate of dropout among clinical trial participants. We do not know whether any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and
safety to obtain regulatory approval to market our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further, our product candidates may not be approved
even if they achieve their primary endpoints in Phase 3 clinical trials or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical
trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential
to result in FDA or other agencies&#146; approval. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of
costly post-marketing clinical trials. The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that
utilize these technologies. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our products in development are based on new technologies, such as Fc Optimization,
bi-specific DARTs and CSLCs. Given the complexity of our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for
our product candidates. It is possible that the validation process may take time and resources, require independent third-party analyses or not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are
based on these technology platforms, the regulatory approval path and requirements may not be clear, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the products that we develop would
adversely affect our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may not be successful in our efforts to use and expand our technology platforms to build a pipeline
of product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A key element of our strategy is to use and expand our technology platforms to build a
pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of
product candidates directed at&nbsp;various cancers and autoimmune disorders, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product
candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing
approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to
our financial position and adversely affect our stock price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may expend our limited resources to pursue a particular product
candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of
opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market
opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target
market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole
development and commercialization rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval
or commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical
trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among
countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional
pre-clinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and
other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval
in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with
regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are seeking fast-track designation of margetuximab and may seek fast track designation and review for some of our other product candidates.
There is no assurance that the FDA will grant such designation and, even if it does grant fast track designation to margetuximab or one of our other product candidates, that designation may not actually lead to a faster development or regulatory
review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are seeking fast-track designation of margetuximab and may seek fast track designation and review for some of our other product candidates. If a drug is intended for the treatment of a serious or
life-threatening condition or disease, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this
designation, we </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
cannot assure you that the FDA would decide to grant it. Moreover, even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to
conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may seek breakthrough therapy designation by the FDA for any of our product candidates but that is not assured and may not, in any event, lead to a faster development or regulatory review or
approval process, and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may apply for breakthrough therapy designation for some of our product candidates. The FDA is authorized to designate a product candidate as a breakthrough therapy if it finds that the product is
intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies
on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the
trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough therapies by the FDA are also eligible for accelerated
approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of
our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may
not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event, does not assure ultimate approval by the FDA. In addition, even if one or more
of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may be unable to obtain orphan product designation or exclusivity for some or all of our product candidates. If our competitors are
able to obtain orphan product exclusivity for their products that are the same as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for
relatively small patient populations as orphan drugs. Under the Orphan Drug Act, FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient
population of fewer than 200,000 individuals annually in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, if a product candidate with an orphan
drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the EMA or the FDA from approving another
marketing application for the same drug for that time period. The applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria
for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or
if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. In the
United States, even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a
major contribution to patient care. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our product candidates may have undesirable side effects which may delay or prevent marketing
approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product
candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
been marketed. All of our product candidates are still in clinical or pre-clinical development. While our clinical trials for our initial product candidates to date have demonstrated a favorable
safety profile, the results from future trials may not support this conclusion. The results of future clinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical
trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential
product liability claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates receives marketing approval and we or others later identify
undesirable or unacceptable side effects caused by such products: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require us to take our approved product off the market; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and
pharmacies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to limitations on how we may promote the product; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales of the product may decrease significantly; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may be subject to litigation or product liability claims; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase
commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the medical community, and third-party payors our revenue generated from their
sales will be limited. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The commercial success of our product candidates will depend upon their acceptance among
physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations or warnings contained in the approved labeling for a product candidate; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the standard of care for the targeted indications for any of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limitations in the approved clinical indications for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">demonstrated clinical safety and efficacy compared to other products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lack of significant adverse side effects; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sales, marketing and distribution support; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability and extent of reimbursement from managed care plans and other third-party payors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">timing of market introduction and perceived effectiveness of competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the degree of cost-effectiveness of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular
diseases; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">adverse publicity about our product candidates or favorable publicity about competitive products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">convenience and ease of administration of our products; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potential product liability claims. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates are approved, but do not achieve an adequate level of
acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the
benefits of our product candidates may require significant resources and may never be successful. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are subject to a multitude of
manufacturing risks, any of which could substantially increase our costs and limit supply of our products. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
process of manufacturing our products is complex, highly regulated and subject to several risks, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process of manufacturing biologics, such as margetuximab, MGA271, and our other product candidates, is extremely susceptible to product loss due to
contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process.
Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the
manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural
disasters, power failures and numerous other factors. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, regulations and guidelines. We may encounter difficulties in achieving
quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any
failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities
or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in
the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also
result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation,
seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be
subject to product recalls, seizures, injunctions, or criminal prosecution. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory
shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications,
undertake costly remediation efforts or seek more costly manufacturing alternatives. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We currently have no marketing,
sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have no marketing, sales and distribution capabilities and we have no sales or marketing experience within our organization.
If any of our product candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function
to a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that is
sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our
products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to certain of our existing and future product candidates, we have entered into
collaboration or other licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower
than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our
control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or
through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our
product candidates, our commercial opportunities will be negatively impacted. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The life sciences industry is highly
competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are
also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established
biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than
we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and in manufacturing pharmaceutical products. These companies also have significantly greater
research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions.
Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these
factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Specifically, there are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These
treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics
that work by targeting multiple specificities using a single recombinant molecule. Amgen, Inc., or Amgen, is in late-stage clinical development of cancer product candidates which work by targeting antigens both on immune effector cell populations
and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann-La Roche
Ltd., or Roche, and Xencor, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop and
commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by
insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to
margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, or
collectively, ACA created a new regulatory scheme authorizing the FDA to approve biosimilars. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable
with&#148; a previously approved biological product or &#147;reference product.&#148; Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years following approval of the reference
product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a
competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#146;s own pre-clinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their
product. Furthermore, recent legislation has proposed that the 12 year exclusivity period for each a reference product may be reduced to seven years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with
us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In
addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our
competitors may render our technologies or product candidates obsolete, less competitive or not economical. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market
acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by
future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels. We cannot be certain that
reimbursement will be available for any products that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a
limited basis, we may not be able to successfully commercialize any of our approved products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which
expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based
on average sales prices for physician-administered drugs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The United States and several foreign jurisdictions are
considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in
the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to
the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In March 2010, the ACA became law in the United States. The goal of ACA is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private
insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively
affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. We also cannot predict the impact of ACA on our business or financial condition as many of the ACA reforms require the
promulgation of detailed regulations implementing the statutory provisions, which has not yet occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If any product liability
lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and
will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials,
patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or
eventual outcome, liability claims may result in: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">decreased demand for our future approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">injury to our reputation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">termination of clinical trial sites or entire trial programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">increased regulatory scrutiny; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant litigation costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">substantial monetary awards to or costly settlement with patients or other claimants; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product recalls or a change in the indications for which they may be used; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss of revenue; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">diversion of management and scientific resources from our business operations; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the inability to commercialize our product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if
we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer
perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our
financial condition or results of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently hold $15 million in product liability insurance coverage in the
aggregate, with a per incident limit of $15 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance
coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product
liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with international operations.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and
collaborative and clinical trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">differing regulatory requirements for drug approvals in foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">potentially reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties in compliance with non-U.S. laws and regulations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. regulations and customs, tariffs and trade barriers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in non-U.S. currency exchange rates and currency controls; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in a specific country&#146;s or region&#146;s political or economic environment; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">negative consequences from changes in tax laws; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">workforce uncertainty in countries where labor unrest is more common than in the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">difficulties associated with staffing and managing foreign operations, including differing labor relations; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods
and fires. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Financial Position and Need for Additional Capital </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no
products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of March&nbsp;31, 2013, our accumulated deficit was approximately $178.8&nbsp;million. We
expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize
any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and
likely will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to
accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA, to perform trials in addition to those that we currently
expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities
for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never
succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our
failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also
cause you to lose all or part of your investment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will require substantial additional funding, which may not be available to us on
acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting pre-clinical studies and clinical trials, is expensive. In order to obtain
such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond this contemplated offering to complete the development and
commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our liquidity
requirements, based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for
at least the next 18 months. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our future funding requirements will depend on many factors, including but not limited to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number and characteristics of other product candidates that we pursue; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the scope, progress, timing, cost and results of research, pre-clinical development, and clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be
required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need and ability to hire additional management, scientific, and medical personnel; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the effect of competing products that may limit market penetration of our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which
we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or
private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale
back or eliminate one or more of our development programs or our business operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Raising additional capital may cause dilution to
our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish substantial rights. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include
liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as
incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our
technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate
financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Dependence on Third Parties </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these
collaborations are not successful, our business could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have limited capabilities for drug
development and do not yet have any capability for sales, marketing or distribution. Accordingly, we have entered into collaborations with other companies that we believe can provide such capabilities, including our collaboration and license
agreements with Servier, Gilead, Boehringer, Pfizer and Green Cross Corp., or Green Cross. These collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional
funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not perform their obligations as expected; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue
or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing
priorities; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product
candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products,
which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit
sufficient resources to the marketing and distribution of such product or products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development,
might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of
which would be time-consuming and expensive; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite
litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue
further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements with Servier, Gilead, and Boehringer may be terminated for convenience upon the completion of a specified
notice period. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If our therapeutic collaborations do not result in the successful development and
commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under
these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development,
regulatory approval and commercialization described in this prospectus also apply to the activities of our program collaborators. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or
commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology
companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things,
upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s evaluation of a number of factors. These factors may include the design or results of
clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product
candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and
industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive
than the one with us for our product candidate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaborations are complex and time-consuming to negotiate and document. In addition, there
have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a
timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or
marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain
additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and
commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential
collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with
third parties for specified periods of time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical trials
may not devote sufficient time or attention to our clinical trials or be able to repeat their past success. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect
to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There are a limited number of third-party service providers that specialize or have
the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs
will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote
sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of
third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly
referred to as current Good Clinical Practice, or cGCP, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects
are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with cGCP procedures could adversely affect the clinical development of our product candidates and harm our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Failure of our third party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could
harm our ability to commercialize our product candidates. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to develop companion diagnostics for our product
candidates. Companion diagnostics are used to identify patients who could potentially benefit from our therapeutic product candidates. We expect that, at least in some cases, the FDA and similar regulatory authorities outside the United States may
require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on
third parties to perform these functions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to outsource the development, production and commercialization of companion
diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not perform their obligations as expected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may encounter production difficulties that could constrain the supply of the companion diagnostic; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may not commit sufficient resources to the marketing and distribution of such product; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">may terminate their relationship with us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third
party contractors fail to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection
with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to contract with third parties for the manufacture of our product candidates for clinical testing in the future and expect to continue to do so for commercialization. This reliance on
third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have a manufacturing facility located in Rockville, Maryland. We manufacture drug substance at this
facility that we use for research and development purposes and for clinical trials of our product candidates. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our
DART therapeutics, but our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial quantities of such candidates. We do not have experience in manufacturing
products at commercial scale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate engagement of contract manufacturing organizations in 2014 to supplement our
clinical supply and internal capacity as we advance pre-clinical product candidates into clinical development. We expect to use third parties for the manufacture of certain of our product candidates for clinical testing, as well as for commercial
manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan eventually to enter into long term supply agreements with several manufacturers for
commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates.
Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for
the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#146;s requirements for the manufacture of our finished products. If our manufacturers cannot successfully
manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#146; cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves,
including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement
third-party manufacturer; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to
meet our manufacturing needs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any of these factors could cause the delay of approval or commercialization
of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required
commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent
volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any
such new source approved by the FDA or any other relevant regulatory authorities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to our Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the
enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents
to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of
discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of
the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign
countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent
applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and
time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to
protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be
valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product
and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our
products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid
and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and
factual considerations. The standards which the United States Patent and Trademark Office and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy
regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many
companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and
uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents
that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may
increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of
narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies
or products, or provide us with any competitive advantage. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We may become involved in lawsuits to protect or enforce our patents, which
could be expensive, time consuming and unsuccessful. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Even after they have issued, our patents and any patents which
we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products
that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following are examples of litigation and other adversarial proceedings or disputes that
we could become a party to involving our patents or patents licensed to us: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment
that their product or technology does not infringe our patents or patents licensed to us; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our
collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the U.S. Patent&nbsp;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of
our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or
licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or
administrative body would decide that our patents are invalid or not infringed by a third party&#146;s activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own
patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties
from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not
adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we might not have been the first to make the inventions covered by patents or pending patent applications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we might not have been the first to file patent applications for these inventions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not develop additional proprietary technologies that are patentable. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may
have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, some aspects of the amino acid sequences encoding
margetuximab and MGA271 are covered by patents held by third parties. We believe that these patents are invalid. However, if we are unable to invalidate such patents, or if licenses for them are not available on commercially reasonable terms, our
business could be harmed, perhaps materially. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patents that we may ultimately be found to infringe could be issued to third parties. Third
parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our
business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be
exposed to a threat of litigation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the pharmaceutical industry, significant litigation and other proceedings regarding
patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third
parties or to obtain a judgment that our products or processes do not infringe those third parties&#146; patents; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to
participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our
collaborators will need to defend against such proceedings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or
misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific
personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#146;s patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our
collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will
order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to
license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry
participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent
infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For
example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs
and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an
infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a
license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product
candidates to market and be precluded from manufacturing or selling our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The cost of any patent litigation
or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb
significant management time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we fail to comply with our obligations under our intellectual property licenses with third parties,
we could lose license rights that are important to our business. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently party to various intellectual
property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and
know-how license agreements which grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271. These licenses typically include an obligation to pay an upfront payment, yearly maintenance
payments and royalties on sales. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is
covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our
competitive business position and harm our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we are unable to protect the confidentiality of our proprietary information,
the value of our technology and products could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to patent protection, we also rely
on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees,
consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the
individual&#146;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services
to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become
assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other
confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related
inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from
that individual, or a third party or from that individual&#146;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially
harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely
affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently
employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by
their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other
requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over
the lifetime of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various
foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many
cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the
patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for the
payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences
of any resulting loss of patent rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign
legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug
Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for
effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise
fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can
enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Related to Legal Compliance Matters </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and
chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the
risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and
workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we
maintain workers&#146; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not
provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations
may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal
healthcare laws commonly referred to as &#147;fraud and abuse&#148; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback statutes.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for
payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying,
soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed
healthcare programs. This statute has been interpreted to apply to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory
safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if
they do not qualify for an exemption or safe harbor. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services
reimbursed by private insurers. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of
promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by
federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our
future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#147;fraud and abuse&#148; laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider
trading. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include
intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose
unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive
practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the
improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We intend to adopt a code of conduct prior to the completion of this offering, but it is not always
possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or
other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business, including the imposition of significant fines or other sanctions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to Employee Matters
and Managing Growth </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified
personnel. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are highly dependent on the research and development, clinical and business development expertise of
Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment letter agreements with our executive officers, each
of them may terminate their employment with us at any time. We currently maintain $1 million in &#147;key person&#148; insurance coverage for Dr.&nbsp;Koenig. The loss of the services of our executive officers or other key employees could impede the
achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage
our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers
and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and
commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and
advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality
personnel, our ability to pursue our growth strategy will be limited. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will need to grow our organization, and we may experience
difficulties in managing this growth, which could disrupt our operations. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2013, we had 156
full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant
added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our
day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to
operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such
as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and
we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively
manage any future growth. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks Relating to our Common Stock and this Offering </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our stock price is likely to be volatile and the market price of our common stock after this offering may drop below the price you pay.
</I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should consider an investment in our common stock as risky and invest only if you can withstand a significant
loss and wide fluctuations in the market value of your investment. Prior to this offering, there was not a public market for our common stock. We will negotiate and determine the initial public offering price with the representatives of the
underwriters based on several factors. This price may vary from the market price of our common stock after this offering. You may be unable to sell your shares of common stock at or above the initial offering price due to fluctuations in the market
price of our common stock arising from changes in our operating performance or prospects. In addition, the stock market has recently experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life
sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the factors that may cause the
market price of our common stock to fluctuate or decrease below the price paid in this offering include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">results and timing of our clinical trials and clinical trials of our competitors&#146; products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure or discontinuation of any of our development programs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">issues in manufacturing our product candidates or future approved products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#146;
products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">competition from existing products or new products that may emerge; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developments or disputes concerning patents or other proprietary rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">introduction of technological innovations or new commercial products by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or
capital commitments; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in estimates or recommendations by securities analysts, if any cover our common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">public concern over our product candidates or any future approved products; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">future sales of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">changes in the structure of health care payment systems in the United States or overseas; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure of any of our product candidates, if approved, to achieve commercial success; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic and other external factors or other disasters or crises; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments
under commercialization or licensing agreements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">general market conditions and market conditions for biopharmaceutical stocks; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overall fluctuations in U.S. equity markets. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of
our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>There may not be an active, liquid trading market for our common stock. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no established trading market for our common stock. There is no guarantee that an active trading
market for our common stock will develop or, if developed, be maintained after this offering on the NASDAQ Global Market or any other exchange. If a trading market does not develop or is not maintained, you may experience difficulty in reselling, or
an inability to sell, your shares quickly or at the latest market price. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital to continue to fund
operations by selling shares and may impair our ability to acquire other companies or technologies by suing our shares as consideration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Insiders will continue to have substantial control over us which could delay or prevent a change in corporate control or result in the entrenchment
of management and/or the board of directors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After this offering, our directors, executive officers and principal
stockholders, together with their affiliates and related persons, will beneficially own, in the aggregate, approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding common stock. As a result, these stockholders, if acting together, may have the
ability to determine the outcome of matters submitted to our stockholders for approval, including the election and removal of directors and any merger, consolidation, or sale of all or substantially all of our assets. In addition, these persons,
acting together, may have the ability to control the management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our common stock by: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">delaying, deferring, or preventing a change in control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">entrenching our management and/or the board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">impeding a merger, consolidation, takeover, or other business combination involving us; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Management will retain broad discretion over the use of the net proceeds from this offering. Stockholders may not agree with such uses,
and our use of the proceeds may not yield a significant return or any return at all for our stockholders. We intend to use the proceeds from this offering to fund research and development of our current and future product candidates. We may also
spend a portion of the net proceeds on working capital and general corporate purposes, which may include in-licensing or acquiring other products or technologies. Because of the number and variability of factors that will determine our use of the
proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Any failure by our management to apply the proceeds effectively could affect our ability to continue to develop and eventually manufacture and
sell our products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced disclosure requirements
applicable to emerging growth companies, our common stock may be less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are an
&#147;emerging growth company,&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public
companies that are not &#147;emerging growth companies&#148; including, but not limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not
previously approved. We cannot predict whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading
market for our common stock and our stock price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; We could remain an &#147;emerging growth company&#148; until the
earliest to occur of the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to this prospectus;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which we have issued more than $1 billion in non-convertible debt during the previous three years; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the date on which we are deemed to be a &#147;large accelerated filer&#148; under SEC rules and regulations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial
time to corporate governance standards. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a public company, we will incur significant legal, accounting and other
expenses that we did not incur as a private company. In addition, our administrative staff will be required to perform additional tasks. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls
and disclosure controls and procedures, retain a transfer agent and adopt an insider trading policy. Once we are a public company, we will bear all of the internal and external costs of preparing and distributing periodic public reports in
compliance with our obligations under the securities laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, regulations and standards relating to corporate
governance and public disclosure, including the Sarbanes-Oxley Act and related regulations implemented by the Securities and Exchange Commission and the NASDAQ Global Market, have increased legal and financial compliance costs and will make some
compliance activities more time consuming. We are currently evaluating these rules, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. We intend to invest resources to comply with evolving laws,
regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#146;s time and attention from our other business activities. If our efforts to comply with new laws, regulations
and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In connection with this
offering, we are increasing our directors&#146; and officers&#146; insurance coverage which will increase our insurance cost. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we
may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our
audit committee and compensation committee, and qualified executive officers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the corporate governance standards of the NASDAQ Global Market, a majority of our
board of directors and each member of our audit committee must be an independent director no later than the first anniversary of the completion of this offering. We may encounter difficulty in attracting qualified persons to serve on our board of
directors and the audit committee, and our board of directors and management may be required to divert significant time and attention and resources away from our business to identify qualified directors. If we fail to attract and retain the required
number of independent directors, we may be subject to the delisting of our common stock from the NASDAQ Global Market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Provisions of
our charter, bylaws, and Delaware law may make an acquisition of us or a change in our management more difficult. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain provisions of our restated certificate of incorporation and restated bylaws that will be in effect upon the completion of this
offering could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also
could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the
opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making
it more difficult for stockholders to replace members of our board of directors. These provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">allow the authorized number of directors to be changed only by resolution of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#147;poison
pill&#148; to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at
stockholder meetings; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">limit who may call stockholder meetings; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">require the approval of the holders of&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our capital stock entitled to vote in order to amend
certain provisions of our restated certificate of incorporation and restated bylaws. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, because
we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our
outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their
investment. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently intend to retain our future earnings, if any, to fund the development and growth of our
businesses. As a result, capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investors in this offering will pay a much higher price than the book value of our common stock and therefore you will incur immediate and
substantial dilution of your investment. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The initial public offering price will be substantially higher than the net
tangible book value per share of shares of our common stock based on the total value of our tangible assets less our total liabilities immediately following this offering. Therefore, if you purchase common stock in this offering, you will experience
immediate and substantial dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this
offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. In the past, we issued options and warrants to acquire common stock at prices below the assumed initial public offering price.
To the extent these outstanding options are ultimately exercised, you will experience further dilution. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A significant portion of our total outstanding shares of common stock is restricted from immediate
resale but may be sold into the market in the near future. This could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales of a substantial number of shares of our common stock in the public market could occur in the future. These sales, or the
perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. After this offering, we will have
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; outstanding shares of common stock based on the number of shares outstanding as of June&nbsp;30, 2013. Of these shares, &nbsp;&nbsp;&nbsp;&nbsp; shares
sold in this offering may be resold in the public market immediately and the remaining shares are currently restricted under securities laws or as a result of lock-up agreements but will be able to be resold after the offering as described in the
&#147;Shares Eligible for Future Sale&#148; section of this prospectus. Moreover, after this offering, holders of an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock,
which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon the conversion of all our outstanding shares of our preferred stock will have rights, subject to
certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We also intend to register all
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market
upon issuance and once vested, subject to the lock-up agreements described in the &#147;Underwriting&#148; section of this prospectus. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Future issuances of our common stock or rights to purchase common stock pursuant to our equity incentive plans or outstanding warrants could result
in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of
June&nbsp;30, 2013, we have options to purchase 51,879,146 shares outstanding under our equity compensation plans. We are also authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to
5,342,394 shares of our common stock, pursuant to our equity compensation plans. We plan to register the number of shares available for issuance or subject to outstanding awards under our equity compensation plans after the completion of this
offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business,
our share price and trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The trading market for our common stock will depend on the research
and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If one or more of the analysts who
cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the
financial markets, which could cause our share price or trading volume to decline. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our ability to use our net operating loss
carryforwards and other tax attributes may be limited. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our ability to utilize our federal net operating losses, or
NOLs, and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code. The limitations apply if an ownership change, as defined by
Section&nbsp;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years
or since the last ownership change. We are already subject to Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of $94.9
million and research and development tax credit carryforwards of $21.8 million available. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another Section&nbsp;382
limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if
we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future
cash tax liability to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus includes forward-looking statements within the meaning of federal securities laws. Forward-looking
statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these
statements appear, in particular, under the headings &#147;Prospectus Summary&#148;, &#147;Risk Factors&#148;, &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and &#147;Business&#148;.
Forward-looking statements can often be identified by the use of terminology such as &#147;subject to&#148;, &#147;believe&#148;, &#147;anticipate&#148;, &#147;plan&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;estimate&#148;,
&#147;project&#148;, &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;would&#148;, &#147;could&#148;, &#147;can&#148;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current
expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under &#147;Risk Factors&#148;), could affect future performance and cause actual results
to differ materially from those matters expressed in or implied by forward-looking statements: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our plans to develop and commercialize our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ongoing and planned clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial
objectives; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the rate and degree of market acceptance and clinical utility of our products; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our commercialization, marketing and manufacturing capabilities and strategy; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">significant competition in our industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of litigation and the failure to successfully defend lawsuits and other claims against us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">economic, political and other risks associated with our international operations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to receive research funding and achieve anticipated milestones under our collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our intellectual property position; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">loss or retirement of key members of management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">failure to successfully execute our growth strategy, including any delays in our planned future growth; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our failure to maintain effective internal controls. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Consequently, forward-looking statements should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee
future results, events, levels of activity, performance or achievements. We do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect
the occurrences of unanticipated events. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_4"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds from the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of
common stock in this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range
set forth on the cover of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate
that the net proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in
the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase or decrease our net proceeds by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming the number of shares offered
by us, as set forth on the cover of this prospectus, remains the same and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are undertaking this offering in order to access the public capital markets and to increase our liquidity. We intend to use the net
proceeds of this offering as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund clinical development expenses for margetuximab and MGA271;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund research and development expenses to advance our remaining product
candidates, including MGD006, MGD007 and MGD010, as well as other earlier stage programs; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The remainder for working capital and general corporate purposes, which may include in-licensing or acquiring other products or technologies.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our expected use of net proceeds from this offering represents our current intentions based upon our
present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering or the amounts that we will actually spend
on the uses set forth above. Due to the many variables inherent to the development of oncology and autoimmune therapeutics at this time, such as the timing of patient enrollment and evolving regulatory requirements, we cannot currently predict the
stage of development that our product candidates will reach using the net proceeds of this offering. Based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing cash and cash equivalents,
will enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
amount and timing of our actual expenditures will depend upon numerous factors, including the results of our research and development efforts, the timing and success of pre-clinical studies, our ongoing clinical trials or clinical trials we may
commence in the future and the timing of regulatory submissions. As a result, our management will have broad discretion over the use of the net proceeds from this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, interest-bearing, investment-grade
securities, certificates of deposit or government securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_5"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never paid any dividends on our common stock. We currently intend to retain any future earnings to finance the growth and
development of our business, and we do not anticipate that we will declare or pay any cash dividends on our common stock in the foreseeable future. Any future determination to pay cash dividends will be at the discretion of our board of directors
and will be dependent upon our financial condition, results of operations, capital requirements, restrictions under any future indebtedness and other factors the board of directors deems relevant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_6"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table indicates our capitalization at March&nbsp;31, 2013: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a pro forma basis to reflect the conversion of all of our outstanding preferred stock into an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock immediately prior to the completion of this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on a pro forma as adjusted basis to give further effect to our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering at an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price
range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This table should be read in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of March&nbsp;31, 2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pro&nbsp;Forma</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;
Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="8" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share data)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.01 par value per share:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-1: 26,874,792 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">269</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series A-2: 7,364,582 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series B: 71,401,237 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">714</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series C: 110,952,217 shares authorized, issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D: 30,000,000 shares authorized, 14,446,227 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Series D-2: 75,000,000 shares authorized; 63,681,176 shares issued and outstanding, actual,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, issued and outstanding, pro forma, and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">637</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.01 par value; 425,000,000 shares authorized, 21,761,589 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Treasury stock, at cost, 270,000 shares actual; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional paid-in capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164,330</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(178,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,355</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares of our common stock to be outstanding after this offering are based on 21,761,589 shares of
our common stock outstanding as of March&nbsp;31, 2013 and exclude: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,346,934 shares of common stock issuable upon the exercise of outstanding options, as of March&nbsp;31, 2013, at a weighted average exercise price of
$0.05 per share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,949,117 shares of common stock reserved for future grant or issuance under our stock option plans as of March&nbsp;31, 2013. For additional
information regarding our capital structure, see &#147;Management&#151;Employee Benefit Plans,&#148; &#147;Description of Capital Stock&#148; and Note 5 of the Notes to our Consolidated Financial Statements. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_7"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our historical net tangible book value as of March 31, 2013 was $(14.3) million, or $(0.66) per share of our common stock. Historical net
tangible book value per share represents our total tangible assets less total liabilities divided by the number of shares of our common stock outstanding. Our pro forma net tangible book value (deficit) as of March&nbsp;31, 2013 was approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. Pro forma tangible book value per share represents our total
tangible assets less total liabilities divided by the number of shares of common stock outstanding as of March&nbsp;31, 2013 after giving effect to the conversion of all of our outstanding preferred stock into common stock immediately prior to the
closing of this offering. After giving effect to (a)&nbsp;the conversion of all of our outstanding preferred stock into common stock immediately prior to the closing of this offering; and (b)&nbsp;our sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock offered by this prospectus and the receipt and application of those net proceeds, our pro forma net tangible book value as of March&nbsp;31, 2013 would
have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. This represents an immediate increase in pro forma net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to existing stockholders and an immediate dilution in pro forma net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to investors purchasing common stock
in this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates this per share dilution: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assumed initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Historical net tangible book value per share as of March&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decrease attributable to the conversion of outstanding preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share as of March&nbsp;31, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in net tangible book value per share attributable to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to new investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $1.00 increase or decrease in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase or decrease our pro forma net tangible book value by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, our pro forma net tangible book value per share after
this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and dilution per share to new investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming that the number of shares offered by us, as set
forth on the cover page of this prospectus, remains the same. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table summarizes on a pro forma basis as of
March&nbsp;31, 2013, the difference between the number of shares of common stock purchased from us, the total consideration paid and the average price per share paid by existing stockholders and by new investors, assuming an initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the price range set forth on the cover page of this prospectus, and before deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares Purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Average&nbsp;Price<BR>per Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing stockholders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New investors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above is based on shares outstanding as of March 31, 2013 and includes
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock into shares of common stock upon the closing of
this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table above excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">66,346,934 shares of our common stock issuable upon the exercise of stock options outstanding as of March 31, 2013 at a weighted average exercise price
of $0.05 per share; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,949,117 shares of our common stock reserved for future grant or issuance under our stock option plans as of March 31, 2013. For additional
information regarding our capital structure, see &#147;Management&#151;Employee Benefit Plans&#148; and Note 5 of the Notes to our Consolidated Financial Statements. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing discussion and tables assume no exercise of any stock options outstanding as of March&nbsp;31, 2013. To the extent that
these options are exercised, new investors will experience further dilution. As of March&nbsp;31, 2013, options to purchase 66,346,934 shares of common stock were outstanding at a weighted average exercise price of $0.05 per share. Assuming all of
our outstanding options are exercised, new investors will own approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding shares while contributing approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total
amount paid to fund our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the underwriters exercise their option to purchase additional shares in full, the
following will occur: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the percentage of shares of our common stock held by existing stockholders will decrease to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the number of shares of our common stock held by new investors will increase to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this offering. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_8"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The consolidated statements of operations and comprehensive income (loss) data for the years ended December&nbsp;31, 2012 and 2011 and
the consolidated balance sheet data as of December&nbsp;31, 2012 included in this prospectus have been derived from our audited consolidated financial statements and footnotes included elsewhere in this prospectus. The following selected
consolidated statements of operations and comprehensive income (loss) data for the three months ended March&nbsp;31, 2012 and 2013 and the balance sheet data as of March&nbsp;31, 2013 have been derived from our unaudited consolidated financial
statements and footnotes included elsewhere in this prospectus. The unaudited consolidated financial statements have been prepared on a basis consistent with our audited consolidated financial statements and, in the opinion of management, include
all adjustments, consisting only of normal recurring adjustments, which management considers necessary for the fair presentation of the information for the unaudited periods. Historical results are not necessarily indicative of future results, and
our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. The following data should be read in conjunction with &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; and the consolidated financial statements and related notes included elsewhere in this prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year Ended December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three Months Ended March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Statements of Operations and Comprehensive Income (loss):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total revenues</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,207</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63,826</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,510</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs and expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41,089</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,433</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12,724</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,051</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,868</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,833</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total costs and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,957</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,621</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,191</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13,884</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Income (loss) from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,319</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,459</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,467</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net comprehensive income (loss)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,717</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,362</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3,320</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basic weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,906,173</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,565,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diluted weighted average number of common shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,254,567</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,337,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">398,917,176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,565,836</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted net income (loss) per common share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.02</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma basic weighted average number of common shares </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">338,665,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,893,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pro forma diluted weighted average number of common shares </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">399,750,864</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">339,893,383</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended<BR>March&nbsp;31, 2013</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)</B></FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="9" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consolidated Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55,218</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">$43,526</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,681</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53,747</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49,898</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,080</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44,419</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convertible preferred stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,947</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(17,484</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8,237</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11,355)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related
notes included elsewhere in this prospectus. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth under the section entitled &#147;Risk Factors&#148; and
elsewhere in this prospectus, our actual results may differ materially from those anticipated in these forward-looking statements.</I> </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising
product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance
the development of our product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development.
Additionally, we have several proprietary product candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase 2/3
potential registration clinical trial in advanced gastroesophageal cancer in 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules and is over-expressed on a wide variety
of solid tumor types. We have initiated a Phase 1 clinical trial that we expect to complete by the end of 2014. We plan to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes CD123, the Interleukin-3 receptor, or IL3R, alpha chain which is expressed on leukemia and
leukemic stem cells, but not on normal hematopoietic stem cells, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the first half of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33, expressed on gastrointestinal tumors, including more than 95%
of human colon cancers, and CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, business planning, raising capital, developing our technology platforms,
identifying potential product candidates, undertaking pre-clinical studies and conducting clinical trials. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the private
placements of our convertible preferred stock, collaborations and government grants and contracts. From inception through March&nbsp;31, 2013, we have received $151.3 million from the sale of convertible preferred stock and warrants. We have
received an additional $180.0 million of upfront, milestone and annual maintenance payments from our collaborators and have been reimbursed $209.7 million through our collaborations and government grants and contracts. Although it is difficult
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to predict our liquidity requirements, based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing cash and cash equivalents, will
enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Through
March&nbsp;31, 2013, we had an accumulated deficit of $178.8 million. Due primarily to upfront fees paid by our collaborators, we realized a profit of $6.7 million and $8.4 million for the years ended December&nbsp;31, 2011 and 2012, respectively.
We have recognized a loss of $3.3 million for the three months ended March&nbsp;31, 2013. We expect that over the next several years we will increase our expenditures in research and development in connection with our ongoing activities with several
clinical trials. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Strategic Collaborations and Licenses </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations which provide us with significant additional funding in order to continue development of our pipeline and to extend our technology platforms and
on-going programs. Our collaborations have allowed us to speed up the progress of our on-going pre-clinical and clinical stage programs. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option grant fee and may be eligible to receive up to approximately $420
million in license grant fees, and clinical, development, regulatory and sales milestone payments. This total includes a $10 million milestone payment we expect to receive in the third quarter of 2013 based upon dosing the first patient in a planned
expansion cohort in our Phase 1 clinical trial of MGA271. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate to be $30 million, based on the number of different indications represented within the
planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well
as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in
additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its options and successfully develops, obtains regulatory approval for, and commercializes a product under each
license, including $5 million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestone payments, we and Servier will share Phase 2 and Phase 3 development costs. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its
territories. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We
are further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and sales milestone payments if Gilead exercises all four
of the options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered royalties on the net
sales at percentages ranging from the high single digits to the low double digits, subject to reductions in specified circumstances. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a
third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to $210 million for each of the DART programs under this agreement. Boehringer
provides funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. From the commencement of the collaboration through March&nbsp;31, 2013, we have received $36.9 million under this
agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5 million and have received milestone payments and funding for our internal and external research costs under the agreement. We are
eligible to receive technical, development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the
program. In addition, Pfizer is required to pay us mid-single digit to low double digit royalties on product sales. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this
program in October 2013. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Green Cross.</I> In June 2010, we entered into a collaboration agreement with Green Cross for the development of margetuximab. We granted Green
Cross an exclusive license for all indications for all pharmaceutical forms of margetuximab in South Korea. Under the terms of this agreement, we received an upfront, nonrefundable payment of $1.0 million and are eligible to receive clinical,
development and commercial milestone payments up to $4.5 million as well as royalties on net sales of margetuximab in South Korea. In addition, Green Cross purchased $2.0 million of our Series D-2 Preferred Stock in January 2011.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Operations Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenues </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our revenue consists of collaboration revenue, including
amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreement with our strategic
collaborators, including Servier, Gilead, Boehringer, Pfizer and Green Cross. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other educational institutions on behalf of the U.S. government,
primarily with respect to research and development activities related to infectious disease product candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and
Development Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expenses consist of expenses incurred in performing research and
development activities. These expenses include conducting pre-clinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and
development activities. We capture research and development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in
research and development expenses: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee-related expenses such as salaries and benefits; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Employee-related overhead expenses such as facilities and other allocated items; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock-based compensation expense to employees and consultants engaged in research and development activities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation of laboratory equipment, computers and leasehold improvements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to consultants, subcontractors, clinical research organizations, or CROs, and other third party vendors for work performed under our
pre-clinical and clinical trials including but not limited to investigator grants, laboratory work and analysis, database management, statistical analysis, and other items; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts paid to vendors and suppliers for laboratory supplies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">License fees and other third party vendor payments related to in-licensed product candidates and technology; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs related to compliance with regulatory requirements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows a summary of our research and development expenses for the years ended December&nbsp;31, 2011 and 2012, the three months ended March&nbsp;31, 2012 and 2013, and from our
inception in 2000 to March&nbsp;31, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>From<BR>Inception&nbsp;to<BR>March&nbsp;31,<BR>2013</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">195.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">389.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">It is difficult to determine with certainty the duration and completion costs of our current or future
pre-clinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed
in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical
trials and pre-clinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including
competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of
each product candidate&#146;s commercial potential. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and
intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Income (Expense) </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other income (expense) consists of interest
income earned on our cash equivalents, offset by interest expense and other expense, including changes in the fair market value of the preferred stock warrant liability. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
management&#146;s discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States
of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the
date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying
values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial
statements prospectively from the date of the change in estimate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While a summary of significant accounting policies is
described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and any affect the estimates and
judgments we used in preparing our consolidated financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Revenue Recognition </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to
treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART
technologies, (ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborative partner or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical
or clinical materials for the collaborative partner. Payments to us under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of
pre-clinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from
the collaborative efforts of the parties in specific geographic territories. We follow the provisions of the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 605-25, <I>Revenue
Recognition&#150;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included
within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received
is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of December&nbsp;31, 2012, we had the following two types of agreements: 1) exclusive development and commercialization licenses to use our technology and/or certain other intellectual property to
develop compounds against specified targets, which we refer to as exclusive licenses; and 2) option/research agreements to secure on established terms development and commercialization licenses to anticancer and other therapeutic product candidates
to collaborator selected targets developed by us during an option period, which we refer to as right-to-develop agreements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Exclusive
Licenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The deliverables under an exclusive license agreement generally include the exclusive license to our
technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some
cases we may have an option to participate in the co-development of product candidates that result from such agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide
that we will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the
achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant us an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the
royalty term depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights. We may provide technical assistance and share any technology improvements with our collaborators during the term
of the collaboration agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not directly control when any collaborator will achieve milestones or become liable
for royalty payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the units of accounting, management evaluates whether the exclusive license has
stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research capabilities of the
collaborator and the availability of technology platform and product research expertise in the general marketplace. If we conclude that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, we then
determine the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of our previous collaboration
agreements, recent pre-clinical and clinical testing results of therapeutic product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood that technological improvements will be made, the
likelihood that technological improvements made will be used by our collaborators and the nature of the research services to be performed on behalf of our collaborators and market rates for similar services. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value.
Prior to the adoption of Accounting Standards Update, or ASU, No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, we determined that our licenses lacked stand-alone value and were combined with other
elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which we refer to as our period of substantial involvement. The determination of the length of the period over which to defer
revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. Historically, our involvement with the development of a collaborator&#146;s product candidate has been significant at the
early stages of development, and lessens as it progresses into clinical trials. Accordingly, we generally estimate this period of substantial involvement to begin at the inception of the collaboration agreement and conclude at the end of our
substantial involvement. We reassess our periods of substantial involvement over which we amortize our upfront license fees and make adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product
candidate under a single target license, but retains its right to use our technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any remaining portion of the upfront fee until
there is substantial pre-clinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, we would recognize as revenue any portion
of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license
has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize revenue related to research and pre-clinical development services that represent separate units of accounting as they are
performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. We recognize revenue related to the rights to future technological improvements over the
estimated term of the applicable license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We typically perform research activities and pre-clinical development services,
including generating and engineering product candidates, on behalf of our licensees during the early evaluation and pre-clinical testing stages of drug development under our exclusive licenses. We record amounts received for research materials
produced or services performed as revenue from collaborative research. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our license agreements have milestone payments which
for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product candidate initiates or
advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of actual marketing approvals for the
compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the inception of each agreement that includes milestone payments, we evaluate whether
each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;our performance to
achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and
(c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective
milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of
substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we did not
contribute effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no
continuing performance obligations, assuming all other revenue recognition criteria are met. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Right-to-Develop Agreements
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and
commercialize in specified geographic territories product candidates developed by us under agreed upon research and pre-clinical development programs. The product candidates resulting from each program are all directed to a specific target selected
by the collaborator. Under these agreements, fees may be due to us (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program, (iii)&nbsp;upon the exercise of
an option to acquire a development and commercialization license, referred to as exercise fee, for a program, or (iv)&nbsp;some combination of all of these fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborative partner. Options are considered substantive if, at the inception of a right-to-develop
agreement, we are at risk as to whether the collaborative partner will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall
objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed
on the collaborator as a result of exercising the options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure a
development and commercialization licenses to a product program are considered substantive, we do not consider the development and commercialization licenses to be a deliverable at the inception of the agreement. For those right-to-develop
agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, we have deferred the upfront payments received and recognize this revenue over
the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any
substantive option fee is deferred and recognized over the life of the option, generally 12 months. If a collaborator exercises an option and acquires a development and commercialization license to a product program, we attribute the exercise fee to
the development and commercialization license. Upon exercise of an option to acquire a development and commercialization license, we would also attribute any remaining deferred option fee to the development and commercialization license and apply
the multiple-element revenue recognition criteria to the development and commercialization license and any other deliverables to determine the appropriate revenue recognition, which will be consistent with our accounting policy for upfront payments
on exclusive licenses. In the event a right-to-develop agreement were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the
date of such termination. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For right-to-develop agreements where the options to secure development and
commercialization licenses to product programs are not considered substantive, we consider the development and commercialization licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue recognition
criteria to determine the appropriate revenue recognition. All of our right-to-develop agreements have been determined to contain substantive options. We do not directly control when any collaborator will exercise its options for development and
commercialization licenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense and related Accrued Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to
obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. In most cases, our
vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to CROs for services performed on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid to investigative sites for services performed on clinical trials; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees paid for professional services. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Expenses related to clinical trials performed by our CROs are dependent on the successful enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated
accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on the estimated enrollment of patients in each trial. We will adjust accordingly should the estimates vary from the
actual expenses. However, we do not anticipate that our payment of actual expenses will differ materially from our estimates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Income
Taxes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax
basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is
recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset
will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold,
the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax
expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recorded deferred tax assets of $79.3&nbsp;million as of December&nbsp;31, 2012, which have been fully offset by
a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily comprised of federal and state tax net operating loss, or NOL, carryforwards and research and development tax
credit carryforwards. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of $94.9 million and research and development tax credit carryforwards of $21.8 million available. These federal NOL
carryforwards will begin to expire at various dates starting in 2023. We are already subject to Section&nbsp;382 limitations due to an acquisition we made in 2008. Future changes in stock ownership, including resulting from this offering, may also
trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred
income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be
subject to limitations, which could potentially result in increased future cash tax liability to us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, <I>Compensation &#150; Stock
Compensation.</I> The fair value of stock-based payments is estimated, on the date of grant, using a Black-Scholes model. The resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the
vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates that include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Fair Value of Common Stock &#150; </I>Given that there is no public market for our common stock, our board of directors has historically determined
the fair value of our common stock. Since 2007, the board has relied on contemporaneous valuations to determine the fair value of our common stock. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Volatility </I>&#151; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical
volatility) or is expected to fluctuate (expected volatility) during a given period. As we are not a publicly traded company, we have historically identified several public companies of similar size, complexity and stage of development and
calculated the historical volatility using the volatility of these companies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Dividend Yield &#150;</I> We have never declared or paid dividends. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Risk-Free Interest Rate &#150; </I>We have historically used the United States Treasury rate for the week of each option grant during the year,
having a term that most closely resembles the expected life of our options. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Term &#150;</I> This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term
of ten year and we have estimated the expected life of the option term to be seven years. We use a simplified method to calculate the average expected term. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Expected Forfeiture Rate &#150;</I> The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled
on an annual basis before becoming fully vested. We estimate the forfeiture rate based on historical turnover data with further consideration given to the class of the employees to whom the options were granted. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The assumptions used in the Black-Scholes option pricing model for the years ended December&nbsp;31, 2011 and 2012 and for the three
months ended March 31, 2013 are set forth in our consolidated financial statements included within this prospectus. The stock-based compensation expense includes stock options granted to employees and non-employees and has been reported in our
consolidated financial statements as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">472</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,328</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,347</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">838</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In March 2011, we exchanged outstanding options to purchase 36,081,455 shares of our common stock with exercise prices ranging from $0.10 to $0.25 per share, for new
options to purchase the same number of shares of our common stock with an exercise price of $0.05 per share, which we deemed to represent the fair market value of the shares of our common stock as of December&nbsp;31, 2010. The exchange was
implemented because one of our product candidates, teplizumab, did not meet the primary efficacy endpoint in a Phase 3 clinical trial and our collaboration with Eli Lilly&nbsp;was subsequently terminated. We recognized compensation expense of $2.1
million related to this modification as of the exchange date. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has historically estimated
the fair value of our common stock relying on contemporaneous valuations. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American
Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, or the AICPA Practice Aid, and considered many objective and subjective factors to determine the
common stock fair market value each valuation date. The following factors, among others, were considered: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our financial condition and operating results, including our projected results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our stage of development and business strategy; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The financial condition and operating results of publicly-owned companies with similar lines of business and their historical volatility;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">External market conditions that could affect companies in the life sciences and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The prices of our preferred stock sold to outside investors and the rights, preferences and privileges of our preferred stock as compared to those of
our common stock, including the liquidation preference of our preferred stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The likelihood of a liquidity event such as an initial public offering, a merger or the sale of our company; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any recent valuations prepared in accordance with the AICPA Practice Aid. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dates of our valuations have historically coincided with our year end and would therefore not always fall on the same dates as when
options have been granted. However, we have historically granted the majority of our equity awards on an annual basis coinciding with the beginning of each calendar year. Therefore, our board of directors has historically used the valuation closest
to the grant date of options granted in determining the exercise prices. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We considered several types of approaches in the
preparation of our valuations as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Market Approach &#150; </I>The market approach values a business by reference to guideline companies, for which enterprise values are known. This
approach has two principal methodologies. The guideline public company methodology derives valuation multiples from the operating data and share prices of similar publicly traded companies. The guideline acquisition methodology focuses on
comparisons between the subject company and guideline acquired public or private companies. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Income Approach &#150; </I>The income approach values a business based upon the future benefits that will accrue to it, with the value of the future
economic benefits discounted back to a present value at an appropriate discount rate. This approach uses two methods to value an investment. The discounted cash flow analysis forecasts future revenues and free cash flow, or net operating profit
after tax from continuing operations, associated with those revenues. The capitalization of earnings analysis uses a single year&#146;s estimated free cash flow and converts it into a value in one step by dividing free cash flow from operation by a
capitalization rate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Asset Approach &#150;</I> The asset approach considers the underlying value of a company&#146;s individual assets net of its liabilities. This
approach uses the most recent balance sheet as a basis for determining value. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we also
considered several types of allocation methods as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Current Value Method &#150; </I>This method allocates the enterprise value of a company to its conversion value. The method assumes that each
preferred shareholder will, at the valuation date, exercise its conversion rights in the manner that is most beneficial. If the conversion of a class of preferred stock into common stock would result in a value less than the total liquidation
preference of that class, that class is considered to be &#147;out of the money&#148; and would not convert. On the other hand, if the value of the common stock would be greater than the liquidation preference of that class, the preferred stock is
considered to be &#147;in the money&#148; and would convert. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Option-Pricing Method &#150; </I>Under this method, each class of stock is modeled as a call option with a distinct claim on the enterprise value of
the company. The option&#146;s exercise prices would be based on a comparison with the enterprise value. The method assumes that a formula, such as the Black-Scholes model, would calculate the fair value when provided with certain values, including
share price, expiration date, volatility and the risk free interest rate. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Probability Weighted Expected Return Method &#150;</I> Using the probability weighted expected return, or PWERM method, the value of a
company&#146;s common stock is estimated based upon the analysis of future values for the company assuming various possible future liquidity events like an initial public offering, or IPO, sale or merger. Share value is based upon the
probability-weighted present value of expected future net cash flows, considering each of the possible future events, as well as the rights and preferences of each share class. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table illustrates our stock option grant information from January&nbsp;1, 2011
through March&nbsp;31, 2013, including the estimated fair value of our common stock on the date of grant. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:38pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant Date</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Options&nbsp;Granted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Exercise&nbsp;Price</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated&nbsp;Fair&nbsp;Value&nbsp;of<BR>Common Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;9, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,456,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;16, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;15, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">211,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;7, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263,600</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;10, 2011</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;8, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,119,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;14, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,878,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">June&nbsp;13, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;19, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,400</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">November&nbsp;8, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">295,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">January&nbsp;6, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,332,100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">March&nbsp;8, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">263,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The intrinsic value of all outstanding vested and unvested options as of March&nbsp;31, 2013 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million based on an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, and based on 66,346,934 shares of common stock issuable upon the exercise of options outstanding as of March&nbsp;31, 2013 with a weighted average exercise price of $0.05 per share. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2010 Valuation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We determined that the income approach was best suited to use for the December&nbsp;31, 2010 valuation. We focused on determining the market value of our total capitalization. The market value of
non-operating assets was added to determine the market value of the total common equity. We used the option pricing method as the allocation method. We utilized a long-term forecast that represented our best estimate of expected performance. We
determined that a 14.71% cost of capital would be appropriate. We developed a long-term model that projected our product candidates&#146; performance and potential commercialization over the next twenty years. We assumed that we would continue
development of additional product candidates in our pipeline and generate revenue through commercialization of our product candidates or through collaborations. This normalized cash flow was then discounted back to a present value at the above
mentioned cost of capital. The total market value of our capital stock, based upon a discounted cash flow analysis, on a minority interest basis was approximately $74.0 million. We added free cash in the amount of $43.5 million and determined that
the market value of total equity, on a marketable minority interest basis was approximately $117.5 million. Using the option pricing method approach, this value was then allocated among the preferred and common stock and we applied a discount rate
of 30% to account for the lack of marketability of our common stock. We concluded that the fair value of our common stock was $0.05 per share at December&nbsp;31, 2010. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2011 to November 2011 </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of
directors granted options to purchase common stock on January&nbsp;9, 2011,&nbsp;March&nbsp;16, 2011,&nbsp;June&nbsp;15, 2011,&nbsp;September&nbsp;7, 2011 and November&nbsp;10, 2011, with each option having an exercise price of $0.05 per share. In
establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of December&nbsp;31, 2010, as well as the objective and subjective factors outlined above. At each
grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between December 2010 and the grant date, and whether those events and circumstances were part of the
assumptions used in the December 2010 valuation. Our board of directors determined that there were no other events and circumstances that occurred between December 2010 and November 2011 that were indicative of a significant change in the fair value
of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at January&nbsp;9, 2011,&nbsp;March&nbsp;16, 2011,&nbsp;June&nbsp;15, 2011,&nbsp;September&nbsp;7, 2011 and November&nbsp;10, 2011
was $0.05 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2011 Valuation </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We determined that the income approach was best suited to us for the December&nbsp;31, 2011 valuation. We focused on determining the
market value of total capitalization. The market value of non-operating assets was added to determine the market value of the total common equity. We used the option pricing method as the allocation method. We utilized a long-term forecast that
represented our best estimates of expected performance. We determined that a 15.46% cost of capital would be appropriate. We developed a long-term model that projected our product candidates&#146; performance and potential commercialization over the
next twenty years. We assumed that we would continue development of additional product candidates in our pipeline and generate revenue through commercialization of our product candidates or though collaborations. This normalized cash flow was then
discounted back to a present value at the above mentioned cost of capital. The total market value of our capital stock, based upon a discounted cash flow analysis, on a minority interest basis was approximately $61.6 million. We added free cash in
the amount of $48.2 million and determined that the market value of total equity, on a marketable minority interest basis was approximately $109.8 million. Using the option pricing method approach, this value was then allocated among the preferred
and common stock and applying a discount rate of 30% to account for the lack of marketability of our common stock. We concluded that the fair value of our common stock was&nbsp;$0.05&nbsp;per share as December&nbsp;31, 2011. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2012 to November 2012 </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on January&nbsp;8, 2012,&nbsp;March&nbsp;14, 2012,&nbsp;June&nbsp;13, 2012,&nbsp;September&nbsp;19, 2012 and November&nbsp;8, 2012, with
each option having an exercise price of $0.05 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of December&nbsp;31, 2011, as well as
the objective and subjective factors outlined above. At each grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between December 2011 and the grant date and
whether those events and circumstances were part of the assumptions used in the December 2011 valuation. Our board of directors determined that there were no other events and circumstances that occurred between December 2011 and November 2012 that
were indicative of a significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at January&nbsp;8, 2012,&nbsp;March&nbsp;14, 2012,&nbsp;June&nbsp;13,
2012,&nbsp;September&nbsp;19, 2012 and November&nbsp;08, 2012 was $0.05 per share. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>December&nbsp;31, 2012 Valuation
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We used the PWERM method to value our common stock in the December&nbsp;31, 2012 valuation. We utilized the following
probability-weighted scenarios in to determine the equity value of our company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by second quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by fourth quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the middle of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we incorporated IPO scenarios as this strategy was considered a possibility based on
our stage of development and current market conditions. We believed that a second quarter 2013 IPO was unlikely given the tremendous effort required to file a registration statement and our lack of need for additional cash and therefore applied a 5%
probability to this scenario. We determined that an IPO either in the fourth quarter of 2013 or first quarter of 2014 was somewhat more likely due to the progression of our lead product candidates and therefore applied a probability of 15% to each
of those scenarios. We determined that the likelihood of a merger or acquisition was low based on the timing of availability of key clinical data and assigned a probability of 10% to that scenario. We determined that given our relatively low need to
raise capital as a result of our collaboration agreements and anticipated milestone payments, the scenario most likely to occur would be to remain a private company and therefore assigned a probability of 55% to that scenario. We concluded that
after applying a discount rate of 25.0% for lack of marketability, the value of our common stock as December&nbsp;31, 2012 was $0.08 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Option Grants from January 2013 to March 2013 </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors granted options to purchase common stock on January&nbsp;6, 2013 and March&nbsp;8, 2013, with each option having an
exercise price of $0.08 per share. In establishing this exercise price, our board of directors considered input from management, including the valuation we conducted of our common stock as of December&nbsp;31, 2012, as well as the objective and
subjective factors outlined above. At each grant date, our board of directors considered the events and circumstances most likely to affect the value of our common stock that occurred between December 2012 and the grant date and whether those events
and circumstances were part of the assumptions used in the December 2012 valuation. Our board of directors determined that there were no other events and circumstances that occurred between December 2012 and March 2013 that were indicative of a
significant change in the fair value of our common stock. Based on these factors, our board of directors determined that the fair value of our common stock at January&nbsp;6, 2013 and March&nbsp;8, 2013 was $0.08 per share. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>March&nbsp;31, 2013 Valuation </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Due to the market conditions for IPOs of biotechnology companies, we determined that obtaining a valuation of our common stock on a quarterly rather than annual basis was warranted in 2013. In the first
of our quarterly valuations, we used the PWERM method to value our common stock in the March&nbsp;31, 2013 valuation. We utilized the following probability-weighted scenarios in to determine the equity value of our company: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:29pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Scenario</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Probability</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by fourth quarter 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IPO by first quarter 2014</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A merger or acquisition by third quarter 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remain private through the end of 2015</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In this valuation, we believed that the possibility of a fourth quarter 2013 IPO or a first quarter 2014
IPO were equal, given that only two biotechnology companies had successfully completed IPOs from December 2012 to our board meeting in March 2013. Therefore we applied a 20% probability to each of those scenarios. We determined that the likelihood
of a merger or acquisition was low based on the timing of availability of key clinical data and assigned a probability of 15% to that scenario. We determined that given our relatively low need to raise capital as a result of our collaboration
agreements and anticipated milestone payments, the scenario most likely to occur would be to remain a private company and therefore assigned a probability of 45% to that scenario. We concluded that after applying a discount rate of 20.0% for lack of
marketability, the value of our common stock at March&nbsp;31, 2013 was $0.14 per share. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Three Months Ended
March&nbsp;31, 2012 and 2013 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Revenue </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development revenue for the three months ended March&nbsp;31, 2012 and 2013:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in collaboration revenue of $8.5 million from the three months ended
March&nbsp;31, 2012 to the same period in 2013 is primarily due to the conclusion of the teplizumab clinical trial related reimbursement from our former collaborator, Eli Lilly. Aside from reimbursing us for the continued monitoring expense of one
on-going trial, Eli Lilly&#146;s participation in the teplizumab development concluded in the first quarter of 2013. In addition, we have experienced a reduction in the amount of revenue from our government grants in the first quarter of 2013 as
compared to the same period in 2012. This is due primarily to the completion of a grant to study H5N1 influenza virus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and
Development Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development expense for the three months
ended March&nbsp;31, 2012 and 2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the three months ended March&nbsp;31, 2013, as compared to the same period in 2012, our research
and development expense decreased overall by $2.6 million. This was due primarily to the reduction in spending on teplizumab related clinical development as we ended trial enrollment and began closing down the trials during this period. In addition,
we significantly reduced our CSLC related activities. These decreases were partially offset by an increase in spending on MGA271 and our various DART-based product candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a
comparison of our general and administrative expense for the three months ended March&nbsp;31, 2012 and 2013: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">General and administrative expense for the three months ended March&nbsp;31, 2013 was $0.3 million higher
than the same period in 2012 primarily due to an increase in patent filing and related legal expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Results of Operations for the Years
Ended December&nbsp;31, 2011 and 2012 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Revenue </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development revenue for the years ended December&nbsp;31, 2011 and 2012:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Revenues:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Revenue from collaborative research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant revenue</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total revenues</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration revenue was $12.6 million higher for the year ended December&nbsp;31, 2012
compared to the year ended December&nbsp;31, 2011 primarily due to two Servier collaborations signed in late 2011 and late 2012. Grant revenue decreased as our contract with the U.S. government to develop a monoclonal antibody for the treatment of
West Nile Virus ended in September 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Research and Development Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a comparison of our research and development expense for the years ended December&nbsp;31, 2011 and 2012:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART-based product candidates</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Other discovery and pre-clinical programs, collectively</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total research and development expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expenditures in research and development increased by $4.3 million overall from the year ended
December&nbsp;31, 2011 to the year ended December&nbsp;31, 2012. This was due to the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased spending in support of the MGA271 Phase 1 clinical trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased spending on toxicology related studies and increased efforts on our DART-based product candidates as a result of additional collaborations;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Despite ceasing enrollment on teplizumab-related clinical trials, we continued to follow the patients for an additional 18 months and closed down the
trials in late 2012. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">These increases were partially offset by: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Completion of our contract with the U.S. government to study West Nile Virus that resulted in a reduction in spending; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reduced spending on our CSLC efforts. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>General and Administrative Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following represents a
comparison of our general and administrative expense for the years ended December&nbsp;31, 2011 and 2012: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="6" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Increase/(Decrease)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars&nbsp;in&nbsp;millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General and administrative expense</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)%&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The decrease in general and administrative expense of $0.7 million is due primarily to
reduced patent filing and related legal expense, which was partially offset by an increase in the amount of bonuses paid in the year ended December&nbsp;31, 2012. Additionally, we realized a savings from a consolidation of personnel from three to
two facilities in Rockville, Maryland. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Cash Flows </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table represents a summary of our cash flows for the years ended December&nbsp;31, 2011 and 2012 and the three months ended March&nbsp;31, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2011</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2012</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2013</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(dollars in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net cash provided by (used in):</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(0.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Net increase (decrease) in cash and cash equivalents</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Operating Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and perform toxicology studies. The differences between the year ended December&nbsp;31,
2011 and 2012 were primarily due to the upfront fees received from our collaborators. The primary difference between the three months ended March&nbsp;31, 2012 and 2013 was due to the recognition of upfront fees and accounts receivable due from our
collaborators. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Investing Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Net cash used in investing activities in all periods was primarily due to the acquisition of additional lab equipment needed to further our research and development activities. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Financing Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other than stock option exercises, we had no financing activity in the three months ended March&nbsp;31, 2013 or 2012 and in the year ended December&nbsp;31, 2012. However, during the year ended
December&nbsp;31, 2011 we sold 18.4&nbsp;million shares of Series D-2 preferred stock to our collaborators for net proceeds of $12.0 million. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since our inception through March&nbsp;31, 2013, we have raised an aggregate of $541.0 million to fund our operations. Of this total amount, we have received $151.3 million from the sale of preferred
stock, $335.6 million from our collaborators, including payments in the form of upfront, milestone and annual maintenance payments and reimbursement for research and development services performed, and $54.1 million from government grants and
contracts. As of March&nbsp;31, 2013, we had $43.5 million in cash and cash equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to our existing cash and
cash equivalents, we expect to continue to receive additional reimbursement from our collaborators for research and development services rendered, additional milestone payments, annual license maintenance payments and grant revenue. However, our
ability to receive these milestone payments is dependent upon our ability to achieve certain levels of research and development activities and is therefore uncertain at this time. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and commercialize one or more of our product candidates. As we
are currently in the clinical trial stage of development, it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as
well as additional clinical trials and pre-clinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our
efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Based upon our current operating plan, we anticipate that the net proceeds from this offering, together with our existing
cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 18 months. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contractual Obligations and Contingent Liabilities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table represents future minimum operating lease payments under noncancelable operating leases as of March&nbsp;31, 2013: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR STYLE="visibility:hidden; line-height:0pt; color:white">
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD nowrap><FONT STYLE="Times New Roman" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Less&nbsp;than&nbsp;1&nbsp;year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>1&nbsp;to&nbsp;3&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>3&nbsp;to&nbsp;5&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>More&nbsp;than&nbsp;5&nbsp;years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(in millions)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Operating Leases</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our current obligations and contingent liabilities are limited to the operating leases at our three
facilities, including two in Rockville, Maryland and one in South San Francisco, California. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Off-Balance Sheet Arrangements
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have never entered into any off-balance sheet arrangements, as defined under the rules and regulations of the
Securities and Exchange Commission. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Tax Loss Carryforwards </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are already subject to Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of
$94.9 million and research and development tax credit carryforwards of $21.8 million available. Future changes in stock ownership, including resulting from this offering, may also trigger an ownership change and, consequently, another
Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance.
As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in
increased future cash tax liability to us. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Accounting Pronouncements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May&nbsp;2011, FASB issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve common fair value measurements and disclosure
requirements in U.S. GAAP and International Financial Reporting Standards, or IFRS. The amendments in ASU No.&nbsp;2011-05 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRS. Consequently, the amendments change
the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years, beginning after December&nbsp;15, 2011. The
adoption of this amendment did not have a material impact on our consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The amendments in ASU No.&nbsp;2011-05 require that all nonowner
changes in stockholders&#146; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and
its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of comprehensive income. This amendment is effective for fiscal years
beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on our consolidated financial statements for the year ended December&nbsp;31, 2012. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We evaluated all ASUs through the date the consolidated financial statements were issued and
believe that the adoption of these will not have a material impact on our consolidated financial statements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Quantitative and Qualitative
Disclosures about Market Risk </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our primary objective when considering our investment activities is to preserve capital in
order to fund our operations. As of March&nbsp;31, 2013, we had cash and cash equivalents of $43.5 million, of which $29.0 million was invested in money market funds. Our primary exposure to market risk is related to changes in interest rates and
our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies and money market instruments. We do not believe that our cash and cash equivalents have significant risk. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_10"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a
clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary
suite of next-generation antibody technology platforms, which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology
and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. We create both differentiated molecules that are directed to novel cancer targets, as well as &#147;bio-betters,&#148;
which are drugs designed to improve upon marketed medicines. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product candidates and enter into several strategic collaborations with
global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of these collaborators to advance the development of our product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have three versatile, proprietary technology platforms consisting of: (1)&nbsp;our Dual Affinity Re-Targeting, or DART, platform,
which enables the targeting of multiple antigens or cells by using a single molecule with an antibody-like structure, and also includes the ability to recruit any T cell in a patient&#146;s body to destroy targeted cancer cells; (2)&nbsp;our Fc
Optimization platform, which enhances the body&#146;s immune system to mediate the killing of cancer cells through a mechanism called antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy
targets such as tumor cells; and (3)&nbsp;our Cancer Stem-like Cell, or CSLC, platform, which provides a unique discovery tool to identify cancer targets shared both by tumor-initiating cells and the differentiated cancer cells derived from them.
These versatile technology platforms can be applied in combination with one another to custom-design an antibody or antibody-derived molecule that is optimized to treat a specific disease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Antibodies, which are proteins produced by specialized cells of the body&#146;s immune system usually in response to foreign substances,
such as bacteria and viruses, or to cancer cells, serve as the primary resource for our product candidates. Many of our cancer product candidates are derived from our library of over 1,900 purified antibodies. Our antibodies are targeted to more
than 70 different antigens, or components of the foreign substance that induce the production of antibodies, expressed on the surface of cancer cells. In addition, we continue to generate new antibodies for our library using our proprietary CSLC
lines and soluble protein antigens. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initially select a specific antibody based on its functional properties related to a
disease target as well as its distribution on tissues in the body. We then utilize one or more of our technology platforms for engineering and optimizing our product candidate. We believe our approach allows us to take advantage of the enhanced
properties of an engineered antibody or antibody-derived molecule to kill cancer cells and to interfere with autoimmune diseases more effectively than a wild type, or non-engineered, monoclonal antibody. Our methods for improving the effectiveness
of antibodies include the following: enhancing the body&#146;s immune system, targeting multiple antigens on the surface of the same target cell, increasing the strength of the binding of an antibody to its antigen targets, and reducing the
likelihood of an unwanted immune response to the antibody or antibody-derived molecule. We believe our differentiated product candidates have the potential to provide new approaches to treat cancer, autoimmune disorders and other complex diseases.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product
candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. We believe the profile of our compounds provides us with the flexibility to pursue either monotherapy or combination
therapy, depending on disease characteristics, current standards of care, and overall safety, tolerability, and efficacy of specific regimens. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below depicts the current status of our product candidates: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754313new.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>, also known as MGAH22, is a monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal, bladder
and other cancers. HER2, or human epidermal growth factor receptor 2, is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to enhance the
antibody&#146;s ability to kill tumor cells expressing lower levels of HER2 than that of currently approved anti-HER2 agents (such as Herceptin) and also to increase margetuximab&#146;s ability to kill tumor cells through ADCC. We designed
margetuximab to benefit a large sub-group of patients, which represents 80% or more of the overall population whose Fc receptors, or Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, expressed on immune cells bind less effectively to currently
available antibodies that have not been optimized by our technology. Margetuximab represents a new class of bio-betters that may potentially help larger HER2+ patient populations than those treated with current HER2 therapies, as well as improve the
outcomes for patients who would be eligible for other HER2 targeted drugs and drug candidates. Phase 1 data from our open-label, dose escalation trial of margetuximab presented at the June 2013 Annual Meeting of the American Society of Clinical
Oncology, or ASCO, demonstrated anti-tumor activity had been observed at a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated (frequently including with other anti-HER2 agents). We
currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase 2/3 potential registration clinical trial in advanced gastroesophageal cancer in 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules which are involved in immune
regulation, and is over-expressed on a wide variety of solid tumor types. MGA271 represents one of the few novel molecules that may provide relief from immune checkpoint inhibition by releasing a restraint, or brake, on the anti-tumor immune
response. Inhibition of immune checkpoints has been shown to have powerful anti-tumor effects in several solid tumor types. For example, in presentations by others at ASCO and in publications in the <I>New England Journal of Medicine,</I> complete
or partial tumor regression was observed in patients with certain cancers who participated in clinical trials of antibodies targeting CTLA4, PD-1 and PD-L1, which are also members of the B7 family or their associated checkpoint receptors on T cells.
We have engineered MGA271 to utilize the same Fc Optimization enhancements that we incorporated in margetuximab, and to target the over-expression of B7-H3 on differentiated tumors and CSLCs, as well as on the supporting tumor vasculature and
underlying tissues. MGA271 is designed to destroy all of these components of the cancer in addition to reducing its inhibitory properties on T cells. We have initiated a Phase 1 clinical trial that we expect to complete by the end of 2014. We plan
to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006 </I>is a humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor, or IL3R, alpha chain is expressed on
leukemia and leukemic stem cells, but not on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In pre-clinical studies, we have demonstrated the ability of MGD006 at extremely low doses to recruit, activate, and
expand T cell populations to eliminate leukemia cells. We expect to commence a Phase 1 clinical trial of MGD006 in the first half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein gpA33 and CD3. gpA33 is expressed on gastrointestinal tumors,
including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells and CSLCs in pre-clinical experiments. We expect to commence a Phase 1 clinical trial of
MGD007 in the second half of 2014. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We pursue a balanced approach between product candidates that we develop
ourselves and those that we develop with our collaborators. Under our current strategic collaborations we have received approximately $101 million in non-equity funding over the three year period ended March&nbsp;31, 2013. Under these agreements we
are entitled to receive substantial milestone and other payments, including over $100 million of potential payments that we believe are likely to be received by the end of 2015, assuming all of our collaboration programs advance as currently
contemplated. Our collaborators include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an
exclusive license to develop and commercialize MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option grant fee and may be eligible to receive up to approximately $420
million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for, and successfully commercializes an MGA271 licensed product. This total includes a $10
million milestone payment we expect to receive in the third quarter of 2013 based upon dosing the first patient in a planned expansion cohort in our Phase 1 clinical trial of MGA271. In the event Servier exercises its option, Servier must pay a
license grant fee, which we estimate to be $30 million, based on the number of different indications represented within the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In September 2012, we entered into a second agreement with Servier and granted it options to obtain three
separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART-based molecule, in all countries other than the United States, Canada, Mexico, Japan,
South Korea and India. We received a $20 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if
Servier exercises all three of its options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, including $5 million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In
addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, under both
agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its territories. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We
are further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and sales milestone payments if Gilead exercises all four
of the options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are also eligible to receive tiered royalties on the net
sales at percentages ranging from the high single digits to the low double digits, subject to reductions in specified circumstances. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules
which may span multiple therapeutic areas. We granted Boehringer an exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a
third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to $210 million for each of the DART programs under this agreement. Boehringer
provides funding for our internal and external research costs and is required to pay us mid-single digit royalties on product sales. Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical,
development and sales milestone payments that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is
required to pay us mid-single digit to low double digit royalties on product sales. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this program in October 2013.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently manufacture all of the drug substance for research and development efforts for all of our
product candidates in-house. Drug substance for all of our clinical trials is manufactured using current good manufacturing practices, or cGMP, at our manufacturing facility, located in Rockville, Maryland. We contract with vendors to provide fill
finish manufacture of drug product. We currently have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. We intend to enter into agreements with contract
manufacturing organizations to supplement our clinical supply and internal capacity as we advance additional pre-clinical candidates into clinical development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our goal is to be a leader in the discovery, development and
commercialization of antibody-based therapeutics for the treatment of patients with cancer, autoimmune disorders and other complex diseases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Key elements of our strategy to achieve this goal are to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Rapidly and concurrently advance our clinical oncology product candidates in multiple tumor types. </I>We intend to pursue the fastest feasible
pathways to approval and to address large, underserved markets. We are developing product candidates that we believe could address disease specific challenges which are not currently being met by existing therapies. We are currently enrolling a
Phase 2a clinical trial of margetuximab in metastatic breast cancer for which we expect to have results in 2014. We anticipate commencing a Phase 2/3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in 2014.
We are currently enrolling the dose-expansion portion of a Phase 1 clinical trial of MGA271 as a single-agent in the treatment of 45 patients with solid tumors, including: 15 patients with melanoma; 15 patients with prostate cancer and an additional
group of 15 patients with other solid tumor types. Servier has indicated that it intends to evaluate MGA271 in up to 90 additional cancer patients representing additional types of cancers beginning in the fourth quarter of 2013. We intend to assess
and prioritize future indications for MGA271 clinical trials based on data from these cohorts and determine the best path forward to potential commercialization. In addition, we are currently optimizing multiple DART therapeutics as candidates for
clinical development. We anticipate that we will begin Phase 1 clinical trials of MGD006, our first DART candidate, in the first half of 2014, and MGD007, our second DART candidate, in the second half of 2014. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Leverage collaborative relationships. </I>We have multiple programs in development under our collaborations and are working closely with our
collaborators to advance these programs. We believe that these </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
collaborations help to validate and rapidly advance our discovery efforts, technology platforms, and product candidates while providing significant funding to advance our pipeline and access the
development and commercial expertise of our collaborators. To facilitate the capital-efficient development and commercialization of our proprietary programs, we intend to enter into additional collaboration agreements with biopharmaceutical
companies. We anticipate that we would structure these collaborations in ways that would allow us to retain development and commercialization rights in key markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Create new product candidates that combine the potency and target selectivity of our DART and Fc Optimization technologies with small molecule and
toxin conjugation technologies</I>. We are working with several companies to combine their proprietary linkers and drug conjugates with our monoclonal antibodies. We believe that such linkers and drug conjugates can be combined with the selective
targeting properties of our DART technology and the enhanced immune activities of our Fc Optimization technology. Our goal is to identify and further develop new clinical candidates, either antibody-drug conjugates, or ADCs, or DART-drug conjugates,
through these research efforts. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Establish commercialization and marketing capabilities in the United States</I>. We have retained commercialization rights in the United States for
our clinical stage programs as well as the three DART programs that we are developing in collaboration with Servier. We intend to build a targeted specialty sales force and marketing capabilities in the United States to commercialize our product
candidates that receive regulatory approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Strengthen our leadership position in fully integrated antibody engineering and development capabilities. </I>We have built a powerful and fully
integrated set of capabilities that are critical to our ability to discover, optimize and develop antibody-based therapeutic product candidates in a rapid and efficient manner. We intend to build on our technology platforms, methods and know-how
that comprise our capabilities in order to expand our product pipeline. Our goal is to file one or more new investigational new drug applications, or INDs, annually for the next several years. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Background </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Immune System and
Antibodies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The immune system, composed of both innate and adaptive elements, defends against invading pathogens such
as viruses, parasites, and bacteria, and provides surveillance against cancers. The adaptive immune system includes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B cells, which mature into plasma cells and produce antibodies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Helper T cells, including those that enable, or help, the B cells to produce antibodies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cytotoxic T cells, which can destroy tumor cells or cells infected with viruses. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">T cells and B cells (and the antibodies derived from the mature B cell) of this adaptive immune system respond to small structural
differences found, for example, on a cancer cell. This normally imparts exquisite specificity on these individual immune components. As a result, billions of different structural variants can be recognized by the adaptive immune system, but each
individual T cell or B cell or antibody can only bind and respond to a single structure or molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As shown in the
following illustration, the antibody is a Y-shaped molecule that has two identical variable regions at the tip of the arms of the antibody (Fab region), which bind to antigens, and a constant region (Fc), as its opposite end that binds to
F<I>c</I><I>y</I>Rs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Monoclonal Antibody Structure </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-right:21%" ALIGN="right">


<IMG SRC="g5754314.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An antibody&#146;s structure is amenable to engineering either the variable regions to improve its
strength of target recognition or affinity, or the constant regions to modify its engagement and collaboration with other components of the immune system, or both. The two variable region arms naturally target the same antigen; however, they can be
artificially engineered to target two different antigens, allowing the creation of a bi-specific antibody. The Fc region can bind, recruit and activate immune cells to amplify the immune response to targets bound by the variable region of the
antibody molecule. The Fc region can be modified to enhance the engagement with other immune cells and increase the potency of the immune response. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Therapeutic monoclonal antibodies are typically derived from natural antibodies and are obtained from immune cells of mammals that have been immunized with a desired antigen and are all clones of the
unique parent cell. The antibody&#146;s ability to bind specifically to a target or antigen is also referred to as its specificity. Using this mechanism, antibodies can tag foreign substances for attack by other immune system cells or neutralize the
targets directly. In treating diseases such as cancer, researchers find antigens specific to cancer cells and create antibodies that bind those antigens to use the body&#146;s immune system to destroy these cancer cells. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Monoclonal antibodies are typically produced in mice and although they are relatively easy to generate, they can have drawbacks as
targeted therapeutics. The major drawback is that a mouse monoclonal antibody is recognized by the human immune system as a foreign target and therefore, the immune system attacks the antibody, rendering it useless against its intended target. Many
advances have been made to genetically engineer and humanize monoclonal antibodies. In addition, fully human antibodies can be created, which also significantly reduce newly generated immune responses in patients treated with monoclonal antibodies.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancer </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other
parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to
tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes
known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in
other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cancer is the second leading cause of death in the United States, exceeded only by heart disease, and accounts for almost one of every
four deaths. The American Cancer Society estimates that in 2013 there will be approximately 1.6&nbsp;million new cases of cancer and approximately 580,000 deaths from cancer. The National </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Institutes of Health estimates that the direct medical cost of cancer of all types, including solid tumors, in the United States in 2010 was approximately $125 billion and according to IMS Health
the amount spent in the United States on drugs to treat cancer exceeded $23 billion in 2011. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Solid Tumors &#150; Incidence
and Therapies </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information about selected solid tumor types for which we are developing, or
may develop, therapeutic product candidates. The estimated U.S. annual incidence and five-year relative survival rates are based on information from the American Cancer Society in 2013. Relative survival compares survival among cancer patients to
that of people not diagnosed with cancer who are of the same age, race and sex. It represents the percentage of cancer patients who are alive after a designated time period relative to persons without cancer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Solid Tumors </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="65%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tumor Type</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S.<BR>Annual<BR>Incidence</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Five-year</FONT><BR>Relative<BR>Survival<BR>Rate</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Selected Marketed Therapies</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prostate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">238,590</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">~100</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">sipuleucel-T (Provenge); radium 223 dichloride (Xofigo); docetaxel (Taxotere); abiraterome (Zytiga)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breast</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">232,240</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">ado-trastuzumab emtansine (Kadcyla); trastuzumab (Herceptin); lapatinib (Tykerb); docetaxel (Taxotere); paclitaxel (Taxol, Abraxane); capecitabine (Xeloda); anastrazole
(Arimidex); letrozole (Femara); exemestane (Aromasin)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lung</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">228,190</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); erlotinib (Tarceva); crizotinib (Xalkori); pemetrexed (Alimta)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Colorectal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">142,820</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); ziv-aflibercept (Zaltrap); cetuximab (Erbitux); panitumumab (Vectibix)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Melanoma</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76,690</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">vemurafenib (Zelboraf); ipilimumab (Yervoy)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bladder</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,570</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">doxorubicin hydrochloride (Adriamycin); cisplatin</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kidney</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65,150</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">bevacizumab (Avastin); axitinib (Inlyta); everolimus (Afinitor); temsirolimus (Torisel)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pancreatic</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,220</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">gemcitabine (Gemzar); erlotinib (Tarceva); protein-bound paclitaxel (Abraxane)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ovarian</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22,240</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">paclitaxel (Taxol); topotecan (Hycamtin); etoposide (Etopophos); docetaxel (Taxotere); gemcitabine (Gemzar)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gastroesophageal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21,600</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">capecitabine (Xeloda); trastuzumab (Herceptin)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the marketed therapies listed above, there are many generic chemotherapies and regimens
commonly used to treat these cancers. Although the various marketed therapies and regimens provide benefits to some patients when given as monotherapies or in combination with other therapies, each has efficacy and adverse event limitations and none
of them are successful in treating all patients. The level of morbidity and mortality from these cancers remains high. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Hematological Malignancies &#150; Incidence and Therapies </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth information about the hematological malignancies for which we are developing, or may develop, therapeutic product candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Hematological Malignancies </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="45%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Tumor Type</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>U.S.<BR>Annual<BR>Incidence</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Five Year<BR>Relative<BR>Survival&nbsp;Rate</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Selected Marketed Therapies</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acute myeloid leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,590</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">daunorubicin (DaunoXome); doxorubicin hydrochloride (Adriamycin); cyclophosphamide; cytarabine; vincristine sulfate</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Myelodysplastic syndromes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,673</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;<BR>&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Highly<BR>variable</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;<BR>&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">decitabine (Dacogen)</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acute lymphocytic leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,070</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">dasatinib (Sprycel)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hairy cell leukemia</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,199</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">cladribine; pentostatin; rituximab (Rituxan)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Currently Available Cancer Treatments </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. A cancer patient often receives
treatment with a combination of these methods. For patients with localized disease, surgery and radiation therapy are particularly effective. Systemic drug therapies are generally used by physicians in patients who have cancer that has spread beyond
the primary site or cannot otherwise be treated through surgery. The goal of these therapies is to damage and kill cancer cells or to interfere with the molecular and cellular processes that control the development, growth and survival of cancer
cells. In many cases, drug therapy entails the administration of several different drugs in combination. Over the past several decades, drug therapy has evolved from non-specific drugs that kill both healthy and cancerous cells, to drugs that target
specific molecular pathways involved in cancer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cytotoxic Chemotherapies </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The earliest approach to pharmacological cancer treatment was to develop drugs, referred to as cytotoxic drugs, which kill rapidly
proliferating cancer cells through non-specific mechanisms, such as disrupting cell metabolism or causing damage to cellular components required for tumor survival and rapid growth. While these drugs have been effective in the treatment of some
cancers, cytotoxic drug therapies act in an indiscriminate manner, killing healthy cells along with cancerous cells. Due to their mechanism of action, many cytotoxic drugs have a narrow dose range above which the toxicity causes unacceptable or even
fatal levels of damage and below which the drugs are not effective in eradicating cancer cells. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Targeted Therapeutics
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The next approach to pharmacological cancer treatment was to develop drugs, referred to as targeted therapeutics,
including monoclonal antibodies, that target specific biological molecules in the human body that play a role in rapid cell growth and the spread of cancer. Included in this category are small molecule drugs as well as large molecule drugs, also
known as biologics. With heightened vigilance and new diagnostic tests, targeted therapies (including monoclonal antibodies such as Herceptin, Rituxan and Avastin as well as small molecules such as Nexavar and Tarceva), have resulted in improvements
in overall survival for many cancer patients. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Next Generation Antibody-based Therapeutics for Cancer </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">While targeted antibody therapeutics have been highly successful in treating various cancers, the therapeutic effects of many such
therapies are often relatively transient. Acquired resistance to cancer therapies remains a significant clinical problem with patients frequently relapsing and the tumors metastasizing to distant organs. The significant need for improvement in the
treatment of cancer through antibody-based therapies is driving the growing focus on next-generation antibody-based therapies. Opportunities to create next-generation antibody based therapeutics lie in several technology advances including:
antibodies that target multiple antigens, Fc-optimization, and ADCs. Multi-specific antibodies and ADCs have the potential to increase efficacy for cancer treatments and reduce systemic toxicity. Fc Optimization may enable modification of the
antibody to enhance the immune system&#146;s response and augment the therapeutic potential of the antibody, and may increase its half-life, which can potentially lead to less frequent dosing (a competitive advantage for injectables) and a lower
cost of goods. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Growth of the Biologics Market </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Over the last 20 years, recombinant biologic therapeutic drugs, including monoclonal antibodies, the largest subclass of recombinant
biologics, have had a dramatic impact on cancer therapy. The improvement of engineering technologies, efficacy and safety of biologic drugs have driven significant market growth, with worldwide sales in 2011 of $157 billion according to data from
the IMS Institute for Healthcare Informatics. Data from La Merie, a business intelligence firm, indicates that therapeutic antibody products represent approximately 52% of total biologic drug sales, with 2012 global sales of approximately $65
billion, an increase from approximately $22 billion in 2006. Approximately 40 antibody product candidates have been approved by the FDA and international regulatory authorities since the first approval in 1986, and the three largest selling cancer
drugs are monoclonal antibodies, Rituxan, Herceptin and Avastin, which had 2012 worldwide sales of approximately $7.1 billion, $6.3 billion and $6.1 billion, respectively. Today, more than 300 monoclonal antibodies are in various stages of clinical
development. According to a 2010 statistical analysis by Tufts University, antibody product candidates have shown a 2.5 times higher probability of successful clinical development as compared to small-molecule drugs. Moreover, it is widely accepted
that it is more challenging to create and develop approved biosimilars to antibodies, which provides for longer product life cycles. To date, there have been no generic antibodies approved in the United States or the European Union. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Our Platforms for Creating Next-Generation Antibody-based Therapies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design highly targeted antibody-based product candidates. Our antibody-based
platforms consist of: DART, Fc Optimization, and CSLCs. Through these platforms, we have designed antibody-based product candidates that have the potential to improve on standard treatments by having: (1)&nbsp;multi-specificities; (2)&nbsp;increased
abilities to interact with the body&#146;s immune system to fight tumors; (3)&nbsp;capacity to bind more avidly to antigen targets: (4)&nbsp;increased potency; (5)&nbsp;reduced immunogenicity; or (6)&nbsp;the ability to target cancer cells which are
resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>DART Platform: Our
Proprietary Approach to Engineer Multi-Specific Antibodies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We use our DART platform to create derivatives of
antibodies with the ability to bind to multiple targets instead of a single target found in traditional monoclonal antibodies. Our current DART product candidates are bi-specific. An example of a bi-specific molecule is illustrated below:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754315new.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because cancer cells have derived ways to escape the immune system, we have created DART
molecules which improve upon the human immune system, by creating alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are
mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are multi-specific and capable of targeting multiple antigens or epitopes (i.e.,
specific part of antigen bound to the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bi-specifics and their inherent short half-lives, as well as the inefficiencies in
manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART
molecule. This results in a structure with enhanced manufacturability, long-term structural stability, and the ability to tailor the half-lives of the DARTs to their clinical needs. This engineered antibody-like protein has a very compact and stable
structure and enables the targeting of multiple different antigens within a single recombinant molecule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The DART platform
has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding, and antigen recognition. To date, we have produced over 100 different DART molecules and have completed numerous <I>in
vitro</I> and <I>in vivo</I> proof of concept studies on most of these molecules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe our DART platform may provide a significant advantage over current biological
interventions in cancer and autoimmune disorders by enabling a range of modalities, including those described below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>&nbsp;&nbsp;Redirected T Cell Activation and Killing.</I> In this version of the DART molecule,
we are enabling the cancer-fighting properties of the adaptive immune system to: (1)&nbsp;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&nbsp;enable the recruitment
of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right), and (3)&nbsp;trigger
T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body&#146;s T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific
T cells that are normally generated to kill a cancer cell. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the
compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, apparently contributing to the high level of target cell killing.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g575431dsp_075a.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>&nbsp;&nbsp;Modulation of receptor signaling. </I>In another configuration of the DART molecule,
we have taken advantage of the two (or more) different specificities engineered in a DART structure to bind not only to particular cells involved in autoimmune processes, such as autoimmune B cells, but also to usurp the immune checkpoint signaling
pathways programmed within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a checkpoint inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on
the immune system&#146;s B cells. Using a single DART molecule, we not only target two receptors with a single molecule, but also promote the interaction of these two receptors to interrupt the autoimmune response. This is critical because
interruption of the autoimmune B cell response cannot be achieved merely by using two separate antibodies. In this particular example, the activity of an immune checkpoint molecule, CD32B on B cells, is captured to curb a destructive immune
response.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g575431dsp_075b.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="middle"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;<I>&nbsp;&nbsp;Simultaneous targeting of multiple pathologic factors, such as cytokines and
growth factors and their receptors.</I> Targeting multiple soluble proteins or receptors that are important to the perpetuation of an autoimmune disease or generation of a cancer may create therapeutic synergies within a single DART molecule.
Examples of this DART include the targeting of different inflammatory cytokines, such as TNF-a, IL-1, and IL-6, involved in the pathogenesis of autoimmune diseases or those receptors contributing to the growth of cancers such as members of the EGFR
family including EGFR1, HER2 and HER3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g575431dsp_075c.jpg" ALT="LOGO">
</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Targeting multiple epitopes on a pathogen for enhanced neutralization and/or
clearance. </I>Infectious agents with slightly different genetic sequences or structures may perpetuate disease. Sometimes multiple variants may infect one individual and may evade the patient&#146;s normal immune responses. Creating DARTs that
eliminate multiple infectious variants of a virus or multiple toxins produced by a bacterium could be an advantage for prevention or treatment. Examples of this include targeting the major genetic and serological forms of dengue virus, the cause of
a major viral disease transmitted by mosquitoes, quasi-species of HIV, or different bacterial toxins derived from pathogenic clostridium species.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">


<IMG SRC="g575431dsp_075d.jpg" ALT="LOGO">
</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, we have the ability to tailor a DART molecule&#146;s valency (number of binding
sites), the strength by which the binding sites attach to its targets, and its half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is incorporated in a DART, changes can be included that can modulate the
DART&#146;s engagement with different immune cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have developed proof-of-concept data and are developing specific
product candidates using this technology, including MGD006, MGD007 and MGD010. We have been able to produce DART molecules in both bacterial and mammalian expression systems. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">To enhance the body&#146;s immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with
immune effector cells. Such interaction enhances the body&#146;s immune ability to mediate the killing of cancer cells through ADCC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ADCC </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431dsp_076a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Fc region mediates the function of certain antibodies by binding to different activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the
activating Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs and with a reduced affinity to the inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs, we have been able to impart a more effective immune response, and improve effector
functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have established a proprietary platform to engineer, screen, identify and test antibodies&#146; Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that
express human Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. These mice can be used for <I>in vivo </I>testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we have successfully incorporated our Fc variants in our lead product candidates, margetuximab and MGA271. We have pre-clinical
data demonstrating that these Fc variants have substantially improved the antibody&#146;s therapeutic effects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Cancer Stem-like Cell
Platform: Our Proprietary Approach to Discover Cancer Targets </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our CSLC platform provides new approaches to discover
and identify cancer targets that are unresponsive to current cancer therapies. Cancer stem cells represent important potential targets in oncology drug development because they are theorized to be the basis for tumor re-growth and metastasis and are
refractory to much standard chemotherapy. Therefore, the ability to specifically target and destroy CSLCs could potentially address an unmet medical need in many hard-to-treat cancers today. Using our CSLC platform, we can create antibodies that
target and kill CSLCs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building on our expertise in growing stem cells from normal tissues using proprietary media
and culture conditions, we have produced CSLCs from primary human tumor tissues. These CSLCs have been generated <I>in vitro</I> from a range of solid tumors and many have demonstrated tumor growth and differentiation <I>in vivo</I>. We believe that
this technology holds great promise in creating the next generation of oncology therapeutics that target both differentiated tumor cells and their precursor cells which traditionally have been resistant to conventional chemotherapy and radiation
therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our strategy has been to generate CSLCs from a range of primary tumors, including those derived from the colon, lung
and ovary. We analyze and characterize the CSLCs for the following: (a)&nbsp;ability for self-renewal, (b)&nbsp;ability to form tumors <I>in vivo</I> that differentiate with the expected histological characteristics, and (c)&nbsp;genetic and protein
stem cell marker expression profiles. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To date, we have created novel antibodies that target antigens on both CSLCs and bulk
differentiated tumor cells, which are derived from the CSLCs. In addition to their value for identifying potential immune-based therapeutics, other opportunities include their use in small molecule compound screening and diagnostic applications.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have generated over 1,900 monoclonal antibodies that we have screened by immunohistochemistry, or IHC, for lower-binding
to normal, non-malignant tissues. Many of these antibodies have been characterized for binding to primary tumors and cancer cell lines and we are developing the most promising of these antibodies into product candidates. This collection of
antibodies is selective for both validated and novel cancer targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have utilized our CSLC technology to generate or
characterize the antibodies we use in our MGA271 and MGD007 product candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Product Candidate Pipeline </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have two oncology product candidates in clinical development. Additionally, we have several proprietary product candidates in
pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Margetuximab:
Fc-Optimized Antibody for HER2-expressing Solid Tumors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab, or MGAH22, is an Fc-optimized, monoclonal antibody that targets and binds to the HER2 protein on cancer cells and is
intravenously administered in order to kill tumor cells or inhibit tumor cell growth. We are developing margetuximab as an improved, more potent, anti-HER2 treatment for a variety of HER2-expressing tumors such as breast, gastroesophageal and
bladder cancer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An important mechanism of anti-HER2 monoclonal antibody action is the mediation of ADCC. In ADCC, the
anti-HER2 antibody binds to tumor cells and then recruits immune cells, such as macrophages, through their Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>Rs. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R-mediated mechanisms play a critical part
in the effectiveness of targeted tumor antibodies including anti-HER2 antibodies. Therefore, we have optimized the important Fc region of MGAH22 and thereby improved the cell-killing properties of margetuximab, compared to current anti-HER2
therapies (including trastuzumab). Specifically, we increased binding to activating receptors and decreased binding to the inhibitory receptor on immune effector cells. As a result, we believe margetuximab has the potential to be effective in a much
broader population than the approximately 25% of breast cancer patients treated with trastuzumab today and may overcome resistance in populations who no longer respond to trastuzumab. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The HER2 gene and receptor have an important role in normal cell growth and differentiation. When the HER2 gene has multiple copies,
which is referred to as gene amplification, it results in increased HER2 protein production. This causes cells to multiply in number and grow more rapidly than normal cells, contributing to the formation of cancer. HER2 gene amplification and
protein over-expression occurs in approximately 25% of women with breast cancer. The level of HER2 protein on tumors can be detected by IHC and is scored as 0, 1+, 2+ or 3+, where 3+ indicates the highest expression of HER2 positivity. Fluorescence
in situ hybridization, or FISH, testing is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
a method used to determine the number of HER2 gene copies that are in a tumor cell. Breast cancer patients with HER2 gene amplification and protein over-expression have a more aggressive disease,
greater likelihood of recurrence, poorer prognosis, and decreased survival compared to patients with HER2-negative breast cancer. Currently, anti-HER2 therapies are only approved for treating approximately 25% of all breast cancer patients whose
tumors overexpress HER2 at the 3+ level, or if 2+, when accompanied by HER2 gene amplification. As illustrated in the figure below, this population of 25% of breast cancer patients represents 60.5% of the 42% of all patients who are HER2+.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Breast Cancer Patients by HER2 Status </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g33s01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to study several patient populations in which we believe margetuximab, because of its
optimized structure, has the potential for particular benefit. The first populations being tested include breast and gastroesophageal cancer, but there is also potential to explore other HER2-expressing cancers such as bladder, ovarian and colon.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We presented data from our Phase 1 clinical trial of margetuximab at ASCO in June 2013. We expect to complete this clinical
trial by early 2014. We recently initiated enrollment in an exploratory Phase 2a clinical trial in patients with metastatic breast cancer whose tumors exhibit expression of the HER2 protein at the 2+ level by IHC and lack evidence of HER2 gene
amplification by FISH. We plan to initiate a Phase 2/3 clinical trial in patients with HER2+ gastroesophageal cancers that have progressed after standard first and second-line therapy. We expect to begin enrollment in this clinical trial in 2014 and
anticipate that such a trial should be concluded in approximately three years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Current Treatments for HER2-expressing Solid Tumors
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management of breast cancer is largely based on the stage, grade, hormone receptor status and type, and includes
surgery, radiation and drug therapy. Cytotoxic chemotherapies are a mainstay of metastatic breast cancer treatment, irrespective of hormone and HER2 status. Patients who have no detectable cancer after surgery are often given additional drug
treatment to prevent recurrence. This is known as adjuvant therapy. Some patients receive treatment before surgery to shrink the tumor. This is known as neoadjuvant therapy. While anti-HER2 therapies have initially been tested in patients with
metastatic cancer, often as single agents, benefit has been shown in the much larger population of patients treated earlier in adjuvant and neoadjuvant settings. We expect that this paradigm will also be true for margetuximab, but in a larger
population. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The management of gastroesophageal cancer is based on radical surgical resection of the
tumor, which when carried out at an early stage of disease may be curative. When surgical resection of the tumor is not possible, or the tumor recurs or metastasizes, chemotherapeutic agents are utilized. The incidence of gastroesophageal cancer has
been declining steadily since the 1930s, yet it remains a major cause of cancer death in the United States and a greater problem in the rest of the world. Gastroesophageal cancer is the fourth most common cancer in the world (989,000 new cases
diagnosed in 2008) and the second most common cause of cancer-related death in the world. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Several drugs directed at HER2 have been approved for the treatment of early and advanced stage breast cancer and advanced gastroesophageal cancer. Most patients treated with existing HER2 therapies, such
as trastuzumab (Herceptin), pertuzumab (Perjeta), lapatinib (Tykerb), and ado-trastuzumab emtansine (Kadcyla, also referred to as T-DM1), will either fail to respond or become resistant to continued treatment. In addition, existing HER2 therapies
are not effective in the treatment of patients who do not highly over-express HER2. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential Advantages of Margetuximab
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Margetuximab is an Fc-optimized, monoclonal antibody believed to mediate its therapeutic activity against HER2+ tumors
by a combination of mechanisms including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Modulation of the receptor signaling resulting in growth retardation or the induction of apoptosis, or cell death; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADCC and improved binding to immune cells to enhance destruction of HER2+ tumor cells; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Presentation of antigens by cells such as macrophages that engulf the tumor cells, digest them, and display the tumor antigens to other cells of the
immune system including T cells. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R mediated mechanisms play
a critical part in the activity of several antibodies including anti-HER2 antibodies. Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R sequences will differ among people and a single amino acid difference in an
Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R can significantly alter an antibody&#146;s Fc binding properties. Clinical data shows improved outcomes in metastatic breast cancer patients who have a higher binding form of an activating Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD16A, in response to treatment with chemotherapy plus trastuzumab. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table
below shows the difference in progression-free survival between patients treated with trastuzumab who have the higher-binding form of CD16A and those who have the lower-binding form of CD16A. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431dsp_079.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Knowing that approximately 80% of subjects express the lower-binding Fc<FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, we specifically optimized the Fc domain of margetuximab to enhance binding to the lower-binding form of CD16A. We believe margetuximab will have greater activity than trastuzumab and may overcome resistance
in populations of patients whose tumors do not respond, or no longer respond, to trastuzumab. In addition, the optimized Fc domain of margetuximab imparts reduced binding to the inhibitory Fc<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>R, CD32B, a
feature expected to further enhance the activating properties of margetuximab. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have conducted <I>in vitro</I> and <I>in
vivo</I> pre-clinical studies that support the superiority of margetuximab compared to trastuzumab. In these pre-clinical models, margetuximab exhibits enhanced anti-tumor activity against HER2-expressing tumor cell lines in <I>in vitro</I> ADCC
assays and in human tumor xenograft models in human CD16A+ transgenic mice. We have also demonstrated superior effects of margetuximab over trastuzumab in <I>ex vivo </I>studies using patient samples from the Phase 1 clinical trial. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Development of Margetuximab </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Based on the pre-clinical laboratory studies conducted with margetuximab, we assumed that margetuximab would have clinical benefit in patients with tumors not currently thought to be targets for
trastuzumab therapy, including those whose tumors express the HER2 protein at less than 3+ levels by IHC and lack evidence of HER2 gene amplification by FISH. We also assumed that margetuximab benefits would extend to patients bearing the
lower-binding form of CD16A. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 2a Metastatic Breast Cancer Study </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently enrolling a Phase 2a clinical trial to determine if margetuximab has sufficient activity in patients with metastatic
breast cancer who are not currently considered candidates for trastuzumab therapy to further evaluate margetuximab in this patient population. We are enrolling patients with metastatic breast cancer whose tumors exhibit expression of the HER2
protein at the 2+ level by IHC and lack evidence of HER2 gene amplification by FISH. This group of patients represents an unmet medical need which may be addressed by margetuximab. Margetuximab will be administered as a 6 mg/kg intravenous, or IV,
solution weekly on Days 1, 8, and 15 of each 28-day cycle. If fewer than two partial or complete responses are observed in the first 21 patients evaluable for response at the first tumor re-evaluation on day 22 of cycle 2 of treatment, no additional
patients will be enrolled and the trial will end. If two or more responses are observed at the first tumor re-evaluation on day 22 of cycle 2 of treatment, we will expand the clinical trial to include a total of 41 patients evaluable for response.
If five or more partial or complete responses are observed in these 41 patients, then we will consider margetuximab to have adequate activity in this patient population to justify additional clinical development. We are conducting this clinical
trial at six sites in the United States. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Anticipated Margetuximab Clinical Trials </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are planning a randomized Phase 2/3 clinical trial to evaluate the addition of margetuximab to standard cytotoxic chemotherapy
(irinotecan or paclitaxel) in the third line treatment of patients with advanced gastroesophageal cancers which have progressed after standard frontline and second-line treatment of advanced disease. The primary analysis will compare the overall
survival of patients randomized to chemotherapy plus placebo to the overall survival of patients randomized to chemotherapy plus margetuximab. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Other Anticipated Phase 2 Development </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We anticipate conducting exploratory
clinical trials in patients with other HER2 expressing malignancies. The design of these clinical trials will be informed by the results of the ongoing Phase 2a clinical trial in metastatic breast cancer. If the results of that clinical trial are
positive, then we will pursue a population of patients with HER2 2+ or 3+ tumors. Such a population would represent approximately one-third to one-half of patients with metastatic bladder cancer, and smaller proportions of patients with ovarian
cancer, endometrial cancer, and colon cancer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 Clinical Study Results </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 clinical trial is an open-label, multi-dose, single-arm, dose-escalation study conducted to define the safety profile and
pharmacokinetics, or PK, of margetuximab and to begin to explore the antitumor activity of margetuximab in patients with refractory HER2+ tumors. We enrolled a total of 34 patients in the dose escalation (0.1 to 6.0 mg/kg) and expansion (6.0 mg/kg)
phases of the trial. This patient population was heavily pre-treated with prior therapies, including 19 patients with other prior anti-HER2 therapies. In the absence of dose limiting toxicity, an additional cohort of patients was treated at the top
dose. We expect to complete this clinical trial in 2014. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During the Phase 1 clinical trial, a margetuximab dose of 6.0 mg/kg
has been well-tolerated in patients with refractory HER2+ tumors who were treated weekly for four weeks. Approximately one-third of patients received additional cycles of margetuximab treatment. Using margetuximab as a single agent, tumor response
was observed even in patients who had failed prior therapies including other anti-HER2 treatment. Responses to date included: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">unconfirmed partial response in one patient with mucoepidermoid carcinoma of the salivary gland treated at 1.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with breast cancer treated at 3.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with breast cancer treated at 6.0 mg/kg; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">confirmed partial response in one patient with a gastroesophageal junction tumor treated at 6.0 mg/kg; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">three patients with times to progression exceeding five months. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evidence of activity was seen at doses as low as 0.1 mg/kg weekly, to which a patient with metastatic breast cancer whose tumor had
progressed after two prior anti-HER2 therapies (trastuzumab and ado-trastuzumab emtansine) experienced stability of disease and time to progression that exceeded nine months. The percent reduction (below baseline) or increase (above baseline) in the
size of tumors from patients treated with different doses of margetuximab is shown below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431dsp_081.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The most frequent adverse events in the trial were infusion reactions, which we observed in
approximately 27% of patients on the day of infusion. Most of these events were mild or moderate in severity. Institution of pre-medications has reduced the incidence and severity of infusion-associated adverse events. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We assessed the <I>ex vivo</I> ADCC response of peripheral blood
mononuclear cells, or PBMCs, obtained from subjects in this Phase 1 trial. Each patient sample was divided and exposed separately to margetuximab and trastuzumab. Margetuximab outperformed trastuzumab in <I>in vitro</I> ADCC assays, reducing the
dose required to achieve equivalent cell killing and increasing total cell killing. The concentration of drug required to achieve a half maximal effect (EC</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">50</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">) on ADCC was much lower for margetuximab (mean 3.5 <U>+</U> 1.0 ng/ml) than trastuzumab (mean 40.7 <U>+</U> 17.1 ng/ml).
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGA271: Fc-Optimized Antibody for B7-H3-Expressing Solid Tumors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 is a humanized, Fc enhanced, monoclonal antibody
that targets B7-H3 expressing tumors and is intravenously administered in order to kill tumor cells or inhibit their growth. We are developing MGA271 to treat multiple solid tumors such as melanoma, glioblastoma, prostate cancer, and breast cancer.
We believe that targeting B7-H3 using MGA271 has significant potential to treat a variety of solid tumors because it incorporates multiple complementary mechanisms of action in one molecule. These potentially include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enhanced ADCC through Fc Optimization; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Targeting of both CSLCs and tumor cells; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opportunity to differentially target tumor vasculature and underlying supporting tissues; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Potential for enhanced anti-tumor immunity by blockade of T cell inhibition (inhibiting the inhibitor). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 has been engineered to have enhanced binding to CD16A. MGA271 also exhibits reduced binding to CD32B. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We initiated a Phase 1 clinical trial of MGA271 in patients with B7-H3 tumors in August 2011. We have completed the dose escalation
portion of this trial without exceeding a maximally tolerated dose, or MTD. We expect to commence an expansion phase in the third quarter of 2013, in which we will be enrolling patients and treating them at the highest dose tested during the dose
escalation portion of the trial. We also plan to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Role of B7 Family of
Immune Regulators, Including B7-H3, in Cancer </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The B7 family of cell surface molecules consists of structurally related
protein ligands that bind to receptors on lymphocytes and regulate immune responses. B7 homolog 3 (B7-H3) is a novel member of the B7 family of immune regulatory molecules. This family of molecules is an area of interest across the pharmaceutical
industry, and is being explored by companies including Amplimmune, Inc., or Amplimmune, AstraZeneca PLC, or AstraZeneca, Bristol-Myers Squibb Co., or Bristol-Myers, GlaxoSmithKline plc, or GSK, and Merck&nbsp;&amp; Co., or Merck. The chart below
describes our understanding of various B7 immune regulator targets and current marketed products and clinical stage product candidates addressing such targets. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>B7 Immune Regulator Family </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="50%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:81pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Antigen-Presenting&nbsp;Cell</FONT></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>T Cell</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Function</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Product or Product Candidates</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD80 or CD86 (B7-1 or B7-2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CTLA4</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ipilimumab (marketed by Bristol-Myers)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-CTLA4 (AstraZeneca, Phase 2)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD80 or CD86 (B7-1 or B7-2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD28</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">PDL1 or PDL2 (B7-H1 or B7-DC)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">PD1</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PD1 (Merck, Phase 2)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Anti-PD1 (Bristol-Myers, Phase 3)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PDL1 (Bristol-Myers, Phase 2)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PDL1/Fc fusion (GSK/Amplimmune, Phase 1)</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anti-PDL1 (Roche, Phase 2)</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7RP1 (B7-H2)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">ICOS</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMG 557 (Amgen/AstraZeneca, Phase 1)</FONT></TD></TR>
<TR BGCOLOR="#cccccc">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H3</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 (MacroGenics, Phase 1)</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H4</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H5 (VISTA)</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unknown</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inhibitory</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H6</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">NKp30</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Activating</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In our own analysis of fixed tumor microarrays representing more than 700 samples across
various tumor types including glioblastoma, thyroid, gastroesophageal, breast, pancreas, prostate, melanoma and ovarian cancers, we saw B7-H3 expression in approximately 70 &#150; 99% of tumor samples, with high expression (2+ or greater by IHC) in
most of these tumor types. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B7-H3 inhibits T cell activation and cytokine production. Other examples of inhibitors of T cell
activation include the immune check-point regulators PD1 and CTLA4. Anti-PD1 and anti-CTLA4 (e.g., ipilimumab) antibodies have shown therapeutic effects in patients with melanoma, renal cell carcinoma, and non-small-cell lung cancer and are being
tested in individuals with several other types of cancers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-Clinical Development of MGA271 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have evaluated the ability of MGA271 to mediate ADCC activity across multiple cancer types expressing varying levels of B7-H3 as
determined by flow cytometry. The cancer types tested included melanoma, lung cancer, prostate cancer, breast cancer, bladder cancer, and renal cancer cell lines. MGA271 mediated ADCC activity against all tumor lines that express B7-H3 at detectable
levels. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 exhibited anti-tumor activity in mouse models when administered approximately one week
after tumor cell implantation (as shown below), or after tumors were allowed to become fully established (approximately three weeks after implantation when tumors were approximately 300 mm</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">3</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> in volume). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-Tumor Efficacy of MGA271 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>in a Pre-clinical Model of Renal Cell
Carcinoma </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g79u13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cells from a renal cell carcinoma tumor line were implanted subcutaneously in immunodeficient mice that expressed
the lower-binding form of human CD16A. MGA271 was administered intravenously weekly at the indicated dose levels as shown by arrows above. All dosages of MGA271, including 0.1 mg/kg, inhibited tumor growth when compared to both control groups,
vehicle or lgG. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A repeat dose Good Laboratory Practice, or GLP, toxicology study was conducted in cynomolgus
monkeys to determine the potential toxicity of MGA271. MGA271 was well tolerated when administered by IV infusion at four weekly doses of up to150 mg/kg. The no observed adverse effect level was considered to be 150 mg/kg. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Clinical Development of MGA271 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have initiated a Phase 1 clinical trial that we expect to complete in 2014. We plan to initiate a Phase 2 clinical trial no later than early 2015. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Phase 1 Clinical Trial </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Phase 1 trial is an open-label, multi-dose, single-arm, multi-center, dose-escalation clinical trial. This trial includes patients with B7-H3-expressing tumors, such as prostate cancer, pancreatic
cancer, melanoma and ovarian cancer, and tumors whose vasculature exhibits B7-H3 expression, such as glioblastoma, renal cell carcinoma and ovarian cancer. The clinical trial began with a dose escalation segment in which patients were treated with
increasing weekly doses of MGA271 from 0.01 mg/kg up to 15 mg/kg. We have not seen any dose limiting toxicity, and we plan to initiate an expansion phase in the third quarter of 2013 at a dose of 15 mg/kg. During the expansion phase, we will recruit
an additional 15 patients to each of three cohorts that represent a distinct patient population determined by histology: 1) patients with melanoma, 2) patients with prostate cancer and 3) patients with any B7-H3 positive tumor other than melanoma or
prostate cancer with the limitation of a maximum of five patients with any single histologic type such as colorectal adenocarcinoma or histologic subgroup such as sarcoma. In addition, Servier has indicated that it intends to evaluate MGA271 in up
to 90 additional cancer patients representing additional types of cancers beginning in the fourth quarter of 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
enrolled a total of 26 patients in the trial through the dose escalation portion, with 15 different types of tumors. Ten patients received additional cycles of MGA271 treatment and all have had stable disease at the first tumor re-assessment. The
most frequent adverse events in the trial were mild or moderate infusion reactions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We plan to have a companion diagnostic
ready for incorporation into potential Phase 2/3 trials and are working with a collaborator to develop it. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD006: DART-Based Molecule for
Acute Myeloid Leukemia </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">MGD006 is a humanized DART molecule that recognizes both CD123 and CD3. We are developing MGD006 for the treatment of hematologic cancers. The primary mechanism of action of MGD006 is its ability to
redirect T cells which express CD3 to kill CD123 expressing cells, such as leukemic cells. We plan to submit the IND for MGD006 in early 2014. In addition, we plan to initiate a Phase 1 clinical trial of MGD006 in patients with relapsed or
refractory acute myeloid leukemia, or AML, or in patients with untreated AML who are not candidates for standard induction chemotherapy in the first half of 2014. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Role of CD123 in Acute Myeloid Leukemia </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">CD123 has been reported to
be overexpressed on malignant cells in a wide range of hematologic malignancies including AML and myelodysplastic syndrome, or MDS. Overexpression of CD123 is associated with a poorer prognosis in AML. AML and MDS are thought to arise in and be
perpetuated by a small population of leukemic stem cells, or LSCs, which generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression, which is not present in the corresponding normal hematopoietic
stem cell population in normal human bone marrow. CD123 is also expressed by plasmacytoid dendritic cells, or pDCs, basophils, endothelial cells and, to a lesser extent, monocytes and eosinophils. The anti-CD123 component of MGD006 is based on a
humanized version of 7G3, a mouse monoclonal antibody directed against CD123. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Potential Advantages of MGD006 </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As a targeted therapy for CD123 expressing cells, we believe that MGD006 will have fewer side effects than conventional chemotherapeutic
agents which broadly target rapidly dividing cells including cancer cells, normal hematopoietic stem cells and certain immune cells such as activated lymphocytes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Moreover, because CD123 is expressed on the LSCs that perpetuate this disease, MGD006 will be targeting the source of the disease, and potentially deliver more durable remissions. This would represent an
advance in AML therapy, because the LSCs that sustain this disease are generally resistant to the chemotherapy which is the standard approach to disease treatment. The resistance of LSCs to chemotherapy may be due to the fact that they are a rare,
relatively dormant, cell type within the leukemic cell population and, therefore, are less susceptible to the primary mechanism of action of chemotherapeutic agents. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-clinical Development of MGD006 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have demonstrated in<I> in
vitro</I> experiments that MGD006 is able to mediate T&nbsp;cell killing of CD123-expressing cells. In an <I>in vitro</I> model of T cell-mediated killing of AML cells, addition of MGD006 led to destruction of AML cells derived from leukemia
patients. Three leukemia cell lines expressing CD123 were exposed to MGD006 or a control DART protein in the presence of T cells. Dose-dependent increases in cell killing were observed following treatment with MGD006. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the chart below, primary AML PBMC samples were incubated with a phosphate buffered saline, or PBS control, a DART protein control or
MGD006. Treatment with MGD006 resulted in a dose-dependent decrease in leukemic blast cell number counts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AML Blasts
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431dsp_085.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We performed pilot toxicology studies in cynomolgus monkeys. Complete depletion of CD123-expressing
pDCs, an indication of activity in healthy animals, occurred at doses as low as 10 ng/kg/day. Importantly, this effect was reversible as pDCs were observed in peripheral blood a few weeks following cessation of dosing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No significant infusion reactions were observed at the lowest starting doses studied, including the pharmacologically active dose levels
(10-30 ng/kg/day). Administration of MGD006 at higher doses was associated with acute infusion reactions, which typically decreased or disappeared with subsequent dosing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD007: DART-Based Molecule for Gastrointestinal Cancers </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGD007
is a DART protein in which the first specificity is for the glycoprotein gpA33 and the second specificity is for CD3. MGD007 also contains an Fc domain which provides for an extended serum half-life compared to basic DARTs. gpA33 was identified
through immunizations using our proprietary CSLC lines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are developing MGD007 as a potential therapeutic agent for the
treatment of colorectal cancer. Other tumors of the gastrointestinal tract, such as pancreatic and gastroesophageal cancers, may also be potential indications for development. In a survey of normal tissues examined, the gpA33 antigen was expressed
almost exclusively in the intestinal epithelium. It was present in more than&nbsp;95% of human colon cancers, and in approximately 50% of gastroesophageal and pancreatic cancers. Studies by others with a radiolabeled monoclonal antibody against
gpA33 demonstrated preferential binding to tumors over normal colonic mucosa. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have conducted pre-clinical <I>in vitro</I>
and <I>in&nbsp;vivo</I> proof-of-concept studies with MGD007 or a basic DART form of MGD007 without the Fc domain. In addition, we are currently conducting several small, non-GLP toxicology studies in cynomolgus monkeys. These non-GLP toxicology
studies will inform the design of the IND-enabling GLP toxicology study, which we plan to initiate by the end of 2013. We are planning to submit an IND in 2014 and commence a Phase 1 clinical trial for MGD007 in the second half of 2014. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pre-clinical Development of MGD007 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The results of <I>in vivo</I> experiments shown below demonstrate that a gpA33 x CD3 DART is able to mediate T&nbsp;cell killing of gpA33-expressing cancer cells: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431dsp_086.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Cells from a colorectal cancer line and activated human T cells were implanted subcutaneously in immunodeficient
mice. A gpA33 x CD3 DART was administered intravenously daily for four days at the time of tumor implantation. Inhibition of tumor growth was observed at all dose levels tested when compared to animals treated with a control. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD010: DART-Based Molecule for Autoimmune Diseases </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Autoimmune diseases including rheumatoid arthritis, or RA, Crohn&#146;s disease, systemic lupus erythematosis, or SLE, and multiple sclerosis, or MS, collectively affect more than 20&nbsp;million people
in the United States. Autoimmune disease involves self-tissue destruction by T cells and antibodies due to lack of self-tolerance. Anti-inflammatory therapies, such as TNF (tumor necrosis factor) inhibitors, have been able to improve diseases like
RA; however, it has become increasingly known that, in addition to T cells, B cells play an important role in many common autoimmune and allergic disorders by initiating and amplifying the pathological disease processes. Current B cell targeted
therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections (e.g., rituximab, or <I>Rituxan</I>), or exhibit a delayed onset of action and limited efficacy across patient populations (e.g.,
belimumab, or <I>Benlysta</I>). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To address limitations of existing B cell targeted therapies, MacroGenics has developed a
novel CD32B x CD79B DART, called MGD010. In pre-clinical studies, this DART modulates the function of human B cells without B cell depletion. In normal conditions, B cells utilize CD32B as one of the key negative regulators to ensure that tolerance
to self is maintained and autoimmune disease does not occur. MGD010 exploits this mechanism and triggers this inhibitory &#147;immune checkpoint&#148; loop. We believe this molecule preferentially blocks those B cells that are activated to produce
the pathogenic antibodies that promote the autoimmune process. Studies in SLE patient B cells and humanized mouse models have demonstrated that MGD010 can block B cell activation in the absence of B cell depletion. To advance this program to the
clinic, we recently performed studies in non-human primates with MGD010 demonstrating a favorable safety profile and pharmacological effects on targeted B cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the chart below, treatment with MGD010 prolongs survival compared to a PBS control or a single dose of rituximab in a mouse model of graft versus host disease. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MGD010 in a Chronic Graft versus Host Disease </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Transplantation) Mouse Model </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431dsp_087.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Immunodeficient mice administered human PBMCs by injection were treated intravenously either with MGD010 at 5.0 or
10.0 mg/kg or PBS control every four days (9 total doses) or with rituximab at 5.0 mg/kg for one dose. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Teplizumab: Fc-Modified
Antibody for Type 1 Diabetes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Teplizumab is a humanized, anti-CD3 monoclonal antibody being developed for the treatment of Type 1 Diabetes, or T1D. Teplizumab has been engineered to alter the function of the T cells that mediate the
destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment of T1D by addressing the underlying disorder, rather than merely using insulin replacement therapy. In 2007,
we entered into a collaboration with Eli Lilly. During the clinical development of teplizumab, Eli Lilly provided financial, manufacturing, and commercial support to us while we conducted our Phase 3 clinical trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In June 2011, we published the results of Prot&eacute;g&eacute;, a Phase 3 clinical study of teplizumab in T1D, in <I>The Lancet</I> and
follow-up data in <I>Diabetes</I> in 2013. The primary clinical endpoint, a composite of HbA1c and insulin usage, was not met. However, an exploratory, post-hoc analysis suggests that teplizumab, when used in a full dose regimen, may preserve
insulin production by beta cells in the pancreas, as measured by C-peptide, and increase the percentage of patients requiring very low doses of insulin compared to those on placebo. Preservation of insulin production as measured by C-peptide,
relative to standard of care, is now recognized as an acceptable primary endpoint by the FDA. The findings suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in beta
cell function (measured by C-peptide) and preservation of glycemic control at reduced doses of insulin, particularly in children, if intervention occurs soon after diagnosis. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">82 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Teplizumab is currently being evaluated in a Phase 2 clinical trial, called At Risk, for the
prevention or delay of onset of T1D in patients determined to be at very high risk for developing the disease. This clinical trial is being sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases, or NIDDK. We retain
worldwide rights to teplizumab (the commercial rights were reacquired from Eli Lilly) and we are actively seeking a collaborator for further development. We do not intend to use any of the proceeds of this offering to fund teplizumab development.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Collaborations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into several strategic collaborations for our therapeutic programs. These therapeutic collaborations have provided us with approximately $101 million in non-equity funding during the three
year period ended March&nbsp;31, 2013. Under these agreements we are entitled to receive substantial payments including over $100 million of potential additional option exercise fees and milestone payments that we believe are likely to be received
by the end of 2015, assuming all of our collaboration programs advance as currently contemplated. Key terms of these collaborations are summarized below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Servier MGA271 Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I>. In November 2011, we
entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an exclusive license to develop and commercialize the Fc engineered antibody we designated as MGA271 and certain other Fc engineered antibodies
that also bind the B7-H3 receptor, collectively referred to as the MGA271 licensed products, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option grant fee and may be eligible
to receive up to approximately $420 million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for and successfully commercializes an MGA271 licensed
product. This total includes a $10 million milestone payment we expect to receive in the third quarter of 2013 based upon dosing the first patient in a planned expansion cohort in our Phase 1 clinical trial of MGA271. In addition to these
milestones, we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive royalties on the net sales of MGA271 licensed products at percentages ranging from the low double digit to mid-teens,
subject to reductions in specified circumstances. Under specific circumstances, Servier may defer payment of certain milestone payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research Plan</I>. Under the agreement, we are responsible for conducting research according to an agreed upon research plan during a specified research term. The activities under the research plan
include the generation of data by us that the parties have agreed will be included in a data package, or MGA271 data package. We will continue conducting the current Phase 1 trial of MGA271 under the research plan. Under the agreement, Servier may
conduct separate development and clinical activities under the research plan, subject to our approval. The term of the research plan begins on the effective date of the agreement and ends on the earlier of November&nbsp;24, 2015 or the expiration of
Servier&#146;s option under the agreement. In general, during the research term, each party is responsible for the internal and external costs it incurs to conduct its activities under the research plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing</I>. Under the agreement we are obligated to supply cGMP produced MGA271 licensed products to supply Servier&#146;s
clinical development needs for its Phase 1 and first two Phase 2 clinical trials according to a clinical supply agreement negotiated between the parties. Servier is obligated to pay for such supply of MGA271 licensed product under the clinical
supply agreement at our fully burdened manufacturing cost. Prior to exercising its option, we can supply clinical material for Servier&#146;s additional needs at our discretion. If Servier exercises its option, upon its request, we are obligated to
enter into negotiations to execute a commercial supply agreement for MGA271 licensed product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Option</I>. Generally,
Servier may exercise its option at any time after the effective date of the agreement until ninety days after Servier&#146;s receipt of the MGA271 data package. In the event Servier exercises the option, Servier must pay a license grant fee, which
we estimate to be $30 million, based on the number of different indications represented within the patient population in a planned expansion cohort in our Phase 1 clinical trial of MGA271. If Servier elects not to exercise the option, it will lose
all rights to develop and commercialize MGA271 licensed products and we will be entitled to develop and commercialize MGA271 licensed products throughout the world exclusively or with a third party or parties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">83 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License/Exclusivity</I>. If Servier exercises the option it will receive an exclusive
license to develop and commercialize MGA271 licensed products in all countries of the world other than the United States, Canada, Mexico, Japan, South Korea and India. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to Servier&#146;s exclusive right to develop and commercialize MGA271 licensed products under the agreement, there are additional obligations regarding exclusivity and noncompetition.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to these provisions, in the event that we seek to grant rights to a third party to develop and/or commercialize
certain DARTs that bind the B7-H3 receptor outside the United States, Servier has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to execute an agreement granting Servier such rights
within a specified time period, subject to specified exceptions, we will have the right to enter negotiations with a third party for the same rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination</I>.&nbsp;If Servier does not exercise its&#146; option, the agreement terminates upon the expiration of the option. If Servier exercises the option, the agreement will expire in
its entirety upon the expiration of all applicable royalty terms for all MGA271 licensed products in all countries in Servier&#146;s territory. The agreement contains customary termination rights. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Servier DART Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I>. In September 2012, we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules,
consisting of those designated by us as MGD006 and MGD007, as well as a third DART molecule, collectively referred to as the DART-licensed products, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. Under
the terms of the agreement, we received a $20 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments
if Servier exercises all of the options and successfully develops, obtains regulatory approval for and commercializes a product under each license, including $5 million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In
addition to these milestones, we and Servier will share Phase 2 and Phase 3 development costs. Under the agreement we are also eligible to receive royalties on the net sales of DART licensed products at percentages ranging from the low double digits
to the mid-teens, subject to reductions in specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research Programs</I>. Under the agreement, we are
responsible for conducting research according to an agreed upon research plan for each option target during the specified research term. Each research plan and its activities are considered a research program. The activities under each research plan
include the generation of data by us that the parties have agreed that will be included in a data package, or the Servier DART data package. With our consent, Servier may conduct separate development and clinical activities under a research plan.
The research term for each research program begins on the effective date of the agreement and ends on the earlier of September&nbsp;19, 2016 or the expiration of the applicable option. In general, during each research term, each party is responsible
for the internal and external costs it incurs to conduct its activities under that research plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing</I>. Under
the agreement we are obligated to negotiate a clinical supply agreement with Servier regarding the supply of cGMP produced material to supply Servier&#146;s clinical development needs for its Phase 1 and first two Phase 2 clinical trials for each
DART licensed product. Servier pays for such supply of each DART licensed product under each clinical supply agreement at our fully burdened manufacturing cost. Prior to exercising one of its options, we can supply clinical material for
Servier&#146;s additional needs at our discretion. If Servier exercises an option, then upon Servier&#146;s request, we are obligated to enter negotiations to execute a commercial supply agreement for DART licensed products subject to that option.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Option</I>. Under the terms of the agreement, each option may be exercised by Servier within ninety days after
Servier&#146;s receipt of the applicable Servier DART data package. In the event Servier exercises an option, Servier must pay a specified license grant fee for exercising that option. The respective license grant fees are $15 million for the MGD006
option, which becomes exercisable upon completion of our GLP toxicology study, and additional amounts related to MGD007, and a remaining DART molecule, which become exercisable after a significant portion of the Phase 1 trials for each of these
programs is completed. If Servier elects not to exercise an option, it will lose all rights to develop and commercialize DARTs that bind such option target and we will be entitled to develop and commercialize DARTs that bind the former option target
throughout the world exclusively or with a third party or parties, subject to Servier&#146;s right of first negotiation, as described below. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">84 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Licenses/Exclusivity. </I>If Servier exercises an option it will receive an exclusive
license to develop and commercialize DARTs that bind to the option target for that option, and pharmaceutical products that comprise or contain such DARTs, in all countries of the world other than the United States, Canada, Mexico, Japan, South
Korea and India. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to Servier&#146;s exclusive right to develop and commercialize DARTs under each license, under
the agreement there are additional obligations regarding exclusivity and noncompetition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to these provisions, in
the event that we seek to enter into a transaction under which we would grant rights to a third party to develop and/or commercialize certain product candidates in Servier&#146;s territory that bind an option target in exchange for certain
consideration, Servier has a right of first negotiation to obtain such rights. If Servier declines to enter negotiations or the parties fail to execute an agreement granting Servier such rights within a specified time period, we will have the right,
subject to specified exceptions, to enter negotiations with a third party for the same rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I>
If Servier does not exercise any option, the agreement terminates upon the expiration of the last to expire option. If Servier exercises an option, the agreement will expire in its entirety with respect to such DART licensed product upon the
expiration of all applicable royalty terms for all applicable DART licensed products in Servier&#146;s territory. The agreement contains customary termination rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Gilead </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview</I><B>.</B> In January 2013, we entered into an
agreement with Gilead to grant Gilead (i)&nbsp;an exclusive worldwide license to research, develop, manufacture and commercialize DARTs that bind to a first pair of specified targets; (ii)&nbsp;an exclusive option for an exclusive license to
research, develop, manufacture and commercialize DARTs that bind to a second pair of specified targets in North America, the European Union, Norway, Iceland, Turkey, Australia and New Zealand; and (iii)&nbsp;separate exclusive options for worldwide
exclusive licenses to research, develop, manufacture and commercialize DARTs that bind to third and fourth pairs of targets to be subsequently identified by Gilead and accepted by us within a specified time period after the effective date of the
agreement, which we collectively refer to as the Gilead licensed products. We received an initial $7.5 million license grant fee for granting Gilead a license to the first target pair, and are eligible to receive up to an additional $22.5 million in
grant fees on the remaining three pairs of targets. We are further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and
sales milestones payments if Gilead exercises all four of the options and achieves all of the requisite milestones under each option and license. Under the agreement, we are also eligible to receive tiered royalties on the net sales of Gilead
licensed products at percentages ranging from the high single digits to the low double digits, subject to reductions in specified circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Research Programs.</I> During specified research terms, we are responsible for conducting research according to an agreed upon research plan for each pair of targets for which Gilead exercises its
option. Each research plan and its activities are considered a research program. Upon approval by the joint research committee, Gilead may conduct separate development and clinical activities under a research plan. The term of the research plan for
the first target pair has already begun. The research terms of the research plans for the second, third and fourth target pairs can begin only after Gilead&#146;s exercise of the options for such target pairs. Gilead has fixed time periods to
exercise its options for the second, third and fourth target pairs and we may decline to accept Gilead&#146;s selections of the third and fourth target pairs under specified circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During each research term, Gilead will reimburse us for all internal and external costs we incur to conduct our assigned activities under
that research plan, subject to specified limitations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Licenses.</I> Under the agreement, we granted Gilead an exclusive
worldwide license to research, develop, manufacture and commercialize DARTs that bind to the first pair of specified targets. Upon initiation of the research term for the second target pair, we will grant Gilead an exclusive license to research,
develop, manufacture and commercialize DARTs that bind to that pair of specified targets in North America, the European Union, Norway, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">85 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Iceland, Turkey, Australia and New Zealand. Upon initiation of each of the research terms for the third and fourth target pairs we will grant Gilead a worldwide exclusive license to research,
develop, manufacture and commercialize DARTs that bind to the corresponding target pair. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that we seek to license
our rights to develop DARTs that bind to the second target pair in countries not included in the license for the second target pair, Gilead has a right of first negotiation to obtain such rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Pre-clinical Milestone</I>. Notice by Gilead to pay the pre-clinical milestone for each target pair category must be provided to us
within specified time periods. Upon providing notice to pay a pre-clinical milestone for a target pair category, Gilead will become responsible for all research, development and commercialization activities with respect to licensed products within
such target pair category in Gilead&#146;s territory for such target pair license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to specified
exceptions, during the term of the agreement, other than with respect to the research and development activities pursuant to the agreement, we may not, directly or indirectly, research, develop, manufacture or commercialize a product that binds to
both targets from any target pair category covered by the agreement in a country where Gilead has been granted a license for such target pair. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will expire in its entirety upon the expiration of all applicable royalty terms for all Gilead licensed products in all countries. Gilead has the right to
terminate the agreement at any time with respect to one or more selected target pairs or in its entirety, upon prior written notice to us. The agreement contains customary termination rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Boehringer </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In October 2010 we entered into a
collaboration and license agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, we granted Boehringer an exclusive, worldwide,
royalty-bearing, license under our intellectual property to research, develop, and market DARTs generated under the agreement, or the Boehringer licensed products, throughout the world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the agreement, we received an upfront payment of $15 million. We subsequently received two annual maintenance payments and
anticipate receiving a third annual maintenance payment in the fourth quarter of 2013. We have the potential to earn development, regulatory and sales milestone payments that can reach up to $210 million for each of the DART programs under this
agreement in the case of full commercial success of multiple DART products. Boehringer also provides funding for our internal and external research costs and is required to pay us mid-single digit royalties, on a licensed product-by-licensed product
basis, on worldwide net sales, subject to reductions in specified circumstances. We have the option to co-promote certain DART products in the United States and may elect to co-fund Phase 3 clinical development in exchange for an increased royalty
rate on net sales. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">86 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research.</I> Under the agreement, Boehringer is entitled to select up to ten pairs of
targets for which we would generate DARTs that bind to such targets. Several of the targets were identified in the agreement. Subsequent target pairs are selected according to a process which permits us to decline to accept such target pairs under
specified circumstances. During the research term of the agreement, we are responsible for generating pre-clinical DART candidates that bind the accepted target pairs and generating data according to specified criteria which will be presented to
Boehringer as a data package. If Boehringer accepts a pre-clinical DART candidate it will be responsible for subsequent development and commercialization of such pre-clinical DART candidate. We have the right to co-fund a portion of the Phase 3
clinical development in exchange for an increased royalty rate. We also have the right to co-promote up to two DART products that are developed under the agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Equity Purchase.</I> Boehringer purchased $10 million of our Series D-2 preferred stock in January 2011. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>. Subject to specified exceptions, during the term of the agreement, other than with respect to Boehringer licensed products, we agreed not to research, develop or commercialize any
product using our DART platform that is directed to a target covered under the agreement. Subject to specified exceptions, we further agreed not to grant any third party rights to research, develop or commercialize any product using our DART
platform that is directed to a specified number of specific targets identified in the agreement, until a specified time period or the date on which neither of the identified targets has been selected as a target subject to development and
commercialization under the agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will expire in its entirety upon the
expiration of all applicable royalty terms for all Boehringer licensed products in all countries. Boehringer has the right to terminate the agreement at any time with respect to one or more selected target pairs or in its entirety, upon prior
written notice to us. However, it must maintain research efforts during a specified time period of the agreement. The agreement may also be terminated by either Boehringer or us in the event of an uncured material breach by the other party.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pfizer </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In October 2010, we entered into a research collaboration and license agreement with Pfizer. Under the agreement, we
granted Pfizer a non-exclusive worldwide, royalty-bearing license and received upfront and milestone payments and funding for our internal and external research costs under the agreement. Under the terms of the agreement, we received a
non-refundable, non-creditable $5 million upfront fee. In addition, we are eligible to receive up to approximately $210 million per Pfizer DART molecule, as defined in the agreement, in technical, development and sales milestone payments if
specified net sales thresholds are reached. We are also entitled to receive royalties from Pfizer at percentages ranging from the mid-single digits to the low-double digits on net sales of any Pfizer DART. Under this collaboration, one DART program
is currently being pursued and we will complete our research obligations under this program in October 2013. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Research.</I>
Under the agreement, we are obligated to construct Pfizer DARTs that bind to a first and second target identified in the agreement that are each expressed on cancer cells. During the research term of the agreement, which expires on October&nbsp;13,
2013, we conduct pre-clinical development of the Pfizer DARTs in collaboration with Pfizer according to an agreed upon research plan. Under certain circumstances, Pfizer has the right to substitute the second target during specified periods. Pfizer
has exercised those rights at various times during the specified periods which have now expired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Product Development.</I>
Upon expiration of the research term in October 2013, Pfizer will use commercially reasonable efforts to develop and obtain regulatory approval for each Pfizer DART in both the United States and other specified countries. In addition, Pfizer will
use commercially reasonable efforts to commercialize a Pfizer DART in each country where Pfizer has received regulatory approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization.</I> Under the Agreement, Pfizer has sole responsibility and authority for commercialization of Pfizer DARTs at its sole expense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing.</I> Pfizer has the exclusive right to manufacture Pfizer DARTs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">87 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License.</I> Under the Agreement we granted Pfizer an exclusive, worldwide license to
use, develop, manufacture, and commercialize Pfizer DARTs. The license includes the right to sublicense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exclusivity</I>.
Subject to specified exceptions, until October&nbsp;3, 2015, we agreed not to research, develop, commercialize, manufacture, or grant any third party rights to research, develop, commercialize, or manufacture, (i)&nbsp;a Pfizer DART that binds to a
cancer target for which a Pfizer DART is under development in the agreement; or (ii)&nbsp;product candidates based on an antibody that we have supplied to serve as the basis for generating a Pfizer DART that is in development under the agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination.</I> The agreement will expire in its entirety upon the expiration of all applicable royalty terms
for all applicable Pfizer DARTs. We or Pfizer may terminate the agreement in the event of an uncured material breach by the other party. After a specified period, Pfizer may terminate the agreement for convenience upon prior written notice to us.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Green Cross </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Overview.</I> In June 2010, we entered into a Collaboration Agreement with Green Cross Corp., or Green Cross, to grant Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 trials
and commercialize margetuximab in South Korea. Under the terms of the agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million if Green
Cross commercializes margetuximab. We are also entitled to receive royalties on net sales of margetuximab by Green Cross in South Korea. In addition, Green Cross purchased $2.0 million of our Series D-2 Preferred Stock in January 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Clinical Development.</I> Initial development of margetuximab under the agreement is being conducted according to a Phase 1
development plan that has been agreed upon by the parties. We hold the clinical trial application for the ongoing Phase 1 clinical trial conducted in South Korea. Based upon an amendment to the agreement, Green Cross is responsible for all of its
costs to conduct the Phase 1 development plan up to a specified amount and, we are responsible for all of our own costs to conduct the Phase 1 development plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Development of margetuximab under the agreement after completion of the Phase 1 clinical trial will be conducted according to a Phase 2 development plan. In that regard, Green Cross is obligated to use
best efforts to initiate a Phase 2 clinical trial with margetuximab in South Korea within a specified period of time after the completion of the Phase 1 trial. The costs of conducting the Phase 2 trial will be the responsibility of Green Cross.
After completion of the Phase 1 trial, Green Cross has the responsibility for submitting clinical trial applications to the Korea Food and Drug Administration, or KFDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Green Cross shall have the option to participate in any additional studies to the extent such studies are required by the KFDA to obtain approval of margetuximab in South Korea. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Commercialization.</I> Under the Agreement Green Cross has sole responsibility and authority for commercialization of margetuximab in
South Korea at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Manufacturing.</I> We are responsible for supply of margetuximab that is used for
clinical development by Green Cross in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>License.</I> Under the Agreement we granted Green Cross an exclusive
license to conduct specified Phase 1 and Phase 2 trials and commercialize margetuximab in South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Consideration.</I>
Under the Agreement, we received a non-refundable $1.0 million upfront fee and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million if Green Cross commercializes margetuximab. In addition, we are
entitled to receive royalties which are determined by a formula that allocates the cost of commercial supply and third party royalties against net sales. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">88 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Term and Termination</I>. The agreement will expire in its entirety upon the expiration
of the royalty term for margetuximab. The agreement may also be terminated by either Green Cross or us in the event of an uncured material breach by the other party. The agreement may be terminated by us immediately in the event Green Cross
participates or actively assists in a legal challenge to one of the patents exclusively licensed to Green Cross under the agreement. Either party may terminate the agreement in the event of a change in control of the other party upon 30 days prior
written notice to the other party. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patent protection intended to protect, for example, the composition of
matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets and careful
monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We plan to continue to expand our intellectual property estate by filing patent applications directed to dosage forms, methods of treatment and additional compositions created or identified from our
technology platforms and ongoing development of our product candidates. Specifically, we seek patent protection in the United States and internationally for novel compositions of matter directed to aspects of the molecules, basic structures and
processes for manufacturing these molecules and the use of these molecules in a variety of therapies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our success will depend
significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business, defend and enforce our patents, maintain our licenses to use
intellectual property owned by third parties, preserve the confidentiality of our trade secrets and operate without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing
technological innovation and in-licensing opportunities to develop, strengthen, and maintain our proprietary positions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
third party may hold intellectual property, including patent rights that are important or necessary to the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary
technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example,
some aspects of the amino acid sequences encoding margetuximab and MGA271 are covered by patents held by third parties. We believe that these patents are invalid. However, if we are unable to invalidate such patents, or if licenses for them are not
available on commercially reasonable terms, our business could be harmed, perhaps materially. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent positions of
biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its
scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are
currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented
or invalidated by third parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because patent applications in the United States and certain other jurisdictions are
maintained in secrecy for 18 months or potentially even longer, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending
patent applications. Moreover, we may have to participate in interference proceedings declared by the United States Patent and Trademark Office, or USPTO, to determine priority of invention. We are participating in post-grant challenge proceedings,
such as oppositions, that challenge the patentability of third party patents and may have to participate in such proceedings again in the future. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">89 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The patent portfolios for our most advanced programs are summarized below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>. Our margetuximab patent portfolio includes one issued patent and one pending U.S. patent application relating to the
composition of or methods of making or using margetuximab, which are wholly owned by us. The issued patent covers Fc engineered HER2 binding antibodies, including margetuximab, and will expire in 2025. Related Patent Cooperation Treaty, or PCT, and
national patent applications filed in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire in 2025. A current pending U.S. application relates to the composition of margetuximab. If
issued, this patent will expire in 2029. Related PCT and national patent applications filed in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire 2029. Issued patents and pending
patent applications in our Fc engineering platform portfolio provide additional protection for margetuximab. As development of margetuximab progresses we will also seek to file patent applications that protect uses of margetuximab that are
identified from its development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I><I>. </I>Our MGA271 patent portfolio includes a pending U.S. patent application
which covers the composition of or methods of making or using MGA271 and, if issued, would expire in 2031. Our MGA271 portfolio also includes a U.S. patent application, which claims MGA271 variable domains that bind to the B7-H3 receptor. Patents
based on this application, if issued, will expire in 2031. A related patent application filed under the international PCT and related national patent applications based on both of these U.S. patent applications are pending in several other countries
which, if issued, will expire in 2031. As development of MGA271 progresses we will also seek to file patent applications that protect uses of MGA271 that are identified from its development. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006</I><I>.</I> The general composition of or methods of making or using DARTs, such as MGD006, is currently covered by a pending
U.S. patent application from our DART platform portfolio. If issued, the resulting patent will expire in 2026. Related PCT and national patent applications filed in a number of other countries are pending. Any patents resulting from these patent
applications, if issued, will expire in 2026. A U.S. provisional patent application covering the specific composition of MGD006 will be filed in 2013. We intend to file related U.S. nonprovisional, PCT and national patent applications in a number of
other countries. Any patents resulting from these patent applications, if issued, will expire in 2034. As development of MGD006 progresses we will also seek to file patent applications that protect uses of MGD006 that are identified from its
development. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD010</I>. Our MGD010 patent portfolio is wholly owned by us and includes a pending U.S. patent application
which relates to the composition of or methods of making or using the MGD010. If issued, this pending patent application will expire in 2029. Related PCT and national patent applications filed in several other countries are pending. Any patents
resulting from these patent applications, if issued, will also expire in 2029. As development of the MGD010 progresses we will also seek to file patent applications that cover uses of MGD010 that are identified from its development. These
applications will expire after the current issued patent and pending patent applications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>DART Platform</I><I>.</I> Our
DART Platform patent portfolio is wholly owned by us and includes a pending U.S. patent application which relates to the general composition of or methods of making or using DARTs, which, if issued, will expire in 2026. Related PCT and national
patent applications filed in a number of other countries are pending. Any patents resulting from these patent applications, if issued, will expire in 2026. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Fc Engineering Platform</I><I>.</I> Our Fc engineering platform patent portfolio is wholly owned by us and includes an issued U.S. patent which protects the composition of antibody Fc regions with
certain mutations that affect their binding to Fc receptors. This patent expires in 2024. Related national patents have issued in a number of other countries or are pending. The issued patents and any patents resulting from the pending patent
applications, if issued, will expire in 2024. Other issued composition and methods of use and making of patents in this portfolio include four United States that will expire 2024. Related national patents have issued in a number of other countries
which will expire in 2024. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of individual patents depends upon the legal term of the patents in the countries in
which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">90 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Regulatory Review Process </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs of up to five years beyond the expiration of the patent. The
length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent
applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive
FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that
the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Trade Secrets </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third
parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our
policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements
provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not disclosed to third
parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal
working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other
advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Also included in our trade secrets are hybridomas which express antibodies that bind to proteins which are or may be expressed on
cancerous cells, including cancer stem cells. The antibodies produced by each hybridoma are unique and may have properties that are absent in antibodies expressed by other hybridomas. These properties could confer advantages and capabilities to
product candidates developed with antibodies that exhibit such properties. We closely control and monitor access to the hybridomas and the antibodies they produce. Before receiving such materials, our collaborators, prospective collaborators and all
other parties are required to execute material transfer agreement or other agreement which contractually limit their permitted uses and dissemination of such materials. In many cases our agreements with other parties granting access to and use of
our biological materials require them to assign or grant us licenses to inventions they invent as a result or their use of the materials or grant us an option to negotiate a license to use such inventions </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In-Licensed Intellectual Property </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into patent and know-how license agreements which grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271. We anticipate
using this technology for future product candidates. This licensor has a business dedicated to licensing this technology and we anticipate that licenses to use the technology for our future products will be available. The licenses typically include
an obligation to pay an upfront payment, yearly maintenance payment and sales royalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a research
evaluation agreement for a technology related to biological manufacturing that we anticipate using to manufacture certain DART products. This licensor has a business dedicated to licensing this technology and we anticipate that licenses will be
available to use it to manufacture quantities of the DART products for clinical and commercial uses. The licenses may include an obligation to pay an upfront payment, yearly maintenance payments, milestones and sales royalties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In establishing our Fc engineering platform, we entered into patent license agreements which grant us the right to use technologies to
generate mutant Fc regions. The licenses include obligations to pay a yearly maintenance payment, development milestones and sales royalties on products we develop and commercialize that include mutant Fc regions generated using the patented
technologies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">91 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Manufacturing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We currently have a manufacturing facility located in Rockville, Maryland. This facility has been used to manufacture all of the current clinical supply for margetuximab and MGA271 to date. We currently
have capacity to produce Phase 2 material for our antibody product candidates and all clinical and commercial material for our DART therapeutics. For our Phase 3 clinical trials for our antibody product candidates and for commercial sale quantities
of such candidates, we anticipate that we will need to obtain additional manufacturing capacity through contract manufacturers to be able to supply the quantities required. We intend to screen multiple manufacturers to provide the drug substance for
commercial purposes for some of our product candidates prior to the filing of a BLA. We currently rely on and will continue to rely on contract fill-finish service providers to fulfill our fill-finish needs for our current and future product
candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our product candidates are biologics and are manufactured in disposable bioreactors in CHO cells in
accordance with current Good Manufacturing Practices, or cGMP. We expect to continue to develop product candidates that can be produced at our manufacturing facility and at contract manufacturing facilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We generally expect to rely on third parties for the development and manufacturing of our companion diagnostics. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commercialization </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
have not yet established a sales, marketing or product distribution infrastructure because our lead product candidates are still in clinical development. We generally seek to retain commercial rights in the United States for our clinical product
candidates for which we hope to receive marketing approvals and have done so to date in our collaborations other than our Boehringer, Gilead and Pfizer collaborations. We believe that it will be possible for us to access the United States oncology
market through a targeted specialty sales force. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to receiving marketing approvals, we expect to commence
commercialization activities by building a focused sales and marketing organization in the United States to sell our products. We believe that such an organization will be able to address the community of oncologists who are the key specialists in
treating the patient populations for which our oncology product candidates are being developed. Outside the United States, we expect to enter into distribution and other marketing arrangements with third parties for any of our product candidates
that obtain marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also plan to build a marketing and sales management organization to create and implement
marketing strategies for any products that we market through our own sales organization and to oversee and support our sales force. The responsibilities of the marketing organization would include developing educational initiatives with respect to
approved products and establishing relationships with thought leaders in relevant fields of medicine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect that our
collaborators for any companion diagnostics we may develop in the future for use with our product candidates will hold the commercial rights to these diagnostic products. We expect to coordinate closely with our diagnostic collaborators in
connection with the marketing and sale of our related product candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Competition </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on
proprietary products. While we believe that our technology, knowledge, experience and scientific resources provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty
pharmaceutical and biotechnology companies, academic institutions and governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with existing therapies and
new therapies that may become available in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There are a large number of companies developing or marketing
treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation
antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">92 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that work by targeting multiple specificities using a single recombinant molecule. Amgen is now in late-stage clinical development of cancer product candidates which work by targeting antigens
both on immune effector cell populations and those expressed on certain cancer cells. In addition, other companies are developing new treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent
antibodies, including Roche and Xencor, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Many of our competitors have significantly greater financial, manufacturing,
marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our
competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their
efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic competition and the availability of reimbursement from government and other third party payors.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are
safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may
obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors
seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to margetuximab. Even if our product candidates
achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. In many cases, these drugs are
administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent they are ultimately used in combination with or as an adjunct to these therapies, our product
candidates will not be competitive with them. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and
are widely accepted by physicians, patients and third party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to currently marketed therapies, there are
also a number of products in late stage clinical development to treat cancer. These product candidates in development may provide efficacy, safety, dosing convenience and other benefits that are not provided by currently marketed therapies. As a
result, they may provide significant competition for any of our product candidates for which we obtain marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
our lead product candidates are approved for the indications for which we are currently undertaking clinical trials, they will compete with the therapies and currently marketed drugs discussed below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Margetuximab</I>. Irrespective of HER2 status, metastatic breast cancers are often treated with cytotoxic chemotherapies such as
anthracyclines and taxanes, as well as capecitabine. Advanced and metastatic cancers are treated with chemotherapy and radiation therapy. In addition, there are several approved therapies specifically indicated for the treatment of early and
advanced stage breast cancer and advanced gastroesophageal cancer that are HER2+, including Herceptin, Kadcyla, Tykerb and Perjeta, and each of those drugs targets HER2+ tumors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGA271</I>. The most common treatments for solid tumors are various chemotherapeutic agents, radiation therapy and certain targeted
therapies including monoclonal antibodies such as Herceptin, Avastin, Erbitux and Vectibix, as well as small molecule agents, including, Tarceva, Sunitinib and Sorafenib. No therapies are approved specifically for the treatment of tumors associated
with the expression of B7-H3. Yervoy, which targets CTLA4, an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">93 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
inhibitory molecule on T cells, is currently indicated for the treatment of melanoma and marketed by Bristol-Myers. In addition, there are several antibodies in development that target other
members of the B7 family or their associated checkpoint receptors. These include anti-PD1 molecules by Merck and Bristol-Myers, and anti-PDL1 molecules by Bristol-Myers and Roche and a PDL1 Fc fusion protein by GSK and Amplimmune. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD006</I>. The most common treatments for AML are various chemotherapeutic agents, radiation and stem cell transplants. No therapies
are approved specifically for the treatment of AML associated with the expression of CD123. We are aware of a monoclonal antibody currently being developed by CSL Limited which targets CD123. In addition, StemLine Therapeutics, Inc. has treated
patients in a clinical trial with a recombinant protein composed of IL-3 linked to a truncated diphtheria toxin payload. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD007</I>. The most common treatments for gastroesophageal tumors are various chemotherapeutic agents, radiation therapy, monoclonal
antibodies including Herceptin, Avastin, Erbitux, Vectibix, as well as small molecule agents. No therapies are approved specifically for the treatment of tumors associated with the expression of gpA33. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>MGD010</I>. Current B cell targeted therapies for autoimmune diseases include Rituxan and Arzerra for the treatment of rheumatoid
arthritis and Benlysta for the treatment of SLE. In addition, several other therapies are available to reduce inflammation, including nonsteroidal anti-inflammatory drugs such as Advil and Aleve; corticosteroids such as prednisone; disease-modifying
antirheumatic drugs such as methotrexate and hydroxychloroquine; immunosuppressants such as cyclosporine; and other drugs which target a variety of processes involved with inflammation such as Actemra, Kineret, Enbrel, Remicade, Humira, Simponi,
Cimzia, Orencia and Xeljanz. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Government Regulation and Product Approval </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among
other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes
for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>FDA Approval Process </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">All of our current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The Food and Drug Administration (FDA) subjects biologics to extensive
pre- and post-market regulation. The Public Health Service Act (PHSA), the Federal Food, Drug, and Cosmetic Act (FDC Act) and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a
company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or
distribution, injunctions, fines, civil penalties, or criminal penalties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The PHSA emphasizes the importance of manufacturing
control for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of
shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction, or spread, of communicable diseases in the United States and between states. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The process required by the FDA before a new biologic may be marketed in the United States is long, expensive, and inherently uncertain.
Biologics development in the United States typically involves pre-clinical laboratory and animal tests, the submission to the FDA of an IND, which must become effective before clinical testing may commence, and adequate and well-controlled clinical
trials to establish the safety and effectiveness of the biologic for each indication for which FDA approval is sought. Developing the data to satisfy FDA pre-market approval requirements typically takes many years and the actual time required may
vary substantially based upon the type, complexity, and novelty of the product or disease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">94 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-clinical tests include laboratory evaluation of product chemistry, formulation, and
toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements, including good laboratory practices. The
results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term pre-clinical tests,
such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An IND must
become effective before United States clinical trials may begin. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND
within this 30-day period, the clinical trial proposed in the IND may begin. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials involve the administration of
the investigational new drug or biologic to healthy volunteers or patients with the condition under investigation, all under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&nbsp;in compliance with federal
regulations; (ii)&nbsp;in compliance with good clinical practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as
(iii)&nbsp;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments
must be submitted to the FDA as part of the IND. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA may order the temporary, or permanent, discontinuation of a clinical
trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed
consent information for patients in clinical trials must also be submitted to an institutional review board (IRB) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to
comply with the IRB&#146;s requirements, or may impose other conditions. The study sponsor may also suspend a clinical trial at any time on various grounds, including a determination that the subjects or patients are being exposed to an unacceptable
health risk. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but
the phases may overlap or be combined. In Phase 1, the biologics initially introduced into healthy human subjects or patients, and the biologic is tested to assess pharmacokinetics, pharmacological actions, side effects associated with increasing
doses, and, if possible, early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer treatments, initial human testing may be conducted in the intended patient population. Phase 2 usually
involves trials in a limited patient population to determine the effectiveness of the biologic for a particular indication, dosage tolerance, and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates
evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically
dispersed clinical trial sites., These Phase 3 clinical trials are intended to establish data sufficient to demonstrate substantial evidence of the efficacy and safety of the product to permit FDA to evaluate the overall benefit-risk relationship of
the biologic and to provide adequate information for the labeling of the biologic. Trials conducted outside of the US under similar, GCP-compliant conditions in accordance with local applicable laws may also be acceptable to FDA in support of
product licensing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sponsors of clinical trials for investigational drugs must publicly disclose certain clinical trial
information, including detailed trial design and trial results in FDA public databases. These requirements are subject to specific timelines and apply to most controlled clinical trials of FDA-regulated products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA review and approval of the BLA is
required before marketing of the product may begin in the United States. The BLA must include the results of all pre-clinical, clinical, and other testing and a compilation of data relating to the product&#146;s pharmacology, chemistry, manufacture,
and controls and must demonstrate the safety and efficacy of the product based on these results. The BLA must also contain extensive manufacturing information. The cost of preparing and submitting a BLA is substantial. Under federal law, the
submission of most BLAs is additionally subject to a substantial application user fee, as well as annual product and establishment user fees, which may total several million dollars and are typically increased annually. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">95 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA has 60 days from its receipt of a BLA to determine whether the application will be
accepted for filing based on the agency&#146;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain
performance goals in the review of BLAs. Most such applications for standard review biologics are reviewed within ten months from the date the application is accepted for filing. Although FDA often meets its user fee performance goals, the FDA can
extend these timelines if necessary, and FDA review may not occur on a timely basis at all. The FDA usually refers applications for novel biologics, or biologics which present difficult questions of safety or efficacy, to an advisory
committee&#151;typically a panel that includes clinicians and other experts&#151;for review, evaluation, and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but
it generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one, or more, clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic is
manufactured. The FDA will not approve the product unless it verifies that compliance with current good manufacturing practice, or GMP&#151;a quality system regulating manufacturing&#151;is satisfactory and the BLA contains data that provide
substantial evidence that the biologic is safe and effective in the indication studied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After the FDA evaluates the BLA and
the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in
order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#146;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such
resubmissions in two or six months depending on the type of information included. The FDA approval is never guaranteed, and the FDA may refuse to approve a BLA if applicable regulatory criteria are not satisfied. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the PHSA, the FDA may approve a BLA if it determines that the product is safe, pure and potent and the facility where the product
will be manufactured meets standards designed to ensure that it continues to be safe, pure, and potent. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. The approval
for a biologic may be significantly more limited than requested in the application, including limitations on the specific diseases and dosages or the indications for use, which could restrict the commercial value of the product. The FDA may also
require that certain contraindications, warnings, or precautions be included in the product labeling. In addition, as a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy (REMS) to help ensure that the benefits
of the biologic outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use (ETASU). ETASU can include, but are not limited to, special training or certification
for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS or use of a companion diagnostic with a biologic can materially affect the potential market
and profitability of the biologic. Moreover, product approval may require, as a condition of approval, substantial post-approval testing and surveillance to monitor the biologic&#146;s safety or efficacy. Once granted, product approvals may be
withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After a BLA is approved, the product may also be subject to official lot release. As part of the manufacturing process, the manufacturer
is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a
release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral
vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. After approval
of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">96 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Biosimilars </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Patient Protection and Affordable Care Act (Affordable Care Act) signed into law on March&nbsp;23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009. That Act
created an approval pathway authorizing the FDA to approve biosimilars and interchangeable biosimilars. Biosimilars are biological products which are &#147;highly similar&#148; to a previously approved biologic product or &#147;reference
product&#148; and for which there are no clinically meaningful differences between the biosimilar product and the reference product in terms of the safety, purity, and potency. For FDA to approve a biosimilar product as interchangeable with a
reference product, the agency must find that the biosimilar product can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biosimilar and the reference biologic may be
switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex,
structures of biological products, as well as the process by which such products are manufactured, pose significant hurdles to implementation, which are still being worked out by the FDA. To date, no biosimilar or interchangeable biologic has been
licensed under the BPCIA framework, although such approvals have occurred in Europe, and it is anticipated that FDA will approve a biosimilar in the relatively near future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A reference biologic is granted 12 years of exclusivity from the time of first licensure of the reference product. A biosimilar application may be filed four (4)&nbsp;years after the approval of the
reference biologic. Although the patents for the reference biologic may be challenged by the biosimilar applicant during that time period pursuant to the BPCIA statutory patent challenge framework, no biosimilar or interchangeable product will be
licensed by FDA until the end of the exclusivity period. The first biologic product submitted under the abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against other biologics
submitting under the abbreviated approval pathway for the lesser of (i)&nbsp;one year after first commercial marketing, (ii)&nbsp;18 months after the initial application if there is no legal challenge, (iii)&nbsp;18 months after the resolution in
the applicant&#146;s favor of a lawsuit challenging the biologics&#146; patents if an application has been submitted, or (iv)&nbsp;42 months after the application has been approved if a lawsuit is ongoing within the 42-month period. At this
juncture, it is unclear whether products deemed &#147;interchangeable&#148; by FDA, in fact, will be readily substituted by pharmacies, which are governed by state pharmacy law. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Advertising and Promotion </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Once a BLA is approved, a product will be
subject to continuing post-approval regulatory requirements. For instance, FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion,
industry-sponsored scientific and educational activities and promotional activities involving the internet. Failure to comply with these regulations can result in significant penalties, including the issuance of warning letters directing a company
to correct deviations from FDA standards, a requirement that future advertising and promotional materials be precleared by the FDA, and federal and state civil and criminal investigations and prosecutions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to
some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be
implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Adverse Event Reporting and GMP Compliance </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Adverse event reporting and submission of periodic reports are required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance
to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, manufacture, packaging, labeling, storage and distribution procedures must
continue to conform to current cGMPs after approval. Biologics manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to
periodic unannounced inspections by the FDA, during which the agency inspects </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">97 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain
compliance with cGMPs. Regulatory authorities may withdraw product approvals, request product recalls, or impose marketing restrictions through labeling changes or product removals if a company fails to comply with regulatory standards, if it
encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Companion
Diagnostics </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The FDA regulates the sale or distribution, in interstate commerce, of medical devices, including IVDs.
IVDs are a type of medical device that are intended to detect diseases, conditions, or infections, or the presence of certain genetic or other biomarkers. If safe and effective use of a therapeutic depends on an IVD, the FDA generally will require
approval of the companion diagnostic, at the same time that the FDA approves the therapeutic. The FDA previously has required <I>in vitro</I> companion diagnostics intended to identify the patients most likely to respond to a treatment to obtain
approval of a premarket approval application (PMA) simultaneously with approval of the biologic. A required companion diagnostic has the potential to delay approval of the biologic and create barriers to patient access. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Orphan Drug </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the Orphan Drug Act, the FDA may grant orphan drug designation to biologics intended to treat a rare disease or
condition&#151;generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity
of the biologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not necessarily convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to
receive FDA approval for a particular product to treat a particular disease with FDA orphan drug designation is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year
exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug
exclusivity does not prevent the FDA from approving a different biologic for the same disease or condition, or the same biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain
research and a waiver of the BLA application user fee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Healthcare Laws and Compliance Requirements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the
FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within
the Department of Justice, and state and local governments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>International Regulation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, and
distribution of product candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pharmaceutical Coverage, Pricing, and Reimbursement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the United
States and other countries, sales of any products for which we receive regulatory approval for commercial sale will depend in part on the availability of reimbursement from third-party payors, including government health administrative authorities,
managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and,
accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not
be available for our products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">98 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Facilities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our headquarters are located in Rockville, Maryland, where we occupy office and laboratory space under a lease that expires on March&nbsp;31, 2018. Our manufacturing facility is also located in Rockville
under a lease with the same landlord that expires on December&nbsp;31, 2014. We have an option under each lease to continue the respective lease for five years under the same terms. We also sublease office and laboratory space in South San Francisco
under a lease that expires on December&nbsp;31, 2018. We are seeking to sublease a substantial portion of this space. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employees
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2013, we had 156 full-time employees, 124 of whom were primarily engaged in research and development
activities and 32 of whom had an M.D. or Ph.D. degree. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Legal Proceedings </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not currently a party to any material legal proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">99 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_11"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table provides information with respect to our directors and executive officers as of June&nbsp;30, 2013. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position(s)</B></FONT></P></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Executive Officers</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO and Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Chief Financial Officer and Secretary</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Research</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Clinical Development</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kathryn Stein, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Product Development and Regulatory Affairs</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Members of Senior Management</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanford Stewart, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Clinical Oncology Research</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eric Risser</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Development</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Directors</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Steinmetz, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Koenig has been our President and Chief Executive Officer and a director since September 2001
and was one of our co-founders. Prior to joining us, Dr.&nbsp;Koenig served as Senior Vice President of Research at MedImmune Inc., where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the
Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr.&nbsp;Koenig
currently serves as Chairman of the Board of Directors of Applied Genetic Technologies Corporation and of the Children&#146;s Research Institute of Children&#146;s National Medical Center, and serves as a Board member of the Biotechnology Industry
Organization (BIO) and Children&#146;s National Medical Center. Dr.&nbsp;Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston. We believe that Dr.&nbsp;Koenig&#146;s
detailed knowledge of our company and his over 29 years in research and the biotechnology industry provide a valuable contribution to our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Karrels joined us as Vice President and Chief Financial Officer in May 2008 and has over 20 years of experience in finance, including approximately 15 years working for, or on behalf of, life
sciences companies. Prior to joining us, he was at Jazz Pharmaceuticals, Inc., most recently serving as Executive Director of Finance, where he was responsible for the company&#146;s financial planning and analysis and investor relations activities.
Prior to joining Jazz Pharmaceuticals, Mr.&nbsp;Karrels spent 11 years in the Investment Banking Group at Merrill Lynch, most recently serving as a Director in the Global Healthcare Group. Mr.&nbsp;Karrels holds an M.B.A. from Stanford University
and a B.B.A. from the University of Notre Dame. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Bonvini, Senior Vice President, Research, joined us in June 2003.
From 1985 to 2003, Dr.&nbsp;Bonvini was with the FDA in the Center for Biologics Evaluation and Research, or CBER, which is responsible for regulating therapeutic monoclonal antibodies and other proteins, ultimately serving as Acting Deputy
Director, Division of Monoclonal Antibodies and Chief, Laboratory of Immunobiology. From 1982 to 1984, Dr.&nbsp;Bonvini was a Visiting Fellow at the National Cancer Institute at the National Institutes of Health. Dr.&nbsp;Bonvini received a Diploma
in Science from the Scientific Lyceum in Genoa, Italy, and his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">100
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Daifotis joined us as Senior Vice President, Clinical Development in December 2009.
Prior to joining us, Dr.&nbsp;Daifotis spent 16 years at Merck, including serving from 2007 to 2009 as Vice President, Global Medical Affairs and from 2006 to 2007 as Vice President and General Manager, Respiratory, Bone, Arthritis and Analgesia.
Dr.&nbsp;Daifotis completed her general medical training at Mount Sinai Center and was a Postdoctoral Research Fellow in Endocrinology at the Yale University School of Medicine. She holds an M.D. from Albany Medical College and a B.A. from Princeton
University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stein joined us as Vice President, Product Development and Regulatory Affairs in May 2002 and has served
as a Senior Vice President since 2006. From 1980 to 2002, Dr.&nbsp;Stein was at the FDA, including serving as Director, Division of Monoclonal Antibodies in the Office of Therapeutics Research and Review at CBER from 1992 to 2002. While at the FDA,
Dr.&nbsp;Stein worked on all regulatory aspects of therapeutic proteins and monoclonal antibodies and was a leader in policy development at FDA for these products. Many currently marketed monoclonal antibodies were approved under her leadership.
Dr.&nbsp;Stein received her Ph.D. in Microbiology and Immunology from the Albert Einstein College of Medicine of Yeshiva University and her B.A. in Chemistry from Bard College. Dr.&nbsp;Stein commits half of her time to us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Stewart joined us as Vice President, Clinical Oncology Research in July 2008. From 2005 to 2008, Dr.&nbsp;Stewart served as Vice
President, Clinical Research at Raven Biotechnologies, Inc., which we acquired in July 2008. From 2001 to 2005, Dr.&nbsp;Stewart was with Corixa Corporation, most recently as Vice President, Clinical Research. Dr.&nbsp;Stewart was with ALZA
Corporation in 2001 and from 1998 to 2001, he was with Genentech, where he was Clinical Scientist on the Herceptin project and guided post-marketing clinical development, including the adjuvant breast cancer program. Dr.&nbsp;Stewart trained in
Medical Oncology at Stanford University, and served as a member of the faculty of the School of Medicine at Vanderbilt University for more than twelve years. Dr.&nbsp;Stewart received his M.D. from Baylor College of Medicine and his B.A. degree from
Rice University. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Risser joined us as Vice President, Business Development in May 2009. Prior to joining us,
Mr.&nbsp;Risser held the position of Senior Director, Business Development in the pharmaceutical group at Johnson&nbsp;&amp; Johnson, where he worked from 2003 to 2009. Before Johnson&nbsp;&amp; Johnson, Mr.&nbsp;Risser started and built a
consulting practice that provided counsel to emerging life science companies in the United States and Europe. Earlier in his career, Mr.&nbsp;Risser held venture capital and investment banking positions with BA Venture Partners and Lehman Brothers
Holdings Inc., respectively. Mr.&nbsp;Risser holds an M.B.A. from Stanford University and a B.A. from Yale University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Costa has served as a director since June 2009. Mr.&nbsp;Costa served as President and Chief Executive Officer of Novartis U.S.
Corporation, a pharmaceutical and consumer health company, from October 2005 to August 2008. From August 2009 to August 2012, Mr.&nbsp;Costa served as chairman of the board of directors of Amylin Pharmaceuticals Inc., a publicly held company, and
currently serves as a director of two privately-held companies. Based on Mr.&nbsp;Costa&#146;s diverse experience in the pharmaceutical industry, ranging from successful product development, launch and commercialization and his extensive senior
management experience within the industry, the board of directors believes Mr.&nbsp;Costa has the appropriate set of skills to serve as a member of the board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Galbraith has served as a director since July 2008. Mr.&nbsp;Galbraith joined Ventures West in 2007 and leads the firm&#146;s biotech practice. Mr.&nbsp;Galbraith has over 25 years of experience
acting as an executive, director, investor and advisor to companies in the biotechnology, medical device, pharmaceutical and healthcare sectors. Mr.&nbsp;Galbraith has served as a director of Celator Pharmaceuticals, Inc., a publicly held company,
since July 2007, and has also served as a director of Tekmira Pharmaceuticals Corp., a publicly held company, since January 2010. In addition, Mr.&nbsp;Galbraith serves as a director of several privately-held companies. Based on
Mr.&nbsp;Galbraith&#146;s depth of experience in the biotechnology industry, ranging from executive officer to director roles, the board of directors believes Mr.&nbsp;Galbraith has the appropriate set of skills to serve as a member of the board of
directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">101
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Hurwitz has served as a director since October 2004. Mr.&nbsp;Hurwitz has served as
a Director of Alta Partners, a venture capital firm, since June 2002. Mr.&nbsp;Hurwitz also serves as a director of Sunesis Pharmaceuticals, Inc., a publicly held company, as well as several privately-held companies. The board of directors has
concluded that Mr.&nbsp;Hurwitz should serve on the board of directors due to his financial and scientific expertise, as well as his deep understanding of the biotechnology industry, which the board of directors believes makes him an important
resource for the board of directors as it assesses both financial and strategic decisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Nadav has served as a
director since June 2013. Dr.&nbsp;Nadav is a Managing Director at TPG Biotech, the life science venture investment arm of TPG, a global private investment firm. Dr.&nbsp;Nadav joined TPG Biotech in 2007 with a focus on global pharmaceuticals and
biotechnology investments. Prior to TPG, Dr.&nbsp;Nadav served as Business Development Director at Eisai Pharmaceuticals in New Jersey for four years, where he evaluated and negotiated notable licensing and acquisition deals. Prior to this,
Dr.&nbsp;Nadav worked for Johnson&nbsp;&amp; Johnson Development Corporation, the venture capital subsidiary of Johnson&nbsp;&amp; Johnson, and for Neurim Pharmaceuticals. Based on Dr.&nbsp;Nadav&#146;s business experience and scientific expertise,
the board of directors believes that Dr.&nbsp;Nadav has the appropriate set of skills to serve as a member of our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky has served as a director since 2000. Dr.&nbsp;Oronsky has been a general partner with InterWest Partners, a venture capital firm, since 1994, focusing primarily on life science companies.
Dr.&nbsp;Oronsky serves as a director of Tesaro, Inc., a publicly held company, as well as several privately held life science companies. The board of directors believes that Dr.&nbsp;Oronsky&#146;s experience in the life sciences industry as a
venture capitalist and his service on the boards of directors of other public and private life sciences companies provides him with the qualifications and skills to serve as a director. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Steinmetz has served as a director since 2000. Dr.&nbsp;Steinmetz has been Managing Director of Clarus Ventures since the
firm&#146;s inception in 2005. He has over 24 years of direct industry and investment experience within the healthcare sector. Dr.&nbsp;Steinmetz serves on the board of directors of several privately-held companies. Based on
Dr.&nbsp;Steinmetz&#146;s direct industry and investment experience, the board of directors believes that Dr.&nbsp;Steinmetz has the appropriate set of skills to serve as a member of the board of directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Composition and Election of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Board Composition </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board of directors currently consists of
seven members, all of whom were elected as directors pursuant to a stockholders agreement that we have entered into with the holders of our preferred stock. The stockholders agreement will terminate upon the closing of this offering and there will
be no further contractual obligations regarding the election of our directors. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our certificate of incorporation and bylaws that will become effective upon the closing of this offering provide that the authorized
number of directors may be changed only by resolution of our board of directors. Our certificate of incorporation and bylaws also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least 75% of the
votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of
a majority of our directors then in office. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In accordance with the terms of our certificate of incorporation and bylaws that
will become effective upon the closing of this offering, our board of directors will be divided into three classes, class I, class II and class III, with members of each class serving staggered three-year terms. Upon the closing of this offering,
the members of the classes will be divided as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class I, whose term will expire at the annual meeting of stockholders to be held in 2014; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class II, whose term will expire at the annual meeting of stockholders to be held in 2015; and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">102
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class III, whose term will expire at the annual meeting of stockholders to be held in 2016. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Class I shall consist of Messrs.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, Class II shall consist of Messrs.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
and Class III shall consist of Messrs. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. At each annual meeting of stockholders after the initial classification, the successors to directors whose terms will then
expire serve from the time of election and qualification until the third annual meeting following election and until their successors are duly elected and qualified. A resolution of the board of directors or affirmative vote of at least 66 2/3% of
our outstanding voting stock may change the authorized number of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class
will consist of one third of the directors. This classification of the board of directors may have the effect of delaying or preventing changes in control or management of our company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no formal policy regarding board diversity. Our priority in selection of board members is identification of members who will
further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business and understanding of the
competitive landscape. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Independence of the Members of the Board of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Director Independence </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Applicable NASDAQ rules require a majority of
a listed company&#146;s board of directors to be comprised of independent directors within one year of listing. Under applicable NASDAQ rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed
company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations, the board of directors has affirmatively determined that all of the members of our board of
directors, except for Dr.&nbsp;Koenig, are independent directors within the meaning of the applicable NASDAQ listing requirements. In making its determination of independence, the board of directors considered the relationships of our directors,
other than Mr.&nbsp;Costa, with certain of our principal stockholders. Our board of directors does not believe that these stockholder relationships interfere with these directors&#146; exercise of independent judgment in carrying out their
responsibilities as directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Board Committees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has an audit committee, a compensation committee and a nominating and corporate governance committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our compensation committee currently
consists of Messrs.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. All members of the compensation committee are independent directors, as defined in the NASDAQ Global Market qualification
standards. The functions of this committee include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and, as it deems appropriate, recommending to our board of directors, policies, practices and procedures relating to the compensation of our
directors, officers and other managerial employees and the establishment and administration of our employee benefit plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exercising authority under our employee benefit plans; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing and approving executive officer and director indemnification and insurance matters; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">advising and consulting with our officers regarding managerial personnel and development. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">103
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Audit Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our audit committee consists of Messrs. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
All members of the audit committee are independent directors, as defined in the NASDAQ Global Market qualification standards.
Mr.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; qualifies as an &#147;audit committee financial expert&#148; as that term is defined in the rules and regulations
established by the SEC. The functions of this committee include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">meeting with our management periodically to consider the adequacy of our internal controls and the objectivity of our financial reporting;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">meeting with our independent auditors and with internal financial personnel regarding these matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pre-approving audit and non-audit services to be rendered by our independent auditors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">recommending to our board of directors the engagement of our independent auditors and oversight of the work of our independent auditors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing our financial statements and periodic reports and discussing the statements and reports with our management, including any significant
adjustments, management judgments and estimates, new accounting policies and disagreements with management; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls and
auditing matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewing our financing plans and reporting recommendations to our full board of directors for approval and to authorize action; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administering and discussing with management and our independent auditors our Code of Ethics. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both our independent auditors and internal financial personnel regularly meet privately with the audit committee and have unrestricted
access to this committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our nominating and corporate governance committee is comprised of
Messrs.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. All members of the nominating and corporate governance committee are independent directors, as defined in the NASDAQ Global
Market qualification standards. The functions of this committee include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">identifying qualified candidates to become members of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting nominees for election of directors at the next annual meeting of stockholders (or special meeting of stockholders at which directors are to
be elected); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">selecting candidates to fill vacancies of our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">developing and recommending to our board of directors our corporate governance guidelines; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">overseeing the evaluation of our board of directors. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">104
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Code of Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors has adopted a code of conduct and ethics that establishes the standards of ethical conduct applicable to all directors, officers and employees of our company. The code addresses,
among other things, conflicts of interest, compliance with disclosure controls and procedures and internal control over financial reporting, corporate opportunities and confidentiality requirements. The audit committee is responsible for applying
and interpreting our code of conduct and ethics in situations where questions are presented to it. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and
Insider Participation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the members of our compensation committee at any time has been one of our officers or
employees. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our board of directors or
compensation committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Executive Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our named executive officers for the year ended December&nbsp;31, 2012 include our principal executive officer and two other officers: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., President and Chief Executive Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D., Senior Vice President, Clinical Development; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D., Senior Vice President, Research. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2012 Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table presents the
compensation awarded to, earned by or paid to each of our named executive officers for the year ended December&nbsp;31, 2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary&nbsp;$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards&nbsp;$(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nonequity<BR>Incentive Plan<BR>Compensation(2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Compensation&nbsp;$(3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total&nbsp;$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,648</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">220,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,675</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">865,323</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Clinical Development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">357,690</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">94,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43,038</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">518,728</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Research</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2012</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">298,143</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">100,000</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,675</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">441,818</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect the grant date fair value for awards granted during 2012. The grant date fair value was computed in accordance with Financial Accounting Standards
Board Accounting Standards Codification Topic 718,<I>&nbsp;Compensation &#150; Stock Compensation</I>. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect the performance bonuses paid in 2013 for performance during 2012, as discussed further below under &#147;Narrative to Summary Compensation
Table&#151;Nonequity Incentive Plan Compensation.&#148; </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amounts reflect $3,675 in 401(k) matching for each of Dr.&nbsp;Koenig, Dr.&nbsp;Daifotis and Dr.&nbsp;Bonvini, and $39,363 in reimbursement for travel-related
expenses and lodging in connection with Dr.&nbsp;Daifotis&#146; commuting from her personal residence in New Jersey to our headquarters in Maryland. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">105
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Narrative to Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Annual Salary </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We review compensation annually for all employees,
including our executives. In setting executive base salaries and bonuses and granting equity incentive awards, we consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual
performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and long-term results that are in the best interests of our stockholders, and a long-term commitment to our company. We do not target
a specific competitive position or a specific mix of compensation among base salary, bonus or long-term incentives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board
of directors has historically determined our executives&#146; compensation. Our compensation committee typically reviews and discusses management&#146;s proposed compensation with the chief executive officer for all executives other than the chief
executive officer. Based on those discussions and its discretion, the compensation committee then recommends the compensation for each executive officer. Our board of directors, without members of management present, discusses the compensation
committee&#146;s recommendations and ultimately approves the compensation of our executive officers. To date, our compensation committee has not engaged a compensation consultant or adopted a peer group of companies for purposes of determining
executive compensation. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Nonequity Incentive Plan Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our bonus plan motivates and rewards our executives for achievements relative to our goals and expectations for each fiscal year. Each
named executive officer has a target bonus opportunity, defined as a percentage of his or her annual salary. Following the end of each year, our board of directors determines bonuses. Material considerations in determining bonuses include
achievement of an executive&#146;s corporate objectives for the year; the executive&#146;s handling of unplanned events and opportunities; and the chief executive officer&#146;s input with respect to the performance of the company, our executives
and our financial performance relative to our plan. Based on these factors and in the sole discretion of our board of directors, we approved the bonuses in the table above for our named executive officers in 2013. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Specific achievements and performance considered by our board of directors in determining bonuses for 2012 included: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing development of margetuximab, including additional enrollment of patients in the Phase 1 clinical trial and the initiation of activities
related to the Phase 2a metastatic breast cancer clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing development of MGA271, including completing enrollment of the 5.0 mg/kg dosing cohort in the dose escalation portion of a Phase 1 clinical
trial and submitting a paper for publication; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Advancing our existing DART collaborations with Boehringer and Pfizer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Finalizing candidate nomination and initiating IND-enabling activities for MGD006; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating a safety study for MGD010; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Achieving cash proceeds from new business development activities of at least $10 million; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintaining a cash balance greater than $30 million throughout the year and ending the year with more than $35 million in cash and cash equivalents.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Long-Term Incentives </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2000 Stock Option and Incentive Plan, or 2000 Plan, and our 2003 Equity Incentive Plan, or 2003 Plan, authorized us to make grants to eligible recipients of non-qualified stock options, incentive
stock options, stock awards, and other forms of award, such as stock appreciation rights. Although the 2000 Plan and 2003 Plan provide for a range of types of awards, our equity grants to our executive officers have been only in the form of stock
options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We typically grant equity incentive awards at the start of employment to each executive and our other employees.
Through 2012, we have not maintained a practice of granting additional equity on an annual basis, but we have retained discretion to provide additional targeted grants in certain circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We award our equity grants on the date our board of directors approves the grant. We set the option exercise price and grant date fair
value based on our per-share valuation on the date of grant. For grants in connection with initial employment, vesting begins on the initial date of employment. Time vested stock option grants to our executives typically vest 12.5% six months after
the date of grant with the remainder vesting in 14 equal quarterly installments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">106
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;31, 2013, options to purchase 66,346,934 shares of common stock at a
weighted average exercise price per share of $0.05 were outstanding. As of March&nbsp;31, 2013, 5,949,117 shares of common stock remained available for future issuance under the 2003 Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please see &#147;&#151;Employee Benefit Plans&#148; for information relating to additional current and future benefit plans. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Other Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We paid $39,363 for commercial airfare and other travel-related expenses and lodging in connection with Dr.&nbsp;Daifotis&#146; commuting
from her personal residence in New Jersey to our headquarters in Maryland on a regular basis. Other amounts shown in the &#147;All Other Compensation&#148; column in the Summary Compensation Table relate to 401(k) matching contributions made to
Dr.&nbsp;Koenig&#146;s, Dr.&nbsp;Daifotis&#146; and Dr.&nbsp;Bonvini&#146;s 401(k) accounts, consistent with the matching contributions offered to all of our employees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Outstanding Equity Awards at 2012 Fiscal Year End </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table
lists all outstanding equity awards held by our named executive officers as of December&nbsp;31, 2012. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date(1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B># Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Securities<BR>Underlying<BR>Unexercised&nbsp;Options</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B># Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price&nbsp;$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option&nbsp;Expiration&nbsp;Date</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/13/2001</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">408,222</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.01</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/12/2013</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/21/2002</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,499,670</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5/20/2015</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/14/2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">340,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/13/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/24/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,497,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/24/2015</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/15/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/15/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/7/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2017</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/16/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/15/2017</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,875,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2019</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">103,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2020</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">468,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,031,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/5/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,137,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">712,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11/4/2019</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/8/2021</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">243,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">300,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/17/2003</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">250,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4/16/2014</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/14/2004</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/13/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/24/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,510,969</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/23/2016</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/15/2005</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.0375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12/14/2015</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/7/2007</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">580,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2017</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2008</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">225,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2018</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">234,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2019</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/11/2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">85,937</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/10/2020</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/9/2011</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">87,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">112,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/8/2021</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/14/2012</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">406,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.05</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/13/2022</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/6/2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">500,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">.08</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1/5/2023</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Options vest and become exercisable with respect to (i)12.5 percent of the underlying shares six months after the grant date and (ii)&nbsp;the remainder of the
underlying shares in 14 equal quarterly installments. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Director Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as discussed below, during and prior to 2012, we did not pay cash compensation to any non-employee director for his or her service
as a director. We reimburse our non-employee directors for reasonable travel and other expenses incurred in connection with attending board of director and committee meetings or otherwise in direct service of our company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">107
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with his service as a director, Mr.&nbsp;Costa receives $25,000 per year. In
addition, with his election as a director in June 2009, we granted Mr.&nbsp;Costa an option to purchase 928,093 shares of our common stock. In 2013, Mr.&nbsp;Costa exercised the option in its entirety. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plans </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our employees, including our executive officers, are entitled to various employee benefits. These benefits include the following: medical
and dental care plans; flexible spending accounts for healthcare; life, accidental death and dismemberment and disability insurance; employee assistance programs (confidential counseling); benefit advocacy counseling; a 401(k) plan; and paid time
off. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Pension Benefits </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We do not have any qualified or non-qualified defined benefit plans. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Non-qualified
Deferred Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We do not have any non-qualified defined contribution plans or other deferred compensation
plans. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>401(k) Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our employees are eligible to participate in our 401(k) plan. Our 401(k) plan is intended to qualify as a tax-qualified plan under Section&nbsp;401 of the Internal Revenue Code of 1986, as amended. Our
401(k) plan provides that each participant may contribute a portion of his or her pre-tax compensation, up to a statutory limit, which for most employees is $17,500 in 2013. Participants that are 50 years or older can also make &#147;catch-up&#148;
contributions, which in 2013 may be up to an additional $5,500 above the statutory limit. Employee contributions are held and invested by the plan&#146;s trustee. Our 401(k) plan also permits us to make discretionary contributions and matching
contributions. We match participant contributions up to 1.5% of a participant&#146;s annual compensation, subject to statutory limits. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2000 Stock Option and Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our 2000 Plan is administered by our compensation committee and provided for the grant of incentive stock options within the meaning of Section&nbsp;422 of the Internal Revenue Code, non-statutory stock
options, restricted stock, and other stock-based awards. Our employees, officers, directors, consultants and advisors were eligible to receive awards under our 2000 Plan. Upon an acquisition of us, the exercisability of options or the vesting of
restricted stock awards issued under the 2000 Plan will be accelerated. In addition, the Board will make appropriate provisions for the continuation of awards by us or substitution of awards by the surviving or acquiring entity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;31, 2013, under our 2000 Plan, there were options to purchase an aggregate of 1,135,039 shares of common stock
outstanding at a weighted average exercise price of $0.033 per share. The 2000 Plan has expired, and no further awards may be issued under the plan. Any shares of common stock subject to awards under our 2000 Plan that expire, terminate, or are
otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under our 2013 Stock Incentive Plan, or the 2013 Plan, up to a specified
number of shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2003 Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We implemented our 2003 Plan in February 2003, and it was amended and approved by our stockholders in 2005. Our board of directors has delegated the administration of the 2003 Plan to our compensation
committee. The 2003 Plan provides for the for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, and other stock-based awards. The 2003 Plan also permits the payment of cash awards. Our
employees, officers, directors and consultants are eligible to receive awards under our 2003 Plan. As of March&nbsp;31, 2013, we have only granted stock options under the 2003 Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">108
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of changes in our capital structure, our compensation committee will make
appropriate adjustments to&nbsp;the number of shares reserved for issuance under the 2003 Plan,&nbsp;the number of shares underlying by each outstanding option or stock purchase agreement, the exercise price or purchase price under each outstanding
option or stock purchase agreement, the repurchase prices, the number of options that may be granted to any individual and/or the class of shares issuable and the terms of any stock appreciation right. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we merge with another entity and are not the surviving entity or if, as a result of any other transaction or event, other securities
are substituted for the shares of common stock or shares may no longer be issued then our board of directors will accelerate the vesting of any outstanding incentive stock options by a period of 24 months. In addition, if an employee&#146;s
employment is terminated following such a transaction without cause or he or she terminates his or her employment for good reason (as defined in the 2003 Plan), then the incentive stock option will be exercisable in full without regard to its
vesting schedule. Our board, in its discretion, may also: (a)&nbsp;arrange for the substitution, in exchange for awards, of options to purchase equity securities other than shares of our common stock; (b)&nbsp;accelerate the vesting and termination
of outstanding awards, in whole or in part, so that awards can be exercised before or otherwise in connection with the closing or completion of a transaction or event but then terminate; (c)&nbsp;cancel or arrange for the cancellation of awards in
exchange for cash payments to awardees; and (d)&nbsp;either arrange for any of our repurchase rights with respect to shares of common stock to apply to the securities issued in substitution for shares or terminate repurchase rights on such shares.
Our board does not need to adopt the same rules for each award or awardee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our board may also, in its discretion, specify
that other transactions or events constitute a &#147;change of control,&#148; either before or after the transaction. In connection with a change of control, our board may take any one or more of the actions described above and extend the date for
the exercise of awards, but not beyond the original expiration date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of March&nbsp;31, 2013, under our 2003 Plan, there
were options to purchase an aggregate of 65,211,895 shares of common stock outstanding at a weighted average exercise price of $0.051 per share. There were 5,949,117&nbsp;shares remaining and available for issuance under the 2003 Plan as of that
date. Upon the closing of this offering, we will grant no further stock options or other awards under our 2003 Plan. Any shares of common stock subject to awards under our 2003 Plan that expire, terminate, or are otherwise surrendered, canceled,
forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under our 2013 Plan, up to a specified number of shares. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2013 Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our board of directors adopted the 2013 Plan in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013 and our stockholders approved the 2013 Plan in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. The 2013 Plan will become effective immediately upon the signing of the underwriting agreement for this offering. The 2013 Plan will terminate on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2023, unless terminated earlier by our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Awards</I>. The 2013 Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights,
performance stock awards, and other forms of equity compensation (collectively, &#147;stock awards&#148;), which may be granted to employees, including officers, non-employee directors, and consultants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Share Reserve</I>. Following this offering, the aggregate number of shares of common stock that may be issued initially pursuant to
stock awards under the 2013 Plan is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. The number of shares of common stock reserved for issuance will automatically increase on January&nbsp;1st, from January&nbsp;1, 2014 through and including
January&nbsp;1, 2023, by the lesser of (a)&nbsp;4.0% of the total number of shares of common stock outstanding on December&nbsp;31st of the preceding calendar year, or (b)&nbsp;a lesser number of shares of common stock determined by our board of
directors prior to the start of a calendar year for which an increase applies. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options over the term of the 2013 Plan is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a stock award granted under the 2013 Plan expires or otherwise
terminates without being exercised in full, the shares of common stock not acquired pursuant to the stock award again become available for subsequent issuance under the 2013 Plan. In addition, the following types of shares under the 2013 Plan will
become available for the grant of new stock awards under the 2013 Plan: (a)&nbsp;shares that are forfeited to or repurchased by us prior to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">109
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
becoming fully vested; (b)&nbsp;shares subject to stock awards that are settled in cash; (c)&nbsp;shares withheld to satisfy income and employment withholding taxes; (d)&nbsp;shares used to pay
the exercise price of an option in a net exercise arrangement; (e)&nbsp;shares tendered to us to pay the exercise price of an option; and (f)&nbsp;shares that are cancelled pursuant to an exchange or repricing program. Shares issued under the 2013
Plan may be previously unissued shares or reacquired shares, including shares bought on the open market. As of the date hereof, no shares of common stock have been issued under the 2013 Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Administration</I>. Our board of directors has delegated its authority to administer the 2013 Plan to our compensation committee.
Subject to the terms of the 2013 Plan, our board of directors or an authorized committee, referred to as the plan administrator, determines recipients, dates of grant, the numbers and types of stock awards to be granted, and the terms and conditions
of the stock awards, including the period of their exercisability and vesting. Subject to the limitations set forth below, the plan administrator will also determine the exercise price of options granted, the consideration to be paid for restricted
stock awards, and the strike price of stock appreciation rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Options</I>. Incentive and nonstatutory stock
options are granted pursuant to incentive and nonstatutory stock option agreements adopted by the plan administrator. The plan administrator determines the exercise price for a stock option provided that the exercise price of an incentive stock
option and nonstatutory stock option cannot be less than 100% of the fair market value of our common stock on the date of grant. Options granted under the 2013 Plan vest at the rate specified by the plan administrator. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, the plan administrator determines the term of stock options granted under the 2013 Plan, up to a maximum of ten years (except
in the case of certain incentive stock options, as described below). Unless the terms of an optionee&#146;s stock option agreement provide otherwise, if an optionee&#146;s relationship with us, or any of our affiliates, ceases for any reason other
than disability or death, the optionee may exercise any vested options for a period of three months following the cessation of service. If an optionee&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death
(or an optionee dies within a certain period following cessation of service), the optionee or a beneficiary may exercise any vested options for a period of 12 months in the event of disability, and 18 months in the event of death. The option term
may be extended in the event that exercise of the option following termination of service is prohibited by applicable securities laws. In no event, however, may an option be exercised beyond the expiration of its term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptable consideration for the purchase of common stock issued upon the exercise of a stock option will be determined by the plan
administrator and may include (a)&nbsp;cash or check, (b)&nbsp;a broker-assisted cashless exercise, (c)&nbsp;the tender of common stock previously owned by the optionee, (d)&nbsp;a net exercise of the option and (e)&nbsp;other legal consideration
approved by the plan administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless the plan administrator provides otherwise, options generally are not transferable
except by will, the laws of descent and distribution, or pursuant to a domestic relations order. An optionee may designate a beneficiary, however, who may exercise the option following the optionee&#146;s death. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Tax Limitations on Incentive Stock Options</I>. Incentive stock options may be granted only to our employees. The aggregate fair
market value, determined at the time of grant, of shares of our common stock with respect to incentive stock options that are exercisable for the first time by an optionee during any calendar year under all of our stock plans may not exceed
$100,000. No incentive stock option may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our affiliates unless (a)&nbsp;the option
exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant and (b)&nbsp;the term of the incentive stock option does not exceed five years from the date of grant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock Awards</I>. Restricted stock awards may be granted pursuant to restricted stock award agreements adopted by the plan
administrator. Restricted stock awards may be granted in consideration for: (a)&nbsp;cash, check, bank draft or money order, (b)&nbsp;past or future services rendered to us or our affiliates or (c)&nbsp;any other form of legal consideration
acceptable to our board of directors. Shares of common stock acquired under a restricted stock award may, but need not, be subject to forfeiture to us in accordance with a vesting schedule to be determined by the plan administrator. Rights to
acquire shares under a restricted stock award may be transferred only upon such terms and conditions as set by the plan administrator. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">110
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restricted Stock Unit Awards</I>. Restricted stock unit awards may be granted pursuant to
restricted stock unit award agreements adopted by the plan administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration acceptable to our board of directors. A restricted stock unit award may be
settled by cash, delivery of stock, a combination of cash and stock as deemed appropriate by the plan administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may
be credited in respect to shares underlying a restricted stock unit award. Except as otherwise provided in the applicable award agreement, restricted stock units that have not vested will be forfeited upon the participant&#146;s cessation of
continuous service for any reason. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stock Appreciation Rights</I>. Stock appreciation rights may be granted pursuant to
stock appreciation rights agreements adopted by the plan administrator. The plan administrator determines the strike price for a stock appreciation right which cannot be less than 100% of the fair market value of the common stock on the date of
grant. Upon the exercise of a stock appreciation right, we will pay the participant an amount equal to the product of (a)&nbsp;the excess of the per share fair market value of our common stock on the date of exercise over the strike price,
multiplied by (b)&nbsp;the number of shares of common stock with respect to which the stock appreciation right is exercised. A stock appreciation right granted under the 2013 Plan vests at the rate specified in the stock appreciation right
agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The plan administrator determines the term of stock appreciation rights granted under the 2013 Plan up to a
maximum of ten years. If a participant&#146;s service relationship with us, or any of our affiliates, ceases, then the participant, or the participant&#146;s beneficiary, may exercise any vested stock appreciation right for three months (or such
longer or shorter period specified in the stock appreciation right agreement) after the date such service relationship ends. In no event, however, may a stock appreciation right be exercised beyond the expiration of its term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Performance Stock Awards</I>. The 2013 Plan permits the grant of performance stock awards that may qualify as performance-based
compensation that is not subject to the $1 million limitation on the income tax deductibility of compensation paid to certain executive officers imposed by Section&nbsp;162(m) of the Internal Revenue Code. To assure that the compensation
attributable to one or more performance stock awards will so qualify, our compensation committee can structure one or more such awards so that stock will be issued or paid pursuant to such award only upon the achievement of certain pre-established
performance goals during a designated performance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Other Stock Awards</I>. The plan administrator may grant other
awards based in whole or in part by reference to our common stock. The plan administrator will set the number of shares under the award and all other terms and conditions of such awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes to Capital Structure</I>. In the event that there is a specified type of change in our capital structure, such as a stock
split, appropriate adjustments will be made to (a)&nbsp;the number of shares reserved under the 2013 Plan, (b)&nbsp;the maximum number of shares that may be issued pursuant to the exercise of incentive stock options, (c)&nbsp;the maximum number of
stock options, stock appreciation rights, and performance stock awards for which any one person may be granted per calendar year and (d)&nbsp;the number of shares and exercise price or strike price, if applicable, of all outstanding stock awards.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Corporate Transactions</I>. In the event of certain significant corporate transactions as set forth in the 2013 Plan
outstanding stock awards under the 2013 Plan may be assumed, continued or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue or
substitute for such stock awards, then (a)&nbsp;with respect to any such stock awards that are held by individuals whose service with us or our affiliates has not terminated prior to the effective date of the corporate transaction, the vesting and
exercisability provisions of such stock awards will be accelerated in full and such awards will be terminated if not exercised prior to the effective date of the corporate transaction and (b)&nbsp;all other outstanding stock awards will terminate if
not exercised prior to the effective date of the corporate transaction. Our board of directors may also provide that the holder of an outstanding stock award not assumed in the corporate transaction will surrender such stock award in exchange for a
payment equal to the excess of (a)&nbsp;the value of the property that the stock award would have received upon exercise of the stock award, over (b)&nbsp;the exercise price otherwise payable in connection with the stock award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Changes in Control</I>. Our board of directors has the discretion to provide that a stock award under the 2013 Plan will immediately
vest as to all or any portion of the shares subject to the stock award (a)&nbsp;immediately upon the occurrence of certain specified change in control transactions, whether or not such stock award is assumed, continued, or substituted by a surviving
or acquiring entity in the transaction or (b)&nbsp;in the event a participant&#146;s service with us or a successor entity is terminated actually or constructively within a designated period following the occurrence of certain specified change in
control transactions. Stock awards held by participants under the 2013 Plan will not vest on such an accelerated basis unless specifically provided by the participant&#146;s applicable award agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">111
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_12"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Transactions with Management and Others </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Since January&nbsp;1, 2010, there has not been, nor is there any proposed transaction where we were or will be a party in which the amount involved exceeded or will exceed $120,000 and in which any
director, executive officer, holder of more than 5% of any class of our voting securities, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than the compensation
agreements and other agreements and transactions which are described in &#147;Management&#148;. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Policies and Procedures for Related Party
Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the written charter of our audit committee adopted March&nbsp;24, 2005, our audit committee of
the board of directors is responsible for reviewing and approving, prior to our entry into any such transaction, all related party transactions and potential conflict of interest situations involving a principal stockholder, a member of the board of
directors or senior management. In addition, our company policies require that our officers and employees avoid using their positions for purposes that are, or give the appearance of being, motivated by a desire for personal gain, and our policies
further require that all officers and employees who have authority to initiate related party transactions provide a written report, on an annual basis, of all activities which could result in a conflict of interest or impair their professional
judgment. All such written reports concerning related party transactions or conflicts of interest are submitted to, and reviewed by, our Chief Financial Officer and our audit committee. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">112
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_13"></A>PRINCIPAL STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table indicates information as of June&nbsp;30, 2013 regarding the ownership of our common stock, after giving effect to
the sale of common stock offered in this offering, for: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each person who is known by us to own more than 5% of our shares of common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each named executive officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">each of our directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">all of our directors and executive officers as a group. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The number of shares beneficially owned and the percentage of shares beneficially owned are based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding as of June&nbsp;30,
2013, which includes &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock resulting from the conversion of all outstanding shares of our preferred stock immediately upon the closing of this offering, as if
this conversion had occurred as of June&nbsp;30, 2013. Percentage ownership of our common stock after this offering (assuming no exercise of the underwriters&#146; over-allotment option to purchase additional shares) assumes our sale of shares in
this offering. Unless otherwise indicated in the footnotes to the table, and subject to community property laws where applicable, the following persons have sole voting and investment control with respect to the shares beneficially owned by them. In
accordance with SEC rules, if a person has a right to acquire beneficial ownership of any shares of common stock, on or within 60&nbsp;days of June&nbsp;30, 2013, upon exercise of outstanding options or otherwise, the shares are deemed beneficially
owned by that person and are deemed to be outstanding solely for the purpose of determining the percentage of our shares that person beneficially owns. These shares are not included in the computations of percentage ownership for any other person.
Except as otherwise indicated, the address of each of the persons in this table is 9640 Medical Center Drive, Rockville, Maryland 20850. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="18%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:134pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Prior to the Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>After the Offering</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with TPG (1)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with Alta BioPharma Partners (2)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with InterWest Partners (3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with MPM BioVentures (4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entities affiliated with CDP (5)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ventures West 8 Limited Partnership (6)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Directors and Named Executive Officers:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D. (8)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz (9)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D. (10)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael Steinmetz, Ph.D. (11)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith (7)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa (12)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D. (13)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Anastasia Daifotis, M.D. (14)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ezio Bonvini, M.D. (15)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group (11 persons)(16)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates ownership of less than 1%. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;21,352,187 shares of common stock issuable upon conversion of Series B Preferred Stock, (ii)&nbsp;19,724,839 shares of common
stock issuable upon conversion of Series C Preferred Stock, (iii)&nbsp;383,376 shares of common stock issuable upon conversion of Series D-2 Preferred Stock and (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">113
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Preferred Stock exercisable within 60 days after June&nbsp;30, 2013 held of record by entities affiliated with TPG. TPG Biotechnology Partners, L.P., a Delaware limited partnership, whose general
partners is TPG biotechnology GenPar, L.P., a Delaware limited partnership, whose general partner is TPG Biotechnology GenPar Advisors, LLC, a Delaware limited liability company (&#147;Biotechnology GenPar Advisors&#148;), and (ii)&nbsp;TPG
Ventures, L.P., a Delaware limited partnership, whose general partner is TPG Ventures GenPar Advisors LLC, a Delaware limited liability company (&#147;Ventures GenPar Advisors&#148;) are collectively referred to as the entities affiliated with TPG.
The sole member of each of Biotechnology GenPar Advisors and Ventures GenPar Advisors is TPG Holdings I, L.P., a Delaware limited partnership, whose general partner is TPG Holdings I-A, LLC, a Delaware limited liability company, whose sole member is
TPG Group Holdings (SBS), L.P., a Delaware limited partnership, whose general partner is TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation. Dr.&nbsp;Nadav, a member of our board of directors,&nbsp;may be deemed to share voting and
investment power with respect to the shares held by TPG Ventures, L.P. and TPG Biotechnology Partners, L.P. Dr.&nbsp;Nadav disclaims beneficial ownership of the shares owned by these funds, except to the extent of his pecuniary interest therein. The
address for TPG Ventures affiliated entities is 345 California Street, Suite 3300, San Francisco, California 94104. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;21,352,186 shares of common stock issuable upon conversion of Series B Preferred Stock, (ii)&nbsp;12,328,024 shares of common stock issuable upon
conversion of Series C Preferred Stock, (iii)&nbsp;3,833,767 shares of common stock issuable upon conversion of Series D-2 Preferred Stock and (iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock
issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock exercisable within 60 days after June&nbsp;30, 2013 held of record by entities affiliated with Alta BioPharma Partners. Alta
BioPharma Partners, L.P., Alta BioPharma Partners III GmbH&nbsp;&amp; Co. Beteiligings KG and Alta Embarcadero BioPharma Partners III, LLC are collectively referred to as the entities affiliated with Alta BioPharma Partners. The directors of Alta
BioPharma Management Partners III, LLC, which is the general partner of Alta Biopharma Partners III, L.P., the managing limited partner of Alta Biopharma Partners III GmbH&nbsp;&amp; Co. Beteiligungs KG, and the manager of Alta Embarcadero Biopharma
Partners III, LLC, exercise sole dispositive and voting power over the shares owned by the entities affiliated with Alta BioPharma Partners. Edward Hurwitz, one of our directors, Farah Champsi and Edward Penhoet are directors of Alta BioPharma
Management Partners III, LLC and managers of Alta Embarcadero Biopharma Partners III, LLC. These individuals may be deemed to share dispositive and voting power over the shares held by the entities affiliated with Alta BioPharma Partners. Each of
these individuals disclaims beneficial ownership of such shares except to the extent of his or her pecuniary interest therein. The principal address for the entities affiliated with Alta BioPharma Partners is One Embarcadero Center, Suite 3700, San
Francisco, CA 94111. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;18,075,905 shares of common stock issuable upon conversion of Series A-1 Preferred Stock, (ii)&nbsp;11,551,327 shares of common stock issuable upon
conversion of Series B Preferred Stock (iii)&nbsp;5,547,611 shares of common stock issuable upon conversion of Series C Preferred Stock (iv)&nbsp;613,402 shares of common stock issuable upon conversion of Series D-2 Preferred Stock and
(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock exercisable within 60 days
after June&nbsp;30, 2013 held of record by entities affiliated with InterWest Partners. InterWest Partners VIII, L.P. (&#147;IW8&#148;), InterWest Investors Q VIII, L.P., and InterWest Investors VIII, L.P. are collectively referred to as the
entities affiliated with InterWest Partners. InterWest Management Partners VIII, LLC (&#147;IMP8&#148;) is the general partner of the entities affiliated with InterWest Partners and has sole voting and investment control over the shares held by the
entities affiliated with InterWest Partners. Harvey B. Cash, Philip T. Gianos, W.&nbsp;Scott Hedrick, W. Stephen Holmes, Gilbert H. Kliman and Arnold L. Oronsky, a member of our board of directors, are the managing directors of IMP8. Each of the
managing directors share voting and investment control with respect to the shares held by the entities affiliated with InterWest Partners. Dr.&nbsp;Oronsky disclaims beneficial ownership of all shares held by the entities affiliated with InterWest
Partners except to the extent of his pecuniary interest therein. The address for these entities is c/o InterWest Partners, 2710 Sand Hill Road, Suite 200, Menlo Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 15,061,999 shares of common stock issuable upon conversion of Series A-1 Preferred Stock, (ii) 9,743,982 shares of common stock issuable upon conversion
of Series B Preferred Stock and (iii) 8,629,617 shares of common stock issuable upon conversion of Series C Preferred Stock held of record by entities affiliated with MPM. MPM BioVentures II, L.P., MPM BioVentures II-QP, L.P., MPM BioVentures GmbH
&amp; Co. Parallel-Beteiligungs KG, MPM Asset Management Investors 2000B LLC and MPM BioVentures IV Strategic Fund, L.P. are collectively referred to as the entities affiliated with MPM. MPM Asset Management II L.P. is the general partner of MPM
BioVentures II, L.P. and MPM BioVentures II-QP, L.P. and the special limited partner of MPM BioVentures GmbH &amp; Co. Parallel-Beteiligungs KG. MPM BioVentures II LLC is the general partner of MPM Asset Management II L.P. Ansbert Gadicke, Luke
Evnin, Nicholas Galakatos, Michael Steinmetz and Kurt Wheeler are the investment managers of MPM BioVentures II LLC and MPM Asset Management Investors 2000B LLC and share voting and dispositive power over the shares held by MPM BioVentures II, L.P.,
MPM BioVentures II-QP, L.P., MPM BioVentures GmbH &amp; Co. Parallel-Beteiligungs KG and MPM Asset Management Investors 2000B LLC. MPM BioVentures IV GP LLC is the general partner of MPM BioVentures IV Strategic Fund, L.P. MPM BioVentures IV LLC is
the Managing Member of MPM BioVentures IV GP LLC. Ansbert Gadicke, Luke Evnin, Todd Foley, Vaughn Kailian, Jim Scopa and John Vander Vort are members of MPM BioVentures IV LLC and share voting and dispositive power over the shares held by MPM
BioVentures IV Strategic Fund, L.P. Each individual identified in this footnote disclaims beneficial ownership of the shares except to the extent of his respective proportionate pecuniary interest in such shares. The address for the entities
affiliated with MPM is 200 Clarendon Street, 54th Floor, Boston, MA 02116. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">114
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i) 24,656,048 shares of common stock issuable upon conversion of Series C Preferred Stock held of record by Caisse de d&eacute;p&ocirc;t et placement du
Qu&eacute;bec, or CDP, and (ii) 287,847 shares of common stock issuable upon conversion of Series D Preferred Stock held of record by Saints Capital V, which CDP may be deemed to beneficially own. CDP and Saints Capital V are collectively referred
to as the entities affiliated with CDP. CDP has a 20% ownership interest in Saints Capital V and a 5% ownership interest in Ventures West 8. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;19,724,839 shares of common stock issuable upon conversion of Series C Preferred Stock, (ii)&nbsp;3,833,767 shares of common stock issuable upon
conversion of Series D-2 Preferred Stock and (iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series
D-2 Preferred Stock exercisable within 60 days after June&nbsp;30, 2013 held of record by Ventures West 8 Limited Partnership. Kenneth Galbraith is General Partner and Senior Vice President of Ventures West 8 Management Ltd., the general partner of
the stockholder. Mr.&nbsp;Galbraith, one of our directors, along with the other partners of Ventures West 8 Management, Inc., have sole voting and investment control over the interest owned by Ventures West 8 Limited Partnership and disclaims
beneficial ownership of such shares except to the extent of any pecuniary interest therein. The address for Ventures West 8 Limited Partnership is Suite 400-999 West Hastings Street, Vancouver, BC, V6C 2W2. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (6)&nbsp;above. Mr.&nbsp;Galbraith is a General Partner of Ventures West Capital Ltd., and as such Mr.&nbsp;Galbraith may
be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr.&nbsp;Galbraith disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Mr.&nbsp;Galbraith&#146;s
business address is c/o Ventures West 8 Limited Partnership, Suite 400-999 West Hastings Street, Vancouver, BC, V6C 2W2. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(8)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (1)&nbsp;above. Dr.&nbsp;Nadav is Managing Director of TPG Biotech, and as such Dr.&nbsp;Nadav may be deemed to share
voting and dispositive power with respect to all shares held by these entities. Dr.&nbsp;Nadav disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein. Dr.&nbsp;Nadav&#146;s business address is 345
California Street, Suite 2600, San Francisco, California 94104. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(9)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (2)&nbsp;above. Mr.&nbsp;Hurwitz is a director of Alta BioPharma Management Partners III, LLC and , and as such
Mr.&nbsp;Hurwitz may be deemed to share voting and dispositive power with respect to all shares held by these entities. Mr.&nbsp;Hurwitz disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
Mr.&nbsp;Hurwitz&#146;s business address is c/o Alta BioPharma Partners, One Embarcadero Center, Suite 3700, San Francisco, CA 94111. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(10)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (3)&nbsp;above. Dr.&nbsp;Oronsky is Managing Director of the general partner of the entities affiliated with InterWest
Partners, and as such Dr.&nbsp;Oronsky may be deemed to share voting and dispositive power with respect to all shares held by these entities. Dr.&nbsp;Oronsky disclaims beneficial ownership of such shares except to the extent of any pecuniary
interest therein. Dr.&nbsp;Oronsky&#146;s business address is c/o InterWest Partners, 2710 Sand Hill Road, Suite 200, Menlo Park, California 94025. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of the shares described in footnote (4)&nbsp;above. Dr.&nbsp;Steinmetz is an Investment Manager of MPM Asset Management II, L.P. and MPM Asset Management
Investors 2000B LLC, and as such Dr.&nbsp;Steinmetz may be deemed to share voting and dispositive power with respect to all shares held by these entities. Dr.&nbsp;Steinmetz disclaims beneficial ownership of such shares except to the extent of any
pecuniary interest therein. Dr.&nbsp;Steinmetz&#146;s business address is c/o MPM BioVentures, 200 Clarendon Street, 54th Floor, Boston, Massachusetts 02116. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(12)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 928,093 shares of common stock. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(13)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;1,000,000 shares of common stock, (ii) 12,037,983 shares of common stock owned jointly by Dr. Koenig and his spouse, of which Dr. Koenig has shared
voting and dispositive power, (iii) 1,000,000 shares of common stock held by the Scott Koenig Family Trust, an irrevocable trust, of which Dr. Koenig&#146;s spouse and brother-in-law are co-trustees, and of which Dr. Koenig may be deemed to have
shared voting and dispositive power, and (iv) 7,205,331 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(14)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 2,750,000 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(15)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of 3,380,344 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">115
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(16)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consists of (i)&nbsp;33,137,904 shares of common stock issuable upon conversion of Series A-1 Preferred Stock, (ii)&nbsp;63,999,682 shares of common stock issuable upon
conversion of Series B Preferred Stock, (iii)&nbsp;90,610,978 shares of common stock issuable upon conversion of Series C Preferred Stock, (iv)&nbsp;8,664,312 shares of common stock issuable upon conversion of Series D-2 Preferred Stock,
(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon conversion of Series D-2 Preferred Stock underlying warrants to purchase our Series D-2 Preferred Stock exercisable within 60 days
after June&nbsp;30, 2013, (vi)&nbsp;16,472,326 shares of common stock and (vii)&nbsp;17,901,644 shares of common stock issuable upon the exercise of options exercisable within 60 days after June&nbsp;30, 2013. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">116
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_14"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following description of our securities and provisions of our amended and restated certificate of incorporation and bylaws that we
expect to become effective upon the closing of this offering is only a summary. You should also refer to the copies of our certificate and bylaws which have been filed with the Securities and Exchange Commission as exhibits to our registration
statement, of which this prospectus forms a part. The description of common stock and preferred stock reflect changes to our capital structure that will occur upon the closing of this offering in accordance with the terms of the amended and restated
certificate of incorporation that will be adopted by us immediately prior to the closing of this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing
of this offering, our authorized capital stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.01 per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock, par
value $0.01 per share. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Common Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Currently, we are authorized to issue 425,000,000 shares of common stock. At June 30, 2013, 36,836,099 shares of common stock were deemed outstanding and held of record by 140 holders. Under the amended
and restated certificate of incorporation and bylaws, holders of common stock do not have cumulative voting rights. Holders of shares representing a majority of the voting power of common stock can elect all of the directors. The holders of the
remaining shares will not be able to elect any directors. The shares of common stock offered by this prospectus, when issued, will be fully paid and non-assessable and will not be subject to any redemption or sinking fund provisions. Holders of
common stock do not have any preemptive, subscription or conversion rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Holders of common stock are entitled to receive
dividends declared by the board of directors out of legally available funds, subject to the rights of preferred stockholders, if any, and the terms of any future agreements between us and our lenders, if any. We presently intend to retain future
earnings, if any, for use in the operation and expansion of our business. We do not anticipate paying cash dividends on our common stock in the foreseeable future. See &#147;Dividend Policy.&#148; In the event of our liquidation, dissolution or
winding up, common stockholders are entitled to share ratably in all assets legally available for distribution after payment of all debts and other liabilities, and subject to the prior rights of any holders of outstanding shares of preferred stock,
if any. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Currently, we are authorized to issue 321,592,828 shares of preferred stock. As of June&nbsp;30, 2013, there were 294,720,231 shares of preferred stock held by 77 stockholders of record. Upon completion
of this offering, all shares of our preferred stock will convert into &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. See Note 4 of Notes to Consolidated Financial Statements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the closing of this offering, the board of directors will be authorized to issue from time to time up to an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series and to fix or alter the designations, preferences, rights and any qualifications, limitations or restrictions of the shares of each of these series,
including the dividend rights, dividend rates, conversion rights, voting rights, term of redemption, including sinking fund provisions, redemption price or prices, liquidation preferences and the number of shares constituting any series or
designations of a series without further vote or action by the stockholders. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control of us without further action by the stockholders and may
adversely affect the voting and other rights of the holders of common stock. The issuance of preferred stock with voting and conversion rights may adversely affect the voting power of the holders of common stock, including the loss of voting control
to others. We currently have no plans to issue any shares of preferred stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We believe that the ability to issue preferred
stock without the expense and delay of a special stockholders&#146; meeting will provide us with increased flexibility in structuring possible future financings and acquisitions, and in meeting other corporate needs that might arise. This also
permits the board of directors to issue preferred stock containing terms which could impede the completion of a takeover attempt, subject to limitations imposed by the securities laws. The board of directors will make any determination to issue
these shares based on its judgment as to the best interests of our company and our stockholders at the time of issuance. This could discourage an acquisition attempt or other transaction which stockholders might believe to be in their best interests
or in which they might receive a premium for their stock over the then market price of the stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">117
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Anti-Takeover Provisions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. Subject to exceptions, Section&nbsp;203 prohibits a publicly-held Delaware corporation from engaging in a
&#147;business combination&#148; with an &#147;interested stockholder&#148; for a period of three years from the date of the transaction in which the person became an interested stockholder, unless the interested stockholder attained this status
with the approval of the board of directors or unless the business combination is approved in a prescribed manner. A &#147;business combination&#148; includes mergers, asset sales and other transactions resulting in a financial benefit to the
interested stockholder. Subject to exceptions, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years did own, 15% or more of the corporation&#146;s voting stock. This statute
could prohibit or delay the accomplishment of mergers or other takeover or change in control attempts with respect to us and, accordingly, may discourage attempts to acquire us. Our amended and restated certificate of incorporation and bylaws, upon
completion of this offering, will include a number of provisions that may make it more difficult to acquire control of us. These provisions could deprive stockholders of the opportunity to realize a premium on the shares of common stock owned by
them. In addition, these provisions may adversely affect the prevailing market price of the stock and are intended to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enhance the likelihood of continuity and stability in the composition of the board and in the policies formulated by the board;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discourage transactions which may involve an actual or threatened change in control of us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discourage tactics that may be used in proxy fights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">encourage persons seeking to acquire control of us to consult first with the board of directors to negotiate the terms of any proposed business
combination or offer; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduce our vulnerability to an unsolicited proposal for a takeover that does not contemplate the acquisition of all of our outstanding shares or that
is otherwise unfair to our stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Classified Board of Directors; Removal; Filling Vacancies and
Amendment</I>. Our amended and restated certificate of incorporation and bylaws will provide for the board to be divided into three classes of directors serving staggered, three-year terms. The classification of the board has the effect of requiring
at least two annual stockholder meetings, instead of one, to replace a majority of members of the board. Subject to the rights of the holders of any outstanding series of preferred stock, the amended and restated certificate of incorporation will
authorize only the board to fill vacancies, including newly created directorships. Accordingly, this provision could prevent a stockholder from obtaining majority representation on the board by enlarging the board of directors and filling the new
directorships with its own nominees. Our amended and restated certificate of incorporation will also provide that directors may be removed by stockholders only for cause and only by the affirmative vote of holders of two-thirds of the outstanding
shares of voting stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Voting Rights. </I>Cumulative voting for the election of directors will not be provided for in our
amended and restated certificate of incorporation, which means that the holders of a majority of the shares voted can elect all of the directors then standing for election. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Special Stockholder Meetings</I>. Our amended and restated certificate of incorporation will provide that special meetings of the stockholders for any purpose or purposes, unless required by law, shall
only be called by the Chairman of the board of directors, a majority of the entire board of directors or the Chief Executive Officer. A special meeting of the stockholders may not be held absent a written request of this nature. The request shall
state the purpose or purposes of the proposed meeting. This limitation on the right of stockholders to call a special meeting could make it more difficult for stockholders to initiate actions that are opposed by the board of directors. These actions
could include the removal of an incumbent director or the election of a stockholder nominee as a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">118
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">director. They could also include the implementation of a rule requiring stockholder ratification of
specific defensive strategies that have been adopted by the board of directors with respect to unsolicited takeover bids. In addition, the limited ability of the stockholders to call a special meeting of stockholders may make it more difficult to
change the existing board and management. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Advance Notice Requirements.</I>&nbsp;Our bylaws will require advance notice by
a stockholder of proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in
writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first
anniversary of the preceding year&#146;s annual meeting date. The notice must contain certain information specified in the bylaws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Written Consent</I>. Our amended and restated certificate of incorporation will prohibit the taking of stockholder action by written consent without a meeting. These provisions will make it more
difficult for stockholders to take action opposed by the board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Amendment of Provisions in the Amended and
Restated Certificate of Incorporation</I>. Our amended and restated certificate of incorporation will generally require the affirmative vote of the holders of at least two-thirds of the outstanding voting stock in order to amend any provisions of
the amended and restated certificate of incorporation concerning: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the removal or appointment of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the authority of stockholders to act by written consent; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the required vote to amend the amended and restated certificate of incorporation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">calling a special meeting of stockholders; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">procedure and content of stockholder proposals concerning business to be conducted at a meeting of stockholders; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">director nominations by stockholders. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">These voting requirements will make it more difficult for minority stockholders to make changes in the amended and restated certificate of incorporation that could be designed to facilitate the exercise
of control over us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Undesignated Preferred Stock.</I> Our amended and restated certificate of incorporation provides for
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of
directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to
determine that a takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions
that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our amended and restated certificate of incorporation grants our board of directors broad power to establish the
rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may
also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">119
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Options and Warrants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2013, options to purchase a total of 51,879,146 shares of our common stock were outstanding, and up to 5,342,394 additional shares of our common stock were reserved for future issuance
under our stock plans, excluding the 2013 Plan, which will become effective upon the signing of the underwriting agreement in connection with this offering. For a more complete discussion of our stock option plans, please see &#147;&#151;Employee
Benefit Plans.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of June&nbsp;30, 2013, warrants to purchase up to an aggregate of 3,394,035 shares of our Series D-2
preferred stock were outstanding at a weighted average exercise price of $0.65 per share. Each warrant expires and terminates upon the completion of this offering. The exercise price and the shares issuable upon exercise are subject to adjustment in
the event of stock dividends, stock splits, reorganizations and reclassifications and the warrants are permitted to be exercised on a cashless basis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Registration Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have entered into a fourth amended and restated
registration rights agreement, dated September&nbsp;19, 2008, which we refer to as the registration rights agreement, with holders of our preferred stock. Upon completion of this offering, the holders of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, or their transferees, will be entitled to certain rights with respect to the registration of such shares, or registrable securities, under the
Securities Act of 1933, as amended, or the Securities Act, as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Demand Registration Rights.</I> The holders of
shares representing at least 40% of the registrable securities issued or issuable upon conversion of our Series A-1, Series A-2, Series B, and Series C preferred stock collectively then outstanding may request that we register all or a portion of
their shares of registrable securities, provided that the reasonably anticipated aggregate price to the public of such public offering would exceed $5,000,000. In addition, the holders of shares representing at least 40% of the registrable
securities issued or issuable upon conversion of our Series D and Series D-2 preferred stock collectively then outstanding may request that we register all or a portion of their shares of registrable securities, provided that the reasonably
anticipated aggregate price to the public of such public offering would exceed $25,000,000. Upon their request, we must, subject to some restrictions and limitations, use our best efforts to cause a registration statement covering the number of
shares of registrable securities that are subject to the request to become effective. The holders of registrable securities may only require us to file a maximum of one registration statement in response to their demand registration rights,
provided, however, that such obligation will be deemed satisfied only when a registration statement covering all shares of registrable securities that are requested to be registered has become effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Piggyback Registration Rights. </I>In the event that we propose to register any of our securities under the Securities Act, the
holders of registrable securities are entitled to notice of such registration and are entitled to include their registrable securities in such registration, subject to certain marketing and other limitations. These registration opportunities are
unlimited, but the number of shares that may be registered may be cut back in limited situations by the underwriters. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Form
S-3 Registration Rights.</I> The holders of shares of the registrable securities issued or issuable upon conversion of our Series A-1, Series A-2, Series B, Series C and Series D-2 preferred stock then outstanding may request that we register all or
a portion of their shares if we are eligible to file a registration statement on Form S-3 and if the reasonably anticipated aggregate price to the public of the public offering would exceed $1,000,000. In addition, the holders of shares of the
registrable securities issued or issuable upon conversion of our Series D preferred stock then outstanding may request that we register all or a portion of their shares if we are eligible to file a registration statement on Form S-3 and if the
reasonably anticipated aggregate price to the public of the public offering would exceed $5,000,000. The holders of registrable securities may only require us to file one registration statement on Form S-3 in any twelve month period, provided,
however, that such obligation will be deemed satisfied only when a registration statement covering all shares of registrable securities that are requested to be registered has become effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are generally obligated to bear the expenses, other than underwriting discounts and sales commissions, of these registrations.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">120
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NASDAQ Global Market Listing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have applied to have our common stock listed on the NASDAQ Global Market under the symbol &#147;MGNX&#148;. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The transfer agent and registrar for our
common stock is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">121
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to this offering, there has been no public market for our common stock, and we cannot predict the effect, if any, that market sales
of shares of our common stock or the availability of shares of our common stock for sale will have on the market price of our common stock prevailing from time to time. Nevertheless, sales of substantial amounts of our common stock, including shares
issued upon exercise of outstanding options, or the perception that these sales could occur in the public market after this offering could adversely affect market prices prevailing from time to time and could impair our ability to raise capital
through the sale of our equity securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Immediately after the closing of this offering, based on the number of shares
outstanding as of June&nbsp;30, 2013, we will have &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares, and no exercise of
outstanding options prior to the closing of this offering. All of the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares sold in this offering will be freely tradable, except that any shares held or purchased in this offering by our affiliates,
as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The remaining outstanding shares of our common stock will be deemed restricted securities as defined under Rule&nbsp;144. Restricted securities may be sold in the public market only if registered or if
they qualify for an exemption from registration under Rule&nbsp;144 or Rule&nbsp;701 promulgated under the Securities Act, which rules are summarized below. In addition, certain of our stockholders have entered into market standoff agreements with
us or lock-up agreements with the underwriters under which they agreed, subject to specified exceptions, not to sell any of their stock for at least 180 days following the date of this prospectus. Subject to the provisions of Rule&nbsp;144 or
Rule&nbsp;701, based on an assumed offering date of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2013,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restricted shares will be available for sale in the public market as follows: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beginning 180 days after the date of this prospectus,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares will become eligible for sale in the public market, of which &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares will be freely tradable under Rule&nbsp;144 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be held by affiliates and subject to the volume and other restrictions of Rule&nbsp;144 as described below.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In general, under Rule 144 as currently in effect, any person who is or has been an affiliate of ours
during the 90 days immediately preceding the sale and who has beneficially owned shares for at least six months is entitled to sell, within any three-month period commencing 90 days after the date of this prospectus, a number of shares that does not
exceed the greater of: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1% of the then outstanding shares of common stock, which will equal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares immediately after this
offering; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the average weekly trading volume during the four calendar weeks preceding the sale, subject to the filing of a Form 144 with respect to the sale.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales under Rule 144 by our affiliates are also subject to certain manner of sale provisions and notice
requirements and to the availability of current public information about us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A person who is not deemed to have been an
affiliate of ours at any time during the 90 days immediately preceding the sale and who has beneficially owned his or her shares for at least six months is entitled to sell his or her shares under Rule 144 without regard to the limitations described
above, subject only to the availability of current public information about us during the six months after the initial six-month holding period is met. After a nonaffiliate has beneficially owned his or her shares for one year or more, he or she may
freely sell his or her shares under Rule 144 without complying with any Rule 144 requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are unable to estimate the
number of shares that will be sold under Rule 144, since this will depend on the market price for our common stock, the personal circumstances of the sellers and other factors. Prior to the offering, there has been no public market for the common
stock, and there can be no assurance that a significant public market for the common stock will develop or be sustained after the offering. Any future sale of substantial amounts of the common stock in the open market may adversely affect the market
price of the common stock offered by this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">122
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Lock-up Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We, our directors and executive officers, and certain of our other stockholders have agreed that, subject to certain exceptions, they will not sell any common stock without the prior written consent of
the underwriters for a period of 180 days from the date of this prospectus. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Employee Benefit Plans </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any employee or consultant who purchased his or her shares under a written compensatory plan or contract is entitled to rely on the resale
provisions of Rule 701, which permits non-affiliates to sell their Rule 701 shares without having to comply with the public information, holding period, volume limitation or notice provisions of Rule 144 and permits affiliates to sell their Rule 701
shares without having to comply with the Rule 144 holding period restrictions, in each case commencing 90 days after the date of this prospectus. As of June&nbsp;30, 2013, the holders of options to purchase approximately 51,879,146 shares of common
stock will be eligible to sell their shares upon the expiration of the 180-day lockup period, subject to the vesting of those options. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We intend to file a registration statement on Form S-8 under the Securities Act as soon as practicable after the completion of the offering to register &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares of common stock subject to outstanding stock options or reserved for issuance under our stock plans. This registration will permit the resale of these shares by non-affiliates in the public market without restriction under the Securities Act,
upon completion of the lock-up period described above. Shares registered under the Form S-8 registration statement held by affiliates will be subject to Rule 144 volume limitations. See &#147;Management&#151;Executive Compensation&#148; and
&#147;&#151;Employee Benefit Plans.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">123
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_16"></A>MATERIAL U.S. FEDERAL TAX CONSEQUENCES FOR NON-U.S. HOLDERS
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a general discussion of the material U.S. federal income and estate tax consequences of the ownership
and disposition of our common stock by a beneficial owner that is a &#147;non-U.S. holder.&#148; For purposes of this discussion, a &#147;non-U.S. holder&#148; means a beneficial owner of our common stock that is not, for U.S. federal income tax
purposes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation, or other entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States
or any state or political subdivision thereof; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate, the income of which is subject to United States federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust, if a U.S. court is able to exercise primary supervision over the administration of the trust and one or more U.S. persons have the authority
to control all substantial decisions of the trust or if the trust has a valid election to be treated as a U.S. person under applicable regulations issued by the U.S. Department of the Treasury (&#147;Treasury Regulations&#148;).
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This discussion is based on the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and
administrative pronouncements, judicial decisions and final, temporary and proposed Treasury Regulations, changes to any of which subsequent to the date of this prospectus may affect the tax consequences described herein, possibly with a retroactive
effect. In addition, the Internal Revenue Service (the &#147;IRS&#148;) could challenge one or more of the tax consequences described in this prospectus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The discussion below is limited to non-U.S. holders that hold our shares of common stock as capital assets (generally, property held for investment) within the meaning of the Code. This discussion does
not address all aspects of U.S. federal income and estate taxation, including the Medicare contribution tax, that may be relevant to a particular non-U.S. holder in light of that non-U.S. holder&#146;s individual circumstances nor does it address
any aspects of U.S. state, local or non-U.S. taxes. This discussion also does not consider any specific facts or circumstances that may apply to a non-U.S. holder and does not address the special tax rules under the Code applicable to particular
non-U.S. holders, such as: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">brokers or dealers in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">tax-exempt organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">pension plans; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">owners that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other integrated investment;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">insurance companies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">controlled foreign corporations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">passive foreign investment companies; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">certain U.S. expatriates. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">124
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a partnership, or any entity treated as a partnership for U.S. federal income tax
purposes, is a holder of our common stock, the tax treatment of a partner in the partnership will generally depend upon the status of the partner and the activities of the partnership. A holder that is a partnership, and the partners in such
partnership, should consult their own tax advisers regarding the tax consequences of the acquisition, holding and disposition of our common stock, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Prospective holders are urged to consult their tax advisers with respect to the particular tax consequences to them of acquiring, holding and disposing of our common stock, including the consequences
under the laws of any state, local or foreign jurisdiction. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in the section entitled &#147;Dividend
Policy,&#148; we do not anticipate paying any dividends on our common stock in the foreseeable future. In the event that we do make distributions of cash or other property on our common stock (other than certain pro rata distributions of our common
stock or rights to acquire our common stock), those distributions generally will be treated as dividends to the extent paid from our accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds
our current and accumulated earnings and profits, the excess will be treated as a tax-free return of the non-U.S. holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain,
subject to the tax treatment described below under the heading &#147;Gain on Dispositions of Common Stock.&#148; Any such distribution would also be subject to the discussion below under the section titled &#147;Withholding and Information Reporting
Requirements&#150;FATCA.&#148; Dividends paid to a non-U.S. holder of our common stock generally will be subject to withholding tax at a 30% rate, or a reduced rate specified by an applicable income tax treaty. In order to obtain a reduced rate of
withholding under an applicable income tax treaty, a non-U.S. holder must provide an IRS Form&nbsp;W-8BEN (or successor form) certifying its entitlement to benefits under the treaty. Non-U.S. holders are urged to consult their own tax advisors
regarding their entitlement to benefits under a relevant income tax treaty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The withholding tax does not apply to dividends
paid to a non-U.S. holder that provides an IRS Form&nbsp;W-8ECI (or successor form), certifying that the dividends are effectively connected with the non-U.S. holder&#146;s conduct of a trade or business within the United States (&#147;effectively
connected dividends&#148;). Instead, effectively connected dividends will be subject to regular U.S. income tax as if the non-U.S. holder were a U.S. resident, subject to any applicable income tax treaty providing otherwise. A non-U.S. corporation
receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; currently at the rate of 30% (or a lower rate prescribed under an applicable income tax treaty). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A non-U.S. holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may obtain a refund or credit
against any excess amounts withheld by timely filing an appropriate claim with the IRS. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gain on Disposition of Common Stock
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A non-U.S. holder generally will not be subject to U.S. federal income tax on gain realized on a sale or other disposition
of common stock unless: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the gain is effectively connected with a trade or business of the non-U.S. holder in the United States, and if an applicable tax treaty so provides,
the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States; in these cases, the non-U.S. holder will be taxed on a net income basis at the regular graduated rates and in the manner
applicable to U.S. persons, subject to an applicable income tax treaty providing otherwise and if the non-U.S. holder is a corporation, an additional branch profits tax at a rate of 30%, or a lower rate as may be specified by an applicable income
tax treaty, may also apply; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the non-U.S. holder is a nonresident alien present in the United States for 183 days or more in the taxable year of the disposition and certain other
requirements are met, in which case the non-U.S. holder will be subject to a 30% tax (or such lower rate as may be specified by an applicable income tax treaty) on the net gain derived from the disposition, which may be offset by U.S.-source capital
losses of the non-U.S. holder, if any; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">125
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we are or have been a &#147;U.S. real property holding corporation,&#148; as defined below, at any time within the five-year period preceding the
disposition or during the non-U.S. holder&#146;s holding period, whichever period is shorter. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are not,
and do not anticipate becoming, a U.S. real property holding corporation. Generally, a corporation is a &#147;U.S. real property holding corporation&#148; if the fair market value of its U.S. real property interests (as defined in the Code and the
applicable Treasury Regulations) equals or exceeds 50% of the aggregate fair market value of its worldwide real property interests and its other assets used or held for use in a trade or business. Even if we were to become a U.S. real property
holding corporation, gain on the sale or other disposition of common stock by a non-U.S. holder generally would not be subject to U.S. federal income tax, provided that the common stock is regularly traded on an established securities market and the
non-U.S. holder does not actually or constructively own more than 5% of the common stock during the shorter of (1)&nbsp;the five-year period ending on the date of the disposition or (2)&nbsp;the period of time during which the holder held such
shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Information Reporting Requirements and Backup Withholding </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We must report annually to the IRS and to each non-U.S. holder the gross amount of the distributions on our common stock paid to such
holder and the tax withheld, if any, with respect to such distributions. Unless a non-U.S. holder complies with certification procedures to establish that it is not a U.S. person (as defined in the Code), information returns may be filed with the
IRS in respect of the proceeds from a sale or other disposition of common stock and the non-U.S. holder may be subject to U.S. backup withholding (currently at 28%) on payments of dividends or on the proceeds from a sale or other disposition of
common stock. The certification procedures required to claim a reduced rate of withholding under a treaty will satisfy the certification requirements necessary to avoid the backup withholding tax as well. Generally, information reporting and backup
withholding will not apply to a payment of disposition proceeds to a non-U.S. holder where the transaction is effected outside the United States through a non-U.S. office or broker. However, for information reporting purposes, dispositions effected
through a non-U.S. office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. Non-U.S. holders should consult their own tax advisors
regarding the application of the information reporting and backup withholding rules to them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Copies of information returns
may be made available to the tax authorities of the country in which the non-U.S. holder resides or is incorporated under the provisions of a specific treaty or agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The amount of any backup withholding from a payment to a non-U.S. holder will be allowed as a credit against such holder&#146;s U.S. federal income tax liability and may entitle such holder to a refund or
credit against the non-U.S. holder&#146;s U.S. federal income tax liability, provided that the required information is furnished to the IRS. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Estate Tax </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Individual Non-U.S. holders and entities the property of which is potentially includible in such an individual&#146;s gross estate for
U.S. federal estate tax purposes (for example, a trust funded by a non-U.S. holder individual and with respect to which the individual has retained certain interests or powers), should note that, absent an applicable treaty benefit, the common stock
will be treated as U.S. situs property subject to U.S. federal estate tax. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withholding and Information Reporting Requirements&#150;FATCA
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Foreign Account Tax Compliance Act, which is commonly referred to as &#147;FATCA,&#148; will impose a U.S. federal
withholding tax of 30% on payments of dividends on and gross proceeds from the sale or disposition of, our common stock if paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; the foreign
entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; the foreign entity identifies certain of its U.S. investors, if any,
or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. Although this legislation is effective with regards to amounts paid after December&nbsp;31, 2012, under final Treasury Regulations issued on January&nbsp;17, 2013 and IRS Notice
2013-43 released on July&nbsp;12, 2013, withholding under FATCA will only apply (1)&nbsp;to payments of dividends </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">126
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
on our common stock made after June&nbsp;30, 2014 and (2)&nbsp;to payments of gross proceeds from a sale or other disposition of our common stock made after December&nbsp;31, 2016. Under certain
circumstances, a non-U.S. holder may be eligible for refunds or credits for such taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prospective investors should consult
their own tax advisors regarding the possible implication of the FATCA rules on their investment in our common stock, and the entities through which they holder our common stock, including, without limitation, the process and deadlines for meeting
the applicable requirements to prevent the imposition of this 30% withholding tax under FATCA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">127
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_17"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated, and Leerink Swann LLC are acting as representatives of each of the
underwriters named below. Subject to the terms and conditions set forth in an underwriting agreement among us and the underwriters, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to
purchase from us, the number of shares of common stock set forth opposite its name below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:43pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>of&nbsp;Shares</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Merrill Lynch, Pierce, Fenner &amp; Smith</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leerink Swann LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stifel, Nicolaus &amp; Company, Incorporated</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lazard Capital Markets LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wedbush Securities Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms and conditions set forth in the underwriting agreement, the underwriters have
agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the
nondefaulting underwriters may be increased or the underwriting agreement may be terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the
underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make in respect of those liabilities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are offering the shares, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of
legal matters by their counsel, including the validity of the shares, and other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer&#146;s certificates and legal opinions. The underwriters reserve
the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Commissions and Discounts
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The representatives have advised us that the underwriters propose initially to offer the shares to the public at the
public offering price set forth on the cover page of this prospectus and to dealers at that price less a concession not in excess of $ per share. After the initial offering, the public offering price, concession or any other term of the offering may
be changed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the public offering price, underwriting discount and proceeds before expenses to us.
The information assumes either no exercise or full exercise by the underwriters of their option to purchase additional shares. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per&nbsp;Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Without&nbsp;Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>With&nbsp;Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds, before expenses, to MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The expenses of the offering, not including the underwriting discount, are estimated at
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and are payable by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lazard
Fr&egrave;res&nbsp;&amp; Co. LLC referred this transaction to Lazard Capital Markets LLC and will receive a referral fee from Lazard Capital Markets LLC in connection therewith. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">128
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Option to Purchase Additional Shares </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted an option to the underwriters, exercisable for 30 days after the date of this prospectus, to purchase up to additional
shares at the public offering price, less the underwriting discount. If the underwriters exercise this option, each will be obligated, subject to conditions contained in the underwriting agreement, to purchase a number of additional shares
proportionate to that underwriter&#146;s initial amount reflected in the above table. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>No Sales of Similar Securities </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We, our executive officers and directors and certain of our other existing security holders have agreed not to sell or transfer any common
stock or securities convertible into, exchangeable for, exercisable for, or repayable with common stock, for 180 days after the date of this prospectus without first obtaining the written consent of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith
Incorporated. Specifically, we and these other persons have agreed, with certain limited exceptions, not to directly or indirectly: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">offer, pledge, sell or contract to sell any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">sell any option or contract to purchase any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">purchase any option or contract to sell any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">grant any option, right or warrant for the sale of any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">lend or otherwise dispose of or transfer any common stock; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">request or demand that we file a registration statement related to the common stock; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">enter into any swap or other agreement that transfers, in whole or in part, the economic consequence of ownership of any common stock whether any such
swap or transaction is to be settled by delivery of shares or other securities, in cash or otherwise. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
lock-up provision applies to common stock and to securities convertible into or exchangeable or exercisable for or repayable with common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for
which the person executing the agreement later acquires the power of disposition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nasdaq Global Market Listing </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We expect the shares to be approved for listing on the Nasdaq Global Market, subject to notice of issuance, under the symbol
&#147;MGNX&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Before this offering, there has been no public market for our common stock. The initial public offering
price will be determined through negotiations between us and the representatives. In addition to prevailing market conditions, the factors to be considered in determining the initial public offering price are </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the valuation multiples of publicly traded companies that the representatives believe to be comparable to us, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our financial information, </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the history of, and the prospects for, our company and the industry in which we compete, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an assessment of our management, its past and present operations, and the prospects for, and timing of, our future revenues,
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">129
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the present state of our development, and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the above factors in relation to market values and various valuation measures of other companies engaged in activities similar to ours.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An active trading market for the shares may not develop. It is also possible that after the offering the
shares will not trade in the public market at or above the initial public offering price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters do not expect to
sell more than 5% of the shares in the aggregate to accounts over which they exercise discretionary authority. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Price Stabilization, Short
Positions and Penalty Bids </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Until the distribution of the shares is completed, SEC rules may limit underwriters and selling
group members from bidding for and purchasing our common stock. However, the representatives may engage in transactions that stabilize the price of the common stock, such as bids or purchases to peg, fix or maintain that price. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, the underwriters may purchase and sell our common stock in the open market. These transactions may
include short sales, purchases on the open market to cover positions created by short sales and stabilizing transactions. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the
offering. &#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares described above. The underwriters may close out any covered short position by either exercising their
option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase
in the open market as compared to the price at which they may purchase shares through the option granted to them. &#147;Naked&#148; short sales are sales in excess of such option. The underwriters must close out any naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our common stock in the open market after pricing that could adversely
affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of shares of common stock made by the underwriters in the open market prior to the completion of the offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of
raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open
market. The underwriters may conduct these transactions on the Nasdaq Global Market, in the over-the-counter market or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our common stock.
In addition, neither we nor any of the underwriters make any representation that the representatives will engage in these transactions or that these transactions, once commenced, will not be discontinued without notice. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Electronic Distribution </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, certain of the underwriters or securities dealers may distribute prospectuses by electronic means, such
as e-mail. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Relationships </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Affiliates of Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated have passive limited partnership interests in certain holders of our common stock, which, in the aggregate, account for less than
one percent of our common stock. Some of the underwriters and their affiliates have engaged in, and may in the future engage in, investment banking and other commercial dealings in the ordinary course of business with us or our affiliates. They have
received, or may in the future receive, customary fees and commissions for these transactions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">130
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the ordinary course of their business activities, the underwriters and their
affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers.
Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make investment recommendations and/or publish or express independent research views in
respect of such securities or financial instruments and may hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the European Economic Area </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation
to each Member State of the European Economic Area (each, a &#147;Relevant Member State&#148;), no offer of shares may be made to the public in that Relevant Member State other than: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives; or </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares shall require the Company or the
representatives to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each person in a Relevant Member State who initially acquires any shares or to whom any offer is made will be deemed to have represented,
acknowledged and agreed that it is a &#147;qualified investor&#148; within the meaning of the law in that Relevant Member State implementing Article 2(1)(e) of the Prospectus Directive. In the case of any shares being offered to a financial
intermediary as that term is used in Article 3(2) of the Prospectus Directive, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a
non-discretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Relevant Member
State to qualified investors as so defined or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company, the representatives and their affiliates will rely upon the truth and accuracy of the foregoing representations, acknowledgements and agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has been prepared on the basis that any offer of shares in any Relevant Member State will be made pursuant to an
exemption under the Prospectus Directive from the requirement to publish a prospectus for offers of shares. Accordingly any person making or intending to make an offer in that Relevant Member State of shares which are the subject of the offering
contemplated in this prospectus may only do so in circumstances in which no obligation arises for the Company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive in relation to such offer. Neither the
Company nor the underwriters have authorized, nor do they authorize, the making of any offer of shares in circumstances in which an obligation arises for the Company or the underwriters to publish a prospectus for such offer. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purpose of the above provisions, the expression &#147;an offer to the public&#148; in relation to any shares in any Relevant
Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe the shares, as the same may be varied
in the Relevant Member State by any measure implementing the Prospectus Directive in the Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (including the 2010 PD Amending Directive, to the extent
implemented in the Relevant Member States) and includes any relevant implementing measure in the Relevant Member State and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">131
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United Kingdom </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made
may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Directive) (i)&nbsp;who have professional experience in matters relating to investments falling within Article 19 (5)&nbsp;of the Financial
Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to
(d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). This document must not be acted on or relied on in the United Kingdom by persons who are not relevant persons. In the United Kingdom, any investment
or investment activity to which this document relates is only available to, and will be engaged in with, relevant persons. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to
Prospective Investors in Switzerland </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares may not be publicly offered in Switzerland and will not be listed on the
SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of
the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor
any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Neither this document nor any other offering or marketing material relating to the offering, the Company, the shares have been or will be filed with or approved by any Swiss regulatory authority. In
particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA (FINMA), and the offer of shares has not been and will not be authorized under the Swiss
Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of shares. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the Dubai International Financial Centre </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority
(&#147;DFSA&#148;). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for
reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The shares to which this
prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should
consult an authorized financial advisor. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Australia </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian
Securities and Investments Commission (&#147;ASIC&#148;), in relation to the offering. This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the
&#147;Corporations Act&#148;), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any offer in Australia of the shares may only be made to persons (the &#147;Exempt Investors&#148;) who are &#147;sophisticated
investors&#148; (within the meaning of section 708(8) of the Corporations Act), &#147;professional investors&#148; (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section
708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">132
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares applied for by Exempt Investors in Australia must not be offered for sale in
Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of
the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus contains general information only and does not take account of the investment objectives, financial situation or
particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to
their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong
Kong </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document,
other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in the document
being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No advertisement, invitation or document relating to the shares has
been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong
(except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the
Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in Japan or to any Japanese Person, except in
compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect at the relevant time. For the purposes of this paragraph, &#147;Japanese Person&#148; shall
mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective
Investors in Singapore </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore.
Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the
subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the
&#147;SFA&#148;), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to,
and in accordance with the conditions of, any other applicable provision of the SFA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the shares are subscribed or
purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an
accredited investor, </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">133
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146;
rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">as specified in Section&nbsp;276(7) of the SFA; or as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures)
Regulations 2005 of Singapore. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">134
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_18"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The validity of the issuance of the shares of common stock offered by this prospectus will be passed upon for us by Arnold&nbsp;&amp;
Porter LLP, Washington, District of Columbia. Legal matters relating to the sale of common stock in this offering will be passed upon for the underwriters by Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_19"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ernst&nbsp;&amp; Young LLP, independent registered accounting firm, has audited our consolidated financial statements at December 31, 2011 and 2012, and for the years then ended, as set forth in their
report. We&#146;ve included our financial statements in this Prospectus and elsewhere in the Registration Statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="rom575431_20"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have filed a registration statement on Form S-1 with the Securities and Exchange Commission under the Securities Act with respect to
the common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information with respect to us and our common stock, please see the registration statement and the exhibits and schedules filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract
or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit
to the registration statement. The registration statement, including its exhibits and schedules, may be inspected without charge at the public reference room maintained by the SEC, located at 100 F Street, N.E., Room 1580, Washington, D.C. 20549,
and copies of all or any part of the registration statement may be obtained from such offices upon the payment of the fees prescribed by the SEC. Please call the SEC at 1-800-SEC-0330 for further information about the public reference room. The SEC
also maintains an Internet website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the SEC. The address of the site is <I>www.sec.gov</I>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon completion of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and,
in accordance therewith, will file periodic reports, proxy statements and other information with the SEC. Such periodic reports, proxy statements and other information will be available for inspection and copying at the public reference room and on
the SEC website referred to above. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">135
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom575431_21"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>MacroGenics, Inc.</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin575431_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin575431_2">Consolidated Balance Sheets as of December&nbsp;31, 2011 and 2012 and March 31, 2013 (unaudited) and March&nbsp;
31, 2013 pro&nbsp;forma</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin575431_3">Consolidated Statements of Operations and Comprehensive Income for the years ended December&nbsp;
31, 2011 and 2012 and the three months ended March&nbsp;31, 2013 (unaudited) and 2012 (unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin575431_4">Consolidated Statements of Stockholders&#146; Equity (Deficit) for the years ended December&nbsp;
31, 2011 and 2012 and the three months ended March&nbsp;31, 2013 (unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin575431_5">Consolidated Statements of Cash Flows for the years ended December&nbsp;
31, 2011 and 2012 and the three months ended March&nbsp;31, 2013 (unaudited) and 2012 (unaudited)</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin575431_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin575431_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board of Directors and Shareholders of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. as of December&nbsp;31, 2011 and 2012, and the related consolidated
statements of operations and comprehensive income (loss), stockholders&#146; equity (deficit) and cash flows for the years then ended. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to
express an opinion on these financial statements based on our audits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit
of the Company&#146;s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the
purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for
our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of
MacroGenics, Inc. at December&nbsp;31, 2011 and 2012, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">McLean, Virginia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;8, 2013 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin575431_2"></A>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2013</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2013</B><br><B>Pro Forma</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,525,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,397,869</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,322,124</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,662,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,927,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,905,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,287,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,440,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,680,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,898,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,051,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,739,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,747,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,261,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability &#150; current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">824,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#150; current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,652,533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,123,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,596,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,289,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,728,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,430,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,097,378</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,360,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,801,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820,517</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,642</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,237,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,956,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,821,716</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,164,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,984,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,253,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 convertible preferred stock, $0.01 par value &#150; 26,874,792 shares authorized, 26,874,792 shares issued and outstanding
at December&nbsp;31, 2011 and 2012 and March&nbsp;31, 2013; aggregate liquidation preference of $27,000,000 at December&nbsp;31, 2012 and March 31, 2013 (unaudited), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
outstanding at March 31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 convertible preferred stock, $0.01 par value &#150; 7,364,582 shares authorized, 7,364,582 shares issued and outstanding at
December&nbsp;31, 2011 and 2012 and March&nbsp;31, 2013; aggregate liquidation preference of $7,000,000 at December&nbsp;31, 2012 and March 31, 2013 (unaudited), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
outstanding at March 31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value &#150; 71,401,237 shares authorized, 71,401,237 shares issued and outstanding at
December&nbsp;31, 2011 and 2012 and March&nbsp;31, 2013; aggregate liquidation preference of $31,000,000 at December&nbsp;31, 2012 and March 31, 2013 (unaudited), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
outstanding at March 31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value &#150; 110,952,217 shares authorized, 110,952,217 shares issued and outstanding
at December&nbsp;31, 2011 and 2012 and March&nbsp;31, 2013; aggregate liquidation preference of $45,000,000 at December&nbsp;31, 2012 and March 31, 2013 (unaudited), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
outstanding at March 31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D convertible preferred stock, $0.01 par value &#150; 30,000,000 shares authorized, 14,446,227 shares issued and outstanding at
December&nbsp;31, 2011 and 2012 and March&nbsp;31, 2013; aggregate liquidation preference of $9,400,000 at December&nbsp;31, 2012 and March 31, 2013 (unaudited), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
outstanding at March 31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 convertible preferred stock, $0.01 par value &#150; 75,000,000 shares authorized, 63,681,176 shares issued and outstanding
at December&nbsp;31, 2011 and 2012 and March&nbsp;31, 2013; aggregate liquidation preference of $41,500,000 at December&nbsp;31, 2012 and March 31, 2013 (unaudited), and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares
outstanding at March 31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value &#150; 425,000,000 shares authorized, 19,694,392 issued and outstanding at December&nbsp;31, 2011,
20,630,906 issued and outstanding at December&nbsp;31, 2012, 21,761,589 issued and outstanding at March&nbsp;31, 2013 and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;at March&nbsp;31, 2013 (Pro Forma)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock, at cost; 270,000 shares at December&nbsp;31, 2011 and 2012, March&nbsp;31, 2013 and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; March 31, 2013 (Pro Forma) </P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,263,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,139,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,329,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,834,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(178,792,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,355,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">62,680,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">49,898,234</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin575431_3"></A>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,054,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,645,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,652,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,066,960</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,152,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,180,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,857,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">531,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,207,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,826,098</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,510,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,598,030</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs and expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,088,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,432,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,724,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,050,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,868,791</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,187,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,466,909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,833,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,957,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,620,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,191,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,883,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,249,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,205,310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,319,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,285,674</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,467,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,445</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,246</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,320,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,254,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,337,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,906,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,254,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,337,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398,917,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,665,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,893,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,750,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,893,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin575431_4"></A>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:6pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-1<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A-2<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series D-2<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Treasury Stock</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR>Paid-In<BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>Equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, December&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">45,253,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">452,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18,786,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">187,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149,024,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(190,551,278</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(38,634,058</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Issuance of convertible Series D-2 stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,427,388</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,830,541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">907,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,077</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,323</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,694,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">196,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">163,263,470</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183,834,158</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,484,284</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Stock option exercises</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">936,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,461</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,630,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">206,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,139,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Share-based compensation (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Stock option exercises (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,130,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Net income (loss) (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:6pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:6pt; font-family:Times New Roman">Balance, March&nbsp;31, 2013 (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,874,792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,401,237</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,761,589</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">217,616</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">164,329,845</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(178,792,323</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(11,355,402</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin575431_5"></A>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,320,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,147,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">959,930</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,347</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">209,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,459,435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150,695</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,551,066</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,351,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,582,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(275,905</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">76,876</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,160</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,922</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(513</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133,782</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,271,048</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,312,331</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(970,335</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(991,300</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(128,980</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,988</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,275,976</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,810,089</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,311,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,815</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,224</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in) operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,757,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,581,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,503,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,848,619</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(500,213</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(940,043</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51,706</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(425,093</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of preferred stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,014,816</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,085,216</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,534</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,342,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,475,206</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,542,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,217,178</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,876,018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">39,675,679</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,525,977</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="fin575431_6"></A>MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Organization and Nature of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. (the &#147;Company&#148;) was incorporated in Delaware on August&nbsp;14, 2000. The Company is a clinical-stage
biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary
suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its understanding of disease
biology and immune-mediated mechanisms may address disease-specific challenges which are not currently being met by existing therapies. The Company creates both differentiated molecules that are directed to novel cancer targets, as well as
&#147;bio-betters&#148; which are drugs designed to improve upon marketed medicines. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics West, Inc. All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in
one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and
assessing performance. The Company views its operations and manages its business in one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Principals of consolidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, MacroGenics West, Inc. All intercompany balances and transactions have been eliminated in consolidation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The preparation
of the financial statements in accordance with U.S. generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due
consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, convertible preferred stock and common stock, preferred stock warrant liability, income
taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could
differ from these estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In addition, the Company utilizes estimates and assumptions in determining the fair value of its common
stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. Management uses contemporaneous valuations in estimating the fair value
of its common stock. The board of directors has determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market considerations affecting the biotechnology industry and the
historic prices at which the Company sold shares of its preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Interim Financial Information </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim consolidated balance sheet as of March&nbsp;31, 2013, the consolidated statements of operations and
comprehensive income and cash flows for the three months ended March&nbsp;31, 2013 and 2012, the consolidated statement of changes in stockholders&#146; equity (deficit) for the three months ended March&nbsp;31, 2013, and the related interim
information contained within the notes to the consolidated financial statements have </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (SEC) for interim financial information. In the opinion of management, the unaudited interim
consolidated financial statements reflect all adjustments, consisting of normal and recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position at March&nbsp;31, 2013 and results of its operations and its cash
flows for the three months ended March&nbsp;31, 2013 and 2012. The results for the three months ended March&nbsp;31, 2013 are not necessarily indicative of future results. All references to March&nbsp;31, 2013 or to the three months ended
March&nbsp;31, 2013 and 2012 in the notes to the consolidated financial statements are unaudited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unaudited Pro Forma Balance Sheet Presentation
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The unaudited pro forma balance sheet as of March&nbsp;31, 2013, reflects the expected automatic conversion of the outstanding
shares of Series&nbsp;A-1, Series A-2, Series B, Series C, Series D, and Series D-2 convertible preferred stock into shares of common stock as though the completion of the Company&#146;s initial public offering (IPO) had occurred on March&nbsp;31,
2013. The shares of common stock issued in the IPO and any related estimated net proceeds are excluded from such pro forma information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and
Cash Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company considers all investments in highly liquid financial instruments with an original maturity of three
months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of certificates of deposit and investment in money market funds with commercial banks and financial institutions. Cash equivalents are stated at
amortized cost, plus accrued interest, which approximates fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding
amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors
including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of
December&nbsp;31, 2011, December&nbsp;31, 2012, and March&nbsp;31, 2013, as the Company has a history of collecting on all outstanding accounts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is
required to maintain certificates of deposit that serve as collateral for various operating leases and corporate credit card accounts. Amounts classified as restricted cash on the consolidated balance sheets are $582,171 at December 31, 2011 and
$404,850 at December 31, 2012 and March 31, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The fair market values of the financial instruments included in the financial statements, which include cash equivalents and money market
accounts, approximate their carrying values at December&nbsp;31, 2012 and 2011, due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with Accounting Standards Codification
820, <I>Fair Value Measurements and Disclosures</I> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC
820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&nbsp;&#150; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&nbsp;&#150; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active
markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market
data. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&nbsp;&#150; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting
entity&nbsp;&#150; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate
level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities subject to fair value measurements as of December 31, 2011, December&nbsp;31, 2012 and March&nbsp;31, 2013,
were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,049,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,049,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,169,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,169,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">582,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,800,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,631,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">24,169,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at March&nbsp;31, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets&nbsp;for<BR>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other<BR>Observable&nbsp;Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant<BR>Unobservable<BR>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,478,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,478,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,930,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,930,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, the Company transferred its money market funds from Level 2 to Level 1 because
the inputs are now based upon a quoted market price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Level 1 securities primarily consist of restricted cash, cash
equivalents and money market funds. The Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determines the estimated fair value for its Level 2 securities using the following methods: quoted prices for similar
assets/liabilities in active markets, inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves volatilities, default rates, etc.) and inputs that are derived principally from or corroborated by
other observable market data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table presents information about the Company&#146;s preferred stock warrant liability, which
was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC 820 as of December&nbsp;31, 2011,&nbsp;December&nbsp;31, 2012, and March&nbsp;31, 2013: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,663,077</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total unrealized gains (losses) included in earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,459,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,695</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,546</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance end of year</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(203,642</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(83,493</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In order to estimate the fair value of the preferred stock purchase warrants, the business
enterprise value was established based on a discounted cash flow model (income approach). The Company utilized an option pricing method to value the shares using a contingent claims analysis, which applies a series of call options whose inputs
reflect the liquidation preferences and conversion behavior of the different classes of equity. After the equity value of the business enterprise was determined, the total equity value is allocated to the various equity instruments such as preferred
stock, stock options and preferred stock purchase warrants. Key management estimates relate to the time period to liquidation and conversion behavior of a particular class of stockholders. The business enterprise value includes assumptions related
to product approval, market penetration and costs to develop the product. Significant changes to these assumptions would result in increases/decreases to the fair value of the outstanding warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The total unrealized gains (losses) on the preferred stock warrants included in earnings is included as a component of other income (expense)
in the consolidated statement of operations and comprehensive income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Substantially all of the Company&#146;s cash and cash equivalents are maintained with major financial institutions in the United States.
Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents,
and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2011 and 2012, and the quarter ended March&nbsp;31, 2013, all of the Company&#146;s grant revenue was
related to contracts and research grants received from U.S. government agencies. Collaborations with Eli Lilly&nbsp;&amp; Co. (Eli Lilly), Boehringer Ingelheim GmbH (Boehringer), Pfizer, Inc. (Pfizer), and Les Laboratoires Servier and Institut de
Recherches Servier (collectively, Servier) account for all other revenue. All outstanding receivables are due from Eli Lilly, Boehringer, Pfizer, and U.S. government agencies. The following table represents the percentage of all significant revenue
earned in the years ended December&nbsp;31, 2011 and 2012 as well as in the three month period ended March&nbsp;31, 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2013 </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table represents the percentage of all significant accounts receivable balances as of
December&nbsp;31, 2011, December&nbsp;31, 2012 and March 31, 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead Sciences, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are
removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following
estimated useful lives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">10 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and office equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Shorter of lease term or useful life</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, <I>Property, Plant and
Equipment</I>. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by
a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of
the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the
carrying amount or fair value, less costs to sell. As of December&nbsp;31, 2011 and 2012, and March&nbsp;31, 2013, the Company determined that there were no impaired assets and had no assets held-for-sale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Deferred tax assets
and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to
reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation
allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. The
Company&#146;s policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which
may include (i)&nbsp;licenses, or options to obtain licenses, to the Company&#146;s technological platforms, such as its Fc Optimization and Dual-Affinity Re-Targeting, or DART, technologies, (ii)&nbsp;rights to future technological improvements,
(iii)&nbsp;research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborator. Payments to the Company under
these agreements may include nonrefundable license fees, option fees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exercise fees, payments for research and development activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments based upon the
achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The
Company follows the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, <I>Revenue Recognition&#150;Multiple-Element Arrangements</I>, and ASC Topic 605-28, <I>Revenue
Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of
accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue
recognition criteria are applied to each of the separate units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the periods presented, the Company had the following two types of
agreements with the parties identified below: 1) exclusive development and commercialization licenses to use the Company&#146;s technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein
as exclusive licenses); and 2) Option/research agreements to secure on established terms, development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by the Company
during an option period (referred to herein as right-to-develop agreements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There are no performance, cancellation, termination or
refund provisions in any of the arrangements that contain material financial consequences to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive Licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s DART technology with
respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases the
Company may have an option to participate in the co-development of product candidates that result from such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Generally,
exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at
negotiated prices which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant the Company an
option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company&#146;s intellectual property rights and whether the Company exercises
any co-development and co-commercialization rights. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In determining the units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements
to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the partner and the availability of technology
platform and product research expertise in the general marketplace. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated
selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company&#146;s previous collaboration agreements,
recent pre-clinical and clinical testing results of therapeutic product candidates that use the Company&#146;s technology platforms, the Company&#146;s pricing practices and pricing objectives, the likelihood that technological improvements will be
made, the likelihood that technological improvements made will be used by the Company&#146;s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that
the license does not have stand-alone value. Prior to the adoption of Accounting Standards Update (ASU) No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, the Company determined that its licenses
lacked stand-alone value and were combined with other elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which the Company refers to as the Company&#146;s period of substantial
involvement. The determination of the length of the period over which to defer revenue is subject to judgment and estimation and can have an impact on the amount of revenue recognized in a given period. Historically, the Company&#146;s involvement
with the development of a collaborator&#146;s product candidate has been significant at the early stages of development, and lessens as it progresses into clinical trials. Accordingly, the Company generally estimates this period of substantial
involvement to begin at the inception of the collaboration agreement and conclude at the end of the Company&#146;s substantial involvement. The Company reassesses its periods of substantial involvement over which the Company amortizes its upfront
license fees and makes adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company&#146;s technology to develop an
alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial pre-clinical activity on another product candidate and its remaining
period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was
classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has
stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue related to research and pre-clinical development services that represent separate units of accounting as they
are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological
improvements over the estimated term of the applicable license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company typically performs research activities and pre-clinical
development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and pre-clinical testing stages of drug development under its exclusive licenses. The Company records amounts
received for research materials produced or services performed as revenue from collaborative research. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s license
agreements have milestone payments which for reporting purposes are aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable
when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries&#146; regulatory authorities or on receipt of
actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk
to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance to achieve the milestone, or
(2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the
consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective
milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company&#146;s efforts during the
period of substantial involvement are considered substantive and are recognized as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute
effort to the achievement of such milestones are generally achieved after the period of substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing
performance obligations, assuming all other revenue recognition criteria are met. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Right-to-Develop Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize
in specified geographic territories product candidates developed by the Company under agreed upon research and pre-clinical development product programs. The product candidates resulting from each program are all directed to a specific target
selected by the collaborator. Under these agreements, fees may be due to the Company (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program,
(iii)&nbsp;upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv)&nbsp;some combination of all of these fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered
substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in
evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront
consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For
right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at
the inception of the agreement. For those right-to-develop agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, the Company has
deferred the upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration
agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option, generally 12 months. If a collaborator exercises an option and acquires a development and
commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. Upon exercise of an option to acquire a development and commercialization license, the Company would also
attribute any remaining deferred option fee to the development and commercialization license and apply the multiple-element revenue recognition criteria to the development and commercialization license and any other deliverables to determine the
appropriate revenue recognition, which will be consistent with the Company&#146;s accounting policy for upfront payments on exclusive licenses. In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue
any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. None of the Company&#146;s right-to-develop agreements have been determined to contain
substantive options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to secure development and commercialization licenses to product
programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the
appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses,
including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company&#146;s clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies,
stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss)
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2012, the Company adopted FASB&#146;s Accounting Standards Update 2011-05, <I>Presentation of
Comprehensive Income</I>. ASC 220, <I>Comprehensive Income</I>, requires the presentation of the comprehensive income (loss) and its components, as part of the consolidated financial statements. Comprehensive income (loss) is comprised of the net
income (loss) and other changes in equity that are excluded from net income (loss). Comprehensive income (loss) equals net income (loss) for the years ended December&nbsp;31, 2011 and 2012, and for the quarter ended March&nbsp;31, 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock-based payments are accounted for in accordance with the provisions of ASC&nbsp;718, <I>Compensation&nbsp;&#150; Stock Compensation</I>.
The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance
condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the
Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend
yield, expected volatility and the expected life of the award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Income (loss) per share is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each
class of common stock and participating securities based on their respective rights to receive dividends. In the event that the Board of Directors shall declare a dividend payable in cash or other property on the then-outstanding shares of common
stock, the holders of the Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock shall be entitled to receive the amount of dividends per share of Preferred Stock that would be payable on the largest number of whole shares of Common
Stock into which each share of Preferred Stock could then be converted. Therefore, the Series A-1, A-2, B, C, D and D-2 are participating securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is determined by dividing the net income (loss) allocable to common stockholders by the
weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) allocable to common stockholders by the
weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#146;s stock option grants and the if-converted method is used to determine the
dilutive effect of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic Income (Loss) per Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,320,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,717,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,361,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,282,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 37,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,254,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,337,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,906,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic earnings per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted earnings per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,717,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,320,366</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: Undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(6,717,120</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,361,755</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,282,876</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,254,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,337,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,906,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">379,011,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,254,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,337,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398,917,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted income per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents were excluded in the calculation of diluted net income (loss) per share
because their effect would be anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,478,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,478,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,478,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,364,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,404,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,404,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,404,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,952,217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,446,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,681,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to Purchase Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,394,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,394,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,394,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,170,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,009,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,346,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The pro forma net income (loss) per share is computed using the weighted-average number of common shares
outstanding and assumes the conversion of all outstanding shares of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock into shares of common stock upon completion of the Company&#146;s planned IPO, as if they had
converted at the beginning of the period. The Company believes the unaudited pro forma net income (loss) per share provides material information to investors, as the conversion of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible
preferred stock to common stock is expected to occur upon the closing of an IPO, and the disclosure of pro forma net income (loss) per share thus provides an indication of net income (loss) per share that is comparable to what will be reported by
the Company as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) used to compute pro forma net income (loss) per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,361,755</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,512,450</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,319,920</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares, used to calculate net income (loss) per common share:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,337,513</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,423,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,565,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Add: Pro forma adjustments to reflect assumed weighted-average effect of conversion of Series&nbsp;A convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,327,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318,327,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in calculating pro forma net income (loss) per common share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,665,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,893,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">399,750,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">339,893,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pro forma net income (loss) per common share:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.01</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2011, the Financial Accounting Standards Board (FASB) issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve common
fair value measurements and disclosure requirements in U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in ASU No.&nbsp;2011-05 result in common fair value measurement and disclosure requirements in U.S. GAAP and
IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years,
beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements for the year ended December&nbsp;31, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2011, the FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The
amendments in ASU No.&nbsp;2011-05 require that all nonowner changes in stockholders&#146; equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement
approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of
comprehensive income. This amendment is effective for fiscal years, beginning after December&nbsp;15, 2011. The adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements for the year ended
December&nbsp;31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all ASUs through the date the consolidated financials were issued and believes that the
adoption of these will not have a material impact on the Company&#146;s consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Property and equipment consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2013 </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,951,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,003,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,129,966</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,910,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,046,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,831,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,667,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,607,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,032,386</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,379,567</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,339,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,591,682</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,287,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,440,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&nbsp;31, 2011 and 2012, was $1,147,300 and
$959,930, respectively, and $255,347 and $252,185 for the three months ended March&nbsp;31, 2012 and 2013, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Stockholders&#146; Equity
(Deficit) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During 2002 and 2003, the Company issued a total of 34,239,374 shares of Series A-1 and Series A-2 convertible preferred
stock (Series A preferred stock) for $1.00 per share resulting in net proceeds of approximately $34,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;12, 2004,
the Company entered into a series of transactions raising $30,261,672, net of related offering costs of approximately $238,000, from the sale of 71,401,237 shares of its Series B convertible preferred stock (Series B preferred stock). In connection
with the Series B preferred stock offering, 13,604,016 shares of common stock were allocated to holders of Series&nbsp;A-1 preferred stock as an anti-dilution measure but remained unissued at December&nbsp;31, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2006, the Company raised $44,898,754, net of related offering costs of $101,246, from the sale of 110,952,217 shares of its
Series C convertible preferred stock (Series C preferred stock). In connection with the Series C preferred stock offering, 10,003,300 shares of common stock were allocated to holders of Series B preferred stock as an anti-dilution measure but
remained unissued at December 31, 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company issued 12,466,039 shares of its Series D convertible preferred
stock (Series D preferred stock) in exchange for all of the outstanding capital stock and convertible notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently, in March 2011 a settlement was reached with the former Raven stockholders
bringing the total Series D preferred stock issued in connection with the Raven acquisition to 14,446,227 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On September&nbsp;19,
2008, the Company raised $24,843,211, net of related offering costs of $156,788, from the sale of 38,337,678 shares of its Series D-2 convertible preferred stock (Series D-2 preferred stock). The Company also issued preferred stock warrants for the
purchase of 2,875,327 shares of Series D-2 preferred stock. The preferred stock warrants are exercisable at any time prior to September&nbsp;2018, but expire upon an IPO, and have a stated exercise price of $0.65 per warrant. On May&nbsp;16, 2010,
the Company exercised a put notice to Lilly in accordance with the Series D-2 preferred stock purchase agreement, resulting in the issuance of 6,916,110 shares of Series D-2 preferred stock and a warrant to purchase 518,708 additional shares of
Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On January&nbsp;11, 2011, the Company raised gross proceeds for $12,016,500 from the sale of 18,427,388
shares of its Series D-2 preferred stock. Issuance costs associated with the sale were not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Due to certain provisions in the
Series D-2 convertible preferred stock warrant agreement, these warrants are required to be classified as a liability. Management believes that the circumstances requiring cash settlement of the award are remote. The Series D-2 preferred stock
warrant liability is recorded at fair value, which is adjusted at the end of each reporting period using the Option-Pricing Method, with changes in value recorded as &#147;Changes in fair value of preferred stock purchase warrant liability&#148; in
the accompanying consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Holders of the Series A-1, Series A-2, Series B, Series C, Series D and Series
D-2 preferred stock are entitled to vote, together with the common stockholders as one class, on all matters as to which common stockholders are entitled to vote. In any such vote, each share of Series A, Series B, Series C and Series D preferred
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock shall entitle the holder to the number of votes per share that equals the number of shares of common stock into which each such share of preferred stock is then convertible. For so long as
at least four&nbsp;million shares of each of the Series A, Series B and Series C preferred stock remain outstanding, the holders of each of the Series A, Series B and Series C preferred stock, each voting as a separate class, shall each be entitled
to elect two members of the Board of Directors of the Company. The holders of a majority of the common stock, voting as a separate class, shall have the right to elect one member of the Board of Directors of the Company. The holders of a majority of
the common stock and the holders of at least 66 2/3% of the preferred stock, each voting separately as a single class (and on an as-if-converted basis to common stock with respect to the preferred stock), shall be entitled to elect all remaining
members of the Board of Directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Dividends are noncumulative and accrue on the Series A-1, Series A-2, Series B, Series C, Series D and
Series&nbsp;D-2 preferred stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and are payable when and as declared by the Board of Directors. Dividends must be declared so that the Series A, Series B, Series C and Series
D preferred stock are paid in like-kind and participate equally to those of the Series D-2 preferred and common stock. No dividends have been declared and none are accrued at December&nbsp;31, 2012 and 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock are initially convertible into 1.506,
1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively, of common stock at the option of the holder. The conversion ratio is subject to change in the event specified dilutive transactions occur. The conversion price shall be $0.66, $1.00, $0.37,
$0.41, $0.65 and $0.65 for each share of Series A-1, A-2, Series B, Series C, Series D and Series D-2 convertible preferred stock, respectively. The Company has reserved 321,592,828 shares of common stock for the potential conversion of the Series
A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Each share of Series A-1, Series A-2, Series B, Series C,
Series D and Series D-2 preferred stock automatically converts into shares of the Company&#146;s common stock upon closing of a firm commitment underwritten public offering of common stock registered under the Securities Act of 1933 at a price of at
least $1.96 per share (adjusted to reflect stock splits, stock dividends, stock combinations, recapitalizations and like occurrences), and which generates net proceeds to the Company of at least $40&nbsp;million. The holders of two-thirds of the
Series&nbsp;A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock, voting together as a single class, but separately from the common stockholders, shall have the right to elect to convert all outstanding shares of Series A-1,
Series A-2, Series B, Series C, Series D and Series D-2 preferred stock into shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In liquidation, the holders of
Series D-2 preferred stock are entitled to receive $0.65 per share prior to any distribution to the holders of any Series C and Series D preferred stock. The holders of Series C and Series D preferred stock are entitled to receive $0.41 and $0.65
per share, respectively, on a <I>pari passu </I>basis, prior to any distribution to the holders of any Series B preferred stock. The holders of Series B preferred stock are entitled to receive $0.37 per share prior to any distribution to the holders
of any shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive $0.66 per share prior to the holders of common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Shared-Based Payments </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Plan
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s 2000 Stock Option and Incentive Plan (the 2000 Plan) allowed for the grant of awards in respect of an aggregate
of 2,454,222 shares, which was increased to 2,821,664 shares of the Company&#146;s common stock in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and other
performance awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;2003, the Company implemented the 2003 Equity Incentive Plan (the 2003 Plan), and it was
amended and approved by the Company&#146;s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 38,517,360 shares of the Company&#146;s common stock. During the year ended December&nbsp;31,
2006, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 8,650,000 shares to 47,167,360. During the year ended </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;31, 2008, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 14,000,000 shares to 61,167,360. During the year
ended December&nbsp;31, 2010, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 10,000,000 shares to 71,167,360. During the year ended December&nbsp;31, 2012, the maximum number
of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 10,250,000 shares to 81,417,360. As of December&nbsp;31, 2012, a total of 12,417,150 shares were available for issuance under the 2003 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or
non-qualified stock options. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Exchange </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On March&nbsp;16, 2011 (Exchange Date), the Company modified certain outstanding options with exercise prices of $0.10 and $0.25 (Original
Options). These Original Options were canceled and replaced with options having an exercise price of $0.05 (Replacement Options), reflecting the current fair market value of the Company&#146;s common stock on the Exchange Date. Original Options
submitted for exchange were replaced on a one-for-one basis with Replacement Options. Additionally, the Replacement Options retain all terms and conditions of the Original Options except for the reduction to the exercise price as described above.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Total compensation associated with the Replacement Options consisted of the grant-date fair value of the Original Options for which the
requisite service period is expected to be rendered (or has already been rendered) at the Exchange Date, plus the incremental cost associated with the modification of terms. The incremental compensation expense was measured as the excess of the fair
value of the Replacement Options over the fair value of the Original Options re-measured as of the Exchange Date. A total of 36,081,455 Original Options were exchanged for Replacement Options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following stock-based compensation amounts were recognized for the years ended December&nbsp;31, 2011 and 2012 and the three month periods
ended March&nbsp;31, 2012 and 2013: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,018,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">471,809</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">92,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,328,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,492</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,347,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">838,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">209,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the
following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B><br><B>2013 </B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.35%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.18%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.32%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected average life of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair market value of common stock at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected Forfeiture Rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.58%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.57%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.06%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Common Stock&nbsp;&#150;&nbsp;</B>Given the lack of an active public market
for the Company&#146;s common stock, the Company&#146;s Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair
value. In the absence of a public market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant
date. The factors include: (1)&nbsp;the achievement of clinical and operational milestones by the Company; (2)&nbsp;the status of strategic relationships with collaborators; (3)&nbsp;the significant risks associated with the Company&#146;s stage of
development; (4)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (5)&nbsp;the Company&#146;s available cash, financial condition and results of
operations; (6)&nbsp;the most recent sales of the Company&#146;s preferred stock and (7)&nbsp;the preferential rights of the outstanding preferred stock. The contemporaneous valuations were performed in accordance with applicable methodologies,
approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility</B>&nbsp;&#150; Volatility is a measure of the amount by which a financial variable such as a share price has
fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not maintain an internal market for its shares and its shares are not traded publicly. The Company has been able to identify
several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of these companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Expected Dividend Yield</B>&nbsp;&#150; The Company has never declared or paid dividends and has no plans to do so in the foreseeable
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>&nbsp;&#150; This is the U.S. Treasury rate for the week of each option grant during the year,
having a term that most closely resembles the expected life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Expected Term</B>&nbsp;&#150; This is the period of time
that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be seven years. The Company uses a simplified method to calculate the
average expected term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Expected Forfeiture Rate</B>&nbsp;&#150; The forfeiture rate is the estimated percentage of options granted
that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were
granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Equity instruments issued to non-employees are accounted for under the provisions of
<FONT STYLE="white-space:nowrap">ASC&nbsp;505-50,</FONT><I> Equity Based Payments to Non-Employees</I>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the
services required are completed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Information with respect to stock options granted to employees and non-employees from January&nbsp;1,
2012 through March&nbsp;31, 2013 was as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Options&nbsp;Granted</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Option<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Intrinsic<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/08/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,119,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/14/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,878,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">06/13/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">09/19/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">11/08/2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.03</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">01/06/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,332,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">03/08/2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the Plan during the period then
ended: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Exercise<BR>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Contractual&nbsp;Term<BR>(in Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,170,532</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,523,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(936,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(748,059</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,009,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,595,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,130,683</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(127,067</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, March&nbsp;31, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,346,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">December&nbsp;31, 2012:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,189,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,345,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">March&nbsp;31, 2013:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,889,867</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and Expected to Vest (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,520,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding and exercisable as of March&nbsp;31, 2013 is
approximately $3,337,549 and $2,316,888, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted for the years ended
December&nbsp;31, 2012 and 2011 was $0.05. Total cash received for the options exercised was $46,826 and $53,225 for the years ended December&nbsp;31, 2012 and 2011, respectively. The total fair value of shares vested in the years ended
December&nbsp;31, 2012 and 2011, was $374,684 and $400,236, respectively. As of December&nbsp;31, 2012, there was $636,308 of total unrecognized compensation cost related to non-vested stock-based compensation arrangements granted under the 2000
Plan and 2003 Plan. That cost is expected to be recognized over a weighted-average period of approximately four years. As of March&nbsp;31, 2013, the total unrecognized compensation expense, net of related forfeiture estimates, was $761,139, which
the Company expects to recognize over a weighted-average period of approximately four years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Income Taxes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2011 and 2012, there was no current provision for federal or state income taxes due to the taxable losses
which resulted or use of legacy net operating loss carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The significant components of the Company&#146;s deferred tax assets
(liabilities) were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal U.S. net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,825,639</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,330,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,714,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,742,743</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,777,899</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,507,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,039,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,194,408</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,218,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,924,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,379,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,515,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,247,772</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,551,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,575,782</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,011,257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,311,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(78,523,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(79,311,042</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">487,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gross deferred income tax liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(487,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred income tax asset/(liability)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that
is more likely than not to be realized. In assessing the likelihood of realization, management considers (i)&nbsp;future reversals of existing taxable temporary differences; (ii)&nbsp;future taxable income exclusive of reversing temporary difference
and carryforwards; (iii)&nbsp;taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv)&nbsp;tax planning strategies. The Company&#146;s net deferred income tax asset is not more likely than not to be
utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net increase in the valuation allowance in 2012 is due to the fact the Company generated book and taxable
income in the current year; therefore, the net deferred tax asset amount decreased, although, the Company generated significant orphan drug credits which increased the net deferred tax asset. The increase in the orphan drug credits offset by the
current year income amount resulted in a net current year increase to the valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has reported book losses from
inception through December&nbsp;31, 2010. The net operating loss carryforwards of approximately $100.9&nbsp;million for U.S.&nbsp;federal and approximately $94.9 million for state will expire in various years beginning in 2023 through 2030. In
addition, the Company has U.S. federal tax credits of $21.8 million which will expire in various years beginning in 2020 through 2032. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The use of the Company&#146;s net operating loss and tax credit carryforwards in future years are restricted due to changes in the
Company&#146;s ownership and tax attributes acquired by the Company in a purchase. As of December&nbsp;31, 2012, $10.6 million of the Company&#146;s net operating losses are limited for use over the years 2013 &#150; 2027 in which a range of such
amounts could be utilized on an annual basis of $0.2 million to $2.1 million. The remaining $90.3 million of net operating losses is not limited and can be offset against future taxable income. Additionally, despite the net operating loss and credit
carryforwards, the Company may have a future tax liability due to an alternative minimum tax or state tax requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The
reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States federal tax at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,350,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,926,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State taxes (net of federal benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,480,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,460,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred income tax adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(512,375</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Orphan drug credit, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,056,607</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,895,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">725,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">279,165</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of preferred stock warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(496,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other permanent items</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,991,131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">787,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense/(benefit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The change in unrecognized tax benefits, for the years ended December&nbsp;31, 2011 and
2012, were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,246,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,533,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for current year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increases/(decreases) for prior year tax positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Decreases as a result of expiration of statute of limitations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,533,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,592,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2011 and 2012, of the total gross unrecognized tax benefits, approximately $1,105,256
and $1,140,067 would favorably impact the Company&#146;s effective income tax rate, respectively. Although, due to the Company&#146;s determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance
would be recorded, therefore, zero net impact would result within the Company&#146;s effective income tax rate. The Company&#146;s uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute
carryforward amounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2012 and 2011, the Company has not recognized any interest or penalties
related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within
the next twelve months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company&#146;s U.S. Federal and state income tax returns from 2001 to 2011 remain subject to examination by
the tax authorities. The Company&#146;s 2001 through 2007 years remain open for examination, even though the statute of limitations has expired, due to the net operating losses and credits carried forward for use in prospective years. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Lease Exit Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16,
2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven was considered a development-stage enterprise as
defined in ASC&nbsp;915, <I>Development Stage Entities</I>. In connection with the acquisition, the Company issued 12,466,039 shares of its Series D convertible preferred stock in exchange for all of the outstanding capital stock and convertible
notes payable of Raven. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company undertook restructuring activities related to the acquisition of Raven. These restructuring
activities included reductions in staffing levels and the intended exit of leased facilities. All severance-related payments were completed in the year ended December&nbsp;31, 2009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with these restructuring activities, as part of the cost of acquisitions, the Company established a restructuring liability
attributed to an existing operating lease. The terms of the operating lease extend through 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Changes in the lease exit liability for
the years ended December&nbsp;31, 2012 and 2011 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exit Liability</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2010</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,054,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(447,019</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,607,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151,994</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at March&nbsp;31, 2013 (unaudited)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,921,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future principal payments to be made under the lease agreement for the next five years and
thereafter as of December&nbsp;31, 2012 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 628,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,438,742</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,641,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,866,031</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,113,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,385,375</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The purchase agreement provides for a specified total of certain contingent milestones that are based on the
achievement of certain product sales derived from the acquired Raven technology. Also, a onetime payment of $5.0&nbsp;million will be made to the Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any
product derived from the Raven &#147;Cancer Stem Cell Program.&#148; No payment shall be made if the Phase 2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding
consideration for research and development and equity) received by MacroGenics for license of a product derived from the Raven &#147;Cancer Stem Cell Program&#148; and a onetime payment ranging from $8.0&nbsp;million to $12.0&nbsp;million dependent
upon a specified level of sales of products derived from the Raven &#147;Cancer Stem Cell Program.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The contingent consideration
will be accounted for as additional purchase price and recorded as incremental in-process research and development expense when it is deemed probable that the contingencies will be attained. For the years ended December&nbsp;31, 2012 and 2011, no
additional amounts have been recorded. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8. Collaboration and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Les Laboratoires Servier </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
November 2011, the Company entered into a right-to-develop collaboration agreement with Servier for the development and commercialization of MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Servier made a nonrefundable payment of $20 million to the Company. The Company is eligible to receive up to
approximately $420 million in license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises the option, obtains regulatory approval for and successfully commercializes MGA271. The Company has determined
that each potential future clinical, development, regulatory, and sales milestone is substantive. In the event Servier exercises its option, Servier must pay a license grant fee. Under this agreement, Servier would be obligated to pay the Company
low double digit to mid-teen royalties on product sales in its territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration
agreement with Servier and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include an exclusive license
to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement and participation on an executive committee and a research and development committee. The Company determined that
these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation during the initial 27-month period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the years ended December 31, 2011 and 2012 and the three months ended March 31, 2013, the Company recognized revenue of $0.9 million,
$9.1&nbsp;million and $2.3 million, respectively, under this agreement. No additional milestones have been recognized under this agreement through March 31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At December 31, 2012, $10.0 million of revenue was deferred under this agreement, $9.1 million of which was included in current liabilities
and $0.9 million was included in long-term liabilities. At March 31, 2013, $7.7 million of revenue was deferred under this agreement, all of which was included in current liabilities during the quarter ended March 31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In September 2012, the Company entered into a second right-to-develop collaboration agreement with Servier and granted it options to obtain
three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by the Company as MGD006 and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico,
Japan, South Korea and India. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Servier made a nonrefundable payment of $20 million to the
Company. In addition, the Company will be eligible to receive up to approximately $1 billion in additional license grant fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all of the options and
successfully develops, obtains regulatory approval for, and commercializes a product under each license, including $5 million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestones, the Company and
Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical, development, regulatory, and sales milestone is substantive. Under this agreement, Servier would be obligated to pay the
Company low double digit to mid-teen royalties on net product sales in its territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research
collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include an
exclusive license to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement and participation on an executive committee and a research and development committee. The
Company determined that these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation during the initial
29-month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the year ended December&nbsp;31, 2012 and the quarter ended March 31, 2013, the Company recognized revenue of
$2.0&nbsp;million and $2.2 million, respectively, under this agreement. No additional milestones have been recognized under this agreement through March 31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At December 31, 2012, $18.0 million of revenue was deferred under this agreement, $8.6 million of which was included in current liabilities
and $9.4 million of which was included in long-term liabilities. At March 31, 2013, $15.3 million of revenue was deferred under this agreement, $8.6 million of which was included in current liabilities and $6.7 million of which was included in
long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead Sciences, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In January 2013, the Company entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, the Company retains development and commercialization rights outside of North America, the European Union, Norway,
Iceland, Turkey, Australia and New Zealand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company received an initial $7.5 million license grant fee for the first DART-based
molecule. In addition, the Company may be eligible to receive up to more than $1 billion in additional clinical, regulatory and sales milestone payments if Gilead exercises all four of the options and successfully develops, obtains regulatory
approval for, and commercializes a product under each option and license. The Company has determined that the other licenses are conditional deliverables, which are substantive options that were not granted with a substantial discount. The Company
has determined that each potential future clinical, development, regulatory, and sales milestone is substantive. Gilead also provides funding for the Company&#146;s internal and external research costs under the agreement. Additionally, Gilead would
be obligated to pay the Company high single digit to low-double digit royalties on product sales in its territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has
evaluated the research collaboration agreement with Gilead and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research
collaboration include a license to its technology and research and development services. The Company concluded that the deliverables do not have stand alone value and therefore, represent a combined single unit of accounting. Due to the lack of
standalone value for the license and research and development services, the upfront payment and the expected research and development reimbursements are being recognized ratably through the expected development period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company and Gilead have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the joint committee as a
deliverable, it would not have had a material impact on the accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receivables of $629,815 as of March 31, 2013
relate amounts due to the Company from Gilead for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues
of approximately $1.7 million under this agreement for the three months ended March 31, 2013. No additional milestones have been reached under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At March 31, 2013, $6.5 million of revenue was deferred under this agreement of which $4.2 million was included in current liabilities and
$2.3 million was included in non-current liabilities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Boehringer Ingelheim International GmbH </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2010 the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up to ten
DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DARTs
generated under the agreement, or the Boehringer licensed products, throughout the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, the Company
received an upfront payment of $15 million. The Company subsequently received two annual maintenance payments and anticipates receiving a third annual maintenance payment in the fourth quarter of 2013. The first two maintenance payments were solely
attributed to the passage time. Because Boehringer has the option to cancel the program after the second anniversary of the agreement, the third maintenance payment will be recognized over the remaining obligation period once received. The Company
has the potential to earn development, regulatory and sales milestone payments that can reach up to $210 million for each of the DART programs under this agreement in the case of full commercial success of multiple DART products. The Company has
determined that each potential future clinical, development, regulatory, and sales milestone is substantive. Boehringer also provides funding for the Company&#146;s internal and external research costs and is required to pay the Company mid-single
digit royalties on product sales. From the commencement of the collaboration through March&nbsp;31, 2013, the Company has received $36.9 million under this agreement, including upfront, annual maintenance and milestone payments as well as research
funding. In addition, Boehringer purchased $10 million of the Company&#146;s Series D-2 Preferred Stock in January 2011. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional
activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license
does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not represent a separate unit of accounting. The Company concluded that because the drug candidate has not yet been
developed, the license is of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the
Company agreeing to provide the research and development activities for the other party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research
and development services were treated as a combined unit of account and recognized over the expected obligation period associated with the research and development services through September 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company and Boehringer have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint
committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the organization period for the research and development services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January 1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receivables of $247,815, $355,568&nbsp;and $146,150 as of March 31, 2013, December 31, 2012, and December 31, 2011, respectively, relate to
amounts due to the Company from Boehringer for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of
approximately $2.3 million, $11.7&nbsp;million, and $8.9 million under this agreement during the three months ended March 31, 2013 and the years ended December 31, 2012 and 2011, respectively. One milestone payment of $2.0 million was recognized
under this agreement through December 2012. No additional milestones have been recognized under this agreement through March 31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At
December 31, 2012, $14.0 million of revenue was deferred under this agreement, $5.0 million of which was included in current liabilities and $9.0 million was included in long-term liabilities. At March 31, 2013, $12.6 million of revenue was deferred
under this agreement, $5.0 million of which was included in current liabilities and $7.6 million of which was included in long-term liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pfizer, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In October 2010, the
Company entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based molecules. The Company granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5
million and has received milestone payments and funding for the Company&#146;s internal and external research costs under the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive technical, development and sales milestone payments that
can reach up to approximately $210 million for each DART program under this agreement. The Company has determined that each potential future technical, development, and sales milestone is substantive. Pfizer is responsible for all pre-clinical and
clinical development costs for the program. In addition, Pfizer is required to pay the Company mid-single digit to low double digit royalties on product sales. Under this collaboration, one DART program is currently being pursued and the Company
will complete its research obligations under this program in October 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement
with Pfizer and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include an exclusive license to its
technology, research and development services and manufacturing services. The Company concluded that the manufacturing services were optional and were subject to further negotiation upon reaching regulatory approval. As such, the manufacturing
services are not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company determined that it had fair value of the
undelivered element of the research and development services. However, the Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not
represent a separate unit of accounting. Facts that were considered included the development of the candidate noting that because the drug candidate has not yet been developed, the license is of no value to Pfizer without the ensuing research and
development activities using the DART technology, which is proprietary to the Company. Likewise, Pfizer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other
party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and
recognized over the expected obligation period associated with the research and development services through October 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The $5 million
upfront payment received by the Company is non-refundable; therefore, there is no right of return for the license. The Company is recognizing revenue associated with this non-refundable up-front license fee through October 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company and Pfizer have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable because it is a participating right and not an obligation of the
Company. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January 1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receivables of $843,821, $896,285,&nbsp;and $936,010 as of March 31, 2013, December 31, 2012, and December 31, 2011, respectively, relate to
amounts due to the Company from Pfizer for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of
approximately $1.3 million, $5.5 million, and $5.2 million under this agreement during the three month period ended March 31, 2013 and the years ended December 31, 2012 and 2011, respectively. Included in the 2012 revenues are milestone payments
totaling $500,000. No additional milestones have been recognized under this agreement through March 31, 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At March 31, 2013 and
December 31, 2012, $0.9 million and $1.3 million of revenue was deferred under this agreement all of which was included in current liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Green Cross Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
June&nbsp;2010, the Company entered into a collaboration agreement with Green Cross for the development of the Company&#146;s anti-HER2 antibody known as MGAH22, or margetuximab. This arrangement grants Green Cross an exclusive license to conduct
specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Green Cross made a nonrefundable payment of
$1.0&nbsp;million to the Company. The Company is eligible to receive clinical development and commercial milestone payments of up to $4.5 million. The Company has determined that each potential clinical development and commercial milestone is
substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the two companies
collaborate under the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the collaboration agreement with Green Cross and has determined that it is a
revenue arrangement with multiple deliverables or performance obligations. The Company&#146;s substantive performance obligations under this agreement include an exclusive license to its technologies and participation in a joint steering committee.
The Company concluded that the license does not have value on a standalone basis and therefore does not represent a separate unit of accounting. Likewise, Green Cross could not sell the license to another party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The $1 million upfront payment received by the Company is non-refundable; as such, there is no right of return for the license. Therefore, the
upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January 1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $100,000 under this agreement during each of the years ended December&nbsp;31, 2012 and 2011,
and $25,000 during the quarter ended March 31, 2013. No additional milestones have been recognized under this agreement through March 31, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">At December 31, 2012, $750,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and
$650,000 was included in long-term liabilities. At March 31, 2013, $725,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and $625,000 was included in long-term liabilities </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eli Lilly &amp; Co. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In
October&nbsp;2007, the Company entered into an exclusive license and collaboration agreement (together, the Agreements) with Eli Lilly to jointly develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. As part of the
Agreements, Eli Lilly acquired the exclusive rights to the molecule. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Upon execution of the Agreements, Eli Lilly made a nonrefundable
payment of $41.0&nbsp;million to the Company. In May&nbsp;2008, Eli Lilly paid the Company a milestone payment of $50.0&nbsp;million and in May&nbsp;2010, Eli Lilly paid an additional milestone of $5.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On October&nbsp;28, 2010, Lilly notified the Company of its decision to terminate the agreement after review of one year of clinical data from
the PROT&Eacute;G&Eacute; trial in Type 1 diabetes patients treated with teplizumab. Such data failed to support the primary efficacy end point in the study. During the year ended December 31, 2012, Eli Lilly satisfied its obligation related to the
cost of monitoring patients under the PROT&Eacute;G&Eacute; and ENCORE trials. The Company&#146;s obligations continued through September 2012, which represented the follow up period for enrolled patients and the Company&#146;s final reporting of
the trial&#146;s results. There is no additional clinical trial activity under the Eli Lilly Agreements as it relates to such trials. In February 2011, the Company reacquired the commercial rights to the molecule from Eli Lilly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Receivables of $263,880, $558,516 and $351,357 as of March 31, 2013, December 31, 2012, and, and December 31 2011, respectively, relate to
amounts due to the Company from Eli Lilly for reimbursement work performed under the above mentioned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">During the quarter
ended March 31, 2013 and the years ended December 31, 2012 and 2011, the Company recognized revenue of $0.4 million, $31.2&nbsp;million and $30.9 million, respectively, under this agreement. No additional milestones were recognized under this
agreement through March 31, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Commitments and Contingencies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company
leases office and laboratory space over periods extending through January&nbsp;30, 2018. Several of the leases contain rent escalation clauses. Rent expense for the years ended December&nbsp;31, 2012 and 2011, was $3,133,850 and $3,190,413,
respectively. The Company incurred $783,463 and $783,463 of rent expense for the three-month periods ending March&nbsp;31, 2013 and 2012, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MacroGenics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Notes to Consolidated Financial Statements </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under noncancelable operating leases at December&nbsp;31, 2012,
are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Operating<BR>Leases</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Year ending December&nbsp;31:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,797,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,557,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,214,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,310,833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,410,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,754,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,044,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Product Milestone Payments and Royalty Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (Tolerance) entered into during June 2005, the Company may be
required to issue Tolerance additional consideration as follows: (i)&nbsp;$10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license applications; (ii)&nbsp;678,398 shares
of common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration required to be paid under the Asset
Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional considerations have occurred during the years ended December&nbsp;31, 2012 and 2011 or during and the quarter ended
March&nbsp;31, 2013. Additionally, certain agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no other revenue from product sales is being generated by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Employee Benefit Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">On
September&nbsp;25, 2002, the Company established the MacroGenics 401(k) Plan (the 401(k) Plan) for its employees under Section&nbsp;401(k) of the IRC. Under this 401(k) Plan, all employees at least 21 years of age are eligible to participate in the
401(k) Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Employees are 100% vested in their contributions to the Plan. The Company&#146;s contribution to the Plan, as determined by the Board of
Directors, is discretionary. The Company&#146;s contributions to the Plan totaled $225,195, $217,097 and $80,891 for the years ended December&nbsp;31, 2012 and 2011 and the quarter ended March&nbsp;31, 2013, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12. Subsequent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">The Company has
completed an evaluation of all subsequent events through March&nbsp;8, 2013, the date on which these financial statements were available to be issued, to verify that these financial statements include appropriate disclosure of events both recognized
in the consolidated financial statements as of December&nbsp;31, 2012, and events which occurred subsequently but were not recognized in the financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">F-31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Through and including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013 (the 25th day after the date of this prospectus), all dealers effecting transactions in these securities, whether or not
participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. </FONT></P>
<P STYLE="margin-top:100px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>


<IMG SRC="g5754311new.jpg" ALT="LOGO">
 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Common Stock </B></FONT></P>
<P STYLE="font-size:100px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>P R O S P E C T U S </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:100px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>BofA Merrill
Lynch </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Leerink Swann </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Stifel </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Lazard Capital Markets </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Wedbush PacGrow Life Sciences </B></FONT></P> <P STYLE="font-size:100px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PART II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Expenses of Issuance and Distribution </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable in connection with the sale and distribution of the securities being registered. All
amounts are estimated except the SEC and FINRA registration fees. All of the expenses below will be paid by us. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:14pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B></B>Item<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC Registration fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINRA filing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">NASDAQ Global Market listing fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Printing and mailing expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Legal fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accounting fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer agent and registrar fees and expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Indemnification of Directors and Officers </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under Section&nbsp;145 of the Delaware General Corporation Law, we can indemnify our directors and officers against liabilities they may incur in such capacities, including liabilities under the
Securities Act of 1933, as amended, or the Securities Act. Our bylaws that we expect to be effective upon the closing of this offering (Exhibit 3.4 to this registration statement) provide that we will indemnify our directors and officers to the
fullest extent permitted by law and require us to advance litigation expenses upon our receipt of an undertaking by the director or officer to repay such advances if it is ultimately determined that the director or officer is not entitled to
indemnification. Our bylaws further provide that rights conferred under such bylaws do not exclude any other right such persons may have or acquire under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our amended and restated certificate of incorporation that we expect to be effective upon the closing of this offering (Exhibit 3.2 to
this registration statement) provides that, pursuant to Delaware law, our directors shall not be liable for monetary damages for breach of the directors&#146; fiduciary duty of care to us and our stockholders. This provision in the amended and
restated certificate of incorporation does not eliminate the duty of care, and in appropriate circumstances equitable remedies such as injunctive or other forms of non-monetary relief will remain available under Delaware law. In addition, each
director will continue to be subject to liability for breach of the director&#146;s duty of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or knowing violations of law, for actions
leading to improper personal benefit to the director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#146;s responsibilities under any
other law, such as the federal securities laws or state or federal environmental laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, our amended and restated
certificate of incorporation provides that we shall indemnify our directors and officers if such persons acted (i)&nbsp;in good faith, (ii)&nbsp;in a manner reasonably believed to be in or not opposed to our best interests, and (iii)&nbsp;with
respect to any criminal action or proceeding, with reasonable cause to believe such conduct was lawful. The amended and restated certificate of incorporation also provides that, pursuant to Delaware law, our directors shall not be liable for
monetary damages for breach of the directors&#146; fiduciary duty of care to us and our stockholders. This provision in the amended and restated certificate of incorporation does not eliminate the duty of care, and in appropriate circumstances
equitable remedies such as injunctive or other forms of non- monetary relief will remain available under Delaware law. In addition, each director will continue to be subject to liability for breach of the director&#146;s duty of loyalty to us for
acts or omissions not in good faith or involving intentional misconduct, for knowing violations of law, for actions leading to improper personal benefit to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-1
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
director, and for payment of dividends or approval of stock repurchases or redemptions that are unlawful under Delaware law. The provision also does not affect a director&#146;s responsibilities
under any other law, such as the federal securities laws or state or federal environmental laws. The amended and restated certificate of incorporation further provides that we are authorized to indemnify our directors and officers to the fullest
extent permitted by law through the bylaws, agreement, vote of stockholders or disinterested directors, or otherwise. We intend to obtain directors&#146; and officers&#146; liability insurance in connection with this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, concurrently with this offering, we will enter into agreements to indemnify our directors and certain of our officers in
addition to the indemnification provided for in the amended and restated certificate of incorporation and bylaws. These agreements will, among other things, indemnify our directors and some of our officers for certain expenses (including attorneys
fees), judgments, fines and settlement amounts incurred by such person in any action or proceeding, including any action by or in our right, on account of services by that person as a director or officer of our company or as a director or officer of
any of our subsidiaries, or as a director or officer of any other company or enterprise that the person provides services to at our request. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement (Exhibit 1.1 to this registration statement) provides for indemnification by the underwriters of us and our officers and directors, and by us of the underwriters, for certain
liabilities arising under the Securities Act or otherwise in connection with this offering. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recent Sales of Unregistered Securities </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>(a) Sale of Stock Pursuant to Collaboration Agreement with Green Cross</I></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In June 2010 we entered into a License Agreement with Green Cross. See &#147;Business &#151; Collaborations.&#148; Pursuant to that agreement, we issued and sold an aggregate of $1.0 million of our common
stock to Green Cross. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In January 2011, we issued and sold 18,427,388 shares of our Series D-2 preferred stock to three
investors at a for an aggregate purchase price of $12,016,500. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No underwriters were involved in the foregoing sales of
securities. The securities described in this section (a)&nbsp;of Item&nbsp;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(2) under the Securities
Act relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All purchasers of shares of our common stock described above represented to the Company in connection with
their purchase that they were accredited investors and were acquiring the shares for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks
of the investment and could hold the securities for an indefinite period of time. The purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a
registration statement or an available exemption from such registration. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>(b) Stock Option Grants</I></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Between June&nbsp;30, 2010 and June&nbsp;30, 2013, we granted options to purchase an aggregate of 21,325,075 shares of common stock, with
exercise prices ranging from $0.05 to $0.08 per share, to our employees and directors pursuant to our 2003 Stock Plan. As of June&nbsp;30, 2013, 27,017,484 options to purchase shares of our common stock had been exercised for aggregate consideration
of $1,182,638, options to purchase 23,210,446 shares had been forfeited and options to purchase 51,879,146 shares of our common stock remained outstanding at a weighted-average exercise price of $0.05 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The stock options and the common stock issuable upon the exercise of such options as described in this section (b)&nbsp;of Item&nbsp;15
were issued pursuant to written compensatory plans or arrangements with the Company&#146;s employees and directors in reliance on the exemption provided by Rule 701 promulgated under the Securities Act. All recipients either received adequate
information about the Company or had access, through employment or other relationships, to such information. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of the foregoing securities described in sections (a)&nbsp;and (b)&nbsp;of Item&nbsp;15
are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of capital stock described in this Item&nbsp;15 included appropriate legends setting forth that the securities had not been
registered and the applicable restrictions on transfer </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-3
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits and Financial Statement Schedules </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-4
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Undertakings </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each
purchaser. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors,
officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The undersigned registrant hereby undertakes that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus as
filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this
registration statement as of the time it was declared effective. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) For the purpose of determining any liability under the
Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and this offering of such securities at that time shall be deemed
to be the initial bona fide offering thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-5
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city
of Rockville, State of Maryland, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>POWER OF ATTORNEY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">KNOW ALL MEN BY THESE PRESENTS, the undersigned hereby constitute and appoint Scott Koenig, M.D., Ph.D. and James Karrels and each of them, his true and lawful attorney-in-fact and agent, each with full
power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, or any related registration statement
filed pursuant to Rule 462(b) under the Securities Act of 1933, and to file the same, with exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents,
and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and
confirming all that each of said attorneys-in-fact and agents, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Act of 1933, this Registration Statement on Form S-1 has been signed by the following persons in the capacities and on the dates indicated: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Signature</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:16pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO and Director<BR>(Principal Executive Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">James Karrels</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Chief Financial Officer and Secretary (Principal Financial Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Lynn Cilinski</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Controller and Treasurer (Principal&nbsp;Accounting Officer)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Paulo Costa</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Kenneth Galbraith</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Edward Hurwitz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Eran Nadav, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Arnold Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" align="left"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Michael Steinmetz, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2013</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">II-6
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Underwriting Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amended and Restated Certificate of Incorporation of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Amended and Restated Certificate of Incorporation of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bylaws of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;3.4*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Bylaws of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fourth Amended and Restated Registration Rights Agreement by and among the Company, the Founders, and the Investors, dated September 19, 2008</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Opinion of Arnold &amp; Porter LLP</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2000 Stock Option and Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2000 Stock Option and Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2003 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4+</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Company 2013 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7+*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Restricted Stock Agreement under 2013 Equity Incentive Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement by and between Red Gate III LLC and the Company, dated May 31, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease Agreement by and between Red Gate III LLC and the Company, dated March 26, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated December&nbsp;2, 2004</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated January&nbsp;31, 2006</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Lease Agreement by and between W. M. Rickman Construction Co. LLC and the Company, dated June 1, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublease Agreement by and between Amgen SF, LLC and Raven biotechnologies, Inc., dated November 21, 2006</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.14*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Indemnification Agreement</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.15&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration and License Agreement by and between Boehringer Ingelheim International GmbH and the Company, dated October 18, 2010</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.16&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Agreement by and between the Company and Gilead Sciences, Inc., dated January 3, 2013</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.17&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Collaboration Agreement by and between the Company and Green Cross Corp., dated June 30, 2010</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.18&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated January 19, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.19&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second Amendment to Collaboration Agreement by and between the Company and Green Cross Corp., dated December 13, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.20&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.21&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated November 24, 2011</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.22&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated October 13, 2010</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.23&#134;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment No. 1 to Research Collaboration and License Agreement by and between Pfizer Inc. and the Company, dated August 9,
2012</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="92%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:39pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsidiaries of Company</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">23.2*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent of Arnold &amp; Porter LLP (included in Exhibit 5.1)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">24.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power of Attorney (included on signature pages hereto)</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be filed by amendment. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#134;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential treatment is requested for certain confidential portions of this exhibit pursuant to Rule 406 under the Securities Act. In accordance with Rule 406, these
confidential portions have been omitted from this exhibit and filed separately with the Commission. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">+</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indicates management contract or compensatory plan. </FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 3.1 </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>State&nbsp;of&nbsp;Delaware</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Secretary&nbsp;of&nbsp;State</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Division of Corporations</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delivered 01:15 PM 09/19/2008</I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>FILED 01:09 PM 09/19/2008</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>SRV&nbsp;080969430&nbsp;&#150;&nbsp;3274005&nbsp;FILE</I></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED AND RESTATED </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATE OF INCORPORATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OF </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Pursuant to Sections 242 and 245 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>of the General Corporation Law of
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>the State of Delaware </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, hereby certifies as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. The name of the corporation is MacroGenics, Inc. (the &#147;<U>Corporation</U>&#148;). The Corporation was originally incorporated on
August&nbsp;14, 2000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. This Amended and Restated Certificate of Incorporation restates and integrates and further amends
the Amended and Restated Certificate of Incorporation of the Corporation and was duly adopted by the Board of Directors and the stockholders of the Corporation in accordance with the provisions of Sections 141,228,242 and 245 of the General
Corporation Law of the State of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. Immediately upon the filing of this Amended and Restated Certificate of
Incorporation, the text of the Certificate of Incorporation of the Corporation is hereby amended and restated in its entirety to read as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>FIRST</B>. The name of the corporation is MacroGenics, Inc. (the &#147;<U>Corporation</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SECOND</B>. The address of the registered office of the Corporation in the State of Delaware is Corporation Trust Center, 1209 Orange Street, in the City of Wilmington, New Castle County, Delaware
19801. The name of its registered agent at such address is The Corporation Trust Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>THIRD</B>. The nature of the
business or purposes to be conducted or promoted by the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOURTH</B>. The authorized capital stock of the Corporation shall consist of Seven Hundred Twenty Nine Million Five Hundred Ninety Two
Thousand Eight Hundred Twenty Eight (729,592,828)&nbsp;shares, consisting of two classes: (i)&nbsp;Four Hundred Twenty Five Million (425,000,000)&nbsp;shares of Common Stock, $0.01 par value per share (the &#147;<U>Common Stock</U>&#148;), and
(ii)&nbsp;Three Hundred Four Million Five Hundred Ninety Two Thousand Eight Hundred Twenty Eight (304,592,828)&nbsp;shares of Preferred Stock, $0.01 par value per share (the &#147;<U>Preferred Stock</U>&#148;), issuable in one or more series as
hereinafter provided. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a statement of the designations and the powers, preferences, privileges and
rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>COMMON STOCK</U>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.
<U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and subordinate to those that may be fixed with respect to any shares of the Preferred Stock. The Common Stock is subject to the provisions
under &#147;Drag-Along Obligation&#148; in this Article FOURTH, B.7. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Voting Rights</U>. Except as otherwise required by
law, each holder of Common Stock shall have one vote in respect of each share of Common Stock held of record by such holder on the books of the Corporation for the election of directors and all matters submitted to a vote of the stockholders of the
Corporation, whether by meeting or by written consent in lieu of a meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Dividends</U>. Dividends may be declared
and paid on the Common Stock from funds lawfully available therefore if, as and when determined by the Board of Directors of the Corporation and subject to any preferential dividend rights of any then outstanding Preferred Stock. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>PREFERRED STOCK</U> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Number of Shares</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.1 <U>Series A Preferred Stock</U>. Twenty six million, eight hundred seventy four thousand, seven hundred ninety two (26,874,792)&nbsp;shares of the authorized Preferred Stock of the Corporation are
hereby designated &#147;Series A-1 Convertible Preferred Stock&#148; (the &#147;<U>Series A-1 Preferred Stock</U>&#148;) and seven million, three hundred sixty four thousand, five hundred eighty two (7,364,582)&nbsp;shares of the authorized
Preferred Stock of the Corporation are hereby designated &#147;Series A-2 Convertible Preferred Stock&#148; (the &#147;<U>Series A-2 Preferred Stock</U>&#148; and, together with the Series A-1 Preferred Stock, the &#147;<U>Series A Preferred
Stock</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 <U>Series B Preferred Stock</U>. Seventy one million, four hundred one thousand, two hundred thirty
seven (71,401,237)&nbsp;shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;Series B-1 Convertible Preferred Stock&#148; (the &#147;<U>Series B Preferred Stock</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3 <U>Series C Preferred Stock</U>. One hundred ten million, nine hundred fifty two thousand, two hundred seventeen
(110,952,217)&nbsp;shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;Series C Convertible Preferred Stock&#148; (the &#147;<U>Series C Preferred Stock</U>&#148;). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4 <U>Series D and Series D-2 Preferred Stock</U>. Thirty million (30,000,000)&nbsp;shares
of the authorized Preferred Stock of the Corporation are hereby designated &#147;Series D Convertible Preferred Stock&#148; (the &#147;<U>Series D Preferred Stock</U>&#148;), and fifty eight million (58,000,000)&nbsp;shares of the authorized
Preferred Stock of the Corporation are hereby designated &#147;Series D-2 Convertible Preferred Stock&#148; (the &#147;<U>Series D-2 Preferred Stock</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. <U>Voting</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>General</U>. Except as may be otherwise provided in
these terms of the Preferred Stock or by law, the Preferred Stock shall vote together with all other classes and series of stock of the Corporation entitled to vote as a single class on all actions to be taken by the stockholders of the Corporation,
including but not limited to actions amending the Certificate of Incorporation to increase the number of authorized shares of Common Stock, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law of the State of
Delaware. Each share of Preferred Stock shall entitle the holder thereof to such number of votes per share on each such action as shall equal the number of shares of Common Stock (including fractions of a share) into which each share of Preferred
Stock is then convertible. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Board of Directors</U>. The Board of Directors shall be elected as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) For so long as at least four million (4,000,000)&nbsp;shares of Series A Preferred Stock remain outstanding (subject to adjustment
for any stock split, reverse stock split or similar event affecting the Series A Preferred Stock after the filing date hereof), the holders of a majority of the then-outstanding Series A Preferred Stock, voting as a separate class, shall be entitled
to elect two (2)&nbsp;directors of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) For so long as at least four million (4,000,000)&nbsp;shares of
Series B Preferred Stock remain outstanding (subject to adjustment for any stock split, reverse stock split or similar event affecting the Series B Preferred Stock after the filing date hereof), the holders of a majority of the then-outstanding
Series B Preferred Stock, voting as a separate class, shall be entitled to elect two (2)&nbsp;directors of the Corporation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) For so long as at least four million (4,000,000)&nbsp;shares of Series C Preferred Stock remain outstanding (subject to adjustment
for any stock split, reverse stock split or similar event affecting the Series C Preferred Stock after the filing date hereof), the holders of a majority of the then-outstanding Series C Preferred Stock, voting as a separate class, shall be entitled
to elect two (2)&nbsp;directors of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The holders of a majority of the Common Stock, voting as a separate
class, shall be entitled to elect one (1)&nbsp;director of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The holders of a
majority of the Common Stock and the holders of at least sixty-six and two-thirds percent (66 <FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;2</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.1ex">3</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">%) (a &#147;<U>Two-Thirds Interest</U>&#148;) of the Preferred Stock, voting together as a single class (and on an
as-if-converted basis to Common Stock with respect to the Preferred Stock), shall be entitled to elect all remaining members of the Board of Directors. </FONT></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) A vacancy in any directorship elected by the holders of the Series A Preferred Stock
shall be filled only by vote or written consent of the holders of the Series A Preferred Stock, a vacancy in any directorship elected by the holders of the Series B Preferred Stock shall be filled only by vote or written consent of the holders of
the Series B Preferred Stock, a vacancy in any directorship elected by the holders of the Series C Preferred Stock shall be filled only by vote or written consent of the holders of the Series C Preferred Stock, a vacancy in any directorship elected
by the holders of the Common Stock shall be filled only by vote or written consent of the holders of the Common Stock, and a vacancy in any directorship elected jointly by the holders of the Preferred Stock and the Common Stock shall be filled only
by vote or written consent of the Preferred Stock and the Common Stock voting together as a single class on an as- converted basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(g) Any director elected as provided in Sections 2.2(a) through (e)&nbsp;hereof may be removed during the aforesaid term of office, either with or without cause, by, and only by, the affirmative vote of
the holders of the shares of the class or series of stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that purpose or pursuant to a written consent of stockholders, and any
vacancy thereby created may be filled by the holders of that class or series of stock represented at the meeting or pursuant to written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3. <U>Dividends</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Series D-2 Preferred Dividends</U>. The holders of
the Series D-2 Preferred Stock, in preference to the holders of Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, Common Stock and of any other capital stock of the Corporation ranking junior to
the Series D-2 Preferred Stock as to payment of dividends, shall be entitled to receive, pari passu, when, as and if declared by the Board of Directors of the Corporation and out of funds legally available therefor, non-cumulative cash dividends at
the annual rate of $0.0522 per share (such dividends subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Series C and D Preferred Dividends</U>. Subject to the prior dividend rights of the holders of the Series D-2 Preferred Stock,
the holders of the Series D Preferred Stock and Series C Preferred Stock, in preference to the holders of Series B Preferred Stock, Series A Preferred Stock, Common Stock and of any other capital stock of the Corporation ranking junior to the Series
D Preferred Stock and Series C Preferred Stock as to payment of dividends, shall be entitled to receive, pari passu, when, as and if declared by the Board of Directors of the Corporation and out of funds legally available therefor, non-cumulative
cash dividends at the annual rate of $0.0324 per share of Series C Preferred Stock and $0.0522 per share of Series D Preferred Stock, as applicable (such dividends subject to equitable adjustment in the event of any stock dividend, stock split,
combination, reorganization, recapitalization, reclassification or other similar event). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Series B Preferred Dividends</U>. Subject to the prior dividend rights of the
holders of the Series D-2 Preferred Stock, the Series D Preferred Stock and the Series C Preferred Stock, the holders of the Series B Preferred Stock, in preference to the holders of shares of the Series A Preferred Stock, Common Stock and of any
other capital stock of the Corporation ranking junior to the Series B Preferred Stock as to payment of dividends, shall be entitled to receive when, as and if declared by the Board of Directors of the Corporation and out of funds legally available
therefor, non-cumulative cash dividends at the annual rate of $0.0341 per share (such dividends subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other
similar event). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4 <U>Series A Preferred Dividends</U>. Subject to the prior dividend rights of the holders of the Series
D-2 Preferred Stock, the Series D Preferred Stock, the Series C Preferred Stock and the Series B Preferred Stock, the holders of the Series A Preferred Stock, in preference to the holders of shares of Common Stock and of any other capital stock of
the Corporation ranking junior to the Series A Preferred Stock as to payment of dividends, shall be entitled to receive when, as and if declared by the Board of Directors of the Corporation and out of funds legally available therefor, non-cumulative
cash dividends at the annual rate of $0.08 per share (such dividends subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5 <U>Dividend Restrictions</U>. Unless and until annual dividends on the Preferred Stock pursuant to Sections 3.1, 3.2,
3.3 and 3.4 shall have been in each case declared and paid in cash, or declared and a sum sufficient for the payment thereof set apart, no dividend shall be paid or declared and no distribution shall be made on any shares of Common Stock (other than
a stock dividend on the Common Stock payable solely in the form of additional shares of Common Stock) or any other class of capital stock ranking junior to the Preferred Stock in any respect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6 <U>Participating Dividends</U>. In the event that the Board of Directors of the Corporation shall declare a dividend payable in cash
or other property on the then-outstanding shares of Common Stock (other than dividends payable in the form of additional shares of Common Stock or other securities substituted for Common Stock in the event of a reorganization), the holders of the
Preferred Stock shall be entitled to receive, out of funds legally available therefor and in addition to the dividends that would be payable pursuant to Sections 3.1, 3.2, 3.3 and 3.4, the amount of dividends per share of Preferred Stock that would
be payable on the largest number of whole shares of Common Stock into which each share of Preferred Stock held by each holder could then be converted pursuant to Section&nbsp;6 hereof, such number to be determined as of the record date for the
determination of holders of Common Stock entitled to receive such dividend. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Liquidation</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>General</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the holders of the shares of Series D-2 Preferred Stock shall be entitled to be paid, in priority
to and before any distribution or payment to the Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, Common Stock or any other stock ranking on liquidation junior to the Series D-2 Preferred Stock,
an amount equal to $0.6521 per share of Series D-2 Preferred Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting
such shares) plus, in the case of each share, an amount equal to all dividends under Section&nbsp;3 hereof declared thereon but unpaid, computed to the date payment thereof is made available, such amount payable with respect to one share of Series
D-2 Preferred Stock being sometimes referred to as the &#147;<U>Series D-2 Liquidation Preference Payment</U>&#148; and with respect to all shares of Series D-2 Preferred Stock being sometimes referred to as the &#147;<U>Series D-2 Liquidation
Preference Payments</U>.&#148; If upon such liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the assets to be distributed among the holders of Series D-2 Preferred Stock shall be insufficient to permit
payment in full to the holders of Series D-2 Preferred Stock of the Series D-2 Liquidation Preference Payments, then the entire assets of the Corporation to be so distributed shall be distributed ratably among the holders of Series D-2 Preferred
Stock in proportion to the amount which each such holder would otherwise be entitled. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Upon any liquidation, dissolution
or winding up of the Corporation, whether voluntary or involuntary, and subject to the prior rights of the holders of Series D-2 Preferred Stock, the holders of the shares of Series D Preferred Stock and Series C Preferred Stock shall be entitled to
be paid, pari passu and in priority to and before any distribution or payment to the Series B Preferred Stock, Series A Preferred Stock, Common Stock or any other stock ranking on liquidation junior to the Series D Preferred Stock and Series C
Preferred Stock, an amount equal to $0.6521 per share of Series D Preferred Stock and $0.4056 per share of Series C Preferred Stock, as applicable (subject to equitable adjustment in the event of any stock dividend, stock split, combination,
reorganization, recapitalization, reclassification or other similar event affecting such shares) plus, in the case of each share, an amount equal to all dividends under Section&nbsp;3 hereof declared thereon but unpaid, computed to the date payment
thereof is made available, such amount payable with respect to one share of Series C Preferred Stock being sometimes referred to as the &#147;<U>Series C Liquidation Preference Payment</U>&#148; and with respect to all shares of Series C Preferred
Stock being sometimes referred to as the &#147;<U>Series C Liquidation Preference Payments</U>,&#148; and such amount payable with respect to one share of Series D Preferred Stock being sometimes referred to as the &#147;<U>Series D Liquidation
Preference Payment</U>&#148; and with respect to all shares of Series D Preferred Stock being sometimes referred to as the &#147;<U>Series D Liquidation Preference Payments</U>.&#148; If upon such liquidation, dissolution or winding up of the
Corporation, whether voluntary or involuntary, the assets to be distributed among the holders of Series D Preferred Stock and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Series C Preferred Stock shall be insufficient to permit payment in full to the holders of Series D Preferred Stock of the Series D Liquidation Preference Payments and the Series C Preferred
Stock of the Series C Liquidation Preference Payments, then the entire assets of the Corporation to be so distributed (the &#147;<U>Distributable Assets</U>&#148;) shall be distributed ratably among the holders of Series D Preferred Stock and Series
C Preferred Stock in proportion to the amount which each such holder would otherwise be entitled as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The holders
of Series D Preferred Stock shall be entitled to a percentage of the Distributable Assets equal to the product of (A)&nbsp;the result obtained by dividing (I)&nbsp;the product of (x)&nbsp;the number of then-outstanding shares of Series D Preferred
Stock <U>multiplied</U> <U>by</U> (y)&nbsp;$0.6521 (the &#147;<U>Gross Series D Preference Amount</U>&#148;) by (II) the sum of (x)&nbsp;the product of (1)&nbsp;the number of then-outstanding shares of Series C Preferred Stock <U>multiplied</U>
<U>by</U> (2)&nbsp;$0.4056 <U>plus</U> (y)&nbsp;the Gross Series D Preference Amount multiplied by (B)&nbsp;100 (such percentage, the &#147;<U>Series D Shortfall Percentage</U>&#148;). The difference between one hundred percent (100%)&nbsp;and the
Series D Shortfall Percentage shall equal the &#147;<U>Series C Shortfall Percentage</U>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The proceeds available
for distribution to the holders of Series D Preferred Stock shall equal the product of (A)&nbsp;the Series D Shortfall Percentage <U>multiplied</U> <U>by</U> (B)&nbsp;the Distributable Assets (the &#147;<U>Series D Shortfall Amount</U>&#148;). The
Series D Shortfall Amount shall be distributed among the holders of Series D Preferred Stock on a pro rata basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) The
proceeds available for distribution to the holders of Series C Preferred Stock shall equal the product of (A)&nbsp;the Series C Shortfall Percentage <U>multiplied</U> <U>by</U> (B)&nbsp;the Distributable Assets (the &#147;<U>Series C Shortfall
Amount</U>&#148;). The Series C Shortfall Amount shall be distributed among the holders of Series C Preferred Stock on a pro rata basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:21%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) Any payments to the holders of Series C Preferred Stock and Series D Preferred Stock pursuant to this Section&nbsp;4.1(b) shall be deemed the Series D Liquidation Preference Payment or Series C
Liquidation Preference Payment, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Upon any liquidation, dissolution or winding up of the Corporation,
whether voluntary or involuntary and subject to the prior rights of the holders of the Series D-2 Preferred Stock, Series D Preferred Stock and Series C Preferred Stock, the holders of the shares of Series B Preferred Stock shall be entitled, in
priority to and before any distribution or payment is made upon the Series A Preferred Stock, Common Stock or any other stock ranking on liquidation junior to the Series B Preferred Stock, to be paid an amount equal to $0.37468 per share (subject to
equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares) plus, in the case of each share, an amount equal to all dividends
under Section&nbsp;3 hereof declared thereon but unpaid, computed to the date payment thereof is made available, such amount payable with respect to one share of Series B Preferred Stock being sometimes referred to as the &#147;<U>Series B
Liquidation Preference</U>&#148; and with respect to all shares of Series B Preferred Stock being </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
sometimes referred to as the &#147;<U>Series B Liquidation Preference Payments</U>.&#148; If upon such liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary,
the assets to be distributed among the holders of Series B Preferred Stock shall be insufficient to permit payment in full to the holders of Series B Preferred Stock of the Series B Liquidation Preference Payments, then the entire assets of the
Corporation to be so distributed shall be distributed ratably among the holders of Series B Preferred Stock in proportion to the amount which each such holder would otherwise be entitled. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Upon any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary and subject to the prior rights
of the holders of the Series D-2 Preferred Stock, Series D Preferred Stock, Series C Preferred Stock and Series B Preferred Stock, the holders of the shares of Series A Preferred Stock shall be entitled, in priority to and before any distribution or
payment is made upon the Common Stock or any other stock ranking on liquidation junior to the Series A Preferred Stock, to be paid an amount equal to $0.66394 per share (subject to equitable adjustment in the event of any stock dividend, stock
split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares) plus, in the case of each share, an amount equal to all dividends under Section&nbsp;3 hereof declared thereon but unpaid, computed
to the date payment thereof is made available, such amount payable with respect to one share of Series A Preferred Stock being sometimes referred to as the &#147;<U>Series A Liquidation Preference Payment</U>&#148; and with respect to all shares of
Series A Preferred Stock being sometimes referred to as the &#147;<U>Series A Liquidation Preference Payments</U>.&#148; If upon such liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the assets to be
distributed among the holders of Series A Preferred Stock shall be insufficient to permit payment in full to the holders of Series A Preferred Stock of the Series A Liquidation Preference Payments, then the entire assets of the Corporation to be so
distributed shall be distributed ratably among the holders of Series A Preferred Stock in proportion to the amount which each such holder would otherwise be entitled. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) Upon any such liquidation, dissolution or winding up of the Corporation, immediately after the holders of the Series D-2 Preferred Stock, Series D Preferred Stock, Series C Preferred Stock, Series B
Preferred Stock and Series A Preferred Stock shall have been paid in full the Series D-2 Liquidation Preference Payments, Series D Liquidation Preference Payments, Series C Liquidation Preference Payments, Series B Liquidation Preference Payments
and Series A Liquidation Preference Payments, the remaining net assets of the Corporation available for distribution shall be distributed ratably among the holders of Preferred Stock and Common Stock (with each share of Preferred Stock being deemed,
for such purpose, to be equal to the number of shares of Common Stock (including fractions of a share) into which such share of Preferred Stock is convertible immediately prior to the close of business on the business day fixed for such
distribution). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Written notice of such liquidation, dissolution or winding up, stating a payment date, the amount of the
Series D-2 Liquidation Preference Payments, Series D Liquidation Preference Payments, Series C Liquidation Preference Payments, Series B Liquidation Preference Payments and Series A Liquidation Preference Payments, as applicable, and the place where
said Series D-2 Liquidation Preference </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Payments, Series D Liquidation Preference Payments, Series C Liquidation Preference Payments, Series B Liquidation Preference Payments or Series A Liquidation Preference Payments shall be
payable, shall be delivered in person, mailed by certified or registered mail, return receipt requested, or sent by telecopier or telex, not less than 5 days prior to the payment date stated therein, to the holders of record of Preferred Stock, such
notice to be addressed to each such holder at its address as shown by the records of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>Maximum
Liquidation Preference</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) In the event that the aggregate payments pursuant to Section&nbsp;4.1 would cause the
holders of Series D-2 Preferred Stock to receive an amount greater than $1.9563 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other
similar event affecting such shares), then the provisions of Section&nbsp;4.1 shall not apply to such liquidation event and the holders of Series D-2 Preferred Stock shall be entitled to receive instead the greater of (i)&nbsp;$1.9563 per share of
Series D-2 Preferred Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares), payable before any payment
shall be made to the holders of the Series D Preferred Stock, Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, the Common Stock or any other stock ranking junior to the Series D-2 Preferred Stock by reason of their
ownership thereof and (ii)&nbsp;such amount per share, payable on a pro rata basis with the Common Stock, as would have been payable had such share of Series D-2 Preferred Stock been converted into Common Stock pursuant to the provisions of
Section&nbsp;6 immediately prior to such liquidation, dissolution or winding up. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the event that the aggregate
payments pursuant to Section&nbsp;4.1 would cause the holders of Series D Preferred Stock to receive an amount greater than $1.9563 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination,
reorganization, recapitalization, reclassification or other similar event affecting such shares), then the provisions of Section&nbsp;4.1 shall not apply to such liquidation event and the holders of Series D Preferred Stock shall be entitled to
receive instead the greater of (i)&nbsp;$1.9563 per share of Series D Preferred Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar
event affecting such shares), payable before any payment shall be made to the holders of the Series C Preferred Stock, Series B Preferred Stock, Series A Preferred Stock, the Common Stock or any other stock ranking junior to the Series D Preferred
Stock by reason of their ownership thereof and (ii)&nbsp;such amount per share, payable on a pro rata basis with the Common Stock, as would have been payable had such share of Series D Preferred Stock been converted into Common Stock pursuant to the
provisions of Section&nbsp;6 immediately prior to such liquidation, dissolution or winding up. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event that the
aggregate payments pursuant to Section&nbsp;4.1 would cause the holders of Series C Preferred Stock to receive an amount greater than $1.2168 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination,
reorganization, recapitalization, reclassification or other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 9 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
similar event affecting such shares), then the provisions of Section&nbsp;4.1 shall not apply to such liquidation event and the holders of Series C Preferred Stock shall be entitled to receive
instead the greater of (i)&nbsp;$1.2168 per share of Series C Preferred Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event
affecting such shares), payable before any payment shall be made to the holders of the Series B Preferred Stock, Series A Preferred Stock, the Common Stock or any other stock ranking junior to the Series C Preferred Stock by reason of their
ownership thereof and (ii)&nbsp;such amount per share, payable on a pro rata basis with the Common Stock, as would have been payable had such share of Series C Preferred Stock been converted into Common Stock pursuant to the provisions of
Section&nbsp;6 immediately prior to such liquidation, dissolution or winding up. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) In the event that the aggregate
payments pursuant to Section&nbsp;4.1 would cause the holders of Series B Preferred Stock to receive an amount greater than $1.12404 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination,
reorganization, recapitalization, reclassification or other similar event affecting such shares), then the provisions of Section&nbsp;4.1 shall not apply to such liquidation event and the holders of Series B Preferred Stock shall be entitled to
receive instead the greater of (i)&nbsp;$1.12404 per share of Series B Preferred Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar
event affecting such shares) payable before any payment shall be made to the holders of the Series A Preferred Stock, the Common Stock or any other stock ranking junior to the Series B Preferred Stock by reason of their ownership thereof and
(ii)&nbsp;such amount per share, payable on a pro rata basis with the Common Stock, as would have been payable had such share of Series B Preferred Stock been converted into Common Stock pursuant to the provisions of Section&nbsp;6 immediately prior
to such liquidation, dissolution or winding up. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) In the event that the aggregate payments pursuant to Section&nbsp;4.1
would cause the holders of Series A Preferred Stock to receive an amount greater than $1.98 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification
or other similar event affecting such shares), then the provisions of Section&nbsp;4.1 shall not apply to such liquidation event and the holders of Series A Preferred Stock shall be entitled to receive instead the greater of (i)&nbsp;$1.98 per share
of Series A Preferred Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares), payable before any payment
shall be made to the holders of the Common Stock or any other stock ranking junior to the Series A Preferred Stock by reason of their ownership thereof and (ii)&nbsp;such amount per share, payable on a pro rata basis with the Common Stock, as would
have been payable had such share of Series A Preferred Stock been converted into Common Stock pursuant to the provisions of Section&nbsp;6 immediately prior to such liquidation, dissolution or winding up. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3 <U>Treatment of Mergers, Consolidations and Sales of Assets</U>. The (i)&nbsp;consolidation or merger of the Corporation into or
with any other entity or entities </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 10 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(other than a merger to reincorporate the Corporation in a different jurisdiction), or any other transaction or series of transactions, as a result of which the holders of outstanding voting
stock of the Corporation immediately preceding the consummation of such event shall, immediately following such event, hold as a group less than a majority of the voting securities of the surviving or successor entity, and (ii)&nbsp;sale, lease,
abandonment, transfer or other disposition by the Corporation of greater than fifty percent (50%)&nbsp;of the value of its assets, shall be deemed to be a liquidation, dissolution or winding up of the Corporation within the meaning of the provisions
of this Section&nbsp;4. In connection with any such transaction contemplated by the preceding sentence, all consideration payable to the stockholders of the Corporation, in connection with a merger or consolidation, or all consideration payable to
the Corporation, together with all other available assets of the Corporation (net of obligations owed by the Corporation), in the case of an asset sale, shall be paid to and deemed (to the fullest extent permitted by law) distributed (in the case of
a merger or consolidation) or available for distribution and payment as provided herein (in the case of a sale of assets), as applicable, to the holders of capital stock of the Corporation in accordance with the preference and priorities set forth
in this Section&nbsp;4, with such preferences and priorities specifically intended to be applicable in any such merger, consolidation or sale transaction as if the same were a liquidation, dissolution or winding up. If applicable, the Corporation
shall either (i)&nbsp;cause the agreement and plan of merger or consolidation to provide as a consequence of such merger or consolidation for the conversion of the Series D-2 Preferred Stock, Series D Preferred Stock, Series C Preferred Stock,
Series B Preferred Stock and/or Series A Preferred Stock into the right to receive an amount (either in cash or, in the case of a merger or consolidation for stock, stock of the surviving corporation) equal to the applicable amount payable under
this Section&nbsp;4; or (ii)&nbsp;concurrent with the consummation with the sale of all or substantially all of the assets of the Corporation, cause the redemption of all outstanding shares of the Series D-2 Preferred Stock, Series D Preferred
Stock, Series C Preferred Stock, Series B Preferred Stock and/or Series A Preferred Stock for an amount either in cash or, in the case of a sale of assets for other property, other property equal to the applicable amount payable to such class of
Preferred Stock under this Section&nbsp;4. In the event of the foregoing redemption for property other than cash, the Board of Directors shall determine in good faith the value of such property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Restrictions</U>. For so long as at least 30,400,000 shares of Preferred Stock are outstanding (subject to equitable adjustment in
the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares), and except where the vote or written consent of the holders of a greater number of shares of
the Corporation is required by law or by the Certificate of Incorporation, and in addition to any other vote required by law or the Certificate of Incorporation, without the approval of a majority of the then-outstanding shares of Preferred Stock,
given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class and on an as-if-converted basis to Common Stock, the Corporation will not: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) By merger, consolidation, reclassification or otherwise (i)&nbsp;create or authorize the creation of any additional class or series
of shares of stock senior to or on a parity with the Series A Preferred Stock, Series B Preferred Stock, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 11 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Series C Preferred Stock, Series D Preferred Stock or Series D-2 Preferred Stock in any respect, or (ii)&nbsp;increase or decrease the authorized amount of any class or series of shares of
capital stock, or (iii)&nbsp;create or authorize any obligation or security convertible into shares of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series D-2 Preferred Stock or into
shares of any other class or series of stock senior to or on a parity with the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock or Series D-2 Preferred Stock in any respect; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Sell, lease, abandon, transfer or otherwise dispose of all or substantially all of its assets in a single transaction or a series of
related transactions, or enter into a merger, consolidation, reorganization or other business combination, or any other transaction or series of related transactions, in which the stockholders of the Corporation after such event would hold stock
representing less than a majority of the stock of the surviving corporation, or consent to, or take any action deemed to be, a dissolution, liquidation or winding up of the Corporation; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Alter or change the rights, preferences or privileges of the Preferred Stock or an series thereof, or the qualifications,
limitations or restrictions thereof, if any such alteration or change would adversely affect the rights of the holders of the Preferred Stock; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Amend, alter, repeal or effect the waiver of any provision of its Amended and Restated Certification of Incorporation or By-laws, whether by way of merger, consolidation or otherwise; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Purchase or set aside any sums for the purchase of, redeem or otherwise acquire for value, or pay any dividend or make any
distribution on, any shares of capital stock or other securities of the Corporation, except (i)&nbsp;for dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (ii)&nbsp;under any
buy-back arrangements pursuant to any equity incentive plan or agreement approved by the Board of Directors, providing for the repurchase of shares upon termination of the service or employment of a consultant, director or employee; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Increase or decrease the number of members constituting the Corporation&#146;s Board of Directors; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Enter into any agreement or agreements to or otherwise take action that results in the transfer of material assets of the
Corporation to any person, other than (i)&nbsp;a transfer to a wholly owned subsidiary of the Corporation, (ii)&nbsp;the license of technology in any transaction approved by the Board of Directors of the Corporation or (iii)&nbsp;the sale of product
in the ordinary course of business; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) Approve the filing of a petition under any bankruptcy or insolvency law.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 12 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>Conversions</U>. The holders of shares of Preferred Stock shall have the following
conversion rights: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Right to Convert</U>. Subject to the terms and conditions of this Section&nbsp;6, the holder of
any share or shares of Preferred Stock shall have the right, at its option at any time, to convert any such shares of Preferred Stock (except that upon any liquidation of the Corporation the right of conversion shall terminate at the close of
business on the business day fixed for payment of the amount distributable on the Preferred Stock) into such number of fully paid and nonassessable shares of Common Stock as is obtained by multiplying the number of shares of Preferred Stock to be
converted by the Preferred Stock Conversion Rate (as defined in Section&nbsp;6.4(a)) then in effect for the applicable series of Preferred Stock. Such rights of conversion shall be exercised by the holder thereof by giving written notice that the
holder elects to convert a stated number of shares of Preferred Stock into Common Stock and by surrender of a certificate or certificates for the shares so to be converted to the Corporation at its principal office (or such other office or agency of
the Corporation as the Corporation may designate by notice in writing to the holders of the Preferred Stock) at any time during its usual business hours on the date set forth in such notice, together with a statement of the name or names (with
address) in which the certificate or certificates for shares of Common Stock shall be issued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Issuance of
Certificates; Time Conversion Effected</U>, Promptly after the receipt of the written notice referred to in Section&nbsp;6.1 and surrender of the certificate or certificates for the share or shares of Preferred Stock to be converted, the Corporation
shall issue and deliver, or cause to be issued and delivered, to the holder, registered in such name or names as such holder may direct, a certificate or certificates for the number of whole shares of Common Stock issuable upon the conversion of
such share or shares of Preferred Stock. The applicable Preferred Stock Conversion Price with respect to any conversion pursuant to this Section&nbsp;6 shall be the lowest Preferred Stock Conversion Price of the applicable class or series of
Preferred Stock being converted in effect immediately prior to such conversion. To the extent permitted by law, such conversion shall be deemed to have been effected and the Preferred Stock Conversion Price shall be determined as of the close of
business on the date on which such written notice shall have been received by the Corporation and the certificate or certificates for such share or shares shall have been surrendered as aforesaid, and at such time the rights of the holder of such
share or shares of Preferred Stock shall cease, and the person or persons in whose name or names any certificate or certificates for shares of Common Stock shall be issuable upon such conversion shall be deemed to have become the holder or holders
of record of the shares represented thereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Fractional Shares; Dividends; Partial Conversion</U>. No fractional
shares shall be issued upon conversion of Preferred Stock into Common Stock and no payment or adjustment shall be made upon any conversion on account of any dividends on the Common Stock. At the time of each conversion, the Corporation shall pay in
cash an amount equal to all cash dividends declared but unpaid on the shares of Preferred Stock surrendered for conversion to the date upon which such conversion is deemed to take place as provided in Section&nbsp;6.2. In case the number of shares
of Preferred </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 13 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Stock represented by the certificate or certificates surrendered pursuant to Section&nbsp;6.1 exceeds the number of shares converted, the Corporation shall, upon such conversion, execute and
deliver to the holder, at the expense of the Corporation, a new certificate or certificates for the number of shares of Preferred Stock represented by the certificate or certificates surrendered which are not to be converted. If any fractional share
of Common Stock would, except for the provisions of the first sentence of this Section&nbsp;6.3, be delivered upon such conversion, the Corporation, in lieu of delivering such fractional share, shall pay to the holder surrendering the Preferred
Stock for conversion an amount in cash equal to the current market price of such fractional share as determined in good faith by the Board of Directors of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Preferred Stock Conversion Price and Conversion Rate</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
<U>Preferred Stock Conversion, Rate</U>. The conversion rate in effect at any time for conversion of a series of Preferred Stock (the &#147;<U>Preferred Stock Conversion Rate</U>&#148;) shall be the quotient obtained by dividing the Original Issue
Price (as defined below) of such series of Preferred Stock by the &#147;Preferred Stock Conversion Price&#148; for such series of Preferred Stock, calculated as provided in Section&nbsp;6.4(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Preferred Stock Conversion Price</U>. The conversion price (the &#147;<U>Preferred Stock Conversion Price</U>&#148;) shall
initially be (i)&nbsp;$0.66394 for the Series A-1 Preferred Stock, (ii)&nbsp;$1.00 for the Series A-2 Preferred Stock, (iii)&nbsp;$0.37468 for the Series B Preferred Stock, (iv)&nbsp;$0.40560 for the Series C Preferred Stock, (v)&nbsp;$0.65210 for
the Series D Preferred Stock, and (vi)&nbsp;$0.65210 for the Series D-2 Preferred Stock. Such initial Preferred Stock Conversion Prices shall be adjusted from time to time in accordance with this Section&nbsp;6. All references to the Preferred Stock
Conversion Price herein shall mean the Preferred Stock Conversion Price as so adjusted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Original Issue Price</U>. The
&#147;<U>Original Issue Price</U>&#148; shall be (A)&nbsp;$1.00 for each share of the Series A Preferred Stock, (B)&nbsp;$0.42716 for each share of the Series B Preferred Stock, (C)&nbsp;$0.40560 for each share of the Series C Preferred Stock,
(D)&nbsp;$0.65210 for each share of the Series D Preferred Stock, and (E)&nbsp;$0.65210 for each share of the Series D-2 Preferred Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.5 <U>Adjustment of Conversion Price Upon Issuance of Common Stock</U>. Except as provided in Section&nbsp;6.6, if and whenever the Corporation shall issue or sell, or is, in accordance with Sections
6.5(a) through (g), deemed to have issued or sold, any shares of Common Stock for consideration per share less than the applicable Preferred Stock Conversion Price in effect immediately prior to the time of such issue or sale, then, forthwith upon
such issue or sale, the applicable Preferred Stock Conversion Price for the Series A-1 Preferred Stock, the Series B Preferred Stock, the Series C Preferred Stock, the Series D Preferred Stock and the Series D-2 Preferred Stock shall be reduced to
the price determined by dividing (i)&nbsp;an amount equal to the sum of (A)&nbsp;the number of shares of Common Stock deemed outstanding (as defined below) immediately prior to such issue or sale multiplied by the applicable then-existing Preferred
Stock Conversion Price and (B) the consideration, if any, received by the Corporation upon such issue or sale, by (ii)&nbsp;the total number of shares of Common Stock deemed outstanding immediately after such issue or sale. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 14 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purposes of the preceding paragraph, the number of shares of Common Stock deemed to
be outstanding as of a given date shall be the sum of (A)&nbsp;the number of shares of Common Stock outstanding, (B)&nbsp;the number of shares of Common Stock into which the then-outstanding shares of Preferred Stock could be converted if fully
converted on the day immediately preceding the given date, and (C)&nbsp;the number of shares of Common Stock which could be obtained through the exercise or conversion of all other rights, options and convertible securities outstanding on the date
immediately preceding the given date and which may be convertible or exercisable pursuant to their terms as of such date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding any other provision herein, no adjustment shall be made under this Section&nbsp;6.5 to the applicable Preferred Stock
Conversion Price for the Series A-2 Preferred Stock. Notwithstanding any other provision herein, in addition, no adjustment to the Preferred Stock Conversion Price shall be made under this Section&nbsp;6.5 for the Series A-1 Preferred Stock for any
issuance or deemed issuance of Common Stock, Preferred Stock, Options or Convertible Securities at a price greater than the then-applicable Series C Conversion Price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of this Section&nbsp;6.5, the following Sections 6.5(a) through (g)&nbsp;shall also be applicable: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Issuance of Rights or Options</U>. In case at any time the Corporation shall in any manner grant (whether directly or by assumption in a merger or otherwise) any warrants or other rights to
subscribe for or to purchase, or any options for the purchase of, Common Stock or any stock or security convertible into or exchangeable for Common Stock (such warrants, rights or options being called &#147;<U>Options</U>&#148; and such convertible
or exchangeable stock or securities being called &#147;<U>Convertible Securities</U>&#148;) whether or not such Options or the right to convert or exchange any such Convertible Securities are immediately exercisable, and the price per share for
which Common Stock is issuable upon the exercise of such Options or upon the conversion or exchange of such Convertible Securities (determined by dividing (1)&nbsp;the total amount, if any, received or receivable by the Corporation as consideration
for the granting of such Options, plus the minimum aggregate amount of additional consideration payable to the Corporation upon the exercise of all such Options plus, in the case of such Options which relate to Convertible Securities, the minimum
aggregate amount of additional consideration, if any, payable upon the issue or sale of such Convertible Securities and upon the conversion or exchange thereof, by (ii)&nbsp;the total maximum number of shares of Common Stock issuable upon the
exercise of such Options or upon the conversion or exchange of all such Convertible Securities issuable upon the exercise of such Options) shall be less than the applicable Preferred Stock Conversion Price in effect immediately prior to the time of
the granting of such Options, then the total maximum number of shares of Common Stock issuable upon the exercise of such Options or upon conversion or exchange of the total maximum amount of such Convertible Securities issuable upon the exercise of
such Options shall be deemed to have been issued for such price per share as of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 15 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the date of granting of such Options or the issuance of such Convertible Securities and thereafter shall be deemed to be outstanding. Except as otherwise provided in Section&nbsp;6.5(c), no
adjustment of the applicable Preferred Stock Conversion Price shall be made upon the actual issue of such Common Stock or of such Convertible Securities upon exercise of such Options or upon the actual issue of such Common Stock upon conversion or
exchange of such Convertible Securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Issuance of Convertible Securities</U>. In case the Corporation shall in any
manner issue or sell any Convertible Securities, whether or not the rights to exchange or convert any such Convertible Securities are immediately exercisable, and the price per share for which Common Stock is issuable upon such conversion or
exchange (determined by dividing (i)&nbsp;the total amount received or receivable by the Corporation as consideration for the issue or sale of such Convertible Securities, plus the minimum aggregate amount of additional consideration, if any,
payable to the Corporation upon the conversion at exchange thereof; by (ii)&nbsp;the total maximum number of shares of Common Stock issuable upon the conversion or exchange of all such Convertible Securities) shall be less than the applicable
Preferred Stock Conversion Price in effect immediately prior to the time of such issue or sale, then the total maximum number of shares of Common Stock issuable upon conversion or exchange of all such Convertible Securities shall be deemed to have
been issued for such price per share as of the date of the issue or sale of such Convertible Securities and thereafter shall be deemed to be outstanding, <U>provided</U> that (A)&nbsp;except as otherwise provided in Section&nbsp;6.5(c), no
adjustment of the applicable Preferred Stock Conversion Price shall be made upon the actual issue of such Common Stock upon conversion or exchange of such Convertible Securities and (B)&nbsp;if any such issue or sale of such Convertible Securities
is made upon exercise of any Options to purchase any such Convertible Securities for which adjustments of the applicable Preferred Stock Conversion Price have been or are to be made pursuant to other provisions of this Section&nbsp;6.5, no further
adjustment of the applicable Preferred Stock Conversion Price shall be made by reason of such issue or sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Change
in Option Price or Conversion Rate</U>. Upon the happening of any of the following events, namely, if (i)&nbsp;the purchase price provided for in any Option referred to in Section&nbsp;6.5(a), (ii)&nbsp;the additional consideration, if any, payable
upon the conversion or exchange of any Convertible Securities referred to in Section&nbsp;6.5(a) or 6.5(b), or (iii)&nbsp;the rate at which Convertible Securities referred to in Section&nbsp;6.5(a) or 6.5(b) are convertible into or exchangeable for
Common Stock shall change at any time (including, but not limited to, changes under or by reason of provisions designed to protect against dilution), then the applicable Preferred Stock Conversion Price in effect at, the time of such event shall
forthwith be readjusted to the Preferred Stock Conversion Price which would have been in effect at such time had such Options or Convertible Securities still outstanding provided for such changed purchase price, additional consideration or
conversion rate, as the case may be at the time initially granted, issued or sold, but only if as a result of such adjustment the applicable Preferred Stock Conversion Price then in effect hereunder is thereby reduced; and on the termination of any
such Option or any such right to convert or exchange such Convertible Securities, the applicable Preferred Stock Conversion Price then in effect hereunder shall forthwith be increased to the Preferred Stock Conversion Price which would have been in
effect at the time of such termination had such Option or Convertible Securities, to the extent outstanding immediately prior to such termination, never been issued. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 16 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Stock Dividends</U>. In case the Corporation shall declare a dividend or make any
other distribution upon any stock of the Corporation payable in Common Stock, Options or Convertible Securities (other than a dividend or other distribution on the Common Stock that is payable in Common Stock), then any Common Stock, Options or
Convertible Securities, as the case may be, issuable in payment of such dividend or distribution shall be deemed to have been issued or sold without consideration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Consideration for Stock</U>. In case any shares of Common Stock, Options or Convertible Securities shall be issued or sold for cash, the consideration received therefor shall be deemed to be the
amount received by the Corporation therefor, without deduction therefrom of any expenses incurred or any underwriting commissions or concessions paid or allowed by the Corporation in connection therewith. In case any shares of Common Stock, Options
or Convertible Securities shall be issued or sold for a consideration other than cash, the amount of the consideration other than cash received by the Corporation shall be deemed to be the fair value of such consideration as determined in good faith
by the Board of Directors of the Corporation, without deduction of any expenses incurred or any underwriting commissions or concessions paid or allowed by the Corporation in connection therewith. In case any Options shall be issued in connection
with the issue and sale of other securities of the Corporation, together comprising one integral transaction in which no specific consideration is allocated to such Options by the parties thereto, such Options shall be deemed to have been issued for
such consideration as determined in good faith by the Board of Directors of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Record Date</U>. In case
the Corporation shall take a record of the holders of its Common Stock for the purpose of entitling them (i)&nbsp;to receive a dividend or other distribution payable in Common Stock, Options or Convertible Securities or (ii)&nbsp;to subscribe for or
purchase Common Stock, Options or Convertible Securities, then such record date shall be deemed to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making
of such other distribution or the date of the granting of such right of subscription or purchase, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g)
<U>Treasury Shares</U>. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Corporation, and the disposition of any such shares shall be considered an issue or sale
of Common Stock for the purpose of this Section&nbsp;6.5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6 <U>Certain Issues of Common Stock Excepted</U>. Anything
herein to the contrary notwithstanding, the Corporation shall not be required to make any adjustment of the applicable Preferred Stock Conversion Price in the case of Common Stock issued (or, pursuant to Sections 6.5(a) through (g), deemed to be
issued) from and after the date of the original issuance of shares of Series D-2 Preferred Stock (the &#147;<U>Original Issue Date</U>&#148;): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) upon the conversion of shares of Preferred Stock; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 17 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) upon the granting of rights, options or warrants or the issuance of Common Stock on or
after the Original Issue Date (or the subsequent exercise thereof) to employees, officers, directors or consultants of the Corporation pursuant to any equity incentive plan or agreement approved by the Board of Directors of up to 21,056,776 shares
of Common Stock (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares), or such other amount of shares of Common
Stock as (i)&nbsp;approved by the Board of Directors, (ii)&nbsp;unanimously approved by the Compensation Committee of the Board of Directors and (iii)&nbsp;approved by the holders of a majority of the Preferred Stock (voting together as a single
class on an as if-converted basis); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) upon the exercise, conversion or exchange, at any time from and after the Original
Issue Date, of Options or Convertible Securities granted or issued before the Original Issue Date; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) as a dividend, stock
split or other distribution on shares of Common Stock; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) in connection with warrants issued in conjunction with
(x)&nbsp;establishing lines of credit and leasing arrangements with commercial lenders or banks which have been approved by the Board of Directors, (y)&nbsp;an acquisition of all or substantially all of the stock or assets of any other entity
(whether by merger or otherwise) by the Corporation or its subsidiaries (if any), which acquisition has been approved by the Corporation&#146;s Board of Directors, or, (z)&nbsp;the issuance of Series D-2 Preferred Stock by the Corporation; or
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) in connection with the issuance of shares of Preferred Stock, or pursuant to any binding agreements
to issue shares of the Preferred Stock entered into, on or prior to the one hundred eightieth (180</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;day after filing of this Amended and Restated Certificate of Incorporation, which issuances and/or agreements are at a per share price equal to or greater than the Original Issue Price of the
Series D-2 Preferred Stock and have been approved by the Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7 <U>Subdivision or Common Stock</U>. In case
the Corporation shall at any time subdivide (by any stock split, stock dividend or otherwise) its outstanding shares of Common Stock into a greater number of shares, the applicable Preferred Stock Conversion Price in effect immediately prior to such
subdivision shall be proportionately reduced, and, conversely, in case the outstanding shares of Common Stock shall be combined into a smaller number of shares, the applicable Preferred Stock Conversion Price in effect immediately prior to such
combination shall be proportionately increased. In the case of any such subdivision, no further adjustment shall be made pursuant to Section&nbsp;6.5(d) by reason thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 18 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8 <U>Reorganization or Reclassification</U>. If any capital reorganization or
reclassification of the capital stock of the Corporation shall be effected in such a way that holders of Common Stock shall be entitled to receive stock, securities or assets with respect to or in exchange for Common Stock, then, as a condition of
such reorganization or reclassification, lawful and adequate provisions shall be made whereby each holder of a share or shares of Preferred Stock shall thereupon have the right to receive, upon the basis and upon the terms and conditions specified
herein and in lieu of the shares of Common Stock immediately theretofore receivable upon the conversion of such share or shares of Preferred Stock, such shares of stock, securities or assets as may be issued or payable with respect to or in exchange
for a number of outstanding shares of such Common Stock equal to the number of shares of such Common Stock immediately theretofore receivable upon such conversion had such reorganization or reclassification not taken place, and in any such case
appropriate provisions shall be made with respect to the rights and interests of such holder to the end that the provisions hereof (including without limitation provisions for adjustments of the applicable Preferred Stock Conversion Price) shall
thereafter be applicable, as nearly as may be, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise of such conversion rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.9 <U>Notice of Adjustment</U>. Upon any adjustment of the Preferred Stock Conversion Price of any series of Preferred Stock, then and in each such case the Corporation shall give written notice thereof,
by delivery in person, certified or registered mail, return receipt requested, telecopier or telex, addressed to each holder of shares of such series of Preferred Stock at the address of such holder as shown on the books of the Corporation, which
notice shall state the applicable Preferred Stock Conversion Price resulting from such adjustment, setting forth in reasonable detail the method upon which such calculation is based. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.10 <U>Other Notices</U>. In case at any time: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) the Corporation shall declare any dividend upon its Common Stock payable in cash or stock or make any other distribution to the holders of its Common Stock; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) the Corporation shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class
or other rights; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) there shall be any capital reorganization or reclassification of the capital stock of the Corporation,
or a consolidation or merger of the Corporation with or into another entity or entities, or a sale, lease, abandonment, transfer or other disposition of all or substantially all its assets; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) there shall be a voluntary or involuntary dissolution, liquidation or winding up of the Corporation; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">then, in any one or more of said cases, the Corporation shall give, by delivery in person, certified or registered mail, return receipt requested,
telecopier or telex, addressed to each holder of any shares of Preferred Stock at the address of such holder as shown on the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 19 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
books of the Corporation, (i)&nbsp;at least 10 days&#146; prior written notice of the date on which the books of the Corporation shall close or a record shall be taken for such dividend,
distribution or subscription rights or for determining rights to vote in respect of any such reorganization, reclassification, consolidation, merger, disposition, dissolution, liquidation or winding up and (ii)&nbsp;in the case of any such
reorganization, reclassification, consolidation, merger, disposition, dissolution, liquidation or winding up, at least 20 days&#146; prior written notice of the date when the same shall take place. Such notice in accordance with the foregoing clause
(i)&nbsp;shall also specify, in the case of any such dividend, distribution or subscription rights, the date on which the holders of Common Stock shall be entitled thereto and such notice in accordance with the foregoing clause (ii)&nbsp;shall also
specify the date on which the holders of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, disposition, dissolution,
liquidation or winding up, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.11 <U>Stock to be Reserved</U>. The Corporation shall at all times reserve
and keep available out of its authorized capital stock, solely for the purpose of issuance upon the conversion of Preferred Stock as herein provided, such number of shares of Common Stock as shall then be issuable upon the conversion of all
outstanding shares of Preferred Stock. The Corporation covenants that all shares of Common Stock which shall be so issued shall be duly and validly issued and fully paid and nonassessable and free from all taxes, liens and charges with respect to
the issue thereof, and, without limiting the generality of the foregoing, the Corporation covenants that it will from time to time take all such action as may be requisite to assure that the par value per share of the Common Stock is at all times
equal to or less than any Preferred Stock Conversion Price in effect at the time. The Corporation will take all such action as may be necessary to assure that all such shares of Common Stock may be so issued without violation of any applicable law
or regulation, or of any requirement of any national securities exchange upon which the Common Stock may be listed. The Corporation will not take any action which results in any adjustment of any Preferred Stock Conversion Price if the total number
of shares of Common Stock issued and issuable after such action upon conversion of the Preferred Stock would exceed the total number of shares of Common Stock then authorized by the Certificate of Incorporation of the Corporation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.12 <U>No Reissuance of Preferred Stock</U>. Shares of Preferred Stock which are converted into shares of Common Stock as provided
herein shall not be reissued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.13 <U>Issue Tax</U>. The issuance of certificates for shares of Common Stock upon conversion
of Preferred Stock shall be made without charge to the holders thereof for any issuance tax in respect thereof, <U>provided</U> <U>that</U> the Corporation shall not be required to pay any tax which may be payable in respect of any transfer involved
in the issuance and delivery of any certificate in a name other than that of the holder of the Preferred Stock which is being converted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.14 <U>Closing of Books</U>. The Corporation will at no time close its transfer books against the transfer of any Preferred Stock or of any shares of Common Stock issued or issuable upon the conversion
of any shares of Preferred Stock in any manner which interferes with the timely conversion of such Preferred Stock, except as may otherwise be required to comply with applicable securities laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 20 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.15 <U>Mandatory Conversion</U>. All outstanding shares of Preferred Stock shall
automatically convert to shares of Common Stock on the basis set forth in this Section&nbsp;6 upon the earlier of (i)&nbsp;the closing of a firm commitment underwritten public offering of shares of Common Stock of the Corporation in which
(A)&nbsp;the aggregate gross proceeds to the Corporation (prior to deduction of underwriting discounts and commissions and expenses related to the offering) shall be at least forty million dollars ($40,000,000) and (B)&nbsp;the price paid by the
public for such shares shall be at least $1.9563 per share (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification, or other similar event affecting such
shares) or (ii)&nbsp;the written consent of holders of at least a Two-Thirds Interest of the then-outstanding shares of Preferred Stock (voting together as a single class on an as-if-converted basis). Each outstanding share of Preferred Stock shall
convert into such number of shares of Common Stock as is obtained by multiplying the number of shares of Preferred Stock to be converted by the Preferred Stock Conversion Rate then in effect for the applicable series of Preferred Stock. Holders of
shares of Preferred Stock so converted may deliver to the Corporation at its principal office (or such other office or agency of the Corporation as the Corporation may designate by notice in writing to such holders) during its usual business hours,
the certificate or certificates for the shares so converted. As promptly as practicable thereafter, the Corporation shall issue and deliver to such holder a certificate or certificates for the number of whole shares of Common Stock to which such
holder is entitled, together with any cash payment in lieu of fractional shares to which such holder may be entitled pursuant to Section&nbsp;6.4. Until such time as a holder of shares of Preferred Stock shall surrender his or its certificates
therefor as provided above, such certificates shall be deemed to represent the shares of Common Stock to which such holder shall be entitled upon the surrender thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7. <U>Drag-Alone Obligation</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>General Requirements</U>. In the event
that any holder or holders of capital stock of the Corporation representing at least a Two-Thirds Interest of the then-outstanding shares of Common Stock and Preferred Stock without duplication, calculated on an as-if-converted basis (collectively,
the &#147;<U>Drag-Along Holders</U>&#148;), desire, at any time, to sell, transfer, assign or otherwise dispose of all of their Common Stock and Preferred Stock in a single transaction or a series of related transactions to one or more third-parties
(a &#147;<U>Drag-Along Sale</U>&#148;), where such Drag-Along Sale is conditioned upon the sale of all remaining shares of Common Stock and Preferred Stock to such third parties, the remaining holders of capital stock of the Corporation shall
dispose of their shares of capital stock of the Corporation, including any Convertible Securities and Options (collectively, the &#147;<U>Drag-Along Securities</U>&#148;), on the same terms and conditions that the Drag-Along Holders are selling
their shares of Common Stock and Preferred Stock and on equitable terms and conditions with respect to any Convertible Securities and Options being sold, but in any event subject to the rights, privileges, restrictions and conditions, including all
liquidation preferences attaching to the capital stock of the Corporation, as set forth herein. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 21 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Notice</U>. At least 15 days before the date of consummation of the Drag-Along Sale,
the Drag-Along Holders shall deliver a notice (the &#147;<U>Drag-Along Notice</U>&#148;) to the Corporation which shall as soon as reasonably possible thereafter send a copy of such Drag-Along Notice to the other stockholders at their respective
addresses on file with the Corporation. The Drag-Along Notice shall state (i)&nbsp;that the Drag-Along Holders have the bona fide intention to sell or transfer the shares of capital stock of the Corporation in the Drag-Along Sale, (ii)&nbsp;the
price for which the Drag-Along Securities will be sold, (iii)&nbsp;the name of the proposed purchaser(s) or transferee(s), and (iv)&nbsp;all other material terms and provisions relating to the Drag-Along Sale. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>Deposit of Consideration and Effect</U>. On or before the date of the consummation of the Drag-Along Sale, the Drag-Along Holders
or the purchaser(s) shall deposit the full amount of the consideration to be paid for the Drag-Along Securities with a bank, transfer agent, law firm or other entity selected by the Corporation (the &#147;<U>Payment Agent</U>&#148;). Cash, if any,
and other consideration, if any, deposited with the Payment Agent shall be delivered in trust for the benefit of the holders of the Drag-Along Securities. Immediately upon the deposit of the full amount of the consideration then, notwithstanding
that any certificate or other document representing the Drag-Along Securities shall not have been surrendered, all Drag-Along Securities shall no longer be deemed to be outstanding on and after the consummation of the Drag-Along Sale by the
Drag-Along Holders, and all rights with respect to such securities shall forthwith cease and terminate at the close of business on such date, except only the right of the holders of Drag-Along Securities to receive the consideration to be paid for
the Drag-Along Securities required under this Section&nbsp;7, without any interest accruing thereon. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4 <U>Delivery of
Certificates and Documents to Payment Agent</U>. The holders of capital stock of the Corporation and Convertible Securities and Options who are required to sell their securities pursuant to this Section&nbsp;7 must deliver, on or before the date of
the consummation of the Drag-Along Sale set forth in the Drag-Along Notice, one or more certificates and other documents, as applicable, properly endorsed for transfer (which represent the number of shares of capital stock of the Corporation,
Convertible Securities and Options that such holders are required to sell pursuant to this Section&nbsp;7) to the Payment Agent, which shall serve as custodian of the certificates and documents until delivered to the proposed purchaser(s) upon
consummation of the Drag-Along Sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5 <U>Delivery of Certificates and Documents to Purchaser and Consideration to
Drag-Along Holders</U>. The certificates and other documents delivered to the Payment Agent by the holders of Drag-Along Securities pursuant to this Section&nbsp;7 shall be transferred by the Payment Agent to the proposed purchaser(s) in
consummation of the Drag-Along Sale, and the Payment Agent shall remit to the holders of Drag-Along Securities that portion of the sale proceeds to which such holders are entitled by reason of the participation in such Drug-Along Sale. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FIFTH</B>. The Corporation is to have perpetual existence. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SIXTH</B>. In furtherance and not in limitation of the powers conferred by the laws of the State of Delaware: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A. The Board of Directors of the Corporation is expressly authorized to adopt, amend or repeal the By-Laws of the Corporation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 22 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. Elections of directors need not be by written ballot unless the By-Laws of the
Corporation shall so provide. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. The books of the Corporation may be kept at such place within or without the State of
Delaware as the By-Laws of the Corporation may provide or as may be designated from time to time by the Board of Directors of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SEVENTH</B>. The Corporation eliminates the personal liability of each member of its Board of Directors to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a
director, <U>provided</U>, <U>however</U>, that, to the extent provided by applicable law, the foregoing shall not eliminate the liability of a director (i)&nbsp;for any breach of such director&#146;s duty of loyalty to the Corporation or its
stockholders, (ii)&nbsp;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&nbsp;under Section&nbsp;174 of Title 8 of the Delaware Code or (iv)&nbsp;for any transaction from which such
director derived an improper personal benefit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the General Corporation Law of the State of Delaware is amended in the
future to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation
Law of the State of Delaware, as so amended from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any repeal or modification of this Article SEVENTH shall not
increase the personal liability of any director of this Corporation for any act or occurrence taking place prior to such repeal or modification, or otherwise adversely affect any right or protection of a director of the Corporation existing at the
time of such repeal or modification. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EIGHTH</B>. Whenever a compromise or arrangement is proposed between this Corporation
and its creditors or any class of them and/or between this Corporation and its stockholders or any class of them, any court of equitable jurisdiction within the State of Delaware may, on the application in a summary way of this Corporation or of any
creditor or stockholder thereof or on the application of any receiver or receivers appointed for this Corporation under the provisions of Section&nbsp;291 of Title 8 of the Delaware Code or on the application of trustees in dissolution or of any
receiver or receivers appointed for this Corporation under the provisions of Section&nbsp;279 of Title 8 of the Delaware Code, order a meeting of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this
Corporation, as the case may be, to be summoned in such manner as the said court directs. If a majority in number representing three-fourths in value of the creditors or class of creditors, and/or of the stockholders or class of stockholders of this
Corporation, as the case may be, agree to any compromise or arrangement and to any reorganization of this Corporation as consequence of such compromise or arrangement, the said compromise or arrangement and the said reorganization shall, if
sanctioned by the court to which the said application has been made, be binding on all other creditors or class of creditors, and/or on all the stockholders or class of stockholders, of this Corporation, as the case may be, and also on this
Corporation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 23 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NINTH</B>. The Corporation reserves the right, subject to Article FOURTH, B.5., to amend
or repeal any provision contained in this Amended and Restated Certificate of Incorporation, in the manner now or hereafter prescribed by statute, and all rights conferred upon a stockholder herein are granted subject to this reservation.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 24 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the undersigned authorized officer of the
Corporation has hereunto signed his name and affirms that the statements made in this Amended and Restated Certificate of Incorporation are true and under the penalties of perjury as of this
19</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of September, 2008. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., PhD</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President&nbsp;&amp; Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I><U>Delaware</U></I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>PAGE 1</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The First State</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>I, JEFFREY W. BULLOCK, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS
A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF &#147;MACROGENICS, INC.&#148;, FILED IN THIS OFFICE ON THE FOURTEENTH DAY OF JANUARY, A.D. 2011, AT 4:30 O&#146;CLOCK P.M. </I></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS. </I></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ROWSPAN="5">


<IMG SRC="g575431ex3_1pg26a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center">


<IMG SRC="g575431ex3_1pg26b.jpg" ALT="LOGO">
</P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jeffrey W. Bullock, Secretary of State</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3274005 8100</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>AUTHENTICATION:&nbsp;8498564</I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;110047333</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>DATE: 01-18-11</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>You&nbsp;may&nbsp;verify&nbsp;this&nbsp;certificate&nbsp;online</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>at corp.delaware.gov/authver.shtml</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>State of Delaware</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Secretary of State</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Division of Corporations</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Delivered 05:37 PM 01/14/2011</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>FILED 04:30 PM 01/14/2011</I></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>SRV 110047333 &#150; 3274005 FILE</I></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTIFICATE OF AMENDMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED AND RESTATED CERTIFICATE OF INCORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. (the &#147;<U>Corporation</U>&#148;), a corporation organized and existing under the General Corporation Law of the State of Delaware, does hereby certify: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">FIRST: The Corporation filed an Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on
September&nbsp;19, 2008 (the &#147;<U>Amended and Restated Certificate of Incorporation</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">SECOND: That the Board of
Directors of the Corporation has duly adopted resolutions: (i) authorizing the Corporation to execute and file with the Secretary of State of the State of Delaware this Certificate of Amendment of Amended and Restated Certificate of Incorporation
(this &#147;<U>Certificate of Amendment</U>&#148;); and (ii)&nbsp;declaring each of the amendments to the Amended and Restated Certificate of Incorporation set forth below in this Certificate of Amendment to be advisable and recommended for approval
by the stockholders of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIRD: That this Certificate of Amendment was duly adopted by the Board of Directors
in accordance with the provisions of Section&nbsp;242 of the General Corporation Law of the State of Delaware, and by written consent of the stockholders of the Corporation in accordance with Section&nbsp;228 of the General Corporation Law of the
State of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">FOURTH: The first paragraph of Article FOURTH of the Amended and Restated Certificate of Incorporation is
hereby amended and restated such that, as amended, said paragraph below shall read as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;The authorized capital
stock of the Corporation shall consist of Seven Hundred Forty Six Million, Five Hundred Ninety Two Thousand, Eight Hundred Twenty Eight (746,592,828)&nbsp;shares, consisting of two classes: (i)&nbsp;Four Hundred Twenty Five Million
(425,000,000)&nbsp;shares of Common Stock, $0.01 par value per share (the &#147;<U>Common Stock</U>&#148;), and (ii)&nbsp;Three Hundred Twenty One Million, Five Hundred Ninety Two Thousand, Eight Hundred Twenty Eight (321,592,828)&nbsp;shares of
Preferred Stock, $0.01 par value per share (the &#147;<U>Preferred Stock</U>&#148;), issuable in one or more series as hereinafter provided.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">FIFTH: That Article FOURTH, Section B.1.4, is hereby amended and restated such that, as amended, such section shall read as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;1.4 <U>Series D and Series D-2 Preferred Stock</U>. Thirty million (30,000,000)&nbsp;shares of the authorized Preferred Stock of
the Corporation are hereby designated &#147;Series D Convertible Preferred Stock&#148; (the &#147;<U>Series D Preferred Stock</U>&#148;), and seventy five million (75,000,000)&nbsp;shares of the authorized Preferred Stock of the Corporation are
hereby designated &#147;Series D-2 Convertible Preferred Stock&#148; (the &#147;<U>Series D-2 Preferred Stock</U>&#148;).&#148; </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIXTH: The first sentence of Article FOURTH, Section B.5 is hereby amended such that the
number &#147;30,400,000&#148; is hereby deleted and replaced with the number &#147;32,100,000.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEVENTH: This
Certificate of Amendment shall become effective immediately upon filing with the Secretary of State of the State of Delaware. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[<I>Remainder of Page Intentionally Left Blank</I>] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the Corporation has caused this Certificate of
Amendment to be executed on its behalf by its President this 14</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> day of January, 2011. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., PhD</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President&nbsp;&amp; Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 3.3 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AMENDED AND RESTATED </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BY-LAWS OF </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A DELAWARE CORPORATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dated: December&nbsp;13, 2000 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE I MEETINGS OF STOCKHOLDERS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. P<SMALL>LACE</SMALL> <SMALL>OF</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;3. S<SMALL>PECIAL</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;4. N<SMALL>OTICE</SMALL> <SMALL>OF</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;5. V<SMALL>OTING</SMALL> L<SMALL>IST</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL> 6. Q<SMALL>UORUM</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;7. A<SMALL>DJOURNMENTS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;8. A<SMALL>CTION</SMALL> <SMALL>AT</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;9. V<SMALL>OTING</SMALL> <SMALL>AND</SMALL> P<SMALL>ROXIES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;10. A<SMALL>CTION</SMALL> W<SMALL>ITHOUT</SMALL> M<SMALL>EETING</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE II DIRECTORS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. N<SMALL>UMBER</SMALL>, E<SMALL>LECTION</SMALL>, T<SMALL>ENURE</SMALL> <SMALL>AND</SMALL>
Q<SMALL>UALIFICATION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. E<SMALL>NLARGEMENT</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;3. V<SMALL>ACANCIES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;4. R<SMALL>ESIGNATION</SMALL> <SMALL>AND</SMALL> R<SMALL>EMOVAL</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;5. G<SMALL>ENERAL</SMALL> P<SMALL>OWERS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;6. C<SMALL>HAIRMAN</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;7. P<SMALL>LACE</SMALL> <SMALL>OF</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;8. R<SMALL>EGULAR</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;9. S<SMALL>PECIAL</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;10. Q<SMALL>UORUM</SMALL>, A<SMALL>CTION</SMALL> <SMALL>AT</SMALL> M<SMALL>EETING</SMALL>,
A<SMALL>DJOURNMENTS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;11. A<SMALL>CTION</SMALL> <SMALL>BY</SMALL> C<SMALL>ONSENT</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;12. T<SMALL>ELEPHONIC</SMALL> M<SMALL>EETINGS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;13. C<SMALL>OMMITTEES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;14. C<SMALL>OMPENSATION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE III OFFICERS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. E<SMALL>NUMERATION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. E<SMALL>LECTION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;3. T<SMALL>ENURE</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;4. P<SMALL>RESIDENT</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;5. V<SMALL>ICE</SMALL>-P<SMALL>RESIDENTS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;6. S<SMALL>ECRETARY<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex"></SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></SMALL><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;7. A<SMALL>SSISTANT</SMALL> S<SMALL>ECRETARIES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;8. T<SMALL>REASURER</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;9. A<SMALL>SSISTANT</SMALL> T<SMALL>REASURERS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;10. B<SMALL>OND</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IV NOTICES</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. D<SMALL>ELIVERY</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. W<SMALL>AIVER</SMALL> <SMALL>OF</SMALL> N<SMALL>OTICE</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE V INDEMNIFICATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. A<SMALL>CTIONS</SMALL> <SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> <SMALL>BY</SMALL>
<SMALL>OR</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL> R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>ORPORATION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. A<SMALL>CTIONS</SMALL> <SMALL>BY</SMALL> <SMALL>OR</SMALL> <SMALL>IN</SMALL> <SMALL>THE</SMALL>
R<SMALL>IGHT</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>ORPORATION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;3. S<SMALL>UCCESS</SMALL> <SMALL>ON</SMALL> <SMALL>THE</SMALL> M<SMALL>ERITS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;4. S<SMALL>PECIFIC</SMALL> A<SMALL>UTHORIZATION</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;5. A<SMALL>DVANCE</SMALL> P<SMALL>AYMENT</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;6. N<SMALL>ON</SMALL>-E<SMALL>XCLUSIVITY</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;7. I<SMALL>NSURANCE</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL> 8. C<SMALL>ONTINUATION</SMALL> <SMALL>OF</SMALL> I<SMALL>NDEMNIFICATION</SMALL> <SMALL>AND</SMALL>
A<SMALL>DVANCEMENT</SMALL> <SMALL>OF</SMALL> E<SMALL>XPENSES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;9. S<SMALL>EVERABILITY</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;10. I<SMALL>NTENT</SMALL> <SMALL>OF</SMALL> A<SMALL>RTICLE</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VI CAPITAL STOCK</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. C<SMALL>ERTIFICATES</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. L<SMALL>OST</SMALL> C<SMALL>ERTIFICATES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;3. T<SMALL>RANSFER</SMALL> <SMALL>OF</SMALL> S<SMALL>TOCK</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;4. R<SMALL>ECORD</SMALL> D<SMALL>ATE</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;5. R<SMALL>EGISTERED</SMALL> S<SMALL>TOCKHOLDERS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VII CERTAIN TRANSACTIONS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. T<SMALL>RANSACTIONS</SMALL> <SMALL>WITH</SMALL> I<SMALL>NTERESTED</SMALL>
P<SMALL>ARTIES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. Q<SMALL>UORUM</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VIII GENERAL PROVISIONS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;1. D<SMALL>IVIDENDS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;2. R<SMALL>ESERVES</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;3. C<SMALL>HECKS</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;4. F<SMALL>ISCAL</SMALL> Y<SMALL>EAR</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">S<SMALL>ECTION</SMALL>&nbsp;5. S<SMALL>EAL</SMALL></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IX AMENDMENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Addendum </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Register of Amendments to the By-Laws </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">* * * * * </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">BY-LAWS </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">OF </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACROGENICS, INC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">* * * * * </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE I </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">MEETINGS OF STOCKHOLDERS </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Place of Meetings</U>. All meetings of the stockholders may be held at such place within or without the State of Delaware as may be fixed from time to time by the Board of Directors or
the Chief Executive Officer, or if not so designated, at the registered office of the Corporation. Notwithstanding the foregoing, the Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may
instead be held solely by means of remote communication as authorized by Section&nbsp;211(a)(2) of the General Corporation Law of Delaware. If so authorized, and subject to such guidelines and procedures as the Board of Directors may adopt,
stockholders and proxyholders not physically present at a meeting of stockholders may, by means of remote communication, participate in a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote
communication, provided that (i)&nbsp;the Corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder, (ii)&nbsp;the
Corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to read or hear the
proceedings of the meeting substantially concurrently with such proceedings, and (iii)&nbsp;if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be
maintained by the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. <U>Annual Meeting</U>. Unless directors are elected by written consent in lieu
of an annual meeting as permitted by law and these By-Laws, an annual meeting of stockholders may be held at such date and time, and by such means of remote communication, if any, as shall be designated from time to time by the Board of Directors or
the Chief Executive Officer, at which meeting the stockholders shall elect by a plurality vote a board of directors and shall transact such other business as may be properly brought before the meeting. If no annual meeting is held in accordance with
the foregoing provisions, the Board of Directors shall cause the meeting to be held as soon thereafter as convenient, which meeting shall be designated a special meeting in lieu of annual meeting. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. <U>Special Meetings</U>. Special meetings of the stockholders, for any
purpose or purposes, may, unless otherwise prescribed by statute or by the certificate of incorporation, be called by the Board of Directors or the Chief Executive Officer and shall be called by the Chief Executive Officer or Secretary at the
request in writing of a majority of the Board of Directors, or at the request in writing of stockholders owning a majority in amount of the entire capital stock of the Corporation issued and outstanding and entitled to vote. Such request shall state
the purpose or purposes of the proposed meeting. Business transacted at any special meeting shall be limited to matters relating to the purpose or purposes stated in the notice of meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4. <U>Notice of Meetings</U>. Except as otherwise provided by law, written notice of each meeting of stockholders, annual or
special, stating the place, date and hour of the meeting, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting and, in the case of a special meeting, the
purpose or purposes for which the meeting is called, shall be given not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting, to each stockholder entitled to vote at such meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. <U>Voting List</U>. The officer who has charge of the stock ledger of the Corporation shall prepare and make, at least
ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name
of each stockholder. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10)&nbsp;days prior to the meeting, either (i)&nbsp;on a
reasonably accessible electronic network, provided that the information required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;at the Corporation&#146;s principal place of business. In the event that the
Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be held at a place, then
the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall
also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6. <U>Quorum</U>. The holders of a majority of the stock issued and outstanding and entitled to vote thereat, present in
person or by remote communication, or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business, except as otherwise provided by statute, the certificate of incorporation or these By- Laws.
Where a separate vote by a class or classes is required, one-third of the outstanding shares of such class or classes, present in person or by remote communication, or represented by proxy, shall constitute a quorum entitled to take action with
respect to that vote on that matter. If no quorum shall be present or represented at any meeting of stockholders, such meeting may be adjourned in accordance with Section&nbsp;7 hereof, until a quorum shall be present or represented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7. <U>Adjournments</U>. Any meeting of stockholders may be adjourned from time
to time to any other time and to any other place at which a meeting of stockholders may be held under these By-Laws, which time and place shall be announced at the meeting, by a majority of the stockholders present in person or by remote
communication, or represented by proxy at the meeting and entitled to vote (whether or not a quorum is present), or, if no stockholder is present or represented by proxy, by any officer entitled to preside at or to act as Secretary of such meeting,
without notice other than announcement at the meeting. At such adjourned meeting, any business may be transacted which might have been transacted at the original meeting, provided that a quorum either was present at the original meeting or is
present at the adjourned meeting. If the adjournment is for more than thirty days, or if after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall be given to each stockholder of record
entitled to vote at the meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8. <U>Action at Meetings</U>. When a quorum is present at any meeting, the
affirmative vote of the holders of a majority of the stock present in person or by remote communication, or represented by proxy, entitled to vote and voting on the matter (or where a separate vote by a class or classes is required, the affirmative
vote of the majority of shares of such class or classes present in person or represented by proxy at the meeting) shall decide any matter (other than the election of Directors) brought before such meeting, unless the matter is one upon which by
express provision of law, the certificate of incorporation or these By-Laws, a different vote is required, in which case such express provision shall govern and control the decision of such matter. The stock of holders who abstain from voting on any
matter shall be deemed not to have been voted on such matter. Directors shall be elected by a plurality of the votes of the shares present in person or by remote communication, or represented by proxy at the meeting, entitled to vote and voting on
the election of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9. <U>Voting and Proxies</U>. Unless otherwise provided in the certificate of
incorporation, each stockholder shall at every meeting of the stockholders be entitled to one vote for each share of capital stock having voting power held of record by such stockholder. Each stockholder entitled to vote at a meeting of
stockholders, or to express consent or dissent to corporate action in writing without a meeting, may authorize another person or persons to act for him by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless
the proxy provides for a longer period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10. <U>Action Without Meeting</U>. Any action required to be taken at
any annual or special meeting of stockholders, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing,
setting forth the action so taken, shall be signed and dated by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to
vote thereon were present and voted. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing. A telegram, cablegram or other
electronic transmission consenting to an action to be taken and transmitted by a stockholder or proxyholder, or by a person or persons authorized to act for a stockholder or proxyholder, shall be deemed to be written, signed and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
dated for the purposes herein, provided that any such telegram, cablegram or other electronic transmission sets forth or is delivered with information from which the Corporation can determine
(A)&nbsp;that the telegram, cablegram or other electronic transmission was transmitted by the stockholder or proxyholder or by a person or persons authorized to act for the stockholder or proxyholder and (B)&nbsp;the date on which such stockholder
or proxyholder or authorized person or persons transmitted such telegram, cablegram or other electronic transmission. The date on which such telegram, cablegram or electronic transmission is transmitted shall be deemed to be the date on which such
consent was signed. No consent given by telegram, cablegram or electronic transmission shall be deemed to have been delivered until such consent is reproduced in paper form and until such paper form shall be delivered in accordance with
Section&nbsp;228 of the General Corporation Law of Delaware, to the Corporation by delivery to its registered office in Delaware, its principal place of business or an officer or agent of the corporation having custody of the book in which
proceedings of meetings of stockholders are recorded. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all such purposes for which the original writing
could be used, provided that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARTICLE II </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">DIRECTORS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Number, Election, Tenure and Qualification</U>. The number of Directors which shall constitute the whole board shall
be not less than one. Within such limit, the number of Directors shall be determined by resolution of the Board of Directors or by the stockholders at the annual meeting or at any special meeting of stockholders. The directors shall be elected at
the annual meeting or at any special meeting of stockholders, or by written consent in lieu of an annual or special meeting of the stockholders (provided, however, that if such consent is less than unanimous, such action by written consent may be in
lieu of holding an annual meeting only if all of the directorships to which directors could be elected at an annual meeting held at the effective time of such action are vacant and are filled by such action), except as provided in section 3 of this
Article, and each director elected shall hold office until his successor is elected and qualified, unless sooner displaced. Directors need not be stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. <U>Enlargement</U>. The number of the Board of Directors may be increased at any time by vote of a majority of the Directors then in office. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. <U>Vacancies</U>. Vacancies and newly created Directorships resulting from any increase in the authorized number of
Directors may be filled by a majority of the Directors then in office, though less than a quorum, or by a sole remaining director, and the Directors so chosen shall hold office until the next annual election and until their successors are duly
elected and shall qualify, unless sooner displaced. If there are no Directors in office, then an election of Directors may be held in the manner provided by statute. In the event of a vacancy in the Board of Directors, the remaining Directors,
except as otherwise provided by law or these By-Laws, may exercise the powers of the full board until the vacancy is filled. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4. <U>Resignation and Removal</U>. Any director may resign at any time upon
notice given in writing or by electronic transmission to the Corporation at its principal place of business or to the Chief Executive Officer or Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at
some other time or upon the happening of some other event. Any director or the entire Board of Directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of Directors, unless
otherwise specified by law or the certificate of incorporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. <U>General Powers</U>. The business and
affairs of the Corporation shall be managed by its Board of Directors, which may exercise all powers of the Corporation and do all such lawful acts and things as are not by statute or by the certificate of incorporation or by these By-Laws directed
or required to be exercised or done by the stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6. <U>Chairman of the Board</U>. If the Board of
Directors appoints a chairman of the board, he shall, when present, preside at all meetings of the stockholders and the Board of Directors. He shall perform such duties and possess such powers as are customarily vested in the office of the chairman
of the board or as may be vested in him by the Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7. <U>Place of Meetings</U>. The Board of
Directors may hold meetings, both regular and special, either within or without the State of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8.
<U>Regular Meetings</U>. Regular meetings of the Board of Directors may be held without notice at such time and at such place as shall from time to time be determined by the board; provided that any director who is absent when such a determination
is made shall be given prompt notice of such determination. A regular meeting of the Board of Directors may be held without notice immediately after and at the same place as the annual meeting of stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9. <U>Special Meetings</U>. Special meetings of the board may be called by the Chief Executive Officer, Secretary, or on the
written request of two (2)&nbsp;or more Directors, or by one director in the event that there is only one director in office. Two (2)&nbsp;days&#146; notice to each director, either personally or by telegram, cable, telecopy, electronic mail,
commercial delivery service, telex or similar means sent to his business or home address, or three (3)&nbsp;days&#146; notice by written notice deposited in the mail, shall be given to each director by the Secretary or by the officer or one of the
Directors calling the meeting. A notice or waiver of notice of a meeting of the Board of Directors need not specify the purposes of the meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10. <U>Quorum, Action at Meeting, Adjournments</U>. At all meetings of the board a majority of Directors then in office, but in no event less than one third of the entire board, shall
constitute a quorum for the transaction of business and the act of a majority of the Directors present at any meeting at which there is a quorum shall be the act of the Board of Directors, except as may be otherwise specifically provided by law or
by the certificate of incorporation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
For purposes of this section, the term &#147;entire board&#148; shall mean the number of Directors last fixed by the stockholders or Directors, as the case may be, in accordance with law and
these By-Laws; provided, however, that if less than all the number so fixed of Directors were elected, the &#147;entire board&#148; shall mean the greatest number of Directors so elected to hold office at any one time pursuant to such authorization.
If a quorum shall not be present at any meeting of the Board of Directors, a majority of the Directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting, until a quorum shall be present.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;11. <U>Action by Consent</U>. Unless otherwise restricted by the certificate of incorporation or these By-Laws,
any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all members of the board or committee, as the case may be, consent thereto in writing or electronic
transmission, and the writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the board or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in
electronic form if the minutes are maintained in electronic form. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;12. <U>Telephonic Meetings</U>. Unless
otherwise restricted by the certificate of incorporation or these By-Laws, members of the Board of Directors or of any committee thereof may participate in a meeting of the Board of Directors or of any committee, as the case may be, by means of
conference telephone or similar communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a meeting shall constitute presence in person at the meeting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;13. <U>Committees</U>. The Board of Directors may designate one or more committees, each committee to consist of one or more
of the Directors of the Corporation. The board may designate one or more Directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. Any such committee, to the extent provided
in the resolution of the Board of Directors, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be
affixed to all papers which may require it; but no such committee shall have the power or authority in reference to (a)&nbsp;adopting, amending or repealing the By-Laws of the Corporation or any of them or (b)&nbsp;approving or adopting, or
recommending to the stockholders any action or matter expressly required by law to be submitted to stockholders for approval. Such committee or committees shall have such name or names as may be determined from time to time by resolution adopted by
the Board of Directors. Each committee shall keep regular minutes of its meetings and make such reports to the Board of Directors as the Board of Directors may request. Except as the Board of Directors may otherwise determine, any committee may make
rules for the conduct of its business, but unless otherwise provided by the Directors or in such rules, its business shall be conducted as nearly as possible in the same manner as is provided in these By-Laws for the conduct of its business by the
Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;14. <U>Compensation</U>. Unless otherwise restricted by the certificate of incorporation or
these By-Laws, the Board of Directors shall have the authority to fix from time </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to time the compensation of Directors. The Directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and the performance of their responsibilities as
Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors and/or a stated salary as director. No such payment shall preclude any director from serving the Corporation or its parent or subsidiary Corporations in
any other capacity and receiving compensation therefor. The Board of Directors may also allow compensation for members of special or standing committees for service on such committees. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE III </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">OFFICERS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Enumeration</U>. The officers of the Corporation shall be chosen by the Board of Directors and shall be a President, a
Secretary and a Treasurer and such other officers with such titles, terms of office and duties as the Board of Directors may from time to time determine, including a Chairman of the Board, one or more Vice-Presidents, and one or more Assistant
Secretaries and Assistant Treasurers. If authorized by resolution of the Board of Directors, the Chief Executive Officer may be empowered to appoint from time to time Assistant Secretaries and Assistant Treasurers. Any number of offices may be held
by the same person, unless the Certificate of Incorporation or these By-Laws otherwise provide. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.
<U>Election</U>. The Board of Directors at its first meeting after each annual meeting of stockholders shall choose a President, a Secretary and a Treasurer. Other officers may be appointed by the Board of Directors at such meeting, at any other
meeting, or by written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. <U>Tenure</U>. The officers of the Corporation shall hold office until their
successors are chosen and qualify, unless a different term is specified in the vote choosing or appointing him, or until his earlier death, resignation or removal. Any officer elected or appointed by the Board of Directors or by the Chief Executive
Officer may be removed at any time, with or without cause, by the affirmative vote of a majority of the Board of Directors or a committee duly authorized to do so, except that any officer appointed by the Chief Executive Officer may also be removed
at any time, with or without cause, by the Chief Executive Officer. Any vacancy occurring in any office of the Corporation may be filled by the Board of Directors, at its discretion. Any officer may resign by delivering his written resignation to
the Corporation at its principal place of business or to the Chief Executive Officer or the Secretary. Such resignation shall be effective upon receipt unless it is specified to be effective at some other time or upon the happening of some other
event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 4. <U>President</U>. The President shall be the Chief Operating Officer of the Corporation, He shall also be
the Chief Executive Officer unless the Board of Directors otherwise provides. If no Chief Executive Officer shall have been appointed by the Board of Directors, all references herein to the &#147;Chief Executive Officer&#148; shall be to the
President. The President shall, unless the Board of Directors provides otherwise in a specific instance or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
generally, preside at all meetings of the stockholders and the Board of Directors, have genera] and active management of the business of the Corporation and see that all orders and resolutions of
the Board of Directors are carried into effect. The President shall execute bonds, mortgages, and other contracts requiring a seal, under the seal of the Corporation, except where required or permitted by law to be otherwise signed and executed and
except where the signing and execution thereof shall be expressly delegated by the Board of Directors to some other officer or agent of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. <U>Vice-Presidents</U>. In the absence of the President or in the event of his or her inability or refusal to act, the Vice-President, or if there be more than one Vice-President, the
Vice-Presidents in the order designated by the Board of Directors or the Chief Executive Officer (or in the absence of any designation, then in the order determined by their tenure in office) shall perform the duties of the President, and when so
acting, shall have all the powers of and be subject to all the restrictions upon the President. The Vice-Presidents shall perform such other duties and have such other powers as the Board of Directors or the Chief Executive Officer may from time to
time prescribe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6. <U>Secretary</U>. The Secretary shall have such powers and perform such duties as are
incident to the office of Secretary. The Secretary shall maintain a stock ledger and prepare lists of stockholders and their addresses as required and shall be the custodian of corporate records. The Secretary shall attend all meetings of the Board
of Directors and all meetings of the stockholders and record all the proceedings of the meetings of the Corporation and of the Board of Directors in a book to be kept for that purpose and shall perform like duties for the standing committees when
required. The Secretary shall give, or cause to be given, notice of all meetings of the Stockholders and special meetings of the Board of Directors, and shall perform such other duties as may be from time to time prescribed by the Board of Directors
or Chief Executive Officer, under whose supervision the Secretary shall be. The Secretary shall have custody of the corporate seal of the Corporation and the Secretary, or an assistant Secretary, shall have authority to affix the same to any
instrument requiring it and when so affixed, it may be attested by his or her signature or by the signature of such assistant Secretary. The Board of Directors may give general authority to any other officer to affix the seal of the Corporation and
to attest the affixing by his or her signature. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7. <U>Assistant Secretaries</U>. The assistant Secretary, or if
there be more than one, the assistant secretaries in the order determined by the Board of Directors, the Chief Executive Officer or the Secretary (or if there be no such determination, then in the order determined by their tenure in office), shall,
in the absence of the Secretary or in the event of his or her inability or refusal to act, perform the duties and exercise the powers of the Secretary and shall perform such other duties and have such other powers as the Board of Directors, the
Chief Executive Officer or the Secretary may from time to time prescribe. In the absence of the Secretary or any assistant Secretary at any meeting of stockholders or Directors, the person presiding at the meeting shall designate a temporary or
acting Secretary to keep a record of the meeting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8. <U>Treasurer</U>. The Treasurer shall perform such duties and shall have
such powers as may be assigned to him or her by the Board of Directors or the Chief Executive Officer. In addition, the Treasurer shall perform such duties and have such powers as are incident to the office of Treasurer. The Treasurer shall have the
custody of the corporate funds and securities and shall keep full and accurate accounts of receipts and disbursements in books belonging to the Corporation and shall deposit all moneys and other valuable effects in the name and to the credit of the
Corporation in such depositories as may be designated by the Board of Directors. He shall disburse the funds of the Corporation as may be ordered by the Board of Directors, taking proper vouchers for such disbursements, and shall render to the Chief
Executive Officer and the Board of Directors, when the Chief Executive Officer or Board of Directors so requires, an account of all his or her transactions as Treasurer and of the financial condition of the Corporation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9. <U>Assistant Treasurers</U>. The assistant Treasurer, or if there shall be more than one, the assistant Treasurers in the
order determined by the Board of Directors, the Chief Executive Officer or the Treasurer (or if there be no such determination, then in the order determined by their tenure in office), shall, in the absence of the Treasurer or in the event of his or
her inability or refusal to act, perform the duties and exercise the powers of the Treasurer and shall perform such other duties and have such other powers as the Board of Directors, the Chief Executive Officer or the Treasurer may from time to time
prescribe. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10. <U>Bond</U>. If required by the Board of Directors, any officer shall give the Corporation a bond
in such sum and with such surety or sureties and upon such terms and conditions as shall be satisfactory to the Board of Directors, including without limitation a bond for the faithful performance of the duties of his office and for the restoration
to the Corporation of all books, papers, vouchers, money and other property of whatever kind in his possession or under his control and belonging to the Corporation. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARTICLE IV </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOTICES </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Delivery</U>. Whenever, under the provisions of law, or of the Certificate of Incorporation or these By-Laws, notice
is required to be given to any person, such notice may be given by mail, addressed to such person, at his address as it appears on the records of the Corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time
when the same shall be deposited in the United States mail. Unless written notice by mail is required by law, notice may also be given by telegram, cable, telecopy, commercial delivery service, telex or similar means, addressed to such person at his
address as it appears on the records of the Corporation, in which case such notice shall be deemed to be given when delivered into the control of the persons charged with effecting such transmission, the transmission charge to be paid by the
Corporation or the person sending such notice and not by the addressee. Notice may also be given to stockholders by a form of electronic transmission in accordance with and subject to the provisions of Section&nbsp;232 of the General Corporation Law
of Delaware. Oral notice or other in-hand delivery (in person or by telephone) shall be deemed given at the time it is actually given. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 9 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. <U>Waiver of Notice</U>. Whenever any notice is required to be given under
the provisions of law or of the certificate of incorporation or of these By-Laws, a waiver thereof in writing, signed by the person or persons entitled to said notice or a waiver by electronic transmission by the person entitled to notice, whether
before or after the time stated therein, shall be deemed equivalent thereto. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE V </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">INDEMNIFICATION </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Actions other than by or in the Right of the Corporation</U>. The Corporation shall indemnify any person who was or is
a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the
fact that such person is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another, partnership, joint venture, trust or other
enterprise, against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and
in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceedings, had no reasonable cause to believe such person&#146;s conduct was unlawful. The
termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of <I>nolo contendere</I> or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a
manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person&#146;s conduct was unlawful.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 2. <U>Actions by or in the Right of the Corporation</U>. The Corporation shall indemnify any person who was or is a
party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that he or she is or was a director, officer, employee or
agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another Corporation, partnership, joint venture, trust or other enterprise against expenses (including attorneys&#146;
fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests
of the Corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable unless and only to the extent that the Court of Chancery of the State of
Delaware or the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 10 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery of the State of Delaware or such other court shall deem
proper. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. <U>Success on the Merits</U>. To the extent that any person described in Section&nbsp;1 or 2 of this
Article V has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in said Sections, or in defense of any claim, issue or matter therein, he shall be indemnified against expenses (including
attorneys&#146; fees) actually and reasonably incurred by him in connection therewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4. <U>Specific
Authorization</U>. Any indemnification under Section&nbsp;1 or 2 of this Article V (unless ordered by a court) shall be made by the Corporation only as authorized in the specific case upon a determination that indemnification of any person described
in said Sections is proper in the circumstances because he has met the applicable standard of conduct set forth in said Sections. Such determination shall be made (1)&nbsp;by the Board of Directors by a majority vote of Directors who were not
parties to such action, suit or proceeding (even though less than a quorum), or (2)&nbsp;if there are no disinterested Directors or if a majority of disinterested Directors so directs, by independent legal counsel (who may be regular legal counsel
to the Corporation) in a written opinion, or (3)&nbsp;by the stockholders of the Corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. <U>Advance
Payment</U>. Expenses incurred in defending a pending or threatened civil or criminal action, suit or proceeding may be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by
or on behalf of any person described in said Section to repay such amount if it shall ultimately be determined that he or she is not entitled to indemnification by the Corporation as authorized in this Article V. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;6. <U>Non-Exclusivity</U>. The indemnification and advancement of expenses provided by, or granted pursuant to, the other
Sections of this Article V shall not be deemed exclusive of any other rights to which those provided indemnification or advancement of expenses may be entitled under any By-Law, agreement, vote of stockholders or disinterested Directors or
otherwise, both as to action in his official capacity and as to action in another capacity while holding such office. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;7. <U>Insurance</U>. The Board of Directors may authorize, by a vote of the majority of the full board, the Corporation to
purchase and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another Corporation,
partnership, joint venture, trust or other enterprise against any liability asserted against him and incurred by him in any such capacity, or arising out of his status as such, whether or not the Corporation would have the power to indemnify him
against such liability under the provisions of this Article V. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;8. <U>Continuation of Indemnification and
Advancement of Expenses</U>. The indemnification and advancement of expenses provided by, or granted pursuant to, this Article V shall continue as to a person who has ceased to be a director, officer, employee or agent and shall inure to the benefit
of the heirs, executors and administrators of such a person. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 11 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;9. <U>Severability</U>. If any word, clause or provision of this Article V or
any award made hereunder shall for any reason be determined to be invalid, the provisions hereof shall not otherwise be affected thereby but shall remain in full force and effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;10. <U>Intent of Article</U>. The intent of this Article V is to provide for indemnification and advancement of expenses to
the fullest extent permitted by Section&nbsp;145 of the General Corporation Law of Delaware. To the extent that such Section or any successor section may be amended or supplemented from time to time, this Article V shall be amended automatically and
construed so as to permit indemnification and advancement of expenses to the fullest extent from time to time permitted by law. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE VI </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">CAPITAL STOCK </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Certificates of Stock</U>. Every holder of stock in the Corporation shall be entitled to have a certificate, signed
by, or in the name of the Corporation by, the chairman or Vice-chairman of the Board of Directors, or the President or a Vice-President and the Treasurer or an assistant Treasurer, or the Secretary or an assistant Secretary of the Corporation,
certifying the number of shares owned by such holder in the Corporation. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed
upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he were such officer, transfer agent or registrar at the date of
issue. Certificates may be issued for partly paid shares and in such case upon the face or back of the certificates issued to represent any such partly paid shares, the total amount of the consideration to be paid therefor, and the amount paid
thereon shall be specified. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. <U>Lost Certificates</U>. The Board of Directors may direct a new certificate or
certificates to be issued in place of any certificate or certificates theretofore issued by the Corporation alleged to have been lost, stolen or destroyed. When authorizing such issue of a new certificate or certificates, the Board of Directors may,
in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate or certificates, or his legal representative, to give reasonable evidence of such loss, theft or destruction, to
advertise the same in such manner as it shall require and/or to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation with respect to the certificate alleged to have been
lost, stolen or destroyed or the issuance of such new certificate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 3. <U>Transfer of Stock</U>. Upon surrender to the
Corporation or the transfer agent of the Corporation of a certificate for shares, duly endorsed or accompanied by proper evidence </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 12 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of succession, assignment or authority to transfer, and proper evidence of compliance with other conditions to rightful transfer, it shall be the duty of the Corporation to issue a new
certificate to the person entitled thereto, cancel the old certificate and record the transaction upon its books. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4. <U>Record Date</U>. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any
meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which shall not be more
than sixty days nor less then ten days before the date of such meeting. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that
the Board of Directors may fix a new record date for the adjourned meeting. If no record date is fixed, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on
the day before the day on which notice is given, or, if notice is waived, at the close of business on the day before the day on which the meeting is held. In order that the Corporation may determine the stockholders entitled to consent to corporate
action in writing without a meeting, the Board of Directors may fix a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which shall not be more than ten days
after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date is fixed, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when
no prior action by the Board of Directors is required by statute, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation as provided in Section&nbsp;10 of
Article I. If no record date is fixed and prior action by the Board of Directors is required, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the
date on which the Board of Directors adopts the resolution taking such prior action. In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the
stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which shall not precede the date upon which the
resolution fixing the record date is adopted, and which shall be not more than sixty days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the
day on which the Board of Directors adopts the resolution relating to such purpose. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. <U>Registered
Stockholders</U>. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person
registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof,
except as otherwise provided by the laws of Delaware. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 13 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE VII </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CERTAIN TRANSACTIONS </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Transactions with Interested
Parties</U>. No contract or transaction between the Corporation and one or more of its Directors or officers, or between the Corporation and any other Corporation, partnership, association, or other organization in which one or more of its Directors
or officers are Directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the board or committee thereof which
authorizes the contract or transaction or solely because his or their votes are counted for such purpose, if: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The material facts as to his relationship or interest and as to the contract or transaction are disclosed or are known
to the Board of Directors or the committee, and the board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested Directors, even though the disinterested Directors be less than a
quorum; or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The material facts as to his relationship or interest and as to the contract or transaction are
disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified, by
the Board of Directors, a committee thereof, or the stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. <U>Quorum</U>. Common or interested
Directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ARTICLE VIII </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">GENERAL PROVISIONS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. <U>Dividends</U>. Dividends upon the capital stock of the Corporation, if any, may be declared by the Board of Directors
at any regular or special meeting or by written consent, pursuant to law. Dividends may be paid in cash, in property, or in shares of the capital stock, subject to the provisions of the certificate of incorporation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. <U>Reserves</U>. The Directors may set apart out of any funds of the Corporation available for dividends a reserve or
reserves for any proper purpose and may abolish any such reserve. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 14 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. <U>Checks</U>. All checks or demands for money and notes of the Corporation
shall be signed by such officer or officers or such other person or persons as the Board of Directors may from time to time designate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;4. <U>Fiscal Year</U>. The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;5. <U>Seal</U>. The Board of Directors may, by resolution, adopt a corporate seal. The corporate seal shall have inscribed thereon the name of the Corporation, the year of its organization
and the word &#147;Delaware.&#148; The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise. The seal may be altered from time to time by the Board of Directors. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE IX </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMENDMENTS </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These By-Laws may be altered, amended or repealed or new By-Laws may be adopted by the stockholders or by the Board of Directors, when
such power is conferred upon the Board of Directors by the certificate of incorporation, at any regular meeting of the stockholders or of the Board of Directors or at any special meeting of the stockholders or of the Board of Directors provided,
however, that in the case of a regular or special meeting of stockholders, notice of such alteration, amendment, repeal or adoption of new By-Laws be contained in the notice of such meeting. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 15 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Register of Amendments to the By-Laws </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:15pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:53pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Section Affected</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:24pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Change</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 4.1 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXECUTION COPY </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOURTH AMENDED AND RESTATED </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REGISTRATION RIGHTS AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">by and among </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACROGENICS, INC., </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE FOUNDERS, </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">THE
INVESTORS </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">September&nbsp;19, 2008 </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">TABLE OF CONTENTS </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Definitions</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Restrictive Legend</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Notice of Proposed Transfer</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Required Registration</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Incidental Registration</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration on Form S-3</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Procedures</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Expenses</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification and Contribution</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Changes in Common Stock or Preferred Stock</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Rule 144 Reporting</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Company</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Binding Arbitration</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">THIS FOURTH AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, dated September&nbsp;19, 2008 (this &#147;<U>Agreement</U>&#148;), is made by and among MacroGenics, Inc., a Delaware corporation (the
&#147;<U>Company</U>&#148;), those parties identified as Founders on the signature page hereto (the &#147;<U>Founders</U>&#148;), the parties listed on <U>Exhibit A</U> hereto (the &#147;<U>Existing Investors</U>&#148;), the parties listed on
<U>Exhibit B</U> hereto (the &#147;<U>Series D Investors</U>&#148;), and the parties executing the signature pages hereto (the &#147;<U>New Investors</U>,&#148; and collectively with the Existing Investors and the Series D Investors, the
&#147;<U>Investors</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration of the mutual promises and obligations contained herein, the parties hereto
agree as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Certain Definitions</U>. As used in this Agreement, the following terms shall have the following
respective meanings: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Additional Restricted Stock</U>&#148; shall mean the shares of Common Stock (the
&#147;<U>Additional Conversion Shares</U>&#148;) issued upon conversion of the 5,000,000 Preferred Shares (the &#147;<U>Additional Preferred Stock</U>&#148;) issued and sold pursuant to that certain Stock Purchase Agreement dated as of
October&nbsp;27, 2003, by and between the Company and Genzyme Corporation, excluding Additional Conversion Shares which have been (a)&nbsp;registered under the Securities Act pursuant to an effective registration statement filed thereunder and
disposed of in accordance with the registration statement covering them or (b)&nbsp;publicly sold pursuant to Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Commission</U>&#148; shall mean the Securities and Exchange Commission, or any other federal agency at the time administering the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Common Stock</U>&#148; shall mean the Common Stock, $0.01 par value per share, of the Company, as constituted as of the date of
this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Conversion Shares</U>&#148; shall mean shares of Common Stock issued upon conversion of the
Preferred Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Exchange Act</U>&#148; shall mean the Securities Exchange Act of 1934, as amended, or any similar
federal statute, and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Preferred Shares</U>&#148; shall mean the shares of Series A-1 Convertible Preferred Stock, $0.01 par value per share, the
shares of Series A-2 Convertible Preferred Stock, $0.01 par value per share, the shares of Series B-1 Convertible Preferred Stock, par value $0.01 per share, the shares of Series C Convertible Preferred Stock, $0.01 par value per share, the shares
of Series D Convertible Preferred Stock, $0.01 par value per share, and the shares of Series D-2 Convertible Preferred Stock, $0.01 par value per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 1 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Preferred Stock</U>&#148; shall mean the Series A-1 Convertible Preferred Stock,
$0.01 par value per share, the Series A-2 Convertible Preferred Stock, $0.01 par value per share, the Series B-1 Convertible Preferred Stock, par value $0.01 per share, the Series C Convertible Preferred Stock, $0.01 par value per share, the Series
D Convertible Preferred Stock, $0.01 par value per share, and the Series D-2 Convertible Preferred Stock, $0.01 par value per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Registration Expenses</U>&#148; shall mean the expenses so described in Section&nbsp;8. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Restricted Stock</U>&#148; shall mean the Conversion Shares, excluding (i)&nbsp;Additional Conversion Shares and (ii)&nbsp;Conversion Shares which have been (a)&nbsp;registered under the
Securities Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them or (b)&nbsp;sold pursuant to Rule 144 under the Securities Act. For purposes of
Section&nbsp;5 hereof, and all other provisions of this Agreement applicable to any registration covered by Section&nbsp;5 hereof, Restricted Stock shall also include all Common Stock then held by the Founders and the University. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Securities Act</U>&#148; shall mean the Securities Act of 1933, as amended, or any similar federal statute, and the rules and
regulations of the Commission thereunder, all as the same shall be in effect at the time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Selling Expenses</U>&#148;
shall mean the expenses so described in Section&nbsp;8. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>University</U>&#148; shall mean the Board of Regents of the
University of Texas System. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Restrictive Legend</U>. Each certificate representing Preferred Shares or Conversion Shares
shall, except as otherwise provided in this Section&nbsp;2 or in Section&nbsp;3, be stamped or otherwise imprinted with a legend substantially in the following form: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;ACT&#148;), OR ANY APPLICABLE STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR
OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT AND IN COMPLIANCE WITH SUCH STATE SECURITIES LAWS OR UNLESS THE ISSUER HAS RECEIVED OR WAIVED AN OPINION OF LEGAL COUNSEL SATISFACTORY TO THE ISSUER
AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED AND SUCH COMPLIANCE IS AVAILABLE.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A certificate shall not bear such legend if in
the opinion of counsel reasonably satisfactory to the Company the securities represented thereby may be publicly sold without registration under the Securities Act and any applicable state securities laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Notice of Proposed Transfer</U>. Prior to any proposed transfer of any Preferred Shares or Conversion Shares (other than under the
circumstances described in Sections 4, 5 or 6), the holder thereof shall give written notice to the Company of its intention to effect such transfer. Each such notice shall describe the manner of the proposed transfer and, if requested by the
Company, shall be accompanied by an opinion of counsel reasonably satisfactory to the Company to the effect that the proposed transfer may be effected without registration under the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Securities Act and any applicable state securities laws, whereupon the holder of such stock shall be entitled to transfer such stock in accordance with the terms of its notice; <U>provided</U>,
<U>however</U>, that no such opinion of counsel shall be required for (i)&nbsp;a transfer to one or more partners or members of the transferor (in the case of a transferor that is a partnership or a limited liability company, respectively) or to an
affiliated corporation (in the case of a transferor that is a corporation) or (ii)&nbsp;a transfer by any Investor to an affiliate or an entity controlled by, controlling or under common control with such Investor. Each certificate for Preferred
Shares or Conversion Shares transferred as above provided shall bear the legend set forth in Section&nbsp;2, except that such certificate shall not bear such legend if (A)&nbsp;such transfer is in accordance with the provisions of Rule 144 (or any
other rule permitting public sale without registration under the Securities Act) or (B)&nbsp;the opinion of counsel referred to above is to the further effect that the transferee and any subsequent transferee (other than an affiliate of the Company)
would be entitled to transfer such securities in a public sale without registration under the Securities Act. The restrictions provided for in this Section&nbsp;3 shall not apply to securities which are not required to bear the legend prescribed by
Section&nbsp;2 in accordance with the provisions of that Section. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Required Registration</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) At any time after the earliest of (i)&nbsp;180 days after any registration statement covering a public offering
of securities of the Company under the Securities Act shall have become effective, (ii)&nbsp;180 days after the Company shall have become a reporting company under Section&nbsp;12 of the Exchange Act, and (iii)&nbsp;the second (2</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;anniversary of May&nbsp;16, 2006, the holders of Restricted
Stock (other than the New Investors and the Series D Investors) constituting at least 40% of the total shares of Restricted Stock then outstanding (other than the shares of Restricted Stock held by the New Investors and the Series D Investors) may
request the Company to register under the Securities Act all or any portion of the shares of Restricted Stock held by such requesting holder or holders for sale in the manner specified in such notice, <U>provided</U> that the reasonably anticipated
aggregate price to the public of such public offering would exceed $5,000,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) At any time after the
earliest of (i)&nbsp;180 days after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, (ii)&nbsp;180 days after the Company shall have become a reporting company
under Section&nbsp;12 of the Exchange Act, and (iii)&nbsp;the second (2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;anniversary of July&nbsp;15, 2008, New Investors and Series D Investors constituting at least 40% of the total shares of Restricted Stock then collectively held by the New Investors and the Series
D Investors, may request the Company to register under the Securities Act all or any portion of the shares of Restricted Stock held by such requesting holder or holders for sale in the manner specified in such notice, <U>provided</U> that the
reasonably anticipated aggregate price to the public of such public offering would exceed $25,000,000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) For purposes of
this Section&nbsp;4 and Sections 5, 6, 13(a) and 13(d), the term &#147;Restricted Stock&#148; shall be deemed to include the number of shares of Restricted Stock that would be issuable to a holder of Preferred Shares upon conversion of all Preferred
Shares held by such holder at such time; <U>provided</U>, <U>however</U>, that the only securities which the Company shall be required to register pursuant hereto shall be shares of Common Stock, and <U>provided</U>, <U>further</U>, <U>however</U>,
that, in any underwritten public offering contemplated by this Section&nbsp;4 or Sections 5 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and 6, the holders of Preferred Shares shall be entitled to sell such Preferred Shares to the underwriters for conversion and sale of the shares of Common Stock issued upon conversion thereof.
Notwithstanding anything to the contrary contained herein, the Company shall not be obligated under this Section&nbsp;4: (i)&nbsp;within 180 days after the effective date of a registration statement filed by the Company in connection with the
Company&#146;s initial public offering, or (ii)&nbsp;within 180 days after the effective date of a registration statement filed by the Company covering a firm commitment underwritten public offering in which the holders of Restricted Stock shall
have been entitled to join pursuant to Section&nbsp;5 or 6 and in which there shall have been effectively registered all shares of Restricted Stock as to which registration shall have been requested. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Following receipt of any notice under this Section&nbsp;4, the Company shall immediately notify all holders of Restricted Stock and
Additional Restricted Stock from whom notice has not been received and shall use its best efforts to register under the Securities Act, for public sale in accordance with the method of disposition specified in such notice from requesting holders,
the number of shares of Restricted Stock and Additional Restricted Stock specified in such notice (and in all notices received by the Company from other holders within 30 days after the giving of such notice by the Company). If such method of
disposition shall be an underwritten public offering, the Company may designate the managing underwriter of such offering, subject to the approval of the holders of a majority of the shares of Restricted Stock to be sold in such offering, which
approval shall not be unreasonably withheld or delayed. The Company shall be obligated to register Restricted Stock and Additional Restricted Stock pursuant to this Section&nbsp;4 on one (1)&nbsp;occasion only; <U>provided</U>, <U>however</U>, that
such obligation shall be deemed satisfied only when a registration statement covering all shares of Restricted Stock and Additional Restricted Stock specified in notices received as aforesaid, for sale in accordance with the method of disposition
specified by the requesting holders, shall have become effective and, if such method of disposition is a firm commitment underwritten public offering, all such shares shall have been sold pursuant thereto. Notwithstanding the foregoing, the Company
may delay a request for registration pursuant to this Section&nbsp;4 if, within 30 days following the receipt of any notice requesting registration in accordance with this Section&nbsp;4, the Company notifies the holders of Restricted Stock and
Additional Restricted Stock that the Company intends to file a registration statement with the Commission relating to an initial public offering within 90 days of such notice by the Company to the holders of Restricted Stock and Additional
Restricted Stock and provided the Company shall, in good faith, use reasonable efforts to cause such registration statement to become effective; <U>provided</U>, <U>however</U>, that the Company may exercise such right to delay a request for
registration under such circumstances not more than once in any 12-month period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The Company shall be entitled to include
in any registration statement referred to in this Section&nbsp;4, for sale in accordance with the method of disposition specified by the requesting holders, shares of Common Stock to be sold by the Company for its own account, except as and to the
extent that, in the opinion of the managing underwriter (if such method of disposition shall be an underwritten public offering), such inclusion would adversely affect the marketing of the Restricted Stock and Additional Restricted Stock to be sold.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Incidental Registration</U>. If the Company at any time proposes to register any of its securities under the Securities
Act for sale to the public, whether for its own account or for the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
account of other security holders or both (except with respect to registration statements on Forms S-4, S-8 or another form not available for registering the Restricted Stock or Additional
Restricted Stock for sale to the public), each such time it will give written notice to all holders of outstanding Restricted Stock and Additional Restricted Stock of its intention so to do. Upon the written request of any such holder, received by
the Company within 30 days after the giving of any such notice by the Company, to register any of its Restricted Stock or Additional Restricted Stock, the Company shall cause the Restricted Stock and Additional Restricted Stock as to which
registration shall have been so requested to be included in the securities to be covered by the registration statement proposed to be filed by the Company, all to the extent requisite to permit the sale or other disposition by the holder of such
Restricted Stock or Additional Restricted Stock so registered. In the event that any registration pursuant to this Section&nbsp;5 shall be, in whole or in part, an underwritten public offering of Common Stock, the number of shares of Restricted
Stock and Additional Restricted Stock to be included in such an underwriting may be reduced if and to the extent that the managing underwriter shall be of the opinion that such inclusion would adversely affect the marketing of the securities to be
sold by the Company therein, <U>provided</U>, <U>however</U>, that such number of shares of Restricted Stock and Additional Restricted Stock shall not be reduced if any shares are to be included in such underwriting for the account of any person
other than the Company or holders of Restricted Stock or holders of Additional Restricted Stock, and <U>provided</U>, <U>further</U>, however, that, except in the case of the Company&#146;s initial public offering, in no event may less than
twenty-five percent (25%)&nbsp;of the total number of shares of Common Stock to be included in such underwriting be made available for shares of Restricted Stock. In the event of such reduction, the Company shall so advise all holders of Restricted
Stock and Additional Restricted Stock requesting registration, and the number of shares that are entitled to be included in the registration and underwriting shall be allocated in the following manner. First, the number of shares that may be
included in such registration and underwriting shall be allocated among all Investors who have requested registration in proportion, as nearly as practicable, to the respective number of shares of Restricted Stock and Additional Restricted Stock
held by such Investors at the time of the Company&#146;s notice under this Section&nbsp;5. No shareholder of the Company shall be granted registration rights which would reduce the number of shares includable by the holders of the Restricted Stock
and Additional Restricted Stock in such registration without the consent of the holders of at least two-thirds of the Restricted Stock and Additional Restricted Stock. If any Investor would thus be entitled to include more securities than such
Investor requested to be registered, the excess shall be allocated among the other requesting Investors <I>pro rata </I>in the manner described in the preceding sentence. Second, once all shares of Restricted Stock and Additional Restricted Stock
requested by the Investors to be registered have been included in such registration and underwriting, the Founders and the University shall participate in the offering, <I>pro rata </I>based upon their total ownership of shares of Restricted Stock.
Notwithstanding the foregoing provisions, the Company may withdraw any registration statement referred to in this Section&nbsp;5 without thereby incurring any liability to the holders of Restricted Stock or Additional Restricted Stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>Registration on Form S-3</U>. If at any time (a)(i) a holder or holders of Restricted Stock (other than the Series D Investors)
request that the Company file a registration statement on Form S-3 or any successor thereto for a public offering of all or any portion of the shares of Restricted Stock held by such requesting holder or holders, the reasonably anticipated aggregate
price to the public of which would exceed $1,000,000; or (ii)&nbsp;one or more of the Series D </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Investors request that the Company file a registration statement on Form S-3 or any successor thereto for a public offering of all or any portion of the shares of Restricted Stock held by such
requesting holder or holders, the reasonably anticipated aggregate price to the public of which would exceed $5,000,000; <U>and</U> (b)&nbsp;the Company is a registrant entitled to use Form S-3 or any successor thereto to register such shares, then
the Company shall use its best efforts to register under the Securities Act on Form S-3 or any successor thereto, for public sale in accordance with the method of disposition specified in such notice, the number of shares of Restricted Stock
specified in such notice. Whenever the Company is required by this Section&nbsp;6 to use its best efforts to effect the registration of Restricted Stock, each of the procedures and requirements of Section&nbsp;4 (including, but not limited to, the
requirement that the Company notify all holders of Restricted Stock and Additional Restricted Stock from whom notice has not been received and provide them with the opportunity to participate in the offering) shall apply to such registration;
<I>provided</I>, <I>however</I>, that the requirements contained in Section&nbsp;4(a) and Section&nbsp;4(b) shall not apply to any registration on Form S-3 which may be requested and obtained under this Section&nbsp;6. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>Registration Procedures</U>. If and whenever the Company is required by the provisions of Sections 4, 5 or 6 to use its best
efforts to effect the registration of any shares of Restricted Stock and/or Additional Restricted Stock under the Securities Act, the Company will, as expeditiously as possible: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) prepare and file (in the case of a registration pursuant to Section&nbsp;4 or Section&nbsp;6, within 60 days of receipt by the
Company of the applicable request for registration) with the Commission a registration statement (which, in the case of an underwritten public offering pursuant to Section&nbsp;4, shall be on Form S-1 or other form of general applicability
satisfactory to the managing underwriter selected as therein provided) with respect to such securities and use its best efforts to cause such registration statement to become and remain effective for the period of the distribution contemplated
thereby (determined as hereinafter provided); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) prepare and file with the Commission such amendments and supplements to
such registration statement and the prospectus used in connection therewith as may be necessary to keep such registration statement effective for the period specified in subparagraph (a)&nbsp;above and comply with the provisions of the Securities
Act (including the antifraud provisions thereof) with respect to the disposition of all Restricted Stock and Additional Restricted Stock covered by such registration statement in accordance with the sellers&#146; intended method of disposition set
forth in such registration statement for such period; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) furnish to each seller of Restricted Stock and Additional
Restricted Stock and to each underwriter such number of copies of the registration statement and the prospectus included therein (including each preliminary prospectus) as such persons reasonably may request in order to facilitate the public sale or
other disposition of the Restricted Stock and Additional Restricted Stock covered by such registration statement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) use its
best efforts to register or qualify the Restricted Stock and Additional Restricted Stock covered by such registration statement under the securities or &#147;blue sky&#148; laws of such jurisdictions as the sellers of Restricted Stock and Additional
Restricted Stock or, in the case of an underwritten public offering, the managing underwriter reasonably shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
request, <U>provided</U>, <U>however</U>, that the Company shall not for any such purpose be required to qualify generally to transact business as a foreign corporation in any jurisdiction where
it is not so qualified or to consent to general service of process in any such jurisdiction; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) use its best efforts to list
the Restricted Stock and Additional Restricted Stock covered by such registration statement with any securities exchange or automated quotation system on which the Common Stock of the Company is then listed; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) immediately notify each seller of Restricted Stock and Additional Restricted Stock and each underwriter under such registration
statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the happening of any event of which the Company has knowledge as a result of which the prospectus contained in such registration
statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) make available for inspection by each seller of Restricted Stock and Additional Restricted Stock, any underwriter
participating in any distribution pursuant to such registration statement, and any attorney, accountant or other agent retained by such seller or underwriter, all financial and other records, pertinent corporate documents and properties of the
Company, and cause the Company&#146;s officers, directors and employees to supply all information reasonably requested by any such seller, underwriter, attorney, accountant or agent in connection with such registration statement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of Section&nbsp;7(a) and 7(b) and of Section&nbsp;4(c), the period of distribution of Restricted Stock and Additional
Restricted Stock in a firm commitment underwritten public offering shall be deemed to extend until each underwriter has completed the distribution of all securities purchased by it, and the period of distribution of Restricted Stock and Additional
Restricted Stock in any other registration shall be deemed to extend until the earlier of the sale of all Restricted Stock and Additional Restricted Stock covered thereby and 180 days after the effective date thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with each registration hereunder, the sellers of Restricted Stock and Additional Restricted Stock will furnish to the
Company in writing such information with respect to themselves and the proposed distribution by them as reasonably shall be necessary in order to assure compliance with federal and applicable state securities laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with each registration pursuant to Sections 4, 5 or 6 covering an underwritten public offering, the Company and each
selling holder of Restricted Stock and Additional Restricted Stock agree to enter into a written agreement with the managing underwriter selected in the manner herein provided in such form and containing such provisions as are customary in the
securities business for such an arrangement between such underwriter and companies of the Company&#146;s size and investment stature. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(h) Notwithstanding the other provisions of this Agreement, the Company&#146;s obligation to file a registration statement, or cause such registration statement to become and remain effective, may be
suspended on one (1)&nbsp;occasion in any 12-month period for a period not </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
to exceed 90 days if there exists at the time material non-public information relating to the Company and in the good faith opinion of the Board of Directors of the Company it would be seriously
detrimental to the Company for such registration statement to become effective. In addition, the parties hereto acknowledge the Company may notify holders and suspend use of an effective registration statement for a similar period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <U>Expenses</U>. All expenses incurred by the Company in complying with Sections 4, 5 and 6, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of counsel and independent public accountants for the Company, fees and expenses (including counsel fees) incurred in connection with complying with state securities or
&#147;blue sky&#148; laws, fees of the Financial Industry Regulatory Authority, transfer taxes, fees of transfer agents and registrars, costs of insurance and fees and disbursements of one special counsel for the sellers of Restricted Stock and
Additional Restricted Stock (such special counsel&#146;s fees not to exceed $40,000 in the aggregate for each such registration), but excluding any Selling Expenses, are called &#147;Registration Expenses.&#148; All underwriting discounts and
selling commissions applicable to the sale of Restricted Stock and Additional Restricted Stock are called &#147;Selling Expenses.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Company will pay all Registration Expenses in connection with each registration statement under Sections 4, 5 or 6. All Selling Expenses in connection with each registration statement under Sections
4, 5 or 6 shall be borne by the participating sellers in proportion to the number of shares sold by each, or by such participating sellers other than the Company (except to the extent the Company shall be a seller) as they may agree. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <U>Indemnification and Contribution</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) In the event of a registration of any of the Restricted Stock or Additional Restricted Stock under the Securities Act pursuant to Sections 4, 5 or 6, the Company will indemnify and hold harmless each
seller of such Restricted Stock and Additional Restricted Stock thereunder, each underwriter of such Restricted Stock and Additional Restricted Stock thereunder and each other person, if any, who controls such seller or underwriter within the
meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which such seller, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in any registration statement under which such Restricted Stock or Additional
Restricted Stock was registered under the Securities Act pursuant to Sections 4, 5 or 6, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof, or arise out of or are based upon the omission or
alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each such seller, each such underwriter and each such controlling person for any legal or
other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action as the same are incurred, <U>provided</U>, <U>however</U>, that the Company will not be liable in any such
case if and to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by any such
seller, any such underwriter or any such controlling </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
person in writing specifically for use in such registration statement or prospectus or from a failure of such seller to comply with the prospectus delivery requirements of the Securities Act if
the Company has delivered to such seller any reasonable number of correct or corrected prospectuses requested by such seller. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the event of a registration of any of the Restricted Stock or Additional Restricted Stock under the Securities Act pursuant to
Sections 4, 5 or 6, each seller of such Restricted Stock or Additional Restricted Stock thereunder, severally and not jointly, will indemnify and hold harmless the Company, each person, if any, who controls the Company within the meaning of the
Securities Act, each officer of the Company who signs the registration statement, each director of the Company, each underwriter and each person who controls any underwriter within the meaning of the Securities Act, against all losses, claims,
damages or liabilities, joint or several, to which the Company or such officer, director, underwriter or controlling person may become subject under the Securities Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions
in respect thereof) arise out of or are based upon any untrue statement or alleged untrue statement of any material fact contained in the registration statement under which such Restricted Stock or Additional Restricted Stock was registered under
the Securities Act pursuant to Sections 4, 5 or 6, any preliminary prospectus or final prospectus contained therein or any amendment or supplement thereof or arise out of or are based upon the omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein not misleading and will reimburse the Company and each such officer, director, underwriter and controlling person for any legal or other expenses reasonably incurred by
them in connection with investigating or defending any such loss, claim, damage, liability or action, <U>provided</U>, <U>however</U>, that such seller will be liable hereunder in any such case if and only to the extent that any such loss, claim,
damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information pertaining to such seller, as such, furnished in writing to
the Company by such seller specifically for use in such registration statement or prospectus, and <U>provided</U>, <U>further</U>, however, that the liability of each seller hereunder shall be limited to the proportion of any such loss, claim,
damage, liability or expense which is equal to the proportion that the public offering price of the shares sold by such seller under such registration statement bears to the total public offering price of all securities sold thereunder, but not in
any event to exceed the proceeds received by such seller from the sale of Restricted Stock or Additional Restricted Stock covered by such registration statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Promptly after receipt by an indemnified party hereunder of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying
party hereunder, notify the indemnifying party in writing thereof, but the omission so to notify the indemnifying party shall not relieve it from any liability which it may have to such indemnified party other than under this Section&nbsp;9 and
shall only relieve it from any liability which it may have to such indemnified party under this Section&nbsp;9 if and to the extent the indemnifying party is prejudiced by such omission. In case any such action shall be brought against any
indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate in and, to the extent it shall wish, to assume and undertake the defense thereof with counsel
satisfactory to such indemnified party, and, after notice from the indemnifying party to such indemnified party of its election so to assume and undertake the defense thereof, the indemnifying party shall not
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 9 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
be liable to such indemnified party under this Section&nbsp;9 for any legal expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable
costs of investigation and of liaison with counsel so selected, <U>provided</U>, <U>however</U>, that, if the defendants in any such action include both the indemnified party and the indemnifying party and the indemnified party shall have reasonably
concluded that there may be reasonable defenses available to it which are different from or additional to those available to the indemnifying party or if the interests of the indemnified party reasonably may be deemed to conflict with the interests
of the indemnifying party, the indemnified party shall have the right to select a separate counsel and to assume such legal defenses and otherwise to participate in the defense of such action, with the expenses and fees of such separate counsel and
other expenses related to such participation to be reimbursed by the indemnifying party as incurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) If for any reason
the indemnification provided for in this Section&nbsp;9 is held by a court of competent jurisdiction to be unavailable to an indemnified person in respect of any losses, claims, damages, expenses or liabilities referred to therein, then each
indemnifying party under this Section&nbsp;9, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages, expenses or liabilities in
such proportion as is appropriate to reflect the relative fault of the Company, the selling holders of Restricted Stock and Additional Restricted Stock and the underwriters in connection with the statements or omissions which resulted in such
losses, claims, damages, expenses or liabilities, as well as any other relevant equitable considerations. The relative fault of the Company, the selling holders of Restricted Stock and Additional Restricted Stock and the underwriters shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company, the selling holders of
Restricted Stock and Additional Restricted Stock or the underwriters, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. Notwithstanding the foregoing,
(A)&nbsp;no holder will be required to contribute any amount in excess of the public offering price of all such Restricted Stock or Additional Restricted Stock offered by it pursuant to such registration statement; and (B)&nbsp;no person or entity
guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <U>Changes in Common Stock or Preferred Stock</U>. If, and as often as, there is any change in the Common Stock or the Preferred
Stock by way of a stock split, stock dividend, combination or reclassification, or through a merger, consolidation, reorganization or recapitalization, or by any other means, appropriate adjustment shall be made in the provisions hereof so that the
rights and privileges granted hereby shall continue with respect to the Common Stock or the Preferred Stock as so changed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. <U>Rule 144 Reporting</U>. With a view to making available the benefits of certain rules and regulations of the Commission which may
at any time permit the sale of the Restricted Stock or Additional Restricted Stock to the public without registration, at all times after 90 days after any registration statement covering a public offering of securities of the Company under the
Securities Act shall have become effective, the Company agrees to: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) make and keep public information available, as those
terms are understood and defined in Rule 144 under the Securities Act; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 10 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) use its best efforts to file with the Commission in a timely manner all reports and
other documents required of the Company under the Securities Act and the Exchange Act; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) furnish to each holder of
Restricted Stock or Additional Restricted Stock forthwith upon request a written statement by the Company as to its compliance with the reporting requirements of such Rule 144 and of the Securities Act and the Exchange Act, a copy of the most recent
annual or quarterly report of the Company, and such other reports and documents so filed by the Company as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder to sell any Restricted
Stock or Additional Restricted Stock without registration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <U>Representations and Warranties of the Company</U>. The
Company represents and warrants to the Investors as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The execution, delivery and performance of this Agreement by
the Company have been duly authorized by all requisite corporate action and will not violate any provision of law, any order of any court or other agency of government, the Certificate of Incorporation or By-laws of the Company or any provision of
any indenture, agreement or other instrument to which it or any or its properties or assets is bound, conflict with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any such indenture, agreement or
other instrument or result in the creation or imposition of any lien, charge or encumbrance of any nature whatsoever upon any of the properties or assets of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) This Agreement has been duly executed and delivered by the Company and constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Binding Arbitration</U>. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Any controversies, disputes, actions, causes of action or other claims between the parties arising out of or relating to this
Agreement, or the breach, termination or validity hereof, or any other matters related thereto (a &#147;<U>Controversy</U>&#148;), whether during the term of this Agreement or otherwise, which are not resolved by mutual agreement within forty-five
(45)&nbsp;days of first written notification by one party to the other parties of the existence of the Controversy (which notification must set forth in reasonable detail the specific points in dispute) shall be finally settled by arbitration before
a neutral arbitrator in accordance with the Commercial Arbitration Rules of the American Arbitration Association (&#147;<U>AAA</U>&#148;) then in effect (modified only as herein expressly provided). The arbitrator shall be experienced with regard to
commercial disputes of the type for which arbitration is being sought. The arbitration shall be before one arbitrator mutually agreed upon by the parties. In the event the parties cannot reach agreement upon an arbitrator, an arbitrator shall be
appointed by the Director of the Washington, D.C., office of AAA. Each party must continue to perform their respective obligations under this Agreement despite the existence of the Controversy. The parties agree that the arbitration will be
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 11 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
held in Washington, D.C., or in such other place as the parties may mutually agree upon. The arbitration will be held in accordance with and subject to the procedural rules and applicable
requirements and procedures of the District of Columbia. The arbitrator may enter a default decision against any party who fails to participate in the arbitration proceedings. The decision of the arbitrator on the points in dispute with respect to
such Controversy will be final, non-appealable and binding and judgment on the award may be entered in any court having jurisdiction thereof. The parties agree that this clause has been included to rapidly and inexpensively resolve any Controversy,
and that this clause shall be grounds for dismissal of any court action commenced by any party arising out of or relating to this Agreement or the breach, termination or validity hereof or any other matters relating thereto; provided that nothing in
this Section&nbsp;13 shall limit any party&#146;s right to bring (i)&nbsp;post-arbitration actions seeking to enforce an arbitration award or (ii)&nbsp;actions seeking injunctive or other similar relief in the event of the breach or threatened
breach of any of the provisions of this Agreement. The parties shall keep confidential, and shall not disclose to any person (except (A)&nbsp;to the extent required by law, and (B)&nbsp;for disclosure to those employees and agents of any such party
who have a need to know and who have been advised of their obligations of confidentiality and non-disclosure hereunder), the existence of any Controversy hereunder, the referral of any such Controversy to arbitration or the status or resolution
thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The parties hereto agree that the party or parties which are principally prevailing in any such Controversy
shall be entitled to full reimbursement of all out-of-pocket costs incurred by such prevailing party and its affiliates in connection with such Controversy (including reimbursement of all reasonable attorneys&#146; fees and expenses) and the
arbitrator is hereby empowered to include such reimbursement in any award or determination. In the event that there is no party which is principally prevailing in any such Controversy, the arbitrator will be authorized to apportion its fees and
expenses and the reasonable attorneys&#146; fees and expenses of the parties as the arbitrator deems appropriate, and in the absence of any such apportionment, the fees and expenses of the arbitrator will be borne equally by all parties involved in
such arbitration, and each party will bear the fees and expenses of its own attorney. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) With respect to any action or
proceeding which a successful party to the arbitration may wish to bring to enforce any arbitral award or to seek injunctive or other similar relief in the event of the breach or threatened breach of this Agreement, each party irrevocably and
unconditionally (and without limitation): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) submits to and accepts, for itself and in respect of its assets, generally and
unconditionally the non-exclusive jurisdiction of the courts of the United States and of the State of Delaware; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) waives
any objection it may have now or in the future that such action or proceeding has been brought in an inconvenient forum; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) agrees that in any such action or proceeding it will not raise, rely on or claim any immunity (including, without limitation, from
suit, judgment, attachment before judgment or otherwise, execution or other enforcement); </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 12 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) waives any right of immunity which it has or its assets may have at any time; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) consents generally to the giving of any relief or the issue of any process in connection with any such action or
proceeding including, without limitation, the making, enforcement or execution of any order or judgment against any of its property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14. <U>Miscellaneous</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) All covenants and agreements contained in this
Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto (including without limitation transferees of any Preferred Shares, Restricted Stock or
Additional Restricted Stock), whether so expressed or not, <U>provided</U>, <U>however</U>, that registration rights conferred herein on the holders of Preferred Shares, Restricted Stock or Additional Restricted Stock shall only inure to the benefit
of a transferee of Preferred Shares, Restricted Stock or Additional Restricted Stock if the Company is provided with notice of the transfer and either (i)&nbsp;the transferee acquires 5,500,000 shares (subject to equitable adjustment in the event of
any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares) or (ii)&nbsp;such transferee is (A)&nbsp;in the case of a party hereto who is a natural person, an
immediate family member or trust for the benefit of such holder or (B)&nbsp;a partner, retired partner, member, retired member, shareholder or affiliate of a party hereto; and <U>provided</U>, <U>further</U> that, upon written notice and with the
written consent of the Company (such consent not to be unreasonably withheld or unduly delayed), the Company shall grant the registration rights conferred herein to any transferee of Preferred Shares, Restricted Stock or Additional Restricted Stock
of at least 3,000,000 shares (subject to equitable adjustment in the event of any stock dividend, stock split, combination, reorganization, recapitalization, reclassification or other similar event affecting such shares). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) All notices, requests, consents and other communications hereunder shall be in writing and shall be delivered in person, mailed by
certified or registered mail, return receipt requested, or sent by telecopier or telex, addressed as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) if to the
Company, at the address of its principal office; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) if to any other party to this Agreement, at its address on the records
maintained by the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) if to any subsequent holder of Preferred Shares, Restricted Stock or Additional Restricted
Stock, to it at such address as may have been furnished to the Company in writing by such holder; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or, in any case, at such other address or
addresses as shall have been furnished in writing to the Company (in the case of a holder of Preferred Shares, Restricted Stock or Additional Restricted Stock) or to the holders of Preferred Shares, Restricted Stock or Additional Restricted Stock
(in the case of the Company) in accordance with the provisions of this paragraph. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 13 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) This Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware without giving effect to any choice or conflict of law provision or rule that would cause the application of the laws of any other state. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) This Agreement may not be amended or modified, and no provision hereof may be waived, without the written
consent of the Company and the Investors holding at least sixty-six and two-thirds percent (66 <FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;2</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.1ex">3</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">%) of the combined outstanding shares of Restricted Stock and Additional Restricted Stock, voting together as a single
class. Notwithstanding the foregoing, no provision of this Agreement shall be amended, modified or terminated, nor shall the observance of any term of this Agreement be waived, unless such amendment, modification, termination or waiver, as the case
may be, applies in the same material respects to all Investors, unless such affected Investor consents to such amendment, modification, termination or waiver. </FONT></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) The obligations of the Company to register shares of Restricted Stock and Additional Restricted Stock under
Sections 4, 5 or 6 shall terminate on the twentieth
(20</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;anniversary of the date of this Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) In connection with the initial underwritten public offering of securities of the Company, each holder (including the
Founders and the University) of Restricted Stock or Additional Restricted Stock who is a party to this Agreement agrees not to sell, assign, transfer, pledge, hypothecate, mortgage, encumber or otherwise dispose any shares of Restricted Stock,
Additional Restricted Stock or any other shares of Common Stock then held by such holder (other than shares of Restricted Stock, Additional Restricted Stock or other shares of Common Stock being registered in such offering), without the consent of
the underwriters managing such offering, for a period of not more than 180 days following the effective date of the registration statement relating to such offering, if all persons holding in excess of 1% of the capital stock of the Company on a
fully diluted basis and all executive officers and directors of the Company shall be similarly restricted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) The Company
shall not grant to any third party any registration rights more favorable than or inconsistent with any of those contained herein, so long as any of the registration rights under this Agreement remains in effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) If any provision of this Agreement shall be held to be illegal, invalid or unenforceable, such illegality, invalidity or
unenforceability shall attach only to such provision and shall not in any manner affect or render illegal, invalid or unenforceable any other provision of this Agreement, and this Agreement shall be carried out as if any such illegal, invalid or
unenforceable provision were not contained herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) This Agreement, together with the other writings referred to herein or
delivered pursuant hereto which form a part hereof, contains the entire agreement among the parties with respect to the subject matter hereof and amends, restates and supersedes all prior and contemporaneous arrangements or understandings, whether
written or oral, with respect thereto, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 14 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
including without limitation (a)&nbsp;that certain Third Amended and Restated Registration Rights Agreement, dated as of July&nbsp;15, 2008, among the Company, the Founders and the Investors
named therein; (b)&nbsp;that certain Second Amended and Restated Registration Rights Agreement, dated as of May&nbsp;16, 2006, among the Company, the Founders and the Investors named therein, (c)&nbsp;that certain Amended and Restated Registration
Rights Agreement, dated as of October&nbsp;13, 2004, among the Company, the Founders and the Investors named therein, (d)&nbsp;that certain Registration Rights Agreement dated October&nbsp;27, 2003 between the Company and Genzyme Corporation,
(e)&nbsp;that certain Registration Rights Agreement dated as of September&nbsp;15, 2000, by and among the Company and the Investors and Founders named therein, as amended by (i)&nbsp;that certain Amendment No.1 to Registration Rights Agreement dated
as of December&nbsp;4, 2000, by and among the Company, Alexandria Real Estate Equities, L.P. (&#147;<U>ARE</U>&#148;), and the Founders and Investors named therein, (ii)&nbsp;that certain Amendment No.&nbsp;2 to Registration Rights Agreement dated
as of June&nbsp;10, 2002, by and among the Company, the Board of Regents of the University of Texas System (the &#147;<U>University</U>&#148;), and the New Purchasers, Founders and Investors named therein, (iii)&nbsp;that certain Amendment
No.&nbsp;3 to Registration Rights Agreement, dated as of October&nbsp;27, 2003, by and among the Company, the University and the New Purchasers, Founders, and Investors named therein, and (f)&nbsp;Section&nbsp;16 of that certain Warrant for the
Purchase of Shares of Common Stock granted to ARE, dated October&nbsp;31, 2000. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) Notwithstanding anything to the contrary
in this Agreement, the Company and Eli Lilly&nbsp;&amp; Company (&#147;<U>Lilly</U>&#148;) each acknowledge and agree that Lilly shall not have any rights or liabilities under this Agreement unless and until Lilly acquires any Securities pursuant to
that certain Securities Purchase Agreement, dated as of September&nbsp;19, 2008, by and among the Company and the Purchasers (including Lilly) named therein (the &#147;<U>Purchase Agreement</U>&#148;). The terms &#147;Securities&#148; and
&#147;Purchasers&#148;, as used in this Section&nbsp;14(k), shall have the meanings ascribed to such terms in the Purchase Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">[<B><I>Remainder </I></B><B><I>of Page Intentionally Left Blank</I></B>] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 15 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, this Agreement has been executed by the New Investors as of the date
first written above and approved and adopted by the written consent of the Existing Investors and the Series D Investors in accordance with Section&nbsp;14(d) of the Third Amended and Restated Registration Rights Agreement. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., PhD</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President &amp; Chief Executive Officer</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>NEW INVESTORS</U>:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONC PARTNERS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ MARTIN PAUL</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MARTIN PAUL</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DIRECTOR</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">FOR AND ON BEHALF OF ONC GENERAL PARTNER LIMITED, AS GENERAL PARTNER OF ONC PARTNERS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">INNOVIS INVESTMENTS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCUS VENTURES, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>NEW INVESTORS</U>:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONC PARTNERS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">INNOVIS INVESTMENTS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Hans Peter Bissinger</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hans Peter Bissinger</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Partner</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCUS VENTURES, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>NEW INVESTORS</U>:</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ONC PARTNERS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">INNOVIS INVESTMENTS, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARCUS VENTURES, L.P.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ James B Dougherty</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">James B Dougherty</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General Partner</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ELI LILLY AND COMPANY</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALEXANDRIA EQUITIES, LLC,</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware limited liability company</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: ALEXANDRIA REAL ESTATE EQUITIES,&nbsp;INC.,</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Maryland corporation, managing member</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Dean A. Shigenaga</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dean A. Shigenaga</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>FOUNDERS:</U></B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Scott Koenig Family Trust</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trustee:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jeffrey Ravetch</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jeffrey Ravetch</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Leroy Hood</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Leroy Hood</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Alan Aderem</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alan Aderem</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Ruedi Aebersold</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ruedi Aebersold</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Institute for Systems Biology</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Pages to Fourth Amended and Restated Registration Rights Agreement </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Existing Investors </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ventures West 8 Limited Partnership </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rivervest Venture Fund I, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Caisse De Depot
Et Placement du Quebec </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alta Biopharma Partners III, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Alta Biopharma Partners III GMBH&nbsp;&amp; Co. Beteiligungs KG </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alta Embarcadero Biopharma
Partners III, LLC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TPG Ventures, L.P. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TPG Biotechnology Partners, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Red Abbey
Venture Partners (QP), LP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Red Abbey Venture Partners, LP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Red Abbey CEO&#146;s Fund, LP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MPM Bioventures II, L.P. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MPM Bioventures II-QP, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MPM Bioventures
GMBH&nbsp;&amp; Co. Parallel-Beteiligungs KG </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MPM Asset Management Investors 2000 B LLC </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MPM Bioventures IV Strategic Fund LP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interwest
Partners VIII, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interwest Investors VIII, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Interwest Investors Q-VIII, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mirtha Ventures, L.P. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cogene Biotech Ventures, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Orbimed
Associates LLC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Caduceus Private Investments, LP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">UBS Juniper Crossover Fund, L.L.C. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board of Regents of the University of Texas System
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Startech Seed Fund II, L.P. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>Series D Investors </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bear Stearns Health Innoventures Employee Fund, L.P.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bear Stearns Health Innoventures Offshore, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Bear Stearns Health Innoventures, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BSHI Members, L.L.C. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BX, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BioMedical Sciences Investment Fund
Pte Ltd </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biogen Idec MA, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grand
Cathay Venture Capital Co., LTD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grand Cathay Venture Capital III Co., LTD. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Prudence Venture Investment Corp. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CMEA Life Sciences Fund, L.P. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CMEA Ventures Life Sciences 2000, Civil Law Partnership </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CMEA Ventures Life Sciences 2000, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cogene Biotech Ventures, L.P. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jennifer Fonstad </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">H&amp;Q Healthcare Investors
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">H&amp;Q Life Sciences Investors </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Integra Ventures III, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Montgomery RAVEN
Partnership </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MUFG Venture Capital I, Limited Partnership </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pequot Healthcare Venture Fund, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pequot Offshore Private Equity Partners III, L.P.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pequot OHV Fund, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pequot
Private Equity Fund III, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PHCV RAVEN Series D Grantor Trust </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ridgeback Capital Investments L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Saints Capital V, L.P. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2180 Associates Fund VII, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S. Venture
Partners VII, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">USVP Entrepreneur Partners VII-A, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">USVP Entrepreneur Partners VII-B, L.P. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vulcan Capital Venture Capital I LLC </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">HCP Life Science Assets TRS, LLC </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Montgomery&nbsp;&amp; Co., LLC </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">George G.
Montgomery </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Keith W. Marshall </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jeremy
Taylor </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2000 S<SMALL>TOCK</SMALL> O<SMALL>PTION</SMALL>
<SMALL>AND</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Purpose and Eligibility</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purpose of this 2000 Stock Option and Incentive Plan (the &#147;<U>Plan</U>&#148;) of MacroGenics. Inc. (the &#147;<U>Company</U>&#148;) is to provide stock options and other equity interests in the
Company (each, an &#147;<U>Award</U>&#148;) to employees, officers, directors, consultants and advisors of the Company and its Subsidiaries, all of whom are eligible to receive Awards under the Plan. Any person to whom an Award has been granted
under the Plan is called a &#147;<U>Participant</U>.&#148; Additional definitions are contained in Section&nbsp;8. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Administration</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.
<U>Administration by Board of Directors</U>. The Plan will be administered by the Board of Directors of the Company (the &#147;<U>Board</U>&#148;). The Board, in its sole discretion, shall have the authority to grant and amend Awards, to adopt,
amend and repeal rules relating to the Plan and to interpret and correct the provisions of the Plan and any Award. All decisions by the Board shall be final and binding on all interested persons. Neither the Company nor any member of the Board shall
be liable for any action or determination relating to the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. <U>Appointment of Committees</U>. To the extent permitted
by applicable law, the Board may delegate any or all of its powers under the Plan to one or more committees or subcommittees of the Board (a &#147;<U>Committee</U>&#148;). All references in the Plan to the &#147;<U>Board</U>&#148; shall mean such
Committee or the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. <U>Delegation to Executive Officers</U>. To the extent permitted by applicable law, the Board may
delegate to one or more executive officers of the Company who are also directors of the Company the power to grant Awards and exercise such other powers under the Plan as the Board may determine, <I>provided that</I> the Board shall fix the maximum
number of Awards to be granted and the maximum number of shares issuable to any one Participant pursuant to Awards granted by such executive officers. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Stock Available for Awards</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a. <U>Number of Shares</U>. Subject to adjustment under Section&nbsp;3(c), the aggregate number of shares of common stock, $.01 par value per share, of the Company (the &#147;<U>Common Stock</U>&#148;)
that may be issued pursuant to the Plan is 4,000,000 shares. If any Award, or shares of Common Stock issued pursuant to an Award, expires or is terminated, repurchased, surrendered, forfeited or settled in cash (other than repurchases or cash
settlements purported to be made at fair market value), in whole or in part, the Common Stock issued or issuable pursuant to such Award as to which such event has occurred shall again be available for the grant of Awards under the Plan. Shares
issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. <U>Per-Participant Limit</U>. Subject to adjustment under Section&nbsp;3(c), no
Participant may be granted Awards during any one fiscal year to purchase more than 1,000,000 shares of Common Stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.
<U>Adjustment to Common Stock</U>. In the event of any stock split, stock dividend, extraordinary cash dividend, recapitalization, reorganization, merger, consolidation, combination, exchange of shares, liquidation, spin-off, split-up, or other
similar change in capitalization or event, (i)&nbsp;the number and class of securities available for Awards under the Plan and the per-Participant share limit, (ii)&nbsp;the number and class of securities, vesting schedule and exercise price per
share subject to each outstanding Option, (iii)&nbsp;the repurchase price per security subject to repurchase, and (iv)&nbsp;the terms of each other outstanding stock-based Award shall be adjusted by the Company (or substituted Awards may be made) to
the extent the Board shall determine, in good faith, that such an adjustment (or substitution) is appropriate. If Section&nbsp;7(e)(i) applies for any event, this Section&nbsp;3(c) shall not be applicable. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Stock Options</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.
<U>General</U>. The Board may grant options to purchase Common Stock (each, an &#147;<U>Option</U>&#148;) and determine the number of shares of Common Stock to be covered by each Option, the exercise price of each Option and the conditions and
limitations applicable to the exercise of each Option and the Common Stock issued upon the exercise of each Option, including vesting provisions, repurchase provisions and restrictions relating to applicable federal or state securities laws, as it
considers advisable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. <U>Incentive Stock Options</U>. An Option that the Board intends to be an &#147;incentive stock
option&#148; as defined in Section&nbsp;422 of the Code (an &#147;<U>Incentive Stock Option</U>&#148;) shall be granted only to employees of the Company and shall be subject to and shall be construed consistently with the requirements of
Section&nbsp;422 of the Code. The Board and the Company shall have no liability if an Option or any part thereof that is intended to be an Incentive Stock Option does not qualify as such. An Option or any part thereof that does not qualify as an
Incentive Stock Option is referred to herein as a &#147;<U>Nonstatutory Stock Option</U>.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. <U>Exercise Price</U>. The
Board shall establish the exercise price (or determine the method by which the exercise price shall be determined) at the time each Option is granted and specify it in the applicable option agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. <U>Duration of Options</U>. Each Option shall be exercisable at such times and subject to such terms and conditions as the Board may
specify in the applicable option agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">e. <U>Exercise of Option</U>. Options may be exercised only by delivery to the
Company of a written notice of exercise signed by the proper person together with payment in full as specified in Section&nbsp;4(f) for the number of shares for which the Option is exercised. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">f. <U>Payment Upon Exercise</U>. Common Stock purchased upon the exercise of an Option shall
be paid for by one or any combination of the following forms of payment: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) by check payable to the order of the Company;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) except as otherwise explicitly provided in the applicable option agreement, and only if the Common Stock is then
publicly traded, delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price, or delivery by the Participant to the Company of a copy of irrevocable
and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) to the extent explicitly provided in the applicable option agreement, by (x)&nbsp;delivery of shares of Common Stock owned by the Participant valued at fair market value (as determined by the Board
or as determined pursuant to the applicable option agreement), (y)&nbsp;delivery of a promissory note of the Participant to the Company (and delivery to the Company by the Participant of a check in an amount equal to the par value of the shares
purchased), or (z)&nbsp;payment of such other lawful consideration as the Board may determine. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Restricted Stock</U> </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a. <U>Grants</U>. The Board may grant Awards entitling recipients to acquire shares of Common Stock, subject to (i)&nbsp;delivery to the
Company by the Participant of a check in an amount at least equal to the par value of the shares purchased, and (ii)&nbsp;the right of the Company to repurchase all or part of such shares at their issue price or other stated or formula price from
the Participant in the event that conditions specified by the Board in the applicable Award are not satisfied prior to the end of the applicable restriction period or periods established by the Board for such Award (each, a &#147;<U>Restricted Stock
Award</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. <U>Terms and Conditions</U>. The Board shall determine the terms and conditions of any such Restricted
Stock Award. Any stock certificates issued in respect of a Restricted Stock Award shall be registered in the name of the Participant and, unless otherwise determined by the Board, deposited by the Participant, together with a stock power endorsed in
blank, with the Company (or its designee). After the expiration of the applicable restriction periods and upon the request of the Participant, the Company (or such designee) shall deliver the certificates no longer subject to such restrictions to
the Participant or, if the Participant has died, to the beneficiary designated by a Participant, in a manner determined by the Board, to receive amounts due or exercise rights of the Participant in the event of the Participant&#146;s death (the
&#147;<U>Designated Beneficiary</U>&#148;). In the absence of an effective designation by a Participant, Designated Beneficiary shall mean the Participant&#146;s estate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Other Stock-Based Awards</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board shall have the right to grant other Awards based upon the Common Stock having such terms and conditions as the Board may determine, including, without limitation, the grant of shares based upon
certain conditions, the grant of securities convertible into Common Stock and the grant of stock appreciation rights, phantom stock awards or stock units. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>General Provisions Applicable to Awards</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a. <U>Transferability of Awards</U>. Except as the Board may otherwise determine or provide in an Award, Awards shall not be sold, assigned, transferred, pledged or otherwise encumbered by the person to
whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the life of the Participant, shall be exercisable only by the Participant. References to a Participant, to the
extent relevant in the context, shall include references to authorized transferees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. <U>Documentation</U>. Each Award under
the Plan shall be evidenced by a written instrument in such form as the Board shall determine or as executed by an officer of the Company pursuant to authority delegated by the Board. Each Award may contain terms and conditions in addition to those
set forth in the Plan <I>provided</I> that such terms and conditions do not contravene the provisions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.
<U>Board Discretion</U>. The terms of each type of Award need not be identical, and the Board need not treat Participants uniformly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">d. <U>Termination of Status</U>. The Board shall determine the effect on an Award of the disability, death, retirement, authorized leave of absence or other change in the employment or other status of a
Participant and the extent to which, and the period during which, the Participant, or the Participant&#146;s legal representative, conservator, guardian or Designated Beneficiary, may exercise rights under the Award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">e. <U>Acquisition of the Company</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Consequences of an Acquisition</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) <U>Acquisition Intended to be
Accounted for as a Pooling-of-interests</U>. Upon the consummation of an Acquisition intended to be accounted for as a pooling-of-interests: all outstanding Awards shall remain the obligation of the Company or be assumed by the surviving or
acquiring entity, and there shall be automatically substituted for the shares of Common Stock then subject to such Awards the consideration payable with respect to the outstanding shares of Common Stock in connection with the Acquisition.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) <U>Acquisition Intended to be Accounted for under the Purchase Method</U>. Unless otherwise expressly provided in the
applicable Option or Award, upon the occurrence of an Acquisition intended to be accounted for under the purchase method, the Board </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or the board of directors of the surviving or acquiring entity (as used in this Section&nbsp;7(e)(i)(B), also the &#147;<U>Board</U>&#148;), shall, as to outstanding Awards (on the same basis or
on different bases, as the Board shall specify), make appropriate provision, subject to Section&nbsp;7(e)(i)(C), for the continuation of such Awards by the Company or the assumption of such Awards by the surviving or acquiring entity and by
substituting on an equitable basis for the shares then subject to such Awards either (a)&nbsp;the consideration payable with respect to the outstanding shares of Common Stock in connection with the Acquisition, (b)&nbsp;shares of stock of the
surviving or acquiring corporation or (c)&nbsp;such other securities as the Board deems appropriate, the fair market value of which (as determined by the Board in its sole discretion) shall not materially differ from the fair market value of the
shares of Common Stock subject to such Awards immediately preceding the Acquisition. In addition to or in lieu of the foregoing, with respect to outstanding Options, the Board may, upon written notice to the affected optionees, provide that one or
more Options must be exercised, to the extent then exercisable or to be exercisable as a result of the Acquisition in accordance with Section&nbsp;7(e)(i)(C) and as permitted by Section&nbsp;7(i), within a specified number of days of the date of
such notice, at the end of which period such Options shall terminate; or terminate one or more Options in exchange for a cash payment equal to the excess of the fair market value (as determined by the Board in its sole discretion) of the shares
subject to such Options (to the extent then exercisable or to be exercisable as a result of the Acquisition or as permitted by Section&nbsp;7(i)) over the exercise price thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C) <U>Acquisitions Generally</U>. Upon the consummation of an Acquisition, the exercisability of Options, the vesting provisions of
Restricted Stock Awards, and the exercisability of and/or vesting provisions under other stock-based Awards shall be accelerated, if at all, in accordance with the terms and conditions of the written instrument evidencing any such Options.
Restricted Stock Awards or other stock-based Awards approved by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(D) <U>Acquisition Defined</U>. An
&#147;<U>Acquisition</U>&#148; shall mean: (x)&nbsp;the consolidation with or acquisition by another entity in a merger, reorganization, consolidation of other form of business combination in which the other entity is the surviving or successor
entity and the holders of outstanding voting stock of the Company immediately preceding the consummation of such event, shall, immediately following such event, hold, as a group, less than a majority of the voting securities of the surviving or
successor entity; or (y)&nbsp;any sale of all or substantially all of the assets or capital stock of the Company (other than in a spin-off or similar transaction) or (z)&nbsp;any other acquisition of the business of the Company, as determined by the
Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Assumption of Options Upon Certain Events</U>. In connection with a merger or consolidation of an entity with
the Company or the acquisition by the Company of property or stock of an entity, the Board may grant Awards under the Plan in substitution for stock and stock-based awards issued by such entity or an affiliate thereof. The substitute Awards shall be
granted on such terms and conditions as the Board considers appropriate in the circumstances. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) <U>Pooling-of-Interests
Accounting</U>. If the Company proposes to engage in an Acquisition intended to be accounted for as a pooling-of-interests, and in the event that the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
provisions of this Plan or of any Award hereunder, or any actions of the Board taken in connection with such Acquisition, are determined by the Company&#146;s or the acquiring company&#146;s
independent public accountants to cause such Acquisition to fail to be accounted for as a pooling-of-interests, then such provisions or actions shall be amended or rescinded by the Board, without the consent of any Participant, to be consistent with
pooling-of-interests accounting treatment for such Acquisition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) <U>Parachute Awards</U>. Notwithstanding the provisions
of any Option, Restricted Stock Award or other stock-based Award, if, in connection with the consummation of an Acquisition as described in Section&nbsp;7(e)(i)(D), a tax under Section&nbsp;4999 of the Code would be imposed on the Participant (after
taking into account the exceptions set forth in Sections 280G(b)(4) and 280G(b)(5) of the Code), then the number of Awards which shall become exercisable, realizable or vested as provided in such written instrument evidencing such Option, Restricted
Stock Award or other stock-based Award shall be reduced (or delayed), to the minimum extent necessary, so that no such tax would be imposed on the Participant (the Awards not becoming so accelerated, realizable or vested, the &#147;<U>Parachute
Awards</U>&#148;); <I>provided</I>, <I>however</I>, that if the &#147;<U>aggregate present value</U>&#148; of the Parachute Awards would exceed the tax that, but for this sentence, would be imposed on the Participant under Section&nbsp;4999 of the
Code in connection with the Acquisition, then the Awards shall become immediately exercisable, realizable and vested without regard to the provisions of this sentence. For purposes of the preceding sentence, the &#147;<U>aggregate present
value</U>&#148; of an Award shall be calculated on an after-tax basis (other than taxes imposed by Section&nbsp;4999 of the Code) and shall be based on economic principles rather than the principles set forth under Section&nbsp;280G of the Code and
the regulations promulgated thereunder. All determinations required to be made under this Section&nbsp;7(e)(iv) shall be made by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">f. <U>Withholding</U>. Each Participant shall pay to the Company, or make provisions satisfactory to the Company for payment of, any taxes required by law to be withheld in connection with Awards to such
Participant no later than the date of the event creating the tax liability. The Board may allow Participants to satisfy such tax obligations in whole or in part by transferring shares of Common Stock, including shares retained from the Award
creating the tax obligation, valued at their fair market value (as determined by the Board or as determined pursuant to the applicable option agreement). The Company may, to the extent permitted by law, deduct any such tax obligations from any
payment of any kind otherwise due to a Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">g. <U>Amendment of Awards</U>. The Board may amend, modify or terminate
any outstanding Award including, but not limited to, substituting therefor another Award of the same or a different type, changing the date of exercise or realization, and converting an Incentive Stock Option to a Nonstatutory Stock Option,
<I>provided that</I>, except as otherwise provided in Section&nbsp;7(e)(iii), the Participant&#146;s consent to such action shall be required unless the Board determines that the action, taking into account any related action, would not materially
and adversely affect the Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">h. <U>Conditions on Delivery of Stock</U>. The Company will not be obligated to deliver
any shares of Common Stock pursuant to the Plan or to remove restrictions from shares </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
previously delivered under the Plan until (i)&nbsp;all conditions of the Award have been met or removed to the satisfaction of the Company, (ii)&nbsp;in the opinion of the Company&#146;s counsel,
all other legal matters in connection with the issuance and delivery of such shares have been satisfied, including any applicable securities laws and any applicable stock exchange or stock market rules and regulations, and (iii)&nbsp;the Participant
has executed and delivered to the Company such representations or agreements as the Company may consider appropriate to satisfy the requirements of any applicable laws, rules or regulations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">i. <U>Acceleration</U>. The Board may at any time provide that any Options shall become immediately exercisable in full or in part, that
any Restricted Stock Awards shall be free of some or all restrictions, or that any other stock-based Awards may become exercisable in full or in part or free of some or all restrictions or conditions, or otherwise realizable in full or in part, as
the case may be, despite the fact that the foregoing actions may (i)&nbsp;cause the application of Sections 280G and 4999 of the Code if a change in control of the Company occurs, or (ii)&nbsp;disqualify all or part of the Option as an Incentive
Stock Option. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Miscellaneous</U> </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.
<U>Definitions</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) &#147;<U>Company</U>,&#148; for purposes of eligibility under the Plan, shall include any present or
future subsidiary corporations of MacroGenics, Inc., as defined in Section&nbsp;424(f) of the Code (a &#147;<U>Subsidiary</U>&#148;), and any present or future parent corporation of MacroGenics, Inc., as defined in Section&nbsp;424(e) of the Code.
For purposes of Awards other than Incentive Stock Options, the term &#147;<U>Company</U>&#148; shall include any other business venture in which the Company has a direct or indirect significant interest, as determined by the Board in its sole
discretion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) &#147;<U>Code</U>&#148; means the Internal Revenue Code of 1986, as amended, and any regulations promulgated
thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">b. <U>No Right To Employment or Other Status</U>. No person shall have any claim or right to be granted an Award,
and the grant of an Award shall not be construed as giving a Participant the right to continued employment or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its
relationship with a Participant free from any liability or claim under the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">c. <U>No Rights As Stockholder</U>. Subject
to the provisions of the applicable Award, no Participant or Designated Beneficiary shall have any rights as a stockholder with respect to any shares of Common Stock to be distributed with respect to an Award until becoming the record holder
thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">d. <U>Effective Date and Term of Plan</U>. The Plan shall become effective on the date on which it is adopted by the
Board. No Awards shall be granted under the Plan after the completion of ten years from the date on which the Plan was adopted by the Board, but Awards previously granted may extend beyond that date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">e. <U>Amendment of Plan</U>. The Board may amend, suspend or terminate the Plan or any
portion thereof at any time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">f. <U>Governing Law</U>. The provisions of the Plan and all Awards made hereunder shall be
governed by and interpreted in accordance with the laws of Delaware, without regard to any applicable conflicts of law. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Adopted by the Board of Directors on:</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">December&nbsp;13, 2000</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved by the stockholders on:</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">December&nbsp;13, 2000</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 8 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>R<SMALL>EGISTER</SMALL> O<SMALL>F</SMALL> A<SMALL>MENDMENTS</SMALL> </U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:53pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amendment No.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:23pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Section</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics, Inc. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Re:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Grant of Incentive Stock Option</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Shares:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant Date:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Price per share:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting Base Date:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fully-Vested Date:</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option control no.:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expiration Date:</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I am pleased to
confirm that the Company has granted you an option to purchase shares of our common stock under the MacroGenics, Inc. 2000 Equity Incentive Plan. To accept your stock option, please sign the enclosed copy of this letter and return it to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General terms </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your
option is intended to be an incentive option. The basic terms of your option grant are identified in the information block at the top of this offer letter, but other important terms and conditions are described in the plan. We encourage you to
carefully review the plan, a copy of which is attached. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchase and payment </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the plan, your option vests (becomes exercisable) as follows: (i) with regard to 12.5% of the Option Shares, six months after the Vesting Base
Date; and (ii) with regard to the balance of the Option Shares, in fourteen (14) equal quarterly installments commencing six (6) months after the Vesting Base Date (or, if no Vesting Base Date is specified, the Grant Date) and continuing on the last
day of the fourteen (14) quarterly periods thereafter (subject to adjustment of the last quarterly installment to prevent vesting of fractional shares throughout the vesting period), so that all shares will become purchasable on the Fully-Vested
Date shown above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you decide to purchase shares under this option, you will be required to submit a completed exercise agreement on a form
approved by the Company, together with payment for the shares. You may pay for the shares (plus any associated withholding taxes) using cash, a check, a wire transfer or any other form of payment. Shares available under this option must be
purchased, if at all, no later than the Expiration Date. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restrictions on the Shares </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As you know, the shares of the Company have not been registered with the Securities and Exchange Commission, and are not publicly traded. In accepting this option, you agree that your rights to purchase
or resell the option shares are expressly conditioned upon compliance with applicable U.S. federal and state securities laws, and agree to cooperate with the Company to achieve compliance with those laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares you purchase under this option may be subject to other repurchase rights and resale restrictions, including market standoff requirements. Those
rights and restrictions are set forth in Section 15.2 of the plan <I>or</I> the company&#146;s standard form of option exercise agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We
value your efforts and look forward to your continued contribution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely, </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr. Scott Koenig </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I accept this option and agree to the terms of this offer letter and the plan. </B></FONT></P>
<P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="75%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optionee signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>7
<FILENAME>filename7.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.3 </B></FONT></P> <P STYLE="margin-top:72px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2003 EQUITY INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purpose of this Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Definitions and Rules of Interpretation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Definitions</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Rules of Interpretation</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares Subject to this Plan; Term of this Plan</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Number of Award Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Source of Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Term of this Plan</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Administration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1&nbsp;&nbsp;&nbsp;&nbsp;<B>General</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Authority of Administrator</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Scope of Discretion</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Persons Eligible to Receive Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Eligible Individuals</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Terms and Conditions of Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Price</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Term</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Vesting</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Form of Payment</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5&nbsp;&nbsp;&nbsp;&nbsp;<B>Nonassignability of Options</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6&nbsp;&nbsp;&nbsp;&nbsp;<B>Substitute Options</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Incentive Stock Options</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock Appreciation Rights, Stock Awards and Cash Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Appreciation Rights. </B>The following rules apply to SARs<B></B>:<B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Stock Awards</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Cash Awards</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exercise of Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1&nbsp;&nbsp;&nbsp;&nbsp;<B>In General</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2&nbsp;&nbsp;&nbsp;&nbsp;<B>Time of Exercise</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3&nbsp;&nbsp;&nbsp;&nbsp;<B>Issuance of Award Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Certain Transactions and Events</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1&nbsp;&nbsp;<B>In General</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2&nbsp;&nbsp;<B>Changes in Capital Structure</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3&nbsp;&nbsp;<B>Fundamental Transactions</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4&nbsp;&nbsp;<B>Changes of Control</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5&nbsp;&nbsp;<B>Divestiture</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6&nbsp;&nbsp;<B>Dissolution</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7&nbsp;&nbsp;<B>Cut-Back to Preserve Benefits</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Withholding and Tax Reporting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1&nbsp;&nbsp;<B>Tax Withholding Alternatives</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2&nbsp;&nbsp;<B>Reporting of Dispositions</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compliance with Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1&nbsp;&nbsp;<B>Applicable Law</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment or Termination of this Plan or Outstanding Awards</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1&nbsp;&nbsp;<B>Amendment and Termination</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2&nbsp;&nbsp;<B>Stockholder Approval</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3&nbsp;&nbsp;<B>Effect</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reserved Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1&nbsp;&nbsp;<B>Nonexciusivity of this Plan</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2&nbsp;&nbsp;<B>Unfunded Plan</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Special Arrangements Regarding Award Shares</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1&nbsp;&nbsp;<B>Escrows and Pledges</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2&nbsp;&nbsp;<B>Repurchase Rights</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.3&nbsp;&nbsp;<B>Market Standoff</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.4&nbsp;&nbsp;<B>Dividends</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficiaries</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Miscellaneous</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.1&nbsp;&nbsp;<B>Governing Law</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2&nbsp;&nbsp;<B>Determination of Value</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3&nbsp;&nbsp;<B>Reservation of Shares</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.4&nbsp;&nbsp;<B>Electronic Communications</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.5&nbsp;&nbsp;<B>Notices</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2003 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><SMALL>OF</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>ACRO</SMALL>G<SMALL>ENICS</SMALL>, I<SMALL>NC</SMALL>. </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purpose of this Plan</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
purpose of this 2003 Equity Incentive Plan of MacroGenics, Inc. is to enhance the long-term stockholder value of MacroGenics, Inc. by offering opportunities to eligible individuals to participate in the growth in value of the equity of MacroGenics,
Inc. Although this Plan is intended to comply with Rule 701 under the Securities Act, the Company reserves the right, formally or informally, to establish a sub-plan from which grants can be made which are intended to rely on federal and state
exemptions other than Rule 701. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Definitions and Rules of Interpretation</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 <B>Definitions</B>. This Plan uses the following defined terms: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
<B><I>&#147;Administrator&#148;</I></B> means the Board, or the Committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B><I>&#147;Affiliate&#148;</I></B> means a
&#147;parent&#148; or &#147;subsidiary&#148; (as each is defined in Section&nbsp;424 of the Code) of the Company and any other entity that the Board or Committee designates as an &#147;Affiliate&#148; for purposes of this Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B><I>&#147;Applicable Law&#148;</I></B> means any and all laws of whatever jurisdiction, within or without the United States, and
the rules of any stock exchange or quotation system on which Shares are listed or quoted. applicable to the taking or refraining from taking of any action under this Plan, including the administration of this Plan and the issuance or transfer of
Awards or Award Shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B><I>&#147;Award&#148;</I></B> means a Stock Award, SAR, Cash Award, or Option granted in
accordance with the terms of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B><I>&#147;Award Agreement&#148;</I></B> means the document evidencing the grant
of an Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <B><I>&#147;Award Shares&#148;</I></B> means Shares covered by an outstanding Award or purchased under an
Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <B><I>&#147;Awardee&#148;</I></B> means: (i)&nbsp;a person to whom an Award has been granted, including a holder
of a Substitute Award, (ii)&nbsp;a person to whom an Award has been transferred in accordance with all applicable requirements of Sections 6.5. 7(h). 8.1(d). 8.2(f) and 16, and (iii)&nbsp;a person who holds Award Shares subject to any right of
repurchase under Section&nbsp;15.2. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) <B><I>&#147;Board&#148;</I></B> means the board of directors of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <B><I>&#147;Cash Award&#148;</I></B> means the right to receive cash as described in Section&nbsp;8.3. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) <B><I>&#147;Change of Control&#148;</I></B> means any transaction or event that the Board specifies as a Change of Control under
Section&nbsp;10.4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) <B><I>&#147;Code&#148;</I></B> means the Internal Revenue Code of 1986. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) <B><I>&#147;Committee&#148;</I></B> means a committee composed of Company Directors appointed in accordance with the Company&#146;s
charter documents and Section&nbsp;4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) <B><I>&#147;Company&#148;</I></B> means MacroGenics, Inc., a Delaware corporation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) <B><I>&#147;Company Director&#148;</I></B> means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) <B><I>&#147;Consultant&#148;</I></B> means an individual who, or an employee of any entity that, provides bona fide services to the
Company or an Affiliate not in connection with the offer or sale of securities in a capital-raising transaction, but who is not an Employee. Notwithstanding the foregoing, no grant may be made to any entity unless the grant and exercise are made in
reliance of federal and state securities exemptions other than Rule 701 under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(p)
<B><I>&#147;Director&#148;</I></B> means a member of the board of directors of the Company or an Affiliate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q)
<B><I>&#147;Divestiture&#148;</I></B> means any transaction or event that the Board specifies as a Divestiture under Section&nbsp;10.5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(r) <B><I>&#147;Domestic Relations Order&#148;</I></B> means a &#145;domestic relations order&#148; as defined in, and otherwise meeting the requirements of, Section&nbsp;4.14(p) of the Code, except that
reference to a &#147;plan&#148; in that definition shall be to this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(s) <B><I>&#147;Employee&#148;</I></B> means a
regular employee of the Company or an Affiliate, including an officer or Director, who is treated as an employee in the personnel records of the Company or an Affiliate, but not individuals who are classified by the Company or an Affiliate as:
(i)&nbsp;leased from or otherwise employed by a third party, (ii)&nbsp;independent contractors. or (iii)&nbsp;intermittent or temporary workers. The Company&#146;s or an Affiliate&#146;s classification of an individual as an &#147;Employee&#148; (or
as not an &#145;Employee&#148;) for purposes of this Plan shall not be altered retroactively even if that classification is changed retroactively for another purpose as a result of an audit, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
litigation or otherwise. An Awardee shall not cease to be an Employee due to transfers between locations of the Company, or between the Company and an Affiliate, or to any successor to the
Company or an Affiliate that assumes the Awardee&#146;s Awards under Section&nbsp;10. Neither service as a Director nor receipt of a director&#146;s fee shall be sufficient to make a Director an &#147;Employee.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(t) <B><I>&#147;Exchange Act&#148;</I></B> means the Securities Exchange Act of 1934. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(u) <B><I>&#147;Executive&#148;</I></B> means any (i)&nbsp;Director, (ii)&nbsp;officer elected or appointed by the Board, or
(iii)&nbsp;beneficial owner of more than 10% of any class of the Company&#146;s equity securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) <B><I>&#147;Expiration
Date&#148;</I></B> means, with respect to an Award, the date stated in the Award Agreement as the expiration date of the Award or, if no such date is stated in the Award Agreement. then the last day of the maximum exercise period for the Award,
disregarding the effect of an Awardee&#146;s Termination or any other event that would shorten that period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(w)
<B><I>&#147;Fair Market Value&#148;</I></B> means the value of Shares as determined under Section&nbsp;17.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x)
<B><I>&#147;Fundamental Transaction&#148;</I></B> means any transaction or event described in Section&nbsp;10.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(y)
<B><I>&#147;Grant Date&#148;</I></B> means the date the Administrator approves the grant of an Award. However, if the Administrator specifies that an Award&#146;s Grant Date is a future date or the date on which a condition is satisfied, the Grant
Date for such Award is that future date or the date that the condition is satisfied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(z) <B><I>&#147;Incentive Stock
Option&#148;</I></B> means an Option intended to qualify as an incentive stock option under Section&nbsp;422 of the Code and designated as an Incentive Stock Option in the Award Agreement for that Option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(aa) <B><I>&#147;Nonstatutory Option&#148;</I></B> means any Option other than an Incentive Stock Option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(bb) <B><I>&#147;Objectively Determinable Performance Condition&#148;</I></B> shall mean a performance condition (i)&nbsp;that is
established (x)&nbsp;at the time an Award is granted or (y)&nbsp;no later than the earlier of (1)&nbsp;90 days after the beginning of the period of service to which it relates, or (2)&nbsp;before the elapse of 25% of the period of service to which
it relates, (ii)&nbsp;that is uncertain of achievement at the time it is established, and (iii)&nbsp;the achievement of which is determinable by a third party with knowledge of the relevant facts. Examples of measures that may be used in Objectively
Determinable Performance Conditions include net order dollars, net profit dollars, net profit growth, net revenue dollars, revenue growth, individual performance, earnings per share, return on assets, return on equity, and other financial
objectives, objective customer satisfaction indicators and efficiency measures, each with respect to the Company and/or an individual business unit. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(cc) <B><I>&#147;Option&#148;</I></B> means a right to purchase Shares of the Company
granted under this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(dd) <B><I>&#147;Option Price&#148;</I></B> means the price payable under an Option for Shares, not
including any amount payable in respect of withholding or other taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ee) <B><I>&#147;Option Shares&#148;</I></B> means
Shares covered by an outstanding Option or purchased under an Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ff) <B><I>&#147;Plan&#148;</I></B> means this 2003
Equity Incentive Plan of MacroGenics, Inc. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(gg) <B><I>&#147;Purchase Price&#148;</I></B> means the price payable under a
Stock Award for Shares. not including any amount payable in respect of withholding or other taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(hh) <B><I>&#147;Reverse
Vesting&#148;</I></B> means that an Option is or was fully exercisable but that, subject to a &#147;reverse&#148; vesting schedule, the Company has a right to repurchase the Option Shares as specified in Section&nbsp;15.2(a), with the Company&#146;s
right of repurchase expiring in accordance with a &#147;forward&#148; vesting schedule that would otherwise have applied to the Option under which the Option Shares were purchased or in accordance with some other vesting schedule described in the
Award Agreement. With respect to a Stock Award, Reverse Vesting means that the Company has a right to repurchase the Award Shares purchased pursuant to the Stock Award, as specified in Section&nbsp;15.2(a), with the Company&#146;s right of
repurchase expiring in accordance with the vesting schedule in the Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <B><I>&#147;SAR&#148;</I></B>
<B><I>or &#147;Stock Appreciation Right&#148;</I></B> means a right to receive cash based on a change in the Fair Market Value of a specific number of Shares pursuant to an Award Agreement, as described in Section&nbsp;8.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(jj) <B><I>&#147;Securities Act&#148;</I></B> means the Securities Act of 1933. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(kk) <B><I>&#147;Share&#148;</I></B> means a share of the common stock of the Company or other securities substituted for the common
stock under Section&nbsp;10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(11) <B><I>&#147;Stock Award&#148;</I></B> means an offer by the Company to sell shares subject
to certain restrictions pursuant to the Award Agreement as described in Section&nbsp;8.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(mm) <B><I>&#147;Substitute
Award&#148;</I></B> means a Substitute Option, Substitute SAR or Substitute Stock Award granted in accordance with the terms of the Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(nn) <B><I>&#147;Substitute Option&#148;</I></B> means an Option granted in substitution
for, or upon the conversion of, an option granted by another entity to purchase equity securities in the granting entity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(oo) <B><I>&#147;Substitute SAR&#148;</I></B> means a SAR granted in substitution for, or upon the conversion of. a stock appreciation
right granted by another entity with respect to equity securities in the granting entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(pp) <B><I>&#147;Substitute Stock
Award&#148;</I></B> means a Stock Award granted in substitution for, or upon the conversion of, a stock award granted by another entity to purchase equity securities in the granting entity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(qq) <B><I>&#147;Termination&#148;</I></B> means that the Awardee has ceased to be, with or without any cause or reason, an Employee,
Director or Consultant. However, unless so determined by the Administrator. &#147;Termination&#148; shall not include a change in status from an Employee. Consultant or Director to another such status. An event that causes an Affiliate to cease
being an Affiliate shall be treated as the &#147;Termination&#148; of that Affiliate&#146;s Employees, Directors, and Consultants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.2 <B>Rules of Interpretation.</B> Any reference to a &#147;Section,&#148; without more, is to a Section of this Plan. Captions and titles are used for convenience in this Plan and shall not, by
themselves, determine the meaning of this Plan. Except when otherwise indicated by the context, the singular includes the plural and vice versa. Any reference to a statute is also a reference to the applicable rules and regulations adopted under
that statute. Any reference to a statute, rule or regulation, or to a section of a statute, rule or regulation, is a reference to that statute, rule, regulation, or section as amended from time to time, both before and after the effective date of
this Plan and including any successor provisions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Shares Subject to this Plan; Term of this Plan</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.1 <B>Number of Award Shares.</B> Subject to adjustment under Section&nbsp;10, the maximum number of Shares that may be issued under this Plan is 12.617,978. When an Award is granted. the maximum number
of Shares that may be issued under this Plan shall be reduced by the number of Shares covered by that Award. However, if an Award later terminates or expires without having been exercised in full, the maximum number of Shares that may be issued
under this Plan shall be increased by the number of Shares that were covered by, but not purchased under, that Award. By contrast, the repurchase of Shares by the Company shall not increase the maximum number of Shares that may be issued under this
Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <B>Source of Shares.</B> Award Shares may be: (a)&nbsp;Shares that have never been issued, (b)&nbsp;Shares that
have been issued but are no longer outstanding, or (c)&nbsp;Shares that are outstanding and are acquired to discharge the Company&#146;s obligation to deliver Award Shares. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3 <B>Term of this Plan</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) This Plan shall be effective on, and Awards may be granted under this Plan after, the date it is approved by the Board. However, no
Option may be exercised unless and until the Company&#146;s stockholders approve this Plan within 12 months after the Board approves this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to Section&nbsp;13, Awards may be granted under this Plan for a period of ten years from the earlier of the date on which the Board approves this Plan and the date the Company&#146;s
stockholders approve this Plan. Accordingly, Awards may not be granted under the Plan after the earlier of those dates. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1
<B>General.</B> The Board shall have ultimate responsibility for administering this Plan. The Board may delegate certain of its responsibilities to a Committee, which shall consist of at least two members of the Board. Where this Plan specifies that
an action is to be taken or a determination made by the Board, only the Board may take that action or make that determination. Where this Plan specifies that an action is to be taken or a determination made by the Committee, only the Committee may
take that action or make that determination. Where this Plan references the &#147;Administrator.&#148; the action may be taken or determination made by the Board or the Committee. All actions and determinations by any Administrator are subject to
the provisions of this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <B>Authority of Administrator.</B> Subject to the other provisions of this Plan, the
Administrator shall have the authority to: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) grant Awards, including Substitute Awards; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) determine the Fair Market Value of Shares; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) determine the Option Price and the Purchase Price of Awards; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) select the
Awardees; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) determine the times Awards are granted; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) determine the number of Shares subject to each Award; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(g) determine the types of payment that may be used to purchase Award Shares; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) determine the types of payment that may be used to satisfy withholding tax obligations; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) determine the other terms of each Award, including but not limited to the time or times
at which Awards may be exercised, whether and under what conditions an Award is assignable, and whether an Option is a Nonstatutory Option or an Incentive Stock Option; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(j) modify or amend any Award; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) authorize any person to sign any Award
Agreement or other document related to this Plan on behalf of the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) determine the form of any Award Agreement or
other document related to this Plan, and whether that document, including signatures, may be in electronic form; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m)
interpret this Plan and any Award Agreement or document related to this Plan; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) correct any defect, remedy any omission, or
reconcile any inconsistency in this Plan, any Award Agreement or any other document related to this Plan; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o) adopt, amend,
and revoke rules and regulations under this Plan, including rules and regulations relating to sub-plans and Plan addenda; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(p)
adopt, amend, and revoke special rules and procedures which may be inconsistent with the terms of this Plan, set forth (if the Administrator so chooses) in sub-plans regarding (for example) the operation and administration of this Plan and the terms
of Awards, if and to the extent necessary or useful to accommodate non-U.S. Applicable Laws and practices as they apply to Awards and Option Shares held by, or granted or issued to, persons working or resident outside of the United States or
employed by Affiliates incorporated outside the United States; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q) determine whether a transaction or event should be treated
as a Change of Control, a Divestiture or neither; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(r) determine the effect of a Fundamental Transaction and, if the Board
determines that a transaction or event should be treated as a Change of Control or a Divestiture, then the effect of that Change of Control or Divestiture; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(s) make all other determinations the Administrator deems necessary or advisable for the administration of this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.3 <B>Scope of Discretion.</B> Subject to the last sentence of this Section&nbsp;4.3, on all matters for which this Plan confers the authority, right or power on the Board or the Committee, that body may
make those decisions in its sole and absolute discretion. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Those decisions will be final, binding and conclusive. Moreover, but again subject to the last sentence of
this Section&nbsp;4.3, in making those decisions the Board or Committee need not treat all persons eligible to receive Awards, all Awardees, all Awards or all Award Shares the same way. However, except as provided in Section 13.3, the discretion of
the Board or Committee is subject to the specific provisions and specific limitations of this Plan, as well as all rights conferred on specific Awardees by Award Agreements and other agreements. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Persons Eligible to Receive Awards</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.1 <B>Eligible Individuals.</B> Awards (including Substitute Awards) may be granted to, and only to. Employees, Directors and Consultants, including to prospective Employees, Directors and Consultants
conditioned on the beginning of their service for the Company or an Affiliate. However, Incentive Stock Options may only be granted to Employees as provided in Section&nbsp;7(g). </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Terms and Conditions of Options</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following rules apply to all Options: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <B>Price.</B> If an Option is
granted to a person who, at the Grant Date, owns more than 10% of the voting power of the Company or any corporate Affiliate, that Option shall have an Option Price equal to or greater than 110% of the Fair Market Value of the Shares on the Grant
Date. In no event will the Option Price of any Option be less than the par value of the Shares issuable under the Option if that is required by Applicable Law. The Option Price of an Incentive Stock Option shall be subject to Section&nbsp;7(f).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <B>Term.</B> No Option shall be exercisable after its Expiration Date. No Option may have an Expiration Date that is more
than ten years after its Grant Date. Additional provisions regarding the term of Incentive Stock Options are provided in Sections 7(a) and 7(e). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.3 <B>Vesting.</B> Options shall be exercisable: (a)&nbsp;on the Grant Date, or (b)&nbsp;in accordance with a schedule related to the Grant Date. the date the Optionee&#146;s directorship, employment or
consultancy begins, or a different date specified in the Option Agreement. If so provided in the Award Agreement, an Option may be exercisable subject to the application of Reverse Vesting to the Option Shares. Additional provisions regarding the
vesting of Incentive Stock Options are provided in Section&nbsp;7(c). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <B>Form of Payment.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Administrator shall determine the acceptable form and method of payment for exercising an Option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Acceptable forms of payment for all Option Shares are cash, check or wire transfer, denominated in U.S. dollars except as specified
by the Administrator for non-U.S. Employees or non-U.S. sub-plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In addition, the Administrator may permit payment to
be made by any of the following methods: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) other Shares, or the designation of other Shares, which
(A)&nbsp;are &#147;mature&#148; shares for purposes of avoiding variable accounting treatment under generally accepted accounting principles (generally mature shares are those that have been owned by the Optionee for more than six months on the date
of surrender), and (B)&nbsp;have a Fair Market Value on the date of surrender equal to the Option Price of the Shares as to which the Option is being exercised; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) provided that a public market exists for the Shares, consideration received by the Company under a procedure under
which a broker-dealer that is a member of the National Association of Securities Dealers advances funds on behalf of an Optionee or sells Option Shares on behalf of an Optionee (a <B><I>&#147;cashless Exercise Procedure&#148;</I></B>), provided that
if the Company extends or arranges for the extension of credit to an Optionee under any Cashless Exercise Procedure, no Officer or Director may participate in that Cashless Exercise Procedure; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) one or more promissory notes meeting the requirements of Section&nbsp;6.4(e); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) cancellation of any debt owed by the Company or any Affiliate to the Optionee by the Company including without
limitation waiver of compensation due or accrued for services previously rendered to the Company; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) any
combination of the methods of payment permitted by any paragraph of this Section&nbsp;6.4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Administrator may also
permit any other form or method of payment for Option Shares permitted by Applicable Law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The promissory notes referred
to in Section&nbsp;6.4(c)(iii) must be full recourse. Unless the Administrator specifies otherwise after taking into account any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
relevant accounting issues, the notes shall bear interest at a fair market value rate when the Option is exercised. Interest on the notes shall also be at least sufficient to avoid imputation of
interest under Sections 483, 1274, and 7872 of the Code. The notes and their administration shall at all times comply with any applicable margin rules of the Federal Reserve. Consultants may not purchase Option Shares with a note unless the note is
adequately secured by collateral other than the Option Shares. The portion of the Option Price equal to the par value of the Option Shares shall in all events be paid in cash. The notes may also include such other terms as the Administrator
specifies. Payment may not be made by promissory note by Officers or Directors if Shares are registered under Section&nbsp;12 of the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.5 <B>Nonassignability of Options.</B> Except as set forth in any Award Agreement or determined by the Administrator, no Option shall be assignable or otherwise transferable by the Optionee except by
will or by the laws of descent and distribution. However, Options may be transferred and exercised in accordance with a Domestic Relations Order and may be exercised by a guardian or conservator appointed to act for the Optionee. Incentive Stock
Options may only be assigned in compliance with Section&nbsp;7(h). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6 <B>Substitute Options.</B> The Board may cause the
Company to grant Substitute Options in connection with the acquisition by the Company or an Affiliate of equity securities of any entity (including by merger, tender offer, or other similar transaction) or of all or a portion of the assets of any
entity. Any such substitution shall be effective when the acquisition closes. Substitute Options may be Nonstatutory Options or Incentive Stock Options. Unless and to the extent specified otherwise by the Board, Substitute Options shall have the
same terms and conditions as the options they replace, except that (subject to Section&nbsp;10) Substitute Options shall be Options to purchase Shares rather than equity securities of the granting entity and shall have an Option Price determined by
the Board. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Incentive Stock Options</B> </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following rules apply only to Incentive Stock Options and only to the extent these rules are more restrictive than the rules that
would otherwise apply under this Plan. With the consent of the Optionee, or where this Plan provides that an action may be taken notwithstanding any other provision of this Plan, the Administrator may deviate from the requirements of this Section,
notwithstanding that any Incentive Stock Option modified by the Administrator will thereafter be treated as a Nonstatutory Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The Expiration Date of an Incentive Stock Option shall not be later than ten years from its Grant Date, with the result that no Incentive Stock Option may be exercised after the expiration of ten
years from its Grant Date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) No Incentive Stock Option may be granted more than ten years from the date this Plan was
approved by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Options intended to be incentive stock options under Section&nbsp;422 of the Code that are granted
to any single Optionee under all incentive stock option plans of the Company and its Affiliates, including Incentive Stock Options granted under this Plan, may not vest at a rate of more than $100,000 in Fair Market Value of stock (measured on the
grant dates of the options) during any calendar year. For this purpose, an option vests with respect to a given share of stock the first time its holder may purchase that share, notwithstanding any right of the Company to repurchase that share.
Unless the administrator of that option plan specifies otherwise in the related agreement governing the option. this vesting limitation shall be applied by, to the extent necessary to satisfy this $100,000 rule, treating certain stock options that
were intended to be incentive stock options under Section&nbsp;422 of the Code as Nonstatutory Options. The stock options or portions of stock options to be reclassified as Nonstatutory Options are those with the highest option prices, whether
granted under this Plan or any other equity compensation plan of the Company or any Affiliate that permits that treatment. This Section&nbsp;7(c) shall not cause an Incentive Stock Option to vest before its original vesting date or cause an
Incentive Stock Option that has already vested to cease to be vested. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) In order for an Incentive Stock Option to be
exercised for any form of payment other than those described in Section&nbsp;6.4(b), that right must be stated at the time of grant in the Award Agreement relating to that Incentive Stock Option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Any Incentive Stock Option granted to a Ten Percent Stockholder, must have an Expiration Date that is not later than five years from
its Grant Date, with the result that no such Option may be exercised after the expiration of five years from the Grant Date. A <B><I>&#147;Ten Percent Stockholder&#148;</I></B> is any person who, directly or by attribution under Section&nbsp;424(d)
of the Code, owns stock possessing more than ten percent of the total combined voting power of all classes of stock of the Company or of any Affiliate on the Grant Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(f) The Option Price of an Incentive Stock Option shall never be less than the Fair Market Value of the Shares at the Grant Date. The Option Price for the Shares covered by an Incentive Stock Option
granted to a Ten Percent Stockholder shall never be less than 110% of the Fair Market Value of the Shares at the Grant Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) Incentive Stock Options may be granted only to Employees. If an Optionee changes status from an Employee to a Consultant, that
Optionee&#146;s Incentive Stock Options become Nonstatutory Options if not exercised within the time period described in Section&nbsp;7(i). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(h) No rights under an Incentive Stock Option may be transferred by the Optionee, other than by will or the laws of descent and distribution. During the life of the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Optionee, an Incentive Stock Option may be exercised only by the Optionee. The Company&#146;s compliance with a Domestic Relations Order, or the exercise of an Incentive Stock Option by a
guardian or conservator appointed to act for the Optionee, shall not violate this Section&nbsp;7(h). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) An Incentive Stock
Option shall be treated as a Nonstatutory Option if it remains exercisable after, and is not exercised within, the three-month period beginning with the Optionee&#146;s Termination for any reason other than the Optionee&#146;s death or disability
(as defined in Section&nbsp;22(c) of the Code). In the case of Termination due to death, an Incentive Stock Option shall continue to be treated as an Incentive Stock Option if it remains exercisable after, and is not exercised within, the
three-month period after the Optionee&#146;s Termination provided it is exercised before the Expiration Date. In the case of Termination due to disability, an Incentive Stock Option shall be treated as a Nonstatutory Option if it remains exercisable
after, and is not exercised within, one year after the Optionee&#146;s Termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j) An Incentive Stock Option may only be
modified by the Board. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Appreciation Rights, Stock Awards and Cash Awards</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.1 <B>Stock Appreciation Rights.</B> The following rules apply to SARs: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
<B>Term.</B> No SAR shall be exercisable after its Expiration Date. No SAR may have an Expiration Date that is more than ten years after its Grant Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Vesting.</B> SARs shall be exercisable: (a)&nbsp;on the Grant Date, (b)&nbsp;in accordance with a schedule related to the Grant Date, the date the Awardee&#146;s directorship, employment or
consultancy begins, or a different date specified in the Award Agreement, or (c)&nbsp;or upon the achievement of Objectively Determinable Performance Conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Exercise of SARs.</B> Upon the exercise of an SAR, in whole or in part, an Awardee shall be entitled to a payment in an amount equal to the excess of the Fair Market Value of a fixed number of
Shares covered by the exercised portion of the SAR on the date of exercise, over the Fair Market Value of the Shares covered by the exercised portion of the SAR on the Grant Date. The amount due to the Awardee the exercise of a SAR will be paid in
cash or Shares over the period or periods specified in the Award Agreement. An Award Agreement may place limits on the amount that may be paid over any specified period or periods upon the exercise of a SAR, on an aggregate basis or as to any
Awardee. A SAR shall be considered exercised when the Company receives written notice of exercise in accordance with the terms of the Award Agreement from the person entitled to exercise the SAR. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Nonassignability of SARS.</B> Except as set forth in any Award Agreement or
determined by the Administrator, no SAR shall be assignable or otherwise transferable by the Awardee except by will or by the laws of descent and distribution. However, SARs may be transferred and exercised in accordance with a Domestic Relations
Order. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B>Substitute SARs.</B> The Board may cause the Company to grant Substitute SARs in connection with the
acquisition by the Company or an Affiliate of equity securities of any entity (including by merger) or all or a portion of the assets of any entity. Any such substitution shall be effective when the acquisition closes. Unless and to the extent
specified otherwise by the Board, Substitute SARs shall have the same terms and conditions as the options they replace, except that (subject to Section&nbsp;10) Substitute SARs shall be exercisable with respect to the Fair Market Value of Shares
rather than equity securities of the granting entity and shall be on terms that, as determined by the Board in its sole and absolute discretion, properly reflects the substitution. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <B>Stock Awards.</B> The following rules apply to all Stock Awards: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Price.</B> In no event will the Purchase Price of any Stock Award be less than the par value of the Shares issuable under the Stock
Award if that is required by Applicable Law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Term.</B> No Stock Award shall be exercisable after its Expiration Date.
No Stock Award may have an Expiration Date that is more than ten years after its Grant Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Vesting.</B> Stock Awards
shall be exercisable: (a)&nbsp;on the Grant Date, or (b)&nbsp;in accordance with a schedule related to the Grant Date, the date the Awardee&#146;s directorship, employment or consultancy begins, or a different date specified in the Award Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Right of Repurchase.</B> If so provided in the Award Agreement, Award Shares acquired pursuant to a Stock Award may be
subject to Reverse Vesting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B>Form of Payment.</B> The Administrator shall determine the acceptable form and method of
payment for exercising a Stock Award. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Acceptable forms of payment for all Award Shares are cash, check or
wire transfer, denominated in U.S. dollars except as specified by the Administrator for non-U.S. Employees or non-U.S. sub-plans. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) In addition, the Administrator may permit payment to be made by any of the methods permitted with respect to the exercise of Options pursuant to Section&nbsp;6.4. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <B>Nonassignability of Stock Awards.</B> Except as set forth in any Award Agreement or
determined by the Administrator, no Stock Award shall be assignable or otherwise transferable by the Awardee except by will or by the laws of descent and distribution. However, Options may be transferred and exercised in accordance with a Domestic
Relations Order. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <B>Substitute Stock Award.</B> The Board may cause the Company to grant Substitute Stock Awards in
connection with the acquisition by the Company or an Affiliate of equity securities of any entity (including by merger) or all or a portion of the assets of any entity. Unless and to the extent specified otherwise by the Board, Substitute Stock
Awards shall have the same terms and conditions as the options they replace, except that (subject to Section&nbsp;10) Substitute Stock Awards shall be Stock Awards to purchase Shares rather than equity securities of the granting entity and shall
have a Purchase Price that, as determined by the Board in its sole and absolute discretion, properly reflects the substitution. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3 <B>Cash Awards.</B> The following rules apply to all Cash Awards: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Term.</B> No Cash Award shall be payable after its Expiration Date. No Cash Award may have an Expiration Date that is more than ten
years after its Grant Date. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Vesting.</B> Cash Awards shall be payable: (a)&nbsp;on the Grant Date, (b) in accordance
with a schedule related to the Grant Date, the date the Awardee&#146;s directorship, employment or consultancy begins, or a different date specified in the Award Agreement, or (c)&nbsp;or upon the achievement of Objectively Determinable Performance
Conditions. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exercise of Awards</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1
<B>In General.</B> An Award shall be exercisable in accordance with this Plan, the Award Agreement under which it is granted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <B>Time of Exercise.</B> Options and Stock Awards shall be considered exercised when the Company receives: (a)&nbsp;written notice of
exercise from the person entitled to exercise the Option or Stock Award, (b)&nbsp;full payment, or provision for payment. in a form and method approved by the Administrator, for the Shares for which the Option or Stock Award is being exercised, and
(c)&nbsp;with respect to Nonstatutory Options, payment, or provision for payment, in a form approved by the Administrator, of all applicable withholding taxes due upon exercise. An Award may not be exercised for a fraction of a Share. SARs and Cash
Awards shall be considered exercised when the Company receives written notice of the exercise from the person entitled to exercise the SAR or Cash Award. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <B>Issuance of Award Shares.</B> The Company shall issue Award Shares in the name of the
person properly exercising the Award. If the Awardee is that person and so requests, the Award Shares shall be issued in the name of the Awardee and the Awardee&#146;s spouse. The Company shall endeavor to issue Award Shares promptly after an Award
is exercised. However, until Award Shares are actually issued, as evidenced by the appropriate entry on the stock books of the Company or its transfer agent, the Awardee will not have the rights of a stockholder with respect to those Option Shares,
even though the Awardee has completed all the steps necessary to exercise the Award. No adjustment shall be made for any dividend, distribution, or other right for which the record date precedes the date the Award Shares are issued, except as
provided in Section&nbsp;10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4 <B>Termination</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <B><I>In General.</I></B> Except as provided in an Award Agreement or in writing by the Administrator and as otherwise provided in Sections 9.4(b), (c), (d), (e), (f), (g)&nbsp;and (h). after an
Awardee&#146;s Termination the Awardee&#146;s Awards shall be exercisable to the extent (but only to the extent) they are vested on the date of that Termination and only during the three months after the Termination, but in no event after the
Expiration Date. To the extent the Awardee does not exercise an Award within the time specified for exercise, the Award shall automatically terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B><I>Leaves of Absence.</I></B> Unless otherwise provided in the Award Agreement, no Award may be exercised more than three months after the beginning of a leave of absence, other than a personal or
medical leave approved in writing by an authorized representative of the Company with employment guaranteed upon return by such written approval. Awards shall not continue to vest during a leave of absence, unless such leave of absence has been
approved in writing by the Administrator and such written approval provides otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B><I>Death or Disability.</I></B>
Unless otherwise provided by the Administrator or in the Award Agreement. if an Awardee&#146;s Termination is due to death or disability (as determined by the Administrator with respect to all Awards other than Incentive Stock Options and as defined
by Section&nbsp;22(e) of the Code with respect to Incentive Stock Options). all Awards of that Awardee to the extent exercisable at the date of that Termination may be exercised for one year after that Termination, but in no event after the
Expiration Date. In the case of Termination due to death, an Award may be exercised as provided in Section&nbsp;16. In the case of Termination due to disability, if a guardian or conservator has been appointed to act for the Awardee and been granted
this authority as part of that appointment, that guardian or conservator may exercise the Award on behalf of the Awardee. Death or disability occurring after an Awardee&#146;s Termination shall not cause the Termination to be treated as having
occurred due to death or disability. To the extent an Award is not so exercised within the time specified for its exercise, the Award shall automatically terminate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B><I>Divestiture.</I></B> If an Awardee&#146;s Termination is due to a Divestiture, the
Board may take any one or more of the actions described in Section&nbsp;10.3 or 10.4 with respect to the Awardee&#146;s Awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B><I>Retirement.</I></B> Unless otherwise provided in the Award Agreement or determined by the Administrator, if an Awardee&#146;s
Termination is due to the Awardee&#146;s retirement in accordance with the Company&#146;s or an Affiliate&#146;s retirement policy, all Awards of that Awardee to the extent exercisable at the Awardee&#146;s date of retirement may be exercised for
one year after the Awardee&#146;s date of retirement, but in no event after the Expiration Date. To the extent the Awardee does not exercise an Option within the time specified for exercise, the Award shall automatically terminate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <B><I>Severance Programs.</I></B> Unless otherwise provided in the Award Agreement or determined by the Administrator, if an
Awardee&#146;s Termination results from participation in a voluntary severance incentive program of the Company or an Affiliate approved by the Board, all Awards of that Employee to the extent exercisable at the time of that Termination shall be
exercisable for one year after the Awardee&#146;s Termination, but in no event after the Expiration Date. If the Awardee does not exercise an Award within the time specified for exercise, the Award shall automatically terminate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <B><I>Termination for Cause.</I></B> If an Awardee&#146;s Termination is due to Cause, all of the Awardee&#146;s Awards shall
automatically terminate and cease to be exercisable at the time of Termination and the Administrator may rescind any and all exercises of Awards by the Awardee that occurred after the first event constituting Cause. &#147;<B><I>Cause</I></B>&#148;
means employment-related dishonesty, fraud, misconduct, disclosure or misuse of confidential information or other employment-related conduct that is likely to cause significant injury to the Company, an Affiliate or any of their respective
employees, officers or directors (including, without limitation, commission of a felony or similar offense). in each case as determined by the Administrator. &#147;Cause&#148; shall not require that a civil judgment or criminal conviction have been
entered against or guilty plea shall have been made by the Awardee regarding any of the matters referred to in the previous sentence. Accordingly, the Administrator shall be entitled to determine &#147;Cause&#148; based on the Administrator&#146;s
good faith belief. If the Awardee is criminally charged with a felony or similar offense, that shall be a sufficient, but not a necessary, basis for such a belief. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(h) <B><I>Consulting or Employment Relationship.</I></B> Nothing in this Plan or in any Award Agreement, and no Award or the fact that Award Shares remain subject to repurchase rights, shall:
(A)&nbsp;interfere with or limit the right of the Company or any Affiliate to terminate the employment or consultancy of any Awardee at any time, whether with or without cause or reason, and with or without the payment of severance or any other
compensation or payment, or (B)&nbsp;interfere with the application of any provision in any of the Company&#146;s or any Affiliate&#146;s charter documents or Applicable Law relating to the election, appointment, term of office, or removal of a
Director. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Certain Transactions and Events</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.1 <B>In General.</B> Except as provided in this Section&nbsp;10, no change in the capital structure of the Company, merger, sale or other disposition of assets or a subsidiary, change of control,
issuance by the Company of shares of any class of securities convertible into shares of any class, conversion of securities, or other transaction or event shall require or be the occasion for any adjustments of the type described in this Section 10.
Additional provisions with respect to the foregoing transactions are set forth in Section&nbsp;13.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <B>Changes in
Capital Structure.</B> In the event of any stock split, reverse stock split, recapitalization. combination or reclassification of stock, stock dividend, spin-off, or similar change to the capital structure of the Company (not including a Fundamental
Transaction or Change of Control). the Board shall make whatever adjustments it concludes are appropriate to: (a)&nbsp;the number and type of Awards that may be granted under this Plan, (b)&nbsp;the number and type of Options that may be granted to
any individual under this Plan. (c)&nbsp;the Terms of any SAR, (d)&nbsp;the Purchase Price of any Stock Award. (e)&nbsp;the Option Price and number and class of securities issuable under each outstanding Option. and (f)&nbsp;the repurchase price of
any securities substituted for Option Shares that are subject to repurchase rights. The specific adjustments shall be determined by the Board in its sole and absolute discretion. Unless the Board specifies otherwise, any securities issuable as a
result of any such adjustment shall be rounded to the next lower whole security. The Board need not adopt the same rules for each Award or each Awardee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.3 <B>Fundamental Transactions.</B> If the Company merges with another entity in a transaction in which the Company is not the surviving entity or if, as a result of any other transaction or event,
other securities are substituted for the Shares or Shares may no longer be issued (each a &#147;<B><I>Fundamental Transaction</I></B>&#148;), then, notwithstanding any other provision of this Plan. the Board shall accelerate the vesting of any
outstanding Incentive Stock Option by a period of twenty-four (24)&nbsp;months. It is intended that the foregoing acceleration shall not in any way suspend the operation of any vesting schedule. but rather the effect of such acceleration shall be to
deem the Employee to have (only for the purposes of determining the number of shares for which an Incentive Stock Option is exercisable) an additional twenty-four (24)&nbsp;months of service with the Company from and after the date of consummation
of a Fundamental Transaction. In addition to the foregoing acceleration, in the event the Employee&#146;s employment with the Company or the acquiring or surviving entity following the consummation of a Fundamental Transaction is terminated without
Cause or terminates his or her employment for Good Reason (as defined below), then the Incentive Stock Option shall be exercisable in full without regard to the vesting schedule. For purposes of this Section&nbsp;10.3, <B><I>&#147;Good
Reason&#148;</I></B> shall mean, without the Employee&#146;s express written consent, (i)&nbsp;any significant diminution in the Employee&#146;s responsibilities as they exist immediately prior to the date
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of consummation of a Fundamental Transaction or (ii)&nbsp;a requirement that (A)&nbsp;the location in which the Employee perform his principal duties for the Company be changed to a new location
that is outside a radius of 50 miles from the Employee&#146;s principal residence as of the date of consummation of a Fundamental Transaction or (B)&nbsp;the Employee significantly increases his level of employment-related travel after the date of
consummation of a Fundamental Transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Board may also do one or more of the following contingent on the
closing or completion of the Fundamental Transaction: (a)&nbsp;arrange for the substitution, in exchange for Awards, of options to purchase equity securities other than Shares (including, if appropriate, equity securities of an entity other than the
Company) (an &#147;assumption&#148; of Awards) on such terms and conditions as the Board determines are appropriate, (b)&nbsp;accelerate the vesting and termination of outstanding Awards, in whole or in part. so that Awards can be exercised before
or otherwise in connection with the closing or completion of the Fundamental Transaction or event but then terminate, (c)&nbsp;cancel or arrange for the cancellation of Awards in exchange for cash payments to Awardees, and (d)&nbsp;either arrange
for any repurchase rights of the Company with respect to Award Shares to apply to the securities issued in substitution for Shares or terminate repurchase rights on Award Shares. The Board need not adopt the same rules for each Award or each
Awardee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4 <B>Changes of Control.</B> The Board may also, but need not, specify that other transactions or events
constitute a <B><I>&#147;Change of Control&#148;</I></B>. The Board may do that either before or after the transaction or event occurs. Examples of transactions or events that the Board may treat as Changes of Control are: (a)&nbsp;the Company or an
Affiliate is a party to a merger, consolidation, amalgamation, or other transaction in which the beneficial stockholders of the Company, immediately before the transaction, beneficially own securities representing 50% or less of the total combined
voting power or value of the Company immediately after the transaction, (b)&nbsp;any person or entity, including a &#147;group&#148; as contemplated by Section&nbsp;13(d)(3) of the Exchange Act, acquires securities holding 30% or more of the total
combined voting power or value of the Company, or (c)&nbsp;as a result of or in connection with a contested election of Company Directors, the persons who were Company Directors immediately before the election cease to constitute a majority of the
Board. In connection with a Change of Control, notwithstanding any other provision of this Plan, the Board may take any one or more of the actions described in Section&nbsp;10.3. In addition, the Board may extend the date for the exercise of Awards
(but not beyond their original Expiration Date). The Board need not adopt the same rules for each Award or each Awardee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5
<B>Divestiture.</B> If the Company or an Affiliate sells or otherwise transfers equity securities of an Affiliate to a person or entity other than the Company or an Affiliate, or leases, exchanges or transfers all or any portion of its assets to
such a person or entity, then the Board may specify that such transaction or event constitutes a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<B><I>&#147;Divestiture&#148;</I></B>. In connection with a Divestiture, notwithstanding any other provision of this Plan, the Board may take one or more of the actions described in
Section&nbsp;10.3 or 10.4 with respect to Awards or Award Shares held by, for example, Employees, Directors or Consultants for whom that transaction or event results in a Termination. The Board need not adopt the same rules for each Award or each
Awardee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6 <B>Dissolution.</B> If the Company adopts a plan of dissolution, the Board cause Awards to be fully vested and
exercisable (but not after their Expiration Date) before the dissolution is completed but contingent on its completion and may cause the Company&#146;s repurchase rights on Award Shares to lapse upon completion of the dissolution. The Board need not
adopt the same rules for each Award or each Awardee. However, to the extent not exercised before the earlier of the completion of the dissolution or their Expiration Date, Awards shall terminate just before the dissolution is completed. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7 <B>Cut-Back to Preserve Benefits.</B> If the Administrator determines that the net after-tax amount to be realized by any Awardee,
taking into account any accelerated vesting, termination of repurchase rights, or cash payments to that Awardee in connection with any transaction or event addressed in this Section&nbsp;10 would be greater if one or more of those steps were not
taken or payments were not made with respect to that Awardee&#146;s Awards or Award Shares, then and to that extent one or more of those steps shall not be taken and payments shall not be made. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withholding and Tax Reporting</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1 <B>Tax Withholding Alternatives</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B><I>General.</I></B> Whenever
Award Shares are issued or become free of restrictions, the Company may require the Awardee to remit to the Company an amount sufficient to satisfy any applicable tax withholding requirement, whether the related tax is imposed on the Awardee or the
Company. The Company shall have no obligation to deliver Award Shares or release Award Shares from an escrow or permit a transfer of Option Shares until the Awardee has satisfied those tax withholding obligations. Whenever payment in satisfaction of
Awards is made in cash, the payment will be reduced by an amount sufficient to satisfy all tax withholding requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
<B><I>Method of Payment.</I></B> The Awardee shall pay any required withholding using the forms of consideration described in Section&nbsp;6.4(b), except that, in the discretion of the Administrator, the Company may also permit the Awardee to use
any of the forms of payment described in Section&nbsp;6.4(c). The Administrator may also permit Award Shares to be withheld to pay required withholding. If the Administrator permits Award Shares to be withheld, the Fair Market Value of the Award
Shares withheld. as determined as of the date of withholding, shall not exceed the amount determined by the applicable minimum statutory withholding rates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <B>Reporting of Dispositions.</B> Any holder of Option Shares acquired under an
Incentive Stock Option shall promptly notify the Administrator, following such procedures as the Administrator may require, of the sale or other disposition of any of those Option Shares if the disposition occurs during: (a)&nbsp;the longer of two
years after the Grant Date of the Incentive Stock Option and one year after the date the Incentive Stock Option was exercised, or (b)&nbsp;such other period as the Administrator has established. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compliance with Law</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1
<B>Applicable Law.</B> The grant of Awards and the issuance and subsequent transfer of Award Shares shall be subject to compliance with all Applicable Law, including all applicable securities laws. Awards may not be exercised, and Award Shares may
not be transferred, in violation of Applicable Law. Thus, for example, Awards may not be exercised unless: (a)&nbsp;a registration statement under the Securities Act is then in effect with respect to the related Award Shares, or (b)&nbsp;in the
opinion of legal counsel to the Company, those Award Shares may be issued in accordance with an applicable exemption from the registration requirements of the Securities Act and any other applicable securities laws. The failure or inability of the
Company to obtain from any regulatory body the authority considered by the Company&#146;s legal counsel to be necessary or useful for the lawful issuance of any Award Shares or their subsequent transfer shall relieve the Company of any liability for
failing to issue those Award Shares or permitting their transfer. As a condition to the exercise of any Award or the transfer of any Award Shares, the Company may require the Awardee to satisfy any requirements or qualifications that may be
necessary or appropriate to comply with or evidence compliance with any Applicable Law. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment or Termination of this Plan or Outstanding Awards</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.1 <B>Amendment and Termination.</B> The Board may at any time amend, suspend, or terminate this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.2 <B>Stockholder Approval.</B> The Company shall obtain the approval of the Company&#146;s stockholders for any amendment to this Plan if stockholder approval is necessary or desirable to comply with
any Applicable Law or with the requirements applicable to the grant of Awards intended to be Incentive Stock Options. The Board may also, but need not, require that the Company&#146;s stockholders approve any other amendments to this Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <B>Effect.</B> No amendment, suspension, or termination of this Plan, and no modification of any Award even in the
absence of an amendment, suspension, or termination of this Plan, shall impair any existing contractual rights of any Awardee unless the affected Awardee consents to the amendment, suspension, termination, or modification. However, no such consent
shall be required if the Board determines in its sole and absolute discretion that the amendment, suspension, termination, or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
modification: (a)&nbsp;is required or advisable in order for the Company, the Plan or the Award to satisfy Applicable Law, to meet the requirements of any accounting standard or to avoid any
adverse accounting treatment, or (b)&nbsp;in connection with any transaction or event described in Section&nbsp;10, is in the best interests of the Company or its stockholders. The Board may. but need not, take the tax consequences to affected
Awardees into consideration in acting under the preceding sentence. Those decisions will be final, binding and conclusive. Termination of this Plan shall not affect the Administrator&#146;s ability to exercise the powers granted to it under this
Plan with respect to Awards granted before the termination, or Award Shares issued under such Awards, even if those Award Shares are issued after the termination. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Reserved Rights</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1
<B>Nonexclusivity of this Plan.</B> This Plan shall not limit the power of the Company or any Affiliate to adopt other incentive arrangements including, for example, the grant or issuance of stock options, stock, or other equity-based rights under
other plans or independently of any plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2 <B>Unfunded Plan.</B> This Plan shall be unfunded. Although bookkeeping
accounts may be established with respect to Awardees, any such accounts will be used merely as a convenience. The Company shall not be required to segregate any assets on account of this Plan. the grant of Awards, or the issuance of Award Shares.
The Company and the Administrator shall not be deemed to be a trustee of stock or cash to be awarded under this Plan. Any obligations of the Company to any Awardee shall be based solely upon contracts entered into under this Plan. such as Award
Agreements. No such obligations shall be deemed to be secured by any pledge or other encumbrance on any assets of the Company. Neither the Company nor the Administrator shall be required to give any security or bond for the performance of any such
obligations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Special Arrangements Regarding Award Shares</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15.1 <B>Escrows and Pledges.</B> To enforce any restrictions on Award Shares including restrictions related to Reverse Vesting, the Administrator may require their holder to deposit the certificates
representing Award Shares, with stock powers or other transfer instruments approved by the Administrator endorsed in blank, with the Company or an agent of the Company to hold in escrow until the restrictions have lapsed or terminated. The
Administrator may also cause a legend or legends referencing the restrictions to be placed on the certificates. Any Awardee who delivers a promissory note as partial or full consideration for the purchase of Award Shares will be required to pledge
and deposit with the Company some or all of the Award Shares as collateral to secure the payment of the note. However, the Administrator may require or accept other or additional forms of collateral to secure the note and, in any event, the Company
will have full recourse against the maker of the note, notwithstanding any pledge or other collateral. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2 <B>Repurchase Rights</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B><I>Reverse Vesting.</I></B> If an Option or Stock Award is subject to Reverse Vesting, the Company shall have the right, during the
90 days after the Awardee&#146;s Termination, to repurchase any or all of the Award Shares that were unvested as of the date of that Termination at the initial purchase price. The repurchase price shall be paid in cash or, if the Option Shares were
purchased in whole or in part with a promissory note. cancellation of indebtedness under that note, or a combination of those means. The Company may assign this right of repurchase. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B><I>Procedure.</I></B> The Company may, in it sole discretion, exercise any of its repurchase rights under Section&nbsp;15.2. The
Company or its assignee may choose to give the Awardee a written notice of exercise of its repurchase rights under this Section 15.2. However, the Company&#146;s failure to give such a notice shall not affect its rights to repurchase Award Shares.
The Company must, however, tender the repurchase price during the period specified in this Section&nbsp;15.2 for exercising its repurchase rights in order to exercise such rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.3 <B>Market Standoff.</B> If requested by the Company or a representative of its underwriters in connection with a registration of any
securities of the Company under the Securities Act. Awardees or certain Awardees shall be prohibited from selling some or all of their Award Shares during a period not to exceed 180 days after the effective date of a registration statement filed
with respect to the initial public offering of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.4 <B>Dividends.</B> Dividends on Award Shares that are subject
to any restrictions, including Reverse Vesting, shall be subject to the same restriction, including those set forth in this Section&nbsp;15, as the Award Shares on which the dividends were paid. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Beneficiaries</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An Awardee
may file a written designation of one or more beneficiaries who are to receive the Awardee&#146;s rights under the Awardee&#146;s Awards after the Awardee&#146;s death. An Awardee may change such a designation at any time by written notice. If an
Awardee designates a beneficiary, the beneficiary may exercise the Awardee&#146;s Awards after the Awardee&#146;s death. If an Awardee dies when the Awardee has no living beneficiary designated under this Plan, the Company shall allow the executor
or administrator of the Awardee&#146;s estate to exercise the Award or, if there is none, the person entitled to exercise the Option under the Awardee&#146;s will or the laws of descent and distribution. In any case. no Award may be exercised after
its Expiration Date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Miscellaneous</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.1
<B>Governing Law.</B> This Plan, the Award Agreements, and all other agreements entered into under this Plan, and all actions taken under this Plan or in connection with Awards or Award Shares shall be governed by the substantive laws, but not the
choice of law rules, of the State of Delaware. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2 <B>Determination of Value.</B> Fair Market Value shall be determined as
follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B><I>No Established Market.</I></B> If Shares are not traded on any established stock exchange or quoted on a
national market system and are not quoted by a recognized securities dealer, the Board or Committee will determine Fair Market Value in good faith. The Board or Committee will consider the following factors, and any others it considers significant,
in determining Fair Market Value: (i)&nbsp;the price at which other securities of the Company have been issued to purchasers other than Employees. Directors, or Consultants, (ii)&nbsp;the Company&#146;s net worth, prospective earning power, dividend
paying capacity, and non-operating assets, if any, and (iii)&nbsp;any other relevant factors, including the economic outlook for the Company and the Company&#146;s industry, the Company&#146;s position in that industry, the Company&#146;s goodwill
and intellectual property, and the values of securities of other businesses in the same industry. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B><I>Listed
Stock.</I></B> If the Shares are traded on any established stock exchange or quoted on a national market system, Fair Market Value shall be the closing sales price for the Shares as quoted on that stock exchange or system for the date the value is
to be determined (the <B><I>&#147;Value Date&#148;</I></B>) as reported in <I>The Wall Street Journal</I> or a similar publication. If no sales are reported as having occurred on the Value Date, Fair Market Value shall be that closing sales price
for the last preceding trading day on which sales of Shares are reported as having occurred. If no sales are reported as having occurred during the five trading days before the Value Date, Fair Market Value shall be the closing bid for Shares on the
Value Date. If Shares are listed on multiple exchanges or systems, Fair Market Value shall be based on sales or bids on the primary exchange or system on which Shares are traded or quoted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B><I>Stock Quoted by Securities Dealer.</I></B> If Shares are regularly quoted by a recognized securities dealer but selling prices
are not reported on any established stock exchange or quoted on a national market system, Fair Market Value shall be the mean between the high bid and low asked prices on the Value Date. If no prices are quoted for the Value Date, Fair Market Value
shall be the mean between the high bid and low asked prices on the last preceding trading day on which any bid and asked prices were quoted. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B><I>Initial Public Offering.</I></B> The Fair Market Value of Shares on the date, if
any, that the Company makes an initial public offering of Shares shall be the price at which Shares are first offered to the public. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.3 <B>Reservation of Shares.</B> During the term of this Plan, the Company will at all times reserve and keep available such number of Shares as are still issuable under this Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.4 <B>Electronic Communications.</B> Any Award Agreement, notice of exercise of an Award, or other document required or permitted by
this Plan may be delivered in writing or, to the extent determined by the Administrator, electronically. Signatures may also be electronic if permitted by the Administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.5 <B>Notices.</B> Unless the Administrator specifies otherwise, any notice to the Company under any Option Agreement or with respect to any Awards or Award Shares shall be in writing (or, if so
authorized by Section&nbsp;17.4, communicated electronically), shall be addressed to the Secretary of the Company. and shall only be effective when received by the Secretary of the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Adopted by the Board on: January&nbsp;23, 2003 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approved by the stockholders on:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2003 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective
date of this Plan: February&nbsp;21, 2003 (Exemption from registration approved by Maryland Attorney General (Securities Division)). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>8
<FILENAME>filename8.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.4 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics, Inc. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>November&nbsp;19, 2012 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&laquo;FirstName&raquo; &laquo;LastName&raquo; </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Re:</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Grant of Incentive Stock Option </B></FONT></TD></TR></TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Shares: <U>&laquo;Optionshares&raquo;</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant Date: <U>&laquo;Grantdate&raquo;</U></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Price per share: <U>&laquo;Pricepershare&raquo;</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vesting Base Date: <U>&laquo;Vestingbasedate&raquo;</U></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fully-Vested Date: <U>&laquo;Fullyvesteddate&raquo;</U></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option control no.:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Expiration Date: <U>&laquo;Expirationdate&raquo;</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>&laquo;Optioncontrolno&raquo;</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear &laquo;FirstName&raquo;: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">I am pleased to confirm that the Company has granted you an option to purchase shares of our common stock under the MacroGenics, Inc. 2003 Equity Incentive Plan. To accept your stock option, please sign
the enclosed copy of this letter and return it to Lynn Cilinski. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>General terms </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your option is intended to be an incentive option. The basic terms of your option grant are identified in the information block at the top of this offer
letter, but other important terms and conditions are described in the plan. We encourage you to carefully review the plan, which can be found on the MacroGenics intranet under the Finance Department&#146;s shared documents. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchase and payment </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the plan, your option vests (becomes exercisable) as follows: (i)&nbsp;with regard to 12.5% of the Option Shares, six months after the Vesting
Base Date; and (ii)&nbsp;with regard to the balance of the Option Shares, in fourteen (14)&nbsp;equal quarterly installments commencing six (6)&nbsp;months after the Vesting Base Date (or, if no Vesting Base Date is specified, the Grant Date) and
continuing on the last day of the fourteen (14)&nbsp;quarterly periods thereafter (subject to adjustment of the last quarterly installment to prevent vesting of fractional shares throughout the vesting period), so that all shares will become
purchasable on the Fully-Vested Date shown above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you decide to purchase shares under this option, you will be required to submit a
completed exercise agreement on a form approved by the Company, together with payment for the shares. You may pay for the shares (plus any associated withholding taxes) using cash, a check, a wire transfer or any other form of payment. Shares
available under this option must be purchased, if at all, no later than the Expiration Date. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant of Incentive Stock Option </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">November 19, 2012 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"> Page 2 of
 2
 </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restrictions on the Shares </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As you know, the shares of the Company have not been registered with the Securities and Exchange Commission, and are not publicly traded. In accepting
this option, you agree that your rights to purchase or resell the option shares are expressly conditioned upon compliance with applicable U.S. federal and state securities laws, and agree to cooperate with the Company to achieve compliance with
those laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares you purchase under this option may be subject to other repurchase rights and resale restrictions, including market
standoff requirements. Those rights and restrictions are set forth in section 15.2 of the plan <I>or</I> the company&#146;s standard form of option exercise agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We value your efforts and look forward to your continued contribution. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely,</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D.</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I accept this option and agree to the terms of this offer letter and the plan. </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2012</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Optionee signature</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date</FONT></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>9
<FILENAME>filename9.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.8</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.8 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LEASE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LEASE AGREEMENT, made this 31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of May, 2011, by and between RED GATE III LLC (&#147;LANDLORD&#148;) and MACROGENICS, INC. (&#147;TENANT&#148;).
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>W I T N E S S E T H: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEMISE OF PREMISES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord hereby demises unto Tenant, and Tenant hereby leases from Landlord for the term and upon the terms and conditions set forth in
this Lease approximately 41,886 square feet of space in the building located at 9640 Medical Center Drive, Rockville, Maryland (the &#147;Building&#148;), as set forth on Exhibit A, hereto attached, said space being referred to as the
&#147;Premises&#148;. Landlord shall maintain the Building, as required, in accordance with all applicable laws, including, but not limited to the Americans with Disabilities Act of 1990, as amended (the &#147;ADA&#148;). Landlord hereby represents
and warrants that the Building is in full compliance, as required, with the ADA as of the date of this Lease and the Lease Commencement Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TERM </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of this Lease shall be for a period of six (6)&nbsp;years and four (4)&nbsp;months, commencing on the
1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of December 2011 (&#147;Commencement Date&#148;),
and terminating on the 31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of March 2018
(&#147;Expiration Date&#148;), with an option for an additional five (5)&nbsp;years at a Minimum Rent (hereinafter defined) equal to 103% of the Minimum Rent payable by Tenant during the last year of the initial term (with the Minimum Rent
thereafter escalating annually at 3%), and on the same other terms and conditions in this Lease, provided that Tenant shall have given the Landlord written notice of Tenant&#146;s intention to do so at least nine (9)&nbsp;months prior to the
expiration of this Lease and that Tenant is not in default under this Lease beyond any applicable notice and cure period. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Landlord agrees to deliver possession to Tenant of (i)&nbsp;the entire basement of the Building (&#147;Lower Level&#148;) on or before August&nbsp;1, 2011; (ii)&nbsp;the portion of the Premises located on
the third (3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;floor of the Building (3</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor Space&#148;) on or before September&nbsp;1, 2011; and
(iii)&nbsp;the portion of the Premises located on the first (1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;and second (2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;floors of the Building (&#147;1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> and 2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">
Floor Space&#148;) on or before October&nbsp;1, 2011 (each, respectively, an &#147;Early Delivery Date&#148;). In the event the Landlord is not able to deliver possession to Tenant of (x)&nbsp;the Lower Level on or before August&nbsp;1, 2011, and/or
(y)&nbsp;the 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor Space on or before
September&nbsp;1, 2011, and/or (z)&nbsp;the 1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and
2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor Space on or before October&nbsp;1, 2011, because
Landlord has not substantially completed the Landlord&#146;s Work (hereinafter defined) to be performed in such space, the Early Delivery Date for such space shall be extended to the date Landlord&#146;s Work is substantially completed and, if any
Early Delivery Date occurs after December&nbsp;1, 2011, the Commencement Date and Expiration Date shall be similarly extended. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 1 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The date of substantial completion of Landlord&#146;s Work for any space shall be that date
on which all required improvements to be furnished by Landlord in such space as stated in Exhibit &#147;B&#148; have been substantially completed except for punch list items not interfering with Tenant&#146;s use of such space. Rent shall be
pro-rated for any portion of the initial month in which Tenant is required to commence rental payments hereunder, which does not commence with the first day thereof. Tenant shall be responsible for the payment of its pro rata share (based upon the
portion of the Premises occupied after each respective Early Delivery Date and prior to the Commencement Date), taking into account any portion of the Premises previously so occupied by Tenant, of all Operating Expenses (as defined in
Section&nbsp;5.A. below) incurred by Landlord during such period(s). Additionally, Tenant shall be required to maintain insurance in accordance with the requirements of this Lease after the Early Delivery Date of the Lower Level for all occupied
portions of the Premises. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If such inability of Landlord to deliver possession of the Premises extends the Commencement Date
beyond December&nbsp;31, 2011 and causes Tenant to incur a holdover premium i) Landlord shall for the period beginning on December&nbsp;1, 2011, and ending on the date on which the entire Premises have been delivered to Tenant with the
Landlord&#146;s Work substantially completed, abate, or cause to be abated to the extent of the holdover premium incurred by Tenant, in the rent (however described) payable by Tenant under that certain Lease dated January&nbsp;29, 2008, by and
between Tenant and Landlord, whereby Tenant leases space in that certain building located at 4 Research Court, Rockville, Maryland 20850; and (ii)&nbsp;Landlord shall waive and shall cause Landlord&#146;s affiliates which are landlords of Tenant in
other leased facilities to waive, all such holdover premiums. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At any time prior to the Early Delivery Date, Tenant shall have
the right to enter upon the Premises for the purpose of taking measurements and planning for activities and tasks to be undertaken by Tenant after the Early Delivery Date, provided such entry does not unreasonably interfere with or obstruct the
progress of work being done by the Landlord. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Tenant shall
pay to the Landlord an annual rental (herein called &#147;Minimum Rent&#148;) in the amount of Eight Hundred Forty-Four Thousand Two and 90/100 Dollars ($844,002.90), subject to adjustment as hereinafter set forth, payable without deduction or set
off in equal monthly installments of Seventy Thousand Three Hundred Thirty-Three and 58/100 Dollars ($70,333.58) in advance, the first monthly installment of which is due and payable upon signing of the Lease and upon commencement of the term all
subsequent monthly installments due and payable on the first day of each calendar month thereafter during the term of the Lease until the total rent provided for herein is paid. No payment by Tenant or receipt of Landlord of a lesser amount than a
monthly installment of rent herein stipulated, or endorsement or statement on any check or any letter accompanying any check for payment as rent be deemed an accord and satisfaction, and Landlord may accept such check for payment without prejudice
to Landlord&#146;s right to recover the balance of such rent or pursue any other remedy provided for in this Lease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 2 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ABATEMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tenant shall receive a rent abatement totaling Two Hundred Eighty Seven Thousand Four Hundred Ninety Two and 62/100 Dollars ($287,492.63). Such abatement shall be applied to the Minimum Rent payable by
Tenant for the first four and one half (4
<FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">2</SUB></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">) months of initial term (i.e. (assuming that the Commencement Date remains December&nbsp;1, 2011),&nbsp;December 2011,&nbsp;January, February, March and one-half of April 2012). </FONT></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally, Tenant shall receive a further rent abatement totaling Fifty-Four Thousand Seven Hundred Ninety-Three
Dollars and 73/100 ($54,793.73). Such abatement shall be applied to the Minimum Rent payable by Tenant for the first eight and one-half (8<FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT
SIZE="2">/</FONT><FONT SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.1ex">2</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;months of initial term (i.e. (assuming that the Commencement Date remains
December&nbsp;1, 2011),&nbsp;December 2011 through July 2012, and one-half of August 2012. </FONT></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADJUSTMENT OF MINIMUM RENT </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. The Minimum Rent shall be increased at the end of each lease year during the term hereof by three percent (3%)&nbsp;of the rent then
being paid. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additionally Tenant shall pay its pro rata share (94.22%)&nbsp;of the Building insurance and common area
maintenance charges (collectively, &#147;Operating Expenses&#148;) in addition to its pro rata share of the real estate taxes as defined in Section&nbsp;6. Operating Expenses shall not include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ground rent or other rental payments made under any ground lease or underlying lease or loan payments made on account of any loan; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of expanding the Building or the Project and costs of structural repairs, improvements or replacements to the Building or the Project, including structural
repairs to the walls, foundation and floor slabs and the maintenance, repair or replacement of the roof; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of leasing commissions, legal, space planning, construction and other expenses incurred in procuring or retaining tenants for the Building or solely with respect
to individual tenants or occupants of the Building; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of painting, redecorating or other services or work performed solely for the benefit of another tenant, prospective tenant or occupant (other than for the Common
Area); </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Salaries, wages, or other compensation paid to officers or executives of Landlord above the level of Building Manager; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 3 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">in the case of any offsite or other employees who are not assigned full time to the operation, management, maintenance or repair of the Common Area, Landlord shall
reasonably allocate the compensation paid for the wages, salary, or other compensation or benefits paid to such employees among the properties to which such employees are assigned and Operating Expenses shall exclude the portion of such compensation
not reasonably allocated to the Building. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of advertising and public relations and promotional costs associated with the leasing of the Building; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any costs, fines or penalties incurred due to the violation by Landlord of any governmental rule or authority; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any expenses for which Landlord actually receives reimbursement from insurance, other tenants or any other source; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(j)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of repairs, restoration, replacements or other work occasioned by (A)&nbsp;fire, flood, windstorm or other casualty (whether such destruction be total or partial)
and (B)&nbsp;the exercise by governmental authorities of the right of eminent domain (whether such taking be total or partial); </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs incurred in connection with disputes with tenants, other occupants or prospective tenants, or costs and expenses incurred in connection with negotiations or
disputes with employees, consultants, management agents, leasing agents, purchasers or mortgagees of the Building; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs incurred in connection with the original construction of the Building or in connection with any change in the Building including but not limited to construction,
alteration, improvement, consultation, architectural or engineering reconfiguration associated with compliance with the Americans With Disabilities Act and the Clean Air Act; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs of repairing, replacing or otherwise correcting defects (including latent defects) in or inadequacies of (but not the costs of ordinary and customary repair for
normal wear and tear) the initial design or construction of the Building or the costs of repairing, replacing or correcting defects in the initial design or construction of any tenant improvements; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs relating to another tenant&#146;s or occupant&#146;s space which (A)&nbsp;were incurred in rendering any service or benefit to such tenant that Landlord was not
required to provide, or were for a service in excess of the service that the Landlord was required to provide to Tenant hereunder or (B)&nbsp;were otherwise in excess of the Building standard services then being provided by Landlord to all tenants
or other occupants in the Building, whether or not such other tenant or occupant is actually charged therefor by Landlord; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 4 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(o)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs incurred in connection with the sale, financing, refinancing, mortgaging, selling or change of ownership of the Building, including, but not limited to,
attorneys&#146; fees, title insurance premiums, and transfer and recording costs; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(p)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs, fines, interest, penalties, legal fees or costs of litigation incurred due to the late payments of loan payments, taxes and utility bills and other costs
incurred by Landlord&#146;s failure to make such payments when due; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">General overhead and general administrative expenses and accounting, record-keeping and clerical support of Landlord; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(r)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fees for management of the Building or the Project in excess of five percent (5%)&nbsp;of gross collected rents of the Building; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(s)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increased insurance premiums caused by Landlord&#146;s or any other tenant&#146;s hazardous acts and insurance of leasehold improvements in the premises leased or to be
leased to other tenants; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(t)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs incurred for any items to the extent covered by a manufacturer&#146;s, materialman&#146;s, vendor&#146;s or contractor&#146;s warranty; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(u)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Interest on capital invested, bad debt losses, rent losses and reserves for such losses; </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs incurred by Landlord which are associated with the operation of the business of the legal entity which constitutes Landlord as the same is separate and apart from
the costs of the operation of the Building, including legal entity formation and maintenance charges, legal entity accounting (excluding the incremental accounting fees relating to the operation of the Building) and legal fees (other than with
respect to Building operations); </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(w)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">All amounts which would otherwise be included in Operating Expenses which are paid to any affiliate or subsidiary of Landlord to the extent the cost of such services
exceed the market rate for similar services; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Costs or expenses necessitated by or resulting from the gross negligence, misconduct or illegal conduct of Landlord, its agents, or employees; and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(y)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Depreciation and amortization, and costs which under GAAP are capitalized. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In no event will controllable Operating Expenses (i.e., all such charges excluding costs of utilities, insurance, repairs and snow removal) for any year during the term increase by more than four percent
(4%)&nbsp;over the amount of such controllable costs incurred by Landlord during the prior twelve (12)-month period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 5 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Additional Rent Estimates and Adjustments</U>. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) In order to provide for current monthly payments of Additional Rent, Landlord shall provide
Tenant with the Landlord&#146;s estimate of the amount of the charges described in Section&nbsp;5.A. above, together with the amount of Tenant&#146;s Additional Rent which is estimated to result from such charges. Tenant shall pay each month during
the term of this lease one-twelfth (1/12</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;of
Tenant&#146;s pro rata share of Landlord&#146;s estimate of the Operating Expenses. Landlord may revise its estimate of Operating Expenses at any time during a calendar year by written notice to Tenant, setting forth such revised estimate and
Tenant&#146;s pro rata share thereof. In such event, all monthly payments made by Tenant after such notice shall be in an amount calculated on the basis of such revised estimate. Tenant shall, in all cases, continue to make monthly payments of
Operating Expenses based on the last estimate received from Landlord until it receives a revised or updated estimate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) If payment of Additional Rent begins on a date other than
January&nbsp;1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> under this Lease, in order to provide for
current payments of Additional Rent through December&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> of that partial calendar year, Landlord shall provide Tenant with the Landlord&#146;s estimate of Tenant&#146;s Additional Rent for that partial year, stated in monthly increments, resulting from the
charges described in Section&nbsp;5(c)(i) above. Tenant shall make the monthly incremental payments of estimated Additional Rent together with its installments of Minimum Rent. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) After the end of each calendar year, Landlord will as soon as practicable submit to Tenant a statement of the actual
Operating Expenses for the preceding calendar year. Tenant shall pay Landlord, within thirty (30)&nbsp;days of Tenant&#146;s receipt of such statement, the excess, if any, of Tenant&#146;s pro rata share of actual Operating Expenses over the amount
paid by Tenant during the previous year as its share of such charges. If the amount paid by Tenant during the previous year exceeded Tenant&#146;s pro rata share of actual Operating Expenses for the year, the excess shall be credited toward payment
of the next monthly installment of Minimum Rent to be paid by Tenant after Tenant receives said statement from Landlord. If the amount paid by Tenant during the last calendar year of the Lease Term exceeds Tenant&#146;s pro rata share of actual
Operating Expenses for such year, Landlord shall pay Tenant the excess amount within thirty (30)&nbsp;days after Landlord&#146;s submission to Tenant of the aforesaid Operating Expenses statement for such calendar year. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Landlord&#146;s failure or delay in rendering any statement contemplated by this Section shall not constitute a
waiver of Landlord&#146;s right thereafter and during the term of this Lease to render such statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. Within ten
(10)&nbsp;business days after receipt of Landlord&#146;s statement showing actual figures for the year, Tenant shall have the right to request a detailed statement of Operating Expenses prepared by Landlord and copies of Real Estate Tax bills, which
shall be supplied to Tenant within a reasonable time after Tenant&#146;s written request. No such request shall extend the time for payments as set forth in Section&nbsp;5.A. or Section&nbsp;6. Unless Tenant asserts specific error(s) and supports
such errors, in writing, within thirty (30)&nbsp;days after Landlord has complied with Tenant&#146;s request, Tenant shall waive the right to contest the statement of actual </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 6 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
figures for the year submitted by Landlord. If it shall be determined that there is an error in Landlord&#146;s statement, Tenant shall be entitled to a credit for any overpayment. Any payment,
refund or credit made pursuant to Section&nbsp;5.A. or Section&nbsp;6 shall be made without prejudice to any right of Tenant to dispute, or of Landlord to correct, any item(s) as billed pursuant to the provision hereof. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REAL ESTATE TAXES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Tenant is responsible for pro rata share of real estate taxes. The Tenant shall pay, within fifteen (15)&nbsp;days after submission of the bill to Tenant real estate taxes, as additional rent, its proportionate share, which proportionate share shall
be computed at 94.22% of the taxes, but shall exclude any fine, penalty, or interest for late or non-payment of taxes by Landlord. Upon Tenant&#146;s request, Landlord shall provide Tenant with a copy of each tax bill received by Landlord.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any reasonable expense incurred by Landlord (including counsel fees) in contesting any tax increase shall be included as an
item of taxes for the purpose of computing additional rent due Landlord and Tenant&#146;s proportionate share of any refund received by Landlord for tax years or portions thereof falling within the term shall promptly be refunded to Tenant.
Landlord, however, shall be under no obligation to contest any tax increase, but if Tenant requests in writing that Landlord appeal an increased assessment or tax and Landlord elects not to do so, Tenant may contest such at Tenant&#146;s sole cost,
such cost to be reimbursed to Tenant by adding such cost to Tenant&#146;s proportionate share of such refund. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UTILITIES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall
be responsible for the payment of all utilities used or consumed by the Tenant in and upon the Premises. Electric and Gas shall be separately metered, with the cost of such separate meters to be borne by Landlord. Water shall be either separately
metered or an equitable allocation made between the tenants in the Building based on the quantity of water consumed. In the event any utility service to the Premises shall be interrupted for a continuous period of more than five (5)&nbsp;days as a
result of any cause whatsoever and Tenant is unable to use all or a substantial portion of the Premises, the Minimum Rent shall abate until such services are rendered. If such interruption continues for a period of sixty (60)&nbsp;consecutive days
Tenant shall have the right to terminate this Lease by delivery of written notice to Landlord while such interruption is continuing. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as expressly provided above in this Section&nbsp;7, Landlord shall not be liable to Tenant for any damage or inconvenience caused by the cessation or interruption of any utility service, or the
elevators in the Building, occasioned by fire, accident, strike or other cause beyond Landlord&#146;s control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 7 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY DEPOSIT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
shall provide a security deposit in the equal to one (1)&nbsp;months&#146; rent in the amount of Seventy Thousand Three Hundred Thirty-Three and 58/100 Dollars ($70,333.58) at Lease signing. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>USE OF PREMISES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
shall use the Premises only for Office and Laboratory purposes consistent with Tenant&#146;s business, and for no other purpose, except as approved by Landlord in advance, in writing, which approval shall not be unreasonably withheld. Tenant shall
not make any use of the Premises which would disturb the quiet enjoyment of the Landlord or other tenants in the Building or prejudice or increase the fire insurance premium for the Building, and shall comply with all laws and regulations of all
governmental authorities pertaining to Tenant&#146;s use of Premises, including zoning regulations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WASTE REMOVAL </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
shall be responsible for removal of waste generated by Tenant&#146;s operation. This includes waste service fees levied by local jurisdictions. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HAZARDOUS MATERIALS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall be permitted to store Hazardous Materials on the Premises and shall comply with all laws and regulations of all governmental
authorities pertaining to Tenant&#146;s use of the Premises, including, without limitation, all Environmental Laws (as hereinafter defined) and laws pertaining to Hazardous Materials and Air and Water Quality. The term &#147;Hazardous
Materials&#148; means and includes any petroleum products and/or any hazardous toxic or other dangerous waste, substance or material defined as such in the Environmental Laws. The term &#147;Environmental Laws&#148; means the Comprehensive
Environmental Response, Compensation and Liability Act, any &#147;Superfund&#148; or &#147;Superlien&#148; law, or any other federal, state or local statute, law, ordinance, code, regulation, order or decree regulating, relating to, or imposing
liability or standards of conduct concerning the use or storage of Hazardous Materials. All such materials must be completely removed upon expiration of this Lease, and any de-contamination certificates required by the Landlord or any government
authority must be obtained and delivered to the Landlord. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall obtain and maintain, in full force and effect, all
necessary government licenses, permits and approvals legally required for materials used in the conduct of its business. If the presence of any Hazardous Materials on the Premises caused or permitted by Tenant results in any contamination of the
Premises or any portion of the Building or Common Areas, Tenant shall promptly take all actions, at its sole expense, necessary to return the Premises to the condition existing prior to the introduction of such Hazardous Materials, provided that all
such actions shall be subject to the approval of Landlord, which approval shall not be unreasonably withheld. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 8 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the Commencement Date of the Lease and on January&nbsp;1 of each year thereafter, Tenant
shall disclose to Landlord the names and amounts of all Hazardous Materials which are to be stored, used or disposed of on the Premises. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any Hazardous Materials stored or used on the Premises must not in any way prejudice the Landlord&#146;s insurance or increase the fire hazards to a greater extent than necessarily incident to the
business for which the Premises are leased. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall indemnify and hold harmless Landlord, its officers, members and
employees against any and all claims, actions, proceedings or liabilities of any kind to any third party or governmental authority arising out of or in connection with the presence of any Hazardous Materials on the Premises or used in connection
with Tenant&#146;s business, or the violation by Tenant of any applicable Environmental Laws covered by Tenant&#146;s insurance policies. Tenant shall maintain and carry at all times during the term of this Lease an insurance policy which shall
designate Landlord as an additional insured which provides coverage for i) extraction of pollutants from land or water resulting from the discharge, dispersal, seepage, migration, release or escape of pollutants from a specified cause; and ii)
radioactive contamination. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LATE CHARGE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any
installment of Minimum Rent accruing herein shall not be paid within five (5)&nbsp;days of due date, and other sums not paid within fifteen (15)&nbsp;days of due date, more than once in any 12-month period, such installment and other sums shall be
increased without affecting the Landlord&#146;s other rights under this Lease, by a late charge of five percent (5%)&nbsp;of the delinquent installment, anything contained herein to the contrary notwithstanding. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPAIRS AND MAINTENANCE </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall be responsible for all structural repairs, including repairs to the roof and load-bearing walls of the Building, for
maintaining the parking area and sidewalks, and the Common Areas (as hereinafter defined) in the Building. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Tenant shall be
responsible for the maintenance and repair of the Premises and all fixtures, appliances and equipment therein, including, but not limited to, the Heating and Air Conditioning system(s) exclusively serving Tenant&#146;s suite. Landlord will pay for
major Heating and Air Conditioning component replacement and all repairs to the Landlord installed heating and air conditioning system(s) in excess of Four Hundred Dollars ($400.00) per Heating and Air Conditioning unit per occurrence. All major
repairs and replacement will be done by Landlord&#146;s contractor. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall provide its own char service. Tenant, at its
sole expense, shall keep all Tenant fixtures and equipment in the Premises in safe and sanitary condition and good order and repair, together with related plumbing, electrical or other utility service exclusively serving the Premises, whether
installed by Tenant or by Landlord on Tenant&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 9 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
behalf. Subject to the contrary provisions of Section&nbsp;20 below, Tenant shall pay for all damage to the Building and any fixtures and appurtenances related thereto due to the malfunction,
lack of repair, or improper installation of the Tenant&#146;s fixtures and equipment. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COMMON AREAS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition
to the use of the Premises, Tenant, its employees and business invitees shall have the right to use the Common Areas in common with Landlord and other tenants of the Building, their employees and visitors. The term &#147;Common Areas&#148; shall
mean those portions of the Building and the land upon which the Building is erected which Landlord may from time to time designate for Tenant&#146;s non-exclusive use, which may include the entrance, foyer and lobby corridors, lavatories,
stairwells, elevators, and parking areas. All Common Areas shall be subject to the exclusive control of the Landlord. The Landlord shall operate, manage, light and maintain the Common Areas. Landlord reserves the right to change the size, area,
level, location and arrangement of the Common Areas and any such change or rearrangement shall not affect the obligations of the Landlord and Tenant hereunder; provided, however, that for so long as Tenant is occupying at least sixty-seven percent
(67%)&nbsp;of the leasable area of the Building, no such change shall be made without the prior written consent of Tenant, which consent shall not be unreasonably withheld, conditioned or delayed. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD&#146;S WORK PRIOR TO COMMENCEMENT OF TERM </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Landlord shall make the following improvements to the Premises prior to the commencement of the term of the Lease: Construction in accordance with Exhibit B (&#147;Landlord&#146;s Work&#148;). </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TENANT ALTERATIONS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
alterations, improvements, or additions to the demised Premises to be made by Tenant (other than cosmetic changes not costing more than $30,000.00 in any twelve (12)-month period) shall be subject to the written consent of the Landlord, which
consent shall not be unreasonably withheld, provided such alterations and improvements do not weaken the structural integrity of the Building or detract from its dignity and/or uniformity. All alterations and improvements and/or additions made by
Tenant shall remain upon the Premises at the expiration or earlier termination of this Lease and shall become the property of the Landlord, unless Landlord shall, at the time of approval of the alteration, provide written notice to Tenant to remove
the same, in which event Tenant shall remove such alterations, improvements and/or additions, and restore the Premises to the same good order and condition in which it was at the commencement of this Lease, reasonable wear and tear and unavoidable
casualty excepted. Should Tenant fail to do so, Landlord may do so, collecting the reasonable cost and expense thereof from Tenant as additional rent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 10 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TRADE FIXTURES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All trade
fixtures, telephone and computer equipment, and apparatus installed by Tenant in the Premises shall remain the property of Tenant and shall be removed at the expiration or earlier termination of this Lease and, upon such removal, Tenant shall repair
any uninsured damage caused by the removal and shall promptly restore the Premises to their good order and condition. Any such trade fixture not removed prior to such termination shall be considered abandoned property, but such abandonment shall not
release Tenant of its obligation to pay for the cost of removing such trade fixtures and repairing any uninsured damage caused by the removal. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUIET ENJOYMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord
covenants that, upon payment of the rent herein provided and performance by the Tenant of all other covenants herein contained, Tenant shall and may peaceably and quietly have, hold and enjoy the Premises for the term hereof and options. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SURRENDER OF PREMISES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the expiration or termination of this Lease, Tenant shall quit and surrender the Premises to the Landlord broom clean and shall
remove all of its property therefrom. If the removal of any such property shall result in uninsured damage to the Premises, or leaving any holes in the floors, walls or ceiling therein, the Tenant shall make the appropriate repairs with Landlord
approved building materials prior to the expiration of this Lease. The obligation of this paragraph shall survive the termination of the Lease. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INSURANCE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
covenants and agrees to maintain and carry, at all times during the term of this Lease, in companies qualified and authorized to transact business in the State of Maryland, (i)&nbsp;a Causes of Loss - Special Form policy of property insurance
covering tenant improvements to the Premises made at Tenant&#146;s sole cost and Tenant&#146;s fixtures, furniture and equipment in the Premises for their full replacement value and (ii)&nbsp;commercial general liability insurance in amounts of
$1,000,000.00 per person, $1,000,000.00 per occurrence and $1,000,000.00 for damage to property. Tenant will use commercially reasonable efforts to cause all policies of insurance to provide that they may not be canceled, except on thirty
(30)&nbsp;days written notice to Landlord, and all such policies shall name Landlord as an additional insured. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall
procure and maintain throughout the Term of this Lease a policy or policies of insurance, at its sole cost and expense (but subject to Section&nbsp;5), causing the Building and any other related improvements to be insured under a Causes of Loss -
Special Form property insurance policy in an amount equal to the full replacement value of the Building and any such other improvements (excluding the cost of excavation) and a policy of commercial general liability insurance with a combined single
limit of not less than One Million Dollars ($1,000,000,00). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 11 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to the Early Delivery Date, Tenant shall furnish Landlord with satisfactory proof that
the insurance herein provided for is in full force and effect. Each party hereby releases the other party from any and all liability for loss, damage or liability, notwithstanding negligent or intentionally tortuous act or omission of the other
party, its agents, contractors or employees which is covered under the property insurance required to be carried by such party hereunder (or would have been covered had such party carried such insurance) and each party will obtain from its
respective property insurers waivers of subrogation of claims against the other party. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEMNIFICATION </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall indemnify and hold harmless the Landlord from any and all liability, damage, expense, cause of action, or claims arising out of injury to persons on the
Premises or due to Tenant&#146;s use of the Premises, except when resulting from the negligence or willful misconduct of Landlord, its agents, employees, or servants. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall indemnify and save harmless Tenant from any and all liability, damage, expense, cause of action or claims arising from (i)&nbsp;injury to person
occurring in the Building or upon the Land on which the Building is situated, which arises out of the act, failure to act, or negligence of Landlord, its agents, contractors or employees, or (ii)&nbsp;which arise out of Landlord&#146;s breach of, or
default under, this Lease. </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DAMAGE BY FIRE OR CASUALTY </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Premises are damaged by fire or other casualty, but are not thereby rendered untenantable in whole or in part, Landlord, at its own
expense, and subject to the limitations set forth in this Lease, shall cause such damage to be repaired and the Minimum Rent and additional rent shall not be abated. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If, by reason of any damage or destruction, the Premises shall be rendered untenantable in whole or in part and cannot be repaired and made tenantable within one hundred twenty (120)&nbsp;days after such
damage, Landlord or Tenant shall have the right, to be exercised by notice in writing delivered to the other within thirty (30)&nbsp;days of the occurrence of such damage or destruction, to terminate this Lease, whereupon the Minimum Rent and
additional rent shall be adjusted as of the date of such termination. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSIGNMENT OR SUBLETTING </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant acknowledges that Landlord has entered into this Lease because of Tenant&#146;s financial strength, goodwill, ability and expertise
and that accordingly, this lease is personal to Tenant. Taking this into consideration, Tenant shall not assign, mortgage, sublet, pledge or encumber this Lease, in whole or in part, except with the written consent of the Landlord, which shall not
be unreasonably withheld, except that Tenant may assign this Lease or its interest therein or sublease the Premises to Tenant&#146;s parent corporation, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 12 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Tenant&#146;s direct subsidiaries or entities under common control with Tenant or to Tenant&#146;s successor by way of merger, consolidation, sale of assets, joint venture controlled by Tenant,
or partnership of which Tenant is the sole general partner without the consent of Landlord. Tenant agrees that, in the event of any such assignment or subletting, Tenant and its assignee or sublessee shall nevertheless remain jointly and severally
liable for the performance of all terms, covenants, and conditions of this Lease. Landlord&#146;s failure to deny Tenant&#146;s written request for consent within thirty (30)&nbsp;days after receipt shall be deemed a consent to such request.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event the Landlord consents to an assignment of the Lease, any money additional rent or other consideration to be paid
to Tenant for the assignment shall be paid to the Landlord as partial consideration for the Landlord&#146;s consent to the assignment. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event the Landlord consents to a sublease of the Premises, or any portion thereof, Tenant shall pay to the Landlord fifty percent (50%)&nbsp;of any money, rent or other consideration paid to the
Tenant by any subtenant in excess of the pro-rata portion of the rent for such space then being paid by Tenant to Landlord under this Lease, less Tenant&#146;s actual costs of such subletting. All sums payable hereunder by Tenant shall be paid to
Landlord as additional rent immediately upon the receipt thereof by Tenant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBORDINATION AND ATTORNMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Lease shall be subject to and subordinate at all times to the lien of any mortgage and/or deeds of trust and all land leases now or hereafter made on any portion of the Premises, and to all advances
thereunder, provided the mortgagee or trustee named in said mortgage or deed of trust shall agree to recognize this Lease and agrees, in the event of foreclosure, not to disturb the Tenant&#146;s possession hereunder, provided Tenant is not in
default under this Lease. This subordination shall be self-operative and no further instrument of subordination shall be required. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any proceedings are commenced to foreclose any mortgage or deed of trust encumbering the Premises, Tenant agrees to attorn to the purchaser at the foreclosure sale, if requested to do so by any such
purchaser, and to recognize such purchaser as the Landlord under this Lease, provided such purchaser shall recognize Tenant&#146;s tenancy under this Lease and agree that Tenant&#146;s rights hereunder shall not be disturbed so long as Tenant has
not committed any event of default as to which the applicable cure period has expired. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDEMNATION </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the whole of the Premises shall be taken by any public or quasi-public authority under the power of eminent domain, condemnation or conveyance in
lieu thereof, then this Lease shall terminate as of the date on which possession of the Premises is required to be surrendered to the condemning authority and Landlord shall be entitled to the entire amount of any award, including all income, rent,
award or any interest whatsoever in or about such sum which may be paid in connection </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 13 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
with such governmental action. Tenant shall have no claim against Landlord or the condemning authority for the value of the unexpired term of this Lease. Tenant shall have the right to claim,
however, the unamortized cost of any improvements or additions made to the Premises by Tenant at its cost, loss of good will, the value of any Tenant fixtures paid for by Tenant and furnishings and any moving expenses (collectively,
&#147;Tenant&#146;s Claim&#148;). </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a portion of the Premises shall be so taken or conveyed, and if such partial taking or conveyance shall render the Premises unsuitable for the business of the
Tenant, then the term of this Lease shall cease and terminate as of the date on which possession of the portion of the Premises is surrendered to the condemning authority, and Tenant shall have no claim against Landlord or the condemning authority
for the value of any unexpired term of this Lease but will have the right to make Tenant&#146;s Claim against public or quasi-public authority. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event that in Tenant&#146;s reasonable judgment such partial taking or conveyance is not extensive enough to render the Premises untenantable for the business of Tenant, this Lease shall continue
in full force and effect, except that the Minimum Rent shall be reduced in the same proportion that the floor area of the Premises so taken or conveyed bears to such floor area immediately prior to such taking or conveyance. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of such partial taking and continuation of Lease, Landlord shall promptly restore the Premises as an architectural unit and
as nearly as practical to the condition comparable to that which existed prior to the condemnation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EVENTS OF DEFAULT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
occurrence of any of the following shall constitute an event of default hereunder: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure of Tenant to pay installment of Minimum Rent or scheduled payments of Operating Expenses within five (5)&nbsp;days of the due date, or failure of Tenant to pay
within five (5)&nbsp;days following written notice any other sum herein required to be paid by Tenant. Notwithstanding the foregoing, Landlord shall be required to deliver to Tenant written notice of the failure to pay Minimum Rent and/or such
payments of Operating Expenses two (2)&nbsp;times in every twelve (12)-month period, in which event Tenant shall be deemed to be in default only if such failure continues for five (5)&nbsp;business days after receipt of such written notice from
Landlord. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s failure to perform any other covenant or condition of this Lease within thirty (30)&nbsp;days following Tenant&#146;s receipt of written notice from
Landlord, unless the failure is of such a character as to require more than thirty (30)&nbsp;days to cure in which event Tenant&#146;s failure to proceed diligently to cure such failure shall constitute an event of default. </FONT></TD></TR></TABLE>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 14 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD&#146;S REMEDIES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the occurrence of any event of default, Landlord may, at Landlord&#146;s sole option, exercise any or all of the following remedies,
together with any such other remedies as may be available to Landlord at law or in equity. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord may terminate this Lease by giving Tenant written notice of its election to do so, as of a specified date not less than thirty (30)&nbsp;days after the date of
the giving of such notice and this Lease shall then expire on the date so specified, and Landlord shall then be entitled to immediately regain possession of the Premises as if the date had been originally fixed as the expiration date of the term of
this Lease. Landlord may then re-enter upon the Premises, with due process of law, and remove all persons therefrom, the statutory notice to quit or any other notice to quit being hereby expressly waived by Tenant. Tenant expressly agrees that the
exercise by Landlord of the right of re-entry shall not be a bar to or prejudice in any way other legal remedies available to Landlord. In that event, Landlord shall be entitled to recover from Tenant periodically as and for damages an amount equal
to the rent and additional rent reserved in this Lease less any and all amounts received by Landlord from the rental of the Premises to another tenant. Landlord may, in his own name, but as agent for Tenant, re-let the Premises. Any recovery by the
Landlord shall be limited to the rent hereunder (plus any costs incurred in re-letting) less any rent actually paid by the new tenant. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No termination of this Lease or any taking of possession of the Premises shall deprive Landlord of any of its remedies or actions against Tenant for past or future
rent, nor shall the bringing of any action for rent or breach of covenant, or the resort to any other remedy herein provided for the recovery of rent, be construed as a waiver of the right to obtain possession of the Premises.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to any damages becoming due under this paragraph, Landlord shall be entitled to recover from Tenant and Tenant shall pay to Landlord an amount equal to all
expenses, including reasonable attorneys&#146; fees, if any, incurred by the Landlord in recovering possession of the Premises, and all reasonable costs and charges for the care of said Premises while vacant, which damages shall be due and payable
by Tenant to Landlord at such time or times as such expenses are incurred by the Landlord. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of an event of default by Tenant of any of the terms or conditions of this Lease, Landlord shall have the right of injunction and the right to invoke any
remedy allowed by law or in equity as if no specific remedies of Landlord were set forth in this Lease. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If default be made and a compromise and settlement shall be had thereupon, it shall not constitute a future waiver of any covenant herein contained, nor of the Lease
itself. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 15 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27A.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD DEFAULT. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
Landlord defaults in the performance or observance of any of its obligations under this Lease (a &#147;Landlord Default&#148;), Tenant may deliver to Landlord written notice specifying the manner in which Landlord has defaulted (&#147;Default
Notice&#148;), and if such Landlord Default has not been cured by Landlord within thirty (30)&nbsp;consecutive days after the delivery of the Default Notice, or such shorter period after delivery of the Default Notice as may be appropriate in the
case of an emergency, then Tenant shall have the right (but not the obligation) to perform such obligation on Landlord&#146;s account. In the event Tenant cures any such Landlord Default, the reasonable costs and expenses incurred by Tenant
therefor, shall be reimbursed by Landlord within thirty (30)&nbsp;days after receipt of demand and detailed invoice therefor. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RIGHTS OF LANDLORD </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord reserves the following rights with respect to the Premises: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">During normal business hours, upon 24 hours&#146; notice, to go upon and inspect the Premises, and at Landlord&#146;s option, to make repairs, alterations and additions
to the Premises or the Building of which the Premises are a part, provided there is no interference with Tenant&#146;s occupancy. An Agent of the Tenant may be present for inspection, if requested by Tenant. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To display, within sixty (60)&nbsp;days prior to the expiration of this Lease or after notice from either party of intention to terminate this Lease, a &#147;For
Rent&#148; sign, and all of said signs which shall be placed upon such part of the Premises as Landlord shall determine, except on doors leading into the Premises. Prospective purchasers or tenants authorized by Landlord may inspect the Premises
during normal business hours following adequate notice to Tenant. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To install, place upon, or fix to the roof and exterior wall of the Building, equipment, antennae, and any other object or structure of any kind, excluding signage
other than Tenant&#146;s signage, providing the same shall not materially impair the structural integrity, dignity or uniformity of the Building or interfere with Tenant&#146;s occupancy. </FONT></TD></TR></TABLE>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HOLDING OVER </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Tenant
holds possession of the Leased Premises after the Expiration Date or other termination of this Lease, Landlord shall, at its sole option, have the right to treat Tenant as a tenant by the month commencing with the first day after the termination of
the Lease at one hundred fifty percent (150%)&nbsp;of the monthly Minimum Rent paid during the last month of the Term, and upon all the other terms of this Lease, including the provisions of this paragraph. Said holdover term shall terminate upon
thirty (30)&nbsp;days&#146; notice from one party to the other. Notwithstanding the foregoing, nothing contained herein shall be construed as a requirement that Landlord consent to the occupancy or possession of the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 16 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Leased Premises by Tenant after the termination of the Lease, and Landlord, upon said termination of this Lease, if Landlord elects to treat Tenant as a trespasser, shall be entitled to the
benefit of all public general or public laws relating to the speedy recovery of the possession of land and tenements held over by Tenant, whether now or hereafter in force and effect. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WAIVER OF CLAIMS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except
as may result from their gross negligence, willful misconduct, or illegal conduct, Landlord and Landlord&#146;s agents, employees, and contractors shall not be liable for, and Tenant hereby releases all claims for, damages to persons or property
sustained by Tenant (or any person claiming through Tenant) resulting from any fire, accident, occurrence or condition in or upon the Premises or Building, including but not limited to such claims for damage resulting from (1)&nbsp;any defect in or
failure of plumbing, heating or air-conditioning equipment, electric wiring or installation thereof, water pipes, stairs, railings or walks; (2)&nbsp;any equipment or apparatus becoming out of repair; (3)&nbsp;the bursting, leaking or running of any
tank, washstand, water closet, waste pipe, drain or any other pipe or tank, upon or about such building or premises; (4)&nbsp;the backing up of any sewer pipe or downspout; (5)&nbsp;the escape of steam or hot water; (6)&nbsp;water, snow or ice being
upon or coming through the roof or any other place upon or near the Building or Premises or otherwise; (7)&nbsp;the falling of any fixtures, plaster or stucco; (8)&nbsp;broken glass; and (9)&nbsp;any act or omission of occupants of property or
buildings adjoining or contiguous to the Building. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>31.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All notices
required under this Lease shall be given in writing and shall be deemed to be properly serviced if sent by certified or registered United States Mail, postage prepaid, as follows: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Landlord:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">RED GATE III LLC</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">15215 Shady
Grove Road</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 201</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville,
Maryland 20850</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Tenant:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACROGENICS, INC.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical
Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite <U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland 20850</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address as either may have designated from time to time by written notice to the other.
The date of service of such notices shall be the date such notices are deposited in any United States Post Office. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 17 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>32.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COVENANTS OF TENANT </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant covenants and agrees: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To give to Landlord prompt written notice of any accident, fire, or damage occurring on or to the Premises. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To keep the thermostats in the Premises set at a temperature sufficient to prevent freezing of water pipes, fixtures and HVAC units. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To keep the Premises clean, orderly, sanitary, and free from all objectionable odors and from insects, vermin and other pests. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To comply with the requirements of the State, Federal and County statutes, ordinances, and regulations applicable to Tenant and its use of the Premises, and to save
Landlord harmless from penalties, fines, costs, and expenses resulting from failure to do so, provided Tenant shall not be obligated to make structural repairs or alterations to so comply. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall promptly pay all contractors, suppliers of material and persons it engages to perform work and provide materials for construction work on the Premises so
as to minimize the possibility of a lien attaching to the Premises. Should any such lien be made or filed, Tenant shall cause the same to be discharged and released of record by bond or otherwise within ten (10)&nbsp;days of receipt of written
request from Landlord. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant is responsible for the security of the Premises. </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>33.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD&#146;S RIGHT TO ALTER SITE PLAN </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Landlord shall, from time to time, have the right to alter or modify the site plan of the Building and to rearrange the driveways and parking areas, as well as the entrance and exits to the Premises
provided such alteration, modification or rearrangement does not adversely affect Tenant&#146;s parking, the distance from Tenant&#146;s parking area to the Building or Tenant&#146;s access to the Premises. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PARKING SPACES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord
agrees to furnish 2.5 unreserved parking spaces per thousand square feet of space occupied by the Tenant. There shall be no charge to Tenant for parking space use during the Term and any renewals of the Term. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>35.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ENTIRE AGREEMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
Lease contains the entire agreement of the parties. There are no oral agreements existing between them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 18 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUCCESSORS AND ASSIGNS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Lease, and the covenants and conditions herein contained shall inure to the benefit of and be binding upon the Landlord, its
successors and assigns, and shall inure to the benefit of and be binding upon the Tenant, its successors and assigns, if permitted. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>37.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BANKRUPTCY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Tenant
shall make an assignment of its assets for the benefit of creditors, or if Tenant shall file a voluntary petition in bankruptcy, or if any involuntary petition in bankruptcy or for receivership be instituted against the Tenant and the same be not
dismissed within sixty (60)&nbsp;days of the filing thereof, or if Tenant shall be adjudged bankrupt, then and in any of said events, this Lease shall immediately cease and terminate at the option of the Landlord with the same force and effect as
though the date of said event was the date herein fixed for expiration of the term of this Lease. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>38.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NON-DELIVERY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
event the Landlord shall be unable to give possession of the Premises because construction of the Premises is not complete or for any other cause reasonably beyond the control of the Landlord, the Landlord shall not be liable to Tenant for any
damage resulting from failure to give possession; provided, however, if due to delay caused exclusively by Landlord the Commencement Date does not occur on or before February&nbsp;29, 2012, Tenant shall have the right to terminate this Lease by
delivery of written notice to Landlord on or before March&nbsp;6, 2012. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>39.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PARTIAL INVALIDITY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
any term, covenant, or condition of this Lease or the application thereof to any person or circumstance shall be held to be invalid and unenforceable, the remainder of this Lease, and the application of such terms, covenants, or conditions shall be
valid and enforceable to the fullest extent permitted by law. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>40.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORCE MAJEURE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the
exception of those provisions contained herein regarding the payment of rent, the inability of either party to perform any of the terms, covenants or conditions of this Lease shall not be deemed a default if the same shall be due to any cause beyond
the control of that party. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ESTOPPEL CERTIFICATE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Tenant shall from time to time, within ten (10)&nbsp;business days after being requested to do so by the Landlord or any Mortgagee, execute, acknowledge and deliver to the Landlord (or, at the Landlord&#146;s request, to any existing or prospective
purchaser, transferee, assignee or Mortgagee of any or all of the Premises) an instrument in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 19 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
recordable form, certifying (a)&nbsp;that this Lease is unmodified and in full force and effect (or, if there has been any modification thereof, that it is in full force and effect as so
modified, stating therein the nature of such modification); (b)&nbsp;as to the dates to which the Minimum Rent and other charges arising hereunder have been paid; (c)&nbsp;as to the amount of any prepaid Rent or any credit due to the Tenant
hereunder; (d)&nbsp;that the Tenant has accepted possession of the Premises, and the date on which the Term commenced; (e)&nbsp;as to whether, to the best knowledge, information and belief of the signer of such certificate, the Landlord or the
Tenant is then in default in performing any of its obligations hereunder (and, if so, specifying the nature of each such default); and (f)&nbsp;as to any other fact or condition reasonably requested by the Landlord or such other addressee.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>42.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXPANSION </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall
have the first right to expand into the remaining space in the building during its term. The Minimum Rent rate would be at the then current escalated rental rate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>43.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNAGE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall
have the exclusive right to put its name on the building&#146;s facade at Tenant&#146;s expense. Such signage shall comply with any covenants applicable and mutually agreeable between the parties. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>44.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SERVICES TO BE PROVIDED BY LANDLORD. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During Tenant&#146;s occupancy of the Premises, Landlord shall furnish the following services, subject to any limitations contained elsewhere in this lease: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Air conditioning, both heating and cooling (as required by the seasons) at such temperatures and in such amounts as are comparable to those provided in other similar
buildings in Rockville, Maryland, subject, however, to Tenant&#146;s obligation to pay for or toward certain repairs to the Building&#146;s HVAC system as provided in Section&nbsp;13 above (understood that current ductwork for each zone will
accommodate a maximum of two and a half tons of additional capacity). </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hot and cold water at those points of supply provided for general use of other tenants in the Building through fixtures installed by Landlord, provided, however, that
Tenant shall be obligated to maintain and repair at Tenant&#146;s sole cost the water boiler involved. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Routine maintenance and electric lighting service for all common areas and service areas of the Building in the manner and to the extent which is comparable to that
provided in other similar buildings in Rockville, Maryland. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Electrical facilities to furnish to the Premises electricity at the same capacity as that furnished as of June&nbsp;1, 2011. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 20 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Replacement of all Building standard fluorescent bulbs in all common areas of the Building and all incandescent bulb replacement in all common areas, stairwells, and
other common service areas. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Passenger elevator(s) for ingress to and egress from the Premises. </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>45.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LENDER APPROVAL. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord&#146;s execution and delivery of this Lease shall be conclusive evidence of approval by any financial institution possessing the
right to approve leases for space in the Building. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DECONTAMINATION OF PREMISES. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Landlord, at its sole cost, shall obtain and provide to Tenant a report evidencing the decontamination of the Premises prior to the Early Delivery Date. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>47.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>USE OF FURNITURE LEFT IN THE PREMISES. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Landlord agrees that Tenant may use throughout the term and any extension thereof, without charge by Landlord, any office furniture abandoned by the current tenant of the Premises and left in the
Premises. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>48.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BROKER PARTICIPATION. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord and Tenant agree, understand and recognize that there is are no brokers other than CB Richard Ellis, Inc. and Woodmark Commercial
Real Estate (&#147;Brokers&#148;) participating in this transaction and that Landlord will compensate Brokers under terms of a separate agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 21 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF, </B>the parties have caused this Lease Agreement to be executed on the year and date
first written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">RED GATE
III LLC</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Illegible]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ William M. Rickman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">William M. Rickman</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACROGENICS, INC.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Illegible]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 22 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640
Medical Center Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lease Agreement</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Page 23 of 23</FONT></P></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754311st.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754312nd.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754313rd.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g5754314th.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXHIBIT B </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building wide (Premises): </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Repaint; re-carpet; replace damaged, missing or discolored ceiling tiles; clean all HVAC ducts; balance HVAC. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Install risers between floors (no trays) as Landlord will drill holes and install piping. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provide conduit from street to the building. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ensure HVAC can be properly controlled for vivarium, labs and offices. Balance air for labs and airlocks. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Replace or repair rusted cabinetry and casework (applies only to existing items and those mutually agreed). </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insure the existing cold rooms are in good working order </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exterior </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Move cooling units for server room if necessary. Cooling units appear to be 3.5 tons (note: told they were 5 tons). If that is the case an additional
one will be needed to address the additional utilization of the enlarge computer room. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord will spend up to fifteen thousand one hundred dollars ($15,100) to purchase an additional fuel tank selected by Tenant (which complies with
local building and zoning ordinances) for the backup generator that serves the Premises. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Basement&#151;as per Exhibit A </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Modification of room to accommodate the additional autoclave as per design in Exhibit A </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord will spend up to twenty-eight thousand dollars ($28,000) to purchase a boiler selected by Tenant. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Build approx. 3-4 offices (in work-out room) and install kitchenette with sink and cabinets in same area. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Replace flooring in the work out room (VCT/carpet only) </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord will pay for the cost of epoxy resurfacing/surfacing the floor in the clean area as per Exhibit A. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second floor&#151;as per Exhibit A </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remove wall between computer room and adjacent office to increase size of computer room </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clear Plenum Space above Server Room as necessary for expansion </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remove equipment test bench in server room </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Construction of several offices/conference rooms and walls removed. </FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third floor&#151;as per Exhibit A </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chemical hoods removed and bench space created </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Convert tissue culture room and lab space adjacent to conference room to office space </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Construction of several offices/conference rooms </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Floor Plan </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Renovations further undertaken in accordance with the attached floor plan of the Premises </FONT></P></TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>10
<FILENAME>filename10.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.9</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.9 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>213030501 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Macrogenics, Inc. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment to Lease Agreement </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Amendment to Lease Agreement (&#147;AGREEMENT&#148;) made and entered into this 26th day of March 2013, by and between RED GATE III LLC (&#147;LANDLORD&#148;) and MACROGENICS, INC.
(&#147;TENANT&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WITNESSETH: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Whereas</I></B>, the LANDLORD and TENANT entered into a certain lease (&#147;LEASE&#148;) dated May&nbsp;31, 2011, covering 41,886 square feet of space (&#147;PREMISES&#148;) located in 9640 Medical
Center Drive, Rockville, Maryland (&#147;BUILDING&#148;); <I>and</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Now, therefore</I></B>, the parties hereto,
intending to be legally bound, do covenant and agree as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commencing May&nbsp;1, 2013, Four Thousand Three Hundred Eighty One (4,381)&nbsp;rentable square feet (&#147;EXPANSION SPACE&#148;) is added to the PREMISES, thus
increasing total rentable square footage of PREMISES to Forty Six Thousand Two Hundred Sixty Seven (46,267). </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commencing May&nbsp;1, 2013, the TENANT shall occupy One Hundred Percent (100%)&nbsp;of the BUILDING and shall be responsible for all of Utilities, Operating Expenses
and Real Estate Taxes. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commencing September&nbsp;1, 2013, TENANT&#146;S monthly Minimum Rent shall be Eighty Thousand Three and 35/100 Dollars ($80,003.35), and shall increase by three
percent (3%)&nbsp;annually in accordance with the LEASE. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to May&nbsp;1, 2013, TENANT shall have access for establishing and installation of any communication, I.T. or infrastructure. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall supply new building standard paint and carpet to EXPANSION SPACE. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Ratification of LEASE:</I></B> Except as expressly modified or amended by this AGREEMENT, all terms, covenants and conditions of the LEASE shall remain the same. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>In witness whereof</I></B>, LANDLORD and TENANT have caused this AGREEMENT to be executed as of this 26th day of March 2013, and do
hereby declare this AGREEMENT to be binding on them, their respective successors and assigns. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RED GATE III LLC</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ William M. Rickman</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">William M. Rickman</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macrogenics Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical
Center Drive</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 1 of 2</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431exk_pg002.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macrogenics Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical
Center Drive</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">First Amendment</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 2 of 2</FONT></TD></TR></TABLE>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>11
<FILENAME>filename11.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.10</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.10 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>LEASE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LEASE AGREEMENT, made this 2</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of December 2004, by and between W. M. RICKMAN CONSTRUCTION CO.
LLC (&#147;LANDLORD&#148;) and MACRO GENICS, INC. (&#147;TENANT&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WITNESSETH: </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEMISE OF PREMISES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord hereby demises unto Tenant, and Tenant hereby leases from Landlord for the terms and upon the conditions set forth in this Lease
approximately 15,180 square feet of space on the second floor in the building located at 15235 Shady Grove Road, Rockville, Maryland (the &#147;Building&#148;), as set forth on Exhibit A, hereto attached, said space being referred to as the
&#147;Premises.&#148; </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TERM </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of this Lease shall be for a period of 7 years, commencing on the 1</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of December 2004, and terminating on the 30th day of November
2011, with an option for an additional 5 years on the same terms and conditions in this Lease, provided that Tenant shall have given the Landlord written notice of Tenant&#146;s intention to do so at least six (6)&nbsp;months prior to the expiration
of this Lease and that Tenant is not in default under this Lease. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event the Landlord is not able to deliver possession
of the Premises to Tenant because the W. M. Rickman Construction Co. LLC and Charles River Laboratories, Inc. fail to execute a Lease Termination Agreement between them for the Premises this Lease Agreement is null and void. Should the W. M. Rickman
Construction Co. LLC and Charles River Laboratories, Inc. execute a Lease Termination Agreement, then this Lease shall commence upon the termination of the lease between W. M. Rickman Construction Co. LLC and Charles River Laboratories, Inc. which
is anticipated to be no later than January&nbsp;1, 2005. Should the commencement date extend past December&nbsp;1, 2004, the expiration date shall be similarly extended. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Further, should the Lease Termination Agreement not be signed by January&nbsp;1, 2005 this Lease is null and void. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Tenant shall
pay to the Landlord an annual rental (herein called &#147;Minimum Rent&#148;) in the amount of Three Hundred Thirty Three Thousand Nine Hundred Sixty and NO/100 DOLLARS ($333,960.00), subject to adjustment as hereinafter set forth, payable without
deduction or set off in equal monthly installments of Twenty Seven Thousand Eight Hundred Thirty and NO/100 DOLLARS ($27,830.00) in advance, the first installment of which is due and payable upon signing of the Lease and upon commencement ail
subsequent installments due and payable on the first day of each calendar month thereafter during the term of the Lease until the total rent provided for herein is paid. No payment by Tenant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 1</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">or receipt of Landlord of a lesser amount than a monthly installment of rent herein
stipulated, or endorsement or statement on any check or any letter accompanying any check for payment as rent be deemed an accord and satisfaction, and Landlord may accept such check for payment without prejudice to Landlord&#146;s right to recover
the balance of such rent or pursue any other remedy provided for in this Lease. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADJUSTMENT OF MINIMUM RENT </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Minimum Rent shall be increased at the end of each lease year during the term hereby by three percent (3%)&nbsp;of the rent then being
paid. There shall be no additional pass-throughs of increases in operating expenses except for real estate taxes or as otherwise provided for herein. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REAL ESTATE TAXES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
event the real estate taxes levied or assessed against the land and Building on which the Premises are a part in future tax years are greater than the real estate taxes for the Base Year, the Tenant shall pay within fifteen (15)&nbsp;days after
submission of the bill to Tenant for the increase in real estate taxes, as additional rent, a proportionate share of such increase, which proportionate share shall be computed at 31.2% of the increase in taxes, but shall exclude any fine, penalty,
or interest charge for late or non-payment of taxes by Landlord. The Base Year shall be July&nbsp;1, 2004, to June&nbsp;30, 2005. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any reasonable expense incurred by Landlord (including counsel fees) in contesting any tax increase shall be included as an item of taxes for the purpose of computing additional rent due Landlord.
Landlord, however, shall be under no obligation to contest any tax increase. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>UTILITIES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall
be responsible for the payment of all utilities used or consumed by the Tenant in and upon the Premises. Electric and Gas shall be separately metered. Water shall be either separately metered or an equitable allocation made between the Tenants in
the Building based on the quantity of water consumed. In the event any utility service to the Premises shall be interrupted for a continuous period of more than two (2)&nbsp;days due to the gross negligence or willful misconduct of Landlord, its
agents or servants, the Minimum Rent shall abate until such services are rendered. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall not be liable to Tenant for
any damage or inconvenience caused by the cessation or interruption of any utility service, or the elevators in the Building, occasioned by fire, accident, strike or other cause beyond Landlord&#146;s control. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>USE OF PREMISES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
shall use the Premises only for Research Laboratories, Office, and Manufacturing purposes consistent with Tenant&#146;s business, and for no other purpose, except as approved by Landlord in advance, in writing, which approval shall not be
unreasonably withheld. Tenant shall not make any use of the Premises which would disturb the quiet enjoyment of the Landlord or other tenants in the Building or prejudice or increase the fire insurance premium for the Building, and shall comply with
all laws and regulations of all governmental authorities pertaining to Tenant&#146;s use of Premises. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 2</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WASTE REMOVAL </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
shall be responsible for removal of waste generated by Tenant&#146;s operation. This includes waste service fees levied by local jurisdictions. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HAZARDOUS MATERIALS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall be permitted to store Hazardous Materials on the Premises and shall comply with all laws and regulations of all governmental
authorities pertaining to Tenant&#146;s use of the Premises, including, without limitation, all Environmental Laws (as hereinafter defined) and laws pertaining to Hazardous Materials and Air and Water Quality. The term &#147;Hazardous
Materials&#148; means and includes any petroleum products and/or any hazardous toxic or other dangerous waste, substance or material defined as such in the Environmental Laws. The term &#147;Environmental Laws&#148; means the Comprehensive
Environmental Response, Compensation and Liability Act, any &#147;Superfund&#148; or &#147;Superlien&#148; law, or any other federal, state or local statute, law, ordinance, code, regulation, order or decree regulating, relating to, or imposing
liability or standards of conduct concerning the use or storage of Hazardous Materials. All such materials must be completely removed upon expiration of this Lease, and any de-contamination certificates required by the Landlord or any government
authority must be obtained and delivered to the Landlord. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall obtain and maintain, in full force and effect, all
necessary government licenses, permits and approvals legally required for materials used in the conduct of its business. If the presence of any Hazardous Materials on the Premises caused or permitted by Tenant results in any contamination of the
Premises or any portion of the Building or Common Areas, Tenant shall promptly take all actions, at its sole expense, necessary to return the Premises to the condition existing prior to the introduction of such Hazardous Materials, provided that all
such actions shall be subject to the approval of Landlord, which approval shall not be unreasonably withheld. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">At the
Commencement Date of the Lease and on January&nbsp;1 of each year thereafter, Tenant shall disclose to Landlord the names and amounts of all Hazardous Materials which are to be stored, used or disposed of on the Premises. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any Hazardous Materials stored or used on the Premises must not in any way prejudice the Landlord&#146;s insurance or increase the fire
hazards to a greater extent than necessarily incident to the business for which the Premises are leased. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LATE CHARGE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any
installment of rent accruing herein shall not be paid within five (5)&nbsp;days of due date, and other sums not paid within fifteen (15)&nbsp;days after written notice to Tenant, such installment and other sums shall be increased without affecting
the Landlord&#146;s other rights under this Lease, by a late charge of ten percent (10%)&nbsp;of the delinquent installment. Anything contained herein to the contrary notwithstanding. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPAIRS AND MAINTENANCE </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall be responsible for all structural repairs, including repairs to the roof and load-bearing walls of the Building, for
maintaining the parking area and sidewalks, and the Common Areas (as hereinafter defined) in the Building. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 3</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Tenant shall be responsible for the maintenance and repair of the Premises and all
fixtures, appliances and equipment therein, including, but not limited to, the Heating and Air Conditioning system(s) serving Tenant&#146;s suite. Landlord will pay for major Heating and Air Conditioning component replacement and all repairs to the
Landlord installed heating and air conditioning system(s) in excess of Three Hundred Dollars ($300.00) per occurrence per Heating and Air Conditioning unit. The Trane HVAC Units and other equipment installed by the previous tenant is the sole
responsibility of Macro Genics, Inc. to service and repair; Landlord will not pay for any maintenance or repairs to these units/equipment. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Tenant shall provide its own char service. Tenant, at its sole expense, shall keep all Tenant fixtures and equipment in the Premises in safe and sanitary condition and good order and repair, together with
related plumbing, electrical or other utility service, whether installed by Tenant or by Landlord on Tenant&#146;s behalf. Tenant shall pay for all damage to the Building and any fixtures and appurtenances related thereto due to the malfunction,
lack of repair, or improper installation of the Tenant&#146;s fixtures and equipment, </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COMMON AREAS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition
to the use of the Premises, Tenant, its employees and business invitees shall have the right to use the Common Areas in common with Landlord and other tenants of the Building, their employees and visitors. The term &#147;Common Areas&#148; shall
mean those portions of the Building and the land upon which the Building is erected which Landlord may from time to time designate for Tenant&#146;s non-exclusive use, which may include the entrance, foyer and lobby corridors, lavatories,
stairwells, elevators, and parking areas. All Common Areas shall be subject to the exclusive control of the Landlord. The Landlord shall operate, manage, light and maintain the Common Areas. Landlord reserves the right to change the size, area,
level, location and arrangement of the Common Areas and any such change or rearrangement shall not affect the obligations of the Landlord and Tenant hereunder. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD&#146;S WORK PRIOR TO COMMENCEMENT OF TERM </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">None. Landlord delivers the Premises &#147;As Is.&#148; Landlord will reimburse Tenant up to $27,830.00 for carpet and up to $27,830.00 for paint when Tenant has presented paid invoices to Landlord
showing the work has been completed and Landlord has inspected the work. All coordination for this work is the responsibility of the Tenant. This offer is null and void after December&nbsp;31, 2005. Landlord will replace damaged and stained ceiling
tiles. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TENANT ALTERATIONS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
alterations, improvements, or additions to the demised Premises to be made by Tenant shall be subject to the written consent of the Landlord, which consent shall not be unreasonably withheld, provided such alterations and improvements do not weaken
the structural integrity of the Building or detract from its dignity and/or uniformity. All alterations and improvements and/or additions made by Tenant shall remain upon the Premises at the expiration or earlier termination of this Lease and shall
become the property of the Landlord, unless Landlord shall, at the time of approval of the alteration, provide written notice to Tenant to remove the same, in which event Tenant shall remove such alterations, improvements and/or additions, and
restore the Premises to the same good order and condition in which it was at the commencement of this Lease, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 4</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
reasonable wear and tear and unavoidable casualty excepted. Should Tenant fail to do so, Landlord may do so, collecting the reasonable cost and expense thereof from Tenant as additional rent.
Tenant is not responsible for restoring to previous condition those renovations made by the previous tenant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TRADE FIXTURES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All trade
fixtures, telephone equipment, and apparatus installed by Tenant in the Premises shall remain the property of Tenant and shall be removed at the expiration or earlier termination of this Lease and, upon such removal, Tenant shall repair any damage
caused by the removal and shall promptly restore the Premises to their good order and condition. Any such trade fixture not removed prior to such termination shall be considered abandoned property, but such abandonment shall not release Tenant of
its obligation to pay for the cost of removing such trade fixtures and repairing any damage caused by the removal. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EQUIPMENT/BENCHWORK </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord will provide Laboratory Equipment and Benchwork listed below. It is the Tenant&#146;s responsibility to service and maintain
these items by obtaining service contracts with qualified vendors. All costs associated with the repair and maintenance of these items is the Tenant&#146;s responsibility. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Benchwork </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Onan Emergency Generator (55 KW natural gas) </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kato/Zenith Transfer Switch </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Note: All equipment and benchwork provided by Landlord will remain the property of the Landlord. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUIET ENJOYMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord
covenants that, upon payment of the rent herein provided and performance by the Tenant of all other covenants herein contained, Tenant shall and may peaceably and quietly have, hold and enjoy the Premises for the term hereof and options. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SURRENDER OF PREMISES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the expiration or termination of this Lease, Tenant shall quit and surrender the Premises to the Landlord broom clean and shall
remove all of its property therefrom. If the removal of any such property shall result in damaging the Premises, or leaving any holes in the floors, walls or ceiling therein, the Tenant shall make the appropriate repairs with Landlord approved
building materials prior to the expiration of this Lease. The obligation of this paragraph shall survive the termination of the Lease. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INSURANCE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord shall
be responsible for property damage and general liability on the building structure, building common areas and parking lot. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant covenants and agrees to maintain and carry, at all times during the term of this Lease, in companies qualified and authorized to
transact business in the State of Maryland, general liability insurance in amounts of $500,000.00 per person, $1,000,000.00 per occurrence and $100,000.00 for damage to property on the Premises or arising out of the use thereof by Tenant or its
agents. All policies of insurance shall provide that they may not be canceled, except on thirty (30)&nbsp;days written notice to Landlord, and all such policies shall name Landlord as an additional insured. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 5</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prior to commencement, Tenant shall furnish Landlord with satisfactory proof that the
insurance herein provided for is at all times in full force and effect. If either party hereto is paid any proceeds under any policy of insurance naming such party as an insured on account of any loss, damage or liability, then such party hereby
releases the other party to (and only to) the extent of the amount of such proceeds, from any and all liability for such loss or damage, notwithstanding negligent or intentionally tortuous act or omission of the other party, its agents or employees;
provided, such release shall be effective only as to a loss of damage occurring while the appropriate policy of insurance of the releasing party provides that such release shall not impair the effectiveness of such policy or the insured&#146;s
ability to recover thereunder. Each party hereto shall use reasonable efforts to have a clause to such effect included in its said policies, and shall promptly notify the other in writing if such clause cannot be included in any such policy.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEMNIFICATION </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant
shall indemnify and hold harmless the Landlord from, and name LANDLORD as additional insured on policy regarding, any and all liability, damage, expense, cause of action, or claims arising out of injury to persons or to property on the Premises,
except for the negligence or willful misconduct of Landlord, its agents, employees, or servants. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DAMAGE BY FIRE OR CASUALTY </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Premises are damaged by fire or other casualty, but are not thereby rendered untenantable in whole or in part, Landlord, at its own expense, and subject to the
limitations set forth in this Lease, shall cause such damage to be repaired and the Minimum Rent and Additional Rent shall not be abated. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If, by reason of any damage or destruction, the Premises shall be rendered untenantable in whole or in part and cannot be repaired and made tenantable within one hundred twenty (120)&nbsp;days after such
damage: (i)&nbsp;Landlord, at its option and its own expense, may cause the damage to be repaired and the Minimum Rent and Additional Rent shall be abated proportionately as to the portion of the Premises rendered untenantable while it is
untenantable; or (ii)&nbsp;Landlord shall have the right, to be exercised by notice in writing delivered to Tenant within thirty (30)&nbsp;days of the occurrence of such damage or destruction, to terminate this Lease, whereupon the Minimum Rent and
Additional Rent shall be adjusted as of the date of such termination. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that twenty-five percent (25%)&nbsp;or more of the rentable floor area of the Building shall be damaged or destroyed by fire or other cause,
notwithstanding that the Premises may be unaffected by such fire or other damage, Landlord shall have the right, to be exercised by notice in writing delivered to Tenant within thirty (30)&nbsp;days after such occurrence, to terminate this Lease.
Upon the giving of such notice, the Minimum Rent and Additional Rent shall be adjusted as of the date of termination and This Lease shall thereupon terminate. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 6</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ASSIGNMENT OR SUBLETTING </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant acknowledges that Landlord has entered into this Lease because of Tenant&#146;s financial strength, goodwill, ability and expertise
and that accordingly, this lease is personal to Tenant. Taking this into consideration, tenant shall not assign, mortgage, sublet, pledge or encumber this Lease, in whole or in part, except with the written consent of the Landlord, which shall not
be unreasonably withheld or delayed. Tenant agrees that, in the event of any such assignment or subletting, Tenant shall nevertheless remain liable for the performance of all terms, covenants, and conditions of this Lease. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event the Landlord consents to an assignment of the Lease, any money or consideration to be paid to Tenant for the assignment shall
be paid to the Landlord as partial consideration for the Landlord&#146;s consent to the assignment. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event the Landlord
consents to a sublease of the Premises, or any portion thereof, Tenant shall pay to the Landlord a sum equal to (1)&nbsp;any money, rent or other consideration paid to the Tenant by any subtenant in excess of the pro-rata portion of the rent for
such space then being paid by Tenant to Landlord under this Lease and (2)&nbsp;any other profit or gain realized by the Tenant from such subletting. All sums payable hereunder by Tenant shall be paid to Landlord as additional rent immediately upon
the receipt thereof by Tenant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBORDINATION AND ATTORNMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Lease shall be subject to and subordinate at all times to the lien of any mortgage and/or deeds of trust and all land leases now or hereafter made on any portion of the Premises, and to all advances
thereunder, provided the mortgagee or trustee named in said mortgage or deed of trust shall agree to recognize this Lease and agrees, in the event of foreclosure, not to disturb the Tenant&#146;s possession hereunder, provided Tenant is not in
default under this Lease. This subordination shall be self-operative and no further instrument of subordination shall be required. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If any proceedings are commenced to foreclose any mortgage or deed of trust encumbering the Premises, Tenant agrees to attorn to the purchaser at the foreclosure sale, if requested to do so by any such
purchaser, and to recognize such purchaser as the Landlord under this Lease, provided purchaser shall agree that Tenant&#146;s rights hereunder shall not be disturbed so long as Tenant has not committed any event of default as to which the
applicable cure period has expired. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONDEMNATION </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the whole of the Premises shall be taken by any public or quasi-public authority under the power of eminent domain, condemnation or conveyance in lieu thereof, then
this Lease shall terminate as of the date on which possession of the Premises is required to be surrendered to the condemning authority and the Tenant shall have no claim against Landlord or the condemning authority for the value of the unexpired
term of this Lease. Tenant shall have the right to claim, however, the unamortized cost of any improvements or additions made to the Premises by Tenant at its cost, the value of any Tenant fixtures and furnishings and any moving expenses.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a portion of the Premises shall be so taken or conveyed, and if such partial taking or conveyance shall render the Premises unsuitable for the business of the
Tenant, then the term of this Lease shall cease and terminate as of the date on which possession of the portion of the Premises is surrendered to the condemning authority, and Tenant shall have no claim against Landlord or the condemning authority
for the value of any unexpired term of this Lease. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 7</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event such partial taking or conveyance is not extensive enough to render the
Premises untenantable for the business of Tenant, this Lease shall continue in full force and effect, except that the Minimum Rent shall be reduced in the same proportion that the floor area of the Premises so taken or conveyed bears to such floor
area immediately prior to such taking or conveyance. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of such partial taking and continuation of Lease, Landlord
shall promptly restore the Premises as nearly as practical to the condition comparable to that which existed prior to the condemnation. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EVENTS OF DEFAULT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
occurrence of any of the following shall constitute an event of default hereunder: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure of Tenant to pay installment of rent within five (5)&nbsp;days of the due date, or failure of Tenant to pay within fifteen (15)&nbsp;days after receipt of
written notice any other sum herein required to be paid by Tenant. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#146;s failure to perform any other covenant or condition of this Lease within thirty (30)&nbsp;days after receipt of written notice and demand, unless the
failure is of such a character as to require more than thirty (30)&nbsp;days to cure in which event Tenant&#146;s failure to proceed diligently to cure such failure shall constitute an event of default. </FONT></TD></TR></TABLE>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD&#146;S REMEDIES </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon the occurrence of any event of default, Landlord may, at Landlord&#146;s sole option, exercise any or all of the following remedies,
together with any such other remedies as may be available to Landlord at law or in equity. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord may terminate this Lease by giving Tenant written notice of its election to do so, as of a specified date not less than thirty (30)&nbsp;days after the date of
the giving of such notice and this Lease shall then expire on the date so specified, and Landlord shall then be entitled to immediately regain possession of the Premises as if the date had been originally fixed as the expiration date of the term of
this Lease. Landlord may then re-enter upon the Premises, either with or without due process of law, and remove all persons therefrom, the statutory notice to quit or any other notice to quit being hereby expressly waived by Tenant. Tenant expressly
agrees that the exercise by Landlord of the right of re-entry shall not be a bar to or prejudice in any way other legal remedies available to Landlord. In that event, Landlord shall be entitled to recover from Tenant as and for liquidated damages an
amount equal to the rent and additional rent reserved in this Lease less any and all amounts received by Landlord from the rental of the Premises to another tenant. Nothing herein contained, however, shall limit or prejudice the right of Landlord to
prove for and obtain as liquidated damages, by reason of such termination, an amount equal to the maximum allowed by any statute or rule of law in effect at the time when, and governing the proceedings in which such damages are to be proved, whether
or not such amount may be greater, equal to, or less than the amount of the difference referred to above, and the Landlord may, in his own name, but as agent for Tenant, re-let the Premises. Any recovery by the Landlord shall be limited to the rent
hereunder (plus any costs incurred in re-letting) less any rent actually paid by the new tenant. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 8</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No termination of this Lease or any taking of possession of the Premises shall deprive Landlord of any of its remedies or actions against Tenant for past or future
rent, nor shall the bringing of any action for rent or breach of covenant, or the resort to any other remedy herein provided for the recovery of rent, be construed as a waiver of the right to obtain possession of the Premises.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to any damages becoming due under this paragraph, Landlord shall be entitled to recover from Tenant and Tenant shall pay to Landlord an amount equal to all
expenses, including attorneys&#146; fees, if any, incurred by the Landlord in recovering possession of the Premises, and all reasonable costs and charges for the care of said Premises while vacant, which damages shall be due and payable by Tenant to
Landlord at such time or times as such expenses are incurred by the Landlord. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a default or threatened default by Tenant of any of the terms or conditions of this Lease, Landlord shall have the right of injunction and the right to
invoke any remedy allowed by law or in equity as if no specific remedies of Landlord were set forth in this Lease. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If default be made and a compromise and settlement shall be had thereupon, it shall not constitute a waiver of any covenant herein contained, nor of the Lease itself.
</FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RIGHTS OF LANDLORD </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord reserves the following rights with respect to the Premises: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">During normal business hours, upon 24 hours notice, to go upon and inspect the Premises, and at Landlord&#146;s option, to make repairs, alterations and additions to
the Premises or the Building of which the Premises are a part, provided there is no interference with Tenant&#146;s occupancy. An Agent of the Tenant may be present for inspection, if requested by Tenant. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To display, within sixty (60)&nbsp;days prior to the expiration of this Lease or after notice from either party of intention to terminate this Lease, a &#147;For
Rent&#148; sign, and all of said signs which shall be placed upon such part of the Premises as Landlord shall determine, except on doors leading into the Premises. Prospective purchasers or tenants authorized by Landlord may inspect the Premises
during normal business hours following adequate notice to Tenant. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To install, place upon, or fix to the roof and exterior walls of the Premises, equipment, signs, displays, antennae, and any other object or structure of any kind,
providing the same shall not materially impair the structural integrity of the Building or interfere with Tenant&#146;s occupancy. </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>HOLDING OVER </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Tenant
holds possession of the Premises after the termination of this Lease or any renewal or extension thereof, Tenant shall become a Tenant from month to month at 150% of the then current escalated rental rate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 9</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WAIVER OF CLAIMS </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except
as may result from their gross negligence, Landlord and Landlord&#146;s agents, employees, and contractors shall not be liable for, and Tenant hereby releases all claims for, damages to persons or property sustained by Tenant (or any person claiming
through Tenant) resulting from any fire, accident, occurrence or condition in or upon the Premises or Building, including but not limited to such claims for damage resulting from (1)&nbsp;any defect in or failure of plumbing, heating or
air-conditioning equipment, electric wiring or installation thereof, water pipes, stairs, railings or walks; (2)&nbsp;any equipment or apparatus becoming out of repair; (3)&nbsp;the bursting, leaking or running of any tank, washstand, water closet,
waste pipe, drain or any other pipe or tank, upon or about such building or premises; (4)&nbsp;the backing up of any sewer pipe or downspout; (5)&nbsp;the escape of steam or hot water; (6)&nbsp;water, snow or ice being upon or coming through the
roof or any other place upon or near the Building or Premises or otherwise; (7)&nbsp;the falling of any fixtures, plaster or stucco; (8)&nbsp;broken glass; and (9)&nbsp;any act or omission of occupants of adjoining or contiguous property or
buildings. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All notices
required under this Lease shall be given in writing and shall be deemed to be properly serviced if sent by certified or registered United States Mail, postage prepaid, as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="70%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Landlord:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">W. M. RICKMAN CONSTRUCTION CO. LLC</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">15215 Shady Grove Road</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 201</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, Maryland 20850</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to the Tenant:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">15235 Shady Grove Road</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address as either may have designated from time to time by written notice to the other.
The date of service of such notices shall be the date such notices are deposited in any United States Post Office. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>31.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COVENANTS OF TENANT </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant covenants and agrees: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To give to Landlord prompt written notice of any accident, fire, or damage occurring on or to the Premises. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To keep the thermostats in the Premises set at a temperature sufficient to prevent freezing of water pipes, fixtures and HVAC units. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To keep the Premises clean, orderly, sanitary, and free from all objectionable odors and from insects, vermin and other pests. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To comply with the requirements of the State, Federal and County statutes, ordinances, and regulations applicable to Tenant and its use of the Premises, and to save
Landlord harmless from penalties, fines, costs, and expenses resulting from failure to do so, provided Tenant shall not be obligated to make structural repairs or alterations to so comply. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant shall promptly pay all contractors, suppliers of material and persons it engages to perform work and provide materials for construction work on the Premises so
as to minimize the possibility of a lien attaching to the Premises. Should any such lien be made or filed, Tenant shall cause the same to be discharged and released of record by bond or otherwise within ten (10)&nbsp;days of receipt of written
request from Landlord. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 10</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant is responsible for the security of the Premises. </FONT></TD></TR></TABLE> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>32.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LANDLORD&#146;S RIGHT TO ALTER SITE PLAN </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">LANDLORD shall, from time to time, have the right to alter or modify the site plan of the Building and to rearrange the driveways and parking areas, as well as the entrance and exits to the Premises.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>33.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PARKING SPACES </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD
agrees to furnish 3 1/3 unreserved parking spaces per thousand square feet of space occupied by the Tenant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ENTIRE AGREEMENT </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This
Lease contains the entire agreement of the parties. There are no oral agreements existing between them. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>35.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUCCESSORS AND ASSIGNS </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Lease, and the covenants and conditions herein contained shall inure to the benefit of and be binding upon the Landlord, its
successors and assigns, and shall inure to the benefit of and be binding upon the Tenant, its successors and assigns, if permitted. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>36.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BANKRUPTCY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If Tenant
shall make an assignment of its assets for the benefit of creditors, or if Tenant shall file a voluntary petition in bankruptcy, or if any involuntary petition in bankruptcy or for receivership be instituted against the Tenant and the same be not
dismissed within thirty (30)&nbsp;days of the filing thereof, or if Tenant shall be adjudged bankrupt, then and in any of said events, this Lease shall immediately cease and terminate at the option of the Landlord with the same force and effect as
though the date of said event was the date herein fixed for expiration of the term of this Lease. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>37.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NON-DELIVERY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the
event the Landlord shall be unable to give possession of the Premises because construction of the Building is not complete or for any other cause reasonably beyond the control of the Landlord, the Landlord shall not be liable to Tenant for any
damage resulting from failure to give possession. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>38.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PARTIAL INVALIDITY </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
any term, covenant, or condition of this Lease or the application thereof to any person or circumstance shall be held to be invalid and unenforceable, the remainder of this Lease, and the application of such terms, covenants, or conditions shall be
valid and enforceable to the fullest extent permitted by law. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>39.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORCE MAJEUR </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">With the
exception of those provisions contained herein regarding the payment of rent, the inability of either party to perform any of the terms, covenants or conditions of this Lease shall not be deemed a default if the same shall be due to any cause beyond
the control of that party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 11</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>40.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ESTOPPEL CERTIFICATE </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
Tenant shall from time to time, within five (5)&nbsp;days after being requested to do so by the Landlord or any Mortgagee, execute, acknowledge and deliver to the Landlord (or, at the Landlord&#146;s request, to any existing or prospective
purchaser, transferee, assignee or Mortgagee of any or all of the Premises) an instrument in recordable form, certifying (a)&nbsp;that this Lease is unmodified and in full force and effect (or, if there has been any modification thereof, that it is
in full force and effect as so modified, stating therein the nature of such modification); (b) as to the dates to which the Minimum Rent and other charges arising hereunder have been paid; (c)&nbsp;as to the amount of any prepaid Rent or any credit
due to the Tenant hereunder; (d)&nbsp;that the Tenant has accepted possession of the Premises, and the date on which the Term commenced; (e)&nbsp;as to whether, to the best knowledge, information and belief of the signer of such certificate, the
Landlord or the Tenant is then in default in performing any of its obligations hereunder (and, if so, specifying the nature of each such default); and (f)&nbsp;as to any other fact or condition reasonably requested by the Landlord or such other
addressee. In the event-the Tenant fails or refuses to provide such a certificate, Tenant shall be liable to Landlord for any loss or damage (including reasonable counsel fees) arising out of or in connection with such failure or refusal.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF, </B>the parties have caused this Lease Agreement to be executed on the year and date first written. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">W. M. RICKMAN CONSTRUCTION CO. LLC</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ William M. Rickman</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: William M. Rickman</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACRO GENICS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: CEO</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Macro Genics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><SMALL>PAGE</SMALL> 12</FONT></TD></TR></TABLE>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>MACRO GENICS, INC. </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord
delivers the Premises &#147;As Is&#148; unless otherwise noted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>WALLS: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Existing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>CEILINGS: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Existing. Landlord will replace damaged and stained ceiling tiles, <U> </U></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>FLOORS:
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>PLUMBING:
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>ELECTRICAL: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>LIGHTS: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>HVAC: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DOORS: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>TELEPHONE/COMPUTER SYSTEMS: </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">By Tenant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>WINDOW COVERINGS: </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SECURITY SYSTEM:
</U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Tenant. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>12
<FILENAME>filename12.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.11</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.11 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MACRO GENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment to Lease Agreement </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This amendment to lease agreement (&#147;AGREEMENT&#148;) made and entered into this 31</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">ST</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of January, 2006, by and between </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">W. M. RICKMAN CONSTRUCTION CO. (&#147;LANDLORD&#148;) and Macro Genics Inc. (&#147;TENANT&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESSETH: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Whereas</I>, the LANDLORD and TENANT entered into a certain lease (&#147;LEASE&#148;) dated December&nbsp;2</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, 2004, covering 15,180 square feet of space (&#147;PREMISES&#148;)
located in 15235 Shady Grove Road, Rockville, Maryland (&#147;BUILDING&#148;); <B><I>and</I></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Whereas</I>, the LANDLORD and TENANT
agree to revise the Lease as stated below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;13. <B>LANDLORD&#146;S WORK PRIOR TO COMMENCEMENT OF TERM</B> shall be replaced in
its entirety with; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. LANDLORD&#146;S WORK PRIOR TO COMMENCEMENT OF TERM </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; margin-left:6%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None. Landlord delivers the Premises &#147;As Is.&#148; Landlord will provide two (2)&nbsp;months rent abatement. Rent Abatement period
must be taken in consecutive months and TENANT must notify LANDLORD in writing thirty (30)&nbsp;days prior to the first month of the rent abatement period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Ratification of LEASE: Except</I> as expressly modified or amended by this AGREEMENT, all terms, covenants and conditions of the LEASE shall remain the same. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In witness whereof, LANDLORD and TENANT have caused this AGREEMENT to be executed as of this 31</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">ST</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of January, 2006, and do hereby declare this AGREEMENT to be
binding on them, their respective successors and assigns. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">W. M. Rickman Construction Co.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ William M. Rickman</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: William M. Rickman</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACRO GENICS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g575431001.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;13, 2005 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Keith Miller </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">W.M. Rickman Construction Co. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">15215 Shady Grove Road </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Mr. Miller: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This letter
serves as notice that MacroGenics is applying its right to obtain two months of rent abatement under Section&nbsp;13 of the amended lease to the months of March and April of 2006. As a consequence, no rent payment will be due from MacroGenics for
those two months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you have any questions regarding this matter, please do not hesitate to contact me at 301-354-0686. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sincerely, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Joseph E. Panigot </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joseph E. Panigot </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Vice President, Legal
Affairs </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>13
<FILENAME>filename13.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.12</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.12 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MACRO GENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Second Amendment to Lease Agreement </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This second amendment to lease agreement (&#147;AGREEMENT&#148;) made and entered into this 1</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">ST</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of June 2011, by and between W. M. RICKMAN CONSTRUCTION CO. LLC
(&#147;LANDLORD&#148;) and MACRO GENICS, INC. (&#147;TENANT&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>WITNESSETH: </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Whereas,</I></B> the LANDLORD and TENANT entered into a certain lease (&#147;LEASE&#148;) dated December&nbsp;2</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, 2004, covering 15,180 square feet of space (&#147;PREMISES&#148;)
located on the 2</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> floor in 15235 Shady Grove Road,
Rockville, Maryland (&#147;BUILDING&#148;); <I>and</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Whereas,</I></B> the LEASE was amended on January&nbsp;31, 2006, revising
Section&nbsp;13 of LEASE; <I>and</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Whereas,</I></B> the LEASE is set to terminate on November&nbsp;30, 2011. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Now, therefore</I></B>, the parties hereto, intending to be legally bound, do covenant and agree as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The LEASE is extended for three (3)&nbsp;years and one (1)&nbsp;month, LEASE shall terminate December&nbsp;31, 2014. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commencing December&nbsp;1, 2011 TENANT&#146;S monthly minimum rent shall be $34,238.34 and shall increase 3% annually in accordance with the LEASE.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT shall have one (1)&nbsp;five (5)&nbsp;year renewal option to extend LEASE at current market rate. LEASE shall extend January&nbsp;1, 2015 and terminate
December&nbsp;31, 2019 if TENANT chooses to use option to extend. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT must give at least nine (9)&nbsp;months advance written notice to LANDLORD of intent to use option to extend LEASE. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD agrees to abate TENANT&#146;S monthly minimum rent for one (1)&nbsp;month totaling $34,238.34. Such abatement shall be applied to the minimum rent payable by
Tenant for the first month of the renewal term. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Ratification of LEASE: Except</I> as expressly modified or amended by this
AGREEMENT, all terms, covenants and conditions of the LEASE shall remain the same. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">In witness whereof, LANDLORD and
TENANT have caused this AGREEMENT to be executed as of this 1</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">ST</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> day of June 2011, and do hereby declare this AGREEMENT to be binding on them, their respective successors and assigns. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">W. M. Rickman Construction Co.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ William M. Rickman</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: William M. Rickman</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WITNESS:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACRO GENICS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ILLEGIBLE]</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By: [ILLEGIBLE]</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>14
<FILENAME>filename14.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.13</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.13 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SUBLEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HIS</SMALL>
S<SMALL>UBLEASE</SMALL></B><SMALL></SMALL> (&#147;<B><I>Sublease</I></B>&#148;), dated November&nbsp;21, 2006, is entered into by and between <B>A<SMALL>MGEN</SMALL> </B><B>SF, LLC</B>, a Delaware limited liability company, as successor by merger to
Tularik, Inc., a Delaware corporation (<B><I>&#147;Sublandlord&#148;</I></B>), and <B>R<SMALL>AVEN</SMALL> <SMALL>BIOTECHNOLOGIES</SMALL></B><SMALL></SMALL>, <B><SMALL>INC</SMALL></B><SMALL></SMALL>., a Delaware corporation
(&#147;<B><I>Subtenant</I></B>&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>R<SMALL>ECITALS</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A.</B> Sublandlord leases certain premises (the &#147;<B><I>Premises</I></B>&#148;) consisting of approximately 66,127 rentable square
feet of space located in that certain building located at One Corporate Drive, South San Francisco, California (the &#147;<B><I>Building</I></B>&#148;), as more particularly shown on <B>Exhibit B</B> attached hereto and incorporated herein.
Sublandlord is the tenant under that certain Build-To-Suit Lease dated the 20th day of April, 1995, with Britannia Biotech Gateway Limited Partnership, a Delaware limited partnership (&#147;<B><I>Master Landlord</I></B>&#148;) as amended by that
certain First Amendment to Lease, dated February&nbsp;10, 1998, and as further amended by that certain Second Amendment to Build-To-Suit Lease, dated August&nbsp;12, 2004 (collectively, the &#147;<B><I>Master Lease</I></B>&#148;). A copy of the
Master Lease is attached hereto as <B>Exhibit A</B>. Except as otherwise expressly provided herein, any capitalized terms herein without definition shall have the same meaning as they have in the Master Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B.</B> Sublandlord desires to sublease to Subtenant, and Subtenant desires to Sublease from Sublandlord, the Premises during the Term,
pursuant to the terms and provisions hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>OW</SMALL>, T<SMALL>HEREFORE</SMALL></B><SMALL></SMALL>, in
consideration of the covenants and conditions contained herein, Sublandlord and Subtenant agree as follows: </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>GREEMENT</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>1. Premises</B>. Sublandlord hereby subleases to Subtenant and Subtenant hereby subleases from Sublandlord the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2. Term</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> The term of this Sublease (the
&#147;<B><I>Term</I></B>&#148;) shall commence on the later of (i)&nbsp;November&nbsp;21, 2006, (ii)&nbsp;the date Sublandlord has delivered possession of the Premises to Subtenant in the condition required by the terms of this Sublease, or
(iii)&nbsp;the date Master Landlord consents to this Sublease (the &#147;<B><I>Commencement Date</I></B>&#148;) and shall expire, unless sooner terminated pursuant to the further provisions hereof, at 11:59 p.m. (Pacific time) on December&nbsp;31,
2013, or such earlier date as the Master Lease may be terminated pursuant to the terms thereof. If the Commencement Date does not occur on or before the date that is ten (10)&nbsp;days after the execution of this Sublease, then Subtenant shall have
the right to terminate this Sublease within ten (10)&nbsp;days thereafter upon ten (10)&nbsp;days&#146; prior written notice to Sublandlord, and in such event Sublandlord shall immediately return to Subtenant all monies previously paid by Subtenant
to Sublandlord pursuant to this Sublease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> Upon the Commencement Date, Subtenant shall have the right to enter the
Premises to commence the Tenant Improvements (as defined in Exhibit C attached hereto) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and for installation of furniture, fixtures and equipment and otherwise to prepare the Premises for Subtenant&#146;s occupancy. During such period of occupancy, Subtenant shall comply with all of
the terms of this Sublease, including, without limitation, Section&nbsp;11 hereof, other than the payment of Rent pursuant to Section&nbsp;3(a). Prior to Subtenant&#146;s entry into the Premises, Subtenant shall provide Sublandlord with evidence
that Subtenant has obtained the insurance required by Section&nbsp;11 hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. Rent.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Commencing on April&nbsp;1, 2007 (the <B><I>&#147;Rent Commencement </I></B><B><I>Date&#148;</I></B>), and continuing
throughout the term of this Sublease, Subtenant shall pay monthly rent consisting of Base Rent and Additional Rent (as defined below) (collectively, <B><I>&#147;Rent&#148;</I></B>) to Sublandlord in the amounts set forth below. To the extent
substantial completion of the Tenant Improvements (as defined in Exhibit C) is delayed beyond April&nbsp;1, 2007, the Rent Commencement Date shall be extended beyond April&nbsp;1, 2007, on a day for day basis: (i)&nbsp;for each day after
December&nbsp;7, 2007, that a building permit for the Tenant Improvements is not issued, provided Subtenant, no later than November&nbsp;22, 2006, submits all necessary information and materials for the issuance of the building permit and such delay
is not caused by Subtenant or its affiliates, contractors or consultants; or (ii)&nbsp;for each day substantial completion of the Tenant Improvements is delayed beyond April&nbsp;1, 2007 as a result of Sublandlord&#146;s failure to complete its
Decommissioning work, as defined in Section&nbsp;5 below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <U>Base Rent</U>. Subtenant shall pay to Sublandlord
monthly base rent (<B><I>&#147;Base Rent&#148;</I></B>) in the following amount: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Monthly&nbsp;Base&nbsp;Rent&nbsp;Amount</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rent Commencement-12/31/07</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">104,850.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/01/08-12/31/08</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">108,000.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/01/09-12/31/09</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,150.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/01/10-12/31/10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">114,300.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/01/11-12/31/11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">117,900.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/01/12-12/31/12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">121,500.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">01/01/13-12/31/13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,150.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <U>Additional Rent</U>. In addition to Base Rent, commencing on the Rent Commencement Date,
Subtenant shall also pay to Sublandlord the Operating Expenses (as that term is defined in Section&nbsp;9.2 of the Master Lease) and all other costs payable by Sublandlord under the Master Lease that may accrue after the Rent Commencement Date
(<B><I>&#147;Additional Rent&#148;</I></B>). Additional Rent shall also include all amounts paid directly by Sublandlord to parties other than Sublandlord to the extent related to the Premises (e.g. real property taxes assessed against the tenant
improvements in the Premises, landscape maintenance, and parking lot maintenance). Sublandlord shall use its commercially reasonable efforts to induce Master Landlord to agree to bill Subtenant directly for Additional Rent. If Master Landlord does
not agree to bill Subtenant directly for Additional Rent, then prior to the Rent Commencement Date, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and then on or before December&nbsp;1 of each year, Sublandlord shall give Tenant a yearly expense estimate statement which shall set forth Sublandlord&#146;s reasonable estimate of the total
amount of Additional Rent for the succeeding calendar year, Subtenant shall pay Additional Rent in equal monthly installments based upon such estimate; provided, that the estimate statement may be reasonably revised and reissued by Sublandlord from
time to time. Within 120 days after the end of each calendar year (subject to corresponding delivery to Sublandlord from Master Landlord), Sublandlord shall give to Tenant a statement, which shall indicate the Additional Rent incurred or accrued for
such preceding calendar year, and which shall indicate the amount, if any, of any amounts due from Subtenant in excess of the amounts previously paid, or the amount of any refund due. Upon receipt of the statement for each expense year ending during
the Term, Tenant shall pay, with its next installment of Base Rent due, but in no event later than thirty (30)&nbsp;days after receipt of such statement the full amount of any excess for such expense year. If a refund is due, Sublandlord shall
provide such refund at the time it provides the statement. The failure of Sublandlord to timely furnish the statement for any expense year shall not prejudice Sublandlord from enforcing its rights under this Section&nbsp;3. Even though the Term has
expired and Tenant has vacated the Premises, when the final determination is made of the Additional Rent due from Subtenant for the Term, Tenant shall immediately pay to Sublandlord any amounts due. Upon request, Sublandlord shall furnish to
Subtenant copies of any invoices for items constituting Additional Rent hereunder (to the extent obtainable from Master Landlord). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> <U>Direct Costs</U>. Commencing on the Commencement Date, Subtenant shall pay directly to the provider thereof all costs and expenses for, utilities, janitorial services, HVAC maintenance and
security for the Premises, and shall pay its own personal property taxes. The level of utilities, janitorial service, HVAC maintenance and security for the Premises to be obtained shall be at the reasonable discretion of the Subtenant, provided
Subtenant shall exercise its discretion in such manner as will avoid a default under the Master Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> Subtenant
shall also be liable for any amounts payable by Sublandlord to Master Landlord which are (A)&nbsp;due to Subtenant&#146;s breach of any provision of the Master Lease, (B)&nbsp;due to Subtenant&#146;s negligence or willful misconduct, or (C)&nbsp;for
the sole benefit of Subtenant, and any such amounts shall be the sole responsibility of Subtenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> Upon the
written request of Subtenant to Sublandlord, Sublandlord shall exercise its audit rights under Section&nbsp;9.3 of the Master Lease at the sole cost and expense of Subtenant and shall promptly provide the results thereof to Subtenant without
warranty of any kind or nature. Sublandlord shall use its commercially reasonable efforts to induce Master Landlord to agree in its consent to this Sublease that Subtenant may exercise Sublandlord&#146;s audit rights under Section&nbsp;9.3 of the
Master Lease directly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. Security Deposit. </B>Upon execution of this Sublease, Subtenant shall deposit with Sublandlord
the sum of $104,850.00 as a security deposit (<B><I>&#147;Security Deposit&#148;</I></B>). Subtenant hereby grants to Sublandlord a security interest in the Security Deposit, including but not limited to replenishments thereof. If Subtenant fails to
pay Rent or other charges when due under this Sublease, or fails to perform any of its other obligations hereunder, and such failure is not cured within the relevant cure period, Sublandlord may use or apply all or any portion of the Security
Deposit for the payment of any Rent or other amount then due hereunder and unpaid, for the payment of any other sum for which Sublandlord may become obligated by reason of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Subtenant&#146;s default or breach, or for any loss or damage sustained by Sublandlord as a result of Subtenant&#146;s default or breach. If Sublandlord so uses any portion of the Security
Deposit, Subtenant shall restore the Security Deposit to the full amount originally deposited within ten (10)&nbsp;days after Sublandlord&#146;s written demand. Sublandlord shall not be required to keep the Security Deposit separate from its general
accounts, and shall have no obligation or liability for payment of interest on the Security Deposit. The Security Deposit, or so much thereof as had not theretofore been applied by Sublandlord, shall be returned to Subtenant within thirty
(30)&nbsp;days of the expiration or earlier termination of this Sublease, provided Subtenant has vacated the Premises. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In
lieu of making the cash deposit described above, Subtenant shall have the option to instead deliver to Sublandlord a letter of credit in the amount of the Security Deposit in the form attached hereto as <B>Exhibit D</B> from an institution
reasonably satisfactory to Sublandlord (the<B><I> &#147;Initial LOC&#148;</I></B>; the Initial LOC and all letters of credit issued in renewal or replacement thereof being individually referred to hereinafter as an <B><I>&#147;LOC&#148;</I></B>).
Sublandlord may, in its sole discretion but with no obligation to do so, draw upon each LOC at any time following an event of default, which is not cured within the applicable cure period, in accordance with this Section&nbsp;4. Each LOC delivered
hereunder shall (a)&nbsp;be in a form and from Greater Bay Bank or another institution acceptable to Sublandlord, in its reasonable discretion, (b)&nbsp;allow for multiple draws, and (c)&nbsp;be transferable, irrevocable and payable on sight draft
made by Sublandlord or its successors and assigns. In the event Sublandlord draws upon any LOC in accordance with this Section&nbsp;4, Subtenant shall replenish the LOC within ten (10)&nbsp;days of notice of such draw so that the amount of the LOC
shall equal the sum of $104,850.00. Sublandlord may, in its sole discretion but with no obligation to do so, draw upon each LOC for the failure of any LOC to be renewed or replaced in compliance with the terms of this Section&nbsp;4 on or before the
date that is thirty (30)&nbsp;days prior to the expiration of any LOC, such draw to be in the full amount of any such expiring LOC, with such drawn amount thereafter to be held by Sublandlord as the Security Deposit under this Sublease. Sublandlord
will not be required to declare any default or event of default as a condition to any such draw. In the event Sublandlord fails to draw upon any expiring LOC and such LOC actually expires, Subtenant shall cause a replacement LOC to be issued in
favor of Sublandlord in the amount of any such expired LOC, with any failure to provide such a replacement LOC to constitute a default hereunder within ten (10)&nbsp;days of notice from Sublandlord to Subtenant of any such expired LOC, and without
any further cure period being allowed to Subtenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. Condition of the Premises.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Subtenant agrees that (i)&nbsp;except as specifically set forth in this Sublease, Sublandlord has made no other
representations or warranties of any kind or nature whatsoever respecting the Premises or the alterations, additions and improvements, title to which is held by Sublandlord under Section&nbsp;11.2 of the Master Lease (the <B><I>&#147;Sublandlord
Owned Property&#148;</I></B>) located in or serving the Premises, or their condition or suitability for Subtenant&#146;s use; and (ii)&nbsp;Subtenant agrees to accept the Premises and Sublandlord Owned Property located in or serving the Premises
&#147;as is, where is,&#148; with all faults, without any obligation on the part of Sublandlord to modify, improve or otherwise prepare the Premises for Subtenant&#146;s occupancy, except as provided in <B>Exhibit C </B>attached hereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> No later than sixty (60)&nbsp;days after the Commencement Date, Sublandlord shall
at its sole cost and expense obtain and deliver to Master Landlord and to Subtenant an environmental study, performed by an expert reasonably satisfactory to Master Landlord and Subtenant, evaluating the presence or absence of hazardous substances
and wastes, radiation and radioactive materials on and about the Property (as defined in the Master Lease) (the <B><I>&#147;Environmental Study&#148;</I></B>). Such study shall be based on a reasonable and prudent level of tests and investigations
of the Property and shall be intended to satisfy, on an interim basis, Sublandlord&#146;s obligations under Section&nbsp;13(b)(xi) of the Master Lease. Liability for any remedial actions required or recommended on the basis of such study shall be
allocated between Master Landlord and Sublandlord in accordance with the Master Lease. Within thirty (30)&nbsp;days of the date of the aforementioned report, Sublandlord shall commence, and thereafter shall diligently pursue to completion, all
actions required under the Master Lease with respect to hazardous substances and wastes, radiation and radioactive materials on and about the Property, and Subtenant shall have no liability whatsoever in connection therewith; provided Subtenant
shall reasonably cooperate with Sublandlord in the performance of Sublandlord&#146;s obligations in this regard. Sublandlord hereby certifies that Sublandlord has taken all commercially reasonable steps necessary to decommission the areas of the
Premises that contain levels of radiation higher than permitted pursuant to applicable environmental laws, and has complied with the Master Lease and all applicable laws with respect to any portion of the Building used in connection with hazardous
substances and/or hazardous waste, as such terms are used in the Master Lease (the <B><I>&#147;Decommissioning&#148; </I></B>work). At the termination or expiration of this Sublease, Subtenant shall be responsible, at its sole cost and expense, for
the obligations arising under the Section&nbsp;13 of the Master Lease, including Section&nbsp;13.6(b)(xi) thereof only with respect to hazardous substances caused to be present in the Premises by Subtenant or its agents, and Subtenant does hereby
agree to indemnify and hold harmless Sublandlord from any and all costs, claims, and liabilities arising from or attributable to such obligations, and such obligation to indemnify and hold harmless shall survive the expiration or earlier termination
of this Sublease. Throughout the term of this Sublease and at the termination or expiration of this Sublease, Sublandlord shall remain responsible, at its sole cost and expense, for the obligations arising under the Section&nbsp;13 of the Master
Lease, including Section&nbsp;13.6(b)(xi) thereof arising out of or in connection with any Sublandlord Hazardous Substances, and Sublandlord does hereby agree to indemnify and hold harmless Subtenant from any and all costs, claims, and liabilities
arising from or attributable to such obligations, and such obligation to indemnify and hold harmless shall survive the expiration or earlier termination of this Sublease. As used herein, the term <B><I>&#147;Sublandlord Hazardous Substances&#148;
</I></B>shall mean any and all hazardous substances located within the Premises to the extent (I)&nbsp;such hazardous substances are identified as being present within the Premises by the Environmental Study as of the date thereof or (II) Subtenant
can reasonably demonstrate that the presence of such hazardous substances was caused by Sublandlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> Except as
addressed in Section&nbsp;5(b) above, Sublandlord has not made an independent investigation of the Premises or determination with respect to the physical condition of the Premises including without limitation compliance with The Americans With
Disabilities Act. Except as otherwise provided in this Section&nbsp;5(c), Subtenant shall rely solely </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
on its own investigations and/or that of a licensed professional specializing in the areas referenced in this Section&nbsp;5(c). Notwithstanding the foregoing, Sublandlord hereby represents and
warrants that as of the Commencement Date all mechanical, plumbing and electrical systems within the Premises shall be in good working order and condition, and to the best of its knowledge, Sublandlord has complied in all material respects with the
terms and conditions of the Master Lease with respect to Sublandlord&#146;s repair and maintenance obligations. Subtenant shall notify Sublandlord of its discovery of any non-compliance with the foregoing warranty within six (6)&nbsp;months of the
Rent Commencement Date, and Sublandlord shall promptly repair or correct the defect. Sublandlord&#146;s obligation to repair in accordance with the foregoing warranty shall expire unless Subtenant notifies Sublandlord of a specific breach of the
warranty within six (6)&nbsp;months of the Rent Commencement Date, in which event such warranty shall continue as to only such specific breach. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> Subtenant&#146;s alterations and modifications of the Premises shall be governed by Article 11 of the Master Lease (as incorporated by Section&nbsp;8 of this Sublease); provided, however, that
Subtenant shall not be obligated to remove any Sublandlord Owned Property present in the Premises on the Commencement Date, or any of the Tenant Improvements described in <B>Exhibit C</B>,<B> </B>at the end of the Term. In addition, Subtenant agrees
that if any of Subtenant&#146;s alterations or modifications require a building permit, Subtenant shall engage only licensed contractors to perform such alterations or modifications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. Use.</B> Subtenant may use the Premises twenty four hours a day, seven days a week, as administrative offices, for research and
development purposes and/or for laboratory purposes to the extent permitted under the Master Lease and for no other purpose without the approval of the Master Landlord and Sublandlord. Sublandlord shall have the right to inspect the Premises at any
time after giving Subtenant twenty-four (24)&nbsp;hours notice; provided that Subtenant may require that Sublandlord be escorted by an employee of Subtenant. Notwithstanding the foregoing, Sublandlord shall have the unrestricted right to access the
Premises at any time, without notice and without escort, in the event of an emergency. Subtenant acknowledges and agrees that the operation and use of the Premises may require that Subtenant apply for and receive licenses and/or permits from various
federal, state and local governments, and Subtenant covenants and agrees to apply for and receive such licenses and/or permits as are required. Upon receipt of Sublandlord&#146;s written request therefore, Subtenant shall provide to Sublandlord
copies of any such licenses and/or permits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. Master Lease.</B> This Sublease shall be subject and subordinate to all of
the terms and provisions of the Master Lease. Except for payments of Rent (which payments shall be made by Sublandlord) and except for those provisions of the Master Lease excluded by Section&nbsp;8 below, Subtenant hereby assumes and agrees to
perform, during the Term, all of Sublandlord&#146;s obligations under the Master Lease to the extent such obligations are applicable to the Premises and accrue after the date hereof pursuant to this Sublease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. Incorporation of Master Lease.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as otherwise provided herein, all of the terms and provisions of the Master Lease are incorporated into and made a part of this Sublease and the rights and obligations of the parties under the
Master Lease are hereby imposed upon the parties hereto with respect to the Premises, the Sublandlord being substituted for the &#147;Landlord&#148; in the Master Lease, the Subtenant being </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
substituted for the &#147;Tenant&#148; in the Master Lease, and this Sublease being substituted for the &#147;Lease&#148; and the &#147;Premises&#148; being substituted for the
&#147;Property&#148; in the Master Lease (except in Section&nbsp;13.6(b)(viii), and Section&nbsp;14.6, where the &#147;Property&#148; shall mean the Property); provided, however, that the term &#147;Landlord&#148; in Sections 1.2 and 12.1 (a),
Article 19, and Section&nbsp;21.14 shall mean Master Landlord, not Sublandlord. The parties specifically agree that any provisions relating to any construction obligations of &#147;Landlord&#148; under the Master Lease with respect to construction
that occurred or was to have occurred prior to the Commencement Date hereof, are hereby deleted. Sublandlord shall not be liable to Subtenant for any failure by Master Landlord to perform its obligations under the Master Lease, nor shall such
failure by Master Landlord excuse performance by Subtenant of its obligations hereunder; provided, however, that Sublandlord shall use its commercially reasonable efforts to cause Master Landlord to perform its obligations under the Master Lease.
Anything in the Master Lease to the contrary notwithstanding, no personal liability shall at any time be asserted or enforceable against Sublandlord&#146;s stockholders, directors, officers or partners on account of Sublandlord&#146;s obligations or
actions under this Sublease. The following Sections of the Master Lease are not incorporated herein: Section&nbsp;1.1, Section&nbsp;2.1, Section&nbsp;2.2, Section&nbsp;2.3, Section&nbsp;2.4, Section&nbsp;2.6, Section&nbsp;3.1, Article 4, Article 5,
Article 6, Article 7, Section&nbsp;9.1, Section&nbsp;9.3, Section&nbsp;10.1, Section&nbsp;12.1(b), Section&nbsp;12.2(c), Section&nbsp;13.6(d), Section&nbsp;16.1, Section&nbsp;16.2, Article 17, Section&nbsp;20.1, Section&nbsp;21.11,
Section&nbsp;21.12, Section&nbsp;21.15, Section&nbsp;21.16, Section&nbsp;21.17, Exhibits C, D and E, the First Amendment and the Second Amendment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, for purposes of the incorporation set forth in this Section&nbsp;8, Section&nbsp;13.6(b)(vi) of the Master Lease is amended to delete &#147;Nuclear Regulatory
Commission&#148; and insert &#147;California Department of Health Services (<B><I>&#147;DHS&#148;</I></B>).&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.
Sublandlord&#146;s Obligations.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Provided that Subtenant is not in default under the terms of this Sublease,
Sublandlord agrees (i)&nbsp;to make timely payments of the Rent due under the Master Lease and to perform all of its other obligations under the Master Lease (except to the extent assumed by Subtenant hereunder), (ii)&nbsp;subject to
Sublandlord&#146;s right to exercise a discretionary right to terminate the Master Lease as set forth in the second sentence of Section&nbsp;15 hereof, to maintain the Master Lease in full force and effect and (iii)&nbsp;not to amend the Master
Lease in any way which could have a material adverse impact on Subtenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> To the extent that the provision of any
services or the performance of any maintenance or any other act is the responsibility of Master Landlord (collectively <B><I>&#147;Master Landlord Obligations&#148;</I></B>), Sublandlord, upon Subtenant&#146;s request, shall make commercially
reasonable efforts to cause Master Landlord under the Master Lease to perform such Master Landlord Obligations; provided, however, that Sublandlord shall not be liable to Subtenant for any liability, loss or damage whatsoever in the event that
Master Landlord should fail to perform the same, nor shall Subtenant be entitled to withhold the payment of Rent or Terminate this Sublease, unless such failure is the result of an event of default on the part of Sublandlord under this Sublease
(including Sublandlord&#146;s obligation to use commercially reasonable efforts to cause Master Landlord to perform the Master Landlord Obligations), the Master Lease, or both. It is expressly understood that Sublandlord does not assume the Master
Landlord Obligations and that the services and repairs that are incorporated herein by reference, including </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
but not limited to the furnishing of elevators or other services or maintenance, restoration (following casualty or destruction), or repairs to the Building or the Premises which are Master
Landlord Obligations will in fact be furnished by Master Landlord and not Sublandlord, except to the extent otherwise provided herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> Except as provided in this Sublease, Sublandlord shall have no other obligations to Subtenant with respect to the Premises or the performance of the Master Landlord Obligations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. Intentionally Omitted. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>11. Insurance. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Subtenant shall be responsible for compliance
with the insurance provisions applicable to the Tenant under the Master Lease. Such insurance shall insure the performance by Subtenant of its indemnification obligations hereunder and shall name Master Landlord and Sublandlord as additional
insureds. All insurance required under this Sublease shall contain an endorsement requiring thirty (30)&nbsp;days written notice from the insurance company to Subtenant and Sublandlord before cancellation or change in the coverage, insureds or
amount of any policy. Subtenant shall provide Sublandlord with certificates of insurance evidencing such coverage prior to the commencement of this Sublease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> The waiver of subrogation provision contained in Section&nbsp;14.4 of the Master Lease shall be deemed to be a three party agreement binding among and inuring to the benefit of Sublandlord,
Subtenant and Master Landlord (by reason of its consent hereto). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. Default.</B> In addition to the events of default
described in the Master Lease which have been incorporated by reference in Section&nbsp;8(a) of this Sublease, failure of Subtenant to make any payment of Rent as and when due shall constitute an event of default hereunder. If Subtenant&#146;s event
of default causes an event of default by Sublandlord under the Master Lease, Subtenant shall defend, indemnify and hold Sublandlord harmless from all damages, costs (including reasonable attorneys&#146; fees), liability, expenses or claims relating
to such default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. Assignment and Subletting.</B> Subtenant may not assign, sublet, transfer, pledge, hypothecate or
otherwise encumber the Premises, in whole or in part, or permit the use or occupancy of the Premises by anyone other than Subtenant, unless Subtenant has obtained Sublandlord&#146;s consent thereto (which shall not be unreasonably withheld) and the
consent of Master Landlord; provided, however, that Subtenant shall have the right to engage in a Permitted Transfer (as defined in Section&nbsp;15.1 of the Master Lease) without such consent (but with prior written notice by Subtenant to
Sublandlord unless such prior notice is prohibited by applicable law, in which case notice shall be given as soon as reasonably practical and permitted by applicable law). Regardless of Sublandlord&#146;s consent, no subletting or assignment shall
release Subtenant of its obligations hereunder. Any rent or other consideration payable to Subtenant pursuant to any sublease or assignment permitted by this paragraph shall be the sole property of Subtenant. Neither the Master Lease nor any other
agreement between Master Landlord and Sublandlord requires Sublandlord to remit to Master Landlord any rent or other consideration payable pursuant to any sublease or assignment, provided the foregoing will not negate Subtenant&#146;s obligation to
pay Rent or any other amount due hereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. Parking.</B> Subtenant shall have such parking rights as Sublandlord may have in
connection with the Premises pursuant to the Master Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. Early Termination of Master Lease.</B> If, without the
fault of Sublandlord or Subtenant, the Master Lease should terminate prior to the expiration of this Sublease, neither party shall have any liability to the other party. To the extent that the Master Lease grants Sublandlord any discretionary right
to terminate the Master Lease, whether due to casualty, condemnation or otherwise, Sublandlord shall not be entitled to exercise such right without Subtenant&#146;s consent, which may be granted or withheld in Subtenant&#146;s sole discretion.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. Consent of Master Landlord.</B> If Subtenant desires to take any action that requires the consent of Master Landlord
pursuant to the terms of the Master Lease, including, without limitation, making any modification, alteration or improvement of the Premises or entering into a further sublease or assignment of this Sublease, and in any event if Subtenant desires to
make any alternation to the Premises, then, notwithstanding anything to the contrary herein, (a)&nbsp;if Master Landlord consents, then Sublandlord shall not unreasonably withhold or delay its consent to any such action (and Sublandlord shall be
deemed to have consented to such action if Sublandlord does not expressly withhold its consent on or before the date that is ten (10)&nbsp;business days after Master Landlord consents to such action), (b)&nbsp;Subtenant shall not take any such
action until it obtains the consent of both Sublandlord and Master Landlord and (c)&nbsp;Subtenant shall request that Sublandlord obtain Master Landlord&#146;s consent on Subtenant&#146;s behalf, unless Sublandlord agrees that Subtenant may contact
Master Landlord directly with respect to the specific action for which Master Landlord&#146;s consent is required. If Subtenant requests that Sublandlord obtain Master Landlord&#146;s consent on any matter, Sublandlord shall use its commercially
reasonable efforts, at no out-of-pocket expense to Sublandlord, to obtain such consent from Master Landlord, unless Master Landlord and Sublandlord agree that Subtenant may contact Master Landlord directly with respect to the specific action for
which Master Landlord&#146;s consent is required. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. Surrender of Premises.</B> In lieu of any obligation or liability
set forth in the Master Lease, upon the termination of this Sublease, Subtenant shall surrender the Premises to Sublandlord broom-clean and in as good a condition as on the Commencement Date, ordinary wear and tear excepted. In addition, except as
further set forth below, Subtenant shall remove any alterations, additions and improvements made by or at the request of Subtenant (whether or not made with Sublandlord&#146;s consent) prior to the termination of this Sublease and restore the
Premises to its prior condition, ordinary wear and tear excepted, repairing all damage caused by or related to any such removal, all at Subtenant&#146;s expense; provided, however, that Subtenant shall not be obligated to remove any of the Tenant
Improvements, or any subsequent alteration, addition or improvement which Sublandlord or Master Landlord did not elect to require Subtenant to remove pursuant to Section&nbsp;11.2 of the Master Lease (as incorporated by reference herein) or to the
extent that Sublandlord had previously waived in writing the right to require Subtenant to remove certain alterations at the time of construction or installation of such alterations. Notwithstanding anything to the contrary contained in this
Sublease, to the extent that Subtenant continues to occupy the Premises pursuant to a direct lease with Master Landlord and Master Landlord does not require any such action on the part of Sublandlord under the Master Lease, the provisions of the
preceding sentence shall not apply upon the expiration of the Sublease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. No Third Party Rights.</B> The benefit of the provisions of this Sublease is
expressly limited to Sublandlord and Subtenant and their respective permitted successors and assigns. Under no circumstances will any third party be construed to have any rights as a third party beneficiary with respect to any of said provisions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19. Time of Essence.</B> It is expressly understood and agreed that time is of the essence of this Sublease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. Attorneys&#146; Fees.</B> If any action or proceeding at law or in equity shall be brought to enforce or interpret any of the
provisions of this Sublease, the prevailing party shall be entitled to recover from the other party its reasonable attorneys&#146; fees and costs incurred in connection with the prosecution or defense of such action or proceeding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. Approval of Master Landlord.</B> This Sublease shall be conditioned upon, and shall not take effect until, receipt of the written
consent of Master Landlord hereto. Upon receipt of such consent, this Sublease shall be effective as of the Commencement Date. Sublandlord and Subtenant acknowledge and agree that in granting such consent, notwithstanding any other provisions
contained in or implied in this Sublease, Master Landlord shall not be deemed or construed (a)&nbsp;to have released Sublandlord from any responsibility for the full and timely performance of all obligations of Sublandlord as Tenant under the Master
Lease as it pertains to the Premises, nor (b)&nbsp;to have authorized Sublandlord to act on Master Landlord&#146;s behalf in exercising or waiving any rights, remedies or privileges of Master Landlord as Landlord under the Master Lease as it
pertains to the Premises, nor (c)&nbsp;to have assumed, incurred or undertaken any obligations or liabilities running directly to Subtenant with respect to the Premises, it being the explicit intention and understanding of the parties that,
notwithstanding the incorporation by reference of a portion of the Master Lease into this Sublease, Master Landlord and Sublandlord shall look solely to one another for the performance of their respective obligations with respect to the Premises as
Landlord and Tenant under the Master Lease, and that Sublandlord and Subtenant shall look solely to one another for the performance of their respective obligations with respect to the Premises under this Sublease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22. Notices.</B> The addresses specified in the Master Lease for receipt of notices to each of the parties are deleted and replaced
with the following: </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="75%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>To&nbsp;Sublandlord&nbsp;at:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amgen SF, LLC</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One Amgen Center Drive - 28-3-D</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thousand Oaks, CA 91320</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: Jerry Bernie</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>To&nbsp;Subtenant&nbsp;at:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raven biotechnologies, inc.</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1140 Veterans Drive</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;South San Francisco, CA 94080</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Attn: CFO</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23. Brokers.</B> Each party hereto represents and warrants that it has dealt with no broker in
connection with this Sublease and the transactions contemplated herein other than Gerald A. Porter of CRESA Partners on behalf of Sublandlord and Chris Jacobs of CB Richard Ellis, on behalf of Subtenant (collectively &#147;Brokers&#148;).
Sublandlord shall be responsible for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
payment of any commissions due to Brokers as a result of this Sublease. Each party shall indemnify, protect, defend and hold the other party harmless from all costs and expenses (including
reasonable attorneys&#146; fees) arising from or relating to a breach of the foregoing representation and warranty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24. No
Existing Defaults.</B> Sublandlord represents and warrants to Subtenant that as of the date hereof the Master Lease is in full force and effect, that Sublandlord has neither given nor received written notice of default under the Master Lease, and
that Sublandlord is not aware of any event which with the giving of notice or the passage of time could give rise to a default under the Master Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>25. Quiet Enjoyment.</B> Sublandlord covenants that Subtenant shall peacefully have, hold and enjoy the Premises, subject to the terms and conditions of this Sublease and subject to the Master Lease,
provided that Subtenant pays all rent and performs all of Subtenant&#146;s covenants and agreements contained herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26.
Damage and Destruction.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <U>Termination of Master Lease</U>. If the Premises is damaged or destroyed and the
Master Landlord, or Sublandlord with Subtenant&#146;s consent, exercises any option either may have to terminate the Master Lease, if any, this Sublease shall terminate as of the date of the casualty. In the event that after a damage or destruction
of the Premises, where the time estimated to restore the Premises exceeds 180 days, Subtenant shall have the right to terminate this Sublease on written notice to Sublandlord given within thirty (30)&nbsp;days after determination of the amount of
time to restore the Premises, which termination shall be effective as of the date of the casualty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <U>Continuation
of Sublease</U>. If the Master Lease or this Sublease is not terminated following any damage or destruction as provided in subsection (a)&nbsp;above, this Sublease shall remain in full force and effect, and Rent shall be abated proportionately to
the extent rent payable under the Master Lease is abated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27. Eminent Domain. </B>If all or any material portion of the
Premises is condemned by eminent domain, inversely condemned or sold in lieu of condemnation, for any public or a quasi-public use or purpose, this Sublease may be terminated as of the date of title vesting in such proceeding by either party, and
Rent shall be adjusted to the date of termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28. Tenant Improvements and Subtenant Allowance.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Construction of the Tenant Improvements (as defined in Exhibit C) shall be governed by the Tenant Improvement Agreement attached hereto
as Exhibit C. Sublandlord and Subtenant agree to comply with all of the terms and provisions of the Tenant Improvement Agreement, which is hereby incorporated by reference as though fully set forth herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[THIS SPACE INTENTIONALLY LEFT BLANK] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XECUTED</SMALL> </B>as of the date first written above. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="45%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBLANDLORD</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MGEN</SMALL> SF, LLC,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware limited liability company</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" ROWSPAN="3">


<IMG SRC="g575431stamped204a.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBTENANT</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>R<SMALL>AVEN</SMALL> <SMALL>BIOTECHNOLOGIES</SMALL>, <SMALL>INC</SMALL>.,</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> S<SMALL>UBLEASE</SMALL>] </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XECUTED</SMALL> </B>as of the date first written above. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBLANDLORD</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MGEN</SMALL> SF, LLC,</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">a Delaware limited liability company</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:1px"><FONT SIZE="1">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SUBTENANT</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>R<SMALL>AVEN</SMALL> <SMALL>BIOTECHNOLOGIES</SMALL>, <SMALL>INC</SMALL>.,</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">a Delaware corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[S<SMALL>IGNATURE</SMALL> P<SMALL>AGE</SMALL> <SMALL>TO</SMALL> S<SMALL>UBLEASE</SMALL>] </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XHIBIT</SMALL> A </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MASTER LEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">See
attached. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BUILD-TO-SUIT LEASE </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="50%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="81%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">LANDLORD:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRITANNIA DEVELOPMENTS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TENANT:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TULARIK, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">DATE:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">APRIL 20, 1995</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BUILD-TO-SUIT-LEASE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">PROPERTY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1&nbsp;&nbsp;&nbsp;&nbsp; Lease of Property.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2&nbsp;&nbsp;&nbsp;&nbsp; Landlord&#146;s Reserved Rights.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TERM</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1&nbsp;&nbsp;&nbsp;&nbsp; Term.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2&nbsp;&nbsp;&nbsp;&nbsp; Early Possession.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3&nbsp;&nbsp;&nbsp;&nbsp; Delay In Possession.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4&nbsp;&nbsp;&nbsp;&nbsp; Acknowledgement Of Lease Commencement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5&nbsp;&nbsp;&nbsp;&nbsp; Holding Over.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6&nbsp;&nbsp;&nbsp;&nbsp; Option To Extend Term.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">RENTAL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1&nbsp;&nbsp;&nbsp;&nbsp; Minimum Rental.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2&nbsp;&nbsp;&nbsp;&nbsp; Late Charge.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">STOCK WARRANTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1&nbsp;&nbsp;&nbsp;&nbsp; Stock Warrants.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONSTRUCTION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1&nbsp;&nbsp;&nbsp;&nbsp; Construction of Improvements.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2&nbsp;&nbsp;&nbsp;&nbsp; Condition of Property.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3&nbsp;&nbsp;&nbsp;&nbsp; Compliance with Law.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXPANSION BUILDING</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1&nbsp;&nbsp;&nbsp;&nbsp; Lock-Up Option.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2&nbsp;&nbsp;&nbsp;&nbsp; Exercise.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3&nbsp;&nbsp;&nbsp;&nbsp; Carrying Costs.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4&nbsp;&nbsp;&nbsp;&nbsp; First Negotiation Right and First Refusal Right to Lease.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">FIRST REFUSAL RIGHT TO PURCHASE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1&nbsp;&nbsp;&nbsp;&nbsp; Sale Restriction.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2&nbsp;&nbsp;&nbsp;&nbsp; First Refusal Right.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3&nbsp;&nbsp;&nbsp;&nbsp; Discount on Purchase Price.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TAXES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1&nbsp;&nbsp;&nbsp;&nbsp; Personal Property.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2&nbsp;&nbsp;&nbsp;&nbsp; Real Property.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">OPERATING EXPENSES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1&nbsp;&nbsp;&nbsp;&nbsp; Liability For Operating Expenses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2&nbsp;&nbsp;&nbsp;&nbsp; Definition Of Operating Expenses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3&nbsp;&nbsp;&nbsp;&nbsp; Determination and Payment Of Operating Expenses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4&nbsp;&nbsp;&nbsp;&nbsp; Proration.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">UTILITIES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1&nbsp;&nbsp; Payment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2&nbsp;&nbsp; Interruption.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">ALTERATION; SIGNS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1&nbsp;&nbsp; Right To Make Alterations.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2&nbsp;&nbsp; Title To Alterations.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3&nbsp;&nbsp; Tenant Fixtures.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4&nbsp;&nbsp; No Liens.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5&nbsp;&nbsp; Signs.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MAINTENANCE AND REPAIRS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1&nbsp;&nbsp; Landlord&#146;s Work.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2&nbsp;&nbsp; Tenant&#146;s Obligation For Maintenance.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">USE OF PROPERTY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1&nbsp;&nbsp; Permitted Use</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2&nbsp;&nbsp; [Omitted.]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3&nbsp;&nbsp; No Nuisance.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4&nbsp;&nbsp; Compliance With Laws.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5&nbsp;&nbsp; Liquidation Sales.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6&nbsp;&nbsp; Environmental Matters.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">INSURANCE AND INDEMNITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1&nbsp;&nbsp; Liability and Property Insurance.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2&nbsp;&nbsp; Quality Of Policies And Certificates.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3&nbsp;&nbsp; Workers&#146; Compensation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4&nbsp;&nbsp; Waiver Of Subrogation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5&nbsp;&nbsp; Increase In Premiums.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6&nbsp;&nbsp; Indemnification.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7&nbsp;&nbsp; Blanket Policy.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SUBLEASE AND ASSIGNMENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1&nbsp;&nbsp; Assignment And Sublease Of Property.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2&nbsp;&nbsp; Rights Of Landlord.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">RIGHT OF ENTRY AND QUIET ENJOYMENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1&nbsp;&nbsp; Right Of Entry.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2&nbsp;&nbsp; Quiet Enjoyment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CASUALTY AND TAKING</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.1&nbsp;&nbsp; Damage or Destruction.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2&nbsp;&nbsp; Condemnation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3&nbsp;&nbsp; Reservation Of Compensation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.4&nbsp;&nbsp; Restoration Of Improvements.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFAULT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.1&nbsp;&nbsp; Events Of Default.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.2&nbsp;&nbsp; Remedies Upon Tenant&#146;s Default.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.3&nbsp;&nbsp; Remedies Cumulative.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SUBORDINATION, ATTORNMENT AND SALE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.1&nbsp;&nbsp; Subordination To Mortgage.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.2&nbsp;&nbsp; Sale Of Landlord&#146;s Interest.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.3&nbsp;&nbsp; Estoppel Certificates.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.4&nbsp;&nbsp; Subordination to CC&amp;R&#146;s.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.5&nbsp;&nbsp; Mortgagee Protection.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SECURITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">20.1&nbsp;&nbsp; Deposit.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MISCELLANEOUS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.1&nbsp;&nbsp; Notices.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.2&nbsp;&nbsp; Successors And Assigns.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.3&nbsp;&nbsp; No Waiver.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.4&nbsp;&nbsp; Severability.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- ii -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.5&nbsp;&nbsp; Litigation Between Parties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.6&nbsp;&nbsp; Surrender.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.7&nbsp;&nbsp; Interpretation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.8&nbsp;&nbsp; Entire Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.9&nbsp;&nbsp; Governing Law.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.10 No Partnership.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.11 Financial Information.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.12 Costs.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.13 Time.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.14 Rules And Regulations.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.15 Brokers.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.16 Memorandum Of Lease.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.17 Corporate Authority.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.18 Execution and Delivery.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.19 Survival.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>EXHIBITS </U></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Real Property Description (Site)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT B</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workletter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated Construction Schedule</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT E</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acknowledgement of Lease Commencement</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- iii -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>BUILD-TO-SUIT LEASE </U></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS BUILD-TO-SUIT LEASE (&#147;Lease&#148;) is made and entered into as of the 20th day of April, 1995, by and between BRITANNIA
DEVELOPMENTS, INC., a California corporation (&#147;Landlord&#148;), and TULARIK INC., a California corporation (&#147;Tenant&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">THE PARTIES AGREE AS FOLLOWS: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>PROPERTY</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 <U>Lease of Property</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Landlord leases to Tenant and Tenant hires and leases from Landlord, on the terms, covenants and conditions hereinafter set forth, the building (the &#147;Initial Building&#148;) to be constructed
pursuant to Article 5 hereof and <U>Exhibit C</U> attached hereto on the real property described in <U>Exhibit A</U> attached hereto (the &#147;Site&#148;), to consist of a two-story office and laboratory building containing approximately 66,127
square feet (measured in accordance with the BOMA standard most closely applicable to a two-story, single-tenant building of this nature). The location of the Initial Building on the Site is intended to be substantially as shown for &#147;Building
B&#148; on the site plan attached hereto as <U>Exhibit B.</U> The Initial Building and the other improvements to be constructed, pursuant to Article 5 hereof and <U>Exhibit C</U> attached hereto, on the portion of the Site designated as &#147;Phase
I&#148; on <U>Exhibit B</U> attached hereto (the &#147;Phase&nbsp;I Site&#148;) are sometimes referred to collectively herein as the &#147;Improvements,&#148; and the Improvements and the Phase I Site are sometimes referred to collectively herein as
the &#147;Property.&#148; The parking areas, driveways, sidewalks, landscaped areas and other portions of the Phase I Site that lie outside the exterior walls of the Initial Building, as depicted on the site plan attached hereto as <U>Exhibit B,</U>
are sometimes referred to herein as the &#147;Common Areas.&#148; The Site is part of The Britannia Biotechnology Center in South San Francisco, California. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) As an appurtenance to Tenant&#146;s leasing of the Initial Building pursuant to Section l.l(a), Landlord hereby grants to Tenant, for the benefit of Tenant and its employees, suppliers, shippers,
customers and invitees, during the term of this Lease, the non-exclusive right to use, in common with others entitled to such use, (i) those portions of the Common Areas improved from time to time for use as parking areas, driveways, sidewalks,
landscaped areas, or for other common purposes, and (ii)&nbsp;all easements, access rights and similar rights and privileges relating to or appurtenant to the Property and created or existing from time to time under any easement agreements,
declarations of covenants, conditions and restrictions, or other written agreements now of record with respect to the Site, including (but not limited to) the portion of the Site designated as &#147;Phase II&#148; on <U>Exhibit B</U> attached hereto
(the &#147;Phase II Site&#148;), subject however to any limitations applicable to such rights and privileges under applicable law and/or under the written agreements creating such rights and privileges. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 <U>Landlord&#146;s Reserved Rights</U>. To the extent reasonably necessary to permit Landlord to exercise any rights of Landlord and
discharge any obligations of Landlord under this Lease, Landlord shall have, in addition to the right of entry set forth in Section&nbsp;16.1 hereof, the following rights: (i)&nbsp;to make changes to the Common Areas, including, without limitation,
changes in the location, size or shape of any portion of the Common Areas and to relocate (but not materially decrease the number of) parking spaces on the Phase I Site; (ii)&nbsp;to close temporarily any of the Common Areas for maintenance or other
reasonable purposes, provided that reasonable parking and reasonable access to the Initial Building remain available; (iii)&nbsp;to construct, alter or add to other buildings or improvements on the Site (including, but not limited to, construction
of a building in the area designated as &#147;Building A&#148; on the site plan attached hereto as <U>Exhibit B,</U> and construction of site improvements and common area improvements in the Phase II Site; (iv)&nbsp;to build adjoining to the
Property and/or the Site; (v)&nbsp;to use the Common Areas while engaged in making additional improvements, repairs or alterations to the Property, or any portion thereof; and (vi)&nbsp;to do and perform such other acts with respect to the Common
Areas and the Property as may be necessary or appropriate; <U>provided,</U> however, that notwithstanding anything to the contrary in this Section&nbsp;1.2, Landlord&#146;s exercise of its rights hereunder (x)&nbsp;shall not cause any material
diminution of Tenant&#146;s rights, nor any material increase of Tenant&#146;s obligations, under this Lease or with respect to the Improvements, (y)&nbsp;shall not authorize Landlord to make any material, permanent alterations in the Improvements
without </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the prior written consent of Tenant, which consent shall not be unreasonably withheld or delayed, and (z)&nbsp;shall be conducted in such a manner as to minimize, to the extent reasonably
possible, any adverse effect on Tenant&#146;s business operations on the Phase I Site (including, but not limited to, reasonable prior notice to Tenant of any pile-driving or other activities that will cause significant noise or vibration on the
Phase I Site). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>TERM</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Term</U>. The term of this Lease shall commence on the later to occur of (i) the date which is six (6)&nbsp;months after the date Landlord delivers to Tenant a Structural Completion Certificate
pursuant to the Workletter attached hereto as <U>Exhibit C</U>, subject to any adjustments authorized or required under the provisions of such <U>Exhibit C</U>, or (ii) February&nbsp;1, 1996, the later of such dates being herein called the
&#147;Commencement Date,&#148; and shall end on the day immediately preceding the date fifteen (15)&nbsp;years thereafter, unless sooner terminated or extended (if applicable) as hereinafter provided. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Early Possession</U>. Tenant shall have the nonexclusive right to occupy and take possession of the Phase I Site from and after
the date of Landlord&#146;s delivery of the Structural Completion Certificate described in clause (i)&nbsp;of Section&nbsp;2.1, even though such date is prior to the Commencement Date determined under Section&nbsp;2.1 and even though Landlord will
be continuing to construct the balance of Landlord&#146;s Work as contemplated in <U>Exhibit C</U>, for the purpose of constructing Tenant&#146;s Work as contemplated in <U>Exhibit C</U>. Such occupancy and possession, and any early access under the
next sentence of this Section&nbsp;2.2, shall be subject to and upon all of the terms and conditions of this Lease and of the Workletter attached hereto as <U>Exhibit C</U> (including, but not limited to, conditions relating to the maintenance of
required insurance), except that Tenant shall have no obligation to pay minimum rental or Operating Expenses for any period prior to the Commencement Date as determined under Section&nbsp;2.1; such early possession shall not advance or otherwise
affect the Commencement Date or termination date determined under Section&nbsp;2.1. Tenant shall also be entitled to have early access to the Phase I Site at all appropriate times prior to Landlord&#146;s delivery of the Structural Completion
Certificate, subject to the approval of Landlord and its contractor (which approval shall not be unreasonably withheld or delayed), solely for the purpose of installing fixtures and equipment and other similar work preparatory to the construction of
Tenant&#146;s Work and the commencement of Tenant&#146;s business on the Property, and Tenant shall not be required to pay minimum rental or Operating Expenses by reason of such early access until the Commencement Date otherwise occurs. Tenant shall
not interfere with or delay Landlord&#146;s contractors by any such early access, occupancy or possession under this Section&nbsp;2.2 prior to Landlord&#146;s delivery of the Structural Completion Certificate, shall coordinate and cooperate with
Landlord and its contractors (who shall similarly coordinate and cooperate with Tenant and its contractors) to minimize any interference or delay by either party with respect to the other party&#146;s work following Landlord&#146;s delivery of the
Structural Completion Certificate, and shall indemnify, defend and hold harmless Landlord and its agents and employees from and against any and all claims, demands, liabilities, actions, losses, costs and expenses, including (but not limited to)
reasonable attorneys&#146; fees, arising out of or in connection with Tenant&#146;s early entry upon the Phase I Site hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Delay In Possession</U>. Landlord agrees to use its best reasonable efforts to complete promptly its portion of the work described in Section&nbsp;5.1 and <U>Exhibit C</U>; provided, however,
Landlord shall not be liable for any damages caused by any delay in the completion of such work, nor shall any such delay affect the validity of this Lease or the obligations of Tenant hereunder. Notwithstanding any other provision of this
Section&nbsp;2.3, however, if Landlord fails to deliver the Structural Completion Certificate and tender possession of the completed structural portions of the Building Shell (<U>i.e.</U>, those portions required to be completed as a condition of
delivery of the Structural Completion Certificate) to Tenant by April&nbsp;30, 1996, then Tenant shall have the right to terminate this Lease without further liability hereunder by written notice delivered to Landlord at any time prior to
Landlord&#146;s delivery of the Structural Completion Certificate and tender of possession of the completed structural portions of the Building Shell to Tenant; <U>provided</U>, however, that the deadline of April&nbsp;30, 1996 set forth in this
sentence shall be extended, day for day, for a period equal to the length of any delay beyond May&nbsp;31, 1995 in Tenant&#146;s delivery to Landlord of all information reasonably necessary for Landlord to complete the preparation of all drawings,
designs and specifications for the Building Shell. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-2-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 <U>Acknowledgement Of Lease Commencement</U>. Upon commencement of the term of this
Lease, Landlord and Tenant shall execute a written acknowledgement of the Commencement Date, date of termination and related matters, substantially in the form attached hereto as <U>Exhibit E</U> (with appropriate insertions), which acknowledgement
shall be deemed to be incorporated herein by this reference. Notwithstanding the foregoing requirement, the failure of Tenant to execute such a written acknowledgement shall not affect the determination of the Commencement Date, date of termination
and related matters in accordance with the provisions of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5 <U>Holding Over</U>. If Tenant holds possession of
the Property or any portion thereof after the term of this Lease with Landlord&#146;s written consent, then except as otherwise specified in such consent, Tenant shall become a tenant from month to month at one hundred twenty-five percent
(125%)&nbsp;of the rental and otherwise upon the terms herein specified for the period immediately prior to such holding over and shall continue in such status until the tenancy is terminated by either party upon not less than thirty (30)&nbsp;days
prior written notice. If Tenant holds possession of the Property or any portion thereof after the term of this Lease without Landlord&#146;s written consent, then Landlord in its sole discretion may elect (by written notice to Tenant) to have Tenant
become a tenant either from month to month or at will, at one hundred fifty percent (150%)&nbsp;of the rental (prorated on a daily basis for an at-will tenancy, if applicable) and otherwise upon the terms herein specified for the period immediately
prior to such holding over, or may elect to pursue any and all legal remedies available to Landlord under applicable law with respect to such unconsented holding over by Tenant. Tenant shall indemnify and hold Landlord harmless from any loss,
damage, claim, liability, cost or expense (including reasonable attorneys&#146; fees) resulting from any delay by Tenant in surrendering the Property (except with Landlord&#146;s prior written consent), including but not limited to any claims made
by a succeeding tenant by reason of such delay. Acceptance of rent by Landlord following expiration or termination of this Lease shall not constitute a renewal of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.6 <U>Option To Extend Term</U>. Tenant shall have the option to extend the term of this Lease, at the minimum rental set forth in Section&nbsp;3.1(b) and (c)&nbsp;and otherwise upon all the terms and
provisions set forth herein with respect to the initial term of this Lease, for up to two (2)&nbsp;additional periods of five (5)&nbsp;years each, the first commencing upon the expiration of the initial term hereof and the second commencing upon the
expiration of the first extended term, if any. Exercise of such option with respect to the first such extended term shall be by written notice to Landlord at least nine (9)&nbsp;months prior to the expiration of the initial term hereof, exercise of
such option with respect to the second extended term, if the first extension option has been duly exercised, shall be by like written notice to Landlord at least nine (9)&nbsp;months prior to the expiration of the first extended term hereof. If
Tenant is in default hereunder on the date of such notice or on the date any extended term is to commence, then the option shall be of no force or effect, the extended term shall not commence and this Lease shall expire at the end of the then
current term hereof (or at such earlier time as Landlord may elect pursuant to the default provisions of this Lease). If Tenant properly exercises one or more extension options under this Section, then all references in this Lease (other than in
this Section&nbsp;2.6) to the &#147;term&#148; of this Lease shall be construed to include the extension term(s) thus elected by Tenant. Except as expressly set forth in this Section&nbsp;2.6, Tenant shall have no right to extend the term of this
Lease beyond its prescribed term. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-3-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>RENTAL</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Minimum Rental</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Tenant shall pay to Landlord as minimum rental
for the Property, in advance, <I>without deduction, offset, notice or demand, on or before the Commencement Date</I> and on or before the first day of each subsequent calendar month of the term of this Lease, the following amounts per month:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:24pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Months</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Minimum&nbsp;Rental</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1&nbsp;-&nbsp;6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">119,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7&nbsp;-&nbsp;12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">13&nbsp;-&nbsp;24</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,770</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">25&nbsp;-&nbsp;36</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">160,689</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">37&nbsp;-&nbsp;48</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">164,656</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">49&nbsp;-&nbsp;60</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">171,930</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">61&nbsp;-&nbsp;72</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">173,253</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">73&nbsp;-&nbsp;84</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">149,447</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">85&nbsp;-&nbsp;96</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">97&nbsp;-108</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">158,705</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">109&nbsp;-&nbsp;120</FONT></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">163,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">121&nbsp;-&nbsp;132</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">148,786</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">133&nbsp;-&nbsp;144</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">154,076</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">145&nbsp;-&nbsp;156</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">159,366</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">157&nbsp;-&nbsp;168</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">165,318</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">169&nbsp;-&nbsp;180</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">170,608</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the obligation to pay minimum rental hereunder commences on other than the first day of a calendar month or if the
term of this Lease terminates on other than the last day of a calendar month, the minimum rental for such first or last month of the term of this Lease, as the case may be, shall be prorated based on the number of days the term of this Lease is in
effect during such month. If an increase in minimum rental becomes effective on a day other than the first day of a calendar month, the minimum rental for that month shall be the sum of the two applicable rates, each prorated for the portion of the
month during which such rate is in effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If Tenant properly exercises its right to extend the term of this Lease
pursuant to Section&nbsp;2.6 hereof, the minimum rental during the first extended term shall be equal to the greater of (i)&nbsp;$144,157 per month or (ii)&nbsp;ninety-five percent (95%)&nbsp;of the fair market rental value of the Property (as
defined below), including any rental increase provisions then customary in the relevant market for comparable commercial leases, determined as of the commencement of such extended term in accordance with this paragraph. Upon Landlord&#146;s receipt
of a proper notice of Tenant&#146;s exercise of its option to extend the term of this Lease, the parties shall have sixty (60)&nbsp;days in which to agree on the fair market rental (including any applicable rental increase provisions) for the
Property at the commencement of the first extended term for the uses permitted hereunder. If the parties agree on such fair market rental and rental increase provisions (if any), they shall execute an amendment to this Lease stating the amount of
the applicable minimum monthly rental and any applicable rental increase provisions. If the parties are unable to agree on such rental (including any applicable rental increase provisions) within such sixty (60)&nbsp;day period, then within fifteen
(15)&nbsp;days after the expiration of such period each party, at its cost and by giving notice to the other party, shall appoint a real estate appraiser with at least five (5)&nbsp;years experience appraising similar commercial properties in
northeastern San Mateo County to appraise and set the fair market rental and any applicable rental increase provisions for the Property at the commencement of the first extended term. If either party fails to appoint an appraiser within the allotted
time, the single appraiser appointed by the other party shall be the sole appraiser. If an appraiser is appointed by each party and the two appraisers so appointed are unable to agree upon a fair market rental (and any appropriate rental increase
provisions) within thirty (30)&nbsp;days after the appointment of the second, they shall appoint a third qualified appraiser within ten (10)&nbsp;days after expiration of such 30-day period; if they are unable to agree upon a third appraiser, either
party may, upon not less than five (5)&nbsp;days notice to the other party, apply to the Presiding Judge of the San Mateo County Superior Court for the appointment of a third qualified appraiser. Each party shall bear its own legal fees in
connection with appointment of the third appraiser and shall bear one-half of any other costs of appointment of the third appraiser and of such third appraiser&#146;s fee. The third appraiser, however selected, shall be a person who has not
previously acted for either party in any capacity. Within thirty (30)&nbsp;days after the appointment of the third appraiser, a majority of the three appraisers shall set the fair market <I>rental and any applicable rental increase provisions for
the first extended term and shall so notify</I> the parties. If a majority are unable to agree within the allotted time, (i)&nbsp;the three appraised fair market rentals shall be added together and divided by three and the resulting quotient shall
be the fair market rental for the first extended term, and (ii)&nbsp;the applicable rental increase provision shall be equal to the mathematical average (or the nearest reasonable approximation thereto) of the two </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-4-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rental increase provisions that are most closely comparable, which determinations shall be binding on the parties and shall be enforceable in any further proceedings relating to this Lease. For
purposes of this Section 3.1(b), the &#147;fair market rental&#148; of the Property shall be determined with reference to the then prevailing market rental rates for properties in northeastern San Mateo County with shell and standard office,
research and development improvements and site (common area) improvements comparable to those then existing in the Initial Building and on the Property; no equipment or laboratory improvements shall be taken into account in determining such fair
market rental. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If Tenant properly exercises its right to a second extended term of this Lease pursuant to Section 2.6
hereof, the minimum rental during such second extended term shall be determined in the same manner provided in the preceding paragraph for the first extended term, except that the determination shall be made as of the commencement of the second
extended term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The minimum rental amounts specified in this Section 3.1 are based upon an estimated area of 66,127 square
feet for the Initial Building. If the actual area of the Initial Building, when completed, is greater or less than such estimated area, then the minimum rentals, specified in this Section 3.1 shall be adjusted proportionately to the change in the
area of the Initial Building, measured in accordance with the BOMA standard most closely applicable to a two-story, single-tenant building of this nature; <U>provided,</U> however, that the foregoing provision shall not apply to the minimum rental
for months 1 through 12 of the initial term, which rental is based on a negotiated square footage of less than the full area of the Initial Building and is not intended to be subject to adjustment under this paragraph (d). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Late Charge</U>. If Tenant fails to pay when due rental or other amounts due Landlord hereunder, such unpaid amounts shall bear
interest for the benefit of Landlord at a rate equal to the lesser of fifteen percent (15%) per annum or the maximum rate permitted by law, from the date due to the date of payment. In addition to such interest, Tenant shall pay to Landlord a late
charge in an amount equal to ten percent (10%) of any installment of minimum rental and any other amounts due Landlord if not paid in full on or before the fifth (5th) day after such rental or other amount is due. Tenant acknowledges that late
payment by Tenant to Landlord of rental or other amounts due hereunder will cause Landlord to incur costs not contemplated by this Lease, including, without limitation, processing and accounting charges and late charges which may be imposed on
Landlord by the terms of any loan relating to the Property. Tenant further acknowledges that it is extremely difficult and impractical to fix the exact amount of such costs and that the late charge set forth in this Section 3.2 represents a fair and
reasonable estimate thereof. Acceptance of any late charge by Landlord shall not constitute a waiver of Tenant&#146;s default with respect to overdue rental or other amounts, nor shall such acceptance prevent Landlord from exercising any other
rights and remedies available to it. Acceptance of rent or other payments by Landlord shall not constitute a waiver of late charges or interest accrued with respect to such rent or other payments or any prior installments thereof, nor of any other
defaults by Tenant, whether monetary or non-monetary in nature, remaining uncured at the time of such &#145;acceptance of rent or other payments. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4. <U>STOCK WARRANTS</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>Stock Warrants</U>. Within fifteen (15) days
after written request by Landlord at any time after execution hereof (but in all events no later than four (4) months after execution hereof), as a condition to Landlord&#146;s obligations hereunder. Tenant shall deliver to Landlord, subject to
compliance by Tenant and Landlord with all applicable securities laws, a warrant registered in Landlord&#146;s name to purchase two hundred thousand (200,000) shares of Tenant&#146;s common stock. The warrant shall have an exercise price of seven
dollars and fifty cents ($7.50) per share and shall be exercisable only after the closing of the initial public offering of Tenant&#146;s common stock and for a period of five (5) years thereafter, and shall be on the terms and conditions as set
forth therein. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-5-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>CONSTRUCTION</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Construction of Improvements</U>. Landlord shall, at Landlord&#146;s cost and expense (except as otherwise provided herein and in
<U>Exhibit C</U>), construct Landlord&#146;s Work as defined in and in accordance with the terms and conditions of the Workletter attached hereto as <U>Exhibit C</U> (the &#147;Workletter&#148;). Landlord shall use its best efforts to complete such
construction in accordance with the estimated construction schedule attached hereto as <U>Exhibit D</U> as the same may be modified or revised from time to time in accordance with the Workletter. Tenant shall, at Tenant&#146;s cost and expense
(except as otherwise provided herein and in <U>Exhibit C</U>), construct Tenant&#146;s Work as defined in and in accordance with the terms and conditions of the Workletter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Condition of Property</U>. Landlord shall deliver the Building Shell and other Improvements constructed by Landlord to Tenant clean and free of debris, promptly upon completion of construction
thereof, and Landlord warrants to Tenant that the Building Shell and other Improvements constructed by Landlord (i) shall be free from material structural defects and (ii) shall be constructed in compliance in all material respects with any and all
applicable specifications mutually approved by Landlord and Tenant, subject to any changes implemented in such specifications in accordance with the procedures set forth in the Workletter. If it is determined that this warranty has been violated in
any respect, then it shall be the obligation of Landlord, after receipt of written notice from Tenant setting forth with specificity the nature of the violation, to promptly, at Landlord&#146;s sole cost, correct the condition(s) constituting such
violation. Tenant&#146;s failure to give such written notice to Landlord within one hundred eighty (180) days after the Commencement Date shall give rise to a conclusive presumption that Landlord has complied with all Landlord&#146;s obligations
hereunder, except with respect to latent defects. Landlord shall also assign to Tenant Landlord&#146;s rights under all contractor&#146;s and other warranties relating to the Building Shell and other Improvements constructed by Landlord
(<U>provided,</U> however, that Landlord may reserve joint enforcement rights under such warranties to the extent of Landlord&#146;s continuing obligations or warranties hereunder), and shall cooperate with Tenant in all reasonable respects in any
enforcement of such assigned warranties. TENANT ACKNOWLEDGES THAT THE WARRANTY CONTAINED IN THIS SECTION IS IN LIEU OF ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE PHYSICAL CONDITION OF THE IMPROVEMENTS TO BE CONSTRUCTED BY LANDLORD
AND THAT LANDLORD MAKES NO OTHER WARRANTIES EXCEPT AS EXPRESSLY SET FORTH IN THIS LEASE. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Compliance with Law</U>.
Landlord warrants to Tenant that the Building Shell and other Improvements constructed by Landlord (when constructed), as they exist on the Commencement Date, but without regard to the use for which Tenant will occupy the Property, shall not violate
any covenants or restrictions of record or any applicable building code, regulation or ordinance in effect on the Commencement Date. Tenant warrants to Landlord that the Interior Improvements and any other improvements constructed by Tenant from
time to time shall not violate any applicable building code, regulation or ordinance in effect on the Commencement Date or at the time such improvements are placed in service. If it is determined that this warranty has been violated, then it shall
be the obligation of the warranting party, after written notice from the other party, to correct the condition(s) constituting such violation promptly, at the warranting party&#146;s sole cost and expense. Tenant acknowledges that neither Landlord
nor any agent of Landlord has made any representation or warranty as to the present or future suitability of the Property for the conduct of Tenant&#146;s business or proposed business thereon. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <U>EXPANSION BUILDING</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Lock-Up Option</U>. The parties acknowledge that Landlord may, subject to the terms hereof, construct a building on the Phase II Site, including (but not limited to) a building in the area
designated as &#147;Building A&#148; in <U>Exhibit B</U> attached hereto. Tenant shall have four consecutive options (each, a &#147;Lock-Up Option&#148;) to prohibit Landlord from entering into an agreement with any party other than Tenant for the
sale or leasing of any such other building then existing on or planned for the Phase II Site (in either case, the &#147;Expansion Building&#148;). Upon Tenant&#146;s timely and proper exercise of a Lock-Up Option, Landlord shall refrain from
entering into such an agreement for a period of six (6) months (a &#147;Lock-Up Period&#148;). Failure to exercise a Lock-Up Option on or before the deadline determined under Section 6.2 shall result in the forfeiture of that Lock-Up Option and all
future Lock-Up Options, if any. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-6-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Exercise</U>. To exercise a Lock-Up Option, Tenant shall provide written notice to
Landlord of such exercise. In the case of the first Lock-Up Option, Tenant must provide such notice not later than fifteen (15) days after a certificate of occupancy or equivalent verbal or written permission to occupy the Initial Building has been
given by the City of South San Francisco to Tenant (or, if the certificate of occupancy or equivalent permission is given to Landlord, then within fifteen (15) days after Landlord&#146;s written notice to Tenant that such certificate of occupancy or
equivalent permission has been given); the first six-month Lock-Up Period shall begin, retroactively, as of the date such certificate of occupancy or equivalent verbal or written permission is given by the City of South San Francisco. In the case of
the subsequent Lock-Up Options, Tenant must provide such notice not later than fifteen (15) days prior to the final day of the Lock-Up Period then in effect. Within ten (10) days after such notice, Landlord shall provide Tenant with written notice
of Landlord&#146;s estimate of the Carrying Costs (as defined in Section 6.3) for the upcoming Lock-Up Period. Tenant shall then pay such amount to Landlord within five (5) days after receipt of such estimate. A Lock-Up Option shall be deemed
validly exercised when and only when Tenant has timely paid such estimated amount pertaining to the applicable Lock-Up Period to Landlord. If Tenant is in default hereunder on the date of its exercise notice or on the date any Lock-Up Period is to
commence, then the Lock-Up Option (and any future Lock-Up Options) shall be of no force or effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Carrying Costs</U>.
As compensation for each Lock-Up Option, Tenant shall pay or reimburse to Landlord all Carrying Costs incurred by Landlord during or with respect to the applicable Lock-Up Period, including (i) interest expense on Landlord&#146;s construction
financing for any site work, off-site improvements or other construction (including, but not limited to, construction of the Expansion Building, if any) on the Phase II Site, (ii) interest expense on Landlord&#146;s acquisition financing or
refinancing for the Phase II Site, and (iii) real property taxes, assessments and insurance on or allocable to the Expansion Building and/or the Phase II Site; <U>provided,</U> however, that Tenant shall not be obligated to pay Landlord an amount
greater than one hundred fifty thousand dollars ($150,000) for Carrying Costs incurred during or with respect to any single Lock-Up Period. Tenant shall pay Landlord&#146;s estimated Carrying Costs for each applicable Lock-Up Period in advance as
contemplated in Section 6.2 hereof. Within ten (10) days after the end of each Lock-Up Period, Landlord shall notify Tenant in writing of Landlord&#146;s actual Carrying Costs for such Lock-Up Period and within ten (10) days after such notice either
(i) Tenant shall pay Landlord the amount by which such actual Carrying Costs exceeded the estimated Carrying Costs paid by Tenant for such period, up to the $150,000 maximum set forth in this Section 6.3, or (ii) Landlord shall pay Tenant the amount
by which the estimated Carrying Costs paid by Tenant exceeded the actual Carrying Costs for such period. If taxes or other Carrying Costs allocable to any Lock-Up Period are increased or decreased (for example, by a tax reduction or additional tax
assessment) following completion of the reconciliation process described in the preceding sentence, Landlord shall promptly notify Tenant in writing of such further increase or decrease and the parties shall make any further adjustment payments in
cash in the same manner contemplated in the preceding sentence. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>First Negotiation Right and First Refusal Right to
Lease</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Landlord shall not lease all or any portion of the Expansion Building at any time during the term of this
Lease, except in compliance with this Section 6.4; provided, however, that the foregoing restriction shall not apply during any period in which Tenant is in default under this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) As specified in Section 6.1 hereof, during any Lock-Up Period duly and timely elected by Tenant, Landlord shall have no right to
agree to sell or lease the Expansion Building to anyone other than Tenant, and therefore shall have no right to invoke the first refusal right provisions in Section 6.4(c). If, however, during any such Lock-Up Period, Tenant notifies Landlord in
writing of Tenant&#146;s desire to lease and occupy the Expansion Building, then Landlord and Tenant shall negotiate diligently and in good faith concerning such terms, subject to the following (unless otherwise mutually agreed by Landlord and
Tenant at the time): Tenant shall have the option to have Landlord construct the building shell for the Expansion Building on substantially the same economic terms as the Initial Building, adjusted to reflect changes in costs of construction and in
cost of money (determined by reference to changes in the Bank of America prime rate). At the time the option is exercised, Landlord and Tenant shall negotiate over tenant improvements and over any additional stock warrants, but Landlord is not
required to agree to construct or fund tenant improvements and Tenant is not required to agree to have Landlord </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-7-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
construct or fund them. The new lease shall have a primary term of 15 years. Upon the commencement of the lease term for the Expansion Building, the term of this Lease for the Initial Building
shall be extended, by amendment, to be coterminous with the primary term of the new lease. The initial rent on the Expansion Building as of Tenant&#146;s occupancy shall take into account, in addition to the cost factors mentioned above, any
required construction or funding of tenant improvements by Landlord, and shall also reflect any changes in Tenant&#146;s financial condition at that time. In any event, however, the initial rent on the Expansion Building shall be no less than the
prevailing rent at that time on the Initial Building, having regard for the fact that the Initial Building included a tenant improvement allowance of $105 per square foot. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) If, at any time during the term of this Lease after the expiration of any and all available Lock-Up Periods, Landlord receives and wishes to accept a <U>bona fide</U> written offer from a person or
entity other than Tenant (the &#147;Offeror&#148;) to lease all or any portion of the Expansion Building and if Tenant is not then in default under this Lease, Landlord shall give written notice of such offer to Tenant, specifying the material terms
on which the Offeror proposes to lease the Expansion Building or portion thereof (the &#147;Offered Space&#148;), and shall offer to Tenant the opportunity to lease the Offered Space on the terms specified in Landlord&#146;s notice. For purposes of
this Section 6.4(c), an offer shall be considered <U>bona fide</U> if it is contained in a letter of intent or other writing signed by the Offeror and specifies the material terms of such proposed lease. Tenant shall have fifteen (15) business days
after the date of giving of such notice by Landlord in which to accept such offer by written notice to Landlord. Upon such acceptance by Tenant, the Offered Space shall be leased to Tenant on the terms set forth in Landlord&#146;s notice and on the
additional terms and provisions set forth in this Lease (except to the extent inconsistent with the terms set forth in Landlord&#146;s said notice) and the parties shall promptly execute an agreement containing the terms of Landlord&#146;s said
notice and all other terms and provisions of this Lease not inconsistent with the terms of said notice, except as the parties may otherwise mutually agree. If Tenant does not accept Landlord&#146;s offer within the allotted time, Landlord shall
thereafter have the right to lease the Offered Space to the Offeror, at any time within one hundred eighty (180) days after Tenant&#146;s failure to accept Landlord&#146;s offer, at a minimum rental and on other terms and conditions not more
favorable to the Offeror than the minimum rental and other terms offered to Tenant in Landlord&#146;s said notice. If Tenant does not accept Landlord&#146;s offer and Landlord does not lease the Offered Space to the Offeror within one hundred eighty
(180) days, this First Refusal Right shall reattach to that space. This First Refusal Right shall be applicable in the case of either an offer to lease all or a portion of an already-built Expansion Building or an offer to enter into a build-to-suit
lease for the Expansion Building. Tenant&#146;s failure, if any, to exercise any or all Lock-Up Options shall not affect Tenant&#146;s First Refusal Right under this Section 6.4. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>FIRST REFUSAL RIGHT TO PURCHASE</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Sale Restriction</U>. Landlord shall not sell the Site, or any portion thereof containing the Initial Building, the Expansion Building or both, at any time during the term of this Lease, except in
compliance with this Article 7; provided, however, that the foregoing restriction shall not apply during any period in which Tenant is in default under this Lease. The parties acknowledge that the sale of any portion of the Site independent of the
remainder of the Site as a separate legal parcel would require a subdivision of the Site. For purposes of this Article 7, the terms &#147;purchase,&#148; &#147;sell&#148; and &#147;sale&#148; shall be construed to include, without limitation, any
exchange transaction in which Landlord transfers or conveys its interest in the Site (or any applicable portion thereof) in exchange for other real property or other non-cash consideration. Notwithstanding any other provisions of this Article 7, the
provisions of this Article 7 shall not apply to any sale, transfer or other conveyance of the Site or any portion thereof by Landlord to any person or entity which controls, is controlled by or is under common control with Landlord, but the
provisions of this Article 7 shall continue to apply to the Site in the hands of such affiliated transferee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>First
Refusal Right</U>. If, at any time during the term of this Lease after the expiration of any and all available Lock-Up Periods, Landlord receives and wishes to accept a <U>bona fide</U> written offer from a person or entity other than Tenant (the
&#147;Offeror&#148;) to purchase the Site, or any portion thereof containing the Initial Building, the Expansion Building or both, and if Tenant is not then in default under this Lease, Landlord shall give written notice of such offer to Tenant,
specifying the material terms on which the Offeror proposes to purchase the Site or specified </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-8-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
portion thereof (the &#147;Offered Property&#148;), and shall offer to Tenant the opportunity to purchase the Offered Property on the terms specified in Landlord&#146;s notice, as modified by
Section 7.3 (if applicable). For purposes of this Section 7.2, an offer shall be considered <U>bona fide</U> if it is contained in a letter of intent or other writing signed by the Offeror and specifies the material terms of such proposed purchase.
Tenant shall have twenty (20) days after the date of giving of such notice by Landlord in which to accept such offer by written notice to Landlord. Upon such acceptance by Tenant, the Offered Property shall be sold to Tenant on the terms set forth
in Landlord&#146;s notice, as modified by Section 7.3 hereof (if applicable), and the parties shall promptly execute an agreement containing the terms of Landlord&#146;s said notice and such other reasonable and customary terms as the parties shall
agree. If Tenant does not accept Landlord&#146;s offer within the allotted time, Landlord shall thereafter have the right to sell the Offered Property to the Offeror, at any time within one hundred eighty (180) days after Tenant&#146;s failure to
accept Landlord&#146;s offer, at a price and on other terms and conditions not more favorable to the Offeror than the price and other terms of the original offer specified in Landlord&#146;s said notice. If Tenant does not accept Landlord&#146;s
offer and Landlord does not sell the Offered Property to the Offeror within one hundred eighty (180) days, this First Refusal Right shall reattach to the Offered Property. Tenant&#146;s failure, if any, to exercise any or all Lock-Up Options shall
not affect Tenant&#146;s First Refusal Right under this Section 7.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>Discount on Purchase Price</U>. If, at the time
Landlord is required to give Tenant a notice specified in Section 7.2, Tenant has at least one class of equity securities listed on any national stock exchange, the NASDAQ National Market System or the NASDAQ Small Cap Market, or registered for
public trading pursuant to the Securities Exchange Act of 1934, as amended, and Tenant has received gross revenues of at least one hundred fifty million dollars ($150,000,000) during Tenant&#146;s most recently completed fiscal year, then the price
at which Tenant is entitled to purchase the Offered Property pursuant to the notice specified in Section 7.2 shall be four percent (4%) lower than the price specified in the <U>bona fide</U> offer. For purposes of this Section 7.3, &#147;gross
revenues&#148; shall include equity investments, research and development funding, milestone payments and royalty revenue. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.
<U>TAXES</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>Personal Property</U>. Tenant shall be responsible for and shall pay prior to delinquency all taxes and
assessments levied against or by reason of (a) any and all alterations, additions and items installed or placed on the Property and taxed as personal property rather than as real property, and/or (b) all personal property, trade fixtures and other
property placed by Tenant on or about the Property. Upon request by Landlord, Tenant shall furnish Landlord with satisfactory evidence of Tenant&#146;s payment thereof. If at any time during the term of this Lease any of said alterations, additions
or personal property, whether or not belonging to Tenant, shall be taxed or assessed as part of the Property, then such tax or assessment shall be paid by Tenant to Landlord immediately upon presentation by Landlord of copies of the tax bills in
which such taxes and assessments are included and shall, for the purposes of this Lease, be deemed to be personal property taxes or assessments under this Section 8.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Real Property</U>. To the extent any real property taxes and assessments on the Property (including, but not limited to, the Improvements) are assessed directly to Tenant, Tenant shall be
responsible for and shall pay prior to delinquency all such taxes and assessments levied against the Property. Upon request by Landlord, Tenant shall furnish Landlord with satisfactory evidence of Tenant&#146;s payment thereof. To the extent the
Property and/or Improvements are taxed or assessed to Landlord following the Commencement Date, such real property taxes and assessments shall constitute Operating Expenses (as that term is defined in Section 9.2 of this Lease) and shall be paid in
accordance with the provisions of Article 9 of this Lease. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <U>OPERATING EXPENSES</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Liability For Operating Expenses</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Tenant shall pay to Landlord, at the time and in the manner hereinafter set forth, as additional rental, an amount equal to one hundred percent (100%) (&#147;Tenant&#146;s Operating Cost Share&#148;)
of the Operating Expenses defined in Section 9.2. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-9-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If Landlord constructs additional buildings on the Phase II<I> </I>Site or on any other
adjacent property owned by Landlord and operated, for common area purposes, on an integrated basis with the Phase I Site, Landlord and Tenant shall negotiate in good faith concerning the reasonable and appropriate treatment of any taxes, insurance
or other operating expense items that are allocable both to the Phase I Site and to any such additional buildings or properties. To the extent appropriate, except as otherwise agreed in any such negotiations by Landlord and Tenant, the definition of
Operating Expenses in Section 9.2 shall be expanded to include items attributable to such additional buildings or properties and Tenant&#146;s Operating Cost Share shall be adjusted from time to time to be equal to the percentage determined by
dividing the square footage of the Initial Building as it then exists by the square footage of all buildings located on portions of the Site owned by Landlord or on any applicable adjacent property owned by Landlord as described above. In
determining such percentage, a building shall be taken into account from and after the date on which a tenant first enters into possession of the building or a portion thereof, and the square footage of any such building shall be measured or
determined in accordance with the same BOMA standard applicable to the measurement of the Initial Building under Section 1.1(a) hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>Definition Of Operating Expenses</U>. Subject to the exclusions and provisions hereinafter contained, the term &#147;Operating Expenses&#148; shall mean the total costs and expenses incurred by or
allocable to Landlord for operation and maintenance of the Improvements and the Property, including, without limitation, costs and expenses of (i) operation, repair and maintenance of the roof (structural portions only), exterior walls and other
structural portions of the Initial Building; (ii) liability, casualty or other insurance (including, but not limited to, earthquake insurance if Landlord in its discretion elects to carry such insurance, which it is Landlord&#146;s present intention
to do, so long as such insurance is reasonably available in the commercial insurance markets) carried by Landlord with respect to the Property, the Improvements or any portion thereof; (iii) real and personal property taxes and assessments or
substitutes therefor levied or assessed against the Property or any part thereof, including (but not limited to) any possessory interest, use, business, license or other taxes or fees, any taxes imposed directly on rents or services, any assessments
or charges for police or fire protection, housing, transit, open space, street or sidewalk construction or maintenance or other similar services from time to time by any governmental or quasi-governmental entity, and any other new taxes on landlords
in addition to taxes now in effect; (iv) supplies, equipment, utilities and tools used in operation, repair and maintenance of the roof (structural portions only), exterior walls and other structural portions of the Initial Building; (v) capital
improvements to the Property or the Improvements, amortized over their respective useful lives, (aa) which reduce or will cause future reduction of other items of Operating Expenses for which Tenant is otherwise required to contribute (but not in
excess of the cost savings realized) or (bb) which are required by law, ordinance, regulation or order of any governmental authority enacted after the date of this Lease; and (vi) any other costs (including, but not limited to, any parking or
utilities fees or surcharges) allocable to or paid by Landlord, as owner of the Property or Improvements, pursuant to any applicable laws, ordinances, regulations or orders of any governmental or quasi-governmental authority or pursuant to the terms
of any declarations of covenants, conditions and restrictions now or hereafter affecting either the Property or any other property described in Section 9.1(b) or over which Tenant has non-exclusive usage rights as contemplated in Section l.l(b)
hereof. The distinction between items of ordinary operating maintenance and repair and items of a capital nature shall be made in accordance with generally accepted accounting principles applied on a consistent basis. Notwithstanding any other
provisions of this Section 9.2, Operating Expenses shall not include any costs attributable to work for which Landlord is required to pay under Section 5.1 or <U>Exhibit&nbsp;C</U>; any management fees; depreciation on buildings (other than
depreciation on personal property); costs of tenants&#146; improvements; interest; capital items (other than as expressly provided above); payments on debt (principal or interest); leasing commissions; costs of goods and services (including
utilities) for which Landlord is reimbursed by tenants or occupants other than Tenant; costs incurred to perform or correct Landlord&#146;s Work described in Section 5.1 and <U>Exhibit C</U>; costs of correcting defects in or inadequacy of the
initial design of the structure of the Initial Building; legal fees; amounts paid to affiliates of Landlord (i.e., persons or companies controlled by, under common control with, or which control, Landlord) for services on or to the Initial Building,
except to the extent that the costs of such services do not exceed competitive costs of such services were they rendered by a non-affiliate of Landlord; expenses in connection with services or other benefits provided to one or more other tenants but
not generally available to Tenant; space planning fees, architectural fees, engineering fees (other than those relating to the general operation of buildings or common areas), marketing, advertising or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-10-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any other expenses incurred in connection with the development or leasing of any buildings or improvements; costs associated with the operation of the business of the legal entity which
constitutes Landlord as the same is separate and apart from the costs and operation of the Initial Building, including legal entity formation and internal entity accounting; any late fees or penalties or similar fees incurred by Landlord, except to
the extent attributable to Tenant&#146;s late payment or nonpayment of minimum rental or additional rent; any debt losses, rent losses or reserves for bad debt; the cost of any repairs in accordance with the provisions of this Lease relating to
fire, casualty and/or condemnation; Landlord&#146;s incremental costs incurred by reason of Landlord&#146;s breach of any leases with other tenants, and any costs incurred by reason of the breach by other tenants of such tenants&#146; leases (to the
extent recoverable from such tenants); or any unrecovered expenses incurred as a consequence of the grossly negligent operation and maintenance, by Landlord or its employees, of those portions of the Initial Building required to be maintained by
Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>Determination and Payment Of Operating Expenses</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Beginning on the Commencement Date and thereafter from time to time during the term of this Lease, Landlord shall give Tenant written
notice of amounts paid or to be paid, by Landlord for insurance premiums, taxes, structural repair or maintenance costs or any other amount constituting an Operating Expense under Section 9.2 hereof, accompanied by copies of premium notices, tax
statements, contractor&#146;s invoices or other documentation reasonably evidencing the amount of the applicable Operating Expense payment, and Tenant shall pay to Landlord Tenant&#146;s Operating Cost Share of each such item of Operating Expenses.
Such payment by Tenant shall be due on or before the later to occur of (i) ten (10) days after delivery of Landlord&#146;s written notice to Tenant or (ii) fourteen (14) days before the date on which the applicable Operating Expense payment by
Landlord is due (in the case of insurance premiums or other payments to private parties) or would become delinquent (in the case of taxes or assessments). In the event of any subsequent rebate, refund, adjustment or surcharge with respect to any
item of Operating Expenses allocable to any portion of the term of this Lease, the amount of such rebate, refund, adjustment or surcharge shall be for Tenant&#146;s benefit or account, as the case may be, and shall be adjusted promptly by a cash
payment from Landlord to Tenant or from Tenant to Landlord, as the case may be. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Tenant shall be entitled at any time and
from time to time, upon reasonable written notice to Landlord and during normal business hours at Landlord&#146;s office or such other places as Landlord shall designate, to inspect and examine those books and records of Landlord relating to the
determination and payment of Operating Expenses relating to this Lease, the Property and/or any other properties described in Section 9.1(b). If, after inspection and examination of such books and records, Tenant disputes the amount of any such
Operating Expenses charged by Landlord and the parties are not able to resolve such dispute by good faith negotiations within (30) days after Tenant notifies Landlord in writing of the disputed items, then Tenant may, by written notice to Landlord,
request an independent audit of such books and records. The independent audit of the books and records shall be conducted by a certified public accountant acceptable to both Landlord and Tenant or, if the parties are unable to agree, by a &#147;Big
Six&#148; accounting firm designated by Landlord and not then employed by Landlord or Tenant. The audit shall be limited to the determination of the amount of Operating Expenses specified by Tenant in its notice of objection. If the audit discloses
that the amount of Operating Expenses billed to Tenant was incorrect, the appropriate party shall promptly pay to the other party the deficiency or overpayment, as applicable. All costs and expenses of the audit shall be paid by Tenant unless the
audit shows that Landlord overstated Operating Expenses covered by the audit by more than five percent (5%), in which case Landlord shall pay all costs and expenses of the audit. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4 <U>Proration</U>. If the Commencement Date falls on a day other than the first day of an insurance coverage period, tax fiscal year
or other period to which an Operating Expense is allocable or attributable, or if this Lease terminates on a day other than the last day of an insurance coverage period, tax fiscal year or other period to which an Operating Expense is allocable or
attributable, then the amount of Operating Expenses payable by Tenant with respect to such first or last partial insurance coverage period, tax fiscal year or other period shall be prorated on the basis which the number of days during such insurance
coverage period, tax fiscal year or other period in which this Lease is in effect bears to the total number of days in such insurance coverage period, tax fiscal year or other period. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-11-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <U>UTILITIES</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Payment</U>. Commencing with the Commencement Date and thereafter throughout the term of this Lease, Tenant shall pay, before
delinquency, all charges for water, gas, heat, light, electricity, power, sewer, telephone, alarm system, janitorial and other services or utilities supplied to or consumed in or upon the Property (including any separately metered costs for water,
electricity or other services or utilities furnished with respect to the Common Areas), including any taxes on such services and utilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Interruption</U>. There shall be no abatement of rent or other charges required to be paid hereunder and Landlord shall not be liable in damages or otherwise for interruption or failure of any
service or utility furnished to or used in the Property because of accident, making of repairs, alterations or improvements, severe weather, difficulty or inability in obtaining services or supplies, labor difficulties or any other cause, except to
the extent such interruption or failure of a service or utility is caused by the negligence or willful misconduct of Landlord or its agents or employees. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11. <U>ALTERATIONS: SIGNS</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Right To Make Alterations</U>. Tenant
shall make no alterations, additions or improvements to the Property without the prior written consent of Landlord, which consent shall not be unreasonably withheld or delayed, except that Tenant shall not be required to obtain such consent for
interior non-structural alterations costing less than Seventy-Five Thousand Dollars ($75,000.00) in the aggregate during any twelve (12) month period. All such alterations, additions and improvements shall be completed with due diligence in a
first-class workmanlike manner and in compliance with plans and specifications approved in writing by Landlord and all applicable laws, ordinances, rules and regulations, and to the extent Landlord&#146;s consent is not otherwise required hereunder
for such alterations, additions or improvements, Tenant shall give prompt written notice thereof to Landlord for purposes of Section 11.2&nbsp;hereof. Tenant shall cause any contractors engaged by Tenant for work on the Property to maintain public
liability and property damage insurance, and other customary insurance, with such terms and in such amounts as Landlord may reasonably require, naming Landlord and its partners, shareholders, agents and employees as additional insureds, and shall
furnish Landlord with certificates of insurance or other evidence that such coverage is in effect. Notwithstanding any other provisions of this Section 11.1, under no circumstances shall Tenant make any structural alterations or improvements, or any
substantial changes to the roof or substantial equipment installations on the roof, or any substantial changes or alterations to building systems, without Landlord&#146;s prior written consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Title To Alterations</U>. All alterations, additions and improvements installed in, on or about the Property shall be part of the
Improvements and the property of Landlord, unless Landlord elects to require Tenant to remove the same upon the termination of this Lease, which election shall be made by Landlord concurrently with its consent to such alterations, additions or
improvements or, if no such consent is required, then within fifteen (15) days after Landlord is advised in writing of such alterations, additions or improvements as contemplated in Section 11.1 hereof; <U>provided</U>, however, that the foregoing
shall not apply (i) to Tenant&#146;s movable furniture and trade fixtures not affixed to the Property, or (ii) to any of the Interior Improvements (as defined in <U>Exhibit C</U> hereto), or any subsequent improvements installed by Tenant at its own
expense, which are readily movable, are not an integral part of the Initial Building&#146;s structure or interior architectural improvements, and are not an integral part of the Initial Building&#146;s HVAC, plumbing or electrical systems or other
standard operating systems. All of such items described in clause (i) or (ii) of the preceding sentence (in all events including, but not limited to, lab benches, fume hoods and cold rooms) may (and, if duly elected by Landlord hereunder, shall) be
removed by Tenant upon the termination of this Lease. Tenant shall promptly repair any damage caused by its removal of any such improvements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Tenant Fixtures</U>. Notwithstanding the provisions of Sections 11.1 and 11.2, Tenant may install, remove and reinstall trade fixtures without Landlord&#146;s prior written consent, except that
any fixtures which are affixed to the Property or which affect the exterior or structural portions of the Initial Building or the building systems shall require Landlord&#146;s written approval.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-12-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The foregoing shall apply to Tenant&#146;s signs, logos and insignia, all of which Tenant shall have the right to place and remove and replace (a) only with Landlord&#146;s prior written consent
as to location, size and composition, which consent shall not be unreasonably withheld or delayed, and (b) only in compliance with all restrictions and requirements of applicable law and of any covenants, conditions and restrictions or other written
agreements now or hereafter applicable to the Property. Tenant shall immediately repair any damage caused by installation and removal of fixtures under this Section 11.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.4 <U>No Liens</U>. Tenant shall at all times keep the Property free from all liens and claims of any contractors, subcontractors, materialmen, suppliers or any other parties employed either directly or
indirectly by Tenant in construction work on the Property. Tenant may contest any claim of lien, but only if, prior to such contest, Tenant either (i) posts security in the amount of the claim, plus estimated costs and interest, or (ii) records a
bond of a responsible corporate surety in such amount as may be required to release the lien from the Property. Tenant shall indemnify, defend and hold Landlord harmless against any and all liability, loss, damage, cost and other expenses,
including, without limitation, reasonable attorneys&#146; fees, arising out of claims of any lien for work performed or materials or supplies furnished at the request of Tenant or persons claiming under Tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5 <U>Signs</U>. Without limiting the generality of the provisions of Section 11.3 hereof, Tenant shall have the right to display its
corporate name and logo on the Initial Building and in front of the entrance to the Initial Building, subject to Landlord&#146;s prior approval as to location, size and composition (which approval shall not be unreasonably withheld or delayed) and
subject to all restrictions and requirements of applicable law and of any covenants, conditions and restrictions or other written agreements now or hereafter applicable to the Property. Landlord is hereby deemed to have approved, as to location, any
signage the location of which is expressly designated on the site plan attached hereto as <U>Exhibit B</U> or on any Approved Plan developed pursuant to the Workletter executed concurrently herewith. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <U>MAINTENANCE AND REPAIRS</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Landlord&#146;s Work</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Landlord shall repair and maintain or
cause to be repaired and maintained the roof (structural portions only), exterior walls and other structural portions of the Initial Building. The cost of all work performed by Landlord under this Section 12.1 shall be an Operating Expense
hereunder, except to the extent such work (i) is required due to the negligence of Landlord, (ii) is a capital expense not includible as an Operating Expense under Section 9.2 hereof, or (iii) is required due to the negligence or willful misconduct
of Tenant or its agents, employees or invitees (in which event Tenant shall bear the full cost of such work pursuant to the indemnification provided in Section 14.6 hereof). Tenant knowingly and voluntarily waives the right to make repairs at
Landlord&#146;s expense, except to the extent expressly set forth in Section &#145;12.1(b), or to offset the cost thereof against rent, under any law, statute, regulation or ordinance now or hereafter in effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If Landlord fails to perform any repairs or maintenance required to be performed by Landlord under Section 12.1(a) and such failure
continues for thirty (30) days or more after Tenant gives Landlord written notice of such failure (or, if such repairs or maintenance cannot reasonably be performed within such 30-day period, then if Landlord fails to commence performance within
such 30-day period and thereafter to pursue such performance diligently to completion), then Tenant shall have the right to perform such repairs or maintenance and Landlord shall reimburse Tenant for the reasonable cost thereof within fifteen (15)
days after written notice from Tenant of the completion and cost of such work, accompanied by copies of invoices or other reasonable supporting documentation. Under no circumstances, however, shall Tenant have any right to offset the cost of any
such work against rent or other charges falling due from time to time under this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Tenant&#146;s Obligation For
Maintenance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)<U> Good Order, Condition And Repair</U>. Except as provided in Section 12.1 hereof, Tenant at its sole
cost and expense shall keep and maintain in good and sanitary order, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-13-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
condition and repair the Property and every part thereof, wherever located, including but not limited to the Common Areas of the Phase I Site, the roof (non-structural portions only), signs,
interior, ceiling, electrical system, plumbing system, telephone and communications systems of the Initial Building, the HVAC equipment and related mechanical systems serving the Initial Building (for which equipment and systems Tenant shall enter
into a service contract with a person or entity designated or approved by Landlord), all doors, door checks, windows, plate glass, door fronts, exposed plumbing and sewage and other utility facilities, fixtures, lighting, wall surfaces, floor
surfaces and ceiling surfaces of the Initial Building and all other interior repairs, foreseen and unforeseen, with respect to the Initial Building, as required. If the Expansion Building is constructed by Landlord and is not occupied by Tenant,
then Landlord and Tenant shall negotiate diligently and in good faith to reach a reasonable arrangement for the maintenance and repair of the Common Areas of the entire Site and a reasonable allocation of the cost of such maintenance and repair
between the Initial Building and the Expansion Building. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Landlord&#146;s Remedy</U>. If Tenant, after notice from
Landlord, fails to make or perform promptly any repairs or maintenance which are the obligation of Tenant hereunder, Landlord shall have the right, but shall not be required, to enter the Property and make the repairs or perform the maintenance
necessary to restore the Property to good and sanitary order, condition and repair. Immediately on demand from Landlord, the cost of such repairs shall be due and payable by Tenant to Landlord. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Condition Upon Surrender</U>. At the expiration or sooner termination of this Lease, Tenant shall surrender the Property,
including any additions, alterations and improvements thereto, broom clean, in good and sanitary order, condition and repair, ordinary wear and tear excepted, first, however, removing all goods and effects of Tenant and all and fixtures and items
required to be removed pursuant to this Lease (including, but not limited to, any such removal required as a result of an election duly made by Landlord to require such removal as contemplated in Section 11.2), and repairing any damage caused by
such removal. Tenant shall not have the right to remove fixtures or equipment if Tenant is in default hereunder unless Landlord specifically waives this provision in writing. Tenant expressly waives any and all interest in any personal property and
trade fixtures not removed from the Property by Tenant at the expiration or termination of this Lease, agrees&#146; that any such personal property and trade fixtures may, at Landlord&#146;s election, be deemed to have been abandoned by Tenant, and
authorizes Landlord (at its election and without prejudice to any other remedies under this Lease or under applicable law) to remove and either retain, store or dispose of such property at Tenant&#146;s cost and expense, and Tenant waives all claims
against Landlord for any damages resulting from any such removal, storage, retention or disposal. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. <U>USE OF PROPERTY</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Permitted Use</U>. Subject to Sections 13.3 and 13.4 hereof, Tenant shall use the Property solely as a laboratory
research and development facility, including (but not limited to) wet chemistry and biology labs, clean rooms, pilot scale, clinical scale and GMP scale manufacturing, storage and use of toxic and radioactive materials incidental to such research
and development activities (subject to the provisions of Section 13.6 hereof), storage and use of laboratory animals, and other lawful purposes related to or incidental to such research and development use, and for no other purpose without
Landlord&#146;s written consent (not to be unreasonably withheld or delayed). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 [Omitted.] </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>No Nuisance</U>. Tenant shall not use the Property for or carry on or permit upon the Property or any part thereof any offensive,
noisy or dangerous trade, business, manufacture, occupation, odor or fumes, or any nuisance or anything against public policy, nor interfere with the rights or business of Landlord in the Initial Building or the Property, nor commit or allow to be
committed any waste in, on or about the Property. Tenant shall not do or permit anything to be done in or about the Property, nor bring nor keep anything therein, which will in any way cause the Property to be uninsurable with respect to the
insurance required by this Lease or with respect to standard fire and extended coverage insurance with vandalism, malicious mischief and riot endorsements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-14-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4 <U>Compliance With Laws</U>. Tenant shall not use the Property or permit the Property
to be used in whole or in part for any purpose or use that is in violation of any applicable laws, ordinances, regulations or rules of any governmental agency or public authority. Tenant shall keep the Property equipped with all safety appliances
required by law, ordinance or insurance on the Property, or any order or regulation of any public authority, because of Tenant&#146;s particular use of the Property. Tenant shall procure all licenses and permits required for use of the Property.
Tenant shall use the Property in strict accordance with all applicable ordinances, rules, laws and regulations and shall comply with all requirements of all governmental authorities now in force or which may hereafter be in force pertaining to the
use of the Property by Tenant, including, without limitation, regulations applicable to noise, water, soil and air pollution, and making such nonstructural alterations and additions thereto as may be required from time to time by such laws,
ordinances, rules, regulations and requirements of governmental authorities or insurers of the Property (collectively, &#147;Requirements&#148;) because of Tenant&#146;s construction of improvements in or other particular use of the Property. Any
structural alterations or additions required from time to time by applicable Requirements because of Tenant&#146;s construction of improvements in or other particular use of the Property shall, at Landlord&#146;s election, either (i) be made by
Tenant, at Tenant&#146;s sole cost and expense, in accordance with the procedures and standards set forth in Section 11.1 for alterations by Tenant, or (ii) be made by Landlord at Tenant&#146;s sole cost and expense, in which event Tenant shall pay
to Landlord as additional rent, within ten (10) days after demand by Landlord, an amount equal to all reasonable costs incurred by Landlord in connection with such alterations or additions. The judgment of any court, or the admission by Tenant in
any proceeding against Tenant, that Tenant has violated any law, statute, ordinance or governmental rule, regulation or requirement shall be conclusive of such violation as between Landlord and Tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5 <U>Liquidation Sales</U>. Tenant shall not conduct or permit to be conducted any auction, bankruptcy sale, liquidation sale, or
going out of business sale, in, upon or about the Property, whether said auction or sale be voluntary, involuntary or pursuant to any assignment for the benefit of creditors, or pursuant to any bankruptcy or other insolvency proceeding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6 <U>Environmental Matters</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) For purposes of this Section, &#147;hazardous substance&#148; shall mean the substances included within the definitions of the term &#147;hazardous substance&#148; under (i) the Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as amended, 42 U.S.C. &#167;&#167; 9601 <U>et</U> <U>seq</U>., and the regulations promulgated thereunder, as amended, (ii) the California Carpenter-Presley-Tanner Hazardous Substance
Account Act, California Health &amp; Safety Code &#167;&#167; 25300 <U>et</U> <U>seq</U>., and regulations promulgated thereunder, as amended, (iii) the Hazardous Materials Release Response Plans and Inventory Act, California Health &amp; Safety
Code &#167;&#167; 25500 <U>et</U> <U>seq</U>., and regulations promulgated thereunder, as amended, and (iv) petroleum; &#147;hazardous waste&#148; shall mean (i) any waste listed as or meeting the identified characteristics of a &#147;hazardous
waste&#148; under the Resource Conservation and Recovery Act of 1976, 42 U.S.C. &#167;&#167; 6901 <U>et</U> <U>seq</U>., and regulations promulgated pursuant thereto, as amended (collectively, &#147;RCRA&#148;), (ii) any waste meeting the identified
characteristics of &#147;hazardous waste,&#148; &#147;extremely hazardous waste&#148; or &#147;restricted hazardous waste&#148; under the California Hazardous Waste Control Law, California Health <I>&amp; </I>Safety Code &#167;&#167; 25100 <U>et</U>
<U>seq</U>., and regulations promulgated pursuant thereto, as amended (collectively, the &#147;CHWCL&#148;), and/or (iii) any waste meeting the identified characteristics of &#147;medical waste&#148; under California Health &amp; Safety Code
&#167;&#167; 25015-25027.8, and regulations promulgated thereunder, as amended; and &#147;hazardous waste facility&#148; shall mean a hazardous waste facility as defined under the CHWCL. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Without limiting the generality of the obligations set forth in Section 13.4 of this Lease: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Tenant covenants not to cause or permit any hazardous substance or hazardous waste to be brought upon, kept, stored or used in or
about the Property without the prior written consent of Landlord, which consent shall not be unreasonably withheld or delayed, except that Tenant, in connection with its permitted use of the Property as provided in Section 13.1, may keep, store and
use materials that constitute hazardous substances which are customary for such permitted use, provided such hazardous substances are kept, stored and used in quantities which are customary for such permitted use and are kept, stored and used in
full compliance with clauses (ii) and (iii) immediately below. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-15-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Tenant covenants that it will comply with all applicable laws, rules, regulations,
orders, permits, licenses and operating plans of any governmental authority with respect to the receipt, use, handling, generation, transportation, storage, treatment and/or disposal of hazardous substances or wastes by Tenant or its agents or
employees, and Tenant will provide Landlord with copies of all permits, licenses, registrations and other similar documents that authorize Tenant to conduct any such activities in connection with its authorized use of the Property from time to time.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Tenant agrees that it shall not (A) operate on or about the Property any facility required to be permitted or licensed
as a hazardous waste facility or for which interim status as such is required, nor (B) store any hazardous wastes on or about the Property for ninety (90) days or more, nor (C) conduct any other activities on or about the Property that could result
in the Property being deemed to be a &#147;hazardous waste facility&#148; (including, but not limited to, any storage or treatment of hazardous substances or hazardous wastes which could have such a result). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Tenant agrees to comply with all applicable laws, rules, regulations, orders and permits relating to underground storage tanks
installed by Tenant or its agents or employees (including any installation, monitoring, maintenance, closure and/or removal of such tanks) as such tanks are defined in California Health <I>&amp; </I>Safety Code &#167; 25281(x), including, without
limitation, complying with California Health &amp; Safety Code &#167; 25280-25299.7 and the regulations promulgated thereunder, as amended. Tenant shall furnish to Landlord copies of all registrations and permits issued to or held by Tenant from
time to time for any and all underground storage tanks. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) If applicable, Tenant shall provide Landlord in writing the
following information and/or documentation at the commencement of this Lease and within sixty (60) days of any change in or addition to the required information and/or documentation (<U>provided</U>, however, that in the case of the materials
described in subparagraphs (B), (C) and (E) below, Tenant shall not be required to deliver copies of such materials to Landlord but shall maintain copies of such materials to such extent and for such periods as may be required by applicable law and
shall permit Landlord or its representatives to inspect such materials during normal business hours at any time and from time to time upon reasonable notice to Tenant): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(A) A list of all hazardous substances and/or wastes that Tenant receives, uses, handles, generates, transports, stores, treats or disposes of from time to time in connection with its operations on the
Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) All Material Safety Data Sheets (&#147;MSDS&#146;s&#148;), if any, required to be completed with respect to
operations of Tenant at the Property from time to time in accordance with Title 26, California Code of Regulations &#167; 8-5194 or 42 U.S.C. &#167; 11021, or any amendments thereto, and any Hazardous Materials Inventory Sheets that detail the
MSDS&#146;s. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C) All hazardous waste manifests (as defined in Title 26, California Code of Regulations &#167; 22-66481), if
any, that Tenant is required to complete from time to time in connection with its operations at the Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(D) A copy of
any Hazardous Materials Management Plan required from time to time with respect to Tenant&#146;s operations at the Property, pursuant to California Health &amp; Safety Code &#167;&#167; 25500 <U>et</U> <U>seq</U>., and any regulations promulgated
thereunder, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(E) Copies of any Contingency Plans and Emergency Procedures required of Tenant from time to time
due to its operations in accordance with Title 26, California Code of Regulations &#167;&#167; 22-67140 <U>et seq.</U>, and any amendments thereto, and copies of any Training Programs and Records required under Title 26, California Code of
Regulations, &#167; 22-67105, and any amendments thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(F) Copies of any biennial reports required to be furnished to the
California Department of Health Services from time to time relating to hazardous substances or wastes, pursuant to Title 26, California Code of Regulations, &#167; 22-66493, and any amendments thereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-16-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(G) Copies of all industrial wastewater discharge permits issued to or held by Tenant from
time to time in connection with its operations on the Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(H) Copies of any other lists or inventories of hazardous
substances and/or wastes on or about the Property that Tenant is otherwise required to prepare and file from time to time with any governmental or regulatory authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(vi) Tenant shall secure Landlord&#146;s prior written approval for any proposed receipt, storage, possession, use, transfer or disposal of &#147;radioactive materials&#148; or &#147;radiation,&#148; as
such materials are defined in Title 26, California Code of Regulations <FONT STYLE="white-space:nowrap">&#167;17-30100,</FONT> and/or any other materials possessing the characteristics of the materials so defined, which approval Landlord may
withhold in its sole and absolute discretion; <U>provided,</U> that such approval shall not be required for any radioactive materials for which Tenant has secured prior written approval of the Nuclear Regulatory Commission and delivered to Landlord
a copy of such approval. Tenant, in connection with any such authorized receipt, storage, possession, use, transfer or disposal of radioactive materials or radiation, shall: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(A) Comply with all federal, state and local laws, rules, regulations, orders, licenses and permits; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(B) Maintain, to such extent and for such periods as may be required by applicable law, and permit Landlord or its representatives to inspect during normal business hours at any time and from time to time
upon reasonable notice to Tenant, a list of all radioactive materials or radiation received, stored, possessed, used, transferred or disposed of from time to time, to the extent not already disclosed through delivery of a copy of a Nuclear
Regulatory Commission approval with respect thereto as contemplated above; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C) Maintain, to such extent and for such
periods as may be required by applicable law, and permit Landlord or its representatives to inspect during normal business hours at any time and from time to time upon reasonable notice to Tenant, all licenses, registration materials, inspection
reports, governmental orders and permits in connection with the receipt, storage, possession, use, transfer or disposal of radioactive materials or radiation from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) Tenant agrees to comply with any and all applicable laws, rules, regulations and orders of any governmental authority with respect
to the release into the environment of any hazardous wastes or substances or radiation or radioactive materials by Tenant or its agents or employees. Tenant agrees to give Landlord immediate verbal notice of any unauthorized release of any such
hazardous wastes or substances or radiation or radioactive materials into the environment, and to follow such verbal notice with written notice to Landlord of such release within twenty-four (24) hours of the time at which Tenant became aware of
such release. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii) Tenant shall indemnify, defend and hold Landlord harmless from and against any and all claims, losses
(including, but not limited to, loss of rental income and loss due to business interruption), damages, liabilities, costs, legal fees and expenses of any sort arising out of or relating to (A) any failure by Tenant to comply with any provisions of
this paragraph (b), or (B) any receipt, use handling, generation, transportation, storage, treatment, release and/or disposal of any hazardous substance or waste or any radioactive material or radiation on or about the Property in connection with
Tenant&#146;s use or occupancy of the Property or as a result of any intentional or negligent acts or omissions of Tenant or of any agent or employee of Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ix) Tenant agrees to cooperate with Landlord in furnishing Landlord with complete information regarding Tenant&#146;s receipt, handling, use, storage, transportation, generation, treatment and/or
disposal of any hazardous substances or wastes or radiation or radioactive materials. Upon request, Tenant agrees to grant Landlord reasonable access at reasonable times to the Property to inspect Tenant&#146;s receipt, handling, use, storage,
transportation, generation, treatment and/or disposal of hazardous substances or wastes or radiation or radioactive materials, without being deemed guilty of any disturbance of Tenant&#146;s use or possession and without being liable to Tenant in
any manner. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-17-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x) Notwithstanding Landlord&#146;s rights of inspection and review under this paragraph
(b), Landlord shall have no obligation or duty to so inspect or review, and no third party shall be entitled to rely on Landlord to conduct any sort of inspection or review by reason of the provisions of this paragraph (b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xi) If Tenant receives, handles, uses, stores, transports, generates, treats and/or disposes of any hazardous substances or wastes or
radiation or radioactive materials on or about the Property at any time during the term of this Lease, then within thirty (30) days after termination or expiration of this Lease, Tenant at its sole cost and expense shall obtain and deliver to
Landlord an environmental study, performed by an expert reasonably satisfactory to Landlord, evaluating the presence or absence of hazardous substances and wastes, radiation and radioactive materials on and about the Property. Such study shall be
based on a reasonable and prudent level of tests and investigations of the Property which tests shall be conducted no earlier than the date of termination or expiration of this Lease. Liability for any remedial actions required or recommended on the
basis of such study shall be allocated in accordance with Sections 13.4, 13.6, 14.6 and other applicable provisions of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Landlord shall indemnify, defend and hold Tenant harmless from and against any and all claims, losses, damages, liabilities, costs, legal fees and expenses of any sort arising out of or relating to
(i) the presence on the Property of any hazardous substances or wastes or radiation or radioactive materials present on the Property as of the Commencement Date (other than as a result of any intentional or negligent acts or omissions of Tenant or
of any agent or employee of Tenant), and/or (ii) any unauthorized release into the environment (including, but not limited to, the Site) of any hazardous substances or wastes or radiation or radioactive materials to the extent such release results
from the negligence of or willful misconduct or omission by Landlord or its agents or employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) In the event of any
third-party claims, losses, damages, liabilities, costs, legal fees and expenses of any sort (including, but not limited to, costs incurred with respect to any government-mandated remediation), against either Landlord or Tenant or both, arising out
of or relating to (i) the presence on the Property of any hazardous substances or wastes or radiation or radioactive materials not present on the Property as of the Commencement Date (except to the extent the presence thereof is already covered by
an express indemnification obligation under Section 13.6(b)(viii) or Section 13.6(c), as applicable), and/or (ii) any unauthorized release into the environment (including, but not limited to, the Site) of any hazardous substances or wastes or
radiation or radioactive materials (except to the extent such release is already covered by an express indemnification obligation under Section 13.6(b)(viii) or Section&nbsp;13.6(c), as applicable), then (x) Landlord and Tenant shall cooperate
reasonably and in good faith in the defense of such <FONT STYLE="white-space:nowrap">third-party</FONT> claims, liabilities and related matters and (y) Landlord and Tenant shall each bear fifty percent (50%) of the total claims, losses, damages,
liabilities, costs, legal fees and expenses incurred by Landlord and/or Tenant in connection with matters covered by this Section I3.6(d). For purposes of the sharing of expenses contemplated in clause (y) of the preceding sentence, the party
directly paying or incurring such costs or expenses shall be entitled to invoice the other party from time to time (on a monthly basis or at other appropriate intervals) for such other party&#146;s respective share thereof, which invoice shall be
accompanied by copies of <FONT STYLE="white-space:nowrap">third-party</FONT> invoices or other reasonable documentation supporting the invoiced amounts, and the party receiving such invoice shall pay its share as reflected in the applicable invoice
within fifteen (15) days after receipt thereof, unless the parties agree otherwise. Within three (3) months after receipt of any such invoice, the party receiving the invoice shall be entitled, upon reasonable written notice and during normal
business hours, to inspect and examine the books and records of the party submitting the invoice with respect to the invoiced amounts. Any dispute with respect thereto that the parties are unable to resolve by good faith negotiations shall be
resolved by an independent audit using the same procedure set forth in Section 9.3(b). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <U>INSURANCE AND INDEMNITY</U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1 <U>Liability and Property Insurance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Tenant shall procure and maintain in full force and effect at all times during the term of this Lease, at Tenant&#146;s cost and expense, commercial general liability insurance to protect against
liability arising out of or related to the use of or resulting from any accident </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-18-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
occurring in, upon or about the Property, with combined single limit of liability of not less than Five Million Dollars ($5,000,000) per occurrence for bodily injury and property damage. Such
insurance shall name Landlord and its partners, shareholders, agents and employees as additional insureds thereunder. The amount of such insurance shall not be construed to limit any liability or obligation of Tenant under this Lease. Tenant shall
also procure and maintain in full force and effect at all times during the term of this Lease, at Tenant&#146;s cost and expense, product liability insurance on terms and in amounts satisfactory to Landlord in its reasonable discretion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Landlord shall procure and maintain in full force and effect at all times during the term of this Lease, at Landlord&#146;s cost and
expense (but reimbursable as an Operating Expense under Section 9.2 hereof), commercial general liability insurance to protect against liability arising out of or related to the use of or resulting from any accident occurring in, upon or about the
Property, with combined single limit of liability of not less than Five Million Dollars ($5,000,000) per occurrence for bodily injury and property damage. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Landlord shall procure and maintain in full force and effect at all times during the term of this Lease, at Landlord&#146;s cost and expense (but reimbursable as an Operating Expense under Section 9.2
hereof), fire and extended coverage insurance for the Building Shell (as defined in <U>Exhibit C</U>) and for the improvements in the Common Areas of the Property on a full replacement cost basis, and for the Interior Improvements in an amount not
less than the total amount contributed by Landlord toward the payment for the Interior Improvements pursuant to <U>Exhibit C</U>. Such insurance may include earthquake coverage to the extent Landlord in its discretion elects to carry such coverage,
and shall have such deductibles and other terms as Landlord in its discretion determines to be appropriate. Except as expressly set forth in this paragraph (c), Landlord shall have no obligation to insure the Interior Improvements and shall, in all
events, have no obligation to insure any other alterations, additions or improvements installed by Tenant on or about the Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Tenant shall procure and maintain in full force and effect at all times during the term of this Lease, at Tenant&#146;s cost and expense, fire and extended coverage insurance for the Interior
Improvements in an amount not less than the full replacement cost thereof, less the amount of coverage required to be carried on the Interior Improvements by Landlord pursuant to Section 14.l(c), and shall have sole responsibility for insurance
coverage of any other alterations, additions or improvements installed by Tenant on the Property to the extent Tenant deems such coverage appropriate. Tenant&#146;s insurance under this paragraph (d) may include earthquake coverage to the extent
Tenant in its discretion elects to carry such coverage, and shall have such deductibles and other terms as Tenant in its discretion determines to be appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) All policies of property insurance carried under paragraphs (c) and (d) of this Section 14.1 shall provide protection against &#147;all perils of direct physical damage&#148; (as defined by the
Insurance Services Office) on all insured property. Each insuring party shall cause the other party to be named as an additional insured on such policy to the extent of the coverage for the Interior Improvements. Replacement cost for purposes hereof
shall be determined periodically on such reasonable basis as Landlord and Tenant may determine. Such insurance policies (i) shall be written by companies rated B+ or better, with a financial rating of not less than Class VII, in &#147;Best&#146;s
Insurance Guide,&#148; and authorized to do business in California; (ii) shall be written to apply to covered property damage and other covered loss occurring during the policy term, or the onset of which occurred or arose during such policy term;
(iii) shall be endorsed, in the case of Tenant&#146;s property insurance, to name Landlord&#146;s lender (&#147;Lender&#148;), if any, holding the lien of a mortgage or deed of trust on the Building and Interior Improvements from time to time as a
loss payee, provided that a condition of such endorsement shall be that at all times during the effectiveness of the endorsement there shall be in full force and effect an agreement among Landlord, Tenant and Lender pursuant to which Lender agrees
that, in the event of an insured occurrence, Lender will make available to Tenant such part or all of the proceeds of insurance on the Interior Improvements which are received by Lender as are required for the repair or replacement of the Interior
Improvements, except as otherwise provided in Section 17.1 hereof in the event of a termination of this Lease; (iv) shall provide that the respective coverages shall be primary and not contributing with or in excess of any coverage that the other
party may carry; (v) shall be endorsed to provide the other party with not less than thirty (30) days&#146; notice of cancellation; and (vi) shall provide for a deductible of not to exceed $10,000 (except in the case of earthquake coverage). Each
party shall deliver to the other party, on or before the Commencement Date, and thereafter at least ten (10) days before the expiration dates of expiring </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-19-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
policies, certificates of insurance or other satisfactory evidence of the continuation of such property insurance coverage for the period indicated therein. If either party fails to procure
property insurance or to deliver certificates or other evidence thereof as required hereunder, the other party may, at its option and in addition to the other party&#146;s other remedies in the event of a default hereunder, procure the same for the
benefit of such party. If, pursuant to the foregoing sentence, Tenant secures such insurance on Landlord&#146;s behalf, Tenant shall not be entitled to reimbursement of the cost thereof; if Landlord secures such insurance on Tenant&#146;s behalf,
Tenant shall reimburse Landlord for the cost thereof within ten (10) business days after receipt of Landlord&#146;s invoice therefor. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.2 <U>Quality Of Policies And Certificates</U>. All policies of insurance required hereunder shall be issued by responsible insurers and, in the case of policies carried or required to be carried by
Tenant, shall be written as primary policies not contributing with and not in excess of any coverage that Landlord may carry. Each party shall deliver to the other party certificates of insurance showing that the insuring party&#146;s required
policies are in effect. If either party fails to acquire, maintain or renew any insurance required to be maintained by it under this Article 14 or to pay the premium therefor, then the other party, at its option and in addition to its other
remedies, but without obligation so to do, may procure such insurance, and any sums expended by Landlord to procure any such insurance on behalf of or in place of Tenant shall be repaid upon demand, with interest as provided in Section 3.2 hereof.
Tenant shall obtain written undertakings from each insurer under policies required to be maintained by it to notify all insureds thereunder at least thirty (30) days prior to cancellation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3 <U>Workers&#146; Compensation</U>. Tenant shall maintain in full force and effect during the term of this Lease workers&#146;
compensation insurance covering all of Tenant&#146;s employees working on the Property, with a minimum limit of liability of not less man Five Hundred Thousand Dollars ($500,000) per accident/disease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4 <U>Waiver Of Subrogation</U>. To the extent permitted by law and without affecting the coverage provided by insurance required to be
maintained hereunder, Landlord and Tenant each waive any right to recover against the other (i) damage to property, (ii) damage to the Property or any part thereof, or (iii) claims arising by reason of any of the foregoing, but only to the extent
that any of the foregoing damages and claims under subparts (i)-(iii) hereof are covered, and only to the extent of such coverage, by insurance actually carried or required to be carried hereunder by either Landlord or Tenant. This provision is
intended to waive fully, and for the benefit of each party, any rights and claims which might give rise to a right of subrogation in any insurance carrier. Each party shall procure a clause or endorsement on any property insurance policy denying to
the insurer rights of subrogation against the other party to the extent rights have been waived by the insured prior to the occurrence of injury or loss. Coverage provided by insurance maintained by Tenant shall not be limited, reduced or diminished
by virtue of the subrogation waiver herein contained. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5 <U>Increase In Premiums</U>. Tenant shall do all acts and pay all
expenses necessary to &#145;insure that the Property is not used for purposes prohibited by any applicable fire insurance, and that Tenant&#146;s use of the Property complies with all requirements necessary to obtain any such insurance. If Tenant
uses or permits the Property to be used in a manner which increases the existing rate of any insurance on the Property carried by Landlord, Tenant shall pay the amount of the increase in premium caused thereby, and Landlord&#146;s costs of obtaining
other replacement insurance policies, including any increase in premium, within ten (10) days after demand therefor by Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.6 <U>Indemnification</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Tenant shall indemnify, defend and hold
Landlord, its partners, shareholders, officers, directors, agents and employees harmless from any and all liability for bodily injury to or death of any person, or loss of or damage to the property of persons, and all actions, claims, demands, costs
(including, but not limited to, reasonable attorneys&#146; fees), damages or expenses arising therefrom which may be brought or made against Landlord or which Landlord may pay or incur by reason of the use, occupancy and enjoyment of the Property by
Tenant or any invitees, sublessees, agents or employees of Tenant or holding under Tenant from any cause whatsoever other than negligence or willful misconduct or omission by Landlord, its agents or employees. Landlord, its partners, shareholders,
officers, directors, agents and employees shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-20-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
not be liable for, and Tenant hereby waives all claims against such persons for, damages to goods, wares and merchandise in or upon the Property, or for injuries to Tenant, its agents or third
persons in or upon the Property, from any cause whatsoever other than negligence or willful misconduct or omission by Landlord, its agents or employees. Tenant shall give prompt notice to Landlord of any casualty or accident in, on or about the
Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Landlord shall indemnify, defend and hold Tenant, its shareholders, officers, directors, agents and employees
harmless from liability for bodily injury to or death of any person, or loss of or damage to the property of persons, and all actions, claims, demands, costs (including, but not limited to, reasonable attorneys&#146; fees), damages or expenses
arising therefrom which may be brought or made against Tenant or which Tenant may pay or incur, to the extent such liabilities or other matters arise by reason of any negligence or willful misconduct or omission by Landlord, its agents or employees.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7 <U>Blanket Policy</U>. Any policy required to be maintained hereunder may be maintained under a so-called &#147;blanket
policy&#148; insuring other parties and other locations so long as the amount of insurance required to be provided hereunder is not thereby diminished. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15. <U>SUBLEASE AND ASSIGNMENT</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1 <U>Assignment And Sublease Of
Property</U>. Tenant shall not have the right or power to assign its interest in this Lease, or make any sublease of the Property or any portion thereof, nor shall any interest of Tenant under this Lease be assignable involuntarily or by operation
of law, without on each occasion obtaining the prior written consent of Landlord, which consent shall not be unreasonably withheld or delayed. Any purported sublease or assignment of Tenant&#146;s interest in this Lease requiring but not having
received Landlord&#146;s consent thereto shall be void. Without limiting the generality of the foregoing, Landlord may withhold consent to any proposed subletting or assignment solely on the ground, if applicable, that the use by the proposed
subtenant or assignee is reasonably likely to be incompatible with Landlord&#146;s use of any adjacent property owned or operated by Landlord, unless the proposed use is within the permitted uses specified in Section 13.1, in which event it shall
not be reasonable for Landlord to object to the proposed use. Any dissolution, consolidation, merger or other reorganization of Tenant, or any sale or transfer of the stock of or other interest in Tenant, or any series of one or more of such events,
involving in the aggregate a change of fifty percent (50%) or more in the beneficial ownership of Tenant or its assets shall be deemed to be an assignment hereunder and shall be void without the prior written consent of Landlord as required above.
Notwithstanding the foregoing, (i) an initial public offering of the common stock of Tenant shall not be deemed to be an assignment hereunder; and (ii) Tenant shall have the right to assign this Lease or sublet the Premises, or any portion thereof,
without Landlord&#146;s consent (but with prior or concurrent written notice by Tenant to Landlord), to any entity which controls, is controlled by, or is under common control with Tenant, or to any entity which results from a merger or
consolidation with Tenant, or to any entity engaged in a joint venture with Tenant, or to any entity which acquires substantially all of the stock or assets of Tenant, as a going concern, with respect to the business that is being conducted on the
Property (hereinafter each a &#147;Permitted Transfer&#148;). In addition, a sale or transfer of the capital stock of Tenant shall be deemed a Permitted Transfer if (x) such sale or transfer occurs in connection with any <U>bona fide</U> financing
or capitalization for the benefit of Tenant, or (y) Tenant becomes a publicly traded corporation. Landlord shall have no right to terminate this Lease in connection with, and shall have no right to any sums or other economic consideration resulting
from, any Permitted Transfer. Except as expressly set forth in this Section 15.1, however, the provisions of Section 15.2 shall remain applicable to any Permitted Transfer and the transferee under such Permitted Transfer shall be and remain subject
to all of the terms and provisions of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2 <U>Rights Of Landlord</U>. Consent by Landlord to one or more
assignments of this Lease, or to one or more sublettings of the Property or any portion thereof, or collection of rent by Landlord from any assignee or sublessee, shall not operate to exhaust Landlord&#146;s rights under this Article 15, nor
constitute consent to any subsequent assignment or subletting. No assignment of Tenant&#146;s interest in this Lease and no sublease shall relieve Tenant of its obligations hereunder, notwithstanding any waiver or extension of time granted by
Landlord to any assignee or sublessee, or the failure of Landlord to assert its rights against any assignee or sublessee, and regardless of whether Landlord&#146;s consent thereto is given or required to be given hereunder. In </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-21-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the event of a default by any assignee, sublessee or other successor of Tenant in the performance of any of the terms or obligations of Tenant under this Lease, Landlord may proceed directly
against Tenant without the necessity of exhausting remedies against any such assignee, sublessee or other successor. In addition, Tenant immediately and irrevocably assigns to Landlord, as security for Tenant&#146;s obligations under this Lease, all
rent from any subletting of all or a part of the Property as permitted under this Lease, and Landlord, as Tenant&#146;s assignee and as attorney-in-fact for Tenant, or any receiver for Tenant appointed on Landlord&#146;s application, may collect
such rent and apply it toward Tenant&#146;s obligations under this Lease; except that, until the occurrence of an act of default by Tenant, Tenant shall have the right to collect such rent and to retain all sublease profits. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16. <U>RIGHT OF ENTRY AND QUIET ENJOYMENT</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.1 <U>Right Of Entry</U>. Landlord and its authorized representatives shall have the right to enter the Property at any time during the term of this Lease during normal business hours and upon not less
than twenty-four (24) hours prior notice, except in the case of emergency (in which event no notice shall be required and entry may be made at any time), for the purpose of inspecting and determining the condition of the Property or for any other
proper purpose including, without limitation, to make repairs, replacements or improvements which Landlord may deem necessary, to show the Property to prospective purchasers, to show the Property to prospective tenants (but only during the final
year of the term of this Lease), and to post notices of nonresponsibility. Landlord shall not be liable for inconvenience, annoyance, disturbance, loss of business, quiet enjoyment or other damage or loss to Tenant by reason of making any repairs or
performing any work upon the Initial Building or the Property or by reason of erecting or maintaining any protective barricades in connection with any such work, and the obligations of Tenant under this Lease shall not thereby be affected in any
manner whatsoever, provided, however, Landlord shall use reasonable efforts to minimize the inconvenience to Tenant&#146;s normal business operations caused thereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2. <U>Quiet Enjoyment</U>. Landlord covenants that Tenant, upon paying the rent and performing its obligations hereunder and subject to all the terms and conditions of this Lease, shall peacefully and
quietly have, hold and enjoy the Property throughout the term of this Lease, or until this Lease is terminated as provided by this Lease. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17. <U>CASUALTY AND TAKING</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.1 <U>Damage or Destruction</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If the Initial Building, or the Common Areas of the Property necessary for Tenant&#146;s use and occupancy of the Initial Building,
are damaged or destroyed in whole or in part under circumstances in which (i) repair and restoration is permitted under applicable governmental laws, regulations and building codes then in effect and (ii) repair and restoration reasonably can be
completed within a period of one (1) year following the date of the occurrence, then Landlord, as to the Common Areas of the Property and the Building Shell, and Tenant, as to the Interior Improvements, shall commence and complete, with all due
diligence and as promptly as is reasonably practicable under the conditions then existing, all such repair and restoration as may be required to return the affected portions of the Property to the condition existing immediately prior to the
occurrence. In connection with any such reconstruction of the Interior Improvements, Landlord shall use its best efforts (including, without limitation, any necessary negotiation or intercession with Landlord&#146;s Lender, if any) to promptly make
any proceeds of Landlord&#146;s property insurance with respect to the Interior Improvements (up to a maximum amount equal to the amounts originally contributed by Landlord toward the construction of the Interior Improvements) available to Tenant
for such reconstruction, subject only to such payment controls as Landlord and its Lender and insurer, or any of them, may reasonably require in order to ensure the proper application of such proceeds toward the reconstruction of the Interior
Improvements pursuant to this Section 17.1. In the event of damage or destruction the repair of which is not permitted under applicable governmental laws, regulations and building codes then in effect, if such damage or destruction (despite being
corrected to the extent then permitted under applicable governmental laws, regulations and building codes) would still materially impair Tenant&#146;s ability to conduct its business in the Initial
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-22-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Building, then either party may terminate this Lease as of the date of the occurrence by giving written notice to the other within thirty (30) days after the date of the occurrence; if neither
party timely elects such termination, or if such damage or destruction does not materially impair Tenant&#146;s ability to conduct its business in the Initial Building, then this Lease shall continue in full force and effect, except that there shall
be an equitable adjustment in monthly minimum rental and of Tenant&#146;s Operating Cost Share of Operating Expenses, based upon the extent to which Tenant&#146;s ability to conduct its business in the Initial Building is impaired, and Landlord and
Tenant respectively shall restore the Building Shell and the Interior Improvements to a complete architectural whole and to a functional condition. In the event of damage or destruction which cannot reasonably be repaired within one (1) year
following the date of the occurrence, then either Landlord or Tenant, at this election, may terminate this Lease as of the date of the occurrence by giving written notice to the other within thirty (30) days after the date of the occurrence; if
neither party timely elects such termination, then this Lease shall continue in full force and effect and Landlord and Tenant shall each repair and restore applicable portions of the Property in accordance with the first sentence of this Section
17.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The respective obligations of Landlord and Tenant pursuant to Section 17.1(a) are subject to the following
limitations: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) If the occurrence results from a peril which is required to be insured pursuant to Section 14.1(c) and (d)
above, the obligations of either party shall not exceed the amount of insurance proceeds received from insurers by reason of such occurrence, plus the amount of the party&#146;s permitted deductible (provided that each party shall be obligated to
use its best efforts to recover any available proceeds from the insurance which it is required to maintain pursuant to the provisions of Section 14.1(c) or (d), as applicable), and, if such proceeds are insufficient, either party may terminate the
Lease unless the other party promptly elects and agrees, in writing, to contribute the amount of the shortfall; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) If
the occurrence results from a peril which is not required to be insured pursuant to Section 14.l(c) and (d) above, Landlord shall be required to repair and restore the Building Shell and Common Areas to the extent necessary for Tenant&#146;s
continued use and occupancy of the Initial Building, and Tenant shall be required to repair and restore the Interior Improvements to the extent necessary for Tenant&#146;s continued use and occupancy of the Initial Building, <U>provided</U> that
each party&#146;s obligation to repair and restore shall not exceed an amount equal to five percent (5%) of the replacement cost of the Building Shell and Common Area improvements, as to Landlord, or five percent (5%) of the replacement cost of the
Interior Improvements, as to Tenant; if the replacement cost as to either party exceeds such amount, then the party whose limit has been exceeded may terminate this Lease unless the other party promptly elects and agrees, in writing, to contribute
the amount of the shortfall. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If this Lease is terminated pursuant to the foregoing provisions of this Section 17.1
following an occurrence which is a peril required to be insured against pursuant to Section 14.1(c) and (d), Landlord and Tenant agree (and any Lender shall be asked to agree) that there shall be paid from such insurance proceeds (i) to Landlord,
the proceeds of Landlord&#146;s property insurance on the Building Shell, (ii) to Landlord, a portion of the aggregate proceeds of Landlord&#146;s and Tenant&#146;s property insurance on the Interior Improvements equal to a fraction, the numerator
of which is the insurable value, immediately prior to the occurrence, of the Interior Improvements that would have belonged to Landlord upon termination of this Lease in accordance with the provisions of Section 11.2 and the denominator of which is
the total insurable value, immediately prior to the occurrence, of all of the Interior Improvements, and (iii) to Tenant, a portion of the aggregate proceeds of Landlord&#146;s and Tenant&#146;s property insurance on the Interior Improvements equal
to a fraction, the numerator of which is the insurable value, immediately prior to the occurrence, of the Interior Improvements that would have belonged to Tenant upon termination of this Lease in accordance with the provisions of Section 11.2 and
the denominator of which is the total insurable value, immediately prior to the occurrence, of all of the Interior Improvements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) From and after the date of an occurrence resulting in damage to or destruction of the Initial Building or of the Common Areas necessary for Tenant&#146;s use and occupancy of the Initial Building, and
continuing until repair and restoration thereof are completed, there shall be an equitable abatement of minimum rental and of Tenant&#146;s Operating Cost Share of Operating Expenses based upon the degree to which Tenant&#146;s ability to conduct
its business in the Initial Building is impaired. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-23-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2 <U>Condemnation</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If during the term of this Lease the Property or Improvements, or any substantial part of either, is taken by eminent domain or by
reason of any public improvement or condemnation proceeding, or in any manner by exercise of the right of eminent domain (including any transfer in avoidance of an exercise of the power of eminent domain), or receives irreparable damage by reason of
anything lawfully done under color of public or other authority, then (i) this Lease shall terminate as to the entire Property at Landlord&#146;s election by written notice given to Tenant within sixty (60) days after the taking has occurred, and
(ii) this Lease shall terminate as to the entire Property at Tenant&#146;s election, by written notice given to Landlord within thirty (30) days after the nature and extent of the taking have been finally determined, if the portion of the Property
taken is of such extent and nature as substantially to handicap, impede or permanently impair Tenant&#146;s use of the balance of the Property. If Tenant elects to terminate this Lease, Tenant shall also notify Landlord of the date of termination,
which date shall not be earlier than thirty (30) days nor later than ninety (90) days after Tenant has notified Landlord of Tenant&#146;s election to terminate, except that this Lease shall terminate on the date of taking if such date falls on any
date before the date of termination designated by Tenant. If neither party elects to terminate this Lease as hereinabove provided, this Lease shall continue in full force and effect (except that there shall be an equitable abatement of minimum
rental and of Tenant&#146;s Operating Cost Share of Operating Expenses based upon the degree to which Tenant&#146;s ability to conduct its business in the Initial Building is impaired), Landlord shall restore the Building Shell and Common Area
improvements to a complete architectural whole and a functional condition and as nearly as reasonably possible to the condition existing before the taking, and Tenant shall restore the Interior Improvements and Tenant&#146;s other alterations,
additions and improvements to a complete architectural whole and a functional condition and as nearly as reasonably possible to the condition existing before the taking. In connection with any such restoration, each party shall use its respective
best efforts (including, without limitation, any necessary negotiation or intercession with its respective lender, if any) to ensure that any severance damages or other condemnation awards intended to provide compensation for rebuilding or
restoration costs are promptly collected and made available to Landlord and Tenant in portions reasonably corresponding to the cost and scope of their respective restoration obligations, subject only to such payment controls as either party or its
lender may reasonably require in order to ensure the proper application of such proceeds toward the restoration of the Improvements. Each party waives the provisions of Code of Civil Procedure Section 1265.130, allowing either party to petition the
Superior Court to terminate this Lease in the event of a partial condemnation of the Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The respective obligations
of Landlord and Tenant pursuant to Section 17.2(a) are subject to the following limitations: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Each party&#146;s
obligation to repair and restore shall not exceed, net of any condemnation awards or other proceeds available for and allocable to such restoration as contemplated in Section 17.2(a), an amount equal to five percent (5%) of the replacement cost of
the Building Shell and Common Area improvements, as to Landlord, or five percent (5%) of the replacement cost of the Interior Improvements, as to Tenant; if the replacement cost as to either party exceeds such amount, then the party whose limit has
been exceeded may terminate this Lease unless the other party promptly elects and agrees, in writing, to contribute the amount of the shortfall; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) If this Lease is terminated pursuant to the foregoing provisions of this Section 17.2, or if this Lease remains in effect but any condemnation awards or other proceeds become available as
compensation for the loss or destruction of any of the Improvements, then Landlord and Tenant agree (and any Lender shall be asked to agree) that there shall be paid from such award or proceeds (i) to Landlord, the award or proceeds attributable or
allocable to the Building Shell and/or Common Area improvements, and (ii) to Landlord and Tenant, respectively, portions of the award or proceeds attributable or allocable to the Interior Improvements, in the respective proportions in which Landlord
and Tenant would have shared, under Section 17.l(c), the proceeds of any insurance proceeds following loss or destruction of such Interior Improvements by an insured casualty. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-24-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.3 <U>Reservation Of Compensation</U>. Landlord reserves, and Tenant waives and assigns to
Landlord, all rights to any award or compensation for damage to the Improvements, the Property and the leasehold estate created hereby, accruing by reason of any taking in any public improvement, condemnation or eminent domain proceeding or in any
other manner by exercise of the right of eminent domain or of anything lawfully done by public authority, except that (a)&nbsp;Tenant shall be entitled to any and all compensation or damages paid for or on account of Tenant&#146;s moving expenses,
trade fixtures and equipment, and (b)&nbsp;any condemnation awards or proceeds described in Section&nbsp;17.2(b)(ii) shall be allocated and disbursed in accordance with the provisions of Section&nbsp;17.2(b)(ii), notwithstanding any contrary
provisions of this Section&nbsp;17.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.4 <U>Restoration Of Improvements</U>. In connection with any repair or restoration
of Improvements by either party following a casualty or taking as hereinabove set forth, the party responsible for such repair or restoration shall, to the extent possible, return such Improvements to a condition substantially equal to that which
existed immediately prior to the casualty or taking. To the extent such party wishes to make material modifications to such Improvements, such modifications shall be subject to the prior written approval of the other party (not to be unreasonably
withheld or delayed), except that no such approval shall be required for modifications that are required by applicable governmental authorities as a condition of the repair or restoration, unless such required modifications would impair or impede
Tenant&#146;s conduct of its business in the Initial Building (in which case any such modifications in Landlord&#146;s work shall require Tenant&#146;s consent, not unreasonably withheld or delayed) or would materially and adversely affect the
exterior appearance, the structural integrity or the mechanical or other operating systems of the Initial Building (in which case any such modifications in Tenant&#146;s work shall require Landlord&#146;s consent, not unreasonably withheld or
delayed). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18. <U>DEFAULT</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">18.1 <U>Events Of Default</U>. The occurrence of any of the following shall constitute an event of default on the part of Tenant: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Abandonment</U>. Abandonment of the Property. &#147;Abandonment&#148; is hereby defined to include, but is not limited to, any absence by Tenant from the Property for fifteen (15)&nbsp;consecutive
days or more while Tenant is in default under any other provision of this Lease. Tenant waives any right Tenant may have to notice under Section&nbsp;1951.3 of the California Civil Code, the terms of this subsection (a)&nbsp;being deemed such notice
to Tenant as required by said Section&nbsp;1951.3; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Nonpayment</U>. Failure to pay, when due, any amount payable to
Landlord hereunder, such failure continuing for a period of five (5)&nbsp;days after written notice of such failure; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)
<U>Other Obligations</U>. Failure to perform any obligation, agreement or covenant under this Lease other than those matters specified in subsection (b)&nbsp;hereof, such failure continuing for fifteen (15)&nbsp;days after written notice of such
failure; <U>provided</U>, however, that if such failure is curable in nature but cannot reasonably be cured within such 15-day period, then Tenant shall not be in default if, and so long as, Tenant promptly (and in all events within such 15-day
period) commences such cure and thereafter diligently pursues such cure to completion; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>General Assignment</U>. A
general assignment by Tenant for the benefit of creditors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Bankruptcy</U>. The filing of any voluntary petition in
bankruptcy by Tenant, or the filing of an involuntary petition by Tenant&#146;s creditors, which involuntary petition remains undischarged for a period of thirty (30)&nbsp;days. In the event that under applicable law the trustee in bankruptcy or
Tenant has the right to affirm this Lease and continue to perform the obligations of Tenant hereunder, such trustee or Tenant shall, in such time period as may be permitted by the bankruptcy court having jurisdiction, cure all defaults of Tenant
hereunder outstanding as of the date of the affirmance of this Lease and provide to Landlord such adequate assurances as may be necessary to ensure Landlord of the continued performance of Tenant&#146;s obligations under this Lease. Specifically,
but without limiting the generality of the foregoing, such adequate assurances must include assurances that the Property continues to be operated only for the use </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-25-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
permitted hereunder. The provisions hereof are to assure that the basic understandings between Landlord and Tenant with respect to Tenant&#146;s use of the Property and the benefits to Landlord
therefrom are preserved, consistent with the purpose and intent of applicable bankruptcy laws; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Receivership</U>. The
employment of a receiver appointed by court order to take possession of substantially all of Tenant&#146;s assets or the Property, if such receivership remains undissolved for a period of thirty (30)&nbsp;days; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <U>Attachment</U>. The attachment, execution or other judicial seizure of all or substantially all of Tenant&#146;s assets or the
Property, if such attachment or other seizure remains undismissed or undischarged for a period of thirty (30)&nbsp;days after the levy thereof; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(h) <U>Insolvency</U>. The admission by Tenant in writing of its inability to pay its debts as they become due, the filing by Tenant of a petition seeking any reorganization or arrangement, composition,
readjustment, liquidation, dissolution or similar relief under any present or future statute, law or regulation, the filing by Tenant of an answer admitting or failing timely to contest a material allegation of a petition filed against Tenant in any
such proceeding or, if within thirty (30)&nbsp;days after the commencement of any proceeding against Tenant seeking any reorganization or arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future
statute, law or regulation, such proceeding shall not have been dismissed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.2 <U>Remedies Upon Tenant&#146;s Default</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon the occurrence of any event of default described in Section&nbsp;18.1 hereof, Landlord, in addition to and without
prejudice to any other rights or remedies it may have, shall have the immediate right to re-enter the Property or any part thereof and repossess the same, expelling and removing therefrom all persons and property (which property may be stored in a
public warehouse or elsewhere at the cost and risk of and for the account of Tenant), using such force as may be necessary to do so (as to which Tenant hereby waives any claim for loss or damage that may thereby occur). In addition to or in lieu of
such re-entry, and without prejudice to any other rights or remedies it may have, Landlord shall have the right either (i)&nbsp;to terminate this Lease and recover from Tenant all damages incurred by Landlord as a result of Tenant&#146;s default, as
hereinafter provided, or (ii)&nbsp;to continue this Lease in effect and recover rent and other charges and amounts as they become due. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Even if Tenant has breached this Lease or abandoned the Property, this Lease shall continue in effect for so long as Landlord does not terminate Tenant&#146;s right to possession under subsection
(a)&nbsp;hereof and Landlord may enforce all of its rights and remedies under this Lease, including the right to recover rent as it becomes due, and Landlord, without terminating this Lease, may exercise all of the rights and remedies of a lessor
under California Civil Code Section&nbsp;1951.4 (lessor may continue lease in effect after lessee&#146;s breach and abandonment and recover rent as it becomes due, if lessee has right to sublet or assign, subject only to reasonable limitations), or
any successor Code section. Acts of maintenance, preservation or efforts to relet the Property or the appointment of a receiver upon application of Landlord to protect Landlord&#146;s interests under this Lease shall not constitute a termination of
Tenant&#146;s right to possession. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If Landlord terminates this Lease pursuant to this Section&nbsp;18.2, Landlord shall
have all of the rights and remedies of a landlord provided by Section&nbsp;1951.2 of the Civil Code of the State of California, or any successor Code section, which remedies include Landlord&#146;s right to recover from Tenant (i)&nbsp;the worth at
the time of award of the unpaid rent and additional rent which had been earned at the time of termination, (ii)&nbsp;the worth at the time of award of the amount by which the unpaid rent and additional rent which would have been earned after
termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided, (iii)&nbsp;the worth at the time of award of the amount by which the unpaid rent and additional rent for the balance of
the term after the time of award exceeds the amount of such rental loss that Tenant proves could be reasonably avoided, and (iv)&nbsp;any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#146;s failure
to perform its obligations under this Lease or which in the ordinary course of things would be likely to result therefrom, including, but not limited to, the cost of recovering possession of the Property, expenses of reletting, including necessary
repair, renovation and alteration of the Property, reasonable attorneys&#146; fees, and other reasonable costs. The &#147;worth at the time of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-26-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
award&#148; of the amounts referred to in clauses (i)&nbsp;and (ii)&nbsp;above shall be computed by allowing interest at ten percent (10%)&nbsp;per annum from the date such amounts accrued to
Landlord. The &#147;worth at the time of award&#148; of the amounts referred to in clause (iii)&nbsp;above shall be computed by discounting such amount at one percentage point above the discount rate of the Federal Reserve Bank of San Francisco at
the time of award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.3 <U>Remedies Cumulative</U>. All rights, privileges and elections or remedies of Landlord contained in
this Article 18 are cumulative and not alternative to the extent permitted by law and except as otherwise provided herein. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.
<U>SUBORDINATION, ATTORNMENT AND SALE</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.1 <U>Subordination To Mortgage</U>. This Lease, and any sublease entered into by
Tenant under the provisions of this Lease, shall be subject and subordinate to any ground lease, mortgage, deed of trust, sale/leaseback transaction or any other hypothecation for security now or hereafter placed upon the Initial Building, the
Property, or both, and the rights of any assignee of Landlord or of any ground lessor, mortgagee, trustee, beneficiary or leaseback lessor under any of the foregoing, and to any and all advances made on the security thereof and to all renewals,
modifications, consolidations, replacements and extensions thereof; provided, however, that such subordination in the case of any future ground lease, mortgage, deed of trust, sale/leaseback transaction or any other hypothecation for security placed
upon the Initial Building, the Property, or both shall be conditioned on Tenant&#146;s receipt from the ground lessor, mortgagee, trustee, beneficiary or leaseback lessor of a Non-Disturbance Agreement in a form reasonably acceptable to Tenant
confirming that so long as Tenant is not in default hereunder, Tenant&#146;s rights hereunder shall not be disturbed by such person or entity. Moreover, Tenant&#146;s obligations under this Lease shall be conditioned on Tenant&#146;s receipt within
thirty (30)&nbsp;days after mutual execution of this Lease, from any ground lessor, mortgagee, trustee, beneficiary or leaseback lessor currently owning or holding a security interest in the Property, of a Non-Disturbance Agreement in a form
reasonably acceptable to Tenant confirming that so long as Tenant is not in default hereunder, Tenant&#146;s rights hereunder shall not be disturbed by such person or entity. If any mortgagee, trustee, beneficiary, ground lessor, sale/leaseback
lessor or assignee elects to have this Lease be an encumbrance upon the Property prior to the lien of its mortgage, deed of trust, ground lease or leaseback lease or other security arrangement and gives notice thereof to Tenant, this Lease shall be
deemed prior thereto, whether this Lease is dated prior or subsequent to the date thereof or the date of recording thereof. Tenant, and any sublessee, shall execute such documents as may reasonably be requested by any mortgagee, trustee,
beneficiary, ground lessor, sale/leaseback lessor or assignee to evidence the subordination herein set forth, subject to the conditions set forth above, or to make this Lease prior to the lien of any mortgage, deed of trust, ground lease, leaseback
lease or other security arrangement, as the case may be, and if Tenant fails to do so within ten (10)&nbsp;days after demand from Landlord, Tenant constitutes and appoints Landlord as Tenant&#146;s attorney-in-fact and in Tenant&#146;s name, place
and stead to do so. Upon any default by Landlord in the performance of its obligations under any mortgage, deed of trust, ground lease, leaseback lease or assignment, Tenant (and any sublessee) shall, notwithstanding any subordination hereunder,
attorn to the mortgagee, trustee, beneficiary, ground lessor, leaseback lessor or assignee thereunder upon demand and become the tenant of the successor in interest to Landlord, at the option of such successor in interest, and shall execute and
deliver any instrument or instruments confirming the attornment herein provided for. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.2 <U>Sale Of Landlord&#146;s
Interest</U>. Upon sale, transfer or assignment of Landlord&#146;s entire interest in the Improvements and Property, Landlord shall be relieved of its obligations hereunder with respect to liabilities accruing from and after the date of such sale,
transfer or assignment, except as otherwise expressly provided in Section&nbsp;21.2 hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.3 <U>Estoppel
Certificates</U>. Either Tenant or Landlord (the &#147;certifying party&#148;) shall at any time and from time to time, within ten (10)&nbsp;days after written request by the other party (the &#147;requesting party&#148;), execute, acknowledge and
deliver to the requesting party a certificate in writing stating: (i)&nbsp;that this Lease is unmodified and in full force and effect, or if there have been any modifications, that this Lease is in full force and effect as modified and stating the
date and the nature of each modification; (ii)&nbsp;the date to which rental and all other sums payable hereunder have been paid; (iii)&nbsp;that the requesting party is not in default in the performance of any of its obligations under this Lease,
that the certifying party has given no notice of default to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-27-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
requesting party and that no event has occurred which, but for the expiration of the applicable time period, would constitute an event of default hereunder, or if the certifying party alleges
that any such default, notice or event has occurred, specifying the same in reasonable detail; and (iv)&nbsp;such other matters as may reasonably be requested by the requesting party or by any institutional lender, mortgagee, trustee, beneficiary,
ground lessor, sale/leaseback lessor or prospective purchaser of the Property or of Tenant&#146;s leasehold interest therein. Any such certificate provided under this Section&nbsp;19.3 may be relied upon by any lender, mortgagee, trustee,
beneficiary, assignee or successor in interest to the requesting party, by any prospective purchaser, by any purchaser on foreclosure or sale, by any grantee under a deed in lieu of foreclosure of any mortgage or deed of trust on the Property, or by
any other third party. Failure to execute and return within the required time any estoppel certificate requested hereunder shall be deemed to be an admission of the truth of the matters set forth in the form of certificate submitted to the
certifying party for execution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.4 <U>Subordination to CC&amp;R&#146;s</U>. This Lease, and any permitted sublease entered
into by Tenant under the provisions of this Lease, shall be subject and subordinate to any declarations of covenants, conditions and restrictions affecting the Property from time to time, which may include easements, access rights and similar
non-exclusive use rights and privileges in favor of appropriate third parties; <U>provided</U>, however, that following the execution of this Lease, Landlord shall not record or agree to any such declarations affecting the Property without the prior
written consent of Tenant, which consent shall not be unreasonably withheld or delayed. It shall be deemed reasonable for Tenant to withhold consent to any declaration or provision thereof which impairs Tenant&#146;s rights under this Lease in any
material respect. Tenant agrees to execute, upon request by Landlord, any documents reasonably required from time to time to evidence such subordination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">19.5 <U>Mortgagee Protection</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If, in connection with any future ground
lease, mortgage, deed of trust, sale/leaseback transaction or any other hypothecation for security placed upon the Initial Building, the Property, or both, the ground lessor, mortgagee, trustee, beneficiary or leaseback lessor requests any changes
in this Lease as a condition to its willingness to enter into or accept the ground lease, mortgage, deed of trust, sale/leaseback transaction or other hypothecation for security, then Tenant shall not unreasonably withhold or delay its consent to
any such requested changes and shall execute, at the request of Landlord, an amendment to this Lease incorporating the changes thus reasonably consented to by Tenant It shall be deemed reasonable for Tenant to withhold consent to any requested
change which imposes a substantial new monetary obligation on Tenant or which otherwise substantially impairs Tenant&#146;s rights under this Lease. Tenant&#146;s obligations under this Section&nbsp;19.5(a) shall be conditioned on Tenant&#146;s
concurrent receipt, from the ground lessor, mortgagee, trustee, beneficiary or leaseback lessor, of a Non-Disturbance Agreement in a form reasonably acceptable to Tenant confirming that so long as Tenant is not in default hereunder, Tenant&#146;s
rights hereunder shall not be disturbed by such person or entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If, following a default by Landlord under any mortgage,
deed of trust, ground lease, leaseback lease or other security arrangement covering the Property, the Property is acquired by the mortgagee, beneficiary, master lessor or other secured party, or by any other successor owner, pursuant to a
foreclosure, trustee&#146;s sale, sheriffs sale, lease termination or other similar procedure (or deed in lieu thereof), then any such person or entity so acquiring the Property shall not be: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) liable for any act or omission of a prior landlord or owner of the Property (including, but not limited to, Landlord); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) subject to any offsets or defenses that Tenant may have against any prior landlord or owner of the Property (including, but not
limited to, Landlord); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) bound by any rent or additional rent that Tenant may have paid in advance to any prior landlord
or owner of the Property (including, but not limited to, Landlord) for a period in excess of one month, or by any security deposit, cleaning deposit or other prepaid charge that Tenant may have paid in advance to any prior landlord or owner
(including, but not limited to, Landlord); </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-28-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) liable for any warranties or representations of any nature whatsoever, whether
pursuant to this Lease or otherwise, by any prior landlord or owner of the Property (including, but not limited to, Landlord) with respect to the use, construction, zoning, compliance with laws, title, habitability, fitness for purpose or
possession, or physical condition (including, without limitation, environmental matters) of the Property or Improvements; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) liable to Tenant in any amount beyond the interest of such mortgagee, beneficiary, master lessor or other secured party or successor
owner in the Property as it exists from time to time, it being the intent of this provision that Tenant shall look solely to the interest of any such mortgagee, beneficiary, master lessor or other secured party or successor owner in the Property for
the payment and discharge of the landlord&#146;s obligations under this Lease and that such mortgagee, beneficiary, master lessor or other secured party or successor owner shall have no separate personal liability for any such obligations.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20. <U>SECURITY</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">20.1 <U>Deposit</U>. Concurrently with Tenant&#146;s execution of this Lease, Tenant shall deposit with Landlord the sum of One Hundred Nineteen Thousand Two Hundred Forty and No/100 Dollars
($119,240.00), which sum (the &#147;Security Deposit&#148;) shall be held by Landlord as security for the faithful performance of all of the terms, covenants, and conditions of this Lease to be kept and performed by Tenant during the term hereof. If
Tenant defaults with respect to any provision of this Lease, including, without limitation, the provisions relating to the payment of rental and other sums due hereunder, Landlord shall have the right, but shall not be required, to use, apply or
retain all or any part of the Security Deposit for the payment of rental or any other amount which Landlord may spend or become obligated to spend by reason of Tenant&#146;s default or to compensate Landlord for any other loss or damage which
Landlord may suffer by reason of Tenant&#146;s default. If any portion of the Security Deposit is so used or applied, Tenant shall, within ten (10)&nbsp;days after written demand therefor, deposit cash with Landlord in an amount sufficient to
restore the Security Deposit to its original amount and Tenant&#146;s failure to do so shall be a material breach of this Lease. Landlord shall not be required to keep any deposit under this Section separate from Landlord&#146;s general funds, and
Tenant shall not be entitled to interest thereon. If Tenant fully and faithfully performs every provision of this Lease to be performed by it, the Security Deposit, or any balance thereof, shall be returned to Tenant or, at Landlord&#146;s option,
to the last assignee of Tenant&#146;s interest hereunder, at the expiration of the term of this Lease and after Tenant has vacated the Property. In the event of termination of Landlord&#146;s interest in this Lease, Landlord shall transfer all
deposits then held by Landlord under this Section to Landlord&#146;s successor in interest, whereupon Tenant agrees to release Landlord from all liability for the return of such deposit or the accounting thereof. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21. <U>MISCELLANEOUS</U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.1 <U>Notices</U>. All notices, consents, waivers and other communications which this Lease requires or permits either party to give to the other shall be in writing and shall be deemed given when
delivered personally (including delivery by private courier or express delivery service) or four (4)&nbsp;days after deposit in the United States mail, registered or certified mail, postage prepaid, addressed to the parties at their respective
addresses as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To&nbsp;Tenant:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(until Commencement Date)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">270 E. Grand Avenue</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">South San Francisco, CA 94080</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: James M. Gower, Chairman</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(after Commencement Date)</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">[At the Initial Building &#151;<BR>address to be supplied]</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: James M. Gower, Chairman</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-29-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">with&nbsp;copy&nbsp;to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cooley Godward Castro Huddleson &amp; Tatum</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Five Palo Alto Square, 4th Floor</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Palo Alto, CA 94306-2155</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Brian Cunningham</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To&nbsp;Landlord:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Developments, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1939 Harrison Street, Suite 610</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Park Plaza Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Oakland, CA 94612</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: T. J. Bristow</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">with&nbsp;copy&nbsp;to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Folger &amp; Levin</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Embarcadero Center West</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">275 Battery Street, 23rd Floor</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">San Francisco, CA 94111</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Donald E. Kelley, Jr.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">and&nbsp;copy&nbsp;to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">SDK Incorporated</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 West Monroe Street</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chicago, IL 60603</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Marshall Lees</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address as may be contained in a notice at least fifteen (15)&nbsp;days prior to the address change from
either party to the other given pursuant to this Section. Rental payments and other sums required by this Lease to be paid by Tenant shall be delivered to Landlord at Landlord&#146;s address provided in this Section, or to such other address as
Landlord may from time to time specify in writing to Tenant, and shall be deemed to be paid only upon actual receipt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.2
<U>Successors And Assigns</U>. The obligations of this Lease shall run with the land, and this Lease shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns, except that the original Landlord
named herein and each successive Landlord under this Lease shall be liable only for obligations accruing during the period of its ownership of the Property, said liability terminating upon termination of such ownership and passing to the successor
lessor, except as otherwise expressly provided in the following sentence. Tenant acknowledges that it has been advised by Landlord that following execution of this Lease, Landlord intends to assign its rights and obligations hereunder (a)&nbsp;to a
limited liability company or other entity having substantially the same ownership and management as Landlord, and/or (b)&nbsp;to an entity of which Landlord or an affiliate of Landlord is a general partner or has management responsibilities and
equity participation comparable to those of a general partner; <U>provided</U>, that any such assignment shall not relieve Landlord of any of its obligations under this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.3 <U>No Waiver</U>. The failure of Landlord to seek redress for violation, or to insist upon the strict performance, of any covenant or condition of this Lease shall not be deemed a waiver of such
violation, or prevent a subsequent act which would originally have constituted a violation from having all the force and effect of an original violation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.4 <U>Severability</U>. If any provision of this Lease or the application thereof is held to be invalid or unenforceable, the remainder of this Lease or the application of such provision to persons or
circumstances other than those as to which it is invalid or unenforceable shall not be affected thereby, and each of the provisions of this Lease shall be valid and enforceable, unless enforcement of this Lease as so invalidated would be
unreasonable or grossly inequitable under all the circumstances or would materially frustrate the purposes of this Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.5 <U>Litigation Between Parties</U>. In the event of any litigation or other dispute resolution proceedings between the parties hereto
arising out of or in connection with this Lease, the prevailing party shall be reimbursed for all reasonable costs, including, but not limited to, reasonable accountants&#146; fees and attorneys&#146; fees, incurred in connection with such
proceedings (including, but not limited to, any appellate proceedings relating thereto) or in connection with the enforcement of any judgment or award rendered in such proceedings. &#147;Prevailing party&#148; within the meaning of this Section
shall include, without limitation, a party who dismisses an action for recovery hereunder in exchange for payment of the sums allegedly due, performance of covenants allegedly breached or consideration substantially equal to the relief sought in the
action. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-30-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.6 <U>Surrender</U>. A voluntary or other surrender of this Lease by Tenant, or a mutual
termination thereof between Landlord and Tenant, shall not result in a merger but shall, at the option of Landlord, operate either as an assignment to Landlord of any and all existing subleases and subtenancies, or a termination of all or any
existing subleases and subtenancies. This provision shall be contained in any and all assignments or subleases made pursuant to this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.7 <U>Interpretation</U>. The provisions of this Lease shall be construed as a whole, according to their common meaning, and not strictly for or against Landlord or Tenant. The captions preceding the
text of each Section and subsection hereof are included only for convenience of reference and shall be disregarded in the construction or interpretation of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.8 <U>Entire Agreement</U>. This written Lease, together with the exhibits hereto, contains all the representations and the entire understanding between the parties hereto with respect to the subject
matter hereof. Any prior correspondence, memoranda or agreements are replaced in total by this Lease and the exhibits hereto. This Lease may be modified only by an agreement in writing signed by each of the parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.9 <U>Governing Law</U>. This Lease and all exhibits hereto shall be construed and interpreted in accordance with and be governed by
all the provisions of the laws of the State of California. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.10 <U>No Partnership</U>. The relationship between Landlord and
Tenant is solely that of a lessor and lessee. Nothing contained in this Lease shall be construed as creating any type or manner of partnership, joint venture or joint enterprise with or between Landlord and Tenant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.11 <U>Financial Information</U>. From time to time Tenant shall promptly provide directly to prospective lenders and purchasers of the
Property designated by Landlord such financial information pertaining to the financial status of Tenant as Landlord may reasonably request; provided, Tenant shall be permitted to provide such financial information in a manner which Tenant deems
reasonably necessary to protect the confidentiality of such information. In addition, from time to time, Tenant shall provide Landlord with such financial information pertaining to the financial status of Tenant as Landlord may reasonably request.
Landlord agrees that all financial information supplied to Landlord by Tenant shall be treated as confidential material, and shall not be disseminated to any party or entity (including any entity affiliated with Landlord) without Tenant&#146;s prior
written consent. For purposes of this Section, without limiting the generality of the obligations provided herein, it shall be deemed reasonable for Landlord to request copies of Tenant&#146;s most recent audited annual financial statements, or, if
audited statements have not been prepared, unaudited financial statements for Tenant&#146;s most recent fiscal year, accompanied by a certificate of Tenant&#146;s chief financial officer that such financial statements fairly present Tenant&#146;s
financial condition as of the date(s) indicated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landlord and Tenant recognize the need of Tenant to maintain the
confidentiality of information regarding its financial status and the need of Landlord to be informed of, and to provide to prospective lenders and purchasers of the Property financial information pertaining to, Tenant&#146;s financial status.
Landlord and Tenant agree to cooperate with each other in achieving these needs within the context of the obligations set forth in this Section. Landlord also acknowledges and agrees that Tenant&#146;s obligations to furnish information to Landlord
under this Section are in all events subject to Tenant&#146;s compliance with, and may therefore be limited by, applicable securities laws. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.12 <U>Costs</U>. If Tenant requests the consent of Landlord under any provision of this Lease for any act that Tenant proposes to do hereunder, including, without limitation, assignment or subletting
of the Property, Tenant shall, as a condition to doing any such act and the receipt of such consent, reimburse Landlord promptly for any and all reasonable costs and expenses incurred by Landlord in connection therewith, including, without
limitation, reasonable attorneys&#146; fees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.13 <U>Time</U>. Time is of the essence of this Lease, and of every term and
condition hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.14 <U>Rules And Regulations</U>. Tenant shall observe, comply with and obey, and shall cause its
employees, agents and, to the best of Tenant&#146;s ability, invitees to observe, comply with and obey such rules and regulations as Landlord may promulgate from time to time for the safety, care, cleanliness, order and use of the Improvements and
the Property. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-31-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.15 <U>Brokers</U>. Landlord agrees to pay a brokerage commission to Catalyst Real Estate
Group, Tenant&#146;s broker, in connection with the consummation of this Lease in accordance with a separate agreement. Each party represents and warrants that no other broker participated in the consummation of this Lease and agrees to indemnify,
defend and hold the other party harmless against any liability, cost or expense, including, without limitation, reasonable attorneys&#146; fees, arising out of any claims for brokerage commissions or other similar compensation in connection with any
conversations, prior negotiations or other dealings by the indemnifying party with any other broker. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.16 <U>Memorandum Of
Lease</U>. At any time during the term of this Lease, either party, at its sole expense, shall be entitled to record a memorandum of this Lease and, if either party so elects, both parties agree to cooperate in the preparation, execution,
acknowledgement and recordation of such document in reasonable form. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.17 <U>Corporate Authority</U>. The person signing
this Lease on behalf of Tenant warrants that he or she is fully authorized to do so and, by so doing, to bind Tenant As evidence of such authority, Tenant shall deliver to Landlord, upon or prior to execution of this Lease, a certified copy of a
resolution of Tenant&#146;s board of directors authorizing the execution of this Lease and naming the officer that is authorized to execute this Lease on behalf of Tenant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">21.18 <U>Execution and Delivery</U>. This Lease may be executed in one or more counterparts and by separate parties on separate counterparts, but each such counterpart shall constitute an original and all
such counterparts together shall constitute one and the same instrument. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.19 <U>Survival</U>. Without limiting survival
provisions which would otherwise be implied or construed under applicable law, the provisions of Sections 2.6, 9.4, 11.2, 11.3, 11.4, 13.6, 14.6 and 21.5 hereof shall survive the termination of this Lease with respect to matters occurring prior to
the expiration of this Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties hereto have executed this Lease as of the day and year first
set forth above. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Landlord&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant&#148;</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRITANNIA DEVELOPMENTS, INC., a California corporation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TULARIK INC., a California corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ T. J. Bristow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">T. J. Bristow</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">President &amp; CEO</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">-32-
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>EXHIBITS </U></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT&nbsp;A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Real Property Description (Site)</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT B</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Plan</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Workletter</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Estimated Construction Schedule</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXHIBIT E</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acknowledgement of Lease Commencement</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>EXHIBIT A </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>REAL PROPERTY DESCRIPTION (SITE) </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All that certain real property in the City of South San
Francisco, County of San Mateo, State of California, more particularly described as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parcel One: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parcel C as designated on the Map entitled &#147;PARCEL MAP NO. 89-268&#148;, being a resubdivision of Lots 4, 5, 6 and 7 of that certain Map entitled
&#147;FINAL MAP GATEWAY CENTER&#148; (SA-81-74) filed in the office of the Recorder of the County of San Mateo in Book 107 of Maps at Pages 27, 28, 29 and 30, which Map was filed in the Office of the Recorder of the County of San Mateo, State of
California on December&nbsp;12, 1989 in Book 63 of Parcel Maps at Pages 32 and 33. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parcel Two: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A portion of that certain 0.572 acre parcel of land described in Resolution No.&nbsp;900 by the City of South San Francisco, recorded August&nbsp;6,
1943, in Book 1079 of Official Records of San Mateo County at Page 77, further described as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A portion of Industrial Way, as shown on
that certain Map entitled &#147;Final Map Gateway Center&#148; filed October&nbsp;1, 1982, in Book 107 of Maps at Pages 27-30, San Mateo County Records, further described as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Beginning at a point on the southeasterly line of said 0.572 acre parcel, also being the northwesterly line of Lot 4 as shown on said Map (104 Maps 27-30), distant thereon North 38&deg; 42&#146; 41&#148;
East, 29.29 feet from the southwest corner of said Lot 4; thence along the aforementioned southeasterly line, North 38&deg; 42&#146; 41&#148; East, 356.97 feet; then northeasterly along the arc of a tangent, 980.56 foot radius curve to the left,
through a central angle of 7&deg; 19&#146; 26&#148;, an arc distance of 125.34 feet to a point of reverse curvature; thence northeasterly along the arc of a tangent, 980.56 foot radius curve to the right, through a central angle of 7&deg; 19&#146;
26&#148;, an arc distance of 125.34 feet to a point of cusp, being the most northerly point of the aforementioned 0.572 acre parcel; thence along the northwesterly line of said 0.572 acre parcel, South 38&deg; 42&#146; 41&#148; West, 606.97 feet to
a line which bears North 51&deg; 17&#146; 19&#148; West from the point of beginning; thence South 51&deg; 17&#146; 19&#148; East, 16.00 feet to the point of beginning. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>EXHIBIT B </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>SITE PLAN </U></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431exm_pg053.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXHIBIT C </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>WORKLETTER </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This Workletter (&#147;Workletter&#148;) constitutes part of the Build-to-Suit Lease dated as of April&nbsp;20, 1995 (the &#147;Lease&#148;) between BRITANNIA DEVELOPMENTS, INC., a California corporation
(&#147;Landlord&#148;), and TULARIK INC., a California corporation (&#147;Tenant&#148;). The terms of this Workletter are incorporated in the Lease for all purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <U>Defined Terms</U>. As used in this Workletter, the following capitalized terms have the following meanings: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Approved Plans</U>: Plans and specifications prepared by the applicable Architect for the respective Improvements and approved by both Landlord and Tenant in accordance with Paragraph 2 of this
Workletter (subject to further modification in accordance with such Paragraph 2). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Architect</U>: Hallenbeck,
Chamorro&nbsp;&amp; Associates with respect to the Building Shell, the Site Improvements and any other Improvements which Landlord is to design pursuant to the Coordination Schedule; WHL Architects&nbsp;&amp; Planners with respect to all
Improvements which Tenant is to design pursuant to the Coordination Schedule, and with respect to all other Interior Improvements except those for which Hallenbeck, Chamorro&nbsp;&amp; Associates is the Architect pursuant to the first portion of
this definition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Building Shell</U>: The shell of the Initial Building, as more fully defined on Schedule 1 attached
to this Workletter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Change Order</U>: See definition in Paragraph 2(e)(ii) hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Coordination Schedule</U>: The schedule entitled Tularik/Britannia Shell/Interiors Coordination and attached as Schedule 2 to this
Workletter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Cost of Improvement</U>: See definition in Paragraph 2(c) hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <U>Final Completion Certificate</U>: See definition in Paragraph 3(b) hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) <U>Final Working Drawings</U>: See definition in Paragraph 2(a) hereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>General Contractor</U>: Concrete Shell Structures, Inc. with respect to Landlord&#146;s Work. The General Contractor with respect
to Tenant&#146;s Work shall be selected by Tenant, subject to Landlord&#146;s approval (not to be unreasonably withheld or delayed), as contemplated in Paragraph 5(a) hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(j) <U>Improvements</U>: The Building Shell, Site Improvements, Interior Improvements and other improvements shown on the Approved Plans from time to time and to be constructed on the Phase I Site
pursuant to the Lease and this Workletter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(k) <U>Interior Improvements</U>: The improvements to or within the Initial
Building, other than improvements constituting part of the Building Shell, shown on the Approved Plans from time to time and to be constructed by Tenant (except as otherwise provided herein) pursuant to the Lease and this Workletter. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l) <U>Landlord&#146;s Work</U>: The Building Shell and Site Improvements, and any other Improvements which Landlord is to install
pursuant to the Coordination Schedule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(m) <U>Punch List Work</U>: Minor corrections of construction or decoration details,
and minor mechanical adjustments, that are required in order to cause any applicable portion of the Improvements as constructed to conform to the Approved Plans in all material respects and that do not materially interfere with Tenant&#146;s use or
occupancy of the Property. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(n) <U>Site Improvements</U>: The parking areas, driveways, landscaping and other
improvements to the Common Areas of the Site that are designated on <U>Exhibit B</U> to the Lease as being part of the Phase I Site. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(o) <U>Structural Completion Certificate</U>: See definition in Paragraph 3(a) hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(p) <U>Tenant Delay</U>: Any of the following types of delay in the completion of construction of the Building Shell: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) Any delay resulting from Tenant&#146;s failure to furnish, in a timely manner, information requested by Landlord, Architect or Contractor in connection with the design or construction of the Building
Shell, or from Tenant&#146;s failure to approve in a timely manner any matters requiring approval by Tenant; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Any delay
attributable to any need to construct the Building Shell in an &#147;above standard&#148; manner, as more fully described in Schedule I attached to this Workletter; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) Any delay resulting from Change Orders, including any delay resulting from the need to revise any drawings or obtain further governmental approvals as a result of any Change Order; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Any delay of any other kind or nature caused by Tenant (or Tenant&#146;s contractors, agents or employees) or resulting from the
performance of Tenant&#146;s Work. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(q) <U>Tenant&#146;s Work</U>: All of the Improvements other than those constituting
Landlord&#146;s Work, and such other materials and improvements as Tenant deems necessary or appropriate for Tenant&#146;s use and occupancy of the Initial Building. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(r) <U>Unavoidable Delays</U>: Delays due to acts of God, acts of public agencies, labor disputes, strikes, fires, freight embargoes, rainy or stormy weather, inability to obtain supplies, materials,
fuels or permits, delays of contractors or subcontractors, or other causes or contingencies beyond the reasonable control of Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(s) <U>Work Deadlines</U>: The target dates for performance by the applicable party of the steps listed in the Estimated Construction Schedule attached as <U>Exhibit D</U> to the Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(t) Capitalized terms not otherwise defined in this Workletter shall have the definitions set forth in the Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. <U>Plans, Cost of Improvements and Construction</U>. Landlord and Tenant shall comply with the procedures set forth in this Paragraph in preparing,
delivering and approving matters relating to the Improvements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Approved Plans and Working Drawings for Landlord&#146;s
Work</U>. Plans and specifications for the Building Shell and other aspects of Landlord&#146;s Work have been and continue to be under development and review by Landlord, Tenant and the respective Architects, but no such plans and specifications
have yet been finally approved. Landlord shall continue to promptly and diligently (and in all events prior to any applicable Work Deadlines) cause to be prepared and delivered to Tenant, for approval, plans and specifications for the Improvements
constituting Landlord&#146;s Work (except to the extent Tenant is responsible for the design of such Improvements pursuant to the Coordination Schedule, in which event Tenant shall promptly and diligently, and in all events prior to any applicable
Work Deadlines, cause such plans and specifications to be prepared and delivered to Landlord for approval). Following such mutual approval, Landlord shall then cause to be prepared and delivered to Tenant, on or before the applicable Work Deadline
(assuming timely delivery by Tenant of all information, decisions and drawings required to be furnished or made by Tenant in order to permit complete preparation of plans and drawings), final working drawings and specifications for the Improvements
constituting Landlord&#146;s Work, including structural, fire protection, life safety, mechanical and electrical working drawings and final architectural drawings (collectively, &#147;Final Working Drawings&#148;). The </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Final Working Drawings shall substantially conform to the Approved Plans. Landlord&#146;s obligation to deliver the Final Working Drawings to Tenant within the time period set forth above shall
be extended for any delay encountered by Landlord as a result of a request by Tenant for changes in accordance with the procedure set forth below, any other Tenant Delays, or any Unavoidable Delays. No later than the applicable Work Deadline
(assuming timely delivery of plans and drawings by Landlord), Tenant shall either approve the Final Working Drawings or set forth in writing with particularity any changes necessary to bring, the Final Working Drawings into substantial conformity
with the Approved Plans or into a form which will be acceptable to Tenant. In no event, however, shall Tenant have the right to object to any aspect of the proposed plans and specifications or proposed Final Working Drawings for Landlord&#146;s Work
(including, but not limited to, any change from the Approved Plans) that is necessitated by applicable law, or to any aspect of such proposed plans and specifications or proposed Final Working Drawings that relates to the Building Shell or Site
Improvements, although Landlord agrees to consult with Tenant and to give reasonable consideration to Tenant&#146;s views regarding functional characteristics of the Building Shell and Site Improvements. Failure of Tenant to deliver to Landlord
written notice of disapproval and specification of required changes on or before the applicable Work Deadline shall constitute and be deemed to be approval of the Final Working Drawings. Upon approval, actual or deemed, of the Final Working Drawings
by Landlord and Tenant, the Final Working Drawings shall be deemed to be incorporated in and considered part of the Approved Plans, superseding (to the extent of any inconsistencies) any inconsistent features of the previously existing Approved
Plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Approved Plans and Working Drawings for Tenant&#146;s Work</U>. Tenant shall promptly and diligently cause to
be prepared and delivered to Landlord, for approval, plans and specifications for the Improvements constituting Tenant&#146;s Work (except to the extent Landlord is responsible for the design of such Improvements pursuant to the Coordination
Schedule, in which event Landlord shall promptly and diligently cause such plans and specifications to be prepared and delivered to Tenant for approval). Following such approval, Tenant shall then cause to be prepared and delivered to Landlord final
working drawings and specifications for the Improvements constituting Tenant&#146;s Work, including any applicable life safety, mechanical and electrical working drawings and final architectural drawings (collectively, &#147;Final Working
Drawings&#148;). The Final Working Drawings shall substantially conform to the Approved Plans. Landlord shall either approve the Final Working Drawings or set forth in writing with particularity any changes necessary to bring the Final Working
Drawings into substantial conformity with the Approved Plans or into a form which will be acceptable to Landlord. Upon approval of the Final Working Drawings by Landlord and Tenant, the Final Working Drawings shall be deemed to be incorporated in
and considered part of the Approved Plans, superseding (to the extent of any inconsistencies) any inconsistent features of the previously existing Approved Plans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Cost of Improvements</U>. &#147;Cost of Improvement&#148; shall mean, with respect to any item or component for which a cost must be determined in order to allocate such cost, or an increase in
such cost, to Landlord and/or Tenant pursuant to this Workletter, the sum of the following (unless otherwise agreed in writing by Landlord and Tenant with respect to any specific item or component or any category of items or components):
(i)&nbsp;all sums paid to contractors or subcontractors for labor and materials furnished in connection with construction of such item or component; (ii)&nbsp;all costs, expenses, payments, fees and charges (other than penalties) paid or incurred to
or at the direction of any city, county or other governmental or quasi-governmental authority or agency which are required to be paid in order to obtain all necessary governmental permits, licenses, inspections and approvals relating to construction
of such item or component; (iii) engineering and architectural fees for services rendered in connection with the design and construction of such item or component (including, but not limited to, the applicable Architect for such item or component
and an electrical engineer, mechanical engineer and civil engineer); (iv) sales and use taxes; (v)&nbsp;testing and inspection costs; (vi)&nbsp;the cost of power, water and other utility facilities and the cost of collection and removal of debris
required in connection with construction of such item or component; and (vii)&nbsp;all other &#147;hard&#148; costs incurred in the construction of such item or component in accordance with the Approved Plans and this Workletter. Cost of Improvement
shall not include any project management fee relating to the construction of such item or component. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Construction of Landlord&#146;s Work</U>. Promptly following approval of the Final
Working Drawings, Landlord shall apply for and use reasonable efforts to obtain the necessary permits and approvals to allow construction of all Improvements constituting Landlord&#146;s Work. Upon receipt of such permits and approvals, Landlord
shall, at Landlord&#146;s sole expense (except as otherwise provided in the Lease or in this Workletter), diligently construct and complete the Improvements constituting Landlord&#146;s Work substantially in accordance with the Approved Plans,
subject to Unavoidable Delays and Tenant Delays (if any). Such construction shall be performed in a neat and workmanlike manner and shall conform to all applicable governmental codes, laws and regulations in force at the time such work is completed.
Landlord shall use only union labor on or in connection with Landlord&#146;s Work and shall use the General Contractor specified in Paragraph l(i) to construct all Improvements constituting Landlord&#146;s Work, but shall use any subcontractors
specified in the Coordination Schedule or otherwise designated by Tenant to construct or install any Improvements constituting Landlord&#146;s Work that are listed on the Coordination Schedule. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Changes</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) If Landlord determines at any time that changes in the Final Working Drawings or in any other aspect of the Approved Plans relating to any item of Landlord&#146;s Work are required as a result of
applicable law or governmental requirements, or at the insistence of any other third party whose approval may be required with respcct to the Improvements, or as a result of unanticipated conditions encountered in the course of construction, then
Landlord shall promptly (A)&nbsp;advise Tenant of such circumstances and (B)&nbsp;cause revised Approved Plans and/or Final Working Drawings, as applicable, reflecting such changes to be prepared by Architect and, to the extent such changes relate
to items other than the Building Shell or Site Improvements, submitted to Tenant for approval in accordance with the procedure contemplated in Paragraph 2(a) hereof. Upon final approval of revised drawings by Landlord and Tenant (if applicable), the
Final Working Drawings and/or Approved Plans shall be deemed to be modified accordingly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) If Tenant at any time desires
any changes, alterations or additions to the Approved Plans or the Final Working Drawings with respect to any of Landlord&#146;s Work, Tenant shall submit a detailed written request to Landlord specifying such changes, alterations or additions (a
&#147;Change Order&#148;). Upon receipt of any such request, Landlord shall promptly notify Tenant of (A)&nbsp;whether the matters proposed in the Change Order are approved by Landlord (which approval shall not be unreasonably withheld),
(B)&nbsp;Landlord&#146;s estimate of the number of days of delay, if any, which shall be caused by such Change Order if implemented (including, without limitation, delays due to the need to obtain any revised plans or drawings and any governmental
approvals), and (C)&nbsp;Landlord&#146;s estimate of the increase, if any, which shall occur in the Cost of Improvement for the items or components affected by such Change Order if such Change Order is implemented (including, but not limited to, any
costs of compliance with laws or governmental regulations that become applicable because of the requested Change Order). If Tenant notifies Landlord in writing, within five (5)&nbsp;business days after receipt of such notice from Landlord, of
Tenant&#146;s approval of the Change Order (including the estimated delays and cost increases, if any, described in Landlord&#146;s notice), then Landlord shall cause such Change Order to be implemented, and Tenant shall be responsible for all costs
or cost increases resulting from or attributable to the Change Order, subject to the provisions of Paragraph 4 hereof. If Tenant fails to notify Landlord in writing of Tenant&#146;s approval of such Change Order within said five (5)&nbsp;business
day period, then such Change Order shall be deemed to be withdrawn and shall be of no further effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Completion</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) When Landlord receives written certification from Architect that construction of the foundation, structural slab on grade, underslab
plumbing work, structural steel framework, decking and concrete on second floor, and roof deck of the Initial Building, and installation of fire sprinklers therein, have been completed in accordance with the Approved Plans, Landlord shall prepare
and deliver to Tenant a certificate signed by both Landlord and Architect (the &#147;Structural Completion Certificate&#148;) certifying that the construction of such portions of the Initial Building has been substantially completed in accordance
with the Approved Plans in all material respects and specifying the date of that completion. The delivery of such Structural Completion Certificate shall commence the running of the six-month time period until the Commencement Date under
Section&nbsp;2.1 of the Lease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 4 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) When Landlord receives written certification from Architect that construction of the
remaining Improvements constituting Landlord&#146;s Work has been completed in accordance with the Approved Plans (except for Punch List Work), Landlord shall prepare and deliver to Tenant a certificate signed by both Landlord and Architect (the
&#147;Final Completion Certificate&#148;) certifying that the construction of the remaining Improvements constituting Landlord&#146;s Work has been substantially completed in accordance with the Approved Plans in all material respects, subject only
to completion of Punch List Work, and specifying the date of that completion. Upon receipt by Tenant of the Final Completion Certificate, the Improvements constituting Landlord&#146;s Work will be deemed delivered to Tenant for all purposes of the
Lease (subject to Landlord&#146;s continuing obligations with respect to the Punch List Work). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Notwithstanding any other
provisions of this Workletter or of the Lease, if Landlord is delayed in substantially completing any of Landlord&#146;s Work necessary for issuance of the Structural Completion Certificate as a result of any Tenant Delay, then the six-month period
between the delivery of the Structural Completion Certificate and the Commencement Date pursuant to Section&nbsp;2.1 of the Lease shall be reduced, day for day, by the number of days by which such Tenant Delay delayed completion of the portions of
Landlord&#146;s Work necessary for issuance of the Structural Completion Certificate, and Tenant shall reimburse Landlord in cash, within fifteen (15)&nbsp;days after written demand by Landlord (accompanied by reasonable documentation of the items
claimed), for any increased construction-related costs and expenses incurred by Landlord as a result of the Tenant Delay. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
At any time within thirty (30)&nbsp;days after delivery of the Structural Completion Certificate or the Final Completion Certificate, as applicable, Tenant shall be entitled to submit one or more lists to Landlord specifying Punch List Work to be
performed on the applicable Improvements, and upon receipt of such list(s), Landlord shall diligently complete such Punch List Work at Landlord&#146;s sole expense. In the event of any dispute as to completion of any item or component of
Landlord&#146;s Work, the certificate of, the applicable Architect shall be conclusive. Promptly after Landlord provides Tenant with the Final Completion Certificate, Landlord shall cause the recordation of a Notice of Completion (as defined in
Section&nbsp;3093 of the California Civil Code) with respect to Landlord&#146;s Work. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Payment of Costs</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Landlord&#146;s Work</U>. Except as otherwise specified in the Coordination Schedule with respect to any matters listed therein,
the cost of construction of Landlord&#146;s Work shall be borne by Landlord at its sole cost and expense, including any costs or cost increases incurred as a result of Unavoidable Delays, governmental requirements or unanticipated conditions;
<U>provided</U>, however, that notwithstanding any other provisions of this Paragraph 4(a), to the extent the Cost of Improvement relating to the construction of any item or component of Landlord&#146;s Work is increased as a result of any permitted
Change Order or any Tenant Delay, or as a result of any &#147;above standard&#148; Building Shell components identified in Schedule 1 attached hereto or otherwise necessitated by Tenant&#146;s particular use requirements or by the contemplated
Tenant&#146;s Work, or as a result of any other plan changes or compliance costs attributable to Tenant&#146;s particular use requirements or to the contemplated Tenant&#146;s Work, the amount of the increase in the Cost of Improvement with respect
to such item or component, as well as the Cost of Improvement with respect to any matters listed on the Coordination Schedule as being installed by Landlord but as having the cost thereof borne by Tenant, shall be reimbursed by Tenant to Landlord by
deducting such increase from the Allowance described in Paragraph 4(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Tenant&#146;s Work</U>. Except as otherwise
specified in the Coordination Schedule with respect to any matters listed therein or as otherwise expressly provided in this Workletter, the cost of construction of Tenant&#146;s Work shall be borne by Tenant at its sole cost and expense, including
any costs or cost increases incurred as a result of Unavoidable Delays, governmental requirements or unanticipated conditions. Notwithstanding the foregoing sentence, the Cost of Improvements </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 5 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
with respect to the construction of the Interior Improvements shall be borne by Landlord up to a maximum cost equal to One Hundred Five and No/100 Dollars ($105.00) per square foot times the
square footage of the Initial Building, as and when constructed (measured in accordance with Section&nbsp;1.1(a) of the Lease), less any reduction in such sum pursuant to Paragraph 4(a) or any other applicable provision of this Workletter (the
&#147;Allowance&#148;). The timing, conditions and other procedures for Landlord&#146;s disbursement of the Allowance shall be subject to mutual agreement of Landlord, Tenant and Landlord&#146;s lender (if any). To the extent the Cost of Improvement
with respect to the Interior Improvements exceeds the Allowance (as reduced, if applicable), whether as a result of Change Orders, Tenant Delays and/or Unavoidable Delays or otherwise, the amount of such excess shall in all events be Tenant&#146;s
sole responsibility and expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <U>Tenant&#146;s Work</U>. On or before the applicable Work Deadline, Tenant shall construct and install
in the Initial Building the Tenant&#146;s Work, substantially in accordance with the Approved Plans or, with respect to Tenant&#146;s Work not shown on the Approved Plans, substantially in accordance with plans and specifications prepared by Tenant
and approved in writing by Landlord (which approval shall not be unreasonably withheld or delayed). Tenant&#146;s Work shall be performed in accordance with, and shall in all respects be subject to, the terms and conditions of the Lease (to the
extent not inconsistent with this Workletter), and shall also be subject to the following conditions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Contractor
Requirements</U>. The contractor engaged by Tenant for Tenant&#146;s Work, and any subcontractors, shall be duly licensed in California, shall use only union labor on or in connection with Tenant&#146;s Work and shall be subject to Landlord&#146;s
prior written approval, which approval shall not be unreasonably withheld or delayed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Costs and Expenses of
Tenant&#146;s Work</U>. Subject to Landlord&#146;s payment or reimbursement obligations under Paragraph 4(b) hereof with respect to the Allowance, Tenant shall promptly pay all costs and expenses arising out of the performance of Tenant&#146;s Work
(including the costs of permits) and shall furnish Landlord with evidence of payment on request. Tenant shall provide Landlord with ten (10)&nbsp;days&#146; prior written notice before commencing any Tenant&#146;s Work. On completion of
Tenant&#146;s Work, Tenant shall deliver to Landlord a release and waiver of lien executed by each contractor, subcontractor and materialman involved in the performance of Tenant&#146;s Work. If any lien is filed against the Property or against
Tenant&#146;s leasehold interest, Tenant shall obtain, within ten (10)&nbsp;days after the filing, the release or discharge of that lien. If Tenant fails to do so, Landlord shall have the right (but not the obligation) to obtain the release or
discharge of the lien and Tenant shall, within fifteen (15)&nbsp;days after written demand by Landlord (accompanied by reasonable documentation of the items claimed), reimburse Landlord for all costs, including (but not limited to) reasonable
attorneys&#146; fees, incurred by Landlord in obtaining the release or discharge of such lien, together with interest from the date of demand at the interest rate set forth in Section&nbsp;3.2 of the Lease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Indemnification</U>. Tenant shall indemnify, defend (with counsel satisfactory to Landlord) and hold Landlord harmless from all
suits, claims, actions, losses, costs and expenses (including, but not limited to, claims for workers&#146; compensation, attorneys&#146; fees and costs) based on personal injury or property damage or contract claims (including, but not limited to,
claims for breach of warranty) arising from the performance of Tenant&#146;s Work. Tenant shall repair or replace (or, at Landlord&#146;s election, reimburse Landlord for the cost of repairing or replacing) any portion of the Improvements and/or any
of Landlord&#146;s real or personal property or equipment that is damaged, lost or destroyed in the performance of Tenant&#146;s Work. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Insurance</U>. Tenant&#146;s contractors shall obtain and provide to Landlord certificates evidencing workers&#146; compensation, public liability, and property damage insurance in amounts and
forms and with companies satisfactory to Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Rules and Regulations</U>. Tenant and Tenant&#146;s contractors
shall comply with any other rules, regulations and requirements that Landlord or General Contractor may reasonably impose with respect to the performance of Tenant&#146;s Work. Tenant&#146;s agreement with Tenant&#146;s contractors shall require
each contractor to provide daily cleanup of the construction area to the extent that such cleanup is necessitated by the performance of Tenant&#146;s Work. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 6 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) <U>Early Entry</U>. Landlord shall permit entry of contractors into the Initial Building
for the purposes of performing Tenant&#146;s Work, prior to the Commencement Date, subject to satisfaction of the conditions set forth in the Lease. This license to enter before commencement of the Term is expressly conditioned on the contractor(s)
retained by Tenant working in harmony with, and not interfering with, the workers, mechanics and contractors of Landlord. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g)
<U>Risk of Loss</U>. All materials, work, installations and decorations of any nature brought onto or installed in the Initial Building before the commencement of the Term shall be at Tenant&#146;s risk, and neither Landlord nor any party acting on
Landlord&#146;s behalf shall be responsible for any damage, loss or destruction thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h) <U>Condition of Tenant&#146;s
Work.</U> All work performed by Tenant shall be performed in a good and workmanlike manner, shall be free from defects in design, materials and workmanship, and shall be completed in compliance with the plans approved by Landlord for such
Tenant&#146;s Work in all material respects and in compliance with all applicable governmental laws, ordinances, codes and regulations in force at the time such work is completed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6. <U>Effect of Delays</U>. Any delay in any of the Work Deadlines (including any item that must be redone due to Tenant&#146;s disapproval) shall automatically delay all subsequent deadlines by the same
amount of time. To the extent that any delay constitutes a Tenant Delay, the Commencement Date for all purposes under the Lease shall be the date the Commencement Date would have occurred absent the Tenant Delay. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <U>No Agency</U>. Nothing contained in this Workletter shall make or constitute Tenant as the agent of Landlord. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <U>Survival</U>. Without limiting survival provisions which would otherwise be implied or construed under applicable law, the provisions of Paragraph
5(c) of this Workletter shall survive the termination of the Lease with respect to matters occurring prior to expiration of the Lease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.
<U>Miscellaneous</U>. All references in this Workletter to a &#147;number of days&#148; shall be construed to refer to calendar days, unless otherwise specified herein. In all instances where Tenant&#146;s approval is required, if no written notice
of disapproval is given within the applicable time period, at the end of that period Tenant shall be deemed to have given approval and the next succeeding time period shall commence. If any item requiring approval is disapproved by Tenant in a
timely manner, the procedure for preparation of that item and approval shall be repeated. Landlord may, in connection with any assignment of its interest under the Lease, assign to the same person or entity all of Landlord&#146;s rights and
obligations hereunder, in which event Landlord shall have no continuing obligations or liabilities hereunder (except to the extent otherwise expressly provided in Section&nbsp;21.2 of the Lease) and all such continuing obligations and liabilities
shall be assumed by and be binding upon Landlord&#146;s assignee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties have executed this
Workletter concurrently with and as of the date of the Lease. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Landlord&#148;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Tenant&#148;</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">BRITANNIA&nbsp;DEVELOPMENTS,&nbsp;INC.,<BR>a California corporation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">TULARIK INC.,<BR>a California corporation</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ T.J.&nbsp;Bristow</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">T.J.&nbsp;Bristow</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Its:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">illegible</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 7 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 1</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GENERAL</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">As approved by the City of South San Francisco and all other necessary government agencies, the premises shell and site shall be used as a tenant improvement with laboratory
research and development facility, including, but not limited to, wet chemistry and biology labs, clean rooms, pilot scale and clinical scale manufacturing, storage and use of toxic and radioactive materials and laboratory animals and other legal
related purposes.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A two story, approximately 66,127 s.f. building, Building &#147;B&#148;. See attached plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">There may need to be modification of the proposed building structural requirements (noted herein) dependent upon the final building design. This may result in a change from
braced frame locations to some acceptable alternate, but in no event will the following specifications be compromised.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Building heights shall be per the following Hallenbeck/Chamorro cross section, dated 3/23/95, conceptual foot print and site plan, all attached.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) 17&#146;-0&#148; floor to floor height.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tenant improvement design will require vertical openings at second floor and roof. The operating assumption is that these openings will be located and coordinated with Building
shell structural design, and subsequent construction activities.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Duct shafts.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Toilets/stairs.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">E.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Design to 1994 California State Building Code.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">F.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Property line to be shown between buildings to allow for individual purchase of buildings - locate at future date.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">G.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Phasing line on site drawing provided by Britannia to show limit of Phase l Construction.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 1 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 2</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">SITE WORK</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Show limits of work for Phase 1 per attached drawings per Hallenbeck/Chamorro, dated 10/5/94.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grading</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rough Pad Grade at Finish Floor, Level One
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Finish Pad Grade at Finish Floor, Level One
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concrete</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sidewalks - per approved City Planning submittal.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ramps - disabled access.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Hinge site flatwork off buildings at ingress/egress - docks, ramps to meet site
requirements. Bay Mud has been &nbsp;&nbsp;surcharged. Geotechnical report states stability.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Raised planter - at courtyard. 50% of cost to Britannia, 50% pro - rated to Building
&#147;A&#148;.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paying</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Concrete - thickened section at truck loading traffic.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Striping and Marking.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">E.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subsurface piping</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Water - minimum 3&#148; diameter.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Gas - minimum 6&#148; diameter (minimum, subject to change) - to building and service
yard.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;&nbsp;&nbsp;&nbsp;Sewer - minimum 6&#148; diameter sewer laterals.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;&nbsp;&nbsp;&nbsp;Storm water - minimum 8&#148; diameter.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">F.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Drains</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Parking.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Landscape area drains.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 2 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 3</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">G.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gates and handicapped signage - reference City submittal package dated 10/5/94.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">H.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pad location for Tularik bicycle lockers - coordinate with H.C.A. package dated 10/5/94.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">I.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landscape materials - reference City submittal package dated 10/5/94.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">J.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Landscape sprinklers - reference City submittal package dated 10/5/94.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">K.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Monument sign, base only - reference City submittal package dated 10/5/94. Final approval from City in progress.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">L.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dumpster enclosure pad, fence and metal gates - reference City submittal package dated 10/5/94.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">M.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fire riser location on plan.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">N.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Lighting - soffit Lighting at building connected with parking lot lights.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 3 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 4</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONCRETE</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excavation</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Pile foundation.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Elevator pits - part of T.I. allowance.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;&nbsp;&nbsp;&nbsp;Dock leveler pit - cost by Britannia.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concrete Forms</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Concrete</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;Ground level structural slab, slab on grade, grade beams and pilecaps, tolerance 1/8&#148; in
10&#146;-0&#148;, 1/2&#148; max, total difference. Maintain moisture content to no greater than 3 lbs/1,000 by means of a sub-slab barrier.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Second level slab - concrete slab on metal deck, perforated deck for moisture content reduction -
to yield minimum one hour rating, tolerance 1/8&#148; in 10&#146;-0&#148;, 1/2&#148; maximum total difference.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)&nbsp;&nbsp;&nbsp;&nbsp;There shall be no interior structural concrete or masonry shear walls.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4)&nbsp;&nbsp;&nbsp;&nbsp;Autoclaves, washers, etc. pits to be coordinated with structural slab system, to be engineered in
coordination with Tenant Improvement Design/Construction team, as required - need very soon. Cost of these pits to be a part of T.I. allowance; above standard shell costs.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 4 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 5</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MASONRY</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A. &nbsp;&nbsp;&nbsp;&nbsp;Concrete block walls, if utilized, at trash enclosure.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 5 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 6</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">METALS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steel columns and beams</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Structural steel braced frame at exterior building line.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second level structural steel truss and girder construction.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 70 PSF Dead/120 PSF Live for this project requirement was derived as
follows:</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 70 PSF Dead load projection figure is only provided as a gauge, since the actual
dead load will not be known until the design is complete. The definition of this load is the weight of the structure - and in the case of the concrete on steel, the concrete surprisingly makes up from one-third to one-half of the dead load. It also
includes loads for roof drainage piping and any core sanitary sewer piping. It does not cover anything beyond these self weights.</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;120 PSF Live load is to be incorporated into the design. Increased cost of 120 lbs Live
load over 100 lbs Live load is to be regarded as above standard shell. Cost to be part of Tenant Improvement Allowance.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Railings, (temporary) for construction.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steel deck</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Second level metal deck perforated for moisture content reduction at upper level - designed for one hour rating.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Roof level metal deck to support 30 psf live load at mechanical support areas, and at non-mechanical support areas within the roof screen. Metal roof deck to be supported by
steel joists.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exterior 6&#148; metal stud to support EIFS, wind load per 1994 California Building Code.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 6 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 7</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:18pt"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">THERMAL AND MOISTURE PROTECTION</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thermal Insulation at roof - R-19 to meet Title 24 calculations.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roofing, 4-ply minimum.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Firestopping.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Roof flashing.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sealants.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 7 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 8</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="95%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DOORS AND WINDOWS</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exterior glass - per approved drawings.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)&nbsp;&nbsp;&nbsp;&nbsp;First floor - per approved drawings</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:4.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)&nbsp;&nbsp;&nbsp;&nbsp;Second floor - per approved drawings</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exterior doors - one (l) pair storefront type at lobby and one (1) pair at secondary
entrance/exit and one (1) single at roll-up door as mentioned in 8.c.. following. Location to be coordinated with tenant improvement.</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Two (2) roll-up doors inclusive of person door adjacent, common platform between roll-up
doors, two (2) at grade level, [one (1) dock scissors lift].</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finish hardware/exterior - ready for electrification.</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 8 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 9</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">FINISHES</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exterior 1<FONT SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&nbsp;1</SUP></FONT><FONT SIZE="2">/</FONT><FONT SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.1ex">2</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">&#148; Dryvit finish (EIFS).</FONT></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Panzer Mesh at first 10&#146;-0&#148; of height and, to reinforce all openings.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equipment Pad Area wall, below 10&#146;-0&#148;, of weatherproof durable finish, for connection of pipe support racks.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 9 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 10</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">EQUIPMENT</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Loading dock scissors lift, 6&#146;x8&#146; minimum.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 10 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 11</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONVEYING SYSTEMS</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heavy load elevator - 4000 lb., performance to meet CBC and ADA. Minimum cab interior dimensions 5&#146;-8&#148;x8&#146;5&#148;. Part of $5.00 T.L allowance.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 11 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 12</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="6"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">MECHANICAL</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fire protection</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NFPA ordinary hazard occupancy (Group 1) for entire building.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimum 8&#148; diameter riser.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Install two layers of sprinklers, one per floor with &#147;t&#148; and plugs for tenant improvements.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Toilet room exhaust (core allowance).</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sanitary plumbing main (gut line) 8&#148;. See Site page 2 - cost to be equally divided, 50% shell, 50% T.L Allowance.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Water supply.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">E.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gas to building. 6&#148; (low pressure). See Site page 2.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">F.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Minimum flow alarm - A.F.S.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">G.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Internal roof drains, connected to underground storm drainage, and overflows as required.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 12 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1 to Workletter </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITION OF BUILDING SHELL AND &#147;ABOVE STANDARD&#148; ITEMS </U></B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHL Architects - Planners</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Britannia Biotechnology Center</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/09/95</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Site Work/Shell Building</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/17/95 Rev. 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tularik Corporation</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">03/24/95 Rev. 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Page 13</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">04/10/95 Rev. 3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR></TABLE> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:18pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">CSI<BR>Index</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">ELECTRICAL</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">A.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Power - 4,000 amp in shell electrical service at 480 volts with primary transformer, bus duct, pull section, switch/ Cost of electrical service over 2000 amp to be part of T.I.
Allowance.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exterior Lighting.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">C.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fire alarm (minimum flow alarm.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">D.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Separate house panel (100 amp), meter for down lights in soffit, landscaping and site lighting.</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">E.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2-4&#148; diameter P.V.C. conduits suitable for telephone/data connection (wiring or fiber optics) between buildings &#147;A&#148; and &#147;B&#148;.</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 13 OF 13
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431exmpg074.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 1 OF 2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431exmpg075.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAGE 2 OF 2
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P>&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431exmpg076.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XHIBIT</SMALL> B </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OUTLINE OF SUBLEASE PREMISES </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>EXHIBIT B </U></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>SITE PLAN </U></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431exm_pg078.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>TENANT IMPROVEMENT AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Tenant Improvement Agreement (this
&#147;<B><I>TI Exhibit</I></B>&#148;) is attached to and incorporated within that certain Sublease (the &#147;<B><I>Sublease</I></B>&#148;) by and between <B>A<SMALL>MGEN</SMALL> SF, LLC</B>, a Delaware limited liability company
(&#147;<B><I>Sublandlord</I></B>&#148;), and <B>R<SMALL>AVEN</SMALL> <SMALL>BIOTECHNOLOGIES</SMALL>, <SMALL>INC</SMALL>.,</B> a Delaware corporation (&#147;<B><I>Subtenant</I></B>&#148;). This TI Exhibit shall constitute a portion of the Sublease,
and failure to comply with the terms hereof shall constitute a default under the Sublease by the party failing to perform. All capitalized terms used in this TI Exhibit and not otherwise defined shall have the meanings ascribed thereto in the
Sublease. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1. Defined Terms. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.01. Tenant Improvements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;<B><I>Tenant
Improvements</I></B>&#148; shall mean all improvements to be constructed or installed in or on the Premises in accordance with the Drawings and Specifications, as hereinafter defined. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.02. Base Building Condition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The term &#147;<B><I>Base Building Condition</I></B>&#148; shall mean the condition of the Sublease Premises on the date of the Sublease, which condition Subtenant hereby accepts &#147;AS IS,&#148; except
as otherwise expressly provided by the terms of the Sublease. All alterations, additions and improvements existing on the date of this Sublease shall be left in place by Sublandlord and shall be available for reuse at no cost to Subtenant or may be
disposed of, demolished or modified by Subtenant, at Subtenant&#146;s expense, in accordance with the Drawings and Specifications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.03. Tenant Improvement Costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;<B><I>Tenant
Improvement Costs</I></B>&#148; shall mean the total cost of (i)&nbsp;the preparation of the Drawings and Specifications, (ii)&nbsp;the construction and installation of the Tenant Improvements, (iii)&nbsp;the costs of furnishings and equipment to be
used by Subtenant within the Premises, including telecommunication equipment, (iv)&nbsp;costs of signage installed in accordance with the Master Lease, the Sublease, and applicable law, and (v)&nbsp;the costs of Subtenant&#146;s relocation to the
Premises, exclusive of any costs incurred by Subtenant with respect to any other lease of space. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;1.04. Drawings
and Specifications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;<B><I>Drawings and Specifications</I></B>&#148; shall mean the final drawings,
specifications and finish schedules for the Tenant Improvements, which shall be prepared by Subtenant and approved by Master Landlord and Sublandlord in accordance with the terms of this TI Exhibit. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2. Construction of Tenant Improvements. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.01. Submittal of Drawings and Specifications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As soon as reasonably possible after execution of the Sublease, but in no event later than ten (10)&nbsp;days thereafter, Subtenant shall commence preparation of the final working drawings and
specifications necessary to commence construction of the Tenant Improvements and inform Sublandlord of the identity of the architect or other design specialist whom Subtenant desires to use for such work. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.02. Review of Drawings and Specifications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As soon as reasonably possible, Subtenant shall deliver to Sublandlord Subtenant&#146;s proposed final working drawings and specifications for the Tenant Improvements. Sublandlord shall promptly submit
such materials to Master Landlord and shall review such materials with Master Landlord. Sublandlord shall use commercially reasonable efforts to facilitate Master Landlord&#146;s review and approval of such materials and Master Landlord&#146;s
agreement to allow all Tenant Improvements to remain within the Premises following expiration of the Term. Once Master Landlord and Sublandlord have approved the foregoing materials, such materials shall be deemed to be the Drawings and
Specifications hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.03. Approval of General Contractor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subtenant shall notify Sublandlord of Subtenant&#146;s selection of a general contractor for the construction and completion of the
Tenant Improvements (&#147;<B><I>Subtenant&#146;s Contractor</I></B>&#148;). Sublandlord and, to the extent required under the Master Lease, Master Landlord, shall have the right to approve the Subtenant&#146;s Contractor for the construction and
completion of the Tenant Improvements, such approval not to be unreasonably withheld on the part of Sublandlord. Subtenant&#146;s Contractor shall have and maintain such insurance as is customarily required in connection with the construction and
completion of improvements similar to the Tenant Improvements, with such insurance to designate Sublandlord as an additional insured thereunder as appropriate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.04. Completion of Tenant Improvements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event Subtenant
elects to undertake the Tenant Improvements, as evidenced by Subtenant&#146;s commencement of work thereon, Subtenant shall complete all such Tenant Improvements in a good and workmanlike manner, using new and first-class materials, and in
compliance with all applicable laws and ordinances. Subtenant shall not allow any materialmens&#146; or mechanics&#146; lien to attach to the Premises and shall promptly pay all invoices received in connection with the construction and completion of
the Tenant Improvements. Except as otherwise stated above, Subtenant shall have no obligation to commence the Tenant Improvements; provided that failure of Subtenant to commence and complete the Tenant Improvements shall not excuse Subtenant&#146;s
obligations under the Sublease, including the obligation to pay Rent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;2.05. Modifications of Drawings and
Specifications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If at any time after the Drawings and Specifications are approved, Subtenant desires to make material changes
in the Drawings and Specifications, Subtenant shall submit to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Sublandlord for approval working drawings and specifications for any and all such desired changes. The process of finalizing and approving such drawings and specifications shall be in the same
manner as set forth in Section&nbsp;2.02 above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3. Payment of Tenant Improvement Costs. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.01. Subtenant shall be solely responsible for the payment of all Tenant Improvement Costs; provided, however, the foregoing
shall not operate to negate Sublandlord&#146;s agreement to fund the Subtenant Allowance in accordance with the terms of this TI Exhibit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.02. Failure to Pay Tenant&#146;s Costs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Failure by Subtenant to
pay the Tenant Improvement Costs when due and payable shall constitute a failure by Subtenant to pay Rent when due under the Sublease and shall constitute a default by Subtenant under the Sublease, and Sublandlord shall have all of the remedies
available to it under the Sublease and at law or in equity for a default, subject to the notice and cure provisions of the Sublease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.03. Subtenant Allowance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublandlord shall provide Subtenant up
to $4,000,000.00 (the &#147;<B><I>Subtenant Allowance</I></B>&#148;) which may be used for Tenant Improvement Costs. All portions of the Subtenant Allowance advanced in excess of $1,700,000.00 shall be repaid to Sublandlord in equal monthly
installments over the Term, commencing on the Rent Commencement Date, and continuing on the first day of each calendar month thereafter. Such amounts shall be added to and constitute an addition to Additional Rent otherwise payable under the
Sublease. The obligation to repay all portions of the Subtenant Allowance in excess of $1,700,000.00 shall survive the termination of the Sublease. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;3.05. Subtenant Disbursement Obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublandlord agrees to
disburse the Subtenant Allowance to Subtenant to pay the Tenant Improvement Costs not more than once per month, upon the receipt by Sublandlord from Subtenant of (i)&nbsp;copies of invoices for the Tenant Improvement Costs and (ii)&nbsp;contractor
lien waivers with respect to any portion of the Tenant Improvements then constructed or completed. Sublandlord shall be entitled to rely on the accuracy of any and all invoices, fee statements and lien waivers for labor and materials performed on or
furnished to the Premises in connection with the Tenant Improvements and to rely, to the extent submitted, on any and all certifications as to Tenant Improvement Costs submitted by Subtenant&#146;s Contractor and/or Subtenant&#146;s architect. In
addition, Sublandlord shall have the option and right to inspect all Tenant Improvements prior to any disbursement of the Subtenant Allowance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XHIBIT</SMALL> D </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM OF LETTER OF CREDIT </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ISSUING BANK</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ADDRESS OF ISSUING BANK</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">DATE: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BENEFICIARY:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">APPLICANT:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMOUNT: USD $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXPIRATION:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AT OUR COUNTERS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WE HEREBY ESTABLISH IN YOUR FAVOR OUR IRREVOCABLE STANDBY LETTER OF CREDIT NUMBER
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WHICH IS AVAILABLE WITH [ISSUING BANK] BY PAYMENT AGAINST PRESENTATION OF THE ORIGINAL OF THIS LETTER OF CREDIT AND YOUR DRAFTS AT SIGHT DRAWN ON [ISSUING BANK] AT THE ADDRESS
ABOVE, ACCOMPANIED BY THE DOCUMENTS DETAILED BELOW: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">A LETTER SIGNED BY A PURPORTED AUTHORIZED REPRESENTATIVE OF THE BENEFICIARY STATING THAT
BENEFICIARY IS ENTITLED TO DRAW ON THIS LETTER OF CREDIT PURSUANT TO THAT SUBLEASE DATED &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BETWEEN
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AND
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, AS IT
MAY BE AMENDED. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LETTER OF CREDIT CANNOT BE MODIFIED OR REVOKED WITHOUT YOUR WRITTEN CONSENT OF BENEFICIARY. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">SPECIAL CONDITIONS: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LETTER OF CREDIT
SHALL AUTOMATICALLY RENEW WITHOUT AMENDMENT FOR AN ADDITIONAL ONE YEAR PERIOD FROM THE CURRENT OR FOR ANY FUTURE EXPIRATION DATE, UNLESS WE SHALL NOTIFY YOU IN WRITING BY CERTIFIED MAIL, RETURN RECEIPT REQUESTED OR OVERNIGHT COURIER AT LEAST 30 DAYS
PRIOR TO THE THEN CURRENT EXPIRATION DATE THAT THIS LETTER OF CREDIT WILL NOT BE RENEWED. FOLLOWING SUCH NOTIFICATION AND PRIOR TO THE EXPIRATION OF THIS LETTER OF CREDIT, YOU MAY DRAW UPON THIS LETTER OF CREDIT BY PRESENTATION OF THE SIGHT DRAFT(S)
MENTIONED ABOVE, ACCOMPANIED BY A LETTER SIGNED BY A PURPORTED AUTHORIZED REPRESENTATIVE OF BENEFICIARY STATING THAT BENEFICIARY HAS NOT BEEN PRESENTED WITH A SUBSTITUTE LETTER OF CREDIT IN THE SAME PRINCIPAL AMOUNT, AND ON THE SAME TERMS AS THIS
LETTER OF CREDIT FROM AN ISSUER REASONABLY SATISFACTORY TO YOU. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LETTER OF CREDIT IS TRANSFERABLE AND MAY BE TRANSFERRED ONE OR MORE
TIMES BY THE NAMED BENEFICIARY HEREUNDER OR BY ANY TRANSFEREE HEREUNDER TO A SUCCESSOR TRANSFEREE. TRANSFER OF THIS LETTER OF CREDIT IS SUBJECT TO OUR RECEIPT OF BENEFICIARY&#146;S INSTRUCTIONS IN THE FORM ATTACHED AS EXHIBIT A, ACCOMPANIED BY THE
ORIGINAL LETTER OF CREDIT AND AMENDMENT(S), IF ANY. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">PARTIAL DRAWS ARE ALLOWED UNDER THIS LETTER OF CREDIT. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS LETTER OF CREDIT IS SUBJECT TO THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS (1993
REVISION), INTERNATIONAL CHAMBER OF COMMERCE PUBLICATION NO. 590 AND ENGAGES US PURSUANT TO THE TERMS THEREIN. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">[ISSUING BANK]</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUTHORIZED SIGNATURE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUTHORIZED SIGNATURE</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>15
<FILENAME>filename15.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.15</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.15 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>EXECUTION COPY </I></B></FONT></P>
<P STYLE="margin-top:240px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BI Contract No.&nbsp;43032525 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>COLLABORATION AND LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BY AND BETWEEN </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BOEHRINGER INGELHEIM INTERNATIONAL GMBH </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AND </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OCTOBER&nbsp;18, 2010 </B></FONT></P> <P STYLE="font-size:240px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange
Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE I DEFINITIONS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE II GOVERNANCE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Project Leaders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Joint Steering Committee.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subcommittees</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meetings</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Decision-making.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Limitations on JSC Authority</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE III RESEARCH PROGRAM</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selection of Collaboration Targets.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Conduct of the Programs.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research Target Profile; Lead Candidate Identification.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Start of Pre-Clinical Development Candidate Criteria; SOPD Candidate Identification.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Materials and Know-How Transfer.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third Party Intellectual Property</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing of Research Material</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Records and Reports.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IV DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS; DILIGENCE</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Responsibility for Development, Manufacturing and Commercialization.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development and Commercialization Activities.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-Development.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Co-Promotion.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE V GRANTS OF RIGHTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Licenses to BI.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recordation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Exclusive Research License to MacroGenics</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sublicenses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Covenant not to Sue</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rights Retained by the Parties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;365(n) of the Bankruptcy Code</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exclusivity</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VI PAYMENTS; ROYALTIES AND REPORTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>32</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial License Payment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity Investment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Programs Funding.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Development Milestone Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales Milestone Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Royalties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Reports; Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Books and Records; Audit Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Taxes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United States Dollars</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment Method and Currency Conversion</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Blocked Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Late Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VII PATENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;BI Prosecution and Maintenance of Patent Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MacroGenics Prosecution and Maintenance of Patent Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prosecution and Maintenance of Joint Patent Rights and Collaboration DART Patent Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third Party Infringement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Invalidity Claim.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Term Extensions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent Marking</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VIII CONFIDENTIALITY AND PUBLICATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>44</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nondisclosure Obligation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Authorized Disclosure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Scientific Publications</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press Releases and Other Permitted Disclosures.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IX REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>47</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties of the Parties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Representations and Warranties of MacroGenics</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Other Warranties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by BI</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indemnification by MacroGenics</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">48</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Procedure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insurance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Consequential or Punitive Damages.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>

<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE X TERM AND TERMINATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>50</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Term and Expiration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Termination.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Termination on Licenses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change of Control</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effect of Expiration or Termination; Survival.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE XI DISPUTE RESOLUTION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>54</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Seeking Consensus</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Arbitration.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Jury Waiver</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE XII MISCELLANEOUS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>55</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Waiver</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notices</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entire Agreement; Amendment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Headings</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Severability</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assignment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Counterparts</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Force Majeure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third-Party Beneficiaries</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Relationship of the Parties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance by Affiliates</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Construction</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Create Act</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange
Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SCHEDULES </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="84%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">BI Exclusive Targets</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.28</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART Platform</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.47</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial Collaboration Targets</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.50</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Draft Invoice</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.58</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Patent Rights</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.77</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">RTP Criteria Template</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.81</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">SOPD Candidate Criteria Template</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;4.5(b)(I)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Promotion Terms and Conditions</FONT></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;4.5(b)(II)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dispute Resolution Procedures</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 8.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COLLABORATION AND LICENSE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Collaboration and License Agreement (this &#147;<U>Agreement</U>&#148;), is entered into as of October&nbsp;18, 2010 (the
&#147;<U>Effective Date</U>&#148;), by and between Boehringer Ingelheim International GmbH, a corporation organized and existing under the laws of Germany and having a principal office located at Binger Strasse 173, 55216 Ingelheim am Rhein, Germany
(&#147;<U>BI</U>&#148;), and MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 1500 East Gude Drive Rockville, MD 20850, USA (&#147;<U>MacroGenics</U>&#148;).
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INTRODUCTION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics has developed the DART Platform (as defined below), which is&nbsp;focused on dual specificity &#147;antibody-like&#148; therapeutic proteins capable of targeting multiple different
epitopes with a single recombinant molecule, and certain intellectual property useful in connection with the application of the DART Platform; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, BI is a company that is a member of the Boehringer Ingelheim group of companies which group possesses expertise and resources relating to the research, development, manufacturing and marketing of
pharmaceutical and biopharmaceutical products; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS BI has developed certain know-how and expertise relating to the same
and holds certain intellectual property covering the same; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, BI has developed certain know-how and expertise in the
research and development of therapeutic agents for the prevention and treatment of a variety of human and animal diseases, and holds certain intellectual property covering the same; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics and BI wish to enter into an agreement to collaborate on and to use their respective know-how and expertise for the
generation, formatting, testing and development of DART Platform products against a series of Collaboration Targets (as defined below), which BI will have exclusive rights to develop, manufacture and commercialize; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics and BI may enter a future co-promotion agreement in the event that MacroGenics exercises its non-transferable option
to co-promote in the United States *** whose initial indication is Detailed by *** and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics and BI or any of
its Affiliates wish to enter a stock purchase investment, whereby BI or any of its Affiliates would purchase Preferred Stock in MacroGenics, upon the terms and conditions set forth in a definitive stock purchase agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the mutual covenants contained herein, and other good and valuable consideration, the receipt of
which is hereby acknowledged, MacroGenics and BI agree as follows: </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE I </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEFINITIONS</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless specifically set forth to the contrary herein,
the following terms, whether used in the singular or plural, shall have the respective meanings set forth below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1
&#147;<U>Accounting Standards</U>&#148;. Accounting Standards means, with respect to MacroGenics and its Affiliates, generally accepted accounting principles as practiced in the United States or, to the extent applicable, IFRS (International
Financial Reporting Standards) or with respect to BI and its Affiliates German HGB (Handelsgesetzbuch), in each case as they exist from time to time, consistently applied. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.2 &#147;<U>Affiliate</U>&#148;. Affiliate means with respect to a Party, any entity that directly or indirectly controls, is controlled by, or is under common control with such Party. As used in this
definition, the term &#147;control&#148; means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through ownership of voting securities, by contract or
otherwise. For purposes of this definition, &#147;control&#148; shall be presumed to exist if one of the following conditions are met: (a)&nbsp;in the case of corporate entities, direct or indirect ownership of more than fifty percent (50%)&nbsp;of
the stock or shares having the right to vote for the election of directors, and (b)&nbsp;in the case of non-corporate entities, direct or indirect ownership of more than fifty percent (50%)&nbsp;of the equity interest with the power to direct the
management and policies of such non-corporate entities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<U>Annual Net Sales</U>&#148;. Annual Net Sales means
worldwide Net Sales of Products by BI or its Affiliates or Sublicensees in any Calendar Year on a Product-by-Product basis, or in the first year and last year of the Royalty Term, the portion of such Calendar Year during which the Royalty Term is in
effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<U>Antibody(ies)</U>&#148;. Antibody(ies) means a molecule which comprises or contains: (a)&nbsp;one or
more immunoglobulin variable domains; (b)&nbsp;fragments, variants, modifications or derivatives of such immunoglobulin variable domains irrespective of origin or source; or (c)&nbsp;the nucleic acid consisting of a sequence of nucleotides encoding
(or complementary to a nucleic acid encoding) the foregoing molecules in (a)&nbsp;or (b). The term &#147;Antibody&#148; shall include any monospecific antibodies and less than full-length antibody forms such as Fv, Fab, and F(ab&#146;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<U>BI Exclusive Targets</U>&#148; BI Exclusive Targets means the *** set forth on <U>Schedule 1.5</U> which are available
Targets for Programs under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6 &#147;<U>BI Biopharmaceutical Technology</U>&#148; BI Biopharmaceutical
Technology means with respect to any Lead Candidate, SOPD Candidate or Product, any Patent or Know-How conceived or generated solely by employees, agents or service providers of BI or its Affiliates or Sublicensees and that result from
biopharmaceutical activities performed under this Agreement, including <B>***</B>for <B>***</B>and <B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<U>BI Intellectual Property</U>&#148;. BI Intellectual Property means the BI
Know-How and the BI Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<U>BI Know-How</U>&#148;. BI Know-How means Know-How that (a)&nbsp;is Controlled
by BI or its Affiliates as of the Effective Date or during the Term, and (b)&nbsp;is necessary or useful to conduct any Program or to research, Develop, make and have made, use, offer for sale, sell or import a Collaboration DART or a Product. BI
Know-How does not include Collaboration DART Know-How or Joint Know-How. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<U>BI Patent Rights</U>&#148;. BI Patent
Rights means any Patent Rights Controlled by BI or its Affiliates as of the Effective Date or during the Term that describe or claim BI Know-How. BI Patent Rights do not include Collaboration DART Patent Rights or Joint Patent Rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10 &#147;<U>Business Day</U>&#148;. Business Day means a day that is not a Saturday, Sunday or a day on which banking institutions in
Washington, DC, USA or Ingelheim am Rhein, Germany are authorized by Law to remain closed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11 &#147;<U>Calendar
Quarter</U>&#148;. Calendar Quarter means the respective periods of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December&nbsp;31. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12 &#147;<U>Calendar Year</U>&#148;. Calendar Year means each successive period of twelve (12)&nbsp;months commencing on January&nbsp;1
and ending on December&nbsp;31. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13 &#147;<U>Change of Control</U>&#148;. Change of Control means any of the following
events (a)&nbsp;the acquisition by any person or group or entity (other than any venture capital or other institutional investor) of &#147;beneficial ownership&#148; (as hereinafter defined) directly or indirectly, of more than fifty percent
(50%)&nbsp;of the shares of MacroGenics&#146; capital stock or other voting securities, the holders of which have general voting power under ordinary circumstances to elect at least a majority of MacroGenics&#146; board of directors or equivalent
body (the &#147;Voting Stock&#148;); (b)&nbsp;the approval by the shareholders of MacroGenics of a merger, share exchange, reorganization, consolidation or other similar transaction of MacroGenics and the consummation of such transaction (a
&#147;Transaction&#148;), other than a Transaction which would result in the beneficial owners of Voting Stock of MacroGenics immediately prior thereto continuing to beneficially own (either by such voting Stock remaining outstanding or being
converted into voting securities of the surviving or resulting entity) more than fifty percent (50%)&nbsp;of the Voting Stock of MacroGenics or such surviving or resulting entity immediately after such Transaction; or (c)&nbsp;the approval by the
shareholders of MacroGenics of a complete liquidation or dissolution of MacroGenics or a sale or disposition of all or substantially all of the assets of MacroGenics and the consummation of such Transaction. For the purpose of this definition,
&#147;beneficial ownership&#148; shall mean ownership of a security by any person or group or entity who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (i)&nbsp;voting power which
includes the power to vote, or to direct the voting of, such security; and/or (ii)&nbsp;investment power which includes the power to dispose or to direct the disposition of such security. Change of Control shall not include any public offering of
the shares of MacroGenics. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14 &#147;<U>Clinical Development Costs</U>&#148;. Clinical Development Costs means the
costs and expenses incurred by or on behalf of a Party that are specific to the conduct of *** for a Product. Clinical Development Costs shall include <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.15 &#147;<U>Clinical Trial(s)</U>&#148;. Clinical Trial(s) means a Phase I Clinical Trial, a Phase&nbsp;II Clinical Trial, a Phase&nbsp;III Clinical Trial, and/or a Phase IV Clinical Trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<U>Collaboration DART</U>&#148;. Collaboration DART means any (a)&nbsp;molecule created from (i)&nbsp;any MacroGenics
Collaboration Antibody or (ii)&nbsp;any Antibody provided by BI under this Agreement, in each case using the DART Platform or (b)&nbsp;derivative thereof, in each case that is Directed to a Collaboration Target. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17 &#147;<U>Collaboration DART Know-How</U>&#148;. Collaboration DART Know-How means any Know-How created by or on behalf of
MacroGenics or BI or their respective Affiliates during the Research Term in the conduct of any Program that is specifically related to a Collaboration DART and any Joint Know-How that is specifically related to a Collaboration DART. However ***
&#147;Collaboration DART Know-How&#148; does not include (a)&nbsp;Know-How specifically related to improvements to the DART Platform *** (b)&nbsp;Know-How that is *** (c)&nbsp;Know-How specifically related to the *** (d)&nbsp;any Antibody and any
related Know-How created outside the conduct of any Program and provided to MacroGenics or its Affiliates by BI or its Affiliates under this Agreement; and (e)&nbsp;any Antibody and any related Know-How created outside the conduct of any Program and
provided to BI or its Affiliates by MacroGenics or its Affiliates under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18 <U>&#147;Collaboration DART
Intellectual Property</U>&#148;. Collaboration DART Intellectual Property means the Collaboration DART Know-How and Collaboration DART Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<U>Collaboration DART Patent Rights</U>&#148;. Collaboration DART Patent Rights means any Patent Rights filed after the Effective Date by MacroGenics, BI or their respective Affiliates or the
Joint Counsel that specifically describe or claim Collaboration DART Know-How, including Patent Rights that specifically describe or claim a Collaboration DART. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<U>Collaboration Target</U>&#148;. Collaboration Target means Dual Target Combinations <B>***</B>with <B>***</B> selected by BI and agreed to by the Parties for inclusion in the Programs in
accordance with Section&nbsp;3.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<U>Collaboration Target List</U>&#148;. Collaboration Target List means the list
of all Collaboration Targets, as such list may be updated from time to time in accordance with Section&nbsp;3.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22
&#147;<U>Combination Product</U>&#148;. Combination Product means a pharmaceutical formulation containing as its active ingredients both a Product and one or more other therapeutically active ingredients. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.23 &#147;<U>Commercially Reasonable Efforts</U>&#148;. Commercially Reasonable Efforts means the efforts required in order to carry out
a task in a diligent and sustained manner without undue interruption or delay, which level is at least commensurate with the level of effort that a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Party would devote to a product of similar market potential and having similar commercial and scientific advantages and disadvantages resulting from its own research efforts or to which it has
rights, taking into account its safety and efficacy, regulatory status, the competitiveness of the marketplace, its proprietary position, pricing, reimbursement, launching strategy and other market-specific factors, and all other relevant factors.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24 &#147;<U>Commercialization</U>&#148; or &#147;<U>Commercialize</U>&#148;. Commercialization or Commercialize means any
activities directed to obtaining pricing and/or reimbursement approvals, marketing, promoting, distributing, importing, offering to sell, and/or selling a product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.25 &#147;<U>Confidential Information</U>&#148;. Confidential Information means any and all information and data, including all BI Know-How, MacroGenics Know-How, Collaboration DART Know-How and Joint
Know-How, and all other scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information or data, whether communicated in writing or orally or by any other method, which is provided by one Party to the
other Party in connection with this Agreement or the Prior Confidentiality Agreement. Notwithstanding the foregoing, Confidential Information excludes information that, in each case as demonstrated by competent written documentation: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) is publicly disclosed and made generally available to the public by the disclosing Party, either before or after it becomes known to
the receiving Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) was known to the receiving Party, without obligation to keep it confidential, prior to the date of
disclosure by the disclosing Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) is subsequently disclosed to the receiving Party by a Third Party lawfully in
possession thereof without obligation to keep it confidential and without a breach of such Third Party&#146;s obligations of confidentiality; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) has been publicly disclosed or made generally available to the public other than through any act or omission of the receiving Party in breach of this Agreement; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) has been independently developed by the receiving Party without the aid, application or use of the disclosing Party&#146;s
Confidential Information (the competent written proof of which must be contemporaneous with such independent development). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26 &#147;<U>Control</U>&#148;. Control means, with respect to any item of or right under Patent Rights or Know-How, subject to
Section&nbsp;3.7, the possession of (whether by ownership or license, other than pursuant to this Agreement) the ability of a Party to grant access to, or a license or sublicense of, such items or right as provided for herein without violating the
terms of any agreement or other arrangement with any Third Party existing prior to the time such Party would be required hereunder to grant the other Party such access or license or sublicense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27 &#147;<U>Cover</U>&#148;, &#147;<U>Covering</U>&#148; or &#147;<U>Covered</U>&#148;. Cover, Covering or Covered means, with respect
to a product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such product or the practice of such technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it
were to issue). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28 &#147;<U>DART Platform</U>&#148;. DART Platform means the Dual Affinity Re-Targeting platform described
in Schedule 1.28. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.29 &#147;<U>Detail</U>&#148;. Detail means a sales presentation by a professional sales representative to
a target physician involved in prescribing the Product in which the primary purpose is to discuss the benefits and features of the Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.30 &#147;<U>Default</U>&#148; means with respect to a Party that (i)&nbsp;any representation or warranty of such Party set forth herein shall have been untrue in any material respect when made or
(ii)&nbsp;such Party shall have failed to perform any material obligation set forth in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31
&#147;<U>Development</U>&#148; or &#147;<U>Develop</U>&#148; means, with respect to a compound, preclinical and clinical drug development activities, including, among other things: test method development and stability testing, toxicology,
formulation, process development, manufacturing scale-up, development-stage manufacturing, quality assurance/quality control procedure development and performance with respect to clinical materials, statistical analysis and report writing and
clinical studies, regulatory affairs, and all other pre-Regulatory Approval activities. When used as a verb, &#147;Develop&#148; means to engage in Development. Development shall include any Phase IV Clinical Trials or other post-approval studies
required by a Regulatory Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32 &#147;<U>Directed</U>&#148;. Directed means binding specifically to a Target, as
measured by a cellular or biochemical assay. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.33 &#147;<U>Dual Target Combination</U>&#148;. Dual Target Combination means
(i)&nbsp;a combination of two (2)&nbsp;different Targets or (ii)&nbsp;a combination of two (2)&nbsp;different epitopes on the same Target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.34 &#147;<U>EMA</U>&#148;. EMA means The European Medicines Agency, or any successor agency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.35 &#147;<U>European Union</U>&#148;. European Union means the countries that are members of the European Union, as redefined from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36 &#147;<U>FDA</U>&#148; or &#147;<U>Food and Drug Administration</U>&#148;. FDA or Food and Drug Administration means the United
States Food and Drug Administration, or any successor agency. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.37 &#147;<U>Field</U>&#148;. Field means any and all uses,
including the use of a Product for the diagnosis, treatment, palliation and/or prevention of a disease or medical condition in humans and/or animals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.38 &#147;<U>Filing</U>&#148;. Filing means the acceptance by the applicable Regulatory Authority of a NDA for filing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39 &#147;<U>First Commercial Sale</U>&#148;. First Commercial Sale means, with respect to
any Product, the first sale for end use or consumption of such Product in a country after all required approvals, including Regulatory Approval, have been granted by the Regulatory Authority of such country. For avoidance of doubt, sales for test
marketing, sampling and promotional uses, clinical trials purposes or compassionate use shall not constitute a First Commercial Sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.40 &#147;<U>FTE</U>&#148;. FTE means *** hours of work devoted to or in support directly of (a)&nbsp;a Program in accordance with a Research Plan that is carried out by one or more qualified scientific
or technical employees or full-time contract personnel of MacroGenics or its Affiliates, measured in accordance with MacroGenics&#146; normal time allocation practices from time to time. Overtime, and work on weekends, holidays and the like shall
not be counted with any multiplier (e.g. time-and-a-half or double time) toward the number of hours that are used to calculate the FTE contribution. The portion of an FTE billable by a Party for one (1)&nbsp;individual during a Calendar Quarter
shall be determined by dividing the number of hours worked directly by said individual on the Program, during such accounting period by *** hours per Calendar Quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.41 &#147;<U>FTE Rate</U>&#148;. FTE Rate means *** per FTE, increased or decreased annually by the percentage increase or decrease in the Consumer Price Index&#150;Urban Wage Earners and Clerical
Workers, U.S. City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States (&#147;<U>CPI</U>&#148;) as of December&nbsp;31 of the then
most recently ended calendar year over the level of the CPI on December&nbsp;31, 2010 (<I>i.e.</I>, the first such increase or decrease would occur on January&nbsp;1, 2012). The FTE Rate for each FTE includes compensation for all laboratory supplies
and equipment, equipment maintenance costs, utilities, waste removal and a pro rata allocation of general and administrative expenses plus facilities expenses, including allocated building operating costs, allocated depreciation, and repairs and
maintenance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42 &#147;<U>Generic Competition</U>&#148;. Generic Competition means, with respect to a given Calendar Quarter
with respect to a Product in any country, that during such Calendar Quarter, one (1)&nbsp;or more Third Parties sell in such country a Generic Product, such Generic Product shall be commercially available in such country and such Generic Product
shall have, in the aggregate, a <B>***</B> or more market share of the aggregate of Products and Generic Products (based on data provided by IMS Health Incorporated, Fairfield, Connecticut (together with its affiliates, &#147;<U>IMS</U>&#148;) as
measured ***, or if such data is not available, the Parties shall agree upon a methodology for estimating the percentage of *** of Generic Products in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.43 &#147;<U>Generic Products</U>&#148;. Generic Products means, with respect to a particular Product commercialized by BI in a particular country, any product (other than Products commercialized by BI,
its Affiliates or Sublicensees pursuant to this Agreement) that either (a)&nbsp;is a &#147;follow-on biologic&#148; (FOB) or biosimilar or equivalent version to a Product, as defined by the competent Regulatory Authority, and administered in an
equivalent dosage form as such Product or (b)&nbsp;for which a Third Party has received Regulatory Approval (based upon then-current applicable Laws governing approval of biological products) whose application for approval relies to a large extent
(but not exclusively) on data generated by BI, including Regulatory Approval under section 505(b)(2) of the Federal Food Drug, and Cosmetic Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.44 &#147;<U>GLP Toxicology Study</U>&#148;. GLP Toxicology Study means a toxicology study
that is conducted in compliance with the then-current good laboratory practice standards promulgated or endorsed by the FDA, as defined in U.S. 21 C.F.R. Part 58 (or such other comparable regulatory standards in jurisdictions outside the U.S. to the
extent applicable to the relevant toxicology study, as they may be updated from time to time) and is required to meet the requirements for filing an IND. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.45 &#147;<U>Governmental Authority</U>&#148;. Governmental Authority means any United States federal, state or local or any foreign government, or political subdivision thereof, or any multinational
organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division
thereof), or any governmental arbitrator or arbitral body. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.46 &#147;<U>IND</U>&#148;. IND means an Investigational New Drug
application or similar application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47 &#147;<U>Initial Collaboration Targets</U>&#148;. Initial Collaboration Targets means the Collaboration Targets set forth on
Schedule 1.47. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48 &#147;<U>Initial Research Term</U>&#148;. Initial Research Term means the period commencing on the
Effective Date and ending on the <B>***</B>of the Effective Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.49 &#147;<U>Invention</U>&#148;. Invention means any new
and useful process, article of manufacture, compound, composition of matter, formulation or apparatus, or any improvement thereof, patentable or unpatentable, discovery or finding. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50 &#147;<U>Invoice</U>&#148;. Invoice means an original invoice sent by MacroGenics to BI with respect to payment due hereunder
substantially in the form attached hereto as Schedule 1.50. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51 &#147;<U>Joint Ownership</U>&#148; or &#147;<U>Jointly
Owned</U>&#148; or &#147;<U>Jointly Own</U>&#148;. Joint Ownership or Jointly Owned or Jointly Owns means that each Party shall own a fifty percent (50%)&nbsp;undivided interest in the relevant Invention, Know-How or Patent Right. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.52 &#147;<U>Know-How</U>&#148;. Know-How means (a)&nbsp;any scientific or technical information, results and data of any type
whatsoever, in any tangible or intangible form whatsoever, that is not in the public domain or otherwise publicly known, including databases, practices, methods, techniques, specifications, formulations, formulae, protein sequences, DNA sequences,
knowledge, know-how, skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical, biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures,
and manufacturing process and development information, results and data, and (b)&nbsp;any biological, chemical, or physical materials that are not in the public domain or otherwise available to the public; all to the extent not claimed or disclosed
in a published Patent Right. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53 &#147;<U>Law</U>&#148;. Law means all laws, statutes, rules, codes, regulations,
orders, judgments or ordinances applicable to the Parties, this Agreement or the activities contemplated hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54
&#147;<U>Lead Candidate</U>&#148;. Lead Candidate means a Collaboration DART which meets the Research Target Profile and has been accepted by BI, or is otherwise deemed a Lead Candidate in accordance with Section&nbsp;3.4(d). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.55 &#147;<U>MacroGenics Collaboration Antibodies</U>&#148;. MacroGenics Collaboration Antibodies means Antibodies either
(a)&nbsp;created by MacroGenics for the purposes of any Program, or (b)&nbsp;provided by MacroGenics in its sole discretion if such Antibodies were either existing and Controlled by MacroGenics prior to the Effective Date or created or acquired by
MacroGenics after the Effective Date outside of the conduct of any Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.56 &#147;<U>MacroGenics Intellectual
Property</U>&#148;. MacroGenics Intellectual Property means the MacroGenics Know-How and the MacroGenics Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57
&#147;<U>MacroGenics Know-How</U>&#148;. MacroGenics Know-How means Know-How that is (a)&nbsp;Controlled by MacroGenics as of the Effective Date or during the Term, and (b)&nbsp;necessary or useful to conduct any Program or for BI to research,
Develop, make and have made, use, offer for sale, sell or import a Collaboration DART or a Product. MacroGenics Know-How does not include *** created by MacroGenics for the purposes of any Program, ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58 &#147;<U>MacroGenics Patent Rights</U>&#148;. MacroGenics Patent Rights means any Patent Rights Controlled by MacroGenics as of the
Effective Date or during the Term that describe or claim MacroGenics Know-How, and are necessary or useful to conduct any Program or for BI to research, Develop, make and have made, use, offer for sale, sell or import a Collaboration DART or a
Product. MacroGenics Patent Rights include the Patent Rights listed on<U> Schedule 1.58</U>. MacroGenics Patent Rights do not include Collaboration DART Patent Rights or Joint Patent Rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59 &#147;<U>Major EU Country</U>&#148;. Major EU Country means any of the following countries: <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60 &#147;<U>Major Country</U>&#148;. Major Country means any of the following: <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61 &#147;<U>MHW</U>&#148;. MHW means the Japanese Ministry of Health and Welfare, or any successor agency. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62 &#147;<U>NDA</U>&#148;. NDA means a New Drug Application or Biologics License Application, filed with the FDA and/or any other
application required for the purpose of marketing or selling or using a therapeutic or prophylactic product to be filed with a governmental agency in a non-U.S. country or group of countries, including a Product License Application or Marketing
Authorization in the European Union. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.63 &#147;<U>Net Sales</U>&#148;. Net Sales means the gross amount of sales of Products
invoiced by BI, its Affiliates and Sublicensees to unaffiliated Third Parties, less: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) sales returns and allowances
actually paid, granted or accrued, including trade, quantity and cash discounts and any other adjustments, including those granted on account of price adjustments or billing errors; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) rejected goods, damaged or defective goods, recalls, returns; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) rebates, chargeback rebates, compulsory rebates, reimbursements or similar payments granted or given to wholesalers or other
distributors, buying groups, health care insurance carriers or other institutions; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) adjustments arising from consumer
discount programs or other similar programs; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) non collectable receivables related to Product; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes); or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) charges for packing, freight, shipping and insurance (to the extent that BI, its Affiliates and Sublicensees bear such
costs).</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each of the foregoing deductions shall be determined as incurred in the ordinary course of business in type and amount consistent with
good industry practice and in accordance with the applicable Accounting Standards of the selling party on a basis consistent with the applicable selling party&#146;s audited consolidated financial statements. For sake of clarity and avoidance of
doubt, sales by BI, its Affiliates or Sublicensees of a Product to a permitted Recognized Agent or Third Party Distributor of such Product in a given country shall be considered a sale to a Third Party customer.&nbsp;All such discounts, allowances,
credits, rebates, and other deductions shall be fairly and equitably allocated to the Products and other products of BI and its Affiliates and Sublicensees such that the Product does not bear a disproportionate portion of such deductions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply of Products other than for cash shall be substituted to price on bona fide arms length sales; whereas the price shall be the average
price of sold product for cash during the period based on quantity of drug substance sold. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any Products used for promotional or advertising
purposes (in reasonable and customary amounts) or used for clinical trials or other research purposes shall not be included in Net Sales. Donations for charity reasons shall also not be Net Sales. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<U>Recognized Agent</U>&#148; or &#147;<U>Third Party Distributor</U>&#148; for the purpose of this definition shall mean any Third Party which
distributes (but does not Develop) Products directly to customers in countries where BI has no Affiliate or Sublicensee. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event a Product is sold as a Combination Product, Net Sales of the Combination
Product will be calculated as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) If Product and other active component(s) within such Combination Product are sold separately, Net
Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction A/(A+B), where A is the average gross selling price in the applicable country in the Territory of the Product sold separately
in the same formulation and dosage, and B is the sum of the average gross selling prices in the applicable country in the Territory of such other active component(s) sold separately in the same formulation and dosage, during the applicable Calendar
Year.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) If the Product within the particular Combination Product is sold independently of the other active component(s) therein, but the
average gross selling price of such other active component(s) cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described above) of the Combination Product by the fraction A/C where A is the average gross
selling price of such Product sold independently and C is the average gross selling price of the entire Combination Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3) If the other
active component(s) within the Combination Product are sold independently of the Product therein, but the average gross selling price of such Product cannot be determined, Net Sales will be calculated by multiplying the total Net Sales (as described
above) of the Combination Product by the fraction [1-B/C], where B is the average gross selling price of such other active component(s) and C is the average gross selling price of the entire Combination Product.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4) If the Product and other active component(s) within the Combination Product are not sold separately, or if they are sold separately but the average
gross selling price of neither such Product and other active component(s) within can be determined, Net Sales of the Combination Product shall be equal to Net Sales of the Combination Product multiplied by a mutually agreed percentage. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">With respect to such other active component(s), the average gross selling price for a particular product shall be calculated for each Calendar Year by
dividing the sales amount by the units of such product, as published by IMS or another mutually agreed independent source. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of
the foregoing, in the initial Calendar Year during which a Combination Product is sold, a forecasted average gross selling price shall be used for the Product and other active component(s) therein, to be determined in good faith mutually by the
Parties. Any over or under payment due to a difference between forecasted and actual average gross selling prices shall be paid or credited in the first royalty payment of the following Calendar Year. In the following Calendar Year the average gross
selling price of both the Product and the other active component(s) included in the Combination Product in the previous year shall apply. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.64 &#147;<U>Party</U>&#148; and &#147;<U>Parties</U>&#148;. Party means BI or MacroGenics individually, and Parties means BI and MacroGenics collectively. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65 &#147;<U>Patent Rights</U>&#148;. Patent Rights means patents, patent applications and/or provisional patent applications, utility
models and utility model applications, design patents or registered industrial designs and design applications or applications for registration of industrial designs, petty patents, innovation patents, patents of addition, inventor&#146;s
certificates and all substitutions, divisionals, continuations, continuation-in-part applications, continued prosecution applications, requests for continued examinations, reissues, renewals, reexaminations and extensions and supplementary
protection certificates granted in relation thereto, in any country of the world. For clarity, Patent Rights shall include any Patent Rights that claim priority to or common priority with such Patent Rights. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.66 &#147;<U>Phase&nbsp;I Clinical Trial</U>&#148;. Phase&nbsp;I Clinical Trial means a
human clinical trial in any country that meets the requirements of 21 CFR &#167;312.21(a) or a similar clinical study in a country other than the United States. Each Phase&nbsp;I Clinical Trial shall be deemed commenced upon dosing of the first
participant in such trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67 &#147;<U>Phase&nbsp;II Clinical Trial</U>&#148;. Phase&nbsp;II Clinical Trial means a human
clinical trial in any country that meets the requirements of 21 CFR &#167;312.21(b) or a similar clinical study in a country other than the United States. Each Phase&nbsp;II Clinical Trial shall be deemed commenced upon dosing of the first
participant in such trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.68 &#147;<U>Phase&nbsp;III Clinical Trial</U>&#148;. Phase&nbsp;III Clinical Trial means a human
clinical trial in any country in the Territory that meets the requirements of 21 CFR &#167;312.21(c) or a similar clinical study in a country other than the United States. Each Phase&nbsp;III Clinical Trial shall be deemed commenced upon dosing of
the first participant in such trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.69 &#147;<U>Phase IV Clinical Trial</U>&#148;. Phase IV Clinical Trial means a
post-registrational Clinical Trial conducted in any country or countries and required as a condition to, or for the maintenance of, any Regulatory Approval for a Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.70 &#147;<U>Prior Confidentiality Agreement</U>&#148;. Prior Confidentiality Agreement means the Confidentiality Agreements between MacroGenics and Boehringer Ingelheim Pharmaceuticals, Inc, dated
<B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71 &#147;<U>Product</U>&#148;. Product means any preparation in final form, either for sale by prescription,
over-the-counter or any other method, or for administration to human patients or to animals in Clinical Trials, for any and all uses, which preparation contains a Collaboration DART. All references to Products in this Agreement shall be deemed to
include Combination Products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.72 &#147;<U>Program</U>&#148;. Program means a program conducted pursuant to this Agreement
and directed to the research, Development, manufacturing and Commercialization of Collaboration DARTs and Products which bind to the same specific Collaboration Target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.73 &#147;<U>Prosecution and Maintenance</U>&#148;. Prosecution and Maintenance means, with respect to a Patent Right, the preparing, filing, prosecuting and maintenance of such Patent Right, as well as
re examinations, reissues and the like with respect to such Patent Right, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to the particular Patent Right; and &#147;<U>Prosecute and
Maintain</U>&#148; shall have the correlative meaning. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.74 &#147;<U>Regulatory Approval</U>&#148;. Regulatory Approval means
the technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of NDAs and labeling approvals) of any national, supra-national, regional, state or local regulatory agency, department, bureau,
commission, council or other governmental entity, necessary for the distribution, marketing, promotion, offer for sale, use, import, export or sale of Product(s) in a regulatory jurisdiction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.75 &#147;<U>Regulatory Authority</U>&#148;. Regulatory Authority means any applicable
government regulatory authority involved in granting approvals for the manufacturing, marketing, reimbursement and/or pricing of a Product in the Territory, including the FDA, EMA and MHW (in each case as applicable), and any successor governmental
authority having substantially the same function. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76 &#147;<U>Research Plan</U>&#148;. Research Plan means, with respect to
each Program, a research plan developed by the Parties that sets forth the activities to be undertaken during the Research Term with respect to such Program, including the assignment of each Party&#146;s responsibilities and the allocated number of
MacroGenics FTEs in the course of such Program with respect to each Collaboration DART in such Program through ***, applicable RTP criteria, criteria for selecting Antibodies for the Collaboration DART, Materials to be provided by each Party and the
number of Lead Candidates to be developed under each Program, which research plan which may be amended from time to time upon the agreement of the JSC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.77 &#147;<U>Research Target Profile</U>&#148; or &#147;<U>RTP</U>&#148;. Research Target Profile or RTP means for any Collaboration DART in a Program the written, quantifiable criteria agreed to by the
Parties upon the commencement of such Program using the format as set forth in Schedule 1.77 (which may be amended from time to time upon mutual agreement of the Parties) and included in the Research Plan for such Program. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78 &#147;<U>Research Term</U>&#148;. Research Term means the Initial Research Term and, if applicable, the Extended Research Term.<B>
</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.79 &#147;<U>Senior Executives</U>&#148;. Senior Executives means, in the case of MacroGenics, the Chief Executive
Officer of MacroGenics (or a senior executive officer designated by the Chief Executive Officer of MacroGenics) and in the case of BI, depending on the actual status of the Product, the board member responsible for research, development and medicine
or the board member responsible for marketing and sales; or in each case such individual&#146;s nominated designee, who is a member of BI&#146;s senior management with appropriate decision making authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80 &#147;<U>Start of Pre-Clinical Development Candidate</U>&#148; or &#147;<U>SOPD Candidate</U>&#148;. Start of Pre-Clinical
Development Candidate or SOPD Candidate means each Collaboration DART that has been accepted by BI in accordance with Section&nbsp;3.5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.81 &#147;<U>Start of Pre-Clinical Development Candidate Criteria</U>&#148; or &#147;<U>SOPD Candidate Criteria</U>&#148;. Start of Pre-Clinical Development Candidate Criteria or SOPD Candidate Criteria
means the *** (using the format as set forth in Schedule 1.81 (which may be amended from time to time upon mutual agreement of the Parties)) after the first Collaboration DART in such Program has been deemed a Lead Candidate and included in the
Research Plan for such Program. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.82 &#147;<U>Sublicensee</U>&#148;. Sublicensee means a Third Party to whom BI (or its
Affiliate) has granted a license or sublicense under the MacroGenics Intellectual Property, Collaboration DART Intellectual Property and/or Joint Intellectual Property to research, Develop, make and have made, offer for sale, sell or import a
Product; <U>provided</U>, <U>however</U>, that a Sublicensee shall not include any distributor, dealer or reseller. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.83
&#147;<U>Target</U>&#148;. Target means (a)&nbsp;an antigen composed of a polypeptide, a complex or more than one polypeptide or a post-translational modification of a polypeptide (e.g., glycosylation, phosphorylation, etc.) that is recognized by an
Antibody through direct binding to such antigen; or (b)&nbsp;a gene encoding an antigen and the products encoded by such gene, including any homologues, variants, alternatively spliced variants, mutants, deletions or fragments or partial sequences
of such antigen. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.84 &#147;<U>Terminated Product</U>&#148;. Terminated Product means (a)&nbsp;with respect to the
termination of a Program pursuant to Section&nbsp;10.2(b), each Collaboration DART and Product included in such Program; and (b)&nbsp;with respect to termination of this Agreement in its entirety, all Collaboration DARTs and Products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.85 &#147;<U>Terminated Target</U>&#148;. Terminated Target means (a)&nbsp;the Collaboration Target to which a Terminated Product is
Directed; or (b)&nbsp;any Collaboration Target that is removed from the Collaboration Target List pursuant to Section&nbsp;3.2(d). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.86 &#147;<U>Territory</U>&#148;. Territory means all countries in the world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.87 &#147;<U>Third Party</U>&#148;. Third Party means an entity other than BI and its Affiliates, and MacroGenics and its Affiliates.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88 &#147;<U>Valid Claim</U>&#148;. Valid Claim means (a)&nbsp;a claim of an issued patent that has not expired or been
abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time
period) or (b)&nbsp;a claim within a patent application which application has not been pending for *** from the date of its priority filing date and which claim has not been revoked, cancelled, withdrawn, held invalid or abandoned or finally
determined to be unallowable in a decision from which an appeal cannot or can no longer be taken. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.89 Each of the following
definitions is set forth in the section of this Agreement indicated below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acquiring/Acquired Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8(c)(iii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Cure Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audited Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Auditing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bankruptcy Code</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BI</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BI Indemnitees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Development Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development Budget</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development Obligations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4(b)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Development Product</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Promotion Option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CPI</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Defaulting Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Data Package</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dispute</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excluded Claim</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Extended Research Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IMS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial Research Plans</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5(d)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Counsel</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Counsel Patent Rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Intellectual Property</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Know-How</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Patent Rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JDC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3(b)(i)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JRC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JSC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lead Candidate Review Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">M&amp;A Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Indemnitees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Shared Percentage</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance Payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Materials</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Defaulting Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project Leader</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Records</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Replacement Product</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SEC Filing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SOPD Candidate Review Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Party Claim</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE II </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>GOVERNANCE </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Project Leaders</U>. Within fifteen
(15)&nbsp;Business Days after the Effective Date, each Party will appoint for each Program (and provide written notice to the other Party of the identity of) a senior representative having a general understanding of pharmaceutical discovery and
development issues to act as its project leader under this Agreement (the &#147;<U>Project Leader</U>&#148;). A Project Leader may support multiple ongoing Programs. The Project Leaders will serve as the contact point between the Parties, and will
be primarily responsible for: (a)&nbsp;facilitating the flow of information and otherwise promoting communication, coordination of the day-to-day work and collaboration between the Parties with respect to a particular Research Plan;
(b)&nbsp;providing single point communication for seeking consensus both internally within the respective Party&#146;s organization; and (c)&nbsp;raising cross-Party and/or cross-functional disputes in a timely manner. The Project Leaders shall
ensure regular biweekly telephone conferences or more frequently as deemed necessary or appropriate, to exchange informal information regarding the progress of the relevant Program. Each Party may change its designated Project Leader from time to
time upon prior written notice to the other Party. Any Project Leader may designate a substitute to temporarily perform the functions of that Project Leader by prior written notice to the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Joint Steering Committee</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Composition</U>. Promptly after the Effective Date, the Parties shall establish a joint steering committee (the &#147;<U>JSC</U>&#148;). The JSC shall be comprised of three (3)&nbsp;named
representatives of BI and three (3)&nbsp;named representatives of MacroGenics (or such other number as the Parties may agree). As soon as practicable after the Effective Date (but in no event more than fifteen (15)&nbsp;Business Days after the
Effective Date), each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other
Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Programs. Either Party may, from time to time, invite additional representatives or consultants to
attend JSC meetings; <U>provided</U> that at least ten (10)&nbsp;Business Days prior written notice is given of a Party&#146;s intention to invite such other representatives or consultants and providing full details about the name, employer and
professional background of such other representatives or consultants, and subject to such representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE
VIII. Each Party shall bear its own expenses related to the attendance at JSC meetings by its representatives. The JSC shall be co-chaired by a representative from each Party. The chairpersons shall set the agendas for the JSC meeting in advance.
The JSC shall be disbanded upon expiration of the Research Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Function and Powers of the JSC</U>. During the
Research Term, the JSC&#146;s responsibilities shall include: (i)&nbsp;approving each Research Plan, RTP and any amendments thereto; (ii)&nbsp;approving the *** Candidate Criteria; (iii)&nbsp;providing a forum for discussion of the Research Plan,
RTP, the status of the Programs, and relevant data; (iv)&nbsp;reallocating resources within and/or among the Programs and the prioritization of Programs; (v)&nbsp;serving as a forum for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
informal resolution of disagreements that may arise in the relation to the Parties activities under the Programs; (vi)&nbsp;determining and approving the overall strategy for publications and
presentations pursuant to Sections 8.3 and 8.4; and (vii)&nbsp;considering and acting upon such other matters as specified in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Subcommittees</U>. The JSC may establish and disband such subcommittees as deemed necessary by the JSC. Each such subcommittee shall consist of the same number of representatives designated by each
Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party&#146;s
representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in ARTICLE VIII. Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties
hereunder and each subcommittee shall report to the JSC. The initial subcommittee of the JSC will be the Joint Research Committee (&#147;<U>JRC</U>&#148;). The Parties may elect to establish a single JRC or may elect to establish a separate JRC for
each Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Joint Research Committee</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Promptly after the Effective Date, the Parties shall establish the JRC (or, if multiple JRCs are to be established,
promptly after each Program commences). The JRC shall be comprised of three (3)&nbsp;named representatives of BI and three (3)&nbsp;named representatives of MacroGenics (or such other number as the Parties may agree). As soon as practicable after
the establishment of the JRC, each Party shall designate by written notice to the other Party its initial representatives on the JRC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon notice to the
other Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the relevant Program(s). Either party may, from time to time, invite additional representatives or
consultants to attend JRC meetings; <U>provided</U> that at least ten (10)&nbsp;Business Days prior written notice is given of a Party&#146;s intention to invite such other representatives or consultants and providing full details about the name,
employer and professional background of such other representatives or consultants, and subject to such representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set forth
in ARTICLE VIII. Each Party shall bear its own expenses related to the attendance at JRC meetings by its representatives. The JRC shall be co-chaired by a representative of each Party. The chairpersons shall set the agendas for the JRC meeting in
advance. The JRC shall be disbanded upon expiration of the Research Term. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) During the Research Term, the
JRC&#146;s responsibilities shall include: (A)&nbsp;prioritizing research on Collaboration Targets; (B)&nbsp;developing the Research Plan, RTP and any amendments thereto for approval by the JSC; (C)&nbsp;establishing the *** Candidate Criteria for
each Program; (D)&nbsp;reviewing and tracking the exchange and use of Materials pursuant to Section&nbsp;3.6; (E)&nbsp;considering and advising on technical issues and issues of priority that arise in the conduct of the relevant Program(s); and
(F)&nbsp;considering and acting upon such other matters as specified in this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Joint Development Committee.</U> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)***, the Parties will establish the Joint Development Committee (&#147;<U>JDC</U>&#148;) and each Party shall
designate by written notice to the other Party its initial representatives on the JDC. The JDC shall be comprised of two (2)&nbsp;named representatives of BI and two (2)&nbsp;named representatives of MacroGenics (or such other number as the Parties
may agree). Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. These representatives shall have appropriate technical credentials, experience and
knowledge, and ongoing familiarity with the relevant Program(s). Either Party may, from time to time, invite additional representatives or consultants to attend JDC meetings; <U>provided</U> that at least ten (10)&nbsp;Business Days prior written
notice is given of a Party&#146;s intention to invite such other representatives or consultants and providing full details about the name, employer and professional background of such other representatives or consultants, and subject to such
representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE VIII. Each Party shall bear its own expenses related to the attendance at JDC meetings by
its representatives. The JDC shall be co-chaired by a representative of each Party. The chairpersons shall set the agendas for the JDC meeting in advance. The JDC shall be disbanded upon completion of the relevant ***. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The JDC&#146;s responsibilities shall include coordinating activities related to the *** in accordance with
Section&nbsp;4.3 and considering and acting upon such other matters as specified in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 <U>Meetings</U>.
Commencing in the fourth Calendar Quarter of 2010, the JSC shall hold at least *** per Calendar Year and each of the subcommittees shall each hold at least one (1)&nbsp;meeting per Calendar Quarter. Either Party shall be entitled to request any
additional meetings of the JSC. Meetings of the JSC and the subcommittees, respectively, shall be effective only if at least two (2)&nbsp;representative of each Party are present or participating. The location of meetings shall be as agreed by the
Parties, and may be held in person, alternating locations between the Parties, or by telephone conference call or by videoconference; <U>provided</U>, <U>however</U>, that at least *** of the JSC and each subcommittee per Calendar Year are held in
person. Each Party shall be responsible for all of its own expenses incurred in connection with preparing for and participating in all such meetings. Within ten (10)&nbsp;Business Days prior to each scheduled meeting, the Parties shall, in
accordance with Section&nbsp;3.9(b), provide a report to the JSC or JRC (in each case as applicable) detailing its progress with respect to the respective Programs. The Parties will rotate the responsibility for recording, preparing and issuing
minutes for each JSC, and any subcommittee within fifteen (15)&nbsp;Business Days thereafter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5 <U>Decision-making</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Initial Dispute Resolution Procedures</U>. Subject to the provisions of this Section&nbsp;2.5, actions to be taken by
the JSC and each of the subcommittees shall be taken only following a unanimous vote, with each Party, through its representatives, having one (1)&nbsp;vote. If any subcommittee fails to reach unanimous agreement on a matter before it for decision
<B>***</B>, the matter shall be referred to the JSC unless the JSC has been disbanded, in which case such matter shall be referred to <B>***</B> MacroGenics and <B>***</B> of BI for resolution in accordance with Section&nbsp;2.5(b). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Referral of Unresolved Matters to Executives</U>. If, in accordance with
Section&nbsp;2.5(a), the JSC does not resolve any matter considered by it within <B>***</B> after the matter is first considered by it, the matter may be referred by either Party to the *** of MacroGenics and *** of BI to be resolved by negotiation
in good faith as soon as practicable but in no event <B>***</B> after referral. Such resolution, if any, of a referred issue by the <B>***</B> and <B>***</B> shall be final and binding on the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Final Decision-Making</U>. If a dispute referred to the <B>*** </B>and <B>***</B> has not been resolved in accordance with
Section&nbsp;2.5(b), then, subject to Section&nbsp;2.5(d), <B>***</B> ***. Any *** <B></B>under this Section&nbsp;2.5(c) shall be deemed a decision of the JSC for purposes of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Exceptions</U>. Notwithstanding Section&nbsp;2.5(c), <B>***</B> to exercise such decision-making authority (i)&nbsp;***;
(ii)&nbsp;in a manner that excuses BI from any of its obligations specifically enumerated under this Agreement, (iii)&nbsp;in a manner that negates any consent rights or other rights specifically allocated to MacroGenics under this Agreement;
(iv)&nbsp;to resolve any dispute regarding whether a milestone event set forth in Section&nbsp;6.4 has been achieved; (v)&nbsp;in a manner that would require MacroGenics to perform activities (A)&nbsp;for which BI *** (except as expressly set forth
in this Agreement); (B)&nbsp;which MacroGenics has not agreed to perform as set forth in this Agreement or an Initial Research Plan, or as otherwise agreed in writing by MacroGenics; or (C)&nbsp;which require MacroGenics to use any Know-How or other
technology not contemplated in an Initial Research Plan and that are not developed internally by MacroGenics; (vi)&nbsp;*** or (vii)&nbsp;in a manner that would require MacroGenics to perform any act that it reasonably believes to be inconsistent
with any Law or any approval, order, policy, guidelines of a Regulatory Authority or ethical requirements or ethical guidelines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.6 <U>Limitations on JSC Authority</U>. The JSC and any subcommittee shall have only the powers assigned expressly to it in this ARTICLE II and elsewhere in this Agreement, and shall not have any power
to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in
the JSC or any subcommittee unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE III </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>RESEARCH PROGRAM </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>General</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Objectives</U>. The initial objective of each Program is to develop Collaboration DARTs Directed to a specific Collaboration Target and to Develop such Collaborative DARTs to meet the SOPD
Candidate Criteria and being declared SOPD </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Candidates. The Parties may also agree to collaborate on additional exploratory projects related to the Programs. Up to ten (10)&nbsp;Programs shall be undertaken through the generation of Lead
Candidates meeting RTP criteria and eventually SOPD Candidate Criteria under this Agreement. For each Collaboration DART that is deemed an SOPD Candidate, BI shall, in accordance with ARTICLE IV, have full responsibility for further Development,
manufacture and Commercialization activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Research Plans</U>. The Parties shall agree to a Research Plan for each
Program and shall conduct each Program in accordance with the applicable Research Plan. The Parties shall agree to <B>***</B> (the &#147;<U>Initial Research Plans</U>&#148;), which Initial Research Plans shall include <B>***</B>Collaboration Targets
and shall set forth the tasks to be undertaken by the Parties (including relevant technology to be used and Materials (as defined below) to be provided) under each Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Extended Research Term</U>.&nbsp;In the event that BI reasonably believes that the Parties will not complete the activities under the Research Plan for any Program initiated during the first
<B>***</B> of the Initial Research Term, then BI, at its sole discretion, may extend the Research Term to complete the goals of such Research Plan as then in effect for a <B>***</B> period (the &#147;<U>Extended Research Term</U>&#148;) from the
expiration of the Initial Research Term.&nbsp;BI may extend the Research Term by giving written notice to MacroGenics at least <B>***</B> prior to the expiration of the Initial Research Term.&nbsp;The Parties shall mutually agree upon the number of
FTEs at MacroGenics needed to perform the research during the Extended Research Term and BI shall provide funding for such FTEs in accordance with Section&nbsp;6.3(b)(ii). The Parties may further prolong the Extended Research Term by mutual written
agreement of the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Selection of Collaboration Targets</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Initial Collaboration Targets</U>. As of the Effective Date the Parties have agreed to include the Initial Collaboration Targets
set forth on Schedule 1.47 as Collaboration Targets under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Additional Collaboration Targets</U>.
Within *** from the Effective Date, BI may submit in writing to MacroGenics additional Dual Target Combinations (which must be accompanied by the Entrez Gene ID, HUGO or official symbol and any common synonyms, if available, for each Target included
in such Dual Target Combination) which BI in good faith wishes to include as Collaboration Targets; <U>provided</U> that in no event shall there be more than *** Collaboration Targets at any time during the Research Term. For purposes of clarity, BI
shall have the right to substitute Collaboration Targets in accordance with Section&nbsp;3.2(d). MacroGenics shall, subject to Section&nbsp;3.2(c), provide BI written notice of whether any such additional Dual Target Combinations shall be included
as Collaboration Targets within <B>***</B> Business Days after receipt of notice of such additional Dual Target Combinations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Limitation on MacroGenics Rejection of Proposed Collaboration Targets</U>. MacroGenics may reject a proposed Dual Target
Combination submitted by BI in accordance with Section&nbsp;3.2(b) only if prior to BI&#146;s submission of such proposed Dual Target Combination: (i)&nbsp;*** in such proposed Dual Target Combination (but only if such Target is included in a
written list of no more than <B>***</B> Targets (which must be accompanied by the Entrez </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Gene ID, HUGO or official symbol and any common synonyms, if available, for each Target) provided by MacroGenics to a Third Party gatekeeper that is mutually acceptable to MacroGenics and BI
prior to the Effective Date and which is subject to *** of such list for each <B>***</B> not to exceed <B>***</B>Targets in total at any given time, by MacroGenics and which is shared prior to the end of each <B>***</B> with such Third Party
gatekeeper), <U>provided</U> <U>however</U> that under this clause (i)&nbsp;MacroGenics will not reject more than <B>***</B> Dual Target Combinations in the <B>***</B> period after the Effective Date and each consecutive <B>***</B> period
thereafter; <U>provided</U> that BI shall *** under this Section&nbsp;3.2(c) unless mutually agreed to by the Parties; (ii)&nbsp;MacroGenics or its Affiliates have entered into an agreement with a Third Party pursuant to which MacroGenics or its
Affiliates have committed any *** included in such *** to such Third Party; or (iii)&nbsp;MacroGenics is in good faith active partnering discussions with a Third Party *** included in such *** (as supported by written evidence *** BI&#146;s
submission of any Dual Target Combination according to Section&nbsp;3.2(b))), and in each case (i), (ii)&nbsp;and (iii), MacroGenics shall provide BI with written documentation on the reason for its rejection of any proposed *** included in
MacroGenics&#146; Target list and BI shall be entitled to confirm any such rejection under clause (i)&nbsp;directly with a Third Party gatekeeper to the then current MacroGenics Target list; <U>provided</U> that MacroGenics shall not be required to
provide any written documentation or other disclosure that would violate its confidentiality obligations to a Third Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Removal of Collaboration Targets from Collaboration Targets List</U>. At any time during the Initial Research Term, BI may remove
a Collaboration Target from the Collaboration Targets List (i)&nbsp;prior to the Parties commencing activities under a Research Plan with respect to such Collaboration Target or (ii)&nbsp;at any time after commencing research under the Research Plan
with respect to a Collaboration Target in the event that BI reasonably and in good faith concludes that a Collaboration DART can not meet the applicable RTP. In the event of the removal of a Dual Target Combination from the Collaboration Targets
List in accordance with this Section&nbsp;3.2(d)(ii), (A)&nbsp;such removal shall be treated as a *** with respect to the Program for such Collaboration Target; and (B)&nbsp;BI may submit an additional replacement Dual Target Combination to
MacroGenics in accordance with Section&nbsp;3.2(b). Notwithstanding the foregoing, in no event shall the cumulative number of Collaboration Targets pursued under this Agreement by the Parties (including any Collaboration Targets that are removed
from the Collaboration Targets List pursuant to this Section&nbsp;3.2(d)(i) or (ii)) exceed <B>***</B> unless mutually agreed by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Conduct of the Programs</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics and BI shall each use
Commercially Reasonable Efforts to conduct each Program in good scientific manner and in accordance with the applicable Research Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Either Party shall have the right to utilize the services of a Third Party to perform its Program obligations under the Research Plan. Each Party shall remain at all times fully liable for its
responsibilities under each Program and this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics and BI shall conduct each Program in accordance with
all applicable Laws, including, all current governmental regulatory requirements concerning Good Laboratory Practices. To the best of its knowledge, each Party hereby certifies that it will not employ or otherwise use in any capacity the services of
any person debarred under&nbsp;21 USC &#167;335a in performing any activities hereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4 <U>Research Target Profile; Lead Candidate Identification</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) The Research Plan for a Program shall set forth the applicable RTP for Collaboration DARTs in such Program. The JRC shall develop,
and the JSC shall approve, such RTP based on the template provided in <U>Schedule 1.77</U> *** (as agreed by JSC)&#148; in <U>Schedule 1.77</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Following approval of the RTP for a Program, the JRC may, from time to time during the Research Term, nominate a Collaboration DART from such Program that meets the RTP for consideration as a Lead
Candidate. For each such nominated Collaboration DART the JRC shall prepare and deliver to BI a data package for BI to evaluate. Such data package shall include the results from all tests and other measures included in the RTP. Within <B>***</B>
after delivery to BI of such data package, BI shall provide MacroGenics written notice whether BI (i)&nbsp;accepts such Collaboration DART as a Lead Candidate and intends to continue the relevant Program for such Lead Candidate in accordance with
the terms of this Agreement, in which case such Collaboration DART shall be deemed a Lead Candidate; (ii)&nbsp;does not accept such Collaboration DART as a Lead Candidate, but either desires to continue evaluation of such Collaboration DART in
accordance with subsection (c)&nbsp;or continue the relevant Program with respect to other Collaboration DARTs; or (iii)&nbsp;does not accept such Collaboration DART as a Lead Candidate and does not desire to continue the relevant Program, in which
case this Agreement shall terminate with respect to such Program and such termination shall be treated as a termination under Section&nbsp;10.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) If a Collaboration DART that has achieved the Lead Candidate Criteria is not accepted by BI as a Lead Candidate in accordance with Section&nbsp;3.4(b), then within <B>***</B> (the &#147;<U>Lead
Candidate Review Period</U>&#148;) BI shall have the right, by providing written notice to MacroGenics to accept any such Collaboration DART as a Lead Candidate, and the Parties shall continue the relevant Program for such Lead Candidate in
accordance with the terms of this Agreement. If upon expiration of the applicable Lead Candidate Review Period the relevant Collaboration DART has not been accepted by BI as a Lead Candidate, then (i)&nbsp;the licenses granted to BI under ARTICLE V
with respect to such Collaboration DART shall terminate and (ii)&nbsp;if no Collaboration DART has been accepted as a Lead Candidate for the relevant Program, BI shall provide MacroGenics written notice of whether BI (A)&nbsp;desires to continue the
relevant Program with respect to other Collaboration DARTs; or (B)&nbsp;does not desire to continue the relevant Program, in which case this Agreement shall terminate with respect to such Program and such termination shall be treated as a
termination under Section&nbsp;10.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Upon the initiation by BI of any <B>***</B>, BI shall provide MacroGenics
written notice of such initiation, BI shall be deemed to have accepted such Collaboration DART as a Lead Candidate and such Collaboration DART shall be deemed a Lead Candidate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) BI shall *** for the first Collaboration DART from each Program that BI accepts as a Lead Candidate pursuant to subsections (b),
(c)&nbsp;or (d)&nbsp;of this Section&nbsp;3.4. For the sake of clarity, BI has the right to select additional Collaboration DARTs from the same Program as Lead Candidates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5 <U>Start of Pre-Clinical Development Candidate Criteria; SOPD Candidate
Identification</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Within <B>***</B> following the date on which a Collaboration DART in a Program is deemed a Lead
Candidate, the JRC shall determine and the JSC shall approve, the Start of Pre-Clinical Development Candidate Criteria applicable to such Program. The JRC shall develop, and the JSC shall approve, such Start of Pre-Clinical Development Candidate
Criteria based on the template provided in <U>Schedule 1.81 </U>and shall <B>***</B> Following approval of the Start of Pre-Clinical Development Candidate Criteria for a Program and subject to the approval of the JSC, the JRC may, from time to time
during the Research Term, nominate a Collaboration DART from such Program that has achieved the Start of Pre-Clinical Development Candidate Criteria for consideration as an SOPD Candidate. The JSC shall have the right to approve any such nomination.
For each such nominated Collaboration DART the JRC shall prepare and deliver to BI a data package for BI to evaluate such Collaboration DART for designation as an SOPD Candidate. Such data package shall include the results from all tests and other
measures included in the SOPD Criteria. Within <B>***</B>after delivery to BI of the data package, BI shall provide MacroGenics written notice whether BI (i)&nbsp;accepts such Collaboration DART as an SOPD Candidate and intends to Develop and/or
Commercialize such SOPD Candidate in accordance with the terms of this Agreement, in which case such Collaboration DART shall be deemed an SOPD Candidate; (ii)&nbsp;does not accept such Collaboration DART as an SOPD Candidate, but either desires to
continue evaluation of such Collaboration Dart in accordance with subsection (b)&nbsp;or to continue the relevant Program with respect to other Collaboration DARTs; or (iii)&nbsp;does not accept such Collaboration DART as an SOPD Candidate and does
not desire to continue the relevant Program, in which case this Agreement shall terminate with respect to such Program and such termination shall be treated as a termination under Section&nbsp;10.2(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If a Collaboration DART that has achieved the SOPD Candidate Criteria is not accepted by BI as an SOPD Candidate in accordance with
Section&nbsp;3.5(a), then within *** after such Collaboration DART was first submitted to BI as an SOPD Candidate (the &#147;<U>SOPD Candidate Review Period</U>&#148;) BI shall have the right, by providing written notice to MacroGenics to accept any
such Collaboration DART as an SOPD Candidate, and BI shall research, Develop, manufacture and Commercialize such SOPD Candidate in accordance with the terms of this Agreement. If upon expiration of the applicable SOPD Candidate Review Period the
relevant Collaboration DART has not been accepted by BI as an SOPD Candidate, then (i)&nbsp;the licenses granted to BI under ARTICLE V with respect to such Collaboration DART shall terminate and (ii)&nbsp;if no Collaboration DART has been accepted
as an SOPD Candidate for the relevant Program, BI shall provide MacroGenics written notice of whether BI (A)&nbsp;desires to continue the relevant Program with respect to other Collaboration DARTs; or (B)&nbsp;does not desire to continue the
relevant Program, in which case this Agreement shall terminate with respect to such Program and such termination shall be treated as a termination under Section&nbsp;10.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) In the event that BI initiates <B>***</B> with respect to any Collaboration DART that has not previously been accepted by BI in accordance with Section&nbsp;3.5(b), BI shall provide MacroGenics
written notice of such initiation, BI shall ***. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) BI shall pay any applicable milestone payment as set forth in Section&nbsp;6.4(a)(ii)
for the <B>***</B> from each Program that BI accepts as an SOPD Candidate pursuant to subsections (a), (b)&nbsp;or (c)&nbsp;of this Section&nbsp;3.5. For the sake of clarity, BI has the right to select additional Collaboration DARTs from the same
Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) If following end of the Research Term and any SOPD Candidate Review Period ongoing at the end of the Research
Term there is any Program for which no Collaboration DART has been accepted by BI as an SOPD Candidate, whether pursuant to subsections (a), (b)&nbsp;or (c)&nbsp;of this Section&nbsp;3.5, then this Agreement shall terminate with respect to such
Program and such termination shall be treated as a termination under Section&nbsp;10.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6 <U>Materials and Know-How
Transfer</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) In order to facilitate any Program, each Party shall, as set forth in the applicable Research Plan,
provide to the other Party certain tangible biological materials including <B>***</B> (&#147;<U>Materials</U>&#148;) and, subject to Section&nbsp;3.7, Know-How Controlled by the supplying Party (other than under this Agreement) for use by the other
Party in furtherance of such Program. MacroGenics shall furthermore transfer to BI the <B>***</B>. The transfer of any such Materials shall be conducted pursuant to the terms of this Agreement, including the following: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) All Materials and Know-How supplied by one Party to the other Party shall remain the sole property of the supplying Party, except
those MacroGenics Collaboration Antibodies as further outlined in Section&nbsp;3.6(c) below, and shall be used (i)&nbsp;only for the specific purpose provided for in the applicable Research Plan, and (ii)&nbsp;solely under the control of the
receiving Party. In the event a receiving Party uses Materials provided by the supplying Party for purposes other than for the specific purpose provided in the applicable Research Plan, the supplying Party shall solely own any results, discoveries
or inventions arising out of such use and the receiving Party hereby assigns to the supply Party all right, title and interest in such results, discoveries or inventions. The Materials may not be used or delivered to or for the benefit of any Third
Party without the prior written consent of the supplying Party, and shall not be used in research or testing involving human subjects, except as expressly contemplated in the applicable Research Plan or in accordance with this Agreement. Any
Materials supplied by one Party to the other Party must be used with prudence and appropriate caution in any experimental work, since not all of their characteristics may be known. All Materials shall be returned to the supplying Party or destroyed
(at the election of the supplying Party) promptly after completion of the permitted use. The use of the Materials shall comply with restrictions and conditions on use (if any) imposed by Third Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics Collaboration Antibodies created in accordance with Section&nbsp;1.55(a), including Know-How that is solely and
specifically related to such MacroGenics Collaboration Antibodies, shall be solely owned by BI, and MacroGenics shall not use such MacroGenics Collaboration Antibodies and/or such Know-How for any other purpose, either alone or in collaboration with
any Third Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) THE MATERIALS ARE PROVIDED &#147;AS IS&#148; AND WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR
IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR OF FITNESS FOR ANY </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
PARTICULAR PURPOSE OR ANY WARRANTY THAT THE USE OF THE MATERIALS WILL NOT INFRINGE OR VIOLATE ANY PATENT OR OTHER PROPRIETARY RIGHTS OF ANY THIRD PARTY. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.7 <U>Third Party Intellectual Property</U>. In developing each Research Plan, the Parties shall discuss whether any Third Party Patent
Rights or Know-How will be utilized in the conduct of activities under the applicable Research Plan. MacroGenics shall disclose to BI the details of the payment obligations of which it is aware that would be triggered by such use of Third Party
Patent Rights or Know-How in the respective Program. To the extent that the Parties mutually agree to utilize any Patent Right or Know-How that is licensed to or has been acquired by MacroGenics and such utilization would require the payment of
additional consideration to the Third Party from which the Patent Rights or Know-How was licensed or acquired, such Patent Rights or Know-How shall not be deemed under the Control of MacroGenics unless the Parties agree ***. For purposes of clarity,
nothing in this Section&nbsp;3.7 shall limit BI&#146;s rights to, independent of MacroGenics, obtain from a Third Party a license or other right with respect to such Third Party&#146;s Patent Rights or Know-How. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.8 <U>Manufacturing of Research Material</U>. MacroGenics shall be responsible for the production of all Collaboration DARTs and
Products for research testing purposes in accordance with the Research Plans. For clarity, BI shall be entitled to manufacture Collaboration DARTs and Products during the Research Term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.9 <U>Records and Reports</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Records</U>. Each Party shall maintain records, in sufficient detail and in good scientific manner appropriate for patent and regulatory purposes, which shall fully and properly reflect all work
done and results achieved in the performance of each Program by or on behalf of such Party (the &#147;<U>Records</U>&#148;), including the procedures, techniques and methodologies used, the progress made, and any inventions conceived and/or reduced
to practice or otherwise made within the scope of or in connection with each Program. As part of keeping the Records, each Party shall ensure that all of its personnel, and all of its agents that are involved in each Program will keep accurate
laboratory notebooks, which laboratory notebooks: (i)&nbsp;shall be duly signed, dated and witnessed; and (ii)&nbsp;shall be created and maintained in accordance with its standard operating procedures that would be sufficient to allow for said
laboratory notebooks to be used in any proceedings before the United States Patent and Trademark Office or United States courts, in order to establish the date of invention for any inventions in accordance with the United States patent laws. During
the Term of this Agreement, MacroGenics shall upon written request by BI, which shall not be unreasonably made: (A)&nbsp;make all Records available for inspection and review by BI during normal business hours in a timely manner; and (B)&nbsp;provide
copies of the Records or any part(s) thereof to BI, as reasonably requested by BI. After each Collaboration DART has been accepted by BI as SOPD Candidate, BI shall have the right to request a copy of the relevant portions of the laboratory
notebooks relating to the generation of such SOPD Candidate be provided by MacroGenics to BI. After such request by BI, MacroGenics shall provide such copies of the laboratory notebooks promptly to BI. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Reports to the JSC and JRC</U>. Within ten (10)&nbsp;Business Days prior to each scheduled JSC and JRC meeting, the Parties shall
provide to the JSC and JRC a written </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
report on the progress of each Program, summarizing the work performed under the Program and evaluating the work performed in relation to the goals of each Program. Each Party shall provide such
other information required by each Program or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of each Program. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IV </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DEVELOPMENT AND COMMERCIALIZATION OF PRODUCTS; DILIGENCE</U> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>Responsibility for Development, Manufacturing and Commercialization</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Following acceptance of an SOPD Candidate, BI shall have full responsibility, at its sole expense, for the worldwide research,
Development, manufacturing and Commercialization of such SOPD Candidate and any Products that include such SOPD Candidate. BI shall use Commercially Reasonable Efforts (itself or through an Affiliate or Sublicensee) to Develop and, following
Regulatory Approval, Commercialize at least <B>***</B> Product with respect to each Collaboration Target in at least <B>***</B> of the following *** (i)&nbsp;***, (ii)&nbsp;*** and (iii)&nbsp;***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall, following BI&#146;s reasonable request therefor and at BI&#146;s expense, provide to BI, or its designated
Affiliate or Third Party manufacturer selected by BI to manufacture the Products, reasonable technical assistance, manufacturing Know-How, including Materials, and material specifications Controlled by MacroGenics that are necessary for BI, its
Affiliate or such Third Party manufacturer to manufacture the Products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>Development and Commercialization
Activities</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Clinical Development Plans</U>. For each Product for which BI initiates a ***, BI shall prepare a
clinical development plan outlining the major clinical Development activities that BI expects to undertake, including anticipated timescales, relating to the Product up to the submission of the initial NDA for the applicable Product (each, a
&#147;<U>Clinical Development Plan</U>&#148;). It is understood that each Clinical Development Plan is intended to be a fluid document and is subject to change by BI based on, among other things, changes in the market, discussions with investigators
and Regulatory Authorities and the results of studies undertaken. Subject to the provisions of ARTICLE VIII, during the Term, BI shall provide MacroGenics a copy of <B>***</B>. The Clinical Development Plans will be created, approved, and amended
according to BI&#146;s then-current internal standards and processes for such Clinical Development Plans. The responsibility to provide a Clinical Development Plan for a particular Product shall terminate if BI ceases further Clinical Development of
such Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Progress Reports</U>. After the end of the Research Term and continuing until the First Commercial Sale
of the respective SOPD Candidate or Product, BI shall provide within <B>***</B> days after *** of each Calendar Year a written progress report to MacroGenics which summarizes the activities undertaken and the data obtained in the prior <B>***</B> to
Develop each SOPD Candidate or Product for which BI has paid a milestone according to Section&nbsp;6.4(a)(i). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3<U> Conduct of Phase I Clinical Trial</U>. In the event that either Party reasonably
desires for ***, such Party shall submit a written request to the other Party, together with a draft protocol, clinical plan and a proposed budget prepared in good faith by such Party; <U>provided</U> that <B>***</B>. In the event that the Parties
agree to the conduct of such ***, the Parties shall establish the JDC in accordance with Section&nbsp;2.3(b). *** its out-of-pocket expenses, specifically identifiable and documented and FTE costs incurred in connection with any such ***. Together
with each Invoice, ***. For avoidance of doubt, ***. All results and data of such ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4 <U>Co-Development</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Generally</U>. Within <B>***</B> months prior to the initiation of a <B>***</B> for any Product, BI shall provide MacroGenics
with (i)&nbsp;an updated progress report (in accordance with Section&nbsp;4.2(b)); (ii)&nbsp;BI&#146;s then current Development Plan and budget for the Clinical Development Costs (the &#147;<U>Co-Development Budget</U>&#148;) with respect to such
Product; (iii)&nbsp;then available documentation for IND update for such Product, and MacroGenics may reasonably request that BI provides additional information to such Product and BI shall provide MacroGenics with such information as reasonably
available for such Product unless such information is proprietary and confidential information of BI related to BI Biopharmaceutical Technology; (iv)&nbsp;clinical study summaries from prior Clinical Trials conducted with such Product; and
(v)&nbsp;copies of material correspondence with Regulatory Authorities with respect to such Product relevant for *** (collectively, the &#147;<U>Development Data Package</U>&#148;). MacroGenics shall have the option, exercisable with respect to
<B>***</B> Products, to co-fund up to <B>***</B> of BI&#146;s Clinical Development Costs which are incurred after the date of such written notice and *** for such Product. MacroGenics may exercise such option by providing BI written notice within
<B>***</B> days after receipt of the Development Data Package, and such Product shall be deemed to be a &#147;<U>Co-Development Product</U>&#148;. MacroGenics shall specify in such notice the percentage of BI&#146;s Clinical Development Costs for
the Co-Development Product that MacroGenics intends to co-fund (the &#147;<U>MacroGenics Shared Percentage</U>&#148;). In the event, MacroGenics does not provide a written notification to BI within such <B>***</B>day period, such Product will
automatically be excluded from such co-development option under this Section&nbsp;4.4 and MacroGenics shall automatically be deemed to have waived its co-development option right with regard to such Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Effects of Co-Development Opt-In</U>. If MacroGenics delivers such written notice as described above for a Co-Development
Product, the following shall apply: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) MacroGenics shall be responsible for the applicable MacroGenics
Shared Percentage of BI&#146;s Clinical Development Costs which are incurred for such Co-Development Product after the date of such written notice and until the Filing of the first NDA in a Major Country (including Filing of an NDA with the EMA) for
such Product (the &#147;<U>Co-Development Obligations</U>&#148;); <U>provided</U> in no event shall MacroGenics be obligated to fund any portion of such Clinical Development Costs that exceeds <B>*** </B>of the Clinical Development Costs provided
for in the Co-Development Budget (with a corresponding <I>pro rata</I> reduction in the royalty increase MacroGenics would receive as set forth in more detail in Section&nbsp;4.4(b)(iii)). BI shall remain solely responsible for Development and
manufacturing activities for such Co-Development Product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) After MacroGenics has delivered such written notice and within ***
following each of the Calendar Quarters I (January to March), II (April to June), and III (July to September), BI shall issue an invoice to MacroGenics for the MacroGenics Shared Percentage of the Clinical Development Costs based on budgeted cost
for the respective Calendar Quarter. Within *** following the end of the Calendar Quarter IV (October to December), BI shall provide to MacroGenics *** with respect to such Co-Development Product, as certified by BI&#146;s senior controlling staff.
Simultaneously, BI shall issue an invoice in the amount of the MacroGenics Shared Percentage of the Clinical Development Costs actually incurred by BI for such Calendar Year deducting the payments received for Calendar Quarters I, II and III. In the
event the actual Clinical Development Costs for the Calendar Year surpass the budgeted amount by more than <B>***</B>, the stipulations of Section&nbsp;4.4(b)(i) will apply. MacroGenics shall pay all amounts payable under any such invoice within
thirty (30)&nbsp;days after its receipt of such invoice. ***. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) The applicable royalty rates set forth in
Section&nbsp;6.6 payable on each Co-Development Product shall be increased by <B>***</B> of the Clinical Development Cost co-funded by MacroGenics. For example, if MacroGenics co-funds <B>***</B> of the Clinical Development Costs for such
Co-Development Product, the applicable *** by <B>***</B>. If MacroGenics co-funds less than the MacroGenics Shared Percentage of the Clinical Development Costs for a Co-Development Product because actual expenses exceeded BI&#146;s budget forecast
by more than <B>***</B> of the Clinical Development Costs for such Co-Development Product, then MacroGenics shall receive *** on such Co-Development Product based on its percentage share of the actual Clinical Development Costs in accordance with
the formula set forth in this Section&nbsp;4.4(b)(iii). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Termination of Co-Development</U>. Upon not less than
<B>***</B> prior written notice to BI, MacroGenics may elect to discontinue its Co-Development Obligations with respect to a Co-Development Product in which case the following shall apply: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Upon the effective date of termination of the Co-Development Obligations, MacroGenics shall have no further
obligations to co-fund the Clinical Development Costs with respect to such Co-Development Product. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) The
*** payable on such Co-Development Product shall be calculated based on the formula set forth in Section&nbsp;4.4(b)(iii) above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.5 <U>Co-Promotion</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Generally</U>. MacroGenics shall have the
non-transferable option to co-promote in the United States up to <B>***</B> Products whose initial indication is Detailed by *** (the &#147;<U>Co-Promotion Option</U>&#148;). Within <B>***</B> prior to BI&#146;s anticipated commercial launch for any
such Product, BI shall provide MacroGenics *** and BI&#146;s then-current Commercialization plans (&#147;<U>Commercialization Plan</U>&#148;) with respect to such Product, which Commercialization Plan shall include<B>***</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Effects of Exercise of Co-Promotion Option</U>. If MacroGenics exercises its
Co-Promotion Option the Parties shall promptly and in good faith negotiate a definitive co-promotion agreement consistent with the terms and conditions outlined in <U>Schedule 4.5(b)I</U>, prior to the initiation of the co-promotion efforts
contemplated hereby with the procedures described in <U>Schedule 4.5(b)II </U>applying to any failure by the Parties to agree on the terms of such separate agreement within <B>***</B> days following the start of such negotiations. Such co-promotion
agreement shall require MacroGenics to comply with all applicable Laws and with BI&#146;s policies and guidelines relating to the marketing of the co-promoted Product. Notwithstanding the foregoing, in the event that a Product for which MacroGenics
exercised its Co-Promotion Option ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Waiver of Co-Promotion Option</U>. In the event MacroGenics does not exercise
its Co-Promotion Option during the specified period described above, then (i)&nbsp;MacroGenics shall automatically be deemed to have waived its Co-Promotion Option with regard to the applicable Product; and (ii)&nbsp;the rights granted to BI
hereunder with respect to such Product in the United States shall remain exclusive. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE V </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>GRANTS OF RIGHTS</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Licenses to BI</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Non-Exclusive Research License to BI</U>.
Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to BI: (i)&nbsp;during the Research Term and any applicable Lead Candidate Review Period or SOPD Candidate Review Period, a worldwide, royalty-free, non-exclusive
license, with the right to grant sublicenses in accordance with Section&nbsp;5.4, under the MacroGenics Intellectual Property solely to the extent necessary to (A)&nbsp;conduct activities assigned to it under each Research Plan or (B)&nbsp;evaluate
the data developed in the conduct of activities under the Research Plans during any applicable Lead Candidate Review Period or SOPD Candidate Review Period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Exclusive License to BI</U>. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to BI an exclusive (even as to MacroGenics), worldwide, royalty-bearing, license,
including the right to grant sublicenses in accordance with Section&nbsp;5.4, under the MacroGenics Intellectual Property and MacroGenics&#146; interest in the Joint Intellectual Property and Collaboration DART Intellectual Property to research,
Develop, make and have made, use, offer for sale, sell, export and import Collaboration DARTs and Products in the Territory and in the Field. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Recordation</U>. Following the execution of this Agreement or at any time during the Term, MacroGenics at the request and expense of BI shall promptly register or record the licenses granted to BI
under this Agreement with the appropriate patent offices in all applicable countries of the Territory; <U>provided</U> that such registration or recordation specifies the applicable limitations of such license, and <U>provided</U> <U>further</U>
that such registration shall have no </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
effect on the allocation of Prosecution and Maintenance rights and obligations set forth in ARTICLE VII. In the event the licenses granted to BI under this Agreement are terminated, BI shall
promptly take such actions and execute such documents as are reasonably requested by MacroGenics to cancel such registration(s) or recordation(s) in the applicable countries with respect to the terminated license grants. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Non-Exclusive Research License to MacroGenics</U>. Subject to the terms and conditions of this Agreement, during the Research
Term, BI grants to MacroGenics, and MacroGenics accepts, a worldwide, royalty-free non-exclusive license, with the right to grant sublicenses in accordance with Section&nbsp;5.4, under the BI Intellectual Property solely to the extent necessary to
conduct activities assigned to it under each Research Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4 <U>Sublicenses</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) BI shall have the right to grant sublicenses under the licenses granted to it under Section&nbsp;5.1 to (i)&nbsp;Affiliates of BI at
any time, and (ii)&nbsp;(A)&nbsp;under Section&nbsp;5.1(a) to Third Parties that are specifically approved in a Research Plan or otherwise approved by the JSC, in each case solely to the extent necessary to carry out obligations under such Research
Plan; and (B)&nbsp;under Section&nbsp;5.1(b) to Third Parties; <U>provided</U> that any sublicense granted to a Third Party under this Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and
limitations set forth in this Agreement. ***BI shall remain responsible for the performance of its sublicensees, and shall insure that each sublicensee comply with the applicable terms and conditions of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics may grant sublicenses under the rights granted to it in Section&nbsp;5.2 to (i)&nbsp;Affiliates of MacroGenics, or
(ii)&nbsp;Third Parties that are specifically approved in a Research Plan or otherwise approved by the JSC, in each case solely to the extent necessary to carry out obligations under each Research Plan; <U>provided</U> that any sublicense granted to
a Third Party under this Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5 <U>Covenant not to Sue</U>. In the event the making, having made, use, offer for sale, sale or import by BI and/or its Affiliates of
Product(s) in accordance with the terms and conditions of this Agreement would infringe during the Term a claim of issued letters patent which, subject to Section&nbsp;3.7, MacroGenics Controls and which patent is not covered by the licenses granted
to BI pursuant to Section&nbsp;5.1 MacroGenics hereby covenants not to sue BI and/or its Affiliates under such issued letters patent solely for the development, making, having made, using, selling, offering for sale or importing Product(s) in the
Territory and in the Field. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6 <U>Rights Retained by the Parties</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except as expressly set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by
implication or otherwise, in any Confidential Information disclosed to it under this Agreement or under any Patent Rights or Know-How Controlled by the other Party or its Affiliates. Without limiting the generality of the foregoing, any of
MacroGenics&#146; rights to MacroGenics Intellectual Property not specifically licensed to BI shall be retained by MacroGenics, and any of BI&#146;s rights to BI Intellectual Property not specifically licensed to MacroGenics shall be retained by BI.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Notwithstanding the licenses granted to BI pursuant to Section&nbsp;5.1, MacroGenics
retains the right to practice under the MacroGenics Intellectual Property: (i)&nbsp;solely to perform (and to sublicense Third Parties to perform) its obligations under this Agreement and (ii)&nbsp;to perform, and grant Third Parties the
non-exclusive right to perform, internal research related *** existing *** prior to the Effective Date or created or acquired by *** of the conduct of any Program; <U>provided</U> that any such license granted to a Third Party does not specifically
include a license to research any Collaboration DART or Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7 <U>Section&nbsp;365(n) of the Bankruptcy Code</U>. All
rights and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section&nbsp;365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the &#147;<U>Bankruptcy
Code</U>&#148;), licenses of rights to &#147;intellectual property&#148; as defined in Section&nbsp;101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy
Code. Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the United
States that provide similar protection for &#147;intellectual property.&#148; The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of
applicable Law outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in such
Party&#146;s possession, will be promptly delivered to it upon such Party&#146;s written request thereof. Any agreements supplemental hereto will be deemed to be &#147;agreements supplementary to&#148; this Agreement for purposes of
Section&nbsp;365(n) of the Bankruptcy Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.8 <U>Exclusivity</U>. During *** the Parties agree to work exclusively with one
another within the scope of the collaboration, *** of molecules, derivatives thereof, or products created from ***. In addition, each Party agrees as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>MacroGenics Exclusivity</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Subject to the
exceptions set forth in Section&nbsp;5.8(c), except with respect to research, Development and Commercialization activities pursuant to this Agreement, MacroGenics and its Affiliates shall not, nor shall MacroGenics or its Affiliates grant rights to
Third Parties to, research, Develop or Commercialize any *** or *** using ***. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) On a BI Exclusive
Target-by-BI Exclusive Target basis, MacroGenics and its Affiliates shall not, nor shall MacroGenics or its Affiliates grant rights to Third Parties to, research, Develop or Commercialize any molecule or product using *** that is *** during the
earlier of <B>***</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>BI Exclusivity</U>. Subject to the exceptions set forth in Section&nbsp;5.8(c),
except with respect to ***<B></B>. For the avoidance of doubt, and subject to the immediately preceding sentence, BI shall have the right to research, Develop and Commercialize any molecule or product <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Exceptions</U>. The prohibitions set forth in Sections&nbsp;5.8(a) and 5.8(b) do not apply to any of the following: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) with respect to activities by MacroGenics, subject to Section&nbsp;5.8(a)(ii), the Development and Commercialization
of molecules and products Directed to Terminated Targets, however without using any MacroGenics *** created by ***, including Know-How that is solely and specifically related to such MacroGenics ***; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) subject to Section&nbsp;5.8(a)(ii), any molecule or product Directed against a single Target included in a
Collaboration Target, however with respect to activities by MacroGenics without using any MacroGenics *** created by ***, including Know-How that is solely and specifically related to such MacroGenics ***; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) where a Party&#146;s or its Affiliate&#146;s (the &#147;<U>Acquiring/Acquired Party</U>&#148;) involvement in such
activity results from its acquisition of or by a Third Party (by merger or otherwise), and such Third Party was engaged in such activity prior to such acquisition or merger; <U>provided</U> that (A)&nbsp;the Acquiring/Acquired Party shall not
provide any such Third Party with rights or access to MacroGenics Intellectual Property (where MacroGenics or its Affiliate is the Acquiring/Acquired Party ) or BI Intellectual Property (where BI or its Affiliate is the Acquiring/Acquired Party )
for use in connection with activities prohibited by Section&nbsp;5.8 if undertaken by the Acquiring/Acquired Party, and (B)&nbsp;in the case where the Acquiring/Acquired Party acquires a Third Party (by merger or otherwise), the Acquiring/Acquired
Party does not expand the scope of, or increase the financial commitment to, such Third Party activities, from what it was immediately prior to the acquisition. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For the avoidance of doubt and for purposes of this Section&nbsp;5.8(c) product shall not be inclusive of any Product including Collaboration DARTs. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VI </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>PAYMENTS; ROYALTIES AND REPORTS</U> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Initial License Payment</U>. In consideration of the rights to MacroGenics Intellectual Property granted herein within *** of the later of the Effective Date and receipt of Invoice and duly signed
original of the Agreement, BI shall pay to MacroGenics a non-creditable and non-refundable sum of Fifteen Million Dollars ($15,000,000). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>Equity Investment</U>. BI or any of its Affiliates and MacroGenics shall enter good faith negotiations with the objective of completing such negotiations within *** after the Effective Date
regarding the terms and conditions of a definitive stock purchase agreement </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
whereby BI or any of its Affiliates shall purchase Ten Million Dollars ($10,000,000.00) of Preferred Stock of MacroGenics. The pricing of such Preferred Stock shall be no less than $0.6521 per
share. The other terms will be no less favorable to MacroGenics&#146; current investors as the terms and conditions established in the Series D-2 equity documentation. If BI and MacroGenics are not able to conclude and execute a definitive stock
purchase agreement within *** of the Effective Date, *** and require that *** of Preferred Stock on the same terms and conditions as purchased by existing Series D-2 investors, including a share price of ***, under a definitive stock purchase
agreement executed by both Parties. ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Programs Funding</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Maintenance Payments</U>. In consideration of the rights to MacroGenics Intellectual Property granted herein, BI shall pay
MacroGenics the following non-refundable, non-creditable, non-accountable amounts: (<B>***</B> within <B>***</B>of receipt of an Invoice, which shall be provided by MacroGenics to BI on or after<B>***</B>of the Effective Date;<B> ***</B>within
<B>***</B> of receipt of a written Invoice, which shall be provided by MacroGenics to BI on or after<B>***</B>of the Effective Date; and<B> ***</B>within <B>***</B>of receipt of a written Invoice, which shall be provided by MacroGenics to BI on or
after <B>***</B>of the Effective Date (each a &#147;<U>Maintenance Payment</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Out-of Pocket Costs and FTE
Payments</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Out-of-Pocket Costs</U>. BI shall reimburse MacroGenics all out-of-pocket costs
specifically identifiable, documented and incurred by MacroGenics and payable to Third Parties in connection with any Program, as specifically contemplated in the applicable Research Plan, in accordance with agreed upon budget for such expenses set
forth in each such Research Plan or as otherwise agreed to by BI. BI shall reimburse such out-of-pocket costs within thirty (30)&nbsp;days after receipt of an Invoice issued by MacroGenics within thirty (30)&nbsp;days after the end of each Calendar
Quarter describing such costs in reasonable detail and providing appropriate supporting documentation. For avoidance of doubt, no out-of-pocket costs will be reimbursed by BI unless covered by an agreed upon budget for such expenses set forth in a
Research Plan. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>MacroGenics Committed FTEs</U>. It is the Parties&#146; intent that the Research Plans
will require <B>***</B> FTEs each Calendar Quarter in the performance of the activities under the Research Plans during the Initial Research Term, and both Parties will use reasonable efforts to limit substantial reductions <B>***</B> from Calendar
Quarter to Calendar Quarter). During the Research Term, on or before the later of thirty (30)&nbsp;days of BI&#146;s receipt of an Invoice thereof, and the first day of each Calendar Quarter, BI shall pay MacroGenics the FTE Costs for <B>***</B>
during such Calendar Quarter; <U>provided</U> that such payment shall be pro-rated in the first and last Calendar Quarters of the Research Term. For purpose of clarity, during the period of time from the Effective Date through the end of 2011, such
quarterly payment shall be equal to <B>***</B>. Together with each Invoice, MacroGenics shall provide supporting documentation certified by MacroGenic&#146;s chief financial officer for the purpose of verifying the calculation of the FTE charges
paid by BI, for the previous Calendar Quarter. In the event that MacroGenics provides <B>***</B> in a Calendar Quarter to perform activities under the Research Plans, then following the end of such Calendar Quarter MacroGenics shall provide a
written Invoice for such additional </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
FTEs together with supporting documentation certified by MacroGenics&#146; chief financial officer for the purpose of verifying the calculation of FTEs to be charged to and paid by BI. BI shall
pay such Invoiced amounts within thirty (30)&nbsp;days after receipt of the respective Invoice after each Calendar Quarter. In case that the supporting documentation shows that BI has overpaid the FTE payments for such Calendar Quarter, MacroGenics
will, together with the supporting documentation, send BI a credit note for the amount overpaid, upon which BI may credit the amount overpaid against any FTE payments due by BI, or in case no further FTE payments are due by BI, MacroGenics will
within thirty (30)&nbsp;days refund the amount overpaid to BI. Notwithstanding the foregoing, BI shall not be entitled to a credit for any such overpayment in the event that such overpayment is a result of BI modifying any of the then current
Research Plans to require <B>***</B> MacroGenics FTEs in the aggregate, <U>provided</U> that MacroGenics had the capacity and was willing to commit the number of FTEs required under the original Research Plan. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) <U>Additional MacroGenics FTEs</U>. In the event that BI requests, and MacroGenics agrees to provide, <B>***</B> to
perform activities under the Research Plans, the number of FTEs set forth in subclause (ii)&nbsp;above shall be increased to account for such additional FTEs and BI shall reimburse MacroGenics its FTE Costs for such additional FTEs in accordance
with subclause (ii)&nbsp;above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Development Milestone Payments</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Development Milestone Payments</U>. BI shall pay to MacroGenics the following non-refundable, non-creditable milestone payments
with respect to the <B>***</B> Collaboration DART or Product in the each Program, as applicable, upon the *** occurrence of the applicable milestone event by such Collaboration DART or Product in each Program. In the event <B>***</B> Product is
developed in the same Program which is not a Replacement Product, then the development and sales milestone payments set forth in Sections 6.4(a)(ii&#151;xi) and 6.5(a)(i &#150; iii), respectively shall be reduced by<B>***</B> for such additional
Product achieving each specified milestone event. <B>***</B> Notwithstanding the foregoing, if (x)&nbsp;Development of a Product in a Program is terminated after milestone payment(s) have been made with respect to such Product; and (y)&nbsp;a
different Product in such Program is selected to replace the terminated Product (&#147;<U>Replacement Product</U>&#148;), then there shall be <B>***</B> due upon achievement of the same milestones by such Replacement Product for which MacroGenics
already received a milestone payment for the original Product. For the purposes of this Section&nbsp;6.4 and Section&nbsp;6.5, a Product in a Program shall be different from another Product in such Program ***. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If the milestone set forth in Section&nbsp;6.4(a)(ii) is achieved with respect to the <B>***</B>
Product in a Program prior to the achievement of the milestone set forth in Section&nbsp;6.4(a)(i) for such Product, then the milestone payment set forth in Section&nbsp;6.4(a)(i) shall be due and payable simultaneously with the payment of the later
milestone event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If any milestone set forth in Section&nbsp;6.4(a)(iii) is achieved with respect to the <B>***</B>
Product in a Program prior to the achievement of the milestone set forth in Section&nbsp;6.4(a)(i) or (ii)&nbsp;for such Product, then (x)&nbsp;with respect to the <B>***</B> such Product the milestone payments set forth in Section&nbsp;6.4(a)(i)
and/or (ii)&nbsp;and (y)&nbsp;with respect to the <B>***</B> such Product the milestone payment set forth in Section&nbsp;6.4(a)(ii) shall be due and payable simultaneously with the payment for achievement of the later milestone event. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Payment of Milestones</U>. BI shall provide written notice to MacroGenics of the achievement of any milestone event set forth in
Section <B>***</B> after the occurrence of such milestone event and shall make the corresponding milestone payment within thirty (30)&nbsp;days after receipt of an Invoice therefor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5 <U>Sales Milestone Payments</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Sales Milestone Payments</U>. BI shall make the non-refundable, non-creditable payments to MacroGenics set forth below upon the earliest achievement of each of the corresponding milestone events by
the *** Product within each Program to achieve such milestone: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) First occurrence of aggregate worldwide Net Sales of the Product of greater than*** in a Calendar Year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) First occurrence of aggregate worldwide Net Sales of the Product of greater than *** in a Calendar Year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) First occurrence of aggregate worldwide Net Sales of the Product of greater than *** in a Calendar Year</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Payment of Milestones</U>. BI shall make the milestone payments required by Section&nbsp;6.5(a)
in accordance with Section&nbsp;6.7. For purposes of clarity, more than one of the sales milestone payments may be earned concurrently based on the same Net Sales of the applicable Product. <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6 <U>Royalties</U>. On a Product-by-Product basis, BI shall pay to MacroGenics royalties on the worldwide Net Sales as provided in this
Section&nbsp;6.6: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Royalty Rate</U>. BI shall pay MacroGenics royalties on Net Sales of Products at the following
rates *** with respect *** achieved during the applicable Calendar Year: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:95pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Annual Net Sales Threshold</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:44pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Royalty Rate</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) On the first *** in Annual Net Sales</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) On that portion of Annual Net Sales greater than *** but less than ***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) On that portion of Annual Net Sales greater than ***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Royalty Term</U>. BI&#146;s royalty obligations to MacroGenics under this Section&nbsp;6.6 shall
expire on a country-by-country and Product-by-Product basis on the later of: (i)&nbsp;<B>***</B>or (ii)&nbsp;<B>***</B> (the &#147;<U>Royalty Term</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Royalty Adjustments</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Non Patented Product</U>. In the event a
Product is sold in a country and the composition of matter of the Product, or the use of such Product for an indication for which it has received Regulatory Approval and has been commercialized in such country is not covered by a Valid Claim within
MacroGenics Patent Rights, Joint Patent Rights and/or Collaboration DART Patent Rights in such country, then the royalty rate for such Product in such country shall be reduced by <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Generic Competition</U>. In the event that a Product faces Generic Competition in a particular country of the Territory, the
applicable royalty rate for such country for such Product shall be reduced to by <B>***</B> during the applicable Calendar Quarter in which such Generic Competition exists. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) <U>Third Party Offset</U>. If BI determines in good faith that, in order to avoid
infringement of any Patent Right not licensed hereunder that Covers a Collaboration DART or Product, it is reasonably necessary to obtain a license from a Third Party in order to Develop, Commercialize, make, have made, use, offer for sale, sell or
import such Collaboration DART or Product in a country in the Territory and to pay a royalty or other consideration under such license (including in connection with the settlement of a patent infringement claim), then (A)&nbsp;the royalty payments
due under Article VI with respect to Net Sales for such Product in such country shall be reduced by <B>***</B> of the amount payable by BI to such Third Party that are reasonably and appropriately allocable to the Collaboration DART or Product in
such country, and/or (B)&nbsp;the milestone Payments due under Section&nbsp;6.4(a)(iv-xi) and Section&nbsp;6.5 with respect to the respective milestone payment for such Product if the Product is the <B>***</B> Product in a Program for which
milestones are due shall be reduced by <B>***</B> of the amount payable by BI to such Third Party that are reasonably and appropriately allocable to the Collaboration DART or Product, <U>provided</U>, <U>however</U>, that (1)&nbsp;BI shall not be
<B>***</B> related to a Collaboration DART or Product to a Third Party that occur prior to <B>***</B> for the relevant Collaboration DART or Product; and (2)&nbsp;in no event shall the aggregate deductions under this Section&nbsp;6.6(c) reduce the
royalty rate paid by BI in respect of Net Sales of such Product pursuant to Section&nbsp;6.6(a) to less than <B>***</B> and with respect to the milestone payments due under <B>***</B> and Section&nbsp;6.5 more than <B>***</B> for such <B>***</B>
Product in a Program. For purposes of clarity, milestone payments which are due for the <B>***</B> Product in a Program that is not a Replacement Product shall not be subject to any offset under this Section&nbsp;6.6(c)(iii). BI shall be entitled to
accumulate amounts permitted to be deducted in a prior period, but not deducted on account of such minimum royalty percentage, and deduct such amounts in a future period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) <U>No Further Deductions</U>. Except as expressly provided in this Section&nbsp;6.6, there shall not be any offsets to or deductions from the royalties payable pursuant to this Section&nbsp;6.6.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.7 <U>Reports; Payments</U>. Within <B>***</B> after the end of each Calendar Quarter during which there are Net Sales
giving rise to a payment obligation under Section&nbsp;6.5 or 6.6, BI shall submit to MacroGenics a report identifying for each Product, the Net Sales for such Product for each country for such Calendar Quarter, the calculation of royalties
(including gross sales and all deductions taken from gross sales), and the royalties and the sales milestones payable to MacroGenics. Concurrently with each such report, BI shall pay to MacroGenics all royalties and sales milestones payable by it
under Sections&nbsp;6.5 and 6.6. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.8 <U>Books and Records; Audit Rights</U>. Each Party (the &#147;<U>Audited
Party</U>&#148;) shall keep (and, in the case of BI, shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the
&#147;<U>Auditing Party</U>&#148;) to determine the payments due and costs incurred under this Agreement. Each Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of
nationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, review any such records of the Audited Party in the location(s) where such records are maintained by the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Audited Party upon reasonable notice (which shall be no less than *** prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying
the accuracy of the amounts paid under this Agreement within a *** period preceding the date of the request for review. The report of such accounting firm shall be limited to a certificate stating whether any report made or invoice or payment
submitted by the Audited Party during such period is accurate or inaccurate and the actual amounts of Clinical Development Costs, FTE Costs, MacroGenics out-of-pocket expenses under Section&nbsp;6.3(b)(i), and any payments under Section&nbsp;3.7,
and the amount of any Net Sales, milestone or royalty discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such
inspection lead to the discovery of a discrepancy to the Auditing Party&#146;s detriment, the Audited Party shall pay the amount of the discrepancy within *** after its receipt from the accounting firm of the certificate showing the amount of the
discrepancy. The Auditing Party shall pay the full cost of the review unless the underpayment of milestones, royalties, FTE Costs, MacroGenics out-of-pocket expenses under Section&nbsp;6.3(b)(i) and/or Clinical Development Costs is greater than
<B>***</B> of the amount due for the applicable period, in which case the Audited Party shall pay the reasonable costs charged by such accounting firm for such review. Any overpayment of royalties by BI revealed by an inspection shall be
fully-creditable against future royalty payments under Section&nbsp;6.6. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.9 <U>Taxes</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If Laws require withholding by BI of any taxes imposed upon MacroGenics on account of any royalties and/or payments, paid under this
Agreement, such taxes shall be deducted by BI as required by Law from such remittable royalty and/or payment and shall be paid by BI to the proper tax authorities. Official receipts of payment of any withholding tax shall be secured and sent to
MacroGenics as evidence of such payment. The Parties shall exercise their best efforts to ensure that any withholding taxes imposed are reduced as far as possible under the provisions of any relevant tax treaty. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.10 <U>United States Dollars</U>. All dollar ($)&nbsp;amounts specified in this Agreement are United States dollar amounts. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.11 <U>Payment Method and Currency Conversion</U>. Except as otherwise provided herein, all payments due to a Party hereunder shall be
due and payable within *** after receipt of an invoice from the other Party and shall be paid via a bank wire transfer to such bank account as such Party shall designate. For the purposes of determining the amount of any sales milestone payment
under Section&nbsp;6.5 or royalties due for the relevant Calendar Quarter under Section&nbsp;6.6, the amount of Net Sales in any foreign currency shall be converted into United States dollars in accordance with the normal business practice of BI. In
accordance with BI&#146;s normal business practice, when Products are sold for monies other than Euro, the earned royalties in such countries will be determined by (a)&nbsp;converting the Net Sales in each country in the Territory into Euro, using
the monthly exchange rates as customarily used by BI in its regular accounting system (as of the Effective Date, using the monthly exchange rates published by the European Central Bank (ECB) in Frankfurt/Main, Germany) and (b)&nbsp;calculating the
respective royalty payments per country based on the respective Euro values. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.12 <U>Blocked Payments</U>. If by reason of applicable Laws in any country in the
Territory, it becomes impossible or illegal for BI or its Affiliates or Sublicensees to transfer, or have transferred on its behalf, milestones, royalties or other payments to MacroGenics, BI shall promptly notify MacroGenics of the conditions
preventing such transfer and such royalties or other payments shall be deposited in local currency in the relevant country to the credit of MacroGenics in a recognized banking institution with a good creditworthiness designated by MacroGenics or, if
none is designated by MacroGenics within thirty (30)&nbsp;days, in a recognized banking institution selected by BI or its Affiliate or Sublicensee, as the case may be, and identified in a written notice given to MacroGenics. If so deposited in a
foreign country, BI shall provide, or cause its Affiliate or Sublicensee to provide, reasonable cooperation to MacroGenics so as to allow MacroGenics to assume control over such deposit as promptly as practicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.13 <U>Late Payments</U>. Payments not made within *** after the due dates pursuant to the terms of this Agreement, shall bear interest
at a rate of the *** U.S. dollar LIBOR rate effective for the date that payment was due (as published in <U>The Wall Street Journal</U>, Eastern Edition) *** annum, Calculation of interest will be made for the exact number of days the payment was
past due based on a year of 360 days (actual/360). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VII </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>PATENTS </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Ownership</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Each Party shall exclusively own all Know-How and
Inventions, invented solely by employees, agents and consultants of such Party or its Affiliates, and any Patent Rights related thereto subject to the licenses granted under ARTICLE V and except as set forth in Section&nbsp;7.1(b). Inventions
invented jointly by employees, agents, or consultants of the Parties or their Affiliates (&#147;<U>Joint Intellectual Property</U>&#148; and any Patent Rights included in such Joint Intellectual Property, &#147;<U>Joint Patent Rights</U>&#148; and
any Know-How included in such Joint Intellectual Property, &#147;<U>Joint Know-How</U>&#148;) shall be Jointly Owned, subject to the licenses granted under ARTICLE V. Inventorship shall be determined in accordance with U.S. patent Laws for purposes
of determining ownership in accordance with the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Notwithstanding Section&nbsp;7.1(a), Collaboration DART
Patent Rights regardless of the inventorship shall be Jointly Owned by the Parties, subject to the licenses granted under ARTICLE V and (i)&nbsp;MacroGenics hereby assigns to BI a <B>***</B> undivided interest in any such Collaboration DART Patent
Right that is solely owned by MacroGenics and (ii)&nbsp;BI hereby assigns to MacroGenics a <B>***</B> undivided interest in any such Collaboration DART Patent Right that is solely owned by BI. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Except as expressly provided in this Agreement, and subject to any restrictions herein (including the licenses granted under ARTICLE
V), with respect to Joint Intellectual Property (other than Collaboration DART Patent Rights), each joint owner may assign, license, sell or otherwise encumber or transfer any such interest without the prior written approval of the other Party and
without obligation to account or provide compensation to the other Party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) With respect to Collaboration DART Patent Rights, (i)&nbsp;each joint owner may only
assign, license, sell or otherwise encumber or transfer any such interest *** of the other Party, subject to Section&nbsp;5.4, which shall not be unreasonably withheld; <U>provided</U>, <U>however</U>, (ii)&nbsp;that either Party may, ***, assign
its interest in such Collaboration DART Patent Rights, in whole or in part, to any of ***; <U>provided further</U> that such Affiliate agrees to be bound by the obligations hereunder with respect to such Collaboration DART Patent Rights and the
assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned. Any such *** assignment, license or other disposition under (i)&nbsp;or (ii)&nbsp;of such Collaboration DART Patent Rights shall
at all times be and remain subject to the rights granted and accompanying conditions and obligations with respect thereto under this Agreement. ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>BI Prosecution and Maintenance of Patent Rights</U>. Subject to Section&nbsp;7.4, BI shall be responsible for the Prosecution and Maintenance of the BI Patent Rights, including any related
interference, opposition, re-examination, re-issue, revocation or any official proceeding involving patents and patent applications, at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>MacroGenics Prosecution and Maintenance of Patent Rights</U>. Subject to Section&nbsp;7.4 MacroGenics shall be responsible for the Prosecution and Maintenance of the MacroGenics Patent Rights,
including any related interference, opposition, re-examination, re-issue, revocation or any official proceeding involving patents and patent applications, at its sole expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.4 <U>Prosecution and Maintenance of Joint Patent Rights and Collaboration DART Patent Rights</U>. The Prosecution and Maintenance of any Joint Patent Right and/or Collaboration DART Patent Right shall
be through a mutually selected U.S. patent counsel. Within sixty (60)&nbsp;days following the Effective Date, the Parties shall agree on a patent counsel (&#147;<U>Joint Counsel</U>&#148;) who shall be engaged by both Parties for the Prosecution and
Maintenance of all Collaboration DART Patent Rights and Joint Patent Rights (the &#147;<U>Joint Counsel Patent Rights</U>&#148;). The following terms shall apply to each Joint Counsel Patent Right: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Joint Counsel shall give BI and MacroGenics (or each Party&#146;s designee) an opportunity to review the text of each application,
office action response or other substantive document for a Joint Counsel Patent Right before filing with any patent office in the Territory, shall incorporate BI&#146;s and MacroGenics&#146; (or each Party&#146;s designee) reasonable comments with
respect thereto, and shall supply BI and MacroGenics (or each party&#146;s designee) with a copy of each such application, office action response or other substantive document as filed, together with notice of its filing date and serial number. In
the event that MacroGenics and BI provide Joint Counsel with conflicting instructions regarding filing, prosecuting and maintaining a Joint Counsel Patent Right, Joint Counsel shall make the Parties aware of such conflicting instructions and, if the
Parties are not able to resolve such conflict within a reasonable time prior to the applicable filing deadline, the Joint Counsel shall take such action as would reasonably expected to maximize the scope, extent and coverage of such Joint Counsel
Patent Right. For any Collaboration DART Patent Right that claims an invention which was solely invented by MacroGenics and Covers improvements to the DART Platform not specifically related to the <B>***</B> shall become solely owned by MacroGenics
(and BI shall and hereby does assign all right, title, and interest it has in such Collaboration DART Patent Right to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics) and become a MacroGenics Patent Right subject to the licenses granted under ARTICLE V. For any Collaboration DART Patent Right that claims an invention which was solely invented by
BI and Covers *** such Collaboration DART Patent Right shall become solely owned by BI (and MacroGenics shall and hereby does assign all right title and interest it has in such Collaboration DART Patent Right to BI) and become a BI Patent Right. In
the event that such Collaboration DART Patent Right becomes a MacroGenics Patent Right or a BI Patent Right, the Parties shall cooperate with each other to (1)&nbsp;amend the MacroGenics Patent Right or a BI Patent Right to delete any claims
Covering the Collaboration DART or its method of use or method of manufacture, and (2)&nbsp;file, prosecute and maintain a divisional or continuation application of said Collaboration DART Patent Right having claims Covering the Collaboration DART
or its method of use or method of manufacture and which will remain a Collaboration DART Patent Right Jointly Owned by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Both Parties shall cooperate with Joint Counsel in Prosecution and Maintenance of patent applications for Joint Counsel Patent Rights, including providing Joint Counsel with data and other information
as appropriate with respect thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Joint Counsel shall keep BI and MacroGenics advised of the status of the
Prosecution and Maintenance of Joint Counsel Patent Rights, including actual and prospective patent filings for Joint Counsel Patent Rights and shall provide each Party with advance copies of any papers related thereto. Joint Counsel shall promptly
give notice to BI and MacroGenics of the grant, lapse, revocation, surrender, invalidation, or abandonment of any Joint Counsel Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) The Parties shall <B>***</B> charged by Joint Counsel with respect to the Prosecution and Maintenance of Joint Counsel Patent Rights and all other mutually agreed and approved out-of-pocket costs and
expenses incurred by either Party in connection with such Prosecution and Maintenance of Joint Counsel Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)
Should BI decide that it does not wish to continue paying for the Prosecution and Maintenance of a particular Joint Counsel Patent Right, BI shall notify MacroGenics and Joint Counsel at least <B>***</B>in advance of the next deadline and shall
allow MacroGenics to assume responsibility for such Prosecution and Maintenance payments incurred after <B>***</B> after receipt of BI&#146;s notice. If MacroGenics assumes such responsibility, then: (i)&nbsp;MacroGenics may designate any counsel of
its choice to handle the Prosecution and Maintenance of such Joint Counsel Patent Right and it shall cease to be part of the Joint Counsel Patent Rights and no further royalty obligations shall exist under this Agreement with respect thereto,
(ii)&nbsp;BI shall lose its licenses to such Joint Counsel Patent Right under ARTICLE V and the covenant not to sue under Section&nbsp;5.5 shall not apply with respect to such Joint Counsel Patent Right, and (iii)&nbsp;BI shall and hereby does
transfer and assign all right, title and interest in said Joint Counsel Patent Right to MacroGenics as the sole owner. If MacroGenics decides not to assume such responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and
Maintenance of such Collaboration DART Patent Right and/or Joint Patent Right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) Should MacroGenics decide that it does
not wish to continue paying for the Prosecution and Maintenance of a particular Joint Counsel Patent Right, MacroGenics shall notify BI and Joint Counsel at least <B>***</B> in advance of the next deadline and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall allow BI to assume responsibility for such Prosecution and Maintenance payments incurred after ***after receipt of MacroGenics&#146; notice. If BI assumes such responsibility, then:
(i)&nbsp;BI may designate any counsel of its choice to handle the Prosecution and Maintenance of such Joint Counsel Patent Right and it shall no longer be considered a Joint Patent Right or Collaboration DART Patent Right, as applicable,
(ii)&nbsp;such Joint Counsel Patent Right shall be deemed a BI Patent Right; and (iii)&nbsp;MacroGenics shall and hereby does transfer and assign all right, title and interest in said Joint Counsel Patent Right to BI as the sole owner. If BI decides
not to assume such responsibility, then it shall instruct Joint Counsel to abandon the Prosecution and Maintenance of such Joint Counsel Patent Right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.5 <U>Third Party Infringement</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Notice</U>. Each Party shall
promptly report in writing to the other Party any known or suspected (i)&nbsp;infringement of any of the MacroGenics Patent Rights, BI Patent Rights, Joint Patent Rights, or Collaboration DART Patent Rights, or (ii)&nbsp;unauthorized use or
misappropriation of any of the MacroGenics Know-How, BI Know-How, Joint Know-How or Collaboration DART Know-How of which such Party becomes aware, and shall provide the other Party with all available evidence regarding such known or suspected
infringement or unauthorized use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Initial Right to Enforce</U>. Subject to Section&nbsp;7.5(c), BI shall have the
first right, but not the obligation, to initiate a lawsuit or take other reasonable action to (i)&nbsp;enforce the Joint Patent Rights and Collaboration DART Patent Rights and (ii)&nbsp;enforce the MacroGenics Patent Rights solely with respect to an
infringement by a Third Party infringing the relevant MacroGenics Patent Rights by making, using or selling a product that competes with a Product. Notwithstanding the foregoing sentence, BI shall not initiate any such lawsuit or other enforcement
action asserting any such MacroGenics Patent Rights, Joint Patent Rights or Collaboration DART Patent Rights without first consulting with MacroGenics and giving good faith consideration to any reasonable objection from MacroGenics regarding
BI&#146;s proposed course of action. MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by BI, including joining any action as party-plaintiff at BI&#146;s sole discretion; <U>provided </U>that BI shall
promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) agreed by BI in advance and actually incurred by MacroGenics in connection with such cooperation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Step-In Right</U>. If BI does not initiate a lawsuit or take other reasonable action pursuant to Section&nbsp;7.5(b) with respect
to any MacroGenics Patent Rights, Joint Patent Rights or Collaboration DART Patent Rights, then MacroGenics shall have the right (in cases where MacroGenics has standing), but not the obligation, to initiate such lawsuit or take such other action,
<B>***</B> and giving good faith consideration to BI&#146;s reason(s) for not initiating a lawsuit or taking other action. For this purpose, BI shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics, including
joining any action as party-plaintiff at BI&#146;s sole discretion; <U>provided </U>that MacroGenics shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) agreed by MacroGenics in advance and actually
incurred by BI in connection with such cooperation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Conduct of Certain Actions; Costs.</U> The Party initiating legal action shall have
the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section&nbsp;7.5(b) or 7.5(c) (the &#147;<U>Initiating Party</U>&#148;). The Initiating Party shall bear its own out-of-pocket costs incurred in any such legal
action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action (in cases where such other Party has standing) by its own counsel at its own
expense. The Initiating Party shall have the final say about the strategy and decisions in the suit and any settlement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)
<U>Recoveries</U>. Any amounts recovered in any action or settlement of any such action shall be allocated first to *** incurred in such action and any reward remaining shall be allocated to the Initiating Party; <U>provided</U> that if BI is the
Initiating Party, with respect to any remaining portion of such recovery, MacroGenics shall receive either (i)&nbsp;***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f)
<U>Section on Patent Disputes under U.S. Biologics Price Competition and Innovation Act of 2009</U>. Each Party shall immediately give written notice to the other Party of any notice received from a Third Party of an application for FDA approval
under the U.S. Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) for a biosimilar biologic product referencing a Product or any certification under a similar statutory or regulatory requirement in
any non-United States country in the Territory claiming that a Collaboration DART Patent Right, Joint Patent Right or MacroGenics Patent Right covering any Product is invalid or unenforceable or that infringement will not arise from the Development,
manufacture or Commercialization of a proposed biosimilar biologic product by a Third Party. Upon the giving or receipt of such notice, BI shall have the first right, but not the obligation, to bring an infringement action against such Third Party
in connection with such certification. In the case of a MacroGenics Patent Right, Joint Patent Right or Collaboration DART Patent Right, BI shall notify MacroGenics in writing of its intent to exercise, or not exercise, this right at least
<B>***</B> prior to the date set forth by statute or regulation for the patent owner to take its initial action in such proceedings. MacroGenics shall have the right to initiate such an action if BI provides written notice of its intent not to
exercise such right or fails to provide any notice of intent at least <B>***</B> prior to the date set forth by statute or regulation for the patent owner to take its initial action in such proceedings. The non-Initiating Party in any such action
shall cooperate with the Initiating Party in accordance with Sections 7.5(b) and (c), as applicable. All other prelitigation, litigation, settlement, costs, and recovery matters in a patent dispute under the U.S. Biologics Price Competition and
Innovation Act of 2009 or any certification under a similar statutory or regulatory requirement in any non-United States country in the Territory shall additionally be governed by the provisions of Section&nbsp;7.5(a) to 7.5(e) for Third Party
Infringement generally. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6 <U>Patent Invalidity Claim</U>. Each Party shall promptly notify the other in the event of any
legal or administrative action by any Third Party against a MacroGenics Patent Right, BI Patent Right, Joint Patent Right or Collaboration DART Patent Right of which it becomes aware, including any nullity, revocation, reexamination or compulsory
license proceeding. BI shall have the first right, but not the obligation, at its expense, to defend against any such action relating to the BI Patent Rights, Joint Patent Rights and/or Collaboration DART Patent Rights. If BI does not defend against
any such action involving a Joint Patent Right and/or Collaboration DART Patent Right, then MacroGenics shall have the right, but not the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
obligation, to defend such action at MacroGenics&#146; expense. MacroGenics shall have the first right, but not the obligation, at its expense, to defend against any such action relating to the
MacroGenics Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7 <U>Patent Term Extensions</U>. BI shall have full and exclusive right to determine and control
all filings of requests for any patent term extensions or supplemental patent certificates or their equivalents in any country in the Territory for any Joint Patent Right, Collaboration DART Patent Right and BI Patent Right, and all costs and
expenses relating thereto shall be paid by BI. MacroGenics shall have full and exclusive right to determine and control all filings of requests for any patent term extensions or supplemental patent certificates or their equivalents in any country in
the Territory for any MacroGenics Patent Right and all costs and expenses relating thereto shall be paid by MacroGenics. The Parties shall reasonably cooperate with each other in obtaining patent term extensions or supplemental protection
certificates or their equivalents in any country in the Territory, where applicable to MacroGenics Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.8
<U>Patent Marking</U>. BI shall mark Products sold by BI, its Affiliates and/or Sublicensees in such countries and to such extent where BI and MacroGenics mutually agree and as otherwise required to comply with patent marking statutes in the
applicable country. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE VIII </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>CONFIDENTIALITY AND PUBLICATION </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>Nondisclosure
Obligation</U>. The Parties agree that during the Term, and for a period of <B>***</B> thereafter, a Party receiving Confidential Information of the other Party shall (a)&nbsp;maintain in confidence such Confidential Information to the same extent
such Party maintains its own confidential information, (b)&nbsp;not disclose such Confidential Information to any Third Party without the prior written consent of the other Party, and (c)&nbsp;not use such Confidential Information for any purpose
except those permitted by this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Authorized Disclosure</U>. Notwithstanding Section&nbsp;8.1, a Party may
disclose Confidential Information of the other Party to the extent such disclosure is reasonably necessary in the following instances: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Prosecuting and Maintaining Patent Rights; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) filings with Regulatory
Authorities; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) complying with applicable Laws and/or submitting information to tax or other Governmental Authorities;
<U>provided</U> that if the receiving Party is required by Law to make any public disclosures of Confidential Information of the disclosing Party, to the extent it may legally do so, it will give reasonable advance notice to the disclosing Party of
such disclosure and will use its reasonable efforts to secure confidential treatment of such Confidential Information prior to its disclosure (whether through protective orders or otherwise); </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) to its Affiliates, and to prospective and actual acquirers, licensees, Sublicensees, employees, consultants, agents, accountants,
lawyers, advisors and investors, on a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
need to know basis, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use equivalent in scope to those set forth in this ARTICLE VIII and that are
of reasonable duration in view of the circumstances of the disclosure; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) to the extent mutually agreed to in writing
by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>Scientific Publications</U>. During the Research Term, neither Party shall first publish or first
present in a public forum the scientific or technical results of any activities performed pursuant to this Agreement without the opportunity for prior review and comment by the other Party. Each Party agrees to provide the other Party with the
opportunity to review any proposed abstracts, manuscripts or scientific presentations (including verbal presentations) which relate to its activities performed pursuant to this Agreement at least <B>***</B> prior to its intended submission for
publication and agrees, upon request, not to submit any such abstract or manuscript for publication until the other Party is given a reasonable period of time <B>***</B> secure patent protection for any material in such publication which it believes
to be patentable. Both Parties understand that a reasonable commercial strategy may require delay of publication of information or filing of patent applications first. The Parties agree to review and decide whether to delay publication to permit
filing of patent applications. Neither Party shall have the right to publish or present Confidential Information of the other Party. Nothing contained in this Section&nbsp;8.3 shall prohibit the inclusion of information necessary for a patent
application, provided that the non-filing Party is given a reasonable opportunity to review the information to be included prior to submission of such patent application. For avoidance of doubt any publication shall be consistent with BI&#146;s
internal publication strategy. After the Research Term, BI and its Affiliates may publish or present any results, data or scientific findings of any activities performed pursuant to this Agreement without the prior review of MacroGenics. After the
Research Term, neither MacroGenics nor its Affiliates may publish or present any results, data or scientific findings of any activities performed pursuant to this Agreement without prior review and prior written consent of BI. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4 <U>Press Releases and Other Permitted Disclosures</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics and BI each agree not to disclose any terms and conditions of this Agreement to any Third Party, except as described below in this Section&nbsp;8.4. The press release announcing the
collaboration contemplated by this Agreement is set forth in <U>Schedule 8.4</U>, and the Parties will cooperate in the release thereof as soon as practicable after the Effective Date. Subject to the other provisions of this Agreement, no other
press release, public statement or disclosure concerning the existence or terms of this Agreement shall be made, either directly or indirectly, by either Party, without first obtaining the written approval of the other Party, which such approval
shall not be unreasonably withheld or delayed <B>***</B> following submission to the approving Party of a draft of the respective press release, public statement or disclosure. In no event shall such subsequent press releases, public statements or
disclosures by MacroGenics disclose, if previously undisclosed, ***; <U>provided</U> that MacroGenics may disclose the receipt of any milestone event but not the actual amount of such milestone payment under this Agreement. Once any public statement
or disclosure has been approved in accordance with this Section&nbsp;8.4, then either Party may appropriately communicate information contained in such permitted statement or disclosure. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Either Party may disclose the existence and terms of this Agreement in confidence:
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) (A) to its attorneys, professional accountants, and auditors, and (B)&nbsp;bankers or other financial
advisors in connection with an initial public offering, private financing or other strategic transaction, or corporate valuation for internal purposes; <U>provided</U> that any such disclosure to such professional accountants, auditors, bankers or
other financial advisors is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and to use such information solely for the applicable purpose permitted pursuant to this
Section&nbsp;8.4(b)(i); </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) to potential acquirers (and their respective attorneys and professional
advisors), in connection with a potential merger, acquisition or reorganization; <U>provided that</U> (A)&nbsp;the Party making the disclosure has a bona fide offer (e.g., a signed letter of intent) from such Third Party for such a transaction, and
(B)&nbsp;such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and to use such information solely for the purpose permitted pursuant to this
Section&nbsp;8.4(b)(ii); </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) to existing or potential investors, lenders or permitted assignees of such
Party (and their respective attorneys and professional advisors); <U>provided that</U> such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement; and
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) to potential licensees or sublicensees or potential acquirors of such Party (and their respective
attorneys and professional advisors); <U>provided that</U><B> ***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Notwithstanding the foregoing provisions of this
ARTICLE VIII, a Party may disclose the existence and terms of this Agreement, however excluding, as far as legally possible, Schedules 1.5, 1.47, 1.77, and 1.81, or a Party&#146;s or the Parties&#146; activities under this Agreement where required,
as reasonably determined by the legal counsel of the disclosing Party, by applicable Law, by applicable stock exchange regulation or by order or other ruling of a competent court, although, to the extent practicable, the other Party shall be given
<B>***</B> notice of any such legally required disclosure to comment and reasonably consider such comments provided by such Party on the proposed disclosure. To the Parties&#146; common understanding, in case that either Party is obliged to publish
the Agreement as &#147;material agreement&#148; in accordance with the U.S. stock exchange regulations (&#147;<U>SEC Filing</U>&#148;), the Agreement shall be redacted by the filing Party as far as legally possible, and the filing Party shall
cooperate with the other Party reasonably in advance to such SEC Filing to enable the other Party to review and comment on the scope of such redaction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE IX <U> </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>REPRESENTATIONS AND WARRANTIES; INDEMNIFICATION </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Representations and Warranties of the Parties</U>. BI and MacroGenics each represent, warrant and covenant to the other that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) as of the Effective Date it has the authority and right to enter into and perform this Agreement and grant the rights embodied
herein, and it is not aware of any legal impediment that could inhibit its ability to perform its obligations under this Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) as of the Effective Date its execution, delivery and performance of this Agreement does not conflict with, or constitute a breach of, any order, judgment, agreement or instrument to which it is a
party or is otherwise bound; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) it shall comply in all material respects with all Laws applicable to its actions under this
Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) as of the Effective Date no consent of any Third Party is required for such Party to grant the licenses and
rights granted to the other Party under this Agreement or to perform its obligations hereunder; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) all of such Party&#146;s
personnel and employees, and Third Parties, including agents and consultants, hired by such Party and involved in each Program or in the research, Development, manufacture or Commercialization of Collaboration DARTs or Products are or will be under
a written obligation to assign to such Party any rights they may have in any Invention first invented, discovered, made, conceived and/or reduced to practice in the conduct of activities pursuant to the Programs or in the research, Development,
manufacture or Commercialization of any Collaboration DARTs or Product; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) it will not, after the Effective Date, enter
into any written or oral contractual obligation with a Third Party that would be inconsistent with the obligations that arise on its part out of this Agreement or that would deprive the other Party of the benefits of or rights granted under this
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>Representations and Warranties of MacroGenics</U>. MacroGenics represents, warrants and covenants to BI, as
of the Effective Date, that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics will use commercially reasonable efforts in the Prosecution and Maintenance of
the MacroGenics Patent Rights. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics has not previously assigned, transferred, conveyed or otherwise encumbered
its right, title and interest in MacroGenics Intellectual Property in a manner inconsistent with the terms hereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)
MacroGenics&#146; execution, delivery and performance of this Agreement does not conflict with, or constitute a breach of, any term or condition of any agreement to which MacroGenics is a party; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) except with respect to patent and patent applications licensed to MacroGenics,
MacroGenics is the legal and beneficial owner of the MacroGenics Patent Rights existing as of the Effective Date, free and clear of any liens, charges and encumbrances, and MacroGenics has valid and existing licenses to the MacroGenics Patent Rights
not owned by MacroGenics; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) except as previously disclosed in writing to BI, to MacroGenics&#146; knowledge, the
conception, development and reduction to practice of the MacroGenics Intellectual Property has not constituted or involved the misappropriation of trade secrets of any Third Party or the infringement of issued Patent Rights of any Third
Party;</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) except as previously disclosed in writing to BI, MacroGenics has not received any written notice of any
unauthorized use, infringement, misappropriation, or dilution by any person, including any current or former employee or consultant of MacroGenics, of any MacroGenics Intellectual Property; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) that there are no claims, judgments, settlements pending or, to the knowledge of MacroGenics, any threatened actions with respect,
to the extent licensed hereunder, to the MacroGenics Intellectual Property. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>No Other Warranties</U>. EXCEPT AS
OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND PARTICULARLY THAT PRODUCT(S) WILL BE SUCCESSFULLY DEVELOPED HEREUNDER, AND IF PRODUCT(S) ARE DEVELOPED,
WITH RESPECT TO SUCH PRODUCT(S), THE PARTIES DISCLAIM ALL IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.4 <U>Indemnification by BI</U>. BI shall indemnify, hold harmless and defend MacroGenics, its Affiliates and all of their respective officers, directors, employees, agents, licensors and shareholders
(collectively, the &#147;<U>MacroGenics Indemnitees</U>&#148;) from and against any and all losses, damages, liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense (including reasonable attorneys&#146; fees and
witness fees) resulting from any demand, claim, action or proceeding brought or initiated by a Third Party (each a &#147;<U>Third Party Claim</U>&#148;) against any MacroGenics Indemnitees(s) arising out of (a)&nbsp;a Default by BI; (b)&nbsp;the
gross negligence or willful misconduct of BI or its Affiliates; or (c)&nbsp;the conduct of any Program or use of Collaboration DART or Product by, on behalf of or under authority of, BI (except with respect to the conduct of such activities by a
MacroGenics Indemnitee); <U>provided</U> that (i)&nbsp;the MacroGenics Indemnitees shall comply with the procedures set forth in Section&nbsp;9.6; and (ii)&nbsp;such indemnity shall not apply to the extent such Third Party Claim is caused by the
negligence, willful misconduct or violation of Law by a MacroGenics Indemnitee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5 <U>Indemnification by MacroGenics</U>.
MacroGenics shall indemnify, hold harmless and defend BI, its Affiliates and all of their respective officers, directors, employees, agents, licensors and shareholders (collectively, the &#147;<U>BI Indemnitees</U>&#148;) from and against any and
all losses, damages, liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense (including reasonable attorneys&#146; fees and witness fees) resulting from any Third Party
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Claim against any BI Indemnitees(s) arising out of (a)&nbsp;a Default by MacroGenics; (b)&nbsp;the gross negligence or willful misconduct of MacroGenics or its Affiliates; or (c)&nbsp;the conduct
of any Program or use of Collaboration DART or Product by, on behalf of or under authority of (except with respect to the conduct of such activities by a BI Indemnitee), MacroGenics, <U>provided</U> that (i)&nbsp;the BI Indemnitees shall comply with
the procedures set forth in Section&nbsp;9.6; and (ii)&nbsp;such indemnity shall not apply to the extent such Third Party Claim is caused by the negligence, willful misconduct or violation of Law by a BI Indemnitee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6 <U>Procedure</U>. To be eligible for the MacroGenics Indemnitees to be indemnified hereunder, MacroGenics shall provide BI with
prompt notice of the Third Party Claim giving rise to the indemnification obligation under this ARTICLE IX and the exclusive ability to defend or settle any such claim; <U>provided</U> <U>however</U> that BI shall not enter into any settlement for
damages without MacroGenics&#146; prior written consent, such consent not to be unreasonably withheld, delayed or conditioned. MacroGenics shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any
claim or suit that has been assumed by BI. To be eligible for the BI Indemnitees to be indemnified hereunder, BI shall provide MacroGenics with prompt notice of the Third Party Claim giving rise to the indemnification obligation under this ARTICLE
IX and the exclusive ability to defend or settle any such claim; <U>provided</U> <U>however</U> that MacroGenics shall not enter into any settlement for damages without BI&#146;s prior written consent, such consent not to be unreasonably withheld,
delayed or conditioned. BI shall have the right to participate, at its own expense and with counsel of its choice, in the defense of any claim or suit that has been assumed by MacroGenics. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7 <U>Insurance</U>. BI shall procure and maintain insurance or self-insurance, including product liability insurance, adequate to cover
its obligations hereunder and which are consistent with normal business practices of prudent companies similarly situated, at all times during which any Product is being developed, clinically tested in human subjects or commercially distributed or
sold by or on behalf of BI, its Affiliates or Sublicensees. MacroGenics shall procure and maintain insurance or self-insurance, including product liability insurance, adequate to cover its obligations hereunder and which are consistent with normal
business practices of prudent companies similarly situated, at all times during which any Product is being developed, clinically tested in human subjects or commercially distributed or sold by or on behalf of MacroGenics, its Affiliates or
Sublicensees. It is understood that such insurance or self-insurance shall not be construed to create a limit of a Party&#146;s liability with respect to its indemnification obligations under this ARTICLE IX. Each Party shall provide the other Party
with written evidence of such insurance or self-insurance upon request. Each Party shall provide the other Party with written notice at least thirty (30)&nbsp;days prior to the cancellation, non renewal or material change in such insurance or
self-insurance which could adversely affect rights hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8 <U>No Consequential or Punitive Damages</U>. EXCEPT WITH
RESPECT TO (a)&nbsp;THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER THIS AGREEMENT WITH RESPECT TO THIRD PARTY CLAIMS; AND (b)&nbsp;A BREACH OF THE CONFIDENTIALITY OBLIGATIONS OF ARTICLE VIII, AND (c)&nbsp;A PARTY&#146;S WILLFULL
MISCONDUCT, NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE X </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><U>TERM AND TERMINATION </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Term and Expiration</U>. This
Agreement shall be effective as of the Effective Date and unless terminated earlier pursuant to Section&nbsp;10.2, this Agreement shall continue in effect *** hereunder (the &#147;<U>Term</U>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Termination</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Termination of Agreement for Cause</U>. This Agreement may be terminated at any time during the Term upon written notice by either Party (the &#147;<U>Non-Defaulting Party</U>&#148;) upon Default
of the other Party (the &#147;<U>Defaulting Party</U>&#148;), which Default remains uncured <B>***</B> written notice requesting cure of such Default. The Non-Defaulting Party shall provide written notice to the Defaulting Party, which notice shall
identify the Default, the intent to so terminate and the actions or conduct that it considers would be an acceptable cure of such Default. If the Defaulting Party disputes the Default under this Section&nbsp;10.2(a), then the issue of whether the
Non-Defaulting Party may properly terminate this Agreement on expiration of the applicable cure period shall be resolved in accordance with ARTICLE XI. If as a result of such dispute resolution process, it is determined that the alleged Defaulting
Party committed a Default and the Defaulting Party does not cure such Default within <B>***</B> after the date of such dispute resolution award (the &#147;<U>Additional Cure Period</U>&#148;), then such termination shall be effective as of the
expiration of the Additional Cure Period. If the Parties dispute whether such Default was so cured, either Party alone may request the same tribunal to determine whether it was so cured, and the Parties shall cooperate to allow such determination to
be made within <B>***</B> after such request by either Party. Such dispute resolution proceeding does not suspend any obligations of either Party hereunder, and each Party shall use reasonable efforts to mitigate any damage. If as a result of such
dispute resolution proceeding it is determined that the alleged Defaulting Party did not commit such Default (or such Default was cured in accordance with this Section&nbsp;10.2(a), the Additional Cure Period), then no termination shall be
effective, and this Agreement shall continue in full force and effect. Notwithstanding the foregoing, in case that MacroGenics was previously subject to a Change of Control, MacroGenics shall not have the right to terminate this Agreement for ***.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Termination With Respect to a Program</U>. BI may elect to terminate the research, Development and/or
Commercialization of any Program by providing MacroGenics with *** prior written notice and this Agreement shall terminate following such *** period solely with respect to the Program that is the subject of such termination notice; <U>provided</U>
that during the ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Termination if BI Challenges MacroGenics Patent Rights or Collaboration DART Patent Rights</U>.
If BI or any of its Affiliates or Sublicensees, directly or indirectly, (i)&nbsp;initiates or requests an interference or opposition proceeding with respect to any MacroGenics Patent Right or Collaboration DART Patent Right, (ii)&nbsp;makes, files
or maintains any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
claim, demand, lawsuit, or cause of action to challenge the validity or enforceability of any MacroGenics Patent Right or Collaboration DART Patent Right in a tribunal or forum, or
(iii)&nbsp;opposes any extension of, or the grant of a supplementary protection certificate with respect to, any MacroGenics Patent Right or Collaboration DART Patent Right, MacroGenics shall have the right to terminate this Agreement upon ***
written notice to BI. Any such termination shall only become effective if BI or its Affiliate or Sublicensee, as applicable, has not withdrawn such action before the end of the above notice period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Termination for Convenience</U>. <B>***</B> BI shall have the right to terminate this Agreement at any time in its sole
discretion by giving MacroGenics *** prior written notice; <U>provided</U> that *** invoiced prior to the effective date of such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) <U>Termination if MacroGenics Challenges Collaboration DART Patent Rights</U>. If MacroGenics or any of its Affiliates or Sublicensees, directly or indirectly, (i)&nbsp;initiates or requests an
interference or opposition proceeding with respect to any Collaboration DART Patent Right, (ii)&nbsp;makes, files or maintains any claim, demand, lawsuit, or cause of action to challenge the validity or enforceability of any Collaboration DART
Patent Right in a tribunal or forum, or (iii)&nbsp;opposes any extension of, or the grant of a supplementary protection certificate with respect to, any Collaboration DART Patent Right, BI shall have the right to terminate this Agreement upon
<B>***</B> written notice to MacroGenics. Any such termination shall only become effective if MacroGenics or its Affiliate or Sublicensee, as applicable, has not withdrawn such action before the end of the above notice period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <U>Effect of Termination on Licenses</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) If BI terminates this Agreement under Section&nbsp;10.2(a) or Section&nbsp;10.2(e): (i)&nbsp;BI&#146;s license pursuant to this Agreement, shall continue; <U>provided</U> <U>however</U> that BI shall
continue to fulfill BI&#146;s payment and/or royalty obligations as specified herein; and <U>provided</U> <U>further</U> BI may ***, as determined (A)&nbsp;in a final decision of the arbitrators in accordance with Section&nbsp;11.2 or a court of
competent jurisdiction, which decision is not appealable or has not been appealed within the time allowed for appeal, or (B)&nbsp;by the Parties in a settlement agreement; and (ii)&nbsp;MacroGenics shall, within <B>***</B> after the effective date
of such termination, return or cause to be returned to BI, copies of all BI Confidential Information and BI Intellectual Property and all Materials provided by BI, in each case with respect to any Terminated Product, except that MacroGenics may
retain one copy of the BI Confidential Information solely for legal archive purposes, (iii)&nbsp;BI shall be released of its ongoing disclosure and information exchange obligations under ARTICLES III and IV, (iv)&nbsp;the JSC and its subcommittees
shall not meet anymore, except to address matters relating to Patent Rights; and (v)&nbsp;MacroGencics&#146; co-promotion option stipulated under Section&nbsp;4.5 and the co-development option stipulated under Section&nbsp;4.4 shall terminate.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Upon termination of this Agreement in whole or with respect to a Terminated Product by BI under Section&nbsp;10.2(b) or
10.2(d) or by MacroGenics under Section&nbsp;10.2(a) or Section&nbsp;10.2(c), then: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) BI&#146;s licenses
pursuant to Section&nbsp;5.1 shall terminate as of the effective date of termination with respect to all Terminated Products; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the Collaboration Targets to which the Terminated Products are
Directed shall be deemed Terminated Targets; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) BI shall, within <B>***</B> after the effective date of
termination, return or cause to be returned to MacroGenics, copies of all MacroGenics Confidential Information and MacroGenics Intellectual Property and all Materials owned and provided by MacroGenics, in each case with respect to any Terminated
Product; except that BI may retain one copy of the MacroGenics Confidential Information solely for legal archive purposes; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) MacroGenics shall, within <B>***</B> after the effective date of termination, return or cause to be returned to BI, copies of all BI Confidential Information and BI Intellectual Property and all
Materials provided by BI, in each case with respect to any Terminated Product, except that (A)&nbsp;MacroGenics may retain one copy of the BI Confidential Information solely for legal archive purposes and (B)&nbsp;MacroGenics may retain such BI
Confidential Information, BI Intellectual Property and Materials solely to the extent necessary to research, Develop, make, have made, use, offer for sale, sell and import the Terminated Products in the Field in the Territory; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) At MacroGenics&#146; request within <B>***</B> after the effective date of termination, BI will either *** (the
choice of (A)&nbsp;or (B)&nbsp;being in BI&#146;s sole discretion), and (C)&nbsp;at MacroGenics&#146; request BI will grant to MacroGenics a non-exclusive, worldwide, license to BI Intellectual Property, including the regulatory documentation
defined in Section&nbsp;10.3(b)(ix) below, however excluding BI Biopharmaceutical Technology, solely to the extent that such licenses are necessary to research, Develop, make, have made, use, offer for sale, sell and import the Terminated Products
in the Field in the Territory. If MacroGenics has been *** pursuant to this Section&nbsp;10.3(b)(v)(A) or (B), MacroGenics shall pay to BI (i)&nbsp;<B>***</B> Notwithstanding the foregoing, if MacroGenics has been *** pursuant to
Section&nbsp;10.3(b)(v)(C) only and has not been *** under Section&nbsp;10.3(b)(v)(A) or (B), MacroGenics shall <B>***</B> a Product-by-Product basis, in each case in accordance with the applicable terms of ARTICLE VI (such as duration, adjustments,
reports, audits and the like); </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) For a period of <B>***</B>, BI and its Affiliates shall be entitled to
finish work in progress and to sell any Collaboration DART(s) and/or Products remaining in inventory in accordance with the terms of this Agreement. Such sales shall be subject to the royalty provisions of this Agreement. Thereafter, MacroGenics
shall have the option, exercisable within <B>***</B> following such <B>***</B> period, to obtain BI&#146;s inventory of Terminated Products at a *** for such inventory of Terminated Product to be ***. MacroGenics may exercise such option by written
notice to BI during such <B>***</B> period; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) In the event a Terminated Product has commenced <B>***</B>
before the effective date of termination, the Parties will negotiate in good faith an *** to MacroGenics of BI&#146;s and its Affiliates&#146; *** for the Terminated Products in the Field in the Territory) relating solely to the Terminated Product
and owned by BI; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii) BI shall, in exchange for commercially reasonable terms to be
negotiated in good faith between the Parties, use Commercially Reasonable Efforts to supply MacroGenics with comparable quantities of the Terminated Products in the dosage strength, formulation and presentation as were being Developed or
Commercialized as of the effective date of termination until the earlier of <B>*** </B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ix) BI shall
promptly *** and *** all *** and related rights *** and any other *** and other materials relating to *** of any Terminated Product, or *** or sell a Terminated Product); <U>provided</U>, that BI may retain a single copy of such items for its
records; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(x) BI shall, and hereby *** to MacroGenics *** Collaboration DART included in *** that were
invented solely by employees, agents or consultants of MacroGenics or its Affiliates. *** and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(xi) In the
event that BI grants to MacroGenics an *** with respect to Collaboration DART Patent Rights, MacroGenics shall be solely responsible for the Prosecution and Maintenance of such Collaboration DART Patent Rights and with respect to any such
Collaboration DART Patent Rights licensed to MacroGenics, MacroGenics <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4 <U>Change of Control</U>. In the event
of a Change of Control, provided all payments provided for herein are paid to MacroGenics&#146;s successor, BI shall have the following rights: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) BI shall be released of its ongoing disclosure and information exchange obligations under Sections 3.9(b) and 4.2; <U>provided</U> that BI on *** and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The JSC shall not meet anymore, except to address matters relating to Patent Rights. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)<B>*** </B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5 <U>Effect of Expiration or Termination; Survival</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Expiration or termination of the Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination. Any expiration or termination of this Agreement shall be
without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or termination, including the obligation to pay royalties for Product(s) sold prior to such expiration or termination.
Termination of this Agreement shall be in addition to, and shall not prejudice, the Parties&#146; remedies at law or in equity, including the Parties&#146; ability to receive legal damages and/or equitable relief with respect to any breach of this
Agreement, regardless of whether or not such breach was the reason for the termination. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The provisions of Articles&nbsp;1, 8, 11 and 12 and Sections&nbsp;3.6(c), 7.1, 9.3,
9.4, 9.5, 9.6, 9.7, 9.8, 10.3, 10.4 and 10.5 shall survive the expiration or termination of the Agreement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE XI
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>DISPUTE RESOLUTION </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Seeking Consensus</U>. If any dispute arises out of, in connection with or related to this Agreement, including disputes over the interpretation, performance, enforcement or breach of this
Agreement, including any dispute that is not within the jurisdiction of the JSC (a &#147;<U>Dispute</U>&#148;), however excluding any dispute resolved in accordance with Section&nbsp;2.5(c), then upon the written request of either Party, the matter
shall be referred to the <B>***</B>, who shall meet in a good faith effort to resolve the dispute within <B>***</B>. If the Parties&#146; <B>***</B> cannot agree on a resolution of the Dispute within such <B>***</B>period, then it shall be resolved
pursuant to the remaining provisions of this ARTICLE XI. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Arbitration</U>. The Parties shall negotiate in good faith
and use reasonable efforts to settle any Dispute in accordance with Section&nbsp;11.1. If the Parties do not fully settle a Dispute, and a Party wishes to pursue the matter, each such Dispute that is not an &#147;Excluded Claim&#148; shall be
finally resolved by binding arbitration in accordance with the <B>***</B> and judgment on the arbitration award may be entered in any court having jurisdiction thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) The arbitration shall be conducted by <B>***</B>. Within <B>***</B> after initiation of arbitration, each Party shall select <B>***</B>&nbsp;The place of arbitration shall be <B>***</B>, and all
proceedings and communications shall be in English. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Either Party may apply to the arbitrators for interim injunctive
relief until the arbitration award is rendered or the controversy is otherwise resolved. Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any injunctive or provisional relief necessary
to protect the rights or property of that Party pending the arbitration award. The scope of the authority of the arbitrators shall be limited to the strict application of law. The arbitrators shall have no authority to award punitive or any other
type of damages not measured by a Party&#146;s compensatory damages. Each Party participating in an arbitration pursuant to the terms of this Agreement shall, subject to the award of the arbitrators, pay an equal share of the arbitrator&#146;s fees.
The arbitrators shall have the power to award recovery of all costs (including reasonable attorney&#146;s fees, administrative fees, arbitrator&#146;s fees and court costs) to the prevailing party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Neither Party shall be required to give general discovery of documents, but may be required to produce documents or testimony which
are relevant or considered relevant by the arbitrators to the dispute. It is the objective and intent of the Parties that any arbitration proceeding be conducted in such a manner that a decision will be rendered by the arbitrators <B>***</B>, and
the Parties and the panel selected in the manner provided above will adopt rules and procedures intended to implement such objective and intent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Except to the extent necessary to confirm or vacate an award or as may be required by
law (including applicable securities laws or the rules of any stock exchange on which a Party&#146;s securities may then be listed), neither a Party nor an arbitrator may disclose the existence, content, or results of arbitration without the prior
written consent of both Parties. In no event shall arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable <B>***</B> statute of
limitations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The Parties agree that any payments made pursuant to this Agreement pending resolution of the dispute shall
be refunded or credited if an arbitrator or court determines that such payments are not due. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in this Section, the term
&#147;<U>Excluded Claim</U>&#148; shall mean a Dispute that concerns (a)&nbsp;the validity or infringement of a patent, trademark or copyright; or (b)&nbsp;any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Jury Waiver</U>. Each of the Parties hereto irrevocably und unconditionally waives trial by jury in any legal action
or proceeding relating to this Agreement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE XII <U> </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>MISCELLANEOUS </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the <B>***</B>, other than any principle of conflict or choice of laws that would cause the
application of the laws of any other jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Waiver</U>. Waiver by a Party of a breach hereunder by the other
Party shall not be construed as a waiver of any succeeding breach of the same or any other provision. No delay or omission by a Party to exercise or avail itself of any right, power or privilege that it has or may have hereunder shall operate as a
waiver of any right, power or privilege by such Party. No waiver shall be effective unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly authorized representative of the Party granting
the waiver. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3 <U>Notices</U>. All notices, instructions and other communications hereunder or in connection herewith shall
be in writing, shall be sent to the address specified in this Section&nbsp;12.3 and shall be: (a)&nbsp;delivered personally; (b)&nbsp;sent by registered or certified mail, return receipt requested, postage prepaid; or (c)&nbsp;sent via a reputable
nationwide overnight courier service. Any such notice, instruction or communication shall be deemed to have been delivered upon receipt if delivered by hand or when transmitted with electronic confirmation of receipt, if transmitted by facsimile (if
such transmission is on a Business Day; otherwise, on the next Business Day following such transmission), <U>provided</U> that an original document is sent via an internationally recognized overnight delivery service (receipt requested), three
(3)&nbsp;Business Days after it is sent by registered or certified mail, return receipt requested, postage prepaid, one (1)&nbsp;Business Day after it is sent via a reputable nationwide overnight courier service. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="90%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics,</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc.</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1500 East
Gude Drive</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Chief Executive Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile:
***</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">with&nbsp;a&nbsp;copy&nbsp;to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wilmer Cutler Pickering Hale and Dorr LLP</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">399 Park Avenue</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, NY 10022</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>*** </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to BI, to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boehringer Ingelheim International GmbH</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Binger Strasse 173</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">55216 Ingelheim am Rhein</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Germany</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: ***</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">with a copy to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boehringer Ingelheim International GmbH</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Binger Strasse 173</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">55216 Ingelheim am RheinGermany</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: ***</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: ***</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4 <U>Entire Agreement; Amendment</U>. This Agreement (including any Exhibits and Schedules) contains
the complete understanding of the Parties with respect to the Development, manufacture and commercialization of Products and supersedes all prior understandings and writings relating to such subject matter. In particular, it supersedes and replaces
the Prior Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date. No amendment, change or addition to this Agreement will be
effective or binding on either Party unless reduced to writing and duly executed on behalf of both Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5
<U>Headings</U>. Headings in this Agreement are for convenience of reference only and shall not be considered in construing this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.6 <U>Severability</U>. If any provision or portion thereof in this Agreement is for any reason held to be invalid, illegal or unenforceable, the same shall not affect any other portion of this
Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent possible. In any such event, this Agreement shall be construed as
if such clause of portion thereof had never </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of the Parties as expressed in this Agreement to the
fullest extent permitted by applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.7 <U>Assignment</U>. Neither this Agreement nor any right or obligation
hereunder may be assigned or otherwise transferred by any Party without the consent of the other Party; <U>provided</U>, <U>however</U>, that any Party may, without such consent, assign this Agreement, in whole or in part: (a)&nbsp;to any of its
respective Affiliates; <U>provided</U> that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (b)&nbsp;to any successor in interest by way of merger, acquisition or sale
of all or substantially all of its assets to which this Agreement relates (an &#147;<U>M&amp;A Event</U>&#148;); <U>provided</U> that such successor agrees in writing to be bound by the terms of this Agreement as if it were the assigning party. Any
assignment not in accordance with this Section&nbsp;12.7 shall be void. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with an M&amp;A Event, such
assignment shall not provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party. If BI assigns its rights and obligations hereunder to an Affiliate or Third Party ***
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.8 <U>Counterparts</U>. This Agreement may be executed in any number of counterparts, each of which shall be deemed an
original but all of which together shall constitute one and the same instrument. Signatures provided by facsimile transmission or in Adobe&#153; Portable Document Format (PDF) sent by electronic mail shall be deemed to be original signatures.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.9 <U>Force Majeure</U>. No Party shall be liable for failure of or delay in performing obligations set forth in this
Agreement, and no Party shall be deemed in breach of its obligations, if such failure or delay is due to a natural disaster, explosion, fire, flood, tornadoes, thunderstorms, earthquake, war, terrorism, riots, embargo, losses or shortages of power,
labor stoppage, substance or material shortages, events caused by reason of laws of any Governmental Authority, events caused by acts or omissions of a Third Party, or any other cause reasonably beyond the control of such Party, if the Party
affected gives prompt notice of any such cause to the other Party. The Party giving such notice shall thereupon be excused from such of its obligations hereunder as it is thereby disabled from performing for so long as it is so disabled,
<U>provided</U>, however, that such affected Party commences and continues to use its Commercially Reasonable Efforts to cure such cause. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.10 <U>Third-Party Beneficiaries</U>. None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party other than a MacroGenics Indemnitee under Section&nbsp;9.4 or
BI Indemnitee under Section&nbsp;9.5. No such Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against
either Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.11 <U>Relationship of the Parties</U>. Each Party shall bear its own costs incurred in the performance of
its obligations hereunder without charge or expense to the other, except as expressly provided in this Agreement. Neither Party shall have any responsibility for the hiring, termination or compensation of the other Party&#146;s employees or for any
employee compensation </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or benefits of the other Party&#146;s employees. No employee or representative of a Party shall have any authority to bind or obligate the other Party for any sum or in any manner whatsoever, or
to create or impose any contractual or other liability on the other Party without said other Party&#146;s approval. For all purposes, and notwithstanding any other provision of this Agreement to the contrary, the legal relationship under this
Agreement of each Party to the other Party shall be that of independent contractor. Nothing in this Agreement shall be construed to establish a relationship of partners or joint venturers between the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.12 <U>Performance by Affiliates</U>. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees
to cause its Affiliates to perform such obligations and shall guarantee performance of this Agreement by its Affiliates. If any disagreement arises out of the performance of this Agreement by an Affiliate of a Party, or the alleged failure of an
Affiliate or the alleged failure of an Affiliate to comply with the conditions and obligations of this Agreement, the Party seeking to resolve such dispute shall have the right do so directly with the other Party, without any obligation to first
pursue an action against, or recovery from, the Affiliate which is alleged to have caused a breach of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.13
<U>Construction</U>. Each Party acknowledges that it has been advised by counsel during the course of negotiation of this Agreement, and, therefore, that this Agreement shall be interpreted without regard to any presumption or rule requiring
construction against the Party causing this Agreement to be drafted. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection,
paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires, (a)&nbsp;wherever used, the use of any gender will be applicable to all genders; (b)&nbsp;the word &#147;or&#148; is
used in the inclusive sense (and/or); (c)&nbsp;any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified
(subject to any restrictions on such amendments, supplements or modifications set forth herein or therein); (d)&nbsp;any reference to any Laws refers to such Laws as from time to time enacted, repealed or amended; (e)&nbsp;the words
&#147;herein&#148;, &#147;hereof&#148; and hereunder&#148;, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; and (f)&nbsp;the words &#147;include&#148;, &#147;includes&#148; and
&#147;including&#148; shall be deemed to be followed by the phrase &#147;but not limited to&#148;, &#147;without limitation&#148; or words of similar import. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.14 <U>Create Act</U>. It is the intention of the Parties that this Agreement is a &#147;joint research agreement&#148; as that phrase is defined in 35 U.S.C. &#167; 103(c)(3).</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>[Remainder of page intentionally left blank] </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF, </B>the Parties have executed this Agreement as of the Effective
Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="36%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BOEHRINGER INGELHEIM INTERNATIONAL GMBH</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ppa.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BY:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Dr. Klaus Wilgenbus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">BY:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NAME:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr. Klaus Wilgenbus</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">NAME:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TITLE:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUTHORIZED SIGNATORY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TITLE:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="15%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="83%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BY:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Dorothee Schwall-Rudolph</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">NAME:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dorothee Schwall-Rudolph</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">TITLE:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">AUTHORIZED SIGNATORY</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Schedule 1.5 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>BI EXCLUSIVE TARGETS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.***&nbsp;&nbsp;*** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*** </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1.28 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DART PLATFORM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART
Platform comprises bispecific or monospecific proteins having at least two covalently linked polypeptide chains, A and B, where chain A comprises the <B>***</B> and chain B comprises the <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART Platform proteins include but are not limited to: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1.47 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INITIAL COLLABORATION TARGETS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1.50 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DRAFT INVOICE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="29%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Invoice To:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Invoice&nbsp;No.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>#</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt;&lt;Company name&gt;&gt;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Invoice&nbsp;Date:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&lt;&lt;date&gt;&gt;</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt;&lt;address&gt;&gt;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: &lt;&lt;name, title&gt;&gt;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BI Contract No.:</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Invoice From:</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt;&lt;Company name&gt;&gt;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt;&lt;address&gt;&gt;</FONT></P></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:37pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amount</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to &lt;&lt;contract and section reference&gt;&gt;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&lt;&lt;payment type&gt;&gt;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>$</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;0.00</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Payment Due</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Wire Instructions: </U></B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bank Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bank Address:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bank Contact:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Routing/transit:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficiary:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Beneficiary Account #:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payment Due:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&lt;&lt;contract payment terms&gt;&gt;</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1.58 </U></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS PATENT RIGHTS</B> </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP STYLE="BORDER:1px solid #000000; padding-left:8px"> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Country</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Application&nbsp;Serial</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No.</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Date Filed</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000;border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Publication No.</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px;border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Status</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1.77 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>RTP CRITERIA TEMPLATE </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#1ea000" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#1ea000"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#efff0a" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#efff0a"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" BGCOLOR="#ff0200" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#ff0200"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 1.81 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SOPD CANDIDATE CRITERIA TEMPLATE </U></B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#1ea000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#efff0a">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#ff0200">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#1ea000" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#1ea000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#efff0a" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#efff0a"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#ff0200" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px" BGCOLOR="#ff0200"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
</TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
</TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
</TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#1ea000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#efff0a">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000" BGCOLOR="#ff0200">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#1ea000" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#1ea000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#efff0a" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000" BGCOLOR="#efff0a"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" BGCOLOR="#ff0200" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px" BGCOLOR="#ff0200"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Key: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="8%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px" BGCOLOR="#1ea000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px" BGCOLOR="#efff0a"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px" BGCOLOR="#ff0200"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 4.5(b)I </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CO-PROMOTION TERMS AND CONDITIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 4.5(b)II </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DISPUTE RESOLUTION PROCEDURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Schedule 8.4 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g575431g01t77.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g575431g94y60.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Develop and Commercialize DART&#153;-Based Antibody Therapeutics </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INGELHEIM, Germany and ROCKVILLE, MD, USA, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2010</B> &#151; Boehringer Ingelheim and MacroGenics today jointly announced that
they have entered into a global alliance to discover, develop and commercialize antibody-based therapeutics which may span multiple therapeutic areas, including immunology, oncology, respiratory, cardiometabolic and infectious diseases. These
developmental drug candidates will be based on MacroGenics&#146; Dual-Affinity Re-Targeting (DART&#153;) platform and will be directed against up to ten combinations of molecular targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;This alliance represents the largest external commitment to our DART platform to date and the latest validation of our ongoing efforts&#148; said Dr.&nbsp;Scott Koenig, MacroGenics&#146; President
and Chief Executive Officer. &#147;We are very pleased to be collaborating with the global pharmaceutical research-driven company Boehringer Ingelheim toward the goal of developing next-generation, antibody-based therapeutics.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Combining MacroGenics&#146; innovative DART-based antibody platform with our experience and capabilities in drug discovery and development has the
potential to generate breakthrough medicines that will help patients with a range of diseases which cannot be adequately treated at present,&#148; said Prof Wolfgang Rettig, Senior Vice President Corporate Research of Boehringer Ingelheim.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Both companies will share responsibility for discovery and certain preclinical activities. In addition, Boehringer Ingelheim will have sole
responsibility for all subsequent preclinical, clinical, regulatory, commercial and manufacturing activities for any DART-based product resulting from the collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the first three years of the collaboration, MacroGenics expects to receive payments of about $60 million, which includes an upfront cash payment, annual maintenance fees, R&amp;D funding, and
near-term research-based milestones. Boehringer Ingelheim also expects to make a future equity investment in MacroGenics. In addition, MacroGenics may be eligible to receive development, regulatory and commercial milestone payments that can reach up
to $210 million for each of the ten DART programs in case of full commercial success of multiple DART </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
products. MacroGenics may also receive tiered royalties on net product sales. MacroGenics has the option to co-promote certain DART products in the United States. Further financial details were
not disclosed. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DART Background </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The DART platform is a bispecific antibody technology that enables the generation of highly stable antibody-based therapeutic molecules that can simultaneously target two different antigens. DART
therapeutics can accommodate virtually any variable region sequence in a &#147;plug-and-play&#148; fashion and have very favorable manufacturing properties. DART proteins are available in both bacterial and mammalian expression systems. DARTs have
also been engineered with an Fc domain, which confers them with additional properties, such as Fc receptor binding and extended half-life. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About MacroGenics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics is a
private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a
fully-integrated set of capabilities in antibody-based product development. The company has generated a proprietary pipeline of innovative product candidates by leveraging its three core technology platforms. These proprietary platforms include:
(1)&nbsp;cancer stem-like cells; (2)&nbsp;DART technology, which allows the company to incorporate multiple specificities within a single molecule; and (3)&nbsp;Fc optimization, which enhances antibody-dependent effector functions. The
company&#146;s lead program, teplizumab, is an anti-CD3 antibody. Teplizumab is being investigated in Phase 3 trials for the treatment of autoimmune diseases in collaboration with Eli Lilly and Company. For more information about MacroGenics, please
visit www.macrogenics.com. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Boehringer Ingelheim </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Boehringer Ingelheim group is one of the world&#146;s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than
41,500 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2009, Boehringer Ingelheim posted net sales of 12.7 billion euro while spending 21% of net sales in its largest business segment Prescription
Medicines on research and development. For more information about Boehringer Ingelheim, please visit www.boehringer-ingelheim.com. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Statements made in this news release that are not historical facts are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#147;expects,&#148; &#147;believes,&#148; &#147;intends,&#148; and similar expressions are intended to identify forward-looking statements. Actual results may differ
materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as MacroGenics&#146; ability to raise
additional capital, and risks related to MacroGenics&#146; and Boehringer Ingelheim&#146;s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. Neither
MacroGenics nor Boehringer Ingelheim assume any obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Contacts: </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Boehringer Ingelheim GmbH:</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., President and CEO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director Corporate Communications</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">or Jim Karrels, Vice President, CFO</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Julia Meyer-Kleinmann</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">+1-301-251-5172</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">+49/6132/77 82 71</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">info@macrogenics.com</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">press@boehringer-ingelheim.com</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>16
<FILENAME>filename16.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.16</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.16 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTION COPY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately
with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P>
<P STYLE="margin-top:240px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>BY AND BETWEEN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AND </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GILEAD SCIENCES, INC. </B></FONT></P> <P STYLE="font-size:240px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Table of Contents </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Page</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFINITIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">GOVERNANCE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">RESEARCH PROGRAMS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">GRANT OF RIGHTS; EXCLUSIVITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEVELOPMENT</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">REGULATORY MATTERS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">COMMERCIALIZATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAYMENTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONFIDENTIALITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">INDEMNIFICATION AND INSURANCE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 13</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TERM AND TERMINATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">70</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">STANDSTILL</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MISCELLANEOUS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibits:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;A</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Access Territory as of the Effective Date</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit B</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DART Platform</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit C</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Patents</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit D</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Content of Pre-Clinical Data Package for *** Research Program</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit E</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Plan for the *** Research Program</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit F</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Schedules: </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>Schedule 11.2.3 <B> </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">LICENSE AGREEMENT </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This License Agreement (this &#147;<U>Agreement</U>&#148;) is entered into and made effective as of the 3</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of January, 2013 (the &#147;<U>Effective Date</U>&#148;), by and
between MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware, having a principal office located at 9640 Medical Center Drive, Rockville, MD 20850, USA (&#147;<U>MacroGenics</U>&#148;), and Gilead Sciences,
Inc., a company organized and existing under the laws of the State of Delaware, having a principal office located at 333 Lakeside Drive, Foster City, CA 94404 (&#147;<U>Gilead</U>&#148;). MacroGenics and Gilead are each referred to herein by name or
as a &#147;<U>Party</U>&#148; or, collectively, as &#147;<U>Parties</U>.&#148; </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RECITALS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Gilead possesses expertise in the Research, Development, Manufacturing and Commercialization (each as defined below) of
pharmaceutical products; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>WHEREAS, MacroGenics controls certain intellectual property related to DARTs (as defined
below) generally, as well as certain DARTs targeting <B>***</B> (as defined below) and certain DARTs targeting <B>***</B> (as defined below); <B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Gilead is interested in receiving exclusive licenses under which it may further Research, Develop, Manufacture and Commercialize DARTs targeting <B>***</B>selected by Gilead, in each case in the
Gilead Territory (as defined below), and, to the extent provided herein, in the MacroGenics Territory (as defined below), and MacroGenics is willing to grant Gilead such licenses on the terms and conditions set forth in this Agreement; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS the Parties desire to set forth herein the terms and conditions of exclusive licenses to enable Gilead to Research,
Develop, Manufacture and Commercialize the above mentioned DARTs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual
covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in this Agreement, the following terms will have the meanings set forth in this ARTICLE 1 unless context dictates otherwise:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 &#147;<U>Access Territory</U>&#148; means, with respect to a Licensed Product (other than a <B>***</B> Licensed Product),
any and all countries and territories where Gilead (itself or through its Affiliates) has publicly announced a policy to generally sell or otherwise make available such Licensed Product and one or more other Gilead products at a significantly
discounted price to patients in such countries or territories. The list of countries and territories included in the Access Territory as of the Effective Date is set forth in Exhibit A, which list shall be <B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 &#147;<U>Accounting Standards</U>&#148; means generally accepted accounting principles
as practiced in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<U>Active Research Program</U>&#148; means an active program to develop products
that bind a Target, in which MacroGenics has generated or is actively engaged in generating antibodies directed against such Target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<U>Affiliate</U>&#148; means, as to a Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with said
first Person, regardless of whether such Affiliate is an Affiliate on the Effective Date or becomes an Affiliate after the Effective Date. A Person shall be deemed to &#147;control&#148; another Person if it (a)&nbsp;owns, directly or indirectly,
beneficially or legally, more than fifty percent (50%)&nbsp;of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a Person in a particular jurisdiction) of such other Person, or
has other comparable ownership interest with respect to any Person other than a corporation; or (b)&nbsp;has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the Person.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<U>Affordable Basis</U>&#148; means, with respect to a Licensed Product (other than a <B>***</B> Licensed Product)
in the Access Territory, selling or otherwise making such Licensed Product available to patients at a cost no more than the sum of (a)&nbsp;<B>***</B> plus (b)&nbsp;an additional amount not to exceed all costs and expenses of Gilead or its
Affiliates&#146; Commercialization activities with respect to such Licensed Product in the Access Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6
&#147;<U>Agreement Term</U>&#148; means the period commencing on the Effective Date and ending on the expiration or earlier termination of this Agreement in its entirety. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<U>Annual Net Sales</U>&#148; means, for any Licensed Product in any Calendar Year, aggregate Net Sales of such Licensed Product in such Calendar Year (or, in the first year of the Royalty Term,
the portion of such Calendar Year during which the Royalty Term is in effect). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<U>BLA</U>&#148; means a Biologics
License Application and any amendments or supplements thereto filed with the FDA pursuant to 21 C.F.R. Part 601 or any other application that is required for the purpose of marketing and selling a biological product and is filed with a Regulatory
Authority outside the United States, including with respect to the EU a Product License Application, Marketing Authorization Application and/or manufacturing and importation license. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<U>Business Day</U>&#148; means a day on which banking institutions in Washington, D.C. and San Francisco, CA are open for
business, excluding any Saturday or Sunday. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10 &#147;<U>Calendar Quarter</U>&#148; means a period of three
(3)&nbsp;consecutive months ending on the last day of March, June, September, or December, respectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11
&#147;<U>Calendar Year</U>&#148; means a period of time commencing on January&nbsp;1 and ending on the following December&nbsp;31. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12 &#147;<B><U>***</U></B>&#148; means the Target <B>***</B> comprising the <B>***</B>
identified by Entrez Gene <B>***</B>, respectively (including any subtypes, alleles, and splice variants). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13
&#147;<B><U>***</U></B>&#148; means the Target referred to as <B>***</B> (including any subtypes, alleles, and splice variants). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.14 &#147;<U><B>***</B> Licensed Program</U>&#148; means the Licensed Program directed to the <B>***</B> and <B>***</B> Targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.15 &#147;<U><B>***</B> Licensed Territory</U>&#148; means the entire world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<U><B>***</B> Research Program</U>&#148; means the Research Program directed to the <B>*** ***</B> Targets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17 &#147;<U>Change of Control</U>&#148; means (a)&nbsp;a transaction or series of related transactions that results in the sale or
other disposition of all or substantially all of MacroGenics&#146; assets; or (b)&nbsp;a merger or consolidation in which the shareholders of MacroGenics immediately prior to the consummation of such merger or consolidation do not, immediately after
consummation of such merger or consolidation, own stock or other securities of the surviving corporation that possess a majority of the voting power of all of the surviving corporation&#146;s outstanding stock and other securities and the power to
elect a majority of the members of the surviving corporation&#146;s board of directors; or (c)&nbsp;a transaction or series of related transactions (which may include without limitation a tender offer for MacroGenics&#146; stock or the issuance,
sale or exchange of stock of MacroGenics), excluding any public offering of MacroGenics&#146; equity securities pursuant to a registration statement under the Securities Act of 1933, as amended, if the shareholders of MacroGenics immediately prior
to the initial such transaction do not, immediately after consummation of such transaction or any of such related transactions, own stock or other securities of MacroGenics that possess a majority of the voting power of all of the MacroGenics&#146;
outstanding stock and other securities and the power to elect a majority of the members of MacroGenics&#146; board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.18 &#147;<U>Clearance Date</U>&#148; means, for each of the <B>***</B> Licensed Program, the <B>***</B> Licensed Program and the <B>***</B> Licensed Program, (a)&nbsp;if Gilead notifies MacroGenics
pursuant to Section&nbsp;3.2.2(c) that Gilead has determined in good faith that no HSR Filing is required with respect to such Licensed Program, the date on which Gilead delivers the Research Program Initiation Notice for such Licensed Program; and
(b)&nbsp;if Gilead notifies MacroGenics pursuant to Section&nbsp;3.2.2(c) that Gilead has determined in good faith that an HSR Filing is required with respect to such Licensed Program, the date on which the Parties have actual knowledge that all
applicable waiting periods under the HSR Act with respect to the exclusive license grants contemplated under this Agreement relating to such Licensed Program (after giving effect to Gilead&#146;s delivery of the Research Program Initiation Notice
for such Licensed Program) have expired or have been terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<U>Clinical Trial(s)</U>&#148; means individually
and collectively a Phase 1 Clinical Trial, Phase 2 Clinical Trial, a Phase 3 Clinical Trial, a Phase 4 Study and a Post Approval Study. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<U>Commercialization</U>&#148; or &#147;<U>Commercialize</U>&#148; means any
activities directed to obtaining pricing and/or reimbursement approvals, marketing, promoting, distributing, importing, offering to sell, and/or selling a product, including promotional activities conducted at scientific conferences or similar
events. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<U>Commercially Reasonable Efforts</U>&#148; means, with respect to a Party, such level of efforts
required to carry out an obligation in a sustained manner consistent with the efforts normally used <B>***</B>, for a similar activity with respect to the Research, Development and Commercialization of products (a)&nbsp;that are at a similar stage
in their Research, Development, Commercialization or product life as the relevant Program DART or Licensed Product; (b)&nbsp;that have commercial and market potential similar to the relevant Program DART or Licensed Product, taking into account
issues of intellectual property scope, subject matter and coverage, safety and efficacy, product profile, competitiveness with respect to Third Party products in the marketplace, and profitability (including pricing and reimbursement status achieved
or likely to be achieved); and (c)&nbsp;solely owned by them or to which they have exclusive rights (but excluding from consideration any financial obligations owed to a Third Party with respect to such rights). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22 &#147;<U>Combination Product</U>&#148; means a Licensed Product that (a)&nbsp;includes a Program DART as an active pharmaceutical
ingredient, together with one or more other active ingredients, and (b)&nbsp;is sold either as a fixed dose or with separate doses in a single package. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.23 &#147;<U>Competing Product</U>&#148; means any therapeutic or prophylactic product that comprises or incorporates, as an active pharmaceutical ingredient alone or in combination with one or more
other active pharmaceutical ingredients, a bispecific molecule that binds both Target members of any Program Target. Upon a Change of Control of MacroGenics, a Competing Product means any therapeutic or prophylactic product that comprises or
incorporates, as an active pharmaceutical ingredient alone or in combination with one or more other active pharmaceutical ingredients, any DART that binds both Target members of any Program Target. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24 &#147;<U>Competitive Infringement</U>&#148; means any infringement or misappropriation that involves the Development, Manufacture,
use or Commercialization of a product or product candidate that binds to the same Program Target as a Program DART or Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.25 &#147;<U>Complete</U>&#148; or &#147;<U>Completing</U>&#148; means, for a Clinical Trial, the date upon which all patients have completed protocol-defined drug administration and study database lock
has occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26 &#147;<U>Compulsory Licensee</U>&#148; means, with respect to a Licensed Product in a country or
territory, a Third Party to whom a governmental agency within such country or territory grants the right to sell or offer for sale such Licensed Product in such country or territory under any patent rights owned or controlled by Gilead or its
Affiliates, without direct or indirect authorization from Gilead or its Affiliates, <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27
&#147;<U>Control</U>,&#148; &#147;<U>Controls</U>,&#148; &#147;<U>Controlled</U>&#148; or &#147;<U>Controlling</U>&#148; means, with respect to any item of Know-How, Patent, Regulatory Documentation or other intellectual property right, the
possession (whether by ownership or license, other than pursuant to this Agreement) of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ability of a Party to grant access to, or a license or sublicense under, such item or right as provided for herein without violating the terms of any agreement or other arrangement with any Third
Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense; <U>provided</U> <U>that</U> any Know-How, Patent, Regulatory Documentation or other intellectual property right that is
licensed or acquired by a Party after the Effective Date that would otherwise be considered to be under the Control of such Party shall not be deemed to be under the Control of such Party if (a)&nbsp;the application of such definition in the context
of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such license or sublicense grants, unless the other
Party agrees to pay the additional payments or royalties to the Third Party and (b)&nbsp;with respect to Know-How, Patents, Regulatory Documentation or any other intellectual property right licensed to or obtained by MacroGenics pursuant to an
agreement with a Third Party, unless and until the agreement pursuant to which such rights are obtained becomes a MacroGenics Third Party Agreement pursuant to Section&nbsp;4.6. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28 &#147;<U>Cover</U>&#148;, &#147;<U>Covering</U>&#148; or &#147;<U>Covered</U>&#148; means, with respect to a product, technology,
process or method, that, in the absence of ownership of or a license granted under a Valid Claim, the composition, manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method would
infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.29 &#147;<U>CPI</U>&#148; means the average annual Consumer Price Index for the United States as reported by the United States Bureau of Labor Statistics. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.30 &#147;<U>DART</U>&#148; means a dual affinity bispecific re-targeting molecule as further described in <U>Exhibit B</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31 &#147;<U>Develop</U>&#148; or &#147;<U>Development</U>&#148; means drug development activities relating to the development of
compounds, products, or processes, and submission of information to a Regulatory Authority for the purpose of obtaining Regulatory Approval of a product. Development includes non-clinical activities, pharmacology studies, toxicology studies,
formulation, chemical analysis, bioanalytical analysis, material performance studies (such as measurements of stability, physical form, dissolution, or visual or spectroscopic analysis, and the like), pharmacokinetic studies, clinical studies,
biomarker and companion diagnostic discovery and development, regulatory affairs activities, and all other activities relating to seeking, obtaining or maintaining any Regulatory Approvals from the FDA or any other applicable Regulatory Authority.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32 &#147;<U>Diagnostic</U>&#148; means (a)&nbsp;with respect to Gilead, any diagnostic for a Target included in a Program
Target that is used in combination with a Licensed Product if (i)&nbsp;such diagnostic is Covered by a Valid Claim of any MacroGenics Patent or Joint Patent in the country in the Gilead Territory in which it is Manufactured or Commercialized or
(ii)&nbsp;the Manufacture or Commercialization of such diagnostic by or on behalf of Gilead in such country would, but for the licenses granted to Gilead under Section&nbsp;4.1, infringe or misappropriate MacroGenics&#146; rights in the MacroGenics
Know-How or Know-How included in the Joint IP, and (b)&nbsp;with respect to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics, any diagnostic for a Target included in a Program Target that is used in combination with a Licensed Product if (i)&nbsp;such diagnostic is Covered by a Valid Claim of any Gilead
Collaboration Patent or Joint Patent in the country in the MacroGenics Territory in which it is Manufactured or Commercialized or (ii)&nbsp;the Manufacture or Commercialization of such diagnostic by or on behalf of MacroGenics in such country would,
but for the licenses granted to MacroGenics under Section&nbsp;4.2, infringe or misappropriate Gilead&#146;s rights in the Gilead Collaboration Know How or Know-How included in the Joint IP. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.33 &#147;<U>Dollars</U>&#148; or &#147;<U>$</U>&#148; means the legal tender of the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.34 &#147;<U>EMA</U>&#148; means the European Medicines Agency, or any successor entity thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35 &#147;<U>Emerging Market Countries</U>&#148; means <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36 &#147;<U>Evaluation Period</U>&#148; means (a)&nbsp;for the <B>***</B> Licensed Program, the period beginning on the Effective Date
and ending on the later of (i)&nbsp;receipt of the Preclinical Data Package for the <B>***</B> Licensed Program or (ii)&nbsp;<B>***</B> from the Effective Date, and (b)&nbsp;for each of the <B>***</B> Licensed Program, the <B>***</B> Licensed
Program and the <B>***</B> Licensed Program, the period beginning on the Clearance Date for such Licensed Program and ending on the later of (i)&nbsp;receipt of the Preclinical Data Package for such Licensed Program or (ii)&nbsp;<B>***</B> from the
Effective Date, in each case ((a) and (b)) as such period may be extended pursuant to Section&nbsp;3.3.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.37
&#147;<U>EU</U>&#148; means the European Union, as its membership may be expanded from time to time, and any successor thereto. Any country that is a member country of the European Union (or any successor thereto) as of the Effective Date or at any
time during the term of this Agreement shall be deemed included in the EU for all purposes hereunder even if such country subsequently ceases to be a member country thereof.&nbsp;For clarity, the member countries of the European Union as of the
Effective Date are Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia,
Spain, Sweden, and United Kingdom. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38 &#147;<U>Executive Officers</U>&#148; means, for each Party, a senior executive
<B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39 &#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration, or any successor entity thereto.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.40 &#147;<U>FD&amp;C Act</U>&#148; means the United States Federal Food, Drug, and Cosmetic Act, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41 &#147;<U>Field</U>&#148; means any use in humans, including diagnosis, prophylaxis and treatment of human disease. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42 &#147;<U>First Commercial Sale</U>&#148; means the first sale of a Licensed Product by Gilead, its Affiliates or its Sublicensees
for use or consumption of such Licensed Product in a country in the Gilead Territory where Marketing Approval of such Licensed Product has been obtained or such sale is otherwise permitted by the Governmental Authority of such country. Sale of a
Licensed </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Product by Gilead to an Affiliate of Gilead or a Sublicensee of Gilead shall not constitute a First Commercial Sale unless such Affiliate or such Sublicensee is the end user of a Licensed
Product. In no event shall any sales for premarketing, testing or sampling be deemed a First Commercial Sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.43
&#147;<U>Fourth DART Targets</U>&#148; means a combination of two Targets that are nominated by Gilead pursuant to the second sentence of Section&nbsp;3.2.1(a) and both accepted by MacroGenics pursuant to Section&nbsp;3.2.1(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.44 &#147;<U>Fourth DART Licensed Program</U>&#148; means the Licensed Program directed to the Fourth DART Targets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45 &#147;<U>Fourth DART Licensed Territory</U>&#148; means the entire world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.46 &#147;<U>Fourth DART Research Program</U>&#148; means the Research Program directed to the Fourth DART Targets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47 &#147;<U>FTE</U>&#148; means <B>***</B>hours of work per Calendar Year devoted to or in support of the Research, Development or
Manufacture of Program DARTs and Licensed Products in accordance with a Research Program, that is carried out by one or more qualified scientific or technical employees or contract personnel of MacroGenics or its Affiliates, as such hours are
measured in accordance with the relevant Party&#146;s normal time allocation practices. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48 &#147;<U>FTE Cost</U>&#148;
means, for any period, the FTE Rate multiplied by the number of FTEs in such period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.49 &#147;<U>FTE Rate</U>&#148; means a
rate of <B>***</B> per FTE per Calendar Year (pro-rated for the period beginning on the Effective Date and ending at the end of the first Calendar Year) for personnel engaged in Research, Development and Manufacturing activities. The FTE Rate is
&#147;fully burdened&#148; and covers employee salaries and benefits and the cost of facilities, equipment and other materials and services including ordinary laboratory and manufacturing consumables. The FTE Rate will be adjusted annually to
reflect any changes in the CPI as of December&nbsp;31 of the then most recently ended calendar year over the level of the CPI on December&nbsp;31, 2012 (<I>i.e.</I>, the first such increase or decrease would occur on January&nbsp;1, 2014).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50 &#147;<U>Generic Licensee</U>&#148; means a Third Party licensee of Gilead or any of its Affiliates (or a Third Party
sublicensee of any Third Party licensee of Gilead or any of its Affiliates) that (a)&nbsp;has been granted a sublicense by Gilead or such Affiliate (or such other Third Party licensee) which (except as consented to by MacroGenics pursuant to
Section&nbsp;4.3) excludes rights to MacroGenics Know-How and (b)&nbsp;is authorized (i)&nbsp;<B>***</B>. &#147;Generic Licensee&#148; shall include <B>***</B> under any license granted to <B>***</B> by Gilead or any of its Affiliates under any
intellectual property related to the manufacture or sale of Licensed Products or the active pharmaceutical ingredient therein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51 &#147;<U>Generic Product</U>&#148; means, with respect to any Licensed Product, a version of such Licensed Product (or a product
containing the same or highly similar active pharmaceutical ingredient as such Licensed Product in a comparable dosage form and formulation as such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Licensed Product (e.g., adult-to-adult and pediatric-to-pediatric)) that has received, under applicable Law in any country in the Access Territory, any required Regulatory Approval analogous to
being licensed as a biosimilar or interchangeable biological product by the FDA pursuant to Section&nbsp;351(k) of the Public Health Service Act (42 U.S.C. &#167; 262(k)), as may be amended, or any subsequent or superseding law, statute or
regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.52 &#147;<U>Gilead Collaboration IP</U>&#148; means the Gilead Collaboration Know-How and the Gilead
Collaboration Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53 &#147;<U>Gilead Collaboration Know-How</U>&#148; means all Gilead Information and Inventions
except to the extent disclosed by published Gilead Collaboration Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54 &#147;<U>Gilead Collaboration
Patent(s)</U>&#148; means Patents Controlled by Gilead and its Affiliates during the Agreement Term Covering Gilead Information and Inventions. Gilead Collaboration Patents excludes Joint Patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.55 &#147;<U>Gilead Indemnitees</U>&#148; means Gilead, its Affiliates and its Sublicensees and the directors, officers and employees of
Gilead, its Affiliates and its Sublicensees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.56 &#147;<U>Gilead Information and Inventions</U>&#148; means Know-How
Controlled by Gilead or its Affiliates during the Agreement Term that (a)&nbsp;(i)&nbsp;was created by or on behalf of Gilead or its Affiliates in the course of conducting activities pursuant to this Agreement (including pursuant to
Section&nbsp;3.2.3), including any improvement, modification, enhancement or novel use of a Program DART or Licensed Product, or a Manufacturing process or formulation of a Program DART or Licensed Product or any improvement, modification or
enhancement of a Manufacturing process or formulation of a Program DART or Licensed Product or (ii)&nbsp;is used by Gilead or its Affiliates in the Research, Development, Manufacturing or Commercialization of a Program DART or Licensed Product and
is disclosed to MacroGenics or its Affiliates by or on behalf of Gilead or its Affiliates pursuant to this Agreement; and (b)&nbsp;is necessary or useful to Research, Develop, Manufacture or Commercialize any Program DART or Licensed Product in the
Field. Gilead Information and Inventions excludes Gilead&#146;s interest in the Joint IP and any Know-How that relates solely to any active pharmaceutical ingredient in a Combination Product other than a Program DART. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57 &#147;<U>Gilead Territory</U>&#148; means (a)&nbsp;for the <B>***</B> Licensed Program, the <B>***</B> Licensed Territory,
(b)&nbsp;<B>***</B> (c)&nbsp;for the <B>***</B> Licensed Program, the <B>***</B> Licensed Territory, and (d)&nbsp;for the <B>***</B> Licensed Program, the <B>***</B> Licensed Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58 &#147;<U>Good Clinical Practices</U>&#148; or &#147;<U>GCP</U>&#148; means the then-current standards, practices and procedures
(a)&nbsp;promulgated or endorsed by the FDA as set forth in the guidelines entitled &#147;Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,&#148; including related regulatory requirements imposed by the FDA; (b)&nbsp;set forth
in Directive 2001/20/EC of the European Parliament and of the Council of 4&nbsp;April 2001 and Commission Directive 2005//28/EC of 8&nbsp;April 2005; (c)&nbsp;ICH Guideline for Good Clinical Practice E6; (d)&nbsp;analogous Laws of an applicable
Regulatory Authority; and (e)&nbsp;all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59 &#147;<U>Good Laboratory Practices</U>&#148; or &#147;<U>GLP</U>&#148; means the
then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, as such regulations may be amended from time to time, and analogous Laws of an applicable Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60 &#147;<U>Good Manufacturing Practices</U>&#148; or &#147;<U>GMP</U>&#148; means then-current standards for the manufacture of
pharmaceutical products, pursuant to (a)&nbsp;the FD&amp;C Act (21 U.S.C. 321 et seq.); (b)&nbsp;relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including Parts 11, 210, and 211); (c)&nbsp;European
Community Directives 2003/94 and 91/356/EC; (d)&nbsp;the European Community Guide to Good Manufacturing Practice for Medicinal Intermediate Products; (e)&nbsp;ICH Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients;
(f)&nbsp;analogous Laws of an applicable Regulatory Authority at the time of Manufacture; and (g)&nbsp;all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61 &#147;<U>Governmental Authority</U>&#148; means any United States federal, state or local or any non-United States government, or
political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any
court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or governmental arbitral body. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.62 &#147;<U>Government or Public Official</U>&#148; means any officer or employee or anyone acting in an official capacity on behalf of: a government or any department or agency thereof; a public
international organization (such as the United Nations, the International Monetary Fund, the International Red Cross, and the World Health Organization), or any department, agency or institution thereof; or a government-owned or controlled company,
institution, or other entity, including a government-owned hospital or university. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.63 &#147;<U>HSR Act</U>&#148; means the
Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.64 &#147;<U>ICH</U>&#148; means the International
Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65
&#147;<U>IND</U>&#148; means an Investigational New Drug Application filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application (CTA). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.66 &#147;<U>Indication</U>&#148; means a discrete clinically recognized form of a disease or any precursor condition thereof.&nbsp;By
way of example, the following diseases shall be considered separate Indications:&nbsp;<B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67 &#147;<U>Insolvency
Event</U>&#148; means with respect to a Party, (a)&nbsp;the entry of an order for relief under the Bankruptcy Code or any other bankruptcy, insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect by such
Party; (b)&nbsp;the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
commencement of an involuntary proceeding under the Bankruptcy Code or any other bankruptcy, insolvency, reorganization or other similar act or law of any jurisdiction now or hereafter in effect
against such Party, if not dismissed, bonded or stayed within ninety (90)&nbsp;days after such commencement; (c)&nbsp;the making by such Party of a general assignment for the benefit of creditors; or (d)&nbsp;the appointment of or taking possession
by a receiver, liquidator, assignee, custodian, or trustee of all or substantially all of the business or property of such Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.68 &#147;<U>Joint IP</U>&#148; means all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered jointly by one or more employees, consultants or agents
of MacroGenics or its Affiliates, together with one or more employees, consultants or agents of Gilead or its Affiliates, in the course of the Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Products.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.69 &#147;<U>Joint Patents</U>&#148; means Patents comprising claims Covering patentable inventions included in the Joint
IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70 &#147;<U>Know-How</U>&#148; means all tangible and intangible (a)&nbsp;information, techniques, technology,
practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and non-clinical and clinical test data and results, and Research or
Development data, reports and batch records), analytical and quality control data, analytical methods (including applicable reference standards), full batch documentation, packaging records, release, stability, storage and shelf-life data,
Manufacturing process information, results and descriptions, and software and algorithms and (b)&nbsp;compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71 &#147;<U>Law</U>&#148; or &#147;<U>Laws</U>&#148; means all laws, statutes, rules, regulations, orders, judgments, or ordinances
having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.72 &#147;<U>Licensed Product</U>&#148; means any therapeutic or prophylactic product that comprises or incorporates a Program DART as an active pharmaceutical ingredient alone or in combination with one
or more other active agents. For the avoidance of doubt, Licensed Product excludes any diagnostic products (including Diagnostics). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.73 &#147;<U>Licensed Program</U>&#148; means Research, Development, Manufacturing and/or Commercialization activities conducted by or on behalf of Gilead and/or MacroGenics with respect to Program DARTs
and/or Licensed Products for a particular Program Target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.74 &#147;<U>License Grant Date</U>&#148; means (a)&nbsp;with
respect to the <B>***</B> Licensed Program, the Effective Date and (b)&nbsp;with respect to the <B>***</B> Licensed Program, the <B>***</B> Licensed Program and the <B>***</B> Licensed Program, the Clearance Date for the <B>***</B> Licensed Program,
the <B>***</B> Licensed Program or the <B>***</B> Licensed Program, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.75 &#147;<U>License Term</U>&#148;
means, with respect to a Licensed Program, each period commencing upon the License Grant Date for such Licensed Program and ending on the date of expiration or termination of this Agreement with respect to such Licensed Program in accordance with
the provisions of ARTICLE 13. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76 &#147;<U>MacroGenics Information and Inventions</U>&#148; means Know-How that
(a)&nbsp;is Controlled by MacroGenics or its Affiliates on the Effective Date or thereafter during the Agreement Term; (b)(i) is or relates to a Program DART or Licensed Product or an improvement, modification, enhancement or novel use of a Program
DART or Licensed Product, or a Manufacturing process or formulation of a Program DART or Licensed Product or any improvement, modification or enhancement of a Manufacturing process or formulation of a Program DART or Licensed Product; or
(ii)&nbsp;is used by MacroGenics or its Affiliates in the Research, Development, Manufacturing or Commercialization of a Program DART or Licensed Product and is disclosed to Gilead or its Affiliates by or on behalf of MacroGenics or its Affiliates
pursuant to this Agreement; and (c)&nbsp;is necessary or useful to Research, Develop, Manufacture or Commercialize any Program DART or Licensed Product in the Field in the Gilead Territory. MacroGenics Information and Inventions excludes
MacroGenics&#146; interest in the Joint IP and any Know-How that relates solely to any active pharmaceutical ingredient in a Combination Product other than a Program DART. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.77 &#147;<U>MacroGenics Indemnitees</U>&#148; means MacroGenics, its Affiliates and its Sublicensees and the directors, officers and employees of MacroGenics, its Affiliates and its Sublicensees.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78 &#147;<U>MacroGenics IP</U>&#148; means the MacroGenics Know-How and the MacroGenics Patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.79 &#147;<U>MacroGenics Know-How</U>&#148; means all MacroGenics Information and Inventions except to the extent disclosed by published
MacroGenics Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80 &#147;<U>MacroGenics Patents</U>&#148; means Patents Controlled by MacroGenics or its Affiliates on
the Effective Date or thereafter during the Agreement Term that Cover MacroGenics Information and Inventions. The MacroGenics Patents existing as of the Effective Date are set forth on <U>Exhibit C</U>. MacroGenics Patents excludes Joint Patents.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.81 &#147;<U>MacroGenics Territory</U>&#148; means, for the <B>***</B> Licensed Program only, the entire world excluding the
<B>***</B> Licensed Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.82 &#147;<U>MacroGenics Third Party Agreements</U>&#148; means any agreement (other than
this Agreement) (a)&nbsp;pursuant to which MacroGenics in-licenses or otherwise acquires the right to practice Patents or Know-How that relates to the Program DARTs or Licensed Products in the Field in the Gilead Territory and (b)&nbsp;that Gilead
accepts pursuant to Section&nbsp;4.6. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.83 &#147;<U>Manufacture</U>&#148; or &#147;<U>Manufacturing</U>&#148; means all
activities related to the manufacturing of a DART or product, including test method development and stability testing, formulation, process development, manufacturing scale-up, manufacturing for use in non-clinical and clinical studies,
manufacturing for commercial sale, packaging, release of product, quality assurance/quality control development, quality control testing (including in-process, release and stability testing) and release of product or any component or ingredient
thereof, and regulatory activities related to all of the foregoing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.84 &#147;<U>Marketing Approval</U>&#148; means, for any Licensed Product in any country,
all approvals (including pricing and reimbursement approvals), licenses, registrations or authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the sale of such Licensed
Product in such country.&nbsp;If no such approvals, licenses, registrations or authorization are necessary for the sale of a Licensed Product in a particular country, then &#147;Marketing Approval&#148; for such Licensed Product in such country
shall be deemed to have occurred on First Commercial Sale of such Licensed Product in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.85 &#147;<U>Mixed
Patent</U>&#148; means any Patent that <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86 *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.87 &#147;<U>Net Receipts</U>&#148; means all amounts actually received by Gilead or its Affiliates from any Generic Licensee or
Compulsory Licensee in consideration of the sale of a Licensed Product less any withholding tax or other taxes as may be required under Law and actually paid from such payment due to Gilead; provided, however, that if such Licensed Product is sold
as a Combination Product, Net Receipts with respect to the Combination Product shall be calculated in a manner consistent with the last paragraph of Section&nbsp;1.88. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.88 &#147;<U>Net Sales</U>&#148; means the gross amounts billed or invoiced by Gilead, its Affiliates or its Sublicensees to Third Parties that are not Sublicensees for the sale or other commercial
disposition of Licensed Products, less the following deductions, determined in each case in accordance with the Accounting Standards, and only to the extent attributable to Licensed Products: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) trade, quantity and cash discounts allowed and taken; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) refunds, chargebacks and any other allowances given and taken which effectively reduce the gross amounts billed or invoiced; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) product returns, credits and allowances and bad debt (provided that if any such bad debt is subsequently collected, such collected amounts shall be included in Net Sales in the period in which they
are subsequently collected); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) rebates, reimbursements, fees, taxes or similar payments to (i)&nbsp;wholesalers and other
distributors, pharmacies and other retailers, buying groups (including group purchasing organizations), health care insurance carriers, pharmacy benefit management companies, health maintenance organizations, governmental entities, or other
institutions or health care organizations to the extent actually paid or credited; or (ii)&nbsp;patients and other Third Parties arising in connection with any program that provides low income, uninsured or other patients the opportunity to obtain
discounted Licensed Products; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) discounts mandated by, or granted to meet the requirements of, applicable state,
provincial or federal Law, including required chargebacks and retroactive price reductions; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) transportation, freight,
postage charges and other charges such as insurance, relating thereto, in each case included as a specific line item on a bill or an invoice to such Third Parties; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(g) taxes, excises or other governmental charges upon or measured by the production, sale, transportation, delivery or use of goods, in each case included as a specific line item on a bill or an invoice
to such Third Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Except as otherwise specified above, any and all set-offs against gross amounts billed or invoiced shall be calculated
in accordance with the Accounting Standards. Sales or other commercial dispositions of Licensed Products (1)&nbsp;between Gilead and its Affiliates and/or its Sublicensees (except where such Affiliates or Sublicensees are an end user of the Licensed
Product); (2)&nbsp;provided to Third Parties without charge, in connection with research and development, Clinical Trials, compassionate use, humanitarian and charitable donations, or indigent programs or for use, in reasonable and customary
quantities, as samples; and (3)&nbsp;provided by Gilead, its Affiliates and/or Sublicensees to government agencies, not-for-profit non-governmental organizations, physicians, pharmacies, other entities, or directly to patients, in each case in the
Access Territory on an Affordable Basis, shall in each case, be excluded from the computation of Net Sales, and no payments will be payable on such sales or such other commercial dispositions. For clarity, Net Sales shall exclude Net Receipts and
amounts invoiced for Licensed Products by any Generic Licensee or Compulsory Licensee. Notwithstanding anything herein to the contrary, if there are material sales of Licensed Products by Gilead, its Affiliates or Sublicensees to unaffiliated Third
Parties at a price in excess of the Affordable Basis in a country or territory in the Access Territory, the Parties shall determine a mechanism to include the amounts invoiced for such sales within Net Sales hereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If a Licensed Product is sold or otherwise commercially disposed of for consideration other than cash or in a transaction that is not at arm&#146;s
length between the buyer and the seller, then the gross amount to be included in the calculation of Net Sales shall be the amount that would have been invoiced had the transaction been conducted at arm&#146;s length and for cash. Such amount that
would have been invoiced shall be determined, wherever possible, by reference to the average selling price of the relevant Licensed Product in arm&#146;s length transactions in the relevant country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing, to the extent a Licensed Product is sold as a Combination Product, Net Sales with respect to the Combination Product for a
particular country shall be calculated by multiplying the actual Net Sales of the Combination Product by the fraction A/(A+B), where A is the total weighted (by sales volume) average Net Sales price of the Licensed Product if sold by Gilead, its
Affiliates or Sublicensees separately in a country and B is the total weighted (by sales volume) average Net Sales price of the other active ingredients included in the Combination Product if sold separately in such country. If, on a
country-by-country basis, such other active ingredients in the Combination Product are not sold separately in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such country, but the Licensed Product component of the Combination Product is sold separately in such country, Net Sales for the purpose of determining royalties due hereunder for the
Combination Product will be calculated by multiplying the actual Net Sales of such Combination Product by the fraction A/C, where A is the total weighted (by sales volume) average Net Sales price of such Licensed Product component if sold
separately, and C is the total weighted (by sales volume) average Net Sales price of the Combination Product. If, on a country-by-country basis, such Licensed Product component is not sold separately in such country, Net Sales for the purposes of
determining royalties due hereunder for the Combination Product will be calculated by multiplying the actual Net Sales of such Combination Product by the fraction D/(D+E), where D is the worldwide average Net Sales price of the portion of the
Combination Product that contains the Licensed Product, and E is the worldwide average Net Sales price of the portion of the Combination Product containing the other active ingredients included in such Combination Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.89 &#147;<U>Other Claims</U>&#148; means Patent claims other than Platform Claims and Product Claims. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.90 &#147;<U>Other Patents</U>&#148; means any Gilead Collaboration Patents, MacroGenics Patents or Joint Patents that (in each case)
contain only Other Claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.91 &#147;<U>Out-of-Pocket Costs</U>&#148; means, with respect to certain activities hereunder,
direct expenses actually paid by a Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Licensed Product, but excluding (with respect to MacroGenics&#146; Research activities) any costs
included in the FTE Rate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.92 &#147;<U>Patent</U>&#148; means (a)&nbsp;all patents and patent applications in any country or
supranational jurisdiction, and (b)&nbsp;any substitutions, divisionals, continuations, continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection
certificates and the like of any such patents or patent applications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.93 &#147;<U>Person</U>&#148; means any individual,
partnership, joint venture, limited liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.94 &#147;<U>Phase 1 Clinical Trial</U>&#148; means a human clinical trial that is intended to initially evaluate the safety and/or
pharmacological effect of a product or that would otherwise satisfy the requirements of 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country other than the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.95 &#147;<U>Phase 2 Clinical Trial</U>&#148; means a human clinical trial for which the primary endpoints include a determination of
dose ranges or an indication of efficacy of a product in patients being studied as described in 21 C.F.R. &#167;312.21(b), or an equivalent clinical trial in a country other than the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.96 &#147;<U>Phase 3 Clinical Trial</U>&#148; means a human clinical trial that is
prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in the indication being investigated in a manner sufficient to obtain Regulatory Approval to market such product in patients having the
disease or condition being studied as described in 21 C.F.R. &#167;312.21(c), or an equivalent clinical trial in a country other than the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.97 &#147;<U>Phase 4 Study</U>&#148; means (a)&nbsp;a human clinical trial for a Licensed Product for an Indication that is required by a Regulatory Authority as a condition of (but is not completed
before) obtaining the initial Regulatory Approval for such Licensed Product for such Indication and (b)&nbsp;any trial, test or study that is required or requested by a Regulatory Authority as a condition of maintaining the initial Regulatory
Approval for a Licensed Product for an Indication, excluding any Post Approval Study. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.98 &#147;<U>PMDA</U>&#148; means the
Japanese Pharmaceuticals and Medical Devices Agency or any successor agency thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.99 &#147;<U>Platform Claims</U>&#148;
means Patent claims that Cover <B>***</B>, but excluding any Product Claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.100 &#147;<U>Platform IP</U>&#148; means
(a)&nbsp;Platform Claims and (b)&nbsp;Know-How that relates to the <B>***</B> (y)&nbsp;relates specifically to <B>***</B>). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.101 &#147;<U>Platform Patents</U>&#148; means, subject to Sections 9.3.1(c) and 9.3.2(c), any Gilead Collaboration Patents, MacroGenics
Patents or Joint Patents that (in each case) contain at least one Platform Claim but no Product Claims. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.102 &#147;<U>Post
Approval Study</U>&#148; means any human clinical study or other test or study with respect to a Licensed Product for an Indication that is not required in order to obtain or maintain Regulatory Approval for such Licensed Product for such
Indication. For clarity, any human clinical study that is intended to expand the product labeling for such Licensed Product shall be deemed not to be a Post Approval Study. Subject to the foregoing, Post Approval Study may include epidemiological
studies, modeling and pharmacoeconomic studies, post-marketing surveillance studies, investigator or company sponsored or initiated studies and health economics studies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.103 &#147;<U>Preclinical Data Package</U>&#148; means (a)&nbsp;for the <B>***</B> Licensed Program, a written report containing the information and data set forth in <U>Exhibit D</U> and (b)&nbsp;for
each of the <B>***</B> Licensed Program, the <B>***</B> Licensed Program and the <B>***</B> Licensed Program, a written report containing the information and data to be agreed upon by the Parties in accordance with Section&nbsp;3.2.2(d). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.104 &#147;<U>Product Claims</U>&#148; means Patent claims that Cover Know-How that (a)&nbsp;relates to aspects of the <B>***</B>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.105 &#147;<U>Product Patents</U>&#148; means, subject to Sections 9.3.1(c) and 9.3.2(c), any Gilead Collaboration Patents,
MacroGenics Patents or Joint Patents that (in each case) contain at least one Product Claim but no Platform Claims. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.106 &#147;<U>Product Trademarks</U>&#148; means the Gilead Product Trademarks and
MacroGenics Product Trademarks. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.107 &#147;<U>Program DART</U>&#148; means any DART that binds a Program Target. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.108 &#147;<U>Program Target</U>&#148; means any of the following Target pairs: (a)&nbsp;<B>***</B> and <B>***</B>; (b)&nbsp;<B>***</B>
and <B>***</B>; (c)&nbsp;the <B>***</B> Targets; or (d)&nbsp;the <B>***</B> Targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.109 &#147;<U>Reasonable Research
Efforts</U>&#148; means, with respect to a Party, such level of efforts required to carry out an obligation in a sustained manner consistent with the efforts normally used by pharmaceutical or biopharmaceutical companies, as applicable, of
comparable size and resources to such Party, for a similar activity with respect to the Research of products (a)&nbsp;that are at a similar stage in their Research as the relevant Program DART or Licensed Product; (b)&nbsp;that have scientific
attributes similar to those of the relevant Program DART or Licensed Product; and (c)&nbsp;that are solely owned by them or to which they have exclusive rights (but excluding from consideration any financial obligations owed to a Third Party with
respect to such rights). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.110 &#147;<U>Regulatory Approval</U>&#148; means all approvals, licenses or authorizations of any
applicable Regulatory Authority necessary for Development and/or Commercialization of a Program DART and/or a Licensed Product for a particular Indication in a country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.111 &#147;<U>Regulatory Authority</U>&#148; means the FDA in the United States or any health regulatory authority in another country that is a counterpart to the FDA and holds responsibility for
regulating development of and/or granting Regulatory Approval for a Program DART or Licensed Product in such country, including the EMA, and any successor(s) thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.112 &#147;<U>Regulatory-Based Exclusivity Period</U>&#148; means, with respect to a Licensed Product, that period of time during which Gilead or any of its Affiliates or Sublicensees has been granted
the exclusive legal right by a Regulatory Authority either to market and sell a Licensed Product in a country in the Gilead Territory or the exclusive right to use or reference clinical data in relation to a Licensed Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.113 &#147;<U>Regulatory Documentation</U>&#148; means, with respect to the Program DARTs or Licensed Products, all INDs, BLAs, and
other regulatory applications submitted to any Regulatory Authority, copies of Regulatory Approvals, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. &#167;314.420 and any non-United States
equivalents), and any other reports, records, regulatory correspondence, meeting minutes, telephone logs, and other materials relating to Regulatory Approval of the Program DARTs or Licensed Products (including any underlying safety and
effectiveness data whether or not submitted to any Regulatory Authority), or required to Develop, Manufacture or Commercialize Licensed Products including any information that relates to pharmacology, toxicology, chemistry, manufacturing and
controls data, batch records, safety and efficacy, and any safety database required to be maintained for Regulatory Authorities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.114 &#147;<U>Research</U>&#148; means the discovery, identification, research,
characterization, modification, derivatization and optimization of pharmaceutical compounds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.115 &#147;<U>Research
Plan</U>&#148; means a research plan developed by the Parties that sets forth the activities to be undertaken during the Research Term for a specific Research Program and the budget therefor, which research plan may be amended from time to time by
the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.116 &#147;<U>Research Program</U>&#148; means Research activities conducted by or on behalf of MacroGenics and
Gilead during the applicable Research Term in accordance with a Research Plan with respect to Program DARTs for a particular Program Target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.117 &#147;<U>Research Term</U>&#148; means the period (a)&nbsp;commencing on (i)&nbsp;with respect to the <B>***</B> Research Program, the Effective Date, and (ii)&nbsp;with respect to the <B>***</B>
Research Program, the <B>***</B> Research Program and the <B>***</B> Research Program, the Clearance Date for the Licensed Program associated with such Research Program; and (b)&nbsp;ending, for any Research Program, on the earlier of
(i)&nbsp;delivery of the Preclinical Data Package; or (ii)&nbsp;the <B>***</B> of the License Grant Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.118
&#147;<U>Right of Reference or Use</U>&#148; means a &#147;Right of Reference or Use&#148; as that term is defined in 21 C.F.R. &#167;314.3(b), and any non-United States equivalents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.119 &#147;<B><U>***</U></B>&#148; means the Target referred to as <B>***</B> (including any subtypes, alleles, and splice variants).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.120 &#147;<U><B>***</B> Licensed Product</U>&#148; means any Licensed Product from the <B>***</B> Licensed Program.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.121 &#147;<U><B>***</B> Licensed Program</U>&#148; means the Licensed Program directed to the <B>*** ***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.122 &#147;<U><B>***</B> Licensed Territory</U>&#148; means the <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.123 &#147;<U><B>***</B> Program DART</U>&#148; means any Program DART from the <B>***</B> Licensed Program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.124 &#147;<U><B>***</B> Research Program</U>&#148; means the Research Program directed to the <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.125 &#147;<U>Significant Adverse Effect</U>&#148; means (a)&nbsp;for purposes of Section&nbsp;5.4, the significant possibility, in the
reasonable belief of MacroGenics, that the conduct of the applicable Clinical Trial or other clinical study poses (i)&nbsp;a significantly higher risk of either an adverse effect on <B>***</B> of the applicable <B>***</B> Program DART or <B>***</B>
Licensed Product, as compared to <B>***</B>, for such <B>***</B> Program DART or <B>***</B> Licensed Product, or (ii)&nbsp;a significant risk of an adverse effect on the ability of MacroGenics or its Affiliates or Sublicensees to recruit patients
for active Clinical Trials conducted, or planned Clinical Trials (for which a protocol has been submitted to and not disapproved by Gilead pursuant to Section&nbsp;5.5, as of the time of submission to MacroGenics pursuant to Section&nbsp;5.4 of a
protocol for the applicable Clinical Trial or study proposed to be conducted by Gilead or its Affiliates or Sublicensees) to be conducted, by MacroGenics or its Affiliates or Sublicensees in the MacroGenics Territory with respect to such <B>***</B>
Program DART or Licensed Product; and (b)&nbsp;for purposes of Section&nbsp;5.5, the significant possibility, in the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
</B>reasonable belief of Gilead, that the conduct of the applicable Clinical Trial or other clinical study poses (i)&nbsp;a significantly higher risk of either an adverse effect <B>***</B>
Licensed Product, as compared to <B>***</B>, for such <B>***</B> Program DART or <B>***</B> Licensed Product, or (ii)&nbsp;a significant risk of an adverse effect on the ability of Gilead or its Affiliates or Sublicensees to <B>***</B> ((A) with
respect to planned Clinical Trials to be conducted in the Gilead Territory, that are subject to a protocol that has received internal approval by Gilead, and (B)&nbsp;with respect to planned Clinical Trials to be conducted in the MacroGenics
Territory, for which a protocol has been submitted to and not disapproved by MacroGenics pursuant to Section&nbsp;5.4, as of the time of submission to Gilead pursuant to Section&nbsp;5.5 of a protocol for the applicable Clinical Trial or study
proposed to be conducted by MacroGenics or its Affiliates or Sublicensees) to be conducted, by Gilead or its Affiliates or Sublicensees in the Gilead Territory with respect to such <B>***</B> Program DART or Licensed Product.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.126 &#147;<U>Sublicensee</U>&#148; means a Third Party to whom a Party, as permitted under this Agreement, grants a license or
sublicense, as the case may be, under the Joint IP, MacroGenics IP or Gilead Collaboration IP to Research, Develop, Manufacture, Commercialize or otherwise use Program DARTs, Diagnostics and/or Licensed Products in the Field or otherwise grants
rights to distribute, promote or sell Diagnostics or Licensed Products in the Field; provided, however, that the term &#147;Sublicensee&#148; shall not include (a)&nbsp;any wholesale distributor, Generic Licensee or Compulsory Licensee or
(b)&nbsp;any other Third Party who purchases a Diagnostic or Licensed Product and does not have a license or sublicense, as the case may be, under the Joint IP, MacroGenics IP or the Gilead Collaboration IP to Develop or Manufacture such Diagnostic
or Licensed Product, other than a limited license or sublicense, as the case may be, as required to enable such Third Party (i)&nbsp;to perform final packaging for such Diagnostic or Licensed Product for local distribution, (ii)&nbsp;to conduct a
confirmatory Clinical Trial of such Licensed Product to support a filing for Regulatory Approval of such Licensed Product in such Third Party&#146;s distribution territory or (iii)&nbsp;to prepare and make a filing for a Regulatory Approval of such
Licensed Product in such Third Party&#146;s distribution territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.127 &#147;<U>Target</U>&#148; means (a)&nbsp;an antigen
composed of a polypeptide, a complex of more than one polypeptide, or a post-translational modification of one or more polypeptides (e.g., glycosylation, phosphorylation, etc.); or (b)&nbsp;a gene encoding an antigen and the products encoded by such
gene, including any homologues, variants, alternatively spliced variants, mutants, deletions or fragments or partial sequences of such antigen. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.128 &#147;<U>Terminated Program</U>&#148; means with respect to any termination of this Agreement pursuant to ARTICLE 13, the Licensed Program(s) (including the associated Research Program(s)) subject
to such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.129 &#147;<U>Territory</U>&#148; means (a)&nbsp;with respect to Gilead, the Gilead Territory; and
(b)&nbsp;with respect to MacroGenics, the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.130 &#147;<U>Third Party</U>&#148; means any Person other
than MacroGenics or Gilead that is not an Affiliate of MacroGenics or of Gilead. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.131 &#147;<U><B>***</B> Targets</U>&#148; means a combination of two Targets that are
nominated by Gilead pursuant to the first sentence of Section&nbsp;3.2.1(a) and both accepted by MacroGenics pursuant to Section&nbsp;3.2.1(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.132 &#147;<U><B>***</B> Licensed Program</U>&#148; means the Licensed Program directed to the Third DART Targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.133 &#147;<U><B>***</B> Licensed Territory</U>&#148; means the entire world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.134 &#147;<U><B>***</B> Research Program</U>&#148; means the Research Program directed to the Third DART Targets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.135 &#147;<U>United States</U>&#148; or &#147;<U>U.S.</U>&#148; means the United States of America and all of its territories and
possessions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.136 &#147;<U>Valid Claim</U>&#148; means (a)&nbsp;a claim of an issued patent that has not expired or been
abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time
period) or (b)&nbsp;a claim within a patent application which application has not been pending for more than <B>***</B> from the date of its first filing and which claim has not been revoked, cancelled, withdrawn, held invalid or abandoned.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.137 <U>Additional Definitions</U>. Each of the following definitions is set forth in the section of this Agreement
indicated below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13D Group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional Extension</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audited Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Auditing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bankruptcy Code</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Biosimilar Product</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breaching Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Chairperson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercializing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Competitive Infringement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Court</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dispute</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing Confidentiality Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">FCPA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead Objection</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead Product Trademarks</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">GLP Toxicology Study</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">HSR Filing</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnified Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnifying Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial Extension</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial Research Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IPO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Development Activity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JRC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Objection</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Product Trademarks</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Breaching Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notifying Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Party or Parties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical Milestone Payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preclinical Milestone Payment Notice</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receiving Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Program Initiation Notice</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B> Initial Research Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SDEA Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standstill Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplemental Data</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">UKBA</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>GOVERNANCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Alliance Managers</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.1 As soon as practicable after the Effective Date, each of MacroGenics and Gilead shall assign one (1)&nbsp;of its employees to serve
as primary point of contact between the Parties with respect to matters under this Agreement (each an &#147;<U>Alliance Manager</U>&#148;). Either Party may change its Alliance Manager upon written notice to the other Party. The Alliance
Managers&#146; responsibilities shall be limited to: (a)&nbsp;coordinating the activities of the Parties under this Agreement, including facilitating communications between the Parties with respect to the Development, Manufacture and
Commercialization of Program DARTs and Licensed Products; (b)&nbsp;serving as an initial point of contact for discussion by the Parties of the Development, Manufacture, and Commercialization of Program DARTS and Licensed Products; (c)&nbsp;directing
and overseeing the JRC and any ad hoc committee established by the Parties on all significant issues that fall within the purview of such committees, including (i)&nbsp;subject to Section&nbsp;3.2.6(c), reviewing and submitting to the Parties for
approval any amendments to a Research Plan, and (ii)&nbsp;for any meeting of the JRC, (x)&nbsp;establishing a reasonably detailed agenda, including identification of relevant supporting information and materials to be discussed, for such meeting,
subject to the right of any member of the JRC to add additional agenda items at any meeting, and (y)&nbsp;promptly drafting and finalizing minutes of such meeting, for review and approval by the members of the JRC at the following meeting;
(d)&nbsp;reviewing and discussing each Party&#146;s plans and related activities with respect to <B>***</B> Licensed Products in such Party&#146;s Territory, including pre-launch and go-to-market strategies; and (e)&nbsp;attempting to resolve any
Disputes in accordance with Section&nbsp;15.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.2 After the License Grant Date for any Licensed Program, and for the
duration of the License Term for such Licensed Program, the Alliance Managers shall meet once per Calendar Quarter (or on such other schedule as may be determined by the Alliance Managers) to discuss any issues and concerns arising under the
Agreement. The Alliance Managers may attend such meetings in person, by telephone, or by videoconference; provided that the Alliance Managers shall meet in person at least twice per Calendar Year. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Ad Hoc Committees</U>. By mutual agreement, the Parties may establish and disband ad hoc committees having such responsibilities
as may be agreed by the Parties. Each such committee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on any
such committee by written notice to the other Party or to send substitute representatives to any meeting of any such committee. Each Party&#146;s representatives and any substitutes for such representatives on any such committee shall be bound by
the obligations of confidentiality set forth in ARTICLE 10. No such committee shall have the authority to bind the Parties hereunder. Except as otherwise agreed by the Parties, each such committee shall report to the Alliance Managers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Joint Research Committee</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.1 <U>Composition</U>. Promptly after the Effective Date, the Parties shall establish a joint research committee (the
&#147;<U>JRC</U>&#148;). The JRC shall be comprised of three (3)&nbsp;named representatives of Gilead and three (3)&nbsp;named representatives of MacroGenics (or such other number as the Parties may agree). Each Party may replace one or more of its
representatives, in its sole discretion, effective upon written notice to the other Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research
activities hereunder. Either Party may, from time to time, invite additional representatives or consultants to attend JRC meetings, subject to the written agreement of each such representative or consultant to comply with confidentiality obligations
substantially the same as those set forth in ARTICLE 10; provided, however, for avoidance of doubt, that such representatives or consultants shall not have any voting rights on the JRC. Each Party shall be responsible for all of its own expenses
incurred in connection with participating in any JRC meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.2 <U>Function and Powers of the JRC</U>. The JRC&#146;s
responsibilities shall be limited to matters regarding each Research Program, in each case solely during the Research Term thereof, and shall consist of the following activities: (a)&nbsp;subject to Section&nbsp;3.2.6(c), proposing any changes or
amendments to the Research Plan for the applicable Research Program, for approval by the Parties; (b)&nbsp;reviewing and monitoring progress for all activities performed under the applicable Research Program; and (c)&nbsp;informal resolution of
disagreements that may arise in the relation to the Parties&#146; activities under the applicable Research Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.3
<U>Co-Chairpersons</U>. Each Party shall designate one of its members of the JRC as a co-chairperson (each, a &#147;<U>Co-Chairperson</U>&#148;) of such committee. The Co-Chairpersons, in consultation with the Alliance Managers, shall have the
following roles and responsibilities: (a)&nbsp;to call meetings, send notice of each such meeting and designate the time, date and place of each such meeting, (b)&nbsp;to convene or poll the members by other permitted means, and (c)&nbsp;to sign and
date the final minutes of any meeting of the JRC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.4 <U>Committee Meetings</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Frequency</U>. For so long as the Research Term for any Research Program remains in effect, the JRC shall hold at least one
(1)&nbsp;meeting per Calendar Quarter at such time(s) during such Calendar Quarter as the Co-Chairpersons may determine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
<U>Quorum; Location</U>. Meetings of the JRC shall be effective only if at least one (1)&nbsp;representative of each Party is present or participating. The JRC may meet either (i)&nbsp;in person at either Party&#146;s facilities or at such locations
as the Parties may otherwise agree or (ii)&nbsp;by audio or video teleconference. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Cooperation</U>. Each Party shall
provide the JRC such information as required under the Research Plan for any Research Program, or as reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities pursuant to any
Research Program. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.5 <U>Decisions</U>. Actions to be taken by the JRC shall be taken only following a
<B>***</B>, with each Party having <B>***</B>. Notwithstanding anything to the contrary in this Agreement, Gilead shall have <B>***</B> on any matter involving <B>***</B>; provided, however, that Gilead shall not exercise its <B>***</B> in a manner
that would (a)&nbsp;conflict with any provisions of this Agreement; (b)&nbsp;require MacroGenics to perform activities (i)&nbsp;for which Gilead will not reimburse MacroGenics&#146; costs in accordance with Section&nbsp;3.2.6; or (ii)&nbsp;which
require MacroGenics to use any Know-How, Patents or other technology not contemplated in an Initial Research Plan and that are not (x)&nbsp;developed internally by MacroGenics, (y)&nbsp;licensed by Gilead to MacroGenics pursuant to Section&nbsp;4.2
or (z)&nbsp;in-licensed or otherwise acquired by MacroGenics pursuant to any MacroGenics Third Party Agreement; or (c)&nbsp;require MacroGenics to perform any act that it reasonably believes to be inconsistent with any Law or any approval, order,
policy or guidelines of a Regulatory Authority. Any matter on which the JRC fails to reach unanimous agreement for a period of <B>***</B>, including any matter subject to <B>***</B>, shall be referred to the Alliance Managers for attempted
resolution pursuant to Section&nbsp;15.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 <U>Authority</U>. The Alliance Managers and the JRC shall have only the powers
assigned expressly to each of them in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall retain the rights, powers and
discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the Alliance Managers, JRC or any ad hoc committee appointed hereunder unless such delegation or vesting of rights is expressly
provided for in this Agreement or the Parties expressly so agree in writing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 3 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESEARCH PROGRAMS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Research Overview</U>. Pursuant to this Agreement and as further provided in this ARTICLE 3, MacroGenics and Gilead shall use Reasonable Research Efforts to conduct the Research activities assigned
to such Party in each Research Plan during each Research Term for each Research Program. MacroGenics and Gilead shall conduct each Research Program in a good scientific manner and in accordance with applicable Law, including GLP and GCP. Neither
Party warrants that any Research Program shall achieve any of the research objectives contemplated in its Research Plan. At the end of the applicable Research Term, each Party&#146;s obligation to conduct such Research Program shall cease unless the
Parties mutually agree to extend its Research Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Conduct of the Research Programs</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1 <U>Selection of <B>***</B> Targets</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) At any time prior to the date that is <B>***</B> after the Effective Date (&#147;<U><B>***</B>Target Nomination Period</U><B>***</B>, Gilead may notify MacroGenics in writing of its nomination of a
combination of <B>***</B> Targets to serve as the <B>***</B><U>Target Nomination Period</U><B>***</B>, Gilead may notify MacroGenics in writing of its nomination of a combination of <B>***</B> Targets to serve as the <B>***</B> Targets
(&#147;<U><B>***</B> Target Nomination Notice</U>&#148;). For clarity, (1)&nbsp;Gilead may independently </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
nominate combinations for each of the <B>***</B> Targets and the <B>***</B> Targets, and Gilead&#146;s nomination of a combination for the <B>***</B> Targets shall not require a nomination for
the <B>***</B> Targets, or vice versa, (2)&nbsp;unless otherwise specified by Gilead in the <B>***</B> Target Nomination Notice, any nomination made by Gilead during the <B>***</B> Target Nomination Period prior to MacroGenics&#146; acceptance of a
nomination for the <B>***</B> Targets shall be deemed to be a nomination for the <B>***</B> Targets, and (3)&nbsp;any nomination made by Gilead after MacroGenics&#146; acceptance of a nomination for the <B>***</B> Targets shall be deemed to be a
nomination for the <B>***</B> Targets. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Within <B>***</B> days after MacroGenics&#146; receipt of any <B>***</B> Target
Nomination Notice or <B>***</B> Target Nomination Notice, MacroGenics shall notify Gilead whether it accepts such nomination and shall provide its reasons in the event it declines such nomination. <B>***</B> Targets only if the nominated
combination: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) includes a Target, other than <B>***</B>, with respect to which MacroGenics has a bona fide Active Research
Program; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) is subject to a written obligation under a bona fide collaboration, alliance, license or option agreement
entered into by MacroGenics prior to the date of such nomination; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) is subject to active negotiations in connection
with a bona fide written term sheet received, in the *** preceding such notice, from a potential collaborator, alliance partner or licensee contemplating an agreement that would provide for MacroGenics to develop products binding to one of the
Targets, other than ***, or grant any license with respect to one of the Targets, other than ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition to the foregoing conditions
upon which MacroGenics may decline a nomination, MacroGenics may (x)&nbsp;decline any nomination for the <B>***</B> Targets if the nominated combination is not directed to <B>***</B>, (y)&nbsp;solely if Gilead nominates and MacroGenics accepts
pursuant to this Section&nbsp;3.2.1 a combination for the <B>***</B> Targets that is not directed to <B>***</B> (as acknowledged by the Parties pursuant to the second sentence of this Section&nbsp;3.2.1(b)), decline any nomination for the <B>***</B>
Targets if the nominated combination is not directed to <B>***</B>, and (z)&nbsp;in its sole discretion, decline <B>***</B> nomination for the <B>***</B> Targets notified by Gilead after the first anniversary of the Effective Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event that MacroGenics declines any nomination for the <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2 <U>Research Program Initiation</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Following the Effective Date, MacroGenics shall begin conducting Research activities for the <B>***</B> Research Program and such activities shall progress in accordance with the Research Plan for the
<B>***</B> Research Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Gilead may provide separate written notices to MacroGenics (i)&nbsp;within <B>***</B> after
the Effective Date, of its desire to initiate Research activities for <B>***</B>, of its desire to initiate Research activities for the <B>***</B> as applicable (each a &#147;<U>Research Program </U>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<U>Initiation Notice</U>&#148;). For clarity, Gilead may independently provide a Research Program Initiation Notice for each of the <B>*** ***</B>, and Gilead&#146;s delivery of a Research
Program Initiation Notice for any particular Research Program shall not require the delivery of a Research Program Initiation Notice for any other Research Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Together with its delivery of a Research Program Initiation Notice for the <B>***</B> Licensed Program, the <B>***</B> Licensed Program or the <B>***</B> Licensed Program, as the case may be, Gilead
shall promptly notify MacroGenics as to whether, as determined by Gilead in good faith, any notifications are required to be filed with the U.S. Federal Trade Commission and/or the U.S. Department of Justice under the HSR Act with respect to the
exclusive license grants contemplated hereby relating to such Licensed Program (after giving effect to the delivery of such Research Program Initiation Notice) (&#147;<U>HSR Filing</U>&#148;). In the event that Gilead notifies MacroGenics that an
HSR Filing is required, each Party shall (i)&nbsp;as promptly as practicable after the date on which the applicable Research Program Initiation Notice is delivered, file or cause to be filed such HSR Filing with the appropriate agencies and
(ii)&nbsp;use reasonable efforts to respond promptly to any requests for additional information made by such agencies and to cause the waiting period (and any extension thereof) under the HSR Act to terminate or expire at the earliest possible date
after the date of filing. Gilead shall be responsible for all filing fees and for the costs and expenses of each Party in preparing and conducting the HSR Filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) Upon the Clearance Date for the <B>***</B> Licensed Program, the <B>***</B> Licensed Program or the <B>***</B> Licensed Program, as the case may be, MacroGenics shall begin conducting Research
activities for the Research Program associated with such Licensed Program and such activities shall progress in accordance the Research Plan for such Research Program or, by mutual agreement of the Parties, with the guidance of the JRC to the extent
such Research Plan is not yet available. <B>*** ***</B>, the Parties in good faith shall agree upon the information and data to be contained in the Preclinical Data Package for such Licensed Program (which information and data shall be similar to
the information and data set forth in <U>Exhibit D</U>). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) If Gilead fails to provide a Research Program Initiation Notice
within the applicable time period specified in subsection (b)&nbsp;above with respect to any of the *** Research Program, the *** Research Program or the *** Research Program, Gilead shall have no further rights under this Agreement with respect to
such Research Program or the corresponding Licensed Program and all rights and licenses hereunder with respect to such Research Program and Licensed Program shall terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.2.3 <U>Research Plan</U>. The initial Research Plan for the <B>***</B> Research Program is attached hereto as <U>Exhibit E</U> (the &#147;<U><B>***</B> Initial Research Plan</U>&#148;). Within
<B>***</B> after the Clearance Date with respect to the <B>***</B> Licensed Program, the <B>***</B> Licensed Program or the <B>***</B> Licensed Program, as the case may be, the Parties will prepare a draft initial Research Plan for the Research
Program associated with such Licensed Program for mutual approval (as applicable, the &#147;<U><B>***</B> Initial Research Plan</U>,&#148; &#147;<U><B>***</B> Initial Research Plan</U>&#148; and &#147;<U><B>***</B> Initial Research Plan</U>,&#148;
and each of the <B>***</B> Initial Research Plan, <B>***</B> Initial Research Plan, <B>***</B> Initial Research Plan and <B>***</B> Initial Research Plan, an &#147;<U>Initial Research Plan</U>&#148;). To the extent that any provision of a Research
Plan conflicts or is inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.4 <U>Supplemental Data</U>. Without limitation of Gilead&#146;s rights under
Section&nbsp;2.3.5 or ARTICLE 5, at any time during the Research Term for a Research Program, the Parties may, through the JRC in accordance with Section&nbsp;2.3.2, modify the applicable Research Plan to include activities to be conducted by Gilead
to generate additional pre-clinical data for such Research Program (the &#147;<U>Supplemental Data</U>&#148;). Gilead shall disclose to MacroGenics all Supplemental Data for the applicable Research Program within <B>***</B> days after the completion
of such activities. MacroGenics shall have the right to use the Supplemental Data in performing its obligations and exercising its rights under this Agreement. The availability and finalization of such Supplemental Data shall not in any way
(a)&nbsp;excuse any delay in the delivery of the Preclinical Data Package by MacroGenics to Gilead in accordance with Section&nbsp;3.3.1 or (b)&nbsp;affect the termination of the applicable Licensed Program under Section&nbsp;3.3.2(c) in the event
Gilead fails to provide notice of its intent to pay the applicable Preclinical Milestone in accordance with Section&nbsp;3.3.2(a) or extend the Evaluation Period in accordance with Section&nbsp;3.3.2(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.5 <U>Supply; Technology Transfer</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall use Commercially Reasonable Efforts to supply to Gilead such quantities of GLP-conforming (non-GMP research material) Program DARTs and Licensed Products as provided in the Research
Plan for use in any IND-enabling Development activities to be conducted by Gilead hereunder. MacroGenics shall use Commercially Reasonable Efforts to deliver such quantities of Program DARTs and Licensed Products in accordance with the delivery
conditions mutually agreed to by the Parties and, promptly following such delivery, shall provide Gilead with an invoice for MacroGenics&#146; FTE Costs and Out-of-Pocket Costs incurred in connection with such manufacture and supply in accordance
with a budget (including a reasonable allocation of any process development costs) to be agreed in advance by the Parties in good faith, along with any supporting documentation requested by Gilead. Gilead shall pay any such invoice within <B>***</B>
days after receipt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Prior to the initiation of IND-enabling Development activities with respect to any Licensed Product,
the Parties shall conduct good faith discussions regarding the possibility of entering into a supply agreement pursuant to which MacroGenics would supply such Licensed Product and the applicable Program DART(s) to Gilead for use in ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If the Parties have not entered into a supply agreement with respect to any Licensed Product pursuant to Section&nbsp;3.2.5(b)
within *** days after the initiation of negotiations by either Party (or, if the Parties enter into such a supply agreement, at any time after the expiration or termination of such supply agreement for any reason or, if earlier, reasonably *** in
advance of the anticipated commencement of a *** of such Licensed Product), upon written request of Gilead, MacroGenics shall promptly (i)&nbsp;transfer to Gilead all relevant MacroGenics Know-How described in clause (b)&nbsp;of Section&nbsp;1.70,
(ii)&nbsp;disclose to Gilead all other relevant MacroGenics Know-How, and (iii)&nbsp;provide to Gilead all technical assistance, in each case ((i), (ii)&nbsp;and (iii)) as reasonably required for Gilead to Manufacture, itself or through a Third
Party, such Licensed Product and the applicable Program DART(s) for use in Gilead&#146;s Development and Commercialization activities hereunder; and from time to time after such initial transfer, as reasonably requested by Gilead *** with respect to
any additional relevant </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics Know-How, MacroGenics shall transfer, disclose and provide assistance to Gilead with respect to such additional MacroGenics Know-How; provided, however, that in each case Gilead shall
reimburse MacroGenics for any Out-of-Pocket Costs incurred by MacroGenics in making such transfer or disclosure or providing such assistance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) At any time after the filing by Gilead or its applicable Affiliate of an IND with respect to a *** Licensed Product, upon written request of MacroGenics, Gilead shall promptly (i)&nbsp;transfer to
MacroGenics all relevant Gilead Collaboration Know-How described in clause (b)&nbsp;of Section&nbsp;1.70, (ii)&nbsp;disclose to MacroGenics all other relevant Gilead Collaboration Know-How, and (iii)&nbsp;provide to MacroGenics all technical
assistance, in each case ((i), (ii)&nbsp;and (iii)) as reasonably required for MacroGenics to Manufacture, itself or through a Third Party, such *** Licensed Product and the applicable *** Program DART(s) for use in MacroGenics&#146; Development and
Commercialization activities hereunder; and from time to time after such initial transfer, as reasonably requested by MacroGenics *** with respect to any additional relevant Gilead Collaboration Know-How, Gilead shall transfer, disclose and provide
assistance to MacroGenics with respect to such additional Gilead Collaboration Know-How; provided, however, that in each case MacroGenics shall reimburse Gilead for any Out-of-Pocket Costs incurred by Gilead in making such transfer or disclosure or
providing such assistance </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) If Gilead enters into a supply agreement with a Third Party manufacturer to supply any ***
Licensed Product, Gilead shall, if requested by MacroGenics, grant such Third Party any consents or approvals necessary to enable such Third Party manufacturer to supply to MacroGenics such *** Licensed Product pursuant to a supply agreement to be
entered into by MacroGenics and such Third Party manufacturer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.6 <U>Expenses; Reimbursement</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except as otherwise set forth elsewhere in this Agreement, Gilead shall bear its own costs and expenses of conducting its activities
in connection with any Research Program and any activities pursuant to Section&nbsp;3.2.3. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) During each Research Term,
Gilead shall reimburse MacroGenics for all Out-of-Pocket Costs incurred by MacroGenics in connection with the applicable Research Program, as specifically contemplated in the applicable Research Plan and in accordance with the budget for such
expenses set forth in such Research Plan (or by mutual agreement of the Parties, to the extent such Research Plan has not yet been approved). Gilead shall reimburse such Out-of-Pocket Costs within <B>***</B> days after receipt from MacroGenics of an
invoice issued within <B>***</B> days after the end of each Calendar Quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) During each Research Term, Gilead shall
reimburse MacroGenics at the FTE Rate for the costs of any FTEs for the applicable Research Program (not to exceed the number of FTEs specified in the applicable Research Plan (or by mutual agreement of the Parties, to the extent such Research Plan
has not yet been approved) for any period without Gilead&#146;s consent, not to be unreasonably withheld) to perform the activities allocated to MacroGenics under such Research Plan (or by mutual agreement of the Parties, to the extent such Research
Plan has not yet been approved). MacroGenics shall provide to Gilead, within </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<B>***</B> days after the end of each Calendar Quarter during any Research Term, a report indicating the number of FTEs actually provided by MacroGenics with respect to each Research Program
during such Calendar Quarter. MacroGenics shall use standard industry systems and processes to record the number of hours/FTEs actually applied to each Research Program, which systems and process shall be consistently and equitably applied to all
MacroGenics research programs with Third Parties. Gilead may, at any time during the applicable Research Term, request that the Parties amend the Research Plan to modify the prescribed activities or to reduce or increase on a Calendar Quarter basis
the number of FTEs to be provided by MacroGenics, and the Research Plan shall promptly be amended to account for such change in activities or any such reallocation of Research activities; provided that, on a Research Program-by-Research Program
basis, Gilead may not, without the prior written consent of MacroGenics: (i)&nbsp;reduce the number of FTEs for a Calendar Quarter to less than <B>***</B> FTEs or increase the number of FTEs for a Calendar Quarter to more than <B>***</B> FTEs; or
(ii)&nbsp;change the number of FTEs by more than <B>***</B> FTEs during any period of <B>***</B> consecutive Calendar Quarters. Gilead shall reimburse MacroGenics for such FTE costs within <B>***</B> days after receipt from MacroGenics of an invoice
issued within <B>***</B> days after the end of each Calendar Quarter. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.7 <U>Reports</U>. MacroGenics and Gilead shall
provide written progress reports on the status of its Research activities under each Research Plan, including summaries of data generated in the applicable Research Program, at least <B>***</B> Business Days in advance of each JRC meeting.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Preclinical Data Package; Evaluation Period</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.1 <U>Delivery of Preclinical Data Package</U>. MacroGenics shall provide Gilead with each Preclinical Data Package within <B>***</B>
days after the data to be contained in such Preclinical Data Package becomes available to MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2 <U>Preclinical
Milestone; Evaluation Period</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If Gilead intends to pay the applicable Preclinical Milestone Payment for a Licensed
Program, Gilead shall provide written notice thereof to MacroGenics at any time prior to <B>***</B> days after the expiration of the Evaluation Period for such Licensed Program (the &#147;<U>Preclinical Milestone Payment Notice</U>&#148;). If Gilead
has not previously delivered a Preclinical Milestone Payment Notice for a Licensed Program, Gilead will be deemed to have delivered the Preclinical Milestone Payment Notice for such Licensed Program and the Evaluation Period for such Licensed
Program shall be deemed to have expired upon the initiation of any GLP Toxicology Study with respect to any Program DART or Licensed Product from such Licensed Program. For purposes of this Section&nbsp;3.3.2(a), &#147;<U>GLP Toxicology
Study</U>&#148; means a toxicology study that is conducted in compliance with GLP and is required to meet the requirements for filing an IND. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) At any time prior to <B>***</B>days after the expiration of the then-current Evaluation Period for any Licensed Program, Gilead shall have the right, exercisable by written notice to MacroGenics, to
extend retroactively such Evaluation Period for a period of <B>***</B>months from the date such Evaluation Period otherwise would have expired (the &#147;<U>Initial </U> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<U>Extension</U>&#148;) by paying MacroGenics <B>***</B> for such Initial Extension; provided that Gilead shall have no right to extend any such Evaluation Period that expired due to the
<B>***</B> with respect to any Program DART or Licensed Product from such Licensed Program. At any time prior to the expiration of the Initial Extension for any Licensed Program, Gilead shall have the right, exercisable by written notice to
MacroGenics, to extend the Evaluation Period for such Licensed Program for an additional period of<B> ***</B> months from the date such Evaluation Period otherwise would have expired (the &#147;<U>Additional Extension</U>&#148;) (for a total
extension of <B>***</B> months from the date such Evaluation Period would have expired but for the Initial Extension and the Additional Extension) by paying MacroGenics <B>***</B> for such Additional Extension. Gilead shall make any payments under
this Section&nbsp;3.3.2(b) within forty-five (45)&nbsp;days after the later of the date Gilead delivers the applicable notice and Gilead&#146;s receipt of the corresponding invoice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event Gilead does not provide to MacroGenics a Preclinical Milestone Payment Notice with respect to any Licensed Program at
any time prior to*** days after the expiration of the Evaluation Period for such Licensed Program, then such Licensed Program shall be deemed a Terminated Program and Section&nbsp;13.7.1 shall apply with respect thereto. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 4 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GRANT OF RIGHTS; EXCLUSIVITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>License Grants to Gilead</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.1<U><B>***</B>Licensed Program</U>.
Subject to the terms of this Agreement, MacroGenics hereby grants Gilead (a)&nbsp;an exclusive, royalty-bearing, non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to Section&nbsp;4.3),
under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize, in the Field, Program DARTs (other than Diagnostics) and Licensed Products from the <B>***</B>Licensed
Program in the Gilead Territory; and (b)&nbsp;an exclusive, royalty-bearing (to the extent provided in Section&nbsp;8.5.3), non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to
Section&nbsp;4.3), under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize, in the Field, Diagnostics for use solely with Program DARTs and Licensed Products from
the <B>***</B>Licensed Program in the Gilead Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.2<U><B>***</B>Licensed Program</U>. Subject to the terms of this
Agreement, effective upon the Clearance Date for the <B>***</B>Licensed Program, MacroGenics hereby grants Gilead (a)&nbsp;an exclusive, royalty-bearing, non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to
sublicense (subject to Section&nbsp;4.3), under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize, Program DARTs (other than Diagnostics) and Licensed Products
from the <B>***</B> Licensed Program in the Gilead Territory in the Field; (b)&nbsp;an exclusive, royalty-bearing (to the extent provided in Section&nbsp;8.5.3), non-transferable (except in accordance with Section&nbsp;15.4) license, with the right
to sublicense (subject to Section&nbsp;4.3), under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed
Products from the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<B>***</B>Licensed Program in the Gilead Territory in the Field; and (c)&nbsp;subject to Section&nbsp;5.4, a non-exclusive, royalty-bearing (to the extent provided in Section&nbsp;8.5),
non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop and
Manufacture <B>***</B>Program DARTs and <B>***</B>Licensed Products in the MacroGenics Territory, provided that such <B>***</B>Program DARTs and <B>***</B>Licensed Products are Commercialized only in the Gilead Territory and only in the Field.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.3<U><B>***</B> Licensed Program</U>. Subject to the terms of this Agreement, effective upon the Clearance Date for the
<B>***</B> Licensed Program, MacroGenics hereby grants Gilead (a)&nbsp;an exclusive, royalty-bearing, non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under
MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize, Program DARTs (other than Diagnostics) and Licensed Products from the <B>***</B> Licensed Program in the Gilead
Territory in the Field; and (b)&nbsp;an exclusive, royalty-bearing (to the extent provided in Section&nbsp;8.5.3), non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to Section&nbsp;4.3),
under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed Products from the <B>***</B> Licensed Program
in the Gilead Territory in the Field. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.4<U><B>***</B> Licensed Program</U>. Subject to the terms of this Agreement,
effective upon the Clearance Date for the <B>***</B> Licensed Program, MacroGenics hereby grants Gilead (a)&nbsp;an exclusive, royalty-bearing, non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense
(subject to Section&nbsp;4.3), under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize, Program DARTs (other than Diagnostics) and Licensed Products from the
<B>***</B> Licensed Program in the Gilead Territory in the Field; and (b)&nbsp;an exclusive, royalty-bearing (to the extent provided in Section&nbsp;8.5.3), non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to
sublicense (subject to Section&nbsp;4.3), under MacroGenics&#146; and its Affiliates&#146; interests in MacroGenics IP and Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed
Products from the <B>***</B> Licensed Program in the Gilead Territory in the Field. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>License Grant to MacroGenics</U>.
Subject to the terms of this Agreement, Gilead hereby grants MacroGenics (a)&nbsp;effective upon the Clearance Date for the <B>***</B>Licensed Program, an exclusive, royalty-free, non-transferable (except in accordance with Section&nbsp;15.4)
license, with the right to sublicense (subject to Section&nbsp;4.3), under Gilead&#146;s and its Affiliates&#146; interest in Gilead Collaboration IP and Joint IP, to Research, Develop, Manufacture and Commercialize <B>***</B>Program DARTs and
<B>***</B>Licensed Products in the MacroGenics Territory in the Field; (b)&nbsp;effective upon the Clearance Date for the <B>***</B>Licensed Program, an exclusive, royalty-free, non-transferable (except in accordance with Section&nbsp;15.4) license,
with the right to sublicense (subject to Section&nbsp;4.3), under Gilead&#146;s and its Affiliates&#146; interest in Gilead Collaboration IP and Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with
<B>***</B>Program DARTs and <B>***</B>Licensed Products in the MacroGenics Territory in the Field; (c)&nbsp;effective upon the Clearance Date for the <B>***</B>Licensed Program, subject to Section&nbsp;5.5, a
non-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
exclusive, royalty-free, non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under Gilead&#146;s and its
Affiliates&#146; interest in Gilead Collaboration IP and Joint IP, to Research, Develop and Manufacture <B>***</B>Program DARTs and <B>***</B>Licensed Products in the Gilead Territory, provided that such <B>***</B>Program DARTs and
<B>***</B>Licensed Products are Commercialized only in the MacroGenics Territory and only in the Field; and (d)&nbsp;subject to Section&nbsp;4.9, a non-exclusive, royalty-free, non-transferable (except in accordance with Section&nbsp;15.4) license,
with the right to sublicense (subject to Section&nbsp;4.3), under Gilead&#146;s and its Affiliates&#146; interest in Gilead Collaboration IP and Joint IP that are Platform IP, to Research, Develop, Manufacture and Commercialize throughout the world
DARTs which are not Program DARTs or Licensed Products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3 <U>Sublicenses</U>. Each Party shall have the right to grant
sublicenses within the scope of the licenses under Section&nbsp;4.1 or 4.2, as applicable, to its Affiliates and to Third Parties that desire to conduct Research, Development, Manufacture and/or Commercialization activities with respect to Program
DARTs and Licensed Products; <U>provided</U>, <U>however</U>, that without the prior written consent of MacroGenics, Gilead shall not have the right to sublicense (a)&nbsp;any MacroGenics Know-How to any Generic Licensee; (b)&nbsp;any rights under
Patents or Know-How licensed to MacroGenics pursuant to a MacroGenics Third Party Agreement to any Generic Licensee; or (c)&nbsp;any rights under Patents or Know-How licensed to MacroGenics pursuant to a MacroGenics Third Party Agreement that
requires MacroGenics (or the applicable Third Party licensor) to consent to any such sublicense; and <U>provided</U> <U>further</U> that any sublicense granted to a Third Party (other than a Generic Licensee or Compulsory Licensee) under this
Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement, including the confidentiality provisions of ARTICLE 10. If either Party grants a sublicense
to a Third Party (including to any Generic Licensee) as permitted by this Section&nbsp;4.3, then such Party shall provide the other Party prompt written notice thereof and shall provide the other Party with an executed copy of any such sublicense
(redacted as necessary to protect confidential or commercially sensitive information). Except with respect to any Generic Licensee or Compulsory Licensee or as otherwise agreed by the Parties in writing, each Party shall be jointly and severally
responsible with its sublicensees to the other Party for failure by its sublicensees to comply with this Agreement. Each Party shall use commercially reasonable efforts to enforce the terms of any sublicense granted by such Party under this
Agreement to any sublicensee other than a Compulsory Licensee to the extent such Party learns, or otherwise knows, that such sublicensee is in breach of any provision of such sublicense in a manner that would reasonably be likely to materially harm
the other Party. In the event that a Generic Licensee fails to honor a payment obligation under a sublicense granted under this Agreement (and has not cured such failure within any applicable cure period), at the request of MacroGenics, Gilead
shall, at Gilead&#146;s election, either terminate the sublicense or pay MacroGenics the amount that would have been due to MacroGenics under Section&nbsp;8.5.2 if such Generic Licensee had honored its payment obligation. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4 <U>First Right of Negotiation For MacroGenics Territory</U>. If at any time during the Agreement Term MacroGenics desires to enter
into a licensing transaction with a Third Party to Commercialize one or more <B>***</B>Program DART(s) or <B>***</B>Licensed Product(s) in the Field in the MacroGenics Territory (but excluding any transaction that results in a Change of Control),
MacroGenics shall notify Gilead of its intent to enter into such a transaction, identifying the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
</B>applicable <B>***</B>Program DART(s) or <B>***</B>Licensed Products(s) that is(are) proposed to be the subject of such transaction. Gilead shall have <B>***</B> days from receipt of such
written notice to notify MacroGenics in writing as to whether Gilead desires to negotiate for such rights, and if Gilead so notifies MacroGenics that it does desire to negotiate for such rights, the Parties shall, for a period of <B>***</B> days
from the date of such notification to MacroGenics, negotiate in good faith the terms of a definitive agreement for such rights; provided, however, that if Gilead and MacroGenics do not enter into a definitive agreement within such <B>***</B> day
period, Gilead&#146;s rights under this Section&nbsp;4.4 shall terminate and MacroGenics shall be free to enter into any licensing transaction to Commercialize the applicable <B>***</B>Program DART(s) or <B>***</B>Licensed Product(s) in the Field in
the MacroGenics Territory without further obligation to Gilead under this Section&nbsp;4.4. <B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5
<U>Subcontracting</U>. Subject to the terms of this Agreement, each Party shall have the right to engage Affiliates or Third Party subcontractors to perform activities ascribed to such Party, under this Agreement. Any Affiliate or subcontractor to
be engaged by a Party to perform a Party&#146;s obligations under this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity; provided,
however, that any Party engaging an Affiliate or subcontractor hereunder shall remain fully responsible and obligated for such activities. In addition, each Party engaging a subcontractor shall (a)&nbsp;obtain such rights to any Know-How, Patents or
other intellectual property rights created, discovered, invented, conceived or reduced to practice by such subcontractor with respect to any Program DART or Licensed Product as may be required for the Parties to exercise their rights and carry out
their responsibilities under this Agreement with respect to such Program DART or Licensed Product without infringing the intellectual property rights of such subcontractor and, unless otherwise agreed by the other Party in writing, without incurring
any additional costs that would be borne by the other Party, and (b)&nbsp;use Commercially Reasonable Efforts to obtain Control of any Know-How, Patents or other intellectual property rights created, discovered, invented, conceived or reduced to
practice by such subcontractor with respect to any Program DART or Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6 <U>MacroGenics Third Party
Agreements</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6.1 In the event that MacroGenics enters into an agreement with a Third Party after the Effective Date that
meets the criteria set forth in clause (a)&nbsp;of the definition of MacroGenics Third Party Agreements, then MacroGenics will promptly provide Gilead with notice and a copy of the applicable Third Party agreement. Within <B>***</B> days following
receipt of such notice, Gilead will decide, in its sole discretion, whether or not to accept the applicable Third Party agreement as a MacroGenics Third Party Agreement, and provide MacroGenics written notice of such decision. In the event that
Gilead accepts such Third Party agreement as a MacroGenics Third Party Agreement, such agreement will thereafter be included within the definition of MacroGenics Third Party Agreements. In the event that Gilead does not accept such Third Party
agreement as a MacroGenics Third Party Agreement, (a)&nbsp;Gilead and its Affiliates shall have no obligations with respect to such Third Party agreement and (b)&nbsp;to the extent there is a conflict between the terms of any such Third Party
agreement and the terms of this Agreement, including the rights granted to Gilead hereunder, then as between Gilead and MacroGenics, the terms of this Agreement shall control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6.2 Gilead covenants to comply with, and to cause its Affiliates and Sublicensees to
comply with, any MacroGenics Third Party Agreements, and to take any action or provide any information reasonably requested by MacroGenics to prevent any potential breach of any terms of such MacroGenics Third Party Agreements. To the extent there
is a conflict between the terms of any MacroGenics Third Party Agreement and the rights granted to Gilead hereunder, the terms of such MacroGenics Third Party Agreement shall control solely with respect to the Patents and Know-How owned or
controlled by such Third Party licensor. MacroGenics shall not terminate or consent to the termination of any MacroGenics Third Party Agreement without Gilead&#146;s prior reasonable consent if such termination would affect any license or other
rights of Gilead hereunder; provided, however, that MacroGenics may (a) ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7 <U>Rights Retained by the Parties</U>. Any
rights of MacroGenics or Gilead, as the case may be, not expressly granted to the other Party pursuant to this Agreement shall be retained by such Party. Notwithstanding the exclusive licenses granted to Gilead pursuant to Section&nbsp;4.1,
MacroGenics retains the right to (a)&nbsp;practice the MacroGenics IP and Joint IP to perform (and to sublicense Third Parties to perform) its obligations under this Agreement and in the exercise of its rights under the license grant set forth in
Section&nbsp;4.2(c); and (b)&nbsp;<B>***</B>. Notwithstanding the exclusive licenses granted to MacroGenics pursuant to Section&nbsp;4.2, Gilead retains the right to practice the Gilead Collaboration IP and Joint IP in the exercise of its rights
under the license grant set forth in Section&nbsp;4.1.2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8 <U>Section&nbsp;365(n) of the Bankruptcy Code</U>. All rights
and licenses granted under or pursuant to any section of this Agreement are and will otherwise be deemed to be for purposes of Section&nbsp;365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the &#147;<U>Bankruptcy
Code</U>&#148;), or any analogous provision of applicable Law outside the United States, licenses of rights to &#147;intellectual property&#148; as defined in Section&nbsp;101(35A) of the Bankruptcy Code, or any analogous provision of applicable Law
outside the United States. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code or analogous provisions of applicable Law outside the United States. Each Party agrees that the other
Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection
for &#147;intellectual property.&#148; The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of applicable Law outside the United
States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in such Party&#146;s possession, will be
promptly delivered to it upon such Party&#146;s written request thereof. Any agreements supplemental hereto will be deemed to be &#147;agreements supplementary to&#148; this Agreement for purposes of Section&nbsp;365(n) of the Bankruptcy Code or any
analogous provision of applicable Law outside the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9 <U>Exclusivity</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9.1 During the term of this Agreement, other than with respect to the Research and Development activities pursuant to this Agreement or
as permitted under Section&nbsp;4.7(b), neither MacroGenics nor its Affiliates shall, <B>***</B>, (a)&nbsp;conduct or assist any Third Party in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conducting any Research, Development, Manufacture or Commercialization of a Competing Product in the Gilead Territory, (b)&nbsp;<B>***</B> (c)&nbsp;grant any license or other rights to any Third
Party under its interests in the MacroGenics IP or Joint IP to Research, Develop, Manufacture or Commercialize a Competing Product in the Gilead Territory. Notwithstanding the foregoing, MacroGenics shall not be deemed to have breached its
obligations under clause (a)&nbsp;of this Section&nbsp;4.9.1 solely as a result of activities conducted by a Third Party licensee, sublicensee or collaborator of MacroGenics if (x)&nbsp;the conduct of such activities by such Third Party violates the
terms of the applicable agreement between MacroGenics and such Third Party and (y)&nbsp;MacroGenics uses reasonable efforts to enforce the terms of such agreement against such Third Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9.2 Subject to Section&nbsp;15.4, in the event of an acquisition of MacroGenics or its assets or equity by a Third Party, the
prohibitions set forth in Section&nbsp;4.9.1 shall not apply to the extent a breach of Section&nbsp;4.9.1 would result from an activity or conduct by such Third Party where such Third Party was engaged in such activity or conduct prior to such
acquisition. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 5 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>DEVELOPMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Overview</U>. Following receipt by MacroGenics
of a Preclinical Milestone Payment Notice for any Licensed Program, Gilead will, subject to the terms of this Agreement, be responsible for the Development of Licensed Products from such Licensed Program in the Field for the Gilead Territory.
Following receipt by MacroGenics of a Preclinical Milestone Payment Notice for the *** Licensed Program, MacroGenics will, subject to the terms of this Agreement, be responsible for Development of Licensed Products from the *** Licensed Program in
the Field for the MacroGenics Territory. While the Parties may choose, at their sole discretion, to work together on particular projects, except as otherwise provided in this Agreement, the Parties will operate independently in their activities for
their respective Development of Licensed Products, but will provide access to certain information to each other as expressly described in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Gilead Diligence Obligations</U>. Gilead shall, at its own expense, use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for (a)&nbsp;in the <B>***</B> and
(b)&nbsp;in<B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Joint Development Activities</U>. With respect to the <B>***</B> Licensed Program, from time to
time during the License Term, either Party may submit a proposal to the other Party through the Alliance Managers to jointly conduct Development activities specifically designed for the purpose of facilitating Regulatory Approval of a <B>***</B>
Licensed Product in both the Gilead Territory and the MacroGenics Territory (a &#147;<U>Joint Development Activity</U>&#148;). In the event that the Parties mutually agree to conduct such Joint Development Activity, the Parties will (a)&nbsp;agree
in writing to a written work plan and time table for conducting such Joint Development Activity and a mechanism for adopting amendments thereto; (b)&nbsp;agree in writing to governance and management mechanisms for such Joint Development Activity,
including coordination of such Joint Development Activity through the Alliance Managers; and (c)&nbsp;negotiate in good faith a budget therefor, a mechanism for adopting amendments thereto, and an equitable allocation of costs between the Parties.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4 <U>Gilead<B> ***</B> Clinical Trials</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.1 In the event that Gilead or one of its Affiliates or Sublicensees desires to conduct, directly or indirectly, any Clinical Trial or
other clinical study, including any investigator initiated studies sponsored by Gilead or its Affiliates or Sublicensees, of any <B>***</B>Program DART or <B>***</B>Licensed Product in any country in the MacroGenics Territory <B>***</B>: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall have the right to review a draft of the protocol of such Clinical Trial or study reasonably in advance of the
commencement of such Clinical Trial or study; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall have the right to provide comments on such draft
protocol to Gilead no later than <B>***</B> weeks after receipt by MacroGenics thereof, and Gilead (or its applicable Affiliate or Sublicensee) shall reasonably consider such comments; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics shall have the right to object to such protocol based on a Significant Adverse Effect (a &#147;<U>MacroGenics
Objection</U>&#148;), provided that (i)&nbsp;the basis of such MacroGenics Objection is consistently applied by MacroGenics to its and Gilead&#146;s active and completed Clinical Trials or other studies with respect to the <B>***</B>Licensed
Program, (ii)&nbsp;such MacroGenics Objection is made by written notice to Gilead no later than <B>***</B> weeks after receipt by MacroGenics of the protocol, and such written notice specifically identifies, in reasonable detail, the potential risk
such Clinical Trial or study may pose. Gilead may proceed with any such Clinical Trial or study in the event that MacroGenics does not provide written notice of a MacroGenics Objection within such <B>***</B> week period; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) in the event MacroGenics timely and appropriately delivers notice of a MacroGenics Objection to Gilead, (i)&nbsp;the Parties&#146;
respective clinical development teams shall, within <B>***</B> Business Days following the delivery of such notice, convene for the purpose of discussing in good faith and resolving the MacroGenics Objection, and (ii)&nbsp;(x)&nbsp;if conducting
such Clinical Trial or study is reasonably necessary for obtaining or maintaining Marketing Approval for a Licensed Product in the <B>***</B>, then Gilead or its applicable Affiliate or Sublicensee may conduct (or sponsor, as applicable) such
Clinical Trial or study without the approval of MacroGenics, and (y)&nbsp;in all other cases, Gilead or its applicable Affiliate or Sublicensee may not conduct (or sponsor, as applicable) such Clinical Trial or study without the prior written
approval of MacroGenics (not to be unreasonably withheld, conditioned or delayed); provided, however, that withholding, conditioning or delaying such approval based on the continued existence of a Significant Adverse Effect shall be deemed not
unreasonable; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) in the event any protocol for any Clinical Trial or study previously reviewed by Gilead pursuant to
this Section&nbsp;5.4.1 is materially changed, such Clinical Trial or study under such changed protocol shall again be subject to the provisions of this Section&nbsp;5.4.1 as if it were a new Clinical Trial or study. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2 Without the prior written consent of MacroGenics, neither Gilead nor any of its Affiliates or Sublicensees shall conduct, directly
or indirectly, any Clinical Trial or other clinical study, including any investigator initiated studies sponsored by Gilead or its Affiliates or Sublicensees, of any <B>***</B>Program DART or <B>***</B>Licensed Product in <B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.3 In the event that Gilead or one of its Affiliates or Sublicensees desires to conduct,
directly or indirectly, any Clinical Trial or other clinical study, including any investigator initiated studies sponsored by Gilead or its Affiliates or Sublicensees, of any <B>***</B>Program DART or <B>***</B>Licensed Product in the Gilead
Territory, MacroGenics shall have the right to review a draft of the protocol of such Clinical Trial or study reasonably in advance of the commencement of such Clinical Trial or study. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5 <U>MacroGenics <B>***</B>Clinical Trials</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.5.1 In the event that MacroGenics or one of its Affiliates or Sublicensees desires to conduct, directly or indirectly, any Clinical Trial or other clinical study, including any investigator initiated
studies sponsored by MacroGenics or its Affiliates or Sublicensees, of any <B>***</B>Program DART or <B>***</B>Licensed Product: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Gilead shall have the right to review a draft of the protocol of such Clinical Trial or study reasonably in advance of the commencement of such Clinical Trial or study; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Gilead shall have the right to provide comments on such draft protocol to MacroGenics no later than <B>***</B> weeks after receipt
by Gilead thereof, and MacroGenics (or its applicable Affiliate or Sublicensee) shall reasonably consider such comments; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)
Gilead shall have the right to object to such protocol based on a Significant Adverse Effect (a &#147;<U>Gilead Objection</U>&#148;), provided that (i)&nbsp;the basis of such Gilead Objection is consistently applied by Gilead to its and
MacroGenics&#146; active and completed Clinical Trials or other studies with respect to the <B>***</B> Licensed Program, (ii)&nbsp;such Gilead Objection is made by written notice to MacroGenics no later than <B>***</B> weeks after receipt by Gilead
of the protocol, and such written notice specifically identifies, in reasonable detail, the potential risk such Clinical Trial or study may pose. MacroGenics may proceed with any such Clinical Trial or study in the event that Gilead does not provide
written notice of a Gilead Objection within such <B>***</B> week period; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) in the event Gilead timely and
appropriately delivers notice of a Gilead Objection to MacroGenics, (i)&nbsp;the Parties&#146; respective clinical development teams shall, within *** Business Days following the delivery of such notice, convene for the purpose of discussing in good
faith and resolving the Gilead Objection, and (ii)&nbsp;without the prior written approval of Gilead (not to be unreasonably withheld, conditioned or delayed; provided, however, that withholding, conditioning or delaying such approval based on the
continued existence of a Significant Adverse Effect shall be deemed not unreasonable), MacroGenics or its applicable Affiliate or Sublicensee shall not conduct (or sponsor, as applicable) such Clinical Trial or study. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2 In the event any protocol for any Clinical Trial or study previously reviewed by
Gilead pursuant to Section&nbsp;5.5.1 is <B>***</B>, such Clinical Trial or study under such changed protocol shall again be subject to the provisions of Section&nbsp;5.5.1 as if it were a new Clinical Trial or study. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6 <U>Development Costs</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.6.1 <U>Gilead Territory Development Activities</U>. Except as specifically provided in Section&nbsp;5.3, Gilead shall be responsible for <B>***</B> of all Development costs incurred by Gilead and its
Affiliates with respect to any Development activities that are conducted with respect to Program DARTs or Licensed Products in the Field in the Gilead Territory or, as permitted under this Agreement, in the MacroGenics Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.2 <U>MacroGenics Territory Development Activities</U>. Except as specifically provided in Section&nbsp;5.3 or the Research Plan for
the <B>***</B>Research Program, MacroGenics shall be responsible for <B>***</B> of all Development costs incurred by MacroGenics and its Affiliates with respect to any Development activities that are conducted with respect to Program DARTs and
Licensed Products from the <B>***</B>Licensed Program in the Field in the MacroGenics Territory or, as permitted under this Agreement, in the Gilead Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.7 <U>Reports; Exchange of Data</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7.1 For each
Licensed Program, from Gilead&#146;s delivery of a Preclinical Milestone Payment Notice for such Licensed Program until the receipt of Marketing Approval for a Licensed Product from such Licensed Program, Gilead shall, by January&nbsp;31</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each Calendar Year, provide a report on Gilead&#146;s Research
and Development activities for such Licensed Program. The report shall describe, among other matters: (a)&nbsp;material activities completed since the last report including the object and parameters of the Development, when initiated, when completed
and a summary of all material results; (b)&nbsp;material activities currently under investigation; (c)&nbsp;material activities planned to be undertaken before the next report including the type and object of any Clinical Trials to be conducted and
their projected starting and completion dates; and (d)&nbsp;material changes in Gilead&#146;s Development and Commercialization plans. In addition, Gilead shall reasonably respond to reasonable requests by MacroGenics for information regarding
Gilead&#146;s Research and Development activities for such Licensed Program. All reports and information provided to MacroGenics by Gilead pursuant to this Section&nbsp;5.7.1 shall be deemed the Confidential Information of Gilead and subject to the
confidentiality and non-use obligations set forth in ARTICLE 10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7.2 Without limitation of
Section&nbsp;5.5, from Gilead&#146;s delivery of a Preclinical Milestone Payment Notice for the ***Licensed Program until the receipt of Marketing Approval for a Licensed Product from the ***Licensed Program, MacroGenics shall, by
January&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each Calendar Year, provide a report
on MacroGenics&#146; Research and Development activities for the ***Licensed Program. The report shall describe, among other matters: (a)&nbsp;material activities completed since the last report including the object and parameters of the
Development, when initiated, when completed and a summary of all material results; (b)&nbsp;material activities currently under investigation; (c)&nbsp;material activities planned to be undertaken before the next report
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
including the type and object of any contemplated Clinical Trials and their projected starting and completion dates; and (d)&nbsp;material changes in MacroGenics&#146; Development and
Commercialization plans. In addition, MacroGenics shall reasonably respond to reasonable requests by Gilead for information regarding MacroGenics&#146; Research and Development activities for the ***Licensed Program. All reports and information
provided to Gilead by MacroGenics pursuant to this Section&nbsp;5.7.2 shall be deemed the Confidential Information of MacroGenics and subject to the confidentiality and non-use obligations set forth in ARTICLE 10. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7.3 <U>Exchange of Data</U>. Promptly after MacroGenics&#146; receipt of a Preclinical Milestone Payment Notice with respect to any
Licensed Program, and from time to time thereafter during the applicable License Term, in each case in a manner and following a reasonable schedule to be established by the Alliance Managers: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall (i)&nbsp;transfer to Gilead all MacroGenics Know-How described in clause (b)&nbsp;of Section&nbsp;1.70, and
(ii)&nbsp;disclose to Gilead all other MacroGenics Know-How, in each case ((i) and (ii)) related to Program DARTs and Licensed Products from such Licensed Program, created by or on behalf of MacroGenics and not already transferred or disclosed to
Gilead. Such transfer and disclosure shall include copies of relevant material, information, reports and data, including pre-clinical data, clinical data, and any data that has been provided to Regulatory Authorities for the purpose of obtaining
Regulatory Approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If such Preclinical Milestone Payment Notice was delivered with respect to the <B>***</B>Licensed
Program, Gilead shall (i)&nbsp;transfer to MacroGenics all Gilead Collaboration Know-How described in clause (b)&nbsp;of Section&nbsp;1.70, and (ii)&nbsp;disclose to MacroGenics all other Gilead Collaboration Know-How, in each case ((i) and (ii))
related to <B>***</B>Program DARTs and <B>***</B>Licensed Products, created by or on behalf of Gilead and not already transferred or disclosed to MacroGenics.&nbsp;Such transfer and disclosure shall include copies of relevant material, information,
reports and data, including pre-clinical data, clinical data, and any data that has been provided to Regulatory Authorities for the purpose of obtaining Regulatory Approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.7.4 <U>Use</U>. All preclinical, non-clinical, analytical, manufacturing, and clinical data and associated reports disclosed by one Party to the other under this Agreement may be used by the receiving
Party subject to the terms of this Agreement solely for the purpose of exercising its rights and performing its obligations under this Agreement.&nbsp;Subject to ARTICLE 10, each Party shall have the right to share any and all such data and other
regulatory materials received from the other Party with its Affiliates and Sublicensees and subcontractors solely for the purpose of exercising such Party&#146;s rights and performing its obligations under this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 6 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>REGULATORY MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 6 shall apply
during each License Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Gilead Regulatory Responsibility</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.1 Following receipt by MacroGenics of a Preclinical Milestone Payment Notice, Gilead shall (a)&nbsp;own and be responsible for
preparing, filing and maintaining all Regulatory Documentation and Regulatory Approvals that are required for the Development, Manufacture and Commercialization of the Program DARTs or Licensed Products from the applicable Licensed Program in the
Field in the Gilead Territory for such Licensed Program, (b)&nbsp;otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the Gilead Territory for such Licensed Program with respect to such Licensed
Program, and (c)&nbsp;comply with all applicable Laws in the Gilead Territory for such Licensed Program, including FDA regulations, local regulations and ICH guidelines, with respect to such Licensed Program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.2 Gilead hereby grants to MacroGenics a Right of Reference or Use to any Regulatory Documentation in the *** Licensed Territory
Controlled by Gilead for use by MacroGenics in the MacroGenics Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by MacroGenics in order to further effect
such grant. Gilead shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. Gilead shall also permit MacroGenics, upon reasonable notice, during regular business hours, to inspect any such Regulatory
Documentation; provided, however, that such inspections be limited in frequency to once per Calendar Year unless extraordinary circumstances (as reasonably agreed by the Parties) require more frequent inspections. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>MacroGenics Regulatory Responsibility</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.2.1 During the <B>***</B>License Term MacroGenics shall (a)&nbsp;own and be responsible for preparing, filing and maintaining all Regulatory Documentation and Regulatory Approvals that are required for
the Development, Manufacture and Commercialization of <B>***</B>Program DARTs or <B>***</B>Licensed Products in the Field in the MacroGenics Territory, (b)&nbsp;otherwise be responsible for and have sole authority as to all interactions with
Regulatory Authorities in the MacroGenics Territory with respect to the <B>***</B>Licensed Program, and (c)&nbsp;comply with all applicable Laws in the MacroGenics Territory, including FDA regulations, local regulations and ICH guidelines, with
respect to the <B>***</B>Licensed Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.2 MacroGenics hereby grants to Gilead a Right of Reference or Use to any
Regulatory Documentation in the MacroGenics Territory Controlled by MacroGenics for use by Gilead in the Gilead Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably
requested by Gilead in order to further effect such grant. MacroGenics shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. MacroGenics shall also permit Gilead, upon reasonable notice,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
during regular business hours, to inspect any such Regulatory Documentation; provided, however, that such inspections be limited in frequency to once per Calendar Year unless extraordinary
circumstances (as reasonably agreed by the Parties) require more frequent inspections. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Communications with Regulatory
Authorities</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.1 Gilead shall be responsible for all submissions to, and communications and interactions with,
Regulatory Authorities in the Gilead Territory for any Licensed Program with respect to Program DARTs and Licensed Products from such Licensed Program, and MacroGenics shall be responsible for all submissions to, and communications and interactions
with, Regulatory Authorities in the MacroGenics Territory with respect to <B>***</B> Program DARTs and <B>***</B> Licensed Products. In connection therewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Gilead shall keep MacroGenics reasonably informed regarding Gilead&#146;s (or its Affiliate&#146;s or Sublicensee&#146;s) regulatory strategy, planned regulatory submissions and communications with
the Regulatory Authorities in the <B>***</B> Licensed Territory with respect to <B>***</B> Program DARTs and <B>***</B> Licensed Products, including any significant changes to such strategy, submissions or communications. Gilead shall provide
MacroGenics with copies of key portions of regulatory submissions to, and key communications with, the FDA and Regulatory Authorities in the EU relating to the <B>***</B> Program DARTs and <B>***</B> Licensed Products in the <B>***</B> Licensed
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall keep Gilead reasonably informed regarding MacroGenics&#146; (or its Affiliate&#146;s or
Sublicensee&#146;s) regulatory strategy, planned regulatory submissions and communications with the Regulatory Authorities in the MacroGenics Territory with respect to Program DARTs and Licensed Products from the *** Licensed Program, including any
significant changes to such strategy, submissions or communications. MacroGenics shall provide Gilead with copies of key portions of regulatory submissions to, and key communications with, the PMDA relating to the *** Program DARTs and *** Licensed
Products in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Pharmacovigilance and Safety Data Reporting for the *** Licensed Program</U>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4.1 <U>Pharmacovigilance</U>. Commencing at least thirty (30)&nbsp;days prior to the projected date for Gilead&#146;s
commencement of the first Phase 1 Clinical Trial for a <B>***</B> Licensed Product, if MacroGenics is then actively Developing a <B>***</B> Licensed Product, the Parties shall negotiate in good faith, with respect to <B>***</B> Licensed Products, a
safety data exchange agreement, governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experience, <B>***</B> Licensed Product quality and <B>***</B> Licensed Product complaints, sufficient
to permit each Party to comply with its legal obligations (the &#147;<U>SDEA Agreement</U>&#148;). The SDEA Agreement shall provide that Gilead will establish and maintain the global safety database for each <B>***</B> Licensed Product. The SDEA
Agreement will be promptly updated if required by changes in legal requirements. The Parties may mutually agree to terminate the SDEA Agreement at any time if a Party determines to permanently cease conducting Development and Commercialization
activities with respect to <B>***</B> Licensed Products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4.2 <U>Safety Data Reporting</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Each Party shall keep the other Party informed about any adverse drug reactions/experiences (as defined in the SDEA Agreement) of
which such Party becomes aware or is informed about regarding the use of a <B>***</B>Licensed Product in the MacroGenics Territory or the <B>***</B>Licensed Territory. As between the Parties, Gilead shall be responsible for reporting all such
adverse drug reactions/experiences to the appropriate Regulatory Authorities in countries in the <B>***</B>Licensed Territory, and MacroGenics shall be responsible for reporting all such adverse drug reactions/experiences to the appropriate
Regulatory Authorities in the MacroGenics Territory for the <B>***</B>Licensed Program, in each case in accordance with the appropriate Laws of the relevant countries and authorities. Gilead shall ensure that its Affiliates and Sublicensees comply
with such reporting obligations in the <B>***</B>Licensed Territory and MacroGenics shall ensure that its Affiliates and sublicensees (other than Gilead and its Sublicensees) comply with such reporting obligations in the MacroGenics Territory. These
reporting obligations shall apply to other adverse events with respect to <B>***</B>Licensed Products as described in the SDEA Agreement, including adverse events occurring from product overdose or from product withdrawal, as well as any toxicity,
sensitivity, failure of expected pharmacological action, or laboratory abnormality which is, or is thought by the reporter, to be serious or associated with relevant clinical signs or symptoms. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) For the <B>***</B>Licensed Program, during the negotiation of the SDEA Agreement, each Party will designate a pharmacovigilance
liaison to be responsible for communicating with the other Party regarding the reporting of adverse drug reactions/experiences. Each Party (the &#147;<U>Notifying Party</U>&#148;) shall notify the other Party in writing of all information coming to
the Notifying Party&#146;s attention, regardless of the origin of such information, and including such information coming to its attention through clinical and non-clinical sources (including journal publications and other media), regarding adverse
drug reactions/experiences associated with a <B>***</B>Licensed Product, whether in the <B>***</B>Licensed Territory or in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 7 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>COMMERCIALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 7 shall apply during each License Term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Overview</U>.&nbsp;Gilead shall have sole control and responsibility for the Commercialization of Licensed Products in the Field
in the Gilead Territory and shall bear all costs and expenses associated therewith. MacroGenics shall have sole control and responsibility for the Commercialization of <B>***</B> Licensed Products in the MacroGenics Territory and shall bear all
costs and expenses associated therewith. The Party with responsibility for Commercialization of a Licensed Product in a Territory shall be referred to as the &#147;<U>Commercializing Party</U>&#148; for such Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Gilead Obligations</U>. Following receipt of the applicable Marketing Approval with
respect to each Licensed Product, Gilead shall, at its own expense, use Commercially Reasonable Efforts to Commercialize such Licensed Product in the <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.3 <U>Sales and Distribution</U>.&nbsp;It is understood that as between the Parties, the Commercializing Party shall be solely responsible for handling all returns, order processing, invoicing and
collection, distribution, and receivables for Licensed Products in the applicable Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4 <U>Ex-Territory
Sales</U>.&nbsp;Subject to applicable Law, the Commercializing Party shall not engage in any advertising or promotional activities relating to Licensed Product directed primarily to customers or other buyers or users of Licensed Product located
outside its Territory, or accept orders for Licensed Products from or sell Licensed Products into the other Party&#146;s Territory, whether for its own account or for the other Party&#146;s account. If the Commercializing Party receives any order
for Licensed Products in the other Party&#146;s Territory, it shall refer such orders to the other Party for acceptance or rejection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.5 <U>Commercialization Plan</U>. For each Licensed Product, Gilead shall deliver an initial Commercialization plan to MacroGenics no later than <B>***</B> prior to the anticipated date of the First
Commercial Sale of such Licensed Product in the Gilead Territory . For each <B>***</B> Licensed Product, MacroGenics shall deliver an initial Commercialization plan to Gilead no later than <B>***</B> prior to the anticipated date of the First
Commercial Sale of such Licensed Product in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6 <U>Trademarks</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6.1 <U>Ownership of Trademarks</U>. Subject to Section&nbsp;7.6.2, Gilead and its Affiliates shall select the trademarks under which
they will market Licensed Products (&#147;<U>Gilead Product Trademark</U>&#148;), which trademarks shall not contain the word &#147;MacroGenics&#148;. Gilead and its Affiliates shall own such Gilead Product Trademarks worldwide. Subject to
Section&nbsp;7.6.2, MacroGenics and its Affiliates shall select the trademarks under which they propose to market *** Licensed Products in the MacroGenics Territory (&#147;<U>MacroGenics Product Trademark</U>&#148;), which trademarks shall not
contain the word &#147;Gilead&#148;, and shall notify Gilead thereof and provide Gilead with a reasonable opportunity to comment thereon prior to commencing any registration or use thereof. MacroGenics and its Affiliates shall own such MacroGenics
Product Trademarks worldwide. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6.2 <U>Selection and Use of Trademarks</U>. MacroGenics shall not, and shall not permit its
Affiliates or Sublicensees, to select or use as a MacroGenics Product Trademark any trademark that is identical to or likely to cause confusion with the GILEAD trademark or any trademark for any pharmaceutical product of Gilead or any of its
Affiliates. Gilead shall not, and shall not permit its Affiliates or Sublicensees, to select or use as a Gilead Product Trademark any Trademark that is identical to or likely to cause confusion with the MACROGENICS trademark or any trademark for any
pharmaceutical product of MacroGenics or any of its Affiliates. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.6.3 <U>Future License</U>. To the extent that either Party desires to utilize the other
Party&#146;s Product Trademark to Commercialize *** Licensed Products in its Territory for the *** Licensed Program, then Gilead and MacroGenics shall enter into good faith discussions regarding a separate trademark license agreement containing
commercially reasonable and customary terms pursuant to which the Party that owns such Product Trademark would grant the other Party an exclusive license to use the applicable Product Trademark(s) to Commercialize *** Licensed Products in such other
Party&#146;s Territory; provided, that neither Party shall have any obligation to enter into any such trademark license agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.7 <U>Standards of Conduct</U>.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7.1 Each Party shall in all respects comply
with all applicable Laws and applicable guidelines concerning the advertising, sales and marketing of prescription drug products in Commercializing Licensed Products under this Agreement, including any applicable anti-bribery laws, including those
described in Section&nbsp;7.7.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7.2 Without limiting Section&nbsp;7.7.1, in connection with any activities under this
Agreement, neither Party shall give, offer, promise, or authorize any payment, benefit, or gift of money or anything else of value, directly or indirectly, to (a)&nbsp;any Government or Public Official; (b)&nbsp;any political party, party official
or candidate for public or political office; (c)&nbsp;any Person while knowing or having reason to know that all or a portion of the value will be given, offered or promised, directly or indirectly, to anyone described in terms (a)&nbsp;or
(b)&nbsp;above; or (d)&nbsp;any owner, director, employee, representative or agent of any actual or potential customer of the Parties, in each case ((a) through (d)) for purposes of influencing any act or decision of such individual in his official
capacity, inducing such individual to do or omit to do any act in violation of the individual&#146;s duty, inducing the individual to use the individual&#146;s official influence with a government to affect or influence an act or decision of the
government, or to secure any improper advantage in order to assist in obtaining or retaining business, or where such payment, benefit or gift would constitute a violation of any Law, including the Foreign Corrupt Practices Act of 1977 (the
&#147;<U>FCPA</U>&#148;), the United Kingdom Bribery Act (the &#147;<U>UKBA</U>&#148;) or any Law enacted pursuant to the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions Convention. If, at any
time during the term of this Agreement, either Party breaches its obligations under Section&nbsp;7.7.1 or this Section&nbsp;7.7.2, such Party shall immediately notify the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.7.3 During the term of this Agreement, each Party shall maintain true and accurate records: (a)&nbsp;documenting its interactions with
any government or Government or Public Official relating to its activities in connection with this Agreement; (ii)&nbsp;payments made by it to any Government or Public Official; and (iii)&nbsp;political contributions. In the event of a claim or
investigation, or an official request for a Party to cooperate with respect to any such claim or investigation, by a Regulatory Authority or other legal authority having jurisdiction over either Party of an alleged violation of the FCPA, UKBA or any
analogous Law in any other jurisdiction arising from any activities conducted by the other Party in connection with this Agreement, such other Party shall provide such Regulatory Authority or other legal authority having jurisdiction over the Party
with access to such other Party&#146;s facilities, records (financial and otherwise) and supporting documentation, as reasonably requested by the Party or its agents in order to cooperate in connection with such claim or investigation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 8 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>PAYMENTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1 <U>License Fees</U>. Gilead shall pay MacroGenics a
non-refundable, non-creditable payment of Seven Million Five Hundred Thousand Dollars ($7,500,000) for each Licensed Program within <B>***</B> after (a)&nbsp;with respect to the <B>***</B>Licensed Program, the later of the Effective Date and
Gilead&#146;s receipt of the corresponding invoice; and (b)&nbsp;with respect to the <B>***</B>Licensed Program, the <B>***</B> Licensed Program and the <B>***</B> Licensed Program, the later of the Clearance Date for such Licensed Program and the
date of Gilead&#146;s receipt of the corresponding invoice. Each such payment is referred to as a &#147;<U>License Fee</U>&#148;, and the maximum amount of License Fees payable hereunder shall be Thirty Million Dollars ($30,000,000). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Preclinical Milestone Payments</U>. Within <B>***</B> after Gilead delivers to MacroGenics a Preclinical Milestone Payment Notice
with respect to any Licensed Program, Gilead shall pay MacroGenics a non-refundable, non-creditable payment (the &#147;<U>Preclinical Milestone Payment</U>&#148;) of: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a)<B> ***</B>, Twenty Five Million Dollars ($25,000,000); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) ***, Twenty
Million Dollars ($20,000,000); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) ***, Twenty Million Dollars ($20,000,000); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) ***, Twenty Million Dollars ($20,000,000). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>Development and Regulatory Milestones</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3.1 <U>Development and
Regulatory Milestones</U>. During the License Term for each Licensed Program, for each milestone set forth in this Section&nbsp;8.3.1 achieved by Gilead or its Affiliates or Sublicensees with respect to such Licensed Program, Gilead shall pay the
corresponding non-refundable, non-creditable amount indicated for that milestone for the first instance of its achievement: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:52pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:30pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Column I</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Column II</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment for First</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Licensed Product</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment for First</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Subsequent Licensed</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Product*</FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:52pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:30pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Column I</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:33pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Column II</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment for First</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:55pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Licensed Product</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment for First</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1">Subsequent Licensed</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Product*</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of clarity, a Licensed Product that contains a Program DART other than the Program DART contained in the first Licensed Product with respect to which a
milestone payment set forth in Section&nbsp;8.3.1 has been paid shall be deemed a subsequent Licensed Product. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In no event
shall the total of the amounts paid under Column I of this Section&nbsp;8.3.1 exceed (i) ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In no event shall the total of the amounts paid
under Column II of this Section&nbsp;8.3.1 exceed (i)&nbsp;*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3.2 <U>Milestone Payments</U>. Gilead shall make the
milestone payments required by Section&nbsp;8.3.1 in accordance with Section&nbsp;8.3.4. If, with respect to any Program DART or Licensed Product, (i)&nbsp;an event described in clause (b)&nbsp;or (c)&nbsp;of Section&nbsp;8.3.1 occurs before or
concurrently with another event described in a preceding clause of Section&nbsp;8.3.1; (ii)&nbsp;an event described in clause (d), (e)&nbsp;or (f)&nbsp;of Section&nbsp;8.3.1 occurs before or concurrently with an event described in clause (a),
(b)&nbsp;or (c)&nbsp;of Section&nbsp;8.3.1; (iii)&nbsp;an event described in clause (g)&nbsp;of Section&nbsp;8.3.1 occurs before or concurrently with an event described in clause (a), (b), (c)&nbsp;or (d)&nbsp;of Section&nbsp;8.3.1; (iv)&nbsp;an
event described in clause (i)&nbsp;of Section&nbsp;8.3.1 occurs before or concurrently with an event described in clause (a), (b), (c)&nbsp;or (e)&nbsp;of Section&nbsp;8.3.1; or (v)&nbsp;an event described in clause (k)&nbsp;of Section&nbsp;8.3.1
occurs before or concurrently with an event described in clause (a), (b), (c)&nbsp;or (f)&nbsp;of Section&nbsp;8.3.1, then in each case ((i) through (v)) Gilead shall pay any unpaid milestone payment(s) described in such earlier clause(s) (under
Column I or Column II, as applicable) when the milestone payment described in such later clause(s) is paid. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3.3 <U>Replacement Products</U>. If Development of the first Program DART or Licensed
Product from a Licensed Program has been discontinued, then the achievement by a subsequent Program DART or Licensed Product from such Licensed Program of a milestone event not achieved by such substituted or discontinued first Licensed Product
shall be deemed to be achievement of the corresponding milestone event under Section&nbsp;8.3.1 by the first Licensed Product entitling MacroGenics to the corresponding milestone payment under Section&nbsp;8.3.1 Column I. By way of example, if a
first and second Licensed Product from a given Licensed Program have been Developed concurrently and the Development of such first Licensed Product is discontinued, such second Licensed Product shall be eligible for any milestone events under
Section&nbsp;8.3.1 Column I not previously achieved by such first Licensed Product and, conversely, any milestone events under Section&nbsp;8.3.1 Column I achieved by such first Licensed Product shall not be payable with respect to such second
Licensed Product. Further, any third Licensed Product from such Licensed Program that contains a Program DART other than the Program DART contained in the second Licensed Product shall be eligible for any milestone events under Section&nbsp;8.3.1
Column II not previously achieved by such second Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3.4 <U>Notification; Payment</U>. Gilead shall promptly
notify MacroGenics in writing of the first achievement of each of the milestones under this Section&nbsp;8.3 and the corresponding milestone payment shall be due within <B>***</B> after receipt of the corresponding invoice from MacroGenics.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4 <U>Sales Milestones</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.4.1 <U>Sales Milestone Payments</U>. During the License Term for each Licensed Program, Gilead shall make the non-refundable, non-creditable payments to MacroGenics set forth below upon the earliest
achievement of each of the corresponding milestone events by the first Licensed Product from such Licensed Program to achieve such milestone: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="93%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:52pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) First occurrence of Annual Net Sales of a Licensed Product greater than *** Dollars (***) in a Calendar Year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) First occurrence of Annual Net Sales of a Licensed Product greater than *** Dollars (***) in a Calendar Year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) First occurrence of Annual Net Sales of a Licensed Product greater than *** Dollars (***) in a Calendar Year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) First occurrence of Annual Net Sales of a Licensed Product greater than *** Dollars (***) in a Calendar Year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4.2 <U>Payment of Sales Milestones</U>. Gilead shall make the milestone payments required
by Section&nbsp;8.4.1 in accordance with Section&nbsp;8.7. If an event described in a clause in Section&nbsp;8.4.1 occurs during the same Calendar Quarter as another event described in a preceding clause in Section&nbsp;8.4.1, Gilead shall also pay
the milestone payment described in such earlier clause when the milestone payment described in such later clause is paid. By way of example, if, during any Calendar Quarter, Annual Net Sales for a Licensed Product from a given Licensed Program first
exceed the thresholds set forth in Sections 8.4.1(a) and (b), Gilead shall pay MacroGenics the milestone payments set forth in both Sections 8.4.1(a) and (b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.5 <U>Royalties</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.1 <U>Annual Net Sales</U>. Subject to
Section&nbsp;8.5.4(c), for each Licensed Product in each Calendar Year during the Royalty Term, Gilead shall pay MacroGenics royalties on Annual Net Sales of such Licensed Product in the Gilead Territory in such Calendar Year at the following rates:
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:90pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Annual Net Sales Threshold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Royalty&nbsp;Rate</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) On the first *** Dollars (***) in Annual Net Sales of such Licensed Product in such Calendar Year</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) On that portion of Annual Net Sales of such Licensed Product in such Calendar Year greater than *** Dollars (***) but less than or equal to ***
(***)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) On that portion of Annual Net Sales of such Licensed Product in such Calendar Year greater than *** Dollars (***)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.2 <U>Net Receipts.</U> Gilead shall pay MacroGenics twenty percent (20%)&nbsp;of all Net Receipts in
accordance with Section&nbsp;8.7. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.3 <U>Diagnostics</U>. If (a)&nbsp;Gilead or any of its Affiliates or Sublicensees
Commercializes in any country a Diagnostic and (b)&nbsp;Gilead or its Affiliates receive sales, royalty revenues or other consideration from such Commercialization, the Parties shall negotiate in good faith a reasonable royalty to be paid by Gilead
to MacroGenics with respect to such revenues, taking into consideration Gilead&#146;s profit component, which royalty shall be consistent with industry standards for diagnostics but in any case shall not exceed the rates set forth in
Section&nbsp;8.5.1. Notwithstanding anything in this Agreement to the contrary, if the Parties are unable to agree upon the royalty rate after exhausting the procedures set forth in Section&nbsp;15.1, <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.4 <U>Royalty Term</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Gilead&#146;s royalty obligations to MacroGenics under this Section&nbsp;8.5 with respect to any Licensed Product in any country shall commence upon the First Commercial Sale of such Licensed Product
in such country and expire on a country-by-country basis on the later of: (i)&nbsp;<B>***</B>(the &#147;<U>Royalty Term</U>&#148;)<B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Royalties shall be payable only once with respect to the same unit of Licensed Product.
On a Licensed Product-by-Licensed Product and country-by-country basis, upon expiration of the Royalty Term for a Licensed Product in a country in the Gilead Territory, Gilead&#146;s licenses and rights hereunder with respect to such Licensed
Product in such country shall continue in effect, but become fully paid-up, royalty-free, transferable (to the extent not transferrable previously), perpetual and irrevocable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) For any Calendar Quarter of the Royalty Term during which a Licensed Product is sold in a country in which one (1)&nbsp;or more
Third Parties sell in such country one or more Biosimilar Products, and such Biosimilar Products, collectively, have a <B>***</B> or more market share of the aggregate market share of such Licensed Product and such Biosimilar Products (based on data
provided by IMS Health Incorporated, Fairfield, Connecticut) as measured on a units sold basis, or if such data is not available, the Parties shall agree upon a methodology for estimating the percentage of unit sales based market share of such
Biosimilar Products in such country), then, Gilead&#146;s royalty obligations with respect to sales of such Licensed Product in such country during such Calendar Quarter shall be reduced by <B>***</B> of the applicable rate set forth in
Section&nbsp;8.5.1. The Parties shall mutually agree in good faith on an appropriate method of calculating the royalties payable by Gilead pursuant to this Section&nbsp;8.5 in the event such circumstances arise. &#147;<U>Biosimilar Product</U>&#148;
means, with respect to a Licensed Product sold in a country, a product that: (i)&nbsp;is marketed by a Third Party that has not obtained the rights to such product as a Sublicensee or distributor of, or through any other contractual relationship
with, Gilead or any of its Affiliates; (ii)&nbsp;contains the same or highly similar active ingredient(s) as the applicable Licensed Product; and (iii)&nbsp;with respect to (x)&nbsp;the United States, has been licensed as a biosimilar or
interchangeable biological product by FDA pursuant to Section&nbsp;351(k) of the Public Health Service Act (42&nbsp;U.S.C.&nbsp;&#167;&nbsp;262(k)), as may be amended, or any subsequent or superseding law, statute or regulation, (y)&nbsp;the EU, has
been approved in reliance on the prior approval of a Licensed Product as a similar biological medicinal product by the European Union pursuant to Directive&nbsp;2001/83/EC, as may be amended, or any subsequent or superseding law, statute or
regulation, and (z)&nbsp;any other country, has received analogous regulatory marketing approval in reliance on the prior approval of a Licensed Product from the applicable Regulatory Authority </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.5 <U>Third Party Offset</U>.&nbsp;If, after the License Grant Date for any Licensed Program, Gilead or its applicable Affiliate or
Sublicensee:&nbsp;(a) is required, as reasonably determined by Gilead or its applicable Affiliate or Sublicensee, as the case may be, to obtain a license from any Third Party under any Patents controlled by such Third Party in order to make, have
made, use, sell, offer for sale or import a Program DART and/or a Licensed Product from such Licensed Program in any country in the Gilead Territory without infringing such Patents, and pursuant to such license is required to pay any amounts to such
Third Party (including any upfront, milestone or royalty payments) in any Calendar Year, or (b)&nbsp;is required by any court of competent jurisdiction, in connection with its infringement of any Patents controlled by a Third Party in any country in
the Gilead Territory with respect to a Program DART and/or Licensed Product from such Licensed Program, to pay any amounts to such Third Party (including any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
lump sum or royalty payments) in any Calendar Year, then Gilead may deduct from the milestone payments and/or royalties (as elected by Gilead in its sole discretion) that would otherwise be due
to MacroGenics with respect to such Program DART or Licensed Product in such Calendar Year <B>***</B> of the amount paid by Gilead or its applicable Affiliate or Sublicensee, as the case may be, to such Third Party with respect to such Program DART
or Licensed Product in such Calendar Year (where any such amounts paid by Gilead or its applicable Affiliate or Sublicensee to such Third Party shall be equitably allocated among all products of Gilead or its applicable Affiliate or Sublicensee, as
applicable, covered by such license or subject to such infringement); provided, however, that such deduction shall not reduce (A)&nbsp;the amount of milestones due to MacroGenics with respect to such Program DART or Licensed Product for such
Calendar Year to less than <B>***</B> of the amount of milestones that otherwise would have become due with respect to such Program DART or Licensed Product for such Calendar Year or (B)&nbsp;the royalty rate paid by Gilead in respect of Annual Net
Sales of such Licensed Product in such Calendar Year to less than <B>***</B> of Annual Net Sales of such Licensed Product in such Calendar Year, in each case ((A) and (B)) with any excess deduction carried over and applied to amounts due to
MacroGenics with respect to such Program DART or Licensed Product in subsequent Calendar Years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6 <U>Healthcare Reform
Tax</U>. Notwithstanding anything herein to the contrary, for purposes of determining the sales milestones and royalties payable by Gilead under Sections 8.4 and 8.5, Gilead shall have the right to offset from Net Sales of Licensed Products sold in
the United States that portion of the annual fee paid by Gilead and its Affiliates to the United States Government pursuant to Section&nbsp;9008 of the Patient Protection and Affordable Care Act, Pub. L. No.&nbsp;111-148 (as may be amended)
reasonably attributable to Licensed Products, as determined in accordance with an equitable method as agreed in good faith by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.7 <U>Reports; Payments</U>. Within thirty (30)&nbsp;days after the end of each Calendar Quarter during which there are Net Sales or Net Receipts giving rise to a payment obligation under
Section&nbsp;8.4 or 8.5, Gilead shall submit to MacroGenics a report identifying for each Licensed Product, the Net Sales and/or Net Receipts for such Licensed Product for each country in the Gilead Territory for such Calendar Quarter, the
calculation of royalties (including gross sales and all deductions taken from gross sales), and the royalties and the sales milestones payable to MacroGenics. Within fifteen (15)&nbsp;days of the delivery of each such report, Gilead shall pay to
MacroGenics all royalties and sales milestones payable by it under Sections&nbsp;8.4 and 8.5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8 <U>Methods of Payments</U>.
All payments due under this Agreement shall be paid in Dollars by wire transfer to a bank in the United States designated in writing by MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.9 <U>Late Payments</U>. Any amount owed by Gilead to MacroGenics under this Agreement that is not paid on or before the date such payment is due as set forth herein shall bear interest at a rate per
annum equal to the one month USD-LIBOR as quoted on Bloomberg (or if it no longer exists, a similarly authoritative source) plus <B>***</B> calculated on a daily basis, or, if lower, the highest rate permitted by applicable Law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.10 <U>Taxes</U>. All payments due and payable under this Agreement will be made without
any deduction, unless such deduction or withholding tax is required by applicable Laws. If the paying Party is so required to deduct or withhold, such Party shall (a)&nbsp;promptly notify the other Party of such requirement; (b)&nbsp;pay to the
relevant authorities the full amount required to be deducted or withheld promptly upon the earlier of determining that such deduction or withholding is required or receiving notice that such amount has been assessed against the other Party; and
(c)&nbsp;promptly forward to the other Party an official receipt (or certified copy), or other documentation reasonably acceptable to the other Party evidencing such payment to such authorities. Notwithstanding the foregoing, if as a result of
(i)&nbsp;the assignment of this Agreement by Gilead to an Affiliate or a Third Party outside of the United States or (ii)&nbsp;the exercise by Gilead of its rights under this Agreement through an Affiliate or Third Party outside the United States,
withholding tax in excess of the withholding tax amount that would have been payable in the absence of such assignment or exercise of rights becomes payable with respect to any amount due to MacroGenics under this Agreement, then Gilead shall pay to
MacroGenics such additional amounts as are necessary so that MacroGenics receives the amounts that MacroGenics would have received if such payments were not subject to such withholding tax as a consequence of such assignment or exercise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.11 <U>Books and Records; Audit Rights</U>. Each Party (the &#147;<U>Audited Party</U>&#148;) shall keep (and, in the case of Gilead,
shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the &#147;<U>Auditing Party</U>&#148;) (a)&nbsp;with respect to
Gilead as the Audited Party, to determine the payments due and (b)&nbsp;with respect to MacroGenics as the Audited Party, to determine costs incurred in the conduct of Research activities under this Agreement. Each Auditing Party shall have the
right, <B>***</B> at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected by the Auditing Party and reasonably acceptable to the Audited Party, review any such records of the Audited
Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than thirty (30)&nbsp;days prior notice) and during regular business hours and under obligations of confidence, for the
sole purpose of verifying the accuracy of the amounts paid under this Agreement within a <B>***</B>year period preceding the date of the request for review. The report of such accounting firm shall be limited to a certificate stating whether any
report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate and the actual amounts of Research costs and the amount of any Net Sales, milestone or royalty discrepancy. No other information shall be
provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such inspection lead to the discovery of a discrepancy to the Auditing Party&#146;s detriment, the
Audited Party shall pay the amount of the discrepancy within thirty (30)&nbsp;days after its receipt from the accounting firm of the certificate showing the amount of the discrepancy. The Auditing Party shall pay the full cost of the review unless
the underpayment of milestones or royalties is greater than five percent (5%), or the overpayment of Research costs is greater than five percent (5%), of the amount due for the applicable period, in which case the Audited Party shall pay the
reasonable costs charged by such accounting firm for such review. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 9 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Inventorship</U>.
Subject to Section&nbsp;9.2, inventorship for patentable inventions conceived or reduced to practice during the course of the performance of activities pursuant to this Agreement shall be determined in accordance with the patent laws of the
jurisdiction where the invention was invented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>Ownership</U>. Subject to the licenses and rights granted to Gilead
under this Agreement, MacroGenics shall own the entire right, title and interest in and to all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or consultants of MacroGenics
or acquired solely by MacroGenics in the course of Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Products. Subject to the licenses and rights granted to MacroGenics under this Agreement, Gilead shall own
the entire right, title and interest in and to all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or consultants of Gilead or acquired solely by Gilead in the course of
Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Products. The Parties shall jointly own any Joint IP. Subject to the terms and conditions of this Agreement, each Party shall retain its rights to practice its
undivided, one-half interest in any Joint IP without the consent of and without accounting to the other. As between the Parties, the issue as to whether any invention or discovery is jointly made, and the rights of the Parties as joint owners, shall
be determined in accordance with this Agreement and the applicable substantive Laws of the United States, irrespective of the country in which such invention or discovery is made or discovered. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>Prosecution and Maintenance of Patents</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.3.1 <U>MacroGenics Rights</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall have (i)&nbsp;the sole
right, at MacroGenics&#146; discretion (subject to the remainder of this Section&nbsp;9.3.1), to file, prosecute, and maintain (including with respect to any interference, derivation, re-issuance, re-examination, opposition or other post-grant
proceedings) (x)&nbsp;any Platform Patents throughout the world and (y)&nbsp;any MacroGenics Patents that are Other Patents, in the MacroGenics Territory; and (ii)&nbsp;the first right, at MacroGenics&#146; discretion (subject to the remainder of
this Section&nbsp;9.3.1), to file, prosecute, and maintain (including with respect to any interference, derivation, re-issuance, re-examination, opposition or other post-grant proceedings) any MacroGenics Patents that are Other Patents, in the
Gilead Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Gilead shall reimburse MacroGenics for the Out-of-Pocket Costs of MacroGenics in the filing,
prosecution and maintenance of any Patents being filed, prosecuted or maintained by MacroGenics pursuant to Section&nbsp;9.3.1(a) in the Gilead Territory; provided that if pursuant to MacroGenics&#146; agreement with any other Third Party licensee
MacroGenics is reimbursed by such licensee for the Out-of-Pocket Costs of MacroGenics in the filing, prosecution and maintenance of any such Patents, Gilead and such licensee(s) shall, on a
Patent-</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
by-Patent basis, share in such Out-of-Pocket Costs with each party&#146;s percentage share determined by dividing (i)&nbsp;one, by (ii)&nbsp;one plus the number of Third Parties (if any) that
is(are) required to reimburse MacroGenics for such Out-of-Pocket Costs. With respect to any Patent owned by Gilead or any Joint Patent that is being filed, prosecuted or maintained by MacroGenics pursuant to Section&nbsp;9.3.1(a) in any country in
the Gilead Territory, Gilead shall have the right, in its sole discretion, to assign such Patent in such country (or, in the case of a Joint Patent, to assign Gilead&#146;s interest in such Joint Patent in such country) to MacroGenics or to cause
the abandonment of such Patent in such country (only in the case of a Patent owned by Gilead), as MacroGenics may elect, and thereby to terminate Gilead&#146;s obligation to reimburse such costs incurred thereafter, upon *** to MacroGenics. With
respect to any Patent (other than any Joint Patent) under which Gilead has a license hereunder that is being filed, prosecuted or maintained by MacroGenics pursuant to Section&nbsp;9.3.1(a) in any country in the Gilead Territory, Gilead shall have
the right, in its sole discretion, to terminate such license, and thereby to terminate Gilead&#146;s obligation to reimburse such costs incurred thereafter, upon thirty (30)&nbsp;days&#146; written notice to MacroGenics, and following such***,
Gilead shall have no rights hereunder with respect to such Patent in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics shall use reasonable
efforts to ensure that any Patents being filed, prosecuted or maintained by MacroGenics pursuant to Section&nbsp;9.3.1(a) (excluding any Patents that are being filed, prosecuted or maintained by MacroGenics as a result of the operation of
Section&nbsp;9.3.2(c)) are not Mixed Patents. If any such Patent is a Mixed Patent, then such Patent shall be deemed a Product Patent (and not a Platform Patent) for all purposes under this Agreement (including this Section&nbsp;9.3) for so long as
such Patent <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Parties shall work together in good faith to agree upon a strategy for the prosecution of
any Patents being prosecuted by MacroGenics pursuant to Section&nbsp;9.3.1(a) in the Gilead Territory, including the list of countries in the Gilead Territory in which such Patents will be filed; provided, however, that (subject to
Section&nbsp;9.3.1(e)) MacroGenics shall have the final right to make such determinations. In addition, MacroGenics shall provide to Gilead such other information related to prosecution of any Patents being prosecuted by MacroGenics pursuant to
Section&nbsp;9.3.1(a) as Gilead may from time to time reasonably request to allow Gilead to track prosecution and maintenance of such Patents and shall consider in good faith any comments that Gilead may provide with respect to such matters. Without
limiting the foregoing, MacroGenics shall keep Gilead informed as to the identity of its patent agents and attorneys and notify Gilead of any changes thereto and consider in good faith any comments that Gilead may provide with respect to the
selection and engagement of patent agents and attorneys for the prosecution and maintenance of such Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) MacroGenics
shall give Gilead written notice reasonably in advance of any decision by MacroGenics not to file an application for or to abandon the prosecution of or otherwise not maintain or extend any Patent described in clause (ii)&nbsp;of
Section&nbsp;9.3.1(a) in any applicable country. Upon receiving such notice, Gilead shall have the right, at its own cost, to file, prosecute, maintain and extend, as the case may be, such Patent, in Gilead&#146;s name, in such country; provided,
however, that Gilead shall not exercise such right without the prior written consent of MacroGenics (which MacroGenics may withhold in its sole discretion) if MacroGenics&#146; decision not to file an application for or to abandon the prosecution of
or otherwise not maintain or extend such Patent is made for strategic business reasons (e.g., in countries with compulsory licensing policies). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.2 <U>Gilead Rights.</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Gilead shall have (i)&nbsp;the sole right, at Gilead&#146;s discretion (subject to the remainder of this Section&nbsp;9.3.2), to
file, prosecute, and maintain (including with respect to any interference, derivation, re-issuance, re-examination, opposition or other post-grant proceedings) any Gilead Collaboration Patents that are Other Patents, in the Gilead Territory; and
(ii)&nbsp;the first right, at Gilead&#146;s discretion (subject to the remainder of this Section&nbsp;9.3.2), to file, prosecute, and maintain (including with respect to any interference, derivation, re-issuance, re-examination, opposition or other
post-grant proceedings) (s)&nbsp;any Gilead Collaboration Patents that are Product Patents, in the Gilead Territory, (t)&nbsp;any Gilead Collaboration Patents that are Product Patents, in the MacroGenics Territory, (u)&nbsp;any Gilead Collaboration
Patents that are Other Patents, in the MacroGenics Territory, (v)&nbsp;any MacroGenics Patents that are Product Patents, in the Gilead Territory, (w)&nbsp;any MacroGenics Patents that are Product Patents, in the MacroGenics Territory, (x)&nbsp;any
Joint Patents that are Product Patents, in the Gilead Territory, (y)&nbsp;any Joint Patents that are Product Patents, in the MacroGenics Territory and (z)&nbsp;any Joint Patents that are Other Patents, throughout the world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall reimburse Gilead for the Out-of-Pocket Costs of Gilead in the filing, prosecution and maintenance of any Patents
being filed, prosecuted or maintained by Gilead pursuant to Section&nbsp;9.3.2(a) in the MacroGenics Territory. With respect to any Patent owned by MacroGenics or any Joint Patent that is being filed, prosecuted or maintained by Gilead pursuant to
Section&nbsp;9.3.2(a) in any country in the MacroGenics Territory, MacroGenics shall have the right, in its sole discretion, to assign such Patent in such country (or, in case of a Joint Patent, to assign MacroGenics&#146; interest in such Joint
Patent in such country) to Gilead or to cause the abandonment of such Patent in such country (only in the case of a Patent owned by MacroGenics), at Gilead&#146;s election, and thereby to terminate MacroGenics&#146; obligation to reimburse such
costs incurred thereafter, upon <B>***</B> written notice to Gilead. With respect to any Patent (other than any Joint Patent) under which MacroGenics has a license hereunder that is being filed, prosecuted or maintained by Gilead pursuant to
Section&nbsp;9.3.2(a) in any country in the MacroGenics Territory, MacroGenics shall have the right, in its sole discretion, to terminate such license and thereby to terminate MacroGenics&#146; obligation to reimburse such costs incurred thereafter,
upon <B>***</B> written notice to Gilead, and following such thirty (30)&nbsp;day period, MacroGenics shall have no rights hereunder with respect to such Patent in such country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Gilead shall use reasonable efforts to ensure that any Patents being filed, prosecuted or maintained by Gilead pursuant to
Section&nbsp;9.3.2(a) (excluding any Patents that are being filed, prosecuted or maintained by Gilead as a result of the operation of Section&nbsp;9.3.1(c)) are not Mixed Patents. If any such Patent is a Mixed Patent, then such Patent shall be
deemed a Platform Patent (and not a Product Patent) for all purposes under this Agreement (including this Section&nbsp;9.3) for so long as such Patent contains at least one Platform Claim. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) The Parties shall work together in good faith to agree upon a strategy for the prosecution of (i)&nbsp;any Patents being prosecuted
by Gilead pursuant to Section </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
9.3.2(a) in the MacroGenics Territory; (ii)&nbsp;any MacroGenics Patents that are Product Patents, in the Gilead Territory; and (iii)&nbsp;any Joint Patents being prosecuted by Gilead pursuant to
Section&nbsp;9.3.2(a), including the list of countries in which such Patents will be filed; provided, however, that (subject to Section&nbsp;9.3.2(e)) Gilead shall have the final right to make such determinations. Gilead shall provide MacroGenics
with a draft of any prosecution filing related to any such Patents being prosecuted by Gilead pursuant to Section&nbsp;9.3.2(a) to be submitted to any patent office in the applicable Territory at least thirty (30)&nbsp;days in advance of submission
and shall provide MacroGenics an opportunity to provide comments on and make requests of Gilead concerning such filing and shall consider in good faith any comments or requests regarding such filing that MacroGenics may timely provide. In addition,
Gilead shall provide to MacroGenics such other information related to prosecution of any Patents being prosecuted by Gilead pursuant to Section&nbsp;9.3.2(a) as MacroGenics may from time to time reasonably request to allow MacroGenics to track
prosecution and maintenance of such Patents and shall consider in good faith any comments that MacroGenics may provide with respect to such matters. Without limiting the foregoing, Gilead shall keep MacroGenics informed as to the identity of its
patent agents and attorneys and notify MacroGenics of any changes thereto and consider in good faith any comments that MacroGenics may provide with respect to the selection and engagement of patent agents and attorneys for the prosecution and
maintenance of such Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Gilead shall give MacroGenics written notice reasonably in advance of any decision by
Gilead not to file an application for or to abandon the prosecution of or otherwise not maintain or extend any Patent described in clause (ii)&nbsp;of Section&nbsp;9.3.2(a) in any applicable country. Upon receiving such notice, MacroGenics shall
have the right, at its own cost, to file, prosecute, maintain and extend, as the case may be, such Patent, in MacroGenics&#146; name, in such country; provided, however, that MacroGenics shall not exercise such right (A)&nbsp;with respect to
(1)&nbsp;any Patent described in clause (ii)(s) or (ii)(u) of Section&nbsp;9.3.2(a) in any country or (2)&nbsp;any Patent described in clause (ii)(v) or (ii)(x) of Section&nbsp;9.3.2(a) in any country in the Access Territory, in each case ((1) and
(2))&nbsp;without the prior written consent of Gilead (which Gilead may withhold in its sole discretion) if Gilead&#146;s decision not to file an application for or to abandon the prosecution of or otherwise not maintain or extend such Patent is
made for strategic business reasons (e.g., in countries with compulsory licensing policies), or (B)&nbsp;with respect to any Patent described in clause (ii)(v) or (ii)(x) of Section&nbsp;9.3.2(a) in any country outside of the Access Territory, if
there is at least one MacroGenics Patent or Joint Patent other than such Patent in such country that Covers the Program DART or Licensed Product Covered by such Patent. If MacroGenics exercises its rights under this Section&nbsp;9.3.2(e) with
respect to any Joint Patent in any country, Gilead shall (I)&nbsp;assign its entire right, title and interest in such Joint Product Patent in such country to MacroGenics, (II) use reasonable efforts to make its authorized attorneys, agents or
representatives available to MacroGenics and to assist MacroGenics in obtaining and maintaining such patent protection, and (III) sign or use reasonable efforts to have signed all legal documents necessary to file and prosecute such Joint Patent or
to obtain or maintain such Joint Product Patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4 <U>Third Party Infringement</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.1 <U>Notice</U>. Each Party shall promptly report in writing to the other Party any known or suspected (a)&nbsp;infringement of any
of the MacroGenics Patents, Gilead Collaboration </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Patents or Joint Patents; (b)&nbsp;unauthorized use or misappropriation of any of the MacroGenics Know-How, Gilead Collaboration Know-How or Know-How included in the Joint IP of which such Party
becomes aware; or (c)&nbsp;notification under the Biologics Price Competition and Innovation Act of 2009, as amended, or similar law, from a biosimilar applicant arising from the filing of an application for the Regulatory Approval of a product
intending to show that such product is biosimilar to any Licensed Product that is a reference product for which a claim of infringement of any of the MacroGenics Patents, Joint Patents or Gilead Collaboration Patents by the manufacture or sale of
such product could reasonably be asserted, and shall provide the other Party with all available evidence regarding such known or suspected infringement or unauthorized use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.4.2 <U>Enforcement Rights</U>. Subject to the requirements and limitations of any MacroGenics Third Party Agreements with respect to the enforcement of Patents, including any rights of, and timeframes
for, such Third Party licensors to comment on and review any filings or materials related thereto, the Parties agree: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
Gilead shall have (i)&nbsp;the sole right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce any Gilead Collaboration Patents that are Other Patents, in the Gilead Territory and (ii)&nbsp;the first right, but
not the obligation, to initiate a lawsuit or take other reasonable action to enforce (t)&nbsp;any Gilead Collaboration Patents that are Product Patents, in the Gilead Territory, (u)&nbsp;any Gilead Collaboration Patents that are Platform Patents,
with respect to Competitive Infringement in the Gilead Territory, (v)&nbsp;any Gilead Collaboration Patents that are Other Patents, in the MacroGenics Territory, (w)&nbsp;any MacroGenics Patents that are Product Patents, in the Gilead Territory,
(x)&nbsp;any Joint Patents that are Product Patents, in the Gilead Territory, (y)&nbsp;any Joint Patents that are Platform Patents, with respect to Competitive Infringement in the Gilead Territory and (z)&nbsp;any Joint Patents that are Other
Patents, in the Gilead Territory. Notwithstanding the foregoing sentence, Gilead shall not initiate any such lawsuit or take such other action with respect to any matter described in clause (ii)&nbsp;above without first consulting with MacroGenics
and giving good faith consideration to any reasonable objection from MacroGenics regarding Gilead&#146;s proposed course of action, and Gilead shall not initiate any such lawsuit or take such other action with respect to any matter described in
clause (ii)(u) or (ii)(y) above without the prior written consent of MacroGenics, which MacroGenics may withhold in its sole discretion. MacroGenics shall cooperate in the prosecution of any suit under this Section&nbsp;9.4.2(a) as may be reasonably
requested by Gilead (including joining such suit as a plaintiff if Gilead is unable to initiate or prosecute such action solely in its own name); provided, however, that Gilead shall promptly reimburse all Out-of-Pocket Costs (including reasonable
counsel fees and expenses) of MacroGenics in connection with such cooperation. In connection with any such proceeding, Gilead shall not enter into any settlement admitting the invalidity of, or otherwise impairing MacroGenics&#146; rights in,
MacroGenics IP or Joint IP without the prior written consent of MacroGenics. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Any recoveries resulting from such an action brought by Gilead in accordance with
Section&nbsp;9.4.2(a) shall be applied as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) First, to reimburse each Party for all Out-of-Pocket Costs in
connection with such proceeding (on a pro rata basis, based on each Party&#146;s respective litigation costs, to the extent the recovery was less than all such litigation costs); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Second, the remainder of such recovery shall be retained by Gilead, provided that (x)&nbsp;to the extent the award to Gilead is
based on lost profits with respect to a Licensed Product in the Gilead Territory, MacroGenics shall receive an amount equal to the royalty that would be payable, pursuant to Section&nbsp;8.5, on the imputed amount of Net Sales of such Licensed
Product(s) in the country(ies) in the Gilead Territory where such infringement occurred, and (y)&nbsp;to the extent the award reflects the amount of reasonable royalty payments due to Gilead with respect to a Licensed Product in the Gilead Territory
(excluding, for clarity, any award to the extent described in clause (x)&nbsp;above), such award shall be considered as Net Sales subject to the applicable royalty in accordance to Section&nbsp;8.5. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics shall have (i)&nbsp;the sole right, but not the obligation, to initiate a lawsuit or take other reasonable action to
enforce (v)&nbsp;any Gilead Collaboration Patents that are Platform Patents, other than with respect to Competitive Infringement, throughout the world, (w)&nbsp;any MacroGenics Patents that are Platform Patents, throughout the world, (x)&nbsp;any
MacroGenics Patents that are Other Patents, in the MacroGenics Territory, (y)&nbsp;any Joint Patents that are Platform Patents, with respect to Competitive Infringement in the MacroGenics Territory and (z)&nbsp;any Joint Patents that are Platform
Patents, other than with respect to Competitive Infringement, throughout the world; and (ii)&nbsp;the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce (u)&nbsp;any Gilead Collaboration Patents
that are Product Patents, in the MacroGenics Territory, (v)&nbsp;any Gilead Collaboration Patents that are Platform Patents, with respect to Competitive Infringement in the MacroGenics Territory, (w)&nbsp;any MacroGenics Patents that are Product
Patents, in the MacroGenics Territory, (x)&nbsp;any MacroGenics Patents that are Other Patents, in the Gilead Territory, (y)&nbsp;any Joint Patents that are Product Patents, in the MacroGenics Territory and (z)&nbsp;any Joint Patents that are Other
Patents, in the MacroGenics Territory. Notwithstanding the foregoing sentence, MacroGenics shall not initiate any such lawsuit or take such other action with respect to any matter described in clause (ii)&nbsp;above without first consulting with
Gilead and giving good faith consideration to any reasonable objection from Gilead regarding MacroGenics&#146; proposed course of action. Gilead shall cooperate in the prosecution of any suit under this Section&nbsp;9.4.2(c) as may be reasonably
requested by MacroGenics (including joining such suit as a plaintiff if MacroGenics is unable to initiate or prosecute such action solely in its own name); provided, however, that MacroGenics shall promptly reimburse all Out-of-Pocket Costs
(including reasonable counsel fees and expenses) of Gilead in connection with such cooperation. In connection with any such proceeding, MacroGenics shall not enter into any settlement admitting the invalidity of, or otherwise impairing Gilead&#146;s
rights in any Gilead Collaboration IP or Joint IP without the prior written consent of Gilead. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) With respect to any
lawsuit initiated or other action taken by MacroGenics under clauses (ii)(u), (ii)(w) or (ii)(y) of Section&nbsp;9.4.2(c), (i)&nbsp;MacroGenics shall keep Gilead reasonably informed of the status of such lawsuit or action; (ii)&nbsp;without limiting
clause (i), MacroGenics shall provide Gilead with copies of any court filings or other material documents or correspondence received from any Third Party in connection with such lawsuit or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
action promptly after such filings or documents or correspondence are received by MacroGenics; (iii)&nbsp;MacroGenics shall consult with Gilead with respect to such lawsuit or action and consider
any comments from Gilead with respect to such lawsuit or action in good faith; and (iv)&nbsp;without limiting clause (iii), MacroGenics shall provide Gilead with drafts of any court filings or other material documents or correspondence to be filed
or delivered by MacroGenics prior to the date of filing or delivery such that Gilead has a reasonable opportunity to review and provide comments, and to the extent Gilead provides comments thereon promptly and in sufficient time to allow MacroGenics
to meet applicable filing requirements, MacroGenics shall consider such comments in good faith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Any recoveries resulting
from such an action brought by MacroGenics in accordance with Section&nbsp;9.4.2(c) shall be applied as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) First,
to reimburse each Party for all Out-of-Pocket Costs in connection with such proceeding (excluding any costs incurred by Gilead in the exercise of its rights under Section&nbsp;9.4.2(d)) (on a pro rata basis, based on each Party&#146;s respective
litigation costs, to the extent the recovery was less than all such litigation costs); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Second, (x)&nbsp;to the
extent the award is based on lost profits with respect to a Licensed Product in the Gilead Territory, any remainder of such recovery shall be retained by Gilead, provided that MacroGenics shall receive an amount equal to the royalty that would be
payable, pursuant to Section&nbsp;8.5, on the imputed amount of Net Sales of such Licensed Product(s) in the country(ies) in the Gilead Territory where such infringement occurred, (y)&nbsp;to the extent the award reflects the amount of reasonable
royalty payments with respect to a Licensed Product in the Gilead Territory (excluding, for clarity, any award to the extent described in clause (x)&nbsp;above), any remainder of such recovery shall be retained by Gilead, provided that such award
shall be considered as Net Sales subject to the applicable royalty in accordance to Section&nbsp;8.5, and (z)&nbsp;to the extent the award is not described in clauses (x)&nbsp;or (y)&nbsp;above, any remainder of such recovery shall be retained by
MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) If Gilead in good faith does not intend to initiate a lawsuit or take other reasonable action with respect
to any matter described in clause (ii)&nbsp;of Section&nbsp;9.4.2(a), then Gilead shall notify MacroGenics thereof (i)&nbsp;if there is no time limit for the filing of such action, within sixty (60)&nbsp;days following the notice of alleged
infringement or following a biosimilar applicant&#146;s failure to act or (ii)&nbsp;if there is a time limit for the filing of such action (including those set forth in applicable Laws) within <B>***</B> before the time limit, and upon receipt of
such notice MacroGenics shall have the right, but not the obligation, to initiate such lawsuit or take such other action, after providing <B>***</B> in the event there is a time limit) notice to Gilead and giving good faith consideration to
Gilead&#146;s reason(s) for not initiating a lawsuit or taking other action; provided, however, that MacroGenics shall not initiate such a lawsuit or take such other action with respect to any matter described in clause (ii)(t), (ii)(w) or (ii)(x)
of Section&nbsp;9.4.2(a) without the prior written consent of Gilead (which Gilead may withhold in its sole discretion) if Gilead&#146;s decision not to exercise its first right with respect thereto was made for strategic business reasons. Gilead
shall cooperate in the prosecution of any suit initiated by MacroGenics to the extent permitted by the prior sentence as may be reasonably requested by MacroGenics (including joining such suit as a plaintiff if MacroGenics is unable to initiate or
prosecute such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
action solely in its own name); provided, however, that MacroGenics shall promptly reimburse all Out-of-Pocket Costs (including reasonable counsel fees and expenses) of Gilead in connection with
such cooperation. Any recoveries resulting from such an action brought by MacroGenics in accordance with this Section&nbsp;9.4.2(f) will be retained by MacroGenics after payment of each Party&#146;s costs and expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) If MacroGenics in good faith does not intend to initiate a lawsuit or take other reasonable action with respect to any matter
described in clause (ii)&nbsp;of Section&nbsp;9.4.2(c), then MacroGenics shall notify Gilead thereof (i)&nbsp;if there is no time limit for the filing of such action, <B>***</B> following the notice of alleged infringement or following a biosimilar
applicant&#146;s failure to act or (ii)&nbsp;if there is a time limit for the filing of such action (including those set forth in applicable Laws) within <B>***</B> before the time limit, and upon receipt of such notice Gilead shall have the right,
but not the obligation, to initiate such lawsuit or take such other action, after providing <B>***</B> in the event there is a time limit) notice to MacroGenics and giving good faith consideration to MacroGenics&#146; reason(s) for not initiating a
lawsuit or taking other action; provided, however, that Gilead shall not initiate such a lawsuit or take such other action with respect to any matter described in clause (ii)(w) of Section&nbsp;9.4.2(c) without the prior written consent of
MacroGenics (which MacroGenics may withhold in its sole discretion) if MacroGenics&#146; decision not to exercise its first right with respect thereto was made for strategic business reasons. MacroGenics shall cooperate in the prosecution of such
suit as may be reasonably requested by Gilead (including joining such suit as a plaintiff if Gilead is unable to initiate or prosecute such action solely in its own name); provided, however, that Gilead shall promptly reimburse all Out-of-Pocket
Costs (including reasonable counsel fees and expenses) of MacroGenics in connection with such cooperation. Any recoveries resulting from such an action brought by Gilead in accordance with this Section&nbsp;9.4.2(g) will be retained by Gilead after
payment of each Party&#146;s costs and expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.3 <U>Conduct of Certain Actions; Costs</U>. The Party initiating legal
action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section&nbsp;9.4.2 (the &#147;<U>Initiating Party</U>&#148;). Unless otherwise expressly provided, the Initiating Party shall bear its own
out-of-pocket costs incurred in any such legal action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action (in cases where such other Party
has standing) by its own counsel at its own expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5 <U>Patent Invalidity Claim</U>. Each Party shall promptly notify the
other in the event of any legal action (excluding any actions covered by Section&nbsp;9.3) by any Third Party with respect to the validity of a Joint Patent, MacroGenics Patent or Gilead Collaboration Patent of which it becomes aware. With respect
to any such action: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.1 Gilead shall have (i)&nbsp;the sole right, but not the obligation, at its expense, to defend
against any such action relating to any Gilead Collaboration Patents that are Other Patents, in the Gilead Territory, and (ii)&nbsp;the first right, but not the obligation, at its expense, to defend against any such action relating to (v)&nbsp;any
Gilead Collaboration Patents that are Product Patents, in the Gilead Territory, (w)&nbsp;any Gilead Collaboration Patents that are Other Patents, in the MacroGenics Territory, (x)&nbsp;any MacroGenics Patents that are Product Patents, in the Gilead
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Territory, (y)&nbsp;any Joint Patents that are Product Patents, in the Gilead Territory and (z)&nbsp;any Joint Patents that are Other Patents, in the Gilead Territory. If Gilead does not defend
against any such action described in clause (ii)&nbsp;above, then MacroGenics shall have the right, but not the obligation, to defend such action at MacroGenics&#146; expense; provided, however, that MacroGenics shall not defend against any such
action described in clause (ii)(v), (ii)(x) or (ii)(y) above without the prior written consent of Gilead (which Gilead may withhold in its sole discretion) if Gilead&#146;s decision not to exercise its first right with respect thereto was made for
strategic business reasons. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.2 MacroGenics shall have (i)&nbsp;the sole right, but not the obligation, at its expense, to
defend against any such action relating to (x)&nbsp;any Platform Patents throughout the world and (y)&nbsp;any MacroGenics Patents that are Other Patents, in the MacroGenics Territory, and (ii)&nbsp;the first right, but not the obligation, at its
expense, to defend against any such action relating to (v)&nbsp;any Gilead Collaboration Patents that are Product Patents, in the MacroGenics Territory, (w)&nbsp;any MacroGenics Patents that are Product Patents, in the MacroGenics Territory,
(x)&nbsp;any MacroGenics Patents that are Other Patents, in the Gilead Territory, (y)&nbsp;any Joint Patents that are Product Patents, in the MacroGenics Territory and (z)&nbsp;any Joint Patents that are Other Patents, in the MacroGenics Territory.
If MacroGenics does not defend against any such action described in clause (ii)&nbsp;above, then Gilead shall have the right, but not the obligation, to defend such action at Gilead&#146;s expense. In addition, with respect to any such action
described in clauses (ii)(v), (ii)(w) or (ii)(y) above, (A)&nbsp;to the extent permitted or required by applicable Law, Gilead shall have the right to participate and be represented in such action by its own counsel at its own expense;
(B)&nbsp;MacroGenics shall keep Gilead reasonably informed of the status of such action; (C)&nbsp;without limiting clause (B), MacroGenics shall provide Gilead with copies of any court filings or other material documents or correspondence received
from any Third Party in connection with such action promptly after such filings or documents or correspondence are received by MacroGenics; (D)&nbsp;MacroGenics shall consult with Gilead with respect to such action and consider any comments from
Gilead with respect to such action in good faith; and (E)&nbsp;without limiting clause (D), MacroGenics shall provide Gilead with drafts of any court filings or other material documents or correspondence to be filed or delivered by MacroGenics prior
to the date of filing or delivery such that Gilead has a reasonable opportunity to review and provide comments, and to the extent Gilead provides comments thereon promptly and in sufficient time to allow MacroGenics to meet applicable filing
requirements, MacroGenics shall consider such comments in good faith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6 <U>Patent Term Extensions</U>. The Parties shall
cooperate with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country, where applicable to Joint Patents, MacroGenics Patents and Gilead Collaboration Patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7 <U>Patent Marking</U>. Each Party shall comply with the patent marking statutes in each country in which a Licensed Product is sold
by such Party, its Affiliates and/or its Sublicensees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8 <U>Joint Research Agreement</U>. This Agreement shall be
understood to be a joint research agreement under 35 U.S.C. &#167; 103(c)(3) entered into for the purpose of Researching and Developing Program DARTs and Licensed Products. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 10 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B>CONFIDENTIALITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Confidentiality; Exceptions</U>. Except to
the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party (the &#147;<U>Receiving Party</U>&#148;) shall keep confidential and shall not publish or otherwise disclose or use for any
purpose other than as provided for in this Agreement any Know-How in any form (written, oral, photographic, electronic, magnetic, or otherwise) that is disclosed to the Receiving Party by the other Party (the &#147;<U>Disclosing Party</U>&#148;)
directly, or indirectly in the course of the Receiving Party&#146;s performing its obligations or exercising its rights under this Agreement (collectively, &#147;<U>Confidential Information</U>&#148;). Notwithstanding anything to the contrary in
this Agreement, (a)&nbsp;during the Agreement Term (except as provided in Sections 13.7.1(b) and 13.7.2(b)), any Know-How of one Party (excluding Know-How comprising the Joint IP) that (i)&nbsp;is developed or generated pursuant to this Agreement
and exclusively licensed to the other Party pursuant to Section&nbsp;4.1 or 4.2, as applicable, and (ii)&nbsp;relates to aspects of the structure or properties (including functionality) of any Program DART or Licensed Product that are specific to
Program DARTs or Licensed Products or relates specifically to the Manufacture of Program DARTs or Licensed Products shall be deemed to be the Confidential Information of each Party; (b)&nbsp;any Know-How comprising the Joint IP (excluding any
Platform IP) shall be deemed to be the Confidential Information of each Party; and (c)&nbsp;subject to Section&nbsp;10.3, the terms of this Agreement shall be deemed to be the Confidential Information of each Party. Notwithstanding the foregoing,
the restrictions set forth in the first sentence of this Section&nbsp;10.1 shall not apply to Confidential Information of the Disclosing Party to the extent that it can be established by the Receiving Party that such Confidential Information:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.1 was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed to, or learned
by, the Receiving Party, or was otherwise developed independently by the Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.2 was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.3 became generally available to the public or otherwise part of the public domain after its disclosure and other than
through any act or omission of the Receiving Party in breach of this Agreement; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.4 was disclosed to the Receiving
Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Authorized Disclosure</U>. Except as expressly provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2.1 under appropriate confidentiality provisions similar to those in this Agreement, in
connection with the performance of its obligations or exercise of rights expressly granted or reserved in this Agreement, including (subject to any applicable restrictions set forth in any other provisions of this Agreement, including
Section&nbsp;10.2.4) conducting activities with respect to DARTs and products other than Program DARTs or Licensed Products; provided<I>, </I>however, that the Receiving Party shall remain responsible for any violation of such confidentiality
provisions by any Person receiving such Confidential Information; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2.2 to the extent such disclosure is reasonably
necessary in filing or prosecuting patent and copyright applications, prosecuting or defending litigation, complying with applicable governmental regulations (including the rules and regulations of any stock exchange or NASDAQ), preparing and
submitting filings to Regulatory Authorities or as otherwise required by Law; provided, however, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party&#146;s Confidential Information (other than a disclosure
to a Regulatory Authority in a filing required by Law) it will give reasonable advance notice to the Disclosing Party of such disclosure requirement and shall furnish only that portion of the Disclosing Party&#146;s Confidential Information that the
Receiving Party is legally required to furnish; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2.3 in communications with existing or bona fide prospective acquirers,
merger partners, lenders or investors, and consultants and advisors of the Receiving Party in connection with transactions or bona fide prospective transactions with the foregoing, in each case on a need to know basis and under appropriate
confidentiality provisions substantially equivalent to those of this Agreement; provided, however, that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Person receiving such Confidential
Information; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2.4 in communications with existing or bona fide prospective licensees, sublicensees or collaborators, and
consultants and advisors of the Receiving Party in connection with transactions or bona fide prospective transactions with the foregoing, in each case on a need to know basis and under appropriate confidentiality provisions substantially equivalent
to those of this Agreement; provided<I>, </I>however, that (a)&nbsp;the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Person receiving such Confidential Information; (b)&nbsp;MacroGenics shall
not disclose the terms of this Agreement to any such licensee, sublicensee or collaborator without Gilead&#146;s prior written consent, except that MacroGenics may disclose the terms of this Agreement to the extent they relate specifically to the
***Licensed Program, solely as reasonably necessary in connection with such transactions and after redacting any commercially sensitive terms, to any such licensee, sublicensee or collaborator with respect to ***Program DARTs or ***Licensed
Products; (c)&nbsp;Gilead shall not disclose the terms of this Agreement to any such licensee, sublicensee or collaborator without MacroGenics&#146; prior written consent, except that Gilead may disclose the terms of this Agreement to the extent
they relate specifically to any Licensed Program, solely as reasonably necessary in connection with such transactions and after redacting any commercially sensitive terms, to any such licensee, sublicensee or collaborator with respect to Program
DARTs or Licensed Products from such Licensed Program; (d)&nbsp;except as set forth in clause (e)&nbsp;below with respect to Gilead Collaboration Know-How related to the ***Licensed Program, MacroGenics shall not disclose
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any Confidential Information of Gilead in a manner that would disclose the identity of Gilead to such licensee, sublicensee or collaborator; and (e)&nbsp;MacroGenics shall not disclose to any
such licensee, sublicensee or collaborator any Confidential Information of Gilead other than MacroGenics Know-How that is developed prior to the end of the Research Term for the Research Program associated with the Licensed Program to which such
Confidential Information relates, except that MacroGenics may disclose any MacroGenics Know-How, Gilead Collaboration Know-How or Know-How comprising Joint IP to the extent related to the <B>***</B>Licensed Program, solely as reasonably necessary in
connection with such transactions, to any such licensee, sublicensee or collaborator with respect to <B>***</B>Program DARTs or <B>***</B>Licensed Products; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.2.5 to the extent mutually agreed to in writing by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <U>Press
Release; Disclosure of Agreement</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.1 On or promptly after the Effective Date, the Parties shall jointly issue a
public announcement of the execution of this Agreement in the form attached hereto as <U>Exhibit F</U>. Neither Party shall issue any subsequent press release regarding this Agreement or the Parties&#146; activities hereunder without the prior
written consent of the other Party. Neither Party shall make any other disclosures regarding this Agreement or the Parties&#146; activities hereunder, or any results or data arising hereunder, except (a)&nbsp;with respect to any Confidential
Information of the other Party, to the extent permitted by Section&nbsp;10.2; (b)&nbsp;in accordance with Section&nbsp;10.6; or (c)&nbsp;for any disclosure that is reasonably necessary to comply with applicable securities exchange listing
requirements or other applicable Laws. Notwithstanding the foregoing, to the extent information regarding this Agreement has already been publicly disclosed, either Party may subsequently disclose the same information to the public without the
consent of the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.2 Each Party shall, if practicable, give the other Party a reasonable opportunity to review
those portions of all filings with the United States Securities and Exchange Commission (or any stock exchange, including Nasdaq, or any similar regulatory agency in any country other than the United States) describing the terms of this Agreement
(including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the provisions of this Agreement for which
confidential treatment should be sought. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4<U>***</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5 <U>Remedies</U>. In the event a Party breaches the confidentiality obligations set forth in this ARTICLE 10, the other Party shall
be entitled to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary injunction, without the posting of any bond or other security, enjoining or restraining the breaching Party from any violation or threatened
violation of this ARTICLE 10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6 <U>Publications</U>. The Parties recognize that it may be useful or required to publish or
publicly disclose the results of Research and Development work on Program DARTs and Licensed Products, and each Party (and its Affiliates) shall be free to publish or publicly disclose </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
such results, subject, in the case of any such results containing Confidential Information of the other Party, to prior review by the other Party for patentability and protection of its
Confidential Information in accordance with this Section&nbsp;10.6. The Party that desires to publish such results shall provide the other Party with a copy of the applicable proposed abstract, manuscript, or presentation no less than <B>***</B>
prior to its intended submission for publication. The reviewing Party shall respond in writing promptly and in no event later than <B>***</B> after receipt of the proposed material with any concerns regarding patentability or protection of such
reviewing Party&#146;s Confidential Information. In the event of concern over patent protection, the publishing Party agrees not to submit such publication or to make such presentation that contains such information until the reviewing Party is
given a reasonable period of time, and in no event less than <B>***</B>, to seek patent protection for any material in such publication or presentation which it believes is patentable. Subject to Section&nbsp;10.2, any Confidential Information of
the reviewing Party shall, if requested by the reviewing Party, be removed by the other Party; provided, however, that (a)&nbsp;Gilead as the publishing Party shall have no obligation to remove any Confidential Information of MacroGenics to the
extent such Confidential Information is (i)&nbsp;described in clause (a)&nbsp;of the second sentence of Section&nbsp;10.1 or (ii)&nbsp;Know-How comprising the Joint IP that relates to <B>***</B>; and (b)&nbsp;Gilead as the reviewing Party shall not
unreasonably request removal of any Confidential Information of Gilead to the extent such Confidential Information is (i)&nbsp;(x)&nbsp;MacroGenics Know-How described in clause (a)&nbsp;of the second sentence of Section&nbsp;10.1 and
(y)&nbsp;related to the *** Licensed Program or (ii)&nbsp;Know-How comprising the Joint IP that relates to <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7
<U>Return of Confidential Information</U>. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing Party all Confidential Information of the Disclosing Party in its possession (and all copies and
reproductions thereof). In addition, the Receiving Party shall destroy: (a)&nbsp;any notes, reports or other documents prepared by the Receiving Party which contain Confidential Information of the Disclosing Party; and (b)&nbsp;any Confidential
Information of the Disclosing Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. Alternatively, upon written request of the Disclosing Party, upon such expiration or
termination, the Receiving Party shall destroy all Confidential Information of the Disclosing Party in its possession (and all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party which contain
Confidential Information of the Disclosing Party. Nothing in this Section&nbsp;10.7 shall require the alteration, modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary course of business;
provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 10 with respect to any Confidential Information contained in such archival tapes or other electronic back-up
media. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party. Notwithstanding the foregoing, (i)&nbsp;the Receiving Party&#146;s legal counsel may retain one copy of the Disclosing Party&#146;s
Confidential Information solely for the purpose of determining the Receiving Party&#146;s continuing obligations under this ARTICLE 10 and (ii)&nbsp;the Receiving Party may retain the Disclosing Party&#146;s Confidential Information and its own
notes, reports and other documents to the extent reasonably required (x)&nbsp;to comply with applicable Law and regulatory requirements; (y)&nbsp;to exercise the rights and licenses of the Receiving Party expressly surviving expiration or
termination of this Agreement; and (z)&nbsp;to perform the obligations of the Receiving Party </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
expressly surviving expiration or termination of this Agreement. Notwithstanding the return or destruction of the Disclosing Party&#146;s Confidential Information, the Receiving Party shall
continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 10. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 11
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPRESENTATIONS AND WARRANTIES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Representations and Warranties of Both Parties</U>. Each Party hereby represents and warrants to the other Party, as of the Effective Date, that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.1 Such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.2 Such Party
has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1.3 This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof, subject
to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights and judicial principles affecting the availability of specific performance and general principles of equity, whether
enforceability is considered a proceeding at law or equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.4 The execution, delivery and performance of this Agreement
by such Party does not conflict with any agreement or any provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any applicable Law. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.5 No government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental
department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is or will be necessary for, or in connection with, the transactions contemplated by this Agreement, or for the
performance by it of its obligations under this Agreement, except as necessary to conduct clinical trials or to seek or obtain Regulatory Approvals or as may be required under the HSR Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Representations, Warranties and Covenants of MacroGenics</U>. MacroGenics hereby represents, warrants and covenants to Gilead
that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.1 MacroGenics is as of the Effective Date, and (subject to Section&nbsp;15.4) will at all times during the
Agreement Term be, the sole and exclusive owner of all of the MacroGenics IP that exists as of the Effective Date. Subject to (a)&nbsp;any MacroGenics Third Party Agreements, (b)&nbsp;any rights of any collaborator of MacroGenics or its Affiliates
as joint owner of any MacroGenics IP and (c)&nbsp;Section&nbsp;15.4, MacroGenics and its Affiliates will at all times during the Agreement Term be the sole and exclusive owner of all of the MacroGenics IP that does not
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
exist as of the Effective Date. MacroGenics&#146; rights to the MacroGenics IP are as of the Effective Date, and at all times during the Agreement Term will be, free of all liens, mortgages,
encumbrances, pledges and security interests by any Third Party (including any rights of any Governmental Authority) other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Gilead under this
Agreement. As of the Effective Date, there are no MacroGenics Third Party Agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.2 The MacroGenics Patents existing
as of the Effective Date are listed on <U>Exhibit C</U>. As of the Effective Date, all documents required to be filed and all payments required to be made in order to maintain each MacroGenics Patent have been filed or made, as the case may be, in a
timely manner, and no action has been taken that would constitute waiver, abandonment or any similar relinquishment of rights with respect to any such Patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.2.3 As of the Effective Date, to the knowledge of MacroGenics, the MacroGenics IP existing as of the Effective Date is not invalid or unenforceable, in whole or in part. As of the Effective Date, the
conception, development and reduction to practice of the MacroGenics IP existing as of the Effective Date have not constituted or involved the misappropriation of trade secrets or other rights or property of any Person. Except as disclosed on
<U>Schedule 11.2.3</U>, there are not as of the Effective Date, nor have there been over the three (3)&nbsp;year period immediately preceding the Effective Date, any actual (or, to MacroGenics&#146; knowledge, threatened) claims, lawsuits,
arbitrations, legal or administrative or regulatory proceedings, charges, complaints or investigations by any Government Authority (except in the ordinary administrative course of the granting of patents and proceedings relating thereto) or by any
Third Party relating to the MacroGenics IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.4 As of the Effective Date, to the knowledge of MacroGenics, the exercise by
Gilead of the rights and licenses granted to Gilead by MacroGenics under this Agreement will not infringe any of the intellectual property rights of any Third Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.2.5 As of the Effective Date, to the knowledge of MacroGenics, there is no actual infringement or misappropriation or threatened infringement or misappropriation of any MacroGenics IP by any Person.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.6 As of the Effective Date, MacroGenics has not (a)&nbsp;employed or used a contractor or consultant that has employed,
any individual or entity debarred by the FDA (or subject to a similar sanction of EMA), or (b)&nbsp;employed any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in the
conduct of any pre-clinical activities or clinical studies of Program DARTs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.7 As of the Effective Date, there is no
Regulatory Documentation that (a)&nbsp;is relevant to the Licensed Programs or any Program DARTs and (b)&nbsp;applicable Law requires MacroGenics to have prepared, filed or maintained. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.8 As of the Effective Date, all activities conducted by or on behalf of MacroGenics with respect to Program DARTs have been
conducted, in all material respects, in accordance with applicable Law, GLP, GCP and GMP, as applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.9 Without limitation of the generality of Section&nbsp;11.1.4, as of the Effective
Date, MacroGenics has the right to grant all rights and licenses it purports to grant to Gilead with respect to the MacroGenics IP under this Agreement and has not granted to any Third Party any license, right or interest in, to or under MacroGenics
IP that is inconsistent with the licenses and rights granted to Gilead in Section&nbsp;4.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.10 As of the Effective Date,
MacroGenics has not granted to any Third Party the sole or first right to file, prosecute or maintain Patents that contain Platform Claims. As of the Effective Date, MacroGenics has not granted to any Third Party the sole right to enforce any
Platform Claims. MacroGenics as of the Effective Date has not granted, and during the Agreement Term will not grant, to any Third Party any rights (a)&nbsp;to prosecute, maintain or enforce any Product Patents, except for any such rights in the
MacroGenics Territory granted to any Third Party licensee, sublicensee or collaborator of MacroGenics with respect to ***Program DARTs or ***Licensed Products, or (b)&nbsp;to enforce any Platform Patents with respect to a Competitive Infringement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.11 Each Patent listed on <U>Exhibit C</U> is a Platform Patent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Mutual Covenants</U>. Each Party hereby covenants to the other Party that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.1 Such Party shall comply with all applicable Laws in connection with this Agreement and the transactions contemplated hereby.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.2 Such Party will impose on all employees of such Party or its Affiliates who perform work under this Agreement the
obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3.3 Such Party will not (a)&nbsp;employ or use any contractor or consultant that employs any individual or entity debarred by the FDA (or subject to a similar sanction of EMA); or (b)&nbsp;employ any
individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in each of clauses (a)&nbsp;and (b)&nbsp;in the conduct of its activities under this Agreement. If, at any time during the
term of this Agreement, (x)&nbsp;any individual or entity employed by such Party or any contractor or consultant used by such Party in the conduct of its activities under this Agreement becomes debarred by the FDA (or subject to a similar sanction
of EMA) or (y)&nbsp;any individual or entity employed by such Party in the conduct of its activities under this Agreement becomes the subject of, or is threatened to be made the subject of, an FDA debarment investigation or proceeding (or similar
proceeding of EMA), such Party shall immediately notify the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.4 Such Party shall perform its activities
pursuant to this Agreement in compliance in all material respects with GLP, GCP and cGMP (including those specified by the ICH), in each case as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3.5 Neither Party shall, during the Agreement Term, grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any
of the rights or licenses granted or to be granted to the other Party hereunder pursuant to the provisions of ARTICLE 4. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4 <U>Disclaimer</U>. Except as otherwise expressly set forth in this Agreement, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing except as otherwise expressly set forth in this Agreement, each Party disclaims any warranties with regards to: (a)&nbsp;the success of any study or test
commenced under this Agreement; (b)&nbsp;the safety or usefulness for any purpose of the technology or materials, including any compounds, it provides or discovers under this Agreement; or (c)&nbsp;the validity, enforceability, or non-infringement
of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. Data and regulatory materials are given by each Party to the other Party, except as otherwise provided herein, on an &#147;as is&#148;
basis without any warranty of any kind. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 12 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEMNIFICATION AND INSURANCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Indemnification by Gilead</U>. Gilead shall defend, indemnify and hold harmless the MacroGenics Indemnitees from and against any and all losses, damages, fees, expenses, settlement amounts or
costs (including reasonable attorneys&#146; fees and witness fees) (&#147;<U>Losses</U>&#148;) relating to or in connection with a Third Party claim arising out of (a)&nbsp;any death, personal bodily injury or damage to real or tangible personal
property alleged or proven to result, directly or indirectly, from the possession, use or consumption of, or treatment with, a Program DART or Licensed Product Researched, Developed, Manufactured or Commercialized in the Gilead Territory for the
applicable Licensed Program (or, as permitted under this Agreement, the MacroGenics Territory for the applicable Licensed Program), in each case by or on behalf of Gilead or its Affiliates or Sublicensees, including any product liability claims;
(b)&nbsp;the Commercialization by or on behalf of Gilead or its Affiliates or Sublicensees of any Program DART or Licensed Product in the Gilead Territory; (c)&nbsp;any actual or alleged infringement or unauthorized use or misappropriation of any
Patent or other intellectual property right of a Third Party with respect to the activities of Gilead or its Affiliates or Sublicensees hereunder; (d)&nbsp;any breach by Gilead of its representations, warranties or covenants made under this
Agreement; or (e)&nbsp;any illegal or negligent act or omission or willful misconduct of Gilead or its Affiliates or Sublicensees or any of their employees, contractors or agents, in performing Gilead&#146;s obligations or exercising Gilead&#146;s
rights under this Agreement; provided, however, that the foregoing indemnity shall not apply to the extent that any such Losses (i)&nbsp;are attributable to an illegal act by or the gross negligence or willful misconduct of any MacroGenics
Indemnitees, or (ii)&nbsp;are otherwise subject to an obligation by MacroGenics to indemnify the Gilead Indemnitees under Section&nbsp;12.2, as to which Losses the provisions of Section&nbsp;12.4 shall apply. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Indemnification by MacroGenics</U>. MacroGenics shall defend, indemnify and hold harmless the Gilead Indemnitees from and against
any and all Losses relating to or in connection with a Third Party claim arising out of (a)&nbsp;any death, personal bodily injury or damage to real or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
tangible personal property alleged or proven to result, directly or indirectly, from the possession, use or consumption of, or treatment with, a Program DART or Licensed Product Researched,
Developed, Manufactured or Commercialized in the MacroGenics Territory for the applicable Licensed Program (or, as permitted under this Agreement, the Gilead Territory for the applicable Licensed Program), in each case by or on behalf of MacroGenics
or its Affiliates or Sublicensees, including any product liability claims; (b)&nbsp;the Commercialization by or on behalf of MacroGenics or its Affiliates or Sublicensees of any Program DART or Licensed Product in the MacroGenics Territory, or the
Manufacture of any Program DART or Licensed Product on behalf of MacroGenics by any Third Party pursuant to any consent or approval granted by Gilead under Section&nbsp;3.2.5(e); (c)&nbsp;any actual or alleged infringement or unauthorized use or
misappropriation of any Patent or other intellectual property right of a Third Party with respect to the activities of MacroGenics or its Affiliates or Sublicensees hereunder; (d)&nbsp;any breach by MacroGenics of its representations, warranties or
covenants made under this Agreement; (e)&nbsp;any illegal or negligent act or omission or willful misconduct of MacroGenics or its Affiliates or Sublicenses or any of their employees, contractors or agents, in performing MacroGenics&#146;
obligations or exercising MacroGenics&#146; rights under this Agreement; or (f)&nbsp;any exercise by MacroGenics of its rights under the license grant by Gilead in Section&nbsp;4.2(d); provided, however, that the foregoing indemnity shall not apply
to the extent that any such Losses are attributable to (i)&nbsp;an illegal act by or the gross negligence or willful misconduct of any Gilead Indemnitees, or (ii)&nbsp;are otherwise subject to an obligation by Gilead to indemnify the MacroGenics
Indemnitees under Section&nbsp;12.1, as to which Losses the provisions of Section&nbsp;12.4 shall apply. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3
<U>Procedure</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3.1 In the event of a claim by a Third Party against any Person entitled to indemnification under this
Agreement, the Party claiming indemnification (in such capacity, the &#147;<U>Indemnified Party</U>&#148;) shall promptly notify the other Party (in such capacity, the &#147;<U>Indemnifying Party</U>&#148;) in writing of the claim (it being
understood that the failure by the Indemnified Party to give prompt notice of a Third Party claim as provided in this Section&nbsp;12.3 shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only
to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give prompt notice). Within thirty (30)&nbsp;days after delivery of such notification, the Indemnifying Party may, upon written notice thereof to the
Indemnified Party, undertake and solely manage and control, at its sole expense and with counsel reasonably satisfactory to the Indemnified Party, the defense of the claim; provided, however, that if MacroGenics is the Indemnifying Party and the
claim relates to a Program DART or Licensed Product with respect to which a Phase 2 Clinical Trial has been Completed, then Gilead may, at any time upon written notice to MacroGenics, assume sole management and control of the defense of the claim,
at its sole expense (provided, however, that Gilead shall not be required to reimburse MacroGenics for any expenses incurred by MacroGenics in connection with MacroGenics&#146; defense of the claim prior to such assumption). If the Indemnifying
Party does not undertake such defense in accordance with the preceding sentence, the Indemnified Party shall control such defense. The Party not controlling such defense shall cooperate with the other Party and may, at its option and expense,
participate in such defense with counsel of its choice; provided, however, that if the Indemnifying Party assumes control of such defense as set forth above and the Indemnified Party in good faith concludes, based on advice from counsel, that the
Indemnifying Party and the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Indemnified Party (or the relevant MacroGenics Indemnitee or Gilead Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim, the
Indemnified Party&#146;s counsel may fully participate in such defense and the Indemnifying Party shall be responsible for the reasonable fees and expenses of one counsel to the indemnified Persons solely in connection therewith. The Party
controlling such defense shall keep the other Party advised of the status of such action, suit, proceeding or claim and the defense thereof, shall provide the other Party copies of material documents and filings related to such action, suit,
proceeding or claim and shall consider recommendations made by the other Party with respect thereto. Except if the Indemnifying Party did not undertake defense of the claim as set forth above, or if the Indemnifying Party and the Indemnified Party
(or the relevant MacroGenics Indemnitee or Gilead Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim and the Indemnified Party engages separate counsel, as provided above, the
Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party&#146;s written consent. The Indemnified Party shall not settle any such action, suit, proceeding or claim
without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not settle, without the prior written consent of the Indemnified Party, any such action,
suit, proceeding or claim, or consent to any judgment in respect thereof, that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the
Indemnified Party or that acknowledges fault by the Indemnified Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3.2 Notwithstanding anything to the contrary above,
in the event of any claim or criminal action brought by a Governmental Authority against a Gilead Indemnitee for which indemnification may be sought under this Section&nbsp;12.3, Gilead shall have the right to control the defense, litigation,
settlement, appeal or other disposition of the claim or action at MacroGenics&#146; expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4 <U>Allocation</U>. In the
event a claim falls within the scope of the indemnity given by each Party in Section&nbsp;12.1 or 12.2, as the case may be, any payments in connection with such claim shall be apportioned between the Parties in accordance with the degree of fault
attributable to each Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5 <U>EXCLUSION OF CONSEQUENTIAL DAMAGES</U>. EXCEPT WITH RESPECT TO A BREACH OF SECTION 4.9,
ARTICLE 10 OR THIRD PARTY CLAIMS THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 12, NEITHER MACROGENICS NOR GILEAD, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE
DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER SUCH PARTY OR ANY REPRESENTATIVE OF SUCH PARTY HAS BEEN ADVISED OF, OR OTHERWISE
MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6 <U>Insurance</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6.1 MacroGenics shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) ***; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) ***; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Upon initiation by MacroGenics of human clinical trials of any Program DART or Licensed Product, Clinical Trials insurance in
accordance with applicable Law in the jurisdiction where such trials will be performed; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that any of the required policies of insurance are written on a claims made basis, then such policies shall be maintained for a period of
not less than five (5)&nbsp;years following the termination or expiration of this Agreement. Each insurance policy that is required under this Section&nbsp;12.6.1 shall be obtained from an insurance carrier with an A.M. Best rating of at least
A-VII. MacroGenics shall furnish a certificate of insurance for any of the required policies as soon as practicable after the Effective Date (or, with respect to clauses (b)&nbsp;and (c)&nbsp;above, such time as MacroGenics obtains the applicable
policy) and upon any renewal thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.6.2 Gilead shall at its own cost and expense, obtain and maintain in full force and
effect the following insurance: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Upon initiation by Gilead of human clinical trials of any Program DART or Licensed
Product, Clinical Trials insurance in accordance with applicable Law in the jurisdiction where such trials will be performed; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In lieu of insurance, Gilead may self-insure any or a portion of the above required
insurance. In the event that any of the required policies of insurance are written on a claims made basis, then such policies shall be maintained for a period of not less than five (5)&nbsp;years following the termination or expiration of this
Agreement. Subject to Gilead&#146;s right to self-insure, each insurance policy that is required under this Section&nbsp;12.6.2 shall be obtained from an insurance carrier with an A.M. Best rating of at least A-VII. Gilead shall furnish a
certificate of insurance for any of the required policies as soon as practicable after Gilead obtains the applicable policy and upon any renewal thereof. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 13 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TERM AND TERMINATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Agreement Term; Expiration</U>. This Agreement shall become effective as of the Effective Date and, unless earlier terminated in
accordance herewith, shall continue in full force with respect to any Licensed Program until the expiration of the last to expire Royalty Term for a Licensed Product from such Licensed Program with respect to each country in the Gilead Territory for
such Licensed Program. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 <U>Termination for Cause</U>. Either Party (the &#147;<U>Non-Breaching Party</U>&#148;)
may, without prejudice to any other remedies available to it under applicable Law or in equity, terminate this Agreement in its entirety or with respect to any Licensed Program if the other Party (the &#147;<U>Breaching Party</U>&#148;) shall have
materially breached or defaulted in the performance of its obligations hereunder with respect to such Licensed Program, and such default shall have continued for <B>***</B> after written notice thereof was provided to the Breaching Party by the
Non-Breaching Party, such notice describing the alleged breach. Any such termination shall become effective at the end of such <B>***</B> cure period, unless the Breaching Party has cured such breach or default prior to the expiration of such cure
period; provided, however, that if the Breaching Party notifies the Non-Breaching Party within such <B>***</B> period that the Breaching Party disagrees in good faith with such asserted basis for termination, the termination of this Agreement in its
entirety or with respect to the applicable Licensed Program shall not be effective unless and until the matter has been finally resolved in accordance with Section&nbsp;15.2 and the decision by the applicable court rendered in accordance with
Section&nbsp;15.2 holds that the Breaching Party materially breached this Agreement. The right of either Party to terminate this Agreement as provided in this Section&nbsp;13.2 shall not be affected in any way by such Party&#146;s waiver or failure
to take action with respect to any previous default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>Termination for Patent Challenge</U>. If either Party or any of
its Affiliates: (a)&nbsp;commences or otherwise voluntarily determines to participate in any action or proceeding (including any patent opposition or re-examination proceeding), challenging or denying the validity of any of the other Party&#146;s
Patents or Joint Patents licensed hereunder or any claim thereof, excluding any such challenge asserted as a counterclaim in litigation initiated by the other Party or its Affiliates, or (b)&nbsp;actively assists any other Person in bringing or
prosecuting any action or proceeding (including any patent opposition or re-examination proceeding) challenging or denying the validity of any of such Patents or any claim thereof, the non-challenging Party shall have the right to terminate this
Agreement with respect to the Licensed Program to which such Patents are subject upon <B>***</B> written notice to the other Party. Any such termination shall only become effective if the challenging Party or its Affiliate, as applicable, has not
withdrawn such action before the end of the above notice period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4 <U>Termination for Convenience</U>. Gilead may
terminate this Agreement with respect to any Licensed Program at any time upon <B>***</B> written notice to MacroGenics if the effective date of such termination is <B>***</B> after the Effective Date; provided, however, that Gilead may terminate
this Agreement with respect to a Licensed Program at any time upon <B>***</B> written notice to MacroGenics if there is a <B>***</B>; and provided, further, that if the Research Term of the Research Program associated with any terminated Licensed
Program has not expired as of the effective date of such termination, (a)&nbsp;the Parties shall use good faith efforts to reallocate the FTEs for such Research Program, first to other active Research Programs (if any), and second to any other
research programs of MacroGenics, and (b)&nbsp;Gilead shall pay the reasonable, documented Out-of-Pocket Costs and FTE Costs of MacroGenics incurred in winding down such Research Program. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5 <U>Termination for Insolvency Event</U>: Either Party may terminate this Agreement in
its entirety upon written notice to the other Party if the other Party suffers an Insolvency Event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.6 <U>Termination for
HSR Act Delay</U>. Gilead may terminate this Agreement with respect to the <B>***</B>Licensed Program, the <B>***</B> Licensed Program or the <B>***</B>Licensed Program, as applicable, upon written notice to MacroGenics if an HSR Filing with respect
to such Licensed Program is made under Section&nbsp;3.2.2(c) and the waiting period (or any extension thereof) under the HSR Act has not terminated or expired as of sixty (60)&nbsp;days after the date on which such HSR Filing is made. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7 <U>Effect of Termination</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.7.1 Subject to Section&nbsp;13.8, upon termination of this Agreement by MacroGenics in whole or with respect to one or more Terminated Programs pursuant to Section&nbsp;13.2, 13.3, 13.5 or 15.5 or by
Gilead with respect to one or more Terminated Programs pursuant to Section&nbsp;13.4: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) all rights, licenses and options
granted by MacroGenics to Gilead with respect to each Terminated Program hereunder shall terminate and Gilead shall not have any rights to use or exercise any rights under the MacroGenics IP with respect to any such Terminated Program; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) any Gilead Collaboration Know-How described in clause (a)&nbsp;of the second sentence of Section&nbsp;10.1 shall continue to be
deemed to be the Confidential Information of each Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) if such termination occurs during a Research Term, Gilead shall
promptly transfer and assign to MacroGenics all Supplemental Data and Gilead Collaboration IP that was created by or on behalf of Gilead or its Affiliates, or both, whether solely or jointly with MacroGenics, in the course of conducting activities
under the Terminated Program; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) if such termination occurs after the Research Term and during a License Term: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) to the extent Gilead has conducted any Research, Development or Commercialization activities with respect to such Terminated
Program, Gilead shall provide to MacroGenics a fair and accurate detailed written description of the status of such activities through the effective date of termination within <B>***</B> of such termination; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the licenses granted to MacroGenics pursuant to Section&nbsp;4.2 shall remain in effect and with respect to any Terminated Program
shall become irrevocable; provided, however, that MacroGenics shall not use any Gilead Collaboration IP in connection with any activities in the Gilead Territory, except in accordance with (x)&nbsp;the license grants set forth in clauses
(c)&nbsp;and (d)&nbsp;of Section&nbsp;4.2 or (y)&nbsp;any rights of MacroGenics under any agreement entered into pursuant to Section&nbsp;13.7.1(d)(vi); </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) the rights granted to MacroGenics under Section&nbsp;9.3.2 shall survive; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Gilead shall, to the extent it has not already done so, provide to MacroGenics copies of all Gilead Collaboration IP that was
created by or on behalf of Gilead or its Affiliates in the course of conducting activities under the Terminated Program, solely to the extent necessary for MacroGenics to exercise its rights under clauses (ii)&nbsp;and (v)&nbsp;of this
Section&nbsp;13.7.1(d); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) Gilead hereby grants to MacroGenics, effective upon such termination, a non-exclusive,
royalty-free, non-transferable (except in accordance with Section&nbsp;15.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under (A)&nbsp;Gilead&#146;s and its Affiliates&#146; interest in Gilead Collaboration IP and Joint IP
that are Platform IP and that were created by or on behalf of Gilead or its Affiliates, or both, whether solely or jointly with MacroGenics, in the course of conducting activities under the Terminated Program, to Research, Develop, Manufacture and
Commercialize throughout the world DARTs; and (B)&nbsp;if the ***Licensed Program is the Terminated Program, clinical data included in the Gilead Collaboration Know-How that results from any Phase 1 Clinical Trial or Phase 2 Clinical Trial of any
***Program DART or ***Licensed Product, to Research, Develop, Manufacture and Commercialize ***Program DARTS and ***Licensed Products throughout the world; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(vi) the Parties shall enter into good faith negotiations with respect to an agreement pursuant to which Gilead would grant to MacroGenics a license under Gilead Collaboration IP (other than any Gilead
Collaboration Know-How licensed to MacroGenics in accordance with clause (v)&nbsp;above) to Research, Develop, Manufacture and Commercialize the Licensed Product(s) from such Terminated Program, with terms regarding degree of exclusivity, royalty or
other payments, access to or assignment of relevant Regulatory Documentation and other technical and other information or materials in Gilead&#146;s or its Affiliates&#146; possession or control, transfer or amendment of applicable agreements or
arrangements with Third Parties and other appropriate transition matters to be negotiated in good faith. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7.2 Subject to
Section&nbsp;13.8, upon termination of this Agreement by Gilead in whole or with respect to one or more Terminated Programs pursuant to Section&nbsp;13.2, 13.3, 13.5 or 15.5: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) all rights, licenses and options of or granted to Gilead, its Affiliates or Sublicensees pursuant to this Agreement with respect to such Terminated Program, including in Sections 4.1, 6.2.2 and
ARTICLE 9, shall remain in effect; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) any MacroGenics Know-How described in clause (a)&nbsp;of the second sentence of
Section&nbsp;10.1 shall continue to be deemed to be the Confidential Information of each Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) all payment obligations
under ARTICLE 8 with respect to such Terminated Program shall remain in effect; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) all license grants, including under Section&nbsp;4.2(d), by Gilead, its Affiliates or
Sublicensees to MacroGenics pursuant to this Agreement with respect to such Terminated Program shall terminate; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e)
MacroGenics shall provide to Gilead copies of such technical and other information and materials in MacroGenics&#146; or its Affiliates&#146; possession or control as of the date of termination, in each case that relate to such Terminated Program,
to the extent not previously provided to Gilead hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.7.3 Subject to Section&nbsp;13.8, upon termination of this
Agreement by Gilead with respect to <B>***</B>Licensed Program, the <B>***</B> Licensed Program or the <B>***</B> Licensed Program, as applicable, pursuant to Section&nbsp;13.6, all rights and obligations of each Party hereunder with respect to such
Terminated Program shall terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.8 <U>Accrued Rights; Surviving Provisions of the Agreement</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.8.1 <U>Accrued Rights</U>. Termination or expiration of any aspect of this Agreement for any reason shall be without prejudice to any
rights that shall have accrued to the benefit of any Party prior to such termination or expiration, including the payment obligations under ARTICLE 8 and any rights of Gilead under the last sentence of Section&nbsp;8.5.4(b), and any and all damages
or remedies arising from any breach hereunder. Such termination or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.8.2 <U>Surviving Provisions of the Agreement</U>. The provisions of Sections 4.8, 8.7 - 8.10 (with regard to accrued but unpaid
amounts), 8.11, 9.2, 11.4, 13.7 and 13.8 and ARTICLE 12 and ARTICLE 15, and any applicable definitions in ARTICLE 1, shall survive any partial or entire termination of this Agreement or partial or entire expiration of this Agreement for any reason,
in accordance with their respective terms and conditions, and for the duration stated, and where no duration is stated, shall survive indefinitely. ARTICLE 10 shall survive for a period of seven (7)&nbsp;years after the effective date of the entire
termination or expiration of this Agreement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 14 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>STANDSTILL </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1 <U>Standstill</U>. In the event that the common stock of MacroGenics becomes listed on a national securities exchange in an initial
public offering (an &#147;<U>IPO</U>&#148;) <B>***</B>, Gilead agrees that neither it nor any of its Affiliates, acting alone or as part of any 13D Group, shall directly or indirectly, for a period of <B>***</B> (the &#147;<U>Standstill
Period</U>&#148;), without the prior written approval of MacroGenics&#146; Board of Directors: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1.1 acquire or agree,
offer, seek or propose to acquire, or cause to be acquired, ownership (including, but not limited to, beneficial ownership as defined in Rule 13d-3 under the Securities and Exchange Act of 1934) of any substantial part of the assets or businesses of
MacroGenics or of any voting securities of MacroGenics, or any rights or options to acquire any such ownership (including from a third party); </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1.2 make, or in any way participate, directly or indirectly, in any
&#147;solicitation&#148; of &#147;proxies&#148; (as such terms are used in the proxy rules of the Securities and Exchange Commission) to vote, or seek to advise or influence any person with respect to the voting of any voting securities of
MacroGenics; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1.3 form, join or in any way participate in, a &#147;group&#148; (within the meaning of Section&nbsp;13(d)(3)
of the Securities Exchange Act of 1934) (&#147;<U>13D Group</U>&#148;) with respect to any voting securities of MacroGenics; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1.4 otherwise act, whether alone or in concert with others, to seek to propose to MacroGenics any merger, business combination,
restructuring, recapitalization or similar transaction with respect to or with MacroGenics or otherwise act, whether alone or in concert with others, to seek to control, change the management or Board of Directors of MacroGenics, or nominate any
person as a director of MacroGenics who is not nominated by the then incumbent directors; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1.5 enter into any discussion,
negotiations, arrangements or understandings with any third party with respect to, any of the foregoing; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing,
nothing in this Agreement shall limit Gilead&#146;s ability to (x)&nbsp;inquire or make a request, orally or in writing, to the chief executive officer or the chairman of the board of directors of MacroGenics with respect to any amendment or waiver
of any provision of this Section&nbsp;14.1 or (y)&nbsp;make or submit to the chief executive officer or the chairman of the board of directors of MacroGenics a bona fide non-public proposal so long as such action would not reasonably be expected to
require MacroGenics to make a public announcement relating thereto. If at any time during the Standstill Period, Gilead or, to its knowledge, any of its representatives are approached by any Third Party concerning Gilead&#146;s participation in a
transaction of the type referred to in Sections 14.1.1 through 14.1.5, Gilead shall, or shall use commercially reasonable efforts to cause its representative (as applicable) to, promptly inform such Third Party that Gilead is bound by certain
confidentiality obligations in respect of MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2 The restrictions set forth in Section&nbsp;14.1 shall terminate
immediately if: (a)&nbsp;a Person or 13D Group not including Gilead or its Affiliates (i)&nbsp;commences or publicly announces its intent to commence a tender or exchange offer for voting securities of MacroGenics representing more than <B>***</B>
of the then-outstanding voting power of the voting securities of MacroGenics or (ii)&nbsp;publicly announces a bona fide unsolicited proposal to enter into a transaction described in clause (b)(i) or (ii)&nbsp;below and, prior to the termination,
withdrawal or abandonment of such proposal by such Person or 13D Group (as evidenced by a subsequent public announcement or by a written communication to MacroGenics that is either publicly announced or provided by MacroGenics to Gilead), either
(x)&nbsp;MacroGenics publicly announces its willingness to consider such proposal or alternative proposals for a transaction described in clause (b)(i) or (ii)&nbsp;below, (y)&nbsp;the Board of Directors of MacroGenics determines to engage in
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
negotiations with such Person or 13D Group or any other party other than Gilead or its Affiliates with respect to a transaction described in clause (b)(i) or (ii)&nbsp;below, or (z)&nbsp;such
offer or proposal is not publicly rejected or recommended against by MacroGenics within ten (10)&nbsp;Business Days after such offer or proposal becomes public, or (b)&nbsp;MacroGenics or its Affiliates initiates a process to consider or enter into
a transaction described in clause (i)&nbsp;or (ii)&nbsp;below, or enters into a letter of intent or definitive agreement with any party other than Gilead or its Affiliates regarding (i)&nbsp;any merger, sale, reorganization, recapitalization or
other business combination pursuant to which the outstanding shares of MacroGenics would be converted into cash or securities of a Person or a 13D Group not including Gilead or its Affiliates and the stockholders of MacroGenics immediately prior to
such transaction would own immediately after consummation of such a transaction less than fifty percent (50%)&nbsp;of the voting power of the voting securities of MacroGenics or the entity surviving such transaction; or (ii)&nbsp;any transaction
that would result directly or indirectly in all or substantially all of MacroGenics&#146; assets being sold to any Person or 13D Group not including Gilead or its Affiliates. In the event that the transactions contemplated by clauses (a)&nbsp;and/or
(b)&nbsp;shall have been terminated or abandoned, and such termination or abandonment is demonstrable by a press release issued by MacroGenics (or, in the case of clause (a), by the party that initially made the public announcement), then
Section&nbsp;14.1 shall again be applicable for the remainder of the Standstill Period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3 Nothing in this ARTICLE 14 shall
prohibit Gilead or its Affiliates from acquiring securities of MacroGenics by or through (a)&nbsp;a diversified mutual or pension fund managed by an independent investment adviser or pension plan established for the benefit of the employees of
Gilead or its Affiliates, (b)&nbsp;any employee benefit plan of Gilead or its Affiliates or (c)&nbsp;any stock portfolios not controlled by Gilead or its Affiliates that invest in MacroGenics among other companies, provided in each case that Gilead
and its Affiliates do not, directly or indirectly, request the trustee or administrator or investment adviser of such fund, plan or portfolio to acquire such securities. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 15 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MISCELLANEOUS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1 <U>Informal Dispute Resolution</U>. The Parties agree to refer to the Alliance Managers for resolution any dispute, claim or
controversy of any nature arising out of or relating to this Agreement, including any action or claim based on tort, contract or statute, or concerning the interpretation, effect, termination, validity, performance and/or breach of this Agreement
(including any amendments hereto), including any matters referred by the JRC to the Alliance Managers for resolution (each, a &#147;<U>Dispute</U>&#148;). The Alliance Managers shall attempt to resolve each Dispute through good faith discussion for
a period of not less than <B>***</B> after such Dispute is referred to the Alliance Managers by the JRC or either Party. In the event the Alliance Managers are not able to resolve any Dispute in such time period, the Dispute shall be referred to the
Executive Officers, who shall attempt to resolve such Dispute through good faith discussion for a period of <B>***</B> after such Dispute is referred the Executive Officers. In the event that the Dispute involves a modification to a Research Plan,
and such Dispute is not resolved pursuant to this Section&nbsp;15.1, then Gilead may exercise its deciding vote with respect thereto pursuant to Section&nbsp;2.3.5. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">76 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.2 <U>Jurisdiction and Venue</U>. Each Party (a)&nbsp;irrevocably submits to the exclusive
jurisdiction of the federal and state courts located in the <B>***</B> (the &#147;<U>Court</U>&#148;) with respect to any Dispute, and (b)&nbsp;agrees not to raise any objection at any time to the laying or maintaining of the venue of any action,
suit or proceeding for such purpose in any such Court, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action,
suit or other proceeding, that such Court does not have any jurisdiction over such Party, and (c)&nbsp;agrees not to commence any action, suit or proceeding with respect to any Dispute except in such Court. Each Party further agrees that service of
any process, summons, notice or document by U.S. registered mail to such Party&#146;s notice address provided for in this Agreement shall be effective service of process for any action, suit or proceeding in the Court with respect to any matters to
which it has submitted to jurisdiction in this Section&nbsp;15.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.3 <U>Governing Law</U>. This Agreement and any dispute
arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the <B>***</B> without reference to conflicts of laws principles. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.4 <U>Assignment</U>. Neither Party may assign this Agreement or any of its rights or obligations hereunder without the prior written
consent of the other Party, which consent will not be unreasonably withheld or delayed. Notwithstanding the foregoing, this Agreement may be assigned as follows: (a)&nbsp;subject to the next sentence, either Party may assign its rights and
obligations under this Agreement by way of sale of itself or the sale of the portion of its business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest, provided that the assignee shall expressly
agree to be bound by such Party&#146;s obligations under this Agreement and that such sale is not primarily for the benefit of its creditors, and (b)&nbsp;either Party may assign its rights and obligations under this Agreement to any of its
Affiliates, provided that the assignee shall expressly agree to be bound by such Party&#146;s obligations under this Agreement and that such Party shall remain liable for all of its rights and obligations under this Agreement. In the event of
(x)&nbsp;an acquisition of either Party or its assets or equity by a Third Party, such acquisition shall not provide the other Party with rights or access to (A)&nbsp;any Patents or Know-How of such Third Party, or any Affiliate of such Third Party
that becomes an Affiliate of such acquired Party as a result of such acquisition, that exists as of the date of such acquisition or (B)&nbsp;any Patents or Know-How of such Third Party, or any Affiliate of such Third Party that becomes an Affiliate
of such acquired Party as a result of such acquisition, that are filed or developed, as the case may be, after the date of such acquisition, for so long as the acquired Party and such Third Party (or such Affiliate of such Third Party) continue to
conduct their applicable Research and Development activities independently of each other, without any sharing or transfer of relevant Know-How, and (y)&nbsp;an acquisition of MacroGenics or its assets or equity by a Third Party, such Third Party
shall not be permitted to use any MacroGenics IP, other than MacroGenics IP Controlled by MacroGenics or its Affiliates on the Effective Date, in the Research, Development or Commercialization of any Competing Product (as defined in the first
sentence of Section&nbsp;1.23) being Researched, Developed or Commercialized by such Third Party immediately prior to such acquisition (provided, for clarity, that any use by such Third Party of any MacroGenics IP, including any MacroGenics IP
Controlled by MacroGenics or its Affiliates on the Effective Date, shall be subject to any licenses granted to, or other rights of, Gilead hereunder). This Agreement shall be binding upon the successors and permitted assigns
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">77 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party&#146;s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Section&nbsp;15.4 shall be void. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.5 <U>Force Majeure</U>.
Each Party shall be excused from the performance of its obligations under this Agreement to the extent that such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the
other Party. Such excuse shall be continued so long as the condition constituting force majeure continues and the nonperforming Party takes Commercially Reasonable Efforts to remove the condition; provided, that if the nonperformance is material and
continues for more than <B>***</B>, the Party other than the nonperforming Party shall have the right to terminate this Agreement (i)&nbsp;in its entirety, (ii)&nbsp;solely with respect to the affected Licensed Program, or (iii)&nbsp;if MacroGenics
is the nonperforming Party, solely with respect to the affected Research Plan (if any), in each case effective upon written notice to the nonperforming Party. For purposes of this Agreement, &#147;force majeure&#148; shall include conditions beyond
the control of the Parties, including an act of God, voluntary or involuntary compliance with any regulation, Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public
utilities or common carriers, destruction of production facilities or materials by fire, earthquake, storm or like catastrophe. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.6 <U>Notices</U>. Any notice or request required or permitted to be given under or in connection with this Agreement shall be deemed
to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or reputable international business courier (signature required), prepaid, to the
Party for which such notice is intended, at the address set forth for such Party below: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to MacroGenics, </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">addressed to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical Center Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Chief Executive Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile:<B> ***</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If to Gilead, </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">addressed to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead Sciences, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">333 Lakeside Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Foster City, CA 94404 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: General Counsel </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address for such Party as it shall have specified by like
notice to the other Parties, <U>provided</U> that notices of a change of address shall be effective only upon receipt thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">78 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
The effective date of any notice shall be (a)&nbsp;the date of delivery, if personally delivered during the recipient&#146;s normal business hours (and otherwise the first (1st)&nbsp;Business Day
after the date of delivery), (b)&nbsp;the third (3rd)&nbsp;Business Day following the date of mailing, if sent by certified mail, (c)&nbsp;the Business Day following verification of receipt, if sent by facsimile, and (d)&nbsp;the Business Day after
dispatch, if sent by international business courier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.7 <U>Export Clause</U>. Each Party agrees that, as of the Effective
Date, it will not export or re-export restricted commodities or the technical data of the other Party in any form except in compliance with applicable Law (including obtaining any required United States and non-United States government licenses).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.8 <U>Waiver</U>. Neither Party may waive or release any of its rights or interests in this Agreement except in writing.
The failure of either Party to assert a right hereunder or to insist upon compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver
by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15.9 <U>Severability</U>. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute
provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties
hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.10 <U>Covenant</U>. MacroGenics acknowledges that Gilead is a publicly traded company and that, under this Agreement, MacroGenics may
learn of material, non-public information regarding Gilead. MacroGenics understands that federal and state securities laws prohibit MacroGenics&#146; employees from purchasing or selling securities of Gilead while in possession of any such
information or from disclosing such information to others. Accordingly, MacroGenics shall take reasonable actions to inform and instruct its employees who receive or have access to Confidential Information of Gilead not to buy or sell securities of
Gilead while in possession of any material, non-public information regarding Gilead, and shall not advise others to do so. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.11 <U>Entire Agreement</U>. This Agreement, together with the Schedules and Exhibits hereto, set forth all the covenants, promises,
agreements, warranties, representations, conditions and understandings between the Parties as to the subject matter of this Agreement and supersedes and terminates all prior agreements and understanding between the Parties with respect to the
subject matter hereof. In particular, and without limitation, this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between
the Parties prior to the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties as to the subject matter of this Agreement other than as
set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">79 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.12 <U>Independent Contractors</U>. Nothing herein shall be construed to create any
relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other
Party. Neither Party shall have the authority to bind or obligate the other Party and neither Party shall represent that it has such authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15.13 <U>Headings; Construction; Interpretation</U>. Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this
Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion,
whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with
the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the
executed draft or any earlier draft of this Agreement. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph,
clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires, (a)&nbsp;any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein); (b)&nbsp;any reference to any Law refers to such Law as from time
to time enacted, repealed or amended; (c)&nbsp;the words &#147;herein,&#148; &#147;hereof&#148; and &#147;hereunder,&#148; and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; (d)&nbsp;the
words &#147;include,&#148; &#147;includes,&#148; &#147;including,&#148; &#147;exclude,&#148; &#147;excludes,&#148; and &#147;excluding,&#148; shall be deemed to be followed by the phrase &#147;but not limited to,&#148; &#147;without limitation&#148;
or words of similar import; and (e)&nbsp;any reference to Program DARTs or Licensed Products &#147;from&#148; a Licensed Program shall be deemed to include any Program DARTs, and Licensed Products that comprise or incorporate Program DARTs, that
bind to the Program Target for such Licensed Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.14 <U>Further Actions</U>. Each Party shall execute, acknowledge and
deliver such further instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.15 <U>Parties in Interest</U>. All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit
of and be enforceable by the Parties hereto and their respective successors, heirs, administrators and permitted assigns. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.16 <U>Performance by Affiliates</U>. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees
to cause its Affiliates to perform such obligations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">80 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.17 <U>Counterparts</U>. This Agreement may be signed in counterparts, each and every one
of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile signatures and signatures
transmitted via portable document format (PDF) shall be treated as original signatures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>[</I></B><I>Signature
page to follow</I><B><I>]</I></B><I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">81 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Agreement to be executed by their duly authorized representatives as of the Effective Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GILEAD SCIENCES, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John F. Milligan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">John F. Milligan</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">[Signature page] </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Access Territory as of the Effective Date </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit A - 1
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DART Platform </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit B - 1
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Patents </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:15pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Title</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Pending Application</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:28pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:50pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Foreign Rights</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit C - 1
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit D </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Content of Pre-Clinical Data Package for *** Research Program </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit D - 1
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit E </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Research Plan for the *** Research Program </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit E - 1
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit E - 2
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit E - 3
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit F </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Press Release </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit F - 1
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Schedule 11.2.3 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>17
<FILENAME>filename17.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.17</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.17 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COLLABORATION AGREEMENT
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Collaboration Agreement (&#147;<B>Agreement</B>&#148;), effective as of June &nbsp;&nbsp;&nbsp;&nbsp;, 2010 (the
&#147;<B>Effective Date</B>&#148;), is entered into by and between MacroGenics, Inc., a Delaware corporation with a place of business at 1500 East Gude Drive, Rockville, MD 20850 (&#147;<B>MacroGenics</B>&#148;), and Green Cross Corp., a Korean
company with a place of business at 303 Bojeong-Dong, Giheung-Gu, Yongin, 446-770, Korea (&#147;<B>Green Cross</B>&#148;). MacroGenics and Green Cross may be referred to herein individually as a &#147;<B>Party</B>&#148; or collectively as the
&#147;<B>Parties.</B>&#148; </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Recitals: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">A. MacroGenics has expertise in, and platforms for, the discovery and development of products for the treatment of patients with cancer, inflammatory and infectious diseases. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. Green Cross conducts research and development with respect to, and sells, pharmaceutical products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">C. Green Cross and MacroGenics desire to enter into collaboration for the development of MacroGenics&#146; anti-HER2 Antibody known as
MGAH22, and if approved for commercialization, the commercialization of a Product in South Korea, all upon the terms and conditions set forth in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">D. MacroGenics desires to grant to Green Cross, and Green Cross desires to receive, an exclusive license for all Indications for all pharmaceutical forms of MGAH22 for South Korea, upon the terms and
conditions set forth in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In consideration of the foregoing premises and the mutual covenants herein contained,
the Parties hereby agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Agreement: </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <B>D<SMALL>EFINITIONS</SMALL>.</B> Unless specifically set forth to the contrary herein, the following capitalized terms, whether used in the singular or plural, shall have the respective meanings set
forth below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 &#147;<B>Affiliate</B>&#148; means with respect to any Party, any person or entity controlling, controlled
by or under common control with such Party. For purposes of this Section&nbsp;1.1, &#147;control&#148; means (a)&nbsp;in the case of a corporate entity, direct or indirect </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
ownership of at least fifty percent (50%)&nbsp;or more of the stock or shares having the right to vote for the election of directors of such corporate entity and (b)&nbsp;in the case of an entity
that is not a corporate entity, the possession, directly or indirectly, of the power to direct, or cause the direction of, the management or policies of such entity, whether through the ownership of voting securities, by contract or otherwise.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 &#147;<B>Allocable Overhead</B>&#148; means costs incurred by each Party that are attributable to that Party&#146;s
<B>***</B> reasonably allocated to the Party&#146;s departments or functions, or used to support activities under the Collaboration based on space occupied or headcount or other activity-based methods consistently applied by each Party. The
Allocable Overhead shall not include any costs attributable to <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<B>Antibody</B>&#148; means a molecule
comprising or containing: (a)&nbsp;one or more immunoglobulin variable domains; (b)&nbsp;fragments, variants, modifications or derivatives of such immunoglobulin variable domains; and (c)&nbsp;the nucleic acid consisting of a sequence of nucleotides
encoding (or complementary to a nucleic acid encoding) the foregoing molecules in (a)&nbsp;or (b).&nbsp;The term &#147;Antibody&#148; shall include any monospecific antibodies; less than full-length antibody forms such as Fv, Fab, and F(ab&#146;);
single-chain antibodies; and an antibody bound to a drug, label or other moiety and any antibody that is conjugated or fused to any other composition, including for example, a toxin, radionucleotide, small molecule, polypeptide or polypeptide
fragment. The term Antibody also includes, without limitation to its source or method of manufacture, any human, humanized, primatized, chimeric or other antibody. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<B>Applicable Laws and Regulations</B>&#148; means all international, national, federal, state, regional, provincial and local government laws, rules, and regulations that apply to either Party
or to the conduct of the Collaboration under this Agreement including without limitation cGMP, GCP, GBPS, and the laws, rules and regulations of the ICH, that may be in effect, as applicable and amended from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<B>Arbitral Tribunal</B>&#148; has the meaning set forth in Section 17.7(a). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6 &#147;<B>BLA</B>&#148; means (a)&nbsp;a Biologics License Application or New Drug Application (&#147;<B>NDA</B>&#148;) filed with the
FDA for marketing approval of a Product or any successor applications or procedures, and all supplements and amendments that may be filed with respect to the foregoing, or similar filings outside the Territory with applicable Regulatory Authorities,
for approval to commercially market and sell a Product, or (b)&nbsp;similar filings in the Territory with applicable Regulatory Authorities, including the KFDA, for approval to commercially market and sell a Product. The term BLA shall exclude
pricing and reimbursement approvals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<B>Calendar Quarter</B>&#148; means the respective periods of three
(3)&nbsp;consecutive calendar months ending on March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 and December 31. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<B>Calendar Year</B>&#148; means the respective periods of twelve (12)&nbsp;months
commencing on January&nbsp;1 and ending on December&nbsp;31. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<B>cGMP</B>&#148; means current good manufacturing
practices and general biologics products standards as promulgated under the FDCA or Applicable Law and Regulations in the Territory, as applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.10 &#147;<B>Change in Control</B>&#148; means the occurrence of any of the following: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Either Party to this Agreement enters into a merger, consolidation, stock sale or sale or transfer of all or substantially all of its assets, or other similar transaction or series of transactions
with another Person unless, following such transaction or transactions, (i)&nbsp;the individuals and entities who were the beneficial owners of the outstanding voting securities of the subject Party immediately prior to such transaction beneficially
own, directly or indirectly, at least fifty percent (50%)&nbsp;of the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors or similar governing persons of the corporation or other
entity resulting from such transaction (&#147;<B>Successor</B>&#148;) in substantially the same proportions as their ownership immediately prior to such transaction of such outstanding voting securities, (ii)&nbsp;at least fifty percent
(50%)&nbsp;of the members of the Board of Directors or similar governing body of the Successor were members of the Board of Directors of the subject Party at the time of the execution of the initial agreement, or the action of the Board of Directors
of the subject Party, providing for such transaction; (iii)&nbsp;the subject Party retains title ownership after the transaction or transactions to properties and assets (x)&nbsp;representing more than fifty percent (50%)&nbsp;of such Person&#146;s
consolidated total assets or (y)&nbsp;from which more than fifty percent (50%)&nbsp;of such Person&#146;s consolidated operating income for its most recent fiscal was derived, and (iv)&nbsp;the subject Party is the surviving entity in such
transaction or transactions; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) any transaction or series of related transactions in which any Person or group of Persons
acquires beneficial ownership of securities of the subject Party representing more than fifty percent (50%)&nbsp;of the combined voting power of the then outstanding securities of the subject Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11 &#147;<B>Clinical Data</B>&#148; means all data generated or arising from the conduct of a clinical trial or other Development
efforts under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12 &#147;<B>Clinical Material(s)</B>&#148; means MGAH22 and Product formulated in accordance
with the specifications as adopted by the JSC and United States and Korean laws, rules and regulations (a)&nbsp;for preclinical activities, and (b)&nbsp;for administration to subjects in clinical trials. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13 &#147;<B>CMC</B>&#148; means Chemistry Manufacturing and Controls. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>1.14 &#147;<B>Collaboration</B>&#148; means the program established under this Agreement, which includes collaborative development
of Products.<B> </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15 &#147;<B>Commencement</B>&#148; means the first dosing of a human subject with the
applicable Product in the applicable human clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<B>Commercial Supply Costs</B>&#148; shall mean the
costs paid by Green Cross to MacroGenics for the commercial supply of Product pursuant to Section&nbsp;6.2(d), provided that Commercial Supply Costs for a Product shall not be deemed incurred by Green Cross for purposes of this Agreement until the
Calendar Quarter in which such Product is sold by Green Cross or any of its Related Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17
&#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means activities taken before and after obtaining Regulatory Approval relating specifically to the pre-launch, launch, promotion, marketing, sales force recruitment, sale and
distribution of a pharmaceutical product and post-launch medical activities, including without limitation: (a)&nbsp;distribution for commercial sale; (b)&nbsp;strategic marketing, sales force Detailing, advertising, and market and product support;
(c)&nbsp;medical education and liaison and any Phase&nbsp;IV Clinical Trials, to the extent permitted by this Agreement; (d)&nbsp;all customer support and product distribution, invoicing and sales activities; and (e)&nbsp;all post-approval
regulatory activities, including those necessary to maintain Regulatory Approvals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18 &#147;<B>Commercially Reasonable
Efforts</B>&#148; means with respect to the efforts to be expended by a Party with respect to any objective under this Agreement, reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar
objective of such Party under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of MGAH22 and Products, such efforts shall be similar to those efforts and resources commonly used by a
Party for a similar biological or pharmaceutical product owned by it or to which it has rights, which product is at a similar stage in its development or product life and is of similar market potential taking into account efficacy, safety, approved
labeling, the competitiveness of alternative products in the marketplace, the patent and other proprietary position of the product, and the likelihood of regulatory approval given the regulatory structure involved. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<B>Competing Product</B>&#148; means any Antibody that binds to the protein termed &#147;HER2/Neu&#148;, other than a Product.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<B>Completion</B>&#148; or &#147;<B>Completed</B>&#148; for a clinical trial means the later of the following
dates: (a)&nbsp;the date on which all patients have completed protocol-defined study drug administration, and (b)&nbsp;<B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<B>Confidential Information</B>&#148; means any and all non-public scientific, pre-clinical, clinical, regulatory, manufacturing, marketing, financial and commercial information and data, in
any tangible or intangible form, including all <FONT STYLE="white-space:nowrap">Know-how</FONT> subject to Section 12. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22
&#147;<B>Control</B>,&#148; &#147;<B>Controls</B>&#148; or &#147;<B>Controlled by</B>&#148; means (except as used in Section&nbsp;1.1), with respect to any item of or right under Patents or <FONT STYLE="white-space:nowrap">Know-how,</FONT> the
ability </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of a Party (whether through ownership or license, other than pursuant to this Agreement) to grant access to, or a license or sublicense of, such item or right as provided for herein without
violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.23 &#147;<B>CRO</B>&#148; means a clinical research organization. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24 &#147;<B>CTA</B>&#148; means a Clinical Trial Application or its equivalent used to obtain approval to conduct human clinical
investigations filed with or submitted to the KFDA in order to establish the clinical safety and/or efficacy of one or more investigational products in conformance with the requirements of the KFDA. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25 &#147;<B>Data Exclusivity Period</B>&#148; means the period during which the FDA or KFDA (or, in countries other than the United
States or South Korea, an equivalent regulatory agency) prohibits reference, without the consent of the owner of a BLA, to the clinical and other data that is contained in such BLA, and that is not published or publicly available outside of such
BLA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26 &#147;<B>Details</B>&#148; <B>or</B> &#147;<B>Detailing</B>&#148; means face-to-face sales presentations made to
physicians, nurses, pharmacists, and other individuals who provide healthcare services to patients, in their capacity as such. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27 &#147;<B>Develop</B>&#148; or &#147;<B>Development</B>&#148; or &#147;<B>Developing</B>&#148; means research, discovery, process
development, manufacturing for preclinical and clinical uses, and preclinical and clinical drug or biological development activities, including, without limitation, test method development and stability testing, toxicology, formulation, quality
assurance/quality control development, statistical analysis, preclinical and clinical studies and regulatory affairs, approval and registration, in each case, of MGAH22 or a Product for therapy of human diseases. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28 &#147;<B>Development Costs</B>&#148; means all costs incurred in connection with any Development activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.29 &#147;<B>FDA</B>&#148; means the United States Food and Drug Administration, or any successor agency thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.30 &#147;<B>FDCA</B>&#148; means the Federal Food, Drug and Cosmetic Act, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31 &#147;<B>Field</B>&#148; means all oncology therapies; provided, however, that in the case of any Products covered by a Patent or
other intellectual property right licensed in one or more Upstream Licenses, &#147;Field&#148; shall be limited to the minimum extent necessary to comply with the terms of such Upstream License for so long as such limitation is necessary to avoid
breach of the Upstream License. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32 &#147;<B>Filing of a BLA</B>&#148; means the acceptance by a Regulatory Authority of
such BLA for filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>1.33 &#147;<B>First Commercial Sale</B>&#148; means, with respect to any Product, the first sale
to a Third Party for end use or consumption of such Product in the Territory after Regulatory Approval has been granted by the Regulatory Agency for the Product in the Territory.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>1.34 &#147;<B>Fully Burdened Manufacturing Cost</B>&#148; or &#147;<B>FBMC</B>&#148; means one hundred percent (100%)&nbsp;of
MacroGenics&#146; actual manufacturing cost of goods produced, as determined for each stage of the manufacturing process, in accordance with GAAP, including product quality assurance/control costs, failed lots, plus applicable Allocable Overhead.
Such Fully Burdened Manufacturing Cost shall include, without limitation: (i)&nbsp;<B>*** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35 &#147;<B>GAAP</B>&#148;
means U.S. Generally Accepted Accounting Principles as the same may be in effect from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36
&#147;<B>GBPS</B>&#148; means the General Biological Products Standards as set forth in 21 C.F.R. Part 610, to the extent applicable to the Collaboration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.37 <B>cGMP</B>&#148; or &#147;<B>current Good Manufacturing Practices</B>&#148; means current Good Manufacturing Practices as set forth in the FDCA and the Public Health Service Act (the &#147;<B>PHS
Act</B>&#148;), and in regulations at 21 C.F.R. Parts 210, 211 and 600, as in effect at the time when any clinical trial regarding a Product is being conducted, provided, and to the extent applicable to such clinical trial, as such regulations are
interpreted and enforced by the FDA, including as set forth in applicable guidance documents issued by the FDA, and in accordance with applicable, generally accepted industry standards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38 &#147;<B>GCP</B>&#148; or &#147;<B>Good Clinical Practices</B>&#148; means current Good Clinical Practices as set forth in the
Applicable Laws and Regulations, such as FDCA and the PHS Act and regulations set forth at 21 C.F.R. Part 312, as well as (but not limited to) the requirements set forth in Directive 2001/20/EC of the European Parliament and of the Council of
4&nbsp;April 2001 and Commission Directive 2005/28/EC of 8&nbsp;April 2005, to the extent applicable to a clinical trial regarding any Product, as such obligations are interpreted and enforced by the applicable Regulatory Authority (e.g., FDA and
Member States of the European Union), and as interpreted under prevailing industry standards, including standards of medical ethics, applicable guidance documents issued by the FDA and any other Regulatory Authority, including ICH GCP, the informed
consent requirements set forth in 21 C.F.R. Part 50 and the equivalent legal requirements in other applicable jurisdictions, the requirements relating to Institutional Review Boards set forth in 21 C.F.R. Part 56 and the equivalent legal
requirements in other applicable jurisdictions, all as the same may be amended from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39 &#147;<B>GLP</B>&#148;
or &#147;<B>Good Laboratory Practices</B>&#148; means the recognized rules governing the conduct of non-clinical safety studies and ensuring the quality, integrity and reliability of study data as set forth in Applicable Laws and Regulations, such
as 21 C.F.R. Part&nbsp;58. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.40 &#147;<B>Green Cross Indemnitees</B>&#148; has the meaning set forth in
Section&nbsp;14.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41 &#147;<B>Green Cross Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT></B>&#148; means all <FONT
STYLE="white-space:nowrap">Know-how</FONT> (excluding any Patent) Controlled by Green Cross as of the Effective Date or at any time during the Term that is: (a)&nbsp;related to MGAH22 and (b)&nbsp;necessary for MacroGenics to exercise the rights
licensed to it under this Agreement or perform its obligations under this Agreement. &#147;Green Cross Licensed <FONT STYLE="white-space:nowrap">Know-how&#148;</FONT> shall also include Green Cross&#146; interest in any <FONT
STYLE="white-space:nowrap">Know-how</FONT> deemed jointly owned pursuant to Section&nbsp;15.1(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42 &#147;<B>Green Cross
Licensed Patents</B>&#148; means any and all Patents Controlled by Green Cross at any time during the Term that: (a)&nbsp;are related to any data, result or invention conceived or reduced to practice in the course of conducting the Collaboration
solely by Green Cross specifically in relation to MGAH22 and (b)&nbsp;Green Cross&#146; interest in any Patent deemed jointly owned pursuant to Section&nbsp;15.1(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.43 &#147;<B>Health Insurance Portability and Accountability Act</B>&#148; or &#147;<B>HIPAA</B>&#148; means the act enacted by the U.S. Congress in 1996 and took effect in 2003 that strictly dictates
the parameters that identifiable private health information (PHI) can be shared outside of the research environment, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.44 <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45 &#147;<B>ICH</B>&#148; means the International Conference
on Harmonisation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.46 &#147;<B>IND</B>&#148; means an Investigational New Drug application, or similar application or
submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47 &#147;<B>Indemnifying Party</B>&#148; means the Party that is obligated to indemnify the Indemnitee under Section 14. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48 &#147;<B>Indemnitee</B>&#148; means either the Green Cross Indemnitee or the MacroGenics Indemnitee, as applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.49 &#147;<B>Independent Ethics Committee</B>&#148; or &#147;<B>IEC</B>&#148; means an independent body (a review board or a committee,
institutional, regional, national, or supranational), constituted of medical professionals and non-medical members, whose responsibility it is to ensure the protection of the rights, safety and well-being of human subjects involved in a trial and to
provide public assurance of that protection, by, among other things, reviewing and approving / providing favorable opinion on, the trial protocol, the suitability of the investigator(s), facilities, and the methods and material to be used in
obtaining and documenting informed consent of the trial subjects.&nbsp;The legal status, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
composition, function, operations and regulatory requirements pertaining to IEC may differ among countries, but should allow the Independent Ethics Committee to act in agreement with GCP as
described in this guideline. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50 &#147;<B>Indication</B>&#148; means a separate and distinct disease, disorder or medical
condition in humans or non-human animals which a product is intended to treat, prevent, diagnose, monitor or ameliorate and which, for a Product, is intended to be reflected in the labeling for such Product as an approved Indication, and which, for
an approved Product, is reflected in the labeling for such Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51 &#147;<B>Informed Assent Form</B>&#148; or
&#147;<B>IAF</B>&#148; means an agreement to participate by subjects who are not able to give consent, either because they are minors or because they are legally incompetent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.52 &#147;<B>Informed Consent Form</B>&#148; or &#147;<B>ICF</B>&#148; means a document that outlines a patient&#146;s rights during participation in a clinical trial. It also discusses the potential
risks and benefits associated with participation, including all available data on previous studies. The ICF must be signed by the patient or authorized caregiver before entrance is granted into a study. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53 &#147;<B>Initial Public Offering</B>&#148; means the first completed offering of capital stock of MacroGenics registered under the
Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54 &#147;<B>Investigational Review Board</B>&#148; or &#147;<B>IRB</B>&#148; means in
accordance with 45 C.F.R. 46, Protection of Human Subjects (Revised November&nbsp;13, 2001) and 21 C.F.R. 45, Subpart C, IRB Functions and Operations, (as amended June&nbsp;18, 1991 and other applicable regulations), an independent body comprising
medical, scientific, and nonscientific members, whose responsibility is to ensure the protection of the rights, safety, and well-being of the subjects involved in a clinical trial.&nbsp;It may also be referred to as an IEC in accordance with ICH E6,
Section 1.27. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.55 &#147;<B>Jointly Owned IP</B>&#148; has the meaning set forth in Section 15.1(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.56 &#147;<B>Jointly Owned Patents</B>&#148; has the meaning set forth in Section&nbsp;15.2(b)(i). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57 &#147;<B>Joint Development Committee</B>&#148; or &#147;<B>JDC</B>&#148; has the meaning set forth in Section 2.2. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58 &#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148; has the meaning set forth in Section 2.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59 &#147;<B>KFDA</B>&#148; means Korean Food and Drug Administration, or any successor agency thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60 &#147;<B><FONT STYLE="white-space:nowrap">Know-how</FONT></B>&#148; means (a)&nbsp;any proprietary scientific or technical
information, results and data of any type whatsoever, in any tangible or intangible form whatsoever, including databases, practices, methods, techniques, specifications, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
formulations, formulae, knowledge, <FONT STYLE="white-space:nowrap">know-how,</FONT> skill, experience, test data including pharmacological, medicinal chemistry, biological, chemical,
biochemical, toxicological and clinical test data, analytical and quality control data, stability data, studies and procedures, and manufacturing process and development information, results and data and (b)&nbsp;any proprietary biological, chemical
or physical materials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61 &#147;<B>Licensing Transaction</B>&#148; has the meaning set forth in Section 12.3(d)(ii)(C).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62 &#147;<B>Losses</B>&#148; has the meaning set forth in Section&nbsp;14.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.63 &#147;<B>MacroGenics Indemnitee</B>&#148; has the meaning set forth in Section&nbsp;14.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.64 &#147;<B>MacroGenics Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT></B>&#148; means the
<FONT STYLE="white-space:nowrap">Know-how</FONT> (excluding any Patents) that is Controlled by MacroGenics as of the Effective Date or at any time during the Term, that is: (a)&nbsp;related to MGAH22 and (b)&nbsp;necessary for Green Cross to
exercise the rights licensed to it pursuant to this Agreement or to perform its obligations under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65
&#147;<B>MacroGenics Licensed Patents</B>&#148; means the Patents Controlled by MacroGenics as of the Effective Date or at any time during the Term that: (a)&nbsp;claim the composition of matter of MGAH22 or a Product, (b)&nbsp;would be infringed
but for the license granted hereunder by making, having made, selling, using, offering for sale or importing MGAH22 or any Product, or (c)&nbsp;are otherwise necessary for Green Cross to exercise the rights licensed to it under this Agreement, or to
perform its obligations under this Agreement, as listed in Exhibit A attached hereto. &#147;MacroGenics Licensed Patents&#148; shall include MacroGenics&#146; interest in any Patents deemed jointly owned pursuant to Section 15.1(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.66 &#147;<B>MacroGenics Licensed Technology</B>&#148; means the MacroGenics Licensed Patents and the MacroGenics Licensed <FONT
STYLE="white-space:nowrap">Know-how.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67 &#147;<B>MacroGenics Licensed Trademarks</B>&#148; means any and all
Trademarks Controlled by MacroGenics as of the Effective Date or at any time during the Term, that are registered for or apply to a Product, as listed on Exhibit B. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.68 &#147;<B>MGAH22</B>&#148; means the therapeutic Antibody which binds to the HER2/Neu receptor described in IND # 107768. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.69 &#147;<B>Net Sales</B>&#148; means the gross amount invoiced for Products (or, as the case may be, a Competing Product) sold by Green Cross or its Related Parties in the Territory initially and
directly to Third Parties which are not Related Parties after deducting, if not previously deducted, from the amount invoiced, the following, in each case to the extent included in the gross invoice price: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) reasonable trade, quantity and cash discounts and rebates (including, but not limited to, wholesaler inventory management fees),
chargebacks, and retroactive price reductions or allowances actually allowed or granted from the billed amount; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) credits or allowances actually granted upon claims, rejections or returns of such sales
of Products, including recalls and amounts credited or repaid because of retroactive price reductions specifically identifiable to the Product; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) taxes imposed on the production, sale, import, delivery or use of the Product (including, without limitation, sales, use, excise or value added taxes but excluding income taxes), duties or other
governmental charges (including, without limitation, charges for product testing required for importation) levied on or measured by the billing amount when included in billing, as adjusted for rebates and refunds; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) costs incurred for importing (including, but not limited to, transportation, freight and insurance, and warehousing in the
Territory). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such amounts shall be determined from the books and records of Green Cross or its Related Party, maintained in
accordance with International Financial Reporting Standards (IFRS) or such similar accounting principles, consistently applied. Green Cross further agrees, in determining such amounts, it will use Green Cross&#146; then-current standard procedures
and methodology, including Green Cross&#146; then-current standard exchange rate methodology for the translation of foreign currency sales into U.S. Dollars or, in the case of Sublicensees, such similar methodology, consistently applied. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70 &#147;<B>Patent(s)</B>&#148; means (a)&nbsp;all patents and patent applications in any country or supranational jurisdiction and
(b)&nbsp;any provisionals, substitutions, divisions, continuations, continuations in part, reissues, renewals, registrations, confirmations, reexaminations, extensions, supplementary protection certificates and the like, of any such patents or
patent applications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71 &#147;<B>Patent Prosecution</B>&#148; means the responsibility for (a)&nbsp;preparing, filing,
prosecuting, and pursuing registration of, applications (of all types) for any Patent (b)&nbsp;for maintaining any Patent, and (c)&nbsp;for managing any interference or opposition proceeding relating to the foregoing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.72 &#147;<B>Permitted Subcontractors</B>&#148; has the meaning set forth in Section&nbsp;3.5. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>1.73 &#147;<B>Person</B>&#148; means an individual, sole proprietorship, partnership, limited partnership, limited liability
partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar entity or organization, including a government or political subdivision, department or agency
of a government.<B> </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.74 &#147;<B>Phase I Clinical Development Plan</B>&#148; means the plan set forth on
Exhibit C. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.75 &#147;<B>Phase&nbsp;I Clinical Trial</B>&#148; means a human clinical trial of a Product in patients in any
country that would satisfy the requirements of Applicable Laws and Regulations for such country, such as 21 C.F.R. &#167;&nbsp;312.21(a), relating to human clinical trials conducted in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76 &#147;<B>Phase II Clinical Development Plan</B>&#148; means the plan set forth on Exhibit D, as amended pursuant to Section 4.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.77 &#147;<B>Phase&nbsp;II Clinical Trial</B>&#148; means a human clinical trial conducted in patients with a Product in
accordance with GCP and intended to demonstrate efficacy and a level of safety in the particular Indication tested, as well as to obtain a preliminary Indication of the unit and/or daily dosage regimen required, or that would otherwise satisfy the
requirements of Applicable Laws and Regulations of the country in which such human clinical trial is conducted, such as 21 C.F.R. &#167;&nbsp;312.21(b), relating to human clinical trials conducted in the United States, or any successor regulation
thereto or foreign equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78 &#147;<B>Phase&nbsp;III Clinical Trial</B>&#148; means a human clinical trial in any
country that is conducted in accordance with GCPs and the results of which are intended to be used as a pivotal study to establish both safety and efficacy of a Product as a basis for a BLA submitted to the FDA, KFDA or the appropriate Regulatory
Authority of such other country, or that would otherwise satisfy the requirements of 21 C.F.R. &#167;&nbsp;312.21(c), or any successor regulation thereto or foreign equivalents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.79 &#147;<B>Phase&nbsp;IV Clinical Trial</B>&#148; means a human clinical trial conducted after the Regulatory Approval of a Product,
which trial is conducted (a)&nbsp;voluntarily to enhance scientific knowledge of such Product (e.g., for expansion of product labeling or dose optimization); or (b)&nbsp;conducted due to a request or requirement of a Regulatory Authority.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80 &#147;<B>Personal Information Protection and Electronic Documents Act</B>&#148; or &#147;<B>PIPEDA</B>&#148; or
&#147;<B>PIPED Act</B>&#148; means the Canadian law relating to data privacy. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.81 &#147;<B>Product</B>&#148; means a product
that incorporates a pharmaceutical form of MGAH22 as an active ingredient. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.82 &#147;<B>Product Brand</B>&#148; has the
meaning set forth in Section&nbsp;5.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.83 &#147;<B>Regulatory Approval</B>&#148; means all approvals from the relevant
Regulatory Authority to market and sell a Product in any country (including all applicable pricing and reimbursement approvals), including a BLA. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.84 &#147;<B>Regulatory Authority</B>&#148; means any applicable government regulatory
authority involved in granting approvals for the conduct of clinical trials or the manufacturing, marketing, reimbursement or pricing, as applicable, of a Product, including in the United States the FDA and in South Korea the KFDA, and any successor
governmental authority having substantially the same function. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.85 &#147;<B>Related Party</B>&#148; means, with respect to a
Party, its Affiliates and Sublicensees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86 &#147;<B>Requesting Party</B>&#148; has the meaning set forth in Section 9.2.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.87 &#147;<B>Royalty Term</B>&#148; means, with respect to sales of a Product in the Territory, the time period beginning on
the First Commercial Sale of such Product in the Territory and expiring on the latest of the following dates: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>***</B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)<B> ***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c)<B> ***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88 &#147;<B>Securities Act</B>&#148; has the meaning set forth
in Section 8.2(b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.89 &#147;<B>Site Regulatory Package</B>&#148; or &#147;<B>SRP</B>&#148; means a set of investigational
site specific regulatory documents requiring review and approval by the JDC. The SRP typically consists of the following documents: Form FDA 1572, principal investigator curriculum vitae, signed protocol signature page, site-specific ICF/IAF
(back-translated into English if the local language is other than English), privacy requirements (e.g., HIPAA, PIPEDA), IRB/IEC membership, and country-specific requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.90 &#147;<B>Sublicensee</B>&#148; means a Third Party that is granted a sublicense under the licenses granted to a Party under this Agreement, as permitted under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.91 &#147;<B>Successor</B>&#148; has the meaning set forth in Section&nbsp;1.10. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.92 &#147;<B>Term</B>&#148; has the meaning set forth in Section&nbsp;16.1. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.93 &#147;<B>Territory</B>&#148; means South Korea. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.94 &#147;<B>Third Party</B>&#148; means an entity other than (a)&nbsp;Green Cross and its Affiliates, and (b)&nbsp;MacroGenics and its Affiliates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.95 &#147;<B>Third Party Royalties</B>&#148; means royalties (other than Upstream Royalties) paid by Green Cross to a Third Party to
acquire any Third Party rights which would be infringed by the Development, manufacturing, importation, or Commercialization of any Product in the Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.96 &#147;<B>Total Evaluable Patients</B>&#148; means, on a worldwide basis, those patients
who have completed protocol-defined procedures and can be assessed for the primary endpoint of the trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.97
&#147;<B>Trademark(s)</B>&#148; means all trade names, logos, common law trademarks and service marks, trademark and service mark registrations and applications throughout the world. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.98 &#147;<B>Trademark Prosecution</B>&#148; means the responsibility for (a)&nbsp;preparing, filing, and seeking registration of,
trademark applications (of all types) for any Trademark, (b)&nbsp;for maintaining any Trademark, and (c)&nbsp;for managing any interference or opposition proceeding relating to the foregoing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.99 &#147;<B>United States</B>&#148; or &#147;<B>US</B>&#148; means the United States of America and its territories and possessions,
including without limitation the Commonwealth of Puerto Rico and the U.S. Virgin Islands. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.100 &#147;<B>Upstream
Agreements</B>&#148; means the license agreements with MacroGenics&#146; Third Party licensors listed in Exhibit E or otherwise identified in writing by MacroGenics to Green Cross as such. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.101 &#147;<B>Upstream Licensors</B>&#148; means MacroGenics&#146; Third Party licensors under the Upstream Agreements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.102 &#147;<B>Upstream Royalties</B>&#148; has the meaning set forth in Section&nbsp;8.6. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>1.103 &#147;<B>Valid Claim</B>&#148; means a claim of: (a)&nbsp;an issued and unexpired Patent included within the MacroGenics
Licensed Patents in a country which has not been revoked or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and has not
been abandoned, disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (b)&nbsp;<B>*** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.
<B>G<SMALL>OVERNANCE</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1 <B>Joint Steering Committee</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Membership</B>. The Parties hereby establish a Joint Steering Committee, or JSC, to coordinate and oversee activities on which the
Parties collaborate under this Agreement. The Parties agree that participation in the JSC and any subcommittee of the JSC is a right, rather than an obligation of each Party under this Agreement. The JSC shall consist of three
(3)&nbsp;representatives from each Party. MacroGenics shall designate one (1)&nbsp;of its representatives as the initial chairperson of the JSC. Thereafter, the role of chairperson will alternate between MacroGenics and Green Cross representatives
on a yearly basis. Each Party may replace its appointed JSC representatives at any time upon reasonable written notice to the other Party. The initial </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
representatives and chair of the JSC are set forth in Exhibit F attached hereto. The chair shall have the responsibility to call meetings, circulate meeting agendas at least ten (10)&nbsp;days
prior to each regular JSC meeting, draft minutes for each JSC meeting and circulate such minutes for both Parties&#146; written approval. The chair shall have no other authority or special voting power. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Responsibilities</B>. The responsibilities of the JSC shall be: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) to provide a vehicle by which the Parties may share information regarding the overall strategy for the Collaboration;
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) to approve changes to the Phase I Clinical Development Plan and Phase II Clinical Development Plan;
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) to facilitate the exchange of information between the Parties with respect to the activities hereunder
and to establish procedures for the efficient sharing of information necessary for the Parties to fulfill their respective responsibilities with respect the Collaboration; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) to establish an overall regulatory strategy for Products in the Territory that is compatible with and complements the
worldwide regulatory strategy being implemented by MacroGenics for the Products and to allocate the responsibility for regulatory activities between the Parties; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) to oversee the activities of subcommittees created under this Agreement, and to seek to resolve any issues that such
subcommittees cannot resolve; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) to perform such other functions as appropriate to further the purposes of
this Agreement, as determined by the Parties; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) to establish such subcommittees in addition to the
JDC, as are agreed upon in writing by the Parties. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii) to discuss any additional studies, including a Phase
III Clinical Trial, in which Green Cross may desire to participate; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Decision-Making</B>. The JSC shall make decisions
unanimously, with each Party&#146;s representatives collectively having one (1)&nbsp;vote and at least one (1)&nbsp;representative from each Party present. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Disputes</B>. In the event the JSC cannot reach an agreement regarding any matter within the JSC&#146;s authority for a period of <B>***</B>, then the dispute shall be promptly submitted to the
<B>***</B>. If the dispute remains unresolved for <B>***</B> after submission to such persons, then the <B>***</B>; provided, however, that the <B>***</B> shall have the <B>***</B>; and provided further that the foregoing shall not be deemed to
limit or otherwise alter any obligation of Green Cross or MacroGenics under this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B>JSC Meetings</B>. JSC meetings shall be held semi-annually, or on any other schedule
agreed by the Parties. With the consent of the representatives of each Party serving on the JSC, other representatives of each Party may attend meetings as nonvoting observers (provided such non-voting observers have confidentiality obligations to
such Party that are at least as stringent as those set forth in this Agreement). A JSC meeting may be held by audio, video or internet teleconference with the consent of each Party, but at least half (1/2)&nbsp;of the minimum number of meetings
shall be held in person. Meetings of the JSC shall be effective only if at least one (1)&nbsp;representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses of participating in the JSC meetings.
The Parties will alternate hosting the in-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JSC meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(f) <B>Duration of JSC</B>. The JSC shall continue to exist until the first to occur of (a)&nbsp;the Parties mutually agreeing to disband the JSC or (b)&nbsp;termination of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <B>Limitations</B>. The JSC shall have no authority other than that expressly set forth in this Section&nbsp;2.1 and, specifically,
shall have no authority (a)&nbsp;to amend or interpret this Agreement, or (b)&nbsp;to determine whether or not a breach of this Agreement has occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.2 <B>Joint Development Committee</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Membership</B><B>.</B> Within
thirty (30)&nbsp;days after the Effective Date, the Parties shall establish a Joint Development Committee, or JDC, as a subcommittee of the JSC, to coordinate the Development of Products as set forth in Section&nbsp;2.2(b). The JDC shall consist of
three (3)&nbsp;representatives from each Party. Each Party may replace its appointed JDC representatives at any time upon reasonable written notice to the other Party. The Parties shall alternate in designating a representative on the JDC as the
chair of the JDC on an annual basis, with MacroGenics designating the first chair. The chair shall have the responsibility to call meetings, circulate meeting agendas at least ten (10)&nbsp;days prior to each regular JDC meeting, draft minutes for
each JDC meeting and circulate such minutes for both Parties&#146; written approval. The chair shall have no other special authority or voting power. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Responsibilities</B><B>.</B> The responsibilities of the JDC shall be: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) to share and discuss the Parties&#146; performance under the Phase I Clinical Development Plan and Phase II Clinical Development Plan, on a quarterly basis; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) to share and discuss the data generated by or on behalf of the Parties in the course of performance towards the goals
set forth in the Phase I Clinical Development Plan and Phase II Clinical Development Plan; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) to coordinate Development strategies, allocate resources and set
timelines, in each case to facilitate the activities under the Phase I Clinical Development Plan and Phase II Clinical Development Plan; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iv) to review and approve proposed clinical trial sites; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) to
facilitate the exchange of information between the Parties with respect to the activities under the Phase I Clinical Development Plan and Phase II Clinical Development Plan; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) to perform such other functions as appropriate to further the purposes of this Agreement, as determined by the
Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Decision Making</B>. The JDC shall make decisions unanimously, with each Party&#146;s representatives
collectively having one (1)&nbsp;vote and at least one (1)&nbsp;representative from each Party present. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Disputes</B>.
In the event the JDC cannot reach an agreement regarding any matter within the JDC&#146;s authority for a period of <B>***</B>, then at the option of either Party the matter shall be referred to the JSC for resolution pursuant to Section&nbsp;2.1(c)
and 2.1(d) above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B>JDC Meetings</B>. JDC meetings shall be held quarterly, or on any other schedule agreed by the
Parties. With the consent of the representatives of each Party serving on the JDC, other representatives of each Party may attend meetings as nonvoting observers (provided such non-voting observers have confidentiality obligations to such Party that
are at least as stringent as those set forth in this Agreement). A JDC meeting may be held by audio, video or internet teleconference with the consent of each Party, but at least half (1/2)&nbsp;of the minimum number of meetings shall be held in
person. Meetings of the JDC shall be effective only if at least one (1)&nbsp;representative of each Party is present or participating. Each Party shall be responsible for all of its own expenses for participating in the JDC meetings. The Parties
will alternate hosting the in-person meeting, and the Party hosting is responsible for preparing and circulating the minutes of the JDC meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(f) <B>Duration of JDC</B>. The JDC shall continue to exist until the first to occur of (a)&nbsp;the Parties mutually agreeing to disband the JDC or (b)&nbsp;termination of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) <B>Limitations</B>. The JDC shall have no authority other than that expressly set forth in this Section&nbsp;2.2 and, specifically,
shall have no authority (a)&nbsp;to amend or interpret this Agreement, or (b)&nbsp;to determine whether or not a breach of this Agreement has occurred. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <B>D<SMALL>EVELOPMENT</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <B>Overview</B>. The Parties shall use Commercially Reasonable Efforts to Develop Products in the Territory in accordance with the
Phase I Clinical Development Plan and Phase II Clinical Development Plan, as set forth below, with the goal of achieving regulatory approval for the marketing of Products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <B>MacroGenics Responsibilities</B>. MacroGenics shall perform those activities for which it is identified as the responsible party in the Phase I Clinical Development Plan (unless such responsibility
is transferred to Green Cross or a Third Party by MacroGenics), including, without limitation, <B>***</B>, as appropriate, <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Green Cross Responsibilities</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Green Cross shall
perform those activities for which it is identified as the responsible party in the Phase I Clinical Development Plan (and such other activities for which responsibility is transferred to Green Cross), and shall conduct all activities described in
the Phase II Clinical Development Plan. Without limiting the foregoing, in the Territory: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Green Cross
shall (A)&nbsp;support clinical trial site and CRO-related activities <B>***</B>, (B)&nbsp;<B>***</B>; (C)&nbsp;support clinical trial site and CRO-related activities for the <B>***</B>, under a CTA filed by Green Cross in the Territory, and
(D)&nbsp;support other additional Development activities responsive to unique regulatory or commercial requirements in Territory; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) Green Cross&#146; responsibilities shall include the submission of all CTAs; interaction with the KFDA; <B>***</B>; provided, however, that with respect to the provision of data, information and
materials, such obligation to assist shall require Green Cross to use Commercially Reasonable Efforts, and shall not require Green Cross to generate any data not within its possession. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Joint and Additional Responsibilities</B>. For activities specified in the Phase I Clinical Development Plan for which both
Parties are identified as the responsible Party, the Parties&#146; respective obligations shall be as determined by the JSC. If it is determined that the performance of activities not identified in the Phase I Development Plan are required for
Completion of the Phase&nbsp;I Clinical Trial, then the responsibility for such activities shall be determined by the JSC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <B>Development Plans</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Clinical Development Plans</B>. The JDC shall review the progress of the conduct of the Phase I Clinical Development Plan and Phase II Clinical Development Plan at each meeting of the JDC.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Review of the Clinical Development Plans</B>. On no less than an annual basis, the
JDC shall review the Phase I Clinical Development Plan and Phase II Clinical Development Plan, as appropriate, and recommend any amendment, and any changes to such plans shall be subject to the approval by the JDC and, subsequently, by the JSC.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3 <B>Conduct of Development</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <B>General Obligation</B>. Each Party shall use Commercially Reasonable Efforts to conduct the Development activities for which it is responsible, as described in the Phase I Clinical Development Plan
and Phase II Clinical Development Plan, in compliance with: (a)&nbsp;the terms and conditions of this Agreement; (b)&nbsp;the Phase I Clinical Development Plan and Phase II Clinical Development Plan, as updated from time to time; (c)&nbsp;all
applicable GLP, GCP and applicable cGMP requirements, including, without limitation those specified by the ICH; and (d)&nbsp;all Applicable Laws and Regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Green Cross Diligence</B>. Without limiting Section 3.3(a): </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Green Cross shall <B>***</B>; provided, however, that if all necessary documents required for Regulatory Approval of
such Commencement in the Territory, if any, are not received within a reasonable period prior to such date, other than as a result of Green Cross&#146; acts or omissions, then such period shall be equitably extended to account for such delay for a
period mutually agreed upon in writing by the Parties; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Green Cross shall <B>***</B>; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Green Cross shall use <B>***</B>; provided, however, that if all necessary documents required for Regulatory
Approval of such Completion or filing in the Territory, if any, are not received within a reasonable period prior to such date, other than as a result of Green Cross&#146; acts or omissions, then such period shall be equitably extended to account
for such delay for a period mutually agreed upon in writing by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Green Cross Rights</B>. Green Cross shall
have the option to participate in any additional studies, including a Phase III Clinical Trial, with respect MGAH22 to the extent that such studies are required by a Regulatory Authority in the Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4 <B>Development Costs</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Phase I Clinical Development Plan</B><B>.</B> Green Cross shall be responsible for all Development Costs incurred by Green Cross in connection with the conduct of the Phase I Clinical Development
Plan, including, without limitation, Third Party costs for CRO-related activities for the Phase I Clinical Trial in the Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics shall be responsible for all Development Costs incurred by MacroGenics in connection with the conduct of the Phase I Clinical Development Plan, including without limitation, Third
Party costs for CRO-related activities for the Phase I Clinical Trial outside of the Territory, except as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Clinical Materials</U>. MacroGenics shall be responsible for the cost of the supply of all Clinical Materials for the initial Phase I Clinical Trial; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Labor Costs</U>. Each Party shall be responsible for its direct labor costs (e.g., salaries, wages, employee
benefits, overtime costs, and shirt premiums) for the conduct of its obligations under the Phase I Clinical Development Plan; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) <U><B>***</B></U> MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross
in US Dollars not later than sixty (60)&nbsp;days following the receipt of the applicable invoice. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)
<U>Data Management Costs</U>. Each Calendar Quarter, Green Cross shall reimburse MacroGenics for <B>***</B> of the costs incurred by MacroGenics in connection with the management of Clinical Data from the Phase I Clinical Trials during such Calendar
Quarter. MacroGenics will invoice Green Cross at the end of the applicable Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than <B>***</B> following the receipt
of the applicable invoice. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) <U>Insurance Costs</U>. Each Calendar Quarter, Green Cross shall reimburse
MacroGenics for all costs incurred by MacroGenics in connection with all insurance policies required for the conduct of the Phase I Clinical Trials in the Territory during such Calendar Quarter. MacroGenics will invoice Green Cross at the end of the
applicable Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than <B>***</B> following the receipt of the applicable invoice. MacroGenics shall include Green
Cross as a named insured on each such policy acquired by MacroGenics. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) <U>Limitation on Reimbursement of
<B>***</B></U>. Notwithstanding anything to contrary set forth in Section&nbsp;3.4(a)(iv) or 3.4(a)(v), in no event shall Green Cross be obligated to reimburse MacroGenics for any costs in connection with the <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Phase II Clinical Development Plan</B>. Green Cross shall be responsible for all Development Costs incurred in the Territory by
either Party under the Phase II Clinical Development Plan, except for the cost of the supply of Clinical Materials, which shall be the responsibility of MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>3.5 <B>Subcontractors. </B>MacroGenics shall have the right to engage Third Party contractors to perform any portion of its obligations under this Agreement (provided that <B>
</B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics shall use Commercially Reasonable Efforts to require such Third Party contractors to cooperate with Green Cross, so as to permit Green Cross to comply with any of its development or
commercial diligence obligations, and its reporting and payment obligations under any of the Upstream Agreements insofar as they relate to MGAH22 or any Product), and Green Cross shall have the right to engage a CRO in the Territory to support the
conduct of the Phase&nbsp;I Clinical Trial <B>***</B> (each such subcontractor, a &#147;<B>Permitted Subcontractor</B>&#148;). Any such Permitted Subcontractor used in the provision of services shall be required to agree in writing to be bound by
terms regarding maintaining the confidentiality of proprietary information that are no less stringent than those contained in this Agreement and regarding ownership of intellectual property that are consistent with those contained in this Agreement.
Either Party&#146;s use of Permitted Subcontractors shall not relieve such Party of any of its obligations pursuant to this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.6 <B>Clinical Trial Data</B>. Except to the extent prohibited by any Applicable Law or Regulation, each Party shall provide all Clinical Data to the other on a schedule reasonably requested by the
other. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.7 <B>Information and Cooperation</B>. In addition to the obligations under Section&nbsp;3.6, each Party shall use
Commercially Reasonable Efforts to keep the other Party informed of its research, Development and Commercialization (including promotional) activities hereunder, and shall provide to the other Party, as appropriate, regular summary updates. If
reasonably necessary for a Party to perform its work under this Agreement or to exercise its rights under this Agreement, that Party may request that the other Party provide more detailed information and data regarding the updates it earlier
provided, and the other Party shall promptly provide the requesting Party with information and data as is reasonably available and reasonably related to the work under this Agreement. Neither Party is required to generate additional data or prepare
additional reports to comply with the foregoing obligation. All such reports, information and data provided shall be subject to Section&nbsp;12.1. Prior to commencing the manufacture of Products or conduct of studies for the Product outside of the
scope of this Agreement in the Territory, MacroGenics shall notify Green Cross of any such activity and consult with Green Cross with respect thereto; provided, however, that MacroGenics shall not undertake any such activity if and to the extent
such activity would have a material adverse affect on Green Cross. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <B>A<SMALL>DJUSTMENT</SMALL> <SMALL>OF</SMALL> P<SMALL>HASE</SMALL> II
C<SMALL>LINICAL</SMALL> D<SMALL>EVELOPMENT</SMALL> P<SMALL>LAN</SMALL></B><SMALL></SMALL>. If the Parties agree to add additional patients or Indications to the Phase II Clinical Development Plan, or replace the Indication specified therein as of
the Effective Date with a new Indication, then the Parties shall negotiate in good faith to agree upon the terms applicable to such expansion or change. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">5. <B>C<SMALL>OMMERCIALIZATION</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1 <B>Overview. </B>Green Cross shall have full responsibility and authority for all aspects of the Commercialization of Products in the
Territory at its sole expense, including, without limitation, developing and executing a plan for commercial launch, obtaining all required approvals from Regulatory Authorities for Commercialization (including, without limitation, reimbursement
activities), marketing and promotion, booking sales and distribution and performance of related services, providing customer support, including handling medical queries, and performing other related functions. Green Cross shall use Commercially
Reasonable Efforts to Commercialize the Products. Green Cross shall update MacroGenics regarding its Commercialization activities at regular meetings of the JSC as contemplated by Section&nbsp;2.1.(e). As between Green Cross and MacroGenics,
<B>***</B>. Green Cross shall bear all of the costs and expenses incurred in connection with all such Commercialization activities in the Territory. Green Cross shall timely notify MacroGenics as to the occurrence of the First Commercial Sale in the
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2 <B>Product Labeling; Promotional Materials.</B> Green Cross shall Commercialize the Products in the Territory
under the worldwide brand specified by MacroGenics (&#147;<B>Product Brand</B>&#148;), except to the extent such branding is not permitted by any applicable Regulatory Authority, or deemed culturally inappropriate, in the Territory, in which case
MacroGenics shall specify an alternate Product Brand. Except for the depiction of trademarks, logos and other symbols that are intended to identify MacroGenics&#146; as a company or the manufacturer or owner of a Product, Green Cross shall be
responsible for designing and supplying the printable artworks of product labeling in electronic version and promotional materials for the Products for the Territory. Green Cross shall be responsible for how and the manner in which Products shall be
presented and described in the Territory to the medical community in any promotional materials for a Product intended to be disseminated in the Territory, and the placement of the name and logos of Green Cross therein, in each case as permitted by
applicable law and consistent with the Product Brand and labeling for the Products approved by the applicable Regulatory Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.3 <B>Sales and Distribution</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Orders and Sales</B>. Green Cross shall
be solely responsible for handling all returns, order processing, invoicing and collection, distribution, and inventory and receivables for the Products throughout the Territory. Green Cross shall have the right and sole responsibility for
establishing and modifying the terms and conditions with respect to the sale of the Products in the Territory, including any terms and conditions relating to or affecting the price at which the Products shall be sold, discounts available to any
Third Party payers (including, without limitation, managed care providers, indemnity plans, unions, self insured entities, and government payer, insurance or contracting programs), any discount attributable to payments on receivables, distribution
of the Products, and credits, price adjustments, or other discounts and allowances to be granted or refused; provided, however, that Green Cross shall act in good faith when doing the foregoing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Pricing</B>. Green Cross shall have the sole right to determine all pricing of the
Products in the Territory. Notwithstanding anything in this Agreement express or implied to the contrary, MacroGenics shall not have any right to direct, control, or approve Green Cross&#146; pricing of Products for the Territory. The provision to
MacroGenics of any pricing data is for informational purposes only. Green Cross shall be responsible for preparing and implementing the reimbursement strategy for the Products in the Territory. However, except to the extent prohibited by Applicable
Laws and Regulations, MacroGenics shall use Commercially Reasonable Efforts to provide all the necessary data so that Green Cross can file for the medical reimbursement price in the Territory; provided, however, that MacroGenics shall not be
obligated to generate any data not within its possession. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4 <B>Compliance</B>. Each Party shall comply with the terms of
this Agreement and all Applicable Laws and Regulations relating to activities performed or to be performed by such Party (or its Affiliates, contractor(s) or Sublicensee(s)) under or in relation to the Commercialization of the Products pursuant to
this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5 <B>Commercialization Diligence</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Prior to Submission of First BLA</B>. For each Product under Development, prior to the submission of the first BLA to the first
Regulatory Authority in the Territory, Green Cross shall submit to the JSC a written summary plan for the Commercialization for each such Product under Development. Thereafter, Green Cross shall regularly report on its Commercialization activities
at meetings of the JSC or, if formed, the Joint Commercialization Committee. Such reports shall cover subject matter at a level of detail similar to that which Green Cross affords to its senior executives with respect to similar Green Cross
products. All such plans and information shall be presented for discussion purposes, and Green Cross agrees to consider in good faith any comments or suggestions MacroGenics may make with respect to Commercialization of Products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Launch.</B> Green Cross shall launch each Product in the Territory <B>***</B>, provided that MacroGenics has supplied Product
ordered by Green Cross in accordance with Section&nbsp;6.2(c) for such launch within a reasonable period prior to the planned launch date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Following Regulatory Approval</B>. Green Cross shall use Commercially Reasonable Efforts to Commercialize each Product in the Territory after obtaining Regulatory Approval for such Product.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>5.6 <B>Upstream Agreements. </B>Green Cross agrees to provide to MacroGenics such information as it reasonably
requires, or otherwise cooperate with MacroGenics, so as to permit MacroGenics to comply with any of its development or commercial diligence obligations, and reporting and payment obligations under any of the Upstream Agreements insofar as they
relate to MGAH22 or any Product.<B> </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <B>M<SMALL>ANUFACTURE</SMALL> <SMALL>AND</SMALL> S<SMALL>UPPLY</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <B>Clinical Supply of Products</B>. MacroGenics shall be responsible for the manufacture of all Product required for the clinical
trials described in the Phase I Clinical Development Plan, Phase II Clinical Development Plan and, if any, additional development plans, including any plan for a Phase III Clinical Trial, agreed upon in writing by the Parties for additional studies
under this Agreement, either by itself or through one or more Third Parties, including all costs of such manufacture, as set forth in Section&nbsp;3.4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.2 <B>Commercial Supply of Products</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Responsibility</B>. MacroGenics
shall be responsible for the manufacture of all commercial supplies of Product required by Green Cross for the Commercialization of Products in the Territory, in accordance with this Section&nbsp;6.2, except as the Parties may otherwise agree
pursuant to Section&nbsp;6.4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Forecasts</B>. For so long as MacroGenics is providing Product, Green Cross, through the
JDC, shall furnish to MacroGenics <B>***</B> forecast of probable quarterly orders for supplies of Product, to be updated quarterly based on Green Cross&#146; good faith estimate of its need for Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Orders</B>. Green Cross agrees to buy, and MacroGenics agrees to sell, such quantities of Product as may be set forth on purchase
orders placed by Green Cross in accordance with the provisions of this Section&nbsp;6.2. The Parties shall mutually agree upon an appropriate purchase agreement. Any purchase orders for Product will reference this Agreement and will be consistent
with the terms contained herein. Each purchase order shall set forth a delivery date for the quantities of Product ordered, which date will in no event be less than <B>***</B> from the date of the purchase order. MacroGenics will use Commercially
Reasonable Efforts to deliver each order on or before the applicable deliver date. If a purchase order cannot be fulfilled or delivered as requested by Green Cross, then MacroGenics shall immediately inform Green Cross of such fact. If MacroGenics
is unable to manufacture sufficient quantities of Products to deliver to Green Cross hereunder, then MacroGenics shall allocate any shortages among its customers, including, without limitation, Green Cross, on a pro-rata basis based on the
comparative order volumes of all customers at the time of such shortage. MacroGenics shall use Commercially Reasonable Efforts to promptly resume production of Commercial Supply. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Price; Payment</B>. The price of Product ordered by Green Cross under this Section&nbsp;6.2 will be equal to <B>***</B> of
MacroGenics&#146; Fully Burdened Manufacturing Costs for such material. All payments due hereunder to MacroGenics shall be paid to MacroGenics in US Dollars not later than <B>***</B> following the receipt of the applicable invoice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <B>Delivery</B>. Unless otherwise agreed by the parties in writing, all shipments will
be shipped F.O.B. MacroGenics&#146; or its contract manufacturer&#146;s facility. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <B>Technology Transfer</B>. If Green
Cross requests, the Parties shall enter into good faith discussions regarding the possibility of a transfer to Green Cross of technology that is sufficient to enable Green Cross to manufacture commercial supplies of Product in accordance with the
Applicable Laws and Regulations of the Territory, provided that nothing herein shall be deemed to obligate MacroGenics to enter into any agreement to transfer to Green Cross any such technology. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5 <B>Manufacturing Specifications</B>. All Clinical Materials and commercial supplies of Product shall be manufactured in accordance
with the specifications determined by MacroGenics and all Applicable Laws and Regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6 <B>Change of Manufacturing
Process</B>. MacroGenics shall reasonably inform Green Cross of developments in matters of process development and manufacturing of Products, and shall consult with Green Cross with respect to the development and manufacturing processes of Products
adopted by MacroGenics to the extent necessary to obtain Regulatory Approval(s) of the same in the Territory. Green Cross shall promptly notify MacroGenics of any information that will impact approvability of Products in the Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <B>R<SMALL>EGULATORY</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.1 <B>Overview.</B> The JSC shall establish an overall regulatory strategy for obtaining Regulatory Approval of the Product in the Territory, and shall allocate regulatory responsibilities between the
Parties in a manner consistent with the provisions contained herein. Green Cross shall participate in regulatory matters as determined by the JSC, including CMC and other manufacturing-related matters, nonclinical matters, and clinical matters. In
addition, Green Cross will have access to adverse event and other safety related data. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <B>Regulatory Filings for Phase I
Clinical Trial</B>. MacroGenics shall hold the INDs in the Territory and be responsible for the filing of the INDs and all additional regulatory documents for the initial Phase I Clinical Trial with Regulatory Authorities in the Territory (such as
INDs, and IND amendments), including, without limitation, all associated submissions (e.g., safety reports, protocol submissions, CMC updates), for responding to inquiries and correspondences from the Regulatory Authorities, and the submission of
all required reports for the Phase I Clinical Trial until the Completion of the Phase I Clinical Trial. MacroGenics shall continue to hold INDs filed as of the Effective Date. MacroGenics will transfer its responsibilities for preparing the Korean
IND and IND amendments to Green Cross, but Green Cross shall provide <B>***</B>, Green </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Cross may submit such filing, submission or response to the KFDA at the same time as Green Cross submits the same to MacroGenics; provided that Green Cross uses Commercially Reasonable Efforts to
obtain additional time. MacroGenics will transfer its responsibilities for interacting with the KFDA to Green Cross, but Green Cross shall attempt to include MacroGenics on any face-to-face meetings or teleconferences, if deemed necessary by Green
Cross, and shall not commit to making any revisions to the Phase I Clinical Trial unless for an immediate safety issues, without prior agreement with MacroGenics. Green Cross shall allow MacroGenics to review any written correspondence to the KFDA
before it is sent to the KFDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3 <B>Regulatory Filings Following Phase I Clinical Trial</B>. Except as set forth in
Section&nbsp;7.2, Green Cross shall be responsible for the filing of all regulatory documents for MGAH22 and all Products with Regulatory Authorities in the Territory (such as INDs, NDAs and amended INDs and NDAs), including without limitation all
associated submissions (e.g., safety alerts, protocol submissions), for responding to inquiries and correspondence from the Regulatory Authorities responsible for regulatory matters in the Territory, and the monitoring of all clinical experiences
and submission of all required reports throughout clinical Development and Commercialization, in each case in compliance with all laws and regulations. MacroGenics shall be responsible for providing to Green Cross any revisions to the
investigator&#146;s brochure and CMC information required for KFDA submissions. Green Cross may request MacroGenics to participate in meetings with the KFDA if it is foreseeable that there may be discussions about the Product beyond the scope of
Green Cross&#146; development of the Product in the Territory (e.g., CMC matters, data from clinical trials MacroGenics conducted). Each Party shall provide information to the other Party as necessary and reasonably consult with the other Party
regarding any filings, and regarding significant or material notices, actions or requests from or by Regulatory Authorities. Each Party shall, at the other Party&#146;s request, review and comment on filings, submissions, and responses to Regulatory
Authorities related to any Product. Green Cross shall hold and maintain all Regulatory Approvals for the Commercialization of the Product in the Territory, as set forth in Section 10.1(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4 <B>Records of Correspondence with KFDA</B>. Following each communication (whether by phone or in person) with the KFDA regarding
matters arising under this Agreement, Green Cross shall prepare a record of such meeting in accordance with its standard business practices (e.g., written minutes) and provide to MacroGenics a copy of such record. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.5 <B>Safety Data Exchange Agreement</B>. The Parties shall conduct in good faith and agree upon a safety data exchange agreement, the
agreement setting forth the safety information required to be shared by each Party and the schedule for the sharing of such safety information and other appropriate procedures and matters, as detailed in Exhibit G. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <B>P<SMALL>AYMENTS</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1 <B>Upfront Payment</B>. Within thirty (30)&nbsp;days after the Effective Date, Green Cross shall pay to MacroGenics One Million
Dollars ($1,000,000), which shall be non-refundable and non-creditable against any other payments due under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <B>Purchase of MacroGenics Stock Upon Initial Public Offering</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If during the first three (3)&nbsp;years of the Term there is an Initial Public Offering which raises a <B>***</B>, and if the
underwriter(s) in such Initial Public Offering permit it, Green Cross is obligated to purchase a number of shares of the same class of capital stock, simultaneously with the closing(s) of, and at the same purchase price as the shares sold in, the
Initial Public Offering that is equal to the number of shares that could be purchased for <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Green Cross
acknowledges that any securities purchased in accordance with Section&nbsp;8.2(a) shall not be registered under the Securities Act of 1933, as amended (&#147;<B>Securities Act</B>&#148;), and may not be sold, assigned, pledged, hypothecated,
encumbered or an any other manner transferred or disposed of in the absence of an effective registration statement or an exemption from registration under the Securities Act. In connection with any Initial Public Offering, Green Cross agrees to
enter into a lock-up agreement with the underwriter(s) if the managing underwriter(s) demands or requests such an agreement; provided, however, that such provisions will not be less favorable to Green Cross than the provisions of any lock-up
agreements entered into by the managing underwriter(s) with other holders of securities issued by MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3
<B>Clinical Development Milestone Payments</B>. Green Cross shall pay to MacroGenics the milestone payments listed below, which shall be non-refundable, and non-creditable (unless otherwise stipulated under this Agreement). Any such milestone
payments are subject to any credits, offsets and waivers specified by this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) For the Commencement of the first
Phase&nbsp;II Clinical Trial: <B>***</B>; provided, however, that this milestone payment shall not be payable to MacroGenics if <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) For the Commencement of the first Phase&nbsp;III Clinical Trial: <B>***</B>; provided, however, that this milestone payment shall not be payable to MacroGenics <B>***</B> If all necessary documents
required for Regulatory Approval of Completion of the Phase II Clinical Trial by Green Cross, if any, are not received within a reasonable period prior to the agreed upon projected Completion date, other than as a result of Green Cross&#146; acts or
omissions, then such <B>***</B> period shall be equitably extended to account for such delay for a period mutually agreed upon in writing by the Parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) Approval of BLA for first Indication for a Product by KFDA in the Territory: <B>***</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4 <B>Commercial Milestone Payments</B>. Green Cross shall pay to MacroGenics the Net Sales
milestone payments set forth below, which shall be due and payable within <B>***</B> after the end of the first Calendar Year during which such milestone is triggered. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) First occurrence of aggregate Net Sales for a period of <B>***</B> of all Products in the Territory <B>*** ***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) First occurrence of aggregate Net Sales for a period of <B>***</B> of all Products in the Territory exceeding <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.5 <B>Product Royalties</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Green Cross shall pay to MacroGenics a royalty
at the rate determined in accordance with the royalty chart included in Exhibit H attached hereto on Net Sales of Products for the Royalty Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Green Cross shall pay to MacroGenics a royalty of <B>***</B> on Net Sales of Competing Products for the Royalty Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.6 <B>Upstream License Royalties</B>. In addition to the other royalty payments set forth in this Section&nbsp;8, Green Cross shall reimburse MacroGenics for royalty payments payable by MacroGenics as a
result of the Collaboration pursuant to: (a)&nbsp;the Upstream Agreements identified on Exhibit E as of the Effective Date and (b)&nbsp;any additional Upstream Agreements identified by MacroGenics after the Effective Date that include a license to
any patent(s) that has any claim(s) that would otherwise prevent MacroGenics from fulfilling its obligations under this Agreement or from supplying MGAH22 or any Product in the Territory (the &#147;<B>Upstream Royalties</B>&#148;). Green Cross&#146;
obligation under this Section&nbsp;8.6 with respect to the payment of Upstream Royalties under an Upstream Agreement shall terminate upon termination of MacroGenics&#146; obligation to pay royalties under the terms of such Upstream Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7 <B>Third Party Agreements</B>. Green Cross (or its Affiliate or Sublicensee) shall be responsible, at its sole expense
and discretion, for obtaining any agreements with Third Parties (other than the Upstream Agreements) for any Third Party rights which would be infringed by the Development, manufacturing, importation, or Commercialization of any Product in the
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.8 <B>Payment of Milestones</B>. All milestone payments shall be due and payable within <B>***</B> after the
event for which the payment is due. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.9 <B>Reports; Payments</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Net Sales Quarterly Reports</B>. During the Term, following the First Commercial Sale of a Product in the Territory, Green Cross
shall furnish to MacroGenics: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) a quarterly written report for the Calendar Quarter showing the Net Sales of
all Products (and Competing Products) subject to royalty payments sold by Green Cross and its Related Parties in the Territory during the reporting period and the royalties payable under this Agreement; and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) a quarterly report for the Calendar Quarter showing Green Cross&#146;
Commercial Supply Costs, Third Party Royalties and Upstream Royalties for such Calendar Quarter, with such detail as shall reasonably allow MacroGenics to determine the basis for such quarterly costs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Submission and Payment Schedule</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Reports</U>. Reports under this Section&nbsp;8.9 shall be due on the ninetieth (90</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;day following the close of each Calendar Quarter. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Royalties</U>. Royalties shown to have accrued by each report shall, unless otherwise specified under this
Agreement, be due and payable on the date such report is due. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.10 <B>Payment Exchange Rate</B>. All payments to be made by
Green Cross to MacroGenics under this Agreement shall be made in United States dollars by bank wire transfer in immediately available funds to a bank account in the United States designated in writing by MacroGenics. For invoices that Green Cross
shall forward to MacroGenics, Green Cross shall use an exchange rate equal to the Telegraphic Transfer (T/T) selling rate as published by Korean Exchange Bank as of the close of business on the last business day of the preceding month. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.11 <B>Tax Withholding</B>. If laws, rules or regulations require Green Cross to withhold income taxes or other taxes imposed upon
payments set forth in this Section&nbsp;8, Green Cross shall make such withholding payments as required and subtract such withholding payments from the payments set forth in this Section&nbsp;8. Green Cross shall submit original receipts or other
appropriate proof of payment of the withholding taxes to MacroGenics within a reasonable period of time to allow MacroGenics to document such tax withholdings for purposes of claiming foreign tax credits and similar benefits, and shall cooperate
with reasonable requests of MacroGenics (without acting to the detriment of Green Cross) related to MacroGenics obtaining such credits and benefits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9. <B>Record Keeping and Inspections and Audits</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 <B>Records</B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Collaboration Activities.</B> Each Party shall maintain appropriate records of: (i)&nbsp;all significant research,
Development, manufacturing and Commercialization events and activities conducted by it or on its behalf related to a Product, and all costs in connection therewith, as applicable; and (ii)&nbsp;all significant information generated by it or on its
behalf in connection with research and development </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of MGAH22 and Products under this Agreement, in each case in accordance with such Party&#146;s usual documentation and record retention practices. Such records shall be in sufficient detail to
properly reflect, in good scientific manner, all significant work done and results of studies and trials undertaken, and further shall be at a level of detail appropriate for patent and regulatory purposes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Green Cross Royalties</B>. Green Cross shall keep complete and accurate records in sufficient detail to enable the royalties
payable under Section&nbsp;8 and its Commercial Supply Costs, Third Party Royalties and Upstream Royalties to be determined. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>MacroGenics&#146; Royalties</B>. MacroGenics shall keep complete and accurate records of royalty payments due under the Upstream
Agreements in sufficient detail to enable the Upstream Royalties payable by Green Cross under Section&nbsp;8.6 to be determined. At the request of Green Cross, MacroGenics shall make such records available to Green Cross. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>MacroGenics&#146; FBMC</B>. MacroGenics shall keep complete and accurate records with such detail as shall reasonably allow Green
Cross to determine the basis for such FBMC. At the request of Green Cross, MacroGenics shall make such records available to Green Cross. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.2 <B>Audit Rights</B>. Upon the written request of a Party (&#147;<B>Requesting Party</B>&#148;) with reasonable advance notice and not more than once in each Calendar Year, the other Party shall permit
an independent certified public accounting firm of nationally recognized standing selected by Requesting Party and reasonably acceptable to the other Party, at its own expense, to have access during normal business hours to such of the records as
may be reasonably necessary to verify the accuracy of the reports under Section&nbsp;8 for any Calendar Year ending not more than thirty-six (36)&nbsp;months prior to the date of such request. The accounting firm shall disclose to the Requesting
Party only whether the reports are correct or incorrect and the specific details concerning any discrepancies. No other information shall be provided to Requesting Party in connection with this audit right. This right to audit shall remain in effect
throughout the life of this Agreement and for a period of three (3)&nbsp;years after the termination of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3
<B>Discrepancies</B>. If such accounting firm identifies a discrepancy, the other Party shall pay Requesting Party the amount of the discrepancy within thirty (30)&nbsp;days of the date Requesting Party delivers to the other Party such accounting
firm&#146;s written report so concluding, or as otherwise agreed upon by the Parties. The fees charged by such accounting firm shall be paid by Requesting Party unless the underpayment by the other Party exceeded five percent (5%)&nbsp;of the amount
owed for such Calendar Year, in which case the other Party shall pay to Requesting Party the reasonable fees charged by such accounting firm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.4 <B>Confidentiality</B>. Each Party shall treat all information of the other Party subject to review under this Section&nbsp;9 in accordance with the confidentiality and non-use
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
provisions of this Agreement, and shall cause its accounting firm to enter into an acceptable confidentiality agreement with the audited Party and any applicable Related Parties, obligating it or
them to retain all such information in confidence pursuant to such confidentiality agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.
<B>L<SMALL>ICENSES</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1 <B>License to Green Cross</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>License</B>. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Green Cross an exclusive,
royalty-bearing (i)&nbsp;license, with the right to grant sublicenses (subject to Section&nbsp;10.1(b)), under the MacroGenics Licensed Technology and the MacroGenics Licensed Trademarks; and (ii)&nbsp;to the extent needed under this
Section&nbsp;10.1(a), sublicense under the MacroGenics Licensed Technology licensed pursuant to the Upstream Agreements, in the case of each of (i)&nbsp;and (ii), to conduct the Phase I Clinical Development Plan and Phase II Clinical Development
Plan, and to distribute, sell, offer for sale and import Products in the Field in the Territory during the Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
<B>Sublicensees</B>. Green Cross may grant sublicensees solely for purposes of performing its Development obligations under this Agreement. In no event shall Green Cross grant any sublicense to any of the rights granted to it pursuant to
Section&nbsp;10.1(a) for any other purpose without MacroGenics&#146; prior written consent. Each sublicense granted by Green Cross shall be consistent with this Agreement and subordinate thereto, and Green Cross shall remain responsible to
MacroGenics for the compliance of each such Sublicensee with the financial and other obligations due under this Agreement. Green Cross shall provide a copy of each such sublicense to MacroGenics so that MacroGenics can confirm Green Cross&#146;
compliance with the foregoing. Each sublicense granted by Green Cross under this Agreement shall permit the conversion of such sublicense to a direct license with MacroGenics at MacroGenics&#146; sole option in the event this Agreement is terminated
and, upon such conversion, MacroGenics shall be responsible for all former obligations of Green Cross under such sublicense. Green Cross shall use Commercially Reasonable Efforts to include in each such sublicense a requirement obligating such
sublicensees to cooperate with MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Regulatory Approvals</B>. Green Cross shall hold and maintain all
Regulatory Approvals for the Commercialization of the Product in the Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>MacroGenics Retained Rights</B>.
MacroGenics shall retain the following: (i)&nbsp;the right to conduct its obligations under the Phase I Clinical Development Plan and Phase II Clinical Development Plan in the Territory, including, without limitation, data management, monitoring,
regulatory compliance and support and shipping requirements and all other requirements in connection with this Agreement; (ii)&nbsp;the right to manufacture or have manufactured MGAH22 and Products for uses pursuant to this Agreement as provided in
Section&nbsp;6 in the Territory; and (iii)&nbsp;all rights not otherwise granted to Green Cross inside and outside the Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) <B>Opportunity ***</B>. In the event that during the period between the <B>***</B>, MacroGenics wishes to <B>***</B>, MacroGenics shall provide Green Cross <B>***</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <B>Upstream Agreements</B>. Certain MacroGenics Licensed
<FONT STYLE="white-space:nowrap">Know-how</FONT> and MacroGenics Licensed Patents sublicensed under Section&nbsp;10.1(a) above and identified on Exhibit A are licensed (or sublicensed, in some instances) to MacroGenics by certain Third Parties
pursuant to the Upstream Agreements. Green Cross acknowledges and agrees that its sublicense to and any warranties and/or representations made by MacroGenics under this Agreement regarding such MacroGenics Licensed Technology granted under
Section&nbsp;10.1(a) are at all times subject to the applicable terms of the Upstream Agreements, current copies of which, for those in effect as of the Effective Date, have been provided to Green Cross as of the Effective Date, including
restrictions on the type and nature of the antibodies licensed as Products thereunder, diligence requirements, and termination provisions thereof, and that MacroGenics is in no way licensing or purporting to license or sublicense to Green Cross
rights under the Upstream Agreements that if sublicensed to Green Cross would be a violation of any Upstream Agreement. Green Cross covenants not to take or fail to take any action that violates the terms of such Upstream Agreements applicable to
Sublicensees, or that would cause MacroGenics to be in breach of any of the terms of the Upstream Agreements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <B>License
to MacroGenics</B>. Green Cross hereby grants to MacroGenics a royalty-free, worldwide license during the Term, with the right to grant sublicenses, under the Green Cross Licensed Patents and Green Cross Know-how that is incorporated into any
Product, and all other intellectual property Controlled by Green Cross that is specifically related to MGAH22 to the extent needed by MacroGenics to research, identify, develop, make, have made, use, sell, offer for sale and import Products,
including, without limitation, as contemplated by Section&nbsp;10.1(c) above, in all cases without any obligation to obtain Green Cross&#146; prior consent. The license granted pursuant to this Section&nbsp;10.3 shall be non-exclusive in the
Territory and exclusive in the rest of the world outside the Territory. After the Term, the Parties shall discuss in good faith whether future licenses are necessary for MacroGenics to continue to use Green Cross Licensed Patents or Green Cross
Licensed Know-how, and determine reasonable terms and conditions for such license at MacroGenics&#146; request. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4
<B>Clinical Data Licenses</B>. Subject to the terms and conditions of this Agreement, Green Cross hereby grants to MacroGenics a non-exclusive, royalty-free, perpetual license, with the right to grant and authorize the grant of sublicenses, to use
all Clinical Data and any data generated by Green Cross or any of its representatives or independent contractors pursuant to its performing its responsibilities under this Agreement for the research, Development, manufacture Commercialization and
sales of MGAH22 and Products by MacroGenics outside the Territory and for MacroGenics to exercise its rights and fulfill its obligations under this Agreement. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Green
Cross a non-exclusive, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
royalty-free, license, with the right to grant sublicenses, during the Term to use all Clinical Data and other data generated by MacroGenics pursuant to its performing its responsibilities under
this Agreement for Green Cross to fulfill its obligations under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5 <B>Negative Covenant</B>. Each Party
covenants that, except to the extent Third Parties generally are lawfully permitted to do so, it will not use or practice any of the other Party&#146;s intellectual property rights licensed to it under this Section&nbsp;10 except for the purposes
expressly permitted in the applicable license grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6 <B>No Implied Licenses</B>. Except as explicitly set forth in this
Agreement, neither Party grants any license, express or implied, under its intellectual property rights to the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7 <B>Diversion</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Green Cross hereby covenants and agrees that it will not, either directly or indirectly, promote, market, distribute, import, sell or have sold Products, including via the Internet or mail order, to
any Third Party, address or Internet Protocol address outside of the Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If any of Green Cross&#146; Products are
diverted for use outside the Territory, the following shall apply: (i)&nbsp;if such Products were diverted by an identifiable customer, distributor, employee, consultant or agent of Green Cross then, upon the request of MacroGenics, Green Cross
shall not sell such Products to, or allow the sale of such Products by, any such customer, distributor, employee, consultant or agent for the remaining Term and shall use Commercially Reasonable Efforts to buy back all such Products from such
customer, distributor, employee, consultant or agent within *** of such request from MacroGenics; or (ii)&nbsp;Green Cross shall use Commercially Reasonable Efforts to investigate the location of such diverted Products and buy it back; but, if and
to the extent that, Green Cross elects not to, or is unable to, buy back the applicable diverted Products, then MacroGenics may, in its sole discretion, buy back the applicable diverted Products, and Green Cross shall reimburse MacroGenics for all
reasonable costs incurred by MacroGenics in connection with the buy-back or lost sales of any such diverted Products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.
<B>E<SMALL>XCLUSIVITY</SMALL></B><SMALL></SMALL>. During the Term, Green Cross shall not (either by itself, or with or through a Related Party or Third Party) Develop or Commercialize any (i)&nbsp;Product outside of the scope of this Agreement or
(ii)&nbsp;Competing Product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <B>C<SMALL>ONFIDENTIALITY</SMALL>; P<SMALL>UBLICATION</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1 <B>Nondisclosure Obligation</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Definition and Restrictions</B>. All Confidential Information disclosed by one Party to the other Party at any time, including, without limitation, before the Effective Date or after the expiration
or termination of this Agreement, shall be maintained in confidence by the receiving Party and shall not be disclosed by the receiving Party to any Third Party or used by the receiving Party for any purpose except as set forth herein without the
prior written consent of the disclosing Party, <B>***</B> The following shall not be deemed Confidential Information for purposes of the restrictions set forth in this Section&nbsp;12.3(a): </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Information that is known by the receiving Party at the time of its receipt, and not through a prior disclosure by the
disclosing Party, as documented by the receiving Party&#146;s business records; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Information that is or
becomes part of the public domain through no fault of the receiving Party; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Information that is
subsequently disclosed to the receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the disclosing Party; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Information that is developed by the receiving Party independently of Confidential Information received from the
disclosing Party, as documented by the receiving Party&#146;s business records. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Combinations</B>. Any combination of
features or disclosures shall not be deemed to fall within the exclusions set forth in Section&nbsp;12.1(a) merely because individual features are published or available to the general public or in the rightful possession of the receiving Party
unless the combination itself and principle of operation are published or available to the general public or in the rightful possession of the receiving Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Exceptions</B>. Notwithstanding the restrictions set forth in Section&nbsp;12.1(a), the receiving Party may disclose Confidential Information of the other Party to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) governmental or other regulatory agencies in order to obtain Patents or to gain or maintain approval to conduct
clinical trials or to market Products, but such disclosure may be only to the extent reasonably necessary to obtain Patents or authorizations; or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) as the receiving Party deems necessary to be disclosed, to its Affiliates, agents, consultants, or other Third Parties for the Development or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Commercialization of Product(s), or in connection with a licensing transaction related to such Product(s) or loan, financing or investment or acquisition, merger, consolidation or similar
transaction (or for such entities to determine their interest in performing such activities) or in order to perform its obligations under this Agreement, in each case on the condition that any Third Parties, other than Regulatory Authorities, to
whom such disclosures are made agree to be bound by confidentiality and non-use obligations substantially similar to those contained in this Agreement; provided that the term of confidentiality and non-use applicable to such Third Parties shall be
no less than <B>***</B> from the date of disclosure to them. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Disclosure Required by Judicial or Administrative
Process.</B> If a Party is required by judicial or administrative process to disclose Confidential Information of the other Party that is subject to the non-disclosure provisions of this Section&nbsp;12.1, such Party shall promptly inform the other
Party of the disclosure that is being sought in order to provide the other Party an opportunity to challenge or limit the disclosure obligations. Confidential Information that is disclosed by judicial or administrative process shall remain otherwise
subject to the confidentiality and non-use provisions of this Section&nbsp;12.1, and the Party disclosing Confidential Information pursuant to law or court order shall take all steps reasonably necessary, including without limitation obtaining an
order of confidentiality, to ensure the continued confidential treatment of such Confidential Information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B>Obligations
Upon Termination.</B> Upon the termination or expiration of this Agreement, or upon the earlier request of either Party, the receiving Party shall return to the disclosing Party, all of the disclosing Party&#146;s Confidential Information, including
all copies thereof, provided that the receiving Party may retain one copy for archival purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <B>Publication</B>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Publication of Results</B>. Green Cross and MacroGenics each acknowledge the other Party&#146;s interest in publishing
the results of its activities under the Collaboration in order to obtain recognition within the scientific community and to advance the state of scientific knowledge. Each Party also recognizes the mutual interest in obtaining valid patent
protection and in protecting business interests and trade secret information. Consequently, the JSC shall establish procedures for review of publications related to the Collaboration, ensuring that, except for disclosures permitted pursuant to
Section&nbsp;12.1, either Party and its employees wishing to make a publication related to work performed under this Agreement shall deliver to the other Party a copy of the proposed written publication or an outline of an oral disclosure at least
<B>***</B> prior to submission for publication or for presentation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Review of Publications and Presentations</B>
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The reviewing Party shall have the right (a)&nbsp;to propose modifications to the publication or
presentation for patent reasons, trade secret reasons, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or for purposes of removing the Confidential Information of the reviewing Party, or (b)&nbsp;to request a reasonable delay in publication or submission for presentation in order to protect trade
secret or patentable information. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) If the reviewing Party requests the removal of the reviewing
Party&#146;s Confidential Information or a delay, the publishing Party shall remove such Confidential Information and delay submission for publication or submission for presentation for a period of <B>***</B> to enable patent applications protecting
each Party&#146;s rights in such Confidential Information to be filed in accordance with Section&nbsp;15 below. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Upon expiration of such <B>***</B> and satisfaction of any other conditions imposed by the JSC, the publishing Party
shall be free to proceed with the publication or submission for presentation. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Upon request of the Party
seeking publication, the reviewing Party shall consider expediting the time frames set forth in this Section&nbsp;12.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(v) If the reviewing Party requests modifications to the publication or submission for presentation, the publishing Party shall edit such publication to prevent disclosure of the Confidential Information
of the reviewing Party or trade secret or proprietary business information prior to submission for publication or for presentation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.3 <B>Publicity; Use of Names</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Press Releases</B>. The Parties shall
issue a mutually acceptable press release announcing the execution of this Agreement. A Party may issue any subsequent press release relating to this Agreement or activities conducted hereunder upon prior written approval of the other Party, such
approval not to be unreasonably withheld or delayed; provided, however, that no approval of the other Party shall be required if a subsequent press release or SEC filing solely discloses the information that (1)&nbsp;a milestone under this Agreement
has been achieved and/or any payments associated therewith have been received; (2)&nbsp;the filing and/or approval of a BLA generally has occurred (provided, however, that specific dates of filing shall not be disclosed); (3)&nbsp;initiation of any
Phase&nbsp;II Clinical Trial or later clinical trial; and (4)&nbsp;commercial launch of a Product or any information that has previously been approved and disclosed as permitted by this Section&nbsp;12.3(a). In the case of items (1)-(4)&nbsp;of the
preceding sentence, the disclosing Party shall provide the other Party a copy of such proposed disclosures at least <B>***</B> prior to the proposed release and consider in good faith any comments the other Party may make, where practicable, and in
light of any reporting obligations of such disclosing Party under applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United States Securities and Exchange Commission or any other
governmental agency. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>No Other Use of Company Names</B>. Except as otherwise provided in this
Section&nbsp;12.3(b), neither Party shall use the name, trademark, trade name or logo of the other Party or its employees in any publicity or news release relating to this Agreement or its subject matter, without the prior express written permission
of the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Approved Press Releases</B>. In addition and notwithstanding anything to the contrary herein,
(a)&nbsp;if the relevant text of a proposed press release has already previously been reviewed and approved for disclosure by the other Party then such text may be disclosed or republished in such proposed press release provided that the Party
issuing such press release provides notice to the other Party of such press release at least four (4)&nbsp;business days prior to the issuance of such press release, where practicable, and (b)&nbsp;if the relevant text of a proposed public
announcement such as a corporate presentation or comments to analysts or investors has already previously been reviewed and approved for disclosure by the other Party (whether in the form of an approved press release or prior approved presentation
materials, Q&amp;A script or the like) then such text may be included in such proposed public announcement (but not a press release) without resubmission and review by the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Existence of Agreement</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) <B>No Disclosure</B>. Neither Party shall disclose the existence or terms of this Agreement pursuant to a press release or otherwise except as provided in this Section&nbsp;12.3(d). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <B>Permitted Disclosures</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(A) Notwithstanding the terms of this Section&nbsp;12, either Party shall be permitted to disclose the existence and terms of this Agreement and the conduct of the Collaboration under this Agreement, to
the extent required, in the reasonable opinion of such Party&#146;s legal counsel, to comply with applicable laws, rules or regulations, including without limitation the rules and regulations promulgated by the United States Securities and Exchange
Commission or any other governmental agency. The disclosing Party shall take reasonable and lawful actions to avoid and/or minimize the degree of such disclosure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(B) Either Party may also disclose the existence and terms of this Agreement to its attorneys and advisors, and to potential acquirors, in connection with a potential acquisition or other change of
control transaction and to existing and potential investors or lenders of such Party, as a part of their due diligence investigations, or to potential licensees or to permitted assignees in each case under an agreement to keep the terms of this
Agreement confidential under terms of confidentiality and non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C) MacroGenics may also disclose the existence and terms of this Agreement pursuant to
transactions related to the Commercialization or Development of MGAH22 or any Product (&#147;<B>Licensing Transactions</B>&#148;), in each case under an agreement to keep the terms of this Agreement confidential under terms of confidentiality and
non-use substantially similar to the terms contained in this Agreement and to use such confidential information solely for the purpose of the contemplated transaction, provided that prior to the disclosure of the terms of this Agreement in
connection with any Licensing Transaction, MacroGenics shall redact in any written summary or copy of this Agreement, all financial terms of this Agreement, in a manner substantially consistent with a form provided to Green Cross by MacroGenics on
or before the Effective Date. The transactions described in Section&nbsp;12.3(d)(ii)(B) shall not be deemed Licensing Transactions for purposes of this Section&nbsp;12.3(d)(ii)(C). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13. <B>R<SMALL>EPRESENTATIONS</SMALL> <SMALL>AND</SMALL> W<SMALL>ARRANTIES</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.1 <B>Representations and Warranties of MacroGenics</B>. MacroGenics represents and warrants to Green Cross that, as of the Effective Date: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, and to grant the licenses
contemplated under Section&nbsp;10, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with, violate, or breach or constitute a default under any contractual obligation or court or
administrative order by which MacroGenics is bound; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) all necessary consents, approvals and authorizations of all
government authorities and other persons required to be obtained by MacroGenics as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) it is the exclusive licensee of or otherwise Controls the right, title and interest in and to the MacroGenics Licensed Technology and
MacroGenics Licensed Trademarks, and has the right to grant to Green Cross the licenses that it purports to grant hereunder and has not granted any Third Party rights that would interfere or be inconsistent with Green Cross&#146; rights hereunder;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) to its knowledge, except for those licensed or sublicensed under the Upstream Agreements, the MacroGenics Licensed
Patents and MacroGenics Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> are not subject to any existing royalty or other payment obligations to any Third Party; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) as of the Effective Date, to its knowledge, the issued Patents in the MacroGenics Licensed Patents are valid and enforceable and it is not aware of any action, suit, inquiry, investigation or other
proceeding threatened, pending, or ongoing brought by any Third Party that challenges or threatens the validity or enforceability of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any of the MacroGenics Licensed Patents or that alleges the use of the MacroGenics Licensed Patents or the MacroGenics Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> or the
development, manufacture commercialization and use of the Products would infringe or misappropriate the intellectual property or intellectual property rights of any Third Party (and it has not received any notice alleging such an infringement or
misappropriation). In the event that MacroGenics becomes aware of any such action or proceeding, it shall immediately notify Green Cross in writing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.2 <B>Representations and Warranties of Green Cross</B>. Green Cross represents and warrants to MacroGenics that as of the Effective Date: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) it has the full right, power and authority to enter into this Agreement, to perform the Collaboration, to grant the licenses granted
hereunder, and the fulfillment of its obligations and performance of its activities hereunder do not materially conflict with, violate, or breach or constitute a default under any contractual obligation or court or administrative order by which
Green Cross is bound; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) all necessary consents, approvals and authorizations of all government authorities and other
persons required to be obtained by Green Cross as of the Effective Date in connection with the execution, delivery and performance of this Agreement have been obtained. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) it is the exclusive licensee of or otherwise Controls the right, title and interest in and to the Green Cross Licensed Patents and Green Cross Licensed
<FONT STYLE="white-space:nowrap">Know-how,</FONT> and has the right to grant to MacroGenics the licenses that it purports to grant hereunder and has not granted any Third Party rights that would interfere or be inconsistent with MacroGenics&#146;
rights hereunder; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) to its knowledge, the Green Cross Licensed Patents and Green Cross Licensed <FONT
STYLE="white-space:nowrap">Know-how</FONT> are not subject to any existing royalty or other payment obligations to any Third Party; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) as of the Effective Date, to its knowledge, the issued Patents in the Green Cross Licensed Patents are valid and enforceable and it is not aware of any action, suit, inquiry, investigation or other
proceeding threatened, pending, or ongoing brought by any Third Party that challenges or threatens the validity or enforceability of any of the Green Cross Licensed Patents or that alleges the use of the Green Cross Licensed Patents or the Green
Cross Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> or the development, manufacture commercialization and use of the Products would infringe or misappropriate the intellectual property or intellectual property rights of any Third Party
(and it has not received any notice alleging such an infringement or misappropriation). In the event that Green Cross becomes aware of any such action or proceeding, it shall immediately notify MacroGenics in writing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <B>Upstream Agreements</B>. MacroGenics represents, warrants and covenants to Green Cross that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Exhibit E lists all of the Upstream Agreements in existence as of the Effective Date. True and correct copies of the existing
Upstream Agreements have previously been provided to Green Cross by MacroGenics, and copies of any additional Upstream Agreement entered following the Effective Date will be provided to Green Cross by MacroGenics. Notwithstanding the foregoing,
prior to entering into additional Upstream Agreements, MacroGenics shall inform Green Cross to allow Green Cross to review the same. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) The Upstream Agreements identified on Exhibit E are, to MacroGenics&#146; knowledge, in
full force and effect as of the Effective Date, and MacroGenics is not aware of any that it has committed any material breach of any of the provisions of any of such Upstream Agreements, nor does there exist any condition that, to the knowledge of
MacroGenics, with passage of time or sending of notice would constitute a material breach by MacroGenics of any of the provisions of such Upstream Agreements, nor is MacroGenics aware of any material breach of such Upstream Agreements by any other
party thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) To the extent required to grant the licenses in this Agreement, MacroGenics has the right under the
Upstream Agreements listed on Exhibit E to enter into this Agreement and grant the licenses contemplated hereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)
MacroGenics will fulfill all of its material obligations under the Upstream Agreements and otherwise comply with the terms thereof. MacroGenics shall furnish to Green Cross copies of all notices received by MacroGenics relating to alleged breaches
or defaults by MacroGenics of its obligations under the Upstream Agreements within five (5)&nbsp;business days of MacroGenics receipt thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) To the extent MacroGenics is permitted or required under the terms of the Upstream Agreements to participate in the prosecution, maintenance, or enforcement or defense of any Patent or other
intellectual property right sublicensed to Green Cross under this Agreement, MacroGenics shall do so after consultation with Green Cross and, as and to the extent permitted by the Upstream Agreements, Green Cross shall have the same rights with
respect thereto as set forth in Section&nbsp;15 hereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4 <B>No Other Representations or Warranties</B>. EXCEPT AS
EXPRESSLY STATED IN THIS AGREEMENT, NO REPRESENTATIONS OR WARRANTIES WHATSOEVER, WHETHER EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR NON-MISAPPROPRIATION OF
THIRD PARTY INTELLECTUAL PROPERTY RIGHTS, IS MADE OR GIVEN BY OR ON BEHALF OF A PARTY. ALL REPRESENTATIONS AND WARRANTIES, WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE, ARE HEREBY EXPRESSLY EXCLUDED. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <B>I<SMALL>NDEMNIFICATION</SMALL></B><SMALL></SMALL> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1 <B>By Green Cross</B>. Green Cross agrees to indemnify and hold harmless MacroGenics, its Affiliates, and their directors, officers,
employees and agents (individually and collectively, the &#147;<B>MacroGenics Indemnitee(s)</B>&#148;) from and against all losses, liabilities, damages and expenses (including reasonable attorneys&#146; fees and costs) incurred in connection with
any claims, demands, actions or other proceedings by any Third Party (individually and collectively, &#147;<B>Losses</B>&#148;) first arising after the Effective Date to the extent arising from (a)&nbsp;activities performed by Green Cross or any of
its Affiliates or Permitted Subcontractors with respect to the research, Development, manufacture, use, Commercialization or sale of MGAH22 or Products or any other exercise of their rights or performance of their obligations hereunder, (b)&nbsp;the
use by Green Cross or any of its Related Parties or Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> except as permitted in this Agreement, (c)&nbsp;the negligence,
illegal conduct or willful misconduct of Green Cross, or (d)&nbsp;Green Cross&#146; material breach of this Agreement, except to the extent such Losses arise out of any of MacroGenics Indemnitee&#146;s negligence, illegal conduct or willful
misconduct, or breach of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2 <B>By MacroGenics</B>. MacroGenics agrees to indemnify and hold harmless Green
Cross, its Affiliates, and their directors, officers, employees and agents (individually and collectively, the &#147;<B>Green Cross Indemnitee(s)</B>&#148;) from and against all Losses to the extent arising from (a)&nbsp;activities performed by
MacroGenics or any of its Affiliates or Permitted Subcontractors with respect to the research, Development, manufacture, use, Commercialization or sale of Products, (b)&nbsp;any latent or hidden defect in a Product that is not caused by any act or
omission of Green Cross, (c)&nbsp;the use by Green Cross or any of its Related Parties or Permitted Subcontractors of the MacroGenics Licensed Patents or MacroGenics Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> or any intellectual
property rights under Upstream Agreements as permitted under this Agreement, (d)&nbsp;the negligence, illegal conduct or willful misconduct of MacroGenics, or (e)&nbsp;MacroGenics&#146; material breach of this Agreement, except to the extent such
Losses arise out of any of Green Cross Indemnitee&#146;s negligence, illegal conduct or willful misconduct, or breach of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.3 <B>Defense</B>. If any such claims or actions are made, the Indemnitee shall be defended at the Indemnifying Party&#146;s sole expense by counsel selected by the Indemnifying Party and reasonably
acceptable to the Indemnitee, provided that the Indemnitee may, at its own expense, also be represented by counsel of its own choosing. The Indemnifying Party shall have the sole right to control the defense of any such claim or action, subject to
the terms of this Section&nbsp;14. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4 <B>Settlement</B>. The Indemnifying Party may settle any such claim, demand, action
or other proceeding or otherwise consent to an adverse judgment (a)&nbsp;with prior written notice to the Indemnitee but without the consent of the Indemnitee where the only liability to the Indemnitee is the payment of money and the Indemnifying
Party makes such payment, or (b)&nbsp;in all other cases, only with the prior written consent of the Indemnitee, such consent not to be unreasonably withheld. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5 <B>Notice</B>. The Indemnitee shall notify the Indemnifying Party promptly of any
claim, demand, action or other proceeding under Section&nbsp;14.1 or Section&nbsp;14.2 and shall reasonably cooperate with all reasonable requests of the Indemnifying Party with respect thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6 <B>Permission by Indemnifying Party</B>. The Indemnitee may not settle any such claim, demand, action or other proceeding or
otherwise consent to an adverse judgment in any such action or other proceeding or make any admission as to liability or fault without the express written permission of the Indemnifying Party. Provided, however, that such permission shall not be
required if such settlement does not involve (a)&nbsp;any admission of legal wrongdoing by the other Party&#146;s Indemnitee(s), or (b)&nbsp;the imposition of any equitable relief against the other Party&#146;s Indemnitee(s). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7 <B>Limitation of Liability.</B> NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR
INDIRECT DAMAGES OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 14.7 IS INTENDED TO OR SHALL LIMIT OR
RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 14, OR DAMAGES AVAILABLE FOR A PARTY&#146;S BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE&nbsp;12. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15. <B>I<SMALL>NVENTIONS</SMALL>; P<SMALL>ATENT</SMALL> P<SMALL>ROVISIONS</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15.1 <B>Ownership of Intellectual Property</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Ownership of MacroGenics
IP</U>. As between MacroGenics and Green Cross, MacroGenics shall remain the sole and exclusive owner of all MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and MacroGenics Licensed <FONT STYLE="white-space:nowrap">Know-how</FONT> that
exist as of the Effective Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Ownership of Green Cross IP</U>. As between Green Cross and MacroGenics, Green Cross
shall remain the sole and exclusive owner of all Green Cross Licensed <FONT STYLE="white-space:nowrap">know-how</FONT> that exists as of the Effective Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Ownership of Jointly Owned IP</U>. MacroGenics shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of conducting the Collaboration
solely by MacroGenics or its consultants or subcontractors, together with all intellectual property rights therein. Green Cross shall own all data, results and inventions, whether patentable or not, conceived or reduced to practice in the course of
conducting the Collaboration solely by Green Cross or its </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
consultants or subcontractors, together with all intellectual property rights therein. MacroGenics and Green Cross shall jointly own all data, results and inventions, whether patentable or not,
conceived or reduced to practice by MacroGenics and Green Cross jointly (&#147;<B>Jointly Owned IP</B>&#148;), together with all intellectual property rights therein, with each Party owning an undivided half interest and the right to exploit without
the duty of accounting or seeking consent from the other Party to the extent to be permitted under Applicable Laws and Regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15.2 <B>Patent and Trademark Filing, Prosecution and Maintenance</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)
<B>Overall Strategy</B>. The JSC shall establish an overall strategy for the filing, prosecution and maintenance of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Green Cross Licensed Patents in the Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Prosecution</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) The responsibility for Patent Prosecution and Trademark Prosecution related to a Patent or Trademark that is within the MacroGenics Licensed Patents and MacroGenics Licensed Trademarks or the Green
Cross Licensed Patents that is owned solely by a Party shall be the responsibility of such Party. Such Party shall keep the JSC and the other Party informed of the status of all such Patent Prosecution and Trademark Prosecution activities.
MacroGenics shall be responsible for undertaking the Patent Prosecution with respect to Patents jointly owned by the Parties (the &#147;<B>Jointly Owned Patents</B>&#148;), and shall do as directed by the JSC. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) MacroGenics shall keep the JSC and Green Cross informed of the status of all matters affecting Patent Prosecution and
Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks and Jointly Owned Patents in the Territory, including providing a copy of any correspondence from any governmental authorities to the JSC and Green Cross upon
request, and consulting on the strategy and content of submissions to such governmental authorities in advance of any submissions. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) Any dispute regarding Patent Prosecution and Trademark Prosecution of MacroGenics Licensed Patents, MacroGenics Licensed Trademarks, or Jointly Owned Patents, shall be resolved by the JSC.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Without limiting the generality of the foregoing, MacroGenics shall prosecute and maintain Jointly Owned
Patents using outside counsel acceptable to Green Cross, and shall instruct such counsel to provide copies of correspondence and filings directly to Green Cross and otherwise permit Green Cross to participate with MacroGenics in any of the
activities of such counsel with respect to the Patent and Trademark Prosecution of such Jointly Owned Patents. Before taking any material step in the Patent Prosecution or Jointly Owned Patents, MacroGenics and its counsel shall allow Green Cross a
reasonable opportunity to comment on the action proposed to be taken, and agrees to incorporate in such filings all reasonable comments of Green Cross. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(v) Green Cross acknowledges and understands that its rights and obligations under this Section&nbsp;15.2 are secondary to and shall be subject to any Third Party rights and obligations under the Upstream
Agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Patent and Trademark Oppositions</B>. The JSC will decide whether and how to
participate in Patent and Trademark oppositions and undertake activities intended to invalidate Third Party Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.3
<B>Costs of Patent and Trademark Prosecution</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Costs.</B> All out-of-pocket costs for Patent Prosecution and
Trademark Prosecution of a Party&#146;s solely owned Patent or Trademark and for maintaining a Party&#146;s solely owned Patent or Trademark shall be solely incurred by and the sole responsibility of that Party. All out-of-pocket costs for Patent
Prosecution of Jointly Owned Patents and for maintaining Jointly Owned Patents in the Territory shall be shared equally by the Parties. The out-of-pocket costs of MacroGenics&#146; participation in Patent and Trademark oppositions, interferences and
similar actions, and activities intended to invalidate Third Party Patents and Trademarks in the Territory shall be borne solely by Green Cross. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">15.4 <B>Patent and Trademark Prosecution Cooperation</B>. With respect to all Patent Prosecution and Trademark Prosecution related to Patents and Trademarks included in MacroGenics Licensed Patents,
MacroGenics Licensed Trademarks or Green Cross Licensed Patents, each Party shall: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) execute all further instruments to
document their respective ownership consistent with this Agreement as reasonably requested by the other Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) make its
employees, agents and consultants reasonably available to the other Party (or to the other Party&#146;s authorized attorneys, agents or representatives), to the extent reasonably necessary to enable the appropriate Party hereunder to undertake its
Patent Prosecution and Trademark Prosecution responsibilities; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) cooperate, if necessary and appropriate, with the other
Party in gaining Patent and Trademark term extensions; provided, however, that any dispute regarding the same shall be submitted to the JSC for resolution; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) endeavor in good faith to coordinate its efforts under this Agreement with the other Party to minimize or avoid interference with the Patent Prosecution and Trademark Prosecution of the other
Party&#146;s Patents and Trademarks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.5 <B>Enforcement</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Notice</B>. Each Party shall promptly provide, but in no event later than ***, the other with written notice reasonably detailing
any known or alleged infringement of any Patent or Trademark owned by the other Party and subject to a license under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Enforcement of Intellectual Property Rights</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The
sole owner of a Patent, Trademark, <FONT STYLE="white-space:nowrap">Know-how</FONT> or Confidential Information shall have the exclusive right to institute and direct legal proceedings against any Third Party believed to be infringing such Patent or
Trademark or misappropriating or otherwise violating such <FONT STYLE="white-space:nowrap">Know-how</FONT> or Confidential Information. Green Cross shall have the initial right to institute and direct legal proceedings against any Third Party
believed to be infringing Jointly Owned Patents that claims or covers a Product sold in the Territory. If Green Cross has the right to direct legal proceedings pursuant to this Section&nbsp;15.5(b)(i) and does not abate such violation of Jointly
Owned Patents, including by commencement of a lawsuit against the accused person if necessary, within <B>***</B> after receiving notice of such infringement of Jointly Owned Patents and immediately after notice of other violation of such Jointly
Owned Patents, then MacroGenics shall be entitled (but shall not be obligated) to take all actions reasonably necessary to abate such violation in the Territory, including commencement of a lawsuit against the accused Third Party if necessary.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) MacroGenics shall have the initial right to institute and direct legal proceedings against any Third
Party believed to be infringing Jointly Owned Patents that claims or covers a Product sold outside the Territory. If MacroGenics does not abate such violation of Jointly Owned Patents, including by commencement of a lawsuit against the accused
person if necessary, within <B>***</B> after receiving notice of such infringement of Jointly Owned Patents and immediately after notice of other violation of such Jointly Owned Patents, then Green Cross shall be entitled (but shall not be
obligated) to take all actions reasonably necessary to abate such violation in the Territory, including commencement of a lawsuit against the accused Third Party if necessary. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) All amounts recovered from enforcement of any such rights by either Party in the Territory relating to the
intellectual property licensed under this Agreement shall be first used to reimburse each Party&#146;s costs and expenses incurred in connection with such action, and any remainder of such recovery, other than amounts recovered as lost profits,
shall be retained by the Party instituting the action, provided that any remainder retained by Green Cross shall be treated as Net Sales and shall be subject to Green Cross&#146; royalty payment obligations at the applicable rate specified in
Section&nbsp;8.5. For amounts recovered as lost profits the amount of Net Sales represented by such lost profits and Green Cross shall be obligated to pay MacroGenics any amounts due under this Agreement if such projected Net Sales were actually
made by Green Cross. All amounts recovered from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
enforcement of any such rights by either Party outside the Territory relating to Jointly Owned Patents shall be first used to reimburse each Party&#146;s costs and expenses incurred in connection
with such action, and any remainder of such recovery, shall be retained by the Party instituting the action. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)
<B>Cooperation in Enforcement Proceedings</B>. For any action by a Party pursuant to subsection (b)&nbsp;above, in the event that such Party is unable to initiate or prosecute such action solely in its own name, the other Party will join such action
voluntarily and will execute all documents necessary for such Party to initiate, prosecute and maintain such action. If either Green Cross or MacroGenics initiates an enforcement action pursuant to Section&nbsp;15.5(b), then the other Party shall
cooperate to the extent reasonably necessary and at the first Parties&#146; sole expense (except for the expenses of the non-controlling Party&#146;s counsel, if any). Upon the reasonable request of the Party instituting any such action, such other
Party shall join the suit and can be represented in any such legal proceedings using counsel of its own choice. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably the
subject thereof. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Status; Settlement</B>. The Parties shall keep each other informed of the status of and of their
respective activities regarding any enforcement action pursuant to Section&nbsp;15.5(b). Neither Party shall settle any litigation or legal proceeding in the Territory to enforce MacroGenics Licensed Patents or MacroGenics Licensed Trademarks
without the other Party&#146;s written authorization. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.6 <B>Defense</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Notice of Allegations</B>. Each Party shall notify the other in writing of any allegations it receives from a Third Party that the
manufacture, production, use, development, sale or distribution of any Product or any technology or intellectual property licensed by a Party under this Agreement infringes the intellectual property rights of such Third Party. Such notice shall be
provided promptly, but in no event after more than fifteen (15)&nbsp;business days, following receipt of such allegations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Notice of Suit</B>. In the event that a Party receives notice that it or any of its Affiliates have been individually named as a
defendant in a legal proceeding by a Third Party alleging infringement of a Third Party&#146;s Patents or other intellectual property right as a result of the manufacture, production, use, development, sale or distribution of Products or any
technology or intellectual property licensed by a Party under this Agreement, such Party shall immediately notify the other Party in writing and in no event notify such other Party later than <B>***</B> after the receipt of such notice. Such written
notice shall include a copy of any summons or complaint (or the equivalent thereof) received regarding the foregoing. Each Party shall assert and not waive the joint defense privilege with respect to all communications between the Parties reasonably
the subject thereof. In such event, the Parties shall agree how best to mitigate or control the defense of any such legal proceeding; provided however, that if either Party or any of its Affiliates have been individually named as a defendant in a
legal proceeding relating to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the alleged infringement of a Third Party&#146;s Patents or other intellectual property right as a result of the manufacture, production, use, development, sale or distribution of Products, the
other Party shall be allowed to join in such action, at its own expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Status; Settlement</B>. The Parties shall
keep each other informed of the status of and of their respective activities regarding any litigation or settlement thereof initiated by a Third Party in the Territory concerning a Party&#146;s manufacture, production, use, development, sale or
distribution of Products or any technology or intellectual property licensed by a Party under this Agreement; provided, however, that no settlement or consent judgment or other voluntary final disposition of a suit under this Section&nbsp;15.6(c)
may be undertaken by a Party without the consent of the other Party which consent shall not be unreasonably withheld or delayed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.
<B>T<SMALL>ERMS</SMALL> <SMALL>AND</SMALL> T<SMALL>ERMINATION</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1 <B>Term.</B> Unless earlier
terminated, this Agreement shall continue in effect until the expiration of the Royalty Term as defined in Section&nbsp;1.87 (&#147;<B>Term</B>&#148;), and thereafter Green Cross has no remaining payment obligations with respect to the Products
pursuant to Section&nbsp;8.5 above and MacroGenics shall have no further obligations hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2 <B>Termination for
Change in Control of Green Cross</B>. In the event of a Change in Control involving Green Cross, Green Cross shall provide prompt written notice to MacroGenics following such Change in Control, and MacroGenics may, in its sole discretion, terminate
this Agreement by providing written notice to Green Cross within <B>***</B> of MacroGenics&#146; receipt of such written notice of the Change in Control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.3 <B>Termination for Change in Control of MacroGenics</B>. In the event of a Change in Control involving MacroGenics, MacroGenics shall provide prompt written notice to Green Cross following such
Change in Control, and Green Cross may, in its sole discretion, terminate this Agreement by providing written notice to MacroGenics within <B>***</B> of Green Cross&#146; receipt of such written notice of the Change in Control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4 <B>Termination for Challenge to Patent Validity</B>. MacroGenics may terminate this Agreement immediately upon written notice to
Green Cross in the event Green Cross or any of its Affiliates: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) directly or indirectly oppose, or assist any Third Party
to oppose, in any patent office proceeding, the grant of any patent or patent application within the MacroGenics Licensed Patents, or, in any patent office proceeding, dispute or directly or indirectly assist any Third Party to dispute, the validity
of any patent within the MacroGenics Licensed Patents or any of the claims thereof, including opposing any application for amendment thereto; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) directly or indirectly oppose, or assist any Third Party to oppose, in any court
proceeding, the grant of any patent or patent application within the MacroGenics Licensed Patents, or, in any court proceeding, dispute or directly or indirectly assist any Third Party to dispute, the validity of any patent within the MacroGenics
Licensed Patents or any of the claims thereof; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) bring any claim or proceedings of whatever nature in relation to the
MacroGenics Licensed Patents against MacroGenics and/or any of MacroGenics&#146; Affiliates (or in respect of the foregoing their directors and officers) in respect of any activities carried out by them under any MacroGenics Licensed Patents which
may be the subject of a Valid Claim of the MacroGenics Licensed Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5 <B>Termination for Cause</B>. This Agreement
may be terminated at any time during the Term upon written notice by either Party if the other Party is in material breach of its other obligations under this Agreement and, in each case, has not cured such breach within <B>***</B> after notice
requesting cure of the breach (other than for non-payment which shall be cured within <B>***</B>). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6 <B>Effect of
Termination</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If MacroGenics terminates this Agreement pursuant to Section&nbsp;16.2, 16.4, or pursuant to
Section&nbsp;16.5 for cause based on material breach by Green Cross: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Green Cross shall pay any amounts due
pursuant to Section&nbsp;8 prior to the date of termination; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) For the avoidance of doubt, the licenses and
sublicenses granted to Green Cross under Sections&nbsp;10.1(a) and 10.4 shall terminate; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Green Cross
shall return to MacroGenics all Products (including, without limitation, all MGAH22) within its possession or control and arrange for the Green Cross Sublicensees to return to MacroGenics all Products (including, without limitation, all MGAH22)
within such Green Cross Sublicensees&#146; possession or control; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) Green Cross shall cease to research,
develop, market and sell any Product that infringes a Valid Claim in a MacroGenics Licensed Patent; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) for
the Products (including, without limitation, MGAH22), Green Cross shall assign and promptly transfer to MacroGenics, at no expense to MacroGenics, all of Green Cross&#146; right, title and interest in and to (A)&nbsp;all regulatory filings (such as
INDs, CTAs and drug master files), Regulatory Approvals, and clinical trial agreements (to the extent assignable and not cancelled) for such Products(s), to the extent that MacroGenics elects to continue development of such Product(s); (B)&nbsp;all
data, including clinical data, materials and information of any kind </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or nature whatsoever, in Green Cross&#146; possession or in the possession of its Affiliates or its or their respective agents related to such Product(s); (C)&nbsp;all trademarks related to such
Products (if such termination occurs after approval of such trademark by a Regulatory Authority); and (D)&nbsp;all material information, and any other information reasonably requested and required by MacroGenics, relating to the manufacture of such
Products; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) all sublicenses under the rights granted pursuant to Section&nbsp;10.1(b) shall terminate; and
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) MacroGenics shall revoke (and Green Cross shall allow revocation of) any powers of attorney for any
MacroGenics Licensed Patents that Green Cross holds as of the time of such termination; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If Green Cross terminates
this Agreement pursuant to Section&nbsp;16.3: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) The provisions of Section&nbsp;16.6(a) shall apply;
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Notwithstanding anything to the contrary, MacroGenics shall continue to provide Green Cross, for up to<B>
***</B>, the Products (including, without limitation, all MGAH22), at the request of Green Cross in accordance with the terms of Section&nbsp;6.2; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) If Green Cross terminates this Agreement pursuant to Section&nbsp;16.5 for cause based on material breach by MacroGenics: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) As full satisfaction of any claims Green Cross may have based upon such material breach and termination, <B>***</B>:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(1) </B>Such material breach by MacroGenics results in a substantial reduction in the profit Green Cross would have
received if such material breach and termination had not occurred; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(2) </B>MacroGenics committed such material breach
other than as a result of a material breach committed by Green Cross; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(3) </B>Both Parties agree in writing not to
undertake arbitration in accordance with Section&nbsp;17.7 to determine whether MacroGenics committed a material breach. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) For the avoidance of doubt, the license granted under Section&nbsp;10.3 shall terminate; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(iii) The provisions of Section&nbsp;16.6(a) shall apply; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)
Notwithstanding anything to the contrary, MacroGenics shall continue to provide Green Cross, for up to<B>***</B>, the Products (including, without limitation, all MGAH22), at the request of Green Cross in accordance with the terms of
Section&nbsp;6.2; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) Green Cross shall revoke (and MacroGenics shall allow revocation of) any powers of
attorney for any Green Cross Licensed Patents that MacroGenics holds as of the time of such termination. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Return of Confidential Information</B>. Upon expiration or termination of this
Agreement, the Parties shall comply with Section&nbsp;12.1(e). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7 <B>Survival</B>. The following provisions shall survive
the termination or expiration of this Agreement for any reason: Sections&nbsp;1, 8.9, 8.11, 9, 10.4 (with respect to the license granted to MacroGenics), 12 (to the extent provided therein), 13, 14, 15.1, 16 and 17. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">17. <B>M<SMALL>ISCELLANEOUS</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.1 <B>Force Majeure</B>. Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under
this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party including, but not limited to, embargoes, war, acts of war (whether war be declared or not), insurrections,
riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party (&#147;<B>Force Majeure</B>&#148;). The affected
Party shall notify the other Party of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. In the event a Party is unable to perform
its obligations under this Agreement due to Force Majeure for a period of <B>***</B>, the other Party shall have the option of unilaterally terminating this Agreement upon providing <B>***</B> written notice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.2 <B>Section&nbsp;365(n) of the Bankruptcy Code</B>. All rights and licenses granted under or pursuant to any section of this
Agreement are, and shall otherwise be deemed to be, for purposes of Section&nbsp;365(n) of the U.S. Bankruptcy Code, licenses of rights to &#147;intellectual property&#148; as defined under Section&nbsp;101(35A) of the U.S. Bankruptcy Code. The
Parties shall retain and may fully exercise all of their respective rights and elections under the U.S. Bankruptcy Code. The Parties agree that a Party that is a licensee of such rights under this Agreement shall retain and may fully exercise all of
its rights and elections under the U.S. Bankruptcy Code, and that upon commencement of a bankruptcy proceeding by or against the licensing Party (such Party, the &#147;<B>Involved Party</B>&#148;) under the U.S. Bankruptcy Code, the other Party
(such Party, the &#147;<B>Noninvolved Party</B>&#148;) shall be entitled to a complete duplicate of or complete access to (as such Noninvolved Party deems appropriate), any such intellectual property and all embodiments of such intellectual
property, provided the Noninvolved Party continues to fulfill its payment or royalty obligations as specified herein in full. Such intellectual property and all </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
embodiments thereof shall be promptly delivered to the Noninvolved Party (a)&nbsp;upon any such commencement of a bankruptcy proceeding upon written request therefor by the Noninvolved Party,
unless the Involved Party elects to continue to perform all of its obligations under this Agreement or (b)&nbsp;if not delivered under (a)&nbsp;above, upon the rejection of this Agreement by or on behalf of the Involved Party upon written request
therefor by Noninvolved Party. The foregoing is without prejudice to any rights the Noninvolved Party may have arising under the U.S. Bankruptcy Code or other applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.3 <B>Assignment</B>. Neither Party may assign its rights and obligations under this Agreement without the prior written consent of the other Party, provided that either Party may assign its rights and
obligations under this Agreement, without such consent from the other Party, to its Affiliate or any successor in interest in connection with the sale of all or substantially all of its assets or a sale of all or substantially of the business
related to MGAH22 or a Product, or a merger, acquisition or other similar transactions. For the avoidance of doubt, the terms and conditions of this Agreement shall be binding on the permitted successors and assignees of each Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.4 <B>Severability</B>. If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in
any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of
the Parties. The Parties shall in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.5 <B>Notices</B>. All notices which are required or permitted hereunder shall be in writing and sufficient if
delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid,
return receipt requested, addressed as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">if to MacroGenics, to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1500 East Gude Drive</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Chief Executive
Officer</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">with copy to:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(which shall not constitute notice)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold &amp; Porter, LLP</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1600
Tysons Boulevard</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Suite 900</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">McLean, VA
22102</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>***</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B></FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="71%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">if to Green Cross, to:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Green Cross Corporation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">303
Bojeong-dong, Giheung-gu</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yongin, 446-770, Korea</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attn: President</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">with copy to:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Green Cross Corporation</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">303
Bojeong-dong, Giheung-gu</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yongin, 446-770, Korea</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Attn: <B>***</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: <B>***</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address as the Party to whom notice is to be given may have furnished to the other Party in writing in
accordance herewith. Any such notice shall be deemed to have been given upon receipt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.6 <B>Applicable Law</B>. All
questions of inventorship will be determined in accordance with <B>***</B>. In respect to all other Patent issues related to the enforceability or validity of a Patent, the laws of the jurisdiction in which the applicable Patent is filed or granted
shall govern. Except as otherwise indicated, in all other respects, the right and obligations of the Parties under this Agreement shall be governed by and construed in accordance with the laws of the <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.7 <B>Arbitration</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) All disputes arising out of or in connection with the Agreement shall be finally settled under the Rules of Arbitration of the <B>***</B> by three (3)&nbsp;arbitrators (&#147;<B>Arbitral
Tribunal</B>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Each Party shall nominate one arbitrator. Should the claimant fail to appoint an arbitrator in the
Request for Arbitration within <B>***</B> days of being requested to do so, or if the respondent should fail to appoint an arbitrator in its Answer to the Request for Arbitration within <B>***</B> days of being requested to do so, the other party
shall request the <B>***</B> to make such appointment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The arbitrators nominated by the parties shall, within <B>***</B>
from the appointment of the arbitrator nominated in the Answer to the Request for Arbitration, and after consultation with the parties, agree and appoint a third arbitrator, who will act as a chairman of the Arbitral Tribunal. Should such procedure
not result in an appointment within the <B>***</B> time limit, either party shall be free to request the <B>***</B> to appoint the third arbitrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d)<B> ***</B> shall be the seat of the arbitration. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) The language of the arbitration shall be English. Documents submitted in the arbitration
(the originals of which are not in English) shall be submitted together with an English translation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) This arbitration
agreement does not preclude either party seeking conservatory or interim measures from any court of competent jurisdiction including, without limitation, the courts having jurisdiction by reason of either party&#146;s domicile. Conservatory or
interim measures sought by either party in any one or more jurisdictions shall not preclude the Arbitral Tribunal granting conservatory or interim measures. Conservatory or interim measures sought by either party before the Arbitral Tribunal shall
not preclude any court of competent jurisdiction granting conservatory or interim measures. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) In the event that any issue
shall arise which is not clearly provided for in this arbitration agreement the matter shall be resolved in accordance with the <B>***</B> Arbitration Rules. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.8 <B>Entire Agreement; Amendments.</B> The Agreement contains the entire understanding of the Parties with respect to the Collaboration and licenses granted hereunder. All express or implied agreements
and understandings, either oral or written, with regard to the Collaboration and the licenses granted hereunder are superseded by the terms of this Agreement. The Agreement may be amended, or any term hereof modified, only by a written instrument
duly executed by authorized representatives of both Parties hereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.9 <B>Headings.</B> The captions to the several
Sections hereof are not a part of the Agreement, but are merely for convenience to assist in locating and reading the several Sections and Sections of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">17.10 <B>Independent Contractors</B>. It is expressly agreed that MacroGenics and Green Cross shall be independent contractors and that the relationship between the two Parties shall not constitute a
partnership, joint venture or agency. Neither MacroGenics nor Green Cross shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the
prior written consent of the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.11 <B>Waiver</B>. The waiver by either Party of any right hereunder, or the
failure of the other Party to perform, or a breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.12 <B>Cumulative Remedies</B>. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and
in addition to any other remedy referred to in this Agreement or otherwise available under law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.13 <B>Waiver of Rule of Construction</B>. Each Party has had the opportunity to consult
with counsel in connection with the review, drafting and negotiation of this Agreement. Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.14 <B>Counterparts</B>. The Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.15 <B>Further Assurances</B>. Each Party will duly execute
and deliver, or cause to be duly executed and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as
the other Party may reasonably request in connection with this Agreement or to carry out more effectively the provisions and purposes, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">17.16 <B>Construction</B>. Except where the context otherwise requires, wherever used, the singular will include the plural, the plural
the singular, the use of any gender will be applicable to all genders, and the word &#147;or&#148; is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend
or limit the scope or intent of this Agreement or the intent of any provision contained in this Agreement. The term &#147;including&#148; as used herein means including, without limiting the generality of any description preceding such term.
References to &#147;Section&#148; or &#147;Sections&#148; are references to the numbered sections of this Agreement, unless expressly stated otherwise. All dollars are United States Dollars. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Parties have executed this Agreement as of the Effective Date. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Green Cross Corporation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics, Inc.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ B. G. Rhee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B. G. Rhee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and CEO</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit A </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Licensed Patents </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="73%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit B </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Licensed Trademarks </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit C </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Phase I Clinical Development Plan </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>****** </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>A.</I></B><B>***</B><B><I></I></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.<B> ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>F. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>H. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>



<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>J. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>K. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>L. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.&nbsp;&nbsp; ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.&nbsp;&nbsp; ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>23. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>24. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>25. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>27. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>28. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>29. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.00em; text-indent:-1.00em" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>30. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Q. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>R. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>16. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>17. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>18. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>19. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>20. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>21. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>22. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>a.</B> ***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="16%"></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11. ***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit D </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Phase II Clinical Development Plan </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>****** </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#149;&nbsp;&nbsp;&nbsp;***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#149;&nbsp;&nbsp;&nbsp;***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-left:4.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&#149;&nbsp;&nbsp;&nbsp;***</B></FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit E </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Upstream Agreements </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit F </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Joint Steering Committee </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics: </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)<B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)<B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)<B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Green Cross: </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1)<B></B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B> </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B> </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit G </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SAFETY DATA EXCHANGE AGREEMENT COMPONENTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>Exhibit H </U></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Product Royalty Rates </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:12pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>***</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>



<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>

<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>


</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>18
<FILENAME>filename18.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.18</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.18 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FIRST AMENDMENT TO
COLLABORATION AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS FIRST AMENDMENT TO THE COLLABORATION AGREEMENT (this &#147;<U>Amendment</U>&#148;) is made
to be effective as of January&nbsp;19, 2011 (the &#147;<U>Effective Date</U>&#148;), by and between MacroGenics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) and Green Cross Corporation, a corporation organized under the laws of
Korea (&#147;<U>Green Cross</U>&#148;). Capitalized terms used in this Amendment and not defined herein shall have the meanings given to such terms in the Agreement (as defined below). </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>W</U> <U>I</U> <U>T</U> <U>N</U> <U>E</U> <U>S</U> <U>S</U> <U>E</U> <U>T</U> <U>H</U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Company and Green Cross are parties to that certain Collaboration Agreement, effective as of June&nbsp;30, 2010 (the
&#147;<U>Agreement</U>&#148;); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the Company wishes to issue and sell to Green Cross, and Green Cross wishes to
purchase from the Company, an aggregate of up to $2,000,000 of the Company&#146;s preferred stock, upon the terms and subject to the conditions of that certain Stock Purchase Agreement by and among the Company, Green Cross and the other parties
thereto, dated as of January&nbsp;14, 2011 (such purchase, the &#147;<U>Green Cross Equity Purchase</U>&#148;); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS,
in connection with the Green Cross Equity Purchase, the Parties wish to amend <U>Section&nbsp;8.2(a)</U> of the Agreement as provided herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and the respective agreements contained in this Amendment, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as
follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. <U>Section&nbsp;8.2(0)</U> of the Agreement is hereby amended and restated in its entirety as follows:
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;(a) If during the *** of the Term there is an Initial Public Offering which raises a minimum of *** and if the
underwriter(s) in such Initial Public Offering permit it, Green Cross may, at its sole discretion, elect to purchase a number of shares of the same class of capital stock, simultaneously with the closing(s) of, and at the same purchase price as the
shares sold in, the Initial Public Offering that is equal to the number of shares that could be purchased for *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.
<U>Savings Clause</U>. Except as expressly modified by this Amendment, in all other respects the Agreement shall be unaffected hereby and shall remain in full force and effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. <U>Entire Agreement</U>. This Amendment together with the Agreement (including the documents and instruments referred to herein and
therein) constitutes the entire agreement between the parties with respect to the subject matter hereof and thereof. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <U>Counterparts</U>. This Amendment may be executed in counterparts, which taken together
shall constitute one and the same document. Signatures to this Amendment may be delivered by facsimile or other electronic method transmission, which shall be binding for all purposes upon so delivering and each of the other parties hereto.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>[Remainder of Page Intentionally Left Blank; Signature Page Follows] </I></B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF</B>, each of the parties hereto has executed this Amendment to be
effective for all purposes as of the Effective Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., PhD</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GREEN CROSS CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>IN WITNESS WHEREOF</B>, each of the parties hereto has executed this Amendment to be
effective for all purposes as of the Effective Date.<B> </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., PhD</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President and Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="5"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GREEN CROSS CORPORATION</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ BG Rhee</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">BG Rhee</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>19
<FILENAME>filename19.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.19</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.19 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMENDMENT </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">THIS SECOND AMENDMENT (the &#147;Second Amendment&#148;) entered into on the date of last signature to this Amendment by and between MacroGenics, Inc. a
Delaware corporation having a place of business at 9640 Medical Center Drive, Rockville, MD 20850 (&#147;MacroGenics&#148;) and Green Cross Corp., having a business office at 303 Bojeong-Dong, Giheung-Gu, Yongin, 446-770, Korea (hereinafter
&#147;Green Cross&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Green Cross and MacroGenics executed a Collaboration Agreement on June&nbsp;30, 2010 (the
&#147;Agreement&#148;) and which the parties subsequently amended effective September&nbsp;13, 2010 (the amendment hereinafter referred to as the &#147;First Amendment&#148;); </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties wish to amend the Agreement for the purpose of reallocating certain costs for which Green Cross is responsible to MacroGenics; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the cumulative Development Costs estimated to be incurred by Green Cross as of October&nbsp;31, 2012 are
<B><U STYLE="border-bottom:0.5pt double; padding-bottom:0.5pt">***</U></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, for good and valuable consideration, the receipt
and sufficiency of which is hereby acknowledged, the parties agree to the following terms and conditions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. Section&nbsp;3.4(a) is hereby
deleted and replaced with the following text: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Phase I Clinical Development Plan.</B> Green Cross shall be responsible for
all Development Costs incurred by Green Cross in connection with the conduct of the Phase I Clinical Development Plan, including, without limitation, <B>***</B> (iii); provided however that such Development Cost incurred by Green Cross shall not
exceed <B>***</B> (hereinafter referred to as the &#147;CAP Amount&#148;). MacroGenics shall be responsible for all Development Costs incurred by MacroGenics in connection with the conduct of the Phase I Clinical Development Plan, including without
limitation, Third Party costs for CRO-related activities for the Phase I Clinical Trial outside of the Territory, except as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.
Section&nbsp;3.4(a)(iii) is hereby deleted and replaced with the following text: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Laboratory Testing</B>. Unless the
Development Cost incurred by Green Cross shall exceed the CAP Amount, each Calendar Quarter, Green Cross shall reimburse MacroGenics for that percentage of the total laboratory testing costs incurred by the MacroGenics during such Calendar Quarter
that is equal to the percentage of all patients participating in the Phase I Clinical Trial during such Calendar Quarter that were derived from sites located in the Territory. MacroGenics will invoice Green Cross at the end of the applicable
Calendar Quarter for the amounts due hereunder, and all such amounts shall be paid to MacroGenics by Green Cross in US Dollars not later than <B>***</B> following the receipt of the applicable invoice. In the event that the Development Costs
incurred by Green Cross shall exceed the CAP Amount, MacroGenics will discontinue invoicing Green Cross for the cost of conducting laboratory testing in the Phase I Clinical Trial that are derived from sites located in the Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. The following text is incorporated into the Agreement as new Section&nbsp;3.4(a)(vii): </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event that the Development Cost incurred by Green Cross shall exceed the CAP Amount, MacroGenics shall reimburse Green Cross for
all eligible Development Costs spent beyond the CAP Amount by Green Cross to conduct the Phase I Clinical Development Plan in the Territory including, without limitation, the per patient subject fee and associated overhead actually paid to
<B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. The following text is incorporated into the Agreement as new Section&nbsp;3.4(c): </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payments by MacroGenics.</B> Green Cross will invoice MacroGenics at the end of each applicable Calendar Quarter for all amounts due
under this Section&nbsp;3.4. Each invoice will be accompanied by the invoices for the actual out-of-pocket amounts paid to Third Parties for which Green Cross is seeking reimbursement. MacroGenics shall pay each invoice submitted for payment under
this Section&nbsp;3.4 which is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
properly submitted and accompanied by the required documentation in US Dollars not later than <B>***</B> following receipt of such invoice and documentation. Green Cross will notify MacroGenics
(i)&nbsp;the approximate amount of any Phase 1 Clinical Development Plan costs beyond the CAP Amount before incurring such costs; (ii)&nbsp;the approximate amount of any additional Phase 1 Clinical Development Plan costs which represent significant
deviations from the historical costs up to the CAP Amount as described in Section&nbsp;3.4(a) immediately after recognition of incurring such costs; or (iii)&nbsp;<B>*** </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. The address &#147;1500 East Gude Drive, Rockville, MD 20850&#148; in Section&nbsp;17.5 is hereby deleted and replaced with the address &#147;9640 Medical Center Drive, Rockville, MD 20850&#148;.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Second Amendment, the Agreement and the First Amendment constitute the entire agreement of the parties and supersede any and all prior
agreements, written or oral, between Green Cross and MacroGenics relating to the subject matter of this Amendment and the Agreement and neither may be amended unless agreed to in writing by both parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the parties, intending to be legally bound, have caused this Second Amendment to be executed by their respective duly authorized
representative. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics, Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Green Cross Corporation</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ B.&nbsp;G&nbsp;Rhee</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">B.&nbsp;G&nbsp;Rhee</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 13, 2013</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">December 3, 2013</FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this
exhibit have been omitted pursuant to a request for confidential treatment. An unredacted version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>20
<FILENAME>filename20.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.20</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.20 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTION COPY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>121752/BR/BCN </B></FONT></P> <P STYLE="margin-top:240px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OPTION FOR A LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BY AND BETWEEN </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>AND </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LES LABORATOIRES SERVIER </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AND </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INSTITUT DE RECHERCHES SERVIER </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 1 DEFINITIONS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 2 GOVERNANCE</B> </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance Business-Development Managers.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance R&amp;D Managers.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project Directors.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Executive Committee.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Steering Committee.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Research and Development Committee and Subcommittees.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Chairpersons.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Committee Meetings. Frequency.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decisions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authority.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representatives.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 3 RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION</B> </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Overview.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conduct of the Research Programs.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluation of Option Trigger Data Package; Option Exercise.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 4 GRANT OF RIGHTS; EXCLUSIVITY</B> </FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant to Servier.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant to MacroGenics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublicenses.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subcontracting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Third Party Agreements.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights Retained by the Parties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 365(n) of the Bankruptcy Code.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusivity.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consequences of Development and Commercialization of Competing Products.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Right of First Negotiation for Independent Product.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diagnostics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 5 DEVELOPMENT DURING THE LICENSE TERM</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>26</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overview.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier Obligations.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Activities.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Updating and Amending Development Plan and Development Budget; Additional Development Activities.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Activities.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange of Data.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 6 REGULATORY MATTERS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>34</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier Regulatory Responsibility.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Regulatory Responsibility.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Communications with Regulatory Authorities.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product Withdrawals and Recalls.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmacovigilance; Safety Data Reporting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Safety Data Reporting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 7 MANUFACTURING </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>38</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer of MacroGenics Manufacturing Know-How.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply Agreements.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- ii -
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 8 COMMERCIALIZATION</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>39</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overview.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and Distribution.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ex-Territory Sales.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization Plan for Licensed Territory.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trademarks.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial Diligence.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standards of Conduct.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 9 PAYMENTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>41</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Grant Fee.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant Fees.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development and Regulatory Milestones.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales Milestones.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reports; Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Late Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxes.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Books and Records; Audit Rights.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 10 OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>46</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventorship.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ownership.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prosecution and Maintenance of Patents.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Party Infringement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- iii -
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Invalidity Claim.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Term Extensions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Marking.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 11 CONFIDENTIALITY </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>52</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality; Exceptions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized Disclosure.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release; Disclosure of Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing Confidentiality Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remedies.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Publications.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Return of Confidential Information.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 12 REPRESENTATIONS AND WARRANTIES </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>55</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representations and Warranties of Both Parties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representations and Warranties of MacroGenics and its Affiliates.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representation and Warranty of LLS.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mutual Covenants.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclaimer.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 13 INDEMNIFICATION </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>58</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnification by Servier.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnification by MacroGenics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Procedure.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allocation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">EXCLUSION OF CONSEQUENTIAL DAMAGES.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- iv -
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="91%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 14 TERM AND TERMINATION </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>60</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement Term; Expiration.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Cause.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Patent Challenge.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Convenience.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Insolvency Event.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination by Servier for Safety or Public Health Reasons.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of Expiration or Termination.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued Rights; Surviving Provisions of the Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 15 STANDSTILL </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>64</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standstill.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8" COLSPAN="3"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 16 MISCELLANEOUS </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>64</B></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;</B></FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disputes.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arbitration.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Governing Law.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Force Majeure.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notices.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Export Clause.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.8</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waiver.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severability.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.10</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entire Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">68</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.11</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Independent Contractors.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.12</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Headings; Construction; Interpretation.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- v -
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further Actions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.14</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parties in Interest.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance by Affiliates.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.16</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Counterparts.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- vi -
</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OPTION FOR A LICENSE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This Option for a License Agreement (this &#147;<U>Agreement</U>&#148;) is entered into and made effective as of the
19</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of September, 2012 (the &#147;<U>Effective
Date</U>&#148;), by and between MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 9640 Medical Center Drive Rockville, MD 20850, USA
(&#147;<U>MacroGenics</U>&#148;), and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (&#147;<U>LLS</U>&#148;) and Institut de Recherches Servier,
a company organized and existing under the laws of France, having a principal office located at 3 rue de la R&eacute;publique - 92150 Suresnes - France (&#147;<U>IdRS</U>&#148;) and LLS and IdRS hereinafter collectively referred to as
&#147;<U>Servier</U>&#148;). MacroGenics and Servier are each referred to herein by name or as a &#147;<U>Party</U>&#148; or, collectively, as &#147;<U>Parties</U>.&#148; </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RECITALS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Servier possesses expertise in the Research,
Development, Manufacturing and Commercialization (each as defined below) of pharmaceutical products; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>WHEREAS,
MacroGenics controls certain intellectual property related to DARTs generally, certain DARTS targeting CD123, certain DARTS targeting <B>***</B>, and certain DARTS targeting gpA33; <B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Servier is interested in receiving an exclusive option to obtain a future license under which it may further research, develop
and commercialize such DARTs in the Servier Territory (as defined below), and MacroGenics is willing to grant Servier such an option to obtain a future license on the terms and conditions set forth in this Agreement; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS the Parties are willing to set forth the terms and conditions of an option grant and an exclusive license to enable Servier to
research, develop and commercialize the above mentioned DARTs as further defined hereafter, upon exercise of the exclusive option by Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in this Agreement, the following terms will have the
meanings set forth in this ARTICLE 1 unless context dictates otherwise: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 *** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 &#147;<U>Accounting Standards</U>&#148; means, with respect to a Person, generally
accepted accounting principles as practiced in the United States or, to the extent applicable, IFRS (International Financial Reporting Standards). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<U>Affiliate</U>&#148; means, as to a Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with said
first Person, regardless of whether such Affiliate is an Affiliate on the Effective Date or becomes an Affiliate after the Effective Date. A Person shall be deemed to &#147;control&#148; another Person if it (a)&nbsp;owns, directly or indirectly,
beneficially or legally, more than fifty percent (50%)&nbsp;of the outstanding voting securities or capital stock (or such lesser percentage which is the maximum allowed to be owned by a Person in a particular jurisdiction) of such other Person, or
has other comparable ownership interest with respect to any Person other than a corporation; or (b)&nbsp;has the power, whether pursuant to contract, ownership of securities or otherwise, to direct the management and policies of the Person.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<U>Agreement Term</U>&#148; means the period commencing on the Effective Date and ending on the expiration of this
Agreement in accordance with the provisions of Section&nbsp;14.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<U>Annual Net Sales</U>&#148; means aggregate Net
Sales of Licensed Products by Servier or its Affiliates or Sublicensees in any Calendar Year, or in the first year and last year of the Royalty Term, the portion of such Calendar Year during which the Royalty Term is in effect. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6 &#147;<U>BLA</U>&#148; means a Biologics License Application and any amendments or supplements thereto filed with the FDA pursuant to
21 C.F.R. Part 601 or any other application required for the purpose of marketing and selling a biological product filed with a Regulatory Authority outside the United States, including with respect to the EU a Product License Application, Marketing
Authorization Application and/or manufacturing and importation license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<U>Business Day</U>&#148; means a day on
which banking institutions in Washington, DC, USA and Paris, France are open for business, excluding any Saturday or Sunday. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<U>Calendar Quarter</U>&#148; means a period of three (3)&nbsp;consecutive months ending on the last day of March, June,
September, or December, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<U>Calendar Year</U>&#148; means a period of time commencing on
January&nbsp;1 and ending on the following December&nbsp;31. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10 *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11 &#147;<U>CD123</U>&#148; means the Target referred to as CD123, IL3RA or interleukin 3 receptor, alpha (low affinity) that is
defined by Entrez Gene ID 3563. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12 &#147;<U>Commercialization</U>&#148; or &#147;<U>Commercialize</U>&#148; means any
activities directed to obtaining pricing and/or reimbursement approvals, marketing, promoting, distributing, importing, offering to sell, and/or selling a product (including establishing the price for such product). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13 &#147;<U>Commercially Reasonable Efforts</U>&#148; means with respect to a Party, such
efforts that are consistent with the efforts and resources normally used by <B>***</B> relating to the Research, Development and Commercialization of products (a)&nbsp;that have scientific attributes similar to those of the relevant Program DART or
Licensed Product in oncology, (b)&nbsp;that are at a similar stage in their Research, Development, Commercialization or product life as the relevant Program DART or Licensed Product, and (c)&nbsp;that have commercial and market potential similar to
the relevant Program DART or Licensed Product, taking into account issues of intellectual property scope, subject matter and coverage, safety and efficacy, product profile, competitiveness with respect to Third Party products in the marketplace,
proprietary position and profitability (including pricing and reimbursement status achieved or likely to be achieved), and (d)&nbsp;solely owned by them or to which they have exclusive rights. If either Party grants a sublicense to an Affiliate or
Third Party as permitted under this Agreement, then, with respect to such sublicensee Commercially Reasonable Efforts shall mean the efforts and resources (as defined above in this Section&nbsp;1.13) normally used by the Party granting the
sublicense, qualified by the items in clauses (a)&nbsp;&#150; (d)&nbsp;inclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14 &#147;<U>Competing Product</U>&#148;
means any product that *** binds a Program Target, is specifically ***, and achieves its intended ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15
&#147;<U>Complete</U>&#148; or &#147;<U>Completing</U>&#148; means, for a clinical trial, the date upon which all patients have completed protocol-defined drug administration and study database lock has occurred. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<U>Control</U>,&#148; &#147;<U>Controls</U>,&#148; &#147;<U>Controlled</U>&#148; or &#147;<U>Controlling</U>&#148; means, with
respect to any item of or right under an intellectual property right, the possession (whether by ownership or license, other than pursuant to this Agreement) of the ability of a Party to grant access to, or a license or sublicense of, such items or
right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such Party would be required hereunder to grant the other Party such access or license or sublicense;
<U>provided</U> <U>that</U> any intellectual property right that is licensed or acquired by a Party after the Effective Date <B>***</B> and that would otherwise be considered to be under the Control of such Party shall not be deemed to be under the
Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party
in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.17 &#147;<U>Cover</U>&#148;, &#147;<U>Covering</U>&#148; or &#147;<U>Covered</U>&#148; means, with respect to a product, technology, process or method that, in the absence of ownership of or a license
granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued,
would infringe such Valid Claim if it were to issue). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18 &#147;<U>DART</U>&#148; means a dual affinity re-targeting molecule , including but not
limited to those described in Exhibit A, with one arm that binds principally to a Target expressed on an immune effector cell (e.g., a T-cell) and with the second arm that binds principally to a different Target expressed on a cancer cell.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<U>Develop</U>&#148; or &#147;<U>Development</U>&#148; means drug development activities relating to the
development of compounds, products, or processes, and submission of information to a Regulatory Authority for the purpose of obtaining Regulatory Approval of a product. Development includes non-clinical activities, pharmacology studies, toxicology
studies, formulation, chemical analysis, bioanalytical analysis, material performance studies (such as measurements of stability, physical form, dissolution, or visual or spectroscopic analysis, and the like), pharmacokinetic studies, clinical
studies, biomarker and companion diagnostic discovery and development, regulatory affairs activities, and all other activities relating to seeking, obtaining or maintaining any Regulatory Approvals from the FDA or any other applicable Regulatory
Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<U>Development Costs</U>&#148; means the costs and expenses incurred by a Party or its Affiliates,
attributable to, or reasonably allocable to, the Development of a Program DART or Licensed Product and that are consistent, if applicable, with the applicable Development Budget and do not exceed the relevant amount set forth in such Development
Budget by more than <B>***</B> unless approved in writing by the JRDC and such other costs as are expressly approved in writing by the JRDC as &#147;Development costs&#148;. &#147;Development Costs&#148; shall include (a)&nbsp;Out-of-Pocket Costs
and (b)&nbsp;FTE Costs of internal personnel that are attributable or reasonably allocable to the Development of such Program DART or Licensed Product determined in accordance with applicable Accounting Standards of such Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<U>Diagnostic</U>&#148; means any companion diagnostic for a tumor expressing a Program Target that is (a)&nbsp;Developed in
combination with a Program DART and/or Licensed Product; and (b)&nbsp;used in combination with a Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22
&#147;<U>Dollars</U>&#148; or &#147;<U>$</U>&#148; means the legal tender of the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.23 &#147;<U>EMA</U>&#148;
means the European Medicines Agency, or any successor entity thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24 &#147;<U>EU</U>&#148; means the European Union, as
its membership may be altered from time to time, and any successor thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25 &#147;<U>Excluded Data</U>&#148; means any
Know-How, other than Safety Data, generated by a Party in the conduct of Development activities in accordance with a Development Collaboration Proposal where the other Party has declined to participate in such Development Collaboration Proposal and
has not paid the Buy-In Amount in accordance with Section&nbsp;5.4.2(b)(iv). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26 &#147;<U>FDA</U>&#148; means the U.S. Food
and Drug Administration, or any successor entity thereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27 &#147;<U>FD&amp;C Act</U>&#148; means the United States Federal Food, Drug, and
Cosmetic Act, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28 &#147;<U>Field</U>&#148; means all human fields of use (including treatment and diagnosis).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.29 &#147;<U>First Commercial Sale</U>&#148; means the first sale of a Licensed Product by Servier, its Affiliates or its
Sublicensees for use or consumption of such Licensed Product in a country in the Servier Territory where Regulatory Approval of such Licensed Product has been obtained or otherwise permitted for sale by the Governmental Authority of such country.
Sale of a Licensed Product by Servier to an Affiliate of Servier or a Sublicensee of Servier shall not constitute a First Commercial Sale unless such Affiliate or such Sublicensee is the end user of a Licensed Product. In no event shall any sales
for premarketing, testing or sampling be deemed a First Commercial Sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.30 &#147;<U>FTE</U>&#148; means <B>***</B> of work
devoted to or in support of the Development or Manufacture of Program DARTs and Licensed Product in accordance with a Global Development Plan or as required under Section&nbsp;7.2, that is carried out by one or more qualified scientific or technical
employees or contract personnel of MacroGenics or its Affiliates, or Servier or its Affiliates, as measured in accordance with the relevant Party&#146;s normal time allocation practices. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31 &#147;<U>FTE Cost</U>&#148; means, for any period, the FTE Rate multiplied by the number of FTEs in such period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32 &#147;<U>FTE Rate</U>&#148; means a rate of <B>***</B> per FTE per Calendar Year (pro-rated for the period beginning on the
Effective Date and ending at the end of the first Calendar Year) for personnel engaged in Development and Manufacturing activities. The FTE Rate is &#147;fully burdened&#148; and will cover <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.33 &#147;<U>Fully Burdened Manufacturing Cost</U>&#148; means with respect to a Program DART or Licensed Product, the aggregate of
internal and external costs of MacroGenics and its Affiliates to Manufacture such Program DART or Licensed Product, calculated as follows: (a)&nbsp;to the extent that MacroGenics or its Affiliates perform all or any part of the Manufacturing of such
Program DART or Licensed Product, the direct material costs <B>***</B> and FTE Costs for such Manufacturing of such Program DART or Licensed Product <B>***</B>, all calculated in accordance with applicable Accounting Standards as consistently
applied by MacroGenics or its Affiliates; and (b)&nbsp;to the extent that Manufacturing of such Program DART or Licensed Product is performed by a Third Party, the costs paid to such Third Party for such activities *** and the reasonable direct FTE
Costs incurred by MacroGenics or any of its Affiliates in managing and overseeing the Third Party relationship, determined in accordance with applicable Accounting Standards as consistently applied by MacroGenics or its Affiliates. Fully Burdened
Manufacturing Cost shall also include <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.34 &#147;<U>Generic Competition</U>&#148; means, with respect to a given
Calendar Quarter with respect to a Licensed Product in any country, that during such Calendar Quarter, one (1)&nbsp;or more Third Parties sell in such country a Generic Product, such Generic Product shall be commercially
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
available in such country and such Generic Product shall have, in the aggregate, a *** or more market share of the aggregate of Licensed Products and Generic Products (based on data provided by
IMS Health Incorporated, Fairfield, Connecticut) as measured on a ***, or if such data is not available, the Parties shall agree upon a methodology for estimating the percentage of unit sales based market share of Generic Products in such country.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35 &#147;<U>Generic Product</U>&#148; means, with respect to a particular Licensed Product commercialized by Servier in a
particular country, any product (other than Licensed Products commercialized, directly or indirectly, by Servier, its Affiliates or Sublicensees, or by any authorized distributors of Servier, its Affiliates or Sublicensees) that either (a)&nbsp;is a
&#147;follow-on biologic&#148; (FOB) or biosimilar or equivalent version to a Licensed Product, as defined by the competent Regulatory Authority, and administered in a similar dosage form as such Licensed Product or (b)&nbsp;for which a Third Party
has received Regulatory Approval (based upon then-current applicable Laws governing approval of biological products) whose application for approval relies to a large extent (but not exclusively) on data generated for a Licensed Product, such as
Regulatory Approval under section 505(b)(2) of the Federal Food Drug, and Cosmetic Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36 &#147;<U>Global Clinical
Trial</U>&#148; means a Phase 1 Clinical Trial, a Phase 2 Clinical Trial or a Phase 3 Clinical Trial that may be applicable to obtaining Regulatory Approval of Licensed Products in both the Servier Territory and the MacroGenics Territory or relies
on patient recruitment from both the Servier Territory and the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.37 &#147;<U>Good Clinical
Practices</U>&#148; or &#147;<U>GCP</U>&#148; means the then-current standards, practices and procedures (a)&nbsp;promulgated or endorsed by the FDA as set forth in the guidelines entitled &#147;Guidance for Industry E6 Good Clinical Practice:
Consolidated Guidance,&#148; including related regulatory requirements imposed by the FDA; (b)&nbsp;set forth in Directive 2001/20/EC of the European Parliament and of the Council of 4&nbsp;April 2001 and Commission Directive 2005//28/EC of
8&nbsp;April 2005; (c)&nbsp;ICH Guideline for Good Clinical Practice E6; (d)&nbsp;equivalent Laws of an applicable Regulatory Authority; and (e)&nbsp;all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant
or complement any of the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38 &#147;<U>Good Laboratory Practices</U>&#148; or &#147;<U>GLP</U>&#148; means the
then-current good laboratory practice standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, as such regulations may be amended from time to time, and the equivalent regulations promulgated by the equivalent Regulatory
Authority in the jurisdiction where Development activities are performed.<B> </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39 &#147;<U>Good Manufacturing
Practices</U>&#148; or &#147;<U>GMP</U>&#148; means then-current standards for the manufacture of pharmaceutical products, pursuant to (a)&nbsp;the FD&amp;C Act (21 U.S.C. 321 et seq.); (b)&nbsp;relevant United States regulations in Title 21 of the
United States Code of Federal Regulations (including Parts 11, 210, and 211); (c)&nbsp;European Community Directives 2003/94 and 91/356/EC; (d)&nbsp;the European Community Guide to Good Manufacturing Practice for Medicinal Intermediate Products;
(e)&nbsp;ICH Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients; (f)&nbsp;equivalent Laws of an applicable Regulatory Authority at the time of Manufacture; and (g)&nbsp;all additional Regulatory Authority documents or
regulations that replace, amend, modify, supplant or complement any of the foregoing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.40 &#147;<U>Governmental Authority</U>&#148; means any United States federal, state or
local or any non-United States government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police,
regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.41 &#147;<U>gpA33</U>&#148; means the Target referred to as GPA33, cell surface A33 antigen, glycoprotein A33 (transmembrane), or A33 that is identified by Entrez Gene ID 10223. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42 &#147;<U>ICH</U>&#148; means the International Conference on Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.43 &#147;<U>IND</U>&#148; means an Investigational New Drug Application filed with FDA or a
similar application filed with an applicable Regulatory Authority outside of the United States such as a clinical trial application (CTA). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.44 &#147;<U>Independent Product</U>&#148; means one or more products, other than a Competing Product, that *** binds one of the Program Targets and ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45 &#147;<U>Indication</U>&#148; means a discrete clinically recognized form of a disease or *** any. For the avoidance of doubt, a
cancerous disease, such as any of the Cancer Types, shall each be deemed to constitute a separate clinically recognized form of a disease, provided that ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.46 &#147;<U>Initial Phase 1 Clinical Trial</U>&#148; means <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47
&#147;<U>Insolvency Event</U>&#148; means, with respect to any Party, the occurrence of any of the following: (a)&nbsp;such Party shall commence a voluntary case concerning itself under any bankruptcy, liquidation or insolvency code; (b)&nbsp;an
involuntary case is commenced against such Party and the petition is not dismissed, bonded or stayed within ninety (90)&nbsp;days after commencement of the case; (c)&nbsp;a court-supervised custodian is appointed for, or takes charge of, all or
substantially all of the property of such Party to continue undischarged or unstayed for a period of ninety (90)&nbsp;days; (d)&nbsp;any order of relief or other order approving any such case or proceeding is entered; (e)&nbsp;such Party is
adjudicated insolvent or bankrupt; and (f)&nbsp;such Party makes a general assignment for the benefit of creditors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48
&#147;<U>Joint IP</U>&#148; means all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered jointly by one or more employees, consultants or agents of MacroGenics or its Affiliates, together with
one or more employees, consultants or agents of Servier or its Affiliates in the course of the Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.49 &#147;<U>Know-How</U>&#148; means all tangible and intangible (a)&nbsp;information,
techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and non-clinical and clinical test data and results,
and Research or Development data, reports and batch records), analytical and quality control data, analytical methods (including applicable reference standards), full batch documentation, packaging records, release, stability, storage and shelf-life
data, Manufacturing process information, results and descriptions, and software and algorithms and (b)&nbsp;compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50 &#147;<U>Law</U>&#148; or &#147;<U>Laws</U>&#148; means all laws, statutes, rules, regulations, orders, judgments, or ordinances
having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.51 &#147;<U>Licensed Product</U>&#148; means any therapeutic or prophylactic product that comprises or incorporates a Program DART as an active pharmaceutical ingredient alone or in combination with one
or more other active agents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.52 &#147;<U>Licensed Program</U>&#148; means a Program for which (a)&nbsp;Servier exercised
its Option in accordance with Section&nbsp;3.3.3 and (b)&nbsp;MacroGenics has received the applicable License Grant Fee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53
&#147;<U>License Term</U>&#148; means, with respect to a Licensed Program, each period commencing upon the License Grant Date for such Licensed Program and ending on the date of expiration or termination of this Agreement with respect to such
Licensed Program in accordance with the provisions of ARTICLE 14. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54 *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.55 &#147;<U>MacroGenics Indemnitees</U>&#148; means MacroGenics, its Affiliates and the directors, officers and employees of
MacroGenics and its Affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.56 &#147;<U>MacroGenics IP</U>&#148; means the MacroGenics Know-How and the MacroGenics
Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57 &#147;<U>MacroGenics Know-How</U>&#148; means Know-How that is (a)&nbsp;Controlled by MacroGenics or its
Affiliates on the Effective Date or thereafter during the Agreement Term; (b)(i) an improvement, modification, enhancement or novel use of a Program DART or Licensed Product or Diagnostic, or any improvement, modification or enhancement in the
Manufacturing process or formulation of a Program DART or Licensed Product or Diagnostic by or on behalf of MacroGenics or its Affiliates; or (ii)&nbsp;disclosed by or on behalf of MacroGenics or its Affiliates to Servier or its Affiliates pursuant
to this Agreement; and (c)&nbsp;necessary or useful to Research, Develop, Manufacture or Commercialize any Program DART or Licensed Product or Diagnostic in the Field in the Servier Territory. MacroGenics Know-How excludes MacroGenics&#146; interest
in the Joint IP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58 &#147;<U>MacroGenics Patents</U>&#148; means Patents Controlled by MacroGenics or its
Affiliates on the Effective Date or thereafter during the Agreement Term that claim or are directed to MacroGenics Know-How. The MacroGenics Patents existing as of the Effective Date are set forth on <U>Exhibit B</U>. MacroGenics Patents excludes
MacroGenics&#146; interest in the Joint IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59 &#147;<U>MacroGenics Territory</U>&#148; means the United States, Canada,
Mexico, India, Japan, Korea and any Terminated Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60 &#147;<U>MacroGenics Third Party Agreements&#148;</U> means
(a)&nbsp;the agreement set forth on Exhibit C(1), and (b)&nbsp;any other agreement ( including those listed in Exhibit C( 2) and C(3)) pursuant to which MacroGenics licenses or acquires Patents or Know-How that relates to the Program DARTs or
Licensed Products in the Field in the Servier Territory after the Effective Date pursuant to an agreement with a Third Party, the terms and conditions of which have been approved (not to be unreasonably withheld) by Servier before its execution by
MacroGenics and which Servier and MacroGenics agree shall be deemed a MacroGenics Third Party Agreement, in which case <U>Exhibit C</U> shall be amended accordingly. For purposes of clarity, in the event that Servier does not approve the terms and
conditions of any such proposed agreement with a Third Party, nothing herein shall be deemed to preclude MacroGenics from entering into such agreement with a Third Party; provided that such agreement with a Third Party shall not be deemed a
MacroGenics Third Party Agreement hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61 &#147;<U>Manufacture</U>&#148; or &#147;<U>Manufacturing</U>&#148; means
all activities related to the manufacturing of a DART or product, including <B>***</B> related to all of the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62
&#147;<U>Manufacturing Process Development Costs</U>&#148; means the costs and expenses incurred by a Party or its Affiliates attributable to, or reasonably allocable to, the development of a Manufacturing process for Program DARTs or Licensed
Products (including <B>***</B>). &#147;Manufacturing Process Development Costs&#148; shall include (a)&nbsp;Out-of-Pocket Costs and (b)&nbsp;FTE Costs of internal personnel that are attributable or reasonably allocable to the development of a
Manufacturing process for Program DARTs or Licensed Products determined in accordance with applicable Accounting Standards of such Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.63 &#147;<U>Net Sales</U>&#148; means, in the case of sales by or for the benefit of Servier, its Affiliates, and its Sublicensees (the &#147;<U>Seller</U>&#148;) to independent, unrelated persons
(&#147;<U>Buyers</U>&#148;) in bona fide arm&#146;s length transactions (except as provided below with respect to clinical trial samples), the gross amount billed or invoiced by Seller with respect to the Licensed Product during the Royalty Term,
less the following deductions, in each case to the extent actually allowed and taken by such Buyers and not otherwise recovered by or reimbursed to Seller in connection with such Licensed Product (&#147;<U>Permitted Deductions</U>&#148;):
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) *** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(e) *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(h)
*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Net Sales&#148; shall not include any consideration received with respect to a sale, use or other disposition of any Licensed
Product in a country as part of a clinical trial necessary to obtain Regulatory Approval in such country. All of the foregoing elements of Net Sales calculations shall be determined in accordance with IFRS or successor standards and guidelines
thereto. In the case of transfers of Licensed Product between any of Servier, its Sublicensees, and Affiliates of any of the foregoing, for subsequent sale, rental, lease or other transfer of such Licensed Products to Third Parties, Net Sales shall
be the gross invoice or contract price charged to the Third Party customer for that Licensed Product, less the deductions set forth in clauses *** above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.64 &#147;<U>Option Trigger Data Package</U>&#148; means a written report (including an electronic report) containing specified information and data for the indicated Research Program as follows, such
list may be modified by the Parties subject to the Parties mutual written agreement: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) with respect to the CD123 Program:
each of the following <B>***</B>; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) with respect to each of the A33 Program <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65 &#147;<U>Out-of-Pocket Costs</U>&#148; means, with respect to certain activities hereunder, direct expenses paid or payable by
either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.66 &#147;<U>Patent</U>&#148; means (a)&nbsp;all patents and patent applications in any country or supranational jurisdiction, and (b)&nbsp;any substitutions, divisionals, continuations,
continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such patents or patent applications. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67 &#147;<U>Person</U>&#148; means any individual, partnership, joint venture, limited liability company, corporation, firm, trust,
association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.68 &#147;<U>Phase 1 Clinical Trial</U>&#148; means a human clinical trial that is intended to initially evaluate the safety and/or
pharmacological effect of a product or that would otherwise satisfy the requirements of 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country other than the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.69 &#147;<U>Phase 2 Clinical Trial</U>&#148; means a human clinical trial for which the
primary endpoints include a determination of dose ranges or an indication of efficacy of a product in patients being studied as described in 21 C.F.R. &#167;312.21(b), or an equivalent clinical trial in a country other than the United States.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70 &#147;<U>Phase 3 Clinical Trial</U>&#148; means a human clinical trial that is prospectively designed to demonstrate
statistically whether a product is safe and effective for use in humans in the indication being investigated in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as
described in 21 C.F.R. &#167;312.21(c), or an equivalent clinical trial in a country other than the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71
&#147;<U>PMDA</U>&#148; means the Japanese Pharmaceuticals and Medical Devices Agency or any successor agency thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.72
&#147;<U>Program</U>&#148; means a scientific and/or Development program undertaken by MacroGenics to generate and Develop DARTs that bind to a Program Target. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.73 &#147;<U>Program DART</U>&#148; means any naked DART (i.e. without any drug or radioactive material attached to them) for which one arm principally binds to a Program Target, including the DARTs
listed in Exhibit A, ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.74 &#147;<U>Program Target</U>&#148; means one or more of the following Targets: (i)&nbsp;CD123,
(ii)&nbsp;<B>***</B> or (iii)&nbsp;gpA33 </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.75 &#147;<U>Qualified Transaction</U>&#148; means a transaction MacroGenics
desires to enter into with one or more Third Party(ies) with respect to one or more Independent Products, which transaction (a)&nbsp;<B>***</B>; and (b)&nbsp;<B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.76 &#147;<U>Regulatory Approval</U>&#148; means the approval, license or authorization of the applicable Regulatory Authority necessary for Development and/or Commercialization of a Program DART and/or
a Licensed Product for a particular Indication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.77 &#147;<U>Regulatory Authority</U>&#148; means the FDA in the United
States or any health regulatory authority in another country that is a counterpart to the FDA and holds responsibility for allowing development of Program DARTs and/or granting Regulatory Approval for a Licensed Product in such country, including
the EMA, and any successor(s) thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78 &#147;<U>Regulatory-Based Exclusivity Period</U>&#148; means, with respect to a
Licensed Product, that period of time during which Servier or any of its Affiliates or Sublicensees has been granted the exclusive legal right by a Regulatory Authority either to market and sell a Licensed Product in a country in the Servier
Territory or the exclusive right to the use of or reference to clinical data in relation to a Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.79
&#147;<U>Regulatory Documentation</U>&#148; means, with respect to the Program DARTs or Licensed Products, all INDs, BLAs, and other regulatory applications submitted to any Regulatory </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Authority, copies of Regulatory Approvals, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. &#167;314.420 and any non-United States
equivalents), and any other reports, records, regulatory correspondence, meeting minutes, telephone logs, and other materials relating to Regulatory Approval of the Program DARTs or Licensed Products (including any underlying safety and
effectiveness data whether or not submitted to any Regulatory Authority), or required to manufacture, distribute or sell Licensed Products including any information that relates to pharmacology, toxicology, chemistry, manufacturing and controls
data, batch records, safety and efficacy, and any safety database required to be maintained for Regulatory Authorities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80
&#147;<U>Research</U>&#148; means the discovery, identification, research, characterization, modification, derivatization and optimization of pharmaceutical compounds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.81 &#147;<U>Research Plan</U>&#148; means a research plan developed by the Parties that sets forth the activities to be undertaken during the Option Period for a specific Program, which research plan
may be amended from time to time by the JRDC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.82 &#147;<U>Research Term</U>&#148; means for each Program the period
commencing with the Effective Date <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.83 &#147;<U>Right of Reference or Use</U>&#148; means a &#147;Right of
Reference or Use&#148; as that term is defined in 21 C.F.R. &#167;314.3(b), and any non-United States equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.84
&#147;<U>Safety Data</U>&#148; means adverse event information and other information (if any) required by one or more Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under applicable Laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.85 &#147;<U>Servier Collaboration IP</U>&#148; means the Servier Collaboration Know-How and the Servier Collaboration Patents.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86 &#147;<U>Servier Collaboration Know-How</U>&#148; means Know-How that is (a)&nbsp;Controlled by Servier or its
Affiliates on the Effective Date or thereafter during the Agreement Term; (b)&nbsp;(i)&nbsp;an improvement, modification, enhancement or novel use of a Program DART or Licensed Product or Diagnostic, or any improvement, modification or enhancement
in the Manufacturing process or formulation of a Program DART or Licensed Product or Diagnostic by or on behalf of Servier or its Affiliates; or (ii)&nbsp;disclosed by or on behalf of Servier or its Affiliates to MacroGenics or its Affiliates
pursuant to this Agreement; and (c)&nbsp;necessary or useful to Research, Develop, Manufacture or Commercialize any Program DART or Licensed Product or Diagnostic in the Field. Servier Collaboration Know-How excludes Servier&#146;s interest in the
Joint IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.87 &#147;<U>Servier Collaboration Patent(s)</U>&#148; means Patents Controlled by Servier and its Affiliates on
the Effective Date or thereafter during the Agreement Term claiming or directed to Servier Collaboration Know-How. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88 &#147;<U>Servier Indemnitees</U>&#148; means Servier, its Affiliates and the directors,
officers and employees of Servier and its Affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.89 &#147;<U>Servier Territory</U>&#148; means the entire world
excluding the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.90 &#147;<U>SFDA</U>&#148; means the Chinese State Food and Drug Administration or any
successor agency thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.91 &#147;<U>Significant Patent</U>&#148; means any *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.92 &#147;<U>Sublicensee</U>&#148; means a Third Party to whom a Party, as permitted under this Agreement, grants a license or
sublicense, as the case may be, under the MacroGenics IP or Servier IP to Research, Develop, Manufacture, Commercialize or use Program DARTs and/or Licensed Products in the Field or otherwise grants rights to distribute, promote or sell Licensed
Products in the Field. For clarification purpose, a Party&#146;s subcontractor shall not be deemed a Sublicensee, but shall be subject to the provisions of Section&nbsp;4.4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.93 &#147;<U>Target</U>&#148; means (a)&nbsp;*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.94 &#147;<U>Terminated
Licensed Program</U>&#148; means with respect to a termination of this Agreement pursuant to ARTICLE 14, as applicable, (i)&nbsp;the Licensed Programs subject to such termination; and (ii)&nbsp;with respect to termination of this Agreement in its
entirety, all Licensed Programs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.95 &#147;<U>Terminated Option</U>&#148; means with respect to a termination of this
Agreement pursuant to ARTICLE 14, as applicable, (a)&nbsp;the Options subject to such termination; and (b)&nbsp;with respect to termination of this Agreement in its entirety, all Options. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.96 &#147;<U>Terminated Territory</U>&#148; means with respect to a termination of this Agreement pursuant to ARTICLE 14, as applicable,
(a)&nbsp;the country(ies) subject to such termination; and (b)&nbsp;with respect to termination of this Agreement in its entirety, the Servier Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.97 &#147;<U>Third Party</U>&#148; means any Person other than MacroGenics or Servier that is not an Affiliate of MacroGenics or of Servier. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.98 &#147;<U>United States</U>&#148; or &#147;<U>U.S.</U>&#148; means the United States of America and all of its territories and
possessions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.99 &#147;<U>Valid Claim</U>&#148; means (a)&nbsp;a claim of an issued patent that has not expired or been
abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the allowable time
period) or (b)&nbsp;<B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.100 <U>Additional Definitions</U>. Each of the following definitions is set forth in the
section of this Agreement indicated below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance Business-Development Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance R&amp;D Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arbitration Request</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audited Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Auditing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bankruptcy Code</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breaching Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Buy-In Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(b)(iv)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Buy-In Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(b)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Supply Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Chairperson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial Supply Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercializing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">De Minimis Overage Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Budget</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Collaboration Proposal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excess Overage Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing Confidentiality Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Global Development Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IdRS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnified Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnifying Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial Development Budget</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inspected Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JEC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JRDC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JSC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant Fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LLS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">M&amp;A Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Product Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Arbitrable Dispute</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Breaching Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Grant Fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Party or Parties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Development</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Plan Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receiving Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reconciliation Payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Program</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Responsible Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.3(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SDEA Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier Product Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplemental Data</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>GOVERNANCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Alliance Business-Development Managers</U>. Within
thirty (30)&nbsp;days following the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its business development alliance manager for each Program under this Agreement
(&#147;<U>Alliance Business-Development Manager</U>&#148;). The Alliance Business-Development Managers shall be there to coordinate any business related activities under this Agreement. Each Alliance Business-Development Manager shall attend all JSC
meetings and may bring any matter in relation to business regarding such Program to the attention of any committee if such Alliance Business-Development Manager reasonably believes that such matter warrants such attention. Each Party may replace an
Alliance Business-Development Manager which it appointed upon written notice to the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Alliance R&amp;D
Managers</U>. Within thirty (30)&nbsp;days following the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its alliance research and development manager for each Program under this
Agreement (&#147;<U>Alliance R&amp;D Manager</U>&#148;). With regard to Research and Development activities, the Alliance R&amp;D Managers shall serve as the primary contact points for their designated Programs between the Parties and shall be
primarily responsible for facilitating the flow of information, interaction and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
collaboration between the Parties and shall be responsible for ensuring that the governance procedures and rules set forth herein are complied with. Each Alliance R&amp;D Manager shall attend the
meetings of the JRDC and the JSC and may bring any matter in relation to such Program to the Research and Development management to the attention of any committee, if such Alliance R&amp;D Manager reasonably believes that such matter warrants such
attention. Each Party may replace an Alliance R&amp;D Manager it appointed upon written notice to the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3
<U>Project Directors</U>. Within thirty (30)&nbsp;days following the Effective Date each Party shall appoint (and notify the other Party of the identity of a representative to act as its project director for the Programs (&#147;<U>Project
Director</U>&#148;). The Project Director shall be responsible for the follow-up of the respective Research and Development activities under this Agreement for his/her designated Program on a regular basis. The Project Director shall attend the
meetings of the JRDC, and may bring any matter in relation to the project management to the attention of the JSC, if such Project Director reasonably believes that such matter warrants such attention. Each Party may replace its Project Director upon
written notice to the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 <U>Joint Executive Committee</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.1 <U>Composition</U>. Promptly after the Effective Date, the Parties shall establish a joint executive committee (the
&#147;<U>JEC</U>&#148;). The JEC shall be comprised of up to three (3)&nbsp;senior executives from each Party. Either Party may, from time to time, invite additional representatives or consultants to attend JEC meetings, subject to such
representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JEC meetings by its
representatives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.2 <U>Function and Powers of the JEC</U>. The JEC shall manage the overall collaboration between the
Parties, resource allocation and major changes to the collaboration requiring amendments to this Agreement and shall resolve disagreements that may arise at the JSC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.5 <U>Joint Steering Committee</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.1 <U>Composition</U>. Promptly after
the Effective Date, the Parties shall establish a joint steering committee (a &#147;<U>JSC</U>&#148;). The JSC shall be comprised of three (3)&nbsp;named representatives of Servier and three (3)&nbsp;named representatives of MacroGenics (or such
other number as the Parties may agree) as well as each Party&#146;s Alliance Business-Development Manager and Alliance R&amp;D Manager. As soon as practicable after the Effective Date (but in no event more than thirty (30)&nbsp;days after the
Effective Date), each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other
Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge. Either Party may, from time to time, invite additional representatives or consultants to attend JSC meetings, subject to such
representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JSC meetings by its
representatives. The JSC shall be co-chaired by a representative from each Party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.2 <U>Function and Powers of the JSC</U>. The JSC&#146;s responsibilities shall be
limited to matters regarding the Programs: (a)&nbsp;coordinating the activities of the Parties, including facilitating communications between the Parties with respect to the Development, Manufacture and Commercialization of Program DARTS and
Licensed Products; (b)&nbsp;providing a forum for discussion of the Development, Manufacture, and Commercialization of Licensed Products; (c)&nbsp;reviewing and approving each Research Plan and Global Development Plan and associated Development
Budget and any annual or interim updates and proposed amendments thereto; (d)&nbsp;reviewing and discussing Servier&#146;s Commercialization Plan and related activities with respect to Licensed Products throughout the Servier Territory and (if
applicable) the MacroGenics Territory, including pre-launch and go-to-market strategies; (e)&nbsp;directing and overseeing the JRDC and any operating subcommittee established by the JSC, on all significant issues that fall within the purview of such
committees; (f)&nbsp;attempting to resolve issues presented to it by, and disputes within, the other committees, including the JRDC and any of its subcommittees, in accordance with Section&nbsp;2.9; and (g)&nbsp;considering and acting upon such
other matters as specified in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.3 <U>Subcommittees</U>. The JSC may establish and disband such
subcommittees as deemed necessary by the JSC. Each such subcommittee shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its
representatives on written notice to the other Party or to send a substitute representative to any subcommittee meeting. Each Party&#146;s representatives and any substitute for a representative shall be bound by the obligations of confidentiality
set forth in ARTICLE 11. Except as expressly provided in this Agreement, no subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC for its designated Program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6 <U>Joint Research and Development Committee and Subcommittees. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.1 <U>Composition</U>. Promptly after the Effective Date, the Parties shall establish a joint research and development committee (the
&#147;<U>JRDC</U>&#148;). The JRDC shall be comprised of three (3)&nbsp;named representatives of Servier and three (3)&nbsp;named representatives of MacroGenics (or such other number as the Parties may agree) as well as each Party&#146;s Project
Director. As soon as practicable after the Effective Date (but in no event more than thirty (30)&nbsp;days after the Effective Date), each Party shall designate by written notice to the other Party its initial representatives on the JRDC. Each Party
may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. These representatives shall have appropriate technical credentials, experience and knowledge, and ongoing
familiarity with the Research and Development activities hereunder. Either Party may, from time to time, invite additional representatives or consultants to attend JRDC meetings, subject to such representative&#146;s and consultant&#146;s written
agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JRDC meetings by its representatives. The JRDC shall be co-chaired by a
representative from each Party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.2 <U>Function and Powers of the JRDC</U>. The JRDC&#146;s responsibilities shall be
limited to matters regarding the Programs and Licensed Programs and shall include the following activities for each Program or Licensed Program, as applicable: (a)&nbsp;during the Research Term, proposing the Research Plan for such Program,
proposing any changes or amendments to the Research Plan for approval by the JSC; (b)&nbsp;during the Research Term, reviewing and monitoring progress for all activities performed under the Research Plan and provide regular updates on the status of
the Option Trigger Data Package; (c)&nbsp;during the License Term, proposing the initial Global Development Plan, coordinating the activities of the Parties under and overseeing the implementation of the Global Development Plan; (d)&nbsp;during the
License Term, preparing annual and interim updates to the Global Development Plans; (e)&nbsp;during the Agreement Term, serving as a forum for and facilitating communications between the Parties with respect to the Research and Development of
Licensed Products, including any joint Development activities to be pursued by the Parties during the License Term; (f)&nbsp;during the License Term, monitoring and coordinating all regulatory actions, communications and submissions for Licensed
Products; (g)&nbsp;informal resolution of disagreements that may arise in the relation to the Parties activities under the Research Program and the Global Development Plan; and (h)&nbsp;considering and acting upon such other matters as specified in
this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7 <U>Co-Chairpersons</U>. Each Party shall designate one of its members of the JSC and JRDC, respectively,
as a co-chairperson (each, a &#147;<U>Co-Chairperson</U>&#148;) of such committee. The Co-Chairpersons shall have the following roles and responsibilities: (a)&nbsp;to call meetings of the relevant committee, send notice of each such meeting and
designate the time, date and place of each such meeting; (b)&nbsp;to convene or poll the members of the relevant committee by other permitted means; (c)&nbsp;to establish a reasonably detailed agenda, including identification of relevant supporting
information and materials to be discussed during such meeting, for each meeting of the relevant committee, subject to the right of any member of such committee to add additional agenda items at any meeting; and (d)&nbsp;to promptly draft and
finalize minutes of each meeting of such committee, for review and approval by members of such committee at the following meeting. Each Co-Chairperson shall sign and date the final minutes. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8 <U>Committee Meetings. Frequency</U>. The JRDC and each of the subcommittees shall each hold at least one (1)&nbsp;meeting per
Calendar Quarter at such times during such Calendar Quarter as the co-chairpersons elect to do so and the JSC and JEC shall hold at least one (1)&nbsp;meeting per Calendar Year as the co-chairpersons elect to do so. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8.1 <U>Quorum; Location</U>. Except where a Party fails to appoint a member or members to the JEC, JSC, JRDC or any subcommittee or
fails to participate in meetings of the JEC, JSC, JRDC or any subcommittee, meetings of the JEC, JSC, JRDC and subcommittee, respectively, shall be effective only if at least one (1)&nbsp;representative of each Party is present or participating. The
JEC, JSC, JRDC and subcommittee may meet either (a)&nbsp;in person at either Party&#146;s facilities or at such locations as the Parties may otherwise agree or (b)&nbsp;by audio or video </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
teleconference; <U>provided that</U> no less than one (1)&nbsp;meeting during each Calendar Year shall be conducted in person. Additional meetings of the JEC, JSC, JRDC and subcommittee may also
be held with the consent of each Party, or as required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings. Each Party shall be responsible for all of its own expenses incurred in
connection with participating in all such meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8.2 <U>Cooperation</U>. Each Party shall provide the JSC and JRDC such
information as required under each Research Plan or Global Development Plan, as applicable, or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under, as applicable,
each such Research Plan or Global Development Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9 <U>Decisions</U>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.1 <U>Initial Dispute Resolution Procedures</U>. Subject to the provisions of this Section&nbsp;2.9, actions to be taken by the JEC,
JSC, JRDC and subcommittees shall be taken only following a <B>***</B> <B>***</B>. If the JRDC or any subcommittee <B>***</B> on a matter before it for decision for a period in excess of <B>***</B>, the matter shall be referred to the JSC. If the
JSC fails to reach unanimous agreement on a matter before it for decision for a period in excess of <B>***</B>, the matter shall be referred to the JEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.9.2 <U>Conduct of Development during the Option Period</U>. Notwithstanding any other provision in this Agreement, unless otherwise agreed upon to the contrary by the Parties, ***. MacroGenics shall
reasonably consult with Servier regarding the conduct of preclinical and clinical studies and shall reasonably consider any input provided by Servier with respect thereto. For clarification purposes MacroGenics shall not have the ability to alter
the the specified information and data required for the Option Trigger Data Package set forth in Section&nbsp;1.63. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.3
<U>Final Decision-Making</U>. If the JEC fails to reach <B>***</B> on a matter before it for decision for a period in excess of <B>***</B>, during the License Term for a Licensed Program, <B>*** ***</B> any matter involving the Development or
Commercialization of Program DARTs and Licensed Products in the Field in the Servier Territory for such Licensed Program and the JEC representatives appointed by MacroGenics shall have the deciding vote on any matter involving the Development or
Commercialization of Program DARTs and Licensed Products in the Field in the MacroGenics Territory for such Licensed Program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.4 <U>Exceptions</U>. Notwithstanding the foregoing, neither Party shall exercise its right to finally resolve a dispute pursuant to
Section&nbsp;2.9.3: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) in a manner that excuses such Party from any of its obligations specifically enumerated under this
Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) in a manner that negates any consent rights or other rights specifically allocated to the other Party under
this Agreement; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) during the License Term, to increase Development Costs for the other Party for any
Global Clinical Trial for a given Calendar Year by more than <B>***</B> above the Initial Development Budget for such Global Clinical Trial; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) to resolve any dispute regarding whether a Party may conduct Development or Commercialization activities in the other Party&#146;s territory; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) to resolve any dispute regarding whether a milestone event set forth in Section&nbsp;9.3 has been achieved; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) in a manner that would require the other Party to perform any act that it reasonably believes to be inconsistent with any Law or any
approval, order, policy or guidelines of a Regulatory Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10 <U>Authority</U>. The JEC, JSC, JRDC and any
subcommittee shall have only the powers assigned expressly to it in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall
retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JEC, JSC, JRDC or subcommittee unless such delegation or vesting of rights is expressly provided
for in this Agreement or the Parties expressly so agree in writing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11 <U>Representatives</U>. For purposes of clarity, a
Party may appoint the same person to simultaneously serve as the Alliance Business Development Manager, Alliance R&amp;D Manager, and/or Project Director for a Program or multiple Programs for such Party and/or serve on multiple committees
established pursuant to this ARTICLE 2. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 3</B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Research Overview</U>. Pursuant to this Agreement and as further provided in this ARTICLE 3, MacroGenics and Servier shall conduct the research activities indicated in each Research Plan during
each Research Term for each Program (each a &#147;<U>Research Program</U>&#148;). The primary objective of each Research Program is to generate, create and/or obtain the data and documentation necessary to complete the Option Trigger Data Package
for such Program. Neither Party warrants that any Research Program shall achieve any of the research objectives contemplated in its Research Plan. At the end of the applicable Research Term, each Party&#146;s obligation to conduct such Research
Program shall cease unless the Parties mutually agree to extend its Research Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Conduct of the Research
Programs</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1 <U>Research Plan</U>. <B>***</B> after the Effective Date, the JRDC will prepare a Research Plan for each
Program to be submitted for approval by JSC. The Parties may mutually agree to specify in a Research Plan activities to be conducted by Servier to generate additional </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
pre-clinical and clinical data to be shared by both Parties (the &#147;<U>Supplemental Data</U>&#148;). Servier shall disclose to MacroGenics all Supplemental Data for a Research Program within
<B>***</B> after the completion of such activities and MacroGenics shall have the right to use such Supplemental Data in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products. For the <B>***</B> and the gpA33 DART
Program, <B>***</B>. Neither the availability and finalization of such Supplemental Data nor any modification to the Initial Phase 1 Clinical Trial that the Parties may agree upon shall in any way delay the timing of the delivery of the Option
Trigger Data Package to Servier in accordance with Section&nbsp;3.3.2. To the extent that any provision of a Research Plan conflicts or is inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2 <U>Diligence</U>. MacroGenics and Servier shall use Commercially Reasonable Efforts to conduct each Research Program in
a good scientific manner and in accordance with the applicable Research Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3 <U>Expenses</U>. Except as otherwise set
forth elsewhere in this Agreement, each Party shall bear its own costs and expenses of conducting the activities allocated to such Party under each Research Plan, including the costs of clinical supply of Program DARTs and Licensed Products.<U> </U>
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.4 <U>Reports</U>. MacroGenics and Servier shall provide written progress reports on the status of its Research and
Development activities under each Research Plan, including summaries of data generated in the applicable Research Program, at least *** in advance of each JRDC meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Evaluation of Option Trigger Data Package; Option Exercise. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.1
<U>Limited Evaluation License; Supply</U>. MacroGenics hereby grants Servier an exclusive, royalty and other fee-free license, with the right to sublicense only to Servier&#146;s Affiliates, under MacroGenics IP, to (a)&nbsp;conduct the activities,
if any, allocated to Servier under each Research Plan and (b)&nbsp;use the Option Trigger Data Package for each Research Program solely for purposes of evaluating Program DARTs to determine whether to exercise its Option for the Program that is
subject to such Option. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2 <U>Delivery of Option Trigger Data Package</U>. MacroGenics shall provide Servier with each
Option Trigger Data Package <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3 Option Exercise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) For each Program, Servier shall have an exclusive option to obtain an exclusive license under MacroGenics IP to Research, Develop and
Commercialize Program DARTs and Licensed Products from such Program in the Field in the Servier Territory (each an &#147;<U>Option</U>&#148;). Servier may exercise each such Option by providing MacroGenics written notice within <B>***</B> after the
receipt of the Option Trigger Data Package for the corresponding Program (each an &#147;<U>Option Period</U>&#148;). In the event Servier elects to exercise an Option, it shall, no later than </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the end of the last day of the Option Period for such Option, deliver to MacroGenics (i)&nbsp;written notice specifying that Servier has elected to exercise the Option, and (ii)&nbsp;payment of
the corresponding License Grant Fee. Provided Servier has properly exercised the Option in accordance with the preceding sentence, the later of the date of the written notice and receipt by MacroGenics of the License Grant Fee shall be the
&#147;<U>License Grant Date</U>&#148; of the resulting Licensed Program. The Research Term and Option Period will be deemed to have ended for such Program, and the License Term of such Licensed Program will be deemed to have commenced, on such
License Grant Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Upon the exercise by Servier of an Option in accordance with this Section&nbsp;3.3, the provisions
set forth in Sections 4.1, 4.2 and 4.3 of this Agreement shall constitute the terms and conditions of the license and sublicense rights granted by MacroGenics to Servier with respect to Licensed Products and the MacroGenics IP from the Licensed
Program that was licensed under such Option in the Field in the Servier Territory, and by Servier to MacroGenics with respect to Servier IP and Licensed Products from such Licensed Program in the Field in the MacroGenics Territory. During each
period commencing on the Effective Date and ending on the expiration of an Option Exercise Period, MacroGenics will not grant a license or other rights to any Third Party or take any other action that would prevent MacroGenics from being able to
grant to Servier the license set forth in Section&nbsp;4.1 for the Program that is subject to such Option. In the event Servier does not exercise the Option for a Program during the applicable Option Exercise Period, with regard to such Program
Servier (i)&nbsp;Servier&#146;s Option shall expire and all right and interest with respect to the Program DARTs, Licensed Products and MacroGenics IP for such Program shall revert to MacroGenics; (ii)&nbsp;Servier shall have no right to or interest
in such Program DARTs and Licensed Products; (iii)&nbsp;the license granted to Servier under Section&nbsp;3.3.1 shall terminate; (iv)&nbsp;the licenses and other rights granted under ARTICLE 4 shall have no force or effect; (v)&nbsp;Servier shall
and hereby does assign and transfer to MacroGenics all right, title and interest in and to the Supplemental Data; (vi)&nbsp;*** </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 4 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GRANT OF RIGHTS; EXCLUSIVITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>License Grant to Servier</U>. Subject to the terms of this Agreement, upon MacroGenics&#146; receipt of a License Grant Fee with respect to a Licensed Program, MacroGenics shall and hereby does
grant Servier (a)&nbsp;an exclusive, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under MacroGenics IP
and MacroGenics&#146; and its Affiliates&#146; interests in Joint IP, to Research, Develop, Manufacture and Commercialize, Program DARTs and Licensed Products from such Licensed Program in and for the Servier Territory in the Field; (b)&nbsp;an
exclusive, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under MacroGenics IP and MacroGenics&#146; and its Affiliates&#146; interests in Joint IP, to
Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed Products from such Licensed Program in the Field in and for the Servier Territory; and (c)&nbsp;a non-exclusive, royalty-bearing, <FONT
STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under MacroGenics IP and MacroGenics&#146; and its Affiliates&#146; interests in
Joint IP and Servier Collaboration IP, to Research, Develop and Manufacture Program DARTs and Licensed Products from such Licensed Program in the MacroGenics Territory for the sole purpose of using, offering for sale and selling such Licensed
Products in, and importing such Program DARTs and such Licensed Products into, the Servier Territory in the Field; <U>provided</U> <U>however</U>, that Servier shall not, directly or indirectly, conduct clinical trials or other clinical studies,
including any investigator initiated studies, in the MacroGenics Territory using Program DARTs or Licensed Products without the prior approval of the JRDC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>License Grant to MacroGenics</U>. Subject to the terms of this Agreement, upon MacroGenics&#146; receipt of a License Grant Fee with respect to a Licensed Program, Servier hereby grants
MacroGenics: (a)&nbsp;an exclusive, royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under Servier Collaboration
IP and Servier&#146;s and its Affiliates&#146; interest in Joint IP, to Research, Develop, Manufacture and Commercialize Program DARTs and Licensed Products from such Licensed Program in the Field in and for the MacroGenics Territory; (b)&nbsp;an
exclusive, royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under Servier Collaboration IP and Servier&#146;s
and its Affiliates&#146; interest in Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program DARTs and Licensed Products from such Licensed Program in the Field in and for the MacroGenics Territory; and
(c)&nbsp;a non-exclusive, royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under Servier Collaboration IP and
Servier&#146;s and its Affiliates&#146; interest in Joint IP, to Research, Develop and Manufacture Program DARTs and Licensed Products under the corresponding Licensed Program in the Servier Territory for the sole purpose of using, offering for sale
and selling Licensed Products in, and importing Program DARTs and Licensed Products from the corresponding Licensed Program into, the MacroGenics Territory in the Field; <U>provided</U> <U>however</U>, that MacroGenics shall not, directly or
indirectly, conduct clinical trials or other clinical studies, including any investigator initiated studies, in the Servier Territory using Program DARTs or Licensed Products without the prior approval of the JRDC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3 <U>Sublicenses</U>. Each Party shall have the right to grant sublicenses within the scope of the licenses under Section&nbsp;4.1 or
4.2, as applicable, solely to its Affiliates and to Third Parties that are conducting Research, Development, Manufacture and/or Commercialization activities with such Party or its Affiliates with respect to Program DARTs and Licensed Products;
<U>provided that</U> any sublicense granted to Third Party collaborators under this Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement, including
the confidentiality provisions of ARTICLE 11. If either Party grants a sublicense to a Third Party as permitted by this Section&nbsp;4.3, then such Party shall provide the other Party prompt written notice thereof and shall provide the other Party
with an executed copy of any such sublicense (redacted as necessary to protect confidential or commercially sensitive information). Except as otherwise agreed by the Parties in writing, each Party shall be jointly and severally responsible with its
sublicensees to the other Party for failure by its sublicensees to comply with this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4 <U>Subcontracting</U>. Subject to the terms of this Agreement, each Party shall have the
right to engage Affiliates, licensees, Sublicensees or Third Party subcontractors to perform activities ascribed to such Party, under this Agreement. Any Affiliate, licensee or subcontractor to be engaged by a Party to perform a Party&#146;s
obligations under this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to the subcontracted activity; <U>provided that</U> any Party engaging an Affiliate, licensee
or subcontractor hereunder shall remain principally responsible and obligated for such activities. In addition, each Party engaging a licensee, Sublicensee or subcontractor shall obtain Control of any and all Know-How, Patents or other intellectual
property rights created, discovered, invented, conceived or reduced to practice by such licensee, Sublicensee or subcontractor with respect to any Program DART or Licensed Product so that the other Party is not impeded from carrying out its rights
and responsibilities under this Agreement by such Know-How, Patents or other intellectual property rights. To the extent a Party cannot obtain assignment of, or an exclusive license to, all Know-How, Patents and other intellectual property rights
created, discovered, invented, conceived or reduced to practice by any licensee, Sublicensee or subcontractor engaged by such Party with respect to any Program DART or Licensed Product or in the performance of activities under this Agreement at the
time such Party initially enters into such arrangement with such licensee, Sublicensee or subcontractor, such Party shall bring such matter to the JSC for the prior approval of such arrangement and for the express approval by the JRDC of the
licensing terms and conditions with respect to such arrangement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5 <U>MacroGenics Third Party Agreements</U>. Servier
acknowledges and agrees that the rights, licenses and sublicenses granted by MacroGenics to Servier under this Agreement may be or are subject to the terms of the MacroGenics Third Party Agreements. Servier covenants to comply with, and to cause its
Affiliates and Sublicensees to comply with, the MacroGenics Third Party Agreements, and to take any action or provide any information reasonably requested by MacroGenics, to prevent any potential breach of any terms of such MacroGenics Third Party
Agreements. To the extent there is a conflict between the terms of any MacroGenics Third Party Agreement and the rights granted to Servier hereunder, the terms of such MacroGenics Third Party Agreement shall control solely with respect to the
Patents and Know-How owned or controlled by such Third Party licensor. MacroGenics shall not terminate or consent to the termination of the MacroGenics Third Party Agreement without Servier&#146;s prior reasonable consent if such termination would
materially adversely affect Servier&#146;s license granted hereunder; however, for clarity, MacroGenics may (a)&nbsp;terminate any MacroGenics Third Party Agreement by acquiring all of the relevant intellectual property licensed thereunder, in which
case Servier agrees to consent to such termination of such MacroGenics Third Party Agreement; and (b)&nbsp;terminate its obligation to make royalty and milestone payments by making a lump-sum payment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6 <U>Rights Retained by the Parties</U>. Any rights of MacroGenics or Servier, as the case may be, not expressly granted to the other
Party pursuant to this Agreement shall be retained by such Party. Notwithstanding the exclusive licenses granted to Servier pursuant to Section&nbsp;4.1, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics retains the right to practice under the MacroGenics IP and Joint IP to perform (and to sublicense Third Parties to perform) its obligations under this Agreement and any supply
agreement entered into in accordance with ARTICLE 7, including for the purpose of performing its activities in connection with clinical trials for Licensed Products and any related manufacture of Program DARTs and Licensed Products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7 <U>Section&nbsp;365(n) of the Bankruptcy Code</U>. All rights and licenses granted under or pursuant to any section of this Agreement
are and will otherwise be deemed to be for purposes of Section&nbsp;365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the &#147;<U>Bankruptcy Code</U>&#148;), licenses of rights to &#147;intellectual property&#148; as
defined in Section&nbsp;101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under
this Agreement, will retain and may fully exercise all of its rights and elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for &#147;intellectual property.&#148;
The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of applicable Law outside the United States, the other Party will be entitled to
a complete duplicate of (or complete access to, as appropriate) such intellectual property and all embodiments of such intellectual property, which, if not already in such Party&#146;s possession, will be promptly delivered to it upon such
Party&#146;s written request thereof. Any agreements supplemental hereto will be deemed to be &#147;agreements supplementary to&#148; this Agreement for purposes of Section&nbsp;365(n) of the Bankruptcy Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8 <U>Exclusivity</U>. For the period commencing with the Effective Date and ending on the <B>***</B> of the Effective Date (subject to
earlier termination pursuant to Article 14), other than with respect to the Development and Commercialization activities pursuant to this Agreement, neither Party nor its Affiliates shall, directly or indirectly, (a)&nbsp;initiate or conduct
clinical development for a Competing Product in each other&#146;s respective territory; or (b)&nbsp;Commercialize a Competing Product in the other Party&#146;s territory. During such <B>***</B>, a Third Party that acquires all of the outstanding
shares of a Party and has a Competing Product in Development at the time of such acquisition shall have the right to (i)&nbsp;continue any ongoing Clinical Trials it is conducting with such Competing Product; and (ii)&nbsp;initiate Clinical Trials
in an Indication for which such Third Party previously conducted a Clinical Trial with the Competing Product provided that under such scenario the provisions of section 4.9. below shall apply. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9 <U>Consequences of Development and Commercialization of Competing Products</U>. *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">***
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.10 <U>Right of First Negotiation for Independent Product</U>. If at any time during the Agreement Term MacroGenics or its Affiliates desires to enter into a Qualified Transaction, MacroGenics shall
notify Servier of such intent and propose to Servier to enter into negotiations with respect to the subject matter of such Qualified Transaction, identifying the applicable Independent Product(s) that is(are) proposed to be the subject of such
Qualified Transaction. Servier shall have <B>***</B> from receipt of such written notice to notify MacroGenics in writing as to whether Servier desires to negotiate for such rights, and if Servier so notifies MacroGenics that it does desire to
negotiate for such rights, Servier and MacroGenics shall have <B>***</B> from the date of such notification to negotiate and enter into a definitive agreement for such rights; provided that, if either Servier does not provide such written notice
within such <B>***</B> period or Servier and MacroGenics do not enter into a definitive agreement within such <B>***</B> period, MacroGenics shall be free to enter into negotiations and agreements with Third Parties relating to such Qualified
Transaction, provided however that if, within <B>***</B> after such negotiations with Servier terminate, MacroGenics should *** of such terms, and Servier shall have a period of <B>***</B> following receipt of the same to notify MacroGenics as to
whether Servier would be prepared to accept such terms (subject to execution of a mutually acceptable license agreement) in which case the Parties will use commercially reasonable efforts to conclude such license agreement within <B>***</B> after
Servier notifies MacroGenics of the same. If the Parties cannot conclude such license agreement or such <B>***</B>, the Parties agree that, MacroGenics shall be free to enter into negotiations and agreements with Third Party(ies) relating to such
Qualified Transaction during the remainder of the Agreement Term without further obligation to Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.11
<U>Diagnostics</U>. The Parties acknowledge and agree that each Party shall have the right to use Diagnostics in combination with Competing Products Researched, Developed or Commercialized by such Party. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 5 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEVELOPMENT DURING THE LICENSE TERM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Overview</U>. During each License Term, (a)&nbsp;Servier will, subject to the terms of this Agreement, be responsible for the Development of Licensed Products from the corresponding Licensed
Program in the Field for the Servier Territory, and (b)&nbsp;MacroGenics will remain responsible for Development of Licensed Products from the same Licensed Program in the Field in the MacroGenics Territory. While the Parties may choose, at their
sole discretion, to work together on particular projects, except as otherwise provided in this Agreement, the Parties will operate independently in their activities for their respective Development of Licensed Products, but will provide access to
certain information to the JRDC and to each other as expressly described in this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Servier Obligations</U>. Servier shall use Commercially Reasonable Efforts to Develop
Licensed Products from each Licensed Program in the Servier Territory. Servier shall be deemed to not have used Commercially Reasonable Efforts to Develop Licensed Products from a Licensed Program in the Servier Territory, and MacroGenics shall have
the right to terminate this Agreement in accordance with Section&nbsp;14.2, if at any point in time prior to the First Commercial Sale of a Licensed Product under such Licensed Program, Servier fails to undertake Development activities, with the
intention of rapidly advancing a Licensed Product under such Licensed Program toward registration (and not for the sole purpose of preserving rights hereunder) during at least the preceding ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Development Activities. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.3.1 <U>Global Development Plan</U>. During the License Term for each Licensed Program, the Development of Licensed Products under this Agreement under such Licensed Program shall be conducted pursuant
to a reasonably comprehensive written research and development plan (each, a &#147;<U>Global Development Plan</U>&#148;), which shall include a detailed budget for all Development Costs and Manufacturing Process Development Costs (each, a
&#147;<U>Development Budget</U>&#148;), and which shall include the resource allocations for the Parties based upon the general principle that the allocation shall endeavor to take advantage of the respective resources, capabilities and expertise of
MacroGenics and Servier, respectively. Within <B>***</B> after the License Grant Date, the JRDC shall prepare an initial draft of the Global Development Plan for approval by the JSC for such Licensed Program. Each Global Development Plan also shall
set forth the specific activities (including non-clinical and clinical studies to be conducted by each Party) and the estimated timeline for Development of Licensed Products licensed under such Licensed Program in order to obtain the data that the
Parties intend will be useful, by both Parties, to obtain Regulatory Approvals of the Licensed Products in both the United States, and the EU. Servier shall be the sponsor of all clinical studies conducted in the Servier Territory and shall be
solely responsible for Development activities and for obtaining Regulatory Approval for Licensed Products in the Servier Territory, and MacroGenics shall be the sponsor of all clinical studies conducted in the MacroGenics Territory and shall be
solely responsible for Development activities and for obtaining Regulatory Approval for Licensed Products in the MacroGenics Territory. The JRDC shall discuss which Party(ies) shall be the sponsor of all clinical studies conducted in countries of
both the MacroGenics Territory and the Servier Territory under such Licensed Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.2 <U>Details in Global Development
Plan</U>. Without limiting Section&nbsp;5.3.1, each Global Development Plan shall set forth, among other things, the following activities to be undertaken jointly or coordinated by Servier and MacroGenics: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) any non-clinical studies, toxicology studies, pharmaco-economic studies, process development studies and other clinical studies,
whether pre- or post-approval and whether sponsored or merely supported by Servier or MacroGenics, in each case, together with all protocols, endpoints and investigators conducting such studies, with respect to Licensed Products in the Servier
Territory and MacroGenics Territory; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) regulatory plans and other elements of obtaining and maintaining Regulatory Approvals in
the Field in each country in the Servier Territory and MacroGenics Territory; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) the timeline for completing such
Development activities; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the plans and timeline for preparing the necessary Regulatory Documentation and for obtaining
Regulatory Approval in the Field in the Servier Territory and MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4 <U>Updating and Amending Development
Plan and Development Budget; Additional Development Activities. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.1 <U>Development Plan Reviews and Updates</U>. On or
before January&nbsp;1st of each Calendar Year during the License Term, the JRDC shall review, update and approve each Global Development Plan (including the Development Budget contained therein) which shall cover the Development activities and
Manufacturing process development activities to be conducted with respect to the Development of Licensed Products subject to such Global Development Plan for use in the Field during the upcoming Calendar Year, and the JRDC shall, on at least a
quarterly basis, review and update, as appropriate, each then-current Global Development Plan (including the Development Budget) to reflect any changes, reprioritizations of, or additions to the Global Development Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2 <U>Amendments to Development Plan; New Development Collaboration Proposals. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Amendments to Development Plan</U>. From time to time during the License Term, either Party may submit to the JRDC any proposed
amendment of any Global Development Plan to amend the then-currently approved Development activities (such proposed amendment, a &#147;<U>Proposed Development Plan Amendment</U>&#148;) for the JRDC&#146;s review and approval by the JSC. Any Proposed
Development Plan Amendment shall contain, at a minimum, information supporting the rationale for the Proposed Development Plan Amendment related to Licensed Products from a scientific, regulatory and commercial standpoint, as well as an estimated
developmental critical path, and an estimate of the cost of such Development. The JRDC shall consider any submitted Proposed Development Plan Amendment during its next scheduled meeting. Once approved by the JSC (or otherwise resolved pursuant to
Section&nbsp;2.9), each amended Global Development Plan (including the Development Budget contained therein) shall become effective and supersede the previous Global Development Plan and Development Budget as of the date of such approval or at such
other time as decided by the JSC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>New Development Collaboration Proposals</U>. If either Party proposes to conduct new
Development activities in connection with the Development of a Licensed Product not included in the then approved Global Development Plan of the Licensed Program for such Licensed Product, including any proposal to collaborate to <B>***</B> (such
proposal, a &#147;<U>Development Collaboration Proposal</U>&#148;), such Party shall submit the Development Collaboration Proposal to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
other Party through the JRDC. Every Development Collaboration Proposal shall include a proposal to collaborate with the other Party for such Development activities so that, subject to the terms
of this Agreement, with respect to the Development activities underlying the Development Collaboration Proposal, Servier shall be able to Develop Licensed Products for Commercialization in the Field in the Servier Territory and MacroGenics shall be
able to Develop Licensed Products for Commercialization in the Field in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) In the event the
other Party approves a Development Collaboration Proposal and the Parties agree to collaborate to conduct the Development activities underlying the Development Collaboration Proposal with respect to Licensed Products, (A)&nbsp;the Global Development
Plan shall be amended to include such Development Collaboration Proposal and (B)&nbsp;each Party shall use Commercially Reasonable Efforts to perform the activities allocated to it under the approved Development Collaboration Proposal, and the
Parties shall share in the payment of Development Costs incurred in connection with such activities in accordance with Section&nbsp;5.5.1(a). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) In the event the other Party declines to participate in and share the funding of such activity (the &#147;<U>Buy-In Party</U>&#148;), the submitting Party may proceed with the activities described in
such Development Collaboration Proposal at its sole expense unless the other Party reasonably objects to the conduct of such activity as reasonably likely to result in a safety or public health issue that will have a material adverse effect in the
Development or Commercialization of Program DARTs and Licensed Product in its territory. Any disputes regarding whether an activity is reasonably likely to result in a safety or public health issue that will have a material adverse impact on the
Development and/or Commercialization of Program DARTs and Licensed Products in a Party&#146;s territory shall be referred to the JRDC for a determination and resolved in accordance with Section&nbsp;2.9; provided that neither Party shall have the
right to exercise its final decision making authority pursuant to Section&nbsp;2.9.3 with respect to such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Once
during each Calendar Quarter following the commencement of, and until the completion of, the activities described in the Development Collaboration Proposal, the Buy-In Party may request that the Party conducting such Development activity provide a
summary of the current status of such Development activity, the Development Costs incurred to date, any significant milestones achieved and any topline initial results of such Development activity. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) The Buy-In Party may obtain access to and use of the Excluded Data in accordance with the procedure described in this paragraph;
provided that the Buy-In Party shall be provided access to Safety Data, at no cost, in accordance with the SDEA Agreement. At any time following the commencement of the activities described in the Development Collaboration Proposal, the Buy-In Party
shall provide the other Party with written notice of its election to buy-in to such Development, and promptly thereafter the other Party shall provide the Buy-In Party with an invoice for <B>***</B> of the cumulative Development Costs as well as the
costs of clinical supply of the Program DART and/or Licensed Product used in connection with such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Development incurred by a Party in the generation of such data as of the date of the Buy-In Party&#146;s written request (the &#147;<U>Buy-in Amount</U>&#148;), which invoice the Buy-In Party
shall pay within <B>***</B> after receipt. Each Party shall thereafter share, in accordance with the allocation of costs set forth in Section&nbsp;5.5.1(a), in the Development Costs incurred after the date of the Buy-In Party&#146;s written request
in connection with such Development activities under such Development Collaboration Proposal and Global Development Plan shall be amended to include such Development activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.3 <U>Unilateral Development Costs and Manufacturing Process Development Costs. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Servier Territory Exclusive Development Activities</U>. Except as provided in Section&nbsp;5.5 and for Development activities
conducted by a Party at its own expense pursuant to Section&nbsp;5.4.2(b)(ii), Servier shall be responsible for <B>***</B> of all Development Costs (whether incurred by Servier or MacroGenics (if the activities and their cost are agreed to in
advance in writing by Servier) or their respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the primary purpose of obtaining or maintaining Regulatory Approval for
Licensed Products in the Field in any country or other regulatory jurisdiction in the Servier Territory. On a Licensed Program-by-Licensed Program basis, Servier shall disclose to MacroGenics a summary of efficacy results and detailed safety
information Controlled by Servier and generated in the course of such Development activities for each Licensed Program within <B>***</B> after the completion of such activities, subject to the pharmacovigilence provision under Section&nbsp;6.5.
MacroGenics may obtain access to and use Servier&#146;s data (other than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive development activities if MacroGenics provides Servier
with written notice of its election to buy-in such Development, and promptly thereafter Servier shall provide MacroGenics with an invoice for <B>***</B> of the cumulative Development Costs as well as the costs <B>***</B> in connection with such
Development incurred by Servier in the generation of such data as of the date of MacroGenics written request, which invoice MacroGenics shall pay within *** after receipt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <U>MacroGenics Territory Exclusive Development Activities</U>. Except as provided in Section&nbsp;5.5 and for Development activities conducted by a Party at its own expense pursuant to
Section&nbsp;5.4.2(b)(ii), MacroGenics shall be responsible for <B>***</B> of all Development Costs (whether incurred by Servier (if the activities and their costs are agreed to in advance in writing by MacroGenics) or MacroGenics or their
respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products in the Field in any
country or other regulatory jurisdiction in the MacroGenics Territory. On a Licensed Program-by-Licensed Program basis, MacroGenics shall disclose to Servier a summary of efficacy results and detailed safety information Controlled by Servier and
generated in the course of such Development activities for each Licensed Program within <B>***</B> after the completion of such activities, subject to the pharmacovigilence provision under Section&nbsp;6.5. Servier may obtain access to and use
MacroGenics&#146; data (other than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive Development activities if Servier </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
provides MacroGenics with written notice of its election to buy-in such Development, and promptly thereafter MacroGenics shall provide Servier with an invoice for *** of the cumulative
Development Costs as well as the costs *** in connection with such Development incurred by MacroGenics in the generation of such data as of the date of Servier written request, which invoice Servier shall pay within *** after receipt. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Servier Phase 2 Clinical Trial Funding</U>. For each Global Development Plan, Servier shall reimburse MacroGenics for up to the
first *** of Development Costs incurred by MacroGenics in conducting or participating in Phase 2 Clinical Trials for Licensed Products included in such Global Development Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Manufacturing Process Development Costs</U>. Servier and MacroGenics shall each be responsible for <B>***</B> of each
Manufacturing Process Development Cost provided the activity which resulted in such cost was conducted under a Global Development Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.5 <U>Development Activities. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.1 Except for Development activities
conducted by a Party at its own expense pursuant to Section&nbsp;5.4.2(b)(ii), with respect to any Development activities conducted for the primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products both in the Servier
Territory and in the MacroGenics Territory (including Development activities with respect to which a Party has paid the Buy-in Amount in accordance with Section&nbsp;5.4.2(b)(iv)) pursuant to the Development Plan: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) subject to Section&nbsp;5.5.2, Servier shall be responsible for <B>***</B> and MacroGenics shall be responsible for <B>***</B> of all
Development Costs as well as the costs of clinical supply of the Program DART and/or Licensed Product used in connection with such Development (in each case, whether incurred by Servier or MacroGenics or their respective Affiliates). For purposes of
clarity, MacroGenics may seek reimbursement from Servier under Section&nbsp;5.4.3(c) to apply to Development Costs for which MacroGenics is responsible under this Section&nbsp;5.5.1(a) to the extent such Development Costs are for Phase 2 Clinical
Trials; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) On a Licensed Program by Licensed Program basis each Party shall disclose to the other Party all clinical data
and related Regulatory Documentation Controlled by such Party and generated in the course of such Manufacturing process development activities and Development activities for each Licensed Program within <B>***</B>; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) each Party shall have the right to use all clinical data and related Regulatory Documentation Controlled by either Party and
generated in the course of such Manufacturing process development activities and Development activities in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products in the Field in such Party&#146;s territory, in
accordance with the terms of this Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) each Party hereby grants to the other Party a Right of Reference or Use
to any and all such Regulatory Documentation with respect to Licensed Products in the Field in the other Party&#146;s territory, and agrees to sign, and cause its Affiliates to sign, any instruments reasonably requested by such other Party in order
to effect such grant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2 <U>Development Costs Budget and Timeline Overruns. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Budget Overruns</U>. With respect to any Development Costs which, pursuant to this Agreement and/or a Global Development Plan or
an approved Development Collaboration Proposal, are meant to be allocated between the Parties (rather than one Party being solely responsible for such Development Costs), each Party shall promptly inform the other Party upon determining that it is
likely to exceed the budget amounts set forth in the annual Development Budget for the activities such Party is responsible for under the applicable Global Development Plan. To the extent that a Party (or its Affiliates or Sublicensees) incurs
Development Costs for the activities such Party is responsible for under a Global Development Plan for a particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such activity in the initial
Development Budget for that Global Development Plan that includes such activity (the &#147;<U>Initial Development Budget</U>&#148;) by <B>***</B> or less (a &#147;<U>De Minimis Overage Amount</U>&#148;), then such De Minimis Overage Amount shall
automatically be included in such Development Budget for such year. However, to the extent that a Party (or its Affiliates or Sublicensees) incurs Development Costs for the activities such Party is responsible for under a Development Plan for a
particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such activity in the Initial Development Budget by more than <B>***</B>, the &#147;<U>Excess Overage Amount</U>&#148;), the Party that has
so exceeded its budget shall provide to the JRDC a full explanation for so exceeding its budget and such Excess Overage Amount shall only be included in such Development Budget to the extent that the JRDC agrees to allow some or all of the Excess
Overage Amount to be included in such Development Budget as it considers equitable under the circumstances. To the extent that the JRDC does not agree to treat the Excess Overage Amount as Development Costs, the Party that has exceeded its budget
shall be solely responsible for the Excess Overage Amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Timeline Overruns</U>. Each Party shall promptly inform the
other Party upon determining that it is likely to miss a Development date set forth in a Global Development Plan. To the extent that a Party (or its Affiliates) misses such a date by <B>***</B> or more, the Party that has experienced such
Development timeline failure shall provide to the JRDC a full explanation for such Development timeline failure. Such notification shall not serve to excuse a Party from its diligence or other obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Reconciliation</U>. Within <B>***</B> following the end of each Calendar Quarter beginning with the License Grant Date, each Party
shall prepare and deliver to the other Party on a Licensed Program by Licensed Program basis a quarterly report detailing its Development Costs and Manufacturing Process Development Costs incurred during such period, with each Party reporting on all
Development Costs incurred with respect to Development Collaboration Proposals. Each Party shall submit any additional information reasonably requested by the other Party related to the Development Costs and Manufacturing Process Development Costs
included in its report within <B>***</B> of its receipt of such request. Within <B>***</B> after the receipt of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
report delivered by Servier pursuant to this Section&nbsp;5.5.2(c), MacroGenics shall prepare and deliver to Servier a composite report that (i)&nbsp;summarizes the Development Costs and
Manufacturing Process Development Costs incurred by each Party for such Calendar Quarter; (ii)&nbsp;applies the percentage of such costs for which each Party is responsible for the total Development Costs and Manufacturing Process Development Costs
attributable to the Development and Manufacturing activities for such Calendar Quarter pursuant to Sections 5.4.3 and 5.5.1; and (iii)&nbsp;computes the amount due to MacroGenics or Servier, as applicable, for such Calendar Quarter in order for the
Parties to share the total Development Costs and Manufacturing Process Development Costs for such quarter based on the Development Plan and the principles set forth in Sections 5.4.3 and 5.5.1 (each, a &#147;<U>Reconciliation Payment</U>&#148;). The
Party to whom a Reconciliation Payment is due shall issue an invoice to the other Party for the Reconciliation Payment, and such other Party shall pay all undisputed amounts within <B>***</B> after its receipt of the invoice. Each Party shall have
the right to audit the records of the other Party with respect to any Development Costs and Manufacturing Process Development Costs included in such reports, in accordance with Section&nbsp;9.10. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6 <U>Exchange of Data</U>. During the License Term, the following shall apply: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.1 <U>Initial Exchange of Data</U>. Promptly after each License Grant Date, MacroGenics shall transfer to Servier the MacroGenics
Know-How related to Program DARTs and Licensed Products (other than the MacroGenics Know-How related directly and solely to Manufacturing) that was licensed to Servier on such License Grant Date. Such transfer shall occur in a manner and following a
reasonable schedule to be established by the JSC. MacroGenics shall provide Servier with copies of relevant material, information, reports and data, including pre-clinical data, clinical data, and any data that has been provided to Regulatory
Authorities for the purpose of obtaining Regulatory Approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.2 <U>Ongoing Exchange of Data</U>. During each License
Term, except as provided in Section&nbsp;5.4.2(b)(iv) with respect to Excluded Data, each Party shall provide to the other Party (a)&nbsp;all Know-How Controlled by such Party that is specified in the applicable Global Development Plan to the extent
necessary or useful for the Development or Commercialization of Program DARTs or Licensed Products under such Global Development Plan in the other Party&#146;s territory, and (b)&nbsp;any Know-How Controlled by such Party that is not specified in
such Global Development Plan that such Party reasonably believes to be necessary or useful for the Development or Commercialization of Program DARTs or Licensed Products that were licensed under the Licensed Program for such Global Development Plan
in the other Party&#146;s territory, in a timely fashion and as promptly as possible for use by such other Party in accordance with this Section&nbsp;5.6.2. Servier shall only use and disclose to Third Parties such MacroGenics Know-How as may be
necessary or useful for Development and Commercialization of Program DARTs and/or Licensed Products in the Servier Territory; or as may otherwise be agreed by MacroGenics and Servier. Servier may not use any MacroGenics Know-How (or permit any Third
Party to use any MacroGenics Know-How) outside the Servier Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed by MacroGenics and Servier (including as provided in Sections 4.1 and 4.2). MacroGenics
shall not use any Servier Know-How (or permit </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any Third Party to use any Servier Know-How) outside the MacroGenics Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed by MacroGenics and
Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.3 <U>Use</U>. All preclinical, non-clinical, analytical, manufacturing, and clinical data and associated reports
disclosed by one Party to the other under this Agreement may be used by the receiving Party subject to the terms of this Agreement solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in its respective territory.
Each Party shall have the right to share any and all such data and other regulatory materials received from the other Party with its Affiliates and any Third Party sublicensees or licensees in its respective territory solely for the purpose of
Developing, Manufacturing and Commercializing Licensed Products in its respective territory. Access to and use of such data and regulatory materials are given by each Party to the other Party without cost (except as otherwise provided herein) on an
&#147;as is&#148; basis without any warranty of any kind. Each receiving Party accepts all risk and liability in relation to the use of the data and regulatory materials received from the other Party and shall indemnify and hold harmless the Party
providing such data and regulatory materials from any Third Party&#146;s claim(s) based upon such data and regulatory materials as provided in ARTICLE 13. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.6.4 <U>Reports</U>. In addition to information and reports required elsewhere in this Agreement, each Party shall provide the other Party and the JRDC with a written annual report summarizing the major
activities performed by it under each Global Development Plan during the previous year, conduct of non-clinical activities and clinical trials, information regarding the status of Regulatory Approvals. The other Party shall have the opportunity to
reasonably seek further explanation or clarification of matters covered in such reports and to provide observations and suggestions to the disclosing Party regarding the subject matter thereof, and the disclosing Party shall provide such explanation
or clarification and shall consider such observations and suggestions in good faith. Furthermore, if after receiving such a report the receiving Party wishes to meet with the disclosing Party to discuss such report, the disclosing Party shall meet
with the receiving Party at a site reasonably requested by the receiving Party within <B>***</B> after the disclosing Party&#146;s requests such meeting. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 6 </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REGULATORY MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 6 shall apply during the License Term. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1 <U>Servier Regulatory Responsibility. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1.1 During the License Term, Servier shall own and be responsible for preparing, filing and maintaining all Regulatory Documentation and Regulatory Approvals that are required for the Development
(unless otherwise agreed by the JRDC on the basis of Section&nbsp;4.2), Manufacture or Commercialization of the Program DARTs or Licensed Products in the Field in the Servier Territory and Servier shall otherwise be responsible for and have sole
authority as to all interactions with Regulatory Authorities in the Servier Territory. Servier shall comply with all applicable Laws in the Servier Territory, including local regulations and ICH guidelines. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.2 Servier hereby grants to MacroGenics a Right of Reference or Use to any Regulatory
Documentation in the Servier Territory Controlled by Servier for use by MacroGenics in the MacroGenics Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by
MacroGenics in order to further effect such grant. Servier shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. Servier shall also permit MacroGenics, upon reasonable notice, during regular business hours, to
audit any such Regulatory Documentation; <U>provided</U> <U>that</U>, MacroGenics shall limit such audits by MacroGenics to a moderate frequency reasonably necessary in order for MacroGenics to perform the Development and Commercialization of the
Program DARTs and Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>MacroGenics Regulatory Responsibility. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.1 MacroGenics shall own and be responsible for preparing, filing and maintaining all Regulatory Documentation and Regulatory
Approvals that are required for the Development (unless otherwise agreed by the JRDC on the basis of Section&nbsp;4.1), or Commercialization of Program DARTs or Licensed Products in the Field in the MacroGenics Territory and MacroGenics shall
otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the MacroGenics Territory. MacroGenics shall comply with all applicable Laws in the MacroGenics Territory, including local regulations and ICH
guidelines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.2 MacroGenics hereby grants to Servier a Right of Reference or Use to any Regulatory Documentation in the
MacroGenics Territory Controlled by MacroGenics for use by Servier in the Servier Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by Servier in order to
further effect such grant. MacroGenics shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. MacroGenics shall also permit Servier, upon reasonable notice, during regular business hours, to audit any such
Regulatory Documentation; <U>provided</U> <U>that</U>, Servier shall limit such audits by Servier to a moderate frequency reasonably necessary in order for Servier to perform the Development and Commercialization of the Program DARTs and Licensed
Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Communications with Regulatory Authorities. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.1 For purposes of this Article 6.3, &#147;material&#148; shall mean any <B>***</B>. Servier shall be responsible for all submissions
to, and communications and interactions with, Regulatory Authorities in the Servier Territory with respect to Program DARTs and Licensed Products (unless otherwise agreed by the JRDC on the basis of Section&nbsp;4.2), and MacroGenics shall be
responsible for submissions to, and communications and interactions with, Regulatory Authorities in the MacroGenics Territory with respect to Program DARTs and Licensed Products (unless otherwise agreed by the JRDC on the basis of Section&nbsp;4.1).
In connection therewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) On a Licensed Program by Licensed Program basis Servier shall keep MacroGenics reasonably
informed regarding Servier&#146;s (or its Affiliate&#146;s or Sublicensee&#146;s) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
regulatory strategy, planned regulatory submissions and material communications with the Regulatory Authorities in the Servier Territory with respect to the Program DARTs and Licensed Products
for each Licensed Program, including any material changes to such strategy, submissions or communications. Servier shall provide MacroGenics with copies of material regulatory submissions to, and material communications with the *** relating to the
Program DARTs and Licensed Products. To the extent permitted by Regulatory Authorities, MacroGenics shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or their agents, as well as
participate in internal meetings or discussions of Servier occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to Servier&#146;s materials prepared for such meetings. MacroGenics shall also
have the right to review and comment upon any correspondence with the *** or their agents related to such meetings. Servier shall provide MacroGenics regularly prepared minutes of material meetings with the *** regarding Program DARTs and Licensed
Products in the Field in the Servier Territory and available material teleconference reports with the *** pertaining to Program DARTs and Licensed Products in the Field in the Servier Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) On a Licensed Program by Licensed Program basis MacroGenics shall keep Servier reasonably informed regarding MacroGenics&#146; (or
its Affiliate&#146;s or Sublicensee&#146;s) regulatory strategy, planned regulatory submissions and material communications with the *** with respect to the Program DARTs and Licensed Products for each Licensed Program, including any material
changes to such strategy, submissions or communications. MacroGenics shall provide Servier with copies of material regulatory submissions to, and material communications with the *** relating to the Program DARTs and Licensed Products. To the extent
permitted by Regulatory Authorities, Servier shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or its agents, as well as participate in internal meetings or discussions of MacroGenics
occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to MacroGenics&#146; materials prepared for such meetings. Servier shall also have the right to review and comment upon any
correspondence with the *** or its agents related to such meetings. MacroGenics shall provide Servier regularly prepared minutes of material meetings with the *** regarding Licensed Products in the Field in the MacroGenics Territory and available
material teleconference reports with the *** pertaining to Licensed Products in the Field in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.2
If either Party or its Affiliates or subcontractors (each, an &#147;<U>Inspected Party</U>&#148;) are to be inspected by a Government Authority regarding the development, manufacture, registration or commercialization of a Licensed Product, the
Inspected Party shall promptly notify the other Party of the inspection in writing as soon as reasonably practicable, and in advance, if any such inspection is a scheduled inspection. The Inspected Party shall, where practicable, permit
representatives of the other Party to participate as observers with respect to such inspection, and shall provide the other Party with a written report of any such inspection, noting with specificity any records or documents reviewed by the
regulatory inspector, and including copies of any FDA 483s (or their non-U.S. equivalent) or written communications provided by or to any Government Authority relating to such inspection. The Inspected Party will use Commercially Reasonable Efforts
to provide an opportunity for the other Party to assist in responding to any issues or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
concerns relating to such inspections, and shall provide copies of all communications to and from any Government Authority relating thereto to the other Party. The Parties shall cooperate in good
faith and otherwise mutually support any regulatory inspections of facilities, clinical sites, contract manufacturers or the like with respect to Licensed Products, including by using Commercially Reasonable Efforts to make available such
facilities, documents, information and/or personnel as are reasonably necessary or useful for such regulatory inspections by a Government Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Product Withdrawals and Recalls</U>. If any Regulatory Authority (a)&nbsp;threatens, initiates or advises any action to remove any Licensed Product from the market in any country of the world, or
(b)&nbsp;requires or advises either Party or such Party&#146;s Affiliates or sublicensees to distribute a &#147;Dear Doctor&#148; letter or its equivalent regarding use of any Licensed Product in any country of the world, then Servier (if such
action is in the Servier Territory) or MacroGenics (if such action is in the MacroGenics Territory), as applicable, shall notify the other Party of such event within <B>***</B> (or sooner if required by applicable Law) after such Party becomes aware
of the action, threat, advice or requirement (as applicable). The JRDC will discuss and attempt to agree upon whether to recall or withdraw such Licensed Product; provided, however, that if the Parties fail to agree within an appropriate time period
or if the matter involves a safety issue that, in order to protect patient safety, does not allow for sufficient time for a discussion at the JRDC level, Servier shall decide whether to recall or withdraw such Licensed Product in the Servier
Territory and shall undertake any such recall or withdrawal in the Servier Territory at its own cost and expense, and MacroGenics shall decide whether to recall or withdraw such Licensed Product in the MacroGenics Territory and shall undertake any
such recall or withdrawal in the MacroGenics Territory at its own cost and expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5 <U>Pharmacovigilance; Safety Data
Reporting. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5.1 <U>Pharmacovigilance</U>. <B>***</B> after each License Grant Date the Parties shall negotiate in good
faith, with respect to Licensed Products under the applicable Licensed Program, a safety data exchange agreement, governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experience, Licensed
Product quality and Licensed Product complaints, sufficient to permit each Party to comply with its legal obligations (the &#147;<U>SDEA Agreement</U>&#148;). The SDEA Agreement will be promptly updated if required by changes in legal requirements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.6 <U>Safety Data Reporting. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Each Party shall keep the other Party informed about any adverse drug reactions such Party becomes aware or is informed about regarding the use of a Licensed Product. As between the Parties, Servier
shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in countries in the Servier Territory, and MacroGenics shall be responsible for reporting all adverse drug reactions/experiences to
the appropriate regulatory authorities in the MacroGenics Territory, in accordance with the appropriate laws and regulations of the relevant countries and authorities. Servier shall ensure that its Affiliates and Sublicensees comply with such
reporting obligations in the Servier Territory and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics shall ensure that its Affiliates and sublicensees (other than Servier and its Sublicensees) comply with such reporting obligations in the MacroGenics Territory. These reporting
obligations shall apply to other adverse events as described in the SDEA Agreement, including adverse events occurring from product overdose or from product withdrawal, as well as any toxicity, sensitivity, failure of expected pharmacological
action, or laboratory abnormality which is, or is thought by the reporter, to be serious or associated with relevant clinical signs or symptoms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) For each Research Program and Global Development Plan each Party will designate a pharmacovigilance liaison to be responsible for communicating with the other Party regarding the reporting of adverse
drug reactions/experiences. Each Party (the &#147;<U>Notifying Party</U>&#148;) shall notify the other Party in writing of all information coming to the Notifying Party&#146;s attention, regardless of the origin of such information, and including
such information coming to its attention through clinical and non-clinical sources (including journal publications and other media), regarding adverse drug experiences associated with a Licensed Product, whether in the Servier Territory or in the
MacroGenics Territory. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 7 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MANUFACTURING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 7 shall apply during the
License Term for each Licensed Program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Transfer of MacroGenics Manufacturing Know-How. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.1 For each Licensed Program, at Servier&#146;s request and sole expense, and on a schedule and a product comparability plan agreed
upon by the Parties, MacroGenics shall disclose (and provide copies, as applicable) to either Servier or the Third Party manufacturer that is mutually acceptable to both Parties, all MacroGenics Know-How necessary or useful to enable Servier or such
Third Party manufacturer (as appropriate) <B>***</B> for such Licensed Program to Manufacture Licensed Product based on a manufacturing process ***. For clarity, nothing in this Section&nbsp;7.1 with respect to MacroGenics&#146; obligation to
transfer MacroGenics Know-How to Servier shall limit MacroGenics&#146; right to use any such MacroGenics Know-How to fulfill MacroGenics&#146; obligations to Manufacture and supply Licensed Product to Servier under this Agreement or the Supply
Agreement. In addition, MacroGenics shall, at Servier&#146;s sole expense, make available to Servier, on a reasonable consultation basis, advice of its technical personnel as may reasonably be requested by Servier in connection with such transfer of
MacroGenics Know-How. MacroGenics shall thereafter during the Agreement Term, continue to promptly and regularly disclose any material new MacroGenics Know-How related to Manufacturing Program DARTs and Licensed Products to Servier or to the Third
Party manufacturer mentioned above at Servier&#146;s cost. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.2 Servier and/or its Third Party manufacturer shall use the
MacroGenics Know-How transferred under Section&nbsp;7.1.1 solely for the purpose of Manufacturing Program DARTs and finished Licensed Products in accordance with the terms and conditions of this Agreement, and for no other purpose. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.3 Servier acknowledges and agrees that MacroGenics may condition any of its agreement to
transfer any MacroGenics Know-How to a Third Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and MacroGenics that contains terms substantially equivalent to those of ARTICLE 11. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Supply Agreements. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.2.1 <U>Clinical Supply Agreement</U>. For each Program, the Parties shall enter into good faith negotiations regarding the terms of a clinical supply agreement, pursuant to which MacroGenics shall
provide clinical supply of Program DARTs and/or Licensed Products from such Program for (a)&nbsp;Phase 1 Clinical Trials and the first two (2)&nbsp;Phase 2 Clinical Trials of Licensed Products to be conducted by Servier and its Affiliates and
Sublicensees and (b)&nbsp;at MacroGenics&#146; option, Clinical Trials of Licensed Products conducted by Servier and its Affiliates and Sublicensees <B>***</B> of Licensed Products to be conducted by Servier and its Affiliates and Sublicensees (the
&#147;<U>Clinical Supply Agreement</U>&#148;). The cost for such supply of Program DARTs and/or Licensed Products for Clinical Trials shall be equal to MacroGenics&#146; Fully Burdened Manufacturing Cost; <B>***</B>. The Fully Burdened Manufacturing
Cost for supply of Program DARTs and/or Licensed Products for clinical trials used by Servier in connection with the Development of a Program DARTs and/or Licensed Products outside a Global Development Plan shall be invoiced by MacroGenics on a
quarterly basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.2 <U>Commercial Supply Agreement</U>. Following each License Grant Date, if requested by Servier, the
Parties shall enter into good faith negotiations regarding the terms of a quality and supply agreement, pursuant to which MacroGenics shall provide commercial supply of Program DARTs and/or Licensed Products licensed under such Licensed Program to
Servier and its Affiliates and Sublicensees (the &#147;<U>Commercial Supply Agreement</U>&#148;). </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 8 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>COMMERCIALIZATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 8 shall apply during the License Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1
<U>Overview</U>. Servier shall have sole control and responsibility for the Commercialization of Licensed Products in the Servier Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in the
Servier Territory. MacroGenics shall have sole control and responsibility for the Commercialization of Licensed Products in the MacroGenics Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in
the MacroGenics Territory. The Party with responsibility for Commercialization in a territory and field shall be referred to as the &#147;<U>Commercializing Party</U>&#148; for such territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Sales and Distribution</U>. It is understood that as between the Parties, the
Commercializing Party shall be solely responsible for handling all returns, order processing, invoicing and collection, distribution, and receivables for Licensed Products in the applicable territory and indication. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3 <U>Ex-Territory Sales</U>. Subject to applicable Law, neither Party shall engage in any advertising or promotional activities
relating to Licensed Product directed primarily to customers or other buyers or users of Licensed Product located outside its territory or accept orders for Licensed Products from or sell Licensed Products into such other Party&#146;s territory for
its own account or for the Commercializing Party&#146;s account, and if such other Party receives any order for Licensed Products in the Commercializing Party&#146;s territory, it shall refer such orders to the Commercializing Party for acceptance
or rejection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4 <U>Commercialization Plan for Licensed Territory</U>. Servier shall pursue
Commercialization of Licensed Products in the Servier Territory, in accordance with Commercially Reasonable Efforts. Servier shall deliver an initial Commercialization plan to MacroGenics no later than <B>***</B> prior to the anticipated date of the
first filing of the first BLA for a Licensed Product in the Servier Territory (the &#147;<U>Commercialization Plan</U>&#148;). After the establishment of the initial Commercialization Plan, Servier shall prepare updates and amendments to such
Commercialization Plan at least annually and deliver such updated Commercialization Plan to MacroGenics no later than March&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each Calendar Year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.5 <U>Trademarks</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.1 <U>Generally</U>. Servier and its Affiliates shall
select their own trademarks under which they will market Licensed Products (<U>provided</U> <U>that</U> no such trademark shall contain the word &#147;MacroGenics&#148;) and shall own such trademarks. MacroGenics and its Affiliates shall select
their own trademarks under which they will market Licensed Products (<U>provided</U> <U>that</U> no such trademark shall contain the word &#147;Servier&#148; or &#147;Les Laboratoires Servier&#148;) and shall own such trademarks. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.2 <U>Acknowledgement</U>. Servier shall use, in connection with all packaging, literature, labels and other printed matters, to the
extent required by Law, and where reasonably practicable in light of space limitations, an expression to the effect that the Licensed Products were developed under license from MacroGenics, together with the MacroGenics logo. The provisions of this
Section&nbsp;8.5.2 shall not apply to primary packaging of the Licensed Products. Primary packaging shall mean packaging that is in direct contact with the Licensed Products or the Licensed Products themselves, including vials, blister packs,
tablets and capsules.<B> </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.3 <U>Housemarks</U>. Neither Party shall, and shall ensure that its Affiliates and
sublicensees will not, make any use of the trademarks or house marks of the other Party or its Affiliates or licensees (including their corporate names) or any trademark confusingly similar thereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6 <U>Commercial Diligence</U>. During each License Term, Servier shall use Commercially
Reasonable Efforts to Commercialize Licensed Products that were licensed under the applicable Licensed Program throughout the Servier Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.7 <U>Standards of Conduct</U>. Each Party shall in all respects comply with all applicable Laws and applicable guidelines concerning the advertising, sales and marketing of prescription drug products in
Commercializing Products under this Agreement, including any applicable local anti-bribery laws. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 9 </B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PAYMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Option Grant Fee</U>. In consideration for the Options as granted by MacroGenics to Servier hereunder and to review the Option
Trigger Data Packages, Servier shall pay MacroGenics a non-refundable, non-creditable payment of Twenty Million Dollars ($20,000,000) (the &#147;<U>Option Grant Fee</U>&#148;) within *** after the Effective Date and the date of receipt of the
corresponding invoice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>License Grant Fees</U>. Upon exercise of an Option and *** after the date of receipt of the
corresponding invoice, Servier shall pay MacroGenics a *** payment (the &#147;<U>License Grant Fee</U>&#148;) of </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Fifteen
Million Dollars ($15,000,000) for exercise of the Option for the CD123 Program; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) *** for exercise of the Option for the
A33 Program; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) *** for exercise of the Option for the <B>***</B> Program. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>Development and Regulatory Milestones. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.3.1 <U>IND Approval/Acceptance Milestones</U>. For each Program or Licensed Program, Servier shall pay to MacroGenics the non-refundable, non-creditable amount of Five Million Dollars ($5,000,000) upon
approval or acceptance of the first IND filed with the FDA (or corresponding Regulatory Authority in the EU) for such Program or Licensed Program (each an &#147;<U>IND Approval Milestone</U>&#148;), within <B>***</B> following receipt of the
corresponding invoice. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.2 <U>License Term Development and Regulatory Milestones</U>. During the License Term for
each Licensed Program, for each milestone set forth in this Section&nbsp;9.3.2 achieved in such Licensed Program, Servier shall pay, depending on the Licensed Program, the corresponding *** amount indicated for that milestone for the first instance
of its achievement: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="31%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">For each of the ***</FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1">Licensed Program and gpA33</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">Licensed Program</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1">For the CD123</FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1">Licensed Program</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii)&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(viii)&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In no event shall the total of the amounts paid under this Section&nbsp;9.3.2 for the *** Licensed
Program and gpA33 Licensed Program exceed ***, or exceed *** for the CD 123 Licensed Program, and exceed *** in the aggregate for all of the Licensed Programs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.3.3 <U>Milestone Payments</U>. Servier shall make the milestone payments required by Section&nbsp;9.4.1 and 9.3.2 in accordance with Section&nbsp;9.3.6. If an event described in a clause in
Section&nbsp;9.3.2 occurs before or concurrently with another event described in a preceding clause in Section&nbsp;9.3.2, Servier shall also pay the milestone payment described in such earlier clause when the milestone payment described in such
later clause is paid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.4 <U>Follow-On Products. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Subject to the terms of this Agreement, *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) If prior to the time at which a milestone payment pursuant to Section&nbsp;9.3.4(a) is to be made with respect to a subsequent Licensed Product, the first Licensed Product has been substituted by a
subsequent Licensed Product in the same Licensed Program or development of the first Licensed Product in the same Licensed Program has been discontinued, then the achievement by such subsequent Licensed Product of a milestone event to the extent the
corresponding milestone payment under Section&nbsp;9.3.2 has not been made with respect to such </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
substituted or discontinued first Licensed Product, shall be deemed to be achievement of the corresponding milestone event under Section&nbsp;9.3.2 by the first Licensed Product entitling
MacroGenics to the corresponding milestone payment under Section&nbsp;9.3.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.5 <U>Reductions in Milestones Payable for
Phase 3 Clinical Trials for the <B>***</B> DART Program or gpA33 DART Program</U>. In the event that the conduct by Servier of a Phase 1 Clinical Trial or Phase 2 Clinical Trial for Licensed Product in accordance with the applicable Research Plan
results in Servier, its Affiliates or Sublicensees conducting a Phase 3 Clinical Trial for such Licensed Product under the Global Development Plan in the same Indication as that studied in such Phase 1 Clinical Trial or Phase 2 Clinical Trial,
<B>***</B><B></B>. Prior to the initiation of any such Phase 3 Clinical Trial, Servier shall provide MacroGenics <B>***</B>. MacroGenics shall have the right to have an independent public accountant reasonably acceptable to Servier audit
Servier&#146;s books and records solely for purposes of verifying such Development Costs, upon reasonable advance notice and during Servier&#146;s business hours, subject to the confidentiality provisions of ARTICLE 11. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.6 <U>CD123 Licensed Program Deferred Milestone Payments</U>. In the event that upon the achievement of a milestone event set forth in
Section&nbsp;9.3.2(e) or (i)&nbsp;with respect to a Licensed Product from the CD123 Licensed Program the MacroGenics Patents do not include an issued patent in a final and non-appealable status before the European Patent Office, which MacroGenics
Patent claims the composition of matter of the Licensed Product for which such milestone event(s) were achieved, then one hundred percent (100%)&nbsp;of the milestone payment(s) set forth in Section&nbsp;9.3.2(e) or (i), as applicable, shall not be
due until the issuance in a final and non-appealable status before the European Patent Office of a patent included in the MacroGenics Patents which specifically claims the composition of matter of such Licensed Product from the CD123 Licensed
Program. For purposes of clarity, following the issuance in the EU of a patent included in the MacroGenics Patents which claims the composition of matter of a Licensed Product from the CD123 Licensed Program as provided herein above, this
Section&nbsp;9.3.6 shall cease to apply and Servier shall have no right to defer, in part or in whole, any milestone payment as provided in this Section&nbsp;9.3.6. For further clarity, it is agreed by the Parties that as of the Effective Date none
of the MacroGenics Patents listed in <U>Exhibit B</U> Cover the composition of matter of a Licensed Product from&nbsp;the CD123 Program in the EU.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.3.7 <U>Notification; Payment</U>. Servier shall promptly notify MacroGenics in writing of the first achievement of each of the milestones under this Section&nbsp;9.3 (other than milestones under
Section&nbsp;9.3.1) and the corresponding milestone payment shall be due within *** after receipt of the corresponding invoice from MacroGenics. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4 <U>Sales Milestones. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.1 <U>Sales Milestone Payments</U>. For each Licensed Program, Servier shall make the *** payments to MacroGenics set forth below upon
the earliest achievement of each of the corresponding milestone events by the first Licensed Product to achieve such milestone in such Licensed Program: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.2 <U>Payment of Milestones</U>. Servier shall make the milestone payments required by
Section&nbsp;9.4.1 in accordance with Section&nbsp;9.6. If an event described in a clause in Section&nbsp;9.4.1 occurs before or concurrently with another event described in a preceding clause in Section&nbsp;9.4.1, Servier shall also pay the
milestone payment described in such earlier clause when the milestone payment described in such later clause is paid. By way of example, if, during March 2015, ***, Servier shall pay MacroGenics the milestone payments set forth in both Sections
9.4.1(a) and (b). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5 <U>Royalties. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.5.1 Servier shall pay MacroGenics royalties on Net Sales of Licensed Products at the following rates with respect to all such Net Sales of such applicable Licensed Products achieved during the
applicable Calendar Year: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:90pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Annual Net Sales Threshold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Royalty&nbsp;Rate</FONT></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:2.50em; text-indent:-2.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.2 <U>Royalty Term</U>. Servier&#146;s royalty obligations to MacroGenics under this Section&nbsp;9.5
shall expire on a country-by-country and Licensed Product-by-Licensed Product basis on the later of: <B>***</B> (the &#147;<U>Royalty Term</U>&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.5.3 <U>Third Party Royalty Offset</U>. If, after the License Grant Date, Servier or its sublicensee or designee: (ai) is required, as agreed by the Parties in good faith, ***, to obtain a license from
any Third Party under Patents controlled by such Third Party in order to make, have made, use, sell, offer for sale or import a Program DART and/or a Licensed Product in any country in the Servier Territory, and pursuant to such license *** or
(b)&nbsp;is required by any court of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
competent jurisdiction, due to infringement of patent rights controlled by such Third Party in any country(ies) in the Servier Territory, *** then Servier may deduct from the milestones and/or
royalties that would otherwise be due to MacroGenics on Net Sales resulting from the sales of such Licensed Product in such country in a Calendar Quarter *** of the amount paid by Servier to such Third Party with respect to such Licensed Product for
such country during such Calendar Quarter; *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.4 <U>Generic Competition</U>. If at any time following the First
Commercial Sale, Generic Competition exists in any country of the Servier Territory, Servier shall deduct <B>***</B> from the royalties that would otherwise be due to MacroGenics on Net Sales (based on the effective, weighted-average royalty rate)
resulting from the sales of such Licensed Product in such country during the applicable Calendar Quarter in which such Generic Competition exists. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.6 <U>Reports; Payments</U>. Within *** after the end of each Calendar Quarter during which there are Net Sales giving rise to a payment obligation under Section&nbsp;9.4 or 9.5, Servier shall submit to
MacroGenics a report identifying for each Licensed Product, the Net Sales for such Licensed Product for each country in the Servier Territory for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken
from gross sales), and the royalties and the sales milestones payable to MacroGenics. Within *** of the delivery of each such report, Servier shall pay to MacroGenics all royalties and sales milestones payable by it under Sections 9.4 and 9.5.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7 <U>Methods of Payments. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.7.1 All payments due under this Agreement shall be paid in Dollars *** by wire transfer to a bank in the United States designated in writing by MacroGenics. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7.2 For the purposes of determining the amount of any sales milestone payment under Section&nbsp;9.4 or royalties due for the relevant
Calendar Quarter under Section&nbsp;9.5, the amount of Net Sales in any non-Euro currency shall be converted into Euro using the average of daily closing rates of exchange published by European Central Bank for the monthly period in which Net Sales
are accounted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8 <U>Late Payments</U>. Any amount owed by Servier to MacroGenics under this Agreement that is not paid on
or before the date such payment is due shall bear interest at a rate per annum equal to the lesser of (a)&nbsp;<B>***</B>, or (b)&nbsp;the highest rate permitted by applicable Law, calculated on the number of days such payments are paid after such
payments are due and compounded monthly. *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9 <U>Taxes</U>. All payments due and payable under this
Agreement will be made without any deduction or withholding for on account of any tax by application of the Tax Treaty in force between France and The United States since August&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> 1994 and in accordance with its amendment signed January&nbsp;13</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> 2009 which came into force retroactively January&nbsp;1</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> 2009, unless such deduction or withholding tax is required by
applicable laws. If the paying Party is so required to deduct or withhold, such Party shall (a)&nbsp;promptly notify the other Party of such requirement, (b) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
pay to the relevant authorities the full amount required to be deducted or withheld promptly upon the earlier of determining that such deduction or withholding is required or receiving notice
that such amount has been assessed against the other Party, and (c)&nbsp;promptly forward to the other Party an official receipt (or certified copy), or other documentation reasonably acceptable to the other Party evidencing such payment to such
authorities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10 <U>Books and Records; Audit Rights</U>. Each Party (the &#147;<U>Audited Party</U>&#148;) shall keep (and,
in the case of Servier, shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the &#147;<U>Auditing Party</U>&#148;)
to determine the payments due and costs incurred under this Agreement. Each Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected
by the Auditing Party and reasonably acceptable to the Audited Party, review any such records of the Audited Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than ***
prior notice) and during regular business hours and under obligations of strict confidence, for the sole purpose of verifying the accuracy of the amounts paid under this Agreement within a *** period preceding the date of the request for review. The
report of such accounting firm shall be limited to a certificate stating whether any report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate and the actual amounts of Development Costs and the
amount of any Net Sales, milestone or royalty discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such
inspection lead to the discovery of a discrepancy to the Auditing Party&#146;s detriment, the Audited Party shall pay the amount of the discrepancy within *** after its receipt from the accounting firm of the certificate showing the amount of the
discrepancy. The Auditing Party shall pay the full cost of the review unless the underpayment of milestones, royalties and/or Development Costs, is greater than *** of the amount due for the applicable period, in which case the Audited Party shall
pay the reasonable costs charged by such accounting firm for such review. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 10 </B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Inventorship</U>. Inventorship for patentable inventions conceived or reduced to practice during the course of the performance of activities pursuant to this Agreement shall be determined in
accordance with patent laws where the invention was invented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Ownership</U>. Subject to the licenses and rights
granted to Servier under this Agreement, MacroGenics shall own the entire right, title and interest in and to all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or
consultants of MacroGenics or acquired solely by MacroGenics in the course of Research, Development, Manufacture or Commercialization of Program DARTs and/or Licensed Products. Subject to the licenses and rights granted to MacroGenics under this
Agreement, Servier shall own the entire right, title and interest in and to all inventions and discoveries (and Patents </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
claiming patentable inventions therein) first made or discovered solely by employees or consultants of Servier or acquired solely by Servier in the course of Research, Development, Manufacture or
Commercialization of Program DARTs and/or Licensed Product. The Parties shall jointly own any Joint IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3 <U>Prosecution
and Maintenance of Patents</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.1 <U>MacroGenics Patents. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall have the sole right to, at MacroGenics&#146; discretion, file, prosecute, and maintain (including the defense of
any interference or opposition proceedings), all MacroGenics Patents. *** MacroGenics shall provide to Servier copies of all prosecution filings related to MacroGenics Patents comprising claims Covering Program DARTs and/or Licensed Products
(&#147;<U>MacroGenics Product Patents</U>&#148;) sent to or received from patent offices in the Servier Territory, unless otherwise directed by Servier, and, shall provide Servier with a draft of any filing within thirty (30)&nbsp;days in advance of
submission, provide Servier an opportunity to provide comments on and make request of MacroGenics concerning such filings and shall consider in good faith any comments regarding such draft filings that Servier may timely provide. If Servier no
longer desires to retain its license under any MacroGenics Patent in the Servier Territory, and desires to ***, it shall have the right to *** upon <B>***</B> written notice. Following such <B>***</B> period, the Patent(s) referenced in such notice
shall no longer be deemed a MacroGenics Patent(s) and Servier shall have no rights hereunder with respect to such Patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
Subject to the requirements and limitations of the MacroGenics Third Party Agreements, with respect to the filing, prosecution and maintenance of the MacroGenics IP, including any rights of, and time-frames for, such Third Party licensors to comment
on and review any filings and correspondence related thereto, in the event MacroGenics decides not to file a patent application on MacroGenics Know-How specific to Program DARTs and/or Licensed Product in a country of the Servier Territory, or
decides to abandon prosecution of any claim of a MacroGenics Product Patent in a country of the Servier Territory or decides to not otherwise maintain or extend any MacroGenics Product Patent in a country of the Servier Territory, MacroGenics shall
give Servier written notice sufficiently in advance thereof. Unless MacroGenics&#146; discontinuation of filing, prosecution or maintenance of such MacroGenics Product Patent is in order to effect a settlement or to avoid an interference, opposition
or other proceeding in which the validity of such MacroGenics Product Patent may be determined or because another MacroGenics Product Patent of similar claim scope is being prosecuted or has been issued, Servier shall have the first right to file,
prosecute, maintain and extend, as the case may be, such MacroGenics Product Patent, in Servier&#146;s name, in such country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.2 <U>Servier Collaboration Patents. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Servier shall have the sole right to, at Servier&#146;s discretion, file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Servier Collaboration
Patents. MacroGenics shall reimburse Servier for the Out-of-Pocket Costs incurred in the filing, prosecution and maintenance of the Servier Collaboration Patents in the MacroGenics </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Territory. Servier shall provide to MacroGenics copies of all prosecution filings related to Servier Collaboration Patents comprising claims Covering Program DARTs and/or Licensed Products
(&#147;<U>Servier Product Patents</U>&#148;) sent to or received from patent offices in the MacroGenics Territory, unless otherwise directed by MacroGenics, and, with respect to patent applications having information not previously filed that is
intended to be submitted to patent offices in the MacroGenics Territory, shall provide MacroGenics with a draft of each such filing <B>***</B> in advance of submission, provide MacroGenics an opportunity to provide comments on and make request of
Servier concerning such filings and shall consider in good faith any comments regarding such draft application that MacroGenics may timely provide. In addition, Servier shall provide to MacroGenics such other information related to prosecution of
the Servier Collaboration Patents in the MacroGenics Territory as MacroGenics may from time to time reasonably request to allow MacroGenics to track prosecution and maintenance of such Patents. If MacroGenics no longer desires to retain its license
under any Servier Collaboration Patent in the MacroGenics Territory, and desires to cease payment of the costs of prosecution and maintenance thereof, it shall have the right to terminate such license to such Patent, and terminate reimbursement to
Servier of such costs, upon *** written notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the event Servier decides not to file a patent application on Servier
Collaboration Know-How specific to Program DARTs and/or Licensed Product, or decides to abandon prosecution of any claim of a Servier Product Patent or decides to not otherwise maintain or extend any Servier Product Patent, Servier shall give
MacroGenics written notice sufficiently in advance thereof. Unless Servier&#146;s discontinuation of filing, prosecution or maintenance of such Servier Product Patent is in order to effect a settlement or to avoid an interference, opposition or
other proceeding in which the validity of such Servier Product Patent may be determined or because another Servier Product Patent of similar claim scope is being prosecuted or has been issued, MacroGenics shall have the first right to file,
prosecute and maintain or extend at its costs, as the case may be, such Servier Product Patent, in MacroGenics&#146; name, in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.3.3 <U>Joint IP. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall have the first right, at
MacroGenics&#146; discretion, to file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Patents claiming patentable inventions included in the Joint IP (&#147;<U>Joint Patents</U>&#148;) in the
MacroGenics Territory, in the names of both MacroGenics and Servier. Servier shall have the first right, at Servier&#146;s discretion, to file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Joint
Patents in the Servier Territory, in the names of both MacroGenics and Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) With respect to Joint Patents, if the
Party with the responsibility for filing, prosecuting and maintaining such Patents in accordance with clause (a)&nbsp;above (the &#147;<U>Responsible Party</U>&#148;) elects not to seek or continue to seek or maintain patent protection on any Joint
Patent in its territory, the other Party shall have the right to seek, prosecute and maintain patent protection on such Joint Patent in the other Party&#146;s name and the Responsible Party shall assign its entire right, title and interest in such
Joint Patent to the other Party. The Responsible Party shall use </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Commercially Reasonable Efforts to make available to the other Party its authorized attorneys, agents or representatives, and to assist the other Party in obtaining and maintaining such patent
protection. The Responsible Party shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary to file and prosecute such patent applications or to obtain or maintain such patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Parties shall establish procedures to coordinate the filing and prosecution of Joint Patents. With respect to Joint Patents, the
Responsible Party shall provide the other Party, within <B>***</B> after submitting or receiving such filings or correspondence, with copies of all filings and correspondence submitted to and received from patent offices and, with respect to
substantive filings and correspondence to be submitted to patent offices, shall use reasonable efforts to provide the other Party with drafts of such filings and correspondence reasonably in advance of submission and shall consider in good faith any
comments regarding such filings and correspondence that the other Party may timely provide. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Each Party shall be
responsible for the costs and expenses it occurs in connection with the filing, prosecution and maintenance of Joint Patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4 <U>Third Party Infringement. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.4.1 <U>Notice</U>. Each Party shall promptly report in writing to the other Party any known or suspected (i)&nbsp;infringement of any of the MacroGenics Patents, Servier Patents or Joint Patents,
(ii)&nbsp;unauthorized use or misappropriation of any of the MacroGenics Know-How, Servier Know-How or Joint Know-How of which such Party becomes aware, or (iii)&nbsp;notification under the Biologics Price Competition and Innovation Act of 2009, as
amended, or similar law, from a biosimilar applicant arising from the filing of an application for the Regulatory Approval of a Generic Product intending to show that the Generic Product is biosimilar to any Licensed Product that is a reference
product for which a claim of infringement of any of the MacroGenics Patents, Joint Patents or Servier Patents by the manufacture or sale of the Generic Product could reasonably be asserted, and shall provide the other Party with all available
evidence regarding such known or suspected infringement or unauthorized use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.2 <U>Enforcement Rights</U>. Subject to the
requirements and limitations of the MacroGenics Third Party Agreements with respect to the enforcement of Patents, including any rights of, and timeframes for, such Third Party licensors to comment on and review any filings or materials related
thereto, the Parties agree: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Servier shall have the first right, but not the obligation, to initiate a lawsuit or take
other reasonable action to enforce the Joint Patents and MacroGenics Product Patents in the Field in the Servier Territory to the extent such infringement or misappropriation involves the Development, Manufacture, use or Commercialization of a
product or product candidate that is or may be competitive with the Program DARTs or Licensed Products being Developed or Commercialized hereunder. Notwithstanding the foregoing sentence, Servier shall not initiate any such lawsuit or other
enforcement action asserting any such Joint Patents or MacroGenics Product Patents without first consulting with MacroGenics and giving good faith consideration to any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
reasonable objection from MacroGenics regarding Servier&#146;s proposed course of action. MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by Servier;
<U>provided </U>that Servier shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with such cooperation. In connection with any such proceeding, Servier
shall not enter into any settlement admitting the invalidity of, or otherwise impairing MacroGenics&#146; rights in, MacroGenics IP or Joint IP without the prior written consent of MacroGenics. Any recoveries resulting from such an action brought by
Servier in accordance with this clause (a)&nbsp;shall be applied as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) First, to reimburse each Party for all
Out-of-Pocket Costs in connection with such proceeding (on a pro rata basis, based on each Party&#146;s respective litigation costs, to the extent the recovery was less than all such litigation costs); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Second, *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the Joint Patents in the Field in the MacroGenics Territory.
Notwithstanding the foregoing sentence, MacroGenics shall not initiate any such lawsuit or other enforcement action asserting any such Joint Patents without first consulting with Servier and giving good faith consideration to any reasonable
objection from Servier regarding MacroGenics&#146; proposed course of action. Servier shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics; <U>provided </U>that MacroGenics shall promptly reimburse all
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. In connection with any such proceeding, MacroGenics shall not enter into any settlement admitting the
invalidity of, or otherwise impairing the Parties&#146; rights in Joint IP without the prior written consent of Servier. Any recoveries resulting from such an action brought by MacroGenics in accordance with this clause (b)&nbsp;shall be applied as
follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) First, to reimburse each Party for all Out-of-Pocket Costs in connection with such proceeding (on a pro rata
basis, based on each Party&#146;s respective litigation costs, to the extent the recovery was less than all such litigation costs); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) Second, *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) If Servier does not initiate a lawsuit or take other
reasonable action pursuant to Section&nbsp;10.4.2(a) with respect to any Joint Patents or Servier Product Patents (i)&nbsp;if there is no time limit for the filing of such action, within <B>***</B> following the notice of alleged infringement or
following a biosimilar applicant&#146;s failure to act or (ii)&nbsp;if there is a time limit for the filing of such action (including those set forth in applicable Laws) within at least <B>***</B> before the time limit, then MacroGenics shall have
the right (in cases where MacroGenics has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing <B>***</B> notice to Servier and giving good faith consideration to Servier&#146;s reason(s) for not
initiating a lawsuit or taking other action. For this purpose, Servier shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics; <U>provided </U>that MacroGenics shall promptly reimburse all
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. Any recoveries resulting from such an action brought by
MacroGenics in accordance with this clause (c)&nbsp;will *** after payment of each Party&#146;s costs and expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) If
MacroGenics does not initiate a lawsuit or take other reasonable action pursuant to Section&nbsp;10.4.2(b) with respect to any Joint Patents (i)&nbsp;if there is no time limit for the filing of such action, within <B>***</B> following the notice of
alleged infringement or following a biosimilar applicant&#146;s failure to act or (ii)&nbsp;if there is a time limit for the filing of such action (including those set forth in applicable Laws) within at least <B>***</B> before the time limit, then
Servier shall have the right (in cases where Servier has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing <B>***</B> notice to MacroGenics and giving good faith consideration to MacroGenics&#146;
reason(s) for not initiating a lawsuit or taking other action. For this purpose, MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by Servier; <U>provided </U>that Servier shall promptly reimburse all
out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with such cooperation. Any recoveries resulting from such an action brought by Servier in accordance with this clause
(d)&nbsp;will be *** after payment of each Party&#146;s costs and expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.3 <U>Conduct of Certain Actions; Costs</U>.
The Party initiating legal action shall have the sole and exclusive right to select counsel for any suit initiated by it pursuant to Section&nbsp;10.3.2 or 10.3.3 (the &#147;<U>Initiating Party</U>&#148;). Unless otherwise expressly provided, the
Initiating Party shall bear its own out-of-pocket costs incurred in any such legal action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action
(in cases where such other Party has standing) by its own counsel at its own expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5 <U>Patent Invalidity Claim</U>.
Each Party shall promptly notify the other in the event of any legal or administrative action by any Third Party against a Joint Patent, MacroGenics Patent or Servier Patent of which it becomes aware, including any nullity, revocation, reexamination
or compulsory license proceeding. Servier shall have the first right, but not the obligation, at its expense, to defend against any such action relating to the Servier Patents. MacroGenics shall have the first right, but not the obligation, at its
expense, to defend against any such action relating to the MacroGenics Patents or the Joint Patents. If MacroGenics does not defend against any such action involving a MacroGenics Product Patent or a Joint Patent, then Servier shall have the right,
but not the obligation, to defend such action at Servier&#146;s expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6 <U>Patent Term Extensions</U>. The Parties
shall cooperate with each other in obtaining patent term extensions or supplemental protection certificates or their equivalents in any country, where applicable to Joint Patents, MacroGenics Patents and Servier Patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7 <U>Patent Marking</U>. Servier shall comply with the patent marking statutes in each country in which a Licensed Product is sold by
Servier, its Affiliates and/or its Sublicensees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 11 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>CONFIDENTIALITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Confidentiality; Exceptions</U>. Except to the
extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party (the &#147;<U>Receiving Party</U>&#148;) shall keep confidential and shall not publish or otherwise disclose or use for any
purpose other than as provided for in this Agreement any Know-How in any form (written, oral, photographic, electronic, magnetic, or otherwise) that is disclosed to it by the other Party (the &#147;<U>Disclosing Party</U>&#148;) or otherwise
received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement (collectively, &#147;<U>Confidential Information</U>&#148;), except to the extent that it can be established by the
Receiving Party that such Confidential Information: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.1 was in the lawful knowledge and possession of the Receiving Party
prior to the time it was disclosed to, or learned by, the Receiving Party, or was otherwise developed independently by the Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual
use by the Receiving Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.2 was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the Receiving Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.3 became generally available to the public or otherwise part of the public
domain after its disclosure and other than through any act or omission of the Receiving Party in breach of this Agreement; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.4 was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to
the Disclosing Party not to disclose such information to others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Authorized Disclosure</U>. Except as expressly
provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.2.1 under appropriate confidentiality provisions similar to those in this Agreement, in connection with the performance of its obligations or exercise of rights granted or reserved in this Agreement;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.2 to the extent such disclosure is reasonably necessary in filing or prosecuting patent and copyright applications,
prosecuting or defending litigation, complying with applicable governmental regulations (including the rules and regulations of any stock exchange or NASDAQ), conducting non-clinical activities and clinical activities, preparing and submitting
filings to Regulatory Authorities or is otherwise required by Law; <U>provided</U>, <U>however</U>, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party&#146;s Confidential Information (other than a
disclosure to a Regulatory Authority in a filing required by Law) it will give reasonable advance notice to the Disclosing Party of such disclosure requirement and shall furnish only that portion of the Disclosing Party&#146;s Confidential
Information that the Receiving Party is legally required to furnish; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.3 in communications with existing or prospective acquirers, investors, consultants,
advisors, licensees or collaborators or others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.4 to the extent mutually agreed to in writing by the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Press Release; Disclosure of Agreement. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3.1 On or promptly after the Effective Date, the Parties shall jointly issue a public announcement of the execution of this Agreement in a form to be mutually agreed to by the Parties (such agreement
not to be unreasonably withheld, conditioned or delayed). Neither Party shall issue any subsequent press release or make other disclosures regarding this Agreement or the Parties&#146; activities hereunder, or any results or data arising hereunder,
except (a)&nbsp;with the other Party&#146;s prior written consent; (b)&nbsp;in accordance with Section&nbsp;11.6; or (c)&nbsp;for any disclosure that is reasonably necessary to comply with applicable securities exchange listing requirements or other
applicable Laws. Notwithstanding the foregoing, to the extent information regarding this Agreement has already been publicly disclosed, either Party may subsequently disclose the same information to the public without the consent of the other Party.
Each Party shall be permitted to disclose the terms of this Agreement, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement, to any actual or potential acquirers, merger partners, licensees,
sublicensees, investors and professional advisors on a need to know basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.2 Each Party shall, if practicable, give the
other Party a reasonable opportunity to review those portions of all filings with the United States Securities and Exchange Commission (or any stock exchange, including Nasdaq, or any similar regulatory agency in any country other than the United
States) describing the terms of this Agreement (including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the
provisions of this Agreement for which confidential treatment should be sought. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4 <U>Existing Confidentiality
Agreement</U>. For the avoidance of doubt, any information disclosed by MacroGenics to Servier prior to the Effective Date pursuant to the Non-Disclosure Disclosure Agreement between MacroGenics and Servier dated <B>***</B> (the &#147;<U>Existing
Confidentiality Agreement</U>&#148;) shall be treated as Confidential Information for all purposes under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5
<U>Remedies</U>. In the event a Party breaches the confidentiality obligations set forth in this ARTICLE 11, the other Party shall be entitled to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary
injunction, without the posting of any bond or other security, enjoining or restraining the breaching Party from any violation or threatened violation of this ARTICLE 11. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6 <U>Publications</U>. Neither Party nor its Affiliates shall publish or publicly
disclose the results of any of the Research or Development activities conducted by either Party under this Agreement without the prior written consent of the other Party, except as expressly permitted in this Section&nbsp;11.6 or otherwise in this
Agreement. The Parties recognize that it may be useful or required to publish or publicly disclose the results of Research and Development work on Program DARTs and Licensed Products, and each Party (and its Affiliates) shall be free to publish or
publicly disclose such results, subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in this Section&nbsp;11.6. The Party that desires to publish results hereunder shall provide
the other Party with a copy of such proposed abstract, manuscript, or presentation no less than <B>***</B> prior to its intended submission for publication. The reviewing Party shall respond in writing promptly and in no event later than thirty
<B>***</B> after receipt of the proposed material, with one or more of the following: (a)&nbsp;comments on the proposed material, which the publishing Party shall consider in good faith, (b)&nbsp;a specific statement of concern, based upon the need
to seek patent protection, or (c)&nbsp;an identification of the reviewing Party&#146;s Confidential Information that is contained in the material reviewed. In the event of concern over patent protection, the publishing Party agrees not to submit
such publication or to make such presentation that contains such information until the reviewing Party is given a reasonable period of time, and in no event less than <B>***</B>, to seek patent protection for any material in such publication or
presentation which it believes is patentable. Any Confidential Information of the reviewing Party shall, if requested by the reviewing Party, be removed by the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.7 <U>Return of Confidential Information</U>. Upon the expiration or termination of this Agreement, the Receiving Party shall return to the Disclosing Party all Confidential Information received by the
Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: (a)&nbsp;any notes, reports or other documents prepared by the Receiving Party which contain Confidential
Information of the Disclosing Party; and (b)&nbsp;any Confidential Information of the Disclosing Party (and all copies and reproductions thereof) which is in electronic form or cannot otherwise be returned to the Disclosing Party. Alternatively,
upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof) and any notes, reports or other
documents prepared by the Receiving Party which contain Confidential Information of the Disclosing Party. Nothing in this Section&nbsp;11.7 shall require the alteration, modification, deletion or destruction of archival tapes or other electronic
back-up media made in the ordinary course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11 with respect to any Confidential Information
contained in such archival tapes or other electronic back-up media. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such
destruction. Notwithstanding the foregoing, (i)&nbsp;the Receiving Party&#146;s legal counsel may retain one copy of the Disclosing Party&#146;s Confidential Information solely for the purpose of determining the Receiving Party&#146;s continuing
obligations under this ARTICLE 11 and (ii)&nbsp;the Receiving Party may retain the Disclosing Party&#146;s Confidential Information and its own notes, reports and other documents (A)&nbsp;to the extent reasonably required (i)&nbsp;to comply with
applicable Law and regulatory requirements; (ii)&nbsp;to exercise the rights and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; and (iii)&nbsp;to perform the obligations of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (B)&nbsp;to the extent it is impracticable to do so without incurring disproportionate cost. Notwithstanding the return or destruction of the Disclosing Party&#146;s Confidential Information, the Receiving Party
shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE
12</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPRESENTATIONS AND WARRANTIES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Representations and Warranties of Both Parties</U>. Each Party hereby represents and warrants to the other Party, as of the Effective Date, that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.1 such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.2 such Party
has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1.3 this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.4 the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement or any
provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Law of any court, governmental body or administrative or other agency having jurisdiction over such Party; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.5 no government authorization, consent, approval, license, exemption of or filing or registration with any court or
governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement, or
for the performance by it of its obligations under this Agreement, except as necessary to conduct clinical trials or to seek or obtain Regulatory Approvals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Representations and Warranties of MacroGenics and its Affiliates</U>. MacroGenics and its Affiliates hereby represent and warrant to Servier that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.1 As of the Effective Date, MacroGenics is the owner of, or has Control via a license to, the MacroGenics Patents listed on
<U>Exhibit B</U>; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.2 There are not as of the Effective Date, nor have there been over the *** period immediately
preceding the Effective Date, any claims, lawsuits, arbitrations, legal or administrative or regulatory proceedings, charges, complaints or investigations by any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Government Authority (except in the ordinary administrative course of the granting of patents and proceedings relating thereto) or by any Third Party relating to the MacroGenics Patents or
MacroGenics Know-How; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.3 As of the Effective Date, to MacroGenics&#146; and its Affiliates knowledge, the exercise by
Servier of the rights and licenses granted to Servier by MacroGenics under this Agreement shall not infringe any rights owned or controlled by any Third Party in the Servier Territory; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.4 As to the Effective Date, to MacroGenics&#146; and its Affiliates knowledge *** it has not (i)&nbsp;employed and has not used a
contractor or consultant that has employed, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA), or, (ii)&nbsp;employed any individual who or entity that is the subject of an FDA debarment investigation or
proceeding (or similar proceeding of EMA), in the conduct of any pre-clinical activities or clinical studies of Program DARTs; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.5 As to the Effective Date, MacroGenics has the right to grant all rights and licenses it purports to grant to Servier with respect
to the MacroGenics IP under this Agreement and it has not granted any license, right or interest in, to or under MacroGenics IP to any Third Party that is inconsistent with the licenses and rights granted to Servier under Section&nbsp;4.1;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.6 As of the Effective Date, to MacroGenics and its Affiliates&#146; knowledge the MacroGenics IP are all of the Patents
and Know-How Controlled by MacroGenics or its Affiliates which are reasonably necessary for the Development, Manufacture, Commercialization of the Program DART and/or Licensed Products in the Field in the Servier Territory; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.7 To MacroGenics knowledge, the Research and Development of the Program DART and the Licensed Product prior to the Effective Date by
or on behalf of MacroGenics has been carried out without infringing any Patent owned or controlled by a Third Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.8
As of the Effective Date, to MacroGenics&#146; knowledge, there are no activities by Third Party that would constitute infringement or misappropriation of the MacroGenics IP; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.2.9 As of the Effective Date, to MacroGenics&#146; knowledge, there is no reason for MacroGenics or a court of competent jurisdiction to reasonably conclude that the MacroGenics Patents are invalid or
unenforceable. To MacroGenics&#146; knowledge, the claims included in any issued MacroGenics Patent are valid and in full force and effect. All fees required to be paid to the governmental authorities prior to the Effective Date to prosecute or
maintain the MacroGenics Patent in the Servier Territory have been filed and have been paid; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.10 MacroGenics has
maintained prior to the Effective Date and, unless agreed to otherwise by Servier and except as provided in this Agreement, during the Agreement Term will maintain and keep in full force and effect all agreements and filings (including Patent
filings) necessary to perform its obligations hereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3 <U>Representation and Warranty of LLS</U>. LLS hereby represents and warrants to
MacroGenics that IdRS is an Affiliate of LLS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4 <U>Mutual Covenants</U>. Each Party hereby covenants to the other Party
that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.1 Such Party shall comply with all applicable Laws in connection with this Agreement and the transactions
contemplated hereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.2 All employees of such Party or its Affiliates working under this Agreement will be under the
obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.4.3 To its knowledge *** such Party will not (a)&nbsp;employ or use any contractor or consultant that employs, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA) or,
(b)&nbsp;employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in each of clauses (a)&nbsp;and (b)&nbsp;in the conduct of its activities under this Agreement;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.4 Such Party shall perform its activities pursuant to this Agreement in compliance in all material respects with GLP,
GCP and cGMP (including those specified by the ICH), in each case as applicable; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.5 Neither Party shall, during the
Agreement Term grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted or to be granted to the other Party hereunder
pursuant to the provisions of ARTICLE 4. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5 <U>Disclaimer</U>. Except as otherwise expressly set forth in this Agreement,
NEITHER PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing except as otherwise expressly set forth in this Agreement, each Party disclaims any warranties with regards to: (a)&nbsp;the success of any study or test
commenced under this Agreement, (b)&nbsp;the safety or usefulness for any purpose of the technology or materials, including any compounds, it provides or discovers under this Agreement; or (c)&nbsp;the validity, enforceability, or non-infringement
of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 13 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INDEMNIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Indemnification by Servier</U>. Servier shall
defend, indemnify and hold harmless the MacroGenics Indemnitees from and against any and all losses, damages, fees, expenses, settlement amounts or costs (including reasonable attorneys&#146; fees and witness fees) (&#147;<U>Losses</U>&#148;)
relating to or in connection with a Third Party claim in the Servier Territory arising out of (a)&nbsp;any actual death, personal bodily injury or damage to real or tangible personal property proven to result, directly or indirectly, from the
possession, use or consumption of, or treatment with, a Program DART or Licensed Product Researched, Developed, Manufactured or Commercialized in the Servier Territory by or on behalf of Servier or its Affiliates or Sublicensees, including any
product liability claims; (b)&nbsp;any breach by Servier of its representations, warranties or covenants made under this Agreement; or (c)&nbsp;any negligent act or omission or willful misconduct of Servier or its Affiliates or Sublicensees or any
of their employees, contractors or agents, in performing Servier&#146;s obligations or exercising Servier&#146;s rights under this Agreement; <U>provided</U>,<U> however</U>, that the foregoing indemnity shall not apply to the extent that any such
Losses (i)&nbsp;are attributable to the gross negligence or willful misconduct of the MacroGenics Indemnitees, or (ii)&nbsp;are otherwise subject to an obligation by MacroGenics to indemnify the Servier Indemnitees under Section&nbsp;13.2. For
purposes of clarity, notwithstanding anything to the contrary in this Agreement, Servier shall not be liable for any Losses resulting from any claim in the MacroGenics Territory that results from any acts or omissions of MacroGenics, its Affiliates
or Sublicensees, even if Servier had knowledge of, reviewed, commented on, or approved such acts or omissions of MacroGenics&#146; or its Affiliates&#146; or Sublicensees&#146; plans with respect thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 <U>Indemnification by MacroGenics</U>. MacroGenics shall defend, indemnify and hold harmless the Servier Indemnitees from and
against any and all Losses relating to or in connection with a Third Party claim in the MacroGenics Territory arising out of (a)&nbsp;any actual death, personal bodily injury or damage to real or tangible personal property proven to result, directly
or indirectly, from the possession, use or consumption of, or treatment with, a Program DART or Licensed Product Researched, Developed, Manufactured or Commercialized in the MacroGenics Territory by or on behalf of MacroGenics or its Affiliates or
Sublicensees, including any product liability claims; (b)&nbsp;any breach by MacroGenics of its representations, warranties or covenants made under this Agreement; or (c)&nbsp;any negligent act or omission or willful misconduct of MacroGenics or its
Affiliates or Sublicenses or any of their employees, contractors or agents, in performing MacroGenics&#146; obligations or exercising MacroGenics&#146; rights under this Agreement; <U>provided</U>,<U> however</U>, that the foregoing indemnity shall
not apply to the extent that any such Losses are attributable to (i)&nbsp;the gross negligence or willful misconduct of the Servier Indemnitees, or (ii)&nbsp;are otherwise subject to an obligation by Servier to indemnify the MacroGenics Indemnitees
under Section&nbsp;13.1. For purposes of clarity, notwithstanding anything to the contrary in this Agreement, MacroGenics shall not be liable for any Losses resulting from any claim in the Servier Territory that results from any acts or omissions of
Servier, its Affiliates or Sublicensees, even if MacroGenics had knowledge of, reviewed, commented on, or approved such acts or omissions of Servier&#146;s or its Affiliates&#146; or Sublicensees&#146; plans with respect thereto. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>Procedure</U>. In the event of a claim by a Third Party against any Person entitled to indemnification under this Agreement, the
Party claiming indemnification (in such capacity, the &#147;<U>Indemnified Party</U>&#148;) shall promptly notify the other Party (in such capacity, the &#147;<U>Indemnifying </U> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<U>Party</U>&#148;) in writing of the claim (it being understood that the failure by the Indemnified Party to give prompt notice of a Third Party claim as provided in this Section&nbsp;13.3 shall
not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give prompt notice). Within <B>***</B> after
delivery of such notification, the Indemnifying Party may, upon written notice thereof to the Indemnified Party, undertake and solely manage and control, at its sole expense and with counsel reasonably satisfactory to the Indemnified Party, the
defense of the claim. If the Indemnifying Party does not undertake such defense, the Indemnified Party shall control such defense. The Party not controlling such defense shall cooperate with the other Party and may, at its option and expense,
participate in such defense with counsel of its choice; <U>provided</U>, that, if the Indemnifying Party assumes control of such defense and the Indemnified Party in good faith concludes, based on advice from counsel, that the Indemnifying Party and
the Indemnified Party (or the relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim, the Indemnified Party&#146;s counsels may fully
participate in such defense and the Indemnifying Party shall be responsible for the reasonable fees and expenses of one counsel to the indemnified Persons solely in connection therewith. The Party controlling such defense shall keep the other Party
advised of the status of such action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. Except if the Indemnifying Party did not undertake defense of the claim or if
the Indemnifying Party and the Indemnified Party (or the relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim and the Indemnified Party
engages separate counsel, as provided above, the Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party&#146;s written consent. The Indemnified Party shall not
settle any such action, suit, proceeding or claim without the prior written consent of the Indemnifying Party, which shall not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not settle, without the prior written
consent of the Indemnified Party, any such action, suit, proceeding or claim, or consent to any judgment in respect thereof, that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto,
that imposes any liability or obligation on the Indemnified Party or that acknowledges fault by the Indemnified Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4
<U>Allocation</U>. In the event a claim is based partially on an indemnified claim and partially on a non-indemnified claim or based partially on a claim indemnified by one Party and partially on a claim indemnified by the other Party, any payments
in connection with such claims are to be apportioned between the Parties in accordance with the degree of cause attributable to each Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.5 <U>EXCLUSION OF CONSEQUENTIAL DAMAGES</U>. EXCEPT WITH RESPECT TO A BREACH OF ARTICLE 11 OR THIRD PARTY CLAIMS THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 13, NEITHER MACROGENICS NOR
SERVIER, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER SUCH PARTY OR ANY REPRESENTATIVE OF SUCH PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE
POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 14 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TERM AND TERMINATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.1 <U>Agreement Term; Expiration</U>. This Agreement shall become effective as of the Effective Date, and, in the event Servier does not exercise a Option by the end of the Option Periods, shall expire
in its entirety at the end of the last Option Period to expire, unless earlier terminated in accordance with this ARTICLE 14. In the event Servier exercises an Option in accordance with Section&nbsp;3.3, this Agreement shall continue in full force
with respect to the Licensed Program that was licensed under such Option until the last to expire Royalty Term for a Licensed Product from such Licensed Program in the Servier Territory. After the last to expire Royalty Term for a Licensed Product
in a country in the Servier Territory, Servier shall be granted a fully paid-up non-exclusive license to use MacroGenics Know-How to Manufacture and Commercialize such Licensed Product in the Field in such country in the Servier Territory.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2 <U>Termination for Cause</U>. Either Party (the &#147;<U>Non-Breaching Party</U>&#148;) may, without prejudice to any
other remedies available to it under applicable Law or in equity, terminate this Agreement in its entirety or with respect to an Option or Licensed Program if the other Party (the &#147;<U>Breaching Party</U>&#148;) shall have materially breached or
defaulted in the performance of its obligations hereunder with respect to the Program which is subject to such Option and/or such Licensed Program, and such default shall have continued for <B>***</B> after written notice thereof was provided to the
Breaching Party by the Non-Breaching Party, such notice describing the alleged breach. Any such termination of this Agreement under this Section&nbsp;14.2 shall become effective at the end of such <B>***</B> cure period, unless the Breaching Party
has cured such breach or default prior to the expiration of such cure period provided however that if the Breaching Party notifies the Non-Breaching Party within such <B>***</B> period that the Breaching Party disagrees in good faith with such
asserted basis for termination, this Agreement shall not terminate unless and until the matter has been finally resolved in accordance with Section&nbsp;16.2 and the arbitration award rendered in accordance with Section&nbsp;16.2 specify that the
Non-Breaching Party shall have the right to terminate this Agreement based on such asserted Breach. The right of either Party to terminate this Agreement as provided in this Section&nbsp;14.2 shall not be affected in any way by such Party&#146;s
waiver or failure to take action with respect to any previous default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3 <U>Termination for Patent Challenge</U>. If
either Party or any of its Affiliates or Sublicensees: (a)&nbsp;commences or otherwise voluntarily determines to participate in any action or proceeding (including any patent opposition or re-examination proceeding), challenging or denying the
validity of any of the other Party&#146;s Patents or Joint Patents licensed hereunder or any claim thereof, or (b)&nbsp;actively assists any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or
re-examination proceeding) challenging or denying the validity of any of such Patents or any claim thereof, the non-challenging Party shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
have the right to terminate this Agreement with respect to the Option or Licensed Program to which such Patents are subject upon *** written notice to the other Party. Any such termination shall
only become effective if the challenging Party or its Affiliate or Sublicensee, as applicable, has not withdrawn such action before the end of the above notice period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.4 <U>Termination for Convenience. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4.1 <U>During the Research
Term</U>. At any time following <B>***</B>, Servier shall have the right to terminate this Agreement in its entirety or with respect to an Option upon not less than <B>***</B> prior written notice thereof to MacroGenics. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4.2 <U>During a License Term</U>. At any time during a License Term, Servier shall have the right to terminate this Agreement in its
entirety or to terminate the Licensed Program subject to such License Term or to terminate this Agreement or such Licensed Program on a country-by-country basis upon not less than <B>***</B> prior written notice thereof to MacroGenics. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5 <U>Termination for Insolvency Event</U>. Either Party may terminate this Agreement upon written notice to the other Party if the
other Party suffers an Insolvency Event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6 <U>Termination by Servier for Safety or Public Health Reasons</U>. If Servier
reasonably determines that a safety or public health issue has arisen which (a)&nbsp;is demonstrated by clinically relevant events which are documented and (b)&nbsp;relates to a Program DART or a Licensed Product, such that the medical risk/benefit
of such Program DART of Licensed Product is sufficiently unfavorable as to be incompatible with the welfare of patients to Develop or Commercialize or to continue to Develop or Commercialize such Program DART or Licensed Product, Servier shall
immediately notify MacroGenics, and Servier shall be permitted to terminate this Agreement with respect to the Option or Licensed Program to which such Program DART or Licensed Product is subject upon written notice to MacroGenics, but in any event
within *** of Servier&#146;s determination of such issue. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7 <U>Effect of Expiration or Termination. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7.1 Upon termination of this Agreement by MacroGenics in whole or with respect to one or more Terminated Options, Terminated Licensed
Programs and/or Terminated Territories pursuant to Section&nbsp;14.2, 14.3, or 14.5 or by Servier in whole or with respect to one or more Terminated Options, Terminated Licensed Programs or Terminated Territories pursuant to Section&nbsp;14.4 or
14.6: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) all rights, licenses and options granted by MacroGenics to Servier with respect to each Terminated Option,
Terminated Licensed Program and/or Terminated Territory hereunder shall terminate and Servier shall not have any rights to use or exercise any rights under the MacroGenics IP with respect to any such Terminated Option, Terminated Licensed Program
and Terminated Territory; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) if such termination occurs during a Research Term, (i)&nbsp;Servier shall Complete any
ongoing Clinical Studies in the Servier Territory for Licensed Product that is subject to the Terminated Option where such completion is required by any applicable Law, requested by any Regulatory Authority or would be dictated by any applicable
Institutional Review Board with oversight of such Clinical Study in the Servier Territory; and (ii)&nbsp;Servier shall promptly transfer and assign to MacroGenics all Supplemental Data and *** and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) if such termination occurs during a License Term: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) Servier shall provide to MacroGenics a fair and accurate detailed written description of the status of the Development and Commercialization of the Program DARTs and Licensed Products subject to such
Terminated Licensed Program and/or in the Terminated Territory through the effective date of termination within <B>***</B> of such termination; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) the licenses granted to MacroGenics pursuant to Section&nbsp;4.2 with respect to such Terminated Licensed Program shall remain in effect and shall become irrevocable; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Servier hereby grants to MacroGenics, effective upon the request of MacroGenics, ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) In the event that MacroGenics requests a license under clause (iii)&nbsp;above and Servier has previously Completed a Phase 3
Clinical Trial for a Licensed Product subject to the Terminated Licensed Program or such Terminated Territory before the effective date of termination, <B>***</B>; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(v) Servier shall promptly transfer and assign to MacroGenics all Regulatory Documentation and other technical and other information or materials in Servier&#146;s or its Affiliates&#146; possession or
control which are necessary or useful for the Research, Development or Commercialization of the Program DARTs or Licensed Products in each Terminated Licensed Program and Terminated Territory or, if Licensed Program remains or country remains in the
Servier Territory, anywhere in the world; <U>provided</U>, that Servier may retain a single copy of such items for its records; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(vi) Promptly upon request by MacroGenics, but in no event commencing later than <B>***</B> after the effective date of termination or continuing for more than <B>***</B> (except to the extent that
requirements of a Regulatory Authority necessitate a longer period), Servier shall provide such assistance to MacroGenics as may be reasonably necessary or useful for MacroGenics to commence or continue Developing, Manufacturing or Commercializing
Licensed Products under or in the Terminated Licensed Program or Terminated Territory, to the extent Servier is then performing or having performed such activities, including transferring or amending as appropriate, upon request of MacroGenics, any
agreements or arrangements with Third Party vendors to Develop, Manufacture or Commercialize Licensed Products under or in such Terminated Licensed Program or Terminated Territory. To the extent that any such contract between Servier and a Third
Party is not assignable to MacroGenics, Servier shall reasonably cooperate with MacroGenics to arrange to continue to provide such services for a reasonable time </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
after termination, not exceeding ***. Within *** after MacroGenics&#146; receipt of a proper invoice therefor, MacroGenics shall reimburse Servier for Servier&#146;s and its Affiliates&#146;
reasonable Out-of-Pocket Costs incurred in connection with any technology transfer conducted pursuant to this clause (vi); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) in the event this Agreement is terminated pursuant to Section&nbsp;14.6, Servier shall reasonably cooperate with MacroGenics to
either (A)&nbsp;wind down any ongoing Global Clinical Trial conducted under a Global Development Plan previously approved by Servier or (B)&nbsp;which is conducted by Servier in the Servier Territory for the Licensed Product, and/or diligently
perform any follow-up of a clinical trial initiated in Servier Territory requested by any Regulatory Authority or dictated by any applicable Institutional Review Board. <B>***</B> the activities mentioned in (A)&nbsp;above and *** shall entirely
fund the activities mentioned in (B)&nbsp;above. Servier and Servier&#146;s Affiliates shall provide MacroGenics written notice of the quantity of Licensed Product that Servier has in inventory for sale under or in each Terminated Licensed Program
or Terminated Territory and permit MacroGenics, at MacroGenics&#146; option, to purchase all or any part of Servier&#146;s worldwide unsold inventory of such Licensed Product ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7.2 Upon termination of this Agreement by Servier pursuant to Section&nbsp;14.2 or 14.3: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) all rights, licenses and options granted to Servier, its Affiliates or Sublicensees pursuant to this Agreement shall remain in
effect; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) all payment obligations under ARTICLE 8 shall remain in effect; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) all licenses granted by Servier, its Affiliates or Sublicensees pursuant to this Agreement, if this Agreement was terminated in its
entirety, or with respect to a Terminated Licensed Program, including pursuant to section 4.2, shall terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8
<U>Accrued Rights; Surviving Provisions of the Agreement. </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8.1 <U>Accrued Rights</U>. Termination or expiration of any
aspect of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of any Party prior to such termination or expiration including the payment obligations under ARTICLE 9 hereof, and any and all
damages or remedies arising from any breach hereunder. Such termination or expiration shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8.2 <U>Surviving Provisions of the Agreement</U>. The provisions of Sections 3.3.3(c), 6.1.2, 9.6-9.9 (with regard to accrued but
unpaid amounts), 9.10, 10.3.3, 12.5, 14.7 and 14.8 and ARTICLE 13 and ARTICLE 16, and any applicable definitions in ARTICLE 1, shall survive any partial or entire termination of this Agreement or partial or entire expiration of this Agreement for
any reason, in accordance with their respective terms and conditions, and for the duration stated, and where no duration is stated, shall survive indefinitely. ARTICLE 11 shall survive for a period of <B>***</B> after the effective date of the
entire termination or expiration of this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 15 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>STANDSTILL </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">***
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">***
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">***
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 16 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MISCELLANEOUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1 <U>Disputes. </U> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1.1 In the event any dispute arises out of or in relation to or in connection with this Agreement, including failure to perform under
or breach of, this Agreement or any issue relating to the interpretation or application of this Agreement, the Parties shall use good faith efforts to resolve such dispute within <B>***</B> *** after a Party notifies the other Party of such dispute,
whether through the JEC, JSC, JRDC or any subcommittee, as applicable, if the dispute is within the responsibilities of such a committee, or otherwise. If the Parties are unable to resolve such dispute, at the JSC, JRDC or subcommittee level or
otherwise, within such <B>***</B> *** period, either Party may, by written notice to the other Party refer such dispute to the JEC for resolution, and the JEC shall attempt in good faith to resolve such dispute within <B>***</B> days after such
notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1.2 Any dispute with respect to which a Party has final decision-making authority pursuant to Section&nbsp;2.9.3
or any dispute between the Parties concerning the validity, scope, enforceability, inventorship, or ownership of intellectual property rights (each, a &#147;<U>Non-Arbitrable Dispute</U>&#148;), shall not be subject to resolution by binding
arbitration under 16.2. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2 <U>Arbitration</U>. If the JEC is unable to resolve a given dispute referred to it
pursuant to Section&nbsp;2.9.3 or 16.1 within <B>***</B> *** following such referral of such dispute to the JEC, except for any Non-Arbitrable Disputes, either Party may have the given dispute settled by binding arbitration in the manner described
below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.1 <U>Arbitration Request</U>. If a Party intends to begin an arbitration to resolve a dispute arising under this
Agreement, such Party shall provide written notice (the &#147;<U>Arbitration Request</U>&#148;) to the other Party of such intention and the issues for resolution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2.2 <U>Additional Issues</U>. Within <B>***</B> *** after the receipt of the Arbitration Request, the other Party may, by written notice, add additional issues for resolution. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.3 <U>Arbitration Rules; Location</U>. Except as expressly provided herein, the sole mechanism for resolution of any claim, dispute
or controversy arising out of or in connection with or relating to this Agreement or the breach or alleged breach thereof shall be arbitration by the <B>***</B> then in effect except as provided herein. Neither Party shall be required to give
general discovery of documents, but may be required to produce documents or testimony which are considered relevant by the arbitrators to the dispute. The production of electronic documents shall be limited to those located in sources that are used
in the ordinary course of business. Neither Party shall be ordered to restore backup tapes; erased, damaged or fragmented data, or data normally deleted in the ordinary course of business. When the cost and burden of discovery are disproportionate
to the likely importance of the requested materials, the arbitrator may deny the requests or require that the requesting party advance the reasonable cost of production to the other Party. The Parties can further agree to limit the extent of
discovery in any arbitration undertaken pursuant to this Agreement. The arbitration shall take place in *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.4
<U>Privileges</U>. If a Party is entitled to attorney-client or attorney work product privileges from disclosure established under public policy provisions, such privileges shall apply and may be invoked by the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.5 <U>English Language</U>. All proceedings shall be held in English and a transcribed record prepared in English. Documents
submitted in the arbitration (the originals of which are not in English) shall be submitted together with a reasonably complete and accurate English translation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2.6 <U>Selection of Arbitrators</U>. The Parties shall each choose one arbitrator within <B>***</B> after receipt of notice of the intent to arbitrate and the said two arbitrators shall select by
mutual agreement a third arbitrator within <B>***</B> after they have been selected as arbitrators. If no arbitrator is appointed within the times herein provided or any extension of time that is mutually agreed on, <B>***</B> shall make such
appointment (i.e. shall appoint three arbitrators) within <B>***</B> after such failure. Additionally, if the two arbitrators selected by the Parties fail to appoint a third arbitrator within the time provided, *** shall appoint the third
arbitrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.7 <U>Experience</U>. If the issues in dispute involve scientific or technical matters, any arbitrators
chosen hereunder shall have educational training or experience sufficient to demonstrate a reasonable level of knowledge in the pharmaceutical and biotechnology fields. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.8 <U>Powers of Arbitrators</U>. The arbitrators shall be limited in the scope of their
authority to resolving only the specific matter which the Parties have referred to arbitration for resolution and shall not have authority to render any decision or award on any other issues. Without limiting the foregoing, the arbitrators:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) shall not have any power or authority to add to, alter, amend or modify the terms of this Agreement but shall specify
rules sufficient to allow reasonable discovery by the Parties; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) shall establish and enforce appropriate rules to ensure
that the proceedings, including the decision, be kept confidential and that all Confidential Information of the Parties be kept confidential and be used for no purpose other than the arbitration; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) shall issue all preliminary awards and the final award in writing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.9 <U>Injunctive Relief</U>. Nothing in this Agreement shall be deemed as preventing either Party from seeking injunctive relief (or
any other provisional remedy such as temporary restraining order, preliminary injunction or other interim equitable relief) from the arbitrators or from any court having jurisdiction over the Parties (and prior to or during any arbitration if
necessary to protect the interests of such Party in avoiding irreparable harm or to preserve the status quo pending the arbitration proceeding) and the subject matter of the dispute as necessary to protect either Party&#146;s name, proprietary
information, Know-How or any other proprietary right or otherwise to avoid irreparable harm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.10 <U>Costs; Exclusion from
Award</U>. The award rendered by the arbitrators <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.11 <U>Survivability</U>. Any duty to arbitrate under this
Agreement shall remain in effect and be enforceable after termination of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3 <U>Governing Law</U>. This
Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed and enforced in accordance with the <B>***</B> without reference to conflicts of laws principles. <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4 <U>Assignment</U>. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by any
Party without the consent of the other Party; <U>provided</U>, <U>however</U>, that any Party may, without such consent, assign this Agreement, in whole or in part: (a)&nbsp;to any of its respective Affiliates; <U>provided</U> that the assigning
Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or (b)&nbsp;to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this
Agreement relates (an &#147;<U>M&amp;A Event</U>&#148;); <U>provided</U> that such successor agrees in writing to be bound by the terms of this Agreement as if it were the assigning party. Any assignment not in accordance with this Section&nbsp;16.4
shall be void. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this Agreement is assigned by a Party in connection with an M&amp;A Event, such assignment shall not provide the non-assigning Party with
rights or access to any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
intellectual property or technology of the acquirer of the assigning Party. *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.5 <U>Force Majeure</U>. No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in breach of any provision of, this Agreement for failure or delay in
fulfilling or performing any obligation (other than a payment obligation) of this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of the Party so failing or delaying. For purposes of this Agreement,
force majeure is defined as causes beyond the control of the Party, including acts of God; war; civil commotion; destruction of production facilities or materials by fire, flood, earthquake, explosion or storm; external labor disturbances; epidemic;
and failure of public utilities or common carriers. In such event MacroGenics or Servier, as the case may be, shall immediately notify the other Party of such inability and of the period for which such inability is expected to continue. The Party
giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up to a maximum of <B>***</B>, after which time MacroGenics and Servier
shall promptly meet to discuss in good faith how to best proceed in a manner that maintains and abides by this Agreement. To the extent possible, each Party shall use reasonable efforts to minimize the duration of any force majeure. If a force
majeure event prevents a Party from performing any of its Development obligations for a Global Clinical Trial or Manufacturing obligations hereunder that would delay the Development or Manufacture of Licensed Product in the non-affected Party&#146;s
Territory, then, if the Parties can not agree on how to best proceed following such discussions, then, notwithstanding the exclusive license grants hereunder, the Party not affected by the force majeure event shall be permitted to either perform
directly or engage a Third Party clinical research organization or contract manufacturing organization to perform such Development and/or Manufacturing obligations for the duration of such force majeure event. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6 <U>Notices</U>. Any notice or request required or permitted to be given under or in connection with this Agreement shall be deemed
to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or reputable international business courier (signature required), prepaid, to the
Party for which such notice is intended, at the address set forth for such Party below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to MacroGenics, </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">addressed to: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical Center Drive </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Chief Executive Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile:<B> ***</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Servier, </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">addressed to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Les Laboratoires Servier </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 rue Carnot </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">92284 Suresnes Cedex </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">France </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: *** </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address for such Party as it shall have specified by like notice to the other Parties, <U>provided</U> that notices of a
change of address shall be effective only upon receipt thereof. The effective date of any notice shall be the actual date of receipt by the Party receiving the same. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.7 <U>Export Clause</U>. Each Party agrees that, as of the Effective Date, it will not export or re-export restricted commodities or the technical data of the other Party in any form without the
appropriate United States and non-United States government licenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.8 <U>Waiver</U>. Neither Party may waive or release
any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar
subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver of such condition or term or of another condition or term.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9 <U>Severability</U>. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the
Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and
shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any
other jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.10 <U>Entire Agreement</U>. This Agreement, together with the Schedules and Exhibits hereto, set forth
all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties as to the subject matter of this Agreement and supersedes and terminates all prior agreements and understanding between the
Parties with respect to the subject matter hereof. In particular, and without limitation, this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this
Agreement and exchanged between the Parties prior to the Effective Date. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties as to the subject matter of
this Agreement other than as set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers
of the Parties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.11 <U>Independent Contractors</U>. Nothing herein shall be construed to create any
relationship of employer and employee, agent and principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other
Party. Neither Party shall have the authority to bind or obligate the other Party and neither Party shall represent that it has such authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.12 <U>Headings; Construction; Interpretation</U>. Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this
Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion,
whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with
the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the
executed draft or any earlier draft of this Agreement. Any reference in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph,
clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires, (a)&nbsp;any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other
document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or therein), (b)&nbsp;any reference to any Law refers to such Law as from time
to time enacted, repealed or amended, (c)&nbsp;the words &#147;herein,&#148; &#147;hereof&#148; and &#147;hereunder,&#148; and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof, (d)&nbsp;the
words &#147;include,&#148; &#147;includes,&#148; &#147;including,&#148; &#147;exclude,&#148; &#147;excludes,&#148; and &#147;excluding,&#148; shall be deemed to be followed by the phrase &#147;but not limited to,&#148; &#147;without limitation&#148;
or words of similar import. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.13 <U>Further Actions</U>. Each Party shall execute, acknowledge and deliver such further
instruments, and do all such other acts, as may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.14 <U>Parties in Interest</U>. All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit of and be enforceable by the Parties hereto and their respective
successors, heirs, administrators and permitted assigns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.15 <U>Performance by Affiliates</U>. To the extent that this
Agreement imposes obligations on Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.16 <U>Counterparts</U>. This Agreement may be signed in counterparts, each and every one of which shall be deemed an original,
notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile signatures and signatures transmitted via portable document
format (PDF) shall be treated as original signatures. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>[</I></B><I>Signature page to follow</I><B><I>]</I></B><I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this Agreement to be
executed by their duly authorized representatives as of the Effective Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LES LABORATOIRES SERVIER</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name: ***</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Title: <B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Name: <B>*** </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>Title: <B>***</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INSTITUT DE RECHERCHES SERVIER</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>&nbsp;</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Name: <B>*** </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>Title: <B>***</B></FONT></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DART Platform </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Patents </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:15pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Title</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Pending Application</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000;width:26pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Number</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:47pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Foreign Rights</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Third Party Agreements </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>21
<FILENAME>filename21.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.21</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.21 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Execution Version </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed
separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OPTION FOR A LICENSE AGREEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>BY AND BETWEEN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B> AND </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
LES LABORATOIRES SERVIER </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AND </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INSTITUT DE RECHERCHES SERVIER </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Table of Contents </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFINITIONS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">GOVERNANCE</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance Business-Development Managers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance R&amp;D Managers</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project Directors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Executive Committee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Steering Committee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Research and Development Committee and Subcommittees</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Chairpersons</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Committee Meetings</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Decisions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authority</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representatives</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Overview</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conduct of the Research Program</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evaluation of Option Trigger Data Package; Option Exercise</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">GRANT OF RIGHTS; EXCLUSIVITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant to Servier</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant to MacroGenics</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sublicenses</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subcontracting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Third Party Agreements</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Right of First Negotiation for Bi-Specific DARTs</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights Retained by the Parties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 365(n) of the Bankruptcy Code</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusivity</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consequences of Development and Commercialization of Competing Products</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diagnostics</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEVELOPMENT DURING THE LICENSE TERM</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overview</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier Obligations</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Activities</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Updating and Amending Development Plan and Development Budget; Additional Development Activities</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Activities</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exchange of Data</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">REGULATORY MATTERS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier Regulatory Responsibility</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Regulatory Responsibility</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">33</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Communications with Regulatory Authorities</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Product Withdrawals and Recalls</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">35</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pharmacovigilance; Safety Data Reporting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MANUFACTURING</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer of MacroGenics Manufacturing Know-How</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supply Agreements</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">COMMERCIALIZATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overview</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales and Distribution</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ex-Territory Sales</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization Plan for Licensed Territory</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trademarks.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial Diligence</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standards of Conduct</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAYMENTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Grant Fee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant Fee</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development and Regulatory Milestones</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">40</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales Milestones</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">41</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">42</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reports; Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Methods of Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Late Payments</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">43</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Taxes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Books and Records; Audit Rights</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventorship</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ownership</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">44</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prosecution and Maintenance of Patents</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">45</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Third Party Infringement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Invalidity Claim</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">49</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Term Extensions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Marking</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- ii -
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONFIDENTIALITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality; Exceptions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized Disclosure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release; Disclosure of Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing Confidentiality Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Remedies</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Publications</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Return of Confidential Information</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representations and Warranties of Both Parties</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representations and Warranties of MacroGenics and its Affiliates</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representation and Warranty of LLS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mutual Covenants</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclaimer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">INDEMNIFICATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnification by Servier</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnification by MacroGenics</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Procedure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">57</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Allocation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE 14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">TERM AND TERMINATION</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Agreement Term; Expiration</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Cause</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">58</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Patent Challenge</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Convenience</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination for Insolvency Event</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination by Servier for Safety or Public Health Reasons</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effect of Expiration or Termination</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accrued Rights; Surviving Provisions of the Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;15</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">STANDSTILL</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15.1</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Standstill</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">ARTICLE&nbsp;16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MISCELLANEOUS</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disputes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arbitration Disputes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">62</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- iii -
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Governing Law</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Force Majeure</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notices</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Export Clause</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waiver</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severability</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entire Agreement</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.11</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Independent Contractors</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.12</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Headings; Construction; Interpretation</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further Actions</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.14</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Parties in Interest</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.15</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance by Affiliates</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.16</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Counterparts</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit A-1: Back-Up Program Antibodies</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit A-2: MGA271</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit B: MacroGenics Patents</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit C: MacroGenics Third Party Agreements</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit D: Press Release</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- iv -
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">OPTION FOR A LICENSE AGREEMENT </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">This Option for a License Agreement (this &#147;<U>Agreement</U>&#148;) is entered into and made effective as of the
24</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> day of November, 2011 (the &#147;<U>Effective
Date</U>&#148;), by and between MacroGenics, Inc. a corporation organized and existing under the laws of the State of Delaware and having a principal office located at 1500 East Gude Drive Rockville, MD 20850, USA (&#147;<U>MacroGenics</U>&#148;),
and Les Laboratoires Servier, a company organized and existing under the laws of France, having a principal office located at 50 rue Carnot 92284 Suresnes (&#147;<U>LLS</U>&#148;) and Institut de Recherches Servier, a company organized and existing
under the laws of France, having a principal office located at 3 rue de la R&eacute;publique &#150; 92150 Suresnes - France (&#147;<U>IdRS</U>&#148; and LLS and IdRS hereinafter collectively referred to as &#147;<U>Servier</U>&#148;). MacroGenics
and Servier are each referred to herein by name or as a &#147;<U>Party</U>&#148; or, collectively, as &#147;<U>Parties</U>.&#148; </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RECITALS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Servier possesses expertise in the Research,
Development, Manufacturing and Commercialization (each as defined below) of pharmaceutical products; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics
controls certain intellectual property related to certain antibodies targeting B7-H3, including the antibody known as MGA271; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Servier is interested in receiving an exclusive option to obtain a future license under which it may further research, develop
and commercialize such antibodies in the Servier Territory (as defined below), and MacroGenics is willing to grant Servier such an option to obtain a future license on the terms and conditions set forth in this Agreement; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS the Parties are willing to set forth the terms and conditions of an option grant and an exclusive license to enable Servier to
research, develop and commercialize the above mentioned antibodies as further defined hereafter, upon exercise of the exclusive option by Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties hereto agree as follows: </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As used in this Agreement, the following terms will have the
meanings set forth in this ARTICLE 1 unless context dictates otherwise: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1 &#147;<U>Accounting Standards</U>&#148; means,
with respect to a Person, generally accepted accounting principles as practiced in the United States or, to the extent applicable, IFRS (International Financial Reporting Standards). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2 &#147;<U>Affiliate</U>&#148; means, as to a Person, any other Person that, directly or
indirectly through one or more intermediaries, controls, is controlled by or is under common control with said first Person, regardless of whether such Affiliate is an Affiliate on the Effective Date or becomes an Affiliate after the Effective Date.
A Person shall be deemed to &#147;control&#148; another Person if it (a)&nbsp;owns, directly or indirectly, beneficially or legally, more than fifty percent (50%)&nbsp;of the outstanding voting securities or capital stock (or such lesser percentage
which is the maximum allowed to be owned by a Person in a particular jurisdiction) of such other Person, or has other comparable ownership interest with respect to any Person other than a corporation; or (b)&nbsp;has the power, whether pursuant to
contract, ownership of securities or otherwise, to direct the management and policies of the Person. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3 &#147;<U>Agreement
Term</U>&#148; means the period commencing on the Effective Date and ending on the expiration of this Agreement in accordance with the provisions of Section&nbsp;14.1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.4 &#147;<U>Annual Net Sales</U>&#148; means aggregate Net Sales of Licensed Products by Servier or its Affiliates or Sublicensees in any Calendar Year, or in the first year and last year of the Royalty
Term, the portion of such Calendar Year during which the Royalty Term is in effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5 &#147;<U>Antibody(ies)</U>&#148;
means a monospecific molecule which comprises or contains: (a)&nbsp;at least one immunoglobulin variable domain or parts of such domain, variants, modifications or derivatives thereof; or (b)&nbsp;the nucleic acid consisting of a sequence of
nucleotides encoding (or complementary to a nucleic acid encoding) the foregoing molecules in (a). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6
&#147;<U>B7-H3</U>&#148; means the Target referred to as B7-H3, B7H3; 4Ig-B7-H3 or CD276 that is identified by Entrez Gene ID 80381. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.7 &#147;<U>Back-Up Program Antibody(ies)</U>&#148; means the Antibodies identified in <U>Exhibit A-1</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.8 &#147;<U>Bi-Specific DART</U>&#148; means a dual affinity re-targeting molecule that binds to <B>***</B> Targets, of which at least one of such Targets is B7-H3. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9 &#147;<U>BLA</U>&#148; means a Biologics License Application and any amendments or supplements thereto filed with the FDA pursuant to
21 C.F.R. Part 601 or any other application required for the purpose of marketing and selling a biological product filed with a Regulatory Authority outside the United States, including with respect to the EU a Product License Application, Marketing
Authorization Application and/or manufacturing and importation license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10 &#147;<U>Business Day</U>&#148; means a day on
which banking institutions in Washington, DC, USA and Paris, France are open for business, excluding any Saturday or Sunday. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11 &#147;<U>Calendar Quarter</U>&#148; means a period of three (3)&nbsp;consecutive months ending on the last day of March, June,
September, or December, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12 &#147;<U>Calendar Year</U>&#148; means a period of time commencing on
January&nbsp;1 and ending on the following December&nbsp;31. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13 &#147;<U>Commercialization</U>&#148; or &#147;<U>Commercialize</U>&#148; means any
activities directed to obtaining pricing and/or reimbursement approvals, marketing, promoting, distributing, importing, offering to sell, and/or selling a product (including establishing the price for such product). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14 &#147;<U>Commercially Reasonable Efforts</U>&#148; means with respect to a Party, such efforts that are consistent with the efforts
and resources normally used by <B>***</B> relating to the Research, Development and Commercialization of products (a)&nbsp;that have scientific attributes similar to those of the relevant Program Antibody or Licensed Product in oncology,
(b)&nbsp;that are at a similar stage in their Research, Development, Commercialization or product life as the relevant Program Antibody or Licensed Product, and (c)&nbsp;that have commercial and market potential similar to the relevant Program
Antibody or Licensed Product, taking into account issues of intellectual property scope, subject matter and coverage, safety and efficacy, product profile, competitiveness with respect to Third Party products in the marketplace, proprietary position
and profitability (including pricing and reimbursement status achieved or likely to be achieved), and (d)&nbsp;solely owned by them or to which they have exclusive rights. If either Party grants a sublicense to an Affiliate or Third Party as
permitted under this Agreement, then, with respect to such sublicensee Commercially Reasonable Efforts shall mean the efforts and resources (as defined above in this Section&nbsp;1.14) normally used by the Party granting the sublicense, qualified by
the items in clauses (a)&nbsp;&#150; (d)&nbsp;inclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15 &#147;<U>Competing Product</U>&#148; means (a)&nbsp;any product
that <B>***</B> and is specifically indicated or developed for patients that <B>***</B>; and (b)&nbsp;any Bi-Specific DART. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16 &#147;<U>Complete</U>&#148; or &#147;<U>Completing</U>&#148; means, for a clinical trial, the date upon which all patients have
completed protocol-defined drug administration and study database lock has occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17 &#147;<U>Control</U>,&#148;
&#147;<U>Controls</U>,&#148; &#147;<U>Controlled</U>&#148; or &#147;<U>Controlling</U>&#148; means, with respect to any item of or right under an intellectual property right, the possession (whether by ownership or license, other than pursuant to
this Agreement) of the ability of a Party to grant access to, or a license or sublicense of, such items or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party existing at the time such
Party would be required hereunder to grant the other Party such access or license or sublicense; <U>provided</U> <U>that</U> any intellectual property right that is licensed or acquired by a Party after the Effective Date <B>***</B> and that would
otherwise be considered to be under the Control of such Party shall not be deemed to be under the Control of such Party if the application of such definition in the context of any licenses or sublicenses granted to the other Party under this
Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such license or sublicense grants, unless the other Party agrees to pay the additional payments or royalties to the Third
Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18 &#147;<U>Cover</U>&#148;, &#147;<U>Covering</U>&#148; or &#147;<U>Covered</U>&#148; means, with respect to a
product, technology, process or method that, in the absence of ownership of or a license granted under a Valid Claim, the manufacture, use, offer for sale, sale or importation of such product or the practice of such technology, process or method
would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19 &#147;<U>Develop</U>&#148; or &#147;<U>Development</U>&#148; means drug development
activities relating to the development of compounds, products, or processes, and submission of information to a Regulatory Authority for the purpose of obtaining Regulatory Approval of a product. Development includes non-clinical activities,
pharmacology studies, toxicology studies, formulation, chemical analysis, bioanalytical analysis, material performance studies (such as measurements of stability, physical form, dissolution, or visual or spectroscopic analysis, and the like),
pharmacokinetic studies, clinical studies, biomarker and companion diagnostic discovery and development, regulatory affairs activities, and all other activities relating to seeking, obtaining or maintaining any Regulatory Approvals from the FDA or
any other applicable Regulatory Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20 &#147;<U>Development Costs</U>&#148; means the costs and expenses incurred by
a Party or its Affiliates, attributable to, or reasonably allocable to, the Development of a Program Antibody or Licensed Product and that are consistent, if applicable, with the Development Budget and do not exceed the relevant amount set forth in
such Development Budget by more than <B>***</B> unless approved in writing by the JRDC and such other costs as are expressly approved in writing by the JRDC as &#147;Development costs&#148;. &#147;Development Costs&#148; shall include
(a)&nbsp;Out-of-Pocket Costs and (b)&nbsp;FTE Costs of internal personnel that are attributable or reasonably allocable to the Development of such Program Antibody or Licensed Product determined in accordance with applicable Accounting Standards of
such Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.21 &#147;<U>Diagnostic</U>&#148; means any companion diagnostic for a B7-H3 expressing tumor that is
(a)&nbsp;Developed in combination with a Program Antibody and/or Licensed Product; and (b)&nbsp;used in combination with a Licensed Product. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.22 &#147;<U>Dollars</U>&#148; or &#147;<U>$</U>&#148; means the legal tender of the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.23 &#147;<U>EMA</U>&#148; means the European Medicines Agency, or any successor entity thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.24 &#147;<U>EU</U>&#148; means the European Union, as its membership may be altered from time to time, and any successor thereto.&nbsp;The member countries of the European Union as of the Effective Date
are Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and
United Kingdom as well as Norway and Iceland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25 &#147;<U>Excluded Data</U>&#148; means any Know-How, other than Safety
Data, generated by a Party in the conduct of Development activities in accordance with a Development Collaboration Proposal where the other Party has declined to participate in such Development Collaboration Proposal and has not paid the Buy-In
Amount in accordance with Section&nbsp;5.4.2(b)(iv). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26 &#147;<U>FDA</U>&#148; means the U.S. Food and Drug Administration,
or any successor entity thereto. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27 &#147;<U>FD&amp;C Act</U>&#148; means the United States Federal Food, Drug, and
Cosmetic Act, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28 &#147;<U>Field</U>&#148; means all human fields of use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.29 &#147;<U>First Commercial Sale</U>&#148; means the first sale of a Licensed Product by Servier, its Affiliates or its Sublicensees
for use or consumption of such Licensed Product in a country in the Servier Territory where Regulatory Approval of such Licensed Product has been obtained or otherwise permitted for sale by the Governmental Authority of such country. Sale of a
Licensed Product by Servier to an Affiliate of Servier or a Sublicensee of Servier shall not constitute a First Commercial Sale unless such Affiliate or such Sublicensee is the end user of a Licensed Product. In no event shall any sales for
premarketing, testing or sampling be deemed a First Commercial Sale. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.30 &#147;<U>FTE</U>&#148; means <B>***</B> of work
devoted to or in support of the Development or Manufacture of Program Antibodies and Licensed Product in accordance with a Global Development Plan or as required under Section&nbsp;7.2, that is carried out by one or more qualified scientific or
technical employees or contract personnel of MacroGenics or its Affiliates, or Servier or its Affiliates, as measured in accordance with the relevant Party&#146;s normal time allocation practices. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31 &#147;<U>FTE Cost</U>&#148; means, for any period, the FTE Rate multiplied by the number of FTEs in such period. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32 &#147;<U>FTE Rate</U>&#148; means a rate of <B>***</B> per FTE per Calendar Year (pro-rated for the period beginning on the
Effective Date and ending at the end of the first Calendar Year) for personnel engaged in Development and Manufacturing activities. The FTE Rate is &#147;fully burdened&#148; and will cover <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.33 &#147;<U>Fully Burdened Manufacturing Cost</U>&#148; means with respect to a Program Antibody or Licensed Product, the aggregate of
internal and external costs of MacroGenics and its Affiliates to Manufacture such Program Antibody or Licensed Product, calculated as follows: (a)&nbsp;to the extent that MacroGenics or its Affiliates perform all or any part of the Manufacturing of
such Program Antibody or Licensed Product, the direct material costs <B>***</B> and FTE Costs for such Manufacturing of such Program Antibody or Licensed Product <B>***</B>, all calculated in accordance with applicable Accounting Standards as
consistently applied by MacroGenics or its Affiliates; and (b)&nbsp;to the extent that Manufacturing of such Program Antibody or Licensed Product is performed by a Third Party, the costs paid to such Third Party for such activities *** and the
reasonable direct FTE Costs incurred by MacroGenics or any of its Affiliates in managing and overseeing the Third Party relationship, determined in accordance with applicable Accounting Standards as consistently applied by MacroGenics or its
Affiliates. <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.34 &#147;<U>Generic Competition</U>&#148; means, with respect to a given Calendar Quarter with
respect to a Licensed Product in any country, that during such Calendar Quarter, one (1)&nbsp;or more Third Parties sell in such country a Generic Product, such Generic Product shall be commercially available in such country and such Generic Product
shall have, in the aggregate, a <B>***</B> or more </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
market share of the aggregate of Licensed Products and Generic Products (based on data provided by IMS Health Incorporated, Fairfield, Connecticut) as measured on a ***, or if such data is not
available, the Parties shall agree upon a methodology for estimating the percentage of unit sales based market share of Generic Products in such country. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.35 &#147;<U>Generic Products</U>&#148; means, with respect to a particular Licensed Product commercialized by Servier in a particular country, any product (other than Licensed Products commercialized,
directly or indirectly, by Servier, its Affiliates or Sublicensees, or by any authorized distributors of Servier, its Affiliates or Sublicensees) that either (a)&nbsp;is a &#147;follow-on biologic&#148; (FOB) or biosimilar or equivalent version to a
Licensed Product, as defined by the competent Regulatory Authority, and administered in an equivalent dosage form as such Licensed Product or (b)&nbsp;for which a Third Party has received Regulatory Approval (based upon then-current applicable Laws
governing approval of biological products) whose application for approval relies to a large extent (but not exclusively) on data generated for a Licensed Product, including Regulatory Approval under section 505(b)(2) of the Federal Food Drug, and
Cosmetic Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36 &#147;<U>Global Clinical Trial</U>&#148; means a Phase 1 Clinical Trial, a Phase 2 Clinical Trial or a
Phase 3 Clinical Trial that may be applicable to obtaining Regulatory Approval of Licensed Products in both the Servier Territory and the MacroGenics Territory or relies on patient recruitment from both the Servier Territory and the MacroGenics
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.37 &#147;<U>Good Clinical Practices</U>&#148; or &#147;<U>GCP</U>&#148; means the then-current standards,
practices and procedures (a)&nbsp;promulgated or endorsed by the FDA as set forth in the guidelines entitled &#147;Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance,&#148; including related regulatory requirements imposed by the
FDA; (b)&nbsp;set forth in Directive 2001/20/EC of the European Parliament and of the Council of 4&nbsp;April 2001 and Commission Directive 2005//28/EC of 8&nbsp;April 2005; (c)&nbsp;ICH Guideline for Good Clinical Practice E6; (d)&nbsp;equivalent
Laws of an applicable Regulatory Authority; and (e)&nbsp;all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or complement any of the foregoing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38 &#147;<U>Good Laboratory Practices</U>&#148; or &#147;<U>GLP</U>&#148; means the then-current good laboratory practice standards
promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, as such regulations may be amended from time to time, and the equivalent regulations promulgated by the equivalent Regulatory Authority in the jurisdiction where Development
activities are performed.<B> </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39 &#147;<U>Good Manufacturing Practices</U>&#148; or &#147;<U>GMP</U>&#148; means
then-current standards for the manufacture of pharmaceutical products, pursuant to (a)&nbsp;the FD&amp;C Act (21 U.S.C. 321 et seq.); (b)&nbsp;relevant United States regulations in Title 21 of the United States Code of Federal Regulations (including
Parts 11, 210, and 211); (c)&nbsp;European Community Directives 2003/94 and 91/356/EC; (d)&nbsp;the European Community Guide to Good Manufacturing Practice for Medicinal Intermediate Products; (e)&nbsp;ICH Q7A Good Manufacturing Practice Guidance
for Active Pharmaceutical Ingredients; (f)&nbsp;equivalent Laws of an applicable Regulatory Authority at the time of Manufacture; and (g)&nbsp;all additional Regulatory Authority documents or regulations that replace, amend, modify, supplant or
complement any of the foregoing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.40 &#147;<U>Governmental Authority</U>&#148; means any United States federal, state or
local or any non-United States government, or political subdivision thereof, or any multinational organization or authority or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police,
regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof), or any governmental arbitrator or arbitral body. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.41 &#147;<U>ICH</U>&#148; means the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42 &#147;<U>Identified Patents</U>&#148; means <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.43 &#147;<U>IND</U>&#148; means an Investigational New Drug Application filed with FDA or a similar application filed with an applicable Regulatory Authority outside of the United States such as a
clinical trial application (CTA). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.44 &#147;<U>Indication</U>&#148; means either (a)&nbsp;a discrete clinically recognized
form of a disease or <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45 &#147;<U>Initial Phase 1 Clinical Trial</U>&#148; means <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.46 &#147;<U>Insolvency Event</U>&#148; means, with respect to any Party, the occurrence of any of the following: (a)&nbsp;such Party
shall commence a voluntary case concerning itself under any bankruptcy, liquidation or insolvency code; (b)&nbsp;an involuntary case is commenced against such Party and the petition is not dismissed, bonded or stayed within ninety (90)&nbsp;days
after commencement of the case; (c)&nbsp;a court-supervised custodian is appointed for, or takes charge of, all or substantially all of the property of such Party to continue undischarged or unstayed for a period of ninety (90)&nbsp;days;
(d)&nbsp;any order of relief or other order approving any such case or proceeding is entered; (e)&nbsp;such Party is adjudicated insolvent or bankrupt; and (f)&nbsp;such Party makes a general assignment for the benefit of creditors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47 &#147;<U>Joint IP</U>&#148; means all inventions and discoveries (and Patents claiming patentable inventions therein) first made or
discovered jointly by one or more employees, consultants or agents of MacroGenics or its Affiliates, together with one or more employees, consultants or agents of Servier or its Affiliates in the course of the Research, Development, Manufacture or
Commercialization of Program Antibodies and/or Licensed Product, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48 &#147;<U>Know-How</U>&#148; means all tangible and
intangible (a)&nbsp;information, techniques, technology, practices, trade secrets, inventions (whether patentable or not), methods, knowledge, know-how, skill, experience, data, results (including pharmacological, toxicological and non-clinical and
clinical test data and results, and Research or Development data, reports and batch records), analytical and quality control data, analytical methods (including applicable reference standards), full batch documentation, packaging records, release,
stability, storage and shelf-life </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
data, Manufacturing process information, results and descriptions, and software and algorithms and (b)&nbsp;compositions of matter, cells, cell lines, assays, animal models and physical,
biological or chemical material. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.49 &#147;<U>Law</U>&#148; or &#147;<U>Laws</U>&#148; means all laws, statutes, rules,
regulations, orders, judgments, or ordinances having the effect of law of any federal, national, multinational, state, provincial, county, city or other political subdivision. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.50 &#147;<U>Licensed Product</U>&#148; means any therapeutic or prophylactic product that comprises or incorporates a Program Antibody as an active pharmaceutical ingredient alone or in combination with
one or more other active agents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51 &#147;<U>License Term</U>&#148; means the period commencing upon the License Grant Date
and ending on the date of expiration or termination of this Agreement in accordance with the provisions of ARTICLE 14. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.52*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53
&#147;<U>MacroGenics Indemnitees</U>&#148; means MacroGenics, its Affiliates and the directors, officers and employees of MacroGenics and its Affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.54 &#147;<U>MacroGenics IP</U>&#148; means the MacroGenics Know-How and the MacroGenics Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.55 &#147;<U>MacroGenics Know-How</U>&#148; means Know-How that is (a)&nbsp;Controlled by MacroGenics or its Affiliates on the Effective Date or thereafter during the Agreement Term; (b)(i) an
improvement, modification, enhancement or novel use of a Program Antibody or Licensed Product, or any improvement, modification or enhancement in the Manufacturing process or formulation of a Program Antibody or Licensed Product by or on behalf of
MacroGenics or its Affiliates; or (ii)&nbsp;disclosed by or on behalf of MacroGenics or its Affiliates to Servier or its Affiliates pursuant to this Agreement; and (c)&nbsp;necessary or useful to Research, Develop, Manufacture or Commercialize any
Program Antibody or Licensed Product in the Field in the Servier Territory. MacroGenics Know-How excludes MacroGenics&#146; interest in the Joint IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.56 &#147;<U>MacroGenics Patents</U>&#148; means Patents Controlled by MacroGenics or its Affiliates on the Effective Date or thereafter during the Agreement Term that claim or are directed to
MacroGenics Know-How. The MacroGenics Patents existing as of the Effective Date are set forth on <U>Exhibit B</U>. MacroGenics Patents excludes MacroGenics&#146; interest in the Joint IP. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57 &#147;<U>MacroGenics Territory</U>&#148; means the United States of America, Canada, Mexico, India, Japan, Korea and any Terminated
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58 &#147;<U>MacroGenics Third Party Agreements</U>&#148; means (a)&nbsp;the agreements which are set forth on
Exhibit C, and (b)&nbsp;any other agreement pursuant to which MacroGenics licenses or acquires Patents or Know-How that relates to the Program Antibodies or Licensed Products in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Field in the Servier Territory after the Effective Date pursuant to an agreement with a Third Party, the terms and conditions of which have been approved (not to be unreasonably withheld) by
Servier before its execution by MacroGenics and which Servier and MacroGenics agree shall be deemed a MacroGenics Third Party Agreement, in which case <U>Exhibit C</U> shall be amended accordingly. For purposes of clarity, in the event that Servier
does not approve the terms and conditions of any such proposed agreement with a Third Party, nothing herein shall be deemed to preclude MacroGenics from entering into such agreement with a Third Party; provided that such agreement with a Third Party
shall not be deemed a MacroGenics Third Party Agreement hereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59 &#147;<U>Major Indication</U>&#148; means any of the
following Indications: <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60 &#147;<U>Manufacture</U>&#148; or &#147;<U>Manufacturing</U>&#148; means all
activities related to the manufacturing of an Antibody or product, including test method development and stability testing, formulation, process development, manufacturing scale-up, manufacturing for use in non-clinical and clinical studies,
manufacturing for commercial sale, packaging, release of product, quality assurance/quality control development, quality control testing (including in-process, release and stability testing) and release of product or any component or ingredient
thereof, and regulatory activities related to all of the foregoing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61 &#147;<U>Manufacturing Process Development
Costs</U>&#148; means the costs and expenses incurred by a Party or its Affiliates attributable to, or reasonably allocable to, the development of a Manufacturing process for Program Antibodies or Licensed Products (including <B>***</B>).
&#147;Manufacturing Process Development Costs&#148; shall include (a)&nbsp;Out-of-Pocket Costs and (b)&nbsp;FTE Costs of internal personnel that are attributable or reasonably allocable to the development of a Manufacturing process for Program
Antibodies or Licensed Products determined in accordance with applicable Accounting Standards of such Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62
&#147;<U>MGA271</U>&#148; means the Antibody known as MGA271 which is described in <U>Exhibit A-2</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.63 &#147;<U>Net
Sales</U>&#148; means, in the case of sales by or for the benefit of Servier, its Affiliates, and its Sublicensees (the &#147;<U>Seller</U>&#148;) to independent, unrelated persons (&#147;<U>Buyers</U>&#148;) in bona fide arm&#146;s length
transactions (except as provided below with respect to clinical trial samples), the gross amount billed or invoiced by Seller with respect to the Licensed Product, less the following deductions, in each case to the extent actually allowed and taken
by such Buyers and not otherwise recovered by or reimbursed to Seller in connection with such&nbsp;Licensed Product (&#147;<U>Permitted Deductions</U>&#148;): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Net Sales&#148; shall not include any consideration received with
respect to a sale, use or other disposition of any Licensed Product in a country as part of a clinical trial necessary to obtain Regulatory Approval in such country. All of the foregoing elements of Net Sales calculations shall be determined in
accordance with IFRS or successor standards and guidelines thereto. In the case of transfers of&nbsp;Licensed Product between any of Servier, its Sublicensees, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
and Affiliates of any of the foregoing, for subsequent sale, rental,&nbsp;lease&nbsp;or&nbsp;other transfer of such&nbsp;Licensed Products to Third Parties, Net Sales shall be the gross invoice
or contract price charged to the Third Party customer for that Licensed Product, less the deductions set forth in clauses *** above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.64 &#147;<U>Option Trigger Data Package</U>&#148; means the written report containing specified information and data on the results of the Initial Phase 1 Clinical Trial. The Option Trigger Data Package
shall include <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65 &#147;<U>Out-of-Pocket Costs</U>&#148; means, with respect to certain activities hereunder,
direct expenses paid or payable by either Party or its Affiliates to Third Parties and specifically identifiable and incurred to conduct such activities for a Licensed Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.66 &#147;<U>Patent</U>&#148; means (a)&nbsp;all patents and patent applications in any country or supranational jurisdiction, and
(b)&nbsp;any substitutions, divisionals, continuations, continuations-in-part, provisional applications, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such
patents or patent applications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67 &#147;<U>Person</U>&#148; means any individual, partnership, joint venture, limited
liability company, corporation, firm, trust, association, unincorporated organization, governmental authority or agency, or any other entity not specifically listed herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.68 &#147;<U>Phase 1 Clinical Trial</U>&#148; means a human clinical trial, other than the Phase 1 Dosing Clinical Trial, that is intended to initially evaluate the safety and/or pharmacological effect
of a product or that would otherwise satisfy the requirements of<BR> 21 C.F.R. 312.21(a) or an equivalent clinical trial in a country other than the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.69 &#147;<U>Phase 2 Clinical Trial</U>&#148; means a human clinical trial for which the primary endpoints include a determination of dose ranges or an indication of efficacy of a product in patients
being studied as described in 21 C.F.R. &#167;312.21(b), or an equivalent clinical trial in a country other than the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.70 &#147;<U>Phase 3 Clinical Trial</U>&#148; means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in the
indication being investigated in a manner sufficient to obtain Regulatory Approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. &#167;312.21(c), or an equivalent clinical trial in a
country other than the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71 &#147;<U>PMDA</U>&#148; means the Japanese Pharmaceuticals and Medical Devices
Agency or any successor agency thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.72 &#147;<U>Program Antibody</U>&#148; means <B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.73 &#147;<U>Regulatory Approval</U>&#148; means the approval, license or authorization of
the applicable Regulatory Authority necessary for Development and/or Commercialization of a Program Antibody and/or a Licensed Product for a particular Indication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.74 &#147;<U>Regulatory Authority</U>&#148; means the FDA in the United States or any health regulatory authority in another country that is a counterpart to the FDA and holds responsibility for allowing
development of Program Antibodies and/or granting Regulatory Approval for a Licensed Product in such country, including the EMA, and any successor(s) thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.75 &#147;<U>Regulatory-Based Exclusivity Period</U>&#148; means, with respect to a Licensed Product, that period of time during which Servier or any of its Affiliates or Sublicensees has been granted
the exclusive legal right by a Regulatory Authority either to market and sell a Licensed Product in a country in the Servier Territory or the exclusive right to the use of or reference to clinical data in relation to a Licensed Product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76 &#147;<U>Regulatory Documentation</U>&#148; means, with respect to the Program Antibodies or Licensed Products, all INDs, BLAs, and
other regulatory applications submitted to any Regulatory Authority, copies of Regulatory Approvals, regulatory materials, drug dossiers, master files (including Drug Master Files, as defined in 21 C.F.R. &#167;314.420 and any non-United States
equivalents), and any other reports, records, regulatory correspondence, meeting minutes, telephone logs, and other materials relating to Regulatory Approval of the Program Antibodies or Licensed Products (including any underlying safety and
effectiveness data whether or not submitted to any Regulatory Authority), or required to manufacture, distribute or sell Licensed Products including any information that relates to pharmacology, toxicology, chemistry, manufacturing and controls
data, batch records, safety and efficacy, and any safety database required to be maintained for Regulatory Authorities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.77
&#147;<U>Research</U>&#148; means the discovery, identification, research, characterization, modification, derivatization and optimization of pharmaceutical compounds. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.78 &#147;<U>Research Plan</U>&#148; means a research plan developed by the Parties that sets forth the activities to be undertaken during the Research Term, which research plan may be amended from time
to time by the JRDC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.79 &#147;<U>Research Term</U>&#148; means the period commencing with the Effective Date and ending
<B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80 &#147;<U>Restricted Indication</U>&#148; means any <B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.81 &#147;<U>Right of Reference or Use</U>&#148; means a &#147;Right of Reference or Use&#148; as that term is defined in 21 C.F.R.
&#167;314.3(b), and any non-United States equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.82 &#147;<U>Safety Data</U>&#148; means adverse event information
and other information (if any) required by one or more Regulatory Authorities to be collected or to be reported to such Regulatory Authorities under applicable Laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.83 &#147;<U>Servier Collaboration IP</U>&#148; means the Servier Collaboration Know-How
and the Servier Collaboration Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.84 &#147;<U>Servier Collaboration Know-How</U>&#148; means Know-How that is
(a)&nbsp;Controlled by Servier or its Affiliates on the Effective Date or thereafter during the Agreement Term; (b)&nbsp;(i)&nbsp;an improvement, modification, enhancement or novel use of a Program Antibody or Licensed Product, or any improvement,
modification or enhancement in the Manufacturing process or formulation of a Program Antibody or Licensed Product by or on behalf of Servier or its Affiliates; or (ii)&nbsp;disclosed by or on behalf of Servier or its Affiliates to MacroGenics or its
Affiliates pursuant to this Agreement; and (c)&nbsp;necessary or useful to Research, Develop, Manufacture or Commercialize any Program Antibody or Licensed Product in the Field. Servier Collaboration Know-How excludes Servier&#146;s interest in the
Joint IP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.85 &#147;<U>Servier Collaboration Patent(s)</U>&#148; means Patents Controlled by Servier and its Affiliates on
the Effective Date or thereafter during the Agreement Term claiming or directed to Servier Collaboration Know-How. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86
&#147;<U>Servier Indemnitees</U>&#148; means Servier, its Affiliates and the directors, officers and employees of Servier and its Affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.87 &#147;<U>Servier Territory</U>&#148; means the entire world excluding the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.88 &#147;<U>SFDA</U>&#148; means the Chinese State Food and Drug Administration or any successor agency thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.89 &#147;<U>Significant Patent</U>&#148; means any <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.90
&#147;<U>Sublicensee</U>&#148; means a Third Party to whom a Party, as permitted under this Agreement, grants a license or sublicense, as the case may be, under the MacroGenics IP or Servier IP to Research, Develop, Manufacture, Commercialize or use
Program Antibodies and/or Licensed Products in the Field or otherwise grants rights to distribute, promote or sell Licensed Products in the Field. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.91 &#147;<U>Target</U>&#148; *** </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.92 &#147;<U>Terminated Territory</U>&#148;
means with respect to a termination of this Agreement pursuant to Section&nbsp;14, as applicable, (i)&nbsp;the country(ies) subject to such termination; and (ii)&nbsp;with respect to termination of this Agreement in its entirety, the Servier
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.93 &#147;<U>Third Party</U>&#148; means any Person other than MacroGenics or Servier that is not an Affiliate of
MacroGenics or of Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.94 &#147;<U>United States</U>&#148; or &#147;<U>U.S.</U>&#148; means the United States of
America and all of its territories and possessions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.95 &#147;<U>Valid Claim</U>&#148; means (a)&nbsp;a claim of an issued patent that has not
expired or been abandoned, or been revoked, held invalid or unenforceable by a patent office, court or other governmental agency of competent jurisdiction in a final and non-appealable judgment (or judgment from which no appeal was taken within the
allowable time period) <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.96 <U>Additional Definitions</U>. Each of the following definitions is set forth in the
section of this Agreement indicated below: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance Business-Development Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance R&amp;D Manager</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arbitration Request</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audited Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Auditing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Bankruptcy Code</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Breaching Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Buy-In Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(b)(iv)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Buy-In Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(b)(ii)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical Supply Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Co-Chairperson</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercial Supply Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercializing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidential Information</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">De Minimis Overage Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Budget</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Development Collaboration Proposal</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclosing Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Excess Overage Amount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Existing Confidentiality Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Global Development Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">IdRS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnified Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnifying Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initial Development Budget</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiating Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inspected Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JEC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joint Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JRDC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">JSC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant Date</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3(a)</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:36pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Definition:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Section:</B></FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">License Grant Fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">LLS</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Losses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">M&amp;A Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Product Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.1(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Arbitrable Dispute</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Non-Breaching Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Grant Fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option Period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Party or Parties</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Project Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposed Development Plan Amendment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Receiving Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reconciliation Payment</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2(c)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Program</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Responsible Party</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.3(b)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalty Term</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.2</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SDEA Agreement</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5.1</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preamble</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier Product Patents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.2(a)</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Supplemental Data</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 2 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>GOVERNANCE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1 <U>Alliance Business-Development Managers</U>. Within
thirty (30)&nbsp;days following the Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its business development alliance manager under this Agreement (&#147;<U>Alliance
Business-Development Manager</U>&#148;). The Alliance Business-Development Managers shall be there to coordinate any business related activities under this Agreement. The Alliance Business-Development Managers shall attend all JSC meetings and may
bring any matter in relation to business to the attention of any committee if such Alliance Business-Development Manager reasonably believes that such matter warrants such attention. Each Party may replace its Alliance Business-Development Manager
upon written notice to the other Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2 <U>Alliance R&amp;D Managers</U>. Within thirty (30)&nbsp;days following the
Effective Date, each Party shall appoint (and notify the other Party of the identity of) a representative to act as its alliance research and development manager under this Agreement (&#147;<U>Alliance&nbsp;R&amp;D Manager</U>&#148;). With regard to
Research and Development activities, the Alliance R&amp;D Managers shall serve as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the primary contact points between the Parties and shall be primarily responsible for facilitating the flow of information, interaction and collaboration between the Parties and shall be
responsible for ensuring that the governance procedures and rules set forth herein are complied with. The Alliance R&amp;D Manager shall attend the meetings of the JRDC and the JSC and may bring any matter in relation to the Research and Development
management to the attention of any committee, if such Alliance R&amp;D Manager reasonably believes that such matter warrants such attention. Each Party may replace its Alliance R&amp;D Manager upon written notice to the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3 <U>Project Directors</U>. Within thirty (30)&nbsp;days following the Effective Date each Party shall appoint (and notify the other
Party of the identity of) a representative to act as its project director (&#147;<U>Project Director</U>&#148;). The Project Director shall be responsible for the follow-up of the respective Research and Development activities under this Agreement
on a regular basis. The Project Director shall attend the meetings of the JRDC, and may bring any matter in relation to the project management to the attention of the JSC, if such Project Director reasonably believes that such matter warrants such
attention. Each Party may replace its Project Director upon written notice to the other Party. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4 <U>Joint Executive
Committee</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.1 <U>Composition</U>. Promptly after the Effective Date, the Parties shall establish a joint executive
committee (the &#147;<U>JEC</U>&#148;). The JEC shall be comprised of up to three (3)&nbsp;senior executives from each Party. Either Party may, from time to time, invite additional representatives or consultants to attend JEC meetings, subject to
such representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JEC meetings
by its representatives. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.2 <U>Function and Powers of the JEC</U>. The JEC shall manage the overall collaboration between
the Parties, resource allocation and major changes to the collaboration requiring amendments to this Agreement and shall resolve disagreements that may arise at the JSC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.5 <U>Joint Steering Committee</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.1 <U>Composition</U>. Promptly after the
Effective Date, the Parties shall establish a joint steering committee (the &#147;<U>JSC</U>&#148;). The JSC shall be comprised of three (3)&nbsp;named representatives of Servier and three (3)&nbsp;named representatives of MacroGenics (or such other
number as the Parties may agree) as well as each Party&#146;s Alliance Business-Development Manager and Alliance R&amp;D Manager. As soon as practicable after the Effective Date (but in no event more than thirty (30)&nbsp;days after the Effective
Date), each Party shall designate by written notice to the other Party its initial representatives on the JSC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of
such change. These representatives shall have appropriate technical credentials, experience and knowledge. Either Party may, from time to time, invite additional representatives or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
consultants to attend JSC meetings, subject to such representative&#146;s and consultant&#146;s written agreement to comply with confidentiality obligations substantially the same as those set
forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JSC meetings by its representatives. The JSC shall be co-chaired by a representative from each Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.2 <U>Function and Powers of the JSC</U>. The JSC&#146;s responsibilities shall include: (a)&nbsp;coordinating the activities of the
Parties under this Agreement, including facilitating communications between the Parties with respect to the Development, Manufacture and Commercialization of Program Antibodies and Licensed Product; (b)&nbsp;providing a forum for discussion of the
Development, Manufacture, and Commercialization of Licensed Product; (c)&nbsp;reviewing and approving the Research Plan and the Global Development Plan and associated Development Budget and any annual or interim updates and proposed amendments
thereto; (d)&nbsp;reviewing and discussing Servier&#146;s Commercialization Plan and related activities with respect to Licensed Products throughout the Servier Territory and (if applicable) the MacroGenics Territory, including pre-launch and
go-to-market strategies; (e)&nbsp;directing and overseeing the JRDC and any operating subcommittee established by the JSC, on all significant issues that fall within the purview of such committees; (f)&nbsp;attempting to resolve issues presented to
it by, and disputes within, the other committees, including the JRDC and any subcommittee, in accordance with Section&nbsp;2.9; and (g)&nbsp;considering and acting upon such other matters as specified in this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.3 <U>Subcommittees</U>. The JSC may establish and disband such subcommittees as deemed necessary by the JSC. Each such subcommittee
shall consist of the same number of representatives designated by each Party, which number shall be mutually agreed by the Parties. Each Party shall be free to change its representatives on written notice to the other Party or to send a substitute
representative to any subcommittee meeting. Each Party&#146;s representatives and any substitute for a representative shall be bound by the obligations of confidentiality set forth in ARTICLE 11. Except as expressly provided in this Agreement, no
subcommittee shall have the authority to bind the Parties hereunder and each subcommittee shall report to the JSC. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6
<U>Joint Research and Development Committee and Subcommittees</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.1 <U>Composition</U>. Promptly after the Effective
Date, the Parties shall establish a joint research and development committee (the &#147;<U>JRDC</U>&#148;). The JRDC shall be comprised of three (3)&nbsp;named representatives of Servier and three (3)&nbsp;named representatives of MacroGenics (or
such other number as the Parties may agree) as well as each Party&#146;s Project Director. As soon as practicable after the Effective Date (but in no event more than thirty (30)&nbsp;days after the Effective Date), each Party shall designate by
written notice to the other Party its initial representatives on the JRDC. Each Party may replace one or more of its representatives, in its sole discretion, effective upon written notice to the other Party of such change. These representatives
shall have appropriate technical credentials, experience and knowledge, and ongoing familiarity with the Research and Development activities hereunder. Either Party may, from time to time, invite additional representatives or consultants to attend
JRDC meetings, subject to such representative&#146;s and consultant&#146;s written agreement to comply with </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
confidentiality obligations substantially the same as those set forth in ARTICLE 11. Each Party shall bear its own expenses related to the attendance at JRDC meetings by its representatives. The
JRDC shall be co-chaired by a representative from each Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.2 <U>Function and Powers of the JRDC</U>. The JRDC&#146;s
responsibilities shall include: (a)&nbsp;during the Research Term, proposing the Research Plan, proposing any changes or amendments to the Research Plan for approval by the JSC; (b)&nbsp;during the Research Term, reviewing and monitoring progress
for all activities performed under the Research Program; (c)&nbsp;during the License Term, proposing the initial Global Development Plan, coordinating the activities of the Parties under and overseeing the implementation of the Global Development
Plan; (d)&nbsp;during the License Term, preparing annual and interim updates to the Global Development Plans; (e)&nbsp;during the Agreement Term, serving as a forum for and facilitating communications between the Parties with respect to the Research
and Development of Licensed Products, including any joint Development activities to be pursued by the Parties during the License Term; (f)&nbsp;during the License Term, monitoring and coordinating all regulatory actions, communications and
submissions for Licensed Products; (g)&nbsp;informal resolution of disagreements that may arise in the relation to the Parties activities under the Research Program and the Global Development Plan; and (h)&nbsp;considering and acting upon such other
matters as specified in this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7 <U>Co-Chairpersons</U>. Each Party shall designate one of its members of the JSC
and JRDC, respectively, as a co-chairperson (each, a &#147;<U>Co-Chairperson</U>&#148;) of such committee. The Co-Chairpersons shall have the following roles and responsibilities: (a)&nbsp;to call meetings of the relevant committee, send notice of
each such meeting and designate the time, date and place of each such meeting; (b)&nbsp;to convene or poll the members of the relevant committee by other permitted means; (c)&nbsp;to establish a reasonably detailed agenda, including identification
of relevant supporting information and materials to be discussed during such meeting, for each meeting of the relevant committee, subject to the right of any member of such committee to add additional agenda items at any meeting; and (d)&nbsp;to
promptly draft and finalize minutes of each meeting of such committee, for review and approval by members of such committee at the following meeting. Each Co-Chairperson shall sign and date the final minutes. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8 <U>Committee Meetings</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.8.1 <U>Frequency</U>. The JRDC and each of the subcommittees shall each hold at least one (1)&nbsp;meeting per Calendar Quarter at such times during such Calendar Quarter as the co-chairpersons elect to
do so and the JSC and JEC shall hold at least one (1)&nbsp;meeting per Calendar Year as the co-chairpersons elect to do so. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8.2 <U>Quorum; Location</U>. Except where a Party fails to appoint a member or members to the JEC, JSC, JRDC or any subcommittee or
fails to participate in meetings of the JEC, JSC, JRDC or any subcommittee, meetings of the JEC, JSC, JRDC and subcommittees, respectively, shall be effective only if at least one (1)&nbsp;representative of each Party is present or participating.
The JEC, JSC, JRDC and subcommittees may meet either (a)&nbsp;in person at either Party&#146;s facilities or at such locations as the Parties may otherwise agree or (b)&nbsp;by audio or video </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
teleconference; <U>provided</U> <U>that</U> no less than one (1)&nbsp;meeting during each Calendar Year shall be conducted in person. Additional meetings of the JEC, JSC, JRDC and subcommittees
may also be held with the consent of each Party, or as required under this Agreement, and neither Party shall unreasonably withhold its consent to hold such additional meetings. Each Party shall be responsible for all of its own expenses incurred in
connection with participating in all such meetings. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8.3 <U>Cooperation</U>. Each Party shall provide the JSC and JRDC such
information as required under the Research Plan or Global Development Plan, as applicable, or reasonably requested by the other Party and reasonably available, relating to the progress of the goals or performance of activities under, as applicable,
the Research Plan or Global Development Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9 <U>Decisions</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.1 <U>Initial Dispute Resolution Procedures</U>. Subject to the provisions of this Section&nbsp;2.9, actions to be taken by the JEC,
JSC, JRDC and each of the subcommittees shall be taken only following <B>***</B>. If the JRDC or any subcommittee fails to reach unanimous agreement on a matter before it for decision for a period in excess of <B>***</B>, the matter shall be
referred to the JSC. If the JSC fails to reach <B>***</B> on a matter before it for decision for a period in excess of <B>***</B>, the matter shall be referred to the JEC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.9.2 <U>Conduct of Initial Phase 1 Clinical Trial</U>. Notwithstanding any other provision in this Agreement, unless otherwise agreed upon to the contrary by the Parties, ***. MacroGenics shall
reasonably consult with Servier regarding the selection of Indications to be pursued in the expansion cohorts included in the Initial Phase 1 Clinical Trial and shall reasonably consider any input provided by Servier with respect thereto.
<B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.3 <U>Final Decision-Making</U>. If the JEC fails to reach <B>***</B> on a matter before it for decision for a
period in excess of <B>***</B>, the following provisions shall apply: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) During the Research Term, if the JEC is unable to
resolve the matter within *** after the matter is referred to them, the matter shall be deadlocked until resolved by *** JEC consensus. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) During the License Term, the JEC representatives appointed by Servier shall have the deciding vote on any matter involving the Development or Commercialization of Program Antibodies and Licensed
Products in the Field in the Servier Territory and the JEC representatives appointed by MacroGenics shall have the deciding vote on any matter involving the Development or Commercialization of Program Antibodies and Licensed Products in the Field in
the MacroGenics Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.4 <U>Exceptions</U>. Notwithstanding the foregoing, neither Party shall exercise its
right to finally resolve a dispute pursuant to Section&nbsp;2.9.3: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) in a manner that excuses such Party from any of its
obligations specifically enumerated under this Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) in a manner that negates any consent rights or other rights
specifically allocated to the other Party under this Agreement; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) during the License Term, to increase Development Costs
for the other Party for any Global Clinical Trial for a given Calendar Year by more than *** above the Initial Development Budget for such Global Clinical Trial; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) to resolve any dispute regarding whether a Party may conduct Development or Commercialization activities in the other Party&#146;s territory; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) to resolve any dispute regarding whether a milestone event set forth in Section&nbsp;9.3 has been achieved; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) in a manner that would require the other Party to perform any act that it reasonably believes to be inconsistent with any Law or any
approval, order, policy or guidelines of a Regulatory Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10 <U>Authority</U>. The JEC, JSC, JRDC and any
subcommittee shall have only the powers assigned expressly to it in this ARTICLE 2 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. In furtherance thereof, each Party shall
retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers or discretion shall be delegated or vested in the JEC, JSC, JRDC or any subcommittee unless such delegation or vesting of rights is expressly
provided for in this Agreement or the Parties expressly so agree in writing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11 <U>Representatives</U>. For purposes of
clarity, a Party may appoint the same person to simultaneously serve as the Alliance Business Development Manager, Alliance R&amp;D Manager, and/or Project Director for such Party and/or serve on multiple committees established pursuant to this
ARTICLE 2. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 3 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>RESEARCH AND DEVELOPMENT; EXCLUSIVE OPTION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1 <U>Research Overview</U>.
Pursuant to this Agreement and as further provided in this ARTICLE 3, MacroGenics and Servier shall conduct the research activities indicated in the Research Plan during the Research Term (the &#147;<U>Research Program</U>&#148;). Neither Party
warrants that the Research Program shall achieve any of the research objectives contemplated in the Research Plan. At the end of the Research Term, each Party&#146;s obligation to conduct the Research Program shall cease unless the Parties mutually
agree to extend the Research Term. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2 <U>Conduct of the Research Program</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1 <U>Research Plan</U>. <B>***</B>, the JRDC will prepare the Research Plan to be submitted for approval by JSC. The Parties may
mutually agree to specify in the Research Plan activities to be conducted by Servier to generate additional pre-clinical and clinical data to be shared by both Parties (the &#147;<U>Supplemental Data</U>&#148;). Servier shall disclose to MacroGenics
all Supplemental Data <B>***</B> after the completion of such activities and MacroGenics shall have the right to use such Supplemental Data in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products. Both Parties
envision that the Supplemental Data <B>***</B>. The availability and finalization of such Supplemental Data and/or any modification to the Initial Phase 1 Clinical Trial that the Parties may agree upon shall not in any way delay the timing of the
delivery of the Option Trigger Data Package to Servier in accordance with Section&nbsp;3.3.2. To the extent that any provision of the Research Plan conflicts or is inconsistent with the provisions of this Agreement, the provisions of this Agreement
shall control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2 <U>Diligence</U>. MacroGenics and Servier shall use Commercially Reasonable Efforts to conduct the
Research Program in a good scientific manner and in accordance with the Research Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3 <U>Expenses</U>. Except as
otherwise set forth elsewhere in this Agreement, each Party shall bear its own costs and expenses of conducting the activities allocated to such Party under the Research Plan, including the costs of clinical supply of Program Antibodies and Licensed
Products.<U> </U> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.4 <U>Reports</U>. MacroGenics and Servier shall provide written progress reports on the status of its
Research and Development activities under the Research Plan, including summaries of data generated in the Research Program, at least *** in advance of each JRDC meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.3 <U>Evaluation of Option Trigger Data Package; Option Exercise</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.1
<U>Limited Evaluation License; Supply</U>. MacroGenics hereby grants Servier an exclusive, royalty and other fee-free license, with the right to sublicense only to Servier&#146;s Affiliates, under MacroGenics IP, to (a)&nbsp;conduct the activities,
if any, allocated to Servier under the Research Plan and (b)&nbsp;use the Option Trigger Data Package solely for purposes of evaluating Program Antibodies to determine whether to exercise its Option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.2 <U>Delivery of Option Trigger Data Package</U>. MacroGenics shall provide Servier with the Option Trigger Data Package <B>***</B>.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.3 <U>Option Exercise</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Servier shall have the exclusive option to obtain an exclusive license under MacroGenics IP to Research, Develop and Commercialize Program Antibodies and Licensed Products in the Field in the Servier
Territory (the &#147;<U>Option</U>&#148;). <B>***</B> (&#147;<U>Option&nbsp;Period</U>&#148;). In the event Servier elects to exercise the Option, it shall, no later than the end of the last day of the Option Period, deliver to MacroGenics
(i)&nbsp;written notice specifying that Servier has elected to exercise the Option, and (ii)&nbsp;payment of the License Grant Fee. Provided Servier has properly </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
exercised the Option in accordance with the preceding sentence, the later of the date of the written notice and receipt by MacroGenics of the License Grant Fee shall be the &#147;<U>License Grant
Date</U>&#148; for purposes of this Agreement. The Research Term and Option Period will be deemed to have ended, and the License Term will be deemed to have commenced, on the License Grant Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Upon the exercise by Servier of the Option in accordance with this Section&nbsp;3.3, the provisions set forth in Sections 4.1, 4.2
and 4.3 of this Agreement shall constitute the terms and conditions of the license and sublicense rights granted by MacroGenics to Servier with respect to Licensed Products and the MacroGenics IP in the Field in the Servier Territory, and by Servier
to MacroGenics with respect to Servier IP and Licensed Products in the Field in the MacroGenics Territory. During the period commencing on the Effective Date and ending on the expiration of the Option Exercise Period, MacroGenics will not grant a
license or other rights to any Third Party or take any other action that would prevent MacroGenics from being able to grant to Servier the license set forth in Section&nbsp;4.1. In the event Servier does not exercise the Option during the Option
Exercise Period, Servier shall have no further rights hereunder with respect to MacroGenics IP and/or Licensed Products, the license granted to Servier under Section&nbsp;3.3.1 shall terminate and the licenses and other rights granted under ARTICLE
4 shall have no force or effect. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) In the event Servier does not exercise its Option rights prior to the end of the Option
Period, (i)&nbsp;Servier&#146;s Option shall expire and all right and interest with respect to the Program Antibodies, Licensed Products and MacroGenics IP shall revert to MacroGenics; (ii)&nbsp;Servier shall have no right to or interest in such
Program Antibodies, Licensed Products and MacroGenics IP; and (iii)&nbsp;Servier shall and hereby does assign and transfer to MacroGenics all right, title and interest in and to the Supplemental Data and the Servier Collaboration IP that is created
by or on behalf of Servier or its Affiliates, or both, whether solely or jointly with MacroGenics, in the course of conducting activities under the Research Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 4 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>GRANT OF RIGHTS; EXCLUSIVITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1 <U>License Grant to Servier</U>. Subject
to the terms of this Agreement, upon MacroGenics&#146; receipt of the License Grant Fee, MacroGenics shall and hereby does grant Servier (a)&nbsp;an exclusive, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in
accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under MacroGenics IP and MacroGenics&#146; and its Affiliates&#146; interests in Joint IP, to Research, Develop, Manufacture and Commercialize,
Program Antibodies and Licensed Products in the Servier Territory in the Field; (b)&nbsp;an exclusive, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to
sublicense (subject to Section&nbsp;4.3), under MacroGenics IP and MacroGenics&#146; and its Affiliates&#146; interests in Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program Antibodies and Licensed
Products in the Field in the Servier Territory; and (c)&nbsp;a non-exclusive, royalty-bearing, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to
Section&nbsp;4.3), under MacroGenics IP and MacroGenics&#146; and its Affiliates&#146; interests in Joint IP, to Research, Develop and Manufacture Program Antibodies and Licensed Products in the MacroGenics Territory for the sole purpose of using,
offering for sale and selling Licensed Products in, and importing Program Antibodies and Licensed Products into, the Servier Territory in the Field; <U>provided</U> <U>however</U>, that Servier shall not, directly or indirectly, conduct clinical
trials or other clinical studies, including any investigator initiated studies, in the MacroGenics Territory using Program Antibodies or Licensed Products without the prior approval of the JRDC. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2 <U>License Grant to MacroGenics</U>. Subject to the terms of this Agreement, upon MacroGenics&#146; receipt of the License Grant Fee,
Servier hereby grants MacroGenics: (a)&nbsp;an exclusive, royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under
Servier Collaboration IP and Servier&#146;s and its Affiliates&#146; interest in Joint IP, to Research, Develop, Manufacture and Commercialize Program Antibodies and Licensed Products in the Field in the MacroGenics Territory; (b)&nbsp;an exclusive,
royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under Servier Collaboration IP and Servier&#146;s and its
Affiliates&#146; interest in Joint IP, to Research, Develop, Manufacture and Commercialize Diagnostics for use solely with Program Antibodies and Licensed Products in the Field in the MacroGenics Territory; and (c)&nbsp;a non-exclusive,
royalty-free, <FONT STYLE="white-space:nowrap">non-transferable</FONT> (except in accordance with Section&nbsp;16.4) license, with the right to sublicense (subject to Section&nbsp;4.3), under Servier Collaboration IP and Servier&#146;s and its
Affiliates&#146; interest in Joint IP, to Research, Develop and Manufacture Program Antibodies and Licensed Products in the Servier Territory for the sole purpose of using, offering for sale and selling Licensed Products in, and importing Program
Antibodies and Licensed Products into, the MacroGenics Territory in the Field; <U>provided</U> <U>however</U>, that MacroGenics shall not, directly or indirectly, conduct clinical trials or other clinical studies, including any investigator
initiated studies, in the Servier Territory using Program Antibodies or Licensed Products without the prior approval of the JRDC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.3 <U>Sublicenses</U>. Each Party shall have the right to grant sublicenses within the scope of the licenses under Section&nbsp;4.1 or 4.2, as applicable, solely to its Affiliates and to Third Parties
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that are conducting Research, Development, Manufacture and/or Commercialization activities with such Party or its Affiliates with respect to Program Antibodies and Licensed Products;
<U>provided</U> <U>that</U> any sublicense granted to Third Party collaborators under this Agreement shall be pursuant to a written agreement that subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement,
including the confidentiality provisions of ARTICLE 11. If either Party grants a sublicense to a Third Party as permitted by this Section&nbsp;4.3, then such Party shall provide the other Party prompt written notice thereof and shall provide the
other Party with an executed copy of any such sublicense (redacted as necessary to protect confidential or commercially sensitive information). Except as otherwise agreed by the Parties in writing, each Party shall be jointly and severally
responsible with its sublicensees to the other Party for failure by its sublicensees to comply with this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4
<U>Subcontracting</U>. Subject to the terms of this Agreement, each Party shall have the right to engage Affiliates, licensees, Sublicensees or Third Party subcontractors to perform activities ascribed to such Party, under this Agreement. Any
Affiliate, licensee or subcontractor to be engaged by a Party to perform a Party&#146;s obligations under this Agreement shall meet the qualifications typically required by such Party for the performance of work similar in scope and complexity to
the subcontracted activity; <U>provided</U> <U>that</U> any Party engaging an Affiliate, licensee or subcontractor hereunder shall remain principally responsible and obligated for such activities. In addition, each Party engaging a licensee,
Sublicensee or subcontractor shall obtain Control of any and all Know-How, Patents or other intellectual property rights created, discovered, invented, conceived or reduced to practice by such licensee, Sublicensee or subcontractor with respect to
any Program Antibody or Licensed Product so that the other Party is not impeded from carrying out its rights and responsibilities under this Agreement by such Know-How, Patents or other intellectual property rights. To the extent a Party cannot
obtain assignment of, or an exclusive license to, all Know-How, Patents and other intellectual property rights created, discovered, invented, conceived or reduced to practice by any licensee, Sublicensee or subcontractor engaged by such Party with
respect to any Program Antibody or Licensed Product or in the performance of activities under this Agreement at the time such Party initially enters into such arrangement with such licensee, Sublicensee or subcontractor, such Party shall bring such
matter to the JSC for the prior approval of such arrangement and for the express approval by the JRDC of the licensing terms and conditions with respect to such arrangement </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.5 <U>MacroGenics Third Party Agreements</U>. Servier acknowledges and agrees that the rights, licenses and sublicenses granted by MacroGenics to Servier under this Agreement are subject to the terms of
the MacroGenics Third Party Agreements. Servier covenants to comply with, and to cause its Affiliates and Sublicensees to comply with, the MacroGenics Third Party Agreements, and to take any action or provide any information reasonably requested by
MacroGenics, to prevent any potential breach of any terms of such MacroGenics Third Party Agreements. To the extent there is a conflict between the terms of any MacroGenics Third Party Agreement and the rights granted to Servier hereunder, the terms
of such MacroGenics Third Party Agreement shall control solely with respect to the Patents and Know-How owned or controlled by such Third Party licensor. MacroGenics shall not terminate or consent to the termination of the MacroGenics Third Party
Agreement without Servier&#146;s prior reasonable consent if such termination would materially adversely affect Servier&#146;s license granted </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
hereunder; however, for clarity, MacroGenics may (a)&nbsp;terminate any MacroGenics Third Party Agreement by acquiring all of the relevant intellectual property licensed thereunder, in which case
Servier agrees to consent to such termination of such MacroGenics Third Party Agreement; (b)&nbsp;terminate its obligation to make royalty and milestone payments by making a lump-sum payment; and (c)&nbsp;terminate its rights and obligations under a
MacroGenics Third Party Agreement by assigning such MacroGenics Third Party Agreement directly to Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6 <U>Right of
First Negotiation for Bi-Specific DARTs</U>. If at any time during the Agreement Term MacroGenics desires to Develop with a Third Party and/or Commercialize with one or more Third Party(ies) one or more Bi-Specific DARTs in the Field other than in
the United States, MacroGenics shall notify Servier of its intent and propose to Servier to enter into negotiations to Develop and Commercialize the latter, identifying the applicable Bi-Specific DART(s) that is(are) proposed to be the subject of
such negotiations. Servier shall have <B>***</B> from receipt of such written notice to notify MacroGenics in writing as to whether Servier desires to negotiate for such rights, and if Servier so notifies MacroGenics that it does desire to negotiate
for such rights, Servier shall have <B>***</B> from the date of such notification to MacroGenics to negotiate and enter into a definitive agreement with MacroGenics for such rights; <U>provided</U> <U>that</U>, if either Servier does not provide
such written notice within such <B>***</B> period or Servier and MacroGenics do not enter into a definitive agreement within such <B>***</B> period, MacroGenics shall be free to enter into negotiations and agreements with Third Parties relating to
such Bi-Specific DART(s), provided however that if, within <B>***</B> after such negotiations with Servier terminate, MacroGenics should <B>***</B>, and Servier shall have a period of <B>***</B> following receipt of the same to notify MacroGenics as
to whether Servier would be prepared to accept such terms (subject to execution of a mutually acceptable license agreement) in which case the Parties will use commercially reasonable efforts to conclude such license agreement within <B>***</B> after
Servier notifies MacroGenics of the same. If the Parties can not conclude such license agreement or such <B>***</B> period expires, the Parties agree that, MacroGenics shall be free to enter into negotiations and agreements with Third Party(ies)
relating to such Bi-Specific DARTs during the remainder of the Agreement Term without further obligation to Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7
<U>Rights Retained by the Parties</U>. Any rights of MacroGenics or Servier, as the case may be, not expressly granted to the other Party pursuant to this Agreement shall be retained by such Party. Notwithstanding the exclusive licenses granted to
Servier pursuant to Section&nbsp;4.1, MacroGenics retains the right to practice under the MacroGenics IP and Joint IP to perform (and to sublicense Third Parties to perform) its obligations under this Agreement and any supply agreement entered into
in accordance with ARTICLE 7, including for the purpose of performing its activities in connection with clinical trials for Licensed Products and any related manufacture of Program Antibodies and Licensed Products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.8 <U>Section&nbsp;365(n) of the Bankruptcy Code</U>. All rights and licenses granted under or pursuant to any section of this Agreement
are and will otherwise be deemed to be for purposes of Section&nbsp;365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the &#147;<U>Bankruptcy Code</U>&#148;), licenses of rights to &#147;intellectual property&#148; as
defined in Section&nbsp;101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rights and elections under the Bankruptcy Code. Each Party agrees that the other Party, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and
elections under the Bankruptcy Code or any other provisions of applicable Law outside the United States that provide similar protection for &#147;intellectual property.&#148; The Parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against a Party under the U.S. Bankruptcy Code or analogous provisions of applicable Law outside the United States, the other Party will be entitled to a complete duplicate of (or complete access to, as appropriate) such
intellectual property and all embodiments of such intellectual property, which, if not already in such Party&#146;s possession, will be promptly delivered to it upon such Party&#146;s written request thereof. Any agreements supplemental hereto will
be deemed to be &#147;agreements supplementary to&#148; this Agreement for purposes of Section&nbsp;365(n) of the Bankruptcy Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.9 <U>Exclusivity</U>. For the period commencing with the Effective Date and ending on the<B>***</B> of the Effective Date, other than with respect to the Development and Commercialization activities
pursuant to this Agreement or any agreement entered into between the Parties pursuant to Section&nbsp;4.6, neither Party nor its Affiliates shall, directly or indirectly, (a)&nbsp;<B>***</B>. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.10 <U>Consequences of Development and Commercialization of Competing Products</U>. *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.11<U> Diagnostics</U>. The Parties acknowledge and agree that each Party shall have the right to use Diagnostics in combination with
Competing Products Researched, Developed or Commercialized by such Party. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 5 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEVELOPMENT DURING THE LICENSE TERM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.1 <U>Overview</U>. During the License Term, Servier will, subject to the terms of this Agreement, be responsible for the Development of Licensed Products in the Field for the Servier Territory, and
(b)&nbsp;MacroGenics will remain responsible for Development of Licensed Products in the Field in the MacroGenics Territory. While the Parties may choose, at their sole discretion, to work together on particular projects, except as otherwise
provided in this Agreement, the Parties will operate independently in their activities for their respective Development of Licensed Products, but will provide access to certain information to the JRDC and to each other as expressly described in this
Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2 <U>Servier Obligations</U>. Servier shall use Commercially Reasonable Efforts to Develop Licensed Products in
the Servier Territory. Servier shall be deemed to not have used Commercially Reasonable Efforts to Develop Licensed Products in the Servier Territory, and MacroGenics shall have the right to terminate this Agreement in accordance with
Section&nbsp;14.2, if at any point in time prior to the First Commercial Sale of a Licensed Product, Servier fails to undertake Development activities, with the intention of rapidly advancing a Licensed Product toward registration (and not for the
sole purpose of preserving rights hereunder) during at least the preceding <B>***</B>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3 <U>Development Activities</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.1 <U>Global Development Plan</U>. During the License Term, the Development of Licensed Products under this Agreement shall be
conducted pursuant to a reasonably comprehensive written research and development plan (each, a &#147;<U>Global Development Plan</U>&#148;), which shall include a detailed budget for all Development Costs and Manufacturing Process Development Costs
(each, a &#147;<U>Development Budget</U>&#148;), and which shall include the resource allocations for the Parties based upon the general principle that the allocation shall endeavor to take advantage of the respective resources, capabilities and
expertise of MacroGenics and Servier, respectively.&nbsp;Within <B>***</B> after the License Grant Date, the JRDC shall prepare an initial draft of the Global Development Plan for approval by the JSC. The Global Development Plan also shall set forth
the specific activities (including non-clinical and clinical studies to be conducted by each Party and the estimated timeline for Development of Licensed Products in order to obtain the data that the Parties intend will be useful, by both Parties,
to obtain Regulatory Approvals of the licensed Product in both the United States, and the EU, Servier shall be the sponsor of all clinical studies conducted in the Servier Territory and shall be solely responsible for Development activities and for
obtaining Regulatory Approval for Licensed Products in the Servier Territory, and MacroGenics shall be the sponsor of all clinical studies conducted in the MacroGenics Territory and shall be solely responsible for Development activities and for
obtaining Regulatory Approval for Licensed Products in the MacroGenics Territory. The JRDC shall discuss which Party(ies) shall be the sponsor of all clinical studies conducted in countries of both the MacroGenics Territory and the Servier
Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.2 <U>Details in Global Development Plan</U>. Without limiting Section&nbsp;5.3.1, the Global Development Plan
shall set forth, among other things, the following activities to be undertaken jointly or coordinated by Servier and MacroGenics: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) any non-clinical studies, toxicology studies, pharmaco-economic studies, process development studies and other clinical studies, whether pre- or post-approval and whether sponsored or merely supported
by Servier or MacroGenics, in each case, together with all protocols, endpoints and investigators conducting such studies, with respect to Licensed Products in the Servier Territory and MacroGenics Territory; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) regulatory plans and other elements of obtaining and maintaining Regulatory Approvals in the Field in each country in the Servier
Territory and MacroGenics Territory, consistent with the use of Commercially Reasonable Efforts; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) the timeline for
completing such Development activities; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) the plans and timeline for preparing the necessary Regulatory Documentation
and for obtaining Regulatory Approval in the Field in the Servier Territory and MacroGenics Territory. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4 <U>Updating and Amending Development Plan and Development Budget; Additional Development
Activities</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.1<U> Development Plan Reviews and Updates</U>. On or before January&nbsp;1st of each Calendar Year during
the License Term, the JRDC shall review, update and approve the Global Development Plan (including the Development Budget contained therein) which shall cover the Development activities and Manufacturing process development activities to be
conducted with respect to the Development of Licensed Products for use in the Field during the upcoming Calendar Year, and the JRDC shall, on at least a quarterly basis, review and update, as appropriate, the then-current Global Development Plan
(including the Development Budget) to reflect any changes, reprioritizations of, or additions to the Global Development Plan. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2 <U>Amendments to Development Plan; New Development Collaboration Proposals</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Amendments to Development Plan</U>. From time to time during the License Term, either Party may submit to the JRDC any proposed
amendment of the Global Development Plan to amend the then-currently approved Development activities (such proposed amendment, a &#147;<U>Proposed Development Plan Amendment</U>&#148;) for the JRDC&#146;s review and JSC approval. Any proposed
amendment to the Global Development Plan shall contain, at a minimum, information supporting the rationale for the Proposed Development Plan Amendment related to Licensed Products from a scientific, regulatory and commercial standpoint, as well as
an estimated developmental critical path, and an estimate of the cost of such Development. The JRDC shall consider any submitted Proposed Development Plan Amendment during its next scheduled meeting. Once approved by the JSC (or otherwise resolved
pursuant to Section&nbsp;2.9), each amended Global Development Plan (including the Development Budget contained therein) shall become effective and supersede the previous Global Development Plan and Development Budget as of the date of such approval
or at such other time as decided by the JSC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>New Development Collaboration Proposals</U>. If either Party proposes to
conduct new Development activities in connection with the Development of a Licensed Product not included in the then approved Global Development Plan, including any proposal to collaborate to <B>***</B> (such proposal, a &#147;<U>Development
Collaboration Proposal</U>&#148;), such Party shall submit the Development Collaboration Proposal to the other Party through the JRDC. Every Development Collaboration Proposal shall include a proposal to collaborate with the other Party for such
Development activities so that, subject to the terms of this Agreement, with respect to the Development activities underlying the Development Collaboration Proposal, Servier shall be able to Develop Licensed Products for Commercialization in the
Field in the Servier Territory and MacroGenics shall be able to Develop Licensed Products for Commercialization in the Field in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) In the event the other Party approves a Development Collaboration Proposal and the Parties agree to collaborate to conduct the Development activities underlying the Development Collaboration Proposal
with respect to Licensed Products, each Party shall use Commercially Reasonable Efforts to perform the activities allocated to it under the approved Development Collaboration Proposal, and the Parties shall share in the payment of Development Costs
incurred in connection with such activities in accordance with Section&nbsp;5.5.1(a). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) In the event the other Party declines to participate in and share the funding of such
activity (the &#147;<U>Buy-In Party</U>&#148;), the submitting Party may proceed with the activities described in such Development Collaboration Proposal at its sole expense unless the other Party reasonably objects to the conduct of such activity
as reasonably likely to result in a safety or public health issue that will have a material adverse effect in the Development or Commercialization of Program Antibodies and Licensed Product in its territory. Any disputes regarding whether an
activity is reasonably likely to result in a safety or public health issue that will have a material adverse impact on the Development and/or Commercialization of Program Antibodies and Licensed Products in a Party&#146;s territory shall be referred
to the JRDC for a determination and resolved in accordance with Section&nbsp;2.9; provided that neither Party shall have the right to exercise its final decision making authority pursuant to Section&nbsp;2.9.3 with respect to such issue. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Once during each Calendar Quarter following the commencement of, and until the completion of, the activities described in the
Development Collaboration Proposal, the Buy-In Party may request that the Party conducting such Development activity provide a summary of the current status of such Development activity, the Development Costs incurred to date, any significant
milestones achieved and any topline initial results of such Development activity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) The Buy-In Party may obtain access to
and use of the Excluded Data in accordance with the procedure described in this paragraph; provided that the Buy-In Party shall be provided access to Safety Data, at no cost, in accordance with the SDEA Agreement. At any time following the
commencement of the activities described in the Development Collaboration Proposal, the Buy-In Party shall provide the other Party with written notice of its election to buy-in to such Development, and promptly thereafter the other Party shall
provide the Buy-In Party with an invoice for <B>***</B> of the cumulative Development Costs as well as the costs of clinical supply of the Program Antibody and/or Licensed Product used in connection with such Development incurred by a Party in the
generation of such data as of the date of the Buy-In Party&#146;s written request (the &#147;<U>Buy-in Amount</U>&#148;), which invoice the Buy-In Party shall pay within <B>***</B> after receipt. Each Party shall thereafter share, in accordance with
the allocation of costs set forth in Section&nbsp;5.5.1(a), in the Development Costs incurred after the date of the Buy-In Party&#146;s written request in connection with such Development activities under such Development Collaboration Proposal and
the Global Development Plan shall be amended to include such Development activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.3 <U>Unilateral Development Costs
and Manufacturing Process Development Costs</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Servier Territory Exclusive Development Activities</U>. Except as
provided in Section&nbsp;5.5 and for Development activities conducted by a Party at its own expense pursuant to Section&nbsp;5.4.2(b)(ii), Servier shall be responsible for <B>***</B> of all Development Costs (whether incurred by Servier or
MacroGenics (if the activities and their cost are agreed to in advance in writing by Servier) or their respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products in the Field in any country or other regulatory jurisdiction in the Servier Territory. Servier shall disclose
to MacroGenics a summary of efficacy results and detailed safety information Controlled by Servier and generated in the course of such Development activities within *** after the completion of such activities, subject to the pharmacovigilence
provision under Section&nbsp;6.5. MacroGenics may obtain access to and use Servier&#146;s data (other than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive development activities
if MacroGenics provides Servier with written notice of its election to buy-in such Development, and promptly thereafter Servier shall provide MacroGenics with an invoice for *** of the cumulative Development Costs as well as the costs *** in
connection with such Development incurred by Servier in the generation of such data as of the date of MacroGenics written request, which invoice MacroGenics shall pay within *** after receipt. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>MacroGenics Territory Exclusive Development Activities</U>. Except as provided in Section&nbsp;5.5 and for Development activities
conducted by a Party at its own expense pursuant to Section&nbsp;5.4.2(b)(ii), MacroGenics shall be responsible for <B>***</B> of all Development Costs (whether incurred by Servier (if the activities and their costs are agreed to in advance in
writing by MacroGenics) or MacroGenics or their respective Affiliates) set forth in the applicable Development Budget with respect to any Development activities that are conducted for the primary purpose of obtaining or maintaining Regulatory
Approval for Licensed Products in the Field in any country or other regulatory jurisdiction in the MacroGenics Territory. MacroGenics shall disclose to Servier a summary of efficacy results and detailed safety information Controlled by Servier and
generated in the course of such Development activities within <B>***</B> after the completion of such activities, subject to the pharmacovigilence provision under Section&nbsp;6.5. Servier may obtain access to and use MacroGenics&#146; data (other
than Safety Data which shall in all cases be exchanged, at no cost, in accordance with the SDEA) obtained in such exclusive Development activities if Servier provides MacroGenics with written notice of its election to buy-in such Development, and
promptly thereafter MacroGenics shall provide Servier with an invoice for <B>***</B> of the cumulative Development Costs as well as the costs *** in connection with such Development incurred by MacroGenics in the generation of such data as of the
date of Servier written request, which invoice Servier shall pay within *** after receipt. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Servier <B>***</B>
Funding</U>. Servier shall reimburse MacroGenics for <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <U>Manufacturing Process Development Costs.</U> Servier
and MacroGenics shall each be responsible for <B>***</B> of each Manufacturing Process Development Cost provided the activity which resulted in such cost was conducted under the Global Development Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5 <U>Development Activities</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.1 Except for Development activities conducted by a Party at its own expense pursuant to Section&nbsp;5.4.2(b)(ii), with respect to any
Development activities conducted for the primary purpose of obtaining or maintaining Regulatory Approval for Licensed Products both in the Servier Territory and in the MacroGenics Territory (including Development activities with respect to which a
Party has paid the Buy-in Amount in accordance with Section&nbsp;5.4.2(b)(iv)) pursuant to the Development Plan: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) subject
to Section&nbsp;5.5.2, Servier shall be responsible for *** and MacroGenics shall be responsible for *** of all Development Costs as well as the costs of clinical supply of the Program Antibody and/or Licensed Product used in connection with such
Development (in each case, whether incurred by Servier or MacroGenics or their respective Affiliates). For purposes of clarity, MacroGenics may seek reimbursement from Servier under Section&nbsp;5.4.3(c) to apply to Development Costs for which
MacroGenics is responsible under this Section&nbsp;5.5.1(a) to the extent such Development Costs are for Phase 2 Clinical Trials; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) each Party shall disclose to the other Party all clinical data and related Regulatory Documentation Controlled by such Party and generated in the course of such Manufacturing process development
activities and Development activities within ***; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) each Party shall have the right to use all clinical data and related
Regulatory Documentation Controlled by either Party and generated in the course of such Manufacturing process development activities and Development activities in order to Develop, obtain Regulatory Approval for and Commercialize Licensed Products
in the Field in such Party&#146;s territory, in accordance with the terms of this Agreement; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) each Party hereby
grants to the other Party a Right of Reference or Use to any and all such Regulatory Documentation with respect to Licensed Products in the Field in the other Party&#146;s territory, and agrees to sign, and cause its Affiliates to sign, any
instruments reasonably requested by such other Party in order to effect such grant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2 <U>Development Costs Budget and
Timeline Overruns</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <U>Budget Overruns</U>. With respect to any Development Costs which, pursuant to this Agreement
and/or a Global Development Plan or an approved Development Collaboration Proposal, are meant to be allocated between the Parties (rather than one Party being solely responsible for such Development Costs), each Party shall promptly inform the other
Party upon determining that it is likely to exceed the budget amounts set forth in the annual Development Budget for the activities such Party is responsible for under the Global Development Plan. To the extent that a Party (or its Affiliates or
Sublicensees) incurs Development Costs for the activities such Party is responsible for under the Global Development Plan for a particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such
activity in the initial Development Budget that includes such activity (the &#147;<U>Initial Development Budget</U>&#148;) by <B>***</B> or less (a &#147;<U>De Minimis Overage Amount</U>&#148;), then such De Minimis Overage Amount shall
automatically be included in the Development Budget for such year. However, to the extent that a Party (or its Affiliates or Sublicensees) incurs Development Costs for the activities such Party is responsible for under the Development Plan for a
particular Calendar Year which on an aggregate basis for that year exceed the Development Costs allocated for such activity in the Initial Development Budget by more than <B>***</B>, the &#147;<U>Excess Overage Amount</U>&#148;), the Party that has
so exceeded its budget shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
provide to the JRDC a full explanation for so exceeding its budget and such Excess Overage Amount shall only be included in the Development Budget to the extent that the JRDC agrees to allow some
or all of the Excess Overage Amount to be included in the Development Budget as it considers equitable under the circumstances. To the extent that the JRDC does not agree to treat the Excess Overage Amount as Development Costs, the Party that has
exceeded its budget shall be solely responsible for the Excess Overage Amount. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <U>Timeline Overruns</U>. Each Party
shall promptly inform the other Party upon determining that it is likely to miss a Development date set forth in the Global Development Plan. To the extent that a Party (or its Affiliates) misses such a date by <B>***</B> or more, the Party that has
experienced such Development timeline failure shall provide to the JRDC a full explanation for such Development timeline failure. Such notification shall not serve to excuse a Party from its diligence or other obligations under this Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <U>Reconciliation</U>. Within <B>***</B> following the end of each Calendar Quarter beginning with the License Grant
Date, each Party shall prepare and deliver to the other Party a quarterly report detailing its Development Costs and Manufacturing Process Development Costs incurred during such period, with each Party reporting on all Development Costs incurred
with respect to Development Collaboration Proposals. Each Party shall submit any additional information reasonably requested by the other Party related to the Development Costs and Manufacturing Process Development Costs included in its report
within <B>***</B> of its receipt of such request. Within <B>***</B> after the receipt of the report delivered by Servier pursuant to this Section&nbsp;5.5.2(c), MacroGenics shall prepare and deliver to Servier a composite report that
(i)&nbsp;summarizes the Development Costs and Manufacturing Process Development Costs incurred by each Party for such Calendar Quarter; (ii)&nbsp;applies the percentage of such costs for which each Party is responsible for the total Development
Costs and Manufacturing Process Development Costs attributable to the Development and Manufacturing activities for such Calendar Quarter pursuant to Sections 5.4.3 and 5.5.1; and (iii)&nbsp;computes the amount due to MacroGenics or Servier, as
applicable, for such Calendar Quarter in order for the Parties to share the total Development Costs and Manufacturing Process Development Costs for such quarter based on the Development Plan and the principles set forth in Sections 5.4.3 and 5.5.1
(each, a &#147;<U>Reconciliation Payment</U>&#148;). The Party to whom a Reconciliation Payment is due shall issue an invoice to the other Party for the Reconciliation Payment, and such other Party shall pay all undisputed amounts within <B>***</B>
after its receipt of the invoice. Each Party shall have the right to audit the records of the other Party with respect to any Development Costs and Manufacturing Process Development Costs included in such reports, in accordance with
Section&nbsp;9.10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6 <U>Exchange of Data</U>. During the License Term, the following shall apply: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.1 <U>Initial Exchange of Data</U>. Promptly after the License Grant Date, MacroGenics shall transfer to Servier the MacroGenics
Know-How related to Program Antibodies and Licensed Products (other than the MacroGenics Know-How related directly and solely to Manufacturing).&nbsp;Such transfer shall occur in a manner and following a reasonable schedule to be established by the
JSC.&nbsp;MacroGenics shall provide Servier with copies of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
relevant material, information, reports and data, including pre-clinical data, clinical data, and any data that has been provided to Regulatory Authorities for the purpose of obtaining Regulatory
Approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.2 <U>Ongoing Exchange of Data</U>. During the License Term, except as provided in Section&nbsp;5.4.2(b)(iv)
with respect to Excluded Data, each Party shall provide to the other Party (a)&nbsp;all Know-How Controlled by such Party that is specified in the Global Development Plan to the extent necessary or useful for the Development or Commercialization of
Program Antibodies or Licensed Products in the other Party&#146;s territory, and (b)&nbsp;any Know-How Controlled by such Party that is not specified in the Global Development Plan that such Party reasonably believes to be necessary or useful for
the Development or Commercialization of Program Antibodies or Licensed Products in the other Party&#146;s territory, in a timely fashion and as promptly as possible for use by such other Party in accordance with this Section&nbsp;5.6.2. Servier
shall only use and disclose to Third Parties such MacroGenics Know-How as may be necessary or useful for Development and Commercialization of Program Antibodies and/or Licensed Products in the Servier Territory; or as may otherwise be agreed by
MacroGenics and Servier. Servier may not use any MacroGenics Know-How (or permit any Third Party to use any MacroGenics Know-How) outside the Servier Territory, nor for any products other than the Licensed Products, except as may otherwise be agreed
by MacroGenics and Servier (including as provided in Sections 4.1 and 4.2). MacroGenics shall not use any Servier Know-How (or permit any Third Party to use any Servier Know-How) outside the MacroGenics Territory, nor for any products other than the
Licensed Products, except as may otherwise be agreed by MacroGenics and Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.3 <U>Use</U>. All preclinical,
non-clinical, analytical, manufacturing, and clinical data and associated reports disclosed by one Party to the other under this Agreement may be used by the receiving Party subject to the terms of this Agreement solely for the purpose of
Developing, Manufacturing and Commercializing Licensed Products in its respective territory.&nbsp;Each Party shall have the right to share any and all such data and other regulatory materials received from the other Party with its Affiliates and any
Third Party sublicensees or licensees in its respective territory solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in its respective territory.&nbsp;Access to and use of such data and regulatory materials are
given by each Party to the other Party without cost (except as otherwise provided herein) on an &#147;as is&#148; basis without any warranty of any kind.&nbsp;Each receiving Party accepts all risk and liability in relation to the use of the data and
regulatory materials received from the other Party and shall indemnify and hold harmless the Party providing such data and regulatory materials from any Third Party&#146;s claim(s) based upon such data and regulatory materials as provided in ARTICLE
13. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.4 <U>Reports</U>. In addition to information and reports required elsewhere in this Agreement, each Party shall
provide the other Party and the JRDC with a written annual report summarizing the major activities performed by it under the Global Development Plan during the previous year, conduct of non-clinical activities and clinical trials, information
regarding the status of Regulatory Approvals. The other Party shall have the opportunity to reasonably seek further explanation or clarification of matters covered in such reports and to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>
</B>provide observations and suggestions to the disclosing Party regarding the subject matter thereof, and the disclosing Party shall provide such explanation or clarification and shall consider
such observations and suggestions in good faith. Furthermore, if after receiving such a report the receiving Party wishes to meet with the disclosing Party to discuss such report, the disclosing Party shall meet with the receiving Party at a site
reasonably requested by the receiving Party within <B>***</B> after the disclosing Party&#146;s requests such meeting.<B> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 6 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REGULATORY MATTERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 6 shall apply during the License Term. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1
<U>Servier Regulatory Responsibility</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.1 During the License Term, Servier shall own and be responsible for preparing,
filing and maintaining all Regulatory Documentation and Regulatory Approvals that are required for the Development (unless otherwise agreed by the JRDC on the basis of section 4.2 above), Manufacture or Commercialization of the Program Antibodies or
Licensed Products in the Field in the Servier Territory and Servier shall otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the Servier Territory. Servier shall comply with all applicable Laws
in the Servier Territory, including local regulations and ICH guidelines. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.2 Servier hereby grants to MacroGenics a Right
of Reference or Use to any Regulatory Documentation in the Servier Territory Controlled by Servier for use by MacroGenics in the MacroGenics Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request,
any instruments reasonably requested by MacroGenics in order to further effect such grant. Servier shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. Servier shall also permit MacroGenics, upon reasonable
notice, during regular business hours, to audit any such Regulatory Documentation; <U>provided</U> <U>that</U>, MacroGenics shall limit such audits by MacroGenics to a moderate frequency reasonably necessary in order for MacroGenics to perform the
Development and Commercialization of the Program Antibodies and Licensed Product. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2 <U>MacroGenics Regulatory
Responsibility</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.1 MacroGenics shall own and be responsible for preparing, filing and maintaining all Regulatory
Documentation and Regulatory Approvals that are required for the Development (unless otherwise agreed by the JRDC on the basis of section 4.1 above), or Commercialization of Program Antibodies or Licensed Products in the Field in the MacroGenics
Territory and MacroGenics shall otherwise be responsible for and have sole authority as to all interactions with Regulatory Authorities in the MacroGenics Territory. MacroGenics shall comply with all applicable Laws in the MacroGenics Territory,
including local regulations and ICH guidelines. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.2 MacroGenics hereby grants to Servier a Right of Reference or Use to any Regulatory
Documentation in the MacroGenics Territory Controlled by MacroGenics for use by Servier in the Servier Territory, and agrees to sign, and cause its Affiliates to sign, from time to time, promptly upon request, any instruments reasonably requested by
Servier in order to further effect such grant. MacroGenics shall permit any relevant Regulatory Authority to inspect any such Regulatory Documentation. MacroGenics shall also permit Servier, upon reasonable notice, during regular business hours, to
audit any such Regulatory Documentation; <U>provided</U> <U>that</U>, Servier shall limit such audits by Servier to a moderate frequency reasonably necessary in order for Servier to perform the Development and Commercialization of the Program
Antibodies and Licensed Product. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3 <U>Communications with Regulatory Authorities</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.1 For purposes of this Article 6.3, &#147;material&#148; shall mean any ***. Servier shall be responsible for all submissions to, and
communications and interactions with, Regulatory Authorities in the Servier Territory with respect to Program Antibodies and Licensed Products (unless otherwise agreed by the JRDC on the basis of section 4.2 above), and MacroGenics shall be
responsible for submissions to, and communications and interactions with, Regulatory Authorities in the MacroGenics Territory with respect to Program Antibodies and Licensed Products (unless otherwise agreed by the JRDC on the basis of section 4.1
above). In connection therewith: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Servier shall keep MacroGenics reasonably informed regarding Servier&#146;s (or its
Affiliate&#146;s or Sublicensee&#146;s) regulatory strategy, planned regulatory submissions and material communications with the Regulatory Authorities in the Servier Territory. with respect to the Program Antibodies and Licensed Products, including
any material changes to such strategy, submissions or communications. Servier shall provide MacroGenics with copies of material regulatory submissions to, and material communications with the *** relating to the Program Antibodies and Licensed
Products. To the extent permitted by Regulatory Authorities, MacroGenics shall have the right to have a senior, experienced employee participate as an observer in meetings with the *** or their agents, as well as participate in internal meetings or
discussions of Servier occurring immediately before or after, and related to, such meetings, and shall be provided with advance access to Servier&#146;s materials prepared for such meetings. MacroGenics shall also have the right to review and
comment upon any correspondence with the *** or their agents related to such meetings. Servier shall provide MacroGenics regularly prepared minutes of material meetings with the *** *** regarding Program Antibodies and Licensed Products in the Field
in the Servier Territory and available material teleconference reports with the *** pertaining to Program Antibodies and Licensed Products in the Field in the Servier Territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall keep Servier reasonably informed regarding MacroGenics&#146; (or its Affiliate&#146;s or Sublicensee&#146;s)
regulatory strategy, planned regulatory submissions and material communications with the *** with respect to the Program Antibodies and Licensed Products, including any material changes to such strategy, submissions or communications. MacroGenics
shall provide Servier with copies of material regulatory </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
submissions to, and material communications with the *** relating to the Program Antibodies and Licensed Products. To the extent permitted by Regulatory Authorities, Servier shall have the right
to have a senior, experienced employee participate as an observer in meetings with the *** or its agents, as well as participate in internal meetings or discussions of MacroGenics occurring immediately before or after, and related to, such meetings,
and shall be provided with advance access to MacroGenics&#146; materials prepared for such meetings. Servier shall also have the right to review and comment upon any correspondence with the *** or its agents related to such meetings. MacroGenics
shall provide Servier regularly prepared minutes of material meetings with the *** regarding Licensed Products in the Field in the MacroGenics Territory and available material teleconference reports with the *** pertaining to Licensed Products in
the Field in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.2 If either Party or its Affiliates or subcontractors (each, an
&#147;<U>Inspected Party</U>&#148;) are to be inspected by a Government Authority regarding the development, manufacture, registration or commercialization of a Licensed Product, the Inspected Party shall promptly notify the other Party of the
inspection in writing as soon as reasonably practicable, and in advance, if any such inspection is a scheduled inspection. The Inspected Party shall, where practicable, permit representatives of the other Party to participate as observers with
respect to such inspection, and shall provide the other Party with a written report of any such inspection, noting with specificity any records or documents reviewed by the regulatory inspector, and including copies of any FDA 483s (or their
non-U.S. equivalent) or written communications provided by or to any Government Authority relating to such inspection. The Inspected Party will use Commercially Reasonable Efforts to provide an opportunity for the other Party to assist in responding
to any issues or concerns relating to such inspections, and shall provide copies of all communications to and from any Government Authority relating thereto to the other Party. The Parties shall cooperate in good faith and otherwise mutually support
any regulatory inspections of facilities, clinical sites, contract manufacturers or the like with respect to Licensed Products, including by using Commercially Reasonable Efforts to make available such facilities, documents, information and/or
personnel as are reasonably necessary or useful for such regulatory inspections by a Government Authority. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4 <U>Product
Withdrawals and Recalls</U>. If any Regulatory Authority (a)&nbsp;threatens, initiates or advises any action to remove any Licensed Product from the market in any country of the world, or (b)&nbsp;requires or advises either Party or such
Party&#146;s Affiliates or sublicensees to distribute a &#147;Dear Doctor&#148; letter or its equivalent regarding use of any Licensed Product in any country of the world, then Servier (if such action is in the Servier Territory) or MacroGenics (if
such action is in the MacroGenics Territory), as applicable, shall notify the other Party of such event within <B>***</B> (or sooner if required by applicable Law) after such Party becomes aware of the action, threat, advice or requirement (as
applicable). The JRDC will discuss and attempt to agree upon whether to recall or withdraw such Licensed Product; provided, however, that if the Parties fail to agree within an appropriate time period or if the matter involves a safety issue that,
in order to protect patient safety, does not allow for sufficient time for a discussion at the JRDC level, Servier shall decide whether to recall or withdraw such Licensed Product in the Servier Territory and shall undertake any such recall or
withdrawal in the Servier Territory at its own cost and expense, and MacroGenics shall decide whether to recall or withdraw such Licensed Product in the MacroGenics Territory and shall undertake any such recall or withdrawal in the MacroGenics
Territory at its own cost and expense. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5 <U>Pharmacovigilance; Safety Data Reporting</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.5.1 <U>Pharmacovigilance</U>. *** after the License Grant Date the Parties shall negotiate in good faith a safety data exchange
agreement governing the collection, investigation, reporting, and exchange of information concerning adverse drug reactions/experience, Licensed Product quality and Licensed Product complaints, sufficient to permit each Party to comply with its
legal obligations (the &#147;<U>SDEA Agreement</U>&#148;). The SDEA Agreement will be promptly updated if required by changes in legal requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.5.2 <U>Safety Data Reporting</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Each Party shall keep the other Party
informed about any adverse drug reactions such Party becomes aware or is informed about regarding the use of a Licensed Product. As between the Parties, Servier shall be responsible for reporting all adverse drug reactions/experiences to the
appropriate regulatory authorities in countries in the Servier Territory, and MacroGenics shall be responsible for reporting all adverse drug reactions/experiences to the appropriate regulatory authorities in the MacroGenics Territory, in accordance
with the appropriate laws and regulations of the relevant countries and authorities. Servier shall ensure that its Affiliates and Sublicensees comply with such reporting obligations in the Servier Territory and MacroGenics shall ensure that its
Affiliates and sublicensees (other than Servier and its Sublicensees) comply with such reporting obligations in the MacroGenics Territory. These reporting obligations shall apply to other adverse events as described in the SDEA Agreement, including
adverse events occurring from product overdose or from product withdrawal, as well as any toxicity, sensitivity, failure of expected pharmacological action, or laboratory abnormality which is, or is thought by the reporter, to be serious or
associated with relevant clinical signs or symptoms. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Each Party will designate a pharmacovigilance liaison to be
responsible for communicating with the other Party regarding the reporting of adverse drug reactions/experiences. Each Party (the &#147;<U>Notifying Party</U>&#148;) shall notify the other Party in writing of all information coming to the Notifying
Party&#146;s attention, regardless of the origin of such information, and including such information coming to its attention through clinical and non-clinical sources (including journal publications and other media), regarding adverse drug
experiences associated with the Licensed Product, whether in the Servier Territory or in the MacroGenics Territory. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE
7 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MANUFACTURING </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 7 shall apply during the License Term. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1 <U>Transfer of MacroGenics Manufacturing Know-How</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.1 At Servier&#146;s request and sole expense, and on a schedule and a product comparability plan agreed upon by the Parties,
MacroGenics shall disclose (and provide copies, as applicable) to either Servier or the Third Party manufacturer that is mutually acceptable to both Parties, all MacroGenics Know-How necessary or useful to enable Servier or such Third Party
manufacturer (as appropriate) <B>***</B> to Manufacture Licensed Product based on a manufacturing process ***.&nbsp;For clarity, nothing in this Section&nbsp;7.1 with respect to MacroGenics&#146; obligation to transfer MacroGenics Know-How to
Servier shall limit MacroGenics&#146; right to use any such MacroGenics Know-How to fulfill MacroGenics&#146; obligations to Manufacture and supply Licensed Product to Servier under this Agreement or the Supply Agreement.&nbsp;In addition,
MacroGenics shall, at Servier&#146;s sole expense, make available to Servier, on a reasonable consultation basis, advice of its technical personnel as may reasonably be requested by Servier in connection with such transfer of MacroGenics
Know-How.&nbsp;MacroGenics shall thereafter during the Agreement Term, continue to promptly and regularly disclose any material new MacroGenics Know-How related to Manufacturing Program Antibodies and Licensed Products to Servier or to the Third
Party manufacturer mentioned above at Servier&#146;s cost. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.2 Servier and/or its Third Party manufacturer shall use the
MacroGenics Know-How transferred under Section&nbsp;7.1.1 solely for the purpose of Manufacturing Program Antibodies and finished Licensed Products in accordance with the terms and conditions of this Agreement, and for no other purpose. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.3 Servier acknowledges and agrees that MacroGenics may condition its agreement to transfer any MacroGenics <BR>Know-How to a Third
Party manufacturer on the execution of a confidentiality agreement between such Third Party manufacturer and MacroGenics that contains terms substantially equivalent to those of ARTICLE 11. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2 <U>Supply Agreements</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.2.1 <U>Clinical Supply Agreement</U>. <B>***</B> following the Effective Date, the Parties shall enter into good faith negotiations regarding the terms of a clinical supply agreement, pursuant to which
MacroGenics shall provide clinical supply of Program Antibodies and/or Licensed Products for (a)&nbsp;<B>***</B> (b)&nbsp;at MacroGenics&#146; option, Clinical Trials of Licensed Products conducted by Servier and its Affiliates and Sublicensees
other than <B>***</B> of Licensed Products to be conducted by Servier and its Affiliates and Sublicensees (the &#147;<U>Clinical Supply Agreement</U>&#148;). The cost for such supply of Program Antibodies and/or Licensed Products for Clinical Trials
shall be equal to MacroGenics&#146; Fully Burdened Manufacturing Cost; ***<B></B>. The Fully Burdened Manufacturing Cost for supply of Program Antibodies and/or Licensed Products for clinical trials used by Servier in connection with the Development
of a Program Antibodies and/or Licensed Products outside the Global Development Plan shall be invoiced by MacroGenics on a quarterly basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.2.2 <U>Commercial Supply Agreement</U>. Following the License Grant Date, if requested by Servier, the Parties shall enter into good faith negotiations regarding the terms of a quality and supply
agreement, pursuant to which MacroGenics shall provide commercial supply of Program Antibodies and/or Licensed Products to Servier and its Affiliates and Sublicensees (the &#147;<U>Commercial Supply Agreement</U>&#148;). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 8 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>COMMERCIALIZATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provisions of this ARTICLE 8 shall apply during the
License Term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1<U> Overview</U>.&nbsp;Servier shall have sole control and responsibility for the Commercialization of
Licensed Products in the Servier Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in the Servier Territory. MacroGenics shall have sole control and responsibility for the Commercialization of
Licensed Products in the MacroGenics Territory and shall bear all costs and expenses associated with the Commercialization of Licensed Products in the MacroGenics Territory. The Party with responsibility for Commercialization in a territory and
field shall be referred to as the &#147;<U>Commercializing Party</U>&#148; for such territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2 <U>Sales and
Distribution</U>.&nbsp;It is understood that as between the Parties, the Commercializing Party shall be solely responsible for handling all returns, order processing, invoicing and collection, distribution, and receivables for Licensed Products in
the applicable territory and indication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3<U>&nbsp;Ex-Territory Sales</U>.&nbsp;Subject to applicable Law,&nbsp;neither
Party shall engage in any advertising or promotional activities relating to Licensed Product directed primarily to customers or other buyers or users of Licensed Product located outside its territory or accept orders for Licensed Products from or
sell Licensed Products into such other Party&#146;s territory for its own account or for the Commercializing Party&#146;s account, and if such other Party receives any order for Licensed Products in the Commercializing Party&#146;s territory, it
shall refer such orders to the Commercializing Party for acceptance or rejection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4
<U>Commercialization Plan for Licensed Territory</U>.&nbsp;Servier shall pursue Commercialization of Licensed Products in the Servier Territory, in accordance with its normal business practices&nbsp;for its internal products at a similar
stage.&nbsp;Servier shall deliver an initial Commercialization plan to MacroGenics no later than <B>***</B> prior to the anticipated date of the first filing of the first BLA for a Licensed Product in the Servier Territory (the
&#147;<U>Commercialization Plan</U>&#148;).&nbsp;After the establishment of the initial Commercialization Plan, Servier shall prepare updates and amendments to such Commercialization Plan at least annually and deliver such updated Commercialization
Plan to MacroGenics no later than March&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> of each
Calendar Year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5 <U>Trademarks</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.5.1 <U>Generally</U>. Servier and its Affiliates shall select their own trademarks under which they will market Licensed Products (<U>provided</U> <U>that</U> no such trademark shall contain the word
&#147;MacroGenics&#148;) and shall own such trademarks. MacroGenics and its Affiliates shall select their own trademarks under which they will market Licensed Products (<U>provided</U> <U>that</U> no such trademark shall contain the word
&#147;Servier&#148; or &#147;Les Laboratoires Servier&#148;) and shall own such trademarks. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.2 <U>Acknowledgement</U>. Servier shall use, in connection with all packaging,
literature, labels and other printed matters, to the extent required by Law, and where reasonably practicable in light of space limitations, an expression to the effect that the Licensed Products were developed under license from MacroGenics,
together with the MacroGenics logo. The provisions of this Section&nbsp;8.5.2 shall not apply to primary packaging of the Licensed Products. Primary packaging shall mean packaging that is in direct contact with the Licensed Products or the Licensed
Products themselves, including vials, blister packs, tablets and capsules.<B> </B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.3 <U>Housemarks</U>. Neither Party
shall, and shall ensure that its Affiliates and sublicensees will not, make any use of the trademarks or house marks of the other Party or its Affiliates or licensees (including their corporate names) or any trademark confusingly similar thereto.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6 <U>Commercial Diligence</U>.&nbsp;During the License Term, Servier shall use Commercially Reasonable Efforts to
Commercialize the Products throughout the Servier Territory.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.7 <U>Standards of Conduct</U>.&nbsp;Each Party shall in all
respects comply with all applicable Laws and applicable guidelines concerning the advertising, sales and marketing of prescription drug products in Commercializing Products under this Agreement, including any applicable local anti-bribery laws.
</FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 9 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PAYMENTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1 <U>Option Grant Fee</U>. In consideration for the Option as
granted by MacroGenics to Servier hereunder and to review the Option Trigger Data Package, Servier shall pay MacroGenics a non-refundable, non-creditable payment of Twenty Million Dollars ($20,000,000) (the &#147;<U>Option Grant Fee</U>&#148;)
within *** after the Effective Date and the date of receipt of the corresponding invoice. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2 <U>License Grant Fee</U>.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2.1 Upon exercise of the Option and <B>***</B> after the date of receipt of the corresponding invoice, Servier shall pay
MacroGenics a non-refundable, non-creditable payment (the &#147;<U>License Grant Fee</U>&#148;) of </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** if by the date of the exercise of the Option, ***; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** if by the date of the exercise of the Option, ***; or </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="13%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** if by the date of the exercise of the Option, ***. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2.2 If Servier pays MacroGenics the License Grant Fee according to Section&nbsp;9.2.1(a)
or (b), Servier will, within *** after the date of receipt of the corresponding invoice, pay MacroGenics *** until Servier has paid MacroGenics a total of thirty million ($30,000,000) under Sections 9.2.1 and 9.2.2. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3 <U>Development and Regulatory Milestones</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.1 <U>Research Term Development Milestones</U>. Servier shall pay to MacroGenics the non-refundable,
non-creditable amount of Ten Million Dollars ($10,000,000) upon closing of the first subject in the first expansion cohort of the initial Phase 1 Clinical Trial, but in no event before October&nbsp;1</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.2 <U>License Term Development and Regulatory Milestones</U>. During the License Term, for each milestone set forth in
Section&nbsp;9.3.2, Servier shall pay the corresponding *** amount indicated for that milestone for the first instance of its achievement: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In no event shall the total of the amounts paid under this Section&nbsp;9.3.2 exceed <B>***</B>.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.3 <U>Milestone Payments</U>. Servier shall make the milestone payments required by Section&nbsp;9.4.1 and 9.3.2 in
accordance with Section&nbsp;9.3.6. If an event described in a clause in Section&nbsp;9.3.2 occurs before or concurrently with another event described in a preceding clause in Section&nbsp;9.3.2, Servier shall also pay the milestone payment
described in such earlier clause when the milestone payment described in such later clause is paid. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.4 <U>Follow-On Products</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Subject to the terms of this Agreement, ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) If prior to the time at which a milestone payment pursuant to Section&nbsp;9.3.4(a) is to be made with respect to a subsequent Licensed Product, the first Licensed Product has been substituted by a
subsequent Licensed Product or development of the first Licensed Product has been discontinued, then the achievement by such subsequent Licensed Product of a milestone event to the extent the corresponding milestone payment under Section&nbsp;9.3.2
has not been made with respect to such substituted or discontinued first Licensed Product, shall be deemed to be achievement of the corresponding milestone event under Section&nbsp;9.3.2 by the first Licensed Product entitling MacroGenics to the
corresponding milestone payment under Section&nbsp;9.3.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.5 <U>Reductions in Milestones Payable for Phase 3 Clinical
Trials</U>. In the event that the conduct by Servier of a Phase 1 Clinical Trial or Phase 2 Clinical Trial for Licensed Product in accordance with the Research Plan results in Servier, its Affiliates or Sublicensees conducting a Phase 3 Clinical
Trial for Licensed Product under the Global Development Plan in the same Indication as that studied in such Phase 1 Clinical Trial or Phase 2 Clinical Trial, <B>***</B><B></B>. Prior to the initiation of any such Phase 3 Clinical Trial, Servier
shall provide MacroGenics <B>***</B>. MacroGenics shall have the right to have an independent public accountant reasonably acceptable to Servier audit Servier&#146;s books and records solely for purposes of verifying such Development Costs, upon
reasonable advance notice and during Servier&#146;s business hours, subject to the confidentiality provisions of ARTICLE 11. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.6 <U>Notification; Payment</U>. Servier shall promptly notify MacroGenics in writing of the first achievement of each of the
milestones under this Section&nbsp;9.3 (other than milestones under Section&nbsp;9.3.1) and the corresponding milestone payment shall be due within *** after receipt of the corresponding invoice from MacroGenics. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4 <U>Sales Milestones</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.4.1 <U>Sales Milestone Payments</U>. Servier shall make the *** payments to MacroGenics set forth below upon the earliest achievement of each of the corresponding milestone events by the first Licensed
Product to achieve such milestone: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:52pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Milestone Event</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Payment</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.2 <U>Payment of Milestones</U>. Servier shall make the milestone payments required by
Section&nbsp;9.4.1 in accordance with Section&nbsp;9.6. If an event described in a clause in Section&nbsp;9.4.1 occurs before or concurrently with another event described in a preceding clause in Section&nbsp;9.4.1, Servier shall also pay the
milestone payment described in such earlier clause when the milestone payment described in such later clause is paid. By way of example, if, during March 2015, ***, Servier shall pay MacroGenics the milestone payments set forth in both Sections
9.4.1(a) and (b). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5 <U>Royalties</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.5.1 Servier shall pay MacroGenics royalties on Net Sales of Licensed Products at the following rates with respect to all such Net Sales of such applicable Licensed Products achieved during the
applicable Calendar Year: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:90pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Annual Net Sales Threshold</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1">Royalty&nbsp;Rate</FONT></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.2 <U>Royalty Term</U>. Servier&#146;s royalty obligations to MacroGenics under this Section&nbsp;9.5
shall expire on a country-by-country and Licensed Product-by-Licensed Product basis on the later of: <B>***</B> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.3
<U>Third Party Royalty Offset</U>.</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If after the License Grant Date, Servier, its Affiliates or its Sublicensee or
designee&nbsp;(i) is required, as agreed by the Parties in good faith, ***, to obtain a license from any Third Party under an Identified Patent controlled by such Third Party in order to Manufacture, Develop, Commercialize or import a Program
Antibody and/or a Licensed Product in any country in the Servier Territory, and pursuant to such license ***, or (ii)&nbsp;is required by any court of competent jurisdiction, due to infringement of an Identified Patent controlled by such Third Party
in any country(ies) in the Servier Territory, ***, then Servier may deduct from the milestones (other than the milestone set forth in Section&nbsp;9.3.1) and/or royalties that would otherwise be due to MacroGenics on Net Sales resulting from the
sales of such Licensed Product in such country in a Calendar Quarter *** of the amount paid by Servier to such Third Party with respect to such Licensed Product for such country during such Calendar Quarter; ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If, (i)&nbsp;in order to Manufacture, Develop, Commercialize or import a Program Antibody and/or a Licensed Product in any country
in the Servier Territory, Servier or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
its Affiliates or Sublicensees *** under a MacroGenics Third Party Agreement listed in <U>Exhibit C</U> as of the Effective Date ***, or (ii)&nbsp;after the License Grant Date, Servier or its
sublicensee or designee:&nbsp;(A) is required, as agreed by the Parties in good faith, ***, to obtain a license from any Third Party under Patents (other than Identified Patents) controlled by such Third Party in order to make, have made, use, sell,
offer for sale or import a Program Antibody and/or a Licensed Product in any country in the Servier Territory, and pursuant to such license ***, or (B)&nbsp;is required by any court of competent jurisdiction, due to infringement of patent rights
(other than Identified Patents) controlled by such Third Party in any country(ies) in the Servier Territory, to pay such a royalty to such a Third Party based on sales of such Licensed Product in such country(ies), then Servier may deduct from the
milestones and/or royalties that would otherwise be due to MacroGenics on Net Sales resulting from the sales of such Licensed Product in such country in a Calendar Quarter <B>***</B> of the amount paid by Servier to such Third Party with respect to
such Licensed Product for such country during such Calendar Quarter; ***<B></B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.4 If at any time following the First
Commercial Sale, Generic Competition exists in any country of the Servier Territory, Servier shall deduct *** from the royalties that would otherwise be due to MacroGenics on Net Sales resulting from the sales of such Licensed Product in such
country during the applicable Calendar Quarter in which such Generic Competition exists. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6 <U>Reports; Payments</U>. Within
*** after the end of each Calendar Quarter during which there are Net Sales giving rise to a payment obligation under Section&nbsp;9.4 or 9.5, Servier shall submit to MacroGenics a report identifying for each Licensed Product, the Net Sales for such
Licensed Product for each country in the Servier Territory for such Calendar Quarter, the calculation of royalties (including gross sales and all deductions taken from gross sales), and the royalties and the sales milestones payable to MacroGenics.
Within *** of the delivery of each such report, Servier shall pay to MacroGenics all royalties and sales milestones payable by it under Sections&nbsp;9.4 and 9.5. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.7 <U>Methods of Payments</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7.1 All payments due under this Agreement shall
be paid in Dollars ***, by wire transfer to a bank in the United States designated in writing by MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7.2 For the
purposes of determining the amount of any sales milestone payment under Section&nbsp;9.4 or royalties due for the relevant Calendar Quarter under Section&nbsp;9.5, the amount of Net Sales in any non-Euro currency shall be converted into Euro using
the average of daily closing rates of exchange published by European Central Bank for the monthly period in which Net Sales are accounted. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.8 <U>Late Payments</U>. Any amount owed by Servier to MacroGenics under this Agreement that is not paid on or before the date such payment is due shall bear interest at a rate per annum equal to the
lesser of (a)&nbsp;<B>***</B>, or (b)&nbsp;the highest rate permitted by applicable Law, calculated on the number of days such payments are paid after such payments are due and compounded monthly. ***. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">9.9 <U>Taxes</U>. All payment due and payable under this Agreement will
be made without any deduction or withholding for on account of any tax by application of the Tax Treaty in force between France and The United States since August&nbsp;31</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> 1994 and in accordance with its amendment signed January&nbsp;13</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> 2009 which came into force retroactively January&nbsp;1</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">st</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> 2009, unless such deduction or withholding tax is required by
applicable laws. If the paying Party is so required to deduct or withhold, such Party shall (a)&nbsp;promptly notify the other Party of such requirement, (b)&nbsp;pay to the relevant authorities the full amount required to be deducted or withheld
promptly upon the earlier of determining that such deduction or withholding is required or receiving notice that such amount has been assessed against the other Party, and (c)&nbsp;promptly forward to the other Party an official receipt (or
certified copy), or other documentation reasonably acceptable to the other Party evidencing such payment to such authorities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.10 <U>Books and Records; Audit Rights</U>. Each Party (the &#147;<U>Audited Party</U>&#148;) shall keep (and, in the case of Servier,
shall cause its Affiliates and Sublicensees to keep) complete, true and accurate books and records in accordance with its Accounting Standards in sufficient detail for the other Party (the &#147;<U>Auditing Party</U>&#148;) to determine the payments
due and costs incurred under this Agreement. Each Auditing Party shall have the right, once annually at its own expense, to have an independent, certified public accounting firm of nationally recognized standing, selected by the Auditing Party and
reasonably acceptable to the Audited Party, review any such records of the Audited Party in the location(s) where such records are maintained by the Audited Party upon reasonable notice (which shall be no less than *** prior notice) and during
regular business hours and under obligations of strict confidence, for the sole purpose of verifying the accuracy of the amounts paid under this Agreement within a *** period preceding the date of the request for review. The report of such
accounting firm shall be limited to a certificate stating whether any report made or invoice or payment submitted by the Audited Party during such period is accurate or inaccurate and the actual amounts of Development Costs and the amount of any Net
Sales, milestone or royalty discrepancy. No other information shall be provided to the Auditing Party. The Audited Party shall receive a copy of each such report concurrently with receipt by the Auditing Party. Should such inspection lead to the
discovery of a discrepancy to the Auditing Party&#146;s detriment, the Audited Party shall pay the amount of the discrepancy within *** after its receipt from the accounting firm of the certificate showing the amount of the discrepancy. The Auditing
Party shall pay the full cost of the review unless the underpayment of milestones, royalties and/or Development Costs, is greater than *** of the amount due for the applicable period, in which case the Audited Party shall pay the reasonable costs
charged by such accounting firm for such review. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 10 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OWNERSHIP OF INTELLECTUAL PROPERTY RIGHTS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.1 <U>Inventorship</U>. Inventorship for patentable inventions conceived or reduced to practice during the course of the performance of activities pursuant to this Agreement shall be determined in
accordance with patent laws where the invention was invented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2 <U>Ownership</U>. Subject to the licenses and rights
granted to Servier under this Agreement, MacroGenics shall own the entire right, title and interest in and to all inventions and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or consultants of MacroGenics or acquired solely by MacroGenics in the course of
Research, Development, Manufacture or Commercialization of Program Antibodies and/or Licensed Products. Subject to the licenses and rights granted to MacroGenics under this Agreement, Servier shall own the entire right, title and interest in and to
all inventions and discoveries (and Patents claiming patentable inventions therein) first made or discovered solely by employees or consultants of Servier or acquired solely by Servier in the course of Research, Development, Manufacture or
Commercialization of Program Antibodies and/or Licensed Product. The Parties shall jointly own any Joint IP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3
<U>Prosecution and Maintenance of Patents</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.1 <U>MacroGenics Patents</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall have the sole right to, at MacroGenics&#146; discretion, file, prosecute, and maintain (including the defense of
any interference or opposition proceedings), all MacroGenics Patents. ***. MacroGenics shall provide to Servier copies of all prosecution filings related to MacroGenics Patents comprising claims Covering Program Antibodies and/or Licensed Products
(&#147;<U>MacroGenics Product Patents</U>&#148;) sent to or received from patent offices in the Servier Territory, unless otherwise directed by Servier, and, with respect to patent applications having information not previously filed that is
intended to be submitted to patent offices in the Servier Territory, shall provide Servier with a draft of each such filing within <B>***</B> in advance of submission, provide Servier an opportunity to provide comments on and make request of
MacroGenics concerning such filings and shall consider in good faith any comments regarding such draft application that Servier may timely provide. In addition, MacroGenics shall provide to Servier such other information related to prosecution of
the MacroGenics Patents in the Servier Territory as Servier may from time to time reasonably request to allow Servier to track prosecution and maintenance of such Patents. If Servier no longer desires to retain its license under any MacroGenics
Patent in the Servier Territory, and desires to ***, it shall have the right to terminate such license to such Patent, and ***, upon <B>***</B> written notice. Following such <B>***</B> period, the Patent(s) referenced in such notice shall no longer
be deemed a MacroGenics Patent(s) and Servier shall have no rights hereunder with respect to such Patent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Subject to the
requirements and limitations of the MacroGenics Third Party Agreements, with respect to the filing, prosecution and maintenance of the MacroGenics IP, including any rights of, and time-frames for, such Third Party licensors to comment on and review
any filings and correspondence related thereto, in the event MacroGenics decides not to file a patent application on MacroGenics Know-How specific to Program Antibodies and/or Licensed Product in a country of the Servier Territory, or decides to
abandon prosecution of any claim of a MacroGenics Product Patent in a country of the Servier Territory or decides to not otherwise maintain or extend any MacroGenics Product Patent in a country of the Servier Territory, MacroGenics shall give
Servier written notice sufficiently in advance thereof. Unless MacroGenics&#146; discontinuation of filing, prosecution or maintenance of such MacroGenics Product Patent is in order to effect a settlement or to avoid an interference, opposition or
other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proceeding in which the validity of such MacroGenics Product Patent may be determined or because another MacroGenics Product Patent of similar claim scope is being prosecuted or has been issued,
Servier shall have the first right to file, prosecute, maintain and extend, as the case may be, such MacroGenics Product Patent, in Servier&#146;s name, in such country. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.3.2 <U>Servier Collaboration Patents</U> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Servier shall have the sole
right to, at Servier&#146;s discretion, file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Servier Collaboration Patents. MacroGenics shall reimburse Servier for the Out-of-Pocket Costs incurred
in the filing, prosecution and maintenance of the Servier Collaboration Patents in the MacroGenics Territory. Servier shall provide to MacroGenics copies of all prosecution filings related to Servier Collaboration Patents comprising claims Covering
Program Antibodies and/or Licensed Products (&#147;<U>Servier Product Patents</U>&#148;) sent to or received from patent offices in the MacroGenics Territory, unless otherwise directed by MacroGenics, and, with respect to patent applications having
information not previously filed that is intended to be submitted to patent offices in the MacroGenics Territory, shall provide MacroGenics with a draft of each such filing <B>***</B> in advance of submission, provide MacroGenics an opportunity to
provide comments on and make request of Servier concerning such filings and shall consider in good faith any comments regarding such draft application that MacroGenics may timely provide. In addition, Servier shall provide to MacroGenics such other
information related to prosecution of the Servier Collaboration Patents in the MacroGenics Territory as MacroGenics may from time to time reasonably request to allow MacroGenics to track prosecution and maintenance of such Patents. If MacroGenics no
longer desires to retain its license under any Servier Collaboration Patent in the MacroGenics Territory, and desires to cease payment of the costs of prosecution and maintenance thereof, it shall have the right to terminate such license to such
Patent, and terminate reimbursement to Servier of such costs, upon <B>***</B> written notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In the event Servier
decides not to file a patent application on Servier Collaboration Know-How specific to Program Antibodies and/or Licensed Product, or decides to abandon prosecution of any claim of a Servier Product Patent or decides to not otherwise maintain or
extend any Servier Product Patent, Servier shall give MacroGenics written notice sufficiently in advance thereof. Unless Servier&#146;s discontinuation of filing, prosecution or maintenance of such Servier Product Patent is in order to effect a
settlement or to avoid an interference, opposition or other proceeding in which the validity of such Servier Product Patent may be determined or because another Servier Product Patent of similar claim scope is being prosecuted or has been issued,
MacroGenics shall have the first right to file, prosecute and maintain or extend at its costs, as the case may be, such Servier Product Patent, in MacroGenics&#146; name, in such country. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.3 <U>Joint IP</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) MacroGenics shall have the first right, at MacroGenics&#146; discretion, to file, prosecute, and maintain (including the defense of any interference or opposition proceedings), all Patents claiming
patentable inventions included in the Joint IP (&#147;<U>Joint Patents</U>&#148;) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
in the MacroGenics Territory, in the names of both MacroGenics and Servier. Servier shall have the first right, at Servier&#146;s discretion, to file, prosecute, and maintain (including the
defense of any interference or opposition proceedings), all Joint Patents in the Servier Territory, in the names of both MacroGenics and Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) With respect to Joint Patents, if the Party with the responsibility for filing, prosecuting and maintaining such Patents in accordance with clause (a)&nbsp;above (the &#147;<U>Responsible
Party</U>&#148;) elects not to seek or continue to seek or maintain patent protection on any Joint Patent in its territory, the other Party shall have the right to seek, prosecute and maintain patent protection on such Joint Patent in the other
Party&#146;s name and the Responsible Party shall assign its entire right, title and interest in such Joint Patent to the other Party. The Responsible Party shall use Commercially Reasonable Efforts to make available to the other Party its
authorized attorneys, agents or representatives, and to assist the other Party in obtaining and maintaining such patent protection. The Responsible Party shall sign or use Commercially Reasonable Efforts to have signed all legal documents necessary
to file and prosecute such patent applications or to obtain or maintain such patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) The Parties shall establish
procedures to coordinate the filing and prosecution of Joint Patent. With respect to Joint Patents, the Responsible Party shall provide the other Party, within *** after submitting or receiving such filings or correspondence, with copies of all
filings and correspondence submitted to and received from patent offices and, with respect to substantive filings and correspondence to be submitted to patent offices, shall use reasonable efforts to provide the other Party with drafts of such
filings and correspondence reasonably in advance of submission and shall consider in good faith any comments regarding such filings and correspondence that the other Party may timely provide. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Each Party shall be responsible for the costs and expenses it occurs in connection with the filing, prosecution and maintenance of
Joint Patents. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4 <U>Third Party Infringement</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.4.1 <U>Notice</U>. Each Party shall promptly report in writing to the other Party any known or suspected (i)&nbsp;infringement of any of the MacroGenics Patents, Servier Patents or Joint Patents,
(ii)&nbsp;unauthorized use or misappropriation of any of the MacroGenics Know-How, Servier Know-How or Joint Know-How of which such Party becomes aware, or (iii)&nbsp;notification under the Biologics Price Competition and Innovation Act of 2009, as
amended, or similar law, from a biosimilar applicant arising from the filing of an application for the Regulatory Approval of a Generic Product intending to show that the Generic Product is biosimilar to any Licensed Product that is a reference
product for which a claim of infringement of any of the MacroGenics Patents, Joint Patents or Servier Patents by the manufacture or sale of the Generic Product could reasonably be asserted, and shall provide the other Party with all available
evidence regarding such known or suspected infringement or unauthorized use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.2 <U>Enforcement Rights</U>. Subject to the
requirements and limitations of the MacroGenics Third Party Agreements with respect to the enforcement of Patents, including any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
rights of, and timeframes for, such Third Party licensors to comment on and review any filings or materials related thereto, the Parties agree: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Servier shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the
Joint Patents and MacroGenics Product Patents in the Field in the Servier Territory to the extent such infringement or misappropriation involves the Development, Manufacture, use or Commercialization of a product or product candidate that is or may
be competitive with the Program Antibodies or Licensed Products being Developed or Commercialized hereunder. Notwithstanding the foregoing sentence, Servier shall not initiate any such lawsuit or other enforcement action asserting any such Joint
Patents or MacroGenics Product Patents without first consulting with MacroGenics and giving good faith consideration to any reasonable objection from MacroGenics regarding Servier&#146;s proposed course of action. MacroGenics shall cooperate in the
prosecution of such suit as may be reasonably requested by Servier; <U>provided</U> that Servier shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with
such cooperation. In connection with any such proceeding, Servier shall not enter into any settlement admitting the invalidity of, or otherwise impairing MacroGenics&#146; rights in, MacroGenics IP or Joint IP without the prior written consent of
MacroGenics. Any recoveries resulting from such an action brought by Servier in accordance with this clause (a)&nbsp;shall be applied as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) First, to reimburse each Party for all Out-of-Pocket Costs in connection with such proceeding (on a pro rata basis, based on each Party&#146;s respective litigation costs, to the extent the recovery
was less than all such litigation costs); and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) MacroGenics shall have the first right, but not the obligation, to initiate a lawsuit or take other reasonable action to enforce the
Joint Patents in the Field in the MacroGenics Territory. Notwithstanding the foregoing sentence, MacroGenics shall not initiate any such lawsuit or other enforcement action asserting any such Joint Patents without first consulting with Servier and
giving good faith consideration to any reasonable objection from Servier regarding MacroGenics&#146; proposed course of action. Servier shall cooperate in the prosecution of such suit as may be reasonably requested by MacroGenics; <U>provided
</U>that MacroGenics shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. In connection with any such proceeding, MacroGenics shall not
enter into any settlement admitting the invalidity of, or otherwise impairing the Parties&#146; rights in Joint IP without the prior written consent of Servier. Any recoveries resulting from such an action brought by MacroGenics in accordance with
this clause (b)&nbsp;shall be applied as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) First, to reimburse each Party for all Out-of-Pocket Costs in
connection with such proceeding (on a pro rata basis, based on each Party&#146;s respective litigation costs, to the extent the recovery was less than all such litigation costs); and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) If Servier does not initiate a lawsuit or take other reasonable action pursuant to Section&nbsp;10.4.2(a) with respect to any Joint Patents or Servier Product Patents (i)&nbsp;if there is no time
limit for the filing of such action, within <B>***</B> following the notice of alleged infringement or following a biosimilar applicant&#146;s failure to act or (ii)&nbsp;if there is a time limit for the filing of such action (including those set
forth in applicable Laws) within at least <B>***</B> before the time limit, then MacroGenics shall have the right (in cases where MacroGenics has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing
<B>***</B> notice to Servier and giving good faith consideration to Servier&#146;s reason(s) for not initiating a lawsuit or taking other action. For this purpose, Servier shall cooperate in the prosecution of such suit as may be reasonably
requested by MacroGenics; <U>provided</U> that MacroGenics shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by Servier in connection with such cooperation. Any recoveries
resulting from such an action brought by MacroGenics in accordance with this clause (c)&nbsp;will be *** after payment of each Party&#146;s costs and expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) If MacroGenics does not initiate a lawsuit or take other reasonable action pursuant to Section&nbsp;10.4.2(b) with respect to any Joint Patents (i)&nbsp;if there is no time limit for the filing of
such action, within <B>***</B> following the notice of alleged infringement or following a biosimilar applicant&#146;s failure to act or (ii)&nbsp;if there is a time limit for the filing of such action (including those set forth in applicable Laws)
within at least <B>***</B> before the time limit, then Servier shall have the right (in cases where Servier has standing), but not the obligation, to initiate such lawsuit or take such other action, after providing <B>***</B> notice to MacroGenics
and giving good faith consideration to MacroGenics&#146; reason(s) for not initiating a lawsuit or taking other action. For this purpose, MacroGenics shall cooperate in the prosecution of such suit as may be reasonably requested by Servier;
<U>provided</U> that Servier shall promptly reimburse all out-of-pocket expenses (including reasonable counsel fees and expenses) actually incurred by MacroGenics in connection with such cooperation. Any recoveries resulting from such an action
brought by Servier in accordance with this clause (d)&nbsp;will be *** after payment of each Party&#146;s costs and expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.3 <U>Conduct of Certain Actions; Costs</U>. The Party initiating legal action shall have the sole and exclusive right to select
counsel for any suit initiated by it pursuant to Section&nbsp;10.3.2 or 10.3.3 (the &#147;<U>Initiating Party</U>&#148;). Unless otherwise expressly provided, the Initiating Party shall bear its own out-of-pocket costs incurred in any such legal
action, including the fees and expenses of the counsel selected by it. The other Party shall have the right to participate and be represented in any such legal action (in cases where such other Party has standing) by its own counsel at its own
expense. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5 <U>Patent Invalidity Claim</U>. Each Party shall promptly notify the other in the event of any legal or
administrative action by any Third Party against a Joint Patent, MacroGenics Patent or Servier Patent of which it becomes aware, including any nullity, revocation, reexamination or compulsory license proceeding. Servier shall have the first right,
but not the obligation, at its expense, to defend against any such action relating to the Servier Patents. MacroGenics shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
have the first right, but not the obligation, at its expense, to defend against any such action relating to the MacroGenics Patents or the Joint Patents. If MacroGenics does not defend against
any such action involving a MacroGenics Product Patent or a Joint Patent, then Servier shall have the right, but not the obligation, to defend such action at Servier&#146;s expense. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.6 <U>Patent Term Extensions</U>. The Parties shall cooperate with each other in obtaining patent term extensions or supplemental
protection certificates or their equivalents in any country, where applicable to Joint Patents, MacroGenics Patents and Servier Patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.7 <U>Patent Marking</U>. Servier shall comply with the patent marking statutes in each country in which a Licensed Product is sold by Servier, its Affiliates and/or its Sublicensees. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 11 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFIDENTIALITY </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1 <U>Confidentiality; Exceptions</U>. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing, the Parties agree that the receiving Party (the &#147;<U>Receiving
Party</U>&#148;) shall keep confidential and shall not publish or otherwise disclose or use for any purpose other than as provided for in this Agreement any Know-How in any form (written, oral, photographic, electronic, magnetic, or otherwise) that
is disclosed to it by the other Party (the &#147;<U>Disclosing Party</U>&#148;) or otherwise received or accessed by a Receiving Party in the course of performing its obligations or exercising its rights under this Agreement (collectively,
&#147;<U>Confidential Information</U>&#148;), except to the extent that it can be established by the Receiving Party that such Confidential Information: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1.1 was in the lawful knowledge and possession of the Receiving Party prior to the time it was disclosed to, or learned by, the Receiving Party, or was otherwise developed independently by the
Receiving Party, as evidenced by written records kept in the ordinary course of business, or other documentary proof of actual use by the Receiving Party; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.1.2 was generally available to the public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.3 became generally available to the public or otherwise part of the public domain after its disclosure and other than through any
act or omission of the Receiving Party in breach of this Agreement; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.4 was disclosed to the Receiving Party, other
than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.2 <U>Authorized Disclosure</U>. Except as expressly provided otherwise in this Agreement, a Receiving Party may use and disclose Confidential Information of the Disclosing Party as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.1 under appropriate confidentiality provisions similar to those in this Agreement, in connection with the performance of its
obligations or exercise of rights granted or reserved in this Agreement; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.2 to the extent such disclosure is reasonably necessary in filing or prosecuting patent
and copyright applications, prosecuting or defending litigation, complying with applicable governmental regulations (including the rules and regulations of any stock exchange or NASDAQ), conducting non-clinical activities and clinical activities,
preparing and submitting filings to Regulatory Authorities or is otherwise required by Law; <U>provided</U>, <U>however</U>, that if a Receiving Party is required by Law to make any such disclosure of a Disclosing Party&#146;s Confidential
Information (other than a disclosure to a Regulatory Authority in a filing required by Law) it will give reasonable advance notice to the Disclosing Party of such disclosure requirement and shall furnish only that portion of the Disclosing
Party&#146;s Confidential Information that the Receiving Party is legally required to furnish; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.3 in communications with
existing or prospective acquirers, investors, consultants, advisors, licensees or collaborators or others on a need to know basis, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement; or
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.4 to the extent mutually agreed to in writing by the Parties. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3 <U>Press Release; Disclosure of Agreement</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.3.1 On or promptly after the Effective Date, the Parties shall jointly issue a public announcement of the execution of this Agreement in the form attached hereto as <U>Exhibit D</U>. Neither Party
shall issue any subsequent press release or make other disclosures regarding this Agreement or the Parties&#146; activities hereunder, or any results or data arising hereunder, except (a)&nbsp;with the other Party&#146;s prior written consent;
(b)&nbsp;in accordance with Section&nbsp;11.6; or (c)&nbsp;for any disclosure that is reasonably necessary to comply with applicable securities exchange listing requirements or other applicable Laws. Notwithstanding the foregoing, to the extent
information regarding this Agreement has already been publicly disclosed, either Party may subsequently disclose the same information to the public without the consent of the other Party. Each Party shall be permitted to disclose the terms of this
Agreement, in each case under appropriate confidentiality provisions substantially equivalent to those of this Agreement, to any actual or potential acquirers, merger partners, licensees, sublicensees, investors and professional advisors on a need
to know basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.2 Each Party shall, if practicable, give the other Party a reasonable opportunity to review those
portions of all filings with the United States Securities and Exchange Commission (or any stock exchange, including Nasdaq, or any similar regulatory agency in any country other than the United States) describing the terms of this Agreement
(including any filings of this Agreement) prior to submission of such filings, and shall give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the provisions of this Agreement for which
confidential treatment should be sought. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4 <U>Existing Confidentiality Agreement</U>. For the avoidance of doubt, any information
disclosed by MacroGenics to Servier prior to the Effective Date pursuant to the Non-Disclosure Disclosure Agreement between MacroGenics and Servier dated <B>***</B> (the &#147;<U>Existing Confidentiality Agreement</U>&#148;) shall be treated as
Confidential Information for all purposes under this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5 <U>Remedies</U>. In the event a Party breaches the
confidentiality obligations set forth in this ARTICLE 11, the other Party shall be entitled to seek, in addition to any other right or remedy it may have, at Law or in equity, a temporary injunction, without the posting of any bond or other
security, enjoining or restraining the breaching Party from any violation or threatened violation of this ARTICLE 11. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6
<U>Publications</U>. Neither Party nor its Affiliates shall publish or publicly disclose the results of any of the Research or Development activities conducted by either Party under this Agreement without the prior written consent of the other
Party, except as expressly permitted in this Section&nbsp;11.6 or otherwise in this Agreement. The Parties recognize that it may be useful or required to publish or publicly disclose the results of Research and Development work on Program Antibodies
and Licensed Products, and each Party (and its Affiliates) shall be free to publish or publicly disclose such results, subject to the prior review by the other Party for patentability and protection of its Confidential Information as described in
this Section&nbsp;11.6. The Party that desires to publish results hereunder shall provide the other Party with a copy of such proposed abstract, manuscript, or presentation no less than <B>***</B> prior to its intended submission for publication.
The reviewing Party shall respond in writing promptly and in no event later than <B>***</B> after receipt of the proposed material, with one or more of the following: (a)&nbsp;comments on the proposed material, which the publishing Party shall
consider in good faith, (b)&nbsp;a specific statement of concern, based upon the need to seek patent protection, or (c)&nbsp;an identification of the reviewing Party&#146;s Confidential Information that is contained in the material reviewed. In the
event of concern over patent protection, the publishing Party agrees not to submit such publication or to make such presentation that contains such information until the reviewing Party is given a reasonable period of time, and in no event less than
<B>***</B>, to seek patent protection for any material in such publication or presentation which it believes is patentable. Any Confidential Information of the reviewing Party shall, if requested by the reviewing Party, be removed by the other
Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7 <U>Return of Confidential Information</U>. Upon the expiration or termination of this Agreement, the Receiving
Party shall return to the Disclosing Party all Confidential Information received by the Receiving Party from the Disclosing Party (and all copies and reproductions thereof). In addition, the Receiving Party shall destroy: (a)&nbsp;any notes, reports
or other documents prepared by the Receiving Party which contain Confidential Information of the Disclosing Party; and (b)&nbsp;any Confidential Information of the Disclosing Party (and all copies and reproductions thereof) which is in electronic
form or cannot otherwise be returned to the Disclosing Party. Alternatively, upon written request of the Disclosing Party, the Receiving Party shall destroy all Confidential Information received by the Receiving Party from the Disclosing Party (and
all copies and reproductions thereof) and any notes, reports or other documents prepared by the Receiving Party which contain Confidential Information of the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Disclosing Party. Nothing in this Section&nbsp;11.7 shall require the alteration, modification, deletion or destruction of archival tapes or other electronic back-up media made in the ordinary
course of business; provided that the Receiving Party shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11 with respect to any Confidential Information contained in such archival tapes or other
electronic back-up media. Any requested destruction of Confidential Information shall be certified in writing to the Disclosing Party by an authorized officer of the Receiving Party supervising such destruction. Notwithstanding the foregoing,
(i)&nbsp;the Receiving Party&#146;s legal counsel may retain one copy of the Disclosing Party&#146;s Confidential Information solely for the purpose of determining the Receiving Party&#146;s continuing obligations under this ARTICLE 11 and
(ii)&nbsp;the Receiving Party may retain the Disclosing Party&#146;s Confidential Information and its own notes, reports and other documents (A)&nbsp;to the extent reasonably required (i)&nbsp;to comply with applicable Law and regulatory
requirements; (ii)&nbsp;to exercise the rights and licenses of the Receiving Party expressly surviving expiration or termination of this Agreement; and (iii)&nbsp;to perform the obligations of the Receiving Party expressly surviving expiration or
termination of this Agreement; or (B)&nbsp;to the extent it is impracticable to do so without incurring disproportionate cost. Notwithstanding the return or destruction of the Disclosing Party&#146;s Confidential Information, the Receiving Party
shall continue to be bound by its obligations of confidentiality and other obligations under this ARTICLE 11. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 12
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPRESENTATIONS AND WARRANTIES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1 <U>Representations and Warranties of Both Parties</U>. Each Party hereby represents and warrants to the other Party, as of the Effective Date, that: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.1 such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and
has full corporate power and authority to enter into this Agreement and to carry out the provisions hereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.2 such Party
has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.1.3 this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against it in accordance with the terms hereof;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.4 the execution, delivery and performance of this Agreement by such Party does not conflict with any agreement or any
provision thereof, or any instrument or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Law of any court, governmental body or administrative or other agency having jurisdiction over such Party; and
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.1.5 no government authorization, consent, approval, license, exemption of or filing or registration with any court or
governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws currently in effect, is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or will be necessary for, or in connection with, the transaction contemplated by this Agreement, or for the performance by it of its obligations under this Agreement, except as necessary to
conduct clinical trials or to seek or obtain Regulatory Approvals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2 <U>Representations and Warranties of MacroGenics and
its Affiliates</U>. ***, MacroGenics and its Affiliates hereby represent and warrant to Servier that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.1 As of the
Effective Date, MacroGenics is the owner of, or has Control via a license to, the MacroGenics Patents listed on <U>Exhibit B</U>; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.2.2 There are not as of the Effective Date, nor have there been over the *** period immediately preceding the Effective Date, any claims, lawsuits, arbitrations, legal or administrative or regulatory
proceedings, charges, complaints or investigations by any Government Authority (except in the ordinary administrative course of the granting of patents and proceedings relating thereto) or by any Third Party relating to the MacroGenics Patents or
MacroGenics Know-How; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.3 As of the Effective Date, to MacroGenics&#146; and its Affiliates knowledge, the exercise by
Servier of the rights and licenses granted to Servier by MacroGenics under this Agreement shall not infringe any rights owned or controlled by any Third Party in the Servier Territory; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.4 As to the Effective Date, to MacroGenics&#146; and its Affiliates knowledge *** it has not (i)&nbsp;employed and has not used a
contractor or consultant that has employed, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA), or, (ii)&nbsp;employed any individual who or entity that is the subject of an FDA debarment investigation or
proceeding (or similar proceeding of EMA), in the conduct of any pre-clinical activities or clinical studies of Program Antibodies; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.2.5 As to the Effective Date, MacroGenics has the right to grant all rights and licenses it purports to grant to Servier with respect to the MacroGenics IP under this Agreement and it has not granted
any license, right or interest in, to or under MacroGenics IP to any Third Party that is inconsistent with the licenses and rights granted to Servier under Section&nbsp;4.1; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.2.6 As of the Effective Date, to MacroGenics and its Affiliates&#146; knowledge the MacroGenics IP are all of the Patents and Know-How Controlled by MacroGenics or its Affiliates which are reasonably
necessary for the Development, Manufacture, Commercialization of the Program Antibody and/or Licensed Products in the Field in the Servier Territory; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.2.7 To MacroGenics knowledge, the Research and Development of the Program Antibody and the Licensed Product prior to the Effective Date by or on behalf of MacroGenics has been carried out without
infringing any Patent owned or controlled by a Third Party; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.8 As of the Effective Date, to MacroGenics&#146; knowledge, there are no activities by
Third Party that would constitute infringement or misappropriation of the MacroGenics IP; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.9 As of the Effective Date, to
MacroGenics&#146; knowledge, there is no reason for MacroGenics or a count of competent jurisdiction to reasonably conclude that the MacroGenics Patents are invalid or unenforceable. To MacroGenics&#146; knowledge, the claims included in any issued
MacroGenics Patent are valid and in full force and effect. All fees required to be paid to the governmental authorities prior to the Effective Date to prosecute or maintain the MacroGenics Patent in the Servier Territory have been filed and have
been paid; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.10 MacroGenics has maintained prior to the Effective Date and, unless agreed to otherwise by Servier and
except as provided in this Agreement, during the Agreement Term will maintain and keep in full force and effect all agreements and filings (including Patent filings) necessary to perform its obligations hereunder; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.2.11 As of the Effective Date, to MacroGenics and its Affiliates&#146; knowledge, all material Safety Data arising from the Initial
Phase 1 Clinical Trial has been provided to Servier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.3 <U>Representation and Warranty of LLS</U>. LLS hereby represents
and warrants to MacroGenics that IdRS is an Affiliate of LLS. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4 <U>Mutual Covenants</U>. Each Party hereby covenants to
the other Party that: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.1 Such Party shall comply with all applicable Laws in connection with this Agreement and the
transactions contemplated hereby. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.2 All employees of such Party or its Affiliates working under this Agreement will be
under the obligation to assign all right, title and interest in and to their inventions and discoveries, whether or not patentable, to such Party as the sole owner thereof; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">12.4.3 To its knowledge *** such Party will not (a)&nbsp;employ or use any contractor or consultant that employs, any individual or entity debarred by the FDA (or subject to a similar sanction of EMA) or,
(b)&nbsp;employ any individual who or entity that is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA), in each of clauses (a)&nbsp;and (b)&nbsp;in the conduct of its activities under this Agreement;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.4 Such Party shall perform its activities pursuant to this Agreement in compliance in all material respects with GLP,
GCP and cGMP (including those specified by the ICH), in each case as applicable; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.4.5 Neither Party shall, during the
Agreement Term grant any right or license to any Third Party relating to any of the intellectual property rights it owns or Controls which would conflict with any of the rights or licenses granted or to be granted to the other Party hereunder
pursuant to the provisions of ARTICLE 4. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12.5 <U>Disclaimer</U>. Except as otherwise expressly set forth in this Agreement, NEITHER
PARTY MAKES ANY REPRESENTATION OR EXTENDS ANY WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY THAT ANY PATENTS ARE VALID OR ENFORCEABLE, AND EXPRESSLY DISCLAIMS ALL IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT. Without limiting the generality of the foregoing except as otherwise expressly set forth in this Agreement, each Party disclaims any warranties with regards to: (a)&nbsp;the success of any study or test
commenced under this Agreement, (b)&nbsp;the safety or usefulness for any purpose of the technology or materials, including any compounds, it provides or discovers under this Agreement; or (c)&nbsp;the validity, enforceability, or non-infringement
of any intellectual property rights or technology it provides or licenses to the other Party under this Agreement. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE
13 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INDEMNIFICATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">13.1 <U>Indemnification by Servier</U>. Servier shall defend, indemnify and hold harmless the MacroGenics Indemnitees from and against any and all losses, damages, fees, expenses, settlement amounts or
costs (including reasonable attorneys&#146; fees and witness fees) (&#147;<U>Losses</U>&#148;) relating to or in connection with a Third Party claim in the Servier Territory arising out of (a)&nbsp;any actual death, personal bodily injury or damage
to real or tangible personal property proven to result, directly or indirectly, from the possession, use or consumption of, or treatment with, a Program Antibody or Licensed Product Researched, Developed, Manufactured or Commercialized in the
Servier Territory by or on behalf of Servier or its Affiliates or Sublicensees, including any product liability claims; (b)&nbsp;any breach by Servier of its representations, warranties or covenants made under this Agreement; or (c)&nbsp;any
negligent act or omission or willful misconduct of Servier or its Affiliates or Sublicensees or any of their employees, contractors or agents, in performing Servier&#146;s obligations or exercising Servier&#146;s rights under this Agreement;
<U>provided</U>, <U>however</U>, that the foregoing indemnity shall not apply to the extent that any such Losses (i)&nbsp;are attributable to the gross negligence or willful misconduct of the MacroGenics Indemnitees, or (ii)&nbsp;are otherwise
subject to an obligation by MacroGenics to indemnify the Servier Indemnitees under Section&nbsp;13.2. For purposes of clarity, notwithstanding anything to the contrary in this Agreement, Servier shall not be liable for any Losses resulting from any
claim in the MacroGenics Territory that results from any acts or omissions of MacroGenics, its Affiliates or Sublicensees, even if Servier had knowledge of, reviewed, commented on, or approved such acts or omissions of MacroGenics&#146; or its
Affiliates&#146; or Sublicensees&#146; plans with respect thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.2 <U>Indemnification by MacroGenics</U>. MacroGenics
shall defend, indemnify and hold harmless the Servier Indemnitees from and against any and all Losses relating to or in connection with a Third Party claim in the MacroGenics Territory arising out of (a)&nbsp;any actual death, personal bodily injury
or damage to real or tangible personal property proven to result, directly </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
or indirectly, from the possession, use or consumption of, or treatment with, a Program Antibody or Licensed Product Researched, Developed, Manufactured or Commercialized in the MacroGenics
Territory by or on behalf of MacroGenics or its Affiliates or Sublicensees, including any product liability claims; (b)&nbsp;any breach by MacroGenics of its representations, warranties or covenants made under this Agreement; or (c)&nbsp;any
negligent act or omission or willful misconduct of MacroGenics or its Affiliates or Sublicenses or any of their employees, contractors or agents, in performing MacroGenics&#146; obligations or exercising MacroGenics&#146; rights under this
Agreement; <U>provided</U>, <U>however</U>, that the foregoing indemnity shall not apply to the extent that any such Losses are attributable to (i)&nbsp;the gross negligence or willful misconduct of the Servier Indemnitees, or (ii)&nbsp;are
otherwise subject to an obligation by Servier to indemnify the MacroGenics Indemnitees under Section&nbsp;13.1. For purposes of clarity, notwithstanding anything to the contrary in this Agreement, MacroGenics shall not be liable for any Losses
resulting from any claim in the Servier Territory that results from any acts or omissions of Servier, its Affiliates or Sublicensees, even if MacroGenics had knowledge of, reviewed, commented on, or approved such acts or omissions of Servier&#146;s
or its Affiliates&#146; or Sublicensees&#146; plans with respect thereto. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.3 <U>Procedure</U>. In the event of a claim by a
Third Party against any Person entitled to indemnification under this Agreement, the Party claiming indemnification (in such capacity, the &#147;<U>Indemnified Party</U>&#148;) shall promptly notify the other Party (in such capacity, the
&#147;<U>Indemnifying Party</U>&#148;) in writing of the claim (it being understood that the failure by the Indemnified Party to give prompt notice of a Third Party claim as provided in this Section&nbsp;13.3 shall not relieve the Indemnifying Party
of its indemnification obligation under this Agreement except and only to the extent that such Indemnifying Party is actually prejudiced as a result of such failure to give prompt notice). Within <B>***</B> after delivery of such notification, the
Indemnifying Party may, upon written notice thereof to the Indemnified Party, undertake and solely manage and control, at its sole expense and with counsel reasonably satisfactory to the Indemnified Party, the defense of the claim. If the
Indemnifying Party does not undertake such defense, the Indemnified Party shall control such defense. The Party not controlling such defense shall cooperate with the other Party and may, at its option and expense, participate in such defense with
counsel of its choice; <U>provided</U>, that, if the Indemnifying Party assumes control of such defense and the Indemnified Party in good faith concludes, based on advice from counsel, that the Indemnifying Party and the Indemnified Party (or the
relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim, the Indemnified Party&#146;s counsels may fully participate in such defense and the
Indemnifying Party shall be responsible for the reasonable fees and expenses of one counsel to the indemnified Persons solely in connection therewith. The Party controlling such defense shall keep the other Party advised of the status of such
action, suit, proceeding or claim and the defense thereof and shall consider recommendations made by the other Party with respect thereto. Except if the Indemnifying Party did not undertake defense of the claim or if the Indemnifying Party and the
Indemnified Party (or the relevant MacroGenics Indemnitee or Servier Indemnitee seeking indemnification) have conflicting interests with respect to such action, suit, proceeding or claim and the Indemnified Party engages separate counsel, as
provided above, the Indemnifying Party shall not be liable for any litigation costs or expenses incurred by the Indemnified Party without the Indemnifying Party&#146;s written consent. The Indemnified Party shall not settle any such action, suit,
proceeding or claim without the prior written consent of the Indemnifying Party, which shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
not be unreasonably withheld, delayed or conditioned. The Indemnifying Party shall not settle, without the prior written consent of the Indemnified Party, any such action, suit, proceeding or
claim, or consent to any judgment in respect thereof, that does not include a complete and unconditional release of the Indemnified Party from all liability with respect thereto, that imposes any liability or obligation on the Indemnified Party or
that acknowledges fault by the Indemnified Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.4 <U>Allocation</U>. In the event a claim is based partially on an
indemnified claim and partially on a non-indemnified claim or based partially on a claim indemnified by one Party and partially on a claim indemnified by the other Party, any payments in connection with such claims are to be apportioned between the
Parties in accordance with the degree of cause attributable to each Party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13.5 <U>EXCLUSION OF CONSEQUENTIAL DAMAGES</U>.
EXCEPT WITH RESPECT TO A BREACH OF ARTICLE 11 OR THIRD PARTY CLAIMS THAT ARE SUBJECT TO INDEMNIFICATION UNDER THIS ARTICLE 13, NEITHER MACROGENICS NOR SERVIER, NOR ANY OF THEIR RESPECTIVE AFFILIATES, WILL BE LIABLE FOR ANY INDIRECT, INCIDENTAL,
CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES, WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY), INDEMNITY OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER SUCH PARTY OR ANY REPRESENTATIVE OF SUCH PARTY
HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 14
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TERM AND TERMINATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.1 <U>Agreement Term; Expiration</U>. This Agreement shall become effective as of the Effective Date, and, in the event Servier does not exercise the Option by the end of the Option Period, shall expire
at the end of the Option Period, unless earlier terminated in accordance with this ARTICLE 14. In the event Servier exercises the Option in accordance with Section&nbsp;3.3, this Agreement shall continue in full force until the last to expire
Royalty Term for a Licensed Product in the Servier Territory. After the last to expire Royalty Term for a Licensed Product in a country in the Servier Territory, Servier shall be granted a fully paid-up non-exclusive license to use MacroGenics
Know-How to Manufacture and Commercialize such Licensed Product in the Field in such country in the Servier Territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.2
<U>Termination for Cause</U>. Either Party (the &#147;<U>Non-Breaching Party</U>&#148;) may, without prejudice to any other remedies available to it under applicable Law or in equity, terminate this Agreement if the other Party (the
&#147;<U>Breaching Party</U>&#148;) shall have materially breached or defaulted in the performance of its obligations hereunder, and such default shall have continued for <B>***</B> after written notice thereof was provided to the Breaching Party by
the Non-Breaching Party, such notice describing the alleged breach. Any such termination of this Agreement under this Section&nbsp;14.2 shall become effective at the end of such <B>***</B> cure period, unless the Breaching Party has cured such
breach or default prior to the expiration of such cure period provided </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
however that if the Breaching Party notifies the Non-Breaching Party within such *** period that the Breaching Party disagrees in good faith with such asserted basis for termination, this
Agreement shall not terminate unless and until the matter has been finally resolved in accordance with section 16.2 &#147;Arbitration&#148; and the arbitration award rendered in accordance with section 16.2 specify that the Non-Breaching Party shall
have the right to terminate this Agreement based on such asserted Breach. The right of either Party to terminate this Agreement as provided in this Section&nbsp;14.2 shall not be affected in any way by such Party&#146;s waiver or failure to take
action with respect to any previous default. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.3 <U>Termination for Patent Challenge</U>. If either Party or any of its
Affiliates or Sublicensees: (a)&nbsp;commences or otherwise voluntarily determines to participate in any action or proceeding (including any patent opposition or re-examination proceeding), challenging or denying the validity of any of the other
Party&#146;s Patents or Joint Patents licensed hereunder or any claim thereof, or (b)&nbsp;actively assists any other Person in bringing or prosecuting any action or proceeding (including any patent opposition or re-examination proceeding)
challenging or denying the validity of any of such Patents or any claim thereof, the non-challenging Party shall have the right to terminate this Agreement upon <B>***</B> written notice to the other Party. Any such termination shall only become
effective if the challenging Party or its Affiliate or Sublicensee, as applicable, has not withdrawn such action before the end of the above notice period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.4 <U>Termination for Convenience</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.4.1 <U>During the Research Term</U>.
<B>***</B>, Servier shall have the right to terminate this Agreement in its entirety upon not less than <B>***</B> prior written notice thereof to MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.4.2 <U>During the License Term</U>. At any time during the License Term, Servier shall have the right to terminate this Agreement in its entirety or on a country-by-country basis upon not less than
<B>***</B> prior written notice thereof to MacroGenics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.5 <U>Termination for Insolvency Event</U>: Either Party may
terminate this Agreement upon written notice to the other Party if the other Party suffers an Insolvency Event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.6
<U>Termination by Servier for Safety or Public Health Reasons</U>. If Servier reasonably determines that a safety or public health issue has arisen which (a)&nbsp;is demonstrated by clinically relevant events which are documented and
(b)&nbsp;relates to a Program Antibody or a Licensed Product, such that the medical risk/benefit of such Program Antibody of Licensed Product is sufficiently unfavorable as to be incompatible with the welfare of patients to Develop or Commercialize
or to continue to Develop or Commercialize such Program Antibody or Licensed Product, Servier shall immediately notify MacroGenics, and Servier shall be permitted to terminate this Agreement in its entirety upon written notice to MacroGenics, but in
any event within *** of Servier&#146;s determination of such issue. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7 <U>Effect of Expiration or Termination</U>.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.7.1 Upon termination of this Agreement by MacroGenics in whole or with respect to one or more Terminated Territories
pursuant to Sections 14.2, 14.3, or 14.5 or by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Servier in whole or with respect to one or more Terminated Territories pursuant to Sections 14.4 or 14.6: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) all rights, licenses and options granted by MacroGenics to Servier with respect to each Terminated Territories hereunder shall terminate and Servier shall not have any rights to use or exercise any
rights under the MacroGenics IP with respect to any Terminated Territory; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) if such termination occurs during the Research
Term, (i)&nbsp;Servier shall Complete any ongoing Clinical Studies for Licensed Product in the Servier Territory where such completion is required by any applicable Law, requested by any Regulatory Authority or would be dictated by any applicable
Institutional Review Board with oversight of such Clinical Study in the Servier Territory; and (ii)&nbsp;Servier shall promptly transfer and assign to MacroGenics all Supplemental Data and ***; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) if such termination occurs during the License Term: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) Servier shall provide to MacroGenics a fair and accurate detailed written description of the status of the Development and Commercialization of the Program Antibodies and Licensed Products in each
Terminated Territory through the effective date of termination within *** of such termination; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) the licenses granted to
MacroGenics pursuant to Section&nbsp;4.2 shall remain in effect and shall become irrevocable; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) Servier hereby grants to
MacroGenics, effective upon the request of MacroGenics, ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) In the event that MacroGenics requests a license under
clause (iii)&nbsp;above and Servier has previously Completed a Phase 3 Clinical Trial for a Licensed Product in the Terminated Territory before the effective date of termination, MacroGenics shall ***; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) Servier shall promptly transfer and assign to MacroGenics all Regulatory Documentation and other technical and other information or
materials in Servier&#146;s or its Affiliates&#146; possession or control which are necessary or useful for the Research, Development or Commercialization of the Program Antibodies or Licensed Products in each Terminated Territory or, if no country
remains in the Servier Territory, anywhere in the world; <U>provided</U>, that Servier may retain a single copy of such items for its records; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(vi) Promptly upon request by MacroGenics, but in no event commencing later than *** after the effective date of termination or continuing for more than *** (except to the extent that requirements of a
Regulatory Authority necessitate a longer period), Servier shall provide such assistance to MacroGenics as may be reasonably necessary or useful for MacroGenics to commence or continue Developing, Manufacturing or Commercializing Licensed Products
in the Terminated Territory, to the extent Servier is then </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
performing or having performed such activities, including transferring or amending as appropriate, upon request of MacroGenics, any agreements or arrangements with Third Party vendors to Develop,
Manufacture or Commercialize Licensed Products in such Terminated Territory.&nbsp;To the extent that any such contract between Servier and a Third Party is not assignable to MacroGenics, Servier shall reasonably cooperate with MacroGenics to arrange
to continue to provide such services for a reasonable time after termination, not exceeding ***. Within *** after MacroGenics&#146; receipt of a proper invoice therefor, MacroGenics shall reimburse Servier for Servier&#146;s and its Affiliates&#146;
reasonable Out-of-Pocket Costs incurred in connection with any technology transfer conducted pursuant to this clause (vi); and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vii) in the event this Agreement is terminated pursuant to Section&nbsp;14.6, Servier shall reasonably cooperate with MacroGenics to
either (A)&nbsp;wind down any ongoing Global Clinical Trial conducted under a Global Development Plan previously approved by Servier or (B)&nbsp;which is conducted by Servier in the Servier Territory for the Licensed Product, and/or diligently
perform any follow-up of a clinical trial initiated in Servier Territory requested by any Regulatory Authority or dictated by any applicable Institutional Review Board. *** the activities mentioned in (A)&nbsp;above and *** shall entirely fund the
activities mentioned in (B)&nbsp;above. Servier and Servier&#146;s Affiliates shall provide MacroGenics written notice of the quantity of Licensed Product that Servier has in inventory for sale in each Terminated Territory and permit MacroGenics, at
MacroGenics&#146; option, to purchase all or any part of Servier&#146;s worldwide unsold inventory of such Licensed Product ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">14.7.2 Upon termination of this Agreement by Servier pursuant to sections 14.2 or 14.3: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) all rights, licenses and options granted to Servier, its Affiliates or Sublicensees pursuant to this Agreement shall remain in effect; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) all payment obligations under ARTICLE 8 shall remain in effect; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) all licenses granted by Servier, its Affiliates or Sublicensees pursuant to this Agreement, including pursuant to section 4.2, shall
terminate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8 <U>Accrued Rights; Surviving Provisions of the Agreement</U>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8.1 <U>Accrued Rights</U>. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that
shall have accrued to the benefit of any Party prior to such termination or expiration including the payment obligations under ARTICLE 9 hereof, and any and all damages or remedies arising from any breach hereunder. Such termination or expiration
shall not relieve any Party from obligations which are expressly indicated to survive termination of this Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.8.2
<U>Surviving Provisions of the Agreement</U>. The provisions of Sections 3.3.3(c), 6.1.2, 9.6-9.9 (with regard to accrued but unpaid amounts), 9.10, 10.3.3, 12.5, 14.7 and 14.8 and ARTICLE 13 and ARTICLE 16, and any applicable definitions in ARTICLE
1, shall </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
survive the termination of this Agreement in its entirety or expiration of this Agreement for any reason, in accordance with their respective terms and conditions, and for the duration stated,
and where no duration is stated, shall survive indefinitely. ARTICLE 11 shall survive for a period of *** after the effective date of termination or expiration of this Agreement. </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 15</B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>STANDSTILL </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ARTICLE 16 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MISCELLANEOUS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.1 <U>Disputes</U>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1.1 In the event any dispute arises out of or in
relation to or in connection with this Agreement, including failure to perform under or breach of, this Agreement or any issue relating to the interpretation or application of this Agreement, the Parties shall use good faith efforts to resolve such
dispute within *** after a Party notifies the other Party of such dispute, whether through the JEC, JSC, JRDC or any subcommittee, as applicable, if the dispute is within the responsibilities of such a committee, or otherwise. If the Parties are
unable to resolve such dispute, at the JSC, JRDC or subcommittee level or otherwise, within such *** period, either Party may, by written notice to the other Party refer such dispute to the JEC for resolution, and the JEC shall attempt in good faith
to resolve such dispute within *** after such notice. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.1.2 Any dispute with respect to which a Party has final
decision-making authority pursuant to Section&nbsp;2.9.3 or any dispute between the Parties concerning the validity, scope, enforceability, inventorship, or ownership of intellectual property rights (each, a &#147;<U>Non-Arbitrable
Dispute</U>&#148;), shall not be subject to resolution by binding arbitration under 16.2. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2 <U>Arbitration</U>. If the JEC
is unable to resolve a given dispute referred to it pursuant to Section&nbsp;2.9.3(b) or 16.1 within <B>***</B> following such referral of such dispute to the JEC, except for any Non-Arbitrable Disputes, either Party may have the given dispute
settled by binding arbitration in the manner described below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.1 <U>Arbitration Request</U>. If a Party intends to begin
an arbitration to resolve a dispute arising under this Agreement, such Party shall provide written notice (the &#147;<U>Arbitration Request</U>&#148;) to the other Party of such intention and the issues for resolution. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.2 <U>Additional Issues</U>. Within <B>***</B> after the receipt of the Arbitration Request, the other Party may, by written notice,
add additional issues for resolution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.3 <U>Arbitration Rules; Location</U>. Except as expressly provided herein, the
sole mechanism for resolution of any claim, dispute or controversy arising out of or in connection with or relating to this Agreement or the breach or alleged breach thereof shall be arbitration by the <B>***</B> then in effect except as provided
herein. Neither Party shall be required to give general discovery of documents, but may be required to produce documents or testimony </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which are considered relevant by the arbitrators to the dispute. The production of electronic documents shall be limited to those located in sources that are used in the ordinary course of
business. Neither Party shall be ordered to restore backup tapes; erased, damaged or fragmented data, or data normally deleted in the ordinary course of business. When the cost and burden of discovery are disproportionate to the likely importance of
the requested materials, the arbitrator may deny the requests or require that the requesting party advance the reasonable cost of production to the other Party. The Parties can further agree to limit the extent of discovery in any arbitration
undertaken pursuant to this Agreement. The arbitration shall take place in ***. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.4 <U>Privileges</U>. If a Party is
entitled to attorney-client or attorney work product privileges from disclosure established under public policy provisions, such privileges shall apply and may be invoked by the other Party. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.5 <U>English Language</U>. All proceedings shall be held in English and a transcribed record prepared in English. Documents
submitted in the arbitration (the originals of which are not in English) shall be submitted together with a reasonably complete and accurate English translation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2.6 <U>Selection of Arbitrators</U>. The Parties shall each choose one arbitrator within <B>***</B> after receipt of notice of the intent to arbitrate and the said two arbitrators shall select by
mutual agreement a third arbitrator within <B>***</B> after they have been selected as arbitrators. If no arbitrator is appointed within the times herein provided or any extension of time that is mutually agreed on, <B>***</B> shall make such
appointment (i.e. shall appoint three arbitrators) within <B>***</B> after such failure. Additionally, if the two arbitrators selected by the Parties fail to appoint a third arbitrator within the time provided, *** shall appoint the third
arbitrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.7 <U>Experience</U>. If the issues in dispute involve scientific or technical matters, any arbitrators
chosen hereunder shall have educational training or experience sufficient to demonstrate a reasonable level of knowledge in the pharmaceutical and biotechnology fields. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2.8 <U>Powers of Arbitrators</U>. The arbitrators shall be limited in the scope of their authority to resolving only the specific matter which the Parties have referred to arbitration for resolution
and shall not have authority to render any decision or award on any other issues. Without limiting the foregoing, the arbitrators: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) shall not have any power or authority to add to, alter, amend or modify the terms of this Agreement but shall specify rules sufficient to allow reasonable discovery by the Parties; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) shall establish and enforce appropriate rules to ensure that the proceedings, including the decision, be kept confidential and that
all Confidential Information of the Parties be kept confidential and be used for no purpose other than the arbitration; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) shall issue all preliminary awards and the final award in writing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.2.9 <U>Injunctive Relief</U>. Nothing in this Agreement shall be deemed as preventing
either Party from seeking injunctive relief (or any other provisional remedy such as temporary restraining order, preliminary injunction or other interim equitable relief) from the arbitrators or from any court having jurisdiction over the Parties
(and prior to or during any arbitration if necessary to protect the interests of such Party in avoiding irreparable harm or to preserve the status quo pending the arbitration proceeding) and the subject matter of the dispute as necessary to protect
either Party&#146;s name, proprietary information, Know-How or any other proprietary right or otherwise to avoid irreparable harm. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2.10 <U>Costs; Exclusion from Award</U>. The award rendered by the arbitrators <B>***</B>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.2.11 <U>Survivability</U>. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after termination of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.3 <U>Governing Law</U>. This Agreement and any dispute arising from the performance or breach hereof shall be governed by and
construed and enforced in accordance with the <B>***</B> without reference to conflicts of laws principles. <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.4
<U>Assignment</U>. Neither this Agreement nor any right or obligation hereunder may be assigned or otherwise transferred by any Party without the consent of the other Party; <U>provided</U>, <U>however</U>, that any Party may, without such consent,
assign this Agreement, in whole or in part: (a)&nbsp;to any of its respective Affiliates; <U>provided</U> that the assigning Party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned, or
(b)&nbsp;to any successor in interest by way of merger, acquisition or sale of all or substantially all of its assets to which this Agreement relates (an &#147;<U>M&amp;A Event</U>&#148;); <U>provided</U> that such successor agrees in writing to be
bound by the terms of this Agreement as if it were the assigning party. Any assignment not in accordance with this Section&nbsp;16.4 shall be void. Each Party agrees that, notwithstanding any provisions of this Agreement to the contrary, if this
Agreement is assigned by a Party in connection with an M&amp;A Event, such assignment shall not provide the non-assigning Party with rights or access to any intellectual property or technology of the acquirer of the assigning Party. ***. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.5 <U>Force Majeure</U>. No Party shall be held liable or responsible to the other Party nor be deemed to be in default under, or in
breach of any provision of, this Agreement for failure or delay in fulfilling or performing any obligation (other than a payment obligation) of this Agreement when such failure or delay is due to force majeure, and without the fault or negligence of
the Party so failing or delaying. For purposes of this Agreement, force majeure is defined as causes beyond the control of the Party, including acts of God; war; civil commotion; destruction of production facilities or materials by fire, flood,
earthquake, explosion or storm; external labor disturbances; epidemic; and failure of public utilities or common carriers. In such event MacroGenics or Servier, as the case may be, shall immediately notify the other Party of such inability and of
the period for which such inability is expected to continue. The Party giving such notice shall thereupon be excused from such of its obligations under this Agreement as it is thereby disabled from performing for so long as it is so disabled for up
to a maximum of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
***, after which time MacroGenics and Servier shall promptly meet to discuss in good faith how to best proceed in a manner that maintains and abides by this Agreement. To the extent possible,
each Party shall use reasonable efforts to minimize the duration of any force majeure. If a force majeure event prevents a Party from performing any of its Development obligations for a Global Clinical Trial or Manufacturing obligations hereunder
that would delay the Development or Manufacture of Licensed Product in the non-affected Party&#146;s Territory, then, if the Parties can not agree on how to best proceed following such discussions, then, notwithstanding the exclusive license grants
hereunder, the Party not affected by the force majeure event shall be permitted to either perform directly or engage a Third Party clinical research organization or contract manufacturing organization to perform such Development and/or Manufacturing
obligations for the duration of such force majeure event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.6 <U>Notices</U>. Any notice or request required or permitted to
be given under or in connection with this Agreement shall be deemed to have been sufficiently given if in writing and personally delivered or sent by certified mail (return receipt requested), facsimile transmission (receipt verified), or reputable
international business courier (signature required), prepaid, to the Party for which such notice is intended, at the address set forth for such Party below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If to MacroGenics, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">addressed to: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Prior to December 1, 2011:</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>After December 1, 2011:</U></FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc.</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">1500 East Gude Drive</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">9640 Medical Center Drive</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rockville, MD 20850</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Chief Executive Officer</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: Chief Executive Officer</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: ***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: ***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">with a copy to: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wilmer Cutler Pickering Hale and Dorr LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">399
Park Avenue </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, NY 10022 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>***</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>Facsimile:<B>
***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">If to Servier, </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">addressed
to: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Les Laboratoires Servier </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 rue
Carnot </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">92284 Suresnes Cedex </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">France </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>***</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B>Facsimile: <B>***</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">or to such other address for such Party as it shall
have specified by like notice to the other Parties, <U>provided</U> that notices of a change of address shall be effective only upon receipt thereof. The effective date of any notice shall be the actual date of receipt by the Party receiving the
same. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.7 <U>Export Clause</U>. Each Party agrees that, as of the Effective Date, it will not export or re-export restricted
commodities or the technical data of the other Party in any form without the appropriate United States and non-United States government licenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.8 <U>Waiver</U>. Neither Party may waive or release any of its rights or interests in this Agreement except in writing. The failure of either Party to assert a right hereunder or to insist upon
compliance with any term of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition. No waiver by either Party of any condition or term in any one or more instances
shall be construed as a continuing waiver of such condition or term or of another condition or term. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.9
<U>Severability</U>. If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original
intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible. Such
invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">16.10 <U>Entire Agreement</U>. This Agreement, together with the Schedules and Exhibits hereto, set forth all the covenants, promises, agreements, warranties, representations, conditions and
understandings between the Parties as to the subject matter of this Agreement and supersedes and terminates all prior agreements and understanding between the Parties with respect to the subject matter hereof. In particular, and without limitation,
this Agreement supersedes and replaces the Existing Confidentiality Agreement and any and all term sheets relating to the transactions contemplated by this Agreement and exchanged between the Parties prior to the Effective Date. There are no
covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties as to the subject matter of this Agreement other than as set forth herein and therein. No subsequent alteration,
amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.11 <U>Independent Contractors</U>. Nothing herein shall be construed to create any relationship of employer and employee, agent and
principal, partnership or joint venture between the Parties. Each Party is an independent contractor. Neither Party shall assume, either directly or indirectly, any liability of or for the other Party. Neither Party shall have the authority to bind
or obligate the other Party and neither Party shall represent that it has such authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.12 <U>Headings; Construction; Interpretation</U>. Headings used herein are for
convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement. The terms of this Agreement represent the results of negotiations between the Parties and their representatives, each
of which has been represented by counsel of its own choosing, and neither of which has acted under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed in accordance
with their usual and customary meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this Agreement of any rule of Law to the effect that ambiguous or conflicting terms or
provisions contained in this Agreement shall be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. Any reference in this Agreement to an Article, Section, subsection,
paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. Except where the context otherwise requires,
(a)&nbsp;any definition of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such
amendments, supplements or modifications set forth herein or therein), (b)&nbsp;any reference to any Law refers to such Law as from time to time enacted, repealed or amended, (c)&nbsp;the words &#147;herein,&#148; &#147;hereof&#148; and
&#147;hereunder,&#148; and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof,&nbsp;(d) the words &#147;include,&#148; &#147;includes,&#148; &#147;including,&#148; &#147;exclude,&#148;
&#147;excludes,&#148; and &#147;excluding,&#148; shall be deemed to be followed by the phrase &#147;but not limited to,&#148; &#147;without limitation&#148; or words of similar import. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.13 <U>Further Actions</U>. Each Party shall execute, acknowledge and deliver such further instruments, and do all such other acts, as
may be necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.14 <U>Parties in Interest</U>. All of the terms and provisions of this Agreement shall be binding upon, and shall inure to the benefit
of and be enforceable by the Parties hereto and their respective successors, heirs, administrators and permitted assigns. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.15 <U>Performance by Affiliates</U>. To the extent that this Agreement imposes obligations on Affiliates of a Party, such Party agrees
to cause its Affiliates to perform such obligations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.16 <U>Counterparts</U>. This Agreement may be signed in counterparts,
each and every one of which shall be deemed an original, notwithstanding variations in format or file designation which may result from the electronic transmission, storage and printing of copies from separate computers or printers. Facsimile
signatures and signatures transmitted via portable document format (PDF) shall be treated as original signatures. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>[</I></B><I>Signature page to follow</I><B><I>]</I></B><I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, and intending to be legally bound hereby, the Parties have caused this
Agreement to be executed by their duly authorized representatives as of the Effective Date. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="13%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LES LABORATOIRES SERVIER</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INSTITUT&nbsp;DE&nbsp;RECHERCHES&nbsp;SERVIER</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></P></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A-1 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Back-Up Program Antibodies </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit A-2 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MGA271 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit B </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Patents </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:28pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Country</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Appl Serial No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Publication No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Patent No.</B></FONT></P></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="27%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="7"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit C </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Third Party Agreements </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit D </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Press Release </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics and Servier Enter Development and
Commercialization </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Agreement for Novel Anti-Cancer Drug </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 is a therapeutic monoclonal antibody that recognizes B7-H3, a member of the B7 family of immune regulators, that is over-expressed on a wide
variety of solid tumors </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics retains full program rights in North America, Japan, Korea and India </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier has an option to obtain an exclusive license to develop and commercialize MGA271 in the rest of the world. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">ROCKVILLE, Maryland and SURESNES , France &#150; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;, 2011
&#150; MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France&#146;s largest privately-held pharmaceutical company, announced today that they have entered into an option and
license agreement for the development and commercialization of MGA271, MacroGenics&#146; proprietary product candidate. MGA271 is a first-in-class, Fc-optimized monoclonal antibody that targets B7-H3 and is currently being studied in a Phase 1
clinical trial for the treatment of solid tumors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 is a next generation monoclonal antibody which incorporates multiple complementary
mechanisms of action including enhanced immuno-stimulatory properties and targeting of tumor vasculature. B7-H3 target is overexpressed in several malignancies requiring innovative therapeutic approaches. Following very promising pre-clinical
results, we will work together to define the clinical indications and the best drug combinations and to identify early biomarkers predictive of response&#148;, said Dr.&nbsp;St&eacute;phane Depil, MD, PhD, in charge of Oncology Research&nbsp;&amp;
Development at Servier. &#147;Today&#146;s announcement underscores Servier&#146;s commitment to develop novel targeted therapies that address significant unmet medical needs for cancer patients,&#148; added Dr.&nbsp;Emmanuel Canet, MD, PhD,
President Research&nbsp;&amp; development at Servier. &#147;MGA271 is a novel immunotherapeutic with a compelling product profile and the potential to treat a broad spectrum of solid tumors. We have been deeply impressed by both the excellence of
science being conducted by MacroGenics and their world class antibody development capabilities. We are looking forward to building a long-term strategic collaboration with MacroGenics.&#148; Under the terms of the agreement, MacroGenics retains full
development and commercialization rights to MGA271 in the U.S., Canada, Mexico, Japan, Korea and India, while Servier has an option to obtain an exclusive license covering the rest of the world. Prior to the exercise of Servier&#146;s option, both
parties will fund and conduct specified research and development activities. MacroGenics will receive a $20 million upfront payment. If Servier exercises its option upon completion of the Phase 1 study and its expansion cohorts, MacroGenics will
receive an option exercise fee which, combined with the up-front and early development milestone payments, will total $60 million. In addition, MacroGenics could receive up to an additional $390 million in clinical, regulatory and commercialization
milestone payments. Finally, MacroGenics may receive tiered, double-digit royalties on future net sales. Both parties will share the clinical development costs following the option exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are delighted to enter into this collaboration with Servier. It will significantly broaden and accelerate our clinical plans for MGA271, enabling us to further investigate the multiple solid
tumor types for which MGA271 may have activity,&#148; said Dr.&nbsp;Scott Koenig, President and CEO of MacroGenics. &#147;This important collaboration highlights the rapidly growing excitement surrounding the B7 family of immune regulators in
oncology immunotherapy as well as our Fc engineering platform.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Servier is a world-class pharmaceutical company with a long history of successful innovation and a
dedication to research for the benefit of patients,&#148; Dr.&nbsp;Koenig continued. &#147;They have an expansive global footprint and are an ideal partner to maximize the potential of MGA271.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 is currently being tested in an open-label, multi-dose, single-arm, dose-escalation Phase 1 study in patients with refractory B7-H3-expressing
neoplasms. The trial employs a companion diagnostic for B7-H3 which will enable prospective screening of patients for expression of the target antigen. Enrollment of the first dosing cohort has been completed. Clinical investigators include
Dr.&nbsp;Howard Burris at Sarah Cannon Research Institute, Dr.&nbsp;Roger Cohen at Hospital of the University of Pennsylvania/Abramson Cancer Center and Dr.&nbsp;Keith Flaherty at Massachusetts General Hospital. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About MGA271 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MGA271 is a humanized
IgG1/kappa monoclonal antibody that recognizes human B7-H3, a novel member of the B7 family of immune regulators. B7-H3 is an attractive target for immunotherapy, as it is over-expressed in a variety of solid tumors, including prostate, pancreatic,
melanoma, renal cell, ovarian, colorectal, gastric, bladder, and non-small cell lung cancers. MGA271 has been Fc-optimized using MacroGenics&#146; proprietary Fc-engineering platform to further augment its tumor killing activity. The product&#146;s
Fc region imparts increased affinity for the human activating Fc-gamma receptor IIIA (Fc-gamma RIIIA, CD16A) and decreased affinity for the inhibitory Fc-gamma RIIB (CD32B). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About MacroGenics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics is a private, venture-backed biotechnology company that
focuses on the discovery, development and delivery to patients of novel biologics for cancer, autoimmune disorders and infectious diseases. The company has built a fully-integrated set of capabilities in antibody-based product development which
supports its innovative pipeline of clinical stage product candidates. MacroGenics&#146; proprietary research is based on three core technology platforms, which include: (1)&nbsp;a leading research capability for screening and targeting cancer
stem-like cells; (2)&nbsp;Dual-Affinity Re-Targeting (or DART) technology, which allows the incorporation of multiple specificities within a single recombinant molecule; and (3)&nbsp;Fc optimization, which enhances antibody-dependent effector
functions. The company has global product development collaborations with Boehringer Ingelheim and Pfizer Inc. which employ its DART technology. For more information about MacroGenics, please visit www.macrogenics.com. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Servier </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Servier is the leading
independent French pharmaceutical company with a 2011 turnover of &#128;3.9 billion. The Servier Group is established in 140 countries with its main therapeutic products used to treat diabetes, cardiovascular disease, CNS disorders, oncology and
rheumatology. More than 25% of Servier&#146;s revenue is invested in Research&nbsp;&amp; Development. Servier has 20,000 employees worldwide, including nearly 3,000 in R&amp;D. For further information, please visit www.servier.com. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Statements made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Words such as &#147;expects,&#148; &#147;believes,&#148; &#147;intends,&#148; and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in
any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company&#146;s ability to raise additional capital, and risks related to
the Company&#146;s ability to initiate, and enroll patients in, planned clinical trials. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of
new information, future events or developments, except as required by law. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contacts: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig, M.D., Ph.D., President and CEO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">or
Jim Karrels, Vice President, CFO </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">both of MacroGenics, Inc., +1-301-251-5172, info@macrogenics.com </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential treatment. An unredacted </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>22
<FILENAME>filename22.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.22</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.22 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Execution Version </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed
separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P>
<P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:120px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESEARCH COLLABORATION AND LICENSE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>BY AND BETWEEN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PFIZER INC. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AND </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MACROGENICS, INC. </B></FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>OCTOBER [</B><FONT STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT><B></B><B>], 2010 </B></FONT></P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:120px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">DEFINITIONS.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">RESEARCH PROGRAM.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Selection of Research Project Targets.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scope and Conduct of the Research Program.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Plans.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">17</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Program Antibodies and Passed MacroGenics Antibodies.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Governance of the Research Program.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alliance Managers.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conformance with Law.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Personnel Matters.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Debarment Certification.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subcontractors.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inspections.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Records.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">22</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Transfer and Use of Pfizer Proprietary Materials.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">General.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Diligence.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Regulatory Approvals.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Control of Commercialization Activities.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Manufacturing.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Progress Reporting.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">LICENSES AND RELATED GRANTS OF RIGHTS.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grants to Pfizer.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grants to MacroGenics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Retained Rights to Antibodies.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exclusivity.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">30</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section 365(n) of Bankruptcy Code.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Implied Rights.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PAYMENTS TO MACROGENICS.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upfront License Payment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Support Funding.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Milestones.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Royalties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reports and Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Maintenance of Records; Audits.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Late Payments.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">INTELLECTUAL PROPERTY.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Inventions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Rights.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">39</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recording.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">46</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Trademarks.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">CONFIDENTIALITY</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Confidentiality.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Authorized Disclosure.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public Announcements; Publications.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Obligations in Connection with Change of Control.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">REPRESENTATIONS AND WARRANTIES.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mutual Representations and Warranties.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representations and Warranties of MacroGenics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representations and Warranties of Pfizer.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">53</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Covenants.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Representation by Legal Counsel.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">54</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disclaimer.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">GOVERNMENT APPROVALS; TERM AND TERMINATION.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Government Approvals.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Term.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination by Either Party for Cause.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Termination by Pfizer without Cause.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effects of Termination.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Disposition of Inventories of Products.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Survival of Certain Obligations.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Right to Termination of Research Project(s) or Research Program by Pfizer upon Change of Control of MacroGenics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Consequential Damages.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnification by Pfizer.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indemnification by MacroGenics.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Procedure.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">61</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Insurance.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">MISCELLANEOUS.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Assignment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Further Actions.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Force Majeure.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notices.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amendment.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Waiver.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Severability.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.8.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Descriptive Headings.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.9.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dispute Resolution.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.10.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Governing Law.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.11.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consent to Jurisdiction.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.12.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Entire Agreement.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.13.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Independent Contractors.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.14.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Counterparts.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.15.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">No Third Party Rights or Obligations.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBITS </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit&nbsp;2.3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Form of Research Plans</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibit 7.3.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">i </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SCHEDULES </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule 1.19</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;1.34</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;1.80</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;1.125</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;2.10</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics Subcontractors and Services</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;8.2.3</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Patent Rights of MacroGenics</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;8.2.8</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Funding Agreements</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Schedule&nbsp;8.2.13</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Litigation</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">ii </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESEARCH COLLABORATION AND LICENSE AGREEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Research Collaboration and License Agreement (the &#147;<B>Agreement</B>&#148;) is entered into as of October [<FONT
STYLE="FONT-FAMILY:WINGDINGS 2">&#151;</FONT>], 2010 (the &#147;<B>Effective Date</B>&#148;), by and among Pfizer, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 500 Arcola Road,
Collegeville, Pennsylvania 19426, United States (&#147;<B>Pfizer</B>&#148;) and MacroGenics, Inc., a corporation organized and existing under the laws of the State of Delaware and having a place of business at 1500 East Gude Drive, Rockville, MD
20850 (&#147;<B>MacroGenics</B>&#148;). Pfizer and MacroGenics may each be referred to herein individually as a &#147;<B>Party</B>&#148; and collectively as the &#147;<B>Parties</B>.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Pfizer is engaged in the research, development and commercialization of pharmaceutical and health care products; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, MacroGenics has developed a T-DART platform, which is&nbsp;focused on dual specificity &#147;antibody-like&#148; therapeutic
proteins capable of targeting both immune effector cells and other cells with a single recombinant molecule, and certain intellectual property useful in connection with the application of such T-DART platform; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, Pfizer and MacroGenics desire to collaborate to discover and research T-DARTs active against certain designated targets and to
provide for Pfizer to further research, develop, manufacture and commercialize such T-DARTs and products containing such T-DARTs, as provided for herein. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties
hereby agree as follows: </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DEFINITIONS. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">When used
in this Agreement, the following capitalized terms shall have the meanings set forth in this Section 1. Any terms defined elsewhere in this Agreement shall be given equal weight and importance as though set forth in Section 1. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B>Additional Third Party Licenses</B>&#148; is defined in Section 5.4.3(b). </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.2. &#147;<B>Affiliate</B>&#148; means, with respect to any Person, any other Person that controls, is controlled by or is under common
control with such Person. A Person shall be regarded as in control of another entity if it owns or controls at least fifty percent (50%)&nbsp;of the equity securities of the subject entity entitled to vote in the election of directors (or, in the
case of an entity that is not a corporation, for the election of the corresponding managing authority), provided, however, that the term &#147;Affiliate&#148; shall not include subsidiaries or other entities in which a Party or its Affiliates owns a
majority of the ordinary voting power necessary to elect a majority of the board of directors or other managing authority, but is restricted from electing such majority by contract or otherwise, until such time as such restrictions are no longer in
effect. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.3. &#147;<B>Agreement</B>&#148; is defined in the introduction to this Agreement.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.4. &#147;<B>Agreement Product</B>&#148; means any product containing an Agreement T-DART. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.5. &#147;<B>Agreement T-DART</B>&#148; means any T-DART that is identified during the course of the Research Program as binding to a
Research Project Target, including any portion, fragment or subunit thereof, and any modified or derivative form of any of the foregoing, and the nucleic acid sequence encoding for any of the foregoing. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.6. &#147;<B>Agreement T-DART IP</B>&#148; means any invention that constitutes or comprises the composition or formulation of, or any
method of manufacture or use of, any Agreement T-DART or Agreement Product and that is invented by MacroGenics or any of its Affiliates, or any Subcontractor of MacroGenics or any of its Affiliates, solely or jointly with Pfizer or any of its
Affiliates, or any Subcontractor of Pfizer or any of its Affiliates, in the conduct of the Research Program during the Research Term, and excluding any invention included in the Pfizer Material Improvements. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.7. &#147;<B>Agreement T-DART Patent Right</B>&#148; means any Pfizer Patent Right filed after the Effective Date covering or claiming
any invention assigned to Pfizer as Agreement T-DART IP pursuant to Section 4.1.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.8. &#147;<B>Alliance Manager</B>&#148; is
defined in Section 2.6. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.9. &#147;<B>Annual Net Sales</B>&#148; means, with respect to any Agreement Product, the aggregate
Net Sales by Pfizer, its Affiliates and its Sublicensees from the sale of such Agreement Product in the Territory during each Pfizer Year of the applicable Royalty Term for such Agreement Product. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.10. &#147;<B>Antibody</B>&#148; means a molecule which comprises or contains: (a)&nbsp;one or more immunoglobulin variable domains;
(b)&nbsp;fragments, variants, modifications or derivatives of such immunoglobulin variable domains irrespective of origin or source; or (c)&nbsp;the nucleic acid consisting of a sequence of nucleotides encoding (or complementary to a nucleic acid
encoding) the foregoing molecules in (a)&nbsp;or (b). The term &#147;Antibody&#148; shall include any monospecific antibodies and less than full-length antibody forms such as Fv, Fab, and F(ab&#146;). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.11. &#147;<B>Applicable Law</B>&#148; means the laws, statutes, rules, regulations, guidelines, or other requirements (including Good
Manufacturing Practices (&#147;<B>GMP</B>&#148;), Good Laboratory Practices and Good Clinical Practices), that may be in effect from time to time and apply to a Party&#146;s activities to be performed under this Agreement, including any such laws,
statutes, rules, regulations, guidelines, or other requirements of the FDA or the EMEA. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.12. &#147;<B>Bankruptcy
Code</B>&#148; is defined in Section 4.6. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.13. &#147;<B>Binding Obligation</B>&#148; means, with respect to a Party
(a)&nbsp;any oral or written agreement or arrangement that binds or affects such Party&#146;s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
agreement; (b)&nbsp;the provisions of such Party&#146;s charter, bylaws or other organizational documents or (c)&nbsp;any order, writ, injunction, decree or judgment of any court or Governmental
Authority entered against such Party or by which any of such Party&#146;s operations or property are bound. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.14.
&#147;<B>Biosimilar Biologic Product</B>&#148; is defined in Section 5.4.3(b). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.15. &#147;<B>Business Day</B>&#148; means a
day other than a Saturday, a Sunday or a day that is a national holiday in the United States. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.16. &#147;<B>Calendar
Quarter</B>&#148; means the respective periods of three (3)&nbsp;consecutive calendar months ending on March&nbsp;31,&nbsp;June&nbsp;30,&nbsp;September&nbsp;30 or December&nbsp;31, for so long as this Agreement is in effect. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.17. &#147;<B>Calendar Year</B>&#148; means each successive period of twelve (12)&nbsp;calendar months commencing on January&nbsp;1 and
ending on December&nbsp;31. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.18. &#147;<B>CD3</B>&#148; means the complex comprising the epsilon, delta and gamma subunits of
the CD3 receptor complex (including any subtypes, alleles, and splice variants). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.19.<B> ***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.20. &#147;<B>CPI</B>&#148; is defined in Section 1.43. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.21. &#147;<B>Change of Control</B>&#148; means, with respect to a Party, (a)&nbsp;a merger, reorganization or consolidation of such Party with a Third Party which results in the voting securities of
such Party outstanding immediately prior thereto ceasing to represent at least fifty percent (50%)&nbsp;of the combined voting power of the surviving or resulting entity immediately after such merger, reorganization or consolidation, (b)&nbsp;a
Third Party becoming the beneficial owner of fifty percent (50%)&nbsp;or more of the combined voting power of the outstanding securities of such Party, or (c)&nbsp;the sale or other transfer to a Third Party of all or substantially all of such
Party&#146;s business or assets to which this Agreement relates; provided that, for purposes of subsections (a), (b)&nbsp;and (c), such Third Party or an Affiliate of such Third Party is engaged immediately prior to the Change of Control in the
pharmaceutical or biotechnology business and is not a venture capital or other institutional investor. Change of Control shall not include any public offering of the shares of MacroGenics. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.22. &#147;<B>Combination Product</B>&#148; means an Agreement Product containing an Agreement T-DART and one or more other
therapeutically active ingredients. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.23. &#147;<B>Commercialization</B>&#148; or &#147;<B>Commercialize</B>&#148; means
activities directed to marketing, promoting, distributing, importing, exporting, using for commercial purposes or selling or having sold an Agreement Product. Commercialization shall not include any activities related to Manufacturing or
Development. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.24. &#147;<B>Commercially Reasonable Efforts</B>&#148; means, with respect to the efforts
to be expended by a Party with respect to any objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. With respect to any efforts
relating to the Development, Regulatory Approval or Commercialization of an Agreement T-DART or Agreement Product by a Party, generally or with respect to any particular country in the Territory, a Party will be deemed to have exercised Commercially
Reasonable Efforts if such Party has exercised those efforts normally used by such Party, in the relevant country, with respect to a compound, product or product candidate, as applicable of similar modality owned or Controlled by such Party, or to
which such Party has similar rights, which compound, product or product candidate is of similar market potential in such country, and is at a similar stage in its development or product life cycle as the Agreement T-DART or Agreement Product, taking
into account all Relevant Factors in effect at the time such efforts are to be expended. To the extent that the performance of a Party&#146;s obligations hereunder is adversely affected by the other Party&#146;s failure to perform its obligations
hereunder, the impact of such performance failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.25. &#147;<B>Confidential Information</B>&#148; of a Party means all Know-How or other information, including proprietary information
and materials (whether or not patentable) regarding such Party&#146;s technology, products, business or objectives, that is communicated in any way or form by the Disclosing Party to the Receiving Party, either prior to or after the Effective Date
of this Agreement (including any information disclosed pursuant to the Confidentiality Agreements), and whether or not such Know-How or other information is identified as confidential at the time of disclosure. The terms and conditions of this
Agreement shall be considered the Confidential Information of each Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.26. &#147;<B>Confidentiality Agreements</B>&#148;
means the Confidentiality Agreements between the Parties dated <B>***</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.27. &#147;<B>Control</B>&#148; or
&#147;<B>Controlled</B>&#148; means, with respect to any (a)&nbsp;item of information, including Know-How, or (b)&nbsp;any other intellectual property right, the possession (whether by ownership interest or license, other than pursuant to this
Agreement) by a Party of the ability to grant to the other Party access to or a license under such item or right, as provided herein, without violating the terms of any agreement or other arrangements with any Third Party; provided that any item of
information or other intellectual property right that is licensed or acquired by a Party after the Effective Date and that would otherwise be considered to be under the Control of a Party shall not be deemed to be under the Control of such Party if
the application of such definition in the context of any licenses or sublicenses granted to the other Party under this Agreement would require the granting Party to make any additional payments or royalties to a Third Party in connection with such
license or sublicense grants, unless the other Party agrees to pay all such additional payments or royalties due to such Third Party. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.28. &#147;<B>Develop</B>&#148; or &#147;<B>Development</B>&#148; means to discover,
research or otherwise develop a product, including conducting any pre-clinical, non-clinical or clinical research and any drug development activity, including discovery, research, toxicology, pharmacology and other similar efforts, test method
development and stability testing, manufacturing process development, formulation development, delivery system development, quality assurance and quality control development, statistical analysis, clinical studies (including pre- and post-approval
studies), diagnostic assays in connection with clinical studies, and all activities directed to obtaining any Regulatory Approval, including any marketing, pricing or reimbursement approval. Development shall not include any activities related to
Manufacturing or Commercialization. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.29. &#147;<B>Development Milestone</B>&#148; is defined in Section 5.3.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.30. &#147;<B>Development Milestone Payment</B>&#148; is defined in Section 5.3.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.31. &#147;<B>Diligence Issue</B>&#148; is defined in Section 3.2.4. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.32. &#147;<B>Disclosing Party</B>&#148; is defined in Section 7.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.33. &#147;<B>Effective Date</B>&#148; is defined in the introduction to this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.34.<B> ***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.35. &#147;<B>EMEA</B>&#148; means the European Medicines Agency, or any successor agency thereto. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.36. &#147;<B>FD&amp;C Act</B>&#148; means the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301 et seq.), as
amended, and the rules and regulations promulgated thereunder. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.37. &#147;<B>FDA</B>&#148; means the United States Food and
Drug Administration or any successor agency thereto. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.38. &#147;<B>Field</B>&#148; means all human and veterinary
therapeutic, diagnostic, prophylactic and prognostic purposes, provided, however, that for so long as MacroGenics has obligations under, and solely to the extent required in order for MacroGenics not to be in violation of its obligations under,
<B>***</B>, the &#147;Field&#148; shall not include the Development or Commercialization of any Agreement T-DART or Agreement Product that binds to CD3 and is intended to be Developed or Commercialized <B>*** *** </B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.39. &#147;<B>First Commercial Sale</B>&#148; means, with respect to any Agreement Product and any country of the world, the first sale
of such Agreement Product under this Agreement by Pfizer, its Affiliates or its Sublicensees to a Third Party in such country, after such Agreement Product has been granted Regulatory Marketing Approval by the competent Regulatory Authorities in
such country. When used without reference to a specified Indication, First Commercial Sale means the First Commercial Sale for any Indication. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.40. &#147;<B>First Research Project Target</B>&#148; is defined in Section 2.1.1. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.41. &#147;<B>Foregone Agreement T-DART Patent Right</B>&#148; is defined 6.2.1(b).
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.42. &#147;<B>FTE</B>&#148; means a full time equivalent scientific person <B>*** ***</B> year, consisting of a minimum of a
total of <B>***</B> of scientific work directly related to and in support of the Research Program by an employee or full-time contractor or consultant of MacroGenics or any of its Affiliates. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.43. &#147;<B>FTE Rate</B>&#148; means <B>***</B>, increased or decreased annually by the percentage increase or decrease in the Consumer
Price Index&#150;Urban Wage Earners and Clerical Workers, United States City Average, All Items, 1982-84 = 100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index) in the United States
(&#147;<B>CPI</B>&#148;) as of December&nbsp;31 of the then most recently ended Calendar Year over the level of the CPI on December&nbsp;31, 2010 (<I>i.e.</I>, the first such increase or decrease would occur on January&nbsp;1, 2012). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.44. &#147;<B>GAAP</B>&#148; means generally accepted accounting principles, consistently applied. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.45. &#147;<B>GMP</B>&#148; is defined in Section 1.11. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.46. &#147;<B>Generic Competition</B>&#148; is defined in Section 5.4.3(a). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.47. &#147;<B>Governmental Authority</B>&#148; means any court, agency, department, authority or other instrumentality of any national,
state, county, city or other political subdivision. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.48. &#147;<B>IND</B>&#148; means an Investigational New Drug
Application, as defined in the FD&amp;C Act, that is required to be filed with the FDA before beginning clinical testing of an Agreement Product in human subjects, or an equivalent foreign filing. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.49. &#147;<B>Indemnified Party</B>&#148; is defined in Section 10.4.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.50. &#147;<B>Indemnifying Party</B>&#148; is defined in Section 10.4.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.51. &#147;<B>Indication</B>&#148; means a disease, disease stage, discrete form of a disease or any precursor condition thereof or a
line of treatment thereof <B>***</B>, for which a separate Regulatory Approval Application has been obtained or is being sought. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.52. &#147;<B>Initial Research Project Targets</B>&#148; is defined in Section 2.1.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.53. &#147;<B>Initial Reserved Targets</B>&#148; is defined in Section 2.1.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.54. &#147;<B>Joint Invention</B>&#148; is defined in Section 6.1.1(b). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.55. &#147;<B>Joint Know-How</B>&#148; is defined in Section 6.1.1(b). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.56. &#147;<B>Joint Patent Right</B>&#148; means any Patent Right claiming any Joint Invention. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.57. &#147;<B>Joint Steering Committee</B>&#148; or &#147;<B>JSC</B>&#148; is defined in Section 2.5.1. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.58. &#147;<B>Joint Technology</B>&#148; means, collectively, the Joint Patent Rights, the
Joint Inventions and the Joint Know-How. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.59. &#147;<B>Know-How</B>&#148; means any proprietary invention, discovery, data,
information, process, method, technique, material, technology, result or other know-how, whether or not patentable. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.60.
&#147;<B>Liability</B>&#148; is defined in Section 10.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.61.<B> ***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.62.<B> ***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.63. <B>&#147;Litigation Conditions</B>&#148;<B> is defined in Section </B>10.4.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.64. &#147;<B>MacroGenics</B>&#148; is defined in the introduction to this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.65. <B>&#147;MacroGenics Derived Terminated Agreement T-DART&#148;</B> is defined in Section 9.5.2(e)(i). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.66. <B>&#147;MacroGenics Excluded Target Schedule&#148;</B> is defined in Section 2.1.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.67. <B>&#147;MacroGenics Indemnified Party&#148;</B> is defined in Section 10.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.68.<B> &#147;MacroGenics Know-How</B>&#148;<B></B> means any Know-How comprised in the MacroGenics Technology, excluding any Joint
Know-How. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.69. &#147;<B>MacroGenics Patent Right</B>&#148; means any Patent Right comprised in the MacroGenics Technology,
excluding any Joint Patent Rights. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.70. &#147;<B>MacroGenics Technology</B>&#148; means any Patent Right or Know-How that
(a)&nbsp;is Controlled by MacroGenics or any Affiliate of MacroGenics as of the Effective Date or that comes into the Control of MacroGenics or any of its Affiliates at any time during the Term and (b)&nbsp;is necessary or useful to Develop,
Manufacture or Commercialize Agreement T-DARTs and/or Agreement Products. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.71. &#147;<B>MacroGenics Third Party
Agreement</B>&#148; means any agreement between MacroGenics and any Third Party under which MacroGenics obtains rights in or to any MacroGenics Technology. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.72. <B>&#147;MacroGenics-Derived Terminated Agreement T-DART&#148;</B> is defined in Section 9.5.2(e) </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.73. <B>&#147;Major EU Market Country</B>&#148;<B></B> means any of *** </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.74.
&#147;<B>Major Market Country</B>&#148; means any <B>***</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.75. &#147;<B>Manufacturing</B>&#148; or &#147;<B>Manufacture</B>&#148; means activities
directed to making, producing, manufacturing, processing, filling, finishing, packaging, labeling, quality assurance testing and release, shipping or storage of a product. Manufacturing shall not include any activities related to Development or
Commercialization. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.76. <B>&#147;Marginal Royalty Rates</B>&#148; is defined in Section 5.4 </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.77. &#147;<B>Milestone Payment</B>&#148; means the Technical Milestones, Development Milestones, and Sales Milestones. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78. <B>&#147;Net Sales</B>&#148;<B></B> means: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.78.1. with respect to an Agreement Product that is not a Combination Product, gross receipts from sales by Pfizer and its Affiliates and Sublicensees (each, a <B>&#147;Selling Person</B>&#148;<B></B>)
of such Agreement Product to Third Parties in the Territory, less in each case, to the extent reasonably allocable to Agreement Products in accordance with GAAP, sales returns and allowances actually paid, granted or accrued, including trade,
quantity and cash discounts and any other adjustments, including those granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargeback rebates, reimbursements or similar
payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers, chain pharmacies, mass merchandisers, staff model HMO&#146;s, pharmacy benefit managers or other institutions, adjustments arising from
consumer discount programs or other similar programs, customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes) or duties relating to sales, any payment in respect of sales to the United States
government, any state government or any foreign government, or to any other Governmental Authority, or with respect to any government-subsidized program or managed care organization, and freight and insurance (to the extent that Pfizer bears the
cost of freight and insurance for the Agreement Product) (the deductions described above are referred to collectively herein as <B>&#147;Permitted Deductions</B>&#148;<B></B>); and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.78.2. in the event an Agreement T-DART is sold as a Combination Product in any country, the Net Sales of the Combination Product, for
the purposes of determining royalty payments, shall be determined by multiplying the Net Sales (as defined above in this Section) of the Combination Product by the fraction, A/(A+B) where A is the weighted (by sales volume) average sale price in
such country of the Agreement T-DART when sold separately in finished form, and B is the aggregate weighted average sale price in such country of the other therapeutically active ingredients included in such Combination Product when sold separately
in finished form. In the event that such average sale price cannot be determined for both the Agreement T-DART and the other product(s) included in the Combination Product, Net Sales for purposes of determining royalty payments shall be agreed by
the Parties based on the relative value contributed by each component, such agreement not to be unreasonably withheld or delayed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sales between Pfizer and its Affiliates or Sublicensees shall be excluded from the
computation of Net Sales and no payments will be payable on such sales except where such Affiliates or Sublicensees are end users, but Net Sales shall include the subsequent final sales to Third Parties by such Affiliates or Sublicensees. Net Sales
shall be determined from books and records maintained in accordance with GAAP, as consistently applied by Pfizer with respect to sales of the Agreement Product. For clarity, in calculating Net Sales, except pursuant to Section 5.4.3, neither Party
shall be entitled to deduct any payments to Third Parties by way of royalties or similar payments. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Parties acknowledge
that Pfizer does not currently intend to Commercialize any Agreement Product solely for diagnostic purposes and that the Parties anticipate that any sales of any Agreement Product for diagnostic purposes will occur only in connection with or in
support of sales of an Agreement Product for therapeutic purposes. Notwithstanding the foregoing, in the event Pfizer, its Affiliates or Sublicensees Commercialize any Agreement Product for diagnostic purposes, sales of such Agreement Product for
diagnostic purposes shall be included in the calculation of Net Sales provided that Pfizer and MacroGenics will negotiate in good faith a reasonable royalty applicable to Net Sales of any such Agreement Product for diagnostic purposes during the
applicable Royalty Term, which royalty shall be no greater than the Marginal Royalty Rates otherwise set forth for Agreement Products under this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.79. <B>&#147;Non-Disclosing Party&#148;</B> is defined in Section 7.3.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.80.<B> ***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.81. <B>&#147;Notice of Dispute&#148;</B> is defined in Section 11.9.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.82. &#147;<B>Party</B>&#148; and &#147;<B>Parties</B>&#148; is defined in the introduction to this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.83. &#147;<B>Passed MacroGenics Antibody</B>&#148; means any proprietary (to MacroGenics) Research Program Antibody contributed to the
Research Program by MacroGenics which the JSC has determined is no longer under Development or consideration for Development under the Research Program. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.84. &#147;<B>Patent Rights</B>&#148; means any and all (a)&nbsp;patents, (b)&nbsp;pending patent applications, including all provisional applications, substitutions, continuations,
continuations-in-part, divisions and renewals, and all patents granted thereon, (c)&nbsp;all patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent
term extensions, supplementary protection certificates or the equivalent thereof, (d)&nbsp;inventor&#146;s certificates, (e)&nbsp;any other form of government-issued right substantially similar to any of the foregoing and (f)&nbsp;all United States
and foreign counterparts of any of the foregoing. The Patent Rights owned by either Party include any Patent Right assigned to such party pursuant to the provisions of this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.85. <B>&#147;Permitted Deduction&#148;</B> is defined in Section 1.78.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.86. &#147;<B>Person</B>&#148; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership,
corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision or department or agency of a government.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.87. &#147;<B>Pfizer</B>&#148; is defined in the introduction to this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.88. &#147;<B>Pfizer Collaboration Patent Right</B>&#148; is defined in Section 9.5.2(e)(i). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.89. &#147;<B>Pfizer Diligence Obligations</B>&#148; means Pfizer&#146;s diligence obligations under Sections 3.2.1 and 3.2.2,
collectively. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.90. <B>&#147;Pfizer Indemnified Party&#148;</B> is defined in Section 10.3. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.91. &#147;<B>Pfizer Know-How</B>&#148; means any Know-How comprised in the Pfizer Technology, excluding any Joint Know-How. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.92. &#147;<B>Pfizer Patent Right</B>&#148; means any Patent Right comprised in the Pfizer Technology, excluding any Joint Patent Rights.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.93. &#147;<B>Pfizer Proprietary Material Improvement</B>&#148; means all intellectual property rights constituting,
comprising or covering any improvement or enhancement to, or any derivative or modification of, or any invention directly related to, any Pfizer Proprietary Material, which improvement, enhancement, derivative, modification or invention is
conceived, discovered, invented, developed, created, made or reduced to practice or tangible medium by MacroGenics or any of its Affiliates, solely or jointly with Pfizer or any of its Affiliates, in the course of performing activities under this
Agreement. For the avoidance of doubt, Pfizer Proprietary Material Improvement shall not include any Patent Right or Know-How that is directed to T-DARTs and any such Know-How or Patent Right that would otherwise of have been included as a Pfizer
Proprietary Material Improvement shall instead be included in Agreement T-DART IP or the Agreement T-DART Patent Rights. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.94.
&#147;<B>Pfizer Proprietary Materials</B>&#148; means any and all biological and other materials Controlled by Pfizer and supplied by Pfizer to MacroGenics under this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.95. &#147;<B>Pfizer Quarter</B>&#148; means each of the four thirteen week periods (a)&nbsp;with respect to the United States,
commencing on January&nbsp;1 of any Pfizer Year and (b)&nbsp;with respect to any country in the Territory other than the United States, commencing on December&nbsp;1 of any Pfizer Year. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.96. &#147;<B>Pfizer Technology</B>&#148; means any Patent Right or Know-How that is (a)&nbsp;Controlled by Pfizer or any Affiliate of
Pfizer as of the Effective Date or that comes into the Control of Pfizer or any of its Affiliates at any time during the Term and (b)&nbsp;is necessary or useful to Develop, Manufacture or Commercialize Agreement T-DARTs and/or Agreement Products.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.97. &#147;<B>Pfizer Year</B>&#148; means the twelve (12)&nbsp;month fiscal periods
observed by Pfizer (a)&nbsp;commencing on January&nbsp;1 with respect to the United States and (b)&nbsp;commencing on December&nbsp;1 with respect to any country in the Territory other than the United States. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.98. &#147;<B>Phase I Clinical Study</B>&#148; means a study of an Agreement Product in human subjects or patients with the endpoint of
determining initial tolerance, safety, metabolism or pharmacokinetic information and clinical pharmacology of such product as and to the extent defined for the United States in 21 C.F.R. &#167; 312.21(a), or its successor regulation, or the
equivalent regulation in any other country. A so-called Phase I/II Clinical Study shall be deemed to be a Phase I Clinical Study unless such study, when completed, allows Pfizer to proceed directly to a Pivotal Study. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.99. &#147;<B>Phase II Clinical Study</B>&#148; means a study of an Agreement Product in human patients to determine the safe and
effective dose range in a proposed therapeutic Indication as and to the extent defined for the United Sates in 21 C.F.R. &#167; 312.21(b), or its successor regulation, or the equivalent regulation in any other country. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.100. &#147;<B>Phase III Clinical Study</B>&#148; means a study of an Agreement Product in human patients with a defined dose or a set of
defined doses of an Agreement Product designed to (a)&nbsp;ascertain efficacy and safety of such Agreement Product for its intended use; (b)&nbsp;define warnings, precautions and adverse reactions that are associated with the Agreement Product in
the dosage range to be prescribed; and (c)&nbsp;support preparing and submitting applications for Regulatory Marketing Approval to the competent Regulatory Authorities in a country of the world, as and to the extent defined for the United States in
21 C.F.R.&#167; 312.21(c), or its successor regulation, or the equivalent regulation in any other country. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.101.
&#147;<B>Pivotal Study</B>&#148; means (a)&nbsp;a Phase III Clinical Study, or (b)&nbsp;a Phase II Clinical Study, or a combination Phase II Clinical Study and Phase III Clinical Study, if Pfizer has determined at the time of first dosing that the
data generated in such trial, if successful, will be sufficient, without data from further studies, to support the filing of a Regulatory Marketing Approval Application for an Agreement Product. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.102. <B>&#147;Receiving Party</B>&#148;<B></B> is defined in Section 7.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.103. &#147;<B>Regulatory Approval</B>&#148; means any technical, medical, scientific or other license, registration, authorization or
approval of any Regulatory Authority (including any approval of a New Drug Applications or Biologic License Applications) necessary for the Development, Manufacture or Commercialization of a pharmaceutical product in any regulatory jurisdiction.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.104. &#147;<B>Regulatory Approval Application</B>&#148; means any application submitted to an appropriate Regulatory
Authority seeking any Regulatory Approval. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.105. &#147;<B>Regulatory Authority</B>&#148; means, with respect to any national,
supra-national, regional, state or local regulatory jurisdiction, any agency, department, bureau, commission, council or other governmental entity involved in the granting of a Regulatory Approval for such jurisdiction. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.106. &#147;<B>Regulatory Exclusivity</B>&#148; means the ability to exclude Third Parties from Commercializing an Agreement Product or a
Biosimilar Biologic Product with respect to any Agreement Product in a country, either through data exclusivity rights, orphan drug designation, or such other rights conferred by a Regulatory Authority in such country, other than through Patent
Rights. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.107. &#147;<B>Regulatory Marketing Approval</B>&#148; means, with respect to any pharmaceutical product and any
Indication, Regulatory Approval (including any supplement thereto) to sell such pharmaceutical product for such Indication, including, in any jurisdiction other than the United States, to the extent required for any sale in such country, all pricing
and reimbursement approvals to be obtained from the Regulatory Authority granting such Regulatory Approval or any affiliated Regulatory Authority. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.108. &#147;<B>Regulatory Marketing Approval Application</B>&#148; means any Regulatory Approval Application submitted to an appropriate Regulatory Authority seeking any Regulatory Marketing Approval.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.109. &#147;<B>Relevant Factors</B>&#148; means all relevant factors that may affect the Development, Regulatory Approval,
Manufacture, or Commercialization of an Agreement Product, including (as applicable): actual and potential issues of safety, efficacy and/or stability; product profile (including product modality, category and mechanism of action); stage of
development or life cycle status; actual and projected Development, Regulatory Approval, Manufacturing, and Commercialization costs, timelines and budgets; any issues regarding the ability to Manufacture or have Manufactured the Agreement Product;
the likelihood of obtaining Regulatory Approvals (including satisfactory reimbursement or pricing approvals); the timing of such approvals; labeling or anticipated labeling; the then-current competitive environment and the likely competitive
environment at the time of projected entry into the market; past performance of the product or similar products; present and future market potential; existing or projected pricing, sales, reimbursement and profitability; proprietary position,
strength and duration of patent protection and anticipated exclusivity; other relevant scientific, technical, operational and commercial factors. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.110. &#147;<B>Representatives</B>&#148; is defined in Section 7.2.1. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.111.
&#147;<B>Research Plan</B>&#148; is defined in Section 2.3.1. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.112. &#147;<B>Research Plan Services</B>&#148; is defined in
Section 2.3.3. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.113. &#147;<B>Research Program</B>&#148; is defined in Section 2.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.114. &#147;<B>Research Program Antibody</B>&#148; is defined in Section 2.4.1. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.115. &#147;<B>Research Project</B>&#148; is defined in Section 2.3.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.116. &#147;<B>Research Project Target</B>&#148; means a cancer cell Target that has been selected for a Research Project, including the
Initial Research Project Targets and any Reserved Target substituted for an existing Research Project Target in accordance with Section 2.1.4. <B></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.117. &#147;<B>Research Term</B>&#148; means the period commencing on the Effective Date and continuing until three (3)&nbsp;years after the Effective Date, or until such later date as may be mutually
agreed to by the Parties. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.118. &#147;<B>Reserved Target</B>&#148; means any Target designated as a Reserved Target pursuant
to Section 2.1.2 or 2.1.3 of this Agreement, including the Initial Reserved Targets. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.119. &#147;<B>Review Period</B>&#148;
is defined in Section 7.3.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.120. &#147;<B>Royalty Term</B>&#148; is defined in Section 5.4.2. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.121. <B>&#147;Sales Milestone&#148;</B> is defined in Section 5.3.3. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.122. <B>&#147;Sales Milestone Payment&#148;</B> is defined in Section 5.3.3. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.123. <B>&#147;Sales Threshold&#148;</B> is defined in Section 5.3.3. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.124. <B>&#147;SEC&#148;</B> means the United States Securities and Exchange Commission. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.125.<B> ***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.126. &#147;<B>Second Research Project Target</B>&#148; is defined in Section 2.1.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.127. <B>&#147;Selling Person&#148;</B> is defined in Section 1.78.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.128. <B>&#147;Senior Executives&#148;</B> is defined in Section 2.5.5(b). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.129. <B>&#147;Sole Invention&#148;</B> is defined in Section 6.1.1(a). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.130. <B>&#147;Sole Know-How&#148;</B> is defined in Section 6.1.1(a). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.131. <B>&#147;Subcontractors&#148;</B> is defined in Section 2.10.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.132. <B>&#147;Subcontractor Information&#148;</B> is defined in Section 2.11. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.133. &#147;<B>Sublicensee</B>&#148; means any Third Party to whom Pfizer grants or has granted, directly or indirectly, a sublicense of
rights licensed by MacroGenics to Pfizer under this Agreement, in accordance with the provisions of this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.134.
<B>&#147;Subject Patent Right</B>&#148;<B></B> is defined in Section 6.2.1(d). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.135. &#147;<B>T-DART</B>&#148; means a dual affinity re-targeting molecule that binds with
one arm to a Target expressed on an immune effector cell <B>*** ***</B> and with the second arm to a different Target expressed on another non-immune effector cell. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.136. &#147;<B>Target</B>&#148; means (a)&nbsp;a specific biological molecule that is identified by a GenBank accession number or other public database accession identifier or by its amino acid or
nucleic acid sequence; (b)&nbsp;all amino acid and nucleic acid variant forms of any biological molecule disclosed in clause (a), including naturally occurring variants, mutants, transcriptional and post-transcriptional isoforms (e.g., alternative
splice variants), and post-translational modification variants (e.g., protein processing, maturation and glycosylation variants); and (c)&nbsp;truncated forms (including fragments thereof) which have a biological function substantially similar to
that of any biological molecules disclosed in clause (a)&nbsp;or clause (b). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.137. &#147;<B>Target Designation Date</B>&#148;
means, with respect to any Research Project Target or Reserved Target, the date on which a Target becomes a Research Project Target or Reserved Target, as provided in Section 2.1. With respect to the Initial Research Project Targets and the Initial
Reserved Targets, the Target Designation Date shall be deemed to be the Effective Date. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.138. &#147;<B>Targeting</B>&#148;
means, when used to describe the relationship between a molecule and a Target, that the molecule (a)&nbsp;binds to the Target (or a portion thereof) and (b)&nbsp;is designed or being developed to exert its biological effect in whole or in part
through binding to such Target (or such portion thereof). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.139.<B> &#147;Technical Milestone&#148;</B> is defined in Section
5.3.1. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.140. <B>&#147;Technical Milestone Payment&#148;</B> is defined in Section 5.3.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.141. &#147;<B>Term</B>&#148; is defined in Section 9.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.142. <B>&#147;Terminated Agreement Product&#148;</B> is defined in Section 9.5.1(b). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1.143. &#147;<B>Terminated T-DART</B>&#148; is defined in Section 9.5.1. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.144.
&#147;<B>Territory</B>&#148; means the entire world. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.145. &#147;<B>Third Party</B>&#148; means any Person other than Pfizer,
MacroGenics or their respective Affiliates. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.146. <B>&#147;Third Party Claim&#148;</B> is defined in Section 10.4.1.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.147. &#147;<B>Trademark</B>&#148; means any trademark, trade dress, design, logo, slogan, house mark or name Controlled by
Pfizer or its Affiliates or Sublicensees and used in connection with the Commercialization of any Agreement Product by Pfizer or its Affiliates or Sublicensees hereunder, including any registration or application for registration of any of the
foregoing. For purposes of clarity, &#147;Trademark&#148; shall not include any trademark, trade dress, design, logo, slogan, house mark or name of MacroGenics, including &#147;MacroGenics&#148; or &#147;DART&#148;. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.148. &#147;<B>Up-Front Payment</B>&#148; is defined in Section 5.1. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.149. &#147;<B>Valid Claim</B>&#148; means (a)&nbsp;a claim of any unexpired United States or foreign issued patent that shall not have
been dedicated to the public, disclaimed nor held invalid or unenforceable by a court or government agency of competent jurisdiction in an unappealed or unappealable decision or (b) <B>***</B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.150. <B>Construction</B>. Except where the context expressly requires otherwise, (a)&nbsp;the use of any gender herein shall be deemed
to encompass references to either or both genders, and the use of the singular shall be deemed to include the plural (and vice versa), (b)&nbsp;the words &#147;include&#148;, &#147;includes&#148; and &#147;including&#148; shall be deemed to be
followed by the phrase &#147;without limitation,&#148; (c)&nbsp;the word &#147;will&#148; shall be construed to have the same meaning and effect as the word &#147;shall,&#148; (d)&nbsp;any definition of or reference to any agreement, instrument or
other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set
forth herein), (e)&nbsp;any reference herein to any Person shall be construed to include the Person&#146;s successors and assigns, (f)&nbsp;the words &#147;herein&#148;, &#147;hereof&#148; and &#147;hereunder&#148;, and words of similar import,
shall be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g)&nbsp;all references herein to sections or exhibits shall be construed to refer to sections or exhibits of this Agreement, and references to
this Agreement include all exhibits hereto, (h)&nbsp;the word &#147;notice&#148; means notice in writing (whether or not specifically stated) and shall include notices, consents, approvals and other written communications contemplated under this
Agreement, (i)&nbsp;provisions that require that a Party, the Parties or any committee hereunder &#147;agree,&#148; &#147;consent&#148; or &#147;approve&#148; or the like shall require that such agreement, consent or approval be specific and in
writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), (j)&nbsp;references to any specific law, rule or regulation, or article, section or other division thereof, shall be deemed to
include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof, (k)&nbsp;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such
agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), and (l)&nbsp;the term &#147;or&#148; shall be
interpreted in the inclusive sense commonly associated with the term &#147;and/or.&#148; </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RESEARCH PROGRAM. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.
Selection of Research Project Targets. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.1. <B>Selection of Initial Research Project Target.</B> Pfizer hereby designates
*** as the Research Project Target for the first Research Project (the <B>&#147;First</B> </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<B>Research Project Target&#148;</B>) and *** as the Research Project Target for the second Research Project (the <B>&#147;Second Research Project Target</B> and together with the First Research
Project Target, the &#147;<B>Initial Research Project Targets</B>&#148;).<B> </B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.2. <B>Selection of Initial Reserved
Targets</B>. Pfizer hereby designates *** and *** as the initial reserved targets (<B>&#147;Initial Reserved Targets&#148;</B>). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.3. <B>Substitution of Targets.</B> Pfizer may request that additional Targets be substituted on a one-for-one basis for the Second
Research Project Target or any Reserved Target in accordance with this Section 2.1.3. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) At any time within *** following
the Effective Date, Pfizer may substitute, without limitation on the number of substitutions and on a one-for-one basis, for the Second Research Project Target and the Reserved Targets. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) At any time beginning *** after the Effective Date and continuing until the earlier of (i)&nbsp;***, and (ii)&nbsp;the allowance by
MacroGenics of the second new Target to be substituted for a Reserved Target under this Section 2.1.3(b), Pfizer may request that additional Targets be substituted on a one-for-one basis for any existing Reserved Targets. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics will allow such substitutions set forth in (a)&nbsp;and (b), except that it may decline a proposed Target substitution
based on (i)&nbsp;*** </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.4. <B>Elevation of Reserved Targets</B>. At any time in the <B>***</B> following the Effective Date,
Pfizer may submit a written notice to MacroGenics that up to two Reserved Targets will be substituted for any then-designated Research Project Target on a one-for-one basis. Any such Reserved Target substituted for an existing Research Project
Target will then be deemed to be included within the definition of Research Project Target. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.5. <B>Former Reserved
Targets</B>. Any Reserved Targets shall cease to be a Reserved Target for all purposes under this Agreement (including under Section 4.5) upon the earlier of (a)&nbsp;replacement of such Reserved Target with a new Target in accordance with Section
2.1.3, or <B>*** </B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.1.6. <B>Former Research Project Targets</B>. Any Research Project Target, to the extent that it has
been substituted by a Reserve Target, shall cease to be a Research Project Target for all purposes of this Agreement (including under Section 4.5). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.2. <B>Scope and Conduct of the Research Program</B>. Under the terms and conditions set forth herein, MacroGenics and Pfizer shall collaborate during the Research Term to conduct discovery and
pre-clinical Development activities to screen and identify Antibodies to the two (2)&nbsp;Research Project Targets (or the Reserved Targets that become Research Project Targets pursuant to Section 2.1.4) for construction of T-DARTs (the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
&#147;<B>Research Program</B>&#148;). The Research Program shall be conducted in accordance with the Research Plan for each Research Project (as more fully provided in Section 2.3 below), and
each Party shall use its Commercially Reasonable Efforts to perform all activities assigned to it and fulfill all of its obligations under each Research Plan. In addition, each Party shall conduct its activities under the Research Plan(s) in
accordance with Applicable Law. MacroGenics will not, without first providing prior written notice to Pfizer, take any action with respect to conducting the Research Program that would require MacroGenics to make any payments to a Third Party such
that any item of information or other intellectual property would be excluded from the definition of &#147;Control&#148; under this Agreement. For avoidance of doubt, upon expiration or termination of the Research Term, the Research Program and all
Research Projects shall automatically terminate. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3. <B>Research Plans</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.1. <B>Adoption of Research Plans</B>. The Parties shall adopt a research plan (each a &#147;<B>Research Plan</B>&#148;) for all
activities conducted under the Research Program during the Research Term, including a Research Plan that covers each Research Project Target; a &#147;<B>Research Project</B>&#148; shall mean the work to be performed pursuant to such a Research Plan.
The form for each Research Plan for each Research Project Target is attached as <U>Exhibit 23.1 </U><B></B>The Research Plan for each Research Project Target shall be prepared by the JSC and adopted within <B>***</B> after the Target Designation
Date for such Research Project Target by the JSC. Each Research Plan shall reference this Agreement and shall be subject to all of the provisions of this Agreement, in addition to the specific details set forth in such Research Plan. To the extent
any provisions of a Research Plan conflict or are inconsistent with the provisions of this Agreement, the provisions of this Agreement shall control. Unless otherwise expressly stated in a Research Plan, the provisions of each Research Plan shall be
independent of and shall not affect the provisions of any other Research Plan. If the Parties are unable to agree on a Research Plan within the specified time period, the JSC may specify the Research Plan, and all disputes regarding the preparation
or modification of any Research Plan (including the approval of any amendments thereto) shall be resolved by the JSC. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.2.
<B>Researchers</B>. During the <B>***</B> of the Research Term the Parties will dedicate <B>***</B> to the Research Program and this number cannot be changed without agreement of the Parties. The Parties currently expect to dedicate an average of
<B>***</B> to the Research Program for the remainder of the Research Term. The number of FTEs will be reviewed by the JSC on a semi-annual basis and may be updated as necessary by the JSC. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.3.3. <B>Responsibilities</B>. Each Research Plan shall set forth the services and the
obligations and responsibilities assigned to each Party (collectively the &#147;<B>Research Plan Services</B>&#148;), and shall include the following minimum terms: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) For each Research Project, one or both of the Parties shall generate or provide Antibodies that bind to the Research Project Target for such Research Project. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) In accordance with Section 2.4, Pfizer shall be entitled to select up to <B>***</B> Antibodies to be investigated by MacroGenics for
possible construction of a T-DART to the extent Antibodies are generated under a Research Plan. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics will
investigate each Antibody selected by Pfizer in accordance with the applicable Research Plan. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) MacroGenics will support
the <B>***</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) Pfizer will support additional in vivo modeling, completion of IND-enabling studies, clinical Development,
GMP-Manufacturing, and Commercialization. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(f) The Parties may jointly decide to expand MacroGenics&#146;s research and
Development responsibilities to include additional <B>***</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(g) In no event shall MacroGenics be required to commit more
than <B>***</B> to support the Research Program during any Calendar Year during the Research Term. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4. <B>Research Program
Antibodies and Passed MacroGenics Antibodies</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.1. For each Research Project Target and prior to initiation of in vivo
modeling (as defined in the related Technical Milestone under Section 5.3.1) for such Research Project Target, Pfizer may identify in writing to MacroGenics up to <B>***</B> Antibodies which Pfizer intends to evaluate for the relevant Research
Project (each a &#147;<B>Research Program Antibody</B>&#148;). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.2. Upon MacroGenics&#146;s request, the JSC will promptly
determine whether any proprietary (to MacroGenics) Research Program Antibody contributed to the Research Program by MacroGenics is no longer under Development or consideration for Development under the Research Program and has become a Passed
MacroGenics Antibody. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.4.3. Other than as set forth in the Research Plan for the Initial Research Project Target that is
attached as <U>Exhibit 2.3.1</U> <B></B>or as subsequently agreed by the Parties and set forth in a Research Plan, MacroGenics shall have no obligation to provide Pfizer with any Antibodies developed or acquired by MacroGenics outside of this
Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5. <B>Governance of the Research Program</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.1. <B>Formation of the Joint Steering Committee</B>. MacroGenics and Pfizer shall establish a &#147;<B>Joint Steering
Committee</B>&#148; (or &#147;<B>JSC</B>&#148;) to oversee and coordinate the activities of the Parties under this Agreement in regard to the Research Program. The Joint Steering Committee shall also serve as a forum to facilitate communications
between the Parties regarding the Research Program. The Joint Steering Committee shall be comprised of three (3)&nbsp;representatives from each Party as appointed by such Party. The Joint Steering Committee may change its size from time to time by
mutual consent of its members. A Party may replace one or more of its representatives from time to time upon written notice to the other Party. Each Party, respectively, shall designate its initial members of the Joint Steering Committee within
thirty (30)&nbsp;days after the Effective Date. The Joint Steering Committee shall exist until expiration of the Research Term, unless the Parties otherwise agree in writing. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.5.2. <B>Co-Chairpersons and Secretary of the Joint Steering Committee</B>. Each Party shall designate a co-chairperson of the Joint Steering Committee and a secretary of the Joint Steering Committee
shall be designated in accordance with Section 2.6 <B></B>below. A Party may change the designation of its co-chairperson from time to time upon written notice to the other Party. The co-chairpersons shall be responsible for scheduling meetings of
the Joint Steering Committee, preparing agendas for meetings and sending to all Joint Steering Committee members notices of all regular meetings and agendas for such meetings at least five (5)&nbsp;Business Days before such meetings. The
co-chairpersons shall solicit input from both Parties regarding matters to be included on the agenda, and any matter either Party desires to have included on the agenda shall be included for discussion. Nothing herein shall be construed to prohibit
the Joint Steering Committee from discussing or acting on matters not included on the applicable agenda. The secretary shall record the minutes of the meeting, circulate copies of meeting minutes to the Parties and each Joint Steering Committee
member promptly following the meeting for review, comment and approval by the Joint Steering Committee members and finalize approved meeting minutes. The co-chairpersons shall be members of the Joint Steering Committee but the secretary need not be
a member of the Joint Steering Committee. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.3. <B>Meetings</B>. The Joint Steering Committee shall meet at least once each
Calendar Quarter until it has been terminated in accordance with Section 2.5.1 at dates and times mutually agreed by the Joint Steering Committee, unless otherwise mutually agreed by the Parties. The initial meeting of the Joint Steering Committee
shall be held within ninety (90)&nbsp;days after the Effective Date. Either Party may call a special meeting of the Joint Steering Committee on fifteen (15)&nbsp;days prior written notice to the other Party&#146;s members of the Joint Steering
Committee (or upon such shorter notice as exigent circumstances may require). Such written notice shall include an agenda for the special meeting. In-person meetings, including special meetings, of the Joint Steering Committee shall alternate
between the offices of the Parties, unless otherwise agreed upon by the members of the Joint Steering Committee. Meetings of the Joint Steering </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Committee may be held telephonically or by video conference; provided, however, that at least two (2)&nbsp;meetings per year shall be held in-person. Meetings of the Joint Steering Committee
shall be effective only if at least one representative of each Party is in attendance or participating in the meeting. Members of the Joint Steering Committee shall have the right to participate in and vote at meetings held by telephone or video
conference. In addition, the Joint Steering Committee may act on any matter or issue without a meeting if it is documented in a written consent signed by each member of the Joint Steering Committee. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.4. <B>Responsibilities of the Joint Steering Committee</B>. The JSC shall be responsible for (a)&nbsp;planning and supervising
research and development under this Agreement, including establishing, reviewing and recommending modifications and updates to the Research Plans; (b)&nbsp;receiving and reviewing all data and other information obtained by either Party in connection
with the Research Program and monitoring and reporting to the Parties on activities conducted pursuant to the Research Plans; (c)&nbsp;documenting and approving initiation and completion of each Research Project and the achievement of any Technical
Milestones, Development Milestones and Sales Milestones; (d)&nbsp;evaluating FTE requirements for the performance of the Research Plans; and (e)&nbsp;such other functions as expressly specified hereunder or as agreed by the Parties. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.5.5. <B>Decisions by Consensus</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) All decisions of the Joint Steering Committee shall be made by unanimous agreement of both Parties&#146; representatives, with each Party having a single vote, irrespective of the number of JSC
representatives in attendance at a meeting. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If, in accordance with Section 2.5.5(a), the JSC does not resolve any matter
within its purview by it within <B>***</B> after the matter is first considered by it, the matter may be referred by either Party to MacroGenics&#146;s <B>***</B> to be resolved by negotiation in good faith as soon as practicable but in no event
later than <B>***</B> after referral. Such resolution, if any, of a referred issue by the <B>***</B> shall be final and binding on the Parties. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) If a dispute referred to the <B>***</B> has not been resolved in accordance with Section<B> </B>2.5.5(b), then, subject to Section 2.5.5(d), <B>***</B>. Any decisions made by Pfizer under this Section
2.5.5(c) shall be deemed a decision of the JSC for purposes of this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Notwithstanding Section 2.5.5(c),
<B>***</B> shall not have the right to exercise such decision-making authority (i)&nbsp;in a manner that excuses <B>***</B> from any of its obligations specifically enumerated under this Agreement; (ii)&nbsp;in a manner that negates any consent
rights or other rights specifically allocated to MacroGenics under this Agreement; (iii)&nbsp;to resolve any </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
dispute regarding whether a Technical Milestone, Development Milestone or Sales Milestone has been achieved; (iv)&nbsp;in a manner that would require <B>***</B> (A)&nbsp;<B>***</B> will not
reimburse <B>***</B> costs (except as expressly set forth in this Agreement ); (B)&nbsp;which would require <B>***</B> to perform a category of services not previously contemplated as being performed by <B>***</B> under the Research Program and
which <B>***</B> does not have the existing capability to perform; or (C)&nbsp;which require <B>***</B> to acquire from any Third Party any Know-How, Patent Right or other technology not contemplated in a Research Plan and that is not readily
available from such Third Party or readily capable of being developed internally by <B>***</B>; or (vi)&nbsp;in a manner that would require <B>***</B> to perform any act that it reasonably believes to be inconsistent with any Applicable Law or any
approval, order, policy, guidelines of a Regulatory Authority or ethical requirements or ethical guidelines. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.6. <B>Alliance
Managers</B>. In addition to the foregoing governance provisions, each of the Parties shall appoint a single individual to serve as that Party&#146;s alliance manager (&#147;<B>Alliance Manager</B>&#148;). The role of each Alliance Manager shall be
to facilitate the relationship between the Parties as established by this Agreement. The Alliance Managers shall attend meetings of the Joint Steering Committee and support the respective co-chairpersons of such committee in the discharge of their
responsibilities. Unless otherwise determined by the Joint Steering Committee, Pfizer&#146;s Alliance Manager shall serve as secretary at each meeting of the Joint Steering Committee. Alliance Managers shall be non-voting participants in such
committee meetings. A Party may replace its Alliance Manager from time to time upon written notice to the other Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.7.
<B>Conformance with Law</B>. Each Party shall perform and discharge its obligations under this Agreement and the Research Program in conformance with (a)&nbsp;professional standards and practices, (b)&nbsp;this Agreement and the Research Plan(s) and
(c)&nbsp;all Applicable Laws. Without limiting the generality of the foregoing, each Party shall retain all records relating to its performance of this Agreement and the Research Plan(s) for the time periods required by Applicable Laws. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.8. <B>MacroGenics Personnel Matters</B>. MacroGenics acknowledges and agrees that it is solely responsible for the compensation of the
personnel assigned to the Research Plan Services, and as employer shall be responsible for withholding all national, state, local or other applicable taxes and similar items. MacroGenics also shall be responsible for all other employer related
obligations, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each employee. MacroGenics personnel assigned to the Research Plan Services are not
nor shall they be deemed to be employees of Pfizer. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.9. <B>Debarment Certification</B>. Neither Party nor any Person employed
or retained to perform services by either Party has been debarred under Section&nbsp;306(a) or (b)&nbsp;of the FD&amp;C Act or any comparable provision of foreign law and no debarred Person shall in the future be employed or retained to perform
services by either Party in connection with </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
any work to be performed for or on behalf of the other Party. If, at any time after execution of this Agreement, either Party becomes aware that such Party or any Person employed or retained to
perform services by such Party in connection with any work performed for or on behalf of such Party is, or is in the process of being, debarred, such Party shall so notify the other Party immediately. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.10. <B>Subcontractors</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.10.1. MacroGenics may not engage any contractor, subcontractor or other vendor (a &#147;Subcontractor&#148;) to perform any Research Plan Services or Research Program activities not specifically
contemplated or set forth in the applicable Research Plan without Pfizer&#146;s prior written consent; provided, however, that Pfizer hereby provides its prior written consent to MacroGenics&#146;s engagement of the Subcontractors set forth on
<U>Schedule 2.10</U> attached hereto for performance of the Research Plan Services set forth on such <U>Schedule 2.10</U>. MacroGenics shall be responsible for the management of all permitted Subcontractors. The engagement by MacroGenics of any
Subcontractor in compliance with this Section 2.10 shall not relieve MacroGenics of its obligations under this Agreement or any applicable Research Plan. Any agreement between MacroGenics and a permitted Subcontractor pertaining to the Research Plan
Services shall be consistent with the provisions of this Agreement. Furthermore, unless otherwise agreed by Pfizer in writing, prior to or at the time of engagement of any Subcontractor to perform any obligations hereunder, MacroGenics shall cause
such Subcontractor to agree in writing to be bound by substantially equivalent obligations of confidentiality and use of proprietary materials as those in this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.10.2. *** </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.11. <B>Inspections</B>. Pfizer authorized representative(s), and
Regulatory Authorities to the extent required by law and applicable to the scope of the Research Plan Services performed, may, during regular business hours and, to the extent legally possible, at times arranged in advance with MacroGenics, audit,
inspect and copy all data, records and work products, and audit and inspect all facilities, relating to the Research Plan Services and MacroGenics&#146;s performance under this Agreement and the applicable Research Plan(s) (including all data,
records, work products and facilities of Subcontractors); provided, however, that MacroGenics may limit the scope of any such audit or inspection to prevent the disclosure of confidential information of MacroGenics or the disclosure of confidential
information of MacroGenics&#146;s Subcontractors (&#147;<B>Subcontractor Information</B>&#148;), unless such confidential information or Subcontractor Information is directly related to the performance of the Research Plan Services and the
disclosure is required for purposes of the audit or inspection. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.12. <B>Records</B>. Each Party shall prepare, maintain and
retain complete and accurate written records, accounts, notes, reports and data of the Research Plan Services and its performance under this Agreement and the Research Plan(s), in a form and of quality reasonably acceptable to both Parties. All such
information generated by MacroGenics </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall be treated as Confidential Information of both Parties for the purpose of this Agreement and all such information generated by Pfizer shall be treated as Confidential Information of Pfizer
for the purposes of this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.13. <B>Transfer and Use of Pfizer Proprietary Materials</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.13.1. <B>Transfer</B>. From time to time, pursuant to a Research Plan, or otherwise, Pfizer may provide MacroGenics with Pfizer
Proprietary Materials. Pfizer represents and warrants to MacroGenics that Pfizer has the right to provide the Pfizer Proprietary Materials to MacroGenics for the uses authorized herein. Except as expressly set forth in the preceding sentence, the
Pfizer Proprietary Materials are provided by Pfizer on an &#147;as-is&#148; basis without representation or warranty of any type, express or implied, including any representation or warranty of merchantability, non-infringement, title or fitness for
a particular purpose, each of which is hereby disclaimed by Pfizer. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.13.2. <B>Use of Pfizer Proprietary Materials</B>.
MacroGenics shall use the Pfizer Proprietary Materials solely in connection with conducting the specific activities under this Agreement for which such Pfizer Proprietary Materials are provided to MacroGenics, including, if applicable, the
provisions of any specific Research Plan under which such Pfizer Proprietary Materials are provided, and for no other purpose. Without limiting the generality of the foregoing, except as expressly set forth in this Agreement or in any applicable
Research Plan, MacroGenics shall not make or attempt to make analogues, progeny or derivatives of, or modifications to, the Pfizer Proprietary Materials and MacroGenics shall not use the Pfizer Proprietary Materials for the benefit of any Third
Party or of its own internal research programs outside of the Research Program. MacroGenics shall not administer any of the Pfizer Proprietary Materials to any human. MacroGenics shall comply with all Applicable Laws regarding the handling and use
of the Pfizer Proprietary Materials. MacroGenics agrees to retain possession over the Pfizer Proprietary Materials and not to provide the Pfizer Proprietary Materials to any Third Party without Pfizer&#146;s prior written consent, except as required
to perform the Research Program. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.13.3. <B>Unauthorized Use of Materials</B>. In the event that MacroGenics uses the Pfizer
Proprietary Materials for any purpose other than the purposes authorized herein, the results of such unauthorized research, and any discoveries or inventions that arise from such unauthorized research, whether patentable or not, shall belong solely
and exclusively to Pfizer. If required in order to perfect or enforce Pfizer&#146;s rights to such results, discoveries or inventions, MacroGenics hereby assigns and agrees to assign to Pfizer all of its right, title and interest in and to all such
results, discoveries or inventions. MacroGenics agrees to cooperate with Pfizer, and to execute and deliver any and all documents that Pfizer deems reasonably necessary, to perfect and enforce its rights hereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.13.4. <B>Title to Pfizer Proprietary Materials</B>. All right, title and interest in the
Pfizer Proprietary Materials shall remain the sole property of Pfizer notwithstanding the transfer to and use by MacroGenics of the same. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.13.5. <B>Return of Pfizer Proprietary Materials</B>. Upon completion of the activities for which the Pfizer Proprietary Materials have been provided, or upon expiration or termination of this Agreement
or the applicable Research Plan, if earlier, MacroGenics shall, at Pfizer&#146;s option and expense, either destroy or return to Pfizer all unused Pfizer Proprietary Materials. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.13.6. <B>Assignment</B>. MacroGenics hereby assigns to Pfizer all of MacroGenics&#146;s right, title and interest in and to any Pfizer Proprietary Material Improvements. During and after the Term,
MacroGenics shall promptly notify Pfizer of any Pfizer Proprietary Material Improvement developed by MacroGenics and shall cooperate fully in obtaining patent and other proprietary protection for such Pfizer Proprietary Material Improvement. Such
protection shall be obtained in the name of Pfizer and at Pfizer&#146;s cost and expense, and MacroGenics, without limitation, shall execute and deliver all requested applications, assignments and other documents, and take such other measures, as
Pfizer shall reasonably request, in order to perfect and enforce Pfizer&#146;s rights in any Pfizer Proprietary Material Improvement. MacroGenics appoints Pfizer its attorney to execute and deliver any such documents and take such actions on
MacroGenics&#146;s behalf in the event MacroGenics fails to do so. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRODUCT DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION AND REGULATORY MATTERS. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.1. <B>General</B>. Except as expressly set forth in Section 2, Pfizer shall have sole authority over and control of the Development,
Manufacture and Commercialization of Agreement Products. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2. <B>Diligence</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.1. <B>Development Diligence</B>. Pfizer will use Commercially Reasonable Efforts to Develop (including to seek Regulatory Approval
for) each Agreement Product in at least one Indication in the <B>***</B>: (i)&nbsp;<B>***</B>. Pfizer may determine in its sole discretion the order in which it seeks any such Regulatory Approval. Pfizer will have no other diligence obligations with
respect to the Development (including to seek Regulatory Approval of) of Agreement Products under this Agreement. For the avoidance of doubt, any actions taken by Pfizer&#146;s Affiliates or Sublicensees under this Agreement shall be treated as
actions taken by Pfizer in regard to satisfaction of the requirements of this Section 3.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.2. <B>Commercial Diligence</B>.
Pfizer will use Commercially Reasonable Efforts to Commercialize a given Agreement Product in each Major Market Country in the Field in the Territory where Pfizer or its Affiliates have received Regulatory
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Approval for such Agreement Product. Pfizer will have no other diligence obligations with respect to the Commercialization of Agreement Products under this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.3. <B>Exceptions to Diligence Obligations</B>. Notwithstanding any provision of this Agreement to the contrary, Pfizer will be
relieved from and will have no obligation to undertake any efforts with respect to any Pfizer Diligence Obligation in the event that: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Pfizer or MacroGenics receives or generates any safety, tolerability or other data reasonably indicating, as measured by Pfizer&#146;s safety and efficacy evaluation criteria and methodology, or
signaling that an Agreement Product has or would have an unacceptable risk-benefit profile or is otherwise not reasonably suitable for initiation or continuation of clinical trials in humans; or </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pfizer or MacroGenics receive any notice, information or correspondence from any applicable Regulatory Authority, or any applicable
Regulatory Authority takes any action, that reasonably indicates that an Agreement Product is unlikely to receive Regulatory Approval. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.2.4. <B>Assertion of Pfizer Diligence Obligation Claims</B>. If MacroGenics becomes aware of facts that might form a reasonable basis to allege that Pfizer has failed to meet any Pfizer Diligence
Obligation, then MacroGenics will notify Pfizer in writing of such potential alleged performance failure (each such potential alleged performance failure, a &#147;<B>Diligence Issue</B>&#148;). Promptly upon Pfizer&#146;s receipt of any notice of a
Diligence Issue pursuant to this Section 3.2.3, the Pfizer Alliance Manager will contact the MacroGenics Alliance Manager to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no
later than thirty (30)&nbsp;days after Pfizer&#146;s receipt of such a notice, (a)&nbsp;the Parties have not reached consensus regarding whether Pfizer has failed to satisfy the Pfizer Diligence Obligations and (b)&nbsp;the Parties&#146; respective
Alliance Managers have not agreed upon an appropriate corrective course of action for such Diligence Issue, then such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 11.9. Failure by
MacroGenics to provide notice of a Diligence Issue pursuant to this Section 3.2.4 shall not result in a waiver by MacroGenics of its rights under Section 3.2.5 of this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.2.5. <B>Remedies for Breach of Pfizer Diligence Obligations</B>. If Pfizer materially breaches any Pfizer Diligence Obligation and fails
to remedy such breach within <B>***</B> of Pfizer&#146;s receipt of notice of such breach from MacroGenics, then MacroGenics may, in its sole discretion, elect to either (a)&nbsp;terminate this Agreement with the effects of the provisions of Section
9.5.2 on an Agreement Product-by-Agreement Product and country-by-country basis, but only to the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
extent that an Agreement Product in a given country in the Territory is directly and adversely impacted by such uncured material breach, or (b)&nbsp;convert any exclusive licenses granted to
Pfizer under this Agreement with respect to an Agreement Product in a given country in the Territory into non-exclusive licenses, but only to the extent that such Agreement Product in such country is directly and adversely impacted by such uncured
material breach. In the event MacroGenics elects Section 3.2.5(b) as a remedy to address a Diligence Issue, Pfizer shall continue to have the same obligations to pay all milestones, FTE costs and Net Sales royalties for each Agreement T-DART and
Agreement Product affected by MacroGenics election. MacroGenics acknowledges and agrees that the elections set forth in this Section 3.2.5 (i)&nbsp;have been negotiated by the Parties to fully address any harm that MacroGenics may incur as a result
of Pfizer&#146;s material breach of any Pfizer Diligence Obligation and (ii)&nbsp;constitute MacroGenics&#146;s sole and exclusive remedies with respect to any breach by Pfizer of the Pfizer Diligence Obligations. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.3. <B>Regulatory Approvals</B>. Pfizer or its designated Affiliate(s) shall file, in its own name, all Regulatory Approval applications
for Agreement Products where, subject to the Pfizer Diligence Obligations, Pfizer, in its sole discretion, determines it is commercially advantageous to do so. Pfizer, or its designated Affiliate(s), shall have the sole responsibility for, and sole
authority with respect to, communications with any Regulatory Authority regarding any Regulatory Approval application or any Regulatory Approval for an Agreement Product once granted. Except to the extent necessary to fulfill its obligations under
Section 3.2.1, neither Pfizer nor any of its Affiliates shall have any obligation to seek Regulatory Approval for any Agreement Product. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.4. <B>Control of Commercialization Activities</B>.<B></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4.1.
<B>General</B>. Subject to the Pfizer Diligence Obligations, Pfizer shall have sole and exclusive control over all matters relating to the Commercialization of Agreement Products. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.4.2. <B>Branding</B>. Pfizer shall select and own all Trademarks, including all goodwill associated therewith. Neither MacroGenics nor
its Affiliates shall use or seek to register, anywhere in the world, any trademarks which are confusingly similar to any Trademarks. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.5. <B>Manufacturing</B>. Subject to Section 2.3.3(f), Pfizer shall have the exclusive right to Manufacture Agreement Products itself or through one or more Affiliates or Third Parties selected by
Pfizer. Pfizer shall have no diligence obligations with respect to the Manufacture of Agreement Products except to the extent necessary to fulfill the Pfizer Diligence Obligations. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.6. <B>Progress Reporting</B>. Pfizer shall provide MacroGenics with semi-annual written reports on Pfizer&#146;s activities to Develop
and Commercialize Agreement Products. Any information or written report provided by Pfizer to MacroGenics pursuant to this Section 3.6 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall be deemed to be Pfizer&#146;s Confidential Information subject to the provisions of Section 7. MacroGenics shall have the opportunity to reasonably seek further explanation or clarification
of matters covered in such reports, and Pfizer shall provide such explanation or clarification. Furthermore, if after receiving such a report MacroGenics wishes to meet with Pfizer to discuss such report, Pfizer shall meet (in person or via
teleconference) with MacroGenics at a site reasonably requested by MacroGenics within thirty (30)&nbsp;days after MacroGenics requests such meeting. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LICENSES AND RELATED GRANTS OF RIGHTS. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1. <B>Grants to Pfizer</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.1. <B>Research License</B>. Subject to the
terms and conditions of this Agreement and during the Research Term, MacroGenics hereby grants to Pfizer a non-exclusive, worldwide, royalty-free license under the MacroGenics Technology to (a)&nbsp;use, have used, make and have made any T-DART
directed to any Research Project Target for any and all uses in the Field, (b)&nbsp;conduct preclinical studies in vitro and in vivo in any non-human species with any T-DART directed to the Research Project Target for any and all uses in the Field
and (c)&nbsp;otherwise perform the activities assigned to Pfizer under the Research Plans. The foregoing license shall be sublicenseable by Pfizer as provided in Section 4.1.4. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1.2. <B>Assignment of Agreement T-DART IP</B>. MacroGenics shall assign and hereby does assign to Pfizer all of MacroGenics&#146;s and its Affiliates&#146; right, title and interest in and to the
Agreement T-DART IP (including the right in and to any data, writings (irrespective of whether in written or electronic form) and information (tangible and intangible) covering the foregoing). MacroGenics shall execute, and cause its employees,
agents and subcontractors to execute (directly or through assignment to MacroGenics and assignment by MacroGenics to Pfizer), assignments to Pfizer of all right, title and interest in and to any such Agreement T-DART IP. Subject to the terms of
Section 9.5.2(a) and Section 9.5.2(b), any Agreement T-DART IP shall be the sole and exclusive property of Pfizer and shall constitute Confidential Information of Pfizer. MacroGenics will cooperate with Pfizer to execute and deliver any and all
documents that Pfizer deems reasonably necessary to perfect and enforce Pfizer&#146;s rights under this Section 4.1.2. Pfizer shall not grant any license under or other right with respect to any rights in any Agreement T-DART IP subject to potential
reassignment to MacroGenics under Section 9.5.2 , that would prevent, survive or be otherwise inconsistent with the reassignment of such Agreement T-DART IP to MacroGenics if required by Section 9.5.2 free and clear of any such license or other
right and shall take no action with respect to any other Agreement T-DART IP that is inconsistent with Pfizer&#146;s obligations under Section 9.5.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.1.3. <B>Exclusive License</B>. Subject to the terms and conditions of this Agreement and effective on the Effective Date, MacroGenics hereby grants to Pfizer an exclusive (even as to MacroGenics, except
to the extent necessary for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics to perform its obligations under the Research Program), license under the MacroGenics Technology and MacroGenics&#146;s interest in the Joint Technology to use, have used, Develop,
have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import, have imported, export and have exported Agreement T-DARTs and Agreement Products in the Territory for use in the Field, with the right to sublicense as
provided in Section&nbsp;4.1.4. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.4. <B>Right to Sublicense</B>. Pfizer shall have the right to grant sublicenses under the
licenses granted to it (a)&nbsp;under Section&nbsp;4.1.1 and 4.1.3 . to Affiliates of Pfizer at any time, and (b)&nbsp;(i)&nbsp;under Section 4.1.1 to Third Party contractors solely for the provision of services to Pfizer in connection with the
performance of activities assigned to Pfizer under the Research Plans; and (ii)&nbsp;under Section 4.1.3 to Third Parties; provided that any sublicense granted to a Third Party under this Agreement shall be pursuant to a written agreement that
subjects such sublicensee to all relevant restrictions and limitations set forth in this Agreement. Pfizer shall provide MacroGenics notice of any Third Party sublicense within <B>***</B> after the execution thereof, including the name and address
of each permitted sublicensee, the date of the grant of the sublicense and a description of the rights granted. Pfizer shall be jointly and severally responsible with its sublicensees to MacroGenics for failure by its sublicensees to comply with,
and Pfizer guarantees the compliance by each of its sublicensees with, all such applicable restrictions and limitations in accordance with the terms and conditions of this Agreement. Pfizer shall remain responsible for the payment to MacroGenics of
all Sales Milestones and royalties payable with respect to Net Sales made by any of Pfizer&#146;s Affiliates and Sublicensees. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.5. <B>Direct License to Affiliates</B>. Pfizer may at any time request and authorize MacroGenics to grant licenses directly to
Affiliates of Pfizer by giving written notice designating to which Affiliate a direct license is to be granted. Upon receipt of any such notice, MacroGenics shall enter into and sign a separate direct license agreement with such designated Affiliate
of Pfizer. All such direct license agreements shall be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by the laws and regulations in the country in which the direct license will be
exercised. The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct license agreements and this Agreement to the terms of this Agreement as set forth on the Effective Date. In
countries where the validity of such direct license agreements requires prior governmental approval or registration, such direct license agreements shall not become binding between the parties thereto until such approval or registration is granted,
which approval or registration shall be obtained by Pfizer. All costs of making such direct license agreement(s), including MacroGenics&#146;s reasonable attorneys&#146; fees, under this Section 4.1.5 shall be borne by Pfizer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.1.6. <B>Right of Reference</B>. To the extent that MacroGenics does not breach any
contractual obligations it has with Third Parties, MacroGenics hereby grants to Pfizer a &#147;Right of Reference,&#148; as that term is defined in 21 C.F.R. &#167; 314.3(b), to any data Controlled by MacroGenics or its Affiliates (a)&nbsp;that
relates to the Agreement T-DARTS, the Agreement Products or preclinical studies with respect to the Agreement Products and (b)&nbsp;that Pfizer reasonably believes may be necessary or useful to the Development, Manufacturing or Commercialization of
any Agreement T-DART or any Agreement Product pursuant to this Agreement, and MacroGenics will provide a signed statement to the foregoing effect, if so requested by Pfizer in accordance with 21 C.F.R. &#167; 314.50(g)(3). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2. <B>Grants to MacroGenics</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.2.1. <B>Research License</B>. Subject to the terms and conditions of this Agreement and during the Research Term, Pfizer hereby grants to MacroGenics a non-exclusive, worldwide, royalty-free license
under the Pfizer Technology solely to the extent necessary to conduct activities assigned to MacroGenics under the Research Plan, with the right to sublicense as provided in Section 4.2.1(a). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Right to Sublicense</B>. MacroGenics may sublicense the foregoing license but only to any one or more of MacroGenics&#146;
Affiliates or subcontractors. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.2.2. <B>Grant Back License with Respect to Agreement T-DART IP Assigned to Pfizer</B>.
Subject to the terms and conditions of this Agreement, Pfizer hereby grants to MacroGenics a non-exclusive, worldwide, royalty-free license under the Agreement T-DART IP and the Agreement T-DART Patent Rights to use, have used, Develop, have
Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import, have imported, export and have exported any T-DART or other bi-specific targeting molecule (other than (a)&nbsp;any T-DART Targeting any Research Project Target
or any Reserved Target or (b)&nbsp;any other bi-specific targeting molecule that consists of or comprises any Research Program Antibody (other than a Passed MacroGenics Antibody) Targeting any Research Project Target or any Reserved Target), either
alone or as part of any pharmaceutical or other product, with the right to sublicense. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3. <B>Reciprocal Non-Exclusive
Research License for Disclosed Know-How and Confidential Information</B>.<B></B> Without limiting any other license granted to either Party under this Agreement: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.3.1. MacroGenics hereby grants to Pfizer and Pfizer&#146;s Affiliates a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license to use any and all MacroGenics Know-How or
MacroGenics Confidential Information disclosed to Pfizer during the Term solely for internal research purposes. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3.2. Pfizer hereby grants to MacroGenics and MacroGenics Affiliates a non-exclusive,
irrevocable, perpetual, royalty-free, fully paid-up, worldwide license to use any and all Pfizer Know-How or Pfizer Confidential Information (other than any information regarding the identity of or Pfizer&#146;s reasons for selecting any Research
Project Target or Reserved Target, which shall only be disclosed by MacroGenics to MacroGenics personnel as necessary to comply with the terms of this Agreement) disclosed to MacroGenics during the Term solely for internal research purposes.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.3.3. Notwithstanding the foregoing, neither Pfizer nor MacroGenics shall have any right under this Section&nbsp;4.3 to make
any use of any physical material supplied by the other Party for use in the Research Program other than for use in the Research Program.</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.4. <B>Retained Rights to Antibodies</B>. For the avoidance of doubt, except as expressly provided in regard to the assignments and licenses contained in this Section 4, neither Party will have any
rights in the other Party&#146;s Antibodies and each Party will retain ownership of all of its Pfizer Technology, MacroGenics Technology or Joint Technology, as applicable, covering any Antibody that such Party contributes to the collaboration.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5. <B>Exclusivity</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">4.5.1. <B>Exclusivity Covenant</B>. During the Research Term and for <B>***</B> after the Research Term, except to the extent required for MacroGenics to fulfill its obligations under this Agreement,
neither MacroGenics nor any of its Affiliates will (i)&nbsp;(either directly or with or through a Third Party) Develop, Manufacture or Commercialize any T-DART or Research Program Antibody (other than a Passed MacroGenics Antibody) Targeting any
Research Project Target or any Reserved Target or (ii)&nbsp;license or otherwise grant any right to any Third Party to Develop, Manufacture or Commercialize any T-DART or Research Program Antibody (other than a Passed MacroGenics Antibody) Targeting
any Research Project Target or any Reserved Target. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.5.2. <B>Other Pfizer Programs</B>. MacroGenics understands and
acknowledges that Pfizer may have present or future initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving similar products, programs, technologies or processes that are similar to or
that may compete with a product, program, technology or process covered by this Agreement. MacroGenics acknowledges and agrees that nothing in this Agreement will be construed as a representation, warranty, covenant or inference that Pfizer will not
itself Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties to Develop, Manufacture or Commercialize products, programs, technologies or processes that are similar to or that
may compete with any product, program, technology or process covered by this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.6. <B>Section&nbsp;365(n) of Bankruptcy Code</B>. All rights and licenses now or
hereinafter granted by a Party to the other Party under or pursuant to any section of this Agreement, including Sections 4.1.1 , 4.1.3, 4.2.1 and 4.2.2 are rights to &#147;intellectual property&#148; (as defined in Section&nbsp;101(35A) of Title 11
of the United States Code, as amended (such Title 11, the &#147;<B>Bankruptcy Code</B>&#148;)). The Parties hereto acknowledge and agree that the payments provided for under Sections 5.1, 5.2 and 5.3 and all other payments by Pfizer to MacroGenics
under this Agreement, other than royalty payments pursuant to Section 5.4, do not constitute royalties within the meaning of Section&nbsp;365(n) of the Bankruptcy Code or relate to licenses of intellectual property under this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.7. <B>No Implied Rights</B>. Except as expressly provided in this Agreement, neither Party shall be deemed by estoppel, implication or
otherwise, to have granted the other Party any license or other right with respect to any intellectual property of such Party. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PAYMENTS TO MACROGENICS. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.1. <B>Upfront License Payment</B>. Within <B>***</B> days after the Effective Date, Pfizer shall pay to MacroGenics the non-creditable,
non-refundable amount of Five Million Dollars ($5,000,000) (the &#147;<B>Up-Front Payment</B>&#148;). </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Research Support Funding</B>. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.1. <B>FTE Reimbursement</B>. During the Research Term, Pfizer shall reimburse MacroGenics for the costs of the FTEs for the Research
Program at the FTE Rate per FTE per Calendar Year. <B>***</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.2. <B>Out-of-Pocket Expenses</B>. During the Research Term,
Pfizer shall reimburse MacroGenics&#146;s out-of-pocket costs incurred by MacroGenics and paid to Third Parties in connection with executing the Research Plans, but only to the extent contemplated in the Research Plans or otherwise approved by
Pfizer in advance in writing. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.3. <B>Other Expenses</B>. Except as expressly set forth in Section 5.2.1 and Section 5.2.2,
MacroGenics shall be solely responsible for all expenses it incurs in performing its obligations under the Research Program. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.4. <B>Reimbursement Payments</B>. Pfizer shall reimburse MacroGenics for expenses pursuant to Section 5.2 within <B>***</B> days after
receipt of an invoice issued by MacroGenics within <B>***</B> days after the end of each Calendar Quarter. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.5. <B>Audit
Rights</B>. During the Research Term and for a period of thirty-six (36)&nbsp;months thereafter, MacroGenics shall keep and maintain accurate and complete records showing the time devoted and activities performed by each FTE in performing
MacroGenics&#146;s obligations under the Research Program. Upon thirty (30)&nbsp;days prior written notice from Pfizer, MacroGenics shall permit an independent certified public accounting firm of internationally recognized standing selected by
Pfizer and reasonably acceptable to MacroGenics, to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
examine, at Pfizer&#146;s sole expense, the relevant books and records of MacroGenics as may be reasonably necessary to verify the accuracy of the invoices submitted to Pfizer under Section 5.2.4
for the number of FTEs applied to the performance of MacroGenics&#146;s obligations under the Research Program. An examination by Pfizer under this Section 5.2.5 shall occur not more than once in any Calendar Year and shall be limited to the
pertinent books and records for any Calendar Year ending not more than thirty-six (36)&nbsp;months before the date of the request. Such examination shall be conducted during MacroGenics&#146;s normal business hours at MacroGenics&#146;s
facility(ies) where such books and records are normally kept. MacroGenics may require the accounting firm to sign a standard non-disclosure agreement before providing the accounting firm access to MacroGenics&#146;s facilities or records. The
accounting firm shall provide both MacroGenics and Pfizer a written report disclosing whether the invoices submitted by MacroGenics are correct or incorrect and the specific details concerning any discrepancies. No other information shall be
provided to Pfizer. If the accounting firm determines the number of FTEs actually utilized by MacroGenics was materially less than the number funded by Pfizer during the period covered by the audit <B>***</B>, MacroGenics shall, at Pfizer&#146;s
sole discretion, either (a)&nbsp;refund the excess payments to Pfizer within <B>***</B> after its receipt of the auditor&#146;s report so concluding or (b)&nbsp;immediately offset all such excess payments against any outstanding or future amounts
payable by Pfizer to MacroGenics under this Agreement until Pfizer has received full credit for all such overpayments. Additionally, if the amount to be refunded exceeds more than five percent (5%)&nbsp;of the amount that was properly payable,
MacroGenics shall reimburse Pfizer for the cost of the audit. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.2.6. <B>Underpayments/Overpayments</B>. If such accounting
firm concludes that MacroGenics under-billed Pfizer for such FTEs, Pfizer shall reimburse MacroGenics for such costs within <B>***</B> after its receipt of the auditor&#146;s report. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3. <B>Milestones</B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.3.1. <B>Technical Milestones</B>. Pfizer shall pay to MacroGenics the amount set forth below within <B>***</B> following the first occurrence of each event (each, a &#147;<B>Technical
Milestone</B>&#148;) described below for each Research Project Target, each such amount (a &#147;<B>Technical Milestone Payment</B>&#148;) to be payable only once with respect to each different Research Project Target regardless of how many
Agreement T-DARTs binding to such Research Project Target achieve such Technical Milestone. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:68pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Technical Milestone</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Technical&nbsp;Milestone<BR>Payment</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Technical Milestone set forth in Section 5.3.1(c) is achieved prior to the
achievement of the Technical Milestone set forth in Section 5.3.1(a) and/or 5.3.1(b), then the unpaid Technical Milestone Payment set forth in Section 5.3.1(a) and/or 5.3.1(b) shall be due and payable simultaneously with the payment for achievement
of the milestone set forth in Section 5.3.1(c). For the avoidance of doubt, in the event that the Technical Milestone set forth in Section 5.3.1(b) is achieved prior to the achievement of the Technical Milestone set forth in Section 5.3.1(a), the
Technical Milestone Payment set forth in Section 5.3.1(a) shall not be due or payable simultaneously with the Technical Milestone Payment for achievement of the Technical Milestone set forth in Section 5.3.1(b), but instead shall only be due and
payable upon achievement of Technical Milestone Payment set forth in Section 5.3.1(a) or Section 5.3.1.(c). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.2.
<B>Development Milestones</B>. Pfizer shall pay to MacroGenics the amount set forth below within <B>***</B> days following the first occurrence of each event (each, a &#147;<B>Development Milestone</B>&#148;) described below for each Research
Project Target, each such amount (a &#147;<B>Development Milestone Payment</B>&#148;) to be payable only once with respect to each different Research Project Target regardless of how many Agreement T-DARTs binding to such Research Project Target
achieve such Development Milestone. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="24%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:80pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development Milestone</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Development&nbsp;Milestone<BR>Payment</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the Development Milestone set forth in Section 5.3.2(b) is achieved prior to the achievement of the
milestone set forth in Section 5.3.2(a), then the Development Milestone Payment set forth in Section 5.3.2(a) shall be due and payable simultaneously with the Development Milestone Payment for achievement of the Development Milestone set forth in
Section 5.3.2(b); if the Development Milestone set forth in Section 5.3.2(c) is achieved prior to the achievement of the Development Milestone set forth in Section 5.3.2(a) and/or 5.3.2(b), then the unpaid Development Milestone Payment set forth in
Section 5.3.2(a) and/or 5.3.2(b) shall be due and payable simultaneously with the payment for achievement of the milestone set forth in Section 5.3.2(c); if the Development Milestone set forth in Section 5.3.2(d), (e) or (f) is achieved prior to the
achievement of the Development Milestone set forth in Section 5.3.2(a), 5.3.2(b) and/or 5.3.2(c), then the unpaid Development Milestone Payment set forth in Section 5.3.2(a), 5.3.2(b) and/or 5.3.2(c) shall be due and payable simultaneously with the
Development Milestone Payment for achievement of the milestone set forth in Section 5.3.2(d), (e)&nbsp;or (f). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.3.3. <B>Sales Milestones</B>. Pfizer shall pay to MacroGenics the following one-time
payments (each, a &#147;<B>Sales Milestone Payment</B>&#148;) when aggregate Annual Net Sales of all Agreement Product in a Pfizer Year first reach the respective threshold (a &#147;<B>Sales Threshold</B>&#148;) indicated below (each, a
&#147;<B>Sales Milestone</B>&#148;): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="20%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:78pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total Annual Net Sales</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Sales&nbsp;Milestone&nbsp;Payment</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Annual Net Sales exceeding <B>*** </B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Annual Net Sales exceeding <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Annual Net Sales exceeding <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Annual Net Sales exceeding <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If more than one unmet Sales Threshold is achieved with respect to the same Pfizer Year, payment will be
made with respect to the higher or highest Sales Threshold achieved in such Pfizer Year and all other previously unmet Sales Thresholds achieved with respect to such Pfizer Year will remain eligible to be met in future Pfizer Years. Any Sales
Milestone Payment shall be payable by Pfizer with respect to any Pfizer Year shall be payable within sixty (60)&nbsp;days of the end of such Pfizer Year in the United States. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.4. <B>Royalties</B>. Subject to the provisions of Section 5.4.3, Pfizer shall pay MacroGenics royalties in the amount of the rates (&#147;<B>Marginal Royalty Rates</B>&#148;) set forth below of Annual
Net Sales of any Agreement Product during the Royalty Term: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="22%"></TD>
<TD></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:58pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Annual Net Sales</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Marginal&nbsp;Royalty&nbsp;Rate</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(%&nbsp;of&nbsp;
the&nbsp;Annual&nbsp;Net&nbsp;Sales)</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Net Sales of such Agreement Product during a given Pfizer Year above $0, up to and including <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Net Sales of such Agreement Product during a given Pfizer Year above <B>***</B>, up to and including
<B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR BGCOLOR="#cceeff">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Net Sales of such Agreement Product during a given Pfizer Year above <B>***</B>, up to and including
<B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annual Net Sales of such Agreement Product during a given Pfizer Year above <B>***</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.1. <B>Marginal Royalty Rate Application</B>. Each Marginal Royalty Rate set forth in the table above
shall apply only to that portion of the Annual Net Sales of a given Agreement Product in the Territory during a given Pfizer Year that falls within the indicated range. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.2. <B>Royalty Term</B>. &#147;<B>Royalty Term</B>&#148; means, with respect to any
Agreement Product and any country in the Territory, the period of time from the First Commercial Sale of such Agreement Product in such country until the later of (a)&nbsp;<B>*** </B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.4.3. <B>Royalty Adjustments</B>. The following adjustments shall be made, on Agreement Product-by-Agreement Agreement Product and
country-by-country basis, to the royalties payable pursuant to this Section 5.4: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Generic Competition</B>. Royalties
payable following establishment of Generic Competition with respect to the sale by a Third Party of product that is a Biosimilar Biologic Product to such Agreement Product in such country shall be payable at <B>***</B> of the otherwise applicable
rate prior to application of this Section <B></B>5.4.3(a) <B>&#147;</B><B>Generic Competition</B><B></B>&#148; means with respect to a given Calendar Year with respect to an Agreement Product in any country, that during such Calendar Year,
<B>***</B> have received Regulatory Approval to sell in such country a Biosimilar Biologic Product, such Biosimilar Biologic Product shall be commercially available in such country and such Biosimilar Biologic Product shall have, in the aggregate,
<B>***</B> or more market share of the aggregate of such Agreement Product and Biosimilar Biologic Product (based on data provided by IMS International, or if such data is not available, such other reliable data source as reasonably determined by
Pfizer and agreed by MacroGenics (such agreement not to be unreasonably withheld)) as measured by sales. In the event IMS International data (or such other agreed data source) is not sufficient to determine the percentage market share for each
country in the EU, the percent market share for the EU countries for which data is not available will be deemed to be the average percent market share for those EU countries in which the data is available. A product shall be a &#147;<B>Biosimilar
Biologic Product</B>&#148; with respect to an Agreement Product if such product (1)&nbsp;has been&nbsp;licensed as a biosimilar or interchangeable product by FDA pursuant to Section&nbsp;351(k) of the Public Health Service Act (42 U.S.C. 262(k)), as
may be amended, or any subsequent or superseding law, stature or regulation, (2)&nbsp;has been licensed as a similar biological medicinal product by EMEA pursuant to Directive 2001/83/EC, as may be amended, or any subsequent or superseding law,
stature or regulation, or (3)&nbsp;has otherwise achieved analogous Regulatory Marketing Approval from another applicable Regulatory Authority.<B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Third Party Patents</B>. If it is necessary for Pfizer to license one or more Patent Rights from one or more Third Parties in order to Develop, Manufacture or Commercialize or use any Agreement
Product, whether directly or through any Pfizer Affiliate or Sublicensee, then Pfizer may, in its sole discretion, negotiate and obtain a license under such Patent Right(s) (each such Third Party license referred to herein as an &#147;<B>Additional
Third Party License</B>&#148;). Any royalty otherwise payable to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
MacroGenics under this Agreement with respect to Net Sales of any Agreement Product by Pfizer, its Affiliates or Sublicensees shall be reduced by <B>***</B> of the royalties payable to Third
Parties that are reasonably allocable to Agreement Products pursuant to any Additional Third Party Licenses, such reduction to continue until all such amounts have been expended, provided that in no event shall the total royalty payable to
MacroGenics for any Agreement Product be less than <B>***</B> of the royalty amounts otherwise payable for such Agreement Product. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) <B>No Adjustment for MacroGenics Third Party Agreements</B>. MacroGenics shall be solely responsible for all obligations (including any royalty or other obligations that relate to the MacroGenics
Technology) under its agreements with Third Parties that are in effect as of the Effective Date or that MacroGenics enters into during the Term. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.4.4. <B>Fully Paid-Up, Royalty Free License</B>. After expiration of the Royalty Term for any Agreement Product in a country in the Territory, no further royalties shall be payable in respect of sales
of such Agreement Product in such country and thereafter, the license granted to Pfizer under Section 4.1.3 with respect to such Agreement Product in such country shall be a fully paid-up, perpetual, non-exclusive, irrevocable, royalty-free license.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5. <B>Reports and Payments</B>.<B></B> </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.5.1. <B>Cumulative Royalties</B>. The obligation to pay royalties under Section 5.4 shall be imposed only once with respect to a single unit of an Agreement Product regardless of how many Valid Claims
in Patent Rights included within the MacroGenics Patent Rights would, but for this Agreement, be infringed by the use or sale of such Agreement Product in the country in which such Agreement Product is used or sold. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.2. <B>Royalty Statements and Payments</B>. Within <B>***</B> after the end of each Pfizer Quarter, Pfizer shall deliver to MacroGenics
a report setting forth for such Calendar Quarter the following information, on an Agreement Product-by-Agreement Product basis: (a)&nbsp;the Net Sales of each Agreement Product, (b)&nbsp;the basis for any adjustments to the royalty payable for the
sale of each Agreement Product and (c)&nbsp;the royalty due hereunder for the sale of each Agreement Product. No such reports shall be due for any Agreement Product before the First Commercial Sale of such Agreement Product in the Territory. The
total royalty due for the sale of Agreement Products during such Pfizer Quarter shall be remitted at the time such report is delivered to MacroGenics. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.5.3. <B>Taxes and Withholding</B>. It is understood and agreed between the Parties that any payments made this Agreement are inclusive of any value added tax imposed upon such payments. In addition, in
the event any of the payments made by Pfizer pursuant to this Agreement become subject to withholding taxes under </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the laws of any jurisdiction, Pfizer shall deduct and withhold the amount of such taxes for the account of MacroGenics, to the extent required by law, such amounts payable to MacroGenics shall be
reduced by the amount of taxes deducted and withheld, and Pfizer shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to MacroGenics an official tax certificate or other evidence of such
tax obligations together with proof of payment from the relevant Governmental Authority of all amounts deducted and withheld sufficient to enable MacroGenics to claim such payment of taxes. Any such withholding taxes required under applicable Law to
be paid or withheld shall be an expense of, and borne solely by, MacroGenics. Pfizer will provide MacroGenics with reasonable assistance to enable MacroGenics to recover such taxes as permitted by Law. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.5.4. <B>Currency</B>. All amounts payable and calculations hereunder shall be in United States dollars. As applicable, Net Sales and any
royalty deductions shall be converted into United States dollars in accordance with Pfizer&#146;s customary and usual conversion procedures, consistently applied. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.5.5. <B>Additional Provisions Relating to Payments</B>. MacroGenics acknowledges and agrees that nothing in this Agreement (including any schedules and exhibits hereto) shall be construed as
representing an estimate or projection of either (a)&nbsp;the number of Agreement Products that shall or may be successfully Developed or Commercialized or (b)&nbsp;anticipated sales or the actual value of any Agreement Product. PFIZER MAKES NO
REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT IT SHALL BE ABLE TO SUCCESSFULLY DEVELOP OR COMMERCIALIZE ANY PRODUCT OR, IF COMMERCIALIZED, THAT IT WILL ACHIEVE ANY PARTICULAR SALES LEVEL OF SUCH PRODUCT(S), PROVIDED THAT THE FOREGOING
SHALL NOT LIMIT PFIZER&#146;S OBLIGATIONS UNDER THIS AGREEMENT. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6. <B>Maintenance of Records; Audits</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.1. <B>Record Keeping</B>. Pfizer shall keep, and shall cause its Affiliates and Sublicensees to keep, accurate books of account and
records in connection with the sale of Agreement Products, in sufficient detail to permit accurate determination of all figures necessary for verification of royalties to be paid hereunder. Pfizer shall maintain, and shall cause its Affiliates and
Sublicensees to maintain, such records for a period of at least three (3)&nbsp;years after the end of the Calendar Year in which they were generated. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5.6.2. <B>Audits</B>. Upon thirty (30)&nbsp;days prior written notice from MacroGenics, Pfizer shall permit an independent certified public accounting firm of internationally recognized standing selected
by MacroGenics and reasonably acceptable to Pfizer to examine, at MacroGenics&#146;s sole expense, the relevant books and records of Pfizer during the period covered by such examination, as </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
may be reasonably necessary to verify the accuracy of the reports submitted by Pfizer in accordance with Section 5.5 and the payment of royalties hereunder. An examination by MacroGenics under
this Section 5.6.2 shall occur not more than once in any Calendar Year and shall be limited to the pertinent books and records for any Calendar Year ending not more than three (3)&nbsp;years before the date of the request. The accounting firm shall
be provided access to such books and records at Pfizer&#146;s or its Affiliates&#146; facilities where such books and records are kept and such examination shall be conducted during Pfizer&#146;s normal business hours. Pfizer may require the
accounting firm to sign a standard non-disclosure agreement before providing the accounting firm access to Pfizer&#146;s facilities or records. Upon completion of the audit, the accounting firm shall provide both Pfizer and MacroGenics a written
report disclosing whether the reports submitted by Pfizer are correct or incorrect, whether the royalties paid are correct or incorrect and, in each case, the specific details concerning any discrepancies. No other information shall be provided to
MacroGenics. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.3. <B>Underpayments/Overpayments</B>. If such accounting firm concludes that additional royalties were due to
MacroGenics, Pfizer shall pay to MacroGenics the additional royalties within thirty (30)&nbsp;days after the date Pfizer receives such accountant&#146;s written report so concluding. If such underpayment exceeds five percent (5%)&nbsp;of the
royalties that were to be paid to MacroGenics, Pfizer also shall reimburse MacroGenics for all reasonable charges of such accountants for conducting the audit. If such accounting firm concludes that Pfizer overpaid royalties to MacroGenics, Pfizer
shall be entitled to offset all such overpayments against any outstanding or future amounts payable by Pfizer to MacroGenics under this Agreement until Pfizer has received full credit for all such overpayments. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.6.4. <B>Confidentiality</B>. All financial information of Pfizer which is subject to review under this Section 5.6 shall be deemed to be
Pfizer&#146;s Confidential Information subject to the provisions of Section 7 hereof, and MacroGenics shall not disclose such Confidential Information to any Third Party or use such Confidential Information for any purpose other than verifying
payments to be made by Pfizer to MacroGenics hereunder, provided, however, that such Confidential Information may be disclosed by MacroGenics to Third Parties only to the extent necessary to enforce MacroGenics&#146;s rights under this Agreement.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.7. <B>Late Payments</B>. If a Party shall fail to make a timely payment pursuant to the terms of this Agreement, interest
shall accrue on the past due amount at the <B>***</B>, computed for the actual number of days the payment was past due (but in no event in excess of the maximum rate permissible under Applicable Law). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>INTELLECTUAL PROPERTY. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.1. <B>Inventions</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1.1. <B>Ownership</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Except for inventions and Know-How subject to
Section 2.13.6 or Section 4.1.2, each Party shall own all inventions and Know-How conceived or generated solely by it and its Affiliates and their respective employees, agents and independent contractors in the course of performing research or
development activities under this Agreement (a &#147;<B>Sole Invention</B>&#148; or &#147;<B>Sole Know-How</B>,&#148; respectively). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Except for inventions and Know-How subject to Section 2.13.6 or Section 4.1.2, all inventions and Know-How that are conceived or generated jointly by employees, Affiliates, agents, or independent
contractors of each Party in the course of performing research or development activities under this Agreement shall be owned jointly by the Parties (a &#147;<B>Joint Invention</B>&#148; or &#147;<B>Joint Know-How</B>,&#148; respectively). During and
after the Term, either Party may exploit (including by license, sublicense, assignment of such Party&#146;s interest or otherwise) any Joint Technology without accounting to or obtaining consent from the other Party, subject to the rights and
obligations of the Parties with respect to Joint Technology under this Agreement, including the exclusive license of MacroGenics&#146;s interest in the Joint Technology granted to Pfizer under Section 4.1.3, the Joint Patent Right prosecution and
maintenance provisions set forth in Section 6.2 and Pfizer&#146;s obligation to pay royalties on Agreement Products under Section 5.4. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) All determinations of inventorship under this Agreement shall be made in accordance with the patent law of the United States. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.1.2. <B>Disclosure</B>. Each Party shall promptly disclose to the other Party any Joint Invention, Sole Invention, Agreement T-DART IP or Pfizer Proprietary Material Improvement, including all invention
disclosures or other similar documents submitted to such Party by its or its Affiliates&#146;, employees, agents or independent contractors describing such foregoing invention, and shall cooperate to promptly determine each Party&#146;s inventive
contribution thereto. The Parties shall cooperate with each other with respect to the timing, scope, and filing of patent applications and patent claims relating to any of the foregoing inventions to enhance the patent protection for Agreement
T-DARTs and Agreement Products, and their manufacture and use. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2. <B>Patent Rights</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.1. <B>Filing, Prosecution and Maintenance of Patent Rights</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Pfizer Patent Rights</B>. Pfizer, at its own expense, shall have the sole right, but not the obligation, to prepare, file,
prosecute and maintain, throughout the world, any Pfizer Patent Right other than any Agreement T-DART Patent Right. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) <B>Agreement T-DART Patent Rights</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) Pfizer shall have the first right, but not the obligation, to file, prosecute and maintain, at Pfizer&#146;s expense, any Agreement
T-DART Patent Right. Pfizer will provide MacroGenics with an opportunity to review the text of the initial application with respect to any Agreement T-DART Patent Right before filing, shall consult MacroGenics with respect thereto, shall not
unreasonably refuse to address any of MacroGenics&#146; comments, and shall provide MacroGenics promptly with a copy of the application as filed, together with notice of its filing date and serial number. Pfizer will keep MacroGenics advised of the
status of the Agreement T-DART Patent Rights annually or more often at MacroGenics&#146; reasonable request. Pfizer shall either provide MacroGenics with copies of, or require that Pfizer&#146;s outside counsel copy MacroGenics on, substantive
official correspondence received from all patent offices related to the filing, prosecution and maintenance of the patent filings in those offices (e.g., office actions and any other correspondence of a similar nature), and of Pfizer&#146;s proposed
responses to such correspondence or other substantive filings (e.g., responses to office actions, elections and any other responses or filings of a similar nature), in each case, reasonably in advance of Pfizer&#146;s proposed responses or other
filings to allow MacroGenics to comment. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) Pfizer shall file, prosecute and maintain each Agreement T-DART Patent Right in
all Major Market Countries and in such other countries as MacroGenics may request, provided, however, that if Pfizer at any time wishes not to file, prosecute or maintain any Agreement T-DART Patent Right in any country (a &#147;<B>Foregone
Agreement T-DART Patent Right</B>&#148;), Pfizer shall provide MacroGenics with <B>***</B> prior written notice to such effect, provided that an Agreement T-DART Patent Right shall not constitute a Foregone Agreement T-DART Patent Right if
Pfizer&#146;s discontinuation of filing, prosecution or maintenance of such Agreement T-DART Patent Right is in order to effect a settlement or to avoid an interference, opposition or other proceeding in which the validity of such Agreement T-DART
Patent Right may be determined or because another Agreement T-DART Patent Right of similar claim scope is being prosecuted or has been issued. For any such Foregone Agreement T-DART Patent Right for which Pfizer gives notice in accordance with the
foregoing sentence and of which MacroGenics, its Affiliates, or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Subcontractors of MacroGenics or any of its Affiliates are the sole inventors, MacroGenics shall have the right to request assignment within <B>***</B> after MacroGenics&#146; receipt of the
notice provided by Pfizer and Pfizer shall assign to MacroGenics all of Pfizer&#146;s right, title and interest in and to any such Foregone Agreement T-DART Patent Right so requested within <B>***</B> of such request. Upon assignment of such
Foregone Agreement T-DART Patent Right, Pfizer shall have no responsibility for any further prosecution or maintenance of or expenses incurred in connection with such Foregone Agreement T-DART Patent Right. Pfizer shall execute, and cause its
employees, agents and subcontractors to execute, at MacroGenics&#146; expense, all documents necessary for MacroGenics to continue prosecution and maintenance of such Foregone Agreement T-DART Patent Right. Any Foregone Agreement T-DART Patent Right
assigned to MacroGenics will be included in MacroGenics Patent Rights for the purposes of this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) If, upon a
timely request by MacroGenics in connection with an Agreement T-DART Patent Right of which MacroGenics, its Affiliates, or Subcontractors of MacroGenics or any of its Affiliates are the sole inventors, Pfizer declines to file a continuation or
divisional application to pursue claims of a broader scope than those that have been allowed or are being or will be sought by Pfizer, MacroGenics shall have the right to file, in Pfizer&#146;s name, such continuation or divisional application (but
not a continuation-in-part) and Pfizer shall have no responsibility for any further prosecution or maintenance of or expenses incurred in connection with such application. Pfizer shall execute, and cause its employees, agents and subcontractors to
execute, at MacroGenics&#146; expense, all documents necessary for MacroGenics to continue prosecution and maintenance of such application. The second, third and fourth sentences of this Section 6.2.1(b) shall apply to MacroGenics&#146; filing and
prosecution, provided that each Party&#146;s name in those sentences shall be substituted with the other Party&#146;s name. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>MacroGenics Patent Rights Other than Subject T-DART Patent Rights</B>. Except as provided in the Section 6.2.1(d) in regard to
Subject Patent Rights, MacroGenics, at its own expense, shall have the sole right, but not the obligation, to prepare, file, prosecute and maintain, throughout the world, any MacroGenics Patent Right. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Subject Patent Rights</B>. MacroGenics shall have the first right, but not the obligation, to file, prosecute and maintain, at
MacroGenics&#146;s expense, any Subject Patent Right. &#147;<B>Subject Patent Right</B>&#148; means any MacroGenics Patent Right covering the composition of, or any method of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
making or method of using, any Agreement T-DART or Agreement Product. MacroGenics shall keep Pfizer advised of the status of Subject Patent Rights (once published) annually or more often at
Pfizer&#146;s reasonable request. MacroGenics shall consider in good faith any comments provided by Pfizer concerning the prosecution of Subject Patent Rights, and MacroGenics shall not use any information generated in the Research Program in
connection with prosecution of any Subject Patent Rights without Pfizer&#146;s prior written consent, which shall not be unreasonably withheld or delayed. MacroGenics shall file, prosecute and maintain each Subject Patent Right in all Major Market
Countries, provided, however, that if MacroGenics at any time wishes not to file, prosecute or maintain any Subject Patent Right in any country, MacroGenics shall provide Pfizer with <B>***</B> prior written notice to such effect. Unless
MacroGenics&#146; discontinuation of filing, prosecution or maintenance of such Subject Patent Right is in order to effect a settlement or to avoid an interference, opposition or other proceeding in which the validity of such Subject T-DART Patent
Right may be determined or because another Subject T-DART Patent Right of similar claim scope is being prosecuted or has been issued, Pfizer shall have the first right to file, prosecute and maintain such Subject Patent Right (in MacroGenics&#146;
name) in each such country, in which event the Subject Patent Right will no longer be deemed to be included in the MacroGenics Patent Rights for the purpose of determining the Royalty Term with respect to any Agreement Product. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) <B>Joint Patent Rights</B>. In the event the Parties make any Joint Invention, the Parties shall promptly meet to discuss and
determine, based on mutual consent, whether to seek patent protection thereon and how prosecution, maintenance and enforcement of any Patent Right covering such Joint Invention will be handled. Neither Party will file any Patent Right covering or
claiming a Joint Invention without the consent of the other Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.2. <B>Enforcement of Patent Rights</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) <B>Notice</B>. If either Pfizer or MacroGenics becomes aware of any infringement, anywhere in the world, of any issued Subject Patent
Right or Agreement T-DART Patent Right, such Party shall promptly notify the other Party in writing to that effect. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b)
Infringement of Subject Patent Rights. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(1) If any infringement of a Subject Patent Right by a Third Party arises from the
Development, Manufacture or Commercialization of a product that competes with an Agreement Product, Pfizer shall have the first right, but not the obligation, to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
take action to obtain a discontinuance of infringement or bring suit against a Third Party infringer of such Subject Patent Right within *** from the date of notice and to join MacroGenics as a
party plaintiff. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) Pfizer shall bear all the expenses of any suit brought by it claiming infringement of any such Subject
Patent Right. MacroGenics shall cooperate with Pfizer in any such suit and shall have the right to consult with Pfizer and to participate in and be represented by independent counsel in such litigation at its own expense. Pfizer shall incur no
liability to MacroGenics as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Subject Patent Right invalid or unenforceable; provided, however, that Pfizer shall not, without
MacroGenics&#146; prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to MacroGenics or admits the invalidity or unenforceabilty of any such Subject Patent Right.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(3) If Pfizer has not obtained a discontinuance of infringement by, or filed suit against, any such Third Party infringer
within the *** period set forth in subsection (i)&nbsp;above, then MacroGenics shall have the right, but not the obligation, to bring suit against such Third Party infringer, at MacroGenics&#146; sole expense. provided that (x)&nbsp;Pfizer will not
be obligated to join such suit unless Applicable Law requires that Pfizer must be a party for MacroGenics to maintain the suit, and (y)&nbsp;MacroGenics shall indemnify Pfizer against any damages, penalties, attorney fees or other recoveries
assessed against Pfizer in or as a result of such suit. Pfizer may, at its sole discretion, elect to consult with MacroGenics and to participate in and be represented by independent counsel in such litigation at its own expense. MacroGenics shall
incur no liability to Pfizer as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Subject Patent Right invalid or unenforceable; provided, however, that MacroGenics shall not,
without Pfizer&#146;s prior written consent, enter into any settlement or consent decree that requires any payment by or admits or imparts any other liability to Pfizer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(4) The enforcing Party shall keep the other Party reasonably informed of all material
developments in connection with any such suit. Any recoveries obtained by either Party as a result of any proceeding against such a Third Party infringer shall be allocated as follows: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) Such recovery shall first be used to reimburse each Party for all out-of-pocket litigation costs in connection with such litigation
paid by that Party; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) With respect to any remaining portion of such recovery, if Pfizer was the enforcing Party,
MacroGenics shall receive either (1)&nbsp;if the reward to Pfizer is based on lost profits, an amount equal to the royalty that would be payable, pursuant to Section 5.4, on the corresponding amount (as determined by the court) of lost Net Sales of
the relevant Agreement Product(s) in the country(ies) where such infringement occurred; or (2)&nbsp;if the reward is based on reasonable royalty payments, such reward due to Pfizer (as determined by the court) shall be considered as Net Sales
subject to the applicable royalty in accordance with Section&nbsp;5.4, unless MacroGenics is separately awarded its own royalty award, and Pfizer shall receive any remaining portion of such recovery; or </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(C) With respect to any remaining portion of such recovery, if MacroGenics was the enforcing Party, MacroGenics shall receive any
remaining portion of such recovery. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) <B>Other Infringement of MacroGenics Patent Rights</B>. If the infringement of any
MacroGenics Patent Right does not fall within the category of infringements covered by the first sentence of Section 6.2.2(b), MacroGenics shall have the sole right, but not the obligation, to take action against such infringement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) <B>Infringement of Agreement T-DART Patent Rights</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(1) Pfizer shall have the sole right but not the obligation to bring an action against a Third Party infringer of an Agreement T-DART Patent Right or otherwise address such alleged infringement.
MacroGenics shall cooperate with Pfizer, at Pfizer&#146;s expense, in any such suit brought by Pfizer and shall have the right to consult with Pfizer concerning the status and prosecution of such litigation Pfizer shall incur no liability to
MacroGenics as a consequence of such litigation or any unfavorable decision resulting therefrom, including any decision holding any such Agreement T-DART Patent Right invalid or unenforceable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(2) Any recoveries obtained by Pfizer as a result of any proceeding against a Third Party
infringer shall be allocated as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(A) Such recovery shall first be used to reimburse each Party for all out-of-pocket
litigation costs in connection with such litigation paid by that Party; and </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:21%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(B) With respect to any remaining portion of
such recovery, MacroGenics shall receive either (1)&nbsp;if the reward to Pfizer is based on lost profits, an amount equal to the royalty that would be payable, pursuant to Section 5.4, on the corresponding amount (as determined by the court) of
lost Net Sales of the relevant Agreement Product(s) in the country(ies) where such infringement occurred; or (2)&nbsp;if the reward is based on reasonable royalty payments , such reward due to Pfizer (as determined by the court) shall be considered
as Net Sales subject to the applicable royalty in accordance with Section&nbsp;5.4, and Pfizer shall receive any remaining portion of such recovery. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">6.2.3. <B>Infringement of Third Party Patent Rights</B>. If the Development, Manufacture or Commercialization of any Agreement T-DART and/or Agreement Product is alleged by a Third Party to infringe a
Third Party&#146;s patent or other intellectual property rights, the Party becoming aware of such allegation shall promptly notify the other Party. The Party that is alleged to infringe the Third Party&#146;s patent or intellectual property shall
have the right to take such action as it deems appropriate in response to such allegation, and shall be solely responsible for all damages, costs and expenses in connection therewith, subject to Section <B></B>10. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.4. <B>Patent Invalidity Claim</B>. Each Party shall promptly notify the other in the event of any legal or administrative action by
any Third Party against any Subject Patent Right or Agreement T-DART Patent Right of which it becomes aware, including any opposition, interference, nullity, revocation, reexamination or compulsory license proceeding. Such action shall be treated as
part of the prosecution of such Patent Right under Section 6.2.1 unless such action is a declaratory judgment action or counterclaim in response to an assertion of infringement, in which cases such action shall be treated as an enforcement action
under Section 6.2.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.5. <B>Biosimilar Applications</B>. Each Party shall immediately give written notice to the other of
any notice received from a Third Party of an application for FDA approval under the Biologics Price Competition and Innovation Act of 2009 (or any amendment or successor statute thereto) of a Biosimilar Biologic Product referencing an Agreement
Product or any certification under a similar statutory or regulatory requirement in any non-United States country in the Territory claiming that a Subject Patent Right or an Agreement T-DART Patent Right covering any Agreement Product is invalid or
that infringement will not arise from the Development, Manufacture or Commercialization of a proposed Biosimilar </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Biologic Product by a Third Party. Upon the giving or receipt of such notice, Pfizer shall have the first right (or the sole right, in the case of an Agreement T-DART Patent Right) but not the
obligation, to bring an infringement action against such Third Party in connection with such certification. In the case of a Subject Patent Right, Pfizer shall notify MacroGenics at least <B>***</B> to the date set forth by statute or regulation of
its intent to exercise, or not exercise, this right. Any infringement action against a Third Party arising under this Section 6.2.5 shall be governed by the provisions of Section <B></B>6.2.2(b). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.6. <B>Patent Term Restoration and Extension</B>. Pfizer shall have the first right, but not the obligation, to seek, in
MacroGenics&#146;s name if so required, patent term extensions, and supplemental protection certificates and the like available under Applicable Law, including 35 U.S.C. &#167; 156 and applicable foreign counterparts, in any country in the Territory
in relation to any Subject Patent Right and Agreement Products. MacroGenics and Pfizer shall cooperate in connection with all such activities. Pfizer, its agents and attorneys will give due consideration to all suggestions and comments of
MacroGenics regarding any such activities, but in the event of a disagreement between the Parties, Pfizer will have the final decision-making authority. If Pfizer does not do so, MacroGenics may seek to extend any Subject Patent Right in relation to
Agreement Products, including through the use of supplemental protection certificates and the like, unless in Pfizer&#146;s reasonable legal determination such Subject Patent Right may not be extended under Applicable Law in relation to Agreement
Products without limiting Pfizer&#146;s right to extend any other Patent Right in relation to Agreement Products. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.7.
<B>Joint Research Agreement</B>. This Agreement shall be understood to be a joint research agreement under 35 U.S.C. &#167; 103(c)(3) entered into for the purpose of researching, identifying and Developing Agreement T-DARTs and Agreement Products.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.2.8. <B>Orange Book Information</B>. Pfizer shall be responsible for all submissions of patent information pertaining to
each Agreement Product pursuant to 21 U.S.C. &#167; 355(b)(1)(G) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products, or any similar statutory or
regulatory requirement in any non-United States country or other regulatory jurisdiction. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.3. <B>Recording</B>. If Pfizer
deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate government authorities in one or more jurisdictions in the Territory, then Pfizer shall submit to
MacroGenics any proposed evidence of such recording and the Parties will comply with the terms of Section 7.2.3 in respect of such filing. MacroGenics shall, at Pfizer&#146;s expense, execute and deliver to Pfizer any documents necessary or
desirable, in Pfizer&#146;s reasonable judgment, to complete such registration or recordation in accordance with the terms of Section 7.2.3; provided that such registration or recordation specifies
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the applicable limitations of such license, and provided further that such registration shall have no effect on the allocation of patent prosecution, maintenance and enforcement rights and
obligations set forth in this Section <B></B>6. In the event the licenses granted to Pfizer under this Agreement are terminated, Pfizer shall promptly take such actions and execute such documents as are reasonably requested by MacroGenics to cancel
such registration(s) or recordation(s) in the applicable countries with respect to the terminated license grants. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.4.
<B>Trademarks</B>. Pfizer shall, in its sole discretion, select and own all Agreement Product-related Trademarks and copyrights to be used in connection with the Commercialization of any Agreement Product hereunder. MacroGenics shall neither use nor
seek to register, anywhere in the world, any Trademarks that are confusingly similar to any Trademark used by or on behalf of Pfizer or its Affiliates or Sublicensees in connection with any Agreement Product; provided, however, that nothing in this
Section 6.4 shall be construed to prevent MacroGenics from enforcing its own trademark rights or grant Pfizer any license or right in and to any MacroGenics trademark or house mark. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CONFIDENTIALITY</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.1.
<B>Confidentiality</B>. Except to the extent expressly authorized by this Agreement, the Parties agree that, during the Term and for <B>***</B>, each Party (the &#147;<B>Receiving Party</B>&#148;) receiving any Confidential Information of the other
Party (the &#147;<B>Disclosing Party</B>&#148;) hereunder shall: (a)&nbsp;keep the Disclosing Party&#146;s Confidential Information confidential; (b)&nbsp;not disclose, or permit the disclosure of, the Disclosing Party&#146;s Confidential
Information; and (c)&nbsp;not use, or permit to be used, the Disclosing Party&#146;s Confidential Information for any purpose; provided, however, that a Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that
such Confidential Information (i)&nbsp;was already known by the Receiving Party (other than under an obligation of confidentiality to the Disclosing Party) at the time of disclosure by the Disclosing Party; (ii)&nbsp;was generally available to the
public or otherwise part of the public domain at the time of its disclosure to the Receiving Party; (iii)&nbsp;became generally available to the public or otherwise part of the public domain after its disclosure to the Receiving Party, other than
through any act or omission of the Receiving Party in breach of its obligations under this Agreement; (iv)&nbsp;was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the
Disclosing Party not to disclose such information to the Receiving Party; or (v)&nbsp;was independently discovered or developed by or on behalf of the Receiving Party without the use of any Confidential Information of the Disclosing Party. The terms
and conditions of this Agreement shall be considered Confidential Information of each Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2. <B>Authorized
Disclosure</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.1. <B>Disclosure to Party Representatives</B>. Notwithstanding the foregoing provisions of Section 7.1,
the Receiving Party may disclose Confidential Information belonging to the Disclosing Party to the Receiving Party&#146;s, its Affiliates&#146; and its Sublicensees&#146; officers, directors, employees, consultants,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
contractors and agents (collectively, &#147;<B>Representatives</B>&#148;) who (a)&nbsp;have a need to know such Confidential Information in connection with the performance of the Receiving
Party&#146;s obligations or the exercise of the Receiving Party&#146;s rights under this Agreement and (b)&nbsp;have agreed in writing to non-disclosure and non-use provisions with respect to such Confidential Information that are at least as
restrictive as those set forth in this Section <B></B>7. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.2.2. <B>Disclosure to Third Parties</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) Notwithstanding the foregoing provisions of Section&nbsp;7.1, each Party may disclose Confidential Information belonging to the other
Party: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) to Governmental Authorities (i)&nbsp;to the extent reasonably necessary to obtain or maintain INDs or Regulatory
Approvals for any Agreement T-DART or Agreement Product within the Territory, and (ii)&nbsp;in order to respond to inquiries, requests or investigations relating to this Agreement; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) to outside consultants, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in
each case to the extent reasonably necessary to develop, register or market any Agreement T-DART or Agreement Product; provided that the Receiving Party shall obtain the same confidentiality obligations from such Third Parties as it obtains with
respect to its own similar types of confidential information; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) to the extent reasonably necessary in connection with
filing or prosecuting Patent Rights as permitted by this Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) to the extent reasonably necessary in connection
with prosecuting or defending litigation as permitted by this Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) subject to Section 7.3.2, in connection with or
included in scientific presentations and publications relating to Agreement T-DARTs or Agreement Products, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to
clincialtrials.gov or PhRMA websites; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) to the extent necessary or desirable in order to enforce its rights under this
Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Notwithstanding anything to the contrary in this Section 7, MacroGenics may disclose Pfizer&#146;s
Confidential Information to: (i)&nbsp;Governmental Authorities in order to respond to inquiries, requests or investigations relating to this Agreement and (ii)&nbsp;to the extent necessary or desirable in order to enforce its rights under this
Agreement. In the event a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Party deems it reasonably necessary to disclose Confidential Information belonging to the other Party pursuant to this Section 7.2, the Disclosing Party shall to the extent possible give
reasonable advance written notice of such disclosure to the other Party and take all reasonable measures to ensure confidential treatment of such information. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">7.2.3. <B>SEC Filings and Other Disclosures</B>. Notwithstanding any provision of this Agreement to the contrary: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Either Party may disclose the terms of this Agreement to the extent required, in the reasonable opinion of such Party&#146;s legal counsel, to comply with Applicable Law, including the rules and
regulations promulgated by the SEC or any equivalent governmental agency in any country in the Territory. Notwithstanding the foregoing, before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.2.3, the Parties will
consult with one another on the terms of this Agreement to be redacted in making any such disclosure. Further, if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.2.3, such Party shall, at its own
expense, seek such confidential treatment of confidential portions of this Agreement and such other terms, as may be reasonably requested by the other Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(b) Either Party may disclose the existence and terms of this Agreement in confidence: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(i) (A)&nbsp;to its attorneys, professional accountants, and auditors, and (B)&nbsp;bankers or other financial advisors in connection with an initial public offering, other strategic transaction, or
corporate valuation for internal purposes; provided that any such disclosure to such professional accountants, auditors, bankers or other financial advisors is under an agreement to keep the terms of confidentiality and non-use no less rigorous than
the terms contained in this Agreement and to use such information solely for the applicable purpose permitted pursuant to this Section 7.2.3(b)(i); </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(ii) to potential acquirers (and their respective attorneys and professional advisors), in connection with a potential merger, acquisition or reorganization; provided that (A)&nbsp;the Party making the
disclosure has a bona fide offer from such Third Party for such a transaction, and (B)&nbsp;such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement and to use
such information solely for the purpose permitted pursuant to this Section 7.2.3(b)(i); </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) to existing or potential investors, lenders or permitted assignees of such Party (and
their respective attorneys and professional advisors); provided that such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than the terms contained in this Agreement; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv) to potential licensees or sublicensees of such Party (and their respective attorneys and professional advisors); provided that
(A)&nbsp;such disclosure shall not include any financial terms or identify any Research Project Targets or Reserved Targets; and (B)&nbsp;such disclosure is under an agreement to keep the terms of confidentiality and non-use no less rigorous than
the terms contained in this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3. <B>Public Announcements; Publications</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3.1. <B>Announcements</B>. Except as may be expressly permitted under Section&nbsp;7.2.3, neither Party will make any public
announcement regarding this Agreement without the prior written approval of the other Party. For the sake of clarity, nothing in this Agreement shall prevent (a)&nbsp;either Party from making any public disclosure relating to this Agreement if the
contents of such public disclosure has previously been made public other than through a breach of this Agreement by the issuing Party or its Affiliates; (b)&nbsp;Pfizer from making any scientific publication (in accordance with Section 7.3.2) or
public announcement with respect to any Agreement Product under this Agreement; or (c)&nbsp;MacroGenics from making any public announcement approved in advance by Pfizer with respect to any Milestone Payment received by MacroGenics hereunder, which
approval may not be unreasonably withheld or delayed; provided, however, that, except as permitted under Section 7.2, Pfizer shall not disclose any of MacroGenics&#146;s Confidential Information in any such publication or announcement without
obtaining MacroGenics&#146;s prior written consent to do so. The Parties agree that MacroGenics may release the announcement attached hereto as <U>Exhibit </U><U>7.3.1</U> regarding the signing of this Agreement following the Effective Date.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.3.2. <B>Publications</B>. During the Term, each Party shall submit to the other Party (the &#147;<B>Non-Disclosing
Party</B>&#148;) for review and approval any proposed academic, scientific and medical publication or public presentation which contains the Non-Disclosing Party&#146;s Confidential Information. In addition, MacroGenics shall submit to Pfizer for
review and approval any proposed publication or public presentation relating to the Research Program. In both instances, such review and approval will be conducted for the purposes of preserving the value of the MacroGenics Technology, the Pfizer
Technology, the Joint Technology, the rights granted to Pfizer hereunder and determining whether any portion of the proposed </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
publication or presentation containing the Non-Disclosing Party&#146;s Confidential Information should be modified or deleted. Written copies of such proposed publication or presentation required
to be submitted hereunder shall be submitted to the Non-Disclosing Party no later than <B>***</B> before submission for publication or presentation (the &#147;<B>Review Period</B>&#148;). The Non-Disclosing Party shall provide its comments with
respect to such publications and presentations within <B>***</B> after its receipt of such written copy. The Review Period may be extended for an additional <B>***</B> in the event the Non-Disclosing Party can, <B>***</B> after receipt of the
written copy, demonstrate reasonable need for such extension including for the preparation and filing of patent applications. MacroGenics and Pfizer will each comply with standard academic practice regarding authorship of scientific publications and
recognition of contribution of other parties in any publication governed by this Section <B></B>7.3.2. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.4. <B>Obligations in
Connection with Change of Control</B>. If MacroGenics is subject to a Change of Control, MacroGenics will, and it will cause its Affiliates and Representatives to, ensure that no Confidential Information of Pfizer (except as may be expressly
permitted under Section&nbsp;7.2.3 with respect to the terms of this Agreement and with respect to any royalty statements provided by Pfizer pursuant to Section 5.5.2) is released to (a)&nbsp;any Affiliate of MacroGenics that becomes an Affiliate as
a result of the Change of Control or (b)&nbsp;any Representatives of MacroGenics (or of the relevant surviving entity of such Change of Control) who become Representatives as a result of the Change of Control, unless such Representatives have signed
individual confidentiality agreements which include equivalent obligations to those set out in this Section <B></B>7. If any Change of Control of MacroGenics occurs, MacroGenics shall promptly notify Pfizer, <B>***</B> </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>REPRESENTATIONS AND WARRANTIES. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.1. <B>Mutual Representations and Warranties</B>. Each of MacroGenics and Pfizer hereby represents and warrants to the other Party that: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1.1. it is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1.2. the execution, delivery and performance of this Agreement by such Party has been duly authorized by all requisite action under the
provisions of its charter, bylaws and other organizational documents, and does not require any action or approval by any of its shareholders or other holders of its voting securities or voting interests; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1.3. it has the power and authority to execute and deliver this Agreement and to perform its obligations hereunder </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1.4. this Agreement has been duly executed and is a legal, valid and Binding Obligation on each Party, enforceable against such Party in
accordance with its terms; and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.1.5. the execution, delivery and performance by such Party of this Agreement and its
compliance with the terms and provisions hereof does not and will not conflict with or result in a breach of or default under any Binding Obligation existing as of the Effective Date. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2. <B>Representations and Warranties of MacroGenics</B>. MacroGenics hereby represents and warrants to Pfizer that as of the Effective
Date: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.1. MacroGenics is the sole and exclusive owner of the MacroGenics Technology, all of which is free and clear of any
claims, liens, charges or encumbrances; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.2. it has and will have the full right, power and authority to grant all of the
right, title and interest in the licenses and other rights granted or to be granted to Pfizer or Pfizer&#146;s Affiliates under this Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.2.3. (a)&nbsp;<U>Schedule </U><U>8.2.3</U> sets forth a true and complete list of all Patent Rights owned or otherwise Controlled by MacroGenics or its Affiliates that relate to the MacroGenics
Technology, (b)&nbsp;each such Patent Right remains in full force and effect and (c)&nbsp;MacroGenics or its Affiliates have timely paid all filing and renewal fees payable with respect to such Patent Rights; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.4. to its best knowledge: (a)&nbsp;the MacroGenics Patent Rights, are, or, upon issuance, will be, valid and enforceable patents and
(b)&nbsp;no Third Party (i)&nbsp;is infringing any MacroGenics Patent Right or (ii)&nbsp;has challenged or threatened to challenge the extent, validity or enforceability of any MacroGenics Patent Right (including, by way of example, through the
institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority); </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.5. to its best knowledge, it has complied with all Applicable Laws, including any disclosure requirements, in connection with the
filing, prosecution and maintenance of the MacroGenics Patent Rights; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.6. MacroGenics has independently developed all
MacroGenics Know-How or otherwise has a valid right to use, and to permit Pfizer, Pfizer&#146;s Affiliates and Pfizer&#146;s Sublicensees to use, the MacroGenics Know-How for all permitted purposes under this Agreement; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.7. it has obtained from all inventors of MacroGenics Technology existing as of the Effective Date, valid and enforceable agreements
assigning to MacroGenics each such inventor&#146;s entire right, title and interest in and to all such MacroGenics Technology; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.8. except as expressly disclosed in <U>Schedule 8.2.8</U>, no MacroGenics Technology
existing as of the Effective Date is subject to any funding agreement with any government or Governmental Authority; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.9.
neither MacroGenics nor any of its Affiliates are subject to any agreement or obligation that limits any ownership or license right granted to Pfizer or its Affiliates under this Agreement, including any right granted to Pfizer or its Affiliates to
access, practice, grant any licenses or sublicenses under, or provide Pfizer&#146;s Sublicensees with access to any intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that
would, but for such agreement or obligation, be included in the rights licensed or assigned to Pfizer or its Affiliates pursuant to this Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">8.2.10. (a)&nbsp;there are no MacroGenics Third Party Agreements and (b)&nbsp;no Third Party has any right, title or interest in or to, or any license under, any MacroGenics Technology; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.11. it has disclosed to Pfizer all provisions of <B>***</B> relevant to determining the extent of any and all limitations on
Pfizer&#146;s rights under this Agreement necessitated by MacroGenics&#146;s obligations under <B>***</B>; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.12. except as
disclosed to Pfizer prior to the Effective Date in written form, referencing this Section 8.2.12 of the Agreement, to the best of its knowledge, the use, practice or application by MacroGenics or Pfizer (or their respective Affiliates or
Sublicensees) as contemplated under this Agreement of any MacroGenics Technology relating to T-DARTs (a)&nbsp;does not and will not infringe any issued patent of any Third Party or (b)&nbsp;would not infringe the claims of any published Third Party
patent application when and if such claims were to issue; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.2.13. except as expressly disclosed in <U>Schedule 8.2.13</U>,
there is no (a)&nbsp;claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to the best knowledge of MacroGenics, threatened against MacroGenics
or any of its Affiliates or (b)&nbsp;judgment or settlement against or owed by MacroGenics or any of its Affiliates, in each case in connection with the MacroGenics Technology or relating to the transactions contemplated by this Agreement.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3. <B>Representations and Warranties of Pfizer</B>. Pfizer hereby represents and warrants to MacroGenics that as of the
Effective Date: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.3.1. there is no (a)&nbsp;claim, demand, suit, proceeding, arbitration, inquiry, investigation or other
legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to the best knowledge of Pfizer, threatened against Pfizer or any of its Affiliates or (b)&nbsp;judgment or settlement against or owed by Pfizer or any of its
Affiliates, in each case in connection with the Pfizer Proprietary Materials or relating to the transactions contemplated by this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4. <B>MacroGenics Covenants</B>. In addition to the covenants made by MacroGenics
elsewhere in this Agreement, and subject to the provisions of Section 6, MacroGenics hereby covenants to Pfizer that, from the Effective Date until expiration or termination of this Agreement: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4.1. it will (a)&nbsp;not enter into any MacroGenics Third Party Agreement that is inconsistent with (i)&nbsp;the rights granted to
Pfizer or Pfizer&#146;s Affiliates hereunder or (ii)&nbsp;MacroGenics&#146;s ability to fully perform its obligations hereunder; (b)&nbsp;not amend or otherwise modify any MacroGenics Third Party Agreement (including any Disclosed Third Party
Agreement) or consent or waive rights with respect thereto in any manner that (i)&nbsp;is inconsistent with the rights granted to Pfizer or Pfizer&#146;s Affiliates hereunder or (ii)&nbsp;MacroGenics&#146;s ability to fully perform its obligations
hereunder; (c)&nbsp;promptly furnish Pfizer with copies of all (i)&nbsp;amendments to the Disclosed Third Party Agreements and (ii)&nbsp;MacroGenics Third Party Agreements and related amendments executed following the Effective Date;
(d)&nbsp;remain, and cause its Affiliates to remain, in compliance in all material respects with all MacroGenics Third Party Agreements (including Disclosed Third Party Agreements); and (e)&nbsp;furnish Pfizer with copies of all notices received by
MacroGenics or its Affiliates relating to any alleged breach or default by MacroGenics or its Affiliates under any MacroGenics Third Party Agreement (including and Disclosed Third Party Agreement) within fifteen (15)&nbsp;Business Days after receipt
thereof; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4.2. it will not enter into or otherwise allow itself or its Affiliates to be subject to any agreement or
arrangement which limits the ownership rights of Pfizer or its Affiliates with respect to, or limits the ability of Pfizer or its Affiliates to grant a license, sublicense or access, or provide or provide access or other rights in, to or under, any
intellectual property right or material (including any Patent Right, Know-How or other data or information), in each case, that would, but for such agreement or arrangement, be included in the rights licensed or assigned to Pfizer or its Affiliates
pursuant to this Agreement; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4.3. it will maintain valid and enforceable agreements with all Persons acting by or on behalf
of MacroGenics or its Affiliates under this Agreement which require such Persons to assign to MacroGenics their entire right, title and interest in and to all MacroGenics Technology and Joint Technology; and </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.4.4. in the conduct of any Research Project, unless MacroGenics receives prior written consent from Pfizer, MacroGenics shall neither
use funding from any Government Authority nor use CHO-S cells. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.5. <B>Representation by Legal Counsel</B>. Each Party hereto
represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree
that no presumption shall exist or be implied against the Party which drafted such terms and provisions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.6. <B>Disclaimer</B>. THE FOREGOING REPRESENTATIONS AND WARRANTIES OF EACH PARTY ARE IN
LIEU OF ANY OTHER REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, ANY IMPLIED WARRANTY OF NON-INFRINGEMENT OR ANY IMPLIED WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE, ALL OF WHICH ARE
HEREBY SPECIFICALLY EXCLUDED AND DISCLAIMED. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>GOVERNMENT APPROVALS; TERM AND TERMINATION.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.1. <B>Government Approvals</B>. Each of MacroGenics and Pfizer shall cooperate with the other Party and use Commercially Reasonable Efforts to make all registrations, filings and applications, to give
all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of
the transactions as contemplated hereby. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.2. <B>Term</B>. The term of this Agreement shall commence on the Effective Date and
shall extend, unless this Agreement is terminated earlier in accordance with this Section 9, until the expiration of the last-to-expire of all Royalty Terms with respect to all Agreement Products (the &#147;<B>Term</B>&#148;). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.3. <B>Termination by Either Party for Cause</B>. Either Party may terminate this Agreement, in its entirety or, at the terminating
Party&#146;s option, on an Agreement T-DART-by-Agreement T-DART basis, at any time during the Term by giving written notice to the other Party if the other Party commits a material breach of its obligations under this Agreement and such breach
remains uncured for <B>***</B>, measured from the date written notice of such breach is given to the breaching Party; provided, however, that if such breach (other than breach of an undisputed payment obligation) is not susceptible of cure within
the stated period and the breaching Party uses diligent, good faith efforts to cure such breach, the stated period shall be extended by an <B>***</B> Notwithstanding the foregoing, a Party shall have the right to terminate this Agreement pursuant to
this Section 9.3 in part with respect to an individual Agreement T-DART only if the other Party&#146;s material breach giving rise to such termination right relates solely to such Agreement T-DART. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.4. <B>Termination by Pfizer without Cause</B>. Pfizer shall have the right to terminate the Agreement at any time for any or no reason,
on a Research Project Target-by-Research Project Target basis, by providing <B>***</B> advance written notice of such termination to MacroGenics; provided that, during the <B>***</B>, Pfizer will retain at least one Research Project Target under the
Research Program. <B>***</B>, Pfizer shall have the right, exercisable upon <B>***</B> prior written notice to MacroGenics, to terminate this Agreement at any time for any or no reason either (a)&nbsp;in its entirety or (b)&nbsp;on a Research
Project Target-by-Research Project Target basis. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5. <B>Effects of Termination</B>. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.1. <B>Effect of Termination by Pfizer for Cause</B>. If Pfizer terminates this Agreement with respect to any or all Agreement T-DARTS
pursuant to Section 9.3 (each, a &#147;<B>Terminated T-DART</B>&#148;): </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) all work under the applicable Research Plan(s)
with respect to each Terminated T-DART shall cease; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) (i)&nbsp;all licenses granted to Pfizer with respect to such
Terminated T-DART and any Agreement Product incorporating such Terminated T-DART (&#147;<B>Terminated Agreement Product</B>&#148;), including licenses under Section 4.1, shall continue and shall become perpetual, irrevocable licenses;
(ii)&nbsp;Pfizer&#146;s rights under Section 4.1 shall remain in full force and effect with respect to any such Terminated T-DART or Terminated Agreement Product; and (iii)&nbsp;Pfizer shall have no further obligations to MacroGenics under this
Agreement with respect to any such Terminated T-DART or Terminated Agreement Product, other than (x)&nbsp;obligations to pay Milestones and royalties with respect to each Terminated Target and Net Sales of Agreement Products incorporating each
Terminated T-DART, as applicable, in an amount equal to <B>***</B> of the amount that would otherwise have been payable under this Agreement, and (y)&nbsp;those other obligations that expressly survive termination in accordance with Section 9.7
shall survive; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) MacroGenics shall remain entitled to receive payments that accrued before the effective date of such
termination; </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) nothing in this Section 9.5.1 shall limit any other remedy Pfizer may have for MacroGenics&#146;s breach of
this Agreement; and </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) the rights and obligations of the Parties with respect to all Agreement T-DARTs other than any such
Terminated T-DART shall remain in full force and effect. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.2. <B>Effect of Termination by MacroGenics for Cause or by Pfizer
without Cause</B>. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(a) If MacroGenics terminates this Agreement with respect to any Agreement T-DARTs pursuant to
Section&nbsp;9.3, or if Pfizer terminates this Agreement with respect to any Agreement T-DARTs pursuant to Section 9.4: (i)&nbsp;all licenses granted by MacroGenics to Pfizer under Section 4.1 with respect to any such Agreement T-DART and any
Agreement Product containing such Agreement T-DART shall terminate and (ii)&nbsp;on MacroGenics&#146;s written request within <B>***</B> of such termination, Pfizer shall reassign to MacroGenics all of the right, title and interest in Agreement
T-DART IP that was assigned by MacroGenics to Pfizer pursuant to Section 4.1.2 with respect to such Agreement T-DART, and in any Agreement </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
T-DART Patent Rights relating thereto that have been filed (unless another alternative approach has been agreed by the Parties in view of prosecution exigencies), any such assignment to be
completed within <B>***</B> of such request. After such assignment, or if MacroGenics declines to request assignment or such <B>***</B> period expires without a request by MacroGenics, Pfizer will have no further obligations to prosecute or maintain
such Agreement T-DART Patent Rights or to pay any costs related thereto. All rights and obligations with respect to all other Agreement T-DARTs and Agreement Products shall remain in full force and effect (and for avoidance of doubt, any Agreement
T-DART IP and Agreement T-DART Patent Rights assigned to MacroGenics pursuant to this Section 9.5.2(a) will be included in MacroGenics Technology and MacroGenics Patent Rights, respectively, for the purposes of such other Agreement T-DARTs and
Agreement Products). MacroGenics shall have a fully paid up, royalty free non-exclusive license under any such Agreement T-DART Patent Right not assigned to MacroGenics pursuant to the provisions of this Section 9.5.2(a). </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If MacroGenics terminates this Agreement in its entirety pursuant to Section 9.3, or if Pfizer terminates this Agreement in its
entirety pursuant to Section 9.4: (i)&nbsp;all licenses granted by MacroGenics to Pfizer under Section 4.1 shall terminate, (ii)&nbsp;on MacroGenics&#146;s written request within thirty (30)&nbsp;days of such termination, Pfizer shall reassign to
MacroGenics all of MacroGenics&#146; right, title and interest in Agreement T-DART IP that was assigned by MacroGenics to Pfizer pursuant to Section 4.1.2, and in any Agreement T-DART Patent Rights relating thereto that have been filed (unless
another alternative approach has been agreed by the Parties in view of prosecution exigencies), any such assignment to be completed within <B>***</B> of such request, and MacroGenics shall have no further obligations to Pfizer under this Agreement
other than those obligations that expressly survive termination in accordance with Section 9.7. After assignment of any Agreement T-DART Patent Rights pursuant to this Section 9.5.2(b), or if MacroGenics declines to request assignment or <B>***</B>
expires without a request by MacroGenics, Pfizer will have no further obligations to prosecute or maintain such Agreement T-DART Patent Rights or to pay any costs related thereto. MacroGenics shall have a fully paid up, royalty free non-exclusive
license under any Agreement T-DART Patent Right not assigned to MacroGenics pursuant to the provisions of this Section 9.5.2(b). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(c) For the avoidance of doubt, if MacroGenics terminates this Agreement with respect to any Agreement T-DARTs pursuant to Section 9.3, or if Pfizer terminates this Agreement with respect to any Agreement
T-DARTs pursuant to Section 9.4, in each case including all Agreement T-DARTs in the event that this Agreement is terminated in its entirety, (i)&nbsp;all rights granted by Pfizer to MacroGenics under Section 4.2
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shall survive such termination and (ii)&nbsp;any such Agreement T-DART will no longer be considered to be an Agreement T-DART for the purpose of this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Nothing in this Section 9.5.3 shall limit MacroGenics&#146;s right to receive payments that accrued before the effective date of
termination or limit any other remedy MacroGenics may have for Pfizer&#146;s breach of this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(e) At
MacroGenics&#146;s request within thirty (30)&nbsp;days of any termination of this Agreement, Pfizer shall negotiate with MacroGenics regarding the possible grant to MacroGenics of some or all of the following rights, it being understood and agreed
that neither Party shall have any obligation to enter into any such arrangement and that if agreement is not reached within <B>***</B> after such request there shall be no further obligation on either Party to conduct further negotiations:
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i) <U>Grant Back License with Respect to MacroGenics-Derived Terminated Agreement T-DARTs</U>. The grant by Pfizer to
MacroGenics of an exclusive or non-exclusive, worldwide, royalty-bearing license under the Pfizer Collaboration Patent Rights to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized, import,
have imported, export and have exported any MacroGenics-Derived Terminated Agreement T-DART and, in each case in the form in which such MacroGenics-Derived Terminated Agreement T-DART or related Agreement Product exists as of termination, for a
commercially reasonable royalty rate and on terms and conditions regarding payment provisions based on the provisions of this Agreement regarding such matters as royalty term, adjustments, reports, audits and the like). &#147;<B>Pfizer Collaboration
Patent Right</B>&#148; means any Pfizer Patent Right covering or claiming any invention made solely by Pfizer or any of its Affiliates in the course of performing the Research Program and &#147;<B>MacroGenics-Derived Terminated Agreement
T-DART</B>&#148; means any Agreement T-DART for which (A)&nbsp;this Agreement is terminated by MacroGenics pursuant to Section&nbsp;9.3, or by Pfizer pursuant to Section 9.4 and (B)&nbsp;MacroGenics provided Antibodies to Pfizer for the Research
Project for such Agreement T-DART. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii) <U>Inventory</U>. MacroGenics obtaining Pfizer&#146;s inventory of any such
MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii) <U>Supply</U>. Pfizer supplying MacroGenics with quantities of such
MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product for a limited period of time. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)
<U>Trademarks</U>. Pfizer providing with MacroGenics with certain rights in and to the Trademark(s) used in connection with any such MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product (but not any Pfizer house marks or
any trademark containing the word &#147;Pfizer&#148;). </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v) <U>Regulatory Filings and Approvals</U>. Pfizer providing
MacroGenics with certain rights in and regulatory filings and approvals with respect to and such MacroGenics-Derived Terminated Agreement T-DART and/or related Agreement Product. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:17%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(vi) <U>No Obligation</U>. For the avoidance of doubt, the description here of these possible arrangements shall not imply any obligation
on either Party to enter into any such arrangement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.3. <B>Satisfaction of Obligations During Notice Period</B>. During the
period from providing a notice of termination pursuant to Section 9.4 through the termination of the Agreement, the Parties shall continue to perform their obligations under this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.5.4. <B>Pending Dispute Resolution</B>. If a Party gives notice of termination under Section 9.3 and the other Party disputes whether
such notice was proper, then the issue of whether this Agreement has been terminated shall be resolved in accordance with Section 11.9 and each Party shall continue to perform its obligations hereunder pending the conclusion of such dispute
resolution proceeding. If as a result of such dispute resolution process it is determined that the notice of termination was proper, then such termination shall be effective immediately. If as a result of such dispute resolution process it is
determined that the notice of termination was improper, then no termination shall have occurred and this Agreement shall remain in effect. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.6. <B>Disposition of Inventories of Products</B>. Following termination of this Agreement with respect to one or more Agreement T-DARTs, Pfizer, its Affiliates and its Sublicensees shall have the right
to continue to sell their existing inventories of Agreement Product(s) incorporating such Agreement T-DART(s) that have received Regulatory Marketing Approval prior to such termination for a period not to exceed <B>***</B> after the effective date
of such termination or expiration and Pfizer shall pay any royalties payable in connection with such sales in accordance with Sections 5.4.4 and 5.5. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">9.7. <B>Survival of Certain Obligations</B>. Expiration or termination of this Agreement shall not relieve the Parties of any obligation that accrued before such expiration or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
termination. The following provisions shall survive expiration or termination of this Agreement: Sections 1, 2.11, 2.12, 2.13.3, 2.13.4, 2.13.5, 4.3, 5.2.5, 5.6, 5.7, 6.1.1, 6.2.1(e), 7, 8.6,
9.5, 9.6, 9.7, 9.8, 10 and 11. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.8. <B>Right to Termination of Research Project(s) or Research Program by Pfizer upon Change
of Control of MacroGenics</B>. If a Change of Control of MacroGenics is consummated during the Research Term, Pfizer shall have the right to terminate any Research Project or the Research Program in its entirety, at any time, upon written notice to
MacroGenics within 30 days after consummation of such Change of Control of MacroGenics. Such termination of any Research Project or the Research Program (a)&nbsp;shall not constitute termination of this Agreement, (b)&nbsp;shall not affect the
Parties&#146; rights and obligations under this Agreement other than those relating to such Research Project or the Research Program and (c)&nbsp;shall not relieve either Party of any obligation that arose prior to such termination. Following any
such termination of any Research Project or the Research Program, as applicable, Pfizer shall have no further funding obligation under Section 2 with respect to such Research Project or the Research Program, as applicable, other than that which may
have accrued prior to such termination. For the avoidance of doubt, in the event that Pfizer terminates a Research Project or the Research Program in accordance with this Section 9.8, such termination will not be deemed to be a termination for cause
under Section 9.3 or a termination without cause under Section 9.4, and the only effects of such termination are as set forth in this Section 9.8. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LIMITATION ON LIABILITY, INDEMNIFICATION AND INSURANCE.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.1. <B>No Consequential Damages</B>. Except with respect to liability arising from a breach of Section 7, or to the extent such Party may be required to indemnify the other Party under this Section 10,
in no event will either Party, its Affiliates, its Sublicensees or any of its, its Affiliates&#146; or its Sublicensees&#146; respective Representatives be liable under this Agreement for any special, indirect, incidental, consequential or punitive
damages, whether in contract, warranty, tort, negligence, strict liability or otherwise, including loss of profits or revenue suffered by either Party or any of its respective Affiliates, agents or representatives. Without limiting the generality of
the foregoing, &#147;consequential damages&#148; will be deemed to include, and neither Party will be liable to the other Party or any of such other Party&#146;s Affiliates, Representatives or stockholders for any damages based on or measured by
loss of projected or speculative future sales of the Agreement Products, any Milestone Payment due upon any unachieved event under Section 5.2, any unearned royalties under Section 5.4 or any other unearned, speculative or otherwise contingent
payments provided for in this Agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2. <B>Indemnification by Pfizer</B>. Pfizer will indemnify, defend and hold harmless
MacroGenics, each of its Affiliates, and each of its and its Affiliates&#146; employees, officers, directors and agents (each, a &#147;<B>MacroGenics Indemnified Party</B>&#148;) from and against any and all liability, loss, damage, expense
(including reasonable attorneys&#146; fees and expenses) and cost (collectively, a &#147;<B>Liability</B>&#148;) that the MacroGenics Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.2.1. the Development, Manufacture, Commercialization or use of any Agreement T-DART or Agreement Product by, on behalf of, or under the
authority of, Pfizer (other than by any MacroGenics Indemnified Party), other than claims for which MacroGenics is required to indemnify Pfizer pursuant to Section 10.3; or </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.2.2. the material breach by Pfizer of any of its representations, warranties or covenants set forth in Section <B></B>2.13.1, 8.1 or 8.3; </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">except, in each case, to the extent caused by the negligence, recklessness or intentional acts of MacroGenics or any MacroGenics
Indemnified Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.3. Indemnification by MacroGenics. MacroGenics will indemnify, defend and hold harmless Pfizer, its
Affiliates, Sublicensees, contractors, distributors and each of its and their respective employees, officers, directors and agents (each, a &#147;<B>Pfizer Indemnified Party</B>&#148;) from and against any and all Liabilities that the Pfizer
Indemnified Party may be required to pay to one or more Third Parties resulting from or arising out of the material breach by MacroGenics of any of its representations, warranties or covenants set forth in Section 8.1 or 8.2, except to the extent
caused by the negligence, recklessness or intentional acts of Pfizer or any Pfizer Indemnified Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4. <B>Procedure</B>.
</FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.1. <B>Notice</B>. Each Party will notify the other Party in writing in the event it becomes aware of a claim for which
indemnification may be sought hereunder. In the event that any Third Party asserts a claim or other proceeding (including any governmental investigation) with respect to any matter for which a Party (the &#147;<B>Indemnified Party</B>&#148;) is
entitled to indemnification hereunder (a &#147;<B>Third Party Claim</B>&#148;), then the Indemnified Party shall promptly notify the Party obligated to indemnify the Indemnified Party (the &#147;<B>Indemnifying Party</B>&#148;) thereof; provided,
however, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced
thereby. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.4.2. <B>Control</B>. Subject to Pfizer&#146;s right to control any actions described in Sections 6.2 (even where
MacroGenics is the Indemnifying Party), the Indemnifying Party shall have the right, exercisable by notice to the Indemnified Party within <B>***</B> after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third
Party Claim, to assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the
Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a)&nbsp;the Indemnifying Party has sufficient financial resources, in the reasonable judgment of the Indemnified Party, to satisfy the amount of any adverse
monetary judgment that is sought, and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
(b) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party shall be solely obligated to satisfy and discharge
the Third Party Claim in full (the conditions set forth in clauses (a)&nbsp;and (b)&nbsp;above are collectively referred to as the &#147;<B>Litigation Conditions</B>&#148;). Within <B>***</B> after the Indemnifying Party has given notice to the
Indemnified Party of its exercise of its right to defend a Third Party Claim, the Indemnified Party shall give notice to the Indemnifying Party of any objection thereto based upon the Litigation Conditions. If the Indemnified Party reasonably so
objects, the Indemnified Party shall continue to defend the Third Party Claim, at the expense of the Indemnifying Party, until such time as such objection is withdrawn. If no such notice is given, or if any such objection is withdrawn, the
Indemnifying Party shall be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the
Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate, and shall cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the Third
Party Claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party. In the event that the
Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party&#146;s intent to defend any Third Party Claim within ten <B>***</B> after notice thereof, the Indemnified Party may
(without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party&#146;s expense (including reasonable, out-of-pocket attorneys&#146; fees and costs and expenses of enforcement
or defense). The Indemnifying Party or the Indemnified Party, as the case may be, shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not
control, at its own expense, the defense of any Third Party Claim that the other Party is defending as provided in this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">10.4.3. <B>Settlement</B>. The Indemnifying Party shall not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take,
or to forbear to take, any action or declare that any Patent Right or Know-How is invalid or not properly owned or licensed by the Indemnified Party. The Indemnified Party shall have the sole and exclusive right to settle any Third Party Claim, on
such terms and conditions as it deems reasonably appropriate, to the extent such Third Party Claim involves equitable or other non-monetary relief, but shall not have the right to settle such Third Party Claim to the extent such Third Party Claim
involves monetary damages without the prior written consent of the Indemnifying Party. Each of the Indemnifying Party and the Indemnified Party shall not make any admission of liability in respect of any Third Party Claim without the prior written
consent of the other Party, and the Indemnified Party shall use reasonable efforts to mitigate Liabilities arising from such Third Party Claim. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10.5. <B>Insurance</B>. Each Party shall obtain and maintain, during the Term, commercial
general liability insurance, including products liability insurance, with reputable and financially secure insurance carriers (or pursuant to a program of self-insurance reasonably satisfactory to the other Party) to cover its indemnification
obligations under Section 10.2 or Section 10.3, as applicable, in each case with limits of not less than <B>***</B> and in the aggregate. Insurance shall be procured with carriers having an A.M. Best Rating of A-VII or better. The provisions of this
Section 10.5 will survive for <B>***</B>. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MISCELLANEOUS.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.1.
<B>Assignment</B>. MacroGenics may not assign this Agreement or any interest hereunder without the prior written consent of Pfizer, which consent will not be unreasonably withheld or delayed. Pfizer may not assign this Agreement or any interest
hereunder without the prior written consent of MacroGenics, which consent will not be unreasonably withheld or delayed. Notwithstanding the foregoing, this Agreement may be assigned as follows: (a)&nbsp;either Party may assign its rights and
obligations under this Agreement by way of sale of itself or the sale of the portion of its business to which this Agreement relates, through merger, sale of assets or sale of stock or ownership interest, provided that the assignee shall expressly
agree to be bound by such Party&#146;s obligations under this Agreement and that such sale is not primarily for the benefit of its creditors and (b)&nbsp;either Party may assign its rights and obligations under this Agreement to any of its
Affiliates, provided that the assignee shall expressly agree to be bound by such Party&#146;s obligations under this Agreement and that such Party shall remain liable for all of its rights and obligations under this Agreement. This Agreement shall
be binding upon the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed to include the names of such Party&#146;s successors and permitted assigns to the extent necessary to carry out the intent
of this Agreement. Any assignment not in accordance with this Section 11.1 shall be void. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.2. <B>Further Actions</B>. Each
Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes and intent of the Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.3. <B>Force Majeure</B>. Each Party shall be excused from the performance of its obligations under this Agreement to the extent that
such performance is prevented by force majeure (defined below) and the nonperforming Party promptly provides notice of the prevention to the other Party. Such excuse shall be continued so long as the condition constituting force majeure continues
and the nonperforming Party takes Commercially Reasonable Efforts to remove the condition. For purposes of this Agreement, &#147;force majeure&#148; shall include conditions beyond the control of the Parties, including an act of God, voluntary or
involuntary compliance with any regulation, Law or order of any government, war, act of terror, civil commotion, labor strike or lock-out, epidemic, failure or default of public utilities or common carriers, destruction of production facilities or
materials by fire, earthquake, storm or like catastrophe. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.4. <B>Notices</B>. Any notice or notification required or permitted to be provided
pursuant to the terms and conditions of this Agreement (including any notice of force majeure, breach, termination, change of address, etc.) shall be in writing and shall be deemed given upon receipt if delivered personally or by facsimile
transmission (receipt verified), five&nbsp;(5) days after deposited in the mail if mailed by registered or certified mail (return receipt requested) postage prepaid, or on the next Business Day if sent by overnight delivery using a nationally
recognized express courier service and specifying next Business Day delivery (receipt verified), to the Parties at the following addresses or facsimile numbers (or at such other address or facsimile number for a Party as shall be specified by like
notice, provided, however, that notices of a change of address shall be effective only upon receipt thereof): </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All
correspondence to Pfizer shall be addressed as follows: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Worldwide Research&nbsp;&amp; Development </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">235 East 42</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">nd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Street </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">New York, NY 10017 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">with a copy to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">445 Eastern Point Road, MS 8200-30 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Groton, CT </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>***</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All correspondence to MacroGenics shall be addressed as follows: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1500 East Gude Drive Rockville, MD 20850 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>***</B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Facsimile: *** </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">with a copy to: </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Wilmer Cutler Pickering Hale and Dorr LLP </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">399 Park Avenue </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, NY 10022 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attention: <B>*** </B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:13%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Facsimile: *** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.5. <B>Amendment</B>. No amendment, modification or supplement of any provision of this
Agreement shall be valid or effective unless made in writing and signed by a duly authorized officer of each Party. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.6.
<B>Waiver</B>. No provision of this Agreement shall be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the
waiving Party. The waiver by either of the Parties of any breach of any provision hereof by the other Party shall not be construed to be a waiver of any succeeding breach of such provision or a waiver of the provision itself. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.7. <B>Severability</B>. If any clause or portion thereof in this Agreement is for any reason held to be invalid, illegal or
unenforceable, the same shall not affect any other portion of this Agreement, as it is the intent of the Parties that this Agreement shall be construed in such fashion as to maintain its existence, validity and enforceability to the greatest extent
possible. In any such event, this Agreement shall be construed as if such clause of portion thereof had never been contained in this Agreement, and there shall be deemed substituted therefor such provision as will most nearly carry out the intent of
the Parties as expressed in this Agreement to the fullest extent permitted by Applicable Law. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.8. <B>Descriptive
Headings</B>. The descriptive headings of this Agreement are for convenience only and shall be of no force or effect in construing or interpreting any of the provisions of this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.9. <B>Dispute Resolution</B>. If any dispute or disagreement arises between Pfizer and MacroGenics in respect of this Agreement, they
shall follow the following procedures in an attempt to resolve the dispute or disagreement: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.9.1. The Party claiming that
such a dispute exists shall give notice in writing (&#147;<B>Notice of Dispute</B>&#148;) to the other Party of the nature of the dispute. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.9.2.<B>***</B> after receipt of a Notice of Dispute, the Pfizer Alliance Manager and the MacroGenics Alliance Manager shall meet in person or by teleconference and exchange written summaries
reflecting, in reasonable detail, the nature and extent of the dispute, and at this meeting they shall use their reasonable endeavors to resolve the dispute. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.9.3. If the Alliance Managers are unable to resolve the dispute during the meeting described in Section 11.9.2 or if for any reason such meeting does not take place within the period specified in
Section 11.9.2, then the dispute will be referred to the JSC which shall meet no later than <B>***</B> following the initial receipt of the Notice of Dispute and use reasonable endeavors to resolve the dispute. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.9.4. If the JSC is unable to resolve the dispute during the meeting described in Section 11.9.3 or if for any reason such meeting does
not take place within the period specified in Section 11.9.3, then the Senior Executives shall meet at a mutually agreed-upon time and location for the purpose of resolving such dispute. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.9.5. If, within <B>***</B> initial receipt of the Notice of Dispute, the dispute has not
been resolved, or if, for any reason, the meeting described in Section 11.9.4 has not been held within <B>***</B> following initial receipt of the Notice of Dispute, then the Parties agree that either Party may initiate litigation to resolve the
dispute. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.9.6. Notwithstanding any provision of this Agreement to the contrary, either Party may immediately initiate
litigation in any court of competent jurisdiction seeking any remedy at law or in equity, including the issuance of a preliminary, temporary or permanent injunction, to preserve or enforce its rights under this Agreement. The provisions of this
Section 11.9 will survive for <B>***</B> from the date of termination or expiration of this Agreement. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.10. <B>Governing
Law</B>. This Agreement, and all claims arising under or in connection therewith, shall be governed by and interpreted in accordance with the substantive laws of <B>***</B>, without regard to conflict of law principles thereof. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.11. <B>Consent to Jurisdiction</B>. Each Party to this Agreement, by its execution hereof, (a)&nbsp;hereby irrevocably submits to the
exclusive jurisdiction of the state courts of the State <B>***</B> of any and all actions, suits or proceedings arising in whole or in part out of, related to, based upon or in connection with this Agreement or the subject matter hereof,
(b)&nbsp;hereby waives to the extent not prohibited by Applicable Law, and agrees not to assert, by way of motion, as a defense or otherwise, in any such action, any claim that it is not subject personally to the jurisdiction of the above-named
courts, that its property is exempt or immune from attachment or execution, that any such action brought in one of the above-named courts should be dismissed on grounds of forum non conveniens, should be transferred to any court other than one of
the above-named courts, or should be stayed by reason of the pendency of some other proceeding in any other court other than one of the above-named courts, or that this Agreement or the subject matter hereof may not be enforced in or by such court,
and (c)&nbsp;hereby agrees not to commence any such action other than before one of the above-named courts nor to make any motion or take any other action seeking or intending to cause the transfer or removal of any such action to any court other
than one of the above-named courts whether on the grounds of inconvenient forum or otherwise. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.12. <B>Entire Agreement</B>.
This Agreement constitutes and contains the complete, final and exclusive understanding and agreement of the Parties and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements, whether oral or written,
between the Parties respecting the subject matter hereof and thereof, including the Confidentiality Agreement which is hereby terminated effective as of the Effective Date. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">11.13. <B>Independent Contractors</B>. Both Parties are independent contractors under this Agreement. Nothing herein contained shall be deemed to create an employment, agency,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">
joint venture or partnership relationship between the Parties hereto or any of their agents or employees, or any other legal arrangement that would impose liability upon one Party for the act or
failure to act of the other Party. Neither Party shall have any express or implied power to enter into any contracts or commitments or to incur any liabilities in the name of, or on behalf of, the other Party, or to bind the other Party in any
respect whatsoever. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.14. <B>Counterparts</B>. This Agreement may be executed in two counterparts, each of which shall be an
original and both of which shall constitute together the same document. Counterparts may be signed and delivered by facsimile or PDF file, each of which shall be binding when received by the applicable Party. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.15. <B>No Third Party Rights or Obligations</B>. No provision of this Agreement shall be deemed or construed in any way to result in
the creation of any rights or obligation in any Person not a Party to this Agreement. However, either Party may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, provided that such
Party shall remain liable hereunder for the performance by any such Affiliates of any such obligations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(The remainder of this
page has been intentionally left blank. The signature page follows.) </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, duly authorized representatives of the Parties have duly executed this
Agreement to be effective as of the Effective Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">PFIZER INC.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">MACROGENICS, INC.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Dr. Mikael Dolsten</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mikael Dolsten</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">President, Worldwide Research &amp; Development</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signature
Page to Research Collaboration and License Agreement </FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXHIBIT 2.3.1 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FORM OF RESEARCH PLANS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g575431g21p84.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>EXHIBIT 7.3.1 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>DRAFT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>MacroGenics Enters Global Research Collaboration </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>and License Agreement with Pfizer </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">ROCKVILLE, MD &nbsp;&nbsp;&nbsp;&nbsp;, 2010 /PRNewswire/ &#151; MacroGenics, Inc, a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global
research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting (DART&#153;) products directed at two undisclosed cancer targets. MacroGenics&#146; DART technology is a proprietary,
bi-specific antibody platform in which a single recombinant molecule is able to target two different antigens. These DART proteins are amenable to several applications and can potentially be used to redirect the body&#146;s cell-destroying, immune
effector cells against tumor cells. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;MacroGenics&#146; DART candidates represent a promising new approach to potentially expand
treatment options for cancer patients, and we look forward to a collaborative partnership with MacroGenics,&#148; stated Dr.&nbsp;Mikael Dolsten, Senior Vice President&nbsp;&amp; President, Worldwide Research and Development, Pfizer.
&#147;MacroGenics has established the versatility of its novel DART platform by generating a large array of DART proteins against a variety of different targets.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;We are delighted to establish this strategic collaboration with Pfizer,&#148; said Dr.&nbsp;Scott Koenig, MacroGenics&#146; President and Chief Executive Officer. &#147;As we continue to make
significant progress in the development of our pipeline of best-in-class product candidates for cancer, autoimmune disease, and infectious disease, this collaboration with Pfizer further validates the promise of our DART platform.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the agreement, MacroGenics will receive an upfront cash payment and research funding. In addition, MacroGenics will be eligible to
receive escalating preclinical, clinical, regulatory and commercial milestone payments as well as tiered royalties on sales of products resulting from the collaboration. Further details of the agreement have not been disclosed. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DART Background </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics&#146; DART
technology enables the generation of highly stable antibody-based therapeutic molecules that can simultaneously target two different antigens. DART therapeutics can accommodate virtually any variable region sequence in a &#147;plug-and-play&#148;
fashion, are potent, and have very favorable manufacturing properties. To date, the company has engineered over 65 different DART proteins and has completed multiple in vitro and in vivo proof-of-concept studies in a variety of disease models. The
company has been able to produce DART </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
proteins in both bacterial and mammalian expression systems. DARTs also have been engineered with an Fc domain, which confers them with additional properties, such as Fc receptor binding and
extended half-life. This functionality can be further expanded with the inclusion of MacroGenics&#146; proprietary Fc domain portfolio. MacroGenics has established and continues to expand a significant patent estate around its DART technology.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About MacroGenics </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics is a private, venture-backed biotechnology company that focuses on the discovery, development and delivery to patients of novel biologics for
autoimmune disorders, cancer and infectious diseases. Since its founding in 2000, the company has built a fully-integrated set of capabilities in antibody-based product development. The company has generated a proprietary pipeline of innovative
product candidates by leveraging its three core technology platforms. These proprietary platforms include: (1)&nbsp;cancer stem-like cells; (2)&nbsp;DART technology, which allows the company to incorporate multiple specificities within a single
molecule; and (3)&nbsp;Fc optimization, which enhances antibody-dependent effector functions. The company&#146;s lead program, teplizumab, is an anti-CD3 antibody. Teplizumab is being investigated in Phase 3 trials for the treatment of autoimmune
diseases in collaboration with Eli Lilly and Company. For more information about MacroGenics, please visit www.macrogenics.com. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Statements
made in this news release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#147;expects,&#148; &#147;believes,&#148; &#147;intends,&#148; and
similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual
results to differ materially from those anticipated, such as the Company&#146;s ability to raise additional capital, and risks related to the Company&#146;s ability to initiate, and enroll patients in, planned clinical trials. You should not place
undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by law. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Contacts: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>*** </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">### </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.19</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.19</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.34</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.34</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.34</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.80</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.80</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.80</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.80</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.80</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.80</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.125</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.125</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 1.125</U> *** </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 2.10 </U></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>SUBCONTRACTORS</B>*** </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** =
Portions of this exhibit have been omitted pursuant to a request for confidential treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this
exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 8.2.3 </U></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Patent Rights of MacroGenics </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
<TR>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">***</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 8.2.8</U></B> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FUNDING AGREEMENTS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***
</B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><U>SCHEDULE 8.2.13 </U></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>LITIGATION </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>***</B>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>23
<FILENAME>filename23.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.23</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.23 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Confidential Materials omitted and filed separately with the Securities and Exchange Commission. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Triple asterisks denote omissions. </I></B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amendment No.&nbsp;1 to
Agreement </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(&#147;Amendment No.&nbsp;1&#148;) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Date: August&nbsp;9, 2012 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Name of Original Agreement:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Research Collaboration and License Agreement (the &#147;Agreement&#148;)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Effective Date of Original Agreement:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">October&nbsp;13, 2010 (&#147;Effective Date&#148;)</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Parties:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc. (&#147;Pfizer&#148;) and MacroGenics, Inc. (&#147;MacroGenics&#148;)</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">WHEREAS, the parties hereto desire to amend, among other things, certain terms of the Agreement including increasing, by 1 month, the time
allowed for Target Substitution. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">NOW, THEREFORE, in order to accommodate the changes, the parties have agreed as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">1. Sections 2.1.3, 2.1.4 2.1.5, and 9.4 of the Agreement are revised to read, in their entirety, as follows: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.13 Substitution of Targets</B><B></B>.<B></B> Pfizer may request that additional Targets be substituted on a one-for-one basis for the Second
Research Project Target or any Reserved Target in accordance with this Section 02.1.3. </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">At any time within *** following the Effective Date, Pfizer may substitute, without limitation on the number of substitutions and on a one-for-one basis, for the Second
Research Project Target and the Reserved Targets. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">b.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">At any time beginning *** after the Effective Date and continuing until the earlier of (i)&nbsp;*** following the Effective Date, and (ii)&nbsp;***, Pfizer may request
that additional Targets be substituted on a one-for-one basis for any existing Reserved Targets. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">c.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to (d), MacroGenics will allow such substitutions set forth in (a)&nbsp;and (b), except that it may decline a proposed Target substitution
based on (i)&nbsp;<B>*** ***</B> shall not decline a proposed Target substitution based on clause (i)&nbsp;or (ii)&nbsp;unless such agreement or term sheet with such Third Party precludes or limits MacroGenics&#146; ability to perform research
regarding such Target or to grant Pfizer the rights to be granted by MacroGenics to Pfizer under this Agreement. In addition to the foregoing conditions upon which MacroGenics may decline a proposed Target substitution, MacroGenics may, in its sole
discretion, veto up to <B>***</B> proposed Target substitutions proposed during the period specified in Section&nbsp;2.1.3(b) by Pfizer for any reason and <B>***</B>&nbsp;proposed Target substitution proposed
</FONT></P></TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">
during the period specified in Section&nbsp;2.1.3(a) by Pfizer for any reason. Any Targets substituted for an existing Reserved Target will then be deemed to be included within the definition of
Reserved Targets. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">d.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding any other provision of this Agreement, during the *** following the Effective Date, MacroGenics at its sole discretion shall be entitled to decline any
substitutions under 2.1.3(b) for any reason in addition to any Target substitutions declined under 2.1.3(c). </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.14 Elevation
of Reserved Targets. </B>At any time in the <B>***</B> following the Effective Date, Pfizer may submit a written notice to MacroGenics that up to two Reserved Targets will be substituted for any then-designated Research Project Target on a
one-for-one basis. Any such Reserved Target substituted for an existing Research Project Target will then be deemed to be included within the definition of Research Project Target.<B> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2.15 Former Reserved Targets. </B>Any Reserved Targets shall cease to be a Reserved Target for all purposes under this Agreement (including under Section&nbsp;4.5) upon the earlier of
(a)&nbsp;replacement of such Reserved Target with a new Target in accordance with Section&nbsp;2.1.3(b), or (b)&nbsp;<B>***</B> following the Effective Date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>9.4 Termination by Pfizer without Cause. </B>Pfizer shall have the right to terminate the Agreement at any time for any or no reason, on a Research Project Target-by-Research Project Target basis, by
providing <B>***</B> advance written notice of such termination to MacroGenics; provided that, during the first <B>***</B> following the Effective Date, Pfizer will retain at least one Research Project Target under the Research Program. Commencing
<B>***</B> following the Effective Date, Pfizer shall have the right, exercisable upon <B>***</B> prior written notice to MacroGenics, to terminate this Agreement at any time for any or no reason either (a)&nbsp;in its entirety or (b)&nbsp;on a
Research Project Target-by-Research Project Target basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">2. Except as expressly amended hereby, the Agreement shall remain unmodified and in
full force and effect. The execution, delivery and effectiveness of this Amendment No.&nbsp;1 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver
of any provision of the Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">3. This Amendment No.&nbsp;1 may be executed in any number of counterparts, each of which shall be an
original instrument and all of which, when taken together, shall constitute one and the same agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">SIGNATURES IMMEDIATELY
FOLLOWING ON NEXT PAGE </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and SCRX have executed this Amendment
No.&nbsp;1 as of the date first above written. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pfizer Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Scott Koenig</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">By</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven Adams</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Scott Koenig</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Print&nbsp;Name:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven Adams</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Title:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">SR Director Operations Oncology Research</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Duly authorized)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">(Duly&nbsp;authorized)</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">*** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment.&nbsp;An unredacted </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">version of this exhibit has been filed separately with the Commission. </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>24
<FILENAME>filename24.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-21.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 21.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><U>Subsidiaries </U></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD></TR>


<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Entity</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Jurisdiction&nbsp;of&nbsp;Organization</U></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics&nbsp;West,&nbsp;Inc.</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Delaware</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics&nbsp;UK&nbsp;Limited</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">United Kingdom</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>25
<FILENAME>filename25.htm
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit&nbsp;23.1 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consent of Independent Registered Public Accounting Firm </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated March&nbsp;8, 2013, in the Registration Statement (Form S-1) and related Prospectus of
MacroGenics, Inc. for the registration of shares of its common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Ernst&nbsp;&amp; Young LLP </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">McLean, Virginia </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;2, 2013
</FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g575431001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`N@#1`P$1``(1`0,1`?_$`&\``0`"`P$``P$`````
M```````%!P,$!@@!`@D*`0$`````````````````````$``!!0$``@(!`P0!
M!`,!```#``$"!`4&$0<2$Q0A%0@Q42(607&A,B/P8;$E$0$`````````````
M````````_]H`#`,!``(1`Q$`/P#^_A`0$!`0$!`0$$-0Z'%U-/7Q\[1KW-+!
M_#;8KUWD3]O)?_)>L`YHQ^AK,FID>0FDY!LS/.,6E'R$R@("`@("`@("`@("
M`@("`@("`@("`@("`@JON=SI[]^GPO""L`U=>)?W_M&#7/E<#CL&<IV2L0\9
M6NHTOT'G5&&1HRDYS_$,&8@=-PW#\[ZZYFCR?+U"U<JD6_:=[-R[I7KNEK7[
M.ML:NCI:5BW?OZ.IJ736#%*6<I3(_P"K,S,P=<@("`@("`@("`@("`@("`@(
M"`@("`@(""N>Z]B4>2M8G.T:_P"^=UUQ35>2Y<4[`GOEKP^VYHZM^O2OQP^?
MRJ\9&M7"C>,80>(XE,\!R#?X3BZW&YMIB&?2Z'=O%VNLZ`S>;FYN6OU.<DY>
M9CHU(^`4Z\?`:E6$!"C"$6BP=N@("`@("`@("`@("`@("`@("`@("`@("#BN
M\[:EPF"75/5-JZ!BAI8G/4B#CJ=!JVCBK5<W.'/Y/,I3'C\I?%XCB_RE^C(.
M;]<\!:QKNIWG77K6Y[%ZX`OW2Y>A4@'E<61R7J/`\U6IO.I0P\*1HB*4<I&U
M#@C9M3*7XO$+90$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!!#]#OY/*X6OTN[:_
M"QL+.MZNG;^D]B0*5(,[%@D*]89K-@C#@_Q&.$R3EXC&+N[,@JKU2/J>OB?V
MEW-#9P3=(6%WA.`W1O5N\#Q\Z`Q9<>@Q2U!3R?9&J.Q9-L18MB53\G\&)9C`
M\IA=J`@("`@("`@("`@("`@("`@("`@(.3+I?ZS88.F]J6">1#PZ*]>KDKY=
MJS:C"&7I3L$A;'7*8S?C'?[(1:7U3<;0&\PZQ`08;%BO4`6U:.*M6`.13V#D
M@((1P;S,A23>,(0BW]7=V9D%88\!^QM:KUIY6'Y/"NR)QE1YZ%%M34IFO4;O
M3:=`@0@OT?(X2R)_,HW%-SM&,Y1\!:J`@("`@(-2^:Q6IV+%6K*Z<`I%'3@2
M(R6?K_RF`,Y_^MK!(,[#:3Q@\_#2E%G>3!]J=RMH5*UZD<5FI;`*S6L`)`P3
M!-!IC(,HY3&2$XR9V=G=G0;*`@("`@("`@("`@("`@P6JM6]6/3NUJ]RG:%,
M%FI:".Q6L`+%X%"<!HS$81(.[2C)G9V?PZ#CXDCP>;IW=S?T=+GXZ=S1?1UX
M_E6N=I:5S[8T36:5=SV\;/MVW@$I1^:5*+?<60Q.1@GM[H<?F<+2Z7<OAH8F
M11+HW]`LO(`4PP^<S/*/R\Q^/]/']?*#SV_*=E[TL#L>Q\F7+>JFLAT*/`6B
MG_>^OSBB*XL[O*U73?+CF'A]);F><!W^QR5F?ZX?D6`],A"*N(0`"&``!P"$
M(81&((AQ:`Q"'!HP&,<(LT8LS,S-X9!D0$!`0$!`0<=DZD:W3[G)V369V&KA
MZG*E9:Q*)<K4M6*UVM6M$C(1VRM<$OD.)/E7#:!%X0&XGF'8H"`@("`@("`@
M("`@("`@Q.X#L8#N(S,WU6`N\",S%&TOK,-_/AB"FS^)-^L7_LZ"HKWI/F=/
MH<34O:6Y8YKFS-=P?6LIY$/7^7J^+/SU:^6''%I%LO([?6,UPM:K!ICKB$(]
MB!0LBQO86?;JY9M&F&]9..C3SH3:=HIWC7E]`*@6F9_QZ]D92>(^`UY,6?Q'
M_D@FD!`0$!`0$!!P?12!F]CPNL]>U,VD?:XZ=D1*;5:M;3RR]#![D+7@[1/>
MY80AO7DTW+.,91E%V^(=X@CM;7RL&@?5V]*CD9M5H/8OZ5H%*H'[)Q&-B6+$
MQBC(I9M&+>?,I.S-Y=V9!6>;[^]'Z[T/V[VWZ[M?N@Z!<Z4>NQ(1N1U=;4P<
MN->9;D(D+J;>'=J5H,_SL6:5@8VE,)&B%N,[.S.SL[.S.SL_EG9_U9V=OT=G
M9!\H"`@("`@("`@("#A]?E#WM$F]D:-S`Z&I.Y&E:8Y[>'IPLXT:`H='SU>U
M1!L4J=KX'%&1!6QFK1^NQ`)"C($/6+[/U;6IF'%E\WGTIWJ-/J8,*]H[#FD2
M-+4IX)F/4I1S:O\`C)CS>-FX\#-"->$ZI0BNAYJEDZ/!1$.QI6!;PK&EIW!5
MKVK?M-:IDEM6:V5GBW3W27RQ^V6>]+,IUIRE<A^""%=@M;4T*^3FWM.V:O7K
M4*A[9S6[(Z=48P#D24CVC?\`JKB9H_Y3E^D6_5!R',7MV&Q;R]HT+\KV8#IA
M6XD'5_;HWSO7C@BS#_B:4JU&0IQ&>=,,GA!OO>5B<O`3&I?NMMXN14,]<5N1
M+5TX:-F^>(JDFL0JEF.K8HY530'7*)[%J8OG+_`#N;QX#8%3VZVK3D+1K6<2
M5.X^J*^`Y=8FI\JK9Y\ZR$X:-2G(7W?D!<#M\F&XOAY)\@YS?-:AUF96)T3X
M.==QKCC>#VXEM:&?^5=F.!+M&SS<8@IP>R1GG&W(=:3/&5?[?`8.;-H5MDM*
MKOZ/7XUL.?<A;N!K>.?ISQXL.!-84:H]6QL:->5OZXP*<<+S>6#5A5B0).T^
M]K;UZME[X\:CDYX`R`+-K:<[M_0MU;/YM@]@?U5OV^IG'K0KP+]CO:F4T&C&
ML\PUZ9>KR-S$Q]"PVYE7X;_W;3T!4/Q9PN6KV#G28&AH6[-ZOBQB`QBA!6/(
M$C?;`Q1U7#F/=NC#(P>.TW,X2UO;7JJN!Y%IBK3GL]MD8!@W)6[E1_H)3U2L
MSB^XT2_"41$\/%!<B#\V.YP]/^1/\R#>N.H/>#ZG].X,[E[#S]S5"#I=34YS
M)L66U,P.23-H'+#LAUXZ`]2MIO18]8-9AE-:07![;]9_Q$Y[G;7*]F#T[Z^T
M+?)CR,:YTH<&%\&;^+^RYMR=/5M5K>_4KQS(@+]A'D4,)"F6+3=T%N^A,[F.
M<]2\S@<?[%SO:/,<[0G2PNNJ:.1>';QX/*SG`LZ&)9L8Y6JU"Q@.=>`*[5V&
MPQ0A&+(*CXCWI[Y]B\73[OC?3'K[I<73MW:>+8Q_<SSR]T6+8U*&GN4-O1XC
M-9\'1ULYZV<8=6Q^0%XW/U"2,8A9G?>W.K]8^E-+V=UGKN!.IRZ].)^!P>I'
MI5R:NMHU\C)H?[<;%ITJE,VE>!&Q>/6'6J"E,I'^$'=!JW_Y&<E#T3U7O3!S
M-KJ,_C\?2NZ_)Y]6=#J:^QD0$]_F[>;MPSK.9J`<\)_"T,4GKD@5HO"</D$Y
M[#]T97KGUO@^QM7++8J[MWD*(L]]//QH@-UAJL(?D[?1SQ\3-C5&>3QGH&HB
M,:,`?.!BC@X2?M'W'R'J6IB%Z&&UIZG2Z+9?/<SS.63:Z/8L1A]UF=2A`@1P
MKU`^/E,I!L4Y`U0_;<LU:Y@KK$_DK6GUV#R?L'U?[$]1?[=]@N3W^[%S0>>V
M;X]"[0CC%OY/0:?[1MVHCI%KU;<1%LMJ5Q":9X7!50[3V7[SY'UEM<]RUS.Z
M_J^OZ:+6L_E>"Y/:[#:JX[70YQNDVJV)4M/C\_7N':/W&\$,PS.`9FKV/J#7
MX/W]P_>]7+@@TNPY7NA<T+J[')=QR>MS.L',E<>C9C&=P,LZY9S[+PB9JQS#
M\$:0YDBTI1"[D!`0:U>J.M*S(;OXM696IQ^(HQ@28Q#FT?K&.4FFXOD[S><W
ME)_U\>&8-E!R?08-[6U>9O4]`U"&)>L7+#1*(E:X,L`B>G<RS4#1O0()IN(L
M;-4E.Q$968S-(;AAZO%V-\V1G52TJ.,Q;-S6UH'M0Z.C9KQ#'+CS@H`>D(UE
MCG^ZT8CO6C"+#"21/L`&/4YFQ]N?H4+6C>T:6^U\4K^LP_PZ&GI/+8!2<V??
MJP$#.L3$,<@.5ZL'`,H9$^Z(3&QFW;=G(NYQZE>SF7)EG^6`YHV*MFL:H<+3
M#8%]3PB?[6\QG\Y#:'D;2>;!"T_]XU-2A/4#1Y?'H4JENY7R[X=J]N[A"W`V
M\R=FWE@%0YG/`(98E@.-Z^2Q#R]*-<@[02YLFV?HX:A#YLLJ&-+/_"GG%)HE
MLGL&):E/0G=>K'/F'ZF8+5OL><9.Y'B_P0:&3BW>>U)ULH-4O,Z+DMF&:Q,-
MS#NB`(+"HC@`@M*AH?7&3L1QG`7[).4L)C$$.<TJW;\[TVKL<[A9O286K3RO
MECU[]7"U0ZD-8PM2V4]UFS+<9T]2-D;Q^@K0IV8EE9*>K$(2=#*W-OI*73;H
M[V&#!GTF?D\Y#2J'JVF+?-FU>CO%S/$[4]+'K1."L<TPUX6V8E:-L$31"O?Y
M#UHW\GU9F,$!+5[WUZC)1(?/R=%JI\7IA=*<XQ:H#2KD_;\0X_OJ_"V&,Y2A
M)F:7D/02#P?[<X/VUZ]_D!G_`,@_663=[+GK^&?,[C@\6M6-KZOXG/7WM#"&
MU<J4J]O:)S>'6H:`@GO1NP8%LP<OY2$%<^T?>_K#VSEO,/\`&#NO9OLJCRM>
ME4J6N+N4;6/:[*=K-S.5J==:S81)5W-VN816+]&4PJ_Y.@2M4-3-9"__`.'G
MKSL_6?I$]'O[![O5;?2]/U&D0N.^1H3:XU:E6:P:W$6UM3)7S(R!>U*F?I%K
M2%$]*I*#5QAXZ_C[C^A-OU;PVK[([GV1SG:7-SJ+_P#K&+T_LOF:@;6H.QHA
MJ"Y[%8`;MZ[S;T=J^3ZF-<UR-=(,=B4!##T;_)F]RVS_`!,R(\WLV^AXBWM^
MN,:>_OAN;5FSATNISL^W=Z#1W)BZ"G=^VG\"7HT]&_"X\?%&U\I"D%0_S-Y?
M1])>M/9DN59ZWIOVCRMOG]O*/K4^<Y+U=UKV:1LO<%:+3U(Y^/T3">L"I5K4
MAOH2F(MIRWZ1*`6]_+>B\_XV^ML*_FCT!W>_]"Y&B9J6;8HYD8]'A_9>*76V
MZ6#GA+9!&L.=MM&N4EB%?Z)R-`HPF_?/46_7?O\`]!]MTH6!ZL>.YS&GT=RV
MP\KGNJVJE^AC0G5!^!&6OO6-"N&K*T6]$D1%#2J0M$^V07;J>^_6%3J^,XBA
MMMUO1=P6K/+I<>!NG#G9MLFD*IT'27LV9J'.8-FQC7!5[-L@XV3U#"`Q""G&
M(4S[S%ZZZ'W=Z\XT??=;ZG]ZZ/(ZQ^'[''HE)S^YART)1N<1KDL$#G7]&Y,-
MBQ6`$U/4'7C9>K:%]A6F',^H_8WL;$_D./TG["]@>L_<EB/K\FW0[?E^?CD=
MWF591J7J4.RJ9EF_BXX=T+%M/$91A.QZGXPHPB64@]YH"`@("`@("`@("`@(
M"#S[UIO]F_D#ZMY6O=SXC]?\]U'M/9J3I"O7YEU*IO7_`#8H%GJ@?&B;]YT2
MQ+^%:D?\:<(D`\7^P/02`@("!X;^W_S^O_Z@>&?^K>?#^6_Z_P!_^J#6MTZ>
MA7)4OU:UVJ7X_;6M@%9KD^,FG'[`FC,<_C.+.WEOT=O*#[&JUK$!CL5@'&(@
MC"@8(RP&8+M()1QG&48$%)O,9-X>+_T08K^?0U:=C.U*-/2S[8W#;HWZP;E.
MT)W9W%8JV($`8;NS?XRB[(.?YC@N(XJ6B3C^/YGER;%AK>L7G\/,R#:EF(A@
M@?1+0K`)=*,`8#@Y'D\!PC%O$8LS!K=QZWX#V9F#QO87&<UV>8`A#U*O1X]'
M5C0LE#.L2WG$MA(;-NRKDE#[@2&5HR=FEX=!K<1ZL]<>M7V)\'Q7.<J?HM*W
MK[]S'S*];0V].[8);LW-;1:#WM`Q+!I2;[23:'R=HLS?H@[Y`0$&.!8DD6,6
M(SA(PI/,1!QE)Q#+Y%*<8Q,/XE9OE'S'Y,\?/EG9@R("`@("`@("`@P6K56C
M5LWKUFO3I4ZYK5RY:,.O5JU:XY&L6;-@TH"!7`*#RG.3M&,6=W=F9!1?IEM?
MK+_7>WM?0N6\WN+=:MZYH7L'2YNQA>N,J#PS13S]&]*S9ET6E(^K^19I4+CP
MM0%,;B$%T%]H"`@("`@("`@("`@("`@C,Z<)FU_B-QO'3>$_DU1I3G'/SV^Q
MVK0B7Q*'CX_>\C/'P_GZW&S!)H"`@("`@("`@\R^X]+<]E;,/0G%DU<\.K`1
MO:W=Y<L[X<7R;CKVY\_4_*(4G^W=;6LCC6^5<@`59$+/YNS"D'I&E3JYU2M0
MI`'6ITP"K5JX81&((`P88QC'!HPA"$(LS,S,S(-E`0$!`0$!`0$!`0$!`0$#
MPS>?#?U?R_\`]OX9O+_W?PR`@("`@("`@(*<[_VG/&TO]&X3(GVWM"]3KVJG
M.U2R!G8%&]9L4Z_1]IM,"Q5YWGPSI69_(K?=;>J0%:!;,A!('9\?QN9R52T]
M<4":^O8E?WM24IEL:-XI#&?Y%+_E&G5D>4`"BT!BA_XQ9W?R'8("`@("`@("
M`@("`@("`@("`@("`@("#G=;K.=Q#&J:&M5AHAH3T_V:O*5[=L4X/.+$HX5&
M-C7T)F(.4!#`$A#39XCC*3>$%2:LO9WMO&'1Q/WKTMR>P-HZ6]H#%5]O1J0'
M4/*OSF/"6AD\J31F>=>=^\0EVHU8OU4W<X+80MSG.4Y[DJ<J//95;-`3\=[$
MA?82S<)5JAIB/>N6)FMWK/T`BTBFG,DY>92=Y2D[AT*`@("`@("`@("`@("`
M@("`@("`@((ZU5O$=GJZ9*OFS$TVG5K68_2PAC>J)I1&XQRD-Y_)WG/Y3?\`
M7QX9@@]3&ZBX0SYW93R!$KZ(A0'@9=V=<]FSEES[,26WFQ'S*]2R+X2B\3?E
M_*7AQ0\A!Z?K8/0U=BETW7=OKTMN&E6L4ZF^3E05,[1%(+4,PO'!P-&D]"#M
M*O;:Q+1$1FFUCY-Y037.<#QG(DN'YWFLG+MZ+46T=`%0<M/0CEM<;+'=TC,2
M]:#F?N-C\:$R/"O^03ZVC]DO(=>@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@Q!+$XXEC$L8R^7B)A$`1OC)XO\A&C`D?
M+Q_3RS>6_5OT=!E0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$$3B?=^W#_($
MX3.>\Y(O2%GO.4K]EW/^(&W=@-K7G[&?['E-I_*31D[Q8)9`0$!`0$!`0$!`
M0$!`0$!`0$!`0$!`0$!`016'-IY5*3!8#N)VF)B9Y?B5B3B9W)E-'/G.16=Y
M.)FCY=_T9_+,$J@("`@("`@("`@("`@("`@("`@("`@("`@((K#LSN8^=:),
M9)6*HC?8(LSC)$C?*!&*3.R9S<D'9W=ZP?U=_P#%D$J@("`@("`@("`@("`@
M("`@("`@("`@("`@/^GZ_P!O[-Y_[-^KH-#*^_\`;,[\KX_DO2JO8^+WGC]S
MA@Y?B^G_`/T?C\W?Q]__`+F;_P`_\O*#?0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0?$F^491?\`I)G9_/G_`);Q_P`.S_\`=!HY0&JYF=58+UVK4:M=@2;X
MN%@`@)A_%[5YX_!H>/#F,[?\SE_5PWT!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
?`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g575431dsp_075a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_075a.jpg
M_]C_X1Y517AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-SHS,"`Q-3HQ,SHP-````Z`!
M``,````!``$``*`"``0````!````C*`#``0````!````QP`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``!T?`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`H`!Q`P$B``(1
M`0,1`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[?H70^B6]#Z=;;T_&?8_
M%I<][J6.<7&MCG.<YS2YSG.5[_F_T#_RMQ/^V*__`""7U>_\3_3/_"E'_GMB
MT$E.?_S?Z!_Y6XG_`&Q7_P"02_YO]`_\K<3_`+8K_P#(+0224Y__`#?Z!_Y6
MXG_;%?\`Y!+_`)O]`_\`*W$_[8K_`/(*^3`)\/FN0S_K5U6_H&+U;`;5A-S;
MB,46!V8]]<[L;UL?#V>AZ[66?M#T7YE_3Z/YNNW)_HZ4[F1T?ZL8M#\C)P<&
MBBL;K+;*JFM:/WGO>T-:J0?]0CD''V=-]04_:2-E,>CM]?U?4V^GM]#]8^G_
M`$?]/_-+"NZ$['IOZKU+J'[).?:'N==ONNG=1U+I++V7778[LGHN95?C>RI]
M61TO^<]'_!ZUGU)QLD9#\K-MNMSJ#7DVBND$VOJ;B7YF,\U/?B?:,5GHOIIL
M]'TDDF)`!(-'0'H:W;XPOJ<<+]H#'Z<<$B1E;*/1B?3_`)^/2_G/9])6?^;_
M`$#_`,K<3_MBO_R"R^N].KZAF=.&/CX_4L7IEA9E=)>]K6M]45U4Y7H.#Z'V
M8..;W58][/H7_H?TGIK)Z/\`6_)QJ!C5].:ZITX_2NG8\LO;>Q[Z_P!E9++[
M+',=B8S&974,NVO$HP*_^Y%=N-9:D56[U7_-_H'_`)6XG_;%?_D$O^;_`$#_
M`,K<3_MBO_R"/T_J&'U+%;EX5K;\=SGM;:S5CC6YU-GIOT]1GJUOVV-]EG^#
M5E)3G_\`-_H'_E;B?]L5_P#D$C]7N@$0>F8D'G]!7_Y!:"22GR"!X!))))3_
M`/_0]%^KW_B?Z9_X4H_\]L6@L_ZO?^)_IG_A2C_SVQ:"2E))))*6/"Y+-ROJ
MA]7NMMM^RO.<_?8\T[GLQS=M]6UN/99Z.+=F-9^E^RU>O;6S]+_.?I-SKG6*
M^C8)R[*K+]0QE=39)>[Z&]WT:F;O;O\`_1B\I?9DY64]U@=;E9%ID"276O=_
M-M:[\[<[TV,3)R(L1JP.(_W?+]+YG1^'<E#,>//Q#%?!'A_3R<,IR]7JX(PA
M#BXIM_ZP]>=U[.]?8:\:EIKQJG?2#7'])=9SMMO]NYG^#_FU+I/UGZWTKV4W
M_:,=K0UF-D2YC`WZ(I>"VVOV^SZ>Q`LZ'UMF:_"&#=9?6??L;N:`?H/];^:V
M/_-]W_@BINKN](VAKFU-=Z;["TAH?!_0O>1[+?\`@TRY"9D*QQRWK(B7#'B_
M2/#Q1X>#_-NQ''RLN7CA(',_=1&7!B]/'.</3P1X^&?NQR?YV<./_6L\O,NS
M<S(ZA)9D76.?+26EL_1K98-K]K&^UJ[K*S_J;U=^(_)R0RW*8*7M)VV/J:7%
MV!U&W:YU.,^]VZVGU:F9=FS^?H7`R'#0R#W"8<MJU>^QP:Q@!<7.<=K:VM_/
MW3M8U",M9&`W-\!]<N$#BE+BCP_]%7-\E#+#%'/,1CA!C[T.'#CXIRACQ8_;
MR2R?-^A^L_Z;[36QE;&UUM#&,`:QC1``&C6M:%-<[]3^F]:P,..I9!](@"C"
M,/-0'[U_TO\`T'_FJ5T*FB;`)%>#S6;'''DE",QD$3\\?EDNDDDBQOD"2222
MG__1]%^KW_B?Z9_X4H_\]L6@L_ZO?^)_IG_A2C_SVQ:"2E*ED]7Z?BYE&%?:
M&7Y+@RMO\IPL?2VP_P"#^T?9\C[/O_GGT6U5_I5'J?4+**[L;`#+^K''MOQ,
M1[MH?Z>UGO=^8SU;:F>]]>__`$GYZP.E_5_+ZME6]5ZRZ[T+K#;AX]NZG(96
M[:6XN14Q[FXE--]%&5CLHM]?UL?$RK/LV5]K9DI3>IZ]U)WUA=A.Q"WICV6O
M;E6M]!]8Q]E=]FRQ]GVC'NOM9]GM?7A?X5]?VBBOUEB==^L?0\?+.7T6FC)Z
MN2&NSMDUL`^D[]VVZUOZ+U*?\'_AO9Z:Z_K%SL?I.;>T![JL>UX:>"6L<Z'+
MR6SI^=BX]=U^)?34]H#++&.:UW\G<[VL<_;[-ZCR2Z>%@U^E^CZI</!_?=3X
M5RT)F629T$A`PX^#W,?#*63T1C*>;]#]3^F]AE_XP*2[IYQ6%@<[?U&IPW%C
M-:W45NCWO^E>RS]'[*J_](HYWUYZ:^O-QJ.GC(J>?U=U@::;B3^DNRJ2`]C-
M_P"DK_G+,C_@%Q8UU(U2.OQ3#D-UQ5TD=)Q_=XH\/Z#I0^%\N(<8@9T./%$<
M>*4H_P`YCCEXY0_6<7%C_0X,?S_K/UC/*O.1D.RKMC;+"`?38*V``>UK*J_:
MW:W_`-2*]]7^JLZ3UBG,O8QV.)KN>YNYU;'Z.R*"-SVV5_X3:S]+1ZBS@!`!
MUA$P\2_J&15A8^T7Y+O3K-AVM!B2Y[R/HL;N_-WO_P`%O2!)U'K,?U?%.6@X
M_P":X(?/'AX<G]1L9<6,1GCD/:Q3B<LH8H<,OU4?Z1[^7UX?TL/!_,Y/1_B>
MS,<US0YI!:X`@C@@J2S.AWVC$9@YD-ZAAULKR6@0'$#8W)H_TF/?L_1V?]:L
M]*ZNRFO35@BC3R.G12222"GR!))))3__TO1?J]_XG^F?^%*/_/;%/JW4Z.F8
M;LBUP#W$5X]9#W&RYW\S2RO&KR,BS>[_`$%%UGI>I;Z?Z-0^KW_B?Z9_X4H_
M\]L6!]9Z\WJG7,3H[1?53NK>X.KW8MU,NMS;775UV>ED8GH4T4?K&%DT9&55
MD8UF_P!))2WU5Z7D=0RC]8NH^H77/%^-786NVV.J91;=AWT7W,_9NWUJL-FV
MI^1CV>IF?:O3P[*^P3`!H@?WITE-7J74<;IN(_+R2[8TM:UK&E[WO>173334
MR7VW6V.;76Q8MWUDZ=D5V8W6\.S!PKO8Z[(-5E&I#6UY5V);>W"M_<??Z=7_
M`'9]57/K+T_+S,.BW":VW*P,AF750YVP6[`^NVAMI]M-KZ;K/0L=[/M'I>I^
MC7/X][+/4%>YEE(#<C'M;LNJ#AHS+QO=L98WZ+_TF+?_`(&ZU/A&,@03J@R,
M2".FMC<.%]8?JYD=$N8XWMR<3()&/9Q9H-^VUG\W[6_X9C_TG^C8LO'H-^35
MBBS8[)L94QQUCU'"O?M_.V[ET^3TT/PW8>,6-Q7'?]@OW?9@\'=ZN(^G]9Z5
M;[G?T;U,/_NG^DL6)T_KF5]7S]ARNC4V9P/JLLR7-AS@=]63BNJIN^T>G]'U
M,>[_`+;0^ZS-B!B#Z0(`:SX>'7^]Z?4ZF/XW&..(S0GER1.27N\7#&/N\4?E
MC^CZ^'@>WL^H71STIF$PN9E5-);U"`;7//Y]_P!%M]>[_`O_`.MK"Z-]2\UO
M6A1UBESL2MCK&9%#]K'O:YGI>]A]>KVN=[/T=F]BR<KZ^_6S)C;E4X8\,:@$
MGXV9KLG_`*-:W?JG]>LBPVXO77&T4AMG[2#&L:UECW4_K[*MC*MENUC<JFKT
M/2_I7V?TO53\O)SC'CG&-7<JX.+_`-%]32Y?XKECQ8X99RXHRB.(Y/1Q>HSA
M_K/3\W]]U>L?5_K.9GY.31:RRNPU>@UV1D8SFUMV_:L"<-K_`$ZLBRO[9]MJ
M_6/4_5[:O1KK2'0_K)Z]0MS&Y%563BWF[U[J;'"C';3D_H:V645MSLMGZ?%_
M2XWV>V__`+56>M7TZ2B87-^KV!F]/Z55B9UOK7UNL.\/?9#'6664U>M<&V6>
MA2]E/T*_H+22224^0))))*?_T^\P,HXGU0Q,EL;ZL"IS)@@N])GIMA]E#7;G
M_F^O5_QBSOJ;;F9F1FYU^3=:W=Z9J-CGT![G.R+/0J?2UN/]G<_T?T67F_H_
MT=MOZ&GT[=%CZOJ9AO9>[%<,/&_3,I=DN;+:@?U2D.MMW_0]GT/YQ/\`4^JF
MOIUQKS+.H.=>19DW4/Q["6,KJ:Q]5P9N].MC/TU=;&6_\=ZMB2G>22224^=_
MXQ^K=1;U.CI5-MF/A_9OM-GI.=6;7N>^C9;;66V>CCM;_-,?_.7_`*;_``:X
MRG?C6-RJ'OQ[J_HY-;BUX_DNN=/J,_>JO]2IZ]-^N3>G9EN+TZ[!;FY8#KV6
MOL?0,>K2I]OVC&_6=^0_;77BU?S_`*>^[V8ZQ,+IG2<&PV6?5[$S2?SSD/O?
M_P!M=7;Z3?[.0I(_$^3P#V<O",NYXNTOWI_HK)<GGRGC@3P=*Z.=TCZVTY3_
M`++G;3<UL_:\5I?40/I.R\:CU7X?_'4^KB_\0MR^C$SL1M.177F8=OZ2L$[V
M.G078UU1]C_^'QK/46O5];^AX=+&9&/D=,K+A52QV.2U[W?0IQ_L'VJJRQW^
MCK5`=(?FYMF9359T/"N.^W%I?LOR7.`)OR&,W5=)MT_G,1W[2R*[/UFW&33S
MF(CC!!QG;AE[GV27#!/Y=>+Q'"\CF_5^JG/./1F6V4,(^TM9COS,K%#OSLIN
M-MJMJ_/WV>GG_P#=2]=KT;H_U:Z']7\OJ)R?VAAY=!=EYEA:X64M:YOH55U!
MM;:_?9^@9^DLNM_TBN,&!TC`VUFKI^#C"29%53).W?8\_P"$L>?IV?IK;%GT
M=%SLAMG6,8.+6Y=F9T_H^4-M#IVN]=U;FUWXN?EWUV9>+=D/M9T]^3_0_6]5
M,'.9,]Q)EP1^6S^:3@CCH@#B.]/1=%KR*NCX-64",BO&J;<':G>&-%F[^5O5
MU5^GYM'4,&C-QY]+(K;8P.T<`X3LL;KML9]&Q6$5*22224^0))))*?_4[[I>
M'CYWU5P,7)K9=5;A4`LM8VQDBNMS"ZJS<Q^QXW^Y9?\`B_OL=@Y5#]SS3:)L
M^RG$;N+=EE3V/#;+<^MU6_J#OYEEMOI4+:^KW_B?Z9_X4H_\]L613U'J/3OK
M/9A9M]MO3\JS;C/R-E;*W6@WU,HN;CUU9#76_J-%%F?9U#?_`-HOLWZRDIZA
M))))3A=>Z+EY655U#IYK=D,K--U%Q<QEE>[U6;;JVV^C?19O]/\`165V>K97
M9_I*^?Q+<[J#W58.,T>FX-MS;+&V8;9^EZ%N,6V=1R*_\)C4>C76_P!F1EU+
MHOK9M_9U+;W%G3WY-3.IN!VC[,XD/%K]-N,^[T*\S_NIZWJ_H?40\O+Q.G45
MF\BMI`KQJ*F[GO@#;1A8F.'67;6_X.AFS9_P:S^<Y;!/()2Q\6276Y5+A_>C
M^DV<&6<8D"=1_ELAZ=TC'P;/M!<[*SWM#'YMH'J1_HL:NN*L*C7^8Q6?\=ZU
MBAF]991:_$PJCG9E<"RMKMM-))_[79D/90[;[OLM7K9K_P#N/_A%7R+L_,#V
MW.=A41#,;'L`O>0?HYW4:M[<5KOH_9^E^H__`$F?_@EG=-Z#T_$Q?2LQHL8X
MFI]=SZB-WTWO^QOJ]^UK:V?^"I_W7(8:&,9?H1(_5Q_P8+?>C?6NI'S%)91D
M9-M67F9=EF902ZA]$554DAS7?9,.P9%7T'[?M&9]IRO^$I5_#^LF=@Y'V+-<
M[J=N2QSNF!K6LOLM86MLPK?1#,?;MMJO^V^E351C^O\`:_YGU;`CI[2]K:\_
M*QB[_N4*LFH3V<]S:,S;_+=D+=Z/T$=/M?EY%YR\RQGI>KL%;&5[O4]'&I;O
M]-CW^^Y]EMUMS_\`"?HZO3CY7E^=QYKRY1/%ZN(`W'^KP0X8^WZOW5^;)@EC
M]$2)]^OUDV>BX-O3^E8V)<X/NJ8/6>WZ)L=[[C7(;^C]5S_3_D*\J&?UWI/3
MK33F9`KL;4;W-VN<17N])KW>FU^WU;3Z6.QWOR;?T>/ZB?"ZUTO/N]#$R&VV
M^DW(#0")J>7,9:TN#=[?4K?6_9_-6_H[%HM5O))))*?($DDDE/\`_]7T7ZO?
M^)_IG_A2C_SVQ9/UNZ(VP?MS%8]V?C5>@XTL-E_H.=^D=T_](S[)FT[[+*\F
MFNU_TZWX^5^CK6M]7O\`Q/\`3/\`PI1_Y[8K69B49N+9BY`+J;FEKPUSF&#^
M[9666,_L.24U.A]7;U;!&06>A<UQKOQRX.=4\>[TKMO\U=Z3J[;,=_Z;']3T
MK_TJT5QO3.CYGU>S+<A]GV;I6"P/R<ZYS7^O2QECOLN/AXXK9@XN-;:Z_;Z-
M=E-^_P!/[=]MN]+J<#J&+U'%9EXA<^BS6M[F/KW#\VQC;V5N?4__``=K?T=G
M^#24V'-#@6N$@B"#J"%RV?B=+QQD8G1\>GI[[6&F[+QJV,>),^E46AOL:[^<
M_,75+BZA;5D9-.1E,O>^ZRS&K:`QS:-VT-%?YS&.24CR/M=&"UN/=4_*8&M]
M3)'\X&_SCO3K_P`,INSJFV`UL+VC63IKX0@=0IILOHM=5NMH#O3MUT#OI-;^
M;_*54UN-[+1:YK&-+32(V.)_/<DIN=,9756^AC[;"7NL_3.WD!WYM;H^@W]U
M:6+U=^#;7CAPM==[:<,N]Q)T:^N?YJACOY^S^;97_P`(L$^OZX^B,<-DND^I
MOG\W^1M5ZU_3_P!I5-<!^T+*7FBR"3Z3?I?I/YMOYVQ%3O7?5G'S'G)S;K?M
MEM3:\BS'>ZEKC79]JQ+&UU_X3I]_]"M_GO\`3V7H_3_J]T[I^8<VCU#<:?LX
M+WN<`S>[)M.O\[=?DV69%^1?ZM_JO_G%=Q+'6XU5CQ#GL:YP/B0C(*4DDDDI
M\@22224__];T7ZO?^)_IG_A2C_SVQ:"S_J]_XG^F?^%*/_/;%H)*09N'CYV)
M=AY+2ZC(8:[&@EI+7"##V%KV_P!E0P>G8G3V65XC375;8ZXU;B6-<_W6>BQQ
M/HUO?^D]*K]%ZGJ/_/5I))3QO1GVL^MEV+EY#J[6&QS:OM-SW6;M[J6W8MN9
MFXWI.Q/UEGI48[\?]%_,>KZ*E9C8XS'7^DWUZ]]3+2/<UFYWZ-JGUTNZ?]9,
M+J&7G448]E@]-K*@,]S&L])W3J;&;K,[`LR[*LA^)5CWYGKY'Z/^;K?7>ZOB
M-IM;D,:6U7RY\\->=?=^YZO_`%:2G$ZECTWUTNL<0ZBWU*FAVW<Z-6[?\+M;
M[]BJ6V.94^QC#:\"6UMT+CX-5VFHY==&1U+%KIRL=[GU,+MXJ,[6V;_H[W-"
MDR\7_:1DX[J:\5Y;ON`A[`W<^^N/S$5-%E%V6&,K>[&=+7V$`.('Y]#OS?=]
M%:&5;8,.]V$QE]K6D4TAPVEX]OI;V_N_Z/<GQ\NC(Q69F,390]A>PM;J0V1M
M]/\`?]NS8B_5JFE]5&3@8_V/#K<ZVQEHV;)GU=P=N][OI_R$E-SJ'U@ZWA/Q
MZ:>BOS+#30_)].T-#+;W/H9CT[ZW-N].RI[\BUUE5>/C_IK%K])ZC7U7IF+U
M*ICJJ\NIMK&/C<`\;ANVRN"ZK=G=:ZG;F=(;>RX!CPVG?@Y[L.*GT9&(_P!:
MW`ZOB.MM]1U6;11E8W]%N]#U_5J]#QF6UX]5=UGK6L8UMEH:&![@(?9Z;?;7
MO=[MB"DJ2222GR!))))3_]?T7ZO?^)_IG_A2C_SVQ:"S_J]_XG^F?^%*/_/;
M%H)*4DDDDI%;C46VU765M?9CN+Z7D`N8YS75/=6[\W=6]]:YN^[JG3NOW,JQ
MWCH;SZ_4+\I[7L<;@REOV!S[/5;ML;^DPG_]8J_28U>3U*#F8>+G8UF)EU,O
MQ[AMLJL$M</,%)3SMG2^F]<Q[:L&^O)P;6UO=4'.:0UX%]3=[?=L>WW^Y66]
M$SG-!)K81H&$DZ#3D!8O7\/.Z'B;>FFYNVK+S;[L:IX:_(]*OI/1\&FJC?75
M5C_::/0QOH,HZ=ZMF_\`27*>35UBC,ZA9U7)S>G=!HJ`NR:KO6=9Z;J&8N1B
MFEEN7B.NI;?^TO1IIV?Z3_#I*=G&Z3]GM8_,=35CUS#`8:=H+XVD,8UC&A]K
MOZBQ.J?6W`RJ&.:S)QNA^I2;[Z39B9#A:;#B7^FZJN[]CYGH_P!+Q,FK+_P>
MST?5]6Y5TWJO7OJSATV9!IR*,SU\;/RJ=V0*<>ZQ^!EMQ[&TMKS+Z*Z-_K5_
MS-MWJ5_I5N=+Z%TWI1L=AUN:;`&2][K-E;"YU6-1ZKG^ABU>I9Z6/5^B9O24
MUOJUT,=+Q3;D5U'JN5#NH9-30#:\%VPV.#:_4>UKOTMWIU?:+_5R?2_2K922
M24I))))3Y`DDDDI__]#T7ZO?^)_IG_A2C_SVQ:"P.A=?Z%5T/IU5O4L6NQF+
M2U['7UM<US:V-<US7/W-<URO?\X_J]_Y:8?_`+$5?^324@Q_K;]7<FC.R*,V
MM]'3!.7:-VQH.[:]C]NV]C_3>VMU'J>K_@U>Z=U+$ZGC_:<-SG5A[ZW;V/K<
MU];C7;6^J]E=K'UO;L=O8N;LQ?J>WH[NE8?5\>FH->W'%N7ZS*MSJ[6Q2[)K
MW_9WT,=B_I/5QO\``65J?3F_5K`KPF,^L+7_`&27W;LQD9%CC=9ZN6WU/]/E
MY%[]G](M]#[5ZWV:I)3:R/K>*W9!JZ???CTY+<"G(!K:V[+=:,1^-6RU[+&5
MU7.V?:K&^C[+?^N&QOK31E74X].)D&Z^G)L96[TVGU<2P8V5@N_3;6Y++G?G
M?JW_`'85"_&^HE]F2\]1HK^UV-OL95G>FP7L<VT9M-55[649F^NO?D5?I'_]
MN)SC?4.:2WJ%#&X]%N-4QF<6M%=^_P"U[@W(]]V0ZSU+LA_ZP^UE5WJ>K4DI
M+B?7.C)?TMHP[&_M2V['`#ZGEEN.7LOVMKL=]JQ*_1L=9FXV^BMGI?Z1:+OK
M'T=OVX>L2[I=;[<Y@8^:FU[MWJ>S_"-K>_'_`.Y57Z;']6GWK(JQOJ-6,%O[
M3JLJZ80[$ILSR^MCFF:'^C9>YCG8OT,;=_,L1ZW?4BO)S,K[=B/MZBQU>;ZF
M6U[;F.+O9=59<ZM_I,>^FCV_H<;]7K_0I*8V_70XQK&;TO*QW&FS,O;-3S5B
M5N97]LL%=KMW\\Q]N/7^L4_I?9^_8;]:\<?MLW8]C!T%ILN+'5V"QFVRUOIF
MM_LOVT.WX]WI^EOIW_SBSOV=_B_<*!;U"F\8P+&"[/-@=47,M^R7BS(=]HPV
M/IJV8MV^C]'_`%U9'_,HG/-W4L?(/5&&G*==FBP^B[U#]FH<^[]6QV^O;LKH
M]/Z:2DC_`*YXF.P#.Q;L7(9E,Q,F@FIYI#V5Y'VVZRJU]7V"NO(H];(W?H_4
M^@JV1]?L2D]2+<&^YG27O&0ZMU+H;78[$L>YOK;J'^LS=CT9/HW96/\`IZ/\
M(H6=._Q=75EF7DX>82RQCK,G+%UA-HK;;=ZMUS[/M.RBBMF3_/TUU,KHLK8B
M6XW^+^ZJVJW+Q'-O9;5=.6-SVWV_;KA99Z_J._6OTS/=^B]2WTOYVQ)3TF-9
M;;179=4<>U[0Y]+BUQ8XCW5N?675NV?R'(JSO^<?U>_\M,/_`-B*O_)IC]9/
MJZ!)ZIAP-3^L5?\`DTE/F22;<S]X?C_<DDI__]G_[29V4&AO=&]S:&]P(#,N
M,``X0DE-!`0```````\<`5H``QLE1QP"```"````.$))300E```````0S<_Z
M?:C'O@D%<':NKP7#3CA"24T$.@``````[0```!`````!```````+<')I;G1/
M=71P=70````%`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E````
M`$-L<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;654
M15A4````!0!0`%,`+0`W```````/<')I;G10<F]O9E-E='5P3V)J8P````P`
M4`!R`&\`;P!F`"``4P!E`'0`=0!P```````*<')O;V93971U<`````$`````
M0FQT;F5N=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F0TU92P`X0DE-!#L`
M`````BT````0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N<P```!<`````
M0W!T;F)O;VP``````$-L8G)B;V]L``````!29W--8F]O;```````0W)N0V)O
M;VP``````$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T=F)O;VP`````
M`$5M;$1B;V]L``````!);G1R8F]O;```````0F-K9T]B:F,````!````````
M4D="0P````,`````4F0@(&1O=6)`;^````````````!'<FX@9&]U8D!OX```
M`````````$)L("!D;W5B0&_@````````````0G)D5%5N=$8C4FQT````````
M````````0FQD(%5N=$8C4FQT````````````````4G-L=%5N=$8C4'AL0'+`
M```````````*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M`````%!G4',`
M````4&=00P````!,969T56YT1B-2;'0```````````````!4;W`@56YT1B-2
M;'0```````````````!38VP@56YT1B-0<F-`60```````````!!C<F]P5VAE
M;E!R:6YT:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL;VYG``````````QC
M<F]P4F5C=$QE9G1L;VYG``````````UC<F]P4F5C=%)I9VAT;&]N9P``````
M```+8W)O<%)E8W14;W!L;VYG```````X0DE-`^T``````!`!+`````$``@$L
M`````0`".$))300F```````.`````````````#^````X0DE-!`T```````0`
M``!X.$))3009```````$````'CA"24T#\P``````"0```````````0`X0DE-
M)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&````
M```!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!
M`"T````&```````!.$))30/X``````!P``#_________________________
M____`^@`````_____________________________P/H`````/__________
M__________________\#Z`````#_____________________________`^@`
M`#A"24T$"```````$`````$```)````"0``````X0DE-!!X```````0`````
M.$))300:``````.)````!@``````````````QP```(P````J`$T`80!C`'(`
M;P!'`&4`;@!I`&,`<P`@`$8`;P!R`&T`(`!3`"T`,0!?`%\`10!!`%,`5`!?
M`#8`,@`W`#0`,``V`#0`-0!?`#$`,0!?`"T`-P`U`````0``````````````
M```````````!``````````````",````QP`````````````````````!````
M`````````````````````!`````!````````;G5L;`````(````&8F]U;F1S
M3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F
M=&QO;F<``````````$)T;VUL;VYG````QP````!29VAT;&]N9P```(P````&
M<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC
M94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T`
M```,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T`
M```*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````
M4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"
M=&]M;&]N9P```,<`````4F=H=&QO;F<```",`````W5R;%1%6%0````!````
M````;G5L;%1%6%0````!````````37-G951%6%0````!```````&86QT5&%G
M5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT
M5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG
M;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L
M:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'
M0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F
M=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I
M9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````C_P````````.$))
M3004```````$`````CA"24T$#``````=.P````$```!Q````H````50``-2`
M```='P`8``'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`
M#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,
M#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`
MH`!Q`P$B``(1`0,1`?_=``0`"/_$`3\```$%`0$!`0$!``````````,``0($
M!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"
M!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'
M!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[?H70^B6
M]#Z=;;T_&?8_%I<][J6.<7&MCG.<YS2YSG.5[_F_T#_RMQ/^V*__`""7U>_\
M3_3/_"E'_GMBT$E.?_S?Z!_Y6XG_`&Q7_P"02_YO]`_\K<3_`+8K_P#(+022
M4Y__`#?Z!_Y6XG_;%?\`Y!+_`)O]`_\`*W$_[8K_`/(*^3`)\/FN0S_K5U6_
MH&+U;`;5A-S;B,46!V8]]<[L;UL?#V>AZ[66?M#T7YE_3Z/YNNW)_HZ4[F1T
M?ZL8M#\C)P<&BBL;K+;*JFM:/WGO>T-:J0?]0CD''V=-]04_:2-E,>CM]?U?
M4V^GM]#]8^G_`$?]/_-+"NZ$['IOZKU+J'[).?:'N==ONNG=1U+I++V7778[
MLGHN95?C>RI]61TO^<]'_!ZUGU)QLD9#\K-MNMSJ#7DVBND$VOJ;B7YF,\U/
M?B?:,5GHOIIL]'TDDF)`!(-'0'H:W;XPOJ<<+]H#'Z<<$B1E;*/1B?3_`)^/
M2_G/9])6?^;_`$#_`,K<3_MBO_R"R^N].KZAF=.&/CX_4L7IEA9E=)>]K6M]
M45U4Y7H.#Z'V8..;W58][/H7_H?TGIK)Z/\`6_)QJ!C5].:ZITX_2NG8\LO;
M>Q[Z_P!E9++[+',=B8S&974,NVO$HP*_^Y%=N-9:D56[U7_-_H'_`)6XG_;%
M?_D$O^;_`$#_`,K<3_MBO_R"/T_J&'U+%;EX5K;\=SGM;:S5CC6YU-GIOT]1
MGJUOVV-]EG^#5E)3G_\`-_H'_E;B?]L5_P#D$C]7N@$0>F8D'G]!7_Y!:"22
MGR"!X!))))3_`/_0]%^KW_B?Z9_X4H_\]L6@L_ZO?^)_IG_A2C_SVQ:"2E))
M))*6/"Y+-ROJA]7NMMM^RO.<_?8\T[GLQS=M]6UN/99Z.+=F-9^E^RU>O;6S
M]+_.?I-SKG6*^C8)R[*K+]0QE=39)>[Z&]WT:F;O;O\`_1B\I?9DY64]U@=;
ME9%ID"276O=_-M:[\[<[TV,3)R(L1JP.(_W?+]+YG1^'<E#,>//Q#%?!'A_3
MR<,IR]7JX(PA#BXIM_ZP]>=U[.]?8:\:EIKQJG?2#7'])=9SMMO]NYG^#_FU
M+I/UGZWTKV4W_:,=K0UF-D2YC`WZ(I>"VVOV^SZ>Q`LZ'UMF:_"&#=9?6??L
M;N:`?H/];^:V/_-]W_@BINKN](VAKFU-=Z;["TAH?!_0O>1[+?\`@TRY"9D*
MQQRWK(B7#'B_2/#Q1X>#_-NQ''RLN7CA(',_=1&7!B]/'.</3P1X^&?NQR?Y
MV<./_6L\O,NS<S(ZA)9D76.?+26EL_1K98-K]K&^UJ[K*S_J;U=^(_)R0RW*
M8*7M)VV/J:7%V!U&W:YU.,^]VZVGU:F9=FS^?H7`R'#0R#W"8<MJU>^QP:Q@
M!<7.<=K:VM_/W3M8U",M9&`W-\!]<N$#BE+BCP_]%7-\E#+#%'/,1CA!C[T.
M'#CXIRACQ8_;R2R?-^A^L_Z;[36QE;&UUM#&,`:QC1``&C6M:%-<[]3^F]:P
M,..I9!](@"C",/-0'[U_TO\`T'_FJ5T*FB;`)%>#S6;'''DE",QD$3\\?EDN
MDDDBQOD"2222G__1]%^KW_B?Z9_X4H_\]L6@L_ZO?^)_IG_A2C_SVQ:"2E*E
MD]7Z?BYE&%?:&7Y+@RMO\IPL?2VP_P"#^T?9\C[/O_GGT6U5_I5'J?4+**[L
M;`#+^K''MOQ,1[MH?Z>UGO=^8SU;:F>]]>__`$GYZP.E_5_+ZME6]5ZRZ[T+
MK#;AX]NZG(96[:6XN14Q[FXE--]%&5CLHM]?UL?$RK/LV5]K9DI3>IZ]U)WU
MA=A.Q"WICV6O;E6M]!]8Q]E=]FRQ]GVC'NOM9]GM?7A?X5]?VBBOUEB==^L?
M0\?+.7T6FC)ZN2&NSMDUL`^D[]VVZUOZ+U*?\'_AO9Z:Z_K%SL?I.;>T![JL
M>UX:>"6L<Z'+R6SI^=BX]=U^)?34]H#++&.:UW\G<[VL<_;[-ZCR2Z>%@U^E
M^CZI</!_?=3X5RT)F629T$A`PX^#W,?#*63T1C*>;]#]3^F]AE_XP*2[IYQ6
M%@<[?U&IPW%C-:W45NCWO^E>RS]'[*J_](HYWUYZ:^O-QJ.GC(J>?U=U@::;
MB3^DNRJ2`]C-_P"DK_G+,C_@%Q8UU(U2.OQ3#D-UQ5TD=)Q_=XH\/Z#I0^%\
MN(<8@9T./%$<>*4H_P`YCCEXY0_6<7%C_0X,?S_K/UC/*O.1D.RKMC;+"`?3
M8*V``>UK*J_:W:W_`-2*]]7^JLZ3UBG,O8QV.)KN>YNYU;'Z.R*"-SVV5_X3
M:S]+1ZBS@!`!UA$P\2_J&15A8^T7Y+O3K-AVM!B2Y[R/HL;N_-WO_P`%O2!)
MU'K,?U?%.6@X_P":X(?/'AX<G]1L9<6,1GCD/:Q3B<LH8H<,OU4?Z1[^7UX?
MTL/!_,Y/1_B>S,<US0YI!:X`@C@@J2S.AWVC$9@YD-ZAAULKR6@0'$#8W)H_
MTF/?L_1V?]:L]*ZNRFO35@BC3R.G12222"GR!))))3__TO1?J]_XG^F?^%*/
M_/;%/JW4Z.F8;LBUP#W$5X]9#W&RYW\S2RO&KR,BS>[_`$%%UGI>I;Z?Z-0^
MKW_B?Z9_X4H_\]L6!]9Z\WJG7,3H[1?53NK>X.KW8MU,NMS;775UV>ED8GH4
MT4?K&%DT9&55D8UF_P!))2WU5Z7D=0RC]8NH^H77/%^-786NVV.J91;=AWT7
MW,_9NWUJL-FVI^1CV>IF?:O3P[*^P3`!H@?WITE-7J74<;IN(_+R2[8TM:UK
M&E[WO>173334R7VW6V.;76Q8MWUDZ=D5V8W6\.S!PKO8Z[(-5E&I#6UY5V);
M>W"M_<??Z=7_`'9]57/K+T_+S,.BW":VW*P,AF750YVP6[`^NVAMI]M-KZ;K
M/0L=[/M'I>I^C7/X][+/4%>YEE(#<C'M;LNJ#AHS+QO=L98WZ+_TF+?_`(&Z
MU/A&,@03J@R,2".FMC<.%]8?JYD=$N8XWMR<3()&/9Q9H-^VUG\W[6_X9C_T
MG^C8LO'H-^35BBS8[)L94QQUCU'"O?M_.V[ET^3TT/PW8>,6-Q7'?]@OW?9@
M\'=ZN(^G]9Z5;[G?T;U,/_NG^DL6)T_KF5]7S]ARNC4V9P/JLLR7-AS@=]63
MBNJIN^T>G]'U,>[_`+;0^ZS-B!B#Z0(`:SX>'7^]Z?4ZF/XW&..(S0GER1.2
M7N\7#&/N\4?EC^CZ^'@>WL^H71STIF$PN9E5-);U"`;7//Y]_P!%M]>[_`O_
M`.MK"Z-]2\UO6A1UBESL2MCK&9%#]K'O:YGI>]A]>KVN=[/T=F]BR<KZ^_6S
M)C;E4X8\,:@$GXV9KLG_`*-:W?JG]>LBPVXO77&T4AMG[2#&L:UECW4_K[*M
MC*MENUC<JFKT/2_I7V?TO53\O)SC'CG&-7<JX.+_`-%]32Y?XKECQ8X99RXH
MRB.(Y/1Q>HSA_K/3\W]]U>L?5_K.9GY.31:RRNPU>@UV1D8SFUMV_:L"<-K_
M`$ZLBRO[9]MJ_6/4_5[:O1KK2'0_K)Z]0MS&Y%563BWF[U[J;'"C';3D_H:V
M645MSLMGZ?%_2XWV>V__`+56>M7TZ2B87-^KV!F]/Z55B9UOK7UNL.\/?9#'
M6664U>M<&V6>A2]E/T*_H+22224^0))))*?_T^\P,HXGU0Q,EL;ZL"IS)@@N
M])GIMA]E#7;G_F^O5_QBSOJ;;F9F1FYU^3=:W=Z9J-CGT![G.R+/0J?2UN/]
MG<_T?T67F_H_T=MOZ&GT[=%CZOJ9AO9>[%<,/&_3,I=DN;+:@?U2D.MMW_0]
MGT/YQ/\`4^JFOIUQKS+.H.=>19DW4/Q["6,KJ:Q]5P9N].MC/TU=;&6_\=ZM
MB2G>22224^=_XQ^K=1;U.CI5-MF/A_9OM-GI.=6;7N>^C9;;66V>CCM;_-,?
M_.7_`*;_``:XRG?C6-RJ'OQ[J_HY-;BUX_DNN=/J,_>JO]2IZ]-^N3>G9EN+
MTZ[!;FY8#KV6OL?0,>K2I]OVC&_6=^0_;77BU?S_`*>^[V8ZQ,+IG2<&PV6?
M5[$S2?SSD/O?_P!M=7;Z3?[.0I(_$^3P#V<O",NYXNTOWI_HK)<GGRGC@3P=
M*Z.=TCZVTY3_`++G;3<UL_:\5I?40/I.R\:CU7X?_'4^KB_\0MR^C$SL1M.1
M77F8=OZ2L$[V.G078UU1]C_^'QK/46O5];^AX=+&9&/D=,K+A52QV.2U[W?0
MIQ_L'VJJRQW^CK5`=(?FYMF9359T/"N.^W%I?LOR7.`)OR&,W5=)MT_G,1W[
M2R*[/UFW&33SF(CC!!QG;AE[GV27#!/Y=>+Q'"\CF_5^JG/./1F6V4,(^TM9
MCOS,K%#OSLIN-MJMJ_/WV>GG_P#=2]=KT;H_U:Z']7\OJ)R?VAAY=!=EYEA:
MX64M:YOH55U!M;:_?9^@9^DLNM_TBN,&!TC`VUFKI^#C"29%53).W?8\_P"$
ML>?IV?IK;%GT=%SLAMG6,8.+6Y=F9T_H^4-M#IVN]=U;FUWXN?EWUV9>+=D/
MM9T]^3_0_6]5,'.9,]Q)EP1^6S^:3@CCH@#B.]/1=%KR*NCX-64",BO&J;<'
M:G>&-%F[^5O5U5^GYM'4,&C-QY]+(K;8P.T<`X3LL;KML9]&Q6$5*22224^0
M))))*?_4[[I>'CYWU5P,7)K9=5;A4`LM8VQDBNMS"ZJS<Q^QXW^Y9?\`B_OL
M=@Y5#]SS3:)L^RG$;N+=EE3V/#;+<^MU6_J#OYEEMOI4+:^KW_B?Z9_X4H_\
M]L613U'J/3OK/9A9M]MO3\JS;C/R-E;*W6@WU,HN;CUU9#76_J-%%F?9U#?_
M`-HOLWZRDIZA))))3A=>Z+EY655U#IYK=D,K--U%Q<QEE>[U6;;JVV^C?19O
M]/\`165V>K979_I*^?Q+<[J#W58.,T>FX-MS;+&V8;9^EZ%N,6V=1R*_\)C4
M>C76_P!F1EU+HOK9M_9U+;W%G3WY-3.IN!VC[,XD/%K]-N,^[T*\S_NIZWJ_
MH?40\O+Q.G45F\BMI`KQJ*F[GO@#;1A8F.'67;6_X.AFS9_P:S^<Y;!/()2Q
M\6276Y5+A_>C^DV<&6<8D"=1_ELAZ=TC'P;/M!<[*SWM#'YMH'J1_HL:NN*L
M*C7^8Q6?\=ZUBAF]991:_$PJCG9E<"RMKMM-))_[79D/90[;[OLM7K9K_P#N
M/_A%7R+L_,#VW.=A41#,;'L`O>0?HYW4:M[<5KOH_9^E^H__`$F?_@EG=-Z#
MT_$Q?2LQHL8XFI]=SZB-WTWO^QOJ]^UK:V?^"I_W7(8:&,9?H1(_5Q_P8+?>
MC?6NI'S%)91D9-M67F9=EF902ZA]$554DAS7?9,.P9%7T'[?M&9]IRO^$I5_
M#^LF=@Y'V+-<[J=N2QSNF!K6LOLM86MLPK?1#,?;MMJO^V^E351C^O\`:_YG
MU;`CI[2]K:\_*QB[_N4*LFH3V<]S:,S;_+=D+=Z/T$=/M?EY%YR\RQGI>KL%
M;&5[O4]'&I;O]-CW^^Y]EMUMS_\`"?HZO3CY7E^=QYKRY1/%ZN(`W'^KP0X8
M^WZOW5^;)@EC]$2)]^OUDV>BX-O3^E8V)<X/NJ8/6>WZ)L=[[C7(;^C]5S_3
M_D*\J&?UWI/3K33F9`KL;4;W-VN<17N])KW>FU^WU;3Z6.QWOR;?T>/ZB?"Z
MUTO/N]#$R&VV^DW(#0")J>7,9:TN#=[?4K?6_9_-6_H[%HM5O))))*?($DDD
ME/\`_]7T7ZO?^)_IG_A2C_SVQ9/UNZ(VP?MS%8]V?C5>@XTL-E_H.=^D=T_]
M(S[)FT[[+*\FFNU_TZWX^5^CK6M]7O\`Q/\`3/\`PI1_Y[8K69B49N+9BY`+
MJ;FEKPUSF&#^[9666,_L.24U.A]7;U;!&06>A<UQKOQRX.=4\>[TKMO\U=Z3
MJ[;,=_Z;']3TK_TJT5QO3.CYGU>S+<A]GV;I6"P/R<ZYS7^O2QECOLN/AXXK
M9@XN-;:Z_;Z-=E-^_P!/[=]MN]+J<#J&+U'%9EXA<^BS6M[F/KW#\VQC;V5N
M?4__``=K?T=G^#24V'-#@6N$@B"#J"%RV?B=+QQD8G1\>GI[[6&F[+QJV,>)
M,^E46AOL:[^<_,75+BZA;5D9-.1E,O>^ZRS&K:`QS:-VT-%?YS&.24CR/M=&
M"UN/=4_*8&M]3)'\X&_SCO3K_P`,INSJFV`UL+VC63IKX0@=0IILOHM=5NMH
M#O3MUT#OI-;^;_*54UN-[+1:YK&-+32(V.)_/<DIN=,9756^AC[;"7NL_3.W
MD!WYM;H^@W]U:6+U=^#;7CAPM==[:<,N]Q)T:^N?YJACOY^S^;97_P`(L$^O
MZX^B,<-DND^IOG\W^1M5ZU_3_P!I5-<!^T+*7FBR"3Z3?I?I/YMOYVQ%3O7?
M5G'S'G)S;K?MEM3:\BS'>ZEKC79]JQ+&UU_X3I]_]"M_GO\`3V7H_3_J]T[I
M^8<VCU#<:?LX+WN<`S>[)M.O\[=?DV69%^1?ZM_JO_G%=Q+'6XU5CQ#GL:YP
M/B0C(*4DDDDI\@22224__];T7ZO?^)_IG_A2C_SVQ:"S_J]_XG^F?^%*/_/;
M%H)*09N'CYV)=AY+2ZC(8:[&@EI+7"##V%KV_P!E0P>G8G3V65XC375;8ZXU
M;B6-<_W6>BQQ/HUO?^D]*K]%ZGJ/_/5I))3QO1GVL^MEV+EY#J[6&QS:OM-S
MW6;M[J6W8MN9FXWI.Q/UEGI48[\?]%_,>KZ*E9C8XS'7^DWUZ]]3+2/<UFYW
MZ-JGUTNZ?]9,+J&7G448]E@]-K*@,]S&L])W3J;&;K,[`LR[*LA^)5CWYGKY
M'Z/^;K?7>ZOB-IM;D,:6U7RY\\->=?=^YZO_`%:2G$ZECTWUTNL<0ZBWU*FA
MVW<Z-6[?\+M;[]BJ6V.94^QC#:\"6UMT+CX-5VFHY==&1U+%KIRL=[GU,+MX
MJ,[6V;_H[W-"DR\7_:1DX[J:\5Y;ON`A[`W<^^N/S$5-%E%V6&,K>[&=+7V$
M`.('Y]#OS?=]%:&5;8,.]V$QE]K6D4TAPVEX]OI;V_N_Z/<GQ\NC(Q69F,39
M0]A>PM;J0V1M]/\`?]NS8B_5JFE]5&3@8_V/#K<ZVQEHV;)GU=P=N][OI_R$
ME-SJ'U@ZWA/QZ:>BOS+#30_)].T-#+;W/H9CT[ZW-N].RI[\BUUE5>/C_IK%
MK])ZC7U7IF+U*ICJJ\NIMK&/C<`\;ANVRN"ZK=G=:ZG;F=(;>RX!CPVG?@Y[
ML.*GT9&(_P!:W`ZOB.MM]1U6;11E8W]%N]#U_5J]#QF6UX]5=UGK6L8UMEH:
M&![@(?9Z;?;7O=[MB"DJ2222GR!))))3_]?T7ZO?^)_IG_A2C_SVQ:"S_J]_
MXG^F?^%*/_/;%H)*4DDDDI%;C46VU765M?9CN+Z7D`N8YS75/=6[\W=6]]:Y
MN^[JG3NOW,JQWCH;SZ_4+\I[7L<;@REOV!S[/5;ML;^DPG_]8J_28U>3U*#F
M8>+G8UF)EU,OQ[AMLJL$M</,%)3SMG2^F]<Q[:L&^O)P;6UO=4'.:0UX%]3=
M[?=L>WW^Y66]$SG-!)K81H&$DZ#3D!8O7\/.Z'B;>FFYNVK+S;[L:IX:_(]*
MOI/1\&FJC?755C_::/0QOH,HZ=ZMF_\`27*>35UBC,ZA9U7)S>G=!HJ`NR:K
MO6=9Z;J&8N1BFEEN7B.NI;?^TO1IIV?Z3_#I*=G&Z3]GM8_,=35CUS#`8:=H
M+XVD,8UC&A]KOZBQ.J?6W`RJ&.:S)QNA^I2;[Z39B9#A:;#B7^FZJN[]CYGH
M_P!+Q,FK+_P>ST?5]6Y5TWJO7OJSATV9!IR*,SU\;/RJ=V0*<>ZQ^!EMQ[&T
MMKS+Z*Z-_K5_S-MWJ5_I5N=+Z%TWI1L=AUN:;`&2][K-E;"YU6-1ZKG^ABU>
MI9Z6/5^B9O24UOJUT,=+Q3;D5U'JN5#NH9-30#:\%VPV.#:_4>UKOTMWIU?:
M+_5R?2_2K92224I))))3Y`DDDDI__]#T7ZO?^)_IG_A2C_SVQ:"P.A=?Z%5T
M/IU5O4L6NQF+2U['7UM<US:V-<US7/W-<URO?\X_J]_Y:8?_`+$5?^324@Q_
MK;]7<FC.R*,VM]'3!.7:-VQH.[:]C]NV]C_3>VMU'J>K_@U>Z=U+$ZGC_:<-
MSG5A[ZW;V/K<U];C7;6^J]E=K'UO;L=O8N;LQ?J>WH[NE8?5\>FH->W'%N7Z
MS*MSJ[6Q2[)KW_9WT,=B_I/5QO\``65J?3F_5K`KPF,^L+7_`&27W;LQD9%C
MC=9ZN6WU/]/EY%[]G](M]#[5ZWV:I)3:R/K>*W9!JZ???CTY+<"G(!K:V[+=
M:,1^-6RU[+&5U7.V?:K&^C[+?^N&QOK31E74X].)D&Z^G)L96[TVGU<2P8V5
M@N_3;6Y++G?G?JW_`'85"_&^HE]F2\]1HK^UV-OL95G>FP7L<VT9M-55[649
MF^NO?D5?I'_]N)SC?4.:2WJ%#&X]%N-4QF<6M%=^_P"U[@W(]]V0ZSU+LA_Z
MP^UE5WJ>K4DI+B?7.C)?TMHP[&_M2V['`#ZGEEN.7LOVMKL=]JQ*_1L=9FXV
M^BMGI?Z1:+OK'T=OVX>L2[I=;[<Y@8^:FU[MWJ>S_"-K>_'_`.Y57Z;']6GW
MK(JQOJ-6,%O[3JLJZ80[$ILSR^MCFF:'^C9>YCG8OT,;=_,L1ZW?4BO)S,K[
M=B/MZBQU>;ZF6U[;F.+O9=59<ZM_I,>^FCV_H<;]7K_0I*8V_70XQK&;TO*Q
MW&FS,O;-3S5B5N97]LL%=KMW\\Q]N/7^L4_I?9^_8;]:\<?MLW8]C!T%ILN+
M'5V"QFVRUOIFM_LOVT.WX]WI^EOIW_SBSOV=_B_<*!;U"F\8P+&"[/-@=47,
MM^R7BS(=]HPV/IJV8MV^C]'_`%U9'_,HG/-W4L?(/5&&G*==FBP^B[U#]FH<
M^[]6QV^O;LKH]/Z:2DC_`*YXF.P#.Q;L7(9E,Q,F@FIYI#V5Y'VVZRJU]7V"
MNO(H];(W?H_4^@JV1]?L2D]2+<&^YG27O&0ZMU+H;78[$L>YOK;J'^LS=CT9
M/HW96/\`IZ/\(H6=._Q=75EF7DX>82RQCK,G+%UA-HK;;=ZMUS[/M.RBBMF3
M_/TUU,KHLK8B6XW^+^ZJVJW+Q'-O9;5=.6-SVWV_;KA99Z_J._6OTS/=^B]2
MWTOYVQ)3TF-9;;179=4<>U[0Y]+BUQ8XCW5N?675NV?R'(JSO^<?U>_\M,/_
M`-B*O_)IC]9/JZ!)ZIAP-3^L5?\`DTE/F22;<S]X?C_<DDI__]D`.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V````
M`0`X0DE-!`8```````<`"`````$!`/_A#@MH='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN
M<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE
M;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]P:&]T;W-H;W`O,2XP+R(@>&UP.D-R96%T941A=&4](C(P,3,M,#<M,S!4
M,34Z,#DZ,#,B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9TPJX@3V9F:6-E
M(%=O<F0@,C`P-R(@>&UP.DUO9&EF>41A=&4](C(P,3,M,#<M,S!4,34Z,3,Z
M,#0K,#4Z,S`B('AM<#I-971A9&%T841A=&4](C(P,3,M,#<M,S!4,34Z,3,Z
M,#0K,#4Z,S`B('!D9CI0<F]D=6-E<CTB36EC<F]S;V9TPJX@3V9F:6-E(%=O
M<F0@,C`P-R(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HV0D-%0S)"-$5$
M1CA%,C$Q038Y0T%"0S`X-#-!-4-%,2(@>&UP34TZ26YS=&%N8V5)1#TB>&UP
M+FEI9#HV0D-%0S)"-$5$1CA%,C$Q038Y0T%"0S`X-#-!-4-%,2(@>&UP34TZ
M3W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED.C9"0T5#,D(T141&.$4R,3%!
M-CE#04)#,#@T,T$U0T4Q(B!D8SIF;W)M870](FEM86=E+VIP96<B('!H;W1O
M<VAO<#I#;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F:6QE/2)S4D="
M($E%0S8Q.38V+3(N,2(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F.E-E<3X@/')D
M9CIL:2!S=$5V=#IA8W1I;VX](F1E<FEV960B('-T179T.G!A<F%M971E<G,]
M(F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H
M;W`@=&\@:6UA9V4O:G!E9R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB<V%V
M960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-D)#14,R0C1%1$8X13(Q
M,4$V.4-!0D,P.#0S035#13$B('-T179T.G=H96X](C(P,3,M,#<M,S!4,34Z
M,3,Z,#0K,#4Z,S`B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F
M.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B`\>&UP34TZ1&5R:79E9$9R;VT@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO
M<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10`!`0``#$A,:6YO
M`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94`````$E%0R!S
M4D="```````````````!``#VU@`!`````-,M2%`@(```````````````````
M````````````````````````````````````````````$6-P<G0```%0````
M,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````%')865H```(8
M````%&=865H```(L````%&)865H```)`````%&1M;F0```)4````<&1M9&0`
M``+$````B'9U960```-,````AG9I97<```/4````)&QU;6D```/X````%&UE
M87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=44D,```0\```(
M#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q.3DX($AE=VQE
M='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="($E%0S8Q.38V
M+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````````````````
M``````````````````````````````````````````````````!865H@````
M````\U$``0````$6S%A96B``````````````````````6%E:(````````&^B
M```X]0```Y!865H@````````8ID``+>%```8VEA96B`````````DH```#X0`
M`+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````
M```6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````````````````
M`````````````````````````````````&1E<V,`````````+DE%0R`V,3DV
M-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@``````````
M````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@
M<U)'0@````````````````````````````!D97-C`````````"Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````
M```L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N
M,0``````````````````````````````````=FEE=P``````$Z3^`!1?+@`0
MSQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7'^=M96%S````
M``````$````````````````````````"CP````)S:6<@`````$-25"!C=7)V
M````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!``$4`2@!/`%0`
M60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`L@"W`+P`P0#&
M`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K`3(!.`$^`44!
M3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!T0'9`>$!Z0'R
M`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8`J("K`*V`L$"
MRP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#E@.B`ZX#N@/'
M`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V!,0$TP3A!/`$
M_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&%@8G!C<&2`99
M!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9!ZP'OP?2!^4'
M^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)9`EY"8\)I`FZ
M"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1"VD+@`N8"[`+
MR`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-C@VI#<,-W@WX
M#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L$`D0)A!#$&$0
M?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02HQ+#$N,3`Q,C
M$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X%9L5O17@%@,6
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M)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[:SNJ.^@\)SQE
M/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G02E!:D&L0>Y"
M,$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&\$<U1WM'P$@%
M2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"34I-DTW<3B5.
M;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3JE/V5$)4CU3;
M52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI66J9:]5M%6Y5;
MY5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]AHF'U8DEBG&+P
M8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ:DAJ
MGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9PX'$Z<95Q\')+
M<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,>2IYB7GG>D9Z
MI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!:X'-@C""DH+T
M@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^BF2*RHLPBY:+
M_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.339.VE""4BI3T
ME5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)G/>=9)W2GD">
MKI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJFBZ;]IVZGX*A2
MJ,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!UL.JQ8+'6LDNR
MPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5
MO8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(QD;&P\=!Q[_(
M/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1/-&^TC_2P=-$
MT\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*W1#=EMX<WJ+?
M*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+HO.E&Z=#J6^KE
MZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"]5#UWO9M]OOW
MBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!9&]B90!D0```
M``'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!`0("`0("`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`__``!$(`,<`C`,!$0`"$0$#$0'_W0`$`!+_Q`&B````!@(#`0``````````
M```'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'`@@!"0`*"Q``
M`@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)44(6820S%U)Q
M@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%565QJRPM+B\F2#
M=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(B8J4E9:7F)F:
MI*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT]?;W^/GZ$0`"
M`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"@2.1%5*A8A8S
M";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"TN+R565U5C>$
MA:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F]F=WAY>GM\?7
MY_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@`,
M`P$``A$#$0`_`-F;X'_R_?A-OGX4_$W>&\/B[TQN7=.Y_CSU-N#<>XLYLS'Y
M3.9[/9O9V*RF8S&9RE:)J[*9/)9"JDFFJ)Y))9'<DL>+>Z]T;#_AM+X!?]XA
M]"_^B^PW_7KW[KW7O^&TO@%_WB'T+_Z+[#?]>O?NO=>_X;2^`7_>(?0O_HOL
M-_UZ]^Z]U[_AM+X!?]XA]"_^B^PW_7KW[KW7O^&TO@%_WB'T+_Z+[#?]>O?N
MO=>_X;2^`7_>(?0O_HOL-_UZ]^Z]U[_AM+X!?]XA]"_^B^PW_7KW[KW7O^&T
MO@%_WB'T+_Z+[#?]>O?NO=>_X;2^`7_>(70O_HOL-_UZ]^Z]U[_AM+X!?]XA
M]"_^B^PW_7KW[KW7O^&TO@%_WB'T+_Z+[#?]>O?NO=>_X;2^`7_>(?0O_HOL
M-_UZ]^Z]U[_AM+X!?]XA]"_^B^PW_7KW[KW7O^&TO@%_WB'T+_Z+[#?]>O?N
MO=>_X;2^`7_>(?0O_HOL-_UZ]^Z]U[_AM+X!?]XA]"_^B^PW_7GW[KW5=_\`
MLC_Q"_X<U_T0_P"RW]0_Z,O]EH_TA?W$_NE3?W5_OY_'/[L?WN_@?D_A?\?_
M`+O?Y%]UX?+]OZ;W]7OW7NO_T-R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=`SOKY#=)=:5.]L?OCM/8>W\WUOU-G^^=\[3J
M-RXZJWUMWI;:PJES_:%7L+'25F\9=EX^IHY*?[Z*ADADJU\"%IB$/NO=4*?(
MO^<;N?O;"[3Z[^&VY<_\0MR57RJZO^)WR@[)^3OQYFRO>'P\3Y.[,.Y?B/WY
M3]!9_=%-M"?KSO'/14^'IZO=M33?PR;+4ZY''TU0DL*>Z]T%?5.Z_P"8IW;\
MB_C_`-[_`"%^,'R>W1O7#],5'QLVO1]7]@UG4_Q^^*'SLZH[8[4ZM^1GR/[@
MZNS6^NN,%VIT-W%UW583>6T<O/C-\4U1CH?X/14$E2T<X]U[HN?2'\K/^8WM
M'XV=I=35]-\D^N>\>Z]S?#;ISY"]I[0^0_46(V/V#M_:'RVJ.Q?D)\R.L]R;
M7W_ENY,CW'E.IH&II]P;EAP6>K<1DTQJXN::AC,?NO=6@?S+M\Y[XP8'^6]\
M&>O/D5OOXB=!?)+N7<73O<'S:W/V54Y/L+K3KCK+K+.=AXSK+$]_]PUNY9=M
M]V_(K+4`PF"W-F:BMKHGIJDQ":HT#W[KW0R?&+YC_'3XW]J57\OK?GSH['^6
M7:^'WUMK&[9[+[,V?/FY.NJ3NO#QYOX_?'3NKY(;-V_!UINCN??%#ALK5[:J
M,O/0YW<M)HA,4M2D357NO=6W8C=&W<[D,_B</GL'E<MM2NIL5NG%XK,8_)9#
M;.5J\=2Y>EQFX*.DGDJ<-D*G$UT%5'#4)'(]/,DB@HZD^Z]T_P#OW7NO>_=>
MZ][]U[KWOW7NJM?^ZOO_`)9S_P#+S[]U[K__T=R?^7)_V0)\,?\`Q6+I/_WW
M^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW7O?NO=:[6<VS\VO@3\R_G5V-TU\&ZK
MYQY3Y\[CP._^@/D=M[<'7^%W)TYO7&==[5Z^Q7QL^5^9WIN/;.ZMM_%SKS(;
M4&>P61P4M=#2TM;4TR4KU]23![KW1@?B?_+-^-O\OS:>[_D7W7N[+=N]KX3J
MG.Q]@=E]HY+&;AVYUQL>??%5\A^P]@==4;[=V[5;CV<G?&0R&?Q66W>,]O62
M5Z6*;*R^")%T[^!`US=.-"BI/`4'V]+]FV;=N8-ZVOEGE^W:7?=QF2.-$!9F
M9V"+04-,G[`*DX&*?-A?SXN^W^7)[4[$AG;XEYJMR>"FZ-V_A,-/N+:.PIFT
M8#>=!F98J;+9_L3'R4T596T\E3%2525$]+"D12)O<1;?[@;F-Y*;A"%LJGM`
M&`>!SQ-*<3UVOYH_NVN04]AY]CY9NFD]]-O*R/?F23P-QD90S6\"!BJV25*F
MX"EE=:MJ%0=DKXL_/WXI?,;!OENCNW<%GZB/+56!J]J;C#[([`ILC2K%-ZMB
M;G&-W--1ST\RR05,,,L$ZWT.2K`3_P`R<M;SR;N,>R<S0>#N[1K(J'34HZAE
M(H2.!%:<.N'VRVVX<Q<O7G-NT6%[?<IPW$D#WJ6LGT`EC<H4\8J%)U*5`#$X
M^8ZH#[D_G7TU;V]\A^C.\/B[U!\JOB5!V5NC:."VQN+'8J7)9?;FT\JN+49W
M;V]\?NOK_>D#9S%RU43UE+1R^I5OZ5;W#$_N%):;C<126H\$.0NDD-08X_EP
M&.&>NN>U?W:7+G-/M3R!OMCS_N.V>X-SL5K-N$5Q#];8QW%PVN&,/#I:)C&R
M:M7B%2!BH(Z6.Z/@_M+<'4-3_,A^'FPMDX:K[;W=A?F!U]M#Y"[5IJJF^!?:
MLN%EQ?9WRUVU5]:3?WN[WVGU]L+;,68P'2^3I=PX5-VQ4F0PHH`GV?L?V<RW
MEK'>H#X3BHKQS7C3[#US(]S.1=[]KO</G#VXWK<X[S<-IW$VCF*FC6O\&K22
M#6HJ-0`IW$=&6_D[_'CY"8B6+N:CFWQT/\1L]'O'>.(V+W-@,3G/F?\`S!.X
M.SQCZG<GSG^;V\\U#69OK2MS"T*OLW8V,>&LH:"=?XC+#!34="7^@,1I)7TZ
MV$O?NO=>]^Z]U[W[KW7O?NO=5:_]U??_`"SG_P"7GW[KW7__TMR?^7)_V0)\
M,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW7O?NO=48_S=/YF%?\`
M$S;5'T?T?FJ`?)GL+'1Y23+QP4^4@Z:V#+-)%_>[(4%6L]#5;IW))3O!AJ.=
M74(LM7*GCCC$P3YNYFCV:)+6QHV]LO:I`.*\3BGE0#[>L]/N._=+C]]=ZNO<
M#W!L)8_9O:'I/(I*_77]*Q6L9!#?3&H,TJD!!V@ZF.C6:^2O\QSYM_*OKW;7
M47;7:6(R_7-#E5RNYZ';^U<7LRLWS/0M#)B8-Z3X5TI\YC,7,C314<<-/`]7
MXY9DE,::6.6.;?;B[Y!YZL/<ZTW>ZYO45VR.*/0';2:5"4U$,>+>76<M[]SS
MFSVE^\'[(\^?=1V[:-J]NFF(YDFWIUW&[M-MU`2S[9'<@!C>QEXHWH70X4@,
MU28_FXXO_M[_`.)L+D?3W!P!9`)`:TR#Q^P_,<#\^NC!D1)C):L5B!.@\*(2
M:`>@(_",>74.''TM&RU-!314-72RFII*ZC:6BJ:6K^L=1%64;15M)*)#;R1.
MK+]0?8DWOFW<N9MX@O.>N9]WORJ*JT4U`4`!0W&@``X^70(Y1Y`Y*]N>3^9N
M5/:+D38]ALI&>:?:39FRVZ3=')=6=H_$'ZC'4]!0DUXGJ/B/XS)33#<$5)]X
MU3/ZZ1RZU,4I+M+(2[R&5W8W<L6D/J/J)]B?W6C]K(.8+9?9O<=XN-F,2:SN
M*Z0'TKK%:<`U0/EU%?W6[W[TUWR+O#_>DV79K'GG^L6FWCVPU!VK5@Z0:-I%
M`I.:"M%.!>+\7OYW_97Q[^+5)T6.KMM=H;^ZU@I=I]1;YK,X,-M7";.I*54Q
M^/['PN+4Y?.YK:^GP4K4#4WW\&DSR121N\IB^]<U\H;-M%CNW)EQ8LU`K;@?
M"4KDU!I6C`C21^$C->L1N?\`[E/LO]X'WHYVY]Y(][;6;E\;M3=MOL&&Y78W
M!G)\..X0-%9&0U):X/Z;!ETNM`E\_P``_P":UT?\S<7A]F;DK<1U5\DHZ%4S
M75N:R*P4.ZZZDCT56;ZIS=>T4.ZL-5C]W[(LN5H062:)T3S.(=CYJL-Y4(FE
M=X"D&.N#_I2>(\QYT_;U@?\`>7^YM[D_=\W/==WMK1]S]J==(]SC0L$#'LCO
M@*^"ZUT%B`C$`JU6""V@?0?ZP]B?[>/6(7#'7?OW7NO>_=>Z][]U[JK7_NK[
M_P"6<_\`R\^_=>Z__]/<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]U[W[KW
M7O?NO=>]^Z]T67Y7][5GQFZ.WMW7C.J=]]SU>RZ"*J_N'US'2/GJR&29(JC)
M5KSL9J/;F$B?[C(5$$%;44].K.E/*01[3;CN2[;M\][)&S1H-1H*X]?]0/4@
M^TOM];>Y_N1R[R-/S7M&Q2[D^@7^XN8X(\8U$#B<!02JLQ"EUJ#UH`?+;N'N
MKN_Y#;P[>[;V36[0W[V7-A=R5VS\QB\W@?[O;'BQM'BMF46!I-SPX_,U.WJ/
M`4J_;UK1,)Y$D:P+V4%<I6/M[S#_`*Z&X^Z?,&Z[/S='$/W2H2@^'%!3()I]
MM2?EUW+I[M^QG*_W:O:W[I'(-ASM[72\Q';N8]R2\L&2PVYG!N9I=#A8[]YY
M+J]B5A=:842,J*B@N;(^!GR<[*^+6:^7^Q-A56Z>KL-NFIP46#Q$-=5]A[DP
M&-4P9WL7:&V8:25]Q;1P6:!H9A3N];+(DLT$4L,,K+'EKR_O][L9WU6K,H.G
MC4@5&H>="1FF>-*]33S%]Y[V3Y.]\D]@^:>818<QU0?O,LC;=`C=R;9-4U1Y
M$HY<@1JS`$J2H*1W7\(/FGU?U)F^^.W?CQO'8'5&)R&+AJ<]F%QJ9;&8S-I)
M)C\]F]K4F0KL_B=LQ_LQ5.1JX*>.EJ:F..54OJ]R7[I<A\A<I\O>W?,')7,>
M[[C<2[,[[I'I`.V[A0,K4(!9!4Y&H``$TKUCA]U_[YM_[O>]7O;[1^Z:;+M5
M[M>\E.59=N+,F[6<;NCQ+)E'D*JDE*@G4P4$H>@&[`Z=[&VCMWK'L;?6TMW[
M$V5V325V8ZTW3GL74XS![YQV/GI&KJO"550\4:/X-#JM0%:HHI?/'&T3+)[3
M>WWN7-[9\I\Z;+O');;GL7,T84-I!:ND@T8@LE2=7:5-1Z=2![Q^SG+_`-YG
MW<]E]ZY.^\*-DYA]JM^2XW7;;"21I&B9PPL=Q`8(2Y0J)"'6-6>T-)&PGHJJ
M"=4E@GAD24&6`PS1R":-39G@57U/&K<7`^O'N*/H)WLC-^YV/+E*&I/[*_+A
MQZS"FWK;H=_?91O2P[[K)7;,!R"=2D`]P!&0/RZ9G3#;6HLAD4I?MZ=RU75_
M;QM)+);\`N0L4488L02J*+G\>Y6MMU]QO?\`YIY!Y1WCFU)-[B(VM%W$!%`:
MFCTK1`H!.:>?6,<NP_=X^X;[4^\/O)RI[=R[5L\[/N^\263/+N-;YRG]E4ZJ
MN3X,(!MK.NN1@">K=?Y</\K'LSYNR;9[<WQ-N'I[XTQUM'E<7O(4\N)[$[,F
MHJA98X>IA4QK+@L?%,FE]S.C11."*)*A@S1EP]K=QV[F'>=GYAUI'MLC)J0T
M)*$@Z2"#3&#6M"*4XB$/>3^\-]MN6?;'E3<?;;:COG.N\[(\L<&Y@4L4OUH)
M=XBPHO`A!2P`RI5V9-2AMX':NWJ+:&V\%M7&S92IQ>V\+C,%CZC.9;)9_-5%
M)BZ&*CAJ,MG<O4U>5S&2EBA#3U-3+)--(2[L6/N51W!&K7`_S#_5QZX2WE[/
M?WFY7=R%!=BQTJ%74Q).E5`55J<*H``H!TIQ]!_K>V^FQP'7?OW6^O>_=>ZJ
MU_[J^_\`EG/_`,O/OW7NO__4W)_Y<G_9`GPQ_P#%8ND__??X/W[KW1T??NO=
M>]^Z]U[W[KW2)_TC[%_T@#J<[MVX.SCLT]B#K\YF@_O@^PAF_P"[3;RBV^9A
MDY=MQ[@(HGJUC,*53+$S!W4'W7NJELU_-IQ5!\[=@_&#KWKRE^2/3O:/:=#T
M'3=Y]"5NYLQ3](=W8[;6?W1O;9W<.2SVUL;U1N:#&8G;U;63#:.Y<GEL!2XR
MJ3+4$$S4PF]UJ@)!(%1T-?\`,+QG\O5MG8W>OSSP?6&X*;K_`.[SFR*#-UA'
M8^8;P2R#:^TL-A,OBMU[H@S]0IC..9GQLDI5Z@*JF12G?X.67@C;?C$%7AK-
M*G-0*"M*>0_+K)#[LUU]Z67?KCEW[MNX;U;KN8"7\\0'T,:5%))V97CB$8)(
MF8"X4!A%J+!6(K_+;_F^]4]J;FWOTCVCL_8OQFVUMVERV:^-U)BEI\/M&@ZB
MVKBEE?KG.U4?CQ--V%M3#44E>#3QPTF0A>6.&,24ZB<AY;YSM+^23;Y@L06I
M0<%TC@,FH-`#\_(UZR.^]1]QKF_DSE_E#W%Y8YAW/FS>MR*C=RR,]Z-QO&*Q
MWJ14:1K>[<F.-WJX8*6KK)1U^)O\Y;I_OW,?,BG[^J-L[*ZGV/09/L#J1MP8
MS'R2;QZ*H::+:^>P6>Q-94RQ[HWSE,JD-:F*C26:>',K3*C"F;4[M_-"S2[Y
M^](!MT,;54M@E.&HU&2?+M/::4Z)?=_[C_,O(/+GL%O7M5NIYAYPW*X&W;C/
MMSM+X6\,VN-XFB4F.TB5O`DF!55FLY&.G5@(>_/YV/PX[&^+]#_=_P"/U/V7
MVG%G<;#MGX[=Z;&Q4^T-BY/!I*<3OO<N0AI<CM^HVUB<=*$I8<1.:^:5S2:*
M=?)*$-]SSL,^WAC8O(0V%84``X,""1GT`S7TZDKVT_N\_?\`Y2]W9+;?/<3]
MS\GO&_C[YMM^IN;XO_:[?"`ZR-<.V?U5T@@/5R`IUB^U=X5G;G:&?[BW;B]G
M8+=6?EBEJL?U_MK&[!V+CDIZ8T5-!A=K8MA0XV.GI+)Y`[33L/),\DA+>RVT
M]U^>+[D[F+VEV^.W&P;QC]W_`+O/B'YA@-0KQJ"*\?/K/C;_`+IWL#R7[F>V
MGWA+B^W"TY[Y0VF2Q&X[ENC%6+EC_NU6\9451J.G`"@@+0*M$H-S56T\QMO/
M4.W,-O";&YW%9:#`;DH6RNT\Z^-K8:Z/#[HQJHR9';^7:#P54+E(Y(9&#,![
M<]H^0K'GB\YPDWSG'^KS[.B:I-S[!N-*#2A)!4)33VD-0"F>G?O3>]6]^VG*
M/(^S\G>T>[\\3\\[R=FAAVE/`DM+&9"7W1;]DDBTAF_2+CPN!)"YZ^B1\+/D
MCU_\K?CQU]V]U_!A<+3Y/;F,H<]L'%U>)GJ>LMR8VBCH<CL3(4>-*C$_PEZ7
M_)8Y(H-="\,BH$9?<A;7NMCO-I'>V<FI"64FI/!B*\3QXCU!KY]<"_?+VFYH
M]E?<_F7D7FD/)-'(6%Z0Q6^5^]+E'90'"@Z7<%AXBN*D@]&]'T'^L/\`>O:H
M\3U%/EQK_EZ[]ZZ]U[W[KW7O?NO=5:_]U??_`"SG_P"7GW[KW7__U=R?^7)_
MV0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=%6^3'R@V[T(-L[-Q6"RW8W?\`
MVIM7N3,]"=+;?AE3)]EYCIWKZKWSGX*W/21'#;.VQ32OC<?59:ODC@@J\Q1Q
M*))9XT;W7NM?/^7YU=\B?F?W7U[\\MM93$=)M2]K9OM_>T5/L/M?$XC:'8&Z
MJ;;>T^]>G=G[3[A@QF;RVP?E=TO28^#LK;\.5K<;UKW)L7%;APM5DYJK)T\?
MNO=;-M=U+UC7[EZ^WG6;$VF^Y^J9=VU/6^<;!T"5VQ9M]T#8S>M1MJ58D7#U
M&Z,6[P5TL062>*20,Q#N&]UHD*"Q-`.OG,_+#+4'9?R<[_WYM/<-?58?,][=
MG93;V9S51692NK-L'=F1BQ\$4]54SRTF._98PPHP@$+)Z```(YY)YWY$Y<WS
MG>?G;VYDYFBW(:5C4G_=8!C6?DWQ=?1#S)['^]W-?LG]UGE?VT]X;_D'FC85
MVF?=9-OB0_O&*2TUKMI$8M@TKJ02S%NXFI8YZ""IEQ]7))C))H7J9(O.:)6_
M=6(-8RJRB\137=2+.H(-K'V!HN6>;K+8[/W`38RW+R[\O^[+\*K7L4CA111?
M3'61][[A>W&[<\\Q>RD/..S1^Y3;"7OMN9R-U_=E\OANZ+6H8&I!7*$U4CCU
M&Q>$QV'I%HJ2-VACJFK$:I?SRBI(T^59&4695^A`!'LY]R?<7F/W7YGCYGYH
MB1=Y0!5"JJJ56@4Z5`&0`>'0.^[Q]W/VT^ZU[?W/M1[46<\FRW4K;GJ>1Y'%
M"Q8!G9F`J34`C)/KUWF9\E3T?FQ=.*VI6=/)2F/RO)`X(=XX_+"7D#D"^L$*
M2>;6)E[1[![><U<V)MGN;O@VSEPG))I]N<]![[V'.?OU[?\`L]N?,_W7_:K:
M^:/<(;KMABVN^!8_N\O^HX5;FT-=5>X,&`SFE#DK<?3YB@6CR,3K%,M/+-!%
M*T<D4Z:6"K/'9@8I;B]N?97RSSIS#[6\Y2\X<E;NLN]Q2N(]0#`HKD(:,",H
M%/Y]#;W8]EN2?O)^TW^MO[Y<FW,.Q[Y#&;C1N&EEW9HU;P@RD-2-R445(`49
M/'K)0RT0C:@HI8V&/T4DL$<K224X4>..*9V&IW`6Q-R`18D$$>VN<-KYRG,_
M.G/FS'P^:&.X$_AW+0<QQC@E.%%I]G3OM!S)[4)MU[[)^T/.FT;A=<D6Z;9N
M.UM(3)M45B!_B3,26+2Z<O6I/GUL@?\`"<;MC&KOWY;]%)0YF+)5N,V#W!29
M@4L";>JZ7;\E7L;/4`JBRU53DA5Y6A)T+)&(T*LZNH4S+RC[<[QLGMGLWN)?
MW8:+F&5@@_WUH5E4+^&JJM#Y@@5X]<5_[RGWHY/YY^\-8>TNS66X_P!;>3;(
MC<=P<*$OQ,T,L4:+6JK$K^&O;20!M))5NMLQ;Z5OP;"_^O;VH`H*5K3K`^H.
M1PZ[]^Z]U[W[KW7O?NO=5:_]U??_`"SG_P"7GW[KW7__UMR?^7)_V0)\,?\`
MQ6+I/_WW^#]^Z]T='W[KW1(/GU\X]C?`?H'+]W;QP+[PJXLSM[;>W=FP;GP6
MSDR^9W/G<=MW'56=W?N1UP6R-HPY;*TU/5YNO`Q]'4U=-%,Z&=#[]U[HAOQ)
MZ%HOYBWQCIJ7^81M/;WR8Q6S.\]_]B]"_(W$;XJ=MY/?>WMY9G<AS6V8:#JC
M/X:LZT7J^GRM=UANK;V)S6=V-NZ@PIF@K,KCZPI'[KW5X]'14N/IJ:AH:6FH
MJ&BIH*.AHJ."*FI:.CI8UAIJ6EIX52*GIX(4"(B*%10```/?NO=2&4,"&`8$
M$$,+@@BQ!_J"/K[]UH@$$$8/5'.U_P"0A\&L?M/<6,W?4]L[[W3N?)Y/,S;^
M;>E7MO+X"6MRU;DOM=FX7"4\6W<51P_=>)DJZ;(23*EV8WM["%KR!L<44L;)
M(7=B2=>GXB3FG'CYU'KUGIO7]Y%]X:]W:RW+9WV;;-@@AB1;%+$2(PAC2,,S
M2$W98Z:DHZ4K1-(SUK#_`#V^$.Y?@=WDNSMW9"ES^S-V4F1SW3_9[Q+0?WKV
MM2R0TM?B,_3#Q4^/WYM99X(,A`BVGB>*IC`CETH37DON,FV[1[+V/,&Y[CRK
M(Y.V[:BJ2\A.HKJ`J:$GC]O71#V/Y_\`NO>[D6X??,WC8=KY?]ZMEB%AS!N#
MEE.UPNM%E^J<T3:V1:VVL%TE#(Q.FI)I45<-/1O7W:6FBIFJR8K2LT*Q^1&B
MT$K('0<6-O8,V/EC>]XYMVKDQHSMO,=_OB;5GB&;!&?,&H/66O.7N-RURK[8
M<Y^\T%PM_P`@[;L3[EXFW'4-SVPCZM_W:175(0N:<233CTVR[BQT&`?<DZS)
M01Q"21`86EC`F\$@9Q(:<Q*W/D#E"O-_8[E]C.:Q[V0^PDNX[,>9I#0+7_=>
M<5&MOBU$?$*UU5%.H(L_OA^VNX?=(LOOFV/+.ZK[;J9=Q^@>S_W9E;>\6RH&
MKIT9K6NC\5:9Z/WEOY='RZP_Q@V9\N?]&E1ENL=XXJ+=!P&#_B-9V?M'8]91
MBNQ>^]W;&EQU/DJ/`5M,?+*M-]U44$%I:A$C;4H6YI]NN9.6;K?;*_:,IM;.
MITD$UC)5J`9*U!T\30<,=%GM3]_+[N7O)SJG)_+>Y2V4>ZHC[7)N*BQA$ST)
M0R,6TR*QI5PH:H",QQU7]BGV[E!65FWYTF>M9:2HJL?)4-(9*IF>-:!`LJF2
MMK'+1&)6\DS?0D^Q5[ER^\NU[)[=\B>Z<:K9;?LS2[40!4E^X5IFM"!GY=+?
MNU1?=#W[F[W[]XONW?N>XY_O=X6/FW<#+>,D>X1EE52MV%C0$JS'Z"MHU2[M
M5B>MPWJW<\O5G\K[IWL;OKX\]A_&/N7HS<VT.N?CY!U'@=MX;M3=O9/9.ZMM
M=<=:9+;FU<[7TN.IJ3OC<^[Z>BW9@MW2QXNM4U-56&-%IYH1KR+N]UM^Q6\<
M^R>!M915>P))#*I)U8:J,2Q9&%&1B3PU`\2_OE[/RMNOWA.==ZY-]UQS(M^Q
MOFW(,=<,O<3MTDA73>+&8]*+&3&8BBKH90P-YM'^9A6T6_*;ION#XS=P[6[%
MQM=@^HMPY/;4_6NY=K97Y75?QPJ/DY+T-M2BQG8M?F_N-Q];8^>;!YJIMM^H
MK5^SER$4@5W,+A+47+&U:L9.*\0#D`G`)`P305I7K'>.I"U`#>?I7S]<?G^?
M75!_-4VQGH^D:S;7QR[KRF&^0GPNWQ\R>O\`.35G7%-0X?#]<X3`YW=^P.U*
M6DWEE,SU=DL9#N>AHX\YD:7^[M?EYOL:*KJ9P%9GK?1X?B]\@MK_`"L^/?3_
M`,C-E8;/[>VKW)L3![\P>$W2F,CW#B:/-0&08[,)ALCEL8M=22(RMX:B13;\
M&ZCW7NAZ]^Z]U5K_`-U??_+.?_EY]^Z]U__7W)_Y<G_9`GPQ_P#%8ND__??X
M/W[KW1P<MEL9@L;D,UFLA08C#8B@K,IE\OE*RGQ^+Q6,QU/)5Y#)9*OJWBI:
M&@H:2)Y9II76..-2S$*"??NO=:PFR,!\B?YEGSD[$W?NC*TOQQZ^VML_<71O
M8&W]G8FGR?8N[/A?D^U%WQU9M#L+#]OX7?W3G8>TOE/2[9J,YB^UNE=QU^+_
M`(15S;>S6.GJ*2FK:/W7NMG';NWL%M3"8G;6V,+B-M[;P&,H<+M_;N`QE'AL
M'@L+C*=*3&XC#XG'0T]!C<;CZ.)(H8((XXHHT"JH4`>_=>Z>O?NO=%?^97R)
MC^*?QG[6[]&V9MZY/8N"HH]J[-IZM,>=V[\W;GL3LGK[;=3D9`?X9C,QO7<=
M!!65825Z2D>698Y60(SUO`;JY2T7BQ'\_P#BNM22"!2S,`OSZH:EW]\X)<K_
M`'TSOSN[0QO;ZCS55)L[8G6/^RRX;*>IIMMX?HG-;9GS>>V%CI&:CCJLAN9-
MQUU.@JFK:>I*A)5')&T"RU%S6GK\N@6>9;NK=@)J?+HQ0^8?0GR9V:?BU_-3
MZ?V!UE5;[\FU=N]Q4%;D*OXN]D9;)QP04DO7?;F1-)N_XW=J5[Q*T.!W-/CZ
MO6J18_*Y5F!(86PYFY)W;;.9MND"36$FM7*@Z3Y$U\A^P@YIQ!^UZNY[)O\`
MR]!O$@V_<;?P]PCC=T1D(IID&K2U,,NM652*BAI75O\`F!TPWQ1^2W;?1.1V
MYD-I8S:FZ\M4=<8>KJ:[.OD.J:^I:?8N<H,Y6H*G<=+78F5(VJ"6E-6LL+@2
M(P]P9O?+?N![D\V<]\W79HO[WB8,HTU#*"'730J3QJM".%>OH?\`8+WR^[_[
M?_=D]CN4-CWQ&(V2T@;:R0WZFW2DRKW%J`M4E:T96'%3T>#^6;\1>]L]\N_B
MKV7N3X^[]JNCJ?>E9N/([WS&UHI]CTAQ&UL]4XH9[RS2MCJFGSBTK)%5PQN)
M2C:;E3[)=OY2YJY=YW6'?-H:E2==22/,$FI/SH30]!W[R7WI_8+G#[MON_M/
MMO[F;+?<Q;I$\?@QT1E'UD?B1QJ-*ZE`*MH]"3FO6]02%`9@M@"6:X`4`<F[
M6L/^('N6O7..N"P%=)8#4!_JIU2'\COY)/QA[Q[)H.[.J,Y6_'7>%5NK#[WW
M%2]<8+"9CK3>6>Q&X:7.RYBHVA(V/@Q>X,I)1E*FJQ]721S.?*\$DFMG)>9=
MLNN;;_8=VWK>9CNUII5"7+U5::5[R:`**8KCSJ*]99?=]^]GS']W_P!O^9O;
M'8^2-EO^2-V:^:3]/Z6]#[A%X4C+.E=7DP#HU#4*4##3;=W-TQUA\ANM-S]/
M]R[/Q>_>M=Z4E)2;EVIF/NHZ6O7'Y*BS6)JX*W'5-%E<1E\'G,;35U!7T<]/
M6T%=315%/+'-&CJ<\#UB=2M*C/\`@Z+IMS^7-\--I[SK>Q,)TO1P[\K]F5NP
MI]WUF]>R\QN!<)DMD_Z-LCE:;*9G>>0JJ'L#(=?WPT^ZH&BW/-CF:!Z\H[`^
MZWTG]F_ROO@]UU+05/7_`$WD-D5V*Z=PWQ^Q63VEVWW9M[+8OIG;>2R.9VYU
M_C\MBNQZ7(T>$V]F,M45=!XY5GHZJ4RQ2)(`P]U[HVG474/6O0O7&T>H>GMG
M87K[K/86'BP.S]F[=IVIL1@L9%-/4O%3K))-43U%765,M14U$TDE155$KRRN
M\CLY]U[H2/?NO=5:_P#=7W_RSG_Y>??NO=?_T-R?^7)_V0)\,?\`Q6+I/_WW
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M?K7L[$;PP_\`H'^2F9HXX7JJGKBJRF0I]S]:[SKEF6:;9^Y*6G>&21H\;D,G
M"J.9<VCF^QW%Q%+VR<*'UI_AQ7H`[CL=[`IDC%4))K^?2[R^)I:V@S.VMR86
M@RF'S%)/A]Q[9W)BJ/*X7,8Z<::K$YS!9:GJ<=DZ&=2-4,\4D;<&QX/L85QZ
MK^T=$`Q7R_E^WUZK*^7OP;[3[!ZUAV_\9>UY:*EVS5TF8VQ\?>[-PYK.]>8^
M3$X^HH,?@.G.UZ^HR6_NE<+2P3F2EV]+45VUUJT1XTH0+@UY4YCO.1;X[GL&
MQ*TF31J:2?G4'B?.AITCW?;AS#9BPW'?9$7^*,D,!\LCRQ@BOGT2S'?S7?YH
MO3:[HZ&B[,Q7Q?W=!_#:K=^P*7HG;:=GTO\`#,!0;<;<&-W7V37;VQ^XL7FX
M,8DYSV)I*F"H?2Z3(6*^QML7M9R)[J[F_,EYOQ24UKMH_P`0?B2=,CFY(&HF
MA%*U\ACH)[MSCS1[?Q)M^V\N`P@BAP0V*`F@PQ`J17U-,UZ)_P!J=[?(OOC4
M.]ODU\C^YX6+M_#=_=S[U?;D?D.IHZ?9NV,AM?9\%.S&YB%!H_!'N9=G]F/;
M/87\2+E%WD]78L?VGC3U\^/4<;A[G\Z;H&6;=$C0GX4%`/D.)^W/1H_Y7_RI
M^07P[^772&*^.CY+=NW^_>TML]*[Z^-FXNP<UA.K.TI]]1UF.V_G8JK+0;IQ
M?7/86S<K3QUE)G*#'JTU(E125BRT\K%(I^\![7\EQ\E-S+L>QG;]\VXC4G!9
M%8X!^=34'-":^G0W]G^<^9;KF*7EV_W=-QV1E)5Z=T;`9%?Q*>!4\"`5(&H-
M]"/XW_(C;_R+VCGLO1;:W-U[O;K[=^7ZS[?ZFWS#14^]^J^S=NQTE1EMK9TX
MFKR6!S./K,7DJ/*8;,XNKJ\5G,+7TM=23/#.ML$Q4@$C/64II4TX=&&][ZUU
M[W[KW7O?NO=>]^Z]U5K_`-U??_+.?_EY]^Z]U__1W)_Y<G_9`GPQ_P#%8ND_
M_??X/W[KW5$/:7R&[:^6_P`]=A]>8/N7M#X\UTF_DZ<V?3]#]ZY7JV/+XOKC
MM^O[$QO8/9W0OR6Z7Z,[(W964^V\)DL7G\'LC.[HP.XH*BEFJOO:"ACAD]U[
MK:N%OQ^>>./?NO==^_=>Z][]U[K4^_X4@?-7O7K;<'0OP]Z<WWN_J+:_:77V
M]NX.Y-Z;`SE9M;>V]MLX3<F%V/MKJG";OQ;4V>VIMZMRN3J:_<4V-G@KJRGB
MI:19H8)J@39`_=Z]O-GY\YIW&7F@TY=L(1))ZDDD`4\^`/Y_9U%'NKS?N7*.
MP[:=EB#75[/X2DBH7M#$YQ6F`#ZGR!!U`WV;M:<Y#^(8*@S<N50Q96LW)]QN
MK*9)"06&0S6YI\OF:HW%PSSE@P#`A@#[SOM.3.5+*S-EMW+^R4/`D>7E4_,<
M?GUBM><P\Q7UZ+W<.8)!I-<,0`?D`0!^0Z/'\:_G1WW\:TQ>TZK^(?(3H^A$
M=+#UKO+/R+V?L;&+Z/'T]VEEVJFJJ"DB_P`UM[<;5-$0--/5TS$`0]S=[+FA
MW'D8D9SM9XL?,ACY$U(!/`\>I0Y:]S8W(V_FT!3_`!J.(\BP'R\US_1/'J^7
MH'Y,]%_)_!5^8Z4WW1[BR.`AA?>W7V4C7;W:_6TLQ\2TN_NO*V=L[A09P8XZ
MR-9\95$?LU4E_<`7-O>6EZ;"_-.8`:4K\/\`1(\J#J689+6XLEO[2/L(JIXJ
MPK2JG@1Y'YXZ=>\.@>FODEM6FV=W7LBCWACL8[5&U\[#53X+?NP\BURN9Z]W
MUCA'GMI9&.7U%(G>CG(M403+=?=(IKNWO1?68.L8]#4>AX];E2WFM#:7C9/K
MD'Y$&H(ZH8^0WP/W9\:]V[7DW-\B^G\7\<MU9&JB?OKN*.NH-_\`5N.C20P5
M'9'36QW7<?:.`CJS'23[FVG"::A+^?)TM,A:02;-[_\`-'+FS?[L=I3<(^%2
M:4I2E0,D4XTSC`/0'/M)L.\7H^@W1[!O1:'5Q^$FH4DTH""/F.MGS^5)_)*Z
M#Z0W=UQ\W<_\G=O_`#5W-#M^?<'Q]W'USAMNX7XZ;.DW/BZO"Y'L39D6(W)O
M6I[(W5+A:N>BQN8K\H]/C(*B<T](E2PG3'WW"]Z><O<-8[#=Y=.T*00BX`IP
MJ>)\A0CAY\1U*O*?(&R\HK+/90@[HXHTGFP\APP*Y-*5)%:Z5I:;U*V*?^8K
M\P1LY8!CX>@/B7!VX80#?M_^)=YS[>CG<WU9>+J";#FITG7]F]#Y/28?<3T`
MP.'0YR<GCT?[W[KW7O?NO=>]^Z]U[W[KW56O_=7W_P`LY_\`EY]^Z]U__]+<
M2_E_UU=COY=WQ%K<7BI<[DZ3XH=15>.PD-724$^9KZ;K7#S4>)@KJ^2&@HYL
MC4*L*RSND,1<,Y"@GW[KW53/PQZ5^4W_``XA@MX=B?!+L#XD=#;5VQNG-[*W
M%4]WY#L:BRC2;+H-N;>Z<WOL+9GRCW_TCM^;9.4R>3K*/=%%@*W(;BO2H8\:
M\$T\_NO=;)GOW7NO>_=>Z][]U[JD[^=7\(?BW\GOC_@.T^_.]<?\4]V_'^OR
M=1UM\BZK'4>X:'&KOR3&XK-=5;GV'45%'5]H;?[(K:&A2GPN/DCS9R]-2RXV
M19PT4XEY%]P-T]KK[^LVV7Z"1*D_64*4]&KI&D4-*U(!QY4)N9.5+'G+;WV2
M_A+Q28H!W5\F4@@@C!!J!BAJI(.L!UG_`"WOB=6Y2CI_D-_-6_T14E76QQXZ
MFQ?P:[KZAH\[C9+>.L3LCY+4E3MW&-4QFY5J)OMP268`>QS9_?\`^7N>I3M?
M)/,W*+RT)/A7L;-J'Q`J[Q@$&M1JJ.'05_X%*YY=T[CS-LV\-'Y:J@4_":HI
M/"E,4ZOP^-'\B7^3=NFFBS6&WMG/F\(*>.:JJMS?*`[WVH9BBJ]3-M'I7+[-
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M62C]DG-?WC+/EC;S:1`;AS#6FD>7RQYC_-6E:].[1[;W>[[@L]P*[/IJ5X$`
MX!)X*#Q%<D`Z0Q!'5E'2WPUZ!Z06ORU!M-.U.S=Q)$V_.]>]J7"]H=P;[GC1
MHP*W.YO%28K:&W($D9*/`;>H\7A*&&T<=.Q!=L,.<>?^:^>[OZO>=Y*1D\!6
MGV`<,<,9\B3U/FQ\H;+L-H+6#:R6\@I*@5^8(9C3B2:$BJJE2.BTX?:/R7^+
M'R5[WZ9_E=]7]*287O3HO9WR6WWU-OW>N2V#U1\>NU'['W'UIG>QNF>N,)MC
M)[:DW9\A=I8W[L;:GKMJ;;J<UMELA-61K-4QS9">S_,&Z;YRWX>YL&>R(C!J
M26`!IW5]!7)H*T%!3J,^<-NL[#=)$LZZ=7&M?($\/X22I.22I+$L2>K/?Y<[
M]00=3;ZP^PJGM63MC&]K[FJ/E=#\AJ3$X_Y'2?(G+4F+K=QY;N"CV[)+M$2Y
M?;)Q3[<DVV\NT6VHN.3!2/C(Z?3+O02ZL%]^Z]U[W[KW7O?NO=>]^Z]U5K_W
M5]_\LY_^7GW[KW7_T]O_`.#&.R>7_EM?%3$X6?[7,9/X@]8X_$U1R>2PJ4V3
MK>JL938^H?,X:^9Q`@K)4?[JC!JJ?3KB]87W[KW5-W\O/?.^]D?S#VZ/[C^4
M.<WUO3:AWYT?E>M)._/G;W-MS-=DXGKS_2;FJS:51\BM\'9^Z\5L+$8"IILI
MGY<`&I,K)'203*TVM_=>ZVB1]!_K>_=>Z[]^Z]U[W[KW5#O\UG[F+Y+?!.JW
M?H'6OC[YH^NFK-2[<A^4]7A]JC9!KI9B,;%ONHZHCW7'M0R@U1F->M(14,M\
M'O[P'^MI]AF7E4.=L_>\)W/1JU?2@&E=/=I$E"U/Z).*=3]]V\<O'W`O/WK3
MZ_\`=;_0:J:?%U+XE:XIX=*ZNW3KKC5T7>2HR$0FIIYJI%EU1U--.TH24-P\
M=13RDK(K7L5<&]^??#<+:L&\+3HKY?Y:>?KUT+4,RQ,ZAG"CR#9(S3CC[/+H
MHW9&P^AMQ[_I^L=L?&_"=Y_)6LHX\S0=7=-X'%;0[$PM%5&U'N_M;M?;E1M.
M@Z-V09&4MF=Q9.GFFB/^24U8Y5#E/[%;%]X??9OJ^1>=M[Y<Y"AX[G)?D[;&
M>!"I(&-^U0>Q5`4C2S+2O4/^XVY>V5A"+3F?:DO]Z.05`/'AD<>(`4').*G!
M/=T9\`L]!C34_,7N;L#Y"8R>MQ69V_\`$+(]M=E=B_#3J&JPSQSX:ECQ79>2
MKMX=^Y[%5$0E:JW/-_=R.J&NDPJ:(9!TH3W(YK7EW^JTO.)W28J`^[L%5G:@
MJVA`$1:CL11VCXF<FO6*1Y;V*XWE]XLMK;;+,?"E:T-3D?PDK@DU8@C3X1!K
M9B[7@:20T]/1XS'O+++(T%%C,/A\73ZC)*[F#'XC#8REB/K/CIZ>-/[*C@!A
M7=@!5I#P]3\Q]O&GSZ/6:WM(LLJ0U_:3_-F;\V8^I/55O='\QT9*HAV[\.MB
M;H[MP/\`'*K;_8'RSP6RSO\`Z.ZHA@AG3(9/K#8`W+LW='S!W7C*N`TXH]M5
M<.VZ6I96J\C-&KP,Y+S/[1<K[_'L_NI[FIMTT@&E`"S$$5J556&VTQW29;)"
M'JS;'SUO>T?6<N\K_50!L]P5R-5,$L*`@&FDAC44>-@1T=[^7'VS\+QE]][)
MZS[BW]V%\L^RXJ+L[OK(_);;&X.M/DIV;-@J-,#1Y9=G;GVKLS%1=;]?4$BT
M&)PFTJ0[=VU2S!$59JF:>HS3Y$YA]M=^VDCVOWW:-PV&,!2VWR+(I-*$U!JQ
M/`DCXJT/EU!?-&T\Q[3>ZN9-F>Q)!H&4@"E:_P`5?F2Q/Y=#=#3T>W?YH!CV
MY*D-3V7\&<AFNW,=1014U/E*WJ[O#`8;IC<^<\"6J\S!C>P=V8VDEE/EDHXG
M0.8Z944?]!CCD<.K"O?NO=>]^Z]U[W[KW7O?NO=5:_\`=7W_`,LY_P#EY]^Z
M]U__U-R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T3S=WQ&[=_X<P'R0VUV)\.]B;"
MIZW8/8'8&]:?KS&XSYQUG5N/V!D^NI?C7N#<\&,I</G/COV'V)C4W`N>RE;_
M`!6GKJ(X^"&9:6">'W7NKE/?NO=>]^Z]U[W[KW0%_(S8?178_36_MM_);;FQ
M-S=%1[9RNXNR:7L>"D?:6+VYM6F?<%;NG(UM8\28$[5BQYKX\G%)#4XZ2G6>
M&6.1%<--!!+`UO<J&4C((J#ZUKTY#<7$!6YM'*NIP0:'\J9_+K75VU\0AWWN
M;`[M^-V[/EE\./A[4.,E1Y#?G;NX=]]Q?(G8]?1*M!#U+U-W-2;YR?Q8Z]RB
MR?>4&[,S7_WTK*0PFEPU!$PJ6P9]S?;S[M-UN'^ZSVPV1N8P^L5!LK`M6I\9
MK0CQ`QH6!4`U/Q5/60?+'-_NA'`5?FQC"5I5M+!1PH309XC2M:$48K4$VB]-
M=(]2_'G97^CSI78V*V%M:>NERV86C>LR6XMY;@J"7J]U]A;RS-17[K[!W?7.
MQ:;(Y:KJJDDD(4C`10S<7,LX42%1`H"JBT$2@8"HH`4(HPHH,9XD]&,<`#^-
M(QDN34ECDU8U.G^$$GRRP`U%B*]`+\O_`)Z?';X2X!JCM?+[@W7V178J;*;,
M^//4N*3>?>F^HTC,D<]'M:&>"CV=MI@K-)G,_48[&I$K-&T[#017RIR+S%SA
M(L6S[2L49(!+`A17S-`<>>`6H10'HEW;F*VVN)VD`<YSQ6HP1Q&HCA0$"H*L
MZ'JH;=ORFV[\MWH)OEYVI2=:=;URXW-[>^'DF'[%ZQZ8Q1JTBR6#?Y$=D;SV
MYMAODENL4C0U"T5158_9<+WDI\;61@5#8^^^5U]Y'D]]XV/D7V:W>SV0C3^]
M#_NPW-S\),,5F"=O0]QC+`RZ&!,\9JHDSV_M/;&]G-WS#SAMM]O12OT1*`"N
M0N2`,4!HI!(S4@/T<3;N4P>YL315&R\KMO<>`Q]+!0X^39&3P>:V]CZ"EB6&
MEHL:-L3U.)Q]!!"@6.*$1PH@`10/?,W<[+<=NW.1-]BD6Z))?QE<.6)JQ?Q!
M74226J2:UK7CUEK8RQ".-MLD14H``&``Q@<<T&!YXZ"/OFKW;BAT9F^LL12Y
M_P"2V)^273K_`!1PE9F#MO([B[<GW121;@VI#N)J/(U>&V/G^I_X_%O*H^VJ
M:.FVT*F>JAE$<:'*O[CAYJ'WC>0UY'+_`+@,U_\`O334Q_NK0`Y('9J$A7P_
M/Q"M,GJ&?O`#8_\`6^WX[SX7B=O[OI37KIC53-=50NO\.O3P/6Q7\8_CUN7K
M'+=F]P]S;OQW8WR3[UKL%5]E[GP-)6XS8NSMJ;2@KZ;KKI#J+"Y"62LQ?6'6
MM+EJUXZFK_W)Y_,9&ORU;XY*M*6D[X'34Z/@KC[/+^77.45H*\:=&Y]ZZWU[
MW[KW7O?NO=>]^Z]U5K_W5]_\LY_^7GW[KW7_U=R?^7)_V0)\,?\`Q6+I/_WW
M^#]^Z]U7'_.I^)I[)J?CM\C=H=';=WYOCK+<==L?<_9>-QG3F=[@V5M/+1R[
MCZHH=F;>^3V]MG_%RJVU)\A,?@I,]EMW)D*G;V+DJ)\5`D\T\\7NO=6;?!?Y
M!P_*/XJ].=SR;EVAN_<>=VM'@>QMQ=>-75'7==V[L:LJ]D=NP]?YBLI:>FW/
MLK']D[?R=/C<M0/58K)4L2ST51/3/'*_NO=&W]^Z]U[W[KW1'OYC/6N]>X/A
M9WOL+KO;DF\]W5NW\!N#'[&@<1U78%%L3>VUM^[@Z[HM;)!)7]@;=VS5X>GB
MF9()IJU8Y&6-F(+MUMY[O;=RMK9J2LA`^TC_`%#\^E&W70M;NPNZ?"P/\_\`
M4>BM4?S$^+&[=A5G=</R`ZJP/7[P564S59OC>>"V=N;9=0AD:OVCOK8F=K*3
M>VUM_8&L22BK,#48]<I'6PF".G=B@;!&;E_>TW&38VV6N^LY(P:9)IBG^`&O
ME49ZGBTWBQCVV&5XV\5$5:`$@D`9#?#0\02V*T:C5`+SO#O'N#N2BJ(.LVW3
M\5^J*ZB6;&=L;VV;$ORC[7H*Q`]/5]-=-[PHI<5\>]HUU,?+#N[?U--N">GD
M6;&;=5]%0)WY']D\K?\`.C54C_DG*10D8(U`\2?2M",D<.@/OG/1EK8[:!3(
MTBM#_IB0-5?-<)0E2&H&Z*UOKXS]8;BV@^S]I['V7MR+-5^.S/8V>W1%N;?^
M^^V-VXMY#3=A=C=FY_,U>^-R[XG2HEBJYZB=J6>.0K%#3Q_MC(FVVZRL[(6-
M@ND4`H,4H*4_(8ZCB>XOKRHOSC[>'1J-I;UWQM+KS$]<TF?I)<=25BY+,SQ[
M>P_AW/7004M#C:7*8JOI\CC9-NX3'445/38_Q_;LBZIED8W"M'=&#JY#TI6M
M#^WI)04H`!GI-YKJ_P"(_8>XL/D^V?AQT32(%$.7WOTIM_,],]EEG5HAN"CW
M'UAN#:DE;DH)W,AC+:F-U1UL!["F^\H\L<S64NV\Q\O[??6TC5D6]LD[_P#;
MLCMGU!H1Y9Z/-KYBW3:95DVK=WL!_IB/V>0]<@]65_%KX/?#GJ+-P=Z]+;;K
M]Y[\R."J\!A^X.R.P]\]R;ZP>V<AXCD=K[7SW9&X-P5FQ:&8Q+'74M`E%+4Z
M`M5Y=(L7\J<B<B<AP7-GR3R9M.TVS$:DV^-%5B*T)H,G->-/E7I9OG,_,/,9
M0[SO,E\%J!K:O^"@X?ZAT;?N'MO8'0?5>_NY^T\_3[7ZYZOVCF][;SW!4Q3U
M`QV`V]0RU]=)!14<4];DJ^9(O'34E/')4550Z0PH\CJI%_1#T1Z@_FE=(+O+
M96Q-Z]3?*3J7.;LQ77^3S3]G]'Y7`8WJJ3N'>6X^O>E<5V[74&5S";)R7;^]
MMLSXO">034XKI8(:V6CDE"^_=>Z,M\5OE5UM\ONO,]V1UCC]Y8C&;6[*W]U%
MN7#;[P";?S^&W[UGFY-O[OQ,B4=?F,+E*:@R2>-:S'UU91R.&02>2.1$]U[H
MRWOW7NO>_=>ZJU_[J^_^6<__`"\^_=>Z_];<G_ER?]D"?#'_`,5BZ3_]]_@_
M?NO=+SY;?%'IWYH](;HZ'[PVKA]V[.SK4N6Q])G<>,QC<+O/!&2MV;NV7`SU
M$&,W$^U<Z(JU,?D%GQU8T0BJ898F93[KW5(_P+^6>Z^E?GMW5\-N^MV_W\[<
MWGF:7';EIMA;#R/2?QVZ=V/\<>AMJTE!W1L'JO+YG>4^T=D=K5^2I,/N;,UU
M9M?$5VZY,7'MS'5]!)-6I[KW6R;[]U[KWOW7NO>_=>Z(]\C,?\;>K,O3]MY7
MH_IC=?R"R-5%4[+W/E>MMEU>_5R>.2.&FW)5[P?#2[FH\;@$5+5"U`F)"Q1,
M";KZF:TSUNOE7JFV#:?8E7WSV5W7N[N/<F[<-V'2QA>N*ZAAAP.W<HC4[+D,
M=.DKHJTJQ,D*QQHYCD"R,P1?:GTQTE]>DOD]W]I;;[M?#[JI=B8GH6KVG5UF
M`S2551)OVIW*L4!@ARU'*WGHZ5JHRA2D3PF%1I<M?W[KW4ZN[?VU+_%L:,;F
M)Z&>AJL<M72S14LE5%74\E%4R1"0K48]%BG+0S&[Z@#86]^J<=>Z1'Q>V;M+
MK/9F2V/MW<^],],<Y69UX-]9:#(5U)231QQ*F$BI1]M3XV)%'G*DR3SWD<`G
MWNI/'KU/4='+V/V)O+K#+'<6R<^<)/':7(4M75*FVLO"@.N//4-5-#020%0;
MS:DFA'J1QI]U*BE*"G7@:<.C];?6G_F`[$S:[ZP%.?A[OGK_`'3U]F-AY*E`
MG^053N?&U>V=X9BLKF5<UMKK7;$IJ(]OS4$M%ELCD4&2$T$$%*M0GZ4])[&_
MRM_CE!NK8^]-Q[L^1?8VXMDX79F'EK.S/D%V/O.'?LW5NZ]Q[WZ;SO:5!DLK
M]EV!N#I?=>ZJNOVQ49!)5QU9XJ@I+/#'(ONO=&4^,WQ<ZN^)^R]S[,ZP.ZZ[
M^_G8^[>W^PMU;ZW3D]W[QW[V?OIZ$[IWGN3+Y!U@_B>4BQ=+&T5'3T=(JP*R
MPB1I'?W7NC&>_=>Z][]U[JK7_NK[_P"6<_\`R\^_=>Z__]?<G_ER?]D"?#'_
M`,5BZ3_]]_@_?NO='1]^Z]UK._S;/BI\GZSY$;"^1^/^0?7.-^+$.3V90[WH
M?DK7;6Q_Q\^.^6H\[BL1LC>^2ZCP^WMMXKY/]MX+L+/)F^KZKMC<:=?;*W*\
M@R@6BFBE@]U[JR'^5=\M-V?+?IO>&YIMO]BYSI_9&ZL1LGH3Y,=E8VFV[N/Y
M1[)H-I8:3.[SS^VUI\0/[];)WNV1V[N3,X?'4VRMP9J@GJ]MO)CB$A]U[JT'
MW[KW7O?NO=4!?,'?W8]%\^<CU?-UEFZGK?,=487>%/VO55TU1CJ&LIZ:IA.&
MHD1#08_&+DJ5H?M79:QZJ0S*&B925"<!TG;B>DDTD,,<TL\WV\:13,]2S*HI
MX_&WEJM;CQAJ<6D%Q8LH!%B?=NM=5Q;-V55;&AS^,K.PMR=E??[FRV3@W'N*
M662;[&HJ7:FBHH)YZF6"&1',CIK\9D/H55X]I>E/3=MRK[-GWENVFW/A,#0;
M#IA`NS:ZAK$FS%>X*AWJB&:2:*:"YF618_!(`J7'/OW7NG'_`$HT6W>R,)L2
M@_O!3[KRN$JLY1Y.@I73&TE##&[O!6USC3>H6)M0`:-2`'(++[]U[HSW;?2E
M'\D^JMJ[0W9N+.;<"5^&W5D:W;+0ELL8:>6GJL;7TTS1TWV]925)T/\`[HG*
MNJDBQ5#I-U=!\!=TPTVU-Q=4KY$I=F#%5VW(JB5YJI<)44R8F>FJ)I&U2R4=
M9CD+-8`F>_UO[2]*>K"??NO=>]^Z]U[W[KW7O?NO=5:_]U??_+.?_EY]^Z]U
M_]#<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]TG=V;2VQOO;>?V;O7;N!W?
ML[=F$RNVMU[3W1AZ#<&VMS[<SE%-C<Q@-P8+*P56+S&%RM!4205-+41203PN
MR.I5B/?NO=5._P`R#XN_,'N#*?$K8WPN[*W/T9U=UQC>XY.R]K]?]AY/I#K[
M>-'@ME[0CZ7Z>WIG.LJ_!]G;(V'N.?$Y'"4V7VE'5U>UWJXZP8^J2)8??NO=
M6-_'?);JRG1_5E9OGK?=_4&\(]B;>H-R]9[]WOC.S]Y[.S.(H$Q-?B<]V3A<
MOGJ'L.L2:A+C-BIDFRL;K4S+'-*\:>Z]U7[L'^::=_\`=]%U3B/CG49C$Y/=
ME=M:EK=A?*CX==I=M8Z#'9-\97[LW-\>]A]V9C?^)VM@RAJ<N:=Z[)XBD5GJ
M:)71XE]U[HN?\QF#OC,[_P![XWIK.X/;F_XLSU__``S(;@:%L-#L>+'Q5&0T
M154%5!+5RF5C*FCR.A=4()N'U^$4Z3MQ/2!BI&J<93X_-FCJI:K'4]'G)J*&
M:DQM94RTZ1Y6:AIY9)*BDH:F<2-&A<ND9'-_=QUKJO+&Y+=\N_.SMN[AV/-M
M#;NU-PR8K9V1JJEZFJW'C8Y)5BJ96+&&5#3*DD;QA0$D"L"P)]I>E/2L5&<Z
M44L>38"_^N;>_=>Z26^MYX38&VJ[=FX8<A)C<:8::9<1COXCDR*N3Q"".--$
MBTUU)<NZQ+;U<D#W[KW1C]R]3R=W=%[7V;FM\;PV5!DO[N[I3,[1"8[._P`+
MI_\`<CA<!D(:HQDP+23QO*C6DBG5?KIM[4@`TIPZ3'SZN)_E]XO;LY[,RD&7
MI<KNG;G]V-E5ZIDZ.MRF,Q_\,3)*V;IJ:9YJ/)9J>%9G$R1EC%=1:_M-TIZL
MK]^Z]U[W[KW7O?NO=>]^Z]U5K_W5]_\`+.?_`)>??NO=?__1W)_Y<G_9`GPQ
M_P#%8ND__??X/W[KW1T??NO=>]^Z]U[W[KW7O?NO=:T.[NM=X_##^95M+L;!
M[$W1F?C9-NG:TV\?DKO_`+CH6Z\Z>R?=>XLYB.Q<)V1MS!Y/:='L^;(2[OV_
MA]CX@;<R-.:BHCKZ[)0P2EHO=>Z.[\SL964/>=77U$,\=+G=J[?JL?/)$Z03
M_P`.2JH*Z&"8CQS2TKQJT@4DH)%N+&_M1'\/3#_$>BLQ)Y9(XPRKKD1-;_H7
M6P4,QX](_/\`K>[]5Z)IA,UF.^=T]B56%V%N/94.P]R_W,;([Q1L;CMZFBEJ
M:89K!RO2Q-]Q%X#YH-+J87A9926("3UZ4_GTE>W>@-W[OP+;6DK-Q8JE%=CL
MC-FMF.DWW(CF,:XVI21X)VC\CASIMXG4.;@$>_=>Z&S9/3U=0UU%'NI:*MQ.
M+@I:;[:LJQDILW]M2+'!4UTZ*BE%D4//K!UR@\6]^Z]TK-E=N56[^RNSNOWZ
M\WAM2'JY\4(]W[CIHZ?#[MDR$C!&P5*L;`T8AB\T#B642T]F81_3VI%<=)NC
M+8CX=T7QK^&OS^[[Z[/:A[C^5'1F]X,,G6NVMV=V;SV8VY-LY[#[8S.S>N=F
M2T>YMZ9G%Y_=G\;>BHFFR$-/3B&"7T%/:;I3U5K_`"_.ANAMV_*[KJK_`):W
M\R'N7<U!TQW1\:-V=O\`Q/SWR'^6FR?[H?&C;/1V\=K?(9>R^@OD545-7O3=
M_:GR0I<=4SXA*2&FVO030:6HUEIX)_=>ZW./?NO=>]^Z]U[W[KW56O\`W5]_
M\LY_^7GW[KW7_]+<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]U[W[KW7O?N
MO=>]^Z]U0E_-5Z/^*O6FYMN_(CL_>W?NT\OWIVOTIM[+]1[/Q?;O:/QH^47<
M7561Q&4ZEV1W9T#U2O\`>'?_`&5O';.U_P"[^T:2"MH,?E\Q08N+(15BT<,3
M>Z]U9)N*AW1\H_C)BMP;DZ<W'TKV=N'&S;IVIU9V;E=FS]A;+K:>OG?%8O=-
M=LS/;IVOB\]G=MQ1R5U'1Y*LCH&J_MYI6DA>WNO=4D[_`-B]ZP=V[%GH=[-L
M/KG:$-9%VEUCD<-%_'\YF$:5J.%C44[&6@RD,JHLHECCIQ%Y(_)K]J>-,UZ3
M9'3IV)O2NHL=F-J;,S6UJKNROVAF<UUMLC<N5ACFS,]`H1*O[.659GQM,=3$
MMH1W0*WHNPWU[ATC:'L+?NP?CO\`Z2N[-MR3=@;2VG69?>NV=HQTLT]9D(*I
MX::.DCHFJ*.CEK89(9*D1-)#2`N?H"/?J]>Z7O66^*+L[K_9?8=)B\C@:+>.
M$I\RF(S`6/(XL2O-%-35$A2..5%FIG,<VE1+%I?2+^_5\CU[J?\`%/&?(KY&
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M_OOQ_O'OW7NO>_=>Z][]U[JK7_NK[_Y9S_\`+S[]U[K_T]R?^7)_V0)\,?\`
MQ6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW2=W)M/;N[Z:AHMS87%9VBQ
MN8Q.XJ"FR^/I<C#0[@V_D*;+[?SM$E5'(*/,8+*TD=325,>F:GGC5T8$>_=>
MZIG_`)M.ZM^=#Y;J7O[XU=/=S;J^8NZ<-GN@^LNQ^M^O]E=C[0Q6(S>8P]?'
MUSV+B=X3224.4WCD\M/4;7>D&,H&R]*:C-Y%<70O2S^Z]T-V,SF(^1/2V"Q/
MR)R_7'27S3Z_V1C<QVIMVNR#;<BVEE#N&JVA45>C<38ZNW'U'N?<M)X<;F(#
M/CZF2I@FHY&2>)9?=>Z`#<O\N_>U!V/0]R-L+;NZ^QL?@O[IT&Y<%N5O/CL+
M4EXGABQ.7_AM,DH2H=#5(IDCB8BUO;X<>O2?2?3H4'^%_>4=%3UB1[/FJ9$9
MI<2NX)%JJ8L"IAEJ)<><?/J5B"%D*'\W]^UKUO2>E!UC\/.SIMZ8"L[`Q6"P
MVTL3E8*W+T_\8I,C6Y>FQS"HI\;CZ/%I-3)25=0B+(TKQD1:AI)('O1=:8.>
MO!37(QT&WR>_FF[!VCOG<WQ8^"&!V%\F_F+M>NWBF]^C,3OF+IC)46VNL]MS
MY[MJCZ<[!WAUWF.GNY?D%UW%5T4;['H<A45N+J*HS9A:2FIY@S/3_5='\L3X
MJ_%7Y5]@[8[P^.\>=^3W\M;-=,#+]TM\V-T9'Y!;B[G_`)F>/WG@,C7]U3='
M]T8W.R]!=_\`7FVX<E3[QW#@WQNW-R1YN@IL10R45&E:?=>ZVNA_C];"_OW7
MNN_?NO=>]^Z]U[W[KW56O_=7W_RSG_Y>??NO=?_4W)_Y<G_9`GPQ_P#%8ND_
M_??X/W[KW1T??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5%_?'\I?;F[OE)2]
M@]:4^\#MWY%=D)O'Y9[QW_VGD,_MW8766U^P>N^ZMT=3="=5RM#4T&Z?E9VG
MUCM:BW#FIJB6#`;2P-334GB,\%+)[KW10L'_`#<_DHW9>Y=_UFX=C5'Q;W%V
MC_-N[?VWGZOK>?>T^R?@Y_+0ZRVCT_@MX8;$;!J]M[QW6>R_EUDZW*U4E3--
M5OAJ2>CIYZ=`'A]U[H1OB7\\?YFWSVHOD3U?\>\M\.=G;Y^,W8/7-/FODCV=
MTCW12=>=J;.[?Z)QW;NQ-J[2Z+P'=6Y:C:N]L1GJ^"BW-D9]]96&DP==2U=-
MCWJY331^Z]TM=\_)[O'^8W_(ZR_>G376_;VS_F)NR0[;V1LKXUYZ'^\&SOE_
MT-\ATV-C,SB=RY?.X;&_Z"*7MWKM<GG9LA5U$46QIJJ.H%3*KH_NO=+3XZ_R
ME=VTO9W3_<?<G;N2P/56S^X-X?-S!_!7&;/VCD\7TA\ROD#L+<N*^06!Q?R2
MQ^6J-S;\^.HW?V7NFNQFU(Z"BI9YZ^,UE55TD24?OW7NKENL>GNJ>E,)7[9Z
M>ZTZ_P"JMLY3,U6X\CMSK?9NWMCX*MW%6TE!CZS.U6)VUC\;CYLK58_%4L$D
MYC,C14T:DD(H'NO="1[]U[KWOW7NO>_=>Z][]U[JK7_NK[_Y9S_\O/OW7NO_
MU=R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO==7']1_7W[KW7=P?H?
M?NO=>]^Z]U[W[KW6-UUBVLJ""ITDB^H:>&4JRL+\$$$'W[KW1).H/Y=GQ*Z"
M["Z^[#Z@ZSBV1/U7\<MU_%;K[:%'F<SD=@;9Z?WUV;2=O[SQM%M;-5N1IIL]
MNC?%%%/7Y29Y*RJA7PRNR<>_=>Z<>U_@=T#V/TI1=";.I]Z_%S86.WF-^4?^
MR7;VS/Q/SD&<J*;(T&=09?I:7:TLN,W;CLM409:FD5XZY75W_>CBD3W7NANZ
M#Z$ZD^+_`%!L'H/H?96*ZYZAZOV_3[8V+LK"FJDH<)BH9JBLG9ZS(5-;E,KE
M,KDJR:LKJZLGGK:^MGEJ*B62:1W;W7NA@N/K?C^OOW7NO>_=>Z]>_(Y'OW7N
MO>_=>Z][]U[KWOW7NJM?^ZOO_EG/_P`O/OW7NO_6W)_Y<G_9`GPQ_P#%8ND_
M_??X/W[KW1T??NO=4B?S<?G)\I?C7O7XL]$_%>FZJV3O3Y(GMYZ?O?OZDKVZ
M>V]N[K_';3BZUZCJ*R#32G</;F[MW1K4QAFR:8'&US8R"HK3&8?=>Z++_,V_
MFZ=Q_'CKW957T5NGK?:>7P76ORIS797:N\?CWW;V+UOV%\KOB[F=A=54'PKZ
MKV_53[`RV&E[=[IWO,5W=DZU<?3;8Q,M7035K2&2/W7NK>^E/F?U!O'.]:='
M;EW]0S_)O<%#V)MG=.R,?L?L#`TU9V'\=J#95!\CZW`RYK;\>.38NR]W[UI*
M&FRK5LF*R%1.*>@JZR6*4+[KW6M7WUW?V)%A_P"<]F-^?(?Y@[#_`)H'7-3\
MS,1\6^A=D[O[SVYU]AOA?MC;6+/06_>JNLMG4B=1YK&9;9CC-_WQDC7<3;G>
M<?<13QI`?=>Z0O=OR`[+P/PH_FAY;XW_`#(^<*_%;;/6OQ<K/B#WAE]U]L9?
MM',_-S*XK=$W;WQ[Z4[7[`V;FNXMZ]-YC^#[>J<]"DQAQ>6K*VCH<A1TIJH$
M]U[H\?8/R;ZX[(_FM_#J7JCY6_('8N"/QZ7L[Y!9K)[][OCZ([9Z_P"P>C\K
M3=6_'_HKHE,'/LW+]M9>KDGW_GMRM0TF1VV,;#"E549*5<?0^Z]U@_E>_(;L
M/$]%_P`X7>>*[FW+D>LNFMQGL#XR]P[DW=\A/F%\9-N8NK^.\>Z:RFZTW[W?
MC]K?(WN3<6$WSBWK.Q]JQI3TN/SN03'8(HTS6]U[I4Y;YQ?S%OD%_)D^97R`
MI^M]P]"?-K9N^DV%G.B>M.N=VQ=M_&GKG&[AZDINSLCMJ'=]/4UW9?9S=![D
MS>_L'EL;3K34PRE'0TT<U?BYS/[KW1(^\>WOBMA-U_&O%](_/3^8@?@_E/C%
M\WLWL?M7K[O#YC;MW]G/F3B<UT'%UKMS;NY<MBLOO+LG=M*F7S%1B=KYA:_`
M-E9ZJE^VT^:C'NO=#KU-WA\EI_YA_P#*8H.V-[]GM\E-V="[?P_\PGI#8O9O
M=&4W3A-W;F^+=1GJ6M[<^+62P]/\2>JOC]M[="X[,Y3=6"JCN=MYY*2AAC01
M-#'[KW2)[@[][@VQ_,-^4+;.[Z^6Z_)S8G\R;XTX_JGH#&9_MO/?'G-_R]J;
MI[I7._*')[_ZNKL;D>E\5U'A=KUN]LM)N2'[//4^Y:*DCH:I:F58:GW7NBQ;
MM^7_`/,>J.C?Y@F8S^.^</6?^S\_']_EI\.\IN^LS.-EZGR>UOE5A]F573?Q
MRK^O\MN3>'6.TMR?$3?^R<S61Y2BV_GH,C'EJJ#'O(S/)[KW0T-UQ\BMY[2Z
M1V9V=W5\\NO^Q=L?SP:[X:=B]3]=?*;Y+U]%U1\0>QML9[?^$V&G>J/M7>OR
M'ZUR&%QN%S^$[.W!18_-T%-FFPRRT@HGB?W7NMR/$XR+#XW'8N"HK:F#&8^C
MQL$^1K*C(9":&AIXZ:*:NR%7)+5U]=*D8::>5FDF<EF))]^Z]TY>_=>ZJU_[
MJ^_^6<__`"\^_=>Z_]?98^!_SCZ^V?\`"GXG[6K^E/FCDZ_;OQ[ZGP5=7[6^
M$_R:W=MRKJ\1L[%X^>JP6ZMK];9G;.Y<-524QEI:_'5=50U=.Z2PRNC`^_=>
MZ-A_PX/UG_SX7YX?^D"_+?\`^U)[]U[KW_#@_6?_`#X7YX?^D"_+?_[4GOW7
MNB'?++YA?RJ]T;ZZ@W7\T>F.]*?>>S,I0U745-W?\4_E!L_'U>2J-V[=_@Z4
M^RMP[3PFVM_,N^H\5]C#7T.16++&F\*K4-'?W7NC+1?/KXFIW=E*J#HWY5?[
M,34]7X5,HH^!WR6D[=7I:FW7FS@Q-1MU8VZZ7K1M[S5_B=8TQLV5$O+3J=/N
MO="V/Y@_6?\`SX7YX?[#X"_+?_[4OOW7NO?\.#]9_P#/A?GA_P"D"_+?_P"U
M)[]U[KW_``X/UG_SX7YX?^D"_+?_`.U)[]U[KW_#@_6?_/A?GA_Z0+\M_P#[
M4GOW7NO?\.#]9_\`/A?GA_Z0+\M__M2>_=>Z]_PX/UG_`,^%^>'_`*0+\M__
M`+4GOW7NO?\`#@_6?_/A?GA_Z0+\M_\`[4GOW7NO?\.#]9_\^%^>'_I`ORW_
M`/M2>_=>Z]_PX/UG_P`^%^>'_I`ORW_^U)[]U[KW_#@_6?\`SX7YX?\`I`OR
MW_\`M2>_=>Z]_P`.#]9_\^%^>'_I`ORW_P#M2>_=>Z]_PX/UG_SX7YX?^D"_
M+?\`^U)[]U[JO'_9Q]B?\.:?Z3O]$/R\_A/^RV_W%_N]_LH'R!_TA?Q3^-?W
CB_C'^C3^X_\`I"_N5]M_DW\=_A?\(_B/^2_<>7CW[KW7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g575431dsp_075b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_075b.jpg
M_]C_X1_?17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-SHS,"`Q-3HQ,SHR,@```Z`!
M``,````!``$``*`"``0````!````C*`#``0````!````G0`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``!ZI`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`G0",`P$B``(1
M`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[3H/U?Z)=T3`MMP:7V/Q
MZW/>Y@)+BT%SG./[RO?\VN@?^5^/_P!MA/\`5S_D#IW_`(6J_P"H:M))3F?\
MVN@?^5^/_P!MA+_FUT#_`,K\?_ML+3224YG_`#:Z!_Y7X_\`VV$O^;70/_*_
M'_[;"TTDE.9_S:Z!_P"5^/\`]MA+_FUT#_ROQ_\`ML*&1]9>FT=7P^DDOLR.
MH,>_'?4W?6=AVO#K&;MOY_\`(9L]ZH9.;U7-^M%_2\;.;TW'Z=13DO'ILL?D
M"US_`%/==_-XU+:O2=Z7Z3U+/YQ)3I?\VN@?^5^/_P!MA+_FUT#_`,K\?_ML
M+F<SZY]3RL3K)Q<1U.%CT9U=.<PG=7=BL+:[+'N'I?K%G\RVG>^G_"K0Z#U7
M)K?UK)ZEDNLP^G,QFC=!VEF)5D9CA^<Y]MMJ2G6_YM=`_P#*_'_[;"7_`#:Z
M!_Y7X_\`VV%:PLZG,J:YL,NVM=;CN<TV5%PWBN]C"[T[%924YG_-KH'_`)7X
M_P#VV$O^;70/_*_'_P"VPM-))3F?\VN@?^5^/_VV$O\`FUT#_P`K\?\`[;"T
MTDE.9_S:Z!_Y7X__`&V%B_L7I'_.S[+]CJ^S_9O4]+;[-\[?4V?1W[?:NM7/
M_P#K:_\`H'_%)3__T/0_JY_R!T[_`,+5?]0U:2S?JY_R!T[_`,+5?]0U:22E
M))+#^M3OK&["%'0*0ZVP.==?ZC:WM8R#Z&+O;9^MY7\W1:]GHT_X1)3>ZUU?
M%Z+TO(ZGEA[J,9NYPK:7.))VL;`_>>[Z;O8N'Z_]8.J6]0SNG=1O=TW!LPWP
MQC"_95>RL8O4#=C>K=;Z63ZU&;_-XU%/^$?98B,PLCZP=;JZMTG>&/FOJ%F4
MX;J3/IYG1>I=-L_G,;[,/U>FIO\`2;K<JR_Z"Z+)^K70</#Q2Z@W.Z<PTX1N
M>]Y#2X6,ILEVW(JJ<QGI5W^IZ?I(@6:430MS.D?5+,&%6W*<SI633D-RL>[#
M>VQWK%CL?+<QCJ:L6G%RJ?97AU4_\)<^VQ;_`%?H'0>J.JOZMBUWOH$,LLD'
M;R6/+2WU*_\`@K/T:P.H8+>HOHLOMM%F-8+JW,>1[QW<WZ*MVVV7/-EKBYQU
MU_@IO8V]7GHQ>[OHGR*?J[]HNN9TZFZW)8:LBW8T;V$;',=I[]S6[7*T_IG3
MNI=+RL?':,89SM^0Y@&[U!L]SQ^=[:JV_P!1<^SJM3L_*PGUNJ&&P/?D/@5D
M'P^]&R>H9F'B.RNFUNRKC&RNLZ.!_/\`Y3&ITN7&D1I(UN>ZT9CN=8^#9ZAT
M#*Z55U#J'0!OS\TV%Y<T.L:+27V.J?+-WH6O?D,K][W_`,RKGU=S'48K<#J-
MUYSZJOM%WVO;N;6Z/\-7OK].IQ]']+;ZWZ.Q`JZIU`LK?8_:^`Y]>A`/+J]T
M+2=D]-ZC19AY`!KO:66TV"`YKAM>R5#+%*/CY,D<D3X>;#H?UBZ=UUES\$OB
MDB=[8W,?N]"]FKOT=[6;F;_TO^DK6HN5ZATV[H;*ATS)NP\#*M>_JF68O=4`
MTO&0/5;8YCK?3KQK+W^I511_@O\`"+5^K_5\?J/3JK6Y(R;`34^QU9H<Y[1Z
MG]'?[F/=3MMV)B]U4DDDE*7/_P#K:_\`H'_%=`N?_P#6U_\`0/\`BDI__]'T
M/ZN?\@=._P#"U7_4-6DLWZN?\@=._P#"U7_4-5R^U]5#[&UNN<P2*V1N=_);
MN+6I*&IKNF265B_6/I&18<<W?9LEOTL?)!IL']FW;N_L*'5\[J.)=BG$%+Z<
MDNK)MW"+(WT[;&;OYUH?^8F3RPA"4Y'T0UD=^$?1E&#)QB!CP2()''Z+K71A
M]8>N870Z6OL]EN78&;JVRZ2-OJ/C^2%3LNON(%CW6$?1!\U6MRKMY=FX[]\R
MY[8O8"/^+]]?_;:!F=2Q*L1U@M+O4!K::_<YKG`AKG-^DS:K'+Y^6R0!Q9(9
M.LI1EQ?\W]%KY<6>)N4"(]*]4/\`'CZ&IGY^3EUNJZ4RUXK?#\ICF,8XL,65
MT&YS77[7?GL_1J_A9^-F-<*7'UJ@!?18W9:P_P#"TG][]]GZ)4>DV5NP:L<#
MT[L1C:LC'.CZW-$>]G[EG\XRSZ%B+DX=.26/LW,NJ_F<BL[+6?\`%VC_`,]O
M_1*;7?NQD"J;V1CU95#L>X%U=FC@#!TUY57-S:.CX^.T4/?6]XHK97J6S^<Z
M5F=4SNLXF*?59]JI8"3E4#:X^'VS'9[JV_\`"XWZ/^HJW2_KC@5T3>ZR[<V6
MMI8ZR'3!:VU^UNW^TI(Q!]6_0Q_38Y6-/K?Z+T/4,PX-(M])U_N#2VOD3^<K
M`.YH,$2`8/(GL5R]_P!>+/\`M'@$>#LBP#_P.@.=_P!-"Q?KKFLO:>HT5.Q7
M&'OH#@^L'_";7EWK,9^?^>E[62B>$UY?RDKBCH+%^;W_`$RVE]5N)DN#FV^T
M,?JUS2-KZ_=^\L+*Z-G8_7HZ8RRQ]>TXS]IKII!C<V_+<&M^SMV[KL?#;9G]
M2?\`H\S+KH5S'NJ+J\BIS;ZI#FO8X.:Z#^:]OM718N95E-)9(</I-/(57+"C
MQ#8L^.6E'HF8'!H#CN<`),1)\84DDE$R*7/_`/K:_P#H'_%=`N?_`/6U_P#0
M/^*2G__2]#^KG_('3O\`PM5_U#5I+-^KG_('3O\`PM5_U#5I)*:>?TO`ZC6*
M\VAEP'T7$>YO]1X]S5SO4/J_9@4_H+;+<7>UWI-?Z=H<T[V%N[]6OV[?SF5?
MUUURQ^MBWU*R?YJ"&C^5WE,ERV/,>&8JP1Q1/!.NW%%EAS6;#'TRN(_0EZH?
M8\KFYW2*L^U]U+G'*V.VEA;8Q_\`-6[_`*/\BSV)=9Q^BX&&[-R:7DM(;6RI
M[@]]COYNMCG._P"J^@M6XU-K==<`6TM+R2`X@`;G;5B];I_;_1*LGI9-[JK!
M=57]$O#0ZNZKW?X;:[]&I^6Y''AQ0QD#)#'4(SG&/N"'C+^K!BR\]E,^+%/)
MB/"`8^Y+A/#'V]/ZKS>5UKJ&3L+=F-;4?T.2TNMR&-_T/VFS9OI_X-];V+5Z
M=]:ZS%75@VEW`RV#]$?^.9]+'=_X"N?KKR+GFJG'NLM:=KZVU/+FG]U[=OL<
MM"CZM=?OXQ!0T_G9#VL_\#;ZEBT)8^7$:C+A[$'B:7N9I2,I#BO>QPO8M=HU
M[3(<):YID$'\YKF_26-U3ZM8N8YU^(X8>4[5Q`FIY_X:EOT7?\+2ETKZN=;Z
M8UQJSJ=AU&"6/-!=_P`:X^IC_P!>AG_6U=_:>/7N9G`X%]8EU5QT(_?Q[6^S
M*9_Q/Z3_`()5[,38-5M+9ETD*.M]'B\RC)P+13GUG'>?H.)FM_\`Q%H]MG]3
M^<1,3I74.J.^SXM-@99[;,E[7,K8TZ/>7V!N]VWZ#&+MV],S>L4EEU8PNGOU
M'VBL/OL_=?7C/]N(W]RRW]9_D5J-CLOH-M5/5<\972[@YM.?D0RVFQ@]3[/E
M.'LNKNK'Z"[^=W_HD!\2C*7M<0XCIQ5_*/$H\H0..C6_"R915T_J>.S&:&8^
M8QU=E0T:;:&M?5D[![6V65!U=VW^<6A]7L#(Q>J7W#)LOKR"7&NSZ-;>^U8^
M);F]7N?G-!PL2ACF]-O(#O4-FEF8YKOS/39Z=7]=&J%>0RS'K'K]3K`<676N
MMK>S\YU&QS*7?R:[O^N*GSW/?=<7$<<IPF>#B'#P0\<DI?)#^NV>6Y7WC?&(
MF!'$/FD(_O\`[G!_AO6976NDXC2<C+J8!S[MQ'Q:S<AX'7*.I6`8=%[\>"3E
M.8:ZM/W'6[++-W\BM5.C])Z+;4W*K!R+&F'"YH;Z;Q]*LXK0VNE[?ZBWAPF8
MY3E$2EPB]:@?<_Y[-D&"%QC&<IC3BGZ(CRQ_-_SUUS__`*VO_H'_`!70+G__
M`%M?_0/^*D8'_]/T/ZN?\@=._P#"U7_4-6DLWZN?\@=._P#"U7_4-6DDI2R^
MKXMKQ]H#P65C5ATC^4U:BJ=2I%V(Z7;=GO\`(Q^\G0-2!6S%Q(<"`001(.A"
MI9UCL+$KJP6LIMNM;11[1L8Y\EUWI_G>FQCW[/WT3-KS;!3]CM%):_=:7"99
M^["EG8C,S'-)<:G!S;*K6P75V,.ZNUK3]+;^Y^XK&3C,)B!X9\)X"?EXZ]+#
M#A$HF6L;]0_J]7.IZ1CT;G47Y5=KS-E[;W![S^]9_@O_``-%:SJU9_19HN'9
MF14UW_@M'I6(.5F=0P!6,S&9<ZP[:QB/W66'_@,&W;=_6]^RO_2+0HZ+EYOO
MZF3C8QXP*G?I'C_N[E5_1;_W6QO^N7+F(#XIAR<,LD\?4F<AEA_@Q]?$[$CR
M>2-B,9_W1PR<OIV1UZ[J>0RIE6<':.LKL<W%QW#AM[GMWN?_`,#C>I;_`*1=
M!A]&JIM9EYC_`+=G,GT[K&@,JGD86/JS'_XW^D/_`-*KU--5-3***VU55B*Z
MJP&M`\&L:J&?UNK'M=B8E?VW-;].MIVUU>>7DZMJ_P")9OR/Y"NSYG+*'#.?
MI'S2/HOQE_WK!'#`2N,=3L-V_==314_(R+&TTUB;+;"&M']9SE@YSK^L6U/;
MOQ.G8TVU6VL`?;;!:V^NFX?HL:NIS_=>W]+^X@789SG>KU=PSG_F4D;<>O\`
M\+X\_2_[L7;[T&_IYJHM=@V65OVDG'>]SZ;!$NIMJM+]OJ?1]2OWUJOR_P`0
MY2.7]8)G7TS'\W_>_?99\OGX;AP@_NR'&?\`G>A"_I>/2<=^)D.NIS+'UEQ(
MVB][2ZBT-:/3VNLKV7>Q;'U;Z;E65LHZH^P7G=N;19M9I]!_Z`,^DL[IYQ,T
MX8Z<PCIV(?M-EA,AV0YL5XM;_P#"NQ_4<_)L^A_@UT_3<UF+7D.L;^CK8ZY[
MP.`P;G;EMY.6P2A(RPPF=/5(<?V2FTOOG,2D`<L@!T%1C_BQ5T/%Q6Y?4,BB
MLMV7?9A87O<YXJ:SU'6^HYS7;;G/8Q;BSOJ]193T?%]4S;:WU[2>=]Q.19N_
MM6+14<8B(`B!$#8`4$RG*1N4C(]Y&U+G_P#UM?\`T#_BN@7/_P#K:_\`H'_%
M%:__U/0_JY_R!T[_`,+5?]0U:2S?JY_R!T[_`,+5?]0U7K[Z<>IUV18VFE@E
M]EC@UK1_*>[VI*2*%M3+JW5/U:\01P@#JG33ZD9=!]%N^V+&^QI_/L]WL9[D
MCU3IHW3ET#8QMCYL9HQW\W:[W>VM_P"8])3B96.<?(=3,Q]$GN"J=&=BY--M
MV+8+VT[FOV<[FB=G]9;=U65U66G]5P?S;6D&ZP?OU/;N9CTO_?\`YVS_`()9
M%?3:.EO?CX]3:)=O.V8<>UFJMXY@BC\S7G$@V/E5]6NFXV+TVC+;^FS,RIMM
M^6\[GN]3])Z37N_FZ:_H>E6K^;GXF!2+LNP5M<=M;8+GO=_HZ*639=9_)8LF
MG'SL0.KZ=EBC'<2YN/;4+FUEQW/^S.W5O8QSO=Z#]]2!A`#JE^YEF3>QD/ZE
M:0YQ/YV/2!^BQZF_Z+'_`+:SON.260G)(<).^\I-K[S$0](UK9;JV7UO,QW;
M-W3<1X+=C#.2[P^TVLW-Q*W_`.BH_3?Z2Y9>!TZOI^"]YR;\7'I!,4OEA>X[
M@QE5PL;8]RZ5SFL8Y[W!K&@ESCH`!](E9%^11DYU+,HEC&CUF4%KB0R?T6]K
M`[]/E?SFW_!X_P#QBDYC'R^*,<9C&4LAJ,,FL?ZV7)Q?HXXKN5&3-,S)D,>/
MU3./Y_\`98_ZTUL3"ZUZ8R774OMO:"^J]CAM`_FVA]!VL=M^G^B4&6]2ZA=D
M=.-;<(5>S(R0XV$M=[7#$;L9^D>W_"6_S:O'K.&<BND"PNN>6!VP@!PT=S_*
M6@RNVP[:VEY\&B4!\,Y&1CD$`>&C8)X)5\OIC+@1EYWFN.8G<"=."J.,?NC^
MZAZ<</)R#TK"LJ;;AL`..#&QC8;_`-'\Y:/5L<T=';T\']+U"ZO&+V]Q8[]-
M_FXS;5+I?1O0S79SJF4VN$/>`-[QX/(1LK]8^L&%1^;AU6Y3_#<_]4H_Z+\E
M6<TP343Z=/M8,42!9&KJ``"!H!P$Z22A9%+G_P#UM?\`T#_BN@7/_P#K:_\`
MH'_%)3__U?0_JY_R!T[_`,+5?]0U+KO2G=4Q*JJ[&U6X]]>35ZC=];GU'<VN
M^J6;ZG?UOY:7U<_Y`Z=_X6J_ZAJTDE/+?\T,@9-^3]HI+GNOLK:VHL]^2RNB
M]MME=GJ>A6VK]"RO9^D_2?X-`?\`46]]`H=E56-IQ:<7'L-)8]@J?7?;)IL;
MN^U/I8Q_^$KK9^C_`#UV"S^OMZD[I&2WI1(SBW]%!`=R/4]-UGL;=Z6_T=_^
M%24DZ1T_]F],QL#U/5^SL#/4@-D#^2$6_#Q\AS76LW%F@[?>N5KQ_K$>I,-)
MZ@S"BJ/M%C#%'IVC,9;[W6?M!]WI_9__`#YZ:K6=/^NM-57H9.198[%MLMK>
M\'TG.%KF8K;S#<C)W/HK98[^:]+^=V6)`D;*(O=W\K"KSK7X^"/094=M^2)@
MD?\`:>G^7_I;O\%_QB!;TS(Q*V@,!I:('IZ@?V5>^K3>IMZ36WJF\Y+7/&ZP
M@O+-SC2ZS;NVN]/\USWO6HGQRR'CYK90!\'@\BGK%_40P-K_`&4P"S>YNX>H
MWAES06N?^D_,^@K'VWJ8ONHKM;=;8UM50;6&GU7^]UDMW.<S&QQZC_\`K:Z^
MQU--3['PVI@+GGL`!N<2N?\`JUCW647];?4#?E[WXE!]H%;CN9[M?3^T;:_^
MM^FJ?/\`*X.:E#CQ`RN/%,DGAPX_5*,?W?<^5M\K*6/%,R(./'Z81X8^K-E/
M%\WSR^7U?U&&'@O]F+2TCTQ$O$1^\]Y/YSUOX.(,6G83N<X[G.&BJ4==K-U>
M-G8UV!DVD,8VUNZM[C^95E4^I0_^VZMZ1^LO1FY-F+;DMINKM=1ML.W<]C6/
ML]+]]K/4V;_])^C5R4[``%1'0-01U,B>*1U)+J+*Z2?M'4NJ9O+?6;BUS^[C
MM]\?^A%UZC5]:_J];2V\9U36/I^T@6'8[TICU',L#7M^DH]*ZAT3$Q3BU9]=
MSJ7/==8YP#B^RS=9ZG\OULEE:8N=E)8N1]</J[0P/.8RS>;&L%4OEU3?4L9N
M;[&>T^S?[$9WUFZ%7799=FU5"ES66ASA+7N!=L,3^Z_Z'^CL24ZBY_\`];7_
M`-`_XK?:YKFAS2'-<)!&H(*P/_6U_P#0/^*2G__6]#^KG_('3O\`PM5_U#5I
M+-^KG_('3O\`PM5_U#5I)*4DDDDI22222E))))*:N?AU9^);B7%PJN&U^TP2
MV9<V?Y?T'*PUK6-#6@-:T`-`T``[*222;-<-Z7=>)4N/ZO\`\T.G.SK+S9=E
M5[LB['87N<]^XW^BQT>GZGJY=;_1W_H_T"[!<U]8.F="PHS\GU*C?D-?8VEK
M[76.;&3:RND>IZ'K?8ZK,NZEC-].,DAJ?8_JS@6%MK['9K!@OR<>VW=M<PUL
MQ'79#VAGT<?W^_\`35X_\VA9#?J5DMH#.H656M-M=!<;=ILML;E>ME5/:SU&
M,R\FG(WW[*??4B]1SOJEFY5EQJNS<K(]*JJQC'O8YMCOL['T;BVBRJBVYWK?
M\(J/1LKZFT]-/[0=:^TO=ZEF4'S8/4#J(V_H[*;=M-E5?O\`9_Q:2F36?53'
MJQ\?&NR<UP#L>^SU'5ES=F.UC,CU17OH>RO%KQ?3_1[$9K/J`*7.^UO?7N?0
MT[K2:V6M<ST:O9NKQ&MR;/1M_FOUC^>4Z[/J'66UM998S6+W>N]DL]-L'(>?
M\'57CN^E[,?T46KI?U<ZUU"H=/=96S!]-]X8US6W,8:VXE#K;?<_&_4ZGM97
M^BMV)*>L8UK&AC0&M:`&@<`#LL'_`-;7_P!`_P"*Z!<__P"MK_Z!_P`4E/\`
M_]?T/ZN?\@=._P#"U7_4-6DLWZN?\@=._P#"U7_4-6DDI22222E)*OE]0P<$
M,=F9%6,VQVRLW/:P.<?S&>H6[G*-?4^G66V45Y5+[J`3=6VQI<P#Z3K6!VZO
M;_*24VDE1_;G1?L[<K[?C?9WO])EWK,V&S_1-LW;76?R$89^"[*.$,BHY8&X
MXX>WU`(W;O2GU/HI*;"22J6=5Z95?9C6Y=#+Z6>I;4ZQ@>UG^DL87;F5_P`M
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MNXW2^GXM[\C'H;7=8QE3GCGTZQ%53?W*J_\`1L]B:WJO3*:ZK;LNBJO(_F'O
MM8UMD_Z)SG?I.?S$F]6Z6_)^QLS*'94EOV<6L-FX#<YOI;M^YJ2FVN?_`/6U
M_P#0/^*Z!<__`.MK_P"@?\4E/__0]#^KG_('3O\`PM5_U#4WUEKZM;T3*KZ,
M=O4'M`I<"&D`N;ZWIO?[&V^CZGI;O\(JG0+.LCH>`*L?&=6,>K:YU]C21M$%
MS/LK]O\`GJ_ZO7?^XN+_`.Q%G_O&DIYK,9UGI7U8R*`_(K#]MKLO(O9ZM8MO
M:R_`QW-=D>BYF)[L>^RVW8^W^=4OJYU+JN#T5E[\+*RV9U]C\.NVTOM8U]WH
M8F&YUVZST:\-CLQV5=^B]/\`KKH_5Z[_`-Q<7_V(L_\`>-+U>N_]Q<7_`-B+
M/_>-)3D=:Z;G?\Y,;JS,!O5L7[(_$.,75M--CK&V_:@,DBO9;7^AMV?I5E87
MU;ZNS-I+NFUU##SLS-.8+*BZZJ_UO2Z?4UOOVY'KL];[5Z=;/176>KUW_N+B
M_P#L19_[QI>KUW_N+B_^Q%G_`+QI*>,L^K_U@?TK/Q?V;ZK.J9F][K78WVNO
M'-;*LE[=I9T]N19L^SXGH_S3/TMJL5?5SK3?K37G5XOI8C,NG(:ZQ]3JVTMQ
M&X-K#LW9SLUD;*OTGV3_``BZOU>N_P#<7%_]B+/_`'C2]7KO_<7%_P#8BS_W
MC24Y5&%U]OUMLS+#9^Q';Q72;@0VWTZV_:O1_P"X]WZ2JO&W_HK_`-9]/](L
M;*^KO6'=*ZUTD=,9=D9=M^11U3U*OTHML;=74_U/T]=WI_J[]WZ#]%_.+KO5
MZ[_W%Q?_`&(L_P#>-+U>N_\`<7%_]B+/_>-)3R]OU?ZQD8_6;*<"K"=UE^/3
M3B.=6\4-:UU&9U)^P^A]H=3:[:S'_2?HJU#/^IV2.JM9TJA]6#6/4<ZPT^F7
M,Q+.G448[V_K[?4W,9=5;^K?SEW^$75^KUW_`+BXO_L19_[QI>KUW_N+B_\`
ML19_[QI*>9^J?U=ZQ@874JLO'%!R\.BAK7NJ=8ZVFEV,_7##:&XOT/0W_K'^
MF6=7]5OK(_#HJIP*L!_[/HZ5EE]C'>LW?4_+R[FXSO=5731937[OM5GVM=OZ
MO7?^XN+_`.Q%G_O&EZO7?^XN+_[$6?\`O&DIXC*^IGUCR<.KI^RFIF"WJ-6-
M:PL?6ZK*;5;BXS69'J74U;O5P]_](HKK99ZBZ+H_0K,?KO[1?A5XU)Z=C4-:
M"U[Z[F&WUZO5_G+',K?6S[1_AEJ^KUW_`+BXO_L19_[QI>KUW_N+B_\`L19_
M[QI*;ZY__P!;7_T#_BM'U>N_]Q<7_P!B+/\`WC6)ZG5?^=V[T,?U_LL;/6?L
MVS]+U?LV[?N_,]'_`*XDI__9_^TGO%!H;W1O<VAO<"`S+C``.$))300$````
M```/'`%:``,;)4<<`@```@```#A"24T$)0``````$,W/^GVHQ[X)!7!VKJ\%
MPTXX0DE-!#H``````.T````0`````0``````"W!R:6YT3W5T<'5T````!0``
M``!0<W138F]O;`$`````26YT965N=6T`````26YT90````!#;')M````#W!R
M:6YT4VEX=&5E;D)I=&)O;VP`````"W!R:6YT97).86UE5$585`````4`4`!3
M`"T`-P``````#W!R:6YT4')O;V93971U<$]B:F,````,`%``<@!O`&\`9@`@
M`%,`90!T`'4`<```````"G!R;V]F4V5T=7`````!`````$)L=&YE;G5M````
M#&)U:6QT:6Y0<F]O9@````EP<F]O9D--64L`.$))300[``````(M````$```
M``$``````!)P<FEN=$]U='!U=$]P=&EO;G,````7`````$-P=&YB;V]L````
M``!#;&)R8F]O;```````4F=S36)O;VP``````$-R;D-B;V]L``````!#;G1#
M8F]O;```````3&)L<V)O;VP``````$YG='9B;V]L``````!%;6Q$8F]O;```
M````26YT<F)O;VP``````$)C:V=/8FIC`````0```````%)'0D,````#````
M`%)D("!D;W5B0&_@````````````1W)N(&1O=6)`;^````````````!";"`@
M9&]U8D!OX````````````$)R9%15;G1&(U)L=````````````````$)L9"!5
M;G1&(U)L=````````````````%)S;'15;G1&(U!X;$!RP```````````"G9E
M8W1O<D1A=&%B;V]L`0````!09U!S96YU;0````!09U!S`````%!G4$,`````
M3&5F=%5N=$8C4FQT````````````````5&]P(%5N=$8C4FQT````````````
M````4V-L(%5N=$8C4')C0%D````````````08W)O<%=H96Y0<FEN=&EN9V)O
M;VP`````#F-R;W!296-T0F]T=&]M;&]N9P`````````,8W)O<%)E8W1,969T
M;&]N9P`````````-8W)O<%)E8W12:6=H=&QO;F<`````````"V-R;W!296-T
M5&]P;&]N9P``````.$))30/M```````0`2P````!``(!+`````$``CA"24T$
M)@``````#@`````````````_@```.$))300-```````$````>#A"24T$&0``
M````!````!XX0DE-`_,```````D```````````$`.$))32<0```````*``$`
M`````````CA"24T#]0``````2``O9F8``0!L9F8`!@```````0`O9F8``0"A
MF9H`!@```````0`R`````0!:````!@```````0`U`````0`M````!@``````
M`3A"24T#^```````<```_____________________________P/H`````/__
M__________________________\#Z`````#_________________________
M____`^@`````_____________________________P/H```X0DE-!`@`````
M`!`````!```"0````D``````.$))300>```````$`````#A"24T$&@`````#
M10````8``````````````)T```",````"`!D`',`<`!?`#``-P`U`&$````!
M``````````````````````````$``````````````(P```"=````````````
M``````````$`````````````````````````$`````$```````!N=6QL````
M`@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG
M``````````!,969T;&]N9P``````````0G1O;6QO;F<```"=`````%)G:'1L
M;VYG````C`````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI8V4`
M```2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P`````````&
M;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E9```
M``!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J
M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO
M;F<``````````$)T;VUL;VYG````G0````!29VAT;&]N9P```(P````#=7)L
M5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585`````$`
M``````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O;`$`
M```(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/15-L
M:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]%
M4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T`
M```115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L;VYG
M``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T;&]N
M9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P````"
M/_`````````X0DE-!!0```````0````".$))300,`````![%`````0```(P`
M``"=```!I``!`90``!ZI`!@``?_8_^T`#$%D;V)E7T--``'_[@`.061O8F4`
M9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.#1`.#A`4#@X.
M%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`S_P``1"`"=`(P#`2(``A$!`Q$!_]T`!``)_\0!/P```04!`0$!`0$`
M`````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!``(#!`4&!P@)
M"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$`
M`@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D
M8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4
MI(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H`#`,!``(1
M`Q$`/P#M.@_5_HEW1,"VW!I?8_'K<][F`DN+07.<X_O*]_S:Z!_Y7X__`&V$
M_P!7/^0.G?\`A:K_`*AJTDE.9_S:Z!_Y7X__`&V$O^;70/\`ROQ_^VPM-))3
MF?\`-KH'_E?C_P#;82_YM=`_\K\?_ML+3224YG_-KH'_`)7X_P#VV$O^;70/
M_*_'_P"VPH9'UEZ;1U?#Z22^S(Z@Q[\=]3=]9V':\.L9NV_G_P`AFSWJADYO
M5<WZT7]+QLYO3<?IU%.2\>FRQ^0+7/\`4]UW\WC4MJ])WI?I/4L_G$E.E_S:
MZ!_Y7X__`&V$O^;70/\`ROQ_^VPN9S/KGU/*Q.LG%Q'4X6/1G5TYS"=U=V*P
MMKLL>X>E^L6?S+:=[Z?\*M#H/5<FM_6LGJ62ZS#Z<S&:-T':68E61F.'YSGV
MVVI*=;_FUT#_`,K\?_ML)?\`-KH'_E?C_P#;85K"SJ<RIKFPR[:UUN.YS394
M7#>*[V,+O3L5E)3F?\VN@?\`E?C_`/;82_YM=`_\K\?_`+;"TTDE.9_S:Z!_
MY7X__;82_P";70/_`"OQ_P#ML+3224YG_-KH'_E?C_\`;86+^Q>D?\[/LOV.
MK[/]F]3TMOLWSM]39]'?M]JZU<__`.MK_P"@?\4E/__0]#^KG_('3O\`PM5_
MU#5I+-^KG_('3O\`PM5_U#5I)*4DDL/ZU.^L;L(4=`I#K;`YUU_J-K>UC(/H
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M%O\`5^@=!ZHZJ_JV+7>^@0RRR0=O)8\M+?4K_P""L_1K`ZA@MZB^BR^VT68U
M@NK<QY'O'=S?HJW;;9<\V6N+G'77^"F]C;U>>C%[N^B?(I^KOVBZYG3J;K<E
MAJR+=C1O81L<QVGOW-;M<K3^F=.ZETO*Q\=HQAG.WY#F`;O4&SW/'YWMJK;_
M`%%S[.JU.S\K"?6ZH8;`]^0^!60?#[T;)ZAF8>([*Z;6[*N,;*ZSHX'\_P#E
M,:G2Y<:1&DC6Y[K1F.YUCX-GJ'0,KI574.H=`&_/S387ES0ZQHM)?8ZI\LW>
MA:]^0ROWO?\`S*N?5W,=1BMP.HW7G/JJ^T7?:]NYM;H_PU>^OTZG'T?TMOK?
MH[$"KJG4"RM]C]KX#GUZ$`\NKW0M)V3TWJ-%F'D`&N]I9;38(#FN&U[)4,L4
MH^/DR1R1/AYL.A_6+IW767/P2^*2)WMC<Q^[T+V:N_1WM9N9O_2_Z2M:BY7J
M'3;NALJ'3,F[#P,JU[^J99B]U0#2\9`]5MCF.M].O&LO?ZE5%'^"_P`(M7ZO
M]7Q^H].JM;DC)L!-3['5FASGM'J?T=_N8]U.VW8F+W522224I<__`.MK_P"@
M?\5T"Y__`-;7_P!`_P"*2G__T?0_JY_R!T[_`,+5?]0U:2S?JY_R!T[_`,+5
M?]0U7+[7U4/L;6ZYS!(K9&YW\ENXM:DH:FNZ9)96+]8^D9%AQS=]FR6_2Q\D
M&FP?V;=N[^PH=7SNHXEV*<04OIR2ZLFW<(LC?3ML9N_G6A_YB9/+"$)3D?1#
M61WX1]&48,G&(&/!(@D<?HNM=&'UAZYA=#I:^SV6Y=@9NK;+I(V^H^/Y(5.R
MZ^X@6/=81]$'S5:W*NWEV;COWS+GMB]@(_XOWU_]MH&9U+$JQ'6"TN]0&MIK
M]SFN<"&N<WZ3-JL<OGY;)`'%DADZRE&7%_S?T6OEQ9XFY0(CTKU0_P`>/H:F
M?GY.76ZKI3+7BM\/RF.8QCBPQ970;G-=?M=^>S]&K^%GXV8UPI<?6J`%]%C=
MEK#_`,+2?WOWV?HE1Z396[!JQP/3NQ&-JR,<Z/K<T1[V?N6?SC+/H6(N3ATY
M)8^S<RZK^9R*SLM9_P`7:/\`SV_]$IM=^[&0*IO9&/5E4.Q[@75V:.`,'37E
M5<W-HZ/CX[10]];WBBME>I;/YSI69U3.ZSB8I]5GVJE@).50-KCX?;,=GNK;
M_P`+C?H_ZBK=+^N.!71-[K+MS9:VECK(=,%K;7[6[?[2DC$'U;]#']-CE8T^
MM_HO0]0S#@TBWTG7^X-+:^1/YRL`[F@P1(!@\B>Q7+W_`%XL_P"T>`1X.R+`
M/_`Z`YW_`$T+%^NN:R]IZC14[%<8>^@.#ZP?\)M>7>LQGY_YZ7M9*)X37E_*
M2N*.@L7YO?\`3+:7U6XF2X.;;[0Q^K7-(VOK]W[RPLKHV=C]>CIC++'U[3C/
MVFNFD&-S;\MP:W[.W;NNQ\-MF?U)_P"CS,NNA7,>ZHNKR*G-OJD.:]C@YKH/
MYKV^U=%BYE64TEDAP^DT\A5<L*/$-BSXY:4>B9@<&@..YP`DQ$GQA22243(I
M<_\`^MK_`.@?\5T"Y_\`];7_`-`_XI*?_]+T/ZN?\@=._P#"U7_4-6DLWZN?
M\@=._P#"U7_4-6DDIIY_2\#J-8KS:&7`?1<1[F_U'CW-7.]0^K]F!3^@MLMQ
M=[7>DU_IVAS3O86[OU:_;M_.95_777+'ZV+?4K)_FH(:/Y7>4R7+8\QX9BK!
M'%$\$Z[<466'-9L,?3*XC]"7JA]CRN;G=(JS[7W4N<<K8[:6%MC'_P`U;O\`
MH_R+/8EUG'Z+@8;LW)I>2TAM;*GN#WV._FZV.<[_`*KZ"U;C4VMUUP!;2TO)
M(#B`!N=M6+UNG]O]$JR>EDWNJL%U5?T2\-#J[JO=_AMKOT:GY;D<>'%#&0,D
M,=0C.<8^X(>,OZL&++SV4SXL4\F(\(!C[DN$\,?;T_JO-Y76NH9.PMV8UM1_
M0Y+2ZW(8W_0_:;-F^G_@WUO8M7IWUKK,5=6#:7<#+8/T1_XYGTL=W_@*Y^NO
M(N>:J<>ZRUIVOK;4\N:?W7MV^QRT*/JUU^_C$%#3^=D/:S_P-OJ6+0ECY<1J
M,N'L0>)I>YFE(RD.*]['"]BUVC7M,APEKFF00?SFN;])8W5/JUBYCG7XCAAY
M3M7$":GG_AJ6_1=_PM*72OJYUOIC7&K.IV'48)8\T%W_`!KCZF/_`%Z&?];5
MW]IX]>YF<#@7UB757'0C]_'M;[,IG_$_I/\`@E7LQ-@U6TMF720HZWT>+S*,
MG`M%.?6<=Y^@XF:W_P#$6CVV?U/YQ$Q.E=0ZH[[/BTV!EGMLR7M<RMC3H]Y?
M8&[W;?H,8NW;TS-ZQ2675C"Z>_4?:*P^^S]U]>,_VXC?W++?UG^16HV.R^@V
MU4]5SQE=+N#FTY^1#+:;&#U/L^4X>RZNZL?H+OYW?^B0'Q*,I>UQ#B.G%7\H
M\2CRA`XZ-;\+)E%73^IX[,9H9CYC'5V5#1IMH:U]63L'M;994'5W;?YQ:'U>
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M+'\W_/77/_\`K:_^@?\`%=`N?_\`6U_]`_XJ1@?_T_0_JY_R!T[_`,+5?]0U
M:2S?JY_R!T[_`,+5?]0U:22E++ZOBVO'V@/!96-6'2/Y35J*IU*D78CI=MV>
M_P`C'[R=`U(%;,7$AP(!!!$@Z$*EG6.PL2NK!:RFVZUM%'M&QCGR77>G^=Z;
M&/?L_?1,VO-L%/V.T4EK]UI<)EG[L*6=B,S,<TEQJ<'-LJM;!=78P[J[6M/T
MMO[G[BL9.,PF('AGPG@)^7CKTL,.$2B9:QOU#^KU<ZGI&/1N=1?E5VO,V7MO
M<'O/[UG^"_\``T5K.K5G]%FBX=F9%37?^"T>E8@Y69U#`%8S,9ESK#MK&(_=
M98?^`P;=MW];W[*_](M"CHN7F^_J9.-C'C`J=^D>/^[N57]%O_=;&_ZY<N8@
M/BF')PRR3Q]29R&6'^#'U\3L2/)Y(V(QG_='#)R^G9'7KNIY#*F59P=HZRNQ
MS<7'<.&WN>W>Y_\`P.-ZEO\`I%T&'T:JFUF7F/\`MV<R?3NL:`RJ>1A8^K,?
M_C?Z0_\`TJO4TU4U,HHK;556(KJK`:T#P:QJH9_6ZL>UV)B5_;<UOTZVG;75
MYY>3JVK_`(EF_(_D*[/F<LH<,Y^D?-(^B_&7_>L$<,!*XQU.PW;]UU-%3\C(
ML;336)LML(:T?UG.6#G.OZQ;4]N_$Z=C3;5;:P!]ML%K;ZZ;A^BQJZG/]U[?
MTO[B!=AG.=ZO5W#.?^921MQZ_P#POCS]+_NQ=OO0;^GFJBUV#996_:2<=[W/
MIL$2ZFVJTOV^I]'U*_?6J_+_`!#E(Y?U@F=?3,?S?][]]EGR^?AN'"#^[(<9
M_P"=Z$+^EX])QWXF0ZZG,L?67$C:+WM+J+0UH]/:ZRO9=[%L?5OIN596RCJC
M[!>=VYM%FUFGT'_H`SZ2SNGG$S3ACIS".G8A^TV6$R'9#FQ7BUO_`,*[']1S
M\FSZ'^#73]-S68M>0ZQOZ.MCKGO`X#!N=N6WDY;!*$C+#"9T]4AQ_9*;2^^<
MQ*0!RR`'05&/^+%70\7%;E]0R**RW9=]F%A>]SGBIK/4=;ZCG-=MN<]C%N+.
M^KU%E/1\7U3-MK?7M)YWW$Y%F[^U8M%1QB(@"($0-@!03*<I&Y2,CWD;4N?_
M`/6U_P#0/^*Z!<__`.MK_P"@?\45K__4]#^KG_('3O\`PM5_U#5I+-^KG_('
M3O\`PM5_U#5>OOIQZG79%C::6"7V6.#6M'\I[O:DI(H6U,NK=4_5KQ!'"`.J
M=-/J1ET'T6[[8L;[&G\^SW>QGN2/5.FC=.70-C&V/FQFC'?S=KO=[:W_`)CT
ME.)E8YQ\AU,S'T2>X*IT9V+DTVW8M@O;3N:_9SN:)V?UEMW59759:?U7!_-M
M:0;K!^_4]NYF/2_]_P#G;/\`@ED5]-HZ6]^/CU-HEV\[9AQ[6:JWCF"*/S->
M<2#8^57U:Z;C8O3:,MOZ;,S*FVWY;SN>[U/TGI->[^;IK^AZ5:OYN?B8%(NR
M[!6UQVUM@N>]W^CHI9-EUG\EBR:<?.Q`ZOIV6*,=Q+FX]M0N;67'<_[,[=6]
MC'.]WH/WU(&$`.J7[F69-[&0_J5I#G$_G8]('Z+'J;_HL?\`MK.^XY)9"<DA
MPD[[RDVOO,1#TC6MENK9?6\S'=LW=-Q'@MV,,Y+O#[3:S<W$K?\`Z*C]-_I+
MEEX'3J^GX+WG)OQ<>D$Q2^6%[CN#&57"QMCW+I7.:QCGO<&L:"7..@`'TB5D
M7Y%&3G4LRB6,:/6906N)#)_1;VL#OT^5_.;?\'C_`/&*3F,?+XHQQF,92R&H
MPR:Q_K9<G%^CCBNY49,TS,F0QX_5,X_G_P!EC_K36Q,+K7IC)==2^V]H+ZKV
M.&T#^;:'T':QVWZ?Z)09;U+J%V1TXUMPA5[,C)#C82UWM<,1NQGZ1[?\);_-
MJ\>LX9R*Z0+"ZYY8';"`'#1W/\I:#*[;#MK:7GP:)0'PSD9&.00!X:-@G@E7
MR^F,N!&7G>:XYB=P)TX*HXQ^Z/[J'IQP\G(/2L*RIMN&P`XX,;&-AO\`T?SE
MH]6QS1T=O3P?TO4+J\8O;W%COTW^;C-M4NE]&]#-=G.J93:X0]X`WO'@\A&R
MOUCZP85'YN'5;E/\-S_U2C_HOR59S3!-1/IT^U@Q1(%D:NH``(&@'`3I)*%D
M4N?_`/6U_P#0/^*Z!<__`.MK_P"@?\4E/__5]#^KG_('3O\`PM5_U#4NN]*=
MU3$JJKL;5;CWUY-7J-WUN?4=S:[ZI9OJ=_6_EI?5S_D#IW_A:K_J&K224\M_
MS0R!DWY/VBDN>Z^RMK:BSWY+*Z+VVV5V>IZ%;:OT+*]GZ3])_@T!_P!1;WT"
MAV558VG%IQ<>PTECV"I]=]LFFQN[[4^EC'_X2NMGZ/\`/78+/Z^WJ3ND9+>E
M$C.+?T4$!W(]3TW6>QMWI;_1W_X5)23I'3_V;TS&P/4]7[.P,]2`V0/Y(1;\
M/'R'-=:S<6:#M]ZY6O'^L1ZDPTGJ#,**H^T6,,4>G:,QEOO=9^T'W>G]G_\`
M/GIJM9T_ZZTU5>ADY%ECL6VRVM[P?2<X6N9BMO,-R,G<^BMECOYKTOYW98D"
M1LHB]W?RL*O.M?CX(]!E1VWY(F"1_P!IZ?Y?^EN_P7_&(%O3,C$K:`P&EH@>
MGJ!_95[ZM-ZFWI-;>J;SDM<\;K""\LW.-+K-N[:[T_S7/>]:B?'+(>/FME`'
MP>#R*>L7]1#`VO\`93`+-[F[AZC>&7-!:Y_Z3\SZ"L?;>IB^ZBNUMUMC6U5!
MM8:?5?[W62W<YS,;''J/_P"MKK['4TU/L?#:F`N>>P`&YQ*Y_P"K6/=91?UM
M]0-^7O?B4'V@5N.YGNU]/[1MK_ZWZ:I\_P`K@YJ4./$#*X\4R2>'#C]4HQ_=
M]SY6WRLI8\4S(@X\?IA'ACZLV4\7S?/+Y?5_488>"_V8M+2/3$2\1'[SWD_G
M/6_@X@Q:=A.YSCN<X:*I1UVLW5XV=C78&3:0QC;6[JWN/YE653ZE#_[;JWI'
MZR]&;DV8MN2VFZNUU&VP[=SV-8^STOWVL]39O_TGZ-7)3L``5$=`U!'4R)XI
M'4DNHLKI)^T=2ZIF\M]9N+7/[N.WWQ_Z$77J-7UK^KUM+;QG5-8^G[2!8=CO
M2F/4<RP->WZ2CTKJ'1,3%.+5GUW.I<]UUCG`.+[+-UGJ?R_6R65IBYV4EBY'
MUP^KM#`\YC+-YL:P52^75-]2QFYOL9[3[-_L1G?6;H5==EEV;54*7-9:'.$M
M>X%VPQ/[K_H?Z.Q)3J+G_P#UM?\`T#_BM]KFN:'-(<UPD$:@@K`_];7_`-`_
MXI*?_];T/ZN?\@=._P#"U7_4-6DLWZN?\@=._P#"U7_4-6DDI22222E))))*
M4DDDDIJY^'5GXEN)<7"JX;7[3!+9ES9_E_0<K#6M8T-:`UK0`T#0`#LI)))L
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M;^CLIMVTV55^_P!G_%I*9-9]5,>K'Q\:[)S7`.Q[[/4=67-V8[6,R/5%>^A[
M*\6O%]/]'L1FL^H`I<[[6]]>Y]#3NM)K9:US/1J]FZO$:W)L]&W^:_6/YY3K
ML^H=9;6UEEC-8O=Z[V2STVP<AY_P=5>.[Z7LQ_11:NE_5SK74*AT]UE;,'TW
MWAC7-;<QAK;B4.MM]S\;]3J>UE?Z*W8DIZQC6L:&-`:UH`:!P`.RP?\`UM?_
M`$#_`(KH%S__`*VO_H'_`!24_P#_U_0_JY_R!T[_`,+5?]0U:2S?JY_R!T[_
M`,+5?]0U:22E))))*4DJ^7U#!P0QV9D58S;';*S<]K`YQ_,9ZA;N<HU]3Z=9
M;917E4ONH!-U;;&ES`/I.M8';J]O\I)3:25']N=%^SMROM^-]G>_TF7>LS8;
M/]$VS=M=9_(1AGX+LHX0R*CE@;CCA[?4`C=N]*?4^BDIL))*I9U7IE5]F-;E
MT,OI9ZEM3K&![6?Z2QA=N97_`"TE-M9_5.B8'5GXYSFNMKQ7.>RF2&.<YOI3
M:UOT]K'.4SUGI#<=N4[.QAC/=L9>;F>FYW[C;-VQS_Y*FWJO376MI;ET&VRO
MUF5BQI<ZKGUVMW>ZK_A$E-8?5KH0=8\8=;76O;:\B0=[";*W-@^S:][G>Q/;
M]6^A75BNW!J>QH@-+=`/3^R?^VWZ)6L;/P<NIUV+D59%3"0ZRI[7M!&IW/87
M-38_4NG95=EN+E4WU4_SKZ[&O:W2?TCF.+6>W]Y)31ROJKT3(9>!CBEV33]F
MMLJ]KO1AC'T,Y;6VRJEE+]C=_IJ[C=+Z?BWOR,>AM=UC&5.>.?3K$55-_<JK
M_P!&SV)K>J],IKJMNRZ*J\C^8>^UC6V3_HG.=^DY_,2;U;I;\G[&S,H=E26_
M9Q:PV;@-SF^ENW[FI*;:Y_\`];7_`-`_XKH%S_\`ZVO_`*!_Q24__]#T/ZN?
M\@=._P#"U7_4-3?66OJUO1,JOHQV]0>T"EP(:0"YOK>F]_L;;Z/J>EN_PBJ=
M`LZR.AX`JQ\9U8QZMKG7V-)&T07,^ROV_P">K_J]=_[BXO\`[$6?^\:2GFLQ
MG6>E?5C(H#\BL/VVNR\B]GJUBV]K+\#'<UV1Z+F8GNQ[[+;=C[?YU2^KG4NJ
MX/167OPLK+9G7V/PZ[;2^UC7W>AB8;G7;K/1KPV.S'95WZ+T_P"NNC]7KO\`
MW%Q?_8BS_P!XTO5Z[_W%Q?\`V(L_]XTE.1UKIN=_SDQNK,P&]6Q?LC\0XQ=6
MTTV.L;;]J`R2*]EM?Z&W9^E65A?5OJ[,VDNZ;74,/.S,TY@LJ+KJK_6]+I]3
M6^_;D>NSUOM7IUL]%=9ZO7?^XN+_`.Q%G_O&EZO7?^XN+_[$6?\`O&DIXRSZ
MO_6!_2L_%_9OJLZIF;WNM=C?:Z\<ULJR7MVEG3VY%FS[/B>C_-,_2VJQ5]7.
MM-^M->=7B^EB,RZ<AKK'U.K;2W$;@VL.S=G.S61LJ_2?9/\`"+J_5Z[_`-Q<
M7_V(L_\`>-+U>N_]Q<7_`-B+/_>-)3E4877V_6VS,L-G[$=O%=)N!#;?3K;]
MJ]'_`+CW?I*J\;?^BO\`UGT_TBQLKZN]8=TKK721TQEV1EVWY%'5/4J_2BVQ
MMU=3_4_3UW>G^KOW?H/T7\XNN]7KO_<7%_\`8BS_`-XTO5Z[_P!Q<7_V(L_]
MXTE/+V_5_K&1C]9LIP*L)W67X]-.(YU;Q0UK749G4G[#Z'VAU-KMK,?])^BK
M4,_ZG9(ZJUG2J'U8-8]1SK#3Z9<S$LZ=11CO;^OM]3<QEU5OZM_.7?X1=7ZO
M7?\`N+B_^Q%G_O&EZO7?^XN+_P"Q%G_O&DIYGZI_5WK&!A=2JR\<4'+PZ*&M
M>ZIUCK::78S]<,-H;B_0]#?^L?Z99U?U6^LC\.BJG`JP'_L^CI667V,=ZS=]
M3\O+N;C.]U5=-%E-?N^U6?:UV_J]=_[BXO\`[$6?^\:7J]=_[BXO_L19_P"\
M:2GB,KZF?6/)PZNG[*:F8+>HU8UK"Q];JLIM5N+C-9D>I=35N]7#W_TBBNME
MGJ+HNC]"LQ^N_M%^%7C4GIV-0UH+7OKN8;?7J]7^<L<RM];/M'^&6KZO7?\`
MN+B_^Q%G_O&EZO7?^XN+_P"Q%G_O&DIOKG__`%M?_0/^*T?5Z[_W%Q?_`&(L
M_P#>-8GJ=5_YW;O0Q_7^RQL]9^S;/TO5^S;M^[\ST?\`KB2G_]D`.$))300A
M``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P
M````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@`$,`4P`V````
M`0`X0DE-!`8```````<`"`````$!`/_A#[-H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB5S5-,$UP0V5H
M:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z
M;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V
M+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@(CX@/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D
M9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(@
M>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN
M<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B('AM;&YS.GAM
M<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS
M=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U
M<F-E179E;G0C(B!X;6QN<SIS=%)E9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL;G,Z9&,](FAT='`Z+R]P
M=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B!X;6QN<SIP:&]T;W-H;W`](FAT
M='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B('AM<#I#<F5A=&5$
M871E/2(R,#$S+3`W+3,P5#$U.C`Y.C`S(B!X;7`Z0W)E871O<E1O;VP](DUI
M8W)O<V]F=,*N($]F9FEC92!7;W)D(#(P,#<B('AM<#I-;V1I9GE$871E/2(R
M,#$S+3`W+3,P5#$U.C$S.C(R*S`U.C,P(B!X;7`Z365T861A=&%$871E/2(R
M,#$S+3`W+3,P5#$U.C$S.C(R*S`U.C,P(B!P9&8Z4')O9'5C97(](DUI8W)O
M<V]F=,*N($]F9FEC92!7;W)D(#(P,#<B('AM<$U-.DEN<W1A;F-E240](GAM
M<"YI:60Z-D1#14,R0C1%1$8X13(Q,4$V.4-!0D,P.#0S035#13$B('AM<$U-
M.D1O8W5M96YT240](GAM<"YD:60Z-D-#14,R0C1%1$8X13(Q,4$V.4-!0D,P
M.#0S035#13$B('AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HV
M0T-%0S)"-$5$1CA%,C$Q038Y0T%"0S`X-#-!-4-%,2(@9&,Z9F]R;6%T/2)I
M;6%G92]J<&5G(B!P:&]T;W-H;W`Z0V]L;W)-;V1E/2(S(B!P:&]T;W-H;W`Z
M24-#4')O9FEL93TB<U)'0B!)14,V,3DV-BTR+C$B/B`\>&UP34TZ2&ES=&]R
M>3X@/')D9CI397$^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%
M=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HV0T-%0S)"-$5$1CA%,C$Q038Y0T%"
M0S`X-#-!-4-%,2(@<W1%=G0Z=VAE;CTB,C`Q,RTP-RTS,%0Q-3HQ,SHR,BLP
M-3HS,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3
M-B`H5VEN9&]W<RDB('-T179T.F-H86YG960](B\B+SX@/')D9CIL:2!S=$5V
M=#IA8W1I;VX](F1E<FEV960B('-T179T.G!A<F%M971E<G,](F-O;G9E<G1E
M9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W`@=&\@:6UA
M9V4O:G!E9R(O/B`\<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B('-T179T
M.FEN<W1A;F-E240](GAM<"YI:60Z-D1#14,R0C1%1$8X13(Q,4$V.4-!0D,P
M.#0S035#13$B('-T179T.G=H96X](C(P,3,M,#<M,S!4,34Z,3,Z,C(K,#4Z
M,S`B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#PO<F1F.E-E<3X@/"]X
M;7!-33I(:7-T;W)Y/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12968Z:6YS=&%N
M8V5)1#TB>&UP+FEI9#HV0T-%0S)"-$5$1CA%,C$Q038Y0T%"0S`X-#-!-4-%
M,2(@<W12968Z9&]C=6UE;G1)1#TB>&UP+F1I9#HV0T-%0S)"-$5$1CA%,C$Q
M038Y0T%"0S`X-#-!-4-%,2(@<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/2)X
M;7`N9&ED.C9#0T5#,D(T141&.$4R,3%!-CE#04)#,#@T,T$U0T4Q(B\^(#PO
M<F1F.D1E<V-R:7!T:6]N/B`\+W)D9CI21$8^(#PO>#IX;7!M971A/B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(#P_>'!A8VME="!E;F0](G<B/S[_X@Q824-#
M7U!23T9)3$4``0$```Q(3&EN;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q
M``!A8W-P35-&5`````!)14,@<U)'0@```````````````0``]M8``0````#3
M+4A0("``````````````````````````````````````````````````````
M`````````!%C<')T```!4````#-D97-C```!A````&QW='!T```!\````!1B
M:W!T```"!````!1R6%E:```"&````!1G6%E:```"+````!1B6%E:```"0```
M`!1D;6YD```"5````'!D;61D```"Q````(AV=65D```#3````(9V:65W```#
MU````"1L=6UI```#^````!1M96%S```$#````"1T96-H```$,`````QR5%)#
M```$/```"`QG5%)#```$/```"`QB5%)#```$/```"`QT97AT`````$-O<'ER
M:6=H="`H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P``
M```````2<U)'0B!)14,V,3DV-BTR+C$``````````````!)S4D="($E%0S8Q
M.38V+3(N,0``````````````````````````````````````````````````
M````````````````6%E:(````````/-1``$````!%LQ865H@````````````
M`````````%A96B````````!OH@``./4```.06%E:(````````&*9``"WA0``
M&-I865H@````````)*````^$``"VSV1E<V,`````````%DE%0R!H='1P.B\O
M=W=W+FEE8RYC:```````````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```
M``````````````````````````````````````````````````````````!D
M97-C`````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S
M<&%C92`M('-21T(``````````````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@
M4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````````````````````````
M9&5S8P`````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I
M=&EO;B!I;B!)14,V,3DV-BTR+C$`````````````````````````````````
M`'9I97<``````!.D_@`47RX`$,\4``/MS``$$PL``UR>`````5A96B``````
M`$P)5@!0````5Q_G;65A<P`````````!`````````````````````````H\`
M```"<VEG(`````!#4E0@8W5R=@````````0`````!0`*``\`%``9`!X`(P`H
M`"T`,@`W`#L`0`!%`$H`3P!4`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`
MF@"?`*0`J0"N`+(`MP"\`,$`Q@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-
M`1,!&0$?`24!*P$R`3@!/@%%`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!
MJ0&Q`;D!P0')`=$!V0'A`>D!\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G
M`G$">@*$`HX"F`*B`JP"M@+!`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#
M6@-F`W(#?@.*`Y8#H@.N`[H#QP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q
M!'X$C`2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%
MQ075!>4%]@8&!A8&)P8W!D@&609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]
M!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(
M^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<
M"O,+"PLB"SD+40MI"X`+F`NP"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-
M#0TF#4`-6@UT#8X-J0W##=X-^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>
M#WH/E@^S#\\/[!`)$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2
M!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.
M%/`5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7
M]Q@;&$`891B*&*\8U1CZ&2`911EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[
M&V,;BANR&]H<`APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>
MZ1\3'SX?:1^4'[\?ZB`5($$@;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O
M(MTC"B,X(V8CE"/"(_`D'R1-)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<F
MZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV
M*VDKG2O1+`4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O
M_C`U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38
M-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ
M-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B
M/^)`(T!D0*9`YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%
MFD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:
M2^),*DQR3+I-`DU*39--W$XE3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92
M,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+
M61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@
M!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]
M9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O
M'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X
M=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_
MA'_E@$>`J($*@6N!S8(P@I*"](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$
MB&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1
M/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IH
MFM6;0INOG!R<B9SWG62=TIY`GJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D
M5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XM
MKJ&O%J^+L`"P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FX
MT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8
MP]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.
MML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQ
MVG;:^]N`W`7<BMT0W9;>'-ZBWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F
M#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_
M\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^
MW/]M____[@`.061O8F4`9$`````!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#
M`0$!`0$!`0$!`0$"`@$"`@,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P/_P``1"`"=`(P#`1$``A$!`Q$!_]T`!``2
M_\0!H@````8"`P$`````````````!P@&!00)`PH"`0`+`0``!@,!`0$`````
M```````&!00#!P((`0D`"@L0``(!`P0!`P,"`P,#`@8)=0$"`P01!1(&(0<3
M(@`(,11!,B,5"5%"%F$D,Q=2<8$88I$E0Z&Q\"8T<@H9P=$U)^%3-H+QDJ)$
M5'-%1C='8RA55E<:LL+2XO)D@W23A&6CL\/3XRDX9O-U*CDZ2$E*6%E:9VAI
M:G9W>'EZA8:'B(F*E)66EYB9FJ2EIJ>HJ:JTM;:WN+FZQ,7&Q\C)RM35UM?8
MV=KDY>;GZ.GJ]/7V]_CY^A$``@$#`@0$`P4$!`0&!@5M`0(#$00A$@4Q!@`B
M$T%1!S)A%'$(0H$CD152H6(6,PFQ),'10W+P%^&"-"624QAC1/&BLB8U&50V
M160G"G.#DT9TPM+B\E5E=58WA(6CL\/3X_,I&I2DM,34Y/25I;7%U>7U*$=7
M9CAVAI:FML;6YO9G=X>7I[?'U^?W2%AH>(B8J+C(V.CX.4E9:7F)F:FYR=GI
M^2HZ2EIJ>HJ:JKK*VNKZ_]H`#`,!``(1`Q$`/P#9K^!WP#^$^^/A1\3=X;N^
M+/2.Y-T;F^.W4>>W'N'.;$Q.7S6>SN7V5B,AE\UE\ID8ZJNR.4RN0GDGJ)Y9
M'DDED8D\V'NO=&Q_X;8^`O\`WB!\??\`T6FW/_J3W[KW7O\`AMCX"_\`>('Q
M]_\`1:;<_P#J3W[KW7O^&V/@+_WB!\??_1:;<_\`J3W[KW7O^&V/@+_WB!\?
M?_1:;<_^I/?NO=>_X;8^`O\`WB!\??\`T6FW/_J3W[KW7O\`AMCX"_\`>('Q
M]_\`1:;<_P#J3W[KW7O^&V/@+_WB!\??_1:;<_\`J3W[KW7O^&V/@+_WB!\?
M?_1:;<_^I/?NO=>_X;8^`O\`WB!\??\`T6FW/_J3W[KW7O\`AMCX"_\`>('Q
M]_\`1:;<_P#J3W[KW7O^&V/@+_WB!\??_1:;<_\`J3W[KW7O^&V/@+_WB!\?
M?_1:;<_^I/?NO=>_X;8^`O\`WB!\??\`T6FW/_J3W[KW7O\`AMCX"_\`>('Q
M]_\`1:;<_P#J3W[KW7O^&V/@+_WB!\??_1:;<_\`J3W[KW7O^&V/@)_WA_\`
M'W_T6FW/_J3W[KW58?\`LE_Q(_X=B_T0_P"RZ=4_Z,/]EE_OS_H^_NM2_P!R
M_P"^OWO\#_O?_=G7_!?[R_P+_(ONOM]?VW'ZO7[]U[K_T-R?^7)_V0)\,?\`
MQ6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW71-K<$W-A87Y_Q_H/?NO=$
M![`_F3_&SKSY:_&GX;5E;N_=/9GRRVGOK=?3^X.N]L56_P#KJNBZ]S*X?<..
MSFZ]K29),-/1BER-34U30OCL;3XNH-=44S-`DWNO=%&[&[L^5G>W\S_M7XC]
M6_*3`?#7JOXB=#=!_(C<5)+U'U[VAO+Y5TO;.Z]WP[QFK,GV9.]+L[I/KG$;
M)&#KY\)#29:/-9E:ALC&L4,'OW7NB']P?SF?DKVYU/\`S*JWJCH#.[!^/_4O
M1?\`,NV!UE\J-HY'<B;MZA[Q^(FP\GA]D[JWKGLOBJ'860D[?WE)+-MVAVS4
M9+*[:FI:1\D)8JL3P^Z]T<+X%_*KLC;.6_F=]H_)[NO=.[NB/B#M#X?;:H7W
M`*#(R;5RNP/@%U5W%\D\W0?9T5+E<UNC?.^^P)*FJCEFGEJZ](XX%0L$/NO=
M6]]+=Z;2[GVUC*Z@>EVUOR/;.T]P=@=-9?<.VJ_M+IZNW?A*3/4.T>TMM8#+
M927:FZZ2DK%2>FF-A,CJC.%#'W7NAK'//^]^_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NJ?\`_NM3_P"6=_\`RP>_=>Z__]'<G_ER?]D"?#'_`,5BZ3_]]_@_
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MW<UT_L7H3KCH/OWK2K@Q^(ZZV]MN9X*:F2OS-;D\AJ5:Z5'6Z'JW7Y;?`7X&
M?+#([%WY\PNC>L^S\WU?0U5!M?=N^:C(87*0X&HF6NK]K;@K\)E\"^\]F5M6
MIGGP.6^^P\D\DCFE+2/J?ACN)2%M4+.?0$],3S6\"EKB153YG_5_+HLV_-I?
MR[D[#[-WO@_AMTOO[=O<>R\OUOW!OH]=[2PJ]A[)S>*H=OYW;>7>LQ+2;@QN
M<P>*I:*O:2%/O:.FBAD:6*-%4<[9[<;SN%MXMTPC\_G^="*?D3T%+SG3;K,D
M6E'/\OV?Y_V=#OE_C/\`';Y2?&+OWK3K3#T/2]%\F-RTVZ^XLGL["XI=S'L_
M&#8\)SNXJ"I5L=F,C)A>O\30'RCP5&-IXT`"\`([ULU[L]X^WWR:2!^T>1!_
M*A'ET(-LW.SW>S6\LY*J30_(^G1+_D%\!NSOB!M/YA?([^71CUW!\F?DAD^S
M,GN2;/;<H<[V+M^@[HW'7[IW7F=@[EI,MMZNSC]8[_W/D=X8K#U5+DLGDI*>
MEQ,,Z00Q`E_1CT9+^7AV]D=A=6X7X[_);L3OZL^2FS>KI.^NQ&^4M+MC^\6V
MNLL_/05#3S=C[-KMP;/J=E=?Y;(S[>IZG<.;?<V0GPN0JIA+!"\R>Z]T,?P=
M_F)_'C^8)B.Q<ST)/N\TO7.8Q,=2-W[?3!ON79&\)-P2=8]J;:--7Y-&V9VA
MB=LUE?BZ>O-!GZ>EC5LAC:+S4_F]U[H]OOW7NO>_=>Z][]U[KWOW7NJ?_P#N
MM3_Y9W_\L'OW7NO_TMR?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=5
M8_S3\G_,8RG35-UY_+KZYQ^1WANC&;HSW9G;4O:.T^N=X;/V+LT8:NK.L.B9
M=SX/=5##\BN]*6JJ<5MC/97%S;:VRT$]57RQ2M1N/=>ZHWPG36_OYCGS9V/\
MQ?AV-]T6%SSY[8/RZWE\E]SX*?<?Q_KX,C3[-^2?\L3YJ_";>4U/+NWI7_0O
MCJ2DV=MS;]'`)-\;DRFZJ_.E(J*HE]U[JY;L7^6U\$ND>G.A)<IU54=C9?XC
M[)KNIOC/6=K[^WYO2OQ^U,ON_';SVYUQO"EK-QQX;MK8'7^=P.-J\%B-T4F7
MH,+'@Z-J:..6G27V=<O[8^\[M;6"8UG)]`.-/F>'Y]%&^[FNT;1/.3D<*T.3
M_J^S`Q3'1(OD#TCC/DSE^K-Q=A]@]N4FY.GNR\;V[L_,;3WMD,1YM[8BHHZF
MER.=PW[N+K4A%$(HBD<4M-3R211.D;LIR;V"YLN6;3>K*SY=1DW*+PP"@)`I
MIHI()4>9]>/'/4$[HL^\76S7][,XJ?4^O'[?0\?3HP.Z=S9[>V9K-P;IR53E
M\G6SM4,]3-(]-3W_`,W#CJ(NU-04D"V6..-0%4`<_7V46-AM^V[?^[]OC'[!
M6OGGB?F>C*\O+_<':^OR:`_EZ<.'11\+\I=IY+OKOOHS-[4W)LF#X^;2PV\M
MR]M;JGHZ+KS-8K*"B\LF.J6B26G@I?OU\<CR.9O'(%6X`(IW?8(=MY4V?FV^
MWH!%;[!^8\Z=!^PNX]TWI-BL-G)=C\Z_ZCT)O9/R`[BZ/ZHRG;WQ@V5G.\-\
M3K@#M;9>Q,S''2;NQ^<G5!GZTIYDR^WL73GR3"%'J-+*5"@.056&P\N\X[A'
M8;SO*_N+CJH-0J/)N(_+HUN=PW3EP$;4*[V333Q6G^EX'HU&V?D_\A*S#[1S
M>XL]-A,[)C,!F=Q;->/"5U)B\O-34U;E]IUF4I,>G\0BHJAI*5YHRI8#4#<7
M]A&[Y#Y51WL;';)":L`=3<*D`Y/IGHZM^<N9F"ED!:@KCS\_Y]'<K^R_CC\G
M-B;KZ7[*QV-KMK=I;5R^R]^]<;[I6I,1N_`[CQ#XK/;>GR4<T-)D:2NQ\[T_
MIGCEEC(T@<`1!N?*&^[0"T]HWA`GYFGJ5&?\-.I-V[F/:+\!4FTN0*UP*^E?
MM]:=5D_(3XY;P^`&)V'3?%7NWNKX_P#QD[I[3WSO'YW_`"*JZ7#_`"+W9T]1
MXG8F3W1C^Y<?'V%MK=V4P&:WW!L[$;'RN[,E%FMO[8VQCJ+_`'&15?CR*!KH
M_P"K`O@%\N>O?DY\=]A[NQ7=U%W'N>#,9+K#<>]LOUADOCWN'>F_]NX2/=UY
MNFMRU=1D]K[FS/6]?0[AJ<9`W[5)5&H%-21'[:#W7NC[^_=>Z][]U[KWOW7N
MJ?\`_NM3_P"6=_\`RP>_=>Z__]/<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^
MZ]U[W[KW75A_A_A[]U[JK[^8+\W^EO@#LO"YG<.O;>\^^NP<1M9<KLK9U/EL
MZ<G5T,&-?>.Y8Z""*7(5>.PE!#!%-5F:?[>`)"DAC6/W*?M9[;;C[@;EN\RK
M_NEVY`[YSGR^PGC\OMZ`W/G.ECRA8A&;]9P3\P/7[3^W&?+HNFXMV[XWQ/CX
M=S[GS>ZYH''\*AKIS-"DE<(],M)3"*%8IZE2@Y4-:P(%B/<@V6R[9MS.=LC5
M23D@`''J1GJ/+O=[_<%4[@25(!%:\#GAU5[WUWYV)W#M[-;5^(&V.V-PP;2W
MRV/W%WWL_/\`6^Q-C[@R&SLA44&ZME=79+L/-XO)=I_P?.0O35F0Q208B6OI
M9*,54RB0J5[[>7NZV)782?$&/S''H0[#MGTQ6_W`C1^V@Z-KTQWIUSWA096C
MV;F\NN_-CTN.H^S^L-];=FV'W-L#*BGCBJ*K?/660=J_&8_*U8>:#)X]ZW!5
M0<?;U<@L`<6ES97:HM>X``_:!G^=>@[<VU];%B<*2:5X<?\`-TM>P-@[9[8V
M3G>M]ZXZHRVU-ST]-392@H*N;'UTRT55'74;4^1HQ]S%)154*O&1J"\V%B?>
M]SVVTWC;VVZ^D8+Z5-/V</Y=:M;F\M+Y=PL`-8^0KT!/='<NQ/A3L'IS$TO6
M&^MP[7W#OG`=,[4VYU[3??U^UA7Q-)%F,I]Z))JBC0S%BH*S54K/8BWL5<J<
ML#>K;>=IVM1MQVQ`U3FM1QSQKQ_/HFW[?#;7O[POAPZ7_P`@NW*CH+9\&[DZ
M]W3V>K;IQ^VJO#;*C,F1HH:WS7R[1BEK)'@#PB*)-`#S2*K.@-_8-WS=%V>Q
M.X2;4VY4_A)'#[.A%MFVOO-['IWH`$`^G$5Z%BFF6OQ]%6/1U5''7T%%7''Y
M2!*?(4/W=-'5?8Y&F5Y8Z>OH?+XYD#'1(#8^S%6UJCD<5!H<TJ*TSZ<.BTKI
M9EKP8C'R-/Y]'<^,NZ=EYG;.^^G>SLG29;&;Z$V#I-L;RFER>W]Q[?SN%GPV
MX=J:,D9J!Z+*0SO%)1$@5$<ALK7/N*_<+9KN:1-RL(!X6GNH!@CS(%"1QR,C
MJ0.1]TMO#EL+R4^(3BIXC-14G[/EU5'VE\.>\.N_GA%!\4MK=C[HSVTH-N97
MI;<4VS,IUWT9T'CLTN'_`(IBNV?D)EL;C<54=082@Q5/7;GVAUK19OMWN_(Q
MPT&\=V4&$A$,48]2/PZV=,5!74V-Q\&3KH\GDH:&DBR.2AHQCH<C7QT\:5=?
M%CUGJ101U=0K2+`))!$&TZFM<^Z]TX>_=>Z][]U[JG__`+K4_P#EG?\`\L'O
MW7NO_]3<G_ER?]D"?#'_`,5BZ3_]]_@_?NO=&(WQN7-;.V5N/<V,V;N3L3+8
M'&SY"DV3M1L)'N?<YA<&3&80YO(X?#OE)*<LT<<U13K*4TAM3#V[<W*0P&XC
MCKC@*UKZ"O\`+/'I5R[M\&[;OM&S7^[K8K))I-[=@K'&#7N?Z97;2,`T0FF2
M.)!3^L/YC'Q'[&W#4]<U?9$O3_;6+\@S'3OR"PV7Z3[+Q$JC6R28/?T.,I,I
M';]$N.JJZ"3ZH[#V$ASAR]>7[;=^]TM-Z.-$@"M^QJ*WRH>IQYE^[%[T<L[0
MO,]IR@V^<D4J-SV-UW*P(P23+9F3PR*@LLPC=2:%`:@)_P"6_>'R%Z;WET-+
MT]1].;AV#V]5;EV'75'9,VYZ."E[)7#ON3KD8S=VU9,DU/2;VQ6-R%)$)*"I
M@^_A@4.IG%XD^\7[T[A]W?D0^Y][R@=ZY,VW3^\=#:;Y$=@%,:T\+26PS,*(
M"":"AZ<]F_;CVY]P=@]Q;/F;<]XLN>=N\*]C-D(W0[>A^FW$M:2Z69[%WMI=
M*W,!9/%J"0.JV]V=F[P?,UU=WSU'N^/./DFJ,KNG"1[;[_VA29:C;2E7-4;+
M%?N;:24*\0+5X2CEIX@+!1R5_LM_>C?<^]S+78]IM^<I>39I54TW`/8,VL5H
M+]@$DH:@L-2GUZ`',WW.^;-TTW7(G.FQ\V-P'U@.Q[A2E0=%[6Q10*4,%Y<L
M3^&O08]O_)#JC:W56=W)2;WJ<Q'NB@SVQL-D>OX'S^?V[NC<NW\IC\7G,QB/
M+09;;L&#K*A*GRUB0/Y(],8:0@>\Y8/<3DW<MG;>^5M]3<-A!S^[B';[:UJ2
M1FOG6O6/N\>T_NAR;N\=ISERCO-E"PPU^HT$>JNHTLO\+`T9:$8/1?OBAN+!
MY'I/8_6]-0_W3W[T-LG:G6/;O4F42/';RZPW9MS%TV-JY<]MMC'5TNW-YS+_
M`!?%9>)),;EZ?(K+%/)(90IKM1I9&S44U9^=#D5^=#GY](;E@0=#ZD^1J/Y8
MZ$'L?J/9G:D^W\ON!<_@=^;+\QZ[[?Z\SM1LON+K>64EG_N=OO'I)6+BYV;_
M`"G$9".OPE:I*S4;!B??KJV%T*4I3'IUX5'#(].BF_*/O#YD=.]8UR[MVY_I
MKV+M['UM;4=Z=(86KVMN3)/3/#_#1\D>G=NM59C:>'QM*KO4YO9#U>(KJFSU
M-'0CA1ERC?;1:;D+'FQBU0*;EC0GRI3.*`UK\(I3-0MS'LEY>V/UNP'O]*\3
M\LT_P=`;\8OYPW16W=AR3[]SW9?8B9'"P9/!8'JS8&YNQ8L-N:FR510UV#QN
M^-Q3X7#?P>HAC\]YJUS1U%QJ1BP]C#?MJAYANUO^1=M?=`1Q0D!OF:4!KQS7
MH);;]1M)/];]U3;*<0^DG[:&OV]..]/YX&>+2)TM\2:JA<I)'!G>]^W,?CH^
M&&FJ?:?56/S>36)A_NF7)1L'^IMS[?VOVFYYOL75GLVVC^DQ/Y$>OK\^D]SS
MERG85,ERVX\::!I^S-1@_+AT'G6/\Z3N7`;UQ=5\E^L.H\KTUD<I2TFZMQ],
MTF\,)OOJC%U]3%3/O"#$[ES&>QO8>V]M/.E1E*9FH\D:%)9H&=HS&;\Q^U>_
M<N[(=_?>5W)1Y``4^SY?Y.GMAYMV#>K[]W)L[[;(?A)R#]OG4^7E7C3K8PZ_
MWEM>LK-F]C[3S6VNR-GQYF@S^%W!LS<&,S^U]UT^*K(ZD'"[CQ,];C*GF+U`
M,9(&],B*W'N)+NW.\;=+MRMI9@17T)K_`(/Y]"J"?Z._%\1\)X'Y?X.KENK.
MXMJ=L8ZIJL&E?C\ACQ"<G@\M"L%?2+4J3%5P^-Y(*[&S.&5*B)BA92#I/'N`
M-\Y=W'E^\\+<!3TID?[!IFG4S;/OECO*%K)B2.(/'_9ST+?LGZ..O>_=>Z][
M]U[JG_\`[K4_^6=__+![]U[K_]7<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1L/
M?J`BGEU[HMO?7Q?Z#^3NW:;;'>75VTM^T]#&\V$R>4QWCW/MFJ_>\=;MC<U'
M]MG,'/&TI8?;U"([?K5AP2+F/E7E_FNQ;;.9-L6\@/J*$5!%0RD,O'R-#Y]#
MOV\]W?<OVDOAN'MQSE<[6S&KK'(PBE&`5ELS6.4$`#O4FG"G5-?R"_E_Y_X^
M;0C/7W8/8^_.GI=];/S@V!@NQ6ZX[;P^YML9FDW#MC)81<J*SICL^HQ%9B1,
M8Z[&8#(O`A3[Z4L;XH^X'W4?=CFS8>;N4/8SW"4\O;KM$B/RYS$IOMNDS5Q'
M?5^LV[B/#(G95."V%`RXV3[XW(U]>1;Y[L[!LNU\YE39-N+[?]9MK?7IX'ZW
MAD;M8:@[,SVMQ>)J-?H_+HAW<W>GQ(VCWQO;.[UZ]SN1JNZYMB[A_@F3V)E-
MK=H["W_3JNQ]^P;CA>KQ57#1Y"AIL9E86QU7605C-/\`;NQY(3_N\O;S<_;S
MVPYK^[G]ZSV7MSO_`"_O1EVIMQVR/<([^QD8L\=NQ1B8X6Q"2=)4UTD`=%?O
MMNWOML?L[[1<[^W7N??_`-7-FOMPVP+83P2[;/',OUU@Q8J6?5-]4A%XL>A;
M<(0*TZR?,CK[X8?'?J+/=Y]H=<[KKIL5DL%MO9FWNN-];DP>^^Q.QMSU!@V?
MM'`9+)9MHJ:JKY8)*FIK*YWI,91TTU1(AT!&Z6VOW:?9]+KP.4^0[G;.8-T&
ME5VYY+0"N0`A<*M*\``!\@.L6.5_O]?>BV#:M[VW<.?;#<^7]%6.Y[787@6@
MJY73;\!FBK4M@*":=4+=I?,[Y!=H';U9C(MH=.;OV37I-UWW/ALQN?N+Y,;"
MV^)(34==4W=6\CM_'[GZ[R5-$8JO"Y3#9/%N)9/"D9*R+EMRQ]V>ZVBR&V;]
MSMI:@%/B<`#`-_\`"".#8XU'6)/N+]Y$\\<S+O>V<A[)M9TT/[MLC8;86_$S
M6-N7<LQS6H.HD_+H^_QU_FJX*J>AV;\P\?A>N,M(\%#C_D+L['U:=-YN61Q#
M3+V7MF$U^5Z:S%1(X$E9']YMMGO:6E7@!?F_D#FCD\&^;_=GR\#Q7_+3/Y\#
M^?5>6^=-BYFK9PM^[>8LG2Q^?%:X8&M0,.!Q&*]7#T58&I\;F<57T]30Y*DA
MR>#S>'R%-D,9E<=51!Z?)8;,8V:>@R>/JH6NLT$KQ2(?K:X]@O#+P&D^7E]E
M/EPZ$I#+52<]5O\`R>_EL=6]T5F:[!Z=R5#\?.Y<D\E?E)\7B7J^E^R<F5N&
M[%ZXQC4J83,UK"TFX-O?:9!1ZIH:KD$1<L\V\S<G7X?E\@,<_+]G^7HJWOE[
M9.98_"W6,,E*#^)?L/F/4&HSY&G5$_;FQNQ/CONF'8_R$V95=5;AKI#%MW)5
M58F;Z[[%C+^*GJ^KNP*"!<1NU:QBML8RT^;@+>.2DU"YR2Y7]V>3-]M2-PW@
M6',7_22`"U\Z>5*UI\J=0COWMUS-LUV'VY1N:>BBA`\@0.&*9X?/I8=2_%GO
MWY;9).N>I^L=^T>!W1JPF[>Y]Y;*W-LOJKKC:>0/V6YMR9+<&Z\=A),_F:'#
MO4#&XO&15-775I1/0FM@0\[>ZO*[;-ONS[.?WGS#NBZ0%PHI@D<*#';3Y?;T
M8\M<B;W!O&R;ES#*(PIJ%XL3^%0!Z'B20%`)R:*=I7$;&VK\=/DQT_A^J\;2
M[=ZQ^1&Q=Y[$WIL6@I:?&;<K.UOCUL/!;BV)W53;>QZ08G#;TWCU]CZW"[EE
MHXH4RQCI*BH$D\7D;&](S872J"0:9R203F@^PFE.`&!@=2V6^MM)2V2&.:<<
MYJ>C@?R]NBNP^I_D_P!I;UB[L[+[2VEVOE<MN*;9>]YHY-L]48%X9)ZZDP]:
MGEDD:7)/!3TB**6F2GB0-$90TA][K;Y8;GR+LFV+L/[NEL)*:C2KEJ^9R:BK
M9)H*GRZKR%M][;\T,J;L):*24`KCTH.!R*?.G5G':?S3^)W36.K:KLGY%=5[
M<BH1+!61_P!ZZ3/Y&BEAU%X<AB=M-ELA3,N@A=<:,6X%SQ[Q"W/G;E;8Y43?
M.8]OBD)KH+KK-<"B:BYJ:8TY/#K,;E+V(]XN?Y(K7D[V\W>YED-%98FB4UJ:
M_57`6-1YZB=*CB:=([HGYQ[$^3VXJ>BZ4ZK[\W+UF:#(U4_?FY.MZWK7IZI%
M%2F:DI<!D]^U.W]V;OJLG4:8HSC<3/!%JURRHO/M5M._V>[E9-ML)3"3\132
M!7@17B&&00,BA\^COW+]@N9?:/;I6Y^YGV2WYN0@?NJVOX[[<J$D5=;'QK2.
ME"2)+I7-#1:]'H7E5-K74<?TX^GL]/$]0B#4`T(^WC^?SZJ!_P"ZU/\`Y9W_
M`/+![]UOK__6W)_Y<G_9`GPQ_P#%8ND__??X/W[KW1T??NO==6']![]UJ@K6
MF>JY/FM3[J_CNRJJJDC?9+T-=3XR"#4&AW-</D9*X:SKGGQVC[9P-*1I*MKD
MWECVS-C]-O8%?WWH&GT(_P!7$'Y=1UST+KZC8]*U3Q/RU4&:<*@4H?+R/1`-
MX5FU\7@LEO+>E!BZ[$]?X7+[KJ,ED,#1Y^MP6,PM#+D\E68=*JGGJHIX::D+
M(D!5W<`+8\^Y3BLGW>ZV*R=JR5XGXA\M1R!^?0+CW/<["TWZ*+?W'+1^)=3:
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M6S\^>P?&T7Q[H>K\55PLIRG?79.T-CRK%,`'CJME8*3>>ZYX'C)#Q-`C&VE@
M`?8;W+WPVY`!L6R5IZTI]M#C/1U:^V5ZPKN&^@'^B"3]E<?9QQU9)\4_Y<OS
M6^*='DZW:7RMZ4EP-;%/70?%BJV'V'E_C[F,^\BSU,]/OG,9*+>/3^2J/6&K
M]KXPT#SE#4T,L8:^/W,W^[B\.X6&RG;*FM<TJ<GCC)].I=V:]CVBR^AW$G<\
M4J2`V/F./YDD>O1GD^2VP-L',X7OVGKOBYV%MC'-E,]L7N"LIOM<QC8Y4IFS
MW36_L'%5;9[\V[45<BQT_P#=WSYHNZQ3XV"8Z"'I;^U@I^^*[:/XCP-/.OSX
M]']O;+=?[@\/\'R_R="=COC/W5\U=G5.%WGL_$?'3XQ;A2+(4<O?'5^,[`^1
M?:DB.DN*W'M/I'<E=283X[XB)D\^/S6>G.\RYCFIZ''J0WO%/W-^\MM&W*^P
M\H;-^]9*D>I-,5!/[>-*<.'4P<H^UVXWK_6[F*FG$'2HS0J2`37B"`IH11@*
MBK9G:WMC^7ANK8&R_EY\L:+N_P"&?86.W/@^L_E?WI!0;$[6^/'8VQ-NMNN/
MJ#O[.4%5/MOL[9W8FSL?62;4W+#'#G(\ICVQM3%.):>0B[V+]^(><'WG9>98
M%BWI4)H`!ZDD<-)S4FI!.HDU/:%?<3VPDV/5>[.A%Q48U$J:\-)(&<$$4!!\
MJ4+!AU1N;N;YG[RW+W]08W*?'+I3K/:&[-O?"7M?)8K#[E_TN5?:4M-0[U^1
MF7PN<GDHJ/:]1LW;L&(P=$13UGV>3J:QQ#,(XO<W74._<RKOEO9[JME'&H_=
MVXU7M8C@RD^M::AFG0?Y(W7DSDGFODC<.;.57YSV$R?[M=KA-WM[%!_#)9JY
M%*\<:B,X/0G[9I-N=E8?>77.WJ6+LSY?[1QF/S5?MKM7NG<W:O66_=GP5=LY
MG>J:C:^<VQUWEJF2F5WH<+N&*C-%D#'2Y)/!>J]_./\`>^YY^]C[5^\6R[5]
MY_W\W.Y^[7N<WAR;ART(K8A"U%&EAK$H`(:@(+`E:$JIZ_\`)MAR[L-CRU[C
M;#RDG+?LUN$[%I-OVJ+:=WV[<:$0Q;F;BWFO-*JRZK^SEG62*KVI$M8^K6OA
M[\3OAGN_:>+[:V_0U';NZ<372X_+4W:FU\!MR?JK?%!%%#GMG5_06(Q&%V;U
MKNG"U6E9(YL=4U@T)-#63PR13R=,/8;VJ]@.6^6-GYY]J[9=[@W&,%=TN97W
M.^N4(JJF[<Z0R@@'2J"E`]2`1C=[W>\_OOMV[;SR7=SKR_L<P)#[;(T@W*SE
M"G4-S=GN[^SD"ZZ_4`59P8U</&MM<<:)%'&J(J)&B*BHJHJJH4*J*`JJ`+``
M6`]Y+B@II%!Z>GRZQ.K4ZJY_U?GUD]^ZUU3_`/\`=:G_`,L[_P#E@]^Z]U__
MU]R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=$/^7?6&Z,Q`O9--N.
MEGVYM3$B"HVMD&2B_ABRU`%3E,35*3%D*_)2/&KQ2A92$58V-])D?V]WRRV^
M9]F:'OE;X@*GA@-Y@#]G0%YUVN[O(1>QN-*#API]GK_A_(=5[2113134]1"D
M]/40RTU533QI-3U-/41/3U5-40R*\4T%1!(T;JP*NC$$$'W,E/D>HP&!2G^;
M]G19N]-R5_0_4VT=J?'_``VR^OMX=C=J;,Z6ZHDBVQCVV1UON#L*JR>2SG8\
M^S:84F-S<FT-LX')9"FQ[D15N46G66\?D4Q/]X?W;N?:+V@Y\]U;M3N>\;/#
MKH,8%`J_G4`GR`/0\]J>1;/GSGK9.1T--A-6)&#YLU.'S\^B];3^)6P]@'+9
M'87:WRFVGO3<E;+E-Y]H83Y%;YHM[=@9>:::KFRV\J)Y:O8=<T]54R2+2QX>
M.DIUD,42+&J@?.Q9?W@7WG;3F`\RV?.]I].[EQ#^[;9HE#-J":69B5`(&6+4
M&6KGKJY/]V?VBN+`;=>\KOK%`2-533'$,,_.@KQH.'0@T.'^5VWIPNT?D_C>
MQ:;4JT6V>_>CMK[CFG')2"??W5-;U]N^>HDC4@3-32N>68,>#DCR3_>V>[&U
M5?GWVKVB_754NA-BH6N3I8W`8TR*D"OH#B&]\^Y%R+="0[)O^[[:@!H3GUXD
M@``?:<=`5\>NP?G=OKY*]RX#:&W>L/DS19&G&*R>\]C=H;EV_P##[XL;BQU1
M&]#B^S\ON+:U1N;.;IHJ4F(;9V359C/5-V->:/\`SJ9Z>VWWS+?FCEW=/<#>
M.5-^VO;MR4+MVV[FJ!G<*=1CH?[,L*QNZKK0]JY!&-W.'W?9-AFV?9K3<]JW
M)M1P*ZL$`:@IK4USY*:EB!U<!T[\.ML;+W9@>Y.Z]U3?)CY&;=^[GVGV7O;;
MN/Q.P^D9,FJQY"@^+_3D<F0V[TY3U$")#/FS)7[MRD:`UF2()C$(>X7O%SE[
MG76C==U6+E\FK;<!I9C0#XADT``!)X!:`4ZD3D_VWY>Y7LSX>!YK\7G7)_PJ
M.WX@6=3T:/>F\]H]>[4W#V+V3O#;>PMB;8I7R.Z]^;XS='M_;&"IB;_<9;-Y
M2:*G6HJI&T0PJ9*JJF8)%'([!3&-G:WV\;A^[=L5M=>`!+#Y&F:_S-.AK>7M
MAMRQW=X.``5%P:"@%%P*"H'DHJ*D=5*]W9/>WS9W7L;/XG^_?07Q5Z<EK^Q-
MC;\[&Z_V]A^PN[NVOX?DL3B.S]J=;]F8NIK=D]);4V+F<B]+7[IHJ:OSE760
MU=+100T_FDS:]F/8#F;9&_K=N^[KMV^)BIH1]C<:$8!%:UK7C017)[]<@[*U
MQL^X>T6U\[R2-18[R6]C5%%:`&SFMB6)J2:"@TIG3J8CF9^+_7^S:KJ'-=.]
MP9KL387R'[&['V/6Y6KK=O5&UJ3O[>.Q<SFNIM_46-PF(@VE1X7*;UV;)C-S
M4<>,0RI50U"Z7C?6->8_NY<C\\7.S#G3W"YRON7_`!*G1>A`*MWZ5LQC%=`X
M\`2,GJ1HOO\`O._+EGO&W>W/W?\`VSY=(B`K8VM];.0%`[GDG9B1YM6I:IKG
MJQO^7'\<.S=R8/;.POECN?LFB["FCW<V;QG2W:DVT-BTM-C:I9=KYZII^K<=
MMJGH6R6/22`QB?1K$9/K8@1][G?W?'W+MON8^8-L]L;;=V%!3<[B2])K@X9P
M*GB:KZ^?0"Y8^^=[P[WN1'-/*_*'[UR0&VI+X$'.1>R7:#U./LT^5B7P=ZNZ
MSQ_;?S%[&Z]V?6X1,#W1+\=*#>66WKV-NS=_9%+U-M':0WGE][U&[MT9C$9>
M7$=EY;)XO&5<<"U-/24#1%K,RG7(_MI[?^U.SKL'M]RI'M>R4Q':%M*U))`1
MF8)I)(`'GZ=/\_>]7N5[E[+L_+7.&X6XY?VQV:PCCL;*S$9DJ7$9MX%(B=ZD
M`44TKIKGJT=>%4?T`_WKV/\`]OY\>HPSY\>N_?NO=4__`/=:G_RSO_Y8/?NO
M=?_0W)_Y<G_9`GPQ_P#%8ND__??X/W[KW1T??NO=>]^Z]T7_`.2>S(-Z=59M
M)\W+A%VXC[J61B6QE9)A8)IUHLM`MGGII=1\>DADG".`=-B(^4MS_=V_6\BP
MZR6"GUH?,?9YCTZ(.8;7ZS9ITUTH*_+_`%>GS_;U0[W-MWNS=%+UXO2F_L1U
MQ48W>E/E]^U^:HS7KEMG)3*'PL5"*:?^("6I)\E/KI_)<'R>FWN;=UMMZNTV
M3]Q;R-6K_+U%.U7%E9R;W]?PT].W=_4N)[NZ^R&QJO.Y?9.4I\WMK>W7^_\`
M;U-1UF>ZT[-V/E(\WLO?&+QN1)QV63%9*-H:O'U#"&NQM34TS,OEUJ7\]\D\
MM^YO(^^^W_-"!MAW12C5\ZTU"HH<L*@^1`(Z5<M<S;KRAS!L?,NT`'?=M)-,
M$$'R(X$$&A!K4=$O[.[<[]^.\6U:/O#H[:78N9WCE(MO[-HOBWV+'N#L[MW+
MRSQQ,O6'Q=[`H<'V5D:B%7-170TV2K<=B80[3URQJ&/#/W7_`+KCF_D^+?=X
MY(]Y-I.R$DHFY*;`(E:#7.JF/6M0"JJ"P!9%T\.C7)_WS=CYEE6RW;EC=TWA
M$JS60U8`J:DLM`,U9JG^(UR3>;%^&7;G>RIE_EA7UW37454/)2_$WJW>'_&1
M-[8]R+TGR>[WVI40-B\561C_`"C9FQZB*'0WAR&9J;/%[#?MI[$\C^V$PW7<
M'7F?W%`4I4?[JHC2I_=EBU3-(II^K>@`LI9%4-T(>;?<[?><4%CMA;;]@/%B
M2"?+`P:G))K2IJ"R]6=[0VAM?8NV=N]?=>;3P&R=E;7HTQ.T=B;*P=%@-M8"
MAUDQT.$P&(@@I(&E=M3LJ&:>1B\C.[%C+]_N$VZ2%]U<F0GSX@\*4\B.%!PI
M08Z!$<,%LC-44`J78YH*FI8\!DF@HJ@X`'11.]/FQM/KK=.9Z?Z9VG-\COD/
MA;19_96W<W'@>JNH)YD_:K?D/W-]MD,'L;0&UKMW&ID]VUBJ5CH8KB52GF;F
M/D[V]VN+>_<3F);:P<'1MS#5NLP`_P!!0&K`XHV$%1J8''2S:-FWOG"\;;^7
M(6\/S<@TK6F*C/XC4XP"`RFHK[WEU!5?('(1;P^9V=QGR5SP:27;O7M?A:O`
M_&+J)F=7-)U!TY+7U,4^=H'"K_>[<D^3W74&-766C%HUPBY_^]+[A\R7'T_M
MY='ECEG@&LN_=V`J`=ROB-,884.E*`?"=5*]9`\O>S?+>S6KOS&1N._DUTTK
M0\:$DD=IP..D`4(&`'N]OC[/L[9&]\A\?]W=A;5SD>V,_6S=2[F[$WKV%T-V
MUCZ?'55=F^MM\[`WQF=QS8REWKCJ>2BILQA:O'Y/"ULT57"[")HGF#V5_O!?
M?_E/FCENQ]Q^;UYFY$4K'N7UZJICB^%-)4`E@"H)H3(*BHJ"`1SU]V/VVYBV
MG>;WE;:1MV_D`&F#J-,_%3C4F@'J.%#,^/=3U1WG+\<*;XQ[?K\?\5^A,A'\
M@MX[MK:^KS&-W#\C]R[)J:+9W1FU=TUB1_Z0,ST_/NROR&]\O3!L;1UM+18Z
M.1JDSK%]$>SQ63P;#)R^NCE]Z/Z8<:@0.(!!JH.0M`U&!`Y5;K/>1S;_`![D
M`>8%JB_8A*@^F:?GD]7E?''NK%=3X#MNOW-B)I=J[1V)N;M?/[DQM!&]1B<7
ML?!5F8S%-F*T!`E'4XZB=J(2/83AE`LY(#?N9M:B/9[\-0&JTKQR:&GKZ^OG
MP'1]R'=:=5AH[B*DTX>M3Z5_G3HPG\OG9><V5\/.C5W9.]5O;?.U9^Y-^U=3
M3F#(3[[[QS>5[?W8,EKO+)7468WM)2N7+,!`!<@#W$IP2/+J237S/1S/>NM=
M>]^Z]U3_`/\`=:G_`,L[_P#E@]^Z]U__T=R?^7)_V0)\,?\`Q6+I/_WW^#]^
MZ]T='W[KW7O?NO=)G=>UL/O/;N6VIN"%ZG#9RBDHLA##/+2S-$Y5U>&HA99(
MY(I$#*?H2.01<%VQN+G;;Y+ZS8"16J/.AX?S'2:XM[>ZM7L[H51AGJF_M'8<
MO7/86;V0*B6KCI)89\+5U2"*?(8JLI8ZNFF8JJ0RO3J[1S/&-(=#<#Z>\B.7
M]U.\;$VXL`&7XJ>1\^H4WS;!M%Z+)*E#D&GEY5\N'1:=E]V]7]G;/WWO+JC=
M^+[/Q6PCO'"YY-GU%5]U!NO;6"KJ^HVO#)44D$L>7JC"$I)8TDC9W5D+V]BK
M==KO=J\&ROU[7H>'D14?R/1#8W5G=!Q8_$,=+3^6K\;NMNH?CEU9W'CI?](G
M>WR#ZPV[V3VK\AMTUU1NGL'=#=ATZ;K&Q,%N/*55?/L_K39D5;%BZ7`8DT>.
M\E"TT\4M4\DGOCE[F<Y;QS'S;O\`;[W4P*[J`34$!F48..``/'SJ2*`=`^5.
M7K';=G6:V-6"H0.`!HIJ:<6U=P)^$:2H4U)-OW1WKU'\>-I4F\^XMYT>T<7E
MJ\8/:6'AHJ_<.^>Q=ROQ2[.ZLZ]P%/7[M[%W=62,J1T.+I9BA;5.\,0:0!CE
MKES=^:;P;+LNRG<=^/PTJ!3T!%!CAQ`K@D='.Y[Q9[5:O<;O1IE'PU`I6E-1
M_#6H/`L14JK4/52?RQ[8^:O>'7V6&!.XOAQTKGJ+(8B/:VULQ2UGRSW2E2J?
MPVL[JW_MULKB/CQLS/1:H9L!M.6KW%%J,60S%*3X?>9W)WW9+78+']^\V_[L
M=]H#I\AC*_[7APH13B>H`WKW=7=KY;/:6#[,":XT@4/DI)R*#N))K73I#$=$
M/Z$^.FW?C;TCN;-UG=??/1O6G7U+G<H]%U1OA\GL_-]A;CR+Y+&[:VSU]V9B
M-X87>6Z,FS3O62@AJAV::IENI;VD]S?NY_=PY@V/>N>?>?DPRPQA?]VA#66Y
MJ``HCC/'2!VH%&:`CH=^S&\^_/N![G\C>U?LK>1R[MO#F.-"%_=VW;;J_5W:
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MB"=JN&GGGCB``GM'_=@VNR^Z%KO7N)[G'<=BVLZOW>EAH%^ZG4@=G8ZXUI1@
M@UZ]/X0W4;<]?>_N+GDM[?E;E!K#?=Q.E-14Z@,`F@P:4(.!^?5DGQZJNG.S
M>Q,A\0>AM[=98[>/Q_V1A\?7]1TF0FHFZZV3@HL=A:*BB@IJ%J:NGQOW5,*_
M[<O*M34>2<AY6)[,<Q_4\H;#L&]W>QD<O,^FGS`)`/I@$`&@%-(X`=8!;0S<
MP[X]G:,/$%6:OK6K<<G).,GSZ.?\L>O)-@_#W"?&ZCR22;R^5G<_5/QWR.X,
M/3R1BJH^T]\TE1V74LK6K9,=B>E<'GS8ZBL41)4+J]X]\Q[Z^][N^Y%2J,0%
M4^0\L<*]33LVUKL]D+-2"022?MZM1AAAIX8J>GBB@IX(HX8((46*&&&)0D44
M42!4CBC10%4```6'LCZ->LOOW7NO>_=>ZI__`.ZU/_EG?_RP>_=>Z__2W)_Y
M<G_9`GPQ_P#%8ND__??X/W[KW1I=[[[V7UIM?,[Y[%W;M?86R-MT39'<>\MZ
M[@Q6UMK;?H1+%`*S,Y_-U5%BL;2M43I'Y)I476ZB]R![]U[H-HOD_P#&ZH.[
MA3_(/HVI_N!MR#>&^A3=M;$G?96TJJ*AGI=T;LCBSCOM[;U7#DZ9HJVK$5-(
MM1$5<B1+^Z]UU5?*#XV439A:SY"]%TC;<VCM_L'<8JNV]A0'`;`W;/3TNT]\
MYCRYY/X9M#<]55PQX_)3Z*.L>9%AD<NH/NO=%SW=M;L[Y@I5XFHT])?'5C,N
M)WSA*_;F;[[[<Q4JE(<_U]N/$5.<VWT[UKG@_FI,E%+7[@R]"%>-,;'-J<;;
M1ONW<IF/<+"3Z_?20=.?H4%*@2#C=GU3M53_`+\H*!K<["ZWZ":PN!]'LO`G
M!D<@^7$1CY_$:TP">J[=O_&W8_Q(R^ZNN>NMA8/K:*?<IW7D8MNBM-+N3)30
MI!0;P\V1JZZ:9Z^BIUNNO3%*KJRAKWG2/F>^YSL%WV]W@`@`$4X$#*@>0'`#
MA2G4.ML(Y;OOH:56O[1Y'\^/05[0V!WATO393:_QD[_Q76O5F9S.9SF+ZB[(
MZ9P_=&W.J,ON?(SY7<,G2&6DW3L_/[<VSDL]6SUT6ULE+D\'0UE3+]H((I/"
M,?\`G'[N7(O.>\#>P1MQXUI6I.2<UXDDGU)ZD_ESW9W[EW:9+9@VXL<=K,F.
M`^$BI```)R`*`]!)TW#3TWR=[/DR6`WYW-V/@MJ1TFY/F]V?DZ'.YW-9B>>!
M<WU%UI08VBH]B]0;#Q3U;1K@-HQ4D44D$BUS5+C7[&_M_P`M\M<G,NR\K;/7
M9:=S>9(P3JXFIJ?V=$O-5_NW,.W?OG=MV"0@DA5P!4U.!\SD^M>C?Y'*8S`X
MO*9W.96AP>#PF-K<MG<YE)UI<7B<-CZ=ZK)9')5$@TQ4=/3J6:X.K](!8@&2
M;MK>QM_J;D5-:?8*XU>GYTZ"NU;5O/,FZ;%RORML;;IS)NK:50`U)'D!\AD^
M@R<=5Y;WWWLKM#N[KO"]O5&0P."QF&A[5VOU;6;8W/ELEB=B35D:[$I]RX+;
MV&RAI.U>\LE%'EZN@F"5.%V=2T](JB:NJ??*FW^\!R/]Y/WNW;G'FKG_`&K8
M?NQ\A.5MS?[@@/,V[JS@W6@MJ.U[8R:&4*U9.(*=Z]>N6?:CGC[N?W;>:=M]
MFMJ@W+WHYN/[JOMQ9U_=RS%?\>C6^8C1M6S1-]/`XHNX;F]Q(#HM(B1YE^8W
M455OS9FQH*+LRKRV_MUYG:%#E9^N\YBL11[CPM4M#DJ>J_B,5/72P4.5D^WJ
MFAA/V9!:0!%-NAG*/NQR9SW8[-S#ROO7[TY=W)BNV[FH(4.,'34`Z*_`2*%:
M?;US8]Q_8;W&]F=R@V'GI=G_`'VZ+NP_W86E\*7@\-:BT-0,5`;N`.16O1O\
M1MS=&YZS^&;<P.8W#61,J-3X>BEJS$0"%:IJ(P*:F70MU,L@]/TX]CF\W6RV
M_.Z2`$>9(!KYD>>>./7J*K:VO[QJ6%2U?*O'Y>@KP^71G/B]\.I.O>Y\KWY7
M=?[.Z^WAF\7-C-T[@H,5AWWYO^EJ(5CBH=PY#'E_#CZ0I'*[._FEFB34I*A@
M`N=_<"SW/8_ZOV>[MN*ZJY!`4C@,TK3API2M3T,>5N3[[;=Z;>[YPKZ2`/M%
M.A![2D;L?^8!\7^O5,O\*Z`ZB[B^3FXXI%$M`^Y]Y"C^/W5$<J&X6K_A6XM[
M5,3,`5-)=""#[B/TZDWH_GOW7NO>_=>Z][]U[JG_`/[K4_\`EG?_`,L'OW7N
MO__3W)_Y<G_9`GPQ_P#%8ND__??X/W[KW7'YU?%7*?+7JK8^U=M[RP>S-Z=4
M]X]5?(38<V]=HMV#UAN/>/4>;DS6'VAVQL2/+[?JMT;`SQJ'2HCIZZDJZ.K2
MFKJ>03TL:M[KW5=B_P`H3?T79?:O:7^E[IJ;);FSWR)W[LK!8;IC<.Q47>WR
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MK*9)4UI&Y*JQ)`Y/LTVW>MUV>UE@L+C2K\1CCPJ*C&,=%NX[/8[JR2WD=2O#
MRZ(=V?TGM_Y`[HW#UQT)12=78/9=74X/M;N?%+6T^/K,U2Q/#5]0]>43N(:K
M<Q1U7/;C@4Q[?B)IZ?[BODE%$=[7SIOEBIMKN0R1,*T-,5]#QP/+Y\>'1?<\
MK;>P!LXQ&?E7_!\_]0Z"W=7QFWYT[MO&4M)MO&3[&PE,E)1P[%%568W`4Z_4
M56,>!,A$LCL6DJBLQED=GE<NQ8R7L?.>R;GIVZV&ASBC4%3Z`UIQ\JUZC_<N
M6=YMBU]=D,!Z9%/*HZK-[#VE\O>POD7086EP.PG^%^W,7@=[R;GR^VAN.@G[
M$V_`9J':_9N(HLIC,UN&@DWAXZR#'/+%C%^WBFF:31X_80^\;[)6?OK[1M[9
MP>\6Z\M76Y57<I+&AW'<(SC1'P"@+C!!H*C('4K_`';_`'HY8]CMWYWYAWWV
MZWOF/>]PC&V;5N"7HL&VEFSN4M3;7)%_?J1%!(!VV6H`@FO0LQ]T?)JFWKV+
MU[M[?^&[%WANG#;3ZVV'0;:ZIQ>U:^E[E[`I*K<&8W?-7X>LS.4RVW.E.GL<
M<UE/,Q'W-70PN095!^?;W@_NR/8W9OO)^Q?W:O;/>]VO-TNI!NO,>X7LC4VO
M:8S06SH.Q7W`LVGRP<U-!T,Y"W3V\YD]F]M]\.8/;Z[VCEC;;G<MP>T;<#??
M5[5M9\&&RB"Z!]1N>Z-]!!I&IXXKFZ50(R.C(]0]&9F-=N=0[*P-?#_<_&&E
M^_W71U-'4441+G,;JW#D:VF:MBR^Y,A--4U;QDSUM14.HN/I]&5K'RAR'RML
M.S[,B+RSMFE41=/PHH554"G!5'#@!4]<J>:.8></=;G?=.;M[M$M>8=Z87]]
M$/@AB!TPVZ&GPQ1A(EI3"5(X]6[=&=41=1;.?`2U\&6R^1R-1F,SEJ>F:EBJ
MJF=4B@A@B=Y)1345+"D::C<FYL+V]Q1S'OK\R[@VXMA#@#Y?/[?\G0[V/:TV
MBS%FIKDFOV_YNAH]D-`.`Z.NB!?$^4=B_(SYW=[&2HFQ[]O;2^,6T4K(R6IM
MO_&C9\<.Z6H)2&04-9W%V-N="(VLSTOK`=?>^O=']]^Z]U[W[KW7O?NO=4__
M`/=:G_RSO_Y8/?NO=?_4W)_Y<G_9`GPQ_P#%8ND__??X/W[KW1T??NO=>]^Z
M]T4+YZT/R0R7Q%[OH?B+45=+\AZG:L$?7TN)K=OXS<C1?Q[#G>E+LG*;LBFV
MOB^PJ[8`RL.W:K(K]C39QZ22=EC5F'NO=4Z[=V!_,,JODCMV;8U9_,)V_P#'
M^3%=,348[S[1Z_R<5#\<H.JNS:'Y(;:WW24^[<WO&L^7^X>R*C"KM"LIII*^
MBJ6I:N3(0T$%;$_NO=`KG^@_YUFS=L[`38/=?R/W9NK-_%+N#?F_-J;LWY@L
MXG3NZ=W8_M#*[>Z)P/9]948[!]R]UX_-9_:N*Q>8KJ..OP;[>GJ*;)&AR$@3
MW7NKO_Y;-%\FL7\3=EXGY;2;PJ^W<9N/L6G3,=A5^+K-^9[KZ;?>?K.L\KNZ
MDQ=;F&P6;.RJFCIY:"LR64R4`IU-95S5#26]U[H^/Y_WOW[KW2$W#7;2V1M7
M<FX,X,7AMH8+#9S<NYI_MJ>GQU)A,5CZK*YW(UL$<0AF@2CI))96926MS[>E
MNV@4SW$NDJ"22:TH*UKQ%!_+IW;=HNMWW+:MCVO;3+NM],EHB#\32MI0`<*L
MQ"KCSIYTZJ%_EJ]>;TW+LGM#Y[Y_8E!-V1WY+V%O/H#JZIJX]KT>'ZQW%DCF
M-L1C+3T^1@VI6=Q?P7$>2L--4_986AQ_#*)8S"'MGRBB<R<\>Z^]AFYPYA(1
M'8T8;7&P^BB9<G!!/<?X6T@U'68_WNM]V3DZ\Y9^[5[?S1_U=Y,MX;3<Y8S1
M-PW."*K!0*!8[!GE%*T-Y/=$@=IZ.7L3YR[=FW?M+J[Y`=+]S_%KMS>V9QNT
MMLX;LK:3;FZVWON^LIFJ(\#L#OOK1]V]5[@E=M0IHJ^OQ&1G_%$CDJ)H%:`'
MTZPS^?F>O3?S)OAIC.Q=V=4[M[LVKU[O?:O:NX^G(L1V#61[8?>&\=F[9VGN
M7=QV)]V[2;DP6W&WG1XRJR")'2KFA)0JS5"A&WU[I/;7_FM_R\]V;,P^_:7Y
M6]4X3`YWIG_9A*&'>N6K-C;ABZ>^]HJ!=YY/:V[:#$;AQ,%1+DJ9X*6HIDK:
MFGJZ>HBA:">*1O=>Z8?BQ\@OA5TSUA7=0[5^6>PNQ,AUYN??.7[&W;N'<.)H
M]R5V^NP^V*',;PK-UI2TM'1Q9Y>R.Y\9BJJG4&:BK\A2T<ZI4'QCW7NL&_\`
M^<!_+PZ_PN-S<WR3V3O&+.Y?LS;FWZ?KILAO7^*[FZFVG3[RW7@9,IB:)]OX
M">;$U]&F/J\K64&+R%57010U3&0'W[KW0B9/^9C\%=M[<W9N;>?R:ZDV52=?
MY_;VT-_TNXMXXF.MV=O/<F'R.:I-JY(XZ?(T.1R5+38/)QU$N-GKZ*&?$U\;
M3AJ.H$?NO='@Q^1H,M0T64Q=92Y'&9*CILACLA13Q55'7T%9"E325M'4PL\-
M12U5/*KQR(Q5U8$&WOW7NJC/^ZU/_EG?_P`L'OW7NO_5W)_Y<G_9`GPQ_P#%
M8ND__??X/W[KW1T??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=`AWMTW
MMGY"=3;VZ:WI6YW'[.[$QL&"W2VVJ^'&92NV]_%Z&MR^"%<8963&[DH*23'U
MP4!WH:F9%968,&MQL+;<K*3;[S,;@`BIJ1@D?*M*'H1\D\W;M[>\W;%SOL>C
M]_;9)XL)(#!9`#H8#AJM6(D6OX@#0\"+>,QF-PV/HL;C**DQF*QE#1X_&8VA
MIXZ6BQV.H*>.DHJ*CIH$2*"DI*>)4BC155$````'M\+IHJ`4&,8_+H.W5U)>
MR37][*TDSNSL[$EF9B69B3DLQ-23Q)Z<Q:W'`_XK[KUKK7"^6O\`PT3\::[Y
M6;HW]5]D=C=S;/DW7WEV+U%M#,]AY[<&^]_5.]<IVC)UUM?-P8J/9K[P_OO\
M@\-D:G;M'E!686CFP-964\5'1TL@]U[K(>G/Y:?QVS]5CMV[AW[D^_\`;]-_
M+=W1W5U)V)W$VX8-F;JV?ENMMN_'G*]B]N[CVOC]LKDHL/U+2M7TC92DIMS8
M;9TDG\/`U%_=>Z#S?N._DJ=GXOJ:DPGR[WYLG=N-RO<&P.L,AG\GWI_`J_L_
MMCMK!=\OV'W[L3<^V\!C]Y8#;G?_`'1MW=])E-TS8S;E35Y+&F:L>)J9D]U[
MH+<=B?Y4_7.T^I.N.LNQODC\D\O!C=X]%=G[SG[6W3UO6[SVU-U[\><+M_:W
M;]3O[$;1@W!UAN?;>TMBXG8<>&A.'_AE8GVE5+25D\TWNO="=C\)_(*BV9E\
MLGR)W?G=N'-]C=)83)3[D[SR^1ZUV)VMMC.[>GZXV)34VRFRFT_CKB,3W9E8
MMO;A$+X&&MW?,$S$]360CW[KW6SEB\9C\+C:#$8FBI<;B\70TF-QN.HH4IJ*
M@Q]!3QTM%0TE/$!%!2TE-$L<:*`JJH``'OW7NJCO^ZU/_EG?_P`L'OW7NO_6
MW)_Y<G_9`GPQ_P#%8ND__??X/W[KW1T??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=4C_/WXT?!7HYZ+Y$]G'LS9%5V?\CMG;PW
MM@NJ=I[_`.Y\[V[N+:U/CNZ][[6V=UK0KNNBZN7LFB^-F#R_86Y-NXW&Y#*;
M=V2M-6UB4[2$^Z]T7KY"]Y_RF>].TMU;UJ=@=R?)#N'M>#I3JW8V[-I===I;
M[V7N?;W8>\Y.F]L9_J>FSV1P/5>]M@=7=@]D5U1N*EB>6.ER])6EHGJ::0)[
MKW17OAKVG_)RV;\;:A/D?F^TMP[NK]V[JBWGN_Y-X;LZHS7;V$D[JQ64ZPFQ
MS8B-]H[TZV["&&VWE]O8>GERL#8S'Q0S25$&-=U]U[HP.`W!_(?VS48/;^,V
MOV%N?!I49**A[8S$/RDWILU<CL:;8.#J,;D.W\_F*^D)V5L;:&T:VGCFK#1X
MW9L.)FB,=')$&]U[I;;6^+W\N/YV]^['I?C=G>R]H87XR#JO>?;6/VCM7>>W
M-L]Z["V;7[#PG0'5F=[`WY5PY/<O2E#4?&O!92AQN)IJO!9NDQJ5*5!J))IC
M[KW6Q./H/^1?[Q^/?NO=4_\`_=:G_P`L[_\`E@]^Z]U__]?<G_ER?]D"?#'_
M`,5BZ3_]]_@_?NO='1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]T4?Y0_"7H?YC9;INJ[_`,/FMY[;Z3W/N?>.!Z\&>K,5L;<N
MX]S[2K]D&OWSC<9]MD-PPX7`9BNCI*7[J&E8ULRU,=1$YC]^Z]TDXOY:OP5I
M\GO#-4?QJZ^QV6WWOK9_9.Y,CBDS>*JY-Y[!W)E]X;0RV&FQV8I7VK#@MT;@
MKZ^*CQ7V5":JMG=X6,LFKW7NI6YOY;_P5WG@:':^Z_BYU)GMO8RFGHL;A\CM
M[ST&/I*CIF+X\&"BIVJ-%*D'2L";>@":?MJ-;Q:)?W/?NO=(?LW^5?\`"?LC
M%=IT4/4&)Z[S/<_3D/QWW]O#K4G;FYJKHB7%[(VMN#K#;[S#(X3:&%WCU]U[
MBMMY2IQE%39*?#4L<:5,<L-/-#[KW1F>N?C#T'U'OK<W9G6W5VV-H;[W=L_8
MO7>9W)BX*HUHZ\ZRH),;L#K_``L=555-+M?8NU*>:1J3#XR.CQR5$LDYA,TD
MDC>Z]T//OW7NJ?\`_NM3_P"6=_\`RP>_=>Z__]#<G_ER?]D"?#'_`,5BZ3_]
M]_@_?NO='1]^Z]U[W[KW7O?NO=!)VUWYT;T)1[<R'>'<W5'3=!N_/4^UMJ5O
M:O8FTNO:3<^Y:O2:?;^W:C=>6Q46:S<JMJ6EIS),5]6FP)]^Z]TTX'Y,_'7=
M&ZM[;#VWWYTCN/??6M#D<KV+LG;W:^Q<UNW8&*P\BQ9?);WVYC\Y/E]J4&)D
MD5:J>NA@BIRWK9??NO=(G_9X_AE_H[PW;A^6WQC7JO<>]6ZVV]V6_?/6"[`S
MO8:-:38N'W>VY1@LGN]$]9QT,[U8C]931ZO?NO="72]^=(5W:59T;1=R]35G
M=F/QHS-=T[2]C[0J>U*'$&@ILJ,I6]?0Y=]V4V-.+K(:D3M2"+P2I)?0RL?=
M>Z%SW[KW0`[@^5?QEVGOK=?5^Z?D5T/MGLK86T)>PM]]?;A[=V%A-Z[+V%#!
M354V]-U[8R6=ILUM[:D%+6P2R9"K@BI8XYXG9PLB$^Z]TT57S+^(M!U]ANV\
MA\J/C90]3[CW)-L[;O:%7WIUC3]>;@W=34\]54[6PF\YMS)MO)[DIZ>DF=Z&
M&J>J1(G8I96(]U[I[H?E)\;,ING!;'QOR"Z-R&\]T]>?Z7ML;3H.VMB5NX]Q
M]2_:-7CM#!X6FSDF1RG7K4$;U"YF&-\>T$;R"4HC$>Z]THNNN^.DNX-M93>O
M4?<'5?:>S,'4U=%G-W]<=A[1WQM?"5N/I5KJ^DR^?VSELGBL;44-%(LTR32H
M\<3!V`7GW[KW35U_\E/CSVSM[=>[^J>^>E.S=H["69]][IZ^[5V/O/;NRUIZ
M.IR52V[,WMS-Y+&[<2FQM)+4R&LDA"P1NYLJDCW7NH.Z/E/\:-C;?V%NW>_R
M(Z'V;M/M>.FEZJW3NKN#8&WMM]FQUD-'44K]?YO+YZDQV\DJ(,C3NC8Z2I#I
M41%;AU)]U[K%C?E;\8LUV6_2N&^1W067[GCS&4V])U%C.X^O:_LY,_@Z%LGF
M\%)L.DW#-NE,QA<<C5%73?:^:GIU,DBJO/OW7NC`>_=>ZI__`.ZU/_EG?_RP
M>_=>Z__1W)_Y<G_9`GPQ_P#%8ND__??X/W[KW37_`#)\!\L]U?"3OS;7P:R,
M^(^4>>VWA<3UKE*#-X+;><H*2MWGMF#L*IVCG]T2TVW,/ON/K%\S_`:BMGI:
M>+,_;%JBGMYD]U[JG+MW%?,;X??RQ.W]@P[C^2&SZ;<<&S^T<Q\A^]OD;UA#
MVWU)C.UOD[MG;/:WQ%ZARV&W+VW7=9Y?;_Q[IZRLVANO*[ASM#B\GG423)I6
M0EJ;W7NE!_+I^2'RJZ!^&>`[`S'Q>^5O?&!^3G>/9^Z_C7L[L;N;)[[[7ZYV
MUO\`^2%#U5\>?C=DLQV:F6WM1]<[3^-NVZWLNMWWN&IIL#1X:GDC,\]76P!O
M=>Z,E\TOC?W>O\QWI?YCX#XEX7Y[=,Q?$3>_Q4J.E\INSJ7`5W1'9&Z.V\'V
M!-WMC\=WCD\?LW)8#?\`M6B3;>?J,8)<]1TF.A\<513RS0/[KW5?G3?\N#Y:
MX+NGKVHRWPBZSV'2_'CYY_/[YC5?R-HNS>D:W=GR(Z:[^B[J&Q_A]L3#X<3[
MG7!=N1=I8NGW*^^I,5A,9!MJ#T5*F*"'W7N@KS_P!^?N8^+7RYZF3X43;RV_
M\WOF?%NO=.5[)W+\(W^9_4OQGS'2VR-B]V[AQ4>#S&`^(>"[<WC3;7EVCU]/
MMFFHFV]C*A\IDXFJHX&]^Z]T,FVOY<_S3Q_\TO9O?^VN@Z?971^W_EGT)WMA
M\KO?L'H3/=:;4Z0VS_+[V_\`%3?NUZ^DVY)EOE5F_D]M?(8T8W`NN9FZ[D\<
ME?505$KQU#>Z]U8'L?I3Y]8O^;3N_NS<%3V0W\N_-MOJCVCUE6_(C&Y&DV=W
M'!U%UKA%[]J^M45JR?IKL1:++X##;,&0JWP.Z(ZG<KX^C7(B0>Z]U6QV;_+K
M^8=?\6OYG?P[I/@]L?L?M7OWMSY-]]=6?.N;M#I"G'=V([=[:VQV1L[KW<D>
MZJZD[9V?V*^T:([.R%+6TL6UJ2@PE,PKYJ:9(_?NO="1NC^7W\P.Q>O_`.9=
MN39'Q+ZC^-^3_F'[J^+G4_6?Q^S^X.G=\XOXQ[8VUM/</4OR+^;NZ:+;60J^
MIJ3MS.=:[\K?L<?M&>JR]0^#QK5+U-0SHGNO=)GOO^3WV)#\J\+@_B#U-N[8
MGQVV=BVW[ELOOC+?&^#K3.;@V+_+OWY\,.J^KNFMQ81Q\LL33[LBSN+QNYL'
MGVI=D4D-+DLO`\E1710-[KW2Z_E/_P`NWY??'CI/YK;5[?ZCH^M*_OGX<?&?
MI3!8G>F\>BL_V'N#N3I7XT;GZ1W"M)7_`!PQ^*ZNPO06.^XQU+M>3*QU&\*@
M-5U.7J92T7OW7NB;[<_E;_S'<YU#UAL[8OQ-ZD^*^?B_EW_'+^6!W_4;H[2Z
MSSU/WQ@?]('5VX^_^_\`L7$]';C%%G-@;.ZZZNS.V\32FN_OUF3V#6(3!3Q2
M3/[KW63M#^35_,6[/Z=V!\;)-K].;&P/QCVO_-DZXZ2WQM+)[`WEUONCISY=
M;:ZKWQT'TMB]L]RT^\NQNN]BC//N'KF7*@_WNVEBL119"BK[-'._NO=7(_$#
MX-9_K?YT/\FLY\8NM.E]BY#^6S\/^G,#BJ/+[(W_`+UZT[VV#N+MBI[1V)+O
MN&&HWCN[*;9VIN3$XJIW?+,XW'34L%ZB;PA(O=>ZNN'OW7NJ?_\`NM3_`.6=
M_P#RP>_=>Z__TMI+X#[C^8U/\(?B-3[5Z:^,67VY#\<>GHL'ELU\E^V-N9C)
M8F/8V&7'5^6V_2?$W=-'@\I5T81ZFDAR>0AIYV=(ZF:-5D;W7NC;?WI^<W_/
MB?B?_P"E8=O_`/W%_OW7NO?WI^<W_/B?B?\`^E8=O_\`W%_OW7NO?WI^<W_/
MB?B?_P"E8=O_`/W%_OW7NO?WI^<W_/B?B?\`^E8=O_\`W%_OW7NO?WI^<W_/
MB?B?_P"E8=O_`/W%_OW7NO?WI^<W_/B?B?\`^E8=O_\`W%_OW7NO?WI^<W_/
MB?B?_P"E8=O_`/W%_OW7NO?WI^<W_/B?B?\`^E8=O_\`W%_OW7NO?WI^<W_/
MB?B?_P"E8=O_`/W%_OW7NO?WI^<W_/B?B?\`^E8=O_\`W%_OW7NO?WI^<W_/
MB?B?_P"E8=O_`/W%_OW7NO?WI^<OXZ)^)WUY_P"<L.W_`*_^D7_7W[KW7O[T
M_.;_`)\3\3__`$K#M_\`^XO]^Z]U[^]/SF_Y\3\3_P#TK#M__P"XO]^Z]U[^
M]/SF_P"?$_$__P!*P[?_`/N+_?NO=>_O3\YO^?$_$_\`]*P[?_\`N+_?NO=5
M:_QWY2_\.X??_P"BOX[_`.D?_96/MO[K?Z?>S_[F_P!U?XCY/XW_`'^_V6O^
;,?WG_C7[/\+_`+M?9?8?O?Q#[C]CW[KW7__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g575431dsp_075c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_075c.jpg
M_]C_X22*17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-SHS,"`Q-3HQ,SHT,````Z`!
M``,````!``$``*`"``0````!````C*`#``0````!````H@`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``"-4`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`H`"*`P$B``(1
M`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[+ZO_5[H5_0>FW7=.QK+
M;<2A]ECZF.<YSJV/>][W-+GO>YWTW+0_YL_5W_RLQ/\`MEG_`)%+ZL_^)OI7
M_A+'_P#/3%II*<S_`)L_5W_RLQ/^V6?^12_YL_5W_P`K,3_MEG_D5II)*<S_
M`)L_5W_RLQ/^V6?^12_YL_5W_P`K,3_MEG_D5IJOEY^'A&D95S*3DV-HH#R`
M7VOTKJK_`'GN24U/^;/U=_\`*S$_[99_Y%`R^C_5#"8VS-P^GXU;W"MC[F55
MASW3MK:;`W=8[;]!9'U@^M?4#]JZ9T^JSIN98TMZ5FW>FX77L<_]4^S6;G8K
ML]E%S.E6YGI_;_\`M/\`S?Z6KC]`^L.0_$SL2TV.P",CI%G63ZSS3FUL'4,'
MJ#*V,S*LSI^13ZN-=ZS_`-';]D]7_1I3IN?_`(OFY&1C.Q\(6X;;77_JXVC[
M.UMN6QEWI>C?=BUV,=DT46674?X1B)BU?43+Z6[K%&+A'IS-V[)?0VM@V'99
M_/5L=],;5CX/0NEY^7U7#JZI3=;D.SFOILQA]HJORV?9LVS"NNMW?8FV>K:R
MO%K_`,)Z>3EWKH/K!T&W/Z#5TS#-9=C/QWMIO_F;FX[F6?9<H,:[]!=Z?YK4
M@0=C:Z4)1-2B8G>I"M#L@Z11]1NM,L?TW#P[_1+1:PXXK>W>-]3GT7U57-9:
MSW56;-EO^#6A_P`V?J[_`.5F)_VRS_R*YOJG6_K6[J6/C8^-5TW/LP_M%6&7
M5VNR[F6/;]A;F7LHQ;,?$J_6,VNG)QLZNO)]7&]17\3ZY,R.HL8&-=T_*M&)
MTXTAUMN3>UWZ]ET1M9^R<+_"9>S_``?J)+75_P";/U=_\K,3_MEG_D4O^;/U
M=_\`*S$_[99_Y%:2=)3F?\V?J[_Y68G_`&RS_P`BE_S9^KO_`)68G_;+/_(K
M3224Y@^K/U=!G]F8FG_`U_\`D5P_[-Z;_P!Q:_\`E?[%P?Z+_P!P?I?T3_@/
MH+TM>>__`'P)*?_0]"^K/_B;Z5_X2Q__`#TQ::S/JS_XF^E?^$L?_P`],6FD
MI22222E+G_K%TWJG[1PNN])J9F9?3V6U'`N<&"RN[;ZCL6]^YF)E_HV_I?\`
M"T_HK%T"8D`$G2-4E/*]"Z?B975<C/ZPW'=U^QS<A^%4[>W%8P>EA-NVG[/D
M=0QJW/9]O]/U?TOI8_ZNM_JG4L;I>%9F9+VL:P';N/TGQ^CJ8/SGO7%9/7L'
MI3.HXG2<EV5?F9)O^TU,`#`=OK4V9+_Y_P#/]&VG?_.+E7N+W!]CG/(T:;'%
MQ$^&\_23<TX1_FY"?3^L-/G_`+OZ#H?#OA>?.;YB$\$!4QZ?YR/%+T1]7'Q>
MGYO;78Z6.-S=][CN;9)!8\G>]S2/Y2V^F?7/K?3V^D^P9U4$,9D$E[3XMO;^
MD?\`]<6&K-62RC$R<.[#999?!9<_2RHCZ,?R&_3]G]M0"4B`?E$!P\0'<\0X
MG?S<O@)E&4!FGFD,AQ2F.*H^WBR9,,,L_P!7CQP]<_8_[MW^G?6Z_/R[,+ZP
MNJ/2L^I]%K&--;*]XCW6RZ_9:W?2YWJ_R_T:Z/ZO8'0JLO(R\'+KSLI[6U-<
MUS'?9\1FF+T[%JJ]N-AT[?\`T(N_37^H]>:+M?\`%\W&JP,JZDUV9UUNUU((
M#VM:(J]3\[;_`#EB=BG(GA.NYUW<[XKR&#'B.>`]LQX8<$!^K,N\GM-[08D2
M(D3X\*#<K&?MV6L=N!+8<#(;H\M_J?GKG>J?5"[J/5K.I',-9<W&;Z#6GTG&
M@W^H_(JW?IOZ1^K>]GH_RU2Q?J+DTNZ9E&VC[5TG'KQZ:]I-5A9Z^ZV^QHIO
M]_KMM]*O^75D?:%.X+V-=M=M;;*G-LK>):]I!:1XM<U365]6>D/Z-TBO`L]/
MU&.>][J1MK<ZQ[K7/KIVL9CM=N_H]7Z&K_!K524I>>__`'P+T)>>_P#WP)*?
M_]'T+ZL_^)OI7_A+'_\`/3%IK,^K/_B;Z5_X2Q__`#TQ::2E))))*4LSK^-C
MYO2K\*][JV9+2P6-GVN'Z1CW;?\`!M<S](M-<A_C#PKW]-JZA7<YM&&[]8IW
M;6%K_8+N6_I&/]G_`%Q"1J)-7X,W*X_<SXX#(,1,APS(XN&?Z'_.>":26B8D
M::<:?N_R5:P,G%Q[+3EXHS*[:C6ULP6./^$9*K[1Z5=S7L>RR0-A#H(_-?M^
MBG;78]C[&B651O=X3]%5_;F)\/#Z@.*OF]-<7%_BO5RYCELN$SED`PRE[7'Q
M'!^L]SV.",I<$N*6?T,`"&@$R1W4_P!+?:!)?8Z&MG\`HI&/N38RZ$G@)!E$
M&N+A9<F(2N<8P]Z,91Q9)P]SVSD_Q9</'&'N0X_UO`IS7`EA]KAH?(KL?JKT
MFGK`QNH9%-5&+T]VRFFDPZV]NW=DY#F[7-:R&>G2[WO_`.)_G.6R>G9F-BX^
M7<P-HS!-+@X$G3=[F_U%T7U"S:Z^L7XE;G,IR:0]K'F9MK/N+?ZU;W*2`'%+
M4`6*A/\`G#Q7P=/T>%SOB&2<N6B<=Y,D8S,L^$?T?&<?ZKF(_P`YZ)9./+[<
M/UW![>1]`3K$Z_\`6`]-^R58@JNORLZC!?O?#:C<'6;[/WG^FS^9W+(;]?;+
M7BNFNGU[\JG'HQ"7NNJJ?<_"MR,UK1M]9KZG6?8J_P!+4S\]3O-/9)+GOJU]
M:+>M9W4<6RAE+<-\4N:^2]F^VC=M<UN]FZC^?K_0_P"!_G*5T*2E+SW_`.^!
M>A+SW_[X$E/_TO0OJS_XF^E?^$L?_P`],1LFKJ-MY]"YN/4QH+?:'E[OSM_[
MM;4'ZL_^)OI7_A+'_P#/3%=?E8]>17C/L#;[FN=76>7!FWU'#^KO:DHD#=(V
M=HW1NC6.)\E6=U'%9U!G3=TY;ZG7!G@QI#-SOW?I>U67-:YI:X2UP@@]P5F]
M-Z#TKI=EE^'2:[+!M=8]SGD,&OIM?:Y^VM.'#1XB;KT@=_ZRV7'<>$"K]5GI
M_5#IKB^LD=1Z_EU9H%V-TL4LQL1^M7J7,]>S.OJ^C?;M/V?&]7V4^G;_`(1=
MIV7'?6SJ7U9ISPY_5/L/6:F-K>*JG90=5/J?9NHX=+7[ZO=ZE>Y^/D5?SM%J
M4/F&G%X)EMO3DY_U?P<O])C1T[*B!;0T>D_^3E8G\W;_`,97LN7/Y6-EX-K*
M>H,&.ZPQ5<';L>T_\#>=NU__``%^RU=!TKZP8'47-QW?J><[1N/:89;_`"L&
M^SZ>_P#[BW_K5?\`PRTK&->RS'OK;94_VVT6MW-/\FRIZDG@A,[&,O#T$_W@
MS\I\2YCEQPQGQX_W)_K(Q/2>/]V4?\3^H\<['M:-6.!\""A7Y6-6U@L=72X#
MW$O$N_L_26EU7ZI/<T.Z78^VE@@=+ON<``!Q@Y+G?^R^7_VZN?KJJJ?96RKT
M;JC%U3V;+6'PNK?[V?U_YO\`X1/CR<,DB,<QCC(#BA(<<Y<!X^*/^%%EA\=S
M0C">?']XS8I2GCR1G+#CB,D98N&<(?SOH_SOZ:=N?AF9M<QK02U[F/\`3GG;
MZD;:MZ[3I/U.OLHP^K].ZFTVOBRM_I[0QKAMNV[76>K:WW5^_P!BX@%VKB?:
MW5Q/T0.^^?9M76_4;+Z]T;!HNRZ''ZMYMWZ&QY:U]`N?Z>+D5U_SWV/(L=7_
M`#K?H6UY5?Z/U/5;GY2'+>U*)XS9^8<7J^82X/YOA6_Z7YKG,>?'*0Q0,8^G
M'PP]'R9<?N3_`%TI9.+_`#O^=_0>]9TS`;CC$^SL?CSN++&A\OG=ZK_4W;[=
MWN]1%%&&R]SFUUMON(>]P:T/>6#:U[W?2?Z<[=R*Y[&"7N#1Q),"2JV7A.NM
MKOIN-%]0+0\`.!:[Z37,<H-=RU0`-!I71.RFACMS&-:Z-LM`!B=VW3\W<=RG
M(6+]9AU$=/J^QMML8VZLYK,;VWNH!_2-H^C]+\]M?O6O6X/8U\&'@$`@M(!_
M>:[W-3C&HB5[DC_%0)W(QHB@#?>TB\]_^^!>A+SW_P"^!-7/_]/T+ZM`'ZM]
M*!_[A8__`)Z8A]/^KV+A9KL\W9&7DEGI,LR;/4+&$[BRLD?]4B?5G_Q-]*_\
M)8__`)Z8M-$2D`0#7%I);*$9$$BS'6+2R;NI-L-6/0UP?'IWEWM;^_ZM?TO;
M^;M4L[#.6VFLN_1->'7-XWM`/MT_E*PVZM]CZVN!?7&\#M(ELH&=U#$P:V69
M-FP6/;56`"YSGO\`H5UL9+GN<@`2:&I22`+)H#NSLK=3B/KPVAKV,<*6"``Z
M#L_Z2\+Q/5=CM<_<;GESLASIWFXD_:/6GW>MO^GO7O2\[ZMB](Z[FV=0Q>D8
MSZG$L.9=??0<G82UUC<?IW^"W_0R\K])=_HO24F/G<7*7/*0(R]/%^EQ?U?W
MN);DY>>:HPNP;>)O=CM8ZO*=6UCOI,M($_V7'=_FK>^K_5^N/-5%6)E=:P"=
MK;&UO]6EO;TL^]M=%]/[M&4__B[UTO2\GIW2G`M^K%5!8(&1@.IR'_\`@XQ,
MYW_;=B?I'UWM;U/)IZW7=@X=]CGXMV76:12)VUU76G]!Z5C=NVSU/T=_Z/\`
MPJ,_BN#/0A[<B=!+BXI_]S_SEV+X?DB)DRK@'%PR]''^]P?O<+"C(HR18:'$
MNI(&12]IKNI)^BS+QK/TM#OY7\Q9_@;K55ZUB]*R:J1U)KSD.D8#L<$YSB`9
M;@,K_2WL;^?ZWZE_I?35IV3E_6G]<QL(8)JN=]@ZX\.8\8XV>FW'H#FW=1]?
MU+O4JR/2Z3_X:]-;&!TK#Z>ZVVD.LR<C^D9EQWY%O`VV7>W94W8W9C8_HXU?
M^#J4.3G8Q&@XI[BEWW:7$02*&AH\0>9Z+T/HN)E8]'UFZ+8+;7^GB]1R;/6H
MML<[]'5EX=5^1A]/R7[V5U4_I*+O\'8NL^M-GJ8=72J8=E]2NKKIK[AE;V79
M62X?Z'&I;[W_`.D]&KZ=U:H?65]+^D7]-+!=E=48['P<407V6F-ES&'_``6$
M[;E7Y/\`-XS*_44A@W?5:]_5'7V=3Q,AS6]0R,H-?ETM<[:V^K)J;7_DVASO
MTN!Z7ZNSU<FC_0V,Q9IY093WO?\`>_QDR@(&HNC]9</J74.GNZ?@UU.;ERR^
MVYQ`K9H=[*VM=ZC_`/J%IX]9IHKJ<\V&MC6FQW+BT;=[OZR5^17CTONM,,8)
M*CCY!R*O4]-]7@VP`'XP"Y3&1,1'2@2?K)C$0)&>MD`>&G9-(3K#R<#+N^M&
M+D9#7V].JH<<<-=#*\@'6R^O<-^^IWZ*SWK<2E$#AHWQ#BT_1_JJA(RXK%<)
MX?[W]92\]_\`O@7H2\]_^^!-7/\`_]3T+ZL_^)OI7_A+'_\`/3%IK,^K/_B;
MZ5_X2Q__`#TQ::2G,QG4NZQF5XUK@^D5NRZ"R6%UC7>DZNW][8SWJGU6O%ZQ
MG-Z;CY#Z>I=,+,L9#&>I72YW\W5DSM9ZE]?Z1N/O]7TOTOT/YRD<[);UOJ^#
MTTM/5,NZIC21O;CTUX])?GY31^9NN<S%I?\`TO(_X+UK*M_I/2L3I.(,7%#B
M"YUEUUAW6VVO]UV3DV_X6^YWT_\`MNO95^C1C(Q(,31"V41(&,A8+:+"^HLL
M,ES8<6Z<B';?I;5Y\VROH5=/2NKO&'=0#31;;+:<BMA_1WX^1K5N]-S/M%%K
MJ[:7_P`A>AGA>>Y?U3&9]8LS'9FW#!H;6[*L<2_)-EH<YF%5?=O;Z;*MMS\K
M])?_`#=7\Y^E53GN7AFQ@3)B(F^(&N&_3_A-SDY0C*1ED,/3I$0]SW#^[\T.
M!*_J%#K!CX8_:.8]I?7BXKFO.W_2Y&1/V?"Q_P#A\A__`!55RT,;H+K2+.LV
M,RMI)KP*I^Q,^CM<^NS])U*]FS^?S/T+/\!BU*_@=.P.F8HQ.GX[,7&!GTZQ
M$N@#?8\_I+[=K?YVUV]5^K==P.E.91:77YUT>A@4P;GR8:Y^XMKQJ/WK\ES&
M*A@Y7'C(]L&<_P!^73^['Y(?WF6>6>0T=ND(_P`O4Z+G$[K'G@%SGN,``?G.
M<?:UC5AW]>MS`:^B!CZY+7=5N:3C@M.UPP*!LMZG9]/]+^AP/^'L67U0=7SJ
M:<W,=AY.);JWHP=:VEK@?48ZW(:QW[4N:VMOJ_::F86._P#FZ$&GZR&S'^V9
M73LNJC<*S?5LOK#OS6;V.K?M_-;^B3^8CS&,?J\7N2.IGZ9\/EC^>?\`BIPX
MC,<1!$!+@]()]7[OI;W37=9Z5DWY=1QNKY&027WY>['RW`P?LM>77]IQ:\?<
MS]#C^EC8]:V>J]<P>I?57*MQ@7VY@=@5XCP!:,JS]!]CNJ&[;=6]V^S\ST?U
MC^8_2+G1]9?J_M+CF06\U&NP6G^2RDU[G/6?]6*79WUWIZD:W5W6V6W;"=:J
MFU^BQKMOL]:UC6?:/^VD[X?S'-2)CGB>$4(RE'VY<5_+\N/B79.1C,3EC]/M
MQE/)?R^@?+_?_JOI[,1CL)F)?^E#6-8XGN6@>[_.:K"IW]8Z5CML=?F4U"ES
MF6ESVC:]C/M%E;I/TV4.]7;_`*-`/UEZ`"]ISZ0ZNG[2]A<`X4QZGJNK^G]#
MWK4<UTTD.C(HR:&9&/8VVFUH?78PAS7-.K7-<WZ2(DI2\]_^^!>A+SW_`.^!
M)3__U?0OJS_XF^E?^$L?_P`],5+ZV==R^DC%KQR*1D^J79+JG7G=4SU*L#%H
M8ZFNSJ&>[V8K+\BFO]%?_.6^G6KOU9_\3?2O_"6/_P">F*O]:<_-QZ,3%Z=9
MZ>9G9+:P&@&TU5M?E9GV9MC;*_6]"AU;7VL])GJ)*<BKZRV8N>65=&:,KJ5K
MW;P[T[,IE#FX7KMK?4[;;7_/OQ;KOU7`9ZOJ^I^C3L^OF7E"I^/TQ^-0<AE=
MMV87,::K*SD4V8S:ZW/MMO8RSTV_F?H?5_I"%_SM^M-V&]]?36TV.HMR*+'5
MWN#PWTFLI93LKO;?BV7/^T>JS]991ZN)^C^A;K^L/UGLRK,9G3ZPRNPUV95H
MNKKK%0<_(?=['>I]KJ9]HPOL_P"BK]>JG(L]9)3I_5?J?4^H],+^JXXQLVEY
MJM#?HN(:RSU&#\S^<V/9^9:RQ9O7[KN@YS^M-J?E]/SA75GTU1ZM5M8+<?-I
MWQ78RRO]6OI=Z?\`@'L6QT+J63G]$Q^HY])P[KJS9=2]I8:X+N6O]^W:/I+G
M?K[U*]W3\?%QV.^QY$695T>W;_VGI=^YZS_?_83<@!@>+9L<GB]WF,>/I*6N
MO!IX']YR.K_77,R&.IZ54_I]42_*O#79)_>9C8[?5IQ__#%SK+/]'4L?*Z9?
M@TT9%KVO=U$>L7AY?<7#:_U,JYWOMM]^[?N^F@V6VW6^I81ZCH$C0::!*RDT
MVNK=&YNA(,B.=%"8<,9&`)QQ/")_+K_6B]!RF''AEAQDQQ<U/&<V;$3]XR2Q
MQ]$_:S5CX<>//DQ_)#]8F?GY=C"QSA[A#W-$.<#S[OS=WY^Q0;=EOH&$Q[WX
MX=Z@QVZC=^_M_P"DB=/MZ=5>Y_4:'Y-.PAE;#'O/YS]6_P#J-5@YS"7M<6$3
M!!U`\-P^E[4T58,B>$Z2X?GX?\)M3@:G##BA')`">*>6/]'.:5\/R?K?U?Z<
MH1;.#D8%5EC^HU69-?IEM3:W1M>?\(XDC\W_`#%Z!]7?JKB]*8,AMKGY=U89
M9:QP<T-)W[:'%C?:Z&_I-O\`F+A*^@=5MLQJ&U,;9FL-F.Q[VMW-:-[N?S]C
MO4V+LN@U=:Z%3:>KMG!EFTMM-QH#1M=9L</9C?O[/YC_`(I38(7Q70E&N`$>
MJ5_UO[KD?&^8`C`X<AE#*2,W#DB81QX_3C_5<7^<]R&3V8?H?K?D9]2^H?3N
MH9.;F/NLKRL\V!]H@[664-PO1%3OT6UNSUO4V?:/^&4K?J:Y]S\VO/LHZE97
MZ)RJV>UC/2KQ7.QZ+GV^CD;:O;E^K]J_265>KZ:O9/UJZ/C9&7C/L>ZW"](6
MMKK<\FS(&[$QJ-H_6,G(:?T==.]0R?K=TC%-XO-S'XK*7Y#/2>7,.1_1Z'-:
M/Y^R/H-4CB.CTO!;T_IV/@MV;<:MM8-;/3:=HC<*MUFS=_75I!P\O'SL2G,Q
M7^ICY#&V5/@B6N&YKMKH<C)*4O/?_O@7H2\]_P#O@24__];T+ZL_^)OI7_A+
M'_\`/3%HFNMSVV%H+V2&N(U`/TMKOY4+.^K/_B;Z5_X2Q_\`STQ::2EDH3I)
M*865,MK=6\2QX+7#R*Q>KX^+T[HF5D9-?V\TU%M5=C-^Z3MQZK&-_G&LL/\`
M.?X-;JR^H=?Z=T_.HP;G%V1<U]SFLB*<>L$W9^;8]S&8V$QS?3]6SZ=G\UO_
M`$B28$1E&1%B)$JOAOA/%\SY?C-Z8[I^0^^ZP9["&X]+=&F?SGR/Z_J?0V(#
M`TO;67;)(!<>!/<KMOK_`(6'9T_'ZQ0&FYUC&&]L0^E[7/;N</:_W;/3>N0'
M4;6]-/36UM--UOK;PP^I8X&/3J_-L]_M]BK$"$@#1$=?[_\`>>KY?//F.7EE
MQ<4999RB>(P/W7TQC*>$<'MY(X_Y_P!J?\Y-:C$OR<QN'C`6W6/+608&@W;]
MW[C6^]/]AS3=?0RAUEV*'.OK9[BUK2&/LC_",:Y[/H?F+>R_J5U7I_3Z.H8K
MWOS*V[\FBL@/K=]+]4+/I^DWV6U_X3_!JA]5<PU_63!R'/+Q>]]3["9+C:US
M1N=_QNQ(@<5$<'$=!^B(G8!6/F"<,IX\L.8&#%PFQP9<F?%\T_1\D<T8^GAB
MU<OI^3CY.-C4Y`S[7M#L7[*\O<P@[]E/YU>QWZ9B]"^K/5.J9F-Z'5L.[&RZ
M0)NL9M9<WCU&_FLN_P!-5_;K_P!'7#JE71.AY5?6OL;G]0O<,3'JQV^ZZZ[4
M-:R64LMVUV;\BST_T7J*YT7KN)UBNWTV68^5B/\`2S,.\;;J7\M%C)<UU=C?
M?3<S]':I88^$DW7@X?.?$!S&*$#`&419RD<$_<)XI\,8>C@_Z:#*^JG3LG*S
M,HOOKMS338\UO#?3NQQZ>-EXSMILINKK]GT_0?\`X2E#J^I'U>KQ3B>@ZREX
MI;8'O+M[:"755/G_``6]SK'U?S:WTE(YZ#!Q*\+#IQ*W/?70P5L=8[<_:W1N
MYY^DCI))*4O/?_O@7H2\]_\`O@24_P#_U_0OJS_XF^E?^$L?_P`],6FLSZL_
M^)OI7_A+'_\`/3%II*4DDDDI2XW+^IF4[*O#"W+Q;P[,S'Y3R;<W+87?L_`R
MMC-M72,/;5^B9_Q?HKLDDE/`=*Z;];,YN79=B4,]E.['ZFUWH79S'.?EYU6/
M5;D?96-K_5_U?]5R[/UNNK_`KH.F]<Z7U7ZKT?6*_'%.+34_*])[6V&DXQ>V
MYU.T>[TW4V>B]FS?_P`&C]<^K&%UJRNVV_)Q;6--3K,2XU&REVMF+?&YME%G
M^?\`RTNJ?5G#ZAT:OHE=^1T_!K:*]F&\,+J@UU/V>Q]C;=]+FN_2-_PO^$23
MQ':SIMJBO^MO3Z,D8[L?++K*G6XCVTG;DN%0R_LV$\G]+E>D[VM=LK]7]#ZG
MJ+FNH]1Z-]JLSV=+9@=3_3[;L\N977U'%%>4S$R65N9@M^VXK_M>-F_;/2R/
M^,72CZHX'[</6#8]Q-IR1C$5E@O-7V/UVW>G]J]M/\W1Z_HUW?IJT?!^K'2<
M3$.-<QW4"^UN1;?GN^TVOM8UM55S[+MWOJJK955LV;&($`[BTPR3A?!*4.(<
M,N`F'%']T\+S'U?Q>JY?7:_K!CTG(QNH-%]&==:0:\>XL=E].RJ!^DMR<%]/
MH=,]+]4V9%V1;999^C74=+Z-;B=1S^IY61]IRL]S6@M8*V5T5%_V;':UNYUC
MV^J_U;['>]:B=%:I))))2DDDDE*7GO\`]\"]"7GO_P!\"2G_T/0OJS_XF^E?
M^$L?_P`],6FN9^K_`-9_JUC]!Z;1?U;"JNJQ*&65OR*VN:YM;&O8]CGAS'L<
M/HN6A_SM^JO_`)<X'_L35_Z424U_K)]8<SIF1AX'3</[=U#-%ME=3GBM@KH#
M;+MUCO\`"6[VU5?F,_GK?YK])2Z]]=QTUE3<6JB_(%-N1DLLO#6--#JZ;NGT
MWTLO;?U)V1;]GKH;^?\`SJO977_J/F&LY?4.EY!H>+*?5NH?L>.+*_4<[99_
M+:L[J;_\7W5+L>S)ZMABK'L==]FKRJ64V6.=ZSKKZV.]]GJ_I-V_])_A?424
M]%B]3PLCTZQ?5]I?N:<=MC7/%E6W[53#3[GXKWM9?_H_SUQ'_.KK0Q^I7'--
M9'43T^N^P8SL;$ILR'8PZA9CUM9G,?B-KV?Y2NKQ;++ZG_I5T+.L?4:O./4&
M=3Z>,HL-0?\`::H:USS?;Z;/4V5NNN=ZE[V-WW?X5.WJ_P!0&W7WMS.DB[*:
M69-@LQPZUKOILO?NW6L?^=ZB2G!'UBZK?U+!Z;@YV9:UV=F8V62S`^U'[-5C
M6[*;`/V=]GJ=>ZRZS;]J_P`#L]BO]#Z[U;(^L?V7)R'?9KW]0%;+F4MK>W%R
M/LN.WI=F./M#[::V_KM>>[U/\+37Z7Z1:.-UKZAXC:V8F=TK'93N-3:K<=@8
M7_SOIACF[/4_PFU2;]8/J0U['MZCTQKZW/?6X74`M=;/KO8[?[7W;OTKO\(D
MIAT7ZSOZIUG.Z6ZFNG]G-/JVBT/]1WJ64L=BUM;[\>NNK]:L>_\`5\S]3]/]
M'ZJY*SZZ_6G]BLR73BV_L=V4W(L^SV-NN^T8>.W*972T^A^BOL_17-KK_2_I
M*OT&]=A3U_ZCT/:^CJ/3*GM:YC7,NH:0U[O6L8TM=]!]OZ5[?](HNZW]1'5"
MEV?TIU0K-`K-N.6^DZ-U&S=M]%VQGZ+Z"2GF.M?6CZPX>5C4X>:YC68C,FUV
M6,1X#GYS<)UG5K<(>E]@93^B_P`D?K%7\Y=^>N@Z+U+/R?K3U+&9U!F=TK':
M6;7BIME66'[[,7&]!K++<;&QK:J[[<CU/UC_``G\\BU=8^H%-'V>G-Z371L=
M5Z3+,=K/3>=]M6QKMOIV/]]E:>CK/U!Q\EV7CYO2J<FP%K[Z[<=MCFD[BUUK
M'![F[@DIY?`^O74<6G'S\W.9G,R*L^W+PBVIAQABOM9A65NH94]M>6]M&(UF
M8]_K76_H$5GUG^L#NGXV'9E7/ZE1FVX^:<;'JKR[:_LMO4L:VGI_5*L=E3/H
MU^^BNV_T/U;U'V+HJ^K_`%`J]8U9G2:_M#FV7[;,<>H]A]2NR[:[](]C_>Q[
MT4_6+ZE&[[0>I=--\@^J;Z-\@%K??OW>UKG)*<;I/5>M]0^L'2ZW]5!Q<SIC
M>HW48]=1J+VOKH=559?3]K91=OW6>H_UV6^I_-?S=7:+#I^L'U)H+#1U'IE1
MK:65EEU#=K"=[JV;7^UCG^_:C_\`.WZJ_P#ES@?^Q-7_`*424ZR\]_\`O@76
M?\[?JK_Y<X'_`+$U?^E%Q?[1Z;_W,H_Y8^U_3']&_P"YO_A7_AOH)*?_V?_M
M+&90:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(````X
M0DE-!"4``````!#-S_I]J,>^"05P=JZO!<-..$))300Z``````#M````$```
M``$```````MP<FEN=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN=&5E
M;G5M`````$EN=&4`````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L````
M``MP<FEN=&5R3F%M951%6%0````%`%``4P`M`#<```````]P<FEN=%!R;V]F
M4V5T=7!/8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O
M9E-E='5P`````0````!";'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O
M;V9#35E+`#A"24T$.P`````"+0```!`````!```````2<')I;G1/=71P=71/
M<'1I;VYS````%P````!#<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB
M;V]L``````!#<FY#8F]O;```````0VYT0V)O;VP``````$QB;'-B;V]L````
M``!.9W1V8F]O;```````16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG
M3V)J8P````$```````!21T)#`````P````!29"`@9&]U8D!OX```````````
M`$=R;B!D;W5B0&_@````````````0FP@(&1O=6)`;^````````````!"<F14
M56YT1B-2;'0```````````````!";&0@56YT1B-2;'0```````````````!2
M<VQT56YT1B-0>&Q`<L````````````IV96-T;W)$871A8F]O;`$`````4&=0
M<V5N=6T`````4&=0<P````!09U!#`````$QE9G15;G1&(U)L=```````````
M`````%1O<"!5;G1&(U)L=````````````````%-C;"!5;G1&(U!R8T!9````
M````````$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O
M;6QO;F<`````````#&-R;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T
M4FEG:'1L;VYG``````````MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``
M````$`$L`````0`"`2P````!``(X0DE-!"8```````X`````````````/X``
M`#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))30/S```````)
M```````````!`#A"24TG$```````"@`!``````````(X0DE-`_4``````$@`
M+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`,@````$`6@``
M``8```````$`-0````$`+0````8```````$X0DE-`_@``````'```/______
M______________________\#Z`````#_____________________________
M`^@`````_____________________________P/H`````/______________
M______________\#Z```.$))300(```````0`````0```D````)``````#A"
M24T$'@``````!``````X0DE-!!H``````T4````&``````````````"B````
MC`````@`9`!S`'``7P`P`#<`-0!B`````0`````````````````````````!
M``````````````",````H@`````````````````````!````````````````
M`````````!`````!````````;G5L;`````(````&8F]U;F1S3V)J8P````$`
M``````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO;F<`````
M`````$)T;VUL;VYG````H@````!29VAT;&]N9P```(P````&<VQI8V5S5FQ,
M<P````%/8FIC`````0``````!7-L:6-E````$@````=S;&EC94E$;&]N9P``
M```````'9W)O=7!)1&QO;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E
M3W)I9VEN````#6%U=&]'96YE<F%T960`````5'EP965N=6T````*15-L:6-E
M5'EP90````!);6<@````!F)O=6YD<T]B:F,````!````````4F-T,0````0`
M````5&]P(&QO;F<``````````$QE9G1L;VYG``````````!"=&]M;&]N9P``
M`*(`````4F=H=&QO;F<```",`````W5R;%1%6%0````!````````;G5L;%1%
M6%0````!````````37-G951%6%0````!```````&86QT5&%G5$585`````$`
M``````YC96QL5&5X=$ES2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$`
M``````EH;W)Z06QI9VYE;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A
M=6QT````"79E<G1!;&EG;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E
M9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E
M`````$YO;F4````)=&]P3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO
M;F<`````````#&)O='1O;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T
M;&]N9P``````.$))300H```````,`````C_P````````.$))3004```````$
M`````CA"24T$#``````C<`````$```"*````H````:```00````C5``8``'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`H`"*`P$B``(1
M`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[+ZO_5[H5_0>FW7=.QK+
M;<2A]ECZF.<YSJV/>][W-+GO>YWTW+0_YL_5W_RLQ/\`MEG_`)%+ZL_^)OI7
M_A+'_P#/3%II*<S_`)L_5W_RLQ/^V6?^12_YL_5W_P`K,3_MEG_D5II)*<S_
M`)L_5W_RLQ/^V6?^12_YL_5W_P`K,3_MEG_D5IJOEY^'A&D95S*3DV-HH#R`
M7VOTKJK_`'GN24U/^;/U=_\`*S$_[99_Y%`R^C_5#"8VS-P^GXU;W"MC[F55
MASW3MK:;`W=8[;]!9'U@^M?4#]JZ9T^JSIN98TMZ5FW>FX77L<_]4^S6;G8K
ML]E%S.E6YGI_;_\`M/\`S?Z6KC]`^L.0_$SL2TV.P",CI%G63ZSS3FUL'4,'
MJ#*V,S*LSI^13ZN-=ZS_`-';]D]7_1I3IN?_`(OFY&1C.Q\(6X;;77_JXVC[
M.UMN6QEWI>C?=BUV,=DT46674?X1B)BU?43+Z6[K%&+A'IS-V[)?0VM@V'99
M_/5L=],;5CX/0NEY^7U7#JZI3=;D.SFOILQA]HJORV?9LVS"NNMW?8FV>K:R
MO%K_`,)Z>3EWKH/K!T&W/Z#5TS#-9=C/QWMIO_F;FX[F6?9<H,:[]!=Z?YK4
M@0=C:Z4)1-2B8G>I"M#L@Z11]1NM,L?TW#P[_1+1:PXXK>W>-]3GT7U57-9:
MSW56;-EO^#6A_P`V?J[_`.5F)_VRS_R*YOJG6_K6[J6/C8^-5TW/LP_M%6&7
M5VNR[F6/;]A;F7LHQ;,?$J_6,VNG)QLZNO)]7&]17\3ZY,R.HL8&-=T_*M&)
MTXTAUMN3>UWZ]ET1M9^R<+_"9>S_``?J)+75_P";/U=_\K,3_MEG_D4O^;/U
M=_\`*S$_[99_Y%:2=)3F?\V?J[_Y68G_`&RS_P`BE_S9^KO_`)68G_;+/_(K
M3224Y@^K/U=!G]F8FG_`U_\`D5P_[-Z;_P!Q:_\`E?[%P?Z+_P!P?I?T3_@/
MH+TM>>__`'P)*?_0]"^K/_B;Z5_X2Q__`#TQ::S/JS_XF^E?^$L?_P`],6FD
MI22222E+G_K%TWJG[1PNN])J9F9?3V6U'`N<&"RN[;ZCL6]^YF)E_HV_I?\`
M"T_HK%T"8D`$G2-4E/*]"Z?B975<C/ZPW'=U^QS<A^%4[>W%8P>EA-NVG[/D
M=0QJW/9]O]/U?TOI8_ZNM_JG4L;I>%9F9+VL:P';N/TGQ^CJ8/SGO7%9/7L'
MI3.HXG2<EV5?F9)O^TU,`#`=OK4V9+_Y_P#/]&VG?_.+E7N+W!]CG/(T:;'%
MQ$^&\_23<TX1_FY"?3^L-/G_`+OZ#H?#OA>?.;YB$\$!4QZ?YR/%+T1]7'Q>
MGYO;78Z6.-S=][CN;9)!8\G>]S2/Y2V^F?7/K?3V^D^P9U4$,9D$E[3XMO;^
MD?\`]<6&K-62RC$R<.[#999?!9<_2RHCZ,?R&_3]G]M0"4B`?E$!P\0'<\0X
MG?S<O@)E&4!FGFD,AQ2F.*H^WBR9,,,L_P!7CQP]<_8_[MW^G?6Z_/R[,+ZP
MNJ/2L^I]%K&--;*]XCW6RZ_9:W?2YWJ_R_T:Z/ZO8'0JLO(R\'+KSLI[6U-<
MUS'?9\1FF+T[%JJ]N-AT[?\`T(N_37^H]>:+M?\`%\W&JP,JZDUV9UUNUU((
M#VM:(J]3\[;_`#EB=BG(GA.NYUW<[XKR&#'B.>`]LQX8<$!^K,N\GM-[08D2
M(D3X\*#<K&?MV6L=N!+8<#(;H\M_J?GKG>J?5"[J/5K.I',-9<W&;Z#6GTG&
M@W^H_(JW?IOZ1^K>]GH_RU2Q?J+DTNZ9E&VC[5TG'KQZ:]I-5A9Z^ZV^QHIO
M]_KMM]*O^75D?:%.X+V-=M=M;;*G-LK>):]I!:1XM<U365]6>D/Z-TBO`L]/
MU&.>][J1MK<ZQ[K7/KIVL9CM=N_H]7Z&K_!K524I>>__`'P+T)>>_P#WP)*?
M_]'T+ZL_^)OI7_A+'_\`/3%IK,^K/_B;Z5_X2Q__`#TQ::2E))))*4LSK^-C
MYO2K\*][JV9+2P6-GVN'Z1CW;?\`!M<S](M-<A_C#PKW]-JZA7<YM&&[]8IW
M;6%K_8+N6_I&/]G_`%Q"1J)-7X,W*X_<SXX#(,1,APS(XN&?Z'_.>":26B8D
M::<:?N_R5:P,G%Q[+3EXHS*[:C6ULP6./^$9*K[1Z5=S7L>RR0-A#H(_-?M^
MBG;78]C[&B651O=X3]%5_;F)\/#Z@.*OF]-<7%_BO5RYCELN$SED`PRE[7'Q
M'!^L]SV.",I<$N*6?T,`"&@$R1W4_P!+?:!)?8Z&MG\`HI&/N38RZ$G@)!E$
M&N+A9<F(2N<8P]Z,91Q9)P]SVSD_Q9</'&'N0X_UO`IS7`EA]KAH?(KL?JKT
MFGK`QNH9%-5&+T]VRFFDPZV]NW=DY#F[7-:R&>G2[WO_`.)_G.6R>G9F-BX^
M7<P-HS!-+@X$G3=[F_U%T7U"S:Z^L7XE;G,IR:0]K'F9MK/N+?ZU;W*2`'%+
M4`6*A/\`G#Q7P=/T>%SOB&2<N6B<=Y,D8S,L^$?T?&<?ZKF(_P`YZ)9./+[<
M/UW![>1]`3K$Z_\`6`]-^R58@JNORLZC!?O?#:C<'6;[/WG^FS^9W+(;]?;+
M7BNFNGU[\JG'HQ"7NNJJ?<_"MR,UK1M]9KZG6?8J_P!+4S\]3O-/9)+GOJU]
M:+>M9W4<6RAE+<-\4N:^2]F^VC=M<UN]FZC^?K_0_P"!_G*5T*2E+SW_`.^!
M>A+SW_[X$E/_TO0OJS_XF^E?^$L?_P`],1LFKJ-MY]"YN/4QH+?:'E[OSM_[
MM;4'ZL_^)OI7_A+'_P#/3%=?E8]>17C/L#;[FN=76>7!FWU'#^KO:DHD#=(V
M=HW1NC6.)\E6=U'%9U!G3=TY;ZG7!G@QI#-SOW?I>U67-:YI:X2UP@@]P5F]
M-Z#TKI=EE^'2:[+!M=8]SGD,&OIM?:Y^VM.'#1XB;KT@=_ZRV7'<>$"K]5GI
M_5#IKB^LD=1Z_EU9H%V-TL4LQL1^M7J7,]>S.OJ^C?;M/V?&]7V4^G;_`(1=
MIV7'?6SJ7U9ISPY_5/L/6:F-K>*JG90=5/J?9NHX=+7[ZO=ZE>Y^/D5?SM%J
M4/F&G%X)EMO3DY_U?P<O])C1T[*B!;0T>D_^3E8G\W;_`,97LN7/Y6-EX-K*
M>H,&.ZPQ5<';L>T_\#>=NU__``%^RU=!TKZP8'47-QW?J><[1N/:89;_`"L&
M^SZ>_P#[BW_K5?\`PRTK&->RS'OK;94_VVT6MW-/\FRIZDG@A,[&,O#T$_W@
MS\I\2YCEQPQGQX_W)_K(Q/2>/]V4?\3^H\<['M:-6.!\""A7Y6-6U@L=72X#
MW$O$N_L_26EU7ZI/<T.Z78^VE@@=+ON<``!Q@Y+G?^R^7_VZN?KJJJ?96RKT
M;JC%U3V;+6'PNK?[V?U_YO\`X1/CR<,DB,<QCC(#BA(<<Y<!X^*/^%%EA\=S
M0C">?']XS8I2GCR1G+#CB,D98N&<(?SOH_SOZ:=N?AF9M<QK02U[F/\`3GG;
MZD;:MZ[3I/U.OLHP^K].ZFTVOBRM_I[0QKAMNV[76>K:WW5^_P!BX@%VKB?:
MW5Q/T0.^^?9M76_4;+Z]T;!HNRZ''ZMYMWZ&QY:U]`N?Z>+D5U_SWV/(L=7_
M`#K?H6UY5?Z/U/5;GY2'+>U*)XS9^8<7J^82X/YOA6_Z7YKG,>?'*0Q0,8^G
M'PP]'R9<?N3_`%TI9.+_`#O^=_0>]9TS`;CC$^SL?CSN++&A\OG=ZK_4W;[=
MWN]1%%&&R]SFUUMON(>]P:T/>6#:U[W?2?Z<[=R*Y[&"7N#1Q),"2JV7A.NM
MKOIN-%]0+0\`.!:[Z37,<H-=RU0`-!I71.RFACMS&-:Z-LM`!B=VW3\W<=RG
M(6+]9AU$=/J^QMML8VZLYK,;VWNH!_2-H^C]+\]M?O6O6X/8U\&'@$`@M(!_
M>:[W-3C&HB5[DC_%0)W(QHB@#?>TB\]_^^!>A+SW_P"^!-7/_]/T+ZM`'ZM]
M*!_[A8__`)Z8A]/^KV+A9KL\W9&7DEGI,LR;/4+&$[BRLD?]4B?5G_Q-]*_\
M)8__`)Z8M-$2D`0#7%I);*$9$$BS'6+2R;NI-L-6/0UP?'IWEWM;^_ZM?TO;
M^;M4L[#.6VFLN_1->'7-XWM`/MT_E*PVZM]CZVN!?7&\#M(ELH&=U#$P:V69
M-FP6/;56`"YSGO\`H5UL9+GN<@`2:&I22`+)H#NSLK=3B/KPVAKV,<*6"``Z
M#L_Z2\+Q/5=CM<_<;GESLASIWFXD_:/6GW>MO^GO7O2\[ZMB](Z[FV=0Q>D8
MSZG$L.9=??0<G82UUC<?IW^"W_0R\K])=_HO24F/G<7*7/*0(R]/%^EQ?U?W
MN);DY>>:HPNP;>)O=CM8ZO*=6UCOI,M($_V7'=_FK>^K_5^N/-5%6)E=:P"=
MK;&UO]6EO;TL^]M=%]/[M&4__B[UTO2\GIW2G`M^K%5!8(&1@.IR'_\`@XQ,
MYW_;=B?I'UWM;U/)IZW7=@X=]CGXMV76:12)VUU76G]!Z5C=NVSU/T=_Z/\`
MPJ,_BN#/0A[<B=!+BXI_]S_SEV+X?DB)DRK@'%PR]''^]P?O<+"C(HR18:'$
MNI(&12]IKNI)^BS+QK/TM#OY7\Q9_@;K55ZUB]*R:J1U)KSD.D8#L<$YSB`9
M;@,K_2WL;^?ZWZE_I?35IV3E_6G]<QL(8)JN=]@ZX\.8\8XV>FW'H#FW=1]?
MU+O4JR/2Z3_X:]-;&!TK#Z>ZVVD.LR<C^D9EQWY%O`VV7>W94W8W9C8_HXU?
M^#J4.3G8Q&@XI[BEWW:7$02*&AH\0>9Z+T/HN)E8]'UFZ+8+;7^GB]1R;/6H
MML<[]'5EX=5^1A]/R7[V5U4_I*+O\'8NL^M-GJ8=72J8=E]2NKKIK[AE;V79
M62X?Z'&I;[W_`.D]&KZ=U:H?65]+^D7]-+!=E=48['P<407V6F-ES&'_``6$
M[;E7Y/\`-XS*_44A@W?5:]_5'7V=3Q,AS6]0R,H-?ETM<[:V^K)J;7_DVASO
MTN!Z7ZNSU<FC_0V,Q9IY093WO?\`>_QDR@(&HNC]9</J74.GNZ?@UU.;ERR^
MVYQ`K9H=[*VM=ZC_`/J%IX]9IHKJ<\V&MC6FQW+BT;=[OZR5^17CTONM,,8)
M*CCY!R*O4]-]7@VP`'XP"Y3&1,1'2@2?K)C$0)&>MD`>&G9-(3K#R<#+N^M&
M+D9#7V].JH<<<-=#*\@'6R^O<-^^IWZ*SWK<2E$#AHWQ#BT_1_JJA(RXK%<)
MX?[W]92\]_\`O@7H2\]_^^!-7/\`_]3T+ZL_^)OI7_A+'_\`/3%IK,^K/_B;
MZ5_X2Q__`#TQ::2G,QG4NZQF5XUK@^D5NRZ"R6%UC7>DZNW][8SWJGU6O%ZQ
MG-Z;CY#Z>I=,+,L9#&>I72YW\W5DSM9ZE]?Z1N/O]7TOTOT/YRD<[);UOJ^#
MTTM/5,NZIC21O;CTUX])?GY31^9NN<S%I?\`TO(_X+UK*M_I/2L3I.(,7%#B
M"YUEUUAW6VVO]UV3DV_X6^YWT_\`MNO95^C1C(Q(,31"V41(&,A8+:+"^HLL
M,ES8<6Z<B';?I;5Y\VROH5=/2NKO&'=0#31;;+:<BMA_1WX^1K5N]-S/M%%K
MJ[:7_P`A>AGA>>Y?U3&9]8LS'9FW#!H;6[*L<2_)-EH<YF%5?=O;Z;*MMS\K
M])?_`#=7\Y^E53GN7AFQ@3)B(F^(&N&_3_A-SDY0C*1ED,/3I$0]SW#^[\T.
M!*_J%#K!CX8_:.8]I?7BXKFO.W_2Y&1/V?"Q_P#A\A__`!55RT,;H+K2+.LV
M,RMI)KP*I^Q,^CM<^NS])U*]FS^?S/T+/\!BU*_@=.P.F8HQ.GX[,7&!GTZQ
M$N@#?8\_I+[=K?YVUV]5^K==P.E.91:77YUT>A@4P;GR8:Y^XMKQJ/WK\ES&
M*A@Y7'C(]L&<_P!^73^['Y(?WF6>6>0T=ND(_P`O4Z+G$[K'G@%SGN,``?G.
M<?:UC5AW]>MS`:^B!CZY+7=5N:3C@M.UPP*!LMZG9]/]+^AP/^'L67U0=7SJ
M:<W,=AY.);JWHP=:VEK@?48ZW(:QW[4N:VMOJ_::F86._P#FZ$&GZR&S'^V9
M73LNJC<*S?5LOK#OS6;V.K?M_-;^B3^8CS&,?J\7N2.IGZ9\/EC^>?\`BIPX
MC,<1!$!+@]()]7[OI;W37=9Z5DWY=1QNKY&027WY>['RW`P?LM>77]IQ:\?<
MS]#C^EC8]:V>J]<P>I?57*MQ@7VY@=@5XCP!:,JS]!]CNJ&[;=6]V^S\ST?U
MC^8_2+G1]9?J_M+CF06\U&NP6G^2RDU[G/6?]6*79WUWIZD:W5W6V6W;"=:J
MFU^BQKMOL]:UC6?:/^VD[X?S'-2)CGB>$4(RE'VY<5_+\N/B79.1C,3EC]/M
MQE/)?R^@?+_?_JOI[,1CL)F)?^E#6-8XGN6@>[_.:K"IW]8Z5CML=?F4U"ES
MF6ESVC:]C/M%E;I/TV4.]7;_`*-`/UEZ`"]ISZ0ZNG[2]A<`X4QZGJNK^G]#
MWK4<UTTD.C(HR:&9&/8VVFUH?78PAS7-.K7-<WZ2(DI2\]_^^!>A+SW_`.^!
M)3__U?0OJS_XF^E?^$L?_P`],5+ZV==R^DC%KQR*1D^J79+JG7G=4SU*L#%H
M8ZFNSJ&>[V8K+\BFO]%?_.6^G6KOU9_\3?2O_"6/_P">F*O]:<_-QZ,3%Z=9
MZ>9G9+:P&@&TU5M?E9GV9MC;*_6]"AU;7VL])GJ)*<BKZRV8N>65=&:,KJ5K
MW;P[T[,IE#FX7KMK?4[;;7_/OQ;KOU7`9ZOJ^I^C3L^OF7E"I^/TQ^-0<AE=
MMV87,::K*SD4V8S:ZW/MMO8RSTV_F?H?5_I"%_SM^M-V&]]?36TV.HMR*+'5
MWN#PWTFLI93LKO;?BV7/^T>JS]991ZN)^C^A;K^L/UGLRK,9G3ZPRNPUV95H
MNKKK%0<_(?=['>I]KJ9]HPOL_P"BK]>JG(L]9)3I_5?J?4^H],+^JXXQLVEY
MJM#?HN(:RSU&#\S^<V/9^9:RQ9O7[KN@YS^M-J?E]/SA75GTU1ZM5M8+<?-I
MWQ78RRO]6OI=Z?\`@'L6QT+J63G]$Q^HY])P[KJS9=2]I8:X+N6O]^W:/I+G
M?K[U*]W3\?%QV.^QY$695T>W;_VGI=^YZS_?_83<@!@>+9L<GB]WF,>/I*6N
MO!IX']YR.K_77,R&.IZ54_I]42_*O#79)_>9C8[?5IQ__#%SK+/]'4L?*Z9?
M@TT9%KVO=U$>L7AY?<7#:_U,JYWOMM]^[?N^F@V6VW6^I81ZCH$C0::!*RDT
MVNK=&YNA(,B.=%"8<,9&`)QQ/")_+K_6B]!RF''AEAQDQQ<U/&<V;$3]XR2Q
MQ]$_:S5CX<>//DQ_)#]8F?GY=C"QSA[A#W-$.<#S[OS=WY^Q0;=EOH&$Q[WX
MX=Z@QVZC=^_M_P"DB=/MZ=5>Y_4:'Y-.PAE;#'O/YS]6_P#J-5@YS"7M<6$3
M!!U`\-P^E[4T58,B>$Z2X?GX?\)M3@:G##BA')`">*>6/]'.:5\/R?K?U?Z<
MH1;.#D8%5EC^HU69-?IEM3:W1M>?\(XDC\W_`#%Z!]7?JKB]*8,AMKGY=U89
M9:QP<T-)W[:'%C?:Z&_I-O\`F+A*^@=5MLQJ&U,;9FL-F.Q[VMW-:-[N?S]C
MO4V+LN@U=:Z%3:>KMG!EFTMM-QH#1M=9L</9C?O[/YC_`(I38(7Q70E&N`$>
MJ5_UO[KD?&^8`C`X<AE#*2,W#DB81QX_3C_5<7^<]R&3V8?H?K?D9]2^H?3N
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M'_\`/3%HFNMSVV%H+V2&N(U`/TMKOY4+.^K/_B;Z5_X2Q_\`STQ::2EDH3I)
M*865,MK=6\2QX+7#R*Q>KX^+T[HF5D9-?V\TU%M5=C-^Z3MQZK&-_G&LL/\`
M.?X-;JR^H=?Z=T_.HP;G%V1<U]SFLB*<>L$W9^;8]S&8V$QS?3]6SZ=G\UO_
M`$B28$1E&1%B)$JOAOA/%\SY?C-Z8[I^0^^ZP9["&X]+=&F?SGR/Z_J?0V(#
M`TO;67;)(!<>!/<KMOK_`(6'9T_'ZQ0&FYUC&&]L0^E[7/;N</:_W;/3>N0'
M4;6]-/36UM--UOK;PP^I8X&/3J_-L]_M]BK$"$@#1$=?[_\`>>KY?//F.7EE
MQ<4999RB>(P/W7TQC*>$<'MY(X_Y_P!J?\Y-:C$OR<QN'C`6W6/+608&@W;]
MW[C6^]/]AS3=?0RAUEV*'.OK9[BUK2&/LC_",:Y[/H?F+>R_J5U7I_3Z.H8K
MWOS*V[\FBL@/K=]+]4+/I^DWV6U_X3_!JA]5<PU_63!R'/+Q>]]3["9+C:US
M1N=_QNQ(@<5$<'$=!^B(G8!6/F"<,IX\L.8&#%PFQP9<F?%\T_1\D<T8^GAB
MU<OI^3CY.-C4Y`S[7M#L7[*\O<P@[]E/YU>QWZ9B]"^K/5.J9F-Z'5L.[&RZ
M0)NL9M9<WCU&_FLN_P!-5_;K_P!'7#JE71.AY5?6OL;G]0O<,3'JQV^ZZZ[4
M-:R64LMVUV;\BST_T7J*YT7KN)UBNWTV68^5B/\`2S,.\;;J7\M%C)<UU=C?
M?3<S]':I88^$DW7@X?.?$!S&*$#`&419RD<$_<)XI\,8>C@_Z:#*^JG3LG*S
M,HOOKMS338\UO#?3NQQZ>-EXSMILINKK]GT_0?\`X2E#J^I'U>KQ3B>@ZREX
MI;8'O+M[:"755/G_``6]SK'U?S:WTE(YZ#!Q*\+#IQ*W/?70P5L=8[<_:W1N
MYY^DCI))*4O/?_O@7H2\]_\`O@24_P#_U_0OJS_XF^E?^$L?_P`],6FLSZL_
M^)OI7_A+'_\`/3%II*4DDDDI2XW+^IF4[*O#"W+Q;P[,S'Y3R;<W+87?L_`R
MMC-M72,/;5^B9_Q?HKLDDE/`=*Z;];,YN79=B4,]E.['ZFUWH79S'.?EYU6/
M5;D?96-K_5_U?]5R[/UNNK_`KH.F]<Z7U7ZKT?6*_'%.+34_*])[6V&DXQ>V
MYU.T>[TW4V>B]FS?_P`&C]<^K&%UJRNVV_)Q;6--3K,2XU&REVMF+?&YME%G
M^?\`RTNJ?5G#ZAT:OHE=^1T_!K:*]F&\,+J@UU/V>Q]C;=]+FN_2-_PO^$23
MQ':SIMJBO^MO3Z,D8[L?++K*G6XCVTG;DN%0R_LV$\G]+E>D[VM=LK]7]#ZG
MJ+FNH]1Z-]JLSV=+9@=3_3[;L\N977U'%%>4S$R65N9@M^VXK_M>-F_;/2R/
M^,72CZHX'[</6#8]Q-IR1C$5E@O-7V/UVW>G]J]M/\W1Z_HUW?IJT?!^K'2<
M3$.-<QW4"^UN1;?GN^TVOM8UM55S[+MWOJJK955LV;&($`[BTPR3A?!*4.(<
M,N`F'%']T\+S'U?Q>JY?7:_K!CTG(QNH-%]&==:0:\>XL=E].RJ!^DMR<%]/
MH=,]+]4V9%V1;999^C74=+Z-;B=1S^IY61]IRL]S6@M8*V5T5%_V;':UNYUC
MV^J_U;['>]:B=%:I))))2DDDDE*7GO\`]\"]"7GO_P!\"2G_T/0OJS_XF^E?
M^$L?_P`],6FN9^K_`-9_JUC]!Z;1?U;"JNJQ*&65OR*VN:YM;&O8]CGAS'L<
M/HN6A_SM^JO_`)<X'_L35_Z424U_K)]8<SIF1AX'3</[=U#-%ME=3GBM@KH#
M;+MUCO\`"6[VU5?F,_GK?YK])2Z]]=QTUE3<6JB_(%-N1DLLO#6--#JZ;NGT
MWTLO;?U)V1;]GKH;^?\`SJO977_J/F&LY?4.EY!H>+*?5NH?L>.+*_4<[99_
M+:L[J;_\7W5+L>S)ZMABK'L==]FKRJ64V6.=ZSKKZV.]]GJ_I-V_])_A?424
M]%B]3PLCTZQ?5]I?N:<=MC7/%E6W[53#3[GXKWM9?_H_SUQ'_.KK0Q^I7'--
M9'43T^N^P8SL;$ILR'8PZA9CUM9G,?B-KV?Y2NKQ;++ZG_I5T+.L?4:O./4&
M=3Z>,HL-0?\`::H:USS?;Z;/4V5NNN=ZE[V-WW?X5.WJ_P!0&W7WMS.DB[*:
M69-@LQPZUKOILO?NW6L?^=ZB2G!'UBZK?U+!Z;@YV9:UV=F8V62S`^U'[-5C
M6[*;`/V=]GJ=>ZRZS;]J_P`#L]BO]#Z[U;(^L?V7)R'?9KW]0%;+F4MK>W%R
M/LN.WI=F./M#[::V_KM>>[U/\+37Z7Z1:.-UKZAXC:V8F=TK'93N-3:K<=@8
M7_SOIACF[/4_PFU2;]8/J0U['MZCTQKZW/?6X74`M=;/KO8[?[7W;OTKO\(D
MIAT7ZSOZIUG.Z6ZFNG]G-/JVBT/]1WJ64L=BUM;[\>NNK]:L>_\`5\S]3]/]
M'ZJY*SZZ_6G]BLR73BV_L=V4W(L^SV-NN^T8>.W*972T^A^BOL_17-KK_2_I
M*OT&]=A3U_ZCT/:^CJ/3*GM:YC7,NH:0U[O6L8TM=]!]OZ5[?](HNZW]1'5"
MEV?TIU0K-`K-N.6^DZ-U&S=M]%VQGZ+Z"2GF.M?6CZPX>5C4X>:YC68C,FUV
M6,1X#GYS<)UG5K<(>E]@93^B_P`D?K%7\Y=^>N@Z+U+/R?K3U+&9U!F=TK':
M6;7BIME66'[[,7&]!K++<;&QK:J[[<CU/UC_``G\\BU=8^H%-'V>G-Z371L=
M5Z3+,=K/3>=]M6QKMOIV/]]E:>CK/U!Q\EV7CYO2J<FP%K[Z[<=MCFD[BUUK
M'![F[@DIY?`^O74<6G'S\W.9G,R*L^W+PBVIAQABOM9A65NH94]M>6]M&(UF
M8]_K76_H$5GUG^L#NGXV'9E7/ZE1FVX^:<;'JKR[:_LMO4L:VGI_5*L=E3/H
MU^^BNV_T/U;U'V+HJ^K_`%`J]8U9G2:_M#FV7[;,<>H]A]2NR[:[](]C_>Q[
MT4_6+ZE&[[0>I=--\@^J;Z-\@%K??OW>UKG)*<;I/5>M]0^L'2ZW]5!Q<SIC
M>HW48]=1J+VOKH=559?3]K91=OW6>H_UV6^I_-?S=7:+#I^L'U)H+#1U'IE1
MK:65EEU#=K"=[JV;7^UCG^_:C_\`.WZJ_P#ES@?^Q-7_`*424ZR\]_\`O@76
M?\[?JK_Y<X'_`+$U?^E%Q?[1Z;_W,H_Y8^U_3']&_P"YO_A7_AOH)*?_V3A"
M24T$(0``````50````$!````#P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H
M`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'``(`!#`%,`
M-@````$`.$))300&```````'``@````!`0#_X0^S:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-
M<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M971A('AM;&YS.G@](F%D
M;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835`@0V]R92`U+C,M8S`Q
M,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@("`@("`@("(^(#QR
M9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R
M,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+R(@
M>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(B!X;6QN
M<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+VUM+R(@>&UL
M;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]2
M97-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B('AM;&YS.F1C/2)H='1P
M.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&AO=&]S:&]P
M/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X;7`Z0W)E
M871E1&%T93TB,C`Q,RTP-RTS,%0Q-3HP.3HP,R(@>&UP.D-R96%T;W)4;V]L
M/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X;7`Z36]D:69Y1&%T
M93TB,C`Q,RTP-RTS,%0Q-3HQ,SHT,"LP-3HS,"(@>&UP.DUE=&%D871A1&%T
M93TB,C`Q,RTP-RTS,%0Q-3HQ,SHT,"LP-3HS,"(@<&1F.E!R;V1U8V5R/2)-
M:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X;7!-33I);G-T86YC94E$
M/2)X;7`N:6ED.C9&0T5#,D(T141&.$4R,3%!-CE#04)#,#@T,T$U0T4Q(B!X
M;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C9%0T5#,D(T141&.$4R,3%!-CE#
M04)#,#@T,T$U0T4Q(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240](GAM<"YD
M:60Z-D5#14,R0C1%1$8X13(Q,4$V.4-!0D,P.#0S035#13$B(&1C.F9O<FUA
M=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@<&AO=&]S
M:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX@/'AM<$U-.DAI
M<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO;CTB<V%V960B
M('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-D5#14,R0C1%1$8X13(Q,4$V
M.4-!0D,P.#0S035#13$B('-T179T.G=H96X](C(P,3,M,#<M,S!4,34Z,3,Z
M-#`K,#4Z,S`B('-T179T.G-O9G1W87)E06=E;G0](D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D/2(O(B\^(#QR9&8Z;&D@
M<W1%=G0Z86-T:6]N/2)D97)I=F5D(B!S=$5V=#IP87)A;65T97)S/2)C;VYV
M97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O
M(&EM86=E+VIP96<B+SX@/')D9CIL:2!S=$5V=#IA8W1I;VX](G-A=F5D(B!S
M=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C9&0T5#,D(T141&.$4R,3%!-CE#
M04)#,#@T,T$U0T4Q(B!S=$5V=#IW:&5N/2(R,#$S+3`W+3,P5#$U.C$S.C0P
M*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!9&]B92!0:&]T;W-H;W`@
M0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB+R(O/B`\+W)D9CI397$^
M(#PO>&UP34TZ2&ES=&]R>3X@/'AM<$U-.D1E<FEV961&<F]M('-T4F5F.FEN
M<W1A;F-E240](GAM<"YI:60Z-D5#14,R0C1%1$8X13(Q,4$V.4-!0D,P.#0S
M035#13$B('-T4F5F.F1O8W5M96YT240](GAM<"YD:60Z-D5#14,R0C1%1$8X
M13(Q,4$V.4-!0D,P.#0S035#13$B('-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#TB>&UP+F1I9#HV14-%0S)"-$5$1CA%,C$Q038Y0T%"0S`X-#-!-4-%,2(O
M/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T83X@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD/2)W(C\^_^(,
M6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)
M``8`,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`
M````TRU(4"`@````````````````````````````````````````````````
M```````````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?``
M```48FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@``
M`D`````49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE
M=P```]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,
M<E120P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#
M;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E
M<V,`````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)
M14,V,3DV-BTR+C$`````````````````````````````````````````````
M`````````````````````%A96B````````#S40`!`````1;,6%E:(```````
M``````````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``
MMX4``!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T
M<#HO+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N
M8V@`````````````````````````````````````````````````````````
M````9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO
M=7(@<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A
M=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````
M`````&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I
M;B!)14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#
M;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````
M``````!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@
M``````!,"58`4````%<?YVUE87,``````````0``````````````````````
M``*/`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>
M`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`
MD`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!
M`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!
MF@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4
M`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#
M0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15
M!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%
MI@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9
M!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(
MT@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN
M"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,
MV0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E
M#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1
MR1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+
M%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7
MKA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL
M&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>
ME!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5
M(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<F
MAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/
M*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHO
MD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E
M-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\Y
MO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A
M/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%
M$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,
M2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1
MFU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O
M6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?
M85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:2
M9NAG/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N
M:V[$;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^
M=IMV^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^
MPG\C?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[
MAY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0
M;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0
MF?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C
M=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$
MK;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBW
MX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?
MPMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-
MM<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CH
MV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D
M_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E
M\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]
MNOY+_MS_;?___^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#
M`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`H@",`P$1``(1`0,1`?_=
M``0`$O_$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!
M````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042
M!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"
M\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA9
M6F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4
MU=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%
M,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F
M-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E
M]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FI
MN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`V;O@;\!OA5O?X3_$
MS=V[_BWTAN7=.Y?COU+GMQ;BSFP,)E<WGL[FMFXK)Y?,9G*5U//793*9+(54
MDTU1/))-([DLQ]^Z]T;'_AMSX#_]X@?'S_T66VO_`*C]^Z]U[_AMSX#_`/>(
M'Q\_]%EMK_ZC]^Z]U[_AMSX#_P#>('Q\_P#19;:_^H_?NO=>_P"&W/@/_P!X
M@?'S_P!%EMK_`.H_?NO=>_X;<^`__>('Q\_]%EMK_P"H_?NO=>_X;<^`_P#W
MB!\?/_19;:_^H_?NO=('LSX8?RO.EMF9GLGN'H+XA=4]<;:ABJ-R]@=DX#KO
M8NR]O0U%3#14LN:W-N=\9A<;%4UE1'$C33QAI751=F`]^Z]T7W(;6_DC8OOS
M:_QBK>M_B2O=>\SMN#;>U:;K2AK\36Y7>FULGOG8VUZGL"@VY4];XC?6_=DX
M:IS.!V_69>#-9K%1?=T5-/`0Y]U[J;\;MB?R6?E]M;L'?/QNZE^+/:.RNJL[
M/MOL#=M!U,F!VWMO,T>._BV0I*G-;KVO@L?5QXS'7EJIZ:2>"ETLLKHX*^_=
M>Z1?Q<J?Y$GS3WEN[KWXP["^*?:V\ME8>?<N4P>/Z=JMOSY;:%+N"3:E3OS8
MM1N_9VWZ+LSKN#<\?\/?<&W)<IADJVCB-3KEC#>Z]T>?_AMWX#_]X@?'R_\`
M3_1EMK_ZC]^Z]U[_`(;<^`__`'B!\?/_`$66VO\`ZC]^Z]U[_AMSX#_]X@?'
MS_T66VO_`*C]^Z]U[_AMSX#_`/>('Q\_]%EMK_ZC]^Z]U[_AMSX#_P#>('Q\
M_P#19;:_^H_?NO=>_P"&W/@/_P!X@?'S_P!%CMK_`.HO?NO=5@_[)A\2/^'8
M_P#1'_LN74?^C+_9:?[^_P"C_P#N;B_[E_WUU_W8_O=_=K1_!O[S?W>_R/[W
M[?S^'^UJ]7OW7NO_T-R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>
M]^Z]U[W[KW09]L=R]4]%;6AWOW)V)LSK#9\^>P.UH=R[YW'B]LXB?<NZLG3X
M7;.WJ2KRM33I79S<&7JHZ>CI(=<]1*UD4V/OW7NJ?OFS_->FZQ[1W;\5-E[7
MWCT/GMZT6\NF^H/G;VQAMI+\>=H?+6/;>W:[8>#W1L#<.1'8F4Z0KMV[TPNV
M:WL5L/\`W,AW5DDQ,=5-/'4R4WNO=5A]/?#3^8U\NNF^G,_D]Y[Z[`P-'N[I
MWY^;6Q?\S+)3;HAZ@_F,]([E["Z'^5'PM[.ZY3;=+OZH^(_9./W#6[EZ]R6#
MQYHMIU6'BFQ],(:V!I?=>Z,+U#\1^FJW^9)N7=G8/S!^-51\M*G=O1';'R/^
M/=;\>9LGM_#_`",ZUZ@.Q]M[I^$.Z>S>R8*/KFABV)F,52O--BMT[KHZG&--
M3U>-2LDI8DAW7:%NVL3.JW`I12:?['Y#J2[OV=]T++V^V[W3;DBZ;D"\9XUW
M,(7C#*Q4J=-=&0W<]%]*G`LCJ?Y:%5M'^4!NK^5MU1W'78S)UGQ?[!Z!VWW/
ME\(F*FK<MO:AS[9#.[FP>#J:DT^,W)D,[/#E8Z:6:=J2JF*%Y#RKZC3JL7Y#
M?)C^8)\7NG?@CTE#\9.EO@-N>.KW#\?:GN_;>]NHNY]K1=>=+]<;*DV9TY\>
M-X]E;4VQU'UCV!\J-R8V.DV7MOL:IP]+DH\"^/\`O8<M)22Q>Z]T/.R_YS&^
M]G)L:D^2G7FQ=F4/0/4.U8OYE.^MMS[BW+'M?YI]K8&FBZ6^!7Q0VAM6?<]5
MW/\`*W.92HBRN[MO8V?+8S:&.G2CFR3UK77W7NMA'$9$9;&8[)K1Y#'KD:"B
MR"T.5I)*#)4:UM/'4K29&AF`FHLA3+)HGA<:HI`5/(]^Z]TX^_=>Z][]U[KW
MOW7NO>_=>ZI__P"ZU/\`Y9W_`/+![]U[K__1W)_Y<G_9`GPQ_P#%8ND__??X
M/W[KW1T??NO=>]^Z]U[W[KW7O?NO=50_S//C/\A>T,U\/_E#\7-N;&[>[B^"
MO=.X^X\/\8^U\[!MCKSY`X3=_7N:ZZW+A:#==?1Y'#;"[IVIC,RU?L?<=?3R
MT>'RID,P$<SGW[KW13^G^@L/\R_F)DOD3_,EZQV#TWWY_=O9V!^/7P`3O+&=
MFYO%=!]1UM5OK#[J^76%V%ECU3W7F4[PSM;O':F-K*&OQVS)1231U-1D0STY
MN-BWMMGEY@CV:0;-%($-[I;2KG\.K"5K047B2:TH*AN7FOEV+F&WY3;?8OZU
MRQ&1;(.I<H`2&H*L`5!;NTX`-".%ZN_-^;-ZQVEG.P.Q=R8+9VRML8Z?+;EW
M5N/(4V)PN)QM.@,M55UE4RH"Y81Q1K>261E1`S,`265K6!3=3RA0B\2?]7^7
MY=##9MCWSF3==IY=V#:);_>KZ58TBC4LS,QH%50,G]@`JS$`$]?.=[D[2H.Z
MN_.]>YMTXILHW9_9&^-Y8+3++2RXJ/(9BH7:-532`I4TS4&#IJ-DTLLL94`$
M6(]@_P!L^=/:_;N8_<3=/<[E1]QV[<-C?]W+DG;MS4D*QR/C`!J:\>'7>CWZ
M^[U]Z3>O9;[JOM9]T_WN@Y0YBY3W2P_K.\@0I>6%O2:6Q*NKHS>(SEA2LG`M
M3HY_Q5_FX_,GXLOC<%5;U_T\=84B1TG^CWN&OK<KD:"E5"D<6T^Q@9]V8=X4
MXCAJFR-)86\*_B/MIYTWS:8HUNP)%]&)_D>(X_['0\][?N+>Q/N[+=;IMVQK
MRKO[N7;<MO'^+ECEC)MF":M4LT91S_'3HWNPOY\7?^Z?D3UI5]R;6ZHVS\8Z
MS=-)ANR-A[?VW59VOI,!E7^VH-Z5N[-R3UV3K*W8N4^VR;)304D4D5-(/&3H
M*GL?N'>/OJ"XC5=@(X@9!(]<<#6HIGJ`>;/[M'VQV;V?YYAY-WW>]T]V/#5M
MN-ZO@1:H\M:^&O:6W(%E@\364)4`\:VG_%_X7?RZ8ODCM;M[I?NWK7L_"]8T
M.XLI\4_CCA]][:WAM'HGL'?M?E=T=]=_8['U.X\_O?M+OGM/*9)I*C=>X9*O
M)83%**&C>.F5-$E07UG>#_$=QC:O"A!IZXK_`*JGKC_S)[9^Y7)5J;CG#V\W
MG:]O4@%KRPN(44JU*:G1<ZAV<&].-.KMY:B&G">22%"R,_[TRQ$I$H,C^OEE
MC#78_11]?:WH&UKGIL.Y<`*F>C_C>&^[IJRBQU13?Q:@^X@R&2YQU!-!Y_+%
M6UZ@F")@'E`](/OW7NI]'D:*O:K2CJZ2J:@JGH:Y:6IAJ&HZV-(Y9**K6%W-
M-5QQ3(S1OI<*ZFUC[]U[J;[]U[KWOW7NJ?\`_NM3_P"6=_\`RP>_=>Z__]+<
MG_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6L!
M\@_E_P!'_!CY`_//='6G<^WNT?D/\@*3:@V+_<[:%/O7=71N^,#2SP9O:G8F
MY<H6V*VS$?[>>GI()YJV!Z803T9:&)O<@;S[W\B7.S^T_)O->US1['L,C_O(
M6#:M<;LI\1@&5@X34*-G4SF@U$@3^SW]V7][;W"NO>'W3]NMOVO:;#F>S%UM
M.[;J3"ZRQ$ZK-1(ET#:RZ57QA&$*A&HQB0=:X/9/:_97:V6RU?O[L[LK?=%D
M\W49XXS?.^-P[DQB5E14O6>9<-D*S^#TTE-4S-X%BIHUIDTK&%``]XI>X^[<
MK[USOO-WRC,^W^VP%=M)+&K^9().3QS6AJ.OI!^ZS[3\P^UOLS[4;)[K;9R]
M?>]FW;.W[UW/:=MLK.QO[T5\*(RJMJS%$T(S`)XA4N5%:=!R3]?]Y_U_8*)`
M%7/VGU/J?MZR-17E9:15F:A(`SJ/$?.AP,G[3T.O2'8/6W6E=O.3MGH^C[CQ
M&[-FUN"P<&0R<F$R&U<E5>0IG\)+(DE.TDY*+),`M5"L=X6!8@C239MYY("W
M7.W);M%N@`7]XU52*8*\,$4(IY4ZQ0YVN&^\A;;?;_=B^]?LL.Z<D;Z)-T.W
M_2;A)&`2&VO=`#@%@PSD$4XCH!XU*H%9KV!%R6:RD\*6?UN%6PNW+6N>3[!I
MXD`8K@>0'D!\@,#Y=98,[,59ZZB%)X_$`*D5X9J5_A'#J]K^0-LCK6+Y%=Q=
MQ[HRFUH-X=>]=4>UNO-G255#'OG,5&]*MZC=.Y-K8(,N4R\5+C,72XLR0*VE
M\DR-I%S[D3VSL[,[EONY*PU@*H]17C0>F,GUQYCKF%_>B\Y<R6'M9[?<HP[7
M-)M>^;RVX;CN9#-&8HJ16$+.`P2K,7TBFHQ@FM#U=]_,!^"'=OSDINM:[;/=
MU?\`'?(;0Z6^8FQ,E2[/RM339+,Y/Y"[$VEM?K_;>ZZXX7<5!E=AXVIV\[[K
M2DCI,C*I08NJ@<-*TN<<]<1V^)L^9ZKTW_\`R/.].R=A;XZ^K>UNH-H5&1^6
M???R>P^_<1/N'<N6W%#V/U7N#:.P]AYO#9;8.-R&S\;MS<-?`M;74V<S&8H*
M626MP5=BZV*%??NM=6B_!;XA=F?'SO+YK=U=G[>Z*V_E?E#OKKS-86AZ#W#O
MR7!46S>LML9+;&V*?>VWMX[6PRYGMK(ME:W([DWC]U45NYJRM5)HJ>&AI4]^
MZ]U9I[]U[KWOW7NJ?_\`NM3_`.6=_P#RP>_=>Z__T]R?^7)_V0)\,?\`Q6+I
M/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW1??DMAML;MZ0[$V)NW=N>V-B>P
M]MY3KT;KVI696AW-MZNW;2S8NARF$JL')#E8ZR@J)EE/B="8D8,0I/OTEJ)[
M=K1G(5Q2H)!/Y_SZ,^6>;AR3S5RQSA^ZH[]MNW6*3PG4.CZ'5M#*000U`IKP
M!K0\#\Y'-;:J-EY_<FRZRJQN0KMH;BSNUJ[)8B3S8S+5>"RE9C*C+T4Q56FI
M<M-2M.C,-1UD-Z@;XSW86-Y4U##$$@\:$BI]:_/KZSMAWRQY@Y<Y<YIL4,<.
M[I&0A&D)K16T:!VKIK0@"F.A-Z)W5U/LSLW#9_N_KVK[1ZVCH,Q1YC:=!,D=
M8U96TGAQV7IXI:FBBK9L5*698FE1=3!A=E`]K]CN+*SOE&^J/#'E3`'EC@.H
MS][^4O=3F_VWN>6O9[G!>7O<4DZ-S8!E3)IV&HQ]G0899L;)ELO)A:6JH\%-
ME<E+@:&NJ!5U]#@Y:V:3%4%=5#_@164=!(D<KFY+J>3:_LND5)/%4BL;$_L)
M-/Y=27R^^ZVO+_+#;_-7FJ)8P7'!I$50\E/Z;AG`^?7.NRV2RR8RGK9S5_PV
M`46/'C02QI+(2`"`"YUO;GZ#CZ>Y&YQ]SO<;W</)/+O,&[KN&Z;2R[?M=``"
MSA577Y$@*JU;TX]8R>ROW4/NW?=";[P_N;[8[`VP1<Y(^_<R_P".W3&FV-+.
MW@+0_06#R27CR$5)+&G:`!AR&/K<552T.2I)J.KB_P`Y3S#3*MQR&%^'/]/J
M/9!SSR/SK[<;O'ROSULPV_?G`(8&H-14$4K@UKU)'L%]XCV4^\YR/<^YWW>N
M<OZR<C0N5DO\CPF4G5&1>`90@KD`D"I&>K?/Y;WQDQOSBQU'TYB-D4O5^"ZP
MW5B=V?)/Y);8W+)CNT-\[;J:C(938W5>S4@E7,82NS]92.:RO5OX=C(*%9HU
MDJVCB]G?*VWV&^6,FWR[6R1)0NRMI8T(P*$'O(IY8)SY]8<?>VY]W;[OW.UW
M[JW_`#P>8=MWW8&VWEKE:_V]6VRPN=0&X[O*3AF`8>'&?B:XQH0%ANP83"T6
MWL-BL'BUEBQF$Q>/Q&,AJ:NKR%1!0XZEBHZ5*C(Y&>JR&0G6GA77-/))-*]V
M=F8D^Y97%%ICT^SRZX>W$S7-S)=W-/$9BS4``JQJ:!0%`KP```%``.G@#_6O
M^?\`??[#WKIOKOW[KW7O?NO=>]^Z]U3_`/\`=:G_`,L[_P#E@]^Z]U__U-R?
M^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^J/7KW7O?NO=4K?SN^O
M^\]P?$/^_O1^_=V[:H.HMSKO/M39^SZI\74;TV),J453F7R5`\68:7KFK*9+
M[:%UBGIC4/*I,4=@USL=P?8Y;FQ=BT8#$#B5`I]N":X_P#K-;[@E][3K[X6O
M*/N7R7M6YP<PH8+%K^ICAW$FL)(':%O&_19VI0F,"@+5TNIL95QXBBSTLD#T
M>2J988Y'K%EK)9R^J266-G:>7RR/J:9R2[L>;W]A/=?:7F;9O:OE#WMNI-F.
MQ<PR%"N:BA*Y'$&JFN*^9ZZR<G_?-]H>;?O@>Z7W']OY=WF/W>Y4V$[C>NMD
M/W.=MCCM6:/;&!IK"7%NJDV]OK*L%=B#UPH,7D<F*PX^CJ:P4%(]=6M3IJ2D
MH8K"6IJ&%M$",1R?R?9%R?R#SAS[/O,O*6TKN-SM@'[R!-`5(JH6O]$8IY#J
M1O>S[R'L+]VZU]O+[WV]Q]LY>N><=[7;-O=59SN&X=NC6%!*A`R*[+_B@8T?
M/39_O7^^_K[!>I"6HPP2*5&*&E/RX=3M(C([*^6'V?MQC/'&/3K(?I_0K9E;
MZ,A'(93_`(>WK6Y2U8J""W&@.?M%,C[1TGGM[:>R^EOL!L5Q0C^$UJ&4Y!4U
M4YQQZ%";I_MJIZI?OJ7:&8JNJ$S8VL=]R5%/-2#*)4"A2%J4U!KEI$KAX#.(
MS$)!IU?3V*=]NN=^<8AS1S3O?[TCC4`;DWX`!15S_``%_+J`_;O<?NT^T7.7
M_`N>VNS[-ROS+J.[MRYMUA]%XQE)O7D+@_1EI"I8@Y)/#RZ/U_*'[GHNF/G9
MT=28_<&0Q^([IHL_T_V/25K)%A:^JSF/J\GL&G7R,?)/1;NQM/X9>")*EXQ<
M.;RFTOLE8[9[3-R5?[K+[B;IM4B[@&/956.ES444ALJ!G2?RZY_?>%Y.^^G[
MJ;=]\_=/?GE/E*P]B^7-P7=N1UV]0=V:`7,:[A>7[AB3"-O+"X^&EXJE5T@-
MUN$_,CY4;=^'GQQ[A[[S.`.^:WJGK;/]CTW6N,W!C,)N7>-!MZJQ-#6P8J6O
MCJFC@@K,W2I/4+35'B,R*(WD=(V$213_`$YF\,D*:$YI6F`3PJ:<//RZY#^/
M;"=;4RC4RU`)%2*C.FM:9R>''/5>^^?YR6,ZWJ>PH=Y]%4NW6ZFV/4R[QQ.<
M[9EV_NW</=D?QSSWRAAZ6ZLVGN+K##Y3.31]7XRFFERFYQLYYYZBH3'T->,?
M4D5^WCT__@Z4G0'\W.@[K^775/Q'KNA,AM7</971FT.Z*G=E+V#-E*#;,&\.
MHYNX:6AFP.Z>O.O,WDL/0X?[?&3506#+#*U<;#$G&:LD/=>ZN0!N`?Z@'_;^
M_=>Z[]^Z]U3_`/\`=:G_`,L[_P#E@]^Z]U__U=R?^7)_V0)\,?\`Q6+I/_WW
M^#]^Z]T*?8,W?V4W:,=U<^S]N;:PF+I,A6YK=]+49!=UY>JFF9L#0I1LTV/H
MJ*F@435&D.'F])-K>_=>].AMQ<E;+04<F2IX:/(24E*]=2T\OW%/35K0J:N"
MGJ2%-1!%.2$<@%EL;#Z>_=>Z0><[6V'MC?NRNJ\QN"@H^PNQ,;NO,[)VL[L,
MEG<5LF#'U&YJZF18VBA@QD>5@N9"FLO9;D-95:[1NL^U;QN]MMI_<]BR*S#A
MJDKI'YD&GGZ]$5WS#M&W[YLO+EYN(&];@',:^96,58_(`?MH>A,!N`?Z@'VD
M!J`:='I%"1UKZ_S*MZ;@[Q^1\_Q&W!F<YB_CKUUTAM/L[M?KK"Y3);8/R#WA
MVYN;>>V]K[2["R^%J:/,9?I'8VW=CUM168BDJ*2FS>:KXHZ]IH*189!ORELE
MINSO<7A/AK3'Y>G'HBW3>+[:)]HNMHN?H]Y,@*MY"@]1Y@UH:X/#UZI^[=_E
MN=([GQS9#X_1T/QB[`I(/\GEVICZ[-=1[N,",*>@[(ZPK,C+$\&@B./*X.;'
MY:C3E?N!Z":<V>UO*O,=D:AMN7T!)7[0E:`GC4`=3%[%_>_]]?8G?SNVR[Z+
MS:JFNW;DH.O-362FLJWD"Q%*"G55&_=L]H]$[JHM@]W;5J.LMP;CF?%;:W%2
M9,Y;J+M4^0>/_1UV%'%2X^NJJD`,^#R:T.<IFLC02D:SCP_+/NO[8;AO.Q<O
M;]7Z]?W<'VX$'<EDR%<D44@,%)/SSY==D.1_O/\`W+/O<[%M.^>\W(>RQ\\\
MFC]Z[=M&YV2W]U9NM"VZ;4S4C9PX)6.U(DP*@D=<)L%5PPNY602(Q1D>GDCC
M+K^J)'87,H`/I('T]C'=ONN\S;5RI_6FRD974`&MD,&F16M&(-17S()Z"'*O
M]ZQ[0<S>[Z^UNX["UBKDFHOK8[Q3R;<-MH195%&O5XVD)5\MU'JJG%4V`IVE
MH_L:^GK)6J,U65,-)CWH2IM#)+4F.&*52"+F2W!X^GL![MS3[77GLAL/+6T<
MG"Q]Y-LWY6O=T`)(VP$^(<$@ZJCM"U6AR:T&07*WM;][+8?ON>Y7NES)[V;+
M=?<DW/EFR^EY7=@+ZPW)EMC&T1:V`(UBXE\7ZSO6ZH4&D=(67Y!;*HZ0=<5O
M>V&QVW:K)Q9*;;$F\ZNKV53YIK*F4R=%BGK,)CZT2:29YS$H>S,0;GVGY(]N
M.;_</<_W'MPDVOEIF)U7RN=M*G(8@+7N%&Q7CPZ:^\-]ZK[L7W=;/F3WAYF&
MQ\S^X6SBL>U;`]C>\R-D@(LCL`"HPRL0!PK@]6__`!#_`)5W>7R@Z9V]\I>E
M>ZNG9OX9N(U>T=H8_+9M=UT^^=D9VEK*6@RN[(:9]K;=FIWIHLC#/$U;'/2M
M$0=,O`FY&]NMLV;GS;K?W*EBDV[;-\#;@NW'2TD:$4"5X54J0OF".'6)_P![
M_P#O!YA[&<R;%]W?D.1.>>;.6+.3:MSW.AL4L-R"Z[IH6HTDT=J\T4L=S!X8
MOHF!KI`.VQUS\:<1ENM,I2_)W#[5[O[1[@V)CML_(;([FQ./W%M?<M)444;Y
M'K_`86OHH<7B>KZ#(:S38VEIX8)YKU,ZR5#&3W*'-_,6T;QN-UMW+D+Q<A),
MQL4<T8@.0&FH36[8`'42Q%**PTCKB+R)RC><O6"[ES/,-QY[OD"WU\*#'$)"
M`J!;).&A%0$]Q6IH':?X-_#-,IM;<&5^-_25;G-K[(EZHVQF,YL?!9*OHMC9
M"BRF)39<57F(JR>MQQQV>KZ2GAF>9X::OJ882D<\J.&>I'````I0>G#\OET,
M+=%]/-NG';X_T9[#&]<1F\3N7%[M_NMB!N7'[AP.RLIUQA\S1Y@4ZUT&2QO7
M^;K,+%*KAUQ53)2\Q.RGWIU[S`\^A9N/I<7'UY%Q_K_T]^J":#CU[RKY==^_
M=>ZI_P#^ZU/_`)9W_P#+![]U[K__UMR?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T:
MVLW)@<?FL/MVMS6)H\]N"GRE1@<'55M/!E,U!A(X)\S-B:*65:JOAQ457$U0
MT2L(1(NJVH>W1',;>2<1DA>)_"*\*G@*^5>DCWUHEW%922HNYR`Z%)`+A15B
MH.6"CB16G3[/3QU,,D$NKQ31R12!'DB8I*AC;1+$Z2Q-I8V92&4\@@CVR1J!
M%>/2P$@@^8Z(3TM\">J^I.\<W\AI-^]U=N=GRX/*[5VME>Z]_P!5OJ3K_:V9
MD%1D,!M:IJZ.EK_MY53PI+635,J4_I!NSNTG<S^ZV^\S\I[1R9^Z-IV_84;4
MWT$7A&5U&D.YJ06QJ8J%JW'``Z@[DWV*Y7Y0YYW/GU>9-XW'?BK!!?7?U0LO
M$!U:,!R-)*HKN^A"0N223^+PH']`./Z<>XRI3'4X5KFM>J2OYKNV?C=MW(;+
M^0.Z?F#T;\/_`));+V5F=J[6J.\-QXB;8W>G5>1S"YFIZO[,ZZCR^-WWG-M4
M6[J+[S#Y_;MLOMK(RSRP"HCGJJ.H.>7[_>[*[,FV0NY_H*6_:`#3[3CHOW"V
ML;NV\.^*A3ZD#/VG_!U3A\=OG/T#\C-RY'K;![NP.W^W\3D*_')LRHR]55;:
M[+@QD@CFWC\>]^9G#[8A[?V17`^2`)14&<A!*5%`I1G,ZZK\T_>6Q_NW`S0Y
MP#45%#6OE7T\NHX:.S`+;?O7[R(XBHJN2*'-5I0T!\AT:G=VT]J[\VQG=A=A
M;4P&]]E[@@>BW'LW>&(ILU@,I'^CQU^+KXW6*KB-_%41^*KIG]4,B.`1>>W^
MKHBY-*4''[0./5[><6I#VF'!X\"#Z`\:?*O5,_RD_EO=W8;%QY'X?]M;ZSO7
MN(CGJ)OB_G=SXBAW[0QR%IFAZ<[OW)15-?F*.CA&BEV]GZB&I\8$-/DBVE?8
MEMN:]SDLMGY4WV0[ER!MQJR\']:5XG34BAK\N@=%R;L.U\Z<V^Z'+$0L?>&\
MC(W#=&U.`K*HPFJE655#,N30%JTIU2]!LG:-5E,Q0;CP&X:[>.W*XT.ZMM]N
M-N>7?6U,K&[)]GNG:.[ZII\35))<1/\`;&EF'J@DE0AC.?MY[?>QD=LVX<B\
MG;*9JU(8:FJV34&IX\?GT2^Z/O/]XCG">WL/='W,WG<K<(`C#<'4%5`"T84&
M%"XXJ*#I=4L%-0P-2T-'24%*ZE&I:"CIZ*DD3C7')2T\,<,L;6`*Z;>YEM(+
M.TI8H@*>@4$#Y8%*#@.H#5U5S(`3*3\1)+'YEB:D^I)R<]7`_P`D;Y,_*OX<
M[N^0.Z]B=`;\[A_EY?WPP([]DV9M/*ST?1FX\7MR#+]B]F["W*)#A*B3KC"9
M1:_<NUUB$LE`2T$L51#'!+RY^\#M&T\O^^FY6W+6TD0[FR?4%*.!N`4Y``H`
M5`#$NH7C2H/75SV92;W)^YZ-YYT]S-MCW[DG=VL]FVW<M7[UW':IV5IDC)8$
MK9RLKQ@V^AJW!60,X)^@/B,MB\WBL;FL/D*+*X?+8ZBRN*RV/J(JK'9/&9"F
MBJZ'(4-7"\D-31UM+,LD4B,R.C`@D'W'!1@2K#N!S]OGU'I90I<D!?7@.@V[
MFZ]S'8NVL91[:W"NVMS[;W+A]W[=R4\<E10+EL*\IIX\E!$?))2.L[7T@L"!
MP1<>]?X>M]!AW7FN^=D?&;M3=6Q\5MK>/R"V]L+<N4VE0;;PN0J<1D=Q4]*W
MVC8[!9"J>KRU=2TB-41TFH"LJ8UB52&TD2<JVG+VY<W<JVG,\S)R\9QXI#!:
M"H_%G2&)TEC\()(((J`/[@[AS+M/)7,NY<JV`N^:K7;I&M!IJ2QK6BC!8?$%
MX-0+0UITG?@QV3_I9^+'46]*_=NY-[9VJVM2X_?N>WKB'P6]7[$H'=-ZX[<N
M';'XM<95XK/O-!%!'"D*4JQ:"5(8FGN5L#\N<_<S;.FTI9+JK'X;!D\(C]+2
M06!K&5>I-:DC%*=!KV.YFN.;?:WE7>+W=C>;H+)H]P!4@B_7_<M,@5"-5%(J
M&`!4E2.CF+;2+?2PM_K6]@8"@`K7J7%II72.VG50'_=:G_RSO_Y8/>^M]?_7
MW(?Y=<)F^`'PTC$LD)?XO=+QB6$JLL9DZ\PBB2)F5U62,FZDA@"/I[T<@BO6
MP:$&E>@SZF^%F]]N?)>/Y,]Y?)W?'R&W%M';&YMD=08/+[.V[LK$[%P>\)(1
MFZFMQ^VC#B\QFI\?3I2M50TM()@/+*';0L<J\S^Y^P7_`"''R3RI[>0[6S-&
M]^XE:[DF=,KIU`%5:@8H'?\`A%!75CYRC[1[]M?N'+[D<]^X,N_;G&'M;`-9
M+9BR60M4T61E<A&=#($37J+-J.G0:#LKN'=>R\O-MG!=1;PW;ELE2THV;E\8
ML,^U\G752&.:+-5\1\V"3$3C54+*OKA&I6`-UBH4H*#'6061@\>G'N7:>^M\
M[+V]MO;^7EP51D]R[;CWU5X>L-!5+M7U_P!Y8\75^19U59"I"J?)(BZ>;D'9
MH...O"AR.'0F;3VMC=E8"@VYAI,G48_'QLE.^8RM?FJ]@Q:0^;(Y*>HJI`7)
ML"VE!PH`L/>CP-!7KPXYZ^5AV5OW?/=W<_;W?'=535;@[RW[VKV4V^<[GD:;
M-[=K-O;XS^V*#KC%&K5JG;6U^M\5B(,-08BF,%/2Q4G^;UNS-U"]DMBV/8?;
M[D;<=GD7Q-VVF3Q'.G#:VU!CP7NK@TZPF]R]\WO<>=-TL;TZ+2)0$2M`!04:
ME:%F%"6R2*"ND`!'Y;#T.X*/[7,T*9&DIYXJZ*28SI/C*VF.JERN,R%/+!78
M7*43C5#5TTL-1"1=''L?7VS;7S%8_N[?-C5UI\O+_5QZ`^W;E>;+?#<-O<JX
M%/3[1\_LX'H]WQF_FG=B=29##]:=OY+,?*_8HJ*/$8FOVI40[Q^5.Q::1EI8
M898,$E2.[<'0*!^UD4H]P1J-*5525TG%CW#Y!VCD@->[5S%&=@&6BUJ=T'G1
M2">T>7F!3K(?D_FC=.8U%CN/+LB$T`8JP0_,L0`I^>5.>&.M@#KWLG8/;."J
MMQ==;CBW'C<=518_<&.J<;EMM;PV9EIHEF&W^QNO]S4.)WEUYN5$8$T&6HJ:
M9AZH_(EG,6VEU97Y^NV^M1^W\QZ^OSKT.[BT-H2K*5IZY_+'^#]G0)?*OXR?
M'+Y`[/K]U=]QT>QZW8N'GEQ_R1QF=Q>P=\]88Y%*ZJG?V4'\(R^V5<`'"9M:
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M7<Q:1C4FN22:D]2-;VZP)%:VJ44+0?*@Q^?^;TZ=</\`Z5>@O@CU7MS%].Y[
MMWM[8?QXZFZXJNK]LY3!0U-5N[']?X3:V92LRF6R5#CUP.$R4,CU4L,LTSPQ
MDPH[$7-N6MOVS<=^VFVW;>AMVS,_>Y4MH44K0+DL!@9`!R3T&>>MZWG:.5]Y
MON7.5QO6^JG;8EPB.6\F8ANS)U@`EE&E:$U#E\`NM>Z.G_BAU/U[\@<W)F.S
M<%CLP<K'595]Q5>WL9D,UD<EMW:55N)YJF3.3[8PE3%2-.9)+",1AW"!R(?=
M/>.5-\Y_YFW;DNW*;)VJF--=**"P%!AF!88!-:D`FG0/]D=BYOY9]L^6]GY]
MF#<RZI&`KJ,:N[.D;$%EU(K`$!F5<*&-.CJ@@@6(/^M_K>P$I!"MZBO4N\:Y
MR./7?'UXY^I_K;^O^M[WU[KOW[KW5/\`_P!UJ?\`RSO_`.6#W[KW7__0W)_Y
M<G_9`GPQ_P#%8ND__??X/W[KW1T??NO=0H<C13UM5CHJNEDKJ.&GJ*FBCGC>
MKIH*LRBFFJ(%8R0QU)@?QE@-6@VO;W[KW26WKO7:/7>V<CN_?&Y]O;/VMAXH
MGR>X-RY2CPV&H?N)TIZ=:BOK'CB62KJIDBBC!+RRNJ("Q`+ECM]_O-Y%MVW[
M>UY*_D!J../;0X`R6.`.)Z)]XW;9>6MOFW7?MU2PV:(=S.0@!)P*G\1)PHRQ
MX`]+&":.>&*>)M4<T4<L;69=22('1M+!76ZGZ$`^Z,NABA%",?LZ-D97170U
M1@"#Z@\.M/W^8W\3_P"7IW[\M>V,]T]T[\I\SW)B-QB@^5&\/C)W'U+T;T-E
M.V6H*&IRN*SF1[HV]O+;6Z._:+$34G]X9-HXN%J:6:,9>K&1,BJ!N9OOX\K?
M=:GAY3WKGB:)[L>(-NALAN.NIK5H*:D+U[37NH:`TZ/ML^[CN'N]$F[1\K)*
M$J%9B`3J-:!J58`U/F`23FI)A]%?&G^2GU<V,/R`^`_RZFS]"\<M9O\`^2N/
MWQ\J-AXYHS8U4]5TOO3?.POL.-;,^W:94/\`87Z$/V7W_/;;W2C+3>_#BK`>
M'=,^W."?)5TPG2OPUK04IT8S?=GYHY-_L?;F$S@$$P!;K&/B!J<^E.C'?$W^
M;A\(-E?/#?'QEZYVET+TA\:MTU>T^O\`HC?NS^L,-T@3OZGQ4,63@W3#6[<V
ME55VU>Q]P57V^+K&AO1U=)&DUTJ?)&?6G/%KNF^SK;K;3[$(0?K5N(W8,U#W
MKK9@GD':@-:MY'K*'<_NT<KW'W:=E]R^4.=Q/[J[5<2'?]J<B,M`'(1;824,
MDUA&$>[16)*R4C)9"K3/E!WE\9OFS\E/D#U?\=^F>TMV?,CXY';&R-B?*WXY
MY+#[0Q-'FIJ7(+O?!?(SN'-8RKZCK.EMB9?'P4D^W=SIN6NR^JJ&%Q@J1'/[
M-[CW+VSE3]Z7<6[:%1:54?$.';P#`-BH%!ZGR@OGKV+N.6^2O;&_WKF:V;>.
M8B;U]LB.J^VR.,UVZ6]*$BE\%9DC4^*D>GQ8Z'M&7I3X$X^AR6TNT/E[N_`?
M*'NO;:T.3V_@:/:\NU_BGT]N>&GC\V9ZAZ.RE3DUW!NR.IU21;KWA+E<Q&]C
M118]%1!CS[D>^W.?N(@L:G;M@X57/RKCS(R:XR13SZ]RK[;[9L<K7\](]Z-2
M:-W5/&K#"@$GX#JP#K7*]'.[KKNL9NF^XIOD1486LZ#EZRWI%WJ-[/'4[6JN
ML:K;]=3;JIL_'6ZX*B.JQLCQ4\(5II:IXD@'F,8]PWM9OFO=GCV!S_68&M0>
MZ@."1Q!K0K4?%2G=3H:;A!M\>VK#=P(&+410IIJ]`%%=)%==/P:M7;7JN?IG
MI'YB=']%_%'YC_*O<=9\R^K/C[U'USO6A^)^8V?6==[_`/BAM+;NSUHX.[-F
M8:CS>:PGRA^1W6W7E<*G)+O:GI,_2BCK6V[-1Y:=Z6MZ%KJ\.(O\>A=7^FTC
M5_QJO6.;_')C&H_LJ:?RZV.=L[NVWO+:^!WMMC,X[-[1W3M[$[MV[N.AJ%DQ
M.8VSG<;!E\/FZ*J8*DE!D,74I/&_T,;`_3W;JO28V-V_L#LFNS&/V7F9,U-@
MWTUT\>,RM/CG`D,)>AR=5108_(()1;]J1C;U6T\^_=>Z(G_,0S'?M'B_CA@.
MI]Q;_P!@=<;[[^VMM'Y#]E=44%15[_V3L++5%/2XZJQ4]#29+(8'"Y/*R-#7
MY2*%OL_VC(RQ,]YD]G+3D8S<_2\Q;9#>[W9[)(^V6<K*D<DX!/<25!(I4)6K
M"H&1J&.?OU=<[+:^W-ARUN]U9;1>[U''N-Y8*XDCB+*H)*#6HTM(Q)(77$@8
M,K>&]EM#1K0TM/2)+/,E-34]+'+532U57(E/$L2O55<[R3U=1(%U/(Y+NY+$
MDGW#=2<D4)ZR*5="JNHF@`J>)IYGY]2_?NK=4_\`_=:G_P`L[_\`E@]^Z]U_
M_]'<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]T5+;5+48_Y,=I)L[?6S<V:
MO#=>YSMO8.4EKSO/9E)F*+/8[8^4H)*2.:E%!N!-MY'[6.<HK>"8?50WOW7N
MBY?S`>K<?\G</L'X[;'[5V5M;Y%;8W!B/E)UWUWNUJW(X3>6WNI\S3X>LJ]]
MX3!PUN0QNR/XYN2EIXJ^6'Q/7D1PI,PD\<H>TG.]E[?;YN6Z7^R";9[[;)=O
MD`IXB++W:DU4%5I49J*UX@`PE[V^VN^^YG*UEMW+6[+#N]AN-O>H]R2;.Z95
M9#'.J!VT`-71H(.FA&ERPL:VQ/GJC`X:HW71XS';GEQ&.DW'086LJ,EAZ'.M
M21-EZ3%9"JI:*JKL;!7%U@EEABD>(*653<",I_IA<2"W)*`G23Q*UQ7RK3CU
M,MM]4+>-KW2)M(U!?A#4[M-:G36NFN:<>M4':<#=$[N["^,_<&4I=F]N[)[8
M[=ST0WM5Q;=A[IV=V?VCNWL;9W=G76<S$M+C-_8O=F*W.M-DDH:BIR&)S-#4
MTE;%"Z)JX7_?6]K/<#E_WKYOYQON7YKOD[>56]L-SC1I6@FB55,+^'K*.A72
MBGXDH5)H0.A_L1SMRA=<B;7L3W$47,.VFJAF4'B36A(.GYG&?+S7?8/8.T>G
M\)2;D[#W$FTZ')5]-BMNP-2Y+)[EWCGJLJM#MO8&TL'35^Z-][IR$CJL%!BJ
M6JJ&+AF"QW<8I<H\C<W\^[Z.7^3^7VW/F$KJ+,I50#2K.[!405.2Q`!QQZFW
M=.8^7^7+(WN];YK9N"A@2U<T`%2?R!)'`'ISQOP\[9^8^+*_*+;DG0?QTRU.
MT<O3&7H-L[D^67;&$J4]4/8>\*F#<&"^+^T\K3,JU&)V_+6;UFB8QSY'&,3&
M.@'L[[$6'M-N`YJW?>FWCW'!!$FWLT&W1L/)1J5MQDC-07E"V88$".?!ZQ>Y
MV]PYN=:6FV;+&NPK4`D4&>!TU&NHI6A`X]P-5ZM-ZKZKZQZ-Z[VSU#TIU[M+
MJGJW:%*E)MG86Q,/#A=O8]2JQO6200ZZC*YFM90U1D*V2IKZN0EYIG<DF;MY
MWB_WN^.Z;K**UJ23Y^>>%?\`!P%!CJ.[:SM[$".):2:0,T#4`P````HI\*@+
M7-*YZ`'O[YE=;=);@J.J\!B<WWG\D7H(:^E^/O6%;C$SFVZ&L7_(MQ]W[[RC
M'9G06RY&9&^ZSLO\2J48?8T%6Y"^R_>;_9.4=B/,_.N^+M/*]3EC1F/HD?QR
M,?10:?B*\>C#;[/<M\N38<K[/]>U!W,*KG^&M`WE0UH:X+$%>JY]O]B?*#,=
MYS]K_,[HKJ?Y>]>[7RNW-R]`?'_I#MZIZXZVZ&W)A7K:B;=&XNO>Y<-A=L?)
M;M6.:6F;&;DW!E4CQ%12M-C:"@>5'B*O;/[ZOW>-GN]',/*7,FW7R$E=RN[.
M.ZE=?(*+.K*I&02I8KI!-1DVYK]@N>;G;MK;:)+8R,^0;F0-2@`5V[E.EM9(
M"HG=0("&9]AWH#YE=(?(OJ#=?<>`RN3V9A.LJO<V'[MVKVMBEV;O;I//;2Q"
M9[=F![3P=1/4T>#DQNW9H\@E9#456+R&,FBK*2IGI94D;H5ROS-LG.NS;3S3
MRANR7^Q7ZJR.K!E*FN?564C2R&A5NT@'K%_=MGO^7[Z39]Y@9-R0TR,4\B&X
M%2.#8##(Z#S^6MMO)1_R_OCQA-SX^MQU+G.M\E78C$UQD2NQ_6F\MP[DS?6N
M)E\KO+324'6N9QD(C;UPA`A"E;`3D4)'IT5>HZ.=U_LG%=<[/P.R\(7?&X"A
MCH:>:98UJ:G2S,]35M$JK+53NQ:1[#4W/OW7NEC[]U[KWOW7NO>_=>ZI_P#^
MZU/_`)9W_P#+![]U[K__TMR?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW5..
MY?D+_H%^5GSDS&W-H5O:G=W:FYOBWT%\<NE,-61X[-]K=D[9Z-RG960I*K*2
MPU,&TNM=@X+LS^.;MW+51F@P&$CFE(FJGI:2I]U[HY_Q/^,U=T?C-X[Z[/W5
M3=I_*#N[(8W='R![B3'2X^DSN6QL%3#MOKSK_&5<M14[4Z0ZHH*Z7';6POD8
MPPO/75339/(5]5/[KW1O_P`?[ZW^V]^Z]UIW?S./@M\R?DU\V<!\<LGWIM7O
M7KS/;<S7?F!SG<V&I)-G?$WKEMQ#:(JLIUCM7&4,6ZM[YW,R/B]JMC)*.?.+
MCZB6OGIHJ.HD>'^>]QON6#)N^Z<QR+R\>[0*!JBF`!EJ5-*!CF@'72_VF^]#
M]W_DKV7CV#E7[O6S)[Q(JQ7DEU"+ZWN8PM1N0O+PS/#.IUM]`-,%=3:@I'5B
M/PL_EP_&WX-XN@JNN\?N'L;MZ*DJ:?(]^=L9&;<G8,"Y2%OXOB]@XZHJZS;G
M3.S:Z5F7^$;:BI1+#9*F>J(U^\<=VYEGWZY:,)M-M`[:B=O0HSYJI8Z02X%*
MEB2&K0BM.L8=PGO=XOIMTWF56$DA<C/A-K6I6R!:B#.$TQQ#%(ZC5T;?MGMK
MJWH7K[+]K]V=@[6ZLZWP;Q05^[MXY$8_'RY"H;31X3"4J)/E-T[HR<I$=%B<
M;!5Y&LE8+%"Q-O9%9;1>[]?"QVVIC_B&1CCW"HKYG\R>KO.%=(HXWEN&I1$4
MNYK6E0*D<#DT!(H"30&FSY`?-3YA=R;67=?Q[Z3[$Z9^))K<CAMU]DTO86P.
MOOG'OJD%5'C/XKL+8>^4JMN]`]<Y*:I\<E?5U<V_74@PTV,8ZDE>\]I><-OY
M+N-_Y8OMH3FH&B2[BA?;5_I/$FIV9?X`N@G+,P[2SMNVW$WN-:^WO,AI<.@'
MTU&-]J==:@?"7J""JMI.D!E5#D%$ZE^;/PHZYQ5=L+'X7L3XZ45'D*K(;J3L
M?JK?<T%;N.6J>ER6Z.P.T,&G8$&[-Q9*O4^7-9K*3550Q&J8`JHYL^Y'W9/O
M.<Q;[-S1OK6_-MS#4DV#K(ZK4T$=C<%(M/\`"E%H.`'6;,/+6X^WVP[))<^W
M>\[;RM(2J4M)&$S$U/A7`;Q'J:5\'630:JD5Z.;M'O7HCL+&-F=C=X]/;JQB
MPF>2JQG9.T8C!`%UO-54F0RU%74*J!ZO/%'H_-O>,>]>WG/W*UXMES%R'S%8
M[R]2KQ)(X(KY%%*@C@0#13@8'3G]9N55;2^^-:R'\,M8W_WEZ,:>M#^WJECN
MWLFL^0GS>C/Q\[7WE#TWN^IZ#Z)W]C>NLG64&P_E;NO;G8<T];2[B@B:.A[#
MZWVA'G8<(^J*2CSO@E@$\M`C1R]?_ND<K\\^UOM!M'+O,D@L>9-TWO6BJ"SP
M[;(4)#TRDC`,Q4C&KN4/GH?>WOL/L/N;R?[B>Y_/7+%/;O;MG>2&.2,(-VEL
M+:^D687SJ)EV]6=T)M=#W;(4=S'IK]&;ST=($IWJ*:$Q10:8GD@A*Q/(M+`1
M$/&J))-9%LH4N=(YX]Y[_8.N*U%&%4*HX`<`/0?(=-%+N_:==/'2T6Z-NUE5
M+DJO#14U+F\;43RY>@A-17XJ.&*I>1\E14X\DT`!EC3U,H'/OW7NG3'9/&YB
ME6NQ.0H<I1/)40I68ZKIZVE>:DGDI:J):BFDEA:2FJH7CD4&Z2(5-B"/?NO=
M3O?NO=>]^Z]U3_\`]UJ?_+.__E@]^Z]U_]/<G_ER?]D"?#'_`,5BZ3_]]_@_
M?NO=(_YX?.O%?#/&["Q]/MG![FWIV)A^X-YTC;SW=4[%V#L_K+X_;#/8W<78
M.[<[B-L[XW9D8=K[>EIEIL/@<'E\SDIZH&*!8(*F>'W7NJY]A?./^7_U7\CN
MZ/E&_4_R$R/?7R!K-E[%[`[*QV(/8NPX]K==5W670F0E^.E9E,]@\K6])#O/
M/X7;%?+M_!09?=&[$^YFQ\T&-EFH/=>Z'#'_`,]?X@[^JL3@^@-O=L=^[MKN
MX.GNI,EM_9N$VYB:?;K]P9G:>*Q6[\SN;=.Z,5MJ';-,V;RL-/,M2RY/);5S
M--3LR44M0ONO=&J_EY_/+`_/7J_=.]:+KS=_6.Y-C[I3`[CVWN>A*4%9B=R8
MRGWMUEN_:69U_P"YW;F_.K<[A\S"\D-+40_?>.2%0$9_=>Z*Q\Z=]8SX9]]X
MGYF=D09*;XV=N==[%^-_<FXMN8?);GW+TQO[:&\]V[FZ@[!JML8J*KRV>ZRW
M12;TR^&SIH%>JQ-:F/JU@GBDJ3%$7O#R;+S-MNU7-O(`=M+.I!IQH?.E17''
M%:T)&9,]J-OY@YBWB?EWEC:6W2^E4OX5L"'94JK%:9[`RL:`T"L#1*E:[/D?
M_.W^/^U=O2X?X@XN7Y5=G9*F<TN?R>.WAUQ\>^OGD0^.NWYO'-8K"[KW=E8M
M0>+`;<HWJ9])$U91H2_N`=IY,:0E^8+A+)2?]"(<GYT6I_S'R/#K+_V[^[5[
MX^ZN\1V=CR3)L'+;#NW7<D(M4'#,+4<Y!J0A!'!A74*+.[H_E3W5%M#Y>?*/
M.[N[*3<.3J\)U9OO)PT.WNMMDU44M15IA^D.J,?6SX;K?&0&@98,BM/-EL@U
M,9)Z^9M7N4(MNFV^P\2VVA-OY=!KV:3Y4K11YY/VL>'#KHK]W_V[^[-[7<[[
MW[7\I;H>9/>_:8UDW-Y!74A49D#5-E$U3IDB+,P.7).!`I/F/V-2[,;:ST*2
MR&H2NE?^,UL6VJO-1H$CW/6;9`*RY@2+Y&C$P@FG];#\>S,<UWZ6GT8)T^1^
M7EGH^NON?>W\_.IYO;='6VJQ,%*W85F+E(]R/ZO@U.I+TD31VH:,>G0:;'^0
M'977G7?<'6&WJK"M@.\TITW_`)+(X:"JW1*$=I*@8O*!HS2)D2Y+QLCQQN=<
M2J_/M%:[ONEA#O%FL<ADW4:=(5BS>6%`U'\@>I.YY]A_;?G'W!]L/<_F"?=8
M>:N02)-IMFG$>SQ$4.M_$9513Q,CE0WQ$Y/0;];];]`;[[/VE0_(,8#;G7,U
M753;NWF=FXC.9RDI*:DEFIZ6*HFQ-?51MDZM$@>=XYQ"&U%#;C>SRR6=_P#N
MO>=YGVK3Q`#*1\V4T*_F!T_[V0\PS<B\Q\T>V'M[LW-_N'<)7:FW2VV^YC#M
MDE'",&B+5"."5914$\>MC7^6W_*7\F_.KOF+5;\>;K/:>Y)=Z]!;0S^TZ2C?
M>FWTI*J#K_?&9I\;FI:G"XFC2J2JH:(I35%3)#%*T5/&54R#RWR?&NXQ<P)N
MSM*:E?Z0!XG/`BIKZ?EUR_\`O2??AYG'(?,/L%+R/:[9S;=Q16.\NMS+HVZ;
M4O[QL;6HT-$67Z7M_36-BHK2G5BWS._EO]Q_*/Y`[<[HV_\`(6HV%C=L]7_'
MS95=L['?Q3#;=['RW4WS#VO\B\^O8^%IZ#,29':<NS,'+18F''U^/K$S4H:I
MFDHRT?N0SQZY64`J%%%'`>@\NB/;1_DA][8_;WQ/BSG8O2=%GOB7G-Z;AIH<
M#7[LJ:'O+*;H^3G77<BKO'<]/UMM3>W6U/)L;:]9C!48:HKL[2U8@@GRF3Q<
M]92-[KW5K?\`+3^)W8?Q'ZN[BP':F*Z2Q&_.XOD?VCW_`+DI?CK6[OI.G*>M
M[#EQ5-0XW96P=V8'!CK3'X+;VWZ&AEH*-JV.OJZ>;)U%1)65U1;W7NK&O?NO
M=>]^Z]U3_P#]UJ?_`"SO_P"6#W[KW7__U-R?^7)_V0)\,?\`Q6+I/_WW^#]^
MZ]T"G\V'?>VNM_CCM#<F2^.G3WR5WC6=[=5[5ZSVMW?M[";DV-LW<>>RM0^X
M^U*['931D:T===:XW.95J+%R19')"F^TC=5F=A[KW5<<O\V_X6;LV^.RMC?"
M'#[O[%^-NQ>_?D#UFV7R7Q@VY1[0V'AMH;:WSGNPNN^PTW?GL3B=P]A[H[+Q
M5!G\)A):S<F#RE7529:G22F8R^Z]TI=H_/[X39?+4/Q_P_\`+JVY7]C9G/\`
M2O7U%U-UGMOXSYW`U_<NT=UY+;F4V?7Y.BRV$H]GX+X]9JMW!DMOY[/4^,IL
MU@:+*Y/!1O3%S+[KW5K_`,"N\^GODMT.O=?2G6>*ZGVQN;>N\=N9':='2[.I
M,U2Y_J[+/U96P;OAV.]3A*;<.(I]FPX_[9*BJ%)24<$,<SPI&1[KW1#OYW/R
MBVOU1\.*KK/&4F"WANCY-92NZWP4E;##E\/@,%@I:;)[UW9(].S0?Q7!24]-
M3XP@ZH\I41N#>`CV$^?-RAL=@GM=!'BC2``2``:EOEYBI\_GUG1_=U^U=SSU
M]X+;N<)-^_=^T<JR)=/I8"9YK@^''8QJ#5UG.KQ:`@1!E<4<=:;>=RM-EJBD
ME@Q:8S[7'TF/>%)IIWKYX8T1JZ62624&6<@EBND%CPH%O9;[N<^\M>X^[\LW
MO(WM?#RWM$:(K&,*')"A2=*`8+`L,$YR2:]=0?N8?=Z]WONQ<H>Z>V^\_P!Y
MV^]QYM_YGW/=S?7#R-^Y;`:F?;(FG=^UEQ<H&6&TTUMU`IT_[@W9V1-M?;O6
MVY]R[HEV;M5FRVU=F9.NDDP.#DRB-*:S%XYE"PM+%.QC:[:!(Q2VKV&_<+DS
MW']N;Z'EOGW;4LK>5`ZE/-&`(;YBA%3P!P37H:?=P]T/NJ?>.AYX^\']VK==
MKYAG,K;%NVX6\!MYJ6'ZJQ5<*S$`@IYNA$@&E@>G?IO`]:;G[-VMA.XM[U?7
M76U9-5'<V[J*B>MJJ..&E>6CHD*P58QRY2L58FK6AF6EOJ*&_`/V.WVV:_6Q
MW#=9/#^8-*?:<=27[N\P^Y?+/MQS#S-[0\M1[][IA*Q[?)0Q$4[:L>VI%//C
MTQ;H_NYMOL#<"]<Y^JW3M'!;DK%V7N;,XM:.MSN%IIR<?D,IB)U:)9*B,6*L
MH60*'T*&T@^Y1YFO?;SGW9.:N49&EDVMB1^\29!FM=)&0/2F0*4R.@/SW[4V
M/WEONRW_`+.>^_+MSMD'/&QZ-]M=NO7$MA2A[-P8%CW"IB[EIV%2HIUDQ^Q>
MR-Y-0YG;^P-X;DCW=N2HP."GVWM3*5])N+=CQM5/MW;<6.HW7)Y@Q!F%)3!V
M*HVD>D@4YFW#F;G+F;>.<]QV@,=SJ"34@Y)^(\1Z5)-./2[VTL?9+[NOMWRG
M[#\O<[6-K:>WNP6=I%;7VX^)N,&R64@A.X[E*AI0>(3&I"XH``,#9&_E3=O?
M-'X_X_#];_([J/O/:/Q&VIU_FX*#<F].J?X3@^JLM4;BBR>/RU3N>;[?=TNS
M$2OJXZS735$>,A\<S"*GBDD3*GEC;?;O>/9SD_EO9MHW2#W?CE=;Z620K%<J
M^JBV2G"$=ND5%3J`R<_.5]^6Z]R;#[VGO![W7W/G(^]_=DW&[1+*;9+VVN+]
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M6#WGMFLJ:.0Q5E-2YW;M=D<9-44DGIE192R$V('OW7NE[[]U[KWOW7NJ?_\`
MNM3_`.6=_P#RP>_=>Z__U=R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T8/?'3?6O9
M&[.K-\;XVK2;DW-TIN;*[SZNK<C59)Z7:6[LSMK*;/K-S4F&CK8L)79V+;6;
MK*6EJJNFJ)J%*N5J9HGD9C[KW6.#I#INFH<3C(.I^LH<;@:3<E!A,?#U_M.*
M@P]'O.G6DWE2XJC3$B#'4V[:1%BR<<*HE=$H6<2`6]^Z]T[XWK'KS#UF5R.*
MV)LG&5^=JJ*MS5=CMH[?H:S+U>,V]+M+&U.4JJ;'QS9"HQ^UIY,9!),7>+'N
MU,I$)*>_=>ZFX_9.W<!M`[&VGB<7L[;4.(J\+B,1M3%8_`8K`T=5%/$%P^*Q
MD-+CJ!8&G+HL4:*'YMS[]U[JNGMGXC]=YKH'=^%^5N8I)>HNLNO=TTE=7;6R
M'\+JLCUSC4K=TU-=75%?21U&V]VXRKI@T-905*O,RJI8&Q*;=(K6[@W(;@FN
M`IG-.T"O0\]J>9?<+EOW%Y-OO:FZE@YNBWF,VK`>(][(Y"K'*HX)XC=V2.)X
M'K2]ZCZ9PW=>`[KWSC^S-H=4[7ZNQ%1O'$X#?]745NY,S@<A4U]1MS%4]1`\
M$E37110TU'4U01V:NF0"&S7$#;'M*[D_,&ZV^]M&VVBJ!CI)'D%K0M3AVUZ^
MC?WF]YM[]KMW]GN3+WVPYCYRN^=)$VJ:>QM8XMNBE*@[D98B*+&U6`=Z*P&&
M)Z`V?(Y#,24TV0J*FHJWBIJ6(5TNJ>&)52."DYX"0:@MAPH]G.]<S\[^Z/-7
M+\?,_,;;EO4!7;5,AHHCDI0U-`%%15JTKQ/2SD#V;^[Y]T'VVY\3V@]KK?DO
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M[ARVQ"U:1?#\3`9%D+:"RMV:=6H&@(#&G1DMX9#Y<===!]*4FZ:W>.R^CZC<
MT78_1V;Q]31T%=B-RTB/G,7D\7G\7)_','/30U#Y3&03E!I=YDNI*^S>Y/-%
MCL6S075Q_P`AW772#PS7@.H#Y-B^[)SU[^>[5]R[^Y;WWPCV([;S/MSVXT3V
M]0$63&0.U6)QJQQZVC/Y3_\`-5P'S"P%)T1W3G,-1_)K;&$=XIP(:3%]X;6Q
MU.T=3NS!4OA2B@W704RALYB8R1Z_NJ=/MWDCIY-Y1YI_?4#VMQ$5W=`>*D*R
MUPP/#[1@XJ.N2?WT/N@_ZQNYKSKR/+]9[8[@_P"K!K#S[-.U3]%=4):6)@?T
MI1567L>D@!D%GY)?RLMK=Y=O;4WIM;>>.ZQZ\I_B=W[\0MQ[#PFWL[%E<9LK
MOC<%/NG+;PZSW'B]WXG$8K<F&RT'CAQF=Q6>V^U++(BT<?I*C>[N;N_NFN[V
M4O)BI.22`%!/Y`#U-*G/6`=C96FVV:[7MT*1[&`?TA4"I8L:#TU,?L\A3H)-
MK_R?-X9#(ONKNSY6Y+?.YL7U5\E.IMA8G977%5U]UML+;_?O4W7/4-/CL1LN
M+?V8:JV!MR@V#+FGV?/5/@?XKDVCI8Z6DI8(2WTMQY<.CS_R_OA/AO@5U'NK
MIC;>^<AV%M_-=BU785!N'<.(BH]Z-49;96Q]M92EWCGHZVKEWID(<CM)VHJ^
M=8JBGP[T>/<2+0I/+[KW1ZO?NO=>]^Z]U3__`-UJ?_+._P#Y8/?NO=?_UMR?
M^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW0"=_;MZ(VS
ML6'%_(S<?7.#ZX[,W-MWJ1<5V?D</1;:WWNOL+(PX/:_74%%F76'<.;W7DG$
M-)01++-.P8Z"JL15XUE0V]RH9#_/[1_DX=*=MW+<MFW#;M\V;=)K#>+)]221
M$JRGU5A0@CB"#4=:\G\XS^6/\<.G^A<A\G^@]BT746;Z^S>W,=NS9NT$D&R=
MW8+=V=H\.^6JL)++/'@=P;>K*N.2.HI/%#4PWBDC8Z'0`\Z<M;7'MG[QLX@M
MPGRQQ\J_;Y==5?N'_>V]W.9_=:Q]GO<?>)=ZV/<JI97,[EKBUD5"XT$]S(=)
M#(U34AE(`(ZU]]C[QZ>P757<FV]X=9U.[^U]X4V'I^K-]C(Q04'6T%*P?(5X
MI_-'4IDY*A=2O&DBU"-XGT@$^XTVZ\L;6P:WD4'>SP8_#3TKP_GUTF]PN3?=
M3FCW2]MM^Y4]Q-OM_:;;+J^/,6U+$1'OBA119J"AP--3Q/"O0^[:^$GRSQ7Q
MMV1\]]G[1J,OL2@W)-N#&P8ZAK,QOK`[9VC7+/B^VJW:LM+(F7Z\J\G12@FG
M\E3#31_=21"E<2J?S0\XW*ISU=;W-<.@IIW$-.0HH`=-"='DO]$<.'4;Q^[?
MW5['G?F_[H&U[5R]LD5WM!C*6D4>W;%+<W]#?V4"042#=)(W51=-0/+V:O$[
M>F_J7Y3;MW-\ZNA/DOV77X*IR;]K];8G<\V'QM/CMNU&Q\K4KLK*4+XX25$$
MN-J,%N"?S^1Y!*&-^``$UES!-N7-=ON6X`LX(H,YKB@KY9P/3'1KO?W=>3/;
M[[J7/OL5[>6NZ0;%%M&Y7]I9R2A[V/<@OU;2-+P%;F)&741J`J*UZVE?D9_*
MM^*V8[$ZZ^0.X-]93J/I[HC.UG:/9'4N<S]/%\=)=I;82JW)EZ]\5N#(T6&Z
MDQM/5T4=5E9Z.:+&R4,<L34\:MY!*NZ\M07UYM3APMA"Q+1T[&Q7\L_*A'F,
MUXL^WWWRN?\`D'V_]QN4H]JVJXWOF&V$;;W+$(=Y@(41DRWJ#Q+F,*-(2;4W
MC$3%S33T;?XD_*/X)?,K;VXM[?#3LWH[N#%[$S8P>Z*WK:CQ-+FMI9>H2K6C
M.8Q4N+Q&X\)39B&DJ#CZN2GCILC##*U-)*B.0([9((:"%`@]``!^P=8Q;EO6
M_;E$T.Y;M=W;,,Z[ER:>>230?8>CR*+*!_0`?[Q[H>)Z0C`Z[]^Z]U[W[KW7
MO?NO=>]^Z]U3_P#]UJ?_`"SO_P"6#W[KW7__U]R?^7)_V0)\,?\`Q6+I/_WW
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MU["WW)O"3>G7_P`G^L^X>N\N,)V9U5W-)E,I59O&[NVYD:;[3)XR:2HQYAE$
MM(6AEBF8J_JGRP;00-MZB,<>.1C/VGSQUD%#]_3[U%GSC?\`.$'N6XW!B3]*
M+:#]W9';']'X84B,D$-342!5SGJVS;'>7Q;Q%=UMTUM3NSH:DS6X]G4=3U+U
MCA^T-@G-;GV!M_&U5%3UFP-IPYM\GN+:>+QV%J$\]%#/3)'22W:T;V$(312)
M&HM,4XCT%/L`ZQ#OKN\W*]N-TW2_:3=KB1[IVJ!JD=BSN:4PS,23ZFM<=:T_
M='QA_E$?*/N?;F]?C!\P:3%MW9W-N;I+%=>?&M]G;MZWK_E)MO96Z.W*;:-#
MO3+TT^U>G,WV3@]G5SX1*MX\)FLA`QQS,=<9!&X<B;1N=_\`O&*\FADXD#@2
M3Q%:D#SX_9Z==!_:O^\:]U^0^0CR)S9R=8<U.C4M[V_GN8IH5"46.[>)A+=Q
MBFE=8=PM0VKB`:^0'ST[>^:':7Q;VWV?M/LRH_E]_(+$[,RVU?C+M3IBK[5S
M7RIS/4FXZ[9/RA^#OR+H*?;-%N/$_-#K_P"1.U<35XR2GSVS>L\=L7&93*YF
MKK5:2B]C4"@`J33KGW/,US/-<NB*\CLQ"BB@L22%&>T5H/EU?-1?$WM',_S<
MI/F)C^N=G=&].]8_%W-]!Y3>FV=U8S)[S^;%?ONNV/N#;%+O;9."QE+3;,V5
M\99=LUE)CJO+5$V7KJRM6.F1<=$&][Z:ZMK'T'XX'^^XX]^Z]UW[]U[KWOW7
MNO>_=>Z][]U[JG__`+K4_P#EG?\`\L'OW7NO_]#<G_ER?]D"?#'_`,5BZ3_]
M]_@_?NO='1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1(_E;U;\P:ZFVON[X%]K]`]
M0]BX_/YO(]C;3[\Z;R&^^JN\*+-8.EP>-J-YYKKW<&RNT=N[FV!)2I78NLQ]
M>\56RFEK898"C0^Z]T6CJ'X+_(GXB?`O?71/QE[>ZQW_`/,/MW?_`&/W'W+\
MD?D5M/<E#LGL'N[OS=$V<[H[1JMD]:9"#(T%92T5=]MMW&Q5)IX8\?1QU<LH
M$TDGNO=5F97^1-\DZ[!_!WH\=R].2=!?'SK[X'4&]\OB\#C-N=C;/[*^).[L
MKO'MO/=?U8Z=RN\NT\;WY4926GQ/\;WA@Z;9WW=6XH<A',U,_NO5Q3RZ/=E?
MY0-#WYV/\MNPOE5V1A,;4]V0?'':/1U)\.-OY[XZYWX[[:^'N_-Y[]^-W;6W
MM]5VYM\;@7Y.[.KMXFE7/X\8_&T..I/LJ:B^TG:%/=>ZLO\`C+\5NE?B%UF>
MJ.B=M5>VML5FX,OO3<M9E,]F]T[HWOV%N5:-MW=C;VW1N*NR.9W%O?>-90K5
M92NFEU554SR%06]^Z]T8GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U3_`/\`
M=:G_`,L[_P#E@]^Z]U__T=R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW1,O
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M+UO\1]TX'`_/ZMGZD^/VX=_];=A]@Y&;Y2]DY'XUTFXNI<KLFKZ]GQ#)%MW)
MX_.SRFHH:OQ1.OOW7NA'Z^_G+9/>7\Q!O@E)T7L+)M3]JP].9+.]==^S;W[4
MQE7%\:=I_(O(]]U/3L_5&WJ,?$Y?[TQ[>I]WMN..KER+T[''*:A8%]U[JPC;
M/SS^/.[OE1N/X6X3,;OE^1^SI\Y4;MZ_J.OMWTLFW-GX;:NU=V4_9^6S4V+7
M"4G5NZ(MYT&-PF>,_P!AELXTN.@9JNFJ(XO=>ZK%Q/\`/ZZ@S?:1Z*Q/6<&5
M[NQ7R1^=_1^\>LL=O^LDSNU=I?"WK#N3LFB[4FJZCK^EP>0I>V8^KJ.EAQD5
M4),2<XCO/4M2RQ-[KW0&Y'_A0MN+$?$WXV?)ZNZ<^)L=)\E]P]C4N*2K^:6[
ML#UQUA1]8?&B#Y%YK8?:796XOBIC)\=WOG):B/;&+P./PU?BZC,5$-\IID"#
MW7NCX[9_F:=Q97Y3?`[IG<OQ%FV7UO\`/;IO)]C[/J\GVJM7\C>HLAMKIW&=
ML;RJNZ^A(-APXK9_7>V,IF*?:DN6_O/+4/G9XE-,C2QT[>Z]TC>P/YMW8/7'
MR-[NVCF?BOC*_P"*OQ[^7_QT^%_:G?F([PIW[*VQOOY+[8ZLR6RNQWZ+KNN*
M.@RO5F)W7W'@L-DVI-UR9N+[HU<%#4QQ2QI[KW05;M_GU;:V]US_`#'-^4?Q
M\^];X78RAWWT?35G;^(I,5\N.DY>^-T_&+-]U8;,46S\K+UML[:O=NPLS05R
MSTV5G6B@IZI`PJ41?=>Z3Q_G3_)K='5G3/9?3_PNZ0[-Q';/S>S'\O\`Q>\J
M#YDY.FZ;WGV\<C64VS^U>CNR:3XW96H[5^-^>3#Y&DK,\^*Q&3H,WCZBABQM
M8L+U`]U[K8<PT^5J<7C9LY14>-S$N.H)<OC\?729*AH<K)2Q/D:*CR,M)029
M"DI*MF2*=H(&E10QC0G2/=>Z=/?NO=4__P#=:G_RSO\`^6#W[KW7_]+<I_ES
M*R?`;X8JRE2/C%TE<,""+]?8(C@_X'W[KW1S_?NO=$D^6/P*Z=^8&\N@^R-]
M[@['V7V'\;<QOC(]8[RZVS&VZ'(4F-[,Q6%PO8&V<QB]Y[2WQM?*X;<^/V[0
MJ\IH$R=%)2I+0U=+*7=O=>ZKX_F+?R@-]_,&7"4O5WR-WOU[-NC,_)3$]J=E
M;][([;W=V!M?IOY5P]98SM?I/IS#8K.8[:J].Y#"=<Q0TNT<D8,503L)HI=#
MU<%5[KW1\MG_``QR_7W?.P^P]H_(7NK'=)["_P!(FY*?XZ3;MS.2V;G=^[YV
M5L?J[;E#D175TF-Q/1W3/7VRG?:>QL50T..H-RY>KR[2/.(T]^Z]T%NX_P"4
ME\9-Y;E^5%7N[='>^Y.K?F;7[LW%WW\;LIV:S=`[BWWO#$[,Q55V;A=IT^"I
MMQ[3['PG^C[$5>)RV/S%/48ROHHJB#3*B,ONO=-O57\H/XV];;QQO9NX.Q?D
MMWGVUC^_^H/D=)VOWOW#)O;?67WQT+U)OSI'JC%Y[(4&W]NX_+[4VKL'LC*Q
M?;RTIJJVLF6KJZF>I7R'W7NA=D_EO?&[_2ZO>M'!OG$]I1_+=_F?3[MQ&[9:
M#*TO:>0Z3Q/Q[W1MN"MBHC6#J7?/5V$IJ+-[;,AHLA)$LK$.B%/=>ZG;8_EZ
M]$[2^7^:^=.*R_:Y^1>YQN[$[KW)5=CYB?!;IZ_W/MS:>`QG46<VF47"U/5O
M7U7LVDS&W,8L<;XS.25-:)I)*J?7[KW21'\K;XH_PG;^$EQ>^ZC&[;[Y^4?R
M.QU-/O:OD5NR/F#L[M/8O<[51,&J?;]=@.XLTN/H20E#))$ZLWCL?=>Z16P/
MY1/QFVEM'IG8>]=Y=_?('9_Q_P`9V3M?J?;WR![-I]_8S;'77:W0<WQLW9U9
M]M2[;P"93KQ^L*AX::AJ_/)3U;&=9B?3[]U[KETG_*8Z/^/_`'KL7Y!]>=V_
M+9=Y;'ZIZNZ-.+W)W8-U;7W=U%TW@LC@]@]>[OH\WM:KR]9M?&2923(STM'7
M44==E[5E2)9]3-[KW7M\_P`HCXO=B]^]A]_;JW1W_5U'9_9FV.\=V=0TO;V4
MH.AZWO;8>Q<)U_U[W._7%+CXXJW??7^)VSCJK$&MJJK&TV5Q]-6FD>>GA9/=
M>Z#^;^1%_+D@VA@MG;3ZKSG6U/0]&Y'X^[PSW6^Z)MI;M[EV-DMZ[#[*DR'=
MNXZ*B>O[,WM3]C=>TF<BS->6K%R5562%BM04'NO=&)J/Y:/QCFRSY**CWY0T
M2?.K!?S%\;MJ@WMD*;;&"^36'PC8FOS.#Q*PD8_:&[J^>IR^8PH<T=9FJZIJ
M[(\SCW[KW5@/OW7NO>_=>ZJ$\$__``]+Y?#-XO\`9.K^7QOX[?WC\=_)IT?Y
MST_7Z\>_=>Z__],O/2/_`#)_K'_N)\_X\C"_\R#_`.9$?2H_YDK_`-^I_P"=
M%_U;_'[]U[H4O_4M3W[KW7O_`%+4]^Z]U[_U+4]^Z]U[_P!2U/?NO=>_]2U/
M?NO=>_\`4M3W[KW7O_4M3W[KW7O_`%+4]^Z]U[_U+4]^Z]U[_P!2U/?NO=>_
M]2U/?NO=>_\`4M3W[KW7O_4M3W[KW7O_`%+4]^Z]U[_U+4]^Z]UX?4?]Q:GU
I_/T_V/OW7N@._P":T_\`=Q7_`,7'_P`OD_YE7_\``N?_`"<]^Z]U_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g575431dsp_075d.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_075d.jpg
M_]C_X1LJ17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-SHS,"`Q-3HQ,SHU-P```Z`!
M``,````!``$``*`"``0````!````C*`#``0````!````I0`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``!GT`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`H`"(`P$B``(1
M`0,1`?_=``0`"?_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`[+ZO_5WZOW=!Z;==TS#L
MMLQ*'V/?CUN<YSJV.>][G,W.<YRT/^;'U:_\J<+_`-AJO_2:?ZM?^)SI7_A+
M'_\`/3%I)*<S_FQ]6O\`RIPO_8:K_P!)I?\`-CZM?^5.%_[#5?\`I-::22G,
M_P";'U:_\J<+_P!AJO\`TFE_S8^K7_E3A?\`L-5_Z36FDDIS/^;'U:_\J<+_
M`-AJO_2:HY.%]1L6UM%V#T\7.NJQO29C5V/;;>-V-7=7358ZCU6^YK[ME:T^
ML],_:G3K<,7V8CW0ZK(I<6OKL:=]5K=I;NV/'\W^>N.P.F_6C)LZ[EW8GV?J
MCLCICF$O+*;[,%U?VF['LVLW8F317N8Q[/9O]+^=24]7_P`V?JS,?LG!GP^S
MU?\`D$__`#8^K7_E3A?^PU7_`*37.7_57*PZF96'@,R<H]:?U+*JKN])]U37
MY3NG?I[3Z7ZIZ]%OV7^:_1_Z5_Z0/1,KZRX_5^D]#S,G(]5E%M_46F@V--K[
M/M9^T9UGZ)^%Z%MF#C685_Z#.J_2^I5^C24]3_S8^K7_`)4X7_L-5_Z32_YL
M?5K_`,J<+_V&J_\`2:T@G24YG_-CZM?^5.%_[#5?^DTO^;'U:_\`*G"_]AJO
M_2:TTDE.9_S8^K7_`)4X7_L-5_Z32_YL?5K_`,J<+_V&J_\`2:TTDE//=<^K
MGU>JZ)U"VKI>&RQF+<YCVX]0((K>6N:X,26C]8?^0>I?^%+_`/SV]))3_]#T
M/ZM?^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E))))*4DDF24I`S<W
M'PL<Y&2[92US6N?V&]S:FN=_)WO6)]9>I8K\5V,RV;ZW-?Z&XUN?!TV:>_8[
M](U]+_YQ<Q9U_-ZCC7XC\H7U>I-NT<.V[?3_`'75;OTNS_2J+)EX1*@9<(N1
M`XHPXO3'W/[TFMFYN&.P-95TU$3_`%WILSKN17UC9ZU>/TW$L+,HG5S_`-'Z
MLG3V;7GTZV5_SBT:OK!TI^;7T]V0VO.M`+<5YBR=OJN9M_?8SZ:\[QJKJJ6L
MOM^T6M)_2F9(_-G=[MS5<9U<8`IR[ZZGCIP><6QS8<U]DAWJ7-_36UO=8ZQ]
M3?YVQ-AFC[LH:S!)C`X_5QR^2'!&7#Z&OCY[U$2&A/\`?_Q?Y?\`3?2I"=97
MU>RFY/3ZGG.9U"\C??=6X$`O][6;6AOI-:WZ+-C%JJ8&QM7@70C+BB#W"DDD
MD4J22224Y_UA_P"0>I?^%+__`#V])+ZP_P#(/4O_``I?_P">WI)*?__1]#^K
M7_B<Z5_X2Q__`#TQ:2S?JU_XG.E?^$L?_P`],6DDI22222E*%MC*:GVV':RM
MI<]W@`-SBIH%^3CU159<RNRP0QKGAA,Z>V?<DI\]Z]U/IM_5ZSAN#VY<EKZF
M6-9/[UOK17ZMG_=?_KRKX^.UUGI4M94;"2=-H)[ET?G+0Z]A#I^4YKLDY.1:
M'9%M+07.94T?SMMI^GN_JUK)QLBK*H9D53Z=G&X01!ARHS!^;@(`,8YB)7">
M67%./^SXH1G^^XF6QD)G&O5<Q$Z=_P#`7RJ[WTV546^E<##+!Q(.ON_<>I;9
MK#+8L.T"R1[7'\X[5/)-%1>ZESK*:V[IB7&![@UJ%1=5D4,OK)%=@TW"/([D
MT^X,>PX(3^>/^<G'Y?=^;Y(<46.0(L::$Z@\0_QWI/JI7U!^;0&7[,#'K<YV
M.R&M]_L8U[&M&^S_``GJ/78A<=]7.KYE'MZB^[`P:G>E4S.I#6O;'MLQ\^O;
M6UK7?FW;_P!'_A%U#^J=-K8Y[\JH-98*7'>W2P@6-IY_G?3=ZFS_`$:O0QRA
M&I`@Z'U'BZ?HR=CE@!C`'%X\9XOL_JMI)#^T4>J^GU&^I6&E[)U`L+FU;O\`
MC',=L3OMKK8^RQX8RL%SWN(`:`-SG/<?H^U.9V:2KT]0P+[*ZJ<FJRRZD9-3
M&/:YSJ7$!N2QK3N=0[=_._05A)3G_6'_`)!ZE_X4O_\`/;TDOK#_`,@]2_\`
M"E__`)[>DDI__]+T/ZM?^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E
M))))*195KZ<:ZZMAM?6QSV5CEQ:"YK!_77G^'@865AU9F=37GY74:J\G+RLA
MHL=8ZYHMV,W?S.-C[OLV-CT>FRIE/^D7H-^11CTOOR+&TTU-+K+'D-:UH^DY
M[W>UK5YGF_6+H.'=/U>-^9A6N=8_`=4ZJAIL(?9;TW-RA4["]^^YV+Z>1@W?
MX*JC^<4F$$RTB9?W1Q+)U5D@>>CI5LSNGAYZ>!GT.`_R?EO][2T?HOL?4+=V
M^FK_``?3\[]%_H[ECY>1BU,L?BVNL&*&#+9D,--]=EGYAPHW^FW_`$[/4H_X
M:Q;&!U#!ZG4ZW!L]3TX]:EXV7U3_`-R<<RYG_',]3'_X5+J'3L'J=3:\ZKU=
M@(JN:=EU<_Z#(;[V?\7[Z?\`@T9\MBG(&420#K$&K_\`0FOEPPR`<6XV/FY^
M!C9>;ZC:ZRRZJOU@QQ#-S?8=U;[2QO\`-V>JB8N7]5\9_J=8ZC0XU6V568-1
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ML&UMU-@WXV5Z?^#L?#ZLBMGZ/[13;Z7Z+TT.8PC#/@B;%7VX?`NAAGQP!X>'
MI0V^CD9'U`ILIJJJSK*VM#1:"T.%CR<EU^<^3_RA^N>KBY/_`&CR**K?35AG
MU+IJP^I8M&;?5^UFM;E7"#8?TV1??9O?N;Z^1C97V)]NS^;IJ>NE24+(\_TO
MZJGIF=AY%.5OHP:+\:NI]0-AJML&134[*W;MF)M]*IFSZ"Z!)))3G_6'_D'J
M7_A2_P#\]O22^L/_`"#U+_PI?_Y[>DDI_]/T/ZM?^)SI7_A+'_\`/3%I+-^K
M7_B<Z5_X2Q__`#TQ:22E))))*>/_`,9[<@_5^AS)^S5YE3LV/H^D!9Z;K_WZ
M&9?V9]B\X>Z)=8X#N7.(_P"JE>R]>ZG3T[IS[K*/M;[BW'HQ/:/6MN/IUX\V
M>S8^?TSW?S=/J6+BZ.ELQ[?79TKH;["=QK^SVAH,S^AOL-K/[;<2E/C\4P\F
M.#*1^L-QUE_SN&,_2LER<\YXH?HBCI;QF/:;LBM^";KLJD_H;,)KWW,/A79C
MM?X_S;_T2['`R_K"S$=D=<Z5D58]7/4&5M:X@#6S+Z72Y^17M_PE^+7Z7_`+
MH,;ZT96-6*[^C/96SO@V57,`_P"*/V:S_P`#5AWUUZ.7_9ZZ\JSJ+@'5].%%
M@R'`_G;+&LK95_PUMM='_")'XCCSD&$L1/\`5E<Z_K?^B*'*RQ"I<7U^7_!<
MJA_J-KOQGBQCAOJNJ<'-('Y[+6';[5AY'1L'K%YRNCX1R7-=^M756?9NG7NF
M'UVV,?4Z_);M=^L=,]F_^D^LMVOZMUYF5=G=4I9CMR7"RSI&+8X8SGCW^MU,
ML].OJ&9N/Z7TV5XW^E^U?SBW`&L8&M`:RIL`"&M8QH_-'MKJJ8T*#+SU:8QZ
MOWKV_NLL.7O61T[-/ZH#HM5=^+A]+'1NH4!@S\1P:;/<"ZJS[6PN^VXSOTOH
M7[_^VU8Z'?\`M+JG4.KU0<%XKP\.P<6MQS:^[)K/Y]+LC(LJIL_POH^I_-K)
M9TS`^MG4;,B;7=*Q\<X@RJ7NK9E6%[GVULV?TW!PMOL<_P#5;,A]O\][UM=%
MRLNG+OZ+U!PLOPV,LQLAK6L%V,_=76]U-7Z.J_'LK?1>RMK*_P":MKKK];TT
MZ$C*()%$[A!`!H.PDDDG(4DDDDIS_K#_`,@]2_\`"E__`)[>DE]8?^0>I?\`
MA2__`,]O224__]3T/ZM?^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E
M))))*<GZQ=+R.H8-?V0M^UX=S,K&:\PQ[ZY#J;3!VLOILMIW_P"#W^HN8LSF
M8S'.S\?)Z:RO^<LRZB*FZ[=OVW'];&?[O;7[OTJ[JZUE--EUAAE;2]Y'@T;G
M+F.GX]G4AC]:ZH?6R;6LR,3&)W48C7`V4-HI]M=N:VJS]/GVL]7?_1_1I]BH
M\]RN#*!/)Q"0'#&4-S^EPRXFQR^;)"Q"B#N"T,?'ZGU,!V,'=-PC_P!K;V?K
M-@G_`+08-O\`1JW1_3,W])_HL9;/3^G8?3:'4XC"P6'==8]Q?;:[_29619-E
MKO\`H(V3DT8M%F7EVMIHJ@VWVN#6-D[6[['?O.=M8U963F]6RV`X5;^G8MDM
MJRKJ_P!;N(=!^P8%OMPV;&[_`+3U#]/_`*+"4/+\L`.'%$0B?FGUE_?G^G_=
M7Y,NMS/$>@_L;74NLX?3GMH?OOS;&[J<&@!U[A.WU'-,,QL?_NSDNJJ6)F4]
M2ZL`>I9'V>H.#V=-Q8?CB#N:WJ+[V[NJ_F^I5^AQ?^#4.G]+S<;U*L7-H]X-
MEEF;2[U;7MEUCLS/Q[FV76?2=OMJ5S[-]8&,99;THW,<W<'X>0QYC_B,UN#;
MN_D;U#F^]\1CR\143K*$HG+Z?[W\W_=78I\O+^<E_@D&,0V<#KW5<"_&IZ@:
M<O!NL9C-MHJ--M+[#Z6-OH:ZRJW&>_;3^B]/T%I8=@S_`*T9.71KC=.Q_L)M
M$$/O>_U\FICA]+[(VNFNW_A[+*O\"]83>E9_7"W!=B7X6!8]IS\C)`I>ZMA%
MGV/$I98^]UF0[VV97Z*JFG?Z7JV+L\;%Q\2BO&QJF4T5#;756`UK1X-:U:'(
MRYB6&^9%3XC5CAGP=../Z+!S`Q"?ZH^FOQ\$R222M,*DDDDE.?\`6'_D'J7_
M`(4O_P#/;TDOK#_R#U+_`,*7_P#GMZ22G__5]#^K7_B<Z5_X2Q__`#TQ:2S?
MJU_XG.E?^$L?_P`],6DDI22222EB`X$$2#H0>"N<KZ3UWIE7V'IS<7,P:F[<
M-V5;;5;2P;MF/=Z5.5]KIQV[&4V;L>[T_P!%9_IUTB@]S-&.<&E\ANL$Z?FI
MLX1D*D+2)$;/)9&)]EZAC9>9D#J?4*P;&;F;<6D$G9]@QFN=74_\W[38_)S?
M^'_P:EU'JUMF&7Y;OT.(QUMKFC5VWBS;_I&_03YU3JLNQNUS&N,C>&M)\7_H
MO8L^C/KOSLG!;5:Q^*`7V6-`K>"=OZ*?IM_ZM8N;+FR3R<(G''C`EF@)[0C.
M,)3CQ?S?%Z/WV*4C>^^C/!R:.H8M.52'"F\2T6-VN$';[F_UD_3>NYO4J;K-
MM^+8QYQR[(^D!/O]"SV[?^']N]GL1';G<=N?"`I.<YQEQ+HTUUT4!R1C&<HB
MCED>"LDSDY>$)?)D],(9O<A/YO\`JGZI&NFKTN)EXK<7<S>S'H&UMM@@/`'T
MZ]Q]2S^M_A%@6],^LKLS(MJL?9BTW,RNG5W6D;C>X79-&4P/:[TNFNK_`%.E
MWZ/]/_A/\&;HF,S(SA:^P-MQSN94?<7-(VN=[OS6KIH6YRTY2QCB$=#7ZN49
MX_\`!X?W?D9!L\@S#^O>.YKJKJ[;+74.ON?Z<OL;7BMR/M-7MJIZ=[<^O9TY
MC,[U_LO^"]:U$LP_KO=T;+PK,@'+RK*13F!S*7T5O96_/AV*W_M/:VZG%>UO
MK_I/476)E.EYSHF-]8/VT<KJE=M-;<.NE^S(%N/=D`CULEN,^W=B_P`VW[/Z
M6/7ZGJW?:5TB222G/^L/_(/4O_"E_P#Y[>DE]8?^0>I?^%+_`/SV]))3_];T
M/ZM?^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E))))*4LKK]/3&8QZ
MGU!QKKP&.?O!<!![$5^_Z6WZ"U4.ZBF^I]-[&VU6#:^MX#FN!Y:]CO:Y*@=#
ML=_)3QM9%N'3G8Y:_%RM<=^LN'<^F_\`2-V_RU(N>=K9EHY'@NAR.DT/L==8
M#9777LHQV#:QC6CZ+&,^F]SE@/Q[,=[?M3#4Y[0]TP2&$[=SMOT/[2P^8P1P
M$WC]`]SVY$>Y.Y>B/O2CP8X_I3Q<$/\`J:RJZ-+-QL^^[$=AY?V6JFS=DLB3
M8W3V_P`KV[F>F[_2>HK9:76`M![PP:JITU_5+F93NH4UT^E8YU'ID&:!])SH
M)W;/;^D=^D5X]%OZMC6XHLLQJW.%5MM1VVL_/_.^DS\RYB:(9#EQ\OQ8_3^J
M]W%&&:/MY_YR9R0_G_;XY^K]#_)+(ZV0-^[H8C\[!Q&95>(S+8Z-HK!&0`X_
MGR/<U=`TR`8B>Q57IN"_!QF8YR+,EM;6L8ZV"[VC:3N:&[MZMK8Y;'[>*,#=
MC>V4;*2224R5))))*<_ZP_\`(/4O_"E__GMZ27UA_P"0>I?^%+__`#V]))3_
M`/_7]#^K7_B<Z5_X2Q__`#TQ:2S?JU_XG.E?^$L?_P`],6DDI22222E))))*
M66!B_6GZL9+;\PY#<>ASQ7]JRVFFJ[9O8W[)?DAE60VM]5WLJ_/]1;SV![',
M)(#@02TD$3^ZYON:N?QOJ?5C7X]@RGY#:LY_4KQD5UN-M[J'85#YH9C55/H_
MI'J>CZEU_P"E_G$"`=Q=*;F3=T5EU/5;,RIC'466[@YI;=0UK7/O:)_2UT,>
MQWJU_F(3?K#T?'^L#NA2^O,O:W(]0C]"]]@(92RV?Z0^JAUFS;[UBU?4"[T>
ME8-N4QF!TS!R<5[:VN-MMN=793GV>H]P952Q[Z[,=FS_`(S_``:-@_5/(S<=
MK.K`U5W]-P\:T!_ZTS,PW7.KS67U>I4RQGK;Z[&6V>_^=]G\XV..$22(@6>(
M_P![Y>)3UR=#QZW4X]53['7/K8UKKGQN>6C:;'[`QF]_TG;&HB>I22222E))
M))*<_P"L/_(/4O\`PI?_`.>WI)?6'_D'J7_A2_\`\]O224__T/0_JU_XG.E?
M^$L?_P`],6DL#ZO=;Z+5T#IE5O4,9EC,2AKV.NK!#FUL:]KFE_M<URT/^<'0
M?_++$_[?K_\`)I*;Z2H?\X.@_P#EEB?]OU_^32_YP=!_\LL3_M^O_P`FDIEU
MGJV+T;IF1U/,)]#&;N<&B7.)(9776/\`26V.96Q9K/K3:WHUG4,SIU^+ELM&
M/5@/(]2VQ[VX^-Z#G>F[T<BZQK&W6U5?G^Q6LOJOU8S<>S%R\W"OQ[1MLJLN
MJ<UP_E-+UF9N%]2,G`=A59>#BAU+<<75OQGV"EMGVKT)RFY#75.O_2.WL_G/
MTG\XDIT^A=<'5<)^1=1]BMJMMHLJ<]KP74N]"Y]-S=OK4>O^B;;M6+]:_K=U
M'HN;GX^-BNR&X_3&9E5C&!S:['6W8Y?E.-M7Z#;77[:V[_YU2HZ5]0Z,+"PF
MYF,ZK`+"USLBO?:*WORJZLRT.:^_'^UV?:_LO]&]?_!+5R,WZHY3K79&3@7.
MOJ%%I?94XNJ!<\4OW.]U6][G;$E//V_7O-P<C,NSJJST[&R^H8+7,(9^EQ:J
MLWI];[+'_P`[F5_:L?8UG\_Z2M]3ZO\`66AW0.G-MQL3/ZC1?=G775E];'XU
M5>0^D,;8S;4ZRQU5EOJ>QGZ1:+[_`*EO8^M]O37,LO\`M3VE])#K]/UIVO\`
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M57U##96P!K&-NK```AK6@/\`S5+_`)P=!_\`++$_[?K_`/)I*;Z2H?\`.#H/
M_EEB?]OU_P#DTO\`G!T'_P`LL3_M^O\`\FDI;ZP_\@]2_P#"E_\`Y[>DJ77>
MM]%MZ)U"NOJ&*][\6]K6MNK))-;X`&]))3__V?_M(P90:&]T;W-H;W`@,RXP
M`#A"24T$!```````#QP!6@`#&R5''`(```(````X0DE-!"4``````!#-S_I]
MJ,>^"05P=JZO!<-..$))300Z``````#M````$`````$```````MP<FEN=$]U
M='!U=`````4`````4'-T4V)O;VP!`````$EN=&5E;G5M`````$EN=&4`````
M0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L``````MP<FEN=&5R3F%M951%
M6%0````%`%``4P`M`#<```````]P<FEN=%!R;V]F4V5T=7!/8FIC````#`!0
M`'(`;P!O`&8`(`!3`&4`=`!U`'````````IP<F]O9E-E='5P`````0````!"
M;'1N96YU;0````QB=6EL=&EN4')O;V8````)<')O;V9#35E+`#A"24T$.P``
M```"+0```!`````!```````2<')I;G1/=71P=71/<'1I;VYS````%P````!#
M<'1N8F]O;```````0VQB<F)O;VP``````%)G<TUB;V]L``````!#<FY#8F]O
M;```````0VYT0V)O;VP``````$QB;'-B;V]L``````!.9W1V8F]O;```````
M16UL1&)O;VP``````$EN=')B;V]L``````!"8VMG3V)J8P````$```````!2
M1T)#`````P````!29"`@9&]U8D!OX````````````$=R;B!D;W5B0&_@````
M````````0FP@(&1O=6)`;^````````````!"<F1456YT1B-2;'0`````````
M``````!";&0@56YT1B-2;'0```````````````!2<VQT56YT1B-0>&Q`<L``
M``````````IV96-T;W)$871A8F]O;`$`````4&=0<V5N=6T`````4&=0<P``
M``!09U!#`````$QE9G15;G1&(U)L=````````````````%1O<"!5;G1&(U)L
M=````````````````%-C;"!5;G1&(U!R8T!9````````````$&-R;W!7:&5N
M4')I;G1I;F=B;V]L``````YC<F]P4F5C=$)O='1O;6QO;F<`````````#&-R
M;W!296-T3&5F=&QO;F<`````````#6-R;W!296-T4FEG:'1L;VYG````````
M``MC<F]P4F5C=%1O<&QO;F<``````#A"24T#[0``````$`$L`````0`"`2P`
M```!``(X0DE-!"8```````X`````````````/X```#A"24T$#0``````!```
M`'@X0DE-!!D```````0````>.$))30/S```````)```````````!`#A"24TG
M$```````"@`!``````````(X0DE-`_4``````$@`+V9F``$`;&9F``8`````
M``$`+V9F``$`H9F:``8```````$`,@````$`6@````8```````$`-0````$`
M+0````8```````$X0DE-`_@``````'```/__________________________
M__\#Z`````#_____________________________`^@`````____________
M_________________P/H`````/____________________________\#Z```
M.$))300(```````0`````0```D````)``````#A"24T$'@``````!``````X
M0DE-!!H``````T4````&``````````````"E````C`````@`9`!S`'``7P`P
M`#<`-0!C`````0`````````````````````````!``````````````",````
MI0`````````````````````!`````````````````````````!`````!````
M````;G5L;`````(````&8F]U;F1S3V)J8P````$```````!28W0Q````!```
M``!4;W`@;&]N9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````
MI0````!29VAT;&]N9P```(P````&<VQI8V5S5FQ,<P````%/8FIC`````0``
M````!7-L:6-E````$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO
M;F<`````````!F]R:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'
M96YE<F%T960`````5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````
M!F)O=6YD<T]B:F,````!````````4F-T,0````0`````5&]P(&QO;F<`````
M`````$QE9G1L;VYG``````````!"=&]M;&]N9P```*4`````4F=H=&QO;F<`
M``",`````W5R;%1%6%0````!````````;G5L;%1%6%0````!````````37-G
M951%6%0````!```````&86QT5&%G5$585`````$```````YC96QL5&5X=$ES
M2%1-3&)O;VP!````"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE
M;G5M````#T53;&EC94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG
M;F5N=6T````/15-L:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO
M<E1Y<&5E;G5M````$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P
M3W5T<V5T;&]N9P`````````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O
M;4]U='-E=&QO;F<`````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H
M```````,`````C_P````````.$))3004```````$`````CA"24T$#``````:
M$`````$```"(````H````9@``/\````9]``8``'_V/_M``Q!9&]B95]#30`!
M_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3
M%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-
M#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,_\``$0@`H`"(`P$B``(1`0,1`?_=``0`"?_$`3\`
M``$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`````````
M`0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q
M@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87
MTE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=W
MAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4
MH;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B
M\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>W
MQ__:``P#`0`"$0,1`#\`[+ZO_5WZOW=!Z;==TS#LMLQ*'V/?CUN<YSJV.>][
MG,W.<YRT/^;'U:_\J<+_`-AJO_2:?ZM?^)SI7_A+'_\`/3%I)*<S_FQ]6O\`
MRIPO_8:K_P!)I?\`-CZM?^5.%_[#5?\`I-::22G,_P";'U:_\J<+_P!AJO\`
MTFE_S8^K7_E3A?\`L-5_Z36FDDIS/^;'U:_\J<+_`-AJO_2:HY.%]1L6UM%V
M#T\7.NJQO29C5V/;;>-V-7=7358ZCU6^YK[ME:T^L],_:G3K<,7V8CW0ZK(I
M<6OKL:=]5K=I;NV/'\W^>N.P.F_6C)LZ[EW8GV?JCLCICF$O+*;[,%U?VF['
MLVLW8F317N8Q[/9O]+^=24]7_P`V?JS,?LG!GP^SU?\`D$__`#8^K7_E3A?^
MPU7_`*37.7_57*PZF96'@,R<H]:?U+*JKN])]U37Y3NG?I[3Z7ZIZ]%OV7^:
M_1_Z5_Z0/1,KZRX_5^D]#S,G(]5E%M_46F@V--K[/M9^T9UGZ)^%Z%MF#C68
M5_Z#.J_2^I5^C24]3_S8^K7_`)4X7_L-5_Z32_YL?5K_`,J<+_V&J_\`2:T@
MG24YG_-CZM?^5.%_[#5?^DTO^;'U:_\`*G"_]AJO_2:TTDE.9_S8^K7_`)4X
M7_L-5_Z32_YL?5K_`,J<+_V&J_\`2:TTDE//=<^KGU>JZ)U"VKI>&RQF+<YC
MVX]0((K>6N:X,26C]8?^0>I?^%+_`/SV]))3_]#T/ZM?^)SI7_A+'_\`/3%I
M+-^K7_B<Z5_X2Q__`#TQ:22E))))*4DDF24I`S<W'PL<Y&2[92US6N?V&]S:
MFN=_)WO6)]9>I8K\5V,RV;ZW-?Z&XUN?!TV:>_8[](U]+_YQ<Q9U_-ZCC7XC
M\H7U>I-NT<.V[?3_`'75;OTNS_2J+)EX1*@9<(N1`XHPXO3'W/[TFMFYN&.P
M-95TU$3_`%WILSKN17UC9ZU>/TW$L+,HG5S_`-'ZLG3V;7GTZV5_SBT:OK!T
MI^;7T]V0VO.M`+<5YBR=OJN9M_?8SZ:\[QJKJJ6LOM^T6M)_2F9(_-G=[MS5
M<9U<8`IR[ZZGCIP><6QS8<U]DAWJ7-_36UO=8ZQ]3?YVQ-AFC[LH:S!)C`X_
M5QR^2'!&7#Z&OCY[U$2&A/\`?_Q?Y?\`3?2I"=97U>RFY/3ZGG.9U"\C??=6
MX$`O][6;6AOI-:WZ+-C%JJ8&QM7@70C+BB#W"DDDD4J22224Y_UA_P"0>I?^
M%+__`#V])+ZP_P#(/4O_``I?_P">WI)*?__1]#^K7_B<Z5_X2Q__`#TQ:2S?
MJU_XG.E?^$L?_P`],6DDI22222E*%MC*:GVV':RMI<]W@`-SBIH%^3CU159<
MRNRP0QKGAA,Z>V?<DI\]Z]U/IM_5ZSAN#VY<EKZF6-9/[UOK17ZMG_=?_KRK
MX^.UUGI4M94;"2=-H)[ET?G+0Z]A#I^4YKLDY.1:'9%M+07.94T?SMMI^GN_
MJUK)QLBK*H9D53Z=G&X01!ARHS!^;@(`,8YB)7">67%./^SXH1G^^XF6QD)G
M&O5<Q$Z=_P#`7RJ[WTV546^E<##+!Q(.ON_<>I;9K#+8L.T"R1[7'\X[5/)-
M%1>ZESK*:V[IB7&![@UJ%1=5D4,OK)%=@TW"/([DT^X,>PX(3^>/^<G'Y?=^
M;Y(<46.0(L::$Z@\0_QWI/JI7U!^;0&7[,#'K<YV.R&M]_L8U[&M&^S_``GJ
M/78A<=]7.KYE'MZB^[`P:G>E4S.I#6O;'MLQ\^O;6UK7?FW;_P!'_A%U#^J=
M-K8Y[\JH-98*7'>W2P@6-IY_G?3=ZFS_`$:O0QRA&I`@Z'U'BZ?HR=CE@!C`
M'%X\9XOL_JMI)#^T4>J^GU&^I6&E[)U`L+FU;O\`C',=L3OMKK8^RQX8RL%S
MWN(`:`-SG/<?H^U.9V:2KT]0P+[*ZJ<FJRRZD9-3&/:YSJ7$!N2QK3N=0[=_
M._05A)3G_6'_`)!ZE_X4O_\`/;TDOK#_`,@]2_\`"E__`)[>DDI__]+T/ZM?
M^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E))))*195KZ<:ZZMAM?6Q
MSV5CEQ:"YK!_77G^'@865AU9F=37GY74:J\G+RLAHL=8ZYHMV,W?S.-C[OLV
M-CT>FRIE/^D7H-^11CTOOR+&TTU-+K+'D-:UH^DY[W>UK5YGF_6+H.'=/U>-
M^9A6N=8_`=4ZJAIL(?9;TW-RA4["]^^YV+Z>1@W?X*JC^<4F$$RTB9?W1Q+)
MU5D@>>CI5LSNGAYZ>!GT.`_R?EO][2T?HOL?4+=V^FK_``?3\[]%_H[ECY>1
MBU,L?BVNL&*&#+9D,--]=EGYAPHW^FW_`$[/4H_X:Q;&!U#!ZG4ZW!L]3TX]
M:EXV7U3_`-R<<RYG_',]3'_X5+J'3L'J=3:\ZKU=@(JN:=EU<_Z#(;[V?\7[
MZ?\`@T9\MBG(&420#K$&K_\`0FOEPPR`<6XV/FY^!C9>;ZC:ZRRZJOU@QQ#-
MS?8=U;[2QO\`-V>JB8N7]5\9_J=8ZC0XU6V568-1-Y<&"&/:W%!M;^F_ZV^M
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MBMGZ/[13;Z7Z+TT.8PC#/@B;%7VX?`NAAGQP!X>'I0V^CD9'U`ILIJJJSK*V
MM#1:"T.%CR<EU^<^3_RA^N>KBY/_`&CR**K?35AGU+IJP^I8M&;?5^UFM;E7
M"#8?TV1??9O?N;Z^1C97V)]NS^;IJ>NE24+(\_TOZJGIF=AY%.5OHP:+\:NI
M]0-AJML&134[*W;MF)M]*IFSZ"Z!)))3G_6'_D'J7_A2_P#\]O22^L/_`"#U
M+_PI?_Y[>DDI_]/T/ZM?^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E
M))))*>/_`,9[<@_5^AS)^S5YE3LV/H^D!9Z;K_WZ&9?V9]B\X>Z)=8X#N7.(
M_P"JE>R]>ZG3T[IS[K*/M;[BW'HQ/:/6MN/IUX\V>S8^?TSW?S=/J6+BZ.EL
MQ[?79TKH;["=QK^SVAH,S^AOL-K/[;<2E/C\4P\F.#*1^L-QUE_SN&,_2LER
M<\YXH?HBCI;QF/:;LBM^";KLJD_H;,)KWW,/A79CM?X_S;_T2['`R_K"S$=D
M=<Z5D58]7/4&5M:X@#6S+Z72Y^17M_PE^+7Z7_`+H,;ZT96-6*[^C/96SO@V
M57,`_P"*/V:S_P`#5AWUUZ.7_9ZZ\JSJ+@'5].%%@R'`_G;+&LK95_PUMM='
M_")'XCCSD&$L1/\`5E<Z_K?^B*'*RQ"I<7U^7_!<JA_J-KOQGBQCAOJNJ<'-
M('Y[+6';[5AY'1L'K%YRNCX1R7-=^M756?9NG7NF'UVV,?4Z_);M=^L=,]F_
M^D^LMVOZMUYF5=G=4I9CMR7"RSI&+8X8SGCW^MU,L].OJ&9N/Z7TV5XW^E^U
M?SBW`&L8&M`:RIL`"&M8QH_-'MKJJ8T*#+SU:8QZOWKV_NLL.7O61T[-/ZH#
MHM5=^+A]+'1NH4!@S\1P:;/<"ZJS[6PN^VXSOTOH7[_^VU8Z'?\`M+JG4.KU
M0<%XKP\.P<6MQS:^[)K/Y]+LC(LJIL_POH^I_-K)9TS`^MG4;,B;7=*Q\<X@
MRJ7NK9E6%[GVULV?TW!PMOL<_P#5;,A]O\][UM=%RLNG+OZ+U!PLOPV,LQLA
MK6L%V,_=76]U-7Z.J_'LK?1>RMK*_P":MKKK];TTZ$C*()%$[A!`!H.PDDDG
M(4DDDDIS_K#_`,@]2_\`"E__`)[>DE]8?^0>I?\`A2__`,]O224__]3T/ZM?
M^)SI7_A+'_\`/3%I+-^K7_B<Z5_X2Q__`#TQ:22E))))*<GZQ=+R.H8-?V0M
M^UX=S,K&:\PQ[ZY#J;3!VLOILMIW_P"#W^HN8LSF8S'.S\?)Z:RO^<LRZB*F
MZ[=OVW'];&?[O;7[OTJ[JZUE--EUAAE;2]Y'@T;G+F.GX]G4AC]:ZH?6R;6L
MR,3&)W48C7`V4-HI]M=N:VJS]/GVL]7?_1_1I]BH\]RN#*!/)Q"0'#&4-S^E
MPRXFQR^;)"Q"B#N"T,?'ZGU,!V,'=-PC_P!K;V?K-@G_`+08-O\`1JW1_3,W
M])_HL9;/3^G8?3:'4XC"P6'==8]Q?;:[_29619-EKO\`H(V3DT8M%F7EVMIH
MJ@VWVN#6-D[6[['?O.=M8U963F]6RV`X5;^G8MDMJRKJ_P!;N(=!^P8%OMPV
M;&[_`+3U#]/_`*+"4/+\L`.'%$0B?FGUE_?G^G_=7Y,NMS/$>@_L;74NLX?3
MGMH?OOS;&[J<&@!U[A.WU'-,,QL?_NSDNJJ6)F4]2ZL`>I9'V>H.#V=-Q8?C
MB#N:WJ+[V[NJ_F^I5^AQ?^#4.G]+S<;U*L7-H]X-EEF;2[U;7MEUCLS/Q[FV
M76?2=OMJ5S[-]8&,99;THW,<W<'X>0QYC_B,UN#;N_D;U#F^]\1CR\143K*$
MHG+Z?[W\W_=78I\O+^<E_@D&,0V<#KW5<"_&IZ@:<O!NL9C-MHJ--M+[#Z6-
MOH:ZRJW&>_;3^B]/T%I8=@S_`*T9.71KC=.Q_L)M$$/O>_U\FICA]+[(VNFN
MW_A[+*O\"]83>E9_7"W!=B7X6!8]IS\C)`I>ZMA%GV/$I98^]UF0[VV97Z*J
MFG?Z7JV+L\;%Q\2BO&QJF4T5#;756`UK1X-:U:'(RYB6&^9%3XC5CAGP=../
MZ+!S`Q"?ZH^FOQ\$R222M,*DDDDE.?\`6'_D'J7_`(4O_P#/;TDOK#_R#U+_
M`,*7_P#GMZ22G__5]#^K7_B<Z5_X2Q__`#TQ:2S?JU_XG.E?^$L?_P`],6DD
MI22222EB`X$$2#H0>"N<KZ3UWIE7V'IS<7,P:F[<-V5;;5;2P;MF/=Z5.5]K
MIQV[&4V;L>[T_P!%9_IUTB@]S-&.<&E\ANL$Z?FILX1D*D+2)$;/)9&)]EZA
MC9>9D#J?4*P;&;F;<6D$G9]@QFN=74_\W[38_)S?^'_P:EU'JUMF&7Y;OT.(
MQUMKFC5VWBS;_I&_03YU3JLNQNUS&N,C>&M)\7_HO8L^C/KOSLG!;5:Q^*`7
MV6-`K>"=OZ*?IM_ZM8N;+FR3R<(G''C`EF@)[0C.,)3CQ?S?%Z/WV*4C>^^C
M/!R:.H8M.52'"F\2T6-VN$';[F_UD_3>NYO4J;K-M^+8QYQR[(^D!/O]"SV[
M?^']N]GL1';G<=N?"`I.<YQEQ+HTUUT4!R1C&<HBCED>"LDSDY>$)?)D],(9
MO<A/YO\`JGZI&NFKTN)EXK<7<S>S'H&UMM@@/`'TZ]Q]2S^M_A%@6],^LKLS
M(MJL?9BTW,RNG5W6D;C>X79-&4P/:[TNFNK_`%.EWZ/]/_A/\&;HF,S(SA:^
MP-MQSN94?<7-(VN=[OS6KIH6YRTY2QCB$=#7ZN49X_\`!X?W?D9!L\@S#^O>
M.YKJKJ[;+74.ON?Z<OL;7BMR/M-7MJIZ=[<^O9TYC,[U_LO^"]:U$LP_KO=T
M;+PK,@'+RK*13F!S*7T5O96_/AV*W_M/:VZG%>UOK_I/476)E.EYSHF-]8/V
MT<KJE=M-;<.NE^S(%N/=D`CULEN,^W=B_P`VW[/Z6/7ZGJW?:5TB222G/^L/
M_(/4O_"E_P#Y[>DE]8?^0>I?^%+_`/SV]))3_];T/ZM?^)SI7_A+'_\`/3%I
M+-^K7_B<Z5_X2Q__`#TQ:22E))))*4LKK]/3&8QZGU!QKKP&.?O!<!![$5^_
MZ6WZ"U4.ZBF^I]-[&VU6#:^MX#FN!Y:]CO:Y*@=#L=_)3QM9%N'3G8Y:_%RM
M<=^LN'<^F_\`2-V_RU(N>=K9EHY'@NAR.DT/L==8#9777LHQV#:QC6CZ+&,^
MF]SE@/Q[,=[?M3#4Y[0]TP2&$[=SMOT/[2P^8P1P$WC]`]SVY$>Y.Y>B/O2C
MP8X_I3Q<$/\`J:RJZ-+-QL^^[$=AY?V6JFS=DLB38W3V_P`KV[F>F[_2>HK9
M:76`M![PP:JITU_5+F93NH4UT^E8YU'ID&:!])SH)W;/;^D=^D5X]%OZMC6X
MHLLQJW.%5MM1VVL_/_.^DS\RYB:(9#EQ\OQ8_3^J]W%&&:/MY_YR9R0_G_;X
MY^K]#_)+(ZV0-^[H8C\[!Q&95>(S+8Z-HK!&0`X_GR/<U=`TR`8B>Q57IN"_
M!QF8YR+,EM;6L8ZV"[VC:3N:&[MZMK8Y;'[>*,#=C>V4;*2224R5))))*<_Z
MP_\`(/4O_"E__GMZ27UA_P"0>I?^%+__`#V]))3_`/_7]#^K7_B<Z5_X2Q__
M`#TQ:2S?JU_XG.E?^$L?_P`],6DDI22222E))))*66!B_6GZL9+;\PY#<>AS
MQ7]JRVFFJ[9O8W[)?DAE60VM]5WLJ_/]1;SV![',)(#@02TD$3^ZYON:N?QO
MJ?5C7X]@RGY#:LY_4KQD5UN-M[J'85#YH9C55/H_I'J>CZEU_P"E_G$"`=Q=
M*;F3=T5EU/5;,RIC'466[@YI;=0UK7/O:)_2UT,>QWJU_F(3?K#T?'^L#NA2
M^O,O:W(]0C]"]]@(92RV?Z0^JAUFS;[UBU?4"[T>E8-N4QF!TS!R<5[:VN-M
MMN=793GV>H]P952Q[Z[,=FS_`(S_``:-@_5/(S<=K.K`U5W]-P\:T!_ZTS,P
MW7.KS67U>I4RQGK;Z[&6V>_^=]G\XV..$22(@6>(_P![Y>)3UR=#QZW4X]53
M['7/K8UKKGQN>6C:;'[`QF]_TG;&HB>I22222E))))*<_P"L/_(/4O\`PI?_
M`.>WI)?6'_D'J7_A2_\`\]O224__T/0_JU_XG.E?^$L?_P`],6DL#ZO=;Z+5
MT#IE5O4,9EC,2AKV.NK!#FUL:]KFE_M<URT/^<'0?_++$_[?K_\`)I*;Z2H?
M\X.@_P#EEB?]OU_^32_YP=!_\LL3_M^O_P`FDIEUGJV+T;IF1U/,)]#&;N<&
MB7.)(9776/\`26V.96Q9K/K3:WHUG4,SIU^+ELM&/5@/(]2VQ[VX^-Z#G>F[
MT<BZQK&W6U5?G^Q6LOJOU8S<>S%R\W"OQ[1MLJLNJ<UP_E-+UF9N%]2,G`=A
M59>#BAU+<<75OQGV"EMGVKT)RFY#75.O_2.WL_G/TG\XDIT^A=<'5<)^1=1]
MBMJMMHLJ<]KP74N]"Y]-S=OK4>O^B;;M6+]:_K=U'HN;GX^-BNR&X_3&9E5C
M&!S:['6W8Y?E.-M7Z#;77[:V[_YU2HZ5]0Z,+"PFYF,ZK`+"USLBO?:*WORJ
MZLRT.:^_'^UV?:_LO]&]?_!+5R,WZHY3K79&3@7.OJ%%I?94XNJ!<\4OW.]U
M6][G;$E//V_7O-P<C,NSJJST[&R^H8+7,(9^EQ:JLWI];[+'_P`[F5_:L?8U
MG\_Z2M]3ZO\`66AW0.G-MQL3/ZC1?=G775E];'XU5>0^D,;8S;4ZRQU5EOJ>
MQGZ1:+[_`*EO8^M]O37,LO\`M3VE])#K]/UIVO\`/^W^=^FEU&[ZE]4%8ZE=
MT_,%)+J_6LI?M)C=MWN_.V^Y)3A8G^,*W)SNAL>RFBKJ#*1EX[BXW>KE&ZK$
M=C?F>@Q^-ZEGJ?X#*H5'IOUT^LV?A=5NWX]-F%B6=1KW4D"*;+ZOLE#76[L_
M$O9B_P#*-?I_9KOT7O76/R?J;8RZM]_3W,R7,=>TV4D/=4&MH<_W>[T?2K]+
M_1[%%MGU)8STV6=-:P568^UKZ0/2N/J9%&T._F;G^^RM)3>Z(_.LZ5C79]S,
MC)N8+7V5,]-D/_2,8QA=9_-L=L_EJ^LZOKGU>JK;57U##96P!K&-NK```AK6
M@/\`S5+_`)P=!_\`++$_[?K_`/)I*;Z2H?\`.#H/_EEB?]OU_P#DTO\`G!T'
M_P`LL3_M^O\`\FDI;ZP_\@]2_P#"E_\`Y[>DJ77>M]%MZ)U"NOJ&*][\6]K6
MMNK))-;X`&]))3__V3A"24T$(0``````50````$!````#P!!`&0`;P!B`&4`
M(`!0`&@`;P!T`&\`<P!H`&\`<````!,`00!D`&\`8@!E`"``4`!H`&\`=`!O
M`',`:`!O`'``(`!#`%,`-@````$`.$))300&```````'``@````!`0#_X0^S
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@8F5G:6X]
M(N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\>#IX;7!M
M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!8
M35`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z
M,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW
M,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z1&5S8W)I
M<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87`O,2XP+R(@>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M
M+W!D9B\Q+C,O(B!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+VUM+R(@>&UL;G,Z<W1%=G0](FAT='`Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(@>&UL;G,Z<W12968](FAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B
M('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@
M>&UL;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO
M<"\Q+C`O(B!X;7`Z0W)E871E1&%T93TB,C`Q,RTP-RTS,%0Q-3HP.3HP,R(@
M>&UP.D-R96%T;W)4;V]L/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W
M(B!X;7`Z36]D:69Y1&%T93TB,C`Q,RTP-RTS,%0Q-3HQ,SHU-RLP-3HS,"(@
M>&UP.DUE=&%D871A1&%T93TB,C`Q,RTP-RTS,%0Q-3HQ,SHU-RLP-3HS,"(@
M<&1F.E!R;V1U8V5R/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X
M;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C<Q0T5#,D(T141&.$4R,3%!-CE#
M04)#,#@T,T$U0T4Q(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C<P0T5#
M,D(T141&.$4R,3%!-CE#04)#,#@T,T$U0T4Q(B!X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240](GAM<"YD:60Z-S!#14,R0C1%1$8X13(Q,4$V.4-!0D,P.#0S
M035#13$B(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R
M36]D93TB,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M
M,BXQ(CX@/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T
M.F%C=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z-S!#
M14,R0C1%1$8X13(Q,4$V.4-!0D,P.#0S035#13$B('-T179T.G=H96X](C(P
M,3,M,#<M,S!4,34Z,3,Z-3<K,#4Z,S`B('-T179T.G-O9G1W87)E06=E;G0]
M(D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D
M/2(O(B\^(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)D97)I=F5D(B!S=$5V=#IP
M87)A;65T97)S/2)C;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O
M8F4N<&AO=&]S:&]P('1O(&EM86=E+VIP96<B+SX@/')D9CIL:2!S=$5V=#IA
M8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C<Q0T5#
M,D(T141&.$4R,3%!-CE#04)#,#@T,T$U0T4Q(B!S=$5V=#IW:&5N/2(R,#$S
M+3`W+3,P5#$U.C$S.C4W*S`U.C,P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB
M+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/'AM<$U-.D1E<FEV
M961&<F]M('-T4F5F.FEN<W1A;F-E240](GAM<"YI:60Z-S!#14,R0C1%1$8X
M13(Q,4$V.4-!0D,P.#0S035#13$B('-T4F5F.F1O8W5M96YT240](GAM<"YD
M:60Z-S!#14,R0C1%1$8X13(Q,4$V.4-!0D,P.#0S035#13$B('-T4F5F.F]R
M:6=I;F%L1&]C=6UE;G1)1#TB>&UP+F1I9#HW,$-%0S)"-$5$1CA%,C$Q038Y
M0T%"0S`X-#-!-4-%,2(O/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&
M/B`\+W@Z>&UP;65T83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K
M970@96YD/2)W(C\^_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT
M<E)'0B!865H@!\X``@`)``8`,0``86-S<$U31E0`````245#('-21T(`````
M``````````$``/;6``$`````TRU(4"`@````````````````````````````
M```````````````````````````````````18W!R=````5`````S9&5S8P``
M`80```!L=W1P=````?`````48FMP=````@0````4<EA96@```A@````49UA9
M6@```BP````48EA96@```D`````49&UN9````E0```!P9&UD9````L0```"(
M=G5E9````TP```"&=FEE=P```]0````D;'5M:0```_@````4;65A<P``!`P`
M```D=&5C:```!#`````,<E120P``!#P```@,9U120P``!#P```@,8E120P``
M!#P```@,=&5X=`````!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K
M87)D($-O;7!A;GD``&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ````
M```````````2<U)'0B!)14,V,3DV-BTR+C$`````````````````````````
M`````````````````````````````````````````%A96B````````#S40`!
M`````1;,6%E:(`````````````````````!865H@````````;Z(``#CU```#
MD%A96B````````!BF0``MX4``!C:6%E:(````````"2@```/A```ML]D97-C
M`````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@``````````````!9)14,@
M:'1T<#HO+W=W=RYI96,N8V@`````````````````````````````````````
M````````````````````````9&5S8P`````````N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="```````````````N245#
M(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````
M`````````````````````````&1E<V,`````````+%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2969E
M<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````
M``````````````````````````!V:65W```````3I/X`%%\N`!#/%``#[<P`
M!!,+``-<G@````%865H@``````!,"58`4````%<?YVUE87,``````````0``
M``````````````````````*/`````G-I9R``````0U)4(&-U<G8````````$
M``````4`"@`/`!0`&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H
M`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`
MVP#@`.4`ZP#P`/8`^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@
M`6<!;@%U`7P!@P&+`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"
M%`(=`B8"+P(X`D$"2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K
M`O4#``,+`Q8#(0,M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#
M^00&!!,$(`0M!#L$2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K
M!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&
MG0:O!L`&T0;C!O4'!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R
M"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*
M$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2
M#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.
M9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7
M$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3
MI!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/
M%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9
MW1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU'
M'7`=F1W#'>P>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A
M'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4)
M)3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I
M:RF=*=`J`BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA
M+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILR
MU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7
M.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]
M83VA/>`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W
M0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)
M'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])
M3Y-/W5`G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6
M#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES6
M72==>%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD
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MC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26
MGY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_Z
MH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ
M'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0E
MM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^
M_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFY
MRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O5
M3M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]
MX43AS.)3XMOC8^/KY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M
M$>V<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX
M^<?Z5_KG^W?\!_R8_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`
MI0",`P$1``(1`0,1`?_=``0`$O_$`:(````&`@,!``````````````<(!@4$
M"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$`0,#
M`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.A
ML?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#
MT^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJ
MM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%
M!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R
M\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S
M*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(
MF*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1
M`#\`V??@+\%OA/NWX0_$C<^Z?A]\7-Q[CW!\=.H\UGMP9[H/JW,9O-YG+;+Q
M%?E,ME\KD=KU-?D\ED:Z=YIZB>22:65V9F))]^Z]T;G_`(;T^!'_`'A)\1__
M`$G'J#_[$/?NO=>_X;T^!'_>$GQ'_P#2<>H/_L0]^Z]U[_AO3X$?]X2?$?\`
M])QZ@_\`L0]^Z]U[_AO3X$?]X2?$?_TG'J#_`.Q#W[KW7O\`AO3X$?\`>$GQ
M'_\`2<>H/_L0]^Z]U[_AO3X$?]X2?$?_`-)QZ@_^Q'W[KW08=C?%O^5MU%B\
MKENROB]\(]H08;9>^^QJNCRO0G32YRHV+UCAUS_8&Y\-MJGVA4;BW#C-H8>6
M.>O-!25#P++&"NJ2,-[KW2IV9\)/Y<_8.T=K;[VC\-/B+E]I[VVY@]W;6S"?
M&GJND3+;=W)C*7,X3)I2U^R:2OI4K\96Q2B*>**9`UG16!`]U[I3?\-Z?`C_
M`+PD^(__`*3CU!_]B'OW7NO?\-Z?`C_O"3XC_P#I./4'_P!B'OW7NO?\-Z?`
MC_O"3XC_`/I./4'_`-B'OW7NO?\`#>GP(_[PD^(__I./4'_V(>_=>Z]_PWI\
M"/\`O"3XC_\`I./4'_V(>_=>Z]_PWI\"/^\)/B/_`.DX]0?_`&(>_=>Z]_PW
MI\"/^\)/B/\`^DX]0?\`V(>_=>Z]_P`-Z?`C_O"3XC_^DX]0?_8A[]U[JNS_
M`&2CX8_\.T_W'_V4?XS_`-S?^&X_[U?W2_T%=7_W7_O)_LRG\&_O#_=_^['\
M)_O#_"/\E^^\'W7VW[7DT>GW[KW7_]#<G_ER?]D"?#'_`,5BZ3_]]_@_?NO=
M'1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2<W=MJEWEM;<FTJ^NS.-H-T8#-;<K\A
MMS+U^WMPT-%G<;4XRIK<#N#%34V5P.;I(:DR4E;321U%+.JR1L'4$>Z]UJW]
M8]%_-&C_`)CWQ6^'_P`A,%W-VYMGXK_&'Y][+V%_,0KJ+*93%=Q?&?Y'[7ZI
MV]TW3=L=CT;QC`?*GJ[<6RJG`YQ9%BJ\Y%34^90NU6\K^Z]TS]9_RQOGIF.L
M]\]K]J;&2G^8FS/Y+/6_Q$^-.Y=P]]OG*C:?R\QFPOD-TUVMO%:C![KK-MTV
M]-\=>9G:S+NVO\[AZIQ]VC?>:?=>Z`[LSY4_S#_@WT_VCOC>+=V?$2FDQ'\N
M?XN_%[K#NRAQ7R7WOD.I^@^O:>+Y;;IZ4QVT=R;\^-FX/EYVMG-[10[?QN[,
M]15&\:?`2P1R&NCC2D]PSU[K<#ZTBW=#L'9T>_LQC-Q;V7;&#&[=PX?:V1V/
MC,_N$8ZG&4S5'LO+93-Y+:,.3J;S?PR>LJI:`N8&EDT:S[KW2Y]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=5A_\`=9+_`,QA_P#ST_OW7NO_T=R?^7)_V0)\
M,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U!KJZ#'
MT=765!TP4=-/5SD*6*PT\3SS$(@+N5BC8V`)-K#GWO`(J:=-2N\<#3*A)%<?
M9U5Y\Q?G#N386Q]B#XOTNS=\[E[4V3DNQ-L;RS%;][M?&[/Q-;CZ9ZA<!3RT
M]7F<GFY*QH:9"\,5/+#()P&73[!.\;EN.X67A<D*LFY2QM=AC0@K%AA0YJ2*
M?(CUZB/FOG??]SL8=O\`:4;7N&\3[;-?Q"5J(;2WQ/3(U-JJHR*$,"A/`S^&
M^7O0]#M#$9S?/;'7VUHDG3;N;W'N'<>"VUL_^^6%VYA\QO"CQ^=RM=3XF:EV
M[79:*EJ)4F:**ND%,K-,KJHFY?NI.:)(+?94-]<M0%8P6;4`-0`4$FAXTX$T
M]:##;.=N7KNPL9YMWB5WC6M"-.O0I=5/#L)H?(''1J*.LIJ^EIZVCJ*>JHZN
MG@JJ6KI9XZFFJ::HC6:"IIZB(M%/3SPNKQNI*NIN/9@ZM&S)(I5P:$'!!'$4
M/F.A@I#*K*:J>!]>I7O76^O>_=>Z][]U[KWOW7NO>_=>Z][]U[JL/_NLE_YC
M#_\`GI_?NO=?_]+<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW17ODEV=A]O]:]B;9Q>^\1MGL2JV9E9<-0_Q#%'<,*24DO\`
ME=#AJZMHZZKI*N.-Z<U5(LTM(\HD52R<%>Z[KMUE;.]W(*4^&H#9KY$U_.G0
M5YDYDV/:+'=6O=V6,A*$'!R#\-:5_*M..,=:Z&*_FH]_8#'U_6>+W#A\C3MU
MM5;2VY3;KFILAV-A*:.<KB]\928-++FLSA:"6;'S-,K1Y"$0RRL)HS(^/^X<
M^<['9]_YCV?E\R^W5JWT/[T8-I623\2D]K%":8)R`3D=82[I]Y#G![G?[?EV
M%3RZ\/A[<Y'>)%Q75Q\F&:C2>&`16-MJL[BI-V[F@W3NZGR'6U%'/3]28ZAK
M):?(;/QN4R$N2S.W8XHA%)C\56UL\E151F22*:J<NMK^V><=]]H[OVU]HXO;
M9-[VWW43;YQN+ZL,FIJ,M33O^(#T/6/UQOM=NVAMHWQEN?%8MQ!5V8M(`!P&
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M-04)1G(((_">W()ZSR]F^>N9^?);_<]T@CL>4HXTBV\$CQ961:22LI.H@D`C
M`6C8J03U;*G"*..%4&PL+@#\?CV*EUE5,A!>F:<*^=/EZ=3MGS-3Z^O7+WOK
MW7O?NO=>]^Z]U[W[KW7O?NO=5A_]UDO_`#&'_P#/3^_=>Z__T]R?^7)_V0)\
M,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW7O?NO=:S/\Z??/26)R
M>Q-W5.^]IPSRY7';?R_VG:6U]Q15NX)9:BBHJ6/JVG;([GPV6Q"1*U3E:22F
MHGIRR5<;O&CK$_,GMYSC[N[WN&V>U.TIN>Z[8@;<4#`_I$=JZ02P8>?GY4Q4
MX2?>?L;'?;OEZ\V2*+<KU'HRIN&10TH;!:ACZDTKPI6IZIAI.N]IQ;\G["I,
M(AWUEL?2X*7,"LJ9O/1LL5/''34\DII87JD$:&4`!D_I<WA9_=+GR^]M^6O9
M*XWD0^VEC=2&PVNF#/XC!PQ]=>K#&ORZQ"BO-WOX]IV.T(4>(U?+30FH^5.'
MY=")N#;V<VQ6OB,[0_PO*O1BI@@JGCF5%G25:&JD:F:1)*<3H/(H.HH#8>PI
MNVP7/*^Z_2\RKWLM0!Y5%0,>G#HQYEY4W_DO=TV;F[9!M^]R`,C*:C2V5;&!
M4$'\^@CZNJ^SJC;]:_:V/P^.W-#FZZGH6PZP+!7X.,A:2MFIZ>::&`S/J""X
M=XK%P&'N0O>RU]F;+FW:7]E-W;<.2FM(A?H00?WJ8UPM>*JY(J,8Z1;K^Y3=
M(NSJ3)0!JUR:9_::]&6^)F/W?T+N7<.Y_BEU;LJ'M#<F5Q>*HMV9+!IN;)8'
M-;CG_AM*FUL9FJ]</1UV3^[,<U0\,STM&T@CTJQN(+GW,]]O<J2/>=^E3<M\
MY;B7;H@:45'4!`/+M4`$YI3J3/;V[]T[VXDYGY)VF/=^8+%3MJ7[D4B$HP-!
MQ1!VEJ4H./6[5MM<RF!PB;D>C?<BX7%+N%L=K&.;-BBA_BKT"R#6*1J_R&._
MJT$7]Y"6_BFW@\<`3Z%U`?Q4%?Y]=/[,7(L[07C`W8C761P+Z1J(_P!M7I\]
MO=*>O>_=>Z][]U[KWOW7NO>_=>ZK#_[K)?\`F,/_`.>G]^Z]U__4W)_Y<G_9
M`GPQ_P#%8ND__??X/W[KW1T??NO=>]^Z]U[W[KW7O?NO==$V%[$@7)MR>/Z`
M<D^_=>ZU2_YC?PIS&WMR;W[HRW7O4>$Z;R>?C^QQ]5A]C;1R.;W9F<C/-$N(
MV3MFHS4F?W!6&26:>NEFIJR2))))8U"M[QRYDM^=_;G>MYYZY9Y@78#=J$+[
M>WT4F*T9RI)9R!5FS4Y/'KG=[W^VO,7+N\[USU8M!M^P9KW1V9+$DG3HN=3$
M\=0%3QH.JO<'NG;.XY<K3;;SN.R\NVZY,5F*?'S,S8FMB0&&EJ%TQM&52/\`
M;*W0E.#<$>XNYJY+YWY.M-BW'G'9?HK#F,G<=L?XC)*F6?5^)I&.MB,DL3UC
M@UK>01B2E5D&H?TJY)!_%QR03ZD]"KN3"Y,87;>\,KN.FSE=NI)(_LVG>HRM
M`E$I2(5CM(X$6A0JJ%30QL;GV]S'LUW!L^S\\7^__O&2_.EU\U(X@CB*$$9`
MX=#_`)[Y<W.#ESDCW)W;GG]Y#?G$!2M2BIVA2*DJ%"Z:D#AT%F'W1MK<%7F,
M?@L]BLO7[>K&H,[14%6DU5BJU69##61<,A#J4U"ZAP5O<6]M\S<@\Z\H;+L?
M,'-FQ#;MIW9M.U,.!<Y#5X&N#7/0%NK*^L2?K%)CKBGF/*A\\='%^%_R?V[U
M'W[MGJ3'X3H/>G:?8LO]YMK[9[DJ\KL3*T;;8I*F>EJ-I]LU%#7;2V]D<S!%
M-]E2U<,OGJX=.J*1XU:>/93VU]WIN2^9?<;E7E9-QY+B&F0%E#EP=+4K6@9Z
MU8J5`-20,]9#?=XYDYTY<EE3EZRV;<!N9*FIT$::G27(HK$"AKDD4'6X]B*J
MLK<7C*O(4/\`#*ZJQU%55N/^[AR`H*R>GCDJ:$5],/MJW[69BGFC]$FG4."/
M<Q(79$:6+1(0*K6ND^:U\Z'%>NB:%V1&D4!R`2`:@&F0#Y@'%>G+W;JW75Q_
M4?[?W[KW7KC@7'/TY^OYX_KQ[]U[KOW[KW7O?NO=5A_]UDO_`#&'_P#/3^_=
M>Z__U=R?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW6K
MOO\`[[[G^76_>Q.RLCWIW1UGTGCNQ^P^O.B.GNC^P,OU#1KL_K+=N3V!D>SN
MTMU[2%)O;>N_M];OVQ75=+C6KZ?#[?QB4L24\]4]14/)'+'*EI?6;7U]73Z=
M!'=-YNUOEL;&E3Y]!SG]Q=RX[*[)_P!-K[W^=G2/7:9$[1Q.X\ACIODUTC6Y
MQX%R>_Z;'QI@MC_,]<%14R)08G-QXO<M-=F23+MJA<+\^^T&V\S3I/:H#&%(
M4'`4FE33S^0.*T\J@@+F?E?8O<"79_ZW0:UVQV=03VAVH"Y`^(Z12G"M":@$
M$D.[]A]1TE-NSY$]`4NWJSK7N#L;>T&,VIMW*9',=VXF/8T/W&4KN\=@U]'0
M9CJW<K+YJVOH,G!CY*.:IT^&.)H`V-W.?+GO-[C7W)W(VZ'5M^WW!&SQ'CM5
M@M/%DX#X_BQ@L2!D=8;^XGMSSGM.YI<?NI6Y5>[OSM"@U9;+P_UM0'PZFK2O
M'@.@PZYW+C>T-Q8O:^T5,NYL[6T&/Q&,DEIO+DJK(524E#'155++/33RS53J
MFC4K*["_!XCSG3VAYUY/N-E2Z#.NZ3-'7217-*FHH-7'-./4-)L-T+N"QL%T
MLZK0<*U`P*\?3'0\=#?#[?G;/8.[\'U)UM1XW?.3VWE]\[BJ<C05.W8-TTFU
MLY'M^LIH<U5Q#&)D9\VT]-`SO%229&GE2216!85&[^Y'N;8<M\D;OOS;CR?R
MSM<[;:C@@+*)"I7/HW:/LZ&/*/)?//N!N+\J6,;*VV@R`N"H-#3#,`#G''CC
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MYJ>/4Q6]A:6M?HUT+4D#R!/'!K2O#^7ET7''?`;YX;4DW7MKK[NC;N&Z]V+V
M5@MQ?'7:&X-QKNG:]:U%W_M_._Z2>^J>LV:=W[WWIA.GMK4LL,(RRP3YN:J\
MBN\OG"'I=U&ZJ^-'\Y-7ZYS&_P#Y0RXFDV5V#B-WU.Q*SLC9V]*O=Q;L?I6G
M[,P_96[Z'I+`KNCJ_>.R*+L'*;4P-##C:K;"93%8Z:LF:F$L'NO=-O?_`,*?
MYBN_^X_G]V5CL]U]NKKCY6?'SN/XZ]>].8+O'M3K+/[#I=I[:VO3_$_L^+>E
M!,,'MW/56\ZG==7N:'$T5+4PT66ACEGRGB\">Z]U=I\?<=OK"=&].;?[/QT>
M,[(P'5NP\)OVCI\__>NE@WAA]LXS&[A6GW/]I0G<$,F4I972K:"%ZA&#M&C$
MJ/=>Z&'W[KW58?\`W62_\QA__/3^_=>Z_];<G_ER?]D"?#'_`,5BZ3_]]_@_
M?NO='1]^Z]U[W[KW7O?NO=>N/Z^]5'KU[K6+^<?5M+\`=X]G=L46_>KMR_&#
M?^[]T]P;CZ?RN_-H;%^0O0>?W?)4;C[%R73&U\[DL7B^].J<UN#[G-#:M.U!
MN?%UM;4)BOXE%*E'"/>6>:)K(?2SQ/)%_15F/[%!/\N@YO6RB\'U4#A91YDA
M1^TX!^WH/.L>SNMNZ]AX;M#IS?.WNRNNL\B/C-V;7JVJ:1:ED65L;EZ*:.#+
M;:W!2HX$^/R,%)70O<-$/K[E0&NG!!(!H00<BO`YZ!#J4KJ'`FI\L8.>''Y]
M!WV[\;^ONW<G6[S%7N'J[N.?;N2VG3=Z]6U%-@^PI=N96C:AKMK[XCEB;"=K
M[*JX&"3X?/15">-5$$U,0'%41%N?WO$#^_1@'Y#A\O(=.2+:S4L;ON4Y]?\`
MBORZH*[BZT^</P2BP#9/?&.QG3>QMZ9;<G7'R4Z)ZVQ)I,579R?$2P4O;<^X
M8]S[@ZGS-#6X>%Z05-/-MYY#(T=99M/L6;Q:<J>]VY\OQ>\V\-9[VI"K-M8T
M6"A:!3*,4<4JQI\5<^?45\R\B[;:6^U;IRQL0W*YVR36%=B&#5U%D`"@T;@,
MD8%&R>@3[1[?[M[YR[;G[O[^[N[CRU=B?X;'D]U=I[BAQDVW:O(29L8FBPNQ
MZO:NTGVS5Y2H:K%.E&U,\SEP#>_O(+:O8GV?V+1N5OR:KA``&)^(#\7&G>27
MIZL3QZ`^X^X?.6[78N8I#MS@4X`MQ)H*@L*,2<4R3YGH'\9M+`[<R.*W%LZ)
M>M=W;<R$&;VKV5U^4V3OS8VX,<QK*'=6W=Y8%:#,8S)X>IB%1Y/,4E"&.99(
MV=2*;_D;E'F':/W#?;"!;NWQ`4`!..[A@4XFF,XZ*;3F_F;9]Y3<[/?F<J*E
M&)*MC(*UX'(Q0BM5((!Z^A#_`"S_`)\]X]R=-_#BG^8776&VGOGY8="8_L/I
MGN'9E96S;,[>SNWL!+F-W;*WIMG(X7"Y'JKNBHV;2+NNFH81D-NYW$M6RXRM
M5Z"HHX^4^XQ1P;G?V\?]G%<2H/L21E&?L`ZSTMF+P6LCBC/&C'[64$_S/5S0
M^@(_(!_U^/:+IP\>N_?NO=>L/Z>_=>Z][]U[KWOW7NJP_P#NLE_YC#_^>G]^
MZ]U__]?<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]U[W[KW7O?NO=5B_P`X
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MXNODJ$BR-.MC!51%1<MYJ]N=GYVC%U=1&PWT"@D05!`P&J,9%#^?1KRWSMO/
M*S"TMIAN/+OFCG33SH*\.)^7G3JZ'XX?S7>ENQ<SB.JOD;7;-^//=E>\5#BJ
M^3=$%7TEV+7$*H.W=R9"?^,=;YRI8@G$;E6&%6;33U\ZZ?>*7-?+6Y<EWR66
M]7L+*S$+21#JXGR8YH*D<1GJ?M@WS:>9[`WVQV\@=1W`HP*G@>(R*X!&#U:W
M(LL`GIZB)&AK:)H:JEJH8:J@R6-KH?5!64E0LU!E,37T\@U)(LM//$W]I3R1
MFE!4#2?7A_Q72_(R:@]4T_+W^6SU7@MM[D[C^/F^>N_C/615$M3F.N>U,O+A
M?C!NW/Y!GDBI-N5<<CYOIS=^9J&)BI\*M7C*R4V_A\8NX%7+'N-S/[>6DEWM
MUP+CEX$ZANC`Q5\P">"C@/1:8Z*=[Y3V7FF[C@O[=K+?Z#3)$-34ICX:@UP:
M&A^8Z%W^5]_*M_E\?.?+5U-V)\X-_P#;&^NNZ;'Y/O+X1XSKZE^-V=Q].DM`
ME;19W(97(Y_LSL[HO*U=9'3_`-X]L9&EQ.8I*J.)ZJ"25Z50!S;]XOGKFRSW
M7:;&Y2QV&8E62$AE(]0ZDBC#@OIBG1]RW[1<L;!?)N,2M>7:T(:0$4:GE6@!
M#5(-*@@$&H'6TQ\T<9M3"K\"NIMH87%4.Y6^9_0C]1;0V]24N/7;>T>I,7N+
M<G8]?A,)0>)<?M7:?1N'S-!4/#&M+305L,#:?-&K0)6N2:GJ4@*`"E.K&A[]
MUOKWOW7NO>_=>Z][]U[KWOW7NJP_^ZR7_F,/_P">G]^Z]U__T-R?^7)_V0)\
M,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]T$W=G6O5O<O4G8O5G=>W]O[K
MZ?W]LS<>V.R]O;HDC@P&2V=D\;409L9*LDEIFQD5+1ZYEK8YH)J*2-9XY8WC
M5UVK3QSQRV[]]:4\Z_*GGY4ZVRZNR7A_JI^?\^M#S(?R[/A/7[YKZ_J?Y9_S
M#-__`!G&4J(-I[[V3\,ME]D05FWJ6>2)7VKW%F*S&;H[6VY2F-HJ?<5'L?(Q
MY*)!-%5U:GSN;;M_>5<K<D7K\@\R^\7*L?,$0*$20EI8S'V^&\J*UIXBTTD,
M-1(.HZJ]%<'W2+[F%'WVRY(OQMSG44#B,.7R62,LKA234`*%`P!3'5FWQP^!
M'_"=:HKZ?&;R[NW'VYN]X:?R;6^:'<?8_3DL.158V=(.O,]C>C=NO.)24$"T
ME5&2Q0%_:RW^\-O_`+I6B/M/NRNZV,@JL=G=0`D>6F*`QR`>E5%.DP]I-OY,
M4>/R.UNX-`UU$6*T/F[(P/VFN/3K8CZ0^'?P8Z]V0N-Z!^.7QEP.Q\QA:O`S
MU6P.MNNJ[';EP5=&\%=C,MG*'%UDNYL?60RLDZ5514+*A*M<>R">2YG;Q;S4
M9#_%D\2#D\<@U^=:GHW@A@A"FV4`>H_R'T]/3JBOM_I7:FU.\JKJW^51FZ+L
M2APVXJG%]]](;WK,]FOA!\8:NI#RUF2VSWOC9JS<75V_J.N=Y).I]J5.?IZN
M[QMB\`J)4LU>>]%I[=VDDNZ,+Y`,1DACP^$"M0,4S4@>1-!U=.29^8+I3;`K
M(?D<\,@4KBHJ>`XD@9Z-IT=\'=A]=;FQ/;G<.XY?DS\B,;#,N'[)WSM_'XS8
M75*U95ZG$_''I5),CM;JK'D#0V7F;)[LK@I:IR0#&(8>>X7O-SI[AWQ>X?1M
M&HG]V?Z&ZYI7RR/,YX<#U,G+G(VT\KT:+]/>BHI0TSQJSBGH.U2!Q!:0'#?\
M\-J22T?QR[XZ[I]J4'S$ZJ^3?2^U_BAOC/"LH*C.;D[:W5%L??W2.[-P;<A_
MO?ENF>R.L,AF:G<^*A>6)*7%BO1(YJ..9'O9[<-XL.=_W%MZZ.7)!61?-206
MI0^AP"1BF"`QJ_SQ9;<-K2ZPMR(S10*`T*@L!Y9-,4UXKJTK04/CG2]M=1_+
MG'9+^8U#@MU?*/O/`[DV'\;._NM*K*#XEXS`43S;VW/\8^F]A[@5MU=$=DY+
M`X&#,9"?<51F<CV%#A97@S4B8J+$4.7QXFG#J%NKHE^@O];"]_\`6]^Z]UW[
M]U[KWOW7NO>_=>Z][]U[JL/_`+K)?^8P_P#YZ?W[KW7_T=R?^7)_V0)\,?\`
MQ6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U7W_`#.=D[_[%^`ORJV1UCB,WN'>
M6<ZLR*C:^VFJ$W'O#:E!E,9E.P=E8-:9DGKLKO+85#E<93TD9UUDM6(`"9`"
M2;_;;A>[/OUGL,JQ;E/M][';-PTWKQ.L+9])2A!X"A/`=&6Q3VUIO%A=[HA?
M:TOXV91YJK*S8^P$_,#JG/9^Z-H]A[5P>^>K<IB-R=<YG&451M++[7,38FEP
MB4\4-#A_LZ0*-O56#IXUI)L;-'!48^6$T\D43Q%!\PF\[-O7*^[W/+G-UM);
M\YQR,L@E4H1)J.L]P`8%JD,"58$,I((/76G:=QVS<ML@O=KF1FTBFE@=1I4D
M4R23DGC7)Z2':W8?7VU*#!8+L2E;>V7WK6MC.O\`IR@V>>U.Q>T\P@*IBNO^
MJHJ3*9+<LRL2):MH8,90+=ZNJIT!;V,_;CVZY_Y^WMK#VXB>/>4H6F`9;5*F
ME7W,Z7C)/`*VJO:H)%.BOF3F7EOERQ<<SE23DK4`UI7(%6P..#0'J;TS_+%_
MOONF@[2[TVO!\5MKIY*K&?%WXQ[_`-P]>;TWA1U4<M//1?+#MCIW<.V]KU^)
MKZ::056Q]HP&B(DT5^8JW5D'4/VHAYK]JMHN=OOO<;>^9^8Y0-4KRUVHOC4N
MWQR'4DR'],S2:)6TEEA!-3AIS>VT<\70O+;E&+;]E!RP`#,`:5"+I)#"K"I8
M58']08ZN0VAM';&Q]L;>Z^Z[VCMW9.RML4BXO:6Q]DX*BV_MO!T9;BDQ&!Q$
M$%%`TTC%I'5#-/*3)*SR,S$TN[G<=PO?WI?DL*Y/&A\P6'$C@QXD\<])[2SB
MVU2ZGL`R2?PC(J3P`!P,*HP`!CHF7?'SFVIU]N#<G4G1&T#\H/D9@(:B',[$
MVONFBVUU/U1DQ$S4B?(KO62FRFW.NIFE'_%@Q\>5W74#]-#"I\JE/-&_\I^W
M^V)NWN/NO[J@D!,:N"=W<<08;-#I=#52K&BE2"6KCI5M>W;US2LUAR;M@O>(
M):E*YJ%J"*BC4U`\*A'7H`_CO\J.GNN-_P"`^0W\P?:?R2H.^-N8S(T5'VMF
M]B[?W/\`";XK4N[(9,7NA>CJ+IO=>\QL+;60H)8Z++;^W?CFW+58X-]_7T5#
M)-3)-/L_[]_=BWX1\O\`MWS6+7F'=-,>BZ5K:_E:@!(:Y#`9JVE6XG"M@=`?
MF[VT]U-LBDO]]VLOMJM5@AUF@K0$#OQ6@)U"G:`HIU:M_,@R&)S'Q&H-R;8K
M<;F=WGN3XJ;A^/V8PM10Y6JR?:==W[UG_H[K=D5$4DL>1J,NE<Z!Z5G\^+GJ
M#S"S^\N$4JH0%F*C-<F@\VI_,T`X]0T10L*4H?V=6*^]]:Z][]U[KWOW7NO>
M_=>Z][]U[JL/_NLE_P"8P_\`YZ?W[KW7_]+<G_ER?]D"?#'_`,5BZ3_]]_@_
M?NO='1]^Z]U[W[KW7O?NO=>]^Z]UKF?*/HCH7Y/=X]L;6^*OQQZ_Z^[&VANS
M(;6^0?SYH:[<_7V+V/VE-CJ>NW!MSJG8_6.X-J/\D_D/M6ES$-1E*G.&#:N`
MR4D4>4J<A5+/C5@SW3W3VUCM%CYWY,VC>-R%1HN((Y(5R>V2X9#+'09I0%20
M:K@]2!RF_-%M%(-BYDFV^Q)J?"9@0.%30Z5!-34U)`;2CL".C+?''XG=/_&&
M@JZG8M-NC>/9^?PU#ANPOD7W!G1OSY"=HT]##'"L6[-^U%-2+B,"QCUI@\'3
M8K"0FUJ5G!=L9H[BU@M/W)L_+Z;5RK4D10+2-0Q)[0N3@X9JLPXL>I4*2S7,
M-UO.[ON>^*HTZ\J*4*TQ3%!0GA2JA:GI>=R=Z=3?'[;F+W+VUN^';4.Y*U\/
ML;;5!CLCNCL3L[<2(&7:G5/7&W:>OW?V'N66X_R?'4LD=.I\E3)!"&D55L/+
M^_<RWALMBV<"(8U4Q3R)/#/S(`.">J7N]V6SVSW5W1K@<5J!0_TCFG$8H6(R
MJD`]4R=P_,7Y$]_;DK]D;LZ@^5WQ4^.>2RDFW\/@^G]FG?\`WAWSC9*9*AW[
M5[9Z;S.ZLY\>MIY&`^.;:VV:%L_4+YHZK,QF\7M_W=Y*]V>15LMG]KMDVG<>
M<9T%)+C=(HX]3+\&U6KHL-S."<FX;P@XI1CD%?*?-GMONM_7G7F"6S3Q*C2&
M&D`U!72KDL,9-"#5E*CM,;KCN#XJ[8Q%!U=UUO/JWJ^AVZ)$H>L,JW^A_(8N
MHJ7+U4LVS^P:7:V>?)U\MWGJ:B*:MK9"99I9'+,>67N%[8^^MAO>_<R^YW)V
M_P`^]IVM)=:[L(Q!8(_A*XC)%2B8!3,8*`'K,SE3FOV_W"S>SY;YGVK]Q\&%
MJJ12-\SW5J>+8`U5-!T8+*9[;VT]N9/?.[\]@MN=?8;%U.7W-N[<%;0P;1H]
MN0P,^3GR.5J)#BYJ":B+(T1:052L8E5RX5HJMK#>-XW/8>7]E@D;FR9M,:*C
MEV9N"HE-1-30`"O0XN+VPL=O8W,BF.@*G4,"O:=513R.JHH<U%*]&H_E;?%#
ML_/='_%SM+Y)Y:KI.N^DZ+=VXOA-\9Y<3F<=%UAM'>&:W:W6G;/>0S]94UNZ
MN\<#U'NA<+MK&+#18?8N$J'CAIYLI*]53_3IR*=[V_DGDRPYDN7;FJ+:(5OG
M!H'81HK*`!Y:0IR26U$XP>3G,[V<G-&_S[62NUFXE(7_`)N,2:\2#Q`_/S'5
M[*VTK;Z:1;_6M_CS[$Z:=*Z?AIC[.B`4H*<.N7NW6^O>_=>Z][]U[KWOW7NJ
MP_\`NLE_YC#_`/GI_?NO=?_3W)_Y<G_9`GPQ_P#%8ND__??X/W[KW1T??NO=
M>]^Z]U[W[KW7O?NO=4(]?]G[$^(F>['^-'R8W1BNE\_B>X^Z^Q>J>Q.R)I-L
M]<_(+K#MKL/.=J8W>.V.R<E!#M"J[!VU/NZ7#;HP5360Y>DK*!*E(I:.IIYF
MQ4]U>3M^'..Y;_:;8LFR;@H215!8X`!)"@TSZT\J5\I?Y-W^TBV]K!D45%*U
M`H17!J1C-5I7SK3%6_?ORPW]OW;3Y/X?[$_O)UXV>I-M[@^979VVLU2]!;::
MIJ'IJZ;I78=5)@-Z?)W=E"()EI)H/X5L9:Z-8I\O4^N`Q5S9MMA[6<JV7/GN
M1MF\6>Q3L%E2*0DHI)"M+Y0J0M5,E*\*>?2#F?G^*P0BQ!2(8-#5O+S4G37/
MPFO`AE..E9AMH_%#K7KWL_>^$WQO_N+Y6[FIZ':V9^2_9TV/S'<^X8LM1&MA
M3:$B4F(V]U=TW3_<2T=1MC:-#AL72QQF.6EEF'GD%VX_>@]G^6_;W?\`^I%R
M:QQK8J`&UR13**WV:ES$&)+88LH`!%*1'NV_Q[C"UW=@%0<``#YU`'J35O4]
M%G@\N+RM'FL32Q[9J:1J"LH8\%)5T<='E<>(G&0I)WF>H@G:==>E7`4-8#3;
MWB/[G?>/WWW"CV([:S[?X*@:D!#%$`43'%0&`#E_A!.3T';G<FH*?(BG\NC6
M83Y$]6;RQ>6V1WIU_P!==L;MW)N&#=&]<OV1@]H;\H<1MU@E+`E'UI7T>0RD
M='C\-2)2XZ()'3/5U#2,ZH7+2K[:_>BY@Y:VBZ;F/9;P[IN^Z1W-]S`D+KMR
M11@)#6J:9)+6V7Z555M2LY*Y)!>BWRVB(CF9&N&-2"P+?DE0Q^7ET(_QL^$_
MP9[.S&6[WPOPCZ6V3!A=Z2-UO!/@QD*-<GABLE1O!M@RU$O6V&S-)E&0T4E)
MC6FI)8M2S!U4C+GV7Y^M_=RSWCW,M>2MOV^Q=WALI#;6PW"334,[7`6B"3M*
M*-)HW>>-1A!S%N]_8BSFN=P7:ZBB-*Q!^>C41I'D"#]G0Y_,WYWT7PPW#U-B
M]T]:Y#=^,[RQ6_=H=5Y'&;A@Q55NOY.XN7:0Z?\`CI'356)J8(,]WQ#F\G_"
M:Y99?MI<'4*]-(&4B>DU:$+`ZJ"OK6F:TQ^S'ITG_P`'11?^'JNJL'MO'YC?
M&ULGA*?9FZL1AN^M[4&'S.2ZQVR=P8?OW.8?9W7V31AN[=_8\V/Z/FFDAFQ%
M+BHH9P\E6AE@5K=>Z&+KS^<%\;>Q>U.O.G*/8'?F`WGO3L67IS<TF?V5M5]M
M]-]NRY;?6$P777:.Y=N[]W!C$S6Z\CUWDDQM3M]L_BIM*%ZN,%M'NO=%DW]_
M/4V5CY/YAN)ZTZYZ_P!T;H^#^Z-KXG8V*W?WM!M&+Y1XVJW+4]7[KI>N)\1U
MWN_^%;]C[\Q-5L7;V%F^Y&>RTU'/]S303L(O=>ZO=VWDLCF=NX#+YC!5>ULO
ME<+BLEE-L9"JH:W(;=R-=0P55;@JZLQ<]5C*NKQ%3*U/++3RR02/&6C9D()]
MU[IZ]^Z]U6'_`-UDO_,8?_ST_OW7NO_4W)_Y<G_9`GPQ_P#%8ND__??X/W[K
MW1T??NO=>]^Z]U[W[KW7O?NO=-F6PV)SM(<?FL9CLO0/)'+)096AI<C1R20L
M'B=Z:LBFA9XI`&4VNIY'O8)4U4T/6B`>(ZI^^;VZ.P*_<6&V-N$9;";5H*VJ
MSV"HX8/X;39*()#34\,E;C*^IP&Z<;C="RTCM3TM;0N[)+'<ZVY^^^WW@O<?
MV\W;F+E+<O;ZTN.7-VMM%-Q"Z2OF()8S-#?5.3;M$C)72S$CH@WBZ=6^B([3
M^0IT2N#5$\-9XHY$@E5P)-(CE,;*[QBY]:M8:@M^#[YLS>'*)H%8J[:AVBF@
MMP7&$(K15-*"@`IT'Q)''(H,B"3R4L`3]@)J?R'1=^E.AL=T56]M9R/L3?\`
MO^K[8WI5;WRZ[SKUFQ^WII9JJ2'&[>QL4DT</ACJO#)4EE>:&*)"BA![RN]T
MO>_F/[U.\>Q?MSRY[;<N[+%RUM1VV"7:HEBN+PLJHW[W;'C(Q6K`URQZ).7N
M7SLTTDEIO;WSEB=+U%*FNGN]*T_P=9J?X\=3U/?W^S314&>':M3M:/:DE0N?
MK(MM244%`,0E=)@(PD<V0&)`@L\C4]P)!'Y!J]J?<'WI]\_;CV.W#[A_-6X;
M))[=[;O<5PUH$$KGZFFX'3N0K)$H=J8-$/96HITY<<M[=%S)#O,B@\P@U5N(
M'Y_R_+H[/6_=.\=AY3;T6`PD6^]T86&;&]:[?RM9N&LH\$V2DGJ*N'!;3P=1
M1T5?F<O,[F2KJ%GG1?TC@61^Q\OO"^U6O.7+.S#>.0-E=@]_)%=20;,-68K?
M;[:2(;IN3+_8R2`UH,C54"NWGW#43DM7Y\?/]IZN,VCUIMK?6V=J;K[5VSB=
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MN(VWO7X\]%[NV]MYJU]O8'<G4>PLUA\`V1S3[EKWPF.R6"J:7%RUNXY&R,KP
M*C/7L:@GRG5[]U[H;<9B\?AJ"AQ6)HJ7'8S%T-+C,9CZ&"*EHL?CJ&%*:BH:
M.FA5(:>DI*>)4CC0*B(H``'OW7NI_OW7NJP_^ZR7_F,/_P">G]^Z]U__U=R?
M^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW0$_(3<_<>T
MMCTN6Z2V?BMZ;H7<6(@R6/RE1H%+MV:5ER5=34S5>/CJ95?QH[-.@IX7>:SZ
M-/N\:AY$1C0$TZ]U3W\ANS'[$WMD:[,[,VOMO<%%X*3)Y/`;YR.]:>I2D@1%
MHTK4J3MQ8H/Z44$9UCU$M?WQ>]ZN<+[W.]PQM6V\J[0_,23R1*]M>R7C,4D9
M0"C]H?&8T`H<`&G05W6Y,]XL3BC+C[?\GYCHAF]>BMD;U[HZM^062W9O>@W'
MU2DU-A<#C,[(FQ,]'/%5QJF9VY*K0)4JU:S230:9*C0@DN$'N1_;+GG[PW+/
MMO[Q?<]V/V=VG<3S/9F^NA=;9%_6':B(X0LMO?%0(R]`8@S`\`,]!&_Y8CW+
M?MAWQU'B(]/LH:?ETK.Z^V]K]$]6;M[;WG2YBOVYM*FHY*N@P5&M;E,A49.L
MAH*"E@25HZ:F6:IF'DJ)V2"G0%G/T!AGV+]F>?O?/WGY6]EN7+S]R<_/*(A-
M=%;&C!M%&>(@:ZC.:DU-,]*>8-YM^7[&;?;J-G="<`$G!]!4]/>R=^XCL'KK
M9?9>W*'*18#?&W,7N3!T&2HCCLQ3T&41FA@R-`U_MZB-T9;@E7`UJ2K`^SVQ
M]A=YO?O'<T>PO./N!RSLO.>WWNX6]]?7EU)/:RQV,9D4BX4F%PY&`'-6.D=U
M1TMVAUWU4O[8>&Q`/=V\0#YT]>C'=$14D':.V\ZG9FSNK,]A*NEJL+E]Z4$]
M=CLH\[&EK\*@UP4-.]10SR1,U1-"5+7C<,![5^Q_/',>R[X>1[#WQM>6-BV[
M?$:&WNHVDM]VJQ4AW%%2-^,;,RT5EHP(Z,]MGNM;*UPJT)XGYTZV"\?D*'*4
ML=9CJZBR-+)=4JL?50UE-(R'3($G@>2-M#<'DD?GWV37440M345!QP-16H^1
MXCY="_[>IONW7NO>_=>Z][]U[KWOW7NO>_=>ZK#_`.ZR7_F,/_YZ?W[KW7__
MUMR?^7)_V0)\,?\`Q6+I/_WW^#]^Z]T='W[KW7O?NO=>]^Z]U[W[KW31F(JR
MHQM=3XZ>.CR$]!70T-9-3+604E9+321TM5-2.RI5105#*[1DC6JD7Y]MD1RJ
M5D%#Y=4<Z86)%<?ZL=4,[&^)OR#Z5ZA/5??6_P"'YA?*?L_>>X]U2=IXO:<N
M%Q'6?4T.1I9J?#KE*V.B@5)Z]9+U%:(Y(8ZF6"'5%!$7Q3^^'8<C7'N5R[N7
MW<_92'8_</=88IY+V($K8':T$GU?CB,6\4U[*`AJ"S`N64X;H%[-LVY[':.+
MM_WGO;L2I>ND#R%6_P!BG`8IT"&Y]L9;:V>J]HY6@HXJK!UK4.8B,PFCIZJ$
M1R'1)9"_[<H:X`-VL0#[PUVCG&WY7W+WGYB]TN>^8=N^\H(2]K##.&3<9'34
M8[C-%<@@2QO1;>.DL(U'I4;EP3K%&\QZ'S'Y''2&EW[UU5;XGZ@JMS;8KM_S
M[8;=%1UQ6R4M=EJO:+2B"3)5>)J89:.:B/ZA#)J=X_W0A0!O<-6G('N]MOMU
M![\;;R5N5ER);;]'M\NY1+/)#)N,Y#++%?>+XTBH[:2\195(85!!H&;K<;*7
M<5V^]8,3Y`C5^SC_`"Z6ZA`H!,<$2*J(L:QQ1QQH@CA@IXE,4*C3&$CC&A;V
M`TCV!;XW-W/<"[&J*-G)&.YU)9J:L%F-6SFIJV23T:A0[*E<<!]GET8/^61V
M?@>\*7M;$]F?&?M[87\0WQ/LG;*]P=95;8O)18''US5.9Q^1GQ9CP0R4-2MI
M]7A251&)78*QZ?\`)7W=^7_N^\\;%[?<X[OM'.\W.'*ECN=K<;7:/=;-:U#2
MFUN;B="T-W&6595;2-2MIXJ>M\C[TV^6]S-=;$8WC<@%EI4*2,ZAP/''5Q?2
M?26RNA-H3;*V&<W_``2IS-=GW3.Y:7+U$=?DE@6I$,SQPK#3Z:=`J*HY!)))
M)]YL("J1J5`TJ!0<``*`#Y`"@^70]_*G0P>[=>Z][]U[KWOW7NO>_=>Z][]U
M[JL/_NLE_P"8P_\`YZ?W[KW7_]?<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW46>D@JD\4Z"2/R12,AX64POY(UE7Z21JX!T
MFX-N?;;K'.-)%5K6GECU]>MGH@O:WP\VSNW<M$=MQ9''Y#=6Z-P;U[([+R^0
MJ,E7Q4LJ2?9[8PN+:2/'LV1RE2I0>-12TL#.79BBG"OW)^ZUL7,&^6S<MVQM
M=TW.\N[W<]SNA]1-0(%2-`2`<GL7&F->)X`MN-LCFR*ZBU2:^OH.J^^S?Y;&
M!ZA[$P7RNDP6-[`[(\6+V9OC<.WZ/-T]5A]I5=52XK[A,/+63191)\8YHIJY
M8(ZB"(J;%;LH!YVY7^\9[=_=^Y:]E)>>8-_^[W9[XEQ<[3:VIB2QA9S*TL$B
MZ[FK-*S-X8PS$TXCH(W')UA;[NG-1CK.GH"3C&,5_ET>#9/PHQVU>T,54;@,
M.]MAY#;/8;YFBK:4-C(IZ^M@QVUL2R./NC,FWLBTK3C2XK*=G0K8>S;D[[H-
MAR[S_P`N7>Y3+O'*+V-_XJ3`E?J9E7P&.JAQ"P4,:'4!7/0I@V:'ZQ)N*&I(
M..)Q_G\NK%,-BJ;"8G&8:B,OV.)QU%C*)9I'FE6EH::*EIUEFD)DFD6&)06;
MU,>3<DGWGEMUDEAMUKMZ?V<42H/D%4*!^0%.C<\>G3VM`H`.M=>][Z]U[W[K
MW7O?NO=>]^Z]U[W[KW58?_=9+_S&'_\`/3^_=>Z__]#<G_ER?]D"?#'_`,5B
MZ3_]]_@_?NO='1]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:M?S#^??R[^/'
MRR_F/=NX/L;MM.C?B)\1_P#2GUGU'O/X\UVV_C54[]PCP=:+U+V=O'<O7F!W
M/OO>G>7:&[</N[8N[-C;YGI9-NT.3Q5?CH9*?6WNO=+W?W\X/Y/?&7X\_P`P
MW<_RAV_\3*GNKX3?(?XH=+[:KNO:_?NV>INXJ[Y!X#I3L+?G6.V<'O'=F7WM
MF>U^HM@=A965FH:QX*Z6B2I>CIZ:"K4;J0:@YZ]4@U!ST%GR.^6_SF[^P?5O
M66Q>_P`?$ONW8?\`/'[U^"%;OW9NTI1LO>E)M#IOM7O'XFT79&T,UD:VMW5U
MQV3MQ-IP;GIJ:J5*_P"ZJ'B2Z)`-=>ZO1^!_REWG\INH,KE.W>E=X_'GY`=3
M[TS/3GR#ZEW1A\M#A<!VMM&*C?-93J[>-;3)B.S>HMV4E=3Y3;V=QM15TU3C
MZI$>3[B.91[KW1V??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW58?_`'62_P#,
M8?\`\]/[]U[K_]'<G_ER?]D"?#'_`,5BZ3_]]_@_?NO='1]^Z]U[W[KW7O?N
MO=>N!]3[]U[KHD#DD`?U)]^Z]UW[]U[I);LK=EM'BMM;SK-K&/>.0.&PVW=S
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M5629@A]1M[]U[J3F^YNHML;RVKUQN7M7K3;_`&)ON(3['V%F]];8Q&\]YPL9
M@)MJ;7R&4I\WN&%FII`&HX)E_;;GTGW[KW3'L3Y'_'KM//S;3ZO[XZ8['W53
M4%?E:G;.PNT=D;PS]/B\5D$Q&4R4^'V]G,ADHL?C<M(M+/,T0CAJ&$;D.0OO
MW7NAH]^Z]U[W[KW7O?NO=>]^Z]U6'_W62_\`,8?_`,]/[]U[K__2W)_Y<G_9
M`GPQ_P#%8ND__??X/W[KW1T??NO=>]^Z]U[W[KW0=]MR=AQ=7]C3=14N$KNV
M(=@;SFZNHMRS?;;<K.QH]NY!MD4VX*G1)]MA)MRBF6JDL=$)8V-O?NO=:^WP
MKP?\R[XT_$SM_L3N.K^1^_?D'VMUCOW);QR?RPWYU%2]._%+N#IGXV[PW@>X
M<9A,5VGVOEMP]7]R]ZUL.%EIL!]E104F-IJN/!8Z@CEFE]U[H`_Y1ORN^0VS
M.K?DQ\JNP:+YE_(OXZXNIZIV'5Y#LWN:A[IS&WMX=9?%_<?;'R3[LZNQ$&9S
MX["H^]?DUNK&;#P.U>OFRU+C*Q:=8HZ"AIJJ"D]U[JS#YM="?)GYHU'\I[L;
MKW#=A?&;<_7GR*QO?7=V4QF0Z>SO9_QIP6X?BWVW@<I@9\?V#C]W]<[SS=+O
M#>='MK(I3XK.1`U$L\4+11F9?=>ZINZP_DT_,K)=25W7N^MG?W8WEMC^7]\A
M=L=<=JU>[.NJG<$7S+VK_-A[%^;'QIS%3'MS*B+"UF]<8F(SN1KZ%8,?1)EJ
MFC8Q2*],ONO='5WQ\#?EIV3_`":OGUMS=O3^/'\P7^81N[>OR0[3Z5H]Y[/K
M:3![MSF]MD46R^B,9V579MMIY/#=?]*]<8G#4DE1DOX?]PLP$FF5W;W7NBJ]
ME_RT/F7\A-Y]^X3K?X8=6?&#XF_.#Y"=#[S[1^+_`&YV!MW"]<[>V#\2^GMV
MQ9/>':&T_B]O')T6!WI\JNXMS;9$=%LVKJZE*?8-/79NHBEG"'W7N@@WU_*P
M_F/]T1],=D]W=&X[<^\_C-\2?@AT5V-L"CW3TG7[B^8N2^'?SE[$W+NM.M?D
M!E\Q'V#\;\YNCI,8'>>/SN*DQ51G*F63#90*6FCB]U[J_#X&_".+X\_,7^9M
MW/6="]9=;8/O;OSKC</1&\]I[;V!C<QF^LXOCQU1AM\4M*-M4Z9W;.*K.W,'
ME:FMH:M:0UV4,U<T4AF$\GNO=6W#@`?T]^Z]U[W[KW7O?NO=>]^Z]U6'_P!U
MDO\`S&'_`//3^_=>Z__3VI?Y?^Y?E7!\&_B)#MSI;X]Y/`Q?'+I^/#9'-?)W
MLC!Y>NQ4>Q\,F/K<GAJ'XC;AH\3D*ND"23TT5?6QT\K-&L\RJ)6]U[HWG]ZO
MF+_SXCXT?^E9=I?_`'%WOW7NO?WJ^8O_`#XCXT?^E9=I?_<7>_=>Z]_>KYB_
M\^(^-'_I67:7_P!Q=[]U[KW]ZOF+_P`^(^-'_I67:7_W%WOW7NN+;J^8=O5T
M1\9]/YO\LNTK6MS?_G"[]-OK?BWOW7NHM'NKY;^"+^']$?%_[7Q#P?9_++L[
M[;Q:C;P>#X7>'1JO^G\^_=>ZF?WJ^8O_`#XCXT?^E9=I?_<7>_=>Z]_>KYB_
M\^(^-'_I67:7_P!Q=[]U[KW]ZOF+_P`^(^-'_I67:7_W%WOW7NO?WJ^8O_/B
M/C1_Z5EVE_\`<7>_=>Z]_>KYB_\`/B/C1_Z5EVE_]Q=[]U[KW]ZOF+_SXCXT
M?^E9=I?_`'%WOW7NO?WJ^8O_`#XCXT?^E9=I?_<7>_=>Z]_>KYB_\^(^-'_I
M67:7_P!Q=[]U[KW]ZOF+_P`^(^-'_I67:7_W%WOW7NO?WJ^8O_/B/C1_Z5EV
ME_\`<7>_=>ZKD_O%\G/^'</N?]#W0G][O^&X/#_!?]F2[$_NY_=O_9F?)_$O
>[S_[*G_$_P",?Q+]K['^$>'P?N_=ZOV??NO=?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g575431dsp_076a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_076a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^$-<&AT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-"XR+C(M8S`V,R`U,RXS-3(V,C0L(#(P,#@O,#<O,S`M,3@Z,3(Z
M,3@@("`@("`@("(^"B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/@H@(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B`@("!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B"B`@("!X;6QN<SIX;7!2:6=H=',]
M(FAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]R:6=H=',O(@H@("`@>&UL
M;G,Z<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q
M+C`O(@H@("`@>&UL;G,Z27!T8S1X;7!#;W)E/2)H='1P.B\O:7!T8RYO<F<O
M<W1D+TEP=&,T>&UP0V]R92\Q+C`O>&UL;G,O(@H@("!X;7!2:6=H=',Z5V5B
M4W1A=&5M96YT/2(B"B`@('!H;W1O<VAO<#I!=71H;W)S4&]S:71I;VX](B(^
M"B`@(#QD8SIR:6=H=',^"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM
M;#IL86YG/2)X+61E9F%U;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]D8SIR
M:6=H=',^"B`@(#QD8SIC<F5A=&]R/@H@("`@/')D9CI397$^"B`@("`@/')D
M9CIL:3YH;W=E<C!C;3PO<F1F.FQI/@H@("`@/"]R9&8Z4V5Q/@H@("`\+V1C
M.F-R96%T;W(^"B`@(#QD8SIT:71L93X*("`@(#QR9&8Z06QT/@H@("`@(#QR
M9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^36EC<F]S;V9T(%=O<F0@+2!4
M6#<Q(')E<&QA8V5M96YT(&EM86=E+F1O8SPO<F1F.FQI/@H@("`@/"]R9&8Z
M06QT/@H@("`\+V1C.G1I=&QE/@H@("`\>&UP4FEG:'1S.E5S86=E5&5R;7,^
M"B`@("`\<F1F.D%L=#X*("`@("`\<F1F.FQI('AM;#IL86YG/2)X+61E9F%U
M;'0B+SX*("`@(#PO<F1F.D%L=#X*("`@/"]X;7!2:6=H=',Z57-A9V5497)M
M<SX*("`@/$EP=&,T>&UP0V]R93I#<F5A=&]R0V]N=&%C=$EN9F\*("`@($EP
M=&,T>&UP0V]R93I#:4%D<D5X=&%D<CTB(@H@("`@27!T8S1X;7!#;W)E.D-I
M061R0VET>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I061R4F5G:6]N/2(B"B`@
M("!)<'1C-'AM<$-O<F4Z0VE!9')08V]D93TB(@H@("`@27!T8S1X;7!#;W)E
M.D-I061R0W1R>3TB(@H@("`@27!T8S1X;7!#;W)E.D-I5&5L5V]R:STB(@H@
M("`@27!T8S1X;7!#;W)E.D-I16UA:6Q7;W)K/2(B"B`@("!)<'1C-'AM<$-O
M<F4Z0VE5<FQ7;W)K/2(B+SX*("`\+W)D9CI$97-C<FEP=&EO;CX*(#PO<F1F
M.E)$1CX*/"]X.GAM<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`*/#]X
M<&%C:V5T(&5N9#TB=R(_/O_N``Y!9&]B90!DP`````'_VP"$``$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$"`@("`@("`@("
M`@,#`P,#`P,#`P,!`0$!`0$!`@$!`@("`0("`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`__``!$(`/$!&0,!$0`"
M$0$#$0'_Q`#3``$``00#`0$!````````````"`8'"0H!!`4"`PL!`0``!P$!
M`0`````````````!`@,$!08'"`D*$```!@("`0,"`P,&"P4%"0$!`@,$!08'
M"``1$B$3"3$402(546$6<9&A0B,7\(&Q,C,DE-17&`K!X96X&=%R-B=X4F*2
M-#4F-U@Y>1$``0,#`P($!`,%!`4("04``0`"`Q$$!2$2!C$'05$3"&%Q(A2!
MD3*Q0B,S%?"AP0ER0[.T%M'Q4H*2HG,7X6)3)'15-Q@X)35E)G;_V@`,`P$`
M`A$#$0`_`(+W&Q6BSVJ<L-]EIJ7NMADW,K89.SK.U+!*2KLXJ.GDDI(>+Q5P
MJ?ZB8```Z``````\S2RW4]X^YOI`^YDZDZ'\C1?K>XQB..87`V^#X=!;P\=M
M(A';QVP9Z$<335H88W.!\223YDZJGA#KBM5E::`U&HK^'@?D?!<<$T%3T"+G
MH>4W31L`+C^KHE#N+2""*=?CT3DS7!XJWHI6N:[])KT_O%1_<N.3$@"IZ(YP
M:TN=T"HJH9'HE_<6-I2[5$61Q4I8\'84HMR"YHZ13(!A3-Z!]PW,/D0JZ7F@
M=0ARE.)B&`+Z]QM]CBP7L;H_4;N;7Q!\01^SJM&X;W-X!W#N<C:<)RUGDKC$
MW9MKML+]QBE;^6^,D$-E9NB<YKFM>2"JUY8K>DX1.$3A$X1<]=\@7`=5`N`-
M/&E?RZ_EXIT(<AO;N#*_414?)571O:X-(^HTI^(J/S&ORU7809/77G]JR>NP
M3Z!06K1PY!,3=^('%!-0"";H>N^N^N5&L>X%S&N+1Y`G\-/%6DUU:VP!NI8H
MJNH-[VLU'71Q'3Q/0>*X7:.FHE*Z:NFACAY$([;K-3G+WUY$(NFF8Y>PZ[`!
M#OD7,<P`O^D'I73]JJLE@F:7P212L#J$L>UX!H30EA<`2`2`=3X+\.AY3W>8
M/Y%5-KJTIH/'P!\J^:Y\1X>X1O\`3?7<2/[^FO12-<'L#V5+3\#4:TU!U%::
M:+CH?KR->NAT!/Y&A4:M!`<0"?/3Q`/7R)%?)?)3%.4#D,4Y1^ABF`Q1]1`?
M4!$/00Y'H"?+\_R0Z4W5%:]=*4--:]/A7J-1HNTW9/7:+IPT9/7;=B7S?.&C
M-RZ08DZ$?-XL@DHFU)T'?:@E#KDS6/>*L:YS0*U`)%/F!3Y^2MY[RTM7QQ74
MT,4\II&Q\C&/D)Z>FQ[@Y]>HV@U&JZ_7](=]_NY2+V@TU/R!*N'D,?Z;OU^7
M^'E7X=4Z'D0:^!K\E*'M)+6FK@ZE!J>M/R^/3XJU$=G/$\IDE_B-A=(IQD"-
M1!1Q!D,IXJ+@155S&,Y#Q^P>3+!!,5'#4B@K(D]1#L#`7)G#Y/[%N1,+OLW]
M'?XD=0/B11<BQO?GM+E^YMSV@L,O:3<]MHZFW!<09&UWPL?3TY9H@-TL3'N>
MQH)(^DTNOT(AW^`]#_B'F-.FE#4?"JZ^P/<[TR*2>.E!7QH3I^'7PZIT/)2]
MHZU'X%&T<-S2"!\?A7]B[+1B^?J*I,&+V0511%PLDP9N7JB+<H]&75(U25,D
MB7\3&`"_OY4C:^4$Q-<X#K0$T^8`T5O>WECC6M?DKBWMV/?L:99&1ASZ@;6E
M[@'.J>@)75#H0[`>P_`?V\-:7.+1^H&A^:N''82'>'7Q&M::CX"ORUZ*LXC'
M.0Y]&MN(*AW.:;W*6D(&GKQ-7G)%"V3D2F*TK#5E5FQ63G96+1`3.&[45542
M@(G*``/*D4%Q,&&.-Y$CG-;])^HM%2!YT"P&0Y9Q7$S7EOE,G86T^.ACENFR
MW$3#;Q2U]*68.</39(11CG4#C0#4A4@LBJW65;KIJ(KMU5$%T%2&36071.9-
M9%9,X`=)5)0HE,4P`8I@$!#L.45GFN:]H?&0Z-P!!!!!!%001H01J"-"#4+\
M^%%.$0P^!3','H0HG']X%`1$`[].^@Y1F>T1.)!<T`UT/[558QWJ`4^JHT.G
M7I6NFOA4ZK=B^'[0&I:T8B@<]S$@6U9BSOCZM3CN52**<13J+8F[*SQ--@$5
M"E64<KD4;K2CQ0`.X<IE33`J*0"?N7$,'!C+%MZ7;KR>)M3Y,-'`?'S7Y\??
M'[D<[W<YY==N;6'[/@O&LG<0LC)#IKN[B>^&6ZG<-`W<',MXF_2R+K5QTS/E
M^GTZ_=Z?]G-N/5>%O%<\@BM'DG!&&<O1CR+RCBS'V0&CU`S9<+;4(*;7%%3H
M#%2>/&2CQJ<?ZITCD.4?4!`>6UQ9V5TVEQ#'(WR+0?\`"JVKB_.^<\(N67O$
M,SDL9=Q.#F.MKB6&CFZBH8\-<*TJTBA&A!"T5/DLJVKM`VMNV.]4:XZ@*51`
M+7K>8+))V&!=Y&0774L;.IA+*O'<;#5T3IL%$_N%DSO45_#Q(4H#Q+E$.+ML
MHZWQ;-K&CZZ.J-WD!X;5^BCV@YCO%R;LM8\L[S7C;S,9)QFLR88XIA8D`127
M!C#1(^=VZ1I+6D1%AUW:0%YKAK33JO4!`(H>BC?LQ%;#RM6@PU[FXN)F&T\T
M7GT5A0;S#UB#A`&P,'\@*D86-:JB91^W.0%'"`=%$P`9(^<XW+@8I'MY`W=(
MYI#2.@^/^"\Q>Z#%>XG*<5L/_MVN[>SR<.09+>-)$=W)'N:(C')*#$;=FKYX
MQ]3V"C:T+77\A$9=O#1*-@>LY*>2CF9)N0CFAV$>\E2MTROW+%BHJL=HS6<@
M8R:8G,)2B`?N##RNC?(Z2)NV(N.T>0J0/[EZ(P,&;M<%9VO)9X+KD$=M&VYE
M@88X))PT>J^&,N<61.?4L!-::T%:+O.$$73=PU<I)N&SI!9LY;K$!1%=NX3,
MBN@J0?0Z2R1Q*8!^H#UR0.<TAS31P-0?)9">WM[N!]I=L;):RL<Q['=',<"U
MS3\'`D'X%67Q/KQBG"DE:)?'\`I&R%L<B=ZNY>+/?L(X%0<)0,."O7V,*@Y[
M4*F/FH)NO(Y@(0"YG*9V_P`O%'#>$%D72@\:4J3UJ?R7$.T'MR[5]C<EE<MV
M_LY8+[+R$R&24R>E#NWMM;<$#T[=K_K#27O+J5?M:UHO;S"KNB<(K59JRFUP
MSCB?R`Z@)FRA$)D*A%0S=13W'*_94591Z1-9.'ATC!VN[4*8J8=``&,8H<R>
M'QK\MD([(/;'&XZN/AY4!Z_FN2=\N[%KV3[:7_<.ZL+O)"T#6L@@8X[I'UVF
M:1H=Z$`H3),YI#!30D@+T,1Y$0RUCNLY#;0$U66]E9"[1B9U)--XF4BIT?N$
M%$S"1[&.C)B=LX`">\D(&\0[ZY1RUF<5>R6;G-D,;J5'0_\`I\QX%9#L]W)A
M[N]ML;W&AQ]YB[;(Q[FP70#7::>HQW1\$C@?0DH/4;1U!57%Y9+IB\FP)SZM
M?FTZHXC&EG4C'I*\ZFD%G,0WF3-SA'JR;=N<BRS(CGQ$Y2CWU^T/049MVW43
MKL$V@>-X'DL+R1G('\=OF\2DM8N5&UD%H^Y!=;LN-I]%\[&_48P_K3QI711=
MU&C=DHV!N/\`S`R)7)5;&^&M-990KNS)+%<+_K+L7J!A9EJSUR/<>CT)@#LR
M?@B)"CM'*I^.&:`X)NUVP5IJ*4%/+7S7E+V=X?W+8W#9MGN$F+FNR$IM([@[
MKX/WDW#VR-.T63SK;QCZOWF?PJ!9\/B>S5EBB[AX2Q;3[W-5_'>6<HPC;)-0
M9%CSQ%P;QT'.E9)2Q73)PZ\6Y3B!?:42'U]>_3D.)W]W:Y>WLX'[;:2:KFT&
MIVN\2JOO9[=\)Y-V-Y!S3/8V"ZY9A<3)]C=.,HEM?4N(2_TRV1K34^+VN(UH
M:*659J+[<+)=MM>V]9M.6JQ%;26K6R@Y5O>S=$U]JE*KCJW*BC1L85H:V:P9
M4R+$^^9Y]EYG0,B"*/8J&,)<U;L&>OI),M'))#]ZZ)CC*V-C`"=&BE7NKX#S
M7!.0<B'M^XS883L7<V>%R=QPV#-WMA:8.YS%W=W#;<`W>0N'S>C863]I'JMH
MX.+G%I:`K17#4[5'`&"]J<D91KV5\G3F'=U,A:KXX;5ZZM:>E*,4:>23J<Y;
MT_TQR4RL`L59XO\`:@0[Y8A$1*5(Q@"TEPN%L+&[N<DV:5\=T^%@:[4Z`M/E
M4`FOR6]8;OAW[[G]QN'\0X/?8/#X[,\"L,_>_=6WKACW7!%S'"=U:S_1$P.H
M(XW%Y<"VJN!GS2K4G">*KM#R4))Q^2B0N`ZO@F]S.Q,&K8\P9,S`S@#W:3L&
M`(^*-/8_AL3&F#/%&;Q-N5RS(4AE@,<B@WE_Q[!6>,?!<Q[7MBA9&\S?6^20
MZ$L%2W:2.O4+3NVWN+[[\_YOCKZUOH9.*NFS5QEK*+!/%OC+#%.E^WAAR[CZ
M=Y+D!&(A)`]QC>YOTD`K\=E=/=&]?8[+E4EK)"I7_`+G';N):DVA@93)VQJQ
MWT$IDNF3F'4:J9;#;YY$R"JL*Y:&?G03\%5RJD\NY+S`\;QL<T$A:RZM@QW\
M[ZY!0$AS2`&[JU%"=-5D.U'?CW,]T;S$9K&V4W_"W)AD8W$X%[,=ABV.7^G7
M,>3;,Y^2:Q\=+ILC(]6NV]&@1Z^7MOB"!V\M%5Q5C`<>2D!5*"ZMZC";CSUB
MPGG,94B6KAZ]38VO0S>H*Q;!8R+XX*NOU1T<SD?:,(D'#\X;:0Y0Q6$1BGC:
MTD_NNW"HVCX#0KJOL*G[A93L;;YWGF8BR^*GO+P63'->Z[M_2OKAER+BXE>Y
MT[996M=`T:11?1TZ2)VIV#S+I'1](L6ZJV,,:XOM>L=%RQ-.X6N5R6:9OR1>
M/NCW5>Z*RL/)%MQ$@,BD:/4,8$T78$,7Q]KPR&5RE[@8+"PPU(K62T$AT#B]
MTAJZOTGH=.OBN4]FNUO;_P!P7(.Y'-^]4+LOR^RY?=XU@EN9XGXFPM"3;/M&
MQRL;;.<`2)B"S^'H*U)\G!^C>(\HXB3#(N*YC&.2+=K?D#/]4R#+;+4TEYLD
ME78N2G&4W6=5V$)^IH8:EW"!D4W+M8KHB)?+R+Y`):UA@+2\Q[A=6[X[QT#I
M1(Z4;G.`)!;&!HP_^M0_!3<_]R7/.%]PS%Q'.6^8X79\JL<1/:QX.=UK;12[
M8'1W&>D>W=E&`[]L33"XC=70M/O84TSTPMR>BN,KE4\RNLK;L:ZR]X"]PF1&
ML?4\:VN$B+#*DG6]67B7+J?&5=1H('9J+D9MD$2F`JBBIQ)-CL+@'LLK6[;*
M<G>V[W@A^C2UI)T\>E/^=67<CW!>X_`7_<'F?&[_``$7`.`\LBLOM)K(NNKR
MWGDCC;!Z[?T-B!WF44D>Z0BH`H<?UDTPT;UGQ5AC/EYPO?L@[.[<8RRI8HS(
M]+O;&E53&O\`#5@=5^N"RI*E?E6%NG95X1NK8EUEVR_V`J)IF`P^1J5QD&6?
M&;7'W9GEGN&R%I:2!'L=M`=2NX?`T\5FN'\3R'+O=AS#N?VVBXQQV'B]S8V%
MXRXM'W,U^+EHGOKD.$@;9SRQ"2%EU$T.E=L$G\QRG7G71S4#"&/,@T.W9%J-
M6S)2=<XC*=<R++[&0B]KR#E]]7(^T%QL36PT`DO%T>Q-W2K:)D$7RKU11,JA
MC&`P`,;[`8*RLW6LLL<=\RW$K7&7ZW/(J08Z:-/AJ?DK3MS[B^_O<?F&+Y5@
ML1D;WMW?<JEL)L?%A7MM++&,F-O]VW.>L3+>0$"6XA?$V(!QH::"->]V&]7M
M>H3$F/L95#)HYBN^*,,YHL]XLEW0?TJ+BKI4'!IBH0M6*Q3=N'4C,H??B\57
M`&H?ZNF04_4,5G\=BL?:Q6=LV7^H2Q,D+R:M(<"2`/F*_)=C]M?/>]/='-YW
MDG+<GAG]O,9ELMB+>T@M71WDLT%R'07,LP_AF**(F,,ZO`#G&JOY;LPY,TQ^
M/C1BP:O6-3&+W/[O*EVS7E.MQ<(O8K/=JO9&L77Z++S\G&2)T(N#C3JD)'#T
M5;[41\1`%?+(RY&]P_&K&;$CTC."7R!K27.J:-)+32G2ODN;X;@7">_/NH[C
M8OO#;.S%OQB*QLL3C)Y9F0P6D\)=+>1Q1OC+Y'.:'MFU_F;C7Z0*CQ9JUKK=
M\58CV/V[L%5C[)N!D;+4O<+/,YQK6MT?B*#@+.K"NYG'^.E:N\89$LXS9CO7
ML<<[1FU;J$1(F43E$:]KAL5<V<&5S1B$]U(\N.\Q>F`2T;&T^MU:$@AM`M=Y
M?WJ[M<>YSF^TO82TO9\%P;$X^&UB@Q#\Y)D998VR>G?7SIVOM;?T:QQS-;,X
MO;N=H#21NHD/%UZ#^*VO0-@:6N!@=_-QX2"M#`H%866&C*Y=6,9860`/7VDX
MP2(Y(`>GBKZ>G+S"1QL9B[=CB^.._N-KCXAL;Z'\05S;OY=W>7O^\&8RUE]C
MDKSMUQ.>6V>/KMYY9[-\D3@2:&)Q,>W31H)H30:[&0@ZR%D$.^^K[=0['ZC_
M`/N>5]1_?SG=P=UQ([I61Q_[Q7U4XL*<6Q8'_P`LM/\`=X_[#X*D>45G$X19
M>/B0U-U(V[R9;Z+L%/7<;O"L6]CI6/(B;:5RL7RMMP(G8#.)5L@-E<RD&N<A
MEV;5PT$S-8%2G,":OCNG$L1@\Q*^&^+GW<='!E=K7-\>GZJ>(7A?WO\`>[OG
MV-XQCL_VQAQ\?&+F1T%Q>NB=/<V5T_=Z1#'N,,<<X#O3E?&[^,TL.W<S=NS4
M^IP5$JU<I=68DBZS4H*)K5>BTCK*I1L'!L4(V)8)JN55W*I&;%L1,IE#G.8"
M]F$1['G8HXXX8VQ1`-B:T-`\@!0+X"Y?*Y'/9:ZSN8E,^7O;B2>:0@`OEE>7
MO<0T!HW.<30`#55)R=8].$7Y+$!1(Y#!V4X>)@\C%[*/H(>11*8/3]@]\B#0
MU/12N&X4^(_:M#?Y0M%++IIG.9E(N/D7V"<GS4M8<:VI<SAZG%N'RQI&9H=@
MD5O-1.<@7+DXMU%SB9^Q,FJ!C*%7`G#.58*;$Y)\S:NL[AQ>UVIH3U:X^8KI
MYA?HW]GGN3Q'??MQ;8K(30Q=R,):M@OK5H:PS,8T1Q7EJP``QOC:S?&T4CD:
MX4#7-KC*`Q3?F((&+]0$H@(=#]![#\.:OH10]"O7^UXH#4N^5*T^'[5SV/(>
MFS04T`H%`DGK4T;3770&H%.FAU3DP`'1/RU->G4GQ/FN.%!.$3A$X1?"J23A
M!9LX22<-G*2B#ANNF19!P@L04UD%T5"F36163,)3D,`E,41`0$.1U!#@2'`U
M%#354YX(+JWEL[IC);2:-T<C'M#F2,>*.8]K@6N:X:%K@0?)<((HM4$6S9%)
MLV;I)-V[=!,B*#=!`A4D4$$4RE32113*!2E*`%*4```ZY!PW?JJ=:ZZ]=5&"
M**U@9;6K&Q6T<8C8Q@#6LC`#0QK6T#6-:`&M``:!0`+].%47/?%`>JB'$"@3
M_M^O(!K0=P&M*?@FYQU))/QU_;Y#0>0TZ:*O,6Y,N>&<B5#*N.Y4D'>:),)S
MU8EE6#*4282:**[<BRD=)(.6#Q,47!RB15,Y1`WT[Z$*\%W+CYV7T)I+$:CQ
M^'3QZK5.<<-P7</B&1X-R6)\V"REN89F,>Z-Y9N:\EKV?4UP+001Y45^\<;Q
M[+8ICK#%4^ZPI6%BR2]S"9*QT"B7$]<RA)JF4DKW1U+17Y4:78WY3"11>/!`
M?;'HH%'UYD;3D5_9L(A]+:Z4RC>S<0]W5PJ#M/RHN7\O]MG:+FU[#?YVRR#+
MBTQ#,76VOKJW==8Z,-$=G>"*6,7<37#>&R``$DN#M*4?=MI<T9(K-RI=]M"5
MAJ&0\X+;$7B%+$0T4:>RF]8A$R,Z22C6"#^*2=Q(F1!LV,1LEY>94_(`'EO-
MFLA<,?#,`8))_6>!].YVE36E14"E`L_QSL=P/AV:L>2\9@N+;D>-XQ_0[25T
MCYF16,;MS`8G?3+)&_:?4?JYK2PU!UR1[*?)1A;-&.,T0D90<F3\ME6EU*I4
MBF9*J^%"U37J1@6L.W4MU*RE6F3G,EPL#<L1_JBDDY0$3*>2IA``+S;<IRK%
MW]G.8HY3+/`T-:YC:1.;T(=3<XUU^%`O'/9WV?\`<W@G.<'D,A?XBUQ6"R%S
M/=7EA<Y'U\W'-ZKS;36$Q&/M(B9=KRR/:&EU-350$R;NOL3F.CO*%DNRU&TL
MY2.AHB>MCK%N-VV4;)&5U5BK",[!E)G6&]XDDV!XQ#HQGI5%"I@50QR]@;6[
MCDF2R=D(9W6]71AKI#&-[MM.I(KU"]5<,]N':/@');;E/%K?*6,EM<32QV9R
M-Z[&V\]RUXD,./,PMHP6R/`:&D#<2!545G#9?,>QQJ4KF&QQEI?T&!+7(.92
MJM:@[`\CB-XYF0UGG(2+82-K?)-(ELDFN^46.DFET3Q\CB:TOLSD<ML9?T<Z
M$4W4`)KIU`%5L';3LOV^[3/R+^WUI<VS,I<&::*2ZFG@C<'OD(M8Y#L@B+I'
MD-CU-0'$@"ETL8?(#MCA['D5BZD9,:EI]94=+4AM9Z11;M*8[5>F4.Y/C^=M
MM>F)6J>2BQC%*V5`B)A[2`G,E;\ES%O9"Q9)&8`W:TO:"YC:4`::5H/#R*T_
MFGM3[$]P>63\]SV+N(\_=EKKO[6[N;2.[+#I]U!!(R.:OZ7DT+FU!K4E?M!?
M(/ME6ZA$4J+R'!C'PE$F<7,9R1QQCV6O9\;3C9^U=T1[?I*M.;8[J[4LDJHU
M:F=>""_BH'8D+U!G*\Q'#Z'J,?\`P]FXQ-W%M"*;^OC^SR5+*>TSL;D,_-G9
M+&\B,V1COWV\%_=Q6++^(L<R[CLFR^@R5QC:U[BUV]I>W0.*H6M[>[`U.R8#
MML#=D&4_K'3GE"PJ]_ARNN"U.KOV\BT<L%V[B-4;SZBC>57)[SXJZQ0,'1@$
MH#RPBS>0@D@F91K[9A;&0`2UKM"/D0?%;+E^P';/.XGE."REC<NQ?+\E'>Y5
MHNI@Z6>(L<Q\4FIABW1M.U@(KN#NNGJU?=;9:FX@>8)A[ZT-CATE;6\<PFJ=
M3[!.5:/OR;M.YQ]&M4W!O;!3V%G3>K@Z38+I`(+*>WX>0]U[;D&199'&1.C;
M9G=JYM7#?JX--*@$ZZ>-58YKVU]H<]SR#N;E<9.WE0=;.?Z5U<P07#[,--L^
MZMHY&Q7;XPQCFN>/K+07U`7W8MV=B+;BX,16BRU&QUPE+1QPG/SF+L<2N3$:
M`U;@T:U%+*3VLK7E*(;-`]L@E>E<D)Z`J'*MSR3)7EHZPN'1R0NC],DPMW%H
M\G]?#JJ>)]N':;!\S'-\):Y*TR0R/]0$$62O(\<;QQW.F..$IM3(YQ+G"A;N
M)TIHK099S+D7-\[`V3)<ZG/R]8H]5QS!N4HR,B2LZ=2V1V%<BS(135H@X59-
ME#`9=0IEE1'LYA$`ZQESD9\I(RYG)+HF"-NE*!O33\3JNA\![><8[8XNZPW$
MH)K>RO\`)7.0E$DKY7.N+MX,SMS]6MJ`&L'T@#3JKP80W=V6UYIC_'6-;W&E
MH+Z6-8D:9=*33<BUV&L8]":PUR.NL)-)0$L=4/<,HV]LIE>U#%$XB8<G8\@R
MN*M1;VDD;K8'2)[0X#XBH*YUW)]M79_NWR)G*N6V-RWE,5N(#<VMU<64L\(_
M3'/);R-=,U@^EE0"QOTAU`*>Q5M^=I*K&S\3_'%<N+"P7.P9&40R?C'&N3"P
MM\M3HSVQVNIA<ZM+DJTI+O#BJJ5D5)L*H^0)`(B(TK7DF6@A-L[TY8W2%^Z1
MH=M>XZD5%14^6BM.0>U;LSG+NWO66=_C+B''0V%,;D;RQ]:TMVAL,-R+=[1=
M-C:-NZ5V_;^ISBJ2IVX6PM"0Q.WJ]X0CTL(Y"NV5,;%-6:PZ_0KUD1N\;6Z8
M6!>(,232E$I%<`;.`4;-_<'VDR=``1&?RML88V&,OMWN<TAHT+Q0_`Z:?!9W
MD?M_[5\J_KDV7LKEXY#B;/'7OIW,P+[7&F-ULUFKA$Z/TV`R-)<^GU;BHWR3
M]U*R4C+/E/>?RK][*/U@(1,%WTBY5>O%@33`J:8+.5S&\2@!2]]``!S$E[I"
M9'"CB:E=BMK:"RM(;*U&VUAACC8-20QC&M8"3J2&@5)ZFI72Y!5E=S!MXQ_C
MO)M9L^5L40F:L<MW96UPQ],O92+4E(1R<B;QQ!2T/(1KJ,L<>3^U9J&.9`R@
M>VJ02'$0O;"XMK6Z9->PMFL]U'@UT'F*$:A:'W.XSRWE?";S%<%SD_'N6EFZ
MUO(FL=ME9JUDK7L>'0RGZ)*`.:"'--11;J>HNG_QIW.*Q?M-J[BJ`:JMUD)^
MGVZ%ME\0G*[.H)&;2<+-1BUM<)L9B-%95I(1[I-1,P"<ABG2.`F[3BL5QJ;T
M\KBH6!P%6N:7"@/@=3KKJTZA?G[[T][?==B[O*]GN\F;O7``P75I-#:F*:/=
MO9)%(V`%\;G`/AF80:@%K@1IE3#]X]_OYL:\FIPB<(G"*G+3$UR9AGS.V1D+
M+5\&JZ\BTL#)C(Q'VZ"8J++/6DDDLS.BDB!A,)RB`%[_``[Y!S(GLI,&F,&M
M"*C2JN["ZR5G=LEQ$DT61)`C,3GLD+B0``6%KM330.U\BOYS^U&1*EE;8W,U
M^H%9KU/H<]?9O^":[58:/@(-E4XQ<8B!<-8J+;-&+=>68,2/7`D3+YN')S#Z
MCSSQE[F*\RD]Q;AK8'2':&B@H--*>=*K]2?9/B6>X/VEP''>27EW?<IBL(7W
MDUS*^64SRL$LC=[RY](R_P!(`DG:P"JC-8['`U&#DK+9Y9E!P$.W%U)RLBL"
M#1F@!RI@=0X]B)CJ'`I2E`3G,(%*`B(!RSAAFN9FV]NQTD[S0-:*DGK_`(+>
M.2\FX_PW!7/)^4W<%AQ^SCWS3S.VQQMJ&BIZDEQ#0`"22``O19/6<DS:2,<[
M;/V#]LB\9/6:R;AJ[:.$RJH.6RZ1C)+(+)F`Q3%$0,`]AR5['1N+'BC@2"/(
MC0@U\BLE8WUGD[&')XZ6.?'W$398I&.#F21O`<Q['-)!:YI!!79Y(KI.$3A%
MR`"(@``(B/H`!ZB(_L#]_!-!7^W_`#^2B!7Q`^:Z[=TV>(D<,W+=VW4\O:<M
M5DW#=4"',D<4ED3'34`BI#%-T/H8H@/J`\F<Q\;BR5I;(/`Z'I6OR5M:7EK?
MP"ZLI(YK5Q.U['-<QU"02US2014$5'B".H*['(*Y`J:#J5U&SYB]%R#)ZS>"
MR=*L'H-'2#D6;]#KWV+OV%%/MWJ`&#S2/TH3L.P#DTD<D1`D:YNX5%00K2TO
M[&_,HL)X;@02NBE,3V2".5E-T4FPN].1M15C]KA7I5=KDBNDX1<@`C].0<X,
M;N/@I@USM&BJM@ZS-C%EDECB-U<(I+($BQ4>MX,5>_$Q>C)1SAX7MHVFGB/:
MJ#,Y@752*)@+ZE\LBS%Y%^/=DQ"_[1II7Q_`>7Q7+KSO1VNQ_<RW[07>:LV=
MP+JW,K+;=Y4+87R?H9<2-.^.!Q#WL!-!H#<[F/74"*&BM1FYGE60QI96>&)"
M,C+\NU$L:YDOR'%OT8':,.Z./VC"=63'IJNX*9$A_KXB)3ERN&?C8[]DF6;N
MM!UU_P`/$>:X]WXL.[&1[6Y2U[*S6L'/70D1.F`WNC_UK+5Q.UEVX?R7O^AI
M!#J5!'<PTWR2UQG4D<OR#*1R'^F)GL"S%LDW*DHH/DV:/3-U#MG4LU;>)72Z
M0$257\A*7H/(U+*NL7Y"1^,!%D3]-?D*_A6M/&BO.REOW2M>U^(C[QSV]UW!
M%NTW!8T#:TU(9,6_2^Z#=HGE;]+I0XMTHKE\QZZJG"@G"BN#`82&*0XIF,4Q
M2J%`AC)&,40*J0JA3IG,F80,`&`2CUT/IZ<F8=K@?"NH\QY*21AD8Z,/=&2#
M1[0"YIH=KFAWTES74(W`MJ-01HHYX!Q1E#&CK(3C(^69+)"5DL[R1KS1TF)D
MH]FHJ90994[DHJQ\G)$,4BK%J(,4"I@)`$1_+G<]E+#)0P16%NV#TV`.(_>.
MNGR^/CXKS5[=>TW=KM;>\BF[C\MGY#:93)OFMHGBK8VN=N-R=PK%+,#M?;1$
M0QAHV=5(WF`7I>@&@I3X=/P7/0C]/7]WXCQ]1-&@N<?`:E0+@W5VC2>NE!Y5
M_P"7H.I(&JI:M7BFW-291J=I@K$M79->'G48B1;O58N2;&$BS9VFD<QR='`0
M*?H4SB`^)AZ'JYN[.[L6L?=QO8UXJ*CJM6XOSKA7-GWL/$,K89*XQMTZVNF6
M\K9'V\S="V5H-6BOTB36,G0/54<MEM:<(G"@G[1^@`'8B/T``Y!S@T5/1#7P
MU-?A_C0+@AR*!Y)G(H'[2&`P?SE$>4_6CV[ZZ!1%2-U#X_,4--?+_$:C1;>?
M_3]8+G*?@&]9TD;9+KQ69;8M%UZAI/%@K<4TH#QW"O[:Z8'[0/:)R2*JV]Y/
MQ\&#5,IO(3]$[%V^MI&XA]X7'TIG_2WRVZ$_CU_`+X:_YF'<+&9WNKC^W]E8
MP"^P-BUT]X6`3R.NPV9EL'"A^W@80]K75/JR2.!#:`["'-\7S63A$X1.$7C6
M&`B;3`S5:GF99&$L,1)0<S'G452(_BI9FLPD62BJ"B*Z9'31P<@F(<IP`W8"
M`]#P0""UPJTBA5U8WMUC;Z#)6+S'>VTS)8W"AVR1N#V.H00=K@#0@@^((6EE
MO-\.>=\"Y0*?72C6_-N&KI*K$IB568K3UQHJRA#N`J5T9H@"HM&9"F*SF/\`
M\NX0(4%S)K]@?C.=X=?6-S7%L=-:R.)#1JYM==?"E2=5]Z_;O[\^W/<+ASH^
M[61LL%W!Q[`;I]P_TK:^;T]>V=1Y$SS0R6YU#B3&',/TX_\`;7XDMEHG6.?O
M.R.)7E'Q6:9K;)=Q_%M>6ND),RKX&L!-DA(5],'8(M9$Y$3F>=$`S@"F3'OL
M*-KB^1\<+<[L;&(C]0)!.T]:@>%::@K9>0=V_;%[M3-[?(LK<7MY?1.N89;>
M.6)K)K4&0&&>:-C73M9ZA:WTY(W#=6NBA]3:?`4"K05,J[,8^`KS!./C&AEE
M7"A$2&,H<ZSA8QU5EW"ZAU%#"/J<P]``=!S6;JYGO;A]Y=.W7$KBYV@`^%`/
M@O6'">(<>X!Q.PX3Q2%UOQ[&0"&&,O=(0T:DE[R7.<YQ+G$FFYQ``:`!4O*"
MVE.%!.$7@6J"/:*S/UM.8EJ\>=B7L4$Y!+)-YF*!ZB9$SR-763532=I%,/B(
ME_D$!Z$*L$H@G9.6M>&/:[:=0:$&AHM=Y?@3RGBN0XTV^N\8;^TD@^ZM7!MQ
M!ZC2TR0N<"`]H.FGG356KUYPNM@?'B=$6N,K<_&6D)4CV02(U:1X/U/,8^'8
M@HX49LQ$ONJ%.JIYN5%#AX@;QYD\YE69F_\`O61B(;&MIK4TKJ?ST7)?;=V6
MO.PO;=O`KW-7&:F;>33[W@MB@$ITBMV.+G,80!+)5QW3/D<*`@"]RZ!7*"[8
MYUDR.$5D#J-EU6K@A%DCI&.W<H&*NV7*4XB10@@<ANA`>PYB*[3N'4:_DN\3
M1"X@?;N+PV1CFDM=M<`X%I+7C5KA6K7#5IH?!1MP%K+`X"EK]*Q5HL=G5NDK
M]RB:<=JF-'1@&%R5N\(FL9O,31WJAQ5D%$R+'3\2@!>U!/L&<Y"_-16[#&UA
MC;]6T4%?VCX"J\P>W?VQ8'V_9;D.7Q^6R&4O,Y>;V&X>X^G;#ZR)?JVSW;IB
M?4N-H+F-%*$NK)?FO+U&G"+D!ZY*]H>W:=%$?V_MX_V*LX]P+BV0RQ'YJ<UI
MN:^QS%1JD]#Q!DN\\4T6L\\8^'M.;!',R&10<F'R*F8.P$Q$S%R[,WE&8QV)
M$I^U<:_$?`?#ST7%[_V_]J\EW>M^]]UC(CSRVAVA^GHOE`#8[J6*FU]U#&/3
MCD/[M"X%S6D7BYB]?'JNT$DDD]2N0'KDCF-?^H54:_21XD=?+\.A^1T3Z\B`
M&B@Z(YQ<XN/C_;\O(>"`'?#B0*A4WDAM10:BM?*OS'[0HVCM!0_[^PU_")MG
M\1_;^`S7Z(Z&("6]O[G[`4@2^_".^S_/^I>`LO+\OGX_VG-@?QO(_P!)_J\9
MB]+P:7"I'GX?]GKXKS/)[JN`-[_GV]LM<H[D0^C[H6[S;&XIN]+;M$OIANIN
M2WT*_O;?K4DO3\/Z>:^TU'4'XA>G'M+'%A()!I4:C\"N.14J^@#OZ=B(_L#O
MUY)_$,NQH&VBG#=W0_4>@\_D:UK\*#YKCE0BAH>JE((-':$+\5T$7;=PT<ID
M6:NT%FKE%0!%-9NX3,BNBH!1`1(JD<2CT(#T/#2]CVR,)#FFNBHW%M;7EM+9
M7C&RV<T;HY&._2]CVEKVFE#1S214$$5J#56/PWKIC/!+^X/Z%'NT5[B_(Y74
MD'0O%(F*0$#M*U%*G*"Q8ELY,=4!4$ZQS&`#G-X%ZRV8S=]G&0QWI&V'I3][
M_2K7^ZBX3V6]MO:_L'?YG)<`MYFW6:FJ\SO]7T+<'<VS@J!_`;)]=9-\I(`=
M(6BBOKS$KOB<@H)PB[T9)OH62CIB+=G82D4^:248]3]L5&D@Q7(Z9N4RJE.D
M<R*Z13>)RF(;KHP"`B'(ATS#ZD!I(W7H#6GAJK7(6-MD\?/C[V)L]E-"Z.2-
MQ(#V/&QS=PH6$AQ`>#5IH1YK;VT$'0_Y+L0&#*NLN"";!8_;,XW*\/"TR(I[
MZ6*N`I,<B0"U63@WPPEE.D85BIG[8/P.@/1!1,?L?'GX#DMAOE@B%XP;9&[0
M#6@U%-:&O7SJ/!?"GW&1^X[VC\\;:\0Y7R)W;F\D>_%2RW4T\;&-/UV<C;@R
MQB:VJ``YO\2+;(W]1IFCPE@_&>N^.83%&(:]_"E"KSF7=P\"60DI4K)6=EGL
MY)`5],.G\BL1:1D%3%!14_@40*7HH`'-NMK:"SA;;6[=L+*@#R7AOG?.^6=R
M^47/,^;WC[_DUWL]:=[6-<_TV-C;5L;6L%&,:VC6@:=%=OE=:BG")PB<(G"+
MY$I1[[*4>^N_0/7KU#O]O7``!W#JGA3P4;-Q,/$SYJYG;$!6`2#Z[8UL\?!-
M0(4QAM#6/5E:HJD!A`"K(V5@T.0>P$#%#ECD[,9#'S6;A7U(R.M-:::_-=0[
M*<V?VY[M\=YN)/3AQV7MI)75(_@&0,G!H0=IA<\.'BVH(-5K+ZK_``*9>N[>
M-N>V%M;X4J((HR3NA5E>.G\CN692`NX2F)H?NZI3B@@`^8E_4UT^Q`Q$S!Z<
MUP_`9I*SYI_IP@5V,/U:?'PZ=`OK'WE_S+.)<??)@^RN/=G,SO<T7ERU\5D"
M20UT<%!<W):2/U>@QVGZAUP9Y04H_P#>5?RXX:.(S'A;I9&M"8R$@K)OTZDU
MF';6NB\DG'2L@]=1B*:JJ@@'F<XB``7H`T6[]`7<C;6OVWJ.#*ZG;7Z:_&G]
MZ^BO`QR8\+Q(Y6?N.4OL(I+V1K/3:VY?$UTP#&DAK6R%P:RIH`!4]50_^'\W
MIRA45IXK:AJ*CHN.$3A1!(U"YY$DDU.I2IZ+CA07/%2H].GE3\!T7'(*"<(G
M")PB<(G")PB<==#T1>>,1%#+EG_TR/\`UTL<,06:^S;_`*J$4*_W7Z:$A[?W
M7V'W(>Y[7EX>?KUWRH)91#]L'.^W_P"C4[?RZ+''#X<YG_B,VEM_Q#]M]O\`
M=>DS[C[>N[T/6V^IZ5=?3W;:^"]#DBR2<@H*UN:J/9\CXTLU/IUU?T&P2S04
MV<ZP#KW/$#"I%/5DR&?,XZ3(/M++-3$<)E'L!,'D0V4PUY;6&1CN;R%LUL`:
M@G_#I\ER7OIP?E7<CM=D^&\+S,V"Y#=M:&7$=?K`K6"1S6E\<4O1TL1$K:"G
MTEP/ZX;I=FQ[C>M5&WW-]?)^(9%1>6"0+_:#^4OA'-EE"@\=,(P/[)!9R8[A
M0@=G$/0I:&4NH;V_==VT`@@=T:#4?,M&C3Y^153LEPKE/;OMEB^(<VS$^=Y)
M9Q[7W4@Z`@4MV._6^&#],<LU97TUHV@5S>62ZLG")PB_5)-191)%%)5=9=5)
MN@@@D=9====0J2#=!%,#*++KK'`A"%`3&,(``"(]<E+7O>&"H:>I\O)4Y)8X
M/X\I:V*-CWN<XT:QC&ESG.)--K6@DU!4Z;5\8^_U09(/W^JV39)LY8(2")JN
MVA[<J5)R@5=)-TQKDM)2+)R0#@"J2R)%$C`('*`@/-@EXOG[>(.;;.E8:4H?
MJUZ%P&H^/DO.N#]X'MASMRZWBYAC8)FN<'?<&:U8-I(.V2>%L;@:5;M>=PI1
M;5&GWQ-:I8;Q!5V^1L,53)V4[-4(%;)DYDR,;W`6]D=1S5U-Q%982R:T96HF
M-DSJ(I?:(IN%"$`5%3CSJV,XQBK"U:Y]NR2\>QN_=1U#3ZMM=!KY+XP=[/>A
MWM[@\YN[CCG(+_$</M;N9EA!82.M&_;MD<R)\TD)$L\DD8#G&5[FU-6M`4HL
M;Z!:DX<R3&9:Q)AB!QE?(IO(,D)FCR=DKS=S'2B/LOXJ5A&<T6"EHMT`%,*"
M[4Z8*ID4*`'(4P9"VPN*L;HWME;MCN7-H7`D5'E2M*?@N/\`+O<1WIY_Q=W"
MN;YZ\RW&G/8_T[IL,SF21UV2,F?$9V/H2TN;("6DM-02%,DH=``?L``_F#F5
M7&0*"BYX44X1.$3A$X1.$3A%161:<&0J)<Z*>;E*XE<ZM.55:>@Q;%FX=O/1
MSJ,<R$0H\0=-4I)L@Z$R!U$U"D4`#"4>NN22L]6%T))`<TBHZZZ%93!91V"S
MMEG60Q3R6=U%.(Y:F.0Q/;(UCV@@EA<T!PJ*M)"QLJ?$OJ9C/7;,6/,.X<@7
M^1;?B.\5&"OEW7"UW=:P2E:?M(5="QV#S0K:II441$\<FQ3)ZC^4`YKLW&<5
M#C);6PMV"=T+FM<=7;MM`=QZ$GQT7J?_`.\OO?RON?@^7\]SUR,#C\U:W3[.
MU!M[,11SL?(#;PT,P],.%)3(7=#6JU-M@_CJVVU8QM'Y6SAC^'K5,?3\55BR
M,5>:M;%T9J79O7+%-TUKLC(&;ME_TU8@*F-X@J!2"/9B]\GRO&,OAH#?7;&F
M'<`=K@2*^)^"^UO:[W:]D^^',Y^'=OKZZGS3;:2Y#9+26",PQ/#7EKWT!(#V
M&FGTU/@5"/K]_-?=-$'F,&KPO1&[4`@_&E"!\Z$^'U?+XIU_[?YO3_MY$/J:
M4*C4$T%?'6AII2E#XUZA?/)U%.$7(!WR21XC;N/2JG8W>[;6A_M^7SZ#J=%2
MG\<5#^,PQW_$45_''Z&:R?PQ]T094(4BY6XOC(?0H>9P-[8C[HI_V@%%/\W+
MPV=U]K]]'&]UINH74(`/7QZZ>2T__C[A0YPWMN[*6@YNZR%V+3>/6^W)V[]H
MKK7I'4/+/XFW9JJKY;Z>&H6V@@BH-0N.01.$3A$X145D'(E.Q;5G]RO,RA"0
M,?XD.LH!EG+MTJ!OMX^-9)]N)"0<B4?!),!,(`)AZ*`F"ZL+*[R=V+.R87S?
MD`M)[B=QN&]J>*7'->>7K+'`6P%7$%SY7NT9#!&/JEG>0=L;`2`"YU&ZKTJA
M;ZQ?JY&6ZG33.?KLPB*S"39&,*2G@84UT%"*%(LW=M5BBFJDH4ITSE$#``\I
M7,%S97;[*]C=%<,\#37Y461X;S'C'<'C%IS'AMY#?\<O6;HIHR=I(T=&X$`M
MEC<"V2,BK"TU51\I+94X1<@'?)7.#!4J9K7.=M;3\30#YG^[\5QV7R`HG(!A
M*<Q2B8H&,5/Q]PQ2]^1BI^8>0@'0=AW]0X89'#=L<&#J?`*@9HVR-A+F^HYI
M<!75S6D!Q:W]3MKB`=H-.IH-4Y-IX:A5B"#0]0G"@G")PBRV_"K@FE9PW:@W
M%Z]IXPP]4)7+L-`.$`7:SMI@YB"AJ_\`=E,(D^W@'LX$D!3%,"B[5(!_+Y=[
M7PRQM[[.-^YU;"PR!O@7`@"OP%:KP_\`Y@W<CD7;[V^3V?&VED^>OF8Z>X!H
MZ"V?')+,&$:A\S8O1KX,<[4$A;R90Z*`?L#K_#^7G;02X;CU*_/;0#0=%]`'
M7I_W_P"7D43A$X1.$3A$X1.$3A$X1.$72DE7R$>^6BVB,A)(LW*L>P<O!CV[
MUZFB<[5HN_!L]%BDY7`I#+>RK[0&\O`W7B)%_.T^5+Y(OFRV4WRJ/QF,%ZYJ
M/0,I9TI.OCU#4J].<@JOI.].(1>5KF0-DX]A#R9;57*):&\Q,UU@WK:[.+=(
MF?L1(J0QR+>RR9IWA'+6M<)JC;H.14Q!7H&A5R(CHN57BYAA'8V"*+6A:3"1
M#N4'2:4,DFJJ'YU$SJ!V`G$W+/(6-OD[1]E=;O0?2M#0Z&O5=#[6]T>7=G>;
M6O/^$2Q1<AM&2L898Q+$631.B>U\3CM>-KB0#H'!KNH6%3Y._BNU.PKIE:\I
MX0JA<:6W#SZ%L3N7<S]DL3J]PTO*L*R^J\NM.RDD(.E5Y=%PQ52!(J;A+Q,'
M@J80T;E/%\7;X1\]FT12Q$$DU)()`I7]B^B'M!]XG>CG7?['\*[AWSLU@LZU
M\`B,<,3;-[`ZX;<1-B8S](C>Q["36-P-:M%=*>@VK9J0S_>:]=J?7(C#;%@#
MJ`EFPJK>:0BHC#'A9E,$E)>5E?`RD@V<)$*S*40*!/R>[IU[;8*/"07%G.]V
M0?H01U\ZM_<`\#XT^*]W=ON5>Z')^XC/\>YWA\?9=GK:`OMY6%SV[:@6KK2Y
M!_CSRU)NH9&-%OJ#L(8'RGYKB]8IPBY`>N2O8)&ECNA0ZM+3T(H?DK#H:WXQ
M0S:KGQ-@^)=E6*R1T0=G_1QF%T"LUK*#41%4LLI&^3<Q0/\`;B4?/VP/Z\S4
MG(+PX?\`HDCJP^!IJ!Y$_/5<`C]M7;6U[Y#W!6MO,.9.B<TQ^H[[<W+F>F;S
M97<)O1^@M!](ZNVAQ5^!#KT#F$C&V,`FM!U\UW_7Q-3YZ:_EI^2XY.B<**I6
M-O5,F+1/4F*LL0_MM7;LW5@K[9XFI)1:#_O[<[A`/J(>GN`43&1$Q04`HF*`
MW#K.^9"+R2%S;%^C7^!*TW$]PN&9WEE_P3$9*RN.78IC)+NU9)6:*.3])+/,
M:"1H)=%5I>!N"JKENMQ5(WFAU')-:D:C=X-G/P,F3Q7:.R""B"P%$J3V/=$$
MKB/D6PCY)+I&*H0WT'KL!N[.]NK"87%HXLF'B/'Y^:T[G_`.']T>*W'"^=6,
M5_@+EI!8\?7&[]V6"0?5#,S]R1A#A4]05Z-7K,%3*[#52L1R$1`0#!"-BXYL
M'2;=LW(!0$QA[.JNL;LZJAA$ZBAC&,(B(CRE=3S7MT^]NG%]P_J3_AY+)<3X
MO@N#\:L>(<7MV6G'L=;MA@B:!1C!U)-*N>]WUR//U/>22=:+W>45GTX1<AR5
MS0ZE?`U2A<0&@&O@32HH:T^--1^:BU?=<9:YY]H694,I6R)BJJE[;^H-GJ[8
M@)MB@=!G7W3(44V49..`#]527(L=<@#T?U`";/;<ACML'<8^:%AE?^A]//0@
M_$#ITHO)W<+VV\@YY[@\!WH'+<I;X.P/\6QCD?&YK8=KHX+5S"UD<-PX'[L2
M"CV@@%Q=1LI1^H_0/4?0`Z`/Y`_`.:RVE!M_331>LR6N)<RFPG2@H*>%!X#R
M"XY%07!C%*4QS&`"E`1,;\"@4!$PC_(`<*(!)`\2LD]/^(W?^\T-KD6#P9[<
M))1K&8AHV7N])A[/-1DDW([:.V$"]G"+I@JU5(<$W1FRP@8.B"/8!L,/$.37
M#/7CAC;'2NUSJ/(^'[5Y)SGOF]LG'N3.XO?YY[[F.5\4LT5K<OMXI&.V.:^0
M0ZD.:[6-KF=-?%9./A(TFV-Q/L[D?*N8,>6_$<-2<?/*$6*N<$XC'5RF;K(1
MD@4()90WVLA$P3.N>\N[;G62]U=%,![$_6V<*PM_9Y*:XNV.C]./;0^))KH?
M$"B\B_Y@WN$[6<Y[2XKA'`,M8YRYR&49>&2WD#OMHK6*1A$S2`^.25T^UL;V
M@EK7._=%=J(G^:7^0`_FYTRE-%\>FU(UZKZX44X1.$3A$X1.$3A$X1.$76>/
M&D>U<OG[INQ8LT%G3QX[63;-&C5ND=9PY<N%C$1;MT$4S'.<X@4I0$1$`X1:
MX6>O^HTUN>;G8$^/C15*'VGSOF+.5)Q5;\FQT@J.`\2PTE963>[2Z%EBS&=9
M3LM=K*;YRFVB#$B"*H=K2(B0[<Q%FKA]--7:\;'"D!A.BPRF)<S7K8:@KQT4
M5!U"9JR;'W2,OV1C/?,SR3LMK:9!E"NUW2BPG%9,0`/MV_M$4F^$6%/YZKB[
MKFB3R":D7$M]RUCBLO5$DU#))L6"\I<3_=K$**:2:[FL(IE`_0'.8"^H^G--
MYW/Z.`+&BIDE:#Y`+WE_EPX-F4]RD61D#:XW"W\[*D`F1T;;=I:#J[:+AQ-*
MD`5Z!:6T?'24N[3CHB.D9B063662CHA@[DWZR2"8J.%DF#!%PZ4312*)CF*0
M0(4.QZ#G&6-+SMC#G'X`GIYTZ?BOOS=W5ICK8W>0FA@LVN#2^21D;`XZ!I<]
MP;N/E6M?!=95%9!0Z3A%9NLF82*(N$54%DSE]#$426*10ABC]0$`$.3R1R1.
M#9`6N(K0^14\,\-Q&)K=[)(3T<PAS3\G-JT_&AT\5^?*:J)PB<4KU4?AX)R(
M'@%+HT::`+GH?YQ``_#L1'H`#OZF$?H'U'D&G<=K=754^TBM:`BFA(!UZ"G4
MD^``J5R`B40$!Z$.A_I[XT(J*$%&DM(<.O\`>/F/`_`ZJ-E&U9QI0,R6S,\(
M60--6,CD[&)<+J&C*X]EA4-9'K`15%9T>;4-V4BWD5L!C@3T,`DSM[R3(W>+
MAQ#@/181N<`*N`Z`CPIIJ%YFX)[4^VG;[O-EN]F'=<NSF2:XQ6SG'T+.6<DW
MDK'5W2^N?TM?41-+J5J`V2/,$O2Z<(G")PB<BH@5-!U*MMDK+^/,0-8%[D*Q
MMJ^A9)QK`11E@,H=1TX$HK.UDT_)1")C4C@=TY$/;0*8O?J8`&]QV*N<T)/M
M&E[8@2:>!'AK2OX+F'<SO%V[[/VN-ONX.1BL+?)9&*U@<X!Q#W4)F<WJV"!I
M#Y92-C`6@GZJ*Y*9BKI)N$#E7;K$(JBX1,"B"R:A0.FHBL01353.00$IBB(&
M#U#TYC&G8YT,OTO:XBAT/]ZZ9`XSV[;B(!UO*`0Z/ZVN:=6NJW<VAZ@U+2*$
M&A7/0\K`5%6_I"@9&@TUK\`3^=.@^)T3KT']X?3U]?YO7E,O:"!K^H>!^2J_
MN$?28S3=J":5KT^-*&A!"V]M<_BNTXVQT[U3RG.TF0IF0)#&%`E+';,>R@PJ
MMO>0Y&R<HE;(-PF^KTPI-#'J(NG(-DGQO=,/O>70AV/'<<PV6Q-G>31TNO18
M-[-":"GU>!Z>53YKX9=U/=]WZ[*=].;<+PV6%_Q:/,7T4-O>L];[=DA?L-M-
M5D\)BWL=$W>8QM`,:V`T4&[-LDW;))-VS9%-%%(A2IHH(($*FFF0H=%3222*
M```=``!S>:`+YMOD?*]TLA+I'.+B3U))J2?B3U6,K57Y<-0=JJ/LCDJ,LDIA
MV@ZQ9#CJA=KAG3]`H%<EZ?:W(-,9YKKLRO.O(X^(\K.4UR04D\4:'<F;J`=)
M/T[*2@7UD/YE/C1QJ3"3^:V\PS)5C/>0+]C6EWFLW>MV&C1ECQE`KSES/<[-
M'RIV%5BH@WVC(SEP/@+^48I@'BY3/PB]/'ORN:93.'L,Y6S#F_#6OCC.Z-HD
M,>5"[YNQ787D_!U_(DYCEA/Q%BI%FGJO,1-CE8@@-56[HY0<N`9'$'B2J)"*
M_CG>C31E8LMU)YM%@IK9,"Q+^=S/#N<EU5%YC2%B)!C$3DI;R*212P[&O2\F
MV9R2B@@6.=N$T7(I*G*02*G0^1?0T^,W&94-OM>'>*VN0WN)EKZPRI4I"L_W
MEQS(\H_I"4DRDW"+BQ,X9(S]1NGY')'E%V/^K@*H$4QF;QK(-&K]BY0>,7S=
M!XS=ME2+MG35RD59NY;K)B9-9!=$X&(8HB!BB`AZ<(NQPB<(G")PBX$>@_R!
M^T>N^@_?Z<(H5PVRFC^Z#S.FK4)D;"&?;+3%+#1,XZZ6%]%OIQ`(UVK'2L7<
ML;6AD26>55>0;^T+_P"P<QB_H9-14.NR+!%I-_TZ\;K5\@FL7R&.F.*J1:H=
MMLA;,W8#Q0V5985Q7=;[%.JW@JL8"9.(E@\>5S'M'L3V/EW[T$EY.7:$DDDD
M"N3-T2+:R#T``_9PB<(HY;6:T4S;?!UTP7?'LA%0=O"'62G(A)HK,UV4@I=E
M,1TQ#@_37:$?(K,Q)^<AB"FH<I@$!$.8[*8Z++63[&Y_E.I334$:U^*Z;V<[
MK<C[)]Q;#N1Q81292Q]0>E+N]*:.6-\4D<H:6N+7->>A&H:1J%3&L>DFN&H-
M?_2<*8\C(>6<-B-YJ]2Q0G,@V,W?YC3%L>E,_%!0P@/VK?[=D00#P1+R%ABK
M#$P&/'QM8::DZN=3_I'J?V#R62[L=^.ZG>S*')=P<I-=1!Q=':Q_PK.#X0VS
M3L:?-[MSSXN)U6I?\TSQY>OD;M]0J\2ZEY6'I^+Z7%PL!&*OY67FWL$%C6;L
MHZ-15=R#Y9>RE)XD(=0>NOH`<Y3S8R7'(S!`W=(&1L#1UZ;C^50%]JO\O^VM
M>,^U2SY#FIF6N/GR-]<237#Q'%'"V;T0_P!1Y#6L'I.)JX"N@U*Q(S$7(UZ3
ME(6=8NX>8A'[V)F(N204:/HR4C7*C.0CWS98"JMGC)VB=-1,P`8ARB`AV'-*
MD>Z!SXYV.;.UQ&VFNFFODO<&-O+7,VL&1Q,T-QC+F)DL4K'$LDBD;O;(TTIL
M+2"'UVD&H--57V3</9#PXXJ$?DJO.:I-76DQ60XFOR?]C.-:K/O9)I!/)N-,
M`+P[J63BU'"39<"K@V.F<Y2B?Q"\NK2YL7LBNV[))&;P/':>A/E5:MPON!Q/
MN'%D;KA]T+W&8W(/LGW#!_`EN(FM,S8'_P"M9$7ACI&C87`AI(U5L>6ZW)<A
MR(TU!(/PZJ9KBUP<.H*CQG_!DQFQ.CDBLG6?'?\`"%E:SCA."[,WDR)J$,#L
MJ:2S95*PQOB/V3@YU$$?<-Y)&[[YGL+F8,.V4/MF3OD:6[G'45_`_BO-7N&[
M#9[O:W`_T7D^1X\<1DVW#Q;NHV1NZOJ-U:X7472*1SGQM!-8BI!(IBB@@B9=
M=T9%!%$SIT8AW+DR294Q<.#III)F77$OD<2D*43"/0`'IS`:5)`#14Z#0+T=
M;Q&"TAMW222R1Q-:Y[W;GO<T4+W'Q<^F]U*`N<2``:+].%53A$X1.$3A%SP>
MB'44'54%?\:X_P`E,HMO?ZI%VEK791&?BTI)'W!;/V@>7H<HD,HT<E(!5VYQ
M,@X*``H4P`'5>QOK_%O<^QE,>]I#J#KX_P"'X+GW/.U/;_NE!8V?/\5:Y:*P
MO8[BW$[20V5N@#RT@F&04;/&3Z<@#=S:!7TV,T0>ZL7N*JUE@9*I-[/68'(5
M"M>/IRS5"O72I66,:OV4M%LXR0;Q0JL%%Q:O6BK<YFSI(Q3%$AB'/F\M+E,1
M.(;QPF$K&O:YS&EI#O#45!%"#1W[5QKM%9=F.[.!N<]V_@OL#FK.[FL[N#&W
MUS9RVMQ!(8_3=#;S"V(>&A\<CH2R1ATU!8V/QJE=8P`-"Y5EE4$2+"+6[UZ`
MLZ1Q$1%/W9*+2JDR":0=!V9=0XAWZB/,>;NTGTN;6+>3UC+F?W?4%U*/A//\
M9)OP/+KR2$N'\+)V5M?@#Q;ZL(LYS7S+W'QU09'+<8F*KFLTFWMR-P4,O7+)
M*UI\H<OJ(I1MBC9*/`!(`F_-)%]0Z].471XF5P'KR0M!K1S0\"A!H""''_LJ
MJV_[X8ZZ]&\PV#RXW@!UG?364I:":$6]]#)%N+033[P-\/BMU75#Y'M=M)M/
MM:<<;;P>6-;`B<3U`Y;9?*S#7.GS"UB9EL!'47*88L^3Y-!@Z-+@*(2#&/7(
MF(`HDF("4.\8*!MMAK:%CM[1"W6E*U%>G@OSC>X[E1YMWWY9R<P/M776;N:Q
M.<QSHS&\Q%KG,)8X@QFKF$M/4$C590\C3H;>::Y(>ZK9DKM>4SEAZ]5_%&<G
M$3+24!5W5DAY:LH7L(=1:O2KDU9<J*N$DSJ-A]]N7R$"]\RJXJL!%>^#>AY7
MU[LP:>;SVO(&N.S^C&(M9EI?,:`Y7AI2&P!F.AWS!-RQR\@D:0@C0JW7(2T0
MB48X2=$6;3I5DG)TRC[A%-.P?$K?V.?S[!XJRQB:%F8_Y,2[S05-M6*I>1IZ
M&/K'J%`:EWS%SUO7K1!.2VE6+8.IN-DT#$9D?&1*X;*`4QQ(L2%U^+;=W6O/
M6OE5Q9AM[M/0<6T'##*+717_`(#P5F"X0?R`YPVJ7C\YO(?/=#L=#A\`MLB1
M<W#*S$#>F$I,QP`U8IE.NW5(I#67X5:I#T+>+$UDVYUV)`HXSVB:5?*=_L.7
MG&5M;H+=C)B.89M7,-1F]BC8#IU1D&\4Y26DF=6@W=I39(/55DUD%C*D5=[%
M:(8CMV6]H*3BK>;2W$FP^8,\8RSWBJ)4N3ZDY[U+>8PTJKV%)&_XHB,3YOQ[
M94KBWKM>=6)RUDF#BLR]:<JM)-H9L!G/"+/!C+9_6=UAUS;66W6!<H5'$->K
MT1E;-,;EO%KBK1DHWCVS%:P7N;KUB5J=+=6)XB9Q[*RS=$JBHD3#Q`.$5:5O
M9?7ZY6;&]1I^9,=6V<S%2+=DC%"-7M,58661Z-0I*`B+I9:5,P[A["6..K$C
M:8])Z+5RJ=`71!,4"]F`BOAV'[0_G#A%SPB<(H*?(E><\T/6^POL%8!R/L06
M;5>U3+56P7E)IBW8VK8?L=:L$9:LB:Y/7[!9I9\T4YVNT<Q$3]W'+.C`<6ZX
MN"))*$6M-B:+E-]3XQQ_.6^X;/6.MV*4KFDWS)8&IAJ1O5HIF:K0LK,,,&_)
MOBH$H6W5E_&D@U&$M(/6YZO<$`$CE!-XZ(](1;6NHEBV)M.M^*)7;2D0F/MD
M$Z\K#9@KU8E(^7J[BX5J4D*Z\ME6=1J[A!"LW]&*3GH]H<XN&+223;+@"R1P
M`BD?PB<(G"+@WT_F^G\O%`="E:>%58BJZVX0I>5+UG""QU`)Y<R._1?6O(CY
MN:5M3H&T:SAVS"/E)$SE:"AV\:Q23!HQ^W0/X>1RG/V;EK'864-R^\9&W[B0
M@N=U-0*#K6FFFE%NN8[G<^SO$+#@>3RMX[AN*:YEM9-?LMV;Y'2.<8V!HE=O
M>YV^7>X5(:0-%B$U2^)"*;;3YMVHV1B8Z:3=9VR=:<)8N>`WD8A..=WF8D8+
M(UT2`R[5\^<)'(O%QAO))N42N'`"KX)I:GB>)PVV5GRN1.^5TKS&PZ@#<:$_
MAT_->W>\?O;O;WLQQ[LIVEFEMK:'CN.M\MD&%T4CWMM8VRV-KH'1QL<"V:>M
M92"QFUH)=@D^8F\I73Y#<_./N4Q8TO\`@RBH***D(@U2K%)A59(IE3B4B::,
MM(.S'$?H(FYSWF=V^;DUQ`T!TK6QL:/(;:Z?B:KZ0^Q'CO\`P[[6^/32$,%X
MZ]O"YV@VR7,M`2?W1%$'$CH!7SK"#3#(OQW9II&Y5YSCL9:8-[JW00M%>Q+C
M&,BCY)S.J\?QL`SD\6N;*BY@[FV)=9AC!`Q0`BWW;])RNHBR$JQ]APW"&26W
MWF=E=%#Z9=0%K=H`)+W.=H`T`FGXDKSQW]_S&\?Q7DK>*]DK"VR]Q:WH9<W=
MR7.M+@-.TV]F(B)';G_2ZY.FE8HW5JK69:QYLOKK$5C(FP&':W2L0W.<CH$+
M#6,C!>;!B.4LK@4:E%YL8(5R&B8W]37,FR<244X>1K62.5(YRE.F8WGKA'>+
MM+W)Y#<\1X#EI[SD-I')(&7$#H&7441.]]G(=)3&T%QC`W.:/4'TKJ/"O>1R
M5_(+"P[O\;L\'Q[)RQV[+ZTNGW#+.YE%(FWL<C&EL,CR&>NUVV-QHX$:KD0Z
M[]!`0$0'O^;G0JCQ7O1[1O=&XM<02-!4=!0M=T(<'5Z5\E\\C11J#K_;I_R*
M,LULB2'V&@,"CC6[.OUQF91&XD9&0CU7!40=+OH]NZ323DZM%-P,5X_37[16
M#Q`ANA[V,<?><"<V^9C0T_H'CK2E3X_!>6<M[I++&>Y.U]O<'&\M=336[#)>
M-&T-D>SU6S1PD5DL6L!;)<;A1U0!HI-B'7X?B/-<"]3?4'%KQ20$@ZZ:$T+1
MU`I3J2O*O<NWQK0SY*N+60BZ:9*4-&RXL5U$I]Y$.6;!Y#U\"EZEIH)*2:M0
M;)"*@KNDBB`>8#RYM["]O)V00M`;)6CCH`&_J)/0`=2?`:E:/S7N+P_@/',K
MR7D=XR&QPUNR>Z:VCY6B9K_M8Q&-=UV]CH[<:F20.:*47W>:-M/ABBT_,>=L
M"QE#Q!<9>MPSB0BLB,[1?<8N[L^;QM-4RU3TH9@WA6TM(O6[5R9@\?#&NG!$
MW`%'OG.^*=W^S_/>7W';WAF:?><KMF3&AMI(X+@V^LWVEP?HF#&`O``^MH+V
MZ:+R1QCWG9:XY)81<^XJ<)P;)W<-O%>,O&7%Q:FY<&6[[^V]-C6MD>YC7OC>
M6P%P#@:*^FA$'@'<O8C)&"IG.]2QBPQCCZY6&W9`LDQ$UVIU^P,VB495$3V"
MQN&$',,@N$@@B_0;K^^**:P)B`E\P[/BN(Y"YG:V^!BMY8I',)_4"T4&[P&I
MK\JK)]ZO>WVW[?X3)NX5<PYGEF$SEE9W5M1S8I(Y7R?<BWGIMD=&R"5FYM6M
MGI6K:!6#R!9JMCFZ62@R5DC+5.UB:=PCEQC)*3R9`2QVZQTV\K7K!2H^9B):
M"E$B@JV=)J^THF/J(&*8I<1<X')6DKH)2QDC>N\A@-!U:74#A\15=NXW[C>T
M?,L+:YWC&0GOV7=NV8065G=WD\1<`XP31V\,GIRQD^FYLCF4<*D@&JNP&`]I
M[!KT\V9I&K&8K5A1LZEXZ0O2J51KD>P3BG:T8^F%HN5LYKB:O-'Z"J2[\L3]
MLW.D(*'#OEVSB]V[&.R,\K?M-IJ65D(`'6C0#^(Z5'FM&E]W'"3W.C[08G%9
M5_<&>*%T<%\ZVQ,3GRL$C8C)=SAS97->TMA(W/IHWJ#M=Y5U2VQ^0W3?!E'G
M:!J3AJ/C<7XXG<<9,F[]E;-62:X[-3('V))K"UZAXFKK!E:8PA$9!B:9DT"I
MG['W544CAUFZP]EF<-#;7'U0B.,M=2CA]`^-==>OY:+XK<.[]]P/;YWZY#RC
MB_IQ32YB^AO[*8F>WEC-U-NC>V-\+9'P.)=$^-[*.%&N#7.!QVZE_`7M_";&
MTZP[+YDAZ[BNJ?>67]3P0>A&FG5HBBI#6H]LTR%2KJ<&"LBI]PNHY:JD!)#V
M_$#G*8NN8CBCK+),=<6[#;1[G"3U"XD@_2"R@`T^!'@O5/>WWO6O,>TUWB^(
M<HS`YA?%D#K>+$P8Z!EO)5T\ANA-=7&^@]./TIF.J2[<LTT+\&WQNH3:UGO&
M%9?,MD>.%GDE)9<R5D"TQ<H[7]KW'#NA,Y^&QD3_`$?8)HPB2!1,80(`CS=&
M8K&,F^X9;P"<5^H,;77KX:_BO`U_WP[RY3$LP.1Y5GYL.QC6MB=>S[0UO0:/
M#CY&I-1H:J>V,]5-8\+_`&IL2:\X3QJNS332;O:3B^EUN2*1(@)I^<G%0S:1
M6,0@`4#'5,;H.N^N7P#6C:T`-'@-!^2Y>][Y'&20ESR:DDDDDZDDG4DG4GS5
M,;PPUYL&E>WL!C`'8Y)G-8<]Q-`*P!0S\]TDL5VIG6",?;'W?O3S2R!4?'U!
M02]<BI5K%UAGOG?WOQXO]9+QGW'VGCK13XX/^6BW8&I&1<DXWKET@7D<;8."
MS;4L>9+H]+(XE:DU80TBMD)E+0S6%,X-&E0DD5Q4(JA^:3=K,C[)N*J/7[SL
M_I/2H+#.X]NR>\96R9QO>Z57L2YSQ-CBO;:PU6Q!DF#L>7:XO5$IQU4H!X_6
M:2[.6]U>/3=II^!%GIJF]-)B;[A#`RV(MC2266\GRV',,VNU0D7(ER71*!@&
M%S--;,+2,A;EK6KAQ-C*-8-[-235*3"TN2-G#4IUBG,18-_DDT1W@S9DCYT[
M7A.<R_2J/F+5K4RM4K&%2Q+C6Y16Z$U4,4Y'BYVCQ5IMT1)7"O.Z5(/2,7!X
M%RP<>4IV8QS$3\2+MP&ON=ZSNA\H:4SA;9T['8.%O1L-!#:I8LM6$+JLY^.V
MCX[8S,AM!*0CK+&/K`:\UU]!MHB,D6D8Z?`BFJF<7:_"*PVKVK^SFA^,<P77
M*GQ]6?>#)5E^,/X^83!U`K^":!6L?(W2@21FD[KIGO&]>:+Q=GR[@/*DLVL[
M^XOP?3\E6V8E;BDX:`!R*].G.#H_!%[^";"-.JN8:GE>K9U^13+>86^7L3GP
MC-K5:VX$M,EG2=K.+/O9$M*PA(9AR?4HNM-_(B8D;-BF[<E.8Q%MM\(G")PB
MUC_FCLN5-QJ58:;IVSR7F>D:CY7L&(MOJ3BZ^7/!\_$Y5R53Z>GCK(.)+NE:
M,6U?8/)6K(3CA^MCU.RHM'-FFXDC\IU6P(<(LE_QOZ^SD%"VO:/-N!(/#VQV
M8^ZBR-,H1$AL,SUFHZC*,PA5-I,@0$G+1V4L]+1T:I.6*95</7:;N4+''=+D
M8$,)%E!X1.$3A$X1.$3A%P(=@(?M`0_GX0@$4/186OD4Q;I)J-5GVZ\IJ+`9
MLV/L.7L>TS$U*0FI*(-F38[,MMC*-CF(L9I-Z^IK5JYL,H1V]D'L<Y(R:M55
MB)**D33-@KW%X."63/W<#!/$#*^2FH#`23^`7<<7[C.^UGPK_P`K,7R*_9PZ
M:!MJVV!92.'5OI1REGK11D$M>&2-JTD&M2L%JNEV)L(6;-F.=VM,-2M8:O\`
M*C(,L6--UM+[IDJQ0>INPLF_C;3B:D6"LY@A(]EB^H6[*4`T?LYFN*1U=E+(
M@1H^;-FRS4K?6^,=P.+\YEN,3$R4':YKHY0T">(U:_90FHVN(<"*T->BYED.
M/97CK(KJ5PHUS7!S`1M<""`:C0-/0_GJ5<+'#R9S#4\YZ9[GTR#_`.8+#@N,
M,[1X^,D)*[D"!GHY0:=FVC$7*FY7QUFBME3F8IVF0IXZ1]U#\B[8O7Q/]P?:
M;DGM<[P6N8X9)-!@)+C[S#W8+BZ,L>'2VLA_2Z2#?L(-=]L1UJ0/?O;;F6'[
MM\'?99P1.OQ;BWOHC^\-`)V^-'U-"/TO#AU:L?NB'Q]VRZ[T*:#9;O(-*G1*
MVXRW1\CR;UNWM><-:8>5:1R,35$5O24RM473M"$G_$#?9HE+)"4Q#D`_U`[+
M\KP??SBMGS;&&&WU,>1MVN!-I>,`]2-HZF&7^;"[IZ9`ZM(7=+3WH9#L7VIO
M>"\JBGR7<[&!EM@[J0%T%W:/:[T+B[>15TV-`,4XKNN-L&NLCA2.U^L=_P!8
MMB;A@RP0ASR83K=S0?TY-VJSMM5M;\X4MW!&<^XZ=`Y!0&!R&,HJD^;JI'$3
MD$1VS+8NYQF4?CI`3K6(GHYA-&T/G\/!>^^R/>/C'>/M38]R,=<,;:BW++W>
M6A]O<6\=;ELVVC0XAKYFD4:Z,@M^D!;DV,/C/P:AHU0M6\K4:N3DPSQZ];S]
MU_28U:XUS(-V<,[/<)ZH691$9.)6:VYNW,D"*I$G"4<W36(HF7QYV6RX_:C"
M,PUT-T;FU?\`Z9UW?,'3Y+X&\Y]S?-KOW*7O?OBMTZ&\COBVT:2=AQ\)]**T
MD::5BF@:`]AT#WEW4`K2DV!P7=M;,RW[".04/:LU"G5HP[PJ9TFL]$*@5W`6
MB-`X%\XNQ0RZ+I$>^B^X)!$#$,`<0R5G-C;Z:UN!M,;Z?"A_21\]`/B:+]"O
M:_N-A>[O;W%=PN.G=CLE;AY`-3;RAP%S;R4_2ZWDWQN)_=`=^DU4E]26*>Z=
M=UT<2]8;(ZH:26W(MDQTI)L6RRFQ>W-IL[I6U93]Q=-05<3X,BF;*&@TB""4
MK84%WJGF1JB0GEKWA]^G=O\`A5OV;XK*(^<Y.![[^6-W\6SLIJDP-I^BYNF4
MK76."I/ZVKY-=P',[N>XSE7<*&Z=+VUMKVWM;.)CG?;WDV-B,#9PT?3,RWG=
M.^!Y!:7O+FG6IJ/?-M;=NJ=L-B>G3U.J.J^FT#`9@WVS/>YQW7ZO(3D6\9V?
M'.JE,F&C%^>9R3.O$&TM+,T!*JEW'L`.1V^32/K'L4]ON6ML?)WSRS/3R<D,
ML.&CDK&"V1I9->RBE2"TNAMZBA:"_P#26N7.^<=U.VD/</%<*[BNO)>#03QS
MY?[-@DFD$0WV]DUN]FT.E#'7#VN+PRH:TNZ6Q^,?5'(/Q&5:P_(KL)HIAJ\:
MX9(CZC+Y`A;==GEOVUU1PI8;&R=MLFQ^/;10E:"X&)),,WT]!M9%.R,X]OX&
M<F4262#Z&X/N!A;OD8XN^YEER#QZ37!C1`^9@JX-=J7&H(J:-K\PO,/<B+B]
M_#<WO!,'_2N/NR4]Q%ZUS)<7@MI*"&!]0R!D<-"\!@,A+RV1SO3#EN>;4?'O
MJ_NM!PKS)%66;V",@0CZ?D:AR0UNRQ$*Y\WC)F@JBDM$3$*FLO[R35\T<(IB
M<WM@03F$=WS&!QN;8&9!E9FU#7#1P'E7Q'F.GR62['^YKNY[?996<`OV_P!$
MN9=]Q87#!-:3.Z;BPT=&^FGJ1.:^E*U``5_\`8&J>O6"<>8"JX*2=3Q]5$JL
MBXE46HN9T#BX6EY27;H)D9G=3K]XNX<$*3VQ.L8.NO3E_9V=O8VK+.#^2QM/
M[?-<Y[D=PL_W/[@9/N+G2(LYE+YUR_TG.#8B2-C8G$[VB)K0R/6H#0KQQ,5'
M0<:QAXA@SBHJ+:MV$;&Q[=%FP8,6B)$&K-DT;D30:M&R"92)ID*!2$*````'
M+@`-:&M_2!0+2YIY[JXDN[ISY+J5Y>][G%SGO=JYSG'5SG.)))U)U\5Z/"II
MPB<(N!#L.O4/WA]?3UX1>+7*S7*?#,:Y4H"%J]>C"*)1L#78IC"0T>FLNJZ6
M38Q<8@U8M"*NG"BI@33*!E#F,/J(CPBI*\X<Q%D][7I+)>+<=9$D*B__`%6I
MO[U2*S;GE6D_)$_ZC7'5@C)!>#>^XW(;W6QDC^1`'OL`Z(J\-'L3O49([-J>
M0;-W+1L^.W1,\;-7JC99XU;NC$%=%N[59HF4(4P%.9(@F`1*7HB[G")PB<(O
M%4K=>5L+:W*P,,I:V4.\KS.S*1;$]@:0$B\92,A!M9HR`R3>'?R$:V76;$5!
M!59NF<Q1,0H@1>UPB<(HX[;;28JTMUYR7LSFIW*-<;8LAV\O8B0*$:[L+TCZ
M38PS*/@&$M*PC*1EWC^13*D@9RD*GKT(B'0D6/K(WP^X/S1EZRY>@-@=CJ'@
M[8/)-"V#V+U*H][KKC6_8;(]2D:I;(.Z3,6_@)R<JSBTRU1B'%C_`(<EF3:Q
M$9I^[_G&4.19D_\`O_I]>$3A$X1.$3A$X1.$3A%#G?/4."W>UHN>"Y"SRN/K
M4I(U?(&(<IP'1I[$N;L9S[&Z8GR5%HG_`+-X:K7&(;*N6INBO6)EVXB7W?(*
M<T4-Q"^VN6A]M(PL>T]"UPH05/'))"\2Q&DC34'R(Z+$_A"\PN^N!,^:=[N8
MUA8C8'&1%L`[N8.(HLE&*3$G'_=UG,.,GBB:;P<:9:C4$;/39EMT=BY+[9#@
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M4K$93Q2^!JK9,5YKIK95K>,*7Y)8AE7L%"7(S&PPC@>@>,BM'28`1VL3GW9M
MQ@^566/Y'CY8[K&R,9<V\S""R2.1M6.:=?I(HZGFO'7"N\/<CM+QOE/;G$S.
MML=R*T^SOH7;@8GM<`^6&A&R5\6^![OWX97`]&TS'F]"C^/0?C_E'^3F>/3H
M3\EQR@.E-"M3OYZZ5B#:;8?">HF+DY5CL_*5A&U;'9?JDC[#;!NH7ZB\3+&V
MEN1)5J]REEB>57CJ:@8Z3MDU,]?*?ZL5(#^?O<5W,XMV:X7_`,>YML<W(Z^A
MCK<FGW5TX'TPYH_U4-/5E>:`-86@[G-"]8^W3N7WCM<7ENSW"LA]KPG,`NOI
M"RLEDQ[0R>6SF!!@GN8AZ+B*AU=U`X;E%'9+,5-U!QK@G63`[W&F-,IYFG:C
MKOK!%W:995W'6-B2C^+JBF5K[)2)R)-Z1C@)9%PY56\E)687;M_SJN#]?)?V
M^]H.2^Y_O'=9SFDL]QQ^*X^]S%XZK3*^1U663*4`=<;2UK0?X,#'-T.Q=R[F
M\UQG:+A<%K@8VQY)\3K>RB%-K&AH#I7-\F-H2>KG'6I)5]=3=:\:9^F*%A;&
M+R2M'QHZ$Y1FIQ:[SQBNGOR<?(Y&2RKC*>RN0'I3J(W3$&'[V9<L64QEX^7L
MZ1?:.M'Q;5-/Z[]S^86G%<='POC^R"5MJR/9$`&6ULUH:V-E-&NV``>+8P:"
MK@5X>XGA)LQ?/Y%ERZ5IE+R7:NDD))<]U=3KT^-?*AEGL!&SGR4;%/\`XU<<
MO7*&O>.U*I<_DRRW%&$0;UA=VULM#TSJ,J4/:3R1F@6";ZTK)']V"JJ1B"(.
M7A4AP79OA$DDK>892,MC8[_W0']XT(=+0ZZ=!7J37PUON=9\%CL/8O&\CZR!
MT'@UOAT_MKILB-&Z#1JV:-44V[9J@BW;MTB@1)!!!,J2**1"^A$TDR@4H!]`
M#GH\$N&X]2N7`U%5V.144X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6N]_P!0
MKM?:M?\`#.)L>*PVO;+$>;'ER97:\[68!>[!X&D[O6)''K;&&#;9$'F(2I8[
M4R4XM<G,J6N<<$;Q$;4GAFH'>&3\2*47PT8_UY@M?\F9'U7H-DQE@+)>=LGL
ML15X,JY-OV);1CC&%QGZ!6,QX-J.29&1/BB@9A",7EV\5&G.P6;F;KHJ'0,A
MXD67_A$X1.$3A$X1.$3A$X1.0(!%#T18:_DXU6R:QLU+^1G3NL&G-K]<:Z\@
MLCXLC!!J&X>JIW8S-[P)*BFF8'&0*T8JL[0'A@,HTGDS->C)/C`37.5\:LN5
MX:3%7H`<`70O(J8Y0/I=3Q'@174$K*8C*SX>];>15,=:/:/WFGKIXD=0H7[1
M8#P-\P>FN)<OX:D:5.VVO/X+874C(MWK;6<A:WE&K239XYQSEJIR**WW--L4
MQ`FK5ZKKM,X)*(F,=,RS1+GE3C.<RO;/E+[:]C=]NUQBN8O,$Z2`=#M;]4;O
M+H:%=?RUC8\KP[);729K28W#SZ@$CIK^H=?Q"Q=U3*T#BN[*;(U^FFPSKGLE
MFMWAS=#7-V8A`^-[Y.O<0961FL@02(1NO&U#\R;V*DTRA&!*.6SLID"2`HDU
M'WI=@K3NQPMG=G@C&R\QQ=IND$8UO[`#>`-HJZ:TUDB!)>6;X@#H!L78'N3+
MPOD3N'<@=3!WDU&;_P#43G1O70,E.CN@J0[IJI,.,KV/XY-F2;[TMC+/<$7E
MG7J!\B&-()LN[6DL<Q2@QU,VJKL,T**CS(>`0<^U,@F0RTI45'!!_M&R:A>'
M>PKW$2XNXC[(\TN1_3KUY=B9WG2&X()?8DN-!',:OM]0UDFZ*GUL"Z)[B^UK
MLA;GGV`@_P#U&$4O(F@$OC'^O%/UNCZ/(J2PAW1E5L![V_(1C?4#5!GL#6`C
MLS6W+1:U4]3,<U26;O%MB<KY(8`ZQE7ZP_9J*$6J\@U4"6E)1,3(L8%NX==B
M)2%/]7,OEL9Q_$7.=S<[+7#V4+IIYGZ-BC8*N>ZO_1`T'4F@&I7C&PL;W*WL
M6.QL;IK^=X9&QM27.<:`"FOQ)\`*^"UQJFA%Z?86S+LGM3D%*VYBOTH_SGMA
ME]-%1P\N^2I1%".BJ11HX1%<U9JR1VE4I4(@`%!`B)$R%.NISX*]V.X/,?=U
MWLM\=QR&5UC/,;+$6M7;;>W#M[KB<BH:^0`W$\O1K&LB)^D+Z.\+XU@.RO;Z
M6;*%N^.(3WDVA=)-2HB9XEHT8P=:_5U*LW7=;LB[#V.ZZU9%K\>SW%WEQ_3;
MAOA-OHV-M3#XU/C3&;2LF(]0*>$JU>QL1M5L0LU3?R*G@#IF]%S*&2`(^/<#
M]>^)<4XI[9.T]KQ;!M$EZ!5[J`/O;V04EN'^.P&@;6HCC:U@(\?$6?SN5[J\
MRFS&0+A:;OI;4D0P`U:P:'ZC^IQI5SBYWD%F)V+R,XU8QY@+1G0Z@U8FS69H
MU/$&I6,$&WE3,/T2J,$FUUV&R4@B1==KBS"$$H,B[66`ZT]-G19E]Y=RJ(<W
MX/QB^[C<EEO\FZ1V+CEWW$AJ"XNU#!_I'3R#?P"V+/9BVX[CFPV0'K/9MC;2
MFT=-Q;U&G^`^(RRZ/Z<XZT;U]K.#Z&]D[3)$?RUURGE.T?ZQ>\UYDN3@);)&
M7;[(G.LN^LUSGU%%A*910C-H5!FB((-TRA[%9#%%&R")H;!$T-8T"@:`*`#\
M%Q21SY)#+(:RDDD^.NI4LGCUE'-S.G[MJQ:I^('</'"39N03&`I0.LL<B9?(
MP@`=CZB/*BEZ+\V$I&RB9UHR18R*29_;458.V[Q,BGB!O`YVZBA2G\3`/0CW
MT/"+O<(O%=V2NL)1C!OIZ%93<F431L.[E&+:4D"@82B9C'K+D=NR@8!#M,AO
M4.$7M<(N!$`^H@'X>O[_`*?S]\(O"@K36+2$L:L6.!L98&:?5N<&"EX^7"&L
M,6*824#+#'N'`1TU'"L3WVJW@NCY!YE#L.$7O<(J;B[E4)R>LE6A+56YBSTT
M\8E;ZY%SD7(3U44FF@OX=.R1#1TM(09Y9B45VP.DTA71#S)Y%]>$52<(G"*D
M:7D"AY(C'DWCR[5&^0T=.3-8D)>F62&M$8PLE=>J1M@KSQ_!O7S5K.04BD9N
M\:'.5=JL42*$*8!#A%5W")PB<(G"+4V^0S<"8Q7OKM/2,%;-Z`Y8N.P.NV-M
M7E\,[+;GI:[VW37(L2:].&EIKM<L5>M.,+VC9I7(3"=?QZ(-K:$A&MD?(J`(
M%,1;/>%*E:Z%AO$M%OEH1N]YI6,J'4;I=&[!&);V^V5NK14-8K0A%-D&K:-1
MGYADL[(@FDF1$JP$*4H```17.X1.$3A$X1.$3A$X1.$3A%P(`(=#W_B$0^@]
M_4.AX1:YNQ]+_P#2CVDEMBX%(8SXX=S<BLR[(0S9(P0&GNV=S?-HF#V&8HH)
MBE`83V"E%D8VZ=E*TB+(=M)B8J;I0@<@[K\$;R?&?U;'-']9M`305K-&-7QF
M@)+FTW,'B1M\5N7$>0OQ5V+.<N-A.0TTI]))I45T`\S\*^:LYN/AG%"N\FJ\
M.U80MK9?)Z>TZ7[E:^HN$7<?L#KG"8ENM]J^PJD<P5,O%W?6*=@VOZ;;VY?<
M282A&P."B5`0UGL7F,P?NL%>;I,;`#(UQ:?HDW-:8]10!V[<65TVF@-2LMSV
MSL?X>1B+1=2$-<`?U"A(=X&OT@=:BNHZ**VBTI8;7K:G5,B3[O(KC'.3=A==
MSV6SHH.)BZTK"N8+UB&MOKD!2_:RL[*U"MMR22W@!7BOF<Q>SF[^0'NPXSA>
MW_N,S&-XG$;.TCGM;N-D;BT0S7#()Y/2(U8T2N,C`*;3](T7N;LWE,ER;M3C
MKC-.;/<NAF@>75.^-KI(AN--7;10GQ`!.I4:-;55IW'GP!Q\RNO+,:CI7\DL
MC6&LDLH]0@7]?SOC*@03Z-2<&4*V>0](7/%-E0_M$&!A2((%$0Y](/?7?7S?
M;,S9*\&ZO\8)J$M$K'-,CHWTZL<]K2X=#0:+RQ[>;2#_`,W)&LC8XV\%TZ+=
MT8YL@:'#KJ`:?(E2#R,B^N.W<X>5JILIP&C'QX9^^2?%>"E&WW-<ROM/BJTM
MZ9AY2_,4^W=CA:"N[/)Q4:EX@:7$BP^X8B9.<B_RU^'8*3$\AY_-;M=REE[#
M81RUKZ-L^W9-(V$$48Z20_6[4N:Q@TU6X^Z?.9**[Q?'(9"W%R6S[AS14!\G
MJ;&E_F&-'T@Z5)/@"ILZSWS7_1;XXF6XU[R8XS),9[A(/9+,V98Y1I/Y$VKV
M1S3&QSMK5:8R8B*DQ8']AD4JK5:ZU#PAV;8B`II`DY.'>>1NY1SSN"_%3Q/9
M<LE?%%&0X,AC:321YH='-HXD5U.@I0+FV+DQ/'..B\:64<P%SA0N>3KT'F?E
MY?%9"/C(T[R50U;WN]M[',AWBVLBHK^+:ZBY"3B-8,'1JYY/&NIV/G@^1"1]
M-(N#VT/4?']<M*JZZ@JD0;GYZJXUQZPXMAXL/CFTB9J]Q_5(\_J>[XD]!X"@
M'2BY!D\E<9:]??79_B..@'1K?(++ES/+'K7@_P"J+(9;XDK\V+%JSQ7F?M6F
M:M?2>%CS6!%SF^I)*01GAU44FY98IO8$YS%(3S\A$`#OA%%EODG*VC]#U9U.
MTRT`H?Q"YH^0_=>;Q<9YDZR4C9NN5FJ4?$\+99W,S*'QYD1W69NX3R((P4/#
MR,DV`RC%8ZB8@HDH!%EZAMQ\O:[V'">J^Q^+=@=HM@[BQ3;S6S&KVI]L9ZHB
MYF;S::[5G60K$%LL$=BB:80\2T7LK47+IM'&6%=,0;J)D*1:SNJ.GVHN[/PH
M[F_);N8P1N6\=A4W1R;<=EK1=+"QR3@7)F'IBY#B:H4*2"<;IX\B:8G!0RC&
M%;)(IN$WQ413.BH@F4BE'K5O7\K>>Y3XXM1,39TPKB*ZYN^&NI;<Y`S!G[$<
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MV<P.'&M5K][;G;GCTW;MVX.J558`;$.[(I-6O9^TXEVG_P"H2OE"NFM&G;[6
MQKH1D*:V0E]="9)M5SK<Y@5_8Y>K9&BV=]IC[)]PFI!XE#50I738S5R\*BFB
MNHOWPBM-(?*)\L<!2OCOP#EU!QCK:/</%^;MH<D6_!^EDWL;DO'6'*T[C$,-
MXX@M;6E[AF*UXEVD@5_;GCQX?]`:JIMP2,X(HH)%>6L_(I\L&>[!\;6GJ$!C
MG1S;[8FA[/99S[=LYX(L<TD-2UPMCNM4MK3L%S]PK\I!K9KC$$I:1;N),744
MU6$[17VR`)R*3G_38&L*F@^5U;>O6W5M5WVW24M3NG`Z+4G=C-EMV,VYJX/E
M%GW\.K2/N&8^^<ZWVHI^9A-V/"+8)X1.$3A$^G]']/H']/"+2\QEFC$+OY#[
M]C+"NX]-R50-G-^Y'(EAPOL%\0%ZN>-)NZ6V]+TFQ(8<VUBI)I%)%D3X9F(^
M(L<D@>'/,0CU\03E3=`)%NA!Z!^/^,>Q_P`8^O"+GA$X1.$3A$X1.$3A$X1.
M$3A%2MWHU-R74+)C_(=6K]XHURAI"NVRGVN)8SU:LD#*MSM)*'FX630<Q\G&
MO6RAB*(K)G(8H^H<B"6FK="AU4-M8/C%T+TNN4OD36;6BB8OODY$A6G-Q;+V
M6SV6.JPN/O#U*L3-VG;*_IM14<D*8\5$'8QYQ3)VB($(!9`UD;7"-K6AS@3M
M`;4U&IH!4_$ZJ,CWOIO<3305)-!^*UJM`Q_^3N1A'_\`N1O+_3MCEGGP;]\?
M_P"3N;_\#'?[M;+Z1>WO_P"DN._TKC_;RJ-VK'_P1\$W_P!#_P`GO_FFQ9SW
MM[[G;?;):D=?O\5_LW+S;[=M.[UU_P##7G^U:LK7Q_I%=_--9`4`/!G\64NA
M[8E*<JY)3;2LBJ"@&[``2_3P``Z$#`<>_IZZU_EN,#>U_(9!^IV?9_W;2,!9
M/W6`?\5XIHZ#&O'X>NX?X+*WCWX@_C;Q5G%EL7C_`%/Q[6\IP]ED+K6GK=U:
MGE-I=UE5%5G]SHF*9*PO<4T:UK+JF4+(1,*S=(J")TSD,(B/T3$<8E=.&M$[
MA0N`&XCRW4K3\5Y=W/\`3$6YWICH*Z?DLDG)E*G"*.>T^J6#=SL3.,([$5-S
M=,;.;53+JO!M;#8*PL:PX_L;"V5=[^K5B2B94J;&;C$E#I`L"2Y0$BA3$$0$
MBHC:[3?5?Y!<:0N/L_51OD6M5*YQU[H]CJ=RGZE;\?Y`KQ7#9G9Z-D+'\W#6
M:KV!BB[514,U>$`Z9Q*H0P`'1%=K7O7W%>KF(:E@W"T"^KF.Z4G)_H[&5LED
MN,TX>SLU(6.?F)VUW&6G;/8IR?L$LZ>/';YVNNLNN<1-UT`$6+_,OP??$59\
MK3&7LJ87B:R\S%DN-G[=02YNR7CO".8LMR4BI)1SJQ87C,@0>,[?;9J33,L+
M0L<87ZP&,=%4PG$2*S&PWQ.X!^0OY%838*Q7#%]WU?P5I]9-*Y?'>$LO6^D9
M7Q/GN"RFG:/TQO+8:DX1.C,H/',X[A)&&7DV[HK60,V78&;J@($4ZKQ\1^A-
MZI.J./E\,.JE7-)7#I36O^[;(61L;S>/F4J#/^)H;^)J;:8>Q6"'NBC!)2:1
MDG3H918#*+F.HHJ8Y%\VKXW-`*5`OKO=::QI]5HVY\Y\FTQ:K-E2V5ZM5C9W
M[0ZL[EZ;F96U-(J+K3-DD91:+<J$KR!"B86Q0#OA%ZEA^-?1;->,-F:T^H@6
M_&>^V0*7G[.3J"R9<EHO)]J@_P"$)JG6ZO6"$LX##0RR=2C'"1(5=LP=)E\O
M$Y53>1%Y.;?B,T,V)<[)NLN8BF+(IMO9<%V_/`-<H90K9;A/ZW0"U9P^]0&L
MV^(4KY*O$KF*9*/,V1>*@55P550A3`14A._"WH)8,<XXQTYI&76PX>N5RO>*
M<ELMG-C29TQY.Y"8149=T:MG)QE!SE)A7;-'PC9-U$#*'BC>T!RMRJ")Q(O=
MRG\/6A>9L88%Q3D'&EXEXO6A[;'F'[FGG3-S',5?+D%V[>Y#8/\`-;2_I94L
M<7?7#Y095O(2SE-P`@``0"$`I%*75'4#7K2+%SO"VL>/V^,<7N;O;\@I4]E+
MSLQ&QUAO$B$I/?I)K!)2CJ-BC.2E*W9)*%;-4B@1(A2AUPBDOPB<(G"+Y,/0
M=_7U#H/3L1[#T#L0#L?YN$6F-@S+6BF5-C?C3AL:PV2JIM/#[573&6<OCNJ6
M:LHJ*X4K6,<K;2YSH.4<\U.=HA$[$PULRA>74K')NG<7%HH6E1!BN_;MVY#D
M6YT'H`=CV/[?3U_FZ#A%SPB<(G")PB<(G")PB<(G")PB<(O@W]7_`-\/\@\@
M>GY?M"E=X?-:6V@__P##&2O_`*Q=Z?\`S6Y9Z_IY\&O?#_\`E#FO_#QO^Z0K
MZ.]A"1VDQM/*Z_VTRCMJS_\``'P'_O\`CZ^10P_O,;8/#1C&']IC"/8C]1'G
MOWW]T'MOB'A_5L9^QR\W^W4G_P`UKD^/V=U_M&+*S\>O_P#M-</_`/ENI_YM
M(KFJ?Y;?_P!+.0?_`.@9_N4*R?NE)/*\97_Y>_\`V[UL^<^BB\PIPB<(L6_S
M1;<+:3_&CM1FR%?'99`7Q^ZQAB+[;WCR*F6<NKI8\H[B+;MP%PZ>0,E8!E13
M(`G%&/.(!Z<(M:+X:=HL6Z2L_E(TXU6S.YR=3:1I2VWTUIMUOJU[B6Y\U4+7
MAA6MFXX:YDNOU.8EV`9@A8R3(BFB5NI'B<H&$2J&`BF+JK\@_P`LF0;M\<L9
MF3-NL+J`^633/8^\8G;4O`DPR<:RY0PWA.)R!3\@6!9[=06RFE8W$HW<S$/[
MD<R1467;-!(FBDNJ18YM5++NH/Q[?"=FW8/,V"=JL`91^3K"6-:?B?.>`)N[
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MFGXUD5*@3[V0V,84K'&%+1A^;5:.RN,@R:UVN458R,A*B=*'3,D41`PF$BVQ
M<#(96;X1Q"CG:6BIW-9,:4C^]R7@HA&`A)#)1JW&FNSB'A6ZSE&+BS6,SG[=
M`JAP32`H=CPBNQPB<(G")PB<(G"*.6V.<+;KA@FVYFIF#\A[$R5,D*:M)XKQ
M.S/*Y%E*C*W6O0=WL%2KZ#5X]M4K1:A)O9PL2V)]U*%CC-DC$.H!RD6+C4;Y
M>F^T=KKCRJ_%I\@-5E+IENTX@M.9)+`E6@L9T^$JN3)FBHV6^9&M]JI5M,UA
MHV'1>SL6C#NW4&]!PQ`KA5KYJ$6=,![#L/IPBYX1.$3A$X1.$3A$X1.$3A$X
M1.$7R;K\OKU^8.OW_7D#6FGP_:H&G4^:_GEZY[Q'PM`YDQR&JNT&3@AMO=T5
M_P"-,:U['LA3Y/\`6-FLH2?LQKF>R%`2BBT<#KV'`':I@"Q#`43%Z,/RP]SG
MMBY%W*[X9#F6-SO'K.UN6V0$-U+<-F:8H(HSN$=O(RCB-S2'="*@+NW#/>%V
M6[5\;M^WO,;U\');02;XQL/\][I&=7`C20>'[5XE*SF?!>$?@:NQL79.RTF;
MX_-Y8YO3L61U>?VQFXL.Q>,SKRKAO8[!7([].9(QI47`@Y,<BAR>!#`(B'JO
MW9=MLCW1[.0\2QE]86%VW(V4IENW2-A<V%CZM:Z**5Q<XT+?IZ:FBT+A'>#A
MG9_D<G.^9S&'`3120L>*5+YG![!Y5+6G^P657X:\^CL-\OF3[0.(\KX<&!^-
M@8#]!R]&UJ,G97SVA@)+]7C$*Q9;.T/$A]U['DJLFK[R9@\/'HPX7V:=I\EV
MCX)EL-D\CC<E/=Y83!]D^1\;`+>.+8XRQQG=5N[1M*$*[[B][.!=\<C;\@[?
MW#KG&643K>1Q`%)2\R4%">C7!;?G/7ZYXG")PBCGL-JE@[:<^&?[\:HYN33`
MF:Z9L+CB*&Q6&'AF.5L?%D/X.L,Y$PTDQ86QO!*R:JJ3&33=,16$IS)"8I1`
MBH7/FA.K^S.5:?FO+]">SN2:-B?,F#8.PQEOMM9,IBO/E5?4W)M/FF-<FHR/
ML$?,0DDN#87J2ZD<X5%PT,BO_:<(O'IGQVZG4"3TVF*MCMZQ?Z"4*[8TU:66
MN5R?EH%/R+3XRAV^-D$GLZNE<U)2KQ"#<%YD'RR)BBHF8JAA,)%9''OPR_'S
MBR$CJM1\16.(J<%M%C_<2JU$^7LM2-6I6=,72-IEJ1-TJ!DKF[C*O6XF2NLH
MLI!M$THEX=U_K*"OMI`0BIF8^##XR[#FF2S[.:_OI7(-ASA,;%W,CS*N6E:7
MD#+<K8E;:WL=_P`=#=?X&N#>N6-PLYB63Y@LSC_?4222!$YDQ(JHS=\,?QU[
M#YOLN?LIX,>3%RO\O5;#E6O1>3,HU?%&9K#1Q0-4IS,.'JS<8G&V29.%,U2$
MJDI&N!7%,/?]WU[(OO9+X9?CKVTR[8<WYQP,>PWNZ4>-Q]?@@LA9)HU5R'`5
M^)4A:>>_TFE6R!JEPEZ*R,G^B/'[1=>-4:M3I&`S5L*1%9[<GXG(79;-7Q+!
M7X[&D)K?\<5[<7.4B;.O9IK)TM$42HTR(PUCBH.5V4BPD:P>?I;!U85I9^5P
MN2.0$GNJ"IY$6:@/\/\``1'A$X1.$3A$X1.$3A$X1:A^R^A^[UGW6S1;JQK#
MG;(6R%SVXHN3M6?DC;[H*U#`>L.L,18Z)+?W;R.`RY"C7"HU2M0\[!RU;)5I
M`EJ%^#D7)@5$"$6W>'0`'0=!^`?L_P`7X<(N>$3A$X1.$3A$X1.$3A$X1.$3
MA%\F`!\?W&`0_E]>0H#U2@/5?SL=;%CN*IDYZKU[TCM3N$^7`/\`,*NMLQE'
MS!(!$1!/\GH'J(<\A]UY#_Q_<@4%/1\!_P"SC*^8ON+^KO+D:]7?9@^=!#`[
MKUK7Q7F53O\`N4^!T?Q_]/C=K_S'X\YUWO$UKN#PM=^G[JW\:?NN7I_W/4':
M.U.G_P"X6@_*.3^_XK*S\+PC_P"K[E4/P_\`39*/T_$=H8'\>6G8UQ=QZ[<:
M5^\'A3_5M\EB/:&/_P"F98__`,J!\-+>/P\_/S6X5SM:]9)PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G"+!!\I.Z&_&H6PV&S8%ID1D#`=\QXD(46
M,UGS/G')F4<W0F48:(FL-TNX8EEOTG%-CMF)K@I.0TI:6"L*5S6'*1A."JA2
M$5+_``-V+=:3J><XK:1/9V4K$>ABR1AK5MG>:)<,AN<[325Z7SU$5&/JTY,6
M;'V+U(M&I3#&IV-)A*5:0EWK`&X(D(/"+8'X1.$3A$X1.$3A$X1.$3A$X1<`
M("`"`@(#Z@(>H#_(/"+J/WS*-:+OY%TU8LFB9EW+QZNDU:MDB`(F57<+&(DD
MF4/J)A`.0+2[0=:C^XI3\UHS9ZT!V.Q7FK-58T\RGKQ8=8LFY.R)E*NY&RPK
M?X>ZZYJY4L<I<L@0R%7@(&1B\QUZHS\P]>0:Y7D8HHD<B#CR*05#<_Y)VNQ?
M(\X,[=22MD^@OC:&T>8W`C5W0D:'J/'JN!\\["\5YSS:/E]_=7<#SZ7KP,#"
MR;TB-I#C]4>X-:'[:D@"FM55]VP?K1FZAZ$:^_'ML!%LMA]%,3W?#U.=;4U.
MUX_P]M30[W'PMGRLS>W*O-+#+8TNRUNIP6"*<+,!:`=59H!5R&3,7/\`*.,6
M7*L0<+=N?'")&O8YH#BUS>FAT.E00=*'1="[A<!P_<;BTG%,J7PVQ<Q\<L="
M8WQ@AA#7:&@--1_>IO\`QJX&LVEN6\R[2[)VK'F1=C,BXXKV$*;C77M_9)3$
M.*,4P%F>721;R>3;Q!5J4O5RN5N50<.G#.)39,FS)-%$5!.<Q8\5XE;<4QAQ
M]D7N#I"]SG;023Y`:`4\/[_`6_;CM[ANV''?Z%C)9IY)9C+++)2LCRUK:AK=
M&@-:--?FLT]1WHK#T2(7:GRT`H)O$7\(X1G6`=B/1U&Z@1\@D4H==^!%A_9S
M9O1D\EOOK1^:EW1\B4W)$6I,4R=:S;)!<&SH42KH.&3D4RJ@W>,W:2#ILKX&
M[#R(`&Z$2B(<I*JJUX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6,+Y
M?L(YTSYI%=:?KZ[R')7&&N..;Q8,28OO+S%MJV3QO5;8P=Y!UO2RC%S,#+8W
M998K2J[-6:;.2F9^`"H15$RJ1R*`?PY;$XZHV8,BZ.0.,=&M9O9A5\BUG4O2
MZX7[9R_XLEX@4XR]V+<S:&NP/]QZF4+&P1BVC-@9\K,+?IYP.X<=%*0BV.>$
M3A$X1.$3A$X1.$3A%1%XR-2L<QAI:XV!A#-Q*86Z"RGN/WYR@/\`91\<B"CQ
MZJ80Z_LR"`"/J(!Z\(L96:-KK5D,'D!31=T^FJ^X@J<B@)V.<0'LIOOG:!Q"
M-9+E[[;H&$QBCT=00'Q"K'%O!-:*C)+Z9I2JCC#W6Z5\4Q@KA:(@4^O#]/GI
M1L0`*'0![2;H$A+^X2B'*GVX\U3^X/DO1LV2<@W1FWCK;<Y^P1[4WN(,9%Z)
MVH*^@@JLBF5(CI8HA^4ZH',3\!#E2.,,-:U3[@^2MM-0\?8(:6@)5$7$5.1K
MV)DFX',F9=A(MU&KM(JB8E.F<Z"I@`P#V4?7E54GOWFI6-?'&@<G4<P1]@G+
M)`3V-ZZ_/)1S-=N\&;GDE$'23:*DF:?M-6"C`ZB9E7!5SE5$G9"!V/C1;"&O
MWU547!`I13R#%L*T#J`G[Y5.O\PD#=9Q1F0>N@ZB[`XG8KP#_P"S[(%Z#KKE
M9222>I2HI1#5O(S`H!$Y+0E2E'\J%RI<4],8/7H%)"KO:HJ`_P#WA2,/?(*D
MKF8DS)G7"=L:V5A4JA:V!_!I88B`N,A7QG(H5.U$?T^RPRS-%Z@(BHW4^^'V
MU/03"4QP-:OA#&[JJ[CF+W;:++74MM(6R0C&P/<0YOA8MVEYJR,?2V>1V+$Y
M._?1>_W33E[DF:J'7YBKM43A]?'KE!5U6\5M!K]*.`9&RQ48*2$0*$1=7JF/
MYL3B/7MA"7E"O2PJ=_U?9\@_9PBO<PD8^5:I/HM\SDF2X>2#Q@Y1>-5BCU^9
M)PW.HDH7U^H"/"+N#^[_``_[^$41-=-\-4-M+-=JCKMEIMDZ8QTI(HV\\54K
M]%PL:O#V%Y5)5!K:+'5(:L3:\=8F"S58C!XZ.FHF;R`"AWPBEWPB@_F;Y)-'
MM><T,->\V;$4[&^69!I3'X5VR,;0VCHUGD66>P-%<V.Y)5]>CU1&US4<LU8F
MDY)I[ZY/$OJ(`)%-[R+^T/P_I$0+_P#B$.@_;^'"+GR*'XA^`?4/J(B`!_*(
MAU_+PBX,<A"B8QBE*4ICF,80``*4.S&$1^A2A]1^G"*CL?9%H.6*97\C8PN=
M8R#0;6S&0K-SITW'V*L3[$'*S,7<1-Q;AS'R#<';=1(3)*&`%"&+]0$.$59=
MA^W]O]'??\W7"(`@(B`#V(==_N[]0_G#A%SPB<(G")PBB_N%B=]ES!MAC8.L
M62^6^EOX?*=`QU7<PS6"D<E7_'#TMGJ..[;D.&2=?84&ZRS(D=--WC9U'NF#
MA0CA$Z?8`1:?>.<CWVHVQM&X7L.-K6?52XM;Y-ZP?'E.,-)?AITXM57>$<*S
M>_6_DPRC['M';*^9(J\G6H[[E"2=MUT?M@\Q(8BW,];<_P"-MH\(X_SOB2W0
MM[H5^BW+J'ME:0L"%;F74/*/J[/+UTUIA*Y.O8%*PQ+I-F[69(`];$(NF`IJ
M$,)%?'A$X1.$3A$X1.$4+]E-F/X`]ZD4%VW7NYP(,K*"DD\:5=N8"F!$$E"G
M;N9QP0>P3.!B-R#Y'`3"4O)@TD]-%*7`>.JP^9IS?`46/5R!EZT2KDS]\G&I
M2#I*0G960D%D5W*3!HB@14Z8"DV.8`_LD"`']7Z<N)F-#*M%#56\+W.?1QT7
MEXORU1,PP"UCH4P,HP:/`CY!%=HYCW\8_%NFY!F_9NDTSI*B@H!BB43IG#U*
M8>AX@_2?FH7'ZA\E<CE=4$X1.$7`B``(B(!T43#V(``%*`F,81$0`"E`.Q'\
M`X1>?%3$3.LDY*$DXZ9CE3JII2$4];2#)4Z"ADEB)NFBBJ!CI*D$IB@81*(>
MO`(/11H1U5CMC<]L,`4UE85X)Y896;DQB(*-2,HUCSNB-S.5UY:5*W<)L6R*
M1?RD\157-Z$#H#&+;2.D#SMK17,;8RP%U*JVV`-L)'-<7,@GBRP*6"OKM"R+
M>KOH9W"@RD4U?LG2DE9).`.U657:+%]D`7,!2>7?0\EC<Z1^UYJ%-(UK&;FB
MCE*"OY.S-6)%.6I=*DJM(EZZ>N<D0T48X=_Z-XW@65B*Z2$?J10#D'\0Y<^E
M'Y!0A>7`[BI!N-P]JIZ%3@K!3=<Y)OX"FY7M;*VVT[PH]=&=Q[6/KD,HKXAT
M;Q3(01_#EHYG\3:`=M56W-\PK/'E[E+S#%X\88%QRD=^U_49;#6'K%1)]NS.
MN0KQPA*U[*4(X<.$&XF.45"CY&*'?IWRI+&UC:M\U&H/2BRXX=UXO>/95E8)
M#;/.V2X90Z+T*I:CT23JCQHJWZ2;I.Y*HRUY29&*J50HDF_<[`.SB'8<MT6`
M6H?%#NIC[XYF.+WDSDS*%R?;H+9>S-I`_P!A*K7L.Y`UD9;=Y0RM9,0XIML/
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MBO6)W44Z606\3D7G9^^+O:_*%0U[B\6Z?7S6[`]9QUGZEV?5;&NR^$,@9#QS
MG'(`8K)6=IZI<,JW(^,HJ?6:UN3:LI2*DG-EJ[@GZHV:F<RD@D4B\G$NF6P&
MPOR(9S>,L66N4A,,?)U$H9=VXO6<GL<9[K1&:.XRK>9-9T\-(2C!>T-\\S]N
M2<O)6)8A%.73APJLJ@I'-2F(K:T3X@MU,<:OX$PU(Z10V2(/&N!=M\+2>((?
M;6M42`CMMLC6>E+8=^1&.F$+.@T>1C*E0JD2BW#PMU9]@SIG'>ZMV8BE?*_$
M!L7-U?=VT9\;Y;S?G6[5/17'.&\J8ISK5V%LMD)B77O7*`V.F&5"S#:H?#KB
M`R)F[$[EQ9H.SI1RMUA$104<I`LF;A%G[T,I68,<:?:^T3/U,QKCS,-4QS$P
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M92,M47\I'=1\F]K4@Y49*N$/[%91`3D_*(<(JOX1.$3A$X10VV2V5;T!%W2*
M0Y1=WEPD"4C($$JK:IMUR#^<W7D1:=.F/:2(^B/8'4_JD-.QCGUV^"D?(UG7
MQ6*U999RLLY<K+.7+E51PY<N%3KN'#A8YE%EUUE3&45654,)C&,(B(CWR\8"
MUH!ZJSD<'/+AT4:MG<$R&?J5#5F+L$?7'T+9$Y])W)M';QHN0L8_CU6ITV:A
M%2'4^\`Q3_F`OB/IZAR$C2]NT=:J,;@QU3T77UEUW)KY6IN.<V!.RSMFDFLA
M+OVS5=A'()L&AF[%BP:+N'!S%1,NJ8ZQ_$Z@G`.@`H!R$3',!!\U&5[7D$>2
MDSRHJ2<(G"*+>W]>R?:L.OH'%:3QY*2$O&M[!%19B(RTK6%/>!XT8.5'#8J9
M`=`D9R0#>2K8#E#T$P#*]I<TM'55(OY@^:LUH=BK*>,6^1POM>DJK$S9JT>%
MBI15OYKOF?ZF$@_;M6[IS]L4&RR29_,I#*#X_7QY)%&65W>*K7'0*<EMIU9O
M=?DZM;H=I.0,ND"3V/>%$R9A)V*+A!0HE5:O&Q^CI+)B51,X`(#RJK54KBW#
MU`PW#NH6@PIHEM(.$G<FNX?.Y)_)ND$1007>O'BJASF21$2E*7P(7L>B@(CR
MWCB<U^XTHKF25KF;16JN?RX5LG"((=@(#]!^H#]!Y3E:7MH.M54B>&.J>E%E
MWU2RM$W7'4/574FF:Y4Y@6,DHYP?P>N(IHH9O$RB!#]"Y:F9`DDH8HF]M4@@
M;KLO=HYA8:%7C'AXJ.BE1R53+Y\"^OI_G"!A_P#>#H`']P]!PB^N$3A$X1<`
M'0B/KZ]?T=_^WA%SPB<(G")PB<(G")PB<(K7YAP_C[.-(>47)-+I%ZA1?Q5A
MB8O(5-A+]6XRXUA\C-4VTJ5>PHK1D@_JUB9MWS8#^`@JB'1R]]\(L6,7HABO
M7>UN_D-^2+:K(&W.2M>X*7M-7R)E.LQ5+U]U>A4B`65M>%]:\9Q\C6:?-M&1
M^G%B?&G9Q!LD50'B0)F4X14?IQ\K>0LJ7S*$ILY!:YXMUQ=;.Y>U7PCE6DY3
M4>NF&;L<9CA\84C!V1QL+TT/?;YGVK6B/MM3E*:=Q%*1J;QNZ2040*JH19SN
M$3A$X16US!>DL<8XM=M,8H.HZ,43BDS&`!7F7P@RBDB@/^=_KJY#&`/ZA3#^
M')F-W.#5)(XM87#JL%RJZ[I55TZ75=.G2JCETZ7.91=RX7,*BRZRA^S'564,
M)C"(B(B/+QC`SI756CY#)2O@OS$>OV_X@$>OWC^P`_:/IR=4T_Q"'\H"`_S#
MZ\(G"+&]MKM7E'#V16-,I,7$1L<2&C9I69L,*>1_B!5R=87#6+.J[1;?IK/Q
M*BL9,/?!;R#R*'CW;NF<UQ``T5TV%I:"2=0IKX<N[W).+*)>Y)@G&2-HK[:3
M?,D"*D;).Q4607.R*NHJM]BX41%1`3&,84CAV(_7DT4A>:&G122Q-8VHKU59
MR$_"Q7?ZC*Q[(0#L2.'21%0#KO\`T(F]WOKUZ\>^N))"QU!140%^#.T5R0$H
M,YR*<&/T!2$>HE5,)N@`I4E#$4,8P_0`#OD&3.<X-H-5,#M.X=0O>]`#]GXC
MWZ=?R_3KE=1?(9*5\%YPR\6#U2-_4F'Z@D!#*,A=(@Y*"G^9VB)P/V8/4`Z[
MZY1?*6NV^"DIHO1_[>5E!.$3A%3ULM4%2*W,6VSR"<77X!DI(2K]0BJOL-4Q
M*4?;00(HNX744.4B:9"B<YS`4`$1Y)(\L;4>:J1,#W4/DK:8.VUQ]?KR1'$U
MHL#"YU]JXFVJCF%>PRAF+1=!LNZ;*K@JV=-CF=$(H@KT)TSB!B"7OE-K1,-[
MM#TT5XQ@8*!9X,#;.0&4$VE;L@MJ]?"IE3!L8Y4XRQF(7U7A%5#B)'9P#R.T
M./N%]13$Y>_&V(H2/BIE*OD$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%U)"/8
M2S![%2K%G)QDDT<Q\C'2#9%XPD&#Q$[9XR>LW)%&[IH[;JF3434*8BA#"4P"
M`B'"+5AV_P!!LL8TQ;D/8BJ:XVJOY(IE6SSA;2S`^B<-4+=C[0AY=&.1RUO<
MW$^&Z[2\=S-\S9FZ<;5MI8W[1%2QT9K*.74>LJDS`6Y%16*_EAN.NE4P1I'K
M?,W/<+:O--VK$$]F]F\@SUZP+H+:#X7@,FYSUZSKN%7PFY_8:QX(_ANURZZ+
M%5U+0T.9-K(O"?9H$<$6TQB3)U(S+C:F9.QU>:/DFG7.`8S4+=L;V)C:Z184
M5T2^^]K4]'N'+>0C`=`<A#>7N%Z\5`*<#%`BK*:FXBN1;V;G9)G$Q,<@9P^?
MOER(-FZ1?ZQU#B'YC#Z%*'9CF$`*`B(!PBQ/[(;%!EQ1"KUQHHTI$3(_?D=.
MR'3D+`_02500>JMQ'IE'H%6.**1@%4PF`Y_$0`@5HV/#P2#1497L+"`1513]
M`_8`>@!^`?@`!RZ+FMZFBM0USOTBJ@5OROE1/']<;T0L\-8=RLB6^#6V\@J^
M!H@R24BB2"\=VLA`*G,O[X"`)J*%3!0?$``;9_J%Q+*[?@KEGIM:`^FY5;HV
M[R$OAD[?("<^3[*R/4*H>RH2"4DM6CL(Y=$43R0`X<1:#TZQ&QNO`I`$I1\2
MAR:(2;_JK3XJ67T]GTTK\%,GEPK94+?X&C2\*9Q>ZO!V:,BC?=D0F85C,"W4
M,=-+W6A':1S)JF.<._$Q?(/KWR1[6[2:"M%,'/Z`E44?*56AX$L=6(Y9L,>S
M290T:2-381;-%(H(MTDT4#^V@T9I=>*92@`@4"AURR!(U&BN(VN)H^M/BK`N
M5EGCA=X[4,Y=.5#JKKJ]"HHHH/9Q$>OH(_A]`#TX))U*K;&>07X^)?3\H>@@
M(>@>@A]!#]@AR`)&HZIM;Y!7$8Y-M#&(5BBN$US^()LY%P!E'K)+KQ.0IQ,)
M7!@#_1F4`13_`'^G4V]WF4V,\@K>G$RJAUEC&674.9119414544,/9CG4.)C
MF.(_41'OD*DZGJFUOD%6U=R#8ZYX)%<FDH\O0&CWQSG`"=^H-G/8KMC=#^`F
M+W_5Y'>_S*;&^05^(;)U5E&Q#N'H1#H"_P!JUDQ]H"F]/]&Z*`H*D'\![*/[
M0#E>%XH=Y_-6\S#4;!I\%6[.08R"0+L7C1XEZ=G:N$G!`$?3H3)&,`#_`"]<
MK;V>85+8_P`BJ#RYCB+RWCRQX_EW"[-K/MT2I2#8@*KQD@R<)O(Z130%1(CG
M[1X@4QDC&`JA>RB(=]A),TN;0=:J>%P#JDZ44:M=M/`P3?7=X<7H;2JK`24"
MS8IP!H@K<)!=FJH]7<&E7WO'!)H)`(!`#LXCWZ<0@M90Z:J,S_J^@Z4\%-\I
MCIG(HF<Z2J1RJI*IF,15)5,P'3524(('343.`"4P"`@(>G)GM!::`54C'NWB
MI-*^:RTZG9F<Y&J;FM620,]N51!,B[IRH!G<S!KF$K"46-Z"JZ;J=MW!NNQ,
M!#F]5.69:YO445X'-=T-5+3DJF3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$$._
M3_N_R<(L3>W&"M;M3G]4^1E2CV-&#T,PMLNMCG6O!U`AT:K9[[L6O4F=CLT)
M2J?6OO?[S;@O&#"F?`06H(33ER\\2E56X1=3X=M,KQJMKY=LB9JBHFI;&[D9
M0L&T.<<84ULG`XQPK8+^<SV"PSC^FQH(5Z$0Q[75T6<L[;H_<2TW]TNNLX*"
M)RD5PMZ[.NXL5+IB3E7[)G#N[#(-"+*%;K.7[P64>HX1*8$UE&R4<J)/(!$G
MN"(?7E5D1>*UHJ3Y0PT(-5B6O&R&+,=9RP?KK9W\RWR=L,POTCC-BSA'+V'>
M-<:124S:1F9E,X(0QTF*P"@"A3>\?\H=#UW5]=HTH52]!QUJ%CXV`VBS-7-D
M%H6`<O(2%Q_/MXN-J":::[:ULW16A7LC-(D`XR99U!<0:>OBT(8@I^*H'$:4
ML@?2G@JL49CK7Q67U$16(@H0ABBNDDLFF!RG-TN0#`0ITQ$JHAY>/9>P-UZ=
M\G9,&M#2#52/A<YQ<"%]=>?MJ=@8%1%-%3R*8%3%\NTT3>0@J<O@;L"]B'B/
M[!Y-Z[?(J3[=WF%Y\A)Q\2W%W)/&[)J42E,X<JE23*90>B%$P_UC_@'UZ]?I
MQ]PWR*C]N[S"M)D6YUV2JSMC&2[1VZ<.6"9DDCG[(D#I-0QC'$A4RE$R0%#L
MWYA'H.^0=.TM(H=0HM@(<"2-"H\F#Q]3]$#W"I=G$"![IA$"I=F$`%4PAT!?
MJ(_ARV5RJ"RADJG8<Q_<<G9`DS1%0HE?D[-8G:3<[U\E%1*!G#P6,8B/W4B\
M`A>B(I`)SF'H.$44H#Y$-?K'0<C9-:0^;XJEXQQNXRG-3MNPK=*;%S%93<1[
M5DE5)>PM64//R\RXE6P,T$G``L17W/($RF,!%]U3>6*MV0L.XI9Z];!QN0\K
MTTV39.KS,%4&;W%.*EK0G58K)&05"6U=J6N33M8CA`K!1TZ!H8#G2`X@F)%.
M?KU.7L!%(P$5`I@,*9Q#L"*``B*9A+Z@!NAZX14?D"_4[%=+LV1<A3[.KTFF
ML1DK187Q7"K.%9`X;M?>=I,4';SU<NTB>)$S'\CAZ=>O"*IFKQH_8-)-JNDM
M'/V3*0:/._;07923=-TP<%,L"8E([;K%,3R`!$!^G?IPB]%J[>1*@N&+EPP7
M0`R@J(+G;G*!"B814$#%`Q"E#L?+LH!]?3D0:$%0(J"/@I$Y:SKBW7_$4YFW
M--RC:-CJJ1+&1G[%(@NL4IWYD&S!A',&2+B0EYB6?+E1:-&R2B[A4P`4H^HA
M<_<-\BK7[=WF%:76;=G#>UTQ9:YCF&S#6+)5X**MCNO9@Q#<<5R<I3IUVNQA
MK=7`LC,C.?K\@[;F(55NL90@^(G3*4P"-5CP\5"C]N[S"JK:_9ZCZ@X-G<^Y
M`AK+9:C`3E+@7,=2R1+N:<NKQ;HFFQJS,)62C(Y1NSDI<AW':X&!(AO$#&Z*
M-,SM!I0I]N[S"O3HUMU4\A[G96PU3XVU0UCUPR%C_&^1Y.72C$8&S?WL512P
MQP5P6D@[>N631`"%7^[1;'*Y(4Q`,'1N4I)`\``*I%&8R2?%;(W**K)PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(@^OI_DX1>//3T/5H61GYY^A&0\2U4>/WS
MD_@D@@D'8B/U,=0YNBD(4!.<X@4H"(@'"+"5F?(P96R),W))JJQ8N$VL;$M%
MS^:Z,7')BDW.X#_-2<NSF,LH0O92&/X]CUV-Y!_+_%6<_P#,_!8(MRF$BO\`
M*O\`%C(-F+Y=FRQWNP1V\;M7*K9HHMC%J#<KERDF9%L94_0$\S%$QN@#UY:'
MJKL=%A4UGU`H]OQ1\0U]M*&9@O&R6?<VX?V`FD\EY/AY.<PO$.+8E&8U7*C+
M-QJ5).S@P3,DT*T462>.A%415`Y(**N'(X^G4\&0NN#%]EB'Q92?G^>X+I3.
M&LMX962IX*?QS^-4@H&X)N!L3&!3;2CGVWGOB":JYE/,5#";A%36<]4J=BW$
M'RMVS'269867TMVHQ6WT[C6F3\KR,5B5M:)RA2=I>TF"<3CMM*/)D9`4W+MP
M5XM["*72A3%%0Y%66\^9%<5Y5^87%=Y#)2%TV)H&"K9@>$AJG<9QK;(R-PK&
M1MIM$.]A6#J(A(>N/`<GDG2RK9-`J2H?F.02@14;?\'5_.&:=B6^1F]\DHJ@
M_&'@V_TV,C+5<("()DJ%QLJ:'L#QE"O6;>=GX!T98S9%R"Q2+*JB9(QA'HBL
M9DR2N5W-JJ.REUJ%>Q59/CWQT%#N.P,-F^<HZ>9))N1M>;`P<8EE8F0:YV9-
MDT%F;J5%<`;ID\"BH<GD13;V<Q3DJ3^.EC,?QE)YR4@M4'40^MI(6>C)JP$"
M+7<1]K-7K&BC;3*2T,JW!P+Q$K\IT/-8@>0]$41@GL?Y9^,+,N.I+8/,F>,@
M8ZUWQU<H[$%XH\]58/"$W3)B)K1"4V984>HELZ3-M818F;NW\J0Z!"J>!O;%
M0I%<@-3ZICS:Z7'`..)>,O5:^+M3,F*3H6"]/E&NQJ\N:+BIED[EIQVFXFQ*
MX$K>+5.=B"XD-]L!@`P$5M=0H>TJLSVO`N9:*QV(C]0,T,;UARFT_89+*UXR
MBK3UUXJ;SC*Y+D9:C)Y1J60U$E63IM]H+Q4WMMDSI"4I"+]65'U4RE\<&<8S
M$];RC:-G:_K?4+EGQ&6#-)G)<NUJV1ZM@?6E*PN4ZW+7]E(N995)!J18YH;R
M,<@D*40(JQEW>HA[IJ:EE$UI+\;XZQW%Q2RIFS8:BO-I!MHEOA+.+,XVM2RH
M-ON2Q!78BT!?P!G_`&?"*GZ/BFYY@A?BNQ-GA++O\!W3(>X3$T;+3MNK-RD,
M$-X=O-8T@;I,,732<:L):.CDT?;<+)JJ1:A4R&*40$"+*!\HD/?5]6L%I4^K
MRV0,?:T;"X#R;;,;14>M89B;Q/BQ)_%.8\S4WNR-B;13%=#WR+&6.=$#+*B(
M$,8"+T-^]\JKN#I-E)+2JR9-N*5;L&%Y7/5EAL8YAKS6`PS8;F5#(-5_5&T5
M7+5(/6H)H&L$=!*G=)PH.!]TI!,8)VR/:-K>B+'IDNFU\FA&^4EA7-6)LJ8H
MLV5-)GT-AS6ZB;!PV)\2VUEE>';3\E4SYP=34JK(W./9IKR[./=KE:ND`,N5
M(3)E&0FIKXHLX7QWN7M6^2#Y6;2X8/TFS#/>JTVR6,V60*_3B<4J.5P8+KD3
M0<F`$_$1*80*)@[Z[#A%NBTVY5V^UV/M%7D$Y&(D4_)-0OY5FZQ>@79/4!$3
MM7S4X^*J1OS%-^T!`1(JHX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%C$W>
MN%D4N4+0S.A0JC>#8V,K)#R)^HRKEW(M#+2!O+_6",DVH`B3T*03F-T)NA"O
M!^H_)4+C](^:Q8Y"V%Q%BNQL*K?+<C`S4@R;2*#8\;+O$T6#M9=N@\>NF+%P
MU9-SJME`[.;L`+V(`'KRN7L::$T*MPQ[A4"H5WX^08RK%G)Q;QK(QT@U0>L)
M!DLDY:.VCE(JR#EJY2,=-5%9(X"!BF$!`>3T"B62`;CT7;_Q%#^0I0Z^H=@`
M!Z#ZC]/V\4"DJ5&J][#C5=G\`:Q0M33L<]F&G9:R9:IU27+&H8YQWC!E$M$9
MTS`K!X>>D;3<IUK&((>XU*F0%5C*")`3-3,D;30]5.(Y'"HZ*N:!G_!66'UM
MB\5YDQ9DB4H3C[:[QU(N];L[RJJ^\JU']>;Q+]TJQ2^X;G2]TX>V*B9B`;R`
M0"G*]CF4:=:JK$Q[7U=THH:9EV?P)6LD&KUZS+B^BV:29-3PU8MEUKL%/NX9
M17[1B[)&2+U!T5"5<@84@$H`M_5\NAY;*Y5;B'0B`E`!#T'\H`/H(_E'T[Z`
M1'T_#A%:R^YPPMBUP2/R=EG&N/W2A(IVE'W6XUZO.E$IAXZC8=VBQEGK=<Z+
M]\S6114*02F.D<`'\ANB+K,M@L$RC6^2<?FO%<@QQ:J1/)<DTOU9<L:&HJ8R
M:?\`%KY*2.VA`64*)"F7.0IU`$@")_R\(NJWV/U^>8[?9<;9OQ2XQ5&O1BY'
M(A+S7#4UE*%.1/\`2GDX+X&*$H)EB^+4Y@7,!P$""`@/"+MM\^X,=2%3B6N9
M,7.):^I0CFCQK>\5I61M[:RH2#NON:TT2D#.9AK,MX=THV40*=-4&RG0]D-T
M1=2N['Z^6]&[O*GG+$ED;X[;JO\`(KN!OU7DD:>S:*&17D;4X9R*A8U@V6()
M#.5Q!$IP\1/WZ<(K19GW8P_C;#N3LM4&UT;-:F*++1Z_=*U1L@5]PYA9*[7>
M!I9#STC'C+IQ*C`)@[D163$%2MCI@8!`PE(KM(;'Z[NJ--Y(9YRQ$[QI6IK^
M'I^[M[W6%J?"V!,X$3AI"73?GCFLN8QP]I`3>ZKY=I@8![X1)/9/7J(I=>R7
M,9SQ-'X_N#P["K7E]?:VE6;&_2$Y5VD+-*2'VD@Z:BF8%R)&,9#Q'W`+PB^U
M-C]?6KVC,E<Y8H0?Y+23=8Z;&O\`6R.+LV6>*1J#JK%_40&6;N)%([=)1'R(
MJN4R9!,<!*!%6VN>WDU:\GYYP3*U,K"?U^OE:KB,:UDA<KV*FW^KL[12+K%G
M&.CP:?K2*CMLNS4*N""[,0^X,4WY2*]6X&;;1A+&\-(4YBBC-6:<&#;RSID@
M[C:X4&*CYRL=MV#524=`F!&WF!DO(ASB!O`H#>.`]+_JJR:3ZW_67AZ6Y[M.
M::E8HZYH"\L%(<1;9>TH-TD&\^TE$G(M/OBH@1`DZV!F;WO;(5-1,2'Z*;R`
M:=OU-?)5;@_2/FLK>LN0KA3\FUZ`KQQ>Q-SF&41-P3A0X,EDE.P/+H]`;[60
MBVQ3J`H4/SID$A^RB`EDF_F%3P_RPLRW*2JIPB<(G")PB<(G")PB<(G")PB<
M(G")PB<(L86]4>LE>Z5*BD<K5[5',>5?P'VCNH^67<'2]SOKW2(R)!\?KXCW
MRO;_`*C\E;W'Z1\U@4VSU*N.9;Q$WRAR,&1ZK$Q=>GHV==N6`)),'#D6\RS=
MIMW2:B:35SXJMP("@BGY$\A,)>5'Q;W;JT5-DVQNVE5+3"6-?[HL853'YY0\
MRX@FCC[V2'WRHNG[YVN^>"R1<***M(])9P)$$?3P3*'H`B/*WA11?/N:6T5U
M>%06'O<&!7K>^V/[U+RLO7:GFSX[-P-:HNZQL>\>ITS(<6LPR:P<&69]"SDG
M]=4<K-`,=,7"C`2E-V7EE+_,*OHOY86(S1VL9XQP^;$6HB<UFZ@:UN\$X5DK
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MD[K*2P1$](LW29)+VE#I@)/(I%0,-H[LU`'=9*6IM4O4W$[H5+9R.PSD'*M=
MG5KU5FV)!H<E&6N]1U$@:0CD"O2ROW3=7]((P.H0QDQ.`$,H15)F7!618R]9
M(RI8\6XAQXOF?4&(U]J/\.2;6Q+X1R"9W>G]C4ICEE`PIFB*#&PM%!D6:34'
M"Q%03+XAZD479'$&4Y_6O*F3++BK&N'HC77X\,E:P@SQU.IV&6S18I-I!/T[
M6_0C:[#ECH)BSA1=)H.U';T9!V<1'Q'RX173DM&=A\WT'(TX?%&$L-EN.MNK
M&$Z9C^GW%L[KE_8X\RO2\HVC(MM5;U2&;P9W%9C%&;5@Z;K/3&.*2IQ`/,Q%
M([(FJ6Q59N^SUGP#!X^A*SE;-&KEOK]<@'=(K5@<X[QECI[5<FM*6I::98J5
MC'(:TNLB,=)+QZYA;@J8AB'.'9%C@S+AG*.M[3#-)R-,5^ER$Y-[Y761L;R\
M1H0Z](S::BMAQ\3)TKA^Z5%?(EGAFKQ`&B%79/3N/%PU7:E$$Q(K_LM+LAY:
M+'7VLX<O9,!;`X%UDK[;%+G.U:Q#=,0-<-Q#6,95_((V3&%IF[1'>ZP1G&3N
M&-&/CO%CG60*HI^0BRZZ'5;^*=Y?D)S:5LJ%=B%-?M?ZV[<D5)^KV3&U&DY6
M]RR`+%#[M**=VAO'@X#R`505*`]\(LMTY7*]:&'Z79H*'L49[J;C]/FXUI*,
MON$@,"2X-GJ2R(+)E.8"F`/(`,/0^O+^FZ/;YA6%=LF[R*^("L5JJM5&-7KT
M'6V2JA5EFD%%,8ENLL4O@559)B@@194I/R@8W9@#T[Y+''L-:U4TDGJ`:4HI
MM:5U8LUE5]/KD(9"HUYTZ1$WB8P24P<(QL8I1]0$C,7(^7X#URWF_F%7$/\`
M+"RP\I*JG")PB<(G")PB<(G")PB<(G")PB<(G")PBL!LGC%7)V,I)C&-!=66
M"5)/UPA"D%=P\:$,1U&I&.)0[DX]11(`[`!5\!'Z<F:YS?TFBE<UKOU+%Y_<
M%FOT_P#EE:O]D0_WGES'(-OUG56TD1W?0-$_N!S7_P`,K5_LB'^\\G]1GF%3
M].3R*?W`YK_X96K_`&1#_>>/49YA/3D\BNJ]USR])-'D?(8HLCUC(-EV;UHY
M8-U4'35RB=NX;K)F<]'2605,4P?B4>N2'T7&II53CUVB@K11H>?'O/4&*?/,
M9ZVST?/R+YL"KUD@N^?I,C"<[AFV6D95P=I&]D+_`&28E+WUWWT'5.01!OT4
MJJL9EW?77:J8#4C9H!*8,'WWS(!BD/\`I[3W"%/WY%*I]]YE*81]0`>AY05=
M`U(V:`!*&#[Z!1,!A+]@U\1,41$IA#[[KLO?I^SA%S_RD[-_\#[[_P"'M/\`
M?N$3_E)V;_X'WW_P]I_OW")_RD[-_P#`^^_^'M/]^X14K<-%\]7N(-!V3`-\
M>L15!PD)6B"#EHZ*4Q$W3-PD_*=!<I#F+WZ@)3"`@(#PB_>LZ.YZJ$,A`5_7
MV[1\6@94X-RL$%1666$!6<.55Y%55PX6$H>1CB(^@!]``.$51_\`*3LT'TP?
M??7U_P#T]I]?]NX1/^4G9O\`X'WW_P`/:?[]PBX'4C9D0\38.OAR^0'`AXYF
M<@'+V)3@0[TQ0.7L>AZ[#OA%]#J7LX81,;"%^,81$1$6#41$1^HB(ONQ$>$5
M8T+6G9FM6%JX4PG?4F#LOV$@/Z>U\2H+'`4W!B@^$#"U6$#B(^OCWPBDK_<#
MFO\`X96K_9$/]YY>MD9M&HZ*R=&\N.AZI_<#FO\`X96K_9$/]YY'U&>84OIR
M>14N=/,=Y"H]TMR]MJ$W7HZ2K#9)!W)()I-UWK650.1N02+*"*WL+G,`=!^4
MH\M92"\D=%=Q`AE#U60GE-5$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
'A$X1.$7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g575431dsp_079.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_079.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,9:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;7!-33I$
M;V-U;65N=$E$/2)X;7`N9&ED.D1$.#A#,S8T1D$V1#$Q13)!,S4X.#$Y,S(U
M,C)%,#%#(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D1$.#A#,S8S1D$V
M1#$Q13)!,S4X.#$Y,S(U,C)%,#%#(B!X;7`Z0W)E871O<E1O;VP](D%D;V)E
M(%!H;W1O<VAO<"!#4S8@5VEN9&]W<R(^(#QX;7!-33I$97)I=F5D1G)O;2!S
M=%)E9CII;G-T86YC94E$/2(Y,S0U1C$U,C$Q-S0U,S`R.3`Q-#(Y,C4T0T$Y
M,D,P0B(@<W12968Z9&]C=6UE;G1)1#TB.3,T-48Q-3(Q,3<T-3,P,CDP,30R
M.3(U-$-!.3)#,$(B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@`.061O8F4`9,``
M```!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("`@$"`@,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P/_P``1"`$U`>L#`1$``A$!`Q$!_\0`N0`!``("`@,!`0````````````@)
M!PH%!@($"P,!`0$!`0$!`````````````````@$#!!````8#``$"`04("@\%
M!`D%`@,$!08'``$("1$2$R$4%18*(I;6%U<8V%DQ02.4UYAYF1I:43(DE;4V
M=K9(N!DYB<DZ0B8WEWAAL25U<7+2,].T57=8H;,T12@1`0$``0$&!P`"`@,`
M```````!$0(A,6&1X2)!47'!$C(#0A/P(X$S0__:``P#`0`"$0,1`#\`W^,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#@I2M4-
ML9D3BC'HM6WL3NN2F;`$S1:E(WJ%!`]@'H0!Z`:7K?IO6];_`&\"D?BNGN[N
MHN2><^BY3Y:.H8S)+LI^#64^1V+\^>/T$<9'26L:1W6-;'IZY,>'?Z+1'J=E
MD;4JE!^RPZV,8A>N\"3OYDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>.K]#K`
M?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>.K]#K
M`?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>.K]#
MK`?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>.K]
M#K`?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>.K
M]#K`?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>.
MK]#K`?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L!^9-VA^N$Z^_B_>
M.K]#K`?F3=H?KA.OOXOWCJ_0ZP'YDW:'ZX3K[^+]XZOT.L"A#_:9>0+\0OUX
M_.;</K)_LF?QQ_/?Q249[/Q^_P"TF_-X_'5\U_%U\U^G?Q4?_#_H7V?5CXG]
MT?1_SC]UP-R?`8#`Q[;#K93)6\R=:<B$<GUIHV-6.!1"82L^#1-[DP]!*;4\
MEEJ1CDJUB8BCC/BJSR&]8HT06+110S-AU@:],&\NO74S\;W+-NAAO/R7M+L7
MR!/_``)`P!;)X/GN`2,J\+:@6[(>V,<FU.Y)'HE":N4*AI2W)(I<EHRO3101
MB*"'2XIY:>^;!G\0\?,?9N7&/R!N'=G37*4BNEXB%D./-X:NYEHJ.=#.ER,]
M6))\DFP))-(G,6]M3LALC,*2+0G&C.$`0``">O*7EH@CAXWW7MWO-X@W/JBF
MK1LV@^@G.+)I6^0(JT:NMYSI\2J!-:=+(9DM:YJZIT:A&C]BM0F$K$6,P8"1
M';"H>H?.ARS:_G`FUBQONEP+\>[;XZTC0!!-))-Z^I)'T>1=\>^=.!<&L`B.
M-Q4Z,B+H62!R"AT<<08(D)HM!%H,9S^GQX7V&SMSWV=RAU>!S_-OZ'J"Z5;$
MB(<G]IKN?1J4/D>;U:Q0@1+G]D:7%4Z,R1<J2F`(,4%%@.V'?LWO+NP29P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!U>;_XER__`"7?_P#!*O`@
MKXCO]V%P7_Z6:=_S.;<"Q+`8#`8#`8#`8#`Q)?T[=JMHFZ[.82$*I]KFI+'G
M;*F<RSCFU0[1"'/,@;B'`E.>E/-0G+&\`30@-+&(O>]:$'?IO0:N,1\[W84H
MI_DN,`@M&%=5GWI4F^UTVXQ,OJ%%^7KIL/GJ-4Q-J_9/KMMS8'Z\6;JJ-?1"
ME:X.28A4POVM$'?-P`T$^&/SUUE+U4Z)A',-Z2E)]>6.L*`?"`-S1&+RL>1=
M2M_)++#5\O?TK7$*L=W>>N93RF"O<%OOBI9ZP?PU9`T&!A2A/,7<"!RN1TZ1
M9D+:Y01O[-=D5.NBNIH"V,BBGO(#&>6H#!GF[#)8>V.DV9VZ7$-FB&YM7@D1
MJ<1R,2AP/3(3@[\3]H2KM;$('.&KDF[G6/*X*19%VN*>65HB*H^))NOWOBN0
M+3D;T]M3Y82MNM1I`I2I6M$%0L:#]G#`F-*&3@9D\C?D,MGDVZ+0;H2NAR2%
M4#XU+IZT?6&9!9$#;8UNR&WH12W/L><),['(EC.QL+\4\'J4B!4F4O*A<F2:
M'[Q$^@8C8O*ET?.?%%V-W'&8[1[;9E3W',JRI8E.^)K*K96CCE@5[5Y3I,CX
M7+ROI,S4C>G,_>TS@C"H1_-CB]:),"(P,`MWG;M]3;G)B!\A];QBI(;%;*B?
MDZ5AC,L>I97/3E<U/TW-I54-2A+DR5.T*X@+E1V>#TZ\EW4GM$B:"Q"(&;\8
M02Q2^;=U-<8C6Y_"ET%]%VB[<^F5%22>U:/4:F4%Z@J^Z[,J2<.MD&RM)"H=
MK15"OS>^MJHTQ6UJ2RS"OGA)@!B"+5O^<KH2;U)<5B\W\X'1*#LO)'!'4M:6
M'*9)!WV8C7=2]&%5:_5A):[5.^FWY\ZEL;RPM:PL_1"-<@-7J3`I5*(6!.>&
M^8EDD4EI*#R_G"=4_*+&Z9N?E&RE]C3R$HJVIJW*9G,'ABF%GVTRZ?8+,9]8
MA,]3N,19RU"'ZPDH5J=,H$M**3*`E3XU;ZLGH;EAODUR.R*16Q`;?Z*H:P)2
MVLJ*.M\N?:"OBPZD)EJ=D;"4[:UF25FB:18I(3%EIBE9QH2@!+T'6@GQ@?/W
M_P!%C_@O_P#.2P/H$8#`8&.+>C]D2JLIM':?L1NJ6SGAA5HH39+M"T=BML-?
MC/;\T>UL&7NK&CDY";TWZI#%:<)GK_;Z],"A.M_!I=D*Y/8^=7KO5+(991W6
M40[;X\M-NYAB\:%25^-,^LZQINJFT6*L1R*N"%V*\V@L3G-:E8W`;D8=%E#,
M#H(0AV1+X1+&BS=`+NK_`+3.9O(G$NKKSZ[?NK'VB&!_@,NF/2%:-5.6E7YM
M"!FJ!*T5F"MXZUH6A*4^F*$)R#X_Q!"/&$(6%\H>.JF.=N,FWC6Q$[3T]%GA
MYFTWN5\N.%1EV0W/9ME3YULZ;S*20=6G=(VC`KF+MLU`C#H[3>2F3A":,PKX
MP@UF+LYJYVJ+[11)*TJZAJ;@%;D>+R/3#4#BU8PQIA)<J67BH0*I0*+)68##
MI]4)$A!`U>R-'#*+"#8MZUZ8_.3^W/CB^R=6Y83XR^1N-?'-U'U'T%#WL%/1
MGJ=MCNGELL2Q&)HJZLE;$L5O*EJB3K)"FM2,J<2=V4K"R5JXX2+6@I4H=DAW
MO735HDF2:L[&R<R/;+)6=LD,<=VN0,#VA2NC,^,C@D=6=W;%I(%"-Q;'-`:>
MB7H59!@1E'%#&68#>MAWO6_7.:G*8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8'5YO_B7+_P#)=_\`\$J\""OB._W87!?_`*6:=_S.;<"Q+`8#`8&`
MI=U-SI`BKM.FES5_&"N;D$3=+X$]2!(AW53=/&P#Q"ULR"<((FI/*FXS1B`0
MM;TJ^4)?N'K8=!UI+V?S4JZ-<N3OQH-*2^&XB*B#"G!&ZM_TLY3"$RJRFF-,
M#VL0DL3Y+RJZARU^5-*928X)&C1:HTH))@!;#,=;6K7%Q1Y7+:MF<?GL80RF
M80E2_P`97E.;27*Z_D[I#)JQA6D;$0:NC4K9%C>KT#8M%JDQ@/7U#O`[_@,#
M$=_1>/3:C;AB$OF:^NHA):SF[)+9VUAC8E\1BSC''%+(W]/J8L4GBON;&8P\
MW?T@WK$F@AW\0H8?76!0]5'C7XSMDF`K*;\DUM3@N^:FI^35XNAC+PDYFV14
M'#4QBI%..C(L1<D#/<X]SS.')G((%H7O2KOFQ*OX@B@``'<'WP7\_P"G"<5Z
M^]Y=7HE/2:A_DCS6BE^Y2:D$I=66=,-MRF85A7(.<TC5`Y(TV4!NDK@\PU`T
MKT[P(E::>$XS0Q!R1/V?*BDL4'"475?4C?'-M+HS$IVZ.\A(')`F>;1CUWN*
MQJDB3EDF3,\@-N**-LG`ZI5A+H2](P*BU`#/=L0<LA\!U/-L==(FCZTZA!'7
MN,'0QY;#HEQHL"ZQ=1<:GH12T.*M=R@I7K"E-W+3I,:88:(\UT-$8,>P[V#`
M]*_O&I`)?T/4B6]/)OURZ6]>]86CSY"HO(8=Q\H-M2N(XMC5^3.&@(:>14T;
M+31AS@*-\$<N)V?Z$B*3FAT:<6:&<'CQ(J)!3\@H![[XZ\<Z7E3N_O\`)*Z4
MPWB`4?>GJ4V`MM61NB_0./P+CEKS8SB>\'C^-K8UAHA?('[G`P)'?%G0<DNV
MWZU8.]>C72ZH3/VSJRZ(WJL^)A+TUB],5S8%-I;5DX%?&(6)Y=+1K.+R-D/!
MH2@D:,M3\4@LP[WF!SE4^!:J:0U'Q5=V'UG&5,3GT?LZ,.9K'R%)'I@F</AD
MAKJ%K6I]EO*[\\HVB$0*6N;.R,X#],S.WKC24:0D(OD#T]^`:G/@QY(#KGJP
MAOBU412C&5H2L'(*-D*J6!V`5:D%A*]D2\KDM+XW0JPRMNS2<O)4K&Y2:=H@
MXLL\X`P[4]^#^'2)\;)$[=P=BJG%JN1WZ%+3!;>1TD==+M>Y%'9@MLB50]!R
MTDB4TD)4OB+6ZI-O")<0@<4)2A*62:'W;"P?B#DA!Q+0R&BFVV[(NI.GFM@V
M`JG%J$0<F5+9':4L<I_-Q#W`HC#FTQ$YSE_<G('S@E2K*&O&5M0,DLDLL)>8
M'S]_]%C_`(+_`/SDL#Z!&`P&`P&`P&!IK=,;$+[8UQ0GV(>TZOC$XA6G]POF
MZL@,%ZJ/"0K)]?A*20J"0&:"/0@Z,`$6M>X(=ZC^<]+["8?D^IG@<$"ZI3=X
MH)\+D:*R35X6`E@CO(M3/ZYNCC'C6;ZLB9#"W'9:F7RS19"+0RT119OH9L!0
M-[SO?^N)GVJ]#C,ZBC^2.9C^8$AZ'G(VB:L,HU$K)="%J2JQ0QGW!TR\E\$-
MY`X$Q[9`5&E0A*/C:%\06Q>N]\U)+8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8'5YO_B7+_\`)=__`,$J\"O#QA(),Z^)+C=KA;^FBLQ<N-*Z01.4
M+6HI]1QN3+*Z3IV%_5LAQI!+RE9W4PI08E&,`5`"]E[%K0O7`I.,\97VH01I
MH@^;JH?:(PP0?2LTY6O:(8MA]"@4<(!7R;_M=;WH/[&M[UK`\/\`9D?:AOUW
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M!;%]:;!7%C?;*F!@A`+$(Z86`ZN3F/>]:W[U>\"4F`P,-]%PA^LSGR]JWBND
MFY18--V?"(WI>IVB0[?I7"7QA9]+5FBS=I$GT@O+^(;H`OA@]1>F_3TP-7,S
MPF=SU:)]BM`3&`,5-.7"I+$T5TDL-^A*^)]*V3/>29!V-1T.E3$VF.,5IOI=
MJYX=EA;TB^&)K>Y2X[^``A1L6@SM0/BMOR#]/<9=(RKGZ`ML'JCJ#KF6L-``
MZ`=)4X<:TE>$`HMKK)##I4O2Z9)XGBUIU;*)2N86W9:9.?-M)DPSB4P_:'?N
MM/%]U+:+[WU;$`=RUD_NKK'FN5UXR&6XYH0SSBVM:^H#=O<[$(96C?ZRKTRP
MK0@;JO4)5K4>V/OS9.2Z#$D/%HL,!(?%[Y`4]J^/IRCR50QPWEQ\YQ?$U@SN
M]XM+;SAL09.CK+E/0=23^21R,LK+-(N"G92V-L5:(HWM;4K;"U#<\JE04R+0
M@ZVQ^%_H6T(+04#ORC80FDE4F=0J.@[DUU5/Y4_]>W).>;YY`ZXZ04@1$LT@
MAQCS:3JVKU#:>K"H2`^X.)&G0)0C#N33XO/)4LOFO+"FUPSS4S;N9*"A\*O>
M%7O$RD='6?"^'E5$6M%[#CDJ@+M9-DP66]`+W*9'@C;BA(?%;D0L6?!6-Y0]
MA,;PU\&WOR#/>BYS;].0^DF^UZ*XCKU%&8Y>KU?#I(K+Y^8;O9[FLA^?7EO2
M"9_QCR*<I'=.G)-/^/\`.C5"GV+C58<"^7`8#`8#`^?O_HL?\%__`)R6!]`C
M`8#`8%:OD_[BEG#E34FZ5W&Z]>K+Z1ZCJ'E.OGZYI$Z1*D*YDEK;?E>K"M^0
M,I!KN1#(^UQA3H2=((I4K5G$EEC#ZBW@5@P/S6].W656?,5,53RX_=[S;N'J
M#CA?(5=@SMSXZ$R<EU8R758-^1IWCJ578KO%9%!Y:U$-;/H[:X#D8>$X_>BM
M!&%IOCX[S+ZRXL-Z=N>.QRC)+6DANZ`]$LP)`-P@D`F/.\PDT2LIX;).Y%I3
M383I/&1NI)ZG6AIDAWL-$,10C!!IV]W]U#??M&=']L^..J5_E&3TKQVS%.5?
M\M/3G,A*RW'5VP61*%LC@$1L<YF+B)MF-)ZH0FXX`1K4Q0]EB/#O7/,OZ8F_
M%]A8OV>YWOY1.`+8*L;G"]N/+GOYJ;V5YH(^JK4NNTH'J#SEM4MFG.!Q"$1Z
MP'IEES;$$ZP*L;,B)2DKRS#=?#!H8_3L_KVIV_)4MQIYRO+?XJ*2Y4XCOWQL
M7Q:$@=IZY0RH-WVRV96-AV)6Z%%$XU#*,H=@+JPM6H<X4N4$A*5*=2<X0'(E
M)I,4#1&]<E+FOZ0GY7OZMAV[_?BY?T0,!_2$_*]_5L.W?[\7+^B!@/Z0GY7O
MZMAV[_?BY?T0,!_2$_*]_5L.W?[\7+^B!@/Z0GY7OZMAV[_?BY?T0,!_2$_*
M]_5L.W?[\7+^B!@/Z0GY7OZMAV[_`'XN7]$#`]99]H@\J;<C5N"_[-SVLB0H
M4QZQ:L5/MPD)DB1*4(]2I4GF\A!+)(()`(8QBWH(0ZWO>_3`N8\.GDR%Y8>0
MS^J!TS^(D1%L36K]P;Z^_C&]=P]OC2[;S]8=P^#[#M?N0^SYO\R_<O@^OQ!>
M[T"%JV`P&`P&`P&`P&`P&`P&`P&`P&`P.KS?_$N7_P"2[_\`X)5X$%?$=_NP
MN"__`$LT[_F<VX%B6`P&`P,5/MZ4K%BK-/DMN5K'B:53,JVX37N;QMK+JQ')
M&TMYCJJPA+7$C4/3OS2<!2B&X?-PJB1:&7L0=^N!B:?=T<>51*IW#+4Z0J2L
M'RLB*X-G8K&E[;!6*.G6ZW2EYK9L52R4F-,4/?I<RPET6I6XA::O^9)!*!D@
M)$6,8288']CE;$RRB,/#9(8U)&EM?X](&1<F=&9\8WA&2XM+PT.:(TY&XMCF
M@4%GISRAC*.*&$81;#O6\#EL!@>(Q@+`(PP00``'8QC'O00``'7J(0A;]-!"
M'6O7>]_)K6!&>3]I\?0JOVNV9?U-SU&:M?)6\P5DL=]N*OVN"O$TCBER1O\`
M$VJ5K'\EC<9$RJF966J1DGC/(&F-T,.MEB]`[Q:O0]"T77B:W+HNBK:HJU::
MT$(K$L2=QF'PM<>_E?'8R$,D?G)"TK#W=/K9B8!1HQ'%!$,.MA#O>@Y"5W;4
ML);ZR=I-8$:;FNYYE$Z^JAP`O"XH["F$Y0+7:),L44->EI3P:^,[:H6DFE;$
M1\R(,4"&$D`AZ#*6!T&SK5K*E(.^69<-@PNK:[C12<Z0SFP9*SQ")LI:Q60@
M1[<W]^6(&Q&)8O5%$$A&9H1IY@"P:V,0=;#&(NP.4`OE-QD72U#ZD71#60]T
M*Q_C9@OTK<S.KUK:-TK%#I\^<S=O6BW[2#6X*@!QFM@!L0M;U@==;>ZN-'T+
MZ.-]04?+0Q6S(/3DLW#;&C4Q^J5G65*@0:!P^6:C"]VW&'253$>FQ'M?\W*,
M6ZV3[]#UO6@E=@,!@,!@?/W_`-%C_@O_`/.2P/H$8#`8#`AYW-1]G]#4(Y5I
M5+;RP_OKC(F-<ZQ;LJE'6^J*E4=0_/-KF9^A#)*X@Z)W4"LU.K0N)*DP24Y+
MZ?"W\3W@"GZ(>#2T*`AW.=J<PWU2D3[BHWI[HWJ-WE\BH(]FY>F3QU?7#=4=
MIU@RTC7,QCCO75:QNOXVQHHV0WNIIB7Z)V,S7O5C&2%HW"'",?Y%XZ(Y;GTD
M07RXS1TMZ97_`"U\BZ-I8+9G5_2R23&UAF0H:ET0M\1<E$I/;D[>8:?_`/#"
M2PG"&,0][;]@I6YRY_HWFG[4#.ZUYZJ.O*4K\7B`1R(<,K&*,\,C1C^Y](QQ
M&X/0V9C2HT&W-:C:DI1IWLT,9:<O6][]NLYXD_28\K["TKHK4H8^A')V;-OK
M*8[&QY*TNB+:ULVXEZ;FI(L(0+R]D!4EZ,%HL[0![UK>_06>O3BZ<(OV>OW5
MXQ8=WKT[X\NE'"Z76#N/`MQ+;8+B3&Q-,C2V44L<H4_D,:US.=4A\6,*?*_2
M!$J"4MT8D4'AT4$S19@>"T??`OY)>@?)+6?8\OZ"0P%$Z4GV/8%004N!,*YA
M3)X`WLK"\,K6[%K75U$YN#2:X&E:6;V68>7[?B!V,/N$%\^`P&`P&`P,?6U\
ME5V9O7[.J^F?^;CE@:S7V/'_`'1SG_ZM+N_P%6V!M38#`8#`8#`8#`8#`8#`
M8#`8#`8#`ZO-_P#$N7_Y+O\`_@E7@5R>-,B=*O$%R*EJY?'FJS%/%$$(KMTE
MR58NBC;.CJT*+B*^3HF_87!9'D<@$G,6E$;T<8F",(/NMZP*=8S5/VP$N41\
MR0=-^.@R/`?VL;V4IC#<I2C90N)&W$!Z9HHUI>3TVT/OT("98F5"#\A9Q8]Z
M'H+!_)O"//3);=@:SQ<7)R/7U*DURG33IGNAA+4S11:()`]FN+FG6N]>SY$9
M%U,<.;BT92<24TI00IV=HS1A6PA(;Q>1CRMQBNK+3^5FQ^>;&L!5,6XZJ5="
M-(FX+9$`-'L>D\K.2Q*%,RH9[O\`#$A"2B$H*#H_XQPPC)`4%H&!0SW[X_[J
MN7M*!S:N6:,*.2^EX[1<7\CWT@]HVUR)B?$MT_G%U"O;HV(0G6:K;2*7N4&<
M@(2C32&8T.S?0`2A`"+T3X;Z'[)J3G?IK9$OJ:Q.F?*9(^];@>US;7J"U:1Y
MN04A<="<U,!,4NJ(R^-.SW$Z=3PY.:S+F%:8D5/2\SYOHT!AV@V;8TSCCT=8
M&`QS6/1C&RM3.-Y<$S0C7NXVQ"0B&YKD<?;&5A2+%XB-FFE(D:1(6,>PDDE%
MZ"`(<U@,#K\L3$K(M)4:B-@F1"I@>$Q\0,^C/ARHD]N4%&QLSZ;/2LWL?`"V
MEW\\-+2^AO[J()?NWH-5Q#PQURCXR^H;%Q%>%17[5G9O;G0/)!=.7CPFBC55
M*.EGBYGJJEDX89I(YI6KA54/C5I%QZ0LZ-N5KTYA`QMB101HHX(3EZ,JWOJ:
M/_%MA2OEV/7\]\6NRDJ?1V#6G4<<;.FY'=_#<QJ6P[4KF*60OAT6KILJ.[9>
MH;@-CZL)5K(^M5+$`1;"!&<&')3S5;W)M%>"V!3GYY)S.83I_4=G+840ZO[1
M"[9G'!M[0"KY,C5I$HE94<B4\5"C3<YB*(`68[)1>A&C-!"$6/&_R1Y%[LYH
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MZ_+OT^7?]G>!_<!@,!@?/W_T6/\`@O\`_.2P-HCO3RA6KS';2'F[F#QY=5=S
MWVX0=NGJG\7#!]3Z)AS,^N#DTL8)O=[N@=F=J=U:YK-$)(!&/19`=",.+V((
M=A`;_:0_:+F<?UG?_!%!W*'Z%L\Z+QGL*M3I^F1:]PM^AQ3Z\%."L!96_0LA
MKV8,0PZT#6_7T"U/QZ>1!=W(GL^-SKD;I[C6YZ6-BI=B5?T5`UC&B-*F8'P;
M&Z5W.])T;38+*/<>4A.-*3I#TXM`V,G0#2AC"R;`8#`8&MNP_P#5<3K^1H9?
M]9EKR+]YZ7V%IW8K:2]32FF908:4G=EJYL/,)]GQ2B7!U8DAIA.C`C+^*`LW
M>P^[6]>NM>NMZSO^?CZ)N^.$G\14<EH&MYK"3.)B^</:%D=0R!$Q+BC$C82L
M5IR4P"FU+LLPTY6+0MZWL6]>GIZ9LOSV7R+V[FNA1WE$\-O@"M?L?C)M=>VI
MQ.GOIN66C:R]VK&+R)E99E(V5B!N*PMT`[P-0Y1=@;B"BREAZ,PU:8(9NCS2
MME"SDIM1\9==U)W;S=6W4]&!EY=8VDD>E4<*G<760^4$[C\B=HLZ$N+*K,4`
M#\-V93]%'ISU*125H)I)I@!:%@2AP&`P&`P,?6U_X569_P#M],_\W'+`UFOL
M>/\`NCG/_P!6EW?X"K;`VIL!@,!@,!@,!@,!@,!@,!@,!@,!@=7F_P#B7+_\
MEW__``2KP(*^([_=A<%_^EFG?\SFW`L2P&`P&!^8C2@C"4(TL)@_E`6(8=#%
M^S_:@WOW"_M=_L?V,#@&>81*0J'U*P2F./BJ+OIT7DR9G>VQS41V3)D:%P41
MU])1*CS&A](0.:8\:11HM0`E04/8-!,!O8=CP&`P&!X^\'IL7O#[0[WH0O=K
MTUL._:+6]^OIK8=Z]-_V-X']V+00[$+>M!UK>]BWO6M:#KY=[WO?IK6M:P..
M<GEH9@HAO#JVM07)R1,S<)R7)4(5[NY&_`;FI$)4:5I4Y+SON"2`>XTT7R!#
MO?R8')8'@886268<<8`HHH`C#33!!`666`.Q#,,&+>@@``.M[WO>]:UK6!X;
M4I]#(+V>3HQ5H0DP-F@T-1H`-&#V0'W>IV@%[]V_;Z^FOE_8P/07OK&UA2C<
MWEJ;@+7-"RHAKW%(C"K>',_29M:4HE!Q>E#FX*-Z+((!ZFFCW[0AWOY,#E<!
M@,!@,#Y^_P#HL?\`!?\`^<E@;?'=%M=R<^N%:W;S'2+)U32,32R5'TQSE&S-
MM?2;RR+5#"I8;%YU<%RI/&Y9)X2D1..E<37"*.?BE19:,T*D(-Z#6>Z^[IZ$
M[`O&R;AY,MSRY/-.EP"",G%<:\:=70I^@<8Z`;HFZ#M.M_(E$9>4"95U8S!;
MOPDRIFD20M(*+:"I2_&+_=3`W'*)46FKI"FU=Z)6Q#=JJJJ]47$B9/F_T,CM
M,Z(M!E@I6GYH8:D^C$\M$K`1\(0B_A:#[=[#Z;P,JX$`?)+W"9P#SPU7,CKA
M-9;W+;BJFCXTW2":$UE6\;D=N20$;:IM<-H*&*4$5O5<;/%\1T=Q-RSX6Q%%
M:!ZFZ$$*W89YN;;M"NZ@B=7\=QN8=D7CUYTGR56M<)>A20<V3<KDV*$36Y>A
MX/TB"L33Y?1S>S*0)D*I+&_G*QV`<DUK6R!#V%FG`_<D;[8Y-:NF7>(&T:X-
M#Y:$'N2`2R2MCH34U@4M+GZ&64T.$R+(:FER86E?'C59+D(I*`;>86::62+W
M@`%-]2V/7=I_:FIU*:PGL*L>,_['1L;=R*!2IBF#$%Q2]*,9ZEO$[1Y>XH`K
MDY"LDP9/Q/B``:`6]:T,.]\\R_I,>5]F+CNS$4A1+*[G+6W;/;XDJ4GJG`WX
M8T21R,<&E0TD*B?CE*30*CTN]>@-?L:WK8@_)GH_/&<5FKS9NE1LHGU`%/+.
MWE+)T\Q%F=VH#<2F*-(>%H4!Z@;4)Q-&!&+10S-!WLWW:!\GNWO)F/EP5X,-
M)V:S8[05LSV=4]%K.MB(5[+Y'7<>=&!))YI/'R.1=Y<V"+OJE*4Z.3@X/+RC
M3H4Q:;>S=DF```.Q>FL:OCGMW,F?%5QX#/+Y?7DF!T_1_3?,,?YMO'BQ;`(M
M82"-;D4:0+GR:/UJM9L8/J.5MHW^KW6!%5R%&L2J'9R$>J,&+V)=`^#DM;%F
M`P&`P&!CZVO_``JLS_\`;Z9_YN.6!K-?8\?]T<Y_^K2[O\!5M@;4V`P&`P&`
MP&`P&`P&`P&`P&`P&`P.KS?_`!+E_P#DN_\`^"5>!!#Q*B,!XO.$1$A]YH>5
M*A$4#?\`VS-0QNV`/[.O[86M:_9U@=MU:O8'IKUIUKUOTUZZ^C3_`)-_?3G7
MX_GYIS?(_&IU_P#D>:_[VG_A3CX_GYF;Y.;C=E]5+9"Q(WZJ&Y`R*WAN3/"X
M#><`:-L.5E%KE01;DA^@B(3"$+6_8+T]/V-_L9ETZ,;*9ODF?G-37=Z+JIWK
MWRE=/>0NX8;"$W-'(G%G.]GIK"M6N9Z^K#'.`G];R&PVKFZ<MT]B4'C-AMR(
MMGT^`6MT@,.`N;`:3DB&`1H1&K+QPW[8MH>,:16+5T'>WJ9T]V%V?UY(KCK&
MQ)W5S+TSTQ=_/MQ#BRP,.GE=$,=O1=@7J(]%U#BL5E)6N-G`"D4!+%O0;;>`
MP&!UZ7?,_JI)_I'3_MO^KSU\_P!133UN4[1_1JGYUJ-ZC?\`WBV_[(]WS/YA
M_=OSCV?`_=?;@:?+Y`Y,?X?[.JADYN\B(+'@?DGG\ZY^@`J)[,)GRFN'SMI=
M;D&E<@:5+3N1SN*(^:A*C!*)&)>E3.YA:8_T=MD!P++_`#(S`_I3@V]8+7_/
M?<C]9$0E7/KM4B&"T=T(VFSF6RI+'K/3NK<R0-,2[2:-0"(_2"*0%2%&4V,<
MI*+0JBM.($X<#)WD3G(GJU_$Q.CT[TQU<[WU<\[1HYQ&W.*.#;=:/A/HB4\Y
M)9G$9:@;W1AD+;("G`PAM<TQ*E.^)R"Q%!4@`'05N\#]#^7#J&BE%@5Y872]
MB)9WS-Q;:@Y_;](<]T02U]"SIOG3A>D'YS7V'5C?`[+H/4'#&G(MX^9N8Q*5
M)0TJ_1BE626$N>SW"_[!YVYGI[H&D>C+5(JGH'E6WN^B6NJ$T[AUM<]/<JN)
ML?X<WIJ.8TL6NP^!RR/Q=XF<4CK.=LAB$G/4)5!)AP=A417/,'5[5J$M$TYW
MZ5-N58Z<6//C'F"^#V,Z%<ITU$?([<]F7-"IW,_>J9^?WQGY`=(\CD#7)3TJ
MQW8PI6;?SH9'S4L.=%6DQH7COO"N(95;L=!V^Q^"IASUU;.N9;@Y-Z`M?K]T
M[0:W*,5=(XA<\LD#I:4BJQY=D/PY6Q(6='LIV.1?!,&4(0`W;=?^W]G]OTP&
M`P&`P/G[_P"BQ_P7_P#G)8&PMYNZFZELA7RTYUI!>P[DYAB[I:FNBZ<X1O1L
MH6_GZ7N[1%BZ4E:E[7+FE;+:ZBRE(]EN#4B6)S@+%Z14/1A9(M!"*G(OB<ZO
M(Y^8.JH)8MD<0^2I#,[+.B#W;DI:[G<[BYI)FKDKHRA?)$GC`4L=O>3M<,"0
ME-E:8`94R@$G$%0<>DTGT&S#5BRQW"M*_7W$RQ>.6RLAD:4V8P0AT7/D,9IZ
M<SHS):V1-X<TR-R<XVC?1'EHCU!19YJ8(!&!T+>\#OF!6#Y8^/KN[6YRAE6T
MI(Z]]8S?E4VM9],W`Y2MBI_J*K*_<EKJ_P#/5H2&$-[Q)F6(RYSVA6&#)1+4
MYRAM*)4D#(,'Z!4Q4_AP[JYV0\^]`4O)N6D-^<U]?=3WE3'(KI,;B-Y$J&@N
MMJD:JMF_/E=V,IBB^PFG3(X-.I$F,(8$C.6X*U)*=(27O8SPMWX`X$%S3PPY
M\L=!O$4N*3W&\WY-^EU4;1.[17LOE/3$NEDHLR-Q9$L-3/R6%)V^5B:$HS1$
M*STQ'QQ!),,V6!9F8NX4K<=\B<W<3?::)]2_+%4,--5@=XD`34Z(QQ6^K4!T
MJ?>C(HW.[V8?(79Y<-JUR%A1E#U\;X?M3AWH.M[%O?/$GZ2^.+[#8T["_P#!
M1R_^?1[_`/.YW_/[)U?5DNJ'1J!5<!(,=&XHW4,8"QA&M3!&6/Z+3ZWH8=FZ
M$$0=_LZWZ;UO)NRJ1B1U3.J(99I:#?99#^F;XX]+$C1\W<3&L]>I,*`B6J"C
MG<]&ITB"(6M?<^OR_)O6=/E-6-.$XLVJ;?'AY2O#['.ZNJJ"AT44T!WIT!TR
MBK^XWQ1!9<-DZFNAJ>I8U%.D0<F5SFK/'$+5(%[CI5IP+CJ=0X.)JT(#1*C#
M`\]4DN)N5-K9MW)([I]U%]O[+J2[1_2.H[MT0_3NV_UV'Y]II^/\_P!H_76]
M?%^'[/77[.8.:P&`P&!T"UP#,JVRBRP#,,,@$Q`666$0S#!BCKB$(``!K8AC
M$+?IK6M;WO>!\\#P7^=JM_%?Q*LY?N+C3L^PI>==EAV7J05I73$9&_HF7-\5
M1(4.]RJ21QU"XIAL!FS=?-_AZT,/M'O?KK07)?TOWF+]7WY$/_+:OOX0\!_2
M_>8OU??D0_\`+:OOX0\!_2_>8OU??D0_\MJ^_A#P']+]YB_5]^1#_P`MJ^_A
M#P']+]YB_5]^1#_RVK[^$/`F/X\?M'?-WD4ZT8>/(/S5U%4%C/\`#)=.$[E<
M;%`6-F3M,0:Q.JK2E,TS=W?OB.!0-@3B`D$6(?\`;"#K6]Z#8EP&`P&`P&`P
M&`P&`P&!U>;_`.)<O_R7?_\`!*O`@KXCO]V%P7_Z6:=_S.;<"Q+`8#`8'$OK
M`Q2AH7Q^3,K3(F%T)^;.;(^MR-W:'%/[PF?`7MK@2H1JR?B`"+VF`$'UUK?I
M\F!RNM:UK6M:UK6M:UK6M>FM:U\FM:UKY-:UK`_N`P&`P&`P.OR.)168)D*.
M6QF/RE&UNJ)^;4LC9FU[3-SXV[,$W/*$AS3*BDCJW[-%LA07H)Q6Q;]HM>N\
M#]HW&X[#8\QQ*(,#+%8I&&EO8(W&8VU(6./1YB:4I2%J96-E;"$K:TM+8B(`
M2G3)RBR22@!``.@ZUK`YK`8'"/D9CDG*;B)+'V20DL[VTR5H)?&I`[%-4C8%
M8'!BD#<6O(4`0O;*O*">D5E:">F.#H98@BUK>!S>`P&`P&!\_?\`T6/^"_\`
M\Y+`VB>\?$J5US;K=TM3':76W$'2K5"VB`ZGM!V(X!@LGC;`N>W%D0V!4JU<
MA990%M52%4(&R5C>(SWA^+LSV!]`@`3XA?-TYJ_J_)?M#%J%U_[OA?.HSS-$
MFFP!I`[^X_[PIIJB7%*Q!$+W&?/1;]?3?R^F!:OX\_&C!O'\ELY](OOI3IVY
M+N,BRBV[GZ7M!RL"2R$R&_6#<?0L+68$EHB;&V[DZS19!03U`@#``U0:$HK0
M`LGP&`P&!K;L/_5<3K^1H9?]9EKR+]YZ7V&P-9U<M5IQ0^)/"YQ;D1ZU"N$I
M:Q)0JPF(#OC%@#M8F5$^P8OD%Z@WOT_8WK.DOQN8RS*#UQ<HPBN:YD<S:W^3
M+W!F"VB(2N6V42,[:YX;VXSX^DK2F4?<%+!"#[1Z^ZUKU]=>NLZ:==MQ4W3,
M)9\_)$JNBJ\1JDR=2D.C119J5026<G-+VI4;V`P@P(BA@]?VMZWK(U?:JFY1
M:O\`%IP]9W1QW?-G4ZZM=E<MW>"S8>YU(H::S2SZQ1V**2#>;-#'&AN<I\Z-
M#ZA;U6A*5I?N+,,+-^*6<8`573+9)LMANW[D'J+(W-OM<,\MB,P>8-D<D_`Q
M;^\N[FC=%C9](EQB#PW:\MQWM4U-R$1K40@T`DPLG:PL8?;\88];C5/C<-ER
MW(\P,!@,!@,!@,!@,!@:B<D$+?VQNO\`6Q;WH'CO6A#K>][T$.X[-Q>T.M_L
M:]PM[]-?M[W@;=F`P&`P&`P&`P&`P&`P.KS?_$N7_P"2[_\`X)5X$%?$=_NP
MN"__`$LT[_F<VX%B6`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/G[_P"BQ_P7
M_P#G)8&\UTO=;=S9SK>_0KNRKI&UT;3]CVTOCS9O8'!]2U[$7>5G,Z,SX1^B
M#W(#5\$)FP"T7L?NWK>M;U@:MM'^6KRI)HGVC8?2J_CAK4LGB1C?E*YAB,$C
M\F<('#V.:R*7%P>O;$E*N3MCS)7MV9H@-*L`F7G%!<%17S=0+VB)V&T+RM<Q
MW1G,G/'0"EE^KBJ[J2JVV%<?U\78&-78,)9)4J:21'B$>-.WJ'0118A[V(8`
M:WOY=X&>\"-'5EP7=25:H9?07+,NZ\FRF7-3$KJZ%V/7%7NS?'EK<\JETR-D
M5H.C1'3T+2M;TR4:4LT2LP:X(P!V`LS80I[J[ST.MS517KK7?!ML/71]V=8W
M5R?1W-XKAJ9,78CSSC"$LUO*SM7,,_=?ME75X$2AO/<BOGP52]-L";XH!;,`
M%J/#':,%[FYCC/2<9C<@K,A8ZSN(SZOIX<W`D=76%5LK>H58D0D:]"<8TJ=L
M#\PG[`L*'HE0C$6=Z%^_8`!39"'UCD7VJN<N,?>FA^;]^&QH)^?,KDB=4>CB
M^EV@0R!*4)YY(3@`,"+8-B]V@B#OT]-ZWOGG_9/2^PV7<Z"/_4F]:HF=[W^Q
M\-A_SH9<K1]HR[D<:MZS@D%KV*1%R8Y.J7L+46A5*$138)(::$TT>QD".<2C
M=@WH>O[8.MY=T6W,9+,.Z_GI57HLPKZHR?X1P_><7\Q8OAFF;WK>QF`^DO:,
M>]Z]?7>O7,_KU-S&LQYTN\^F83+_`!TIJ5N*;TY&)AWU#D3HAKQT.A*V2Q).
MY,>D$9FIS"H(U)6#1#P=\Y;E0CD"H9GJ<69L(-ZS5IFF3S)<MT#(:8#`8#`8
M#`8#`8#`U$I'_P!8Y`?Y/!9_FW-<#;MP&`P&`P&`P&`P&`P&!U>;_P")<O\`
M\EW_`/P2KP()>)(P)7B^X/-'OT`7RM3Y@]_+OT""&MPA;]-?+OTUK`E=#^@*
MKG;\CC,8D)R]Y7E*CDJ4;.[I`F%HTXU2@6SU:(D@'L)+WOY1:]?3TU\N5=.J
M;V9CP;.A*H=Y21#$$B..D*AW/8BD6V=X+")S3'')SB-J3$(4P=!-3BU[]C]F
M_3Y-X^.K&<;#,W/T4W_5B27C@A\A.!)P/94>$@^B'<0-.QYQ9!2;YV%%M)Z"
M-.#KW^_V:]?V?3'QU8SX&9N9FR6J?Y;V[?G^UB,XDC8Z_8Z<BM24'9;^L5T'
M?%GS:6J;=>;S;7AI_&A7ST55E(I&8BJ4PD:V5I-)UYBHT!(C!%#"`/9BG7O5
M5Q=2=<DUOKGJ%\E\'6PT4];;3835*UUYVTZ)*;B%S67*HG*]3J(UW5;+&V>=
M($;#]+HG%([GD*SEBM"0$&P!C"G_`#DU3>#M#(/7?.EQR^U9ST?^;FSPN&2Z
MC)BQ?/!4@U]&:L?5I,=G'5PX5ZDJ)<>M5*$3@J4DK$1J0!)HQ$B,#JAGG`K_
M`$"$WI(Z^M.JN7'&GN[+)3[EL#ALBFEPH..Y13\)=I/!'*+W&H-A#>.<31:R
MMS<\LPU$A4&E*-G-B4C1BD,AUIYKZYM60UW!8?RWTM(+"F+M>9,@CD;;Z]?F
MZ)1;GIGJR43Z=MDJ(FZ=FLZ.*HS<#1MI#&=N:QQ>/C-8"0JRAAT$W^-.QF?M
M_FTKH6KXDG8PNJF0MK%#)#8$*?')&]-2),I2,%A*Z\<)ENMY20J6EI7MC<2-
M/K`J`:6I1[$$'Q0JUF7D>[>2^-.U>L4PN2X%>]+=&=5T@\PASAURV)%[@F%&
MW=/:3JFEZ+CK1+(K-WNQ+NG$90LZ58H$,99BP1X6SY!%$A)/O?M7K;G'G[EN
M<0^K([`YA;2)>JZ`F$HJRW>B8%S@_,="R*S$T)>X?2"QLF*XN?6LSIX8ED!B
M@MM:OG(E1P#A[()&'X._D,L.85CXBYQ#V-M@+EWHA;+KMAJ7H`23<7IV$\AS
M'IZSH5%3%AZ(LV0O;PVM3(WN!F];+1J#E.@^_0?0.J5UYQJ<F4-5S.2\T])5
MLG<J<Y_Z,K-DEZSGEK>+5Y_Z/,E+?!+2CRUXO9FA[0A(?8:L3*VQT=D;SHHU
M*>4E-`</1(9OZ)[MF17.O)<_YP86*-SCMKI*K><JZ=+I1M<U8*M'/`SIV?)M
M+H_45DJF>;*&2-UPX_,6ULE9!"MP4)@&K"P:.#H*NH+YINMYTQ2.?$P*@FV-
M<E2[F"L>M(N)EGZEYN.8]#=W6CQ&Y/E!R(4N2HJTC43_`!;:E"$EY12(]P&N
MVWF#)T3I2:&25WDX[\V[=QU;"ZVA-C6SSE9_'Z2(I&[DSIJ/SA/4EYSM_CEZ
MV#KEQSG"BZ[HK>F&%A$L8I:PF-R.7F_'`G2@^#Z8$O\`D'OV3W[T?04-3V-7
M%O4YT;X_73H2)SBOJ_E5=(R+EI2]DU3W2D2QJ<N+C.(^R.X)ZV)],[T(:]E<
MH^L),-&(X00!<-@,!@,#Y^_^BQ_P7_\`G)8&^+;KS7$<JFS)!<1K&14;)7\R
M=;1-DZ<"R-EUVWQUQ5303^C,*/+6,WU<*4_.BM@'HPGW!]HO7TV'SU*/Y8\'
MW0TVZPN%LYZ\NM>4#S=S$3V`"CIQ/XY&*KO;E%JGKXX-QU6PIV^#:"ZJ1O3<
MX.K60=+`I3BTZ@9)Y:D.P[#Z#%$2>MIK2%.S&FDR)'4,JJROY%5B)N0EM:!%
M73U%&EQA2-&UD^I38F21M0F+`G#\A`0Z!_V<#*V!%+N1EZ5D_)%^Q/CWZK$=
M*3"NWF'5,[3.1J(I'HQ()6$N/GS)4^)6I[4)ED,:'%2Z(BPI3/G"Y(22+V!'
ML80J)F?BUN_E.N_$')N$XI5]M63XN&ZX(V_578\\7U*P7DAZ7J$4%NR8H9\1
M%9@!@ERJ>[%("0JT`RC0JCB]BT((`#":GCQX'?J&X#DO,G3ZJ+R^;]!R#I&P
M>D&^O7![30DMYZGF,QDLVA$,>3P-<AVS1]@E@6DM?Z)SSC4XU)>BO>#0<LS,
M7<*4N$>(.;O'Y]I3GE`\K0A;7]7&>);Z]F,"^52>8G"E$@Z(A[4ZN&G>6NKP
M[!+4((VC!\'XVR@;*V((=;&+UYS3-/Z9F^R^PV_,ZC\5"9.K)&G5$$J2#/3X
MA"@H!Q(_:+0P^\LP(@"]H@ZWKUU\F]8'%_5N._\`Z"R_WK0__@9N:'U;CO\`
M^@LO]ZT/_P"!C-\QJ;^7N?QKGWGFX^L';G2J^BG;DZ[X9:5;QFW8VO>(+%K"
M6W$@@D8DK@:R'MKHD(;?K*8:!&6K3$.!J<LHWW:`'V==6/AF[T_RODV8>3+E
M<^B^5^:>@GIE0QMXO2@*<N)VCK8H/6-C"YV97D=FB]F;E:H(52I"UJGH9!)A
MNM&#+!K8OEWO.*D@<!@,!@,!@,!@,!@:B4C_`.L<@/\`)X+/\VYK@;=N`P&`
MP&`P&`P&`P&`P.KS?_$N7_Y+O_\`@E7@03\2(`F>,#@X`PZ$`?*]/@&'?RZ$
M$4-;="#O7[>MZW@30C]25I%75.]QR$Q]F=TH#RTS@@0@)4D@4E"(/"69K?J'
M1I(]AW_9UO-^5OC68CP1U!6+<]E21#!X\E?B5YKJ4ZDH0!6@<3C3#C5@3=;]
M='F&FB%L7]D6\9OF8CS.J6M5+^*4GPI@-D0W$MW$\#1`$NVYE&`.+7;.]?7Y
MP`PL(M"_:WK'RN[P;B,B9@Q@RTS6<>MN>WLS15,AMBSX=7\`G<Q`N=C%4AB%
M6+YJYP%F/;CUYK*E*CJZQ7HPLU.F)/.^?"T<,P("M%A&6S_&KQ5<=QR>^+"I
M8IWL6>LJ1@LHU!.K+C,0M=`V1EPA;,.VZUB\Q9JYM%P8XDZJ&U$K?FIP4ID8
MPE@'K1)'P@\J>\;'%]$2>)3>MJ=,;YI!I43-HS+G^Q+3G$B;Y,FIP//B%Q,=
M)O-Y"H7@;:5++CB5.HV:E2MQ)02BP#*+&$/<.\</$BF$1"MEG/L4<()`J[Z!
MJ>)Q=S<Y8YM357O4[\UR>_(U\%?(5(EZ>PI`R)%9IRG9RE"<0#:(Q-Z>F!RD
M`X(YAK9RC;^PQ&:.LJB$5LV#QB9SJ[+OLB:L<1N%)#$%@,#9+9]8LC?T3>[H
MJ]9@$Z+/")OVA"-)L@TPX9H=]I7E*C.>X+/*\JF+.S"QVE*9-.+)<W"=3Z43
MB<S28-+<PR"726R)3)GF?N4E5LC.C2EK1N7SA,0D)"0,OX0/0(GD>'+QWIHB
MQ09/2DP)CL8MU[OR-`!TGU*%XCUS21`YMLAL=CD_XZOK0TR=\(>UIBL\A87\
MX5*SE`]"4&C-$&6);XYN3)M');%'Z&6`)EL%1!S;"*;>@NAF9=/TM>UN.H8\
MRS=X:K31O$ICA]=&";G-O6GG(WKW;4N!:E7_`'1@<OT-Q?"+Q+YF$PO1M1K.
M5I^IE-;BAS`SF-9,1>Z;G]#RRKA,9NDJ!#$'VNK!/(+"GT6)"H1(S2M?N&@;
M##W$WBDY'XIIR/UFP5\SV=)OQ84[6]CV/9Y+Q.%UA@IEB5MD<6)HU/Y!.&2O
M&(+P\NCJ0P,7S1H0KG52,HKW#V+89@LSQ]<@VWJ0;F%.(`'2!JJEJTJB<HG%
M?GQ?\1TIE,UJ9XKK<%DT=+K&4PF3S5U4IW>/!;',[2TPE0><GW\+0='3>++@
MM"_5#(6[GUG;5='LD,CT'0M\ML-)'UC=7$N=K`KT=BQHF7!8;@=81/W]<_-:
M^6)GI<D>EIZX!VE1@C=A_&OQ>\;LB"PR&B&6:@?+140T<QL,GI+I'=NK&RO1
M/`H1%6^X#;8-LUC@\:U(%VB&-$ZD-(MJC!F)S#!;'@<[2?`-+<^WM&[>JQ*"
M(Q2MN5F?DVFZ<96XE+$*SA`K+<[2G[ZD=%"A:_2*3V5(@,PG%4N-&=L3-HX9
MAIZI08()T8#`8#`^?O\`Z+'_``7_`/G)8&[GV8S4_(N1>H&#H-]4Q>B7KG^W
MFJXI.B(5JET;K-?`GY+-7]"F0(G):H7,T>-4*20%)E!@C2@Z"6/>_;L--FF_
M%%Y<>IXFT3&C/(=R'-N+NB>$(!PE'^E1578T6NY_X3B$HD[A'VD52N\":DS=
M9:QHD"UJ6J#W8HU2BWK0EH#]?.<#=CH:GXWSY2%/T/#CEBB)TO6$$JR-JG#9
M>W!6R0&,-D7;5CALD("=KE:1K"8=[`A!\00O;K6O36!EC`8#`8&MNP_]5Q.O
MY&AE_P!9EKR+]YZ7V&R1EA@,!@:XG>7)+AW#2'4G#K@X/-?F]"RMF>4,Q`UB
M4N#*.J;&7V8T*4L?<=H"I"WOAS1\$0`*"!&%[WHDSWB#O7:R73P3G&JQ7WSQ
M]JJ\?7,M'T=S`7S/Y$7W7/M5UK0X'U=3%5H7!Y_%5$F6OPNRQI.NE$X(UCC]
M!?&,3#3%'%C'L&R@BU[=<5+G?(1YRN7?&_\`FO?CGJKIB3@ZP8R9!`38+6[(
M21'$JCZN_";9Z;8$R@H6&3@U)"MG-17SIP2Z*,V<47]Q[PN?*,T:46:'6]!,
M+`8'6_3UUH8="UK?IO>O76MX'G@,!@,!@,!@,#42D?\`UCD!_D\%G^;<UP-N
MW`8#`8#`8#`8#`8#`8'"29`H=8W(&Q)H.U3DR.J!-H8O8#:A8@4)R=#'OY`!
MV89KUW^UK`H]Y!E_E*Y8Y;H#F]9XPHO-E=(51"ZS4R]N[PJ)I0291$65*T'/
M:)K6UV:L;DKD8FV:60:,9A01:"(0MZV+82-_.K\H/ZIIC_G`*8_@XP'YU?E!
M_5-,?\X!3'\'&`_.K\H/ZIIC_G`*8_@XP'YU?E!_5-,?\X!3'\'&`_.K\H/Z
MIIC_`)P"F/X.,!^=7Y0?U33'_.`4Q_!Q@/SJ_*#^J:8_YP"F/X.,!^=7Y0?U
M33'_`#@%,?P<8#\ZOR@_JFF/^<`IC^#C`?G5^4']4TQ_S@%,?P<8#\ZOR@_J
MFF/^<`IC^#C`?G5^4']4TQ_S@%,?P<8#\ZOR@_JFF/\`G`*8_@XP'YU?E!_5
M-,?\X!3'\'&`_.K\H/ZIIC_G`*8_@XP'YU?E!_5-,?\`.`4Q_!Q@/SJ_*#^J
M:8_YP"F/X.,!^=7Y0?U33'_.`4Q_!Q@/SJ_*#^J:8_YP"F/X.,!^=7Y0?U33
M'_.`4Q_!Q@/SJ_*#^J:8_P"<`IC^#C`?G5^4']4VQ_S@%,?P<8%*?^R?\@'X
MC?J#^*6NOK#_`+*G\0GP_P`=D?\`FGYP_P#M%/SEOQ9_.?H+V_0?XL/W3ZR^
MGS+Y[^X?`]?EP-AOK#I&G(O.J>X>FDJF,.MKR`1B_JUI201F(I)*C9'&%5:N
M?I8_.JEV+4L"!2R,KCI2A)7)U*=:I+T487LOWX&LOQ_X2FEQ=>@.9N0_.UY,
M*^2\AVA^+FUZT@"N359!81/Y4VZF!R.,M""1L457)G$A5M0::T@$F^,(7NW[
MM_*&XK6\47P2O(%!W66/\]<X;"XM%'*=2H_2J431?'6-"T+)9)%.MBTH?Y&H
M1B6+!ZWOWJ#A[_;P.Z8$7.P>M:XXNILVW[%:9E+AN<RA-85W6M:LI,CLNV[9
MLR0)(M7M8UZPJES6C<I3*7M8$!6CU29.226:<<:`HH8M!$*S?*$]TY6=*JK%
MX@Z::.H>C;4EE4TEQBU.M(26VITLA$7/G4IFA,N9;2552TU\P0U,-6M7JWDH
M],9Z%"3_`"^_`EKQ5U_6/=7.T,Z/J=!*V&/2E;*8^[PZ>M9#).X%.(')W:&3
MB#S%I2+7)(C?HU)F12G,^"H/(.+T`XH8BS`[V%,3#\GVKB<_^WPSLV_VOV/S
MF6O7_OR/YSTOL-DC+#`8#`K'ZF8W^37XQ,,8*./?W"*M9+840K"@.V<`]Y/'
M\-8,X@)'H46+?K[]?_USMHN-.;N1JVU+ZD+):)&TIX`:I7#F]?L+8TR],K2G
M`"2XMOJS*PE+QB&2Y#+6(A!&:`8]"WZ"]?NM9SU2S;X54JM;S?>/>(^13GZB
M*XF/2<.YB05OU56%H$2^<IVI0SRD]$@DL<-@C:%WD<9(U+'M'(##&L(3S-FJ
M4_P]E""/8@2U<N@/2*$:<U"J(6I/AZ+)5)CBE!)NB=[)%L)I(A%#V$9>]"]-
M_(+6]?M8'N8#`8#`8#`8#`U$I'_UCD!_D\%G^;<UP-NW`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`I!\N'C7ZR[9M+BV^.,^K(
MGR?=7'[S=3HP3:30+Z^'&;N"*1Z'+3&IO5IW-DT84PH%R8X"Q$H`,M=[@;`,
MO6\"J:JO"-Y[*0F]X615GF=JN)S;I";HK(NM\(YQC;B;.ILW,Y3`B?5:1YA;
MFWM!I#00`C13<2D3["'6]E[%\N!MQ5LT3"/UU`6&PY01-Y^R0J+-$YFB5M(9
M4TOF#:QH$<FE"=G3!"F:2']Z)/5@3%ZT`@)N@!UZ!U@=UP*@O-+QE97:7-E+
ML=60=);3_0/8=!=./%)*)_NJ5-X0>M%4D:)U5C+9(G-C(A,AD47F*DQ"O-7(
M2BE*8&MJ"O=H>@I_IOQM^0SF>4<V=E5QS85)#N>NV.RK-JOQLK>H8HYR&FN6
MNL:!C-.$0V,WK.7YRK$B4QJ6184B4LB9W4,J8IQ,*1J3CMF:$%R'C>X4G5/^
M/*9<Z=1@0L]B=*RKJ.Q[SCM:2M0J1P)5U7-9K(7B$0^<I24QRAQAT8E)*/Z4
M3`T#Z2),.3B&7HL8LLS,"F+@#A^E?'W]I+GU!4(KL5;!3O$X.?&G6A.W2Q)+
M]/R'H>&-+@$I_>`@5DM04D:3;*2ZU\(HS9@@ZU[]ZUS^,GZ9X7V&X5G4,!@,
M"#-X0FW1W<Q6+7,5^FOH-A0$I51YJ#:/2X(G8H\DU.H7HSC/80LUOY/37KO7
MR_)G33=/QQ4W.<Q$1+8=BUG,+$E"<U&P3=4Z*$4A(/0HEJ8E2Z.*YT<TI:<X
M2A.7H"]&#8-A$+T#KT]=^N=,2S'@G-F?-ZGE[\?T&\N'#$PI$N0/#C=M3,CE
M<-/L,8ES-$FY3T254TR9ZU9;$5.S,[I"(:[O$B&!4`.TH@`W[]'EZ#O><+,>
MCHRSX2.8[IXX\6_)7-_1#$FC%S5S&)Y]>(\ED#9*0,JV7V]84\;6TY^9E:]H
M7K4C%*$H%/S8\\@M1H98#!A!H6\%J>`P&`P&`P&`P-(#R86+UGQ5]HM8^\JE
M\>W4G9U>,'&\=K3YO3->62?'E;W)D,P;%A8;"C58V(R%+F#1Y9AZ/X(CO0P.
MA;!ZZWL)(_TECNK^KK^0S]Z7!^B1@/Z2QW5_5U_(9^]+@_1(P'])8[J_JZ_D
M,_>EP?HD8#^DL=U?U=?R&?O2X/T2,!_26.ZOZNOY#/WI<'Z)&`_I+'=7]77\
MAG[TN#]$C`?TECNK^KK^0S]Z7!^B1@/Z2QW5_5U_(9^]+@_1(P'])8[J_JZ_
MD,_>EP?HD8#^DL=U?U=?R&?O2X/T2,!_26.ZOZNOY#/WI<'Z)&`_I+'=7]77
M\AG[TN#]$C`?TECNK^KK^0S]Z7!^B1@/Z2QW5_5U_(9^]+@_1(P'])8[J_JZ
M_D,_>EP?HD8#^DL=U?U=?R&?O2X/T2,!_26.ZOZNOY#/WI<'Z)&`_I+'=7]7
M7\AG[TN#]$C`?TECNK^KK^0S]Z7!^B1@/Z2QW5_5U_(9^]+@_1(P+TO&5W);
M?>](RBU[BXDO+A:0QZPW&%(*VO4EV)?)2THF1C=BYFQ?6"%5X]C9CE3L:CWL
MUJ+*^<)!Z+.-]!>P,KV/=?5L6O-C@T%XP4V92;LY0MB67DFOVN(JKCZY]7)E
M,NDSO63TD$^BKV"QKYQL:E*J4/;D]%%(T[3\T.^DBPK%?O*)V*CYAZJNLGGR
MMTTEI3R$2+D=GW"XW?\`T+"8'4%;ACWXX+WM9MJ^+MUG2QMKI46_(U@H^T)4
M^E:(D(0B!L0Q!,--WI%I'R+(;#A?5?#KG>$*HF`7E/YDM?)DFH"$0.>(625M
MMF/D-`^CME!#WF!NX5;,A6*T:UR5&D$;.)V;O80K)B'F4[=?J_JN323G.FX%
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M%HSIA&UQVNEAO)Z$[I*4<GM:FU%@;)"URA7([AA3N4V(88?)ERUH;5+@$K1`
M->\.<DGF^YIB;M9!#U4_1:6,0MIZ*4PV>?4^'&QJ]'WE_HN'<NV=&:>+)GQK
MX]*#+8L)F0M"YP1MC8[&*3"B%&U"<TK0=(OSS-0RL[_88E&8W(7*JZQD_7T2
MZ")##3'ZR)W+*#<N=Z>KV&<]M[=*$J)Q=[&Z5Z6:HRC,<@E`5*V=R)V%,60-
M6`.#DOG.0IGZ!M,0X?Z:>Q:DW8;)?3,^.5)QN64X@XD@4.>KM=TJ8^UE,0F*
M",3JQV5G.4EO25(:#YT8E-4GEE)C0[%3OFHKA3#J866]![)=4$L*@L-M'HZ&
MUHU0&AH)?=A\Z+>L6>EUL1EMORRTD,D9J4*).>ST8'QG8W$XM,M<2C1C`2$P
MN&?(O7/>"^QVV%5%>U1K*]@M`V>%)>$7C,872FO.DHO)I364G944=F,M/1A7
MHH<OV<C<M(EY)/S8_9/PE10MA83@,!@8AZ!N-BYXHFYK\E#:[/,;I2K9[:S\
MT,1(5#TZ-%?Q=TE3BW-10]A*$X+4C6,LKW["7H8M;%O0=;WH-9:G_++]H(Z<
MK&']`<^^&BF'*DK79B9C5CI*NHHLW/KQ"G3W&L3NK2.\LB#CL#FDT$XHPQM1
M:/*$$P!>BQ@$(-I.MW.:/==P)YLB-HH=8;O"XLYSV(-KD6]-T5FB]C0JI3&V
M]X)$,IV1,;X:>E*4AWL)Y96AZWZ"P.Z8#`8#`UMV'_JN)U_(T,O^LRUY%^\]
M+[#9(RPP&`P&!!2D4R=5TU?9:D@E07H;F/0#R@'`T+4C3ZT+03`B#K>M;W\O
M_MSIJ^D3-]1!Z]?)ORWP[Y0)\DL=GKRU$?+U[3>KGE@F*$,TC\D8ZWLEZBSX
MWE^X*QL=V]:K1G(A>W8M&Z#L']KK&J_*3'@28J&GA?\`+55B+P.1CKWJZ[;)
ML-PY-.E];=.V!)F:83>?ZE?XR-GP-JTL/2J'*=J38%8T43%KRSCRP_$]JH\!
MA*@0.:EZ'&/85*]Z\Y0+J?GIPD#K4ED'2Q/&%THCRR+/9QD+F+]!7SYVR+A"
M4I`EO\;5!*V+>]&E:"/7R"U@2DP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P.L/OU=DA3[7ZU[^`X/,86:<6QEDJI@ER2//05;*)Z;5C&X(),Q;
MV=\4M*Y)#"#2%1?N)-":#6]!7VT>)?C:.U0ZTE&D/0<=K21SF=6#+X\T=@]7
M$#F[W:)`2;,1S-Y-N,]\D<>L`SWJ'9N4J1I52P\]3L&CSSC#`S!?'C_Y/Z0I
M^NJ#LNLU!-25,^U[(J^AM<SBP*=0QQRJ9OVVUD$E34\HAC@L;8(GT6-K0J3C
MD2-2G3GEE:.3D&%AT1M\=/%>KXBMOZCD@DMS56RU8?ZR>\;5G!ZQTK=MF+#2
M]I6C%91/'M'85GPQK?WI.P2N2IG!Y)]Y@B5.S4Q0R0Y9D\>G'"B24O9C1"5;
MR^TTY2"0Q&2ZLJ=/9<LD\@G:"R7>7V8>.4*DMN2@-HLB=_*7/_TB>F>4I1Q8
M@B(*T6&.;A\<O/UU2NQ.DZ7>$<)Z,L$[ZRQ:W1/LWM6H(K=+1`C*1;>A4_/B
M>S8Y4,DNZ%UF6>Q-CZ844N0[)+%LS8R=Z$'#V!XKJRG/-_!/))5C3N,T=P]*
M*NDY"2+N;U$K!LE72]02RNJZ4[LF$R**R.`O;7+9$GE)R]L$(XYQ;RP:T`(]
MCT'O(?%=X]F^01)RA];H&-VHF-UO'-1=MM*PS(,K/JB2/]MTV^7]6I$[*C5O
M22"SV8+Y4WN$P3."\YS7&+C3C3-@-`&(J"\(G%4$YN_%#/03._'J;5O%XK.+
MF=[1M%M>WC2"VF[HU6_U!IML-P+H9OE%]-Z:8GIX@J0%JG9.G//,/$26+09.
M'XI_&P@9'"K4U<ELBDQJ1-0`)KVM<FQ6,^4="KNHVJ1,TG5V.?.&:;/E^L9K
M\E?"E(7=4>V_-P*!I4NB`!VHSQ)<(?03!&DM4R=L96&&]00`:=LNBZT:R2Q+
MLM7])='-4X?"[!^GYMNQ'@(%QBAS5*5*-:24<E,)&47L(>,B\4/`KG)Y]-9%
M4ZT)-ALLN9W^,G6O:3;6C<Y6'4"?GZ;SB)U^GFR2&0FT)93*<$;529J2)'S;
M<(T):D!BA0,T):T_SO2E)/%A2NIH@CCCI;BB`K9NYI7=Y=@OA=8UO&:FKY*E
MTZN;BF:FB,5_$4"%*E0A3I?N##Q`$H//-,#-)JU&0>2E.5IB5*GU^;IS3RBS
MU'M_MO@DC'HPWV_M^W6_3`]G`8&.[>CXI;4UH14$M30`<FKN:Q\$[6-C*](X
M4)ZC3FVAEJMGDG_=YV31O:GYX8F7_P!Q'A)V`_\`<A"P/G9TI..1Z6?([Q_2
M/VK_`*:K2)1MX<(Q$BH[S)84?Y^8'!R=5:]2A8)X9.RX,RQ4YZ7&B*5$J"6,
MOXFQ%G`)WH6!]%BL6%SBU:U[&'N;+[+>8Y!XFPN]CNH$Q3G8#FT,#>WKYLXE
MHS3TA:^5*DXUYP2AC+T8?O01;#Z;P.\8$4^R.Q:JX<IXBZ;>:;&D,?<)]!*Q
M8XW4T(<+%L"33FR7TF-PZ/1J'M1I3B].3P\J`$%$D^XTPP80`",8@AV$7Y9Y
M;Z"A%'U;<<HICL=FDUXVD_T]37,SGS).6SJ^S)G%VQ<^OVHO2+I\R>AQ]MCS
M8>O-=%1R9`!,#6Q&Z&,L`@F)RGU-3G9]$0?HRAWQP?*YG9;P4AV]LR^-R5D>
MXT^N47E45E<;="RG*/R>+R5G5(5J4X/J`XC>P"&6(!@@I`8=;U]JWG&]ZWK0
MO#.R[#O>MZT+7YS38'UU_9U[@[U_].LB_>>E]ALCY88#`8#`K5+>9Q4W33PH
M$QDI45HS'Z+3*'8G9H5L?62%+\5>U;2K`;*-T(>M:V;K>M>ORASKB71Z1.V:
MO5D2QZ0YT99E'2YJY/\`MRF+P,XMC=RMRQDDXSW1-HYJ>$;HT.R,3.><KT0-
M,;O1`B#-AWKVZS)JUV7&XLF>+O727-#%:/'72O+]7,$!KX-TT1<]81Q,3'$+
M/"6:3V5`9!&&Q^=&=@;@@^:HGAT)4J!DD#/V$KW!UL>M9S4B_P"%KB>T?'AX
MVN=^2;H>H<_V;6@;+7RI?`5KFYQ0"J?VS.;$2M[6Y.[6RKW#Z*;I42F..$E)
M",\H>P!V#V[V%IF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!K2
M]"57Y!C_`"BV;U-0#?=$<9D-K<:\S1:/HHM%M5?;W.M2TY=W2=]/MA/<EC3F
M\HZ_?K&GP(*T+&MQ:/24K"SAFJ-I2P$!&:M;D\TS97,GZ'`T]Z6BXU^T^/VQ
MYGSS9E"UI6CW:]NV7=,I4=Q4QS_%#8''90TTE6,!"RLJ`]T4G*4I:=6YE+AI
M5)9X@D]0Q7E_<.Y:;J/HJ[+5AL'JUIIN8RN3Q+GQRF%*="CE$#E%H]%P]WM1
MD@9541AM8[!D95?,0W-\:I`TMT42K43:M.=Q*M!TBS8CY$:][_ZE[,I:-=&)
M6&6WW)8:93C'6\>>H!;/-O&WCPECM#WMV-<HTX3-Q=[DZMFY;)`BFYQ1$#6A
M<3=$*?G'Q"@B77'1/<-&7Y1O'C++;C9;*I5%'VA7S-1]44TWT7/:)I#QXH^F
M+K?C"(Y!E+D.]KK[$?-Q%(A9#FT+&C+(3#2%F.10SP_6J*W\OO$7-D:H:OW3
MI!;5Z9/PG"IP]E4L=.Y)3;U,J6N2].M%W/\`':5JR46<Y0/5GO$-@3@[:;)2
MXM[R>Z+AFDC`:80%K/-,.\KSI-Y](9/>$@F9//\`7_-=45*QW]"47/\`4?3\
MT>:C3RWHKH&QV>&UK,+3"L:'>>IV%E;$"QO0D/D</,6:,,^(`(5>JV?R=HK=
M\DMAU%5W4R9PZ!<.[%DUJ>=\_,&J->_IQFIGD3@Q]K)RET/4.ML2X<<BBF8O
M9>G%0R-44;SR7)`G^>:&L#-\L-\R5-#G,PH(JZW&+UI%O(5&:2YJ!2M;HZ:C
MM0\Y0JOJ.Y$*98PRP%HE$FLNS+#"MF\5;BW,M,Y1IN$D3(-IC=>\(S'U)Y$V
M1VO.\*ZJ[K:Z;">;%LV<5+:/5-`P!3=[TW\E<1[KCD)P5Q4%>,3972J7];=>
M2A^8"B&QM?D<?9'`E6+>TR\(P[KUOTWY%.'8O9S5=W2W6#A3R2W>@W2'W@AK
MFD6B^)ZZ4!QY3KU$([#&;5<?52,<WWCUM-'L2=<)E7#3-<:+;!KO_C!)AX6%
M=B\N];=<TQXB^99L%IG#T)Z:;N[1MBVZ=%:=*BF50<SO7HPV]6$9E=5-[HV6
M1=,_!]&-9;FWDZ.;??Z&`3#+&$29[>G;7+-4SBS6E)TQ"9U27>U!\VU3Q`QT
M]`JFY'L3F1QZ>C]'TQ4_-$EDL(-(F<JNFK$I#HM>T,I7%L1KYM*?I/M$2'`P
MS<G`WD$O3J2MICT_'WZW4L"FWC<H6SK<BM8:(LYG3O5D6#U#?MP\=VD@6M*2
MK*UJ*R9PPP&4.I3`I<G>%-!H1+$R@@X9P;E>`P(\];T^^="\K])4-&)`"*R.
MZ:)MBJV"2FC/+3L;Q/H(^Q=M<U0TH#%.D218Z`&=\,(C/A:%[=;WZ:P-+]PD
MG;1'CA%X>C/L[,[-O(-)E\W:OA&RQ)1S8*6Z8P0L'4!=GIX;MFU*QK_22;5"
M?@C`[;^,)?K6M@P-T/DJJI/1/+'-U)S5^!*)C4-$5-6<JD11QRDAZD4&@C#&
M7ER3*%("E*A*K<6PP90S`A,$7O6Q:T+>\"0>!6_Y3*XAMH<R-['.^;^E^GV%
MFN"L9N7!^1IDV0>\HN_0EV4R.+69%7A=859+1_4V2-Z4P1;<Z!<0C.`<46()
M0Q`"@:J*$\H-/K^%>X[CHOJOI*-\G]G]ZN%=\PR^QX%;'<$#XLZFHR/U?2P)
MU)GZ;HH_/YS7TJ9%9ZQ&:]J7%&V.8`B4;`6,"<+BO%OQU;U;>.";T]?J60T3
M:73<ZZUM>41R%2=L/FE#$=0V!.9"PLC'+6;:QH(GL$C,B1G[4)=G$(W@(@@V
M9HKW"7;,"GWQ[\=IN'/M(T]I%+?W0G219GB='-=V-TS/-6-90!OG0L+:Q1TN
M1Z0-W_=IMU']'I4_POW(Y4?OUW[\Y33C],^<OL-Q'.H8#`8#`@KTG_X[4!_\
MS1?YS-V=-'UU>B;]H[MU!'61*&&6L_.CJ0CK]Y0:"SM#>B5JG8Y:[H%!8`GK
MEZ$E,$'S+?NW]UOV[WO6O77IO-%OUGBVO0[&.FEB\!=5FU&VRL^Q)OR#>WXL
MFB*B4@G!\UD--RH,,;XV)H/TL#*C7U6F+1;3&?%TKV#X8O=Z;R;,7#6MSX<?
M(+<'C/\`%%(VORP<Q=(<T5WQ_(8[$8C<ECM4GDDMO11?%I3I\;HU'8"\H4<F
M;]5@2[)48C0J%#8%M"5H)A)A?S<6#;JBDG9)M%XW,XRMTY1R7,#/)X^XZ)/3
MZ7LC^W)W5J6Z3JBB5)&E2!66/V&``8'W>@@ZWK>L#G\!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,#TTSBWK%#@D2+D:I6TJ2D;JE3*B#U#8K/1)
M7(E*X$E&",1J36Y<2H"`S01").`/6MA&'>P]S`8'06BJ:NC\YD=GL-;0%DLJ
M8I$R"76&T0Z.MLYE*%&%,!(BD<M1MQ+^]I$H$1.BRU2@T!>B0:#K7M#Z!W[`
M8#`8#`Z#-*IJZR%T5=+$K:`SUR@KKM]A#C-(='92NASX(286WF*JWQN7*(\Z
M[$C)WM0D$2=ZE`W[ON0^@=^P."?HO&I26V$R>/,<C)97QID[,4^M+>[EM,E8
M%05S%(6P#@G4!0/C*M!HY(K*T!0F-UH98PBUZX'.X#`8%8_;?,#&]V,F[>G/
M9'1_/=9\W<N=*QN?P*LIB>S5FXQN85O,$SM;CVQIBCS54^K!`XC=F<\!1YNG
M%J;Q%Z#LC83@U$^F*PXPY/BG-$FM/SL^>%03U/4;9T!!([$9Q/7V6Q6BWA*G
M6(+;L^*B5(W6'1$X@T0@Z$6>X#TG/V!,+1)FPAOG4.&/`HZF@1*?NEKQ4%4U
MX",VD^.6WEZLJ/AB+.%FGSP[[`7MU=)BW:+<5"G80[/.4B'Z:]WI@96P&`P&
M!K;L/_5<3K^1H9?]9EKR+]YZ7V&R1EA@,!@,"OWK1X*CEK4Y(5"<]4F8@B=U
M!"?VZ..);WY"I,**$/\`<PF&`+WH.Q;UKU_9SIHW5-WRLC3>PJXMVA5\KE:*
M4M$6U(-)0HF\:?;R>ZM9HOF97QDY#BG3I59XO:(P8=A+UOU%Z:UF26:L3>W,
MLX,LT++VN:5C'W!F:E[.V-@#(XC1NBU.X+M$,'L;BSE"I*0F(,,.`5K>_:`/
MR_M9FJ8NW>V;E2'VC#C[H7N3Q@6/0_+\#_&9;:VRZ@E+9#"W^.QM6ZM$;F*5
M0]C0N4K=&5B^<($1^U&RSE1.QDE#]FQ#T$`I%O=#Q)Y@%'4U!)&4G(D,*JFN
MXD_$I5`5:4IZC<09V9T*3*@:T!2G+7(AZ`8'6M##K6]?LX&5\!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@1]ZKZ:JCC?GBVNF[N?BH]6E/0YSEL@
M4[&5I:Y&)@!)9XRQD&C!I?)98]GIVUM3:WH2A<J*+UZ>[UT&D)]F?\U<QZ`\
ME_9U6=)2!,W+/(#,G.^ZF0*G`7T1&;4A+7]%!JQ@&L-!ZI5M)-*-$AV+]U,#
M$4Y.M",.U@;_`+@,!@,!@,!@,!@,!@,!@,"._7:.FG#E/I5#T4K.;Z"5T-;:
M>ZEZ;XWSM#5AL#?@3Q8A^;$*E.W!+&-J3$^BBC#=G!#[`"%Z!V&DR]M/CU\;
M--/#O;G;W:70MX>2OQSME-419TFYA26-.N.?&RZQX+6WOLIJ=7-F$]LBWU8$
M$LQ2-9I1LQMV<4UAT!7H\-VKDJ&5M7/*_-L!IN3"FE20RAZDC%8S(1GQARZ`
MLD"86Z(RD9GM+T,<A84Y"S>]!#KU.^36M?)H)"8'4I]/(=5D&F-EV'(FR(0*
MOXP^S.:2IZ/^;-,<BT9;%+R_/;D?[1;*1-C8C-.,WK0A>T&_36]^FL"MY)YG
M/'XZ<P5WURP6K+915-OV2^U!4[7%J<MN16M9-D1E2YDR"+0ZG&F&JK*>%C,0
MS*E*DT+;I.2E)V8,S6A`]P3=YNZ0ICK>E8-T)S]-4=@5/8J!6NC,E2(W)K,,
M,;'-:QO36Z,STC;WIB?6!];%*%<A6)R5*16G,+,!H0<"BAA_ZKB=?R-#+_K,
MM>1?O/2^PV2,L,!@,!@8\M=.G-K>>FFIR#3"H;)=E&&%%F#+W]$*]^H!##O8
M-^NO7Y/V\W3OGJ(X\TDH%/-#ZG=6UQ>6P\Z;$N+2T!-&ZN:(Q-[%2!M`0:0<
M-<K)WL!6@#`+8Q:]-ZW\N5J^Z=/U=7KBUY!72EKBNJ;7UY57UB5;5R63&R8.
MFA`Z+#=EN+FN>`&ITZA0:,H(@"-^$$P?M#OT],VZ9?'.H^2N;[2GU%<7._B0
MGUU\O7%**MFJJSZ4:&BR*U?!L[^!A?)H0%S3L[^AWI6C)<R4VBCAD#`(PG8R
M][V6,81<U+//'3U5%>U^)^=NE8>X25W;+$KYO"O=Y:P;C+V[2N*'*(9-W(]I
M_P#NBTRV8Q]<8G-*_<#R-@,+]`"#K`FM@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,"`G=O`?-G=T>A[;UV9/IG1U2+UUAK:1:YR[PJKYC(VI(8:C
ME%E)XB)FE<M'%FX!X6]&-V);2?G)XS$YI@@#*#1H^S->*KF/R#Q+LJ^9ZWSZ
MLK`ISI>LW#E6YZ8FSG#IK2,A94\JFNS8J6?IVBCT0@,6L8]IWAL7E;`G!H/L
MV+8L#Z/S(E<D+,THGEUT^O"-L0)75[TA(:]/#BG2E%+773:F&8F;_I!2`1WP
M"Q"+*]_L#O>M:P.4P&`P&`P&`P&`P&`P&`P,/=#0VKK$H.[8%=ZE*BIF9U+8
MD8MA<M<"VE(WUP^1%W;IJX*'8T(BVHM!'%"D[:H6MZ3^SXG_`&<#1MX&*\;"
MJJ_*DL@79W=UTS"-^.E94V^K;_YP(>05-X\&P]3`E3;SS"%4F#(9RS)FI`+0
MU*I*SI@E-H3R$96R%19H;MG(L3K.!\I\T0JEWX^55!%*#J&/U=*56Q"52:OF
MF`,"*'R)5L8"Q?.7Q@)3JC->T'H,W>O:']C02'P*PO*SS!T]UW1->5#SDYT@
M)F#>];SJ^X!?;W/8W!KIJ*O5RB6;J!W>ZZC,JD*:.RR=-C,-Z(+3EZ<&E*>C
M$9HI0:`8:WG+E%=^<J&<'=;]%\@3N20GE/R$^4Y[G=/<PP*;3^W$L4Z_C<GC
ML=MAIJA[;V1U?H(U6.6>!C4MFC3A1EP3*C0%C&8'`O6\37+EW0?QG3FN[*33
M?EZT^E+"["MID9B/F1%F<X-W2-D3U_KS6TZ8\;>UV#"&-\0NHD@3-:1.._@&
M>TPL>M+NP*G/'WS'9?)/VD:>5-:_6=T]G2H?B=.E8;@OE0!5-TK4\]%0Y$CA
M*<X+FZ^Z/,AS.<J3^XW0M'N!_KK_`+0N>/\`9GA?8;AN=`P&`P&!T*T__#.P
M/\C)+_@=7FS?/40IYLORN*^KI%$Y*X.)#R-^<5&B4K2L6$_"<3R`I=[4$`$7
MK8M_LZ_9#^WG35HU6YFY,LQA,*Y(.XV57#_#FA:B0+GCZ*V0K<-'[1EZ0NZ!
MR,^+I,6:=]V4DV$/H'?W6]>OR9STW%RJ[E9O1G7<8YBY.N@B74>BN11S=54_
MDHF*1`;CX3+7ZLF9V=T'QBW5I<3$;:K7H0>A^TXSB2Q;$$/NUK+NG,NO.QF?
M!E[Q$]?J.\/'ESGU$KJ^*4RIL1DE24VMH*:,R'1G<+GLI@X"(V`Q(B,2M2PJ
M.!4%D;!_<_Q=E^X>@^\7-JR7`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8$"?*7=A'.OCA[>N4T_YNJA?,UNFL@_>$OW2I[A[G&X>1H8_D")5*GE&
M5K]G?J/Y-;W\FPI5^Q]4WNMO$:FGJA$-.KOWHFW+%+4&`$$2MJCH8Y4B`18A
M!UL2<"JNE7M]-[#[A"WKY=BP-J#`8#`8#`8#`8#`8#`8#`8$:>S8;6UB<B=0
MP&Y)PGK*IIIS];\6LFQUB@E(E@,'?H"_-DFF:A0H-(3EDQAH4FK1?$&$&]$^
M@M^F]X&E?6O!/G2O-CVDI:0^/FPN<+W\<U<^,V-=G1&5OY48=^-8?*I8K;+,
M8*\$K#($EG/<2E:MN6A+91(@F!]R8HH_7SO8;OW-],-7.7/=&\_,CFI>VBD:
MCKJIVYZ6$Z3JWE)7T2:8J2[*4^C3PICW(#5\<9>AC"6(>PZWO6M;P,T8#`8#
M`UMV'_JN)U_(T,O^LRUY%^\]+[#9(RPP&`P&!ZRQ&E<$BE`N3DJT2P@U*K2J
M"PFD*$YX!%'$'%CUL)A1I8MA%K>O3>MX%??6L)B$2(K(V+QED8#%LF5E*S&E
MN3(1J2B0-XRBSA)RP;,`6,>]ZUOU]-[SKHMN<LONL+!_:!_^J'_W:SDU!'R3
MU8Y75QK=U0-;H[QLBTH3*H'(I*PI=*54?C,IB<@:7I\6$;,()/:VHA3H]2`X
MPLD98-Z$(.M^[5:<6XNYE4R>+CR9^&?QY<-\_<;G>3VE+&=*I:'Q([3(]HE<
M;1N;_,IF_P`T=BTJ,#(YHT+.U.<E,2D&F+#=#3D!.&9KW;])K5T/3_DUX'XQ
M40))T]U+5U1*[0CYDL@"1^<ES@JE,7+&27J1MJ>/-SR<)B/,/"$E6,("#Q:%
MHL0]A%K0>WSAY)^#NN(Q9<SYVZFJ2R8K39+4JM1]1R#;"WP!"^%N)K0YRDZ5
MIF'Z):'$+0JT4L,UI*(28P/Q/<`6M!-5"N1.B)&Y-BQ*XMS@E3KF]P0J"5:)
M<B5E`/2K$:I.,PA2E4D&!&68`0@#`+6];WK>![6`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&!JA?;".EOQ2>,!DH9H6G`EO65W0R%`;4@A:6+8-7!P;*E
M1Q190]'G%:D31'T9@`A%H85_MW_;:UL+U?&3S>+D7Q]<?<Y*4>D#S5]"P!JE
MJ70``]D]=6<F26",6B][!L9TW>G`8A:_MA"WO]O`F;(Y+'(>RKY)+9`R1:/-
M97QW-^D;J@9&5N(]P0?&7NCF>E0I"O>+6O<88'7KO6L#W&IU:WUM0O#(Y('A
MH<TI*UM=6I8G<&UP1*`:,3JT*Y(8<E5I3R]Z$`PL0@"UOUUO>L#W\!@,#KJJ
M7Q)#)V>$+I1'4<SD+6[OC!$53VVIY.^,D?.;D[^\,[`<I`ZN;6R*'A(!8H)*
M&2F&J)"8(.S0:$'"--J5@_3Z4U4QV-!'FT(.V-#U-*X:I<P.$\B#/(`[&Q.L
MGB*1P.?V%N>0:]R4Y4G*+4!]-E[%K>L#ON`P&`P&`P&!@3JK4=WS!T?];WUM
MB\3#0]O#DTG>8838S1&V`%?R$;Q('.O5!9I$Z;V5O"8I.9QA$%S+*VFWK>C,
M#2EX8Y@N1%R<ZN'%'VIR,-7,U!5JLMJ51!LH^,GK*`KAR2+)BXF2^"RVTWB;
MUDU-NS%/O:CR22D2O1B<LK1OJ#8;9GC:[RYA[MH!I?N<NDDO3*VIFZ,5O;4Y
M4Q)]KV5.4]:V!,F6RN1P*2-3,YQ\N?GH#W1+LLH:(P)AA9)HMDF!`%A.!@3I
M#I^A^1JW';?1-B-M;0/Z=:8LD=5K<_/J]YE#[M1]#1J.1J*M3[*9/('(",X9
M2)O1*5(BB##/9["QB"$:G+RQ>/!KYJB/7A_44'4\_P`^F)U=0J8M39,7IWE%
MA)C%P%D$9J[:(RMLM7,4`6T\U2V:9_GB9.7LXTL!/W>!+JC[RJ/I2J85>-$S
MZ/V?4UB-6WJ&3B,*1J6A[0%JE#>IV5\<I.K2+$#BC.2JDR@HE2D5$F$G%EF@
M&#04&L/_`%7$Z_D:&7_69:\C^<]+[#9(RPP&`P&`P(-]K?\`^+5'^53A_P#V
M6W.GY^+-6[_E.(']J'_ZNO\`W:SFU'+J>0R6.54>JBYII:U:]M[4L++;4SL!
M6U+TR\M>B4H%:1:G/2*2PZ"8$1>];#OTW\F]ZW6B2W%W,N<;%:,6\5'A$4$1
MI*\\2<=!FRLACTXMAU:LA2C<E5DI#5",QNV1I*`P;B;L.R/9HK7K[/;[?DQ=
M-SNV&4L.IN4_&ETE((FV]:49SM:<DJ]GW&8<18L0:'%RA[`YZ1JP1]I'\V+,
M0LQFBB3"DH1?`+W\H`AV+?KDENYN9%-GG)Y1XEXU\+'D0KSE"C:AHB2V5%:,
M?Y/'ZLB:1B>I<BC7058JDBYV$W$"6+VUA:=.!P=&#V0F*$H,]`Z$8+;%QGP%
MS7B9*4$>+KQUIU92E.K3<2\PI5:=84>0K3JDU-0XA0G4D*0@/)/(.+$`81ZT
M((M;UO,%@V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!H;=O*=^8W[3WS
MCR"R;^LG.7CF)+D5L[(,-4,@WN!N+38]O!6B+T,!>GR=@B\#4@]`[TI2#]1:
MUZ["&^3@:^_DX.BI?D+XV>.Q*<LZW^`*^H&^IDQQB(478G15>R7M]9)(0Q5V
MT6E65?1>9E.KDW5*:^FQ$3TW#0%O*HP1(P'A^(6%2T)G'D3X#IMWJFN:/Z8K
M(=Q<B^0:^^8>;JLI]RGT>IB_>J^N&Q)S76DC<(_'I1$JW4\FTTIW)W!I6KDS
M8@,>%*4):DX(2MA?/PM'^MY3>/8%T7K<W0;O7]+6>Y<T\YT+*&R*PF!6`R5/
M2]/1V?\`0+N(V$MTEF+I:URLSZJ9%_TB6SI"CE1I!1A:D'P`UY8/W[Y-IA^,
M.7UK<'6\JO:/\,R._NFZ5DM&)1PCG^W+OZSB%)19'S[3BBK&>=39FY8H<F9O
MA9!:U];90YQLE3HQ8,2TO`DRY="=VQ9D)9D5H>3.1\%6AUO,RZUZ.*I,Z0]Y
MR:J*GY$02XB&,+270Z9Z@L-Z0ZU2JV^./+Y$4)A+.WGDZ,3(E9)VPF?XLX9U
M/.^GZFOKLPNR'>Q:3\2=&Q>7V/:D4*BOS^\NP;BFW0UPQY`:G8F"/%N=506!
MQ!A<R$916VW8=)SPA%^R%-=)/'1$.@"R]H=;7?+1"O(TN\@'6+%;'.]7LMJW
M1<M]0>X=4IPCSF;.HI1DC#6[).J@9R)4XFN8$3$]#2)""CFY(0K*-#8,X#:O
M(!;/3,XE_7UN7#$(US#3?(%4&5&PL45BE-7ITV\<N(97U9:"]R^IYCQ-8FR6
M7906YM+9'-,S`=V40M_%TF`4$+Q,!@,!@,!@8!ZNJ%\Z"Y?Z+HB,R8,,D5ST
M=:M5L4L,`883''>?P=\BS>\J"R0&'F)6]4Z!,-"6'9FRPBT'[KTP-`:9>-;R
M7FMJ:BZI\>/$U,665Q&\>.JP$%#=CT:Q3F\"9?(H$[N_6%HP[3P!_?F1KU7I
MIZAN<`!D7SQV$I-$<21LHD-D3PPT;U4AZB[$Z;Z"XC8_'['I52_)_-<:IM@D
M\5D2&PY7SNV6`DF=P)S8@WM+>:QK-21*B:50R-B.0:"6$X_X(S1!L9X$$_(M
M:B"HN;7*0+IOT-4WTI*H]'DMU<R\^[Z6L>G%"L#@XF38ZN-5_:6RXRJ0M9S*
ML<OH%?\`-!.Y0?0O9FC0!J<<C1Z[.;T/C@Z_NWF^_#^6.;/(;Y.WJ0607SW9
MZ_H.Y8/U+3Z=JH[M6[>;V9',)S$Y))IX:YMQXD+>40A(VD$G3DEG%"/"^[P[
MT)=T7\7<RB[BBF'+L_Z!LGLNV*>:Y3%BTLYY^C-^VC84@IQR>("Y#)3MC]'6
MUY1/NV4_X7PAG:(/"69\4(<N[B*M?'W1'1_.OVDB>5YU-UN_=IV>+Q.F2`JX
MY%`&*M%Z:+N70\,2-,)!&HZM<&X25D7-BQ4%3LW9IHG`6A_VFM[YR6?IMNS%
M]AN'YU#`8#`8#`AOVA&5;E`664IUA"<F&O`3U!`]&_.%(GP]O:DVTI@->PL:
M8\6C!;%Z?<Z^3Y<Z?G=N$ZMS/E,N"YUJBO')S6*7!P71)E4K%RLX:A4J4&HR
MQ&GGG&;V,TTP6_78M[WO>\B[+6S<R9F-865\^U2ME1DU41TP<C->@R$:[3L[
M!#MU`I`K"HTF"LTFT'YP#0O9H'L_:]/3*^6K&/!F)O>4IY_JJ9R%9*9#'3%K
MVO&E&J5A=G9-HP2(@E,GW\!.L*(!["4X=?('7KZ?+B:M4F)N,3.?%7/YJ+?8
M^-.".B>V&FJXI:=C5)&8(V1N-3QQD14*<1RRRXG`"-25N8'1L5.36UE3`U4-
M,6:2)7\+1(C0!'L04U:I,0Q&3N'?(ES7>WCIJCM)YLZCJT@#=4D(>+V$TV"T
M[KV@K"51B.KYG6LB>W1:69'5T5?7XM&!&X;+6;T<0'VC$:#8Y:[A6'E:\:UT
MSZ+U95'<O,<^L:;.0&:(PR-VY$7"021W,+,-(:F9N`XZ.<')2$K>BB"]"--'
MZ!`$0MZUL.8NCR<^/+G2PWBI;U[/YQJFS8Z2W'O\$FUJ19DE#(6[H27-LT[,
MZI>%8W&KFY26H*`<$`Q$&@,UKVC#O8=[UW7QEOGK?66NHJ,WS0%;]%BO+5DQ
M?=:Z=OIC4?\`H?<I^D?HW3Q]-[TE^:>_YS\;?M]GK@9SK&SZ\NB`Q6U*FF<=
ML.MYPU%/D/FT3<TSS&Y(SGC,+)<F=T2#,3+49AA0M:&`6];V'>!WO`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8%8'F!\BT1\87"]L](NJEL46*-`9!*$B3@,L0IE
M=,H1+"8BBVB%O0UC/'M$'/3MH/IZ-;<?K6_B"!H04[_90^`)92/+-A=_7VG7
MKNC._P!]%/"'>1%B%)$U+Z=7!\875::=Z&%N%N2IT6214(.M!5H!-9F_N@>F
M@VCG6SJV8EBYN>["@S.X-C>Z.SDA=9:PMZQO:F,M.:]N:Y,K7DG)&]G*5%"5
M'&!"6G"8#9FPZ%KU#S6V77#::PDN,_A*`Z4MVGB,%+94Q)39&TBVD"%T82SU
MY8G=N%M>1K1Z?1A6]G%_=?=A]0_!UM2L&/Z<^F['@3/]6$Q2R2_2LPCS?]7D
M9[H-B(5OGSMQ)^B4QSV6)&`:CX81*M;*UOXFO;@?URL6L2B&%,[SN"%)YTXJ
MXS&"'"4,!94P=BS#$*Y@8"U"X(7]R+.T(DU*FT::$?J$0?7UU@1%X[:?'%73
MA=,.XB9.9X$[QRVQ5?>#/2[+$8HY_C<8V(A[)B,G^BDB!6]NS4R.XC$Q01*"
M"="4@)WH9:D(0F/JP8%L@Y5J;Q#:9,E2KE"C4E9MD$(EKL<PHEAQOSWX9256
M^)S$11@MZ`8K`(D.]F!V'08`567SKTK6-DPBUV%N+K%^F%@T7*(5?K,V1AEL
MXB-2LRO7LQI8I0JT5,(!*)$':1N5Z!LIRV+00!]1!#L,H1204-6M=M;/"G^I
MX+55=FH*Q:&^./,2CT#A2IE$F8FV`HB6]2D8F!6V&?"2%-@=%&%"V$O1>M[U
MK`QFY]FT&T]*1'E=9+206--:96WFR.WSAG+@1L0)L9IJMI;-RQ0[$)E$PEDQ
M<S2&EL3%J#U@&]8+7M^#Z""56`P&`P&`P(X=B_C?_-*Z=_-]TNW>WYO]P?B<
MTU;&%W_&;^+]_P#J1]#[!]UIY^L?S?YI^U\Y]GK\F!\XT31]G7;O&<&;([%Z
M';/,DCJO3D!8!\Z?(Z/3]W@;/0QJ$VA(*JTN.:M_>P;5:]BWZ*^Z^=?26!]'
MGD1?;;IRES0YWZ0K2WBX4'4*VX$S@G$D<B+,50%@/G!3FD$$&TKH"2#4Z4E>
MFM%G^\.M:UK`D1@,!@,#6W8?^JXG7\C0R_ZS+7D7[STOL-DC+#`8#`8#`C9U
MK_X&R;_YC&/\XVS*T?:,U;G?**_\&ZS_`,C&+_\`(E9FK[7U)N97S&F`P(J]
MK5+S]>G-T_JCJ."'671TN'&2)I"B52]$)Y^B94RO[#ZJ6MU95Y6D$C:4BGU+
M4E[]2=:WZZ]0[V3-Q!#>G^-_%U"N(KEYQKSF2+L7)$M>R'&Z*M6-+^N#,9*M
M'%C$[N^."I\<)([NR(UE:A)E12_0T>T16R!%_##Z;=%E^/BS,WL0<Y>++PHU
MO.4W0%$<706*S[G]6WV&R2LXJQG!;&'=OTN5M+ZSM<FF#NU+'9L.;1G)AB3C
M&G4`+-+V$P(!:739LIF.Q61XW?#IWO=<]N6VN0X99MS/[*BD$ZFSX18$9<7]
M'&F]JC*%6X`C\K96U<Y)6I,E3:,^#\<PDD&A"%[-8NFS>2RHV]L<A\F63XD.
MF?'EP7S8T`<%=>2^PZ-IMK9E;<6IMUC7)Y@GD#2_2IV,4'S@X](/24Y8NV,_
M?L2^[X6]%XNBR9IGP6-^'JD[.YR\8G%%(W/%5,'M*O*-C;--H@M4H5:^./)Q
MZYR,:'`YM4*T6G%&2N`%0`LT>BCM"!O>]AWDM638#`8#`8#`8#`8#`_@A:#K
M8A;T$(=;$(0MZUH.M:]=[WO?R:UK6!ZJ%>A=$B=P;%J1Q0*R]')5R%02K1J2
MM[]-&)U*<9A)Q>]Z^381;U\F![>`P&`P&`P&!TFR+(@5/0&8VG:,M8H'75?Q
MUTEDTF4E7DMC%'(ZRI3%KFZN:T_>@$ITR<K>_37J,8O0(="%O6MAH%1LJROM
M6GE@13)T:)=%?$GP\]?#0(7(A6V$STHQ8F7;9U0!>TG5EWXI:4YKF47OXT;A
MR<LH0PJ_@C6!]!QK:VUC;&YE96]$TL[.@2-;2U-J4E$W-C:WIRTB%O0(DP"T
MZ1$B2D@+**+"$!8`Z"'6M:UK`U77SP23R?6ZKZ"M2K.8[%LN46CY3^B[#*EI
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MWD,\@72LC<SYH?$H]8Z"_8/<$;Y2M-[4Q6HQ/B1JYZ+N->D+A>]*#`Z*V:E6
M)MJS=E!^=<>$SIN%V=X[)DYM7/C]7O#E6432L^JA3)Y4`'4HF9CF]TV#<%EN
M2=F3,I_XH^RY$WR"OXPL0N!0SB5SJL5%*3DZ<L,;/WV?*\K+HIEKZV4U&RF<
MQODCFVBXO)W%\='4$1M>T>X)/U;Y'+JC!JJ+_.&>8N#/(_HN).B?13BK&6/8
MC$6C1B$'/V=X1NG(]*[$74A2_',NJ.5=$]S63`^9IZ_*XS1E?N-F\U55SUR;
M>K]$$U;2EDFLTKYGA#^K<6LQ&%04\27:XI?M3\546'I3/P4='2J4UO4RFON;
M72GXQR;XX^1XAT2\SMZ.M7G&)\HR]+=/2LZK"M?Q>GHUUG7]82D]L:GA,\M:
MEO+*&>H$$E4:7L-O/`8#`8#`8&"^H"I@=S5T$77C[.(O/=TI:0H5(ZRCR.6V
M.R2L$(>QQ]S@,5<!E(I),T;J$H;8@-&`"M;HLK8@^[W:#3XXY\J'0E55;5B_
MJ[[/[V]>O9$$;1-<QZQ;^5D6["LI>W.*DQGG#G)'RK4$O:).J;=D!5%:5*`E
MGD[$6>((M!`&Z/6\M63ZNX%.G"*O\%7S2%Q:6KH1*TX4DIARR1L:%X4Q62I0
M;V%,_P`>.6"2+"]?(!02/7[6!W3`P[>_0E&\OUPZV]T1;$"I>LF50C1.$VL6
M2-D882W%R,V2VM1"QR/)TN=W(T.PIDA&C5*@6MZ+`+>MX&$'?R,\(,/.C-UN
M[]:42AYLD3KI@8+C-L%B%#7J1_&5$#C#6M+4C/72D@U`?HUL*+$O)T0;L90=
M%CV$)+UE9]=71`8I:E23>+V16TY:"'Z'SF%O2"11>2,ZG8PE+VAX;#E")81\
M4L98_:/U+-`(`]!&$0=!KXL/_5<3K^1H9?\`69:\C_TGI?8;)&6&`P&`P&!@
M#IQC>I'3LA:8^TN+VZ'KHZ,AN:TIRU::!._-YYXRTY`1F#"226(8MZU\@=;W
ME:-FK:R[D<8?;'1L,BT?BB*AG-8DCS2B:$RI4Q2H*E02B)"2`X\)0-%!-,T'
MU%H/H'U_8R[ITYWLEN-SL?X_NE__`./JS^\DM_\`L9GQT^9F^1^/[I?_`/CZ
ML_O)+?\`[&/CI\S-\C=_=+^F_P#_`)]6?L;_`/\`22W]G]K_`+./CI\S-\DM
MF@C4XA+**=1E#H]X:FU<]QIV0:4I4;@(LI28D.0N19@M"1J=?)HP/N"(/]G6
M1NNQ3V$T"@Z)J<&)'#XRE9'4PLYT:$[&VDMKB:5\+X9BU$6F"F5#+^"#TV,(
MMZ]FO[&L9N_-R#;`H0S)G-&TQ",MB1Z3Z2.Z9`QMJ1.Z)0A."%,X$D)@%K"-
M!4&:]AFA!]!B^3Y=XS09H'"(Z<H4L$0C+(H5I1H51[4QMJ`U2B-&`PQ(>8E3
M%#-3&&%AWL`M[#O8=;]/DQFW>*G_`#5"<*!\6_9-R\_MK76]M5U5)\AB4YA[
M,S-4BC!I3VSIG%T;%H$H!$G)VI0?OU^ZWK]G6M[UK-FJ^-9B,K>&6V+#O/Q9
M<-VO;$H7S6Q)E0L87RJ5NNB?I1_<4IRYK"Y.1A!9)9[@>E0%[.-]NA'&^X8O
M40M[W+5FV`P&`P&`P&`P&`P/X(.A:V$6M""+6PB"+6MZ%K>O3>MZW\F];U@5
M;5!%&:@_)U:--5,C(A=-W%Q_'>AI#5C*$:."LMU1FYW2N76>0R,E&!98<OGT
M2>DA3^4W)TR=S5-"56:`2K9QI@6E8#`8#`8#`CKU'UGSKQ;4;_>73ML1.HJV
MCQ0OC/4F7:+5N[AL`AIF"*L28*A\ELF7^W>D[<VIU*P[TWL)?M"+>@T5+EOG
MO3[5]T49SCRXRRKF/Q35++D"RRK-DZ,\OZW*&X\*A&]ST2)26@F5@*2/0^.P
M5`I-2-0S"USDHWL):L@-X_C'C>AN">=H!S'SE$BHK7,"0:!\4[X*B0R^2*BR
M?K!.IJ[%$)Q/LQE"PKXZQ3L``:]`$D@)3%$DEA*;`8#`8#`8#`8#`8#`8#`8
M#`8&MSY][SM!#8?COXOA_:VO'C6G7EE76KOKJXF5-,#<HC`*3KIODZ2)H)P[
MR"*D1P4Z>7P"((@N*+:A9M*4,P9`CDYX1\\2?D4@7,G0_:W"W5?EGHSK&E*;
M2TG8W+77-R=!U8D=I:R68P/(IW5BJ>.T\<F^:.%?.C6CULLIT7G(A'&^[X)1
MI*8@-KAG>&B0M#6_L#HW/C"^-R%X9'MG7)G-H>&AS3%+6UT:W)$:>C<&YP1G
M@.(/)&,HTH81!%L.];P.1P*R?+7U_6O#G(KG?D^HK\XJ1-4V88_2=;F0H<P0
M&W6_-$C+B;^]JRV1^-@T<C[6F<E#D^%$;4IT`32$VC%*DD@T-7GG)#S3R='_
M`!$=(*[./N[F.H^TN^9]WS:\2H&X6.HJQZZZ;YO9S*Q6,-5/U=MLJ::Q@R\T
MME8G8EI$D+.$$T'P3SQ$%!>]X5ZQN:.>*:5)(0VJZ,E%NV9VI:7*S99,15H-
M5A#+=MNR)%S^\22O7!/\[0,.@N:-]^BC"O<:@5!UL'[KZ8N[9O%:/C^@O:5=
M_:2I['^]+SK+H6]1^)PQQ(GM3P(NN8L1!%'1$,(C\=-CY34SE&/#<Z)7$\Y4
M$GT-+5E!]?W/VAY3Y?V;=V+[&QN&9U#`8#`8#`8#`8#`8#`8#`8$0.\*=8^@
M^6+2I"51=SFL/M%N00Z8Q9HV[`6O$8=G-(6[IRCF,93JE]A`?B:.)&`90@:'
MH6O3*TXSW;F7<I7^SS]T/MP.797!KE6M?U17OCTLQNHKG>,0QOF07O=81ERF
MD77!L)WE+V^[>9>2X18A6J6?W&8I5.)_J3Z`UO66>,W-C9GS`P&`P&`P&`P&
M`P&!6T/_`'OZ;^3:6_ZSZ#`LEP&`P&`P&!JP=6_9LS^_O)-/>H^T>P;4LWD8
MM2RNE0<QHWY\`^1OYRV(S)9`@24\2=DKVM`21.::G+8$@G9>D4:`<L3*"?G)
MP;)=*4=4'.%916FJ(KF)535T*;P-L9A,+:$S,R-B<.M;--^"0'XBUQ6F^IJI
M8H&:K6'B$:>88:,0]AE3`8#`8#`8#`8#`8#`8#`8#`8#`B'U=P/QSW*EA2/K
M;GV`WJGKE0^*H.&:I5YID:.DI;84_;;3VU>WGE@=0,J3XP!"$`6TX-^GJ'6\
M"&?]'\\-'ZOFB?WK*?PFP+9XE%(Y`XI&8/#V=%'HC#(\S12+,#:7LEN8XY'6
MY,T,;.@)V(6RD38V(RB"@^N_:`&M8'8<!@,!@:V[#_U7$Z_D:&7_`%F6O(OW
MGI?8;)&6&`P&`P&`P&`P&`P&`P&`P&!0IXN.1^'*$[0\CMC<N=>)[]M&U[\E
MK_?U5%+8\YGT5,%\C>WATA:E6R?#4&":Y*\.)'Q5(/=Z%A3"WLY,<,S=N,>`
MOKS`P&`P&`P&`P&`P&!69+7)#"?+I43A*%2=F;[IX/LZMJW7+S=)4LFL&M+P
MA,_DD+;E!V@D*9+]2)+MV(1!'M2>@;UIP`"+2G"`%F>!Z#HZM;&W+'=Z<D#.
MTMY`U*]S=%B=O;D*8O\`MU"Q:K,)3)B`?MC&((=?V<#T@R>-"5,J$,A8Q+9(
ME.6QU&%V0;5/R).0!2H5LJ?2CXKHE(3F!,&81HP`0"T+>]:WK>!^KD_L3.J:
MD3N]M#6M?5FVYC2.3DC0JGE?H'Q=H6HA2<4:XK-%:]WPB=#'[?E]/3`])5,H
M@A+=3ELJC:,EB*&<^&JGQL3ELQ)9H2##74PU4`+<46<+0!".V#6A;UK?RX'+
MEN3<<L$WDKT1J\").Y#0EJB!K`-RPT\A(O$F"9LX*)4<E-`6;L/PQB+%H.][
M#OT#C)7+(K!(X]3&<26/PV(1MO4.\BE4K>6Z.QM@:48-F*W-Z?'=2C:VIO2E
MZ]QAQYI98`_+L6M8'OL[PT2%H:W]@=&Y\8GQN0O#(]LZY,YM#PT.:8I:VNC6
MY(C3T;@W.",\!I!Y0QE&E#"((MAWK>!R.`P.':Y%'WQ2]HF1]9WA9&77Z"DB
M1K<T3@IC[Y]'H';Z&>R$AYQK2Z_13JE4_-S]%G?-U)1GM]A@-[#R=GYC8=-P
MGQY:64+N[(6%I$[.*-NTYOCH,138S-VUAQ.EKLXF!V$A.7[CCA:WH`=[P.6P
M&`P&`P&`P&`P&`P&`P&`P&`P..=WAICS4Y/K^Z-S&QLR%4YN[R[K4S:U-3:A
M)&I6N#DXK324:%"C3EB,---&$LL`=B%O6M;W@8XE%]4;"*T2W/,[EJJ)4^N1
MMSBAM:2V%$F.N%R!X+T:SK$,W<G=-&EB5V*%H249:D05&MZ^'L6!WZ.22.S%
MA:)5$7]EE47D#>F=F&21QU0OC"]M2TH)R-S:'AL/5-[DWJR1:&4<28,LP.];
M#O>L#718?^JXG7\C0R_ZS+7D7[STOL-DC+#`8#`8#`8#`8#`8#`8#`8#`U$7
M;[-[/Z/[/L;O&E>^.C6)3->F#NA7JF:D8E42-E8WVRQSE;!)&X,,I$D>HP1I
MT5(3C%+>I^(@$+W$^HQZRIB[,L9E[J\3?4?D0M.?],A[G[7Y"71^#Q.*QF@:
MA7S%#!G,YE)7B5.D=;DTUBII*MW//T8MUI.H,&HWL7Q/;L(`;9IS,789N&5>
M8/'#TM%O'-T[P=,^P^T%,CL+Z4F</ZCDCQ(2;GAJU6LC2T4`KY8YO"UQ31A=
MJ(#+5I2W/2@\+VMT681\4/M:M.F8Q<DM1(\>OA"ZGI#K.IKJL7R2>0B61BJ7
M,4V5P*<O4Q30VPCF[1*<,%E6Y!.)$VJ(Z_%+3`K2-HS33TP!@+$4,6CB\NF3
MQ,\',]1>''K'O'LV9W8O\@'>?*L2LHQOU^+^OW*:IJVKLJ+PU,T)T<6()G,5
M0H6Q\7,NE(BQD:'I8N.%L9FQ:S;ITR;+M,I!$^.SJE?PHW^,L_KCLY&G+M;:
M\WMX;E*]7.*.%S]3(`,1CC]82U&J^VCV$H*43QL6B]!W\;96M$X^.G&9=IFY
MQA%#@KQOI>+O*W6$/M3S"]+75.(Y'K(DU?<TV[9CFE%<Q8(:I9SEY\2>+&DG
MTVRQM&]+7/11200QGM83`C"`@W,LGQSG:9VX;?\`DM,!@,!@52=@P5J[$Z\I
MGANP5"I+1$?I26]<6TVLH"FV4SZ01RR(=6]/1!HGJ<L$JKEG;7%T?79S71U4
MW/BD:5&F+6ITHU9:D+1E#00<QGL*=2X-R8UJ-:"5;>M/)=4!`T8D1:E"XF".
M4E."4O>A%'BV,83`Z%O>]X&LMY-?'J^U=5-45IS0S=?6?"II;T9ELN>WU3-N
M_(O1ZRCHM+IQ`67?*-DR@U!9L?Z/NA[_`.\BE_5*6%H7&[<%.TY!",DH(9\J
M>/3JUFM+G.`O?)4EJ^\:`MSD2QH9<$\--FU$T5S+S]QJY/CK3$#OUN5B<5[A
M;W:]E/Z&5QF.)RS!MZI68<7]&IFX>@S3V_S9VCTEY#:$D5S\UNLT25$3R<S2
MLVH:T=971-MUQ%KH7=%738567_/'@I\Y*G-3N<=:&L#.W?"E]G')M-IAI;4<
M2:G#IU=<%67.ZP[1B[;S=8J1AMF]*HF%$W?-.0ZOY]ZPOBYI_8]GV]<#-U^3
M(&V4;E?)=43"3H%14AEC40I($CV%H1NIR1K+4A/GQX0KN2@:3[X97&A$KS=M
M8U^KBU`V7-HV]1:4="6%43%:T`J>#$N$FE2UM?:09XA"86NC8VWZ*9T)<K5H
MS#5KH4ZN9P5G2V-];=+(Z.X\Z-N/LE##NQ.I.%T087T$&NZ]OJ1**(@%N]$^
M06Q&"KR(3MSAW,R&70^(L\=1+T(V@E_0?.$NU*`TK2L)W]17'VW9?D:G'._&
M\GZ*:(SS:?X_H4SLE:Q:#I>8D,G<)VZ77U$[]-3]S8CUK.A#R8ZM+*TQE(<D
MTZ+W1(:E+$>G^X"$\JZ+\L$!@VYQ.)AVU64NOQSY\HF:L4LJR`KWB,=9V/U4
M5-;`9."ZC,8%?UL@U-<<0&3HOG@C7)HE>U2,\HY4XE*Q@#,J^?>:2+11N@L>
MA_:4D+MJGNEVZCI>]QRM7:<54INSM^)LM'RSJ23"2)4$<L_GSCM"I>B47S4T
MWYX[C2&ICCDAXDP8FFM>^66).-N(Z4B_8M02+H2T.B^B8*YTS%*^,:7&[K8[
M054='W'JB2S%GD21@KZHN**WCDG:F).%.>ZZD`AEB&H;=Z3!S4EH;R9,EM7W
M;E4,/7-ESYC[&\B5TQNMNBD$(E5!KT]&\^*8=P,_5VBE,6*3J7Z=290Q+8^Y
ML;F@)+TVF-RC11P59HPR<PM'EJD:)<PQ*QO(JW\[/DLFMB$SRQXG545[#>F"
MF^*'8^80EN:7^"+`5,V=&==R1O11!K4M.UR,MG6*4.TZ(:7U#8OX[:[I9.3N
M:FGH]\727H!!1=6)[I?'0I`2Z.-H!A;-]=SG,+640VC<@R':@!YA``%&FA$,
M(=:%K6@DA@,!@,!@,!@,!@,!@,!@,!@5M>7#7+(N`.AOSOG6"-=5:A#Z8TAL
MB1GQZ).EI$L3L=5C2M"6XMR20+54S+2B1MBKYPF5+`%>XD8@`]`UDZWO/DV7
M\S_9BI;>$_IV9\-T8R6M5/6CA.%K'(:2K/J9AX@8-4O$KM(=P*8PRRJ./KTN
M$F)=@Z"F5*0#]/NPBP+E_!FRV6D\1;YNDBF^.DR:RNVI'Q"58+:\HX@U5E)+
MDLY=SHN7LIQ('I+6RI2>0N()++T(UF/",C6P&%[VN<;-XKI\?+;W2U?:1YXE
M\ATCH.4=`_[)PPTASYP;9$UUX&OA]#PS4<2G)Y0E2.HI*2\!=-JA[!HH1`R/
M9^QO6N4^7]G=NQ?9C<0SJTP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P-1?JJO9
MY-?M5OCNGD2I^4&0BO:$LA#.;&98^O71G2Q#"KF$H=)/($R$+:T*DFYBU(-`
M4G?$%M0F"'>]G`#O;+B7P9EMT9C3`8#`8%;0_P#>_IOY-I;_`*SZ#`L8<G!&
MT-R]U<5`$C>V(E3@N5&?(6F1HB#%*H\?IK>_8204(6__`&:P*@>9/.'PM?G,
MB?HJ6V:R4^M;D=<'3JK7#ZW3*7Q1QN=]E#14#`S$LD&2.%GO4[+BBO9)490N
M@"5*54GV,6TAH\"44+\F'"-B,:220OI6!OS&X+Z9;&YQ2ER$HER6="3N95E3
M0&P*MD3G.!4[G%>/:!*:0$910FP\T\11(-F8'*0?R$\F6M";\G%1VRT6&@YN
M@/XS++3M[=(60U)"%L8DLMC$P:#I.RLY$D@TW9H@X',L@;-K&5T*2F&)E)H`
M^[`P96'EXXZDD/JD^V[&8Z0MB?47$[MEM4.^Y5*BJK^LU$&=)'5U*K':86DA
M0;*:Z=1JWS3"8:F?5;:D&I(0C*V7L89S*\C/#YRY2W@Z4KC2E%)(%$5^S5K@
M0E;Y!9E+//1<,1.+@>W%H$!;E1\=728Y0<:!,WM:0TQ881L&PX&+"?)?XW7;
M3%;.KAAY\B/G8.>XNY+*OL`JUU$PDT/:[90U\PQI9`2[-&@E\$4H9$C^`C^C
MG-N,(6%#,+V`>!ZM_P#D9YAY`[*J[F.TBXY73CT-7+G;+Y;"CXR)$7)0V35U
M!U;'Y,BC\5=ECBYV$]2?:%.].JQ`WMB=D"2:?OXA(`!UY\\J7#$??%#5T98]
M4UW(([>MFP^I4JMP7V@X/)-5V>LYT=K83CC\*4_BXTCM!0Z1E>:>/132>$PH
MY=L)^]8'2[[\T/,576N]4W6;BQW3+*\AW4,QNQP)E#G`X54:?F>"B<G%O=9T
M[PEUBDE6/]L.;/"5.FI4J^@75Q'M9KXR?:0T,\-7E4X,/E<[KE^Z2K>/654,
M-LJ87+&SEK\>S5P520&<%U-CC.S8ZAB#DY5FL?4H%R9.IVNV4I(."G^&>7L0
M<JX>2KE17RGTQUY7DU5V77'*47G+U:S6UQZ1Q.6,\B@L#26&MKY:P6$SQ-R9
MIDL9'5#H*9843\(:XK1NP>N_0,7U1Y6Z->XC"7;H-$EYRFUDM[_+H57"6;QO
MI%T55;'26\A;:4EDG-?XR(A`XH&1J%+,(QY6(_8Z(C4^]_%]`8'7>E/,7S!2
M[=6!%7.;%T+,[5>(`4S1MGL>#U0P,41LN@Y]TM$)_,;)MYPBT'C4>?:EKY0X
M)`'JOG9VUB0&R@;4%^X)W\L=`L?5G.5+=(QJ(S6!L%V5W&[%:(?8K42RS2/H
M)(@+7)V]_;TRI:E+5``9H0#"3C"3R1`-+%L`P[P,^X#`8#`8#`8#`8#`8#`8
M#`XUV96=_1C;GUJ;7IO,&68-`[(4KBB&84+0RC!)5A1Q`AE#UZAWL/J'?RZP
M.!/KV`J6%7%5,'AZB+N"@*M?&SXTRFL*U6`1(P*E;.8B$WJ5`1)R]Z&,L0M;
M+#\OW.L#M2=.G2)R$B0@E*E2DE)TR9.4`E.G3D@"620026$)91)18=!"$.M!
M"'6M:UZ8&MZP_P#5<3K^1H9?]9EKR+]YZ7V&R1EA@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@47>6WB+MCHI76B_@/JBQ>.)84Y25VMR:5TG=ERVPTJM$QMS`Q
MN:E#+XZN:T[()J$<62GW\V4".$(T.QEE;U6^8M9Z,*\$\/\`ERXR?'ZQ+Z\B
MMG]SM]BP!1%D=06#%7`U+5LHTZH'%+/"7>46!(#371$B2&I"TR<)"=2%6/:C
M1GPRMA2:<V6FWP0,>_#OY\5;*;.$_G5Z-^G724+1#@Q,8E;>>WMQJU8<2LV2
MV6LDCJ<C119?]RIDI24&C-``'0->W3$SOV&W'%89W/Q7Y8^L:GI171?D-M#C
MV:4TQ*(M/V2$0\:1?T&ZJDL22DV0[N<3FL>/:7,HU(N-,;Q".;P:-%LD!8][
MV-C3G$NPVN5\<7%_E+YLJ?L5#T[Y`[=Z9G5BU\WLO/JR<1O3BIJ29EL\P2J)
MLP&2R5R4YS7`7NK>;]'C,(0&"0AV:$>Q?<L3S)GQ1EX*\7OF?K/J6LK5Z0\P
M=]6-4-?2`F232HY3''QT8[7:/AJDZR$*2GZQ7IE:TSA\8/O5?,S3D@/W1-H!
MP2Q@62;KDF?%;_HP!OF#$24+XAB#QKEF+@@UL7S,#OU"8%J$IWK6PD?20F19
M\#0MZV;\T.]OK\,7I+4X;BKS\;E1VG5&Y(\PW5G5S-Z]W+XZ%&.0174TC+G&
M]R1B`XD*F\3RQZ<OG271Y1A.SR@^\(@^NMA5$O\`"Q5K8^UW,*JONW*GG%0.
M_-I-42AH9JWDPJ_K_FKE6Q.4(O`6!CET3=H]HMPC5O2>1:<3TIRI!*'/2LC6
M@$`)V'&1SP3<NLD@I9Y76+=;TAI3C,CD9I83']B;VV1NJ1HM]@;^CY-\R8`&
M+[R8FR_9B)K5_(@;5CX:J(3!."`6@RA37B<@-0\(7?PHBM%8"/7E6KC3TAM2
M"U!3=3V"37RZ`IZSTG7F0B*)$<OE6XKI2$YW>-+#Q'K31$@3EZ`2$.`3>'&I
M]VA.I`]7/:3[2,DM&U;[B_-REL@2:$PN][BY^'S-);!%)DL:!,98BC56+5R>
M,L[BI&@8U"\9@=':)1@3!'B%?9S.1(A$IY%E%JWS)13_`))D?,3J]/3]&S70
MN33)DE<0E726AZCNREMU+Z\E9D73G*0FMJ*-`V@*3?#,%O`E[1_BJJBJ7[GV
M2R.4(IFMY_CG1K0U,$8J&IJ8@4I>^DV"!0B3S20Q&LXVU!42IAKB$&L*%88J
M.4[0/*X!IHP"(+)#H$G\+]$NES-LVAT_EU84EIFY\BTFY=AD5KHNM9'#^:+H
MD?2-?Q`B1.L9<9_'(\^WQ)#'V3)T3B`+^64!(;["M;WL..B_A-HF/1\4>7VQ
M:LH)<8S0$/E2][)A@G.61ZG>OIUVQ.4#HL2QT@TL'0EQSC>Y5\+8-#0H22TV
MBA;,&(.E,'@IJM$F5L4JZ6O6;P=(A>HE"8,ZM];(&6%5E,>V(IV_9$+(4M<1
M3NLA7VG-XDG8Y"\N)ZA<N9`EA#\(TH`\#A.C?"VPR*B9&RUO.9G8%H-,=OI3
M!&Z8/T*@S*NM#I;M&"=B6M9CR[IJSEK<;(%+E`6^.)T:MK4M:N-(@-JH&M'"
M5%!E2F/%[*I%X^[IY8ZYM16^6=US?LSZ)Z:G%>C:%VWASF-RQNP#*]2K7:(,
MK,Y,@JWA#1#G`XED;4PT`#](4R4O1&@!FQ]\=S+$;TM*_>?)>56+=:/.#=1<
MZYL98#6;;44^*@1=S.=;A(>01,V45DV#DUU.:A]*8QDA=C`D&F^@BS-'!!>B
M?L_M`-_*7.].]!.[S.)O#.?;LA]S&*S6"<,\RO#I"FJ[IZ36>F=99&35GSR@
MH1`D\<K71)"-.Q,Q!/H3LT&AX%[-404=75;6M9F25[F8Z[@$.@HYA)A)AR26
M#B,=;F`4ED`T1*9&-[?=M_SI7LDLLK9YH_:$(?36@[_@,!@,!@,!@,!@,!@,
M!@,!@,!@:V[#_P!5Q.OY&AE_UF6O(OWGI?8;)&6&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P/$6MB"(.A"!L0=ZT,/M]P-[UZ:$'WA&#W!_9UZZWK^
MSK`C]2?,U:T4]V+,XZ9*Y59EO.#.X6?:UCRAQF=@S,,:(6I(HS*W=>(M$RQ*
M((W)06TLC2E;V=O^<GF$I0&J#S#0D'@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,#7\[>X*\A4>\@YOE`\<LUYBE-Q/O-D9Y"?J+ZCC<Z;8
M4CKQ-,WNQWZQFVPH),4CB=)=/Z)I1)VL;6$GYL:I-$HV(("]QJFK,NG_`#_,
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M^'+J+./'ZZ^3YT8;,%Y,HOR1&9(2]1T-2E<G.%AN#4J8!M[CN4#F8K`<7!0!
MQ*<@I?F?S;8`;*$9[];WH.]U,^(L-S0P&`P&`P&`P&`P&`P&`P&`P&`P&!73
MV[Y#6KD*:4_3D-Y_N/JOH.[F6RII#Z7I0<(0/2.M:=:FYVLBPI-(K#E,3C+(
MS-`7A(D1$;4&+'9Q4@2I2AF;WZ!)'D_INL>R^<J@ZAIM0ZGUM=$/13"-%OR(
MMN?VT!IRA`Z,3^@(4K4Z-^CKVA4H%I91YY(528>BS#`>T8@D+@,!@,!@,"N_
MK+R0U=R+?W*7.\PJZ\I=)>LK@KRG(S.HA`S-T]!)!9KI(&J*ESJS'U:T1X#V
MY"BKDH*9&P;B\[0H3E)B<HGX(S@PIV!Y<X_Q3>$,@5N\A]5ET3*+<K>BU?7J
M&-PD%,(;+M5$F6Q9O96Q9,R+"EL?2;4"(<G5(TZ2IU:<].1M4>5LO86]X#`8
M#`_(\W1!)QX@F#"248:(!)8C31Z+!L>PE%`UL9A@M:]`AU\N]_)K`J/YZ\ML
M?N+L]NXBL[D;J?E.S9[5LBNFD%E^1Z$-R2U:YBCF<V/3B)LB,TE+O`WHO:8T
MX#:[EDJ0%%""HTG/V428'<N)_*]0G>71_47/5+1&RBBN9BV)9^-F2-C*BK>X
MV-YE<T@VY54JQ*]+'=]B9<K@#FF(<3DI"9<`CXI`A`WK`M#P&`P&!A3H.VY!
M257/,_B=*VKT+)T:UC:6"IJ:11M5-Y.ZR!W1LR3X2N92.(Q%A8VP:SYTYN3D
MXI4B!"2:<,0MAT`05?0WS<TW).>9[:KQSWT-&;N@'86^`E'(>VV"O]QRGKHX
MM$J05="7YFF9]8/B$QJ6#7JGHQY3-Z!`B5GGB"`HOXP6@\^V78=LUHV3*TZ&
MFO-LT4N#LA<ZKGDHKF:/386WK3$Z)U(DU5RJ8P]U:7Q)H"E,,I9H\(!^TXHH
M>MAP,UX#`8#`K^\D/D8ICQE\^'7U;S#-9X-8\C88?5U8HFQUL2;K6UB>)E+5
M;*W.KDU(2F*`U]&760/:]0>6F0-;<:,8O>(H`PA;T5YW*;H<+`I9N<;[MUL;
MN/:M[NO-?$E]0Q[=%<X6VN2-<9?'))/;'C*BPY<4X*1`4M$<TOV7H&MZ/V(8
M0;"[F-O[=*XZP2EG$>-HDK*UO[6-4E/1*1MSPA(<4(E*)4`I2D/$F4AV,HP(
M3"Q>H1:UO6]8'-8#`8&&^AKZK/ERCK5Z)N5\''*NIN$/L^FSN2D-<%A#(P(S
M%9R=L;4_JH='AQ-"!,B2E_NBE6<64'[H>L"O-\\J;I6/,\KZ7Z)X@Z:H-"IE
MM10:@*JDCK24KMSI*87L[@C]:PN'Q:"V@_EPN<*7A006Z-<C/;36LLW8A#-V
M4<`L)$<-]SQSM1FN1`=5-BT#<W.5JJZ:OJBK4.B:^6U]-`,33*&LTE^@D@E$
M0E,8DD=>B%3>Y(5@R5(=&:UK7L]1!.C`8#`8$'>U^OY_R*QQ61P_CGH7JUF=
MD,T=9DXT6JJE&CJMHAJ)G<-N<X46=84$`2C>TC@I&F&D^<A`%M4;.V5^Y?$"
MO"1^=YG;^**G[QBGC\[;G='3RM)9=4[>FA@JYM1TQ4\3G[W`S)'+7=\L5"@?
M7=^`QF/3>V,^UINV$P"U28F(&`0@NNJ*T(E=]45C=$!4JUD%MZO(7:$+5N"(
MUN7JHE/XVVRN.*5K>?\`NR!6>SNQ(C"1_=%#WL._EU@9#P&`P&`P&`P&`P&`
MP&`P&`P&`P&!2IY`J+[)C7;7,7>W'5&Q7IYXK?GWHGF>P:6?[:CE,NI""VUL
M,ED%L%AE4O)''EK<QR^'Z(>D@AA6;0':$E`:9[OAA*CQ7<F2WAKQ^\R\NV`[
M-#U8%:0EQ-GRZ/''J8^&<3B72.Q)<WL2M20F4+&5GD$M4(TIXRRQ'D$!,V$.
MQ>F@L#P&`P&`P&!1!YBZK[PNVRN"TW*?(K+><,Y6Z_I/MF53)VZ,KBI1O3M5
M2>T(RLIA#')>C,<4ZUU:Y:F<`/VA'I"O79&TXA:$+08([!J;R:]#>0*G+"L;
M@9@OOB/F%97%G4#3C/UO4%<-B_I51'&5>_W;>),D;G-WGBND7MU<FR*LR9,D
M;A')-N`A'?.=EB#95#O>PZV+7M%O6M[#Z^OMWO7RZ]=?)OTW@?W`8#`_!4,\
MI,H,2D:5*2R#AITPC0D:4'@+$(DC9X@C"3HXS6@^_>MZ#Z^OI@:KO/?(/D]O
MF\^M;,[BYN_$=T!UU2UI\Z1#M2O.E*EL"/<-<_N3`['P:KJ"H5H&5+'5Q=9*
M,M0^2`UX3.*]U.TJ]R4LL81A('QD^+OL7B#O^YI]8%ZQ&R>7B^/.<N>:S5Q^
MG*WJP^6`J/;\CC,;W$(K)GMU@R>HFM2<$2P6S?K.8\;-/'\1-@;%&`P&`P(F
M=P,$XEO-%AQ*"<]-_5"R4E-+#(:,6W6HY[53:%N#NC*E1##:J<GT8)&WM7O4
MHP&J6XE4:5\$2Q/H?OT&K0U>&#LQ7RT@1OO-D0+KFM?*,S=ET_XS%_3)4D?&
M?G1U@\N@]LU6JZB-5HFM3/)FY2_Z;2E+'@]N)`F-3FK=_.1%:"^OP\\IW7R/
MS78L,N9E(K<B?]+7/<%0\Z(K'4VVW<L4I.71N,@E!H[".-4I)!]6"T"A8<)"
M:<WE*'$99`QA#L6PM?P&`P&!0GYA/%OTCVN98%R\\]+)XG-V?AKHKF&#<^2J
MH8'-XK,%=Y-:\N>CCMAS23M(::F%M,Z-LBZR2)DIJIN:B-_#-"68<`05"=9>
M'+R'6LU46TV#2K)U?.*D\?5!T7RY<,'O&K^:`\>=-0Q<2_2Z7W#%#2#S[\A;
M&^M#'\Q*3&OJ$]&S'?#;B%C@-4`-R^LFV<,M;5\SV=(6Z6V2TP>)MMA2MG0?
M131)IP@84"662%K:_87]&MST_%*%)"?VA^"48$'IKTP.\8#`8%>GE>Y-FW<W
MCLZNY4K9U:6:PK<K7Z.A"Q^4FH60Z5QR1,4U86EW7DD*C&YM?G.-%H3U.BC/
MFY:C9FPBT'TV&NNB\0_<"]BMJZJGY@B?*QL'Z!\=72]%<#/74Q=IL%F7'QS,
M9!);CFKO9@G*5Q"N7"W&N4";FP[2P9[@)`6H=]IC!:$$+QO&%SAT/7\][PZO
MZBKUAI:U>Y.AHW8R.C6">M5GBJZMZPJZ-59`VZ33F/IR(X\S5[3LZI>X!;1'
M(B-'%``9L7O``+;<!@,!@5B^72ENI^F^,Y1R[R@F;D,CZ2F$+INWK!<9,U1S
M54\XRMT]MW35N(<3RE$F=3X:F-:"FQ($Q4>6ZF#!K>RO380$\IO)?:DYA/*W
M"_)7+B.TO&E!(1$$'15>P[HN`<_61:['6!A#;7?.HI;,RE*J-U4:1&VY=)%C
M<E-<7LDS:,!Z30#A'A?+28GX505D&45:WT@_DP:,IG2G6B0LTM:JP4I&A*EW
M!6V31Q*B87Q!&0$Z2$J49)28PLK6RPZ#Z:P,H8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'K)5B-<5L]$J3+"=&FD[.2GE*
M"M'$&"*/*V82(8-&DFAV$8?7U"+6];^7`]G`8#`8#`8#`]8]8C3&)B5*I,G.
M6F[(1E'GE%&*SPEB-$2F+,$$1YH2@"%L(-;WH.M[_8U@>S@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#\CRMG
M$'$A-,($:484$\G>M&D[,!L.C2MBT(.C"][]0^NMZ]=8&CQUESGVI1/EL\>W
M`4>\R'DN=*Y[,BMORB:S%TMUH!,(BI@;)+WMJ1Q(IN8T,?"D6&L!11VE20[V
M`$+9?I]R$(6614VNN7_,KSESQ.KX[ZZ#O^L_%Q/)GN<6-=$454C8\1;[*M-8
MH>+*KA+'T3H^W*+2$],6ZEJ24.DR5M^(28>G$=H,&M?VK>`KJ@JGJ17XY^NF
MGCV3V"EJBV.D5:F*G1:L[#6NSLG*8(FV)"#S+;+2L2`I:J4IU+464><)`#1J
MPOX0PGOQMYOVWI/LYZXPNOC:^N*YH[T>LZ2I1TOE<Q$*+/II$H]1/[W'4*<@
MZO'<QI+4+-HC53B%/I`L(4'$J$^BS`C^5]H[CIK(V]+ZX:O`/C)=[W+H)O[Z
M'85:EH3WLZ4&PHF=;Y^-/+LLFL!R4D17TL,T.]`#L'P?GGHBV%L_D\Z3=>3O
M';V#TG$U0"Y/6?/\[?H*X%G!"6GFKHS#8H*XEF^TP(P)I2\HCM:UK?OT'TU^
MS@:EO3*;J#C3P<^"ZFN3[_LOGJVNO;^I=-8EBP:3NK3*7Z3=:12664O%*'PH
M\+RX)4<IG282@K9P??I$6'?K\,/H$PXIYC;X;_L]LKL5[E#NX>26'V>\^,_1
MA@T)\[5]@+9>*!QJ1_-Q$_"43)%7;B7)!&&$B`H<T!V]A']T'`X;P_>26S^/
M^,?+';7DTZ5M;H1-PEUZZTT*02EX.F,R=WME0M,(*@T!"^+231FR^P?:6B3'
M*BTR<1XCC1E%Z.,T%D//OG!E\GZ7YKYS[)\?5X\)B[4:'-RY+L*?V!!+&C=F
M.#<WH78J+2A)$TS>Y5I*W%`Y)M%MR\)JTI4L3$GDE:/+-V$59W]IZ;V>-=$3
MNM?&OU=;5;\@WA-:EZ?M!H?(BT5W6C/&9>1$6:4M\D,1.890]2-1\908R?"1
M[:D^B#%:L!2D!F@Q]W!YQNO8!Y&?'/#>2.;KDN3EKHNB':Z&^O8XPUR&4=AM
M,UJ)-8#!^+E[>VYV?8*XTG](%&OQ&E9.SADFE["('PQB"/CKY#NA.6_/5Y2G
MJO>0^HNP))(.6>1I`AYRKF0A*:JB;FVAZ?F,Z>9DY+!O\?BFV4YU,1E@;FY8
M>ZNZH11`=B.&/86DN_VA^EGCB_BKIVD^?K$MJSN[[8>**IKG59-H+6JIOM:)
M.AC'-6:;VS,%!4(CK&T.WS<M&X#`+Z0+7IC/@D`V?L@(U><&S[^F_B;@7D!F
M'.<[X[ZHX'[#IF\V&LI).HM.'=G.8;0;:Q<MH)U7BLZ-2^`S5KFQ"H8PA`4H
M3I]@-*]`[]P;0U>S)NL6`P>P6?7HTSJ(1J9->O?HST;I.RHGM%KX@=!T9Z)E
MP?NM:UK?[.!V_`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8%"?:7"G2ER>;;Q8]H0"'M#ISYS%!+N9+DE:J71U
MK<XXXS",31MCY"*++UY,@?\`2]8^I@Z$B(/"7ZCV9L`0^NP]6]>$NF)OYU(?
MVY'(8T+.<FGQD3[FU=,3IC&DCF5;SY,+2=6Z/?5-0X`D@T9Z&4H1_/PIA(P_
M$'H1FA%[UL*D=^&?R#Z^S@UMX\0U/'-]5QOJPBSW.!BM.O0M*>%`N*22W;AJ
M:ZD`XB:=IG<BC]IRU@CO06]>W9FM@P+7+U\>70MN>;6FNK#(PD*Y:;O&_9W,
M$^L!-,(T6_LT]G`[*1?1R"(J'`,D7;TBEB8TM84F&E]PA>XS6P;UL*(.5O"=
M<_.C.@Y,OSP:5%VR^1NT'@EF[I6]RK:PJ*5U>Y3!0YMTHF-0%213(TSW&6-0
M+13<F:"CU0"RR3`?&T8<>&UMY@Z%?.@_%?W#2,%;#5TD?><9HHAS$AT/X[D]
MP1"3-H^Q(BR]"&8>Y+HN2E*+UZ^\1F@_MX%#SQ1-Z>5'Q1_9Z;#Y>C;!-@\Z
M7CR38%V[4S&,Q<,9C?.C$?5=EN*?3ZXH-.B]KDD44:V@2?%6"]=?#*%K]@.X
M'>#SHL[SW']+[^8E^,Y3>;7WXJB^I9&]IU/9+-7BEB0G&0+YQ]9=/)5EKSGW
MZ1VFVAVB,&5LWXN]`T&)GGP7=FVYQ/YJ:'DK9$:YLGJ/R+R#K_E)2Y36/OL>
MG;`PS4R5QU)*%,>5N@XC]<&D1R,L#B668B6GEF*"M%%CWL)&,_/'E%\E/9?C
M1L3LOC6+\,TOXUY4MMR6/!MY0:VI-?ESHVR+IF1-7+-!!JQ1B""?(>D4F!<C
M/=I$>H+V<::`@)@='J+Q1=PQ+Q<^<'F9\K-A37!VAU/T%9_/$<*LB$*D<OAL
M\60TZ.N2]](>A,L54.!3.HU\W<CTQX/9K1H0>[6!QG0/!GDAHE^\"'4G/_+3
M!TW8_CMYD74C>_/R2Z(-7;DEE,FI^-P%0J;9X_*#HXX,C:L,</B*T05WM,2%
M;T284?[P!83RYQ;U3$?,;Y)^V+(KEFB-/=3<O<TPVNUR*P(Q(U1MB0VJ:W8Y
MS&3VUN5`>TJ:-R9B<$I:]2D3)UA9(#BO4)NM:"J.C_%[T]17AHY[XMZG\5$0
M[W5M=XW]+K2J>/=-UW6EJU&&4.:@ZKK,IVR2'D+"K<5I;DK3NA"5X2*R4A@/
M<`X/Q2,##77=&]A\@_9KUG%74KPYOW1G7/8=;4OSA43Q8A=P2NLH=/+CB,W@
M=(J9^4#:>9N;&TU\Y&;.1^]*EVZ%D$^P)82@!NW5#!BZPJ:KZT*-^.57E=PJ
M#%G^X0_C%Q*--C``WWB^Z'\0+?Z^N_EWZX&1,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#Q'[/8/X
MGM^'[1>_W^GL]GIOW>_W?<^WV_L^OR>F!&'D+\T'\3A/YCOXC_Q#_7";_-/S
M>?JK^+3Z[?6)9]?_`)E]3/\`X!],_6?X_P!(?"^Z^=>_W_=>N!*#`8#`8#`8
M#`B_T#^:!]>>;OSF_P`1WXPOQN)_S5/QN_53ZP_CO^C3?F7XG?K+_=/XQ/HW
MW?`^CO[N]O\`]W\OI@2@P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
#/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g575431dsp_081.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_081.jpg
M_]C_X1"#17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-SHS,"`Q-3HR,#HQ.0```Z`!
M``,````!``$``*`"``0````!```"2:`#``0````!```!70`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```]-`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`7P"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]56-9T/.LS!D#J5S*VW>
ML*6FP`M+Z[30^;W,?7^BV,_1?X6[_!?HELK&MI^M1S@ZJ_&;A"X$M,FPT[VN
M</YG;ZGI[F?3_P"N>I^F8E/.87UFZD[_`!GY'07BM^,VLUFXAWJEC:_ME;?;
M8W&]EMS_`'_9O4])=XO+.G[O_'LRMT3M=Q,?T9GBO4TE*22224I))))2DDDD
ME*22224I<R_K74FU56-ZETP;GY3'/L]05GTW-=C^_<S9Z-7MR7N_1_I*?273
M+"MZ-U5]&P6X>_[1;=N=CM+8?.WV?Z3^7_.?I/TEV3Z%GVU*:_[=RW-L_P`I
M](:_=^A:+B)#?6TL<]SOSAC_`,W7]!F1^_5;43%Z]?\`:V,R^I=)]``NM]*Q
MV\@Z,]/U+/3^G])$_9/6/1ASNGNM8X[",8M:6EEC/TS767?2>ZA]C*?0^A97
MZOZ13HZ+E.L-6=5TVW">7&VJK%+7/)&QI_276UM_,W>RQ)3;'7NBF=N=0\-`
M+BQ[7!H+;+=[W,+FL9Z5%UF]W^#KWJ=/5^DY%K:<?-Q[K;)V5UVL<YVV2[:Q
MKBYVW:B?L[IY:6'&IVN(+F^FV"6C:R1M_-:ILQ,6NSU*Z:V6?OM:`?\`.`24
ME22224__T/55F9W4>JT=2IQL;IQR,6P5FW+WAH87V>E8WT]NYWI4_IDW7+NH
M5?9!A&QH?>T9#ZV!^VKZ5DM]')=N='IU_P`U[W^I;?LK3Y_U@PL#J%/3[F6N
MOO\`3V%C06_I;/L[?>YS?HO'O;]-)3Y_T\D_X[,HEI:=KM#!/]&9^Z7+U->6
M=/<'?X[,HB8VNY!!_HS.SH7J:2E))))*4DDDDI22222E))))*4DDDDI22222
ME))))*4DDDDI_]'J\[J+^JXF!=;C-K;5U>NH@DOUJM-=5U>^BNS]([^31Z?_
M`!2Z#(ZGT_%OKQLC(97?='IU$^X[G-J:=O\`QC]BYFH4V8.(]EUK/4ZQ6Z[U
M6>JYUH+?T3;J?V>UE/LV>L]F1L_F-C_YI=/?T_I^1D,R+\>JW(IV^G<]C2]L
M.]1FRPC>W](-_P#724^6OS:\#_&YU7J%DNKP\:Z]X:`XEM>(U[@QNYC7/]OT
M?4K7>_5;ZSX76.C8N6ZXA][W4-=>UE+[;&?2V4UVW-_S7KS;K8`_QA?64``#
M]FY>@T_[0H?1NJ=1P.C_`%/Q\+(=CUYO4,AF0&1[AZV+5^<#_@[K6?\`7$E/
MM:2\SR?K[D-P?K0XXS@.GYE=(+,A[7_I7W8N^JUS;/0V-PZW^DUOI[[+?S/T
M:[KH_6!U'$P+G4OKLS<.O,,-<:F^HUCO1^T0&>I[_H)*=))!Q,S&S<=F5BO%
MM%D['B8.TECOI?RFI9.9B8C&V9=U>.Q[@QKK7!@+C]%@<\CW:)*3)*E^V^C<
M_;\;3G],S_R21ZUT8.+3GXP<TP0;6`@Z'][^4DINI*-=E=M;;*W!];P',>TR
MTM.K7-</I-<I)*4DDDDI22222E))))*4DDDDI__2Z=U-^)@XK^K.&(P=599M
M>T6$M;[,7](S*?70S;5O?:YUFQGONJW^HMS/Z#@Y^=1G9!>;<79Z0&T`%EC<
MC]S?[K*Z]WO_`#%6^LYJ<SIU%D$69U!+7!I:6L=N>'MLLJW_`,AC/7M]3_`?
MH_5JT.H8F1E-H%&2[%]&^NVPM!/J,89?CF',]MO]O_BWI*?(^M-#?\8/UE`F
M!TW+Y))_H/[SB50P@/V?]1N=>I9'<_\`<C"7?Y/U*Q\SJ_5.L%N99DY=.3CE
MU=F.RNQIK^Q^C5795ZE-KJ_T/K6^SUJ_6?\`HT&O_%_C55=(I95G[.EY-MV/
M-V)-9=?CGU<C]#^F9957]J]*OZ'H_9_IVL24\+F@?L[Z[\Z=2QXU/_<C-_SD
M=MEM7UGZ794]U;V?5]KV/:X@M<WI=^Q['`^QS/S=J[.S_%_BV5=7I?5GFOJF
M15=D;;L6;'-OO/JT34/0KJKM^TOKL][_`%?0_P`$I#Z@XYSL;*=5G"VG`&&'
M>MBEC6'&MPG4[?2WV9#&.]+UOYGUK/7_`)IGII*>3Z#]?>H=-^KV);GOR^I7
M9'4[@+'93FN#*:L+]7L==7E;\>QV7O\`3_1KNZ_KCTA^5UG&-['.Z47`,M-E
M+&EI;B/JR<O(<^C?=FN=74]G^!>L5W^+#IW[-Q<5M/4"VB^R]M?VC%WM?:S&
M98Y]AI]-]7ZJQK&L]_\`.?Z16;O\7^+;;UESJ<^.K6`Y);=B@/G*&2Y^*UU?
MZ'9L9D_IW?S7ZO\`SR2G>Q^I="=DX.%2,2,VEUU89?5W)]M%&YMN0RU_VC]-
M57^8_P#X13Q^J]'R\-N974RYCK_L[O3?5=MW.AMUKZK;&>DZKT\IWO\`YA_J
MK%P_J155U3I&9LS:K>G8K**K76XKF5-VY1?3=6VG=D6U/LV>I7^C?]I_X"Q4
M1_BVPG?5\=../U`5MR#E-QOM&)ZGJ.QV-<XY'H^EZ7JL^R;/_0C^;24]L;J&
M/R:Q5DQB,#Y:+-KP0Y_IXL._3/;LV[*T[<G"+L6MSK:K<UA?158;&O(:UMEC
M7M<?T=E;7^^NQ<CF_4#&OSNL9;J\ZRSJ5;Z[G-NQFML&_%R6C':ZG]`ZRVK_
M``WT&8[_`/35(^%]3;<`]+JP[^JTX^"XAM3<NEM(`OMR=^;CL8W[5ZWJ^_TO
M^T^S'24];4W&M#C58;`QQ8XMM<Z'-.U['0_Z;'?3:I^@SQ?_`)[_`/R2YJKI
M/4/L5M5].7>RV]E[J'NP6'U6_KOVG?@T8K'.^W5U-L]5SWV_SO\`-^LK63B=
M1;?FW5-O%IQRP91%%K;14!;34,)KJ7N<Y^3E4_SF/_,_SWZ6I)3M>@SQ?_GO
M_P#))_09XO\`\]__`))<1>[ZP867T#&J=0<>NTU/?E;,>^NL6CIN[#QGY-CK
MM^+>ST_6^V;[+*?T==EGHK%ZCUOZTXO1^KNR,7$M#\RH-II(O%HL-]=UV0S$
MRK[<=[7X-'_<>OU?7_1;_H)3ZAZ#/%_^>_\`\DG]!GB__/?_`.27E;_KSUYG
MU@+7LH;>.D')=8:W"P$87[9.,1ZFST?MGL_FO7]#]'ZOJ_IE3Q_KOU<=)Z`Y
ME6.T6YUU5;`QY;4*ACUUOJF[U'/V]0R-_K66U?S?Z-)3Z_Z#/%_^>_\`\DG%
M+`09?IKJ]Q_[\O+,WZU]2]#ZYM=70^O!O;38QS'?K#7VCI#CE%MK=K_L=-?]
M%^S^]:&#]:>K97UO^KV+;Z,]2Z<V^R\5D6,%['9E^-3[_2]%]F%3_.5V6_RT
ME/\`_]/U0@&)$QJ/BLW-/U@.?4,)M`P@6>LZPDN+=[/5],#9Z=C:O5_TV_\`
M1_S:TUEYW5<_&SZ<6GIMV1186A^6'#8W<^MCO:SU;/T;'OL_2MI9^C_ZXQ*;
M>!O]!V\`'U;OHDD1ZMGB&JRJ>%5792YSZRT^K=HZ)_G;/W'.1_LU'[@24E20
MOLU'[@_%+[-1^X$E)4D+[-1^X/Q2^S4?N!)25)"^S4?N!+[-1^X$E)4D+[-1
M^X/Q2^S4?N!)25)"^S4?N!1LQ*G,<UOZ-S@0'MU+21]-N[<WVI*30#R.$&_"
MQKV;+&PTN#SL<YAW`S.^HL>J`Z)E[=IZKDQL+)V8X<"=P9;O&-_.,W?]<3_L
MC/)=/5+8)]H%.-H/GCNW.24X/UE^IN%'4^M8V,'9?[/R*F.%EKK"?LC\*NMF
M//I._1^S_P!2KS(XN5B]+^K5653919^TLH[+6N8Z)Z;KM>&KWE^'BV5NK?6'
M,L:6/:>"UPVO;_::5C=9^IW2^J68)?37LP7NL8'FV0Y[Z++'M=3?3N<YF/L_
M3>K^9^Y^D2GR[-_F?\87_ARO_P!OWK4Z1_XN_J=_Z9Z/_;?*65F@.H_Q@/(U
M^UUEI^.<]:?1V-'U[^IX`YZ10X_'[/DZI*?_U/55EYGUCZ7A=0KZ=<]WVJTU
MAK&MG6U_HU^[^M_K_-K43&.Z2D&"X.I<1_I;>01_A+/WE82224I))))2DDED
MVV?6EN7;Z5.%9B;HH)?8RP,B=UOLL8Y^[V[&?Y]:2G626)3E?6]];;+,'#8Y
M[032Z]X+'1N=ZEE=5S'?Z/\`1?\`;MBF+?K;-8./@D%[?4<+;-*YK%@:WTOY
MW9ZVWW?]N)*=A)8SK/K<U\-IP+6#<9WVL+@7.]-GT;=GI5;-[_\`#V?]QTGV
M?6SV;:</=O=N`<\L],"GTQZAV6-L?9]I]WH6>G7_`."I3LI+(%WUH-;MV-B,
MLFO9MM>X&2[U_4W5U^FUK?3]S/7_`.+L379/UHJ-19A8U['"MMHKM<'-<6SD
M6?IFU,=2VSV5^_UOSTE.PDL;#N^M/VRJC-QZ!CUG;=DU.D6-VO+;:V.<VVA^
M[TM]/I6?X3]+Z?Z1;*2E))))*<O/^K^#FXV1CVM]9F2YCK&9+[;Z_;8[)]E+
M[F^E[K+-OI>G_@F?S--=2XYWU?ZCC?XR>BWUXY=T_!PV8[LBMNRH%M.37[*R
M^QU;=WYF^Q>BJI9^ROVA5ZOV?]HP/1W;/7VQ;'I;OTVW9]J^A_W8_P"$24__
MV?_M&)Q0:&]T;W-H;W`@,RXP`#A"24T$!```````#QP!6@`#&R5''`(```(`
M```X0DE-!"4``````!#-S_I]J,>^"05P=JZO!<-..$))300Z``````#E````
M$`````$```````MP<FEN=$]U='!U=`````4`````4'-T4V)O;VP!`````$EN
M=&5E;G5M`````$EN=&4`````0VQR;0````]P<FEN=%-I>'1E96Y":71B;V]L
M``````MP<FEN=&5R3F%M951%6%0````!```````/<')I;G10<F]O9E-E='5P
M3V)J8P````P`4`!R`&\`;P!F`"``4P!E`'0`=0!P```````*<')O;V93971U
M<`````$`````0FQT;F5N=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F0TU9
M2P`X0DE-!#L``````BT````0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N
M<P```!<`````0W!T;F)O;VP``````$-L8G)B;V]L``````!29W--8F]O;```
M````0W)N0V)O;VP``````$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T
M=F)O;VP``````$5M;$1B;V]L``````!);G1R8F]O;```````0F-K9T]B:F,`
M```!````````4D="0P````,`````4F0@(&1O=6)`;^````````````!'<FX@
M9&]U8D!OX````````````$)L("!D;W5B0&_@````````````0G)D5%5N=$8C
M4FQT````````````````0FQD(%5N=$8C4FQT````````````````4G-L=%5N
M=$8C4'AL0'+````````````*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M
M`````%!G4',`````4&=00P````!,969T56YT1B-2;'0```````````````!4
M;W`@56YT1B-2;'0```````````````!38VP@56YT1B-0<F-`60``````````
M`!!C<F]P5VAE;E!R:6YT:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL;VYG
M``````````QC<F]P4F5C=$QE9G1L;VYG``````````UC<F]P4F5C=%)I9VAT
M;&]N9P`````````+8W)O<%)E8W14;W!L;VYG```````X0DE-`^T``````!`!
M+`````$``@$L`````0`".$))300F```````.`````````````#^````X0DE-
M!`T```````0```!X.$))3009```````$````'CA"24T#\P``````"0``````
M`````0`X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!
M`&QF9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&````
M```!`#4````!`"T````&```````!.$))30/X``````!P``#_____________
M________________`^@`````_____________________________P/H````
M`/____________________________\#Z`````#_____________________
M________`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`
M``````0`````.$))300:``````.)````!@`````````````!70```DD````J
M`$T`80!C`'(`;P!'`&4`;@!I`&,`<P`@`$8`;P!R`&T`(`!3`"T`,0!?`%\`
M10!!`%,`5`!?`#8`,@`W`#0`,``V`#0`-0!?`#$`,0!?`"T`.``Q`````0``
M```````````````````````!``````````````))```!70``````````````
M```````!`````````````````````````!`````!````````;G5L;`````(`
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG```!70````!29VAT;&]N
M9P```DD````&<VQI8V5S5FQ,<P````%/8FIC`````0``````!7-L:6-E````
M$@````=S;&EC94E$;&]N9P`````````'9W)O=7!)1&QO;F<`````````!F]R
M:6=I;F5N=6T````,15-L:6-E3W)I9VEN````#6%U=&]'96YE<F%T960`````
M5'EP965N=6T````*15-L:6-E5'EP90````!);6<@````!F)O=6YD<T]B:F,`
M```!````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG
M``````````!"=&]M;&]N9P```5T`````4F=H=&QO;F<```))`````W5R;%1%
M6%0````!````````;G5L;%1%6%0````!````````37-G951%6%0````!````
M```&86QT5&%G5$585`````$```````YC96QL5&5X=$ES2%1-3&)O;VP!````
M"&-E;&Q497AT5$585`````$```````EH;W)Z06QI9VYE;G5M````#T53;&EC
M94AO<GI!;&EG;@````=D969A=6QT````"79E<G1!;&EG;F5N=6T````/15-L
M:6-E5F5R=$%L:6=N````!V1E9F%U;'0````+8F=#;VQO<E1Y<&5E;G5M````
M$453;&EC94)'0V]L;W)4>7!E`````$YO;F4````)=&]P3W5T<V5T;&]N9P``
M```````*;&5F=$]U='-E=&QO;F<`````````#&)O='1O;4]U='-E=&QO;F<`
M````````"W)I9VAT3W5T<V5T;&]N9P``````.$))300H```````,`````C_P
M````````.$))3004```````$`````CA"24T$#``````/:0````$```"@````
M7P```>```+(@```/30`8``'_V/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2`
M`````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04
M#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,_\``$0@`7P"@`P$B``(1`0,1`?_=``0`"O_$`3\```$%`0$!`0$!````
M``````,``0($!08'"`D*"P$``04!`0$!`0$``````````0`"`P0%!@<("0H+
M$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("
M`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1
M`#\`]56-9T/.LS!D#J5S*VW>L*6FP`M+Z[30^;W,?7^BV,_1?X6[_!?HELK&
MMI^M1S@ZJ_&;A"X$M,FPT[VN</YG;ZGI[F?3_P"N>I^F8E/.87UFZD[_`!GY
M'07BM^,VLUFXAWJEC:_ME;?;8W&]EMS_`'_9O4])=XO+.G[O_'LRMT3M=Q,?
MT9GBO4TE*22224I))))2DDDDE*22224I<R_K74FU56-ZETP;GY3'/L]05GTW
M-=C^_<S9Z-7MR7N_1_I*?273+"MZ-U5]&P6X>_[1;=N=CM+8?.WV?Z3^7_.?
MI/TEV3Z%GVU*:_[=RW-L_P`I](:_=^A:+B)#?6TL<]SOSAC_`,W7]!F1^_5;
M43%Z]?\`:V,R^I=)]``NM]*QV\@Z,]/U+/3^G])$_9/6/1ASNGNM8X[",8M:
M6EEC/TS767?2>ZA]C*?0^A97ZOZ13HZ+E.L-6=5TVW">7&VJK%+7/)&QI_27
M6UM_,W>RQ)3;'7NBF=N=0\-`+BQ[7!H+;+=[W,+FL9Z5%UF]W^#KWJ=/5^DY
M%K:<?-Q[K;)V5UVL<YVV2[:QKBYVW:B?L[IY:6'&IVN(+F^FV"6C:R1M_-:I
MLQ,6NSU*Z:V6?OM:`?\`.`24E22224__T/55F9W4>JT=2IQL;IQR,6P5FW+W
MAH87V>E8WT]NYWI4_IDW7+NH5?9!A&QH?>T9#ZV!^VKZ5DM]')=N='IU_P`U
M[W^I;?LK3Y_U@PL#J%/3[F6NOO\`3V%C06_I;/L[?>YS?HO'O;]-)3Y_T\D_
MX[,HEI:=KM#!/]&9^Z7+U->6=/<'?X[,HB8VNY!!_HS.SH7J:2E))))*4DDD
MDI22222E))))*4DDDDI22222E))))*4DDDDI_]'J\[J+^JXF!=;C-K;5U>NH
M@DOUJM-=5U>^BNS]([^31Z?_`!2Z#(ZGT_%OKQLC(97?='IU$^X[G-J:=O\`
MQC]BYFH4V8.(]EUK/4ZQ6Z[U6>JYUH+?T3;J?V>UE/LV>L]F1L_F-C_YI=/?
MT_I^1D,R+\>JW(IV^G<]C2]L.]1FRPC>W](-_P#724^6OS:\#_&YU7J%DNKP
M\:Z]X:`XEM>(U[@QNYC7/]OT?4K7>_5;ZSX76.C8N6ZXA][W4-=>UE+[;&?2
MV4UVW-_S7KS;K8`_QA?64``#]FY>@T_[0H?1NJ=1P.C_`%/Q\+(=CUYO4,AF
M0&1[AZV+5^<#_@[K6?\`7$E/M:2\SR?K[D-P?K0XXS@.GYE=(+,A[7_I7W8N
M^JUS;/0V-PZW^DUOI[[+?S/T:[KH_6!U'$P+G4OKLS<.O,,-<:F^HUCO1^T0
M&>I[_H)*=))!Q,S&S<=F5BO%M%D['B8.TECOI?RFI9.9B8C&V9=U>.Q[@QKK
M7!@+C]%@<\CW:)*3)*E^V^C<_;\;3G],S_R21ZUT8.+3GXP<TP0;6`@Z'][^
M4DINI*-=E=M;;*W!];P',>TRTM.K7-</I-<I)*4DDDDI22222E))))*4DDDD
MI__2Z=U-^)@XK^K.&(P=599M>T6$M;[,7](S*?70S;5O?:YUFQGONJW^HMS/
MZ#@Y^=1G9!>;<79Z0&T`%EC<C]S?[K*Z]WO_`#%6^LYJ<SIU%D$69U!+7!I:
M6L=N>'MLLJW_`,AC/7M]3_`?H_5JT.H8F1E-H%&2[%]&^NVPM!/J,89?CF',
M]MO]O_BWI*?(^M-#?\8/UE`F!TW+Y))_H/[SB50P@/V?]1N=>I9'<_\`<C"7
M?Y/U*Q\SJ_5.L%N99DY=.3CEU=F.RNQIK^Q^C5795ZE-KJ_T/K6^SUJ_6?\`
MHT&O_%_C55=(I95G[.EY-MV/-V)-9=?CGU<C]#^F9957]J]*OZ'H_9_IVL24
M\+F@?L[Z[\Z=2QXU/_<C-_SD=MEM7UGZ794]U;V?5]KV/:X@M<WI=^Q['`^Q
MS/S=J[.S_%_BV5=7I?5GFOJF15=D;;L6;'-OO/JT34/0KJKM^TOKL][_`%?0
M_P`$I#Z@XYSL;*=5G"VG`&&'>MBEC6'&MPG4[?2WV9#&.]+UOYGUK/7_`)IG
MII*>3Z#]?>H=-^KV);GOR^I79'4[@+'93FN#*:L+]7L==7E;\>QV7O\`3_1K
MNZ_KCTA^5UG&-['.Z47`,M-E+&EI;B/JR<O(<^C?=FN=74]G^!>L5W^+#IW[
M-Q<5M/4"VB^R]M?VC%WM?:S&98Y]AI]-]7ZJQK&L]_\`.?Z16;O\7^+;;UES
MJ<^.K6`Y);=B@/G*&2Y^*UU?Z'9L9D_IW?S7ZO\`SR2G>Q^I="=DX.%2,2,V
MEUU89?5W)]M%&YMN0RU_VC]-57^8_P#X13Q^J]'R\-N974RYCK_L[O3?5=MW
M.AMUKZK;&>DZKT\IWO\`YA_JK%P_J155U3I&9LS:K>G8K**K76XKF5-VY1?3
M=6VG=D6U/LV>I7^C?]I_X"Q41_BVPG?5\=../U`5MR#E-QOM&)ZGJ.QV-<XY
M'H^EZ7JL^R;/_0C^;24]L;J&/R:Q5DQB,#Y:+-KP0Y_IXL._3/;LV[*T[<G"
M+L6MSK:K<UA?158;&O(:UMEC7M<?T=E;7^^NQ<CF_4#&OSNL9;J\ZRSJ5;Z[
MG-NQFML&_%R6C':ZG]`ZRVK_``WT&8[_`/35(^%]3;<`]+JP[^JTX^"XAM3<
MNEM(`OMR=^;CL8W[5ZWJ^_TO^T^S'24];4W&M#C58;`QQ8XMM<Z'-.U['0_Z
M;'?3:I^@SQ?_`)[_`/R2YJKI/4/L5M5].7>RV]E[J'NP6'U6_KOVG?@T8K'.
M^W5U-L]5SWV_SO\`-^LK63B=1;?FW5-O%IQRP91%%K;14!;34,)KJ7N<Y^3E
M4_SF/_,_SWZ6I)3M>@SQ?_GO_P#))_09XO\`\]__`))<1>[ZP867T#&J=0<>
MNTU/?E;,>^NL6CIN[#QGY-CKM^+>ST_6^V;[+*?T==EGHK%ZCUOZTXO1^KNR
M,7$M#\RH-II(O%HL-]=UV0S$RK[<=[7X-'_<>OU?7_1;_H)3ZAZ#/%_^>_\`
M\DG]!GB__/?_`.27E;_KSUYGU@+7LH;>.D')=8:W"P$87[9.,1ZFST?MGL_F
MO7]#]'ZOJ_IE3Q_KOU<=)Z`YE6.T6YUU5;`QY;4*ACUUOJF[U'/V]0R-_K66
MU?S?Z-)3Z_Z#/%_^>_\`\DG%+`09?IKJ]Q_[\O+,WZU]2]#ZYM=70^O!O;38
MQS'?K#7VCI#CE%MK=K_L=-?]%^S^]:&#]:>K97UO^KV+;Z,]2Z<V^R\5D6,%
M['9E^-3[_2]%]F%3_.5V6_RTE/\`_]/U0@&)$QJ/BLW-/U@.?4,)M`P@6>LZ
MPDN+=[/5],#9Z=C:O5_TV_\`1_S:TUEYW5<_&SZ<6GIMV1186A^6'#8W<^MC
MO:SU;/T;'OL_2MI9^C_ZXQ*;>!O]!V\`'U;OHDD1ZMGB&JRJ>%5792YSZRT^
MK=HZ)_G;/W'.1_LU'[@24E20OLU'[@_%+[-1^X$E)4D+[-1^X/Q2^S4?N!)2
M5)"^S4?N!+[-1^X$E)4D+[-1^X/Q2^S4?N!)25)"^S4?N!1LQ*G,<UOZ-S@0
M'MU+21]-N[<WVI*30#R.$&_"QKV;+&PTN#SL<YAW`S.^HL>J`Z)E[=IZKDQL
M+)V8X<"=P9;O&-_.,W?]<3_LC/)=/5+8)]H%.-H/GCNW.24X/UE^IN%'4^M8
MV,'9?[/R*F.%EKK"?LC\*NMF//I._1^S_P!2KS(XN5B]+^K5653919^TLH[+
M6N8Z)Z;KM>&KWE^'BV5NK?6',L:6/:>"UPVO;_::5C=9^IW2^J68)?37LP7N
ML8'FV0Y[Z++'M=3?3N<YF/L_3>K^9^Y^D2GR[-_F?\87_ARO_P!OWK4Z1_XN
M_J=_Z9Z/_;?*65F@.H_Q@/(U^UUEI^.<]:?1V-'U[^IX`YZ10X_'[/DZI*?_
MU/55EYGUCZ7A=0KZ=<]WVJTUAK&MG6U_HU^[^M_K_-K43&.Z2D&"X.I<1_I;
M>01_A+/WE82224I))))2DDEDVV?6EN7;Z5.%9B;HH)?8RP,B=UOLL8Y^[V[&
M?Y]:2G626)3E?6]];;+,'#8Y[032Z]X+'1N=ZEE=5S'?Z/\`1?\`;MBF+?K;
M-8./@D%[?4<+;-*YK%@:WTOYW9ZVWW?]N)*=A)8SK/K<U\-IP+6#<9WVL+@7
M.]-GT;=GI5;-[_\`#V?]QTGV?6SV;:</=O=N`<\L],"GTQZAV6-L?9]I]WH6
M>G7_`."I3LI+(%WUH-;MV-B,LFO9MM>X&2[U_4W5U^FUK?3]S/7_`.+L379/
MUHJ-19A8U['"MMHKM<'-<6SD6?IFU,=2VSV5^_UOSTE.PDL;#N^M/VRJC-QZ
M!CUG;=DU.D6-VO+;:V.<VVA^[TM]/I6?X3]+Z?Z1;*2E))))*<O/^K^#FXV1
MCVM]9F2YCK&9+[;Z_;8[)]E+[F^E[K+-OI>G_@F?S--=2XYWU?ZCC?XR>BWU
MXY=T_!PV8[LBMNRH%M.37[*R^QU;=WYF^Q>BJI9^ROVA5ZOV?]HP/1W;/7VQ
M;'I;OTVW9]J^A_W8_P"$24__V0`X0DE-!"$``````%4````!`0````\`00!D
M`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``
M:`!O`'0`;P!S`&@`;P!P`"``0P!3`#8````!`#A"24T$!@``````!P`(````
M`0$`_^$."VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T
M(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@
M/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB
M061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V
M+3$T.C4V.C(W("`@("`@("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z
M+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N
M<RYA9&]B92YC;VTO>&%P+S$N,"\B('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]P9&8O,2XS+R(@>&UL;G,Z>&UP34T](FAT='`Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]M;2\B('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O<U1Y<&4O4F5S;W5R8V5%=F5N=",B('AM;&YS.F1C
M/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(@>&UL;G,Z<&AO
M=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C`O(B!X
M;7`Z0W)E871E1&%T93TB,C`Q,RTP-RTS,%0Q-3HP.3HP,R(@>&UP.D-R96%T
M;W)4;V]L/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X;7`Z36]D
M:69Y1&%T93TB,C`Q,RTP-RTS,%0Q-3HR,#HQ.2LP-3HS,"(@>&UP.DUE=&%D
M871A1&%T93TB,C`Q,RTP-RTS,%0Q-3HR,#HQ.2LP-3HS,"(@<&1F.E!R;V1U
M8V5R/2)-:6-R;W-O9G3"KB!/9F9I8V4@5V]R9"`R,#`W(B!X;7!-33I$;V-U
M;65N=$E$/2)X;7`N9&ED.C)$1#$R1C8Q1D1&.$4R,3%"0C(V14$X.3(Q,3@V
M-3`P(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C)$1#$R1C8Q1D1&.$4R
M,3%"0C(V14$X.3(Q,3@V-3`P(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT240]
M(GAM<"YD:60Z,D1$,3)&-C%&1$8X13(Q,4)",C9%03@Y,C$Q.#8U,#`B(&1C
M.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB,R(@
M<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX@/'AM
M<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO;CTB
M9&5R:79E9"(@<W1%=G0Z<&%R86UE=&5R<STB8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]J<&5G(B\^
M(#QR9&8Z;&D@<W1%=G0Z86-T:6]N/2)S879E9"(@<W1%=G0Z:6YS=&%N8V5)
M1#TB>&UP+FEI9#HR1$0Q,D8V,49$1CA%,C$Q0D(R-D5!.#DR,3$X-C4P,"(@
M<W1%=G0Z=VAE;CTB,C`Q,RTP-RTS,%0Q-3HR,#HQ.2LP-3HS,"(@<W1%=G0Z
M<V]F='=A<F5!9V5N=#TB061O8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB
M('-T179T.F-H86YG960](B\B+SX@/"]R9&8Z4V5Q/B`\+WAM<$U-.DAI<W1O
M<GD^(#QX;7!-33I$97)I=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C
M92(O/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z>&UP;65T
M83X@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`\/WAP86-K970@96YD/2)W(C\^
M_^(,6$E#0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X`
M`@`)``8`,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6
M``$`````TRU(4"`@````````````````````````````````````````````
M```````````````````18W!R=````5`````S9&5S8P```80```!L=W1P=```
M`?`````48FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA9
M6@```D`````49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&
M=FEE=P```]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#``
M```,<E120P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=```
M``!#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD`
M`&1E<V,`````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'
M0B!)14,V,3DV-BTR+C$`````````````````````````````````````````
M`````````````````````````%A96B````````#S40`!`````1;,6%E:(```
M``````````````````!865H@````````;Z(``#CU```#D%A96B````````!B
MF0``MX4``!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@
M:'1T<#HO+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI
M96,N8V@`````````````````````````````````````````````````````
M````````9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````
M`````````&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````
M``````````!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%8
M65H@``````!,"58`4````%<?YVUE87,``````````0``````````````````
M``````*/`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`
M&0`>`",`*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&
M`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`
M^P$!`0<!#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+
M`9(!F@&A`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"
M2P)4`ET"9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M
M`S@#0P-/`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$
M2`15!&,$<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&
M!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'
M!P<9!RL'/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ
M"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*
MF`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG
M#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/
M"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,
M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4
M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E
M%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:
MQ1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`
M'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB
M)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G
M)E<FAR:W)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@J
MFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D
M+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T
M*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E"
M.7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^
MX#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*
M1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*
MQ$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&
M45!1FU'F4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7
MX%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]
M7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F
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MD`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9
M))F0F?R::)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6
MHP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RL
MT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;P
MMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!
MX\)?PMO#6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RU
MS37-M<XVSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#8
M9-CHV6S9\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/K
MY'/D_.6$Y@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP
M6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8
M_2G]NOY+_MS_;?___^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#
M`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@!70))`P$1``(1`0,1
M`?_=``0`2O_$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#
M`0$!````````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$
M$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A
M4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)
M2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(
MR<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$
M(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3Q
MHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6U
MQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EY
MB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=>]^Z]
MU[W[KW7O?NO=5"]R?S,=\]6_S/OB;_+[F^)F]Z;KOY157;V'P_RJW=O;;F`V
MUE]R=0]+R]Q[DQO5O7F.3/[HWAB,%35&/Q>2RN4?`P1Y*KDCI(ZM:9W;W7N@
M@[Z_FH_*/XP_-/X[=(]V_`>#:OQ<^57RRH_B%TGWMC_D=M+=/:VY-UYFLI<;
MMSMG+=&X;;LC[;ZQS-54/.8:C,')4>+@:JJE@FD@HI?=>Z"[K[^>;N[=W>W4
M62RWQ-I\#\`/D5\X-V_R\>A/E5%W3C<MO_=O>^WZ_/[>V]N[+=)Q;5BCP_5/
M8N\MI9/&8V?^,O7TZT;553$FN*G?W7NMBA?I]2;7%S_@3[]U[JI7^<UOWNGK
MGXF[6S75VX>V-B=<9'Y+]`[=^87:70M%N"N[OZD^%^;W=]MWOV-U;_='&YO>
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MSB-J9?<>)S$^&V%N_`X#-Y/&Y>@BDBFKZ6J<(#&"(V*^_=>ZT//YI?\`.H_F
M.?RP?YDWR\^*?Q%^0N=P726R\_U#4;:V_P!M4..^0N<Q+YWH3K'<^76EWCW=
M3[XW+##79W<-54211U$<)=QZ!8>_=>Z#7X-_\*9OYP_>?S5^(72O8?R)V?E.
MO^V_D[T1UIOK%4O0G2F)J<IL[?/9^V-L;EQT&5Q>R:3*8R>LPV4FC2HIIHIX
M78.C`CW[KW7U&E!`/T_4;6OP+_3F_/OW7NN7OW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[H@
M7\U/NCLCXZ?RXOFGWIT]N7^YW:757QY[&WIL+=/\,QF9;`[GPV$GJ,7DX\7F
MJ/(XBMFIJ@`I'4T\T!>VM&6X/NO=5(_RY_G/\[Z_,_*+J#MFBW-VUOOK#L;X
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MJ_D)T/\`&7`]P[H^+W7&T>VMH+\DL_VYT)VCO#Y";1WYV)U;\:]R8/"Y'N+X
MU;4Q7QTW/O"FZC[*QN7-91[F[)HMFX[`5@BQU:9I95F]^Z]TD?FW_..^6G6^
MPOY@=+U)U!U=TQO+H'H&C[Q^-,G>.9W_`%._>\^H:4=7UV[/D?UYB*;KFJZ+
M[)Z_P]+O^IQIPU!NR;-X7+T47\6IX8ZI4C]U[HV_\P_Y0?++K#I3^7UUC3[N
MZ_\`BMWM\[OE9U!\8^X.Z]DU=)VKM'H.'>.T-W[OW13=-Y?L7;>*P.?W]O*;
M:D>$VQ69K#O3K/622BF:5(9%]U[H"?E-_,=[8_E74NP>IMP=K[`^?L6QI=I;
M@[KW!V#O*JVC\Q*'KCM7Y#X_IS:'W>S>B>A9N@L.VQ/X_!"FY-X9C:";LJZ&
M:BA@%:'ED]U[K%G_`.>?O;KWNKM).T/BMC,5\5.M^^_Y@_QII^T=H=PS[K[D
MW'V)\!.DM\?(G<.?@Z>.RL9B\7L_>^PNOZW%TL7\:FK8\TZ22!*0QM+[KW3%
MO_\`G/?,CK[K/XCKD?A?U-N'Y'?.?979GR'Z"ZQZP[K[,[<VNWQUZWZ2V=W2
MN!W17[&Z2J][2]^;JDWK1;9H(,5AJW:*UDDF6FRD=!3RJ?=>Z.Y\8?Y@G?7R
MC^96Z^A,1\5L5UCU7T_T3\9^X^^]X=E]KUE%W-U]N?Y6=*U?9VPNGZ?J/%[,
MJ\5D-U[0W!AZS&;@JILY!2T\4'DB$DK")O=>ZM]]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U__1W^/?NO=>]^Z]U[W[KW7O?NO=<="DZBJD_P!;"_\`M[7]^Z]U
MWI7_`%*_C\#\?3_;>_=>Z]8?T'^V'^'_`!3W[KW12OGS_P!D._,#_P`5G[N_
M]]QN+W[KW7RC_P#A2A_V^P^<W_:XZ+_^!FZ6]^Z]T1C^5W_V\L_E\?\`B[/Q
M:_\`?W[(]^Z]U]PP?3_8G_>S[]U[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T@NT.M]@
M=P]?;NZK[4VCAM^]<]@8+(;5WGLO<5$F2P.YMOY>!Z;(X?+44EHZFAK(&*NI
M(!]^Z]T43J_^7=_+WZ\V+D.I.J?C'T+A-DT/:FSNT<_MK`X#&5Q7MWK.MI\K
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MP\^97=O6^X<;BL1N39?V&4JJS'8#`;GHL#0?Q2GQD5&,G+04TM5Y98(G3W7N
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M]325F&W`V]*7$8[;>X]T;,J*7/TN],;B<=MRII<954>+J(L33XN6.D>!:9UC
M/NO='8Z]^/?374^Z=W[WZVZTV7LC=W8.!ZTVMOK<&VL-!B\CNG;?3F"K=K=6
M8+,3TX5JO&]?[:R,]%BD-A2T\K(HL3[]U[H:/?NO=>]^Z]TG\1NG;^X/XI_`
M,SBL[_`\S6[<S8P^3H,F<-N'&B,Y'`93[*IG-!FZ`3)YZ27141:UUJNH7]U[
MIPH,KCLH:S^'5U'7?P^MJ,97FBK*:K^RR5)H^ZQ]7]M++]M74WD77$^F1-0N
M!?W[KW3A[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z__]+?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T
M4GY\_P#9#OS`_P#%9^[O_?<;B]^Z]U\H_P#X4H?]OL/G-_VN.B__`(&;I;W[
MKW1&/Y7?_;RS^7Q_XNS\6O\`W]^R/?NO=?<,'T_V)_WL^_=>Z[]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=5^?S5\)\G=R?RY_F#@?AK+G8_DIE>EMR4?60VI52T.\JBHE
M:E_O-1;&K::2&MI-^9#98R4&#DIWCJDRTE.8&64(P]U[K6D^*?:70W7W9WS:
MI?@?U$OQ`Z'V1\`=L9K$_-KIKX6?)_.?+[JGL*#MSKS"9/H;Y.=3=YP9W9?R
M<^14-7-E,Q49>DH:ZL6B,C"LDC6HF;W7NK&OYU5%!6]A?!?<_P`D]K;H[._E
M\83;/R"J.X:6KZT[%[+Z,Q'ROK-B;4J/B-V+\T.E^IJ67L/='06,S5+FT:EI
M*8T-#G:N%*XQ*\+#W7NJD=P_-GY0=*?R]OCG4?%/8';GP\[$K]M_+OMWI3J_
MXU=,[BPGP_[FS76?R-CP.VL+B^O?D-TKWC\@JS)=P;4>KW+B.NX*O9F.IMLU
M<^0:LA>*"G3W7NA6^>7=_P`Y^YML_P`XCHG$=\_)3>>5VMU)BN]NII/C-LNI
MV7L'HGKK8G;'4T>5^,G8NW<QTKANU]M_(T8>IS&4CS6W=[[BQV^=JTU35PQT
M(I7IV]U[HP'</RA_F0G&_.KMWXX?)WY`]B=%_&3I#X`4WQ[S,GQ6V=GLCVWL
MWY/[/V3+\C_F'D,#3=3[/W/V3O\`Z2V:N9W#2;6QE+1XK%YB-FK\8\*?8GW7
MN@+WU\^/YAN+Z6PL.Q_D;W5DOA3FOG1VQU9LK^9AV3U`W7/;.7Z3P7QMPV[N
MKVWM28?XI;^7&==5'RBJ\CM_^^]/UJPW/!AACO)0QU$E2WNO=#MF/FW_`#,M
MB_(2@V_'V1N#Y9]Q[A_EO5N^^K^@?C?TWGME]4[-^3VU_BGFM_5N]?DOL_M?
MI+9^\-Y=2=\=E/CJC9F9VYO+;U?C-P%=KUN!B,[,/=>Z+EC_`.9-\SMI]&;U
MW?MWYM_(;??3<W:/\KO:.X_ECVK\1MJ[9["ZL[O^1W8^Y-K_`#BZ,ZJZGJNB
M\%CNV<?UILK[#-4F'I<1F*_;63EBQ4=55R$,WNO=)C([F^?WR1G^*7>N$[I^
M0NV]X]-=6?SV#\<?F12_'+;A[;[[^.G5-;T/D/BSN#L?J_>G6-%M38^>[O&'
MGIU']V</FL[CL4!2PP3UDE1[]U[HPM%_,O\`G)F_E/\`"K(1;@^16S\GE]N?
M#A_E[TQV#U5M/#_'";9_>'PLRG;?:W:/6&UX^FZ/LC#[`V3VY3TU)D-W;B[*
MQ9Q&XO/@_P"&"EBDF7W7NBA=4_S,?YE>Z/BOG.YG^3W9F3SO8F?^"-1VCL/<
M&U]BOVO\<_C#W#7[RROR=^=W6V'V=\4Z:NV]T)OG<]'A]H[)FI\'V8VR,7/6
M5M6M74+2U!]U[H:/DS_,,_F,]7]%?%5ME][][=F?)>+I^#N':^]NH^EZ.H^*
MGRKVZGR^3KB@V=E]M;Q^*.+[H[7[TH>@[UV[J&@CZOP6,Q<:[@HI9FJ(X_?N
MO='YZ^Z_^3M!\!?^%!F#^,VVM][7^16^/G[_`##\]T?_``_%9?:N\=TUNY-C
M=7K2[AZOK:J#&560S.<HHZR';^5H)"KY2.,T\_ECU+[KW1/\#W5\"^COB-L6
M+^6'MGY9_%_?G8>YNB.F/DSVQUCTKO7JRNVCV%C>N]_Y/"XSY7=F?(KX\]QX
M8;HCWLM53YG-[:VSGL]FLW/28Z7(Q4M=%,?=>Z9]S_-3^;]NKH3:'>]/VUW3
MUON[I+^7S_+Y^2V[>HL#\5MI93']\?(/LCY5=C=.=Y[7[`I,AUW6;WPV/J>K
M<%3UN5VYMV3'R451/'DHA0Q0&";W7NE]W;\[/YA6U\?_`#.\KMGN;Y`1?+3J
MCN;?^SMK?$''_%HY#J?H'X)XGO7K+;>T?F%UON^FZ<S^7[(W[+T9E,CGDKY,
MYN"#)SY2>5-LR08;QI[KW0O_`!^[@_F2]W;\_ER]34/S7S>3Z4[7[%^?.\-]
M?(SJ?I*/<V:WYT1\?<UT7F?COU9V9OWN/X^=3X[#]@9*;/9["Y;=F(VC@Z7<
M^.@;[.)ZKRU,7NO=;3ZWTK<6-A<7O;C^OY]^Z]UW[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO__3W^/?NO=>]^Z]U[W[KW7O?NO=%>W/\U/B
MEL[Y)[`^'FXN^.NZ'Y1=H8_+97971<6;3(]AY+&8;;^1W75U]?@\6E;)MNDF
MVYB*NLI),FU&M?!2S&F,OB<+[KW06YS^:!\`MM?++&?!G._*3K3'?*K+5^*P
MM'U+-4Y<UB[ESU)'78'9E?NF/%/L7$[\S]+/&U!@:O*0YBM,L8AIG:1`WNO=
M=8#^:!\`MT_+')_!O;_RBZURGRIQ-?F<+6=34U1ES5MN?;=)+7;DV50;K;$K
ML/+;_P!MTU/*V1P%)E9\S0^&03TT9C<+[KW2]^>[!O@W\OV7D'XS]WVX(_YI
MSN+\$`^_=>Z^4A_PI0_[?8?.;_M<=%__``,W2WOW7NB,?RN_^WEG\OC_`,79
M^+7_`+^_9'OW7NON&#Z?[$_[V??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7ND_NK<N
MVME[:SV\]YYO#;8VCM##Y/=&Y]S[BR5#AMO[9V]@:&HR>;W#G,QDIZ;'XG#X
M7&4TM355,\B1001L[,`I/OW7NB6_%G^9K\&_FIO7/==?&SO;&]@;[V[M&A[$
MDVK7[.[&Z^S6<ZYR61&&HNR-D479FT-FOV#UW/E9%IOX[@_XABUEEB4SCS0Z
M_=>Z&[Y)?*7X_?#_`*V?MWY&=C8CK'8S;APFS\;D*V@S.<S6YMY;HJVIMO[,
MV7L[:>,SN\]];PS<\<CT^+P^/KJ^6.&:41>.*5T]U[H.>E?Y@GPP^0>R=D=A
M=4?('8V;VYV3V_E/C_M-<Q)E=C[EKN^,'A<IN++]-9#9&^L;MK>NWNT,=MW"
M5%=)@\CCZ3(_91B<1&)T9O=>Z%/X^_(_JGY/[$K^R>H<KDLSM/%]B]G=6U-=
ME<%D]OU";QZAWYG^L]\4L5#EZ>EJY:.AW=MNLIH:E%,-2(]4;%6%_=>Z&J.O
MHY@98IH9HD^Z_P`HCEAD@'VDK4]:OG60QJU+4(8Y5)!1U((%C[]U[HK_`,I/
MFY\7/A=M_:>Y_DGVG1=>T^_\]+M;8.'H]N[PW]OC?F:I:,Y+(T>RNN>M=O;P
M[`W7%A,?:HR%10XR>FQ\,B/421*Z$^Z]T-?7':?7O;VP]E=E]<;GQNZ]C]B;
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M<T]+&7:_NO=&N"J"Q``+$,Q'&I@`H)_J=*@?ZP]^Z]UUH0E3I6ZBRFPNHXX!
M_`X]^Z]UR]^Z]UZW^]W_`-XM_O7OW7NO6''^'T_P_'OW7NN)1&OJ4&X4&X^H
M4EE!_KI)N/Z>_=>Z[````%@/H/?NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[K_]3?X]^Z]U[W[KW7O?NO=>]^Z]UJ5?S,?DI\*.G?YZ_\
MJO=4V2VSLO=_0^]?E3DOFKO7`=-;T?*X2I[L^+.U]B?&RJ[0WMM?855)O-]Q
MU-;%BL0XK,B,5"VB;[:!3I]U[JNW+)7PY3Y$_P`M+*;2WW'_`#&>R_\`A2)A
M_F-L?%IUON_(9"?XZ9#L[8>^L'\OX=_TF"GVSC>K\#UQB\A')5KD4JL=%(T3
MT\:R26]U[KKHJ:MWCE_Y>G\NC#;:WX_\P;XQ?\*!>Q?EQ\H,=5=6[UQ57M_X
M][7[.[FWIO3O3=78M9MVFVY6;,[0V5N/"4F(K'R+IN`PQPP^40P!O=>ZVN_Y
MG=-\FY_BO\C)NG<YT!C^M4^,W=S=A4O:VV>R<UN^L8;)SK,-FY#9>[<%B,:A
MPZR*GWM+5WK"C-^UJ4^Z]U\M?_A0I'V)%_.#^9D?;%;L#(]A+D^E3N.MZNQN
MY\-L.65OCIU"V/&!QF\<GFMR4ZQXAJ=*G[FJEU5BRM&1$R*/=>Z*/_*[_P"W
MEG\OC_Q=GXM?^_OV1[]U[K[A@^G^Q/\`O9]^Z]UW[]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z(_P#S*?B_NKYI_`SY4?%C8NZJ/96].[>HMQ[-VGN+)S5M/AJ;<4H@R&'H
M=PU&.@JJ^GVUG*^@2@R4D,-1(E!4S,L,I'C;W7NJC\_\:/G+\R.SMO\`=7R8
M^`>P>B=L?&+X`_+KXT;>^,N`^5FSYY_FEOSY/;$VCLO+]:X_LWJ>D9^B?CQC
M\+L9H<3EJVJI=R8RNRL51'0Q>"1Q[KW1G?F'\7/DC4[=_E:_(/XW=#;7WKO[
M^7SNR'<V>^$^9[IH\=CL[M7>_P`=LUT?G=L;)[JWS2R;>W#V-T<^:CGP&6SS
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M8?85?AZ6&K3[FO\`)-[]U[HD.(_D=_._KKXZS;/ZIV;C,)O7M'^7!TGL7Y>[
M?C^4&X,-)\H/DOU9\P=F]E;UZKW+O>++YBKPLW9/QHH\UM.FW732)C:2AK1A
MI&CQSDQ>Z]T*W<G\J3Y4]K=S_&K<^V/BKOSXZ?&3#=0[/V9UQ\?OC]\F/C]3
M]D?R[^T]J?*R?N3</9.V-Y;]&;V?MK_2IMM:2KR&2ZU.6S4=/2MM]HWH761O
M=>ZNF_EM_!3*_&[LGYV=_P#;6R<92]^?)?YH?)#=V'[`3?.5WID<S\6\UVEE
M=W=#;:2*JR=9C=F8G$T68J:E<)30P/1U%1)Y+NQ`]U[JVKW[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7_]7?X]^Z]U[W[KW7O?NO=>]^Z]UX"W'_`!O_`'OW[KW7
M`QH6U%5U:=&JWJT7U:-7ZM%_Q]/?NO=>$<8)8(-1549O[3(A<HC-^ID0R-8'
M@7/OW7NBE_/@`?!SY@`?0?&?N[_WW&XO?NO=?*0_X4H?]OL/G-_VN.B__@9N
MEO?NO=$8_E=_]O+/Y?'_`(NS\6O_`']^R/?NO=?<,'T_V)_WL^_=>Z[]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO==$`\$7'OW7NN'ABM;0MK$6(N+'ZC_6]^Z]US"J```+
M"UA_2WTM_K>_=>ZX^-+WTK>]_I^;W_WOW[KW77BCL!H6P-QQ]#]??NO=<@J@
M@@"X^G^'%O\`>O?NO==-&C?J4'D'Z?D?0_ZX]^Z]UQ,,1TDQKZ.5X^A_J`.+
MCW[KW7+QI8@(H!M<```V-Q<?Z_OW7NO:$Y&D<@`_X@&XO_6Q]^Z]UR"JHLH`
M']`+#_;#W[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_];?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]T4GY\_P#9#OS`_P#%9^[O_?<;B]^Z]U\H
M_P#X4H?]OL/G-_VN.B__`(&;I;W[KW1&/Y7?_;RS^7Q_XNS\6O\`W]^R/?NO
M=?<,'T_V)_WL^_=>Z[]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=?_U]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=<&D"\D-:]N$9N
M?\;`V''U/'OW7NO"12NOG38&Y5EX/TX(!Y]^Z]T4OY\$'X.?,`CZ'XS=W$?^
MBXW%[]U[KY2'_"E#_M]A\YO^UQT7_P#`S=+>_=>Z(Q_*[_[>6?R^/_%V?BU_
M[^_9'OW7NON&#Z?[$_[V??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO_T-_CW[KW7O?NO=>]^Z]U[W[KW71('U-N0.?Z
MDV`_UR??NO=:)&Y>[^ZI?YKN4["R7?WR$J^M-O?SM-L=%Q?S`]K]L=MCX<['
MZ/;9]+D9?Y6^X_C+CB=BU.ZZG>%1!M');[>ADP_\:R2Y"IKX6C;R^Z]T[=-]
MT?(V&K_E^_S/*KOOY&5OR`^9O\\[<WPF[JZ3S';.Y<QT7@_B[NSL7MOKJ/I7
M!=)2U#[,PM#U/ANM*7(X^N2C&0BR$T]5//)(8'B]U[K9S_F>=\XSK3XM?(W8
ME?UEWYO)]Z_&/O&2GW'U9TSNWL79NW%79N8Q93>>ZL'"V*VO+KJ?,RU4B%*-
M))^4C/OW7NOEJ_\`"A'>M)V+_.!^96\Z#;N_-I4F<RG2\D>W>SMFY/K_`'UC
M/LOCMU%C9(\[M',?[DL/)/-1&:G$H!GI)(I@`L@'OW7NBE_RN_\`MY9_+X_\
M79^+7_O[]D>_=>Z^X8/I_L3_`+V??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO_1W^/?NO=>]^Z]U[W[KW7O?NO==$`V
MN+V-Q_@?Z^_=>ZJI_P"&7/@`/D54_)./K;>\.>K>]8?E)7=54_<G:E/\<J[Y
M-4\D,\'?U9\?X=UIUC4]G1U5.D_WKX\Q&H42F$OZO?NO=*/8O\H/X&]=?*FN
M^86V.J<U%VI+V!O/M["X#(]C;^R_3VRNY>QJ:*DW_P!P;$Z9R6X*GKK:O9.[
MH8S]WDZ6@617<O"(G",ONO=#Y\]T"?!_Y@NI=6_V6CNYKAW%F'7.X;,!>UQI
M'OW7NOE(_P#"E*[?SL?G,S,SM_&>C"6=BS$GXS=+W))Y)Y]^Z]T1C^5W_P!O
M+/Y?'_B[/Q:_]_?LCW[KW7W#!]/]B?\`>S[]U[KOW[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]+?X]^Z]U[W[KW7O?NO==7%
M[7Y-R!_4"U[?UM?W[KW7?OW7NO>_=>Z][]U[HI/SY_[(=^8'_BL_=W_ON-Q>
M_=>Z^4?_`,*4/^WV'SF_[7'1?_P,W2WOW7NB,?RN_P#MY9_+X_\`%V?BU_[^
M_9'OW7NON&#Z?[$_[V??NO==^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO__3W^/?NO=>]^Z]UI@_-WI/^5U@,EWA4?*'IGY>
M?+WYB[.[RBP0VG_,*^8W?_2VW*'JKL7>N1HL5\I>NMR]5YFKV%#\(]EKIH?X
MULG:^9K=K$4N/S5)CJDO,GNO=7:_R7^INM<!\7\#WQTU4_*7876?R$PE%E<!
M\8^_/D%O?Y"]>](G8VXMW;4;)]!;E[1QD'84.P.SHH%R])554Z09G$OCZQ**
MA=Y(S[KW5Q/OW7NO>_=>Z][]U[HI/SY_[(=^8'_BL_=W_ON-Q>_=>Z^4?_PI
M0_[?8?.;_M<=%_\`P,W2WOW7NB,?RN_^WEG\OC_Q=GXM?^_OV1[]U[K[A@^G
M^Q/^]GW[KW7?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[K_]3?X]^Z]U[W[KW6E;5Y[XB?(KYW]Q;[^6'\WGH;`=/;%[1[^K]H
M83LGY4=W?&;Y>]([YR,F/Q'56UNH^F>[8NL]H_$S-_&#+8ZL6CWIL.IK7[)H
MU09JCK*.OF#>Z]UL0_RV/F+T[\D-C;GZPV!\R,3\\]^?'IZ+`]F_(_:'5E?L
M79VZ(]SY;<E9L*CJMQ8/&Q=.[L[%H-HXN%,\VU*MJ4SJM8]'CTK8:8>Z]U9C
M[]U[K7BV_P#SA]^=T?S*MY?$WJ+LO^7OU)U'TK\G*7XN;QVE\F^U-Z8GY?\`
MR)WGMREQ%3VU6?&[8FVZS'[;P=)MG)9<X;`?QJ#)Q[GRU)+'#)3DO'#[KW02
M];?SO?E#NWMKXY]U;@Z*Z$Q7\M3Y=?S`MR_RZ>D\Y0[KW])\M*#L2ESF\-F;
M$[?WMBZJG7K1-A[YWAL7(0RX6"*+)XB%5+U-3>-IO=>ZN_\`GK=_@[\P$NAD
M'QF[NU@,%`/^CC<=_P!9%@=)M?Z^_=>Z^4G_`,*5%,?\[/YSHQ74,ST8+*Z.
M+_[++TL39D9E-OS8\>_=>Z(M_*[_`.WEG\OC_P`79^+7_O[]D>_=>Z^X8/I_
ML3_O9]^Z]UW[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z__]7?X]^Z]U[W[KW51GSM[^^#.QOD/\=.A^_/A_2_*SN'N;.;%HX:
MNE^//77;M%T1L#?W;.T^C-H=J]N[LWW!&NS-BYOM?>=!A<?]LU775E9Y5BIR
M(6/OW7NCJ_#SN?IWO_H#9G9_06UJG8_55=D=_P"T\!LVLVCC=B5NU<MU=V-N
MOJS>NW:W:6&EFQ6&J<)OC9>1IM%.[PND8=&(:_OW7NC/>_=>ZUAM[?R.^_LQ
M\D.\<9M_LCXQ0?"?Y$?S%=@_S)]_;CRW7&\*KYR;1['VUN+;6]]W=0=8[WI3
M%L[&[(W;NG;")09EJR*MP-#D*](Z2H^ZG$GNO=3>J_Y*7RAVMVYT)U1OKO/H
M/*_RXOB;_,&WI_,:Z(VKM[9._(OE1ENRLMN'?&].O.K>PLUD*YNN*/9'7&[.
MP*Z>7)41J*W,HH22"F!B^W]U[JT;^9S\;>A.W/BA\C^QNT>I=E[]WKL'XR]V
M#9>XMS8HUN3VTJ[(SF71<54K-#-2JF5IHZ@`'_.H";@6]^Z]U\M#_A0KU_L;
MJW^<)\S=@]:;2PFQ=C[>RG2L6#VIMRF:DPV*2N^.O4.5KEHZ>26=XA692OGJ
M)!JL99F(L+`>Z]T4?^5W_P!O+/Y?'_B[/Q:_]_?LCW[KW7W#!]/]B?\`>S[]
MU[KOW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M_];?X]^Z]U[W[KW6L;_/&VSL'N?Y*_%[H"A^)E=VGWUENG^T>U-L]Z-\]<E_
M+QQ>&ZWZ_P"R.LZO.]4T/9>.VWNI>W=P?WX?";A3;U11O-@/M(\M2-%>JFC]
MU[JY;^7-L*AZP^%GQ_V#C.E.OOCMCML;3RN.H>G.K^X'[_V9L^G_`+V[@G0T
M/=4U#CJKLW+[C6;^+9?+3QM45.7KJDS232ZYG]U[H[GOW7NO>_=>Z][]U[HI
M/SY_[(=^8'_BL_=W_ON-Q>_=>Z^4?_PI0_[?8?.;_M<=%_\`P,W2WOW7NB,?
MRN_^WEG\OC_Q=GXM?^_OV1[]U[K[?^1R-#B,=7Y;*5M'C,9C*2JR&1R61J8:
M+'X^@HXI*BLKJ^LJ9(J>DHJ.GC:2661E2.-2Q(`]^Z]T4CXU?/WX??,+/[KV
MO\:>_=B=M;@V1CZ#-[AP^!ER]!D6VOE*ZJQF-WOMRFS^+Q#[TZ]R62HI*>FW
M#A_OL)43`)'5,Q4'W7NCB^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[K_]?8T[%_GX_%G9/R=[L^(FTOCO\`/;Y`]U?'W<$>V^R\#\;?
MBYE^X%QE7-3154-=24F!W*FX:O"SK*1'6&@2&3264E"CM[KW5K7QZ[KI/D1T
M_LGN.@ZX[>ZCH]\4.1KH>N>_.O\`(]6=P[7_`(;G,E@WI=[=?Y::HK]MUE7)
MC#4T\<DC&:BFAF'ID'OW7NM,O^9+\]OC)W]V_N/:W;'<W\D7MO>'1'<WR+Z]
MQU%\N?AK_,<[$SG6W5]+OG&4^PMGT^4Z[Q6-V^_8.-7#5T>\:RD>;%UM=%3R
M4++`67W[KW6T=_*AR6S,S_+Z^,V7Z\'QT&R\EM#<-9M__92=A=E]8?'-J2HW
M]NN667K#8O<7_&3<#C9JII'K%S'^43Y-JF9+12(/?NO=6(>_=>Z][]U[KWOW
M7NBD_/G_`+(=^8'_`(K/W=_[[C<7OW7NOE'_`/"E#_M]A\YO^UQT7_\``S=+
M>_=>Z(Q_*[_[>6?R^/\`Q=GXM?\`O[]D>_=>Z^T'\NNB&^4OQ3^2GQICW/4;
M+?Y`=%]L=,)N^EIC7R[8D[+V1G-G)G&QXJ:,Y*GQ;9@334HFB-3$C1:TUZA[
MKW59WPK^&7R\QGR=Z&^0_P`J=I?'?J*G^)7P3D^#77VT?CQO+<F^1V_79;<O
M6^8W5VOF\AG-B==0]?\`5E#1=5T";6V9X,M74%3D:N:HK5\422^Z]U=W[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T#'?S;-_=P_*
M3Y?]O]*93^6IVYT9L_IG+T&"V)_,>ZA_E\?);Y3?,+=\^-I<97P;M^-_9W2=
M?T[MGKK%TVHPT4V5W-GZ<!%=Z42"2"+W7NMGW^6>U0_P;^/7W>]/E=V)51[6
MS5/4;U^<6W*[:7RJS\U-O7<U/+/V[MW*PQY7'9"FDB,&-^Y>HGEPD5'))45+
MN:B3W7NJS_YPV\OGGU/WY\3NV^BMF?,WLKXN]?Y7:F[=Z]=_!.EV;7;EW7VO
MM[O;KO-;VPGRDV_G)Z+<&Z_C_NGXPTVZ,?B(*">'&1;K=),W+'"U(WOW7NK/
M/Y<4/R8C^&W3=1\PAFX_D'EH=^[AW70[IS&W=P;OP.V-S=H;TW#U3M;>6<VE
M3TNV\IO':O4N2P>-RLU$G@;(4DUBQNS>Z]T>&_OW7NB.=T_S&/B3\?\`Y4=`
M?"OL[LU,3\D_DVDM3U'UQC=O[BS]7DL::NOQV.R^XLGA\95XC9^+SN4Q%=2T
M$V1F@2KFH:@1DB%RONO=!)M+^<-\"M[_`"KD^'>W.U\U6=IR=C;JZ7Q&Y)>N
M.P*+I7<W>6QJ!<GO'I+:_=U7MZ+K;.]G[<HVO48V"O8F:T$;/4,D3>Z]T8;Y
M[DM\&_E^38,?C-W=<?T/^CC<0(YYX/'OW7NOE(_\*4?^WV/SF_[7'1?_`,#-
MTM[]U[HC'\KO_MY9_+X_\79^+7_O[]D>_=>ZVR_^%MF>SN#[Y^!38;-YC$_<
M]1]V"=<9E*_'I*T.\ME&-Y(Z2HA1W`D(N1<CZDV%O=>ZT=CO[?+`JV\]V$$$
M$'<>9((/U!!K2".??NO=?;W_`);TDK_R[O@?+--454\GPV^,DLU153S5=543
M2=+;*>2:IJJAY*BIJ)I&+/([,[,2222??NO=+V+YD_%2?O\`/Q6@^1'34WR/
M2FEJ).E(^P=N-V,LE/CDS=3CAMH5QK6SE+@'&1DQUOOTQQ%4813GR>_=>Z,O
M[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]&Q7YO]R?RFL+\LOD%M
MON3^<#_.&Z,[HQ^\JN#>?3GQ[[F^;N#ZRZ_W.V!Q<U/@NK]O==](;EV%3TB0
MS034L%#55M*U5,02P+(/=>ZO`_E&;Q^2?8'\O+XW;Q^6AWE/W7F=O;K.0RG9
M6W8MH]F[CZ^H.P]W8[I/=O9FUX6=,)V'N[IBEP.2S418RG(54CS:9FD5?=>Z
MJ7_GCQ?'+'_*'X^OW#W_`/)2@QO9W3D74_R!^'WQS^-W8/R`W'\A?BY#\F.J
M=X';(W)UWN7;>4^/F-[H[>Q^+V)F,@GW57O+&93^#P*C1L)/=>ZM>_E!8K8F
M%_EW_'7'=7[PW+O;KB*E[0FV)D=V[(W!UIE]N;4K.ZNQ:W!]70]?[LW+O'=&
MT]O]-8^HCVEB*/(9.KK(L5A*<2LK71/=>ZLGF-@MRNDN`VH$DCDV4`B[&WOW
M7NM*?O/XB?S5=B_S%OCMWWO?XQ?'KN;</;O\W6G[@IN^MF]@=A9S<.U>A]E]
M1[RZRZ0ZH[#H\;U-%2=.=+=2=35>2R"59K,F<ANZL<U"O/5ZIO=>Z#?X^]&_
M(3*I_+X_EBR_';Y'8'O7X2?SO]S_`#=[V[IW+U3N+!]#U/QNV)V)V]V%C^S,
M/W94QKM#<L_;F(["H,?AZ.DJJBJJJB">.5$`BU^Z]UM`?S-]D]W;A^*?R/SO
M6_?&'ZSV3BOC)W<V\-GU_3>$[&J]XR#96<J]5'N7+;JPLNUQ+C8GHQXZ6I\3
M2^=?6@4^Z]U\M+_A0OB-Y8+^<+\S,1V!OBA[(W?0Y3I5<UO;&[*H.NZ/.R2_
M'3J&>CDAV=C,IFJ'"BBQTT-,P2JE\[0&9M+2%5]U[HHO\KO_`+>6?R^/_%V?
MBU_[^_9'OW7NMK;_`(7`_P#,]_@'_P"(D[Q_]['8_OW7NM%[W[KW7W(_Y;9_
M[%V?`RPN1\,_C`;"U_\`F2FR?ZV'OW7NJ7L+_+7^9/\`?S8OQNR/4G4E#TOU
M]_.+R_\`-4JOG9'V/BJK>^^-N5/:.X^XZ387^B>#"4F_*/Y!9B/<L>P\IFZN
MI?`IM6CE,<U2KPT8]U[K9T5=.KF^IBW^M?\`'OW7NB>?(_YY?&GXK[PVAUQV
MENC=V1[.WOMS.[WP?5W4G4_:G>W9<?7>UIX:7<_9N;V'TSL[?.Z-M];X&KG6
M&?-U]-34#U`:&*229'C7W7NC98?+46=Q>/S.-D,^-RM#1Y+'U)BF@^YHJ^EB
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MPGRFX._^B?C)OOYA;L[WS_\`,$Z=["Z_VK6[5^!N.ZUVL.L/BS\;)<51OO[9
M?<^8[*H)J3/Y":DEKJ-HZBN5ZS'UIIS[KW5JW\JZL^4M7\$NAA\SXMZ1_(:C
MH-]XO<K]FT6,H.TZ_9N%[/WGA^GLOVK2X:>JQL79F9Z>HL%5YTQRR-+DIII)
M3Y6<#W7NJ+OGI\IL/\G/EEV+U9TW_+O[P[=[7R.Y-_\`\L'I7Y)8WY<[5^,F
MQ]W=R]3UNP_FAVE05-92U55V/UCN7XOY?JBEW7U_N^'&UJY'<%'54M/H#O')
M[KW5U_\`)]SO4&Y_Y<?QCW!T7M/?VQ]@Y7;^^*JMVUVKO*3L;LRA[0/:N^8^
M\JC??8LD5/\`Z0=T9?NV/<5;69U8::/+S5!JHX($E6)/=>ZLN]^Z]U[W[KW7
MO?NO=%)^?/\`V0[\P/\`Q6?N[_WW&XO?NO=?*/\`^%*'_;[#YS?]KCHO_P"!
MFZ6]^Z]T1C^5W_V\L_E\?^+L_%K_`-_?LCW[KW6UM_PN!_YGO\`__$2=X_\`
MO8[']^Z]UHO>_=>Z^F-_.DWOO7KW_A+W\+]S;`WCNO8NXH.M/Y>=+#GMF[CS
M.ULS'35/4>&2IIAD\%64%:U-4*!KB9S&Q4$C4JD>Z]U\\1?E]\LM2ZOE#\BB
M+\@=V]E`V/U`/]Y3:_OW7NOIW?\`"2G?^\=^?RE:O=G8^^=U[TS/^S-=TQ5&
MX]][JS&Y\E3XZCP^PC%3_P`6W%7UU138ZD4O((]:PH[N]@7<GW7NC!?S"/A7
MWOW5W)VOWA\-_E-T9USN;Y'_`!0VO\5NRJC?/;/:'5>\>K:OK'?6\NR>F?D!
M\?>X.@\H=]4&Y]G[HW]62Y/9]8:;;>YTI:9:^1HS*C^Z]U=1U-5TV.V/LW9]
M7V)C.S-U[5V9M7";IW9!EJ&MR.Y,SB\/2XO)[IR5/3UM=4P3[ARE'+4N9&8F
M24C4Q!/OW7NB(_S,?B_WCWD?B3W)\>L'L+L7L?X;_(S_`$[471_:6XY=G;0[
M8QV5ZN["ZIRB8+>8P>YJ+8?<VP:7?QSVR,]6X^LH<7GJ*.2:/2=2^Z]T*G\N
M#KOY7=8?%O`;8^9^[:W>'=C;W[/S'W.9WWBNT]T8#KC,;\SM=U-LO>O9^$V/
MUQB>Q-Z[.Z[DQV/RN9I\-10U]9`\B)I(]^Z]T>_W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7__T[MNM/YH
MW\Q0=\_S`>M]D_R\^SOGEU[T/\XNQ>G.O>T>J^T/CUTQA-B;3P?7/56?I.G<
MOA=]Y3"[BW/NC:59N2>NJLS)]P*J/+PQ:U,&CW[KW5ZOQT[([&[;Z9V-V%VY
MT?N/XV]D;FH,A5;IZ1W;NG:N]=Q;"J:3.9/&4=%DMT;*JJS;.6;*XRBAR$34
MTGHAJTCD5)4D1?=>ZHO_`)B/PC_X3C]1=J5G=?\`,6V3T9USVW\C-R;BW>V=
MWKV]W?MK<&_]Q4\V-DW5N[%;4V-V!2)C76JFI5K<A1T%+"99(T>0LRJ?=>ZM
M\^!=#\0L=\3>F*3X%-M5OB-#@<TG2QV/6Y[([5;#-N[/ON!\96;IFJ=QU$S[
MS;)&J:MD><U9DU'W[KW1P??NO=>]^Z]U[W[KW12?GS_V0[\P/_%9^[O_`'W&
MXO?NO=?*/_X4H?\`;[#YS?\`:XZ+_P#@9NEO?NO=$8_E=_\`;RS^7Q_XNS\6
MO_?W[(]^Z]UM;?\`"X'_`)GO\`__`!$G>/\`[V.Q_?NO=:+WOW7NOI/?ST_^
MX6#X:?\`B._Y=O\`[Z7#>_=>Z^;$/J/]<?[W[]U[KZ4?_">4:O\`A,U\SU-P
M#1_/<$JS*POT70#AE(93_B""/?NO=?-</T'^M_Q)'_$>_=>ZW@_^$0HO\GOG
M,Q))'0W6@^IM8]@Y#ZB]B?2/];W[KW6O3_-Q[K[GV]_-)_F'8;!]O]IXC$X_
MYE?(>EH,;CNP]X4E#0TL/9VXXJ>DHZ6',K#2TE-"JQQ1(%CBB540!%4#W7NA
MM_D&]S=P[G_G$_`3";C[9[-SV&K.ZBE9B<QOW=>2QM7&FS-UR"*JHJO+2TU1
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MK[=,N]\,@W;G:N"!:VBIGJER$PJ31S^Z]U=)_*<Q_P`C<3\`_C]B?E=N++;L
M[KQ&.WUB,IG]S;YVAV=O2NV/C.T=[473T?878NP<IFMH;T['H>HX<)!G\A15
M=2*C+1U#32O4>5F]U[JF+^=EOG,]4?S'/AOV-A_D13?#*E?XB?)':&7^2.W/
M@MNW^8!NO-+6]H=39'&]-[UZEQN%RV&VKLFJJ*"7+8;<%(K92/*4]723!**J
M=C[KW5[_`/+NWJW8?PTZ&WDW>$GR4.<VOEI7[S?X^U/Q5/8DE)NW/T$F6/Q[
MJZ/'S]8_:/2FC%&84%0*;[I;K."?=>Z.M[]U[K@7(O=&L/R"IN/\`#?W[KW7
ME<M8Z'4&YNVG^MA<!BP)^O\`K>_=>Z*9\^?^R'?F!_XK/W=_[[C<7OW7NOE'
M_P#"E#_M]A\YO^UQT7_\#-TM[]U[HC'\KO\`[>6?R^/_`!=GXM?^_OV1[]U[
MK:V_X7`_\SW^`?\`XB3O'_WL=C^_=>ZT7O?NO=?2>_GI_P#<+!\-/_$=_P`N
MW_WTN&]^Z]U\V(?4?ZX_WOW[KW7TI/\`A/)_W#-_,[_J$^>W_OBZ#W[KW7S6
MS]!_K?\`$GW[KW6\'_PB$_[*=^<W_B!^L_\`WX.2]^Z]UK._SBO^WKG\QG_Q
M=#Y%_P#OT=R>_=>Z'#_A/A_V^=_E^?\`B;)/_>)W;[]U[KZM/\TOX[]M_++^
M7W\K/CGT5FZ7`]K=L]4Y+;>TYJ_+5>`QF<DCR6+RN7V)E<[1,DV&Q796`Q]7
MMZIJ2PCA@R;-)^V&]^Z]T3W^7Y\=.RH/FYWG\P$^'D'\N_I'=_Q,Z!^-^/\`
MC.T_3E-G.P^U>L-Y]@[NSO<N?V]T%F<]U[BL1L;;N[Z;9>W*J6KER>3QE&\Q
MBI*04T'OW7NKO2P4J"?4U[#^ND7-OZ^_=>ZU@OB;_,C^9G9NYOY='R$WWV_U
M9N[K#^95\D/D3T++\'=M]98C#[X^,>W>KZ#N?+83>>`[0ASO^D+>>Z.JJ?IV
ME@[*7.8]\8E5N`K2P8]8J9IO=>ZV?EX5;FYTBY'T/'U'^O[]U[KOW[KW7O?N
MO=>]^Z]UCE4LH4%A=@"5-B!^3_L/?NO=4']#?SW>L^U]_P"Z<+ENA>PH]@U_
M9M7U/TAO3IO(Y/OO-]B;_C[<[9ZNQ76^^]D;?V9@O]%?9N;VOTMF^PQ0#(YB
M@QFP(QD\I74)T1S>Z]T/>1_G=?"'&X;.Y9SWQ55%)08#>.Q]N470O8,^[>[.
MD]RX+?N[L;\E^DMNG')7[_\`CG_<KJO<N;EW3$(:5,7AI)])%10BJ]U[KV[_
M`.=[\$]FTN8K*W+=PY6''[FPFR\,NW^E]ZY6HW]N^NZ_PO:^Z=K];4D=''5;
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M^\LCM[';5I.LIJ"G\>-JJ;)U62HI:>H>EF2=_=>Z#/HK^=%T#W`W4^1RNV=U
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MNO>_=>Z][]U[KWOW7NO_U;):S/\`\FK/_,#^9#1?S:^H/Y>/2?>77OR6R*]9
M8?NWK7;6S=]=H?'6IZWV9F-C]\OO;<\ZR][Y[M?+3Y266+%"6JQ,E$M$80S1
MM+[KW5O7\DC=F1WW_+&^,.[ZWJ?8'2U#G<=V=6;3V3U7UBW2W7M=U\_=/8QZ
M[['VUU1)6Y.78\';^R#0;JFI#4S*]3F))U.B5??NO=$:_G*YKMVA^2GQZH]U
M9O\`F7'X91=*=F9#-;8_E([DR^/^2X^33[QVM3[(W#W+M[8V6H>S<GT0-DQU
MU-AZRBBFQ-)O%H$R+1B>#5[KW5H_\L)_E'+\$OCG+\SH]T1_(M]HY<;Q7?JX
ME.R#MM=Y;D'4[=JI@U3%IVTW4/\``CND1@/_`!\U?EM)J`]U[H^_OW7NM1_O
MCXH=.]K_`,\OXZU'P&R_;#_*'H;Y!0?)O^:#\H)N\>QMR;(V!TAF9TK-K?#+
M,8[-;JK-GIE.VA')B,1L["T4#8#`S/)/"U,]3)2^Z]U71T1-73UW\MK^9IC-
MR;Y_X<5^4O\`/NWG\7?D9F9.S]Z9*OR7QHSO8?;FU][]`9#KBIW#+MO'=7]8
M]?;8P<]%2?PY5P221R1F,3PZ?=>ZVT/YG7<6=V%\4ODALW%=`=Z]J4>ZOC+W
M<U9O3K+%=?5NS]E!MEYV@?\`OA4[K[%VGGJ?[6";[Q_L,?D/\DB<CU@(?=>Z
M^6C_`,*%-U5^]OYP?S-W3DM@[ZZQK<ME>EVGV-V51X*AWM@#2_';J*ABCSM+
MMG/;HP43Y"&D%73_`&]?4!J6>)F*N61?=>Z*3_*X4-_,M_E\!G2-1\U_BZQ>
M0D*`G=FR7M<`F[:;#_$^_=>ZV?\`_A:-O"MWIV]_+YRU?L/?'7TU1TQWA5MA
MM^4NWZ7+4\A[)P&)^PG3;>XMS8\5R0XA*XA*EXQ15]*VORM+%%[KW6DG_P`;
M]^Z]U]&;^>!O+(9'_A,1\6MMR]>[\Q=+MW;W\N;`0;MR-)MU-J[DI)^@<-N`
M[KV[/2;DK,S+MB*KMBG>KHJ.K&48**<TY^X/NO=?.:'U'^N/][]^Z]U]&G^0
M/O7(8#_A-Y\Q,%2=>;^W7!4[+_F![E;/[7I-M3X.FK*/J[:V`CV=429;<^(R
M@W=D:;+ODZ>-*1Z)L=15#/4I.(J>7W7NOG+L+!?Z$<'_`&)]^Z]UNM?\(KMR
M56VODO\`,B6DVGNC=IS?6?2NV*B':L&&GEV[29OL?+PS[PSPS.;PBQ[3V^(@
M]?)2FKK41U,--,=0'NO=:UW\VG*U&=_F?_S`\U5X#.[5J<I\POD'6S;;W/#0
M0;APKU'9NXI/X?F(L77Y7&I70!K.(*F>*_Z7(Y]^Z]T-7\AC-5&W/YO/P9W!
M2;>S^[:G"]K9/*0;8VK#CJC<N?EH>O\`>-2F(P4&8R>%Q4N4KVC\<`J:RF@,
MC#7*BW8>Z]UL%_\`"KSY^_-+HO\`F&=3[/Z$[U^6GQCV;)\3NO,W5;9VKVEG
MNN=L;NSV:WKV)7Y#=F-Q.PMY34N0K*&)X,#7U-8L<XR&%FBB#TT<,\WNO=:P
MS?S9?YH+J4/\P[YI`/Z6/^S+=O+P3^63=8>P]^Z]U]._^8Q_.P'\KOXC_%_O
MOL'XA]Y]G1=N9V@ZXK8\[N_8VPFV]G<?M'+9:#(;AS=)6]B35N8WO2;<J,CB
MJ=*2U1C_`"S5,]+41BED]U[K6XV3_P`*Q_Y?O6O<V\_D1U__`"8]M;+[U[#:
MO;>W;6V>QNL\-O\`W%)F)8)L]/D=R4/2,.3>JW'/212Y.19%DR<T,;U32NBL
M/=>ZV[OY<'\SN3^87\5NK_E-@OBAWEUW@>T-^/LNCQARW7N]<)0XZ'=V\-H9
M/L"GW/\`WDVI7U^Q]HU>T",Y(V)I\A25%6D5+25P221?=>Z8.Z_YTOQA^/>]
MLYL'M'J[Y28K,[`VMUANSO/)X7J+'[PV1\9J3N;L6JZ_ZTQWR2['VEO+-;`Z
M<RV[*.C;<E,F6R443;8:.K\GDECIV]U[H_5;WIFZ6/+R0?'OOO)KBY>W8X/X
M=B>MI?XY%U:*-L+584S]GTZSTW=7W3?W.:8P&I\,G\3&+LNKW7NG*/N+-29>
MGQ7^@ONN..?=N&VNV8EQFPAAZ>DRO7DF_*C>,\R]A/6C:."R"?W:K95IVK5W
M$PBBII:(_?#W7NF2'N[/Y;%XZ63X[?(/&-F<3UA634E;B^MZ:NPS]FYZMV_E
M<;EFH^T:I*;)=34U.,ENG[>2:.FQ\T;XZ3(SEH4]U[HK&`Z>^/.P-E]%;?VG
M\"NVZ/;7Q%VKW55_'O9.-QNS98ME.D&7Z#W!M_#4&0[E..W#N?NCK;>.4K,/
M-F9*D56WZRJFK*FAKY33O[KW1`OD%_*!^*'9/7&W>ANLN@_DCT3LS!]N;N3=
MV[]CKM[>G8&\>L]F]%+MVBZ\V?VOV-W7EMZ[`Z.WGUW5OUUM/$TZMC:5UDI)
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MXA[]?$Y7</\`+W[8BQF;W!U3VYF>N,C3[9INNI=][XVYB>B*";?'55#W,_6^
M2S_QSZRV5CXZN`4510[>P6@X-JNHEFA]^Z]TB<S\%/A;DMD]5;>W)\`?D3OS
M`?'G:_:63ZDVQN'?%?GYL3@]J=I[%BQ_2XI\M\AHJ/<^V=ZY78.!W7M+;.;D
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M/X]=]9,8L=O&%L=BNMW7-#JN.C?#_P`'^Y[-I3*W=+5939PG^W^Z>&09+^%@
M*7]U[J?%W'FI<K#C/]!7=B0R[IPNVFS$F+V",3!3Y?KQM]S[JFD7L-ZP;7P.
M27^[5=(L#5:;B/CBIYJ*]=[]U[IMH>\\_6TF-JG^.OR`H'R&*ZKR4M'7X?K:
M.KQ<W9FXZW`93$9-8.SZB!,IU)3T8R>ZQ#)-!3XZ>-L?+DIR\">Z]U@KN^=P
MT>+RF23XW?(6NEQVW]_9R'$T6'ZR.4R]3L?>E/M&@VWBXZGM.FI9-P=AT4YS
MN`26:&FEPD3R5D]%5!:1O=>Z=:KN?,TV4R.-3H?N^LAH-Q;SP*9>CQ?7[XK)
MTVT]BP;SH-S8R2;L6"MFVWONNF.`PDDD$55+G8VCJZ>CI`*P^Z]U"H.\\Y6U
M..@D^/7?>.CKJ[JJCFJ\CB>MXZ;%Q]EX>JRN8R.2-/V;53+C^GIZ84.[6A2:
M2GK947')DXBTJ^Z]TVCY";A.'7*CXR_(_P`QVUC=PG"'"=6C-+5Y#L)MBR[4
M:'_2S]E_>C%XU1N:IC^X^T&W&$L=1)6WH![KW3GD>\LY0#,M%\>^_,F,0>VQ
M%_#</UTYS8ZO2A?#/A15=F4AG3N8UC+M#S>`U+02C)#%@*7]U[IQB[BS4F8&
M)/1?=4<1W7@ML_QEL9L$X@4F:Z\;?E1NXRKV$U;_`'6VYDE_NSD)!`:R/<;"
M.&GGHKUX]U[ILH>],_6T.,K9/CK\@,>V1QG5.2EH:[#];+7XN3LW<E3M_*8O
M)1TW9]5"N4ZBIZ<9/=:PR314V-E1L=)DIRT"^Z]UAKN^-P4>/R5='\;_`)"U
M\F/P&_\`.1XVAPW6;9')U&Q]Y4^TL?MW&QU':=-2R;@[$HYSF\`DLL---A8G
M>LGHJK32-[KW3G4]T9JGRU?C$Z'[NK(*+<F]-OQ9BDQG7S8K(TNT=BT^]*#=
M5`\_8T%8VV-^5TYV_@Y)88JN;/1/'54])2`5C>Z]U%H^\<Y55.+IY/CYWS0)
MD:[JNCFJZ[$]<)2XB+LK#U>5R^2RK4_9M3+'CNH)J5:+=C0I/+35DT:X],E$
M6E7W7NF^+O\`W#)B8\H?C1\BXII-LT&XOX-)ANKAEXZJM[`.QI-J2Q+VPU$N
MZ,?CA_>2>,3FD&W3Y$J'K;T/OW7NG"O[RSE#_%O'\>^^\C_"Y.X$B^PQ/6[?
MQA>JEI#A9<3]UV=2^2/NQZHILWS>!JIH9/XF,6`I;W7NG&#N'-S9>CQ3=%=U
MT\57NS#;8?,U&,V",/14F6Z\DWY/N^LFB["FK4VI@\A&-MUDB4[UB[B81Q4T
MM%>O'NO=-6/[USU?1XFKD^.OR!QK93&]7Y"6DR.&ZWCJ\/)V/N.JP&4QF72F
M[/JHHLCU13THR>Z!"\\4&-EC;'R9&<M`ONO=1ZOOO<%+C*W(I\;OD/624F"[
M"S,>*I,-UD<K7U&Q-XTVTZ#;U%#4=IT](V>['HJ@YS;R231TTV%B>2MFH:H+
M2-[KW3I4]TYNGR=1CEZ$[QJH8=R[VV\F6I<7UZ^,JJ;:&Q8=YX_=-.\G8\59
M_=C?U?*=OX.1X4JY<ZC1U=/1T@%8?=>ZP4/>&;K)\1#)\?>^<>N5K^K:*6HK
M\1UTD&&C[(PE7F,OD<P:?LNIDAQ_44]**#=;0K/)3UTT:XY,E$6E7W7NFR+Y
M`[BEP\>5/QF^1L4[[9HMPMA)<-U;_&(:NL[#.Q'VI)$G;#T7]YZ'&C^\LR"<
MT@VX1(E0];_D`]U[ISK^\<W1/E$C^/G?61&-/<`ADQ^)ZXD3+CJJ.BDPK8HU
M'9M,9$[L:K9-FF80?<O3R_Q/^%`(7]U[J?#W'FI<O!BWZ*[LIX9]U8;;39F?
M%[!&(IJ3+=?2;ZJ-W5,D?8<E:NU<%D(QMRMD6!ZQ=PL(XJ:6BO7#W7NFO'=Z
M;@KZ3%U4GQS^0.-?)8CJW*R4>1Q'6L=7B9>RMQ5>!R6&RJT_:%3#'F>J*>E&
M2W2D+SP4V.FC:@ER,Q:!?=>ZPUG?6?I,=D*]?CA\A:R2AV]V%G8<91X;K-LE
MDZG8F]*;:-!MG'QS]IP4K;C[&H:@YW;T<LT5+/A(GDK9Z&J"TC>Z]TZU7<^:
MILE78]>A^\*N*CW!O/!QY6DQ?7SXS(4^T]C0;SH-QT+S=C05;[?WU73_`,`P
MKR0QU,N=C:.J@I*0"L;W7NHN/[QS==-B89/CYWSCADZOJJEFGK\3UPL&'3LO
M$5F4R];EC2]FU4D='T_/2K1;M:!9WIJV>-<<N2C+2K[KW37_`+,%N+^&KD3\
M9?D<LAVE0;H;%G"]6G*+65O8+;&?9QB3MEZ1MW8_&K_>2HB$QHUV\1(E3)6W
MH1[KW3IDN\<YC_XQX_CWWUE!BE[=:$XS$=<RC-#JR&AEPXPQJ>S*7RGN=JQD
MV?Y_!]R\$O\`$_X6`A?W7NI<?<V;?+08MNA^[HHIMR8+;YS#XOK_`/A$%-FN
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MP^Y-M]_?;YZ:5#02+11SH<C(SFE7W7NKV?Y7N;^3.Y/A)U%N#YB8G?.`^1&=
MR_<V;WCM_LO';>Q&_=O;=RW?'9N1ZJP&YL7M2.+`8ZMP_4M3@Z=8*=0(H8T5
MQKU>_=>ZUGOF]\T1W5\^NK:??_6/\WSX"?+OH;I?Y2[%R63^%GQ]QW=<^^NH
MI/D'M3"[:K:#*5O7&3R/<'4&^,%AL3N)<O20G;NW<[/'1HTU8\=6?=>ZVD_Y
M>^=KMS?#WH_.Y+>WR.[&K\C@,[)4;V^6_7D/5/R*SYAWEN.E2?L[8%/A-NP[
M>R%-'`M/0@4D9J<7#33EI3*97]U[HY_OW7NJN=Q?R6/Y7FZ>\,C\D\S\/]@U
M'>&6[8/>F3[`I=P=B8C)9#MQMTOO5M^5E%B-Y46%GSAW5*]=J:E,?GD<Z+.X
M;W7NA3VA_+$^!.P?E+GOFOL[XO=8X+Y1;CR6>SV1[6I:/+25D6Z-V4]12;OW
MCA=LU.5GV5MG?.[Z:KFCRV<QN-I<OE$GE%542^1]7NO=+KY\(!\&_E^&"DCX
MS]VGZ7Y7KK<3*>?RI%Q_0^_=>Z^4E_PI1_[?8?.7_#,=%V'X_P"R9NEA]/IP
M/?NO=$8_E=_]O+/Y?'_B[/Q:_P#?W;(]^Z]UM;?\+@1_QG?X!_\`B).\?_>R
MV/\`\5]^Z]UHO>_=>Z^D]_/4Y_X2P?#4DDG_`$>?R[B22223U+A[DG\D^_=>
MZ^;$/J/]<?[W[]U[KZ4G_">3_N&;^9W_`%"?/;_WQ=![]U[KYK9^B_ZW_$GW
M[KW6\'_PB$_[*=^<W_B!^M/_`'X.1]^Z]UK.?SB0!_-:_F,J.`/FA\B[#\"_
M:.Y/H/Q[]U[H<?\`A/A_V^=_E^?^)LD_]XG=OOW7NK>_^%J8'_#EWQ_(`!/P
MLV7<@"Y_XS/W>.?Z\>_=>ZT\O?NO=?2,_P"%@OI_E+_!$KZ2/DCU801P01\:
M>V+'C\BP]^Z]U\W/W[KW7UT/^$P.9PNW?Y%OQ2SFX<GC,)A<75_(2NRF8S-;
M28S%8VCI_D)VBT]9D,C72P4='30QB[22.JJ!R0/?NO=)3Y6?#C)=O=C_`#OV
MYTU\\OAYLSXR?S0Z?J6/Y30;[R>+W!W;U0_7O7NV^H-WO\>Z_$;NI=FYY.TN
MLMJTL&G<PT[>R9EJZ85*.*=?=>ZV#NN=W=8;CQ,>(ZRWKL_>6.VC18O"S?W5
MW5A]UMB((:):?%TV3J<97U\L%1/14UT,Q#RA2W/)]^Z]U6M_->^;W>/PIVW\
M;(_C_LK9V\M[=_=R[NZT,6Z.J.[N\:B@H-K=#]L=R)%MWJ;X[/\`Z5-UYC.5
MW7,>.,M%#408R"J>LJH_MX)'3W7NCM?#KOB/Y3?%+XZ_(TT.U<95=V]-]?=D
MY7#;,W92[\VQM_/;KVUC\IN';6)W?24]+#G8MM9RHJ*!YC%%)Y:=ED1'5E'N
MO=#QN'.[=VC@\SNK=.6PNV]M[>QU;G=Q;CS^1H,+@\%AL93R5F3S6:S&2FI<
M?C<9C**%YIZB>1(XHD9F8`$^_=>Z0W4G=G3'?VU(]_=&]H===Q[&GR5?ADWE
MUAO#;F^MLG,XLQG*8B7-;:R&2H(LICS-&9J=I!+&)$+*-0]^Z]T*+Z%5F*`@
M'40%!)-_K8_5K^_=>ZQH\3ED5!=65)%`1O&[(LNB55)\;"-U-FL;,"/K[]U[
MK-H2UM"V'T%AQ[]U[KVA./0O'`](XYOQQQSS[]U[KKQI<'0MQ]/2/S[]U[KL
MHA^JJ?\`74'^G]1_A[]U[KQ1#]54\@\J#R.0?I]0??NO==>-+$:$LW##2.1_
MCQS[]U[KPCC%[1H+D$V51<CZ$\<D>_=>Z[T)_J%X_P!I'^(_I_0^_=>ZXB*)
M?TQHO!'"J.#]1P/H??NO==^.,?1$'_((_(L?Q_3W[KW7C&AL"B$#@74<7^MN
M/S[]U[KLHA%BJD#\6%OK?_>_?NO=>T(?JBG_`)!']+?T_I[]U[KQ1"22JDGZ
MDJ+G_7XY^GOW7NO:$O?2M_ZV%_\`?<^_=>Z]H0$'0MQP#I%QQ;@V_I[]U[KK
MQH?JB?G^R/S]?Q^??NO=>\<=@-"6!N!I%K_UM;Z^_=>Z\(XP`!&@`O8!5L+F
MY_'Y/OW7NO&.,@@HA#?4%00>;\@CGGW[KW7O&@!&A+$@D:18D?0D6^HM[]U[
MKO0G^H3\#](^@Y`^GX/OW7NO%$)N44D_4E1?@6'X_`]^Z]U[0A-]*W_K87_'
M_%/?NO=>T+P=*W'(X'%KVMQ_C[]U[KP1!]$4?ZRC_BG^/OW7NO!$'`10#];*
M.>;_`-/Z^_=>Z\$07LBBXL;*.1];'CD7/OW7NO:$_P!0GX_LC\"P_'X'OW7N
MN+11,+-&C"P6Q52-(M9;6^@M]/?NO=<M"?ZA?I;](^E@+?3Z6'OW7NNC'&;7
MC0Z3<75>#:UQQP;#W[KW7O''8#0EEO8:1Q?ZVXXO[]U[KL(HY"J#<G@#ZGZG
MZ?4^_=>Z\$0<A%!^MPH'YO\`T_K[]U[KKQI<G0MS:_I'X^GOW7NN]"<^A>>#
MZ1R";D'CGGW[KW7M"?30O_)(_P"*>_=>Z]H2VG2MA^+"W]/I_K>_=>Z]H0<!
M%`OJMI'ZC]3]/K[]U[KP1%-U1`2;DA0"3_7@?7W[KW7+W[KW7__7,1\TOAS_
M`#4-Q?-GY)]I==_%'YM[UG[!^6+4];\B?C[_`#!.M^C<=V)_+4/5NW<#3_$?
M8_6N[.P:>AZ\R;[]QB9:?<!Q5/DDG%6\4JRSHX]U[K:5_ET==8_J7X9]'==8
MOXS9[X<T6V<'N"GC^-NZ>S:3N;<W6LU;O;<V4KESW:5'G=RQ;URF[ZVN?/35
M9K9Y=>3*2E94=%]U[HLOSA_F6/\`$SY4_&OXZ;<Z8V]OK,=I1[)W+VWV=OOM
M7:_4N$ZCZ-W[\@^MOCNN<V><YCZ[*=L;JHM\[\ILAD\-0-20XG$T7WM=/&DT
M+#W7NC<?!?Y78;YN_&;K_P"36WMN-M'$;_RG9^&I\"FY*'>6/67JWMK>_4U;
ME\'NW&4E!CMR[;W%7[(ER.,KH(4BJL?50NHL;GW7NC>^_=>Z][]U[KWOW7NB
MD_/G_LAWY@?^*S]W?^^XW%[]U[KY1_\`PI0_[?8?.;_M<=%__`S=+>_=>Z(Q
M_*[_`.WEG\OC_P`79^+7_O[]D>_=>ZVMO^%P/_,]_@'_`.(D[Q_]['8_OW7N
MM%[W[KW7TGOYZ?\`W"P?#3_Q'?\`+M_]]+AO?NO=?-B'U'^N/][]^Z]U]*3_
M`(3R?]PS?S._ZA/GM_[XN@]^Z]U\UL_0?ZW_`!)]^Z]UO!_\(A/^RG?G-_X@
M?K/_`-^#DO?NO=:SO\XK_MZY_,9_\70^1?\`[]'<GOW7NAP_X3X?]OG?Y?G_
M`(FR3_WB=V^_=>ZM[_X6I_\`;R[X_P#_`(I9LO\`]_1WA[]U[K3R]^Z]U](S
M_A8/_P!NEO@E_P"+(=6__`U=L^_=>Z^;G[]U[KZ1?PU`;_A&%VN"+C_9</F.
M?]BO>O9[*?\`8,+^_=>Z^;I[]U[KZ$__``ATA3^X7\QR5%19WW;\9(C+;U%(
ML/W<\:%ASH1Y&(']6/OW7NA`^:?_``IM_D^][;D_T1?);X=_-'>U;\?.WMVR
M[8S6T]R83K;+;>WO@:?=/6>9W!MC=W6WR$V%O*D@S6W<KD:*2)JB)9:*L9)(
MPW"^Z]U8U_*6_P"%"?\`+\^9'<_4'\O+XB?&+O#HG&XOKK<<?7N.SVV>L<#U
MMM+:W6.V9LQ_!(:;:78.XLE"9\=1.L;_`&SF6H.J9]<A<^Z]U:=_-A^-W:7R
MO^%6[NJ.G]M[<[#W=2=C]#]HU'3F]<Y2[:V5WWMCIKNW8?:.[^B=T;CR-'D,
M1B<;V=M[:E1C4DKX),<U3)$E9HIGED3W7N@N_ES_`!X[DV;\D_G]\M^RNCJ/
MXJ[3^7&8^-M%UW\:(MQ[*W+N+;D?0/7&X]H;G[9WR.K<KG>L\3NSMFLW-30?
M:8RKJJE,;M^D:NE,[".+W7NK0NR:?>>1ZXW]1];Y"AQ'8==LK=-+L'*Y6-9,
M9C=ZU.#KHMJY#(QO%.LE#19UX))04<&-3Z3]/?NO=:M'\K7H7L_;7R9_E\;@
MZ_\`C;\I_CUV1UA\:>]=M_SD.RN_\#V#M[#_`".[VW#@=JP;1@?>F]<WGL+\
MB][5G?T69WEAMPX*HK:7&;0K%B^ZB@JX*"+W7NMLU[Z&M];<7U$7_P`0OJ(_
MUO?NO=:F'R4^<6^=B_S%>S]M]Y=R_(G;>]]D_./XF=&?&WX>]3=]?[+WA<_\
M4^U<7UQ+COE#M[8U5UCNG&?.*/=W;>:S^-WUB):TMM+"8IX4EH7`;W[KW6V<
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MN;3V?E\ME,C'CLC41T]`8X::::5%/NO=-7P@^8&XOD\_R(V#VGU*G1WR#^*7
M<PZ3[LZ^QF^Z;L_9DN2R&Q]J=D;*WWUWOR#![7J<WLO?NQMYT5;3QU^+QF4H
M9Q-2U5.&B667W7NCH[GS<>V]O9[<,U-/618'!Y;-R4E,0*BJ3$T,U>]-!J]/
MFG2`JE^-1'OW7NJIOY6/\V+:W\SG']D56W^HGZWGZ]V9TEV#-4X/M_8'=NU9
M\'WQAMSYW;6U,[N39(H)ME=T;3I=JS?WGVED:..LPOW5)JFE,Q$?NO=6[#GG
M_>_?NO=%TSGR]^+.V>\,/\9]P_(;IK"?(;<$5'+A.E,GV-M2B[-R1R=%/D\/
M34VSY\JF9-?G,92RU5#3-$M164T3RPHZ([+[KW1BQSS_`%]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__0W]PJ@D@`$_4@<_C_
M`(I[]U[KB(T5BRJ`S6!(')`_'^M?W[KW6J7_`,*!-\Y?!]]_&_!]J_%?J7Y1
M?%O%=4[BWK#L/M3XJ]F=Y5_8?;"=S=?8SL/KOISMOI7'U&]_CIV=0]#M7[B?
M(9J2;:N2H\5IJ,?6RTUZ?W7NC&_R$?FAVA\F$^176F8CV+)TOTUB.I<OU-M/
MKWXY;D^,^%^*,78&8[:H:?X25&U]PX/;Z[TDZDZRV+M7/4N<IZ?R2T6ZHUJ'
M8F"WNO=;%7OW7NO>_=>Z][]U[HI/SY_[(=^8'_BL_=W_`+[C<7OW7NOE'_\`
M"E#_`+?8?.;_`+7'1?\`\#-TM[]U[HC'\KO_`+>6?R^/_%V?BU_[^_9'OW7N
MMK;_`(7`_P#,]_@'_P"(D[Q_]['8_OW7NM%[W[KW7TGOYZ?_`'"P?#3_`,1W
M_+M_]]+AO?NO=?-B'U'^N/\`>_?NO=?2D_X3R?\`<,W\SO\`J$^>W_OBZ#W[
MKW7S6S]!_K?\2??NO=;P?_"(3_LIWYS?^('ZS_\`?@Y+W[KW6L[_`#BO^WKG
M\QG_`,70^1?_`+]'<GOW7NAP_P"$^'_;YW^7Y_XFR3_WB=V^_=>ZM[_X6I_]
MO+OC_P#^*6;+_P#?T=X>_=>ZT\O?NO=?2,_X6#_]NEO@E_XLAU;_`/`U=L^_
M=>Z^;G[]U[KZ1GPT_P"X,+M?_P`5O^9'_O\`3M#W[KW7S<_?NO=?0L_X0Y?\
M>!_,8_\`#P^-'_NE[J]^Z]UHF_*G_LI_Y'_^)Z[@_P#?A;B]^Z]U>_\`\)*O
M^WTW3'_B)/D!_P"^SR_OW7NC1?\`"G+YV_-GH7^;WW=UYTG\NODGU+L#'];]
M$5F.V/USW3V#LO:6-J<EUA@,ADIZ';VW<]CL533Y'(U,M1/(L7DFFD+,QXM[
MKW5-OQB_F<?S'=S?);XZ[=S_`,\_F!E\'FN^>G\=E\3D?D5VQ68_)T%;V%MV
MFK*&OHJG=4M-6T573R-'-#*CQ2HQ5U920?=>ZWK/^%5?\S/YK_RWMN?"#)_#
M?N->HY^V<_\`(2D[!_WX^PMYG<,.S,=U#+MA&&^MM;DBQT>,DW77L?MEB:9Y
ME+L1&H]^Z]UIV_\`04/_`#NS<'YCQ@$'D=&_'[C^EK=7WO?W[KW6]9F_YF_R
M?Z2_X3>=?_S-*FMV=VS\G*/H/I3>N9K^P]O_`&6T=U;@W]W!LWK[.9'-[=V'
M4;1BB>'";EEFBBH7HH351(;*A9??NO=:I$W_``LY_F.5-=C\G4_'/X0U&2Q(
MK!BLA/U]VQ+78P9&-(<@,?5OW*T]$*Z*-5F\;+Y54!K@#W[KW6VW_(`_FU]^
M_P`TWXH?(SO_`.0NR>K=HYWIWMS(;)PV)Z?Q>Y,%C,C@J#K7;6])),A%NO=.
M[JE\O)6Y:2)95FCB\>D>.X+-[KW6OK\H/^%4_P#+#^:.WMO;5^4W\I_>_<N)
MV?DJ_*[3;=79.S1F=M5>5I?X;FEP6Y,5C,7N/#T6XL6JT^3I:>K2ER,"K#51
MS1HH'NO=7@_R7/\`A0+\>?YD?=$7PHZ#^(.[_C=MGJ'X_P`^[=I_=;IV?5[+
MP&R^NLIL;8F*V)@]L[:Q6-.*I:*@W+3)1".\$4%(R%5]%_=>Z</YH_\`-O\`
MY).4W7NKX7?,7Y&]L=8=R_''M_8_86$W/U5U?W1#V+T9WIL2G@W%LCL7K/L#
M`=;;LVLNY<-C=PR0ZGAR6/J*2NJ*:H@EBDDC/NO=)G^7+_.4_D9[&WGB/C7\
M;OE-W5VWWM\M>_J7*[E[#[HZR[SS?:'>7>W9E1@MFXC+[[WSE^L-K[4Q,46/
MQV+P^/I:.FQ&!Q&.HH8H*:!`[-[KW5HGS_\`YK?\O;X#Y?;W47S2[OJNJ<QW
M'L3<65V_CJ7K_LS=\N4VF:B7;.6K$R6P]H[FI,5.E7,\<:SM'*Q4LJE5)]^Z
M]U0;\'OYH_\`PG1^!&3K-U[#_F`]V]I[MI>DNO/C?MG<7;/4G:=?7;/^/_4>
M4W#G=@]7;>Q777QSZYP>1IL5E-RU<SY3*TN1S]7(X62M,8$?OW7NMP+86_-K
M]F;'V5V-LK(G-;/[!VEMS?.TLLM-548RFU]V8BBSN`R?VE?%35M**_%Y"*7Q
MS1I*FJSJK`@>Z]UKO=<_#7^9/T1\RGPO6FSMG/T7O[^9MVQ\S>ZODS#O/IW(
MXSN/XX=SID<RG3O;75_8.S]P=XT??O0%?38_`;(SFT\C08"#;PE5C"S!(_=>
MZV34;DQD."@'J9;!_P`$J;F_/OW7NM>O^;A_--^4/P6^0VQNONC=C]>[PV;0
M?&/<?R:[$AW=UQVGO8U>-VWW_P!6=39NAW=OWKO.4N.^-_5F#V7OO(YRNWWF
M<7FL=CZO&Q02TKI,P]^Z]UL%XVOHLKCJ#*8VLI\CCLE14M?09"DFCJ:2NHJR
M!*BEK*6HA)BGIJF"17C=?2RL".#[]U[H"_DE\INA_B)L/%=E?(7?B[!VCG][
M;:ZWV]50[:WAO+,;CW]O&2JAVOL_;>T]A;?W1NW<.X<Y)12BGI:*AGE?QMQ8
M>_=>Z6737=/57R%ZQV1W1TGOK`=E=6=CX.+<>R=[[7J_O<)G\1++)3M/32LD
M4\%12UD$M/4T\R15-)50R031QRQNB^Z]TJ=Z;SVEUSM#='8&_MRX/9NQ]DX#
M+[KWAN[<V3H\+MW;&V<!03Y3.9_.Y?(2P4.,Q&)QM+)/43S.D<42,S$`>_=>
MZ+U\7_FK\=OF1C,YF?C]NK=&Z<7@:/;>7FK]R=4]L]84V7V[O*FKZW:.[-IR
M]H[(V:F\MI[DH\;-)29+%&LI'11=UU*#[KW1J7;0I:S-;^RHNQ/X`']3[]U[
MHF/6_P#,(^)';_>N;^.G6/9]=OCLG;VXMX[,R=1MWKCM'(]9Q[XZ[HCD-_[%
MI^[8-EMTU7;TV73`?Q+&0YZ2LIIM4!3SQRQ1^Z]T<YF"*S&]E!)M];#GC_'W
M[KW1,.\/YA'Q*^.W:>(Z2[0[-R%-VME-N8[>E7L?9?6_:7:N;VCLC,9Y=KXG
M?'8D/5FR]Y1];[/RFXY!1T^2SK4%+/()&1S%#/)%[KW1SU8,+C\$C\?C_6)X
M/OW7NBY_)#Y:]`_$O`[4SO>N^GVP_8&Z:?8_7.U\'MG=W8'878^\JFEJ*Z/;
M/7_6_7N"W3OO>&4BHJ9YZ@4&/GCHZ=3-4/%""X]U[H3>J^T=D]U=>[5[3ZXR
M=;F=D;TQJY;;V2R.WMR;3R%31F::F<5VVMX8C`[HP5;!4T\D<M+7T5-50R(5
M>-2+>_=>Z;.[.[^IOCAU;O+NOO+?F`ZSZKZ^Q(S6\-Z[FJ6IL3AZ&2LI<;1H
MPBCGJZ[(Y7+5U/14-%2Q3UM?75$5-312SRI&WNO=![\;/E]\?/EO@]VYSHG?
M4VYGZ^W.FS>P=L9_:F\>N^P-@;GGQM'FJ'$[VZY[&P&U-\[7ERV&R$-90RUF
M/A@KZ602TSRH"1[KW1D9IXJ='DGD2*..-Y9))'6.-(XP6D=W<A52-`68D@`"
MYX]^Z]T1KX]?S+/A)\JNQ*WJOH7O3%;\WI%M_/[PP-+'M??>W\+V-LS:FX/[
MI[GWGT_N[=6U\'M'N3:6W]S7HJS([7KLM2P2:79Q%)%))[KW1ZASS[]U[HEN
M]_YA/Q(Z^^0*_%S/=H5E9W=33;$I]S[3V?UYV;V%1=<3]HU7VG6T';F[=A[.
MW)LWJ.??<A5\8FY,ABWJ*9TJ+"G=)6]U[HZ0Y`/(O^#]?]C_`(^_=>Z*A\E_
MF[\:/B+/L/&=Y]@5F#W1VE5[AI.MNO\`:6Q]_P#:G9N^EVACH\QO'([8ZUZL
MVOO+?.5P6T,5,D^4R$=`:&@26,32H\T2O[KW1B]F[NV_O_:.UM][3KGR>UMZ
M;=PNZ]MY*2AR.+DK\#N'&TV7Q%9)C,O24&6QTE305<;M!500U,).B6-'#*/=
M>Z#KY!?(?ISXL=69SNKOG><.PNM-N5^W,5E-PR87<>XYAEMW[BQ>T=K8G'X#
M:.'S^Y<UEMP;FS=)0TE+14=1//45"(J$GW[KW4GHKOWJ#Y+];87MWH[>^.W_
M`-?9ZJS>-HLY0TN4Q<]-F=LYFNV[N;;N=P&X*#$[EVQN?;>>QM11Y'&9*CI*
M^AJ87BGA1U(]^Z]T)^8R^.P&*R><S%5'0XG#8^MRN4KIM7AHL=CJ:6LKJN70
MK/XJ:EA=VL";*;`^_=>Z*O\`%7YW_$WYLTNZ*OXQ]OX[LO\`N91[3RVXZ`[:
MWOLK-T&W]_4-=DMB;LBV]V'MG:>=R6RM[T6+JI,/FZ6FGQ.3%+.*:HE,,@7W
M7NC;NZHI9C8"US:_U-A_O)]^Z]T3?`?S!?AYN?Y,9/X>X?NS#R_(K%9W/[3F
MV!6;=WMBJ>NWCM39V-[#W/LC`;VRVV:+KW=&^MO;"R]/FJW"8W+5>5IL4YJI
M*=8$=U]U[HY7OW7NO>_=>Z__T=_CW[KW7O?NO=:Z'\X#9GRVW;\GOC7+UUMO
M^9OV+\6Z'ICN!.P]E?RU^[,)\<-XX/N^;=NR4V#O#>_8=?OC9\^^\/5[/?+T
M2[>>2%*!UCKHYI-4U-+[KW5L_P``\+D\!\2>E\5F]L_);:.9H\#F$R.!^8V_
MZ+M/Y-T-0^Z<T1_I;[`QV;W%1;FS532K%)22I63&'%-2P$1F(Q)[KW1R/?NO
M=<774`-3+S]5-CP";>_=>ZU/>I_YQ7S?W3OKXJ?+O=+=#'^7[\U?YF&<_EO]
M:]#XC96Y8.[M@T%5N/>^Q.L^]\WVW-N27'9C/9W>.P:U\UA1B104^/,2T[^6
M9I*;W7NKVOYBG8W7FU_AQ\J=K[IW_L?;&X\_\9>[3@L'N;=VWMO97-@]?Y^D
M4XF@S.2HJK(*]7(L*F)7#2NJ`ER![]U[KY5'_"B[<^U]X_SE_FON39NY]M;Q
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M('(Y/T'/U/\`A[]U[KZ*O\@GN_I39G_"</YA;(WAW'U1M/>>0I/G.*/:6YNQ
MMFX'<M0<KTE04^,"8/*YJDR=\C,+07B_=N"MP03[KW7SJR+:>1^F_!O:Y/!_
MH??NO=;I'_"+[M'K'J[Y(_-BO[-[(V!UU193H_K>DQ=3OS>>V]H19.IBW]D)
M)X,:VX<GCOOY*=&4RB'7X]::K:UO[KW6N)_-OS>$W+_-$_F$;@VUFL/N/`9G
MYB_(3(8C.X#*4.:PV5H*GL[<<M/6XW*XV>JH:^DG1@4EBD=&_!/OW7NAK_D(
M;BV[M/\`G!_`S<>[-PX#:FW<1W)+597<&Z,UC=O8+&TXV7NM%EK\QF*FCQU(
M)9G6./R2*9)76-;NR@^Z]U:__P`+'.R.NNS?YC?0V:ZVW_LCL/$4GPWV;05F
M4V+NW;^[\?15Z]Q=UU!H*VKV]D<C!1UOVT\<OAE9)#%(KVTLI/NO=:DWOW7N
MOHC_`/"M;N+I[L3^5;\)MO\`7O;W56_<]A?D;U?/E<)LCLC9>[<O0TD?QQ[6
MI9<A-C=OYO(U@Q<-5-'')5!#3I)-$K.#+&&]U[KYW'OW7NOHB_#[N3IV@_X1
M\=H=:9#M[JK']C57QT^8-/!L"O[(V71[UDJZONWLZIH:`;6J,Y'G!DLC321O
M34I@%14K-$8D?RQZO=>Z^=U[]U[K?E_X16]Q]0=6[)_F#T?9G:_6G7=9F-U_
M&Z?$TF^=^;6VE5Y2GI\1W-%43XZES^5Q\];!!+,B.\:LJ.P4D$V]^Z]UI&?)
MZLH\C\E/D-D,=64>1Q]=WEVS64.0QU73U^/KZ.IW]GYJ6LH:ZCEFI*VCJH'5
MXI8G>.1&#*Q4@^_=>ZN__P"$K6^-E=>?SB^GMS;_`-X[4V+MRGZJ[YIYL_O+
M<>&VOA8ZFJZVR\=-3-E,Y6T%%]S4-?1'KUL`2!8&WNO=1?\`A4YO?978?\X_
MO+<VP-X[4WSMNHZTZ#IJ?/[.W%A]T86:II>J=MQU5/'E,'6UU$U132"TD>O6
MEQ<"XO[KW5*WQ0JZ.@^4OQJK\C6T6-Q]%W]TY5UV1R5938['4%'3=B;<FJ:V
MOR%;+!1T-%2P(TDLTKI%%&I9F"@GW[KW6Z]_PM5[BZB[1VC_`"[J7K/M7K;L
M6JPFYOE'+F:78N^MK[NJ<3%68[H>*EER5/M_*Y":ABJ):25$:555GC8`W!'O
MW7NM"/\`XW_OO]C[]U[KZ+'R([LZ8J?^$=6V.LZ;N#JNJ['3XP?&:A;8%+V+
MLZIWJ*^F^2'6-35X[^ZT&:DSG\1HZ>GD>:G\'FA$3ZU4H]O=>Z^=/[]U[KZ'
MW_"0CN3IWKG^7/\`-?!=B=N]5]?YK-?(7<4^+Q&^NQMF;/R5;22=$[(I4KX:
M'<>;QM4V->IB>-:G3X"\4BA[QR:?=>Z^>++8NUB"-3<@@C];?T]^Z]UM;?\`
M"/;L'K_K;^9KVKG^QM^;)Z^PDGP][&HH,MOK=NWMH8ZKKY>T.F9(\?15FXLC
MC:>MR#PQ/(((F>;PQ22:=$;LONO=5G_\*`=R[<W?_.,^=VY=H;CP&[-N9?M3
M"5.*W#M;-XS<."R4*];;'ADDH,QAJJMQU6(:B)XI/'(QCF1XWLZLH]U[H$/Y
M0>X,'M;^:7_+UW'N;.X?;6W\+\Q/C_D<QG]P96APN%Q..I^Q\$]569+*Y*>F
MH:&DBC'KDE=4'Y//OW7NMB'_`(6>=H]9=H?*/X99#K+L?8/8E%B^@M\TF3JM
MA[RVYNZ#&54W8SRQ0Y&3;V2R*T,M0BL8Q+H,@1M-]+6]U[K3$N?ZG_;^_=>Z
M^D1_/+^6VVMO?\)\OAM2?'[Y18'`]M8V+X24-;3],=XXS%]@T^-@Z+RRYBBJ
M(MC;HAW&<=!501/416,:O"CN/0"/=>ZT'3\Y_FUR/]G$^4W^/_.0?;7-OI_S
M%W/OW7NOHB_\)UOYAVPNH_Y)W9/=?R>^1M/OG?G56_?DWV5E-N=A=VX+,]Q;
MAVYL7:V'W33[:V_2=A[N3,2UV:BH)(\933/'#+4U*E;"34?=>Z(3\A_^%-?\
MD7Y:;SV7V%\D/Y:?R)[:W=L+#R;=V_D=SCK1Z;^[53G,?N:KVCG\1C^XL?A-
MZ[.JMPXJGK)<5F::NQTT\*.\!(]^Z]U?E_+'_P"%&'PD_F1[N[.V/MG`;F^,
MT/4VT]N[A.2^1.[NH-DX;<-)F<I4X6'$[53'[ZKFJ:G%&E1IE"B.**1`2"RA
MO=>Z%?\`FF0=1_-'I7IS9G3?R]^(>(W;U+\K.D/D+44>]_E/4]4T&Z=O]6UN
M<GS.TL3VMTGGJCM/K/<>:@RX6CS>%T5E$Z$JZZC[]U[H2OY;N:Z)^&'PNZ,^
M-'97S:^*W86Z^J\-N3'U.=VGVMU_B=LT6/SN]=Q[GP.S\(V4W.=P;@QVPL%F
MJ?#)F\L?XQGOL3D:^U74S`>Z]TI?G_7_`!$^<OPS^1'Q-G^:70'7\G=W7E?M
M3&[TINW>L\LFV\]!5T6<VYD\EA6W=2+GL!%G\33#)8\S0BOQ[34_D3R:A[KW
M1=?@!O[L'K3MOY-]M_-'YY_#/+T?<N-Z3H]B]*=/?,7=W:7477&Z^O\`#;NQ
MO:F_^O<=WIF:"JZBP7<-=EL;4Q[/PJRXO#ICE43S.2Y]U[JU6C^5WQ>R;S0X
MKY(]!9*H@C\TD%%W'UW52*A.D-(D&XY'C1F-M3`"Y]^Z]U0+\(_B_P!P?$7O
MSXP;1I_Y@'Q<'P9^)4GRIQF)P^TOE!OG';X^2'7_`'QEMZ[SZQV[WY\?:C(P
M_'J/LWI3L/?%97S[[H:J?+;@@CIA)%%)Y;>Z]U?U)\K/BX:K^%GY*=!QY)RL
M:T/^F/KM:_R.GD15I?[Q&<N8_4`%N1S]/?NO=4"_-#XO]Q[P^0_RA[3^$G\P
M3XM]08WYLY+XF[G[(W_E?DUO?J;N?X_[[^*F/CV5297K:KZ:R51A^[^L.QNJ
M35X_);'W;/1XF+-UAKU=]4@'NO=7]5GRJ^+F(9(\E\D.@L8TX>6)*[N'KNC,
MB1A1(\:S[CC+JA/)%P/S[]U[JL#^83LC$=[=K?%[Y.?&?Y._$]^UOC?MSY']
M;U777:OR`J.LML=@]5_*G9FTMJ;^JMH]X]0U&?[2Z-[<VJ-BX^IV[N/!4<E1
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MCY;#8_>VWLCMZHR&/J(=PS"CR=-35[R4TA'$B`V-O?NO=4T_#KXZ[RV)VC_+
MYR?R>^5OP';K[^5=\=NR_CS\?*SHGM.>;>'?;;]Z_P!A].4/8';>,WL<;C.K
MZ;#=4[`I#4X'$5V=2NW-//5&L2E@I(C[KW5Z$7RM^+DU:<7#\DN@Y<DAE1\?
M%W%UV]:C4ZZYU:D7<C5"F!>7!6ZCZ^_=>ZH+['^-'<.#^5/8FZ/C1\^_BWL3
MX]]Y_.?ISYR;ZW0WRBW]USWWLW+;;P77&R.^.D,KMKK_`#%=U?\`)3IKMW8_
M6M/387&;IFQM/M=ZZI"Q5!$4H]U[J_.L^5WQ;QLT5+D/DET%05$R!X:>L[CZ
MZI9Y4+F)&CBGW(DDBM("H(!&H6^OOW7NJ</YA_3>:[@[\Q?RC^'7R^^*N`[)
MS7Q#[7^$_8&W^QOD[O#I6JP^Q-_[YVWVILWM[I3NKH/*Y#L'KKL_K[LG;-//
MD*84LU#N7##[.62!HHG/NO=68?'WNSJCI[XZ="]>=X?,OH_LCM/8'3O5^Q.S
M.U\MW#LV*3LSL?:VQ\+A-Y[ZEJ<WN/\`B,]3O'<6.JLBQJ&:I<SEI"7U'W[K
MW1:_YF>.ZT^;7P[W-TITY\H?C-A=Z9+L7H3L?;F8W7WQ3;7VS7#IOO#K_MJK
MQ)WQUIE:[?6SZK/4.RY*.ES.&7^(XRIG2IIW26)77W7NN/\`+;Q?7?PJ^-62
MZK[=^7?QRW1D:[N?O7MZ@H\%W1C-Q;=ZKVQW!V1G.PJ/J^G[3[(SR=I=S':M
M;G:AZC>.[F.XLU4U,DE6Q*I[]U[HYV\?D)\;>Q.O]\;9V_\`)3H"67<FU-R;
M:AR"=M=?Y*@HJS-X2MQU/+6+2;@F#Q0R5:NZ?5D!XY]^Z]U3+_)W^+,'\ORN
MW37]P?,'XHY'&Y7XY?&OH$;,Z]^1NZ^X:?=.X?CQ0;NQ4'<]?OGOS*TNZ.M*
M?,X+<RXV@ZZVQ%!LK!4\#34D:2S.H]U[J[^'Y6_%S(3R4%%\DN@JNM0.9*.F
M[CZZJ*F+PNJRM)3P[D:51"Y`:X%CP??NO=4*;/\`APVWOYH6<^9<?S(^)&"Z
MPF^6N^ODU15F.^0^Z]R;ZRNT]_?%W:OQXSW1\W06X<I!\<-FY#+U^V8\G6]C
M8WS;SEH8X\:LOVI*1^Z]U?\`8SY*?'7+9_&[2Q7?W2N6W7FJN*BPNV<9VIL:
MOW#EZVJU&EH<7A:;/2Y/(UE2$/CBBB=WMZ0;>_=>Z&GS+_1_^2&_XI[]U[K_
MTM_CW[KW7O?NO=:L_P#/T^-WQN[.[7ZD[*^6_P`C_B%LW:&#Z#W'MOX_=$?+
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MFP,_6O%@\MF\57UV)C^^C6<"GDC`F19!ZU##W7NBF[GH?Y0'0G9'07QKWU\.
M_CA0[_[0VSU4\4^V_A9LC/[!Z\/;FX9NM^G9.V-[X7KBJVYUS'W3VAC*S;VV
M6R$R?Q+,4\D1*"SGW7NAJQG4O\J'<GR=WA\,Z+XA?%JK[SV;U#BNZMS[7J_A
M_L*EP$?76X,^FU:.NI-W9#K6#:6>J7RE2D<])15=3+3B0"94-U'NO=-?R/Z:
M_E0_#38N$WCV'\(/BW2KOK?^W^K]A;+Z\^(/46?WMV3V5N2FR=?AMH;3V[B]
MD4ZY'+R8C#UU;))42T]+34='-++,BKS[KW2!^2U7_)^^(^0ZOQ?=_P`/_CW@
MZ[L_%S;I\.%^%FQ]SGK7KO'Y_96S\]VKW(V!Z]KTZRZSVSO3LG`8?(9;(E(:
M?(9:%+,JSO%[KW1C^R/AQ_*XZ.V#V!W=V3\.?A)L+8G6NUMR;Y[`WSD?C!TU
M##@=L[<Q]3F=Q9BLDHM@S9*K$-%2R2>.%)JBI>R1I)(RJ?=>Z+IEHOY4FW?B
M]MSY8;D^!'4^!V5OC.[<VGU[L*N^$'7,_=?8N\-[[CBVKU]L_9'5^+V;D<YN
M#<N_\K4Q?PNEC(9H9/).8%CF\?NO=#9TC\5_Y5?R@ZHZZ^0W5'PQ^&>]-A=C
M;=H=S;+W-4_%+I^AR9H?++&U'6T.9Z_ILS@<U@\K3STM915$<510UL$L4B+(
MC`>Z]T$6P*'^4=OS?WR;ZSF^&?Q^Z\W7\2-NXS?7<D/:OPNV%L/&X[K3.P;P
MJ<+VEA,OE]@)C<[L;+1;`S+Q5$<JU(BH&E>!(I())?=>ZE_%C8'\HWYS;2W7
MN?JWX0_&R<=?[AQ>"W3M+M7X3]=;`WOMYMT;.V_V)L;/5.T=Y]=TN53;?8W6
M^[,7G\%7HAAK\77QL"LBRQ1^Z]T_MUI_*KIODW0_#O;_`,*/C;N/MRAV+C]^
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MVR^P\56XC-QUM-%!C*JBF\LHC59&]U[H[E3_`"[?Y>:539FI^"?PV:OB`E_B
M+?%[I2:O4T\=U9:A=C/5%XXXK+8WX`'X'OW7NB4[!SG\G7?'7GRE[+R/Q!^/
MW5^"^%^5S&,^2%!V[\*]C;#W'UTF*V30=CT^2J,'7]?S569H=P;'RM+D<>E!
M]Q5S)41PM"E2PA]^Z]T)WQNZ/_E4_,KK_(=A;!^"'QICCVCO?<_6>]]E=L?"
MWK'8O9G6'9&TVH6W'L7?>Q]W=?09C;&Y*.CR5%5F)E*S4=93S(S)(I/NO=>V
M;UM_*QWW\CNQ_BQL7X4?'#<V^^F,3BI^TLW@_B+U5-UKU_G,SB<1N'#=?9W>
MAV;%C8M]U6UL_0Y+["!9D@I:J-99(YCX??NO=('X_P!%_)O^7'9?:'2_6'Q`
M^,.?W#UI3UF8D7=7PRZZP.U>R-HX;?6Y.K<WV#U%GL_U[#A^S-A[=[3V=E=N
M5F4QS2P0Y:A=+F.2"67W7NEEVYU?_*E^/O9W270F6^$'QHR?:??>1S*]>=;]
M;?#_`*FW)FEVWMRJPU)O#L;<%%C=ETU'MO8.U<AN7'PUM?/('>:M18(IF$@3
MW7NDKNA?Y/6UOE3M_P"&F=^)'QJ_TL;EFP&!EKH/AQU_6]88/?&]]H[KW]L+
MJC=O9,?7[;2P'9O8NP=C9G,X;"U,XJ*['8]W`#24Z3>Z]T(GR&Z$_E.?#GJS
M)]P=H_"_XA[:VU_'=J;.QE!M?XF]/9/=.]]\[TS=/MO8FP]I8#$;&6KW!NK<
M^X,C'2T4`*QHSM+-)#`DLJ>Z]T%/R.R7\H?XG['ZJWWW?\*NDMN4W;&$SF[\
M=MK$_!_96[=[;/Z^V1@,5NCM?LWL;;6UNO\`+UNSNO.E\%FZ2IW5E9M=/BTJ
M(^93(@;W7NC7YKX,?RT-J[=S?:6<^%_P@P^W=O[=RF\<WOFH^-71T5%C]KXW
M%39?*[AJ<RFR6;^&4V'ADGDF#E3`I-[>_=>Z*A@J_P#E%9SXE5OS8/PDZ4Q/
M1;5>)I=FUF8^$>PJ?>G:C;NS^`VIUBW5^P:;8E9NG=3]O;GW7C*#;4"T\556
MU=='%+%`PD">Z]T-G17QF_E8_*WJ;:7>/7OPA^)F:VGN)]P4%/%O#X@]4[<W
M?M;<>S-S9G9>^=E;MVQN;KZFS>UMX[%WQM[(XC*T$\:24N0HIDNP`9O=>Z:^
MLNLOY47;_<?R+Z'V-\2OB[6=C?%2IV'2=T4.8^(6Q=LX?`3]D8?.9W:[X?<6
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M_P`%/Y=W7.W-S[]/\OWXKY.7`X7)YNKH-D?$/J#<.],XE%":F3'8+#8?8IRF
M<S%?(JI#3H2TLK"Y`N1[KW1,:???\FZN^*^V_ESC?AETGE-B;Q[+K.D=I;`Q
MOP;V96]X[J[TQ^^\YUM7=+[:ZJ@Z_?<&>[!I-Y[8R5(T%*):1HZ&:I2H:EC,
MWOW7NC3=/?$[^5=\D.L^M^_.K/AM\+M\;#[0VC@M\;$W>/BQT[#45^WLO3QU
MF,G>'*;`@RV*K:8N8YJ6H2*II*A'BD1)$91[KW0,]747\H;M[:GR#[*VG\2_
MC#%TY\9\AOK']B=V9WXE=78?JNN'5HW#'VED=D[FGV8S[JQ'7-?M/(TF4JH(
M!"9J5FIVGA9)6]U[IU^+_5W\IKYO[(S^\.M_@M\<!'LC=,&U=V;*[>^$W7'7
MO8&S\OEMI;8["VO/F=E;UZ]I,M08W?'6^]L+N'#U8C,-?B,K3RJP;R1Q^Z]T
M@\OLG^2K@_ECC/AID?@Y\3XNV\I58K`+E4^"_6<G5N/[&W#L'.=L;8Z=S':2
M=9G9^,[;W1U1MG(;FQ^$EJ%J*G#TC2*?(\4<GNO="'U5\?/Y/'=/<_R'Z"Z]
M^#WP^RG9?Q:R&P<5W+B\A\(^M=NXW"5_9>*SF9VK%A,[N#JK&8C>-/4T6W:K
MRU.)FK*6"6/QM+Y+J/=>Z:_D-T9_*%^-6X.F]E[Y^`'Q3SO87?V\:[9?4_7?
M7WPIZ9WAO+==9@J2ER6[LS!C*/8D,%'MG96*KH:G*5M1-%'"DT4<8EGFBB?W
M7NDCV[L;^2OT?\A.L_C-O[X-_%"#L?LR38T$5;@_@KUON+8>PJGMG=>7V#TM
M2=J[\Q'5]5MOKVK[K[`V_7X/:\=?,C9')4<D9\:Z';W7NF?YV?\`"?W^65\V
M]@[/VAGNE=I?&/';`W17;T.[OBAL#I3I#<F7C?"5F+K</N_/4W6>1&0VND<B
MU1A9$5:B".0L-'/NO=5GR?\`",W^55`-<W;/S'1-4*AI.S>K(HV>HF6GIXQ+
M)TRD9DGG=41;W=F`%[CW[KW2^_F1?RD/@;\%?Y#7RMV#U9\?NK]U[KZ;Z'W3
M4;8[\[+ZMZKW!\AJO*Y?LJ'=)S>7[4H-CX;/R9?%5><:FHIH3`U+14\$*66(
M>_=>Z^5S[]U[K?>_X1K_`!>^,_R!Z<^<^3[Y^.W17=N2VWV;TI1;>R/;O4FP
M>R:[`T=9M;?M15TF&J]Y;?S4^+I:FHB5Y(X&C5W4%@2!;W7NM&ON>AH<9W#V
MOC<914F-QN/[*WU0X_'4%-#1T%!0TFZ,I3TE%14E.D=/2TE+!&J1QHJHB*%4
M``#W[KW5Z_\`PEPZEZJ[K_F[=6;$[EZRZ][<V15]3=Y5]3LWL[9FW-^[5J*_
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MD\#5,I2WD>_NO=:+/OW7NOH$_./XM_&';?\`PDBZ4[UVY\;N@MO]W9+HGX4Y
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MAD=FM<GW[KW27_DU;-V?V'_-3^`^R.P-I[9WULO<_P`FNL\1N79^\L#B]S[6
MW#BJK-Q+48W.;?S=+6XG+4$P`U0U$,D;6%P??NO=7E?\+$N@^BN@/F1\5,!T
M/TKU)TG@\W\9:[*YK#]1]<;.ZWQ>8R<7:>\*.+(Y7'[-PV&H\A70TD:Q)-*C
MR+&-(-N/?NO=:@WOW7NOH5_\*!OBA\6>JO\`A/S\1.T>K_C1\?\`K;LS,97X
M9Q97L38/3?7>S]]9*+/=&;DKLY'7[NV_MS'[@K(\S61++5B6H<5,BAI-3`'W
M[KW7SU/?NO=?4/\`^$F_QA^-&Z_Y7G4/>FZ/CKT3N3N[;_R![EJ\#W)G^H]@
M9CM7"UN$W%#!A:W$]AY'`5.[<;68>F`BI9(:M'IX@%C*CW[KW6W-XU_H?^2F
M_P"*^_=>Z__3W^/?NO=>]^Z]UJ?CXE_-_P"=OS5[Y^3W3O\`,4^.V5S?Q$[!
M[[^"M,_8?\M+![DVSBL97;@V+V?NWJ>BK]T]J5"[_P`CU#EH<9C)-T4U'C9F
MRT.2IHWFI:F=)/=>ZN__`)7';E/WM\$?CWVC#V%C>TI\_@MX8_*[TQ/1J_&F
MEK=P;2[)WCL[<F(FZ*3*9N'KK*[3SV`J,374D=5+%-64,M0EDF51[KW5@/OW
M7NO>_=>Z][]U[HI/SY_[(=^8'_BL_=W_`+[C<7OW7NBO=J_RX,)\A.X^J?D&
M>Z=^;!PK;#^,M/V[U-@=N[(R^W>X<M\3^P,[WM\7\W5;BS^+JMT;+GZS[>W;
M/D<E!CI13[EH8(*&J5(D9G]U[H2MC?";L+`?,[9?S*WC\I=Z=A;BVU\4,5\4
M]P['R/6'5NWMO[VQ]/F,?O+/]D5V2VUBJ#*X3=>Z.Q<<,O+2X_P8NF1OLX8%
M@4'W[KW6;^8A\`=I?S!NLME=?[FW:NQ<MUUOVHW]LS=%5UYL'MS`4]7FNOM[
M]4[KQ>YNL>S\=E]F;II<KL3L3)K0RSP"HP^9CHLE3.)Z15?W7NBN=N?R:]N=
MNXWK+;.6^3W<])LWKWK%_C%D\34X+KS.9_?GPK-?T-N1/CMN'>>2P[YM\\F]
M_C_09-M^%Y-S3IF,G3S/(DM.]-[KW5E?RD^.^S?EM\<>Z_C1V-59G';+[OZ]
MW+UYG\GMZHIZ7.XNCW!024D>7Q$M3#541R&*J3'41)4134\K1!)HWC9D/NO=
M5C[9_DXS[.Z'Q/3>V_E?O+!Y3;G=5+\L=I;GV_TOTY@-J;*^7F-[2HNP\3VY
ML_J;$XFEVCMO85+B*1\#)L"C,6WIZ6MJZTVR<[50]U[JRSXG?&_:7Q%^.G5W
MQPV)D<YF]N=6[?GQ%/N'<]133[AW1F,GE<CN/<^Z\TU!!2T$&1W1NK,UM?+#
M3114].U08XD2-%4>Z]T1/%?RJ(8^T/EOV9N#Y$;FJ3\T\?ANO^]=H[$ZFZIZ
MQVIOKI7'TO9N-RNV]XXO;N+>/='<FZ,1V=+CJWLJ3P[D3$XNBI:?PJLS3>Z]
MT8#X'?!:B^%&VNR(\EV]NWOCLKM;+[`GWEV?N[;NU=G5=;MSI_JG9_2'46UJ
M+:^RZ.BP%#!M#K38M!!4U81JG*9*2JK)2OF6&+W7NB]]V_RD=E]M?..#YX;?
M[HWGU;V?38O;&2IZ?;^S.OL[DJ'M;K7K/L[JCJ_?&'WSN#&5&Z,;LC%;:[3J
MIL_L<2-MO=M?CJ"3(1%()(Y_=>Z$;X[_`,MO#="_);<7R*KNZ]]=F4WW'?FX
M.L>M=P;9V/@\/U?OSY=;PV#V1\K=Z0;@VWBZ//;NJ.U.Q.NJ.OQ]%7R_9[8I
M:BJHZ-&BDC,7NO=8_P"9%_+%ZW_F04/45+O??><V!6]6/V=A!D<9M#8N^8<M
MUWW;M?'[.[3P5!C=^8G+4VSNP)\5B*.HVSO+&"/-;3RE,*NC+,60^Z]TC][_
M`,K.+L'O?9/=&ZODSVMF,9B\]T_6]H=>3[5ZS%%W+MKXI]Z;V[_^&^T<YNH8
M(;CV[#T?NW?%1393(4,@K][4,40R<GF#RM[KW1S_`)=?&Z@^5W2&7ZAJ=WYS
MKG,G=/7'8VQ.R=MT&&S&8Z\[0Z>["VQVIUKO"FP.XJ:LP&Y*7#[UVC1/68VM
MC-/D*'S4[E1)K7W7NB*[U_E3YO=OPK[3^$]/\N^S\+LON2GILKOG=T7673];
MN.H['W?W/O\`[X^1_8&+IY\#'0T,GR"W]OE?)C'\V/VQCL=%3XI(6EGE?W7N
MK7<-BLY1[7PN(SFXIMP;BH,#C<?EMWC&8_$U.;S=-C8J7(;D_@M$C8C&U&1K
MT>J^UB4TT+/H4%`![]U[JG;;?\FW#T/6WRRZQW-\D-Z5^U?F]N+=>?\`D3M;
MK[JCJ'J386:J<QU(W6VW<WL38.V\/4X'K?L'&;DAH]WY_<&/`K-X;AH8OXDK
M48%,/=>Z/I\-?BHWQ0V%OW#9KL_</=79O<O;^\>^^Z^V-Q8#;NT*C??:6]<?
MMW!5^4QNRMI00;;V=@\?M;9^*QU)CZ3R(D=%Y'DDED=S[KW1-:C^49MC#?-G
MM/YR=7=\[UZO[+W_`)'=.\,'3XKKWK#.U&TNR>Q-E=6=8]CYNNW7G,//N/L+
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MBC2`>Z]U;AV%T]L[LCI'?/0&;I*_']>;^ZNW+T]EJ';^1DQV3H=D;IVI6;)K
MZ;!Y5UGEH,A38"N=::<AVBE57-R/?NO=5%=5?R4<1U-\>]P]#;<^4_86/BW)
MO?:/<<^=V[U+TKM';V+[YZ2JNA)_C+VO@.M,%MN#:6#K>LS\?L=4;EH*=$I>
MQ,KE<G79>TT\7@]U[JSCXG_'#%?%;HG`=,XS=6<WYD*7<'8^_-Y]@;FI,/C<
MUOWL_N+L;=?;O:6]*O$;>I*+!X"GW'V)O?)5-)C:.,4^-HGAI8RRPAC[KW1=
ML7\&.Q<3\F_DM\D*/Y5[PCA^3<'0NW-S]8/U3U148#;_`%KT1DLS)2=<X;<-
M5B*G<,U%O3;^\MQXW(Y*>1\E&N9^XII()J2F*>Z]UR^!W\O7#?!H;TGI^W]]
M]UY/.[$Z6Z-V5DM[X39NWY>N/C;\:L?O+%]!=24T&T,7C8MSY+9U'V!EOXEN
M*MOD,[+-')*L?A4'W7NDSW]_+0P?>/RJPGR9I>ZM]]>TLC]`[A[(ZJPNWMF9
MK;?9'9'Q'W%V5O/XL;\GS^;H*C<6V).K-Z]I5V0K\70R"@W,E'0T]6$CAE$_
MNO=.NSOY>M?C?FOL7YQ;^[[SF^>R.O\`H[(=)P08/JKJWJC)]D4FX\+L^@W3
ME.]MW[!Q5!ENVL!!GMIOG-L[?J4I<7M;*9">2E5U$2Q^Z]TN_G9\'X?F?M_K
M$8;N#=W0G974.Y-[YC9':&S]O;4WA6T&&[6ZHWOT9VMMFKVKO:CKMNY"#=G6
M'8F3@IJIT%1BLDE+6Q:S"T,ONO=%V[._E24O9VU/C/U76?(;=>'Z<^)O9G6&
M].EL%0]6=5#M?K?:O2,/6L75^P^K?D`,6O8G7DU/#UTU%G<_`]3F=PX?,5M#
M/+&C1/'[KW5G':NT,SO_`*[WGLG`[CIMHY7=>V<SMZDW)6[5P&^J#$29:BDH
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MS[`FW3WM7&C[&KPV[*#"8O'XF*7[>.H:H]U[H^7PA^&TGQ`VUV+#N+MS<_?G
M:';V[=L[M[([<W5MK:.R:O.'K_JGK[HOKC!X_9NQZ*AVY@\=M;JOJ_#TDCQJ
M\V0R`JJR5@U1XX_=>Z`SM3^6)2]@_*O=WR@V_P#(GL;KZ7<.=P?<N+ZZQNS>
MM=QX';/RXV)\?-R_%OJ_Y%T.9W-@J[,Y*EV1T_N>6/\`N=6&;`9#+T\-=4!M
M+02>Z]T.72_Q"W5U1\O/DA\J\K\@=T[^A^1NQ^I-D93JO+[#V%A<'M*'I.CR
ME%LC*X?=&!H:?<U?6:=UY^2L2JD>*IERU]*+2TZ+[KW01_S%?Y8O7/\`,4JN
MFZO?F]\ULB7J4=B[<EFQ&SMA;SJL[UOW$-DKV5A=O3;[Q&4;K'LQGZZQ,NV]
M\X0PY[:M1'++2,6F:WNO=)O>W\KUNR.^MA]X[X^379^>AQFZ.H]S=O;$DV9U
MA1X_NT_%GO;?W??PZQN2SU'@8\SLJ/HO<._7H,A48QQ4[RQ]#3G)2"<RS2>Z
M]T:SYO;!R?:/Q8[?V!C^M\MVK6[IV\F,@V7@L#U%N[,U,TF2I)8<KC-G=\;B
MVGT_O*IVY-&M>N+W!D*6@KOM_&S,Q5']U[J@C?7P6^>&?_ES?`WXL=@?%4]O
M'XN[,I\9V_U)0?)/:%3BNY=S;Z^.WR!ZRZ\RT.[=Y[SQ3C)?%GM7<.T-R9C[
MVKCQ\56[S[7^^&(HU/NO=7?9_P"'&,[U_EUX'X1?+C=6>W?#N#XU]:=0=];X
MVSN>HH,_N?<.UMH[7H]Y[LQVZ\M15%4)\SN;`RUC5573LTJ2,94]3#W[KW6K
MILC^03_PG?WU\=.TOEU29'YA;>^-/5E-N/+5/<&[]\9[;NT]];3VR'6IWQU8
M*S8+9G?NU<I61&FQD])3&7)U#1K312>:`R>Z]U=__)%^&?P`^*G2W;6ZOY?X
M[OH=K]J=D2[=[BVC\@JK,T?977':72D^<VCF.O\`=&RMP[?VWFMB;GV[59:H
M%=254,DDRRP2H[PM"Q]U[K7.RO\`PDR^#_:GR=[6Z?Q7\RGMG*=V8RIK^Q-_
M;.PGQ\HLGC]CP;RJUW)C<-N7>=)E6V1B-TU&*SE-5Q8BIKZ?+ST$T=8M&M-(
MC^_=>Z.+_)'_`)*7P+^*7SKW1\@OBU_,9RWRB[`^-&,WUUOV3UC_`*.,1MVA
MHI=]TNX]A-EX-Q1Y6=,_@*#.[<RM''DL.M?BYLKBZFC^[6:FJ(A[KW6KI_PK
M'!'\Z_Y`7!`/6WQZ()_(_P!#FTQ<?U%P1_KCW[KW5(_P[!_V;;XM-Q;_`&8_
MH\&Y'%^R]M?CZV]^Z]UO!_\`"XS_`(L_\N'_`+6GR?\`_</HWW[KW7S[??NO
M=?1^^?O_`'!G=#?^*^_!+_WZ_5OOW7NOG`^_=>Z^D%_PD@_[<U_/K_Q83O/_
M`.!9ZC]^Z]U\WWW[KW6Y+_PBD_[>,_);_P`4NS__`+^KI7W[KW5+/\_?_M\C
M_,*_\6!R_P#[H\'[]U[I)_R._P#M[W_+J_\`%J^J_P#W>1^_=>ZO_P#^%MO_
M`&6]\0/_`!57(_\`OW-Z>_=>ZTK??NO=?2I_X4A_]PWWPR_[7/P=_P#?`[H]
M^Z]U\U;W[KW7U@/^$C'_`&YIZY_\3UWQ_P"]-#[]U[K9X]^Z]U__U-_CW[KW
M7O?NO=4J]S?R?,ON3NGN+M_XL?/KY@_!*A^2NYQO;Y&=7=!9K9-9U_OOL&?%
M4F!SW:>SJ/>&W,K7=4=I[QP^/IER^:Q,VNLGI8)FB$L>IO=>ZLH^+/QHZK^'
MG075_P`:ND<1783J[J3;9V]MJERV1?+YNOFJ\C6YS/[DW'EI$B;*[GW9N3*U
MF4R52$C6>OK)G5(U8(ONO=&"]^Z]U[W[KW7O?NO=%)^?/_9#OS`_\5G[N_\`
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M*[_;K?OK;VU=@[SHMO=8=7[+!V)T]UW-LSXZU*4.&HCC&[;Z\W`*3<.Y]Z>%
M<KV%D:"GBRZ?;1K$/=>ZM`^&WQ7_`-E/ZOWAM7)]B9CM[LCM/MSLCOKN3M3-
M;?PVT#OSMCM')PU^X\UB]E;>EGPNS-O4M)0T=#08RGEG%/2T::Y996DD;W7N
MB$8/^5SW1UK\]N\OFITG\FL=LF#MG/[IWX-A9O:>_LU3;BW?V!LWI_KO<6V.
MY<=B^V<%L7L#K#8.$ZEDS.R%IL-B]PXO<&<D^ZR-30TJ4DWNO=+[^7O_`"R,
MO\*.R-V[UW)VSC.R\5@^H,9\8N@<5AME3[2R>V?C[BN[^W>_J1NV,E4[CSE-
MOGM23=7<,^-ER..I\/COX;B()5HQ55=4P]U[JO/^:YUO_+0/\P/I/"?)'X4=
M$=@;M[BVAM;L+Y'_`"C[AP/<6?Q6RNJJ#LSKKXV=;X&:+JB/(1;>W'NS=N[Z
M'%4&X-P"@VYC33005<KM5(T'NO=`]/\`#C^6'UM_,HVMT5M?^5;\8:/JC9OR
M4ZC^,S=JTNZ=_#N3$_)K?GQ7W=\W]A[TP6R$DFVC4]/[>V7L),17O59)<L<U
M4^=*=Z.GE#^Z]U7U_P`+C/\`BS_RX?\`M:?)_P#]P^C??NO=?/M]^Z]U]'[Y
M^_\`<&=T-_XK[\$O_?K]6^_=>Z^<#[]U[KZ07_"2#_MS7\^O_%A.\_\`X%GJ
M/W[KW7S???NO=;DO_"*3_MXS\EO_`!2[/_\`OZNE??NO=4L_S]_^WR/\PK_Q
M8'+_`/NCP?OW7NDG_([_`.WO?\NK_P`6KZK_`/=Y'[]U[J__`/X6V_\`9;WQ
M`_\`%5<C_P"_<WI[]U[K2M]^Z]U]*G_A2'_W#??#+_M<_!W_`-\#NCW[KW7S
M5O?NO=?6`_X2,?\`;FGKG_Q/7?'_`+TT/OW7NMGCW[KW7__5W^/?NO=>]^Z]
MU[W[KW7O?NO=<0ZDV#`G^@_U[?[#W[KW5/\`N_\`G2?'#K_YA[(^(&_^F_E]
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M&BIJM(EJ8(94]U[I';)^!GP[ZW[3V5W=L7X]=<[9[9ZYV`>L-D;[QN)D&=VY
MLO3DX5QM!+/4S0&OBH<W6T<>1DC?)QX^LGHTJ%I99(F]U[JHC_A0W_+&^+_S
MOZHZ=[D^6_S-D^&'4GQ2FWW+E-Z5.U<'N'!Y:H[@KNOL'0P5\V5S.)JZ:O@R
MFV*:"DAI5J)*IJQU,=U5E]U[K7N^1/\`PE(_ET_$W#;"S_R*_FT;HZGQ/:&X
M(]L[$K-R])[?=<[D&I(J^KK1#B]WUU10;9P5!/%/E<S5K3XC$02QR5M53I(C
M'W7NK<_Y\WQOQWP__P"$R^?^+F'W96[[Q'0VWOB-UEC-Y9'&TV'KMS4>U^[N
MM<?!F:K%T=77TM!+61QAO$DTJI_JVO?W[KW7RU/?NO=?2"_X20?]N:_GU_XL
M)WG_`/`L]1^_=>Z^;[[]U[K<E_X12?\`;QGY+?\`BEV?_P#?U=*^_=>ZI9_G
M[_\`;Y'^85_XL#E__='@_?NO=)/^1W_V][_EU?\`BU?5?_N\C]^Z]U?_`/\`
M"VW_`++>^('_`(JKD?\`W[F]/?NO=:5OOW7NOI4_\*0_^X;[X9?]KGX._P#O
M@=T>_=>Z^:M[]U[KZP'_``D8_P"W-/7/_B>N^/\`WIH??NO=;/'OW7NO_];?
MX]^Z]U[W[KW7O?NO=>]^Z]T3;Y>=)_++N;#;(HOBE\U:CX69G`Y^OR&]<_!\
M=>KOD0>PL)44D<%!MYL7V?5TE)M5,95JT_W=&6FF\FA@%4>_=>ZH<[?WG\G>
M_OYMW6N?^67\O;YZ[D^*'P>[?H\5\+J7ISK/K#='4W8G=U7FVV9E_G#\A=VY
M/M3;>3QVS]FXW1EMEX;$8ZMFQ]*WWD[15`JZ"I]U[HIO0_PC^:K5'P._EJ[H
M^*?=.VJ#X(_SB-P?/_?_`,T<V-LP_&KL'HC:._NUNR-BS=>[QAW'-N3<_8_9
M$W8L%#+A3C5J\48]59H#3BD]U[K8X_F;]9=@;O\`BG\DMS;9^0?9O4NW]O?&
M?NP9W8^R=M]3Y?`[YOLO-5CR9^MWQL'<NZ:)I:*-J.08ROH1]O(["\H5A[KW
M1F_C=UWOGK[8]%%O7O3L+O.7-8S;60QF1["P'6>!J-LT4>WZ*!L5B(NM-E;-
MIIZ:KE'FD:M%94"0D"73Q[]U[HQ?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z)O\_\`XW[T^7GQ"[U^-&PMZ;3ZZS_=VPLSUK+OO>6SJ[?V,VI@
MMUPG$[CS6-VQ0Y[;<E7NBEPE3/\`PR5JN..GK"DCAE4J?=>Z(W\O/Y;GR:^6
MF!VM0Y;Y)=1[-R]%T_W9\5=R2XCH[<=;AO\`98_E?U!U+U[\C*;`4>2[.GG;
MN"#=/6+Y;:.4J)/X704=?]E74568ONI/=>Z+/_PJ;Q-)@/Y%7R(P6/$HH,+N
M#XRXFB$\AFG%)CN]NLZ.F$TS6:67PPKJ8\L>??NO=?)+]^Z]U](+_A)!_P!N
M:_GU_P"+"=Y__`L]1^_=>Z^;[[]U[K<E_P"$4G_;QGY+?^*79_\`]_5TK[]U
M[JEG^?O_`-OD?YA7_BP.7_\`='@_?NO=)/\`D=_]O>_Y=7_BU?5?_N\C]^Z]
MU?\`_P#"VW_LM[X@?^*JY'_W[F]/?NO=:5OOW7NOI4_\*0_^X;[X9?\`:Y^#
MO_O@=T>_=>Z^:M[]U[KZP'_"1C_MS3US_P")Z[X_]Z:'W[KW6SQ[]U[K_]??
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=<0H!N+\DFU^+G\V_'OW7NBE_/G
M_LAWY@?^*S]W?^^XW%[]U[HQFQ?^/(V=_P"&KM[_`-U%'[]U[I5>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZI'_`.%$'QB[X^87
M\J3OSH+XU]=9+M7M[=NZ.E*_;VR<1D<%BZ_)4>UNX]D[FST\-9N3*X7$)_#L
M)BYYV62H1G6,A`SD*?=>Z^<'_P!`V_\`.U,J1+\"]\.SD*&B[-Z%E@5BQ0I)
M41]JO!$T;@JX=@8R"&L0??NO=;M?_"=WX/\`RL^!7\K#YP=3_+KIS,]*[^W+
MVGW1OW;VW\SG-HY^;+;2K/CKU_MR'-4];LS<&X\8*=\SMVL@"O,LA,!;3I96
M/NO=?+0]^Z]UN2_\(I/^WC/R6_\`%+L__P"_JZ5]^Z]U2S_/W_[?(_S"O_%@
M<O\`^Z/!^_=>Z2?\CO\`[>]_RZO_`!:OJO\`]WD?OW7NK_\`_A;;_P!EO?$#
M_P`55R/_`+]S>GOW7NM*WW[KW7TJ?^%(?_<-]\,O^US\'?\`WP.Z/?NO=?-6
M]^Z]U]8#_A(Q_P!N:>N?_$]=\?\`O30^_=>ZV>/?NO=?_]#?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]T3+^8M_>+_9"?F1_=5]OQYW_9:^X_M'W1
M!E:G!K#_`'%S7\0-7#A)8,F\G\-\W@\;`"HT%[H&!]U[I5;:3Y-'!X(X.MZ-
M7;A7./A8\OB-_-G(]DR=68Q.K8<M-19I,?)NNE[/$LFX9(42DFP&F.C2*K!D
M/NO=/6-3Y7?<XDY>O^/KT0KNI?XZ,9A.R(ZI\;%@JQ>^$Q#5>>DBCKZW<_V[
M;0:8-%34`D7(B:8JP]U[IJ2/YE?PF,/D?C-_'?[I8M)9$P/:JXC^_8[(>7-S
MQQ-N$UIV@W3^F*ECU?>KN:\LCFA_:]^Z]TXY-?EBPS8PN0^/2%H^Z#MILI@^
MRI%22=*+_9=1G?M<]$)5Q\BU/]]A3Z#5JT7\+-.0U_=>Z=HT^3!S4+25W18V
M[_>K`M/&N([!&:.QQUJT>YH897S'V(W7)W%:6@D9#2)MF\4J-6_O>_=>Z9<<
MGRX^UQW\6R/QS-8,%T\N7_A^"[02F?<T6Y<@WR`DQBU6=:9<%6[.-*FSDDU5
M%-DA,^1:>`H@]U[K#D8_F%_!\J,5D/C8,\VU^Q5PCU^$[2?$1;T??5._4DN5
MBIL\E;-M>GZS$T>XXX62KFSI22C>*D#1GW7NGBL_V9XY/(M05O1*X0;DWT^,
M2MPO8C96/9\FP*5>L8:]Z?,K23;GI>TO-)GY(56EFV^4CI$CK`TA]U[J'C%^
M6'WN+.6K?CVV-%?U&<U_#\-V3%6MBX<)6KWT,4:K.2P)7U^Y33/L\RAHZ:@$
MJY(3RE6'NO=-AC^9/\&4?Q/XS?WB&U<2LDG\`[5.$&^!V0TF<F6/^\(KO[IR
M=/@14D>O[Q-R_NR.U#^S[]U[IUR2?*YDS38>O^/<99NYCMT93"=E2>..5:+_
M`&7G^.+2YR(R24+BI_OGX-`J@8_X9]O9K^Z]U/C7Y-C,0M-6]%';W]\<$]0D
M>&[$_C/^CY>LC'N:"&4YAJ(;RE[FM-02LAHDVQ^U+&]=^][]U[IJQ\?RW%'B
M/XID?CFU>,=T\,^V/P?9R4;9>+=%<WR`?#QU&=DG3&UFS/MDV<LS-+3902OD
M6G@*(/=>ZP5L?S!.+R?\.R7QL&8.![%&&>MP/:38Q=SOOBG?J27)QP9]*M\#
M3=:^5-QI$RU$^<T/1O%2ZH_?NO=/%8OR@.6R34%=T.N!.ZM]/AUK,-V&^738
M\FP*:/K&')-!FUHWW72]IB:7/R1*M'-MXI'2)'6:I??NO=0J!?EA]UB#DZ_X
M]FB7*=2'/K0X/LM*M\+#@ZM.^DP[5&>>),I7;F-.^SVF#Q4U`)%R*SS%6'NO
M=08X_F)_!8Q-DOC4=PC:^-65X\#VFN&.]1V29,S-%"VX6KQM9NGR(J:,L:L;
MEO*[FB_:]^Z]U,KD^6;#,G%Y#X\*6G[H.W1D<'V8WCI9A1_[+LF;^VSJF2IH
M2*C^^I@T)57C&,%/9K^Z]TY(GR=&;IC+6]$G;8WIA7K%BQ'8?\;/7:]:2Q[D
M@IG;,&A7>LG<926AE930+MD-%+&U<1-[]U[IIQJ_+<4.%_B^1^.C9#^%]1+N
M!L;@>T$HWSD6Y:UN^GP\=5G7GAQ-;L_[=-H"=FEILGY&R+3P%4'NO=8ZF/Y@
M'&9`460^-JYDX#LH8IZK"=HMC!NE]]P2=/29".+/1U;;?I>L/+'N58V6IJ,_
MIDH6AI+Q'W7NG2M7Y1?Q6K;'UW0O\#_O1OPT"5>%[&?*C9DFP((^L(JJ2#-I
M2-N>F[4\DN?D1!23;>TQTB15@,I]U[K'CT^58J,.<M7_`!^:E%?U(=P#'83L
MA:A\7%@ZL=\)AS4YUXX\A6[D-.VT&G#1T]")%R(GE*L/=>Z98D^98P\*U&2^
M,QW!_='&I420[?[5&&&_1V*TV8J(HGW&:X;/;J*T--$S_>C<O[KN:+]KW[KW
M3KD4^5Y;+G$5_P`>TC9.Z_[O_P`2PG9,CI).N/'QQ&8%+G8A(M`XJ_[[^#1]
MVIA_A?VY#W]U[IPIT^38S5*U97=$_P!W/[U85JQ*;#]A_P`;.R1UK+'N&&FE
MDS+4(W3)W"4DHI'3[1-M:HY4:MM+[]U[IHQD?RZ7'8/^-9'XXMEA@^HQN1L7
M@NT$Q\FY8MRUS=]/@TJL])50X.LV=]LNT$G,E139,2/D&G@*H/=>ZQ5D?R__
M`(96?89+XW+E_P"Z_92T#UF`[2;&KO23?=))T]-61PY]*IMK4O6/GCW+&C+5
MSY[QR43PT@:(^Z]T\UR_)X92N;'UW0XPAW'OHXU*S#=B/E4VE)L*G3K&.O>#
M,I2-N&F[0\LF>DC5:67`:8Z1(ZL&0^Z]U#Q:?*X387^-9#X^/`*SJ,[B&+P?
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M>O;O]\8M1G99HL+6[+-*NSEF9IZ;*"5LBU1`41?=>ZX9"/Y?'$Y08K)?&X9P
M[:[$7"25^![1?$IO"3?-&_4LV4CIMP)5R[:INM!41[CCA=*J;.F.2C>&E#1'
MW7NG:M7Y/_QC)''5W1"[?.Z-\-AUK<-V&^979DFPJ>/K6')2P9I*&3=%/VD)
M9<[)"BTDVWRD=(D=7>7W[KW4/')\L5JL9_%Z_P"/348R'41S"XS"]DK5/B8<
M)5+WXN,>ISKP19&MW(8&V<9@T5-0AUR0GE*L/=>Z:S'\ROX*%&2^,_\`>3^Z
MV+4R'`=J_P`".]QV2TF;F$8W#]^NU&Z?M%2QE_O!N:\KN:&T7OW7NG/*)\L;
M9O\`@U?\>T8MW)_=P9/!]E2B-)XZ#_9>OXV://1>9Z"851WI]OH%4IB_AGVY
M#W]U[IRB3Y,_QM#-7]%G;9W?MYVCCP_80SG]PEZRDCW9`LK9EJ`;OD[ETRXZ
M4I]G'MB\4\;UW[WOW7NFBB3Y<"AQ:Y+(_'-LI_#.GQF7H<%V@N/?,Q;JJG[_
M`&QB3YUYX\;6['\*;.69VEILL'?(FHI],8]U[K'7Q_+XXS*C%Y'XW#,_W=[%
M&$:OP?:+8M=V2;YIFZDDRB4^>2JDV[3=:^9-QK"RU,V<*24;14H:,^Z]T[58
M^4'\9R)HJSHA,`VZ=\-AXZO#]AR9==E2]?TT?6<&2G@S4=$VZJ3M59I<_+&B
MT<VWC''2)%6!I3[KW0#=$?)+=7R/.5K>D._?A-W;B-A[NZGVSVC-U#N'<F\I
M-M55+A,D.^L/+-A]WY*'%9O*[D@C;91JU,"8^&H^]^YD4,ONO=+K/;H^4&TM
MO03[KWE\4<'N"79<]5&*R@[,AQ]=O#;^\JW<.[YL1C9-QC-Y3;&.Z&H)IE@@
M\E?%G87J)":`>/W[KW22WMWWV5L[I^?Y`Y3M;XI;<Z4RN*WKGMH]C;HH^S*3
M;M1ANS:W:N*^&]3DJE<Q#+(V=R^YJ>GW2L4<;Y"6MI8\4M.[,#[KW7"M^3E9
M@OD1MKXW[D^0GPPQ/;>X,[M[.4?2E7NC-T'=&:ZLJ.JLM49<X':59NM*V?>>
M1[8Q,];BS]M)3OL^DJ"T,E5$]0GNO="]BHOET*/##-9+XXOD5QG4B[B.+P?9
MT5%)FH]T5;=[OA15Y^6:+%UFRC3IM)9C)+3902/D6G@TH/=>ZPU47S!.)KEH
MLE\;!GOX#V6,>]5@NTCB%W1)ONG?IN2K2+<"U<V!I>LO+'N9(V6HGSVB2B:&
MEO%[]U[IVJX_E'_%9S0UO0@PAW5OMJ5*O$=AG*C8[]?Q1]8Q5$L6;6C.ZZ;M
M77+GG5123;>*QT:1U@,I]U[J+0+\KEJ<+_%:_P"/C4G\0ZE;<`Q^$[(2H?$0
MX.L7O>/#-49YXHLE7;E-.^T6G#14M`)5R(GETL/=>Z;88OF1_!HUJ<G\:#N'
M^ZM$LLD.`[47"'>P[)DDR4Z1R;B:M&U6Z>TQ01%S6#<UY6<T-HO?NO=.&13Y
M8--EQB<A\>DBOW6<%_$<'V7(ZB:*@'QR&6:FSL22''U"U1WOX0HJD,(Q?VY#
MW]U[H*/D=LWYK=@=%]Z[&ZQW7TIM?>F]=A;TVGU]N/%KV+@=S;>?<70>>P<&
M6QFX!E9H,#O?'=\UE+5XS(>&2DH<#'^[%+6KK/NO=42=$_#_`/FIX3^6YE_B
M-W!\7^D9ML0[KZ5[$7K?KC=O6_5F]NRMA=/=P]";A^1'QU[;J=E[KK=@;HW)
M\L=J8C=<6!W$,KHK,9"T&\*R.KR?I]U[JQ[X[=)_+OX^_P`N'-]7;DH.H-D3
MXKI+YDY[$=;;NRN\-^5G3TN_.T-];\^//4%1NW:N8?$YC873W2&X!MW,1XZ2
MH9*^@IHL54O00*TONO=?&F]^Z]UMZ?\`"-%]]'^8WW='L.?9\+GXN5,F\AN^
MDSE5YNO8>Z>GUW+#M4X6JI13;T:>2E^REK#)0JGF\D;$I;W7NJ:OYY2;M7^;
M9\^!OZ;:M1O`=_9S^+R[)@S-+MAB<7B32#'T^X*BKRR2K0&(5/DD935"0QVB
M*`>Z]TD?Y-2[N;^:A\#UV#)MR'?+?(W8(V?+O"GRE5M2+<QKG&$DW+382IH\
MQ/@DR/C-4E++'.T`8(P:Q]^Z]U?=_P`+04[%7YT?&`[ZGV--CV^+='_=-=HT
MFX:;(Q0KO7-+NG^\CYFLJZ.H,F\A7MC?M1&4QIA6?5,&=O=>ZTX1;F_]#;_7
M_'OW7NOHG?\`"AJ+OE?^$[WP<.^*[IV?;"5/Q7&XDVAB]\4V:ER[=7[@/6S[
M?ESF6JJ.GQ<&QO*N;6KCDFERA5Z9HX;H?=>Z^=A[]U[KZIW_``D/7L4?RE-I
MM7S[#?8K=^]MG;$-!2;D3>$-.N5K1N==RU-55MA)ZZ7.&D;'FCB2%*`2+-JG
M(*^Z]UM5>_=>Z__1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]TRY'<FW<1D</B,M
MG\+B\MN*6J@V_B\CE*&BR.=FH8XY:V'#4-3/'4Y26CBF1I5@5S&K`M8$>_=>
MZ;8M_;%GWA5=>P;TVE-O^AQD6:K=CQ;CP\F\*/#S:/#EJK;*5AS5/C)?(NF=
MX!$VH6;D>_=>Z+I\^"&^#GS`(((/QG[NL1R#_P`8XW%[]U[HQNQ?^/(V=_X:
MNWO_`'44?OW7NE5[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7N@Y[APV^=Q]2]G[=ZQS>*VSV3N#KW>>#Z_W+GH*ZJP>W-[9;;F2Q^U<
M_FJ7&2PY*IQ.&SM1!4U,=,Z3O#&RQD.0??NO=:W6ZO\`A/[OO`[!^.G7?37?
MM)D$VYU%L7JSY$;[[;W/V_C=X39?K;&=;;6ZN[1Z-CZ:S.Q\?#D^E.OZ3L'#
M;(P6>:3&827?M5E*EJ^L0^3W7NG3MO\`D*[O[2QFQ<MG]W=2[S[CJL'\Z\EV
MQVGO?=?R2_BN-[C^46X\#'T[V9U!_"=\:\+2?'3JZ@J=KX;"ZL;04T$L<Z*Y
M5D?W7NE'L[^2[\F'[_R?9/:WR'Z^WGM*J[VZRW?N`25?=V<W7W=U3UI\EZ#O
M3;5-VOMW<NZ)NK]O[ZVGL7KC8^P<#!@\:F/QN$Q-;.\TL]99/=>Z4_R?_DY_
M(_N[Y#_(SY0;&^3^W]@]F=O[LWO7[%H:BCWG-L_JO%8GXK[:Z!^.W9&U,7CJ
MB*7;WR<ZTR4F\(WWA3O,E'@=YU/V=(U73PO[]U[H"^\/Y1WRZZZZIPU)\8\_
M21YJ+H;>G00VA-W_`-X=D9+#;W^4/=>TY>P.R^O-S[KAZ^I.AMM=4;6R67K:
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M7</4_9@P6POBIO"'L7K'I_:75R;`[)[VZKR'8'>?Q!R<NSXS1Y>K^+^ZZ.@Q
M\L=?(=Q4+9$4^9U5D6H^Z]U\W?\`G[_]OD?YA7_BP.7_`/='@_?NO=)/^1W_
M`-O>_P"75_XM7U7_`.[R/W[KW5__`/PMM_[+>^('_BJN1_\`?N;T]^Z]UI6^
M_=>Z^E3_`,*0_P#N&^^&7_:Y^#O_`+X'='OW7NOFK>_=>Z^L!_PD8_[<T]<_
M^)Z[X_\`>FA]^Z]UL\>_=>Z__]+?X]^Z]U[W[KW7O?NO=>]^Z]T3_P"67R-[
MG^/F.V%6=0?#7N7Y?UF[]P5V&SN(Z<W/U9MJJV!0TT%/+29W<=1VEO#9]#/0
M9.:9HH_MI)/&T+F4HI4M[KW6FC\E?DO5]H?SCOB-\GOD?T5\WMA]F;$_F?8O
MXW_';K?.?'_LZFZQVU\2NNMC[QP/\7V/DOX)0;<[,[B[[[TW,-T9C^%2Y2HH
M-LT%'%',]-2J9O=>Z0?Q\I-@S3?RRN_-O56SJG^;)O\`_P"%#_9VROE3N/&Y
MVFK?D5DNH3OKN/!=[[1WI1I7ON:FZEVUU-3X,2T4L:XK&TE2C1)']Y+Y/=>Z
MW`?YG?8/<FU_BI\C<#U_\>ZCM79>:^,O=O\`>[?,/;&QM@Q[')V3G:5@<#NB
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M0(H6-E`M[]U[J9C<-B\.M4F*H*+'1UM=692KBH*.EHHJK)Y&=ZK(Y*HCI(84
MGK\A4R-)/,X:25R69B??NO=?&9_G[_\`;Y'^85_XL#E__='@_?NO=)/^1W_V
M][_EU?\`BU?5?_N\C]^Z]U?_`/\`"VW_`++>^('_`(JKD?\`W[F]/?NO=:5O
MOW7NOI4_\*0_^X;[X9?]KGX._P#O@=T>_=>Z^:M[]U[KZP'_``D8_P"W-/7/
M_B>N^/\`WIH??NO=;/'OW7NO_]/?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW2`W?
MU7UQV!F-B[@WSL?:N[\[U?NA][=:YC<N!QF:R.P-XOB<E@6W3M"KR%-/-@,^
M,)F*JD%73&.9:>HDC#:78'W7N@HP'PV^*6U.\]Q?)_:_QRZ0VY\D-VTU52;E
M[WPG5VS<;VOFX\A3I1Y62OWO2XB/.S568HHDAK)O-YJJ%%25G55`]U[I/?/8
M:/@W\OU!/I^,W=P!_-O]'&XA;_;>_=>Z,;L7_CR-G?\`AJ[>_P#=11^_=>Z5
M7OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KYXG\TG_A+Q_,/^8'\POY1?)7K?L+XFX/8G??;
MF4W7U[B]]]I;UP>[ZO'287'#[6LP^/ZNS=,F3@2AE>2*"IJ+1IKN!]/=>Z9O
MY;__``E@_F.?$GY^?%#Y&]E;_P#B;D=D]$]T[![0WSB=H=G[[R^[SM3#96:H
MGDP^%R'5.%IZNKK?L98J82U,$4DB-Z_0P]^Z]T%G_"VPZOFY\/V`-C\5,@1<
M6-CVYO,\C\'GW[KW6E=[]U[KZ5/_``I#_P"X;[X9?]KGX._^^!W1[]U[KYJW
MOW7NOK`?\)&/^W-/7/\`XGKOC_WIH??NO=;/'OW7NO_4W^/?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=%)^?/\`V0[\P/\`Q6?N[_WW&XO?NO=&,V+_
M`,>1L[_PU=O?^ZBC]^Z]TJO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5"ORR^+?SBSG\U[I
M+Y8],[0VOV3U)LOK;JK:U(=[UO4=7M7K7$;7W?W!N/Y&X"@P>_:67L3:7;_<
M^W\]M:AV=NO9DD$<==2/#N*5<531J_NO=(CXR_"?YB4'\T_(?+CL_K*FZ[V_
MEL_WWV?OCMENVMM[LS>_^M>\^D/CQL_J/X7Y+`[>KJC+UM-\6>Q>O\Y6FIJ(
M4VRDE/'6XF66;*U03W7ND;_/(_DH_%3^8WV5T]\A_D_\T,G\4\7U]M/%=";=
MBJ(NO:7;VZ-Q;MWMD\QMVAI<OO;)XIY]VY_*9S[.FQU.9I:DQIXDU:]7NO=4
MU]B_\)"OY=W4V[>M.O>R_P":!OCKS?G=&<FVOU)M7>6W^I,+G.P=Q0I$7Q.U
ML37YVDK,S5K/4P0A8N'JJB"!6,T\2/[KW1Z/^%6?75)T_P#R*>E.I*#*U>=H
M>J^[OC#UO19O(004N0S%)L;K#?\`M>FRM?2TH6EIJW(0XL32QQ@1I(Y"^D#W
M[KW7S!O?NO=?6`_X2,?]N:>N?_$]=\?^]-#[]U[K9X]^Z]U__]7?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7KV^O^M[]U[KWOW7NBD_/G_LASY@?^*S]W?^^XW%
M[]U[HQFQ?^/(V=_X:NWO_=11^_=>Z57OW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>ZK?\`YHOQ2[.^9WQ;K^D.G(NC(=_S]I=0;YQ>YN^J'<E7M[9U/UIV%@>P
MJO);8EVEB,MGJ+>66?;46+BFA-*(J#(53&4D"*7W7NB=_,#^6I\H_E_WQCNS
M-R=@?'G:NUMT87KOIGL.CQ5+V-6;IV=T?TM\MNKOE[L'='5M76X\T&2[FW5N
M'8U5@,]'5MC<33TQH,C32R34K4<GNO=$M_X6,$'^43BB#<'Y;],D'_`[6[2/
MY]^Z]U\KWW[KW7U@/^$C'_;FGKG_`,3UWQ_[TT/OW7NMGCW[KW7_UM_CW[KW
M7O?NO=>]^Z]U[W[KW0%=S_)_XW_&ZCP&2^1O?_27Q^QF[,G58;:>2[N[6V)U
M50[JRM#''-68W;=7OK.X*GS=?2P3))+#3-))&CJS*`03[KW6M)AOYMG8/:7\
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MM;-3^M89M$NGG3]??NO=&`]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]UKX?\`"E?X5_)CY\?RZL=T-\4.MSVGVG#\CNL-[S[87=&TMI-%M/`X
M#?E#E\Q_%-Z9K;^$=:*KSM*K0_<B9ED+(K:2/?NO=:"W_0+S_.]_[PV7_P!'
MG\>__MI^_=>Z^@U_PG.^'?R+^"_\L[9OQ_\`E)UZW6/;.'[>[>W)7;5;<FU=
MU-#@]QY]*G!UYRVS<UG\&ZY""-G5$JFD1;:U5B5'NO=7O>_=>Z__U]_CW[KW
M7O?NO=>]^Z]U[W[KW00=H]!=)=Y4^&HN[NG>INY,=MNNJ<GMNA[6ZXVCV'2[
M>R-9&D-378.#=N*RT&)K*B"-4DE@6.21%`8D`6]U[JI#<_\`)"VCN'Y#=C[P
MI?E'VW@OB#W5\JME?.'N?X,8_:G7\NPM^_)_8U3M?*T>Y6[1J\7+V!A>O-R;
MCV5BLEF]LPZHJZJHHA'54\4<,<7NO=8.M_Y&^Q]@_(K9._*WY0=O[N^*73/R
MEWM\W.@/A!E-M=?T/7?5?RAWY5[@R59O,]CXW$0]@;IV?M+,;HK:W;>`G>&+
M$U4S.]14^:I%1[KW5X-5A,1D):>IR6+QF1JZ5;4]568^EJ)X/4'/@DFBD>`:
MQ>RD<^_=>ZR4&)Q6*65<7C,?C5J'$DZT%%34:S2*-*R2BGCC$CA>`3<V]^Z]
MTX>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z`OY-RK#\?NWY6
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MQ^4?'14\F0RDV+AV[63P3Y:FBJH*2LJ)Z*:98ZA(W]/OW7NC0EV'`C<G_D'Z
M7M<G5;_C7OW7NO%R+^AB!>YX'TM_4BXM^1[]U[I']@]B;'ZHV1NCLKLW=>W]
M@]?;(PE?N3>.]-W9:BP.V=L;?Q<+5&1S.<S-?+#18S&T5.I>269T1%%R1[]U
M[I34-?2Y.CI,CCYX*W'Y"GIZR@K:6:.:FK**KB2>FJZ::-F26">"0.C`D,IN
M/Q[]U[K+-4+3PRSRJRI!#)/(0-=DB4L]@FIF(47L`2?P"??NO=!#T!W[UI\G
M>H=G=Z=.9#/9KK??L&6J-LY'<NR=[=<9RICP>>RNV<E]_LOL?;VU-Y81HLQA
M:A(Q6T%/YXE6:+7#)'(_NO=#%K;B\;"YM^I3_K?GZ$>_=>Z+MW5\I^I>@-]_
M'CKCLBMSE#NCY1]JS=-=0TV*P-=F:;*[VI]I9O>LT&8JZ%7BP.,CP>WZEC53
MVC#J`>"2/=>Z$CM?MGK_`*-ZVW[W#VQN2DV5UEUAM/-[XWYN_)Q5D^/V[M7;
ME#-DLUF*FGQU-6Y&H@H:*!W*P0RRO:RHS$`^Z]T7+XF?S#_AK\Z!O&/XJ=Y;
M>[6R?7\>"J=Y[;7#;PV3O';V-W32-7[8SN0V5V+MO:.[5VUN2B4RX_)K1-CZ
MU.89G'OW7NC*[E[2ZXV9NSKO86[=\;6VUO;MS*9["=7;3S><QV.W#V#E]K;=
MK=W;DQNT,54U$=9GZS`[7QM1D*N.F61H*2%Y7LH)]^Z]TE^C.]]B?(G8\O8?
M6\6\!MN'=>\=F2?WVV'O'K;.+F]B[CR.UL^/[L[]PFWMP?PX97&2_;57V_V]
M9#IDA9T(/OW7NAA+L+?MN0;WM:X`-KVOS;^GU/X!]^Z]TA=L=I]<[UW/V!LK
M:&]]K;GWAU/E\/M_L_:^#SF.R6>Z^SNX,!0;JP.(WABJ:HDK<!D<QMK*4]?3
M15*1O-23)*H*,"?=>Z(WOW^;)\(.J9OD#4]I=F9C8FTOCAW[L?XM;S[`K]B[
MNW!M'<OR&WSL.#L6GZAZT.QL5NO<6^M[[;V_51+F**DQWDH*J18F#$W]^Z]T
M8OXO_,3XU?-#8N1[)^,';>V>W=H83<%?M'<=5@QD\9F]H[MQBPRUVU-Z[.W-
MC\'O+96Y:>GJ$E:ARM!1U/B='T:&5C[KW1DO(U[")OI]25%C_MR+'W[KW7>M
MK7T&PO?D?CZ_GZ^_=>Z*]W7\PNFN@NVOCYTEONJW'+V)\EZSM?\`T<83;6`J
M-P/%MWH_8%3V/VEO?<QI9%DP^T]IX-*:"694GJ)LAD:2FA@DDF&GW7NA3Z7[
MDV)\@.K-B]S]75F8RO7W9&`IMR[3R.=VKNC8^7J\35/)'#+D-I[WP^WMUX*H
M)B;]BNHJ>:UCHL0??NO="<LFH7"G\\'@\&QN.?\`D?OW7NO%V`)T'BUS=;<_
M[$GC_6]^Z]U[6UKB,\VL&(6Y-K`V+6]^Z]U6AU=_-@^+/:WR!Q?QQPZ]C8G>
M^\?D[\G/BAU3E<ULV9=H=M=B?#KK;`]C?(;-;.W!C*S)4T6Q-E#-R8:')9`4
M0R>:Q]5!2QR+%Y#[KW5F`9B!="#<`BZDB_U)YM8?X7]^Z]U6TG\UGXJ+CZ;)
M9!NS\/31?/V;^6MNLY7K^MIVZX^3$M3/2;>B[#\=9.FW.MMZ32XT8C<A:7'U
M(SN.+F/[@^/W7NK)4?6";$$$J0?P1]1?Z'GW[KW7/W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW75A>]A?^MN?I;_`'KW[KW7@`/H`+FYMQ<GZG_7/OW7NN_?NO=?
M_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW6J#_-)^%_RD[&_F(=X?,/H3H7<V]>
MP_B]\/OAAWO\2MXICYVV]O7Y!?&[Y8=C;U["Z"H:BAK*3*9;)=G=&[KRV*J\
M;3.C3PU\(8F\:/[KW12=I?`KYI_'VJ^4O=--\0M\?(CNSY,?R=,7V!W[MJ/=
M6[>IL9V9\X_D+\X^P>]>_.H(]_\`6.[-M;[;=?476V\(*:##X7*4E;F\7MZ'
M&PU<+5:.?=>Z8.N/@1\M]]]8[:^/[]._++8_Q,WA_.@^,>^SL;`XCMGXMU.&
M^$V[_B9OW;7R)JJ79-;WAV5VIT[U%E.Q*N&GS>(GW945<515>;12UDQ2/W7N
M@*V5_`\]_-/[;R,F^,]@,?U]_,"[^^)'PA[,GSO8>_IL]\A.NOC7B^O?BO\`
M$;>V8P/<$-)LKX^]'=B4<>[*.:NZ]RS?QF@%/ELI50U5=4R^Z]TINEOY;WRE
M[8^$GSVZT[$Z;^:D'?.[?Y?=;MOL_H[M7JW=O775O?'SMZ^[,7?6V._L3\@\
M[\I.T3\D^]3DL97I29#"XS#;8W!@:RDIZV)3'%2^_=>Z&'N+JSY>;*V!N_#?
M%SX&_P`P;&]6_)_^29C_`(H]%=942Y*DW'\=_D=LKM/L;/;ZE[WHMW]J5==U
MIE:_"Y1,CAJ[[JNKLY2S04%"#+*8(/=>Z-5C/CM\VL=_-)Z3[FR_4OR>ROP)
MPW:OQ+PG=O7=/O3.F7=7S4VW\2\OM>A^:>*V((*3)0_%_JC+9/`X'=U.F7BH
M<CNS'29F:CR2TAB7W7NB";"_ET?/CM[XP=>[7^2O5'S"R&[^J_Y'/S.KMJ8_
M*=M]KX/*S_S(-O?,;L'>WQ7Q>?;;/8=%4;R[+QNW,G39C`4.5:JHVI/M0RND
M"11^Z]T9FF^('RX^/O5OS/I=J_%_Y+][X?OO^7'_`"X=\]J]7]D=J=^;U?M_
MYH3]D&E^6V\:G+8#N/:_8N<[3V9LR,Y;<6S]K;@P<>ZXJ'^%V%/5Q0O[KW1=
MZ/X2?)`?&'IK"=F_"WYF]I=!]2?SK.W.\<+T1L##;RZM[@POP.S7Q&Q%+3IU
MEL;-=Z[DWUUEL/+]AY+++%LQ-Y#*SSS5.,5X:NI,8]U[JTKI[XV?*]?^$[WS
M'^/VY^J^YZ/L'L7K'YMT?Q8^.?9.3KMZ]_;"Z,[`RF]IOCETIO2JK\WN'*U>
M^</M>OIX8Z">NJ*FA@E@HVT/`88_=>Z"_M7^6WWMTW\/\UWSV3A^S/YC/R9[
MSZS^$?QU[:V/DMD9'KD?'KXE]8[DQ^[-Q8C;?07Q?W]U7V'\B<GUUN6O:KS>
MV3O""JWB\(AFDCHXZB&?W7NB![1_EM=Q;@PW\NW<ORG^&'RG[CZAZ/\`YE'S
M5ZWJ-@82C[!VQV1US\*>^,+Y/C1E:#KC%=U5^Z^NNF=I]B9.'*Y)?[SY2OVS
MCJ*:AFKJV%5@F]U[KCVA\)_G93?&SX8]8]Q=3_,/=GQZV!G/YFFQ=U;/V'L3
MM;Y/]K=9=F[J[ZW/_LHW=>5ZZQ/R,Z<W]O:BP/3D$:;`W149O*T6UJ]14SPH
ME8LS^Z]T*_RW^!/SGWGMSYF]L;:VW\WNR?D5T3\3/Y0V4^"/9-1OS>NS=Z;J
M^3.S$H\%\E>S9>N-M]DY7K+,=VXK;=#IW7%4R9B&A,M:(9IWJ!4O[KW5I'\O
MKXCXOXV_SE/YJ.]*[XI]U[1I^_,MLGM?I+Y-&MW3FOC[N38VY=E;`KNX]DR9
M_([]K\:G9N5[SJLED8L94XAZJ@HX*B.CEI,<D,,GNO=5<R;#[6K.F^X*'8O2
MO:O<O:OQ"_X5B9'Y9_(?KGJ+`0[M[AK^G:+>-1VUB>S\!L^?)8NNS5#N;K+<
M>'AP[EX8JHIH5U2&5H_=>Z$OO#XX_.7NB'^9/\V=E_%+O[IWJ/YE?(+^6^G8
M'Q"V_EL3L7YO]Z_"SXJG-8KY29:+!;&WW3R['[,[DP^?AQ^/PL&?HL_D,'C:
MNEF]53$M3[KW0`=G_$CY#R?$[?,777Q1^<F(^/8^;^_>U_@/_+Y[/V%VIW/@
M<IL"/X\X?:5=US\N=F[8[WVKVQ\=^H^PNZJ?(YCKRO;.NNP<K++D*VDCCGBE
M;W7NAL[0^*/S@W1_,WQN^^VMD_+_`*RGK-Z_`G<OQ)[0^/6P-Q?)38WQXZRV
M5L#;&/[_`/CYE>XU^2?777G4.R$W_-G:3>\NX]J9V7?./89&-*G7%#)[KW5F
MOS8&8P'\Y_X8Y2OJ*H4G;W\N+^8/TST/3TDS4U4_?V&K.L>Q\W0X.N66#[3<
MN;ZZQQ:F"O'-(E!(4/[;%?=>ZI?S_P#+P^;/=?2^W:;N;JOY@Y;</4__``G1
MVG2=98JF[2[:VK+2?S-.M^[NV-U]?T&7Q>U]\8BIW;WIMK%9#'U-'2Y-:R/[
M.H\<T;-X5C]U[JYS^83T;\I/D9\/?Y0W73;<[SW!NNH^:GP(KOG##U_N_<>Q
MM]XCIA^JM[X+Y-93L/<^R]Q[:SN-VS#D<X:7/R4=7Y5>HO#:41R)[KW56WQP
M^#7>_P`0>W.@/D3-LOY0]<[<Z'^>/\S/8NZMX;Z[F[4SVR^K?Y76V^G^W<M\
M?L158G>^[=U[6Q73%/FX*7(X;)5V,K:MLR15.T[&G0>Z]T1C^5_\I]@?#7KS
MO_YF]L97<6$^7]%_*4P/;_1G4U=4=F[BVE\A,EOWLBDVKC?DGV3O3<7>W<>/
MW7\B?D-WWNK:&VZ^B_A>WJB/'TOGQ^-"3SPP^Z]T?7YB?RK?GCL7X]_R:_CW
M\+?[XXWOGH;H'^814=X=^X6LIYZ7;G=GR"Z!QFZ>T\-D>QJ_)TN1Z_W)\ENR
M<]NC;.V=W1&6KP.0R,%6CQ-"LJ>Z]T0/Y*Y[JS=WS1PN,[=V]W3\>?B/\8.H
M?Y2.U=];.W'F>U.P^^_@AC]U)E<GD_C)B,%@.Z^O=X/DOD/7SXO#[TW!D,/V
M!FZR@EBS,$@;P01^Z]T;+YH3578.UOYY?^CO*T8D^1O\Y7^6/\5OC$E+D*-&
MRGRUZ>R?QCINWJ+;202$5&Y,:^W:L5PA#5$9QU1Y@&IYM'NO=;PRD&]OH&(^
MEN?[7_)U_?NO=<O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=?_2W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UTVGC5I_4+:K?JOZ;7_M7^GOW7NN
M)\=A?1;4+7M;7?TV_P!JU?3\W]^Z]UR]-_[.JQ_I>U^?\;7_`-Y]^Z]T1?;W
M_#:_^SA9S^ZO^R/_`.S[?:5W]XO[O_Z"Q\M_L_X=+_%_XO\`P^_;I3^#ZON_
M+S]I;R_MZ??NO='G&CTVT_3T6M^FP_3_`(6_I[]U[KL6YM;Z\VM];#Z_XV]^
MZ]UT-/\`9T_GZ6_KS]/]J^O^/OW7NN^/S;ZC_;\6_P!C[]U[KHZ.-6C]0M>W
MZ_Q:_P#:O_L??NO==\7_`!>W^QM_O=K^_=>ZX#Q7-O'JU>JVF^K_`!_.KW[K
MW7?[6L?YOR<V_3KMS>W]KZW]^Z]UWZ=0_3KTFWTU:;B]OSIO;W[KW7?%_P`:
MK?X7M?\`V]K^_=>Z]Z;CZ7YT_2_TYM_L/?NO=<1X]/&C1<VMITWN;_3B^J_^
MQ]^Z]T%&S?\`0?\`Z3^X_P"X/^BK_3']QL/_`$_?W/\`[I_Z2OO/[K_\8Q_T
MP?P;_?R_=_W(T_P/^,_N?PG3]M_D^GW[KW0L'1J6^G5SIO;5_CIOS[]U[KOB
M_P"-5O\`"]K_`.WM?W[KW70TV].G3_A:WT']./I[]U[H(^Q/]!G]Y^HO]*W^
MBK^^?]_ZC_0+_I!_NK_>;_2=_=3/_=?Z(_[P_P"Y7^^W]Q_XIYOX/_EO\+^[
MU?L>;W[KW0N+:W^Q_/\`6_YOS?\`U^??NO=>&B_IT7Y^EKVOS].?U?7_`!]^
MZ]U&KOL_LJO^(?:_P_[6;[[[WQ_9?9>)_N?N_-^S]IX=7DU^C1?5Q?W[KW5?
M'Q__`.&H_L^T/]E=_P"&^OX=_?C9O^F?_04/CQ]E_I%_O/'_`*._](QV*1!_
M>S^^NG^!_P`1_P`J_BO_``$_RB_OW7NK#F\6EM?CT7]>K3IO?C5?B]_Z_GW[
MKW1&^TO^&V_]FIZT_P!,O^R0_P"SL7PW^B#_`$F_Z#?]F?\`+]RO]VCU[_>C
M_C*)G%7?^&C'^OR:O!SJ]^Z]TL<9_LCWBV%_"_\`96OMO]F/WM_HS^U_T6Z/
M]F\^YWO_`*1_[H:/3_LRGWG]X_XQ]I_OY_+_`!+[CU?=>_=>Z-L+6]-K7/TM
M:]S?Z?F_OW7NN_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
#?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g575431dsp_085.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_085.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!/`&R`P$1``(1`0,1`?_$`/```0`"`00#`0``````
M```````)"@<"!0@+`00&`P$!``,!`0````````````````$"`P0%$```!`4!
M`08'$1H("@4)"0`!!`4&``(#!P@1"2$2U%:6%S$3%!46UI=!46&1,S14-55U
M5W>W&#@*&G&!T2(RTK/3=)2TM3:FMC=8>)BX&3EI>2HZH;%B(R1DURCP0F.3
M)=4F)^B9P4-3E2GQ4G*"DK+"1&AEI49F=D>G2(@1``("`0,"!`,%!P,#`@<`
M```!$0(#(3$2001182(3<8$R\)&AL13!T4)2(S,%\6(DX7)#@M*2HK(T1!4&
M_]H`#`,!``(1`Q$`/P"_Q`"(<QIN"-':,9R/G!QG(UPD1AV.>+=E2UI74D>Z
MV3:+8M]W)4D8VETR]G\:V>:9#S.W>ONZR1^I.CI-69+)&C4E`F)D*QNF,F%'
MD5JJZ7)OX]>FVL?@6XRFM3$%\MJ"]+4/B\2HW<;33KQOQ/<>/#4RVN8X;DEF
MA=%G+>11!GKU"A:BT9)J.=*N#1L<TKAH*D]`5'$W*_\`3ZI9+IGZQ.L$=&*E
M[9W5J:WOQK'J]3:JE'12]7KXQ!EENJ8%>&G7%[D/1\?5]]O3;TZ+1*99R;RL
MRBNE:*X5B\?;`VI;-Y\B,A:5T7"U$.X=Q#MI[6M*WUE$-(6;@/-\/M#95RG0
M5F,J;L0D-&($$`]4-*2N%2O5+E"YBM+"O1Y.-6M-6O\`:]/O+)+VYRQS>E8Z
MV6L=(4:SXPO$X(U=L%<M\VU&YV/N(QI_$;/XL)^6F8+8N#>-'MZYK1MOLMN&
MSUZS=LP26B[DN[5ZR%:S+S4BH'*K<;QM-12H=7TS"G1IT[8JTRX:]W/_`!&V
MIW<QR3XN'$-3\UN6K5WR?IU/ZB8CI*MQ>OQT7GKL9/7]J.XZ;X4'@S;&%79A
M,R<B;)XJW+R,&Y0(MQTNYU\DRWE9+=S6LD:9!@NOV@M^Y;NMI#<1\TOIRSU6
M>-5T]/.%B,]2MGB:K2N7+/#*[<'O/&UZ.5_#%L=O&83>CA9IO-AR9,7U8J.[
MG2%6JNX\7Q>BTG:4R7BNIE4PG6/*9JD3*D2]8RH'#4\M`L5H4*=6M7-&*U49
M*1<L7HTIIZM2H,LE.241$0`!&-K8DGS0QY*VQ4M9-6O*2\Z[R8EMOE!C3>0N
MK&[0Y#V,NJ40:I:@N&K;W:8#Y+(U<[)/4)T%:NV'`J4TZL;ITYIJ4M89!J!*
M(RZZ#%"YDKLY9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!
MK<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&M
MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*
M!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$
MGA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>
M%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7
M`#LY9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`
M.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>%P`[
M.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY
M9/'!K<H$GA<`.SED\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED
M\<&MR@2>%P`[.63QP:W*!)X7`#LY9/'!K<H$GA<`.SED\<&MR@2>%P!X%],D
M`$1>+5```1$1<*2```!J(B/5>X`!`'M=EC8XQ(7E=UW\N$WRH\U?'7E9_E_$
MOY4`?00`@".':`8CWOR[;,MM6.],:4.VKO8[OM^^Z5]\<S5ZWDQYWC0ZUUKJ
MV(6R]P6<2;=RT1$,59"--3+'4^0[2*FIY9@HST*U:+U*V1:U?Y><?<7323WG
M[;^7D<9+D;*:YSE<5S;?-W)R4GB+DK)C`=RA:+Y91YWY!KBKBPUK>L:C7MK>
M4FZ$%'2)<@&7:=`)/,RNH2V=+U*!LRFST:QT1H:=MDR=OD6>K_K4RJ]>JE-1
M,]7";\YW.1XG;'7#:'7]/3&[:S-;6;<>:LTI;^!]FX<<,ZKXN:V^6)6X%G;%
M9+V/O)E2@639UP+:JUQ;='\-KTF$!LHC%ODC,JY3873%VY*5ND-WEE1!7RI<
MJ:ED3C-"M3J&1EP>.N-O)VZ_K9*U5G;RM+B-''1M2YUT22Z+3:J7A+7DVH,/
M'-D#>.WS,JVQQPRS36@S;UXKD\3,QURY=HBKU?MPTKLNNB\EN^]H#R,YVRB6
M]O`KU+Y.]-IDE,JMMTF3/DJLI:>LFAU3?'6JR6HU';-)*JTV24[:2O2X\)U;
MTO7):N19E_<K>:Z[3;D_NZ:?%F23FRU?I:Y#@8C7OBU47`U^9'V9RU?5BS-M
MU!1O)/="R27;*FF6[;UX9WC(BE[-/AVV;;B\KRF4&NOT:I<V2*':9<X$Q:N+
MG7#BP-+ACYI-N7%LN3(NBT_J.%TVE[F3JGB=5I>V_@U%5QUC=)R].FA,8:3B
MJF2-IZL2)*!!1*5R*DGG"],V0/%3=*I1.%#94S)4HF2AJA5FDJ4YPFDGDF&6
M8!`=(UEEFM8K]"<KY[E?RU6-F.MB]O\`J]OK(V#LM9Q@K&QO+.988]J[6,:W
MK/5G(&;0IDKA4VTT4)(13ZY332=(N!NM0FKA0DEIA/O90`(!/)S=V_XBL[DR
MB<!@!S=V_P"(K.Y,HG`8`<W=O^(K.Y,HG`8`<W=O^(K.Y,HG`8`<W=O^(K.Y
M,HG`8`<W=O\`B*SN3*)P&`'-W;_B*SN3*)P&`'-W;_B*SN3*)P&`'-W;_B*S
MN3*)P&`'-W;_`(BL[DRB<!@!S=V_XBL[DRB<!@!S=V_XBL[DRB<!@!S=V_XB
ML[DRB<!@!S=V_P"(K.Y,HG`8`<W=O^(K.Y,HG`8`<W=O^(K.Y,HG`8`<W=O^
M(K.Y,HG`8`<W=O\`B*SN3*)P&`'-W;_B*SN3*)P&`'-W;_B*SN3*)P&`'-W;
M_B*SN3*)P&`'-W;_`(BL[DRB<!@!S=V_XBL[DRB<!@!S=V_XBL[DRB<!@!S=
MV_XBL[DRB<!@!S=V_P"(K.Y,HG`8`<W=O^(K.Y,HG`8`<W=O^(K.Y,HG`8`<
MW=O^(K.Y,HG`8`<W=O\`B*SN3*)P&`'-W;_B*SN3*)P&`'-W;_B*SN3*)P&`
M'-W;_B*SN3*)P&`'-W;_`(BL[DRB<!@!S=V_XBL[DRB<!@!S=V_XBL[DRB<!
M@!S=V_XBL[DRB<!@!S=V_P"(K.Y,HG`8`<W=O^(K.Y,HG`8`<W=O^(K.Y,HG
M`8`<W=O^(K.Y,HG`8`<W=O\`B*SN3*)P&`'-W;_B*SN3*)P&`'-W;_B*SN3*
M)P&`/`V[M_I]0K.Y,(H_P=1;L`;AV'M+BLW/*OK)Y2)GE-YD>-?*O^K^)?R8
M`^B@!`"`/`@`@("&H#N"'?@(:#K[Z`/$LH2RA+*`2A+N2@`:``!W@!N:!J$`
M:H`0`@"%27]XNJ_J5"_X\YJ`)JX`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(
M`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!
M`"`$`0J2_O%U7]2H7_'G-0!-7`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"
M`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(2
M@/\`#_#PX`:P!"I+^\75?U*A?\><U`$U<`(`0`@!`"`$`(`0`@!`"`-I7%I,
M;B2I+RV?)I2*C)YU66%52,TB2:E)285JG5%24#M>:2@3(D2E">K5JSB$DDDH
MS3"`!K`'&*EGIA)7I4ZU++C'"I2K4Y*M*I)>:W\TD]*I*$].>68%[099Y1U`
M>@(0!^GK[\)_NM<<N[*P/]?0`]??A/\`=:XY=V5@?Z^@#Y\WM%L#T]4(HI[,
M/&LNJ*02"1)S7C9`U#(5)QIR#2$%8:8A-/*(!K,&ND`?0>OOPG^ZUQR[LK`_
MU]`#U]^$_P!UKCEW96!_KZ`'K[\)_NM<<N[*P/\`7T`9>ME>JTUZ2*DK6AN2
MQ+H(B.H@CJRPP'6BNQ.3%<2E(\"6?.(APZ7*G^HS%.KTJ:8*@4ZDLPAI,`B!
ME&`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`X<Y69N6IP
M[)I:Q=5J7P66U42%=UO)WVJLA<2ZC3M';UO3T)''<J[*ZST90)-%E-Z0QTXW
M4$:YRF4I5S(%Q+EJ]6G19*<JTOI=_<M8W#TH[/HM?^A\R<V@%J9LAT_&UHV\
MR`NNYJE*UYMRW$M%9ESONQ]ODV\2:;6V$JORZZ=TMMH":I-TIUQK5Y9J],J2
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MS!M2JW40[;O!;QW:-Z+L(2>Y[664>5\""5.S4*YMP4%93S*<2FJS4?\`2R?1
MKUZ)D\4HUMGIOU*7:5;-0^*UEQ'Q.?18Q-6DDGJ4IJ$X@&^I5-R:2;491#OA
MW9=R#4$4L[8Z7:AV6J\((7Y?WBVJ/>#L5*``/>:RYSF=\&O?AJ&OO8@N35P`
MU[SO>CI`"`$`(`\;Z7OPW=--T-W4=`\,8`\P`@!K``!`>@.OO(`0`@#`>5<L
ML^+V2,LP!-+-82\,LTLP`,H@-O'$`@("&@@,`=94@IY'K&B_T(H`@DIH>-J(
M=`G1#3XCO(`W;J`CY"*?.U'XR`'4!'R$4^=J/QD`?H!4K+)-3E+4):<^N^D"
ME3"2;7HA-(`:3`(`'1#PAU@#\^H"/D(I\[4?C(`=0$?(13YVH_&0`Z@(^0BG
MSM1^,@"X/[6THT*.,.0TM&E2I239'5IM[2DDIA-,-L&``S;V0)=9AWNFO@>]
M@"QI`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`/`]`?>#`$
M1^U$1LN[J)#+QYLQCE<BZV-=ST5SU<MG;9^[UD;=W5662FRE:9'&UD$[QW`M
M^52"-^)C-0@Z7/1,5*R:UI#I0G*!\]0,E,Z8Z^_SE<JZKXK;[XU?5:;:-HTZ
MO9HX]Y0XAW,NQD/;-[X[81K^.%]4]8Q6KD,_6WD:S&BV[8VHMPHI:[<.V#ZL
M>Q7]*K7<.(S+F7&"3;)EN*[65RZQ)7F5BA:E+-1O19,;Y.S:]Q6:TAQ_"_\`
M:UHXUZ[F63$KX7AIZ5$)K=.(33WE?$^M?[YR.O->^P6>./F)+INHW,:KA9QX
ML5K4F;E6[M^^KP6Q>)RWR&W\E[2J-R%1H,DNTZER[,3$:B<L*)(^80C<ZB2E
M-A)1HF,J9*^]?+2TO)CK1K;Z;<N2ZO5P_P#4U=*W58T]MMJ-G->,?#K*ZG$5
MJ8*YZXY6ENK;%E6(8U\EW-K!`MCM<I>0[P-5H,K%Z_"E<C)%?5C[H*/B1%<#
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M;<1&[C1MW'+:E#O?E;=A/<6R#*/&L\,A\C+AWJN0D&:>:$J/30VT^7>H&5Q`
M:(TBLU>9*H5)2`G*U2N%,*M2>:87+!?-21X[W3[H;AX1`$2>T7RDNOAT_K7-
MJV2F<7TY^M)TKJM.^78]5$R4.H2PBD"DJ943EU/EI4*M!2GZ9+.$^LP`(:;N
MH$>?Y63*#R"TO^_+C]ML`/RLF4'D%I?]^7'[;8`?E9,H-!_H+2U&68`'K[<?
MX680$)9M.RWX;>B.N@[@P!L*'M4\P$^0S*OKK.=,U2I3F)U*9)[M?J"C($^_
MH5*9!^J(*(UAG`>F3C(,H2Z:#KJ`&_?E9,H/(+2_[\N/VVP`_*R90>06E_WY
M<?MM@#\Y]K'E#,-*GU$U)0K&2A>::1>N/+/+(8-4:,XR3=ENY.$E0=![^`+.
MQ>UI.L7+UIGM=()JE&E4F"6X3A"7?3R!,.@=4CN:C`'[<U)'CO=/NAN'A$`.
M:DCQWNGW0W#PB`,'Y-VT)D,;,ASDKPN49F+6+NY6DHG7VNFBM2:FP'!.$M<O
M5,34J](9I0UEG`99@U`0$-0@#K?4(=41&'0)=4I.'>RAI++J4H[DDH;DLH=X
M$`;K`"`$`(`0`@"VO[7<:=!RXRY`35UUV)(T<B1IRRMQR*2%1&6G;1DU-]/1
M(5I)*E:L)G2I/,`S3!3IAKI)I`%@;FI(\=[I]T-P\(@!S4D>.]T^Z&X>$0`Y
MJ2/'>Z?=#</"(`<U)'CO=/NAN'A$`.:DCQWNGW0W#PB`'-21X[W3[H;AX1`#
MFI(\=[I]T-P\(@!S4D>.]T^Z&X>$0`YJ2/'>Z?=#</"(`<U)'CO=/NAN'A$`
M.:DCQWNGW0W#PB`'-21X[W3[H;AX1`#FI(\=[I]T-P\(@!S4D>.]T^Z&X>$0
M`YJ2/'>Z?=#</"(`<U)'CO=/NAN'A$`.:DCQWNGW0W#PB`'-21X[W3[H;AX1
M`#FI(\=[I]T-P\(@!S4D>.]T^Z&X>$0`YJ2/'>Z?=#</"(`<U)'CO=/NAN'A
M$`.:DCQWNGW0W#PB`/`VH(B&G9Q=0/>7$<(#X?5,`;YV!D^,3V^I[L=^JY9\
M2\U_''U1_P!>\<?RH`^X@!`'C0/XOX.A%55*SMU8/RJ4I:LD].89M)Y9I1T'
M=TF`0'=_A[^(2LMW^7[B4X<FBD7EH@(2S3B$TV^'?#KIH``$LHZ;DDH2AI$N
MM7T2;4:="K4N3]>ER]^/AA\"(X+S)D=+#O!'^#0?X.A$/&FHER'KH]C6`:>^
M#3WT72BL=00JR_O%U7]2H7_'G-1()JX`K;;<?[;^._I<7#^R9K0!"1`"`$`(
M`0`@#2/BA3SP3?I@6@"_P1\9$_F4O\BD@#VH`0!@7*GV,&1_I"W@]3UQ0!UF
M:!Y1(OG2G?0=&`-V@!`"`$`(`0!<"]K<>QCR&^^,J^IBP(`L70`@!`"`$`(`
M0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`$*DO[Q=5_4J
M%_QYS4`35P!6VVX_VW\=_2XN']DS6@"$B`$`(`0`@!`&D?%"GG@F_3`M`%_@
MCXR)_,I?Y%)`'M0`@#`N5/L8,C_2%O!ZGKB@#K,T#RB1?.E.^@Z,`;M`"`$`
M(`0`@"X%[6X]C'D-]\95]3%@0!8N@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0
M`@!`"`$`(`0`@#UQJC+IOAW9AT#X74!W0#3<Z`CKN12V6E=_P%DW_;/R$Y1E
MD"K-4TIC4"EOADG#X<9@E"3X:27=WVY%P>[`"`$`(`0`@"%27]XNJ_J5"_X\
MYJ`)JX`K;;<?[;^._I<7#^R9K0!"1`"`$`(`0`@#2/BA3SP3?I@6@"_P1\9$
M_F4O\BD@#VH`0!@7*GV,&1_I"W@]3UQ0!UF:!Y1(OG2G?0=&`-V@!`"`$`(`
M0!<"]K<>QCR&^^,J^IBP(`L70`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@
M!`"`$`(`0!P(VB&56/V*V.CI/7]R2#%&A>%(=]F;9WDI-]UN14:5T':QW),V
MW"AI[20UTX*VU1*3JA<:TM*ATPF`#4E$0".#+2W=:UFF53J_@X<?%ISH_!R6
MQTX^FJV*^NR;OFEWKSCL2[U/:@6IR%R35[77A9U^+#V>7<NEBT2S8VV=L[2,
M^P#?MHD7\8B,@*3F07,V%BX3U=ZI43G&9<+D-)Y8#I&K//+Z4*S>3;&]5X;_
M`&^VIC=9*)+_`,JW^Y_MAEG>^.6V,>-*BR4C(&_=JK-*5QE.5(9!.XKS16O6
M<!R8V43]^4ZZFBTM,A34%`N7G-U1IE*=<Q2I3U0GJR2S9JRY*N]GLEU-.-VN
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M<)8*529Y0*2%&Y4,]6S'5)-2C9HF6$`,G"I6M6H25*5&I-+&*F6L^[:9>FB4
M?=N19PI.1=.K)6EEJ4YM]),`B`Z"`"`#H`AJ`#&DJ8>XK964HA9E_>+JOZE0
MO^/.:B22:N`*VVW'^V]COZ7%P_LF:T`0D0`@!`"`$`(`TB/\X4\\$WZ8%H`O
M\$?&1/YE+_(I(`]J`$`8%RI]C!D?Z0MX/4]<4`=9F@^42+YTIWT'1@#=H`0`
M@!`"`$`7`O:W'L8\AOOC*OJ8L$/XP@"Q=`"`$`(`0`@!`"`$`(`0`@!`"`$`
M(`0`@!`"`$`(`0`@!`'"#/)BK;HL2N.XCE[>S#!N683G/>&X=T;&)%N5QRG6
M$R&@OJKD2%9-N+;ZXI8RAE"%.=0&0@3D.U#!6G+).,HC3GY\^2F*OZBVT/\`
M#;JO"/CIH6QSQ]NVN1QY?;\"(#9LY`.1T7[LO4N=E=M/U17N\K7[MXRL=\Q&
MWB"#853]L+-6HOA*Y7N>L-;=N+[26U^U-XTE?0D\#57I%0L<*':O3*4LE;IQ
M/E-6JPM=O]R4-Q,J=5]+GZNAED;WK];^2V\%H<L-K]=@9&:D8FDK77,F3,NK
M?/VWU\LF6OC%<S(1J6*QIZ45+W-0*"=;)A/E=<E[+LD%"HCLE"$OUO)GIZRX
MH3RTDVD6/Y8JW?=K)9)JKJ^-HAQ:8<KK&VR3TU::E7CM^6-\;<7JMUITZ?OZ
MZ'`')&U[C/J.T!QN8.-EYE]\YWO'9SN_#2XQ2TSZ-L3FNM&QK&-HNJ7#O`:2
MC!"RRGB<OVM65]337@?1U[IJG1KIA8V<4*DH:]ICS6RUR]XL:X=XKVA[XE>M
ME2/^Q6I*\8ERF9=SB6;M\G;+3);!:)_F=6D_"9::Z?D<SL@LC6&Z\N\3,Q42
MW=Y;J8ZXDW'S[Q'NNX[?V/?MT5:W602NV+;-Q$?#;8+';SG?[R92L99CC8O9
M0A)IU/(J2M,4-UBY:N:JR8XZUQVSY<S3Q9,6)8UYS:U[+H^5'1/?Z7"A2][)
M7K55^JEFW\&FDOOUG][(O&58ZYN.&/\`>*TMY,,;T.]SYC[*VGCOC$PV9:`Q
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MN?F>W:`*[FVJ+N`K=;'N5P*J>K&AMW<$*-9.2*B/3I4P=+>&H-6E55%4:U2K
M+/3`!EFIA($G0F$1F@"&.`$`(`0`@!`&B;7?%]`UFZM3]Z&^"7X?JXOO=T=P
M-V`+W!)'N2)(GH^6W+_1"@"`L$T.Z!>F$PZ]FVGPTP:Z=`.A`'M=9KE<>VUW
M/S/;M`#K-<KCVVNY^9[=H`P9D\E7!IXTY$SG'FWC126Q%WA,4*+',E:U6GS?
M.'?2TS`O`Q+1J#)KI,,DX`.FLHAJ`@=;<A#JAHP@`R_Z*3M)=]OM[+U'1T`9
M]`WVGO`U@#=8`0`@!`"`$`6WO:ZY-TFL9;_]CJ\EI$@9%B%>51;U59FWTMLF
M5TV>C/27$D`EK23T0W@RB,HTQFWP[X98`L(]9KE<>VUW/S/;M`#K-<KCVVNY
M^9[=H`=9KE<>VUW/S/;M`#K-<KCXVNY^9[=H`=9KE<>VUW/S/;M`#K-<KCVV
MNY^9[=H`=9KE<>VUW/S/;M`#K-<KCVVNY^9[=H`=9KE<>VUW/S/;M`#K-<KC
MVVNY^9[=H`=9KE<?&UW/S/;M`#K-<KCVVNY^9[=H`=9KE<>VUW/S/;M`#K-<
MKCVVNY^9[=H`=9KE<>VUW/S/;M`#K-<KCVVNY^9[=H`=9KE<>VUW/S/;M`#K
M-<KCVVNY^9[=H`=9KE<>VUW/S/;M`#K-<KCVVNY^9[=H`=9KE<>VUW/S/;M`
M#K-<KCVVNY^9[=H`=9KE<>VUW/S/;M`&F9&N9O1WK\;.O@V_-=#=U#ZMN]@#
M<^M[WXS(?E-U+]3!CR]\U_+_`,8?U+XK^L0!'WM2\DW)BUCPQ7PGIEOIK>OC
M)C'2QN0SYN\C3N*U5G\<KRW(2V5=ZYEP$H#Z20K-T@WU'K7-54#-)+*UU>G7
M.:EZ4\LW$ZTM;#VF2,G:O1V</DG6\IN>L)>'J:?0KZE3+?%:<U=4WNFHA::P
MFYA:^!%_C?83"C#_`&MV-EJ<(ID.\A&\.->4[VN&54[[OG(E;PT9[=JV1*V]
M=%L:R^_W@AVFMW>V4M19YB6L7ZX*U!!3:!8]U,2K4:G?V]LJP9L>1V=4T^;<
MMKDI3T22ZZS9M)V;A,IDA^WD?U637!O1KC,Z/795_EAZ:MEG+>AT.AN:;@B'
M@]YI%-W/4T224+8_$*%()II@I@`SZ#.,N^EWTVNH3"`:`,X#_C=$._BOMU]Q
MY=?<B-^B+<G,RY7Y>!L389[492,4;K.;:(U4%/F.S$45NIA-&2BDZF?-JJG5
M+$$ZD7*T:JDJ'ZYHQ/+*$U8Q6GJSC-/,,PQ6E:5X445XUK'E515>22V(\7XF
M^2DRT@3!)1IR!-(-.8)90E":01FF&4=.C+--.(CX,%CHLKSJJ]YJ.76)G[IU
M!JZGH[SI84Y0I[FL@:RR"&@!\2`[T>A$JE4H2T;(:5OJU/TEIR2Z!+*`:!IN
M!N:1:-(Z$[$*\O[Q=5_4J%_QYS42":N`*VVW'^V_COZ7%P_LF:T`0D0`@!`"
M`$`(`TCXH4\\$WZ8%H`O\$?&1/YE+_(I(`]J`$`8%RI]C!D?Z0MX/4]<4`=9
MF@>42+YTIWT'1@#=H`0`@!`"`$`7`O:W'L8\AOOC*OJ8L"`+%T`(`0!%]D[M
MGMF3AG>):L#DYE8V+37=;J0WW`KLU995U5:N42'22%20#8*S88:X@&.KR&E7
MI5(W/6HRS2]-EDWTH"!@'W2'L2ON]V!W/;X_V70`]TA[$K[O=@=SV^/]ET`>
M)O;(NQ*EE&8<]V#H'?6\OE,/OI9;7#,/O@@!+[9%V)4TLLP9[L$`F#72:W=\
MI)O?R36N":4?>P!Y]TA[$K[O=@=SV^/]ET`/=(>Q*^[W8'<]OC_9=`&5;&;=
M/909*W=85A['YBM"X-VKG+-1OL5FIC&N\1-+JQ33CRM,3D4%NWB8BD)NMZ;6
MG"<T9H4Q&0)`FW\TLLP$M4`(`0`@!`"`$`(`0`@!`"`$`(`XVY7WDQZQ[QXN
MO=C*E59J-81LL]4EN.+\*I"BVUQ$5:?6SL/-(JY+,FN4\\S9FFEDTJI+4ZZ'
M#=(K+)/-5EE'%VI55Q*OH\-DOA/STV+8\+O=\-*Q+73XOI\]]R,79^9G[%HW
M<JUEC-FXVL>6^_LIK<KUY7"U\8+5V];AIE(=O$%N+LQ+)CF[+%JMO7(2!ZRD
M4X@K=,WBG3-EJ8TZ@:5.FW)X_;L_Z<S&Z;\86D[;ZQH8*OJYKZO'K'Q_8M)U
M)S(H:B`$`(`0`@"%27]XNJ_J5"_X\YJ`)JX`K;;<?[;^._I<7#^R9K0!"1`"
M`$`(`0`@#2/BA3SP3?I@6@"_P1\9$_F4O\BD@#VH`0!@7*GV,&1_I"W@]3UQ
M0!UF:!Y1(OG2G?0=&`-V@!`"`$`(`0!<"]K<>QCR&^^,J^IBP(`L70`@!`'5
M1^VL=S;/7D$!$/\`<KCQJ`;FO^PU0`]Z.G>]]N0!7,U'OQ\,8`:CWX^&,`>/
M#\/=\/HZP!YU'OQ\,8`:CWX^&,`-1[\?#&`)=]@8/_C+;/C='[="KT=W_P#;
M%_?Q_P`7O(`[AB`$`(`0`@!`"`$`(`0`@!`"`$`8-R/:"M<*P5ZF.WD]@*;E
M==I;B(37(W60B3FME5=:FTU4FV9[@()^@9**S-H+E:C.I%ZD@RU285`$--=.
M3N>*I6]M5775)ZPX;E/K#;V2U>AIBM:F;T.R?BG&GAT;DK3[)C*N\-T,G[!-
MTI?W#!N,->M3<ZWCYV?]A[T8>7'-V(M]CQ;FT[3MI<U+4<?"Q=Q.&Z-V[S)3
MH631%.,G6NW6*8)DZ](N=+4M/1_I9*Y\CGEGLK4?+9>4;Z2H_B<O:$L+/9/9
MELJ,2X@!`"`$`(`A4E_>+JOZE0O^/.:@":N`*VVW'^V_COZ7%P_LF:T`0D0`
M@!`"`$`(`TCXH4\\$WZ8%H`O\$?&1/YE+_(I(`]J`$`8%RI]C!D?Z0MX/4]<
M4`=9F@>42+YTIWT'1@#=H`0`@!`"`$`7`O:W'L8\AOOC*OJ8L"`+%T`(`0!U
M4?MK+\\]>/TE<>/L&J0!7+@!`"`$`(`0!+OL#/SRVSX].E5]3%_0!W#,`(`0
M`@!`"`$`(`0`@!`"`$`(`X$[0Z[]M[;XYN]CW38N2SZ:F1#:?-A#A?%>QMQ[
M[W'0R[_8;C2E-?%OVU1EM6021!+JUAI*%:D%"0X-&GKOYY0FPOAPYL*Q9WZM
M.L2XA_Z;-;IK0OC?_P"17=-;_;R(*]FC8.S:3GA8A^6S1LL&,W&'9AQHJ`AW
M1V3ER\14EQ7')X\6;L/<9QN3)%P-Q':P6W=R)9PJOIS!HTNFT'B9KF`.322T
MZ4_8LRO^HRYTN5K2]$HU3A)3MM'IA/1=##)Z:I_;9ELJ,C0\:AWX>'`'G4-=
M-=WON]@!J$`-0A*!XU#OP\.`(59?WBZM^I4+_CSFH`FK@"MMMQ_MOX[^EQ</
M[)6L/\4`0D0`@!`"`$`(`TCXH4\\$WZ8%H`O\$?&1/YE+_(9(`]J`$`8%RI]
MC!DAZ0MX/4]<,`=9F@>42+YTIWT'1@#=H`0`@!`"`$`7`O:W'L8\AOOC*OJ8
ML"`+%T`(`0!U4?MK+\\]>/TE<>/L'G^#`%<N`$`(`0`@!`$N^P,_/+;/CTZ5
M7U,7]`'<,P`@!`"`$`(`0`@!`"`$`(`0`@"*[:X)N3:UC4QD/&5*R-6:RQDA
M9FC?=-Q%>"!;S)8YC604U!8N>2M"_'`Z610:+D4:Z8G%9S5!63S$Q.O7HRUZ
M(5IJDO&I=L*7UO?X<;;O9*>.K\-I+8$N&9V^-?C->GC$^9$3LN[9;0MKYC6+
M>5V[&[0)AR+Z!EJD9NW;RXORR[G6[O$S>NY`Y@JGM]D-R[KQ;[7N9:AL))9,
M/J"*W$$:M4THC6K*$IR:K2ZZ6QKM73*[.UJKV]7_`'TT[NU6E%(5N%FH;X\4
MN*G/,OZB>'2GX[0MO./P\"1_;+F&VVV5BK<E=R!=%IS3$S4Q-KH[((7D(6G9
M#^I+F15LT9SJMPDV0XBJEQDIJ-8R:&FFF3PHA>4S5,&RE>:2E/1T_P`?P_\`
MVO*[C^CM*4Z6U:ZM-)+P;TW9R]VKOLKJE9L[[Q.G):_)2YWTZ0F<1LZ4)O67
MS_2LWSCDQHR=3^<_"6W:#C6?O/=A"RYMHXG.XZ;&0#^-K'9UQC5L7FI+U1_E
MGI,@K+8I3KZ6GG:DQZ6A3H5:7/VU;3DJIJLN95<[=*Z_=/P;9TY[5MCN[)M8
ML-G"WZV7P3>DP]84')':&.&P=[,L,)+`Y`W81*.(+EK9AT+P(Z;>$W;QBN?)
M&S;)MLK6WM?=I\LUS-T\DK;-9[E<[D*-LTID)JAY.D.3TJTZ?2WDXW9=_:U%
M"KBK:KZNW)*//BM5.R;?4G(HI6KU=FU;X<=_*7H0N)[Y9EV\;GTXLO\`(^Y:
M0[,<=E,FWSV=3D<-]GS;EYN!R4KQY1MYD9--@$UQMXY=>]ID6#:]%*'3<BB<
M42:D4HSEJTK@K3'[)6]CW<:CO9K$=9HF_'293\%IH:7KBR9_TF37L+V?+X+(
MN,>$+5:_@<B'&[S*\_KA9`W'N<[$':BVXVEV%E@+1VODNDZ&\X$RR=PFMC*=
M7;.I^/I-?)-L[:BZUM7L_P!RKM6=&K43M>B<49S,LR13$E.#V5VO:_HM';WO
M>EZ\OU.>9VB(HYCS3.=_J[=GW*SP\E<63VTDG/I].D.;/6%#;T6Q;"43IU*1
MU<ZD)51>421%2JI*+2-4B,RNH4*)BJFI<JB;U*D>N%>G)0ZHJ_S5(9]_/I*`
MC'1D=G5.T2R]J5IFK6GT+MZ1UT6GV\2M_C!>G*JZ^W6<;QR-PI4\3KF)^R$*
MHB):`]D+:&]IER-@<S:!^=YRO:VM46TCT*2J8K$>HJ\PFIYJ'3=Z%.:48P+E
MACLMN/Z$AGENV/CX`KT;:126U.Z>/U9>;<[8-4[?7`DH%*BLGK`F:4SE;F_J
M]-3M:=#I6\D'28=9^F;GQ,VH$,\`(`0`@!`"`-$X[V8M-WDI].UUUZ/5Y80Z
M`".Z(:!WP[L`7J23MN,!(EI:4S-J4+"/^VS8#01H2#-+\7N[T=SP8`]GLMN/
MZ$AGENV/CX`=EMQ_0D,\MVQ\?`&#\G'0_J^->0U(Y:\R0*U+%W=D,G!>#<,]
M349K?N`)ZW4]&<:E8))1$=[+NCI`'6]H(`"&C`$P3`"4G@$V]&4)@`G1TF"4
M=V7?=\.Z$`;K`"`$`(`0`@"VO[7<6'.EXSW\E0&=4<]*KD/4FJUZ2^D)'2:P
MVT94M0N-!1F"K/TF2E3FWX;D_3=SXD=0+!'9;<?T)#/+=L?'P`[+;C^A(9Y;
MMCX^`'9;<?T)#/+=L?'P!U</MIPVH'-LC=PPII4R,;GLGCL-4A.;+'IZ,PL+
M?32B9*3S%Y][/--)K*.@A+KWH0!7>@!`"`$`(`0!+?L%JIBCMC]GU.7*S'*H
M7L/R@7DK42\TTD]MWU)6JRU*\TM+4O1FFJ;T1`9]YO0$!$!@#MT.RVX_H2&>
M6[8^/@!V6W']"0SRW;'Q\`.RVX_H2&>6[8^/@!V6W']"0SRW;'Q\`.RVX_H2
M&>6[8^/@!V6W']"0SRW;'Q\`.RVX_H2&>6[8^/@!V6W']"0SRW;'Q\`.RVX_
MH2&>6[8^/@!V6W']"0SRW;'Q\`.RVX_H2&>6[8^/@!V6W']"0SRW;'Q\`>)G
M?<>4->:0Q[]\-</X1GT@#=.R5X^A]7^I[KE]5*!Y>\6O%/%?ZWXV\&`,89-Y
M$$<8+7U[I*%G\@[X%J*ZC(,S$QCM`XKX73JS+5:K0D6"[":W^EJS?2^E#,>-
M2ZR%Y)I1F#40C&F;DTH]4>*^?R\R%CJMHU(V+9;1:^F3^;&+]L;1X<YMV5QQ
MK-/(9;RD>F6^%=SK&)9=02&LU*MAD]DW">%4LEEE0\[IU.0X1DDK53E(:>@R
M!3FWVF+MZ-9[6;Y6:\(</IK+27QB-D5M55HJ:M?ZO]A*5=G'''Z_4R1-?*Q=
MF[SBW2ZJ6;PW8M@R;C"A%UVE0H+A9&%X(JQUKH+1<M3D-R4-X!F2G*%3?!*&
MF6/#PSO,F^3_``ZZ/IJYT_,T_,_(KCE8(@_F]=<A8ZSQ*Z;0;Y-HM.Y12UK'
MH/\`:[13R%1)(M1NO&DA4W(B-HFD5JA.D1+&J9:F5GFI2R2RS:1:F5VO:L?/
MQ_?\"(_`QNWL(,8D:V#@L^N6A9%SV(\;KO"^CZ2+QM!L72I/N\+Z=1YXN"X[
MNH/!&4R"P[)E<Z$A4W-1"H0*%Z!<OTNC1IR2U61MM0TJ=?'I]HAZO4G<RV[[
M$V;?ZC;U9?=J+:/=6M&JRKEJ5-WV_:+G4K8K4LI2E(L6\/+*.<.,A5I4B!>6
M4PESE:LLM"F&NDDL;J%99%/)??MX[E+3&F\_M/T,62M*=N4E7I/VRMX?O.B(
M)AJ(]X#C$:U>ZB2UC75'53;3+A5$H7800C75E;IA2D;EH5.FSZR_#3:UQIXU
M92W.O^OC\_*(@M9ZI)=/V?;8RG2I!2IRTY=1EE#24![R77<`-S<"4-P/`BX(
M69?WBZK^I4+_`(\YF(!-7`%;;;C_`&W\=_2XN']DS6@"$B`$`(`0`@!`&D?%
M"@?_`&@F]'YO+=_`%_@CXR)_,I?Y%)`'M0`@#`N5/L8,C_2%O!ZGKB@#K,T#
MRB1?.E.^@Z,`;M`"`$`(`0`@"X%[6X]C'D+]\96]3!@0!8N@!`"`.JC]M9?G
MGKQ^DKCQ]@U2`*Y<`(`0`@!`"`)=]@9^>6V?'ITJOJ8OZ`.X9@!`"`$`(`0`
M@!`"`$`(`0`@!`$:NU9L*3R+PZ>;)4,T'%@$50EUOOGUR:*^IK>H[;G;50UT
MM$?R]2>]M351@."8]O#Q<NX$FO4FITII*\HR:#S6I17P.):>FS_A:A3X[KJX
MV\)JG9:3.I!9L17_`"O?+:HA$6!D_?%$MVQW>BTMH-:W+[/>\VSEN@K@6D)'
MTKL$S+KE"*?<7I<LE&6BA*;Q(%#\^_*FYJ,H&)>UVYX%G7HMYRI\TK-6^4:;
MMSH8W=*7Q+&TU10VH:JXV<)JO_;R731MPK?L9FHB(ZK<")`@!`"`(5)?WBZK
M^I4+_CSFH`FK@"MMMQ_MOX[^EQ</[)FM`$)$`(`0`@!`"`-(^*%//!-^F!:`
M+_!'QD3^92_R*2`/:@!`&!<J?8P9'^D+>#U/7%`'69H'E$B^=*=]!T8`W:`$
M`(`0`@!`%P+VMQ[&/(;[XRKZF+`@"Q=`"`$`=5'[:R_//7C])7'C[!JD`5RX
M`0`@!`"`$`2[[`S\\ML^/3I5?4Q?T`=PS`"`$`(`0`@!`"`$`(`0`@!`"`(9
M=NB;P1(8+&%':'H]VG%8Q.O#;4XVV_9`\H)=R%V\4M57HV]34-4HK+;04L*T
MU4W-.86U--2*0RR]-KR5.E:\MFU[7\JE/Q7I<><?5MKL:+DG/@1P[)U$R$<&
M>CO1J-NLF+$V.Q4MZA%WPRLM=I_>/,YY/Y+R89!ER8^JK!M(TG"YL7&&GIB(
MVS)M0DF558X1EJT*96>6??[WT:TN^VG(G9V6C;F>+4^'WPGTV.?+=4]NM;)X
MNYBVV[?)Z><ULY:_AMKM-KB,#00`@!`"`$`0J2_O%U7]2H7_`!YS4`35P!6V
MVX_VW\=_2XN']DS6@"$B`$`(`0`@!`&D?%"GG@F_3`M`%_@CXR)_,I?Y%)`'
MM0`@#`N5/L8,C_2%O!ZGKB@#K,T#RB1?.E.^@Z,`;M`"`$`(`0`@"X%[6X]C
M'D-]\95]3%@0!8N@!`"`.JC]M9?GGKQ^DKCQ]@U2`*Y<`(`0`@!`"`)=]@9^
M>6V?'ITJOJ8OZ`.X9@!`"`$`(`0`@!`"`$`(`0`@!`'##-+)?$G'*W#?#,MU
ML1N6DO*XU2U-.E<]NTG%;MT+,K$>-PS35=E%53CS7I%%5JL!3`M35)J=)0/R
MT"-`*QLR7H5,,N;%/%J6_)>2ZQXHKVU,V2G/';E5+6.I'1@;8G8V)60;4R)V
M<MXK:6T?=X[>&G<Y\9<=\CB*&P;L-]<02JHE+]S,.J3E4"S><=J$]?GK$J1)
M'1*K=,G:],U2";X27>E<_;X[8+3:M+1;=I0]W+;_`!;Z))0C%Y<.54[M)>[1
M16.,M/Q:C3JTWI$OZ=)Y=0[\/#B$U92M4=!H"K3'4`G`1#<'O=.^U[[6,:9\
M66?;<\;<7\?`;J5L>=_*'1'3P1U#^.-7>JLJO=AZ*7L-_('^,'0U]\'1'WD6
M&ZGH:0K4QW`F#7H=Z&[IK_%NQ,,K>RQM5OHV?H`@/0$!]Y$3TZEM]5L0JR_O
M%U;]2H7_`!YS4`35P!6VVX_VW\=_2XN']DS5@"$B`$`(`0`@!`&D?%"GG@F_
M3`M`%_@CXR)_,I?Y%)`'M0`@#`N5/L8,D/2%O!ZGKA@#K,T#RB1?.E.^@Z,`
M;M`"`$`(`0`@"X%[6X]C'D-]\96]3%@0!8N@!`"`.JC]M9?GGKQ^DKCQ]@U2
M`*Y<`(`0`@!`"`)=]@9^>6V?'ITJOJ8OZ`.X9@!`"`$`(`0`@!`"`$`(`0`@
M!`'$_,YA,^X>*]_$-\8]M7*D@F6GN`ZD3']YMQ-="5=%WM9J*JVT6H43E$F>
MZF7EE=)T"I`X7DE.%#->6I0GDJRRB'-;)':+/DK%M7&^VO3\_DM6AAR/)W?M
M_1CE*?)N'^?P\2K]L7G7;M"ROP^2+5/3`C*4YD!AY<6Y5W4C&C#BQ-C;M[+Y
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M%C)7$?#NP5XYL<S%^6UD;=-^WO2V`QKCO9);-A4>WI-'8S%;MSD=RV_I'G8Z
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M3B"8.&*!.WK^H5YCB0L(\P3UG*VQIA3I+!!/JF`U+S@(TY9PE$/AM[J&H$-<
M`(`0`@!`"`-(CI4+".X$IY/FF'O`EE/EQ$===W24-?!Z`0!>D*7IMW(4*2S*
M:UKU*6'ZBGP.Y-1DF`1_V<'=$.\Z(0!['/7;GS46N1+Y[6X`<]=N?-1:Y$OG
MM;@#!^3=W6$IXV9#$":BKSFC=B[NT*,E1GO(O)-/48#@DEWU:NWZ5&E+K-NS
M332RRAJ(CH`P!UP*'+-(AHTDP:32I2?*(`("`"!.B`@$P;Z7<\#4![R`-T@!
M`"`$`(`0!;4]KO/EM-'&F_U%=-GR]0UD-.9H@407`KR#1GMHQZ<HS5D9,/T:
M=09BE362:8)P"7?#+O1E$0+`W/7;GS46N1+Y[6X`<]=N?-1:Y$OGM;@!SUVY
M\U%KD2^>UN`.KG]M-JY)<VQ]W5%/G,3E:]DL=9Z<QHD>3JHR5&$%:G-U(HER
MAN0)Z5668-](&Y-`%=V`$`(`0`@!`$MNP8.T"&V-V?1DT-4*,EZSU+^8+&C=
M4:ABW#Z+4)*98G2KF:DU2M6E#2600#HCN`(P!VYO/7;GS46N1+Y[6X`<]=N?
M-1:Y$OGM;@!SUVY\U%KD2^>UN`'/7;GS46N1+Y[6X`<]=N?-1:Y$OGM;@!SU
MVY\U%KD2^>UN`'/7;GS46N1+Y[6X`<]=N?-1:Y$OGM;@!SUVY\U%KD2^>UN`
M'/7;GS46N1+Y[6X`<]=N?-1:Y$OGM;@!SUVY\U%KD2^>UN`'/9;G4`ZZ+0:C
MI]1+XT]_-V-Z`$`;_P`XK2\G*'U/]D_U.N3RF_[?RI\=?U7QU_DX`X4;3?-)
M?P$Q0=.23?M_;.Y2HV%5-3Z;2NGD@P<7V\;HG"BH<KF$^X%PR"HEN)REJ*8(
MD&R2+UEA=J"-$E+-6``C&]_:7MUKRH_+I^]?>W#F)&%6RTG)%,GQGY?!]7T.
M&6SEVFB#E5?5[VG*;.&].-;S5VM;JYUR;T(*;8U]60/*3WM:WKHHQ.ZMW[0N
MY0ZVW"72+K&9$2CH*"O4*U):BC(EF:E0G2Z%AY4<VTXM1XSII]\^12UK/2Z4
MSXS]H_$Y^YBX,V[S82V4@W.N%D.RT5A+U!W(R=8N^3LLY0.N])5DA?:+I<`-
M6>C.M+C"<*&64$2M6F&4@<D&H$DVL9XD\3IEJVLM8K$N..TO6'"UB-?'4C)7
MFTG/%Z/_`$_;HS'KOV8F-3^O&C7I>):[2RN"4L^%T&C->9YT+5Y'K^/PD:ME
M7ODI;0L>+M2\SUMR>2RAHF>4R_\`2:I,M*<IF:14M3HSBR9&K>XE6U;MUB9V
MT::>CV^>O0TQ[<KZ6AUC>:M_ZQUA[R?,JFS10;I-(H-_+S7T7[TI>0EZL@V5
M?FTMWWW:&XEE9[S&#:(IV?LDZ$98,N%GV7+VOD)-\RASF*Y4].7F/#)2-=(G
MH9UOW&3M^W_4JOZG#VRI9U_CO/*T[+U/=QM$:F>-7Q9+_P`5+MO77C,:)/HH
M^;;T-=Q-D5A?<%.M<WZ3'?-O6=;.T:3CH98EI;NO^VS/NYCHD+9ERE;'7Z2&
MZM2#=BWO9(H'CYBDHU9SQZNJJ(5S,])1/R&+<%=1?2O@OM^XTWUV:ZGWRSLU
ML9%[(^EDJ>0GQ07YGJQ;L*]KTJYSR3L=W/>^UZ`G-.VM\W)8F@I2L52NRQ&P
MAIQ0@J=(DD`4PB8JTJILB4,48F]LJ=D^-5O*^WXD/TX72E:\GY>#Z>3\#G\%
M+?!*%27?::#NCKI.`[DP#T=9>\&-"*)JL/<A;E$?=%=23?3C++L5J$P2;Z89
M0&;.8Q+-,`#K\,(2!J/1'2!8FJT#P?#'X,`5MMN,&EWL>`U'3FXN'IK,(_\`
MXF:VO1UZ(_Q![X"$F`$`(`0`@!`&D0UJ%0'=#J].#3WIXN`_QP!?V(2`!$F`
M:[A0L'1'7<HR`&[KNP![>@>#X8_!@!H'@^&/P8`P+E2']V#(_09@_P!PMX.A
M,("'^[UP]`0'4!#P(`ZS1```0D4````$A-#<^8Z/AP!NT`(`0`@!`"`+@/M;
MKX;&+(0/A@WN1M;0`F$`W;8L$>@`Z=&;W^YX$`6+M`\'PQ^#`#0/!\,?@P`T
M#P?#'X,`=5'[:Q#3;.WDW?BK+X\3#X`@Q:@!T=T`\`-S=&`*YD`(`0`@!`"`
M)>-@8/\`XRVSWTU#_?0K!J`]X-L7\`]]IJ`?^7<&`.X7T#P?#'X,`-`\'PQ^
M#`#0/!\,?@P`T#P?#'X,`-`\'PQ^#`#0/!\,?@P`T#P?#'X,`-`\'PQ^#`#0
M/!\,?@P`T#P?#'X,`-`\'PQ^#`#0/!\,?@P`&4!_\[WTTP?Q#`&GI<O\K_VY
M_#^*Z/@P!C6[=F;37Z9"K;2]=M61==@+<DTBFS[@-I*=2`9GF+URTAKK<L%C
M1>@H%J1FH%$S2"0Q0&81ISRS;L5:5EZOQ)5K5UK*?EH<-;";)O9VXOWSDR3Q
M\Q)M59F]%%M`SRKIMX66FXGD&[,A%VV;*IS/3U6DRB)M82BLG7`Y23I3JB9F
MG,F:M4Q4J59KUL^,7\#.ZLXX1,DB\07$`(`0`@!`$*DO[Q=5_4J%_P`><U`$
MU<`5MMN/]M_'?TN+A_9,UH`A(@!`"`$`(`0!I'Q0IYX)OTP+0!?X(^,B?S*7
M^120![4`(`P+E3[&#(_TA;P>IZXH`ZS-`\HD7SI3OH.C`&[0`@!`"`$`(`N!
M>UN/8QY#??&5?4Q8$`6+H`0`@#JH_;67YYZ\?I*X\?8-4@"N7`"`$`(`0`@"
M7?8&?GEMGQZ=*KZF+^@#N&8`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@
M!`$*DO[Q=5_4J%_QYS4`35P!6VVX_P!M_'?TN+A_9,UH`A(@!`"`$`(`0!I'
MQ0IYX)OTP+0!?X(^,B?S*7^120![4`(`P+E3[&#(_P!(6\'J>N*`.LS0/*)%
M\Z4[Z#HP!NT`(`0`@!`"`+@7M;CV,>0WWQE7U,6!`%BZ`$`(`ZJ/VUE^>>O'
MZ2N/'V#5(`KEP`@!`"`$`(`EWV!GYY;9\>G2J^IB_H`[AF`$`(`0`@!`"`$`
M(`0`@!`"`$`(`0`@!`'C4`_P]_\`Q1%G%>6X`CIW\$Y1#<*3QO@UT_A[R))>
MAJ@"%27]XNJ_J5"_X\YF`)JX`K;;<?[;^._I<7#^R9K0!"1`"`$`(`0`@#2/
MBA3SP3?I@6@"_P`$?&1/YE+_`"*2`/:@!`&!<J?8P9'^D+>#U/7%`'69H'E$
MB^=*=]!T8`W:`$`(`0`@!`%P+VMQ[&/(;[XRKZF+`@"Q=`"`$`=5'[:R_//7
MC])7'C[!JD`5RX`0`@!`"`$`2[[`S\\ML^/3I5?4Q?T`=PS`"`$`(`0`@!`"
M`$`(`0`@!`"`$`(`T5?$ZFX(_"3;@=$=P>AX,2E+2\01"/K:,.]K;10EA)1I
M8N6];M"I9,:*WD!>BX-O;KWCENLEN-852>.30(VC6[?/Y;;DC>F(T")ESD3!
MU3&:CO*6E,:N7N5;M77W5;BEIJVD^KTWZR1FXX,;S7:6-;MN$H\>B.0N664-
MUK:W+L%CECC:YDW.R&R*H73<C;DNW<!<MC9YC6YL@BH*J_78^W2T6;<9YUCR
M@KO!&14A.3$,Y/6.J0US$]`L5JS39TSX;]S;MJ3;+CIRLHV3<+5Z:VT7AJ_"
M9;HE5W<*[BOFXF%Y\?5\#@.>VO5X'];2O<_'7$I,>"?9+%<GEMF(U+EWFE8;
MFMVBT'9<YGN"R%GZJ&T'8F7)NZ4,V->"B5-J<Z$WS)%/(R3F:591"0KT5M5O
MWFU^DF)\NCAZ1Q?*.O2-R7CM:Z[>M?\`E-QQ\7,-?&=(C<R6K[4=[@_E%_LF
MQ+<<N"[%R0LKBE<J]ZA<X^BWA*7)ODDVRJ$'VTK/=AQE"5[26X<MY&\B+DQM
M>*+->O6.FR!.N7(R]5L.-TPX\F9NGZA6M56Z1:U=M5]5+)P].+;F5%+W]S'?
M/@3R^S2U[JJU5:IVLUJI]$6G31HF5K*$A:E5K&0EH4J`3SUJM6K))2I4:>^&
MJ8JU9][)3HT:<@S333"`2@`B,+)I^G6D;^9,KEP6KX*S\IZ>;D@^;+T9[R]L
M-'%MHNQKNE'+;%R@2-JC:<*.ND2AV7..M6ZD-&THX:H%ZPTJP32RSS!O@U$.
MA`DG$ZYIOF@1^>R_RR`*X&W"K4:]W,=IZ-6G6D&V]PA">E/+4E$!<[8E`0FD
M$0TWU.8/>RCWT`0F0`@!`"`$`(`TCXH4\\$WZ/+0!?K)J2=*3)A,?)2CU(6'
M28U0`=)J$DTHZ#4Z`RCJ'@0![/7--\T"/SV7^60`ZYIOF@1^>R_RR`,$92GR
M-7&+(^2D=*5)^82\([VF9HSS:!;QQ"([V6<1T`-T8`ZSY!\HT7SI3@\(G1@#
M=H`0`@!`"`$`6^_:WQHL7QBR&&N8H4`]<;4#^>JR4]V:V##WOQ<P?%A3FT[_
M`'H]\,`6)^N:;YH$?GLO\L@!US3?-`C\]E_ED`.N:;YH$?GLO\L@#JK_`&U?
M/)4VSEXIZ<TM20;*8[S!-),$THA,Q9II1":41`0FEF`0[\!@"N;`"`$`(`0`
M@"7;8&S!+ME=GN,P@`<]2G+J(@`:S6S?TLH:CWLTVX'?C`'<&=<TWS0(_/9?
MY9`#KFF^:!'Y[+_+(`=<TWS0(_/9?Y9`#KFF^:!'Y[+_`"R`'7--\T"/SV7^
M60`ZYIOF@1^>R_RR`'7--\T"/SV7^60`ZYIOF@1^>R_RR`'7--\T"/SV7^60
M`ZYIOF@1^>R_RR`'7--\T"/SV7^60`ZYIOF@1^>R_P`L@!US3?-`C\]E_ED`
M?MU84\E%O$NG>+TO$?\`M?BO$OY70@#V(`0!XF#?2S2]#4!#PPT@M')#VT(V
M<K\,KWY8N6BP'QD0R$O#,S<.R]T'%:-/L3)4O964[*.MOW"3FFW[[5;C=:$!
MLN>X323U(V>D:<[A)T)*I0D>H]-"O2C$JX:5]M?\BF575O!IS$1'S\XU2:;-
M3%GP/!DKI:K3<[I^7VU,8+^+N:M\'';_`";.7BMG8#)NR=Z<IDRR"4L6E"[-
MO:>(%ZITMJHMLKT-AO7,9"BX;F2%F&A.^@M([B)42"I2E(F"YLO,9EGFMK4M
M=4A5R4XVTU?'5.?*TN-G.Q-E2W'FN7!MU\FUQ?WUT^9B8UL>G\RV15MI8#,!
M48#4N]BL0Q,R[5'M9]!N"]KLM^5YW(>J[>2V:L4=#11;3WK7I[TN],Z<<3W(
MWRB>K%YJ29U0FT*M2<:Q57M9*<NV;7*LQ*5>,-_"%ML3SRK(L]+1W"EJWA9N
M9_\`BUW,CJ.RP7><%PM%MW\)-["%\Y&V8RN>V.`6ME4;A&[H631;>E4QF(=\
MC+WEE3;./5UVD;3@6R)ENG5R8X0,%BBH5*GJDE-C<=MCP9V\GM*RJ[;I6O;)
M"A):6OD>B_B\M:5K[-,F/MO17+1TOYULN-O"$Z)5T?226I302BXEJ*,M42JH
MEK!,XEJJ>=*4C!-02E&A5*GDXV6K!4I5RILI7GI5)9@$!IS"'>C"UG:RXZ8U
MT'%)JR^IXZUMYM;V\I97OLEB;B_C=M\5FUU@L>;-6<MXN['DN\UYFVYMXV6H
MVEQV!FJ"-*XU5#24XNG'UV1))4BW5E6G.9F+TY*0SC)3DE""Q/OS9VW]#YD<
ME$'@$`5T]M8WD-NW9Q^H(2*D(A<Q;NX%6L71TPFF4JU61SMP9:E:F4I49*DT
M@5A"41#4-1Z&ND`0Q0`@!`"`$`(`_.>49A+R@(!OCR?*.H#NA,>+@(:`.Z&@
M[O>C`%\(A;.W/4)()F"RIQ`F5EWTS50AF'>T)`#41(;N@`$`>WS9VW]#YD<E
M$'@$`.;.V_H?,CDH@\`@#!.45NF`4QGR*-%&,SBIFA8F[U8N9+MA%HUZ%:G;
M]P3TZU*K3)25*52G/*`@,H@(#T.A`'6SH(B*&C#,(S3"E)PB(]Z/4='48`W6
M`$`(`0`@!`%N'VNDU&RXL:+_`%9?;B"N5"V1-2G1G6$=.4YZ-*6V;(GEI4ZA
MTO7J222U#4\P``[T!F'3HCJ!88YL[;^A\R.2B#P"`'-G;?T/F1R40>`0`YL[
M;^A\R.2B#P"`.K,]M0IB<D;96\))*($DPG)9?'>:0HGE*)(M)HPAI!I0+RTZ
M0"$D@!J$O0``[R`*[,`(`0`@!`"`);]@L4*G=LAL^RQPM0-EZEZE&:>@:HTZ
M]">:E;1^5:0STJLL\DXTJM.6:74-P90'<W-`.WJYL[;^A\R.2B#P"`'-G;?T
M/F1R40>`0`YL[;^A\R.2B#P"`'-G;?T/F1R40>`0`YL[;^A\R.2B#P"`'-G;
M?T/F1R40>`0`YL[;^A\R.2B#P"`'-G;?T/F1R40>`0`YL[;^A\R.2B#P"`'-
MG;?T/F1R40>`0`YL[;^A\R.2B#P"`'-G;?T/F1R40>`0!HGMC;F:2:65@,B4
M9@TU[$T(=`W-=P",O\<`>WV!,[BPW/*OK)Y1)GE-YD^-O*S_`"'B7\F`/KX`
M0`@!`"`$`(`0!"I+^\75?U*A?\><U`$U<`5MMN/]M_'?TN+A_9,UH`A(@!`"
M`$`(`0!I'Q0IYX)OTP+0!?X(^,B?S*7^120![4`(`P+E3[&#(_TA;P>IZXH`
MZS-`\HD7SI3OH.C`&[0`@!`"`$`(`N!>UN/8QY#??&5?4Q8$`6+H`0`@#JH_
M;67YYZ\?I*X\?8-4@"N7`"`$`(`0`@"7?8&?GEMGQZ=*KZF+^@#N&8`0`@!`
M"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`$*DO[Q=5_4J%_QYS4`35P!6VVX_
MVW\=_2XN']DS6@"$B`$`(`0`@!`&D?%"GG@F_3`M`%_@CXR)_,I?Y%)`'M0`
M@#`N5/L8,C_2%O!ZGKB@#K,T#RB1?.E.^@Z,`;M`"`$`(`0`@"X%[6X]C'D-
M]\95]3%@0!8N@!`"`.JC]M9?GGKQ^DKCQ]@U2`*Y<`(`0`@!`"`)=]@9^>6V
M?'ITJOJ8OZ`.X9@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`#4._@!`$*D
MO[Q=5_4J%_QYS4`35P!6VVX_VW\=_2XN']DS6@"$B`$`(`0`@!`&D?%"GG@F
M_3`M`%_@CXR)_,I?Y%)`'M0`@#`N5/L8,C_2%O!ZGKB@#K,T#RB1?.E.^@Z,
M`;M`"`$`(`0`@"X%[6X]C'D-]\95]3%@0!8N@!`"`.JC]M9?GGKQ^DKCQ]@U
M2`*Y<`(`0`@!`"`)=]@9^>6V?'ITJOJ8OZ`.X9@!`"`([=J+M"6SLPL2U_+%
MWVU<5V$)O/1B,TRSVLMI:`LF*K[7*:&7/EU%8HF24M,A5JA/-3FD$:FY*`RA
MK,`%:CW:UCP&X.!]^M?`NA;00^AH`>[6L=_N#K]]U"VG!H`>[6L=_N#K]]U"
MVG!H`T^[6\>=_IZPZ_02=Y-SHVU&IWV[1ZD#3=_E0!J]VM8[_<'7[[J%M.#0
M`]VM8[_<'7[[J%M.#0`]VM8[C_\`T/OYIH.Z%S[:B/0UW-"T`6N,&,JDC.#$
MBQ.62`SU1@HU]&31>R:S5M3)K*JWRU=0/I\I$XJ)]$N3/5=2`SA4DIT_A9P`
M90'4(`Y8P`@!`"`$`(`0!^=09I9!$!`!#3=$-S34-=SWD1;9QN2HG4CQ>>TM
MQU9.1=''%0J7*,GJ-R618YTWE2+6N-8QSMW?ZYJ:05K=V&?MWR8]9T*Z#Q)+
M*=T@O)1,$"9E6(%#YHH<.EZ%2.%[Q[3CG/'2=:[K?>%$>.W(Y\CRUQ5AKWE]
M6CASM&T?'67O")!Z-6<:5,:^]EG$-[-N"'P^NF]WH"(ZZ]$.]&+0ZZ-R;3R:
M==NOD0P2!,/MBRK/O9PD'8JE@WPRS!+OO7S&1WN^$--\`=$.B$"2:J`*WVW!
M*FC%W<>)J!8Q7EEMS<.6::C1J5`EF[)6L.@C)*(`.D`0F];5'R`=^=:_RN`'
M6U1\@'?G6O\`*X`=;5'R`=^=:_RN`'6U1\@'?G6O\K@!UM4?(!WYUK_*X`=;
M5'R`=^=:_P`K@#2*:H],*?T`[Y8)H^-:_>'RPC_U?>!`%^LCXR)_,I?Y%)`'
MM0`@#`N5`338PY'2RRS3S36&O`$LLDHS333#;UP@$LLLH"(S3".X'1&`.L^0
M"!T4)%'J0SH*0FB'\S4W0$G1$!^)[V`-VZ@/>1#/^9J?&P`Z@/>1#/\`F:GQ
ML`.H#WD0S_F:GQL`.H#WD0S_`)FI\;`#J`]Y$,_YFI\;`#J`]Y$,_P"9J?&P
M!;\]K?4*U#&/(/I]&I2W^1=<9.F232Z@%L6``B&^`-P(`L4P`@!`'51^VL0'
M\L]>/X4=.97'C=T'B//X'?Z^%`%<S0>^'PA@!H/?#X0P`T'OA\(8`:#WP^$,
M`-![X?"&`&@]\/A#`$O&P+EF';+;/@`EF$>>A7'0`$1TEM>_YIA]Y+*&H]\$
M`=PO`"`$`5J/;9H".QNN8``(B-\,>=P/3&(!_&,`=6/O1[X?"&`&@]\/A#`#
M0>^'PA@!H/?#X0P`T'OA\(8`:#WP^$,`>-[,.H!+,.X.N@"(AN=\&[T(`[@_
M8"`(;&O9[Z@(?[@DL=W<W!<#@$!]X(#`$P&H?X;O\4`>=?>]'3H#`"`$`(`0
M`@#\:\HS4I@E`1'X7<#<$=)@'0-=P-1#PHASQ:6_%_DR&D]ROT\L,,P3MQK^
MXPHUJFD>QGR/VBUJ\]SV65>YS?*5F&Q6\Y[-70N%9L_9VK1K/T]=V=]63E3$
M!0(TS#<KHZW(<-G"9HE.3,<?MUSX<7*85[6T<-2[O5]=;OY>2&1WBW!Q:R2;
MWT22V^"1/BKHQ=?1E1&/5#Y8NKD%%-KF$P\:3%0K04BM<E5KIRD2J43B<?HT
M:XS4:]&>6I1J`$\@A,`"':5QIU3GJY_$K;TMA82I[26=\!='.[UK8X(TV'SN
MCM#L@);N#?8,A:CDFMN#DIW0DNF%MY6#HJ=;1$6R*I-T\*8'PW\"YS=_(HXY
M?=+[3/\`YE&7O]J$`?#._8`X07!,IQVX-R<\7Z=2"U<DDG7IGSE$YC:42-UI
M3)HDG5UBXANH2*&S4DM6I3I#++/5`)A`1"`/D_<X.SA\GY@?AJY&=O4`/<X6
MS@\GY@=_[-7(SH<NH2![G!V<'D_,#\-7(SMZ@![G!V<'D_,#\-7(SWG'J`'N
M<'9P^3\P/PU<C.WJ`'N<'9P^3\P/PU<C.WJ`'N<+9P[@]79?[@RB']]7(OXJ
M40F`0_VZZ,HAJ`]'<@#,H;%+'$-R7);:92RRRRR22!M*,O=[)))*$DDD@<Z`
MC++3E#0`[P-SH;D`<1\\=C"YTW$2^)O!3(':,+.6U)M)?,D1<.TLR5I)-1QB
MZV_UR$S.][ND&@$H-?J_RPJ!1U^)TJ=+$`.6_P"12QS$`_O+;3*40DE`0EVE
M&7TP:@`;X0&:Z`;L\P:CT`UZ``&Y`'JJ&Q"QB5D]02%?(;:2JZ0K$C28JI*G
MM'\N#J8J)AZA4*GTU1)5[GST#A`^5JSTJU*<!DJ4YQEF#01@#`4GM9'984Y)
M:5)OY,TJ<DLLE.G)ES?N22G)(`2RR222O()9999=P``--`@#7[F3V6?F'DY^
M%W?SMS@![F4V6?F'DY^%W?SMS@![F3V6?F'DY^%W?SMS@![F4V6?F'DY^%W?
MSMS@![F3V6?F'DY^%W?SMS@![F3V6?F'DY^%W?SMS@#)[$V`N$MK$T\BVLN;
MGI;!&4U`%=42+>9]Y2,]+5%>4O(3D55$@AW%)%3:G(1I240KSR#4"E)++OM`
M@#[;\BCCE]TOM,_^91E[_:A`'%/&W8QK1YZY<4\D+^[1M+9Q7)U9H8G54C:6
M9,51.8T#;*VAE'KJ`(%WSQ^4[+<HPY:0]>NEJW2Z-/?2C1"E4J@<K/R*..7W
M2^TS_P"91E[_`&H0!QXN5[62V65Z'28?=Z$')N\+\.DDY-.OFZ675^WX\#J8
MCE92*.FFG$Y7FH*9@@D$I):)6E-4WE"D`2R`$H`$`?!>Y.]BWZ"-U_PB+N=L
ML`/<G6Q;]!&Z_P"$1=SME@![D[V+?H(W7_"(NYVRP`]R=;%ST$;K_A$7=[98
M`>Y.MBWZ"-U_PB+N=LL`/<G6Q;]!&Z_X1%W.V6`/JF/[5WV2]KW<@W!M>R<A
M;:7!:AZ54:C]8&55\6B\VLJ2TJE`%-NN5#=Q)613X4*T\G32]62?>3S!KH,`
M<FOR*6./W2^TS_YE&7O]J$`<1<LMC$Z",^,7K4<@=HRHR&<O[-%<F16=I;DM
M3$MB-4+ND;PG$P7/=HL,RI2K]:^E2IF_61#?`6#Q00`Y=?D4<<ONE]IG_P`R
MC+[<_P#Y0@#XBXNP#PBO&TS5O[RW*SRO#;X^>3E108-T<^LHWRS#ZJC3U*J,
MIG&VX;BG4HRHI%:M/.5K3TQGH3SS#((:C`''(?:G>Q<$1$;(W7_"(N[_`-+E
M$8`>Y.MBYZ"-U_PB+N]LL`/<G6Q;]!&Z_P"$1=SME@![DZV+GH(W7_"(N[VR
MP`]R=;%OT$;K_A$7<[98`>Y.]BWZ"-U_PB+N=LL`>9?:GNQ<EF";F1NOJ`[G
M]XB[H=$!#<$'*`A\5W@P!RA:.PBQ"MXUD!B6\O3M#&`PVFG@DM-C,K:&97-E
MGM5(E,5S<J2VVZDW)+):*FRFS56J%&A3DD"I5GFTUF$8`^B#8IXWRS2#4R0V
MF!BGTRETRA/M)\OQI5I`J`,U.MO+J4JG2IO\;>S2S`'Q(@,`5@?R=OMG/T7,
MIOMF\QGLZ&7["3R?]L/[:7_YJ^K7_+0!V`<`(`0`@!`"`-.]EZ.G\(Q55K5)
M+9#<U18"`/RJ3"&]"6;2:8=[IIJ&N@CT=-R,\SNL5G3ZXT^(:;V.'MEL_,0L
MA[FK]HK+7N0;@OE!IN4P)9)1G:6;CF*LM9I-YWG+;/U5;Q!@W9)-1<,2%5*L
MUU-7I$:X[VO-((#IK;%>C3MHK5GX^8=ELMSE\%<`J#2F">6;>[X!&3<$-1U&
M49=\$VG>Z=#O8AIM.-R8TF3XA:N4PV\]&9;E<>*"DOVX2>[EABL\^?+EG$[T
MI@TD0P]E!O)=28#2H5:]!Q$9CL]*6>6B!REOA`)Y=82<;[+4QO[BK/\`N7_5
M?$^WI51$=Y--,,TTF_`!DWN]`!T^&'H`(B.H:Q#W=5;5J5\#9J,C6G%08FEO
M=;VO?!3QTI+1L+L)-I4.]IY!F1E24G1MXXW>X&(DJX+DY0$:<V8<K:-T)B<M
M835.6F%2:0))Y9IHQ4R0\MG-*OB_C'+\B;4MCQ+/;^U:W%?]VG_N1QYN-M"L
M9+.*%VJ-U7LN-))LQ<RT]E',X96&[W8F."\MYFV5=K.M7;\DP4=UN9]/RFA*
M9&JH)Y!.J52(GZ`3:C-/O,<;M6CODLGZX7DM--O,R3?-TF75:_'?\CY=S;5;
M`AH6VM9=M6R`*&6+>F2Y4]NCC9MS=Q[+RH%FND<[LBPR&:P%Y\LNO:N<S+(X
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MB^;<N,SE:S2XRBMR$RZ=!PI=-A&&`<2.OU%YS.@R8H(Y9N2HVIBH;JU9*-*G
M+,,XR[V8`E6=4N3F?D2O5].ILEB<@K/9-VI:E\["OY)N7:9]2+$[0?"%1/4D
M=P4D%?5&JJUT\%,D0.U*!5?1C1<*@TI9*@TAFD&:G-)--GW&:O9V=,\RL7N[
MKZ'$?FO-=15\TW7I]OVHR_/5&0*<L\TP3U1WDO\`-C-K/N_"B$H"`:@`CJ.Y
MINQNK+CS:A?RF;KD]KBK?U/&/V'S+W>C>MVS'8_GBJT$%J,EJN!Y.A;.Z`21
M&ZUT@VMK:J=G#4*99/3"-6M/_)D&#FU/3Z;/1+S>R-*_2N7U+<^<L[=%+O1:
MFVEWVZG.%+;-U60UKAMH@Z$69"<Y-N/)%).!"D<:&)@W.C*\R:>DF,%IIYIR
MT\V\J;V<!"*9*Y.$4<76_P`MP>@\+ZVW8-U+,V7="T;(W"O[7N$7M@D4T95-
MEURM:]JR/-Y`;52A2LF(P)S>JRU:<QRK1`S/\)2WT_PL:5UK/AN#,<2!`"`-
M$\V]#4/XM81.FQ6UN-7:)@XQ9*9CXXX@H#;<61%S2C!+/%5549I)A5N/!\.U
MT&T!#..9RUD!B6\;SL>RNE--MD*I]7/T$^<BDDY>GG*M&G-+,-:Q5\+6Y67V
M_:OO(QVOD5='-K1\9\/`^L7<CK'MBQ9K)E>NTR4['XM;\M=::\%1<)U6)6MR
M?3"RTENP@N%YJI=2359/.T1)=3]-JG*E>G3HR5*D\L@QGK;)7V^W;KEM$/?;
M?0SQ/(DUD<M7>O\`MC3\=/B8');2K!PWC[<#*4UD8T&Y8VU+A46?<MVOI-==
MNU5B/--H)YR=CNE@OQO-RXJ0]U`DK%*Q!'K)$JFIT#="H4H5I*U*:>MG;W:V
M_P#%ZEY.R\_'R.BE+Y6Z8M;1.G1)2_WG,ENN=%=*,D.!!/@J(Z\CIR\D*%&C
M6EHGDE7)4%)+.T9*E.2J$AU/-TZL@3`$^]'=E`0$`T=TLG![E:666GNU^A^?
MS_+\S?`KRC/-)I/+/+T99I=-S4``0'XD0G'4`'7=A*F)4Q/R\23!5],@6/8%
M+9"P]*JS6YQ+M6UL<S6^WD@5=P..XUU7'1;C92B!/IQ2D),G+4KJ*D8GK24B
M*20-&IQ&6B(#%;<[O"M+I3/EKK^'YD6?&O+=?M,Y4ZDTLLP5`J#-*,XZA3FF
M#23HA*$DH#-KIN;@#-KN0;F4GJ5HKI>M\G/P,/-.^]NWU=>[UEFPMFS5PK&%
M;:'[DI!A#5B!9%+7;0EEQ,>8JJGB=%/5YE-+0C,]60M4JSE)J82U@DFF"4;X
M:OV_<R[/;_Y?_<BV:M\5*7>V9\:>36_Q,T4YM]+KKKW@^]#HP(J](ZK1_%;F
MN(+"`$`<.+W9\XB8XW2:5F;VWR;EO[BO8NWCZ4A*24YSY-&1W8[9&$T7!<%S
MHJ$IM6U39=KVJ]:DI2<YY'(**A+-0+U:E22>4.9>ZLCO:W]"T*BC7EU^,]"&
MY4)ZF4LA\E;$XF6K7[VY(W4:5G;5M@2M%8>CS4`(I\IT_5ZG3DI/+4J==16U
MU4K:RE2!&@8.F9@$*5*80&+*SM;V4_ZD?4TB5+KRC0S"25D]2))J@0,":)*Y
M*BHIYFE2J#(9)F2],T7KRZTY1D"M0J2S2A,`".NFFNY'1#6CW%6K_3M$_(]X
M*TN^FDTG">73<&734!T^&"80WF@Z^'N1`,#7ZR"9>/#))OI\"N&R:E<"VUK4
M)MM=*IK;O=3]NV^D"WK);;919C1054^>77#2J599*H=((TJYB;X2C,$37C;)
MPKNM_*3!9JO%E:3=ZWBO7[S.TM2H`"$\LP"(S!*.FLH!*'?AH(@(AN"(:CK&
M>7E''%N^OAYLTI:W%NZAK\3%+:O?;QV7?N/8Q%6#IBY%IVC;5\/=%KHJH3+)
M;>NU6>5!D&J*J;)T4U0,J51A*85:%"I/6*=)EZ=+)TVGOIICR/$NZ?\`8Y</
M_4TK?DS5U:HKO9F7XL5$`(`0`@!`"`$`(`0`@!`&*KY,=6N;9B[=MD%P3--<
MN';&X#&1G33Z>%1M*KN:2NWTUP4YBL],U+,C'%"0QK3$*@=+UE$!CG[E?T+.
M8K#GPAIK7REILOCLEEJFI3LM/&-7^X@+/39?/[9M%\$F=@WD592[^/N/UH;;
M7*/)[HM[;>VUQ6]9U6MP@7,M)BE>QOOKK@XE#)FTR`O$4-3*T$:1)HGY**N9
M3#4^\#6_*RK[;A.&]?/;3KOMY')E_4.F1=M9UR6LE5_R*5-E.^FFJ>KE3"9B
M-FX3K5T%I"(,3$"^&/F!3UVA.,=P2&)K_63%MU1KM"W>.-_V_D-=AW6H17L>
MHL&RUT;CJ[33#C:`]6HN4RFF#YM.ZF4JDU?7E1NB4*Z5FY6NVFNVAUT>/MKY
MW>.*PTXV5FD[^XN3F5+5-V]]]8;-ZLWA,X[>9%;-9_7*P^?3O:...1NTBLLP
M%J1-3WZMX]6C>U\:;IP:=JK647;67T^Q309R6I4TA1J=<*[:H'"=`:%"G-)T
MKFP9;6PVME?]:V.SE^5U$SK].GP\M2N;'5=SFIOAKE7'9I>FKT^<N=Y_#'K6
MP(5+-XP;/DY>?"N\V0]L9#=[WOM#<>&J:IW)O3<*_P`[4"DB6(NU=1FKKY(5
M+Y-2V-,HJI1-%E4C!-M]>R!XL2FI$):A/=VL^[QY<-TL2[3&VM?KM6EK/>.3
MMS3TE/Y0<\G>VMWU>_S.=>S6QQR0LY>:W:W>YDO9&24O9WMBVI)4=SUHW'46
M55IYB7]N%;?']QOFLJ'U1T/RS5BG6W$I1-33&BU2<I_-G#6@UIXPYLEO\?;%
M=^JV:EMNC=JV4^#32C=;;HTRY*6[*G;97*_4*R3VGTZ_&4G_`.GXG&!9LG>B
MZQR_-H[:&W<V[NV[]L,,Z^[V=C/)LY=>5J+*/"V[/>3.O3U@N$15&P?;DK`5
M"I*B!Q/42]2G1K22%ZPT1"7&^/W,';Y:5:K[V3D_YG6^5:KP5713ILF9VR4P
M.[=5DO:E?&:S%5:$_P"%5?RDW?,K!0_8=UXBE[<%MHW<1D5*FT$=&2=\,,E%
MF'\IG;>K*<O:A7/NE]5JI)`;B,WKA'6^>I%9$-*()R'52TZE1E)T*$DT;YLU
M\N?-[B4/%CKC:WHZSRAN5/'BM96C>[93'5+%5I\F]9VWUZ>?V9\::M1F19BV
M6$$MF\=\B[=[2ABXSV.LP+ML@@6U/X`NJU3<N(LS)F.N;!%8>9]L)5&T]OC)
MPXI+#<*$EQ)6ULW.U%4]0KS$JRM^W_48[V]6&N3%7*EO::KFYW6[]4-+HO"+
M\GVS5(]Q6A>*G?R:?69U\R5_`::FL7KVGKU;QL18+ASM.MYOTI9="]9VVQQV
ML3;N[:F4G\3K2#<5!.)U89`T`VEU99A&>6:.7L,=J]FJ9+VNUFSM5Z5K[UW6
MJ\G7QV-,]L%,WN4K6MJ5HLC3^I\6Z\O"*VI]Q)U3^)#=UZ.[[_P(Z*MNLVW*
MI-:/<UQ8D0!$WG"6NC:C++"W,-L6%NWDI;NSK.RCM'<)C6*2&^[KKM!1ON1M
M4?8UPFZR5]=;-->1ZJE:^LAJ]8L=HUDVBJ43%4)B<AJI2RI7CW&7.]:WQUK1
M=$ZOE:R\[;/X(K6K:KB63^I2SM:8U3323T_AZ):O0^0PN;[XQ=PSM]C)?O%B
MXKW.L?'Q_7XN`EL!N,NZEM*JX_[UOMZS8G-<O5<9>N^;QLH@XB]/J*FG`@F*
M!66H5/U`&24:Y:\Z567U0DK+QT2<K9ZZ[06IQ5G;&^-=8\.OS_$^>V<9>[)C
M9Q7;M$Z<=[^V3NRTS.6H)+9O*RD=GJ#NJWGN)>.ZEOC#&JI3J<28JE::`^4X
MD:`*]$"*E+4+3!_-[Z,N]PKNL-F]>Y_2^Q/7VU6*T_[:OC'PWUUOV=<6+)2%
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M-X3EE;E*CH<>U,Q!(-E[(EPG,VS)/`XI9ZQC$R#(,KK`\TP&O9AR)Q=PI;Q3
MR5,M,X:-.>0S1KA1*34].S=*WO\`JN7)5R.VKBW+D\4[)Q-?'5-.9<]_?42H
MJ=M;AF]NKM&\RDX7C&GBEJM=3(.,&)=ZK2Y.8I(:=9]Y-;'W';-3:CS6Z*FU
M(D?:]J\<;I6Z)TK%EVY(973Z@F6X<KC4CQ=OD*<H@0D'J>6D7+TJ<DO+2[3I
MQM-+X;M[ZOW:\6WXJJ>KU:<ZZE,+3IG637+7-1+I%7CEJ.OJC53JBQ1&@$`(
M`TS!J'O.A[V*\4^FP;T(E<SPNK9/,O%S,EJX]7AR=MXR[&Y*8_.YEV'2FVZ;
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M<T%O)-`=K.Q8=%C$V_[]8!AUU$RT)$X\W(8*%SM=4E6B2"0HFC%*A*:I4)=)
MJN.LN6XCZ6U$_&$D^D1XL]#M;7P]Y[];QB5%I+4M<N2V_B5E7^5I:J-^2%W[
M:O\`RAV=^$UO);(WT:QKGRP<0KW6J=(5[5W3;ML;77+:B)>4^Z)F\[:*HDM:
M5N()PU7K)JG,8.HU4.E;[IV\&]'@=N6>JM1IQO/+6-5U74Y^UXXO\?GP<'[Z
M[=UQO1/W$J*ME#\*QO,:00UY58UW"9Y@OA@E6GWUI@R5VEER[&V&>:VPEUB-
M'$>K:.Q)(C=NUK`N?D?81G)Q*U;\N"YCK%,5'&$[363M02Z,"?7F-DN?';);
MO<.#+9_J>.2,K3G&O<BM?BZP]9^G7SZNXK6N.[[2O&KKBG66[+&ED?SO+U>K
M>J\96,:3-N,C+CX/MG&\\YE3&7`O9^,>]K-K.XK22'8KWJR:M6=M?CN6N*WC
ME"CU#<!M6&174NG=)0$#3M)FI)YJ5>A5GOF6:U,W=XVK=]2UL6-1$W25K6KI
MZI2K7:/J^)CA6/\`IX;2Z\U?(NEJ+DHCI+;LW/\`"OB<`V)LE%6I;&WR(Z\:
M[M@H+>Q]N@>NN05;INPV?=.T90G`RC=D%)]UQN'4IN/()@%E5?%FK%>>M*W*
M$W2B1DO(7)RT=WGQ7R9^\QU=/=KAX+5<863W:I-]7[:?71^+G3NK4O:S[=<:
M\K<(Z5_A6K>WA),/L][87Z;-^,F;AWU:#N2#]S,?]G*3E=CNKIIHT[[C,"P;
MI1KS%ZI@BH':AA<;+P4^IU.><):4QNO_`#4U0!WT6SY*7OG]G_[1]UDMCJMJ
MXW7'QJGO$U>[F9U,^ZL\W;X<?\6&SM7R;>Z\XW\26ZB&DFG>:S"'O!$=/X(R
M?["K2G3[/=GZQ4"`$`5N\Z;*9'5+K[32TC$QAN#>PGM0[08XL&S%W&S1:QBT
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MQQU?BRU5BSJI8M-P;L\8>#\9MM+AW_L,RIFS;F^+X7UE`DK.Y+[&W16J'":7
M7H5IZY7AP9+=S:U>[GW%D;J]9:GT]/O-W&3!;/B<526LIS:,DN=83:3\FO`D
M#PW"S.0B_LN;+X[G'FN8JX/XF-?*U3/7'1BA-S+ERGFWW+CUC!2N`5DKG94Y
M[R$DZX[NK34:]4D;K4B)XG6,E:E`Q/IDMDMEOP:69T>OQ\O+]OW\=>"Q5;<X
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M,Q`"`$`(`0`@!`"`$`(`0!IFDEG#2>4)@W=P0UZ/P0B+)6JZVUJ]QU36ZV/Q
MZE+[[?!1IZZ::[P`W!#H:Z;H:AT.A!))0MDH^7A\`M)CJY?G\3\A($YA#4K0
M'2490$:8:A(,V^WH;FX&H]"+2]YUAK[RE<6.N#]-6J6#7T]-=]//J:Y29:73
M>T*<N@@(:2`&F@:!T`[P(R]K&EQXJ(:^5M_OZ^)HVVVV]6Y^<)?L'497>;P"
M]+>ZZ@&\E``'<W0W-P=0BU4J**J(JJZ?RQ$?"-(\!,[FJ4L7ETTHTPWO0TE`
M._U'<`-T=8A55:PEHDOP<I?!/8AI6B=8<KXFP$&<TDI>7G2EM=`37,Z:2*7<
M[C((R>37')0;98T4;U)?5BY>F>6::"5/5J1(#-2J!6G6GEI!)+-,`V4UQUQ+
M^U5RET3>LKPV4_+P(:3R6S-?U;*&_%:O7QW?WOQ/H)B]&<`EGHTY@`-`WTH#
MT0'<W0U'HQ''UK)'K3;3ZR_VDJ$DELC0!0L$X3A0IA.'Q,X4PEF`0TTTF#2:
M40`/?Q3VZ/EZ5Z[*STWLM%9^:C1_B0DEHO&396ZT6LT$[K.U&VA-A(%05U44
MMO(Y!%315%]4-+J\IB23J!<J*@MKA^N<.5M[TTR:KU*M09IYYIATA+;3=Z?C
M^+DAUK9W=EZLD<O]S2A3XPDDIV4(^C``E#0`T`.\B2S<ZL\P!^=2ITL`'>S3
M#-,$H2R[W41'OM\,H;D`1FT<W+O7A?SX1<-\2:V0MKK:.]T6V=N0UP;TH%@[
M4K]RF8?E27BT;,2G&7<=YW:),=>IF4E7<%)+(-ZFL$3),D=/5BQH*%>*TT^E
MRO)OJO!E5CHG:Z2Y7K#\UT3\4?6<\NT'IR:#@)9*G(,^OPV<U&649IMT9M?6
MP]$=/>Q-DLGU:ZDT2QT]NFF/P6Q^U.\FT,I[DF`]DI=T?B<Y0`1UZ.O]U[48
MA*J<HFOIKPKI7PZ'RKP=>:UQ&JNL5_[-G&M],AT)]5)<S->.8R4YVJX4JO-+
M/635QO+>*1Y(5B-6>0!FHF*-2F(RAJ&H;B*NSR.'DY5<]9JH3^2V)Q-X/[,T
M?-VTT]3<\OB_$V%@3976F;Z&U+5[+3$RV;7:U):I-IMV^RN;++06[2<9FD><
M5-"26YB4FD$FFOG"\E4\!>G3ZKJTY9ZN_$`&#585+?150EO"2:2UZ0W^TJTI
MM;2;-M^;>[?[7N?=UKU;0&G5I4JV!=CJ4]4)J-+IF==*01UD&;I<DDV,<M01
M&24?B0'<W8A*E[Y-$[36UGXNL0WUTG1N"(JLGN/ZW6)\O`^BQOS`-W,NHY<<
MKZ6,<6,63C7:0W)(V[6G2W[DLJYMIYEV1MU+E63NXUZ))(?;?05HV5(KA$V1
M1UY`.'2H'$^G0-DC)F%CHN*22X)I>2?@3UM;^*]E:WFTHE^?@<[XT)$`(`0!
MP-R0S#4[<W0;>.5AK".?*')-PM?G(5;>I+J;UM&#:RUP+E=N%;D7NNZZJ"@D
M,9)<:T2-E&^GDR"RX%XR1-"53YBQ,X:+5XIV61KUU<U?5/[:=2U;6I;E5P_$
MVJ6\.T(&64?6"V0T&641#U\8"&HR``@/]UW2?3H".[K%Y;T;T*42QZTT?6--
M7N:Y;Q[0J23>28#63DD`=0EDSDWLH#NAN!+BZ&FFL5XJ9ZE7BQNO%I1,QY_O
M/'/%M"]P?6#V3'09A#^_*`[LXZS#[%WHB,3;UJ+:J9U\C2WKLKV<V6SZKX&)
M;MHF2E_DI&0K[[)W#F]:(W%*99;Z/=O)]G7(2D-6J4)BM141T]XXBK)1-4:A
M:8:<U:C))4FICO1$0W(EVLVFVY\>HY6UE[F1R%QL[TGJKK5L[L?4SJV4C(<Z
MW9J%"/5<B80+I2;(:ZEQ7I=42IR65I%J`3ZA1+TI*<FDDH2A77G6\^NFM7U3
M:UCPTTDA:6Y+ZHCY:_O9N,MX-H0&@!@+9$`"8)@_OR`.@@&@3"`XN]X`Q6M:
MTJJK2JF(V4MMQX3.H\NB/U"\NT,E'?2X$64";0`U#.4`W`'XG7UKW0[W3H19
M)*BQ+^VNG1?`'Z!>O:(@&@8%V6``_P#KG_X7HD'GGLVB7W!EEOPY_P#A>@!S
MV;1+[@RRWX<__"]`#GLVB7W!EEOPY_\`A>@#UQO#M"9IM_-@+9&:??;[?39Q
M@,VH]$=]ZUWH_P#1$-)[E7JDFM$Y^?[SQSP[0G6:8<!;):S#\,/KY`UF$0W=
M1]:[NAN=Z,4]G%U57ZU?;^-;6^*Z%H7/W/XUUZFOGCVA8:"&`UDM90$)?[\H
M:R@(ZB`?W7=S=[Z-4VM@8HNTF9.7\;Q)I7UV4F']Z6JFJDBVG-F[.432N,WR
M"S3H5BM-6)(SOQ'64TJIR%C%2GT^2G+4"G/-+OM!$(K>JO;G>'=??]^G@B*Q
M7'[5=,<1'2-MO#5_B?=(S]SG;E$2[>V<V/"!0ZB24SJ=%S/3TJB*:A$)$I$3
MQI$,5B]/J%%2Z<I4I2TWA8N`4Z82R;D2M+<E]0=:M<8]*_8;T%X-H1]P)9'H
MZ^SCE`1F#<`?8N]'3O?`BKHK*+>?X[_?U)-07CVA<LP32X#63":73>B&<H!I
MIT-/[KP1"JD^27J;;^;W?Q:21+<[]#]^>S:)?<&66_#G_P"%Z+D&/+B9D9E6
M.13-R;T;/<Q6LPV*!A6NBZ,>,ED.^ER6`U"-&8RHO(I9E3M5:Q:?Z,@EY)C*
MB30CQQ<ZCISSDT\[5E"A,!R7]>ABU]T';'V-7KQ_JA+>Q9]';TN_Z]\3X$`<
MJ8`0`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@#3-T9-S_&_P#AF'_H@"$;
M%I?NE:_8/-9ZXX-JBM7Q:&"ERWM9]O%"%`_66[ME&D\7,V0II%23I"VHJCRF
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M4K?/RXC&47TC,QMU+DM]'--XFTZQTTGTW`KT%@G-U81*T8I5X<?>=IEO=VIF
M[#-DAVBLUR<=4DN3:X\;3-=8GE`O2ZPYL6-Q=9$N6C:TWZKY1#_%YI4-I=M"
MD'$NXF4;OR2L>SFK>#:8CL\K9/%QV)3R=NL#+8(>1MUK;O#+6^RY4=I(O=50
MF04%.2BQ!1J-YM)9V8@;.F9Y#!T);8ZMX.WMD:KDSTK=:M3Q62:^;MQVVTTA
MZK2:.O<X\;=EBA2DFU'%3K5QR5TWJ_!?RGS-OLJ;KY4W;V9-:\-X+99%*&.N
MVUOWC4Q<I[0MLHQK?95,1IX2/MRE+NHC<1UM>:I8X767280C\R`;-H%4X0$"
M=>N$U288[.U'_F,>.U+I/L.[M_MLU5)76VM84;QK#APL^Y<=EEMCT_Y7;ZK5
MU3LYI\UOM*W1.KE#0D#:0;+$S+)(%>F7SE*!6`-Y4`J:L>U#%<M+/+H(EZQ@
MC0J3TQUEFGHR3?%22C%BQ)Q`"`$`(`C*Q5)T!VANU9/U*5*H:KN3#!-FKS2!
M-7!-3\:21TDGC4F#?=2%3ZP<KTZ>N]DJFJLP!OIYA$"30`````#0`Z``&@`'
MO.\@#S`"`$`(`0`@!`"`$`-0[^`&H=_`'C4._"`/,`(`0`@!`"`/`ANZ[FNY
MIN=#W_1UT$?#@#K/NM1'R+3^T#V*?%U?J3XJ?%?4W_4O&O\`DX`[,*`$`(`0
M`@!`"`$`(`0`@!`"`$`(`0`@!`"`$`(`TS=&3_TA_P#<F@".W9+2@.S9PSWP
M`.ED6R(:@&Z(3FQ#O]T-(AU6W3[?ET&VIR0KV5Q>MP?N"\)[/6#9*E>4N=1;
MM.N9@VZ;!VZ)96E,3'TFXJ[42B-9\T566O6&J74ZQD#`33C-+-K-$MMTXMOA
MX=%^P3-^3?K_`!^\_9OVRQP:=O&<B-2UUEFY:&WBF4?UODYN,]@)%M&,KIM8
MV=(O=G$TPB7;#744\PH&*U)2)24:U*:M4GEJ`,\PBR6>)>IM-*(>D=-=H7D*
MKDHKMY1TU_!K;Q2?0]9VV^QBG:\R,^K>6*J,IQOGG7G37:UK=BTU^Y@GJ3FD
MN0!5<)`BJ[ZZY2R*'7C2HH!7"6OTW?Z3Q#JH56O2E"6T)SZ8Z+5Z=1+U7\RA
M^:ZI^.F\[GOJ:/C@1:"_;5?0;)IC(>TJZN.BW2TGL`HU7A3>1\RJN-976J;I
MR(K@HNU3,UC1PR8H593]>I/4JS5)A&8;NV1M7;<TKQJ]955LD^B\$H@B-6UU
M_'2-?DHUZ?`WYK6GLF2;=MD]GVPM:G-*V%3KG9\@VV6T2S<M_,93CR=*IVS+
MI2;33&KU4D*QF@%9*E+[\L9JR:C)4F`85KJ_)-\G6&Y>SW7P<*5MMX$[J'M*
M<=)6S^*\>C.%.4/YQG9:_P#^W?4+;\0"3"`$`(`0!&KBK^<!VJ7_`.L,//Q8
M4&`)*H`0`@!`"`$`8SNR=,I]M;FG2AJL2,DK>/(X6.%ZTQ<P4,%FXHUJ)FA6
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MB7`V:QS+"^][\>,4G/LQ,Q+A(1:[6T1N&UG(UKI6ZS1KL!J*"CDDB.:SE:\B
MNQ&J24)6Y.I%3%2LC)Q:H<I'I"L\\W/DTR=QESQ7*NSPNJB$FWI:(<6M5MV;
M5I<Z-G315KVV''1JUOUW<5U:<I-<:IK^%1%8B%M",$G,G7[?FQK$I9T9F7RM
M];JW&R6SIR/PENXIWJ?&.+WR(OG:C*AY6\QGO4X*Z,O,A3O->VI91OMXVD-X
M\!PXLTE*=1E)&)U"I5FEVYU7<]VJX_\`*6P]N[8ZI+&G96;:K'%.S59TEJS^
M6E*462F+$[6[)YLRMDF;>FU4ZSU54[-0X41MOD![9)WO=;UN#=R^&2=SF'M*
M+/7'V(S+PVL"7O,Z6&3<Z%D(PK!JN1Y))QQ3U]+;5W:%W%JX#LJ/`V=2%>H2
MG2J9268E1H3%ZG1VGO+O.V3K5=_D_P`KW6+N<:2=<?;5IZ+5JT^.GJ<)<9YJ
M(E<-GBO_`(JUG9U_Q].PI?!D_BR9.;]5K2G:7%5>UO4FTTVH?*3"7+1]K&UV
M/K%])DF[%T[P;0//3%=CI:#FM>XQ?/&6V5FDUVRLQ%=>`Q&BE8^H^-:4RFC2
MFZ^FJ!]=-+2MUZJ'9:LQ>E/S]FU;MW9)PUUVUUB/)Z>6T0;]W-E1*$TE,>.W
MS\?]WB7191$991$-!T`1#HZ#IT-0W!B0MC5`D0`@!`"`$`=:?_8_`'980`@!
M`"`$`(`0`@!`"`$`(`0`@!`"`$`(`0`@!`&F;HR=_OAT\'X2:`(XMD6=+'-F
MSAN)6M1,TY+)H5&>N7K4ZU.0V3/*1`^2G&281D-)YXM/1KR#H-.K)-)-I-*(
M0!'G[8R,67(68V=2IDH5;AK&M+VLF+1W('LT3CJPPJ-J)69>>DZ*CY3BI,[U
M6UQDK4Z9FG4IST9]_*%0!D&:6.#!^F?_`/2]E[O]O]#W\)SQ=O;IQF=)5XX\
MEH]HW.G$ZKLNX6+?T3UCUZQU6FFGB0A*[F3'.W,GL0]GU9V[UX=G7M&<\<>F
MCBKC^P%,]:4F^;$V*MR%Z=JZX,7%Z]*DQD9AV7>3@249M%5"<\0;LZFJJ--*
MJR;T):?H7PXLW;]M6[2X=S>UDX;LE6KHG#4U5T[*K>R;>LSSVOAQ)9'J[:1#
M?E*JM=GJU&G6#XLTV[YY!VNV6>`Z_92S*IDGA)G3FKBQZWG/@JH72LW*TFYB
MXY[U8TMB^5:S2HID7?1+634$A+1E1%.&DJHII%$U5Z<5EK2S\KK7N.^H\/+)
M_DZ_XG-;)3U)*71*RG@DXK5UM9IJSCE5M"/9[>[OZ>R?<557UY;53C76UX<:
M1XGVY#$[#Z[FS<V$CH=-HZ5T[K3;4G&W#;(,_>)HBHW$9+=+W2R`EO%A\IF:
ME915"5@[7O.:NE-Q&,FJI6DWBQ*:?>S5)Y([>U5'_D^VRI.U+?X_,ZM\O;<8
MGZLU6TJYU:?:Y8U9WJE/'U65KR67'F<9:7V6D.5"36ZB-9W?285ZZW=OF3:=
MCM*V5MVPBLJW["04MI,IGMPA12V^UVPA$Z2<BH**G%Y9:!),3"%"2C1IR!O9
M*<H2AN!H&7)3$ZF:GE'F1_Y1F*8;2'98E=])TZM1SD,24MV:H-`K8YK4JU?>
MRRCI1HUCE*2:81``GJR!KK,`#)<DW@!`"`$`1GXJ5J/Y0K:J%.F2`;D<^&AV
M8J(@%<"!O&=.*E#P4]=^),R;3#-&G/IO9JI:K*`B,DP`!)A`"`$`(`0`@#U#
MI,N?*F2)NA1,E3A>L5,ES-*0P6,%Z],:5:@8H5`&G6H5J4PRSR3:RS2B("`A
M#\?+Q"TU6C1B=%L!91MSL^=O6>M0@36^:"M;Q@3H5MV@DSL1@+]0C4<#&9LY
M%)HS-AF+TR66ZM2R0T21D2],:E.;>2Z)>OFDGYI;)^,,:?=^;W^_=OJ?/N_%
M?&FX%N&_9A^X\V)?-FFI.1%JVB>5HK?NBV+7ZU4AHI/8TPEEOG&L@];*=2>2
M@)4I2Z5+.(2Z:Z0;YJ-TM_/XO\ON"LL<<94^'C]M387GA;B#<DBRTRXF*N-+
M_2[:)]-'MLFO>PUKW4GVY1BYFB=+)+$)+;8.E6FG%SI>G7DH$)*%(*M.6<`W
MP`(&^?KMJW&_5+9/K'ET&GT+I:?F]97[S[I_8^6.NW*R9+LV:M)=*C;-9*N6
MVM*XEM6<]);=N4A3H4"#@8DKD1U.1HJY*@6IR4C*>!>O3"G*$LX```!Z[[_?
M^(U6A^Z[86S3HN<T;V.>T=JG'>=@IJ@BL6[Z];EHJ]T60BJ4QB8\C,]_**49
M=;;2C_5M;JB@4-TJ=7ILV^EUF$85?%MUE.(^/Q^*T_!AMV25M4MO!?#P/*18
M*RB#<YRWN1+06K1[UO-&*-MXWD2K>-),NL[&X1$N))!<UPR*30=JZD$^I*0T
MBYDW5H2=+ETD#>A"=X&^^OVT,O!N``::;G>=#X,`>8`0`@!`"`/`CIX8!X>F
MOA!N^\@#K/.O25Y-H_:%[(NA4\H/-WXCRC_KGC?^5`'9B0`@!`"`$`(`0`@!
M`"`$`(`0`@!`"`$`(`0`@!`'XUO\33H],ET\/=@"MJA>OCYZ+T_D;>QGUFW.
MS<WLW]=-U@];OZXWLC,<]GK&>L7^]SFWYR>KNR7JO_87LSZY]CF[U?`&7#'N
MB'I7],_)T]*UEUZI[.NE[[=TUZ;\+KKKI#2?,:?G^S_J)?=#_3*'2_R='3.I
MYNIMYV=;_J7^;W_2=-WI&N\UT^%Z'@0>_E.@^/C^W]Q^0>Z'NJ)_S<_5N^DW
MWU<=4[_I4W2M]_UN^Z5OM[K_`(NO>:PZ^</[?"?D',+^4T2^Z'M\.]_)R>/!
MW^][-?+#X77?:?\`SFG_`*\0HUVC[23I.IN7[17_`(WY/#>][KV?::>#$D&Z
M;/7G"]>-=#\H3V8?E*.:0QS?]4]BWK9/6C=G9;KWZRCL+_HG479[UIYP^RK_
M`'@=7=:>J_\`0_6J`)UH`0`@!`$%VT"YSO7<,+\G;V7?E'N:&ESC]+[%?6O>
MM6[,S_8KZ]CLR_F=[V;]>>;CL5_V^ZIZ\](_T'UU@#9)/=%>]DT_)X?$4]=.
MSW37>!KIIN::ZZ:;D`:OVBS]'C]?T`/VBS]'C]?T`/VBS]'C]?T`/VBS]'C]
M?T`/VBS]'C]?T`/VBS]'C]?T`/VBS]'C]?T`/VBS]'C]?T!IU'[19^CQ^OZ'
MY#\Q^T6?H\?K^@!^T6?H\?K^@!^T6?H\?K^@!^T6?H\?K^@!^T6?H\?K^@!^
MT6?H\?K^@!^T6?H\?K^@!^T6?H\?K^@!^T6?H\?K^@#`&1WY;;FZ4_74=AOK
M3^HU7UT/Y.7J#UX',WUL-=E7-MSE_P`[U#ULZ;UU[%O]N.M_3>Q__2728`YV
8_P#@[?\`TP_FQ_\`+_FNO[)?_O*`/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g575431dsp_086.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_086.jpg
M_]C_X1II17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``+<;````G$``MQL```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q,SHP-SHS,"`Q-3HR,3HR-P```Z`!
M``,````!``$``*`"``0````!```!5*`#``0````!```!*@`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$``!DS`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`C`"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]5224;+*ZJW6VN#*V`N>
M]Q`:UH$N<YQ^BUJ2F2RNN1Z_27?G#/9![B:LAKH/\ICMBN?M'I\;OM5,14Z?
M4;&V\^GB.^E]'*L]F/\`Z;_!K/ZO?1?;TTT6,M%?46UV%C@[:]M>0VRM^WZ-
MC'?38DIV4ED9G4NN5=5Q\7'Z;ZN#9:&69?J`^PM#GV>F/YGTG;OYW^>]/TZ_
MYUB)U+J'4,9F`:<5SCDW,KRBUCK_`$6EKK'#906?SEC/LK<E_P"K8_J_:,C]
M%['@2!)&NG@R3PRA&$B8D9!Q1X9PF:_K1A+T.FDN:K^M/6'BI[N@Y+:WQO=[
MY;^D].R*CCMN_FG-?7ZE=.^SU?YK%K^VV6NG=9ZME]2;C9'37X=+:W&ZQVYP
M]3;2YC*[O3IJ=[K+_H>IOK]+^8R/M&)26-VTDDDE*22224I))))2DDDDE*22
M224I)9M^-CGZP8EYJ8;AC9$6EHWB'XK6^_Z7M;==_P!NV+20!N_`KYP$1`@W
MQQXMJX?5*%?\Q__0]&S.O]"P;CCYO4<7%O`!-5U]=;P#]$[+'M<K.17]IQ+*
MZGAOK,(98/</</:_V.9N;_4L9_QBY6W)L^K/4:^G67.ZI^U:_4NMSK-H#JW5
M8C]HP\3+ML^T-R:6;+ZZJ&,QOZ3_`#BZVJJNFME-+&UU5M#*ZV`-:UK1M:QC
M6^UK6M24\DW_`!<8365L^VVD55BMOL9,/JKP,V?;_AL.BIF-_P!Q+_UG]8]1
MZ+_S>Q^CV]/++7W.LZDQS2?8&L&/;C5,=57MJNL915[LBUGJV6;[5U:RNN_S
MW2O_``^S_P`]9"2D^75UA^0QV+?550UWN8YA)<(_/=/^D'^#]/V/5;K74.KX
M5>%]BQOM5EUP9E.:Q[VL8*[+'.#*W!]?J7,KJ98_^:]3_"(V;@]4NRJ[,7J#
ML>D.FVK8QVD!D5.+/^,?^G];](A=9JZ]Z>$SI-LN9:/MCW&MKG5BNS]^FVOW
M9'I>KZ5=;_S*O1_G*V1^:6DAK^D;C_@H$S(F)@8B.TO3Z_\`%<IV3]?K:1:W
M%KJ=934&UM],%M[;6VV/MKNMM]/%R,.QV/<UF1D9%-M'Z#Z:T,6[ZSMVB^AK
MVNSK6N<\U[FX6X_9[?T-K*_6_,V>_P#0_I;/T_Z"W.?T+ZXW4`W=7:+[*JJG
M[2Y@8YEK<K[2UU#::K;=;L.ZJO&P_MF+Z7J6U+0Q.F]?I#9S@6G/NR+6N)LG
M%L<XUX(LO8YWZ+=O:^OT?2]/[)_W:3TM*L_7;U!ZP>!-WJBL8I9_A-GV;>\7
M;-GV?]F?:/?9?]J_:WI4^@IO?]=A]E+*V.?]@9]I:32*_MAKO]?W3ZWJ,R_L
M'I>E^I_9?M_^&^RH;.@?61KI?G^H1ZY>_P"TY#2_?OV.])OZ#%^T-LJK>RME
MM?2_LWK]-]^39Z9']`^L<XFSJA:ZC`9BW6%]KM][:[Z+<AV/O;78ZVS(HR_M
M3W_::[,"NG^;R[O22F&-7]?'OC*L94T6X@!J]%TL9LJZL3ZC/H9/Z3*Q?;ZO
MYGZ#^:O)5=];W6YSC635LRF88+:FP\7/;T^SWNK>_P#5V_I-_P"@LI^Q?X?[
M9Z<,7ZL]=8\NRNK67CU,1S=MM[`&8NVJX;1<=W[1HWOR6/=Z?VG_`+D?SE),
M7I'7VY67=;E^I3<,JJNKU[6P+KK+,=S/3WLH?BT[?3MK9]H_6+,;^9P\5)2V
M+;]=&8^4Y]0LR15BC&;D>B*S83^OO_4[66?HZ',]6NSV?;*[OL=OV7TD(]1^
MN%^0[I[\7[+9Z;#]KHKE@?NMNMVW9#KL;8ZBFC#]'9;;]HRO6]E52M?LWZU>
MG@&KJC*SC8]+,JG:VQM]S`[[0]V1?4_(V9'Z)N]KF/\`YW_"*C1T[ZX.QF95
MV8UG6::2T4.L:YEHV6^ZRNJNK&JW9N0W_`6?J^#C4?:=]U^0DIL]/ZE]:;^J
MU8V=B?9Z:;*V7N8PECVNQK[<BT9+B]CJVY_V6JCTO3L_T_\`.>A1TJROJ[C]
M5HQKCU2SU+[;6O`+Q9M`IQZKF^QE-5>_+JR;O3HK]+]*M5)2DDDDE-&[_EK%
M_P#"V3_Y\PE>5&[_`):Q?_"V3_Y\PE>0&\O/]C)D^7%_</\`Z4R/_]'H_KE?
M53U_I(?:['<ZNW;=7<W'>8MQ"ZAUE^=TZFZFW\^AGKY'Z*O]'Z:[)<Q]8LGI
M^!G$9/5^H8'VRMUEE>/L?4UM3=ILW78^59A^JUNUGV6RGU;?^%WV+I*:FTTL
MI:7.;6T,!>YSW$-&V7VV%UEC_P!ZRQV]Z2F:R>NB;^DF2(SV&!P9JR6^_P#S
MM_\`76LLKKO\]TK_`,/L_P#/60DI%U;ZI]-ZKU#&ZAD6Y3+L1_J,;5>]K)AC
M=&2[[/\`S3?Z']FW_P"$1.L=)SLNK!JP,MV,S$M#[=S[2Y[&UOJ8U]M=U=UK
MFV.KM_36/]5[/T_J?S=NLDI)YLDXPA*9E'&*A$G2`\$4/M>4=]176T!N3U2^
MZYU-6/=8\!\UU6MS6FOU39=Z]63ZKL6W(ORO19;Z=E5ZT,7ZMG&#=F98R,^W
MJ#VUS6QQN<7NQ'L8_P!^-M?NVVNL_6?TO\S^JK;24:7EF?4:ICP\9+7.;ZY#
M[*&N>XV^IM=DW;Q;<]_KOKZB]CJ7]3HKQJK_`.9_33?]1\=QQ(R[&?8\!G3F
MO:QGJ%K*[\7>+7!VUME.9=ZM&S8_(JPKO^TWZ7IDDE/,8GU"Z;C/+S<Z\^IB
M6`VLJ,#!VUX;:XK:VO\`5F?9[WL_G?\`@OSY5?4YK;\VZS(;8<YF52YCJR6F
MO+NLR;*[',LJO=6UCJV-J9=5LM^UY%?Z3,_1=*DDIP#]5K=N%LZIEU.P**J*
MQ6\UU.-6Z++L6AU5-GJ37ZE?^BI])4Z/J=U%N"QUO4G_`+7IK].C,87D@>G;
M6&7V7667W-^T9>3E?3IK]7[+^@]##JH75I)*<OZO](OZ7C7,R+AD79%C;7O&
M[EM./B&7W/MMM>_[+ZK[;'_X1:B222G-HQ\=OU@S+VU,%SL;'FP-&XR_*:Z7
M_2]S::?^VJ_W%I*C3_RUE_\`A;&_\^9J5]^;?DT5]/-?V8/)S,DD/@5NVOQ*
MZFG^?M=['V._H_Z3_"IH(`^IV_O,^2,IS%D`#'C]4SZ8B.*,O_18N>>JG(^M
M=&)BT^O111?5D932=K+":;+*OH['OI]+'98QC_\`M5_P2WEFMQ\?%ZIA48U;
M::68N5MK8`UHFS#<8:W^4M)"%^JS>O[$\R8$8O;CPQ&.M3<I?K,GKE_>?__2
MZCZX-O?UCI,5%]->ZQMGI!VRYMF-Z3F7LZ=UBZE^W?\`FX5?^$^U?HETV:RR
MS#OKJ&ZQ];VL;ZCJ9<6D-;]HI_38_P#QU7Z6K^<K7'?78F_JF-C9==%--9:^
MK)D.N%?J8_JY3KOV=F_LBJB[]%]HLR&47?\`!_X/N$E/%'H7UW:UC*\]SFMK
MJ8YUF0\/<[TJZ6.=LK]KNGYS+\ZW;_RM1=]ES;+O21Z\#K6+;A'J>2;=_56N
M:S>;=P^SVUNM%EC6?9679#7Y5>%3^AQ?Z.NN65UW^>Z5_P"'V?\`GK(24ZJ2
M222E))))*4DDDDI22222E))))*:^;FX^#3Z^07"O<&RQC[#+M&^VAEC_`*2.
MUP<T.$P1(D$'_-<J/6_^3W?\93_Y^J39>4W)NNZ3BVOJR_2WV7UM#A0'$"OU
M'$MVW7-W^@SZ?L]5-,J)'@*\V:.(2A&0L'BE[DMX0QP]OUU&/^L:(RLG(^M&
M9T\8[V8_V6MM^42YDM_3&O[,^MOML?9E/;O]7_M-?L_FUL8N+CX>/7BXM8JH
MJ&UC&\`?Z_25+I^+3A]1NQ<=NRFG$Q6L;),`/S>Y6FA`:$G>S]-?E7\U,&48
M0L0$,??]9(8_YV<;EZ_4T;O^6L7_`,+9/_GS"5Y4;O\`EK%_\+9/_GS"5Y.&
M\O/]C%D^7%_</_I3(__3Z?K_`$_J74.OUMQ\/[?CT.I-@S&-JQF-D76,HS:+
MJ<O(:]U5-MV-?@=6Q?M-='\SZ:ZY<M]:\OJ.'U3I]V%]L#7->RT8Y!98"^K]
M6KHLP^H4OSO\)4^]^!^@]?\`6MGK68_4I*4LGKN[U^D1&W[>S=,S'HY,;/[>
MS^PM9977?Y[I7_A]G_GK(24ZJ2222E))))*4DDDDI22222E))(&;F4X6+9E7
MSZ=3=S@T2X]@UK?WG.2)K4IC$R(C$7*1H`=27,^M>5E4=,VX5+<G)?966U%T
M$-;97^E],%MEK&W.HJ?L^AZ^]:>%2^K'9ZY#\IS&?:+@UK2]X:&N>X5^U9.;
MAM.*_JE]1JSLD8K+&.<+/2:VVIWV>I\-VLWG?;L_G+%NID;,R3V%#_&;.4QC
MR^/'$#2<^.?64^'%Z>+BGZ(?U?YQHT_\M9?_`(6QO_/F:KRJUX=C.HVYIN+F
MW5LJ]':T`"LN<P[_`*?TK;_^W%:3H[?4L.4@R!!OTP'UC",9!K/P*7YU><76
M>M4TL:`]P9M=].:9]-V[V?F_X*K]Q655L:?VE2=[P#582P..TEIJ:TEGT?\`
M#/5I(==*U6RE(B-DFA4;_1C^Z__4Z+ZZ"AO7>DVY.QU/IV,#'MHL][K\+8_T
M>HV,I;[0]GKX[?M2ZW+?97B765$-L96YS"6.L`<`2TNHIBZ[W?X*K])9^8N=
MZITSKW4NJ9#+<>C(Z5795]G;=E7T!S-E3\EMF)@BRC.K]=KMGV__`(2O^874
M)*>+?]9OK@`R.FZNJI<_]6O]MCL>G(]/;OW.^V9]F1TW_P`U/V?[3G>I7:K#
M>H]8SK\+]H8HHKKZHUK7;7U.'ZO8_P!$5W;_`+9Z%[K<9^?4^G'R/Y_'J76+
M*Z[_`#W2O_#[/_/60DIU4DDDE*22224I))))2DDDDE-#J;LIMF&,>]U(MO%=
M@:UKMS2U]A_G&NV_S7TDV,;<W,;U"O(#NG>E&-763#W./Z6Z]K@WZ&QC<?\`
MZXLKZQT]0ZGF8V#63C8#;F,OL?(]<V-<YU5/I>_TF4>M7=^DJWOM]-=&QC*V
M-KK:&,8`UK6B``-`UH"C'JE+>@1]K;R`8L&(W$Y,D96`(^C'*7Z<O\Y/_P`:
MA_S*W5,._-Q3CTW#'<7-<;"SU/H$6-&PN9^>UBM-G:-QET:D:"?AJG23ZUMK
M&9,1#3AB3(:#>7S>K_!0MR:W9+\8!WJ,:'.):0V#]&+/H?\`G",JN]E>;D66
M.#&-HJ+GN,``.R)+G%"^WWY.G3JO48?^U5LLI_K5C^=R?^M_H+/^Y2;Q@;[V
M:`WW5PWMM0U*:PC]HTB=?1MT_M4?W*RLRK!#.J4Y&0_[1E>C;%I:&AH#J?93
M6WZ#/TEGT_4N]_\`/+32@2>*Q6O_`'(5*M*-Z/\`_]7U5))))2EE==_G^DB.
M<]FO8?HL@Z_]2M5977?Y[I7_`(?9_P">LA)3JI)))*4DDDDI22A;;734^ZUP
MKKK!<][C``&KG.*HLZQ5F47.Z/MSK:75M/N+*ILVG^D['L=Z-3O5M93ZMO\`
M@_YQ`R`W/TZKX8IS%QB>$$`SVQQXO2./)\D/\)OV.V5N<7!@:"=[OHB!])VK
M?:L#I6:_ZS8.13>[=B!X8[(QPZ@60=UF+Z=C[LAM;JO2]:W?5ZGK^@S^;]1:
M#^F/ROLV1U!^_)QVAWHU%S<?U@6V,N]'=NM=4YOZ+U;%2Z%FXV/T]N/C-^U6
M;WD5XU361N=O_2;+K<6CZ7Z/U<BK]$HY2]0$M(D'3][Z-G'[<,,S$\6<2AP2
MJHXN$SXIPG_@P_<;74Z+&?L^O$`KKIN;M8RMK@`UI8ROW7XWI5^D;/H>I_Y/
M46-G,R[GXIS+VX+3</3KI?[YAWT[K-E=G_%?9_\`KEBN_LUKB3;D9%I/_"NK
M_#%]!J49'BE4>VYX>G9@F28P$I?+>PU]4OWOTUNK_9_L1.06AF]FKS`^FT?2
MT_-W*/[0?D#9TRH7-X^TN]N./ZC_`*63_P"@_P"B_P"[%*%F]+Z?7CNL-0<[
M=7+[2;#]-GYUSGK42`D9FZCH/EUE^E^DMN(B-SJ=]G)Q^ET'J=UV7&5D"NI^
M]S0&AQ=:W]%3[MNSTF;'/]6[_A5K*LP6_M"UQK(J=6QK;);!+#8YWMW>I_AO
MW?S%93L<1$&A6I^NJ)DDBS>@:[_^4*?^)M_ZK'5A".-0Z]N0:VFY@VMLCW`:
M^T._M(J<`=?$H)V\G__6]522224I<=D?6S"ZB,"[T,BL5=09M#*GY!=6:'WT
MV_J+<CTWVTY%?ZL_]89^D_1_HUV*P^LV9W3'8HZ-AL+<G)+\GTZ2_<][F[_5
M]'9]F^T-?=;;U.[U*J/1_3?SZ2DQ^LW3&ZNJS@)`D]/S1J3M;_VD_>2/UFZ:
MT2ZK.`T&O3\WDG:/^TBUDDE.2[ZS],:TN=5G!H$DGI^;`'_L(D[ZS=-:TN=5
MG-:T$DGI^;``Y_[2+6224X74/K#TFS`R&78N;?6:W;ZGX.96UPCZ+KK<6NNG
M_C7O_1_SB!@=7KKP:L?IN([%Q:P6L<VC(R6:%V[TOLU7IW-<[_#.REJ=:S,K
M#Q*[L:MUKCD4,M8VJR]WHOM97E.;7C^]OI8[K+?4]_T/H('U<S.KY5&2>JT"
MA]=VVH"MU7MV5OLJVV.?Z[<:]]N.S,K_`$.9Z7K5)DH$D$2K2CIO_A?,GCR"
M/`"."^+A/%(<>W%P\7!_S&LW-P+ZQ;DGJ&:UP#FAV)D-J(^D/U>JBJNQG_AC
MU4W1?K!@NP1Z=&9L#G0!BN<!/Z0C=T]N1C?2?^^NA20&,@V"/.CQ?;Q+"<IT
MXQP]N'[*]3AY7UKZ92:0<;+L]6PU`_9WLAP<*W_TH4.MVO\`\'C^M=_P:M-Z
M_A.G;5EG:2TQAY.A';^86DHV.VL<X=@3P7<?R&^Y_P#5:G5+N/L_/U(K)KZA
M73T_^A.%U+ZT]%KQ['78]^4*;!7;4<=S=KRSU@U[LYN-0Q_HV,?M=;ZFRU7&
M=>P#[659?M`EHP\G21+?\`LKH75OK'E9N)7FXY%%M+K+W.Q;<<CW7-KNM?>]
MS*LIK:\7'NZ=^E_G;<O'R;L-E:ZA*I=X^=:_])59-?4*Z>GKU_2<1GULPGY]
MN",;+W5-W;Q0\DZ5N_HS`[,K_GOIW8U=?_@7J%=]8\0.VC%SG.`G:,2^8XG6
MI:R2(XNIC]`?^_4!DZR'TC7_`'3SS_KECLZE5A/P<QK+6[C8:+-X,6'3"8Q^
M9;7^B_GJZ?3_`.FM#$Z]T[+RFXE?KUWV-<^MN1C9&/N#-OJ>F_,HH98YF]OL
M9[UHKENN=6^LV/G9E72\4Y%5(H--CL:QP#W,R++,</W5?:&Y%U.#C/R,??5@
M?:[;LNRK[,C9.X`_NW_W4IIB)"^(@ZZ4.'1__]?U5))))2DDDDE*22224I))
M))2E0ZOUC&Z3539>U]C\JYN-CU5[0Y]KPYS*VNO?33NV5O\`IV_I/YJK?<^J
MI7UB?6_[#^R'?M'[3]AW'[5]EV_S.RS[1]J]3V_9O1W_`$/UKU/2^Q?K?HI*
M;=/7^C7N<VO+KW-M?CEKCM/J5VUX5C-K]O\`VJR**?\`KU2KXOULZ#E69+:\
MJOT\5S6F\O9Z5FX4>[&L:]WK-8_,QJ'_`/#75?Z2M8-W_-G]HT>K]N_Y1R/2
MF/1W_:L'[3.[])^SOV[]E_\`0SU_^T:HXG_-K?T?[%]H^S_M.B?M/\YL^R_Y
M)]*/^T/_`"+]/_NE]J_6TE/7/^LW3JNJ6=-N%E/I/%+LI[0,?UC4,X8WK;MS
M;?LCO6]]?H_X/U?5_1JQC=<Z1E.8W'RZK'V$-8P.]VXBXAAK^FVS]4RO8[_N
M/=_HUSN?_P`W?^<.9]I^W^MNU]/?Z'VS['[?L?V?]-^U?V3_`$?_`-E_USTU
M6^K_`.P?V]TC[']'[)G>CZVWU_7^TN]7U?1_5O\`RU^R>A[/2^W;/T:2GN4D
MDDE*22224I))))3_`/_9_^TB@E!H;W1O<VAO<"`S+C``.$))300$```````/
M'`%:``,;)4<<`@```@```#A"24T$)0``````$,W/^GVHQ[X)!7!VKJ\%PTXX
M0DE-!#H``````.4````0`````0``````"W!R:6YT3W5T<'5T````!0````!0
M<W138F]O;`$`````26YT965N=6T`````26YT90````!#;')M````#W!R:6YT
M4VEX=&5E;D)I=&)O;VP`````"W!R:6YT97).86UE5$585`````$```````]P
M<FEN=%!R;V]F4V5T=7!/8FIC````#`!0`'(`;P!O`&8`(`!3`&4`=`!U`'``
M``````IP<F]O9E-E='5P`````0````!";'1N96YU;0````QB=6EL=&EN4')O
M;V8````)<')O;V9#35E+`#A"24T$.P`````"+0```!`````!```````2<')I
M;G1/=71P=71/<'1I;VYS````%P````!#<'1N8F]O;```````0VQB<F)O;VP`
M`````%)G<TUB;V]L``````!#<FY#8F]O;```````0VYT0V)O;VP``````$QB
M;'-B;V]L``````!.9W1V8F]O;```````16UL1&)O;VP``````$EN=')B;V]L
M``````!"8VMG3V)J8P````$```````!21T)#`````P````!29"`@9&]U8D!O
MX````````````$=R;B!D;W5B0&_@````````````0FP@(&1O=6)`;^``````
M``````!"<F1456YT1B-2;'0```````````````!";&0@56YT1B-2;'0`````
M``````````!2<VQT56YT1B-0>&Q`<L````````````IV96-T;W)$871A8F]O
M;`$`````4&=0<V5N=6T`````4&=0<P````!09U!#`````$QE9G15;G1&(U)L
M=````````````````%1O<"!5;G1&(U)L=````````````````%-C;"!5;G1&
M(U!R8T!9````````````$&-R;W!7:&5N4')I;G1I;F=B;V]L``````YC<F]P
M4F5C=$)O='1O;6QO;F<`````````#&-R;W!296-T3&5F=&QO;F<`````````
M#6-R;W!296-T4FEG:'1L;VYG``````````MC<F]P4F5C=%1O<&QO;F<`````
M`#A"24T#[0``````$`$L`````0`"`2P````!``(X0DE-!"8```````X`````
M````````/X```#A"24T$#0``````!````'@X0DE-!!D```````0````>.$))
M30/S```````)```````````!`#A"24TG$```````"@`!``````````(X0DE-
M`_4``````$@`+V9F``$`;&9F``8```````$`+V9F``$`H9F:``8```````$`
M,@````$`6@````8```````$`-0````$`+0````8```````$X0DE-`_@`````
M`'```/____________________________\#Z`````#_________________
M____________`^@`````_____________________________P/H`````/__
M__________________________\#Z```.$))300(```````0`````0```D``
M``)``````#A"24T$'@``````!``````X0DE-!!H``````XD````&````````
M``````$J```!5````"H`30!A`&,`<@!O`$<`90!N`&D`8P!S`"``1@!O`'(`
M;0`@`%,`+0`Q`%\`7P!%`$$`4P!4`%\`-@`R`#<`-``P`#8`-``U`%\`,0`Q
M`%\`+0`X`#8````!``````````````````````````$``````````````50`
M``$J``````````````````````$`````````````````````````$`````$`
M``````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``$J`````%)G:'1L;VYG```!5`````9S;&EC97-6;$QS`````4]B:F,````!
M```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$
M;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T
M;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R``
M```&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``
M````````3&5F=&QO;F<``````````$)T;VUL;VYG```!*@````!29VAT;&]N
M9P```50````#=7)L5$585`````$```````!N=6QL5$585`````$```````!-
M<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q497AT
M27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG
M;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L
M:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O
M;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET
M;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T
M=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-
M!"@```````P````"/_`````````X0DE-!!0```````0````".$))300,````
M`!E/`````0```*````",```!X``!!H```!DS`!@``?_8_^T`#$%D;V)E7T--
M``'_[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+
M"PT.#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`S_P``1"`",`*`#`2(``A$!`Q$!_]T`!``*_\0!
M/P```04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0``````
M```!``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3
M(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T
M-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=7
M9W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!
MD12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T
M9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7
MI[?'_]H`#`,!``(1`Q$`/P#U5))1LLKJK=;:X,K8"Y[W$!K6@2YSG'Z+6I*9
M+*ZY'K])=^<,]D'N)JR&N@_RF.V*Y^T>GQN^U4Q%3I]1L;;SZ>([Z7T<JSV8
M_P#IO\&L_J]]%]O3318RT5]1;786.#MKVUY#;*W[?HV,=]-B2G9261F=2ZY5
MU7'Q<?IOJX-EH99E^H#["T.?9Z8_F?2=N_G?Y[T_3K_G6(G4NH=0QF8!IQ7.
M.3<RO*+6.O\`1:6NL<-E!9_.6,^RMR7_`*MC^K]HR/T7L>!($D:Z>#)/#*$8
M2)B1D'%'AG"9K^M&$O0Z:2YJOZT]8>*GNZ#DMK?&]WOEOZ3T[(J..V[^:<U]
M?J5T[[/5_FL6O[;9:Z=UGJV7U)N-D=-?ATMK<;K';G#U-M+F,KN].FIWNLO^
MAZF^OTOYC(^T8E)8W;22224I))))2DDDDE*22224I))))2DEFWXV.?K!B7FI
MAN&-D1:6C>(?BM;[_I>UMUW_`&[8M)`&[\"OG`1$"#?''BVKA]4H5_S'_]#T
M;,Z_T+!N./F]1Q<6\`$U77UUO`/T3LL>URLY%?VG$LKJ>&^LPAE@]P]P]K_8
MYFYO]2QG_&+E;<FSZL]1KZ=9<[JG[5K]2ZW.LV@.K=5B/VC#Q,NVS[0W)I9L
MOKJH8S&_I/\`.+K:JJZ:V4TL;756T,KK8`UK6M&UK&-;[6M:U)3R3?\`%QA-
M96S[;:156*V^QDP^JO`S9]O^&PZ*F8W_`'$O_6?UCU'HO_-['Z/;T\LM?<ZS
MJ3'-)]@:P8]N-4QU5>VJZQE%7NR+6>K99OM75K*Z[_/=*_\`#[/_`#UD)*3Y
M=76'Y#'8M]55#7>YCF$EPC\]T_Z0?X/T_8]5NM=0ZOA5X7V+&^U677!F4YK'
MO:Q@KLL<X,K<'U^I<RNIEC_YKU/\(C9N#U2[*KLQ>H.QZ0Z;:MC':0&14XL_
MXQ_Z?UOTB%UFKKWIX3.DVRYEH^V/<:VN=6*[/WZ;:_=D>EZOI5UO_,J]'^<K
M9'YI:2&OZ1N/^"@3,B8F!B([2]/K_P`5RG9/U^MI%K<6NIUE-0;6WTP6WMM;
M;8^VNZVWT\7(P['8]S69&1D4VT?H/IK0Q;OK.W:+Z&O:[.M:YSS7N;A;C]GM
M_0VLK];\S9[_`-#^EL_3_H+<Y_0OKC=0#=U=HOLJJJ?M+F!CF6MROM+74-IJ
MMMUNP[JJ\;#^V8OI>I;4M#$Z;U^D-G.!:<^[(M:XFR<6QSC7@BR]CG?HMV]K
MZ_1]+T_LG_=I/2TJS]=O4'K!X$W>J*QBEG^$V?9M[Q=LV?9_V9]H]]E_VK]K
M>E3Z"F]_UV'V4LK8Y_V!GVEI-(K^V&N_U_=/K>HS+^P>EZ7ZG]E^W_X;[*AL
MZ!]9&NE^?ZA'KE[_`+3D-+]^_8[TF_H,7[0VRJM[*V6U]+^S>OTWWY-GID?T
M#ZQSB;.J%KJ,!F+=87VNWWMKOHMR'8^]M=CK;,BC+^U/?]IKLP*Z?YO+N])*
M88U?U\>^,JQE31;B`&KT72QFRKJQ/J,^AD_I,K%]OJ_F?H/YJ\E5WUO=;G.-
M9-6S*9A@MJ;#Q<]O3[/>ZM[_`-7;^DW_`*"RG[%_A_MGIPQ?JSUUCR[*ZM9>
M/4Q'-VVWL`9B[:KAM%QW?M&C>_)8]WI_:?\`N1_.4DQ>D=?;E9=UN7ZE-PRJ
MJZO7M;`NNLLQW,]/>RA^+3M].VMGVC]8LQOYG#Q4E+8MOUT9CY3GU"S)%6*,
M9N1Z(K-A/Z^_]3M99^CH<SU:[/9]LKN^QV_9?20CU'ZX7Y#NGOQ?LMGIL/VN
MBN6!^ZVZW;=D.NQMCJ*:,/T=EMOVC*];V55*U^S?K5Z>`:NJ,K.-CTLRJ=K;
M&WW,#OM#W9%]3\C9D?HF[VN8_P#G?\(J-'3OK@[&9E79C6=9II+10ZQKF6C9
M;[K*ZJZL:K=FY#?\!9^KX.-1]IWW7Y"2FST_J7UIOZK5C9V)]GIILK9>YC"6
M/:[&OMR+1DN+V.K;G_9:J/2].S_3_P`YZ%'2K*^KN/U6C&N/5+/4OMM:\`O%
MFT"G'JN;[&4U5[\NK)N].BOTOTJU4E*22224T;O^6L7_`,+9/_GS"5Y4;O\`
MEK%_\+9/_GS"5Y`;R\_V,F3Y<7]P_P#I3(__T>C^N5]5/7^DA]KL=SJ[=MU=
MS<=YBW$+J'67YW3J;J;?SZ&>OD?HJ_T?IKLES'UBR>GX&<1D]7ZA@?;*W665
MX^Q]36U-VFS==CY5F'ZK6[6?9;*?5M_X7?8NDIJ;32REI<YM;0P%[G/<0T;9
M?;8766/_`'K+';WI*9K)ZZ)OZ29(C/88'!FK);[_`/.W_P!=:RRNN_SW2O\`
MP^S_`,]9"2D75OJGTWJO4,;J&1;E,NQ'^HQM5[VLF&-T9+OL_P#--_H?V;?_
M`(1$ZQTG.RZL&K`RW8S,2T/MW/M+GL;6^IC7VUW5W6N;8ZNW]-8_U7L_3^I_
M-VZR2DGFR3C"$IF4<8J$2=(#P10^UY1WU%=;0&Y/5+[KG4U8]UCP'S75:W-:
M:_5-EWKU9/JNQ;<B_*]%EOIV57K0Q?JV<8-V9EC(S[>H/;7-;'&YQ>[$>QC_
M`'XVU^[;:ZS]9_2_S/ZJMM)1I>69]1JF/#QDM<YOKD/LH:Y[C;ZFUV3=O%MS
MW^N^OJ+V.I?U.BO&JO\`YG]--_U'QW'$C+L9]CP&=.:]K&>H6LKOQ=XM<';6
MV4YEWJT;-C\BK"N_[3?I>F224\QB?4+IN,\O-SKSZF)8#:RHP,';7AMKBMK:
M_P!69]GO>S^=_P""_/E5]3FMOS;K,AMASF95+F.K)::\NZS)LKL<RRJ]U;6.
MK8VIEU6RW[7D5_I,S]%TJ22G`/U6MVX6SJF74[`HJHK%;S74XU;HLNQ:'54V
M>I-?J5_Z*GTE3H^IW46X+'6]2?\`M>FOTZ,QA>2!Z=M89?9=99?<W[1EY.5]
M.FOU?LOZ#T,.JA=6DDIR_J_TB_I>-<S(N&1=D6-M>\;N6TX^(9?<^VVU[_LO
MJOML?_A%J)))*<VC'QV_6#,O;4P7.QL>;`T;C+\IKI?]+W-II_[:K_<6DJ-/
M_+67_P"%L;_SYFI7WYM^317T\U_9@\G,R20^!6[:_$KJ:?Y^UWL?8[^C_I/\
M*F@@#ZG;^\SY(RG,60`,>/U3/IB(XHR_]%BYYZJ<CZUT8F+3Z]%%%]61E-)V
MLL)ILLJ^CL>^GTL=EC&/_P"U7_!+>6:W'Q\7JF%1C5MII9BY6VM@#6B;,-QA
MK?Y2TD(7ZK-Z_L3S)@1B]N/#$8ZU-RE^LR>N7]Y__]+J/K@V]_6.DQ47TU[K
M&V>D';+FV8WI.9>SIW6+J7[=_P";A5_X3[5^B739K++,.^NH;K'UO:QOJ.IE
MQ:0UOVBG]-C_`/'5?I:OYRM<=]=B;^J8V-EUT4TUEKZLF0ZX5^IC^KE.N_9V
M;^R*J+OT7VBS(91=_P`'_@^X24\4>A?7=K6,KSW.:VNICG69#P]SO2KI8YVR
MOVNZ?G,OSK=O_*U%WV7-LN])'KP.M8MN$>IY)MW]5:YK-YMW#[/;6ZT66-9]
ME9=D-?E5X5/Z'%_HZZY977?Y[I7_`(?9_P">LA)3JI)))*4DDDDI22222E))
M))*4DDDDIKYN;CX-/KY!<*]P;+&/L,NT;[:&6/\`I([7!S0X3!$B00?\URH]
M;_Y/=_QE/_GZI-EY3<FZ[I.+:^K+]+?9?6T.%`<0*_4<2W;=<W?Z#/I^SU4T
MRHD>`KS9HXA*$9"P>*7N2WA#'#V_748_ZQHC*R<CZT9G3QCO9C_9:VWY1+F2
MW],:_LSZV^VQ]F4]N_U?^TU^S^;6QBXN/AX]>+BUBJBH;6,;P!_K])4NGXM.
M'U&[%QV[*:<3%:QLDP`_-[E::$!H2=[/TU^5?S4P91A"Q`0Q]_UDAC_G9QN7
MK]31N_Y:Q?\`PMD_^?,)7E1N_P"6L7_PMD_^?,)7DX;R\_V,63Y<7]P_^E,C
M_]/I^O\`3^I=0Z_6W'P_M^/0ZDV#,8VK&8V1=8RC-HNIR\AKW54VW8U^!U;%
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MXN*?HA_5_G&C3_RUE_\`A;&_\^9JO*K7AV,ZC;FFXN;=6RKT=K0`*RYS#O\`
MI_2MO_[<5I.CM]2PY2#($&_3`?6,(QD&L_`I?G5YQ=9ZU32QH#W!FUWTYIGT
MW;O9^;_@JOW%956QI_:5)WO`-5A+`X[26FIK26?1_P`,]6DAUTK5;*4B(V2:
M%1O]&/[K_]3HOKH*&]=Z3;D['4^G8P,>VBSWNOPMC_1ZC8REOM#V>OCM^U+K
M<M]E>)=940VQE;G,)8ZP!P!+2ZBF+KO=_@JOTEGYBYWJG3.O=2ZID,MQZ,CI
M5=E7V=MV5?0',V5/R6V8F"+*,ZOUVNV?;_\`A*_YA=0DIXM_UF^N`#(Z;JZJ
MES_U:_VV.QZ<CT]N_<[[9GV9'3?_`#4_9_M.=ZE=JL-ZCUC.OPOVABBBNOJC
M6M=M?4X?J]C_`$17=O\`MGH7NMQGY]3Z<?(_G\>I=8LKKO\`/=*_\/L_\]9"
M2G522224I))))2DDDDE*22224T.INRFV88Q[W4BV\5V!K6NW-+7V'^<:[;_-
M?238QMS<QO4*\@.Z=Z48U=9,/<X_I;KVN#?H;&-Q_P#KBROK'3U#J>9C8-9.
M-@-N8R^Q\CUS8USG54^E[_291ZU=WZ2K>^WTUT;&,K8VNMH8Q@#6M:(``T#6
M@*,>J4MZ!'VMO(!BP8C<3DR1E8`CZ,<I?IR_SD__`!J'_,K=4P[\W%./3<,=
MQ<UQL+/4^@18T;"YGY[6*TV=HW&71J1H)^&J=)/K6VL9DQ$-.&),AH-Y?-ZO
M\%"W)K=DOQ@'>HQH<XEI#8/T8L^A_P"<(RJ[V5YN198X,8VBHN>XP``[(DN<
M4+[??DZ=.J]1A_[56RRG^M6/YW)_ZW^@L_[E)O&!OO9H#?=7#>VU#4IK"/VC
M2)U]&W3^U1_<K*S*L$,ZI3D9#_M&5Z-L6EH:&@.I]E-;?H,_26?3]2[W_P`\
MM-*!)XK%:_\`<A4JTHWH_P#_U?54DDDE*65UW^?Z2(YSV:]A^BR#K_U*U5E=
M=_GNE?\`A]G_`)ZR$E.JDDDDI22222E)*%MM=-3[K7"NNL%SWN,``:N<XJBS
MK%691<[H^W.MI=6T^XLJFS:?Z3L>QWHU.]6UE/JV_P"#_G$#(#<_3JOABG,7
M&)X00#/;''B](X\GR0_PF_8[96YQ<&!H)WN^B('TG:M]JP.E9K_K-@Y%-[MV
M('ACLC'#J!9!W68OIV/NR&UNJ]+UK=]7J>OZ#/YOU%H/Z8_*^S9'4'[\G':'
M>C47-Q_6!;8R[T=VZUU3F_HO5L5+H6;C8_3VX^,W[59O>17C5-9&YV_])LNM
MQ:/I?H_5R*OT2CE+U`2TB0=/WOHV<?MPPS,3Q9Q*'!*JCBX3/BG"?^##]QM=
M3HL9^SZ\0"NNFYNUC*VN`#6EC*_=?C>E7Z1L^AZG_D]18V<S+N?BG,O;@M-P
M].NE_OF'?3NLV5V?\5]G_P"N6*[^S6N)-N1D6D_\*ZO\,7T&I1D>*51[;GAZ
M=F"9)C`2E\M[#7U2_>_36ZO]G^Q$Y!:&;V:O,#Z;1]+3\W<H_M!^0-G3*A<W
MC[2[VXX_J/\`I9/_`*#_`*+_`+L4H6;TOI]>.ZPU!SMU<OM)L/TV?G7.>M1(
M"1F;J.@^767Z7Z2VXB(W.IWV<G'Z70>IW79<960*ZG[W-`:'%UK?T5/NV[/2
M9L<_U;O^%6LJS!;^T+7&LBIU;&MLEL$L-CG>W=ZG^&_=_,5E.QQ$0:%:GZZH
MF22+-Z!KO_Y0I_XFW_JL=6$(XU#KVY!K:;F#:VR/<!K[0[^TBIP!U\2@G;R?
M_];U5))))2EQV1];,+J(P+O0R*Q5U!FT,J?D%U9H??3;^HMR/3?;3D5_JS_U
MAGZ3]'^C78K#ZS9G=,=BCHV&PMR<DOR?3I+]SWN;O]7T=GV;[0U]UMO4[O4J
MH]']-_/I*3'ZS=,;JZK.`D"3T_-&I.UO_:3]Y(_6;IK1+JLX#0:]/S>2=H_[
M2+6224Y+OK/TQK2YU6<&@22>GYL`?^PB3OK-TUK2YU6<UK022>GYL`#G_M(M
M9))3A=0^L/2;,#(9=BYM]9K=OJ?@YE;7"/HNNMQ:ZZ?^->_]'_.(&!U>NO!J
MQ^FXCL7%K!:QS:,C)9H7;O2^S5>G<USO\,[*6IUK,RL/$KNQJW6N.10RUC:K
M+W>B^UE>4YM>/[V^ECNLM]3W_0^@@?5S,ZOE49)ZK0*'UW;:@*W5>W96^RK;
M8Y_KMQKWVX[,RO\`0YGI>M4F2@201*M*.F_^%\R>/((\`(X+XN$\4AQ[<7#Q
M<'_,:S<W`OK%N2>H9K7`.:'8F0VHCZ0_5ZJ*J[&?^&/53=%^L&"[!'IT9FP.
M=`&*YP$_I"-W3VY&-])_[ZZ%)`8R#8(\Z/%]O$L)RG3C'#VX?LKU.'E?6OIE
M)I!QLNSU;#4#]G>R'!PK?_2A0ZW:_P#P>/ZUW_!JTWK^$Z=M66=I+3&'DZ$=
MOYA:2C8[:QSAV!/!=Q_(;[G_`-5J=4NX^S\_4BLFOJ%=/3_Z$X74OK3T6O'L
M==CWY0IL%=M1QW-VO+/6#7NSFXU#'^C8Q^UUOJ;+5<9U[`/M95E^T"6C#R=)
M$M_P"RNA=6^L>5FXE>;CD46TNLO<[%MQR/=<VNZU][W,JRFMKQ<>[IWZ7^=M
MR\?)NPV5KJ$JEWCYUK_TE5DU]0KIZ>O7])Q&?6S"?GVX(QLO=4W=O%#R3I6[
M^C,#LRO^>^G=C5U_^!>H5WUCQ`[:,7.<X"=HQ+YCB=:EK)(CBZF/T!_[]0&3
MK(?2-?\`=///^N6.SJ56$_!S&LM;N-AHLW@Q8=,)C'YEM?Z+^>KI]/\`Z:T,
M3KW3LO*;B5^O7?8USZVY&-D8^X,V^IZ;\RBAECF;V^QGO6BN6ZYU;ZS8^=F5
M=+Q3D54B@TV.QK'`/<S(LLQP_=5]H;D74X.,_(Q]]6!]KMNR[*OLR-D[@#^[
M?_=2FF(D+XB#KI0X='__U_54DDDE*22224I))))2DDDDE*5#J_6,;I-5-E[7
MV/RKFXV/57M#GVO#G,K:Z]]-.[96_P"G;^D_FJM]SZJE?6)];_L/[(=^T?M/
MV'<?M7V7;_,[+/M'VKU/;]F]'?\`0_6O4]+[%^M^BDIMT]?Z->YS:\NO<VU^
M.6N.T^I7;7A6,VOV_P#:K(HI_P"O5*OB_6SH.59DMKRJ_3Q7-:;R]GI6;A1[
ML:QKW>LUC\S&H?\`\-=5_I*U@W?\V?VC1ZOV[_E'(]*8]'?]JP?M,[OTG[._
M;OV7_P!#/7_[1JCB?\VM_1_L7VC[/^TZ)^T_SFS[+_DGTH_[0_\`(OT_^Z7V
MK];24]<_ZS=.JZI9TVX64^D\4NRGM`Q_6-0SAC>MNW-M^R.];WU^C_@_5]7]
M&K&-USI&4YC<?+JL?80UC`[W;B+B&&OZ;;/U3*]CO^X]W^C7.Y__`#=_YPYG
MVG[?ZV[7T]_H?;/L?M^Q_9_TW[5_9/\`1_\`V7_7/35;ZO\`[!_;W2/L?T?L
MF=Z/K;?7]?[2[U?5]']6_P#+7[)Z'L]+[=L_1I*>Y22224I))))2DDDDE/\`
M_]D`.$))300A``````!5`````0$````/`$$`9`!O`&(`90`@`%``:`!O`'0`
M;P!S`&@`;P!P````$P!!`&0`;P!B`&4`(`!0`&@`;P!T`&\`<P!H`&\`<``@
M`$,`4P`V`````0`X0DE-!`8```````<`"`````$!`/_A#@MH='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O`#P_>'!A8VME="!B96=I;CTB[[N_(B!I9#TB
M5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^(#QX.GAM<&UE=&$@>&UL;G,Z
M>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N
M,RUC,#$Q(#8V+C$T-38V,2P@,C`Q,B\P,B\P-BTQ-#HU-CHR-R`@("`@("`@
M(CX@/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY
M+S`R+S(R+7)D9BUS>6YT87@M;G,C(CX@/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(@>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C`O(B!X;6QN<SIP9&8](FAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO
M(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UP.D-R96%T941A=&4](C(P
M,3,M,#<M,S!4,34Z,#DZ,#,B('AM<#I#<F5A=&]R5&]O;#TB36EC<F]S;V9T
MPJX@3V9F:6-E(%=O<F0@,C`P-R(@>&UP.DUO9&EF>41A=&4](C(P,3,M,#<M
M,S!4,34Z,C$Z,C<K,#4Z,S`B('AM<#I-971A9&%T841A=&4](C(P,3,M,#<M
M,S!4,34Z,C$Z,C<K,#4Z,S`B('!D9CI0<F]D=6-E<CTB36EC<F]S;V9TPJX@
M3V9F:6-E(%=O<F0@,C`P-R(@>&UP34TZ1&]C=6UE;G1)1#TB>&UP+F1I9#HS
M,$0Q,D8V,49$1CA%,C$Q0D(R-D5!.#DR,3$X-C4P,"(@>&UP34TZ26YS=&%N
M8V5)1#TB>&UP+FEI9#HS,$0Q,D8V,49$1CA%,C$Q0D(R-D5!.#DR,3$X-C4P
M,"(@>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/2)X;7`N9&ED.C,P1#$R1C8Q
M1D1&.$4R,3%"0C(V14$X.3(Q,3@V-3`P(B!D8SIF;W)M870](FEM86=E+VIP
M96<B('!H;W1O<VAO<#I#;VQO<DUO9&4](C,B('!H;W1O<VAO<#I)0T-0<F]F
M:6QE/2)S4D="($E%0S8Q.38V+3(N,2(^(#QX;7!-33I(:7-T;W)Y/B`\<F1F
M.E-E<3X@/')D9CIL:2!S=$5V=#IA8W1I;VX](F1E<FEV960B('-T179T.G!A
M<F%M971E<G,](F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W`@=&\@:6UA9V4O:G!E9R(O/B`\<F1F.FQI('-T179T.F%C
M=&EO;CTB<V%V960B('-T179T.FEN<W1A;F-E240](GAM<"YI:60Z,S!$,3)&
M-C%&1$8X13(Q,4)",C9%03@Y,C$Q.#8U,#`B('-T179T.G=H96X](C(P,3,M
M,#<M,S!4,34Z,C$Z,C<K,#4Z,S`B('-T179T.G-O9G1W87)E06=E;G0](D%D
M;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I(B!S=$5V=#IC:&%N9V5D/2(O
M(B\^(#PO<F1F.E-E<3X@/"]X;7!-33I(:7-T;W)Y/B`\>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B+SX@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!
M9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!
M`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__``!$(`2H!5`,!$0`"$0$#$0'_W0`$`"O_Q`&B````!@(#
M`0`````````````'"`8%!`D#"@(!``L!```&`P$!`0````````````8%!`,'
M`@@!"0`*"Q```@$#!`$#`P(#`P,"!@EU`0(#!!$%$@8A!Q,B``@Q%$$R(Q4)
M44(6820S%U)Q@1ABD25#H;'P)C1R"AG!T34GX5,V@O&2HD14<T5&-T=C*%56
M5QJRPM+B\F2#=).$9:.SP]/C*3AF\W4J.3I(24I865IG:&EJ=G=X>7J%AH>(
MB8J4E9:7F)F:I*6FIZBIJK2UMK>XN;K$Q<;'R,G*U-76U]C9VN3EYN?HZ>KT
M]?;W^/GZ$0`"`0,"!`0#!00$!`8&!6T!`@,1!"$2!3$&`"(305$',F$4<0A"
M@2.1%5*A8A8S";$DP=%#<O`7X8(T)9)3&&-$\:*R)C495#9%9"<*<X.31G3"
MTN+R565U5C>$A:.SP]/C\RD:E*2TQ-3D])6EM<75Y?4H1U=F.':&EJ:VQM;F
M]F=WAY>GM\?7Y_=(6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJ
MNLK:ZOK_V@`,`P$``A$#$0`_`-_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
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M9OJ_[)#[K_3];_W-R-O^0;_7_#W[KW5A/6%O]&O7EKV_N-M*U_K;^`8^U_\`
M'W[KW2Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U__]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U5[_.PO\`\-'?S&;?7_90^[/]M_<S):O^3??NO=6$]87_`-&O7E_K_<;:
M5_\`7_@&/]^Z]TN??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=8XIH9X
MQ+!+'-$Q8+)$ZR1DH[1N`Z$J2CJ0?Z$$>_=>ZR>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NL<T?FAEB\DD7EC>/RPMHFCUJ
M5\D3V.B1+W4V-C[T14$5(J.KQOX<D<FA6TL#0BH-#6A'F#YCTZI)Z2^,V]<1
M\^.P>K\A\WOGCN[8WQ_V)\?>[]O;?WCW_#FJ#>>=W[NKM*GW%M3LJG_N=31;
MGV!/3;%HXTQT:TCJDDP,S:UT0MLO+5[#SYN&V2<Z[[-8V$%K<HDEUJ$C2O.'
M28>&-<1$2@(-."<YQTY]SO>WEG</NG<H<\VGW8?:G;N:.;MUW_9;BXL]A,,E
MG!8VNUM;W6VM]8QMK]6OIF-PQE!98R(QI.J[KW-77,/KWOW7NO>_=>Z__]+?
MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5[_.QL?Y1W\QFZZA_LH?
M=?%[<C9N2(;_`)!//^P]^Z]U83UC_P`RTZ]L+?[\;:=@>;?[@,?8'Z7M[]U[
MK4[_`)G/17\\#/\`36-3MS>VWN[^KHMZ54V2V;\4L/GWW+2HR.V"R&_=M[?Z
M^VCF=P[8I5+"+Q_Q&GHZE1+4A&\,QQ']R]C][)]GC&[7L=[M@F-8[%6UC^$R
MHD4;.@\J:PK9:G:>OHA^Y![I_P!V!M/N1>M[?<LWG*_/+;:HCO.:9H!;,01X
M\=A<W%_=PV]RQH6U?3R31DQP%AXL8M4_E@=??/?:GP"ZCV[V/EJW:G9=-WOM
MK,TN*[J7(U>[</\`%B+=NU*G=FR\E296@R^;Q.Z<AMR#.IA:6M6GGQT5320E
MZ1(E$4I>V6W\]VO(6TV^XRM%N0OD8+<U,BV7B(9(R&#,KE!*(U:A0%!5`!3`
MW[\G-WW3]_\`O:>X.\<F[?%?\DORI<PM+LQC2TFYH-I=+:WD;Q20P2VL=PUB
MU[+"9$N'CN)`MPSL7L_^2=5VW1?'7ORMZ!IZ>L[WI.E>TZKI2DJXZ6:EJNVZ
M?8V=EZWIZF*N#44M//O%*)768&)E)#^F_N9NN:'6HU\:?DA\?OCW_+ZW;W'\
M'-\]TXS^8:VR?AOMW^;/V[W3@OE;V]NCXUYWL'M3$;'^3GR3[=Z<[FEJ>O-X
M=R='YRLW571XN@AEK*3"01UE33S[:I@']U[I6YK^85_-5[#Z/P7^A3Y'"+;^
M!V;_`#>>T^N_E]%\4=A[CSGS3Z>^#>)Z!W7\:-Z8[KZNP6.V!L5^X<WOC<.V
MI\AB<.E#GL=C9*W$T44TM/40^Z]TD,A\_P#^85LW>?\`-#[GPO>F^L7VIO+X
MB?RH/D1\7?B7N_JNMWMUUL#'_)7_`&7K9'=O8_6F.RN.GJIMK=0;PWIF\#D\
M=2&GER554/5Y,RUU&E5%[KW1JNW/G+_,#Z&^>W7WQ,SGR5R6[-[]>=B?R]NJ
M^O\`I>M^*&U:6?\`F>==]W2X6'YI?*A]X[9VM/%TAB^A_P"(9PQIMK(TFW]H
M_P!U2^<%>F0B`]U[JS#^1/@JS;/\L7I3!UU)EZ.7']J_,V.&+/4%;C,K)CY?
MF]\C:C%5M319&&GJXER.+FAJ(BR`/#*KK=&4GW7NK=_?NO=>]^Z]U[W[KW7O
M?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5Y=7?]O-_ES_XJ
MY\2O_>O^0WN/ML_Z>7S;_P!*NP_ZN7?68'/7_B$/W>__`!>N:_\`M$Y?ZL-]
MR#UA_P!>]^Z]U[W[KW7_T]_CW[KW7O?NO=>]^Z]TU9XTPP>9-9EY-OT8Q61-
M5GXJJDH9<)3"CF\^7BK:^*:AHY,;%>999D>*,IJ=2H(]^Z]UH.=M?(KYD_!F
MK_FO[9VCNGY2=!;PC_EK=5]O]!;![/\`F?F/YA%=V=M7*?+##]%]J_S&L3W6
MVXLS3]%;^&P=UQRT^V:.EHA43U(R%.T:T-)#%[KW0U=N[R[0Z-^;/9'\L7K7
MY0_)2I^$/8?\Q+^45U7NG=V<^0G;&[.S]GX;Y1]`=V=C=M=(;7^1N6W95]H;
M9HOD?N/K+:^0J$QF:IGI8\[414/V\>3*M[KW3YTAV!VMWYWA\5?Y=';OR<^0
MU/\`#R+^85_/`ZCP>]\-WYV-LWM?M_J;X0;8V1E_C?M7</R,P&YL5V9N3!]7
MU&^MQ5QEJLM/#EEVS3"H\U-0*B^Z]TL=W_*K^8+W3_PF#Q6^L_U!MKY`8[LO
MX+_)["_(/Y$=E]\577'9&W-J[&W_`+WZXV'V#1==UO5^[J[N//[QZCP,&:FD
MJ<WAZBNJCY)ZAIIM<ONO=;A7604=;]?!6UJ-D;3"N1;6HP-!9K7-M0YM[]U[
MJ+OSMCK3JY<4_8V^ML;(CSLM7!AI-S9>DP\63GH8XYJR"BDK)(HZB:FAF5W1
M26"&]K<^R/>N9N7N7!;'?MYM[-9BPC,SJ@<J`6"EB*D`@D#-,]&>V[+NV\>,
M-JVZ:X,8!;PU+:0<`FE:`D4!]>G'9'8&R.RL/)N'8&ZL'O'!15]5BWR^WLA3
MY3'#(T0C-91"LI7D@:HI?,HD4,2A-C8\>W]GWS9^8+1K[9-RAN[(.4UQ,'74
MM-2ZA45%14>736X;9N&TSBUW.RD@N2H;2ZE6TG@:'-#3'KTL/9KTAZ][]U[I
M"[Z[1ZSZO3:LG9G8NQ>NX]];RP?7.R9-];NV_M%-X]@[G:H7;6Q-JOG\ACUW
M#O+<+4DHH<72>:NJS$_BB?2;>Z]TDD^1_P`>).Z9?C;'WSTR_P`B8,*-QS]"
MIVALANYX=O''QY89V7JY<X=[QX<XJ9*H5)H1#]NXDU:"&]^Z]UUT_P#)#X\?
M(7^]W^@/OGIGN_\`T?YE-N;\_P!$/:&R.RO[E;AD^Y\>"W;_`'-SF:_NYF)/
MLIM--6>&8^%[+Z&M[KW0T>_=>Z!#.?)KXW[8[>P_Q]W+\@ND=O=][APE3N7`
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MW'AMF[LGW>F`W1E=OQ>JNIZ&HGFI%YE51[]U[I5Y;Y6_&O$=)8KY)-WAUKF.
M@\_D=KXG;O;VT-U8S?6PMS9/>N^,;UKM2AVON+9<^?H-RU.>W]EZ?$4Z4#5!
M>ND\7#*VGW7NE'M#Y!="]@]D;^Z<V%W;U'O;MWJD4Q[1ZLVCV1L[<G8W6XK6
M1*,[\V1ALS6;EV@*IY%$?\0IJ?66`%R1[]U[KE6_(#H?&]Q8CX\9#NOJ6@[_
M`-P;>GW=@>CJSL;9]+V_F]J4L5?/4[FQ/6L^83>>1P%/#BZIWK(:)Z=4II6+
MVC<K[KW4'JWY)_'7O+/;[VMTIWYTKW!N?J[+/@>S-N=6]I[&[`SW76<CK*['
M287?6(VGG<MD-HY9,ABZF`T^0CIYA-32H5U1N![KW0U>_=>Z][]U[HLN1^97
MQAP_>>2^->7[CVKBN[,5E.KMOU>QLE_$J"I;<_=."[#W5U?M"AR]5CXMO97>
M>[MJ=4;ARL&'I:N;)18S&/5S014[PR2>Z]T9DFP)-[`$\`D\?T`!)/\`@/?N
MO=!GTWW+U;\A.LMH]R]*[WP?8W5^_,?-D]I;SVY/)48C-4=+7U>*K&IVFB@J
M(IZ'*8^>FJ(98XYH*B&2*15=&4>Z]T)OOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NJ\NKO^WF_RY_\`%7/B5_[U_P`AO<?;9_T\OFW_`*5=A_U<N^LP
M.>O_`!"'[O?_`(O7-?\`VB<O]6&^Y!ZP_P"O>_=>Z][]U[K_U-_CW[KW7O?N
MO=>]^Z]U#R..Q^7Q]=B<M0T>4Q>4HZG'9+&Y&FAK<?D<?6PO35E#74=2DM/5
MT=73RM'+%(K)(C%6!!(]^Z]T2WI7^6K\`?CI@^U]L])_#[X_=>8#O3$93;?;
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M!5XW#8/`83%P4N-Q&'P^/IHX:6FIXHX8(HU1%55`'NO=63]8?\RUZ\XM_OQM
MI<#Z#_<!C^!_K>_=>ZK_`.ZO@%N_L#8N=HQ\D^X^Q=R8]*O-[&V]VIE]NY'9
M<6Z4%5]@*\4.VJ7*TE*U-5R4IDIYD=(V!.H`JV/'-WLENF^;->1?U_W6_OTU
M26\5X\30";.G5IB5U6C%*JP(!\Z4,O<O^YEAMFXVS_U2L+2T:B3/;JZRF/%=
M-9"I-0&HP()].A.ZE^%>4ZF.PH\)\D^\X,!L[)8S,5/7U%E-LT6P\S/#4/D,
MUB:O%T^W(ZLX+-Y&HE:5#.9RC`&4M=B(N6/:2YY9.RK9^X&\BQM)$<VRO$MM
M(0=4B,@BU>'(Q8L-6JARQ.>BC>_<"'>_WD;CE+;C=3HRB<K(9E!&E&#&2FM%
M`H:4K^&F.A!^=G9.4Z;^$?S#[<P>Y,AL[.]8?%OO_L#![MQ,%/4Y7;&;V?U3
MNO/XC<&,IZO&YFDGR.'R-!%40)+1U432QJ'AD6Z&9>HXZTENGOD1V^/B?LC'
M'Y$?-K?';N_/YE/\L;:'R"Z3Z/\`E%VONS<-/T[VU\3-X[VS74'QN^0^Y/DQ
MV'0;AWS\A*['9;=N[L71[NV_+B\OD(\28<9]KBJ@^Z]T;WM_X`?S5_FQ\;OC
METWN?JJJJ,A\=?C9\K.U>O=\_,[N_>-%V=MSN/O;OO/U7PI2/=77L'8.2W=\
MK_B9\=>N<;!D*G.SPT-%7;M:&KKJBI2:1?=>Z-Q#LGY@?(K^9+_+>[SR'PY[
M]ZYRO7?]V>YOE!B^W.F_CAU]\9^O=Q[V^+.9Z[[2[)V5\@^J=ZO\@.T^_J?/
MU='M;'[4W&N6Q4=+2I/-0T-)3T]:/=>Z&7^4=TWW_A_GC\S^^MV?'/NGJ;HS
M?O374/6>S<_\GNH/C_\`';M3;>Z.LM^=C55-T;U5U7\7=RY'J[=/Q_V-LW=,
M!I=XUM!%F,I6+%"M=D*>(R)[KW2R^!/7_P`^=N?S&N]=W_(.E^3<WPJW@OR<
MR'PEVWV!V:NY:7IZ3(]X;<G[#HN^]O(4RLS]BRXT9/I1,A6YI-I[!>LQBFCF
MJ7A'NO=!%U+\?.UNH?D?_,8Z;[7^!_8G=':/R]^5GR/^2WQZ_F#8C:?3^[>L
M]@=6[WZ'DVOTQMS<_9^Z=[4/:O6.\^BD6MV9B\+C\4T_@R,E1C5>FJZJ:3W7
MNBK_``W^)?>=+B/C!V)4_P`N?N/X^8_X9_RD^R/B1\JJ?)]<?&*;MCYW=O;@
MV5T_C\%L3KSJK+]B9/:G<FT>M-U[`RNYL;DNPI:#'9?)UZTJT;M+-?W7NK)?
MY)W1W?\`UGT5\W,KW'U7V)L@?(7Y7]F]V==YWO;9?7_4WR0[=Q^].M]BX+*[
MV[HZ7ZGS^7ZEZER;[BV[)C<9C,+3X**7'42551BZ>:=JBJ]U[JKC^7Y\7/EG
MU;'_`"[NW,%_+Q[8Z#W[_*Z^$?R\V;\D<AN;%=0[-WA\[>P][=;4]-U)\;NK
MX]A[_P`[N#L_`+V70KN.GSVZ5QN&QV00B!XZBJF9O=>Z+'G?Y5O\TOK3XG_+
MKHK-?'_8V]<G\_O@[UUN;LZNZ.WQG=\9;-_.OJ?Y3[=[?S^_>\8NQZ'9>#P'
M979VP^YL_15:8*;(8/(MLBEA>9D$;>_=>Z.9W#_+0^2M1_+-_G`_&#.=`R=X
M?*7??S`VUW#U5W%A]F=8;-VO\E,'NS._'VMQ78_5/7F#3`;'Z8WALSK/:];M
MS=E%CX:>2KK<3-6/65LE>RQ^Z]U:-_.!VIBNO.KOY;64VU@,/LOHSI?^;C\"
M]W]KX_;M#C]K[-VAUY4]@;CVKMW,Y&BQT-%B<5MW"]Z;UVI73'3'$LR*Y]7U
M]U[JLWX/?&;Y<_'[O[J7=^Z_B#W=_?'^75L7^<!N?Y"]NT.'ZPI$_F,[E^7?
MR$H^W_C9L_H7=T'8,VY.VL[EMKXK^(U<VZ(,32[<RBQX^H>&I=4]^Z]T\]B?
M$+Y2]A?S(:6HH?BEV=0UG8_\U7X7?S*:3YF;@I-B46SNO_B5T?\`%O;?7V^O
MCIO'=^+WMD]X8[MG$;HQE?M"EV?!255!74>;GR*SFAC>0^Z]T9[^6+UCNFI_
MF3?+3Y&]E?R^^X_A;EMQ=5U'1?0^+PW5W46QOC3A_CEL/M9]UP5NZ-S]?;_G
MR&^_DUWKOG<<^Y:VVVH<?@L-1+CX\E6.C35'NO=%`WC\)/YF_8_R0W1N3<79
M'\P3#]>=L?+;^;IB][4>SOEQOW9FT=J?&/;VT*O='\N>CZZV]MWL6AI.O\#N
M/M3'TTU#/B8(<O4K4RT&2D3%-]FONO=%1R?R4^05+_,`^&&POF9\H_D!U./C
M]U/_`">\+\D<?MKN#>F/W2GR+[`Z6[%["[FZBW?TCUEVUU_A=_;%[OWY0XRN
M[&WG-MK?2;?QN!:!:FCH:B:*#W7NC"9OXS_/#Y=?#3I;YH?%.D&U/EG\W/YG
M>_?Y@^W][[[P^!K*?H?H<_$;Y&?'_P"&T.YI:ZEJI)<'B>C:?9U/C:LT=></
MFMU"N:DFCADB;W7N@AZR^1O8&9_FQ_'?K7M+MWY=='=:=1=C_P`OWHO"].;A
M[_[(WYW13]M[E^'NY=[9?XR=]]>[4[HP&+[/V-O+LZHAWEOGMO+[.WC][/BZ
M:FGS%)BZQJ;'^Z]U?C_(YE_BOPRW[O7`S0OU%V9\X_Y@'9'QXAI5$=!!T5NW
MY>]NUVRY<3"O[<6%S-2*W(T+1@13TE;'-'JCD5V]U[JXGW[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW5>75W_;S?Y<_^*N?$K_WK_D-[C[;/^GE\V_\`
M2KL/^KEWUF!SU_XA#]WO_P`7KFO_`+1.7^K#?<@]8?\`7O?NO=>]^Z]U_]6W
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M\YO_`+\;:7/]?]P&/Y_V/OW7NF'L/O#JKJW8V[.Q=Y;VP-!M796&J\[N"KI<
MA39*IIZ"C(1Q!CZ"6>MK*J6=UBBAB1I)9G5%!9@/8:WOF_EOE[:-QWO<]WA7
M;[6(R2%6#L%&*!%)9F)(554$LQ"@5/01YBY\Y2Y5V+=N8]XWVW3:[*%I)2KK
M(P5<45$)=V+$*J*"S,0H!)`Z5N+WSLS-08NHQ6Z]NU\6:IZ&JQ/VV9Q\KY"G
MR<$=5CY*2):@RS"LIYE>,*"75A;V9VV\[1>);26VYV[K,JE*2*=0<`J5%:G4
M""/6O1O:<P;%?QVDMGO%K(DZHT>F5"7#@,A4:JG4""*<0>E/(L;1R+*$:)D9
M95D"F-HRI#B0-Z2A6][\6]F71OT3S87<G\OREV'75_6':OPYINL.OMX/E\E6
M;"WSTI#L/9&_ZE-P5[Y2NJ-O91=O;:WA41X3*S&>0PUKK25;ZB(IBONO=)/Y
M-_S+OAK\2MH?';L#MGM[#S;(^4_8VUNN.F-W;$:'?VV]RR[KITJZ;?'\=VU4
M5N*AZPQ-)44\N0SZS24-+'5TY+-YDO[KW7>Y?YB'26R_F1LCX4;RV;W_`+4W
MUV=6UVW>M.U]P=([TQ?QQ[![`Q>PJGL_*=9;.[GJ:1-O9S>N.V-1SUDJPJ<<
M)8):,59KXI*5?=>Z[^*7\P_I/Y<]F=P=,[2V9W_U3VMTOCML[HW%U_\`(SI'
M>G2.Z<YUSO>OSN,V3VGM+$;OI(*K*;&W57;:K8Z:29:7(1/`144D!9=7NO=&
MQP?:_5NYZ[$8S;796P-PY+<$N^(,#C\'O';N6KLW/UEFZ7;/9,.(I*#(U$^2
MEZ^W'70X_.+"KG$UTR057BE=5/NO=$LK_P"9U\=(_DKO#XS;>V[WWV#D^L*K
M/X'N7NGKOHW?>[_C5TIO_;VP*GL^MZP[2[PQM`VTMM;\79<"U,T`:>DQTU1#
M2U]325<JP'W7N@[^/O\`.)^)OR/PF>R&S]K_`"=VUN"DZ)R'R;V%UUV!\9>V
M-N=B]_="T%+CZA>R_C=MN'`Y,]YX6OFS%%!!#M^:LKFEK("T"12I(?=>Z,?\
M0?G'TW\TNMNP^Q.ML/VCLBKZ>[&W5U%W%UEW1UYE^M>V.K.R=G8G#;@S6TMX
M;/R+57BKEV_N*@K8I:.HK*6:&J4+*95ECC]U[H"OAS_-R^)'S:W;M/8_6T/=
MW7VX^S]E9[LSHV'OOI#?G3V*^0_6^U*B@I=U;WZ)W-N;'+M?LC%;:DRM*]=3
MT=;_`!.GIIUJ6I?M@\R^Z]TRK_.<^!]1U)\V^ZL9V!N;-;)^`&_XNN._I,1L
MW)5F5_CE=N=MDX*OV!C@Z-O?;6Z-Y4U7C,9D:9EI:RIH*@HWBC$C>Z]TA=]?
MSQOB%UST7FOD!NOKOY?8[:/7O:F3Z9[^V_+\7>Q8=_\`Q=WY1X+;.XL72_(K
M:%53TU=U[@=XX[>N'&"S`:KQ&7GR4,-/4O)Y%C]U[HQO:/SJZKVU\5^HN_=^
M=)]T4-/\ANV^D^CNM_CIVUUM1]<=X9KM+NOM_$=8[(VMN;KOLS)8>@VI6X_(
MSOGZK^)547@PF/EJH_)((HI/=>ZA]#_S/OB[\B_D=N;XS=?2=I4^Z<?_`*6/
M]'G8.[>K=T[7Z3^0W^@#>]'UIW\?CIVMD:9=M=KITQV!7PXK.-1.J&9C-1FK
MI(Y:A/=>Z%)/G'\?YOF>/@139?=<_P`B$ZIS/<=7C#L7=-'LNDVEA)]GQ5<"
M=@9'&T>U<SN#P;ZQM0U%C:BMEIH9U-3X&:-7]U[H;]W]V=,]?;DVYLS?O;?6
M.R-X;QK\7B]H[4W?OW:NVMR;IR><DR4.$QVW,%F<K193.5^8FPM8E+#312R5
M#4DPC#&)]/NO=)6J^4_QBH>M,;W16_([H>CZ=S&X?[HXCMBJ[?Z^I^M,KNO^
M)UF%_NQC=]R[A3:]=N'^,X^HI/LHJIJG[F"2+1K1E'NO=$F^8_SR^,/QEWQU
M#V-E>GX/D!G,I\:/E?\`)6;M?JG'=;[KW)UE\3/C1U=2]A]E;YQ&Z\OD:$U^
MW]^9G=6#V[A*"ERE)29K)YL-YA#!.Z^Z]T<RN^5/QKVMLFDWMO?N[J+J[;:9
M3:6U,@_8W9&Q-CC:N]-Y;*QG8.V>N=R?QG<%+18+?F0V1EJ;)P8>205DN/E2
MHB1X&60^Z]T$_1'?_P`=/DA\C?DCM_;.P<''WK\3J_K?9&;W_DL%LK+9?<W5
M7>O6&![BZOWSUKV)@JC,5V3ZHW_A<S5PQ)]S!_N2Q-;')!^VKO[KW1S\;C,;
MA:"DQ6'Q]#B<7CX(Z6@QN-I(*&@HJ:(:8J:DHZ6.*GIH(UX5$55`^@]^Z]U.
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U7EU=_V\W^7/\`XJY\2O\`
MWK_D-[C[;/\`IY?-O_2KL/\`JY=]9@<]?^(0_=[_`/%ZYK_[1.7^K#?<@]8?
M]>]^Z]U[W[KW7__6V=\__)I^%F'^.>Z>H(Y.VL/A/]DVRWPEK.P\=NBER_9E
M!\2X>TLMW1+U;BQ5[9R>VZDXZMR-3C**O;#3YE<853SR50%2?=>Z(ATM_.G_
M`)EWR6Z]VMW/\0?Y$6_>U_B_O>IR$/3_`&?N#YV=$]:YO=NS,#N&NVJN?R'7
M^X-G5V6VS,9<1*/MI*JJBU1GQU4T=IF]U[K9MB9WCC>2,Q2,B,\197,;LH+1
MET)1BA-KC@VX]^Z]US]^Z]U[W[KW7O?NO=>]^Z]U5[_.PO\`\-'?S&;"_P#S
MB'W9_CQ_<S)7/^P'OW7NK">L.>M.O+CZ[&VE<?C_`(L&/N/?NO=5*?*+^39T
MSV5A]MX[XY8;870N4ASM?F-X;GKZ3?6\\OFZ9H)108;&PY#>#4&,HGKJV:HJ
MG"&5VB@1"B*ZMB9[C_=4Y4YCL[&UY'M[79YQ*SS2L;F=Y!2BHH>=E5:LS-C5
M4(`0H(.#ONU]R?DGFW;]NL_;BUL]@N1.\EQ.YO+EY!2B1HLEPR(E69G(`8E8
MPI"JRL*/Q,_E6]'=&8+9.4[1VCL?LCNCKK>1W1MCM?`IO;;-2[8[)C,;7JLI
M@7W94X:IS&"JI7B#>$P30PPEXVD5F82>V7W<.4.3;+:9^8-NMK[FJQNO%BNX
MVN8B=+B2(O%XWALT;5`["I54U!F!8BWV>^Z5R'R!M^QW/-&U6FY<Z[;>^/#?
M1-=PDZ'$L)DA^H\%GB>H%4*,BQZPSJ6)K/G-MG=N]?A1\O\`9>PMJ93?>^=X
M?%[OS:FS=E82>GILQNW=.X^JMUX;`;<QE159;!4\-=F<K6Q4\3-6TNEY`1*A
MLPR/ZRUZTX>J/A#\O-T?%/IWK_'_``).>[.P_P#,G_EF;XWAVAWIU9O7K;JG
MY#[;Z?\`B7G>O]SXONWXX9/I[9.^.J^AOC"V&QVU,AN%-OY+&;KR]=)FX&R4
MDM9)4>Z]U9/@/Y`G?^].FMI=(=M_*'8'5&P=H_$#Y9]18?:'QJZZVOEML8CM
M+Y[_`"(W9WI\A]FX7']X=:;JAVU\>=AXS%;)V[M&KV]'M[>4U-B:R<5&'$J4
MS>Z]T.>R?Y8OSGW1\Y/@]\O>]]T?%;;_`&#\8-B;8V]VO\B.H>QODMNWMKO3
M$TO2DO7N^NG9.C^TL-%T'M'9W8&]<E59;([OH'@W-+314T4=-!*LDK>Z]T-'
M\L;^7-\B?B?\H_EK\E.VJGX_]9XGY-;=V+1[EZ/^-_87?W<VTM^=K[5W!NK-
MY+Y';LWU\F**DWSL7<E?C=TS8:BV=@VJ=N4&.LWFEGC#M[KW7'X3?RS.[_C)
M_,,^0_S7W7GOC[E=N?*RG[XDW9UILO&;NHYOCYD,SW/M_<_61Z$R.3PL%#60
M=[;)Q`SG=SU,&'?.=C4M%D*1:BG@M[]U[KAUK\"/FWT+V_\`,KK+JC>OQ9SW
MP7^<OR#^0'R;[&SO82]L4WRKZTW=\C^M<EA>P^O=AX+;N*?JS=&W6[$QN'KL
M5G,KEH*G$XJ:NI7QM<4HS'[KW1?/CW_*S^?FV=H]"5G>V\OAEEMW_`KX`[_^
M%?PSZ_Z^R?R!.Q>P<WV=L'K7KW>O9GR7[/?%;'W]MW'Y3:_5M'04V*VCB7J,
M;)739".O>6&.F?W7NCG_`,I[^7[VO\$^@>^^K-_97JW;F+[=[IWWVAUYT=TY
MNGL_M'K/H##[NP&)P];M[%=S=W8_%=S]K9'<^8Q;YO*5V:IJ805M7)#21+"N
MI_=>Z(9\7_Y2_P#,-ZQVW\11V9VQ\0\=N;^5]\6_DMU7\#8NL?\`3!FJ3L#O
MGO[JZKZNH.VODYN'=^U,)+MS8^R\$D21;;VSB<C/43U=152U[^*FI1[KW0/[
MM_X3N?(C#=#;EZ%ZW^7^&["VMVW_`"^-C?#OM6A[HP&#VGBL'NOISOK9O?'5
MNY=@T_375&%K]R[>7,Y[L2EK*_==1E-VP0Y^G/\`$JM@33>Z]T:S?G\FKMJ7
MX*_S-_@CUIV/UM!LCY8_(O!]X?'7?G8.6W_N?LK;^(S6YNF]\[]VA\A]]9+"
MYS>G8N0VIFNNZS%;7SM?D]RYRHP+4,&0K`*9(XO=>Z.3_-FZ8[)[-V1\*.Q^
MLMGY[L.N^*'\RCX?_)G>&Q=J8F?/[JW!UGM[<V>ZQ[#JMN8.G*RY;*;+VQVM
M/N,1`K^UAW<$%1[]U[HB_P`</Y3OS0^-F]=EY3;.^?BOG=O?`SK;^9'1_P`M
MJ7.5W<`RW8':GS[[.':>/K_FICL?MNDI=N;!ZJJ:.+$34^RZS)Y'-T]1)6B:
MBFB2FD]U[HW6[?C)_,#W7_,S^+'R]JG^'*]+]*=![KZ-WUB*?=W=E)VAG$[O
MAZZW/W-N?:>'EZ\R.TZ8[7W_`-74%/MBBK,M_EV'JZB2NJ*>H6*/W[KW1;OY
MJG\EO<O\P[M7Y%=F4&1Z%AR/9'PM^-OQKZDRG:&WLOF=P]9[SZK^8VX/D!V9
MNBBKJ/;F5FP.)WUUKETP2SXR85U3,&@J$6DNS^Z]U5__`#&OY6G>O2$5)@.F
MNF/[]=)=H?.#^8I\B8MH?''I3=6_-O=:=2]^_`_8/0VW/CO7=?["Z]W?E>M=
MR]Y[JP^=QU-NO"[9J,-M"IR7\4DRN+G"RR>Z]T?K8GP#^07RMV%_,1R^^.@\
M+\,\_OS^75U=_*Q^$?3>^]S1[RP'2'5..Z(CW9VN*K>&S#FUW;L3(]_=AQX&
M+,T](*[)8O8--.U-8PQ#W7NJR_FS_*S^5OQIVAT=TCM?K/._+?IK:>6_F%[@
M7>W7_5^\^R.Y_D'M[Y/=4=*)7]&_*G=FV.NM^9G:O??9.\\%F=H8/NE\?!!A
M]FT.+FJ<MA:JDDBF]U[K8'_E[])]MX'YJ?S`?D#OOI";X];"WUUG_+UZ`ZMZ
MZ:LBKJ.&7X]=`;@W)V2,#EZ6EH<=N[9VQ]Z=Z/LW%YNDA2AR,FV:MZ:\6FWN
MO=7&>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[JO+J[_MYO\N?
M_%7/B5_[U_R&]Q]MG_3R^;?^E78?]7+OK,#GK_Q"'[O?_B]<U_\`:)R_U8;[
MD'K#_KWOW7NO>_=>Z__7WWMR5%31[=S]71U]+BZNEPN4J*7)UU++746.J8*&
M>6"OJZ*!DGK*6DE4221(0\B*5!!/OW7NOFA?"+N3^6A%T+MFK^3'\WO^<YT%
M\A-Q=H]J;L[6ZX^)&X>U^OOC'5[UW=VOF\L^^.H-G;%^.E?M_#;3[+IZNGR.
MB])D&J)Y!+0T)6*G7W7NOIH4V@TU/XWDEC\$6B2;69I$\:Z7E,@5S(Z\MJ`-
M_K[]U[K/[]U[KWOW7NO>_=>Z][]U[JKO^=F\<?\`*,_F,M(XC4_$7NA`Q8*#
M))M#(1Q)<D"\LKA0/J2;#GW[KW5A?6'_`#+7KSZ_\>-M+EOK_P`6#'_7_'W[
MKW5&/S2_X4?_``!^+6V-HYSJ_=V'^7&7S^[<GMG/;1Z<WGB*3/;+IL9CIJIL
M]FH<]1HK8^HKT6DCTZ0TC$ACI(/27V)_NN_O'^[N[;UM_-NRS\EV5M91SPW.
MYVLC0W32.%\&(PL>]4)D-:T4`$"M>@?N?.NT6$<;P2"X8L00C"JT'$U\O+H;
M?A'_`#U/@?\`,G9O5E74=G[6Z3[A[<WS5]?;7^/F^=T462['EW%)N:3;>V*1
MDPU(:$OO!V@FHM116%0J:BP/L`^_G]WO]X?V.WSF^&+E.[W[DC9=O6\N-YM+
M=DLA"(!/.U96UTMN]9:5(T%J4Z5;7S7M.Y16Y,ZQ7,CZ1&QJU:T'#U\OMZMX
MW?NW;&P-I[HWWO;/8K:NS-E;=S6[=W;HSM;!C<'MO;&V\;4YG/Y[,Y&I>.FH
M,5A\51RU%1-(RI%#&S,0`?>#'0FZK:HOYSG\NFKV/NCL&?NK>.$P.T.P.H^K
M,O1[H^-_R>VMNZ??_?VS*[L7I#;6WMA[@Z;QV]=WUO;&PJ)<Q@FQ-!6Q5]!5
MT<B/_EM()O=>Z";Y1?SMOCET;TK\7?D'U'M;=GR?ZL^1^<WMG\GG]ATV<VO4
M]1_'/I+.8K;'R9^0.]MO;GVH-ST-)\?=R[CQF-S>WJZBQF23(U;4TKTTL+CW
M[KW0@;N_F:Y79?\`,IZK^`F2Z,VOF<#W)3Y)MG=F;)^2?7>]NW<;2XSJNJ[-
M?L7L'XJ;>PU7O7KOH.OGQE9@J/=V3S,1J<O3@+0"":":3W7NLW\OW^9;G/FI
MW1\G.C-T]#[:ZQW-\;DV3693<O57R/Z^^5?6LXWODMX8J/8&\^P>ML'A-N[`
M[[VG5;-G_CNSTERYQR.KBOE4J6]U[HRW47S[^)/>_;V3Z#ZF[=HMX]R[>G[J
MIMW]<T>V=ZT6Y]A3?'SL+!=5]H#L.ARVW*`["7'[ZW+14>*;+FC7<L4IJL,:
M^CBFJ(_=>Z*=@OYG/8?8W?/R"V]TO\/<_P!B_$3XE]E]G=&_(OY=5G=FP]FU
M.U^Y.H.M<KOSL7"[%Z&R^)J-V]C[*V+FQBMN9;,Q9.AK%RV2D-!C<C!0U,H]
MU[H%?CK_`#FNP^V=M[,J.U_@[E^C-X?(CX=;Q^:?PIQ]1\ENJ=V=>_([K_8N
MT]I[OW+M+</:&4Q/7]+T+OG!X??V&KJ]=PXU\328FHFJC7-)3FE?W7NC<_RY
M/YA)^?/0_:_<53U/C.N:GJ'N3L;IS(2;#[=V_P!_=,]EU/7V+PF8DWWT1WSM
MS;VT<)VGUYEH<ZE(N2BQ=$L.4I*NE*L:<NWNO=%@^"W\Y+._*??'Q7VKW7\/
M]S?&#!?/7K/L7M+X4;_A[FV9W7MOMW&]1XF'<_86S]Z46`P&T-R]1]AXO957
M'FJ2CK*&NQV1H$J!%D/N::2G]^Z]T&9_X4`]=3?&O^8'\CJ3XX;V7&_#2'9^
M^NJ-O9C>V/P@^6WQU[-[5W%TKUA\C-AYZIVK+3[5V!NSL#8V?BEU4^7.-HZ"
M*>>375)"GNO=,F]?Y[/9>U_AEW#\P\-\$Z+?>`^+W?V:Z*^3=%L_Y=]?Y[8.
M!6.EV"NUNP.@^Y<'UQE]J_(G;F9W!V5C<3DZ2FI\'E-OUZ54=73EJ?3)[KW1
M\^__`)O]V=!?&CXO[T[%Z`VKUM\I_E+\G_CU\5=O]$9#M,=G;'V3O[NSL]L)
ME*S,=J;/VS@9=S83:'4N$S.YGFH<5"[R4:TQ0#7(/=>Z"/XH?S>,=\G/DGL?
MJ:;X_938'2OR-7Y8M\*_D(_:&`W8_P`A4^$W9U#U5WU-N7JJBV[BL]TQ"N9K
M37;<-9D,JV9Q,3S3+03::9O=>Z4M#_-`R^>_FD[S_EO;<Z7ZR:CZW&S/[Y=G
M;M^6W6FQ^U,A%O+HY>ZH\OU7\4LQMI^QNV]K;>AKJ+%Y3)8O(B&BGGEE<!*:
M5??NO=#C\HOYH_P1^%_9>*Z@^2_?=#UCO_*[.V]V*^*JMB]G[CQVW^N]T[PR
M77^$[`WMNC9^RMP;3V#LBJWOBI,4^5S5=044%=)!%+(C5-.)?=>Z1%1_.)_E
MWT_35)WNO>N7K-BU78/9W5\F-QO2??N3[2Q6\>D]JU._NY:/<71U#U?/W3MG
M&]4=>TIW#N'(Y#`4V/Q."DAKZB=*:H@DD]U[H!?F3_-GEZACZ^W!\8]N;$[H
MVBW\O?Y2?S.NSGWK4;QV)E1\9^H.LL36='Q;;IJW&4>:VSN3O[M[>6-Q]))E
M<35/1XK&95WHA-&IC]U[H<<M_.!^".S^K_\`2;O;N&H^PQ.3WWMS=\/6W67<
M?=`PV>Z7ZXVKV;\A,EBDZIZ\W=D-V=9=`8+>%%'N_>.,@JMKX#(2_P`/KJZ#
M(K)2)[KW2_\`B7\W$^27R#^87151MJEQ0^/;_'#L+K;==!%GZ&G[.^/ORHZ>
M@[%ZPWAD,)NC'XS.;>W51[CV_N7$9.AF@B,#8Z%BD;R,H]U[JP#W[KW7O?NO
M=>]^Z]T2SYJ_)[M7XH["7M/9GQLK^^>O=M8+=VZNWL]CNV=E]<U'6>VMKT5!
M70Y*/#;HI*S);VERT,U5II\<AEA^T.H$RH/8,YSYFW3E6P_>EGRXU_M\:2/<
M,)XX3"B`&NEP3)J[L)D:?F.LEONS^QW(7OYS8>1.9?>F+E3F^]NK2UVF"3:K
MS<5W*YNGD0QF:U=([(1$15DN#I?Q<$!&/0I_&[L[N#MKKZ7=W='051\==PSY
MJ>'";-J>S]G]KR9C:;XW%UV(W;_']E10XS'_`,4EK9H302K]S`:8L_ID7V:<
MN;GN^[;>;O>=A.W7!<Z8S-'/JCHI637'@:JD:3D4SQ'0$]Y^2/;OV_YN3E[V
MU]V4YQVA;93->+MEWM0ANA)*DMIX%Z3))X01'\=3X;B2BY1NC`>S_J).O>_=
M>Z][]U[JO+J[_MYO\N?_`!5SXE?^]?\`(;W'VV?]/+YM_P"E78?]7+OK,#GK
M_P`0A^[W_P"+US7_`-HG+_5AON0>L/\`KWOW7NO>_=>Z_]#?IRO\3_AF1_@G
MV!S/V%9_"!E34#&')_;R?8?Q$T@-6*#[O1YO$#)X[Z>;>_=>Z^?Q\>/G=C^W
M]A4>^?F?_P`*:>\?B[\I*SL??V#[A^.W7W5.U*GKSK?<>U.RLSMJFVYL7+;*
MVMN39>X]E9##XRFJZ#,8NNJ,95TE8K-9XZA![KW7T$8&5H(664SJT4;+.=-Y
ME*`B4Z%5+R#G@`<\#W[KW67W[KW7O?NO=>]^Z]U[W[KW5/7\_/J;KGMG^45\
MYHNQMGX?>"]=]#=@=L['&7ADD;:_8VQMK9>LVIO#$212PR4V8P<U1*8GN59)
M'1U9'93[KW5IW6;,_6_7SN;NVR-J,Y/Y9L#0%C_L2??NO=%=^9?\O#XE?/S:
M.S=B_*/K.??6V-@[FKMW[8QV(W?O'8;4.?R.+;#UE;+6;$SNW:VM$]`V@QS2
M/'=0UK@'W/7L9]YGWF^[CO6^<P^T?-:[?NVXVB6T[R6UM=ZX4D\55"W<4RK1
M\U4`Y(K0]%>Y[-MV[QQ17\&N-&J`"RY(I^$CH1_BW\2.@_AGTWMKH/X][).S
MNL-H93<.9V_@\AG,]NZLH,ENG,U.?S52,_NW)9K/3/59.K=QY*EA&H5$LBJ`
M&/=WWG]QO?/GC=?<;W+W[Z[FV]AABFE2*&V5TMXEAB7P;9(H0%C4#"#4:L:D
MDE^PVZTVRV2TLXM,"DD"I.2:G))/'Y]2?E]UOOON3XG?)WJ#JZ7;=/V5VM\?
M.Y>MM@5&\:W(8W:5-O/?776X]K[:J=S9#$XW,Y2CP-/F,I"]7)3TE3,D"L4C
M=K`Q9TMZUA.EOY0/\Q#%?&OI+I:BI^N?CT.I?Y@'PF^0^QM]39[K3L?Y(;.H
M.C?CSN7K+NWN#LC<F&VM_HG[I5MY?PBFV!MJNIYJNEV;":#(31>*G@IO=>ZL
M7Q7_``GY^,VX=JXK:7R"[:[Q[WQ^*^/G:W4,5MZ[AZ7BE[!^2?<&_.]?E1W3
M5T72FX=ETF9JNZ^P=W4).V,HN0VWBL;M^@I5IZG2\K>Z]TL]B?R=,[0]^?#W
MMWN/YD[T[JVQ\)MO[!;J;:<_0W1?778>6[!V!U+5]/8_<&__`)#;(V_1]L[Q
MV%58/)55?-M2JJ6IJK*SEZRJJZ5$I%]U[H8O@]_+(KOBE\AN[/E5V;\C\S\A
M^[^X]B[>ZGGR^.Z5Z>^..S:#K;:NZ\YO3$2;AZ]Z1P>$VYO[MBLS^X:E\AN[
M((M7/`PIZ>GI*>\3>Z]TZ_&7^67B/C/\O.W_`)H8CO;?N[^T_DU3;ZB^4%!G
ML+AX=K]M5#;TILO\?:O%XFFJ&CZZ;XW]>I-M+&IC=2YS&U#U&1\E9:;W[KW2
M:V__`"OMP=>?('OO>W4/R][/ZY^+?RJW_P!G]T?(GX;Q=;]2;GVIO;NKMWKR
M786_=V[=[:W#MVJ[.V%MO=]1%29S*X:BG=ILS3&2EK**&:2#W[KW00]`?R9]
MP=-;7VS'N?YR=M=K]D=%?%+<GP[^%N]=P=-]!4&U_B=U9N;;^T]NY/)X/JMM
MF9?;';.^\SC=C8JCRN3W;)D_XCBZ8TABB$C2^_=>Z-)_+[_EV8KX,===Z8"N
M[<RO</8GR5[0S';G;N]:7KK8'2NQUW3DMI8/8U-1]9=(]98^CV/US@*';NW*
M7R1HU=75];Y*BKJYBT:1>Z]T3GX^_P`CV;I?:.Q<#N;YO]T]J9KXT_'?O#XZ
M_`S.5_774NRJ/X=X_OK9AV+NWM7!8G:&#HZWM;N6BV^B4E%E-R9"HH8*-IHA
M0ZYFE'NO=(K=7_";_P"(9V#4]<=2]D=T=4;>W5\08/AUVI%6;TW5VXO8>R<'
MV9U=VYLO/08_M?=>YL-U[7;5WQU]75*8W;M+CL+*NY*^,4L2/9O=>Z,GOC^3
MAU)N3XP_.?X<;5[0W;UK\=?F7VYMWN3`];[3VYMN/!?&W<,>9ZZW;V%@^H*&
M9?L*'9/8N^.O1F'PXAI\?B:O)UC4<2-.[-[KW0Z?S)?BYV+\EMA_&?.]0+AZ
MWM+XI?.'XP_+C:6W<_F%V]AMX4/5V[ZK`=D[4J\^])D$Q%1ENGM][B%%*T$B
MMD$@C;0KF1/=>Z*UTW_)DCZ+WUN7=6P_EQV318/KO8GS!VC_`"_]H2=7]3O3
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MIWX\]9]`+M"O/66W]X8?%S[4BW?WIV'O;<9P#&HI*>D?&QM4.\92'W7NJ\?F
MY_(O[SP..Z%Z]^%M+C.V?COT_6?+#.=4]%=C[OV7@MO=%;[^1VSNNJ>@VCG<
M;OW;N?PO:WPOK.T]LYG<6ZMJ2/+G8J;,R8S&QU-&WCB]U[JZ3X7?%;O3K3Y5
M_-WY2?(+([#FW-\@]N_#SJG9V*Z\CJ*?;T.T?C/TC4T.Z]U46.JY*FKV[0;X
M[O[/W;+CL7/45-31X2BH/-(97<#W7NK./?NO=>]^Z]U[W[KW1'?YE_\`V[\^
M8O\`XKWV7_[SE9[!/N3_`,J#S?\`]*^;_CAZRA^Y/_XES]W+_P`6_;?^TA.C
M;[#_`./&V9_X:FW?_=/1^Q98?[@V?_-)/^.CK'WFO_E:>9/^EA<?]7GZ5?M5
MT0=>]^Z]UCEE2"*6:4E8X8WED8*S%4C4NY"H&=B%'T`)/X]Z)"@L>`ZO&C2R
M)$@J[$`>63@9./V]:I?Q6_G+['[0_FI;IJ4ZES&(Z_\`D[!U-\;=E9QL^M5N
M+#U>R=S[[BV'NW.8,XFFIOM]\9C?ZQ5U%'4!\-$4<359C=9,6>5O>*RW/W1N
MF&TNEAN8@LXVU5=3&\OA2,ND"DK2T90?TQ0ZGH:][??C^[=YHY&^X=L4+>X%
MM<<W<CONO,=[`("MO,E[;6)OK2"?Q6;590V!:"9HZ7C:E,5N'4IM<>\I^N!_
M7O?NO=>]^Z]U_]'?3W*^(KZ&NVI7-BZVMW+@L]3TFVZ[+C%U&?H8Z-*7*0PO
M!Y,C'1HN1BCJ*B"*1J83JUKE0?=>ZU$/AU\%OYXGPPZ'V9\<-B?"'^3%O?8/
M7^YMWUFT]Q]K9G?^Y.RHMM;KW[EMX4F-W7NK`[2VM1[NSNV:;,&ABS+T$%96
M4])3R5"2U"R/+[KW6X#C<MCLG][%19'&5]5B*PXK-18VM@K/X7F(Z6EJY\96
MB)VDHZR.GK(I/%*$E$4J,5`87]U[IS]^Z]U[W[KW7O?NO=>]^Z]U5[_.QM_P
MT;_,9N"?^<0^Z^`;&_\`<W(V/^LIY/\`A[]U[JPGK"W^C7KRP(']QMI6!^H'
M\`Q_!_Q'OW7NES[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HCO\R__MWY\Q?_`!7OLO\`]YRL
M]@GW)_Y4'F__`*5\W_'#UE#]R?\`\2Y^[E_XM^V_]I"=&WV'_P`>-LS_`,-3
M;O\`[IZ/V++#_<&S_P":2?\`'1UC[S7_`,K3S)_TL+C_`*O/TJ_:KH@Z][]U
M[JD;^8O\B?ECV9W7@/Y;OPIVKNO979/8NT:3>7;'R0R])D,#MSKKI[)U38VO
MRNR-PPJ9Q*9UDI*W,4UZBEJK8_&K)DYO+10K[A\P\U[EO4'MSR7:RP[E<0B2
M>\8%4AMV-"T;C/&JM(,JWZ<=935.G?W./9WV!Y)]L]V^^?\`>9WZPW/DO9MP
M>SVKEV)XY[C<-WB7Q(XKVW8Z::=,L-G)^G+%6[O2EC'HN0>^$?\`+)^,7Q[_
M`)A&^\+3X#);]W/\?/CO\=M][6WANW*9*8S]L=@Y;M[#[W['_NZM=+B:;(5T
M6U*=L?2R?<P8ER98;U(2H4GY*]M.6>7_`'`OH5MVGN=OV^TE221B:SRM<+)-
MHKI!.@:%-0G$=U&ZD7[SOWW??#W>^Z%RKN<N[0[3L?-_./,%C=6=I%&NG:K"
M+:9K+;OJ-`E:-#=2"XE7PY+H422D!:$[#7O(+KC_`->]^Z]U[W[KW7__TMPK
MYR_RX/BS_,-P.P,?\B-M;O\`[T]097/9_IGM3K+L3>/5O:G4F?W-1X^@SV8V
M5NW9^6Q[)+E:3$TJSTU?!7T$K4T4C0&2*)T]U[JL5/\`A/-15DZ87='\WW^=
M/NWJZ*5F3K/+_-FI7'UE(YLV(R^5IMD1S5V)>+]MHXH::0)^EU/J]^Z]U;]\
M.?A5\;_@3TY'T3\7M@OL#K^3<V:WQFHJ[<NZ-Y;AW7OO<L=!%N3>N[-U[RS&
M=W#G=Q9M,73K+++4>.**".&".*"*.)/=>Z-5[]U[KWOW7NO>_=>Z][]U[JKW
M^=A?_AH[^8S8@?\`.(?=?)^EO[F9*X_UR.!_C[]U[JPGK#_F6O7E^3_<;:?(
M_P"U!C_?NO=+GW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW1'?YE__`&[\^8O_`(KWV7_[SE9[
M!/N3_P`J#S?_`-*^;_CAZRA^Y/\`^)<_=R_\6_;?^TA.C;[#_P"/&V9_X:FW
M?_=/1^Q98?[@V?\`S23_`(Z.L?>:_P#E:>9/^EA<?]7GZ5?M5T0=4>]W?S&N
MZ^Z_EEM/X??RUL/M+L#<.P=V8W-_)/NO=E++E>G]H[9P^0\6<V0^2H%=Y8ZI
MU:FKJ^BD^\-2/L\;KJ?--3PGO7N)O6]<UVG*'MQ#%<7$$H:\N9!JMXT4]T=1
MZ\&93JKV1U:I7J#[8_<V]L_;/V`W_P"\5]]/<=PVC:-VV^2'ES9K5A%N]W<S
M1U@O1')0`J*2003+X/AGZB]TP^''->!H37Y-"^33H\FD:]%]6C5;5IU<V^E_
M<UT%:TSUS`U-IT:CHK6GE7UIZ]5Z=7?]O-_ES_XJY\2O_>O^0WN/]L_Z>7S;
M_P!*NP_ZN7?67W/7_B$/W>__`!>N:_\`M$Y?ZL-]R#UA_P!>]^Z]U[W[KW7_
MT]^/.RY>#"9B?;]+25V>AQ60EPE%7S-3T-9EXZ29\;2UM0GK@I*BM")(XY5"
M2/I[]U[KYMF"_F>?)C;-;\JNF$^:WSZWI_,B^1_QHZ%P^+^/6X,;V7C=V]-?
MS0\;\VLY'OKX_P#0'6\&U:'K#JSIW"]'8O%5%>1.^.S6`K:N`5<E3-_"*7W7
MNOI/T1JVHZ1L@D$=>U-`:V.E9WIDJS$AJ4IWDM(T"S:@A;DK:_OW7NI/OW7N
MO>_=>Z][]U[KWOW7NJO?YV-O^&COYC-U#?\`.(?=?!_J-FY(AO\`74\_[#W[
MKW5A/6'_`#+7KRPL/[C;2X_I_N`Q_'^P]^Z]TN??NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=$
M=_F7_P#;OSYB_P#BO?9?_O.5GL$^Y/\`RH/-_P#TKYO^.'K*'[D__B7/W<O_
M`!;]M_[2$Z-OL/\`X\;9G_AJ;=_]T]'[%EA_N#9_\TD_XZ.L?>:_^5IYD_Z6
M%Q_U>?JO3KC^9?LGO#YP9+XD]#=?;A[=V7L?;.<JNW/D)M:NHWZ_Z^W=0-(,
M;A#+,BTN>Q%;44<V/-93U7DFR3!:2"IIX:FHCC[;O<FRWOG:3E/8MODN[*")
MC/=H1X44@X+Z,I(*:@U2^$5E5F&7W.?W)^9O:_[K]E]X+W6YNL^7N9=TOH%V
MG8+I'%_?VC@>)-0$M!,BND_@R1:4M@3<2PS20PN>?KCI7J7J"JWS6]7==[3V
M'5]E[MK=][]J-LX>EQ<NZ=W9%$2LSF6:G13/53E2Y`M&))))`H>61G'&W;+M
M.T-?/MFWQ0/<RF64HH77(>+-3B3^RI)I4FN+?.?N9[@>XD'*]MSSSAN&ZV^R
M;>EC8K<S-*+6TC)*01!B=*K@5RQ540DK&@43_9GT!NJ\NKO^WF_RY_\`%7/B
M5_[U_P`AO<?;9_T\OFW_`*5=A_U<N^LP.>O_`!"'[O?_`(O7-?\`VB<O]6&^
MY!ZP_P"O>_=>Z][]U[K_U-^C+/DX\5DWPD-'49E,?6OB*?(RRP8^?)K32&@A
MKIX$DFAHY:H(LKHK,J$D`GCW[KW6B%\?_G'WQWEU_3;_`/E+_P`*=>M?A5\B
M:WL+?^U>V/BO#\2_C'73=);AV7V7F-NU'7&"WO/EX<IN?::4N+AEHLM!55F.
MK(:@,:BM:*>:7W7NM\B`W@A/F%1>*,_<#1:>Z`^8>.T=I?U>GT\\<>_=>ZA9
MF%*G$96GDR=3A(ZC&UT+YFBGIJ:LQ"2TLL;9.DJ:R"IHZ>IH%;RQO+')&CH"
MRLH(/NO=:*&]>T.ZNA_CS_.%^:'\NOY7?*7?/PQVC\;.O?CUU#VCW?\`(??/
M?F[.\/D]1=[[#Z[^4/S7Z*R.[\[E=PX7;/56RMSUV/;<N+IL;ALMGI&J\0QI
M:&`4GNO=*CMO=&^^D_FOV1_+-ZL^2OR)G^!O8O\`,7_E#]7;NW!DOD1V[NS?
MFU<1\G.@N[>Q.WNC]L_(O)[TK>T]M8KY*;EZTVO7U\>,SM,U.N=J(:'[:/)E
M&]U[I\Z1WQV%WSW9\4_Y=_<OR2[\3X3Q?S#/YX75&W=V8[Y`=E[.[![=ZC^%
M&V=D97XT[3W'\B\!NW$]F;FV[U75[XW'7PO5YJ>#*#;-*)_/2X]8U]U[I>[H
M^2'\P_NW_A+]B^P<SLGKGNK"[[^"?R<P_P`A^[NX^XMW;([BI]I;)[`WMUYU
M]OS;>S8NK]XP=J[BW=T[@8,O/+E<YAYZ^L<2S5+RREIO=>ZW">LM(ZWZ^"L7
M7^Y&U-+E=)=?X#068K<Z2PYM^/?NO=+?W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5?\`_--W
M3MC:O\OKY7ON?<>"VXF?Z9WOM;!/G<K0XI<UN?.8&NI\)MS$FMGA_B.=R]0I
M2FI(=<\S`A5-C8`^Z%U;6O('-1N;A(Q)9R(NI@NIV4A46I%68X"C)\AUEM]Q
M'8=\W[[W7L$NQ[-=7C6G,EE=3B")Y?!MH)T::XET*WAP0KW22O1$%-3"HZA]
M*_)7XJ_.[9?=GQBZZ[$KMZ+LCKS`]>]HY7959FL-05.'W]LZ7%RY/878&(>&
MGR=/#40UM"U12SAEJJ23T/3/%)-79>9.5N>;+>N6=NW!IA!;K%,T9905ECTZ
MHI5PPKJ6JGXE."I!*GW,]E??G[JW,OME[X<X\G1;8VZ;Q/N&V17J0S2+-87@
ME$5_82@M$Q4PSB.5*&*5.Y9E=(QN^)'Q#Z5^%?4.*Z=Z3P,F/P]-)_$-P[DR
MS4M7O#?>XY8TCJ]S[PS%-2429'*U"(J1I'%#2TD"I!3Q10HJ`ZY3Y2V;DS:(
MMGV6#3",N[4,DK^;R,`*L>`H`JBBJ``!U&/W@OO#>Y?WE_<._P#<;W-W83;B
MX\.WMHM26EC;@DI;6<+.YCB4DLQ9GEED+2S222,S$SWL3=0=U[W[KW5>75W_
M`&\W^7/_`(JY\2O_`'K_`)#>X^VS_IY?-O\`TJ[#_JY=]9@<]?\`B$/W>_\`
MQ>N:_P#M$Y?ZL-]R#UA_U[W[KW7O?NO=?__5WWMRTD-?MW/T-12)7P5N%RM)
M-029&;#I6PU%#/#)2/EZ<BHQ25*.4-2A#P!M:\J/?NO=:&?PVVQ\G/B1\?\`
M87Q_/\OO^0]W)C-@[BW(,/V9V[\N/BSGNV,OM_/[ZK\_A(^PMSTN.AIMX;VV
MS1Y)<>^9BIZ(UL5'3L***1"C^Z]UOQ0DF&(LL:L8T)6)M<2DJ+K&^E=48/T-
MA<?CW[KW47)XS'9K&Y##9>AI<GB<M0U>,RF-KH(ZFBR&.KZ>2EK:&LII5:*H
MI:NFE:.1&!5T8@BQ]^Z]T2/JO^6)_+NZ.R6[LOU#\*?C3UU7[_Z_W-U/OF7:
MG46S<5'O#K'>:4D>[M@;FI8,6*7-[0W/'00K7X^H22FJUC`D1AQ[]U[J;@_Y
M:_P#VU\>MU_%#`_$#H'&?'/?6;.Y]Y=1TW7.WUVGN?="RT<U-NK-T[4K560W
M3C'QM**+)22M74"4E.E/+$L$03W7NG3?'\O'X+]D]#;#^+^^?B;T/N/X^=6U
MU+E>M^HZ[KG;HV7L7*TLE=*<MM3%T]%`N#RM>^5K#6U-.T<^0^]J15-,*B?R
M>Z]T6K^<7MG;>ROY-7S[V=LW;V$VIM+:OPJ[8VYM?:VVL508+;NV]O878%7C
M</@\#A,9!2XW$8?$8ZFC@IJ:GBCA@AC5$554`>Z]U9+UA_S+7KSBW^_&VEQ_
M3_<!C^/]A[]U[I<^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>ZJ@[0^0?\`,9VY\I\5\>-D=>?"VOHNQ<+VGV1U7G]T
M[[[NHZN+J_K/<NU<+-3[_BQ.R:N*AW[E*;>M!(D6.2KQRN)@9@$7R17N?,'N
M);\T1<O66W[,R7"3S0,\MR#X,+HM)=,9I*PD4@)J2M>[`KGUR-[1?<WWGV(O
M_>'F?G#W+AN=FN=KV[=(+6QV5T.Y[E;74P:P,MZA>QB:RG5FN#%<%?#(C)9M
M%KJ:]">0*)-*ZPA)0/8:@A8*Q75]+@&WN4Q6@KQZP';3J;1717%>-/*OSZY>
M]]5ZU]/Y_GQ=WW\E?C/M7N3J[>&"K=O_`!<J>S=V]B;3FS4<5)F<'+0XFBS>
M6Q<]-'4T55NS8D^V9X315$D+F&KJDC83H()X!]^N6+[F3EJUWC;+R-K?:S-)
M+'JPRT4,RD5!DB*$:21AF`.H:6ZZ_P!TK[Y\J^ROO;OWMOSUR[=1;OSTFVVF
MWW0A)>&</*\,4JL5=;2^6Y1Q-&K@/%`SJ8F,L1M/Y.GPVWO\+/B#2[)[+K=O
M5>_.Q=[93MC-TNVWBK:/`4VX<!MG$X3;DV<2CI),W6T.+P$<U1(/)3PU-3)#
M!)+%&LT@K]H.3[WDSE%;+<GC-_<3M.P3(0.J*J:J#40J@DY`+$*2!4X__P!X
MU]X_EC[R_P!X>?F;DFVO(^5-FVR+:H&N`4>=K>>YEFN!`7<0H\L[)&O;(\<:
M22HDCF-+5_<I]8%=>]^Z]U[W[KW5>75W_;S?Y<_^*N?$K_WK_D-[C[;/^GE\
MV_\`2KL/^KEWUF!SU_XA#]WO_P`7KFO_`+1.7^K#?<@]8?\`7O?NO=>]^Z]U
M_];?DS<<4N%R\4^,;-0R8O(1S89!"7RT3TDJR8Q14/'`6KT)B&ME2[\D"Y]^
MZ]UH$?)3X1T_R)ZNBZG^('_"8GL7XI_(W,]D=79CK7Y`=G[DZZCZQZYJ=J=B
M8+<6=R'96,S63RN`W=L'-[7Q];B\I@\E33T%;1U[LJ//#3`^Z]U]`*C2>.CI
M(ZE:9:F.F@2H6C5THUG6)5E6D22\B4PD!\8;D+:_OW7NI/OW7NO>_=>Z][]U
M[KWOW7NJO?YV/_;HW^8SZBO_`#B'W7R!<\[-R("_ZS'@_P"!]^Z]U83UA_S+
M7KRQN/[C;2Y/Y_W`8_G_`&/OW7NES[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
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M8`!6S#^Y-[=>QW/?NW<;I]X7GS;]H]M.7-NEW6XM;AVCDW;Z6C"Q@-`'U?'-
M#&QN[B-3!:1,\C2P%%W'\*\9\&_Y/GRXZSDW3E-]=@[IZ4[5[`[?WG7Y3*UU
M)N+LC.[29,Y4X2FR<S-18>D2ECIXI#''4UHA^YJ1YY7"A*XY,BY(]HN;-M-T
MT^X2V4\MQ(68AYFC[BH;@HH`#0%J:F[B>LA=F^\O??>C_O%/N^<[)L4&U<HV
M',VUV&TV<<42/;[=!=U@6=H@-<SEFD==31PE_`@_2C4FZ'8?_'C;,_\`#4V[
M_P"Z>C]S+8?[@V?_`#23_CHZYK<U_P#*T\R?]+"X_P"KS]*OVJZ(.O>_=>Z]
M[]U[JO+J[_MYO\N?_%7/B5_[U_R&]Q]MG_3R^;?^E78?]7+OK,#GK_Q"'[O?
M_B]<U_\`:)R_U8;[D'K#_KWOW7NO>_=>Z__7V^OG_P#R]OB_\_-E;*QWRBF[
M(I=L=,97<6^\-7===J;QZMFH9J[`/CLU5YBNVA7T-1DJ.'$PEE62YBLV@@/(
MK^Z]UI!XOK#X9?Z.L+\Q,W_*$_F+;>_E<5>_<=%2_.^H_F;;TKM_TW6M1O:/
M:&&[AS/Q(%2F]<?LJ7/".669*]X8L>PJ8JN5C&K^Z]U]'.E:!Z:G>EE2:F:"
M)J>:.7SI+`T:F&5)]3^9)(R"'U'4#>Y]^Z]UG]^Z]U[W[KW7O?NO=>]^Z]U5
M]_.PO_PT=_,:L+_\XA=V?[;^YF2N?]@.??NO=6$]8W_T:]>W%C_<;:=Q_0_P
M#'\>_=>Z7'OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NJ\^RO\`MYU\5/\`Q5#Y6_\`O=_'GW'^Y?\`3S.5O^E5??\`
M5VTZR_Y*_P#$'_?K_P`7_E;_`+0>8.LW\Q/Y\;*^"?3RYYJ:#>7=N_Y)]M=%
M]2TS2U67WGNZ;Q4T61J\;0$Y0[2V]4UD#UTD05YI)(:.)UJ*J'WOW"Y\LN1M
MH\<J)MZN"4MH!EI)#BI`[O#0D%B.)(0'4PZ;^YW]T[F7[U'N*=J6=]M]L=H5
M;G?-U:BQ6=H*L8TDD_2^KN%1U@5R0BK)<R*88).A5^$(^4A^,W6=3\R,C@,A
MW[D<9/E-UC!XBCPT^-I,E4R5N$PVYJ;$^'`2;OQ6,FCAR+8ZGIJ))U,4:R&-
MJB8TY*_K/_5K;6YPDC;?F4L^E0I`)JJN%[?$52`^@!:X`--3`+[SQ]BA[V\[
M0_=PL[N'VFAG6*U\>5YED>-0DTULTM9Q:2RJSVXN)))BA#NR:Q#$COYE_P#V
M[\^8O_BO?9?_`+SE9[2>Y/\`RH/-_P#TKYO^.'H1_<G_`/$N?NY?^+?MO_:0
MG1M]A_\`'C;,_P##4V[_`.Z>C]BRP_W!L_\`FDG_`!T=8^\U_P#*T\R?]+"X
M_P"KS]*OVJZ(.O>_=>Z][]U[JO+J[_MYO\N?_%7/B5_[U_R&]Q]MG_3R^;?^
ME78?]7+OK,#GK_Q"'[O?_B]<U_\`:)R_U8;[D'K#_KWOW7NO>_=>Z__0W)_G
M9\P,!\)^F\7VWO+X_P#R&^0NQ,MOK$[!WUA?CAU@G;NY]A[6W!A=Q5N1[*WI
ML\93%U,G66".&2DRE1#YY8GKX%$,A?2?=>ZU6?B?\1?Y>_SHQN,^*7QT_GQ]
MO;Q^`$V^(L_%_*MW7_=[KOM`86@W?'O:;I1,SV;_`'4[LRG4F(W/&M.]!3;?
MJZ>.G50E6U24K6]U[K=SBBB@BB@@BCA@AC2*&&)%CBBBC4)'%%&@"1QQH`%4
M```6'OW7NLGOW7NO>_=>Z][]U[KWOW7NJMOYW-52TG\HO^8M)65$--')\2NX
MZ6)YYXZ=9*JKVG74U'3H\C*'FJJJ5(T0>J1V"@$D#W[KW5B'6'_,M>O/J/\`
M?C;3X/U_XL&/^O\`C[]U[I<^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>ZII^;_`,I.GOBM\W>G>WNT-V8BCH.N/AA\
MJ,I+MB'*4/\`>K<>:RV]NB1L[9^#Q3S>9L]O>NQD\&/\PBIV$$\SR)!3SR1P
M[SMS/M'*W.NS[ON=T@CM]FO6T!AK=FDMO#C5?XI"I"5H,,20JL1TA^[![%>X
MOOS]V'W&]O.1M@N)+O>?<KE>(7+1/]+;PQ66^?67<\H%/`LDE1[C1JD'B11J
MC2S1(YW^N<5T3\S-F_&KY:;CZ2,.YL5B:;LGJ&I[0VK%CNP^NI]PT+Q,\5WD
M_P`FJH]%72,'GHJG129"G&M::9!MMT6Q\XV?+?-=QLM+E$$UN9DI+"7'^`X9
M<E3V2+D*1C#SE?\`NI]V[F3WJ^[_`+-[G:MDGN&V[=EVRZ,FW[@MNX-#@=RG
M5%*-*31UN+.7M::-C;^Q9UCYT1W^9?\`]N_/F+_XKWV7_P"\Y6>P3[D_\J#S
M?_TKYO\`CAZRA^Y/_P")<_=R_P#%OVW_`+2$Z-OL/_CQMF?^&IMW_P!T]'[%
MEA_N#9_\TD_XZ.L?>:_^5IYD_P"EA<?]7GZ5?M5T0=>]^Z]UCF\WAE^W\9J/
M')X!,6$)FTGQ>4H"XCUVU6!-OI[T:T.FFJF.KQ^'XD?C:O"U#52E:5S2N*TX
M5Q7JI7J;I?\`F7;?^5^=^0F_Z?X+_P`%[3P74/6_:>%V?N[OZJRN&Z[ZQS^[
MLG)ENOUS6P*"CK=YY&EWW7`0Y&:.A\E/`-:AI&]Q1M6S>Y-OS5/S!?KL?@W4
M=O#.L<ET66*%Y&U1:H@#(1*V'(6H7/'KH%S_`.Y7W)]W]@MJ]H>4IO=/]Y[%
M=[MN.US7=IL*Q3;AN<%I$(K_`,&_D=+.-K&&KVZ-/IDE.DD(.K;O<L=<^NO>
M_=>Z][]U[K__T=R#YY=S?+[I3IW!YCX1?%&@^77>&[.P\'LBEV5GNS\!U/M#
M8NW<IAMQY+)]J;SW#GVBCR&W-N5N&I:27'4T]+5U,F10QR@QE']U[K7V[7_D
M-_.+^:9O;:O:G\U_Y!?%#IRFP>=H]Q4W4WP(^->T_P#2)&L-FIL?D?EUVQAZ
MOMFBEI(0$J*`'/8>6<"5-3112>_=>ZVWHT$:)&"[!$5`TCM([!0%!=V)9W-N
M23<GW[KW7/W[KW7O?NO=>]^Z]U[W[KW50O\`/IZRZ^[-_E%_.Z/L#9FV]Y+L
M/X]]C]F[+_O'BZ7)':O8.SMJ9>JVQO/`/4QN^+W)@I)Y?MJJ$I*BRNE]#NI]
MU[JT/K(LW6_7S.=3MLC:9=B;ZF.!H"QO^;GW[KW2W]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=->;SF%VUB,EN#<>7Q>W\#
MAJ.?(Y?-YO(4F*Q&*Q]+&9:FNR62KYH*.AHZ>)2TDLKJB*+D@>VIIX;:&2XN
M)EC@0$LS$*J@<22:``>9)ITNVS:]SWO<++:-FVZ>[W:YD6.&&&-Y999&-%2.
M-`SN['"JJEB<`=:3OS._E=_++MK^:KG<#CJO;^X,1\DMY;J[PV1V7E-Q86LQ
M.&ZCPF=VY%FCF,1D)Y,I-)U?0;DQ>*CQZ4DZ5\7@%*LD'E,.%_./MCS7NWNE
M/!&\<D.Y3/<QS,ZE5@5DU:E)U?HAT0(%.H:=-5K3Z:ONV??G]@/;_P"X9M6[
M7EO=VFX<E[;:[)>[;%;S)+-NTT%P8?!EC41`;G);W5TUPTJ&!O%\<I+H$F[C
M!$L$,,"6TPQ1Q+9(XQIC0(+1PI'$@L/HJJH_``X]YJ*-("C@!U\Q4LAEDDE;
MXF8DY)XFO$DD_:22?,D]9?>^J=$=_F7_`/;OSYB_^*]]E_\`O.5GL$^Y/_*@
M\W_]*^;_`(X>LH?N3_\`B7/W<O\`Q;]M_P"TA.C;[#_X\;9G_AJ;=_\`=/1^
MQ98?[@V?_-)/^.CK'WFO_E:>9/\`I87'_5Y^E7[5=$'7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7__TM^'<%;48[`YO(4DM%#5T&(R5;2S9)*N7'15%+13
M3PRU\=`KUTE%'(@,JP`S&,$("UO?NO=:LWPP_P"%2_Q)W/\`'K8E7\W*O>NQ
M_DY_'-T[=[!Q_3/QB^0&3Z=S34N],I0;-W;UG75F-W7FCM3<VTI<?*L.4J8<
MO'6BH26EB'B#^Z]UM6QR++&DJ7*2(LB%E9"5=0RW1PKJ;'Z$`C\^_=>ZY^_=
M>Z][]U[KWOW7NO>_=>ZJ]_G8V_X:-_F,W%_^<0^Z^/\`'^YN1L?^03S[]U[J
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M]R+G3V!^[E[<>Y?WI^<MYV_>??;:IOW?R]R^Y*S13W,1'[Q=6"EXF!D22>`L
MMI;Q3(7^KO+>-!NCZXVAT]\]O@[U5L#&-AMD==_"?Y);.VIBGJZO(24.!V_N
MSXY8W&T\U?7S5%;6S)2TZZY9I'DD>[,22?9V-NM-HY[Y)VNPBT65OLMY&BU)
MHJ26@`J:DF@XDU/48OSGS#[B_=0^]#SYS;>BYYGWCW-Y<O+J4(D8>>XM>8I)
M&"1A412S&B(H510``#JT7W)W6"_7O?NO=5H_S8^Y^INN?A-\A]C[][&V?L_>
M':G1O:F&ZVVUN'.4.,S6^<M28."EJ<;M?'U,J5.8K8:G-4B-'"K,IJ$O8&_N
M-O=7>=IV[DOF"RO]QAAO+JQG6%'8*TK!0"$!RQ!9<#U'6:_W`O;;W`YR^\W[
M/\T<I\F[CN/+NP\T[7-N-S;P/+#8Q/.S+)<R*"L*%892&<@$1M3(IT;;XX]S
M]3=W]6X'<73_`&-L_LO`X.BQ&ULQF-EYRASV/QNXZ#;N%KJW"5M30RRI392D
MI,E3R20O:1%E74!?V+.7=YVG>]K@N-HW&&Y@151FC8,`X125)'!@""1Q%1UC
M[[S>VWN![8<];KLWN+R;N.R;M=22W4,-Y`\$DEO)<3(DZ*X!:)WCD57%58HU
M":=#Q[/>HJZ][]U[KBY94=D3R.JL4CU!=;`$JFH\+J/%SP/>B2`2!4TX=;%"
M0":#HGVTOD5W%N+M!^KLE\9,EM_(XB/:V6WGDI.W-AY.DVOM+=N0R]!C=Q)%
M1QB7.R*<#5N]'3'S@1@?VUO%FU\^<UW_`#$>7+CV\D@GB$+SN;VV=88)F=4E
MHN9#^FY,:]V/F.AU?<J[#:[.-XBYO26*3Q%B7Z:93)+$JEDS\'QJ`[8S\CT<
M/W*G0$Z][]U[KWOW7NO_T]^+/UM?C,%FLCB\9)FLGC\3D:W'8>*589<M7TE'
M-/1XR.9@RQ25]1&L08@A2]_?NO=?/\HOYB/R/P'PVQ/\T#_A\MMU_.:;L;$5
M68_E*U>#ZY@VID<E5]Q4VQLO\4J;XW1R3=OX/)4NVI'1=SPX@50BC^Z2=7D7
M*CW7NOH(4<TM31TE144ST4\]-!--1RNDDE)++$KR4TCQ^AW@=BI(X)''OW7N
MI/OW7NO>_=>Z][]U[KWOW7NJO?YV%_\`AH[^8S8@?\XA]V<MR+?W,R5Q_KL.
M!_C[]U[JPGK#_F6O7G(/^_&VGR/H?]P&/Y'^!]^Z]TN??NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4#_,[^>F^.D9=@?%+XD"#=?S
MA[_S&(Q.Q<-1T6+SHZVVW5UH-7OC<F-RD-;B89*VGI9DHDR$1HX::*JR%3_D
M]'HGB/W,Y[OME-ARKRG27G:_=5B4!6\%"<R.&!7(!"ZQI`#2-VI1NB'W'_NH
M\K^YR<V^_?W@M=A]U_E*VEEOIG>6#]XW*)V65M)$R2D(S(TQ@;QGD:"S@_6N
M=45JNQHMYP;+VE#V/6;<R'8,6V\)'OBNV?1Y#'[3J]VIC:9=Q5&V:'+U-9E:
M7`RY82FD2IE>=8"NLZK^Y2L1>+96@W%XVW`1KXAC!$9DH-90,2P7572"2:4K
MGK`SFB3EJ7F7F"3DVWO(>46O9C9)=O')=):&1OIUN7B5(FG$6@2M&JH7U:1I
MIT1SLK_MYU\5/_%4/E;_`.]W\>?8)W+_`*>9RM_TJK[_`*NVG647)7_B#_OU
M_P"+_P`K?]H/,'5AGN0.L0.O>_=>Z9,QMK;FX32MG]OX3.-1&5J(YC%4&3-(
MTX03&E-;!.:<S"-=6BVK2+_0>V9K:WN-/U%NCZ>&I0U*^E0:=&>W;WO.SB<;
M3N]U:B6FOP97CUZ:TU:&752II6M*FG'K-B,%A-OTST>!P^*PE').]3)28C'T
MF-II*F1422H>"CAAB:>1(U#.1J(4`G@>]PP06ZE((51":T4`"OK04STWN&Z;
MGN\RW.Z[C/=7"J%#RR/(P45(4,Y8A022!6@J?7IU]N](.O>_=>Z][]U[HKFS
M_P#LK[O'_P`0QT9_[T/;7N.=J_Z>CSC_`-*G;O\`J[>]#&__`.5&Y=_Y[[O_
M`(Y;=&C]R-T#NO>_=>Z][]U[K__4WZ,M55E%B\E6X_'29>OI,?655#B8:B"D
MERE93T\DM-CHJJJ9::FDK9D6)9)"(T+78V!]^Z]UHZ_&N;YK_,BIPW\PC`XG
M_A.)\8N]-Y=M;RRTU#W)\=ZZC^972V^]D]A9':N5V_V;N[-4L6\<;W?B*C$$
M5=14B++$30N)*=9T2+W7NMY>/7XT\I1I-"^0Q@K&7TC645F9E0M]`22!^??N
MO=<_?NO=>]^Z]U[W[KW7O?NO=5>_SL?^W1W\QGB__.(?=?%K_P#,&Y*Q_P!@
M>??NO=6$]8?\RTZ\_P##&VE_[H,?[]U[I<^_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[I/;DW;M39U%#DMW[FV]M7'5%5'0T]?N3-8W!T4]=*DLL5'#59.I
MI8):J2*%V6-6+E48@6!]I[F[M;-!)=W,<49-`78*"?2K$"N.'1OLW+^_<QW,
MEER]LEY?WB1EVCMX9)W5`0"Y6)68*"0"Q%`2!7(ZP;:WQLK>?WXV?N_:^ZSB
MI((LH-M;@Q.=_ALM4LKTT=?_``NKJOLY*A87*"327"-:]C[K;7ME>>)]'=Q2
MZ*:M#JU*\*Z2:5IBO3V]<K\S<M_2?UBY=OK#Z@,8OJ;>6#Q`M`QC\5%UA20&
M*UI45XCHNOS*^9O3/P:ZAF[@[EK<E)CYLUB]O;=VGMN.@J]Y;QS.1J8Q-0;:
MQN2R&*HZE\3BQ/7U3S5$$,5+3M=_(T4<@>YQYQV?DC:#N^\.QC+JB1I0R2,3
MD("5!TK5F)(`4'-2`9B^[?\`=M]R?O1^X<?MU[;VT*WBVTMQ<75R9$L[.&-3
MI>YDCCE=1++H@B5(W=I9%[="NZ+G;O371.YNS<'\L\9UCA:?N'</6U!MVB[%
MR6WJ[![W_N3FXJ#+4^+S&,R,='4T.7BIDBIW>KI4RE)`&HV=(M<)76^S['<[
MG!S7%MB#=Y+8()BA63PVHP5@:$-2@.I=:BJ5`J.@OO'N1[J;)R1NGW?[[G>Y
M?VZL]Z>X?;X[A)[+ZV$R1-+#)&75X2Q:11%*;660K<A6DTR=#S[/>HHZKT[*
M!_X<Z^*A_'^RH?*T7_Q&^_CQ?_>_<?[E_P!/,Y6_Z55]_P!7;3K+_DK_`,0?
M]^A_X?W*W_:#S!U87[D#K$#KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HKF
MS_\`LK[O'_Q#'1G_`+T/;7N.=J_Z>CSC_P!*G;O^KM[T,;__`)4;EW_GON_^
M.6W1H_<C=`[KWOW7NO>_=>Z__]7?@W#"]3@,Y3QR9B*2?#Y.&.7;TL$&?C>6
MBG19,'/5$4L.81FO3/(1&LP4MQ?W[KW7SZ_B5\*L/U9TQM39'R=_X3&_)CY3
M]WXO>6\ZS=WR4W/V308C=7;5/G.PLMF]N;XWE@J[L3/?W?W6=N9"EARN/AKZ
MW'?=TLDT=08ZAQ'[KW7T)X%"P0JL7VZK%&JP'3^R`@`B]!9/VQQP2../?NO=
M<I5=HI%CD\4C1NL<I0.(W*D+(4)`?0W-B0#;W[KW6E'V?W?\C_B#\9/^%,U+
MU+\K_D'W/V#T/VA\7Z#KON'M+L>+L'M+9&([MV-U53=P[MVG4;6QFVMM[&BV
M70[]S53BX-N8K$4>WDQM/'3I$U&C+[KW0<]M[AW+TQ\T>ROY:W4WR)[\?^7K
MV'_,8_E#=8[TR=3\BNX-T[GVQA_DKT'W=V'W)T?M[Y%Y'?5;VIMW!_)?<_6^
MUZ_+QXW<%,T`SL\%$:2/)>-O=>Z>^D]X;M[V[G^*'\OCN[Y$=X-\$H?YAW\\
M3JW:^X:;Y"=H;.W7VSU%\,-L;)R?QBVCN3Y$[?WIANR]S[8ZGK=[;DR%&U9G
M9Z?)G;-+YQ/38](E]U[H0]S=\_S'N\/^$OF&[(K\?TQVGMG=GP4^3>)^1_:_
M?/9'9^V^^LALS9G8.]M@]=;VV'M_$=<;OPW8>Y-V=,8"#)SS[AS6*FKZV5)I
MJEWD=Y?=>ZW$.LM/^C?K[0S,G]R-J:&8`,R_P&@TLP!(#$?6WOW7NEO[]U[K
MWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N@%^274'5/<G5&Y\-VWUML;LW$8##;B
MW-@\7OS:V%W7C\1N.DVQFZ&DSV,I,W1UL%#F:2DR$\<53$JS1+*VA@3[(N8]
MHVK>-JN8=VVV"YAC1W5945PKA&`8!@0&`)`89%<'J5_9?W$Y^]N.?MCW+V^Y
MTW39-PN[FWMIY;&ZFM9)K=[F%W@D>%T9X7>-&>-B48J-2FG16_Y6G574O6?P
M?^-^\=E]?[#V)N/LWH?IG,]C;FV]MW"[>RV^\_\`W9BDH\IN_+45-356X<L:
M_/5/CFJY)9?)5.%/KM["_M?M>T[;R3RY>65A!!<7-C;M,Z(J-*VC#2,`"[59
MJ%B35CZ]3K]^SGSW`YV^]![S\N<R\W;KNNS;)S7O$.W6UQ<37$5C!]20\5I$
M[,MO%X<$>I(E5=,2DCMKTGNT?Y=M1WQ\_MD_*[O'L>#L;ICI_9M`.E>@*["?
M:8W9?94<]%)79[*2))-C]SXV;(T7\8\LJ1UDU>M'33:Z+'1),GW/V];?>?;+
MFK>]Q%QLUG"/IK4K01S5%6;R<5'B5-&+:%-4C`)OR-]\.+VJ^Z5S/[!^UW)C
M[-[D\Q;E)^^=^2;7)>;:5<)!$"!);2"-_I-*%H4@-Q-'IN;R1H[/_<F]8.=>
M]^Z]U7=OC^5#\`^R-\[N[+WIT)_&M\[ZW9D-[[GW$>TNZ,?5UVY<MD#E<E64
MT6*[%H:/$4M;D#Y)*.BCIZ)B`/#8`"/;[VKY"W&^N]RO=AUWT\ID=_'N`2['
M42-,P"@G)50%^768?*_W^OO:<F<K<O<E<M>['TW*VU;?'96UO^[-FD1+:*/P
MHT8R[<[S,D?:LTS23"I/B5))L/1%C14065%5%%R;*H``N22;`?GW((%``.'6
M'S,79F8]Q-3UR][ZKT&'8W=/4_4+X1.S^P=K[%?<CUT>!7<F4@QIRSXQ:9\@
MM%YB/,:1:R(R6_3Y%_K[#N_<V\L\KFS',6^6UF;@L(_%<)KT4U::\=.H5^T=
M'&U<O[UO@N#L^V37(BIK\-2VG5736G"M#3[.G/KSM#KSMG"U.X^M-XX'>^"H
M\G4X6JRNW:^+(T4&6HX::HJL?)-"2JU4$%9$S+]0L@/Y]J-BYCV+F:TDO^7]
MU@O+)9#&7B8,H=0"5)'F`P)'S'3.Z;/NFR7"VF[6$MO<L@<*ZE25)(#4/D2#
M^SI>>SKHMZ][]U[KWOW7NBN;/_[*^[Q_\0QT9_[T/;7N.=J_Z>CSC_TJ=N_Z
MNWO0QO\`_E1N7?\`GON_^.6W1H_<C=`[KWOW7NO>_=>Z_];?BSXI#@LT*]*V
M2A.)R0K8\:*DY&2D-'-]RE`*(BL-:T.H1>(B77;3ZK>_=>Z^;M\ENL?Y<F_>
MJTVG_+K^+7\Z_=7S"RG9/5W^B79O;6*^2])U/O3[?L;!S[VVGVCDJO?5#48+
M8N>V0N1CJ,ECJN@RN-JOMJE:J"**I?W[KW7TE:(2"BI!-`*644M.):43FJ%-
M((DUP"J(4U(A:Z^0@:[7_/OW7NI+*&!5@&5@596`(8$6((/!!'OW7NB3]7_R
MV?Y??2>2WCF.H_A9\8^N<EV'L/<_5N_JO:'2VP<++O;K;>LM)-O#86[/L\'&
MFX=H;G>@@^_Q]6)J6J6)%D1E4`>Z]U)PO\N;X&[<^/\`NGXJX/XA?'S&?'3>
M^9.Y=X=/4G6&UH]D[FW.L]#4TVZ,WBOX>1D=T8Z;%TAH\E*S5U$*.G$$L8@A
M">Z]TY;V_E__``@['Z,V+\9=]?$_H+<_Q^ZPKJ3*=<=093K':DNQ-B92C>O=
M,IM+`IC4I,!DZHY:L%544HBFK5K:D5#2BHG$GNO=%C_G&[<V_L_^3=\_=I;1
MP.&VQM7:_P`*NVMO;:VSMS%T.$V_MW;^%Z_K,=B,)@\-C8*;&XG#XC'4T<%-
M34\<<,$,:I&JJH`]U[JR'K#_`)EKUY<6/]QMI7']/]P&/X]^Z]TN??NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]T#'R([$V'U5TEV;O;LG=^WMC;1Q>SL[#7
M;AW/E:3$8N&JR6.J,=C*%:FKDC6?(Y7)545-24T>N>JJ94BB1Y'523<P[A8[
M7LNYWNY7<<%HL+`N[!5J00HJ>)8D!0,L2``20.I*]GN3N:^?/<[DCECDOEV\
MW3F&?<8&2WMHGFE*QR+)*^E`=,<4:M)+(U(XHU:21E168:O/3-?VA_-#V3\+
MO@KU-7[FVA\0OCATMT5N3Y<=L8I9L3/N?L';NVL141]8X#)QO+$V0P.5IOMZ
M&)R&7(I/E):>2/&T?DQDV:3<_<ZRY-Y'VJ26'E';K*V>_G6JEY413X*-ZJPH
MH_CU2E2(TKW,]R;7D;[C/,WWE?O3\_VECN/WA^<^9M\M^4]JEI*MM87%S*IW
M.>(@$1SQ-XD[`$&W,5C'*CWMSHVXL?0P8R@HL;2FH:FQ])34-.:RMK,E5F"D
MA2"$U61R,]5D*^H,<8US3RR32M=G9F))RQC18HTC6NE0`*DDT&,DDDGU)))X
MDUZ^?&[NI;V[N;V<()YI&=M")&FIR6.F.-5CC6I[41511154*`.I?N_2?KWO
MW7NO>_=>Z][]U[KWOW7NBW?,"""3XO\`?<LD,,DD/5&]C"\D4<C1'^"U#WC+
MJQ0ZXU/'Y4'\#V`?=)$;VZYU9D!8;9<4)`-/TSP_8.A9R*S#G#EI0Q`-[%7/
M'O'0Y[8@@I]O81:>"&!6Q.,=E@B2)2WV%.FHK&JJ3H4#_6`'X]C';D1+&S"(
M%!B3@`/PCTZ#EXS-=7!9B3K;B:_B/3][6])NO>_=>Z:<[GL'MC$UV>W)F<7M
M_"8V!JG(YC,U]+C,904Z_JGJZZMEAI:>,$_5V`O[2WE[9[=:S7NX7<<%G&*L
M\C*B*/5F8@`?:>G[:VN+R>.VM('EN'-%5069CZ`"I/Y=4S?&?OGN_N#YF;H3
M:^X>N]U;1K*.FHMY=A8':>4BPF:ZDZ]R^?DV?7[96ISS?99O=.0W0U(]0QJ:
M=V69XH@L()Q0]O>=.<.:O=C<1MU_87.UN@6>YCA<1R65J\O@-%63MDF:8H6.
MI20Y5:(.I[YNY;Y>V+D*S-Y:W4-\K$Q0/(NM;F=4\59*)E(UCU:>UAVAC5NK
MK_>7/6/O7O?NO=>]^Z]U_]>][_A1;G>W=O=0_P`LVOZ!AP.0[P/\Y/X3P=28
M#>.6RF$V!NGL-\-W+)M/;78V2PM3296#8>6S44*9,P.)?`#H!:P/NO=8E[9_
MX4_?<0J_Q1_E-BG-73K/(G;O?3$4AJ(UJ70'/HP84^HJ=+%3SH:V@^Z]UL.1
M^3QIY0@ET+Y!&2T8DL-81F569`WT)`)'X]^Z]US]^Z]U[W[KW7O?NO=>]^Z]
MU5[_`#L;?\-&_P`QF]P/]E#[K_3>]_[FY&WT_!/U_P`/?NO=6$]8?\RTZ\M<
MC^XVTN3]3_N`Q_U_Q]^Z]TN??NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UJ
MY_S6^YLM_,LWO2_R^/AOBH-^GIG<M;V[WUW1+F:RAZKV;5[*VUNK$IM2KR^-
MI,C3Y-*:HS$R3SA)@V5CAI:5)72I>#&+W4WB7W(O5Y`Y/B$_T<AGNKC41!&8
MT==!8`AJ%B":'O`502&*]T?N#^VVW_<IY8G^]W]X^_?:1S)9)M.Q;,(4?=+Q
M+VYM93=)#(\;1EEA1D0LA%JTD\[1JT*RFQ_D&_#W=GQN^+F4[8W=N_'YF7Y4
MTO7G9>W=K866NJ,9M/:%+M_(5&WYJZ:LAI$.[<]#N5SD8X(FA@CI::,32D-H
M%?L/RA=\N<L2[K=W:N=T$4R(M2L<80E*DT_48/W@"@"J-1\H!_O8_O%[![S^
M^ECR!R_R]-;1\AR;AMMQ=3!%DN[MKB-;@(J%S])`UL/IV=@[M+,YBC!&J]OW
M.77*SKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z+G\O?^R7.__P#Q$^]?_='5^P'[
MH_\`3N>=O^E9<?\`5MNA5R-_RN/+/_/;%_Q\=#IMW_CW\%_VI\9_[A0>QC8?
M[@V?_-)/^.CH.77^Y5S_`,U&_P`)Z[SN?P6U\379_<N9Q6W\'C(6J<CF,UD*
M7%XNAIU_5-5U];+!2T\8)^KL!?WN\O;/;K6:]W"[C@LXQ5GD8(BCU9F(`'VG
MKUM;7-Y/';6EN\MPYHJHI9B?0``D_ET1NO\`F-NGMRMJ=M?#/JZL[?DCG:CK
M>Y]X&NV;T+@)5:(2S09^IIX\SOR:G5F)I\3"5<KQ,0?<.S>ZNY<T32;?[3\N
M/NK`Z6OY]4&VQG%2)"!)<D9[85H:8>G4BQ\AV>QQI=\^[PMB"*BUBI+>./0H
M#IA!_BD./X>I6"^%;[\RU!O3Y>=C97Y$[HI)HZ['[(E@?;/16U*M?$RK@^MZ
M*;[;-R4[Q"U5EWJI);79`?;EE[1G>KF'=O=+?Y=^W%2&6W(\+;H6Q_9VJFDA
M%/CF+D^:]4N?<`;;#)M_(VU)M5FPHTU?$O)!_3G(JE:_#'I`\CT(>P:"AQGR
MR[EQ^-HJ/'T&/Z.Z'H:"BH:6"DI:*BI\]VS'3T=)3P1QQ4U)`B@)&@5%`L`/
M9[LD$-O[F\V06\*)"FS[<JJH"A5$E[15`H`H\@,#HJW.62;DG8999&:5MQO"
MQ))))2VJ23DD^9.>C7>Y+Z!?7O?NO=>]^Z]U_]#?AR^W\#G_`.&?QW"8C-?P
M3+T6X,-_%\;1Y+^$9['>7^'YO&?>0S?89>@\[^&IBT31:VTL+GW[KW3O[]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>ZJ^_G87_`.&COYC5@#_SB%W9]>./[F9*
MY_UP.1[]U[JPCK#_`)EKUY?Z_P!QMI_3G_EP8_\`/Y]^Z]TN??NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=5D]>?S+]E=V?.&N^(_0W7VX>W]G;*VUG:KM_Y!;5KJ
M-]@==[LH#)_#,*TTRK29[$U=31RX]ZRGJO))DG"4D-3##4SQ1IM_N39;USL_
M*>Q;?)=V<,;&XND(\**0<%]&4D%-0:I?"*RAF&;O.'W)^9O;+[KUK]X/W6YO
ML^7>8]SO8%VC8+I'%_N%I)3Q)@`2\$J*ZW`ADBTK;@M<2P2R0Q.;23I?J;J+
M8W>^0ZQZ\VGL2M[,I]Z[ZW]5;9PU)BIMU[MK]OUD=9G,N]-&AJ*N<JSD<()9
M99`HDEE9Q8=FVK:;'?9-LV^*![D22RE%"ZY"AJS4XD_LJ2>))./Z>Y?/_N%S
M3[56G/'.&X;K;;(]E8V"W,SRBUM([A"D$(8G2BX'FVE40G1&@4*_Y;W_`&0%
M\-O_`!6_J/\`]XS$^ROVY_Y4+D__`*5T'_5M>AY]\[_Q+3[Q_P#XN>[?]IDO
M1UO8SZQFZ][]U[KWOW7NBH[E^7&UMK[YJ^NZOJ;Y"Y'<L-5F(\;!A>I,ODJ;
M<F,P%=1X_+;EVS4Q52C,;9I*C(T^JK0!-,\9MZA[C3</<_;=NWF78I.6=]DW
M`,X41V3N)4C95>6(@]\2EE[QBC*?/H:6G)%Y>;<FZIO>UK:$+J+W*J8V<%EC
MD%.V0A6[3G!].C6J=2AK$7`-F%F%Q>Q'X(]R4#4`]`LX-.N_>^O=$?\`Y@'9
MZ]=_'O=6(JMIY[.8[M#$YWK<Y_$38Q:#:.8W#AZF'"5NX8JVK@K6Q=?.)(@]
M+'.ZS*B%1Y%(A_WNYB&Q<C[E:R;9--!N,4EKXB%-,$DJ$1M*&8-H8U%4#'50
M$=PZD/VRV?\`>G-%E.E[%'+9ND^A@U951@7"$`C4!0T8@4J:X/07;'^:7:7=
MVV\?@OC%\=-SY;/4ZQXC);\[5R%!MOJ+:HHH:6G:MJ<YAJO)5N[:R_D/\.QH
M%0H0>1HR=(#>S^[?,?-^WP6?MWR'<2WJ@(]S>,L5E#I"C49(V=IFX_I1=PIW
M$5IT<[CR!L_+UW+<\W\TPI;$ZEAME,ES)4DT".%$0X=[]N<`\>A!P/PK.^LM
M0;U^7?8V5^16ZJ.:.NQVR9X&VUT7M.K7Q,JX+K:BF^US4E.\0M599ZJ62UV0
M'V>67M&=YN8-W]T=^EW[<D.I;<CPMNA;']G:J:2$4^.8N3Q(Z*[GW`&W02;?
MR/M2;59,*-*#XEY(/Z<Y%4K7X8PH'D>CR8_'T&)HJ7&8JAH\;CJ&".FHL?CZ
M:&CHJ.FB73%3TM+3)'!3P1J+*B*%`^@]S'!!!;0QV]M"D=N@`55`55`X`**`
M`>0`IU'<LLL\CS32,\K&I9B223YDG)/S/4SV[TWT5S9__97W>/\`XACHS_WH
M>VO<<[5_T]'G'_I4[=_U=O>AC?\`_*C<N_\`/?=_\<MNC1^Y&Z!W7O?NO=>]
M^Z]U_]'?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U5'_/+W'MS;?\
MHK^8/)N3/87`19GXN]L;<P\F:RM#B4RNX\UM7(4N$P.->NG@6OS67JR(J6DB
MUSU$AT(K$V]^Z]U9'UA_S+7KSZC_`'XVTN#]?^+!C_K?F_OW7NES[]U[KWOW
M7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NJLOE=W1_,)ZO[\ZOV)TQ'\-JSKOY`[\?KCJ>;LS;_=]9O7;F;P
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M!B:>3^(;BW+EFI:S>&^]Q21K'5;FWAF*:DHDR.3F1`D:1Q0TM)`JPT\442*@
M.N4^4=EY,VF+:-E@*Q`U=VH9)7\WD8`5;R``"J*!0`*=1E]X/[P_N9]YCW"O
MO<7W-W99=P=?#M[:+4EI8VX)*VUI"SN8X@269F9Y97+23222,6/'Y:P;^K>L
MX,5U_P#(#JKXZ5V:S+X7,;O[<VC1;QP>9P>4P.<HZG;.)H:_?>P(://U%1-%
M50SBJG81TDB>%@Y94_.=Q-!M2"'F>QVKQ)-!ENE5D<,CCPUURP@.?B!U$T4]
MIXA#['[U[?\`+W.+;O[A^VV[\T;=!`)(+;;[_P#=\L5S'/#(D\DHLKWQ(0BO
M&T7AI4R*WB`J`P3_`,OSKS>G3O5D73F?^3_4/R0VKU1MC8&P]A#K#9>-VID]
MCX7;N*R6-%-O6IQW8F^_XUDLY24]*87D6B*&CE:TGD.@H]N8S9;6VS+SAM^[
M6UE'#$GTRH&A558`2E)I:LX`I73\+<:X'GWJ/<GD+W=Y\N_<;E/VCWCE7?\`
M>K^^O=R^MW$W\=U/=2QR@VJFQLOIXXF,NI:S:A*@JGAC4?KW(O6+_7O?NO=>
M]^Z]T5S=O_98/2O_`(A'N_\`]ZCJ3W'.Y_\`3T^4O^E/N'_5ZRZ&-C_RHO,'
M_2QM/^K=ST9RJJJ6AIJBMK:F"CHZ2&2HJJNJFCIZ:FIX4,DT]1/*R10PQ1J6
M9F(50+DV]R'))'#&\LTBI$H)+$@``9)).``,DGAT$$1Y'6.-"TC&@`%22>``
M'$GHC&Y?F?)O;.9'K_XA[`J_D/O.@G>@R^](JI\%T5LJK4R([;D['EC-+FIZ
M=HB318@5,TOT5U;W#FX>[+;O>3[)[7;(V^[LC%7N`?#VZW;/]K=$4D(I_9P:
MV/`,#U(UIR"-OMXMSYYW-=KV]A58J:[R4?\`"X!E`:_'+I`\Q3H#N^/B[O/)
M=']P]O?)OMO,=L]B;=ZUW?F=I;1VQ)7[+Z8ZWRT&)GFI:S;&U*&IBJMPY>A:
M!-&1R[S2MR3$#8@'<Z>W.[7')_-7-'N'S/+N>_0;?/)#!"6@L+5PA(:&%2&E
M=:"DLY8G^$'H1<M\X6$7,6Q;'RALD=EM4MW$LLL@66ZG4L`1)(00BFIJD0`_
MI=69;"PF)VWLC:&`P5!3XO#8?;6%Q^-Q])&L5/24E-CJ>.&*-$"CA1R?JS7)
MY)]Y";+9VNW[/M=E90+':16\:HJB@50H``_U?/J(MRN)[O<;ZYN92\\DSLS'
MB26-3TK?9GTBZ][]U[KWOW7NBN;/_P"RON\?_$,=&?\`O0]M>XYVK_IZ/./_
M`$J=N_ZNWO0QO_\`E1N7?^>^[_XY;=&C]R-T#NO>_=>Z][]U[K__TM_CW[KW
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MEE1':"!H*;6'J)(HKN`YS)S9R]RE9F]W[<XX$H=*DUDD(\HXQ5G/"M!05JQ`
MSU,_LK]WOW@^\+S(G+'M+R1>;K=!U$TRKHM+16K1[N[?3!;K0,5#N'DTE8DD
M>BG4#_G']O\`RR[U^474NX^K*_M[,_'CM'KK8>X_AU%UO2[ICQV[XNP^NX8-
MZ0XVCVLAEK^TZFNSN6Q66Q\GDR]-C)4I9(UI94$F(_O!N_->^<S[3<;6]V_+
M]U;Q/M_@AZ2>+$!)0)QG):1)$-9`A"D:2*_1#_=Q^W?L![6>Q?N!LW/=KR[;
M>\&Q;S?6_-YW%K4R6AV_<&:S,CW1I'M:I!:W5I.NFTDN5:=',\;%-L/X#?&3
M:/Q0^*W4/6&`V#B]@[G;9&U,]VS2T4XR61S';64VYBI-]Y7.YYM51FZX9M9*
M>)RQAIZ2&*GIU2FBBC7*OD/EJTY5Y6VC;+>P6"Y\!&G`-2T[(OBLS<6.JH'D
M%`5:*`!P'^]E[W<P^_OOQ[A\\;MS9/NVQC=+J#:F=?#CAVJ*XE%C%!`.V%/!
M*R,`-<DKR33%II)'8Y/L8=8W]!MVQCMC9+9>5BW[0;2R&-BI,A-CHMX4N'JJ
M"/,KBL@*:6C3-))3IDE@,NADM*$+VXO[#_,UOLUQM-RN]P6KVX5BHG",HDT-
M0KX@(UTU4IFE:>?1MLLNXQ;A"=MDG64LH;PBP.G4M:Z,Z:TK7%:=`S\+<;L:
M@^/'4[[6H-HT6<K.L>OIMY/MVEPM/E*K)C;\0BEW*V+1*J>O$K3V:JO)J,GY
MU>PI[2P;/#R+RRVVPVJ7C;=;&?PA&'+^$*&71DM75\>:ZOGT?\_R[C+S3O8O
M))VMEO)A%K+E0NOA'JP!2GPXX?+HU_N2^@5TB\WV1UWMD.=Q[]V7M\1W\AS>
MZ,'B@EOKJ^^KH-/^Q]E-YO\`L6WU-_O5I!3CXDT:?\>8=&%OM.Z7=/I=MN):
M_P`$;M_@!Z`3/?.?XA;;J'H\E\A.MI*M"5-)A\V-QU)8<%4I]O0Y260W_P!2
M#[!5[[R>UM@YBN.>=O,H_#')XI_9$')Z$MM[<\\W:"2'E>[$?JR>&/VN5ZK:
MW9\R>V][_*S`5O0NSMK=IRT.)W3L_J2.;;F]=K/NK;&\&VUG=PUF<BW)7X-Z
M>HVK4[5\4N14TV-6!7E9;LJB`-S]U^9]X]RK*7DK:K;<F2*:"R!BN(?&AG\*
M25I!*T=#"8:-*-,06K$9`ZEBRY"V3;N2[F/F6^FLE9XY;FDD4GAR1>(B!#&K
MU$@DJ$.J2M`#@GHZ5/\`%7M#OJI@S_S-[&_CV!,T=90_'#JRKR6V^H<9I(E@
MI]YY>.6GW+V76T_D9)/N9(:/4/2CH;>Y;C]MN8N=)$O?=C?O&LJAEVJS9XK%
M/,"=P1+=L*D'452O`$=`!^<]GY:1K7D':O#N:4-]<!9+EO(F)<QP`\1I!;U(
M/1Y=M;7VWLS"8_;6TL#B-L[>Q,"TV-PF"QU+BL70P(+".FH:**&GB7\FRW)Y
M-S[F/;]NL-ILX-OVNRBM[&):)'&JHBCT"J`!^SJ.KN\N[^XEN[ZYDFNG-6=V
M+,3\R22>@0^7O_9+G?\`_P"(GWK_`.Z.K]@_W1_Z=SSM_P!*RX_ZMMT(>1O^
M5QY9_P">V+_CXZ'3;O\`Q[^"_P"U/C/_`'"@]C&P_P!P;/\`YI)_QT=!RZ_W
M*N?^:C?X3T\>U?3'7O?NO=<7=8T>1R%2-6=V/T55!9B;<V`'O1(4%F.`.M@$
MD`<3U7=US\DNC\Y\LM_5^*["Q591=A;$Z:V+LNJCH\RD&X=W8W</8QR&"H)I
M<9'&:ZC_`(W2^0.45?,MS];03L/N!R=>>YN]S6V^Q/%?65A;VY"R4EG26ZU1
MJ2@&I?$2M:4U#J4MUY3YBM^2=LBFVMUDM;FZFE%4JD3)!I<@-P.AJ4KPZL3]
MSOU%G7O?NO=>]^Z]U__3W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=5>_SL;?\-&_S&;B_P#SB'W7Q]>?[FY&Q_V!Y]^Z]U83UA_S+7KRW`_N-M*P
M_I_N`Q_OW7NES[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7N@=[V^0/3?QFZ\R/:O>N_\`"=<[$QE1#129K,M52R5V3J8:
MFHI<-A,3C::NS6X<[64]'-)#0T-/454L<,C+&51R"??-_P!GY:V^3=-\OTM[
M%334U<L:D*J@%G8@$A5!8@$TP>I&]J_:/W(][><+/D+VLY2NMYYJG0N(8=("
M1*55IIY9&2&W@1G17FGDCB5G12X+*"1?X5_S*:KYR]P[RQ?5_P`;>VL!\:-O
M[9KI=O\`R/WI0Q8G"[MWQC,S1T-7MNEQB^7'PP34$\LT(ILA7UT?B'WE/1F0
M*`1R9[CMSON]Y%MG+EW'RW'$=%Y(-*R2*P!0+PI0DBCLPIWJE>LIOO+_`'*X
M/NM^W7+E]SS[T<OW?O7=WR"XY=LW,LUI92PNZ7+2XD+"151_$@@@;4?IYKG0
M27Z?^5#\1MQ_*/L/Y8]I;:S?=.^=[Y?'9C$;5[4R[[KZXV'446-@HZA,!M*L
MB^URM-65:25$=+EVR-#0,ZK1P4XC0A]O:OE.XYGW#FO=+9[V^G<,J3MKAB(`
M!T1G#`FI"R:U6M$5:#HIB^_U]X39O8KD_P!@>1=[M>6N5MKMY(9;K:X1:[C?
M*\C.IGNT.J)D0K&TMH+>><*6N99B[=(SY9[&^:F[^^^D-P=.=<_&.HZW^-'8
MS=B;';>O=&Z=G[CW;_&>G=Q==Y'`YK;F+ZUS6.VM2XJKWG6/2R05-4)8:6#T
MQZW54'-EKS?=;_LL^TV.U_N_;;CQH_%N7C=]5N\15D$+!`ID8J06J%7`J>C_
M`-@N</NP\M>U/NALWN5SQSK'SKSKLPV^^%GM%I=V]IX.[V^X1SPW$NY0R7+2
MI9PB57CBTO++W/I4FSK9E7N>NVAM:MWMC\)B=XUFWL-5;KQ>V<I4YS;F.W'/
MCJ>7-4.!S-908NKRV'I<BTB4U3+30230JKM&A)42=9/<R6=K)>)&MVT:EPC%
MD#D#4$8A2R@UTD@$C-!UA'S'#L5MS!OEORO>7-QRU'=S+:2W,2PW$EL)&$,D
M\*22I%*\>EI(UDD5')4.P%2'W;OR%Z9Z)QT>0[3[`P&UI*JRXS"S5#5VY\W.
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MP^K2@^I+/;/VBW!N5=LW>UY^W+;XMSB2YEALQ#$"TB#3JF,;2N0E!6H`-:*.
MEO.ON#:#?;W;Y^4[*\DLG:!)+DR.0%8UI&&5%!:II0FE*GHRG_#?'2V1G%3O
M3>??_8LI(:9=Z=Y;[JZ6H;ZMY:'$Y'#T>EC^`@'N0/\`6-Y2G?Q-VW;>[]O/
MZC<+E@?M5&C7^702_P!<_F")=&WV&V6B^7A6D((_-E8_SZ6F%^!_P^P4Z5=)
M\?NOJRLC((K,]CJC<]4S#^V\^XZO*R.S'DDDW/LVM/9?VLLG66+DBQ:4?BD4
MS'\S*SD](+CW(YZN5*/S/=+&?)&$8_9&%Z'K!]6=8[86-=M]=;%V^(@HC_@N
MTL!BR@4`+I-%CX""`/K[&MGRWR[MP`V_8;*"G^^X(T_XZHZ#5SO.[WE?J]UN
M9:_QRNW^%CT"6[:>G/S$Z1E,$/EAZ/[O6&7Q)Y(E.YNI4TQOIU(NEB+`VL3[
M"&YQQ_ZZG*#:!J&S[A0TR/U;+AT(;%F_J)S"-1H=QM*Y_P"%W/1J?<D]`SKW
MOW7NBW_+^:%/B_WW$\L4<DW5&]A$DDB(TA_@M0EHP[`N=<BCC\L!^1[`/NDZ
M+[=<ZJS@,=LN*5-*_IGA^T="OD56/.'+3!20+V*O^]CH<]L30S[>PC0313*N
M(QBLT,B2J&^PIGL61F%RC@_ZQ!_/L8[<Z/8V91P0(DX&OX1T';Q66ZN`RD'6
MW''XCT^^UO2;KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_U-_CW[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW57O\[#_MT=_,9]6G_G$/NSGZWOLS)#
M3_R']/\`8^_=>ZL)ZPYZUZ\-[_[\;:7/]?\`<!C^?]C[]U[I<^_=>Z][]U[K
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M[+%O&R66V\V6MO>3!(C*--8FF0`EE5OPZP2`1D&A%"1UQGMO<[</;?W0YHYU
M^[]ON\<N;<]Q?1[>XF"7\&W7+.B02S1$CQ1;LJNZ,2LBB2-PZJX'+&8S&X3'
M4&'PV/H<1B,724^/QF+QE)3T&.QU!21+!245!0TL<5-24E+`BI''&JHB````
M>SR**.&..&&-4B4`*J@``#```P`!P`X=1;?7U[N=Y=;CN5Y+<;A/(TDLLKM)
M))(Y+.[NQ+.[,269B2Q)))/4BIJ:>CIYJJKJ(:6EIXWFJ*FIEC@IX(HP6>6:
M:5ECBC11<LQ``]^DDCB1Y97"QJ*DD@`#U).`.DZ(\C*B*6<F@`%23\AU0#\T
M>SNN-P?)C&4_7O6_Q[[XR$\V$J*Z7!15V[=S;TW)+AJW9L'678R8.JGILM#`
M\M+6XVGIBTFJ&(.%\;E\(_=KF'8+[W"MTV/E_8]ZG)C+&,---<2F-H!:77AD
MAP*I)$J9JJU`TFN3/(&S[M:\HS/NF[;IML0#@!R(HXHPXE-Q!K`*D]R2,V,M
M2M10]6VMF_-;MS;>W]O5]?L_X6=6XS!8K#T^VNNX*7>G;TV-H,?1T\%)1Y:N
M,^U>O:&-(/%!%3BMK::*RLY8'W,VW[3[N<T6%C8SSVO*7+D<*1B*U`GO2BJH
M"J[5AME%**%\21%P34=1S=W_`+?;'=W5U%%/S!O#R,QDG)BM@S,225%))R:U
M);0C'(%.C`]1?$3HOIG)2;GP&UI=R]@U3>3)=H]B9&IWUV-D9S(TIGDW/GFJ
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MI62[5JOO:O\`C5!1SX\B64+&%\D?'JX#?M7>W3<I[1LE]L.X65[MUG;PR?4P
M^$LCB/2QA.H^(JE<F@I5?7HZY[MH!O\`N&YVNZVES;7EQ-(O@R:RBEZ@2"@T
M$AL#/`^G1J_<E=`OKWOW7NO>_=>ZKH["^2G2V$^6>R,ED]X34]!U]L3M_KW>
M-8NU=YU%-A-XY7<_7)QN$FGI=O31U,]8,'5E)(#+"1"3KL5O`^^>X'*5G[F[
M1<7&ZE8;&ROK:=O!G(CG>:UTQDB(@EO#>A6J]O'A65-KY2Y@N.2=PAAL`9;J
MYM9XAXD0+Q+'/J<`N*`:UJ#0YX<>K%E8,H93<,`P/]01<'GGZ>YX!J`1PZBO
MACKOW[KW07=D])]2]PMA'[0Z^VQOIMMO728$[CQL60_A3Y-:5,@U'Y.(C6+1
M1!_]5XQ_3V'-_P"4.6.:C9GF/8[>]-N6,?BH&T:Z:M->&K2*^M!T<;3S!O>Q
M"X&S[G-;":FOPV*ZM-=-?LJ:?;TY]==6]=]282IVWUGL[!;)P-9E*G-56*V_
M1)044^6K(::GJLA)#'PU3/!1Q*S?D1C^GM1L/+FQ<L6<EAR]M4-G9/(9"D2A
M5+L`"Q`\R%`)^0Z9W3>-TWNX2[W>_DN+E4"!G-2%!)"U]`2?V]+[V=]%O7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]7?X]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U5[_.P_[='?S&>"?^<0^[.!_X9F2YY_"_7W[KW5A/6'_,
MM>O/Q_OQMI<?T_W`8_W[KW2Y]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=!WVUM'K/?W6V\]D]R8W;F8ZPW5@ZK!;TQN[*B&CP-7A\CH
MIGCK*Z:HI/X?()W1J>HCFAGIZD1R0R)*J,"O>H-HN=JOK??A#^Z)(RLOBD+'
MI;'<Q("Y(H:@AJ%2#3H5<C\U<W<C\W<O<W\A[K<V7.&W7*3VD]OF6.6/(*K1
M@X(J'C=6CDC+)(K1LRDI/PV^'/P=^(<^^'^+V,VK1Y[=-+#5;PSK=@2[\W,F
MW<=4/+28XY'*YK*U.%VQ154VMDB$,<\H1ZAI7CC9`=R5RW[?<L/N`Y3EMC<R
M+JE83B9Q&IP"2[%(P>/`$T+$D"D[_>&^]-]XK[R2<MQ>\_,<UUMFVEOIK>.T
MCL[<3.H5YC%!%&LMPZC2'?48U++$(U=PP@;^^<?QUV1EY-JX[=U7VEOM98X$
MV#TUAJ_LW=+3S7$<<T&V8ZO&XXZ[*QJJF`*3S:QLDWOWBY#V>Z.VP;HVY;S4
M#Z:PC:[FJ>`(BJB_[=UIY]0MMGMWS5N,`O9;%;/;:5\:Z86\=!Z&2C-_M5->
MD#_I&^<O<*Z.N>G-F?&[;-2C"/=W>F7_`+W;[55EMYJ+K79\PH:">2+E4R%>
M0#^H>R3]_>\7-0IL/*MIL&WL,3[B_CW/'BMI`=*DC@)9/MZ,_P!U>W6Q&NZ[
M]<;M=@_V5FOA0\.!GE%6%?-$_/J33_!C$[VJ8LI\F.X^T_D77":2H.V\WFGV
M1U;`TRJ9*>FZZV7)C<?/2HX](JYZFZ@!K\^W$]F[7=Y%N?<'FO<M^EK7PI)#
M;V8KQ`M8"BD5X:V?Y]4?W&GV]3#RCL-GM4=*>(B>+<&GF9Y0S`_Z4+TS=@=/
M]C;:WOU;3=$_&KJ"AZ[Z4WDV]-OFDW]C-C3;MGR'7^9VK4X^;"T?7N1&WJK'
M5V>9Q623USU`I4)52UU2;WRKOVW[QRW'R9[?[6FQ;1=^/%IN4MS,6MI(2IC6
MV;PBC2$ZRTA8(#0$X?VS?=JN]OWA^8^;;YMTW"W\)ZPM,(@LRR!@QG76&"4T
M@)IU')ID^F#J,M5X7$56>QM-ALY4XRAGS.(H\A_%J3%Y2:FBDK\?2Y3[6A_B
M5/1U3/&D_AA\RJ&T+?2)ILWN9;2UDO;=8KQHU+HK:U1R`64/1=84U`;2NH"M
M!6G4;7"P)<3I;2F2W#D*Q7264'M8K4Z210D5-.%3TZ>U/3/7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M==7%[7%P`2+\@&]C;^AM[]3S\NO4-*TQUW[]U[KWOW7NO>_=>Z__UM_CW[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKI_SF:#J?M/YM?RK?C'\P=X2;9^!/;M
M+\X]V]X8/,]C9SJ7K+?W9O4?3NR\YTGBNQ]^8'<.TZC')M.HS&7S>%I),E2Q
MUF4I%;3.8`B^Z]U5]N'L'^9_V;_PE_V/O3'Y+H#>'669^!_R?I?DQNSY*Y3N
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MIV_F=K8NKS-/U?UMO#Y;T6^-]_9J7&V]H5N^<=MO:5+N#(#TP/DJZFI`X];J
M#<>Z]TLZ>N_X4/3Q>=]O?R9Z7S0PS04M1N?YMM4TK2P*\E-6M#M62!Y:>=BA
M:)BK`7']/?NO=%B^:DW\_.;XI=S4^^:7^51B]K5>SZBBW57=/Y'Y>9WLR#%5
MM;0TLB]>87>.T3MC*[HG:81TT&1*TLCN`[*.?9AM>]^U'+E^F]^^?+S;O[0V
M\5P=TL44M+>6YMIE2V@\DGFN6@CBF.(682X*`@,\Y<[R^VW*^]\^6T\D=YM4
M!N(B@8LTJ$>%'106I+)IB/E1R6(6I!._B]L+N'Y,]D[BV]T!L?I>3`X395)G
MMRT_?&0[=V7L_=N1@SZXC,;2A@ZMQOW.XZ/:F6<+5T=94+##*0I1Y`Q3F)[+
M\E7/N!%N$$.X6]AO=K]/KL=PL[UTO+9HBTTS7-M<6@D^FNO#MF@D0"?7]6A`
MU1J'A]]KW&][N:%V7V%_<^PV=KLME=SMO>U7MW=&]GB0[A#:N)[>&"+;KAQ9
M*XC>2YTFX5S$0!<+LGJS^:KUGC8L+UMLK^5CU[B$A2)J#9^([[PL#>.VCRBF
MV^LE6W]7E=G)Y-S[R^VKDSW.V"$6O+^X\G6%J`!HM]JNHUH/6E[5CZEB23GH
MIW9OO2;[<O=[M[D\J3SL2:OMVXM2O\(.X$*/D`!TTXG='\\#+]F;\V#5;&^#
MFW=N[0VYLC.8'MS(9#M6?8W8^1W8^?3-;4VOC**"KW?CLOUZ,)"V3FR-%3TM
M0,G3_:M)IF\9E^Z/>\L2>=>7`OD!MMUCYU-Z:U]-(IZFITD_[C^\>6)/N#RD
M%/D-JO<?/4=P.JOIH73C+5.E>/B/YTK'T[H_EZ1C2.5@[R8ZOR+/MHBP_K?_
M`&'OW[E][3_SO6P#[-NN/\MUU4\O_>-/_@QN5A]FUW7^6\/5'_SK@_FG3][[
M]HMW]E_(:BSAZTV?@*)?@_N[N[!]-8"H%-E<PNX=B03[8A&UNX:E*\467RK_
M`'T$]%4)&L:>-D4&<Y?>.]]/:O?/9/E[9^5.4^8VY8W^;>KN5^4IKA;E[F-K
M--KW>9[P#>MJCLG:\BL(S9+;W<H)N9+B-)8<-/?KW#^]'RK[B<J;3LEZNYQ;
M3,EV\EAM-^EJ9I8FA,%V%G=;V`02F?PXVB*RD*7U*`MR.QZ+^<]EME[.RE#O
M;X*O0Y+:6VJZE?<M)W<=RF*JPM#,IW$9MIQ2/GV#WK6*QZJK61'&+(HTELO>
M'=IKC==N]P-A;;KF5Y82-HGMP8I&+Q4MVN2T`T%:0.6>$?IL[LI8Y>;9MGWA
M=VVW;MTM?<OESZ:X@CD77M%U&]'16&J-KK5&QK5D;N0U4@$4#3VIF_YXO7'6
M^\=];9V_\)NZ=Q[7PM1E<1U1L&?L?$[QWY5P/$L>`VWE=YXW!;6H<I5([,CU
M]5!3C006N1[;?9/>_20G/NP!O(G;9R!\R/JUK]FH?;TL?EW[Q^DA/<OE<,>!
M.TW+`?/3]:E?LU+]HZ+'\_!_-^I?CM"N\M_]9;5Q&6[`Z[CJ<E\),[W7M?Y#
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M>]OXHI&DM-RW2]%X$W3<+A'DBENEBMG5;>-9HY683,"_NU\R?>1YSY#_`'9>
M<R[;9[ELYCM].Z;9?/=RPA3X4\MQ]3$D\DU&UE8P4,8U`:AJ.SU3NS^>!V'L
MN+=.Y]@?!KIS,RYW=V'.P.P,IVQD]QP46V-UYC;F*W'/7[)I\Y@3B=]8S%Q9
MK'HD[5,./KH4J4BJ%EC05IM/O>!1^=.6V->/[MNU'[/KF_;7/&@X#(=-D^\@
MN'Y_Y0<^O[JOE!^5/WBQQZUSQHM=($L0?SG5(_RK^7"XMZBT_P`BE(/^`3"6
M('^P]N?NOWM'_.W\M?\`<OO/^VWIP;/]XT?\[QR<?^I9N'^3<.BX[+^4'\V;
M>ORI[V^(^.VU\!:;?70'5W1_;.Y-UY*K^0*;/W#A.^<AV3C=N8G;Z4U`V6CR
M>!GZMR!KY)XQ"_FA$5R)-/AMOO<"2>:^6"/3]W7N/G7]X9KZ:13&3FGAM7WC
MP:_UTY,(/D=KW$4^>H;GFOII73C+5.FFOY`]B_S(Z+Y5]J/F^^.]L)O/'_(#
M855!MGIWM3N*@^+F(.S9=J4,NV=K05>+-5A>G-U,7DW7CJBGJ*FHDHYPI;S?
MN);O[Y7.W)WNY[3<DW/*OMO=\I;+RU?[)N>XORG?S6[7>]D/<7^XPG<EN]RW
M389$ABVW<+:>U2%&E\*V<%Q+@_SU[[^_FQ>_=AL@Y@V]MAV]VL[B>"POQMJO
M<F(SO-:M<O/-)9-$L<;I,`1),5)J"+YMY[V_G;;;W7UAMW#]8?`[>V+[#W3F
M<!N/>FULUW12[<Z=Q&,VQE]QT.\=\4NXWHL[F,-GZ_&1X>FI\1!65<=?6PO*
M!`))%4+MWO@R(6YKY85J`D#;[UJFG`,;]:4/XM)KCM%21G"VU?>.<ZEYTY,1
M>-!M>XM6OX03N?;3UH]<"F2P734O\YYB;5_\N6-;&Q27Y#,;VXN'P1%O]B??
MCM7O<?\`G<.6A_U+[O\`[;.JG9OO''_G>^4!]FUW_P#EOSU5U_,UP?\`-$R6
MW.AX.W]P;17$8[L?-;FI,=\&-Q?(+!Y_,5>&VQ+&F'[:@7%8^?</65=)7JAI
MH:BEF%:8V9GBUJI7S;[P^^WLM[7^ZNU[7N'+.Y;_`,W;2-GA5.7[FZOK2"=R
MU[N&UWKW31;5?6T2I'%<O#<NXN&$$<4L8N$QR^\QOOWC^4.1(K*SYHVZ[W3<
MI'@4;5ME_'=QQ%`)IXY_J9HXFA##1XL3AS(=(+("H@_R[]L_S9J/XV4V#ZI[
M"ZD?:F$[`[!@I:CYFU_>6Z^_3-D,PN:,&=RM7MV2(;6IX\DJX6%6GEIZ#3'-
M-)(K:!')[O\`OA]X&#9/<3<'Y/VO>FVNTL[NSM]ANMKCAN;*(6[LT$=XT<TU
MS&D5W<7<7APSS3OHMK;08@,_8_>/O#\^>WFU;Q<<V;-9;BCM#/!=[7?"=)$T
M_&TER/%+H5D,B*L99RJ*H32IUIMG?SNZ@JJ=M_`>@5R`\D.W.U9VA!(#,B5&
MU'$N@<@'3?\`J/;L4?O!%37?\JR4];7<17_>;T=2^-C^\"!GGWED_9MUR*_M
MN#T"G6V+_GY]F;-_O-N'?/Q5Z,S+[BWCA!L7>>WWS6X(\?M?=>7VYB-TO7[9
MV7N3!?PC?>,Q<69QT0F:I@Q]="E2D=0)(T-K>]]U(3^KM_)4U/XH-[0'Y43=
M:X]:YXT6ND>38OO`C$G/W+9-3D;=<*/.F#<.<>M<\:+\(4<_3'\^>>2/1\O_
M`(A4$>H>0P=>/,$6_)"5/2\K2`?TU*2/R/K[-4YA]R(8W/\`4KV_FDH:!EYD
M7/EE-YQ7UH:<:'AU<;%[]C+<^<O4^5C/_EDZUJ_CI\3?EAU_\N^F>T^C=KT$
M?R>PGR1[)W<^]/D=1=QGX\;PSW9U-O#;>YX]SY[K;:>*R-%M"IFKQ6[=>@Q<
M31U%:$JQH,S@=;5_>@>^'N%[G^_/MA[J)'?>RW,W(UARQL1VS:;W;MMLK[8K
MJ&XVK<UL[^[O[N$;A_C=IN<KW3S2A[*73!%;)#'A3[/>ZGNC-]Y:6UYUBN;G
MD"]D:S@FALKFVM5F0R?3W212K)(GU<DKQS^)(%'Z3@1HI`V>A4_\*&?,FK"_
MR9/M_%)KMN;YO>;S7'BT7VEH\5OU7Y_I[#_74#I*;>^5?\UOHKY6?#3J#YO;
M"_E]9GJWY=]E=C=/469^*.XODC)OW9F[MI]+[^[EP^>KHNW,!1[;KMMU%#UY
M4T-53J5JO)4I+&X6)U;W7NKQO?NO=?_7W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z
M]U[W[KW05=Q=$](?(C:'^CWY`=-]5=Y[!&5HLZ-C]Q=>;1[-V@,WC4J(\=F/
M[M;UQ&;PO\5H(ZN58:CP^:(2N%8!C?W7N@3^6WR]Z/\`@9U-M/=78&!WOFTW
M/NS;O3O2W2717760["[5[4W[D\;7U.W>LNI.M=N1T_\`$\HFW\!5U"QM)1T%
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M$_D]V9F<U=B3\\\,#]@ZL[O(=3N6:@%2:X`H/V#`^75H_NO5>O>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HN/RF^3FT/B9U7+VEN[8O=?:'G
MS^*VIMOKCX\]1[P[M[:WKN?,1UM31X7:VQ=F4-76U$HH,955$M3524E#!#3M
MY)U9HU?W7NB`9?\`GE?"&'X[]%?(K9..^0_<*?(W+]IX3K/I/J'H+>F\?D76
MU/0<_B^0%1F.K%BH*W#8KHU&67<57+4_;10RQ/2O5":+7[KW5G72'=76?R.Z
M@ZW[XZ:W12[TZK[:V?A-][#W1205E''E]N;@HHZZ@GEQ^2IZ/)XNNC23QU-)
M50PU5)4(\,T:2HZ#W7NA3]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW3!NO<V*V7M;<N\<[_$!A-IX#,;ES!Q.'RVX<K_"L%CJG*9#^&8#`462
MSN<R'VE*_AHZ*FJ*NJDTQPQO(RJ?=>ZJQZ^_G3_"_=?7_P`J-_\`9%'WY\77
M^&>U-K=@]Z;$^571&]^F^SL%L#L!ZZFZWWEA-DY2EK\GN+'=C5]"U'B*6EU9
M2:LEA@EI(9*B!9/=>Z#?_A^WX;?W<^T_T8?,W_9D/])W^B?_`&0W_97-\_[/
M1_>/^X'^ES^)?[+]Y/XC_='_`$1_[^?^+?>_9?PGG7]Q_D_OW7NO_]#?X]^Z
M]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U47_-,Z)^1.\MW_`7Y._&KJ8?
M(/=_PI^54O:N[>AJ7?&SNO-R=@]:;YZNWMU5NVKV+N/L/(X38K;VV:-TT^2I
M*/*9#'05<$4ZI4+.(HY?=>Z5_P#*'^,?<OQ@^*&>H/D)M["[&[G[V^1OR,^4
M^_>L=N[FH-YX?J7(?(#M'.;XQO6-/NS$PP87<%;M';]51P5]30!\>V2^X%++
M/`L<\ONO=6B^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNJ-_YUG7/S-[KV[\4MB?%#X@9SY%T_5_RQ^/_P`M=Y[HHN\.C>J,;C8OCAV)
M0[P3K#^']J[PVYE\EN#L2C\D=#74T4N.H9([U3H"H/NO=5W_`"@_E\?/[NCL
MSYM]%;?^,]+2]&?S/OD7_+]^3NY/D;DNY^IZ>?XF8SHVBZFS'>_6/86S*7/U
MN\MY=@8+,=.08_;4VTH,Q@\DF8\KU]/'%/I]U[K;8]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=5\_S.]Q?//!?$C>>/_EN]8XKL;Y0[
MTRF)V-@,EE]U[`VRO4NUMP15Z;L[AQ-)V9N3:.T=W;IV?04ZQX?%560A@;*5
ME/53QU5+2U%'4>Z]U1CU_P##WYL_%W"_R^^Z?C;_`"V^QJN/XF]9?.;XS;N^
M*?:?RW^,.Z>\MV/\D(MF;]VY\L\WV]0;OI^EL]DNS^V-OU0WM019"ER.+CK+
MT%#/111Q1^Z]U>G_`"K?BAN_X._R\OBA\5>PLMC,UO[J#JVCQ&]ZW"5<U?A(
M]WYS+9;=VY<9A<A44]'-D,-A,SN&:BI*AH83/3TZ/H35I'NO=6`^_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[I&]BY'=>'Z^WUE]B;2&_][XO9
MVYLCL[8C;II]CC>FZ:+"UM3@-I_WTJZ6NI-H_P!XLK%%1_Q.6&6.@\WG9&5"
M#[KW6G.W\J#^8-W5TK_-@Q^#Z1WUT%0_*/8GPNW!UCUE\T_E7LKY:_(3MGY!
M?$7M7:7:M4=R?(S`;H[`RM)U+EL!M:HVIM_';GW-4T]'75HKXZ?'4DLP7W7N
MEI_LB?\`,C_X=4_X?E_V2T_WN_OA_HR_X;W_`--_0_\`IS_T,?[*5_H)_P!*
MW^F#^]W^@K^]/^D?_+?X9_'/N?[L_L?\"./?NO=?_]'?X]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[
MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U_]+?X]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW52'\Q3^9EN[XB=W
M_$CXC=`_'W'_`".^5WS.R?82=8;1WCV[ANA^L\!MSK#"4^<W1G-U=C9S;^Y_
MN,K4PU'CQF(HJ*2IKGAE`D27[6"K]U[I!]D_SJ>H_B@/A-L7^8-L"A^'OR'^
M6F:W5B]Z=0YGO/IC?6(^-6$VYF-R8/']H=G]D4.Y<!AINH=Z5N`7^$YRGIE2
M5II(9(XYZ2IB3W7NK)H/EG\9JK*]T8.F[UZPGRWQTV'M[M'O:@AW=B9*CJ?K
MG=FT*OL#;6]=\*M01@=MYO9%!+E:>KF*Q24">8'003[KW09]@?S%_@GU9M;I
M?>/87RY^/.R-N_([#0;AZ%S&\.UMH[9Q?:N#JZ.CK:3/;4KLODJ:&KVY(F3I
M5?(G31PR54,;R+)+&C>Z]T4/^47_`#5=O_S`_B]\<]\]SY7I_JOY2]_83O/>
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M.8_";\V%FZ/<6ULM6;:S=?MS/0X[,4$DM'6'%YS%U%+*T;,HEA8`FWOW7NA7
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MGQE^?W6WQ"_DK_([YI_$_P"0_P`S]X?$[Y8=L9WMWK/;77>$^2_S&POQ8WGC
M\I%TKLCL7;_W+Y#?V7Q<=/Y:R"IJS2XGST=/7O2SQE8_=>Z'_P"6.`^7'4/S
MB_G'IU__`"]/EMWO@OYN7P&Z:ZY^-^Z>IMB8"3KSK'=&R_BIN?J;=>W?D+O;
M(;DH]L=39#;U7E:AXZ)YJFMR$]+!244$S5D$GOW7N@6Z_P"B^Y_CCW!_+A[L
M[Y_E9_)+YJ=6[V_D.]!?`S&=2[7Z2QN\LQT9\GJ+)T<V]=I]X[)[%J<+BNE-
ML;IQ>3FI\SNC<*T"XNFRE7%(&2GK8U]U[HO,O3WRF_ED_P`DO^5Y_,0R73V9
MZV^5O\J_Y`?*K:^\^J>UJ.NV775G2'RT[S[;ZVR^'S<$WBR.>PU9NW<NW:_#
MM&E73U./RDU?2.:>;S2>Z]UMN_R;OB57?"K^6U\6NDMRP5"=ER;!B[.[HJJ^
M2HJ<Q7=R]P5E3V5V*,U758%9D<AAL_N63%B:7UM!01@V"@>_=>ZUO?C1V7\[
M?C5\4OYF?P#Z^_E4?/#L?Y&?*CY=?.+/=.]F9KJ3![%^(U-M'Y!O2;"P&\MU
M=V;\WC@*-:;$45#4Y5*<4/\`#\E!]NHKXHYWFA]U[J;\@_B_\YOA1LOX+_"G
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MO?NO=>]^Z]UKO_\`"E?_`+(S^+O_`![7_;R_X5?\?[_S++_C\,__`,S3_P"_
M=_\`.R_YMV]^Z]UL0>_=>Z][]U[KWOW7NM=C^>W_`,S\_D:_\>5_V]@ZE_YF
MG_S++_CV<_\`\7'_`+^#_P`\A_U??%[]U[K8G]^Z]U[W[KW7O?NO=>]^Z]U[
LW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g575431dsp_087.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431dsp_087.jpg
M_]C_X``02D9)1@`!`@$!+`$L``#_X0RY17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````4````<@$R``(````4````AH=I``0````!````G````,@```$L````
M`0```2P````!061O8F4@4&AO=&]S:&]P(#<N,``R,#$S.C`W.C,P(#$V.C0U
M.C(Y``````.@`0`#`````0`!``"@`@`$`````0```:*@`P`$`````0```.@`
M````````!@$#``,````!``8```$:``4````!```!%@$;``4````!```!'@$H
M``,````!``(```(!``0````!```!)@("``0````!```+BP````````!(````
M`0```$@````!_]C_X``02D9)1@`!`@$`2`!(``#_[0`,061O8F5?0TT``?_N
M``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43
M$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-
M$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#/_``!$(`$<`@`,!(@`"$0$#$0'_W0`$``C_Q`$_```!
M!0$!`0$!`0`````````#``$"!`4&!P@)"@L!``$%`0$!`0$!``````````$`
M`@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R
M!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5
MXF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7
MI[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q
M0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*S
MA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_
MV@`,`P$``A$#$0`_`/3<AKLG'MJQKQ5;]$6MAQ8X:_1GZ7\ARSJ<+J6(^FFW
MJ=V0<AQ8;"RL$!M3W;@US+&;M[-__5^HJWU1QL>K[;92V@NMM]UN.:BS:W<*
M*&_9GV.VTU?GY&RZRZRZQ6<7JKNHY&$\X65AC>YT958K(FE[MCAN<[U/=_T$
ME-PX&7M(_:62#Z?I[MN/.[_N1_1/Y[_V7_X!._!RG;XZAD,WM:UNUN/[".;&
M;L5WOL_/]3U&?Z-7$DE--V#E.+R.HY#=[FN:`W']@;])C-V*[VV_X3U/4?\`
MZ+TUG5W9UO0#U5_42VPX+WEV-77=0'[76MS*:O3^T9#JO\'1]H]*[]SU/TBW
M5RV3T3IG[*OKMZ6ZG)]"P/RJ65![7EKMV10_U&?I6N_2UO24]2DN+ZOD]*Z)
MU'"S\;IEM%.'>YN3?C5-VV>ICWL^R-]&SWNKO]'?Z[:Z/4_F[?56DWZ^_5HY
M#Z7Y#JFM<QE=[ZW>G87-=:?1<T.=^B]/9;ZC*_TB2GHDEB?\\_JQ_P!SV?<_
M_P`@E_SS^K'_`'/9]S__`""2G;257IW5.G]4I=?@7MR*F/-;W-G1X#7['!T.
M:[:]CE:24I))))2DDDDE/__0[GZNM;]NZR\/DNS/=7+W;#Z=?M]1[C4YWNW[
M**V>C_,_I=BT<O\`I>%_QC__`#U:J70,?.IOZD_)K]&K(R#;15N80T.'Z6?3
M?;ML?;NM_P"$KLJM].J_[157'%Z+A])R,-F*;"'/+2;'N>890^MD[OI^UC??
M8DIVDDDDE*5;J7_)V5_Q-G_4N5E1LK996ZNP;F/!:YIX(.C@DI%BNW>K[]\6
MN'T=L?R/Y>W_`$B;,Q\B[T747FA]+R^(W-?-=M3*[F;JW/J;;;7?M:]G\RJ5
M%C*<L5&VQKS<]NQV]^ZMK'V,;OL+MC?\)N9_46C3?5<W=4[<(!C@P>):[W)*
M:K:NM`>[*QB?1+9&-8!Z\G9=_37?J[6;=V-_.?\`=M,ZGKD.VY>*":VAA.+8
M0+1M]6UWZ\W=2_\`2>G1].KV?K-WI_I;Z22G#P;L_#Z]EXN9674=1>VW%R&,
M:&%]>/15DM?^M6Y#=WV=WIU_9-E?_<J[U%I-KZC%_J7TNW.=]GV5.86-(/IM
MM+K[O6L:[9^D:RG_`(E/D8?KY>+D[]OV4O.R)W;V&KG\W;*&VSK!ON:^C'9C
M@/\`0M;<][R?\#ZM!QZF,W?X39DO24Y[*?KGZ9]6_"%IU:6!^P'W^TL=67O;
M_-_X5G_I:;JOK5Z-@]7&]78!46S&^7G>_?7[*OYMEG\Z_P!/^;_2_P`[!F5]
M<"R7X6(Q\:,%KG"??HZW]'_P7^`_ZO\`0%&1]9_3<78M`>&MVAKMTOFS?]*R
MO]$YOI,_?J_G?UC^9K2ELL?6UK'OPG8+G^H]S:KA8X>GL9Z-;+*_L^VSUO5W
M^IO_`.M_X-80^M(S*QFNQGX;MUCW5@BQI<&[<:"=FREWJ_I?\-^C_F_\))N1
M]9I,XF,X;=`;"SWFXL$O'VCV58.VUWZ/]-?_`*%!_:'UL<T6#I53`Z:S2;VN
M<QP<-N5O:65W8SJW?S7Z'(WU?\*DI__1[3ZIFHY/6BQK6/.?8;``!#OHO;]%
MECV^HU]K7O\`I^K_`-;1\7(ZS=EXIZEB5XH]1VQK+-Y!]%_M]LML_P`)^D_0
M?\5;_.(7U8>'YG6=NW;7F&H?2+_8UK9NN?\`SO\`)]UG]?\`P==]^9B9.7A_
M9[J[MMK]WIN:Z/T5OTMI24Z"2222E))))*:V95>]]%M`:YU+RXL>XM!!8^KZ
M36V?O_N(->1D-S-MM5+?5+6.-=A<\';98SU`ZJO<WV>Q7U6OPQ=:VP6OJ<W4
M>GL^D`YN\[ZWN=['N9^XDILI+/IKLL8TV9MM=CB6[-U+M1^;N;3]+;[E(4SM
MCJ%IWSM@TZQ]+;^A_-24WDE6PG.(M:;C>UMD,L=MDM+*W\U-8WZ3U8+F@$D@
M`<D]DE+I(-67BWU^K3=7;7`=O8X.;M(W!VYI^BI/R**Q-EC&#75S@/H@O?S^
MZQKGI*2)(%6=A7;?1R*K-[/5;M>UTUSM]5NT_P`UN]OJ*3LK&8]S'7,:]C/4
M>TN`(9);ZCA/M9N:[WI*?__2]#Z3@96+?F7Y(J#\I[7'TG.(<YH+76[',J;3
MO]GZ']/8S_"9F1_@XMZ;@X&3AC$I;5NL<'$:D[:;&-][I=]%JU%BY5F55UBB
MJ_,JK^U7._9M)J<]Q#,=WVBMSJ_2;7[O5O\`TMC_`/T6DIVDE3]+JL:9-&Z.
M?0?$_#[5]%4NJ]5LZ4*W9N=CTM>2[W8]CB6,`]7:*KWNW^]GNV[$E.RDJGI=
M5_[DT=_\`[G\W_M4J?5.HW=*H9=FYV/2RVQM59./8Z7D.>YD5Y#OI5UV>FDI
MUTE2K'4;6,L9DT&MXW-/H/!+2)9SD_20.H9>5T[&^T9>;C4L);6U[Z'[?4>=
ME8.W)^BYR2G1%-(((K;()<#`^D?I._K)A10W;MK:-D[8:--WTMO]95,=^?DT
M5Y-&52ZB]K;*G''>"6.`<V=V2WW?V4/J&5E=.P[,S,S**J*A[WG'L(!<175[
M:\A[_IN]_P#WQ)3:QF.JONK%194YP?6\;=D;*Z]@:';V^YKO\&F<[':+Q]G<
M!#G6$,C?`]T$?3>]JK=/R<SJ&(S+QLS'MJL$!XQ[`"YCG57P+,AK]OJ,=Z?_
M`*,4LN_+PL=^5E9=%=%9!>_T'F`3L'T<AWY[OI;4E./TS"^KN=DUT?L.W"=0
MUSF-O8&L::S68#:;;:?4;]K_`$'[GZ7TOH+2;]4_JXTL+.GU--;0QFT$``-L
MJ]H:?I;+[/?]-%Z-UK#ZI4]M%[,C(QMK<HUL?6P/(_P;;_=L=M=^?8M))3F?
M\V^B$;7XC;`6M81876`M;9]L8'>JY^[;D_IO<@#ZG?5QM+*1AC96\V,_262T
MN+7.:U_J;_1<ZMGZ#^9_X-;222G_T_54QB1//9?*R22GZJ4'>EN;OV[OS9B>
M1]'^UL7RPDDI^JE%^S8[U(V0=V[B/SMTKY7224_2N;G=:IS75XN`,K'`K#7%
MPKU>YK'O=;-GT&^IOK^S>ST_YS]*B]*SL[-I=9GX)P/H.K8YX>2'M#X?[*_3
MNK=[+*__``5?,J22GZH;MVC9&V!MCB.T)W;8.Z([SPOE9))3]4Z=DS]FWWQM
M[SPOE=))3]3U^G'Z/;MT^C$<#;Q_(VJ:^54DE/U4DOE5))3_`/_9_^T15E!H
M;W1O<VAO<"`S+C``.$))300$```````''`(```(``@`X0DE-!"4``````!!&
M#/*))KA6VK"<`:&PIY!W.$))30/M```````0`2P````!``$!+`````$``3A"
M24T$)@``````#@`````````````_@```.$))300-```````$````>#A"24T$
M&0``````!````!XX0DE-`_,```````D```````````$`.$))300*```````!
M```X0DE-)Q````````H``0`````````".$))30/U``````!(`"]F9@`!`&QF
M9@`&```````!`"]F9@`!`*&9F@`&```````!`#(````!`%H````&```````!
M`#4````!`"T````&```````!.$))30/X``````!P``#_________________
M____________`^@`````_____________________________P/H`````/__
M__________________________\#Z`````#_________________________
M____`^@``#A"24T$"```````$`````$```)````"0``````X0DE-!!X`````
M``0`````.$))300:``````-#````!@``````````````Z````:(````'`&0`
M<P!P`%\`,``X`#<````!``````````````````````````$`````````````
M`:(```#H``````````````````````$`````````````````````````$```
M``$```````!N=6QL`````@````9B;W5N9'-/8FIC`````0```````%)C=#$`
M```$`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO
M;F<```#H`````%)G:'1L;VYG```!H@````9S;&EC97-6;$QS`````4]B:F,`
M```!```````%<VQI8V4````2````!W-L:6-E241L;VYG``````````=G<F]U
M<$E$;&]N9P`````````&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-
M875T;T=E;F5R871E9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM
M9R`````&8F]U;F1S3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N
M9P``````````3&5F=&QO;F<``````````$)T;VUL;VYG````Z`````!29VAT
M;&]N9P```:(````#=7)L5$585`````$```````!N=6QL5$585`````$`````
M``!-<V=E5$585`````$```````9A;'1486=415A4`````0``````#F-E;&Q4
M97AT27-(5$U,8F]O;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!
M;&EG;F5N=6T````/15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R
M=$%L:6=N96YU;0````]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB
M9T-O;&]R5'EP965N=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90``
M``ET;W!/=71S971L;VYG``````````IL969T3W5T<V5T;&]N9P`````````,
M8F]T=&]M3W5T<V5T;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X
M0DE-!!0```````0````".$))300,``````NG`````0```(````!'```!@```
M:H````N+`!@``?_8_^``$$I&248``0(!`$@`2```_^T`#$%D;V)E7T--``'_
M[@`.061O8F4`9(`````!_]L`A``,"`@("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5
M$Q,8$0P,#`P,#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,`0T+"PT.
M#1`.#A`4#@X.%!0.#@X.%!$,#`P,#!$1#`P,#`P,$0P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`S_P``1"`!'`(`#`2(``A$!`Q$!_]T`!``(_\0!/P``
M`04!`0$!`0$``````````P`!`@0%!@<("0H+`0`!!0$!`0$!`0`````````!
M``(#!`4&!P@)"@L0``$$`0,"!`(%!P8(!0,,,P$``A$#!"$2,05!46$3(G&!
M,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?2
M5>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'
MEZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A<2(3!3*!D12A
ML4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8UPM)$DU2C%V1%539T9>+R
MLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'
M_]H`#`,!``(1`Q$`/P#TW(:[)Q[:L:\56_1%K8<6.&OT9^E_(<LZG"ZEB/II
MMZG=D'(<6&PLK!`;4]VX-<RQF[>S?_U?J*M]4<;'J^VV4MH+K;?=;CFHLVMW
M"BAOV9]CMM-7Y^1LNLNLNL5G%ZJ[J.1A/.%E88WN=&56*R)I>[8X;G.]3W?]
M!)3<.!E[2/VED@^GZ>[;CSN_[D?T3^>_]E_^`3OP<IV^.H9#-[6M;M;C^PCF
MQF[%=[[/S_4]1G^C5Q))33=@Y3B\CJ.0W>YKF@-Q_8&_28S=BN]MO^$]3U'_
M`.B]-9U=V=;T`]5?U$ML."]Y=C5UW4!^UUK<RFKT_M&0ZK_!T?:/2N_<]3](
MMU<MD]$Z9^RKZ[>ENIR?0L#\JEE0>UY:[=D4/]1GZ5KOTM;TE/4I+B^KY/2N
MB=1PL_&Z9;13AWN;DWXU3=MGJ8][/LC?1L][J[_1W^NVNCU/YNWU5I-^OOU:
M.0^E^0ZIK7,97>^MWIV%S76GT7-#G?HO3V6^HRO](DIZ))8G_//ZL?\`<]GW
M/_\`()?\\_JQ_P!SV?<__P`@DIVTE5Z=U3I_5*77X%[<BICS6]S9T>`U^QP=
M#FNVO8Y6DE*22224I))))3__T.Y^KK6_;NLO#Y+LSW5R]VP^G7[?4>XU.=[M
M^RBMGH_S/Z78M'+_`*7A?\8__P`]6JET#'SJ;^I/R:_1JR,@VT5;F$-#A^EG
MTWV[;'V[K?\`A*[*K?3JO^T55QQ>BX?2<C#9BFPASRTFQ[GF&4/K9.[Z?M8W
MWV)*=I))))2E6ZE_R=E?\39_U+E94;*V65NKL&YCP6N:>"#HX)*18KMWJ^_?
M%KA]';'\C^7M_P!(FS,?(N]%U%YH?2\OB-S7S7;4RNYFZMSZFVVUW[6O9_,J
ME18RG+%1ML:\W/;L=O?NK:Q]C&[["[8W_";F?U%HTWU7-W5.W"`8X,'B6N]R
M2FJVKK0'NRL8GT2V1C6`>O)V7?TUWZNUFW=C?SG_`';3.IZY#MN7B@FMH83B
MV$"T;?5M=^O-W4O_`$GIT?3J]GZS=Z?Z6^DDIP\&[/P^O9>+F5EU'47MMQ<A
MC&AA?7CT59+7_K5N0W=]G=Z=?V397_W*N]1:3:^HQ?ZE]+MSG?9]E3F%C2#Z
M;;2Z^[UK&NV?I&LI_P")3Y&'Z^7BY._;]E+SLB=V]AJY_-VRAMLZP;[FOHQV
M8X#_`$+6W/>\G_`^K0<>IC-W^$V9+TE.>RGZY^F?5OPA:=6E@?L!]_M+'5E[
MV_S?^%9_Z6FZKZU>C8/5QO5V`5%LQOEYWOWU^RK^;99_.O\`3_F_TO\`.P9E
M?7`LE^%B,?&C!:YPGWZ.M_1_\%_@/^K_`$!1D?6?TW%V+0'AK=H:[=+YLW_2
MLK_1.;Z3/WZOYW]8_F:TI;+'UM:Q[\)V"Y_J/<VJX6.'I[&>C6RRO[/ML];U
M=_J;_P#K?^#6$/K2,RL9KL9^&[=8]U8(L:7!NW&@G9LI=ZOZ7_#?H_YO_"2;
MD?6:3.)C.&W0&PL]YN+!+Q]H]E6#MM=^C_37_P"A0?VA];'-%@Z54P.FLTF]
MKG,<'#;E;VEE=V,ZMW\U^AR-]7_"I*?_T>T^J9J.3UHL:UCSGV&P``0[Z+V_
M198]OJ-?:U[_`*?J_P#6T?%R.LW9>*>I8E>*/4=L:RS>0?1?[?;+;/\`"?I/
MT'_%6_SB%]6'A^9UG;MVUYAJ'TB_V-:V;KG_`,[_`"?=9_7_`,'7??F8F3EX
M?V>ZN[;:_=Z;FNC]%;]+:4E.@DDDDI22222FMF57O?1;0&N=2\N+'N+006/J
M^DUMG[_[B#7D9#<S;;52WU2UCC787/!VV6,]0.JKW-]GL5]5K\,76ML%KZG-
MU'I[/I`.;O.^M[G>Q[F?N)*;*2SZ:[+&--F;;78XENS=2[4?F[FT_2V^Y2%,
M[8ZA:=\[8-.L?2V_H?S4E-Y)5L)SB+6FXWM;9#+';9+2RM_-36-^D]6"YH!)
M(`')/9)2Z2#5EXM]?JTW5VUP';V.#F[2-P=N:?HJ3\BBL398Q@UU<X#Z(+W\
M_NL:YZ2DB2!5G85VWT<BJS>SU6[7M=-<[?5;M/\`-;O;ZBD[*QF/<QUS&O8S
MU'M+@"&26^HX3[6;FN]Z2G__TO0^DX&5BWYE^2*@_*>UQ])SB'.:"UUNQS*F
MT[_9^A_3V,_PF9D?X.+>FX.!DX8Q*6U;K'!Q&I.VFQC?>Z7?1:M18N59E5=8
MHJOS*J_M5SOV;2:G/<0S'=]HK<ZOTFU^[U;_`-+8_P#]%I*=I)4_2ZK&F31N
MCGT'Q/P^U?15+JO5;.E"MV;G8]+7DN]V/8XEC`/5VBJ][M_O9[MNQ)3LI*IZ
M75?^Y-'?_`.Y_-_[5*GU3J-W2J&79N=CTLML;563CV.EY#GN9%>0[Z5==GII
M*==)4JQU&UC+&9-!K>-S3Z#P2TB6<Y/TD#J&7E=.QOM&7FXU+"6UM>^A^WU'
MG96#MR?HN<DIT132""*VR"7`P/I'Z3OZR844-V[:VC9.V&C3=]+;_653'?GY
M-%>31E4NHO:VRIQQW@EC@'-G=DM]W]E#ZAE973L.S,S,RBJBH>]YQ["`7$5U
M>VO(>_Z;O?\`]\24VL9CJK[JQ465.<'UO&W9&RNO8&AV]ON:[_!IG.QVB\?9
MW`0YUA#(WP/=!'TWO:JW3\G,ZAB,R\;,Q[:K!`>,>P`N8YU5\"S(:_;ZC'>G
M_P"C%++OR\+'?E967171607O]!Y@$[!]'(=^>[Z6U)3C],POJ[G9-='[#MPG
M4-<YC;V!K&FLUF`VFVVGU&_:_P!!^Y^E]+Z"TF_5/ZN-+"SI]336T,9M!``#
M;*O:&GZ6R^SW_31>C=:P^J5/;1>S(R,;:W*-;'UL#R/\&V_W;';7?GV+224Y
MG_-OHA&U^(VP%K6$6%U@+6V?;&!WJN?NVY/Z;W(`^IWU<;2RD88V5O-C/TED
MM+BUSFM?ZF_T7.K9^@_F?^#6TDDI_]/U5,8D3SV7RLDDI^JE!WI;F[]N[\V8
MGD?1_M;%\L))*?JI1?LV.]2-D'=NXC\[=*^5TDE/TKFYW6J<UU>+@#*QP*PU
MQ<*]7N:Q[W6S9]!OJ;Z_LWL]/^<_2HO2L[.S:769^"<#Z#JV.>'DA[0^'^RO
MT[JW>RRO_P`%7S*DDI^J&[=HV1M@;8XCM"=VV#NB.\\+Y6224_5.G9,_9M]\
M;>\\+Y7224_4]?IQ^CV[=/HQ'`V\?R-JFOE5))3]5)+Y5224_P#_V0`X0DE-
M!"$``````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O
M`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``-P`N`#``
M```!`#A"24T$!@``````!P`(`````0$`_^$83VAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2?ON[\G(&ED/2=7-4TP37!#
M96AI2'IR95-Z3E1C>FMC.60G/SX*/#]A9&]B92UX87`M9FEL=&5R<R!E<V,]
M(D-2(C\^"CQX.GAA<&UE=&$@>&UL;G,Z>#TG861O8F4Z;G,Z;65T82\G('@Z
M>&%P=&L])UA-4"!T;V]L:VET(#(N."XR+3,S+"!F<F%M97=O<FL@,2XU)SX*
M/')D9CI21$8@>&UL;G,Z<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R
M+S(R+7)D9BUS>6YT87@M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E
M+F-O;2]I6"\Q+C`O)SX*"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED
M.C`T,#DW.3%F+68Y,#$M,3%E,BUA-C0P+6$X,&)C9#5F,3-A-R<*("!X;6QN
M<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\G/@H@(#QP9&8Z
M4')O9'5C97(^36EC<F]S;V9TPJX@3V9F:6-E(%=O<F0@,C`P-SPO<&1F.E!R
M;V1U8V5R/@H@(#PA+2T@<&1F.D-R96%T:6]N1&%T92!I<R!A;&EA<V5D("TM
M/@H@(#PA+2T@<&1F.D-R96%T;W(@:7,@86QI87-E9"`M+3X*("`\(2TM('!D
M9CI-;V1$871E(&ES(&%L:6%S960@+2T^"B`\+W)D9CI$97-C<FEP=&EO;CX*
M"B`\<F1F.D1E<V-R:7!T:6]N(&%B;W5T/2=U=6ED.C`T,#DW.3%F+68Y,#$M
M,3%E,BUA-C0P+6$X,&)C9#5F,3-A-R<*("!X;6QN<SIP:&]T;W-H;W`])VAT
M='`Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\G/@H@(#QP:&]T;W-H
M;W`Z0V]L;W)-;V1E/C,\+W!H;W1O<VAO<#I#;VQO<DUO9&4^"B`@/'!H;W1O
M<VAO<#I)0T-0<F]F:6QE/G-21T(@245#-C$Y-C8M,BXQ/"]P:&]T;W-H;W`Z
M24-#4')O9FEL93X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I
M<'1I;VX@86)O=70])W5U:60Z,#0P.3<Y,68M9CDP,2TQ,64R+6$V-#`M83@P
M8F-D-68Q,V$W)PH@('AM;&YS.GAA<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87`O,2XP+R<*("!X;6QN<SIX;7`])VAT='`Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"\G/@H@(#QX87`Z0W)E871E1&%T93XR,#$S+3`W+3,P5#$U.C`Y.C`S
M/"]X87`Z0W)E871E1&%T93X*("`\>&%P.D-R96%T;W)4;V]L/DUI8W)O<V]F
M=,*N($]F9FEC92!7;W)D(#(P,#<\+WAA<#I#<F5A=&]R5&]O;#X*("`\>&%P
M.DUO9&EF>41A=&4^,C`Q,RTP-RTS,%0Q-3HR,3HU."LP-3HS,#PO>&%P.DUO
M9&EF>41A=&4^"B`@/'AA<#I-971A9&%T841A=&4^,C`Q,RTP-RTS,%0Q-3HR
M,3HU."LP-3HS,#PO>&%P.DUE=&%D871A1&%T93X*("`\(2TM('AA<#I&;W)M
M870@:7,@86QI87-E9"`M+3X*(#PO<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z
M1&5S8W)I<'1I;VX@86)O=70])W5U:60Z,#0P.3<Y,68M9CDP,2TQ,64R+6$V
M-#`M83@P8F-D-68Q,V$W)PH@('AM;&YS.GAA<$U-/2=H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C`O;6TO)PH@('AM;&YS.GAM<$U-/2=H='1P.B\O;G,N
M861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*("`\>&%P34TZ1&]C=6UE;G1)1#YA
M9&]B93ID;V-I9#IP:&]T;W-H;W`Z,#0P.3<Y,60M9CDP,2TQ,64R+6$V-#`M
M83@P8F-D-68Q,V$W/"]X87!-33I$;V-U;65N=$E$/@H@(#QX87!-33I);G-T
M86YC94E$/GAM<"YI:60Z,S%$,3)&-C%&1$8X13(Q,4)",C9%03@Y,C$Q.#8U
M,#`\+WAA<$U-.DEN<W1A;F-E240^"B`@/'AA<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YX;7`N9&ED.C,Q1#$R1C8Q1D1&.$4R,3%"0C(V14$X.3(Q,3@V-3`P
M/"]X87!-33I/<FEG:6YA;$1O8W5M96YT240^"B`@/'AA<$U-.DAI<W1O<GD^
M"B`@(#QR9&8Z4V5Q/@H@("`@/')D9CIL:2\^"B`@("`\<F1F.FQI+SX*("`@
M/"]R9&8Z4V5Q/@H@(#PO>&%P34TZ2&ES=&]R>3X*("`\>&%P34TZ1&5R:79E
M9$9R;VT^/"]X87!-33I$97)I=F5D1G)O;3X*(#PO<F1F.D1E<V-R:7!T:6]N
M/@H*(#QR9&8Z1&5S8W)I<'1I;VX@86)O=70])W5U:60Z,#0P.3<Y,68M9CDP
M,2TQ,64R+6$V-#`M83@P8F-D-68Q,V$W)PH@('AM;&YS.F1C/2=H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G
M92]J<&5G/"]D8SIF;W)M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F
M.E)$1CX*/"]X.GAA<&UE=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H\/WAP86-K970@96YD/2=W)S\^_^(,6$E#
M0U]04D]&24Q%``$!```,2$QI;F\"$```;6YT<E)'0B!865H@!\X``@`)``8`
M,0``86-S<$U31E0`````245#('-21T(```````````````$``/;6``$`````
MTRU(4"`@````````````````````````````````````````````````````
M```````````18W!R=````5`````S9&5S8P```80```!L=W1P=````?`````4
M8FMP=````@0````4<EA96@```A@````49UA96@```BP````48EA96@```D``
M```49&UN9````E0```!P9&UD9````L0```"(=G5E9````TP```"&=FEE=P``
M`]0````D;'5M:0```_@````4;65A<P``!`P````D=&5C:```!#`````,<E12
M0P``!#P```@,9U120P``!#P```@,8E120P``!#P```@,=&5X=`````!#;W!Y
M<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD``&1E<V,`
M````````$G-21T(@245#-C$Y-C8M,BXQ```````````````2<U)'0B!)14,V
M,3DV-BTR+C$`````````````````````````````````````````````````
M`````````````````%A96B````````#S40`!`````1;,6%E:(```````````
M``````````!865H@````````;Z(``#CU```#D%A96B````````!BF0``MX4`
M`!C:6%E:(````````"2@```/A```ML]D97-C`````````!9)14,@:'1T<#HO
M+W=W=RYI96,N8V@``````````````!9)14,@:'1T<#HO+W=W=RYI96,N8V@`
M````````````````````````````````````````````````````````````
M9&5S8P`````````N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@
M<W!A8V4@+2!S4D="```````````````N245#(#8Q.38V+3(N,2!$969A=6QT
M(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="````````````````````````````
M`&1E<V,`````````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)
M14,V,3DV-BTR+C$``````````````"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ````````````````````````````````
M``!V:65W```````3I/X`%%\N`!#/%``#[<P`!!,+``-<G@````%865H@````
M``!,"58`4````%<?YVUE87,``````````0````````````````````````*/
M`````G-I9R``````0U)4(&-U<G8````````$``````4`"@`/`!0`&0`>`",`
M*``M`#(`-P`[`$``10!*`$\`5`!9`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5
M`)H`GP"D`*D`K@"R`+<`O`#!`,8`RP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0<!
M#0$3`1D!'P$E`2L!,@$X`3X!10%,`5(!60%@`6<!;@%U`7P!@P&+`9(!F@&A
M`:D!L0&Y`<$!R0'1`=D!X0'I`?(!^@(#`@P"%`(=`B8"+P(X`D$"2P)4`ET"
M9P)Q`GH"A`*.`I@"H@*L`K8"P0++`M4"X`+K`O4#``,+`Q8#(0,M`S@#0P-/
M`UH#9@-R`WX#B@.6`Z(#K@.Z`\<#TP/@`^P#^00&!!,$(`0M!#L$2`15!&,$
M<01^!(P$F@2H!+8$Q`33!.$$\`3^!0T%'`4K!3H%2058!6<%=P6&!98%I@6U
M!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L`&T0;C!O4'!P<9!RL'
M/0=/!V$'=`>&!YD'K`>_!]('Y0?X"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG
M"/L)$`DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*
MW`KS"PL+(@LY"U$+:0N`"Y@+L`O("^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS
M#0T-)@U`#5H-=`V.#:D-PPW>#?@.$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/
M7@]Z#Y8/LP_/#^P0"1`F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H
M$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4
MSA3P%1(5-!56%7@5FQ6]%>`6`Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2
M%_<8&QA`&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;
M.QMC&XH;LAO:'`(<*AQ2''L<HQS,'/4='AU''7`=F1W#'>P>%AY`'FH>E!Z^
M'ND?$Q\^'VD?E!^_'^H@%2!!(&P@F"#$(/`A'"%((74AH2'.(?LB)R)5(H(B
MKR+=(PHC."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W
M)N@G&"=))WHGJR?<*`TH/RAQ**(HU"D&*3@I:RF=*=`J`BHU*F@JFRK/*P(K
M-BMI*YTKT2P%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'
M+_XP-3!L,*0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XT
MV#43-4TUAS7"-?TV-S9R-JXVZ3<D-V`WG#?7.!0X4#B,.,@Y!3E".7\YO#GY
M.C8Z=#JR.N\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/>`^(#Y@/J`^X#\A/V$_
MHC_B0"-`9$"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D55
M19I%WD8B1F=&JT;P1S5'>T?`2`5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+
MFDOB3"I,<DRZ30)-2DV33=Q.)4YN3K=/`$])3Y-/W5`G4'%0NU$&45!1FU'F
M4C%2?%+'4Q-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8
MRUD:66E9N%H'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S
M8`5@5V"J8/QA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG
M/6>39^EH/VB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$
M;QYO>&_1<"MPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV
M^'=6=[-X$7AN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C
M?X1_Y8!'@*B!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(
M!(AIB,Z),XF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6
MD3^1J)(1DGJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R:
M:)K5FT*;KYP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/F
MI%:DQZ4XI:FF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN
M+:ZAKQ:OB[``L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9
MN-&Y2KG"NCNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#
M6,/4Q%'$SL5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XV
MSK;/-\^XT#G0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9
M\=IVVOO;@-P%W(K=$-V6WAS>HM\IWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$
MY@WFEN<?YZGH,NB\Z4;IT.I;ZN7K<.O[[(;M$>V<[BCNM.]`[\SP6/#E\7+Q
M__*,\QGSI_0T],+U4/7>]FWV^_>*^!GXJ/DX^<?Z5_KG^W?\!_R8_2G]NOY+
M_MS_;?___^X`#D%D;V)E`&1``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#
M`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`Z`&B`P$1``(1`0,1`?_=``0`
M-?_$`:(````&`@,!``````````````<(!@4$"0,*`@$`"P$```8#`0$!````
M````````!@4$`P<""`$)``H+$``"`0,$`0,#`@,#`P(&"74!`@,$$042!B$'
M$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.AL?`F-'(*&<'1-2?A4S:"\9*B
M1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#T^,I.&;S=2HY.DA)2EA96F=H
M:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJM+6VM[BYNL3%QL?(R<K4U=;7
MV-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%!`0$!@8%;0$"`Q$$(1(%,08`
M(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R\!?A@C0EDE,88T3QHK(F-1E4
M-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S*1J4I+3$U.3TE:6UQ=7E]2A'
M5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(F*BXR-CH^#E)66EYB9FIN<G9
MZ?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1`#\`W^/?NO=>]^Z]U7K_`#&_
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M625=+*OVK>Z]U8?L#YN_#CM;:E%OOK7Y2_'_`'ULS)5F1QU!NC:O;6Q\U@JR
MOQ$D,64HZ?)4.:FI9:G'25$:S(&+1EUU`7'NRJ["H4TZ]TUU?S]^"=!O6/K6
MO^:?Q/HNR)LE28:+KNL^1/45+OR3,9"G2IH,1'LZ;=\>Y'RE=32+)#3BF,TJ
M,&52"#[U0UI3/7NE5N7YA?$W9F#R&Y]Y?)SH#:&V<2D+Y;<FZNX.O]N;?Q25
M%1'2T[Y+-9G<%%C*!:BJF2*,RRIKD=5%V('O95@-14TZ]U`V=\U_AQV)BI\]
MU[\K_C?O_!4]=-BJC-['[NZUW=AZ?*4T<4U1C)\IM[<N1H8<C!!41N\#2"5$
M=6*@,"=!6;@IZ]TQ9KY__!+;>[(-@[C^:GQ.V]OVIEQ-/3;&SOR)ZBP^\JF?
M<&C^`PT^U<CN^FST\^<\B_9(M.6JM0\0>XOX@@T(SU[I9[@^7'Q5VCA<ON7=
MGR3Z(VKMS;]*]=N#<&YNV=BX#!8*ABDC@DK<UF,MGJ/'8JDCGE1&EJ)(T#L%
M)N0/>RCJ*E3U[IDV9\WOAEV10U^4ZY^6WQI[#Q>*KH\9E,EL3O/K'>&/QF3F
MIUK(<=D:W;FY\C2T-?+1N)5AE=)&B(<+IY]Z"L>`)Z]TS;H_F`_!#8^X:?:&
M]OFI\3=F;MJX\5-2;4W=\BNHML[FJH<[.:;!S4V`S>[Z'+3PYJI'CHV2$K4O
MZ8RQX]^((-",]>Z7>:^5WQ@VWC,OFMQ_(GI#;V%P%'4Y'/9C/=I[)P^)P>/H
M@6K:_,Y+(YNFHL50T8%Y9IWCCC'ZB/>RC#BIZ]TE]D_.;X4]ET^3J^MOE[\8
MNQ:3"U%+29JJV#WSU=O.FP]770/4T5+E:C;6Z<E%CJFLIHFDACF*/*BEE!`)
M]Z`)X`GKW3=O#Y_?!'KO*T>"[!^:?Q.V#G<C205^/PF^/D3U%M',5]!553T5
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M9\1EZS:67R]-C<G#-2RH]/,R2JT;`K=3;W7NA5]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__0W^/?NO=>]^Z]
MU6O_`#1?@SVO_,,^/M%\=M@?)G%?&O:N1WML[>?8.3J^BL?W9E-VR=9[RVOV
M9UQC<5_$>Q^O8]I083L?9N.KZZ1#6/DJ2)Z/]A)&D/NO=%4WU_)LW=V5\DCW
M+O#Y=2U'6G:_9WPJ^1?R_P"EL3T3AL;#WI\D?A#M?'8+9>[-@;SJNP\M5=(]
M7]BY#;&`K=Q[7-#N2M=<,(:3,T_W4TH]U[I2?!O^3S_LH/<&S-X;L^1U;WIU
M-\>NG.\/C[\/^GLGU-A-GR=2]5?(/MVE[7W]3=G[WAW7N6H[MW73TV&QFW,;
M6#'[=H(,+22&:AJ*JH\T/NO=3_@GU7U;N3Y<?S@<=GNO-C9V@VY\W>L:+!8W
M+[1V_7X_`4U=\&OBMEZZFP=%54$M-BX,AELA/5U`@6,3U4TDKAG8L=@D"E3U
M[H_%7\%_A-7[WB[,KOAY\6JWLB')T>:A[#K/C]U/4[YBS&/@2EH,M'NV;:3[
M@3*45-$L<-0*@2Q(H56``'OU36M<]>Z5FYOBM\8-ZX+([5WG\<NB=W;8S"PI
MEMN;HZCV!N#`91*>HBJZ=,EA\OM^LQU<L%7`DJ"6-@DB*PLP!]^))%*GKW3?
MLSX@?$SK?$S8'KSXO_'C86"J:^;*U6%V5TKUOM3#U&4J(XH:C)SXW!;;H:*7
M(3PT\:/,R&5D106(46\"1PZ]TQ9OX+_"7<N[H.P-R?#OXL[@W[2S8BHIM\YS
MX^]39;>%/4;?\9P-1!N:OVE49N&;!^)?LW6<-2Z1XRMA[]4UK7/7NEIN'XP?
M&K=^%S&VMV_'KI#=&W-Q4CT&X-O;DZIV+G,'GJ&66.>6BS.)RF"JL?E:22>)
M':.>.1"Z@D7`/O99CQ8]>Z8]D_#GXB=:4.0Q76_Q8^.77V+RU='E,KC=D=(]
M:;2Q^2R<-,M%%D<A1X#;./IJVOBHT$2S2JTBQ`*#IX]Z!(X=>Z9=T_!7X1;Z
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MJFKJ6AHLGG=HU];2T=-62--'$CJB2L7`#$GWXDGB>O=4Z_*39&[X/YZW\MOI
MO:_4&#K?AYNKHSNO?W=>W(NE]HYGJH]H=;XC?^Y>GMU[DR=3M*LH<'O;:>]\
M+A:O!5(J*>LAK(8GISJ6XM5RK9)7SZ]U>1W#\;/CK\AUVZG?_0?2W>2;/FR<
M^TD[AZLV-V8NUY\U%209F;;J[UP6;&%ER\-!`E2U-XC.L$8?4$6U.O=3.H/C
MYT)\>\9F\+T%TAU#T?A]RY2+-[CQ/4'6NS.M,9N#,P44&,@R^:H=F87"TN5R
MD.-I8J=:B=))5@C6,-I4`>Z]U6]_+0_EG9GX"_(7^95V@,YUDW7OS0^16&[>
MZLV#UKMVIVQ3]:;5QD>\I#MW,XP8_'X.GKC4[M(5,<KTY$+2%@TFA/=>ZN`]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=?_1W^/?NO=>]^Z]U[W[KW7O?NO=>]^Z]U4W_+X(/S$_G-C0%(^='4X)
M%[O?X$?$DW:Y(!Y_%A[]U[JV3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW53?=W='66W/YN?PPZ3S>\8<=VAV/T/W)F]E;-;&Y
MZ:7<.+VSCMX9+-5D>5I<;-M^A;'4..GE$=550S3+$_B5RI]N*1X4@KFHZ]U;
M)[;Z]U[W[KW6O]_)_P#D7WGW1\Z/YY&P.UNU=Y=@;+Z'^:F`V5TUMG<N7DR.
M(ZTVE/!V/3S[<VC2.`F'Q$B8&EU01V0R0ZR/(SLWNO=;`/OW7NO>_=>Z][]U
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MKW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]UKG_S3OCM\@L[_`##OB+\K_A'_`'&S
MWSEZ6Z0[)VQTAL#O&>:E^/.X-O[LJ]QX+M"L[%GP57A-YC)8W8>[,A+B5Q^3
MI%;(1P^77&&1W`H,;-Y@]>Z#C_2#_P`*UO\`GQ?\HC_S_=T__;4]M]>Z]_I!
M_P"%:W_/B_Y1'_G^[I_^VI[]U[HA7Q'^8_\`PH)[E[Q^<NP?C-\5_P"3-M;M
MWH;N_&['^6V;PVS.U-A5V_NUZG'9:.BW)FMR8[LBGK.R:N"CPE33#)5S&H01
ME!Z??NO='U_T@_\`"M;_`)\7_*(_\_W=/_VU/?NO=`]E_P"9'_/J^)OR[_E\
M]2?/GIS^7?0=3?-;Y/[9^/AGZ*/;F4WQCX<ODMOX[,9>DK\OV97XC$U.-I]R
MQ5%,9J2MCG>!XGCC#+)[]U[K;8]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U__3,=\B]O\`9_\`,,_FB]Z?&>+ICJ7HSLC<F[>S
M^L-YTN$Z1^47]X]Y_'SHS$5F>Z1[/_F,Y'.8C;WQ1^2OQS[[RNT*&+:-;LW.
MX+M;K>MS&WJO;.X35X^NIO?NO=;'/\J7J^'HWXRY/I:H^&#_``CW5UOVOOG$
M[\V1C^P,OW+L;MO>.3_A6X,A\A^L^\-UYO.]B=L;)[4I,M!+#6[M>FW5BZBE
MFQ&0IT..CDE]U[JS'W[KW7O?NO=>]^Z]U4[_`"^0P^8G\YG4;@_.?J<KR#Q_
MLA'Q)XX)(Y_K[]U[JV+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW5?W::I_P`.(?%AO[9ZD[C##5_96AG*>G\6+-_K_P"P]O+_
M`&,OVCKW5@/MGKW7O?NO=5!?RX_Y?G;WP^^5O\U+O7L?=/7&?VI\Y?D]A^Z.
MJ<;LK);FKMP;<VKCX=Z&:@[!IL]M7;^.QFX&FW3&JQ8ZJRE.5A9C."0GOW7N
MK???NO=:R?\`/J_[+C_X3U?^--ML?^[GJ_W[KW6S9[]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K_]383SO\J_\`F*]:U=1COA?_
M`#ROD_U3UW/D<ID8=C_*KH;I/YVY;"+EZZIKWQ&W>SNT5VKOFFV]AWJ?#CJ6
MMFR,M-211PM/)IUGW7NC._#[^7[WYTEVK%WU\J?YD?RC^;?:E+M+-[.QNWMP
M46R^B_C7A:7/U.,J:W<6+^./5M$NW9=[1ICC3P9*OR-<:>FGD6.)7*R+[KW5
MI'OW7NM2CY>_++Y5X+^=AC<+M'Y)=M87XF=*_(O^7KTMV=6['RV&H>F^E,Y\
MC-O;BRV=^,?;_P`=*[;=9O/Y-[Z^6$N0V\<%V)@IY:3K),U&LK12XVLCD]U[
MIK_E8_,GYE=@=U=#;]R?>V^?DWV'\X/A#\ZODQVS\2^P=\;:P?571'=GQW^2
M6`ZNZ6V)U=)CMEY#<'QSV=,^3J]CYF2KBRU-5Y"CDR$]+45\3`>Z]U9M_*,W
M'VMN[O+^;?N/O3J_;W2O;N3^<G7;[RZMVGV8G<FW=J/3_"#XKTN&7&]G)L_K
M]=T#+X2&"LE_W#4)I)9VIRKF/R-[KW5VOOW7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NB$?)3K;O6+O[IKO_`*5V=MWL6LV+M;=V
MS*W:.:W#!M;QMNB.H)SE1E:R6.$T$%.QB6.)9)O.RDKX]3*[&4TO&YI7KW3?
M+V]_,)C90/B=UFX*WO%W#C90.;:6/FCTFWXL?>],/^_3^SKW62+MS^80Z:C\
M3^LEY8:).Y,;$YTC\)KD%C^.>??M,/\`OT_LZ]T5;XD=B?.^/Y%_(2CWEE<M
MW9L[<G?6VX=R[/W0^Q<!@OAKMVJAK'RG7W6V:V]5P93MK%QX^J2H;(5<8E4T
ML2>-G>223SQQJM=9J1C'7NG7YQ?,W^8UMWL?&[&_E??#CJ_YE1;)_O!A?D;5
M=C]LX?IFHZNWIY<14[*P6*&]=T;)BW9!N'"RUM3)48P9&"#P*DLD+D([14@`
MD8/7NJ//GEW%\T.Q>XOY%>_?YD/QYZZ^'?<>W/YNDE'MC8&TNU-M=A[4S'5>
M)V[TCE\'OK,[SPNY=T8C!39+>]57XV>&:IC>GIJ5*AXE5P3KKW1UNOOYF/\`
M/;RG8VQ,/V5_+@^$.S>MLCV!M;$]A[OQWSZZ"S.2VEU[6[FH:/=VZZ+$P]YO
M492KP&V)*BMC@CADGF:$*M.SL(3[KW1__P"8?\X/F)U32]12?RV.FOBW\Q*K
M/5V](^Y(-_\`RIZEZI7KV@Q])MV38U5BWW+V3M),VNYJJKR<<W@:J>F-''JC
M59=8]U[KG\&?G?\`*3>75O=6\?YD'47QP^*V\]CUT^2ZWV5U?\F.I>V)-_[&
MQ.SVSN>S#5NWNR]U4V/KZ7+T\M)'%424;,%U%/&!,_NO=+O^6W_--Z1^?_PV
MZF^560R>T.D,CV$V[\9F.N=Z=A;/@RN"SFR-WYG:&5$#2YB*IFQ=?/B!5T;S
M1PSM2U$;/&NH$^Z]T>G_`&8+H3_G]_4/_HRMF?\`UZ]^Z]U[_9@NA/\`G]_4
M/_HRMF?_`%Z]^Z]U[_9@NA/^?W]0_P#HRMF?_7KW[KW7O]F"Z$_Y_?U#_P"C
M*V9_]>O?NO=>_P!F"Z$_Y_?U#_Z,K9G_`->O?NO=>_V8+H3_`)_?U#_Z,K9G
M_P!>O?NO=>_V8+H3_G]_4/\`Z,K9G_UZ]^Z]T\;?[@ZEW7EJ?`;6[1ZZW+G:
MM*B6DPNW][;:S.6JHJ2(U%5+3X['9.IJYHZ6!2\A5"$07-A[]U[H1O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__5.]_,H@V]_+N["I\9
MV?\`S1_Y_O;NXM^;5W_WWD.N/B/N;H3="=,=0T'8>W=H-O;?%7V!MK:>)VKU
MN-\;^H-O8IEJ9S]V4@*Q`PA_=>ZNH_DP=FXOL[XL;[J:'?7S]WSD]E_(_M3K
MK=__``Y35=7O\G-G[SVI1;2I]Q;'RF,ZKKJW%[>VI@ZNH#T%%D!#DDEGJ)/&
M*26D9O=>ZMR]^Z]T73<OQ#^*N\^\ML_)K=OQOZ/W/\B=E4M-1[3[PSW5^S,K
MVIMZ"@$JXT8G?-=AYMQ4<N)2HE6CD2H$E&LTJPM&))`WNO=.O6?Q@^-W2V^^
MR^T.H.@^G>K^R.Y<G_&>VM^;`ZXVCM'=_9.5-759%Z_>NX<%B:'*[DJ9<G75
M%6[54LIDJZB:=KS2R.WNO=$1_E\F_P`Q?YS8\82WSFZG&H7_`'#_`+(3\2O4
M;D\@?TL/]C[]U[JV3W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5?_`,/_`/F>_P`\?_$\8G_WFF]N/\,?
MV=>Z%?H?IC>'6O;/R@WON*HP4V%[B["P.Z-HQXJLK*G(4^,QF#FQU2F<@J*"
MDAI*MJB0%%ADG4KR6!X]^=PRQ@<0.O=,'S9^`7Q+_F(]74'3WR[ZBQ':VR\/
MN"DW1@/+D,QMO<VVLW2LJR5FU]Z[6K\-N[;39*F3[>M6AK8%K:8F&<21^GVW
MU[JJ3_H%4_D>?]XF[E_]*/\`DG_]M?W[KW7O^@53^1Y_WB;N7_TH_P"2?_VU
M_?NO=1JW_A*A_)#GH<A34GQ6W-0UE5CLA1T>13Y%?(^HEQ=95T<]/296"GG[
M6:EJ*K%U$JU$4<ZR4[R1JLL<D99&]U[H+NCO^$D'\H7KKK#`;/[<ZTW]\A=_
MXVJS4^9[=W#VUVSUYF=R0Y')SU>+HJC:/6O8&`V5BZ?;^/DCI(6IJ-)IUC,D
M[R2-<>Z]T+7_`$"J?R//^\3=R_\`I1_R3_\`MK^_=>Z]_P!`JG\CS_O$W<O_
M`*4?\D__`+:_OW7NO?\`0*I_(\_[Q-W+_P"E'_)/_P"VO[]U[KW_`$"J?R//
M^\3=R_\`I1_R3_\`MK^_=>Z]_P!`JG\CS_O$W<O_`*4?\D__`+:_OW7NO?\`
M0*I_(\_[Q-W+_P"E'_)/_P"VO[]U[KW_`$"J?R//^\3=R_\`I1_R3_\`MK^_
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MEL/N&E\T3D.%?W7NEW_(-W;\-=__``?SV^OA=O#Y1]B[;W=\@NS,YW7V'\TL
MY0[J^3F]/D%4XK9D6[LOVONW"35.UMTYFFV?!M^A@K<3-/124-'`IEDJ$G=O
M=>ZNT]^Z]U[W[KW7O?NO=5/?R^O)_LX?\YG7(&7_`&>;JC0`P.@?[(5\2R00
M"=/)O8_Z_P"??NO=6P^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK_P#A_P#\SW^>/_B>,3_[S3>W'^&/
M[.O=+SXY]H;[WSW1\N]J;JSPRNW^LNS=N8#8U`,;C*(X/#UVWIZVLHS4T-+!
M59$RU:!O)4O+(MK`@<>_.H58VIDCKW1Q/;?7NO>_=>Z][]U[H.NWJ>NJ^I^T
M*3%P5M5DZKKO>M/CZ;&Q5,^1J*Z?;63BI(*"&D#54M;-4,JQ+$#(SD!1>WOW
M7NM<_P#D.=\[3^#O_"?;J3OWYLY[=W3NP^K\_P!U9'L#<?8&T>P\KN#!8K/?
M)O=NT-MR2[6QFW\YOG(Q5V8S5'2TZ4M!.;2`A1&K,ONO=62?$K^==_+&^='<
M='T!\5OD_1=K=MU^V\_NZDVG3=6=W[4,NW]KK1OG*TYS?76FV-MQ/1I6QL('
MK%J)E+&)'"/I]U[J#\JOYX/\KGX2]U[@^.WR?^4M#U=W%M?$[=SF=V?4=4]Y
M[H:AQF[<7%F]OS_Q[9'6.Y=LU+UV+G28Q0ULDT*NOE5"P!]U[HRU)_,`^(U?
M\,G_`)A%+VY%+\04V-6=D-VZ-E=C*HV?C\Q/M^LRG]Q7VBO91FBS-,]/]G_!
MOO3(O$)!!]^Z]T6'XN?SR_Y6/S1[OVG\<?C/\JJ#L[N??%%N;(;7V;3]3][;
M8;*4FS\!7[IW$XS^]>L-M[8HY*#`8NHJ1'/6Q23K"PB5V&GW[KW3]\N_YTO\
MLWX']OGH7Y7_`";H^INUQM/!;X_NK4]6]V;MOMC<E5E*7"Y(9S8?6VZ=N%ZN
M?"U(-.*S[F((&DC17C+>Z]T8'K[^8!\1>T_AWE/GYL/M^FSWQ)PNSNP=_P"4
M[;7:'8&.@H]I]65^?Q>_<K+LW+[3H.PM>`K]KUT;4PQ)JIS!>&*0.A;W7NBB
M_'7^?;_*9^6/='7_`,>?C_\`+>@[![A[2KZ_%[%V=%T_W_MR3-U^,P63W)6T
MS9K=W5.`VYBFAPV'J90:VLIU=H_&I:5D1O=>ZIW_`)_'R\^.GQR_G$_R,MR]
MT=D4^R<)T!FN^^Y.W:Z;;F[LTFSNMNQH]I;-V9N:>';F!R]5EH\UN7KK,TPI
MJ".KK8/LC)+"D<D+2>Z]ULX_$KYA_'+YT=.8[O\`^*_8\7:G4>6SVXMLT&[H
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M*!&]1%%92PX)Y]^ZUUK88/\`X4D;4RG\L;=WSSJ_B-NK']R[>[6PG5N*^(*]
ML4M9E<__`'KZG?Y)[6WR>UDZUA3%[&ROQ>QV5WF]:VVYO"N&JZ/2YC-1[]U[
MHQG:O\X_L+&[MW-B^D?C)U%N'9?55'T;@.V^QODU\V^MOB%M2O[^[YZFVYWG
MMGXO]"9?>FPMVX7MGMS%=6[II<E7??U>VJ*&4/3%]:LZ>Z]UUF_YS/8.U.V^
M]:W<WPS\?PF^.7SOVY\`^WOE3A/D-AJ_>^PNPMVOU+AL'V?N3X[YOK';$W^A
M^/>G=F`QE=68S=>3RE-'4M4PT-4J-$/=>Z?NAOYQV;[L[HVOLJG^*V0'6/R+
MP7SER/P4WEM3N7:V<W_\E,Y\`M^Q]>]J;5W)U_NK;_7^T^EJ[?V3,E3M2KR6
M[*S'3TB!LA/0!BR>Z]TQ[`_G(=D=N_&+X?;\Z\^'^-_V;3YI_(CY!?';KGXQ
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M;2-G@M#15S44X;W7NC,_)+^:_P#`_P"(W:65Z<^0'<V1V+O?;>(V'N7>*+U3
MW#N3:^Q-K]G9+)X/8FZ=\[\VIL+-[(VEM_<FY,6V+IZBNR$*MDYX*8@2SQJW
MNO=!OF/YV7\NW!]74O;M7VGV+/ME*ON6'=F&Q?QN^1N9[%ZJQ_QYR^V\#W9N
M3NGJS%=5U?8G3NU>MLUO7!TF1R.X\9C:5:C-4,<;2/4(/?NO=%H_F&?S=NS?
MC'OW<HZ!ZTVGV5UST;\0NM/DIWU)ONBW1MW*Q[B^5'R2ZO\`C[\5NN*;(+78
MZKZYS=5C*O>FZLY29?#U-7)C\/21#[`N\DGNO=&?[,_G6?RY>J-IIOW<O=>Y
M,KLMJ[MD-N;8/27>/9F)@VGTEV5B^E^PNV9Y^O\`KO<;)T?2]R9JFVIB]ZZ3
MMG<6=D--B*VN,<K)[KW0W?#;Y5[O^0&^_FKU/V7M7;>S^P_B5\ILUU$M'MBJ
MRD]'N;J'=VP-B=S="=@Y"GRY>LP^Y-S]:=B4L.8H2Q6FR]!5!`D92-?=>Z/5
M[]U[K__7L\_F2=8]B?)7LSXM4_RF^%7\N?NKY08C=OR*I.H?CW\A?YCF[.H\
M)5]8XOLZ'']5;\VAT'0U$N$[QS6^MD0QS9V2NI:P8VH1:9Z*`D1)[KW5Z_\`
M+UVYW=L[X\4NT^]OBM\</AQN#;N[L_C-J]*?%;.X_.=2X[8<5-B9L+FJ(8G:
MVT,7B,OD\C-6I/20TFE8X(I2P:5HX_=>Z/+[]U[KWOW7NO>_=>ZJ;_E\!1\Q
M?YSEF)_YSHZGU`J`%/\`LA'Q)-@03<6_UO?NO=6R>_=>Z][]U[KWOW7NO>_=
M>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZK_^'_\`
MS/?YX_\`B>,3_P"\TWMQ_AC^SKW1DNLLCT;6;Z[HINK8]N)OW'[KQ<'=K87%
MU-#DY-VOC9'Q3;BJYJ2GBR=<,8&T21O,JIP2/I[JP8!"W#RZ]T-WNO7NO>_=
M>Z][]U[KWOW7NDQN+96SMW[;K]F;MVEMG=&S\K&D64VIN+`XO-[:R44=7'7Q
MQ5^"R=)4XNLC2OA2<+)$P$RA_P!0!]^Z]TB-G?'[H;KO.Q;IZ_Z2ZBV+N:&C
MJL?%N+9W6VS=L9V*@KC":VACR^%PM#D$HZPT\?EB$@230NH&PM[KW6/=WQYZ
M`[`S]3NO?G1O3^]MTUL%)25FY=W=9[+W)GZNDQ\9AH::IS&9PE;D9Z>BA8I"
MCR%8UX4`>_=>Z5"=7]:1[#/5<?7FQ4ZP.,DPG^CA-HX!=A'#2R-++B#M!<>-
MO'&22N6:G^W\18DE;GW[KW25VE\=OC]L'/T>[-B]%].[*W1CHJN#'[EVGUCL
MK;FX*"#(4[4E?#1YG#X2BR-+%6TKF.94D`DC)5K@V]^Z]U(WGT#T3V/F_P"\
MW8?2G4N^]R&BIL8=P;RZXV=NC-_PZC>>2DQYRV;PU;7_`&5+)52M'%Y/&C2,
M5`+&_NO=*7&]:=<8;9,G6>'Z_P!DXKK>6@R6*FZ_QNU,%0[(EQ>8DJ9<OC9-
MJ4M!#@7H,I+6S-4PFG,<[2N7#%FO[KW2*VS\;/CILK.XS=&S>@NE=I;FPLLL
MN'W%MGJS8N!SN)EGIIJ*:3&9?%X*ER%!)-15$D3&*1"T3LI]+$'W7NM>3^?Q
M\>^\YOE?_*L^=G47PNW+\V-F_$OL?MK&]W=3=8[7QN[>S=RX;L'&;/;85')M
M^7;^?K,MLW$93"96>6HE@GHL555"LXB-491[KW4OXY?SR\KM7Y*_%3X9]G_R
M=/DC\`,%\K.QL]LCK'-;VQ>`V)M*3<\=-#D\W7XK:%/L'9M-FDAR>6HOXK)3
M2K-`M<D[+*Q"/[KW6SY[]U[H!>QOBO\`&'N'<HWCVW\<.ANTMWC&4F%7=78W
M4'7N]]R##4$U544.)&<W-M[*93^&4517SO%!Y?%&\SE5!=B?=>Z6&#Z:Z?VS
MUS)T[MOJGK?;_4<U!E<5-U9A-B[8Q/7,N+SL]559O'2[(H<73[9DH,Q55LTE
M5":4QU$DSM(&+L3[K9))J3GI7;@P<&>VWFMM-*U%39K"9+!M-31QZZ2#(T$U
M`98(F'BU01S752--P!]/?NM=4(T__">WH!:+`1UO<>_*NOP'\K?<7\M2&>/;
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M%3NW^5S/U;_+8^,7Q2^'5(=][Z^"_?WQA^372M%VINV+`#M/L'I'Y#8CN7?_
M`/??==+1"CP^1[/BRVY9C+%3I2TV1R$2JL<*`I[KW2WS/\KWM+?/RXSOR_[.
M^;N[MS;[Z\V;\GMI?"&EVWT!TMU_+\49OD_A9=O9C<.Y<S@:"6;Y,Y3KO#P4
M-/M^'=,,6/1:,S5E/5UL\U6WNO=(#<G\E\;U^1F%[JWC\ONS\]LG>FZ/B'W-
M\N>GWZYZVH*#Y2?)GX3[6V]MWJ#N&?=5!1P573^$SE7M/&Y#=.U\!1?99BHH
MXUBJ*./6K^Z]T,_RA_E4[&^3^Z_EONK-]M[NVM+\M-M_!/;F=H\3@,+7)LZ/
MX+]_9/OS;55AIZR='R$F_LIDOX?7+.%%)`GDB+L0J^Z]U3M\^_Y)OR0RGR1J
M^V_C5M_!]_[;[$W]\N._&V[V1F.IZ#9FS/DO\C-T?'"KV_C>\.ONQL0V+[(^
M)&W\)T/329>DQ#9;=61J1H%`T<<)/NO=6!8C^5#V%\C/CS_,2VQ\U=W;-VQW
MA_,3^1'7N]>QMR=+Q5&[]O;:Z0^-^8ZMQ?0O5.,3>M!BGRF`J]K]75<]=3U,
M0>G.[JZ,R2S(9G]U[JM_Y7?R1_ECLWNSI>+XGX;:O?\`T?TKU=V!M/XJ;<[M
MW!UW+L#X[[DWG\KMI=[[9ZL^2&SNQ*'+YWN/XC]/8'"Z-M28'^+[TIYJ*BI&
MI/%C:&I;W7NK[O@]\:^SNI>WOY@_?7<M!@\5O7Y;?+:3>NV<7M[.C/TM'T?U
M)U-UST7T[59*I6DI4I,_N?%;#K,W/2#6U!!E(*65C/!*3[KW5BGOW7NO_]"\
MW^<)L[<GRR^4OQO^`777QO\`Y;7:78G971W;O;P[4^?W7W8>_LQUWL':VZ=H
M;4WA1]"TW7>'Q>7I=\&7.TF1,8W+CTJ12@S0^&%IA[KW5@G\J7X"[H_EL_$C
M#?&;=GR-WE\F\EC=Y;CW;3[SW7CLE@L=M;&9ZDPU+1=<;!VYE]W[[K]N[`VN
MF)+T=*^3GO4U51,%B$OB3W7NK)_?NO=%6[2^;WQ,Z6[VZC^,7:'?77^T?D%W
MK/2P=5]15N3EJ][[H&0K*K&8JL.'QE-738+$YK+4,]'05N2^SI*^L@EIZ>22
M:-T7W7NL?2WSE^(/R+[;[;Z'Z-^1'5_:'<'1=5-2=J;`VEN.GR.?VJ]'DAA<
MG.T`5(<SC\)GV&-R-5CGJZ;'9,BCJI(JHB+W[KW12?Y?%O\`9Q/YS=E`M\Z.
MI[D7NW_.`_Q(-S<D7N?Q;W[KW5L?OW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[
MKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NJ_\`X?\`_,]_GB?Q_IYQ
M('^N-L7/^]^W'^&/[.O="7\?>HM\]>=P_*W>6Z:3$T^`[9['V]N39$V/ROW]
M758C'8&?'U4F5I/M8/X74K5.`L>N74O-Q]/?G<.L8'D.O=&U]M]>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZUD_YU__`&]=_P"$Y'_BV7R"_P#=-T/[]U[K9L]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=?_]&_O^<5\&-\_+?MGX[;LVK_`"^ML_,F3JW:F^:;
M%;YW!_,/[E^%M9U'EMTY/#PY*BP&"ZNAG&X)]T8JB1JK)A14B&F6F<E!&K>Z
M]T(O\A?-;/J_B7W+L[;?0T?QEW'T[\S/D!TMVUTBWR=[0^6F3V-VYUNVTL%N
M^ES7:W:*R5AK,BD=-604>(JJ["F@J*>LBG-165,<?NO=7<>_=>ZU>NY_B#_,
M=VG_`#DNX?D!\=6[VV_L3Y)=N?R^]V4':&R=_=,Q_%K&=`=%;&R/67ROZV^5
MW6>]*Q>U=U[T&`J*RLZ_I-OTDM)-D-R?=1U>/JJ*KG/NO=(G^65_+J^7&SMZ
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M#,[HP_76\/X%A\ON".-H9L[5Q24=54S5]7$54AI3%&%M$B`L#=96``H#3U'7
MNBC]*_'?)=H=H_)'8F5^07R)QN+Z5WYA-I[<K,;V57C(Y6ARF%DR<U3GGJH:
MBFFKHI8]"M3Q4R:>2E_H\SZ0A"+4CTZ]T;')[DROQ'/QMZ=P]=N+M:C[<[AR
M6T,MN_LS=-37[KPU%F349IJJFJH,<T>4^Q>7PP02>)4A4#5Q[;IXH=CB@\NO
M='C]M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z]
M[]U[KWOW7NM9/^=?_P!O7?\`A.1_XME\@O\`W3=#^_=>ZV;/?NO=>]^Z]U[W
M[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW46LK*/'4M175]5345%21//5
M5E9/%34M-#&-3S5%1,Z10Q(.2S$`#W[KW4E6#`$$$$`@@W!!^A!_-_?NO==^
M_=>Z][]U[KWOW7NO>_=>Z8*#=6V,IF\]MK&;CP.1W'M5L6FZ-OT&8Q]9F]MO
MG*%\EA5SV*IZB2OP[9C'1M44HJ(XS40*9(]2@GW[KW3M5U=)04M175U53T5%
M20R5-765<T5/2TM/`ADFGJ*B9DA@@BC!9G8A5`N3;W[KW7?WE)_RM4W_``&^
M\_S\7_`3_E:_5_P&_P!K_3_C[]U[K__2.'_,K^0OP0^?%1/4]G?`^G^37S>V
M%_,+[F_E7?#/X^K\Q^W>IL]OF79&XMOKV%W9VK3].YS8DO5?6M#FH9<A)#D8
MLA,M!%CI9<C305LC4/NO=7,?R+<[TBOP\WWT]T[\5=O_``TS_P`7/E%W=\:_
MD%T=M;?6>[7V]BOD)UW4[>K-Y[BQ';FZYJK=?9^/W3MW<>&K(,GDIZBJAB=:
M#S2QT4<C>Z]U<[[]U[KWOW7NO>_=>ZJ=_E\AQ\Q/YS6HW!^<W4Y7]/T_V0GX
ME7'!O]?Z^_=>ZMB]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5?_`,1_^RB?GK_XF3:/_O+5?M^7
MX(?L_P`W7NC+]H]/[&[+W1U!N7=N5RU!E^J-\IO79=/CLO28VFR>?6E^V%)E
M*:II*F7*T?AY\,31/?G5[:#$!@.!Z]T-/NO7NO>_=>Z][]U[KWOW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HJ'?/PJ^//R4[A^,'>_;N
MTLEN#LOX>[SW)O\`Z%S-%NK<F"I=K[FW73[?I\W5Y'$8;)T6+W+!4IM>A*PY
M"*HBC,/I`#N&]U[HU_OW7NJ7OGKF?Y\-#WI'!_+CVE\`LS\>O[A;<>6M^2U5
MV7#V(.Q6R>:&YX8TVEN/%8P[<CQ2T/VUXO)Y&D)8\`>Z]T3.+<W_``K.\]'Y
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M[\Z*[<_E]_RX^JN^?DM7[G^!-)_,>^;W7_SXWEG/D%O_``]90;:DE^4_9/PM
MVWWYV]B-XX'L+%=?=AY63;F3I9Z_)P8_,3)C_+([*L?OW7NCH'.][=@?\)_O
MY6&S/E%4;VW-%\B?F;\$.H?D#E^T?XE-NW<'Q3WA\X:*38=?ONOR`ARU5!O+
MJ?#;1@K*FJ(FR-)D")RQJ'U>Z]TQ]Y?(^+KGY]?STMC?$_Y9[U[)^1.8_EDY
M?=756PJGN3)=@;LV;\F^NZSY!YCL;K;X^[/-0:;!;NZ6V6<364FU\'2RU]#)
MIFDBFG:I8^Z]T*/\F_Y+?%SHCM?Y.X?J_O\`SV6^"_9V>_EG=._'/<>[-]=F
M]N;*W1_,%^1G4&]MP=W;!V5O/<=3O&K3LG>N4J=MU>\Z'[Q*3#;@G,-6M%4^
M>%?=>Z`3^1;O;<^X_F+T%D\?V/VAO#Y)]B?%;YG[F_G&;9W?OW?VY6V=\E-J
M?+'!;+Z+QW:6P=PYO([-Z?['P%%C\]A]L8W'T>*K)]G4ADBADH")W]U[J1N;
M^8M_-IW7NK;B;*^5G36P]L]_S_S@L7LNA?XC83=>8Z5QO\J[L3(5&W,K193(
M=@T]+O?>7>V+\>!RS92E_A6(QL)GHJ&3),:CW[KW2U^*7\XKY7_*OYN=(;0W
M'W_U3\=^LO[F?'GM/N3JC.[)ZLQVS\QUCNGX%;`^3V_\3L???86YJ;O/=W?V
MX.W-XUU%'AL)ASA,/U]BI<HE75U5)5--[KW1#.W^W?DET[!\!_YHNP-C9C._
M(/YQ]M_S6/G>^'SM)09:JZA^.>YOC)L?K#HK?.4P=,:>I[<V_P#&'X6[>Q6[
MZ39T%1#6YR9JJFI98VEED;W7NK$NF_G[W9\W/YB'8'PEWC\H.FMY_#44O:W5
M':>TLSM/IG!8KY3?'EOA-LG=F/W/T_G3EJ/MC>7<G;6XNQ\UN'=F(PN*BVOM
MS96'66AED5:AI_=>ZUJ?]G.^<?\`V=__`'#&?Z)?\]D?^9$_\_B_5_Q\G_5^
M_P"!W_-_W[KW7__3VP^UNJ_Y4GP^^3V%^;W<NWOBWT%\JN[,K_HXVKW1O>NV
M[M'?W8.YLU24FW:^CVC2Y*N@3)[QR>)R45#D\GCZ/^)RX^I\-94&FD*M[KW1
MF?BOUK\6NJ]G=A;:^)\>QDVI4=\=T9[M1ME;UFW_`%#_`")S>]\C6=WIOO<-
M?N'<V:'8M%O1IJ;*4%?5"IQ1@CHA#3PT\,$?NO=&<]^Z]U[W[KW7O?NO=5.?
MR^1&/F)_.:*OJ8_.?J?6+$:#_LA/Q*`6Y/J_U_\`8?CW[KW5L?OW7NO>_=>Z
M][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW
M7NO>_=>ZK3;K_P"7G2G=??6[.F>O.LNS=K]U;JP^]#D-T[PFVI5X2:AQ<F+&
M#3'K+++4RTX+/)4$K'*'70JV8>WJQLJ!F((Z]T7SY&;J^7.5W_\`&*L[*Z=Z
MLV]NK"=OQY#J/&X/?51E\?NG>XQVA,-N2LD75@<2:4EOND);5Q8?ER,1T>CF
ME,XZ]U:-W)G.\L)LW%5W2.Q=H;WWO-F<=!E\'N[<DNW<128.2BK9,G6TN1CL
MU15TM>D$<<9X='9OQ[3J%)[FH.O=(7J??GR6:/?65^1/5NPMB;>V[MV+,X&H
MV%NZ7=61R]12+E*G.4E52U#QI3"FHZ:%H#J`D>1@2+>]L$QH8D]>Z%3IKM?;
MW>'66T^U=ITF9H-N[QHJBOQE)N"EIZ+,00TV0K,;(*^EI:NOIX9#/0N0%F<%
M"#>YL-,I1BIXCKW0G^Z]>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>ZZ(!%CR#P0?S[]U[K"*6F`"BG@"B$TX
M`AC`%.WU@`TV\)_*_I_P]^Z]U%JL3BJV7'U%;C,?5SXB?[K%355'35$V,J3$
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MJY:^*EI:&EIZ>*NFGDJIJR.&*)(DJY:J9Y&D`#M(Q8FY)]^Z]UEI\=CZ.HKJ
MNDH:.EJ<G-'49*IIJ6&"HR%1#!'30SULT2+)5S14T2QJTA9E10H-@![]U[K-
M]M3BUH(18RD6B3@SF\Y'IX\Q_7_JOS[]U[JMWLS^4=\">Y-\]C;V[-Z@S^[X
M.V-XY[L[?W7.0[B[H@Z7S?<&Y^MWZ=SO=<?3F/[`HNN,3W%7=62/@_[QT6.I
M\G#2.SQ2I4,TQ]U[JPK;>UMN[-V[MO:6UL+C\%MK9^#Q>VMKX7'4R04&!P&%
MQ]/BL3B<9"HM2T-!C:2."-%X6-`/H/?NO=5^5O\`*9^#E?V5V-VE+UIN^GSG
M:.X>XM];BP./[K[IQO7F-[2^0.P<EU;W/W+LKK>@W]3;)V#W'V!U_EZG&U6Y
ML-0T66@2>2:EFIZF669_=>Z%C_AO?X8_]X_;*_[(U_X;W_5F_P#LC'_O'[_B
M[?\`'E?X_P#`[_F_[]U[K__4L+_X47=/;([)^1/0]-@_E9\(^G_D#O;XS[[Z
MVPG6O\P#-[UZUZX'7^+[ZZA[>3MSX]=Y4.`R&P.M_D=3;ZZ[H]MR4N3J8ZO-
M[9RM4E-H:GU/[KW5V7\J?XO]H_''H[MW=O>78/4_8/=GS#^3_;7S0[5J>@CD
MI^B-L;I[CH]IXF#9_3^4S:QYW/[+Q.V]D8^49&N45=;7U%3+(TI;SR^Z]U9W
M[]U[KWOW7NO>_=>ZJ<_E],K?,3^<T%CT%?G/U.&;43Y&_P!D)^)5FL0=-A;Z
M?Z_OW7NK8_?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW5?WS+_YG'\%/_%C8/\`W3>WXO@F
M^S_/U[JP'VQU[ICW+B9,]MO<&#BF2FES6$RN*CJ9(VEC@DR-!44:3R1*R-)'
M$TP8J&!(%KCWL8(/7N@G^-74F1Z)Z.Z]ZERV<HMRY'9>+K,?59S'T$^,HL@]
M5F,EDUE@H*FJK9Z=4CK@A#2N25)OS;W9VUL6]>O=#I[IU[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[K_]6R'^;A_,'ZG^1FU>M.N\%\GNB.B/BMV)/\D]E;
MSWCW3_+&[O\`G;W+DNWOCGVC1]5;PV]USU'E>M]P=)87;M%DI)DDRNXC%6>=
M8WID90X7W7NK&?\`A/\`=9?#?J/X$2[0^#_;'=7<_4Z=W=AY+<F]>\>O<YU5
MGINT:_%;/;=]!M7K[-[(V'_=?8M/3QT3T5+2TM131U$M0#4RS^8+[KW5WWOW
M7NJAODW_`#1JKI?Y\?%KX6==].2=GX?M#M?9G4WR+[ADW)_!L!T#O'M[K[L7
ML?I38=)118^N?=G8N\]F]49S/5E`9*9<3@XZ"HE8_P`5I2/=>Z+S\,_YU>X.
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M.)'7NEJ?YC'Q`_Y^I?\`Q&U-WB_^(O@P?>O`D].O=,FY?YA_Q4K-M[AI,)VV
M]/F:C!9F'$31;:W;!+'E9,=4KCC#.V#T0S?>%-#L0BM8L0H)&A"]1C'7N@C^
M,GSYZ5VQT3US@>[>Y,EE>UL?BZR#=];F,;N/<&4J<A+F<C-2M59G&XBIH:]S
MCIH55HY&`"A38CW=X6U$J.WKW5CW7/8^SNV-GXK?FPLPN=VQF?O%H,@*6LH7
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M:DFU-IX??FT:K<%7L[^&P4U'BGEJL=CZ'*31XB*E>I:CGK*>H]U[J/\`"G^4
M;U5\*^W,?V5@.YNW^T=N]6['[4ZG^*?5?8,>P8=H?%WJ?NWL^D[B[-V9LZNV
MGL_;VY=Z2Y?>M!3PT>2W#69"MQF!I8,9"WAC+-[KW6;^7V;_`#%_G-'6SG_9
MYNI5.H<J%^`_Q)THIORH4\?2WOW7NK8O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW42MH*
M+(P&ER%'2U],S([4]93PU,!>-@T;F&9'C+(PN#:X/T]^Z]TT_P!TMJ?\\QM[
M_P`\N-_^IO>ZGU/7NFW,X79.%P^6S-?M?!&@Q6,K\E7+%@,=-*U'14LM35+'
M"*:\SM!&P"?VCQ^?>JTX=>Z"O8.XNJ>W>DJ/LWKS:V/I-I[IVMGZ[!)D-I4&
M"R$5/!_%,=,*C&&GUT;-4T<GI_M*0?S[N0ZMI)SU[H(OY<A)^(W6Y)N36[S)
M/^OO+.>[S_VAZ]T>3VSU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7
MNO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][
M]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__7.3_-3[J_
MDZ_.KNO=6Y]P_P`ROXN;<SF.^%OR.^'46![#PNXMR3]3]SY7M/KKLKJSNK8L
M<VT,A14.8VSOGKJJP^Y3&(I\GMJMDIZ6H`=BWNO=6V?R",9MI?AYVKN_;W>G
MQ=[LJNU?EUW9VGNRB^%6'WC@?BOTOO#=V/V/-F.F^E<;O_&8?=T&U<<E+#GY
M!64T1^_W#4"/7"(Y']U[J\/W[KW7O?NO=>]^Z]U4U_+X*_[.+_.<TJ`1\Z.I
M]1&J[?\`.!'Q*-VU$B][_2P]^Z]U;+[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_
M=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K
MWOW7NF'=&*FSNV=Q82FEB@J,S@LOBJ>><.\,,V1Q]1212S+'^XT4<DP+!>2!
MQ[V,$'KW0"=#]39SHSXP[;ZGW'E<5G<YLS9NX\?7Y;"05D&*K9:JKS>31Z.&
MO'W:1K%7*I#\ZE/XM[L[:W+`9/7N@U_ER`CXB]:W!%ZS>9%^+C^^6<Y`_I[O
M/_:'KW1X_;/7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__0O#_F]=O_`!Q^,W:G
M3F$W'_-.PO\`*VJ-\;1W;N6HV/MCX/=6=]KW'-3;DQU+4;WR>Z]R=-;_`%VU
MD,1+624GV[RQM6>9I@C>*5C[KW0\_P`@OOWL_P"1OPR[(WSV1VUN?Y"T&(^7
M/R#V+U+\C,YTWLKH3!]_]*[2RN"H>O>U]@]8;+V1L1=M[4W!0/)%/!DZ>JRD
M.=I<C"]5)!%3I%[KW5WGOW7NO>_=>Z][]U[JIS^7P2?F+_.;N+6^='4_]J__
M`'(/\2;<?V>/?NO=6Q^_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]
MU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NB
M)93X"[!RV;RN;J>X_D>C9C-9#,U>.A[:R,>+'\3R$M?58N.E^Q)3$N)V@$.K
MBG.B_P"?;WC'AH6GV=>Z::S^73U1YZH;>[)[VV9AY<C6UU#M;:O8T^-VS@XJ
MV9YOL,+BUQ[)1T<!>REFDE8#UN[7)]X[?B4'KW23H_A'TD=W5FP(_DIW[-O>
MDP\&XZK:<'=+19^EP4T_VD.7J,7%1?=C'RU1"+,RZ-7`/OWC-2NA:?9U[I8?
M\-Y=??\`/[/DW_Z.'(__`%![]X[?P+^SKW7O^&\NOO\`G]GR;_\`1PY'_P"H
M/?O';^!?V=>Z]_PWEU]_S^SY-_\`HX<C_P#4'OWCM_`O[.O=>_X;RZ^_Y_9\
MF_\`T<.1_P#J#W[QV_@7]G7NO?\`#>77W_/[/DW_`.CAR/\`]0>_>.W\"_LZ
M]U[_`(;RZ^_Y_9\F_P#T<.1_^H/?O';^!?V=>Z!3<72L'QR^3OQ)HMF]G]S9
MZD[`WCO.AW%2;W[#RVX**:CQ.V'DAI8Z(+24CT]0:\F5)DE!9$9=)'NVKQ(I
M"5&/EU[JVKVGZ]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=
M>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U__1
MN/\`YWWS-W=\;OEG\->M=T?S`MZ_`_XU=K=2]^9W=NZ?COTYMKO;Y`97M78>
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M=>Z][]U[KWOW7NO>_=>Z][]U[JO[Y1_]E5?!'_P^^R/_`'E*/V]'_9R_EU[J
MP'VSU[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWO
MW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K__2N$_G8]F=
M=_'WYG_$;Y`4?\RS!?R[N^=O=#=V;`PLDG\O;N+YJ9+N+J[?&\-AUNX,3N"O
MV!'D=N8;;NT]T[8Q]30T=13Q9""OJ))HYS#4/$WNO=66_P`H?Y#Y#Y0?$VI[
M5K?FUB_G[!5=L;XP>+[\POQ.W7\.<7]AAJ7;\3['H^K]W4=%7YA=JY*6H#YR
M)#!523M2EFFHYC[]U[JT?W[KW6MA\P>Q/)_.J^)'5_0/SY[MV9VU0;TZSWU\
MN.D=X?(O;^!^'.QOC3-MO+[6VQTEC.B,K+M[$[U^3_ROWYF\>^#IZ<;@W70T
M[-E'6BQYQ1/NO=$U_E)_+/Y4=K=[=%[BPWR7WO\`(3O[Y3?!7YT]W?*KXU=R
M]N9ZMZ=^/GR2ZF^3F$V7T!AQUU24.Y<O\1-I4]5G:_9U518?$Q#(8ZB^Z?'U
MM;3I(/=>ZMF_E(U?<E?WM_-RK?D+@>L]K=T3?.;KP;XV[TSNW=&_.L,=)%\(
M?BO%@FVMN_>NS]@;IS*5NWUIIJK[O#4#05;R1(C(BNWNO=79^_=>Z][]U[KW
MOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>
MZ][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[HKG=&8^7F%W10/T3M+IW
M>NSZO%VK:;>^2SNW,]ALQ!*1(WWU'DWHLM0U\,BF)4IX6@,;!R^I2'$$1'>2
M#U[I;XW+]]2='R9C*[2V%3_(!=N96>/9]+FJ^7K]MTQU%8N'H&SCN<B,754R
M0--)JUHSL!]![K1=?$Z.O=!1U?NGYO9'?F#HNV^KND-N]=S+DCN+,[1WAG<I
MN*B:/&5,F+_AU!63-33B?*K%'+J'IB9F'(]V814.ECJZ]T]]S[C^7V)WA3TO
M177'4&Z]DM@J.:IRF^MTYG#9N/<+5=>E;1Q4E!(E.V/BHDIV20C47=P>`/?E
M$9'<Q!Z]T(&S,MWM5]0U^4WUM/8N)[L3&;IDQ^V,%FJ^MV3-EJ9L@-H4]1EY
MW:N2DR*)3&L8&\1=]/T'NI"ZJ`]O7N@2Z]W;\\J[>>U:3LSJ7H;![%J:_1O#
M+;8WIG\AG<;COL*M_-AZ*JF:"KJ/XBL*:7!'C9C]1[NPATG2QKU[I<]W;A^6
M.(W)AH.@>O>IMW[5FP<LV>K]_P"YLOA,K2[@%<Z14=!38^5(IL>^."N78:A(
M2/I[JHB(/B,0>O=%([`RO;64[P^!=5WGM_9VU.PV[2[?CJ<+L?+5N9P$>#3`
M44.`JTK:_5.:VM@:\R:BJ/P+>W!HT3!344'7NK4_;'7NO>_=>Z*GW'WEW1U[
MO-=N[#^+F].WL`<)09([QP&[,!AJ!<A55%=%4X7[+)4\M2:FABIHY&DOH83@
M#Z'W=55A4N!U[I?[3[([$SO3-1V)G>E=P[2W_%C-P5L73M;G\/7Y^>KQ5770
M8O'+G*./^%++GX*:.6)BMHUG`87!]Z(&JFK'KU[H0-Z9.NQ6QMVYFA?[+)8W
M:>>R5'(ZQS?:UU'AZJJIW:.17BE\$\8)#*5:W((]UZ]UHA=$?S2_G96?#CY5
M]@=T?(7Y5Y3';>_E3=-_+'+XKL?(?&WHKY"9GN;M;Y%T^R<+W+\#=\=3=/[K
MH8_B4-FX6OQ6;J-W8O)YC';A>D@2DI_NY&7W7NKQ,I_-"^7O2W>'\RZ'MGK_
M`*4WQTU\=?G#\&_C!T9BMM;PW!@MYX?%_*RN^/F*DK-UO4;!^VRU-2[)[>&Y
M)JF6K,L&X_N,1")L:D->GNO=!KWI_P`*#=R=+YK<M!/\<-F9FAR'SR^7/\MS
MJNKG[HQFWEK/D'T;NGJC`=6;]['FS^,QZ;9Z"W.O8-9%O',4"9*HVE74-/"8
MJG[U"GNO=)6+^;1\B^L.U>\ND.F.LJ?O7L?>O\P3^9WUW@,G\H?D+D<'L+K'
M:_P>^.'1G=^;I]FCK_HS*Y[$=;9>EW'74.`VH\>1K:/(U2RU.;>GEF>F]U[H
M4]I?SL^^=S;,R55NWI'XU](;Y[B^.GP5^5?PXQVZNY>[.U<5O3K;YQ;]WEUM
MM'KC>NV^GOCIF^VMW_(^DS&Q:BNQVU-D[>RT.4HJLB:NQZX^JJ7]U[H@F/\`
MY[7REKNS<]\T=J=5;;RW2.T_Y7'7G?OR%^,N^OD'F=FXK8F5ZU^?WR/^-O<&
MZ.@<0W7&6DWQV;O/^YL,=",[!MD4E%3TM'D)'K33T;^Z]U;[\T^V_DAO;Y\]
M)=#_`!M[!W+U[F=K_P`L_P">GRYV?M[^,T>`VEVIWM54W6/1'Q]PO9N.S3IM
M_,X/K//]DUF=6BRFK'09%H*N=2:2)T]U[J1_*0^2V\,I1=_?'3Y7]E_*67YE
M_'G,?'/%?(C8WR[S7Q/RD.TM_=]]1T^\=GX3H7?OQ3H<;USO386_&Q5?5XV@
MK*BJW/1,!%6(C,FOW7NB/?RCOG+\O.\N]_AIN_N'O_.]O[:_F)_%3YE_(_L'
MI>MV]L''[(^+&Z_C_P#)?;/6G7FW>G'VSM+![XP>T<?M+<;[9S4&Y,CFI\GG
M\?)6M/'4,\*>Z]U/W'_/)^;,VY:#%;`^&'QPK,)V;7?S'L5TGF=V?)W?N-K9
MT_E@;PK(.\MU=E8?%]#5RX?']A;52&CVEB\94U]2<\';(U-)CM-1[]U[H6OC
MC_.X[A^7GR^Z7Z3Z,^-NQUZKWOMCI3>W:&2W/O#M"O[*ZDZT[+^*>R_E/N+N
M/=&4VMU)D.B<#LG$3;^H-@8K&9'=5/N7);M*R3T5%1SH8_=>ZJUWU_,][ZZ!
MWU\?/YF<NXNT][],?.CY.?S'-\[!Z+IMT9[;FPLO\:>A^C]H?&KX2/V919VK
MK-O=1]/T^Z<74=F[OW13434^-I]P296:"ME2(2>Z]U;AU_\`S._DM\D/Y@V\
M_P"79BN@-GT^RMI9+>W3GR0[?ZY[#[AHM\=.R;;^.^S=^;E[KV]NG&=72=<X
M#:.^>Q>S*?:W7]+)N1-WFMQLE?D*2@U>&F]U[K3:_P"'[/YD_P#S_P`WC_V2
ME_PV=_Q_&X?^9P_]Y[_\7/\`YFA_V=W_`!<?^;WOW7NO_]/9-[#[4^8OSS[!
M[*/\L3YE[+^.FQOBGV[V-\8.]7[D^)U!VSM[LKO78K[;K]ROUONBNWE@\A-@
M=@OE),)7RQ0Q0ODXYQ&9E1)![KW4S^1UM':.S?C?\C\=C?D-NOY'=J5GS\^6
M65^4.Y-T=44_1`V;\GJK=V,B[6V%MSIB@W%NO%=>;8@FIJ3,4]/25KP9&7,R
MY/QT\E<]/%[KW5S_`+]U[H"-T?%OXR[X[$QG;V]?CIT3N_MC"9?`[@PW9^Z.
MHNO]P=B8C/;66D3;&;QF]<MMZKW+09?;B4,`H*F*I2:C$*")DT+;W7NE/LKI
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M77_`+X5Y3:F!V+D/C%TW5[.VQTMF/CG@]M3;+Q;X>@Z(S^=V_N?+=3K1>(13
M[%K-R;5QU><?*'@2LI$F0+)=C[KW7NRO@)\,.X=R=X;O[/\`C;U7O;<WR4Z_
MVSU?WSF,WMR*IJ^U-D;*K<;D=FXK=Y1T3(U6U*["T$N-K]*Y&B?'TAAG3[2G
M\7NO=)W"_P`M7X![;VEE=A;?^(70V$V3FNOM[=5Y/:6)Z]PF/V[4[`[*R6U\
MUV#MP8BE@BH8*?>N:V3B*W*31HE36UF-IYY9&EB1Q[KW0@4_PK^)E+N9=Y0?
M'KJI-VKN3M3>/]Y3M/&OFWW7WELC`=:]Q[DFR4D3U<^;[-V%M;'8G-U+LTV0
MHJ.*.9F"CW[KW25WK_+T^$?8FSZ#86\?C)U/F=JXCK+J/IK!XUMMQ44NWNL.
MA,YDMR]+[-VWE,;)19?;F*ZRSN9JZG#?8U%/+1254WC<"1P?=>Z1&6_E4?RV
M<Y)U9+E?@_\`&JK;I&3%_P"B=&ZJVO%#L2DP^Z]R;ZH,/@:>&ABIZ?;B[SW?
MDLI)C&5\=45]4TTL+R!&7W7NEK\@?A%U9\C>\.D>[M\UF5:IZFZ\^1?2^[-A
M"EPV0V%WMT=\G=DXK:O8_4O;>(R6/J:C,[5&5VQA\S1K#-"T5;CRC^2"HGC?
MW7NFWJ[^6S\#.ENO-E]4]6_%'IC9FP>O>Y]K?(K:.`Q>T:1_X7WML=V;9O;D
MF5K&JLUE-_[70B*@R=94U%32TZ)#&RQ(B+[KW2[Z5^$WQ)^.?9G;/<O17QXZ
MJZJ[3[TR4F5[7WULS:>/P^X-XU=17-E:T5E7!'_D-%D\R[5]72T@IZ:LR+-5
MSQR5),I]U[K+#\+?B;3R;?EA^/754<FU&[Z;;3C:.,U8,_*.I:L^17\-)A)I
M1W-5.7W`%L,B?\Y<>_=>ZJHW/_PG^Z"RG<N^NQ-D=Y]K]([1W9F<GNK`;6Z4
MVETUL;L#K/-57QOD^*F%V7L'O>'KZL[`Q?QVV;U)($Q/7$OFV]3Y&..=Q+$G
MVY]U[JT:@^#WQ2@ZXZ-ZIS/2&P=Z;/\`CCT[G.A.HJ/?.W<7NF7:_5.[>L:'
MIS?&THGR5))#/C=_=;4"8G.1/'X\G2%DF5E8CW[KW5='4_\`(VZ?Z)^4N1^2
M?47=W86QXL?OGM?M3K396*V3U2,GL/??:G3/^@V';V0[5.TQV)OWX^]6;2CA
MFVAUYDJHX7%UE)3_`'#UE-$*<^Z]T$/_`$#-_P`O?_L^O^W=G^R`?\PK_P`#
M_P#O+'_CW_\`LHO_`)O?\6'_`*MWOW7NO__4OOWQ_+*_F/\`0/=WR(WU_*\^
M>O5W2/3?RM[8W3WYV3T+\ANB:/M+%=<]X]@BE?LCL;J+==$\F1C@WID*5*U\
M'74Z8ZFJE8WF$G[?NO=6$?RV_@K%\`N@<[UKFNU\]WUV]VQW#V-\COD7WGN+
M"4&V,AVWWUVS64%5O?>4>V,945M'MS'S4V(HJ2FHUJ*CQP4BDN2Q`]U[JP'W
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M2*^0BTIKU/<D`V/NC1.@J>'7NC3^V^O=!KNKN/JC8V6_@6\^R-D[5S0HX,@<
M3N#<V(Q.0^PJI9H::L^TK:J&?[:>6G=4?3I9D(!X/NP1F%0IIU[I.CY)_'PE
M`O=O5K&0HL>G?.W&UF1M,86V0.HNW`_J?>_#D_A/7NA5SF8IL#@\QGZI)9:/
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MO=>]^Z]U[W[KW7O?NO=5-_R^%M\Q?YSAU$ZOG/U/<%;`'_9"/B3]#<ZA;W[K
MW5LGOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[J-54=+6QB&LI:>KA#AQ%5015$
M8=;Z7T2JZZUN;'ZB_OW7NL<..H*:02T]#1T\@4H)(::&)PG%U#HBL%-AQ]./
M?NO=3??NO=`YOCX^](]EYW^\V_\`J[9F[]P''TF*.8SN$I:^O.-H9JBHHZ(U
M$JES3TT]7(Z+]%9R?S[L'8"@8@=>Z2`^'GQ;4H5Z$ZQ4Q&)H].UL<I1H6+Q%
M;1@`HQN/\?>_$D_B/7NATW-ACG]L[@V]'4"B.;P65PT=48O,M(<ECYZ):@PA
MX_*(#-JTZEU6M<?7W3KW6O-B?^$\_3&P/Y7N7^#G4F0ZHVWWOOJ@^.K=S?)/
M=G5FX-^8GNS(_'_N79O<=/@=];#S?9#9I>L=SY+:LE-+MRBSE-C*4UDDT<.J
MZM[KW47-?R2NZU^(7:_QBV[VE\'*["_)#N/L+LSM;JG>7P@S=9\4NDHM_;!P
MFP,16_"/IC%=_463Z$WOU7_#ZS.X[)/E\@V5W%DI:R0T+`B3W7NKXOC[U,.A
M.A^E^CAO/=78PZ=ZJZ^ZO'8&^*S^(;SWO_</:F*VO_>S====ON]P[@_A?W59
M)<ZIY6-S]??NO="_[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7N
MO>_=>Z][]U[KWOW7NO_6W^/?NO=>]^Z]U[W[KW7O?NO=$NZ%_F'_``O^3W<W
M9OQ]Z'[]VIV+V[U'3Y2NWEM/%X_=%`LN)P&YWV3N/<&R-PYS`XO:W:6V-L;T
M7^#Y7*;7KLQC\9E62DJIH:ATC;W7NBW?R^0!\QOYS?%F_P!GFZE)X?Z'X#_$
MDJ3JXN0;\<6M[]U[JV+W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?N
MO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[
MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?__7W^/?NO=>]^Z]
MU[W[KW7!UUHZ79-2LNI#I==0(U(UC9A>X/\`7W[KW6K+_+0_EA_+SKK>WQZZ
MD^4'5%%U/TS\'?A=\ROA[2]T]?=UX9L[\L:[Y4=YX7<M#V!U92=;YJ+L[IG%
M8#KS:YR-5D,W483<E)N7)H*&!_%)61^Z]T:;HO\`D2]1;([0^8VX.P.R_DY/
MLCN;O#:.^^GH=B?/_P";^'WE0[*PW1W6^R,K!V[FJ3M?;]9O#><F_L%F'I*Z
MOK,[5P8(T-*E;'%$*2'W7NAGW/\`R3?CGF,WUM7;?[_^?VT,%M#<V1R^^-L4
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MVQ1[-^0G\P'K2JPW8&S=T9[*8?\`F!?,C/5>[MEX'*?=[MZMKX]R]X9&DQV`
M[#QI^RK,A2QQY>A0"2BJ*>2[-[KW2]C_`)-_Q&2NCK7WU\YIA&ZEJ.7^8_\`
M.\4<L:L#X)(X?D'%)XW4:25=9+&X8-S[]U[HNGQ5_DF[:VST1M'"?+GOOY=]
MF?(*#([[DWUOC87\Q/YUT&U\WC:SL;=V1Z\BQU&>V]I1TD^#ZSJ\-CJKQ8ZF
M#U5)(Q,[$U$ONO="7_PR1\>#V0=SM\AOY@!ZX'72[4CZ>_X<"^98PL>^ANML
MY)VU_>Y>]!O63<4NW67!_P`.>K;#+1KYEIA5DSGW7NNNS/Y(_P`>MW;*S6`Z
M_P#D7_,#Z?WC7MB#A^R-O_S`/F+N;,;:6BSF+R&66BP.[^[\KM>N.?PE'48N
M4U=+/X(*UYH=%0D4J>Z]T(#_`,F[XC-5/5)OKYT0AG!6EC_F/_.\TL4:MJ6"
M-9OD'+)XE!TW9V<CZL3S[]U[I![$_DE?'?;E#NNDWC\A?Y@79-1F]_;RW+@,
MCE_Y@/S)P-3LW9.?R:U>UNK<8FV^\,?39'!=?8\?:4>1JTES%8C,]94SR6*^
MZ]U[,_R2?CK7[WV!GL7\A/Y@.!V1M?&[VI-X]94_\P/YE5F([-R.X:/$T^T<
MUG-R5G>4F[L'5];U5'55%#%C*REIZZ2M9:Z.HCCC0>Z]TR=Y_P`EOJ;,=,=Q
M8_X_]R_,W9O?V3ZH[#Q/1^\=U_S%OG35;3VAV]7;1R])UKNK<=!_IGW!#5X7
M`;RDHJJK1\=D!)3Q.#33W\;>Z]TIMA?R8OCQ1;&V;2=@=H_-G+=@T^S-IT._
MLSA?YCGSOCQ&:WK08''TVZLYBX9^]Z5J6ES>?CJ*I42"F11+988D"Q+[KW4?
M;G\DOXYXO/\`8]?G_D!_,`W;MS=6>PF2V%M*N_F"_,W&4O46$Q^VL?BLSM;;
MN8P_>=)F=R8_<NY*>HS,]1FI:ZMIYZG[>"6.FC6,^Z]URW9_)/\`CMFLKUY6
M;:[_`/GYLO&;6WNNX=\X.A_F!?,W+4O:VTAM_-8UNNL]5Y;O6:OV[AI,Y746
M4-;B)*3)B7'K")A#-*I]U[I65/\`)H^)TL53]OV1\[::KEH:JDI:L?S&_G1+
M]C434\D--D(Z9N_UIYJF@G=9D$@9&=`'#+=3[KW29V!_)0^-^V=C;5V]O7OC
MY^=F[RQ.W,7BMV]DY?\`F#_-#;^7W]GZ6G2/);MR.!VWWK0[;P-?F:D&5Z;&
MT]-20W"QH`"3[KW4:A_DE_'.#?.ZL]7_`"`_F`938F8VUL_$[8ZOD_F"_,ZE
MQ.QMQ8*?-/NK>>,W/2]Z1[OS&2[`@K:*.LI<A5U%!1_PX-1PPF:3W[KW0>?(
M7^2GM'.[=ZZA^-G>GR\V)NG']]=&YSLC*[P_F)_.RJI\W\><'O\`Q-5WWL3"
MPCM[<M+'NC>_6JUM%CIWI89(JYHF6LH_5,/=>Z'V+^3?\18ZI:EM\_.>>/R(
M[T4W\R#YX_:2Q)*)#3,(OD+%4"&0#0Q219"AX<'GW[KW0?\`6G\DCX][2V90
M8#?WR+_F"=O[LIZ[<T^1[#S_`/,`^8FV,OF*+,;FR^6P6-J,+L[NW$;;HXMH
M[>KJ7#4\E-312U-/0)/4&2IDED?W7NN<O\DCX[2=BT&YD^0G\P*#KREV!7[9
MJNH8_P"8)\RVPF2WO4[FHLQ0=JU.[).\FWK%N#$X"";#1X^*LCP\M+4&:6F>
MI1)A[KW7'LW^23\>]W;(SF!Z_P#D5_,"Z?WK708V'`=F;?\`G_\`,3<V8VFU
M'FL9D*ZHH-O;O[NRNT\I-EL51SXZ7[^DJ42"LDD15F2*1/=>Z7K?R;/B,9ZF
M:/?GSIA%2S$P1_S'_G<T$*LUQ'`)OD%+)&J#@'46M]2??NO=(397\DKX[X&+
M>D.[_D'_`#`.PX\_V'N;=&T?XE_,"^96!DZ[V/F$QZX'JC$3;>[RHI<YM[9S
M4L[4N1R9JLS4&K?[FIF"1Z?=>Z#;L;^2EMFO[[^,^:ZR[T^6N#^/&VCW0?E'
MLO.?S$_GC+N_L@9C8>/QO18V?51]P9!:+^XN_8ZC(UI7(8GS0R:916I:!/=>
MZ&#=W\ECXRYO:NZ<1MCNOY];%W1F-KY["[:WSC/YAGS5S&1V1GLEC:JEPV\<
M9AL[WI6X#+93;&2FCK8*>O@J*.>6!8YXI(F9#[KW4K;_`/)=^+>,P6%QV:[<
M^>FYL[1X'$8S.[GJOYB?S?QU5N?,4.,I*/+;GJL;CN^XL5BLAN*OIY*V>"BC
M@I(9IV2".*()&ONO=)W;W\DGX[8S<_9&2SWR#_F`;KVENS)[1K=@;'K/Y@?S
M-QE)U!18+:T&%W+B=OY_$]ZTVX-S4F^]PQOFJQ\S-6S4M5)X:1H*5?$?=>ZS
M[M_DG?';-Y/KNNVQ\@/GYL>DVGOO'[CWIB:#^8!\R\S2=J;*I,-G*&KZQW!)
MFN\JFIP6$RF8KZ+(2Y#$O29=),:D4=0D4TRM[KW2P/\`)J^)(-0Z]A?.T23P
MRQZC_,>^=3+$TBL%GBB;OXQ"6!R'6X*W4!@5N#[KW2/Z[_DF_'3:^P=I;9WW
M\@/G_P!K;RPN$@H-T=FYK^8)\S-MYO?F95I34[DRN!VKWECML8:LJED5/M\=
M34U)&L:Z8PVIF]U[H:/B+\'=W?$/Y)]]9K97:W8^YOBEV3U%T9C]D];]O?(3
MO;Y`;VVMWALO<';:]H[P@R/=V<WI4;<P&\-G[@VQ`D>.S)2JJ<;*9:2$10R2
M>Z]U91[]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[K_T-_CW[KW7O?NO=>]^Z]U[W[KW2<W?FZC;6T]T;CI
M,;-F*K`;=S6;IL13EA496HQ6-J:Z'&P%(Y7$]=)`(ELK'4PL#]/?NO=:TG\G
MWYD_+3MKY-?'S!]U_)?*_(3:OS;_`)6]?_,(W9L_+;:Z]Q&&^/';U-\CMM=9
M4NR>G7V5MO!9K!]1R;1W:^(;%Y^ISE<^9V[-5K7^26JB'NO=;/WOW7NO>_=>
MZ][]U[KWOW7NO>_=>ZHC_G3]B_)O8M-T+@/AG\N>Q.M_F#VSNFBV-\4?B/U_
MLCJ/<N,^0G8U+NW:^;[$[![OK]^[*WAN3'?'KICIF++U>XZJEGP>*Q35%/45
M=9+4/1TDWNO=%%S7SK^7;_-ZD[.Q7;V^:;KJC_GF[=_E`3_$.?;O7K=25G0%
M5\3X>TL_WQ4R#9$G;;=L5/8,LNX:'++N./&PX.!:)J62E,E_=>ZVEO?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]UJT_S!_YN>_>M/YM7Q'^)_7G>F+Z8ZOV!\K/C/TG
M\@>O<IL^*OW?\D*OY0[0W/NBHR6(RN6PN27#].],XVDVQC)<CC)(:O(;JWA)
M3OHAQ1F]^Z]U[^5C\Y/F'W+\@_A-O/N+NG='8>!_F,=*_P`PKM/M#X^YC`=?
MT>QOB7N3XG?)3!=9=9X+I^3;.R\#OS!8BAVUE9-L[@BW)E<V^5SM-)6&9:@B
M-/=>ZVEO?NO=>]^Z]U[W[KW7O?NO=>]^Z]UI?9+^;W\J-DK\W/D5OG</R/Q.
M\<YM+^:5@O@KUI+#\:\I\*:6/X&[IFP<]-F^O=MX'-_*A>VNN-N8Q-Q9G<&Z
M<CBL#G:FHK**&GAH4HQ[]U[JX#^55W%\@*CY._S#/B'W!\BMW?*W9_QGQ7P=
M["ZS[G[%Q6P*/?\`)6?*WH7-=D=D[&RV3ZQVCL7:N3VW@]R[?BRVWXFQRY#'
M8;<$%+--4PQ4TS>Z]U>#[]U[KWOW7NO>_=>Z][]U[H.NW]WQ=?=3=H;]GW+M
MO9D.R.N][;OFWAO*"MJ=H;4BVUMK)YF3<NZJ;&O'D:C;>"2B-57)3LL[TL3A
M"&(/OW7NM,/XZ?S&?Y@E;U;CM@=B?(3Y!8C?WR]W#_)]QVW]\=H8/H/)[WZ_
MZ_\`GEW?O7KOO?YH_%NJVGTKM/9&U_CAOV@QF/PG7VV-XXW+[EVKE9?N<C34
MCZ8ZOW7NMBO^4=WCW-W%TK\CMI]V[RSO:&=^+7SU^7_Q`VCV]N['[?H-[=L=
M9]!=GU.V]C;SWT=H8#:FT,EO,8J?^&9&MQF,H*:LJ<<TS1"=YBWNO=6K>_=>
MZ][]U[KWOW7NO>_=>ZIN_F8=M?*'I+Y-_P`JW-=5=^0;+Z/[G^<^P_C3W-T?
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MX]^Z]U[W[KW7O?NO=>]^Z]U[W[KW16OC_P#"3XC_`!4W1VCO7XX?';JCI;=?
M=.:7/]G9WK[:6-P%?NNOCGJ:J&&IDI8U6APU/6UL]1%CJ04^/BJ:B:9(%EED
M=O=>Z-+[]U[KWOW7NO>_=>Z][]U[KWOW7NB??)?X`_"[YD97!9WY1?&SJON_
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MVOV!LS:.,PVX]XSU->,OD%K*RFB`H:7,YL#(9""C6G@R&2`JZE):G]WW[KW1
MI??NO=>]^Z]U[W[KW7O?NO=>]^Z]T4+!?`/X4;9[A[E[_P`)\6^DJ+N'Y"[=
MS.TNZ]]?W`P55E>R-M;HC6/>.%W)!64M1C:F@WV$1MPHD"?W@DC1\C]TZ(R^
MZ]TL/C+\1?C+\,]B5_6?Q9Z2Z_Z,V-E]QY#=N9P&P,'#B8,UN;*)!#59K-59
M,V0R]>**EAI87J9I?MJ.GAIH=$$,4:>Z]T8WW[KW7O?NO=>]^Z]U[W[KW4'(
MX['YC'U^(R]!193%92BJL;D\9DJ6"NQ^1Q]=`]-6T%?15*2TU915E-*T<L4B
MLDB,58$$CW[KW1#=F_RK/Y<W7W5_=?2VS?AMT1@NK/D6V,7NK95-LJBEQ&_:
M;`Y%\SM3&Y$5;5%31878^;E:NV]0T<E-1[>KF-1C8J68Z_?NO=&OZ7Z4ZE^.
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MF5J.T-^;,J-I=V=)=`;YVUV;\?\`OSK'>W7N_P#Y()DI>BZGL'96^^M\#N?9
M>Q.S(L5,V.W+D:6GP`L%FJXG.GW[KW2Y[1_FI_"/J'<7=6S]V=F[EJ]Y]#]N
M]-?'[=^SMF]1=N;]W1N+OGY`;6KMZ]4],=3X79NR,W6=R=E;BVSC9ZN?%;77
M*U&*CB<Y`4NAM/NO='"Z5[BV%\@>K=F=R=89#+9/8F_<6V7V]5Y[:NZMCYSP
M15E5CJNFS&T-[X7;V[=NY2@R-%-!/25]%35$4L;!D^A/NO="C[]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U
M[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO>
M_=>Z][]U[KWOW7NO>_=>Z][]U[K_T]_CW[KW7O?NO=>]^Z]U[W[KW7O?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=5`_SB/AI\D?F#U[\,J_XLCJ*L[1^)/\`,&^.
M_P`T(=N]U[IW3LO9.[\7T?C>P&.UIMP[0VGO/,455E<QN2C4E:,`4XE8.'54
MD]U[HEVY_P"6G_-"[BW%\XOF]O7O_P"._0W\Q7N3XBXOX:?$&B^/M9V+F.I_
MCGT[0]DTO:>Z!FNT=\;4HMZ9'LSLK*+/1'<&,V[32;6DF>NQ_FD:&*D]U[HH
M.>_E,]S8#H+^<YVK\V*W;W4_5?R4^#'3M=@5J_F#\BOG)V=UCV-\.]O[U[!Q
M^^NQ^Z.\]K8+>FZZC%[YP.-S]+1XD"AI*>;^%8^("#RS>Z]T^_$3X`_(7O#^
M3ST[O[L_H?87RG^3?R]^4>2_F2]W8_M?OWM+X>=F[2[`WQM[,8SI'MOH3O/J
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%Z]U__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g575431ex3_1pg26a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431ex3_1pg26a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`@`!^`P$1``(1`0,1`?_$`&\```(#`0`#`0$`````
M``````@)``<*!@,$!0(+`0$`````````````````````$``!!`,!``$$`00"
M`04!```%`P0&!P$""`D`$A,4%181%Q@*(2,R42(S)"5#$0$`````````````
M````````_]H`#`,!``(1`Q$`/P#?Q\"?`GP)\"?`4MU'[C>8G)KYS%YKU!#K
M&M%(SF--J3Y[VWOBW7LGQ^1KB.;1&N,F\A"WY#;9';0JN/T37SA/??7?;&,@
M!<R]_+U.PP]-J%\F>FA$.&/AS-G:W>5HTEY^U"LF]-,F2)%Q++HE"VF&!8<1
M0W&[)8W4>.E<HXUU^RKM@!KDOO\`]G-2RB#4+X@0W&C=GEQ&I9["5#)3XEVJ
MU17<-B!>/:"`ZZVFZG_B@EMII_XX44_I]60\@7_8&[138%G.M7^-]R$6VXK\
M:.U5[,\^Q$RU;.W^C!X0=YL'"XAXQ:[.DU%-\.VNR"2>^?I5VVUUP!DOO?H[
M4[)$[U3Y4^B%/0'"K/4A=-8PJ!=.T0P:/$E/LG-;4JB9*!"L>=*H[*M73'5U
MJ[8;HNDL;:+I:[`T'D?TKX1[M;O<\H].UC;9<7HJJ6AC`F[CED"6Z*B2*KTI
M64S91RP&`S1POJEAVH-U:[*9^G53.?\`CX!Q_`GP)\"?`GP)\"?`GP%8=\^N
M'-?"LABU+?B2GHOLFT54AE,\:T0TTE=S3<T29+N`2L@;-L.&E<1!\JGKE0H4
MQC?\3[KAJU>:-UL:!G=EQ'U!]4+(DPZS9A9).,Q(FX!D.$?.V]V%/\U5644:
M[B)%`^Z/2[1)^.F,Y%:H*8D$&KX?.2S3[^R6Z`)17&N`[SG#E;GNFYMB!45/
M)#9UC1%R7:O>7_$6NF-2UA#Y%%D!SI>)]/\`I]8IY];AQ<BVU20>[22TXNZ1
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M>:77I-917MV^6%B]8>;<QO6)@]!TBL^:TD$MT=S95W4C.._])I1F`LF0M]VC
M9!TFBX;Y25P'*2W@[G/K:=ZLZDE,1Z8O@-',6.VISN8#(.`?32.I8()OA-C4
MEVU1E90.17BW:.#.R3<[*X_9<96)?A*J'-M-U,K!U?.W;'IEYZ60=J:PU[W]
M`JS`BCDKD?*O1H0)$/5"K8='M,Y.3>@Y*-+F:O\`0VJ1+IYK^63B9LL_T10Q
MG=F"QC*&X::N*N[.9?02GT+JYAL)"91Q`@J!ED>(LG,>L"MI<TQG!&%V1"2>
M$C42DK#?3;_K6TR@Z3QA=JJX;[Z+;`7WP)\"?`GP)\!%7J+ZA2"J9(:X>XK-
M0QWV>8K\A/+9M^=N4FM#>>U`ZL?OR'IOHR3.6SH*/>!Q*^%X]'U<+.2+Q1KN
MJW6T78LB@)&I+D2`5L17(74ET9.Y#U4[(D!U>,%'V_K3[!MWRK9P;LZZ2*LJ
M%RC@WAX`_2;*(1A(Y'-EXZAO_-B6BBNHA8".3LF;7M<DCX(G/]G*8!1);'.%
M<<6Q*P"/,/.5(6M**MG,UI%F3KE[$X3=GH]'6.($H[,KX_@E1%QS!=``QE#M
M73"H$+24&K_SS[NL:.]/SM250&2\E1BR^+^I9;*4X=7U7B&D>#U'T1RNY<14
M56?.]=U](9[L'E<6$JLQH3^CU'?&RA!HANW!4'*]8=$P3E4YS?R5$+GM2@NY
MN*AT3Z.ARM`$B@T1V9O"S=66O+N:9XG.>-Z+Q#W,!%A4GI$5,)?J6<"-7KM#
M9;#]P[!H=;4)UK2]7=WU/!*Q(N^>KB@KX%;<AO'L[E`**@=J&Z^("^E+P_@8
M^INHH]$IS:.7_P"YFHN1&G,?>%E5B:0]M^<L@B'1Q;I*3N^*SOFM;=*2J9`9
M3R-&.>J_L"D>HN:)G=EAUG=%?':YB!J-P6>@^.P[R9A(+G"XX>,;KD2R8MPK
M^-E5)394`IOCJ&V*ZJKCT7;<)B?.MC>>_/TT-\E\^$JUG503#H+LN%<ZSFBJ
MJD+<E<<8K6@HG04,CIAR55@\.G4Y+EW[ALPURZ0:Z87!G/#7BA2X#G*)0[L:
M&U=<>D>@<9BD,TA!:XQT4.B!H"''AW21L-/37\KJ[KDO+?WFZYZ*.Q"PL.^1
M'HJ[ZH:92!;T6Z/@71HFN8G.(;-NQ^"2LP=[\]@>KYK#X5Z$0TR'L.PJ6B<W
MXTZ*#S>!3&?6PRGM=E1ZM<2@@'O1NQV:.VI0SLLH.1"BIE5UT4Y/(YWSQ+U9
M!6,KL`I%ZXC'=TE;K1&#]03=(WLQ2X:]?:*T::AJKZ%R4;,P8:V,"HOA8IKE
ME*=F$B(CW^P:C/.CT8K_`+V@<J'O(P7I'J>C"C:"]7<JSK.S2Q:.LI)'Z'K9
M1LY3;+R.OSCI%90#(&Z?XA-KK_\`S7T613!C?P)\"?`4WZY=Z3WC:D8C`>9X
MZ-LCNWJV8(4SR'5SU/1XV<2MWA!:8VM*FNZ[=%G75,Q590N5?.]TQK=3#;#U
M1)GNNLD&=&AZQ@/+U5H6Z?F8?I")SVXWLYHLY;$I=1MQZ>=Q0-N1DMG^@W5L
M[PT=OF'F=Q^Y:.R\(R]4?ADVC)24J9>D2T;PY"\+[%=,LZ'L+K^.69T^7#R@
M7+*R[7Z%5I&^N/.AHR=7@L@>4AVO2!4*92E9CS1YJ>'69!M6`,/]Q(00-2`]
MJ:/X=ZHAVKZRNG.M^H>>91SG6T=KOONK^87]22ZUPUSU9=<%MSEJX@<7GL&M
M_H.RXM7*[NH:=/RN.-Y-$F:<?86=(#!%R@)%B@^STY@+#OBMZ]\P#/&\:M@Q
M:?9EEEZ4>UD(G\LY6L3LV&\S&:DC=4PJGI#3G)5;6!#([2=>/2^23\J:UR=L
M`_D/^'DRY76<.=0M<W8TQZDGT9M27]&->?HA+2MM_P`8[#H\K0+1G6W(E*9C
M<%:2"A)Q;02U7$88=K]'V&!U?.G8[8DY0B:P1%1=K^`[7`>W#]W4,]M::P^8
M$+KGW-W._3W9U5&>C*IJ.J>PK=D4"JB.$(D)OD=S]O7<VE7.]AS^W@1L:O-H
M+&)FK(XHJV6;/FRC5RW"R99S);KGBLOTK,>J>G>E;<@LI=Q;JCC;K8?&+KYY
MZ,M*'S=>`6#SS3=3!JS'ZTL=LFV<-6=6S.(Z*K!4G8]7.CA%9QOJ!1T_V?R:
M%42YJE5FUMT)0D[8S.+E*ODG6%`]D'J$A<7/S)J9(VV-<O#5H3"BD8VTS_+C
M9LO+FE>*-L,GB_ZAL\(,0'[K?B:EJH?.>3.+>FY34I"VY#$I6CP9+9A9\DYT
M?SUD5(6O5`VFYRT82]3CBT9+**P?R$*+7V,P0\(CAC9[#B`I@]W:@)RKB`3J
MCY=YS5,TFL;DO0/1UVW[ZL=9=6;\VNEO/N<3:0/7M^M2,>!KIPFJ;<LC+5H-
MJ8X)'#XLX;F<'P19VZ8NM4`N)"4\Y#K(LJON6K]->C%J31C<`*X^<Y#64MMF
MJ.T.4*6@T1UDM)6CT"VA;NI)WUI34?.)-8A89<H\*R'4^(BTD7>M7@Q^.`)[
M:B%O\TW#4W;/`1TG/)DG"LM>1IO*@,DR8["Y-@+4QM?/DUTDO,6!*7%.V.?M
M*G5?UX\*?TEA4#&R0EUML:`)XR&OCC;K.H^YN9:@ZKHXJH4KFX(JA(!J+O&B
M9:.EVSAP(E<+D*">=TF\EA,I'O!1#5/91'\IIOLBHHCE-3<";^!ZSQXT',W9
M!^Y09L6+9=X]>.5=$6S1HU2V7<N7"RF=4TD$$=-MM]MLXQKKC.<_\?`PLL;%
MAOI7UQ;_`&];<G>P6F[HKV\Z]JF8KJZCG7.7BMRFH=`=5]`));E5GX::=X7*
M<4K02Z199-#`9&5+#]\*M&RJ0$3#+9IKI;H;H&F;U1B58N+<I"!\B+T1$5YL
MXZ8XXI.\$QY+E6L.2J8A8?9H/_@^`<>FE[2!!F]1!S3=D%<-M!D0RX^!<C:T
M_0JX9=0'.37JGE7J4Q5P.^IOFYQM'SVNPHZN80RN;C29="]U"[(=/X8PD+(T
MK,@T5@H%EH&GLN'.BKI^WCH5XD[!2M"YTY$IF3^T-,W=-K.F=&]DEX/9P&X7
MR!0SV/#KF@U#9M21Q67L&FTD'"[7C8W6;B'AR&LL@H<P9N!([*+;+LJ#8N77
M/^;+[J3O6BN[I5T!=D/B<YN:&^?$BBM0!K&Y5[`;T5,X-`8*;GR(1JXM*KN?
MQ=G$0D'UW#+0US)"!$THN0+*K*IA;MK-&9!292FM7-@#*S+1;FJ3<M6S'ZU#
M.CSOG2!TP[,2DE5':DQFB5%<I1LN:LPDWD<ZE3%K.P;\R8<,DB+MY'7#,%16
MG*`(V!17,"/7'S%QUT%`;6A%H]>\_P`%C8&LN@HKJ+:C[!KBC%NC\%+,N*2'
MHG/WLZ(7+8ZNTVLI_!GS.!:LE\(LUP,^MW5A=HBC]12+L+E[HBE;`EK!0IVE
M2U@Z6!T3.X1-G%4\^`0U8<H,YB'&\Q=(IPN`8<RFQB@8PE%U2YPK'M6:>FZ7
MP.BMWG^2W->G`O`5<5W7%36Q0%1]H6K&K`A\8B,X/<+5]&;3B9+SJ1MU8.L7
M%LQ=PQ6*;QB>Q5!VDE*VKHNT;.EV?Y*NX"OT1T[+?)V;QJ07PSH*TK^K883!
M<Q<Z<Z6M95I,*]?2<<*IW>[;BM2UZO;2B.LZ6K4PO":>J_`^8'6+29'%7+Q\
MU5>$F847?G,-K4-W+PE%Z;L"(22\^Z^<?LV=9EUSA"3\X7_&+)LNWY3-Z>Z7
MJ\6$#8DX&XG]JQ)B$D+`C''/\H9.%HTPR]69LF0,>I>Y(PVD72,]'U!T/U%Z
M$]KKO*"B7-U9!GG*\JY$K'G5I$XE:'-$XZ=`%`L'JUG3M@D<%B\T8NVY>9!3
M<9),V#A!PWPW"K:7HOHFHMCG'?9\C>P\=;UB5A$MKTBK\O(F5%>B$?B,'D'+
M/HASG+K`%PB7G8?;TQ38P.R7KT?JQ)7H-1Q]URG-3">@==Y5=`2KD+T:/\UR
MZ)"Z[HWT=E]]'L5R(?Y<17F+U"YN(.!?6-+PW=PZ&-1%47;&QK6?0]'=BFY=
M@9%'-&J.J>7.^P:^_@(Y_P!@BY[%A7!>.<Z,)$QG0GH)<]6\-T^Z#YUP\8NK
MK-;(V`2<J:[ZNF0?6KQ!ADX=H8RLTV?IJ:Y3_I]Y,%*U13Q>;PUM1''XV#6`
M:MR,R6QJ99ER+-A!SW"'DBR&4OQA")8W=[I!-HYU;WL^S.CVC=SLW-"31+)-
M#1)RO]H/WT%:\BN:-PWGST/JM8,[K^+S&50BT<6W6Z?M5S>C!0VDO;='RL?S
MQ$@-)0.']`SYF)J\".B9Q%V=(2H&@XR0<N72*8$=P/U7SW6W'7>`B'P&5O\`
MKL/6T[L6VXI6FC-[%Y:ZA8K2AA]6\G3NN)5:AN1T+QJ>;L:_6.-L*/<D&SR3
MX:NW)Q5P[!"&R!GH:E>(.-9.:+V-+.YO6R4`NF;K+K"))%;M"4F(J:!%;SJA
MM.F"YJQ8'(()99!J/?.%ORFZX5%RE@7A%JS;`^OJ3P#L.E+O<]C>.-C17F^U
M1CQ>8)\_E%2,.KLE(6(ALW2BT-E$>1?"F]6R)P&9;+U_+@QV)-G:?UB%HZDL
M[PL`I31]W=*WE-A;/_USY5;%EUO+R*LF'.NFFP?A9Y/W;H>;6N:/\OA+!*4(
M<DDDLA^2>O"15@YP/;((/6[A55?9)J!;3#S4];/5$./!>FG1D)X]Y^'N1+Q/
MFSC]LW?2\L:C^Y9PR+E92]D,U@PIIJ\>#]D$GSJ9_;P+VW02'JN<[)A4TPX+
M]8.3(_BLG'.O"GL-R>#>;OF8.WJVCHOH<'"@1A$\*BH0;94D3$[*1Y)LHH`8
MM#)M!D\RDV:-4&^4]6P?(JW7U:/TS,>7_/GQFK;R*6LR4[E[8O*16/6@,(L!
M*Y(L'+D+L`B,FE+J88")(#LOTA1=Z.;+J*CM6"B:"B8=C+_]<BM*\X+[<D-K
MR-_U[VK/.9;&<0B437#TU%XA:,2K!UI`S$.0G9<S()/:BA((BU_G,D(.2K;5
M\[T%(!!KM<7L"[`EZ1"355X]7K%@UV&5V=/!JAE=2H;3DLGU[(.,NCHY:-84
MW!CM6?W`,C;@9K)$;"U9'"ZL5>?:%B5DUM,.W0P#Z[A]&@+'M^YR?G]-I=5]
M\:UC..<KMM:21ZGY)0DTE%&6#&8[75E1H1);&?.G<@HN]K#_`+93%\7C@I/>
M)39V3T?Y91EJYU"R>=?*^7]1KR3H"9]!37H*N>OH=.JLN6X.IXO;<%[0"T&_
MK>2,U*$%5-(D@]-4@>JOLX8$F@-Y#X\`1%K11/[:Y+1;#A<%X=OK6.XJQ_=*
M$E#/^I1C4O=F'<5;E5\*>J_A%,'5<78:2!MT=5W$:Z5XL1-OUF*CO.V6L,;_
M`-<[_6DFL&O;_,ZJO\%/\\_Y!&?[4?XW?Y%?MOW[?^/?J/X'_,?U7[W[?T_=
M_+__`#__`(_O?D_]?VON_P#7\#/-[L78[U]`>>8M%)7JE*N+O/CO#MN+QUL2
M':[MNB9E#F_/?(A5PQ>HX2VD"ER'V[8`U6_/1+E':3/=GMHKG;8*U]!"0OSS
MZ2\:JB&V9/>:J^8T#5?+A.44"\<UN:3"Z6G5^+4D%XR:2-);$'M*U;!H^6E#
M9F@T(.6<D444/*Y#OMOO`>/;6>PDCW._,-\2"I\.)-9LUE%,]T.6(&OJSM6?
MT[3T\M+ERCNAH[E^V>U19>.I@D5EGXX+=_&I@RARNK1)JX57$I`EH:D*@_.?
M='8TWKJ&<X5Y27(')WC93T>@9P/,FO1<_'2^MIQTLQ>6'1U@1J#F(O=4P,(0
M0Q*F$F<OPS!H045?-GXY\QW"W^#*GE@#UD\BHN=U?"M(=Q%?5^N:581BQ1R_
M+.;5:W,:WJ&1L;$;$7\(BPM2]AS1BQ_-RNDHU8-MOM-$QF'@,Q]K^K4(`VOY
M2>E))'Z!XKYHC%SR6`YETIA<7ZTZ9Z#DLR#<F5',G]>$6,K)TG&#%$R!64"5
M73)K(GQ4>Q6_JU3<94#/_P#Z^?LY#X+T)=S7HE5WS;R81PFA%#X%A:MBTX"F
MEG3M1>MHC>5MS*93(9!B42CV%0\>=#QHEN_0:/U2:^WXRBZ@?T'X-.8;9L-B
M]AUY*`<U@LU!C9-$9=&234Q'Y''S#5-Z,+B";)15J]8O6JNNZ:FFV<9QG_U^
M``?;G?J'/[HQ1E(0B6W!UX8@"TSBD,&UY+BM;U]&'.2K;2U[JL53:*5M%X-'
M/TSQXH/>2@21+ZL=V[?=#Z\N4@SL6?[Y^@-;U##S9>LJ-".K5C506A"[.U,2
M"\%X+3DH/M)P%3N.F*G@D.2TN6\:4.I$&@^.3,@/'#]66NWZX@[;+$0;/X,U
MUWNWYHD-J][7[_<V4V8NVC\8KE99T5E,%TKTC)(E(Y-=I4E()`L/OZ6[M6@Z
M1QE/#32+Y`)-GJ&AI4MIH&0>`-93#O-:3!T=WJSCF7M+I.N[,&S>!LY#/(-&
MGD#B^%[]"#K)DD(A#2U(+CEEY&X>+T<H2-X5T4%@7HTFHU70!OH+GUS5G6?2
M?+]K&:FJKC2Q^@IYZAZ=,70:B=,SJ0\E];<D7+6G4U81R,2V'.3)Y]&YC+TV
MA#"Y5B3B2X]D3?L4D5QVKD&DU//_`$'O;S2@W1EPN)W5<:KWC5A9;2IZ\)RM
MOU[V)8<,I](P%/6;8$:#)2"A(S94R"I$TP,4;/9,39D4\DGX]/9X$4!9WG=*
ML6IY512X98CK*HI1/H7"+1D]ZK`4&*-W&>JY&M1/="2NI&6R:2NP]=E.EYFA
MF0//L9D4<8LM6S!IGZ=D0X.M(7:,U_U?NA.%DYV65M"H>Y@OFRXDR;G*Q1M^
MS]-*/K3`9PQW)I,V@_:)6?HQP-T(JM,C%-4OR<:;[?0%V]Y#!UD^R/6L=D,?
M#D\LJC\4::8/=(LSD)Q.!6%Z?U/*IJ(;-WJZ>5\R!XOA-UC11'39JW2^K7?*
M./J`=/\`8&##$N[RUHSJPHVO28N,5/$):VFL"'VZO&;+Y]KFQNHX73$*KV#2
M<-88Z#V3O)QK:PC<@)@(^F%L)'1)!]JB\?#0V21U&HNN.>(40G$7K6[:MMB%
M0Z6/`<EBX>;UO*M'#<;(&3U./RL>1%E!K<N@FY9;K([_`$[))JZ9^K&NWP$'
M>_YBM`G.O.7FU3E/#I@5O&P(Z@#Y9H[%?UR12KU@6UA40PXU+0S>&U'2$HN:
M:!8X7/L2L7--%B2:0IPKE1[JF"^:/OZON#_;1W-^NYM6O-,7H'QPJ&E+ZP_D
M)78#B=`&G+YIR-JT`V:OI1-A;F<31=H)9M-3;AP@)=K(?\-ULI@RCIOL7_7G
M[P6A4DZ$ON.R%/40`6V%E1/1U6LKBK%F6UF<4C5E0Y>'19.WZA;R[*)T/J2:
M/&+8HCE=@LGE5WJN"-O7ZKO+CJXCS$CP]Z`0;G6GZE-$WEJ<[5'4-OS8'MD'
M&Q@RNI[1_/L,KH5$'=M#?Q'0G9T=*A1::A9)QE^T5V=[O`9+4_\`L/\`.-(5
M%1?/W+O.UA6&W$P2/(1B6=(61!Z*7M9I@$Q,R^P'I"G83?S1Y:<EDQ[!:2,U
M1@S*1`HNH\W:N]OP]@\%X>]7.7;W'UU<RV;%;HY4*]'P&>4J1MVL1,*Z9A0&
M,'V.PBP3<7'FCE)V).AJD$-:ME/PHRF3:K$\[)M\[-L*;@.$^AOE78S"PI%<
MGK;K<%NMJN-PVO(T8HMQQM'-+&&T_BHH*0Z5>\[4A"N@YXM`!H,&V1;$3*!`
M.V%9:X3V3WW;_`:/R5ZM>3W!?.-34(:[K)76Y1-3=]+;K9TG<[Z-NI[.)RZF
MDCT-+Q>OC(.O@K4G.<-@HQR[569A6B6JBJWVME]P1G4=.P3MVL_]C3$>AT#O
MP7%^WBW3E3$?Y-!2L1D[('=W09V0FQ$M>:_>@`B8T^HJBZD@AY@^X!;_`-1F
M76<),]PU+^4-RUQWUYV<SR*WGM4]`6Q64,BD#O-L5B08QO"+WB47%M9`T*@3
ML>9M0\H5%/&SO+P>T2&$47FKL8HL.<-U=P\_N%<0FH?.6[4#EG,J=#6XF)HZ
M0V)O')3+3D6AEG+J`[!.0R.Q"11(L3F0:!;$G;#7!)OA/=#*FJ;Q75-@Z#-U
MP98LN>>-OM=+K0E_\GZ48TS#>CY<+C@:.M**@[MES<QTHI"J,11LVBB,F@B=
M)(!Y(V'9<Z"S<92TV<Y<:J(-09-Q84%&RWL;4;R&Q+$&@'L_S!>00.D-4U04
MG=A6QRA:9IT]0W<;M%$&T_A+8HW^A--35TLMOOMOG.GT@.G=B*49]C^OB,AR
MRT:$ZZ\/+*:,,DHW^R?P:(>GU0QR3R!`<=45:;LX^9:9U=?>1WPCIE-3.,?<
M2VR'5=-\]4KW;[E=.\C]01["HJ9\\U@!IF=P.5Q$(?%PZ-TJ8G-D0<H,2'MU
M%[-8VO+XI-D'Y#<R>:AHV*:X8;QLB\^@/;YZLKVN\S8K'^?K"YA8V_49Z>W2
M!JVP&0EU?11K9!8E9ULQ1CLVYN(,IJ,K&^Y([40;%)+%(X-KM11%LZ4V9*(I
M-`)_B?S&[6M+I1#L[UCM>0'+JA\9JME%*TJ6R([MS\[,Q>S9Q;6HUI!P<.$8
M9P:%/M($NW2=[[G5YI&GCO<F\&:L/NAE]_V=X`K#O8%>3MXF:58S"H8#<3\U
MN%0D(D$.AK*&,Y).4`[\TP`$@FHVFW+`DP(Z)(O\:N$ON9RMKNW!=%B@#\`M
MV2N9_=UE5"$=`6<[MV94X7*T(A`JX>-RPRI.>T=8+&95J1=GM1PB497T%%B9
MAJJV=[C7&FO[G`<!,9*SDT-DP&=7C<G4U:#RJZ$9L#-H+7E.*XCD>:R5^<H)
M0'9VL*,PB+22L]R)=:9)BMX^H_"?0,'*/_J5'AWM>PJPKE@PI2G^2NCN@P"N
M\B%[OH_45M];V+&S<7#/-TI\QN&*S.KH++8G,02+?3[+D>FBP=C7K1`6V5;_
M`'G`?7D;:;Q'\-E.ZME'/5A?AJYC-36'35JT'%`^$2KZ'/(K/F\@.3F:V87E
M3`R[.IA?W&FBVC,9ML\6RX1'MP]*$-*TD;/]U8O8_0_)88H/))5K5\)F14*?
MEK57=-$5:YB(0=>2EQ:<SEF"3G40437+*CMVB#$DL/09K[AS=<JFW;J:.#*&
MT^3J5I&Z8Z".2=<N^FDBD\OGZRU*7'`;A#FC0ZIII8Z;M-@D;WRNJ/T;_E*Z
MR)TAIJW#55_J=\XQ`WSEWRUD,8*I0.P9D3I1H'+&B2I)E7I):QF9^)*ZOA0H
MD+=.@Q!D]5>--M$'^7^BGT)JH_0D!),^'/3KR]ZI^KS=&+VGQ-/CE;,;$:W;
M8"-Z%XS!F,$J2@X:R3@9).'WN?/428_<2I345,T13V!L&P=HFS<M,)JA]2%\
MQ>J?I=T90EF^@\7>TWR3`)S))F,JZIK#?T`J4#1\,J#B3R603=O(N@FANR3S
M3<B5!%CZ28X:Y;IM7K1PTW4?`&G-"%A;^7WNU1MM:@8M?)>*R^-E8G%#HW6D
M95-;FVM*N(O:?/L9_@\4(0NLK:G>-`ZJ#-R]B;F4AR3L,FP0<+(9`X^+&(8(
M1]C+C>32)Y@-@>SW,%'`S23]?9!.<U[;7*-5&F[U7=KHV3;.+`FK<6WSHHIO
MLY16UWUT_II]04I[KT.W<>C-/R8#&7SF:]E^:G9/,T$+MD7ZVCWH[FYY&^N>
M5@3-8@191C25D;7BK+`D?G;'[I='9H[35:;J9T#XW)5S57;?L$[Z9/67;(.A
MX)!)MT77#+H62%HG6(MG='*46D-R]=5+,'XM2NB5,.=/OPXJ`P5PQ`JB6AEL
M_P!DU73!`'5]F^@4GC_%0/KSAT82NN."N@JWB4_59T_9\E)CZK;6HE`KE/I5
MPD"$V0\8Q+.FZKIPQ'+J[#$UG#3/T93=)A97F?T5<G4%33ZV;`6WE562>U9F
M7YMM1U#Q%:$)O4KJ0%VB0-6O6ADG(&XFN#8QP)$GSS*-'9**U;N7P)@ZT64=
M@A[_`&:*CK*&]&>6_:5OQ]-S1<=OAG1'1A!@==0XN3A\N.A7D?!K2N/-\RH6
M+3B1":OG+A!=KHFU8J(:N$G#EMJH!B>FGGGY(\></6YTT/\`-CCN98J8.!D8
MJ`NB8NA1%CX7/AF+@&UDX+9KI+9PZ`.W>\9%*(OGA@SE%DTUPN\^K():Y@ZO
M\7:<ZU?NNA?*3GGC&A&=>,\B)S-HV?Z-F-=7D--2'!0?>$7:,Y9#8"@U&-M`
MK7=B)+O@4LV6&.B*+I5ZS&AJ#@'MAY!G&ZX4#W3SC7Z8)N-WQ';*.[T$[18&
M1S,X(=B8[;HJOGKT45%%$';=PT05;KH+ZJ:;YUVQG(?B<>L'CC:8^0U;-.N^
M2KICZXUD_D\-_:`+HB+P6J4&,F#@LP%#);&W[7!TBS;Z94^O&CY=%+_A;?37
M(4M4_DUX-]@0T5T;2G*O,=PP&=$#;R/V'7CL_O%UWHB0$1AAE'4@4C8#HZB!
MD#%RWU8,T&B+!1+*:22>NN,8#X/H1P5Y;<@^<O3=E(<9T%#T*=J"8RV#2^,A
M!=>6\QM'&'"U9+@NBFF6]K1N2O+,)CT&Q/\`<[JM\*XTSC=#&4<@"WF0VZ"\
MWO)KEZ=5-0+JSJPG#PM=%^$J2@DOL#H.7#)'9\`KRI1M159EEN\E+N8U0QW.
M$C!!B.8MQN--=4F[MRL53#C#GIYZB3ZV^7)=7(N=MC%X.N8]:YY>A_.FKOG&
M7H%:Z&$^X1MTWS(HA(9-&9ASG-&<N$DAC&;!#$-(QYMH0#$-OR4W(:/><?03
MC?K62$X-0M\1.8V*$C`^8GJM(-ST'M4%&B2N&NA4S64^$1B=#FS)]MJV>Y58
M:Y8.M]$7'VE-]-=@R(4(!C,%Z)[P@4FYV+UU")QV;RGRG`[(UD]RG8NTYHY\
MLF7]'&JMBZ,^7D`V=U<#H7EQUN4DS=4>J%)GR+-77\!`5LN'65I+;/A7^KKT
M)W`G"3Z5G6]V^%]'W`!/[Z)]SJ,],*/L?!YP:W'JZ.T-8C6&A#!;1@DA@>GJ
MO^/G73;.X.N_V#X!,V'&M?\`:E4`MI);OFETC4/:\7`)CGI#631&OSGZ2V(T
M5P-=-'S>+;5_(G98IMIOC7\4-GZ\ZZ?4IH%"4#US1,:\QNHZ:<PL)<E9P,Q$
MJDYKIM^3)`&]P\P>D6(X1X(A<BDIAA)&L5$OF%Z?VU*$\:OTPR\-([K:;*MM
MT]@JWG>@NIZ;O")\J2CIV:^=?14BUD$W@LJ"VE9/>5(]SU^+`HIREM#R/5&(
MA5T0Z!J9RDLZ-@V$'#F=P;AN8^V21_(=M0K@$]YSJN4$E^#>E.K+QZ)YFV,3
M&FKVL[H9],>=^WG\%DTILWKKSXJ^`A"<)J6W+(?0\H7+JN(A$"CH.:),7>QQ
M-=DHTP#F.^>>:R]?_,Z31ZFIH%D#"X*W'7!S38[-RIH"=2E2./7<33*N$VC@
MF/BT^!&7T6DR22291`&:(H)Y0=XUW3!-'"D5A?N#Q/3E!=$VY:U!>@?D=:FE
M9SN0UP_;_P`]"2$)&"=;!IE)8K;\1/!I"I/(@'68%E20O9^TE`8CLELW25^V
MN"NNMO,2-^4?H[Y^2?J#IRX^@_.JT[`LS+I>3Z01O/:SMC<@(M21AS++1JP%
MMJMDD@B8`R]>1YJV?Y9,"(]NV;*J-U78,&Z5J;_5TY/EY\I>,EB4@D>TG7BL
MJ$E(XM?QB1/XVG#24IT_G$C@LUDII\&BMRL-GCT6>V-K-D=M62BQ$;KJB"!^
MK(SYVQ_F<W?OFF8LQU=+`E0T^KY];FE/0(9SJM$;EFTL:N:DBL*&FCHVYWH$
MK%G[@,[RU9/(BYW*/798XF0RB&J/_5IJZ14!RWT!21&5.YS%5+"H/I*O9>_2
M58+F8SUOQY0ERJ[MPF21!(",;F2+G1%OMA!UOM]:[A/3=;&,!7WMW));Z1=P
M\I>)U#SEQ&F#&0Q?I_L^;1EZ[<D(+$@>SEY`(@Z:#G+-NA(F0;\F7H)$%T44
MWR0!77ZU5T$E0/WO`W1Y`M%^3985;Q_C#BND@'1/7L-&R;>)C9J(:)KUQQ3R
M&\DR$GC;=%>U9Z%=&]P+ESIN8_C09@JFHV-8U5!7O$S#E;)QQ?M+=1VEP8RX
MT%RSLN:43;=EU-V?S,YK;JAC(X_+)A!K@U,$+.S")Z?KC1M)@#8V&.B)>R=M
M]6*!1[^:N!<<.$N@^>I!S%<]F\;4*`KWJ:V"]+&>AY:%D<9]))"8O-M*+*$7
M[?T<(L9<,KZ-WG941%ZD*Y3E#UU%-2HW97=##!0:R`8??"T)1<MGR:GJOV6_
MEU?1*/\``M#X;N3#363=R^HZ4>`3%-]N-6<):QZAN$09EZ_?:M\KL'%C-OZX
MSKG_`(#17_A94?\`@?\`X#?QH+_9[_&K_'#]'^(E^M_0_P`"_AG[#Z?Q_J_8
M_?\`_O?E?1^1^;_]C^OW?_=\`LC@47)0AB.G&3<D%/BR`4P.=I)KM"`LJT68
MD&3I!77=)9NZ:+[I[Z;:YUVUVSC.,X^!_/\`WU3.N&K-N?@&RIJXC+SC=CO(
MZ,M20MFQ\K./-NT+G8WMSM=OZ-9'.9>=\K^YXR)F1Y/"FRB\$(3=LT1T1;Z(
MJ@2,+C_2&LVFW.M:F_YM>ET7!:,M'T*.M^4V7<O+O6=93V1]%T7Z)2=U<8M&
MKX-S`/+&`,?)22.8W:7-7<H#90#:G420A<+MO*WUVW-IGI$=55X(RH4[F<;'
MUQ+.@PTB@G#/I1S8;).HQ1_*'"D:INR64FE<%*U0O)XX5P(09NH$]=/B)-NQ
M>/7&@,,\VND%ZF_L6WD4:D4)Y-](E']P\Y$I7''=;QJD>L["'+V5<'.D;C\J
M?NRS*F.DY$N;L&H5=GCS5;+HB*14VU5$(_``;U4H;H#R8[XCWMEQ5"W,_I^:
MH%8;WESS%Q.0Z!B*&=QYT[*W1P>)+AHR$D!T4M(5S[UDBJ.F&,[NGCAL6V:I
M@4GK_P!!<L][^)3BW(=1MD]3O[S3&`^;()6T2EDEM"ENJ3\4E8!!U/D:Z;&W
M]<2"C<N3C&6-'VV&;G9%P%7RIJ1TPH"@?*KR!X;NSD'T@F7H32%U=%RB@>G+
MOB\8Z\6B5[Q"WK.INIJOB#`8O3=;O"Z\[(FP/Z%_JU#K@7NVCIXW8-MG:K;"
M34/0JCRIJ&RI)Z6>L\EYAO'D#D9.G[$I7B?DND(+9M1]-F6$/@E95Q%.@8Q"
M86TCA<.YN%]'R&,`S@HEJ\>G';TELHDWT(N@KJF4K+\4^%^&>U3G9EMANMK*
MHE<$7\ORT8>R\ETFD3.68SYN0.P0W((=/*Y"4-#YDV8%2SD683:)#D1PO&JN
MK1!8&M^=536_Y=<P6#Z"]LBYO>WJ1Z-V&B%K?G17=B'EIZW+<=KR*(4J*:(,
M-Q5;&)CK&VIF>/MM$146C$6:ZN$$_P!'OHJ%4WFK<=9W16_%L4QS/VQT<PG1
M?L#N2*]-`2,&QTGTS**^9/)3'J?,2HJ&CDRC,.Y_GC2$UQ&XB-FQ&$$%XY^Y
M%LV6C<FU"S;8C[RB$I3S_`J?LOHVL^&@,JZ=Z,MR#T0`,GK>ZSU#E;+\].8N
MPHW!C"=IWRPYOJ`I'Y+-9&@F>?&GXV+NR.S5=9QHJ%1<Q#<P"=ROO*;VPUZN
MK:"S6H39N=4G%SP<)Z&^@9!.U*NYWKNJ1]D&%W$DM!Y,NF%W,A),DA$1A+]O
M%H<+UV:1,XY0#K_*7GBR>M/1PGT/9LJCDZK3S9F-\C9O-P7YA.,7UZN=0-F)
M/J^40IT8&IK/*MYDA[P574664VQNW$1<`JQS]I5SC4-AOP)\!,WL#P!8O3L*
MK;IKD1M$`OH%R&8>RNBC,H3T;@+:KXZU<B+AY?LM;.R;0S7-P0P@]9_B/_ZM
MM72NR/WF3=^^<?`"?QM]!ZHVB\0ABD;_`+<<U6A-2-.<TFYP^:?W!Y;N@4:-
MD3GEST%OOIL^A^*Z./R6]&.R*C9K((2HU#82;F6J+<@!1^B-"U;3T^FG4%T5
M8&NC@.[V,,'>A=1D`?[G6L9?7S=,'5W>X%B@K@TLE#8:DE#+);B,IO7,+T'D
M=]7#8(\07#M/1F94US;0-Y#>@%X-T%2][0RGZ'XE\Z15=`09:27B/'205'('
M4YZ%;_S5X_L:0/8^JQ),V[36N40.I-@LEMCZM0&/G[T7?U#`9!SQZ45Y*WW/
M<;)F^;;`Z7M;2)V:/JJ5*Q(0^=\V>AVD-8D8:D]?5_+6&PVV6J.8!88,HT<D
MM0I15^T^`+-D^3?;7FW>D@[6\-K"%3>JK0D#29VAP1.9.S2IV5`3OV7AE>OF
MR/X8(JBZ:X06#$FS\9(`;5JDS:K%62^S1(#`XU_V2^%N@B*-==+X.^?MYMV[
MG0K#NF7XZ/5NZ+"DG63XZ.W2ZU$1ANY%.&*J>64F;Q<PKGZ<)LM\[8Q\"I^C
M_P#8E!65.'?+_D)39GM_H^0N&@&-6NZ%E1G+4<*O2;,8Y*JGD5ATCGX\(HJO
MA9TA^GC>-T-]\FMM4MT]@&7FS@2/<17^GW?ZXV^0[_\`6'H%/]7S_P`KPAF+
MLHFV(845:!4*W@[D6)$,M8NAM^(K)7B(*O("U^^ML[TSC5_@#AY/Z(Q/O0%:
M9=%LX!<=ZNY])^9ALRA%N5H\YX\^)TYK8];+?C&C&,F?B[!N?HB:UI&UR5H3
M<6+:Y)/V^`S/3`T*Y:,P+;J29M`5$<W,KD@U']T]JS2ZG\IX9C$"ABD:@DBN
M(+M+)E5]N-,EY186\&KZCZKW:%Y=+U2#EBCEG]]FG^<\$L=P*_F"C81PGS*X
M&SRQV90H/UF-Y]0]"3TFU")V!;,GU5EUU7/,"Q5RFSCP-P025RT066PU`Q]D
MS8)[X;,T_P"@9>^\.N^B.X^LJ>H#F/1:(WC<["6`.%8$82)?9YQHF2BS+&V_
M6KH"/K-([(ZEN65U4\="*1#O$L&`<>+$RJNB90V-;8#4MPOQM5'`7*U0<HTV
MVWVB561I$>^D+QLBW.3V8/\`?<E-;$DV$=U--I#-I*Y<OW&NN^R3?[VK='Z4
M$4M-0+;X$^!/@9P/5?RMG'\PF_>_`L'!RNW9()9M.UN(#*Z@VFO1>J0:F7BX
MXR,;8_%CO2471UW=1:4M4]"J)--%=NLF03347"O>#/8"NWE32T%T2?F5F\J1
M[?2OY'/K<AS\ET?QTDZ8LP9FD/3RM7;9:1NXJU6*I#PUS-A3J,R5AOOK*-QI
M-%TY>!Z5Z<C!.++?IWH@?.WH"@:C'EF'(/=Z5;!.D]N&ZZM)ZDQE?,_34<,&
MTBLTXET9EM7=;V`+=C2-6M\.A90HB"4^\]`9Y?2%F-NK(;"ZQMZ=6&R=2IOT
MEVUWC9-QQ?E`%VM-NKXV(YKIY2ARK,-**JN#F[D^M\).-Z_$ZF0#YYD4`73W
M=.UM'H%AP/0O2DGL_J.KZ,Z%2YG:\<GHI0DFLBBM'\GYBNOJ$W4U6V/?:Z7"
MEK"Y'4=;Q^&2Z4N&_P!^OI#!=TWNV6VHQLEJMLL`N=,F*RZAJCI4UV%,..K*
M(<J]'0;GJXK4.^:W0\`L4^3F!QJ-HV<,2=9>@,1=KT#-Y')$!P&5$C#>,O';
M#+M1--#5N[U"Q^=8GBMK)M#D"I+D>\]@X)UM5''4\I#S]XUKGG6Q2IB>P0]<
MS>R3W2MRW?TW:A.KVM<Q8S(5Y"CD<>V:)O&+7&CY5-PB%2VG-2S6BNP_\5Z_
M%0'HWB>TA4Y]&:<K_HJ6V-=/?'$4DV9R^.V9"/1D>40Z7#CTZW9ORSIN,63(
M,C0TD(4&YU6:LWX<'6`R1$*9XMMF2RRX81WM!@K6@0=\405J/I>YO5WER=,I
M\Q<".>#*#H42C[JM"AV-(ZW38`*/.JW35>N"#A?==VDN#CN7J1J#R]J53L+T
M`L.J*ZM1Y!8Y3U=0:-?E.:OY.IM@P0(1'B/CV,__`+,VL`PX<A]5SCP6W=22
MQ3C)-VHW4T:MDTP5;VSZ`=/=D='!^1Z?IAO,KM=N@LDI/S_D.XY^-I`V,8C3
M@KJ_UNE<?,'H`'!0;0PF<A]+-W9)+!1N/>R?&Q/0:*P#]O-7S9A?!T".2>7R
M'>]NT;O5UEG6?7$M24(V'<4](;(O'XQD8)X4*`JMC+A/1J"!H90:-VS9-7='
M#C=3;X#-O@3X$^!/@3X"?.]_(.LNJK!3ZMH2?R/CWO\`BT>=BH=T[5Z#-5M,
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MVR!1R@IJP;ZI@4/,O.]#,277<`4H7MRE^1^J.0:]Y;NWFFR>".JG<T5M"O(]
M(X.TN2JK3B+^^(VA&GL!F#]BZ::$':B!0>.=LGBR>FRJ@<-3<4AW(ERP:T(+
MRIZX=4714/+)&CYS83WF-"DZMON[/V<G(#>KI5.NGK$KMUB6LFMJRZ,BL/DC
M&@6.2%9'5ME!JC]04'"25?Q5AR!5,]MKC_C.X.3*DDG.U&S0W:D4]&_24I`9
M0\&QU\%BO-G(4>BW-CO>1O1VXP>B<$6.Z8*MM]\CE7;IRJH%R61Z!4?P$_GI
MRNQI6GKQL41J%D_<7K,1L";]970+9D66P2/T'QQ!6[WI21PC7\K8B(C+T=2U
M>CB&Z&J3;3+K?=,*IH'GKT]]*K3`W9'E[RY0B8)DY$I>BW=D1B+_`+/DT2D6
M%6TQCW#G&@(0*I'B2-2O*&VRAU)JYEGX>[/;63%4T=VF0TT\*^=_+OG=6Y*O
M^<H2Y8%)>];'K8M:7EGLPN"ZIFGHOL[FEH3TPHL5/%WKUZZ<ZMT_QQC)5VM^
M(U;Z*;:Y`X?@3X$^!/@3X$^!/@>%PW;NVZ[5T@BY:N456[ELX2T6;N&ZVFR:
MR"Z*FNR:J*J>V==M=L9UVUSG&<?T^`D>\_\`7T\[;.GZETTS&[/X5OS]AL71
MN;A>R2O/TAU)8RLY365B@E`G6?T;%MDWB^R(1NY<+HX^M;^FRF-P":V_"KN<
ML]9+!/0'GSK48Q9.`S5+TK\^*#Z.LIJ!6<NU41*G0'ZW:S2(QCKOHM^)ME%N
MY?KNW"F,8<[I9`(;9\4?80S/SI`#6/D1+!*NHI)G(A=G^D5$,RNC0*.:*.-*
MEK*[64"ABFJR&VBC<6DFU5WURMC77*F<8#I:@\0?55PUFX&RZ^\9XF$/BQ+=
M)68Q[L[M5F^<,2R9'"2$`Z=M.5U\"W1RWQG9[ABLYV^K&NF-<ZX4T`[JL\(N
MHE8@3A]Q>GTQIJ&29T\WE52^8G-'/_`,',#2H]@V)#31ZN(@[DLK>*:MOP,D
M'R>%U1*"2.=--LJ;9!B'&OBWYU<-GTK"J2AF$MN_[R3Y_P!$7B6(7/>+XUJS
I48NSS6;3;<AB)%2R2ZF7F8^V$(N,[YQLG].--=0:E\"?`GP)\"?`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g575431ex3_1pg26b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431ex3_1pg26b.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3P#\`P$1``(1`0,1`?_$`&L``0`"`P$!`0$`````
M```````("08'"@4$`P$!`0`````````````````````0```&`@("`@$$`P$!
M`0````(#!`4&!P$(``D2$Q$4%2$6%PHB)!@C,B41`0``````````````````
M``#_V@`,`P$``A$#$0`_`.W>E=GJ>OZ57I!*\D*D^=ZVV>OJ2Y84]M:QAE$.
MDQ*8+FQ+U30XEE*5$4G,>-*=&!U*P-$[-YN#21YR$P``D#P'`<!P'`<!P'`<
M#2]\;%T9K#!%-EW_`&E#ZIA9"DIO3NTL=2D9[V\JOG#?&HHS%8/?9C+G<W'K
M0M#2F6N:\[."DY!I@L!R$,3=V]I[)E*9EUEZWKPDL,_>>8LYW7M+.8;I]7Z5
MI+;QJE,W9H%*4T[V9D+`2K,)()"*`(!J\B,$6+`2\9&&+.@N\A\=G5<Q!ZJ:
MR8?N?79HN^E[;76\!1ITR<L;DOG38LHA$I&YK<&FEI01TC*0G("Q&GCP(>0^
M%#5G=ZL2EJG?<KKE8W$\1IJEH9='+Y?VINR,XS):5$\N6YK&O<22B?'&##4A
M(\Y^?G&?CRR'D.R?NJKA(X.DPV2ZF5D#:U:0]PL.<T%LU6QS>U*Q(4QWY%L(
MV<<XRC,(7GC+3B&Z!"HR,O`A%B%\8"O*Q._:[]6['@E"VY3.H&\MQ2&11U@D
M#!UA[7.<\M-O.E;F8-F3-&K=DUS^^GY[/C*A.L^JVR5S3%!"(Q:K0%')\C"7
MDZVEW+WGW-MW2G2QU5:HT3JZ5!TVV.[3K$8=8%D*K&F\4A=BMNNVOD$EYSC#
MH]-6Z)2,PJ12!\;7XMG48$6%"48%(:N#?D.ZR[(K!5)9'7?:;V8*9N]D.@TB
MZZ+6IR_((A<5@1&H!&5;/Z)-BR9G;7`63?K,_P"%/-*%DC[("@E8*#W:>VGV
M$IZ_H9J/V`$U(.7W&U&&ZM;+TC'YU$JIV!DL68U[O8U2RZ#2UPF>:7O*/,S4
M)\;V\<E=&V5LXU)K:,D]M5H@!G-"=HFDNS^SECZDT-<22R+9JR-ODDDY[&RO
M08$KQ%)6DALQ98A/UJ)+&IV\PYZ<T87(+,<N3)P*R\^X0@FA+"P/@5\3SL4K
M8,FEE;ZR5K:V\%K0E>H89A&M:6V-NL$K^5$Y:<_M:S[ZF\EAM'062%$.X%![
M0:^J'XE,2</\>+(,`$'B*K2[4YDSB=('J'J-4IREG+^JQ;"[=SQXE3>_B,68
M-R[-]$:XS^'GM!)82,A"ED1AQN1#^1%_&.!Z$92=LSQ&B3IB_P#7;7,QPM<0
M*&V,Q'92Z(T)N^H,MI4$O;I-J$=`+?OC":H)$WB+])>2@&^1F#B@\A2K[A&5
M^*)2,'6M9,83?2`>XJ9?M#23\]^UJ/&Y*2F8J$;`M\7^@]^HL@C*]X^VE\C!
M&IC/@O@>R?97:-'5K.J=]3-/)XPF)W\V1-]9[C68WRU":B0>V/)H^39.I\4C
M3X>^.(L%&_:7M92,`<CR89\XQP,>;]U-O&!8F-M[JQV/CT:4GN)9K]4%PZRW
MRN9T[8VG+QN+S$6>T(G*34;D=@M.B*:DSJN/.R9@:8K`2\G!N/4#?37_`';_
M`)A;:>/G[/-]?)T76MX5A:M<2NL;$K":GIE"Q(RR-ADS>F).$M2)#3"CT*A8
MG%@`L>S`L?'`F=P'`<!P*9-VM1K>I[8)M[0.OV$M4@V38H^9$ML->BW#,>0;
MST*B3L@DS"%P-&-G;=A*M31L`H0[GD8]X3C6U4;E.:`'`L/U6VIIK<FF(O>-
M(2++O&7\@M.\Q]T^DAG5:RXE*E4/]9VI%DRYP4P:S(>>K"G=F=4/WI#OC]1E
MC+,&$C.`X&A[3VEUGHZ2Q&&W1L)2E32^?."=IA$6L>T85"I%+7%7[L)4L>99
M$]-SB[&*!IQA!Z2QX$/'CC/EG&,AO%,I3+4R=8C4$*T:L@I2E5)C2STRE,>6
M$TA0G/*$,HX@XH>!`&'.0B#G&<9^.!3996W=];P6W:.J761/*[B<6I=Z5UKN
M%O/)V-WF+;2\T>&XTPFM-5HT66FA%T7[&4R<\3ZI<5_[>A:@Y%A82X*31(0!
MXDUZ3(,Z1Y?,(=NGO^W[@M"0A;5^W$^VMM.QY%!Y,V)A#:B5E/KWULHF1UXJ
M=35`W%@-CA92A*O4D$G)L")$2&Z>K'<6T=C*\MJC=J119NWITJLQ91.U;-$D
M1S4P2%P``]RJZ\(JVG$)<$PN^:_`0^HLE$IB`J1*BBB$Y90"@A:*J4DHDJE8
MI%X)TA!RD\>`B%X$D%B--%X@P(0O$`,Y^,8SG/`YS-2+9I*QT$=[C=[9"PI9
M'MS9HZCZS:MME,@(24;52J3/R:DX+4Q+V$N/H+SVK'`29DYR(T"1>82I0-^%
M92-#XY#+]9^RK;O>ATE<,AKKI;H!<\9LI="'W5':D-EV]M]%(VS&89E\R<ZT
M;Y?K<V+!2![(/4,`VP3TQ+4'JP-Q]_N**"9+EJ'V$R]O4(Y=VP36,"<FI<UN
M@:'U!UQKU.7EP>5QIJZ/*[,1WO*6!P21=26B2G8=#S"%I.%OR+.?KX#V7+K'
M@DN@T?A%I;8=A5GY859CB*5+MSK9K"4O3B+*X!2I[/UZ7TTS*0I4B\1!:<I$
M2E\``&(H1V,FY#&&CI/ZP$*UZ<Y)JHP6^YR$A"G=W'8R?VYLRJ4`;U:MP)RE
MSL#8%DEM`S7%<:H.RB"F]YPL#,\L@!XA-VEM8=;M;VDMBU]H*FJ1:"TI:/Z-
M4UI#H"4<G*R,00J\QAG;#%H\C-&,0SA#&,8Q"%G(A9SD*X.C,E8;IM83[,HR
M&.WC(]X-]5VQ)J@"H]Z>+:1;96NS#-?'U>$+A)3V*#-K(SI59V,9"WMR<D.`
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M9(S#X<R-L<C3`T-R<M(A;6AE:4Z1O0(TJ8D(`%EEA#@(<8X&7<"#]M=E6A%(
MOB^)6%MC2R>?-APDZRKHE+T=F6^6>6I2)#B05!6>)?9J@U.<N*]H2VD>2@"R
M,?B`(A8#1C[V66&_2V1P37CK3[![J>61Y,:V^83*JHKJM34E2HBR%#F\M%@[
M.3>MGC+<2G.^$N3&(`G`X.2R,"QC(\!]9]Q=N-@G2M#`=*-4:!2I4;0GBLJV
M1VXDE@KESDNR?EW=#JYU\IE[2+&V/X*#@*,Z6-1R_)@/%03C(_4&!2C2#LBV
M`$6AV&[47ZIH*KPWDO\`7G7]0$7UZ='-&2D^XKPEO.TY3?EOQYS,?E`B,J6E
M4W%G-:0H/H*///'@)YZN:BZ\:8UTJJ[7"N$%?1AVDKS-I2J$Z/LHET\G4B."
MHD$YL.>2]T?9I/)B\F@#[W%V7JU.2P`*"())998`DEP'`<!P'`ISV>U6NC5^
MX91O[UQ0N/.DYDQ>77=#3M.(J-1O=5B:5F'#$TA2DH`62$[<1Y`K<?QS^:2(
MN48."@=,F9R2<`)K:8;O:[[[4ZBNC76:!D;,2M''IK%75"LC\_JR>(2@?GZ[
MLJ'.Q*5YBTNCZO(B3BCBO2?X>U,:>G$`T00^L7;*_MQ;&GNMG7`;'V2&UO,R
MJUV9[!G]8R/4(IJ4(%*(VP*AUR@:MO?`71LI'8TXDG"6.*8,&C*I23A><O5!
M&V\#V&#I1Z[!UI*H7<U"1K:BP+(95[=;&S&SC:T6WL_9#LZ)E"55*7*YWUL_
M=$7>D0%&`M88^-H2,I9"<M`2G`05@(4=->Y.W^H+_?W0=7ZRPWS;-XMB"5MU
MB7%(&A!*DD'Z^K3:3CA6_.9PD2,@I*\:E5_%'X@Y4N1A4FNY2-*`:\*0\00Z
MK-9=:J=U!HRNM=:%B22&UA6,?2L3"VDA*,<'$X&/:ZR:3.8"23I!,94Z&&N#
MLY'XRH<'!0:>9G(QYX&^.!S@R)FD]!_V>JW?8OEK1U_OKUURUIL1H0*"R5KO
M8FMLH-<6Z9OZ$+2`!ZMOBH&IK0'_`&1GB(.5!$()98"QAT9.*8:UO7(RS`DF
M*T:I,6:,L)P"AGD#*`8(H7^)H0"%\Y#G]!8Q\<#E$HN*MVQ7]>'<#1JU<)%N
MQG7C`=E=?I<@5LHX\^P>X=7#I9/M;+2C;*UHTCTSHW&/,T;>&->D!D2T(3@%
MGGYP=G(6S4%7VI?;OH5J!L'LOK?6=K*;'HZO9H0.PV!IDTM@\O.CXD<G!$["
M*P"6LJELE)CC]9<B6(EGD+!X@D*,B``/3CG55#ZF7)EVLVX>_NNI*9J;6;]K
MMNS;[?\`7QZ1(\C=5ZD4#W!:-BF!"\NQ)F4QBU"!(>22$/IR#R.]P?BR0'N$
MII:U"2[`Z?;MQ$AR?RG5DMNI9AJ1;*IH<GA,*-*P6I4#I<%9*7&,MBD["LH%
M=H"UY24``"+.-$<`/E=NSN34:VI';>71?:C5:,!RK*?K@C+=#MLJ$C8T9[KD
MQQ?9AK9()K9D5BIC4V?=_+R*%L2$@HS`%(DYOB`06*5/<M27O#6VPZ4LR"6Q
M!7<HHUNEM>2IEES"HP<06H"5^28UBU,4J"2<'(R1B"<7G/P,(<_IP*<YQ*9O
MU.[<W[L)9SBOD?61NA/(W8-@R]O0+W5ST>VA7LL3KUXE\W9VM$+)&M-UHF%(
MH<Y"4$[]O2,OR7@*(5_:."QG8O?K374^`--E7WL=54$C<H:/S<#(-EC8]2BT
M$AB?*A$54\+CYSI+;07.@<8"D(8D:\U2,80@QG(L<#E8KZ+QS>'N^NO<+:`N
MX],]6]>JJU[[#8-26SE:)*[D5YM&L<3G=;139&1/"M4K5U[75'NKVH>#V%P.
MPO!^=+$K0I#35`@A?3UC&`V7G.S/:&MA4M@R#<597<`U]CT^:7%GEB;4S7I%
M(6BLIHI;7-.@4-!%Z2N6OTS(2_7"(IK<V\`SE/K"9P(:Q:P%E%?V@[CKJ;3&
M')X[NOUM59,*R1.[DXD2$,GI*P'6+HJ]C@5Z@EL,<'5&VRY_.1IBS?:F)P<'
M(#0J`C#I%X%"O:$WS>W=[^NW46VK4G53]?NR;;>K/;3?7LH=(`;L5>T0:F"2
M5IK-/;)CQ;;)H?$YS'4[DJ*;T#LB-EI21>VX_P#3!0L!;51^J&L.LZ'#=KQK
MS2M(ILH`MAXJMK.'0=8O18-`H$2ZN4>9T#B[B.4@P::-4:<8:=_Z#$(?^7`D
M!P'`<!P'`<!P'`<!P.3WLNH2Q%F^=DR3K9;9PGS(:3*1]Y<%H,]A(E5J4"^+
MXDXUY$JWC#VS+F]9O/85.&3@,=7M`T;^6SC*R:M1&N#<8M#H5T<<M4W?4NB5
M^D`(F#584$;T5-@A:!<VLY<<9C5#&H3*DCN0F?RY,B>6U40\_E`?E\NY2G[^
M<J_=G(2MX',Q?)]8,']J?2IPG)J&/2.4=8UFL56N!3RN;E$OL8NR[.$&/NR5
M-A&D="TE=?N(U(E5#5$#/"$T(`J"2!8#IGX#@49=CZR.5;VB='U\.;A(R%SM
M=6T6JA[6RIVU0B=FO82@E9K,:[%J2R5N"F>Q(,R'",+48"0D&I'ZC1^(>!>;
MP*4]X])[TKZVYCOIUXLL:?[JL-@98ANSJM-9"K9*[WII")-`V]*QM#B:F<$5
M<;*1R/%&-,6D9>42,U,O.3N0C"\ASD-)_P!9RH=HJ!Z[I)3>S]+SN@S81L]<
M^*2KBQFK#7*&FDI6"+3IHRI\EJQ0O3AG$H?RBU!O@(?JR'&,@"`8PZ&.`X#@
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MB#6#K9557ZSNIJV3Q&6RBHM@F*N43Q8MB5%8IL$;FQ<28[&B1(LG#^NL$::`
MP)O51V^Z]QM1$:7WS3E==>V!_P!%B<Z4OI5^$KY_<<KB6-*^4??84A=-VI7K
MRN&#Z2A"[!6I`CP4N2IC`_`@^K8GJKU@W,W8TX[+VNQI6Q7#K"\,JEDDE921
MI>(7;D$B[A)W)JA3]G.'!&2A229_58.6MQH#%"$]6B."/V%&I0MPX&B-E-;Z
MIVQI^34C<C.O<XA(S6AR3.#"\+XS,8=+(R[(Y##9_7\O:#4[W#9]")(W)G%I
M=41A:E&L(`+&<A\@B"M-BN[>'KN<%\5W'997NAIHRA*%%=Z:IBHW[8BK(LC8
MC3/QVVVN5>,"B1S\Q"YI0I<36`MB\)J805KRWI!"4'@"TBD[ZI;9&OV.U*%M
M&$6W7LC1)US3*H+(&]_;#2E)03@D*\HCAGM;D3@7B>C5`)5IC<"+-+`8$0<!
MMO@.`X#@.`X#@.!KFW[*8*:JFR+:E*Q`@CM:P>43AX5.CBD:&\"&,LRQW."J
M<UYI")"6=A)X>TT80!R+&<Y^.!%'KEU6>-5]=B$MCJC'K9"]I<_;([92I0XE
M/)C[L9;9:%WGK8VNI(AE*89702$L5C8`"R65'V1&''R+R$((G6LP3WJYNF1;
M*U0WM;[UXW_:K;)-S*@(0#2/6J-GV$XL\:D>ZU8+DA1A)E+.2@"5?:\=."$M
MIP6HE*`0<B>"C0N08GUDE#(SR6-/#5(HY(FIO?8_(&)P2.S(^LCLD)7M3PSN
MJ`Y0@<VIS0*"STZ@@P9)Q(PC`+(<XSD*:-U^IEZV)[*M!NR^HKA;ZTL_4UV1
M1:RXO*V%QE;!9])&O+P:[L$9+*<2$\.FG[>G,F1EK<D'E'C<4Q@_6)&`0PNL
MX#@4Y=JM`6G:]R=3-HUG7LGL)%KQV05E,[2#%"$JU9"ZLDT-FD3>K`=$*ER0
MF'1J-/ZQKRY&D%J#TB0T:CPP44;G@7&\"-4SW)U0KQ3(D4UV*IV.KXD4$V2-
MZ^>Q[#BT8&688`M4WE+C5GV1A)%C!(0"-R+'CX^7Z<#2+;VGZ"/J-V6QC8IA
MF0&)*!8ZIH-$K'G+HE3F9&$H7X:(PUZ=SS#Q%BP6`L@8S,AS@.,YQG@:*7=T
MVL)KC)6Z#T9V'6X&,F&%'.57==NW4B9W0W!9PDV&IR656T)QE.)J<9:<Y1E.
M0:(&18'Z\>S@'KLPV,E<08G_`%MZB]^[1>7]-ER3M%S@H/4EO0-`3"`Y/>%M
MOV^*2M;H>$T62$!K+A4/`/D82P9P/@><TV+WCVTL6HTFN&AVGT;=VQ<O:I39
M]UV5L]/HIA8WG!9V5UKRL(Q5T-=Y<VKE!)BTTF4"9P93FEDC5A$6,08^R=2D
MZO.:Q:P.T+<V>[Z)X2]`?(KK<W5[&-?=*"5Z0S[C*X3G7J,N$J,N1\CCI@"E
M$JE+VXD@&4#&4V0>8!!=(222F)*3IRBDZ=.4620026`HDDDH&`%%%%`P$!91
M8`XP$.,8QC&/C'`_7@.!CLJB$3G;"Y16;Q>.S*,/20U`\1R5,C;(6%V0GXQ@
M]$Y,[NF6-Z](=@./,LTL8!?'ZXX")0^)0"-M$-@D6CD*B$?2_188K$F1LC<;
M9$6#!FX1M#&S)4;8VI<&FB%ZR2@`\A9S\?.<\#(N`X#@5Z7;UDZRVS99E_PI
M+-M7MGLMYS;_`-)ZK2HZGK->$IA8\%([%0M:597ETM*=1ZS`HIHQOZ;&2`!P
M`(,>.0UOF5=J6L[DR))?!JD[&:?*3^M_GE3X:M7=K(^F;FDU:X.ZZHY?(WNB
M+?<'-87DA,F97^$F>?AC"0?F+(`V54_9SJU8CJQQ">K;)U1M&1N(&=FJ7<RK
MI=K1,WMW5.(FYI:(FOL5"@@%ANKZ/Q,1I8T]O"@XL>/\`C",``L)X#@.`X#@
M.!7;VXJDZ#K`WY7JQ^I&WZI74O6&^(A^E(AA#LJ5'>`,"&/U$$B%\!QD6?CX
MQC.>!8(V.*-W;6]V;SOL('-"D<4)_@87[T:U.6I3'>LT(#2_82:$7B+&!8^?
MC.,9X'PR>,Q^:QJ0PV6L[?(HK+6-VC,FC[LF+6-3['WY`H:GEG<T9V!%*V]S
M;51A!Q8L9"86/(<_IG@4SZ]E2_JROFM=(9,84_:`;`2R7,^DUK/3R4C>-<;8
M?G!^GB+2&=&N6`)W^'R%.<X!JEQ`HPN`E;PQX\E0>4D5*`NTX#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.!J&^:#IS9ZJ);1U^U]'[1JB<IT">40N2D'&MCE
M^)=4+ZT*@&I3DJY`Y,SXV)EJ-6F-)4I%:<LTHP!@`BP$#)MUNV>UQ].CU<[(
M-Y-?'IF>SG^/)YM8#+MG!`GY'A2E89.Q['LDSL"10XA847@2`$L1#$F]A.#@
MX'Y!#`E.T?:#JPK9FC9O2=BV_JUN;4R=]V:T-F1`YX$#;](#G*IOIS:14?E*
M!2L;`*UQB"%R67BRH)PG2DB$H**+"4%"]FVB.R!K>TUOLK72.=.#D6QXJ*RW
M$ZF[N2O^4Z`X]C4TW:Z>'60)>D.<0)C,E-II'W`F$`,$848$(3M"((PA&`01
M`$'`@B#G`@B"+'R$018^<9#G&?TSP/[P'`T3M'33?L5K3L'0+J$`F^ZZ4M&J
ME(AD)E/I#/H4]Q<"HLA9G"49Z0QS":7[,X#@P&,YSCX^>!J#KGO86R6CNLUM
MK2%B*4NU6L<7LEH<2D9#A'[@K3*BL[DC2TAO./1E*8Y:40=T0L%YP'/HQG`0
M_/C@)J\#1FRNO-<;6T98^OML(5BV$64P":%ZAI7J6E_8'-*J3.T9F$5>D1A*
MUCET+DS>C=FE:2()B1P1DFX_^?C(0ZZV-E;`GC);>H>S$I#)=U]&9,S5??DA
M$U(6,BX8C)6]0_T3LQ'FML^6U(Q7E7)9*U4D*SYM3^F<4)H0^DL1@6<<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(_W[JCK1M1&'"&['4/5-U1US1)6
M]2BL2$L,E.+2(%PW-`6@<UZ(QU:AH'$P1Y`TIY)A)PA#`((A9SD*_%?4-"::
MB"]'U][)[7Z,O;.R&D0*&U]=3_:VO+4Y86X=S@+-=]CLV]5Y1$B<2@_>4-Z1
MN6_(A"`>'!B@!X8]_%/>1_Q!^PO^I-1?^R?Y4^K_`#!_$[EY?\[>_P"K[O+\
M?_&/_27U_P#=^]^R/V?\_P"C^-\O_P!+@72<!P*0=0FM;H3V%WQII-I0W.L`
MW\>[CWQU>=`>*)6JM@F9#<-NJY=6HY9]=E<6UHFD1<F-"SIP-:EJ;7%>;C#D
M:XC-"[[@.!4?NFP074C:2D^S7VFM9CZX5/HOLLK4!R&/`H.X[+4-4`F2@MO4
M-N0R&#["RV-#-<G$MW^K'CER=*6B">J/&%N'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`C'M'06;MBT1?XH3&4-[47-$MOZ[R^4%+`MD;LM
MJ:79A4-3PO:TZMX00VR(:_N<8?QI25"DIH=SE"<H:Q.FR`-':H=@<3NZ<O&L
M]XQ,W6#>B!MP%\^U>F[^B<UKZR92_;)LVA9P0F;F&]ZA=4P!F`=F8.5#8:6:
ME=$J%24(O(6&\"FG^P)'$SYU(;<O*E44F_C./0BY48#LN19:MWJ2S(=/6-+A
M2S/<>=D:C+RQD#(-(5@$`\`/(!P,C),"WJ,.A3Y&H\]$*C%I#NQM+H2M.2A1
M&JRG!`G5EJC40!#`D,4`-P,16,YP7G/CC.?C@>YP'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P*^-YJBZ^+S/JVM-QI14,+M-_=EP=;)0Z6XR
MTALDS2XDL`UB[6^PF^2Q6U6V1)\>`E13`I$6H!@(%9)Q.<@R$5#ZV[C].5^1
MTA:-5=H%")EY?XRJ]FU[;KYMXQ,!C4(HMK:=F8<S'5!8F&E>@+$6HD<22.2X
M*\83UN,D!.,"%>[S'N9V*5[$ZA[*J,J'J4ZYXK9,!LC:"TY_O!2]EOMSHXO)
MV\Z"4;'Y!'DT(C=7(9=-C465#RX+A*`G%$`1DFG^)9@=/+:4B(;T!#;D`FXE
M$E*0"*.RI+$B+(`!+DM0(9HCP9(P'X'D0LBQ^OSGY^>!]O`<!P'`<!P'`<!P
7'`<!P'`<!P'`<!P'`<!P'`<!P'`__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g575431exk_pg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431exk_pg002.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#*@(+`P$1``(1`0,1`?_$`2<``0`!`P4!`0``````
M```````)!P@*`@,$!08!"P$!``$%`0$!``````````````$"`P0%!@<("1``
M``8!`P("!`0($0T5$@,9`0(#!`4&!P`1"!()(1,Q02(44146"F%QD3(C%Q@X
M@:&Q0C/4E;56MG>W>-@9.5E28G*R)#0V=C>7UYBX\,'1<[,E-74FEB='5RA(
M6,C)V1J*@I)#4]-41575QH<I>8F9N3K:X?%$9&769RJBPM)C@Y-TM*:(286E
MQ49FAJ>H:1$``@$#`P($`P0'!`8$!PD1``$"$0,$(1(%,09!42(387$R@9$4
M!_"AL<%"(Q714F(SX7*R)!8(\8*2-*+20U-SLS7"8X-$5'2U%S<8.)/#TX24
MM"5%E:4F=E5E=?_:``P#`0`"$0,1`#\`S^-`19XPY2<^<]0,_D'#O&/BRIC=
M'*&9L>UAUD'E1DNN7&1;X?RW=<2O):;@H#B_:XF)6EY*DK.DT$9!T!$52`)Q
M'?0%1OE]W1?]K%PG_MP<Q_M/=`/E]W1?]K%PG_MP<Q_M/=`/E]W1?]K%PG_M
MP<Q_M/=`/E]W1?\`:Q<)_P"W!S'^T]T!R&E_[G0.FPO^,/#`S$'"(O2LN867
MO?#-/,+[P#07'#\$`<BEOT=?L=6V_AH#O&F0>XH$L<S_`(N\430'NVR1&7,/
M)030/?L?M*&<<0/B_P!T^O\`1[?UOT=`=TGD/G?YB_F\6>.`HB<GNH)<Q;QY
MH)^43S/>.OB%T"<5^KIZ/#HVW\=]`;WVP^<_^U8X[_VXMS_:A:`?;#YS_P"U
M8X[_`-N+<_VH6@.(ZR7SO1.V*AQ*X^O"K+D27.ES+M20,TC"'4Y5!QQ'2,JF
M0/25,#''U!H#S3K,G<*0%`$.#>$'GFM7RZHI<X'20-G#55R1JR4]XXLI"HK)
M$1(=,Y.I-,%B@H8HE.``=3]O/N-?P?V&_P"WM;?M8]`/MY]QK^#^PW_;VMOV
ML>@'V\^XU_!_8;_M[6W[6/0#[>?<:_@_L-_V]K;]K'H!]O/N-?P?V&_[>UM^
MUCT`^WGW&OX/[#?]O:V_:QZ`?;S[C7\']AO^WM;?M8]`/MY]QK^#^PW_`&]K
M;]K'H!]O/N-?P?V&_P"WM;?M8]`/MY]QK^#^PW_;VMOVL>@'V\^XU_!_8;_M
M[6W[6/0#[>?<:_@_L-_V]K;]K'H#D-,X]P\SI`K_`("8E;LC*E!TNRYQ,'SQ
M)`1]M1LS<<<(U!TL4/00[A$H^LX:`](3-/-T4RBIP=J)5A.<#D)RUJITBI@8
M_EF*J;%J9SJ&(!1,44R@41$`,8``3`;Q<T<U>DO7PBK`&V#J`O*VHF*!MO$"
MF'&Y!,4!]`B`;_`&@/OVZ.:?^TCK7]M74/['.@-)LT\U"E,8.$%<.)2B($)R
MLIO4<0#<"EZ\=D)U&]`;B`;^D0T!XA?DKSQ16523[:<LZ(F<2D<H<NL"%16`
M/0HD5R#=P!!_CTR&^AH#:^Z9YZ?P9DW_`&W?'W_JV@'W3//3^#,F_P"V[X^_
M]6T`^Z9YZ?P9DW_;=\??^K:`?=,\]/X,R;_MN^/O_5M`/NF>>G\&9-_VW?'W
M_JV@'W3//3^#,F_[;OC[_P!6T`^Z9YZ?P9DW_;=\??\`JV@'W3//3^#,F_[;
MOC[_`-6T!SF/)3G$J+OXQ[;%F9@1DNHR%IRLX\/_`'F0*)/=VCD%96/]S:+`
M)NM<OG&3V#9(^_@![-/D)RC$NZO`+*)#]1_9)G3C(H7I`Y@(/6.44QW,0`$0
MV\!';<=MQ`U_=!\G_P#:"Y3_`*^/&/\`LJ:`XSOD7RB:MU%R=OK+SXQ.C9JQ
MSAQ9%TKU'*0?*![E]DV^Q@;J-U*E]D!VW'8!`ZB4Y0\IXP=D^V[GN8#W@R'5
M#9LXAJ`)2MVZX.=I//$4;W4YEQ2`=O,\U(X"0"]!S@=1]UMRK_@PN3']>;A=
M^V0T`^ZVY5_P87)C^O-PN_;(:`?=;<J_X,+DQ_7FX7?MD-`/NMN5?\&%R8_K
MS<+OVR&@'W6W*O\`@PN3']>;A=^V0T`^ZVY5_P`&%R8_KS<+OVR&@'W6_*O^
M#"Y,?UYN%W[9#0#[K;E7_!A<F/Z\W"[]LAH#UT3RCSNZ9MU9GMZ<I8=ZI[Q[
MRR0O/#R6(VZ%1*WZ7B')]NFX]X2]L=BAY8^R.XZ`[;[IG+_^T+Y6?YX^(7[:
M?0''7Y1Y=;G:D-P&Y:JB[<`V(9O-\1ER(F%%9?S79B<IMFS;I0$OF&]GS#%+
MZ3!H#Q[SFOE%D=1,_;GYUN!3=O&8F8QW%EVF8[(R9#KIG2Y2;*,G`J[H*A[*
MP`82^@=`<+[N3)O\&_SY_,+B]^VDT`^[DR;_``;_`#Y_,+B]^VDT`^[DR;_!
MO\^?S"XO?MI-`/NY,F_P;_/G\PN+W[:30#[N3)O\&_SY_,+B]^VDT`^[DR;_
M``;_`#Y_,+B]^VDT`'G+D[U=M[GR(^H/B+B\&_T-QY2`&@/2H<S+>J=,JW!/
MG"T*??K46I6#U2(;-6R^RI6G(!RJ83+K'0#RRG^R(',.R1DE%`-QAS)MKIHD
MN\X-<VXEP?S/,CWE)PNY<(`54Y""HM$YWDF!_.3*!PZ%C[%,`&V,`E`"D7[J
MOA3Y#?;"^TORJ^(/E%\@.G[3S;XQ^VY]T3]S!]I?W+Y6]7VS_ME^U[CU>1\5
M?S7Y_3[&@).]`6`=LIHZ:<4R%=-UFQE^1?-1Z@59,R8JLWW,K/+MDZ3`P!UH
M.VJQ%$S!X'(8!#P'0%_^@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@.DEV[
ME96*4:F$#-9-NX7)X@!V8IKMW._J$2`N!@#T[ET!W>@&@&@&@&@&@&@&@&@&
M@&@&@&@&@,5CXH;_`''?5Y[K?[I3X\VW:[>\?N[/E>Z_SIO[EMX[;^?O_P!%
MV\-`94^@++^W[]Z]6_U4.2O]TSE_0%Z&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@,6W_8<_^'K_`'][0&4EH"RW
MM]'(IQ;K)TSD4(?)W)0Q#IF*<ARFY,Y?$IB'*(E.4P#N`@(@(:`O2T`T`T`T
M`T`T`T`T`T`T`T`T!LBNB!_+$X`??;8=P\>GJVW$``1Z0WT!O>GT:`:`:`:`
M:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`
M:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`Q;?]AS_X>O\`?WM`926@(\>U0LHY
MX(89<*]`JKS>;U5!311;I]:G(#*9C="#=-)!$FX^!2%*4H>```>&@)#M`-`-
M`-`-`-`-`-`-`-`-`-`8V7*WN7<K\/=\+C9P;IDY04>.F4B86);862H*+VWK
MKY`/?TIU:/NWQFBJR.0:VV,@GY!^C<^^Y1```R24_$N_PF/X>H/;$-@^IH#<
MT`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`
MT`T`T!'SW/N6>0^$_#+*7(?%E=I5GO=-D*%'0</D,)DU15/;;S!U=RO+DK\I
M#2ZQ&[*3.=,B#E,P*@43;EW`1;O3=NVYKJO[3F]L+E=>N;O!K!/)[)=>J55O
M.3F-T6L,#1"3*=38NJMD:WTM'XE)8)*7ERMW+.NIJF\YRJ/F*&V$"[`!%<76
M&Y]:%_.A(T`T`T`T`T`T`T`T`T`T`T`T`T!BV_[#G_P]?[^]H#*2T!'9VH?O
M"L*?Y;YL_7^REH"1/0#0#0#0#0#0#0#0#0#0#0#0&&'S_`3?.;^%&P^";OBX
M)M_7U+9?`-OH^&@,SA+ZS_FC_P`N;0&YH!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"%OYP"`#VNL_`(@'^/V%_$W
MH`?MNU';ZNA;O0=RVX+JSF?-]P$.T1Q"`0$!+&Y;`0']7C*'X6A7%4AM\:$S
M&A(T`T`T`T`T`T`T`T`T`T`T`T`T!BV_[#G_`,/7^_O:`RDM`1V=J'[PK"G^
M6^;/U_LI:`D3T`T`T`T`T`T`T`T`T`T`T`T!AA<SBN+E\Z$XM0\>5-LXJK_C
MD195RJ(HNB0='RCD-V8A4T3J)'-&N3(D`1V%0`WV`=P`S-T=^DQ1*<.DQ@`3
M[;G`!$.L-@V`#[;_`(.@-[0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0$'GSAR:90_:YS*F]56(:>R!@JO,"I-S.!
M._=Y;JJS=(X%WZ"J^[G#J'P#P#TCH0Y**K)T1[WL%QSN,[2/#Y)ZHBHL[KN1
MY8AD.OR@:3.9\C2S$A>M)(=TV;Q,!\!\0'Q'0E--570F&T`T`T`T`T`T`T`T
M`T`T`T`T`T`T!BB_+>F_<<_T4P7]5/Y;?Y((?T'?N[^WRG^N_P`@]_\`Y1]9
M]'0&5UH".SM0_>%84_RWS9^O]E+0$B>@&@&@&@&@&@&@&@&@&@&@&@,,;D24
MB?SJO!1MA$R\CB4!'J$`+Y7&3(A@V+X@._F?A:`S.=`-`-`-`-`-`-`-`-`-
M`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`8W'SG/($E#<
M'<<XJCX)O(AF7D-2FKZ66D5F2M>9XS:O\GG<,T$FC@'[B4^3@-0(84RD*J)N
MH3``:%C)_P`B7V?M1<+\W>RH_P`F]K7"L8_K[6!^T_8L@X7:*-I-62-/LZ98
MEW*=C=$49-"QKJ1/-&`S8AW!"@F!@5'KZ2R78?Y?V$X6H*AH!H!H!H!H!H!H
M!H!H!H!H!H!H#"_\^;^Y3^+/C>>\O[E+[;W3[\Q\_P"6'[M!\K?E!YGE^1Y7
MO7M='\\^[>Q^2^.@,T#0$>/:G07;<#<))N$E$5#269%RD5*)#"@ZSODYTV5`
M!V$4UVRQ%"#Z#$,`AX#H"0[0#0#0#0#0#0#0#0#0#0#0#0&&+R.*/_&K,!CO
MX>^8F'U^OC7D4/Q-`9G6@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
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M#0#0#0&&7_L:O_-Y_P"^TZ`S--`60]N!DT8<)\"H,T"-T5(&Q/3ID$PE,[DK
MS:)%^N/68P];I\Z45-X[=1QV``V``+WM`-`-`-`-`-`-`-`-`-`-`-`89'(W
M<?G5F`?3TB\Q8`CZO8XT7\2^/\D8=`9F^@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@`B`>D=OIZ`MUY/\H<.<0\16O-V
M=;I&4FA55F<QW3Y1(9"?F56ZZL35*K'&637G[5/K(BBS9)""BA]S#LF4YRE%
MJMR3_E>0/SR.6W.8G=HY@83NW+JZY(XK=OJ6RA/8OQ_:D*L[EJGCB(:1Q)"<
M>O9QN+VMJY;LS-ZR;SD@47S.$9*)N/(,@V4(:O?!Q4K70'Z)''+"F"L!X<QQ
MC#CQ7:O6<25FML1HK*IN&KF(D(F00([+8TY%HHHG8'=C\\':\D8ZIWIU?,$Y
MMRZIJV"O.H`T`T`T`T`T`T`T`T`T`T`T`T`T`T!AE_[&K_S>?^^TZ`S--`65
M]NO[RS`?]*\I^FRPZ`O4T`T`T`T`T`T`T`T`T`T`T`T!AE\C#?\`U5-@$NW_
M`,LQ<;?_`/1OR"&VV@,S30#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&DQMO4`_
M#N.VVH<HQ59.B*6Y5I!5?S/H#OZM1%U5>A4]'0^ZJ`T`T`T`T`T`T`T`T`T`
MT`T`T!;7RKY386X?85N&<\]W*.I%$JC8>ARY7(:2L,ZLFJ,15:U&!L[F+'-.
M$P(W;(@81`1.<2I%4,6I1;!A;5"N\POG,_*I>[7@;%QWX!82E&C:*C62SN28
MQYWI$"OX.JO%&C6'O6;)IL#A&3ECHG90+17RDB[`1-6I*46U)IVGX4_?Y"IE
MJY+[8?#K)G#1MP/E<40T3Q\A89".I<-"%,TG:'.,D'A(Z_UVQN#.Y0M^;NGJ
MBZTBX.LJ_477*Z\U)=1,:-/X50&/YQFY0\B.PWG^I<!>>,E(9.X%W&=68<4^
M6I6C\4<61+]^9)O5[@OY#EJUK\8L]+\919W2CFOI"+EF"L<H"2<`R]X:78ST
M:RF(MTU?Q<DU;/XR28.D'\;)QSU!-TQD8V0:F4:/X]ZU5(HBLD<Z:A#`("(#
MH#M-`-`-`-`-`-`-`-`-`-`-`-`-`-`89?\`L:O_`#>?^^TZ`S--`60]MU=-
MUP>XZND2.DT7-+=.$DWR2Z#Y-)>RSJJ:;Y!T`.D'A"'`%2*_92*`(']H!T!>
M]H!H!H!H!H!H!H!H!H!H!H!H#"_Y(&.'SK'C\&X@07^*R;`/@(_<RY!4$-OH
MB&_T]`9H&@&H;2Z@;ZC=$#50&@&@&@&@&@&@&@&@&@&@&@-M0VQ1'JZ=A#QV
MWV\0W#;;UZE)MT74C<OUT+8([.4U)\I[CQX2KS).*JV)(')"-G"0<'E'KR5G
M4(P\2JR62!FBU(DL8Y5?,,<1(("`!L(\K:[@OW.]+G;$K">#;P;=]W:KZISN
M0VTK7103K2FIU>5VM*QV-9[QC=:O7N0NXJA32EJW;N;J]-7-JGA2I<NFX3%=
M1(3&\Q,"]11`WAUB'28OA[13;^(AX!Z]=)!JXW=\>B7P\SE:2BE%+T4^KX^1
MM2LQ%04>[EIJ28Q,6Q1,X>R,DZ19,FJ!!*4RSATX.FBBF!C@'48P!N(!Z1U5
M=NV[-MW;LE&W%:MZ)%VQ8O95Z./CQE._-TC&*JV_@D<I-PBJ`B0^X!Z?9,'T
MA\0#<!]0^L-5R]%=VE&E]_0L;EHG5-UZIKIUZF_H5#0#0#0#0#0#0#0#0`1V
M`1'U>.G0%JO,#F)@KA)A.QYWSU;TZW3X$2M&#%ITNK1<;&Y(H,;4*7""L@M/
M6.2%,1*B0>E%$IUE3)I)G4+-'3=X$;E2IAKXNQ%S$^<G\IR9PS.O/8D[>.*;
M:>/A*RA)*?%K1HW*W3E*7C)5-JT);,E6=D0_Q]:E042AP5!%$"[)-QK4HI:#
MJ9P&&,.XTP'C*I8AQ%18#'6.Z-&%AJS4JXS1:1D>R2.83*B"8"H\?OU3&7=.
MEA.X=.%#JJF,H<QAH;9)5+4`MMY7<4,'\SL'7/`&?*4TN%!N+8HJID,FQG("
M;:F!:)M=3G"IG<P%HA7)2J-W:7CL`IJ`HBHHF<#%TXS\E\__`#?C/,7P7Y[S
M]CR'V_\`),T\^Y0Y2D9K/V..4EY,OO$%:%#KN7T97XILY34F8<#'/!J*@[8@
MI'*&$H&85$S,3/QT?+P<DQF(F68-92*E8QTB^C).-?)%792$<_;&4:/F3M`X
M'252.8BA!`Q1$!`=`=GH!H!H!H!H!H!H!H!H!H!H!H!H##+_`-C5_P";S_WV
MG0&9IH"/OM4*J+=NGB$LLH=59;#D$LLJJ<RBJJJKA\=1510PB8ZBAS")C"(B
M(CN.@)!-`-`-`-`-`-`-`-`-`-`-`:#GZ>DH!N8XB!=P'I#8/280\`#\,=`?
MGUY@[@G&:Z_.!,1\U&MHL,%QTI5ZH59ME[M-0F*^G7U8#%5RQ/-R\K%OR$E&
MM?B[E*HI+/!2!(K8#K>)2["!EF$[V7:>`#^=W`N+Y3%-ML&1V``4-@]D_F%*
M('`1\0]6@-0][/M,!X?N@G&'?;?;[9$;OM\/H]&JHQ<G1*H-(][?M*%'8W<&
MXP`(>G_1)C`V]?\`$_!JIVI)5HZ$@.]QVDQ]'<&XP#]+),8/XA1U;('[MQVD
M_P"$&XP?UR8S_P"UT!]#O:]I8WB7N"\8-OU28S_`#0'W]VS[3`^CN"\81_\`
M"1&:`TCWM^TH`[#W!N,`#Z-OMDQ@>(>GPZ=`?![W/:2#_P#6#\7_`,')48'_
M`-CH#T1^\%VQBIJJ?=Z<62E0(R76,?*D``)-W[AHW;*B4713&(JJ_2*`AX`)
MA$W2`&$@&N"[PG:_GY1U!L>>G%IQ+,DUEG*`98KS1%-%%4B1C^]2#ALT-XJ%
M^M4-N`[EW#QT!ZL.Z=VX3'.F7G/Q4$R94SF#[=5'``(L43)"!OCCI/U%*/H'
M0&L.Z5VY?7SEXK`'P_;JH_\`?S`!H#[^ZE=N3;?[N;BKM\/VZZ+M]7XZT!I_
M=2^W)_MYN*@_2S91A_$F-`;:G=*[<?083<YN*P%`0$>G--($?`0$`#:7](_2
M'5<4U<5.K1%^#C:WTTZEO/&KDS@7D9W*\Z/\#9=H&7H2#XKT'XSG<=6!G;(A
MBZ<7D&P,G4Q$JN(I%^06QC&;"KYY2"4XEZ3`.N$QL"Y#O_)Y=ZV'QUFW]L;E
MR3_VCT;.YNSD?E9A=LQTRK?+Y&0W_AN6;45^N#)9)90[%F>110.[=,Q`/)('
MMK)+*D351#P'<`*??Z&VNXFT[BHJ1<3SN5V-QM0Z1=/M+5N=DI"53AWGVU6J
M12C8B#H#N1G)=P90&L3$M).-<OW2HE'[$T8((BH<X[]!2"8?`!UQOYA<=R/+
M]E\AQO$2<.2O6-MMKJI;HO\`8F=;V%FXW'=X8&=F34,:U?W2D^B6V2J_O/"?
MNH';G2\POW='%8`5]HH#FNC&$I3!TE`#!,>(`4/1Z0'?777+5SW;DW_$X17P
MG1+]NNAQMMO+W1A/W-\)[/EK^I>/B<K]U+[<A=BCSFXJ`8`]`YLHP&V#TCM\
M<;[:N)-*DNI6EMBDS2/=/[<`&Z1YT\40-X!TCFZB@/CL(>`S._B`_4T)/H]T
MWMQE^NYS\4R[^CJS;12[[>G;>9#?0'P.Z=VX1'8.=/%$1]&P9NH@COXCMM\<
M[[[!H#5^ZF=N/_;S\4_Z]M%_[LZ`^E[I7;E-];SFXJ&_D<V48?Q)C0#]U+[<
MF^WW<W%3?X/MV4;?ZGQSH#Z'=*[<G^WEXJ_@9KHP_P#\9#0'8%[F7;W]]*Q-
MS?XIBX409.4T29PQ_P!1D9+86!P.,^*0BX*H78-]_A`-`41Y&=Z'MS<=L7S.
M27_)W%V556CLD)!X\P?<JODS(]IL:X!Y43%5^"F''NB92'!19X\,W8MDBF,=
M7?I*8FDZOH'T,7CCS@CF#\XTY+'SURTG+'C3A#AR?EV<#6ZV@X@HQ)*4<)'<
MXQP\*K?HEK4]:,6Z5DMB@NE&I`*B42.`312N;9PG[R=;3\"UUU\#.3Q/B;'F
M$\>TO%V*JM%T?'M"KL;6JC48-`K>)A(B.;^2@@W*('<++J]0G775447<JF%1
M4YSB)AH;3;:Z,NKH5*U`&@&@+=N4W%;"',O"UQP'R"IK6ZX[N3$$'310WN\K
M"2;<X+Q5GJTJ4IW$#:(1T4%&KM'8P>TFH"B)U$C@8LG'7DWR%^;XYWK?"7G5
M997*?;NR;)R8<5N3JR+]\]Q`Q5?D67KMJCFK%X]8PC1R]ZI6(!58\8(&?1I5
M&*BB*8&836Y^)M4!#V6"E(R:A9Z.:2\1,0S]I*1$K&/T2N6$C&23%9PS?L'K
M4Y5$5DCG343,!BB(#H#N]`-`-`-`-`-`-`-`-`-`-`-`89?^QJ_\WG_OM.@,
MS30$?':C_>Y>'WZC%>_Q5YH"0?0#0#0#0#0#0#0#0#0#0#0&TJ03@`EV`Y1`
M2&'?8/$!$!#U@8`V'U[#X#H#"WK/S63,Y\CP[W)/*3%=HQ0M?"REW@(:IY"A
M+G8*,_O)K18X6/L'QZNWBK!)QRRB!'8$,5)8W6`;!H"2=;YK_P!K]82F38<A
M&`E(0I@9YMD505,"`)F46!_!.RF.*@B?P`I`,.X%#<0T!LJ_->>V&L!`,7D>
MF4A$R@FGFUR8HF32(D*@F6KBBO4L).LQ>KI`YC"4``=`;7_%=.V%L)0/R3`H
M@(=/VZS;;#Z?35Q'QT!"!WDNS[Q/X&2_!B-X]O\`+T>GR/Y%I8HR*XMU^3M+
MDM7<JU9KU5X5X-H2)DTBS:Y@7V/N/2`@(:`F\+\UQ[8)3;@KR6]>P#FTY@`/
M@]JK"8=OA$1'0&X/S77MACX"IR4V'_Z=0_\`T+:`V1^:W=K\?0IR6)_(9M.7
M?Z>U7\=M`?!^:W=L$1*/G\F/8#8/]&XWP;>.]6$1T!\'YK;VP1\?/Y,_U[1_
MOZJ.@(S,H?-/LI2-\O*F).4V,X3%;JQ21\:0]_IELLE\K%)4<"K#0,[96;ML
MTF)>.2'H4>@B'G'^R=!1W*($DL;\UK[:01<:E.O>1KZ638,B2J[/,RK>.<R2
M;9(CY=FS5K*HMFBSD#&33$PB0@@7?PT!S@^:U=K@/^A<C1_\,XA^)5@T!NC\
MUP[7FVP)\C0^EF8-_JC5AT!\#YK?VNP$-TN1I]A\0-F@P`(?`/15R^`_0V'0
M%I?"[YMQV[LX<=*9E+(;OD"YN5DF\G,I9Q!Y71AHU5O5,M7RI0GD1J=76(W4
M2@H5L140,/F*E,<?$V@(^.Y-V<N(?$;FIVS>/6'W67TJ#R^RC/4W+YK3?6EC
MFS0C.VXJKJ!*M(.*V@$`Y&,N3\JB@$5$PF3$`*)-Q`RU>`/:_P"+_;<8Y2C^
M-*&0&[?+LG6G]S&^7$]L56=4]E)1\.:--\71Q&(>1**>=[)Q4';?T:`D:T!1
MOD+@RE<F<(Y/P!D96?1HF6ZC*4FV'JTRI7[`,',)@B^3C)E%%PI'KK(@)!.!
M#^P80$!`=`8?/*7YJ7D)_E9PMPLRYAVH8)+7(%"+K7(.0OEFOD=9D6ZB5C<D
ME:I1U(XT,_5324;IB;K3,)P]D!`-`5VGOFY';QXZ<36V4^7-DSE/9(I]2A"9
MENV'KS_F;=V^:>-J\I-5"JS-8B5$X%M,23<Z:*_EF\HH]91$1`<FS9EE7EAV
MU63Z)Z>%=?N98W6<?&>-D)7+$)53G31R?SIH089)[8W!G'N<)3%"O-_*@Q%<
MOG&ZGO9F9XH3R]A;-<G+Y#2RDM()PU<7AEYJB-("(*S%`%4Y)615!(CD$@Z;
M5VV[=QPEU1VV1V+W'"SC7;UBW-9$:V:7;5$M-?KHJUKK2B^JC.LP+VH,49^C
MY<]=Y+3[IY5:1Q9F+$V2P8Q9EA+3R,YG3_&Q]`MPLIJ_\?,:W06<?/MW+0YD
M7,FZ4:JJIE1,0MLQ>Z^T>7[+Y:?"\S;4<N"3W*<9[MR4NL92I2O1T>O0ENX6
M?-A<"9EA;U<LW\D\KRD!7<N\A,/PU<Q75Z+C:07<X;SA;\7QMQEI^3BKNFX&
MP05/3<KQI&90;NW)Q*Z4(``(YHOC_P"*9=NG_5?YB_UQ\6?V%=`;P?--^W/T
M@7[;7,(NP[[DR-BD!'Z`]>$E`T!]_P"*<=N?;;[;7,+Z?VQL4]7T]_M(]._X
M&@-/_%-NW/\`ZKO,;^N/B7^P;H#XI\TW[=(E+Y>6>8!.D_6/3D3%0F,&P@)0
M%3"A@(8=]P,&P@(!XAH"+VR?-6^8<!-75QCG-'%^6J"$Y8UZ$VN$ED>.OCRH
MMG\H-,C;7+0^-OB$MH"".U0>+)"+,')3&`13],KJ"5/L)<PL?8BI*7:@SSC"
M7XM\R,"N9]TI1;N=PT3S\WGI24LLAD*B.9%PJ20F'31P5PZ9-CB@NW#WA@!T
M"K)MJY*NJZ$&3>4P&*4P;;&`#!L("&PAOX"'@(?1U;)/N@&@&@&@(T.ZL^X*
M_<6961[@Q((^!ACE#F9NCH%O"]P\E<*ZGA]=,?C$F30?*`#!1F8ID@4,+@Y6
MHK#JXJUT((F_FSD;S;1P3=%\E2$Y]P:,F_6X7L\LG.;-(PJ]H>&7,W,T,5@3
M&I(<`*!!(#4\P*IXS9F)^JF7U$F4GJD#0#0#0#0#0#0#0#0#0#0#0&&7_L:O
M_-Y_[[3H#,TT!'QVH_WN7A]^HQ7O\5>:`D'T`T`T`T`T`T`T`T`T`T`T`T`T
M`T`T`T!BQ?.71(%H[3PG$`_UZ\>`;CZQ?4#PT!E.Z`:`:`:`:`:`:`:`:`:`
ML-[9INOA=BXV^^]FSEX_2S_E(/[[0$,/>^)U]T7L8FZ=_+SO:#;_`,2`9(P&
M(C^``:`RBD0$OF[AMNLH(?1`1`0'\$-`;V@&@&@*>Y2QM3<LT6=H=[J%9O-;
MFDFYW%:N$:66KCU_&ND)2&6DX\VWGI,)AF@N'2)3E%,!((&`-7+%Z[C7OQ%A
MN-ZG7]/F8F=@8G)XLL/.A[F-/K&K5:?%-/\`68W>4\-=XR]\S<BL<1NNWA.R
M.-VG!S+UJ>W5GR"H%;"1QU+<AU*+4:I'1#J\24G'/F[^0&7>KJ-#)B#0K4.H
MBX:HE*4GNDZLRXUC;C:BY>W!42W.B7DJOIY^?C4M7NG#OO=<8J%#W-VT[<5G
MCXUAPYP(5!G<>0+R9<_)'GNEF?',PH1_4Z]&@#S*.6RQ\V(+$`M=0$[8A7A`
M.>"_EY61G94\[,G*YEW*;I2;;=%15\-%I6E:4\B4SB5!=ZCC<UME<R7QZX/9
MIIMIR=FW)Z2..>0>1,6V6$L>8,H3V5'Q`DK;B^\1LC4XY];7<>S:F;%D"HMD
ME%G)S"8#"P7P?;N[BOA_K"<,[[>(?=RICL/P;_<REWT!J+FWN)COU<"\,D__
M`$XR#O\`4XS:`WRYI[A@[=7!+#1?AVYNE-M]+_6TEWT!<7A:WYTMD7-.<Y89
MJV&I=I)((0475,NER^UFHLS0JKB0=RI:#0!AG"+L3)%;^[N.LI0/Y@;](`5N
MT!\Z2["78.D0$!+L&P@/I#;T>.^@(D^ZMVMJ=W"Z!6+#3IX^&^7.%W*EBX[\
MAH07C"9J<TW6]_+5K'(PRS6<7I,V^`#J>[G%Q'N0*Y;@80416G<P4'[7G=(N
M>3+],=O[G[$IX9[B&'4UX9_$2B)HV`Y%UV%;'.VRECMP9BSC5G4LP;'<K-6X
M@D_1(=ZR+Y(+(MZFM*@GB(H10H'(8#%'T"'X@^L!U1T!KT`T`T!&-S;[6O'C
MG_EOC7DOD(M=9Z`XV2-L>-<3-9%-OCG)Y;3\4N197V*5;G=+-8V1@VRA#M5F
MZBZ/FME#@BH<-2I-=`22Q$7'Q$;'1D;'LXN/C&3:/CXR/;)LX^.8LD4VS-DQ
M9($3;M6K-NB1-(A"@5,A0`OAJ`=IH!H!H!H!H!H!H!H!H!H!H#X8>DHFV$>D
M!'8/2.P;[!N(!N.@,)CY:M?N:^GXFFOWKGY=[[1>WNW[K+YGQ#_DGO\`'_XW
M;^=.K_H_KT!FT:`CX[4?[W+P^_48KW^*O-`2#Z`:`:`:`:`:`:`:`:`:`:`:
M`:`:`:`:`Q9/G+@%&S]I[J#?_7LQO_Y=01T!E-Z`:`:`:`:`:`:`:`:`:`L)
M[9'WE6+/Z9LY_P!T#E/0$-G>Y_?0>QS^KC;/UP\$:`RB`](_3_O@T!]T`T`T
M`T!9'AV15?<Z.;+90C8A(?&O#Z-0%!RBLLJDI'YUES*/$4UU5&:WG2IR%(H5
M,QDB%.!1*8#&`[KG6&_'U(/_`*?_``[_`+K_``5H"\+0#0#0#0#0#0#0#0$3
M/=`[6./N?U,@+?6[&IA/E[B-XRG<`\E:TV,RM-6E(ETK(QM7LC^,49RTK1UI
M145P(1<KF.=?S0V,`^<BXKC)]/`%N7:Z[HV2+Y>I_M^=Q*`987[A&(/(CS)R
MIV<97.1M;*@92-N]#=M@3@W=DD(TA':[-D8R3]`PNV9`*"Z#9**ZKH03YZH)
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@-M8=DE1V`=DSCL(;@.Q1'80'P$-`8'
M'QE/_<^^[>X5OWK]P5^6N_Q'#?D/[IU\;_%?F>[;?)SXG\/BK^=?QG1OH#/+
MT!'QVH_WN7A]^HQ7O\5>:`D'T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!BT?.
M6C&)9>U`8``0^[:BB#OMO[<A02AMOZ/'0&4OH!H!H!H!H!H!H!H!H!H"/SM<
M*@MP@Q2H`B(#:<]E]KT[DY$Y8(/K'UET!#UWN`_\:%V-S>HN=+6(_2#(F!]]
M`91'P_0_^/0#0#0#0#0%A.!T2DYY<_U0^N6J_#OJ_P#O=&R:4`#X`\=14'L^
M=2Z:&`6@*`H/G\@N'K8G0F90`45Y<X/Z#*=(#Y:8"'B8?`NI!>'H!H!H!H!H
M!H!H!H#X(`("`@`@/I`0W`?I@.@(M.YQVP\>=P:CP,U'S"V)>4.'?.GN.W(.
MNK/(ZPT6TH/&,JT8S;B),WD9>I.W\:F)D04%1DL/O+<`4ZBGJC)+0$8&$._?
M%<7Z)FC`/==@I[%G,WB["-&QV<-$KR$?RKC4O)8P-NQNX2CV\(E,6!51-9VL
M)TXD6J@OTSD(5=!O7..U*6E&"OW:`M7<RY69.R;SZY9W*3Q)QHS7#)LN.7#M
MU%)B$15&ZZ9ZW?U_C*,9R<$1Q&=9DG?5[]83.C.%2D9D:E&EM4H@9!NJ`-`-
M`-`-`-`-`-`-`-`-`-`-`-`;2_Y`M_A2G\H.@,$WH>?:7Z?+:>=_Q<CKZ?DY
M'>3[K]WUYGF?%OQE[M[W[C[7O_F^\>?_`#=Y7G_8-`9V^@+`.U:U<,NW7P_;
MNDA16#"M84%,3)G$$W`.7")NI,YR?9$52FVWW#?8=AW#0%_^@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@,5_YS$J9.R=IX`*8P&YN10B!2B;;HD*")1';Q#QT!
ME0:`:`:`:`:`:`:`:`:`:`LA[<;-NQX8871;-FS1-1&^O3IM`$J1W$EE"[2+
MQT<!*7=R^=NCKKCZ!64,.X^D0(5N]R(!W/\`L=`(@`CG.V``"/B(CD3`P``?
M"(B.@,H4!`>K80'8VP[>.P@`;A],-`:M`-`-`-`6)8,*`<ZN>I@#Q-5^(.X_
M#M2LF@'X6H75@XG<<*4^"<>`8-P#F'P8,'TR\O,,B`_5#4@OXT`T`T`T`T`T
M`T`T`T!\$`'<!#<!#80'T"`^D-0NK!8QRI[='#_F9><+9"Y&89@<D6G!DVYE
MJ4_E3/"(N&JR9E35FVMVBR2=LIP20)/OBM^"S)1R@'402*+$4K;;5/`G0O=:
M,VS1%NBV0301;H)H-T4DRHHH(ID*FFDB@F`)H)$3*!2D*`%*4``````-4D'+
MT`T`T`T`T`T`T`T`T`T`T`T`T`T!M+_D"W^%*?R@Z`PA]Q^UKZ1_]F4V_`^Z
MTVV^IH#-Z4_(U/Y`W\J.@+0^WY]XWQ'_`&/&)OTEQ&@+O]`-`-`-`-`-`-`-
M`-`-`-`-`-`-`-`-`8L_SEPG58NU$.^VW-N(+Z/XN0H1=_3ZM`93&@&@&@&@
M&@&@&@&@&@&@+*^W=X<-<)?Y6VO\/(%L'0$(_>]_?0>QF/\`]/JS?AY)P%_@
M:`RA4/0K_AZOXN@-_0#0#0#0%C&#B;<Y.>!]_KJSQ&+MMZ.BE9)'???QWZ]0
MNK!Q^XFCYV#,?EZNGHY=\(5M]M]_(Y:X=5Z?2&W5T;;^K4@OOT`T`T`T`T`T
M`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!M+_`)`M_A2G\H.@,(;_
M`$M/^3*_[K30&;VI^1J?R!OY4=`6A]OS[QOB/^QXQ-^DN(T!=_H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H#%I^<M'Z+#VH_9`W5S=A0\=O#_'*A>/CZ_'0&4M
MH!H!H!H!H"C^4,_85PE*8]A\O9.J&-7>5K&XI^/5;I+H5Z,M%K;QZDI\FV,U
M(BA#)3CMDD8S5JLX26>&*)$"J'`2ZIVOS9)6#52T(&@&@&@++>WA]YMA/_*V
MU_K@6S0$(W>\`3=T#L9@'I^WW9A_`+D;`QA_"+H#*&2*)?,W_'*G,'TC#X:`
MW=0_`$6>);+`I=S3/E&C*6U3G28[C;C8[,ZS)E][*-&TR2$B(A1ABZX*QN,#
MQ=A^3QRG+6&+HT2HS*L\D#J2!6R&WO0E_2[=QR].ZB6V/A6OJ7JJJ_Q/6M$M
M*G/8UR']>O68P]>Q2;WSKK1*D)4A1T_@3I35^JBE,UJ3H1H"QK!XF'G#SM`2
ME`H5OB3T"&VY@&DY'W$VWB&PAL&^@-/<)*)L'40`]/W67"L0_P"9Y78A'\0-
M`7SZ`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`VE_R!
M;_"E/Y0=`80W^EI_R97_`'6F@,V^4>I1L9(R*^XHL&#QZL!0$3"DU;J+J;``
M"(CT)CZAT!:-V[W2;[@;PY?I;@B_XUX:?)`.X""3RAPCE,!`0`=P(J&_@&@+
MR-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`8L7SF$YB6#M1"4`$0YMPYO$!'ZV
M2H&WX'CH#*=T`T`T`T`T!!WWB87C399+A]#\C+#QG@'$GE2Q1V,`Y'8XRC=(
M:6NJS2N":"C;!B^\51Y0C2+0O21Y(I/VAY7W``(18B9AO1=M)N2;9-:DWZ'Y
M$F&P`)2](@`&``$GLCL!_;VW#U^.K3ZD&[J`-`-`65]NT>KAGA`PB0W5%6@_
M4D?S$C=5]M9@,F?T'(8!W`?6&@(2N]X/3W/.QTIX`*>=;48!'P*`_;#P1Z?1
MX:%,FUT,GUN^:.5GC=%VU778JE3=HHN$55FAE$P.F1TFF<QVYSEW$`.!1$/'
MT:$HY8CMI2I4M2%W#,=43=Y?DNS)CG`\?/06#H"WM<DU]OE%QF::?W3Y(PTW
M7[%89*><XV.BQCX%JL[B&S-NJS068K($.95\MK>7G/\`HMKU7'%W&J/;M5*Z
MI4K\G\Z^!RV+"W_Q/D+V[*FK*EN6_>W*B:;;V]$G1)4T:ZMDT>M&=0;)W#<B
MR3<ZZ)'"Y5#(('5(598J73YIDDA,!U"I]0=0@`[;AOH"Q3!*H'YV\^4@$1\J
ML</Q'X`%2CY+'P^@)2AH#E=PHPDP=1!#;?[K+A4'C_'<K\0%'\(=`7SZ`:`:
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`VE_R!;_"E/Y0=
M`80W^EI_R97_`'6F@,URW^0%2M'O1/,;?)V;]X3^R^VA\6N?-)]A,1;VD]P]
M@0-\`@.@+2NVUY7[GQPD]W+T-QXK8(%N3V_8;CC:N"@3[*8ROLI;![8B;X1$
M=]`7KZ`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`Q9?G+_^3G:I'X.:L4/_`.\\
M?Z`RFM`-`-`-`-`1%=T/#=,RK*\-['=:51[K%X7Y%Q&4&[&W9P;82?&EX)JT
M/!-H)T%9M4I?#*S9FZB\`W;)B^*@0!4*;H-K;<=QL^0G.TGLE%-K1R3ZOPZ?
M:TC#Y#DN-XG'CD\G>C9MS:4:INK?@J$MC-0%FR2H!MYI14_(Q2\3F$PB*9O:
M*(B._CXZU<DXR<7U3,J$X78*Y;=;;54^E5]IR=4E0T!QG@]+1T8/25LN(>(A
MZ$C#Z0\0T!8MVP=ON!>,&P"'^AT7TF$X_P"3LSON8WM&\?AU"=54$-/>^V'N
M<=C@@AOUY_L(>/HW#(N"?PP_!#X0'T:DIE&K,C2NXGJ<!>+GD1DBZ5LUS*R9
M2CAPJB5N@QC'"[M%BQ;M&S4004>KBLH=<RZQC>'6!/8T)2H53'Q#2M-2:T(R
ML;90MC/N$Y+Q,ZPUC*"J%JA;+>&&48JKV^!NMFF*9%T.LJ/'SR:$8JQ/U64U
M[@[DF3)HR619)()OGBC8R*>VN6H/C8WE.;G%I;:II)U?AT\TFV_&B-'8R+BY
MF>,[5M6Y*4MR34FXJ*U;T?6C:26B570DVUJ3>'@9S'4!8[17K5+>^JOZP916
M+12>*H-0<B9,4G2Z:8%4,JF4#%$I3E34`P>84_278"T3`H;<]>X%Z/&K\.=O
MP*+DX/[[0')[BB@)8+H`B`CU\N^$"7AMX"MRVPZF!O'U%$VXZ`OPT`T`T`T`
MT`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!M+_D"W^%*?R@Z`PA
MO]+3_DRO^ZTT!FPVAR[9UJQ/&!R)OVD%+.62BGD]!':#!PJV.?W@0;]!5BE$
M?,]C;Z[PWT!:3VWUW+KM_<*G3PQ3O'7%S!SIX<GE=!WCG'->6=')Y`BAT'<'
M,(='L;#[/AMH"]/0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&*]\Y<<;VSM5,C
MMS>2/,)I(&=^\($)U-)_%R!6!$>H'8N'8O/94*`ID`HE-XG+H#*AT`T`T`T`
MT!T4E`Q,J>/5DHB-D%HQV1['+/(]F]5CWJ>W0[8J.DU#LG)-O!5,2G#X=7(7
MK]J3E"3H].K6C^75?`M7K>/<VPR+,;MN+K&J3VOP>O[CMFR1$$2))I@D0@"!
M4RE`H%#J$?``\`WWWU3-UE5EWU/ZZ;OAT-_5(&@.*^_G)Y_^*N/\2/J'T!8Q
MVPRB7@-QA*8-A#'9=P__`&[,CJ(_2@0H=[B58#W6^R%$&(J5ZUS'*R:RQNCW
M<S5[E'#C1HF0`6,IYZ;A@J)MTREV,78QAW`M0,IXH%V'IVV$QA';UFWV,/T]
MPT!]'4/H_D0RR*K<=;9$<ZLB\BW52PVQIU@Q+"U**OT(]R6GGNRRPNX[W^GW
M]NZLBN-I#'-9)#`[B`28@X;N70@F1,P+JK["63!\?'&K/W%*K3IM7Q6E=SK1
MZFKMX5R/+SSG&TK4K2BI+?[C>GIEKM<52JTT;^;=[VL`VHT!8Y@IHW)S8YY/
MRF$7;AAQ39K$$I@Z6C+&UL7:'`PN#$,!UY%</!$@AT^)S^!4@.J[CING!&/!
MWV_UX?!@`^F/+S#(!]70%_&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@-I?\@6_P`*4_E!T!A#?Z6G_)E?]UIH#-4O7]!%R_I5L/YT
M/-`6F=M'][OX-_L3L`_K85G0%[N@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@,6
M#YQ/'/;+R0[0%31>`V2E.4JZB1E5UV[9L\)<<-I@^54:A[SNDB82^QX@43#Z
M/'0&4_H!H!H!H!H!H!H!H!H#BO?%F[#_`.95_P#$CZA]`62]M-'W?@GQI0`1
M'R\>E+N.V_A-S'IV\-1'Z4"#?N^1;2:[XO9+CGI1,V/8Y%V<I=@$RD;DFO2+
M<H[@/L^\-B[_`(6J@95)!ZB%,/K#?ZOCH#7H!H!H!H"R[!I"_=><YUNE,#B^
MXW-Q,4@@H8B.(E%B^8H)Q*<I3.S=(`4O3X^([^`'6]P&/;2N'<:,'BKA%!7E
MYPL6%1JF958%6'*3%,DW*!"HK_8U7#,A#CT^!#".X>D`+X@\0`?A#U:`^Z`:
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`VE_R!;_"E/Y0=
M`80W^EI_R97_`'6F@,U2]?T$7'^E6P_G0\T!:9VT?WN_@W^Q.P#^MA6=`7NZ
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`Q?._R(%Y?]F4X_6DY5JB;X=ANF&RC
MM\/I^IH#*#T`T`T`T`T`T`T`T`T!QGO\YN_7_,R_H_PH^@+(^VF)C<$N-`GW
M`PX]*(@/IW^.YCTZ`A([LXB7OI]D80VV/.6%,V_\3\MXDX;?1ZBZ`RET?R,O
MT@_E0T!NZ`:`:`:`LSP:'^NUYR#\,KQT_"PZEH#D\UAVQ]B7;_;:\1@__P!A
M*!H"\/0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&TO
M^0+?X4I_*#H#"&_TM/\`DRO^ZTT!FJ7K^@BX_P!*MA_.AYH"TSMH_O=_!O\`
M8G8!_6PK.@+W=`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`8NGS@$YB\ONS$4#`
M`'Y6J]8")=^@MTPV(CX^(``[;CH#*(!1,3^6!R"?81Z.H.K8!`!'IWW\!'Q^
M#0&O0#0#0#0#0#0#0#0'&>?SF[__`!9?_$C:`LC[:9Q4X)\:5!$#"?'Q1$0V
MV$?CN8]&WAH"$?NTB`=]+LB`(@`C8+#L`B&X_P";2,]`>O0&4PC^1E^D'X@:
M`W=`-`-`-`648$]_^ZZYZ"[`0;?*'CB$8(E:EZF@8.BQ6$!0<*N#@$@98-UB
M)']10$@%,,+JP=IS7_J>XE_9:\1O[H2@:D%X>@&@&@&@&@&@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@.(_5.@P>K)H*.5$6CE4C9(2%5<'31.<J
M"9E!*F5140Z0$P@`"/CX:`P>_?E_M:[?%KK_`-F!^,-_,0V]Y^ZRZOBKZ_\`
MGS?PZOR+?\=H#-EO7]!%Q_I5L/YT/-`6F=M(-NW?P;`?`?N3L`_K85G0%[N@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(Q>Z1VS\4]RS"C*BVB6D*#EV@KR-CP
M3F&$5<DDL?7%9%`0+(-VRR)I*K33ABV*^0*)%RF126;G(LD01`C>[7W=%S%1
M<V*]KONDMPH?,"@IA`XAR_*]3:H\E:O'HI-HIR-B=BU8REUEFZ7GL7[9,K:;
M1*8A_+D$E$UJ]NE4#):*.X>(;>.VWTO3X^OQU2P?=0!H!H!H!H!H!H#BOAV9
M/!VWV:N!V#<=]DC^'@`CH"S+MQQ#N#X,\8F+TR)ESXLA9(!0,H9,$)M5W--"
M"*J:1P5(TD"%4`2ALH`@&X!N($&?=M#_`,>MV/Q__J&Q!]6YQFA#='0RGTOK
M`#^)]GZ>P!XZ!.IN:$C0#0#0%@W&D#?=E]R0QE55`^V/QJ(F10XF(@F7B]CX
M_E(%'P33,JH8X@'I.<P^O4+JP>CYSR";&@853.=$AI'F#Q+9I`L#@?,43SC4
M)'RTS()J$34%-@8>I42)@4!W'?I`9!>J'B`"/I$`_O>.@/N@&@&@&@&@&@&@
M&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@/(9"4.C0;PLD<Z:J5/LJB:B9
MS)J)G)"O3$.FH00,0Y3!N`@.X#H#"N^UL3Y+_%'QVZ\O_BB7OGF]#K^>OMP?
M+?WGH^,M_>?>?L/F=77^/WV]C0&:ED`P$H=V.(=0$J-D,)1\=P+#/1$-OH[:
M`MUX!1+F"X+<-8AV\-(.8_BW@1NL].=54SDY<75<15%18`5,(@/I-XZ`NXT`
MT`T`T`T`T`T`T`T`T`T`T`T`T`T`T!I,4IO`Q2F#Q#V@`?`?`0\?AT!%IW2.
MUYB7N7X7:5*U/38]S30'AY[!>=81H"EFQU8BKMUP8+*-UV<A)5*77:IB[;D6
M3614(5RW,FNB3JK4DB"-[M;]U'+>.<N?N6O=.]XH'+FAN4JMB++5D2"-K/(:
MLQZ9V5<.%C7%G'S5EF6C0IH^6(5-&P=0)GZ)(JB2D2:;JB3)I*LF<QR%'J%/
M8#;>(`/4<O2(A^.`2#N&J2&TNIN[Z$GS</AU-&!N&J-Z`Z@^'3<B*JM*JI\`
MP#\/U!U4M>A/W'W<-*"J.)(#LP>CZ=FCD=O'QV1/X:$51:9V_P!-%/A-Q;*W
M(BFD.$Z&H!$!`Q`.K"MU5>H0$WV853F%3Q_).K1.NI)`SW;A_P#'K]C[Q]-B
ML/Z<XW0I:;::,I]#ZTW\F/X@:$Q5$;VA(T`T!URDM'HK-VRSI))T[\\&C50Y
M4W+H6R8*N"MFYS`JN9!(>HX%`>DOB/AI)QA=C:DTISZ:D-M1N32D[=J24FDV
MDWTU18WQJ^_%[CYMO`<D<;]AVVWVXOX]#P^$`U2NK)K7[#;[@A2&J?&,#`H8
MP<Z.)PI`0"B'F!DIKXJ=7CT`3J]'COMZM]3*2BJOH"_<!#?I#PV\`V#P#;\+
M4*<6Z+J176AJU42-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-
M`-`>,R/_`%/+Y_29:/SC?:`Q`/\`L?\`\D)_[Y]`9@.1/ZG]Z_I.LWYR/M`4
M6X4_>;<2OV,N!OUK*KH"YK0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0&@Z95
M"])O$NX"(?#TCN'T0V'Q\/'0$6W=)[6N'>YAAA&I65T-"S90E5I_!6<8Q+IL
M5`M:917:L7BS8J3^6ILF](55TS!7J1<))NF_0X2*(@0+<0_G"5JX8Q&3^(_<
M\I62<J<@N,=L-C17+V#5:CDQ/($3%KJ-3JW:5?W>#AU+-`CY)%Y%!8%GWFD3
M=M6[U%P!I^9#G&+2EXF0UC[NT=NG(E&J5[9\R..U<;6RNPUA"O7#+5#@K;7/
MCF/;R'Q+:H1:Q'4B)Z,\_P`AVW,8?*7(8H"(``C4E4R?PUR47*"J_LI^VIZ)
MUW2^VZQ5;(/>>'$ENL[/T-TU<[XY2.N/C[*)#6$14/O\&IV_I5%O\-E?I3^T
MYA>YOV\5-_+YQ\4S`4ICF$,XX_$`(0`$PB;X_`"@4!\1\=M5>VUU_:O[2K\+
ME_W(U^:.N:]T_MMOEUFK3GEQ+<N6_45=NCGC'2JB!B^D%2%G@.0`^CMJ?;?E
M^S^TI]C*<W;V1JOC^B.2Y[HW;A9(F</N=?$]L@0/:66SICU!,NWIZCJ3_3JB
M47%Z_M7]I<G@YEMJMM:_%'(3[G/;M7*4R'.7BDH50A5$S%SECT2G3,4#%.4P
M6#82F*("`ZI*?P^1#6Y!*/P:+2N4W?B[<'&A&IM'6<8[.+Z]DL[5M'<:'59S
M*_K9X.,9NR.+DT@;.FY@6DT>0*BQ.8#`X534`.GRS#JE]"5:W)OI0][V6N7&
M+^6O`W&,KC2(N$$GA5O%8%N[:Z5^.K:Q\ATNFU.5LRD(W83$L1_"=5E2`CHX
MHG66!3=,-MQB/0LM-/4BW[N2Q2]]CL<CUI@F:RV$G6)B@43#=(OV.H1VZA`?
M`/2.I(,J5%1+HW!1,0,(;"50A@'<@#X"!A`=P`1^EH]%5]&%KT-[K)_%%_YX
M/\'0>-/$TBJD7<3*)E`-]Q$Y0VV$`'?<?4(AH1NCYK4X+Q45`*B@Y!(5C>49
M=,R1_=]MQ'V1,`^8IL)2CX](^.IH_(E)NJ6K77X?,@S[C/<#Q_V\N2_&'(.?
MCWR3PQ.$OU:KT=0,4R=GL#"XR].=%47):?C9M#6)D\,Q0378F%*1:++D7)UM
M1,)-9R.'>R.6PK]N5+4-U5TZT_BZ4^#1WV+D=N8_Y<WL2WB2?.96=:I<]V+]
M,=W_`))TVO5^O<U)4K1Q*6=N3O`<*.1'*7GM/IY%;X7A;7-8$N%.>\AGU6PX
M:S14+B"$QO.H,"VFT)%<S,7:ZF\!5HD90R;(R"XF`%@*&RTW2V]-S_:>?UDK
MDXRBX.,Y*CH^CI6JJM>J^!=QS>YB<19^M\=DX+E%QUGUXGF3QGGGZ$)FO&LN
MM'Q$3?D'$E,OD(ZQNUF\5&-P%1PN8H)(D#J.8I0$=51AO='T,BQ8]^3BFDDF
M_N\"\I#G5PM<@!V_+CC2J7QWZ,X8V4`/H;DL9MMM2[>W4LRE&,_;\3ZISLX5
MH&*1;EQQG3.?;H*?..."&/U#T@!2FL.YA$WAX>O5`-_[N'AKMO\`=8\;=OU;
M,=?_`$0[:`TDYR\+U3BFGRVXU'43-TJIES?C<QRFVW$HE"Q[E,'T=`=39.?/
M#"M0DO/N^57'A5C"1,A,/4V>8J`^?*-8UN=RX28,6\^*KU\HF3I11(/6LJ8J
M9?$P"`%D?$WOQ]O_`)CY6I^&\;6C(E0N60&KM:B!EZA_:_A[G)-1;=-7K\L\
MFW2"]I?$<]35F<"J.0(<$^HX`40)F""(E\1W$!,`B'P@80V'8`#<-MA^CH#7
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#QF1_ZGE\_I,M'YQOM`8@'_
M`&/_`.2$_P#?/H#+PRY*LH+%.3IN2.=..AL>W25?J))&64391];DG;HZ:)-S
MJG*@B80*'B8?`-`4DX2J%5X9<1E2;B13C%@10@B&PB4^*JH8NX#X@.PZ`N=T
M`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!I,8"AN(^D=@^$1].P?".P:`BW[K
M?<2X_P#`'C+=K/ER6"9N-YK,O6,98A@+8I5KSD"5EFBT8HXB9B,53G*K!1(/
M/->S9`*#,A`!$3.3I$-7%-@Q6>S]\WZEN8>*77(?F--Y3PWBR[L2+X;QU5W#
M.%R)=(QXZ;27VS+E,VF$FG"=??`D1*+15:@O*(=3L_2D9$Z\S9")B%_FJ/;L
M<*'5-D7E.0RHB*HHY&IR8G,(``B.V.1V\0U;)HCC#\U&[<P@F!LB\J3BD(B0
MY\CTPYR&'?VDS&QON0V@HB.#-W8-X;XV[E/"3B%`77/RN+^1>*^15VO;^2N=
M:=6UI,XGCX5W6$JU+)4UJVAX]964.#I/W=7S2D*&J+FMU5^!BW(KWE\:$D1/
MFI7;F3.HJGD+E*110IBF,3(=+()A'PZCBGC<@J&\/$1](ZN-U=3*HCZ/S4OM
MT&*(*9#Y3'W]'5D6F"4`]>Y#8X,4VXZ@BB-9?FIW;J*.Y<C\K@V#;PR;4```
M^`"_:WV``^#U:$FHOS57MX-S*+H9+Y6I+^68H+ADJG"J!>D0$G5]K@HB0P>D
M-PW^AJ5U'ZRBR_S:7M'.LD(XN6Y+<F$,I2+-W*#0F/(*K,+*JFQ;).7SQU"1
MU.3,5PFR,50>HOF';DZR]29#&"]5OP+O]/N.W^(]J[L\]S_M*D.?FGW;J51;
M>3E?E^11`[8P.'66X!\](W14,L+9J\7HIG4>"AA`QCHG*<3%`1$0WUB54)?Z
M\Z&$U&%N:553U:]5X_:5W[5/"ZE\$>37-WBGC.XY%N&'-\0Y)K@Y0F(NSV*O
MV9:MK1DX5&:3A6)EVDTT>>6F02E%)%L(>V<YSZY'BN[)YO>6=VS*UNL8./">
M[6E9N2I\]$STCF>RX\;V!QG=<+E+O(7[D=OC2*BT_E6J^PG+DZZU8II'8$!1
M9=ZW!4I&D8"IFPG*9XJ3=H`%!-`.H1\=@#78NZY.$8Z6WZDOT^9P^+-2NJ$W
M2:4XN7E6$J:_%TT^PB@[SN/DLC\2F^"'*$LVIG(O+N(L77J]56>)7KM38]YD
M&NSD?880J48NSF`7=11FBK=P)4#$6+N!RB8HWIK=%2\:I??X_'XGJ7Y2_EIQ
M7YB0Y?&S,V&+G<-P63G65+ID2M4_E5K1-N6Y:.M&J$0OS:OA%3*QCG._.*.L
M&0;7EV(L67>,D+19J?;NJ*^K-8C,=VUA*"S=,E9`+A/RJH,UUS.3-0;B'E-T
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M44FOBEJ]?-]3T7_%%^%W28OW5',#I.42G`9'"(]11](>.'?0/K^'4$&A+YHG
MPH2'<O*/EX'T"O\`")`'^2`F'2@<?HCX[Z`CI[A/S=WC%Q%D^&25*SQR%M(<
MD^96'.,UM/<SXJ>J5^H9*?.VLK8:J,5CF'*WM,8DWW:F=@[9]9MSH&$`$`)&
MC?-&>%X@!2\J.7Z90\=B2&$O3]$38?-H#Z3YHUPN2+LERFY>)F,;K64(^P@"
MBPCON*A@P]N)OHZ`W/\`BCW"\?K^4W+U38=P\V0PBH`#ZMBGP\)?#Z6@(PNZ
MAV`+UPBPU`\A.'>2,V9XJF+I8U@R!7YUO`KY4Q@Y:*#*QN7J"O0*]5O>8JNK
M,4@D4BH^^-P*DZ`RB)5#(UPZAF5%VD>Y1A;N)\8*58Z79MLNT&L5RM9LQY/3
M2$E=:]:&,<VCUK*X5-Y2\[6;<Z0,Z9RA">6J*HI*=*Y%"`E%IU!*OJ@#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0'C,C_`-3R^?TF6C\XWV@,0#_L?_R0
MG_OGT!EC\E/O<\_?J*94_2+.Z`\-P<^\IX??L6^/WZTU2T!=)H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H#090A-NLW3N(`&^^PB([``#MMO\`0T!&;W-.Z%Q]
M[:.'%+SD]\-KR1845BXLP?7Y9HRNN1'3=8J+QX519!X-?JD243J/I1=+RDR)
MBFD"JYB)B!`UVU^UUG3N)9Y3[K/=;BE)Q"VR*5FP)QOL:;PT6G7/C$\K2Y6Q
M5^4/M#XMKK-0AX.O+%.I)F'WM\4$SE27FK70&8H@W0;)E2;HI()$*1,B2)"I
MIIIID*DF1-,@`0A")D`H`````&H!O:`:`@PY6)F-WSNU88"B8"<>>:QC"`;@
M4"P]1$3#\`;#Z?P-85^4UFV8)O;)2JO.D3$N-_B;*\XNOW$YI!W*`@.^_K^'
MQUFHREJC5H2-`:3_`%A]PW#I-N'IW\!\/P="'2FNJ(;5\_U2([P[;C=(4V^L
MIN]X*&]P-N8Y0Q'(X]E9^LUAT=^2:PZS8#EFLR:%36602EWCY-)XJ0I4FQFI
M@7+EQR$K'L;(5Z[J>KY5_3R+2Q9_C?Q#OW_PVQ+V=_HKTK3S)AD4C`B4!+M[
M(^SOOL`@(`&^Q?5]`-:ZY%RE;=?IN5?ZR&E.VW%4C*TE3["R[$.-;]6N6/+3
M($Q6W+6I7UAAY*DS*SR/!O.GKD)+MIQ-J1)TX>-RQ[ER0#^>BEUB("7J#Q#S
M_M_B>3P.].>Y.4?]QRH6';?G*/N*27V.)ZAW1S_$<KV#VYP%NY3D,"=_W4JZ
M1E[;C7SUW=&7`Y.RACW#D/&6_)MB;UJ)EK)7Z1&OW#&3?D7L5M?)QL!"M&\2
MR?N1<RC]0J1%#D*0!'VC`&O1-UBU<K<=*;8KR3=/VLY;MKM;N'O+D9<5VQC/
M)O/&NWKD8SA!JU:6Z5QN;C%[5U5:TZ)O0\[F_$T7EG'SVL2,A(Q#%*Q4Z[%4
M8`W7'WK'=HB[RQ9>2Z`Z:;66=0)&[@2[&!-4=O'55ZUNN*4;DJ+JD]'1ZZ?,
MU?$<ID<7?>38W6<EV;F.TG1TDFFZKX-]2%GYM*F1?@IF,YB@??FAFT`$>DY-
M_DOBX#>68`#J3(<!`HB4H^'H#1*&W:TMIK(68J=R+2]F<W)KP;?5_-GC/G61
MTV?:M5\LRC<7G)'#J*@MTR&*L*4?=G29'9#;=;<IVP&]8@8I=3-^Y';/6*\&
M7ML=D;=/Y<>B\OD9!6$O##.(P]&V,:"&WP?YE(G4=-%T)*GZ`:`@I[W8",KV
MJ]@'<.ZOQ7$-O5_CQ(^OU>&@)UM`4(S3GRG8*CH*7MS*W/X^=L36O>\U:O.K
M"2(6=N&[<KN7(V,11!J#AVF0B:0+.EC"((HJ"`@&RXWCKO)2G"QMK%-NKI]B
M_2AK.3SG@6(32;<KJ6BZ+]/`K<U4\Q/JZCFZMC`)@,'LFWZ>GJ(F(EV]'@`Z
MUKHIN/BF;*M6Y=$Z?L"K9(Q.CR2&*/442B4HEZ%"B10HE-N42"0=ND?9$/`0
MVT),,KN@=K;D#V[^0RG=;[4+5[76D#(/[KR,P15RN/<F\<#]I+6B8@*DP<$)
M:<260HKJ6&NII^9'>T[9`!0*#>I-MT;T!D`=L'NDX![FF&4[[CB1+6<G0#./
M^VSA&8?%=VO',F]!4$G*:I44/E!3)8Z8J1\JBF"1DS%26!)<IDP2BT"3T!`0
M`0\0$`$!^$!\0U2#[H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#QF1_ZGE\_
MI,M'YQOM`8@'_8__`)(3_P!\^@,L?DI][GG[]13*GZ19W0'AN#GWE/#[]BWQ
M^_6FJ6@+I-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`?!'8!'T[?!M_?B`:`BR[I
MW=,PUVQL)#=[HD2XY:N+6588:Q$S<^[O[;/-&ZG7)S[I,B[JO46+5V.[?B@8
M51*#=N51=0A=5J->G0$(/:[[66;N=V94>Z7W8R/;;*V]PTMN"./UM:G+&DB#
M+JR=9GK=4WZ125ZAP`JD4K==`O2ZV*^>%`#`DM0^H,P=%$B"94D@`J:92D3(
M4I2$3(0A2%(F0A2D(0I2^````'J\-`;N@&@&@(5>1S91SWP.VT8CHS<L=Q0Y
MN2BB9=_YM*13&<>#8^RA-DRFD04'P-XIA]/6!>5>0Q_*DO\`91C7(UR(2_NQ
M_=0FE1_(B[>CQV^EU#MZ0#QVUG(R:4T-W4@:`VUO!%4?'\C/Z!Z1^M'T&]0_
M1T?3Q^SJ3%I23DZ1KJ_+XD/\82Z3?=O?2\S\62^/*AQZ<0F/7[C$F/7RE2R%
M,-(I>^U)MFU!!MD&+GG,0V;OUH$ZJZ#A@Z!;H23(43];B\7Q]SLFYSEZ_9CR
M4,E05G57?;\9TUK]B2^TX"?/Y]K\RWP=R.0^'N8VZ-U1_E.:KU=/M6M27](-
MTTQ$=Q$I1W#Q`=P]7I\/'7'PBDFXU2?GU7^D[N,7M2FTY+Q71_Z#X9$##N)C
M;^.P^'@`[;@&X#Z=M2TZ-)M52Z?"O]I$;<8S]QZRUI7PK3I]QTD[5:_9FS-G
M8(F/F6L?*1TVR;R;-N]1:R\2L#B,DT$W":A4GK!P`*)*!L8AP`0'4N,7-SDD
MW5/Y-=&9W'9V?Q-Q7>-OW;$_;G;DX2<7*$TXRA)JC<9)ZKH_$Y$NB"4')D*)
MC^7%/P*!MA$VS-4``P@`;[ZJ=&ZT53$V_O\`M;UJ8[_S8)P#K@)F18H*DWYP
MY_)T+"`G)T0F-"]/@`!T@'H^AJ"?"AYCYU_^]6H?LF,1?G)D#0&0EA/^HWB;
M]3.A?I4B=`=OD6_0.+Z;.WRT&D"UVLLAD9<T5$R,[)@U!=!MLPB(ENYD)!P*
MK@NR229U#!OL4=M(J4[BMQZLIDVM:I176INT2[PV1:K7;K6Q>FKUIBFTS$'E
M(F4@Y0S)VD"B0R$-,M6,G$N?49!PD14OH,4!\-57K<[-S9)?I2I5!QN0]V#3
MMOI\2%OO;-7+ZP=J)JQ5,9X/=8XP+@P3,GYCUJS>3#M\)"'V,?W-LD*I@+X]
M!1^AJD$ZV@(D.[-1J5?\6XN@+>TR<!QS%7I**MF,<1TC+,CC=6.=1SUW?)[Y
M92,2K1JM#((`1U.,'2+E@"Q3!OL`#3/!R,Y?[ID7L=Q^KVVEN^=4S6\C>Q[&
M/'\4DZWE0E?C$#-VQ4Q.50"=)"'+O[9$B%2(<VXB`"<A`'8OLAZA'TC*2BE"
MKE)+5OJW\39.CDY+Z71K[D=AJ0<9PW(N10IQ`2G34)TF*D<FRA!(8!*JFH00
M,41`0$!`0'80$-`847=$[>&4NWIRC4[FW:46D8Z?HSF5N/*#`]92;2U?IT/9
M3/#3]AAZB"B03./;283IS58;)JJ19SIR+8$$@W2O)UZ]"#(>[6'=*PMW/<'M
M[Y15&53RC54FL9E[#KM\52<ILT+9N<LS#>:<CFP8]G3+@:.E"IE*)NI!4"KI
MG#47(*).A*1JRJ^(&I`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!XS(_P#4\OG]
M)EH_.-]H#$`_['_\D)_[Y]`98_)3[W//WZBF5/TBSN@/#<'/O*>'W[%OC]^M
M-4M`72:`:`:`:`:`:`:`:`:`:`:`:`:`:`VU%`3*!A`3;F`H`7;J$1^`!$.H
M?H>G36FFH(L>ZEW0,/\`;3P6[NUA-%V_,]P(XA<+8A&122>VJQ*-3F3F[`BB
ML5_%4&%5Z!?OB$$ZIS)MD.I94H%EJ48J;3VMH$)W:W[6.;N;N9Q[IO==3F[A
M;+$]B[+@?!%Y:'C8ULP9*@YK=IMU%<D%.N4Z"*'3`5A=NF904BOGP'.8OFUN
M:Z+0@S`2ATE*78`Z2@&Q0V*&P;;%#U`'JU;)-6@&@&@&@(8>0([][WMW?L.N
M;WY[X?UA33>?CR71*7[#'FZY$(^,UI]WC]Y,VGXD`?A$P_5,.LQ:HR*UU->I
M`T!H4_(U/#J]@WL_#[(^'X.I77R#VI5E]/C\BR]CGXS7EF^P&-2OCE%U2&-M
M>W(V)9\E#8+!&O73")9Y59"K`/G*C9LY,*#T"KHKG!NF<PCTAFWKN#=M1M1A
M2^GK*NDO)M-:-=-'1]:&):A>EG.W<OR;<:VX*"VQ7DWNK^IEYZ/2**0E^M%,
M@E]/UHE#;T[CZ-84M6S+]7\=-_C3I4W-0!H#IK$NBUK\ZZ<*`DW;0TFNNJ(&
M$$T462ZBJ@@4!,($(41\`$=`8Z/S7%XWD.WSE]\T/YK5[S>S\[:J["4%6SF#
MQHJ@H!3`!BB=,0'I$`,7T"`#H#IOG8*@)]JD#BD*VW)3$?L!XB/^,M_'P#X?
M#0&0CA(0-AC$9@#8#8PH)MO6&]4B1\?I:`H+S_85F4XA9XB[B^L<96IF@24%
M,/ZI2;5DB;;-9EY'L$U&=$I$Q7[5:.EXLD*C1F\;J*(]0&$R?6F?(Q+MNQD0
MO7%6,7T75_+[/T\3$S\>63@WK=MTN2MM)^";6E?T^PZ?MVQ2<-PRXSQ+:Y2^
M06D5BZ)9-[K/5^>JDW9DVJCUN5_*5FT24Q8H)5$/L`-GCE19,$P`>D.DA+_(
MY%C*R97K*E&$I:1?5:)?KZ_:8?"<?E<?PV+B9=Q7,FUNWRBZQ=:THW1NE41[
M=[&T1$-E+M!P]@91J\)+=S;$<N^>2LZE7FL<%3@IZ2;.%I)R)&J*"3U=-P8#
MG+YGNP)!OYH[8!MFTE5]$3O)O4E?K`,(=8D`P=`E,(&Z=P$IQ`0]>IFI0^I/
MI4MN]'<U&K45#5=/6DXT^R2K^\H5FGCK2L\C7E+G*9`8&JSET]@1HN2[KCL&
MSYVI''^,)`E.EHM*><-"QXE13?`X;@1=4@IB!]PO6,AV8UM?Q=:EC-PK6;:4
M+NNV=4T5Z;I"B3H'IV+L!-NH1Z"ATDZQ-XF,!0#<?$1]>K4MK=5U?4S*).B^
MG2GW&\([>K?^]^%OJD%#KW=K%+3I,;XT(BI8EB%4L]E5Z31])BU.@16.82J)
MKSRQ#_8&XE$2B(&,&J]M-7T![.FX]@J/%*1T.@"JKU8[N;E'V[B3G9%<"E=R
M$DZ4%11PJN4H`!#"*290V*7;?42EXL4H8C'=#[9.>.W7FEYW7^TVG(U1Q`NG
M\[R-P!4HWWR`;5052RMLLU=J3<"$G<8S'Q=[Q9(`-RQ9A]_CR%*"A4$)?W_I
M!.UVL^Z9A3N98';WVF'0J^6*FDQC\R8@5?IO)6E3;@!(25B55#$<S=$F%$S&
M82`%';84%=EDQ`TRHW6/T@E,U0!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H#QF1
M_P"IY?/Z3+1^<;[0&(!_V/\`^2$_]\^@,L?DI][GG[]13*GZ19W0'AN#GWE/
M#[]BWQ^_6FJ6@+I-`-`-`-`-`-`-`-`-`-`-`-`-`:3'(7ZXQ2[[`'4(!N([
M[`&^VXCL.E&")[NM]TW#_;.PE\JK0=K<,TW)I()84P^@\\MW;9-H*;=W8;*L
MA]GA*#6Q=E4=O!Z%'"I/=VXBJ<!+7&6RK:TH$0T=JKM2Y;Y=9J9=VCNBMQMU
M]R'+,,DX4PE.,!&,9-ERMW=1NUQKKX%FL-6H-B*!JO6]C`@@BB[="8_0GK*O
M9D9XD+,8ZKK\/T\09>J:*2/6*9=A4$#*&$QC&.8"@0#',<3&,8"E`-Q'?8-8
M0-W0#0#0#0#4/H"&#D!^_>]N[]AUS?\`SWQ!K%?_`'NQ\G^Q&+)I9MB+^JG_
M`+DF;2^L+^#^*.LF/3[7^TR8]/M?[3<U42-`;:P[(JCX#LF<=A$0`?9'TB`@
M(!^"&@I70B+AJ7;5>YS*7)SQ9FHFL!7;!'Q_)5H";5Q,O0Q_7FSQ&V3$;EJ4
M1F*(_P#))'P\0[J3([.20,Y374Z3E-L5#"6#[]5[E:?Z/G0U.#*_+F;LYP?L
M0MI*33HWY+^S]9+F@`%01``Z0!,@`78"](`4``O24`*78/4'@&M=IX:(V=MR
M<$YIJ=-4_,W="L:`\K>EU6M(N+E!8K==O5;"NBN<O61!5*(>*)K&)T*=14SE
M`PATCN`>@=`8YOS5-=9UVV\@NW#I-\X>\PLROG#Y%(J*+UP\J.*G+AVD0I$Q
M*FZ64,H4#$3.4#``D+Z``WOG6@`/:R1Z@]D.2F)1-OZ`#XCR!XC\`;Z`R",)
M_P!1G$?ZF-"_2K$Z`YF3Z,7)%.F:6I8KI3R3S)5C\J\=6-U4;O7E#&342DJ[
M8VG4M%OD5$@V/T*`8HB4Q#%$0U=M3=N:G2,DO!^)1?MJ]C3M;I1DZ4<71U.N
MQ!CI7%>/J=0E;?<[ZI4X<D6M<\@R;:8N-E6\UPNO+6.2:L(UL[DW2RXB<Z:*
M1!`H;%``#5>3D2R;KN;803?1>&B6GW?M+.)BPQ+$;2G.<J>/[S&N^=&)%7I7
M;91.052*<YZT0R0"/V0!KRXB40#T[$W'Q]`AOZ0UCUIKY&31/1]/'Y>)D+4&
MU3T#BR:NN:K)7(=6F/<AR]NNCV+=T2J1=2K-DGG823\;.5B,?$Q%0;I'<OU.
MAJKY)UB&*GXC=_$QR&DXN,*+JFOAX_M^9T/<^/PUOE8QX%I<9/'Q6_7&;WJW
M;]Q-Q;2:DI+:]8]&4%CN['VQI*(4FF7/OB.K&(O$F"BYL\XZ0.#I9#WI-,K5
MQ/(NSD%#QZP3$@>@1W\-6J4T.<C3;IT/5,>YCVZ9(YR,^=W$!4R;9B\.!N1F
M)$0!O))'69G`R]L2*854TQ$2@(F)Z#`41`-"H]Q&9YK?(.J,I#BKD*B97K,[
M+6&N/\P8]ML%<Z34'=;>!&V!LG+5]Y(L)&T,'"I2%:%5`Y>L%=NCI$:HT3U!
M7*BTB'H<"E#18+N%3**.I67?"566G9-90ZKF4E78?9'+E=0X[=0CT$V*'@&H
MDW6H1;ERPYNX5X:*8C3S`K*D'-%\C<>U(D+(T)!V68E)ZL5M)XO$VZ\5*9EX
MMG)V]E[V:&;2KAF@<RZR)$2"?4*KZDT9=JY:HK(K)G2!0%BB10NP#YA3`)!*
M8#;E,7I,/@/@(>'HT(,.3N?]K#/O`+/JO=9[4+#X@&I/G%^SUQ[KB)VD&FS(
M[;N;5,5FHPIX\]EQM8V9EE;'6T`,NT)YSI@4W4*1+D6J49#\R>?M;]T/"7<Z
MPF.1,?O4JWDJJM8EGF+#K]RBM,8\GW22R8.6+HNWR@IL\Y9+JQLB3<#I%\M4
MJ2Q#%&EI=$0I1>B>I)^`@/B`@(?0U2551]T`T`T`T`T`T`T`T`T`T`T`T`T`
MT!X/*;@&>,<C.S>3TM:';W`^\.DF3?9"OR*H^>]7W0:([%]I4_L)EW,/@&@,
M07K_`,;_`,9_[(+U_DA?T3_RG\=Z-`99?)3[W//WZBF5/TBSN@/#<'/O*>'W
M[%OC]^M-4M`72:`:`:`:`:`:`:`:`:`:`:`:`^&$0`1`-Q#U?#X^@-]@W$/1
MH"*GNH=U'#O;,PR:T69-E=LXW1A(-\(X59OEBS%SF4#H-S2TP=HV6<PU(B%G
M!3NW8%\QP8GN[8#JG$25Q500V]K_`+2^:^6N;1[H7=X^-KUE&U+Q]FP7Q\NZ
M**L'6(1N8DE4K/<:L`E9P<1!D=@->J9T$",^GWJ024=#MJ9T2HB#+D01*@BF
MB0"E(F4"$*0A4R%(7P*4A"^R0I"[``!X``:MDF[H!H!H!H!H!J'T!#!R!_?O
M.W?^P\YP?GOB'6+_`/',?_5?[$85W_VIC?ZK_P!E$SB?UA?P?Q1UDQZ?:_VF
M;XFO50&@-M8-T50\?%,X>SOO]:/HV$H[_@AJ5HTWT"='4A\H\I#NN\9FB'/0
M85&TP'%>D&'(Z^0C)34A6YAW&J@R8XN8U]HQ6#XY^Q/)=P_=+(ID;I)%334$
M@=/^&MOMC\2GZ7D4:I\.KEX*G14U?B<G8YA1[SGP3\;'N=?W$P:7Y&G_`"!?
M5MZ@]6N8E1MM=#K*UU-S4`:`\7D?PQY?1^"EVC\XWV@,<CYI]^]C6X/XGEEE
M8/\`\Q,1#_?Z`];\Z1,@7MJU;WHA%&IN6V!DW2:I`.DHV53N:2Z:I3>R*9TS
MB`[_`(NV@,A*AE;$HU,(S*0C0E4KI&I4@Z4BMBP[,$"I%$`$J94M@`!`!`/5
MH#UF@&@(">]54ZW>,]=FFIV^%C+)6IWN-5UI,0,RT2?Q4FT#'=G6]V?,EP,D
MX1!=`AP`P>!R@(>(:`G4M=1K%[K%FI5U@8FV4^Y04K5[76+!'M96"L-;G6#B
M+F8*9C'B:K.1BI2.=JH+H*D,15)0Q3`(".@+`R=G[M8D,F<O;ZXD`9+I\L1P
M=1#=($$#%#VH<=R@)0\!\-`:G'9_[63I99POV^>(RBSA=9PJ;[1=`*!EG"AE
M53@0D*4A.LYA'8H``>@`VT!'AV%<=TG&.6>\[3L>4R&HU.J/<[R11JI7ZPV;
M1%6@JG4:M!-*_6("MLCD8PK*!;.S=/E()E5*N4.H_E[$`R*]&Z*H(M^Y6-W.
M?C"VJ,)G5\U3SC7Y:?F,0XBP/ENO0;.,FZV+=7)2&:J7;'-1B7"[CI:RT&O%
MNV9@55,N)DT2A=MTN:5HBC(O^Q;<_!$HX#N`#\(`/U0U;>C*HO=%2\T<9RU1
M=D42<)(KHJ)*(G171(LDHDL0R2Z2J:@&*HDLF82F*(;&*(@.^H)?0P?^YKPE
MO?;1YFU_FCVC$;XTN;Z*N5WY!\><8UIU<:?0:G&"VEK)892M-&JD7%8EN(.A
M(]B5O")>!Y[(6X*I^3=A3Q,:%%-M=:?O,DKM;=T/"?<YP1&9#Q^[C*]E*MM6
MD?FK#RDF1Q/T"QG(*?OS-%7H>2M&GUDSJQ<D!1(H3=%42N4E2!3*-.I>6K)0
M-4%8T`T`T`T`T`T`T`T`T`T`T`T`T!0SE!U?<T<B.D-S?:,RWT@(`;<WR!L&
MP=(^!O'U>O0&,)\6XV]VVW3\K_BFGN7^3RW]!/QOU_7?%N_1[[_\KVZOQOE>
MO0&4%R5$`XY9_$1V`,)Y5$1'U`%%GMQT!Y'A2R>1O#7B5'2#99D_C^,N!F3Y
MFY(*;AH\:XKJB#ELNF/BFL@LF8ABCX@8!#0%S6@&@&@&@&@&@&@&@&@&@&@-
M!U"I@`FWV,8"^`;^([[>`>/B(:`Q0.Y?\Y`><6>2,O@#BQBRD9H1Q5,R%>SC
M<L@25GCH<EX*FLT''V/25M1-R^=59^HD$F_$KI!1V4[)`@&W7*!QNU9VL\Z\
MF,P_NI_=;"2O.9K6[CI["&$+VR22;46+;"W>U:YVNHK)A'UPT&W`OR<K94")
ML"B#YVF+Q0H)@990!MM]`-MQ\1^J/B.@/N@&@&@&@*6V_..%\?W2E8WO>6\:
MTS(627!6F/*+:KQ6H"X7ET=VC'D;U&MRLDUF+&L=^X(B!6B*PBJ<"![0[:`J
MEH!H"%SD$LE^[B=N]L"A1<?<;<W5A1`Q15*DI,XB*FH9(!\PI%#$,!1VV$2B
M'I#5B27OQ?BH_P!I@W/_`&EC/P2E^PF>3-[(`)3@.XAL)!^$?'PW#8=7_$SC
M<W#Z/U!_P-`.H/X[_G3?X&@*?Y.RMC/#-/D;]ER^U/&=&C%6C:3N%XGHZKUR
M/7DG!&;!)W,R[AHQ;J/'2Q4T@,<!,H8`#Q'3H#QM*H.&9J=+GK'\15IV9R%%
ML)E+)D&NC(&M<!)0C-G'.(^>;KK)/JY(P[=N=)%(YF1C%(L1,%/;'(>1-VO9
M;?M5JHUT^[H6E8L*]^)5N'XFE-^U;Z>6ZE:?"I7$N_27<-AZ0W`!W`!V\0`?
M7MK'?4NFK0&@IP/Z"G#^2(8G\L`#H#Q^1]_M>7S8-Q^1EHV``W$1^(WVP`'K
MWT!CC?-/#B?MCW$1V';EKE<`,7ZTY0H6(-CD'8-R'`=P'U@.@/7?.D7*+/MK
M55VY5(W;M>6^!W"[A0P$3;HI(W4ZCA50P@5-)`A1.8PCL4I1'U:`GCP9D['6
M7<4TN]8MO%6R)3)*&:-&%JILVPL,"]=Q*1(V4;MY2,6<-57$=(ME$%R`;K16
M3,0X`8H@`%5%52$`!$#F^@0IC&](`([`'H#?Q^#5%RX[:W4JAL4W1NC/.6.;
M]Q9$2:N6[-[(+$;-7;T2^[-`.4ZBSY4HJ$ZP;MTCB0HB!3K=!#"`&WU1<NVK
M+49SC!SU3DZ+S\2(J[<3E:A<N.+2I"+E+73Z5JZ>/PU*-6[$>"LNSF-IF[05
M/R;:,)7)EDS'TQ,NT)V?I5Z:1KF';7",*T>@$=*%CW"J!3"GY($./L[AOJJQ
M>MWFX8]RS/SUJ_U,O9&!EXT5>RK<K4?_`'V$X_M:7ZBXTIP-Z`';;TB&P?2^
MGJX6C5H!H#'8[+F3,<,.6O>CQ(]OU-:95G>Z-R#N\)C5S9H="^2],C8JG1,A
M;(RI*O"SK^ML90?=EGJ2!VR2_L&.!O#0&1,/H'Z6HDVHMKK0+J4.S!@+'>:W
MM#D[RSL2[_&]@3LU4<UZ]7&E*-I(%F:BR<C\DYN').1;L&*95VCT%VZJ8&*)
M-C&`;^'F3LUI%5?FD_NJ8>9@8>:DLN4U%?W9-?L96XGL))@<0$2D(4QO#81V
M`!'U>`CJU)IR;72IEQC&,5&'T)47R\"V#->7K`E+)X=PRS)8,P6)GLH[V`T)
MC2(5$`6M=L>`)D&JJ2!S"Q:F$%7*X`!0-Z-3#V)S]N\VE2NA/P/7X?PI6\25
MYRP9JN+)9["9.0O=VGA\^>N\V=+RW$E,'5,L";<"&,1%J`>4D3I+L.PCJ%*&
MYVX=%^G7S%%U\3$Y[HW;"SMVZ>0B?=J[5Q7=;95R85LG(7CY4H]V\CV$#(.@
M6NEKKE78%,E8<:V5(3?']=3;F^*%/\<60>6"B:%U-/TL12W$@G:][^U"YG9.
M0X_9_J=7P=F>[@25P7\G)^=LU'R[&*,W;YQ68B6EHUJO%WF#8LC*';.A2+()
M!NC]GZD='&G3H1'ZJ&1L`[@`AZ_'X/PA\=621H!H!H!H!H!H!H!H!H!H!H!H
M"A'*7[V3D9^H1EW];^PZ`@)Z2_Q)?_9DMOK2^C^)]'UOT/1H"?[DU][=R#_4
M0RO^D.?T!R..'WO&!OU&,7?I'@]`5GT`T`T`T`T`T`T`T`T`T`T!L..KI#I$
M0$!W`0+U["780W+N4P@)@V$`$-P'0'Y^L!PQK/&_YQCA#`=DG6F:*S-Y]/FI
MRYN=8C6[A>1R)CG(>78UE*PA%Y".?*5&U((JMW9RE,=RV36$H'T!^@8DBFB!
M@3+MUG.H;Q$1,<YA,8PB(B/B8=`;N@&@&@&@&@+5\T<*^-O(/,N`\_Y:QY\J
M,L<9)QU8L+V@MDM</\E99V_B)51PM$PDW'0T^0DE!-5R)R#=TF0Z?@78Q@$"
MZC0#0&#C\Z+R!=\7\R.,EUQ[>KUCVT0?%FZ^X6"@6^P4Z;0:2>27+>79)R=>
M?1[TC:3;HID6(54@'!,O4.P:QYK=)2\:(Q+L5^)MW?XX=/MT=?,TT;LF=[2_
M5NI6!GW0CP`62I56TOX.P<@N7#*S5M*R1",D,4[BDXQRU=.HTKHJ2BR;T43N
M$SD#I`O4:[Z_-&7H>C<]A+OH$.F#+NG0SA,4$#JF><E.8#0Z;HZ1#.D$R(5U
MX55!NN)B)JB8AEB`!Q33$1(5Z_@-#C.^Q#WT&C55R\[IE6:MFY.M9RIR<YA)
MII%`.D#'.-5)N'4(>&X"8?#<-]]2MWC2@(R<Q\3.76)>>W$W@3SXY07CDOCW
MD#<<"VZVUB'S=F^PT:7HMRRG/TM"*DV60R5^2:SJ2U7<KD53;"*!5$CIJB<!
MVJ!^CSCR@5?%E$IN-J2P-$T^@U:!IE6BS.%W8QM=K,8VAX9C[TZ.JY<>Z1[1
M,G6H<RA]MS"(B(ZIV1![/570'P1V`1^`-_#Z&@,76\=A/DW/6.T6EKWCN?A'
M=GM-MM1:Y5+"M#5J':3\W)O8^L1!W624U&B4`G((%3ZB`D=%L8`*41Z04J7[
M%JW=DU<DH)+K\?+0I;R#[,N2.-W#?DCF.Q=V'N990R1BG%^1+W7EDLSK5&@2
M*L%63K-ZY/5$R5ND9*/+))+$<+$E$!,BITF`O0)S7&H;:JE?F8URL9TBZQ+S
M/FR6'I'%':_@Y1V]CG,?F'-^5\KUUHR6>N7$/!KFKN/4XV8<O4$16EC2./'+
MD_E"HB1)PF0AS`7?5LJ+@>]?PRRMW#^&RN`\!2U/;Y"KV6:GD](+DZFH^MS"
M5"A[45Y34YZ'BI9M'6*>7F46[<7@)-$Q.8RRA`#Q/5I190YM0FXI;Z4CN=%7
MYHQ-L/8[[]G#R`MG&C!&;Y7$M"P!'9$OEIQG`/>-LZPJ<8SEJG;<BR,),VNM
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M,.A.-IZ`@[C6DZAB['UHEW;M_)5<JS9^Y8`DF1NJ)'!"KE3/J.:X#C^:A&WR
M:G)0Z*,G'P\:=33\A'N?\G^ZG9XB_?Q,]XF->A)QM.6W)QX7&U.$Y2BI[V]O
M5)[6D4<YI<%^\+VO<75_FO=.:N%9!/$V2*VTK*6%(R797%.?NXN:^DG(-Y;$
MM2A)^I.TCB62CGKA5LX3`H^2<Y0$,3B^V>&X:>_!MR4O\4G+]IK.YOS)[T[P
ML+&[AS;F1:7GI^LSQ^/EDF;C@S"]NL3L']AMN(<:6JPO_)1;B_GK!3XF2EWI
MD&Y$D$1=/5S'Z"%*0N^P``:WYPQ6/0#0$;U:[97'/!^>LT\P^,M7=XTY7YO=
MVF6OMYE+UD>QTZZR%PGD[//M+30).SOZJG%OIE+SDA8LFZL>H/4V%,.HAKMG
MV]_\U-P^!*I1_(N7PUGMEDDE@J]ACS5#+V/U6\?D?'+E0BDA$KNC]#"PPY1,
M"DK3IXA!69/"B)>@>@X]8>,7(Q5?;>G@RAN2M*;3K4KH9_T`<RY101*)Q\XP
ME.D"90WZU5"B((!_):MPG&GKT9-RY8MQC)RWQGI51TB_)EO.5,O3JMB:X=P[
M[K+92F&J#J1DUD#.H''4`Z*J![#8E41,'OAN@?=&PANJ;T^DN]RBZOH*./IK
M5H]UB7#E:Q)!NVD8=U+6.=??'-SN$J?SIVW3P@8#2,JN(F`R:13B5!$/L:)-
MND`-N(Q6OH_A7[_B5Q52W?*-USO&<P>/E8JCQV.$K-4K4ZR)'L7>)RD:6*,3
MD',::88V65;9-DF4JDJ@BDM`M5DFBC01/U%55\N\G:A;I.+W/1/R_3R\^IBS
M=Z63&W;DE:3]2:57\B]LZ;=RU.5VDFLBX1$CI-=,JB"R*I.A9)9$XG2,DHD(
ME,4>H!*.P[AK'<J24%XU,A:R:7@8#'9WXGQ_*;NHY,RM7;@TQ]2^%F9I_,]:
MJ+.GIN5+DTMN:LQ0454@<?&+!&HQT/'M`Z!;I+EVZ"BGL4!"]+I1^)$?K^\S
M]M6"1H!H!H!H!H!H!H!H!H!H!H!H"A'*7[V3D9^H1EW];^PZ`@*_]V3T!/[R
M:^]NY!_J(97_`$AS^@.1QP^]XP-^HQB[](\'H"L^@&@&@&@&@&@&@&@&@&@&
M@&@,,'DD;;YUCQW+M]<\QAX_!MQHR,.@,S[0#0#0#0&VH<4R]0%ZO'T=12[!
MZQ$QM@``#4I5#KX*IMMG2#Q(%VRJ:Z1A,4JJ*A54S"4=C="A!$AP`?#<!$-1
M1KJ/5_$J,Y&@&@&@,$/YV-]\YQ__`&*EJ_7,?ZQY=?L,6[_FK[/VF;-0H=K)
MXTQNL8RK1^ACZKHLI1F8$G[$KBO1?G`@J)3%$B@IEZB'`Q#;>C5^FAE'HCV%
M6)5^+9E(57IS&3BW+4`%"7V1463][$A/(@G)BI])O>!304/^1&,(]`2DR&Z'
M*0A57;@CZPF;2#ENY46CF::)BQT60#D%N8J*IU0=R27E@(N3AN4PCY8$#4?,
MD@SY"]OZ@\P>\S4LQ72]W*JR7$3CMQ1RE4(2JH00,;=+ESSR(ES1MK=RD>]?
M%B@=5-J`$:&1/TF5W-[6I;2U>B(=:::LGR$XAZ@]6VYMM]P\?5ZM4J2>K^GP
M?F'NVUBJR\5Y&L/0&_A]#4IU5256FO4TB;VNG8!`0#?Q^'</1\'AJF4G&25/
M2_'R(JNB?J\OAYD:O;6Y?7[GE@*[99MU;J^.)"N<A,Z870CZ<K*/BK0>*;N-
M>AY07<RJHJC*2\8!C.^D.A-<0%$"@&VB<VY)K:E)KYKS^%291@WUJE^THCSW
MP+E2D8![I&77V>Y>>P_EGC+;BU_CVZJ<(K&4NQ5[#=.IY[HROZPGMQGC].J/
M`5B2&^+5/>RKB'O0J'-<5.C=$3%5]*/(]ERVQ^+NS-QOMUE7=L8=C5LB3CMY
M%Q4Y8W[6.?9>N)2BA"U>.EK`ZD`1<_D39LJLF<-Q+L4PA<MV)WI^W"E?,S,'
M`N\IFQP,!QG>DZ*K457YR:2^UKR/:<R>0>#<HX=J5:H&>WV&&](RGC[(=KM]
MEQ'R&CXYOCJDR:TW>(E1_#U",(DZG8E)1)59\=1F)#JF6#<0.7;\?A9>(Y;K
M3N0H].GCUU7AK7H=MC_E;^9>3F6L/@,&QD<A<NP4+4IV;ONNM-L(1O1DVVU1
M:^5&V1'Y(I$"_P`K<G)N!RASQDZ_8<7YV3I-K85#-DF\R3(6%KQ:+5:?+.%<
M-O$IF*M_Q!,G4*D5N=R2!1*LLB#9/S<B=RL(VU[54XUU6C2E6CK7TMT76E=*
MGZ@]@=P9/$=E=I\?G\=V3_4\/E^+_%6<F]QT7AV[-SG7?R85Y"$H7<=7L91<
M]VUY=QPA-W);;AW-UKM?&1K<8IR8R,V:SG<50;7B_83SA,VJPH99PK5X3&LK
M/S1<5Q"3XUQG&BK!BL1LD3=`I#@78#&HL*EN6Y6]S=K^**2VR;DNOEU.-X[C
MLN]B1R,I]N<?>N6NS)2QL;DN+MV+;XWE,F]G6[<'FW'!8UJY&Y.+G)TDVMW1
M2B=O7.N,Y"J'PJ>6GH/*CVVYKR!'4JY4+(-$F):F)Y#,JK8H4MUJ\`WF(U!*
MRL#*&;**F2!VGUE*(B`:[.LSC/W4E[=(JJ:>M/@SY4_YD>Q>YH\M'ONU9L7^
MT;>#Q>'/*Q\K#RK=O)_!*/LW/PM^Z[<V[%Y1WQBI>W+:V6._.>!V[5%S'X,V
M81'ZEF7UKSY8)H>+)-N-''53?Z[`N'R[;>CIH$".^_T>K0%>]`-`?!#?5$XR
MDJ1=-0=`>M0H32]F)$Q1;"O%%AEIPL>T+,+1*:WO)(M:3!(KQ2/(YW4*D*G0
M4X[[:NQE14>I*<E%*+]2::+#,LY"L-NSA8\.8JL<3(9+KL"S;249'V=H3[5=
M6ND2V=/;=D>L)NEWK09INQ*6!<.6OD+BJH4A@,;<+-['=V%(SVRK\_F;I<AC
M6^`7$6L>"RI7-URZ]=U&VE%:..C:>KKH_`NWQ!AVJ8>K:<-7DUG;]V87D_99
M(QG$_8Y%;<RCN5>JB==0$^H"))=7EI$*``&_B-Q5C!0>K22^XTLJ;GM5(U*L
MJ%ZBF#?;<I@W\?6'T!`?J:+1U"="++-<78I/N.\7CML-W6?K]1QM(R2V9HFN
MO9"E55_,K7U@M7K!+I5E=A!O"I,6ZJ0KRR)UO?RE31*(&,IN\">,\7)A?V^X
MX+96E:UU2^SR3.>Y>WG?CL2_AM^VKLO<276-$EKT6OF2B)$$&Z1`';I*4OL>
MUL)!\!#</'I$/$-OH:T<&W.3E]-=#?R;W)]*]48<_P`VZ<I+\Y^Y48KU.06,
MPA#K/TV@QX21E<^9K`9+W(R:)FH.@`#`3I``#;;?TZOSZ%NW<W7&J>9F2:LE
MT:`:`:`:`:`:`:`:`:`:`:`:`H1RE^]DY&?J$9=_6_L.@("O_=D]`3^\FOO;
MN0?ZB&5_TAS^@.1QP^]XP-^HQB[](\'H"L^@&@&@&@&@&@&@&@&@&@&@&@,,
M3D@!0^=7<?.K;J%[BSR_6.WW-&2.O;T]/JWT!F=Z`:`:`:`IIF)\RC<59&D)
M1VHPBV-*M3J4?)-Y9VHSCT()^HZ<%9P*[2<>@DD43&29K(NE"`)4E"*"4P9&
M/%2O1CYLL95^>+9=Z*JHJOW%NW;V;R;;B=C-.8C:7$O^F?!5ACZA6/'-42(E
M8)%NBI&U^V34[/+^\(HE45?+K@9ZJ<ROEDZMM9')V/P^6[?P3ZI]57P_Z3$X
MKDOZKB?B]:[I1U37TNGB7J:UYLAH!H#`_P#G9:HI<G./^Q3'-]RK:O9*03CM
M]LR0#U`/KU8EU^PQ;O\`FK[/VF:]CQ]*.J!0HF&;';K-:)2PD)B19N"L&GFU
MV,.*$>F<J02\@")P-[!O=T]_;/U!Y8WS)=>B*AMH".;MWK<[?WT93<99=^4K
ME:4,)1((O1,4$S)@41`B92E23*.Q"E#PT%$=2*<Q6Q741*]GX'<RH,P%1U/Q
M("(G4*S.H83S3`@;]"`C[TG]:050V*66Z_,A)IT_A,;WFGSGSWQA[ZW&/#^'
MZUCZQ53F'A7BUCN_IW>)L!;(QK#7/6>V[J1I;QM.0$?%2J+*==',9^D\(840
M*"75MJ&E);9?2^I+K33J3LXOSP_R/DWD30$ZK[HC@BZ5>I!(IRA5E[$A8*DV
MLQY--LHW13;.&QG`(@EUB4W2([@/AK1<)S<>4Y+-XY02MX5Q04E1U=*I4_?X
M'2\QV\^'XGCN1A)RN<E9=Q)^%)[/TJ5_<3J*;-%9L@X?N'`@DDT:E`BP&W$J
MIU3.!(FW2;B40.<X[=6Q0W,)2CO$W))TUDJT5&<Y&+E39JI-I/SIU^7GJ4UI
M66V5UR%=J=&)Q;MI38:IO'$S&2QGX*2<[*6F,D(=VU.R:+,742K70$0.`"<%
MM]@#81T^)ROXOF\CB8I.Q8Q[=S<FOKG*XG%KKHK:=:>)O>0[<S.-X/%YS(MR
MA/+R+EN*DJ;H6XVY.<7XK^8U7Q:TZ,A\^;T2D>GPNRZS5?-2O"\ZN8)O=#.4
M1=]*F3UA3$&H'%P('#Q#V?$/1K:QO.>V-UQ60X;MJ:;VUI5I-T--<LPMI.S5
MVFM71I;O%:]:.O330O\`.YX<I^W3S34+N)!XVY6-]:<#"4*G(]0=.P'`=@'P
M$/IZN4@]+CI!]2VHN?IC+:Z/75T^-%5D:_8^Y$MFG$3BMQSDCQ;*14P?`V3&
MB1HJQ.%;<YD)[*=EO;-Y/-D5H"'48-(])1J14R1Q0%3I14`!VU>'R%R?+7^*
M:I<QX;I5KI%OK7H]6E15?PZG<0_+SE;WY<VOS$XJQ<N\/C[)Y-Y3MQ]N%W(C
MC6W[<I*[)2O247MA)K=5TCJ2:\R,G0T#Q[L+2T8QO&1JAD*PQ&#,J5FJ/3L[
M-6Z=E8ZM-L%B3<-"+**-&C>80*D='H$3.TE!,F`&$O1X-QNXI1:A))ZTKK_T
M/0YGB.5RN#YG"YW`G:L<ABY,)PN3AN@G&<9IRBE)M)I.FUUIT,4R^\5:16;I
MR*A8SBWS/BF&/*'EV0@8I_R8J#AW27M7)@1&!L=@?ES0X3GHR"5NKTSEJU,\
M6<EF6I$DUQ;K&;Y$L3&FXSWR=7%5W3UT?15^ZOEJ?M;V1^8O-<MVKVWR,^Y^
MT[UWD.3X^S=N?T?)2R%?7*RO8MI/C_Y=V2Q;<8W9.-N+Q;SE<C[D%<KW*=O;
M"3ZAYBMZ]?Y(8JL-2J_<!E(>@6O.TS+SE3D\`T'',OC%I-.ZY:+)7I?XKDYQ
MVZ4%M(.D'J;L@*JG*0I"TV,6UNBO4TY6DWNE_$Y)TK+Q2TK]IS/%?G9WGE]P
M<+Q%C([>Y;!RN0[/L3RL?C86[61'FLS-LYDK<;UFS=M[X6;<(JY:MRM2@W&$
M6VW,#VO^"G'_`!`G*<A*FSOKS*"4_FG%"$O;<D6VV,F=/;Y%]U!DTB)B07CD
M':C:K,B*.`(*JGE"(CN;6'E1C;N;85VN,>K;UIKU;\3X[_YJ_P`]/S![HG:_
M+3E)X$.U7C<9R$K=C#L69RR986YRE<MQ4W%2R+K4*[5N22T+=?G0*ITNU)<3
M$(*AAS?@\H$`-]^JS.-]PV'PVUC'Q233<5C";C1QTW$?'`.'#=.^X`)J!!;B
M'J\=OPM`5^T`T`T!I/T])NK82](]6X;AMMX[AZPVTZ$I-M)=2.7&O!Y_C7N.
M<KN?)LB1\VUY)84P7B)CC`E97CGE2##Q'GO\^[N`S+Q*:"=%<@I-BL&ONX%'
MJ44\-%.VGK):DQ:J]5H2(MW2"J8>6(@)``ATC%,"J0@7ZTY-MP#;T#Z#!XAN
M&IFG%UET?W%-4Y;:K<U6E3E`(&#P]`_@:I33UBT_D2U31FV*9`WZ2!X[;[``
M>!0$"AMZ-@`?#4U?F15K5*K-12@4``"[``;!Z]MO1JEN2DDEZ?,5<M9=3#%^
M;/B0_-7N-F%N*2Q("I(F4V``,D&<\S^64?QQC`7UCZM@UDW$U%/P_P!!C6O\
MU_;^TS/=6#)&@&@&@&@&@&@&@&@&@&@&@&@*$<I?O9.1GZA&7?UO[#H"`K_W
M9/0$^_*-8S?C-R*<%;N79D,%9<6*T9)E5>.C)8_L!P;M$CJ)$5<K"7I3*)R@
M8P@`B'IT!SN./AQYP,&X#_H,8N\0]`_YB(/Q#Z`Z`K/H!H!H!H!H!H!H!H!H
M!H!H!H#"NY&JNU?G7N`"J-E4$$)/%R:*IS$,1V0>,%^/UI`0QCD`3K*?7`'Y
M`;X0T!FHZ`:`:`:`IAFB`:6S$V2:L_MSJ@L;)1[3`O+PQ7;M7E-;RT(^8*6E
MLZ=G2:-EX`KCWHJBIR)D%+<QB@`F"[9W;TEK)]"W<@G%NY_ETU1;=V[,,I8"
MXJT?&#3+U`SC'04I:U(K(.,:Q$U.G/XY_8'SMNQ81T-:KFS<.XP53)/'/Q@J
M99V"@[$`"D"YE1OQNTR-V^BZJCIX=?U?`HQ[F)<MUPDE9JUIY^/ZR^#6,7QH
M!H#!O^=`5%_D3GIPEQO&*1[9]DS%,'C=G(RJ;Q:+BW-^SZA44)201CSI/G#&
M/6F"K*IHG*HH1,2@.XZL2ZKY(Q;O^:OL-O\`XKUW#$`4*EW-(U%$""F4@6KE
M4BDDW3,FH5(J265B(HIHF1`P=(!TCOM[(B75Y*BH91YIU\VMYR-E"H'[IL:Z
M=`BNLJVB+9RTEUDDVXB4ZRB,1E!\NB0%%$RCYA0\=P`1$=@D'JD/FR_<<>*E
M*?NB.CE9IM#-O>;#RW;%;E:$*V8D;K.\G$25!J@B8A0+[29!*(``;#H"QS.'
M;=YR=L3GGV]9MCF3'_,;D=F/+KB1PG'7JQ9-8PZEJQQ-UM1K7;S;\A6B:EV5
M:F'U^.X*9FN3RE4%S'#K6*(U0V[EOKLJJTZT\092_8QR_G'DUC?EOR;SU%X^
MJUWR/RLMU'?T7&X2CZ"J$GA.-8T"P,T;+*N7JMI:.YANH=LZ(H<@H@`%'IZ=
MM#PO#X7%7LO-Q6Y2RLASE7S5$OVFWS^Y,OG.*X[&RHJ*PE.U%+^[OJOO)@X.
MXTJ;NE]J<%:H68M]67B4K966;U!65J!)1DF]C?C)F!A6:%F6YO/`QB@0_I#<
M0UO;=J%J[OM5:?U:UHVJZ(MY?!\Y@\5B<OGXE^SP.9*["Q>7TS<6XRE%TZI_
M=IU1$GR8<=UG!O*O(=QX&\3N/>>\099IU&E+C/9ES6CCFQQV1JXA9XMRRAV;
M!1JJ$"W9.8]=0SENLHN=-0A%R@<!1U6'P_'X/)7^0Q9-Y.3&,9)]$XN37V>I
MFPY#NC/Y3B.*[>Y"OX'CH7E&?C2;3UJWKHJ:=/*FL"SCMW][V'PU'U'%/$W&
MF'N1->S!/9<J7+&A\OZ%'6.L.[;9[C+6J`9T9I48IA8:[*UZS$B16G7TP^32
M;).0`B@E33R+?%8F)DO*C<<\QPV-/PC52=-/%I=6_A34TSS5D<?8M6E2TZR^
M->BK5^3;T2^-2_V]O?G&63>'LMQ*OG!/C#9W-NP@\PY=LVS?+.,D+O:'+VJD
MKKZ_/HA!HVA$++)N.M^X2$RK0RYQ3*`%\=9FW=Z>A8@Z25'3X^1<7V1N#G,7
MC16;BVYQU"E5Z4H1Z'6N,Q*Y:Z]9I&%ID;7KA'VXDFZJKA1HJY<.;:JGYKSS
M%U2GW]GH*($\5YEW(A!?B+T%!OQT_P!*1M_^*>X,7@9]J8N7)<#=MPMSMT6V
M2M9,<I5JJ_5;3T:U^XJCW.V_>Q/DV'B^V3%X87Q)8\4KQEWL%T=T2/OE>R<>
M5F69)^NN;@Y0\MPQK*C0&BIDGC0BQ!$R0B&KEF<5!MK7I_H-#<:N.,/)U,?>
M5X#_`#F^8E;A-33V(E9G(4=,PN0WY\_X38FN\)/EKY)N(E&L?6VS-@E)(TF#
M1`[+R5DD8\X%$OO"X*4QN9$HJ2I2NAZ7B?F?R7&\=A<9CO(V<;7(M*O\N%V'
MOQM."\)0=^[)?&<GKI3FRO!/YSC+DL:4PI`SB5P99`8VQ%_G?";9M.-\Q-(:
M-S"03M(`KELVR!$P+5D8B?E#&HID.T%$X&WO6KUV&E%X>/1QK3Q\"+?YA\SB
M8F'/`R+EG+QY8$K?LU2C/`ED7;$Y;F];,KJ=MKHZUK4KO@G#'SK#`DBK\B28
MFFZJN%A<KT?)^1<,WBKJ3=FEQG)N>$S?Y+6AO-K3)U5DC)R0-4TUU$_)$HE`
MMNXKCENFUT.6[E[BY'N?DX<EF3MS<<7%M.JDII6\6W!16M*1:H]/[38YG<9/
MG,7/7!S_`(_9_P`3\5!QY(V2OVMRC0;10JK/J3%475>PH#,O+W/E3CP>J`98
MB:`**`4"]8%$P&MFB,AN_<:.;4S"=NJ.P+R?C>/,!QY4QLARTQXM68JWM<[4
M:LP]`8S./HR76BGB\*Y3^3TJU3?MU4"'(_ZPW$I1*!*)H!H!H#:6-THJFZ3&
MV3,/24`$P^`^``(E`1'Z8:B4ML7+K1$I-ND727GY?$QJ^X3WE.5O&/E_D7BK
MB3@U+YVK-4H^-K<RR'5+S*5*>54N<<H[=,5&TI5G\.\9(R20L04:*K'`W4!R
M@<.D-1R_</;O;;LQ[AR[.-+(TC55IK2O7]$=+V[P/</-9RGVQQ<N6OV_KMUI
M%_=KUUZE)^-7?4YPW%2ZP4SV;>3V3)RI(5(Q7>&+?$6A\VA)AM*I1KC(;RQQ
M$$Q2L4BO$N%$O<B^4JB4W45,Q>G5[CN9X?F(3?"9*R;$'M<GHG32J^?@6NZN
M"Y_A.6V=R\;_`$Z_<;E&"UV)Z[4NM(O35NC+KD^\=S5$NX]B#N)$]H?`7&.A
M';Z'\U`&LZU&$8TA':J]/B<\U1]:HW?W8WFE_`1=Q3_\/C7_`+HZN`V#=Y/F
MJ4P[]AWN*]`#MUE6QT<?$=@'H([,;;?T[;[!XZ`BK^:]33ZP<L^?\W)0LA6G
MDU1<>3#R`ESHGDJ\]?9DS`X=P$F9`01^,H=PH9NX`O@"I#`'AK)O?Y<?T\#%
ML_YLOM_:9K.L8RAH!H!H!H!H!H!H!H!H!H!H!H"A'*7[V3D9^H1EW];^PZ`@
M*_\`=D]`3B<Z5%$>$G,99%11%9+BOR$4261.=)5)0F)+<8BB2B8E.FH0P`)3
M`("`AN&@*C<=_O?\%_J.XR_25":`K%H!H!H!H!H!H!H!H!H!H!H!H#";SB=R
MY^=@8E.HX2,1K;<7-T4T?+W(V1XF6Y0A'!DC&]L7$BOL4X`;Q#1D3_A,V,OK
M^GJ63X+Y'W4`:`:`I'GR)KL]A++<);CMDZM+XYN4=8C/+*[IK,(1Y7I%"4]\
MMS!L\>UAJ#(Y^N011659EW5(0YB@4;MG_-C3K4MWO\I_(ME[9Y*N'#S&ZE/G
M8^RP3F2N[I"9BLZ3'(Z.>+N+E-J.U6F69R#KC^>3.Y$QA1%HD1D810+N">^L
MKDFWDU=56,>JIX&)QNF-3_%+]I?MK`,\T'`1*(!]#?U;EW#J#?8=NHNX:`A?
MY/\`<NY*8OYK2/";C%P"F.8EWB<`UWD!+R<=R0QS@Q*'J\K9G=1=E60R)7G4
M>\,UEUV)"@W>`N?W@3='2F80`@@[F7&7O.]Q//\`@[/=:[:4MQPFL#U6'8U=
M!UROXQ92?+6^O9'+D2"L:BRD_7XDS&-?M&P>YKM5RK"4P'-T")3`>GC5_G=[
M1)X27J]=NA7*J#A!&X1/`1ZE&G;^8($8DBYF&+T.14]OKZC%$A>DP>.X'4UC
MD!\ZSLF0,BXU@:?1%;QBQG2W%\A2UGAFB6'1O\=(2U3'XT-;6[!^>0C8E=3H
M;K+BAT`"H%$Y-Q3+=X'W*/(3YUYARHJ7G(-;I$'6$K#2ZL:03J'#^8.$YD*Y
MP&/ZBR!E"6Z1>[2ELL[%L944RH-RK"JJ<B9#&`1%R;U+3:Y,=\_EOW!\1W;,
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M#8W;')9MRYP6%-SL6F_1;E*2E)07A5K7SH5'3```0#^*'Z>_T?AU8DZLU2:E
M625&WK\S7JDDTG^L-]+X=OPQTVQGZ9).+(E6GIJW\.I8WG^[<LX3*E<A<!8\
MJ5WJSBIUF3L871=>#C$5E\J14-;%(VQ)*I$4GHVANEG;5@<P%4`AS['$`*-N
M=W.MYD;=FU&6/3JW2G7Q\TM4OL/;>Q.`_)?D>Q,CD/S%Y7.P.=AR]^%N-FLY
M.S;XZ_>QGLU6V>="S;E*E4FG5+4N!P98+I;,6TNPY'A4:[=):)4=6&%39KL$
MV$@$@_0]W1:.CG<(D*U13-L<=S`;?8-]M7XOTMKJY/3R/.^^^,X+AN],[BNV
M+CO]N69696+C:;G*5M2G5I)54FT_)Z:TJ5A3``(4`]`!L'T@]'X6HG7<Z]3E
MJMMM]=S_`&FYJDD:`:`:`:`:`:`T*#LF<?1[)O'\`=2JUTZD.E-4VO)=66_3
M[[CME.Z6/%5I6Q1>\AT6'@I*T42;2K<_;JI"VP3J5YW)0SU%S*1#">41.+7Z
MPJYBB)-Q#6-EX>)D1_WRQ"XGYI,VW#\QS?`7UG<!EY>%DK5.W.49+[4_(]QC
MW'U0Q]'!%4RHUJFP94FK1C$UN%80R)&#%,2LO>B,6J`JK!YJ@^V(B`&_BA,.
MKD+>%C6X_A;6RD4M%1+X+X?>8_*\KR7.94\KG,R[F9MR;DY3;;W2=76OCY^&
MA43P`AQ``WV-OT^GT#\(#X_A:NQE*2K(P8Q>^LZ;_P!W@6;W?EC`4WEOB/BF
M^85E&<RS1)^ZPLO+7Y&+L"P5]P]3?1,)24X"05G'($8B?=S(,"G(506X+>0J
M!;L,=WH3N)5]M)O[?,QKF9*SEPM2^F;:7AJNI>2B('(0X!L`@!@\.GU#X[#X
M@`[[AJS52^PRJ;9R^)AT_-HXE13E?W))Q4O6*)J;!IF*H3I!-7*V89`Z8(;@
MH!MR@(FVZ?5Z=9-[_+B8MG_-E]O[3,=UC&4-`-`-`-`-`-`-`-`-`-`-`-`4
M(Y2_>R<C/U",N_K?V'0$!7_NR>@)P>=OWD',G]BIR&_6BM^@*D\=_O?\&?J.
MXR_25":`K%H!H!H!H!H!H!H!H!H!H!H!H#"JRX9>2^=8X\0.FY7+&7G'9DA#
MR/*0:M^'TDY'82M05*D1P],8P&,8QC&WZ@*`%U)>NQBK4)4UI^\S5`_O?4#1
MEGP7R/NH`T`T!X/*-6=7G'%ZI;$\.F\MM2GZVV5L42I/0":TU%NHY)2;A$7L
M:M+Q!%'`"Y;$<('71`Q"J$$0,%47*+W1ZHHN1E.VXQT9Y/C[C>9Q)BBLT&?D
M:9*RD'\8E<.\?8[C,54_9W(NGB3>$H\2]D6L2V:I+@F)A755<'*98YA,<=57
M)SN2W3DY2IU9C8-N=NQMN?5N?A0K1JV9AI..Q#"'P:`@OI0%_P",19;'PZA[
M6-1`1]>WV_8#\+0%UL\\YDY8Y+\AJ3B7D5CC#V.<0(X@C(6"FN/J&2YR1E+I
M1C6N?DY"QN\BU@H(`NLDFW03;;)E`W48PB&L>Y'*=Q.W**M?%??K4M2=S?I]
M!WZN%^X6!1Z>=&*"B`CN8>'4:;8`V'?8,SB/@&K])54?%EUU=%;59/\`4>_X
MQ<=\GXFO.<LH9CSDPS??,TJXW;N7\+C!EBJ#KT+C2$FHB&8,H)I:[>9TY=EG
ME5'"YG)`,8"]*9?$1;H5<(NLX]12:]%R*5/'S_Z#S'<@*F;BT[*I]:.>>('X
MX2CO]UQA'IV,40,`[_WMM211%BO;F;ICW2N^,8R0=*N7^+`F-L`=1BX%2#<!
M$0V$-OH:$]-:5^'F2HAC*DH9!"RK5Q=LZ/*#--Y5]89Q_%KS"C<L<T;,*^>0
M/!Q#<4RF5!`42`94!.0OF=1M:W*XW$S<BWDWX6W?M:QE3Q732M/O.IM]V\Y9
MXO\`HOO*/%NWLV;8*5&ZM;MNY2KXU*MS5HJM49M'EILE?K;1RH5LV=6":80[
M=RX*3S/)07DG3=-=8"$$W241-TAOMMK*NY?M-RO7;48?%4_;(YFU@W<E+$Q+
M4[JBZQ44Y2TZ523=2"OGYS(YQ2///BIPK[=.8^+%:D,T87S+DFV6?,4`_P`C
MP[*3QO)1AD(\IJ7(.9*.77B#+@FEY`@=4>HY@*00%#)LY5E7,6Y":W[:Q::T
M\/&C+F1AY>)/;EVIVIT^F47%_/5)T+5\!]R#N6X5[F4QPQYZWWC-D6AU6)QL
MTN=GP?C:WUDL?)9I@'\W19Z$>R(KRJJ4([9HLY)LY8"FJ#DRB:A`3$P8G)\[
MQ7%W;./F2]N=^2A%_P"*E?V)G0]M]H\OW5;SI\3%2GA8GOR6FL5.,-*M*M7X
MLG.YBM^9,M1*DVX;97P'B:]+6I5:R3>?JC9+E`2E02AY$5(ZOQ=:6(Y1GPE/
M(6`ZHBF*!1(&YS!K:UL[4I:IKQ.6<<BW+V[RBI1>M*D>K*@]^Q\1P@XY@=N5
M5Z5HFY9-T,#96V?(@=3WD3$<)%7`B:20F`B!5SB;Z[I`0WJC.-5MK4IDHZ>[
MK;4DZ?%/1_-/H4+G<F][ZJ\7[?RAFN3G`XU;JF-YK)_R.A\&7IU<7<)#QS]8
MS`??I.+CVSYR[9%!,YTP3*F<>O82>-,KEJVW<K6W3I^FIJ^/Y3'YOB;7*<9_
MEW(3?G6<9N.Y?*C1Z=M8>^M+)<C)"N<I>!;R)X\W&:JCLLM@F_0DC;48C$5$
MS`>3CF361G$XD1B[^WC_`"%%EP!RV44\WH$@"O7(2C6VJ3\:MLS.0SH<?ARY
M"ZH^S9M>Y<JVMT;<-URGCZMK?PKIT/<Q<!W\YBLU:R%Y:=NF)3LT!%3S9C(8
M5RJ$BFVEH]"233<,T4'!R*M2./+4,413ZB;@(;[:LVIK;6Z^O3]-"</*CFXT
M,VW3V;T5.'PA))Q7QT?4D`X5QW/.)0O8<W<P\<<JNWIX(V-R\?J;;*=\2-FA
M9-&TK6E*V)H*R)7[M5B#044P*CT*E,8W4`ZN^F>D.ID-M)M>"K]Q%SW&NX!S
M@CN<_&KAMV^K[A>J3637]NH61Y/.V+Y^?AZKD"*8MK5!OQDF+MLXD8"0JRO1
MY<:DX5(L<ISB4OAJ96IKQ72IM^?X7D^W,;CLK/C;_#\M!SLM2K*,4JU<:JE=
M522\*JI[5IB?YRTP<&=2/+CM;R4>FF8RK<F"LX"XZ2AUF,BDS2:JK*[%V*7S
M"@(CJGXFJ)>LXYC'"^').XSDLR;V16%^)H-^E#R4C`J9$D8)\K7R.HUH)WZ$
M'(3K8A3=9P$B2A2B<!$3:F=RU9QKF;=_R[,6Y+S54OGU:H;OM[M+N'O#*N<5
MP,8/,5J=U-M)[82MII)Z/1R=.M/D1-X_B/G&-BK$/:SYR[3:[>W0T%8V$;,8
MCY-%<P365A63HD=YD-9&!%U=U?,6%0R^RYCE(<$@*4+&-D0S,>.7;5+5Q*27
MDO(P\W&_`9][!S([<BS?N0<8O3T2<::NM52E?VGE^U1W*N56?>5G,3BMS9?X
M=+><%7U+&F/7^!\?6^O42TS]-^.QR0Y)+6VS6*:3,9I\7.FK=\FW,*1E1(;<
MHI:R[<5)O^]Y&3@=O\CRO;F3W%86W#Q\E6Y:JJ34FG1]4VJ::KY:DA_+V,[G
M4M;ZR7@??^%54J"%><DO;#E)2<RVFQ+V99\<T6]K#O&,]$QS6"-%E`BJ+HAE
M_/`3%-TB`:4BUJC2M2=Q4?\`+4'7XOS(]N--&YC</>;.9>2?<<EN/5BBN9U2
MQ+C9OESC/&WR!Q3B*V8<!]$TRJ9!B,BI.[)#-LCQ\^8S68%ZNP2DFHHK`@"B
M9QA1B_IZE"6Q[H]3(.3!(0)MMU&*!@V/U`/LE'P,`])O`P#OZ]]]4N3Z>!=3
MIY5-2A0$#!M]>42F]'B`@(#X#X#JAZ1HNE2EJDU)?4V1=9:MSM7N/<:*-'Y#
MK<:U98YN,S.X[=PT<ZLDNG-,+4UC7S&<<XZ?/HQL\&$5.9NE8FYEP:*"9`@;
M&<;K%Q;EWC\B];;BK<8MT?5.5%5>-'J<_P`KDSM\QB6J;H.<O#IZ>I*$@("D
MD.QB^R(>T(";P$0W$0$P#U>GTZT<-8U6FNOQ.BF_YGV&'_\`-GT'A>2G<X>J
M/7`,$K)0FB<6((^["JK?<QK"_*8$Q<>8)2BD/M=.P>`;^.KTI2DJ-Z&-:_S'
M3XF81J@R1H!H!H!H!H!H!H!H!H!H!H!H"W[EF\1C^*W)A^X!04&/'[,KQ<$B
M>8J*+;'-D65!(@F*!U!(0>D-PW'UZ`@8\H_\;_[,OY7I_'__`&OT=`3>\[?O
M(.9/[%3D-^M%;]`5)X[_`'O^#/U'<9?I*A-`5BT`T`T`T`T`T`T`T`T`T`T!
MMG/T[;!N(^(%^'80#T^@/$P>G4Q]74&%)#Y0H&1/G5C.>HEDA[5!(30U(9^M
MO2RD0\GX+B2]@I^/3D&"CMLNO#3L:JR=!L5-)TS.03`8NXPU-.C1<E<W04/)
M&:\&H3;ZEL^ZD#0#0'P0WU-24Z'W4$:+H-`:3!N4P?0'0$%5)/\`_5$^6T]O
M1VK:B;?_`,/]?#;;\'0$AN#?'E=SA_RYX\A__AEE_@Z:]!X4/0<S\CSF'.+6
M?<IUM^_CIN@XSLUDB'T<M"H2#:3CV@*M5F)K!#6"'.Y24`!337:+D6-['0(B
M`AG<9_[4L1NVXW+#ZJ3:KK\*/I\36\EDQX[ALK(K)32;4EU6B2IX/4<)[)DJ
MV\8<0V#,5B-;<GRE53=76QFAG5="5F32,D0SE.">U^JNHM$6R:8$2.P;#T;&
M`#%$#FO\W;QH<G=EB6XVK+EI%:I))+K5U^\Q>W+]W)X>S>OW9WKLHZN22?ZB
MF'<O<`UXI.UA`!VY`<-DP`1V`17Y@X+0#Q^$/,W#Z.M4;P@9QWR>YB8`[KO>
M,9\7>WY9>;S"RY9XX!<'5?SO0\,)X]598'CQC47R=TA)E6>"=;J.3$%J4!1,
MW`I@$52:;MKW:Z:Z=?L*H54TTZ.JU\OC]A<3VJ.<.:^6&+Y>X<J.:58Q1E2&
MY29'QJ[XXKT7";>>80=2N[1I7Z3(2'Q$RL;F07,J>-!\F4IW(I`NEXG#;F.X
M,Y8_)8N/F\M9PLBY);+*5MSN]-)1E5Q;\5%)?&IV';_&W;O$Y6:N#N9UU1E_
MOK=V,+>GU)0I;DEU6[R,A6_T"N7ZJOJY98EK+Q;ELX(JR519`<R;AJJU7*T>
M.D%31SHS=8Q2KI"FH3?Z[;?70W<>Q?7^\6X3;6M56K?4YWC.3S>'S8YV#-QR
M(-/X-KQ:Z/76G2IX/'N'L&T^3]_H6.:36IV+C&,8:0B:7$1<^RC(YJ9DPC_C
M]&/0E'39NU,9+I]X4*H0Q@-U`;46,7&Q8^WBVXV[=:TBDDWHJ_<DOL*N2Y?D
MN8NRO\I=E>R')M2EU2;K3Y;FW\VTJ+0Q[V.#)S,WSB?E;)D8UY_4,88;XHW:
MZQ\M(O&<DZ14QS)14&G")LVQS*N"3*X',(JH]()^!A^M'F.?[7L<SR6%R%YR
MDL6^I[-*/TN/7KX^!ONV>Z;O;V'G8]F4K=S*Q?:4H_&<94E72FGQU\#)5@V(
MN961?R:S:0=1;E.)C02;I@WC6X,V3]<S<#'64*Z=+.2^:J)NHQ4B;`4/#76R
M33;HDUX>6BZ>)R,JW;DKLDM7H=S,MDG+-T54HG,FT<+HJ&WW0632.9-5)0HE
M414(8OI*)1$/#?;5U--)T75%F_\`S;$DO2U4B&S(=4W:!R:!B1X)$X@71;WC
MWPYY%54\1+("F9M[L413$ZPB)S*G]&W3N.^M1Q$99G%6876_7O=?'23_`%+0
MY'L"$,;L_CK-I;4E>:^/\V5?VU^\JCBB392U4[G0M06(JVS9E2"51>[MU??(
M+AUQXBWB[5F<I_>&QW#8P$7`Y.M,2^SL.^LC*N>S9G=?3:WU\HM_;T+_`'M'
MW>SN6M-T<N+RDGXJN/<U7QU+X,`)$6Q!BZ8712&6E\88[<2;P$RE6<+?)"'+
ML8WB)42=/LD#8I1W';<1U=QW&5BW<AK&5N+K\U^XR>TYRGVOQDI*DOZ;C57_
M`,&E7[:%0+&P1,1O,)B1M)1:R)D7@$**JC118J;R.4W$OG(/$5#%`ANH"J=)
MRAUE`=7DJR36DCH)14DT^C1`5S]Q(O!=VSM'9<9L*_%-;9D3)56L2T8X?(R,
M_;8ZFK2)7KR-.46`H)U\A"%<>RZ.).A03%3)K)5U[&G2M*?J,G*RLC/L8V-G
MSE>MXE5:W=8)^"?6BU:715=.ID+*J>6&^P"'CN`@;T>`#]:4WCX^`;>(^&L:
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M3\*^39DO,&'NA#F47,Y<.%`6<KF(4H**@0B0=!"^"::::?24/'8/'<1\='.I
MKEI;C;_NJE?/YG$LM9K]Q@I6L6J'CK!7)UBO&S,)+M$7T=),7)>E5L[;+E.D
MJF/I#<-RF`!`0$`'5*="-I8_7+):>'-@C,>Y'EWMHXT3TL6%Q;E255?OYO$3
M^04(6%QIE!ZH+I1Y5#&`48BPKG(".Z;1SL/0IJO;77Q*(SDW1I;2_1(X.$RG
MW(8IR@8ITC`=,Y#%W(H0_B4Y%"&W`0W#Q]>J))4+S2=&O`IX\P]C"1R$PRR^
MH%-=Y.B8A&!B<@NJQ"N;E%PJ!GYDXN+LB[-27C6(?&CD!316(4P+J`("!AU?
M61<C9E9@VH2ZT;U^?F6(VK;R'?N13E14KX?%%22D$H%`3".VWJ`-]@V]'J#?
M6-2B27@7EHV_/]1AC?-P<F8^J'*ON$42U7BL5RYY,OU898XJE@FF$98+RM`V
MS-4C+(52,77*\FUHYDF=5<C=-0R1`ZA#;3^9XK0QK3_FO[3,\#Q`!^'4F2-`
M-`-`-`-`-`-`-`-`-`-`-`6K<ZW:S#A%S'?MO)%PRXK<A7:`.&S=XAYS;$=O
M62\]H[36:ND>L@=2:A#)G+N4P"`B&@(TOM45[_IYOWBG[5']%!_Z'O\`I_\`
M0]]=_P#/3Z[_`.9-`25\[?O(.9/[%3D-^M%;]`5)X[_>_P"#/U'<9?I*A-`5
MBT`T`T`T`T`T`T`T`T`T`T!M*D,<"`'2.QRB;J#<-B^UX?1$0V_!U,7M^X'Y
MI?)BH9C[&7=*2OM9<5O((4RYS6;<8+SYWSB*O&*<QO;M%.*9>)!!H@E4[V^0
M"38E7`14.\2!XW\U(5$=93N6)+U)U8,]K@-SPPCW!<!PF<L,R*J/F+#$7W'L
ML\8+W/%MS0*<SZJ6MHS=.!2%0">?'NMBHR#!1-=(``PD)CRH_IZ`O?U0!H!H
M!H!H!H#X/H'Z0_B:`@LI/_M$>7/_`"6-1_7\K^@)`\$#_KL^=/T)WCKM]#_0
M3CM`>EYKO\%07%7/MAY-Q+V<P'"8\FIK*,+&*+!*3%9B4D'RT=%$;R,.Y4EG
MKAHFBU22=('674*0IP$VKEF_=LSWPTDGH6,BS#,LRQ<F*=AG3\`;)@"X\0,'
M6KBQ6)NF\?)ZJ+R&+:U8T%FLY%0"D[+D50DFKF6G7#=<TJFX4`IWBY@(<-Q#
MZT*K]^YD7'=NZS?4C%QK6'96/85+4>AX?N9%ZN*+H-M_]<%PS';;?<0YB8)$
M-@\=QWU9,@LD[<H%/W2^^,40]D<N\6BB'\E@5,#;?!U;!O\`#L'P:5:U6C1$
MHJ47&2K%JC7G\"12/XFX`)E>T9)F,+5.3O\`:;2RN+N]3<!".UU)F)09-8=6
M(5:MFON;MHE'I*]:I#N3*DZSJJ''J#FLSM7MW,Y2'-YN+')Y>#3C<G)IP:I]
M*HT=E_QAW1;X&WPG&YKQ^'A%QE9@J[EK7>VTZZTKT\DBL^5<A1V/H./=25=O
M%G8/I)..>QU$ILS=I<S<6RZPG69PH"LR9'53*4ZZA1((")`#<P"&PYKEX\/B
M1SKMC(O1E)+;8A[DDW\*Q-+Q7%3YG(=N%_%Q_.5ZY[<?DG1ZEM];[@F"Y7DA
MCCB4]KN9*9F/*E,MU\H<+><46*IQ,U4J$B'RCDD)61^P$3CAZ$N@0ZS*&#PV
M'?5SB^1_JF,\GV,C'6YK;>ALFZ).J59>EUHG7JF6^4XN7%Y7X5W\;(>U/=9G
M[D-:Z;J+7354Z-%AO&-PF?OY=SY,!,?R.+'#8%`*4QBIF&#.L4HCL)0,)%`,
M'T]P]>ME1^%*FMVU:B_%_I4FU>H2+20"1B037*N0A)")64*@1T9(-D'3)?ZQ
MO(%2W(8%`Z%DP*!C%%,NK"G<=V5MI;J5^:^'Q_T%$HJ5)MTUI2O5_O.IL4M)
M-HUX^>(LX"(CV+Y[-2<H\;+(I1[=LZ,Y*D*"Q46P@4A3&77.1-,@^@P^`9$5
M-TBM.ACY%Z%G#N7Y?Y<4VZ:O3R1#3R(R)C&6[/.6::RRK1V5@?\`%"XP3"*8
MW"O+V<9"3CW3-J6+B`F$G[N7,Z6*+-(@`HJJ)"%Z3B!@P.%A#$QK./<N6W<A
M&:>V55ZI5_=1G'=@9.'E=NX-F%ZW&]#WDXRDDZNY)K3KT*;=ON+A>+/&;N%8
M'R[RN4S5DNB9XY!14QD;-=W:166+X,AQZPZXA9.7@;':YV1V3;(_%K(XO'!1
M;L2%3-]>4DYMW%LX5R&3<BE[;K5JM-KK6KZ^--3/[KN8_P#P[R&-.[:A<G@7
M[?KFHUE*S)+1]:U6O7YDM&+LRXH@,:4%BPR?C5\R:T6G-&L<KD6K-)*/*TK4
M8W!B=9S*@5R<IT3>*HD5W]DPB`!J,+(P98=KV;UMVE!4J]:4_3]A/;_*<1C<
M#@V[F58BX85F&US6ZL84:H5_;O/CQHQF7*S,E=*FVEVPMW;=\1Z1,I7;214D
MD%#,3Q9"=*Q3)&,4>GJ$XE].=!QD_1*+KY'4*Y;G;5V#3LN-=RZ4I7J0]\^[
M-6;=S9[,4]5)V%LT(]Y.YF*RFX"3CYJ*=F;XA?).`;2<8X=,UQ17*8A@(<>@
MX"4=A`0U>]NXHRWQ<6O!Z,MQR+,U"5J2G&?1QU7VM$V:Y3F`#$`1,F)C@4HE
M`Q_L9B@0HG$"`81,`@)O9W#QUC1TFS(,;S"G(SEE0E\YG'C!0./F0K3SDKE,
M-*8GQ%:>5J.7L56%6XV.3F;G`<=\EV"LX_RO2J[(MFDA-O9=&*<R**J;PB0A
MNEE1N0R<C;D3=;=M[8N2CY4IN6OV:FBS[_X5*?';7?NWTIN,)77XUJH/T/\`
MUJ+S,D@A0+U;```(AZ/1Z`]7JUC:N3;K]OR\#>5D])=%T,<7L'XQG8O)_=?R
M\MD2P/*Y<>X=GZD,<3GZ_DK6INE7R>?2MY:'4<J`K/6UK8VS5<$T42D;QR0"
M*AO:"09'N@*)Y/SY1\26K&E0M;*XK2.5I[Y-UEW7J?.6&&:RAGD8P1)89:,;
M+M(%!=W+(@"BX@0I.M0XE23.<N19QIWZ['%.*KJZ5^11<N1M-*75E2K168"[
MUJ:J=IAX^?K5EC'43-PLH@1U'R<6_1,BZ:.T1'91)9(XAX"`@/B`[@`ZLKTR
M^15):>GJ610$]8N&T_!XWR#+R5BXS6*39P>+,J3;PKF1PT_=`5M$XNR=)NEC
M.'E16.3RX.=5Z0;[%:/#;`FH,M;W5%N"G%TE])?L1RD8?`W4`](E,40,40,7
MS"F`Q=P$HIB!MP\-MM_2&HVZ:%YT(;N[MW<<8]LO%J:4:2+R'R=R.FO'X?P\
M1^FJ*#A0R34M]R$W8.0DXBB1;AXGY?4*:TJX$K5ML(**)S"*<O5])!BZ]B7B
MUGOD)W!<4\JXZJ)M,8\;K!>)_,N1I:,E*]%2&0[W6;TP6QY2F$DB=_*V)H[N
M*;EX05%"QC-,"+G!11/KR9RM;6DG5]"Q"VXW-WAJ?H2:PR^-`-`-`-`-`-`-
M`-`-`-`-`-`6F<^/O%>:7[$SD;^L]<=`6F^[F_Z[??O37N_Y.7Z[_KO\B_G[
M^/\`1_&Z`NZYV_>0<R?V*G(;]:*WZ`J3QW^]_P`&?J.XR_25":`K%H!H!H!H
M!H!H!H!H!H!H!H!H#'>Y8XHQQF#NYTRA90J,->J;=<=X1K%EJ-D1+(0$W$/:
M'SB%4CB+<"9N#YN<A3(/$RE=-3`!DU"&`!`""'EEQ3Y=_-Y^5I.6W#>2E[)Q
M'NT^TC5XR9=OYNOC67KP%%<&YS;F45,19@9=1.K6Q8WG&.J&R@.P6(O<A1JA
M!F1<#^?6`NX5A:/S+@VPB8&X-XS(&/9PS=K>L5V_W<JSVL6^,(H)B[")C,WR
M0&92+<OG(*'*(@6EQH27N`("`"`@(#Z!`0$!^D(:I%4?=`-`-`-`:3"`%,(B
M```#N(CL`>'PZ=>@()*([;+_`#BK,C=!R@LLS[6=.3=HI*IJ*M55<[UMPDFX
M(0PF1.HW5*<H&V$2&`P>`AH0FI*L=47U8@N=,K_+GG*UG;57H)X::X["+6:F
M8V*65+]I2-.5=!-^[1470,10"]92]/440WW`=155IXE+N6U+8Y)2\JZE<\NH
MX$SCC.Z8BR!>*B_I60(-U6[*R87N'C'CJ*>B0'*#:0:R)73)50";`HD)5">D
MH@;80DKJCL^.^/,0X;Q!1L+X->LU\;8HK["FU=BWM2ER<Q$.P*<6$>^G'3^2
MD7BZ2)]@.Y5.L8H`(F'TZ`MO[F\U(U;B#:+K&XYRAEI3'V5^,F1GV.L+UAU<
M\IVF$Q_R8Q'<;"PI-8:`*DO-$@H5PJ1,PD2`J9C*'(0IC@!CT\4>Y/9<%<T.
MXUR,L7;9[I4C2.7=^P;:<;QL9PZN@V:*BL>XN0J-E"WQZZI6,8["7$?(3;NW
M?G(AU`8!$0*5/'H-?#J2\=KB\\Y>4&!G><N4F0<K8LLDIG#*:,'ABX\=Z3BB
M9AL50=O\O'\=-1L[2&=G,_DJPD'G/DW"@*>?N103D$=83Q\U7_=CEMV:=/;5
M.OQ5?U&PP<K"PL:Y;R<&,\RXM)*ZUM?_`%7M:^9(;R#Y`5KCA3$+[<*OD:R0
M/OB[9^7'-->W%W"HMX]W)N)6;0:KMB14*BBT,4SI50J?F'*4P[B&L/D>37&1
M@[^+D7[<KC>ZU!W&EJ]SC&K2?Q6AO.RNR>2[[Y*/;_&7<3'SIQ37OWX6(2?3
M:KEQJ+?DM6S'8S[0KEW7^Y]Q0R+QXL7+_C-BS!/&W,T+D;DIC^(AL9V>LSUZ
MDHQ[4*I7)V?^4D?*A;D&ZB3Q!)!11-J83#T@;S"1P7/8_<./=RL:UD686K\K
M35Z$K<FXJ,MT5+5P:DDGTJFO`K[P[*YKL#EGP7.NP\U04T[-V%ZVXMM*DX-Q
M;]+JNOC34\-QIQ]?N%W<+[T<*GFC-G*&^4#@K@R\PV0,RV5],9=M+HM5DYYA
M#JSF/XJ/E2MH8QRM&9V#07*"12CON`"/18J@\F'N*L-ZJO-5.(Y"W>RL.[CX
MER-O)E!TDVDH:=6W2B^+)M>USE"W6O@G@N_YRR>-OMML):9->[7!Y8XE:?CG
M=HE7%=5:+Y$B:K8)%HWKWNY45SLTR.4]E4A.F<%#;3N>]QTN7=S&@K%F-N*2
MHH^JBK7IJWKYG-=N^]PW#PQNYLFU++]YN%QW([9==NUMT?V5J2`.;ICEZ@JV
M=6^F.6SA)1%=NO8()9!9%0/LJ:J*CPR2J9R_7`8!`0].M`LFTG]</O1NI\EQ
M$[3LRR<?VY=?YD/[2*_N@(8!:\0\BMD+C5L;-I)JG&N;)C#'U-ND[[LY5*G\
M6O'4;6YR2HT0\$0!2P-SL5HY3H$CE,Q@WQLB[BV[6_%A&5R7BDM77X?IHCG>
M5RN,Q\>RN"AC3SW-45OVY?Q*KK%U55XKY>+-/&6&HB><>X@68AL82+<G,%:1
M@[+/Q=$?V"2M[S#&-5K'4I%]9#J.2Q4"U9Q:A5`%$Z:D@KLH8YA`L5LSE)9,
M8>XI/:G%5:7Q?A\BNUDW;O)9UKNRSAV^,MW8_A+EU03N0VIR?KT>V6[5=*4K
MH7)+9J[?DHJ\AI?(/%AP=0RL;*Q"[C'0-BOT2JA*-E7*R*:)BD,D<AC"?I`0
MV$PB(:UMSF>VX2]J[?PNOI6^VJ-=?'Y&HR.Z_P`JKCN0RLWAY94-NYRO6(I/
M6B3;6OG1Z:="H>9IBH!P_P`F_:B:,+A6(_"$VRJ,#C.Y1-9(O7E*FJTB&=<M
M3>7C6==:I1!RF17!XWZ$">PH0=C!T''9%KWK=ZQLE8BXR5&I)I:^'6IV%G)X
MWF.(G'A<BQ=PY6914K4XSCZHM1]46U\M=>ACBX$F,;R+'L),<6TLF/Z-!<MN
M4L)6(A7WMB^GV4=4[`D^O#J"F;7<['!N;7,.%G"K20D'#A%0_@;RC)!K=\OR
M-OE,RYF0C[:E%+:].BI1:+I3RUK5ZF'VUP^1P'&V^/ORE>GND]S3T3UJ]73[
MS+O$0#TB`;^`;^L?4`?"(ZT*^MG2F(=9N*.4Z+)9$KV-+_B"^-\E]S^`RY)J
M\/,93.0+O4(R:966R-JO?"QDG3H.F$CW!3-'#Z9GE8V/2\XO2J=T=$-[O<IP
MN7+;4%8:4IM+Q73J_CTU/-;F'=LW[F+8N69W99ZG*-E;IQZO;-)K9Y5DZ+7S
M,O`H[[_3UI&J,](C)NM?!D%O8O(4E9[CXE_']T_E^8WCO[0VF.W^EH5$Z@Z?
M/H"(#N-U''MNY$=O]:T2F3H6TU/-S&PU*3H^'4L@UKI5N./XA_#W2^&G89;$
MK&Q/7K-G[\0'(.$5%2&05`@$U=Q[UN*E*VG*"76*;2^=/WF)FN,9VT]).6GQ
M)?$OR-/8.D.@GL[;;>R'AMZMM6J[M?,RSI;)7:_;(*8K=HBH^>KTW'.HR:AI
M5NF\C9*.=HF2=-'K18#)+(*)&\0$/#TAL/CJ4V#&O[B?=->]FYC)\=J\HER!
MM^1Z3(S?%FOO;"UF;?AIXI(,HAA6<O1!5#6&9Q\BYDP6JJVXO)$&9X\1$H>:
M6YH]2"E/:)[/>4;3E<_<U[HAG^2>3.3WK.\X\QI>&ZSY;';A=$ZL5;[_`!JZ
M0QL?:V$89).$@$4TV5;;`4IDRNR@1%*5%1`RJXVOPL,FY1B(QE%HO9%],/4H
MYLBR3>R\HX4=RDJ\(W(F5W)2CM4RKA=7K564,)CF$P[ZMU9)W&H`T`T`T`T`
MT`T`T`T`T`T`T`T!:9SX^\5YI?L3.1OZSUQT!:M_P4>@+L>=OWD',G]BIR&_
M6BM^@*D\=_O?\&?J.XR_25":`K%H!H!H!H!H!H!H!H!H!H!H!H"TZW\6L8/^
M0C7E9(Q,C/Y0@H.J0]:!P_51B*N-38Y+C$I=@T9)$67=2,5E*1;NBKF61Z.@
MY2%,3JT!5JUU:B9TH%IH%\JL1=*/<X%]5;M5)YJF_A9F(E&YTGT>N0Y!3<)J
M$/U)*I"!TE`*<HE4(42U)@P8N6/$7EA\WBY30O,GAJ_E[QQ.NDDE4I2.L9EY
M!A'1$F[%PA@[-I6QBN'#!SL/R8M!-U$GB:93=+D/+<W$U+0IEHC+*X6]U'B)
MS'P+7,S063J7BY^N=6%NV-,H76KU.XT&Z1R"*LY7G[69DV`23%`RP*,Y%#=N
M^:F!0O2<%$TZ)1H0B0ZN66OV^'8V*JSD-9:_)I"O&3M?E&4U#2*15%$5%6$K
M&K.&#U)-PD=,3)*&`#D$!V$-M4%9WF@-)S=!#FVWZ2F-L([`.P".PCL.V^V@
M.,5T82`<43!X'W\1Z0$NVWMB4`Z!$=M_3OX@'3N(`<5\^(FBX`"**'1;@X43
M1Z3K>)@\I%(H^RJX6'P*7?VC"`>.^J[>LTBJ$92G&$)1C*4DJR^E5:6OP,0#
M!?=1XDT_OD<[<S\E,U4K"..67'7'7'O#E@R0PEJ>]D'%-M$+*7.M/F;E.071
MLC6TD?D6+L@FX09)G3(8H"<3B][CUD;?G.#R^W^0?&9,K<[KM0N?RWN5)*JU
MTJJ4IH2&Y'[COS;_`"Y;9*^9;S+V]LD7N12CV<O<,@X\J5IM<@A',R,HMO(S
MM@HSR6>)L&"!4$`45,"21`(78I0`++V;M:;C2.Q";]R44Y+QHJGAPYJ?->2@
M"A;;VQ"@7V@.7#V.@V$!\!`0Q[N`@.JQ6-?B4UXA=U7LJ\=^3?-]7'?)KBYA
M3#E[<\;WE`1IK5"D8_M,A7\9S#"Z/ZQ#0=>CXLSF.EW::$@LFB45%Q`#&,8H
M[`J5="17]WK[.?\`"&<=?\\S_P#[DZ%1S&G?:[0L@)PC^?>`'WEB4#@SGI9R
MH03E$2]2:$(H8"FZ?3Z-`7\\?.2&$.56.FV6^/62*WE?&KV5EH-G<JHNY<PS
MF7@G(LIJ/25=M&2IEXUV'EJ>QL!O#?<!V`JA.MBO(UZA[VHS,<";+IH)NQ`2
M+IJ`DJS6(9)TW7$OEJ)CMUD,(;AON%,/<MI[I:-U7P^'^@F$;D;\<BU6-R/1
MQE1U\_A]YM0B4@*!B2$>TC5$3``%CU4U63D12`AEFY"D1<-@,'XQ0HG)OT@8
MP!OI!**=(J-75_%^97*[>FV[\ISFWUDZOY)]:5UU\3&YPZDTLGSEWG;6IM%E
M+0:G!G&K=W%G:L5V3XDK#8BCI..FQ*BY6<-SQZ90,W<*HI")QZ""(F`U^U.5
MN7N0^J.J,"]AV<A2AD1<K$U25'33X_,FDR)PJXO9:I=.Q/;</5%?&^.91Q.5
M2H0<>M4J_79"2:O&:Q()I6'$4W8@HFZ.*B)2>7L(;@!MA#%SXV.=MN'(+W*>
M;=?OJCG.=[)[8[CQ5@\GCNY@PJXQ<VHU=*ZQHUT\"D7[DUP"`>H./D440*8H
M=%FN9=@,42&'V;#L/43P]&M)_P`)\#_YI_\`:E_:<M+\E/RW=JG]-MT_]->_
M\8C5[K_!3B)Q8X-Y,S)B3`<&SOL1<\'5V$?C.VUX=A\N,XX\ISQ\@R=6'W!X
M]8LYLZJ!'(';BN0HJ$,4!#69C\!QL':M8MA*4-52;K^WX$<+^27Y;]MY]ODN
M(XZ-G(MO<I._>DE77HY/QZ%8L+\$^(_(#EAW$Y7,6&F=XNS3DK$32]M?6.RM
MU7<99,7TM!E!!#QTFSC6B,$>"./FIAU./>!`_@4-:[CKF)RG+9EJ_8C*>'<V
M*3DZ/?%2Z*E-&8.5P_9/YH]Q\CP?.X4+N3P]U0=Q7;D:[X*:3BFDFE*FG4O;
M;]K/@NW;@T1P='IM@`P%;EL5N`I2F`"F*!?CX2E()2AX!L'T-1=[0[;<G/\`
M`VIS;;KNEU?VDV/R`_*/&M3L8W$VX[VG)J=R3;\&W)Z>/0^6[A+3\6<:^2F,
MN(4,;%MXR[CJP,(:01L]P,!;DTK[YC5$V<BG=JU*UTZYEQ;`Z9RL<9N98JPJ
M!Y8@.\X[CL7!MTP[4;>G1-O]IVO;79O"=H6'B<%8E9PY-56ZJ5'IH_B8ZT-B
M+-N#^XQV2L><DY29F,RHL,S6BW$F[6_N:M>?6BW7Q^WK;&S/[UD16?B(EH@D
M5J[/(^<J@"8'10,4Z6LR3;1U,\GV\F-I_P`4:&9N8H&]/B`>D!#<!]`AX".V
MX"&_COJW'ZV9!%/A/MMPH6_-ULY6HPF;(ZV<EY'.&%:'8[OD3*<#C!DE!N*]
M%J.7=[^)V+Z0>H.C.4XLD4+"#,FBF@NZ,D1<N?D<A)6X0M-Q:A1]-?EY??J<
MUB\!CPR+V1FVX7;ER^[D=92VZ43;E2K^%&HZ)-TJ2LE_`^#P^D&L+P.C3B]4
M07=C#^AGN/?^5/Y@?IICM"2=(P;E$/A`0\/#\/2K6JZHIE%3BXOHT4*RK@6M
MY<M&,K9,6[*-:DL5V-.Q13*@Y&LU/K]D$KI@]5A+]78EXE#7.ONW$8AYC=XB
M<Q2E,5,Z8'4ZLS#S;V'8N6U"W2ZM:JK7Q3\&:S,P+&=?MS<[BE:?@Z?>5RW%
M-,OX\2@4HB8P`)M@`!,(CX;^L=8?7X&U6BH0B=X+O(8Z[;E09T&EQ[3*'+O(
ML0DXQEBI('CEK`QLFY>1;._WM-B0'7Q*G*M_(8Q;<_O\R[,1),I4^I4+D55?
M`@L/[0W9GR4OE)WW*^YJ[?9)Y=WQZ>WX_I5^70M)L;DDD6;B(MUQ:.#+L$[U
M%->E&%BD@!I5D$DP2+[RD3R(FUT0,JQ,HE(0IC"<Q2E*)Q])A```3#]$WIU0
M2:]`-`-`-`-`-`-`-`-`-`-`-`-`-`6F<^/O%>:7[$SD;^L]<=`6K?\`!1Z`
MNYYQI>?PIY@([@'G<7.0"6YBB8H>9B:VDW$H&*)@#?T;AO\`#H"L6)8GX@Q5
MC."ZT5?B7'U,B?,;H':H*?%U<C6?6BV47<G;(G\G<J9E%!(&P"8VVX@5!T`T
M`T`T`T`T`T`T`T`T`T`T!\$/`=@`1^IN(>(`(_!OH"/;FUP(C.9["E0DIE&=
MQW7*6ZEI=&$@Z72+&B_L$L4B)IGW^PM1E&*K9H!TO(25!HKYG6=,QR@8%6".
MBP_-[<3V2(7A9S/MFG8UR*1E8V=P[B6=BU3H"*B*B\1,LG46Y.D<-T_.24*F
MITF`-R@(371U\BJ.U2K+5(Q4^7?94Y2\8^4E>XI8[I0\AV>4CW"P\=;?%.JG
M7IJ_5"!8L9>T1]H8RLLW;5RRT)-<$'"0J>Z/4C`HTZ2#Y9-A#\9+!WV(6VHO
M5M*J^=?@4PX/D\OWN1QYQ6-"+JF]%Y:>'P9DI=MK$7?*XL<0L3X'CL)<+JO4
MJ&RG$*Q"Y+R+>U,G,6<Y;;+9WB-W+5B3551>D>S)O))'NUDRM>@!Z3`8H97$
M6.W?:5OGY9+NIU;LM*J\D_T1O,27;]V[R$LUWH16(UAJ"3W9--%<3Z0JJOQ\
MM"^%U:>^D(]+/%W``_@/0<,B93!+S!*(%$X*1!5O*Z]A-L`CT[]._AK;Y2[!
MN2<\>>9'&\*M;MWDW'T]=&J_,[[M3$_)-=EV;G=N1W"N^U9EOA9MV'C.[KTE
M)[MJ>B?E0M1XJ\O>^CR9BLH3D?AWM]1<?B_,MVPA*(N;ME-HZ?6?'CY-G8Y)
MD)"RK=U7W"C@A6:P"F=8FYA3(("&M;9Q,#!O*//1G"Q/U0<7J[<OH?E4Y[@N
M,[1P?<7?+Y.S*Y95W&VVXQ<HW*NVYK14:\44SSUPM[U^;^8O''F2[5XDU>P\
M:&`,:YCFKY:RS&T&YI/7TH]E%+K'?%Y4Y)44Y$R"?L@'0(;B(!MI?L]L7,F4
ML>YD1LT6W=6O7Q4=*?97S(P,;\OKE^U/E<[-LX:N3]S9:C)N%%LHY/K6M2</
MB*MS:DJG=E^;57X_5NZ#<3I41OQ]GK7/0;ZADC6GNBMJ-;F3-9G8T9(JQ>AJ
M=1`4>@=^O?6JO>S;E3';<5XNJ?ZZ,X_E?Z;/DLB'#;KW#1DG9E<V[I4=?5%:
M5_?J8]')KL\]P"!YN<R,]<6*3P?Y!XRY=8S)3UDN:;NQO[GC.5FHLK6>EZ42
M"J$@@SL4&_*H,;)&6,!V9T4E$.IOUGQG7<Y5U+W*<KE<I=M9L80C?MVHVW1;
M=RCHNG[R9/M]=MW%>`N%W&_"W(+C[QON&8\:8SCJO?[,ECFE75O*SS9_(.55
MVUHGZBUFIE$2.@'SG"29Q$1]G5&U-U:53"4I)43:1>3]QYQ(`-ON6N.>WP?:
M1QGM]3Y,:DIHO('X>\2%#"=3BWQS.<0`!.?".,S&$`#8`$QJP(B`!Z-">A\^
MX[XC_P"U9XY?UD,9_P#T,:`QY^\SV1,O\N,PX%O'"3'/&G&U:H6.;O5KU'+*
MLL0+2DW8+'#2$0_1;TR@RS>9291S5P0QE_*43$^Q.H#"&@)5NS=P^S%P8X.U
M'CYG4:<.0X3(&5K,^&ASKNQ5OXMNMUD;%#E:2;V&@'*JZ4>\(5<IFI`(L!@*
M(DVT!()?4<EK,FX8W?T9E*)R)E'1[PRG7\:JQ%!<"%20K[^.=%>(NA3-N<YB
M"4!\`-MMCYMO-N6U_3]D;U.LU5,S^*CQ%J[.7+1S)69:KVHPK7Q^I/3R\2*+
M*7<1R3QB[@/'SBWRCN7%&B88S7A;,&6'67GT[9L9K04GC]U$04'3D9&^VA>I
MNY&?E9<5@ZSI*&;MU`('44O5;PH<C;M./)SMSR-VC@J)1HJ+Y]2>2?$RR$^&
M62L7:JJ_MW[JNM-M$HTI33S?2A83QQY0\)@[Y_<2SW8.2O'6(ISOC?QOHV/<
MFSF;<;Q-2LCU]!1`W2/J-A5LR,+97;0]903>^[K++L!3*18"'4$-9E6NAKWJ
MMK^EDYQ.XGV]FZ(=/.#A^FDF&X`3D=AX0*'P@!;@([[>G4;8KHD4J$(I)))+
MIH6P6WOJ]IZD3SZNSO,;'XOV#U\P,ZA82\66#>K1KM1@]5AK)7:K*0$ZR0=H
MF(+AFY70$0\#CN&I*ZOST(P.X/W.>WKR[XTS%3QERXJU\5Q[DK&V2;KC5-Y8
MZRMD:CQN1XM-5HV9W>.K:,M(TF2=M9@L='N7#S>/\Q-(Q4@`-#S>-E^S;N<:
M]MVW<3EM;54WX]/N.&[_`."[HY3CL1]NYDL>Y'DK=R;MW'!RLQ3WP;BTW!OJ
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M76<*IH(HM^2F''"RJRI@333320N*BASG.8```#Q$=6?B7B\Y%PW<)HKH'(JD
MNDFLBLF('2526`!2.FJ7<ARJ%'<H@(@(>(>&H:3ZZDU9O[`'H``U)2DET(LG
MF%U>W[<,F9VP+4[%+8(S%?I?)O);"<$XD+)(0%ZL+ER\L^>\8MG:Z[QH=^40
M6L<,FH9!R1$JK<B8D$"U1566,G(ECQC.,=U9)/X)UU)'*)>*ID2HU^[TJQ1U
MJJ5GCF\I!3\8Y2=M)%DZ#=,X*I>!5DSB*:J9@*=%0IB'`IBB&IDD9*E"<5.!
M[`1*'I^GZ/H@&_X&_P!35#2>CZ$+3H0;]X7O%43MYT<F-<7%ALI<R<B,TV>-
M<5M3*SH4[XV4!G&WC(4)$K'EO<W#I8"1$24I'4VZ`"$Z4"JG`"S?M!=G:X&O
M/[IEW)'%@R;S,R985\C4^F7DR)D,1_&#44(BR6."*5-F7(BL2Z$&<8)085AD
M*#<B(NT143FK\`92`$(41,4I0$WUP@``(^)C>(AXC[1A'Z8Z@&K0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0%IG/C[Q7FE^Q,Y&_K/7'0%JW_!1Z`N]YNE`_"_EX
M4=]C<7\^E'8PE'8<4VP!V,40,4=A]("`AH"M^/6Z32@T=HCYODM:?66Z7G+K
MNEO*1A62:?FN7*BSEPKTE#J.H<QSCXF$1$1T![#0#0#0#0#0#0#0#0#0#0#0
M#0#0%K>?.1LCA&U8YKR&.BW-ID"1;QOQ@3)V+J0\BUE)N*BG!F%=O=EA)RY&
M9-I4':R,2BX6312$-A.HF4:K4+MZ][-JW*3VU<O!+^TLW,G&L/\`WBXHMKTJ
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MIEZY=JH@Z>$:H("V274*5-0R"9N6GB=P1O?RLO#_``+DWM>/+<O%*JO4<O-T
MZU=/`]#X.]^5G]*?]?X_E+O.QMJ,;EO,A&&Y]9.#Q9.G5TWZNB\V==P.X?.N
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MZJA@$YK4XJ+T>B?WZF3&;E&$MC6Z-77P^!WVJ"L:`VA02$W4)0WWW$?A$?3J
M)*4M')T+?LV]VZGJKYLPAOG1]686?F_V]*]-E=QT'>:3-8_6G$V:9TDE;+FB
MC1#MM&N7S1S$J6!M#RSAP@BJ!QV*)ND0])))470N=2]$_P`U$X,JNCM%\]\K
M$3%'K;(.)O%BC0Y!`B?6T,.-2AYABE(!B`/L[;`7;QU(.>7YIUP;!("?;XY0
MF)L)=AE,4=)@$1`2CMC8%-C;[#[6^@.F/\U)X.L5DVD)G#E4Y<@N5%V5O8\6
MI-HQ(R8+**N0/C@Y$BJ@/4"21.M4XC]$0AMKHJ@LY[7O`/CQB'OH<O>*%DID
M-GG%^&N,2TA2"YYJ%+O#YM(3LIQ_F%Y5=FYKJ,#\<-QM#UNFZ2:$6(V6,F(A
MN;<TI;FUI.C:\"TK4-L8]8J+5/"C==?B2)X0XH\8?W?3F=C,O';"),;P?`GC
MS:82@DQ922TJ&L\M=UHV4L,15_B3XCC)J1CFR:*[E!!-95,NQC#N.]57N4GK
M))+[%T7R*W!-PW:PM_3%_2OL)R3<(>&ARB0_$_C@<HEZ#%/A/&YBG+U`;VRC
M6^DWM%`?$/#;53N3;JV'"+F[C2W/]QL*\'^%A"?>C<9MMR$#?!6,1`!,8"EW
M`:R`;`(Z1<F^I.V/DBA5(XN\`<VHV=LZX!8<AQJ<XG!NXW+/#^C5)P\653*[
M:R<"SL=0,29AET3^PZ1'RA.`@;;<--S]O=7U#:BJ,;VY^W["RL5.PG!_B1"S
M4%)LIF'EX?CMB2*DHR5CER.6+]D]85)NY0=-'!`.F<I@$I@`0\=4$GKH>4L>
M$+`YKUM>NYS#TG*`-1N\DX4=2-%>2SATJ6FVE5PX6=N*VT4*DC&R9@V2\\C=
M8?9`XUJ*:T^HM*4][3IL+FR'`P=6Y1`0`0$!`?`0`0W$-P]`AXAZ0U2TET+N
MG@%"`H`%$1`-]_#;X!#QW`0'TZBKB]`TFFGT:(Z+W3;;PNL-LSAAF%=VKC[-
M.E[1G+!D<=89"E+=1UYK*N%XX/YD(KTJ>?-09/*0<((J*MB@O[(WDXRB]VDO
M`Q\?%ACN4H.3KX-U7V:$?7=*[]>%N)6+ZO6.*TU4>2/*'-4:U)C"J5EX-A@:
M8VG3>XQMIO:$*=P]<3:D@H",96$@)*R#THE5*@@FHH:/;_EN9DE'.SWV9KMC
M_(:G<*[B,F]R?S)R1(KWZNU.XC\=KX<E9Q)9<+18G:KAPR>97%@X21;HI$%K
M6&_4U1$Z^QD+1!E`$(!`Z2[[;B/B.X^/T=`:M`-`-`-`-`-`-`-`-`-`-`-`
M-`-`-`-`6F<^/O%>:7[$SD;^L]<=`6K?\%'H"[[FW]YCRZ_8PY\_6IMF@*ZT
M;^@FG_TK5_\`.EIH#U.@&@&@&@&@&@&@&@&@&@&@&@&@(2^Z5D[&M/Y"\$V5
MIEXBO6Z&R86QUR=DG-43=QD?8;-4ZA(JQD?/Y&JSN;!RLHFU<H(14F8B3D#%
M,4PBFI7;R;MN3L8\G&[-?]5QZ-/XE-["]^TLF4(RC"75ZM/KT1T_9UX\]T3!
M56MB7.',L;.8N=J6)/%&";"LTR)EBB>;8&[N'EI3,;*171;P2L+Y[=.N*+31
M6I3(G3<M#%5;C1NBJJ?2GEH)-.C>M/#_`$=27RPKR2-G.K&,OC"23QU9W$=&
M"[38"^D$'\6=JQ^,#[),A=N1(GYQO92WZA\`U59E&<5.*]%:=>GV%W;8V[IJ
M/OUTUH_N\2/'M1WB_P"2*#G6TY&LM1M\\IF5>,;6"C<@C\B*V,0QK$,LTA$[
M(:=F4(B3KR[U9JY;II-"K@0CCR_LGA<NRC7T]*&!8QI6KER<]KWM/Q?[23IZ
M5TY740C5_<W:()G.[.W!9L?Q_G=5/J3,<1)ZP'V=:VW*";C;NR4Z]&J_KI0V
M-F[<A%[K<)VVZ=:-?+H_W'@K_6LMS4ICAW0+U7:G'PUSC7^3&,O5OCXURI*+
M=T22@()8[I$];F'#DZ1D7NZP)E*8!((B`A7D69WE;2E39<J_C'Q2IT?D_O-]
MP.5VGC8_)+G<*]DY5_%4<24)[%8OQ:I.XG_F0I5./R:J5<33$FXB("([[;;^
M!=Q$`_#UE2UG5?31?><TDV]TU%3Z:5Z+H;NH*AH!H!H"-3NK82J.?>+PTNXY
M.N.)6,1D"JW:/M-.Q5/9H77F*^C+H,H.9QW7%$)*PP$@$F<[E$JR(""(;GVW
M`<W!PLC/O>QCI.=*ZM+1?,P\[*Q\*S[^1NVUI1==2_ZBMU6E-J#5>1<3*S:K
MP#=68=Q"<`[E5$8EFFI(N8%))%.$</CD%4[,I"%;&,*8%`"[:Q;D7&;C+1Q;
M7P,BU).U&2DW&237RH>MU07!H!H"F^1J11[G'IK7&C5*ZKU5-S8*X-JJT+91
M@)EN@H="5AC3+"1+'293H%$JB)"J;D#QU$M$W\`^A[1RR0E&"*3P@J`8B2H'
M`12527`@&*NBJ38R*I#"(@(?2]&I70'G$G,B[%VT,J=.,1*FDG82@DDX743-
M_-;8Z([^4(FV_FDH=/@/K\=`>F9-6[1IY;5-,J0D$Q?+]KKW*.QC*B)SKF,'
MX\QC";0&+EPN`/\`C,?<*,(@4WW)T&`I;;&+]BXP[^&P`'2(;:A=%\@7>X0+
M_P#5$/-XWJ'MX\;@^ID!WJ03PZ`XC]R+-HX=`W7=BW3,J#5J5,[IP*8"<$&Q
M%5$DSN%1#I(43%`3"`;AZ=506YT^!#W_`,$=S^:6GB]:+1:D._9Y'-3&B<F$
M<Y8OO>+Y]WR/LDM6H*Y5ZT0J)*)(QC!&H-8*0M.8LQ#9#-(IDF:0=-GC=()!
MPJ4_G+`HJ-4K-R*]:<8OHVJ5+,<BW<G[=B4)R3UI*.GSU)D]6R^=1.PL78H>
M2@YN/9RT3*-56C^-?(@X9O&R@;'0<(FV!1,_P>&I3HZD2U6G4MP9S4A@&<8U
MBT.7,AA^>E",*1:W3A9T[H3MT1(&M2LSHY#B6L`IU)L7RYQ%(!*DJ8?9-J7+
M<_)4ZE%N$H54G55T^1<\9RD!"*`8#D/T]!B"4Q3`<H&(8IM^DQ3@(;"`["(A
MJBC<DETZU+A`MWD^\M7^`\`TP5@AFUR?S<R@U:1](H\<DE8V>-2V!9%A#V>[
M0S)Q[^]FY9140@8,J?G2*Q`45\MN8@K78TVNO05\"UOLI]C-U@"92YP\X8B'
MM_+JY23J[U&F2[%F\884?6-RM+/;++H-DT8E_EY^L].83$1\BO`<4FG2MU'+
M4[O\O8O(&4F4!`I0,.X@4`$=]]Q`/$=]B[^/T`U9!JT`T`T`T`T`T`T`T`T`
MT`T`T`T`T`T`T`T!:9SX^\5YI?L3.1OZSUQT!:M_P4>@+ON;?WF/+K]C#GS]
M:FV:`KK1OZ":?_2M7_SI::`]3H!H!H!H!H!H!H!H!H!H!H#:4622Z?,.!>H1
M`H#ON;;T[``"/LAXC\``(CX`.@/-Q%XI=@G;%5X&VUJ:LU049(VVNQ4Y&/YZ
MK+2;;WR.2LD0U<JR$&H_:AYB)72:0JD`1+OMH#J+=C+&M\E*Y/73'='NLY2G
MJDA3YFT5*`L4K4I-4`(L^K4C+L73N"?*%*`'5:G24$`#<?`-6YK3U*MOQ2ZD
MQE=C56I.,Z:/P_44`SA$<TWEEB%N.UGP9!50(4$YQIE*O6>8FE+"#UR8'$<Y
M@G;=J2+^+12#H,'658#[;E$-N.[KC^8,LNW_`,'7>.A@[/4LA3W;OAM^!W/9
M-W\LH8][_CZQRKSVTH3PW;VO3^)3DM*UZ?#0L$E,L\ZJ[S*QCQ9Y`1?'S*%!
MY-\=>101[_&`W/'5FJ$G08&/</&CNP/GKY1=K<E)=!FD#=)NJQ$IW8.0,D5%
M3H^WK'<2XSW>XOPKR(R2<K.[;73P:*><XKM_,PKW.=GX^6^%QKD83NWW'="4
MW2,6HMZRHUII\2\/M]<>K5QGQ-+X[L]`B\=M6DM#EK$5%<B<Q<BVYZ^RJL,Q
M;H!.YB$DA5BP[A%1D2-C4DH[H0!8A=U!UM).$I4MNNAP[?B<2YP7<B6M-H6H
M=_XN-JFK.2)Z:WL%/NJTXV@#K*?%2$\X:2`-5I!-'8%SHEZ1VW*'I#7FF7C_
M`)L0Y:N#?XA<'O?IG&Y[FVNB322W4IXTJ>O\3>_(IX$9<UB\Y+E?87KMRM>W
M[NVDNK3V[JTTZ,T=N7DCF3D]@BR6_-]=J4!?J-G++^&)5:BJR!:]9!Q5<%ZT
M:RLXZ3!9Y"I2BK8Y00,NKNF0%=P$_0'K7)<3G</.S9Y""A?NXUN]ITE&Y'=&
M2\:26JKJ>.1Y#C.2O7KW$2<L"-^<(UZK:Z4?Q7B2"ZUQ<&@&@&@&@(UNZIC"
MT97XP)0%/Q@ZR_-1V4<9S04=`]J%"0C26-*+FWCYI2WD989!O#P<HY=@DD[:
M$!1$IC*'$"MUMSP=_&Q\WW,J;A;V-57GX>9J^8LY%_#]O&BI7-Z='Y(D3A&Q
M&D5%MDVQ62;>,8-R-"`J";4B+1%,C9,'`%<`1`I`*`'`#^'B&^M1<:=V4E5U
MEU-C:WJS",J54=3MM4E8T`T!B`_.,>26><1<S>WQ3L?\@,H8BQK)%:VRZ0%%
MO4K0("P.4\TT>!D9"Z/H)[$N)F*0JKARB9L^<'8)D,)A3`3G,(&2E]V-Q'=N
MBK.^6/&MNW;JK%08IYXQ:<RPE.9--RX43M/B55,.HJ0;]("'4/5N`0J^(.Y6
MYB<0$4D3K\I>-R2#LO2W.KF[&1$'!1%QX)'-9@34*(MU`\-PW(8/5J0=0ER[
MXGE="G%<JN-[IJHFH*L8EG'&9W"2G2<Y5&`$LYNDH@01,F.P;!N&V@,>G@79
MZO</G*G<`GZA8X&V03WB3$%93U8F8^P0CWW<.+R*_N4Q$N'<<\!%4.DPI*&`
M#`(>D!`(70%]6$6;@WS@KG3)E*A[NUX"\6(XR@O2INRKR%\G'`$)'?DCEJJC
M'F$S@/90,0"C^2AJ03K:`XC_`']R=;-CO=D%1]R3\CS'H`0V[-,72J#8#NOK
M`%0Y$P$WM&`-QU,>HHFG&2K%IK[R''L\O\ISE/Y2R&6L1X1Q%))\D)1I!0.$
M`QI\6/89O5X!=%[:#XOS)F6&4M;91U[NY%1XS/UHFV;^DPY67F9.;;4,F;<(
MJBKX(UN%PW&8#E'%LQANEN<M=7_H_>3,ZQ#9#0'4345&3<<^AYAHV?Q<HU59
MOV#M(JK=VV7(8BJ9TS@8A]R#\'L[;[AMOJ'Z_P"5YKJ28W/=)[M;CMLQKSBI
MQSE$L]<J[^C`,\+T3W!>X2^#(R;,E&-5<B-V"@#:W<@L!DZO`IE(^.8Q3N1]
MV*03U0C[5+;K3K4@Z[LO]FBSX2GW?/3GV5[DWG'E*5=7)@WN3_Y1NL/A-E_F
MJ1GU5W+B.D\M222YP571(5"!;=+5H!#E.8M<I+HB#)M``#?8-M_3]'^\&K9)
M]T`T`T`T!TI++75+`O4TY^%/:FT4A.N:R248FL#>#<NE63:97ABKC(I13AX@
M=$C@R8(G5(8H&$P"&@H=UH!H!H!H!H!H!H!H!H!H!H!H!H"TSGQ]XKS2_8F<
MC?UGKCH"U;_@H]`7?<V_O,>77[&'/GZU-LT!76C?T$T_^E:O_G2TT!ZG0#0#
M0#0#0#0#0#0#0#0#0%+\U1.09[$V1X7$MGBJ1E25HUKC\;76=C`FH2H7IY!O
M6]5L\M#]"HRC"#FU$'*J`%-YB:9B[&WZ1`_/:X)X%[N.*.Z3>ZWA@M>A>9E1
M2NUTY"&Y`W*3:8ES5432]-DK(SM=CK$-)KW%K8OMC0THR+'$+(,"239V0&H=
M74!D[CF;YR67H*EPO[80=3(SLQS<C,PB!'!4E#A&'`(SK.].9,I`4#^9^HX"
M*@%`Q@`Y<IESYR.R31,TXA]K::,J=P4Z<?R%SBW.V!%VN@DHJ,K!QJ9R.T$B
MKD!,QS%35*4X%4`Y2RE%M;O#]/B1);H22=)4T^=5Y->%?%?N(M,R\M>[V\YT
MX6O#[#_`]SFWC;5^<](D*76+CF=;%;V(HN&<)9:NK^8NTNV;V%S-*P%T;,X1
MJU9-4_C1%T1Z<$/*6+L;4<Z'$76H+\(KL')^2;:5/BZ/[CJL*SW.^RN5OX-N
M+X2%[&]UOZ=\Y2]M_:XS7V:OQ)AL,9N[VN8,/XMRN3!7;AB6^3<?U+(+*,=9
M8Y`INV,;<X1E8HIJ\20JCU%!^A&R*17!"+KD(N!BE4.4`,.?B1[9=NN9<SHW
M?\$;;7_A-/\`44=MV.S;R7_%][DK7G^$C;?_`*R<?T\2J*UJ[V9&ZAFN'>VZ
M+L$A\HJN6>0A415`OL@H8M+$WE]?I'81VUM+>)^7%;EZ[D<Q[KAZ4H66G*G1
MIW*)5\4JT-5W$N+AB?\`]+2R+F:KLDEE*,8>UN>QMVW*6]QIN6J4JT="(H+E
MWV>U!Q)S]E6TX2[<63\95;(^:N1]V5BLK9L&X049D>W2%MEHV%B35:JQ<S&P
M[U\1!H0[D7ZB2A?,$QRF$.<Y3D\GE<B-[)E*?MVH6H5ZJW;6V"?R1H\+&AC6
MFHV[5J<YN<HVTU'=+635?%OJ91.#KW)Y1POB+)<TQ8QDOD/%V/KU*QL:9<\=
M'R=NJ418'S%@9T=1R9BT=2!TTA4,904RAU"([CK6F653T`T!85W..5=^X2<(
M,W<GL8U:I76[8P;TA:%J]X7EFU:EE+5D>H4A9&0<0CMC(H^4WLIE4S$5*`*$
M+U;EW`0+`7F8/G(J+UTW9<0NUQ),T4FRS650Y#9N1:2(."M3'2:HNH1!^DHV
M]X/UBLDF0WDGZ!/NGU@=6.:OG*1D"K#PG[8WF>>9(6@\C<M^\`GY0']YZP:>
MZ^28QA)MY@J=0#[/3L;0&\AFGYR>HDZ,?A7VQ6IFS8%D$5>1F73G?J@X;H^Y
M-1;L%DTE_*5,KU+&22Z$C!U]8D*8"FN9.<O?8XS1->NN?^*7;VC,;R[US$OY
M_&>4LUWZ<AYI.G7&W-HY:KN$ZZZ<MSI4]1-T\25,V9)+>>(J$24*`&07BBX.
M\A8OQQ?7S-O'/;M0J;;GD>U.HHV8.K-7(V;<,T%%A\U1!LL^$A#&]H2E`1\=
M]`5`T!AV_.&.(.<.<O/KB#@+C[%4Z:R$XXK9EO*47>K6O2J_)P-2RC1PL,4M
M8$&,BJU<R3*4!)/H3`P`)S@<@D*.@(K5/FV/.U8_F_<(\:F8B8P@W;\_\B&1
M*`J*'+TF=49TOL0IP(&Z@CTE#?<W480..;YMESP\P1/P3XV')U$$X)<_KP@X
M4(`^T4BPX]$"JF(<X`8P&`.H=P'T:`LGB.U3FV;YR6CM],.$V(E>2E.QFEEB
M79J<V,B(T4M17C:W)HF;6H*44CF5.TMK0HMO+)L)CCU=)1'0$V/#;M:]YK@!
M:KWD/B9Q)X>X_P`E7;%TQB9G<KKR[N^565/@IFPPMG6E(:DR]?AJ\_F4)6OM
MA(9YYZ7EE$@D$HB&@)H.V#QL[E=8Y:\@>4O<8A\&,+KE#`N&\/LYK#5A1E4;
M$^Q;9;')$F92OH,TF]:<2$9/]"Y&JA62AT$S`D4V^@)\]`:#]72(E`!,&P@4
M1V`P@("!>KQZ>H?#?4H$0?9^XI9EXAXZY(4'+50G:BRM?):XY,H:4]=<779:
M5A[O$PTO891D^QC7X!)K&N+DL_%!*43+(`F(%%)%,I2C3<_RV5+H2_ZDI&@(
MZNZ9R!SKQNX:Y9R#Q>IBN1N0A(J/B\=4]A%.;)-E&7F6$38+G$56/$\A8UL?
M03Y>6%L1,Z1CMD_.`4]P&];MUB[C58Q\?W?;_:#"C[!E1R-D?N\8WS'>ZOD&
M^/D%^2LOE3*URI4N^"/RX^Q[8%)$;=8W47\5P=[3F7X$!)=1!ZD8Y4BD(4"E
MUCJ\[TM_AT!^C4UW\A/J'<P%V-]:(;AX#MT@!>GX-O#;50-_0#0#0#0'EKPG
M<U:9:TL<NJVROZE=F4Z2\N322?U)I:SQ[@M?<V9C#.F4N\@4)04C.TFRR2ZB
M`&*0Y3"`@"/SVL&<>^[[,=ZZ527L$TPYFTJWM;9F7.$ZC[WBMM@Z0<-F!YA<
M2,DXB4PU=*DB$=`0#5%-4R@$;)I-GC-PHU`_1.T`T`T`T`T`T`T`T`T`T`T`
MT`T!:9SX^\5YI?L3.1OZSUQT!:M_P4>@+N^;X'-PNY=@F<$SCQ@SYTG$GF`4
M?M56OQ$@F*!O#Z(:`KQ1OZ"J?_2M7_SI::`]3H!H!H!H!H!H!H!H!H!H!H!H
M"$[$S%%#O#Y?>D,/F/8+D("A.MP8I?=<-]KY(!*FHNHV2$Q3!N*2:0GV#K$X
M@42T+ZOO))J=5D#0&*GD%PP'N%YS2:E.@H,GW4^ILNZ(Z<.%T>$G$4KURW`C
M=N)&QUS;E3$#"D!P*)SC[0]IQV58M=E<EA2:]^Y?Q9+S],KM:?8T>G]O\C"Q
M^6'<7&2FM]_*XZ2CXO9.ZW3Y;OUF0KPM,4_#GB8<OB4_&;`QBC_&FQ75!#\(
M=<6>8%R^@(O^]1%R$WVJ.=,/%)"M(R>!["Q:$Z%3D*LY?1:155_)*8Z;1N!O
M,64]"213'$0`HB`B70L'POWM,0XKP]B;&,QB2=E)7'.,J%0I28@,]<6G%?EI
M*G56)KK^1@73G,39X\AWKJ..HV56125.B8HF(01$H"(NIZFV?.'N.%)C74O/
MXLL;1BT;$<'<&S]Q/(B8QT"K>Y$.OFA(#R("(I>2&YC+`)"=0["(J*&Q_P`Z
M-X_S$;'34-P>YZS,/+LFLE%2L3BV'DHV2CWJ1%VCQD^932S5TU<(J`8BB9S%
M,4=P$0\=`6%]R[OUXIYE<*<^<8Z)Q$YA4>[7]EC-)O-9"HD5$0D"#/*U3LT>
MI,E0E)"29C8BU%VSC!,VZ73TH$((B4VV.[UMJF^?W%=Z[9QHVXW[MN$6Z14H
M2E&5*53<8O[=="I&=?G*D?DR8P4TPIB/GS@>CQ=A?/,QRE8Q!@VV7"\5RPT&
M91QI#40UQ3R3"*!)6I-.0(L#-NH_CVJHMSG$HDU=C=@]:2<?N)OXN4[OX6Q*
M*NRCI/;)P5?XJT6D/XZK2JJ>@P5WN4N0F7<;X9QY;^[E*6?)-T@J='NDL$\'
MGT1"*S"P>\2]F=QN&EPBX&"BRK2#U<1#H9M5#EW``WKW*71-?,BY"Y&Y)RCM
MMM^E4DJ+R]6K:Z/5F03D[!'(JHXTR';H?G_R(-*UFB6VQ10.L=\45V0R,-7I
M"38BY0#CZF9=K[RV+U$`Y1,7PZ@].A06'=Q'(%RMW:OXEY'M$Z=]>;ZPP;/W
M&>;1\<R^.9V_<:;\:VN@C6B+:-CT)Q>;<@=-NFFFW36'R2ATE#0$R7&P-N/&
M!@'TAA;%>_T1"BP0:`K7H"T[+7"7CEF[D#A+E%D2DOY;-W'=M*LL27-A<;A`
M?)MI.+&<2K5W!P4U'U^RM':W2<491L\2`Q0$I0$-]&JJ@*XJT^88D\ZO7&=1
M=D2.4J,ZX"=CW`E`IFZ2J3D@*-DP.78RB7V3I,/T-6]DE]+=?CJ13R/D;;G8
M.$Z];6!(.P.6YC,CI*^?#S'24W7\7O-Q\MP7;<R"@@<OJ$P>.IC-UVSTD50D
MHR3EIJ8B>2<ZQW'SYU)=+;/"JA5;5@&KX^N<BTKLI9'L-`2&`*Y94YANQAR*
M.BHMK%5X\'3@Q5$FK053F+L.^KL8[I46AM^`X#D^Y^5CQ/!V%<Y"?1N25?)*
MM%\.IF(1DJ9R=)!PD5(Z[8CMDJB85&KQJ8I#%41.)$S%.4ARB8H@&V_AOJ&J
M.C-5=MSLW96;BI<A)IKR:='^L[T0`?2&_P!/4%`T!M+`J**H('(FL*9_).HF
M*I"J](^68Z0*HBH0#[")0.01#PZ@](`10]IO"W+S"])Y+LN85GRY:[5;.2]M
MLN/)7+5XA+H[7QD>!KL?!+UU.$RQEE"J0SITR<'^*C.T1:G'8`5`?,$"6/0%
M,<FWP:3"*?%$,M;;I*^:SIE)9NVS)]9YORQ,BU,[<C[O%1"6P&>/UMD6J&YA
M$3=!#96+B_B;BCD/;A_Q2I]*_>_)>9CW+RQWZ=9R\/B=;C:F3<>F2U9#?QDW
MDR6:-TI=]%-U&\+`-0'S`K-7075<+I1318Q@46.<5W:HF44'Q*4N1R/(8N1-
M8?'P<,*W6*_O2>KWR?GKHOX4DO`MPL0M-O>U.<E*GAU2I]O0C+[-4;'L*9S:
M7CVP)!,]P?DO,/W`D4(I(/WDY&@N_<%530,==<$P`QO+3$W3XE]`CV?YE<)Q
MW!\GQUK`C25[A<2Y<Z4WR4]W1M?M^9PWY9\[R7<'#YN5R-W?[7+95N"ITA'9
M3_03*:\Z/11H!H!H!H!H#9*W;E75=%01*Z72006<E2("ZR#8[A1LBJL!?,42
M;J.E3$*(B!!4.(;=0[@;V@&@&@&@&@&@&@&@&@&@&@&@&@+3.?'WBO-+]B9R
M-_6>N.@+5O\`@H]`7#]R.4?PO;ZYM2D6Y.SD&?%;.ZC9RF5,QT3CC6QIB8I5
M2*)B/0<0\2CZ=`78TTH%J%4*4-BEK<&4`^``BVH`'X`:`])H!H!H!H!H!H!H
M!H!H!H!H!H"$W$)@6[OV6G!"+%*:-Y*MQ%10%$A,TQ%VO6XF0!-91)(IU"'W
M#8B@B'M!X!JA?5]_[@35:K`T!A8<X>-;[DCSIR'7&MW<X^1@<C=S.UN95C%N
M95V_+7N)G#B=3C"H-YN`*FE)'C/(45.N<"$,/V)3?8-UB\5>GPV5RD;E+5J=
MI..FON.27W;6_M.DP>T[^9VMR?<?O26-B9&)6"=$W=E*,4Z>3MMT^)E<\+RG
M)PZXFD4$!4)QGP.4XAML)RXLJH&$-@*&PF#X`UI3FRI=XS/B'&4Y3JSD;*%`
MHECR))!#4*!MUM@Z]+W.6,[81X1M7CI1ZV=SCX7TJV1!)L10XJN$R[=1R@-R
MW9NW:NU&4E%5=%6B\V6;N18L;5>G&&Z22JTJM]$J]6_(J7_\("`A^`("`ZME
MX\5DB_U+$N/+WE.]O31-(QM3[)?+A*H1CV56C*O4H=Y/3T@G&135Y)/S,XM@
MJH"2"2BI^G8I1$=M`8T6',49F[^.8*=RNY5TN3Q3VJL6SCJ=XL\6IER9.:Y8
MS3-^=%AF/.D6T>JLU*<B9GNUCU"B@L3^9VWFMS.GSX#*(CV+&)8,HJ*9-(R+
MC&;:/C8V.;(LH^/8,D2-F;%BS;$3;M&;1NF5-)),I2)D*!2@```:`B^Y:';?
M;#SFDX;G<`^K7;19'!)J=R("7FEDM=HH[%(IC-V;14RAP6/L1$Z@CN`FW'8V
MH1_#6YT6[?=_5"-/N;=#ZM_*7A.-S^V.!OY-C&N77E]YRF[D8/<L;MS"NV4M
MZ>Z5J[)W+455J=9Q554MYQ*T:HR7'$I&S<GDQG:Q12`J*902(WPQFXB!$@`N
MR94"J&`@!L!0,.WIU=G;CLDZ+_ROZG$]4[GX7B+&+W2[6)CQC!]^*"C;@MGL
M\EQ<;6VB6U6HR<;:6D$VHT39<)VR*M(MX+,=@?P,M%0=GM%??5QU(Q3F*2F&
M+>*F(UT"/O""1CJQ#@5&BQ"CU-UBG2/L8!#5/*;=UN,*4C#P^2\?$\=_YEX=
MO8>=Q/#\++%_&X:RX9,;.S2Y*=F47)P^I-)NW+5.+;CHR_O/)TD,&9D45,":
M*.*,B&.;8QNE-.G3(F'H+N<_20!'8/$=M:L^8#&ZY5\GN.>7^USPOQCB+/>&
M<E9,KK'`K*?QS3LC4NRWB(7Q_P`8;G)WEO,4ME+NYYB-281ZZDD1=L7W0J)R
MJ[&*(:`R,^-IBCQYP,`"`[X5Q68-AWW*-&@]AW]8#H"MF@&@&@.CL,#'V*-4
MCY!N"Q>HJS=0#'(LU=$W\IRW52$JJ2J0CON40$0\-1**DJ,-5,57'O;$[BV6
M>\3$<_.76*.-,7BM]'V*DW:LX_RG/S:3BFML0SF):M*Q,7(QA["6PNVIVCUP
M3WU,J"YC="@"0!U4FXNJZF=Q_)9_%9<<_C;URQF0Z2@W%K[C(IY/R')BLX<7
M=</:/BN^YJCY6O-Z_6,QV.9K=$-`^]%;3SI_,0BY)4KIC%`)FZ93B"JP`!]_
M$=5T3N+=7977]Y8A*W<OQGD2;L3GZY^*3;<FDM*U^!'@AE/OU&V\SC!V^MA.
M(G$F7\G&Z2B;<0_GT=S$`1#X!VUTUC%[3=E/*R,J-_Q2@FOOVGIEWC/R@6%&
MYC\OR-S-VK=%64HITU57;\/F<ASE+OP%Z?=^,O;],&_MF/EW)9=O1L!?YL]?
MCK(CA=E_Q9697_47_B&5QG%?DA>QG+E^<Y2QD;E398C)):UK6V]>E*/S-E;*
M7?K*"`H\7NWV<3'`'`*9?R<4$R>LR8@[]L=M3^#[(_\`E>9_V%_XA1C<5^3,
MN0RH97*\M'C84]B:L1W3Z5W+VG14KU2U-;C*7?G*4XM^,';[4.`^P"F7LFD`
M0^B/OG@.H_!]D?\`RO,I_J+_`,0V']'_`"'_`/\`-<Q_^`C_`/DCXGE7OR"H
MB53C%V^RE,!?-VR_DP3E,)3]0%+[[X[&`NWIWWU/X/L?K^*S:?ZB_P#$,')X
MO\DH85]XW-\E/E(Q?M0=A*-R7@F_;JJ_82;XCI]F2BHZ[Y7;Q:N8++!0YKF2
M&6<O*_4WZL<T5EZ32GCO9Z>GQLR"ID5%?LCD1\Q41,/AI.1S+,5^$P9/^GP;
MVU2W2_Q2HOJ/'+4(S@KTX.-V75/JOT^!6D4P+T`7X0'<PB8=]PVW,;<1VVUH
M9SMVW%NJ;=%3XZ:_V]2ZX*=4^J6C\FG5?K($^T!R3P>V@N:T-.Y?QG7[*CS]
MY-I/*[-7.OP\L8(ZS-6)YE%@_=LG#F-DSHB9!P0GEK@03`"8[D#K?S)[U[>R
M[^'?]^W9L8W'6;.ZXU%?RZ^G5ZM5T56WKJZ&@_+GL/G./XO)MXN/>R+M[,NW
MG&U!RININDU%=&Z:]$3DU*[5&_0C2RT>TP%OKSU19%I.5N58S,2Z5:K&;NDV
M\A'K+M5CMER"0X%,/28!`?'7&8F;8SL:&;AR5[&FU24-5\_DO$Z;+Q<G"O>S
MEQE9N_W9JC^YTZ^!ZO686AH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"TS
MGQ]XKS2_8F<C/UGKCH"U;_@H]`5X[FW[W7SC_8IYV_6WL.@+P:=_0C5OZ7(3
M\[&N@/1Z`:`:`:`:`:`:`:`:`:`:`:`@@XV='[K-FD")$2$T_P`U3F\L3[&.
M6J=M)(QS`<QO%4"@8VVP=?B&P>&J%]7W@G7U6!H#$1Y+9BQSAOGWDV6R3;XJ
MF0LQ.]T>$:2<N==-HO/3/$/B/$PL9UH(KG!W(/W:::0;;")O2&NIX_D<.UVE
MR''R5<J[?QVG7ILE<<E3QJI+R._X7FN.P?R]YOA;UQ_U'-RL*5N-/"S.XY_J
M:^\R6.%XF'AWQ.$X=)QXSX'$Y1](&'%E5$P#](=<L<`6D<XE<<'Y4\$8O(>/
MI7(2\G>)A;'S=IG>RXK0JF0H>VXVD(>ZMZ0U4C*ME:5KS0'#@6+E[[ZE'I.A
M1;+I&6Z>CX+`>9BYM^-YVI6,=R?\KW%*-)5BVM;=:)*5&JO5K0Y?N3F,3C;O
M'XE^S&]?RLV$(+W%;E%IQ]<=U%-PKN<$U)I.E=24X?2/T]<X=068]QEVJR[?
MW-MPB5T=0O%+/J8%9I@JX$%\869N?H3,RD0$H$5$3?83;$W'<OUP"'HJE.>T
M8(#VO^`W2`@4.*N&BE`1WZ2%IL:4I0\1]DI0``^AH%JJE[63LC5/#^-L@9:O
MK]:+HV,*5:,@W*3;L7DFXCZM381[89]ZA&QR+A_(+-8N/5.1!!,ZRIB@4A1,
M(!ITU)2JZ+J8J6=^_9V^<CV/*-PQ]+YYM4-:X#A4RK[IAQLS"9K)N\+\E+WD
M7([8KH(%!-J,#5)=FN!U>LKE50R"*:RI!*&1;S+4;,+<XW$XRN/Z?[T8I=?B
MM?@>^?E]^8W&=L\5Q?%<ECY$Y8.7W%O]IVI2;YCA\?C[&V,I*OM7;$IW/5%[
M&MLJZ%'\<][[A'%/\+K3#?D1&DJ33@8G8S'XVY:=%CU,)XRRG7\G`C[C77*T
M@G6YNQ,6X&1(<7OG];4%DTU#DKER-F5MP:E&3]SJM?6TU7Y4.MY_\[^"Y.WS
M=G%Q,J$.0_XHG!S]M2C'F\[$O8ZN15QJ,K<<2:N).2W26UR6IE!<#'\H[XEX
M9EWU3LU7&QP,K;&D%;HQW`V=A$VZV6&T0Q)J$D#+/HA^O%3*"HMESF61*H!3
MCU`(:IOSLWI^[;;U71KIHO[/]!X/^8/<6%W3WCE\YQT+EK%R[L9TN;?36U%.
MDK;E&24X[:TAHT]JHXJ[IP/O**B#EEYB*A1!5,_MI*I#]>FH02]*B:A=RF(;
MV3%$0$!`=6$DWH<3NG%)SV)U==9.B7C].OR+.L[\#>+/(RGNZ7?\/04,V=R*
M,H-EQDB&+;Z@\,UDHYT*%\H:4)9F[63BYEXS>H%<>2\:NUDEBG(<P:J<(>#_
M`%%QN*;3:T;Z;NE:1_AZM:ORZ%VM2K\54JU`5.!:^XP-6A(FN0C+K56%I$P;
M!O%QK8RZXF75,W9-4R"93VS"7<?3JV2>BT`T`T`T`T!MB3?\</U/7_@:E-I%
M,X[XI=&OTZ&GR2].PB(^UU;C\._P?!J$YUKN95%RC5QHI->7[C4*>^WB'@`@
M'L^C?;<0\?H:+3Q?WD4JJ2HX^.G7R^5`"10]'AZQV\.H?A'4[F3*LFFV].A]
M\LOT=*LC7Q;H:`1V-U"8!W``$`+MXEVV$/$=M5.=50IE%MT5%;714U7V_P"@
MW`*``!0\`#5FY%W'5LK3?BZL\#=\F4;';JIM;G9X>MN+Q9(^FU!*7>$:#8;5
M*&/\7P$8!@$7,D[*D<2)AXCMK(MV]T:MJB^\W'$=N]Q]Q6\V7;N%=R_Z?B2R
MLAQ^FW8@Z3G)_#RH4]IE3Q\W)850J-%8R3BYSRKA&(JM92=R#A61,B1X\(QC
MDEG+YT8=U5U^I0QMS&-K&>/9E;=O)C"ZG+^**:I\M?O-<[V4XV\BQ<OV\.Y;
MK%I[&WXZIOH_#QT>E$5GAHAO%L46[9HSCP\U5PHV8-4&C<JJZHK+`"38J:/6
M90?:,!0$WK\?'16K4(JW9BK=E=(QT2*9W9W-;CE-^<GN?WG=ZN%H:`:`:`:`
M:`:`:`:`:`:`:`:`:`:`:`:`:`:`L4[H"RK?MQ\Z%D71F1R<4<[]3DKM5AY:
M)L<6`K@!>(B"K<BB`F*8Q?:V,.P#Z-`:>C'/_:R!^\2Z/Z(Y[^IS_P!K/\A_
M\@?_`)X_S_\`_,^@.3W-OWNOG'^Q3SM^MO8=`7@T[^A&K?TN0GYV-=`>CT`T
M`T`T`T`T`T`T`T`T`T`T!`_QN+Y?=HS(`@!A5F>;1P$1/NF'R<[:7UH%.!!Z
M@#8>H#;>K;QWH7U?>"=C58&@,0KE5A3'&9N>^0HG(\.[FXR&F.Z/:&#%K.V&
MO?X]PG$+B;(1CM=]6)6&DE46;MH106YEA;K](`J0Y?#748'#8\^U.0Y>K]ZU
M>QU3_P!)*<7^J"/0>([;Q^0_+[F.ZHK_`'CCK^':;?A^(G=3HGUJH1U70R7.
M%0B/#;B4)AZC#QDP*)C;`'4(XJJ@B.Q0`H;CZ@#;7+GGQ8AW)#6=;DWVY6,3
ME;%>.&2N<@<MV-VPSD_(MUM\LTLU`7D:YC*WT6HV*%H,M,U`D@U>+2;N-1,R
M54444%JFY.GE8G*3P'<QH2DOQ%N46E6DE\?#2M4GXZKH:CDN/XW-OXU[-C7*
ML7=]E[:[9Z5:?6-5HZ=4VGI4F)'TC],=8IMRR#N7N)9KV\.<"\(@=S)$XJYT
M!%$C,'YS(J8YL";TP-3$."GELCJ&WV]C;J]6A#Z'CNTB*`]L3@7[L<BC<.+.
M'BI'(H"I1*2H1Q/R0!'J$HEV'U@(>/CH%T+T,L8TJ^:,6Y(P]=TGR],RK0[;
MCFVHQCU2-DE:U=8%_7)Q./D4@,JP>GC9)4$EB@)DE-C`'AH]=">FIB*<D.Q/
MP]P`YR-6L99+YB5ZL4IGPWE8:"9<F+8U8$5S7GS)E(R6D9LSCVS9,LS5ZJS2
M:F*0#,G7F.`\PQN@,K&P(Y+C*4[F][_XG_#%-??4^A_RH_)KA?S$L\9?Y'(O
M6+^?D]P.4[4+:E%\1QF)G6FO32ERYDSA=37T*.QQE5OQ&/.RCQGL+G"I)#-G
M-?INS/@BYGO=N4=W0$RN>\;9+M60C,3`F)FA'$O568LP]H6:95"D$?,':JY@
M;-RG)MQ<UKJZP:77XU-MW!^0W!<'+N"W:R\F[;X]]S6H.<;3E-<)FXN/9E-^
MW]5U94I7*42DEMHJHXW'OM#8*O\`(QT?:L]<Z%D4^2K'#CU1ORUO;5=_4G7&
M/)^6W+PONZ0(1\NI=*ZT$%"$'H;)'3`H`J(A5=P8V$MSW5AN7AKN2H_@=)^8
M?_+]VQV7@Y#X_)R9J]VI^/BFH149V>?X_"MP6V.L7:N2;;]5=$T><IO:6PS,
MMN.3ESR'YPG)DWBO2,KW`@<J\A)"K>I[`'*7(\@_B03,/Q;&*V3$,/T,^HZ:
M38JZ>Y_.$Q+L\:%J[<MT6Z$W%_+=%?O9<YK_`)=^V>+N]S8KR<BXN-[FR>)M
M2;^NWC\KPV%[D_\`'*WRMR;HE'=;AI2JE>SQP[%?&7)%DLT;9N0//QPRA\4<
M9[Q'D8\P\AQATYO*-'GYNX>8JB455F:\E%I*-B"(&:B)@(?;8`PKV+;3WRT2
ME)*G^%T/%?S+_+_CNT.'XO)X_(R;EV]RO-X=U.4=OM\;DV;6/)K;5MJ;4DFJ
M*FAE-U6O-:I78*MLEI!RRK\+%0#)Q+/EI.5790K!O&M%I*1<'.N_D%F[8IEU
MU#&.LJ8QS#N;;5D\D/0Z`:`:`:`^"8`#<=0VEU:1*571&GS">G?P^'U?@#J:
M/R82;EMHZ_(=9/XH-15^3^YC;+K1GT#E$-_1]/P_%TK\']Q"U\&.LO\`%!]7
M37R?W$T=:4U/GF%^'QVWV]>WTO3J55QW4=/D0ZJ.]I[1UE^CM\.P[#](?0.H
MK\']S"UDXT=4:MPU&]=-2:-%/;QCRDWUY47UOJL-9G=$L;:X4]Q+LTGIZU:6
M2*[5I/QA5@%-O(MV[I0J:P@(I]0F#8P`.KL;GM==$_A7_HI]YLN.[B[@X/'R
M[/`Y>1C1S;/L7HVFXJ];;K*W<:ZPET:>GF6NON77%3%UJNM%O.9:1#W:L6!=
M6VLFZKI9>N/+"NVD(>)L,C'-U6C::%A((+F8JK>\I-UR*'3*F(&UASY+BK>4
ML"[E8]O,G5QC.Y&.BZZMI?O.S[8_+3OOOW"EF]E\;DY_'6]&K;4YPE!>M>TG
MO4:M>K;MZ:U+O:I<:O<X=O-U2P0MEAW"R[9O*U^2:R\8NJV5%)4B3UDJN@<Z
M9@`#@!A$IO`?'5.+G8F;&<\2<;D+=S9)QU2ETI5=?F<5R?#\KPN9+CN7QKV+
MG0596[L)0FJ^<9),]1K+-<-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`6(
M=T0P$[<7.4Y@$2DXL9M.8"EZS&*2@S9C`4GX\P@'@'K]&@*O?*&,_P"UTG][
M=\H?\AC_`.1G_:[_`"S_`/F/TZ`I9W-OWNOG'^Q3SM^MO8=`7@T[^A&K?TN0
MGYV-=`>CT`T`T`T`T`T`T`T`T`T`T`T!"9Q<CT''=!Y'OU")BO'2O+#W<QT$
MSJD!]%]NE!<45C!YB`&*W*!P)X'V#?T!JE=?O!-7JH#0&%[SNY%S/'[G3>IZ
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MQ$U&+*ME$'2)7;!V<GF)'(H01ZB&*8`$`,6W#5PY!?-[\_5?C;R%L\WE[M`Y
MON,E&8%Y$3)'3J6X<7"??*/65'RS*`C[E$TQ^J<YEQ'R6+@YUI=EY*I)5CH#
M*YC9&/F8YA,0[]E+1$JR:R47*QCI!_&R<<^03=,9"/?-3JMGC)XV5*HDJF8R
M:B9@,41`0'0$0?/DI_E%G4`(<YC0';@`I"%$QQ%;E3F]%'I*`"81553,4OA[
M1BB`;B`ZV.+<5N,)>*=S]<8H^Y?^6GD^.P\3MZ.5?L6Y0O\`>SDIW(1:]SM_
MBX6V]TE3?).,*TWR3C&K312G#:B:CKC08ITQ*>&[4ZJ8@H0>LBF$\W"0Q=C>
MT4X%'I$/3L.WHU=NW(SA*555NZ_O<3IN_.2XVY>[O=O(QWOR._\`;2[![O<Y
M7C';VTEK[B3=NE=Z3<:I,\5P];IHR,$U:IN"D^[9KZ+9%P9XJZ,FGP/S2=$I
MC2!2R*ZWNQ`,8RP><8-S']K?5W-G%J&J;]OS7_G%Y'4_GUR_&Y=N[.&7B7+D
MNQ+T7LNV6O<?=G&S<$K4G!2VJ4U"&B@G**V*IXO&3A+XFX6]:R)57?`?%SMJ
M054P,Y0+Q"YYB9PW*)MUD``X>V7<OB'CIDRB\W(::H[S\?\`WR)D]W<CQL\S
MO2Y;R<>5N7YB\C)-7;;3C+N#M.49)J5'&483DI*L7&$Y)TC)J3+A$1$+ODLZ
M7F"HXP#P?<K]2KM0AC#A^P($4;D<?84FYDD"ALWW0,H4XB/FBJ`864TX)57U
MW/\`:1\N_GMG8^5VYP]NU>LW';Y_NATA*VVHSY*S*#EL;EZ_4X2N4E*--M;:
MBR1S<-]MPW].V_C]36"?,A]T`T`T!T5BG&=?BUWSM=%$P[(,R+>8;WEZL/0V
M0(DB4[A;K5$.HJ93'Z`$0#PU3*:@MS%::F+AC+GCWL,I=P[-'`-N^[>5:MV&
MJ>OD>PV,:GFJ?JYZY(?)5W7H*)>!.14X[G2L+FT*]468)MTETE03,H4`-K)P
M;G&PN^[R:N>WY16OWE=FCN4G]/W$F8UCO@F2W)D_MQ^:8@=)OM>9U$`/X>(@
M,X`[>G79*[^732KC9]:?WX'0XG_"D<BN=;R7;I_"XUK\S<3J_>]Z2]64>W+U
M?CNG'N=`*!@#VA*'QYOXCJQ<N]B;G[5C-4/C*(R[G:$YP>!:RE8B_5N:J]?#
MR/OR9[WH>)<H]N;T>(FQ]G4/1O\`_/LOPZJA=[`2?XC'S6O"DX:>?4U&=/C+
MN3[G%PNPL-=)M-Z?%:E$<R92[P.(L>Y2N<CGOM<*2.,:/9;I(5MQ#9992JI*
MS!NK`M'*-W=L0.T<R#1H8B/F]!1.<HB(%\=:W/Y'\O9696.(MY']5_AC*Y;>
MBUEZ4Z_37P_43+CL]8SSWCY#P$M9J$MFNB];6W5T2UU>AXOAEF_O4\QN+F%.
M3]>N?;SJ]=S53F]VAZ_,4'-2\M$Q;UVY;M6LHI'V1U'C(D]U'S00542`1]DP
MZGC;W:;Q:\A9RO>K_"XT^XS<5]LO#_W^WD>_7P<:?<7(2<9WKHE@YE9++_;7
MC(]HW4</9*1HV<&C)DBGL!G#IRO/II)();^UN(;^C<-9KN=D+1V<S3_%$R<1
M]H0R9O/M93M^&UQK]Y>QQ>Y$J9IQS7'EIC_B#)*#5Y&6:.)$2L5!6N4K2Y8B
M>O6+4YCHDIO%5BE$SN(5\H`*&9J)@L!5-P'0Y>/84W=Q-WX.3;A7JEX*775>
M/GX&@R;V!++N1X]M8>][%+26WPJO,N0<2:R)TQ48.P(=9NB4$BD<FW5.(%.J
MDD?K01#;Q.8-@]>M?"V[E-SHMWZ/["S.MI2G",IN-J<M-%2,6Z:]9/HDM7H0
M)]J'B#QBNN,N3EUMF&J9=+)9^<_*1Z\G[''NIV0.P)=`^+8YN_E3$=EC8M!Z
MHFW3,1(2$5,``(&$1L]U]I]N/DK63D84)W(P34M&TWX^'7]WQ/<^\9\G^3/<
M6-A]@9V=@_BN&PLNY[5U1;N9"N.<7235$X*JUHZ5\"<N@8XHN+JVQJ&.:E"T
MNJQZZ[AC7X!DG&QC19\X,Y>JI-4`\LIW#@XG-X^(^G6/Q_'87%V96./M1M6I
MR<I)>;/'.9YOF.X.1ERW+W[^3RMSZYW9;FUXMOQ=#W^LPP!H!H!H!H!H!H!H
M!H!H!H!H!H!H!H!H!H!H!H"Q'NA;_N<O.+;;?[EO->V_B&_R#FMMPW#<-]`5
M[_FS_IK7^H7_`-;K?SY_TW^>_P"=?_N?U_\`]TT!0[N;?O=?./\`8IYV_6WL
M.@+P:=_0C5OZ7(3\[&N@/1Z`:`:`:`:`:`:`:`:`:`:`T'4*F&YA`/IB```;
M@`B(B(``!OH"%#BF^:+]T+D^T273.Z:O>4WG(E$3'3(9OV[A*<^P;%W,(AL/
MCX;^C81I3]0)JM5`:`Q.LMK*I=PC-CM)JH[69%[MQT&;?W8KMXHGPGXF*$;M
M5W:K=!%5<X=!>M1-/J$!,8`#<.[XEO\`X"Y=>'XC#_V[IZUVUCV?_JE[HOU_
MFK*XNGVW+R?ZDC(HX2[#PQXB[#N'W,&`=A#?80^U14_$-P`?'7"'DI<[H")O
MOG6JQ4CM1<Q+74YF2@+!"5*ANX^4B)26AGJ(CF#'B+IN,A!/HR7292#-51NZ
M(W<(G6;*J)]0`<=`40Q?VL+!:,=46V'Y)O8IW;ZE`W"28157RTC&(RULC&MB
MEC,TU.2OG`FM)R2RFYS&.<3B8XB81$0.7D#LHPF5:K(TG(^<VEYJDL"7QA7;
MCCR_VJ!=*M5`7CW:T%8N0TG#+O(QV4B[915!045B%.78P`.@+0*S\VAD*77X
MJIT[NN\_*G5H%J#"!K-8O4E`5V"CB'.=",A82*MC6.BXUMUB5)!%,B9"^`!H
M"//NF=F&P\)N)&1^4K3N%\N\R6R&L6%ZXXB,D61VY;3+5?)+2+KJLE,)V)>;
M6/1G=K>OX<!5,5B]6.JD!#J',,M4)M7+D/\`NJNQE\_OZKIX,OGC/FP$.Q4B
M9"+[F_-:,5C$JP:'.P>0[!6)2I\4^BJ2G&F:RA/BX*7$R[MK$`ET_%C=TLDV
M\LBAP-;<*NI=>3ERDY3N2<FVW51?7K736KU=>OB;##YKC"Q1T3Q7<WYHQ1F\
MBVF&YXM:`C5$I=E"/ZRREP59/T#_`!NRK<JZCDG0;+IL'*K<#@BH<AIC':,G
M(NY=O9?E)M.J:T:\UHO%ZFEG\ULKD>E%(LNY9S):I0D,G6X@C8:\@2)KB$9-
M0C:NQ":3XJ<3`-H6R2+(C)N";8K.0=(`0$G"Q#U%^]R.==48J[*,8^&CJ]-7
M5:O1.KUJD_!%IO-CLD6CA=CBOW^@]S+G"\FL@V21Q[)&2N3FN'^*,?<><X90
MJY%'U;L<:]71@4\:!&QR2IET(]N^4\A,FQ=AA2DYNMV3;;^6OQHC,*X\N%WV
M"L+R3ER[>N9#$.,GCEY(N#O))XY=4J%6</))\J(K/7SE0_4JJ<1.H<1,(COH
M"L1S@F43CZ`VWVV]`B`;^(@&P;Z+4%DV3.?N"L5\O,*<(Y]EDB3S;GJGSE[I
MH5:CO;!38VMUX\LC)/[?9V;CRZXF1Q#J)%.HB9+S%42F.452;GH"Y96Y3DF!
MD*Q3YA182]`/K"B,''M5A,;85TG!@>N4@3((B*11V$2@.V_A;WR?TIU^.A%?
M(YT14E@<$F+4]3G[`386RPH^7&1`%)T%"(CSB=)NL;;J46$/,.8?2```:F,'
M7=/67Z=!3S,:[B4<3?.8NX.78H`7CK!%`"E`H;?%&!S"8WB(G.8R@B(ZK),H
MD/``#X-`-`;2F^Y?$``=]P$0#?T?#XZM7)17I<HJOGK4--K2+;^#I0MPRWB[
MCNW@<@9*S+B_#LK68&NS%QO%KN.-*O:ED:]6XM>3FWDP#JO2LE*-XZ)CC*](
M$74$A.DA1'I#6+9P,6WEK,CCXRO4?\R,$KFJII+JJK1^:-I#F.97'/B[F;EO
MC94_D.[+VM'55A7:]KU55HZ/P.\P-D+`MQP/0,D8`E*6/'V>J25CQ],U"(0J
M-(+3SBL=-U%PQH^$2@HY,4U!,F9JV!,P&ZBE'<-;+JZ^)J+C\2C:,?+\MII)
MU,LY"'XRQ#L'D=$//>6$EG"3;*."(2;TA'";MECJ.=)@HBV4*09!0A%!`4]A
MU+>U?$J+QDH]NT!,4&S-$6[9%DB9%LDD9%F@(>2T3$"]1&C<OB4G5L`AZ-4S
MWSBHP=$)1QXM3G!.7F41,BUG,YNTI";D4'%6J35O%P+>3D(EG)-+$^:R4@Z<
MQ9P(RG58U>!3`'*1O,;D7.D(`!S"-^YA9?X:&3&3_"J;3\==-']QOH]R8>+Q
M?]"MV[?XR[-W7.44VE&$H4B_"M>FJKJ1_=F5Z7[GO/"(*D=*LN;W*Q@]\DQ.
MIN^C[I'M7#-8BAB*HN45B"0Y#%*8A_`P`(;:SN<N6YYD/;ENC[2Z?#_I/3OS
MYS,+D.Z^-R,"]9O68\#B1D[=-)>NJT\5X^>A,&0W64#;;>GP^D(AZ=@W_$UJ
M#Q0U:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`L2[H/[W-SA_8N9J_2'
M-:`N!_L)Z`H/W-OWNOG'^Q3SM^MO8=`7@T[^A&K?TN0GYV-=`>CT`T`T`T`T
M`T`T`T`T`T`T!0?DY,YNKV`\KS7&RN5BX9[C:/8'F)ZK<I!2+K<[=$&"JD,P
MDWJ22G251T4HI)G%))PX!-%19$BAE251I77H#\]WM>Y9[J$AW,KY;^.T!`Y#
MY<Y#;9"A.5\-R.AK%&8[JT6>:CG4TYRRO`+,[%16]/M40Q0A4XLZ;A<Z*3(J
M3A,3)C2TE)T+=7NH9</QI\XP'Q"H=F@@#^,-9N9QC%'<0VZRQ8`<-MA`=B^G
MT!H5JOB?!E?G&!0W&H=FDPCX%`EEYG!N/I]H3QI0*78/2&X[^K2E?%+YE3I[
M5R6KNJ%8KP<JK1OP5*NOFD0PY>P'W>&7/;&%!<(\$"\A>2E)YZ9%>R;&U9G?
M8+A*]E[%>(,3S4?\6.:@RR%"V"LP&."+12H.)5K)/G*QG7D))D2/T^)/(AVG
MDJ,TK-R_;4XKI)P;<7\:;_L.NX^UW;:[,Y+(X^VI=G7LG&CD7&]8WK='"%/)
M.;H^FI++B>G?.%,08KQIB6OUWL_R,%BV@4[',+)3=JYA*S$E$4BO1U9BY"5.
MP@&;+XR>,8Q-1P"*2:7G&-T%`NP!S!R![HLG\XQZQZJCV9_+_&]-EYH=?T-]
MXK;0%MO,/CAW]N:?&[*7%[([#M)U>C9=B(V%L<]2K-RX+;(QK%V*&LS9U`J3
MM>DH<CXLA")!NY;+)@41]D1VT!D'8PKTG4<>T2IS'NYI*K4FI5U^JR5,NP5?
MPL"QC'IV*RJ:#A5J+IH82&432,8A@$2%'PT![W0#0$:7=PX@96YT\',C\<L*
M3%%@<BVBQXYG822R._FXRHIA2[O"VITE)/*]#6"52%RWBC)I^6T5]LP;](>T
M`%MR;_YQBBB5).I]F@Q4B@FD*MCYG%.*9/93!3HC3EZP(`;B`["/B`!Z``U%
MD_G&O2'54>S&!O6`67FCM]#;_&O0&]\9_.+MOZ$>S3OM^B7F?MO^96^V@*`9
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M7RLH2/5\.X@?D"``&IW1E%-*C*X^\I-7-FWP:J<HW*_YSL*!Q)VW.$P+](B0
MILH/@+U@/L@8?N@_`HAZ?'5)6=/VQ.+'<K;]T;D#SKYQ\?J%AS[=N#U:HZ;X
MWO%<L%9C[-%/<=1L7'QT>6WV:R%!_$54ZYEEU#I@8NPB`B&X&0=R0G\ZU;!&
M3K#QGH]8R3GV)JKMYBVAW243AJM:+80Z`-(J=E5)NMILF*R9CB907S4`$H>V
M'K`V>,MASW:\#8QL7*&B57&.?Y:NE=91H5)E4YNJ5BR"]>)FCH.52G;*F^9@
MQ(B?K!^Y#J.(=?AL`%=-@'0AI/J>(R718_)N.K_CB3>OXJ.R%2K32)&4B?=/
MC6.8VN"?0#M]&^_MGC$'[1L_,='SD54O,*'60Q=RC-72G@1LCNW4]1'32N-=
M?XVU?!?$Z6L+Z.X<XOK\+6<;(R#A5_+VZ2AP$K2IYJMJA4$5T'SQRL\*5!JT
M8NS"5$P`!>G5R.BTZDM5T9)XD>+C446J/NK)!LW110;I%(@F@U2(5%NFDD0"
ME(@D0I2%``Z2AL`;>`:MMD[6GL_B9RTET%B%424*J0P;@8GM;^'5Z@].WX.J
M7;BWN:50TX^F75$3W>!Q9R,S+QE)COB7E2G8@SI<)]2$K-@FWT_6;K8V1Z]/
MR4YCW&EZA`-\C;%=8I@JR6</">ZJ,U5$A5;B<%0OJ5Z=EXR;]F;UC71M?O,K
M&XS(Y*-R-N$79A;>^354D]'7X4Z_"NAB$_-Y:D^Q3W::AC')"=BHETJ^/^15
M<E:)9+._9N$,F%B(U*P1;^"/*&8S%A<L6BK@XF*N+H&Y7(&4\M-0,=0BGNIZ
MDJ?9Y&OC#,E>G<S52]:2M+_5C7:ODM:?,_16:F`Z!#%VV$3[=("`?DAOA$?P
M?HZJ+QR-`-`-`-`>2OKZYQE(MTCCF`A;7?V%;FG=*K%CGEZM`6"TMXYPK!0T
MS9&T5.+P49)21$T5G9&;DR"9Q."9]MM`8`'&/GEW>([O"24?-5VY7CD1?[ZV
MQYF[B?+NY*)QS'XVA7+99RQA8QU)/ZYCJM8ZK2QI6(M:`J)*)N#.G"S].15*
MX`_0LT`T`T`T`T`T`T`T`T`T`T`T`T!8EW0?WN;G#^Q<S5^D.:T!<#_83T!1
M#N5-%Y#M[\UX]H0%'<AQ?S8P:)B8I`4=/<?SK5LF*AQ*0@'65*'480*&^XCM
MH"\&MLW$?78%@[(";IC"Q;-RF!RJ`FX;,4$5B`<@F(<"J$$-P$0'U:`[K0#0
M#0#0#0#0#0#0#0#0#0&TJD"H%`PB`%'J\`*.X["&P]11\-A\=O3J4Z`\A#8[
MI%<L=CMM>JE:@;)<G#)Y<)R$KL)$3-N>1J"C6.=VF7CF#:3L+F/;JF(@=VJL
M*)#"4NP".H(H4MREREP=AF_4?&.1+N%>NV1E8=O4(<U8N4NG).+!8D:I!IN)
MF`K\I!0GQM8UR,D!D'+4JBYP`!U5#9*:MMTDRQ=R+5B<+=QN#G*BDT]E?)OI
M7[3SV>[5R/K0M9/#:6.I>,2;-B/ZQ-46UVN[/GJSLR2CV*-&9(HT.C$MFYB^
M81816`P&$IC>!-:S,P^Y[[E'A9\<FHU7OJY3JE3TW(*NOG0]![.P>S\]3Q>Z
M8\A#)4J^[9OV+-C9Y5NV+TM[=*:TI73Q++Z]QSY-Y)[@/';EMEBYXLA*]A'#
M^:L>NL?U6DW:M6"SCD-PR9Q<PLK.6VVQA6<>Y1!1,H+$4$@'W#<0`O2X%W(Q
MNVGQW)*S+E)75*3L[O;C2E:;I2=*+Q;Z_=KNX<_^EY%[@^W<J^NS\B49.S<O
M6KFZ[&CC)[+5NLM$JI):+0EL,NH`"(%*.P;AOO[6YB@&WC]'ZNM?*%.G4Y&=
MV4%+<J;9I5?2C?4Y11$2E$0V$0`1#X!$/$/P!U;+[HFTNA]T(&@&@&@&@&@&
M@&@&@&@*19W@(RT8=R/7)F@)Y6C)RJRD<\QNH=DD2YI.D_+^(3+/SHLT"O#&
M`OF*'*!-NKJ`0`0OXURY9O1O6]+D7HRQD8-CD;,L/(2>+<5)+S(@J532U;N]
M<7HA]7&%>D:=VLK-#(0T1!MR1M<]WRO`LE8-D+=V[3@6D>D`-R&355(Z!("@
M/CX=1FY%F]VS._3=DRRY5;\ML'2OQ=7\C2PQK.-W%:P,2%M8-K#BHMUW_5->
M=*?9XLG6)OOOOX;>OP'\$/AUQ\(J,$D;ZD_=<G]-#<U)6-`-`-`-`-`>?M%6
M@KG`R5:LL<WE866;*-7K)RF4Y%"'*(%4((@(HN$3;'34+L=,X`(#N&I3H$Z.
MOD>!(PA</4!J1#Y1VE&JQS>(1D)V42G+<[CSO")ID>V&<=,3O"M/>`,8Z[@G
M2BGZ1$H`-Q054WTI^HR\-?U+-JY1M[6]]>BT;JOT?R+:?E1F'+,O6<<T.UGK
ML?5YQC,9ASI6JXS:14VVAYI20#'5'1?*/6Z+R9:`DW?O#><";?KZ=C'#5+DJ
MT6L2>1N<?>SKMWBO=_ISEZ/<:<Z47U.*2;K7HB\>6CUY-`[-Y'(OVCM)1HY2
M1=)M"$:/`514*18X"XZP04VZD_+-U#N78=A`IR6B98LY%_'FI69RCK6B^&I`
MYW<^RK4^6%1A\[\55B8<YK8<903G'UNAI)W!DR4SI*9G%;IUFF&ZI'3>VMEF
MR"<-8EE3.45DDTGBBS<=TX5&]1>O7+\_<F_4^OQ?G^GF=#V:.\>_Y.G<<,.9
M[-'$G/G$KAU4I>`LS/Y-.<U!5&R;2?FV4>X%)M&9,C%T%%YN()L#@HB[8D,@
M*I&\RC35="R9%VJ"1H!H!H!H#Q;3&^/&%\E\IL:'36>39^!CZK.Y$:UF%;WB
M9K$2X4=QE=E+6DR).OX./=*F41:JKG03./44H#MH#VF@&@&@&@&@&@&@&@&@
M&@&@&@&@+$NZ#^]S<X?V+F:OTAS6@+@?[">@*3=PLO7P7Y<$`YTQ/Q\RD0%$
MA*"J8GJ4F4%$A,4Y043WW*(@(;AX@/HT!>$F04TTTQ.=02$*05%!**B@E*`"
M=02E(43GVW'8`#?U:`UZ`:`:`:`:`:`:`:`:`:`:`:`:`A@[B.$JKD'EUPER
M$OCZ9F+3CRX0"(W`^/+?;Z(TB9R\,4HYE:Q@\7VN`DIN"=HO'M>"2FX9&#EW
M";X1$%.K65CW)*$K<(P<Z5K+1KY:,LY=S?CV\:[?N1QU>4_:4-T).B57+JGH
ME2G15.C[2^2NZ1?L?V5#N+XP:5R$BI24/B/)]K3BZ3GNZ+J6J<:K1=YPS7(E
MM!1,$PB2D]R?JDAG!VY$1%L\*J+LF%<N6K45>R$]D9+5*3H]4M(1DZ?90R$K
M4JQO0A.+3=).,5IXK<TJK[Z5)2K4]NS4EKD*Q"1SVX,L96%U3H%U)>7'2M@1
M76-`,95R9-N1FB\D2)$6,502E(8=C^O5R%VW<O*%:RE&K>J5/AN2=?FD9O"8
MO%Y/)XN%S-^.-V]=R;<;TX6]\[=F4DKDU1NKC!MI+Q1SL&O<H2F*:/)YNA(2
MN9;?UJ*7O\!65C.J[#V4R(F?Q\0X,[D15:-5!\L#"NJ)ND!$QA\=7:4I1ZTU
M^?C_`*#8=[8W:^)W3FX_:.1>RNU_=I8N78[;DK<>DI154G+6J3^6A6(-]@W]
M.P;_`$]M6GU-!IX=#[J`-`-`-`-`-`-`-`-`-`6M\SX"QV?C'ER!J>0*KBJ=
MD(%H1MD2ZE\RKU1LC/Q+F2DIA'R'(.&_Q:BJF"0D$JJARD$2@83!M.&OXECD
M+=[/C*6)%NJC2K]+2ZM+K3J^AA9MG.OXSQ^/N6[>5)Z.;:5*Z]$W6A',Q0D6
M?>KP"QA3Q$I46G:\M2;B4^RH&712S!`H1;Z"0;^>T,204*)U"F.!2H*!TB80
MVU<S<R\\!XT$OPDK\I_&K2^'DDBA<7"WF0Y"_O>5"RK;:KL=')MUTUUTJJDW
M)?2(_0\/'U;_``:TBLPA+?&M6J?`S83E+1KT^9N:K*QH!H!H!H!H#;44!,!$
M0$=@'X`\=MP#<1``W^'T!Z]5*-06C7])GR?2D\4PZ)7N%!D"Q^4;8``9C<3P
MLFQ=N,<U1TF[056;NUT!))22(&*D4HI)&$PF,66M"W=A[J3C*4+B?AX_!O\`
M:7)PL!$U>!C*M5H6/B(:+;HQS.,8)`VCHUFB'2!$DRE'JZ2E#;P$1$=Q,/B.
MJ"M=.B7R/3)$\M,J>XF`@`4#&'<P[>L?`/'0DXCY`ZH%,!"N"%$.MJ?8"F#?
M?S$Q$H_9D_QH#L'T0U*=&"!#O`]G2.YOL(WDMQKET<-\],2_%LWCS)L+(/JT
MMD4*EYCN(J=GEXQ9J:$MK!X0A8.P$-Y[)3=NN*C-0?*JW*E/!D'F^T!WDW7)
M":D>%/-U@?#//G%9SUJ3B+7'ITYOF<T,51%=W!13U5+W?(K1!#S9*-0+Y#Y,
M0>QW6V.9-"'%I5),B$I@,4I@WV,`&#?P'80W\0]0ZI!]T`T`T`T`T`T`T`T`
MT`T`T`T`T`T`T`T`T!8EW0?WN;G#^Q<S5^D.:T!<#_83T!2CN#_>-<M/U`,G
M_I4DM`7AZ`:`:`:`:`:`:`:`:`:`:`:`:`:`MQS-QOH^:;SBB]VB5R;'R^'I
M5S.5QI1\CVJDP$JZ=O8AZ9O<X2!D&3"XL$UH),"-W8*)E(HH`ALIJG=",UNW
M[GY*L?M?A]YD6LC(MVY683A&S+5UBFZ_"J9N9,M^<(*PM6]`P*QR7`!$IK&G
M7&68&AKMY5994KB,-%2T')*G33;D3,5<I@*(F,78-O'E^9R^XL*_3A^,MYMF
M;H_][]B2ZNNJ::5/IZ^/@;O@^,[5Y&.[N#E;G'RBV]SPWDI^"CMC*.VNKW-_
M#Q+.X7G)?HWGGAWA]EGC#)XVL69\.Y(R#5K]&9DK.0:VU@L;.$7DPSF8B)JD
M8[9/7;DQ46Y_>M@Z]Q(/I#M>(XWE\[M67/YUB.,[60K;AN][5[:KW4HKH_+J
M<YS$^%P>=_I/&YDLN#M;HR=KV$XZZ^VVWX:Z]/F2A`)>H1(<##T[[`(_6[B7
M?VA$!#<!\?6.K&Z*5'HBW2[+TRDE#RBE4Y)#E,`;&*(](".P@.WJ_%#5M]="
M[M<=-0)R!N`F#PV$?'^*'8/JCJ:,A:NBZG5SD[$UR)D9V;D6D5#P[%[*2LD]
M5*BS81T:U5>/GCI8WLI-VS=$QCF]10U7"W.;VQ3<B:-*KZ(\VMDR@-XR)DUK
ME74V\]$+SD$!Y-O[W-1;6,"8=.XB-ZPDI,&T6;SSD12.H5/Q,`:J>/?2;V2H
MGKHS!N<EQ]FY&S=OVHWI=(N4:O2NBK5Z:FACE/&DA8'U1:9!I:]OBXIE/2E1
M)9X7Y61,))H$=1TK+UH7A9J+8O&ZI3IJ+H)D,40V$=4^U=_NRI\C)]VUMW[E
ML?C4]*:?ABD`0DVJNZ"SD!0635$4&ZR2"ZFY!$I?*66*4P"("!AVU1M>SW/_
M`"?GX"5ZU&?M2DE<?AXE.;AR!P9CV79UZ\Y@QK4K"_FH:MM*_8+K7HR>7L%B
M!L:!ABP[J03D0DI@KQ(S=$4@.L50HE`0,`ZOV<7)R(2G8MSG""K)I-T7F_+H
MQ=NVK-/=DH[NE72OR/0165L7SMB?T^%R+1I:VQ;Z9C)*KQUK@WEB82-=(R4G
MV+N$;OE))N[A4Y%N9TF9(#-RKIB<"@<N]N=F[;<%.+3N*L:KZE6E5YJI;MY6
M-=G.W:N0E<MNDDFFXOK1KP?S/=`NB8=BJIF'Q\"G*/H$`'T#ZA'5M^ETEHS(
MHTTGU9],JD3<3*$*!1V,(F```?1X_!XZG;*E::$1:G/VX.LUX>(!9(1V!0@C
MX^@P#Z!V'Z@ZA/=TU)ZQ<OX4Z5+0>>B9W?$/.J3)&%>O24_WEFQGF;I_%/GC
M*9C';5F[;,G;!T)7+E`I"F*LEY9Q`PF``$=5VK<K\O:5:O\`2I?L7,/'O1O\
M@O\`=EU?@JZ1U^;18/0I+X][L_'B;4CR1*\EVK';TT814138B\R_7W"K5/90
MW6FB93V1'\:(!N.VX]'/&QK7:DIJ<99*RYQI6KHH0_48^1W#R-K)?;UB%F7%
MS?O;W]:D]%&OE2*?VLFW*(B/TR_`._P:YB,JQ2?U^1-5T\?/P->I`T`T!\W`
M-_$/#T_0U#:6KZ$;EJJ]``@(;@("'PAJ0I*2K%U1I.<I2&,8X%*4!$QA$``H
M!ON(B/@&VWI'T:AIO1>9):[9YJS9LL2]#I*SB-Q5%O!CLEWMJLNP?SZB0**.
MJA17A"D4<LU^@B$A)MS]*0*F32$3`82Y$-MM5E]?@"X2(B(JO1L76:_'H1<5
M%,6[&/8LT?*:QL>T2!!!%,I=R?6AZ!\3"(F'<=Q&WIX@[XA"D*4I0V`H`4/A
MV*&P;_".P:I>KJ#7J`-`=<[1*F11?V/)*4RCE%38$#$*&ZBQO9$04(0N_AZ=
MM2NI,8RG)0@JR;HEYM^!`'W;^T-4^X'$QW)_C384L3\X<6MF$_BC+-;?JQA<
MGKTYJ9W5JA;Y!%9HI!V",D4"HP\\41<QHB)%BK-0\HEQ22?P+F1CW\6Y[63"
M4+OE)49XSLR]Y2?Y)SS_`(+<XV)L5<^,/*2E2E&5B0:0/VYUJBF<DNJE%[I!
M#Y3A&J`JRT6D!D'R!?C!D((G.BE$HT55T+-:.CZF1\4Q3AN4P&#T#L.^P[`.
MP_`.PZMDFK0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0%B7=!_>YN</[%S-7Z0Y
MK0%P/]A/0%*.X/\`>-<M/U`,G_I4DM`7AZ`:`:`:`:`:`:`:`:`:`:`:`:`^
M".P"(B``'B(B.P;>OQ'P]&@(^>7'<#K_`!'L50A9W#-[R#&W2&?2L3:ZWD7C
MC28`7,8\3;2$*`9JS7C"5?R;))9-946;9RW3253ZE`,;I`"R:V=][#M:@9&;
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M*(;!;Q?P25,E.OP;K^H]/XW_`.I/&Q/9[IL\RN=4:2MPC%1W>>LDTUTIHO-=
M&702[OYP4`)C`1?;F*4QP7,DXD<G`4J1QV%LF/EJ")$P'P.)A$=MM59,N-E_
MD*=?C4Q<SD?R4M\<[6!Q?,+DU)TE*];2:K]5-^E5K3PZ&J)D/G`A&ZP34%VY
MEG2KH%"JMY7)P`@V(!0*V3`#)$4,<0$1,H4PE$?#T:QX.RK%)QE[U=.I18S?
MR8E;C>O8'+/+4:24;L-K?S<JZ?<1ZY9[C7>DI?/+%';OD,;\'7N5,SU4MO@)
MU-CD1Y1(V"2A[;+R3AY*OI!%RH[0;4UR0R9&BR93+I$,8!.`AKH_BXWE.,H0
MMIZMNC^SQ;^1J+^?^5V3GVK4N%SI\;&3=QW+\6Z:4VI2;3ZUT5?B7(5KBWW6
MJ7/O[56..O:GB[!)OI^3?2S"NVA@_<R-G*H6=>_&3%%J]:NY05C^\*(&2%8#
M"!P-Z==M#E\6>'^"S<[*G9DM;.V6R5-55[M*.C6FK2-KQW;W_*K#D9\OR/"<
ME8Y.-79NVIQ<H2::=-\DO4FXOX-G?&Q3WNGEM&[3.$.T[)7%!$C%I?UJ];#7
M="&)'.(<88)PK))ZI''AG(M1244,F"``0"@7<!T-B/%^^W>=SV'T\RG`SOR@
MN\Q*WR/'\U#@57:XW;;;7@VE<KH=.RXG]T1!G>(Q'C;VIXUADN.G(W(;5&%O
MJS*]-K'-M;+.LK%'J'7:.T)F<9%>.`*1,%')2J#X@&UW)N\>L&&.\B]5/QCI
M7SZ^7D9F?>_)2%N=W"P><GDM:5N07V5=Q?K9'SQ.I'/+*N=>3N*,9<+>TU5[
M+Q`Y(5P,BV%W2;R8SW*\C6E9JNW&ER,ZXF'95XB+;]#=9(K8K0RQB(I%!,AB
MX^'?_"2O6+.3=5JY3I'JJ='KKXG,\8_RKSL]7NX>-S985MO;%S4IQ^+:;57U
M6K5*%Y=HX+=RRVW.2R%9>(O:+F[Q.RTO.SER/"Y#B[E*2\E()OEW<A98D\?)
MBO(*@)G)TE"J.=]EC'#V=7G?34-V5==RU%J/I=$GY*NAL[V#^0&)>OWN*XK-
MA*^JO?)5<TFE*M=>KK7[$7/4"-[ZE'K\%5F6..VU#0%8BVT#7X6'F<LIQ\?#
MQ[9-G%MDRJ/BJ=;%LB0I3")A$`'?<1$=6<66'LG//O2N3<M/33]:95P4?R>M
M\?>CS&-R=G-WUM.PX.J5?2]SHD_&CK]QW;V6[][%N[>A`=O"3*BV=.`:O)+)
M;9#K1;*G3#SV[A)8I2J%`1$QC>`>/AJU/\-M<L>3;HZ53I7P-E?R_P`FI\3*
M-C!YN',QUA_,AMFUK&+K-I*323=-$VST/;SS5SUYO<2\:\DYO+G'7%DK=Y"_
MQ+^E1''NU6YG&.<?Y$MF/%ET;(YSI"C)HRZE7]]3,1F@1,BX$`!`.H=0I<A<
MMUWPC)_X7+_W2ZFKXOF/RJL6)6^;[<Y.[>FZM0Y2-G:WU32Q<A.G1-3U75)G
MLN;-!Y_M.+.;UZ;R2H[BRK5I`D&CBKCQ8JODGWYQ-1C9NE4+(7-L^2+E0.L`
ME<&CGIBIE,`)&,(:S,!\C#(596)R\-T7&*T?5N35/FC-NY_Y`9MQ6<K@.?X_
M!N3A[UZQR%G+O1BFFYPLRQ,97)56D?>M*E=2BN&<>9JIW=IQ8;-V4JWE:<9]
MM!Y$-)^!Q\]QZ[.W2S!%(R*]C8/K?;E)2<DI%B"ZSDBC0@G$0!`@[B:9\C=O
M77QUUJK;N)+IJZ?NT^!L>=[=[2S/RLN]_=OXN3CV;'+_`(/_`'B[&]<E_)MW
M=VZ,(**VSILI*CKZF3K$/U"/T!,'_P!=J'%5W+KT/%Y:-4^EQJ;NH`T`T!:]
MRBSY(\?ZM6K''LL:.`G;Q$55TYRIE%OBBOLF[^/D7JBS"56@;$O/30%8?8X]
M!OYAT^M03`5,VK^/9_$R=M*M%\Q&5BRIW<F6V%-/V>)<E'NP>MT5P!$"K-T'
M!105]X1,58G4!T5P(0JZ`[>P<``#E]H``!#5F4=LG#R(ALE;5R'T2Z%I_+:R
M6NL5RKO@93*F%U9YPAR#F*@JO\MZY0%F*Z*,O&M4V[EPXK;>0.`S8MDS/$XT
M%#(AZ3!7:^OPK1_L)+B:6%7/2*\..OB0:<K#Q[BHG@S)G@58-TBFNQ6C56A_
M)69K-E>M,P?7`(";Q$=4W*NM>H/7H>7L8J9P/T#T&]8@8/2`CZ=]4@W]`-`-
M`:%"]29R^'M%,'CZ/$!#3=L]5*TU*9;W%JVZ3IH_)^#/`S$4]AAD9B".8R:S
M-VK(0R*769R]Z2^5(1H>:FFE($+U`<-ME0V'T@&^IRL?)5]YV-)N[_<\_P#2
M;O&RX9OM8'(+5-)7/%+R;\57IY$&?=O[/T-SQH]=S_QNG8_%7.?$H-K#CS+D
M.<M+D\F.HLB1F-1OMP@BM9*%EXA=,RT1-F(JYC7)2I*&]U.J`;NW*;A&4U23
MBFUY.GE\_`U?(6?P]V4.CC)K[GY^5/$\=V:.\?+\A';G@USG;NL5]P/%+Z1J
MCV.N$6>K*YM1KK15PZ?LF`M4&D;DR.CFX*247TH_&"&TBR*HBHH1&B:H]#'A
M-7([ET,C[5)6-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`6)=T'][FYP_L7,U?I#
MFM`7`_V$]`4<[BT@RC."7+5V_<%;-@P/D5L*QRJ'+Y[ZONV+1/I2(H?==VY(
M0!VV`3;B(!N(`7GZ`:`:`:`:`:`:`:`:`:`:`:`:`M7E>2>+9S/5@XIH6H(7
M+T-%U&:-79A%=@A<8FX0=PL:3>J2""RAY)>&@:/(.9)(")^40J8"(@KN`%0<
MCWC%N!,9VW)N7K%7ZGC^@0+ZUW"XVD6#.(B(V/1ZW+E9=<2H-S+F2*DV;I^T
M=0R:*8&.8H"W*/U:1\Q)Q4*S55^NI@QYIS=RJ^<E<HV_';CG6%\/<#<76)O-
MSSV7B2@G)L&[Q))KE7*BK=J1O)V=^S*)JQ54EDDT-C`=8RX+KISOC+TVZ.'G
M^XW6%QN-;M1Y+DE*VH2]$'HV_#3RIU?@9A_%?MQ\3>*.&J5AZDXDI-A:55N=
M1];KK4J[8;=:)]XB5&:GI:2D8]PJE\:'Z^EFB)&;5$2II)E(4-0X0;4MJJNC
M:Z?V&1<[LYVY*2P\K(LXDE39;NSA"B\-L9)/YM5?ZB^6-BHN'CV<3$1K"*BH
M]LBR81D:S;L8]BS;D!-!HS9-4TFS9L@F4"D3(4I"E#8``-35FAN7;MVX[UV4
MI7FZN3;;;^+>IO$60.<R9#%$Z?LF(`EZD_3T@8H;F3`Q0W+N`;AZ-4QM2@]U
M7K^\L.<&ZNCD;W2'2/24@CL.W4`;"/JW$`'PWU4VPHP>J2^X@OY>*KCWONTB
MT,?=J3$'-UWY)@3$/?$Z=7FY7/@D`^8"2Q@*;J\`,/@`B(C2TG2NM"M:="<]
M3RR)F,8H"4H"80`O4([>.Q2@&YC&'T`'B(ZFC>A$HQGI))KXZFP5PU,.Q1+O
MMU"&Q?`O6*>X[;[%ZPVW]&_AZ0$-2[<GU;I\RKJMK^GR-U?\C$?@,4?I>T`>
M'U=1UZD$%?:Q*`\]>][U`4P?=E8P$`'8>D2XB6+Z!^M$-O#4U?F/CXDZX@4/
M4'P^@`\?A]'IU&YUH''?]6M#935;JG$""0YBF.41`2&#K3$`4+N&_M)F'8?6
M`^`[:EVFENE5Q)E;;6Z6M/,Z>V``56S"```A7YG80\-O\;G.J4DM%T(?GXD-
MWS>0Q3]HGBN8OK<9L$1'TB;[?F3>H1^$3&W$1]>I730ICTU)BK54ZO>:_)52
MZ5V$ME7F4DD9>NV.,9S,)*(H.47B*,A&/TEV;M)-TW34`JA#`!R`/I`-$VM5
MU):35'T(ZI5NW;=W:A-VS=%NW;]OF?;MT$$DTD4$$LYIII((I)E*1)%),H%*
M0H`4H```&M/.Y)<]""^EX_7_`*TCZ#P4G_RO9J>J_P",8?\`ZE:),6_Y(J'P
M"/XH:WDH*,53Q/GB#;E]L_\`;.9JV71H!H"*#NV8]>9"PKB]C'Y(@\./HGD!
M0IUCD^;L^3JS\GGB$;.1Y(F-7Q8LG8G,A=4GYH42B`HD;/UCEZ5@(;5['_".
M;CG[E8IIM=&_A73]IB9=_D,>,8\9"$[MQTEO2DDO-)UI^C)1(%N+6.9MQ,4P
M(,&*.Y%'*P"9%N5$P@L],=VJ&Y/`RIC*F#83B)A'5ENLVH+^2OI?5OY_J,B&
M^,5;G3<EK3I5]:';+)D52.FH0JB:A1343.4IR'(<.DY#D/N4Q#%'80'P$/`=
M3'K\2XBP.7KE@X:2\I<Z*QDK)Q;EGWQQ?L5Q2+A]*8+>KF=+REVQ9%,^M9]2
M)*0=%=3$"0IQ9&*J[9@/6=+5YSC<5']7G^G[3!R;]KC\9W-LYR<ETUI7X>2_
ML+WX"P0=IA8NR5>583<'-L4)6*EHQ=-S'R;!VF"C=VW=)"8BB:I#;@.^X"`@
M(;@(!0TU5-:F=9H[='K\3OB&+TEZ=P`?``'<1`?HB/CJU'H0;FI!H/OT^`B`
M[^D/2'TOAT;2^HIFFXM)M/X:LBGS#8HQ/NA\:J^?..:Z],GQO-+%P94J!-RF
M'+NT=L;VJ2S90OQ+2C`P3^-^*U?BIN:-\\ZZ`^*P'**&\Q+67+CKT[4;;QU!
M[FTMRZ=/']9H>0RL*?,XN%*Y?65!*2452,M6_53]?[B5K8/@#ZFM'XU\3H#S
M;>#;Q\C)2;51V47R8>?&E6_QN%4IA$[M)ET>6F\5*.QS`/M[>(;ZPK/'J'(/
M,=R;C)=')M5^71&1>SY9./'#E&.Z/1T]5/GXH@L[OW9UAN=1(;DEQXFT\*\[
M<2IQ\OCG(\0[7@&]_5JIPD(>LVZ1C2INH^U12R!`A)L!,JT$I6ZXF:"'D;"-
M56NJJ_N\#%5$J+P*?=G3O&63D#8IO@WSTB%</\_,2F6@)%I9VC>K!F8(8>AP
M9E`J>[-XO)<<R$BKV.9E.VEFPA)1X`BL9!%-4Z="3(W(<JA"G(.Y3E*<HAZR
MF`!`?P0'5!)JT`T`T`T`T`T`T`T`T`T`T`T`T`T!8EW0?WN;G#^Q<S5^D.:T
M!<#_`&$]`6T=U4A5.W;RW*<YTR_:CEC=28&$VY'T<<I=B%.;I.8H%'PV`!'?
M8/'0$@>@&@&@&@&@&@&@&@&@&@&@&@/@B`;;B`;^C<0#?Q`/#\$0T!C/Y]R[
MCK!/?`D,Q9>N$10\9XYPE`6*U6J;7,G'PT9&<<^1[IX\.FGYB[EP=-<J*""*
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M*!=P`>HQRAU!N(&4$0$-@#<!$WX>JZLYI0BHJ*KM1OZI*R*=@ZD(3NJJM27^
MJ%C[CA:516QRZQOFQE=U58AHR>!-,<KNUW>&+'`(F9E`L4B+=9B8Z@@C[QYB
MA]M<C%\;[E'N36NE/N7Z,YN]=RUW+##MSC_3Y6JN-/5NVU^KY^'D2K$^M^GX
M[#ZOH:U-:ZG11ALK&M54@KY>"/[N+VCOX_"W.$QOHC\D*H;\#Q..A43FNQZ6
MZH[`(``;@(@`"'47?VA,4"#MZ#"(`4?'3<X^I*K'7QI\2(R\!-5[NK8GFFMY
MK)&-WQS(5R1Q]-8QS@-D,2&JEC??'E+R['$D,,**.BH$!Y!O19"F0AE1*H[$
MBFMLH6_P3EMENKUKIUZ4_?XFHR,K(M\O;Q;=R'L26L::_8R79Q^0G_YG^6+K
M4FW(*.U80Q>>W?#5,4X)GYG8R*0Y@,"9C$Q&<IBD,(`4PEZPW`!\!$-`3M&`
M-RB/PZA?53X!R<5\&R+;MT2:2V1.<$&-_P`<7UY7N1S]NZ+2*1F.B6"GDD6;
MZ5:5#(3'*G7&3$W$I.A]VD()5=JZ:G*9901\H"[GD8*.+CR2:<H-NM-=5TIX
M?/QZ&KX[E+F??R;-RY"7LW$DE&C2^/GT)*[;_0I9OZ7IK\[7.M.;-]"&?YNV
M(CV@^*HF\!]YS=OX;?Z?N3O5H1#Z438Z%1&3+)I_NPE1434()_W/V:*Z3!43
MG(/V]3>[B=,3B"`'3$VVQ2]>PB.^WAK6E_5D_'V/_=,^@,2=Y?\`+%E0>EI]
MX1IIU_W.U6C\?#SI]I)FW_)5@^B/XNMHTE'3S/GF'U?;/_;.7JDO#0#0$>'<
M@M-DJN%ZTK5KY-X]E9;,6-(I&<A\<TS):*GF2Y'81LM'7Z;KM<@DWRC$J;%^
MH]043ES-"I@H)S)GW/"8']2S5CU@H*$F]W33XZ_L.?[FY:]PO&K)Q8MW9S47
MI71NFGEH7\PW49BV44\T53M6@K&7(1)<5?(**@*HI&.@F<IQ'J`AA*4VY0\`
M`1U5V+A<E!N,MLFM.E#<XMSW,:W*DE6">O6K.T-MMX[^D/0.WCOX:MTKH7FT
MEKTZ?>4RO%7EYV(70@9Y2`L`+IO8]\JW._B7"R76F>*GXE,Z1I>$D&HBDNAU
M%-Y8B9,Y3>.JHQBM?&OZ?]!LN,Y+$X[.]G,Q_?XV<&FOXJM=8RU<9)ZI_>6M
MXKQ1G+`N3Y=G4&M%G./%]FBRCFDQ*LQ#OL76A_".G4W,U!A)O'$3%4B7LR13
M.8ML)_(,Y`[9,NRW54YN<-TOJHS5*,UGW%8=..BO2GK+[7XE\YS&(T%0A1*H
M4G6!1`1$#?`("`";;?X`U:70JC+=%2\SE%-OON(;AZ0]8!ZA$/5OMJ2H^&Z3
M!ZA#</HZIE-059="5]J(ILH9I)7^ZG@?#QT,K1_RIPQ,2S<&.0[9#8JM8(NI
M]-=X^QU$T69K]PF*6H1)-1R^F8U-C\:HG$HJ%;@KGVKMG\+*+?\`-?3Q_?U?
MF:JY;N1Y..5&KDX['Y;7UT\_B2N:PC:&CH+]'U^OX1W'\75.U4IK2I-?5N\:
M'#<-A`3JHEZO,_)D/0"P^``<#>E-4@>@P>.J]S*5%+IXL@2[R_9VA>?5?B,\
M\?'Z6+^<>($$)#&^0HMZ>M)Y%+7E$).(J5PGXLK9]"6&+E&2!Z_8.OWB*=)D
M(81;#NA*UT?0DIYV=>\E/Y\L[[@3SMCU\2\]L/K/JA(%MK9I7D\VKUXQTG)F
M;3S4T([)\4Q1*I(QZ9?(EDA&0CS&1$Z2<RC151!D=BJD&VZB8=0F`NYRAU"7
MZX`\?$2[>/P:H)-S0#0#0#0#0#0#0#0#0#0#0#0#0%B7=!_>YN</[%S-7Z0Y
MK0%P/]A/0%L?=<,8G;IY;F(8Q#?:FD0ZB&$H[&DXLI@W*(#L8HB`AZP';0$A
M&@&@&@&@&@&@&@&@&@&@&@&@.GG9).'BI"663660BV$A)N$$/*!9=NP9.'*J
M*0K'23\U0$]B[F*'5MN(!N(`?F=Q4;E+OK=Q25M&2+S"8_6R#>(2N56+<P_F
M1-*Q37I2T(4^'3C8Y46DO-PM=;."'.Z.J=[(R"P"L1$_3JS.\H7HVJ?4NOD>
M@=F]KX_-<;RW.94O3PV"LE0I_F;KMNWM3K2+K<W;FFM*4\3]#3B'Q&PSPNPK
M7L(8/@B1%<AA,_E99T"*U@N5E>IIC+6VTOFY$2/IF46('H(5)ND!4DB$(4`U
MD-;70XW/S;N??=W(^GI%+I&/E\?GXE?+M2JUD2J3=)N4-&6*L61@M%SD),,T
MGT;(L')?+<-W#94-AW((B0Q1*=,X%,4P"`#HG1U,'Y="RZN6NT</K#7,7Y5F
M7]IXZS3UM7,1YHFG*CR<QY(K&_QJQIF63<CNZ8+)G*V@K$81%82`V>B"HD.:
MKZEIU(+^4U2JAU$V,F(%,10I@,50IM]C%$/2`@&X#Z!`0$!U0T21[P_'^WQW
M/V1Y%AB>DHP,S1IC'SW*T=E&QK7=Q#-(2M.(=C/XPDJ\%208+3\>NV;KQCT'
MZ)&Q5%S&37.GK97+T7@+'3]6C^7[W^SR-:L*W',_%N/KHU7["0<#B`!U!XB(
M[;>OTC]';6LBJK3H;*-95:5$B"SEZ(_NXO:+\/`,*\X-Q]0;U"I`'U=/5N22
MK'6K\J?VEEW4E!R6LFU\B<]?=1$Q0(!A-T](=7X[<#$/N'B'08`'</$-MPU%
MN4G-Q?I<7XZU+D]NW76.E/B1WSG&VT/.=E9Y,#B>@OH^*@0IB&4@RK9F^0XR
MN%J$B@HR'&#^J+4M:'<3DDHW`S601E1-NL94J)A0-MEF26+^&3TU\/%NO7]$
M:F_QT+W(PY"C6U=/T_L)$U_R$W_,_P`L76J-P07]JU8P\[N^"F!ES()<S\;]
M!3F5\HJY\1IF7!$!'H`!$"=6W@(^G2D_+3S"4Z^M;8OH_,G2$WM;?!_\>H;C
M&2;>K1;<JO;3H]2Q7ASQQEL#VWD=-2&-,<XV0RUE(]V:EQYD*Z7M&W"HA(>\
MV:P-KI`0RM2GW"[[I49,3N&70`>68I2@`[?.RK-_&LV[<G*5N-'I2E:.G77]
MQK.-XK$X^]?R+46KM^:;UZ4^'VG0]RWG`UX%\=PRRZPGDS.R=EM['&A:GBQ!
M%>?8+6:$G'1+`[(NW<E+#L"Q@E6.!/9$Y?'U#J3;EI_S==0RO:`XIJ&$HF,X
MS:(])NL-_M^Y.\.K8-Q+Z!]7AX;AXZ$)45";30DB\D5TS]Y"NH)NCJ&1[?C\
M738PF\MJ*N<7!FXI@(B4!<D3,)M@#Q*&^M=Z?ZMU]?L+3_K,^A\>TO\`[ER_
M<FXQD^\?2J:RIAV*NOPK1$H"'Y(L._X[\4=];-MTHUH?.D(I:UUK/_:.7JDN
M#0%MO+[D:UXD<;LJ<BGN/KGE5OC"'C94^/L?-DWEQLQI.PP]=19PC=4#$.JB
MM,E75$0-TH)'-L(AMH"P3DMBO)7=%X9<<\F84?N>/ESM;JB9MAJWF%M$G^34
M?.568BI2OWVK/:+D:)L\@VB;`X328J-6GDNC$<%<MUDR[;#C,G\%E+*6ZJBU
MIU?]AB9^)'D,;\-=IL4D]57HZDN4*T58M$$5ECKG19L6ACGV*)CM&Y43*`0I
M$R`"PAU;]!1\=M@```,*XHN[*2ZR;9F4Z15%!122.JO5ZK&.:M+7&X2:,3`P
MR'GNG*GMJ*'$>ENS9H%V4=OGBP@FBD3<QSB'JW$$8MNBZE,U%1K/H40PO+Y5
MRE,O<MVGXTH5#DXA6'HN+G*4>HI(QIWS5ZUO]G.K'EF6%B6325;H().2M%&2
MP&,B)BD6432BZ)U\R+<YN+T27A5:ESO3X`'K#UC^+Z?AU1X4)C6*2\#X8/8$
M#=([AL._LE'?PV^AOITT14Z5TZ%&K]DH*+8J374X$[UK<9!2(6FTI-L@Y@WC
ME)PA`BTAW+91W8WDG+`"/D(&#W=(#K*B"91WNQA&4=SE1U\OA_;I^LVV%@\?
MD8&3E967&SE64G;M;')W:]:232A1>:=7HOA8SVP.Y$MW$H3D(^=\>[_@)_@+
M,TQB1TSN;]&89VHL:=V1&6B91M&Q38'B(,!]^9I$.1F=9,H'-U[ZMS@O'4U$
M:NW&[_!)?:2+R&.:5+7&&R!)U2M/[M7&SAE7[:\@HYU9H2/=E.5['14XX15D
M(]B^!4XK)(G3*H(@(AN'C32*Z+4G3RU/;ZD@:`:`X:R)R"95L'MF``,F`]!3
M>UN)_@Z]OJZJC2NO0&-/\X2[=6$\R\=KQSOCK2;"')CB[5R6ZLY7@7"\,K=H
MN#DP<QU)L+AD[:/D[8UDW)!KTPV,,C'N"E0()DC>6A7_`(2"%_M]]\KN#)<Q
M\)U;*<RZY8TC/SZ@85E,4U^OQS&V03N%:L8%MEFE*MP`YK,S154D+.5XI[K)
M)@JJ!45")=,;/B*GZ`@?5^C\/U/#5LD:`:`:`:`:`:`:`:`:`:`:`:`L1[H0
M@7MR\X1,(%#[ES-(;F$`#<:)-``;B(!N(CL'PCH"X+^PGH"V'NO?O='+C]2>
M0_/2*T!(5H!H!H!H!H!H!H!H!H!H!H!H#8<(@N04S`4Q#`)3%,4IRF`1#?<I
MP,0P=.X"`AX@/JT!A.\<,;T'%7SB;--%Q?5(FD5&(S'%O&%;AV(LX>,5FJ(\
ML$X$6S\P$6:$E-2ZS@$T"%13%;<@`&X:P<B2_&VUXT/:ORTC*797><U]*X.V
MG_\`I>.9I\E)(0T=(23LP)M8YD\DG)Q,F0"-62"SAP<5%!(B7I32])Q`H>(B
M.P#ML&]T]JZGB]5<=(ZO_26Z\4>6N)^8M'G\A8A>OW<'6+E+4*8]]7@7?DV&
M':QSYTDB\K<U/Q+I#W241,!B.`.43"0Y"G*8`F=N=OZU1EM2BVXKJNI<!;:E
M6;S6YRHV^`C+-6K%'N(R;@I=JD[CY-DY(*:K=RBJ`E'<!W*8-CD,`&*(&`!"
ME/4J+)ZA.W#B+;(+$F0)![8.-M@490.&\M32ZCR4QQ-NER(1>(\FR!2BJK"K
M"J*4%/.C%#I*1JY/UE(<U>DM?$@OS3\L1`2`!CC_`-$V`3&```NXF``#Q#\#
MQ^CJAN?BM"5.$M*ZG$=O!24!`A?,6,4#`4H@'0GOTF45'Q,0N_@40`0$0U,4
MJJ":4GT5?W$7'!0WN3C"+2E1-_5TT2JZ_`Q%.Y[S1O%'[P_"VVXKCJ))&X_<
M>L_3+TMD7"4230LTM::SD1E,N(6P,XIJ\C8?'S=W'B1X0Z/G'3>$(<12+S?<
M7/1XC`ED8[4Y1NQC+X:T?Z(]&[0_+?D>X^],+M)6<C^H9F/*Y;@[<X;H[5.,
MHN<4JM.M*UHU)>EQ;RTX&P,)R+A9R.<MW\-.Q<=*Q$JP5*[8OV4@S3>-'**R
M7411!RV6*=,Y=R&*8-A'713W_B*Q5;;MUK]J^WQ."RL.[C9%W"R(NU?Q;\H2
MC+1K;6+5'K5/1I=#TH%*;8W041].X@'4`B'\=XE$0-]#TZBLO(L^DTNOK";F
M$I?,+U#L(AL(&+[0%$#"7J$/6'CMJ2DQ@>`O(Z7H7=;[F&,S-JVG0LP\O+4E
M)61PLB>2@;?CO'E;BXEHJ]/964>JRDG;XR`LV[!>1]Y$2F,`)"(:*]ST,7EX
M<3D2A"Y=7\NK59+]U7IK1^1Z#P7Y>WN=[%Y/NBW<G/,Q+\=EF$7/^6U'=*6U
M/;M:;]32I6O5&3HR<JKE."Z147!!`%$R'%8FP[]`E5%-/?<`\2[;E]`ZWDMK
MHFJOQZ:?`\]ALE_-B])+]:T=5U7VG.(0H&Z@3*43!N)@``$=QZO'T#XB.H5N
M$7NCU*W3P.BMI2_):SFZ0ZAKTR`CMXB`1KGPW#Q'5120T_-W!`>T)Q5$/1[Q
MFP`\-O`N?,FE#<-@'P`-`38:`BV>^4'>4A]TFZ9S]OU<15(X*HX<].;7VWGM
MO-.9N#<-P(/03K`PC[6VX:K;#^M*=?YGL+37^]+[#Z+M8</_`+EBYGSG*J[Q
ME%1<6DJ8>.VTZ4?U*NKIITJ2D(D,0YQ$-M_K?1X@&P;_``^K6VE=W/8^J/G)
M1_B?6LOURJ<G4="HVQ5(&_B/AXC[)A]6_H`-3M=*^!%=(O6DG1?IX?:;@>(;
M_#J"30)"FW`Q0$!$!\0W\0``W_"U$7-2=.@/)7B[53'%9D[?<99I!0$4EYCI
MXX'83G,(^2T:H$`5G;UTJ/2DBF4QU##X!Z=(*<KC\=-`Y1BMS+3:'1[9R.M+
M/,.9HUQ%XWB7@N\28?D$E`:KI)@NDUN]UCW29/?)!TFIYC5)4A=B&`1*"8%!
M3(E)06R/U>+_`'%I)W'OG]/@OWE\6K!=&@-)_$H[!N/AL'T=PVW^A\/T-`1P
M<DZ7>\89`?9OA6<Q>,:7A>L0&9DFSIZ^R'ABD1K=['SMLQ"V(=R48>=8NTT9
MUJU13?,VQ57+53<3`6[:3D]JZEF<\NW<@\?;[6[UIKP\U_872/,RXNHM8QHK
M#/RS%9NCNLUFCNZP`SK1PVFX]=6!DE56BCEVI$+M6`^8Y*18Q?KSATE4,2_C
MXE[,NSM6%NNV[;N254J0BTF]:)ZM:+5UT1C9W*8V!2[R,O;5V\K<*)NLI)M+
MTITZ/5T2\RNZ*Z:I`,4Z9A]!O+."A2G`=C$ZR^D2&`0'T>(>K6$FI+='5&Q<
M9)T:U-WJ#X=549%&?=00!\/$?0&@*;Y9RUCC!^-[IES*]SA*#CG'L!(V:WVZ
MP.BM(F%B(Q'S7*RZ@^VNY4\$V[9(#N'2YR)(D44.4HS%5=`87"L[R1^<Y\J'
M=7BS7S!/:=P'<EG<C(L6Q(>P9'FFC548EV[^,DP;360;.4F[=$@.F-3C%Q45
M34>+&`]S2*^)!E#\7^UUP=X?7R2RA@+`%8H]_E:E!TA2R>]R<Z\80$$R*R,$
M,$X\?)PLG9"D!28>-2I.I-4.I=0P`!0I<J@D(U02-`-`-`-`-`-`-`-`-`-`
M-`-`1L=X@[$G:^YP&D472[7[05O#RV;A)JO[R8K8K%3SED')/(1>BF=4G1NH
MD4Q`,43`8`+PO'X0_J-?`/I^'T^CZ&@+6NZ]^]T<N/U)Y#\](K0$A6@&@&@&
M@&@&@&@&@&@&@&@&@&@,+3`#A>0^<@\H5U4YE(&'("'9IA.%;@N9-/&TNU\Y
M@HCY8&A%`(G[GN43BB<@&$3%$1UN1_WZV>X_E>O_`.@N]G__`*6W_P#K>.9E
MLX<Q8R1$C=VY.2-?+$28E;G=*F22.8J#5-R0[=9TX/TE3(J!DSF$`,`EW`=M
M:FE=VZ5T/"5<]JR[GBD_WEAO;<3M2.'[PG<(3.<#,*YBO#@T=R%Q;BO$]_;,
MEVT`ZCD4X?$$?'5B>@",W1?=I54GOKL>KS-ND`#+S96Y23AM6GA6GZS#XV[.
M];G*:DI;_%49(AK`-B>>M%5KMU@I6LVN)93M>G(]U%2\/)(D<L)"/>)BDY;.
M$%`,4Q%"CZ0V,40`0$!`-2FUT!CO/LV]T.K\[\F=MCA9<>)TQ3\$8,I6=8W(
MG,FOY=L-M)3<CSJT+7L:HR>+;)'JS!:.JQ70:R#MH"B[("D65%5,`/<='&K,
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MA.3E^HYK@..<K1^'+K%-*R_`5NL5_#R^9&%EF,40#>%?0K15G:F-854L[V.1
MI[)RU0]V4%7WDR1A-T@8=;F:C5R3UI3]:T."S<S/Y#+ER')M7N0OWYSN2BJ*
M,IN4I.GQD_O9&E\0_.,R@4"Y)[.`[!L)C8[YC^T(;["7HM!2@'3M\/C]35HH
M-]*O?.*S`'O&1NSL90H]0>7CWF&!0\-@$!4LXCN'T-`4:X!]JGE7B+E[G[E-
MS,R%QFN*N9KB\RVG3N.</DR!9Q&8Y7W>.6GFSFWIQCZ-KS"#*X$&AG$@H^>O
M555S;@36CR>W>+RN;L<Q<C)YEJV_%TK71K]/L.GX3O#G.VN+S.+XJ^K&/GJE
MRJ4E.--K5))I5Z?O3),>843W&'*M#-P$LW#FO&1+-%R6'+"OY@G".BG-'?$(
MTP,4/X\S4Z)".A<@\,8#"*8$`/:'6YMZIO:XZOKXG,)-1K-IW'JWYD;>;,D_
M.!N/N,9K+5XMG:>L5:K,I3V<Q%4;'7*]Q:G;6V7.OTPJD"RGKO$Q;V1:N+"F
ML1NJ[0!<$Q(4X&,758.NPQ??G`?)?#-<RO5[GVEJ_2\F0DLO#QEDH'*TEJ91
MH/Y2#$TK\47.:@V[]3W(R@D16<I)=0%$Q]AW`JOV^>.?<C[?_%;#_$5ICGAQ
ME^+QLG>EE\J#R&RY2S23FWW^U7HC0]+6XYSSE`[0UC!F!TWJA3^3Y@@7J$H.
MG4%YBM_[F!$6ZB?&;AXNJJ=P55L7EEE-(6Q$SK`W6%<_%L4EP=$3*/03Q3ZO
M$1VT!&'R&POWRGG+:$YF<<:!P.KEC880/@"9Q1?LO90R-7Y&$^5TG<_EJRF$
M<?8H=1TR#MPDT*T*<4Q(43G$XF`"V?P\7DK)_BV[?LU_M.[PN[LBYV?#L'-N
M>WP+Y">7*D:OW)6[5NOQHK:^15FC*_.0['$J/;8Z[1>/),KM5!*$>P_)VT*J
M-DRI"B^"0KEJ58ID<B<P`D8WF$%,1'P$-K[7\5#B\E82R)QP+KNX\946B6GQ
M_P!)Z\T'\XD(!S&R-V>MO'H#Y!<P0'?;8`'_`#2G$1W^`!TBDY)/H652OJ^D
MM.QER-^<`Y;SWR0X^P5B[2L!9N-#ZCL[)-SE'Y3O(6VMK_$O)6*D:ZC#W9U*
M,DV16AD7*;U-$X*E]D#%'<*;4W._*W1;8M?K54NO6B.EYWM+E^#[=P.Y\M4X
MCEM\<9T=:PDH2?BG232\OD71!!_.->G<,D]FXVQ=P'[7?,K8?1L([6KT#]#5
M3ZG,T<?2^J-PL%\XQ$`ZLE=G(!'TB3'?,80#?UAU6GQ\/A'4`N6XZ81YEY"D
MG$[W*G7%ZYSE%F&C[$C'BTME:.QK),W[-8LLMD2B99;/72MBA9%NF+-TWD%F
M[E%42*()^5]FJC-Q32\2B4%)IOP)*@`````-@#P``\```]0:I*QH!H!H#;.F
M4X@8W5X!L(`.Q3`(@.Q@]!O1Z_4(_".CGL6X(CIOU"LW&*>D;SCMC(RO'.<3
MDW5UH-?CD):RX,LTF=PH\RSBQ@NQ>*JUDHG,M+PB:;CW=43N6R`@*J0W[=R<
M4\BVZ3IZO\4/%?/H_L+%^SC75"64JPA-25?[RJE^UEU&!ZY2ZEA^C16.+"G;
MJNI$H/HJX#)!,$LP2+A5^YFUI%-04UEY-VX44/T`F0IQ$`3)MT!;ED69KWK:
MI9EHE\7I^TRYW4Y^[+I+TK]Q6)F^;O2K"@H0YVRYVKHA#`;R'28`*B)Q#;VB
M@8!^D.HJ&J,Y_H#Q\-@U26V4ES7F_%_'G&]RR]FFYP>/<8T6%5FK/;Y][[HR
M8-2_8TD$DR`9R]D7S@Q46C9`#N7;@Y4D4SG';0&&+8DN4GSG7D!)-*A+6/C?
MVNN/5H08@M,B]";RC:$7K=TY?/H.*?I,IS([R$\TS=$RY8^H,UR"85GQQ+JN
M#H#,UP3@O%?''$U!PKA>H1M$QICB!:0%4K,20?=V;)LETG5=.5@,[D9)ZN)E
MW3I8YEW+@QE%#"8PZI;JP5@U`&@&@&@&@&@&@&@&@&@&@&@&@&@(ZN[6(%[<
M/+4QB&4*7&(F,FF8A5%`+8H(PID,H8B93G`-@$P@4!'Q$`\=`2!^87_K=?\`
MR-\S\D;_`%O_`%O^3?D_\=^1_P`=H"P?NO?O='+C]2>0_/2*T!(5H!H!H!H!
MH!H!H!H!H!H!H!H!H##+P-[B?YQAR@.R:)QR1,]UU$Z*)R]+J0"@39I)Z8`'
MS?-?N=E5"^T4#>T(E\`UK[]A_C;=SX5/<ORSG<L_ESWI%R6R?%V]/_SO'T,Q
MJ3B6TPQ>Q[Q$5&D@S<,'28*N&ZBC5VW5:N4@7;"1=`5$5C!UD,!R[[E$I@*8
M-GHFVNK/#6FI.KK5E)L#<?L>\<:M*4K&B5F;5J4L\O;?<;/=KA?%XV1FRM"/
M&,/)W26FY>/KZ(,B>[L@<&1;^UT;=0ZANH*X'-TE,(%,80`1`H`.XB`>`>CU
MZH:JFA5+5]#Q-@MD+#.4!EIUC$-4#H@N@Y=-"KNUWBR#9LD+<53.DTR'<D,(
MB0-P,!OK0$=41O1LJLNGV5,K&Q,O,ELQ(QFW7ZM.B;ZO3P9Y.D_:OM,^[RK4
MH2`-:[)%GK4C<RUIC&W*5@*Y)/&[2)DY1PQ:V5S7V4D155DBL)FY@/YR6Y5"
MF'*26CZII/[.OZ?V%/)\3?XG/N8&;;M+DI6HO?%QE12BI);HMKHU6C='HZ--
M%8B`(!L([COZ?7^#JW)IO0QHU44FZM*E37JDD:`:`:`:`HKR#R1*XAQ!D/)T
M)2Y?(TK1:E+6-C0JZ#@U@MKEDF7R(.(!HT?N@=/5#`4!305-\!3#X:OVHQE%
MJ5?/3X*M/FZ47Q9TO9?;6-WEWAQG:V7G8_'8N=F0M7<B]_EVK,JJ5R;JJ0B]
MLI:K1'G9"L4WE-Q^:5K,>.7"U-R_1JZ_MV-K"XDX]['%DV<7/!"R3J,<PTZQ
MEH*1(395!1LY(N@!BB0Q?"U<A&4'%>+\:^.M/[?C4U_.8"[<[DS>$Q,FWF6\
M'.N687;5-MVW;EMC=@WILE3<JMZ-=3O*)4L=X(I-$PUC&&B*73ZA#-H"E4=N
M]4.F6(2(Z7;Q\:O*/WLNLX.FV<*`=PJ<ZRA3"8YC=0ACPC&REB+25=/O^\L1
MQ\S/M9&7.Q=E!.DI55%JDZTTTK_HH<;.F2)7%N(;WDNL4R5R#(TZJR-CBZ1!
M$7-.VQZV*46\/%`VCY9T5XY$X"7RVRYO@(;6;>NV,6RYYD97%'P2\O+XOP-K
MV+VU9[O[]XCM?-Y'%XC"S<WV\C(R/\NS!16V<VJ/:E5NCJ51H\ZYM%+J-F>1
M#RON[#68*<=0,@"A7\(YEHMJ_7B'P+(-E0=QJJXHJ`9-,W60=RE'P#'C*W.*
MG:_RFDU\GT-;S'&V^&Y;*XBS>ADVL7(N68WH?1=5N;@KD.OIFENC\&CU&I-<
M:3&Z=OHCM]/X?PM2E4IG51W+HCQEEL<7#D#XXEFE>CEG3"/^,WSIFP*X?RCG
MW1A%MG#\Z:7O3]<P)H]/4950>@@"?PU+A5--I17G]AD8^#GY]^6-Q]N=R5NU
M[C4*N5*_#HEXOP\2*.`N[3`F0NX-GFE8:GLI7.;Y*8>H\C%4X7DA:)B$6H>/
MF('_`)B:38-X^K+V-X^.F*"94RJ"*@I[&,73*>/Q\\JY=MRFWEPJH]:^E)^.
MD:M_*I]8<CP,N_.T_P`O>S.5Y?%XKA<3MWE\K=D.L(Y$<O*N*WI3U7G"$(:O
MU4=*=9CR#U$(;;;<I1V^#<`';\#6X=*Z=#Y+DJ2:ZT9JU!2-`-`-`-`-`-`;
M*Y!43$@"&QMRFW*4^Y1*8!#8P&*(>/CN`@(>'KU,:5U)2B_JZ$?ELIEGXDS,
MS>,;IOICC'8';J0R?B6*:.%Y;$,G+N%WLOE7%ON0*/`KJCM7S9N&#9)LF91Z
MVVZ%$S53MO(@[*=)33BG\]#%E?GC7XW%'=8C)-KX)U^WH>KQ]?[!!7.-CHV>
M>YAJV;+A(V:I2T*:-<0N,L=,(1D38T\Q9&1G&#^6,"B*!C@HA[STE,)`\(][
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M\R2L.H`T`T`T`T`T`T`T`T`T`T`T`T`T`T!'AW8OWNKE9^ITA^FBO:`D/T!'
MKW7OWNCEQ^I/(?GI%:`D*T`T`T`T`T`T`T`T`T`T`T`T`T!@7*X+><C>^OS(
MQ)*95RSAWY3<H*TY1R'@>TM\>Y1J\?`UZ8D8P:A;6+20+!2+]/V'+HR"RZR!
MU"J$W/U!K\BY<_&VHIO:>S]A<3_4?RV[ONV;LK;M<;;E-1ZM++Q]-:F0PGV6
M&Y2^WW5.\J0QA%0Q1YPJ>`F'Q'<<<CL`C]+6SN.<IO:]$>,.$87);'Z&]%X+
M1=#=3[+K,3;$[JO>14,(&]D.<1S?6FZ3;=..@W$I@V'X/7J(U3K/5?$:&I7L
MLHF3.!>ZAWD2&$H])QYO*F`IMO9,8OVO/:*`^D/0(:N1G!23<8M5Z:D3W;7L
MIOII7I7X_`BGY"?-G)_(V6+_`)'1Y19ZS:><7K@Q+W.6?Y&8RHZC&$!&1`!8
M[HYQK(12ZK)RS<%;'*E[#`J*0`!R!OYYW)9[]GD.YV^N-CCI_3D>XZ_]F43T
M'LV/Y:W9*'?5_EK2:=98;MI+R],DVZ_#1>)?3V<>T'?NWKE;)^8[;D&078WW
M&;#%\;BN2M;[(K^$6BK<,\K:5KH:-J\2DRD46J:;:,:QAA;)GZCK]8F3#J>)
MQN<L8\?ZS=Q97G!-JVI;8NFJBW+HO"M=/$UWY@<=^7V-W7=G^6>;R/(<%+&M
M5N9J49QN;$[D8J/A&58Z]:56C1D/)[]/B.X[CX^C6RA+<JU3U\#CXUVJM:T-
M>JB1H"C_`""R#=,48.RSDS'.,YC,]]HE`L]II^)Z^LX;S>1+%#13E[%5&+6:
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M$$KDE,UZ&N-.IK&PPDJV1M</[;1R0XI2)"D4$PB`9JQ-T4H26[1U^_\`L.SX
M;_D^X#F<#&RX=^<0K;Q,?*E_N\H*>-<N94?>C.63)NOX:XEI7^5-RHE5VT0F
M$>]O.2BC&E\@>=L_<GTK?J^BP96S*3>2D;+CB295/*3!Q-NI42-'%1FGR+)_
MYQRFW.`[&#J'5F6$O>_$3:=Q).OP?3X4?R.:[I_Y>>$[6[8R<Y=[<-=XZ-K"
MO3M683<IPR\6=V#C6[I')NP7X:6M;.Z4O4D9E/:HPAW*<&4Z^U+N'Y\HF="-
MFE"BL)/*FL=[-5^$A(B0CK&6V3#FG5*4EI.1,#$WO+LSITH<B@G.`B(FHG<;
MGMFO]-#Y*N3QHJ$K?KN.<E*76K5%'[4E1T^TAO[X7<<[A_'W+.5Y;BKE='"6
M%>.,!AFGW",F:C5IRRY$R#F:8N:K:T0+2T4Z4,VKE885Y)%4XNBHND54E4>H
MQSAJU[^/^(_"42N1AN?R>J_5J=3RO8G/<-V;QW=]_P!J/#\G<]NS/U-)VW2X
MFZTW:-->#JO`ICR(RUWC\'Y3XP4VA=W+'G(FFY\DW[#(>3J-@7CNPK''!"/6
MJF\O?RI6F?(XBG,=/NW*:B[B.(8L6L4IC&'8MJ]"]>L3ACRC"XYQDGXJ/C%>
M:T_TG)ZN]*44O9VR;_PT22I]M62<]BKGGGWDUBAFRY8Y;;92OF0*\EE/&<V&
M/HRH.$JV1X\@[567;^J(,ZY*(P;MLT<M#':-GG2]5`QUR@GY>OX+E'S%WD'%
M14<3*5G;'X1;?ZT>M<_^4W(\1^5'$_F9A75D\-FMV[TFTG"7U1=%X/;):=*:
MGMNY;VI.27.+.M+RU@/N#9%XG1-,AH921H49$6^YUY[DB`4E6\%DVM,V>3JK
M$5*P,:]+&8F5;,O>#J)E7\SK(76??A[E;;?I9YGQW)\KQ<[M[C;\K6)EXSM2
M<:>N+=7%MIT7G1ILMAQCV@^[;QV+=YK"O=Z(ZM5^D("1OSC(&%W]F5R%(Q95
MD5[>_FKW9LFJ5FW#'/#,MF;-9!PW9-A6\>K9:QYQJHR2W2J]*U?FWU\%IT-]
M9[CXO/Q<;BNXHWI8F+O5IPDE[?NS<Y[=U%24VY/5T;=%0K[`<&^^8]0=JV7O
M)4^NKB[/[@PBN(..+@D1CY:`I*/)AP2B"+U185@.B5EY:9`)TJG$1`+[A31.
MOV4,;*R^U(93AQ=C*NV:=;DH_JV+[=:&M>'[N7`ZSP>;\U<K&G<,X[1+25;9
MHQE4N/\`3<19%J<"X;`HUR+3CPKV5&=)5'"`+/D#."B9J*@"B(?9DK3MW;;E
MD5<K*I6/BO-KS\WJ=Y^5?8O:'YG<]<[/R>7M\)W/DQ?X%Y5'C7[J7IL.XG%V
MIW'Z(.6Y.326M$YM,39;H6:Z'7<EXSM4;<*3:8QM(PLY%*D707*J43JMUP`W
MF-)!D8P).6RI2K-EBB10`,&VLAJ#BIQZ2U6O@>?=U]H]R]B]PY7:_=6-<PN6
MQ+FR5J]%J=:NDZZ*4)K6W**HTFZOPJ60_48OM".^X^KI$!+N'JW\-0XT3T.<
M6YSVR>V<.J71U-_5LN#0#0%N.?<UO\1R6+(N(-C-W,Y'N`UF-K5_R=&XTF+1
M[NS-(2#'':DM'/6%EM;./24<>X*J-@.@0PD.*G24;]JT[D)249/:JNBK1?'X
M5+5R_9LRC&[.,93=(INE7UHOC0]1B/D-A#/:U\;8:R?4,D+XOMCNBY"1JLHG
M)*5"X,15*[KTV5,`%G)(&0.!B#_$CX^&J;N/?L.,KT7%2C5575>9;L9>+F;X
MX\XS<);94?1^3*P*I)&(J)R$'K3$BG4!1`Y.DQ>@_5L4Q-C"&QO#Q'X=6TW4
MR*+IX$57("Z53MCQ-IY*%!-IP_<S#-WF['\6HV(]Q18;!*"U#)>)X9W(-3R[
M6:F9-(DO6&":KU4X^\LD1$BA`R-T&NGK\_/YF/:BK-U^UHF]=6_VU_48X<1'
M<J_G,G*4C^W15XP;VDL(7%RJVAFYQA9;(LW!@@W*@YD@6<-[+EJ4`RFSMH16
M,JD>N!"^8ZZ5'5.D>G4OJ<;OIBJ/S,SW".&,:X!Q72,-XFIL31<>X[@V=:J]
M<B&B+1!K'L$DTP=.#()I"^E9%4@N'CM3J7=NCG65,*AS:M2>NA4X[=*U*M:I
M`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!'?W91$O;HY7&`HG$N.$A`A>D#'$+/
M7Q`A1.8I`,80V#<0#?TB`:`D,ZS?])4_(^OTI?7?])_)?R3Z/UG\=H"/GNO?
MO='+C]2>0_/2*T!(5H!H!H!H!H!H!H!H!H!H!H!H!H#"@XR.6[OYQ/RJ!N()
MF9\I5T5]RE#J6&J3Q5`3``+L*A$"]0B(B.M??BOQMMU\#Z"_*B&-+\N._4F_
M=AP5B5/C+-QTS,[G'0M(V07ZE`*DQ=K`9$3E<E\MJOL+0R:+A0'`'#V3`FIT
MG$H@4WHUMH*<KVR*5*5?W_LH?/<8WG;V68ISBJZ^.E>OG^XCK[6&<[KGS!EV
MLU]>V1_.UW-.0Z.1S8Y][9#&C*P>';,4HB3EJ!CF=4BD`6,4??F2RYG8+B"Y
MTO+`NVY[C8<==M0M3WV[EI3;HE1O^'1M?'P\#0=N\[<YRUD3N6O:E8ONW376
ME==23<0W`0'T"`A]76@<-RHVZ,Z&OEU.J>QPK'1<H+BW<M@$A#"43I*H&VZV
M[A,!#S$A$-P]91#<-3&%J,-CA&6GCJ_O9<C."^N-?M:_8684OF9%6WGME[@D
ME19%G.8@X_8^SM(Y&5G$%(J<2O\`/NH1*M1]=-'`\;'BBHD64=&>'`XJ`3R2
M[=8SL@M()1U\$4SA<=KWTZ6TZ;::/QU?4OB3#8OK\1$?'Z.JG7Q*(RE-;I=3
M7J"1H!H#'1^=,.BM.TK>EC)BJ`9JPD4"E^$UG6#?P]0:`FNXL#U\8N.!@#8#
M8%P\(`/JWQY71`/P]`0:\]NZ!PH=9+R-0F&7';VU4S!/('!EB8-\?Y&%%CE(
M^8L%N$JP5^-5*R="=+'TP/OB2AV(>Y[>=NJD!]UB6;MJRIRBJ>Y"75=%&?\`
M:C]*_P#E]_Y:/SGP.W.,Y[+XF%OC<WN#B.5LR>5AUG@QX[E(N]M]]RC1YF-_
M+DE=?N5V>B3C8)R#[@G%F].;&.->2ECI"[WEUF#*R-NC,+6F8=#2KNVP5\4/
M`A+?4%6@$)(U9^J`&(5V*D0!3$(DZ`JF3C4LI7KL%)*U&-&Z5?J3Z.O1_I0]
MY[,_(?\`,?M^UQ^7W-V]9R%9[/XWC'9ER-BVOQEA\K&Y'W,?(4J2MW[4&ZNW
MMR'ZI3M-QXN&^=&%8O+4,^MW<.O2-:=92YER,T\:\46)U7<-ES+--E(>3_F;
M'#A['N,Z1C%:24(0"'K8MO)22;]?A=M7MEU7XV8*$8PT<FU+8U2-=7T37Q1I
MOS:_(WN7D_RYS^.XKL&Q+.AP/;\-[Y>]+\-/"XO*MWU%1R)0E_1I35JW*=5F
M1D[ER5QQ,JWC-B&X8<PW0Z!;,CR&4K)3T9IFED&9CG#25LE<D++*RT(C,HN'
MCYRI*,X)VU0<*]?BND82%(78H:WF,V&;R$\BW95J#EK&+T3HDTJ_+Y'XN\#Q
MF1PG&QX;D;LK^5#(N2<VX5?J;\)--?$QB/G$G&J=Q_A;D_F\K>$2QWF[,O#]
MBS:MI60>3SBU13BZ)W)S+L'29TXR.>F%,$/*7Z#$.8"$3'80XS#XWDEW9DY=
MW8N&GB?57U*2C3IT_P!)]`=T_FY<[C_)7MS\N;T(_C>#S[\[<U%/W(7I2I;F
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M99]^82,HIB=[56K/WE<P>'6H0H``B([!J[[=S3Z2+:=]3A;BFK?5;[7AY5GJ
M2H@3<"]0B([>O80W]0[>CPU1N\BBGKWJJ5.E3@N8U-SYGGJ"HF9,Y#(J`441
M*<IBG`P>L#%,.^^_AJXKU%1)5\_%%$K,&TE_EJ6ZGCN\)1E]46O\+5?$A<RI
MAO(';;O%OY.<4ZO.9!XWWJ<6LO)CBS$*JN7%>D7)P^-<UX49@DZ,TDD$^@TE
M"IE31.DD8Q``FYD,6Y<>-&>3+_NJUDEU7^*"\?\`%'X'VEVGW3VS_P`T'$X?
MY2?G#GXO'?F9C6?;X;G\BJCD*&JX[DKJKY+\'=?\4KL9N/IW2KX:S+0,[X^J
M64<6SS2TTBW199&)F&0G(`;^:FX8O&JX$=L)-BY2,DX;+%*JBH&PAZ!&_"Y9
MNVE<MR4H2^G1ZKX^1\K]Z]H]Q?E_W1E]H]V8E[$[APYN-VU+;Z8K6-Q23<;D
M+BHX2@Y*2:?0JT103`&Y=A$=A`?#;Z.P[#XZ2C1Z=#EX7(W([]8KPW*C-W5!
M6-`0E]X):KK6?@S'O<JU;&EO4Y$L$JNI/U"EY$4?%EUH.-D2'I]XM4'!(1;M
MF51H>7<-'A(U=PF=(Z#@4A4W/$*5+S492A[>M&U^M*M?AXG-]P^UNQE.Y&W<
M][2L5+K2NC:5/"K3I7P9['M-9=K^25^9$!$6O(-SE\<\BI"`N=@N=XI]RAY:
MU.V*[E_)4TM2Q-B=:+8G(@1L\^-4'THN[:&%5P<I$SJ1RUJ5M67)1BI6]$DU
M1?&LI5^%*)+P*NW\FW?_`!,8RG*4+U&W)--^:I"%/C6KJNO0D1Y$\AL3<6L0
M7G.6<[;&T?&%!BE92PSTD)C]:8E*FUB(IBGN[F;!,NC@W9,FY#K.'!RD`/$1
M#44JCH6Z*IAM0%)Y3_.;^1;;)=W<3O'KM<8#N:K&JU<BI2VF^2A4Q&3"-.0@
M-YW($W&`"4E)*",75VRWNS4B[H%?-HVM^+,12N.>]K1>!FCX>PWC3`F-Z?B3
M#].A:!CBBPK6#JU2KS0C2,BV+=/81V#[([>N5!,JX<K"=PY7.914YCF$=5UT
MH9E:QZ4;*G@&VH(5?'4^Z$C0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$>'=C_>Z
MN5GZG2'Z:*]H"0_0$>O=>_>Z.7'ZD\A^>D5H"0K0#0#0#0#0#0#0#0#0#0#0
M#0#0&$YQE*V3^<7<JQ2(3S3\GE#*CU"`^8-7LNY@+ML)MM85_P#[Y;^1]'_E
M19PK/Y9]_P!SU?B)]O8_AI7\;C^-3,QMB2ZT#-%:HR2[@\'+)-DH9VC'RZKE
M9JZ(V3B)%TX:M6$J=<Q"MUE%$RI+&(8RA"@)M;.-NLY2;I6*1\W3O4N1M+>H
MT4JI5TI2GZBSOMYU:Y4W#,]`WI#E*C-M,DVXVW+FS5^Y9-3;*A&?S/'6>K3M
M@@IVFINR+&CW:"P$<`H8VPCN.KN1+=&"<DVHI.G]OC\/(QL3)E?=U>Q[$%<T
MTIN^+^)?J(@4!$=]@#<=@$1_```$1UB&66X9^Y!Q>(6L'78"&<7[--_"198F
MQ;&&,$C:)1J1--Q)2;H@'1@J;"*.$SR<DL)4FZ1M@$3F`-5;&4[D6T\1^.<7
M`9TS'RKR"FI9^2^0X.'Q3D+)(%GHJ"4@ZS(#)LL>8^K#\B<0UH5)<>2W;2*'
M6O*.0757,)QV"=M%U-[R6#/C<*S;O2A*Y=A&Y2$MVU254IZ*DJ/IK0D,96*#
MD9"4B8^6C7LI!G:)S4:T?LUY"(4D$"NV"<FQ27,[8'>LS@JB"I"^:F/47<-4
MT-(U30[K4`:`:`QT_G2@@':8N_4&X#FW!X;;;_\`\T*[:`FNXM#_`*V3CD(?
MZ@^(!#^M[7=`1.<N^)N(L07')TWA]?)V)760,(\A.05Q;XZS;ENJ1DYFC[;G
M'^-#(3F&CKD2,)+?%URDT#)II%9BDY`HH[I(BGL\5RO;7=<7!3C'5+HU)^7P
M/OK\F?S-[M[[X;BL3O-<9RUKCN?X?A\=Y?'8%Z=KC7Q_+W/PBN2Q][AOQ;,E
M*4G<3@_7ZY[K(^21`Q9D`6[&X\M'%=#DER0QZ->QYF3D%<YLM7Q^_P"*#>KM
M#1Y+P_E19,V-\G^A<#"=5[+HIB8X^Z@G=]JW<C'6%7;BWHEJ]U?#X(][_+GC
M,?NKM^S<R,/M/^H3[4X7/=W+P.)QK7XC,AW`[[4WC0M[W/#Q/1T5O'N2I'^:
MY;./+1C?(V0W6.K=3><5EJ%GL_/:!?U;($KRE;563K]0R94X/$-0N1I"S.S,
M8/'%7?NV5G4!(9*(763+(BH<V^LK"QT[RC+VW"D*M4;56DVJ>/EJJOH<;^:F
M'W/^7_Y9Y/>G:^5V3;Y_$XGMG)MW+$>)]Y9%[C<G(S[MIX^.YK\=D6[=S#D_
MY-ZS&<["BDXN5WB%AW&'*#CCBK.SEGR%Q^ODFOKS!Z8KRHY('5KS5"9EX1!$
MBSNYP[D!.A'`JF4R">Q#E,`?6ZCE,RY8RIXUB[)VXOJU1O1>3?W_`*C\XN+_
M`#7[PY?C[6;R-CBUG7;DIW-N+B/;N?G^'C7XQHJ/H6$_.=HI.([:-%BVJ;DS
M2/Y-X38-U'*ZTHY*@TA+D@@=_)O?>'B[@Q$@ZUSJBJLIN)S&W\>>:DYM3G)P
MG7=YT\D<]D9-W)OSRIQA[[FY*B455NM=J245Y)*B\#(EQXF!Z!3"'*4R9Z?6
M2F*;8Q3%&`CRF*8H@("40\!`?`0U*HEM7TK1?(MJFLG]<G5_/I^XWDL>4!%N
MFT1HU.2:(E*1%LG685-ND4@@)"IHE9`F0I1`!````#;4$5=?@43RUQ(XLY=1
M;+Y9XUX)R.2%]Z6BG%SQ+0[6ZAE'J0)/74>$U7GAFYUB)DZN@1$VWM;@&VFG
MCT(;<?4HQFTT]LNCH^CIK1_`I)B?MQ<,\.V:-R#1>.N#T[E$3+>RU*ZML,8B
M@;12I-%NJV2>5.=JE&KLE%G!-RH('$ZJOM&`#``[:E1M]&Y4_3X?J9N.9Y6'
M+SLSM8F%B>RJ-6H7*3^,JW'5_%47P+]R[])=]M]@WV]&^WJ^AJ#4'T0`0$!#
M<!\!`?$!`?2`AH#@/FYG'EE#;8"J=6Y2F`2FZ2B40,4P#U%$0V$!*(;@/@.E
M8159K=72GA]I3+\0FIV)J*3UK&K^$HZJDH^#\*D%O()@][;6<&F=^.JY+!B7
M*<\Z<Y]X:Q$F@K,%;F0\V>SY@ZGMU"N&KJOIMP6GD&Z'N@HB)E.DGY!9MXT.
M-BY6=TL>[*LHZ^E^<%]E&GX5/L7L/N'MC_F&[3M_E#^9R6/^9N':DN!YK='W
MK\H5E^"Y*<G%SA<BY6[#3;5QPK5KU2_X;S'C;/&/*WE+%-H9VVDVED60B)F/
MZB`.P)IN&3]FN"3N.E6*GV-PV6(55!0!*8/`-\U-N&Y4<7T^1\N]Z]E=T?E_
MW+<[2[WQ;V'W-@MJ>/->IQ>JFJ:2BTTTTZ:^=2K_`)A?$/'V=M_P?@\=6MK.
M=C*,GM36[R\OF:@'<-]4DD5G=*RQ'X>J^`IZ9J=-LL)8\X4BFOW%HPC1<SN(
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M<UK0FD:%1]`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`1X=V/\`>ZN5GZG2
M'Z:*]H"0_0$>O=>_>Z.7'ZD\A^>D5H"0K0#0#0#0#0#0#0#0#0#0#0#0'FKA
M/?):L6"RBB9RG7H*9G5FI#D35<HP\8ZD3H)J'(H4AUO=^@#"40*)@$0$`V$#
M`-[5G)Y+D%W:[ARIR!'5O&26;LVL+>6)6FS#%UX+$G;X6`AQFI9*,!VY7*+5
M+S#I)><Y7`"$`#$#6#>E&69;46M%1GT9^3S65^77?V-!J63/@K$+<%K*<XYE
MB4H0BM9244Y.,4VDFVJ(_0)V2.(F'8PE,&P]>Q=MQ$!#I$`-T]8^GX=;&4FG
M34^<G.[%R4%ZE1-?"B9NHI))"/EDZ.H3"8PB;Q,/2`_7#L`FZ0]'P:IW-Z.I
M5)R3V_PO7[2WS/?(!CB(*U4Z[#FOV9LDK.H[%F+8YT5O(V-VR*F>4G)5WT'3
M@:56VROGR,BM["9``A.I4Q2B2U^!2^AUN"<".Z2O/Y(RG+-[[GK("8$N]T(5
MP6.B8E-QY\?CZA-W!4UX2B0724$T@`JCQ<#+K;B8I25.7ET*:,N#/$%,<P@_
MDTPV#I*5W[!``3>R4/+WV$#"'B(_5U3UU+BFXK:M6RV'*&!Y)C<EL^X(:1,!
MG%HQ39V-N],6*KF;*['H![K3L@/&Z*JA%VQB$^+90$S+,5"`0=T=P"M-=/`H
MC[E/YCK(M(PUWA\!Y6Y;US@E,XPS]BKE-+0LE*3%$O52IWQ+6'$)7W%FE&<Q
M::[?+`1(AXYFH=F8S5)9XW,DN"1$UDQ&EI>!42W$,)B%,(;"(!N'P#Z_P]4@
MU:`A,^<!\8<Y\O.W39L,<=\?R62\CR.6<2SR59B7\/'/S05>L"KZ<D$%YU['
MQQA8M?:$AE`,??8H";8-`0N8_P"]/WI<;4JH8UB^SS-NHC&-'@:F66F:5R*:
M.GD?1(YE5E7"Y"5@J`R#SW`ATDT?-(MUB*0G('4,M/KX%=FS.Y)JY/;7Z/Y5
MZ2^.Z48.*^_H6E3,9\X-Y4J2&99#C'RF9Q&1W-^`E4DLKQ5$:5K'EVNA+#*X
MSK5+NDI"6:"JS1U7H=!JE(MDU'*,4BNION0PYV)FK$A*+M1N-M/7PHGT^\^U
MOR[_`.:[LK\N.U<+@KWY>\#F\G@9&-=EDPCMN9%ZQ9NX\,F]ODG*]&-^\]R6
MGN7/,ZR3XP=_B<DUYJQ<;N24Y/'D)*Q)32^?J09VWM$X:KGL4KYJUP5.LK*C
M08#V@$!'XJ;@(`"90U#Y-W9>V[$+<*=4O+P_6SN\;_GD[$LVI8.%^6W!XG'2
MACXVS;%VHV+'XEQ2MPDW2/XS(4733WKM761;YGK(/>&X),JIECD%5,[8'0L]
MRN->IN09S-D5+,!R=EE0;[DH/\S<K+N"NLC2%6"0>>\$32=J,0`Y@..^JEFJ
M%6EI1>"\.B.)[N_YN^U.Y.U;_;]O\O.W;$[UG"LN<(NL(8^+<MVE#<WI@2G[
M&-3_`,E.33:JS.I[9W)J^<RN$^#.2V1ZG6Z5:LIP,O+/8&IRDM,PR*</:IZK
M-%T7\VBC)G5>MH(%U2*@;H55,4IC%`!'$E<4WN2HGX>7R7@?$<Y;[]R[[<+<
M+DFTHTT3\-/+HO@0C_.D;_='N(N%W%BHU)A97?)#D0X.P<=3CY2HV['R=6B:
M77Z\B"J4:L:T2.3S)N#.%$P*5$A2F*)C;6Y.K;+<(>W!6ZUHJ5,H:C-'4?3:
MK'OD3-WL?6X)B];GVZT';.)9MW*)A*8Y!,DLF8H])C%W#P$?3J"H]2(@&VX@
M&_@&X[;_`$M*-]!1GS<OHZ@]H?XKT_2W^EJ$TVXKZEU7D1NCIJM>GQ(:^Z'*
MRL5R1[/#6(FYR(:3O<+90TXUAIV7B&LY#GPIE"3-$33:+?-$)B+&0C6ZHMG)
M54!.D7<FI;2='U#:C12T;)$^5/)?&W#KC]DGDIE\+`.-\5QD9+6@*K%I35@%
MI*V"(K37XMC%WT:D[5^,IM'J`RZ>R?4;<=MA$GI<`YMI?)+">+<^XZ"8)0\O
MTB`R!42V%@G%3@0%D8)24;\:QR3IZFR>^[+%\Q,JR@%'P`P^G0'D<[<AJ_B%
M.*K<.U4ON8[F@]1QIB"OG(XLUMD$4U#"^=`GYOQ#4HP$3J/I-P4J""29Q*)S
ME\L3DH*K3>I8ORNJVU8_SGT\OM\CQ6$..CNHR,]EO,$HPR+R`OK<$K5;2QGE
MQ%9A3($;H8]HD>*(&CJFP9$31<',4%I11,%5]^DA";&[E0ELA&*C"*_TUKYU
MZ?K,7%QIVI_B\N=S\="LHS@VG"BK6+5-5U2ZMJBKXV*99P]E#M[Y"M?)[B=3
MI.[<=+;(%G>3O%J!:*J.(@@"`RV7\&PB0MT`LC-N!??HH@%27;%,8@#T](8$
MD\5O(7J3:K%:OXN-/UIGVUVQWQP/_,;VYA?EE^;.;'!_,[&@[?#<]=:K>25(
M8?*79ZJ,I4C9G.5=SVU3>LI&%,SX\Y`XZKF6,46N/MM'M<<@\BY5@<G6FH<I
M#KQLFV\5XV9CC'%%RV5V525*("&VPC6KEJ6L&I1\ZIGRKWIV5W5^7W<&=V=W
MAB3PNYL+(E;N1E%Q;HZ5CIZHO^&2T:*OIF#H*`F)U;>@#`/KV\/'QU1+5U7T
MFA]O8J13VKS+7.7&4N,F`L6.^1/*(M!:TK#"H6>"LEOKL'8IF%M:HIIPK;':
M4HT=2!;U.OD4D&*<>)'2JH%\0(43DKA<G;BU%M;NM&U5>3IU+4[5JXU*Y&,I
M1=55)T?FO)_(PDV^;K+\XN[D>-\'\@[=:<`<2*TVLEVQ3@BII2DQ8+`TI[EN
MY66O#Q@G(1$;D2Y03I0KF8=IIQ<1'D49-#*K+%.O/N*E%U*8WISN.VTU"G4S
MT\9XQQ[B2AU+&V+JC!4.@4B'80-3J-68-XJ"@8J,2(W;,F+-HDB0"D!+VU#`
M*JQQ,=0QC&,(VVV7BH.J0-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`-`1X=
MV/\`>ZN5GZG2'Z:*]H"0_0$>O=>_>Z.7'ZD\A^>D5H"0K0#0#0#0#0#0#0#0
M#0#0#0#0&PL@582=>P@3KW*)"'`X'()!(;K*;V!WW';;?8/5H##]YJ_-O<@R
M6=<A9HX4Y<I%0I5BC;??TL-9':SSUU]M%5TG84:A!V09`K)*GW&R'443=/%D
M#0*QB%)YB8=1+4\:W).</\U]3=\'W#R7;V9'D>+N.U"&ERVNEWS;^+*U=HSN
MXW-I:%>!W/PTM1L[4&R(XY@9W(RGN-H1G6Z;9O'T#(?F%,#Y=\J(E@+%U&:2
MC<A"K*@L)#*W+,;BCMO?5X?%?'^T[CN#@.-[FXO_`(K[=?M<CJ[V,NO]YW(K
MP77<J:O5:U3R"\\YX+BUO!U6J5QSD;,]\6*SQSC.)4.#F05,H5%S:+0^*B8E
M8H-;'==_)+"0/+(*:/6N8I=7?&CT/*VW)U>DHZ-?']$:,%\>T\;O9K(]ZG@R
M)GF^)M#7O(SMJ*2"#-N8RC.E4.+6463J5"@RJBDU:-Q**XAYZXG5,(A#EX>!
M)<OJ@$?-2Y#<J'_.RY8)M.!(>-XTMZW+/J9E^-GJ6_E%7\3"U1^V=6!-AEN6
MM+92P2TE)LTXMQ38OW9)HBX]_7!0R0796I1BI:[6DRAW8ITKJ2!F`#IF#PV,
M4P"'JV$!`?#5MZ$QEN52!GE37X>*[Y?:G?Q\9',Y"6P]S67F9!I'LFKZ9<-Z
M?66[9>5>-D$G$BJT;E\M$RQCBFF(@'I'4%1/04.DH!Z=O7H#[H#0H<"!N.WK
M\!';T`([^@1V#U_`'CH"B5!OF(L\PSC(N*[+3LHP`2,G4CV:LRC6=BR2]2EU
MVLM!*NDA%NF[@9PABN$P`%4U2B`CN&P5;M*&5#.OVK7LVFU!5T3IJ_'YT*Q,
M&PM$C)&5.J<5%%E#GW]I1=518XAN([!U*;``>`````:I,7=.>L^ISM`6#]SR
M"B);@%S(4EXN-EAC^-N8).,^,XYC(?%DDTHLV1&0C_?&ZPLWR7FB*:R?2J0W
MB!O1L!03L/>/:1X4?J=63]<^^:`BH^<O7FOXQS5V>LE6Q9XWJN/>5UGN]F<1
MT<^F)!"OU6SX"G)A5A$1B+F2E7I(]BH*+9NFHNNIL0A1,8`T!(4'SB'M9$\#
M93S:`B(FV'AYRU'P.(G#Q+A@P>@WPZ`U&^</]K(VW^BMFD=AW\.('+$?4(?Z
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M\S$ODR$>1DLQ;2,>[3*<BQ".F3Q)9LN4BJ93`!RB`&*`^D`UFEK1ZKH6X9OS
MY`82:0F.Z;6VUKRU;&0Q.),20RC:,"76132:-UGOD%*E6Z=%&4*#AT)"I)))
MF`.D"B8M<8UUZ(H?4XN!>.ZM#F[#EK)4]]L#/M[:M&UIN:S?W>/KD*@<ZS+'
MU$8=8A$U2!%04R*ALXD!("RXB)MM)_J)B75%`0*4!'<0``$=@#<0#;?8-@#?
MZ&J"HVU4RJ$4*8I#E.02'(<@'*=,0$#)G*8>DQ3`/H'1=25*4'OC526JIHZK
MI1^#\F0O9JQ#D[@#<[+RFXDTV0OV$+4_4FN37%.%*9(R:`BX<2&6\*D!7W6(
MFHU(3'?Q::0I."F,<NQ`.!*9V)6<C?826/IN2^'BEY^?F?87;'?_``O_`#!]
MO8'Y9?G'E6<+OGC\=VN&[@FENMJCV8'(I:Y#FZ6X7FU*,FF]S2K=_>.X)Q2Q
MMQ*<<T;'E&"1P$R@"2:%@1=I.9&3F5Q,@RQ_$PI!%\^R"[F?\;B10%!=-V`@
MH!"$.8N6TWZDUMDJI^9\M]U=D\_V#W'D=I]U8U_%YG#;6R6JN=6IQ?\`%"<?
M5&71ITZU,5_$^*^4GSE'D8TY'<@1MN`^V'A:TNVF,L4,919&4R"]8NED9>+C
MY!F<K63O+L8XJ-BL9RG0ATUBM(LWFE6$MF:HU\CF<6Y=OV(Y%Y*,IU]/]U)M
M4?QT,EOM^=J?BMVX8JZ$P=#S<W<+_(+GLF3,@NVD[?EZVBOYL#1FDNV91R,?
M4X$@;@W11(+M<QEG!E%!`2T%\DI3)T$`N^^V_CMMON(B(C]$1'<?5H#7H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H"/#NQ_O=7*S]3I#]-%>T!(?H"/7
MNO?O='+C]2>0_/2*T!(5H!H!H!H!H!H!H!H!H!H!H!H!H#09,AOKB$-L.X=1
M0'8=P'?Q#T[AHM-5U(HFZOJB#OO%=H&L]P.DFRIB!2*QUS'QU"F&C70`)&Q.
M5(F.ZW:.*<H.FXH*K1+Q9,I8R3,85X=P;J`?*$0+%USG8=J+];^]?)FQX[DL
MKC,JUEXURY!PN)R49..Z*ZQE1JL7XIZ$9/9W[E+#'V=\F<7><]2MV(^2ZLE`
MT-G>LQ34K,V6$2K,8WBXC%%MGY\&YXJK/"MO?Z_)-BEBY$'7V<YU0276C$LW
M+5C;>;<Z]7^RO[/UGJ_=D;/YBXRY?M#"Q<?,QL9N[:M6K=MSHUNN4A%.<]=:
MU;6JUJGEX-CE$I#=1C`([%V$3%]K<0$>D1*!3;;@/H\=@U=D_#Q/%7ZI)SK&
M]#TR715^7ZSFZH*R**H-O?.Y_;)J9X[7F+60H5EKU4SI)5APVKCE"-AJ@XED
M6EJ3B5XN283Y)(C=B@#Y-TDLR=^8F("`:V^5",<*U-7*UBJJNB^%*^'B<YB9
M&3+F\G`N1?L**:EY;EX,E9*``0WCX>T.XC]#Z/JUJ6]VJ.AA]*273]*F-WW2
M>4&!N(_=H[6N;>1.1(K&6,*WB+F`VF[7+-)1ZWCUYZ(J,'%D7:0[&0DNEY*N
MR)`8$1*`[B/@4PA!47(!\XU[+P``#SGH&X;`.]4R=OOZ/'_,1H#<_P",8]F'
MP'[N7'_B`"'^97)GH'_^R=`<=3YQCV8#D,'W<U!^M,(C\D\FB`!TCX;C2@`!
M,/@&XAN(@&JBO:_(\[\W4EXNP=N-M/0KA-[$3G)CE%,Q;U-)1(CV.DLO3;QB
M\(15--4".6RY#EZB@;8P;ZI*9:,G>T(&@+'^Y5M]P#S/W]`<8<T"._CX!2)4
M1\/7X:`MI[#!@/VBN$9P'?JQO8QW'TCODV]#X[^/KT!&U\X>3`_*7LBG$PAY
M?-M80+X[&$+]QV#V@]`[>GQT!E,$'<!W\?;4#ZAS`'U`T!],(AM]/Q\?';8?
M1^#JF7N57MTZZ_(AN"7J="@^8L$8OS`O`2^1:%$V]W4@EVT0\=K2;65BHF?*
MQ^/$(E[%/V+M!.04BVIW"8&$%2M2AL(].N>[B[5X/N6$;/-V89.,NMN2JFO)
M+YF\X#N3F^!O.[PMZ6/DOI/2E5T<JIU773IYE&L>\%^*>-;54<@P6.(R8O5/
M?/G]&N5SG)FX3U=DY-LY0>NZXI8Y!^VC98\:<R(*HH%<%1*!0$OM",\+VCVY
MV[!+@N/LXS^"2_?4WG=_YD]\=\0A#N3)L_@["I2U:A;JDEUV16[I6KK6K^!<
M=F.Q7JJXQM4_C&G*WZ^L(E4]4JB3ELU)*S:I01CB.EG;V/2^+F[I0BCC98AO
M((82[B&P])%:ZG"W'Z:QU+;./>"+Q2;=)Y3R9,C:,H6.(>DNTX_:FD$T1EW3
M29C*9C^3>/%G<?2Z:519F=/R$5'2Q2GW%,H%U7)*FC^PS;<>.M<="]<DWFR<
MJJM4DFUT\'TIU\:E[+0>H@&,7I.)$A,'K*/1[1?0&VQ]_P`'5MUI7P,>222D
MNC.7J"D:`M.YB<N\`\)<'V/.^?[>TJU.KR:C>.:)%(YLMQL*S54\74:5$>8D
MI.6*65*!$T@$$4R]2BYTTB'4+7OE6K;+MJRKEQ2:22ENKY.O7X/X]3#$X8<%
M+QWQ>2]BY.Y$Q&UX[]N:%S99;RTQO7)^TP['+LNX8!&J5FIPZ#U*"1D&R[%)
M:QV-FV;)J*/GC5KT&`A4Z<7?:N3G/6,OI3Z+XTZ'<]\?F'W#W[;X^UW%>O7\
MCB,=6+>1<G*Y>NVU5K=<DW.456D4V]%0SLL>8[I&+Z76\=X_J5?IE&IL-'UZ
MJ5.NQK6.A8&$C&Y4&<>Q:()E*FDD7?<1W,<PF.81,8PC%:R;\*GGT92DY2DJ
M1;T_3YGNM"L:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`CP[L?[W5R
ML_4Z0_317M`2'Z`L$[I#,LCV_>4<<?S^B0QT#`_NJ?FNNEY8(1L;W5+I-YKG
M97[&78>H^P>O0%_>@&@&@&@&@&@&@&@&@&@&@&@&@&@/@AOJ*>K=XCX$('=]
M[/U,[@5%)D7%LE'XMYAT6(<,:-DSVH]A?Z^5!05L6Y0>QZ)7KFN/$0,6/>@(
MKQ3DP&#J1.JF:][J:<;G3PIIK^G4V?&\SR'#94,WC[CMW8>"^F7^&2\8OQ55
MTZD>7:([QMYK]_2[>W<!,XIN7\;2Y<4U^\6\RK6896>&=GAVN/LG2;T_N[X7
M8(%3@[$4QD)(H)D6.*JB:BEJTKL4XY>W<_I:T\-$SMK_``N)W;Q,^;X);>;C
M6YD64M)T=9.S'JI=:JKJM4JZ/+$16%0IA`2CX@!1+L.WL@/M=)C%$1'Q\!VV
M$-5;:=3S2,FYRC).+CX&H$";B<!$!,'M"78O5]<(;B`;B!1.80W$=MQU1..]
M^INB)]+W222<DJOQIX%OW(#/;'"4-#,8N!>9!RC?)`U>Q7BF#=)(6.\V`4RJ
MKB1=3=.&KL$UZG4G)K%!LR;%$YS%\-51@J?`BL8TAXE,</\`%&*)89?.?(Z*
MI^5^2%YA6T)-3LG",9RMXUI:+T\LPQ)BIM,M%QAJ?%OU`6>."$3<3<@3WIS]
M:BFD=/#H5%PWVF\0?ZE.-?\`.)5O^Y6H`^TWB#_4IQK_`)Q*M_W*T!]##>(-
MP#[5.-?$0`?\PM6\0W_RJT!#A\W8331[=8I(I)HI)\H^5Y$TDB%323(7-<\!
M2)IE`"D(4H;`````'@&H3JJC9?M^C)I[WC3IKJOU4)VCF$HE]'2/I'UAXAX^
MD``-O7IKNIIMIY^/@4S;26VM7)+I4LNX@\B[MGIWG:.NE;FZXYQ/F.PX_C?C
M[$EYQ4K,P3`#?%DU')7"2E4+-&OQ14,C(,U4RG3`/-;HF,3JSLO#GB[)2V[)
MQJJ23TT^'Q,'!S?Q=R_;::=J:6JIU^UG#[E?[W_S2_8O9K_2-+ZPC8%LW83_
M`'H7@_\`J:V']<R\Z`C?^<.FZ>4O9&+X;&YMJ[[_`$;]QV]'X.@,I<GUH_R:
MG^*&T!J$-]0]5Y"B\3YTAL(#X[^G?ZFH4$O.H>JIX$+7=,ZV')SLSG8KNF0O
M.XRV:NP9NW+5-VU<X&RNJX:NT$%4T';94[-(1(J4Y0$@"``/CJ=L>K2;*]\Z
M4J]M*4\/TU9-()"B4"CX@&VV_CZ`V\=5)TZ%N24NI2#,%OO]#K![#C_'K7(Z
M\8\1<3\*I8SUZ31K2:1EI&3@RA#29)J3:`0/+9=3<%2]6RG4`$$VV41M0CX'
MI,;Y$J^4*PQME4D4I".?))F4)L5)]'.A`15C)9F)A792#4P])R'*4?0(;@.H
M+E7T\#WN_P!+0%IG,CF9A+@UA6SYSSM9F\-6()`J$3"-5&BEIO%B<@(1M1IL
M8[=-"RT[(J;;EZ@3;(=2ZQB)%,8*J>/@9>%AWLJYM5*>?@EXM_N\WIYF(%QB
MXX<E_G'7))]RRYF/+/C/@+A^T.HG%>(8H):+C;VT%TY54JU,?.FR*#PY6;9)
M&WVM$#.'"PBR:>6)5"MJY1BOF3R-R4)_AL>GX=]7_$_D_P!*(S?Z%0Z=C:F5
MBA8_K<32Z53H2.KM6JE>9-HV$KT)$MB,V$3&,FJ::*#1H@D4@``>UMU"(F$1
M&W/5;?`Q%Z4H+Z4>Q`-@V\?P=4I)*B(;JZGW4@:`:`:`:`:`:`:`:`:`:`B[
M0S%SAROEOEK"XAOG$;&V.>-^9&6*F8Y>Q)E>X3\BV-A##V67UEG++6\[T&#:
M-BN<DNF_01@0$46:9C',)C"`'D<E94[D=(Y!<?L%Q&4>$<ZER!KF7)N&MCOC
MSF]D2`7Q%`52=D$7<6SY/OTY5E/%M12-E4G2)D01$QBGZP`LT)H?.362>YSQ
MHXYY@S_*Y+X+VPN(Z?-7=U5F/'K/41\>1<)'J.EF#>87Y-2(L)%RX*4A#&;*
MI%((B/CX:@@K2O&]RY-VE&AG[@(G*2(/G4+&NN.>=$7TA%LR-^MT5H/*P'2Q
MFQW)/>!2(9-(#DW'<P!H"A6`,G=T//<-DJ8C\C\#ZV3&V>,TX*=-WG'_`#])
MGE9##-\EJ*]L2*B/)9B5HTGUXH7*3804.W(H!#**"`FT!L/LI]TEGREK7&$M
M_P"""[^P8$N>=SW4,!9\3CXYA4<@T?'X5I2$-R6%RY>RSFZ@Y(Y*Y`B2;0Y#
M)B)RF`"N9XGNAIOD(M3._;X3DW39P\;1Q^.V?2OG+1H=!)TZ0:&Y3@X6;-E7
M215#E*)2&4*`B`F#<"BL'DWNA3?)')/'(F2>!K>3QOA[$N7W5I/Q_P"0"C*4
M998MF6ZHU@T8G[I5-5HY@U<3*KJN#.5"+D?IE*0@I'$P'69KS'W-,/-<&OT\
MI\`[I'YSSSCW!4/(0N",\(LHEYD%*>4:V@SDG)F20EF$<,$8IFZ9DC*BH&RI
M>D=P*LI3'<=7G3UE'DQVWE;$D=5)2!)@C.@S`*-U6J#D/BT.5/O8BW6?(E4V
M+[`JDWVZ@WNJQ>E#W(QD[:\:%F=^W":MR<5)^;U^ZA;=G_->1>0/9>Y&9'RP
MVIC;()6^::!91Q[&S</37CS$/)BR8F2E8*+LDW8YN/:S#.E)NC(N'K@Z:BQ@
MZM@``QTY;G7Z=*%[PUZDY&JP6-=RIFC(\&^0\<Y$P-I"J1+!R)6Z;LP-WMPK
M;9<2M%D7*+HP)*CLD=-0B@^R8A@$2B!?+H!H!H!H!H!H!H!H#CJK@CN)B&$H
M>'4&VWHW]8_@:FFC?BBG<JM/3U1C\]S2_>6V7CE#`TW([W%;#%^:\B6N,JL'
M<I3[6U#&R0L5"V20EHR$&2G5Y.+C6C]^Y@W0D;&4\WRT3'VZ2B(8]S(MVLG\
M+)7'+:FVH-Q56UJU\CU'M[\JN8YSMJ/=F7R'"\7PUS,O8UIYV9"Q.]<L1MRN
M.W;VRG*,5=AN:5(N44Z.4:\(>4#POE`/&GE,)E0,(`3&<.8"=)>K90_RR!-,
M1]`;CXCZ-4RRHJ>U0NM>>QT_69<?RG4VU'N7M.B\^0I^VT:ONGGNWWM'*7?X
M/M;0/A_^>VI_$+=MV7*>>W0J?Y2T;7_$W:-$NO\`4>OR_DU-<)RH@I/(-'QK
M,XIS90I_(BEC2JCF^TIG"PLBK58%Q8YE$))E/2Q$%V\4V,H!5"D`_H`1'PT>
M5:C<5NXIQ<M$]NC?D6<W\H>=L=K\IW;QN?PO)<9P]O%GE+$S(W;D(YF3'%M>
MEQANI<DG+;6D>E7H70D-UE*;82[AOL/C^&'@.LC3PZ'E35'0U:$&@Y>KI]'@
M8#;CZA#?80^B`ZAQ4NI#C%_5X:KYD)?>![/]([BV.5+KC_Y-X\Y=X^8K*XQR
M8L@,9'V]B4J9W.-LINXUHJ_E*M(^4(LG)@66B78E53`4Q43-5->Y12KHS:\5
MRV;PV=:Y#CYN&1:N1E_A>UIT:\4_$CA[1G=WMN)K2CVZ^X\]DJ%FK'M@0QO3
M;9D%9%I*QTFD86T/1[]*J/7!)&.D454"5VPB(-GC?I274%0"'-4Z:*3^T[3E
M>/P>\L>7-\`E;YJ-7>Q_&Y+QE;4?'JW'K+JM:UR0<\\CZ_AQA`P<;#25^RYD
M)92+Q/B:M"BK9+M+$3!0SM43J$;P5-B@$%).7=G2:,VQ3&$PFV*,NVU'<_#]
M*?,\TWJ&1+$O.$,I1;47)5E3JDNM4]-3I<`X!E:4_?9=S%8/MB<B[K&$;6JU
MJ`3X@I$,NX&0+C'%<;Y29*_189P8I#'V%Y*K)`X=*&'RTTJ*NE/`E16[=XLN
MFU!4-`62NN4T]&\ZHKBA*0L&SKUEQ<ZN]6EU(+)J<S,/(MJN^F#M[@O5DL4.
MC1_D"BK"(2*LF@@8CQ14"J`U+EJWC2Q)7%*?XN,E5:;=KZ>.ZOQZ>'Q-3+(Y
M"/+QQY1L_P!-G;='Z_<WK5UT]O;X4KN\:^!>V'I#Z8?BZQ#;$%7S=H>OMWK>
MK;E/RR#Q^AFN>'5$'6*95*=R<MUUIW'U_=^HG2<#TB!]MP*`[^R)MPWW$`(4
M#'.8"AOL`>.J_:A<:<DG),HHVZJ4HI>"IK]Y%#VP)J!L%@YE2-?N64[2@?D.
M]4=M,A#+GAJTZ5CW75`T4TNLJJVCD2DZW;4.DS=<Q0,4`$H:W7+96+DPLJQ9
M5J4(4;3KN?GTT-)Q'%97'9&5>R,F=^%^XI137TI>#_T%P_<K_>_^:7[%[-?Z
M1I?6E-X6S=A/]Z%X/_J:V']<R\Z`BG^<U7*-QOF;L\9!F6,[*Q%&Y762Y2D9
M5XAQ/V60C:W;>/,R^8UZ":#[W-3CEJT,1HT2^RN5Q*F3VC!H"1-/OY<2#@;I
MP%W#_9.8AM^"N=/`X>)B_P"07CTB.WP:`W1[]O$LOB.`NX;_`&BV<Q_$@QT!
M3ZY?.1NWOC8S,F2J=S+QN:4!T:&"_P#$S)M0&;(P(B>24B`GF[$7J<81P45S
M%#8@#OXZ#7PU+#\V]WKA]W%.;/:/QMQR=945L]#YVQ5^L:>0L93E!8MZ^MB/
M)M81%L[F#B#Q^M,2J:942%$0Z5.H0$@AH3<2LR4)Z2ETT?\`89=0#N`"'H$`
M$/P?'0@&#<!#X0$/'Z(:`LUR'CJUX<L[[,F#XI)\WE5O>,I8O;"#5I9V*1BJ
M.K#7DP4208V5HW`YA`NQ5?$P!N(E&J*3ZM(13E<5M>-=?!4I^VIY/DYW%>-/
M%WBQ8.5.1K:"%+CFBC.!KS51K\L[C>S)F".QM6XAP<QG%M>OR>0<!`46A>I9
M4P)$$VIV:5333,AXF5",9W;<HPDJU?EX/[6FE\C%8XJ\4^4_SAGDM%\\^<8&
MHO`:CV62B\+X9;+2$<GD2L1LD^$M5JJC15!92LGDR)HV2TK&2=3)@.V8]!`'
MW<XD?C+SB[6+Z-=6_'[OT1F[5*GUVB5^%J%-@H6J5&M13.$KE9KL<VB82#B8
M](B#.-BHUDDBT8,FK=,I2)IE`OKV`=]XW::EK=5:ZR/4:I*1H!H!H!H!H!H!
MH!H!H!H!H!H#'BY2`!N&7SBPI@W*:UY,*8!]`E'@/QJ`0$/6`@.PZ`N/@#E2
MS9V6U3B`$3XIY_4,(CML4G'_``(81$1]0`74Z>/0J2E+TP6Z;T2\WX+[3M>X
M5R=P1F#@+S9J6-\CPEJLC+CIDR1<Q#%.31<E91)"Q<DY3&08,TG"+-^J5,YD
MS'\1\-P\=:/![AXGD<M8.)=4\IPE+:D]%&3BZZ::IFYY+MSF^(@Y\GCSLJ+B
MG6CHY)271OP:/,YM0;N.][V\EUD$E%6O";F4X:'4(4YVJRM@PXW.J@<0$4E#
MMESIB8NPB0PAZ!UO&J.AHTTU5=&5VX'6F`IN-.5<[:)B+K\(U[A?.`CN8FI)
ME$Q;0SGD/:6[8'+Z07;MD?>'"Q4R=1@W.8`]>IC%R3:\#.P.,Y3E\A8/#8U[
M+Y&2;C:M1<[DZ*KVQ56Z)-OX(YLD1G(=V#&,D4"+&0[=V9%6+A)<QTO*?<CL
M&%4.04E`173722*)3&`VP>)=MQWI\*F)*+A)Q=5)-IIJC36C33\4]"A.:`#]
MW/X/&V]H."/+XH#ZP*;(6&A,'TC"0!'X=@^#0I*SLOWQ/F;^P&XL>CP_TS.9
MF@(L.'12D[3G8Z*4`*4O,7`8%*`;``?+/.(```'H``_"T'C0OHLYG"^4\7\E
M;G2;)=WC;+!V>*I>.R/%TI[BJ"NN7<>X6EH0M0@(L[2Q0EI;OO?)M%ZZ?GD"
MQ29P(U7$#DZSMQQY#A<G?<ACRVS6RY%R<J1DZ[EI%^E*.JUDJU."[QMYW$]Y
M8F+:L/*L25N7N0;BHU46TT]72NNE-"WNRE$G8YY3D$0'HR/S1+X;!];SVRV'
M@'B(`(AKD8R<EKU3_<F=[X+2BH9"VJ@64]Q7[S#.7^4]9_3Y5=`7K:`:`:`:
M`:`:`:`:`X;H.I-0NWP"'@'B<H=1/3ON'4`;ZCP=.M44RMPN.,;K]&^+TZIJ
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M5#QW9$S-6,DI*J(624O1%&1_**8B;8WFE#J`0W&3P,L7C)<C._:<E^'?MTEO
M:R(3G%]-OI4*2U_B5#!S,3,P[\+<[-UX\[,;GNT6Q*:K;3=:IW(UE'351E6E
M#MLU@`\F^%X>'5\?YYZ`-OMN.&I4IA$`\!`"&'7+WHW'?M.VE1-UK\O#[3W;
M\M__`+$?S)E1-+$X/JZ?_O>T7=(E`B29`#8"E````VV`/5L(B/X>LIO<ZGS_
M``MPLP5JVJ0BJ)5K^OQ-W4%0T!I.'44Q1\0$HAM],-2G1U(E'=%QZ55"%;NW
M]GW&/<6I"5RJ32$QWRUH,0=/&&6?=>B.L3!D"KDF+LJM&Y1&=HTP(F30<B51
MW#.3$6;[I^<@K3<]2TZFRXKD\CALZWR&"W&_;>GQH1'=H?N1/L$<G,J\1NXY
M1;%B7D#7V])Q?7<KY$M<E;24Z"BD4&%6Q%+34L^D$XRB3\@X&2A9YH<S&0]Z
M3(]6,"394FOMW)8MSVLF==[JGKIY1?A]IZKS5E?F9QMKD^W,'$Q>7P;,_?Q[
M6WW,IMN=S)@]JE.Y_P"<MMMT5;:;W)YBG_Q@(>("`^@0'U@.MB>,C0#0$4:D
MK3[!W58YO+1W$%>=I%-EXVG2#6V3J7,AI8)+%S)_-J/ZVG8D*H]H!ZO(.&X)
M'9N)1)'RW`()H;NM9$)82QYQK)9S:TTVN/W5375:TZ_`T<[DY\Y;MMX[M0C+
M2K]Y2<?+=M<6JUT;Z/S9*Z'I#Z8?BZQS>$%?S=L2CV[U1)ML/*?ED&X>@3?;
MKG^K\'V1^IJBVFH)/]-29=2=D2E'T@`_3_P-5.4ET(/G07JZ^D.L"]'7^.Z=
M]^GJ](AOX_3T3;T:T!9!W+!`.W]S3'Q$"\7\U`;I`3;":BRP@`@4!'<0\?I:
MD%L_83_>A>#_`.IK8?US+SH"-?YQ0<2\H>R,8#;&#FV($,'I#;(?'$1V$/1M
MTA]30&5"']^/XHZ`^Z`\M:8"+FV>\E#,9GW8BX))/(]@_5(1XF5NX]R.^;.1
M:J=!2G$2`'4)`WW]&I74JA.5J:N1HY1:>O33S/!1=1Q'37$2HNA66DG-2Q$J
MTXLJL86;<RZ3;<&=;4D^A]\8@4AE!29[&ZA,<"[B81J=?'J9.7EW<JY&34%3
MR5%]Q64H@)0$OB`@`@(>@0$/#;;Z&J#$`B`>D=O[V^IHR:,LRYU\X\!=O_`5
MAY!9]GU6,!$J?%=:K43Y2ULR!;W"*KF*IU18JG2*YE9`6@F.JH=-NU0*9990
MA"@(T3A"32N/:9&-8N9$W;BZ*E6WT7S^?3]&8GW#CA?GKOT<BR\]N8]0B\6\
M#6EP>SN(\.1!'L?)92;P3HD?$UB(!59(&>/TRM5E;'.HHLE;!(NETVP"7S5D
M:HV8PE[BE5T_T&UY#GLK(XG'X5Q:A9DZNM6]6^K?37[%HO(S8*92ZM0JM`4F
MFUF&J=0J,2QKE5K,!'-8J$@:_$MTV<9$Q,8S(DU8Q[-LD"9$R$*4"E#T^D:V
MUYFAE1*L/J/7ZH`T`T`T`T`T`T`T`T`T`T`T`T`T!CP<IE")\,?G%1CF`I1M
MV2";CO\`7*<"^-":9?#?Q,<P`'T1T!<A!I^;FGLNI!_T3BCR`)_S_'[`I?H_
M#I2JI6A*E*#WPHYK55T55TJ_`IGS3X85G`/!KF3<8:TOI@(WB[F2KQ$8O3J-
M7E$6-MDF-D?KS-@K<0PG[?(-G+("(N)-9PJ0AC>UN8PCQ7!]F6N&Y.'*QR)3
ME&U=@H^W;BVKDW*LY1BI3^&YRI5T:JSTGNC\R[G=?'W.-GQUK$O3G:G<NPNW
MIQF[=O:E;A=N3A:B]-RMQ@FUJG1,J#FC?]VX[?6X"`_<0\Q]P$=Q`?E/A?<!
M'UB&NT73S/-?E6GQ/9<6\*4'D-@/F%B7)\0M/4:S]P?FP$U%H/7,<HNI%\E)
M^8C5B/6BB;A!1I(QZ:A1*/UQ0W\-]7H3VVY1:3W47V5K_8=-V5WEW)^7G=F'
MWKVG?5CG,!S=MRBI1?N0<'5233:BW2J\65')'H1/=,QA%M4S)-8[MR95CVJ1
MA,84VK+D=A!NW3$YQ$QS$1(4!$1W'TZHE+=\ZO\`=_8<]?OY&3=G?RY*>5<N
M3G.25$Y3>YT7P90W,YR#WT.$"8&`3DX(<N3F+ZRD4R'A\I##ZMC"D;;Z6J2T
M5F:G(GW$.9ZAS`4B?`3BT<YA]!2%R5S-,8P[;CL`!H"+/ASX]I[L=_!]V+@4
M0'Z=SSG_`'VE0Z$MN1J)SE<Y2QTX2N&+YSCNSR_&25NIF%Z])8ES.6F)S[-W
M5@E[C=[7>*[9ZO7I(J3NU,8D*Q(R\>W63:JG!8\>ON+-[C/8G&ER.5[;HYO=
M#=372*33:TBWN2=*K2IHLFUSD\NU.=RW/"5SU*"<+NVOIK*4I)Q7\:CL<DJ*
MM7%QYV,/_$;\I3#MN.1>:'B`;%$/N]<M^@-@V#?6H;\$;Q.6J?1/3[C(8U!)
M8;W-98\+PBS0[(5J<7"^+X80=JK(I`2PYCQ]`*'(9!)8YG2:<F)D""`$47`A
M3F(03&`"_+0#0#0#0#0#0#0#0'&7\0$/HAJF/67S7[BE]5_K1_VD6I8[$P\P
M^30"8PE+B/C)L41W*&\CG41$`]0COX_#MK'A_P!_O?\`H[?[9GO7=J2_Y=>R
M/CS_`')_L<(>IY/M+,?$DI-8_@V4YE6I2L18\2$?5F%M3=ED--P:)AUE65@F
M*_&QK*19R[F.>2(O6ZT<Q>K.$3>:F0!WO$.T\U6LF[[.'.+C<EN<?1U:]*DV
M]$U&CW223T9\]\CG<G@<?>GQ/NO+G%0VVTFYIRBW"2<HQV2HMS;I%>K5Q11#
MA@TY#3Q[G:N66%\/XMRE$2;]*H-\.1,-*T9*`OKA*>NTK6LE?&SVTV*;NMDA
MVRUE0>LXWRY"/1.7WHIRKCLN?GPD86;/`W<BY8V_S)79/?*4=()VU%1A&$6U
M!J4FU)UVTH8'!\AW=>>5C=QMV[3=EPLPJ[24(S47O<V[DXJ35'""MITAN4VR
MH>9B@/)CAJ8?26=SOM^#AV4`=<?>N;,NQ#^\Y?JC4^F/RY_^P_\`,K_YGPG_
M`-+VR[<@;%*&^^Q0#?\``UE);50\#;JZFK4D#0#0#0$*O=L[/N*.X_26-PBY
M9'%W*;'+!\EC?+S5J02S<8"<@Y;XPR.@W,BK+422D7?453VG,8H<RJ(&(91$
M]UNS<C[>5%.V]%\_-/\`=^\O86=R_$SEE]O79XW*/_+E5]5_:_AX_`B\[1?=
MUR)@W(;;MH=S$\ECC*>/EFM$IUXR,K[I(P$R@9)K"4>Y3ZAUHR<H4ZR,DI5+
M49R8%D%$D')A3,BN77N<,3(_".6ZW1.,G\?!_+S/0N1Q.'[OXJ'+\$XKNZTF
MLW%A2EV4?JOV8K^-];EM*DOK@D]R>7+Z/`=99YN-`=*>M5Q22;S2E?@U)EI(
M+2[67/$L#2C:6<PX5UQ*-WYFXNT9%Q7R@P.N4X*'9!Y`B*?LZ413LA7=1;JU
MK3QI2OW:?+0[L/2'TP_%T*B";YNIX]ND_P"RLY:_KV6?5,>@)X-5`:`C=[OD
MA\4]L3G?("Y3;>1QFR?]E4:&?%*52!414*+4B[83F."H%*;K`4S&Z]C`&P@4
M@[!9P5[0/!Y0HB)38UL?3OXCX90O@>GU_P#P:`CE^<.F05Y2=E)F*B'O'W9Y
M'0E46(F*2(Y+XZD!4.K^+.ET?3';TZ`RF2CN`_R1P^H80T!JT`T!!!W9$BGY
MR=C3K`#`7G)<C%`2)"`*IXF?*)J@)TS&*HF4#%`2B78%#>O;:M/1D$[_`*/#
MX-4$EF_-[G#@K@-@^TYRSU9VD-#1C)XA4JRD[:%M61[:1F9>.IM,BUW"2\G+
MOC["H8A?)9H`9=<Q$PW&N*KTZD0C-W-W\!BH\/.'G(SO\9\7Y\=Q=A;:-PV@
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MJD9R_P`29W<2)8V7H.#:E0V:('QC[[-R$HW,W4%5-,2"0Q3G,45T"J@=_P!Q
M7N(\.LG\).4N+:;EQ[)7>Y8:L\%!PRF*,ULU%7LRS119*.5'6.$DVC/9T10Z
MR@@0J0]6^VVX'O+-RL[8DYR6Q7R[L6<KJCE+$&-LD82IX!0,ZM*4G#7B2K<I
M=DWT`IBL$WEE;.(1F3S?.(9!(P%43$13$H%.^#?<1X=8^I?(HEKRZ[C5)_FA
MR[R0R3#%>:G)D*?=\^6IQ5I22,WQPHG'&EFZZ1BI*F*HF98B:@$6ZDR@=7*]
MR/A@;N44W)`9?=_(J-X-Y+I;^<'%V8BI-;+-9YP_/Q4<JS-C\)$`>Q$6NL5<
M$1;EZ2E,H!U$RG`JG8^6_:UL'*G'O+R8SQ;2Y@Q;B:ZX7K*!*-G)"I)5#($W
M"V*>5?UD<7B1Q.F=PJ)4G7FDZ41$IBGV3$@%(X7N%<(Y+G9R?N$QF=VGCJ]\
M/N,^-FTXRQWF5!PO-1F1>5KFQQB)6M`^-HQVRB+2R63<'333.+@/(.<Z2P)`
M4'R!R9[<^`,%=NWC?Q]S-9)3'7';F-@V81/:J9EV2GV%'@SY&EIR8F)F0QS$
MA+NDG\[^1H)"NH*A2II"`>`$K_[K!P"_U>C_`-:G-G]C?0$<8V")MG83Y!VJ
M`='?0-GM/+JQP;U1H\8'>PTYSGRI*13L[&1;M)%D9TP=)G%%PDDNEU=*A"G`
M2@!D7Z`C_P"Z,D5;@WF,AV:SX"R^&E010Z^M,R&=\9+D>F\MH]-Y,<=,'"FY
M"E\M(W4HB7=4@%_X^@?I#I6FHU\.IXV[RTA!5B8FH=I#O92,8+.VC6P3#BO0
MJAD>E149*;;QDT>*:)MRF,9<6JQ2;!N'COJ[;7N-)=&1=:A:;O:KX%(<099L
M6581>82)B<K!W&MGE6F:!E$^3(^2%<5$`<O44JQ5E&T65XD)4U"',*X%]D2C
MHL>_&3_$K^5732FGAKTZ%N$W+$5V*UK1+_#T3*:5G)?)B/RZWJ&2*707%&>7
MLM0C;/2H._1BZC=3&+J__*9<\V_EHTT2C,MAA3EZB_S6("4PF]@=MC\;QN3A
MY%S<U.W;BXITU>Y)KP\ZJGQ3,/N?*CPN1P]GB:W(9UV:OU=?;I_JUZT?7SZ*
MAX>R\R<D_;K<XDIV";&QE*J#-:3KV3(V;K<_F!J_N*-9?+X#LL4A*X\FHJF5
MYPG9)-^Y?K`#19-FL@R.#ETUR[7!8:PEG7LB+C/12@U)6Z1W+WHNDTY2]"22
MU6Y.6D7K+G-Y7]1GB6,>2E"7TW$XNXMVW^4TG!J,:7)-OH]K2UDI$0].N9EX
M?,Z9]#7H4C0''6'T?R0"/X&HC#ZGYM?N(ET7^M'_`&D6HX[`?NPN31OXK$G&
M7\*0SIK#MRKR5^'E;M?KWGN_=?\`][IV/_\`][N3_8X4J-R&OT3BO#EUR/-T
M"2RC'4MI'SJM'AG5,92TRHWF8Y-N:/=Y"L53IZ#J.76*Y*9[(MB[(B!!,J)"
M&W&#CO+RH8RFK;G5;FI-+1]5%2EKTT3ZZZ59\]\GFKCL"[G2MRNJW&NV+BI/
M7HG.48_?)%D7;-I&**O%YK5QE;9"87@K-7\36NHRE`^14SCJ5H1+#8@K=OE&
M$I8*CD"^$7R*O\93==D7D`Z3(W!H;8#&-O.5Q;W#<#A\`[,88KR\S/A=]S>[
MOXUV%*B:4H6X?AH^W&<8SK*=4M#G^,Y>?=_?'<'?.9FW,GELNYC8UVT[3MQQ
MOP=NYMMINL;LW[[WW+<I6VE!1>C;N+S8*GW3O"T"=/EC/9[\W<1ZM@PU*='2
M`!L/M?#KB,FOX[%_UY?[+/J[\N=O_P!1/YG5Z_@N#I__`!>W^XN_3WZ";^GI
M#6RE]3/`'U->J2!H!H!H#X(`("`@`@(;"`@`@(?`(#Z0T%6G5=3'^[^W;PQ3
MR;XLY#Y)QE8FXSE'QSI#NRXTOV.JP:Q7>RPD:5Z+W%\_"H`;X_I\H:6564.9
M)9>-*"BJ7L"LFI"M+-;PYZ0ZU^PRL'D;O%9UGD,:;679GN@E5>K373["%KMR
M?.2&G&3`Y,1\N:3E3,</0&D3"XHO]'7B)ZW&A6B2#=S6+H_ND_7DI&/B&Q%%
MHUZ+@[Q-NB9F=,Y$T3EQ+?NXUR6+)2E"%-K\:/P.B[AY+B.X,A<A8C'$YN:<
MLBUHK<Y/I<MTZ2EKOC2E?4J-LD>DOG5/#F+9-)A;BUS25@70-A+,H4K%QVIA
M=,V[E$B'5E4@.53J+B0"%-U;%`WH,`:[&/:/<,\2&=#'D\::JG5?VGG]GF<"
M]D2Q8+)]^#I_W>\X_P#;C!H\W&_.U>#<BHU:&XW<PX^4.9V60BI.KXE9OF`M
ME03*8B*F6NMZDJ00-U$``(/LCXZUUWA.6M?78G^K^TSKN5B6LB.+.Y+WY*J7
MLY'C_P#`GH8OYUAPLD%$DC\;N7C54RJ13IGK&+%1(10Q=U">7E+[.*1.H3%+
M[7L"`;[ZE\'RR@YNQ*B^7]I3^+QE*ESWK<?.=C(BO_5,CA[5???XU\*N(Y\*
MVS#^>\BV9IF+.N2IB1QS#5=]7XJ+R-D&4N$5'`^EK,P>NG\:RD`1??S,BDDX
M(($$Y=CZN8_;_+<M!SQ[%Q7;7U071/Y^/@_FV6[G)\#.Z[-JXVX^$;&7-5\:
M25A5KXZ=?D2&K?.K^(#"-82LQQAY>PK*3<E:1B[^M8[(A(+J'*#=NR<*7DA7
M2K@AM^@HB</1M\.7?[2[EQ;5O)R<.Y&%SZ=5K^OY&%_6N*C)P<FI1T6ZUE1E
M_P!5>QJ=Q+_.C.(D.9!%WQQY>-Y5TF55!C(4RBQQE@<+,O=BI":]*J+%7255
M,40((@"1`V$3[EKN=L\[:O6[2Q+C=Q573^TKCR>!>E1//4/AB9%V'_9<(??7
M0L[YV?.*.)_*;B9R>XK0>&N0](N&8\66K&D;8;K"5$M?KTS8V"+-@_LR4/:Y
M"9:1R:BP&6!!%9<$@ZBIF$0#6@Y*U>XK*>)F1NV[\8MTIY*OF;#"=KE;L<6T
MG*U*24O=3Q_2VDZ[DVE3K\"YCMA\CZ-7>#G;WQW3<I9HDE>,+FRO<RPF#L#9
M=RC3LG0UEG,@FK]><3U5B?+18=,HA)(@Y(?<!#K2`P`&L/"RI9L:V_K_`(DH
MR?GY(^D>S>R58[6YJ[FX7#<C'E<96<+(GR&/;>'<M5K.$;E)3HI13TBZQ5.M
M2Q[O>=P/CSFK/W!&]T=_992I\).0[RT9:CIJC3U6N#V^L,GXT%UB""A+$>$D
M$[6DSQP]64%TDDP:JIID67*90":HQ\FYD9CQ+-N_<FY-.BHJU\*TT/-LW\O.
M5[?[;_XHYO*QKG&RG[=+5^W?E-T7JC"W5T<JT5:_`D::?.A>*BC-:07XQ<NT
MV/6<_O+2KT5\@4NZGO!C+HW4$2D:G3`HF,<`$3!]`1[>WV)W0[2OV\&:L257
M)TZ_*IY%?YG#M7W;OSNP2?IW6<B#V^=(VIIZU]54WY+QXT?\ZAX3NI*6CWN`
M^6C56+;-EE$$J?CYZ_+[T4@E!TP^V`@LR0*81V5$QP$/5N.VM)+M[E7DRLV[
M-YWHK5*E$J_,OQYCA[M+<+SE)^"LY4G^JQH=+(?.LN%#1F=X;`7*UK'HK$;/
MI%]7,>L6[-4Z:*@C]DO)C.C`8ZA2[]/4!`'PZ_";G!<OB6WDY./>5B"K)Z=/
MO+]WD>/LKV(7)>]/HG9RK2K_`.DE8I#YM$?W+COF<?N5O(+MT9PQ[ACD6UI7
M#WD3.YAR#\:5FIB_L%>G,?N*RWC:NW86QVW=2A)58QOYH6;)>20I@-N;I#/Q
M>U.?Y*U^(P,2[<@_BO'YLQ\CF^*P[5<QY+GU_EV<F_\`KC97V?:7Y/\`YUWP
MP;-7GD\=^4ZD@5N92,C',/0VAY!X7K`$'"J5M<BQ8><!"BX*FN4.L!Z!]&M9
MG<;R/'2V9=I;OG^HVMF%F<5*Y^*A*232O6W!4:T_B;^QK0B,XAMIWOY]UR(R
M3S-C,D6'!.-H24L5=P?3XR0FL*XZ:PBWQI4L<Y-G%5T6M8@+F:-7.N]13"1L
M,@@9H<4T%0*CA.T[?KVN+HM'^GCU+MQRA_)EMJO[O2GA^KK\3]`*OP,56HF/
M@8.-CX:$AH]E$0\/%-&T?%Q,3&(`SC8R-CF:*#1@P8LTB)I(I$(DDF4"$(4H
M;:IG/=3X%A0VMOS.[U05#0#0#0#0#0#0#0#0#0#0#0#0#0#0#4?Q?8")*2S=
M<>/]7YRY`HM<+:9\>?U;JJ,6I5[3<TTFEMPGQB@W<FI7*0[3N4DC$)/!<G3B
MVTB],1,03:*[B),_CL:WEY'M77MAMD^J715I66FOQHOB:_D\NYA8WO6H[IN<
M8_3*7U-*NV/J:75[5)^29622L\S8>5'`6<GV:2$S;./G*F1D203::^)6[I\S
MXTRQU@)-,F$Q%1JW3]B3?HIN$5%"(*@*OB-B_"-N]*$-8IM>'@_AI]VC,RTW
M<LPN3IO<4]*I:^2:37R:JO$L#M7.T>;';N[@D@#*#JTWBO'"M7GH$R=LKSBM
MV19.593`3LO(`JT-`N'\`9XR?QSH[A&.7_FA-!PGL;/Y7C+G&W(QE1VYJL7I
MJM.M.E*T?ZC4<+S5CF;,I6TXY%M[;D6FMLJM:/HTZ56M4NM&2!YCY29<I7-+
MC?QNHE'IT_CK(5=DK%F.].G4[8;31DE'$@QJ+1I6*BX=25=C[*[B%TTIZ<:)
MP1U0%$7)%B"0['P;%WC;V9=E)7H-*$=$I>>KZTKTB]WP(S.3R[/,8_'6(0EC
MW(MW):N4>NWTQU56GZI+;X5J6I8LS;?,*<?N0UQK%@QS66B7<TYN0%DO6:&%
MQF\<8_JZ^8LL23)[,H4Z6B9>-:S-T:QT0@N"ONR#N7*8R9S&`HV..QK>5>=J
MXIR>VJC"BDW5:+<FM%5T^!E<IEWL/'5VU*U!;TI3N*3A%4EJ]K359;8I^<BK
MN-[):;AW"..]JNS!C$VZS=KJ[6&S1,44R<5'3TQG?`3^4:1I#2DV(,F[M<Q$
MA%VY$4R@(J&].L?(A"UD3MVVW;C-I-]:)TUT7[$9>+<NW<:W=O)*[*$7)+HF
MTFTM7I7XOYE!$.YIR'<X(Y*W.K8BA,B9@Q#E>$Q)3Z'*8\NV"V4Q..7MF7GG
M2#2[9"M,UD@\97X4BZ$5"&:3RZ@^+$"+HF'?2XC"ADV+=Z[[>/=AN<MT9^5%
MI%*+;?5U7QT9R]OGN4O8&5?Q;'O96/-14=DK:\=TGNG)R22K2-)?X=4>F=9J
MR!4.07+[-\"PCY^\PO;(X89#1AG%1R`SK[R<#(?+J5?'/03&#(D;'M_/7/[@
MOT2;=,!(L8AP.8-39QK5SD%BS;5IW-M:QK2M/J^G[>AO,C,O6>)EG6TI7U9W
MTVR2K2K]/UI?!ZKQ-O+^6+MF/'/".[6Z5Q?96KGNC8/CJ1><,N7Z^/\`(-":
MQ]Q"&M<261L%G>-%G+M5TU=-U'B@HN&ARB`"&VJ,ZQ;L7O;MJ<6HK=&=-T9>
M*=$O@UIXE?&9%[)QW>O2M3BY/;*W79*.E&JN33ZIJNC1[J,YI\B2WJ'H\XIQ
MU4RDYS[&X[F.+=;K>7G^:HW&;O+:E3?9&3L\G.1<.O`1&+6Z]L4L!H$E<6;M
MS))+F,8@FV3XS#E:E>M^][*M.7N-QV;E&NW:O%R].W=N\6C2?UCD;=Z-F[^'
M_$2OJ'LI3]S8Y[=^YM)K9Z]VW8^B9:7=W+IMV,N4*C1JZDE#Y8Y=-S@V%$%0
M:ONX;D]H_D5/>AZ1;1S)=1TOM]E%%,_E[J=.N?BU)53U\3JJ^IQIZ5X^9D2Z
MJ)(]NZ@Z69\%\P*H&`ISV#!K0PB4#`*#_D'BIBY+L/H$[9P<`'T@([Z`D)'4
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MMJ+A=JE*-N$5%2AL@TW-R^JOU5H3(E'<"#N'M``[E\2FW#<!`?@UQ;:K1]3N
M-^B^)NZ@#0'$6$>H0]0``A]/4IZ->%4BW<DU%T\*O_LQW+]>I:ICH=^7_)8-
M_'[4/&(PAZ]S/\Z>(A]$0U@VX17)9$E]3A;_`%;Z'O\`W?%1_P"77LBG3_B#
MN7_U?"''YR(Q#GC+D1M/8ION<XITE%-W.'\<TVLW^?R,=64:E9U->J7-9*I2
M<++O_*2=C(`HW03'S1(8Q"AK=\;[CS;:M78V)5_S)-Q45XNJU3I7IJ?.W(W+
M-G#E=R<66;CQ<7*Q&.YW5N58-:>E_P`3ZQC67@>([?UERA8,2SZ.48]K5'D/
M;UF-7Q3%8LBL80>#*8I&,%ZWA9B2*=`2TOJ'%G20?/U&$4(.3BD1L"1$U#[3
MN5X3RK7X+'RK,/8CNNWY2D\J=7NR8;E16YNJCM<H^EZUJES?9-_D<CC;T^3R
M,:[D+*N)6;,(P6'#1PQ)J+J[EJ+3DYJ,GN7II1OW.:``>37#'?\`[?9X_6<E
M-<=D_P#?<;_7G_L,^L/RX_\`L._,N/\`"\+A/_I>V7=%``*4`]&P;?4UL'JZ
MG@)JU`&@&@&@&@-E5(AP,.WM"4WB&_I$HE\0#?J\/4(#]+4I[75=24]KJDJ^
M=%4@JR/\W@[<^2\WS6<WU5R-67-DN<%D"5QA3;7%P^(7%GA)9":<*ITAQ6))
MNQA[*Y2.61CDU09KIK*[$(*@AI*3FFI>-*^>GQZEEV;+F[DXQE<?C)*37R;J
MX_90DFC>!/"&,C31;+B!QG:L%4TR'9I80QQY)032*B0J)3UTYD`(F4"AT"4=
M@UM%SG,*U"RLF][-OZ8[G1?9T?VU.CQ>Z.X\*$;>'G95JW#HH7)17VI-)_:F
M:DN!/!Q%PW=I\.N+WO;5%PW;NCX&Q>JY31=+@Y6(#A6KG6$#+AU`(F$2C];M
MOK'N<CGW76Y>N-_ZS+5WN+N"_F+D+F=F/,727O7%^I22_4<I/@OPJ28C&DXC
M<:?<3'!0S<^#\:J$,<%C+@8PJ5LYC;*G$?$?7\&CY+/:H[URG^LR_>[K[GR(
M[+_(YLX4I25ZXUK\Y!'@KPF;&.=MQ`XPM3*$534%I@;%S45"+>7YH*>[U9/K
MZ_*+N([CX?3U79Y7D\:,H8^1>A&3UVSDJT^3+&)W'W%@_P#<\_-MKRC?NI?8
MMU%]B-*G!/A*NHNJYX@<8G9G#A!V<KW!&,'J1'+9($4%VZ#JL+(M%$T@VW2*
M3?TCXZ7.7Y:];5J[E9,K<>B=V;I\O5H1D=P\]EW(W<K-R[EV"I&4KMR35?)N
M39]:<%>%+))1!#B-QJ%)42]9'&$,;/`'IWZ0#WNMKB4I>H=@#8`]6IGR_+7)
MPG/)R'."I%^Y/1?>94.[NZK<=EODL^,/*-^ZE^J2(@>>7S=/C7S+S6QR[3\@
M+\5V"&-8K'LIC[">'\<1]3FUHR=GYA6WO6Z#>+2"POFLZ5HHH"(F.BS1W-[.
ML#(NSR+[S,R=RY=VM-RE)MQ\5U?5?"OD:*]?N7[_`.*S'[]VM7[O\RM//=7K
MXGM^QQA65X[X9S/B1O*O76.*EE:<AZVFG34*_$O;7`RLE"VZSI/&:[A%2<MI
M6$>X?1Z8G0CG1#BD<2+`!>,[-[QXWN2WFW^.L7+6/B9+M;9Q:K)+ZDY:OP^1
M[3^:?;W;7:W:?:W%\;B8V)W18Q)Y&==LS?\`.MY$M]J,K2?MQV1W+=%)RW4:
MT)1WO"/AW9)&7LMJXG\<+%9;1/2=NL<W8L*8WGYN9LLZY%]+S<M+2E<>/)"8
MD'AO,7<'4,=50.H1$?'7<0R<JVT][5V*ZK37S5*'AMNTK,(6HI1]N>Y;?2M_
M]ZD:*M=>AMI<$>%"'N'E<2N.1`C&Z[5D0,-8_%-!!R<JBQ/+&`$B@F,4-C'`
MQB[;`(!K9_\`$?/TV_C<K;Y>Y.GW5H=#/N;N&Y57,S(:=/XWX*E%Y+X*B.:E
MP@X7-UW#I#B'Q@0=/$@1=ND<!8J2<N42AL5)==.J%563+MX`81`-87]3Y'<Y
M_B+^]]7OE7[ZEFQS_.XMSW<;-R[=UJE8WKD6UUHVI*J^!MK\&^%+M`S9WQ`X
MONFQQ()V[K`6*G")Q3+TD,=-:J'(<Q2^&X@(ZBYR'(7K;M7;]Z5N2HTYRHU]
MY7F=R]Q<A;=G/S\V]9EHXSOW)1:\G%R::^#5#B)\#N$2*#UJAQ"XSMFTAY`.
MF[7!^-FJ)@;``(E13;UM,C4A-O0D!`$?$=QU>M<QR]B'MV,K(A;2Z1N37[&B
M</N;N/CHJ/'Y^9CQ2I_*O7+?^Q)%G'*3LC]O;E>&/_E-ADN*'..2SZ<,_P"/
M@5[#[Z3;V-..2>-K4Z@*TJM96[8(I,6H.NL6INH2;=8ZPLB_D9<U<R;DYS7B
MY/\`M-?R&?G<K<]WD;UV]<K6LI-Z_'77][UZEVG"O@QQTX%8@;X;X[T]Q`P)
MY9W.S]@GG2$Q>[G-N'"RI)6Z6DC-DZL+I@@K[NT\TH$;-2@FF4H";JB5VY/Z
MW70Q'24MS2K]W["\(``/P=6J:U%3[J0-`-`-`-`-`-`-`-`-`-`-`-`-`-`-
M/B#';YY/Y=CQ%[D?Q)`DM$@ZY\5%%*O&JF1+<>5%##'&*12;(-,6S5?MT8N5
MPQ(<KY-TFW0Z-E]TSFUONW%%\I'<]JVRUK%4TI_$FG\J?(YCO"4X\'<]N.Z3
MG#3;.5?4G_`U)=.M:+QT+Z((S5UF[MC.(I^C'QQ^)/(-9G'Q[*2B6<LS4I7%
M\K2-;,+BX?V^*:M2'*X31<N3R:`-BD<JG$%A-JLJJR[BEU]R7D_XGY:/[-#>
MX.V6#9<?I]J%.J_A7A)U7R;JO'4LNG\&P&+.`_<MKBV>L19E8W6/F)&Q'Q9-
MVF1L%<1F&WN<J_RH\L^8LN"3(4LBJJFHND#,#(1R8F%QTE*AL.7R7DNTW:N6
MDH4]223_`-2D(^E?;U\/'4<!APPWD1C?LWMUVKV.3:^,]URYZG]FB77PNZRG
MQVDLA=Q/%6;3XLS79(_$-9J,%%9"4NN"H_"U49OW%@FY8D31;S2)O)<W/"[*
MV-(R,"^9NB"9NBDND":Q1N6,N-GB)XRG;3N-MQVS<WT2K)244O)2376J+65Q
M\LCN"UFNU>DK48I3W6O;C6K=(RBYM]*N+3Z)/1E-\/X,>9SXT\JJ86\-\4N4
M^Y%S'ND9>I5A:UD(I&O<C;JHL^;?)3(V)Y8J3AN"Z`N"3!&Y"B<#IJ@`E#7\
M?D_A,CW=CFJ-;=-:_.,E^HVO*8;S<1V8W%:DI*6[U:4_U9P?_A?>>\Q-4RT3
MGWQLI9+>GD$E4[6%PKJ=[1,X.E<DH?.N`F*5G3.[G;.Y.6<(D#GJ/(O3&\S<
M5U/KALY5QW<F=UQV;IM[?*KZ=%T^2^1D85KV,.U9W^YLMQ6[^]1);NLNO7J_
MFR-JC85M.?L&<CZ=$8<SDDTMG/-BR7JN++EA:@9#MN.Z5BVS_%TWD6X#BZG8
M('$]A=`D+=)*.E3O554F;Y9=0XZZ^YD6\7)LW)7+58XK=9*<HJ3DM(K<Y[EX
MZJG54//[&)>S<+)LPM7U&>=1QMRMPG*$8/6<MD;7MR\J2KHI-ET-CQ2O(Y"Y
MEX9+49EHZ+VGN&E(1H["-3N4XR>1]UY;1[:N(Q^*4Z<WGGS9=N5$?B`D:BH8
MHF:E1)T@'.8]]+E8Y&Y4]ZN[HNO7U5I_UJ_$[#,Q=W`RQ-C3_#J.U+<]%2E(
M;:O_`%:+RH>+B:RI4L&\/8A2+S1"(_NOF,WS2+STPLS*^QR,FUM3OXM35M]@
ML5AE:K$O'"C2'>.U4W"\>@D*Y#+@JLJYM[[_`/+E;4G:BMUO:UY5HEMW/Q5&
MJORZ6NW82MX335Z/\^>EW=N^59-R<5TBW1T6NM6ZVY.M]-9*8?J=?M][F[)&
M95QDRNMTKSA\6"A:^ZYCTB+8SL^]8V,Y)!I=[A#K5V(8E!5R=F:06,1-L@J4
MW:=E\/=X^QD6^3=N6)+C\FY%R45[MR.)<N))[?2X/:W2BZ1=:G']_P#.PY[,
MQ^<QU<M0_'XMAPMN5;45DV[,FXI]+BK1M5I*JH4$NSU1AV->4BH,7+T3Y7Y=
ML1;,@2,H@64[A64(U5X?S#IE]RBB.Q<KB`B;R$C](&-L4?-85:<ZZ-Z?<CTY
MII[4OY:6C\7J^OV4,B758([NZU]XEEW^FG`']T=B30$B.H>BJ#H[-/-:M7)^
MSOD'KIE7825G7C6,;"\D7#6(8.)!PA'M`,073U9%N)4D]PZU!`NX;ZKMVI7[
ML;4&E*325>E6Z:_#S*+MR-FU*[)-QA%MTU>BKHO,M2IF2J9R'PWF7*.+FJV&
M;3(UZY457)-TKT16[+79>+IB#V)L\](MW"[M2$J*LVBY)Y[@"I>['$`*4`,.
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MD"IM(RG.L*6[&AK4FR5R$IDV8R:YRA&W=6DNE94`:11&9)8QV00AD]W6M+E9
MO&YF):LY-]SMVL:D)5DKL9[:[/;5M6W'=Z=95V^KW*Z'48^#R&+FW;^/CJ-R
M[DUG&D':E#<O7O<_<4]OJTBEN]/M^)+JFGY9"$`=P+OX[;;[B(_#X;;ZXIR_
M6=IH;N@&@.&X\#;^GJV+]+T>.K;G24HTZ0W_`'>'ZBW<5:0_O*?^PRU''`_Z
M\3DW]#$'%\/I_P`WYW'?\/6):G7E+\/*U:?WNY_8?07>/_WN?9'P[B[F7W6^
M"_M.EYSUVRRV'8*R4YI89.T8NRG1,GP43"UZIVZ-D9.M.'S=I\KZM<\C8HB)
MNN1*TH$BF4LXT<-95FS=)@H*`IFW6#.Y'+MQMV[EU3DHRA;^N4)-*:C12:;C
M5;E&5%5[7T/#;',_T3`Y&_'VU>O<9DV83FTE:N7(?R[BJXJ6V:BI0E*"N0<[
M;N0W[UX;@;2*]`L+]9X"I9?J_P`<Q6.:M(.\II85#Y92-19623E[VRD,/76[
MFL5@N=AN+Z4EI*7<E76%XW2;;MD2`7JN[.[.3[CQ<3%SX^W9QIWY6[>Z[+VH
MW7"*M15S2W;MPM6[<(6_3Z')^N4CRCL3LOC.V^4Y'F,+W)9.?;Q(79NWCPC<
ME8C=D[K=BLKEV]<OW;MVY>;D]\(1>R$2I>;#"7D]PL`/0,_GO</AVPU*"'X>
MO/;\=V;C?"4_]EGV3^7.GY&?F9+RPN#_`/IBT7?D'J(4=MMR@.WX&LU.NIX$
MU1T->A`T`T`T`T`T`T`T`T`T`T`T`T!I,7J*8H^@Q1*/X(;?0TU7TZ2\")1C
M.+C+Z6J/Y'3QU?BHE%5O&1\?'-UW"SQ5"/8MV2*KUT<57;U5)L5--5TZ6,)C
MJ&`3F'Q,(CXZM0LVK55;A",)/=)1BENEIZG3QT7]I<R+M_*F[E^Y.<W",*RD
MY4A'I%5?1?HCN"%Z"E+Z>D`#?Z0;:O2>YM^93)[I.7FS5J"!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H#YOXAJW*;C-12JF20:YVY!T#CY@;N,9
M(O6-(?.-.3YV,ZO,X]<9,AL;$F576#.-B2R+:R2`J@O)PKM@*AXYN4[M8$5"
M@38AP#=<-BW<O.C9LW';N4;4MKE2GP7[?`T?<6?9X[BIY%^TKUJL4X[U"M7Y
MORI6BU9=O(2D;+\H>`2\;!M:TTDN+'*&=BHIBNUE8*M,'3'BR5M#,;%&=,6]
M)&-WQ4456QP(Y;IF43^QZU]Y-7Y1;;:DU7Q>O6C\_(VN/*,\:$H)1BX1:2=4
MJKI5:.GFB$7B#&P#'@%W++<Q.D*UM:T]><G);(./[?/2-I=3=D=S""3*C6:0
M&GTU>P3BB\#'3;%M8C&?KB[<NQ,F1MTG<\I;[,)=(Q=$HR2IZ4OJ6LJ*C<6X
MZ*B7CQG9,(*&3=CJY3C5N49-OU-Z1;VQJVXJ24]75OPF\S5=\\DYBX0I5,E,
MTP6)C.Z^_O1*[2*',XYL*)U+9Y[>1L3RC3-J8,C+-&S>8,,[$F9%,V4:MG`J
M*'UCX6!CW.%OYMSVO?C51K*6[PZ)-*ODJ/KJS)Y3ELRQW)B<;9][\-<HYTC'
M;XUU<7*FNK4E2G0LESM'?''`?+\.3(4)B,D[W!^3<:[R)81QLI5(1J_Y;9C1
M??+:)RA/5B`LM(GV0GC)I@FY4>.8IVL`-G:)5FJN/PB4<ZK@YM0D]JW5K\'%
M-J2ZI]*KJM&;'N>._C7!7%93NQ6^6S:DW_$IM*46O3)5JTWHU5.M''I%"-YF
M<0FB#=-DU8]HR5:-VQ9&HRB+9JSR_P`=T44DI6@II4B11203`"+Q!"QRI0`S
M<`2$NM?F*4LV[35N[*O5=6_"6OV/4V7')KCK$8);O:@DJQ_NK2L?2_\`JZ>6
MA9?-Q#/@KQ5N,H:;Y7XH@+_RF@$;=)YIM&*\$V.TPDE4\F6A>NTG*N%9C(D_
MC+'19QNFY;J,8]>6,Y3^+D&Q49!TNEU"D^2S8JEFY.%AT4%*:33BJN$U%2E3
M35I>+=4D^(E;_HV!.+EDV(3R5N=V4+3:<;DG&,[>]PA5:43E7TI4DVJS`A*9
M2K_*[)!7URM\Y>.U9P90,DX1FS7B><STIRHLZLR]6PG-0DXK9%/>Q%PG6W*!
MU%BF%N<O4!=:;$M-<ZK,5&,8Y#7A31_XTU3P]7VG39-SWNVU<FY2]S&B]SKN
M;:ZOVVG7Q>QKX'A\0X;OF*^*_`/%V2FUE:W2M=SO&\E,R\JWR-.$M8)0^0;.
MULL`M>I:6LJU5FV!4R)NA;Q;-ITK&%FB"*IU(YZ=O(Y"5RVT[;BM%M6VFE'M
M254UKU?Q*.U\6_A<7&QD)^]&<JM[FI5Z2BY-MQ:>G1==$5CQ78<5PUNM*-=S
MEQAI7,#(/+J(;9,Q;'W^B/:S<J_6\XI1Z,0E2FTA)/!R`..S*%BG@(M)HU@%
M/S@(L97JZ27)Y>1BV[&9CWOZ1CXEV-OZDXNY::<]Z2K%S:G*+]+2VM[3DX\/
MAX%ZY_3\^S<YK)S;<KE=C35N]&<;2M[GM:C'9O3K7U4KH4ARI45WW9%R_5SJ
MG8'MW(S(23=TN5)U[JA=.Z'*JM'ADFZP>:FDC*E4\L3D4$H=)^@^X!P$(J#<
M5KTU_5^X],BW**E+1M=#(AU621Z]U)(BW!;+Y%'*+0I;%@I8%7`+B0ZC?D+B
ME=)J4&Z*Y_/>JI@BD(@"8**%$YB$ZCE`D*U$NC^0/.VJ3F8FO2\C7:VM;YUF
MS46C*RC)QT(I-.R]()LBRTNHE&L`4ZMQ46'I``'P$=@&]9A"<XJY)0MOJZ-T
M^-%JRFY*4(MPCNE315I7[>B*$4#D"C;KQD;&=DH3FGW/'M4B[=8*B2QUJZ6!
MQ&SWQ@9G_C345I$@G?LFB0HE,H*CA1;RRD'IZC9M_"5JU"_9NQG"4J)T<:?]
MJGC7Y4J8=O-]R]+&N6W&:C5]))^:TK\-/&IXVKY@X]Y3RE188*)?*]D&E6B:
M-37%OQ9=L?)PUS=8PDW$G#*N9".C&0S+W%M@=.4VCL#`=H85"%\PA!+DRM<K
MB8=[^;&6+>@E-*<9U@KD6GU;HKD5JO'1Z5,10XS+S+-R5J4<JQ<D[;<)0VS=
MN47Y)MVY/1UT=5JE2EUHY.R3;D_B##5&R*O/UJP9`ML;E"31HKBV.J]-0#%P
MTAL/BA#0L0C2HF7=G</'%J?N'9$%(M-H7VG75K<8?;M.!R^5SK;5^-J$K,7.
M,$XR=974VV[CBJ15I)-[W+^$YWD.ZZ]RX/"\=<7X>5Z<;\HVY7&IP34;+225
MI2=9.\VTG!0IZR1S7%M=/F=V-2!H#A./KB_R9?J;!J''=&>WZG!Q^U]/VE%Q
MI3@WTI/_`&66IXZ$/NQN3A0](8AXP"/AZAD,[[?B:U.-7^M92?16+"^VMYO]
MJ/H'O!/_`.YR[(?@^XNYO_5<$<_EWCY?(6*&235^Z8NZ7?*?D=H"E=AKC5'3
MJEOE)5`F0Z=/V&J1=DIC!0H/5$SR+,6C]JU>E4`S8`'JN(Y&YQF:LBTKCE*$
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M]W_OECYR_P!D^O/RXDG^1WYE6?\`RD\/@TOLYBTR\-+\C)_(A^)K)CT/`FTW
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M-$'KP6)"F;D54*`&'"R'NR9S;3K-Z]4]>O15KYT5>IM,6WLQ+<*.-+<='HUI
MTI5TITI5TZ5+!*=0W=)X"<^R.,;9=QN1Q',VH%RJUOD8ZOSU&6D)N1R3[C=\
M3XC6E[1.+6,K.6G?<W3^7"-:B\7.=$AS[7F[JNSMM3MS]+^G:]O1;=)2HE2J
MC5)5=%J:#MJP[,+U;=VVMZ7KW+=U;GZK=NLG6DI4;E15>A=MF>&Y-*]QS$,O
M6+.JQP4,A0H^?I3K+>3X>4GV3.NY`D+)8ZGCBL>Y8\?U*/D'C-&P*3C>35<N
MT6:9'+,JB:8W,:YB+AKD)JN125'MBTG6-$Y/U5>NVE**NCI4M9=OD7W)9O0:
M6(MJIOFI-;9-N,8^G:FTI;JU:C1JM"I>%\#8TY'<;\S8GRY$2L_09GF/S,7F
MH&+MEKIY9DK'E;EX[=G*/Z?-04F^BQ5,!SM%%C-E3ID,<AA(7;48V7>Q+WXB
MPTKJZ-I.GRJFOM.BSL.QR=B6-FIRL2>J4I1K\W%ITKX5H;?Q`S@.Y_B>MQBC
M_P"+X/MO92AF"LE*2$W*`RCN0V"V38[V7FG$A*2[WR$B^8X=*K+KGW,H<QA$
M1M>XW<=Q_4W7143\?#HOD7XVK<(Q@J^A>EMMM-*B=6ZM_%U^)83+<C:US`XQ
MY2=Y<D*@\K-2Y&0F/+7"1G)EK-TR&;,H6P$@9IO)X$0IUCL+)26(TDE8"6.5
M2160,HUZ111`W90Q[>-GPM*4K61=LMVY>TZN;I1-3JEXK<M$M'U/,;F;DY/'
M7.3Y!+,Q+6:HY$5?C';956Y)V]KE33T:RD]5T+C\>Y4E(1+DOEW'<G"!,L^W
MCP;N%3GK8VOMJK"#D2\J';&>FT79WN2)B%9^:#EP+HYY)0A#"N?KZS:Y?+Q_
MP/+W<;-<I*U><;FRB\4GM6D:/KY*IZ!A7GR7$PR>&<(JY9W6E=;HE1M;V_4Z
M)?-OXL\7AG+.0LS<;^WI=,L9&@LO9#'GD2"M&1:E)T>6J%I>0U3Y`1[>2J#G
M'\1"U\M7-&@B#,HHBZ\@H"N<ZAA'3DGA_BY/`TQ:*B]6FFJ>YMMUZM:>13Q"
MY%8$%RSKG)O<_31ZNC6Q))4I14KYZGAK:A'7'FNNSL66X*-4R%FK#T9:JBNC
MBDLH6`P#FK[9&"H+%JT;:6%BK17UI?+$M;N10FY"<6>`1L5@)44$]QC7<B6+
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M5VB;'&6^`RS3Y69L:MQ#'E>E+U7T(")<6]<6*#A2&400,WBG+8_FF!3K#<<G
MB;+]O-R4[>#=NJ&UIPDDMN]J+J]OAN5?4FO`U/!788^-=X^S-7\^%K?[B:G%
MN3EMCN3^K2KC_=:=:,]3A.F5Z9R1-65[R%JF9;E49U.3M=:@Z_BEC*5?(RM$
M9TEW*V%Y3F9)U.10J3H&*!5!02]T4*4X*&V-K$S;MZWC1M_AYV;$X^EMSI*&
MYRHMVE-VK^/D;+$]F[?DXWX7;MN7JBME8RVTJ]NM=KI\B/UMD7+*L%]L,KWD
MG&Q"$A;<;2673W"->8U^5<WS7K4=$/\`XI1R3)6-5M%UU@>J&*2O>]I,%!10
M221W/KT.6%QRO?@6L&5QJ%U6=C5W9'!DY*OM*-7)^[_F4<M6V]#R2/(\J['X
M^O)1LJ5RR[_N)V=\N1@HO;[TITC!.Q_E;E%TBDM2=O7D)[>-`-`<-Q]>7^2#
M\34P_B^:_<6KW\/^K/\`V66G8Y^_)Y/?J/\`%W\\,\:U&/\`^VLS_P!'9_\`
MQA]"]X__`'M_8_\`_<?<W_JN!/=\DZ;@3)>+'V+.24?#SV,,H3U9HKFI3+^9
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M,F0_)SAL8Y=S)2F?#I&ZS%`IS8D<(CN0$S>9U)JF\.HNWI\?1KGIK_>;+?@Y
M?L/I[\NYN/Y.?F"M*2Q^%7_\UMO]J+N4M_+)O\'P;>CZ&XZOKH>#Q^DUZDJ&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&H>FH,?6U&*EA7GS*)9%B\0K0/=@F)YM=I'.59X]IQ[J%I&
M#GH(MLEW6HWV$CWTP*!D"MSQC@5?-'RP`2!K;\-KEN.QW*VY+;L=SK_A3B]/
MF:3N'3C]RN*TU<@]SN1M4HZ_7*,EKTI0O/1L4O.\KNWHTFRILYB;X;<J[)(1
M[6U)9$9%=&5XDLS.T<IM19*W'?XS#ID$VJ99(J@N@,0>D@X.0HQR)QCK%3?A
MM\?[OA\O#H;7%E*YB6Y3HIN$:^K?X+^/3=_K>/4L$KF#H3C;P<[DU54Y#4C/
M5E<3K`MD946_9#R,_P`4*NGS-C#X]M*=SO-X>P[Z,6?*"8_0T<G3`ZCT3BF`
MI;7F\J67[-SV96H;-*QC'=_B6V*JOO7D<]VU@1P%DVOQ%N_<]W7;.4G#32#W
M2E1K['YU9*OE+B9*9)Y6X=S^C;ZQ"UW&9TI";K;_`!93;#=+%,0K230K(5;*
M[]$;E1Z_O8'0RL<U4!J[.W1,4@&5<&-BV,Z-G`N8KC)SGT>YI).E:QZ-Z*C>
MJ^XSLKBI9'*6<]3BK=O5Q<(N3:K3;-^J*U>Y+1T7Q.YX0F$^,LI&,F=(P\O^
M;.Z:@D$Y=N5V70V,*1U$_$`W\##X#\/AK6&Y*86'S?W5:B^[F`C@>W=F,J!S
M%ZRD7-R/P>5(YRCL!B%.(";Z`:E-52?1LE1WNB='J0I\GF4O%<;<K5G%JUYM
MLG-YGP461LC3@\''64FW1S9>DYZ!KF*JM`X8G<X/*\G"(OI!^1PZ219/PV$B
M95C&WN5?O8K62XTFHRHHWI7FOII*KE+9JZ):=#@+>/:EBW<1[IV978;G+'5G
M=5SK';MB[E*)MZTJEH7W4S!BV6L><D./\5#53(ZEK[<7;\H;:)R8O9JI3KFS
M<J\DRNDKH>F3SBS1<9*H$.+M&/DU5R@)D2N#"(GUB9ERW?YG(O9N]6I9#<J?
M53X57ZV=#@6G8X2S;XK;[RQO1NKMKIUI^S_258?8`6XX8KX!XB;Q>/:I\G^=
ME/>(P^'R7QK2(^.<T/-+Q*.B4LJ6G)%H3;J1A`173,]*B4IC$;%;%`AB85]V
M'<KC*:LT5-S3?WI)&VQOQ7LK\8[;O^.Q-1I72BDV^G77J5ASY.PCO)6.IVV<
M?\W%=0&6\342,OJ;VF0F/5T;#FW'RT7,22L1:INROX]G8XQBZ315CT07Z#)'
M\DJIC%ZOM:_E^]DXUF]8M698.6_4JR?^ZW4X1K1*4UZ(ZU3DFDW1'#=\<1@7
MY8?*9%C(NW[6=B)>VW1?[S:UE%5>V/63Z43J6:Y.*<O9YLQ5#]9@Y"H#U=!4
M]@'N:H=*?2`COY8!MU?CMM]<9#Z%T._;]3@EZ%JOMKI]E">351)'=W6OO$LN
M_P!-.`/[H[$F@)$=`;:R*3A(Z"Z2:Z*I1(HBL0JB2A!])3IG`Q#E'U@(;:E-
MIU74AI-4?0M$RIB"IU!ARLS78+KF%S"7_!DQ$6VEUJP@>/J]>IE%FFKV7Q-7
ME$DVD+?Y&+\PP.3'-Y[L$^K8I2@&PP)7)YN/"UM]WWH;=_TUW*BE_AKU^!B\
MA[<>/ON[N5GV9[MGU4VNNW_%3Z?C0L>XUDGDL_<:V^8Y7%4E)LZ5D5EQYJG&
M^N5:&+B^K(U-).3BN13BNV^P.`(YKZ/N+1K&`I44)Z/2ZEEWHL3)]1RGMOC\
MIX2O*#N0=Z5Z4G[DMVCLUBNCU;E_,<&]%'=7E.*5S^HXJSG9<E;FK,;$8KVX
M[=5>VREX:)1_EJ<5JY;6NU;RU-#,#7D6HP,UPPQS)8Z:;*A,6/H7&;/(!+ZZ
MHQ)AS1FN;1;S4M)7)<T$7(BM146&2*3<Y$NA9.IWL_\`I[X?>GENQ&7M[T[K
MM[%/;[CM545'U>PKJ6WP?1V_PO$?U-<TK+5B-^4?<2DK7N;W#>[2N[93<FX_
MB':<MU/52C4Q>N"?A\SNAJH#0'!=>D/I_P#V.K<NL_\`T+_:RU>ZP^4_]AEJ
M..?OR>3_`.I!Q=__`"_/&M9C?^V<G_YO8_VKQ]"]X_\`WM_8_P#_`'%W-_ZK
M@2H^>\.DS538N!:SLM4[+6[?`W*GV^!E%HB:J\S'>]Q,E(Q;LC200*]>U";D
MV!//;+I$%YYG1UD(8O1X.??X^][UF-N=5ME&<=T)1JG1KYI/JM5Y5/"L;,NX
MUG*QH2E&SEXES'N;:*6RXEK%OZ91G&,XR6JE%=55.TCMZ382C"ZQ1,-QN+E:
M-1,'X]FSQ:^2EFT59*7$7"#<X4+]LMLU?"IAJ`:QHKK,RBU=NYQ9QU',J*AN
MK[FAR,N&X_-Y;+C=SLJ]EWG9B[;V*<[<O?K#_P"4R<J;J22LTI1)'F7;61VV
M^]><XKM+#N+@^.LX&+'.N0N0GDSM0OJ6-)7%UPEM?I<E_O-6]S=:\9A(<W)?
MAZ<J93%2E,[G.<1,`D`<5*D+T@!#`(F$_K$O@'KUPD^J?S_8?6?Y?R2_)[O^
M/C+'X9?_`,TMO]Q=@COY2>_I`H`/T1#PW\-_3JM=#PN'T)&YJ2L:`:`:`:`:
M`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:`:
M`:`:`:B70$"2_':4Y483[BF&HAE(NU9WNCV:2=J19L>E>QT9`57`4E)2*1,F
M0,_7W`-VK<P"D1-%TJ4PE(H)!425V/'9TN.R5E1CN:35*M5JJ=4UTZ_Z:&MY
M?C(<O@RPKDW"+E%U2C+Z77I)-:]/TH[NK)'N(7N!<$XE=NVCEH3AQS2B`:MS
M,U&S4D3;^';%`A?BYA%1X%(@@01*W;-T"CN5-,A``H8=R2E<<_[SK]_WFQA&
M-N"MKZ8I+[$EY47W$>UXJV!JIVY>?==X[7YA9L?*91HUH<-&R-S8P,'<I[)^
M/']R+"DNU0CI4B5BL3195%,LY9T0,9---X@F!$";3EYYMR5N6=%1N[*)Z5:7
M2M&UI\H_)]32<';XJU;O0XF<I6'=<G%UI&3Z[7**;3>NKEY)TT,CS6G-X65<
M#5I!SB')*\LDP0D5.7O-X72,6Z,]CR&+RVS&1(&SHY2G6`S<I!/N`=*@F+ZM
M`>"EDQ#NR4-4553$4[=V6D_(,*?NZ0I<E,*F,LD`)@H"JX+`"@F.8HE2)L!1
M`PF#5:HBNM?/S/>2L!9$M%PM=/Q99H;DXWQ#4+#+$+C,M#N!,7WF;O%%8R%6
MK')V4MT'63L4FC>8"/B7LZDN[*I[HW`H&ZF^K/#9-C\/9=^$XUE&K>Y53BWI
M%INE=NJCIK4X2WGY?*\9F9%^:LW[+<8RHH[)4]2^J55'1*;HY5>BT)`>WJ^>
M/;Q..)*5-/2CG@3VX'$E8/-<KH3CU=KR756F&R[ME'.E49`5?-ZE6Z"@F,/4
MF4?#7/Y.5+/RYY]R.R-R4O0_C^C.EX.Q/"XG$P9RWW%C5W_96OWLN*Y>[A9.
M%8^T<1YJ4$/``#8/M49L`1\1`.DH>(_0#6/)122BDHFRMV[ENKN2W-_I^\L/
MKV9\8R?(N$BRIG<<@4>0D;3[)QD<9&S^:WTA@XN;MY]M9R*LX^Q_+1L;0TT)
M]:.^+TJ][HDKY#P5B>2/;2X>^L:>3:E!\4\=-7&K;]2BM\:5W5W54:*J^/4\
MIAS7"+G8_C;B_P"))7MKQOQ=Z$XQJU;D\=75:58T>L*33JZZLZ3)_3^X[V,0
M'J_UP+3Q\-Q#]TR;;&$/5U#OKB7^H]92JE-*B:7]O7KX_I4GCU!)'=W6OO$L
MN_TTX`_NCL2:`D1T`T!YNVJJ(5:SKHI6%=9&OS2J2%2*U/:UE$XYR<B58(^,
M1B>PJ&`"L@6,"0N1)UB!=]9&,D\BVGL2<X_779U7UTUV_P!ZFM*T+66W'$N2
MBKC:MRTMTW]']%=-W]VNE:5(HN*^'\Z8ZY`H+$QE>,9U27LLS9KNI-N\13-5
MDL1/\2LF%0J;RST>J5R1ELL1^;P<R3IHBC[NP8**@+MP4Y#+^@\]G<'E<,]E
MVQ>RHVXPALC=C-7E>;G/;.4DK+L4BFW64J>E4HO,NV\'N/%YR*NVLJSBRNRG
M<]R=FY;>.\=1MPWPA%N^LFLY12I&#?KDFMWA\5L;_3^0>6<85&Y8M4Q%-<K9
MFRK8_P"2%FQ3+L7:\V:L6:2L^&:O5I!?)CNW'O:*Z<2TD?BV)9.=W*;=5R`F
M#!R[F+?XZSE7HW?QT<-1WV5<3TW14;LI+8H[*;FMTFM&TC<X5C/L\C?QK,K?
MX"66Y;;[@TZ[9.5M1]>[=7:I;8IZI-DW.N"?A\SN1JH#0'#<`'43Z(_WVHBD
M]]?@OL?5%J]UC_JS_P!AEI^-P6^['Y0F';W?[4G%XI/%/?S@=YT,J'3OYP!Y
M9B>(ATCZO'JUB6X17(WY)*KA;7W.=/NJ?07>+M__`'.?8\5_F_\`$'<K?7I[
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MBWF*'*?U*Y+*;E%3C*&*W"-,:W%.4H0@J.,;C<VFI2K)N4NVS`9N');B`"HI
M@N9_GCW<#[=8B7%HBKY6Y##N!/3L)?#X=<\TG)5/J#\OTW^4'?U.GL<-7_\`
MBD/WEV">W07;P#;^]Z=]5'ART->A(T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T
M`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!C=9L@E[)QK[@\.W
M?HQAWG=GE"&?*6JI4A5%$*7A#SO(MEZM=1J4"FHEN1TY>K.TTF!ES`S<G`J8
M[K@9;,_=UI;EX-_JBFW\$J:TU1SO=-MW.*V)[6[L-=T8^/\`>E*,5\6ZZ5T9
M>S7B5T.7G;<)472+JLCP&Y9?$;N/MZ^0VRL:>7X9"U487E^4BMP;>6/V&1.0
M@/"=*G04I@*&ORW)95QW-);W6JV^/BO#Y>!N<*,/P=I676W[<:4EOTHJ4E_%
MUZ^)'NTQID/`7`GN*0=ZK.58I*9D,(S43-94C)GS[0[N-NAHJ>D8-&R7*Z_%
MK9!XJFHK'M'X-HA98`2;IJ=13[/G;\,KVI0E!M*2I"FB35$Z*-?*K57YG.]M
M8F3@QR(WXW5"4XN,KB?J;33:K*7C2L4Z1;Z(R=-:(ZLL2[=LB,O@B]20M5&(
MN^77.8PM%>KS$?*YA9L;@!NL`-[8(]0;^HV@/,S8&/W7:*D`=`#V[<OE*L<J
M:B1CJ\D<)$`GE]?684Q*`F`P%*8#``"/M;1K54Z$/H1QPF1:`?BG?+14[1Q_
MS=CVV9JJ\))HY;PQB3B_3\269JA;5YJ.='QU/8^K^3KLU:1K-J=2.LRSUH0Z
M@**=`+MS=G;LY<N5M6IN>/.,:J<9W+LJ:>I)IRA\-%6IYGG9D;?!W9XT;.9B
M79J,X3A;L13UK!N-(S=%JU)TIJ21\994\[R;S;*JPT%`*2'$;@8_^(JO+Q<_
M7(<KY]RE>%C8"7AA&,D8)B"P),UT!%%=N0BB8]!BZY/.M)9$[=NXY-3E23JF
M]7JT]4_/YG?8,I3X^Q.5GV_Y44HQDFE%KHFM-OE3R/7<QG14+9P:;"BH<7_-
MFDMRJ%,B4J`H87SN_P"M4JBI%3E.5H)`!,IS`<X"(`0#&+8BJ1H9Z2_44WF.
M,')2_<JJ;G')]DXW6/'^++Y(R>(Z8WJ.5VD_1JO(HH14C8%'K&^Q-9M679&&
M8ID:R4K'O&,$#EXBS;F(X,IK=QS\2U@2Q+*OJY.%)/=&C?6E-K:A7JDTY:-O
M0YR?%9U_E89V2\65FU<;@MD]T4]&Z[DI7&NCDFHU:2U+/LD`K^XWSIG":*3D
M<^L@7(W5.L@10.Y>T$Z:*RB+=15$AQ$"F,F01#Q$H#X:TOA3P.BHMSE_$_\`
M3_:R>?0DCN[K7WB67?Z:<`?W1V)-`2(Z`:`\_:73)A6K$^D+"6I,6D)+.7EJ
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M"I+&4`AM@`#;_#N.P^KQ]7X>M/NC)5753H;&2E"<HN+HJ4=?,Y.JR!H#AKB&
MXB/_`$,.KT^GP#^_U4HT55_%)%B[79*YX04O]AEIF-7*AN8_*-H)S^6EB3BV
MY!+[+Y15G#G.B:BA=S^3YIR-R@;8H'Z2EW$0Z0#%BJ9MU^#C#]LSZ%[RL;?^
M7/L;)I'U\]W*D]-U(PX1T>E:)RJM:5;HJUKN\K8M2;6XS1+:I25E?N>5..WK
M.3CGJK4M&3KM6O\`:)FUR;<(B992L2[KD(\A%VSE-),0F`4362<)HF#>\4XP
M_$W9."4<2YI+^)RVP26J:DG)235?IZ-5/(N`M6+MOD)9%Z-J$..N246D_=E[
MEJ,+:JUM]4E.JJZ0:HTV>+XERU[M%WR7>LGX;1QGD'(&+..]OMDJU6LIV#N4
M?,LD,/M=LD+!#08MQQPVC$UW13I'?E?SC@BYQ1(U`O0<W*S/M#B?9R5-0R,Z
M'X>D=UI*6/)79M-R;O[MJJHP4;*V*N]OS:?#V.#_`#=[IP,"U*]Q2AQ[M<@Y
M5CE4ADPG:MJ'\I6\=QW*493G-Y$G<E3VXQ]IF5NLKR8X?.$3;`T?9[44**?4
M0Q%<7E0*!C;;D'S5"[>(;[^O7$[=TEKJ?2/8^7CV/R=[^LRDEG7;'#>TG]+V
M\G!RW?92FOBV7;(B84DQ/T]0E`3=&_3U;>UT[B([;ZJDJ.AXI&49Q4H_2_M_
M6;FH*AH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H")3C=C"8R[!]P^F065LA88D77<?RB^3O6,0IPVM
MHFPQQ@U96/0^7-3N<&#*2('EK_S'YW3]8H3QWR,6_''N^Y*W"XJ/TRK3_P`%
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M.]N3O>RW9?\`<A[5NWZ'UCNW?!F0]KF3I2/OMGJ*+<;[6HLHHLH?EOSMZU%3
MG54-MS-SH4.HYQ,<VQ2@`;CX`&V@/*2\TDX[OE:K@(+IK0_;4R!.*.T3E.=9
M*P\G\;LDF[=N!!4*NU/5CF$WCU^<4"@`E'=Z=R;IH]*]"F<7.+@G2OBNJ^13
M_BRO8OM9W5DYX+U3&M=+E-Y$WBK+U&U51]>J9%U>8EQRBA5+QC.E$O=\F[`9
M!B0K9LH+A1QN=UNF0-=-?M6KE^+EEN5S8MK3JHNJ6UM2E2*6M6U^TY3C=]KB
M,FY+"45;FZPVM>Y%=9;7"+<GT5.M/-%;>-\='PW*G/5?BZTE26->XG<$89E3
M$G:;Y2H,HY]RG;L*RN[(LN+I2$9D(V*H8PBH1,#`(@(".AR6OQ$Z24Y.3K+S
M=7K]O70Z#"7^Z6YSALA&"2A5Z*BHNOAT/5\PQ/\`*GA$!7!$BCS4I'F(F(03
MO"AAW.1BHIF,<ADS)J`"PB4#")4Q#8`$3!CK30S:UU1>N'AH"!;(B(M^S7,M
MQ5!84,^,4A6*DBW*KY?<M9$\P$&Q2-T0/MOTIE`A=]B@`;:`GIT!'=W6OO$L
MN_TTX`_NCL2:`D1T`T!3K+M/;9!Q7DBC.R,#H6ZCVFO'"4<O&<8!I6%>M$CR
M+N/_`)O;,4U52F641^RE3`1+X[:O8-^5K+A>U]%Q/35Z/P3TKY%G*M^[C7+6
MGJ@UK6FJIK36GG0LOX<<X)3DDVJL,]Q))-W,E48N;7R)C%_(7?",<'Q48Z[2
M9N4]$5->"FUIAJLR0AD0F7Z:J1A<'33*"Q^AYK@8<6YSC>3BIM;)I1NO7PBG
M*JIKN>U:Z5Z&BX+GY<KLMSLM5MJ3G;;E:Z:IR:C254TH^IKQTU=%Z=><"-,7
M-J`\@\EO*5*3TMR#B)MVA5V5O;)O^1Z5$9HNIF)6^,).42OCD5"/SKC)KP)$
M_-<F5W1#<<7#DKO/+'P)6/Q$\><).;GLI&RYRTII6*HE3:I>'B8WYL8W;/']
MC0[IYSW[F!:Y+&M*&/3WO=N3MI2]3BO;6];Z2W=:)T):&9@`$B^UOX]>^PAO
MZ"AX;`7I#P``#7!WHJ;T\)M_=H_GU.BL/&MN4;2>W^72M:^J+:_5U.UU090T
M!L*I&.(B'1L)=A`V_CZP]`>C?55?33QJF4S3E'8OH==WQ3BT1WYHX]\TW>=;
M9E?C'R$PYBJ%O-(Q]6+/!9$Q#)Y'D'4A0'%P482+)^WLL$A'ME4;:H4R12&$
MPD`1'P#6%E6<B=QW<2XH.6VJE#=HJU_B7F?2W8_YI?D]B_EQA]C_`)I]L<GS
MV1QO)YN1B7,?DWQ\+5O-CBJY"48V+SNRD\6+W/:H+15W,[J.POW!AAF9I;FU
MB].P^0W*_3C>*4.K""OM_-1VBCK)*,@"748?+`X;[%#J'TZN1M7E=K*[6UII
ML2?Q_B^XFY^87_+0LV;L_ESR3X]KTJ7<F0KB=-*TP'%Z_'H=P.%><H`)@YP4
MXYQ7)[!^*%4!$C;I*"@$Z<C>:*XFW$!$PE]'AJU;CG>W#W96_=4WNI6CAK1*
MJ336AAV_S!_Y=DJ7/RYS7Z7JNY,E>JNG_P`0Z4K4Y=)X[<A4,LT3)69>3,-E
MN/QZWO"4!5(G"4)C%'WBXPZ$,+]]+1=JL3MZ=FU1_(A(1(QC=6VX%$,B-MN:
ME<D]JKT7FOF:ON7\S?RVO]F<AVGV'V=+A[_*W<;W\F]RU_/E&UC78WHV[5JY
MBV8*4KBUFY5<=--:WK(E,1),AQ`QRD*!A#P`1`/$0\`\-794KIT/"4I)4G+=
M+SI2OV)NGRJ;FH)&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
M@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@(\.`7]$/<#_\`*'YC_6PP=H#9S07J
M[D?$(O0DIOQ'YU!Y:P$%$^]RX@AT*@J()"F;?8W4(%V]/AJJ/U+YD/Z7\B)*
M/<Y#4[4W*^.R'=,5VMS68_C548%ECO../L]2-7A*[=Z&Q"'L-BHD4V+4XT9#
MSU(>NJO))O$MA4*W7,)US'W?/1MK)4K:FHRW/U0E;JVZZ*3UTI65$V^JZ'+]
MJN_^%G&_.U)QV12A=C=:2C2C<4MJK7;"K45T?4R@M:(ZDCX[9?WMEI_9;\[O
M[L_.N@/$R[EPKWA&#,BSLS5AVR+,]<(JIH(1+=9_RBK*;8X2)`,NF\D$8I8B
M@+?8TTD"G2`1\[:4Y)IP='\JE,HPEI<BI0H]&Z>#(_.+/)Q&P\<L\9(Y#\@<
M?UV.QMDI/'LO=>/MXRWDZGVR;7J!ESLLP,:W6)FP5F.81\(=(9:M`PA%FKA1
MPW<F<)D4UV_)X_XC)M8:MW':N0JTXPA-0;U]MN2U=>C>ZO6E3R[BI1L<??S_
M`,1:A>LY"HX3N3M2FE6EV,8MJ*\XQ<:=*T+_`'APHF/,7EPV:'1/&M^-';R/
M&>06Q@0&[^O\CI(Y@5N91NZI%5W1C$^.3'DDR"!%]CE$H<9?A;MW96K.[VXR
M:5:5HFTJT;5:=:-JO1GI>+.]/&A<O;?=E%-[:[=4NFY)TK7JD_-(J1S;%/[8
MW;O`[X[8X\[J\"30J*BA)0X<;.3!C-552&*1L1LD!G0&.!BF.@!`#J,40M&0
M7]Z`QZ%7/OO8PA7G3T>]92J+CHZ4R]/G=QB(4Z>E(I$B[=7H*`%#U!MH#(7T
M!'=W6OO$LN_TTX`_NCL2:`D1T`T!YZV0K6QU:RUY]$1U@93T#,PSR!F%E&T1
M-M92.<L7$1*N$6SQ9"-DDEQ17.5%4Q4CF$"&$.D9Q9RLWE=3<91FFFNJHZU7
M35=447H1NVI6Y)2C*#5'T=52CZZ/H]"RWC5AO.]0R+*7W,4)CRNM5J>\IE-I
MV)\MW%?%^+J4C822U;I=4PP?%U,J`2Z+,$R2UF6>KO7:S4`:H-&BHMD^AY//
MX^_C+&PI7)2WJ4I7+<?<N2I24I7/<E*E?I@DDD]6VJF@X[#Y#&ORR<Y6H1<'
M",;=R7MVXUK&,;7MPC7^]-MMM:**="DTA5\ENLZ0CR6P=:,+\<:':$(!1ZI<
M\$OXO*H/;(NYA7=J:S=^<NJ%BQC;Y,DBTB(:/7GIZ87;'75:BW*V4V./?Q[=
MAWL6_&[S4[3^F%U2MK;ZE&D*2N.":E*348Q3HG6JQL]7^0V<9S-EP[;MWXR:
MG*RXW;B:5N4]TZQ@I;=D4G.4G&M*;7)\FHF4R9-P*;<2@4^W7N/J]`"(^'K]
M&N+2FW%O^[)_K1U,:S2<8QC6KIXTCI^JISM25#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0$>'`'^B'N!_^4/S)^M?@[0&YEHJ9^YAPW(L!#(FXH\XBJE4`HIF
M3&[\/@.50#>R)!+ON`^&VBU>G44KH19V>QTF?[<7<,1H^`$^/,37LTTF`85B
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M6KDMEQ681G*:VSI#;MG'5NLFTFTGKT1[K@-)6&9Y-\DIBW)/4+7+</\`MDR=
MG1DF!(J11L+['V?'4TD_BTV<<G&O4Y%50%6Y6Z!43@)`3(`=(:C+C".7=C;_
M`,M7))?*KH;G`E<G@V9W:JZ[4'*JHZN*K545-?"B^167G`0ILF]N,XK)IF2Y
MZ09B)G!7K<";C#RA2%-$2)'3`Y"*"H/F&(7H(.PB;I*;',LD#T!CNM?WB*L_
MJD4K_P!8G"Z`R(M`1W=UK[Q++O\`33@#^Z.Q)H"1'0#0#0&R<VQP+XAN!?'T
MAXCMZ/H:42:EYZ$.BE&NM:Z?(@SO<-AG)]41O!,39%JKBS*4G-+>=)EK)UF2
MCY6(Y55RIO8)2L6&UK8_%U+KLUG:*!6GD-VJOV)$#)$UZAP'*\J^9CPLKMJB
MQKT4G9LQJEC3HM\8*YT:UW5;6O5L\O\`S)[8[0X3L27>=I9,N0?/8=B45?O2
M47<R[7\Q6YW7;IO;AMV;57TK1$X:8$74(L`ANF<Y0^C[7M"'P@.P;#KR]>FB
M6JI*K^U'IRV.?N-24H)Q7_74)'/T*QH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!H!
MH"/#@#_1#W`__*'YD_6OP=H#;S(HDCW)N'RRX@"*7$KG0HL(^@$B7/B"901W
M*<-@(`_C1^D.EJNE.M?WAO;67D1")W^@7CMQ<^2X]IME@8V-GL`.WEFM>3KE
MDF3N2\[DZL/F9V?Q_1<=52L5Z!BTT&[!E7(M&,%$XJ"910PJ&Z#GK%RP[*N.
M/TR248J*C1KR<FVWJW)U.7[;S(9TLBY%3<MT6YSN2N2FVG1UE&*2222453YO
M4RCM<^=01\=LO[VRT_LM^=W]V?G70'2@R16[LUG>E;('DVW;?J[)@[4+LLW1
MDN2MX5=MDU@(H=)!XXC&QE0`H]0H$$0'I#4QI55Z5(E7:]OU4(PL&\1I7+^"
M\Q8-Q5:./>2VL-SA5N&6[/7+KEFN1]>MU<K4HXLD<TND7C&G3"CUY+GC6ZIJ
M>\0!)D_=)$D$4P%%7J^1Y#(QLBUDPC*$WC[4II/TOH]JE+_PU\:,X_M[AN-S
M,#,PLRXI[<G<G9<E_-76+DX1IX:VVM&UN2T)+^*L%\E^<W-6M"@R;&K_`!Y[
M>T&=M&KRCJ.;FB*[R+CQ0CW,XZ>S3ADD#;I2.\66='(`"J<R@F,/*SG*<W.6
MLFV_O=?`ZZW"-J"MPTA%)+Y+1==3U'./^JAVW?V>\-_<M\I=4E9(/H#'=:_O
M$59_5(I7_K$X70&1%H".[NM"`<$LO"(@`!:<`B(CX``!R.Q)N(C\&@)$=`-`
M-`?!`!](`/TPU'B/CXD3EBQGRMD<OK3-,JN7J/39JSU]"FC)<CQM]5K(0.5`
MG+Y<LIXRE9I2$B:Y=L>)*L8.!A"V(B`J)&6)'N-C(^F6.1[=M\:H95W&NYL+
M<M[6-LN2W6=MNW9O1CN<H7&G<N3=JJJDYQT?C6=PW=F7S#N8^/EVN.NW[;MJ
MYF*]:@[>3[EV]D8\Y."C<M)JS;M*_M>UM6IZQEB`I2[`4I2@'H````#Z6VO,
MWI2GF>S5;ZFK4D#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0
M#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$>'`'^B'N!_P#E
M#\R?K7X.T!KRZF*W<MX<I%$"BKQ/YQI@8>O8HGNW#XH"/EG34V`1_&F*/P"&
MBT8>J+$N17$"V\3^WCS*;VW/5JSFM>GF$58=6S-K$B%*@*SEFI-XRLQKBT7S
M($J]9-$Y@R")C.D2D:-6Y!3,H5153:<GR-OD'!V[2M;$ZTIJW2KTC%>'WMFE
MX?BKO%JXKM^5YS:I6OI4:T2W2D]*T6O1+2M6Y^=:LW1'QVR_O;+3^RWYW?W9
M^==`<1G^^R6?QVW[=U%]'I#_`%RF0_\`!U*ZDJM2*=2VXRGN/&79+'L#9>WO
M3V/->TUZL42-I>3LP2F4RR>('Y'P2V#*L9FWQ9#Y)@17F'"4(J=@<&H/TUC.
MA*LKU^18R93C8E..1D2QE6;VI1]7]]ZRI6E71^'R\[MOC+F)=RI6[V';M9;]
MN$'<;G+96KMQ5(*2K*B].FZK;UD%X,14I#\J^441,2SB<EXKB=VTX^4FW2$H
MT=2\@SHN?V[V3<MIH?CINN^=)&5,F\_FH@GZ5?;`VN5SY>YDWY122DYT2Z*K
M?2FGRH=CQ]F<>-L6I2DYI0;;;J]$]:Z_"C*O<X_ZJ';=_9[PW]RWREUCP5(I
M?`V1(/JH&.ZU_>(JS^J12O\`UB<+H#(BT!85W,Y)>&X:Y!EFL:A,N8V_<<GR
M$2Z0.Y;22K;DOA]9-BX;I@91=%T8@$,0H")@'8-`7ZZ`:`:`:CQ!`9$QU/B,
MLQV,YG*<I'9=89*2D9+ET_RGFZ#.O#*YFD/=Z,7%5DFU*@UN%I:LQJYGATTJ
MF8CE8&BBJI4V1_3YXG(W,!YUO'4L!V=,=0LRU]I-SWQ];C&ON4UN*BW)*LCR
MF',<);Y)<;>S-G)J_1WY2OQZWG%0V37MJ4FO:4J^TVVHMND7/GKR]^'S/5AJ
MH#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#
M0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0#0$>'`'^B'N!_^4/S)^M?@[0'(RM^
M^:<,_P!BIS?_`$\\/=`</NP_O?W('_",:?KQX\U2HI`D3U4"/CME_>V6G]EO
MSN_NS\ZZ`ZOS11[K-Q6*8Q#)=N6F*$,1+SS@8G)#(IBB1#K3\\W4'@3J#J'P
MW#?1)MJA#3:TK4BH;\#;1=.&T!A9#%N>\ER2_(].TP3CDY0HNFM:@K-8EM<!
M5YB?Q1#9JGF3["=>GI=)@\]S>1TC7DG2;LL;)F9&1<=H^2A'D'D^[:MQ]FC]
MJ3=:23:4W#2;2JJIJ5&JQK5>=K@[MWB(X;M7[LOQ%5[T5':W;DHN4%<?\M-T
M=&G'KMEMHY'^$U54HO+KE=2%XD8!:F\5^VU55H(9OY2C"JUZE<@8D\2-C]RC
M?E`,:=F*/OWN[?WOH\WRR=72''Y,]]^=VNY2FW6E*U?6GA7RKH=[AVG8Q;5J
MFUPMQC2M:4BE2NE:4I6BKU*F<X_ZJ';=_9[PW]RWREU;,@D'T!CNM?WB*L_J
MD4K_`-8G"Z`R(M`64]PEJF^XMV)FL)P2=96XPMU!)Y?6!%>4.&R&$GFIJI=7
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MQ``$P"D)!WW$2@!]R;&O'?<HXB/T$R&:Q/%'FH=\<RZ"9DBOL@\/FK7RT55"
M+.1.L`@()%.)`\3;!XZ`Z7NP_O?W('_",:?KQX]T!(GH"/CME_>V6G]EOSN_
MNS\ZZ`ZDR"CKNL6]NBY,S65[=%)(D[(DBN=JJ;DGD/RG!$7!%$%#(G`#`4Y1
M*(AXAMJJ#2DFU5>13.4HQ;BZ2IUZT.@YU<;<[<@>-EWQNGDQV5Z[LX6$[3%[
M-I3#354JYY29JU%L#2>L:*UN^4LBDP;S:);)5FK@"`=-=JD4R9]OB\GCX.0L
MBQC[E&+KNDFZOJX^FB:72J9I<_B\OD>.GB9F9*&^2VN,725'I"2W5<6^J33=
M-'X&YQ+:?%_-WF?'C&(0HQ_'/MX,AAFB2*+6)%I6>1*`Q;9%O,V)!%"/,F*)
M"$D'Q"@38'"P!YAM/<DYMW)=9-O7KYZO3]AN;</;A&VND4ETHM%31-NB^%7\
MV>QYQ_U4.V[^SWAO[EOE+JE="LD'U(,=UK^\15G]4BE?^L3A=`9$6@+,N?OW
MLLS^J[Q<_NI,,Z`O-T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T
M`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T
M`T!93PL^MY8?LUL]?XK6=`<:^^[_`+HEQE\UPDDO]R;R_P#=4#K,R*.A^V?Q
M`\\$$G!@=KB@GL8WNX")0\3[%T!Y7NJ-O?.!>=F?F%1]Z/BQMYQBB8J7GYHQ
MTEYAB@)1,4G5N(;AOMH"0G0$?';+^]LM/[+?G=_=GYUT!PV@"/=CLX`&_P#X
MNVC!MX`/CR4R'\.I3HR'&,TXRZ,N=S3A5IER(`@2TE"V"':/S5AP9_*.JF,J
MNDB=J:YTIK)Q\1=X#WE`I73!YN5PWZTNL@*".L["SGBRG"45*S<BU+15H_)O
MH_B:WD\*_EV;<<2Y[638DIVY>"FNC:\5YHM"XK0KNN<Z^<$`^&,4>PV`^W[&
M.U8.(;U^&7=LX'D8B\7B8%LHHVA8]P[*H=)J0QB-RF`@&$"@(XMV4)7&X5V5
MTJ9UO\3[*_%R5W(IJUI5TIXTZ]?MH>LYQ_U4.V[^SWAO[EOE+JT7%T)!]"3'
M63%R'8BJ?NR:"F^4:&5QYZJB70T'N+P@.5$?+16\URFEN*9#=!3F\!,4/'0&
M13H"R/N&N3->,3\Y5`2*?-O$U!8YFR[DOD+\KL*I+`<40$&I#)F$!74V10^O
M.(%`1T!>YH!H!H#:.LBD=%-15)-1P<4FY#J$(==0J9UC)HE,("J<J*1C"!=Q
M`I1'T`.@-W0&CS4^H2>83K*43&)UEZBE#IW,)=]P*'4'C]$-`<1K)QKY5P@Q
MD&+Q9IY7O2+5VW<*MO/+UH^\)HJ'.CYQ`W+U`'4'B&@-+V7BHU(B\C)Q[!!0
M3%36>O6S5(XD\#@11=5,AA*/IV'PT!URENJB1S)*V>O)*$'8Z:DU&D.0=@'8
MQ#.0,4=AW\=`:/EE4/T55O\`-R,_+6@'RRJ'Z*JW^;D9^6M`/EE4/T55O\W(
MS\M:`?+*H?HJK?YN1GY:T`^650_156_S<C/RUH!\LJA^BJM_FY&?EK0#Y95#
M]%5;_-R,_+6@'RRJ'Z*JW^;D9^6M`/EE4/T55O\`-R,_+6@'RRJ'Z*JW^;D9
M^6M`/EE4/T55O\W(S\M:`?+*H?HJK?YN1GY:T`^650_156_S<C/RUH!\LJA^
MBJM_FY&?EK0#Y95#]%5;_-R,_+6@'RRJ'Z*JW^;D9^6M`/EE4/T55O\`-R,_
M+6@'RRJ'Z*JW^;D9^6M`/EE4/T55O\W(S\M:`?+*H?HJK?YN1GY:T`^650_1
M56_S<C/RUH!\LJA^BJM_FY&?EK0#Y95#]%5;_-R,_+6@'RRJ'Z*JW^;D9^6M
M`/EE4/T55O\`-R,_+6@'RRJ'Z*JW^;D9^6M`/EE4/T55O\W(S\M:`?+*H?HJ
MK?YN1GY:T`^650_156_S<C/RUH!\LJA^BJM_FY&?EK0#Y95#]%5;_-R,_+6@
M'RRJ'Z*JW^;D9^6M`/EE4/T55O\`-R,_+6@'RRJ'Z*JW^;D9^6M`/EE4/T55
MO\W(S\M:`?+*H?HJK?YN1GY:T`^650_156_S<C/RUH!\LJA^BJM_FY&?EK0#
MY95#]%5;_-R,_+6@'RRJ'Z*JW^;D9^6M`/EE4/T55O\`-R,_+6@'RRJ'Z*JW
M^;D9^6M`/EE4/T55O\W(S\M:`?+*H?HJK?YN1GY:T!',\XUYDK=ZRO/X.[B@
M8EI65,E3V5%\?/,+8)R(E7K+:6D6E84HVT6(S>;=1CQ[&>\))..LZ`JF(!Q*
M!=@/!R?$?DE+Y2J&99#NEMW%^HE*O./ZO(FXR\;!:1U:R/+T><MR)69E#;OI
M%_CF)Z5P.4Z22)TR^RLIN!N9/XD\CLS4B7QSD;NE?&M1FUX1Z_81W&_C9&.%
MGU9GXNUP!SN3@^(=FWL$&U4<("F(.FY#HB8H*"8`/?\`VFN8W\*VQ_M7N-WY
M;T!X#&?$?D3ARK&IF.>Z&E"P#BSWV[OFSOC=QODEG5NR??++DF[R@.3&;JD0
ME+9:WBR2!_,%NF8J13B0I0*!PT^'G(A+,+W/9.Z0/VT7V-8S$*\Q]SGQV&,&
M@Q5HE[FUC`@Q<"U*_"Q3*RHNP,"@ICY8@(`42@5+^TUS&_A6V/\`:O<;ORWH
M"FE>X?<C:OE#).8H;NEE0ON6H/'E=O$BKQPX[KLI"*Q:2V)TQ)G&'=^[1RK$
MMVD`643]IQYA.O\`(RZ`9!X?<C\GS&*YVX=T[WR0PQD9+*]!,TXW\<V*+&[(
M4ZXT)%_()).!&4:)UJ^2:8-CF!(552*B`G2((`5+^TUS&_A6V/\`:O<;ORWH
M"W3EKC2K<7NU/'X!K.1&N3_DADSC9&R5DEGM9BYVR&M?-'&%HM<RG$P:R$='
MKB^GW*C=NW26*@D4I>A7I$1`G!T!9'W#[?'TWBQ:G<EA;'W(1&Q7S"&.V^)<
MJN4V>/+-*Y0S7C_'D&XM;Q2OVKW.,KLU9F\F*I8]THD=F4Q""<"Z`C[#AQG,
M!`/W*[M0;`(>(YFNW5ZM_`>(H^@=]O'Q#X-`;OW'6<?7VL.U'_7CN8_[D8-`
M??N.LX?P6':C_KQW/]J/H#94X9YK5.BHIVJNTZJ=N<RJ"BN7[@=1NJ9,Z1E$
M#&XB&,DH9)0Q!,40$2F$/0(AH#Y]QQG7^"M[3W]>>[?M0]`<5QPRSR8#&;=J
MSM)D7.9(@J.,OW@^[<1*#DIC)<1TU#&,0H`0-^G<`W]&@*-43"=\M&8\V8:K
M_:,[5<5;<+L<8/KO+FR?/,8B<3R?!3<U5B0S]CQ04DY`\:R@EDW0.T$`0,8A
M414*(B4"ISGA!G61=*)RW:<[/DG#)H];-H[RG=73A-\?K!4RA7G$1=E[L8O2
M/LI@<3;[^H=`42N?%K+-,M6'Z18.T%V:7EIS7?9VGUI^QNUK<Q+92L8TN&39
M49T[OBBWDTA7@:*\2052!T4'*B)3I@4QU"U1:_BZ$5I*+^_].GWG:!P@Y`+O
MY6#8=K'L*K6:&%N_F(8UYO+A[&0,B18\2ZDHU+BR9_&&=F05Z%52%07*0>CZ
MP=0XWMN_;Z6Z1=-'YZ^?3H16"EL;]"U>NM/[/MH4Q+@+*BN7<;8:8]I?L>6*
M:R9CW)>18>R5F[623IZ,7BV2Q?%SC-W)H<8#O$Y-\ME5@LS22;KIJ-B*&443
MV("DWK>3CR5J[;E"Z^NY-)?"CUUUI\GY%JSDV,FV[N%<M7(+I22E7I7556E5
M]Z.=F/C?D#C]2FM\S5VX?F_.)ZVO/(5]2U7S(.1(:MJR4F5PK"0S%0>*!UEI
MEVBS7.)0V`2)',``4IA#,X[CN5Y>^\3C+#O7XPE-QA'<]L564FDEHO&KT,/D
M.6XK@L;\=SN3:Q\9R4=TGLCNE],:R;U='2B\/@4HHU:1R=#O+'CO@O\`-V+5
M7&3:==KS;"[9:",21JD,]G[24S]UP^;-%'<%"1KAZX;IG.X(S1,L).@!'5N_
M@9]B,93M_52G36O2E*UKX="O`YCA>1C*[BWU<A&NL956FK3JDM%J^NGP.7&T
MB0FH"K6J$[?GS?>Q5JZQ$=.UB=J\QG&RQ4G'2SN5CX]07L#PTD$(YPO(P3QL
M+=X+=RFX;'3.F4X=.LFQP7,Y,Y6\.PW<C7>I-1I2C=-S71-/3P=3#R^Y.W\&
MTLGD<E1L3:V."G.M6TJ[$Z-M-=.J:+ES\`N60"'E]I7L-B&WCUV/)8"`_`&W
M%`VX;:UKC!);6VVM:^?PU>GW?(WFGAH:_N`^5OK[2W8>_P`\62/VJ0:@&L.`
M7*KU]I;L0[_0L.1_VJ>@-I3@'RP#;RNTKV'#>GJ\RQY)+\&VW3Q0-H#4;@#R
MO*J8H=IGL-J(@(@54M@R60QPV\!\LW%$>GZN@`\`^5OJ[2W8>_!L62`_W*(Z
M`U&X`\K"J*%+VF>P\HF4Y@34"?R23S"@80*<4S<4Q$G67QVW';T:`[A'MZ\E
M%$BG5[6?8B;JBS27,C[UDY<"/#N'*:K`%2\74P,"+=))7SM@*;SNCI`2")@.
MS8=NGD&Y3;G?=LWL1QBBB*YW"(,LJ2'NRZ;@Z:"!54^-;8K@CAN!51.`$\L3
M"3I,(=0@<HO;DSO[ZDB?ML=B?W([-599\2'RJ)T'I%4"I,BLS<<RF626244/
MY_F%Z13Z1)[0"%BN3Y0^]_V%N:N>Y_+I[7QK7^P^H=N3.JGO7G]M?L4MA2=G
M1:?XTY47!XT*"0D>G$G'(@LSG$YP\D04$.CZ_P!KPO1W;?73=\.A>]/A6@9]
MN7.JQWH.^VOV*F1$'AT61R1&4WOO[,J2)R/CD#CFW%B<ZISD\D15$O1U=8@8
M`"2'3P*-V#BGDZO<AL9\<W/;$[(SBQ91QAE?*D/9F\)D4(",A\13F,*_-QDH
MV5X_DE!E)5[E5D9GY)%$?*;+BJ<AO+*<05N#MP9K$@"/;C[%95!(`BG\GLJF
M*"G3N)/,^YY`1*!O#JZ?1X[>K0&TEVXLXF2`ZW;=[%*2PJF(*)8/*JI2I`N*
M8+`O]SJGU"9N`*='0&PCT;_CM`<H.V]F;PW[='8P^B`5K*@A^!OQ_P!M`#=M
M[,V_L]N;L7B'KZJSE0!^H''T=`;9>V_FL0W-VY.Q60VYO`*[E50-@,(%'J^Y
MZ3'<Q=A]'@([>/IT!MJ]N'-Q"`*/;@[%:YQ41*)#5_*J``F=9,BRO6/'E7<4
M$3&4`NWV02].Y=^H`.27MO9E_'=N;L8!X^'36<ICX?@\?@\=`<)YVX\YHI%.
MR[;78J>JBY:IF14A<J,RD;+.4DG3KSAXZN>HS)L<RP)]("KT=`&*)@$`.8';
M>S-T^/;G[%_5X^BLY3Z?H>(\?M]`;?[F_FKJV_<Y.Q9T=("!_D[E7J$^X@)?
M+^YYV`H%V'JZO$1VV]>@-0=M[-'K[<W8N#Z(5K*N_P#<^AH#6';>S)Z^W/V,
M1'^EG*@_ACQ_$=`42R%Q.R5CO*>`L32';+[(LE.<A+)?*W6Y)C7LD$BX!7'V
M-[#DN6?3H.,`D=*MW<97CM4"MRG4]Y73$P`F!SE`K5^YO9H_@YNQ;_G:RK^U
M\T`_<W\T?P<O8M_SM95_:^:`?N;^:/X.7L6_YVLJ_M?-`;1.W#FXQU@/VX.Q
M6FF10I4#A7\JJ&<)BBD<RAB?<\D]W$JQC$`NY]P)U;AU;`!K/VW\U@413[<G
M8K,8/04]=RL0H_0$X<>E!+X?QHZ`?N;^:NK;]SD[%?1T[]7R=RKU=>_UO1]S
MUMT]/COU;[^&WKT!K#MO9G]?;G[&`?0+6LJ[?W/X:`V7';AS<1,QFW;@[%CE
M0"F$$U8+*S8#&`HB4H*?<[NMNLP;;[>&^_CZ-`:Q[;^:NLH!VX^Q8)!*83'^
M3F5`$I@$@$*!/N>QZ@.`F$1Z@Z>D/`=_`#JHCMUY_>)N#2_;*[%$&HFX43;I
M)-,HS(.6Y3G*1R95/C9'@W%4@`;RQ`XEZMA'P\0-3GMTY_2()FW;.[$KP_O)
M4@3%EE1H/NPJF(9V)S<:ER@8B0`?R@W$=^GJ\-Q`U&[=.>P<Q:1>V?V*3MG:
M;DTH[]PRD48A5)$AVR*;8>-W5*@[6,*8G*9#R@+U"!M]M`4QR-POY`XRQE?<
MH6#M5]C!>+QW4+;=YN)BE<D.Y1W"4^L.[,^+%G<<9F+)61=E8JMD4E3I$\P"
MG,H4AO`!C7A9R"RE1\?9#A>U9V,(^KY&QY6\A11Y13)1)>.0M==;6*)A9*.9
M\:%T??01>HI+K).5$4SF,)?,*7VJHJ#JKE=K3Z=:_J_;4IENTVTK4]3'=O?E
M`X$H2':J[#\847D>@82R>4)$P,W"BI9!^`$XN-@,:,3(4P([@9QU[`8G2(C0
MU11C#5+K7]'^MLI:FY.6E'\7_P!'W)'<&[=G(KW:05+VPNQ)[RV:BM'MA)E/
MHE'0+/2`S,Y^YF`(T!1;HG\TQ%0W<=/3]C$37*6Z4K+]/M_>5UE6M%3]/@<1
M3MY\E"Q35TGVM^Q"K**H+'=1(KY0339KI@J**!9,>,"B;LKCH)[8)$Z!/X@/
M3N-%*:+5$]?@>,MW"/DO2Z9;+K+=IOL4N&=0K<E9WK"/E\BJ/7;*&C'LK*MV
M9G'%MNV!V@W9;)`H<A%CG`!,0`$=`<3%G#O/&7\28\S!5>U7V,4H/)V/Z;D>
MKQ<JODEM)#"7>`CK)$MY%1#C"Y:M'R4;)I^<!15("@"4IA#8P@>G^X"Y5>C]
MR7[$'T_E#D?8/H_>I;^&@"G`'E64YRI]IGL/JD*<Q2*?'^24_,(!A`I^@>*9
MA)UE\=A$=O1H#9-P#Y9?C.TKV&Q'?\=8\E!X?@<4!\=`:/N`^6W\$IV&/\\N
M2_VIV@*<9.PSG7B-&4W.F3^U#V8(NH5[,N"ZVYF<12609C)$!+9&S%1\=5JQ
M5&-><98)NYEJ_8;2V>$W=(F("(G((F*!1`RCOLVWUYOYUV]7Y-OMU^CZ[\+Z
M&@+$^Y043<98\"AN(<F>%!@_YGF)@PPC^``;Z`OQ'TC],?Q=`4:Y!YMKO'##
M5]SA;:UD&WUG'44WFYROXLJ+V^7QY&JRC"-<KP-2C3IOID8PC_WIR1(>I-F@
MJIL/1L(KMP]R:A5*OBW1?>4FXH<]^'O.&$>3?%K/M#RR>*;`\GJW%/UXN^5A
ML:1>Q)'%HQ]86T3=*ZW6D(]9-)5VQ227Z0,F8Y3%,(I:<6XOJB[W0@:`?4^J
M&_AMOX>GPWT!'_@`1'GUW#@W\`KO#+8-_1OCK(_U-]1X@OV?.5&;%X[19.Y)
M9JT<.4HY@+4'T@H@B=5-BR%\Y9,@=NS$!-/SEDDNLP=9REW,$D2=(MI-M+HN
MK^^B(T_M\0W(S)W!*^05,O-&;Q/*KD!2)&!O[>L(S;:<J7$_D'%S@`I4+1;X
M%RV92WFLE!2>G.D];+H*%(HD8H526RBDM9=/[?M6J^#1AX&;;S[+O1A.#4Y1
MI+;6L71_3*2\UUZU3U*"<CZWC!CS0Y5W:Y^]W&?+VZ+\52GL(JW5>TLL<-8:
M80L,16LM*T(U&JD79EC.-G8SCERG)*["S$4@VWW&=QXUJS:[?AOM9D<JWD.]
M23A!1=%)QILG).C46ZTB_!LT7*<!R'+\C<FHV+V#/!NXZL)[<B[.^J;5/K;@
MTG'?%/U2C5:*M"NW[2DZSR[XZ61M!58\5DGB_P`D+M6<FTR4NWR>RK4+(3A+
M:H>:2J=V*V=U:7B75C<LWQF[5FV>+IF,FW;$3*W2V/>?,PYN]AY2O;DL904)
M*&^.QS6LH44JI*2K62C*-6WJ]#^7W:LNR_QW"7L>=G)>4YSE*4Y*Y)VK,KCC
M&=-FVY*4)**47.+HHKTJ0_NDY]D^,G%*3S1$8_P]D9[4+M5EDX?-B,.[K#$7
M*<J@64AX^7LM34D;@=42LF"3)Y[_`+O#G11<=!D%.9PHYT[WM\?*4;\HM>ER
M58^*;CX/XZ>9WF:^)C8]SFE!X477U*,DI?PM;]*UZ-:^1"8/.##=ML/(3$V5
M.`>-824I>4:+5*SCJJ<;<JY$JM&J=DF)=UD')&>7N!2WHT+-O(MFH$8T4JM?
ME7+F113ZG;'WIPE3<O9=AP6VZFGHZZ4\'%TZ+RZ&%'C.'BY_[O:CCNTI/;"E
M7)5=5'QJ]=-U*ES>(>5SUO3^8TOA["?#FUV?B)+8]QUQ^H6#'4[6DJM&6'D#
MFG&:6*<X_&]JB(N"RC&P%/\`E,9-NE'IIA.@90!44]KH^&_I?(Y.+#N/D9X_
M%Y&3=A>E3?.W*,([)4HZ[YN-NG71T5$C3]R9-[B<3,Q^S<&%[D,+#QIVXW*6
M[<O<G)7(UBX[5",9SCYU3;K*AY#('>FSPQO5>>5B(XO8XP5DC+*E?Q59<S/'
M+*Z/L-%I^.IMCE2XQ\YG;$\)`-9:8MDDV*BFJN]0"'7+[FJ)`.KJN8X7D.`R
MYXW*VI1MITA.+K"XTEN<6TDTI/:O/KXT6UXON?MSG\?%N]NY*RI3H\B*23QX
MR6Z*EZFZN'JJU15I1TJ]S`O>DY%7MDPF):G\5\ZQTEC.1R++LN,$QD][.8KL
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M'=<QQD[A/:>0F(<B8`NF5*@-?4NU;0M,DZJ6(:Q;\T#C6*RGEN&A74I=ZSCZ
MO5(QK)(G7]V%1BT7,59!+[*G=6'BWL]XN-=7L;&XR?C2#E3PU<EM7QH8_(W;
M6*W+'C.=I.*2?6C:3;HND6VWIT18^\[U&96><,?XQ1N?"">H<O58^9F\UUTE
MU:8_M[I[F/,N.%76/G>2<S8RE5H1I'XV9AYT.SNB+B0<JBV770.U,MB6[?NY
M?X6W"XVXJG2N[Q71Z5\.J74R,R7%XO`6^3>5;6=^(E&[!_3"RE%QN5K_`!-R
M56UK'2+/:T#N<]Q+.<E5*]1L$<=\)6E&W\6L5Y(@\ZP^5K%[K=N0^,K[D@]V
MI$C2KM!LIO&*<75F"T:!C'=JDE!165*LV4ZM[G]O7,+'MWU.,U.-V6C6BM2C
M!I^*DI.C3\M"C@LCCNX[=Y<7[TLC#3NY*DE!?A_2[=RU6NYW(R4E5T5=>A;E
M1>^+S8OF.GJM4Q=QNR#F]7*/R,C,68RJ]AMDZG6JW4L_V:]V(E,:<FCWF2,T
M^TZU*E\9-JS[NF]/LF\7,@@?38N)=N5]^+2C+U-=$JI+6CI5LN=V7N)P<_\`
M#]L7)W\6Y%1LRO4W3NJ+E=C2.W2%/"OG5UH7U9L[HF6\>T[A79(Q?BW59SD1
MQGIF<[%1LAR5YE;#D>[V6>P_!+X4XWEJ,Z0\M:SK9">BV.Y1E3`*"`G2\OSE
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M:W:J2,A\!W`!W`=P`=P]`@(;@(;"(;#]/7+G?GW0$>N33@'="X@$$/$_#KFV
M(&\?`$\F\-^H/H_7AJ/$#./,G.>+):;84/A!E_.S:(EI.,]XHKN=CW!"1K9L
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M<HQ>Z*;2?G\?M-^JT6Y4E3YG>;#\`_4U02-A^`?J:`;#\`_4T`V'X!^IH!L/
MP#]30#8?@'ZF@&P_`/U-`-A^`=`-A^`?J:`L'Y*@4>9?;8$0`3!DGDMT"(>(
M"/%O(0#L/J\-0WJBEUW+R+K,DY`>4NJVB8K56DK_`&:N(PJQ:9#HRYI%^2:E
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M.?@Y3`D4:ID$S)-!LZ>G)%G65`5WC=$Q%34V^(XV49JYF*-R$)2Z6FG2FU)^
M_JW75).2\(R=4J%SG<*S+=NYQUI8%R]""N*]?E**DVIRE#\&E%1HJ.4U!_Q3
M@J-U)XR9=R-G#%3"_P"4<!W#C9:7\I)-!Q=>Y5I,V9A&M#(@PEI!W'L6+)+X
MX*<RB:!0.HBF!06$BWF(IZOD<7'P\EV,:_'(M)+UQ5%7Q6K?3_HTU?0<=EWL
MVP[M^Q/'FIR6V?5I/27REU7PZZZ*X/8?@'X-8)GC8?@'ZF@&P_`/U-`-A^`?
MJ:`;#\`_4'0#8?@'ZF@&P_`/P_@?#H"WGET3KXG\GR"`['X[YK+Z_'JQK9@_
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MU">>0Z%[R.8&CTX,X]%9FQ.XV7%--$2[GC\G@[O;%_`R^&OW.0LQO7(Y5MRK
M&5QPA95Y;5_*MO>M94<]JVU;,;D%RF+W)CY5GFL:WB9$[5MXMW8M\;<93O>S
MZG6[..V5%%.,-SW42)"W-@@6:0+/)R&:(F*J<JKF48H)&(@L9NL8%%5RE$J+
M@HD,.^Q3@)1\?#7`N,H_4FCT&V_=UM>KY:_#P^)37/ZB:F`,VJI'(JDIAS)2
MB:A#%.FHF>DS1B'(<HB4Y#E'<!`=A#4,4HZ/J=5Q<3*EQEXYI$WZ$\#X@3)U
M#U&Z28]KQ2[F'Q,.P>GUZ(%=M`-`-`-`1D]W:*?SO#%2'B@,:2DN37"!FP(5
MZ,<8[M?F3@Q-`"O`_(3@H8!`?6(;:`D^T!8GW&4@6XVL""(E#[I#AJ?<-A'=
M+EQA14`\?482;#]#0%\H^D?IC^+H#YH##I[EF%.!$?WM:6]Y17&)X;8Y-P-D
M,DL\U8ROKCCE;'F;&64IJ,JMZ:6ZIC'K6;($$U;*)L4%$7HNP9D(L@X(@4@5
M*-55&+*]=6;#&45[4H-U\:I]*=->I=-V\.0?<2G.0^.Z+@V\9KYU]N!VY73M
MG)OF;@(>/&3J-7&J$M#QJ&,\DR<C3YODHJ22CD'#F0<591==-8I15)UG6)5M
M@H-R?K+KE<5W:EZ/'P_Z3)PU;+I$Y@@MT/W5N8#X]*RH3&RN-JG&1]\GL7Q;
M/&);S'PN+U9RNTS*:,HYE7;AY#N&;E=@HW23<.45S&`ONJ1EM_DYCN<!8P_=
MB]EQO8FZI/=1M4H]6]:MI/XG+6>+A;[ON\NH2W7,-6]VQ-:2BVE.M8UHJQI2
M6U-ZQ17/`R!"<[>?RP?7+P'#T#__`'K'V0RE_"-KGSJ2W[%_+.1R7<>XMCZ?
ML+RPQG&ZC7`#P]L#&LU64FR]CSHU\MVSID(63,@VC:<5DLPDR.UC1R+<5A4<
M++`'9\U/AKW#\?=P,.SBY<FU=<+E^<IN%NS'=)7).,=\E.Y2W1*4Y15(QBCA
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MV]?MR]S*S,>'N0:WQC.;A)1BUZY/<FDY)1IT=:K'[J=C@<"[WSC_`(>-WCN/
MR[E^%QR_G^W"-RU6:H[4+:A-2V*<IJ=:PVTE1GM_8XP%BSEWQP@\+,90DC8N
M._-"P7J:FJ%D2BR5AL4/?.(5.FGJK>_6^ZI/`8V.&>-%?BMVC'(O$5TTFR/2
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M`XZ\WW'TJ6$15.-/'+'>4KAD.O2%JO\`!VF*G<=PT`]L-85LUGF*\H_A+E;+
M-%59&43(L0BJSI\#0Q$2I@<-9?#_`/#<,EW><=^YB0C*EJ#VRG+;+;Z]K4?7
MM;5.B:K6AJ^Z7W`K%RUVBK,LJ>5&-NYD*D86-T=T[D8RK*2AN2C!_4TZ43-V
M;?=P"U\E"5V1XL\:&O&*K9#9/*UE)[9XFT9"LE"6)%MW`+4Z8,Q4H=@;13]^
M151L5V<SELD1,H(**":G"M]O3XV_/D[N0^32:LPBJPK1-2D]7]553336I'<?
M]>Q^0XR/:4+$^-G&+SY7?1.+]R<96[*3I*/M;)J;UW5A2FI:G`7GOG,U[>I`
M\.^(-9:/;G9G<$O-VFLP4^[@(VQ-8^I/IIK2\E66+=34M0(HZ"RIG)3).9+P
MZ$6I$U<_B[/9CO17,WLOV::NVEIZ7_>CX2=?E&GCIJ^:R>^X1IV[8PFG72]*
M2HJIT],O55+X*KK_``ZS-8>:W!/&-)^V56*O5LA*5YN>YP53!FK`,9]V4JDN
MDQ4:%%J)':Y047(D=5$%A$I5%2E*H;F\]8<<R['CG)X'N/9NZ[:Z5Z>'C1/S
M2Z'3X$L^>%:GRNW^H^VO<VNJW4UI\/A5I=$VE4]TV@X1DDY19PT2T1>I>2\1
M;1K-ND[1Z#I^2Z321(1PET*&#I.`AL80]>L0S#;/7H!06@J04,<6"946(GBV
M)A9)%.*A4F@F0'W9,IQ$P%)T@`COZ=2FUJNHHGU.R]V;;@;W=#J`4C`/DI;@
M9`!!`P#T[@9$!V(/XT/1MI5A:=#@M8.$9+*.&4-$M%U1,*J[6-9MUE!,!RF%
M11)$ASB8JA@'<1W`P_".E6&DW5]4;BD3%*G9**Q<<JI&]/Q<HHQ:G.PZ!()/
M<CF2$S3H%,HAY?3MTAMZ`U`JS?!DR*=%0K-H51OYGNZA6R(';^:(BKY!@)U)
M>:)AZNG;?<=]*LG=*C571]3C.8:'>`D#R)BW8(*JKH@YCVBX(KN%/.772!5$
MX)K+J^T<P;&,;Q$1'4MMNKZE*C%:))*M?M?4[+4$C0$6UZ;G<]YOC>L9Z=-*
M-[=7*95-B9%^LDY5?\@.-+=55-1!)1@Q5230+U&7,D*Q=BD$PE$`C^+[`6IS
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M]_%M0EE87L8\XQBG9DW;?O0FEOC<CLI5UW;I5>NOKTL`]UJ`=)S=$^+82LML
MVTK-4!A>Q<B9NY_$Q*EB6`Q2.)IS)4R_4FK%BN8LPJ6Z0:J&55='CA3$!=.A
M./HU[E^Q;^-?]^Y"?(7./G9C<6(K:C<G<E>]SVX145<C16%*/13JO1&B^>,?
MAOS$P<ZW#&M?_L:WR4+VQYL[DW:A;A8]MW+DG*4):WW"5:N%))SE4I1(\&.[
MW0L<W&@5'E!9LLW7&50RX_QIF"7R6G2H+D4XY0N::YR?BB^8Z>/YV<H$A@V<
M;RLMCZV(3:(L@2;L`;)-UE1)YGP^;C<?R-C)RK?O8MN\IR@XQDI*+K&+W=4^
MDD_2X^;Z>F\WQV7R'&Y.)ASN6<FY8E"$XS<6G<5)M4:<7%TE&75/I3QNQY>\
M=>X3?+[?7F";:M%4:U5?`4@1%MF:<JTZ2X<;)D,E(5Z#*E(M8ZK06?9V3=U>
MT.$TUCJQ[=NX4`Y"F3/MN.S>"Y3B)<3SL)8-_'S7<LW[4(W'>M7HVU<C=26Y
M*S*-;<:NJWTUDJ48#[@[9[S_`.(..M6>3XC)XUV+V/DS:C:NPC=4+MF+;AOF
MKOJDTGNC!U]-2U9[PT[S\=DEQ:(?DJRE4YFRY;Y>5]^YO*T;7,:YBO5`-6HS
M@]/X^7<S,=?<!Q1T446%@3.1%FZ$\@1B@N!O/YW+P\&Y"5ZUDS_$6+J]J.UQ
MC=CJG*XUTC37:ZRK1':6.;]I3XRUQ]N&#FXRA>OSE&[>L234E*S&6BN-JC::
MC2O7H>DEN.'>$DVL_D*1NTC*,,RT:CXUN_%J+Y`EJ$UAVJ8$N=/EJ_.TGD-%
MJJFG\F\F*&RM,9;I..:UOW:3L;98JA4&1#([.S=XV4)0R9[90K*#C:3WRFM8
MRK2D8NC5:JB=%5G,+$S)9ENU[CC@3:C.;;<X1@UMDHK23FMV]+;+54>A2"R<
M0^Z\_88*^,Z];YJ.J-#RHA*U+'_+'(-)=1%@F<MV>1Q>PMTU,\MW+"RVJMTF
M54<N[.",_P"<D\1CO=!!H15/`Q_P\[L5D3V6G+U-1K1>:5-?EY_`VN-:OX=V
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M9N%RXX>U&5NY!K<H_P`VL)1JI42ET9=+#X8Y2<6L/<'?M28TR5R>OF/BSS_D
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M.0A%AY<]MT7@(B\)?^1/O!D#'.B#D>+U]*X%`RI2*&2,H)ND3`!A+Z0`=:U1
MBTVW1KI\?T1E3;5R"2JFW]FAP^=.'<O\@,%YUQ#@>WNJ#D^YDPDQA[C'6.>J
M+^`@X_*]0F[V]1FZS-5R<!0*-'R)?=FT@Q4?E'W3WA(%A.7XA_*B>+<_Y]OS
M3E<]OW[/:G:T4]CW)2CFS<6Z>M3<8KJ]OPU.WLSQK/"8,\ZKQ'<RM$JO=LI%
MT>GU..O5)5(X8KA=S\JF*)W'5S?Y#SK6JGD)NVDZI4.6UYPQ-\B<;*99Y&7>
M*6J&1)7(%JON&@K2.1J>I(1[^>,\E65>5C1?J(`D"GW/>CBXJA/"D[DI14VO
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MR';=^Y"3NW([KD%2$90A97I4523JGNEII5LN`XU<9>X94,@YHL6;,J2=KQ[D
M/$/+%UBZBN\GO)6=P[DW,.<C6BG4)S--W2<=9*]!41FS/`2X!YU?%9ZQ**2'
MNY`OPO\`;F%@V<:Q*>1E1SK5RY<G;2W6E"LH1751C-RBT]9I1EYFEY&_W#FW
M,BTK6+;XW\'.%I6VXW97HN4+<YRHE'?;I)M.L9/755+7YKA%WDLHLFN*)?E@
MCA6MK\?,68S=YVK%JD[/:X^W\=YDMFKUC9UEO9(EVG9.05E?(FM,\50[UO%P
MYF9RN".Q+K;=Q\QVM>V3[>M1M0_&W+\XRM)RVWM'9BW';[5J*VP3?66Y).K.
M,[3XOO/&R+G_`!*_<A_3[=BU2])P4[-&KLZ2WNY=DVY32W4C23=4>OGN+O=R
M>WFNW&H9;E:='Y]LMO<Y[JUBS!%9&C^+%OG\0/L0L\K8(;)LJ2RNF-V[6RGF
MTJ*Z`%(^<@&:Z+HYEE%0YN]D<?APRN.Q)V\G&N1I;ONULG&DXW*)2JTZQV[J
MUVN47Z70Z_BHY^7;Q^2YK'NXV="Y6>/"_&Y;=8N#<KBVUC23>U)M-)K55*2V
M3AWW@*T&-\=L;2^SG+XJE:E2\1<DY_DE<ZG3(W'5#EK:M.W7/.%(')U`L5JR
M1F"J62-8@_27MSJ&=U\!*!".?/#7Y5W%A;MRQHJ=V4?YG5.KZ]5MHFM-E*[M
M=$;6V[_NWI*+A;>D(R:E%)/2C59:U_BUT.PXO\7>ZYC;',#+O*];(7-]!R%7
M\H@EE[E!.Y%HN5FYL8S^/)[%]F:+\BLR+*MFKZ=4E4Y01B45G*+8XLRG3`J.
MW[3R>#A*_A=Q;K>'E6'#W5!7)V)*4;D9Q2JVWLV.GA-Z4.-[PP.YK\\3DNVD
MGGXF5&[*T[SMVK\-D[<K4]4J4G[BJOJC'Q2+;ZAV[^[=2;9F?'#F\\D;ZRGB
MY.@<6<GI;E$FR+!U^T5FM5B"LJ5?5Y/NC56;BW\0Z?,HY&BOET$%4@/*>8)B
M(:_CX\1>Y56\Z4K'&*C<Z2FWI5Q45K6NE71>)WO<>5F9>)<RL"-F6?*U"*MP
M7M)2HE*6ZBCIJ_-OS)0<9\`^2MBN>/;?RBS'E:VV&B\I,G666D,:\D<P8OI&
M0,)MJS44\2OK!C*DWV)K9G<C<J2RG)>)%MTDE#N6X;Q;@Z)\GD\GBLK9+"3L
MPM8T$HJ*;E<J]ZG*FM%+1^48^-35VKW,0C:M7(V[G\UQG)[5_+49;9I+Q<J+
M;\7X(TY%M/='K.;7R5,X:V7*>-J-RXLN4X.VQ?,/%E2B\GX-L.-[?0JS1&=0
MMC]&8K_R>L5B:3<DPDB$8(^X"+1-=<R(DYS`=WC;&9NIE7,J5(J>CL1<K<OY
M3I338UKU4Y?`ZNWE8.;#9EPAC.UCJW%PAN]R2DG[D^CW254_LUH>'KF-N7]0
MJO.:VYZQ#:(I6Z8#Y/35XS=<N6TGDVL6N-FZO8+%B?'F'..,"^<4?&08LK;U
M&!EI$8Z'!RK%+JMC/B/?.#*7M;4F^E.B7C]57\/`U7+9,;N4KF!:MVL%6J-5
MDVG&"556KEOENG)M^FNU+0NZG*Y6+/V]N+S2X<5UN8L.UQAQY>JX@02K+E0A
MS8OCX]6WECK<Z:PTF:OM'ZH%0,(J"=<#$Z3%`Y+F+?NXV4IXUV5J3=-Z=&DW
MUJM:>=#79''\=RV#*QREN%[&]O=LE'>IR2TC1^+KHWT(WS\6^(F5J^WQI>NR
M/RHB&$QEINNS1=V-O$P9'T@E*L'-MF[36\WQA:KC^.:J,RKQZ1/<`!0@MVBH
M,"F)U5;V5>LY61RN,I;7)N2DW#8JI.*@]\I4I'K5TW-5.+P<+$XKCLGC>-X;
M(A8<J;%.*5S>Z-QF[G\N,:U:5%%54(O;0N`G<OX\PYCW)]7+V8^4RF.J)(V-
M5*$QSC*AVZ/N`UMHIB:K6.C0D9<D["=]9\<OGBBSM)HBLSC>L%UE552]6-D]
MT=RWK4,F]R5ZY?L05JW'>W+VY35YQKT]N-VDMLG3<JI(LX_9/9L+5^U_0K%J
MQDWI7;J5N+4KD;4L6-VB=5<GCMP<XI2V2:E)ME#KEA;AY=L<W:F#V7.;-QJT
MP\@WU8KTNA)59[.IG1DYN071D9C.[5_BZO1TD],*[`BY'4BZ7`XL%%$PZ;[>
M3W/EQAS?*8MN&VLIW:T3HJ*ENW64_"O14^I(GM7DK7Y<2NX?9G"<I8A;N2E;
MVI3MS:;;<7>NS4(MNL8M5=:J'5$O5P>-:SQSO>)*QB2Y4BCTSC5D:M0#B2%N
MK!5N!I=1FZC5*Z5^\E7LM)KNH"'3724$5SE0,D*QQ.<1#F<C$M68UC>M3^G2
M-:ZQ3?AIM;VOXITT/099]_-R9W[\+BNSE*4I-))R<FWHO-U>BHD59XPAT\:N
M/`!ZL%XD#ZE`KX:PNFA=*Y:`:`:`:`CS[GC9)YQEK3=8!%)3EQP-ZP*82B(%
MYI8(-MU!XAXAH"130%CO<.63;\<F2BH")/NB>'I-@*!AZEN6.&$D_`1#P!0X
M;CZ@\=`7MCZ1^F/XN@*+<A\7VW-.%[]BZBYCO''^UW&+:QT/F+&R<<I>:,JC
M+1T@YD:X65(HP*^=LF:K03*%'H3<&,'M`&JHM1=6JHIG%RBXIM/S199QU[0O
M";`%G+E&4H$IR)Y`.CN'<UR$Y06&2SAD^1E'SE"1?O8UQ=5I&OU`BDNF=RBE
M$,60-CKJ`F8`,.YR;^""BE1O625*^)?MC7+^+LS14[.8IR!4\B1-7N-EQ]97
M]1FV4VWK]YI[X8VT5*9%DJH,;8()Z`$<M5@(JGU%,(=)BB,SMSMM*::;557Q
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M3>NJIT6FJ?3_`*"WDMS4XQ]2]K1OHW1^FFKT^6M="TZ>2G>+^6N`#0N,,A99
MDV/*GE@)(7%N'Z3B^T61">XCV-=2>B\>N)+'5`:14.=46BKEH:-0<HLA5*DH
MX$_FY_+8EG$GCQQ)VI6[N/&<U&XI[9-R6UN/26BDXMMQW:OP7/=I9=[/Q<W\
M;;O6[N/FW(6W=LRL.Y%1MRW6X2IOAZG;C<2C&;@VEXNN9GJ3SD]:^2LMPBYN
MSCBWXT-CN8HDWB[C,_@UDEX^.AGKP9-?/QI5W'R%?CP:+1B_FLC&554V`5!#
M5=OE;N/QT<&PMMY7U<5V,I*47&M.C23JZJ2]2HBW<[>L9_.RY?+<I8\L2=B5
MBY"W*W)7-JDVW5M.,=K@ZP>YMGA;=RCLJ//_`(TR+'@YR_@4H/B_S`2;4TE-
MP.SFK`I.9,XN+N9J";LL^?$!H]DLSZI`Z[M%T1>1:_83@HL='4_S;]WW;DI:
M*C<FZ>%%XO1*B\D=%9C:LK\/8@K=M5>U123UJVJ:+5ZZ:MU9?&;F7<4U$//X
M)\VFC95/[(\=USCR@BW=J+-D&L><IN1WFJNGBC@03%,ITQ,3IZNHY`,E!ITA
MZW_A3>GB_DO$N.<8QW3I%5IJTM7HEU\3KE>;5U3DBQY>`O-XY3"BG[R,5QB2
M-YJRP[)A&K<GTY@Q@8)+.@`&_4=%`_2`F#IU5[;\UM\]:/Y:!7(;G%M*:=*5
M57\4J_/XZ,X+CG'D--=JBU[>'.5Z#@D@/F$;<3T-E&"!#"DDDYY5)+.Q,[$R
M!S)%,5N8O4J)"B`ZIV2HWXKPUK\/O(=V%8J#C*,I-5BTTJ=6]>E=-*M/1I'*
M3YN7EQ%+/V?`+FX[>=3T&$2VCN,"ZTJFT>"V*JSD4.3RL/TJ);*F`[@ID=^A
M0"G]D::23I.,HOXJA7&=N:K"<):OHTZTZTI^GF<);F]ED@?8>VMSS<?8$5-@
M9\3TOLQ^CSFWV;E23VF_4;<_UANGV1'<-VE*^)0[C4MNV37GI3]IO$YLY5,@
M^4-VW^=R:S?^<VQV/%83R8>>BG]A53Y2'0:""*AU?LYDPZ4Q+]>8A39:QK;Q
M_?\`>M*5/H>[=\OIVU?^L0KDFZ;)4^S^TX!N<68B[;=LKGJ;^1)Q&\/I[\K@
MUAU?D7*_!FL.<&81V_\`%G<\@W#UDXD>'T!VY5CXZBOP8K\#[]V]F'^#0YX_
M\YQ)_;5:D5^!NEYM9?'T]M7G87^2)Q-\?J<IQU(K\&?1YLY?`-_W-;G6/T`+
MQ.W_``^4P:"OP9MFYNY@`=OW-'G>;P])2<2MOI>/*D/'0DUAS:R^/I[:O.P/
MIDXF_P!]RG'5O>_[LOU?VEF5V49[5;FUYJE/UM/]1]^[:R__``:W.O\`YSB;
M^VFU6G55I0NU^!]#FQE\?_U:_.HOTR<3_P"^Y2CHW3P)1;=B[-%URUW8*&\M
M'&W.V`$F/;\SE&H-LPIXF.O.`'(7C\^&08FQEE/(Y&T>V-LB)G)FZBBZ@`4A
MBE,8L5]7V`O0OG)Z_P!,R6C1&O%_+]CAW:TBUC+E%Q[U[%SCF)3F73LD8X@8
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M1DE;?`=QC/-@8Y*DFO;?Y.J,:':T*C"N46KYL?(C\LQ9TI-Y5(F>IT%84H9E
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M4$5RMFI4$#%="51`W4&'C\':OV,R[+,Q+=W%2<83FD[]71JUJTVEK3QZ53,/
MD^YK_'9F!CPX[/R,?-E)3N6[4I+&I&L7>23I&3]+E7T]:-=-##EER*),9&0M
M/"FZUJMU#`]CS97+*C;YBR?*>19*E-6,1.HF#QBX=,LI3C$%%7L;&FFE(I0G
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MLB`@8H8N3VWCXW*OC9<CA7+49QC*];GNM*L]DG%O;N4=956CC1IT:9FQ[GS)
MX,\F'&9RR%;E*-N4:.5+;G%-K=M<FME*-QD]5H=E:N9&3JQDBF8I#A?R$F)Z
MPL\;2-ANL/#+RV%ZDVN$,+^VL#Y*AHF4^,[!091-1@HV^+VZ+LY05,NW3-K`
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MC&LD9MO(Q,(Y0>O6+%-R)`0\HI5P!-14@%5/@9=BS8OW+5BXKMJ-*3I2O2M%
M5^.G7XZ=#9\/R&5R''6<O.QY8F5=W-VI/=*%&Z)MQCJXI-Z45:)M:N[RV-,F
M-T5&U7N[Y.QPCV#=6Q]"X_KLW,VV%D5V+)NTBV4O*LHN(7C$@666.(J`*8"<
M"F$.@WB'9/YA?E/=_/WO?LOC.`?_`-8>#QG$9&?D_2K]O+MRA@OW8W%<G^'A
M9NQE:E&,5%QG&3DVC&[B[?[XR^&X^YQ7,PP<?WY[YO&A?G.,7'=&$)R4+3?]
M_;.K?2B=;`QY&<S;E03VNCTG/E0L\+*46&MU`OG&U@ZD(I_8[4R@;0:/E%(Z
MHGLL?4H1W\>%<0K*6:.8X"@JX;+G.BA]0V\GM*]>O8GX"Q&2=U0NN_?A;>QR
MVM)W9-JYMT<I+ZDU4YW*XGO?$GCWERUR>)1>Y"./BW+DZRHW6,(*VXUKMV2J
MHMZ5122+Y@\Z47=DC;1CCE1'EK%]O-2?6ECPAB).HK1-9?RI8VT1[F+OLC:7
MT*\A/BM\9PC"*HN2OED6)G2K1;;=\7B]FY]K(W8N!;O*PI6E<S[UENYI6*W;
MHR;]22E*-*)MI.CX7D5^:.+F8^1+E\V.`LB<;UNUQ./D?RZO;-33C-4BDY4A
M*NYJ-6JG?9<Y`=Q#'F'&F4X=IDFTR+VQ8XK3:DP_%)N\L;I:[UU>PS<TU@T)
M)Q:F]?HR@$C':TK&1*BTKND0A4C%6&Q>Y'\O<3$AC/AH7N4VSK./(7G;4HMI
M5I%+U4JMLI+:UXMI97*=O?FY*?\`4N-[LE#BY2@U9EQ&-*]&,FDZIM2JDZN+
MHU1U>FO6L^5?/"/Q"RN=GJ7)+Y?/&:L"OCB!X-*2\U'Y#:U6>G'HF<I6)"%6
MQV$K%),VLNDZ<'<`H8%4&ZHHD5C$Y+\O<C(QN)N<*K>;>O.,K\L^ZL>$$DTY
M2UVU555JF^BUKIEXW:7YR9.)F=Q0[LLPXK`PU=EAW>/Q5FY,Z[)6L:*@E*>Y
MQ<8UDW;W2=-NOH:UD#N=N<XT?`^3):QU5E=ZQ1[0OFNG<?Z_*XWJR[NBFL%\
MJ[RPMALL<6P5J\-CP96\B:+3=-A*](N'F)-U+]]]A/&R.7P,*P[%J<HPQYY=
M[W)>O;&5'*,FG#UUBI4?IIHVM9B8?YF9?*/A.5YCEL>%W'M7+>1:P\!VXR=O
M=<A*7X6<5*%Q.WLE3='U*2JD]F*RCW#I1GC9%6+SO56M@H66;5<;Y8:-2)5&
MDSN+*DF\4@+-BAI@J&MPCD*]&;,*TE&2LH[?1RB[E$C@2&`F3?YKL/%SY85[
M@>.OVI."C.SE9:TE+K[KRIVMR@WOK;BMZ2:BDZZ3'[/_`#<Y#M"?*87>G-X/
M+VE<K#+X_C;TG.,&W3'AQ^/=G9=R"5MQNR;A)[7.4TX]*\RUW"K/A)7+]`=\
MGPF$7E<=)8EL_&3&E;R')0+FR5F&M8,F\F#%G\9L(,TK*QWL+).D4VI#=*JJ
MR:6S7,_E?@XWN7.W\*_D[I6W%Y^7124;DE/;&:D[;?MP<MRUW45%%OFN+X'\
M_>;E;W=V\MB8<[,;RE<X7C[=W:[MNU*W.L7"%^BO7H6]DOY;M.3K*:7NV6>N
M3*L*_?3@<^R'@EZ[6O<:UQ#Q_P#'=DL\Y6+M.N[!&H2%'(W'&D._CHN&/(&,
M#LLPY`R[9*/_`)N"].]V"OPRQ>&[?5[+G)O?R6<X8]M2M**N-9*<;K_FRDJ2
MBK=-KE.L#I>+[._-OE+/)SRN]NXK-OC,/=%/BN'L7,R]2YN6)OP;D;J]5KVX
MR<'*4)N347%G+M65N749BYS9:1;>4LSEZOP+.99X?NG%.ILRWI]/MF$Q`UYY
M;:K5)JLU%=%I.BRE%5'3L6#R.6ZBID(43ZW(Y'\O9\ED=OPX/C(SE-*&9#D<
MR5BVH^F<JSE%75)P<K:BHR<9)M2JC'X[A?S9Q>+PNYLGNSN'(LVH1E?P+O#<
M;')O;_5&&VS9K9GMN*-RLIQC.VTG"C.KM_*7FKCGD)C_`(UV7'&>+I*71.H!
M*YZQGQV:N..U-3FH:)>6"07NC>*N"\^[KUA=KQYHU9.#`6Z`NU7J!1(F?3V_
M^!\FR\VSA6+6-;4VX7,NZ[MS;7;%13CL<U1I^M)Z4?4ZR_B_FCCWIX-[F<B>
M3-VU"Y9XW']JWOINE*4O<]R-MU4HKVVUZMRZ/P>;>=O+;COD#(5?F\.<N.0=
M<J5E;U2LO>-G$-Q/#D.=D&;9TPC(ZS6**BJW56C(5E4Y&74^-6)E`0!B#@IE
MCI:OD<KM+$XO'R,;C(SS;T9.2_%7)[/7+:Y0@XM+;33<GU;IT+W"<;^:F9W+
MD8/(=P;>$QE%.:XVU:=Z3BG)6[L]T-&WZE"2KZ8UU9<E*W+-F7>)G)[*-IFK
ME6\>N\%<@V,)B_*>&AQYD%>)6Q5(OZU/2SEXQKSY!T+9[LY1)'@V2=`NV*HM
MY/GGU/)W>&MX$,>QAVX<I+;-W;>3*Y!*KK!P:>V72J<FUH_$['@\?N>7)WLS
M,Y*Y>X6#G"-F[A0LW&THM35R+COC5NC4(QEJNJJ5GHLXA#\">/C$,WPO'JPV
M_CSANCT?*,VTJTBW@[[9L31+&K*,X6Y'3@9V10DA*Y18JG)[T+?H$0()M:?`
MM7+V4I*Q+(A;]<[<=VL(ZRJXZI4ZR\#I>2OQMX6QY,<3(O4MV[C4=+LU2"49
M:2E7I'QI0M;R9DJU2U=E<:U?O*X%H&?@4IE2>N1J/'`T5!7;X^KL_.ECZ?*2
M<A,MW-EJ;9\P:L7S]X9%5XB8#BH02J=+B8]J"LN[PM^[:NN<X-2O[KEN,95V
MT5&H.DG*,>D771Z<AFW,^["]CXW<-BUR,%"$E[>/MMW'*+;<7ZDY14HJ,IOZ
ME35:U+J]USZ2_91HDCW%>*UFN%9C9!1UCQ#$U<86?%K6`L3>5&<L[%ED[XV>
M.G-/9.VTLDZ0:-T^L%VH-_+ZS:N:X[(XKVL?"R(\L[JVW5<<K;C)44';<*MU
M:<6IIMNCKH97XGEL?FW._P`Q@2XBW8:NV)6HQNQG![W<5Q7=%L4E.$H-)+=%
MJC*;5[/UMM<@]PZQ[LO$>6R9>Y28CL6.:ICK'H9&+,R]AH,C48-"H+9'DX:S
MDCHR'L44=-)J1T\2ED%O,!=J`GSKN#BQPU%<9F1S<9061)S>RL%-76X[*VW)
MNVZ.34-LE2C)X+F)RR7=S>7P,WC\J[*6*K<8PELN;/:AN5R2N[?6HR23FI1K
M5HD"R3%VZ'XKY6C+W:FMVM[;"^40G+0Q@6]792KQ:JV-<IV<"V<O4HQJU05(
M@F3SE3B1(#'.8YC&'F<J=BY>E/%@[=A](N6YK3QDTJU>O3QH=3QMC-Q\.%GD
MKZR<Q.6ZXH*VI5DW%;(MI;8M1ZZ[=SU;.XXP!MQIX[@/I#!>(P'^M_7M8ZZ&
M<5RU(&@&@&@(^.YK][36/V7/`W^[2P3H"0_0%A'<F5%'C*P.4P$$>2_"I/<=
MMA!;F'@U(Q?:\-S`?8/7OH"_`?2/TQ_%T!2O-<7F2:QA:XWC]<*'0LP.&K,:
M5:\G4V7R!1(QZC)LEWH6*IP-IIDO*-'T4DNW**$DW.@JJ57V^CRS/D2J5UZ$
M;)\8]\X1-T<O.VP`;CT@;AGGX1`N_@`B'*P-QVU0_<KI2A#^'0H-Q&[='<GP
M!SCR'RIMW,CC`KC3D%+PTQR4X\XCXW7JH4F]S<%`GB&U\J86K+EO>TK)K]1-
M(SZ42<J-WH&4%PU6'R_+ORNRN1BKFKBJ+Y>1"5"?+5LDM&H/$2BT/EAF'ENQ
M2AU<@Y@KK2J3DA\22C:?+!QT=1&4=%_&R5P7KCB(:&I0*;?$3>0557^R.CD3
M(4VUN\D[G%6^,:=(3W)U5/XJK;LK7U+7>U1:1U.;L]M8=CNB[W1:45EWL;V9
MZ2W22E!Q>[W-BBME*>UN;=7.BH>"P(H(\\NX(3<!!.O\.1*&P;AU8]R*([[>
M([[>O6J.B75GIJ=Q`Q/QR-RKR7A2%MC:^<BVD[;+TU-89Z>^-[HF>]3;-_76
MB4I$S,2]<2=U<)@A'R#/V$D00,@J4537+=)7DY.B<E6O3P7Q_86YQ<+4O9IO
MVNFGCJ]:4;U?G\J%@F!*5FVA6?M=U?D1+S=BRG%9MYCA*V>?DK_).[+'J8$R
MB,!+-DLH6BVW:&8C"&113:O'"9@\D5"I`14#GSN16/+(E*TX;5&.W;2GA5>E
M)-^;\_$UO&V.6QL>W9Y>[:N9N^;D[=7"475P2JVUMBTI*J]2953*I)IMW$9E
M-'E#6:],M>/%MR-4\2(VC*SK(%4JS+'%@I$S*-:$89+`Q:R_O+IC80?R4<\E
M5'T*5)-!9(%>G*QHV(<)?O7K-R<G<MJ,ULV1HVY;G_F5<?3%*D75MZQ1J,G(
MOS[LM<=:R[,)2QYS5KUN[3:X52_RMNYJ=95E6%(K;NI0S@_><TY?Y*<3KYFT
MF6&-_3XZ<X5K-5\U5ZM5FWT=B^OW"E&`KC`T%3\>C;84R8B^3E%89DLL9^8H
M)@W21.?67]SA"?X>Y9M2C6+DI)32<H[X[F]R;358MQK%KK5'28LE%W,?\5:R
M+UJ>VXH2A)PGMC+9/8EMDHR4G&2C*DXNE&F2@\Q,.8,S=B%"J\AKVXQSCV)O
M%/N);0UO</C=1K9:X_4<5Q$+9-)F1CS*OU0$GDG1=&4*7RE"F#QV7`<]G]NY
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M324<RAG2J;4"I.4FP*`("'68<3,Y'D<W,]S(3_$;+2VI26EJW&W!T3K],55^
M+U-GPO`]O</@0Q>.]N6);NWYQ<G"7JR+UR_=6ZG3W+DJ+P5$ZZG243B]Q#?Y
M*Q-E#'N3F4D3CS9;E.8[HV/KWCF+QO5[9G>))%3+N2@\>0\2YD7-K:M!.R9/
M'9V:B@"=)`PAX8V7RF5F3D\J>^ZXQBW)MRI'Z563;TZ(S<?M'`Q+MC.QK,[=
MFU*[<M*$5"UNN4]V248I2K5;M6E5-ZLO&B\QXAG(VU3,)E7&TQ#T0#C>)6*O
M57D(VF@F#H3C:W[246:UT"`Q6W]\.CMY)_X@VV`FFJKH;R$)W+BM6TY76Z))
M5;KTT6IT!N1W'@D*6RGSUA<E<-)?$Q9\V4Z,6%-,>ZF>_%1949T&(R7N1!6\
MCS/-\H!/T](;ZN2MW(J+E%I3:VU3]571;?.KT5/$IM-7W=C8]<K%?<VZ^W35
M[Z?13QW4H<R7S[@FO.'K2?S7B.#=1K9@]D6TODFFQKA@SE4V:L6[>HO9I%1J
MVDDI%N9NH<"D6*NF)!$#EWB<)VH>Y<3C;\VJ+[WH6HW[,Y2A"<7.*JTFFTNM
M6O#[3Y(9_P`#Q,%7;1*YMQ%&5FW@^&IV*0R53&4%:`BW/N<F-=EW,TG'S81S
MS[$O[LHKY*OLGV-X:HJM'7J5N48QWR:4//P^\]%/Y/QI5(.'LUHR)1*W6["Y
M:LZ_89^WU^'@YUV^2479-8:6D9%LPDW+Q!(QTB(*',H0HB4!`!U7&$YND$VT
MJZ*I3.]9MP]RY.,;?FVDM>FKT.,_RYBB*D;-$2F3\=QLM2XT9BXQ;^[5IG(U
M.(+[F)I2S,G$FFY@8XOQ@WW7=%22#ST_:]LN]-?'P+CTZ^5?L\_D<)UF["[&
MGL<AO<OXN9T"3?FBHV\NL@5)O3Y"4(+D#QK&S*RY(5V_(+)8!137,H'E'\/9
M-L?I:4M&Z4^->E/GX%#N6U'>Y+9YU5/O/5HW*GN8)_:&]KK3BLQ*;M:4L:,]
M%*P,:E'I`N_5D)A-V:/9)LD!`ZQE%"@F0=S;!JX[-Z,E"4)*<DJ*CJZ]*+QK
MX>9+G",/<DTK:5:UTIYUZ4-U*UU9=X>/0LU>6D$YKY-*,4IJ-4>$L0PB=E"`
M.U(Z,N6;&N+$D/=1+Y_N1P7Z?*$#:IV3:;2=$JO3PK2OWZ?,E-/IJ=_JDD:`
MCXF"%_=7,<*;>T';RS83?<?K1Y)8",(;?3#4?Q?8#U`8FYHQ_(NO9`CN3%=E
ML!DL5N6M^#K%288J[ZM6"2DOD\A7KA%UI"<BI"C1!VGD)JKK%D'*:GGK%3-M
MK,E/$E_#*+]I+3^^OXM7T?CY>"*+,KMO`E8NQA<SGF2FKC<E3'?2WM6CE%NJ
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M77^6>WL9*#/%TY9$D'CTDE210JRD@TAJH$G+EA6$ZDJ^49`=9R];J^P"8D+M
MN:Y3\O\`,NQEQ/&Y6-!8^U_S=)7MEZMQJ4KC4?<E9DHJ=%"$HZN537]M<-^:
M^!":[@Y?`RW+)W1_D:PL;\>EM2A"RG+VHY"<I0;<[D)52C1>;7QOW#H++TW8
M:]R/PA=</6&]?'J-`O\`BJ0@K!2*8M:&:JE,K5GJ"ZAYD[.E196R+Z0)YIY%
M^Y<*`)4VY"X%C,[+GQ2Q\S#S(<M&+7NV[J<9/8TG*$]%_,:DU'^&,8KJV=UP
M^-SECG[]_FLFU?[;G:N^W:MV]EZW==?:K-MQG""4=U:2DW/_``FP7'W<=+R'
MM]M2Y!X`+QVE,<1D15\7R&+9AU;('(<:G+J.["6P,'<>/NL\^>-RK*.'<@B@
MS;%(FP\WJ6-K./O=OV[MQ\I8R;EFL-BMW(P:Z>YO<HRW:5VQ6UUIZDNMS(AS
M<^,Q;.+<QK?*1NW7D7)0G.,[;_RHVXJ<=DH^,GN5&ZQDZ4\V;'W=/<9RF9A;
MD+Q59<?SY*C9NNU.-Q7<1OS+'+(@1SNI2\H]=.(Z2>3#`YWCA8BR*Q)0"B@X
M0:![MJA7N"4:>S?<O;I]2^OS^2>G3IU3>IB9>/W-/)M2P[^-#%5U.:E"3DX=
M'%?%K6M5KXTT*+8]PIWK8/,3>7R'S,XJWO"!;!&*NJ@PQ`_JMQ/76MK:RSY-
M&::U%XD5X_KX.(\Z(K"7RS)=+@BA#+J:_=B_C+]UQE^#E&EJ%56#IUE+K+S_
M`'+H='B3]O`LV,N,9YT;MQW+B;2G"22A%1K1;&FZK5UHVZ$QHB([^([?3UC%
M(W'X1^J.@&X^C<=M`-Q^$?JZ`L-Y)*=/,?MO$$P`*N2.28``B&Y^GB]D$^Q=
M_$1``W\/5J4Z:>9CW8R=ZVUT3=?^RRYO,D0YD:#-DB\E'PP^5?555YDMDK6F
M+Z(BF%IAW4HT+(6N)F8)$\S$IKL$C.6ZI2'=!T@`[:U6/PG#X?+W^X,+"PX<
M_EPM0OY"LPC>OV[-?:A>NQBKMV%I2FK49R:AN>VE69%Q7[]K\/&<TETIKM\6
MXIU2;IKI\RWCCW#\I(NB9$K-PY&X@S_<HV2GDH+(C6,9M'M8MJSHKA"AV^KT
MQA'PC.*KL49!(#[_`!HHHH==5/I,1(O:Y&1P-W+Q[SQ;UC%HO=A"3>Y5=90E
M-MU?D_3HEYR?)8.)W9CX>7CW<W&R<URD[%R4*;&Z.-NY"VHIQCTJO4Z[G72*
M\/CJO\U<59"L,AF[EE@>[8_G+3:4JQ7+%665.G(FG-)!U9(%PW=L48$CFPP-
M'2<)RS8QUT7!$"O2N42I*$4IOW>%R,?V\3&O0R_31J6Y-TI)-:O65'%KITHZ
MZ7\>QW'C9KR,S*Q[G%1C/?%QVR2K6$]^BCMA533JG]2DJ4?0<?(#N(4K*I;-
MRQY8<4KW@D]%&M4N'QY1)&@V&T7+XTA;`6]6.2FI!ZP=23JAQDF'N48\(P0!
M0%RH'*4RA:<B]Q%S#R+6+BW(YCOPG&3DY*U:C!J=MZ^-QI[FJI)*J\=C)9'X
MW%O1R(?@O8G&<'3^;=E)2A.#I6D;2:VI^+E1KIII9.641=;;>KAS<X\R.$;M
M8;L\PW"@TJS\$*N>8.-7:$N0QE=";>UXZIFD@9%=X57S$R`=,S?=?;VLOMN_
M9Q[*XN]/(MK^=*$YIS]-*I;IJ.JW+1>/5.BX?)XWOUYM[)P><Q+?%SW^U"=F
MW<V^JJ]>V#:C]$M6W5:IQ]5R/*6(Y!2D'5%>/^=\;X*F(V4FWLP\R75F5HA;
M>D6O//=X)5-VZ:J1[2%CO?YM51L8%S*QB`'_`)D]Z'6M[=O\#9NW?Z[AW\RS
M*,5%6IN$H>I5E5)U;>V"3TI.3^K:=#W7C=R9%O'_`.'.0Q^/O1NMR]VW&XKR
MVNENC::VK==K'U;H13]&\I),UCN#6SC)>Z]5LY\=(;DC/S.4HVI97KM=EI6@
M4-@Y)),*<1O"2,'+_'%AQY9$S-'B3QNJ5<K4?.,*X*$&CEKG;DLB?]'LY5O'
M]FVHJ[*+E[B:]R4J/Z9QU271OI2ATG&2OPO8]SD)6[N/!R]Z,*K>]K2475;5
M&?U>-%3K4X;['G<H:\9F5,@>0F`7O*!O6Z:BMEVT8XDU*,XL<9<VCBVJN*I#
M-6"B[>?HK0S<BI6R`)O7*IBHI@5,Y,>[>X:6UVK-V--'ZJU]/77IZ_#71>9J
M;./W"K4XW\BQ*]*=8M6Z*$=]=O\`B]&FYTU;\DSGI8Y[BDAQ9RS5);D-@R$Y
M9VIR]6QKDZLXWE7F,L?-G9(!/W!O6YI/XQ=$;D;2(LU7J4HJT5<HG7%\"1DS
MU<U>X/)E87"6K^/;C8C&ZYR4Y3NIRW32Z)23BJ:)4=$C-[8ARF%DWKO=$[.;
MCO(E*W"VG:VVG%*%N4EJW&=6WU:=-WB>'XB8Q[JM/OK9US-Y*\<,NX[:M)A(
M6&*<>2E0L;]5S$,6T2+TKBL13)-5G,M#.CK)N``2*JI^4)3D\G%ADX?]/GCW
M,:*SG*+C=4YZ)5JG%O;ZJ^6E%3X[K+L\<[_XK"NY:K"GM35KVTVTVU)5N.B2
M4:O2KJG4DVW'X1^KK`,8;C\(_5T!;SRZ4!/BAR?4-X@GQWS6<?'U$QK9C#X_
M2#544G))]*D--IJ/U>!2#'5;4MW`_CLBUQ'0LX.X_COB"Q1.-LBN(QC"6":C
M,.QSB`:-969@K%%0LF[FS-FX/5VITVK==938PE`A\S"N*WFJ+O3Q[$Y;9W()
MMJVWZGM3BY::[:JOF8F795S'K*S"_D6_7",J)>Y'Z6I-/8Z]))-HHO8^*L8]
ML%<<PG;.X.KQ=@JT9-W)_;"45*7JUS)%13YY7%2PN(Y@+02.EU7#5!^W`I5Q
M;%6Z4BJ%#6RM\ME6&IVL_+5_&FX8[C*2VVY5C)Q]=;>Z/6*ZIT9K%P^%?N+\
M3@8BLY"WY%8PE+W$DXU]-+M):;FT]*KR.:SAN2['/V?7R';GXN_:ZNL0]:)9
MFC\P5F.R;G-!Q6@5:QF2*VXQ61ZS;KS*AF+HK^0>`D@'F$!4!$H8-B['=!7,
MBY",)JC2;VZKU+5:I:JGD4YV)=C[\L;`Q;SNQDI;G&+NUBZ*;<'5-TB]U=&W
MKT*H\?>.[0?D3?\`,_#3B%B?)K$B]I.[Q;%0-KL%*NK9"&:PQXNT.,=UQ8CX
M&CR3*JZ9N#@W%%$$U%?-,8FRY7*P;-V_#ALW-O6KLZ2E<6SW5)R<G)*<G*K4
M7ZE5U=4J:X7!8&<[&/+E^.X[%G;MU4;+4G:G%048Q_EJ*HG/6$FHTBDW5M5W
MY3/QB^,7(Z3!^G%#'8&S`_"468*2B4:+3'EB<>_JQB)B*R*;/R_,,@40,L!>
M@!`1US3Z,ZY=3D<90$O&WCV42B42X.Q,`E'TE$*#7P$H_1#1=`^I6_4@:`:`
M:`C\[F)!4XV5<H%$W^NWX(&V*`B.Q.9^"CB/AX[%`NX_0T!(7H"PSN/B/W.$
M%TJ"D<>4G"$I%"L0DS`<>8V#`*!8\2*`Z$P^'3TCMOU>K0%]H@.X^`^D?5H#
MYL/P#]0=`-A^`?J#H!L/P#]0=`-A^`?J#H!L/P#]0=`6(8#CUR<X^X%*F1<E
M0=,N)$6DL9-#W156+Q;:GBY$%2N3.3.42S:?FE.B1,I3)B0Z@F.5*%U8+[]A
M^`?J#J06&\DU"I\QNV\F;P,MDODD4@#X;B7BYD100`!](])!'\#4KHQMKZO+
M]^A9IFG'MWFNZU%3U#P#?&EC?\<[K7:WR;?TW)[_``U0;@YQK94JW<G%B+(2
M6))"^M)%=*`+$2$*!/BQ950ST7"J34VPA<__`&9=QW=E&,VDXJCKKXI^"I5.
MO72E#09/%RGS=OEH0M._;LS5N34MT9THFVGM2>YKZ6Z;M?`K=A7#=]Q!S;Q_
M#9!OK#)$H_X\\JIV,ND;3:MCZ1GX-S>^#T*S1NU?I$%`UQU.P[B&60073(L<
MS$K;K4ZP$I:<W,NY=K%MSN79V\;&C9@IR<HP492DU"K>V+<G/:J14I3HO.[Q
M/$6^,OY=ZUCV(2RLF5ZY=@HPE<N2C;A6[&,([IN-M1W-R:A:@G)]%5/N/\.[
M1S;P%!XFI]MJ5*L%?RS1LF,YBZP$S8810E33FFSN-%M`2T)+M'4@TFCD(X1<
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M$V^ZVQ+>7E8EZW;6-95NZK<5.3>[=*-$YK14W):K75O4[7EL[C^4XW`P96+D
M;F'8E!OW'MG-W7-3V;4DE%J+CK5I.NE#FXH[7.1H/#/-##62\I8?2K')W$M1
MP[5*Q@C"Y\48[I+.J5VTUMSD62I"M@GFKF_W)K,LEI0K)9M'BY8F423(9<XA
M:G?QIN$7;I9BWN555UZJM.GE^\T6*\G`R/Q6#<<;\5'97I%QK1Z4K\>AX+.O
M8JQ5F1W4H!AE:T47&=*J<A$0D;!PT(.05;*XQ_D&I-;9,W@S`K:7<C,7GWUX
MFK'B+M!L5OUD*5,4Z7?A.S;MW5*4K4U*&NB::>B\.G@^NIT3Y3CUP5WC+&*K
M7(9+G[U^$MKN*4H-5BHZN,5)5;==_P`*/KFO9JLT_&Y'K63;CQEG:U?^-F5,
M/.TZSQL5A5W5]R+&U1"$R!)QLW=K+$HN<<O*\H+!Y'%8S#M%4H+N=R$Z>F_K
MG!2P;>-?PKMV['(MRDYW4XNW#<IP7\O<O<JJU<E%KTHX?`X_-Q.ZX<K.Y:EV
M_&VU+'C!QN7&Y0=9W-SAI&,HJEM-[O56B+W<I=MG".4,C<>+4K'QM-IG&[']
MKJE&QG1:S`5NH?',_;:':V3]U!M(_P"*`K39W4EQ<Q:"+?WI5WUBL'28#\GN
MA1K:JUT^"\E^JGR.AN2QKN)/'E;]<KL9)U^F*4JQI3JVXZ^2:IJ6AVSML<M<
MCXTQ91<EY&X-7IYB6EW?"];<6KB]D2S55MB^_P!=@(:3O,=29[-+V)K^?X=U
M7RJ,)>/,U8%:NEVJB!DC%VS,?D;^')/&T3N1E+6C>VM(U5'1UU3JGUT-+D\5
M:ORALN3C9A9E#8U&46Y4]=&M)0IZ&O!M23TIU-@[*[2SLIK%\U?,?/\`#31A
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M&-R3<86W&,H.-(]92:FGJW6C3HEHF3F[#\`_4'7/F[&P_`/U!T!8#+I_^-/Q
MTH)1W_<^\TD`=A_VQF!3"`>&WK#UZCQ^P%_VP_`/U!U(&P_`/U!T`V'X!^H.
M@&P_`/U!T`V'X!^H.@&P_`/U!T`V'X!^H.@&P_`/U!T`V'X!^H.@&P_`/U!T
M`V'X!^H.@&P_`/U!T!8'R8)U<T>VF(E5^QY)Y-'W32%0I=^+60$]US@)002'
MS-@..^Y^DNWM;A#ZH%WN4,8U+,-'F<=WMBZD*O.J1*T@U9OG<8Y%>#F8^?BU
MD7S)1)RB=K*Q:"O@;I/T=)@$HB`Y.)E7<._')L[?<C7ZDI+5-.J=4]&_VF%R
M.!9Y/#GA9$KD;4]NMN<K<TXR4E2<&I+5*M'JJIZ-EG\QVQ^(LQ'J1(U*_P`1
M%.YZ2M<NPK69LLUM*P6V7?VR0D+78EH6WLGDU8W![Q*)"[<*G5!LY%$!\HI"
MES+_`#&=DQ4;S@TJ4]$51)122HE1>E:=*Z^)D]OVX=L6LNSQ*I;SK#M7O<;N
MN47-S;3N[G&;DZ[XM2T2K1(I!']E'M^-8UQ%R6.,BVI%U,24TNO;L[9EL#M9
MU(D39]"J[RZ#YR;&#(>,0.<#+EC5E4#*'*<1UL%W9S4;UN_;G;C<M*D:6X*F
MG^KU?7YZFBRNUN%S;>5:RK<YV\Q)7D[D_7&/2.DE1+I14JM'4NIR5PCP)E>1
M)(VZ+NIBMZI,4>-BH7)%YK\!"5*QU^,JEB@H"!B9MK%0;*>KL,V9N_=4DCJH
M)](FV,?JP,;F,W$MSMVO;<;DU*6Z$9.3BZIMM-NC;?E4IRNU>(S,BWE7(W8W
M;4'"&V[<C&$914)1C&,E&*E&*3HNB+7:[V5.W;5K;`6Z'PQ-D5JZL0X@:Z\R
M?DJ2IL>YAK*YM:+A.L/[.XC53.Y5=/WDARF371;I$,78#]>;<[JYN<7'W5&J
M:K&$8NC5*>E+P_:S'X[LGMSBKCN85F4=W5.<Y1KN<JTE)]6]?.B*JS';)XK3
MN)<A82D(G)BM!RQG>R<BLCMAS!D56P6_(5K17;S#>5N#B>7M(U$Z"I2)Q*3M
M-HDFBF0I03`2FPL'FL[C\A96*X*\K;@FXQ:2;KHFJ5^-#8\CV_QW*XRQ,U3E
M8]Y7**<DW))I5::=*/I77QKJ>[XG<#N/'"KY:C@:(O<6?(80QK::X91R#D,D
MBZ@W4X^;R#=K<[!,LHF1>/K&\7=K,TD#.U5NI7JZ2[6,WD<K/I^)<7M;:I&,
M>M*]$M-%1>'@1Q/;_&<)<NW<"-Q7+^W?NN3G7;NHTI2:B_4Z[4JUU+Q]A^`?
MJ#K!-V-A^`?J#H!L/P#]0=`-A^`?J#H!L/P#]0=`6Y\P@VXD<IA$!``XXYPW
M'8?`/M96?ZNI75$Q=))_$I5B?">/>0'!#C5CS)4;*R-<>\=<,N$5(.QV&I34
M9(K8=BX9*7B9RLR47*,9-DSEUQ0."@E35,!^D3$*(7\?)NXF1'(LT]R$JJJ3
M6C\4ZIHN*[<A&Y"VZ0NPE"7QC+JO-5HM51_$]5*<(\&SZE'6LGVU+(YQ_65Z
ME"/9S->5G[]Y$+.%G)1L;]2V`\LTBV%;H2=/3K+D2(0G5TD*`9*Y3*4+MN/M
MQA>DI22A!:K^[IZ5\(T1I+?"X5O.M\BO=>5:M.VF[DVMK==8N34GY2:;II4I
MA(]L?B]+Y4REF"1#-JUJS!'&B+>T:\ALSPU:+%N*PE4Y1A!P$%<HQE!MIN-2
M$SHJ&W6N<YRB0#B4<=9=Y14%MHO\*\Z^1E7,&Q=O>_/=[GPE)+RZ)I'L.*/`
M3!'#9>3=XC?YBDWDJSD6"Z^4,TY&R@DW:RXU=23)'1MNG7\1&*O7509K'50;
MD6Z_,`#`10Q-;//[@Y#DL&UQV0K*QK6VFVU",GL4E'=-1WRHIM:NCT=*JHM8
M-BS?_$PW^[MVZRDU1T\*T_A6M*_$J+S*#_6@<K.KV0^YLSIN8?0`?:OM.X^(
M@'A],-:)]&9JZGJ>-Q1^YVP'MN(!A7%8;[>G:BP/P;AHNA#ZE:-A^`?J#J0-
MA^`?J#H!L/P#]0=`-A^`?J#H"P;N3=9>.%<,5,QP+RLX.B?;PZ"?=BX0*)S"
M/H*!C!O]/0%_^X_Q/X8?#Z/J:`I!G?!]$Y%8UEL4Y(1L*E5F)2KS:JU2M]EH
M5HCIFEV:(N=7F:_<*?)P]E@):%LT"T=(.&CI%4IT0#JV$0$"T(G;!P4;8Y\O
M<ZRGW`=OW0?F2(>R``&X%S0!/$`\0VVWWT!O&[8N"C[;Y?YT!M_$=P/F07ZN
MV9PWT!I_<PL$?ZL'.O\`](-S*_LT:`?N86"/]6#G7_Z0;F5_9HT`_<PL$?ZL
M'.O_`-(-S*_LT:`TG[8&!SE$HY@YV;&#8=NX1S,(/X!BYI`P?@:`\W%]H_B[
M"3=DLL1?N:<98[DI$K6V>8\^>8B$S9U8&/")A%)Z23S,5W*GAXL`;-A6.<44
M`Z";%\-`>D#M@8'+XAF#G9_Z0?F6/XN:1T!YB9[17%:Q3U5M,]=^9DS9Z*ZE
M7U(L4GSQY?/9NGO9V*6@9MY6)-?,9WD$ZEX1RHS<J-CIF7:J&2.(D,("%72G
M@=\IVM./ZQ3D6R[SM6(HDJ@<BO<*YGG*9%<H%63$!S7]:J4``?AVTZ:@Z4O:
M/XMDGHFTEOG-'Y3P5??U*%L8\]>81IR)JTJZB7TI78^5-F47S6%DGL`Q6<-B
M'!)95F@<X"9(@A.Z35&]*U^TBBZ^*/0_N7V!?]6#G;_Z0CF:'XF:M02;2O:V
MX_K^5YV6^=2ODK)N$NON$<S1\M=+?RU2_P"C5X'()AVT!]5[6^`%@`%LN<ZE
M``%``#]P?F88-E4S(J!XYJ]!TCB4?H#H#='M?8&'??,'.SQWW_\`&$<S/'?T
M^'VZMO7H#J8SM1<<(9%5M$Y3YT1[=9PH[51:]PKF@FFHY5*0BBQ@^W:.ZAR)
M%`1^`H:`XZO:7XRKP(U9;)/.!:NF;%9FAE.X+S..Q%J10%2-Q3'-FXIE4*`@
M&_I#2NM?$'GGO9IX>R2OG/[5S-=J[%#S%^?O,XQ]B-V[0GB&;@^M:M$DP_C4
MP#U:$-)O<^IQ%.R[PT7%'SK+S.5!LW!HW!3G_P`T#%1;%455*@F7[>&Q4RJ+
MG,`>H3#H]>I/C7Q-];LR\.7!E#KVCF8J99-LDJ8_/WF<(J),TTDFI#?Z-WB5
MNF@0I?@`H:FKI3P%*M/Q70W`[-/#T&JK$+7S-!FO[KYS;[OWF=Y2ON2CE9GU
ME^W=X^[*O%3$^`5#?#J"*+7XFEWV:.'KYLV9N[5S.<-F1/+:(*<_^9X$;$\M
M!'I1Z<W`8@>4U3+](@:AI-U?4.*:H^B"?9IX@(I*(I6[FF1%5A\5*IE[@O-3
MH/&[JF]Q,'V\/%OU+'';^.'557U)6C375=#A#V6.&!O38.9`@(;"'W??,WZG
M]6WUZBD:M^)9O6H7;ZNR6OPT7W'H%^T#Q1=J^\.KOS3<./=A9^<KS^YEG4]U
MV:%]WZOMV!]B$K!$-O@2+\&AD2=770ZY7LT\.UVS1HM9^9*K6/(NFR0/SYYE
MBFU3=+F<N"(A]NSV2K.#B<WPF'0I-AMV7^&+.VQ]^;3?+Q&\Q,>XB(NY%YU\
MO_E1'0[P[-5W#LIPV91DF\2[6CFZBK4J@(**()G,03D*8%$#NI;M"<5)T71Y
MB]<U9,[U1NN[%WW`.9A_>5F8N3-3JC]NP-S(&>*](^KS#?#H#KG'9PX=N(QO
M%JRW+=1-F/\`,S@W/+F.5^FGU.5!:A)%S0+SW4%7BAP3W$O6._I`-`;;?LT\
M/4%$'"-GYF-UT")$1,GS^YG;H%16*Y233'[=VVR3@H'#^.#?0&M3LU\/5ES.
MEK1S*5<G4\T7"G/KF894JOGG<BH4XYMW*<7"AC[A^.'0'QQV:>'KM0RSJU\S
MEUCM&[`RBG/WF<)S,FB*#9JU$?MW!NB@@U3(4/44@:`W'O9OXAR2C99_;^:+
MI9G'-XAJJKS_`.9PJ-XMJW.T;,4C!FX.EN@V.)"AZBCH#8)V9^'R979$[=S2
M(1^BLW>E+W`N:(`Y0<':*+I*_P"CA[1%3L41$/A3+\&@.3^XY<11;Q;4;CS1
M%M"*F7B$?N_^9W1'+'<G>'5:A]N[V#F=*&4$?'VA$=`;#?LT</&BJJS:T\S$
M55^CSCDY^<S0,KY;I!Z3K_T;A`W2[;)J?R9`'0'*4[.O$99]\9JV_F<>1]]5
MDO?#<^^98K^_KJE76>=?V[/R=58@&$?6(:`X"O9AX;+D036LO,I0C5$S=L0W
M/SF=TH(&76<BDF`9N#I(+ARH?;^*..@-P_9FX=J+F='M/,TSDR9$3+CS]YG>
M89)-N1JFF(_;N^M(W3*0/XT`T!S$NSUQ&:.V,FWGN7"TW$R<K,P-A=\[.7R\
M_59:?9)QEBDJK-+Y@<R$$]L46F#9\9L=(';</+4W+X:`ZD.RUPQ](V'F0)A$
M1$1Y]\S=Q$1W$?#-P!OOHM.@6FJZG9LNSIQ&CGJ$DPN/-%H_;++.&[M'G]S-
M*NBLX.51=4AAS:.QU3D`1'X0T(HJU\3=+V>>)9$$VI+KS4*V2="]30#G_P`S
M?+([%%PW%P4/MV^"HH.U2;_Q*@ZFK"22HNAPC=FCAX>/;Q1K5S--&M'3E\V8
MCS]YG>[H/'B3=!TY3)]N[P5<(M$BF'?Q`@:BI/35'<O>T5Q9D8HD$_O_`#:=
MPR;-E'IQBW<!YFF:%8QJGG1[4$_MV`((LU?:(&_@.E611/0[PO:PX]$]RZ<K
M\Z"_%R8I,=NX/S-_F1,R(-A(C_HU^R44`Z/I:"B.N==IGC,]=>_.\D\WW#SI
M=E]Y5[@?,TRO2_3;(O2]7VZP\'*3)(I_A!,OP:FKZ"B?4[%KVL./3))N@SRO
MSH;(M&B#!JDEW!^9I2(,FQ2D0;)A]NOV4DBE`"AZ@#45)22Z`>UAQ[%<KG[;
M/.D'!/>.A<.X1S-!4OO8H"YZ3!FO<//]U3ZOAZ`T!N#VM\!C_IP\\!^C^Z'\
MTB_RN;`T!H9]K'CW'-R-&.6.=#5LF94Z:"/<'YFE3(==91PL8`^W6/BJNJ8X
M_"8PZ`XRW:FXYN`Z5\J\Z%"^[O&G2;N$\S^D&LB*8OT``,V``)NQ2+UAZ]@T
M!L3/:<XU6*$E:U8,F<WYRNSL6^@YN!E^X#S)D(B8A9-HJPDHF3CW6:%6KZ-D
M&*YT5D5"F352.)3`("(:`W(?M0<:Z]!Q=8@,D\VX2N0<2R@86!B>?G,6/B(B
M$C6:<?'1$;'M<SI-64:P8(D1113*5--(@%*```!H.O4[4.UY@4H%`N7^=H`4
M``H!W">9NP`4```#_1J]0!H#9;]K7C\T02;-<M\ZD&Z)>A)%/N$<S2D3+N)N
MDH?;K\`W$=!T-[]R]P+_`*L'.W_TA/,W^S5H#JI[M0<:K3!S-8LV2.;5AK=C
MBI""L$!-\^^8DG#3D)+-56$K#RT:\S,LTD(R28KG1705(9-5(YBF`2B(:`Y,
M1VK..<!%1D%!9.YNPT)"1[*(AH>+Y^<Q&,9%14:V29QT;',F^9DV[-BQ9HD2
M123*4B:9`*4```#0'-'M?8&$=QS!SMW'_P#Z$<S`_"#-0!H#Y^Y>X%_U8.=O
M_I">9O\`9JT!\-VO,"F#;[</.X/Y'N%<S@'ZH9KWT`#M>8%`-OMP\[A^GW"N
M9PC]4<U[Z`XYNUEQK6E:K*3MLY9W]&H72FY!B:YDGFMRDR%3#6S'MFB[G396
M6IUTRI.5N;-!6>$:O$$W+95,%T2")?#<`)(-EOXH?R#;\9^3?Q7UOI_"^AH#
M>T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T`T!\]9?P?Q-2%T
M/NH(0T)&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&@&
5@&@&@&@&@&@&@&@&@&@&@&@&@/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g575431exm_pg053.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431exm_pg053.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"6@'N`P$1``(1`0,1`?_$`(0``0`"`P$!`0$!`0``
M```````("08'"@4$`P(!"P$!`````````````````````!````8"`@(!`P,#
M`P,"`P0+`@,$!08'`0@`"1$2$R$4%2(6"C$C%T$R&%$D&6%"4C,E<8%#4S0F
MD:%B1%0U*"D:$0$`````````````````````_]H`#`,!``(1`Q$`/P#OXX#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!XD@DT;B;
M?^6E4@8XRU?<$)/R<@=D#,W_`'2D60)DWWKBH3)ON%`\>``]O8>?IC&>![(1
M!&$(P"",`PX$`8<X$$018\A$$6/.!!%C/G&<?UX']<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`Y:OY5T/?G#5C3VQ(\FJ%V/K7="/G.\?O/\`QJY5
MLZQF35#:S<^J'R(7+*X?6$R$R$)0K"D;BM(."85@P@TGU-,"'33`AHC(+"QM
MJ]L=&X<3C@T#FRI4*%F<40F='E*O:438>J;4;8L(R$P@I.:8064((2Q"#C&<
MAEG`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P.:+^3?(-2&C6?6AIW.
MDV[,>J28;$+HH<FTPQ7_`.4D"Q\J:>M:IEL'_):E-&U#4I9UJG[),#!RY29@
MX!)?KDPPH.C."MR=GA$-:$9SPH2-<5CS<E42')`I`>G0M"-,0<^"2@*2B>#2
MBL"4Y+"$O)^1>N,8\8X&5<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`HP[]MU8IIUJ?6R*7:\5+M,U;(WU%-?%E*W4D=LPR5-DR8I)EP$G>&YD?T;#
M)&W*<I0F4*R0%X3EJ<DF!58(P(+OVAM1LS2V,[>E*0H&IN1-J%$0,PTE&C0I
MBDJ9*28;_=,*3DE!`$0OU9QCSGZ\#T.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@<T_P#(8KW<&?R/KR=-5-3;#VEQ2-RV5L!*TL)?WV(HX3(X-&8R
MQP!W>9!$)/%9HM,$3+WH],Q-:Q,J?!H\DX,$$(R#@Z52QX,+`9C`PX,`$>`F
M`$68'`@X%C`RQXP,`\>?KC.,9QGZ9X']\!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#P)+*XO
M#&E:_P`PDC!%&)M2J%SB]25X;F)I0(4@,&*EBUR=%*5&E2IB\X$888,(`8SY
MSG&.!$F<]D?7M6OWX)WO#J;&5#6F6JW%`X[!58%U1IFXW!"XX]H)E!KF`"51
MGXQ_V?TF?I_W?3@1R,[O.M5>>\M]?WK*+O?6,H\Q5'=?=?\`8N\W8T1.3,`+
M(S6%429MQ]YDD?VYAJ@L@_`!"`/(0B%@-:O'?#J,RJ7TA11W8><2UK)<B9UY
M/7WL\6@FPXHU$N@#8H>M@2,0B9&(1R=%^0"WC)-2FF+PHDV2E!@?T1WZZ!A;
M5SR]MNX43:$&%1AKK)]$]M&]M$F3,1#L%7A<34JM*22L=#LLZ?!PBC3G4&0!
M!]N,I08'\D?R!.MTU>E;AR39-*>J6QY-Y5:4[;`"0ED##^<R[G@!3AA^&MD'
MD*)<(`!G%+!A]"S",_/P/I3_`,A#J9&N<VMPV3D<?=V)*S+9"RR/7/9IE?(Z
MA>FQ>X`<'YE64\!U:6IL/;A(%ZTXD*-$Z&DHS30GGE`&&9MW>[U+.D>3S%-N
M?!2H,JD<7AQ-@N,1M1HKS]W2]&Y.+/%SIZZP)%$4L@);6D]2O2&K`'M*8.#5
MP4Y8@BR&,HOY"?3"OR4$CL!I@&3D92X'WJ6>-N/@.?QQL`!B<8<EP4LPXEY,
M$G%ZJ`(/"X0,(LX49#,%?>WT^(DZQ2H[#-;`A0*7Q(I(+FF5"[!\==&YG<<$
M-J=$:X*RS5CH6)&,DH9;DF`<H29/3IU!I0927W3=4*C+F%!OWK4[F,Q<O4.A
M3#83>_G(T,#^W%*74TAE"O-RRH"%(3RUP0Y2*TP3#TYAI)1@P!6EV$=KW7C<
M2W4B/TWVH.E?*#=P()"K#6ZN[%Q>MD95<NYF02B9VL].\!F2)XJEG5(TB-,J
MPH;FA6<YFCPL."09@H+9SNV+J_3&.1*GL/TJ2G-"U_;W`E5LU3J8Y.LB^20O
MI'Q'R\LPW*`2@&,Y!@03,B\%Y%XSX#V/_*'UKY,5E8[`-,,C0J'Y(K\;-4UD
M!"B+MZ%TD)(S,3+)>!L[>Y$&G_7]`30\#V\=C_7H,\]*5O7IXH5)0.QBA,EV
M5IM6I)+8&`Z4O9AA":9&FA+:(VG&N4BSCP2E!DP><!QG/`]1A[!-#92K<4$;
MW7U+?EK2<O(<DC1L74+@H1FM,<','7!Q267FC"%LBA1CDH%X]2$11AP\A++&
M((;'CVT>LTN)3J(IL514G3JSFM,E/CUN0!Z)4J'QI4/[*G3FML@4@..>&)(:
MM2@#G(E"0H9Q>!%AR+`9,3=U+J2$*I/;M8'IG/#/EM4$SZ*&D.&)$)0"/Y0F
M@=A%J\/@TAN$?QY%]UDH>"_;USX#[66VZIDAHR8]9M>OQQ:!(ZF%,LTC;H:!
MK7NHV)"Y#+0N1XPH%KV6)&4=G'QF*@Y*#G)F/7@>J;/H(0$P9\UB1("DRE8:
M(V1LY82TB-S+9%BHP0UF,`3)7DT"0P>?T@5"P4+.#,X#P,G"I3B_VJ"1?_I&
M?TFEY^B0W!"K/T%__+'9P`S_`.`6?&?&>!$#L(LF\*?T>VLL_6EC4R._8-1=
MAR2IFI$PXE:[,R;6!48UN2**Y3K,294Q&Y^]+;\D'A6F)\$Y+,P/T$$L&(*X
M+(S!<U9K@Y!:F\+@O.1!;3EJ["0G"M6:W``6!`:I/]AB)P$."LB]<8QX\<#U
M>`X#@.`X#@0AW2A2"SUVJE821YG2&"379YE_?#-`VVT$RR6-\,J:W+&C3,^6
M154CB[M4L<16##F=R4.BY3EL<Q(`,IP!B=`!R'G/O6_J^_.<V=32[\:C;"C*
M"*29)&]NMKHXUC0-<NC4V;ES(ULUSHT,3?T;W$T@0.#4!$LRB$>D$9E,I4%&
M!$:8:XU>#:G7;1ZO9E?:VM&J(7CMKL@QYV\V+7RTA&"9QEJH%HF<N6V@KL,V
M)2:T)9(%K0TY<R4BP$1-"8!0G1#*X%U'`<!P'`<!P'`<!P'`<!P'`<!P'`<#
M^1X%D(L`%Z"R'.`CR'V]19QGP+USG'MZY^OC_7@4*U/2^PFW$1M>H-B.Q':R
MG-RZZK&;4O9$&I-WK>D&-I<EEV/T\I[<*MXU$8<FD;[%IG`T[*RH%Y+J8W'M
M:9Q9UN0/0'7)86YZOSY=9NOE23%X.DA\C6PQK:YB9,6%'%99^^HN$<6G0)+&
M$#@ZHXZ^ER]E6A5(2U)P4IV!%>V?7@;F<WMF92C%#R[MC204C7.)ISFO2H"B
MF]K)"H<UYABHTH`$;<0+`SS<YP`D&<9'G&/KP-*R3:W5R&F9*E^R=!14W"O[
M#)4DN*NV,S"[\1F0?9Y`YR)*+[O\#C*WX_'O]ICYO'Q_JX$?HSVH==\[?TD5
MK;;JG;8D:Q?7#:4S4Z_G6^O+46R\BC\#,6$5FBE0F]"ZO.`)U"H_XTS8,XG[
MXQ-@\G(PUF7W`ZD.3+9SQ%(UMO.#J;1QP^R8]%-)-JU4KC"^4R,<=:H\LCCC
M4[6Y&2/T#AS-2%@&,EF&!<+P0,(LAK//<HSN[TQQV`=;/;7/G64)E*N-F@TN
M<*Z8W%&2^`9B7%:_7+.*X0QYF5%*4RW[UP^V3)TBLK"@9*CW3@#T5&__`&'O
MAK@57?2=LBJ"D%D"93:^T^F54IE8QN:@I.+(45KS]8$@3*`M0:(HD_)2D8D_
MJ((<*!A]!-P=W5@C`&-:5:*:[HUJ5R$4ON_;NQ[B>&8\+@::T?EHM2U(,;4O
M--:"`DJ2$D@R66J4?*!2,LG)9P?LUTWW83)HFA4\W<T>I=T>64O$+%2>GE@V
M8*$/RJ5-R]5A8Z6[>K0DE[<U1(A4WIC3&I$-4I4@4FDE_#DHX/!2]:6Y\U8S
M6;8#NEW>DX%KH:X.&->:]U@U5#D@Q8<Y%MK6]16I)E/F=&F6Y*"#XGW/LD+R
MG,]RS!8X&5%]-&LTC"I3WO<^]^U#0I)`0*,;"[R[&22'?&4,PXK!T/A\W@L9
M<1$J3<F@RK2J,@,P'(?'H#U#84-Z=NKZ#KFYS;M(*$D+DU(%S8A<+,B7^85Q
M2%R\86DC56RJFIZG)X<8#[FB&,(<8P'.,8QC@2TK[5S6:I,GBJK76BJR$J;\
M-*D5?5'7\,RI:L'%J,-A^8Y'VW)S?@\H(_A%Y+]PXSX\XQG@;T"$(<8"$.`A
MQC&,8#C&,8QC'C&,8Q],8QC'`_W@.`X',=O/=F^T?[99O7%+JAQO4IUZ\YRJ
MN1<\H&E&^KY'"Z?VQE<<EM3OCXG&Z`:H=.I3%B'C]OFEK3G!00$PLTA*I,3!
M=GI"TL+WHSIL!6R-*IO.U?U[="4"MM0'I"5!]210T*@"41`DI:C&%`OU`#C.
M/;/C/C/`DJ*#PH?C`X?%AX#Z^OM'VD7KZ"P,'CRDSX]!X\X_Z9^O`\I;5%7.
M2\;JXUM`5[H8662-R6PZ.JEXR2@X`44-8>W&*!%E@QC`0Y%XQC'C'`J.DE+[
M7ZZ[F;<W)K]HG06Q-6[%P+7IH8_N+[AU#OC&LK"'SJ*32/O4?=Z9F"1<BD1<
MH!ZF`5?"<GQZ&A^N<!#1-J61MROL?KSA-_\`6]1NL5;S/<.G87(I-!]EH-=(
M"28_6-T2N$UG^Q6:EZ_^Y8V]];L'%F94G-[:>F$-.4,0RCPA=0^ZHZMRAP6.
MTFULH*1.C@86:O<GVG:[=W!<:24H)),6+'".*%"DPHE6:`.1B%D(31XQ]!9\
MACQVDFF*A,>B4:C:PGHU24M$I2'4'51J90C)]?B2'D#B@BCDI7H'U+%C(`^,
M>,?3@?Q&-(-+H2]M$EAFH>L$1D;`>J5,3_%Z"JF/O3,I7-ZQI6J&IT:8FD7-
MYRMK<#TQHBC`9,(.&`7D(A8R'RDZ)Z2)FL#(DT_UA1,Y<*F5;E-2"AZO0MY5
M?V)D.9["BD:.+DIRHO,Q8\NB$(<)UV<BR<$>1"\A'Y?TT]3;BF.2*.N'2\LD
M\1(S/L-=ZQ:CO8@61%Y+4M<=1J2/ZYP+T&'WQG.!><9SC@>6GZ4NI%*$82>N
MG4;U&,!@L&TM#U&/D+P+!8P_.WF^@@8'GUSCQX\Y\?USP/`.Z+NH(XY4=_X]
MM:TPEOO]T6WP@#8F.`-2!9\(DC<K2I<)BU10#`%8!@LL18,A#CT#X#.B>G;J
MR32)7*T^@NKJ=^62.*2LU:14\9)`6]0H:8Z/F(T1:0+>W-Y:M&6H5(4Y12%R
M58R>L)/.$(>0QI^Z4>K.3O\`(9._Z;UPZO4J=I(^/JA4[3T2=:Z3!['))2I"
MVAEX6Q&%_?A_=JBB"2BCC\!$(.<A#X"'&\/4CU<:Y:=;2[`,FJ4>2.M,T5=E
MJMA2JX=AVQH.=&J&NDA6HE!++=,>-RFD"II3E&IRE*<*@1*8'G'P$?&%2>D-
M+=:N^M[ZXPV#:)[9T/5\P9=J!SZ/7UMGM:UV%/FIKK'7V60"8/S4V[$+Q*X7
M/(K:7G`#C!?DB<IAEC-1@%@P.B\/2GUE!PY?_P",X1"=XV.*KSC+BOXU2:V*
M&U$RN*LM4;:@U"62OK*W$(G-Y*$!X=49>"%BH\KR#(?:^].>A;W+2YJ3!KDB
M;PE%%C6Q+7&V^VM91UD50N#IZWCJ]@BD`NV.1ID<44(3!;Q*$J4HXXD1F3!#
M&::(8?B_]/\`J(_92C_=6Z[.<GP=@T]C[&=]$1J_Y<E^F5^3-BE(3LIPE^"_
M&`^N,Y\^?/`_5!U):X,4>116*7#OQ#X^@)-3)VR/=B6YY*<"8:A2X`(#A?=+
MADH)#RHPM"(O(!Y/+#@8A$Y&4,/:0=7=.(0QO`MA>P5>*.2A3)AFN78#M:J,
MD1:QQ1O:F,R86;.!ARC!C\WDK,$!P4<`8,D@."E,-3C#^I9UJL<B:V9$S[K=
MC\`=&H4M$IDT/W#FYSL_AF,M,EZ\#TWS-!,(F+\6JR6B;!I6Q*:V-1(4:<19
M(C@FA!:Z]1K:JW=7KG@T/['^PHULLF:[7NDBS,[2JB>IQND>UV>7!L5@C\EI
M)7$5A*7[M06G1KFY8WH,*!FHB$JGU/"$Z#-(=GUH0I73M?W4-;#A8+<26FNM
M&&!R4(QXR!00B>T&I/WS2I-+%G`%!/\`=)%X$#.!8QG@2>UXU9IW6%IE"6LV
MAZ52:PGA+);3M&>2=]L*W+9E"-"%N32&Q['EBYSDLD5(D>!%(DPC@-S62,1*
M%,F(S\7`D3P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"+.Q^F&O&U1D:=K:A:[$\
M@H%@*[N&O9;+JFO"N0N`RC'`F"7%6CW%K#C;>Y&$`RL0D.&$"[T#A20:''C@
M4O//39H81?;7J*\W=V8G/EJUS?.RB9./=JW$=;NT<-MR`EW%%SR4<C0X=7>3
M6);"5]<@&(5*E8:K-5+%HC1%8R$JD?\`'VZG,JRG24ZV2&S7P`7G"A]MK8K9
MJRW)Q'(\)RY$:X_N^X71$J,D*9&20O\`).`K$Y!91V!@!@.`W^Q=//5+'"P%
MM?7'I3CXQ'""<XZVU.]JO)^0Y,QE8]Q=P5B!^C'J'(\A!]?7&/.>!,6L:$HN
MDR#$M,TO4]2)CDH$1R>LJZB$#).1EB+&!(:7%F=J`8F`,H&<`%C(<9#C/CSC
M'`VSP(6K(;!3.Q&.V"*ZPE68CTOF4.(UT$@P8-;!'&\(*]*[J)<\K,91@;9`
MUD,9A&$^?N<J@#R9CX,!R$TN`X#@.!\RQ:C;TYBM>K3(4I7K\JE8>4F3E^XP
ME@^0XX8"P>XQ8#CSGZYSC'`CI86YFH-2%*3K3VIURK<M%DT*O,ZNVM8IE.(A
M42B/"<!\DJ$8!$K%!90\9QY"8,(<^,YQC@0OF/>QT^P0T\A][#M:%1J98<@-
M#$IR"?XPH(`(9F0"@:22`-3>`9Q@\&1$B%^D(\BSC'`B5+/Y0/4XS2)-&X/.
M+[N]0K1C5D+J@UHMQY;SL%*%Q"@E-F3Q^(KEPDQ:`1PS$Y!J?XA8R$S.<#"`
M/?C'\BW4:=B3`KS5KLTL0:P!9B8$'T5M&1B/"=D>"/A"A.'D_!_Q#R#(/;`O
M7/C/TSP,?>OY(&L;;('R$-VDO:J_60P$)U*^MT6C\L134@I0+.0#5L3O)$"Y
MM!DHHT81*@$@'@D7KG/C@0;4?RXH'$'\YLN#JXW[K-M,<269H4*XNTFO[@]J
MW$LE$SFQZ2IX40F<5386I."26N4&B/(^$(1!$(XL*F+7[=>LG9#9S>O<NQZ4
MW8C6Q4AUR5T1J$6]5F=^6JXV3ZPWA0EA,DB+AL_<F%'$Y/(K/^\`0L">>E<L
M"5EX"8'(>!>CK_\`RA^GNO:>J&LIM;-H01XKZHJZB;^%9KA;H&-K?(W$6)E6
MLB,EBBSJK*`2H(%@CPGPGR2''J/ZAQD-^1W^4YTC/R7[@_;%ZC@\8<!922*A
M;[3JL80')RP9\-U<.A`LN(%'R)\8,R(0`#P/`!!R'@30UV[KNJ[:N81FO*-W
M7J"4SZ8G"21F%/"B00&3/2\*(#AEM;FBPV**JE;D)./P`@O`C33`B++P(8!!
MP%I'`J)[(YRF7[)=4='1)>%^L]SWSC=U/U>LB$]\DC=1%;4C>[)-K6>T2%.I
M.C4"C$NF+&A.=E0DZ42Y>2G`,P8A`P%NW`CM?^W6K6J:)A<=EMB*5H9)*5N4
M$:,MRS8;7PG]2#]2G#,7*GEJ,<P(2L9,4")P/!)8<Y%X^GD(^![:^L$Q.6L3
M[_ZC+$)QIA!3@WWQ7;@W&J"0%F')BW!"_*$8U1!9P!#+P/)@`F!R+&,"#G(8
ML=W0]2Q`C0&]C>G.!DB&$P(;ZK\P6!%^<"#C!;T+(Q8SCQX#Y\Y_IP,CBG;K
MU9S862XYV(:8JSON,)0IUFQM5,JDPX1(U&`DIGR3MQYX,%%BSD8`B!CQXSGS
M].!G*'LLZYW/+:%NWYTO6F/!I1#40GV@I(U0XGGGA2DDHTP9OD]0::H%@`0A
M#G.19\<#+#=\-'2#!$G[F:I$F@\>Y1NQ%0EF!\XP+'L`<PP(/D.<9^N/Z<#R
M#.Q#K_)"(9N\^G90`?48S-FJ5`$&,?3.1"%-L8#XS_UX&[PWM1XTJ9:&Y*J$
MB6%`.1JPV'$<I59)I>#BS4RC#QDH\HPG.!!$'.<9#GSCZ<"LSN5NFE'SJI["
M8ZW6W5KJ]O&HUVHVAF16)#C7)R<%$(=@-Y"%)A\`<J/,5X#Z%@P(9F<>H0B%
MG`<A`+J&UKNC7>\]7X]LEL;"]AEA6D]WV73A+>SPB*2>C&Z>D]?:*T(%,4U>
MJLQR1N">=IUZ1*\&'.1B]"DPH$I^4TTHD.FX;^PE`R88]M!8,9#C(QN2,`,9
M%GU#C(A'8QC(A8\8_P"N>!\IDNBA/K@Z3QXK(_/I\CTV@]_7Z"]?93CV]?\`
M7Q_3@>Z2<2H)*4)S2SR#RP'$'DC":2<2:'`RS2C`9$`PLP`L9"+&<XSC/G'`
M_3@.`X%9>S@?NNRGJY1G#']LB8-[I(04#.`>SP@J:MHXD-,'C'R&%%-,N7A^
M+SZ"&8$><9$6#.`LTX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!%^TYS2,/
MV6U68YM!EKI==K%WC7U(6"DBI+BGAZ%L@S=:-GQYUEIB@@R,HYDQ5VD,*3@"
M<)Q4-8/T8"0(P`2'=Y''H^5\[\^LS(1XSGYG=T0MI7C`RB\Y^18>2#Q@9X`_
MU_J,./\`7'`TI*=N-4H,!R-FNSFO</+9QE%NYDINBN(^!J,49!@@MQ$[21(%
M",_)@<`P;ZY%D6/'GSC@1`F_=AU)UX:-/)>P_5(2@I8K0')HU;<:G*DA4A$$
M*DM0GA"J1')PA$+P$8PA`9GSZ9%XSX"NBPOY:/3-"53HC8;8N"USVW)82?\`
M'%%3;X'<8BC3#`M2J?$P-*8%.,L(!#.&27D1@<@$,.!B"%<L<_D-T):V_DBW
M$UIT%[-]@)"@TZ1ZR#@,1I.-KT!>,W>]6(U2=X.BLSG*V.I5CPG-;?F^V,]A
M!-QDL8R/7@6,)^ZOL[G2E,CJ#^/1N2L$X-:I4B6W%:4=I5&4L*/7$%%+C)57
M?V"0KRC]L@.6$*!X%CT+R$90S`^E-MK_`":+7/:%D`ZN=+-<64[!GWQ6Q.S0
M[%<Q?(T_.G/R&J96Q+VLD"TW`1%";CSOE#@L7J#`S.!H.:T[_+OO=S/;A[*]
M>6I,:7E$!4'U<UK7U6WEE+,Y,P@52RI[=D65YY!F/?(5Q!>0%8P$18A"]@\F
M,]`W:S9$SA:C;WOJVIE]7I5KL*<0JB)#8U5212D"Q/((Z=%Y6.9K8X6O!)%:
M82S[Z/'8$@`86`7R?$(L)0+?XNG7_,"6Q)<]V[^W^VHU3<O<6.W=LY(^L+ZX
M(BB2CE2]$VL+.J3C7_&+(Q)E!!Q>#!8*,!C`?4);U]_'^Z9*J-*7,.@%%KS$
M^2!?+8Q<IM9-D910DQ8C4MJ2:7MXODP9Y%C)?J,SP/.,CP'.`WZX5AU.:H9%
M*G:O>O/6\<;*-3BD;C%-<*B-8RG<I.,XC+NI01\UOPZ$M961`^0/SA3A^@L`
MQX#*H-V0]=5@V7$*>J_<K5NP+0FZHMJAD*KFWH!,GQ^6'(75W*;FHB*.[H`Q
M2:WLZL_!6!8%D!(\^/\`J'B.?:KUVLY^$Z[;>H\"%*5\').2.RYQ1*YHV.:]
ME7Q)`X-S<K0N$E3/#4J2B0D&&*?N$QI>`9$6/&`P//='U88Q(!!W=I0TN))R
M5<K/3NCNI319(H-`00KDBI.S&)V)*>>8$`#%0B@"'GUQGS].!B2KO4ZB"CBT
MRG>BEQ+/.#DZ'_\`6H]P-R6'!GRHV\$8,6J<@+,P+V*+%X"+&?Z9\\#G5VLW
MFUCNCL!VIN2E]F6.?0:T>M_8JM:!M:&7BRU=`X3L'&]:K8:R*2MILF]@0H1X
M7Q7(C'N-@4,GPJY,ZIU"9?\`*T*RR`ZJH1LOI1_C6!-DWV%U44/&8/#2WQ-(
MK?IY<J4.:-D;"3Q+Q+)&?]XI*7)<X^3(A^3"_.,YSC&>!K.?3;IKL9O-;;.F
M'69.&TH(B#$<XD6K4B2$8+3Y3B!\3ZM5ED"*3?H^F`Y`#Z?3'`K2VFT#_C)[
M,0IXCLDD/732[T:V%(FFR=?[XH*CYE$E!2D*E&Z(1PZ5-L8<U(#1>N0.[<X$
M&ECR$0,_HR$*1>N[N:W&T:V]M[J3?+'C_90P$)W:K.MZTT\\K52AE<]<G`3A
M1^9W<Z:9J4*VI)5'WL(7L!SV\O$;.;@-;<$P8/ML!V4:,Z9+M:F&4V;=DU1W
MMNQ?(VR0;/['&M);:;+'AO($6P5Q7C:(HK,*HJK$)GXV,L28M,1@H!B]05]^
ML5&"#Z=^=GIOKY7,&A5$,L<F.VFSEB-]$:N0V5J5A,6_?KNU.D@DUG3X+4G6
M/`*JHVO&)TE<B&G)$8<E;0(2Q%J%I`N!KG5[KAU@UY(5V-:9,7V8VVL%O2&7
MQMQ>R%GEUF6;*#`?.[%1\$G4/3?4]:D+,Y*9XA'?LF5I;B$Y&"S1DY/&$[6X
M%21E$6RM(*YC[<488K*:6X,9:D19IX0%FJ2T";"<@!AP2`A$/`/(L`QC.?IC
M@8^(.O1!@LC#3))I8Q#%D6(06868`61C&+.?`@#"+&<YS_7&?KP/B15IK1.U
M[@[MT`HR9.@,DX=7-%%8#(5X<J`#`GPX+2$"Q1C)Q:46`?(+]02\XQYP'/@/
MP<=5M8'A6%P=]<*%=%X0!+"M<:?KU<K"6#SZEA4J8Z:=@`?/TQ[>,<#RC=.=
M13TY2,[5?7`Y(0>2I)2FT?61B<E0G.PH3J"B!QC)19Y!X<#`/&,""/'G&<9^
MO`QP6A&BPA9&+2[4T0Q"R,0Q:YT_D0A9SYR+(LP[SD6<_7S_`%\\#R'+KHZ^
MGE2H6.VBVG;FK5C0#5*E^L]+JE*D37DO\=D\\Z%#-.^RP4'!>!9S@(0X#CZ?
M3@5R=G>B&A^N_7]NO?=-:$:?QZZ(1KI;+W7<ICVJ-$.+\SSI;&%Z&//")&Y0
M-8B4Y0/2TD\90R30B+`+&"Q9SZY"FOHSUDU$G]QP>/SB+ZJ;0/LNK?=B?V*I
M#KK2:!97%JQ&;:"1B1U7(A1>*(HRX-\9>9*ZNT21(4+>CC\7D!*(:8M;E7P.
MH)=U8];#E@G"[0_4Q2$@L\HH(Z'KCU"!2D*0G8]0Q\(19$E)"'&<^<A\><9P
M+.<\#`W#IDZGW0U><OZ\]2U!CGA)A7G-,0X`<X0EEE)_M@%-P"T/@!6/?X,%
M_+GZC]LYSG@:^?>K!HHAI2RSK,M>=::67#&HS]KU8;.9W8NFEE&(RL920^XM
M?9H^2=E:61V))"@R_P`/PQR9H)&$].<?\`4I@3#T]V:.V8K1S73"$*JBOBJY
M2MJG9&CW-P`[+ZFN)@0MZ]W9T#X42F3RZ!R9G=43[%9`G+"F?HVYHE@`EC,,
M(*"6'`BQMKM3'-5J^:WK,4D%K6U8TA+KO7R@8.--B?WK;;BW+W)HA,>-68RW
ML#0D0-JAR?Y"X?&T1EA1JW)<8$A/G`@IVFFJNUUR[J:)2#>79J9-LGFT&W&=
M4U+Z=O2ZCJZU\+S"JH(#$(S=,=*27]8[H:WNIZ9XD*QX:DCDJ*(&B;6PL."C
MPGFIZNHFWN1C]7VZ/9/7,@*;2T+.L3;MVW9C,T*"E>%N'$<(O9;:T'?SSS0X
M`:6Z-RT@1/D`0`\^V`SC3_86UE]D7!IKM2MCB[9N@$4?E[/8$;;"8LP[/:XS
M90N0U]L-'X2!4M!$'DA_:5\7F3.F//1MLI:C3TN2FYQ;BL!8+P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<"J_M.VOV$HRM8S3&EC!"9%N9L,R6\?5:NQ'`Q'!JJ@
ME.5RXSFU+PE:=,@=5#H1$"S&IH9T8DYB17)Y"V%JO9+\Q8PJAMKJFZ_+AB'6
M'9.VDQW#O^8[,V9%&9YM*P-B[;=7:PYK;^KMJV(P-<G*;+88(K2D0R\L@C&U
M+!&I,$I9A,V^N4*A2/(2>4?Q=.F-Q1%)7S76PI$H+1."0;F^[,;&."]0:O"G
M"%>=[6:!%A:@RG"(CT)`5@7U&`?@/J&31#^,CTD0US1.Z32IK?%3>M2KR"9?
M;M[2ML,-2-P&\)*UE>[,5M#DB/$'*@TA20:28H%D60^/`<!"39;0_KLH7:9=
M4E:Z-ZW,4<1.G3V(\@RIX<XDIS+P[*;+B<N=,N#TW/+BO_-1N(ELSB0<('W3
M:H+2BR-,'!8`Z;HQ0U&PGXL0RF*HB."$N$)'[8KJ(,'PH0X)"%&5^*9TGQI<
M!3EXP7CP#&`!^GTQX"`VQEN:YZ>[G,FR]];&1Z&)IUKM'M9Z_P!>6*-S"=VM
M,YP\VG-;-2R>,5Q72253&0X?$<?5-R,*-A,R:J2*`Y4Y%ZE<#34Z[WM9XI&[
M5F4=UF[%;,AU)."MGM&71;2NSXI&X2^(2&5>K8Y,Z7-BJRV%T3LLE;7(92S!
M`L-S@0?]0C^@?RO[1]TI%+I3`*CZ;-FW.9PZ#,%CO++>.Q.I-$^8C*GI\:(\
MYMRE-9UGX<A+!1=S^<DH.3T1Z3X3P`$86(0:KB6]O:Q>;MK4=7E>]7%#1?<"
M).UBZ^EVK?\`L?>TYFL(8H8R3IZ-;&"NZ<J*..4@9HR_$KU*0;RB"$D)H0C'
M\0C>!K,ZPNT2P&36J?Y[2:"BE=;,[.R;5?)-,Z&-,0?(C(XZ5?S:^*XLX[!V
MW::MRE#78-*C92DJUK&2).88H]3!%A$:&G;&J;8$.MO8/8=X]HG8+,ISIKLF
MA@#J9`IY7NLL>4U8UMU&6@M/-BU(UO'G$!DHK&V5A)B\I88,7H`Q&0$T@`!!
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MD-^&E)UJ-3@#&3!9%E2-&=*A'GBQ_H?C&/\`I@+&6\Q2U]E^JD/5GH%:%LZR
M]B5B`8$2;!PWI'>FF+,Y.*8\PG#@02<W`)!@(A8#ZB\>/.<^0Y!'*=U=)MMH
M<KK1SFI<O6:5[ZL+O((U8JN0Z[W`GA-"[^/CJE.C;'%`QN)7UK^^NC8LQ]X^
M+5ZA([D'_9-^32U1X6RV=%ZGF77UW1.&()7[">J[-&FL3WE1"X(M7-[9(!Z(
M0AY,;_R3(>D"K>FY^4GDD8"%1]PM]0C"IS@W`6J(*)UN+[49E!3M=J&3Q]EZ
M^*UG",D%3P/X<.CCL7:S,XJQHL1_X$YJ%#'DF"C0!^0>#!!SGP6''`INU>K*
MC)GJ/_'@D;]0NOCVJO#;>PFJPWQ;35<O3E(&@ND-Y)>@C87!U8%ZL45-DR`@
M_*<P8O7*8D7Z3`><!6]O%JK6RC<Z%SRLX)`*Q?X)_)OI/7YB>H1#VUM8(]$)
M[JYI_,FAA,!'VMH2IT*275N>MRWA($60X+E@BQ"$8:8>'_0WX'/'O[-\Y[,I
M8VN*#\K_`,?.B+?.^JZ)6K1)&MHF\ZLZO8)('?)Y.,FMZI9%H26WC5#P+XTZ
MH>"_&<C]@B=077-H>Z#Z'V1UU2UFD*RY--9S/+I.?*G93W6VU+1JE3CD*420
MD],Y$OCX3.ID0X&*G)0H4%GJ31%"R,P8L!H=%UU=>:R@HVO(TVH4YR?N_20:
MZH'U;7K2X+$]-MV^$CB!E<J%A*D2T4&'7$5S'BF_[@*4I.,`1%"#\@#`]3:7
MK:Z_H15?\A]XCNCVL;>JUQIF/O%$+TM?H4RVMW([0R,V`K<(D-+@D^(N:6;K
MC78!S<:G^Y5C"(\(LA%D82C@O57UC)-]=7Z88=.:K8XK.>M.VKFEC6Q'S2/F
M/,P9K8U>BT1F+AEEE"0HR5,;7,G\A(YAR%Q3X=%/J?X,QX".=":QT1)M-^NF
MY`,-J1>7;$=ETNI:U38OM7MN@`]UFGOG;.+MD&&I3W>4<X,C*U5^T($IRS(U
M):%*+U'@XT61AF-VZB:ZL$=[YW5@4["GN.F<%B3K2/C<S<9(;6C\/2&'W`>%
MI<#[L5'N(CINZ"=3L+,+DY_SX3B\DX$4`)!H>JO39?V(P*E%;7L2JJ>3Z"R.
M[5T.4;M;I92J[)9[NKB(!D:I4"_PN(!"CDJ-3_9EGA0"R(0\D?($`L!">L.N
M#5&=ZX]85@R1IOA0_P"Q>^EB4U<)P-QMN3`2"`MS+N=AJC"0HZZA%-B!J=:B
MCXB524*9Q$0B%@PXP1ZCY`_W:77:G(9H'W(V#&[)W8=R=$MA'>K*>9%>_P#M
MY^,9HG"Z@U?EYD*,3.UD.+6Z,[?.;#>E1&7)O<C2A#*`6H&423D(:AZR=>K.
MMJP+@QLKM)9EH2XC1JPM@JOLJBMU-CD4L:'>;6HG1.BBQY,S/U?RA5,FP=:Q
M^/&#5I\H)$UPMN<1IA_($8PL=UUJBT5(>G5M/WCW[7M.[&L$NMF\T[[LP^2A
M<[S=@UMJFQV@UA>I2SO;[$6,F02=Q--1MJM,`_(R0F>X`"#D,8ED4O(W6+8Z
MPD.]F]2"Q8)VIH-1J]7)+W3IV=#6;UNG55"(&)S0YAQQ"S(*\FRC!CFI+5.(
M'/`5(1Y"'!60DLHU6>W';7;2G/\`GUV=IXU2.JM`W(S)4&U@6_)<JM.5;1)'
MP2-P-K]8<I3E,U1,Y*<M2%2G3F!.&,!PSA>H>1H?/I0P;%]6\E?I`_S:>[]=
M/A<KV)FT@>#S'&>3C6LK7J55O/9"@"7E$YS<E#LK)VY8YX^,]6E/)"9[`3)P
M%!T3<"JBE\([H[8]TIW(5ZMU'IE36O.M54QU<A]6N$NM\1M9L1=DS8C#CCRS
M'NQ&=9"&I4K*`2:%)'`I\YR`0O8)26/7[$_;DZMV&K-FI<BKVHMIVMF*;X$8
M\5\>VSQQU[)?,2JPQ!^WA$J).C*/+*BQGYGI-ERSC'HC,X$L^!`=T86)+VB0
M:3DLR`N3/V@]K,+C(`84!<UC%$]AJ:<&9F4"^?*4U`VN$T7GDXP5@P!BHWR+
M.!XQ@)\<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`I=W@8YW(>R+42(P-_:(2]VE
MU_=GE<,4_>X6BGK=#I0J<=/WAE>5$:7KFDEZ3HS$8C3D/W:?"XDL10QA!G.>
M!'JG=;V11I)URW5MYMU8;GK]2SWULW)3-/QRJX#&6&&6.S5_!J:IZ$ODHB46
M>K*F<;<KPL)J=#52A4086$H!"@>$65&>!T3\!P.;G<,T*KLHD+&G/"K&^[%=
M$R,U"6/V2JE$6N#?.QG!G<Q9S]L6K:&.-`?0$G>/;X$PB\9.&1C(='2UQ;VT
M`#'!<C0%F#^,LQ:J(2@,,\9%\8!'C`$0_7&<^,?7QC@<^_9_3B1DVYU)WE*G
M$4=26C9'K:I&'0%F+$X3QP=\[2W##IXX-02'A,F>F]5!MFS\Y)*`88CPU*#C
M`#!XR6'[[,5-<$]K/^1+43!')JK76)#8A:%(&L[`^NJZ8/[GHS7D;Q&X.W+2
MQ()"Z?O>EL(_C;OE]E2L)(@?,'TR$WF*!VV\]A,:NC\-*`U)9'6@5`WMV6(<
MMK0SVW&[N:)6R,TG1K2B'))*'6,V8YFI"/A)R04WK@G!R+)80!&C3O2;8^MZ
M%Z66ZS(^U-UC:,@L.(WM'ULQ:7DYNC\FUXN"H$C_`!>1M@G9#)""'U6Q"(0E
M&%#$VKLB&(L:01.0W8U]=\Y!3]=5<]7(VKCJG[-7G>F&OIT<6.BX-=+]I)Q?
MJ>I5*QP<`+$$@S'9\M9C75((!60"R5DDQ,8<`P-S2S0>#S]%V$1B:361K8'V
M$$,9,SCK.@:FISKHYOH*(T&ZN\2?UP'L"Q\=&F%('$@]2CP6A6$`]"A^N1""
M4>*<@(K)A]OJ6M4LLB#UI**C8Y,>[NN#/V+,WJ$2*2M;BUDK"F1U/<'NO&I0
M%2H3&*$PB3,$#+">>$P/$B6MU#0:(U+`XM4T(:XC0SR;(:79,LB9<FJ]^-;)
M(RC>(28Y!6*H^Y?A9@Z(\')S`&!2+SB0YP6/(>!L%M@<'9D,F:VB&11K;)J[
MO4@F3<W1UH1(9:_24`"Y&]R9(F1E)WYW?RRPA6J5033E00XP:(6,<#W$K6V(
M42!M1-R!&W-928EL0)4B=.B;B49>"492!*46`A&4E)#@)82PAP`./`?&.!^2
MEC95A+NG5L[6J(D!`DK\0I;TAY+VF$D^P$G=RS21`<B!(/[&0'8&')/Z/'K]
M.`_!LF7=/(,L[7E^2-:AC2/?X])^72LJQ2D6JVA.Y?#]X2UJEC>0:8G"/!0S
M2"Q"#D0`YP'&[M)-Y[$-[.]?7RK*WHT[72S^O6\+QLRX(PR-+?-*VV&A>GT8
M@+;"5[JSSQP9V5]D)DU1*7$+BRMCJZY>,CQ[E`R<>%PO1NR7+9_6%6;GO!&4
M<WN*PYY8\ML5]G<;A#@7;>6"SUR.L;-7(&N+LS>\$F1*'L(F9P7)CEYJ1M1*
M@G9#]OD`7&XAT2Q+%$\Q%X_B;JHVFARJ8?AV_P#<ZF)(W)6\I(N>_?;_`)0V
M/IG=P/5%HQ&Y3@4'#,P#`QBSD,09J-I:.L5;Q=@J2M66-4XZY?JD8&N#QI`S
M5B^":WQD$\P!M2MI2.(.HV>3.27*A`!.=E.O4%Y%ZG&8$'-SWPZ[:[UI?'5)
ML7#J3A,>OBU^YG2IDGEJ,*0]C?Y2WI0R3)V).G;3"6F1N2U.P("1+U9!B\)*
M(H`3O0.0\#J9X$.MF.O_`$\W$>V*2[(4;'++D,=B[U!D#VI=97&W15`Y&M1N
M3[`I`NAL@CJB5P1U<4!2@]E=!+&L9X<F9(]A"SD-U!H:FRY14<T(K>*HY/0L
M4DL%IIV0-A;>=7$,F#7'&62Q6+$HLITK<P.S5$&L@Q)@O)(0("/4(<EAS@,9
M6ZJZ[N#:V-"NI8H8W,VP/_*IK3`3J2,(MAQ2M=-S+9)-(5%'8E9\H<U"HTS(
MLE&Y/,+&`10Q`R'S3/4W7J?QS9>*2>LV=8S[ALXV+9$"96[MJRTVX=<M]2``
M].+<XIER,]/7;2F;"C49B8PLDD(L9P9Y'D,B2Z\T\AN"(WRBAB5):L%IM[H"
M+2=.X.Y7XNHI#)(C+G*'`:`N'X0]**009M/*/-3#5D_`(`#0@,,"(-:LVCNL
M,:KVD*IC%9D1NO=<[J/V#IZ+,K_)DC?$;45/L_DBE]+S^8&I=$9SU9[V=E`L
M,/0ARLQ@)00E$X+#^IGI1KW.(_N!'W.*N*$K>MG"R[(N3-(WI$[2].34K52*
M10V*#%:@B,+$-=LB9(4-`40'Y2_G$$1HA"R&QTU`URENV/[!%(W7%D1FEG.@
M6I:)X6":@5R[RV-S9:C/9O;[(]U&_11&,*P0?F"6$0,9]1YX&JXWH_0T3@.O
M-:LC=)T\6UANEVOVJB#92XJ5B2PWLNURW%2^+E'R'/K2<&Z'WPD-_M@^4GU\
M?"#@1_V=T`H1VTW[(:LR":)X_N4*V[XMXXJ4Y_(XL9?6L1:/O(JK5(3R&!H)
M(JAG$%&(H\CW`=D6!!-$'@4D="#=HW<TJCEH:G0X<1<[FZXD=,;?O##7Z>H&
M2:;!TTXTDPS65Q6OVQ*1"650/-GJ2E*]F1D(G-46$\TLQ1@XX\.C2%:3U-`Q
M:6"9G6<G9T2JQYJ*G?R#PUGX>(P^5E%ZH6*9]\+$G_-O(8Y$DII9J3\>6%6(
MP>2\@%@L(8PIT$JA96UB5>?*)_ECLC<EJW:=5A:]A`Z(+,9[WA&P:6.MQN8^
M--B$"F$$2IAD&E&+1-QIH,*<&Y`<`-NE:UP\N\KLO;+U(QOU[TI5M&RMCR<W
M!9&Z.U2\7&[LKLQ9"W8<4STXBNEP+59../(R%*GR66`6#,F!#/47K7E>M5LU
M//9UM7*-@(CK5K:]ZLZNP21T_6$$7U764D652)Y'(IO"4J5RLB0F-%+,*$E6
M>E09`6!4,P)IBG.0!:MP*>YGKKV14EM+LQ<VDKGHY+JQVHF-:V7-X1M"JV`B
ML[C<YA=-0^EG,,9FM8(ILQG1IP::\:UY:=0SX,`H.5%8$`/QCR$-;`W;[-8]
MN1+:-==7=(W2^=<]&Y#M$YSYIW$V>:Z1*J6Q)JX1AU;!UG_Q^(43&Q02>E23
M4@EZ<&6YN&>6F<2LKE&,A=CI7<UA;%ZC:VW[:T%9ZSL&YZ7KVSY-!H^]BD++
M'UDWC:"1$)FQU&'!QB10A<"CPDF",-2X-^`PPT98C!!K`X0L=FK>#(LB"+1-
MX$`(\Y&$H0-@&/!@D^!><$948&'YO3Q\OQ%>_GXP>`G9P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<"L[9=L6'=D76RY@3*A-N:XWXCBY:#`\HTA[U!*2=$1(\^?A
M"O5%QH_)/MC.<EE&^/Z9X&K8/']<I;TQ:V@VWEF8%0,=UJU%G\XF)<F<H?F.
M*:K/JFP84Z?GVKW<4F"9W%&OV+*P+*K&<D>N<&9QD+@^`X'-)LJ0:?VQFM*+
M`1+W;<CJ)<T8#A>A(LLE'=D<@D.#3?I@L),/ABLPC']3%00`\_KQC`91V:QB
MO9?VEZDL]MZ53C?^ORM#]M7`=$Q*)UA/@1F1XNO61O;[5.C-Q3^O(2C,0-3@
MM9_R`%9KD`;H4405G`QC`'@Z+T9K`3V)N]@P[I,MW4I@<JFA8*EM2S=5]?H7
M&:MM2#OMVOUF2L#W$+=GZR#/MBQZ:QUM:U+4@3*E9B$TE1ZE``9@.E'@.`X#
M@.`X'@R.51B',CE)9=(V&+1QE`6:\/\`(WAO8V1I+.,))*,<G5S4)4*`!IRD
ML`<FF`P(1@<8^HL>0@9M[V;Z^:;V+%Z;E<1V'NBYI3!5]I@J35VAIY?L]CU7
MH'@V.BL68-$+0'DQ:(K)"F/0I52LXO*I4G.`6$7Q#S@-L0+>76FQJLU.N&/S
ML\N';MND?8=<LND<D*)XFT@DD!EEF(V10T?CC5,?6)H=!G92I,7?`E)RC$#)
MN1F%8,#UIENAK97D#V.L^:V.3'8%J9-2:]OR2JX]*CTD'EA\3KF:EMOVR!D6
M.+^#]OVNQ&9.;259.#%F2_;W*-"`,X%L33H-A3M5A3(C_/":E<;#J8)^->?F
M34\.;#KHF8GO7X[]O%D*)B2:C+3?=_>"R2,SXOB#[\#BSA4CT<VTL;NIW%CU
MR2?-R[#V!;6I-:U&[2-TB3-?.N,UUXU?:8!:JRHUB9M>7!AC(HG)GQD>@A3G
M*&1QR)0'"D2'T#K4UM6:7ZP44Y0FDK)96:E*YV"E]+J3I+9LEFB6*7M,[GS%
MW.FT\GGKT]/&'=';DS*CZ!H"J-PD5&EHB\8$#.,!)T=O5>5.9?6AT]BZ>>5_
M!&"T)Q%U+ND3ND3KR4KY6UQZ9OY1YA8&N/.R^"O!92DT02\Y;C\YSC`,YX'@
M,NQ-#2,NDS8_<-</0-DFQP>]?Q-<O9%W^9F9IB9D[=7:M<)UAF9@VML-+RYJ
M#T7S%$HLX-&+`1!SD.6OO5V+I"X^S'H\U:A-UP>83:L.RNOWF\JKA\S1.,NK
M]YS):>-@Q\S9&]0I"RJSD3HO"3A4`*@`33`!P'W,QP.OG@1RNW<'5#6I\B49
MV'V5HFC9%/1>(4Q6S:L(K]WE0<+D[8(UA;I0]-BMR3@<%19`C2@"+":+`<BQ
MG@;O4RF,(Y`SQ-9(V%+*I$VO#Q'XTI=V\B0/K1'C&LE_=6=F-4!<7-M8S7Q$
M%8>06,I,)81@P0<FE^P?,7-H8<F:UI,NC!J-[?U44959;\U#3.\H0GN:5;&V
ML\*O)2]_1J6586:C*R-06-(<$0,9*'@(?[F:PW!<H-S+8Q@J$*/M9H9E^:L%
MQ!5^-2O'VTH']WZL"C\0N(5>BO)(OMC@&^/0819#U?S#1EUPPX=&[+X)NR\!
M9OODWY7+1A3A'ETPW?+]YENPL%@KY_3XODSZ^WM].!]1:I*:62<4I3FE*<^J
M<TLXL99XLA$+&"1A%D)N<A`+/Z<Y^F,_].!^@1@'D80C`(10L`,"$6,Y+'D`
M#,`'C&<Y`+)9@1>,_7U%C/\`3/`_O@.!$_?21-D0T:W-E;T0:J:(UJEL,^N:
M0A4-"H6(6JHY>N4HTZPM2C-2J591&2RQ@.*&$8L9",.?&<!2QTGZ]W5J?9L7
MUVV!?*KEDY@NE9+[%)K6218WYGM2SV[Q.\(FLT;W%.F6))R9A"HCZS.08]D$
M:0%^PRR"1Y#I7X#@.`X#@4>=CM44J?=*&8RCJ=VHWFD+[7[:X/EIT#8,4CS$
MSELKFK8D4-<6&0[+U$Y+)0B1!)4_]FT'X.1J`9">;DD\)`59:--E:,W8%VH.
M,9TZN31ED;.J>L<%5=L<[$+YL<WJ7FYE4IFY!Q-E6FTIH<ZJVM.B#\3J,O)K
M.8:840::<#(=(_704H)Z^-$R599Q*HG3;6$I24I`86H*4%TE"`'%G@-Q@T!P
M#,9P/`L8%@6,^?KP,=;\^W9I+L&Y]OBT4KK*+`_U?%\]_P!H_E,I?;S\?S_;
MH_G]?'O\9/MY]`>`G7P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"".Q&,8W-Z\Q^
M/&1R/9U-D7_Q%&T(Z'C)\_ZX&8E`/Q_K\>,_Z<".-7:_53M7TL5#0%YR=;#*
MIL'4.IVN8S!O>&1@6Q%MCS'&G]"_IGJ1HU[$U&1UP84Y^#E1(RBL$^1>/'G`
M6\EY#D`,@'\@<@#D)F!8%[ASC&<#]L?07MCZ^<?UX']\#FHO0T9W;0<N/%_W
M+=O_`-9\>1G^`E9)8P:+=@+FG38]<!",)CO,'/'RB\F&?<Y*R+(0``$,H[$9
MI5#)VWZS)+FW:?=`8PT=>FQCBSW'&K(J"L%T]>Y+L-0"%75;D^WC"IU#5K:6
MTQD3R6F3)2G+!Z3Y@'!+*'@09SU\BJ)R[`+HEE<]OCQN^Q2;6NFDD(JIQVAU
M4MQQD.(Q*+:_?,S>H'3$*B[ZSH8$?(FPIO6I4J`LXU[587&KOC2`1!?MP*3K
M2[5K/@?9"@U&:M;F5VUWCEVZY:SVM?[A9N$,V:+HVIIR:6_5H8C5R>.*R':!
MHTL>1-SFX*W-*:%:K&$DH6"\9&&47]V#7?!ZG[.GR+US!XK-M&+IIVOX&ID2
MMVF;-/X-8T,U]L17-I"T-AT84M"HV/VRXITZ<I4(I*<B+--&8$)@!!]=U[+;
M-LM_]H%(1A\;F1'5G6W6^QNJ#P7&F82J-V=(T&U<9DSNY*G0A45+<%S2MV$X
MM.J`-$E+3_&(O/SF>X893^Q]JV!>/3!/'&T)DM@&WG7[<DHGD8*1MC=#)K<@
M:PU>MZ+RU[;6TD@**3@87"5C3%!!A*05\P"<%^18&$2)+85U/^AE,S1_L*R'
M6Q-:N^!EADW6EV"]@7/$$:^U&5TXAAEH*B%P%SI`T%862VA(933!)`DI&S]`
MDY009#T=OX2.2P#^2[4J="X!RXT55&Q+`W*&A8^!5R%;II]DWRAA*=33DRH1
MTLUQ"044FR%.C6M8C`EA-R/(PE:C.2F]PFO]F-ST@<G&_P#J"M!@DK>E?&]4
M?D=27_1D[ASQEL:5JA,I"O#?;R$A5\?P"![X3F##DS&`J$U%VSTS9-./X[D$
ML+9[7&.R^D[S6N]EQ*4W;7L>DE3JXIJ'M['<J+!9U\G0N4'PS2R2M3<,#H!*
M`*Y>F3"#D9Q8!!EVS6XVELMU6[UXBDVLUAD2BU=L84ZPN.HKUJUQ4V'%Q:^Z
M*QIV=(DW)948?*&C#NQN"`Y0A"<7A6B/)R+!A(PA";I.W>E)_=Q.[3%MAJU^
MV63JF@U8!F9FPM2E,*22NNV%ARMSAXW$<R`W&/6&A`WKCDXLB.3)C"1BP`"@
M.3`Y?]:E57HK-@,\+44]C%E]9[+'XO>;):^O+D*8RNJH3K)!I]0#FUQ.4.TR
M;Y="%:-*L+%(0-3YC#6J(3%*4`Q9*"^P^W->LZ(7[^!N:G?NI]WV"EA(@63&
M'$IVRH[@*\=DSTS%I'E6;]LMA3$6YX-3`,)REP8L\8*$,S`38<["B[]V!=HL
MLC=A0Y2SLW6/J]%&YT)E-?.+&?)L2C>E[,"%X+7&FMA[)\Q>%*-</`/^XP</
M'Q9*SP(B:YR*!DF_Q@$CY85;I%-:ZDS]QD;:7,H:)W9I,\=?<<C[*>N-2.9I
MR1C5)1O9)H,>B90M`1Y%DP@L.0K);EE?6?O?H`J+CL97,,Z_D==I<[=GIK&2
M9ETEU.)8&EKUTPZ-A:4ET)/5MJ-<`S&!%FX3E>1#"(8S`[Q^!R^]@D(BEB;4
M=VLCD$$ATG<:BZ+:S:HTIF49CTK6-KT]N6]$[3/<7)?6QS(:RTREA3Y.%C)9
MN5B$@S&!>A8@!8)(&0EX[+^KN18^$93)H%O`J1J#<J_F,&Z/6BB'PG^,6`B,
M$F59$+[C&0^GGU_N>.!7_K]'"8SIGU2E#-"?@_NPOY]/]DX"L(%LCO'L5R)$
M`(!F8,RE<7+"?!H?'OY]LXQC.?`:%W_3K8YI+_*"E+,>B1DONT%+,:A*G^!2
M<4BQK?HPU3$Q7Z@&EQ^;:Y"I%Z8%E07D8O;`3/7R%PK7'<A[NPS$Q.B&2]]1
MK+'F19ZA$X`RP[;N+I($^19*P-*B/!*6H6,>_@\8,^0_VO/`J^T]@,P?]./X
MT8S&EX-;8MLQ,WV6_<*CTV4I*76/<YWCJ]<2-<D4KTIJ]"2>0+'REB!Z#R$9
M8O`@\3=9EE++U^?R292P2-U9I/*-V6%J:W=C<'Q&_LC2W4QHDU%IDZYH.PY9
M3B2.RH84R+R8,I283@`A#R#(6A,;@\I^XG9=C$[.HD8>I;6AT:V[[]>6@*<R
M=B-K$+@ZIV\TX!*%S.\)@#.R`!XP@!@6?`,8P$#M0VR>):I_B\HUL@?7$U;%
MK6EM@G8E;TJ!(U3QH';DA`Y2,Q:N`=)5`7Q\P=G"G!_Q*3,B!CQC&<!&;L%E
M4_1=,W;>D=EL@LB1V/VZ6M6E>19RD+\[$N[*MW5JN.1NJG,XQ2!>V09R01\Y
MM&VH%B`LMO48))/(R/(>!KC3QQV/9H7V?V+-KYC-@3NJ.BJ.1NCK.H<@<,C,
M*CD9>MZ4<#;VS"%Y>%,:L.!KZR(+^Z3KSU!^$I*Q0<-2+(^!=91DVM%\VTZI
MFDJ=2M17,@ZEKDL.;QM7)W7+5*IL0YZ-MD>F$B:#50RI#)FQ/*EY9*Q7@U0G
M"O4^@\9.-]PC93=XW8[Z,Z^RMXMNQG&7F=Y+W3LGDBN9ORE\=:S)[1[-K5+7
M*YU,7"6.,'+A0$3-AL&/*/#62!/@OX2\`P$G;'NRX8I,.]F816PY.A<-=M9:
MV74FRN#D-[C-?39CU$L6W/WK&8X\861MM5OTHD2+[\G*085@V8H:C)H!`++#
M0_7N[V?6VV.CU=N-\WQ:<7V>Z?3-E[;17+<$^MU(^[!1J=:UIU%B1I-8+T]?
MXY&ZH[@>0JD#)A`VJ`GDA$F#]H1ZAT0<"B/>+:/5RN]B9;#+'[U9AI#+VI)"
MU#IKNQJM/2TL2%^$0NJ!=G_+FM]BSHLJ8H%92Y04J=3B3@G^"@EE9"`(5>ZN
MV74%J[2]ZUCP'=EPWMCK?U<U0T$;&285<%`849,.V85RN#$CJ&`UM`2V9E5(
MTJX>4C1@P)AX_D,,-P9Y#J'TN2K$.G6IR%Q2GH7!'K11*5<A5!"!4C6)ZMBI
M*E*I"$0PA/3G`$`>,9SC`L9^N>!HMLDS$K[69G$4KB6?(V3K\KE\>&L!:C!K
M<U/^Q-F)&)8>:,H*88'50QK@EA+&,8?M!Y,P#&2\C"PO@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X$7;M;D1UYZ:.9Z-,:L06U9J9"M,)`-2C_(:W7$)46F-SC)A
M(%92''R>OC`L`QC/^G`A53="M6U/2O$=<G:1)8BWW)IH=6JJ6+VQ,\(XNH>H
MFK:0OZIK6*$:=>0QK\84"!DXGVP5Y"8#/@>`MK;R?MT"$CY`'?"C3$_*7_\`
M+-^,D`/D+^HOT#]?./KGZ9X'V<#F0NES`H[8@18\G)CO*NU/1](W.YH\8(:X
MS5O5K?5J%,YP`!$:<%<YK7O[7`0^2U2T0C1X+R#&`WSM$V[%RONKKQBU[:=8
MG)\C_5[,G9P'LO&IY(6@#!)]JXLVR))&LP5Q2*4#LN.CK6`1BD!A7V^#,8"/
MSD.`W/HW3^^D7W'O^:[7T3I#`JN_Q!448IN2:R&O!YS>\$ND]7SIKC!DEK")
MRW*%^^Z0#D?Y%0E)"<A:@H2E0,*#"0N/X'*Y=-;VS<>P?<I/:=JN16#;.N^]
MW4+;D#JEE7QU++IZ9JU#*1M&4BC:N2N31%0'2ZKG]QPV$JU/L(\&2Q!^096,
MAL`!W9_>$VW4+:>H2,P>H-T`0+,A5;4;R5S6TC2'0RHVNKSUSA'M?HK?,@3G
M.;1'F4:0`3`')#TAY9Q@@9*^,-G2*FNVHVT[`VUO>S^K?4]A?-:R=?;17%-6
MP.PK5'Z[CDZD\U9)4)7,GK7B.B=2UDZ=4HDR@S[(12T&3/G,`66`,D@'4CN?
M&&C3ID=NTPY&W:0P\B(4I_C?1^BHX[M"4NHW>CSE"IZG\CM<MP&NKUX$G4`.
M2#(-4%%*<%@.!@6`S%LZ.X(KBTYB-B;Y]B<[8;.N1_OZP6)JNBO:AC\EMM\F
M#-.RIH-#3-/P5S:W)GE<;;G!(6C7$(R%J,!P"`Y\XX&R7+HUZ[9<\2>1VW!K
MPOJ2S9)&&^:/UY;>[860LF#;#"W$N+M<K3/-S9:9&T,?YA8)*C6)CDI`EBCX
MRP_,9@02MU]Z\-&]4YFHL;7'5>E:;L!7%!P53-H-"6IHE1\.-4M2PV-&OX"A
MN@V<Y4Q(S!D9-]!#3%YSC/IC@;S.H:C5"QP<%%,50>O=EQKFZKCJZB!JQS<C
MCC%!S@X*1LXCEJXU0:,P1I@A&"&+(LY\YSG@8FNU*U4=!Y,<M9=?'$S*@I5D
MQ=3%<*QY5$8%@A3D:B-F"RH)P//H/_<'SGQGZ\#YU>GVI+@G)2+]7-=%J1,K
M+7ITRNDJT4IR%Q1Q:@I:22=&1EE*RU!03`F!Q@>!AP+&?.,9X'%#>K,&R-IN
M]89]8:\Q#4?7%!5U6UY69M/ZOQR2I;K8[6U.8E<N9/Q,&0W"XMKRT8=BTZE2
MJPU`_<*1,`:@Y3DM.'82Z]9?7"^97"=M!-,%QCF:<>XG'ZQ4MD]:>H/2*5!Z
ME0&%!.-.//0E"&/(O8608\Y_KY#FLVVZFZXCW8(?7\`ZV*)D+CL+-Z.D6CER
M05#4M<:\ZRU52`82Y[;,6PFOR,IG16@[N.5[HX!,7L<C%+4<B2-2=2UC;\&`
M#HD>>HWJSD`T8W?KJTI5C;RA$I<_\:*A(^,H?]2QX31,G!X<9SYQ@SV]<_7'
MC/`IKWAJ:B-<NWK^._K;1530&HJG;+/WJLE+6==0M@B,+32=QJ1C&FDI*)F3
M(ROS);W[GYSZ>?(2\^<^@`A#JCX'*3OXZO#A='\DYL+-P0>U]-.O*1C-0X/3
MJOLP0?<QV-(/,`;\ARQ4Y/B@`1`]`_%D`,XSG&<B#?S?I`WK=V--:S<=I.P%
MO&X]<U[S-0]E[=SY+*FU]8;.TU97-"0L)2%C:$D@`_8&Z)$64R!0H;D>0)B<
M)\8&$1:PU)A$@ULZIUJ#:;=Y"VV=V/6NBB[<EO=.E`SN!7_..:9EJ!"X1=4<
M3(_O8F:M-6F86+,J'!1\H\X.R(`1SM+2YA1:9=Y&6W8K;N91*);C1^AY9!WJ
M81L@%Y/('W5N<6+:%F/SS&ER>:7?+W:RCF$#^C$Q(D+&QM"3[,HHD[Y0LTF^
MJ%I3/L@V$USA_8=O)6T@%UF0.8,UO@DM"/#S%"IWL-=<=3L#2F+H-G7MK&R&
M10*DU2@7('X[R5@MT)&04,`0@TRU^V##JGT;G1;L"OF)1B\;[L9]B<7C$0I*
M9QFET;CJAMC,(ZVU7(+JK:RK'=XRTM#(I:22)0\/A0T#R<844F,)2!3A]&S]
M!VS'=,>T^:'[X718\9C&^Y$?M&`RJ"4Y$V&\9^YP_5&K8H9(IA4%80"S:X51
MB</L>4"41AP1HS!QPO.4WJI4C&$QF;5/;AE[#KS;)+V?6MB:QWK3UM<YG<Q>
ML.I!DC>(V&Y-J4:R-%MRFJ%K,V1IN>&)<[AR4D&ZJCG#!9ZPP"1/C@1,H/7?
M<=Y8>A+$;WD70=3(M76A\IIA7417CFEIPB)49'WVTWO*9(0%OM0VSJ.D^(BE
M+>U"4UF&K_*$Y.4?*4$(M;SQFZZWZS=VK)N?:&/S2H:F[@9DYS"N`Z95S-AV
M7,6_<B"/`WQ\12&V6=E41T:H\\X^/Y)^U<4WLW'FY)4"/*#3VC=73=_UA[<K
M6UCN6K==:XD6F%B3"ZJMG.L@VF2'1B6G;?.*.J810!-P-K7H_'*]<6J5LZ<A
MOD4Y;GU2L+=QITYQ>4F0N$J:@^Q1CVJTKKAIW4I%KG#+U06^3$'=QTG6_<4[
M%BY[IRR(8^^,BK8\*:>N[H[M*`D:XPU*)&%I68$BSE<2-,$%JUB6];MH'H^_
M-6S=4QF&/?<%7##%X>IUU=++GCU>J'>>>,=JVC:=C,EF5$S2.!NU_LTGG2-A
M1Q9O4)6'+<U&NF!IS%>`EC:-;=AF7#OB91;2ZNKEJ*B*W<+7=3=0K`1F3J)K
M]+)8F5-400I]JSR*]>RXRU92EJE&9"4)8;E3DD(`X2Y"5FBB;#UNYUYOQYZ;
M*=H_CVUF8RM:E:(2QN4RVU*#&\+FA+@(`JB5B2/)"'`_.,?'DE'C&/[F?`=#
MG`KKO&.]BCO9\X#4U=]=<OI9P(CR6)#O%TO)#9ZE,E:4ASXGG!,:@,KB:X@N
M3C49;@)AA"4D"6(SR:(6`!1=$H?>!&P7\AU??[!JG74U;NLNO8#^P]97^2*V
M]8P_X+V`E+%/1,\PB<1?#4[@FD9J!4K,3!*+6(L)09,`7@T8=..KZ@2O6C7=
M6((0B5474B@009SD(1'0"/F9"'.?KD.,B^G_`*<"`L4_L=ZUW@Q]?R'51K<I
M'[?U`)OVQV:3`P7C']0#"LSD7G_7&/'`MNX#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.!H"WE:9+9NJQ1S4E7G.-T2U`D7GC."H9#0ZWWNY&+46"\X*,-5)VT:483
M,9#\1XLX_5C'`K]IFCGG9_I/1ZY1U\;(P_W7IU/Z?99"]$*U3,T.TMCDHB*!
MT=TR#_OC&LI6I"8H`3@1OP^V`X%GQC(6V,3?EH8V9JR%.#+8U-S?D"4/JE!E
M$C)39"F#Z%>J</Q^`8]0^`^/IC^G`]7@<XZXDG/;IA>J**5KB>UV-,1:HXL`
MC`-6>A&4OC2B!YP(("V5Q<%YI.<8]\C7FYR+'C&.!A?8<VP%Z[@V-1.Z!WHO
ME)"^L-`J1MNBTEL*&SEC=)KM3)R4"^02&M[HI%S$B^U@RP29"M<%214>7\@$
MXCB`YP&Z.K&/E$[@;-K$%0=M-25XUUW7^:A:]]+$V1DM4_</GHON0$71V;9U
M@PQ7-U4H4MF2Q"6.2DI,E6"0FITXE!8PZ!.!SJ[C6)HEKEN=<SLZW3V<ZZW7
M;B"MY9>?_$JE[^G=0V8NCM>%16OY.M<&O7FY(8*1IHBB2-)Q\>4I!"-;2DZ_
MR-.;C`1TUGOQ=9NQDRF50;[]C]EU)5M[]>%90R%7^T,->I;&D.P5E3ALO)LF
ML`G>M=0SYQBK)!XWZE&(RT@4JEM6G%GJ/4P!03O[>->-I;`H[81\8=UE\3HR
M9M=,0MIUH#KM4\B3BDKO9T"BPBB[6<U"2=J13>2.2?("<F$_9G&8"4:$O_:$
MV7.FM_U'RX:MY:@;,9,/$G^?2@#B,L`@F82EGB_Y)HP'X*%D.3,A"5DW`<X#
M\?GS@*V9M;?9X_[=L.G.LVZE"6[/8<*.RG;:9+M%5#)5&L%7/J!P4-A,AEZ3
M:!Y'(=A)PH)3F1R"IBOG-:S!N+DH;D("E*D+#G#7_L`.'@3;V'Q9`'/V_P`@
M%&E\!7XQG!IV5?VX@V@C$7@TD182??Y<E#"(0\FX%@(`U8YZO]KIXS@M7:Q5
MC<0)2#*<2KKFA+BM*183X]RS3@[$H4AZH:S&?UX(`#!.?7T]_P!?`PY]U-[D
M#4I/[=[?J?2K0GX^;\EUGP(U&8ER69[>`D[$B/PI"=@'KG`L`]<B\XSGUS@/
M):M6^[EC..<!]L>M$U/,+"G`PROK9;&E@3X$:7DQ>4KB&RK2_B7%E`S@`#%`
MR!>^<9!C](@AE391'=6@*<R5?8AI0]#4"3FMRQQZ]YP0<B$,1?WJ;"=HW!;$
MXTI`<C^#)GS&CR$/N+&,BQP*A]E>M&]-=*?VMV+LZ,];]E73?EBM\0FUG1VF
M]IH99%WYV-V'H\N-1MQ/:-@G)-`SU%R1^)C1H49#Z4V91GG(U!0URD&0M\`V
M]\1F,Y,F74<ESC/C``5IN0X8%C_XLFBMAMR#/GZ>OH+_`*^?],!`/9JPNWVI
M]N-)<3!TZT[+MV=Q3=9BI.&QEGV3IZ+M[A'Z%3V+)9+/)G*)7:0#V%K'"VQ$
M67]JU$F'N6`GK$X1!-+#\='-E>V>Q`B>Z:8IUM.S**LCRZ_5/8W'V/2R'UQM
M6%U1-$QKW4R9T=0LJ66W6"%*WN1BORTO$?0X*0F(Y.L4K%:4(:4LH&[LZ_D%
M=-[MN)$-5*W<6:MM[7>#5_0=E6=;J]OC2&FC4KN^3223ZO*U;"W-[=G!.!IP
MVM)?H6WJON#QB^$!8=;W`HQW7ZUMHK:M'=>4:T6;KY'(QV+:]4_KE?JR[(S/
MW.;5-':M2V)%UDGI@405B990ME4(LY8$38\X;TR-V;TRG!YP##B<!8X[:ZO*
MK<6D]E$4D;`1NK]8;UH%WC2M(J&^N[C:-AZ[32/2!`M*$%O(1-">FUY*PL8?
MD,,7$9+SZ@'C@0XK[K7F<4KCK?ACE:$7.<M%]KK8V$?'!`P.IB.=QRP(UL_&
MVR(LQ*E:2<U.J%-?*`1ZQ1DTO(FT_("\_*#U#TY;UVSAVHK<>JV>P8GAXV?W
MYA>X#6L=D+^)CCT6C]K:V3AX@KVEP:N&O7NC'1ZY-G[<HI"<<Y`":#(?G,&&
MXG[46;/6^=P;0ADL72UW9^@,1U,+9`F/(IJAG<=N"W9Z=)C20H"V<$6_`6.2
M27DI;]X)649[%!!@!@@T9277W:%/45T[5`"05PM6]>STRK+B=FU5(R$$M*0Z
MC7;0[JJKQ,J8L'+53S.;,3.`_P`CAOR%(`X>,_)ZE"#6^QO7O?T[TW[(:4A2
MJ`.4[VEW48MDZB3JY`X-K4DB;=,=7Y2H;I8YJV/.&V1X44^\#"266I2B^1,#
M)V,#'DL)CO6NMGN>Z6PEX^L2%6EF:*U?KO%R_P`PO!)3+"B%F[#2UY_/-WXS
M[=OCV6JU$`4RM.I.,,'\X1D@R4`1@:!IG3F]8(7TQ$R%)%3%&D>N$LJS8)8V
MR("A(DD3IJ]!ZK3$0\!R%*IDJ!3.8X+P?@I/D"0OY!!#[^F0KA[?]';A<.E?
MLOBJ%J8D4M?ML;>W9RB#,TIQ6:J8-@F^U%+F@<U:-N1D2A;4\7$N*:3,X]'`
MS[7!HS?7.0KV>L[2:D6ELAH/?K98VU>Q7;QUV5AKOIC+HG!:^KG$'8ZOANQ=
M?-+/M,C7SE>JKMRK5LMEEQ(5Z,4B2*3R5JK[P\X8LY#JA9Z)LY#O;1UVJ69&
M*O(=H'9]$RV0EO#;DTJSGZXM=Y;'F9,S"/"[*D:AC@[X?E861]L7DL`#!8&8
M6'@5RPS0O9)@U&Z\JT)@X0S2B^WJ1;9V4R+)+%"3(C2,AV>VKGAKVF6EO![>
M^&IH+;#8:%&G..<1@4B#DK!Y8P!"25C:FWM8#5WD1Y)'FYO7[F5RE@6MDA7O
MZ!"ED6#=#HW3Z,MQ7H5BYXC+4QV^<YE#RI)(P7DPY224()N1F!JCK;BUWS/:
M%#<-CZJWSK)$Z1ZW=<-+VY->:*LV#$MLJ&V#-938B^MX_7L]GP#X0F;TS,`M
MR&-N`I_MEX(%@H&2PO;X'.;O!$J.DVT5J*99I%WKVK)0&Q<EPGVI%UW3!==G
MGXHBQDI3JS96'<^I8H622D)`2Y?9L:;V="U`S<"-&(TP*_=>8_`H["?Y+>:R
MKV\:B3Q?2R.(\Q#;K_(<LW%9,ONDUER-O<91<4_LNR7M97;H[I7$3.Q?DU^4
M1B82L)Q1"HE.`.NNFB"$U/U2F2DD)DJ>MH,0F3I2BR$Q!!47:RR24Y!(0$DD
M%%AP$`08P$(<8QC&,<"#=3H41W;5NNZ'I$YSFWZ2:#MK:XGE`-7(&MSMC>A8
MZ-R!49@1Z1N<%S8F.4$E9"4:<06,0<C#C/`LMX#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.!";980P;*]=?H::`)FP]PE&E@-&$HXO.E^RYV,'%!%@!N0&D!R'(L9
M]<_T_KP*Q[5?9!%_XX%\/T4?'N-2*.:/W\HCC]&W1>R/[0M9RYN6U*VIV:ST
MSBC7$?;E^II1@3,Y_P!?.>!?/!3E*B$0Y0LR8)6?%8\<J$;@6#1*36A&,_)N
M!_KP9DT6?;S]?/\`7@95P.;^EEPI1W#;!%/`L.R:,=B\B5L):U-C`6EU:.G:
MAH\F7I"S"2LA6M[8^.*0A1XR+"9>HP`60'YR(/4VFLY[9>X:TXTT;X5#H)\'
M6UK@,4OM*.U%*3+*6J=E=GE3:A84MPRB+M*(N&`^Z^]+1_='*RW<O(Q)\DDC
M$$C>NC8>Y;EVGV\@$H[`J`W"JVC4E:,D20U/6=415Z6/DXA48FCU*C'ZNK>G
M1RN-Q<;A^)S@U`62>Y*CP8/"-)\7`N?X%:6P$AWQ1W\:S4QM9UWUE5RE(S'Q
MZM;TJ*S9?=J]64R%'/1*YUCNS%:M1[:Y/!!AB8U*SA-3(3?U8.,*]S`JE8UU
MWK]Y[X-OZ=TC84Z;=L>G1*2]:^,DOCM>-;<<+94)#*8SS2=V*ZH96%&Z"4K2
M\./PY3KTQ@209'[F!<]V19R'4:7F8^@R+0UB5%"__+.2[1TRH(-Q_IY*.*"+
M'GZ?3Z_3@:5V5VTN:U;FE.AW7T)E%L)&6Z/+=D=F9<QBD5,Z31&7I25[3ER:
M_D)36GLO*X\IPNBL&":4F`F$%S>E"9`$LI8$KM0-1JOTOJ!/5-;&R&0KW9_=
MY]:EJSQT'([4O&W94(@^;V]:\L/`!5)9Q+%A`,FFBP$A(E)(1I2R4B8@DL)2
M\!P'`<!P*V^V+].FQYV/TB2[0Z!JBS<?3)!B??36PT"C`O\`\/)(@^WM_P"W
MQYX%DG`Y7.]^^:`C6W^MU76U8K_'6\_KM[;6JR&F-QF0.Z]DAUY:^1N)1*5&
M&YC#E&5!3@[01T0$>%A!J5P^VRK&4C.%\P0)ZM>V^8:F:>:1ZYUFV:U63041
MU.B<TF-J6G8]Q5M*FRXK"MZ7N%IU8W(8-2UPIG,ND4STI4J#PH0IER1N&0%8
M6N'A/@-(77VL3N?]D?51N&D9=:YAM/`=7]YX?8&L4/N.?M,299\4&R4D+B#G
M.'6`/HHFX6)!53:K;U"]O+28=PJ$R]6F3$%*0!;"7_)BC\=M2+UT_4?55JPQ
MNU^S:MO;$45LXQ(J::;("<J)54G5[_>L)JF)SZ:M2C[4D]*=(FY2/)QXR2S!
M)!DF!XZ;ODL#8F!4O<M*[*=5FG`P5-=%B7=KGN+LC^^9TE6*#4!&N;.J>JY!
M$GZ-/CU'D[P^OS*@:79\:#$:1$H2"RO*%@+"M+^V?6-#KA7N-Y.T;J^E6S"A
M`M=+$649L16#!7C?^2<CE+(R-:.03PUU6JV1G4ITRQ7DE(6>J"/("`@\"$$P
M?_*AUD_=J4/_`)#=(_ND:U*W*2?^4M(^2UJTH!R4CV_>WH/)Q8\9QD.<AQ_3
M.<9\XX'HOW99H`TQN4O[=NKJ/(SHNP/+X:S,^S-*'."W+0G<A_CR,?O;("U*
MQ6U')B\C\!^8&<9_VYX%/-6?RB-0[*J?7*T@43>Y8]@K+O*N#8/&G>F91-:V
M_P`$Q&.3A\ELL8E-E1MQ/C,@CSZ><VY2DC5JLM*PLH@P[[8I2&845_)^Z^+W
MDEUL#9!=FX$70U/7;=4T5V3`(,P.!T;H=#&W.7M#5%$-G/$MS*%:&18$B2*T
M23!IB<TO(PB`/T#<L"_D*Z*S=DBDD/BFST68I/K78>V2Q>XT@NDYL*IN`W#)
M:1(=)PS5H^3J2,KK,I?&#3&P@M$H*+0'DJ5QR,HS`L!*6L^V'5&QJNA%F+2;
MCK)186J=K;LQBM[-J"5L]CK=:Z>5)R9/8?XYA(DT:R4YHW!"N9T8'4:YV0.2
M0].4,!X/(11:?Y&?6Q(:KB-N1ITV&DD=L>U8W2U5MK'K?9RZ0VO8TA1MYY\>
MK="!I"CE:F+N3NC:W;"=3G*1W6ID>,&'J"0F!+WMZ=$*/JE[#W%PPH)1FZ6[
M#%C`-(<-26)RJN1I$Y9B4)9AI9F#U0,#\A\%?7(O&`YS@.4KJMIE'?%H=8%G
MQT>Q&Y,)H*#0!YD.Q\;L-?&+*I:7S79S;-W:JWMQ+/Y5')E+J+KDR!)FB5!:
M4*]M=L-B$HH@I'D`5`=ZO`<!P(K[';I:Z:F/M21^^YR=!U-UNLR:X4O'&Y(\
ML9(*]BQLUFSY+7MC:G%M@\2BT7(&L7N[L8D;4A`<B-.`'&<\#TM4MOM>]W*M
M,NO6.='V757[KDD,0S@$1FL59'YYB2P+<_&Q<Z:QV.&2AC1N'LGPYMX%+>8H
M)-*`<(PDT``@?LYN#7U:NMCU:X=RND.L-OM=RX?R6>W62D7=_K2KG"#-!+?2
M\E@LAOB!N:R09D0AOA,B5F)%1J-6!+]D(``J!!2/K_:B>Q5O\I&:N&VE0[G`
M4Z/4NE!L51\68HC6$F2(]/-E&Y(QLC5%)I9$?&NB1A@6Y<>F>5GSK"QY%@D6
M!$%AUWTBE4H:7J)"M3FI5B.KX"E5I3P^AZ92GBC22>G.!GZ@-)-!D(L?Z9QP
M(2T?@Q?VF]@;@N&+*ACUDZ_(TS@!@`"0L*I]W&D1HCL`#['*A/R]5^L8O."\
M!#C'C&,Y"RG@.!X;$7)2P.F),L8UIHWQU,91,3:O;`)XT8HR)D1N@'!V=Q+'
MQ*D\`5*2A$)SS,>Q9!(<^F`]S@.`X#@.`X#@.`X#@.`X#@.`X$`=KY6V->U?
M6)%%.?5TEFRUV*6P7S)@?V8YI#LVI<09)&8%6=@P+@5CR6$00Y\>_CR'R$4(
M>+7_`/\`";+46U4T>JXUU74[=\8N2;QQ*N5O\1A;O94[C3RXM"=MC\J6!<FW
M*O`2L@;E>"1AP(1>0ASX"Z-#\'V2/[8W)Z;[5/\`;GB%[".(^$'Q&Y%XQ[9,
M+\9\^,>?/`^K@<W>KOLZ=N.SJMVR,3CCL+O\\)_GX1Y!!>L?26+PI%\1>,)_
MM`1JQ7@0_`,&*1EDF#'G)&,"#9.Q4)F,L[6=@"HII!KMN9D?7CJ66X-.P-AQ
MB!HV%%G8S;8P+8P!DE+7,G>`2$U*(]3[$H"2#6M/[C,$,OXPVIUFB6`V.W/A
M[CUCZ@Z)K*8?(%"1S#7=W@#U+9H=/:[@5LJ6"5NL.INL_P`VU*"I&G<@*P#+
M(+-P!(8E&H3"5#"Z?@4%;H:L55:FX4KDLVZ%(YNFGD+)`6B1;:.]B:JHU\@%
M^$"UM:5!![4GS#*,(8*E1_8.*XS[)84421E.4K)^(0`@1J#!(-5.R=J5+!-*
MR]!HC%^Q/KT`KUY'+XG-S5HE='WY)&:RG=S@DNG,/^662%(A/2)TC@:(C\6F
M-."6?[>`N0[G9++6O2;,(A#P3$I'?.R&HVN[;8HT8'915"RY=DJTAS=:;:P'
MY"CDKM`G5<G<$S<H&6F6'$A+-%@O(N!-#5O5^M-2*I(JVMOSKKE?(I%/K#L&
M:.IDCLFW[7F[@-YG]LV?*E``*9+.IH]&"/5*!!+))+"4E3%$)$Z<@H)&<!P'
M`<!P'`K<[6L?=ZG,[`;GXT$MVXZ_XJ[*P>,J6]L>=Y]>2%"Y$6+R6<L(&$/H
M$>,@SYSYQ].!9'P.;[N28-DK)WVZXZGU<AM?3";277?LB23IMM5''WJ#N%,S
M"-ZWP&>M2Z-2&0Q=%(CEYSZ@(,2&+"PG(SSOZ^N<X"+B:^NT31644GJS((Y3
MFJ=836+6.WZZQ6@.O+_E/%W9]KX;3-[)$;2^IFT"6S8BB6XEREQ`M1,@&@DP
MP?W@"C3`#&&BJ8VFMC:K^0OUJQ^[Y-&9#(Z-UHVPD4>?X[JIL_IS))&EL:N'
MUO\`GFM-;1)U[RWMYR-H.$@7,+R[MJL11F!#3&X,2@#M.$@0C3#1#1I!(S/?
MW2"3DB3#^4P1IGN1D&2A?(:+(A><?46<YS]>!RD=F3Y<5H2OM<:&>1ZY02A]
M&6'61W>ZDD&I58V8[;!K[OJN/21VD\LM68.Q3]"YS'/E$W1]6RI0*484:,>!
M&FXQC`6]2UIJ-_W>L;7-_P!:M:I)#XII=$-CV1=(J;A[N_*;`?;:M>!.*9Q7
MK6\Y*%B):(BB$4`L@*C)IYXLG>OJ'`5UZX3RI;7@72/+I)I+H\:X=D$-LT&P
M*EJUB@Z;+$-HU9F=U?9U^4).L_"1]RE\-(3+0.0W,!R+T+SX-R$P(8Y()9K@
MSZV;%VL#KZZ_BGJF.V]ET$B[1_Q8KA0Q"J9SV\IN@U$A6)?L4AYTZ40N?*UV
M3B3"4);E@O\`[49)0@&!*6QJVT6!<'8A#1]=.A,L=-*M4:BO:/N3OKK4JMWD
MTBL6);$R,<2F2@V"'B:6I$33+;]ME-@PW[=P,'GZX+#@,&@M3Z)W$+JU:9-U
MH:$@;M^]:)7>4\^TUMK`HV%OT=I"J+20L,5^.*E#4LRA?8:L@P:T9QH"4Q7K
MC(QB&$(JV%#^NIHUUV<O3/4[I"8[:Y=EB#KX;&=MK>,,*5^A$CV,I2CE<^?G
M%BB*1P4N2AJM(:\;5@HY/\Q("?<9>1C$&SY!H-U+8O;L0J''6'0Y!6FNK--W
M!AT9'J3QDNT4=M1>[90JA*AICYJ!'$&QJ'2*0C!I7WV5`E631%A^((!!C-':
M*]3]K-?7#51O7=$66.[V:CRO<HZ.MM\727!Z@?(I!=?'Y2B8(,&9!3/$D<5M
MZE$$2`D#4K2A;1&^XSC@@`%<O991FA%4]24KW/J/5.>PVUY1L=8NK$`877=G
M;:>,B=YB=^V51"N7O:!VLQR8YN-XC=.JUR!E5M2Y&2J6D$'!5DDF?*$LVO:J
MAML(QV8[F.FMVP%-UUJ-JUK58""BZSNFXM+[MEM@"5[8V+:+99`Z,D$.4(G=
MXF;XK0A`X8=LJPE`<#""U2C)8`FSG17424[IJ]3CS.P]C&EU*BVVCO*4_9UN
MJ7&TB206:\UBDJ_,047@<_9<<GQI4X'K0'@`'TP5C`1BQP(,PC7C3>QJBZV;
MNPE[.R(WV37<94T8CZKM"V8<5-+$N<,MZ?1J1.@2YD)7)$KDP52/)Z7`R3&\
MI3G)QXS",A.#)K0ZZ=*':M^S>1CL#M(KM%UWIYO'WF7Q;?ZYI6ZV8>RZNP/9
M%2]Q!JL>1.<:)=6%%.RVLE`N,$B-4%>ZD7H=@)0;"ZT:7BU6]G<?B-[GWA6]
MM0_KQA+QJ325X;\.^YL:<JULR4N3+<\FK!5,8S#'J.2IO+J9F1R!C1)%+:G3
M%%JT@@I1X`2'4#&(I%H2RIXW#(TP1&.I%#DK2,,89FY@94JIY<UCV\*4[6U)
MDB$E0ZO+BH5J1A+P(]4>8:/(AC$+(5Q;&R#;A#.Y<FKKJXUZV7A/YMB4-4UE
MFU5?P"5S`YN:2%"&0.L.ENN\F2-9T=<\F(R,FO:E26``32<>HO0(46Q)1-G%
MB_E7D6%0<8U@E)6L=/K#Z8B4FADS98LW':&V6J;E`9-`66/QUU7RDH@3JH$!
M-@TDU=\)@S!%^^0ZX*_.PI@4(48#D&#XC&SL`SG&<AP:S(AX#G./&,Y#[>.!
M`>AC`'=H/8F),+"@A/K]U\-RX\OZ`1/)!^W3B:T&X%XSE4!F>$*O.<?I^)6#
M'GSYQ@+)N`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5#;V+42;LBZ2TYRI.%:LOS
M<D"1#DP&%AY(-%[CRJ6%$YS@0T:(P9)9P\?[!J"L9Q^O'`ULS51K_>?3%):>
MVFGKA6-!S0^SXK9<W:W%(TKFE`GVSE1*,M&X+FMZ3D?FI&A2HL>R4P8P*O4.
M`C%@00N]((*2D$IB`8+(3E%D$EXSG."RB@8++!C(LY%G`0!QCZYSG@5Z6](Y
M@U]F^DD813J;H8),]8=XG*05TWR1:B@3_)X%*M201:42&,ILDHWIZ86V=NI"
M,]5D_"8*L62@%B$,8@K;U<1#QV?W+,A##@B;=C6Z+0F0!\B.0&U_H-IE"3SU
M!^<`+.+=1Q(:D`0AQDH)X09R+(<BX&L-TF^-NG;1L8MN5H[$Y=#XOHWITH@2
M'K:,V2:I"S)E%R[1KG1%=IVNS^PNSXZ&R)"<OCQ2T1Q/V`5@2R_<LSW"274!
M)J??+PW':*K4]I"0N%22+1]3&]^I%M%((VV)W&OZTF)@FY!L*RX#";*)>I0K
M)PWA=5SBLCN$J_SE$H38+"9'9I<MN4W#]0,U!/%E>+[7[%=,J-G#RWLL;?%S
MC6-H6>4QS.-IB)2TO+<D"_),%D'*`%!4EI\F?"86/.!8"#&X.P^IT?W'L2+S
M[LH[1M=Y['D,4:7JK:-J">O6N44RMB<?<DRUC?0Z26[$5JEZ;EI*U:M,?EQ:
M=88H!@Q/Z#(+"O2@=D]:VF[K+L,W:BW=@J;?.U;1J/)]PKFCL?2*6AP:],'5
M?&XQ<#O^T:)0PJ!G3A6:P,SF%APF+<78KY,&Y/,4B"ZSN8R$W777-L)SDUV>
M>RGK40,+86`8E#RZ%[F5$YB;4HL!R44?^,;U)_L9D(/0@6//MD.,A;?P'`<!
MP'`<!P*W>U'.#=:J];R,_*[.V\'7.WL+=CZ&.[L+>[7I2!N),SX**,$B2GF^
MP\A#X*SCSYSC@61<"GZ_W1+_`.;7KA:2_E$O+TL[$%*H(B_4@I$X3#4#"(TH
M[VSDX\:AD/",'J'``^HO.?;Q@(+]Z2)_<+UB664^3+%K%TZ=W#XPL$5^Y_-+
M9`JK77"*EC9?L%*-R_*Y32/W`%.9@\S*8)9>!"'ZY""^M5<P.O.X+^/(KCJV
M0L\M>NF%QBDGJ:7+4"B45TPQZFIM,(VZOQ6'%?($[W+Y%-W\I24LP$DL;7D!
M`LB`>64':CP.2C>YI7RF/_R6LH,H0NBJ<=:%?L2):>)(B5N[146O4@937!QR
M`_*0AV=YV6D,R`DP1!9'R!P8(7I@).O]N]BY'8_=\I0:`5/*)BCZ\:QBPX-&
M-[8O@L$<=[POMUCDD42"74/$!I7!X>&IR191"0?:E!2`.^]'[C+)""6I5H;N
M1^M.B-'7W7HVOT;J+7*9/=0K![CU8V'7UE^TN5M[G@#<ZQDQ?68BUCZ!:/\`
M)#5A)]LI\8SGU'@,+_R7M.ZZ/S$F<]>LE7`L3N*I"\;6D$;N2L(<B9MA93V(
MU<[3C7YB9)]*29$^N%:S1G2UN;+DQJ)B<'7`EH/C;R59W`V]<NR^Y,0N?N]L
M;_QOV4:;.M,M5HK.F,-^4))%U+L#=6^SC&HL65MM?R:62&8L&8Y*5+OANBJ-
M[>@IV4\(R`C4)PX#,-7]@=C#G[I,2?\``/8IQ04+JC?4)C4G:I30K2S7[!(M
M1].U>UVO6S/9EKUQ-XNV2\MG:GY(U3!KCKK^(>`Y+*4#(,S@(>;";A6(S:C6
M(WH^OK9Q5';#[L9C>[W)Y>WUVS,J=\IW=1%/RM?DBNKI[:<Q7[%V7.Z=%7D?
M)PU`:37MP2E@<3B1$94!+*RMLGMQN;NLD[AH7V%-"R[]%->*[<VHBOZI<9#6
MR!-3>VC6V2:9-D9O9S5QMB>54E-RE5MXUQY'V2DY64C"7@8PQNEMZQ1#<'J/
MCCCIEN$2YT]UP.=%"B"*M&Q!+9.XW!!:2?E-H5!667H1\VI*J`:OK&F4R`M6
MA+:E4H92P%&X4%A.")>P%@2*:=2NIM!I=<-O(P[&=GEDS9?/'?5%7;,,@K>9
MMIM7,7EP<Z\42]Q/LUZKYJ?3%`&)6;X4NK4+!PC/MC"AAIZO-DK(!I+W@-=K
M0V];LMNP:SJFFF"XZSH5XCT940.B&Z94#4!E\Q.-J0_\=;LD,:9RI,Z1MV&`
MXR//;4I+"<2J++&%T,B["H=`>T?8;8%QUEWX=VB"=6-8Q=RKM)IM=&;%>5;'
ML9?DM.?$#:>S$(&V(JD)1J8#TL4$-:I64<`I3G*0_&`KUU<WAIMTUJZ'*F-K
MK9<MRUQWDDR!YD5=T%8]ZU6^(J[H#;F,)2:VN&IV"4P*ZC5N)@W"/#%5;FM1
MIT;JH/3%A;C\8#9VV.]E1.6EW?['&N'[6-;[L38DZ1P9MEFE&UD>;V`+GH_K
M#6R]38\I<ZH;8?5R8]]8%AF#)`Z(!I&\U(N.)PF4%?*&_=YE!4!V<WIOE9&8
M.^W-HETFZN["T#)Y0B`XCIB_H+96Y3PV.#&\-2E"XI$[XI:2`.30)5^/DB'&
M$B\E4A-&2()DZ);O[)WI>F@$#L#8?7E_-N?J=@.WVP-#((*\-%S%3V7+8RB8
MKDADQ8BEU9.%:2M?(CD"EE(4)EC0J;?DP6<2L!]N'C;85GI2_P"P]EN%G5/W
M1/5@I90E5+))KJJ[35-08$LCC8)9BJE=$RS%6(8L\$J`%K26<L@O"Y(8'T+]
M18&%;.I%:PI%7/\`*,5URQ[%QZG)-5<7B$70;1);K*O9.YL>A<L>)F7,G;80
M]=:BI22X3HK+<2[F&GIV?*(8,Y2G)O(=A<20$M45C+6G$8,AMC[,@)&=D(CA
MDHVY,G+$;D`0!R8(!>,BSC&,>?\`3'`K]US:EZ;LA[*W<2?(6ATA.BB9,JR,
ML6#GAL@5R9=D^`8'DXO"9N7-XOJ'`,Y-_3G.?;&`LBX#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.!33O<P&/':AT=K2E0$XX_96^KH,!A0C0*DPM.9`C/3@]!EY*4
M9$I`(`\YR'&`BQD.?./`>!7=".%F=/**D=FYH/5IQE,DD2J<3&QF)OCYD3.-
MW(=YQ',NK'*72,-[>.??&@2I`FJ"/J[$C)P,62RQ!=KP*0EFVMGRKO\`&'2;
M%:4(ZUE4N@<BV"2VN[1B4_Y_B*JQY_'X9*(C$9:.0!C1<<E;HP1T]Q1EM>0G
MD(2Q#4?,0$L(:&U;<L*>S)VCZ8O`VEQWA[5[);WK`LB^Z45]2.A-3/3,63G`
M,?"7*+$="S#L^!%G,V"\!&$W)F`SFY;2D4%[5-J0P'=C4S5-R.U#T,225NVA
MAC;+2I>)NMO<1U](C]SL+0[DA,01=W/`J$2%U(^5P2"$,@8?0P))];NREO;#
MVCN*BFVQ6FMWP^FK<:ZN8U.L=8.\)?Y.]%U75,W663)7E9L/=*%ZCGV,U+C:
M/X209$J8CL_=>I>$I00YF?;M5-EN5&,-XZ9DREKD_=F]Z"T8O%.$$H2,4_U[
MF9#5%=K5('.$-((N^,,^+,^T8,F87@+(&I3JSP!R'(6*W_(.RX-JR9%K'*NN
M1#4Z-"R$L"6_QWZKM7$E-;VPQ\;9,GKY[;8VWH?G4&J$)I.#5`TXR0&$XR+)
MV0IH9ZYVCORR+]JO:NL:CN:42#N%U!;=H(AKVQR>?:[)J"QUXU\L6&2=):Q'
M[J*@R9!EK&ORJ)R%)(U0!E>A(L#"&P[UERHG535RCSZ_W$BH-/\`NAZ_J)C4
MVW0:6,$VN*+Q_:2&*H7.HC,F-S7$VI`"X6_HV]`_'X+<%I:,.5PC5X50\ATW
M\!P'`<!P'`<"M;M".+#4^M"(OV&[.78SUW%,*8`!C,5KVW;:K9"N`#`0Y+\)
M(ZS+E(\F9"#!9`OK[>N,A93P.<7M4-E:7L7H,Z`*WMNG*GJ7[<T\57QE6X()
M(FD::)4PLC*B/+VK`G1N?$C\$DQ(>DQ]R6?@.2_(L8QP*P.O*2[225C_`(_F
M=>Y]`9YL&NZ_>QR:R:<;7G6U-HN[Q257]0Y[O&UCM'Y"&>%/S$Y-)+8@5F&F
MMR1,G#@H@TKX2,!MJOXELY__`-5VOSYM6IUSD%KAZWYP]JR]:6ZQ"X?$X<0^
MV=%V!>^`M)6XR!!*'!>YG)S#DY@4QB120`.,",.P(.Q_@<D?8BADK!8G;/0*
M>MKHD=L;W;&=:LRU8C<)HRX9HQ6&WTNR:I)+"EAMFQR$N=511MBKA73D6K_,
MO:`2?+.:,PL(!E"-"Y*<1VT$V^>X4V98'*'6-*NL*FHY#GAG8%21/++)9[;W
M!=S8,TROTRF<Y8E2O"`PM&`S!B$#B49D&,*,#&$(-'JPN%H@_P#'3&^U;8;<
M&J],K=CMP.CQ&'9LS5SVOUCJME9HI8:-Q2IW&+O+^]-II)`%A10\J6TPH6<&
MB"$8&>'3ITU'8F3%?SM/E5_(!<9:LBRV)/1;ABO".W-ZG)TI<V@M(<(R%A;"
M,/GY$?NWX1X`L^7!00CP&U[Z:Y&WS_ON>D+'*`%NW7C2>(XX-30\"-?']MH7
M<,A2FBRI(GP)W?D`CD0!$HAC4$F&D8S@(C`>P?A2#<](;AZ%A.`'A$H2];NP
M+*]MBQ$)*!(Y"IS2!0:4Z%')"U:)V*5-8P8),&#./0S'Q^P<Y"$4'A_?U.FC
M,G;LOL.72W^21AG(%EJ<!+69"/MS<I!\ZM,/[$Y,A<<-7RX-.]2AA4@\><#!
MG(2`O9[++?OY(+P$&7-;%M+ZQ8<DB0KEF0(VW26XI>D8@I$@2E#@3A5,E*G`
M",B,$)<(&!>V,!`&?5)(5H]\.IV-#P/X\=0.QCXH59QGY5)BN4]?:0Y.<9C.
M,#!@U`6;D/C&/?QG_IP*"=Y79QF_\=30@3W%B;H?K`[+WUC6PUXD3XSGV(Z2
MO9?<AD7QDQ?&Y;7[R:KD67$U&(!+\RY#DW/NJ*`$?`WO3"F&-757W`U[7U?6
MU34`J9FU+C#53][,^([9M:O;%J_K25(44K;#'9\.+6)ES62%.J.6JC34*1-D
M9PQ`R/(7UQR5#!W4[#M:P`"6Z-=76L3Q[D%GFJEA:W9S;`U4,P@&!B4_8A0Y
M"4$L.18R<+'UR+&.!5!04@)34?\`Q6FEJ/`VQV16/*I``M#DQ&2<<GT:V&`U
M$G-J;)+=\BL,I."=\V/N233!!P'(AG8X&R]R%RM7UJ_R2<&K52DYOOJ\4Y>#
M%)QIR)(3IQJ`<G(![#$-,E*3"]@`QZ@P7GSC'KP,:W,MM\I^X.\FU(.&NWR5
M03IXTHER-KL5B8YW"7!V97S=%2$F50Y[)<&.3"$B4A^%"X$')E)AQ(#@#),\
M"#[NN\F!6YV;Z:[-KYXXN%RS'^/7KNY.T#A5"BKVL2&>P[AQ)W*>*7^/NJB#
MPT#Q)$BM(VQ!*E#A-DDTTL_("\%<">.V4AW+JJUWI6I[=-`=3*WGCPH<J=K?
M8;62.JIHFC[6B:BG5I)F$EW`JT$Z^R7X,-/5)VDH985>`Y]/!?@*I(#9MP*]
M'?Y%,W=MBFS8EW<++6Q=!>-90>)M6K$E*>-4*6@<G>*29$<^M`09,WQ1>0BE
MB<]W6(DRU"A.(,^4U4`L.N=O1@;T"%O+,,-`A1ID8#3<^QI@$Q("0F&B_P#<
M8/`/(L_ZYSP(0Z\!"HW(["EYWT6)Y5K1&R<!_0#+(W:_L4@1#&5CZ&*,O$N<
M@B/_`-PRP@+S]"<<"=7`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*G=QF]8Y=G'3
MIEM2'*SF&2[X2=\$0#VRV1`K5=3%5KNL%G.`EMP)A,&)$+./(ON5Q&,8\9%G
M`8ZRZH1O:GJFJK7%H<('746D#O34H-.3V*3M9$6YLK?9V*6\]-+):0G)N3V(
MM?P1$]"B=##C`)5JL&3`G_`(!@7"<"A>,)?W9_)#LB7(K0K9Y0U;U7L51NE7
MLMEHS;+B,CDE^L5GC<IA6A3)A24TNK"]H3DZDQ=[$@.3F8#D*D(0!IK45,K-
M[-6XQ&G4FI6_:KNX,6FIB334Z%`O?M",9,5&%A$6F2*W_P#3[#S@(U?Z<9]_
MIP/.MB$2^P^U+L47H.L[7CL)2PZE=$X^RF7?)Z?A2N"_)%[RDB^/15;;%6V*
MF=5,J-?Q'*ADG-Q!64B4M0(6,@,*"=766DKE5,]EU44ZL:GZ[I;`9:QU/8C_
M`%^/7)8ML>7)HQ'[!<8\%SHUJ;URZ-QMHF[6K(4+L%D*3UP_0D!I1N,!S^0O
M6'<2,,FAK;/];+4:X@P?R0;SV5L-F?(G.)`^M4/D;^[/E.6:)+6[!/BAP`9<
MA=E!L@5FIV9.X)R0'J@$'C4`"T/=C5S4BQMDK2F-A?Q^;GVWFJI^CRA^V(AV
M-6FAKM!4V1EK1MSZUCE>TM=R]S"@1*0MZG*]J2&FFM^/D":$@@S`:;Z_:MUW
M@EQSZ+P:DA:71$KMT@*2GM:KM8Y:_60Q6-".KMOD\LQ&W&L+9F$.B4FG<6=G
M1W2*WEY?(^:P`5)OMOOE*,*<(K4;!KCB]`U^_74SWJQ*;"_E/06?UVT7RP3Z
M,K4]1/UIEIX"Z0IEGXOD3PE_#DT].:A++1&K#C@AR,P(AB#M!X#@.!3'VT=G
M=_=:954S*$Z8LNRE/S14)EE\O%LM#J@E$7E:A>%&U1]F@,@B$@>):4M).)'A
M6A$=X//`G$2`8BQF!^FV_;2_:R]BFGG7='-3)==,TVQCD8EHYU&K+969MJZ.
M.$[?8E,7V0QPR*O+BN9("U1\]U4*QGH"%96,D$BR<$6,!<QP'`K2[-_&8EIF
M7C.,G&=ENB?P%XSC)QN2;L:%*C!!>/[IN24)!IIGIC/H068,7@L(\X"RW@<[
M':9`7&XNP.G:NA1BU5:3UU#=NS5`6IH6%H',^76&RZ^U]$@!4*5+<E")<L<U
M84^1JTH2U!.#!&EX#[9"/O5[6%BTA=?2)5EN-SPQV'#.I#>*(25H?<1O*YJ=
MVC8#44X<;`HB#D[L#BWL"`11"-24I-,5HBBCS\X4&&!P'[?E5S__`"\OLBOB
M5IX1U59;5/V>"C!MB-;.`/.,.N2O(R3#'"5%^GR^!9`H)\?I$'@=4?`Q^52N
M-0:./,OF+^S1:+QY`<YODAD+H@965I0)\>35;BZN:A(WH4X/.,9&:8`&,YQY
MS]>!6=7W<+J1:33I2ZP9NN]X'O[/YC!M>&0VI7AHDSHA@)+@IEEF26./2MO=
MF"IFI*UGGY??B/(-3%#/+",@!A@`WVY[_P"NC1:.QU5JW*;#<-4Z'9]C+DE[
M?7\H=Z[::Z?F)]E+2!AF#2A6H);*E\:C#BN):FW"E6H(0J/B"8-.>`L,,IKL
MUUIOF7-<5KQ)<BPAVU#BV[Q$N=*9G3/$$M%SA[D;+#5#HXK6P"]JFDN!%%J]
MI9%"4M<ZMA.5*,)Y>!>H;XU)VLJ+=F@8'LO1*F6+JJLDAT5Q)PF<(D]?O#BC
M:7A>QGKRV*5MS:X&M:E8W&"2K"@FI%9/J82:,.?/`D?D`!"`,0`Y&#V]!9#C
M(@>V/47H+./(?;'TSX_KC@?D-,G,#D!B<@P&3BE.0#*+$'*@DTL\D_(1!SC)
MQ1Y01A%_N"(.,XSYQC@?F)`A'E9D:)(++B6$IPR),2+*\H)62`EK,Y!G[HL)
M`L@Q@?MC`,^/Z<#X<-C"!W;U>&IM"](&=<W-:\+:1A<@8E"EK&X-B)PP1\B-
MN5*D*,9J8`P@-$G*%D.?B#D(4^=[D5@S/T^[@-)==1-X:6R-0];&8-F,,PX^
MMF;Q<\)PRI@M_EM2,PG^5/6`*G(@Q.K1X6'*RS,'!]LAY'5S:4]VP3[&S[:&
M@8/54ULR!:SOD\I$EG;WZ.H&TZ+3QNCY#DK<TIQ<U3.<>84:I(L494DG(!IL
MIC!),)\\"9F@.Y%1=AE))=O*DJJQ*^CTF?936[([VY#HU&IM+F"NI$O;C'-I
M5Q]^E&'*`_N<]Q+0Y$LP'"PI7_:`+V$,)6EU?6A),'3DUW!2B*R5F+ZV(+B3
M``FO5QS8N9#EL'+"WX!$U9K,YJ4@C$&$XQ)5!I6<^A@@Y#ZW"OH$[,\TCKI"
M8DXL%D8<<6&R+HXSJFF>?EV5)&W7,R;SD8TDFRY1U`0@/RM`?DY$062+R6`(
M<!5+M1I+U\ZB=;N^S+&*6%K[0<NI.PYKL5C6%K8HW:TZA\:BZI?((VS/S^@>
MB!K9!&T*AE2E*_*)&0X&_%]O[B-"$`>O*G+/=.RK5#;^AJX=:PZS)ETFTA1]
M%-4ML2N'R1MI"&3-]E0FL5S8DETBG,BD429%ARQ>O^1Q+)$>+!JW^X$D(6;;
M-.FU$QEDB:0]3FO&U$)BS@[LL'E-J;/U4U.DEC3FC3@5KT$2FE`S,N+$O`1F
M$*T)[@'(L%X]LF@%YP%'T>BAC%IY_)@/,I>):U&([,;6$6OM=N41<Z^KM%#]
M/Z.><JHVIKQO88,:LF8'XQS692MB-7]R=@"[(U(!X+#L0`+`P!&'SX&$(L>?
MZ^!8QG'G_P!?&>!!;7@6`[E=AA.?]XI/K,LQX_V_$?0+*D!C.?Z^_P`K>/SC
M^GC./K]<XP$Z^`X#@.`X#@.`X#@.`X#@.`X#@.`X%!%I=CF_96X&VU*4-K]1
M%A1C3Z8:\M3M4)KG,WS8"\X5?!<$7D3&NY7'Y(CAL)=(ZR/CRO<6EWCZL+6U
MM'WQZP11GI@)?[+G%INR[K6..&666*INP<@(SA!`3\W[2UX6X":,0@A++^V0
M&C$(6<!Q@&?.<<"(6N&K+YM#TH]=]5UNXQRM3T)VBM^J_P`H2]$,N&.I[[K:
M_IHTMI*(M8M,4R5NCBPIMP/_`+4T]23D9@"1?($+]>!SPZX3K\U_)7['(D@2
M*&I)%^O_`%7:GXM,$PAOE#ZC?F^5-DB=0$^J5>[-;+97XY,<?['EIBS"R\X+
M]L<#)^O!06?NU::`&1!.8[9[E5"OSX]#<2??#6PY$63D.<YR-,2Q"&;[>N/"
M@OU]LX,]`A3L$\QH_M3[,<3F2]K[&3&X[HBA9C.LMFN)T0D,)E.21W`&UDM2
M1V295OZZ3/:S"+*P@1WX\K(0^I&#/8+'NHI;K*<^[AJ->;0[$[#>CK0CZJ^4
MN]4,M*.#37"GC06]T?H=BP:IKT!4P?8TA;$KZVHQYRD2MK6+[!&2:08J#G.@
M49N?6VM>B^F=IHY:=5SC:ONQMG:;]D*`/D4?89`39(V#B,*EQB&6EO+:1('^
M?-;J:R.1!:@2$T\E8D+.2B+/"^/;G9"A&G9"T(BX]ON[&M$\B#K'4[I4%:Z[
MQ*8U9!C#6F-*1(&EV?\`1ZQP2LMX:QFGG&#DKGA,K7B%G(,)PD`"O#6?96&U
M+-GBS1[#VKN%#7[O%+8U=KEZRY?[UM_[GJ))2$,,=IFNJ=:9-A_K>2$HVUV=
M(U'FM;AL;CE*@64RA4$T-":@7+(+:@>LM,6/9EXV;:$W_D0+[I*E4YJW:`Z(
M$P&GGR5R<FO4UR79`HY"XD_0U]K8P@^,)E1BP!A)Z,I,`T2@X@.X?@.`X')#
M_*`FA<5M'J+3FQN$1E6Z[52!/'-G90?9"YWHE_,4UBF^"/1.KIA%WV0E2I(?
MD]86I+5),Y:B`^2!9]A!X_8V_LB+^33U@-5AM*^1+E-30`.O)L-L%F@"J)/R
MVQ[F+MU=9[>9`9F\3^/+XZC2#:VTQQ82##"#R4QV3C3Q9#KVX#@5K]CI+.I6
M]?J=UFT-AQO_`))=;U;01+%3T0KF3H@9+,5DPV&DLK*]#6RYS**&:4!5A*A"
MD3J##E).`8SD+*.!S%=DJ6<V)VN6)4U1UZBL.Z!?QZ]WS*BC0SVMG/E4_M2[
MHA7K#'U3V[KD#5E*+\:<`DI:86E+&K,\C#DW(@A^O7'0TZUCVWZGJ%MMD&Q6
M7671==4<F$:5*VAU,AT[1;$ZCJ)BU`7,JYU93CDBUX$ARJ1*#0*0)LYR,0?'
M`A?8,6MN5_RM]AW;6VTFN`[`5KH?7,LAL1L*-2);3%W-9;=6S7.*DM=YCQ0I
M!'(RZQJ2%KVY];P*OQ<C;T9PB%@DPT"@+]W#<#L494P?O>HN?/Z\"HE&HQ`M
MS-479I,R<'(\KVU=,Y-7;JH:B,>`&#4MZ)3@SS@)`@8P9D(+;VV=?6V=`L](
M[A=3ED572,XV2U%9I#.)]L9KM9=>QM&[[+5BT"<;%B-)W8EL%<P*@.'XXTE*
M2O2EF+@G*@_;DC%P*I<U[U"7A_F&ZM#>N&5[!549HTOFZF5U?)3->WS72+QF
MSMK:KD\T@;K:FRD&6%O,T/K=UP!CBC$W*!HVH!K@L.+=RR"PW<WZ[?QY('&:
ML.E4;CC'%:1JAA3;4YDV-MB$+`"R]78]:D76.)4-MK$"CTW<XW.`G&!:DTI$
MD*>7!I*^U.5&&<#2P==NM5ID9'Y?7B_JCU")WGG$&6[=2/8#92%53*8=KY2$
MWL`-52^%JMR"KT85U3,-=.&(S*UT60M+=F,E(B$I.1X^<+5>O=5URZ;M/8]M
M3K//9[*-9:=I'7J9^QTIO>R4\)U\A6M`[IC,9K0-QS5^,=V50PR-4O:4:,E#
M]E]X%#^D(<8P%T:?:FI55O4?1Q*J0BG^P5+SF_*^2?MU?^+S7=>J:V1R%6_/
M&,90LSGA3:S2`A*,0AFY$;_M]0^X:P9NQ/5!_KBH;8:)\[+H1>^T:W3>K7,F
M"S82B37TWS^>5LJC@6W##^0;64J15H\B$\*BR6L"-)E0(\)8@YR&<3/=76.O
MFO:EYEEI(FQOTF:V=XV?.!'Y:X9JQ#(*^;[39Q+2FY@5FR`Y;`G5,X8*:`N!
M@`'!+'@)WDO`9RS[&TG(+1B=*-%@-2RU)Q2YNQ$6A04KL4[NM+DOS%%S)\'Y
MV\I(E:L2"2H4N"SS"E633_H5G`#,A"F?NIW2U8>NK:%RY7="QMH;<[835JFF
M>V80X.\7<@UX]WS%I1;<K87D]N`]QW,?J*NY*J`N^R-$2:G!X*'[AP(,$ZRY
M=K?I>A[#$(=K\V[JYK`'3BG&39&>3$V?)1$+*C0G,$6/ET6)7I'Q*S+;69FQ
M)EJ&<4#"LH@L)7I\8`R+^,K/8Z=U2UU!AR&+C65E8&R+@:D;USN2H05Z_;17
MSB,2=Y;I22CD3"WO#I&'PE(%Q*(59(;!"/``W!F,!=XT;!4I("*04LEEQ1U(
MV4:SGRAC4+B%2&U&1/"#K(/>(A\819<FLJ#$9<A*/TDX3B!GV]C"PB#X%^R^
MO[7"KIL=RN&`(8%KF^2B,WI+U4C0$1^JY%"6)HDTL8YDYF&A3-#K'V1^1GJ2
M!B^0O[D`,X]\^O`Q2I[_`-8=V818:"IY]&;EA;*ZG5W93>VA>$I;>YK6A`\'
MQF0(7%(T.)6'!B=2#1%B!\2A*?CZB`+.,AAFRVE%=WG4M?0F!G(:`L37IQ9I
M;J/;5=1=D(7ZV3N+->62.JHC%0%H&!PK];'<C8G^*FA+:'V-J3V\T)>!%&DA
M0PZN=%2NXYM!-J'7NCJ?L%1)I/95F5AIU<'8M,JD41IDF(X4ON[5EJ@9SG7P
M];)XZ_&)C1X0!6,Q:P#4I3E+2<>X1TJI\BI^@'\D`B`J=B'2+K]@A1)I7[;J
MK+/V"+/D>M6O<%<C['%;J!OLW.61U-.$V)G@H"X+,2E($8+&`G9#L^*!\999
M><^<@``&<XQX\^H<8\^/.?'GQP($:S(UXMR.RAW5N.%28=H:W1YK0?:%DY:T
M31JK6;T:#[HL7E9A6XRL\W]8?<OSD/MD/I@(3ZX#@.`X#@.`X#@.`X#@.`X#
M@.`X#@<:>]]W:.D]F:O8^P:L=]K-AJ"N**TGK<F?=N9U4\(@LW@LA@C?-FZ"
M1V'ZXQB+GXJRQ[(3BEA3]+I.0G5J0E&&@"<%&4%ZVT*QO%V,ZNC7*"TR&$:"
M]C\T?5*TL8TC:T+9=I:Q!=T0"P*##G%)ZGEF!``!F$IQGJ/.!"+$&KM?Z`F]
MZ]0G5W!(ZH3L+_"H?U96^XY7O2UI`.*T9+:#M26)2U362MPI5.T-B2H"=(:`
M2=28:$DS(,"^0`73\"DFAH.H([VM[K'8;\JMU0.>H^NT,LW6YA+L0NSXL],Y
MZ)YJFT)L>]1(NOE:9V9'F1HDP&=Y&80E,(R<G$:8<(H/STA0ID6W+.<022!0
MYQ?MI4.B@LDLHYR<4G:JC2_DUY@,>ZM:8WB3I_D,R(S!*4L'MZA"$(15L*8V
M-5'9YV,OU9=C6A^FSO8IVF+$JK_;B%MTRDLU51R@C`L3Y$BU6QU#*T+6J,?E
M*,!9)+KE6I2F^!$Y*]3`FIU`R==*FO<9P_Y:Z][8$YVNFPIJ_4/4<MJ]OCMV
M";FHFSR@*I/L#>9,LA3F%*V@9%*'#6B+&C6`(^X)^/)0:LT_@U@=6T`INC=M
MGC.SMG[9=G=Q1VGK49WY\E(X>UVW7%B6='96\`LWW>H$)MA]8.;6M:&50O)(
M-6XR6I/`>I,X$F+2GO:$WW9+&6HI7U:.558D2@N%1RTY9L+%[K*8<-*/)+;*
MPQ@,HC@I$2["..,.2(PDC29+!@@`\B,X%:=4TOL/=TS6K%<U75QL*W]S-^3:
M9;!:@BA=IUO1)Z#KD;Z\,(6-^PU920I_A4EBH$$/<"5"!"J321P":6+`"@$"
M#$3NOVQ^MYSZGJP,V_F]X01Z[:'Z22*,N=5PJ#ESV=7'4^T,\%8-@R5J<W>6
M/DHCN"5)?Q_=X:%R@PD_[%,8E)&$.J7@.`X'-3WU5SH@]7'U]RS<Z.[1SB2O
M-GJ:=UQ:]<K;K.,+JXM><3>LU#-;155RN6QZ:V"]MK^A:T@E32B>&]N2B_\`
MJ*;`S$.<A,+9#JRE5[=J^J?9>V;(8BY^JL&;(+':14UZE=&YT:'IYGZ>SERN
M5DR-"OPHE\,GBA$B")'G"!<F+4"&>7C*?@7*<!P*D>T9.U+;1ZCD3HW)5^!]
MJE6K$0C\J`&HW!GUKVG>$2Q,8GR`03$ZI"`>0B%@`\!]18&'.0""V[@41-[P
MK4_R7Y&SG83B2-G2:QF(<_#C"@K*[=M8<K\G>WD83#"@_P"GTQC@2E+P3CN8
M6Y_M#/,ZR&KV]O09R8LC:AYP7DG_`/$3EK1*AX,_T-R0#_\`+X%=/=+6$DTI
MO>B^^*B6_P#)2?5Q&RTENC7)84Y)5OZ;V#*`,3LZ(1%X)4&3RLW^3$JD0AB&
M687A.:;_`&FS!)X=&D;D3)+XZP2V,N:1ZC<H96J11]X0'`4(79D>T)#FU.:(
M\O.0'I%Z!26:6,.<X$`>,X_KP*Z>V-GG[IJO&5]?UY/+3-A>V6DUE32&5G#5
M]BS1PK"M-KJCG5C*6BOVC(GN:_C8HP*5!S:B*/4J2"QXP7D'OG`56RC8!E;Y
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ME:)V<]=-*;.-0HGBP6IR92LN1J$A*D)R=@W)9F!`";3WOIJ4FWLT7O1.^WW'
MJFU\TIV9J6PWI1IKN4".QF4VA)]12J^B+R<MI,I2TGJTT"=E&%625!`0-V`'
MFEY,)R,*YHAOWIJR:P]3],J;83PNQZT[;91L+*(C)*VN2)G-M0FW9N+*7>P0
M"D4#3)7-K51NT&Q4:-(8:`DQV)R,)(?;!89)M!NWIO-*]_D5MD;N=D5&[A1&
MN6+7LE-"K2,-MN31_2N#ULYCB"(<#`6\@+GS48W@5)3SBU"A,8/`0%@":<$W
M(GV4==C'V@0&W5NZU*+H!"^L(6OCU8[E)'!(TNEDK-@*XE;>R%.BIH0M"IY<
MF9$8J&4#^^(9GH$L(BS@!"DG:79W4.Q>K;I]UO36)1%Q6!3.Q4>E-XZT6+.&
MV%P1JJA5";Z:'=KN.5SW$,9:X6%II2A96%]<CVU,"0KR#B%!>!`/"'R4%MEJ
M/#^K/L8JI@NRB=;Y3;FR6G!^N.O5H6U7#C-XTR5U$](HXJL=ZC\7D($#]%D[
MI"U;LL&C4X">D:57S*\#`8HX%CO1YL!KEJ?K]=5-;'[N:$YDL*U8K9@*D=;[
M&U(H@TB8$-W;X/B54FDG[C0YE<J`RS=M5/!PB\.83'5+A8#[@W`S0V_KANSI
MLQL'\=8+]MMK*SKZSU@F;!8Y;I>]6MYE>B'H]'(\!KG(%4I)#$5HY,B3(,%.
M'VYPEP?@QC)OL'@:2OO973A]ZW>X6"QK:[6(R87WV4SB40-J*OZLG);+?S5Q
M:THF>5,;4AE*UQ7QW*2+"6#/3$FI\I$ARGZDX$+@=".FEEUS;&T/83+ZHL&$
MV;#%5@:\)B957LL89K&CGA#KU%$3JB*?8XO<VP2Y#A.2`\@)ON5GQ[!QD7U"
MR'@<NFZ$J@]O;6M\A#_(*Z_]<['UBN:9O5+0-QJBA`6I2+L@3!B]@4Q8-AOV
MT3!(9)%I,F]6R7LBQ`A(=\$EY&E+5(DIB8*]=1)'9UA]7W?S9-R3ZFK2M6U-
MZ!Q%XE6N+R3)J*DL]=&'7*-Q^35E*@NSB4X0AZ=I:W^AHSA!2%)QY']0B+"'
M<KP(4:M_2]NQ+`/_`).=L8,/&<?J!D_.D^I(%'@SZ^1!$7C`@^?T9QX\8SYX
M$U^`X#@.`X#@.`X#@.`X#@.`X#@.`X')Y==N[1&=GCYH'1&MNI(],9;L`5-M
MH93%1Q)YV&6AO537L]LZ03*"O5HOLZ:T$VEA>!.3XU1$I*:6G+-PI2Y1C4$A
M*'>^QMK8WOJVJ6'6ZGI8A;^N;L3;8NJ6;6'PL,FJO]]ZBK7:82<MXH=25`Y&
MQ'D$`RV`/<D:H"DPS\F4%*()H2@H^"7%:/5SU4):4?1-+TQ13JXL>9JT\D/C
M!3E3\")I:7VPTF*4>#!.R9Y@C8L)_&Y_M.7O@@>?08N!<%P*==<-7D<&[E>Q
MC9G.P</GSU;U":GLZFAD9SZ.>T7'6YI>F2/*Y$!68J9,1NPG>OGE>U82C3C"
M9A5[D?J^8P,9TA]A;DOJ8SR(EFB_9.%L`+_^4P^=JE@&.V09QX$+*\3(C]\B
M]OHF!Z^/U>P1Y(7V=9F\G:K'V'KFIG=J#1^_]>(@L7W-9]413#*XM^EU&N:M
MA;F&Q:KG(7)A+#(/NPCPI"$"EQ/"$G&<F#$$X>JZ*0R+1/8P$)TOK?3I.KV%
MFQ$H::TL*K;#8I5/F)R7L$R:4JJM(7!L,#76KLW9:TK:M1XPDR,T";(BL9&,
M/VWP*D!FY'3WF,C287%[C7,8[%K%"<D)L1QHUL[^Y<D@4$*L&*RT_P`8BOC!
M@WW\!"87@8A<"'6S^H6J$YV$MJ43;^/E)-DI*Y2@US=M@6$&E"9);BE4@)7*
MIB0&:;*0:9'N"E<9D@S\FW)EY@R\C'CQZ^0UCU;.>O=1V$31Y>I*RAWU][/=
MUF_7JIWIG@[P[:OCBVFU9RR?8R\0R=2J,1\B3L#JJ2@.:%SPF-+?2D_DH(\Y
M*"</9LU$O&SO3"D4'*B22NR!<Y^4IOQ^ZACTXVG?499H1A,)&4:K;``'Y#[_
M`!"'@`@Y%YX%P/`<!P.1WO\`[;A$0[1>C1OE3)-G7->W:\66(MA1.#RQ+!2Z
MV**KAF+6(V.:09QC;LQ*?N74A\4K<H4V4@2!HW("@Y,$+X)=URT[-^P:$]C;
M[.;J!;==TZUTW%H(Q6,Y1BH\-+<]3IX->)%%8^6W*Y@L79GAX#$;HK5-7LF(
M.^U^8L(\!8%P'`H0_D*7\\:I:OZV[*5[12;8*^*>W2K234+"U0Y\<4EFH:RN
M0$D>C6.N'!ND$G2IJN"_EFHQB&D+";]V<`>$N,<"XF.6)+G*"T7(P0-UEJZS
M4L.%,U<:$R1UKKU(_05=*'*9.[3+Y,0\?MM*\HR6X*!$8ZNY9[B1Y+,*+4'E
MA3!-[BI&B/Y"<]FEX6G5=-L2[ITK=N;Y9:TWB=>M*P\K<BPE"Q`A?I>YM"(X
MXLDLL9I19N1>H0"%CQC&<!F5&;$T#L7WC3F2Z]7=4MXQQGZI86PO\AI^Q(E8
M[$WOB3;R:.!;,Y/$.=GAN3NJ-`\`/RG&9@XHI6`>0X":'(@M?V?HF-[0:XWK
MKG+OM"X[>%33ZKG%6M;27@EJ#-(RY,29]`VGFD%JE;`L6EK4^/D+%@].#(1@
M%C`L!4A_'LN:>O.F,JTTO%S1..Q/6?<\WTFM)4A=!.R-X9ZV69_Q?(VE69@*
M@Y@,A)Y3.E,-P$PT3(:+(0^?7`7MJU:5`E4KERE.B0HDYRM8L5G%IDJ1*F+$
M<H4J5!P@$D)R"09&,8\X"$.,YSG&,<#G7OKOSI][>WZ$:AVMJ'&6!J<U,:4[
M=;D72A@=)+)$G./3F)Z,I"*+Q[![1(<*$:@D#XUIV"%'*2!EIWY4,(B^!`A=
M.7K9&![#6;;G=#V56H.`5W95OP>;=<NJ%OZ::[5Q75/UFJG<P3R)WD5>9@%@
MRA]&E7HV;#G/QDKL?;@P:!0/`B@U/`83*-E-JM0=9]#>PKLTUHJ_9/2QDWR4
M7%=6R5VWM8#]$G.:/$4,IM+$I9.5]*0N7.S&@"]!<$1[NL2_CS23BRP&"+&%
M[,,Z>YY'"F)6]=P/;])I`W!;E#JL.V4K@E@>'1`H`M&<"+.E(/Z5&UGKB2\B
M1&'*@&)P93GC/*-.":$+4E>[6S;:QTHQI[2NP6/Q%LW<G6L9RX)&H9SRFCD0
MZ^X+M:F<Q.>=80E&/+W/)(J)),,2B*$SDB+P2`T&%`@A0X6S=C3MEV--,2W*
MVZL*WNHF(P,^`R+:?8K2*IZOLIPV.;V]JF98CIIH^@AU<FMK$`*-K7.)J\IW
M<#DY):E(4L`=D+3]MHYO[1NA]F;:1KLXO]/-8M3[19:2#O5'Z#2F+-+B\E,B
MA8RK'R+ZU-V9`V,('4P/WJ)866J"1@TL?H+'D/<U^UT[!KSBEBJG_N%V+:5]
M?;%WO48LLVK^B@"7%HJ6PW")1AQ,(7Z^.`DCNL3M`5RDP(\EB,/#@HLK!>!"
M#0&^%>;IZ$ZR6+LU??<1<ECT[&9S1C3-$+IH7IA)U,9B,LO:"1$^3K6]OA+6
M?)DT-(DF')4F*)$>M`BR4E*+--#D(1TC2C<B:4MV+[M0;LKA$L@,1JNL+S@3
M_;W75"UXWBKFO3V)70QF,4$=)LR*:Z:IFROH2?ARV+#C<A^]R2(9^"PA,^@.
MM3L":=>=<8PLW*TY1EPNAZMCB)IF/5Q7L[D<(6M\08B5C<AE@-A6)&\'M^4N
M$PU@F\C[T>!GC*",8<`#5]DOV[%87+*=2:=KC6G<*[JTK:N+AMN41;KHIF!,
M2"&W'++0:(`B5$SKL6IY(YOQ:RM%V,@;TZ@HI*068<9D\P7`AP\W;NY$IJ;!
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M4[5%25GZ?3]91N!?_?\`7Z\";7`<!P'`<!P'`<!P'`<!P'`<!P'`<#GIOC4I
M];^R*`[-#ZUFB^I5+=@ZOBC?NO<6PLFV&;M;:H9B4CBD>:UU7^T;E=0)B9$>
MO3(5#1[M\<>EV9`XJA)_G!P-M[-/?P=Q%2DHOB2*XMU`[WR1T=G:*+Y=&4")
MUO/5]*T'O$?:\&N$I1)UT?4"4M90/E5%B"45[#.QC`2/*:;=LC5'KD601Q(6
MFCEVFD[MEQHE$\TK`W*MV:&HI3)3V.$N"I@D,:J):\ID`PQ90#Y@M@BT"I,,
MO!Q7`LLX%3VO[8O!W&]DKM]J8%L.U(ZXD7W>,@P28O+D6Z)@BA!P/WR<%-XS
M[9#_`+<>//T\<"+W58LS(;_?'XT1Q(38AO[)VM.>/)BO*:S.W#9L;@W.HA"&
M'[N,YKM(4'!0L@P)8;CSG&`>`@W8I&B3]O'VHKMD[![&H-(W3;^DX8$>H`]_
MFV$$M\=TKUX+1*I1C4B/O4".=5JQ2Y?,>]8,=,("T^0A*(R3D86Y=1C#IQ'8
M!?B'338C:_8**FW;('*PS]IWB_'=S@MEO2IR>Y/&8P.^8'!GH"D;DY''/8B\
M+UYKEGV<E(U7`DOLGJC*[QV6T+OR.V4UPMOT[M6V;`DD47Q`4B46.V6?2$NI
M\;,V/`7IK_:ZMN*E)IOS"*5@&$?MZ>Y0,""GO:6?ZT(=C;>;91_(.VZUI=T$
MTD>72E8XXTHWP>JWQ&<>I<88RO4BUH>C#6=H^/[=*A6.BY5D98BOG.,SD.`Q
MKJHD<4?K3J8$%V!L+9>%+-T>SA[1WS-GQOS(KJ?&*N*(84DNEQ<00L47D``-
MLA<26T.$*8A*C3I_1.087@!86"]B;44\;R])Z96<I(0D;H7BZ>R<S`<#<V71
M[8QY:230"",`@'G-XPBSZ^V"\CQ@0<B\\"T*T[5K:CZ\EMM7!.8Q6M9P-H.?
MIC.9D\(V&-1UI($64)8YNB\TE,0$P\X!10?.1G'F`++"(P80Y#E*V]_D";&+
MC"I7K=7[/IKJ.]Q%_E5(;O[PZU[,SN&;;2".N#:4U06JX=44?".JVF>9R?EK
M=9:=A2]MHRS429.>:7C@=06L=A6%;6N%"6G;4`/JJT;'IRMIS8E9J?N,*(#-
M)7#VA\DL1/+68PM3FL#NN.3"*/\`[Y.2_0W^X$7`C[LAURZ_;46BPVI:<@V"
M*5M:.)-C]`X-L=<D!J*Q&:#R@,SC;-8=6Q>7-\.D"%))"RU)V0IDYZS)185)
MAH"P!"$].`X#@42=\&N]A[85SI!0-,7*WT3=\SW6"[U+8+RQ9D[$W2VOM3]I
MK`3)GMA^V6EJFIT#&_LSSC"%($A2D1WVZ@0`D&!=M"TLG10Z)HINX('>9I(T
MQ)9<ZM1(T[6YR=.UI2G]P;4XRR1D(%KJ`TPD&0`R$L6,9QCQXX%2S=$*FN;N
M:VIC5E5/"IN=`NNC4!E0'SV,1F9I%+/,+]VND3N6V)7="X8;$:M<VHRU1!@0
MB4&H"C?&0!+SP+1813505FL5N%;U36U?+W!+A"O70B#1>*+%J()I9P4BM2PM
M:`Y2E"<4$>"QB$#`@XSX\XQP-D\#F6Z2BS&GM#_D2QQ*@5&-`=S*LE&'Y2<C
MR(YWE;;;CFYLH2$@S`A);#1>Q(LB]\DF!P8$)F!AX&_.R_9FG[(LB2ZM7//T
MM8:%ZY,]9VKV<W,<YOI+(^)[-DI46H'1/!\.3*Y,4[7/(W1ND<U+2Y+.)A12
M5$;G!#^(8`DG%+YZTM;GW:>%U5342KI?H/`ZG07D.I]8C65##XK.6-/8U90F
M-OL8AB--+%7XR:Y<RFAO.4&)35QYN2PF#.SP+3UZ!"Z(5C8YHTCBVN*10@<&
M]>G)6(5Z%82-.K1K$B@!B=4D5)S!`,+&$0!@%D(L9QG..!1-%6[9^M^]&O*&
MJV%6;6_6A`.M$Y6R0V$QD,:U2;;>)ME4THTS80TQM#$&Z<(&(Y.26U$JOO@)
M0?<@*"G$=[A?)P.;Z(*1![7$A><*TX0]N>Q"$PI02H1_<'J^C*E71(<62H"5
ME2F^T;S1%G8P(`@C"(O(@#]N!5[NSI9M3MZ_?R<H+4U'V-)[3NRR>L6.T@QR
M=F611IGD+IY;&7F1ND`L>>I(K7#JRIT[6I7&I4;L8:E^W#\X?<:;)P7F=N3_
M`(HKHWO?!T55(`,.O=+5DHBSJXMR9PCA4MEM6U8>0M6M12IH4N,3+D&31%I_
M"94<E^(!A8#,&!"6/78_IY'#-I5B<D9&$78-O`P&EF&%F9RHC=^2IB.."(OZ
M>BD;?\H0YQ@0,#]<^<X\Y"&_\AUN?Y1U[,];Q)6E*E]M[C:0UE$VYQDSU"FF
M0R&2;,5X)M9'F8L"%S=(JTG&(LG'N)2<XU$`CYBBS#@%EB#G*VXC\WF$SW%T
MUM[9MEZXVLC3[K,++U:<-F:2J77URF;]#X!66PT&F-S3Z(2`BST574K785#$
MVI'9$6X"`3DP(Q*3<9"4B/N<WJKV0TS#:TE[9=-=P*SWZN8,9:5?UW_E?L_I
MZ-WI94337/1LI8)E7PWHR2UXQLT?B_[!ALER?+"E+C)"VIG4IE`@O/A\SA%7
M=R&\<DLF=0:OV.0Z.:`-[,XS>91N(EN;@EM#=T1Z-L*D+FW'N@B"2!#-&G"8
M43Y"$8@B$'&0IFNJ;0]HWI[[;0D\$:9Q!MDJ`T1UMUMLNOTM'W(KLZS[+88C
M2\,@5;1*WRBZCGCXEN"5-[@^HG-S^S;B65.<K)&64`\D)^]"52/E!/FXM*2S
M6UDU1FM>1W1)EG511M]@\H8PS=%JLS,\NG"*20![D;4_?Y!D3.I=1*U:PYW.
MRH\KL_/[9R'19P.=R^H_U02F[+;2VS#>SM+/2IA.'&<R&#-7=&V5UA\2R("*
M2K(6X5"8&M,QL3JLP)%F/`_#B3>!(\?!Z<"(>@TBA1NC'8W&JJ_=F*8KCO)K
MQMJ!-/&VP&R>IX.Z[*:.SPHJ8&7`E37*X2$UZDBPP:F6Y-?,@,`$T7Q`*`$.
MM_@0CU%.+56AV"*DPOE1F[JX()4>,@^10V:E:H-#H5\0\8,!]D[-YY'MG'@S
MX_</D.<9R$W.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@<VG:#L%!]8>P*667-;E
MC]%N;QT?[L0VJ)L^R$45-#;YUV4\[0I(P/XP!2H)-^52DC;L9-`><KP6`@(S
M<X#P)N1N<[1+=->H>00<ZS'^6SZ2Z1?\H'8#4*12=36+]0KD^6H\V4O=DRQ<
MTH%,P(0#>'$0BU/W)F"Q&>3A8$%M_`US':AK&(V+9-N1B#1QBLVX4<'06E-V
MQN)2R&>I*T;W=I@)4F7%XP8Z?M-K?E:=$(SR(H@[(,9]<!Q@*$>HI6Y`V?F3
M&><0-K;*(VB/1DA$F"<4ZJ>Y/L)2/1_KD05QZ=6G;D6`9]1%%9)%Y]!&>!!K
MB$O>S\+W:[4C:.[`M#-:&63;LQ(:JI=HZK-GDY<9"FT]U.(S,&=T;]D*7<4L
M>D+::G0$I!-ZP'W"`X91^!F""`+3.K^J+GINJ;CC5V[)4#L_)I-LE<ELAGM"
ML#G&T2)7;<M7SB3Q^5M"Z>3M(VN;7+75:4B1I#B2D#8`A,+YC"AG#"R_@5(3
MNP>XDNRWUJK!EZG7BN06,]MD=_>ES[,M-D!@"=>X*6@R3,K)6;PR))V4PI2\
M+DR4]0F+5?(,O.2@>,A!#KWE$IQLK4R.W8I7R>Z9SO!W/ND_7P*52MVC+/*H
MA)JO8#"X&:X-3`7)HD.)%-K?]XZHD2\.$A`\)<&G*1@">V^:=6Y[Z=+K6E*(
M\)]JME90I5'K"B?C3,&B&Q20Q(2C]1JE1ZO\[[A&'&"B_AR$P0<F`\A:!-(1
M"[(BKW!K$B,8GD)DJ(3=(X?,V%JE$7?V\1A9HD+TP/:5<U.B/)I01?&>4,'L
M'&?'G&.!S;=LG9GV%5?*E6OFH&J<FH>M"+MIF@9AOY<[17#FV-:NU996K$VR
M#4W7.2RIN>=A`QT<SP0H5$)%Z9,>2,&4I7Q_=$A>KJ1K(TZGT^DK4BQ;)N66
M.K\\SNT;FMZ1J)+8EKV9*!IS)+,G]2,06]H3G!2$)&YI;RB&YH:DB9&G+]"?
M802<X#@.`X%>6[;DE0WAUAICV-I<SG7>QR0I'-<4<)RCIH-+=OUPW!B/*-+"
MG5JRDF4A_P`@3`&(U!H/7`A!$$+#>!4C6V,)^\7;0L)>/#AUHZ6+#30AP'U,
M1;%[DI`!'XQ_=&:6;_NSG&<8+QC'G']`MNX'G/#PU1YH=7]]<4;0R,;:N>'E
MV<5!21O:VIL3&K7!Q7*SA`)3(T20@9II@\X"``<YSG&,<#ET_C#R(R9:\=D&
M[4J8A,3!M#V';%76T3QP<"_64U\@3M[C]T6E/`$Y`SQ5X<'<@)IQX_D.^?'Z
M<%9R(,MA_6H\=C72\TPEZFJ2N[&WXV`9.Q&Z95+8VZNY$N!9MTH+C9XC)&.-
M2:+NH$C?1R..QM`6F<BOLB6=*$HT`2PF`"L/82EX);^]G?A)K"_R`WLL5V8Z
M2*98VN-VM;]=1":-$OE])5?/HG+DL$FD5C-@*9#7KN)(!&[IW!2W87C4H<D&
MYR;P.D5QZ2>OAQD2J6YA^PB&1J#7120[M>\.[2!8U*G=*I2*E3(81L'C\0<`
M"L>2O@]`E"S^G&`X\<#]G'I8T9=%:E6H_P"6Y8E)H31$)NPK?-.D+&$H!(?A
M3%['8++Q@`/],?USG@8&OZ&=!UZI2<)QW(3I%)@AB:"=_P#<\QM+`+ZB(`%9
M=RM:(G(OKX&<,7G_`%\?3@>3&^A/36"'+C:TMO?>KPN4B<IFO+@>]^Q[,)5.
M'1E(BA\W/7&S98Z&2P,(0I&'[W)^3#6=&2G.^3`19$'I+NDFIW!,W$*-\>W3
M)K>G^`2P/9)L%\Z[S@OR:J)&\#0$F",`(><)B$X,B,%^GQ@.`A\"CH_J]3#7
M*OU6^7:4\1!_7(G&4,$WW!/M=GE*EL<D+JV8>V>WH#/F@U,A6-Q(L$$IR"3<
MEA$<`P00BP&S"^K%^:VQ8V1'LM[)8.%TD;S*G@^*V'K6UC=WN0N"UV?7-P)(
MU9"D/=7EU694K%F2_NU9^,C.,&,8Q"#35M=-5HV:RH&W_P`NG9$-0QRR!S2.
M"GKUK;8+.QR&$2=/)$S^D9<:^Q<8).B4(DYS,X@4EG,KBG+5`P=CW(&&%:^Z
M3W/)9QN)5#=VO;P2AOJ>V(97[^IL2M]$;+6N\K=Z$JZS#%KT_3K5V8+Y*@;F
M6PFU"4@/);RT(D1N`!'A1DS`:`W&C^_^C4]TM*8NQ?;W99UN*P;9A$NC[)I-
MI-:4F8(A#Z)G5DKI354'8Z^JMP9'%"X1-`A5%Y>5)`FM6H,R6:802F4!!C1W
MKKVMVHVMC.V-JS`^]V:P*;MZ52C:;<_4>BK4I:ZZDN^20NQM16>C:S76J?,H
M^X,\*.PO>F/+=#T-?*@+V5-]X%>(XT,FL&*O^N?:X9J"XH>E'7:.L&L$7W)A
M&W$MZP:]BKZAL11<+%4D9CIQ!&P<<*8I`58KJ0K3/A3RF-(*$7@&,J,#,X&8
ME6+V6U75._\`V85SMQ0-BJFS;2JJW11.%Z?NS3$-WFG7LR!Z^"A5;R!XNBQG
M"O([.K4E+W$4SZ@+=LJU++AS)<$:([.2@ZF=9+B<-A==Z3O1V@KG6#I;E8PV
MP7&NWAQ(>7.$K92QHW=3&5CRD3(DCP8SG*LD_=DDEE*@@P:`.`CQC@58VNNV
M(37#9"Y@[[=::DCP9),#XY1LOUSU2D(ZV1`5J?MHI)WURN",3N18A!(@DG'&
MFMBLT97LH%C.<AX%;FAC-)0Z0]G2Z274R[(3J7=[$50*KAC$8C\.C5K2]KO[
M1MA026.1V-.SU'6ALD2Q$3@I,E6J$96`^`'C!GWR'7)P(,::9*)G6^I/L$.!
M;SRG!01"Q[&&GZZ:WKC@@\^,C%[&&"\8^N`8_P"F.!.?@.`X#@.`X#@.`X#@
M.`X#@.`X#@.!687V]Z(?YD_P4KLF=MDX47`NHEG6KZ$O@N!2*RFNT$5(.K2R
M6:17"BOU+:V7*XDQ<YR,<2FX+V9A/@[.<XSD*;/Y)E:M+`@EMM2*8K8W&MD.
MN[:738*EQ(<E44:+:K65U[NY2J+!+>G<C,/]KETE)HT5G[<&,&F)AB-S@O`<
M!XCE:E:,<3U6;J;[7>T^BFN<GTO%)E$I51#E)(E6-:XHM\DV5+6_V[H\X89,
MA7)&A,:['NSFC":IP`S'IG`R`CW8F_>Q\)G6Q<;A6_G8=+*4U\9B4]>7`CAF
MA:^<[231QC,'D8H[74%LO2JOF;#1'W*3NZ,]X-DPQJ,,)I*1&I5C3IC0F!K;
MMY;UA:VZ^V!;7?14&MEI6A%&!>XT_>E6:.26R69V5)#\_A7S+2;5(C7E2U)@
M+%9`6PHUK7FF)E!AN21!$$']!+[G(;FG8:V[L-"HZ&)TNF8)39MPZ\UB0ADB
M]^W3W%G>&R+F8V;K5H<UDB3+U4G7G-IZI.E2OZ).8G2C**$,-%O6YTIB.V.T
MM;O+7U;[NV9<M^SZ70S8I\U@H*45Y:[=66M=`KIE%$TMF>^48?((=!V1:B;&
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M1C>$*10B;$R?)J1`<I$#(;[NG>#;6]>R_K):8OKQK<]3VF[2O]8GB<+VON5Y
MA3[BV=)9](B&5_LN3:7P2!-TH05X2I<TGXXY]6$'^$BI&D`H,4%A<J];*=J#
M>0(;7U>4^_GXRG]2$O8M&T01X.$?@[P:YZQI,8$EP4'(L9QC`L&A]<BS@>`A
M1;VVZD=@6^*:N-@Y!UB4=K[;VKCU'[(4;&X[&9"[3M-3M5IY[,W>MX<=3U4P
MR5110J?7O+J%V;C@NA"I*5@C!F<X^(/%Z[^S+LAT_K^F=<=YD-?;4;"[9US'
MME]-XG9FW%>4Y;J>E9BA;5".L[4GML0QF3OEI#7N!N&M(K-4N*DYO<$PCO\`
MMR0<"XZ2;B=MKY&9`T-73?*8B[/D6?6IEDS9O[J,\.L4E2IO&E;WL;4Y91-2
MIJ;E:C[A.;]P<<<)/@)J,L(^!3JQ4!_)D:JNL2)N]V;022S+&M:IG'-C9D?7
M@ULT0I&,F1@^5L<'92[+/65_;2WY'<*P]&%P8GH*=$2:$K)RI;P+]B-NMN(>
MUM<=_P#%YNE/3&!`V,*B7N-Q]?HGB4*4"-.D-DCCALV?9&\Q4ZC!]PI,(0H"
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M[/:CW62AWVOU$:M6K-1OF[KI9E6Z-T)*M=%L.O5AUC=VF8(;`NE=.(7+GR,X
MD=?,2IE:SD;B:,HL]]$O$L+PAR2<'ZV1L!V]:^Z$0#2_2/1"[HK25=]?%85?
M/16;I9=+S/W_`&,EC+*(WM!%8N\,STV-[8S($4F5RINEAK>J9SW%MPD",W*X
M'R!?QJ_VL:YUQJ;JJP+Z.WW`D0ZXTPW-"F-]=NX#_'G-$SUQ$VT"F..L7IUQ
M9'%F,R(K[4],8)*>28`9(A%9P+@4J;2S#7B./^ZNSZ5]WP52+>K<#JWDR^KY
M9U;[/T\B@).LFVU7+F7]LR9XK)N9)_-5L"3*$A)*Y4E<'UQR422$]4>G3@#I
MN>NTK3^/.)K2ZK]CR'(@LDU0C!HQO(I.3EJ`8,3B/PFUT-"7@X'U#YS]?&>!
MK>8=TF@-?MIKW-9=L-%V(A0G2'/KYHOO(V,Q:I4'`DZ<QS6ZZ$I"SCL9\!"(
M6,BS],?7@8$V=^_5RYON(X*Z+79W/RH"8&2Z>[DQM*08F(,/$2H6/=!HDQ"@
MT)?J46(6!FF""`&,B%C&0S=R[PNJUH^/#GMY$T0SC%!191T&MT)XC$F0!5@^
M#%>Y.P)(,T`3<9#_`&A##@7C(L8R%4Y'\E=WDNXU@U#6NJ<-G6K<'CL_D<?V
M+4;'L5=.-OHXRW,@X^D@+!:D/A,7:):^OCZ4D"QOCP@//(*5JB%`L(Q$G!97
MIMW`4-;.N<(MC<FVM0-,[7G2A^>$]%R+;FK7B1QF%F.)AL*%*U#XMB1R*7.4
M:-3JEB$M./!&#BQ9R`1N2"@D>9VJ]990,C%V!Z:9QC.,>"]D:C.'YSGQCP63
M+!F9_P#7QCZ<#4ET]C/3[;];2:L+=WSU%<J]F:5.W2)`FVGBT1-5ITS@C<TQ
M0)1#YVP2!H,^^1%"P),M3F&8#D'G(<B#D(A=9FV'7#6$W[#D53[,:B5]09VU
ME?%T^F;K[I]IBSK&V'3+5^,/+]&OFFHSE[8IE[(X)SUYN<C5N*55DP0S@&YX
M&I>S_=.N[%VLZSV?439[KRFLH:7G<:6OKY=NQK*EIN,M*[7,RK"\2R753('F
M1-*^0MML+2VE$`D.7-85C.#B@IABX'IZA6_V:UEKS3&J-*.72O82^BJ5B%4,
M,@;M^;AF+PXM]:Q1JAZ22.4/CNOBQ84('VJ<]41]YDHL0_B^4.!!%@(8W)I1
MWO;!`F#'LK;_`%:31MLNKGJGI[.J+61^H+UE]9.IZ56II^3VO-=99M(S*2DA
MXU?Y=C9ALRQ9\@L%+TP1"]PQ'89'W+Q:E*SHG8)ST'C^FSWL5J]0*RNM-;'8
MJIN&`UL]WE7\3K!33LE=(TDC=>ND8D!S)ZK_`(\DMJ-(I,RE"6(.20L0U:[U
MM#JUUZ5U(GF.YFP<QU0>H[K*[RY]H63RF?[#6'&)9$ZJ>9%')8S.SW7+@O'(
M):T*UP71_:32DCLE&44+!I9?`V#<CE?:*<SQUA_0SI#=A3E-7Y2AL%TVXU4C
M$DGL?$M7'@G\N0R[7HQR:GMZ`,D]2D-6N1I)Z@P(U!GI@TT(@:%,\@8-+]^0
MRBKXO1;FO[\(7)T].Q"3Q&3QZLFXS<739B$Q,3C#$C0RY9&E^CCBC3J2F]M+
M4Y2&&%DX!G`A!UA\#CT['TNNC9L?*738R@K'VU9)ON%M+1D?UJJBP0Q2R?RT
MUTOT7G_^?*UCBQ*P-2N9UFGA7XX;Z.8194S()0+*?\@)3E/P+Z.I@N#K-&ZQ
MFE:LV8;`[3D=J6G&:N(G:BQFJF$4WLZ6.JBG6:2*XE"U!:6NW$1[>H;?LQDL
MSB6I0)E"I*F(/,"R/@.`X#@.`X#@.`X#@.`X#@.`X#@<F>L6L>D:/LD/<+(N
MJ[-E.TA@VAL.TKP!1M>(S*!JM(NFTS<ZN%.OW=3#.PPN.-=5_AFYP.:WI:]!
M?"3_`(5@\#^007`]T>K,BV]ZVMEZQKYE<7NX8[$`VY229A-7II2=:-4*BYBS
M,D36-9R=R2/L\:FY=&L9)&$9J=Z-)SGU,%P*\=)M_E<6M33G5R@6C]TZN[8M
M=0W]0'[E12QQEFNFM=EU!M$OGFO3PM4#+R6=3=_Z_IT$85K35)">,O!C2'`@
M-2,XP.EG@1^?K^UG2["1'6F26?5)>S+Y#UUAPBH'=[8<VDX0HK\P0X2B/1Y4
M,3R-JP"/K_D-(#]2T9PL^0%CS@.5R"/QM57!0VX#C-J9;JWI;4?4QAV6K^[3
M*PA\#DU8;M;N[G@F+M'Y18)<>CD=G52N3>F>(]\;F48I;43HSY*/.<_40;"1
MK>MJ)W_V!,]][";&Z\K$V]3NHC33KWC8!CIDF,2?7'6G#&[9-J*MI73S:L>G
M(!QQB@\XE;D9&##,A*SY&%BG5SJQHI-J&L1<F'`-S70Z^;`<958EQ0!KL<]F
MP%U`NK"+,$BLBE:Z<ES;'*G$P&'FEHCR\/1BT?W1IN3!<">TETIZZ;;6IE,K
MU2TTL1T?VM2G0K'>E*6DKH[L[:<(A6!"L/C:M:L0MJ@.0#R4,0"#,9Q^D6.!
MSX6-K;TCP:7S&/A[4Z'H]#'9P]M353H(9U9KV:F!)GER!_BAL36)J+*9F!CB
MAIJI,D2O3@N<"U&!'''G*?<P0>?U@:;Z/75(*K:#JMU\VJA#Y8W;])0WY+ZF
MKEYG=BQJN-P:I@543=AF<0:(JSQEL<6*P7,K)3$@2M:E*>4$A.00$GP$[;<T
MNU%UJ[.^H@BC-=:YJ]1*Y]N@^.3A$D;BTDF.L0U.>A-(OPY*_P#`GN1GWV3O
MNQI\K0X29P`S`##\##H*X#@<?W;]KJ\]?%VV=NUJE2C3MEL_V0615-8HF7;6
M/1VSM<-=WBK0BFR`]D<IHH;B6.7V_,F./LL&:U[LWH4;\'!:$W)GV20`=%]$
M7S9D*TBKC8+L?S4NL]GH:X;)=L827(4[!5E4N[JN]`-BU_?I(_(FS#<G7HDR
MS(W560!Q$8`L\P'H+(3';W!`[($3JU+4CFV.:1,X-SBWJ25B!P0+"0*4:U$L
M3#,3JTBM.8$PLPL0@&`%@0<YQG&>!]?`<"M'=HA`Y;:]2S4<F^[<2]P;?DB,
M`1JBC$R2/Z)[6!7+_<@910B4RAT3!&68+.!_)C]`L8SX#\>X[.<]:VT287@2
M-QC\&9W<D0<"*51Y[MB!-$D0J0BQGV1KV!:I)/QCZ_"8+QG&?&>!A&O!0([V
MN=K,P?%2!DB^*'ZXRS'9S7)6]"1^)C^T1R]6J-4FDDID:<E66')YF0E^0B#Y
M_1GP$=^P#OYUKUF#"JDU/1%[V[;7?,_\04C6U).R"15EBVW?*5KCK38MO-RS
M]F(/CD+LC+5M#<O4O0`#SD\M$3G*L`;/ZL.NR\*(DMG[M=@5EM%\]C6RK6@:
M9U*6HD)T+U\JA&O,>&76^E!BP`ALA38XC+5.@D1*9,N<""_'W'V^%JH-TW;:
M-\Z?[0F739DQ>[7T'OTVM:K?&!+$6S#EHO9A.36!AL]8O8&PA?)M=;@=73[:
M8.CP8H5P]XRW*@CPS&+A(0\;J>E*R*U):FELO&N3V+HG<\YIA,0\J3SW&5:]
MOK^[3O5.U&T2@LO"J*3"E7Q`W$'D9&E`YL+@D+%C*08`!CO=?#['DNGL%?*K
MF,2BDRK3=+1FPF5%889J;7,V?4&T=9QZ&0VP$T`<6R2JX@KL"2M"Y6629Y\(
M`B#Z&A+-+#=&A5[[1VF][95=MFDH159.L=Z1VJ@S'6]KL)DK>7-TIHNJ+J3B
MRSV4_P`GD#9)6!/:!2)>5A8:3[%@&#Z#\Y"P[@.`X#@8^[Q.+2`9!C]&H^]F
M)<BRF&[LS<Y#3Y'@O`\D"6ICA$Y%@D&,^OCSZX_Z8X'REP2$$CP83#8J49CS
MX&7'F@`\><>,^!!1X%CSC/`_%SKR`/:/\>\P:'NZ#"I(NPA<XRRKT>%J`W!Z
M%9]LJ1&D_=(C\>Y1GK[EC^H<XSP*H=&:JJNP=@NV,4LJ^CY8QLN^;-"V`G_'
MD)<CFQO8=*M4"7!A<_:-E%8^U5NI^<DBR8()JE1[YR(P8AA`+M/U:M^0]B>A
MM;:;4%IY`%ED:P;]Q-IMV9Q]0P_MJ6.,&@R%<\R1DKROUKH,JL"%C.[1$\M1
MGYW]:H*,,0!+`8K".%0='79!6;'2L)L$>C&PL=K>TCK>L1X>[9LVMGV^7`8)
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M[DV)WUGD(D2AR=21*"ST"001A`ZZ])WIT=-MF*UM>JJJK8^V;A=+&KF+5Z';
M9]3:L5^1)$J1?3Z5'6^B;U5DK4D.Z!R)Q)VM4]QEU.#A.222B"6=P)9Z;ZU7
M2+0^UK4URGKWH_1[1V!PFHX(D)96*W[FO^U)5V0U!"(K8VY3/:%9PX#LAUM8
M36E-&6YJ/0'J7`#B>I`D+4GMY@=U&ME8V'3=(5]7%LWE,=DK*CC08":W7.V>
M*QZ03J1+URIT<U^(_#&AE8&)E1J5HDK8B++--2MI!!1RA4<$Q0:'*WN_$JWG
M-X)P6;!]1SL7;M+V54F@N;L%-ECWJ+5:Z/1[7I>D@JMBBTG@"YMO*XH[0X%$
M=E1LB9_P;2S.K<E`N4')2\!>3TR.T'E77[6%@US"F2OHG9L\OVPD$:A:L9E4
M!/DM\6*H<7VBVI2PQ=TB-#2YP+-=X<QN#<D<F9@7)DBP(E)1I@PM-X#@.`X#
M@.`X#@.`X#@.`X#@.`X'-=4'4+<DMV$I&_[*>(?'V"F-L+-V,BLMNICF]@]A
M*%(JNF:20NI%UM1[8F7:ZI*EG"!.VE$FML>`L_9)J=O.1)'4"A7P.CYZ6G-K
M,[.*<H!RA`V+UI!)F<A+-.2I33RBC!!S@6`&#+QC.<?7QG@<A>E;G:>N^FG0
MMM#0U?KYY>%N5]-]<[8J-/(VIH07)K$M@6P6W;@RL1KN88B!<T!>*VRYP+&3
M4A:]6Z+FE>H((<<J$H=7-+V_![^J>O;JK5<M<8)9L5:9?&%+HU.#"[8;'=,$
M\"5X8W8A*Z,KR@,R(A6D4%@.3*2AECQ@0<\"@*UF5G7_`,J35M>1]R>],G5%
M9;PXDX21PE&@3FW%-H^UK@KAJ\/RY6J"\*232OB]B`8(R5D1(U62PI@WO1-[
MEU]W.WG'J#%<FTPZ+'%"4U%(5+FWO\T[`=R98!D(&N=VE"F=T2&3C**-.&()
MY(,G?"$DS)I`7C4DU;N,UA[T@UFVYT7J")N._=Y.8J[OZA)M8$P:E!C/`6H]
M2;)HGLK4B8:%RRT8-1I_PXOMRA?%E29D'H4$I:,CNPU3=8NSC1NY9E?;"32/
M1;<N2/KOKD\/$)6NU?2`VR)TB8$DXD\RF?X&9.#*^#$U*\81$1U`I0)1DFF(
M3%:D*4NJVC80_P!]]"UUTE2TMK;7^$]?FYKLPQYVMB%6I((+.+:L>2+S5<XD
M!)4&?I,TRH#P^G@7(HZ66@7K$:%02F&'/H%ULD;^Z,<EFAC;4G47*HH9,7I?
M#AO\XVEC\J=XBA5G?M,J5@+J27-1,V4-GC[E40::D2GB%@LLP&/(@BIU-D3<
MNTJL<K488C%[;D)O=XOMR.UZO5N=?,EGD=G%&-LF:8&M7(VY:IAS:4UD$(#C
MDY!QY1?R&@"<,S@2VVY``SMJZ>L*0X.3$P[LD5(R1YR,LA^!3U,)$;F63G/H
M!80Q+7-,`_&/<!*PTO&?4X?D+=.`X'COT>8)4TJV"4,;/)&)?\&%S*_-B)X:
M5N$RDE8FPK;G$A0C4_;JTY9H/<`O0P`18\"#C.`YG;#[K+AL=WVST&;>JRU-
ME]V*_M^=4G)-?6-&ED>L&*,EY2<ZHK9OVZI$W%Q:,PZU(&^!4";3T@@K`D'>
MQB0D>!%A\/\`&LV'=(-!=A.I*\9!!S=E=!;!D"]N;Z_G_P#DF$/-%V6[$2]J
M*@TL^0X2YOJF6RTUA6(Q9`8TDGMR8P!9ORE%!U$<!P*T]O<@_P"='4MCY"\G
M?YUVD%A-@6,J<I_^$5Z@-6X)Q^O[),>,HHPS_:`U04'.?)@<9#S>Y]`F=.L#
M;]O7%_,WJJ]9RW(CY#B<J&O]^Q$3DF"<G&4>0)0@"8#`P#`,&1><"#G'M@*S
M]4.I[4Q5VR]F4@EU9PJ?4W7\<T]CU6Z]3MC/FU9P5\D=2#E#_)D,9E[@^1]4
M)2J3&9(*/2FA(4+EQ@/3!V`X#=O\A'7N-@ZE[$?Z;6P2@YOIM)(+M-KNZ,3?
M#(01#)Q3$AQ)34M>B/,8VZ.R-QCQ[EA&6WX^X5JLA(`2>([XAA'777M4[;G^
M*]:5W;&ZJZ>P36S?BY*2IU&[1NS+&<;V;R+?C;J^1J=&P1:E;HHTHI@UL"AU
M2)B5KF:B2&E@5%%_4>`L<[V:NL:[NJ#;ZG:BKR96I9EG1B`PJ%0B"8#A]<WY
M\N"O4J16>>:,I*CC;'YRO>#U!A*0AI3*1GFE$X&8`,4E%'2"(U+IUOCI3%A2
M>W*`UGK:O))4;._15W-VITY%%F)W?:%#)H^Z/4/=[3@BY,&15T[I7(YMQ)"5
M+?A7^+?EQ_`_G=?9FE-K.N@NWJ,FZ"91<K:30@#V@^-0TR^%29DWXUG-?J_L
M:&NI2235Y84>4EB3.+,[I4B]$?CU-*QCQG(;YT>S\6R?:^DS]1!WG@R[WQ]`
MY`NT*TR]"_&?K[%_;Y\Y_IGS].!9'P'`<!P'`<!P*O>MYD1-=C]IJ]/\N5;[
MV;V.O<AC,]BAG$ZSZJ(TV""O'@@!2`@H`L><^XPY']/;Q@-)=@%O5-K+V2=9
MFP5V6Y`:CK8NK-]:OE<EMJ3((W#&E`^12CY@@5L"YQR0C;YPX2"&HTXC33L`
M-:,*B\8]_7V#X+O[=8-<<HHS7#J=O33/9[:>]K#=V-09(K(63:MZ4JR'0"63
MR=6U/F*JG<F5.Q"/+`C:FU`2K196.+F7G)GQE&^`B3K&X]T56,ES1UJLOI_C
MRPS;;9N22=IN-HVIACP^/,KMAWE#W)8IA)8*HQ%"Y&Z.ZL33@](I&2D`4(1Z
MKWSZ!6GM%'][MG,;91207+HS7LZMW?K2/6F\Y;4S!=-DMK;+H%4D)LF!V5JB
MX'O7A[41RJ9ME=)6![3*7)&X1YP+)-`6J2B*#J%T3VOIN7:V:)1`%\1FY9W<
M-*/+!$9Y#J^E\'C-MR76)H981>\A9HN\Q",&U\D:98F,Q^+<4;6,H0LDD$BP
M7G&`U1,(IO*9+''\1V\:OPQB.=G`2",.&F5?.K\W)?RRS.&4QW7;2H<+#VIN
M(RF^82(!@E!(S#`>/)6`JGUFGL:E75_L\LM:WESR=57>L!->FP,K>FF-5?*7
MV+]H="V&^VC7+*N>7.+4Y33BQ.R,X;26N.;T+@%R584&_<Y.&'4NTV/7C^CA
M;BQ3R&/3?8Y!RFO%[3*&-Q1SU,G:SWP]1"U2-<<1*""&5*:L&-"(\(4I8C<Y
MP6'(L!RR[9K:=@4B_P`K3)K?6FSHSOUO_!J]N"+[-TWK](J]B5@(:Z=+';$<
M<ON'V)65L`E'_9%_:*V0XQ!]F$85)'SB`>%X/59:;[<VBU,V`^QR5QO\DLLY
MK82IM*:XFDD?8A&+9G,9B,R626HH!5U:.J2:1YH3N:(UE8T2`2%43DK)X<_<
MG!89P'`<!P'`<!P'`<!P'`<!P'`<!P'`Q>;N"9IA<O=5GR_:-D7?W!5\`,&G
M_;(VE6I/^$H0RPF&_$7GU#D0<9S]/./Z\"BGJFOEHKGK@Z+Z[40=MEKKL-#V
M^N6-S7.B!`X5\&&:YW/9SG.VE*K;5ICHH,00#+0:G3G)3P$/0A_*,`!E&!-[
MJ,;E[5UX:YH73*H2\M#9!JHQ61]N:>8KN&PE?W0"_N56<I%83\&D#R/V,(&`
M8@@R+(`A#V42ZS4G\B^M8*K@%=8JAWZU7N5,]K..N[$[65F5-UMR9J<ZVC^Q
MZ)K%)XRR&)C2W90TK%P6\>"A%ED?,L`8(**-C;"=ZQU`F[JQ5M25M.+]1/0K
M"B(9L#6S+:=>+37^V=SH@4I4QA^7MJ`MS*/0`,)6?<$F)@&&8`87G/RA"PZI
M8TF76)O6H4])$?WZPF[$]O$1M[K%.D&7)T9GN4(%KS'B4FP,M8+`&IC0!`:P
M)AE80*2R"\DJ0ASD!83'THKU\H+J2V7:)%HZ7H7,&:-;:S!]K1)7U'6R&8#<
M$4TE+),RJZK!YEL=LXD$;5(V(IC>2BS5Q+2%"62)MRD$(*=.K>7V;L/V(])M
MU393`<IL]/NPDR'&J^A,/KV%QN1.5_6;"I`X1"(UW"HW`8V`YK6L3>J;V[!`
MT9B<6#2\#&,Q4$\K8@O6FIM:9KY5T,[^R>=I9I+,.\U@.I#F8QR)<>[NGWLU
M8Y5$;J;&!Y;9=DX2HHX@S[L9"O`5!)(L&EEA[72=AERKUU0Q6N9/446:8UW,
M.,4K:<)G=#*HA!I!V<UDABT:>DCZZOSV3((T7&#43@!6N6#+4%B!]P<,(Q<"
MS38K``]G/6B=D`!B%4_8&B![A#G)/SQS6]6(\L6<9R$S&&_X_IX\A,%]?],A
M9?P'`<#EO[K=+5,6V@H;>"+239F+Z\W])Z\U+[4(;JLY2UMEL^H;YG8=36:_
M?L!E<9>GC4)D2G#)+%C>8!S/C:M.C1Y+$(P0PM]KGJET0I:V-=+HHNBF6C)M
MJ_$)U7]<F5`XNT$:GB$6*F6!DD8M)K9EA)-LMQCLO-=B12#*\\MY'E;\F5&<
MCX%B?`<"LW:</GL3ZK<D_P!U2!TW5R>2#]8R6C.O!`53B8`/DP"5.ZB0)Q&Y
M_M!-5E@SGW,+QD,3[M75<S]<EK*D!H2Q'VWIXUK"S"RSB5S2];F4`T/+6J+,
M"((T;JU+3DYP?_<48+'^O`S?43/C>/MC!G&!"_SMJ^;@X>/8X)9FD=$A"D"9
MG]6$9)A8S"R_]H3#S18^HQ<"@C^2U#:^V.[`NC;4"R$+U8<"N"];.9K'J-AE
M9\(/51V9NM.0I-,QREO..7-KG&TZY>I1@RGQ\Y:904`T&#C,X"QC>[0FXJ/U
M+ZV*WZ[Z/>=EP==NZ-.WJQU-8E]-46G$CK2!QNW&E7'T%F6.$3*8H3JK"(3)
MPJ!!+;FTH($R<8"`$X"7/7SOQL!M9:NSM%[/:5+]*K>UK:J.D*^'K;VA5\@E
M$=O-)8ZM@=D[_`V%I8VX"7%='!R7@Y28/)N<"P5DOP(,3>4C-U<7?%WB,%`8
M=`-K[7(B,QA)`<B9=4=L[9D*-#!9C7382(Q2T4CLG,G#+0^,",C*".S18B=$
M@$R-S=OA",7>QI05/:H@=]:ZMS-5&R[MM=I9![$MN.RPVM7.>UFX;`PMACT=
ML4A"$UDML$9LETCSDS)WAO=5;8J0%GHL!^$11@39ZX*ZCM83+L1BC#+[&L,U
MMW@*2O,ZMR8.,]L5[<@:B:H*!HWR5N9*94Y(H^!7A$W!R#PF;R2B,"'@O`LA
M9[P'`<!P'`<!P*VNOL(2[*[/"2_H6#LAF1F,>?.<#5:JZDJS\YSGZ_J//%GQ
M_IC/C'TX&HMKWU(N[?.JFO%165J-RHSL>D#NUK4B56S+D944UY:DF3BU`3?D
M5%&J#@^N0^F2C18SG/GQP-C;*LS!%=[>K9)&XM%60+W9^U);BL:XVSH7(9+?
MJ19:@A*6XI4A2HA(8>/`S2@BP`T19>18SD`?`4G:FPTZQX_?TO8.ABB-W&)[
MWEWY6->S=F3K3)KE%BIRMO+I38*6M5ULCS93;^US4'X(HI:+!/HB*$1X3"P(
M`2)NC76N7.MM)+&FW5_2'7U;,9[1M78=!XQ$"=>9D_H(J]3A(2JFK=)*09"(
MDVE2)Q..Q]@:(XXP*(LQ0'U,"6$-_5'KG:^KU\=.]%6A9*"[Y94T5[&6!PM1
MA@;77Z5\@BYMB;A`5+W%(^06RLSXFC:QE1.9Y7D*QW*,.^0P2C(AAK2<4=L"
MY6G99J_^.9UI6=%G:P).]@L1VV&UX+D]E&G.RW\783ZVR;4%P6D2-]0JSU2T
M"TT:D!ZL0<G#S\@Q!5O"VU,V_P`?/M39IM2E2PA!&.TJ[$L@UP>YP2RT9!TS
M-O12"IWI-78\,%!T[;6;`(!S,%X:\M)9:$&#TV$P,`"`+DJW6X>4O\=A^'4<
M>H?+BTS94WTW%UBERCU4LSKUO7$M;8"PKUYZM<H;8\W%IDI8SC!GY`3C`Q9%
M[>0@%M_7>^>P95DU%HJP68@FB#9W=N]Y3-F79&P=?JDE"J-;/U]2##2LU9H?
M%US-::IRBK>;(5C4ZOC'_P#26]PRE.^X6%X"'01USM=BQS3JIH9;-<0&J;#K
MI59-82:(52R2V.U>)36=KSB")99731.C#I:FA-AMT?)D#;E<88::D<P&8&,(
M@BR$W.`X#@.`X#@.`X#@.`X#@.`X#@.`X&L+N=&YCIBW7MW$8!I9ZPGSHYC*
M`,TT#<WQ1V5K1%%E>33#`IB19"$/ZLY^F/KP*2-(+FJC4/KZZ:8#,X$[V>FD
M>F3_`'@Q3E)%02::5HEK/4P^Y9@L@L+8F-]E<@F;U')HJCK>E9@@<5B10<5G
MY1'9(-#[M,.UW6.FM0-=XOL39-^/MJ_XW$[RE_(TWWBE&'MQ5/[@I.P)Z*UO
M)$XO)13@4$\&2RS<B`(7I@/C/`P"B=AY#MSW9LNP^L\RO.:Z`1S0"8P&P)&F
M37Y&*0/VB:K4;GE+'W^L[);(M&FF<(ZT=TRE"YHVKY'`OY"L'F&$'`*"I^Q+
MFF5=Z-_YSJ&K(3<CW.8YTY5&WPZWJ&;KSA"*O70_8>?,,V>:W?B#<MLM:5-G
MC"F<<XP-&H`D++"`XP9P@F76,JTA*DVY#??VX?8=3EEA[#MY0*&.@+2WRC4'
M;VQ'L#*DK$-A;*0CCM5PP99"$N#Q%8/,^YP8`[.#0F``%CV@VX-+4WUEJ]HK
M[V-NR5Q:*3*8ALVP-C@6<]6(AER^6HX]%:XBK'+87'9F_"<4SFR(F-L:VQ2-
MP<E^2RLG*C#N!JN`U'*)UW1:B;0-VMRZI:$2=1TK30QJD1D9ADHJ*V+"O%KE
M#Q`Y%5#'(1$L<L00R2'$.?V25:D*4JS0&J,FE@]0PB;[!]?JJ:25K4?R(;R@
M;PZR:P1AAK;LAJ&A10=U12%S3ND?(*?=:7!V:&N'N>3$2)(ZK#1"*)+![G^,
M"$'I],4D1.[?K0WQVPY5:,84:[;]66ALJ5JHT>[V@CM;LJ>US!,WK$89&QI.
M>U2*-J%AJI'\"%5^6R(I*3@/`VEVCR*\JZW;ZV+7UFCA-I7#!8ONR\N-!.[Q
MA"BNBE6B#U([VW$('CT%^(OE:E2M^(>XGB*:LN'E&XC^W5A\!;?K]?M6[/U!
M"KQIJ18DL`G3:)<V*3DBEK>&E>D4'-[[%I6P+P$NL6FD2>TJAM>&E:64M;'%
M,<G/+`86(.`W+P'`<!P'`<"O"_%[+CL7Z\6@<6_+R<VM=XGA%)0/KDB,B$8;
MXY1#?(!&,"8/XQ]1R!Z>F=,(U2+V1'`*R5C.319"&G.\#W5]?SY'/?"<B:[/
M:$PI8X8![J&A')-YM>$!SNAQD8"<+V_(\#)R9Y+]\8]L9QP-)=:W^8'KM0[T
MI3);`P[5,DOG6*!Q"`J`XRM897&M:8BM=Y"7D*(D!#:Y1-Y9T)?@XP9V6_.1
MA#\81#"H?JCZ[:$WC[#>QK?*RK`N@&R&H_<)<J"KK'@DU4Q(IU@404"+;ZPE
M$3?$$E0Y@QJ=4H;E!:3")8<VY$F`I+(%Z8#J.WDWCI[K]I^/W9=S=-G.(22V
MZUIM$1`FAL>G@F2V>]Y969>K2NSY'TI3(WY+,.5F!/$<$L'@LLP8L!X%-B:N
M5'8%OYV3S;4S:'?71:Q=>S::U:OM=!V#7A96M^3FJ$=CR2&.\-23A!,Y22HC
MC3*Q$C,/RRE*T#DF&$SU4'@+"8'4SNK=.U,6FNN.W&KENT;L1IU`=9T]F.=^
MO,#DDBMR43./RO*2V$"&(LK0V-@W-\K)4X@/)3X)^=5C!`_<D><!OGM9QZZJ
M1L_^F4NY'7<HP=_3[?(=]=<08/P9_P#A9#[^/;SCQY_]>!AG6J_.+];_`&UC
M<\DA.:^SN8,B<DDK)`2FYJU+U%1M@QDY&+^\I0E`,&9]/F$+W\?JX%JW`<!P
M'`<!P'`KZT*=V>2/N^TF8R<EH7/L#N1G,.-2EHUBMVKBNJ9J:1FJB0Y$:(),
ME@2PE,:9GV/1%$FAQ@L8,<",&TS:I<.[_J84I!)LA8=9>REU=0"5%%J`-REM
MUH9$PPI\B^8_`W-S*P$/CQG&!BQ_\L7@/![.[:#2&^W3Q8A\"MFSTC?8^ZC5
MF#TG"E]B6`\K7S51Y0)#&N'MRE*<O3-90CE2L_(P@1HR331YP$(N!53I%>^A
MT*IZ3R&V[,[;*NL26[.[O/4C@E:PSLX:Z\B"M^W&NUZ_;3=%=?X.]TRTR%N1
M')\/($1JI<F>/NR%)_S!.+"$Y[ELJF%.H&G4BIBQ=IK4C#KVBZ].#)(]N";M
M;K@<'ZM7ITMF0LJ!#LI'(3.@L)47K=6!H)+0!;CE.18"+P)2:`-;:"]DFQVQ
M-V=-2.](U2$Y*W&TAVMNQRN-IKA3&IM'+6ALO3@?8-`2L2Y:3$8VTP<EI;W@
MP250!_5%A/+$4$'QEA];_8F@[9+)B-7%?Y!"1R_?4H`L:HRU]RXXZT.2)UP0
M[%10,8=#68F)/&"$YB8"<TQ,))@KXL%_J#P*R0/M4#_CM;L?EG*45C36QO:M
M:,2L&P;U26Q+9I5M<S?>N$L:RP+287-29<4PE<3B$?2`>T`U1;^I7`48./"N
MP:/@7.1&Y8[5>S_17I/&(M5MJ5-(]3YY8E)[(RQ':S-.C'JE];4\(,-K2(N2
M]>=%G"5U%-SE"G$L5N!^$*X],+(%I99I@61Z&$BS#MC'+&0_;O&\NY1R4/G/
MS`"SWM+(FK"H!X]0#RYQT\0/&18$2(`O.,BR$(3FX#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.!'G;E\(C.J&SLD4HC7)-']>;I?%#<1Z?.O(::WDJ\U$3\@1%_*J
M+3Y`'VQD/D7UQXX'--$]B[F==9>I/0_42"L"K;N(=;5$7//[JD;"ES)*?K%3
MK=%DKW4>LMD/T?D<"8ML=AH>RNR1C5NP5+"TH4(U3@48$90R`GAK/N#!=)ZS
MA!4ME%O33KCD<7"VT5=<VA%HV1?FJ]HQ)6)BL?3[<9FB\;E<\0/C!(4RL#"^
M.J,M0VK4:Z.NQPCT[4J<`V1:?>UUK-D!L\$?V#D1TL:X3(<Q5&+7K8MO#*Y8
MK2+6F)QN$N<FJ!LC$ND<CDQB9&VI$RH["X]22$'N$S&>!S:2^3S%%1^FM#;`
MLKUIE8\(M#I6D%OQ?;B00>A'V:TMIQ`)1&]@;EJ.1/LI6Q63L$/LA8U94H_<
M4A*2>`GM*<TU.`06J/NZ-8:XHKIG>NG>WUFQVDGR^KHV,>X#8-',]OSYL+MJ
M9/EG2N%QM;66U4-E%GNP7]]&G1%(V0MT,(-+!C(AA!@00DU*[9J1E$U0[`=J
MDX?=D;OHQ=7SQKM`];H\@L776EQV!5#99;#.PUVWSI>_O^XJA/8"ED>UJ](Z
MDP<]$!K:5*8XIS4FAEG_`)B=/@]PDX[$IF"_V[7FNNLO&O\`&E[A3SJG<XO:
MY]V&6[*8+(H:V)9+)BULD@PVYV2/)AC:W(RQ"2*_8S(?0+1*VV&[>[1UPC.X
M++4_3^R5K9M70V[F-GG%QW_&'6%UY-6!-.#4%FV>17C[!!/,587),-Q6DA(;
MA'D'CQZ!]/`?+U,K)*TS+5>)V"I@3[8<NZ_;UV5>Y;7+/*&Z'.[;LOO,MM=D
M1PP^9-,;DHX@W(9$'*,I8VIC0E'`-#DP!N,\"?=T1Z'2/L^T,6.YB@4LKW63
M?R8Q(@DTTDH`GF2Z9P5U4J\8(&2K)_%2`\`2\C`()@@C^OKXX&![/TE<VLU@
M2+>+1N,JI<]NJ]N>]P].F@M`0T[71)K((;W.R:P)4#2)HIM]"8V1[-JTLTI+
M.$2,MG=0&GA:U:()]T5>55[+5%`KVI.7H)U5MEL),BB,G;@*2"UJ(9QR14E6
MH%Q*9R9WIF<TIZ)P0*RB5C>O3G)E!99Q0P!#;/`T3=&T6L^MX646PVP]'43B
M2EKS8YBXK7@E:"D!35E-AT,8P3-^9ANP&[*PG!^4^#,$Y.!@?CW#Y#0O_E,Z
MR_C`;_Y#]'_C,">,`_\`E71GJ("4A2I4"QG]]?T*(1&BS_Z`SP,Y2;_:(+W`
M32AW7U)6N@$&'0;:DV/IU0O"V9(^ZPXB2$S(:C"'*;^Y\OK\?Q_J\^/KP/3#
MO'I2(],E#N#JV)4L-)(1I@[`U-D]6<H*).3DIB<2WY#S3R5!8P!#C.1!,#G'
MG`L>0BY:TC02CL?T3LN..,=?Z?B>MF]S3([199,R.D4897-I+J*")1YX<T:T
MU$WGR1)#78:(8S,84F-YY8,9$6+P'D=K,LK.6:M1..&2R$OY;CN?UU95,)4E
M95BET0)M^];#EI)#>G<,JUWQDX]Q`*"(6`XSGQXQG.`]/1N%,\7W8[A'=`2N
M+7RK:^@7!P-4G&')CB_^"VM:TG[/R6`HOT<'59[!QD0@AR#&?&,!\ARELM"]
M@'3QW&:LT@LVH9''7/L][$9A=;A&::?53(^2-I,ES6&0,-MQ280]S.0(',$U
M:2!?9.K@!00A5DDJ2#1Y.P'8KOMH!3_8?!Z8KNZW>5MT5IK8RN-CD;?%S6<)
M<L>ZW1R1"DA\H3OK4](%<2?4\F."L`$C"G&`!R2:4/\`7@*\NH"BYA4FZ_=Y
M+);>-&6CFX-VFN9M,+J6PFF52NJFLU+/%K4TV[#VPA.=74M41UY0-OVRS&5:
MTYB4FB$8`(#C`U=7&RQFI7>?O%$]AJ0V5;FKL#FNC-/:D7V@JY4X:[NZ:M-=
MI@J70AQLC\PG9VIX+G3G(3"TQ)2I>:9]R,THHDC(@A*+O%D=VL]":DL-2QK]
MPQ2?=F>@,1OLXIK*<U['5`=@HO)FUP;LC4DC;E"RX8W%$&5!8#1^BS)7J$)H
MC`!DO4HV)D<F[8%V`#_)NO;OLX<ZJ##SC\J/M:UH)(T8#\I@P%%I6(M,3@`,
M!"'T\>/.//`N!X#@.`X#@.`X%9O6.6,,=W;.],B2JNS'=TU$L#]4RXLFT<HE
MAB0W^AH4#LD4HCLX_P!BM*:#^H.!KFWV]"=W@Z/+5J8*@Y+UZ[W&LYGD>!(7
M(NYM.4IZOP$0`BP8TNB@C&,^^/[N<^,9\"P&N.R:LRKK[%.H:K7"=6;7#6X*
MM]I:5+:;FB^NK';)%%Z"B*!M_%3)K+,<&]I6L4G=4JX@O&/N@*`8%G`0YQD(
MC=;39L2EU/A$*J[M2H.J#T5M;?(2ZUM:BH%<MIENI.VMY*%3A+)0Z[!5_+)3
M(W4\)[DZ*U;>6K6G*A'"R7]<B#?/88;9+'K;I:IMW8JAK;G#+N9.RU]\`@PZ
MBI1I`=I1N\U,CY.(ZU6!:9S"TP<E>2I?E25T&9\:8XT@DD7H7@(;];^NHZ+W
M`ZAD:.Y=7K<9X7T^SVLVS_%MUH')S>$;W:)D]<;_`*WC,RAR"96+6\XPC;$(
M#T.6@YG4&K`F`,2`,!P+'#S;J</E<4W?)3Z-L5*5@T&6FDM+AI2P`4F%B286
MN3\[85@0CQ\6<XR$S`@Y]Q9%YX%(5DNA$2Z-I"?)[KB\M/6=M]H1ZP[AM"OJ
M>?*/632/]B=TS!WME'5<B./JY=`;'D*=(,]M?G0YA3I%`18&643\AH2TG]>*
MFWND_CSL3E.:Y>&"O=&=CUT9>ZX@!%<U;9$R(I/#1)UU4QN%FGPJ',;VS.*9
MZ;VA-G[%$UI0IPF#P<GQP+P=&7^/,%$RQUDC\S,JN1;;[WKUBEW=$;4F7N8=
MT;W2G"0@7*"0!`%,F)QDL&<^N?KG_=P)WDG$J"2E"<TL\@\L!Q!Y(PFDG$FA
MP,LTHP&1`,+,`+&0BQG.,XSYQP/TX#@.`X#@.`X#@.`X#@.`X#@?B24,K!F!
MJ#E'N<8:')V",9*`8+R%.7\!).,DDX^@?;V'X_W"%GZ\#]N`X$9MU$XU>F^V
MB4K(<&*=9KX3EY'G.`8&=5DJ+!D6<8SG`<"%]<^,_3@4.]/KA4,AV6@)4L:#
MUEPL?6#UF*J6.*3/QY+'$V;4M"*U9*X+4AI,=0J'<5S,[24G6`/.R$C)B87]
MP_!87/7AHQ%+?FBFPHE?&T>LLL=V\AOEJK6.W`5XRSD:-8K6(GJ70M\C<R@S
ME+4^5QI(GHMM)=U"7):=0I.)3I@$A2>XZ4RR6M7;=%I)V1=BKC'M>+`B#K]M
M8-ETE8$6DI\2U)H78=(JDL<>J2;"$S`%_6!2JFMB6QA*K0I0X.'\XS50PSG1
M.)[?=C$D6[K7%MH3K_:S1KG1=:P.,ZH4U7>(`DKC9"E*+W'<%4V2;.-&P3C)
M)?\`GIRW-:K"'+2C"F9<_'[86&!*"/Z2,;S7ZYM&P575[M9LFWTO8&Q%;4';
MDACO3#%#0+FB=/M$678,(@S]6T3>"FF5JZ[-`#"UQ0'*6H`!`R,)N/(8EK9K
M=VRVG";-O!QJ.I"FG8ZQH9=,?B5L0'1J4'R2.L%0UY"(V]SF'QN('1=FFKQB
M(X.*4-3XG*"FPG-,(3*1*`\#Z+^J;N?9H%+9:OTPT'5-T5A$HD<@=U5):F.2
M9`J9XZ\.(),@#)K0$H0D1AI1!(``T"XSY3!9\'$9\%!KZ/ZGKWZ4Z+P?/7/U
M4[AV)9VDC/LXR-ZPRU=27!-`:M:*`:E1ECQY&SWM4=BSB92JV$Y*):K;4Z41
MZ52-0623],A,[8C<(]-/(=>UY43O5U)WE54+E=7IMH6>CH7O1J+(*]7+AN#C
M4=H':WO=IMSS&6V4LI3HVFK4$3<&M>F-`2X)\&*TY@1SQ='9/;NSM:;4Z[;,
M:E]B%;PW7'8J%0R:Z$U!`%\_K]--);KY)).DNJD+LVWC#>)W79@[7EJ;&R9%
M/QYY*Q/E$4$SY`A+*%[:[26)+VJK5?;306MES/@<HFFC]P.K^3:ZW0[O7A,L
M)Q%8C:&V$72SQG4-Q@_50P'.I!AN/!9^?48<!NZM]&^V'7"<VW8E%[NZ33A/
M>,B1RB95%8VDL_K*GVV8EI!)G>WHF@J79I8Z-EESI,F2%2/T&!L>CB<+S2L.
M'S'J`VHW0+OD2XR:NV6ZM7,P\!@S$INJ6SB=.@.$?GT)1J4FT!)ZM.!.`.<"
M."$?L8+&?/J$0@C7C2'M;MS<B8["[!.O57A+'M=H]0=5R#&O]W76G=2,66&S
M7V3J*OG5GQ(ROWC[L8T8\D2=T*/`4G%@&<@]PAM<S1+>N-.SD^1P?3?.5KO&
MT[0M+DW7'/*Y5F+2U!II/W<@BVR4R6NC"U8-&(I$:0'YA'&8]R,YP/@1.*T8
M[-W38!=%)#HQ_'X,UX)K'#:"P!ZOR]<-[D)^4ZI6SEP@]R'*&Q.H<S#"QHSC
MCVL*0O!_W!JG/Q<#`=J]:97J13[[-+CTV_C[$1UY=4L(@#)$]0[);+-LRP)D
MGRBB-553`VF*R]WE-IRB3FB+;"D)XO./[YP$Q!)Z@H(YZL=3W8JFAM"H[HZL
M.B5N74O6[A5[!^_6R<*7UT6*HK7)"ZUKJ:H!&[,A-NR*0%1(:`(31DK&]Y.5
MN)1P"#?54%B<>ZY]JXM,F6;1;KG_`(]<1>X9(F260-XCE76NWRN-2!F,$82[
M(92V4&T'(7E,(8A(5J=,`:$_(3L`,&6'R%:]3W3W9LCYV/6-L0?!Z*H=T[!Z
M@B6S%BZS"37C>^M]:HZJ@;)8;[K?&(_`IPE?V"+50.ORGI_D#6L>F5N&N<2&
M@U<G5_;!H'8!AW`N/;7J.[`Y[4.Z^ZFLFN.P.SC#5LQJ>GH[&MJ+3@<"E2NP
MJ!M:Q*A5-=:L<>:K`*B?VY[F<DCA4@C3"6KR0@7N9!)P=,W5GV_TKVSL]Q2N
MB*6V&KF#5#*62$GS6ZHW!X\QRZ7.;(-^=(K&11:?S%4=)8FW?"H<TII9?VZ5
M:D-]\_/Z`"'/0V[Q@V\>[B+Q\+>]CBO:C<X<V"4TN0GN3-+V:J<T,=DLS>$)
M3I,'"OG@3FWE_.J4Y0IQ`"5@*8P@9P21[:C7?_,W30E;<+E1"KMBJT;BUI,&
MC*4)D>O&R:LQQ5%%!%D93&F*-4Y$+'J6`(A9SC&,YP&R.V%L62.&:.1)$HRG
M').T?0TP_P!1>@CD$(MXFT7(H.1J""<Y^P@9@\A'@W`\`R$(,F9`((>)U(!P
M-%V2KC<B-7K^W'>(3@L,%G(U>6N00^/-&,E__*)"V1IF0H08!C&!%I`C%Y,$
M,60MQX#@.!29VS=ODAZR[%U#K:,:J.VS#UM?,GJ)MX&2V66"KXL:R.L0:S!Y
MCO[3FLB=RU?[N`9A9E,E;$^$X@&J<#&$.`NQ!D60!R,.`#R$.1@P+WP$6<8]
M@X'X#[8#GZ>?&//`_K@.!6UUC"SBN=JT_P#[$G9'V%EEY_\`<(*C:6PW`61_
MZ><&K18QX\?IQC_7SP-16"@.<.]_6(\QQ5A31_J^VP<4K;G/R(LJG/976!I6
M'%EB$'"90H)R3\A@<9R8%,6'/TQYX'H;8A$X=N'42W%^I(F:O.QZ8G'C\CPI
M2IJOI&(B;"B@X#DI0:JF)*G!V19"$M*,OTSDP(P!39UWTX*>Z>0"5.O1KK;N
MLXN%G[,G'[&V%*=/4D[LE29M?=:!6_R`-L0U9-@KV[/R%*,K%1A@RD_DC`\"
M`5P)L[9TH]2/3?76GHAIA5FDTNF<]W+;HCK2VRVFVVMH5/7W0[=1MBEC/4OJ
M]J'5C0;A<K`_FK0$'B1EB%@[&3\""$([:34!:5#]H'6;!8[%<75K]4'2?+*7
M'LE73F^3?71!/2;K)<GP$&L'\:!C/7J\1IJ:RP*1`<E38M*$,`OMQ9X$E'BC
MK66/H<JOXVW7@_*2ESBY_NE3?NJGV0EQHG#_`+\HQ;J49(LN+F!2/)@AI`YP
M-2+V'GR,7`J)1V,Q5STMUY(9PZU+K[%VKN_N`I_=;!KLVXJ7IM.W;'WK)PM$
MHK*'CCI=AUVROK<6QJ$3?A$2:UF9,3@*P`L.`MBD-EZOINYCJ2I>.4/6DF5+
M>OZQYIK9<,?=K?@TEI"((85(4C,R,%,YD:*"L-<3>N&A<A()?6D]W(,+"GR<
M6)$6`05)=@+3]FGU2MJ+P2KK,FK_`"3>J-W6UV[K:^[10:JM?WSL&MY\DVR2
M^-/.LNP5:TQ%Z:?)"M6/$D`80]+D9I"0;<[)TI8"0ZINK&,L$.Z[=/XW%H%)
MJQC[;244PU0F8NSB^2-H3*BCEN#W!S=H=7;@<%Z&IRO(`8P,GPIU1904"0(,
M$%A/S@.`X#@.`X#@.`X#@.`X#@.`X#@.!"?LJ<7=GZZM\W5@6&-SXW:;;,K6
M=>2=A,<B<D],3,U$J)49-)"0<0H"$0!Y&'`18QG.<<"L+JQKZG(ALR8K>_FC
ME])-#M*(3`86)8X%D(:UC6K]#EV8D(:RRS4(\Q^08C9`SE1V3P?($!/D(CLY
M#H5X%#\]*".*?R06[.<X*.8W-0(S'CY,#<>JJE"C0XQG'KZEX3X]?I_7.?/`
MD5U6L+*Q1"\$C`V)&)I:G?4J*LS$V%83M#,P1[K<TK&SMK<F_4(@A$2ZC)#C
MVSC!18,>/.,YR%%6K^SNG==:W-<`GG</MAJ-9,<NO:LMSKR&ML060B)%(MI[
MK"6U)%$TU(M!L3Q@:81!QJD3HJ)39]PA-``(RPAT8]8MJ8NW26CK4.V95[9O
M,UBZ1YEMLJ0UX`L$V.3IP3&#MX:R@E<QO+7!)&6I;2!B;`*S@$_(<88(>!<"
M5%Y5ZNMNE+AJEL?<1=RLZK;!KUODHD0'$,=732).\;2/N6\P99:_#2>Y!4?"
M(0<&_'ZYSCSP*F]#]<=P*YG,ENC9&GX%!)5K_H;2.C.O\:K^V$MKIK8*J)3+
MY98-L_<&16&*(,W6M(R8RG;616(2U.0VYRK'@>`9X$U]"Z'FM+:=:EP"QW>0
M-=HPNOFR67(VIG!,<ED5Q6,SO,IMQ%)#3PNQJ]"19LY<UQ04JHH.%B<D01B)
M#\0@H7E]*4%L)2T'V/34O$U6S_9#V<NT`UMO:L61PJ:YJTUT;[4=6H^7M]J5
M$L@M@)6UET]UH>99CY'0U*H=UX!G8/\`E%@0?3L*17<-V7NG2R2;R2R0517]
M2.ECQ:E=^Z#C'8O7,KL&K:L=-@MB4(9I8;8VVVS1^K]=WJ(J`I%,W(7F*).=
M]F8(102>!IFEK#O>CJYDEB.%/;>Z-UC1S)$DES63H9>3+M1IY3CJ^TQ75]O1
M\QT-VN9I98D%CU9Q6:IT,P3UZE7":51:@HM6:(`CB@M/UX['-H)#7KG9+-#:
M,[0:695Z!K4VUUS2A+#[WC9IBH:8]%<>FU]3!$X1*9)TPRSU;6V3%4Z%9+/\
M-10<8`$-[F=T^A<7;3#;SE=QZKR5(9DIRK_9O6N_*HF*`63S4Y`RRW"O5L>?
MTRL1?DH]I<7`@?L''O["P'@8LB[Z.K^4!$GJ6])KL&_^Q@"HCKMK?LK=4I.,
M(-2DJ"Q-D#J1W`B$GRL+R+[HPCZ9^GG/TX'W!W#[#-E\&MVGNA;MK_%5"HI(
M'83LC<1U6F1E%#,_)KXUJ=6[G(;SEP@D_']D%]<(.2>8+/N:$(,^P8(F@^AN
MEMID[.]B6^M=7'N#&&U8-GLW:2U:T@J*FD;\C3-[ZRZN:WI'9!'*68WLA6`H
MTQN1.<H<$YN`+G=:$7U#/4W?5U!'J,I3]ZJE9C,?)X,E"">1!(,1(4XSBB5T
MIA[.B//))5E&#+`8(82C`F9Q@`L"X$Z8=M12EU5G*K"U>M"JMG#&6(NTC8V:
MG[1ADN#(G),TJE[)'\ND?='=.S*7]:2!*`Q2'&"AF>1!_3G'`HDZ7-J+%GMX
MR1@/N:F-B\[CPF;;Y;.Q"K((]P24]>.QCIFH:WSK+9"E?(Y"C?DRMJ;#&-&D
M="VJ7$NL,<ERA,:C5X$F"TGM1[)*8ZN=2IGL5;"XU2^JP+(;3$#;R_F>[*MQ
MR9G-;&8TB#G^TB:T_P!@8M=%QV<$HFY,:/&#3LDD'!R1]:G6Q,-<]:.H+9W8
M6"*VO9:_.WBN)W&T`TQL)E$'H^Q:GNF3Y1RXN)IT2R0+IJ;"D<C.(?@*SD3<
M%*VYRB3_`'9&`[)M/M#:8TD>=G'RH7JRW57MCL-,]F;-*L&7%2=(BL:=&_(]
MEQ`@EH:OP[%Z!`6`L\2M7DLDL)B@S!8,!"M4!NT'83V9R)B5/U)5AJUU([MP
MQ_1,9<-G3IL';<XD.FJTPA2JEBB7AKUGA2C_`)`K`X)+9\+,ITY0_ER+']P-
MO=R-T.M0JNK]*TP"43@R?=KNI\56&QTI;\4=0*A3,@YR<CR&Q>C^,TY866$D
M\9'R@^00!>Q7T#+NH\>!)>RH)8@C3E]N6[@4^09P,O\`N.T'/58`8'S@?AQ.
M.]OKGU,]@_3U\8"W3@.`X'(1_(\)=H]O7TZ39<;-_P``^6/.ZE@J2HK;;M?+
M`=+BFMGZ[IFYBE-PJH+-3VZJWR+G*BUR/(4J<0BS!#.!D6/8.O?@.`X'-?U*
MS[8)[[1.UZ!J%\U+TUBMH61+::8@/E=R:``MJ=;&62U75(U[BTQ1AL9BDK[.
M("Z!:V5V.4DH4:=>(HQ00:D4##9NW&SD;UV[P]9U[_6UYV'A9UC['M:=KH&G
MIS>,O7K9/LS02M"%=$*]9W=Y:H^T%015D]T4A`A*4K4Y(Q@&<#V#X4VV<,V_
M[<.MXZOZPV4K-35VOW85()<FV/URMS758M8I0BULC325%L6M%XX7-3@O:8!J
MHEL$JRB)$6:H^/Y"\""N+2NWM:JYUCB<:F.^/;/1#ZW6+M`K=ZZU^UPMJ8U#
M'U(]FK=<W(N%21GT5N5C<6(K*W!N!I)`M*`(P6!9`9@98`M=5-]8;%TOH=&8
ME>6S-SUS;NRFQU:*KAV(B+E7][FM\RTEW6AL@+Q'YW2U3"0`9<'FEM(E45PD
M.+(+'G"HO.1#"1>H9-8=?R35;J4:E=@3]^@^GED6K%[0''&9M;7V'T[8L#AT
MA1.#6TNJAQ(FSFZVZC/2ITJ924<42:(9P3<@"8%9DPG>OKE*'8I%L/\`R1H\
MN4MJE0&(P^B-W#D#)A2<4GR[H#I#JR]K!'?.28444I7J4A>319"0'U*$6%1;
MS`(K=/0,[0=YKS8:Z(D]=N.QB[-?P8E%G9:0-K=++OE;>)2AD1)98)^CPG+<
M9"E-++4FB+6E@#@\80\#J(K^*ZF/^].G,]25M9BS9<76Y)GFL+>7/`&9A0Z\
ML<NJ)E<X78D:CS\U,;S-ECY;R18E#^(5H40ONQ%#3#^#`@YYMW`RFZXA55#4
M=K%C9VTZ9GFRLEM:-MM%0653%IKO:+LEOFH:[AL,N^RYPIA=0GSA\KAYPXKG
M"O9>VLR9M+6K#VT@)HQAUAZ!2J/3;2+4^411FD$<CSM0-7&-L;ECQ&Y#*(V4
MGB38C-CLB?X<T1^*/;VQ*4PTBI6W($:-0<2(PH@H`L`P$N^`X#@.`X#@.`X#
M@.`X#@.`X#@.`X%<O;])([$^JWL2=Y4'Y&0>FFP[(>3]T4B&I62BL))&&A(2
MI.*/++4K'AW(**\@'D1@PXP$6<XQD*MNON712G^S&QJ4V?O4M]V8#6L(JZAW
MD$'BE:5?<,7SK'J78,IK2.,)R^5RUGO6D&Q"B6N(#WK`9)'Y0E4$$"&WJB48
M=,?`H&LU8J(HW^2U*"3,@?D>;7:TJD(`""6AB_4UKNJ8L81B"-,,Q.H<S\Y,
M$#(CO.,#]L!QC`3/ZX&S#<5MP`DW&&U-L/63`QH`8_M-3!$M#-+XTT(P&B]C
MU0LI6W!@CC1F&&>^,Y%X\8P%>?67(MWO_&O4-A0RV=,HO"I4P7K;C1'KII>U
MWJ9`06%=EJ66F3S15!;WB[)]P)K?L?=`:F7X?<[.$Y&2RP!-"Z/3Z663/M9J
M9GML#J8<OG4'9YIC%(,,SC-9EQF5D8?H25'F*P5"F7-HRX<O0X5E+/00%ORX
M"6`&`AP$D^`X#@:H7494B][J"0C@K(D<:"<9`[4\!H*/8FJ!KY1#GN`/AS.P
MLIZ!CR%9#Y&N0X+.3FE$EJ1B+"`SP/`4^[M=4<:D=06'*Z:HNN-F=DYOM2MO
M>7/UT/,<A5BNU46';,$D]V4A5=IYB3FVP/\`<5-5VVP!M,6$!3Y8BA86'C,,
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M<G%DHS6VI6U`\W+>,O1-JAU<&^'QL:IO1(61D;$8UC[)'90@CT?;RA*7%:G+
MP'W"+B753<;:]OQ(-U=E)C04-D*(LS_AWI%,#Z_:X\VKB#_N(W;6VJ=M2WA:
M$A"G4A)6GP\^`,V#2A%E$JR<_.:$A:5ZY=#]>#FYQJ#4JB(K)VT\U658*BO6
M&46LM<#S%AI[L^6Y,$K_`&;(WI08X'Y,6N#LJ5F?*+`C,XSP-C[97[6FINN-
MT;/6RR.SY`:.K^1V)*FZ-,[:\R=Q:F9![*T#$A=5K6WJ'-R``!`,'JDY&?./
MD,`7C(L!39&Q=4F^.XK1KPR:+HHY9\RTDJG>U%LU%([$]<['2UU;*Q`77S='
M['IZ7Q*^1RE-B6&C<5"!3EN;UH/@-/,&(&>!)RX&S8KK4K:P=CH]LHCV`U;J
MF.N4\N"JMM3(RV7`U0>.IS%KPLJ;::,L\=7S*=$-R?"5H9[%;WU7(G`TM.=(
MTAIV#^!4#HM5#G_(MNQH[.=V<M"?377"T9/%M(M"T:YO=D@'9L_;SHKMW:#)
M0U`7M[D!&&]20R&@*3KB2RA>N6?(`O`=#/8AJ'4VX^LLSA%FUJLLQY@+;)+3
MIEL9IM.*ZD33<\=@TL;(8Y1Z8UV],4G9UZS#ZH;C,EFF%&I5QI9A)H!9!D.=
MV#W?3_88=TN]?D<'O*K;:H:'`.\`CHUN9K.X-9]7:63)M):;&NL\BO%SRJ6W
MTE0@/PE=U?W*DO(`'A`<'Y@Z0-.-"];]$&"PV+7M@F*$VV9BGGMDR:PK0L2W
M)I,I2C9$,<0N+U+;*DLF>SOL61M)3E%A.`6$`?\`;G.?/`TOV1Y^X=>NQF/S
MD+8]=F.NV'08,Y`<']M0RX9VPX)-#G.2\&2^)-H#<>HL&)Q&%Y]??W"&`]0.
M/C@>^2?./4Q/VT=CH32__P`O*C81]6E8SX_3_<3*@&?3_0?U^OG@1"[,XCW:
M[@3'8?7[3MMC.I&N5.1*-2&,6\.QLMEP[X2UQ:&I]<J;KN919\;7#6Z#EEGK
MVAS>U/V[G^33IOC4X1*5/VX8YT3/-L0RT-M]?G0;F_P*-/K%,I)#V3:";[9T
M_H]8*]BCK0WZG1O8BRT2V17;=4L)3/$ML%,TN(X]`C?Q20'R*W=0$@.D_@4_
M]E?5O*.P2]=$[E:=F'2CTVCEI.%TQZ*(*]2S1'-K&#**R?XXZ/9JR5,B4MN9
MD4#5(A)Q)C3#"G0W(#BL?(`T+@.`X#@4"](^M$78W?<W=$B=6HJLK8/<'=ZO
M;2@3A,CU=.`<:HWFV&21J81>!_:%HX]*!1U:4B/-(.$0,&#3`%@.4J1FAO=Z
M0*W+OP@#@A7$EIXCU*V.7(F\1JLI0H*G>W5?AC1Q)8"<HUA):F!.'RX&9@1(
ML%YP'/OYP&X+5\&=K^E8%?\`>3$:3[]*6PHW'REI'D5LZ(ISER8L7L%*L,:#
M#B,G!Q@0BAB+\^!9QD*LNN*9;1M6AVLB.!]D>C%>)$Z*R5CO$;_I!TL*P6TU
M;;%@J015YE*+="L3%AD<,6X39.$T)#Q82EXR'&,BQD);[I6!NM$]:=0+EH>%
M5#V*[&UOMR!W>BZ5C[K7]5J8L]5+L77CQ*&9E#;MC.+2H@[/,$Z$\1TB<`&.
M!@S1$@"+!)02L0JG51V&U6\RM`D9'Y9UYS]6]HL&%&$,KL&[Z852!"!3\YX0
MI42Q7@'M@T8!A+\Y%GUQG@0?_P"6'HXM2!+_`"$.ML]$M4.Y91+C7>MBN4NB
M@I0K492(G-LVZ9V,!3,F-)*]<,YAH@E9$8/(A^<!4MU)S%^LJC]5RW^4I92L
M=?Y%NRLD-F+:D1I6=[&#3>][A7NC8VMHOMOQ<W?7Q2M3X`:82CPM#@&1E%`Q
MP.EU_:$9O:)4SZ:6+*Y#H/L&TMQ@31X`6D<]AM95;N6,C&<%C$::THL@%GSD
M.`"QCQ[9\A^W7&A;5&M+?,,-3<FD,KMK:A>[N!"0C[_)#AM_L%*"6`3I\05R
MYG8'23KL(PFB]0_,89@(1FF>0G.WMS>THDS:U(4;8W(R\$I$#>F)1HDI(?.0
ME)DJ8!9!!8<Y^@0AQC'`^S@.`X#@.`X#@.`X#@.`X#@.`X#@.!S1=_=[S)_6
M4CJ/6F8.I98/(*RW;VT(LEM<WROWFG:VM]E9*/I"7L;2Y-)KVW;`WFB_[I*:
MK0E8:(JM,&=D/]HT-KT%KM4.XFY_8M+;J+1JRWIYJ.-(ZP-RV-T@:'YTTZZ]
M;#<+2A#V,"6S(7,:<F4<9BVMY:S48F]R4D'?(%600((67:"WA7MVT+@5?[1&
M;@AJR;RZH91=BZ$B@<A=Y'$UI:HIGES42S1]F=)<Q1IX;D[@[-B)(WNZD(E9
M1!'S")+"N+8][K.'4A_(H9(I<=?V?9[K5,PMBQ:IBRI8"44@US+K[B%21!DL
M0\TLY"!YDH*@<7I*!.+(L(#B@#"`?U$$Y.NMMRS,&T;08J_(*F;:^1,2ARR4
M(H;@1'J3HEA95&0"&8,LL$;;$11)>1"R006`KS_;X'.5IUJO&WS1"AIV]]!&
MJ.S:0VNWMSD5XRS8?7*"/<W19?7L3S84G_R%"@.#0I<4B42Q=E<X9-1""9@(
MQ!#@0@Z3]8)U2FMVGM#BL*MZ<Z\88\*DL4AM(N=T52ZP.,/\VE#N?$HE"K%C
MCR1`IBKGGW6')N(:C1C-`L]`E^Q8\!")O8QV7[`:ZP/8>4Z;:_T;LG'=8ZKE
M<QOZWY5MK6D6C5&2UF;9::7!9%4<7+EUJR*:LYD>+5JFA6&-!6%'EI4JP2@1
MN4P;DU.VKO!NUTVWG.XKO5\TDNHUNVG!U$_IYFQ6<;MB+P6LH#8B9<DA\VG<
MD2PB4F/4Q51S"58^?":I0%FC$1\P@A"R]@<5+PQ,KLM:EC$L=&EN<5;&XB(&
MX,RE:C)4GM2X28PU,)8W&FY)-R6(0,C!GUSG'C/`_5K>&E\2B6LKHW/"("QP
M;QJVM:F<$H%[2N4-CHA$H2&G%!6-KDD-3J"LY]R3RAECQ@0<XP'H\!P()0SK
MOUQI&#;)1_6*((Z+E^Q[-)`.DU(4O]B$PZ6.9$P7QZ0Q"(6%('V.1UEBDZG#
MG(R6!K+;F8UW7JCQ$X-4FCR$`8/L7MWURZR5IJ9+^O:P[CM&OJNC5,:RS_4(
M*VU-<+IFT=BY##%5-R.SFGCEB:MX>W=,!?)%\C;E[(E(&K4$/*TX/PB#2-]]
M>-5P:*5.Z;#9<=J>W;<ZUXO`XIM,SR]ZKJQJ.EOXH^13JQM8<QYV8'"HZ`TV
MKAJ<W]"R-_VP7[*0E&\'*%;X9DP-^,6QN\VJ]T6G33>MD':A2>N,5KQXO63-
MD*B58[H5(JLA*K=8_%VD,9Q&*)VKEC5"F?,B<V1"W0B2(V=V:QX&[*EA0#@M
M/U6VVUXW8IV/7SK)9[!:=:R+Y4Y;JSB4)7-C>$OKAQC,NCCF2CD$0E+4,6,*
M6YQ3)E1>!!'Z9+&`8@^'<W56![O:NW1JA9SQ)X_!+NB!D0D+Y"U;>BE+0G_(
M('9*XLBAU;G=L"M2.#:2/`5"4\DP.,A&`019QP*-J+J5'1?\AQ=$(D]H&>GJ
M"Z/:;K'\:K=X\PJ$L0C5V*VV-O;NRIB&5$M9V4B'F!/4)2,)VPU42#!9!!@<
M!"/E=2V3?R7=G9@<_(9#%>DG3ZS@(&F,DC7,#GV!WU&#TRQN.FJLLT"LNEX>
MG^-S_%E?;'?"X(PJ/*Y0/+.%W^QNL;Y4$G4;H:5QMNC=ZPB),#/:U),):>/U
MYN%2%?(RTZ.J)(RHR`-#+<$%B:<\FM)6446>TJ\%M"X1K$J/()"9],W1!]B:
M3KJ^J9=T\G@-NP!AL.O718%4UEN3-*&<EV9@NA`TYZYH4A"H"4L)&2(](:$P
M`@9&#(>!Z=1K+:<*\CBV]&"OXM:BDI>;*X]5LGD$T@C0:)U7?BD;%*I3%H2^
MON"V/";*D\]I0>RO)N`%8+P#.0V/P*+^U;;>GX;M!U.ZR!D#5);CL'L5J&4_
ML>.2*.KY7%(JQ1>=1=1*)5%2W(4C:X^<OG9(BU8TN$XPI%&,#]P8#D-\]2S&
MX(*WW-DR@).&FQ^T/L+F<7&`X(U)K(5L1)X:<-P38QY0*P2"(+R\%9$+(B0%
MF^?!F`X"7&X>K,7W-H:4:_3:Q+JK2)2]8R'R)[H2PU%83UU:69S(<ED1,E29
M$O-!&)441E&Z)<`#A6C,&7D0<9\\#E>Z7]U-7>N;8'<31"YI#+-28*LV+KN$
M:Y:U32=F[1PZI+,?(\K3S>/2/:JLX8K@359EQ2`Y&J,B3B\*!L2A`<FRI&?\
MWD.T#@5Y;B]8VL^\EJT#<EV*+<2S36]]2OM?"KNUY1`V92-/)665"02AD9S\
M('I&J=&!/@P>`DJ_AQDL!P,9QX"PW@.`X%1_2L,2W4.R)$`'QM\NWU['Y,S@
M,%C*L#6OWCO8DD+@4#`BDZT!Z0S`@`&:'UP'.!9\^,!%[=>R)Q2W8SMY<%9N
MK6S6)6?\?RW;-A#J],Q<B:6R4U??\XE;$H<V$Q8@+=T)KC@&#"1'%!$`O.,Y
MSY\8#&^OB]KJV7GG3-L;L1((M*;?O7KRW]G$J=88S(H]'`$R*WM,GZ.(4;0W
M*%21*L9HMA$B6`P+`OO"C<CP$?D&`UCH)JQ-9II)KQ,F?K/ZNKX;Y+"GZ3LM
MBWM,SFJU)K'I-+)C*XTMEZ8[1ZS0L[^XD.Q/WA.7IT+3G'CS@XWUSD01H_D1
M5&_13J6U1A!VIU'U!^VMOF_\UKQK;8>&BKX(P+*TO\Y9**]EC=&-<$HI"0A-
M_)EEGLA:#\HK$%4F6@P+)@=1T7HROS[)A^Q3*LE1C^CUS3T9&X^Y2`U7"2*_
M=WYCG/WAS"<F.'F5+5K,B(4N&#LB/2$`+&`?H`00J]5ZE[,-Y;@I-ZU>CQ,U
M(WEPE:I8:_ST@:A:7\Q@I(:F#HT82C?Q)08$<I&:<9C/G'OG'UX%0W4Q$$D#
MJ'29*A7$.0'7NQ,L`T:-.B2-)2Z\NF]VLYW;F(AN3(TA4;C[C-3DC7@!)7N@
M()R(`,YR'`=9AU#(U&T+=L\=-I68X--"/5#-U<"PS?L=&CD-AL%@O,V(%AL#
M(<2MQ/C"!`;@2P2+*-*7ZDA-P(8PC=U72#$JT@K:1!290A=K"V95@2".PH$G
M`+:2Z`!+$?@HG!HL!!CSG``XSG_3@6&<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`XR]]7=<#7/N>NH<?.G-KRKM/IC6`9ATOQZET]2E34T]U9$&!0YG'-<;;XNY
M6:_N2A%Y`4)>Z+1Y#\XPAR%QVA52I'7?CL%V"+D!GR1RQV"HDS`!N*,2N14^
MT[Z[IZX._P"9RKP:2LC:N"`0G),$CQD:K(AC+$7@`@UM_'2$_K=(KFD4AD;Y
M+#I/OQN4XMT@D$V13=P<6EIL\</2'84H4J4EF2X,C!@2D>,"+$#'W1/JG5%%
M@"O:P7;7Q=:'\L%\@TJLA19Q6LM?0JUF!_KYEBU?LSJ3K3:C%&SX:_,<[D+K
M8*U[=S3"%S@[,K*<@`26`GYTXA&8"_;0O"@AFVW<5!(2%9VY-OD*$'RX-"D5
MQ&)5O!E1/W0,>AX5"J)C.P,(<8P$[`<>?7V$'+S2&S?7W".MNOW"U.P'LRC"
MP6M4H>Y'K1#6"TTE6+7($?D3G,JLBCZ=J`_P%5!7%RRJ:R%:YY7,H$0\#/49
M)P:/(66;2:^SK??1KI[+U";B]HH!"MT]:-DY59FQKE6K40P4W5J2>F21MFC,
MEK^M&R5)OG>`1=(AC\6(PJ(3DY^`10OG$$6[LL1CFNC?\H5Y3U13-:/C9LE9
M5$/1%78?VMUG*9EKVM8;'+7L]&L>'EDQ*Y0FE`EBY4U(&_[Y64KR>`Y3@1X@
M]ZQKX98!IK'M$=R8':VK%J7KNBND^Q<LM;7NQY?1UXUT;M$][&W^CJ&TZ<C-
MFPN59?:+C64:;"E4S*TC6+)QN$GVQ@B@N<D6^E#"J[8O=:#75J+8-(U921"&
MFK%B]^,JA>]V"O1OKX_UI91KDO:X+!3)%+D$40,:82H;H>H//PHP1C))8@T6
MV1RTJ^B_4!I:D>W>N+-G\K6[/[9+:D"U05M<VZDX2?<NPC0M!`&QOC145M?;
MJW(RA=$B8))+J@=%8,Y,"88+(2&B6Z,G3N79Q?%@C;$VI^ESLL@4!1)&<#?+
MY#)*$J$5C[+28][4N)Z9W;U\ME2:,,Q`0$8*61Q5YQD9^?`2HC&R</-;=8&N
MTDJJGKBVHBX7:$4E(,J'R6HI,T5J&S["AB]>P(%+2%57#(`\MQ7'#3(<GE!+
M`9DP\@LP)&<!P(#;GSG4;40Q%V%[(I7AC>:C@[W2C%;J2#VQ;2&J(E:[^QNL
MC<E<%KM#(2HVR.[U$VS#S(?L4QWVB4E&:M`48`H84\V;<=+,E/:AZ,59?W[^
MEG:](D>Q&XFS-4U!=JZ6611MX&)TECVG&XE7T6G*ZF4^RKR4@K>+K7IP;T$%
MC7R#*-_^B@R6'V2&OH-/;.VN[%M<+X,ZX]8]/H2OI:,W5048B3K%=P)IKZ8>
MT6G*KXJ9V;!0Z]*8IQTCX*V@R%()')'!T2O/XYW(+$U8P%A6GO8Q8,GEE6:R
M=A-'XTVW)LVM6VP:Y8U3\B=J<V&;P(41LI0T]+A+5`VJVH.H5AS):Z<SCGYD
M+-`>E4.Z#RX8#F=[@&MCWP[GF/1_0"X+S7[37+7J77??NTV29LJNEZ#TU:W!
MFDUH4<P,I45(6I'%.YM!,@D!F'7/R/*T#!\PS'1:A3!VE:L:P4UIE0%9:ST!
M%BXA5-41XJ/QIKR;]VX*QC/.7N\@?W+("S'>329Z5J'!Q6#"$2E8H,'ZAQG`
M<!('@5.:92+%![N[H]?(32?V&W-<.WNUQ0`/P,R*UML[,)\UW+6Q:?\`[1.@
M8X=L=#7QU9TJ1.(A$TRDA,(S'PEAX%K*Y<B:T2QS<UB5N;FY*H7.#@N4$I$2
M%$D)&H5K%BM0,LA,E3$%B&88,00``'.<YQC&<\"FEGM;9OM+$XJM:;!DVGV@
M2&5.K"3M!&2&=7LGN*UQYW6LCRX:S9=4CJP4C0CT:D-_'6`J)721]`$![0B0
MIL@7G!CUN::ZS:B67UL1'6>GHG7\GG_84C>)S-1D*)!9MHD1_4_:Z5RMXM2X
M98H?+(L)^/PW86X/>'58>>L+#X%Y^G`D[U19^ZU)<W\7Z#I9MMV`R92F#]2$
M2AQWKV*`8D3#%_=,3E?;XR$0\Y'GSGSG^G`LDX'*[V_4[4G75=LJ[AU%70]\
MJ:$U))9`Y4FSOLO:VFT>SAUE#!$=4M@K-J=*Y(:PG!<2CLD?4ZM_&%/(6?)A
MC@3]ZK"F^$+9>L/="=;0TZVLVQT^TO<-JF-H;'Z6PK4F_6NU$RB$.C%&'!LG
M4C@:D6)C5#D:ZR`;:O:%9CDG2K$X1E+C"U)18`L]X#@.`X%2'27^C1]V3!^A
M*+<_L71I@_UR%.1OGL3@L.1?U'G&,_USYSG@0SW.:+(#V;[[2:I%B9)/F_\`
MCO2IMB`CPN"@\N>NE_WLKA*Y&E0-SLH-RA6,!V<@*(.,,.&3C!1OUQ@-%].+
M<YQR)=/:-S92XX_L/3WNV2H:QL;TR*&-Z;MF=2RE9Q[1*0"<FZ2GGY'ET."`
MLE6J$8,D.$HB08"'O7JHUX=M!M35,^UK[\9,]F4<U*938FMDRWM24NH=7).:
MI6/M8L%4[`LS(LBZQ>J,4M((ZP#1EA__``"R_4'`DKVT2Z$PG3/JT?X*]P:J
MFIKV*FIL2SW/QVQ98K);D5172%>AN-!>,/M^QVJ?O2L!1,>>WQM4_B<*T9N3
M"2!%8R'5@V'IW.#-ZG\>F&D<(FD/_%1588-().K9RS/Q\;<,E,!HDPBC/C1G
M>B(60^@O4G/T"',XJIC5AG(?GEGZW>^DIS_;[^EPAQLOLB!$@PO;1IUN$Y)O
M8>!M4#/R2'&?@&H"/(<"#@6/&<A&#J8-RMB'72C/*%AO4=C4&=!-I^,B+`O1
M?QZ(8X(#3@CR(0EK6K'D0!9$(0#,B^N?.?(=EW`K/Z?_`%,Z^::6$Y]F]VF.
MR+\Q&_T"IC,@VBNA\BRP`1?W`%+8XX)30!,P$T(1XP9@(\"Q@+,.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@<2.W<O^YT<[F']2WA`!@[_/PR9(F/SG)OVD+U?A
M1BH9QP,^1JRQ#4"!X\%B'ZASX#C/`N_Z^*0>6_=WL1N(4F0FLD2OB1T*MCF4
M2L)SA(5^N&B%@CEA)^5.4*9!X3*B!)\@$?\`WB_U^H,8R&#?QRI>ML+KR=9V
MXQ'7B)K9#M'LB28;K/6L5JJO967%IT.%$S`^,1!&B;3'AZ#&_(58P?.H;0),
MCSGQC@5Z6JSZVHP?RI%M.R*\7:V5E21URV.9+&KZ#L5;129(Z8LA1!4U13IC
M>'&72UM=6M.H5K2'4E*61C)&2B_(S!""^K3UU3L51;;S168F)R7N!O`^N9BT
M[[=L)+B-MS".D&&CR,O*5(%FBI`E`LC_`/F?(/&0XSC`0I.UUDG8:R](='6(
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MBC$$=@DE?DTZLI4$+=85L;5%N7;MAVAN$NC4VU`T6HB94GKY,H@ZMTC;98\D
M,C/<NYEF18_.2T:A6M71Z)0!I$4?@1BV,NY019+68]P_VM;)VMH"D]0ZY7^\
MZWK[#-A7VX;&:[562Z6P;76N'U1BY+W;@-Z-<P',\.UOI<#57T=;DQ[>C52]
M8VF#"/[M3@P+3(3>40L"V[JIR.M\K,?:%Q7:><R)9'STD&/?;(8'"5-\4C4G
M&;E,_P`GCL;(1K7I*4#'XTAY;_<61*/4`4&?RJYJSLG60R0%ZL4^KVN[-F:D
MKMYE9BN5-,<Q$B&N:SB;-4M?X<QRMY:V1WB,06$A`4SO1B]4(E(!`HR=X"$%
M-[Y;6<:VU_CV3F'6`Y,;2Q411[(;$(^BGJ-QLZJ;HF=!5[7#`XN,$L&AK$6I
MCWDPT2!M?&<,>&9E0-P;A$?>H,AT:W%H?#)JEU/K9I6((9I;J@X`L1UU/AT,
M+5(;@G%6BCCKKFW/CP)Q$J402KI*VK)`I8A)E`Y+(R6LY8>("4XI2',5V-[$
M7)=5A$:ZH]<4=X=JN_K6Q$ZY:RSHH]7&>JK3QB>%LCK>UY\K:'P3?!]P7QW1
M8G,A?4ZH)T=4IDJ09PF]E;R7D+&M4]+*5_CU4E3$M41U;M7N7O+MOKWK'>^P
M;_+BHZ]N\IV$GJC#HOCSA*B'AR+@$)-)5NIJ#]3M)EY.%2]07_;^Q#IIX#@5
M/;-+D$#[9.L&6A4%(%UOU/O=KDXBPF,+_-)@1*H+]8$"QQ`M3DF";5M/+3$:
M<XH_R)2>(O`19$+@?IOZ:[[16Y3W6#&U[BRP^^87+[MW,E3&\?BGQIT[KE^C
ML8<*I93DPRW%(\[1V-)$<5.4E#+&1$4LD,*%A2`C(0M&C[`Q11A98M%V9JCD
M9C;2W,$=CS$WI&ED86-G1DM[2S,[4@*(0MK4V($Y9"=.2`!1)0`@`'`<8QP*
M;>U?89/3&PW5BW,5.WE?=BI=G+CN9!5]`PUIEDY>:\KO4RZZUFZU!^XI/#H\
M2<V2&^8Z8).I<"!'(ONC@>WVH@B"4/5Q#+(A&F,,26Q6TEIZ9RRUMI;9-J^:
M',ILP@\=NW:BZ+AA$?E0(ZYO+*CD2.%3EO\`O4I"HX*13D9.1>P!8P%A'`P&
MU*RA=SUO-ZHL1E1R&$6%&7B)R5H7)$2TE4UO2(U$H$62XI5J/"Q-@W!J<P90
M_A/``S&/(<<"E#J,Z<(/UV638<]>:UKU+:L3KU'K)7-^U>X?MI#L!KFF>VV;
M,,UMVFT#:A98GL>E5-;>RRMX(.6E243(G<@#">J69,"U0.WM!YVY.T;,F0TN
MR1=&)=C$\(6L[LB3.E6*9@M@PG9ED*I(4QO3BB?D(L*4*4\U4G(S@X8,%^V0
MA)G@.`X%4'3$@5IM,G]T-3C(;)=N7V#S2,&B]0!<(I*-W[[=&!S*(P+Y4A2]
M"<$S!)H2SB_/@8`B\XX$6-NWRR8MV2[M2&G$,I<K=:^@*0.U4-T'0GN4S<K&
M9=@+\41`B(MR8LY0Y24J2*46$1)8!F"4FEA"'.1>,A&SK*EM_P`UOWJB==DS
M[E47.\],VZBJQR+T"_%V4NG0-LM3D#FY2=#(V]K>"EKDB3)S$OW9&#_QHTP1
M&&_0P81XZ[-H(A4N@^G<#5]_>H.N)S)0$0$II:7P#61^E%:JA%.2APA<A=9C
M8+!(LN<:4D'(,E+T1"T1J0SSD_R$?`W=VB(5&S5(]9**(;.Z4;?N\TL/8HII
MM>X)+&ZKUTV@RE@DC9CZK8'BLGR3,C!*Y@;DN*$#;EH@"6EGAR-.H-"$`=1C
MRY%-$-=7B0.R2&DMD97.3V^E'I#$$5*1-1JIR=BU+JC$@,2,8"AG8&I3Y)R`
MKR87Z^0\#F*D?8?KC^)>DRS^3%&5(!H'--E$V4%I>M-.%E.>6),J)!1KD(\D
MS'D&<`P3D><^,#QYX$=^NAD:8G?'7Y5493F8;G.Q]#=@VUP&9\:,YH<OX_-P
M0)W^8KP(9K\Z.L&RH^4`?0XGP6/(<IPY&'9'P*R>G'&0];VMQ0OH8G3VJD.#
M_J6>DO"RTJ@K/^GDHXD0<^/I]/I].!9MP'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<#BNOZ!I)3HEW^%/ITV9T31W52F=L)D0K-\LE6ZO,1A^K3^B;C6AE5H%#+'7
MES2A3NL@SDU,Q)C3%RDLPHD8<A=[H1#)D;OMVA60%Y2BK?-\16%CCX)`^F*#
MYTIU7U`E8Y$*,>N8KA*HC2LDH+F#.'%0+(BC/)!9.<!^71%9UPVUHJ;*[NJ"
MKJ+EQ-^7;'T-<4_3;;1\,9HS'Y,4VL@R(DS#,:5S@H`29D]P)%G)V<8*-R(\
M@T60I57%(E:S^73/X^<H2$/[W6U,N<?=%*L:],)EIF1QJ738]A<G=4Y)4KCF
M8+!,BW))#8H2H0"2X&66<`(=`>OY.<ZN;X-X/8P9&Q?8(C"4+'R#S\D[G9A7
MN#QG`AJBSPFYQX_7DSV_]W`YS=<]5-6B^K+6>VK;_C_E7M$6;1^M[!L:\8=;
M>KK)(YJRXJ%#*9K9Z-*HNB%V>3(7PH"EU.!D@AX2F'_&5D1Q?K@+C;`30:U:
M5Z]^L*M*+>Z&KW:.(!L^Y*,D\G12%]I[1VAED3F%AP9_D45F,W1N"JXIM*(M
M!O!;NL`<TR)SSDP(THP`"=VD^BC3IJ[;DN*:R7*S4^XNVUI;9/S8]11G8$<+
M>K32,S<YPIL`WJUH'EB0-K`E*`<H"68;ZC$('D><<"2=7ZZZ_4@?+55+T73U
M1*9^J2+9THK"LX7`CIFL0$GD(54J,BK*U#D!Z,E4:$H:O)HB\&C]?'N+R'AC
MUQ@R:Q:'F\=/<H7'-=H584+KZGX:0Q1ZI""YX@B#(E>SXH@9R\)G:"1J,JFQ
MBPC.2ID:)\7EY*'\H,EA7M+>O.P551Z]ZW*9078L(F&^;WMWO18ZL]/&EMBM
M3=/I[LG'8:.)FJG!0]1U[N%K@\7,1EJO^WC#1C!GN6$0,AKJ>["2*H7/L9[(
M)?%I(Z.%9.3=H1H]4S^A<D1TQDL<F#1#3!,;:02!061LYN9,T3,-P"`W)T>B
M34MP9]N`.`!#:5]7E9N%J:TZ0PZ76!7^S$P@2O=;L@V4J6:NC)%KL6,$W)<0
MHK2H]<K553:8+UVM?1+&]'(8^:%)#8JY("S\!"`O`8M7N\&SE)3':CLNV[JN
M9[,T=5,>NC4K6ZXZ5C4`B<&1.T"V=EU?C-@=,$6;,;761;:B512&HW>6F!=#
M$SVQ`*2)L,6"58PD='&Y[D.J5`Z/T-=#-;-_]EKM:-[;L[@40_,BZ.0^O7UZ
M8E6Y5JPZ4LJI<@9'Y2?*&RIJS3A!A2V%"3'X`'+"H!@/WW!C=4[M2>2:WI=!
M7C>#37KCRWP>01"/V:QUTHD^UCA6QT900B$/L^N:H8(\Q/6>EY&=B6+E[BL7
MHY1)&TMN`!8S.0L!"?86=5PM>>B^TZMZIJ[NG2N8P^CJ9;]B]E8E9TPMO3F/
MNEGUO%*T9%<I:P2E0QIV(XI,KCTF=P.[:_*SL#1."5*K.5K`N$[@.T=-UQU3
M7D9K6!.%S[F;52934VGM*($1ZM)+K*/5L#/A[E9A"E&:1$XTX2QOR:04:!2Y
M*E!*4L1(!G*TH<[>LM#;5:5;$..V4$G41V>[&)'.Y-K]N;,9ZZN$G@>Y^S5S
MR"NIPUZ&:NFD',>:P2:GUE!C'>;66$H+)$`I5"(YK7(&Y4WM`7([Z7O#-W]&
MKSQ'%Z'6C<3KQLNFML9/1FT2]H@9E=VCK;.&2TX^@E$@6K@PZ7TQ;"1E6L\?
MG;*N6Q=R,6EG%J?D(4)BPM<TKW5HK?"CV"[J-DA:U,H`!JGT!=<A06+35AHP
M?%)ZMM2**,%.T2F\5="S4RA.I)+"H"7A0G$:F-*.&$MN!4]N(:-W[-NGR)EF
MY,`U2+>>V5R+"8"DO[6):PFUTE7FC`+*E`),Z7&0$LX0?MA9,$6(6#1D8$'X
MZ"-YMI;@]I.U[PY_E%"W8V*Z75TC-(+$"(U?I[7[60]MC4K,+PK+*D=[6G,%
MRTO&<%C/++\8%@L`LA,O=>73ZO\`3K:F?U7,6VO;*@FN]RS6"3EX9FZ0M43E
M43KV02!D?G!D>#"FER2MJ]N`8,M5D2?.`^3`C!C(!!1_K5>5CWK+_P"-G:EE
MSJ06#*[IUYW"L>>RF4-</;7U_GSAK+#W(2I2EA$<BT<2)&PMX<TJ?"1"G"8G
MP2(_!A_L;D.ES@.`X%=G:%8>WU,ZN'7GI@P$SV?4;95>6S9E0A3,XWF[->8>
M[F*[KJ^*N+R@<@,4G>(D8-6E5IBAN&/L1%)0F'F@*,"@YDJ;L7[AF6A^Z"E+
M7UEHF>47^9F?7UKO7S<CFKM-8>L?5359U2[@[(.2-$Y-S].H\B<(XI8FE%AC
M8UJDTTTLA1D\T(=>S8>L5-K>J<4'XIP4H4AZYLRJ)6Y;EAQ!9BI!E:GQ@A7]
MF>(1?R@QZ&>OMCZ9QP/NX#@5H]0@,E:#UDG%G&1I+1VS1&9Q_M$:BV^OA(:(
M'GQG(!&$YR'SC&?'CSC'`UV5_;[XUWM]?O.HUI^/Q_[?QNY#S\WOY\>/?\J7
MZ^//^T7GQ]/(0V[2J=+NOLDUU9DM&LVQCI#>N[<68_L%WVCF>I[?&RO\TZP(
M$LV?+"KQM=9@K0^?N$:9$05\`CQC4F"!]J`P`9#UPL.T3CUGZ;$1'1/1.=1!
MPU7HM<SESG9:;-KI.&\J`-V&!RDR)=I7.$Z9].;#PG'Y4.#F$LY48$M0:'R8
M(-!=VLL_X[T1UT6R[Z*49:&PU?7Q(F^!ZPM2M+:.O-8IY"UB>IW9C/'\PBHG
M:P)3#R(TUYCAR=)'\()$]8,,`JS@LI0'3\ZFOAD?<CXXG0`DAC,L-8DDC,4$
M-8'P2(P;6G?36P*Q42@"OR`*H2?!I@2_;)>!9\>0JUDI';*GC<G&]UCUB+F,
MR+2D#ZC;;!V<:UZM(*.NF0%)UG^*#<!P:NP4$T.<EBR0(>0&`&$.<A4?HD^-
M;GN#U)158S.");GKJTCN>.*B3#<-&$J?0_<:H53<6H-`:)SP@,4+`Y\F9&'V
M)$+SGZY#K3X%9G3UCTZ\:.(_KE)(]@D`A?Z#&W[*W"B&8'']<!-$1D6,9^N,
M9^O`LSX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!R!7%.E-=Z.]IBR426T(J^6SW
M2;:0-&54CRV11O<0&U*@8&:.67A^RY'R:H9E!H*`]^;TOQJU9JP`"LEEEB'P
M+4M$*WMEOW1[*)^V&C;JT5WY9D/8"5KRH'&CK)#7^MSFV/"B%)QIQN)2*/%E
MH<N)9I1A9:0U&'.,8`+`;%Z1]2;<TDZ[*HH&_(LS1.YV::79*+$1L#Q'G]I<
M7F<7#-92A>T+O&SE"16A<H\YHA)@'C$M3)0EIU&<&E"Q@/5[<(C#(OUQ[Y/T
M?A\<9I3:-7$-,I?61B9VIZF,@<US!!(JOE[PE3)EKX)I+<2$X#U9AYB5$#(2
M_P!(<`R&V=,XXURJGMEF=S^Y^&;[A;VLTC&F-P4(1(MAK+A(<M^1`,"F&&.M
M28/G(1>3PB,SC/MXX$#)WUYW/K3IT^UHL[>[_A^H=)Z^R"&2IILS6;4:X1H*
M%B$3<6I;'75S,I$J721L;*S(RU_"$*IR6!)#Z"&:+!>0UU`*,OK4#LVT;GLS
MV^<]L7G<>K;&U8=VF?:Y5M3CA7FOM!UA8VQL?7PI;6?[6(:%S?82IH1KT3JU
MK5JXE>+V.*RE++`%WK_L%"(;%KIG,Y;Y;$X71T@$Q2&1'QU5)024HN-1*0&O
M,%9(&.62F1MY2V6A:,D80%..79$I)"ER`!9IH;5S*HP&3)X4.1L0)DK854J3
M1$;N@!*%$80N"-I6R,F/B48=C&)&ZN*=*:KP3E.6H/++$/`QA#D/>X#@:[L6
MIJYMLB');(B;9+DU?V'#[8AR=T^YR2Q6+`'#+M"Y6F*3GD`-<HXZ>%*7Y<&%
M`/"$?ID0`YP$([6U?NF")][+SUEDK3*=O=N$%6P*OY!/S$L8B%%02$Q]-7L2
M+;A(TKNK?V^I5<SEL_$G,P$]_>%PD/\`8`(H8`C:DIZ%)+II#7)"E'$]$^GB
MK8';LR?7Q&YI0SG9ALKAQS4*)6[F$DA>V:CJC7+I[(SR!J`+)-(F,0\B.1*2
M\!`:TJRET2AL9WVU"<I/H9OUV@6=7,3ANL,!(JM_1["U0!TD$P;@2N-3^II'
M"*CV"+UP"YS^03!2B4)HN_?,@<AN&#,@4!BL!L&6-,/ULZ(+L0_\:+DMH+K)
M=\[V<K@BDE0WE$+/D,HFDUBM2VRA/2+G_:+?.7J75,O:')$S2!DC@GU:W)E!
M132I,"26P-GSUSMF=[U:RVH&C=,.I:#SJHG^"3&RI1`=5]ZY9!VU>T6-5B&-
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MC=%1`"<Z%J"5:8D8@PXC7;7+97;N3QFR4UV=5W;F7$1.SY8FH=KO=?P[;Z#1
M=(B3H[1K1X=X[FK-J:Z8!92F.K)(H[F6QO/_`&#L3@@HM4:%G>G6D%J:QSVP
M;!M'?[;S<1;-XXTQM!&+\?8,5`(24UNJIR$]16%P.'Q9G029P+-+3'K`A#DP
M@`@B#GV#\8:IJEQ7[$=M.Q%EID"555FB%`1W4>*R$62SL.&PVP3A#=@=@4;4
M84M5$B#"ZTCE;H%`\E)CB5C@K3YR;ZBP4$7Z5W>@>D$*L>.3F&2R22B\>]^]
M].X?'V-7'T*T,[V@NAWM"$R=S4R1X;__`-5$$$F"1<I&7\JKXA@P65DO.!X#
M([AW-B?87U4=OC@TQV5:_ME/Q[>;5L3M8#J@9UKV=6E3*@([$+/4!:T3%')H
MJ?,$IR3%!OH6`6!'9$+(0A`C1B7Q!>I_BGM<(+>CV)QU/W5^V4/YZ`;DB61'
M5V#,4E;E/X].0G69324P\D@X`"L#3DX$,`1C]0AUK<!P'`_P00C"((@X$$6,
MA$$6,9"(.<>,A%C/G&<9QGZXX%=NAG79"^OE_P!ID5065,5]([#74IO&$T`[
MH6@J$Z\R.1I#<V`U5LN2@_*F1Z7NXB3P(SLEIFY.C())+R/YU"@+$^`X#@5I
M]0QA:G0>L')/D64#Y9NUTD9Q&8]3QL,FVZO:01\Q65]<$+C65R3B4%8SG!1V
M1`\Y]?/`UR@"-=WPR@SV"4",=24'(P#UR,:X4WW#GQN1Y'[!"G"UX@7C&/`\
MG95YSY!\7@8:NV?R:1VTHAICS4JA?TJ;IDX5$CR4<D&V[!Z^')5*4T/@11Y9
MJ\0O;Z^,A#G'C_4*9-&:CU..T'U%E]@4KWW.K@\ZIT;F7"H^?;^.M5R(]TB:
M9<Y.%>QRH+>/;`UVXNP#G%K3-J1.A3M1Z3($Q.#0E9"QC8RA@7Y$^IZ@-;+,
MO37)W]MAK2I^:[64R?<]_P`654Y%6Q_82+:CNTC.]V,QM^96Z-PSE)RUM>"B
M`-Y*4\H0DPR0Z))0V(7F)R)F?6DV1-KK'7=L>&-!G!![ZA7-JA*X-*/)J]%@
MDUS(-&27[*B?7(\>30_[\!R66GIEUK1R`V<O:NE7M3:'M1!)26>\DSBV!(6X
M+5$E@V9<YKT^^2]O.:&WR$DH!85?VP"\AR2$H/U#.]*JLD3/N'_'WEKZ_D1X
MIPZ2W%&Y,J1'EQ0S:44[7%5MC`RE.F#`%HS6&/;0/#F6:7C/N`HTLP(OE*$4
M'5UP*TNGE*H2];>KPEA"DE<XQV:OS@-:`X"M<Y22U)W('%W48/P$637M:YF+
M,B#@)0OG\EX"7D.,!9;P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#DSW.U_41'L[
MJ[66V9C(W'3_`'=W>IW>:M:5+J=#,(+-+;I>IINLVF@TPGZU$\/+3E,[5C#I
M@2PA!A&^HW]P3$@^0@8!!9GJ[8T:A.]-C2R,W`^3?43LWK2JMA=0GH]2SF56
M/8:.,4T1[#5]%7`Q&CE+?.IS54>BLJ2LSGG!HT[.^!3E`,;%I10;5L>47=H;
M:EF7A)7BP;_T2M*1CGEH(CS7><6SH](U*)`@DDXAK8`1[C,M.QHVL+F],2`H
MY[@JL2QQ1%+VH\]*UAGO8:HB5D:4KC$2MEFU?V/9>GR;[EL<272-36!SC:JB
M4BH"1U:U`T[E'I7&789>#TQV0G)5'L6/P+`N!EFAA1W^+K@7""'[-UW4WL6M
MAN!8]STA6W%PMIQAI?GW)&!T;U!>`BQC.0`"+QX%C.0R_>:"U'9VGNR%>WW9
M"^H*7F-1S&/V99K6]$1U?"X>XMAI#P^)GA20I)2"3IA9QG&2Q_*$62\8SD>.
M!0UV)=H>G&G/<3I%$+'E4@F*Z@=5MDXLZ0.!/L2,=ZZL>_'774FMCIXYVE-J
M^BN5,@K&#O`BRAO:EV"%4F/-2X+5$G##&"NWC079"NH72,4VHU:@=DW#V-1B
M67S%W998NOHV.F8%L,JM%6KD+_.7]"UN=G/]<U`PLCTN;GPV.N3LXF@1A&D-
M)),"W9JM&;'6CV`;.HG5)*J;@-.5'6FKQS>_PD$4F\G88)++/L)\@$U<5J>/
M*@SRP;.CT5,..<,(1.T8P0/P,@6,!,O66#S>J-;J.@-L3A[L*R814<$8[,L.
M5O)KV]2V=-<8;RYK)G9[5D(S5HW.0@5'_*865GXQ8\A#X\<"/M,]@=8V72-`
M7G+&1YKI@VRO)RIW69EP4ZS-^M)N<9%/`5=/L(V-@)-CC'8U80%3-1Y5!^V9
M6`?NJ5>0"SP)W$."!4H7(TRU(I5MAI)#DE(4DG*&\]0F*6)R5Q!8Q&I#3T9X
M#0!,P'(BQA%CR'.,\#Z^!KZTZSC%Q01[KB9B?L1B1B:</!<;DKY$G16E:7MM
M?<-WYR-KFUX(;'0YL"G7D%G``M0FG)C<").,"((L7.?;M2N^P>T#S63%L0BJ
MBM6=LTWHRIJ^3.-ZCDKLTF$V8C/GCNVJ'!F77#-5+,U'%MYH&5JCK`2N6!,,
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M6)Q@02BU2YSR(S[=*E,#G`0C$8`*W>S[;'7K:V",L*UEM:L)`Y4`\1#966]A
ML!<T=JPK0LUB>1`KY36BZO'<TVZ]JKZ?$0XM&:J:%QALC0+507DK[$](C<PV
MM&.WJQZYI1LK3:[6J4U[V?O\3C1=)ZBIP%)TVW4GFYI;3!I'4$F;5\JCK%'D
MK@>%18[:J<U:ZJR$J\QS&>WDHW%>&QX=>]!]1&OM>4YL98,IN392:"G^Q^Q`
MJ.K&6VE8#[(+$FCS/]BMGY9!(6A>)'"->H-(7A:4!\=@DITK(U)V]-]RK(`D
MR$=WZ!S,[M.JZ!PF34O*M+-[YE&NT)IE+L0U2US569JA3-=U<[PFFLNT4DL4
M<UMIK72LIZE?&]S1.J!H87X27/QF@'@%.3SL+I;JA[5;MVF=K>.V+A\R[`9O
M014O:8I*WR(5A7T9<VZD5D*BKG&&2-O$,1*XV:\(`*TJLEW2#^YP$PI06G"&
MLIN#8S9VD_X]\Y9)I#J+W.G1L@G^+M2PB./R9%(,Z$6Y9,[BKG%&Y&T-)M6[
M`R..-V)BSMP&TT*46!(3DBI(G$$+F-1=P2=@#YK4=I0X='[?4<!J27[K\Z./
MY(30!VRI(C]I59(C$Z(NSJ!L<2`X^.R1*4#.<`,0N)"%U2K$)`38X#@.`X#@
M.`X%:73\C6HNNS7T"]$K;AJE%QNJ-$O(&D6IV9[OJT7A@"J1'8"H0'Y8UR?(
MDYP0'I\Y^,T(3`B#@-=M>?C[XIP#&?3"KJ/JP8P_T^<2/<>X0`%X_P#?E,%;
MG'T_V_+]?]V.!K"]0D']Q,IPX8P<E0=(E\&)`*#?4E*%RV@AA3X--DT024XE
MR=N2!4CQX\A)*]\^`AX%>>A][R1DT'TO9FCOVZ_J."VZN4`WMU92:F];37.N
MTB"MXHF4P.1$R;9:(R)?((DF)$VJ%*A(V'C7$C./38SD1/`MZA;\Z/\`L7UO
M/;M>T"V5<7?6S=/[^^:L9F.-U[:9N7K6$W+_`!=DC,NG;`@;#LH\!P2E=UY7
MR)A"P9],A"%DL^=43%!)J]N4J_8C<S1*1NJ^;_`@5?LU$WLZQ6JE7VKJD<&M
M3^WB"1*_C4D'IQ_#X,+&#.0Y#E,O'=ZO#*XM[]J_R;Z_=HWB'2-.9&GS5W4.
M?R7T'%G1L-C2MUAT)A@!'OYZ3)9>/QI"G*P1H0"SD02R@DW1!3NDLC^,/+`,
MRY3'G7K\NZLG%_).3Y3-<FDVE&MMC1YL<LFG86*,NK33[T,O``#Q@Q)D0\A\
M8\ATB\""G65D6="=7<"R+R"L4)6,"\^0@)<G,H!>,9_H`L`,!#C^F`XQC'TX
M$Z^`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5!=LD0M"Q7SK=@=)6:V4Q;COOZVO
M<)M)PB".>8B9\*U0VJE;K\D1<C4;9(6B0-#8<UN20Y4D&:WK3<D'E*0DF!"L
MJ66MC6UTVQIGL`HA_HJM;#5T/:M0QV'VY$XKKY)-M5]HSAQNN\.O;9J:!@#5
M1TZ4&HX]/D<%G#]&WT$QRX#0!.PN5*E@6'TGNMM+':?9+!FE5*]T*'/$ECR2
M\H&FAVM6Q'W_`.71PS\1;FLU^O\`6U;O,E<9.?\`;$O$(EIC/(S3`B:VDHLT
M@LP*SD=PR0]],U7TIUMVCD>JMW7Y0S\VTX]5*TL*'0BQ(OL=4=FV+(8[(FR:
MOK(UZK/(V]>L<F$SXLPJ1?J9@J&9R"F;@O3U&LFMZX@L]@<\L>O(9+Q[;;I+
MT</D4\B+9(P-LUW$NN1Q$>610\A<2,R-G?DJM(486$XTI67G`?UXQP([=ZM^
MU?4G5%O@YR60,JYR'4ZVKFJ-(Y"RE/I]G67EG9($Q?CCSC51KCA;(D;J:A"7
M]V<U%&&EX"'P8$(S]5_5O!7_`%VF-X]GM+Z^;&[L;RSM[V@O1!;%-UA-%M4I
M+)86%!&*7C0)&SOSFQQZ'Q-O2_*C*.P0B<%9Z<K(@$EFC#7NY?\`%%ZJ]I5:
MJ1UQ#97J!.%&$'R+=?'!`A@J@*4TS!WW=5R5$\Q1%E8E'Z9RTX:O[A8#!>^<
M&8,"B-P_C(]UF@LX?I3UC[WL[W$,+DSBVM#;9<QH2724"5<<L0M\RKER(D=-
M2;*`0"\B_(.QB50(8LY)+#G(.!MM1_(*[B-##)!7':GUYV1*Z^,:OVLYV&WP
M\5;R4:94S/*%^DK)=4(C[MKS,Q$G93"*)1-*,L6!&#$J!D'H(++=6.X[K;VA
MN:@+423YKU?U1T<UBE*BGXW?[+&:]6NMU22*N,%=TT1=V%XD,+3"HK7B#O#0
M!G+7(U[J;-<?9)%!:<&0A8+1QDYKJO$)3E)IG66[7;G?=@[`HU39#XG-7W7^
M&-=?1LR.ER..3@2>*"8M?=;H%#XJZA584B-ESL'!)!XU6,8"?L;VTB[_`'#L
MY`<L:EJJS4:*Q4^WMAWYZ:VV`H['=XNIL:5ULB)R7@TY96%5*69^D3B(TI&@
MP_IDN`B.+4X)"2D0ED<GT3B\ZASNDD$1FD=9)9%7Y`(8D+W')&VIGAC=T0C`
M%F"2.38L*.+R((<Y`/'G&,_3@9%P.0'N>V\$LG>\VDW6DTP9IV?LNDD,T[-M
MIGJ2/K4@JZLXK#&:MJBI&)O1"EQ_);`V^7*DD/C;$T)1B)<I%@`2?R*Y6L0!
M)[5S:S5W4'4>C>N+J?@SI8.YZHQ?!R==KB8'&%V71D\RH1+;KV'[!$C:VY5U
MVQ00]VRN59#D>)2?]@SQHP]*:G/3!JF0Z56EI7V*:?/L#CEQV+55=Z/]AMD;
M3;EK8)]YBP=H;S;WF=S2>6M,880-[22Z5OT';\M3:F3G'M;<4V-C9\I0,A*"
MRO\`C_1!W@_3UHZQR&)OT)D!U<2:0OL>DS8^,SV4[RVSYU*%[HM;I$E1NJ?]
MQ*'C+B7G)>"#"E81I\Y3B*SD(H]J78G.'U?(=:]7$\I;:BK>P"(+V!;IFUW(
M9%KYK_[H61R+HB5S5G;7XYM"]@D"'-F/:)I=4T+B:DQ.H,1KE^5K.%5232RS
MP,S-16CEA2>/R"<.#CL5J;1+V='FC&+<23-@9I]W6S!(P)GF`Z^53(D"QV:*
MIJKV*:7).J0O#,%$]$F%(@LVVJOZ<.=+OE,;TZ[[F5=:&J<D8!5;VR4S3L>F
M5:,UX,,:4F1/:"',]='J+`C4<G:5<E;Y+'DL0<XXI,?G&*JS%";!@S`C93E/
M-4FW>UUMW0FY+.O?=TC7Z1R[>.P]IJP<6(ILCVV$0+4U_)MV%#7(H6JALBA:
M*'(@5A14:8BPH$:%1DXQI0JCGO@>-6T+>*/$BTKJO8X%ZUSK+LO6JW3O>U\@
M3.QUMJOV2R1UD;[-M#[.,K1P1)'+7^_HU/E45(&RD*D\('./VFJ--7X922@Z
M0=-MK2]IJN&[S>&,U+7E&)=8-<W/KF?8;)8,JJB;U])3V1T8WIR;FUBRY)G5
MC4-CVC4@0E)U+0]HE!8C"5!1A@:-VM+QCL,ZHS!`#Z`E.YI)8LA#G`%!FL3H
M,L(,?7(!B3)S?KCQ^G`L>?KXR&Y-M]6'2YS(1<U*R=NJG;^A?SCG0]KK$(E;
M"XIWI'@N3TG<K<D*$OEM!6F%.02^-Y6<+&]40E=VT9+HWI3<![^K&UC5L:CG
M,7D,%E%*[`4P[HHS>U"SH(!2*"/#C^0PQ22.OB<HEIL>H+!*:%:N*2UL\M[V
MC(-QD*=:F6HDH2RX#@.`X#@?R,7H`8\!$/(`B%@`,8R,?KC.?4.,YQC(A>/&
M/_7@5W]3(9Q_XZ]6C[+8YI&I^O@KH[2YCL9F=(_.F]\>9I)W9<5*V=Z(3.:%
MZ&:L]S@F@QD0A>V,Y#G&<A&2*6+!HGW?;E/5I61`X(GCW7MI-$H2GF4D8(T-
MS;9#<>VLJD1[:I?75'DT2)T;"\*@$`S@0#$^3/'QEY$&N[MM6IK6W(VCL6L;
M.KFR(/&^F.\H^_3JO)G%9PPQAU2W!(U;DU.[S&W1S2M*X)+::8(@X98A_9&>
M<>2!>H?QH+#]LBM*=,R$?7]U\/$;*U8H9"Q/J[9.8MSZIC*>JXV?&5STVJM(
M)08E<UZ$T)BU,%R7X(6J#/52H#@1HPF0XN)\>VITA=;:C%?4PI9=3=R'A]B<
M=F"=[KJO)/F:Z=-RE,SS1;&*\3N+<C;WI4F+6&M3:`W[D7]@(A!X%B$A,?Q1
MM[-AN&-1*!,CB9%L2$Y:7&SGW*$X3)A[4-12AQ`R&+_B^Y&F`,[!&19+#D7C
M'`IWV'5=LR#7K8'#G3?6NJ:'.F+3*?38[>6QD?=TJ<4*?S3GE/ARUO=F]\6(
M@F&F%I%`T8#3AXR)45CV%P(V8LZ.U8+^,&VG)VILATQ:D\.;5BE40S!;7B1=
M;4JB,$:DB7/E&++TZR@M(60'.!B4C)**\Y'XR'1>K5$HDJE8H%D"=(G.5'CP
M$0\A)3EB--%@(<9$+(0`SGQC&<YX$-NN-*>CT$TT*4`P`8]:*:5`Q@01X$G7
M01D6I3/(<YQCY4J@`O&?`@^?&<8SC..!-'@.`X#@.`X#@.`X#@.`X#@8%9#1
M83Y&BVZLIBS0.2CD414J9&^17]Y)RXLAE#2NFK4B91.[*0%YD,33K&]$L--,
M*;U2D"D1"C!7PC#/>`X#@.!6YN#^C='J<.']"L[([%I?;^N/N%&BFRAA!?C'
MG/D8$P\XS_3'K]<_TX&UV67S>T-L=I==K0@$6>M=8?1FLDHA0)%"%;DDG$CM
M"0;!HK-1.KD]961*3-;*37;&7A`!/\R(9WR'>0J"N!%^>=$G4?8K@^N3[H]5
M+2?)"BBG9-7JZ<U0S&B3J#%B=2FCM7RV'Q]O7)EIN3RU"=*4<`[&!X%[!#G`
M:YCG\=WJ/@2[+S5.MLNI:2F-1K"IEU,[.[5UE*U["J`F"N8W%_B5UMJ]<T.8
MD90U2<T0BU!I01F8$,.,\#5BK^+UTJJE2ES_`.+,H)?E)YR[]RE['[)FR$IW
M.,$?E\+=%EKJCS'H"P7W&%!OR#R?CW%[9\^0U#=_\5[0B[94YV<[WCNT1<SC
M)D$Y-M:1W@RVE*%\Y:Q,A3=*I*JL^`2I;*5J!K8$Z(DI6H$G*3`]0@QG.<Y#
M]]D.E?=&5[*PG=&BMR=4#-F*]D9#^@G=P]>]8-TZGPT;.V1]H#:UNUG(4B]\
M.CK,V83HA-D=:<`+,SYQ[%IQDAB6Q]=[P5ELA"-Q)!T>T7M7=S.[QYZFMTZG
M=@4_C,H<I-$T2"/5VO1UI8L#K@;U'X^U%DDG-[D@>D@!$C4#R#!83#`GK+.^
M/KNJ"5P:N=G9K;6IEF30G)8XAL5KE?M=(V!W)`C"K;ET[=*WQ7KDB+5J\EEN
MC>Z*VHT)>3?N`E9"(07#+$;8^-JE`O2H7=G=T)R18B6$)W!M<VU>0(I0F4IS
M@FI5J%8F-R$8!X$686+.,XSC/`HKW0_CTZ([,N*RS*8B;3IOL*#*=8EL*E83
M#SZQF"]O6A=4"&\=;'UM.IFXHP8ZE@/6)E;>E6JQ`#@:SU#@/`IA46YV:]*L
M@;7+96OT$IIVN(0Z0NM[E)B]B[%Z2MK%(7LAUDPTD]C;8\;<Z$*W\;2S%+6E
MP0SV%K34(26M`WHT:0)82LUMV=I?>>B=8^NN&6&LADFVOED]O_?*QGTIA0LF
MP$4/DY%GW_7M!6"D7?M"V#=D+)F::+`;F]8=*(Q6:=S"\-3>H2E)LA:]&MV%
M*7.V6[$KDZN.:$4&VKM?==:]86-D-==CK2@DM.CL^M"#&%IAN<H_?5K%HJRK
M!H;E82'I6@6JP%'!=&\98:P[(NRZWZ5JC7G777&LT)7:#O=$TZ"H*)DTJCJX
MO6P"Z%+7ZS+KN!](*5QTZ%:_@1K?E4>@D3JN;C1EA/2)E>`AS1ZB5/:4"V7U
M?HS6"=44BL2:6I-MN5L]WJ=7B26]V`S>>(YE4C?V206)1ID:(VHH^E%K;(I'
M3D+D$G4RE[<'!0[FHR!K0NJ8.\2EZ<8:8@L7B:-S>9I(V>,L3%*+5FYY+S9]
MG.K0W)42R86'*LDEKI!)'Q0GRH4&#S\8!C]"@%E```(1NEMCSIN[,*'J<B4.
MA-9RO23:*>.D+*&1AF<IW";OU.8F&3KB\D_<B<6:/SAR2ILX,],%KCL9!YSC
M.`U5O?M1914PC>@FFI_W.[VP,-7/H)Q^-`\P[3JC#G`R/2+::VB\YR2$:(\M
M6B@[(;X%*)40!/Y"E(5F`#6SU+Z_Z]:PJ'K-T6K4%];6RJ`R!UA5>3!W4K69
MK;WAP6F6'M[N[8P"3U+'"9+.G1:Y.J@P.7V</9JAL8TQIWR91A]&FT(U1ZTU
M5$Z/II`79&Y]OP.)9L5=7$!D#K(72*01OD:9HGDR9643^VZ_ZR0-2)<P0],X
MJT+.B"("!#A2L$I$(+2K0K]IMFM;!JU^=).R,=D0F4P-Y>83(G*(3%J:I<QK
MF!P<8I*V<TAVC4C1)%XS$2],,"A(I"`TO.!!QG@<8+=J/.M;-]7ZJ[FGO:DG
M?KMF]B-MW;EH9E5:^&;&]=,)9D);5AZM!JED+Q2A-.+7QD'9D@_$*K+/+,4N
M#$H1IG-=]J'S@@%,0-S>-5*LBNRNOG5WVI[*VC>DTVH*AM94!%:JK>@JZ;Y8
MPGTJPO,-7R&DZ1D[RS0Y,BL&;)VIU??QYBQF38"OPY\"86O5G1J4[30S;`BC
MY)8&\\"UUF5:V!^]*@?*4M3LSZ_6Y\:&V&[L:EM4I$TI3;I8D;8@/?(>M^P<
MW!N<S6_PF('&#LAM[6/KRZI=V)I1^T.EK%(6"!Z\6ML)7EY1F4S/:V(V_(7]
M5#GF$E1&1))]93994$$Q2EP*=!$N9*<Y6B+PGR4$O(B\!8I_X:=#AN#JO4QK
M8A?AU`J!^.<-X]W5K.V"5`*`(YC:S]A1I&901@O/PF$!`,C(Q>F0^>!K>3]%
M&CRTU:^5G)=Q]>[(<XPB@SI<=*;Q;1MEI.L"1JE#AF"NL@G-FSU"YQ12YJS5
M8TAZ,P(%9QAY62S3!C$&ND'0?3K5DHQJ[".X-M4E#,,^\0]AEFD*!B4X)+7Y
M%ZM7PXRXITX"CA!`$0@!QXR$00BP'Q)NAMA3%/C6'M:[ILQAY,3&8CF=\'$P
ME)\2[+B>`+LIKY0]G`4*@@S^I1@6,`S@61X$+&0]TKI5F247_9=R?=`22++<
M>82IVUASMD:UN.RH"HP>\4RO/)(4&^/E3%B`G.!CT-`8#/KP-6;<:5[!T%!:
MOEK#VX=G;PXS7:K5*CW@ESG&L):($3O_`&(KZG)`K;TK9JVVX1/C(Q34Q2C4
M9$:7]TG#DPD8!"#P,:U(T8OC;"B6&[A]O7:Q!DDJF-Q1XJ*D6OKL[*&Y#6MS
M6!5R4>'\O6=L&8I<DL,`K$(*<O!0S\@QC.`XSD(#[XZV;0:B[7Z35/6?93VR
MWQ/]M?WG4-PO"234K)G&N]<ETYK!H?)1`6M56K8DC<S0RZ4MJP3@C(5NH6MM
M6YPI1)L&#X$[](M/MSKYTVUDMVJNY7>^LX'.::A#[%H/9]4:?6C.8HPFLB4E
M$P2N>.]/9?96^M>"!%GKURE4J/SC'R&"'C(Q!4?7>O.D7:WLIM/4[GOS=.WF
MW:.*0*'TQ=VQ=`ZU-U!VF/6>4R&SEE?-,=A-4IID?6P)`]!$]*4RN*N<NC2E
M4:T*7%"C.-+"Z'5[JRMW6^@^T&0R9@J0=Y;D4E*8+$(94*AFD93>0PP&Y4T4
M9#ISBFM>4+@!UD%H8;FYN_;Z9.ULK2VDGK%AX3E&`AC46N.@*"C*#C5@Z8]Y
MT<GD%J2#QZ4,$8*[7$;?&IBD@K)'):C;C(992>"")(,2'H"Q,/AH&B#Z)@X3
M9+QP/)W,F>O>[5?4MJ;K)KEL+?E2H]$KZ45L&YX?:[(RW)&8Q=>D#S((_7EV
M7T[-KV_WC"VN$N*,*Q_=$0T$L&B3B5C5F$E"#J&=F>,M^M"J.**AE;[#"*5Q
M'5-$LQ;6KFCA%A0L+0HJ]$6LD;*T*'\3.(39C`W5.2(['_Z2''@S@<NFS^KV
M@D'U4V==(QTJ=AU6NIU!6\!%*SE);DT,#JFKV1GLS_(4,6W=EP\LC$L%E4<:
M<A4)R223,&!S@80&!F/8PG^P1?QV9ZG<R62/4*Y5;>)\;;VX*MI>@1P6G5>)
MVI(F3B0Y3Y0L=HKLHA`]"P9\8R'USXP'5X^D_<,CRGSG(<'M3@3[!QY%CY4A
MP/.,9_KG'M_3@12Z]#OGT*TJ-SC`?.J6OH?&,^<?VZIBI?GS_P"OKYX$PN`X
M#@.`X#@.`X#@.`X#@.`X#@.`X%)9D;WZM3>O>NO::["3ZDKVO@ZMRF-0J=ZE
M5];3?"O\@UW-OS46@CX=8,+.619R/CA#BK4+4YK@)U&,H)P221X4!N2PM+MT
M+"Q2,S>]WJL<;PUWNEZM:L)NMTYRFA!37,*?M*EYA$I57+3L6A6/PQ1VSS%3
M6O(>T!B)6A+^<M6$P?J%>KKO=V@12Y;.I6,O49V#<*PES%#W>=0OI[W73UN%
MY`-<CE"$4]1[:)F)S):\X3G&+VLM<B.,P>!((XLO`\AN27=@._$40(U>876R
M].4G*2.;H+KK[<R@'/PL#Q@"-D9J9DRQ&V*/A$,(Q*%.2\9]<B%XP(8:+D/;
M'OA'V_\`++H?52%":NRWHSE'69W5J$)YX`&?*5AR(U[+'\X#$YV/3[7&,?'G
M]6>!B$=[N-U&E]<FN9:^5E*&)2;[L4Z.U7[>M>6%G1I$`UJTV5D2G1BZ"Q?>
M#"(I.(E83@`@!]\"^;&"@FGK7VC;8;,-,GDE3:/5=>\5@DA2Q";KJ0W'2L$^
MC<HRTIWI:Q22E=JZ&UEG,(>RVY<F.)1O@T(E!1^!%F"!C(^!(\[LK50UX+:K
MTT&[#Z70`1(E*^;$:_->P\!;C#TP5*TI4\:C3R_WL@AJ"8'!RDYL)(]O.`BS
MD`\!#<=`]C&CNS[\LAU)[,5E*+`;G`QI<:M=W15`+>;W(D/L<C75%8R*)66C
M/)QC.!X,:@^HL9QGQG&<<#F(NKL*V=`JOE\V+::QL5A=8[O'(+?TK[#*$4TY
MJAK_``#46S61CK!LH*WWJMAO&S%MW3!I,THU*5H4R1,N=Y<C<`"1)6L*-4&M
MM=%^GU_VE1=K=86_&U/6==[JOC<>I34F\[#>=A]0;HBB\+78;;69<49[*L2.
MU1&I6\+Q-JF/*GUN=F=:K+*(CZ5:I2`."\B0=IVUVJ]N0>&]C/7\=2&O\J4M
M,67[V4+>*2_-:8A+UYB@D+Y:2)QKZNI[2E7K#Q)RLN\B3%`0FF"^3)J<(U(`
MM[K^VJ5O=B=U=6695]RQDD"1M?E,`F44L-B*+D+"A?4"!W.CKB[H``?(P\IE
MA11V<84H519H<"*,"(04#;M_QN];;B>GFT]+Y$ATUL]Q.<'U[K%LBY<GU#LR
M5G-8FI(_RVBDZUH2P"7I4)AI2*30T]G=F=0=EP3`$N+`;P*:V[>W>?K-:M8=
M>^Y30ZP[`@6F+>O,T=FFL\?B4CIK8K82*,2>#:RH[,=VM.N9&Z00EK6*P1X]
M(6@?2')<G=%S`K<DA!X0MIKCJTJ.Q-?=M=\^]=/`7B\]IJ^1S*UE+JJ/CK'H
M'1,39CW2'TW2\T`M5/T0D<#3JO=[<VX_Y'=U!]H,*X&3S'`,KZ].LP.PM*S:
MX]XFIPG3K:;\[O>JU@V'`VRO=RZXJ]M*.C.O%W29Y9#01RDKMB=4-C`*(,,9
M8V4N!'$*EQ@,O;Z^`"&'VHY=HO53>EJ[CW3L%-.QC5B6QNNJZQ4#;#:RI<R#
MI6ER/@\%ES_*G>3M4"K^>J9S/&<#LX(4:=EE*1<\N"[#8)J9V\P+>957ZE'L
M5678S:EG-5(5-4.D]KP2?U)93!'4*Z!'V?*ZFMF8S&8VTAF:B/-!<'05.F;E
MR0LI<AP80:<0LR`><B"D/07:BU7&+V^@H2F+:MOMYW.LD5C;53R^:1GE.49J
M+#')N(;M?'2QI))FEE3N])U=1"MH6P>&1]>ODTQ$H4GB"WB6JCDH>R&!VMH3
M:MLI>M.;6[V#[I2F'F"[.G^TT2F?0O$W:6%>_P`!O!VD0'UB9H;?<!32,U)%
MJ(B*\9DBAZPM*:E;AI43V8$IM7[OKN#Q\=8=;87;L(VROY:TVIM-NC907!CJ
MR,2U_;D8!RO:FPT3:C.B+[$&8>$,6HJ,I\2&/-R8MM,1,B;[ATX%HFNMNQ<A
M]7ZI2#8D[9C9>F8BDD=^39O@B6/-[2[2IW.6MC7*@05J'65:2!<F<L#9H@:Y
M&2$N/)R59P5)><KSPUQV'Z'P[>:JF%`HF=MU7<M*N<DLG76W*1GRZO9]`K24
MPM^C"(XEP(.+;7>/O:9VRD<VY;C"=:D$(H1A01"'P*4FF`;`UY`M+[CWBH_9
ME-UYZK1):CG6I,@FSKLI?%:;`QR4G/,4V=V4%`W*=N>X=!P=6F^"*MK88H51
M4L;<[K&=7A&><@#+-U[FEUZ7129NU6F&U^NU+,-#VUM5#=MX;)\HYSHW)ZU4
MV2HI]P;7.+5\L8XSM#?3`PI4;_!GJ2NC*:E>V:/'(5BX:WY@U5/:%W"23+6.
M7[/:P1&4[U;%QA8S,^QG69L:MT>W19"HG7*B<6$FV3CLH)#K7<C9$6E$@9E3
MDX/*QA*?EJ=*W-1!2Q,+`?.^W]>4!A-DNJ/:7OA11^C+ES3URN&:NZGKF!!;
M34%UZ6*N,SISCZ1;)TY"NS6-&E<$05*58>JR(.?D"HP6'^SBW]R%\XG==PW8
M+O\`(S.ZIK.(6U8C`YZQ]1$D*8Z[EJRP&MBD8Q!<X@G6'R=UK1["E3I%:I47
MAJ.#E/G`BQ9#4\5V?W=*4Z_3*+[#]^DX:MF8T1-:#^?2KJ0DL<LZ+.T'66(D
M4%MY]CI,,QW[`3B=?C<P-:DLG`1?&`P02\AO='V";/-]0SZTG?9/LMB3)6=R
M**7M%3:/6/IS,W2O[%125B@>(4,=*S1IB^1+)7)VP&5H#W5-@2S`<FE>!Y*#
M8KQM'OJUSZ15@IOGL;63F(01JLV1L<7ZIM6%7XR#/ZN3-S(^GNBFVG5F<`NS
ME#'5,F3(E!BP1Z$T`BO.0>0TU+=@[JO>#:Y.DQVO[1'*/W'+:VNK7Q*P=2E&
M&FS205L-%?-?O;6"/L4I.$D(:8L4_B)4J2RU3:2/VQ@/R%A#`*KV4N/7BNF.
M*4QM3V:1NF(5;;]3.6>9=.M:/YR_8&U[K=B'2).$H7N,16%2M_N:RPMK<D*+
M3(25!Z=/GY`^V1!%;<F\'J3;*4_<.P.YG:16=\:4H765QLV%]7T+JX;#%;%+
M:Y:[,=F+(K<C6@FL9FC!5YQF8\>L$<L;DBTPI-DL"@>`FUJ!8N\-1ZN:?4'#
MMO;BJUY:=:HPJ:JNDW1?LA:\GPRQ-LB*:6KS)@FN"/II;^VG:=M21<YIB@I#
MC%R86`X$=G(@C=JFZ0W5N:U;>3#N-?=J-QDWN6HM:&1_Z*]K6BEH19ME3.2M
M\XKVBFVO;!ALD<)-'E$,D,6:V60O<AQ'6I,M;6LE"2`T`@GU).UK:*/EVL<Y
M7<O9T=%MB5VND]3T/=@(E=3-YD-)GYCG/L*-K4K?&6P4-'EW":L,*#AJS@_.
M<X_J'K1_L;W%DTJ;X7G9PABF,D9A2N"UR;T']@ZJS)A!&I$PK);9+<Q$[/+6
ME=7;".6LZ;\HD7&@"M<B4QH`G'$`,"J*"0BQ=JJEZ_=>$MZ576TKE^JUU&4^
MQ7_KK:\!K*Q;.1]@=06](&%JMY0Y/,8G#FMS4:`UWKM*:TR-D*)1HLKU1ZU4
M<F#M?O1\,AVOUGR!]N'%+G1RLI&Y.]YMT5:7L-<J&YA4'+;$0PN2))6S.06$
MXL2TIN6$N!)F`8*&$[&<^P<J>W^ZM>3[43;N#E_R#XK9*Q=K/>L;5UD/537R
M$K+$4/59R)`&$_FE$%;UJ%3*?NOQF#VXU,>F&J]PC`:#`@AO/L\A#WBD=$H\
MA^9UD=+=9.T5SLREO3!*/%*M>T_7V_DOWV:@PT)R&/HB%KR)%G!@E!J`HK.#
M0>Y)P=-U@GX-K>;J4IQF`F0B2GIU"<PPDW&!L*TPHX@XL19Q1F,9P((@Y"(.
M?&<9QG@:'T,\?\&],\X"`'MJEKP/(2P`+!@0ZBB`Q9"`&`@#C(A9SXQC&.!*
M_@.`X#@.`X#@.`X#@.`X#@.`X#@.!6AK(A7%=D':$XB2G!:EC3HRD3+1@+"2
M>ZH*@GIKHE(&$XPPS[-"X(1BR(!?C)_C&,_UR%E_`K[H.-N;=V"]A4D,E\5?
M6220G2I,BC38]"<Y7!WEAAUPDO+?*FXPK(XZC>T"]N<6U*`WX30*#E."@&'F
MF'!8)P'`<#X4[6V(UCBXI&Y"E<'<:8QV7)TB<A8YF(DX4:,QQ4E%A/6C2)`!
M**R8(62R\8"'P''C@?=P(\W_`*EZQ[51X<6V-H:J[F:/`?M/W[#&5\=6<XL6
M!DKHY(5"7]P1AT3B#C)2MN5)5)6?J`P/`K/M[ILC*J%G02C;1`Y5.F:),TL^
MJ^Z<8/W%U[86^6QQ=&)&V59+YV^H=I]=S7YF7FI_NXE/BDK?@?R$-PLAP#(5
M#[SZI`HZG[=LG8[7_<2#S]$^L;]!9QI1=4S?]5Z_BKAM"KN*TSX6GJ0NG9%`
M)*AS9SP^QE5;$:PQL[HR-!(7W!:'Y!AI'5+?:Y^O(=F6#;"9'2?4]7XK_GNO
M.N@K<JK88FUJGFZVPFZL*:I:6I,3N=3BZ'NZ6=0ZC4DS53"6.')W;[@LQ/\`
M;.6`D+8[%IOK#O/%]G=1G(?6UMN72M863=51V&R2S'6AL"\['PF6OZ6E+=?:
M.6&Y@%WQ9J0.SX4Z$M!*`@#.%Z$TKR@&FY"WR@^W9(*[YIK/V%T<1UV6\U-B
MV95E*+)N2$2;6:_*[*<&)J0NM.;$.2>OV"73!2J>,G&Q\"`#@G1$B-,P$99Y
M)(2PM'LJZXZQ:#UUF;K:HMR=&!.[E,P[JKB221<:WKTQB$R/PMC?'B52%T(=
M`DB3$MZ%2JRH"')0<CQCP%8VS46W-[600*:U92C97VEVNUKPV[(S0.WZ"551
M+>RN7UZ[)GR--LOCP&IRD.OU`L*M/ASC_P"ZV9R52E\`B/=&-&VIP&&!<%K)
MME7.SC3(T;.D>Z]N"M5R1@O'7FQ2T+/<=)RM4FPJ3M4TCB98L*4L;VFS]RQR
M!N-6,$B;\A5-RQ03G.0AGVP]AT]4U%6Y9&P2AA(I&'5_*'JTPR9H*D+&MA*=
MJ4A?6A=&S4J_$FP]HQB1EM@4Z@QQ-/"F`48,T(!!Q126:=DTH9UFOE0VQ>U5
M:+6?L0MB6I&L#!JO%+8WZ*KJM@.;O:M$-L<O^4Q6#IM:==$3JA;)/*Y:].38
MUR-(@C;0I<T`<&*PZ8]-*-NIZT(L&#O"B_M2=BKME]PO\ON^RW"GY_LD_2F7
M20UM1["/S5#\.M60R8R:!MS>4U1<@!R.#($J)I39.);$YI@8RS0%X00BQ=&]
M1H?:&FNN-8L\B:;DWTD!R>&6,MGQQC3()V_TOFSXP].]UV%-$:A<IEEO/@B&
MM(O4FJV]8[N91OV(4ON,XNRBI!)EG4J1;%.]0\N7TL&\]M`U@5;K23,'R<KX
M%M3M=2#]<4[3689'8]3R!L>W2P$T6GD5?Y(W*7;(<%??N2L+=-?I(A,KY5J=
MU)1=M8::AJE6GL/L4G9:2PZT76<MD32=9T@AV75T223='8.3H,.2IWEYBH40
M12`9'WS@Y#)4-``M&HG8"H-C8H]S"DIZCLZ(1>;R>LU\X9D+B",/4N@JDELE
M?[6D![8WL4V9VUW$-(-U8S%K.8M(4$$J!&)S@%A]KY?U(1JXH3KU(+:KQGO:
MR(^^2R!4^X2UE36/+HQ&R5:A]D+##S5@7UP9FTEO4B,4@)R5X2G^!9^$WT#$
M=CM=FC9)MJ2.2>3N[1#JYOFLKQDT4;TJ)4UVD*I%RV5PR"RW"S&<AC"2S$S'
M(30EX%D]0PDD#QDDTW&0U2YTE8LJ[&8EL&_MJ<BGJ9U!F%8UJOP_IE2AWMB]
MK:BK]:)IT7"(*IGQ%812,<)3KA!$!?A\4%!R'[46!!4A;.J=_ONF7:+`XY2D
MV5S:UNXF`7M6L8((0@52ZN&K8'226KK/B8\N(@JH\0RP-W=3S#!$&@/0+`8+
M_MAR()MV%5MI+MR.R:<M=631QC\UZSJ"K&NGT!1HF&S+"8G_`'9='>#Q,X:Y
M*@,D#3B:M!:D@0R#"LN9`\B``[`\AJ2CZ8MN((OX^,=6U=8"(FBM<Y.P72L-
MC+HF05*[I=$VF"I8]8_W`SCXLZKYD=EN3$J\_K6IC"O;!F`A$$?[4H/9*7]?
M_9W!66E+!)L6R^V]3/*TAZ"/+43O-*H0;E:RNI5D1Q.H^#"Z)O$'B+@]J'``
ML)Q$%*CLB]0BSP)T3B`6*9O/O]8^*TFKE#W/K'H:NH+)D,?&J1329M4[W1D4
MD@,*6!"0%ZDR(F2-`U"()N1@&X)/;(<&E^0CK3],7.E=_P".6X`K2?)HY1NK
MT_:+S4*V!R1EU2_.^AD.A\>:K&3*"TYT:<E<L*4MA92LH!@5X1$9P$S].0U.
MY4;L,GU*M6,O=16>=(IO_("8+?RQY87]X>04%_Y+JXG#=:C4%"K`K9Z_#7L>
M*>LN:?)R5,W9,.&$`<FY*"J7NSIC_(79!NDT/VFEN[:O3_HA5$\I6`PL*%(7
MDR)I;!K^5V_7C.M>TCM/9Q6\^F<4*>3XZU.KZSQP!Y6#""EF/4+V=*$[@LMK
MJR)C$H46;!ZNZB)Y6\WGD>7)Y-%F^RSC>O\`/:FZ5/L?<I`P-$SE3`PK%Z5(
M>N,4*TB<XTD1Q10S,!#376.W@@Z]^HIDG]-67'K'-[@9/*+4BYT(EJ9=5;<M
MV4W0FRY_E[>ZD+'N-1`TQ<D3D+UH\IS`.:463Q@/",8;IV48;#?X?_)P0-T#
MF85;_KG'V&M\-T?D!ZBR!YZXRR!*H0%.WX%)E>9$O/:1%MN50\*TF2,_W?)>
M`]JY+WI;4_:SJFOC9FS6BD*N8NN3::&&3&=)GQOCZF;/A^C*Y%#E[BF)&!I?
M#VQD6*BB%A(Q'91C+`#!_KP-;ZLTG-+%ZR^DAQ8M2(=<<8A=_P!'7Q9$<F[@
MV12=TNQ2.6S%\:[LA*&1Q1P5KG*O97-T4G<TZ!<SKUJ!",D.5"-2J3B#HGL5
M18"6"RI352&%N5C$LRPR&H;%>'N/P52^A+\HBY4]1QDDCZVLV1_4XU*A5'!#
MC](,\"D+?V9]J)6B^YYDSA/6PRPW&J>PG[J<F2\]D)$_EQD512_$A$PLKA0<
M<0+GXMK^7*(D]862>HP`!@@!%D6`C9VE16XYAK+KN+7MH62.PQ=/>^C5'F]O
M>4+,^K$TN@VCC&\#:53@,I(<N3Q%4X*<E9,`(X!(BR\_(,&.!T*0R7MMEZW1
M:>1_T,:9[23+*V;!6#P@&@DT%3.R`)>%9*53@.2%H<8^0LL?_P`00Y\XP&N]
M!A!'HKI:(.?.,ZG:Z8\_^H:@AX<__LSC@2TX#@.`X#@.`X#@.`X#@.`X#@.`
MX#@5QZQ.`5._G9XB"8HSEM>M/2QDGGJ#"RQ*=>@*L&)"3S3"TZ8T)F,9P2$L
MH1P#,YQDS)@LA8YP*S=8<>G9%VC@\>F36S1A7Z>/7Y,&4W.$F%7K]/?!F4&2
MO?Z^?A]?/Z/&`LRX#@1&U5MRQ[8D.W9%@`:DR"JMN)I45:M[>@"B6(JYC%8U
M"Z-YC^8%0JPXNSU))"Z.19_L'R@6I@9`#(,AP$LTY!:8DL@KY,EE!]09...4
M&^,?_&>H,-.,%_ZB%G/`_;@.`X#@50;/=6T$G2>R)?JRIAVOECVNTRMFNB`K
MHFI>]6=HV*<,9T;F;#L#3<>=8P-+(Y/'E:E%B>1!9'YTA"K-R)P6$",1FA6[
M7D:-JKL\H2Q]P(@5K.\N+K=DF,/LB\YQ_AV;[.S^M:^I2)2G6&ZXU&6JM+AA
MQE#U>EB#76-D?LZ51M,K-7IT;NK/R:(.@39C5V@MQ*>E5#;*5?%K9JV7I#"'
M*.2=`!3E"L^`XE'((XY@^-UBTK9\GB,0.K><F7HCOUDF@%]>!SDZ^0BF>C:7
M[-RS<9EJVU=<Z^>(4LU^VHH[3:GG"Q-<8\8Q-S,&H=DE-`P8-NQ*P9(B5-;@
MG?G)O%''KW,5`7(5"P+8`.G.J[5K:\*\B%M5!-XU8]:3UD12.'3:(NJ9YC\@
M9G`K!J98@7I!C+%],Y"86+U-)-"(LP(#`B#@(=;HZF.-D/,'VIHB?LE#[>ZY
M-[XL@]IOOR)ZZL:MSR@NDRUYV73HQ%'R*@9J:W$GG*?UN<2<2"WAI$!04<4J
M"H"5V/4O:I6[9NIV/15+K]U&T-$U+I":DGUDJ%+=M?L8><!B?K@>3*W6IE=B
MTK6CBW+V6IT"#`UU@.#B-[`AP4)M2#"5O4E1S?0-;SC9O8@ZS:Y=K<L$JDM2
MD^Y5D(%5RU3HXWR)(@U2UT7@?EA8(5(Y"^.2E=EA&I621Q.5MI+N>K<DH0$!
M>OP(H;:ZLU/M/#XTQ7D58<NJROI$98LFI"*/:U)"KT,C[6L/9(9;<1:R`K[0
MB3<]!(<TL<&I*;W%U2)L+"E9`<IQA"-535_]A"!L/V387[37K_9@IEK;J"0Y
M)HW>NQ4-3,:E.4@VYD42?3&2FZ:$C/`(VLV-2H7K2"\E/[B2`)C0`*RX7,W"
M:QM[T^B]K#JOH<@;Y(#4._3H\O<-9IO1T8=(XR.W7C%;>E"QH3,%+)IH]JXR
MBM3[W[210Q-^U616:YDF.8PL8KZZD5COD:N>K9?']4>G/1>'N[K'Y[&537`H
MCM6Y0J,.$93&Q(EL(`@:]':88!'#0J4_VX)S(DZ82$!K.@+-<@CM=.L,7VEA
M=B[HGQ.;0S?S>.&5[7_7M"KUFL.J&ZM/$%7M$ID$(DU//C`>IDD.>&EO<WVY
M9HS8,->5B,9L9<"!B*RE-#?DDTXW\U@5D;*:\;2V;O3=4$UCK[7AKUFV<G^:
M]IRS%K,Y!<9M="US8EQ+0@NZ0OF"5I3DYE*/B:PK&T2@?W"0]&%QL*7RMTA\
M6<IW'6N(S9?'F=9+HJQR(R7,T<DJE`0<]L;3*C66.&R-M:W$9A)"X3>A$J+!
M@S)!61>@0I2UY3=G>MLEW701?0>J9W$K9W8V#O2J7V4;O,<&<':(3A2T)&-:
MZL#;3=E?A"I`?'<.11`E9:A,4X9).3DF$9R:&RK[G_<!;M#6O757:<TQKY9D
M]KB41>%6XCWZ3O;[5TO?6-2C9I@WM1&HZM$Y&QQR/`;D&%!)@_CS\1A8_0W`
M5B6+J]_)`>!5H[PS9UQK1^B6G]44W("H5:U'VW&I[LA$!&-]F7K,HM;M*5^F
M:&>Q6-7\R4#<K<7I*[I\'&G8(R$C@8A4>MO\G&):]6-4<SN=C?;1L"44T:FO
MA?LA`I:\P>&L#C9V+Q1P1J=*-:!1=XGD?D4;+90^Z[*!Q8SCQK2BE(22PD#:
M=%?R!YV=L.CKZSVRGH];4QH%+!0`OV#2F55?4%8PZ$QBRD$'DRBE_M(3;5ON
M[:_/;F\`;G9"8K<4A11"0)!II@;9V`<>^>11V^*_U[KA#7YRB2:Y-NO%I2.U
MM8GEYCD'KXMC%?[Q,'9RCS\*:2N\<9483_<1-K)8CBS,$@&6(L9@:KJ5+_(5
MAFP%<2*W6.6W3KW5[=:!KI7K%.](JPE]W2B4R$@R`XLR9EF2("Z)0IE<EG_]
MB;X6JQ]BB#\"C(U61AK;</8_>5;VC];`(X1"M&9]**XMF-7/4MC6C2=CO-L4
M:IN^JG,V.5S)_P`2]1Y5*'K$".5Y2MQB1Y"G&206/[M064$-*_QVGJ>:W:0O
M*G5C7M_W:56W8#/9%M/$/;VK5!VKJ9O]3UV[J8S*%FSDQ8&*W_+J[.!+6\PL
M9K5EK1$FJ`%'*@?(%_:';K>$I6F%(NJ2[$K0>J1IS#XOLYIQ)GE$4>J)`J6J
MV=PN*+(Q)T:+Y3?!"XXPPP("\!\#$,L-G?\`*#8`?Z2>NS:3)F?]N#[&TI3E
M9\?7/L=G:PS`/I_3Z?7/TX$*+%V$VA3[K5A90NK+<21Q2!ZH[#19^7,TJTY>
M"_RUB6!1$GC+;'EH]F2V!U>%@Z>5IEJ#*],N)"K2'@*/(^81(16U;JGOD.U*
M&R5_.M?-9UTWV@LIY@4>VAKL,MO#7G41YLT4AB1*YEK5=(*]G=V/3>_.RES0
M/3C]NE2ITB8I64I4&G(POAV!C#+)=>;*B,_J-SV98WF`+V.64ZQ)HFD=+>2J
MD0$CI&T"292F'P](:^^PLX+6NZ),7C/C)V/&,Y#EJW:TBT:BFGVU,@BO\?*U
MZ_>F/5NZ9&U6B[E:EX;ZOE#?5LF<DLI4!8]PWZ5!Q!G%.!8-8TH%BK`4^1)B
MSA>`""PC?J&W1*X9K95^JYLG:;+6Z"VK%8NXQ!.QO,T;(#-;LZZJRM!?&RI<
M86RYD$<IM^>5Y"A5DWP8GSG`,F8!G@3QT_P<U=4NN2=D<U@5#'H=6K<T/1YP
MCE_S,=$M2!O=CE`O89JP0T8#Q#SYR(>?/`WEH^!,7I;J&!&0%*D#K!07VR8&
M,8`G(_Q3%,EDAQCZ>"P9QC_[N!*'@.`X#@.`X#@.`X#@.`X#@.`X#@.!6MJ+
M\1N\_;$><'!CB1=VK;46J$'&30,";2NE'1L;`F?_`-*D>7MS4`!_[3%AF?/Z
MO&`LIX%;VM+NM>NQ#LVP<83]A%D6D\*1$Y2)"E83B*=F$Z6'Y6$$A4*T!V+"
M*`4$\P8RCBC_`%P$`@^P60\!P*X^O5_7/\C[$1N(TXU31V.70P8RF*P47A"U
M551!#2`6,"%D:@#1DC!PL^,B-P+/CQG@6.<!P'`<!P'`PBR*SKNXX/(ZSMB#
M1.R:\F#<8TRF$3A@;)/%I`W&B",21V9'A,K;UI032PC![EYR`P`1AS@0<9P%
M&^PMWWAT]M;;5M.MIFW5-62RSC_C)2<DD4YE6Q.L:N,-1CT].$B,9&6<6!<F
MB-5A6D'N[P(`Y9`6XU*V$B>RU3:0D"S_`%6J6CO\`G.D6<JUO1GV53'V7<=L
MLK7!GV,[*R:;QUN89!-)&=&F9#%IBVNT<:TK03\B80,M"(A.8$7H+R%45O2/
M8+HT8Z]24!0*/87JI%;J]1.8E"TQR>_]'8?8JIT7/),5!A4D8[)HQMLA[_,D
MN3V8%QCJ`U2V+%0D>43@A"1W:0E>=EGG0_0YB=W]HKC=:\'E]V0/8EJEI.DN
MHM!5JZ6M:E:+'MM&%<UMMNR%5&(XNRF.+-4-KDJ3^_QFF<#-]^]+WF7XU#V*
MUXA+',+"ZX)>YV-3^I;D8SL-*W!%U4*!`WBOVEG5I<Q.`6]$8:5\U7R82?[:
M,OQ)9)@2T2M0<0$`:PV`I:QEM6[^[<R`_:[:JSEDD'H;UR5#$U$VDFJJ^..A
M;)+H1'ZR?DC*H3[-PE]`!NL^UIJ2P-L26$&($JEI;"_*X+UJ/LJ:O,<A,3V(
MS4%?[0R"'.]C2:C:\L0$Q/C$0_=1S8@4-YSJF9)%*6^-IG)M:WA[(;B6DU]$
M:%-G!)A&!!(#@0XV\U,4;AH*]K296Q)8IK>F?7)VV#IB((<MB[9AA+1D`CE5
MS"Q4KNE>HS41KE\ITF:&]-]Q*4GQH#E:=%E42K"#VP:!)V$S5SZYZ&:"X?J)
MK^_P0G;/8VNEC;%E586C3KY';(I?5_5@G,??(BNMF$3&(1]TFBD]O5,<1CV`
M-60">%P24`0:*)9X4LC^C2B-7CL?U0=?5MP!#9]XPN'`M>8++AK@YTL-CU7O
MV(0DIOD=L4YKK(E\;D4GD\3C;L,"]N;X\_(1F)7QP&$P:WV!KZQI1L]W'321
M-DRUCI"N);0VAJ..JVEZ4RN'L3FC%>EGPU,G7J`J[`VIOAA;(9%$?DEP7,\7
M:_B+#^;$6(-P5E/=E-:*UZU]:9[)T-H[8;.69)Y!L/(+`7/<B)B\111B?;%;
M*J8N>E<DAI;9`']Y:H)$@9SAO0%N3;C*?)!6",AL^3=C,(@U+]B&P<MA#MBL
M-!;'GM='*(V[(WZ06ZYUK4=:SB3$1YN^W1-[*Z#L&>GQ).G-5GAPN;AF*#",
MY,))#_(SV#&BU0;]C;0H*85?,D>R4.U7G](#FD*F;M"+/E6TD7U94&%SN.*A
MQ23QMFD4K(=A*DOJ8>W@$`)6#_T<#;2K<^!);MVQI',9EASMI_0-4W]83X2!
MJRV/33;">Z'!IC$7)&X`5'OK8U4PH.4"4X3$9$X$``+/J8+`?[&]TZXE"S2)
M"WQN:@4;W5Z]67603T;-_P#JG'&&H6BXEV9_@EZ.&@4?AGU(A#E#A>3^1."6
M(P(!`&(-2I^RFKUU'W;>C;`)^O8:1W<-T8=&4C,<P\R.PRME8)K"*6,61O.$
M.(?F83PE=C*@TI9EO3F9^'Y<@+$&V)KNY44*G^UM:'H98[RC3O6J);06P2TM
M[:)&9#9LDN)>P1V.J5CLDRNF)R"E7$\P@X"=(66L1Y^XSDPS!0?G"MV*YG3O
MI.T-48FJ<S>BCY5?%:'KTS(45%8O%()65@+&J<A)>U!B5^5-5I(BB@(,+D_W
M"<_`C0@P6,88?'^Q6DI'`6BQ4,?L@MD>MY7W0!(G4,K$%R!<D?O!_H-8_'DE
M28Y."O3)C'#SRUF#1+LMX@&"1A-SDD(47=B6WO7Q&NYYSAN\\?@Z1GUHZ]V2
M<U)++"-;PO"W9!;?47MROVFE,8,(=T,Z+;8F0$LXI024O$8:C5X"D]@J@V-_
M&RDUO576UHZ7;.,^S#'L!5!S&8-HV$=I,X%LD#AM9TFG0,\$:WJTY]&8S`&S
M_**)!'BXVC:F]<VM^3U29.LP,G`7,51V&45<-,:>WG&&NQ$42W=LD=64X@?(
MZUI)"CDQ45MN9FCFZ-%(7%`PM8&*EGD7S$J5@LFY3@P#R;GT#5.VO<#I-I*Y
MR-EOZ6S1A>8];+/29;,RP-XD3Q))Z^4DTWTA3Q1I;LC<GM@+A\C:TJIW`4%K
M1/#FG2*%!6<F#+#=VRN[#'KK/*TJ=IH78O8RVK1A=B62S5OKU$X,^/[/7M6+
MH.T3&7R9QL:QZQB38WHW^R&5O3D`<CUZQ6N"$A.,(1B"&]:`O*`[+TK65^U:
MI=%=?6S$&F:14U\:53$]`;'8GY`I7AF6XPI;75"<$9"@D618`<6+`1"#X%D/
M]OXEG/I*U0R*=6-6+`5!)(J?+"J$MP-M"'-")L/6.,@@9+3&IDZG2=N1D#,2
M@2M3@I&9C&"B#!Y"'(<GFZE@Z9H])MMVIC[6>X29N)NM]L)FZ+3R)7PMC4B=
M#*Z?&R/QN;N[[I&TA;H7+E_Q-SP<K=&Y*:E5'#/5$CSE0`+5=J7V^V-TU`?=
M;4#FLN]7H]+T;"WQYF:WY=EF7[2=7J&R?L6IX*5-PDZ6L79],/-,P+*5*6(\
ML03"@BP$Q--BR%O5]KZF+^J0[3>'HR<DYS]4F*L(2DY+$+VSD62`X\9SY\Y^
MO`V[HD<)1I!ILH'Z^Q^JFO)PO7'@/L;4<0'GUQYSX#Y%].!*O@.`X#@.`X#@
M.`X#@.`X#@.`X#@.!6[I+GTVA[8D^?UYQNM6:KYA_4SU5:#Z<X"F\Y\Y^!/D
MG.08\^,9&+Z8\_4+(N!7=K$BC:?>KLV5M;B]JW]PEVIQLG1K6?*-D:S$^MK"
ME9R&)W]LA>35#>3\RL/C&4HQ@#GZ"QP+$>`X$!M#[C>+E6;MK'&**8LW5SOQ
M>].QD:W\Z%9)F>N&&N&5;*C2GMU=`$IW*4X<BTGV6$J$Q"02860`0S!#"?/`
M<!P'`<!P-2WC<4>H:L)19TB9Y5*2H^C_`/I$(@#-^Y;$L&2*\_;Q^!5Y&`J$
MADDF\L<QEHVU$$TOYE!@<"&`&!#"$1](=>K&;WN?[F;4M:4G;_8].0F71@+S
M^YFS6#7YN<3G.K=4(&[X2($0DL6*._+S%Q2)B0R.;K5JD0SD:9K"G#7-C5E8
MVA%CRC9#6.%OM@ZMSQQ=Y9M?J%!47WTBBDJ<#\.#UM#JO%_F)3"E*O/SJ)W!
M$."02[(LN[87^X`J2'L+#X'/*LV$JJ.S^`O\5M6H+8B)+LPOC:)(_P`2FD/D
MB$0<X$4>6:F6H%Z(\9*E,>7[!S[DG%A$$8,!S=3;5Z3=87:#J9L<\6S:#MUC
M.PIK0,+C4TG:V157H#,K=A[7$J\AB-H?<*54%HZ:31K3M;4]@6@:F'[Y*TKR
MB$J9M5"#J%1K$;BC2.#>K3+T"],0L0KD9Y2I&L1JB@GIE:120(9*A,H)&$99
M@!9",.<9QG.,\"A+?VNKGZ_+1N+L5TEA5-(D.R3)7M>[V/<[B$@D(J;3QMR!
M'XGO6WL,+P&5S>/4Y%GE5F?1%`8G_/MZ-$Y_(G,;UZDX/?IZ01*B)<]Z^:"M
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MA>SS"U3U:$I;PD^XAJ1D!`3?CK-I+8K>W6'773$,5U7N6GJ[4;2W99D3KI5)
M()7C!&YK%FG6B?K*Q;)A"X#)]G7:TX.X`CKH\E*#S(TWOXUV502D1/`W#3\U
MWO)WOV.V5M&CH%N`RZTUZS:.1.6:M63&JE;FE2$U%L'L#-3*IV/FR%B2S1Z5
M/$*87LMMF9A*13&!)L9-R4/!`0G<]B!VEU+YHMPUIVAK:S][=JZ]F)$BG5"6
M*52[V9O+V(Q^U6O#A>S86IBAZ`%3SI,C`O7N)0#AEIT9.31")39#9MO[:50R
M:K;"U%*GJ:9M$?=\:&.M+-2MS2%K6E0[MF@<R3HFZ61>O':%.3NFA$84*@I2
MUYBI2:0).`L:O.",A@TV[%]1[*V)[KGJ.&V>01;?7PTTO!9-BH[+"3,)'K=7
MFQH+.*D,6;V=SL2M!M"W8%B3M3C*6:,I'M*$\U`)42G^X,#;K-V/:@,]Y=/,
MI<+,D2=IK#3/81HG[J11]\G(VW$BJ?6=O0@0_95<:![;UC]$C@X/;0J4Y8DN
M/880B![A!"M-]=5$6B.S%6YETWCDZN#MOKG;&K8@]5S)Y`,RH[W["*+V-K5>
M&2UHWSN*MC^JK-.<Y+8\\K4$H:W(![:H;@G%D8/"8%R=AVG+C?/</*DLD?7%
M3;.A6J-`URF;:>OY%*9O,Y0T[C,31&']DE%?L"2'FJ)19#8D)<'$3<TX3*<&
MFK0X)5Y3A^-8=A^EL*LCI@:3;A=AEZO:JWU25P*@5A:\@-B\K8:7HNLEC*I<
M(E`GAADA@9S`5*8U8R'+VX1J;!A9^2#21F!'D/8EI7#=8*A:T,\>%CFI[N+J
MVU>@,]:V=G+-2-?]@]L6S/;.><O,8;<%X;JN"2HRRI<*)$;E6444VB-^7!00
M[[,]AV:V]C>W23T4FUIOV%2.!:T)Y566Q:JSHG.RHNDUI604VT*/K%VIT*QY
M=H%,I6D=Q.0GYM`2X,*,)"%4<:`PP+^57:)INQ=BT,E<AO=I;ZG@.F3Q2LJL
MASC4L01M)?UES2OKAC->*U2MK(>Q/SE4M7N;Q[":RV],'`$QBS[]06CP%.!N
MU.MD@Z].EG6"$;B,E#+$TRL&26+9]:O9V;AU[>'C6';=GA<UC:]R=F!H8EJ2
M;3L9:U.H7D+4Q9I8"@!SXQP/F)VUU22T)W567<>UM;RO86ZJM@,#J"RVE))(
MQ'MCHE2E),^MJ^]]?&6SB53IETLJW(^^1V7B8W%8WFJHZ5DH9Z(A*N4AT%1/
M9.B-E^U^`KZ*N:`6\W5SUH[%+%2RM92VR--'W*P-B-:0!`[+68XX(5#HCAQ0
MR"#1^Y/VPA^@,C\B"2?46`LOJ^T'^(!8/DU4IE0=\80A^16IA;6H6GF^N,>Z
ME0L-,,.%G]8S1"$+.19SG@3-MY;.6VM)BOK60UQ$YTE:!G1R26\A>'.M&5<$
MXGV7S%O8)%$GA6T$IOD]@$.2(>1^O]T.//`YH>S+8?L92=>VW[E)=K.H1\K]
M7K9;R*6I:@!L$WVD]-2U@=V-V8*P78V%<T&92YM:\HE*<>6<2%<H^`U,<5]3
M`L*W'LRQZTNK4644XPKI#/677IY9<I4+$?(ACA]Q[F=:=3S-R(:6],J,6D1J
M&O3FXK!Y`62B2D_=9&'!6<A#<&L6,@ZBZZ+2#,\I]*5R5+D@P632OM*R=$R<
MHD9>?<)A&"L`#Z^!!R'QCQG'`ECI_P"F=2]7<E^GQ_\`'6DOC^/`<%^G^-(S
MZ_'@'@&`>O\`3Q]/'].!(K@.`X#@.`X#@.`X#@.`X#@.`X#@.!6WH7_>NSM-
M6G?W5IG8-]D8K,_6I,1-FF&GB=M2#.S^L2=O3BR62#/T+!],?3@62<"LC1ZO
M9E$=M^VJ4R%J5-4=LC;VI'Z#B68,`-X:VK2;6>/NKZC+,#^IK4/C><F+,"+(
M1G)#0XQCTSY"S?@.!5-U12MRF+#O\ZNJPU:>C[5-Y8TG$<H$I$F:XC/VR+M"
M'`QFG9`6C;&@H`2_;U+#C`0X"'&`X"UG@.`X#@.!CLNET5@$5DDYG,C8X?"X
M<QNDFEDLDSHB9([&HZQHCG)Y?7QX<3DZ!K:6MO3F'*%!Q@"BB@"$(6,8SG@5
MMZVP.=[1[).._MOGG(*MAR"45[UYU:A<0FLI%0RM.A3R[;V7@3F9PXV+LDA2
M@!&DYP2\QNO_`+<H10'!V=,!"T;@.!439R-PZT[LDVQL1;'U;H=>K@YO6U$"
M9"A+6G5F[7)Q+5$[9Q1H^ZQ^WJ=LLY>H)M<E(3]FSKRDTL&$HK,A4&!S]RCN
M!D8MH44<[(W^UDU5VI0FP!FRO6\EUWCC=1]74*_,[B77[%_DNSE$7?-C[=5L
M<=<Y"[2ME="HZ[,B8U%%D2XXX`3@N?T9V;L?5*]ZEZK=BV233&%RV%2]XZW=
MP4J8E1&KSUPK.+M#_%*=M3X2$BUGV,IVMPG)798>F2E/R!K3KQ%@4K/)X7JJ
M$Z=8G/2*R"52542:G4IE!0#TZA.>`11Q!Y)H1%G$G%BR$018R$0<YQG'C@<P
MUVTG:?7!(&G3ZK[/:]4^IS;N^W.4/.R,/92F:;:3.%@'/;Q9>K4<?&=D"P5;
M`=AY:<D+AMFOAX2J]"N<FP(BS`1XXD)_4Q8V)W/XI5VE@XGKKUDZ-9=FFTKD
M9V>/((K=TVKP)J=;0=+.+Z8)M;Z5K0T"MPL6P,EF_E7@D+6VK!#`]+B@GYK7
MLM`=IJACUZ5XV3-EK2<.KJ16SW8<>_9BFRHJE<U"".65$69>L,>!P*QDA&'&
M.J%Q")8Y-1Q*K[4LLXO(@T-M!O\`1C5NXZYK214[:\ZASU'SIM=ER5RFCLJB
MVL-=J%3PRQZPK?AS2]K+620M[DK,>G&[)F(UI0I$JQ4>K"%$>7@-,03MZZY[
M%V,F4&9K'CJ$B'1/#.U[BR5!'HYJQ8;F!S2+912-4[2O#BEALZG$4..3+G%C
M0K!DBR$T9`CS4*S"<)E4_04=J6>;-7LUOSO9,UV<FT<L)R<U8VO!K?$8/64:
M@U;U3$%))Q#=F&Q\EH7N*$9HP_(XR)<>89GY<BX%=*^!W'JKTMWL&1L*_P#Y
M66-3=_V98R.-E@D+V'9S;1^EDC>/)[$(PES/ATXL\E%\J4P\@A$U@P28:04`
M8@_WL5@3!5=`]6&M3>[F-$,1]A_7A4Y3B<$DD(H[0JE;:30D5JBQIR6[+H.C
MTJ?!@0"!\IH2_4(1Y$$(JL2Q5C01^EW[F`[XF/?T%^6.*0:0*$A"+NN9XXD0
M)%2`TQ&N1%DLB?T.*_\`F#'Y^HL9%D-YV^^&Q6Q_Y",C;TZ?+LP:/4M)4P$^
M"4"M68VZJ[''H#%*](4!6(9BIK&46<8(9I82\8#G`0`Q@)&5^UEQBV^I:.IW
M(YQ2-6F=X1TEQ-QDDQW"V5OJP!.I/)",>,&JR6T1^0YSG`18S]?.,<""Z0_]
MN]?E@K&0"1@4KN]U2"6GLB%"T#<<G=VK`TJ!NV6U,FPO4FM25&G$:+W-$024
M#(O`,8P$DIUE2Z[$=X!*D0E2I'HEK3'V@H8@X"4P'5%N"[IT(08R$D10I&].
M1N!&8R9['#QG/IZXP'S4DE60NVNCF`EE)V1J2==NP*%4P-9:0EJ`]1JK=)DB
M0L@I"6%.$MO3JE^"OC\$Y"/.?&<^G@(@Q)*TR?3/4)>\+&Z;H)__`"";!E3L
MN=$[2]X2.B+LDV7?6K\*XA)-)"83)XJA!E2GP$PU.:<4+/H:9G(4J=X$O2+-
MZ^WI^FLVW!KMIHRGM&6RLY;KPX6^5`8]9SI2EFRZ"&6T96S5^S4#/,IM*$D=
M)_<KHT&E)7EP5-Z@:DDE.(.KAI$6Z]J]-O8F]`IDS)U.6`N<'423&30'S+8B
MD!-A*5>O/4NYI"L^(.&30C.&(`0@^08A&8SD*4IG$;@SH_\`QVIY2Z%QOB1E
MSUF<VC21_L*(5%5=Y6G(=:KOMP$YF-E/+4YN[013BR/.1J%O^V<$*Y(L&F,`
M`TP!X@T=:=M.U'ZQ]INFV]LKU)9NQ'=>Y443A,WUTALS0QRY),^UK1OV4/F'
MX"))DL*E4#BLGC^0A7'I4CFIEB(!BA8ZJW`XX.E%ZQE1V\5^WD$X`*.=9-T"
M4&^`A"K,F6SE$$(0)0%A$+&4>8&?D[Y,A\_<%?'[^#/0,RZGV9PC_6CHPSNI
M(4[@CUDJ7"@D!I9X09/BB!27X-*$(L7DHX.<^,_3.?&?KP)3WXW(W6G9\@7T
M8FV62GLO]RB595=G)[*&4L2GDL!I=LNK)7.<8/+"HQEV5$I@Y)QG&??`,9#E
M#[#ZBAK=UT;</"?^.A`=7I"XT99K0*XV<GKB./I=,J;UA)=G_>5I.%%D#S&P
M$E.6"F5N-<!G`"63YSGY<!<;M#8D]I39O6IPK1J3266QW6R.UVL*41]YD"=9
M%;LWLT"J&8NS:R,JI*ORM8X>-S6A-4'IT:(7Q*%!F2"3L<#9.KSBC9.HV).2
MG)F43#J3.#E@B0_,;\3)%)3A9DD./CP<+_M!^G^W`_I_3SP)?ZB-RAHU/UA:
M5>2\JFO7FE6Y3DD>3"<J$5;1I,=DH>0@R,OY"L^N?&/./].!(;@.`X#@.`X#
M@.`X#@.`X#@.`X#@.!3OI)L50[7OYV=ZGJ;3CF-DWK:=MN\BF\D/)4J*JW.G
MVH4;)F.#3FP#&L:3W)#D.1)U9HR1&``:$`Q8#P+B.!59U[/KD^;0]P?Y;)7W
M+3O[$&1($H&08"S-VC6H931D>,F&8$8--GR+.,X\BSG/KCSXX%J?`<"OWKNL
MN'VK!MEY#$8>HAV6;?+<NOY22M+A`7"03"MKJD$%>92K-@D+A*!2!Y"PE92C
M7%.+P%"`@"]R7J0#4""P+@.`X#@.!658S77W9%/G2FTL@7OVKNKMZ)FS9)F1
MIE&83L3<M?-)CP#7&0'K6Q$1(ZYJ>8N["^2?+:M7-SB_M(HXXE>J9S3Y"S(L
ML!0`%%``666`)9998<``6`&,!````XP$(`AQXQC'TQC@?WP'`^-Q;F]X;U[2
M[($;HU.B-4W.;8XI2%K>XMZT@:9:@7HE(#4RM&K3&B+-*,"(!@!9"+&<9SC@
M<I6V.C,9K.>1C7FRT<VDM/19+?TPT6AT&;:]&\;/P1^KG#HX]7[G8MBI0?XK
MN:L5<9^PJB5)U>9-FH'-X8F!<@6(ERC`:YZ_)Y-.PO62+:;6_J+=E8P"OI@V
M_P"`.P*G++8+$9:-W*8X=*;59)Q1K/#VMG05MK#5296?%:^>F=9((8K0(BXV
MY+%`W(PQ0%PG5KM9LE)C+4TG["#(TW;SZQO2Q*IDZ$U"QI=LJ,4J"3(;M-7$
M2(:&1'B)./Y(IH=\-@3T[:]$")4A1'FX1EA;3(XW'9C'WN)RYA995%9*U+V*
M1QJ1M:%\C[^R.B8Q$YL[VS.9"IN=6IQ1G#*/3GEF$G%#R$8<ASG'`YM-F-/[
M=U22T]K_`"!PG5T]%[/8JN:6]4D$ABJ87A0<!CJ)SDL4H>Q36QQ-E5P=?3//
M/MW1V)0-KG+&YB;PLCC]\P8.'D)-P^T:/VTFSWV33J2($/75U_()QG3UT0O8
MD]:VA/H4Q/4:O3;G]N-I21ND3#7X4RN`5F4=E2$"E(^N20GV<6PTL-)Q2=[K
MKK2B+G>T'JRI'[N*A,KJ:#'TXU)8AO3HM%(%65QV#5IMC*'Y3(8S?D?JN%2#
M[Y]=0?@385.9']B!*X$*DOJ%MZ/332:9ZRQO3PZE*7LC6:J3(W#T%1.[%&YA
M#61[J]<A5H4KVV#+5)QRYN=T@3W,2K'WBM0>?E9\F5!V#`T-1NJ.YM(;V6S8
M*/:F/RGKSL2%-2N):K/40P3(Z2L=A8X[!8]%*@6(413%"Z68H9%4YP42106%
M4Y*CQ#0A'Y5FA:!P-4W51=-['UV]U)?=8PBWZRD8D8WN#6#'6V3QMP.;U):Q
MO4FMKH0>0%8A5E!,).!@)I0\>0BQG@?/"=?Z-KBK8A2$$J"MXK3T!-9U,*K)
MFAK`D@\761Z0E2]C<62-@0_BT#HTRXD#LG5`+PH*<PX5A'A1_<X&2/=85O)4
M\^2O\"ASP3:L9#"[."X1MH4CL*(@;7=F*C,T-,29.DS$0TOZY,6E6".)+(6'
M@"'`31X$'V$P"#D+H<YDQ&.%N->M"^/P1>!G0860YC=4;8WN;1&E/P?,RMS@
MA9DA)Y*<18#2TQ018S@`<8#&SZ0IU3&%L*/K""&1!RL'%LN$:S&&C#*ML_%@
MD6Q_D%2W!2X3'3'_`":F+?\`+B(.5678&%7O\V/;@>HHJNME3K8#ZH@L6->K
M7C;/#[,=1LJ'\A/(M'DC^@8F"5J\$X/?&IH0RIR)3DJ!#`26N."'&,&"QD/G
M!4-8%O\`6\I+@D9+D5/1J00VK7@MK3@70**RI''&Z1Q^,'!#C+4U/*&(M91Y
M)?@(RT).,X\`QP/]S4%3Y:6)@_QE``,47F^;,C;*7#X^4TL%C9?7&4"GK.W%
M-X$;;,1R9X5N(G(D`%@ERHX_)F33!CR',5VA6E5>OG:XLK@W70JV#^R?K?EM
M%WLZ-R]PC\7A,2BS_8`E5S7<W$LKVPV"W-4`8QMZ(Y9AO6,R!E/++7`(5BP6
M%_>H=?P)PI'5^Z11)DS9JS3^EJ_S.!HRAR7]A*HE&)6*)9=/'S"9!2#.%F2?
M]F5&/?\`KP-D,NL.O\=9*(C;+4\/;F/6%PRZZ_-I#>+X*F<,PZ15]E3#O<T9
MC<+]E2QQ;?'L(/VRH0?'G`<A#V))K_2DO8+-B\FJ^&/+!<KF-[M-N6,J41<Z
M>3&2+1S+O(#0``H6.8&.$,Z8"CWP:66V)O46,DEY"&F=DM"]9MKY*PSBWHM-
M@3V,PZ0U\RSZK[INFC)JFA$I4$KGF**Y+2U@0)S>H\H=4Q*T*)>-4F+6$@-"
M#`L9SD(1Z4UUNWJ?N$#1U>_.-K=:U3Z>HGRA+CGT+BK=:3%-T%EM<0A^OKO.
MXY,BC;#1US51`L_EU47;UJLL!'W1HSL?.K"QC;5QK=HUOM]SM^UI_1U9H(DH
M53.V*LDDDB%APAF*5I!'.T2DD/0.<I:G<1F`$@&WIS50L&Y`6'V%C@<DG99;
MO7O(>OO;9)5G:?OM;%AIJ>E(X_5%BW)L`KCTA?VQS;D"**V3%I!5,=`F8Y&Z
MC"@$G>C4:5<$P>,9'@`Q`"^O9NZ55![ET%8J1I1/`Y%KW!*D4(G`UP*3HT%Y
M]@VCE&N#N5EK1KEJE<S(+7-6)BL%?&8H2E@,R`H0Q@#U->"<'=.64619!@O4
M^[6KY,>!9R%(RV"W8.\8SZ^P\$^_C&?&,Y\>?'UX$\=7E&5>L^NRK(<`RIHN
MI%&08SD6`9.@$?,R'&<XQG.`Y%X\\#>G`<!P'`<!P'`<!P'`<!P'`<!P'`<#
MFCU&(U:>N_+<FSF^K;MCNTCVR6C5+A<*)!,UFM%G1FK(UK`W.T1:G]U"KBA5
MC0-K3LN7E(ARG,3.)AH19R$80"#I<X%=&CJJ,+[T[05#%$$,:<DF];<S2=U2
MN2]>HF3LWZ;ZF*"Y`X$K/[38H+1N`$@2",Y*P6G"/'C(LAP%B_`<"M;JW3IT
MM,;#)R2"2C`=BO9")6<4264):I/W3NA1]T?Z!P(P[!!I961#R(60E8QY\8QC
M`64\!P'`<"#FWKC++D;U6G%"W.SUC=%B-D9?;6?6AY=&ZTJMU2=9:3&;2GU;
MK6ID=TL<M23M^%+##EBXU"),Y*%#JD$<-F.+P$F:=IZLZ`K&%4U3L/:(%6M>
ML:6/1.+,I0P)&]O3>PS#E"A08>O=7=S5F&*E[@K-/7.*X\U4J.-4&F&"#97`
M<!P'`TGL1KU5FTU02^D+D83'V$3!*0$T:!<J99)&WQL5$N<:FL)DK<,EWB,[
MACZE(<F=V1&%*VYP3E'%"P(/`KYZZI6'556FZL[>CZ""S^EFB2/6LLS;TAS7
M`-L]=/W$O=B9[!2C52ELC]N0`]ZPCG\)1")3,BD1+@SI2(\L1IT025WHT*I?
M?*LD41L,#A$+'@ZX<HHJ^X8$A':5%V$1D@]ME</=1XP%<V&+42?+LQ+?E9WQ
M,3@E62+U*,*"+>OW97#ZFE%4:/\`8O,6FBM\5OWD*9#9"@DR2H-IDT50A"V7
M=2MMK(TUP%2T64A("::RN*MN>VJ1"4-`THC0I1J@N!X%1VUO4[7=INO^5-:)
M4OUKN%%9,'NAYA#2LD*C4+8FPJSDZ&;14G:76EF>6B%S<A7)6PDY2_-A3;)@
M*@E*S%2L:8HC(05D/8`XZLVAM#L]V74RTZW[?1FA<U#I35K<ZR6S*>MV&LC0
M7.7MKHW8\<>88$Z6/L)?KDA0O$<6I8](4#1'H_\`=IU!9`E00D!7$%G5-2;K
M&Z[8U,7A':PP3#L`[`+$K]X7MIDX4Q4U0^3XV2O3<0F$\-.RFZ5L)3?MU!OJ
MOCD?<4@PB(!@O(2`;.PV1LU&7WL;)X2TRV%_\[@:B:E16)+<L+U:"0VYZ\U*
M1.<@?'-2^$)U2[8P<L/&H"C("3'6XHP*<P6/<T)P*=EJD03V]:_=7U0S+M;*
MRA-N7'(79N4((?$H;/$MAN30H-D)^`IEBQ$RUBYKUY1(1X1I,D#,%C)V`X#-
M([;]7RQ'6*UAGD96!NB(YGM4(S71.WO,_AQ;.RR!3(8PPN0D;VYMS<S2-`H5
MB`GSE&!83\^"\F!QD/P(NRG536D?$MJUVJ9E]CGTZA=4LRCREN66REDBN'*J
MS2K"7`:<^>I98@/;36D(LKRUQ!A`BL&`$'`?>^VO5T7;+#>I)9$#8&BHT6'&
MUG1YES`VM]9M^6(B4!6V`K6.!)$.2BC*HIQP8XB3ARA,`?Y^(6!Y#U?WS"LO
MD:C.)?&,R.9L+O*8@P!?6L3S*8S'Q,0'V11UMPJRL>F)F')VW"I6F`8G3Y<$
MV!C#\Y7L'E(;7JUS9&Z3-MDP!PC;Q+C(`T2!#,8ZK9'6=E2-5#S82W.Q#B8@
M72XN7(3VH3:48)9AQ)&FR7\P!`P'T*K,K="KG;>ML"$HU]7,B&368B52MB3J
MZ[C;HWN;NVR&=)CEX#HDQN+4R+5)"MPPG3G)TAY@!Y`49D(?83/(.H>8]'")
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MKBV!1T&9*P8'+S32(F'+PW8%*#R&Y4\'$QT/W/E[-):41RH04WRY"F)&9G]`
M!"P'TJ'YC2)7!<J>6E,B:#_M798H<49*5L5>J<7VS@H,."2B/]596?0S(1>#
M`?3]6/(>',K&KVND[<KL&=PV")7=;^-:5,RE#)&$[HXY!\F$#<<]KD):U;\>
M/;XBLB'X^OCQP(1D:)(\]H0.RQ/9QJ_*[2M1J6.JEL>3+4B$([::+1;Y[%IB
M2Z$C;BEJ=,>D6H1HE'W`A%F@4`#@160F?:95IGP"3%4FO@#9:8T1.(<OM-ID
M3[`$SA]ZER>.3-,2>H[(EJ++=@[``I5J<>#L@SD60X$'(<_':M'>U_\`\?\`
MMN&V['ZYI!2ZVJGS_([1%*;V-B\Y*@A1"`+VU0YSD%VS*,N4D>Q@&%.)S1`1
MDY-P`PLX/G@3KVGM6,4QO5KH_O+(R2$E^I1-4B)B<7%`@`F>;EWXT-JF)O:8
MM4E7!ROB3I+<NZ$D!035)[=\91A0\8-+#]M7B"S.I8:,P/NG!0NPK?@&<YQ_
MVA#E:",LKSC.!>`IR\!\^?;Z>?/GZ\":&HQ@S=4=8C3,^PS->J6,&+QC'L,=
M;QH0L^,8QC'G.>!(7@.`X#@.`X#@.`X#@.`X#@.`X#@.!6;UH8$<GWW="P9`
MVNW9EMMEK^00,J1!8'.(PYZ&H+!D6"L"E<:</@QY\B2_$//C(LXP%F7`KWT2
MBZV-3[L8,<WIK?G"1=@<UD>5C>!=A4C;''736;+`P/!BY.2(UPC[(60EQ\(S
MDX$Y900"QXR6`+".`X$&^OQXKZ2TU9,HK)N*;8O(=O=V5PP@;E;::NDJ3:RV
MV6:NZD"J838*PUVF#4N4!5$J4R=248`PM"@"+"0H)R<!P'`C[LOL"P:X5H*9
MN+2\RV4R*1QZO*MKB*(TSM-+,LZ:+P-<7B468SW)I$Z&EB$:Y.8PGE@;6%O7
M.!XBTR0XP`?71%8/D,CB*8VN@JATV<G4/@:'8>T:IA!L,9[$E,,:5:)O"B*=
M5SQ*3HG%Q.JPAE(<ERDY,F.'G]`S3`\#>_`<!P'`<!P-"[':VU?M+6Y];6@B
M>224KJ@E,*F\-?%L0LVJ+!9,'"C%FU3.VD1;U")_&#SQB2+DPO`RC#4RDM0C
M4*$YP0^UWV>LRF;-9-)M\7QOS<JXLPC6_9P+61&:UW5B*(PTE,0#)!"6-P;:
MV.H2B\RN$E"*+<<BP[L!9K<<<F;0DMM[I9K-O;4+S2.T=3QFT82YIUN&TQV1
M$@D\*=UB020$JKZ5%`"^0J6(0BQDE<@.)-_3Z#]RLC+$%(%Q;5]M?5#<=<&;
M%QJ&;Y]8AQC/7KWLU"(R&O-D:!9UTC1-;+9FT2=O/-@;LFB[0X%DNSXUM;0P
M.29()8>-H5C^W4!T60NS:WLE&G<*[L&$SQ"J8V*3IED,E3%)TJB-2@I2?&I`
M2>R+UQ1C)(2$1PT*K&<D*PE#R4(6`B\!Z$TA$,LB+/D&L.)1J=PJ3(#FJ1Q&
M8,;9)8R_-BD/JH;WAB>4RQL<D9P?H(LXH8,_ZXX%4+CU%1ZG97*[0ZZ=C+5T
M-L2619EB+O&6=`P7]KF\,D862]SC32HH^Z"WP^%,["YS5::C1PE_B2%+\P\@
M(]ABSD(,ET_V$ZIUYH'K]9.ED.V1U@TEMZ*V5*;ATOL_\_;]C`KRLK"98=+7
MW5^ZDT)>139WN29IIA(\,DLDIABM*:)&4,8P!P&K;/[*-5$6O/<I+[,E$KUX
MNO9I'8T1JBI]GZYL6AIB^P]CU.@=&52)"S7+$XPT`-D\L_*N&$@%AI6<*Q#,
MP5D1W@)WQ2X-4W;L0T2AM;[%T#.VW6_KIV<(5OK-;U<R]:F;9#-]+H+%AJ%[
M6_N)S6<]((HL4`/,.P!>24=Z>^"ABP$;V8ID;M1]8LHWV-N(7SO^?9<S_AW]
MI=B0M<E[/;M$A-1C0'#++PK0J_.0AR/S@_/ZLX'P/LW(PF<Z9_D^-J(Q&I4+
M:58"RTX#TV?D<L]<<)08$;CW\`.+/1`+$(?C(/A\9SCT^@3M<4QC?O\`=7R%
M4-/^3;]&]V&9S^!4G5"`J2J=$\J4HCTQA@#B\*4WOC.!9`/(/;'GQYX%?E=L
M+.Q==^F>4``@+6]YP7LWY3RS2TSHZ=N5R)E047TP%(6(1F2PE`_V^X@_^[/`
MD5L%%0*7?^04YB,:<D2S1:MXID@ST$H$K:]4-AQFB<P?'D(TBA/*"`%8SD0A
M8+,QZXQZ^P9@B@RZ/=F'5:U-R1'EO@'6'N`PNQ[5\*=O3(T,FT/86\*4@7P'
M#;LK@A"0`)>?CP+&<A#P(JTA&CG#K\ZFFYJ0)"CVGM0)=3D^?MD.$A4>V'VO
M6/>08'\00+"$"-0#)8?[A@O)>,9R+QP.?/NR@5(O?85V[.%LU/L*X3MXA>O\
M:UQL*A6&VG)@E=CG:GU[(%%*W2;`#U\35,$C?F.-C3)7M$7G+8K=3R#AG%)Q
M)0ZW5BH4;[,98J:F0EJ<F3IW9%2%B&C483I!,]_3(Q`R9"=@D:@EL/#\.2<C
M^0H(_P!7I\F,B"#NJU;%I:1_BVH@D@9<1Z.O$V&%(A7!3&.+_P!:=WORIM)P
MZ9(6H2'4U^/4!QGSCXR?``Y+QC.`R78)S7R72GN):WD!6`NW9Y!ZU5")2@3'
M((Q(GO0N%Y<RB\!R#+D@C+O]X2<,(@C."`P>!!SG&0WIN;2=)7=OI<R^^:WB
MUSQFENHN=.S-6U@PN.S>-_>VC<DS->Y-%TTF+5IF2:D-U+$MXE:8LA1E.N+Q
M\X<!QC@62Z(*2EFCVFBLC.<D*M4]>%).1"R,62CZBAYI>1#SD61YR`6/.?.?
M/`CIVQ,R26ZWUC7SZ)R.@=H[K:+U=:3,WO#RQDRNL;`VIJV+S.&OB]@7-KKF
M.2QK<<H%Q)9Y85*<\10_(!B#D/J*Z<.K@E]CTC!HUK]ETBZS#@S?+#2SVTE<
M`1)A"M8QG*#&1W4(SDX#$XEB<_*8T/N5Z#_5P,6O[77K\U'L^([L*]0X*MO&
MS=AJ7I978,3C[>D>5<WVBV-K:,M]C3=.L7I6%\612Q7)"_%NBE*K=V]20,3<
M,DY0,0@^;7AS61WJ8FCLD3DK'*.5-N`K)1J/?X#W)CFEUBPB4>@@#P5E8D^(
M?J+&?'GQG^F>!.K5UK2,>LVNS*@4'*T#/151M:)4HR')ZE(WP"/I$R@_(`%@
MR<<22$0O`0X]LY\8Q_3@;UX#@.`X#@.`X#@.`X#@.`X#@:SKY3;I[W;`+/;H
M(@CR6QQ)J4.AJMY5.KI5&(/"3PN-A@=<83(IMFPSY`1DE#_VF&HA$/\`^<,W
M@;,X#@5N=;):,AGW93H#S3B"NR/<<P>#C4QHR%B^=HW1R(QA)_:**"XKC<EA
MSX,P`6,F?W,BSD+(^!6;UM&94NG8FO/S@;@M[,MC"UYF,!!D>&6'U!&F;`R0
M8"65DB,,B$K&<!#DT(,&C]C#!C$%F7`<#G%HG;"U-1*NUGA-7T&WV#6VP/<A
MO+K):4C+/=H^RZ_L4VWRO1JBDA^&/,;HWHPJ'A7]FD1JBTJ0]2(I/@XD1H1<
M#HZX#@>/(9"PQ%@?)7*7EKCD8C#.YR&1R%[7)FME86%E1'N3N\N[FM,)1MS6
MUMZ8P]0>:,!1)0!#%G`<9SP*TM8*7G=_7\\=@FT$:5,;^SG3.OM&:6?!IC\Z
M]4(Y#+97RTGQ&A6N#,*_=E0-XG!Q7DFGF,T/.;V4DT&1.F%`6B\!P'`<!P'`
M<!P-67-2-2[#U\]U5=L`C=DP"0`!^0CLF0!5D%+"/82!Z:%A8B7*/25F/%\[
M>ZMYR9R;E(0GI3RC@!'@*VW&Q=ANL\X)=SN%D[9Z"EF&F$[`91*)OLYJ$U?<
M$@"CO]K:"LO^P-$,:0S(P3=M1JIBQ)23!/R=S)`)V"%I<0F$(M&&L4V@DFC,
M_@$U94SQ')3%W9LDT4E$?="/D3.+2[MIZQJ=VM<G'Y"848868'/]<\"GW8+H
MKU&G5ML^T>K)LAT*V\BK^TRMCN/6HPV*Q"3O#*X)7`EJN*DVM>R02QX8]"3C
M(>41.&A8[)3S2CUN0#SC(:,GW8SVEZ,7_%VSL%U#H^;Z/2QW:&)WW=T^76ZL
MC]'(L$IRWFP+RK5_0V'+XU&/N598CL&`2-[<'!N`.SA@O(N!:O1/8EH;L_+C
M:_UXW$UNN6=EA$,N%U[<$'DDK7$EM`WY2H:8\WO)KL])$#248:J.2$GE)?A-
M"<(`RC`A"97`\E]8&*4-*YADK*TR)B<R<IG)E?6Y&[-+@G%G&1$+FY>2H1JR
M19QCR$P`@Y_Z<",<NT(T8L#WS.M,=49D(9F3A&2C7BHWXWYA$EILGX.<X@I-
M"?E.4$OWQG`O0.`^?&,8X&HL=1_5V`D1"?KYT^0EY3G)@8;-?ZU:QIP'Y+$,
MQ&:W1Y*:A5A$4'(#R1%G%BQY`,.<YX&-&=,?5*:E<T@]`=8,DO0LC=L_XO8@
MJ'`8L^1F*U82<*SC#/Z"%D?L/&<XSG.,YQP/7*Z@NK],J-7H=$]:FIP/9UK`
M-R9JS8F5RPU.)A1JQ.4XM)*-:08:(@'@X`PG`"#`0CP'&,<#RL=-'5=@M`1_
MP.UQ^T:S1J6UOS`4.6Q"L&<K4B<$K9D>6\ES^Y7G&X4A*PHP89D>!X%]>!Z!
M/3YU=D$.24.B6MAB5Z,3'/*136S,K2.YZ(@Y(B/=4JLLY.XJ$:10824,X(QE
M$F"`'.`"%C(?.]=.W6)('HJ1NFEU+F/J=J(8TSJE:')L6I65,+W):$IS8ZHQ
M)FP!G@?P%^I61XP+(<YQC/`\XGI=ZJR"D)!>BM`8(;%(ES<0.*#-)0KAB/$:
MN2E&K1ED+CQ*C<F'!Q@TS)QF1"S[C\AS8]J6D,$K;L!CM8Z;Z[T3`:BCFFKU
M:>S%?&LB1)%+`->FO9^0P"RG-@S&W]`=(Z@_XUJ4J!Q--0N!ZA^2-B92$I0>
M#@=`=.]0G7G,JEK";V%JS!'>T)?1,$9)Q-"9#8)4B7)W>"-Y$@8T$E2R].]-
MT:/,7J0%(TIY"4LHSP`L./IP,^.Z6>LLTV,&%ZPH$`8200FA:9GM.\&-OAQ"
M9E''"BXFV,UF(6^-XPPFC1B^R*(R-.8,`O(1BQD/Z<.E_K9=&"2Q5;KVZFQN
M937_`"/+&4%\[()VZ23K![6J!*'M,FMXHMR=B5;&B.+,-]OB/1DF`P$90!!#
M3^UNO>L76WIUNC?&O%9N*"\[/H<RAX6JD]B6G<DLL6QYRJ=H+KU535BWYY-U
MJE*[W#9I`"FM%DL"@U::(18\^>!*G7[KWI2J=?Z&J:6LKC+))4]*U=6#U)@6
M!9Q!3\YP.%L\;<7@D@,O)P22YKV\T\`?4/H$S`?&,8QC`1B[+-:::I;4F7;(
MP*HG=_D^J-CT3MT8TM4SFRIV=(UK5==>V[8I",ET>GE(N5YK6(.XRDYI`P'*
M`A_VF9P8$+@8Y(6271YAE<:<T3W').S-<A8'EM4DK6YV9'I"0Y-3F@6)AFIU
M:)>A4EFE&EB$`PL>!!SG&<9X$9]W2Y]G6Z9GU)0T<V0N%"^UJNIRMI@8T)XB
MDMM-9L0'7%GRQ8\C`2@BM(R_[29.9Z?.7`M`Q'91XRJ^+'`JWIVTDFN7\?V9
MSN_Y<OD3K`J#VBB4^EA37@EYL*T%UG6Q6X36=A&8D\/UG6<YDDMR#(BLY5N1
M1.<ASGZ!<IKG&)+"=>Z(ADS./43")4U6$9E9ZI.@2*3I*PPEC:GTU0E:@A:T
MQYCHD-R,M-C!`!9S@O\`1C'`W+P'`<!P'`<!P'`<!P'`<!P'`<!P/R.,,+!@
M19`U`LFD`R66(H`@EFGEEFG9R<,L&0)BAY,%C&?8009P'&19QC(5E=8X#"4>
M_"8\WYCR.SC;T1AF"P%XR!<\Q5S2`P$'Z<_$A7%`SG^N1!SY^OG@6=<"M[KG
M=53\JW[>3D[40C/[(=D6IJ&UMB=J$J2PYFK2"+5#H2GSC"EU_.Q=868J&$!B
MH!8#1>WO\@PLAX'XG%F&9)^-081\9P3#,%@)'\Y80BP).9\Q9F0%CR+&<Y!Z
MCQZ_3.,>?(<U\4KR6AJWJ,-T>LYU;J:9NU+9M]FK=.HBWNIL[KM^M;;V3V(Y
M/4CE<)1.T2?FV-II,S,YQ*<@U:I>B4Y2LX>4RW(=*W`<"GR*N2KM$O@N=-LC
M?6WKYU(N)0BA26-NY[>U;S;*UBXD@=I=(5B0`!/VKFN\X2#0-3>2=E%,INW*
MU*S!K:T)"EP7!XQX^F/IC'TQC'^G`<!P'`<!P'`<!P'`<"NB3==L3B$CE%EZ
M6V?,])K1E#JJE#^VUHG1R76VP)<J`8%4\VIJU(S0UN[*G;YS!.+E&A1*2KC1
MX.,=OF``>`UDY;X;"ZEX(;^P[6EU0P%(>V(%.Z6I*-]MW7<M,H/^Q/E=P5>>
M5F]M<4`#Q$FJ_D1S"/MP%'ZWXP!1@PA9)65KU;=D.;[!IZQH+:\">!'E-LRK
MN5L4UBS@8F'\2M.F?8ZN<6PY0D-_0<7@S(RA^0CQC.,XX$(+<ZD>OFX+29[Z
M7:[Q^M-@XVJ7.4<OW7U\E>NMPL[TXD*4JI^_>]*OL(<7MW-2K3BA&NGW^#"#
MC"AA$48,`@BXQ]4&T],V\&Y==.WK=M>=A],?%].[D/";:VCI&4-G4,^6%TCY
M#I4DH;&P`%8SBC$#J0<2H+(,_7DG&!!X#6H_D6U9<I<IF;=UL;8:^C5O"UYK
M"JU=L:]V_P#8J4.26AH@\EL;$NAR!4UNF2S\C>5C@%4F">6(XHPPD9(?B5V!
M=SC/98Q3;HQ?RJ+1NJ@MS>JXWAUHL.WLLF$QI2):Q0=6^0Z/O;D<YB*$:F$Z
M)0%)1&"P:,1>,##*7#MUV+*89`%JZ4>T57/T9)^8S''*&T:VP]\4%EHS"BW:
MQ4-ROA$?3BPO+]S"FUP'C.#<%EFB)."`,6AW;[N*?#9\NLSHY[#XC8C.>NQ7
M4.A0*TLB+S1,02H*2#D=@F/L.'"CS71*(LT)#0\A"F&6H($HP+`.!\,.[G=G
M@L<G<;CZ.NT"$.J-"B/AC16<"B-UADZTTE>%>C>UB=Z@Q\/*2.)28HLT29<(
MXE0(_)982<X$'WUWW";:J,OQUZ]'_8U6:!$SD'QXVLVN!WTND,A5J\EI(^H:
MT#I`SV).:BQ\PW$T1B1*,(BU.2<Y*$:&/UWW4;3*3DRV\NC3LXK**K6=8O3.
M]<P1FO1]"X%NOX]`W.$*08@S^U@6$%&FF&'!"<1X!GX1D&A4<#U(3W<6XYOR
M,NQNE[MKK>$.1CF6AF*;7`Z?KRQEN1K>PE.\)B[@*1-!SV()>!^V!EI1F8SD
M9B?'W/`_=@[K[?6V8FCLGZ8NV.(U>YJGM(T66;KN.0/9YB)$>O9!.5<,#@L6
MLI;V4D-P,1SCX1C^,(_;(Q>@49[D;90';7?2Q;3MKJ;WDBA$9TO(C53V?;M&
M6:R7M6LH@*[;ARKV7U14]8L\EDCK'[KET\2-CV0\K4[.0T,2P]?ZA2!QD+JZ
M?[EY:PIH)`Y#U-=M2"L(M7$6;EUY)=09.Z,YRED@K::J7)J^;5JN?*&-2YI3
MDR<U.F4J1XR4:).$H8A%A_0/Y!D!/M\->$=:W;7^R"G]J8'*XU&C]BDQUJ,=
M&XQ:%8LA9.%5G_"4>0:3\06?*LS)>1A*R#QG(>9-OY$]5Q-\E#:V=;G;E,&A
MG:T2F/RIIT@F+*SRMX4%>ZIB*23)VC3\RF(#,^@CU:0)9@@#R#V#@.1A`:6]
MKZ28[%U=L5N+KOL;:4-IY>FG&O&J.L5*V#.(1KG8+CASBRV[MFYK9\6J5RM+
M8>$QMS5%-Z:/M"N'0I"M4J$*MS=3/NTH6371_(>TY@#[$VVG:YV-VK9WJ+2"
M72N3TW4LC9V^LVR/O+4RC3S5#;2.NG=$YO!SJ$:`D!`_N0@SC`L"&5@P/KNW
M^0QU_P!=!C33'T%O7SB60^?/TC+KZO24<>AN80C1Y=X/+WNU'2OV19-7XQ8<
ME;VEN&Y&KCB!`\!^9+]P%6^LO=;"-1%*ANJ^G+/E'6V<R1>2P:HY?*JJ2;?:
MBJYN]9PKJ>LZ9:)Q(Y+;%*,7Y`*AJCZD](_0])D:$DT]N3HDI(3QUT[==(&F
M93VPG?:[;W<O86WQ*?VC0T$TBVH95=7UJT/+TY1BM:ZU[CM6JF1H<&T;H6E?
M9<]NBYR?UX"!'N)*`M$C2AL33C62R-NFFCIY>%507631J@+*EMK:SZ-PFQB;
M@>+$LXFQYE(8S<&V$S*/=F5I<JPDKH:X--;M+@Y)&28!-/=%9IC:A0)0OXX#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.!69UHXR8'?Y:4$8FY=V9[79;5@P9+PNPV
M&P=@>A%EB\#P!NE30X(?.<8P9E)D8?(!!%D+,^!7MUZ((DV-FY*6(2-=)2!=
MA.V*]^/7LQS(8TRUYES<\R2.)R3A#_((6!Q<!)B%H,Y`K+!@S&`^V0X"PG@.
M!QYZXU?LU:%(Z?6)(>NU]O:%:3[M[56WK';VNVW5:0RX1M3/M192=Z33[7JZ
MT$0K60M]@?9K6Y3\4I&[$$)BU*/#><<8`8='>NN_.NNR<R?:EC[O*ZTV"B+<
M2[3/6J]X:]U#?,9;#RRS@.^8-*B4_P"[8U@HXL7YJ.J7EDS\H/59G(L8R&&7
MW*FS:VP++T!A#_84<3,\-B+YM=:M?.:J)JH'`;`PYJ6*F(;8C6L$Z,5V6FU-
MA:A640ER8U0=6H685(ERYF,,":=>U]!ZG@L1K*LXHQ06O8%'FJ)PR'1AN3M,
M?C4;8T93>TLS0VI`%ITB%"C("``0X_ICSGSG.<\#,>`X#@.`X#@.`X#@.`X#
M@.!7C876!JK)9'*K#JAJGFH=Q3+P;(;@TVG[[KU*GYQPK`MR\3*-P\P-56:Z
MFG@_N'2J.O@C`9R$7G&>!@B*K.V"D!MZ*OMEM;=T(4A(68,:]K:V>Z!NH\LD
MQ$%J1FW5KFBD-;.RG*(LX)RHVLTA@S\A&/(L"%D(8NO[,+OII,MQMWUC[EUK
MAM6%E*ISK8V1'=JI#6PP916'XASI]V;[C2H@&G@P84M@J105C(A9!DLL9F`R
M.'=VG59+UJ1F5;JU#6<G5&D)Q0R_53YKI-4"E0L5("4[K$KU9J]?FPP:I&,.
M/F(`'(<A'C/H86(030BVU^K4Y4C1PK96@9@L+)3J#$L6N.NY`I+3JRL'I3QD
M-,C5FA)4DYP,L6<>HPY\XSG'`W''Y+')8W`>(K(&22M!A@RBW2/NJ!Y;C#2\
M!R84!<W'J4PC"\#Q[!P+SCSCSP/;\XQ_7/C@?D(\D.<A$<4'./'G`C`8SCS_
M`$\XSGS]?/`^$;VS%!$,QW;"P`QG(QC7I0!#C'TSD0A&XP'&,_\`7@?JB<VU
MR^3+<X(5^"?3YOLE:=5\7R>V2_D^`PST]_3/CSX\^,^/Z<#[N`X'+CW"M&Z(
M-M[;4:K0.JY3%K)Z[HK3MQ.M@1Z<.DY98JYJ]^)`_+Z#=&7""(,\^001`\A6
MC<G`E0-.K3D(R%2E0408'19KP0>FU_HQ,I,$<I3T[61"@T1*E.(T\J%,A9I@
MDZU.D6$"&8'.<@-**-#Y\"`$6,XP&XN`X#@.`X#@.!!OKAG,QLC4."3">MK$
MTR9RGFPR10BC449H2SA:V+8^VH_&E">.,"5$UI#UT9:T9Z@X!83%BDPQ2=['
M'&"R$Y.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5J=898SJ_P!M'H&<?C9%V0[[
MKV@O/T4%)FO8B6Q1Q"J!XS@LPV11Q::#&!#\D&%B\XSG(`A97P*P^L4U6<CW
MZ,4M3HSEY[.MORT:5U2&HSCDR=YBJ<3FEP8''W+8[JR3528X.1`-).#G&?\`
M3`6><!P*_P#J^86V.Z7P)`RO*&0,JJRMGI"RN[8Y,KN@5L\LVGNF5-6$SC'G
M)V:5!:=`\EE?VSQC!D'J;@!H1@"&I^T1F@%L1ZK=9V"OD<WW)NMQDA>K$O:U
M*B-3C5L4=3M0+#W'0VBRD?NBLHY0:-[;U0A(3R392^K&J.>I@78>2PF=J_K!
M6FIM8EUM7.9&\JG1Y63.R+)GK^OF-IW-:#VE0)Y7:]K39W,.=)9.Y3EM)^=0
M8()"9.00C2%)T29,G*"17`<!P'`<!P'`<!P'`<!P'`<!P'`<#$I5`8).T:AO
MF\*B4R0*D@D"I#*HXSR%&I0B'\HD2A,[HUA)R01GZLEB#D&1?7QYX$3WOK-Z
MXI(:2>_:":7.RA,`DM.I7:OTF>I(*3G%GD%$J10GYRR2S2@YP#`L!^G]/'G@
M86LZDNLU6L7K"M']<V;\H6J`O01:N6:',:DQ:>4I5+!QV*%,S#AS--(!Y5X3
M84X`'`,&8!CUX'BF=.?5Z<#)9^D5$*`Y\_51&#%`P>2QEYP4:<M&85C(3,^<
M!SC'MC`OZA#G`8^'I*ZG,+4+B+0W7\]6W-XFQ.8KBZA:$:49*DC.5I"MP.(<
ME>"U8_"E2$U0'.`YP/&2P9"'GF]&?40<=]P;U]ZX#,^8)^0YAF<$C&#.,XP8
MFPMPG-*SG'ZBQ`R6+_7&>!]C'TE=5T52.:&(:9UK"4[RY&NSKB#.D\A1S@L-
M">$O"M5%9<T*CD:$*DW[1-D?VR+Y!_;EE^PO(?RNZ3NL9R;C6Q;K*`XDT\*C
M*K_,=_EO`!`]/4DA_*M4M]3(_(/.2"U(",YR+.0?J%Y#Q$G17U4HU"=4'5%`
MI.3F`-#^4MZ_GDH\8,^?^^3NUJK4[D`?_O"H":$S'T%C..!`#;WK1Z?->+<U
M,J*5ZK!A\5W&M!74;C.?^4FT%1U_&'Z*-8I-!6H'[>E3M&)3<%F2QP3,#`TK
M5+2N<VX]R^W5Y*2GE""Z0_0?5U9%VZ).$+EK@WME*P37M.XJ;FNL,HS5E;2I
M'-XFT&R]-82>3"?$TL0$K53YA5A\<1EA`K5G%!P7@-:+NK;4YP$K&I5[5?*L
M<!.`SBM^][2#219+$4%$D&3L:#*5K+"+R!,#P2'.,9P'Z8X'F9ZF=+1XR$YJ
MV24@%CP86IWOWK/+.QG^N#BS-C\A-P+/USYQ]<\#&%'37HNID**0F-6S>#&]
M0@5IF8.^F]&(W]PW&EG%&'L(MBQ-ZL*C)?J>6:$99X,Y",.<9SP)A_\`%RJ\
M2M7,PJ[7+>E]U-U_K`%WS=Q;*HL%JB'[&0IQ1H%@8CH*^+8,!]XD!*&+'*P!
M5FMXU0<'<#1#KUN48[D'%'VGNXF.4+G)<>M;NP+=)`L,RY+@+1),&)KR++*0
M(\!R0F*``(24XL@#_P!>!CG_`(K];1_I461O.K)_U3G]CN^/Q"S_`.W.?AV&
M),\@S]<>!8^O]>!X+UU%:KO01!,L'>E#G*428H:#LAWT`-.,2M(JRK3Y5;#J
M\%K/5+\7MXSCX3!A\><XS@)UT=2M?:ZU/"*4JQN<FN!5\T9:&!,]R)_ESX:`
MY8J<W!R?93*7%WD<B?'AV7GJUJU:I/4J5)XS!CSD7`VMP'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<"N?K.;U[=56R`5Z10CRK[%.Q=>CP>7DO"A`KW%MXQ*K3^?T
MF)CP^<A%CZ9SC./ZXSP+&.!6=U@R`4EA.XB\3@!R$F[*]]&7!Y9QR@LHI@OF
M0LR5$`P_]6/L4B(LK(<?H+$#(0_3&.!9CP'`H:TZVNC>H74SK[*EL6?;,LZ:
MV7<U04/1D.R5^][NO&0['W61&ZYCAAX#$C6F#AK5KWEX4X^P8F%O6N2G/P)A
M8$%F&K]!SBO$;E:6PDN8+1VJLA'D-G3R,-;BQP:.,^'IT>8_4E11MR7+1QVN
M(`B<26PM4+!;M)Q-Q+F\"-6BQ@D):\!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`Q"30"$S1S@[U+8LQR)UK65&3F`+WAO3KE$1F!D8DD+%)6(
M9X!_8/'[5E[FAP>#P,*=::'&<>WG@9?P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<"G.JZ>[<:6@MF0R#2#KU=U[AL5?\`:$5E=@H=A5(YE%+G
MM^=6TG-DT?APH^D@$A:!30MN$E1J'Q-D*')OS"$;^D-C(Q=T.4F"WQIZPG`X
M>%'S@9I5MI&\"_MFB2`(7"C3TJ3Y^?!>#!X#G/ID6<!^F`Y"(/7:D["JZKO8
M@BNZ\T`M5MD6YVY$PD[@QWYM!6:=FNETNF9'6I"B&B9ZNS!6K9V"PT:EJ3N)
M2K)"L`?O"P_$((,A-?\`S5VLI40$Y^@^J#F\",<@C7MG8%+T<>`628<!L-^-
MRTMP\C^[`$`QA^+R#`O']<<##Q;-=MB=^;4!_5A2:MB,<@(WA^:.QV.G#2H2
MG-.0K>6UJ=M9&52O(/:S#%"0@T28\9A?QG8(\X%P-)=4FD2)EC=>;.VI<,(V
M)<X"Y;+QG3<^MBG<FHZ>IZV;UG\CE4H8`OB=$X2JZ;1)5%HY!(CTY`$C4E*:
M6TDI/]\I<PO*X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%*76]M[J;&:^
MVN:G_:'7AD-:>QK?@P93Q<]=-8RT<AV1F\N:E`AN$B3`/)7M4@)4%&E^Q8BS
M,8P+.0BQ@-<R+^1UU]1MRV\(4-E]/+!IL\@CDYF<0@48FD8G[XI%)#6PNIU4
M5GSLJD$?>&J*+'`A_<"6F/`0X*,/7$Y4$!,"WVLMB:XLBNH+8*IQ(K<^<Q5B
ME6(%9,@A31/XH!^;R'$EBF#2R2J1-;9(T!2@):M,2M4X(/P(O(\B#G&`ASTS
MG'G=:&K?W19!*DE@GJ,\A*J+6D)C4-N6`C$E+6E?VU@4V2/3Y<>,&>OMXQY\
M<"SS@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X%&]+;_=B$XW<9J+F^C8F374W8G8^G)M<A,6N.
M.KZ_8(4WV?)Z*E1+P^,KE7,]CTJA,`8UCQ(43@D:E+E8+:UMQ?WC4Y@$%Y'`
MY7MUNPCLLUH1JI+_`)MU<.9X#((G)A#@M3@E\:O:N;VWXBVM-7M[:Z'64\**
MY60BJE+FO<S0*W,X3XDRG.SZG%9*"WKKKN;<.V77>-EV_AY<.6TIO%<=.T*$
MFLG.`DS36]E31V2U'91;PLDS^VSS$PC4K*SE<WEI4Y(DV23`B4A/]0LGX#@.
M`X#@.!H=PU8UB=FA%'W77*AW-@;7=_D#<R.%0U\M:$#]*UJASE#VB;5,>,1)
M7>2.2LU0O4@`$Y8>:,PX0Q"SG(8VNTGTT<PB`Y:D:QN`!'$J!`74+5:L(E"=
M.)(G/$%1%#,9.(2CR4`7^X)><AQG&,^.!@DBZU^NR7?+F3Z&Z;/HSD(VT9[G
MK-3"I3A"9@W`DQ:HR%Y4DE8^<>0^@@Y#D6<X\9^O`U?T_M$(9>M?4Q+7,<;(
MG##Z[5.3$PM38F:$Z!(Z2N1+\`4(4WL$MS$)1G*L0Q&'#4Y&(P8QY$+(63\!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`Y2JTJ9G;NV2K)'3-?];:)(EW3V1>K:>J'[$K,LN^RV
M)555O$&OD]T_EL@BE91JU54Q=4!,C,:DDA=F,]7]NG3IT>5*P(=4[F>K2MK@
MJ0)0+ER9"K/1HC5&4A:Q62088G2F*@D*1)@*#@X!DS!9F08SY]1>/&0_YX%I
MVI$=I*:T%@-'4ZPZ/:JWWKON!,)!6JEQ?-@9=#)-UT[6O^SSQ#V>6N:Z(NS,
MYV);11RAVRM2+1IFQW)^,'N'XBP[<=*[DVGMTS:9+M71C;1+M5NU]C5C2[:T
M9<5R"P]>F>/PMUK2V0214Y.#=)54V_-K3#S4(49*,TK*(U,2J3'XR$W.`X#@
M.`X#@.`X'\C]_07QX#D?J+TP/.0@R/QGUP(0<"S@.<_USC&<^.!`/JSK>Q*@
MZ_-7:RMF).$%LB&5\:RS&)N?QY5LKR1)'XP]/[E&&@-3&@-":09YQDP@P`LX
M#G.0X"?W`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/R,/)*&06::`L:DW)*
M<`A8"(XX))R@19>,_48\$$#'G&/_`&@SG_3@?KP'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`HDK+J9ZYH5MK3U\5Q;35G9:GKBGT_/2M\GI=7*I
ML[O\AVTDK_%I<VM,;2S`1[:OVH="59A1Y:H]'&&8I7@8D/R9"]O@<C/>O!9H
MV;::\2>I6NE6&,02M,46Z1I_BCVB5+)!VV7RX:X36T6E?$U:1"FD4)<(:G>3
M1')#37(U>LR<(X1F,8#I:UW>=IG@-S9VAAE/PT3=><]:Z&!44ED<D_<6O",3
M<"NI/8PI"D2X:;,=_*L;DC1>41(<%>F`B]\<"1G`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`Y6]5M5(ULAVGP_M$KSK^>:5KE-:>R<$.G+3)M:V!!(;`J
M!ZOG7U=LG-X>;&HQ?;4LMHY^>B%C"CPN$Z.25L>'`_($I9JL.J3@<LG>R_C8
M[VJI,4E`>9(K,ZGFW!PS1`^P.:^P6?2%,L`5@`@J<YPVF$9+%D(<X/\`?SY+
M#C(=3?`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#EYT$M>\&KM2NJKW#
MLFJM%0TTNO9-^KWK.F26UK)V"(9FLZ7DF2N.6#>E;US/(!$U,W8'*4`;&I0^
MQ)(WB$W-AYR?!:@`=0W`Y)N[LR3VEV)T)J_$V)&:].]1:Q;4CE3D^)V5J8H#
MJ5M[,9];@#@J?G/=9$;&E27\,D2%EY--&I^<X`,%^0O)ZZ]ZW3>R,;+O#U4R
M*GG?6W;NZ=3'A@(L$4[6O+K3BIH*4RQ<2;#(8JB@)`G>R3DS>>6I-^WR$[Y<
M@,!C@6(<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"NFINMV#TOMS8.X40
MV.VZ<Y9:Z]>HL&M;!MQHLVJGMG&3*!QV%MQ$\A#_`&-#X%`WF7K'%D9662-[
M<C59`')1B<L!(0L6X')'VZR(V&]TFO\`)`)"EW_^J?9AN`E,,&4'(3[+,3KC
M1C`'.<")0+QC*QCS@9P`A%ZASD6`ZQFUA8V90\JV=E:6E5(W3\Y(5+:W(T*A
M]>LMZ!IR\/)R4DHQT=/Q34E3?<'Y&;]NF*+]O0L&,!ZW`<!P'`<!P'`<!P'`
M\QL2N*7"[#BZ?E<GN:U4B%]B0A^P;CS,"1M?@@0L*OL08]?G'X,-\^18X'I\
M!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<#F<[9=4MC+.[$Z4N>KM<K(N2"JM&;;UKQ,8.HA?X
MNN;:LVX(FKBSO,TTCFT6<DT.2Q\*XQV7)T[A]FB&(P)(C`XR`+9NO?>I#OM"
M]BIHW5T=6J:A=P[[U1"VK)25)G*0_P"$G)E0@FCHG*8V,42724IY"=EF']V-
M$#`<_='8,QG`3]X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?`ZNK6PM
M;D^/CDWLS*S-ZQU>'AU6)VYK:FMN3F+'!R<G!882D0MZ%(2,TXXT8"RBP9$+
M.`XSG@0ZOCL2TSUOCL!DUF7G'5"2U$BUTK5KK)KDUWRN>1UI"(U^F$4A=,,<
M]ECW!XRG+$:Z/A"(;2W`#_W"@O.0X$&K==^Q#K]LN]K.H.FY<PQ.V'&;D2!Z
M`MK=YK>.7Q*Y+$F)<TSNOK(71YJ@EYNDS@+:@5MRQL<W%R=6%$!40$U"G^4`
M63<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P(J;V1)RGND6XD'9W9`PN
MLQU;OZ+MSTZGIDK4UK7ZJ96V)ESJJ6)%Z5*V)S56!*#1D&A+)P(7KGQXX'*5
MUK2+=:-5G3$KT$J>GM@+*AV@6EM2SF06K$H"X'1*"-3=.DQ$<H&=*-LZ&<7V
MIY-9+*_.KN>-H3(U<@1*``5N9B,HS`:^N`#^AI+=\R=&R:G=IZNGU:8H&L=4
M:$K!=1D=N-JG9,JLB&0%1'MB+Y%)JRC-NGQN33!6\CCA=/6,_8/:3"7E]7LZ
M\.YPGY?A*^?Q\WQ%_-ZY\A^7TQ\GKG&,8SCW\^/IP/UX#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@?@I4ID290L6*"$B-(0:I5*E)I9"9,F(+$:>H4'FB`420
M24#(AC%G`0AQG.<^.!A+=:M7N[6A>VFR($YLKFA2N;:[MTPCRUK<&U<26H1.
M"%>F<34BM"L(.`,HTL8BS`"QD.<XSC/`P^RG2A;/KZ;5?8DS@KK!K+B$E@<O
M9ASY"S">HK+6=8P2)L+=&E\;G9#]\TN!I7SI3R5!7O[%C`/&!8"!,QTKT,S6
M=/5E5%YO.J;K0=6CI&I[5UZV.00ZYXQ22\2++G5BJ;2UPFA\KAKB8W%'$%O2
M=Q/:5Y85S6:A7`"HP&NM;^L;1^(7P[6,WWY)-C%;.\122531TJM."R:LZ1::
ML///KHIAA<0;V]\F`Z]D;XN>4[C+%CX:.5.JF0J<FR-2:ZF!="%4F%DO`5!`
MLG"$`K`32\Y-&#!@AA+Q@7ZQ!"2/.<8\YQ@.?^F>!^_`<#YQJTI8<C&I3@"'
M_<(9Q80X^OCZYR+&,?7@?(8]LQ/C)KNV%8%G.`_(O2@]LX^N<8]C<><XX'T)
M%Z%>$8T*U(M"4/`#1)%)*D)8\AP/`!Y)&/`!Y`+&?&?KXSYX'U\!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`^5<A1.B)8V.:-*XMSBE4(7!O7)R5:)<B5DC3JT:Q(H`80
MI2J2#!`,+&$0!@%G&<9QG..!3K=O5S"Y1MCJK)*ZUQT(+TI86>V6+:VB)'JE
M1@I/+W9UB*D^G)U#7\ZIW586.%S)O3$*$1#@TX^U5FCS]T'.2RPS:[NM+IUJ
M.JK+N:VNOW3ELKNK8E);4GCPCU?@3LK;(Y"8\:[OSFF9XW#5;VY#2LC,(7VB
M0@TQ1D'J$L8A9QD(.TM`/XP]NIFL,+HKKN9%,C);)(R--ST#%:9?GLB7MYV6
ML4<;;YA4+<G]"M2D&9((;,*4I8P9,*#@6,#X$P67HKZ<%30UKHMHU1!;6K;S
M#&]\B)TE0C>F=X`2<,)TBC\J3JY`SKR0`R$!RA0G&7G]./46?(5,7QI?UR5A
MW):'=>4)TOU4;J_V`HB\;ALD9\9N`=QM"F`,\R7P4N#SMCMAF98>TR-PB2_Y
M\C;U)II+>L(&/U5EAX$TM0>L3KZLFX>PU'(-5:VDD.K'<A!6-9E/2F9/14;:
M&?5/61_ET>9RW^4N"AK;B[(D[PL$01@E()4L-&4'U%P)EN'2?U4NA112W2*F
MS/B*7%8-+2R%,K,"XEG%J!*%J5_)6*C0@/%\(S1C&FS@.2L@R`&0AXRCHNZC
ME?KA1HA2)@0@P7Z?92()8@X)*3X]RP2`(#!X+)#GV%C(O?R/S[YR+(8V]=`'
M3>__`/\`<M!:9\?(:9C"`^;LX0#.`66/XPL\N0!+#ZE8]<!\8!GSD.,9$+.0
MUT5_'(ZF6C]TY@='6=4XY6M&XK,5-M1M#`$*%;]D)$G.:V%AMU/&R0(,"^0@
MHU&<0`>/'IDOR#(4O]@L;0=>V[NO^IM([#=D`Z?F^NK++IM`VGL0O",JFB17
M+NC1&K<,L2%2F0GS=W/?HBFL!\7',(25#>X'%)!"(*++/$8%R3UT<N#HM^1)
MW`]US0U?"4'+0GW>*58^Y+R+V5?D5E9G.']S`L>2_?TQX^F.!^J'IDN6-C3Y
MAO=7VYMY2!&L1MZ>6W=5MBD%A4@*&68O!*:=/R[G%+<GF9-49$?@LP!19A02
ML9$&5D=9&\Q:(99O>)O":XY$1@M4"I=1`(PDDI\IQ`$@.I52>,XS!90ODPI#
MY$$8A8&,S(L!XAO6AV3H&L;;%N]W:)'E6F&>X+97J[J?-5OYU.=_]+4M"I3#
M6I4SQ\"4P85K=@PT:TW!8PJ2`@&6:'^NN@O<4J(;S$'?&_(W)M6@&`>>M[5+
M\4M;U`,D.!+JW@=?F7K`%9P-(9@\LL@W'D99F,_I#VV#43NLBB\YTSW$4W9@
M$B88&Z-6-UKU\T,CH8B"IRV_GG&MKRB;ZF-=1GAPXG(C2PXP4'*8DK]6!A]9
MM1=]8RU8@;J]<!1V2R,I"P:979\6330E95@,.-V4.&G+2#$/!(O0_)V`!R,(
M/;.`AX*NGOY!*8"!0W;J];+JH)$!2M;734:YFAO4F$8*-PVB<$-U.:T:!<;@
M11IQ9:<\LOP,O'OGP$/BCK)_)$;Q`-D,\Z89!C)A/RHRH7N@TX`01C`3/A7I
MWTW(CU^,Y$+(D_J0(./7`\9\8#+8Z[?R#T+B['RR#]/TE:BSW`IF;8]8FXT,
M<#R1GIOQBM6[N5=SE.7A.F*-P:3A'['#/#G!A>"LA-#+,O\`WN&?I#5G4TER
M+'T.-O3;Y4`K/CS^L@O7U,(W^GCZ##]<^>!C#](_Y`Z028#!4_4*[X,"8)0<
M?=>X2$*?(<AP`K!)M+>YF3<"SG`L"\8]<XSCZXSP,>'(OY%Z@H8B*MZ;FLW.
M,A+`JMC<IWP$6/'@X>4]:-.#`"\_[,9#G'C_`'?7@>^>Z_R#ST"8M)".G5M<
MA%FX5*U=D;H.J(!IB3`"!E-R>M&L[`$B[/RF!RJ'D\K'Q!$6+^[P/*R#^1>:
M8;C[CI61E#,R(D>$^\K@:27C`<8)&`1[<`\0LXSG)GD'CS_M^G`Q!X%_)=`N
M&2S!Z3U"`HLK(%YP=V4IBHPP/L:'*$P]5E-A,+'KC/RB^3&?/C'].!^S%C^2
MLG4GJG[_`,*;FG.(P60U)C]V&K*(\)F,B4#<0(7,:S!A8?&`?&7@/M_7/C@8
M]<EO]\]`U7/[KN*5=)L"JRKXN[32?3(]MW\D!,8B[&F&L=7@UG9$:AV<@(DP
M,BR6G*&:+&/TASGZ<",+?V"]O,SE-"0&N-C^B:13C9BFG/8JDX^>P=@+(?/Z
M0:&Y4Z.$^;%3DE.1($*5"@4'93+Q(EHBDQX@E"^`W`0PBL.R#M^N$>M3E7NU
M?0A*F_;.561$M=F]G:.P$0KC?Z8)$KM-F8U:V/)E#.;%$^,84F+R4@,"&5\0
MC<FEA&$EJ*VO[K]C;)NZ$U'/NE>9.>KEF**;V!BB%D["6A1$[&+(3.*B-I9A
M(HR@97E:U)"SBC#VTE>DP?D6!Y#D(<"",H^YKL]:*^-L![A/4NH<C(%;EMQZ
MFO\`/VSL3N2;U=1EIR^H+#E47;Y!4JF'#)3RB&JSB2CG8"H*0O&3"/D'Z`"S
M%!L7WELK@A0R7K0TYFZ4WY1K7N`]@;S&$"<.1*@DD_9337!6Z8.!\98A"`6<
M`01X\>!>P2P^9QV^[KTYOJ@Z:J96DB`,03`]GE=@,+$`XXG`#2U.OJ3`A&A*
MP<#U%D/Q&@P(03/<``RU/M]VWJ4IQV>G&)H5`%25,4C<>R:EL&'%*0C$:X8-
M;*@=$X$2#(<8.QD>%&<BQ\11N/.<!X#AN1W($%DB;^EN#K3!FG@-!GLUI8K!
M)9/I@LT63:<*P+"K(\Y+P'(A8P`7O@&?7`@\(6YO=H8=Z)^E&L""?B]LFN':
M!4`?[F!^N2\!0TFM'[9#G`L9\>OCSYSC/C&0^Z(;I]R(GI:GL7I29T#&)O5&
MM;A7W8SKI*%6'(@\W!"-V2RF/07X$RQ,3D0#D_W`@C-*",L&,FY)#\'3L-[1
MV\X],1T27FXFD&%%_.EW;TS$WG?+DO'N0J#,QG#`#)N/;/PXQCP+.?&,>>!^
M\?[#^S9R0'.3QT5;#-:?V`6D3HMQ]+5KJ</!IY)^5+6\V-&%*0D`BL9`+'R?
M($7MXP'UR(/].[&^QT(S/@Z+=I3"09`'W-VGTL)-%D0?.?!(+948$'&<9^H1
M"Q_3SX\^.!YYO8QVA!*-&3T.;!C$`LPP`3=T-+R_?``9,]<X*GBDT)@@A\8"
M$`Q9%X#C&<YX'A+NRGM51"*#_P"`N^S\#^W&8(C=?4E1@LD\H!WZ?M'E5[J"
M@F>HR\^GJ/&0Y%C.,\#:;?V+[O'J#\K^D_=I(W@]OA4)KGT>5+C,A4&X_N-R
MK9)LP7C*'!9GD!QO]X0BL><`P8,/?9>S2W_QRI=-NICLSBA_Y<IN:FYI@NN<
M]5KTIK:);AQ5_M?9$\MG*"J3GD"^;.2@YP5D1F!'A+P'^+NTJ:(U:A"'JC[8
MEBI.8(H6$E$T,8B,R'Q[B(=L[/A:CR\8_H(!V<"_H'SGZ<#'(WV[N;W(P,CM
MU7=OD+;P_>@72B1Z@LJYC0GI2S!$DX+A=LRUY<@KCBOC*-1I%!.!""(8PEY^
M3`9Q*.UJ$PN-2*:2G2_LB8H=$6)WE$FDSMIY,6QJ8XZP-ZAU?'ER$X.J54E0
M-+<D-..&(K'@LO(L><>/(?Q'>U1FE[%'I-$]"^S"0L$N8D$FB[NAU7+);WIA
M=D:-Q:G(A6XS]"G2$N2!>4<2%4).8,`L_I\A'@(>0O[8L(%JAN%UJ]M*M4D'
MD!WV&FHU:+Z8QG(D[N78GX9>#]6,>4Z@WSG_`.S/@/`>NX$+"$HQ7U>=PJDH
MW&?4QHTGP]>N<8)%D)I+79BM23GPH!XR,&`YS[8QG.0&8"&9UUVSUQ,&V3.L
MYTU[.J$21PUD`GQ;>@-]K%$F+?,K@$*(ZEIYAMH\120]%@L\*T*(T`CB\A`(
M.1"`'W(NWS5%U#),LD$W??3(<\&QZ6)V;KLWD7*(V_D-[8[J&1[++H/'XQW(
M:'I&J$F.R`["=449Z^I@,Y#RGCN,U?8W%0T+J?[!L.:+)>%R(KK8WC,.1Y.*
M`>1@_.:*"7X/),P(.0B%C..!YG_F;UL'GREU^[(UI.?H%2EZT-UQ$"S_`$%@
M(C*9*'Y`+Z9_3CZXX&-NG>#K"S&@3N6NW9.B5G%8/2(UG7%MJA5+21"$$LU(
M4NK1-DPLX0<X"+.<!SG']<<#[TO<_3;D-(2T::=J+LH7HC7-$0DZY-DB1JFP
MC)03W$@;C%$)!J4H:@H.<X'D7DT/C&<9\\#T4/;]#78].0T:!=LSA]R6B-+.
MSU]V^TI@@<1#"C&<ID&&@D@LS!><B&/(0%!^IF0XX'JE=K)2A8H0INN'M=-.
M3,XGW)ANFRMN2'-X2TYGHF7.T\;T9[OD*H&/QH1_DO;V#E/[%F8`%B?^2!_X
M?_R[_CZR_D_QS_D/_%G[:(_S![_MO]Q_L+]H?E/MO\C>W_T_\=][Z?DO[/S>
M/U\#9?`I"V9G5^Q[O*ZV(6UV!=#!K38FO>SY$LA##)P(*7F]MQ2+R.01PN81
ME.T'GOCXU1L*A7@2E2$LH:9"8G$0(I0!:%JFR!]@I=>[Q4U-*:]@]H)ZDL,^
MO)G;6`9JV*30J)NID:D5C?($96(0S/`25#ID81`PB+,R((L><9#C;_XY4G6B
M6C+UVC[!]0%5C5]!":<;*4U*CLNWS>GR3RZTK*NF72IBH.,2^/5>M+CDHLE[
M<CD:6G54=CK"WX)+(R40`0PZQ=`:,HS774VJ:SUOL#_*U/%D2>91BR"GF)O3
M?,U%DS&06!(7UCS`&QBKYFCJJ1R17AO:F%`@9VE&$M(E3EEDX#P(0[!UK9\@
M[N="9^VZ?0N:U'"];;Y')]RE4&?5\VJ*6*D$O:6>N4L\16&R1QF;'XJ0`P0C
M<6%W4FY=E@D7I@2L]($@NO\`S@%I=H)&?`3"NQN3&#)_IDL*K4G4)24/(?Z8
M^X+,P9C/_NP+S_KP+).`X#@.!QX=TZ=I4=SVG25XCEGNOWVNFL:QF>:OIV0W
M&KCSK!>TJE++.Q)DD:.3K89'9$V1$UJ_,FBR04M6IR<@,R=Z\#L/X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@5"]]:T*+J)WA&97,EM1.94P"UD1C,R70$X:#$HCY
MZY]?9,V/<?<"8=%DA(W)Y1%*/9W;4IS?DLT*H18@YS-?`.!/83U.F.T?B-BM
MIG\=EX;Y6[QT+,B'>Q)%76$N4UQK>2`V+MS"XL!9J1-A;%DK`X&(E:TM8>,C
M`Q`#3_5U'2T2C^,6]M+S7483N=@]GZXQV`1'G6+MT;<Y.E/9*7AHY4U?"YW6
MK4A$W.KR4F%+"TH5`,.@RBBP9#HGZ=FN,LVSO<TD8KR<[3>E6_;X]6/#<T.@
MIJ,578;DA>@.#=%WLJ=35SM(+Q&D;26M=U06WY53;DX"4/W(\Y#F(ATFUREU
M&18QI0WPW[(2CJ,V=E+*L(=J^<:7=*I4=D>QT5C<&F[:\0YRLI-9;S,)J6%"
MXM#XW(%:G"1.K+,P,SR'_1=X#@.`X#@.`X#@.`X$5]Z7I]C>DFXLBB[XY1B3
M,.J^PCU'9*S."II>(\^M=22Y<T/C2ZH32%K8Y-+@06H(4$C`:2:6$8!8%C&>
M!SI]`=V6U.]KI9%K+V!V%O)(^=2O65<C6FN*PGV1L<.EDSKX9MFC8&=S?GTM
MS73&1K2W$YY/^%Q$;D\@WY2_B,X$M-_KYN**=W74Y141M&]HI6]BQVR9#,X+
M7M@QQ@KB;GLXGP!P;#KI>C7/%H-I#:EP!6(K!.8^0(I<2/`OF&4%#INU&])'
M6%W>V6DV8WS367379?%H92;\JD4__?K'3&;W;DBF*5UG,;2*H,%UC4G7B=0)
M#`H"@IT)`DR5.$(%`=UE#A<@4=3(7ASDCV[AJFNPNKS,G)*\R]W<L1!GPN<Y
M4\(2B$3M)%ZG`C5RDD`"CU0QC`'`18QP(X=GAB0KK8[!AKE:=`D_X2;4@.6*
MS"RDY`3*,G1>!FF&C`6$.1#QCZYQYSGQP-LZ>_<?\2-6ONTIZ%7_`,<Z1^Z1
M*BS"E*-1_C.,?,E4%&@+-+/3F>0#"((18%C.,XQGZ<"1G`<!P*VNO%8L52_L
MC+6JU*T:'LEMM&0<J/,/&6C_`,':XJD:0O)HAY*3("%02"@8SZA++QC&,8^F
M`Q?J%>Y1)=:;7?)3:DXN(U3O'O<V,DOL%P?UKX3&XGM/9T+9XVF(D+](E#0P
MQDF.91H$:<XM(0E*!\1)?G..!)J['B0M^QNG*!F3V8L;G>4W$3)4\1MVL8/`
M26HBJ'09+E;%;2Y:1/KE:T#B(K\0EBI)Y[,[C*7+_1('.<ASFZK]B^RUV:$]
MMDL9^P&JWF9ZX.\U?ZF79AK-)=A]4ZB46A:0T>+LFSBQU[05ISEXK2'G@BYC
M.D4H6Q6F+^_5J31X2$A@EW[5;&2;3+IJE<:WGN*,(]E=OK0".XK'DIE33J[:
M4+F\S<J<IN["]3:XN0+!/Y+71"!,L<T+<6VLZU"H`ZEI3SQ92AV08_ICS_7_
M`.WS_P#OSX\\!P'`<"/<LU6H.<;%U1ME*:^2.NP5'Q*:P6KK$&\R1,KBT6L-
M.))+VHID1/*>,N875,8,&#5J)2>GP8/X1EY%G@8EOBPQV4Z3[:1N73R`5;%G
MW72XFF161:L703:M((RKX$^IG*5SR(N@@()'%&)(8)2N1F9\'IRQ!QYSG&.!
MRT:^XZ%M<J=IMF98=5>^6_C?#V>/2HWKVC%D!M:QL&)4Y4^ED+"R2N)-L;CL
M2KDT;@YI1.[=\B1&(DDC!QQ*;(=4VE:;5!'JS3*71LRO3=44\7-*ID=6+1.,
M(S'P/+IAR_%KC3U2Q2MQ)?OL.(E1@EWY/"C"K/W'R\"47`@KH^:!6OW0<#4J
M`MU5;T78G=EZ-`D1'NWX5@KR/L"AR-2E%#<5K=$6IN;\'G>QOPHRP>V0@#P)
MU<!P'`<#F)[$6.NK*[H:4JR?[%#UD*'I]JQ,F.7"6$)<67,&#M"@#]"*`0$"
M?612YN-MOL4RA"6`1V"!X+4")/`4,&`Z=N`X#@.`X#@.`X#@.`X#@.`X#@.`
MX%8G=`^PN+]5V\TFL"!1BT8O'J%DSXIKZ:%2HV)RMS:E"!?&VJ18A$P@,L+:
M#9*0C$<8@=T1Y0`Y'@0\!R4,*6M9WFEWK=WIS<L:S57'ELDZ%'2=861Q_N1-
MFL:]-CC48HJJM6=?8*^,.S`8;-UZ4LV0!='<E$H,$);\WP&<"+773=>O\L2?
MQF'9ETFJB,V#:\S[0"ZJ10"<WBRQ;7:-1B1RI/84OA[3);&F*:4.DM2M8%3B
MCDBAU`4H/._'"3>P<`"ZKITU+V+URV#[B+`O&!KX9$ME>PZQK0HQQ>7QE='>
M<UOESDN$$O`A:71U/:(^X)'-*%O`M^W5C``>!$%@`#(@H8JG<2(5]T_Z[]>Z
MNK)`Y6K9NH%O;2)+;1&QL,4C]<0?L;DZA@C#N:H5$R9>X/BE($2@A*7DI$>I
M)SX'@9IB<.\+@.`X#@.`X#@.`X#@0=[-)9((+UU[RRZ)R-NA\H8=3[[71Z5N
MS@-J01MZ#6<D+;'P]Q+0.F4F6M88`X`\IS0_(`/MCU\YP%%?1"=#WG=>_P!W
M;;ZL*[9VT=:'5@QSQ1-(*P*(\@&]T<GFK>OK6ZD$T6/<RCS^[/;HX*TJV/-@
M`J%A84QZA,C)SP)!]B,Y4H>\GILKZ/)WE#+WPBYWX#Z)JH@QA5P9MA\V*G[`
MA>I1'L7DE>S67P)4G87I.VG(S0B-1J3`#R$.?R/;-K7+K+[<MG)XAI:=HYMO
MIK:QS&'R55N,Y1%K@#W;ZF.X<E$A0VNV6%A(V-\FRX,Y<3=BPD%H/)C,28>2
M48'?-2$0;J^I:H8$SXQAHA%7P"(-6,.+P[XPW1J*-+,AQAVD(AR!TQ]LB#_W
M"X65A_\`O.SDP0N!#SMX)+/ZJ>R,LW'L#&C&U!GCSG'ZB:3FAQ>?./\`3!A>
M,_\`KP);:_'&*:&I)0=GV./J*MCC1>/'L8;#648\^,?3'D0L_3@;=X#@.!RK
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MAE*<:'0#V`[F.&E].()A"ZQ2WG;DNDK=&J\IO_)<*K1PD).#B3I?+3'&6+/R
M"R,U^Q&?>.(6AO=5_L:G*P0$)^3R@K.I;NEO:07A6L'O?4&N:SJ&=/BIAD]L
M1W:6+*UE2$'C3HH]-)E%[/B=5$N<*7OBHE&K&VKSW!'@[Y<)CA!`0<'0YP'`
M<#RGUB8Y2R/$9DS,U2*-R)K<&.01]];DCNR/K([)#4#JSO#4X$J$#FUN:%08
M2H3GEC).*&(`PY#G..!&\K1K2@A.0D)T_P!72DJ5J5L:8@N@*H`4G97!.G2K
MVDD`8GC!;:M3(RBSB,>"S0%`"+&<!QX#?\,A4-KF+,D&KV)1F!PJ,H2VR-P^
M&L+5%XM'VTH0AE-[)'V1*A:6I"6(8LA*()++QG.<XQ]>!DW`@EHX'!;CNN3C
MZA*WMNH0<Y_W9RKB]9.!GGQ]/TFJQ8Q__#C'^OG/`G;P'`<!P.13MK6/<?[M
M=;9;$H\U/,L:=7](B$;HLJ^/6J\P^/N_;;7D8G4CA[;(8E,`Q5_!!I,Y$"?$
MB<A>@3F"R0I(,SC(@ZZ^`X#@.`X#@.`X#@.`X#@.`X#@.`X%1'?2AE;KU"[S
MLL)A[Q/9%(*F0QQ-%8\TNS[('%)(IS$61V.8VED)4."YW:FE>>L3@"6,OY4^
M,FX^+`^!2_J?7EV,_81U&-4EJ>QV"-03^.RCAS^X2*`/+4K8IHI1$MSS`IPL
M&B*&R2IG-:6TL;4J+3'D*5&<!#G)OC@0VZSJGN2OG/\`BN1N;TS9T"70J4=L
MRU[<)C`YK'YC$6Z2JYPI01R8LBUJ;T\9B\S:'=$Y-ZQ;X$M#D(B@Y*\CR'>R
MJ.^W3*%&0B'\!!QWH#(<#'\18A^H<CS@.!"]?&//T\\#_GFP^..SYIOI?9Z7
M72Q7-@?>IG92KVG8<G#XJ@,/L"P^RN"YK"KWQ<F)Q#&V4E!"L1!$<<68JQ)"
MSO&24/N6'_0YX#@.`X#@.`X#@.`X%>G;;'%\MZM^Q./-@2!+W#2K9?[8*D0P
MDY,25#+5WC.2RCA^_JFSZ>`YS[^/Z?UX%*G0V]L#]O/MR>P&M3^O!UR]-SK8
M,F7IE14N;)Q(=/XZE*AK>X`<1(7N&%QF+HW,0S$WRI'1><669\8A8$'3:_4U
M4,IL6&6_)JLKJ16Q7"-U;Z^LU\A4<=;`@R!]3J$CTBB$P7-I\ACB5W2*S2E)
M:-02`\LT81XS@8L9#_GS5U1T[VCZ9^TRM*(C-G62NN7O8=2WB"TK5&)=.F2N
MD<_K1]7NK;7+@3!$F5+6W)2G`:5>ZM3>F+3DDJ53>7\WJ'_0Y@K><TPF'-2@
M!Y:ALBT>;SP*D"%J4@.1M*1,:!0UMBE:VMIX1EYP-.G..()%Y`6,0,8%D(!]
MQSHN9NJ#L;7MP2AJ0Z7[%),A/(PH+^U<JODC<OSDH7Z<Y"@5F9QG/T`+&!?7
MQP)M4NT(6"G:G86PX]0VLE:01H;SU1V%"D]"VQ9J1I#E!X0%A//,3DA$,>`X
MP(6<Y\8\\#9?`<!P.5N2.!S_`*5=C!3Y:$KJDQ1_($;8H9,X0T.3@]HDN=V]
M6(U'6(2&/R2'+0ML@;A(D*T\"T&0I5(SAA.%[%C"V;I]36(#2!A=+5DL3E,W
MDU[[<RET70B25E+HXC(?-J;B5M;.GD51)DL)<'%J:\DE.(2`_.E<L*$Y^`&E
M"*+#:U\*HR9NKH>T/"BD0/F0;,O4633:66:TW6H5H*O;4;EFD(M%D^*ZEB(E
MM<ABD^92?@*%!@DUO*&JS[E!R$ZWN3I-^F#N+D\WN^91]//G&OY%=Q4NF&O%
MA30=WN5K29'LFS&PBMII&;/K&+7ND1-T:31F3$-<P3APJ,825ZLXE,(-Q32T
MH#%J>_C3HY;LC#62JWYIMHJ736T(9$4EL3)C0FUI^SXI"FS8.JKO=X]%P3-$
M@9%+EE6B>E37E,,HT"@XHU,%@O\`(=@*V$+M<=R'E;4PJ_@HW;7]85)X799]
MGQN6W&[(3V)ZAD\KJ)6&2CC+^!D$A=4+LW-J<)Y*09#C\Q_VPPH.BS"HV4M&
M,:Q&H:1F-F7#+H]4-8)%+1=\UBS4RB6YD;M8UOU.BUR&3/(U%(8G&J<1.TB;
MD1RU%[+G%,0+`DX?]$[\29^W?P?W1?R_A?Q/WOV"7X?D^Q^S^Z_%^/LOC]OU
M_;^/B\?H_P!O`]K@.`X#@?D)00#`LC.)#@/G(LB,`'`<!_W9%G(L>/'CZ\#X
M1/3.'U]G9L#[C`6#V7I<>QA@L!++#Y-_4,8L^,8Q]<YX%>W7:A=&U=OTD=DP
M$AO_`)'-B5R,D&`A#EK>(]5[TV*?4)IV,#7HW$"@>?.,B&;D60ASGQ@+'.`X
M#@.!Q\]T[DX,O<!K$N;7%<T&J=>M'$BI8@6*&\:AO_\`-#K&0K2*5"8TG)R'
M);CD!I8\Y*S@[P+'Z\>0[!N`X#@.`X#@.`X#@.`X#@.`X#@.`X%?W:7KU?&U
M.A6PM#:RSU=6MY3QBBY4!EK=-76N5*5:PS^)R=U;/WPQH'1VC)<A8&56WB5$
MISL@PJ_4`0,B#D*H:NZW>R6.WMUYKIG=K@=3]6]5\PT^VB01Z_YH8RH+T,@<
MTCT=LV%,JYK2.4FGCDZOC2-3*E*<Q03AL&(LHOT3A&&-:G=;W:MKVOZ;6*:;
M"O\`,8EJ[:&[:W>!`S['SE_CEBQ2T7"3NFOCX^@E2*+NER',")V^QPF7H/+,
M8,O)!(2_D-+#I]5`$8F4`#CR(9!H`X\XQY$(L6,8\Y\8QYSG@<ENL@@A_BN4
MV+/T"@+C65?T_P#E89^Q,G\A],?[_@^S,_V^?;U_3Y\XX'6SP'`<!P'`<!P'
M`<!P((]H*5S7]=.[3>S0^S+"<G+6>WFU+`Z;<U+-9\R$XPYT1#C$,<T49F:Q
M([OA1XDV!%-+B9DLP6`IS19P#(>5H!JI1=,U;7]UP?67.MET7-K3JS$[AC3X
M^NLDL)I;*9J1HB==UO8+XM"@2ODGJI@.$S*G`+>B5+3$^1*`Y$``0!8`8`)I
M8RQ^WJ8`0!>HQEB]1XR'/J86((P"\9^F0YQG'^F>!S6_QA)I&9;J-M`CCE=T
MC`!P[>"YXD\*ZCL.;V?(+%<6I#%RQ67;TRGDBD3I*)S)@Y\%/!.4*5X:DZ94
M!$1D8O<.E7@5R]OS?^5ZK^PUMR9DH"W3O8!.8;C'L(LDRMI!@X8`Y^@C`%><
MAQG.,9%XQG.,?7@3O@;<4SP>&-"<XU00UQ2.MQ*@X`"SCRD+0C3%G&EEY$`L
MTT!6!""'.<8SGQC@97P'`<#GIHW49YV@U7WAAZ><LT(_??=M;>Q)3FL:%KV4
MT,>K^\=;/3U'5A!2ILRH<I67KJL"G/+'@I+AS)R,)F2C,""1'0@>!9U?TJY)
MYA&ILWOED;3R5I=(BN<W1A0-,JVJN>2H(VF<G5CCQZY5&2';"%486GRFRK(,
MP0:<5@!HPG+:*N1!VCU=1M[]<R"-X8;Y=).R0V2TJW4\]Y11B-(V<5S1F6F?
MYODREM5.@S8X*'%B0HE_R#>1!*$EP(..J%RQ@G_5;WB`IZ4PV>U+A\HZ,ULH
MJS2.<ZWR1BLEYM-U=)7<4H;G9XF5HV$,IXD;0_`G+E*7QU9R&@YP$S(@)P(%
MH;GL=;;:_4_H3=HC=6WS8\TXW2>X["D3[I<W;<6(Z1-FGE;U4;9=B+)L_L;N
MP0I,MG)3>T?9$N$@<&&0HW7#:$3<(28.TER;&UZ0*FMX;T+LV+2LDK&YR2)U
MR!63G.!9*5(U19J=05D0<9]1ASCSC@8@P575\3?391%JW@4:DRAL_"GR)@A\
M>9GTYF^4E1^)-=VYN3.!C9\Z8L?P9,R5[EASZ^0XS@,]X'Y'D$JB#DR@H!R=
M0480>28'`RS2309+-*,#GZ"`8`6<9QG^N,\""X^L7K_-7EN1NIU.F*BBU1>,
M&1SW2#"L,3FGY/;A*<MZDS(TP?01A0A%X]L`R'`QX$&$NO4#UH/33ED<M.JD
M/;_OU;EC!:1[2K0+%QI!JD93HD>B'0DH0DX<!*`=@HL'L$`0A$+&0P=;T==3
M[B!$!;I/5I_X\)X4YHE\X"HR%0J,6#"J5`EH5*[`3C<X+P>,SXB_!8/4O&`X
M#Y5'13U%*U>5JC0RCC%`AB,'G+?(,$FC'ZY%DY,%_"F/\Y#_`.\`OZY_ZY\A
M\#AT+=/KCYR;H/2"4ST-"6>T)I0PJDPS1I3,*D2MCDC>I0+TQB,`DZDD9:A,
M+VR4,&1CR(,WCW3EU\1%J7LL3JBS(JVNDB=):YD1G;';Z/"<9&]?#AT=UZAG
MOA$I6+%A:8H`Q&#%Y`26'^A8,8#SGOIET*?3@J%,:V.2&APGQD35OCO:U_+A
M/E1D.#L(MD"L'?+A1ZF9%YR,)9>,Y\`#C`8VZ]'/76[%K"S81L(EPM($2+*'
M>?>,C!.<DX*P<02+8DQ.$\.0_)Y$`6,F?JSC.<YX&"QOH1T?AQ[XMB<\WGC3
MD]D+&\3HP[^;8M#@WL+AZY71I&H;[13Y4,BS)1?R@685FC^('DS/C/D,U4]/
M%?`1)6^.;W=LD-2I,&!`6P]BE]+LF`&JRJ`$T<O=I0/P3Y^,&0Y#GX_IG.<_
M7@8A"^D^OH#=QNQK+O;V//\`<W^.'>I$,VMJ]:VOI<RUT\S&.S\^*L:>\*/L
M%&U($TNBZ->2,DL*DM42$W!OOCSD-C.W7GMFM"4!O[D-\VL`4QP#<?X_T:5#
M.6Y5*C4RKY<:GIC2B"4QA10R0BQ\OQ9'[!R/.,!@:SK2WB4*\#)[O=X2$(1%
M>J?-1:<?=_'ZY^Y"):EH=$2,9H_&2Q9(_M8QG&<#\^<!^!G5_N.<88:9W<=@
M.,B&+UP3#-2DP`E8%G!0,E$4*`K)@2_&!B"$.!BQD7C'GQ@,*3=6G8JSK9*?
M'^^/<`M([MXD#0GE-!:TS)0S9RKPLPI..<XN2B5*,&)R`9,2)6T[X?F+P/`3
MO``R(?7QVO"4X,#WQ6T6F*&J&02#0G37)PL*U`5`@+#C8^82I`1G&0$^I)62
MR\^N,^/ZAZB72_N03(7U(9W71A<>J/`!A<UW6A0F5S6A`:<=D2D#?9;:VK'0
MWV`4(T2?*?X@Y]2`F"P,(9:X4!W2A^Z_%=C^FYH<%&?8X<.NV5D&&&X%@).%
M9R;<)065[E_48P%"Q@?]"\A^G`UZYZ_=]^48L-78OHL-;\A.`A4:+3!`5\63
M0X4"RI_SP\^HP$^<A#]OG`Q8P'V!Y]L!\#+7?\BI@1#3*-E>I^>*$Z\W"9=*
M=?-EV)8Y-HR#Q%FN(H?9S<WH%12HX(,$D)#`_$2$0CA"$/&0_),3_)*;U0C5
M2WI7DR/"@`\)"D^[$:/,38P(D9(5&<O@2#!9S@[WS@WUS^CU%CZY#^T\S_D<
MD)?"ZC.GUQ6%X,"(YNNW;=N(5".5)RDQA2196:X24M&G&88>$2@P1N`^`>HO
M`1A_([D_D,(`(@GZ3]:[Z:`)B1P-9=L[C;2E"H2@8RG9(4\U+@Q"U%I2_C$G
M&)2I&8,(\""'`B\!L%AV;[HPL;4"2=5VMJJ1EIB2'Q4T]C3>TM"M?[9P>N:6
MQ1K;(5:!L$'.!8).6J3P9QG'L9],Y#S7?:[NM19]F[J(U^=P#6*DP`)>S.,D
MFDD$EI1D+U'Y+6EM+RE5C4#"`)>1'XR0/W+!C)>3`QU-M/WM&&Y"?U-ZMDEB
M/5C"8/L8;`A+3"-]D)!F2:'5F#4$$8]#3,`P$X>?;`"L?IX'U$[&=\2P@?KU
MGZ6M"@G!(<B=-_'M86K$<:``S$Q+5K^=DHM*#`A&!--"+(18]/86,AR&5F7+
MWGC<34I.BW7P2D`8@++<3]Z+=/2'!5@.$H4%X*U.)<?A;!$X"?@:4!@LF@^$
M)V,#R$/W7V1WMD"1EI=4>L=7]ZI+3F*$VXFQQA;,49G'EP<25VIS28L2I\9_
M6!+DPX7C](>!\3I/>_`@M1ELUMZL%AI"PD@K&=HMG?"Y*8E^8U:0$_6]#]N6
MG4"P3D)HL&"$'(@AR#P+(:_'+_Y(`W4UP3TMT]IV!08,!$877'ML>_MH2$*(
MO"@Z6(Z[*:G$I>X"/-"6%K*&27C!8A"SX'D/;)M+^08T%'C>-1NL"8B4K0)D
M),0VLV`C1C6FQDL!JYTS*:+6E.28S[CV#]N(D\`2#,9*%D1?D*RX!J=W.0'K
M#A'6LET;U54Q]H3EHW6TD^\:_#U\J*^"[O=G7,.7468A39D[H<H(1$%/*L*0
ML>!&^F`8)R%N$NW([6(ZH$2R]-7[Y)`827]Y'>PW71"08$XH)F322I7%(XLR
M6G'G)9ON46+WQ^C`P9]N!@YF\G<,,\)B;HR<\)ROF+R4I[*M3$^5`O8`<'#"
M%@5F``7\8LE^I@?<(_(L?TQ@/,+WZ[ADRE(8[]#\@RU&KDJ96*.]CNJST])D
MZM,<IPK);5[0P(%`4F2\%GX$M)P$T6,!R+'ZL!G#_P!@'8TVHA'-'2#LF[K,
MYS@M*?MII`B(S_0(<F*4%QO9Y?DT8?/@@6,`]A?^WQD/=>^Q'<%F/4$_^&/>
MMQ+3&G$C4MEF:.N!)PB3RR!&),(-I%9JA.9DX(@#]0^X/86,>H!YP&%F=GFY
MGS&%$=(V_1F`B,"6,Z=ZC)\#^/`LYR(6+Z.)!C.0Y\9P,>!?3USGSC@9;'>Q
M#=!S;7U>]]+V[;,<T&-Y:9`EMO21P5.N%AAI9XD87+9./"-PB]`B'DK!P?07
MG.<>/&0^)1V5;;E$J#RNEKL%-`C-.)4!%,=+`G9&2:G(SE$F(V@5*'$H1BD.
M0C)",`P8$,.1!`/(0\E3V9;G$B!DKI*WU-),2"6@&*Q-.@F_"7D83`&DI]A%
M?PJ_)>?0@0L'F8\9P#QG'D/@5]E^^*8:@H'1UNH<<3\F`>+KT\&09D&,B#_W
M*2Z5A60BQ_J7\OU^F/.>!ZJCMPL!`>0D<>H+MW+4_9(W!QRVZ_TJ^H4*10J*
M1*,DN+3L<I2NBM&>;YRC3Y&N$3C)N",%XR+`;2C_`&D11T1&+7_2/L\@F"30
M)C4LBT0N-Y687&!$<%(617**=_<@PCP$X2LG)B`/O@G)^%(3"0!^;GVNU$TE
MKCE>K795]NWEA.4G$]<VV9V,%"$0``RR@5IE2;[#4@QZA!D6/;SG&,8SG`5Z
M:#;#:WZ%(+KC::&=KTEB^Q5_OMKPE!;/65L,V*HP^N[%&H^]0"-)*>HEM:5"
M7"YF$M+4&LS6$PHSP(:@TLQ0:$YU'<SJN2:8G*J'L(6'D&&%*24O6IO/DQ,8
M6+(!!.P?1!&,9]\9Q],B^N,\"'^]_:AKW>FFNS=(1FA.Q)5(+II*SZGB/W/7
M;N`PH':7S*).T?:F(+N]U(A2H5*IR6`)$,SZ%><B\"]<XX$ZV/MGTN`C,;\_
M\JF<ME5"CR4I\T&WK3*G,UJ3I2S<MA0-<S3EY90C0E9'@(?8[`@XQGQP/J<N
MW+2YJ1'N*P[:<"-+@`E)W_C]WX"!.68:`@!IHS=:BP!+R<:`'GS_`+A8QP--
MNO?GUH,KD:SK[!V!)=4Z0E<J;A:-[N%K4:-266<G4*TAVOA2A.2>2<`8!"#@
M(@BQG&?KP/Z+[YNO)0K^Q1N.UR]5DE,I`0BT#W@/--3+$`W1&I+)#0&#A$*V
MTH2@H?KC`R`Y,QY!C.>!HOKS["M8814UT-,]<KQ@KG8>YFZ%JQ&/OFJFUC=+
MU%=7+LK,9G7D@/:T],*%K<?(&&=-JDDL6`GDA6D!,``S.0X#&^K/;W6S1G0J
MDM:+PN6>3"P*TD=VLCI*(MK-NW,FQX$^W;8MALA1K^[ZZ-SPX2!-#I>W_D_G
M3EB`N^8.,C"'`Q!M2UNT70AUV"HNVS[U7L4>IAIMZ-RYKDO6]MC*;(7.-JQN
M+E1TFO+G6482]TR6B)9#5+RB1$*/W(E&F+/^,"8`A!2C2:S0VC=,MQM/#>XS
ML%E#WMV]Q%?";H%I3O@V6/3F88J(-0,,`,'6;FZ2%HD,89$30Z)$SBW%JVM.
M:61]L`W^V&^K*NWIZD\4T.C=G[J=DZ]XT'3$J*L?5.NN]('Z<68CEU82X5A6
M@*3ZY/3C.SV\4"_%D-:]0I0)&=Z.38!D6"#0!<'$^^3K3F;KEG9;*O02WW)3
MEA4Z3;KE!4+E*D"5.V)_37TTPUR.-'CT)P'W%CSX\^.!N,7;#I@<'(2U6SJP
MDS&0X,3:`;[JDQX18]<X+-+UH&4:'/G.,^,YQ_IP)W?NV/\`^-_WS^'DO[6_
M9/[J_`?L:4_N_P#`?@_RWXC_`!M^%_>O[C_'_P!G\)^._*?<_P#;?;_/_;X&
M<<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<#Y5R<Q6B6)"EBIN-5)5"<IP18396H3#BAE@6),+4RQ'E4E$+`R_E)-*]PX
M]@"#Y#D/[2DC3IDZ<Q2>L,((*)&K4X(PI5#*+"`2E1A,2F38//$'V'\998/;
M.?4(<>,8#]^`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
:.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g575431exm_pg078.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431exm_pg078.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"7@'Y`P$1``(1`0,1`?_$`(4``0`"`P$!`0$!`0``
M```````("08'"@4$`P(!"P$!`````````````````````!````8"`@(!`P,#
M`P,"!``/`@,$!08'`0@`"1$2$R$4%2(6"C$C%T$R&%$D&6%"<5(S)9$T)AJA
MDD,HL<%B4T0U)Q$!`````````````````````/_:``P#`0`"$0,1`#\`[^.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!6]<?9
M%!ZDWZHGK]_QA+9%8%SPUOGZN>*)G4T$AD4B[V[3)A91M#?8$YCLSM9]&[01
M<%:VQ9M<U2`D1!@PBR;@`0LAX#@.!C1R'`IBVN?W*8(BHT]H<(Q#\+#L*'2/
MJ,J2B_EQ[)DV4V`C%Z9]1F@Q[8\^!!DO`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<#DY[%[#I-I_DE=4J-64@/NIDKA!$/@>']4S)#8U;;W>)+"XIFIT
MHFP&1^.C"V-KP$&(9+&W'#L]H2,&_")0,L.L;@.`X&**UR,N<,#<-,4)>LBL
MM6IU>2CLG%)&YVA1*M,6<'/VX"E!SH2,818]Q9*#D.?`1^0RO@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.!2OM6T]I4>[4-,;!I5=&)1UM/B%MKW8Z&M
M,`KB06'$Y:OQ8IH)D]N;RQE641"@KSX]DEP9GD"9F,`J,5(AEF"R>%U'`<!P
M//,;P&NB-URI5A,1(')O"D`:$*$\#FH:E!BA21\>1&*DPFD(218%C``&FXSC
M/MC.`]#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!S=WW8=V2/\`DQZ4
MTQ#K.DD:J&N])K"N.V(&US^R&F+V*&7ANF#1=GD=?IY6Z5A)'>+2%H(=TBDU
ME:7`)`Q9,5+/M4190=(G`<!P,?6.QR:2L3*$).2'1KD"TT0BS\GA,:3F(LG!
M1H/^V`6(+H/WP/\`4+.`^GTP+@9!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`Y]9#J2D4=^;#M'_P"22LHQ)3JUBH"^N!')%+;8=DP:+TQ:4+*FLECB
M"WV97(L163S1>^-(SXPY-Z=,)2+(`&A^YR'05P'`<#"7<?K.H6'^[_<:IB#'
MH;ZE><8CQG]TKXA?)GP#/KGW#ZY\_07GZ!FW`<!P'`<!P'`<!P'`<!P'`\*0
MRB,Q%"4Z2N1,48;#UZ%K)<9"[M[*A.<W-0%(VMQ2MR4)DYB]P5#"403@63#3
M,X"'&<Y\<#&$]OU,K4.:1+:%=J53(E"M>4R>;1HY0T(AG!3@5N9);F(Q`E$H
M&$&##<`!D><!\^<^.!DJ:5Q=8C<7%))&!4WM"Q2W.RY,\-QZ-L<$9A92M"XJ
M2E`B$2Q*::$)A1@@C`(6,"QC.<<#W^`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M!$^]]WM:-<'N00^S;!/_`,B1RI3[R6U7!XA-+.M-35Y4S:J[3RIMKZNX])I.
MO1.<Y>2&M'Z)_94I^7X\"`F4C)#T*`V[J/9";WS6T$)GS)/=;Y@R0^T(E9%>
MRFNGQ%F5-!SU$90S()0WH#GR%2U&B5_CG(C&25(T)^,8Q@.,B"4'`<!P'`<!
MP'`^%>Z-C64$YS<4+<2,TH@!J]6G1E"//R/!)(3%!A8!&G9+%ZAQGR+QGQ_3
M@12LGL!T1IQP3-%L[H:JUL[+"6I2E:IQL#5,8=#TCX8>4SKBV]XE:19EO<C$
MQF"5'I\(_C%G`O`<^`AZ\=]O48VN+TSM6Z4%L-W84J=8N;*;B-J7:J,3JDXU
M)1K=FI8',R'4LL(/4\:89I:4S.`'B+'G&,A];+W$53-S"!U/IOV<VTTJQ$_9
M2:,:'7+%XNM3B"08K6)WNVT5:HQ$-Y)^!C"+(33_`/:F`>/.`Y#)C=[-QI6-
MD5U!U&[7.D==25.5#U>%Q:B4"N:E2<0_0M;#UEX3N9EI5``?H-&@+'D8@X^/
MU]AA#Y%UX=PDG(9,PS0+46M1O48<7!8.Y-[93(54/D(%'Q-C)(6NJ-77I&YG
MFIQA--PUN2M)C(#`868S@L1@8Q*&;OEDK,(F-3KJGJES6-N"#30P;:RUE;0X
M'9+,-6-CHXRJOFM4)$$(BB@J6@PLW(OE&''C!7`\!RAG\@(LD!K5>O5(N5Y%
M)?=*MHO:-E0`+=VQ&ECN0GE6Q(E9ID/<R#5>/H##E@_))N"P@"+`>B9G^0`F
M6G#()Z@'=$L///+3J7#<IC,8B`,AR%*W@4$LSYE_^9^"4Y&*!`19"0(Q`$OS
MZ+PA_>9#W[-B4U6HJWJ3EAZ4$7S^&9KAVZBISKE.F7%33[5V>*C?4K:8\+"T
MYS6`X@T+:48(D\Q<(/S\#0,2[".V]?!Z"GJG171J=(+KFK36#8P0C?M[C,J=
MY:G2SIVDKTS)YC02B.H6<^-05>Z)VC+FX/J!,WJ`'E'G8$`D),2/8KN,B1[&
MWD=:6M5K&+(RS.SV_P!>[_`C+&SR%8^&9>8F%#96N["^K3F:,X#ZK2RA)5+A
MGP'(2<Y$$,?-W![@D7WA)_3?$'<_)$A-;5+!V-TD%NR=@U*;$D;H)^KEF<$_
MRHS32G,XA.HP2I)QE.`XH>!!#YL;U]K.%:PL?1U/\HP$/?V"HO?[3H1BA:C;
M2_PQ2Q,8]E"1HG9_+/)-/+RH,3-_PJ@$GG&#1DAXE/\`9YNO?%-Q2[JTZA;N
M6QB;2M''8VV2'9;7>,R-<SKT+VC!89K>L=32&^!M,X8Q-[B<I.)<"VY00YI$
M:TDS)00BLW;(;B_^359<<IZ<K);W9KTPE[(2S1*V]%Y;;SJ_L-EMB%+/,2M?
M840>2XD\>BJ.-`3'D1REO'E66@``:@DH)E9[5[U2/3:U.W3AVA)4[@J(2B<F
MV$Z[R!,E&%A4+'/)YC3L*>C3EHY$`M`2:>>0F5DF95%FXP#XA!];;VT3I6`D
MU;U(=MK86;AO$+!NOE1J#BP'-*YP=#!$$;`Y,Q^'6)`),@SC!JHT\&4X#`^<
MX#T&KMH<G2.2&4BZO>VEI;HJ@C3D\H7O4YC020Q*^OIC"XXCD8#:Q[W-%L4,
M,2JEZ1G)7*Q(%.5"<L\M,LR0'@OO;(UL9J>9SS1#L]KAB@39&A3Q,XZH&242
M!RMIW;V6),J5%7TSF3C.'%J0E#=704<+=4[,GQA,L,*<C"T`@\U=WT:1LK>:
MX2>`;U1+!)2S)B:3=?VVS8=A6G<BD*1LP<*JC$&7!W3&96IP_-Z82EB^81)V
M,$Y#(%?>WUUHT3LX&RO8D:-HS*AF*2=)]Q34ZM'%4R54-U1J@T=]H)G?B57E
ML5&#*)5Y*-_4'XQ<#ZF7O=ZPGY<Q-J*\K!*5RAW3,D9+<M5=MFK$A<5;6N<D
MY#&)QHU-AU&:>V'H`!(^08W4O[,(<GB"`0;"A'<AUUV+,&:`P^\Y$Z2Q_DBN
M'M;4;K_LDTB/E#2R+)')F(Y4\U"WHD*^#,B$2B1!4&%!CH3"L.64HC2\"#&4
M7>?U(.!"90FWNI+U5A;QEEJ%DC1*BL.:D:1+A:B61].L;AA.+S\P5`"A)@?K
M.P`&<"X$1-\>U;KUV"UQ8X50?95K+')6\[#:HR%>O2;"QFN7P595_M]5+E<!
M9*UW=&0\"8^#QAWP8F.$22YMOMG&3$AX1F!80;V[]6!(%0Q]BNEGHA(^Y5B!
MLE4QH2$_YXJ,_./)4I'CXL/1X2LBQYQ@.<F__2QD>`]@':QUF#!(3<;_`&GN
M"HF)Q#)3C-AJM*)9/Q:PA`JRX&F28!:<!BM46%.+.?59@6!$9,#]>!L+'8#H
MA^=6Q<>Z>J!,F;5+DC<8XIV&J5*_H%;*S%R)Y3+693+2G%*>SL)H5BL(R@Y3
M)_(S/4.,YP&1D;HZ=*CDB=+MCK0I/7FMJ="01>U6G'+3WEO.=F@E(67*A#4F
MNK4G,4I@@P+)Z<`C`8$#&<X#9C'=%.R=*B71JV*TD*)RPWB;EC'.XL[)7`+L
MLRW-0D2A`ZJ"E6'-PQ\"?)>1?,=^@'D7TX&8&2:-DX.$=(&0H*8(!J!&.R`&
M"`&+<-A8CLB48P4$;EG[?&1>,9/_`+?^[Z<#TR5:51D04ZE.>(`SRAA).+-R
M$Q*;\"DL6`"%D(TY^/0S&?J`?TSXSP(:;A5-%[H>=387/:X<;5K_`!LZAD$O
MB*A'6CW78R(S2=UOD>>;9BEC%*3)3$H_,D+:L0D,A)SLEDA38L]<)$RH80]N
M0Z!:,2MPE#M(].=8'ETF\6.A$S<5U%5F:MED04.T??CHW)%7[:P<]LPWJ*-B
MKX%.3"\'H$X\8\E`S@*])UKGI]8.Z%.:34]KWKZNIRK<W)MWN]7$9K6+#KIO
MF\^A)554)&[18VIKQ$S9Y9KG*WN4(FIQ`-3E-#@N>2`^$2@07@@``L`"RP!+
M++"$```#@(``#C`0@`$.,!"$(<>,8Q],8X']<!P'`<!P'`<!P'`<!P'`<!P'
M`<!P'`@GM-05JJK#@.W&JXXOC9FI(V[P-T@4W<1QVOMEJ,D#JB?7^DYS+$+.
M].T+?&9]1!>X7(RDRLMC??F*5)CVYS<"\A798G9\]4GM=&97-M'.T@@$XHN1
MUQ8]20C553:,5CEK5H_-LT@2Z'S:KV.41*WW>>M$WD+84Z-\XPRM:1E+$H2I
MS%9IA0;62=Q4QD9;J;`^HSMVD934JR`P<@UCAM696MJAA+<FIV:R;/MZ+*7(
MM>[B$B&G)+&K2!*$><6`(R0G!\+)V/=ELS-%B']%^Q*%(I&PY:E]J[8:JU>6
M,G[')TVR]H%4F?GAC4-#B`2=E!A,J"]EY"<<)MQG)>`\C_DIW\31(63%^LG3
M6EG)2@)0Y771O,JG[6UOH9&0H4/QZ&GZR&N=(P=#\#2@2%FIUY3H/*G(S$Y.
M$JD)56;7':S*8RD4UAM'IY4\P/D<V)7,[IJ[8EDQUM@DC=V\<+,22!7?<;<'
M.QJQ8`*2C%0VU.S2-:,!IJ!"5CXN!H?8BG>T.)([OND_M4A-7T?7,.L&QVJ'
M5]H#6+]-$$;BL,7.V4#W+;(L^8('D]M`U&+/=.V)!*E0\AS@M/ZD!#SJHTOV
MOV#I*GK-G7<!O6F66#7D)L7)=80#3.G$@,3.O48@)#6UEUVE"LL)2!\&:,H3
MFJ*"Y8`J*R$TDD0`R=QZ;X7)UHU%@]@7;#8*(]0F6K6%TWKG4/85JY"UDM#>
MK$@J5EKG*`:1,3[Y+1C3$*%`A'J`''9]^!]Y/1#U5*#&U5,=6$MMN;8@RVA=
M[QMF\;K<'!.#+IA`-Z,L^RY20]K&,EY4DMBA46:>V$&?&E&2'&,<"5#!UR=?
ML7=&1\8=(]3V]]C<=9(FPOP-?JL.?6J.1MK;V1A:$;RIBYSF6D:FAJ3)R<?+
M[`*)"'SXQP);M4>C[%\GX1C9V;Y@%EG?BFQ$W?*`GV^(!GVA!/N`KVSZXSYP
M'SGQP/8X#@.`X#@.!\#HO3M38XN:M2G1I6Y`L7J5BO.0I4B=&G,4'*5(L"#G
M"<@LO(AY\X_3C/UX'$CT*Q^EH^_5+(:_G=G3!_M[LK=Y/+"K:J]96RE]D(NK
M_9"PU%B11$\%*7I9%9XLL-4^LY:E8<4C;CTQJ?(C%2@TT.WW@.`X%+E<]6VT
M],PN.5747;YMQ!ZG@9)S-7L+Q26E\F51J(A4FFM<>62V4T`[R.2G-9!OQA7+
M#A*#?'L/SG@?+J]75Y5#VG3Z"75M-.]KU`^O&NW]AE]@US3]>/,9(-V.L)I5
M,X"*:A<(9'8#K^-*4&'K4QBK)I8O0>"_T!"ZW@.`X'Y#/)+,)),.*`:HR,)!
M0S`!,/$6#)A@20"S@1F0%AR+.`XSX#CSGZ<#]>`X#@.!^):=.3D622"2LC^H
M\EE`!D?]?]V0AQ[?US_7_KP*?>[2VF[4[K[L38.)U=`II-(-96NB:/1.1QEA
M.8YH"5;$U7'9#7TC7*VI8)LB=B1M:J9G8P`<"&A5C+SG&!><!"_KP<Y?L7MP
MEBFX.I6GM<R&":C6&2T5S5520M[KQL"P;.&54:Z5[+G,^6*'J.GI(>8B/,3C
M0)#!%@)^S+&G'D0=`BRBJ1<,/H5].56N#*#XHIDP5E>Q)3B1*8($D$'4/N#F
M@>'<^&A3%X:AJ/D$W8+#]ODOUQX#")5I_J5.WI9))OJYKI,I$XKEKFX/\JI*
MM)"]+G)R(,3.+@L=7>,K%RI<O3'#+.-&8(PT`LA%G.,YQP-:.G6OUU/8<!=]
M!]+G/&,EBQ][J[2"G.,E?-\7U-@XL_V\J#,A_P"F1B\?USP,;D'55UF2=O*:
MWCK^TX,1)TIZ),6AURJ=F,2ISP@"(*52S15O5)3"LEA$486,)A!F/<L01_JX
M'GL'4UUHQ<V"G,.CFMC>96TD<Y=#,@J^.G8:I$[FH%2UR/`I2G`>19<&M,L*
M+784DIEZ<M42`M2`)N`\";=/W6W8*:-)9)JQ$0E1)!*6UF%&Y19$'4Y1S>:*
M+&EI;RLA,TCRN3#D$Z5&.JDQS&K,,6YP9[><!\!"^Q^K+3N$[PZ,M=61FW:O
M5E1_;Z>#=X+M%LVPN[48AB%=Q5<MC;EFVU9L?<G/_)/VBO*#"4Q:W&#).&,D
MH!7`G#CK1K$;Q^54[+=B*U/^0_(88E'83MD%D^BC!^$64Z:T$ZL2#`?)?QY/
MSY+SG&<^?KP)=4I0E.ZZ0\R!TG7[!7T95/+E)79.T%*#W.2REY&`QYETQD;F
MH7R2:2]Y&4#*QV=E:QQ5>@?E.'ZA\!M[@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.!'K;9NN=VU:V+;M<W54R7^KI*SBJ4=$.&K[Y':G[->!0,:/+[@3(%6.3
M!3!+$LQE*$8L9-_MX%P-R1%8[.$4C#@_MJMG?5T>95CTT+S$1JYJ=E+:F.<F
MU::VFGMQBM"L&,HP2<8R,C#G(!9#XSP,AX#@.!&O<RWVW7W4/:2]7B,-4W:Z
M<UYN6SET+?2?N&.7IH/7DADAD6>B/@58-:)!AN^T4A^(WR0<+]`O]N0V'1[K
M^<I:H'O]O,<1_,5=`'7]IQ@C*6-QC\A$VE7^WH\F$G2"3L;+\WVR0O)160)R
M@8]`^/&`VCP/)>7]BCB(QQD+TTL3>4`TPU>\N*-K1%ED%#//&8J7'$$``206
M(8\Y%C`0!SG/TQG@0&M'MNZPZ7=#V.RM]M58X^)%)R1:R!NB$O;R@5$)RU1J
M=>U1YU=G!":$DX.<!.+!G(A8#CR+Z<"%TO\`Y,/2C$BR_7=%KERL\]0E(;8%
M4EY2Y><I3EEF!*+*:ZU,+SA5DS`23/?!(Q8SCW^F>!IHS^3UI9+37Q'KKK%V
M+[5KV,9&3BZ/U(D;JE,1J4V3R70P<@?&!Q;F\0Q`!Y5)"319,P()8@_7@>NS
M]T._]K,9\AU\Z#MXY$TGH$![*MO.?5KK><O4JQ#"?@QGFJ-Q<<-Q&23,@/(P
M?DS&`9&`G!@<\#TF?;[^1%;<<=UL(ZHM4]=%ZTX]/&CMCMQ03-0UA*<P$?>O
MT6JEC2+G(H:'`Q!"!6@SG/@S'MCP48'YL[C_`"F7LS`5[!TK0DLL\)8S7)7M
MP_9/*&F5G94EE,KD?D`"3TY9.0BS@0LJ,"Q^D`N!G6(;_)8.8G52JNSIU0R$
M@`S6=H:*BVR<&YQ&$GW"E6/CK,T1K7@9V<@P(*%5XQC`LYQYSC`:5=:R_E33
MZLS\AV4ZJ*/GCE]BI)31*M[;D3RP`+.2*5"'#Y,8S8\+&H4%A,3GXRTN!>`9
MSDD\(LA-`$(Y+%_YBD'8Y$WR6P-#+JBZV//32_NBO_%L9;6]G<&\XQSD)ZS]
MITPL2!:$)AA61Y#D``@R,1)GC!N0B#JCM%W8VU%=!&^E-;^NJW4.F*U37=(1
MA':,]KV:/\FB>H^*_P`AFK?8-A1]4:H0:ZVRDDA0RRDR96C7)E)`C`'$%C"Y
M$>[G\E=A1M[:\=,VMDN?<'HU3C(H=N77[3&5#>)3DI6UI6-[G#@[MSL,LO(@
MJ#%BD@D(PBR49XR'@:F>^Z7N]KP@>;"_CN7([F$N*G!YU8W<HG!06Q-A.(P)
M1$*JN=C4*@A-SZ'!,^`_QGT#^@>,!N/3?^2]K)=ER!URW)I*VNM6\WMU:V>`
M1G99*[I(M.')<H&SJVP$U<(=#B(DXI)*G.1%Y>4B)"J%@&`*ON!"3`#HOEDL
MC$#B\AFTVD#-$X?$F9RD4GD\A<4K0Q1]A9TAJ]U>'AT7&DHV]N;T1`S3CC1A
M`6`.<YSC&.!5)HW.)3MSM]?>_P#%Z^DT(U1GFN=&:\:Z26Q6X^+3B]4U8V3>
M5@RFZV6!+`8>XU43Z?::=)&U+N%(XO2=*->!*6C.3C,"T^=SR$5=#)-8MDRZ
M-P*`PMF72*73.8/3?'8Q&6%L)$H<'A\?'50E;FQN1D`R(PTXP``X_P!>!5A_
MY>(]89:AQU(T=W[W(AF,MIK1;E7TDPUK2TP;EQ9QICI`K"V1GM+%3QL3EE!R
M!6T)%B%3@TL1*@98ODP&U@;V7ZVP1IEDKZL=[T#TM)#EQAL4==-ITZM2DTTW
M!!.1-FV",Y60)/@L9AN"`?"(>0##C(!9X&E7OM<M]J.08!TZ=K;@4<H5DGFI
M*LUR6#3?;IC3<C`!NV;7^`&^N,!,,R46/_:#(S,A!D)"N/8K$VM!AP4:G=A9
MP<"3EG)6[2BZ79>08H+P8$.4;6R+#5`2LY]3#"/E*+%_N%C'UX&OG7M9@S4%
M6(>E/:&L^S3)UA@6_K]OM28-(J4C2$&DE_@@#-,R<6+V(QC[DL&/<980?JX&
MN7ONDK-A(^Z6Z%]N&4PS<)R#R>N.^\@4J<EA-PG*":UDF!,R$7TR,(`YS]//
M`V-4_;SK):*-`I<*OW>J$Y<_K8OE)<>B&U<4`A?D0%9F6QP?&RK9#%4ZM2!)
MG!9?Y`0_E,`2+`3A?'@,@<.WC05KRH"MM:PRQ)%2Y"K"7JYMBIRC6-@@!<$R
MO"6CSLI348C`X,P9Z^N<\"E_NV[!M'=[]!;)U'IJX)D^698%MZX(C&Q3K;MP
MRDL;#&MBZS?+`D+ZNQ1.%K:V1&'-;@N4C3@,5A"G\$%F'9`6(-R]<5Y]?&H%
MWW[5E>[RDVE2$7J.O7F'3Z[IP\R)YC3G.-A]I764U8R6/+DH%DN9H,IP@1GY
M*4'_``N'L6JP%?\`=>P6LNW;-UJ,0RRWC=K7EN&;\V"`J;!:@"4#3"P!24FQ
M[YRH/3F"P$PL'L,`A!QG&,BQC(8`I[NNI!$J"B5]A&L295E0)(,HZQVTO*92
M`8"S2%PA8P!`82(>/DP?DOX\?47C'G/`L%K"XJBNZ._O"F+3KBW8E]Q]K^Z*
MPG$9GT=^Z^(L_P"V_-Q1S=FW[CX#0#]/E]O46,^/&<<#8_`<!P*\[L>U2;LJ
MT'CP""?LW77S?=T.5"P9D\)S,Y:AIR4A7U^'!9X7@1@\YQ[XR4'&,XQD6,A8
M9P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*UMK^RVC:'E4WH*)I[NNC91
MCKURE+Q7>KE"S38V54^C<F!:NB4IM9%%6\V*P8AU&6%2W(GUP1*'4H'L44,D
M7OP*OM=?Y$C$]ZU4E(YQU^]M=J62HI6!/%C3:O-%5JV!S&7)H2UJIO-8J_MD
MK:XRIB+Z\%JER(Y(44G$D-!DLH`?`,!^CG_(\D!JG#?#^E[M_D#D>[M#<A3N
MVLAD=*6%/1)K@A-P:0ZOYY2U8R)S%2=/DG.#,`\",+QY'@,)GG?5V/):RD%K
MP+H*VH:(&P(E+RLE]\VLTU&F0QX;MEO:7=?&G2MQ/GL>1X-5D%"'A%[8S\AA
M/@\08HIW9_DZ[2,CN^:PZ#:8:ZL48G=CUG(<6K=S-:LMQ,ZMDRF'RU"C5(II
M&&$"5%+(^O0%G?C3RE'GW`9\6`*!!&O:6@?Y64NHF^)C?FZNBU7TDPT]<;U9
MU>PR&,4B3OU<@KYS7RJ,80.&MTJ5NY:UF2J4!!:ETR+V/'D9@PY"+@2UB?45
MWGRE(A9['[^9/%(`8S%DHT=&ZXQB)NK>G3L06N/HF(QH7P##(U)TPP^Q:<9/
MK\81A#\WJ8`,N2_QVKQF:=I#L%WE=I]G&X`@#*$L3MY=7C.[X;59;BB*:F]Q
M>I]AF"E</D,`,P2PSSD&<9"(&,Y#Z5G\37J[?VU8AG4NW-LA2L=%3Q^8G&R*
MUU<4Z]:(_*E244FBB!H-5*"S@@,/.2FGF!+#[#SG(\B"2-/?QI>E^G&L]`FT
MWCUCJE*A$I4/EPS.?6(Z"&@&0<4`@IWDH65O3FG)_8\I,D)+4!$(LS`BA9!P
M)H0:(=7G7G$T<!BING^K4<C),AD"-K?9=6L+<6Q$[.:R6OR[#E,'LN0X;,KU
MIJG`1'Y(3EY"$K`"@`"$,#EG=9U10D;RG-WBHR4*(\A<G)\15([.=U*VIM8T
M6%3BX+D=.,\Y4)D*)"5D>3A!P7\90O46<%B]0QE;W/:PK'N&16MJ<WHN676B
MR/<HJ".07238%B';<5C06@4BED%D=N0^L(0IB;'F0-X5;HM=$*`@2]-[&X^<
MKW#5CAW02%:T4_)8)UF[TR"*7U8BNEZMD,M5ZK5F2[72A>)_'UM</[3(]CSI
M%#5Z%YK1W(/5.2,A,#*7.<9%[%_(&9I.T:W'6)RN*-VERA#N'#MN:UU)D6L,
MGV,@:%E8'>TZ3;MA(S8CW>D:BLPC&(B*L52A0,AO;7)R^\1C3!(R,0,Y#3\A
M[7MV86Y[8I)%UPU\](-#VU#*=J76`[TQ)R`PQ!^IW_.;0KKA)-*0@1LQ?&F!
M&EFNR-R$P_&9]$8U?R`X$@W+L9V/9I71E:*^N*T7>T]@JML*WX-$XGL7K4N;
M28K63I`D<I1O<JE4VA3<CD2!!:3`IR046>F-^\-+(4'93&BX$:)YVQW%.]<W
MB;K.K.]WBH[/GL[U6!\NS6I3$]/MA`G\PH"4Q=,B_P`JFK$:(N=1MS0X<L#^
M/"=.):#RF]3<A4CU8;4,-/Z_Z_VO-'"569K[I?8>Z4M:;'IV'Z\2IZE-%F:O
MU2_FN5PM=:[(SJ<9N:GVV5J!29*C1.>4J`Q"G&`DE,DP$.BI_P"U*&QVPHM5
M*K3GL#6V#-HA(I_%8VSZX)W,YZA<0*B`I5(DS@FG8F8""/JI^RI%6#%(#0+W
M(E-@&3\B`$-/_P#F]J,ZNVJV6K2?LJ?ZZ?;`#53'*&/5I&O2NUACLL^FRHFD
M1!L<#MAU.M5,-@+"8G+"8Y8P4$6?8.<A5OVR[EZA=A>LFR.M-R];79`R615M
M4*K`9;AG>BZQUQJ8\R*/RA;`;IE+S%9^OF$7@'S1-P.=?M`&A7M38O`).HP2
M(O@5<_Q[)I=/8EARZD^PBPYFKIW3I>BV;,UZG#'+!3;8>+8=8\7%ZCN6:NSJ
M#Y]>ZBF[^UR=/&STQ@Y,8](B1G":&T*40?\`0R))*3E%$$%%D$$%@))))`$L
MHDHL.`%E%%@P$!998`XP$.,8QC&/&.!SV[GW+1NR&WKM`MFK!0,77-H--*6;
M+HC9S0Y2J,;0]@]LK$DEI*AI:S1AGD[C,H/0$9,:)&YL02<$+96_-I3@284V
MF%\"6;IW?=543+?$KIM;'F4F$EI2)(G'65TD$Q(DQ(-2B+>RRJT^-B)&WIAF
ME8/P4'*<H0P_H`+.`Q%W_D"=0C`-*6];C,[68N18<6\"RH=@R1N+?G).,+6X
M`JFP)>ER)25C!A/N'V.+QY\C!C(9ZG[ONIQ6FC:U'O;01Z*4F(RVI3F4&I@B
M&X-2IU1IU!:Q"G/2N!@$N2!HS`A6$JL_"84`T(PA#8L6[;NL*8E+3F;?C5(D
M+8:F(<0R&ZH/#SD"A;E9]FF6D2YW8STJI6!":844,(3#"L8,#C(!!$(,T1=E
M_7,Y$JE*'?C3%2G1+$J!4>7L[2OPDK%V1!1)QFYFN`?(KR`7QXQG]?J+QY\9
M\!LB'[F:?V$8Y$P':W6R<&LR8M8[E0^]*ODQC4D.R+!*IR`RRE:)"F-R#/J,
MW`0B\9\9^G`R=1LMKDDR6%7?])I1'8R(G"BU8(1DW`1>@LEX,?@Y'@(_IGQY
M\9^G`\$_;_4M+C&5.T6NJ?`A9`')]V5H3@0\8]L@QDR3!\BP'Z^/Z^.!4_WB
M39PO+1IAK/5:SWJ43ZQ]B]9`?<:RV&G7VDFKPBR6F52&0Q`,%E[)(7'[AK9,
M%)<(ER<2E2I("6;["#Y#4G1S%(U#K"F3?6">\&2E3M1JF_:$"V"1R%AF=/S$
M&YG8&CL2FV5AG?BQ0Q&%OS.:2W&/HUKT-&6`Y>J/4'B'D.D(198\A$,`!Y!G
MR#(@A%D.?IGR'.<9R'/G&/Z?].!XJF+QE8%8!9'6)4!QRHRX`4M#>>%=E4#)
M:K*P)J<6%65)><A,]_;WQ],^<<"N+8'K(JR22<_8;44QITRW58403(G>53,F
M&")SHY&JRX%PG9BIHVI8X=?M9R`S(TJXEX3F/"`D\1[6N1*RBC0A(73;95RV
M3K%X43V&AJR_JAFKS36RE0?>GN15=7%%$S<M<BF!V4ITATCKF=1QX;91$7?X
MB_RL7>T"@8"CQG$%!+7@03W0VTEU(!A=*:ZUXEO'=*^$DC!1%2N*Q6U0AC:H
MUAN(EUXWU*D(1'02A:S/?$7Y-4#RY/"]6E:&HLU<L!DH*QG+KN8)AN[JI'=[
M[UL_>&WIIK1N9,9H"0RE\J^HJ_4(IEJ4U)AT33%5O,9055%$F']0U%J5"AQ=
MW<`\#<5ZI02G^`)KI.EWKKC[2%OKNF9;3[BC`,<>EE0W[L'7LOB+E\WW1+U&
M'Q@M!.:W.A*[^_D0@F%*#/.%!9P!C"(,TTVMFU(K;UW:([%V`=;%LT+'X/:U
M5W(N8DK)([JU8M);)&"!2:QB&)*EB@;A@<Y@S[&9$<WD($[N%"A=RT:;+@:0
M2%C7`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`B%O\`;(+=0-)]I-FVIM`\/=*4
MG/9U'6PX(!)5<G:V12&,%N&!Y\?B\/YR82KQY%A-@?C&<^,9"M/K$JRLM([`
MWFUTFMM)9-)I*_:Y7?:%Q6[+8J.2W7=E]T$(5MRE8J>'`MP)*D,JKAQ=4\?4
M>4[4C69^U#]L9G/`GKU>6RNO#KVU&LUS4-2QP?Z7C")6M86J*L3"N.BX#XB)
M>Q,L&""&-3(N_!?*D3M00MY2<8`D8P7@.,!/3@5P]M;JM:M`[J`B4_9XD$@H
M:"N2K`2LC(CUB[%U+`90:3D\!A):@,;DBKXQC"()9G@6<9QC@;,T.**#3EB'
MX#C[I9N'OF>X&^<^ZA65NG?"$)QH?/H`S"-&4#P`(0^`8SX\YSG(>]OC-J=K
MG379.9[!5\[VO2+-4DMS:-:L)1!KQ.(8O0":WJ-H`J7F/$A.=$JW)7OE<E^,
M.<CP8'.,9X%3#AV&]F4IKBG[>KNB=(Z=K"YMO,Z>,3-<%EW99=K5F_XO>8T&
MW/MA1:O8E#8DL<LR6(9*4L:.0%#2'J"PB7"QDS)0:INJ]^X`E!V:N.-V]2:A
M<NONM6*>G1NL-)G^9I9@R/E!FWB6[`=[3V%?W-B5A+2*VPH0T+DF$:C&;\(_
MU$X#.'?7K:2Q-QJFULL[N#WD>8#=6J-B[*,+K3#3JIK6[J7.M;*H^++(\SN,
M$H-1)#H^^QVV@J\@(6`6-_VWME0;@[R6&A(1U^:06$@ZY)E<S7MIL*U[<6)8
M-:/2#9W>[:2U@Q^61RBKPG:1;EC;)K'(:\&NBRI5Z0X)R%(E*)6YQ@G.<8"$
M,?8]#.N:F=8K4MA@TCUZ53/6+MP:8<-Z75A'GR;0^`)^P&N6A"RN4I?1N+RN
MBK+25@)5*9,L7GH$[.-/[%!"2$HL+*76'MAFU?;OKU%61JBJ:U-!-<YPR1YB
MCZ=C_.OTRBNW5+R&6)5C6C2&K!_:05@:A!"=X($A!\8`#&8,88C34EETFD/\
M?JWD1$F4LD[U)L^"SMZ4H'5P&6JL342I+6;6Z5K$IAS:V*W204MD_P"=6'(A
MJD7Q%FAR:,!H8L=4%VD:TURV,586/))WKSWC/EEM34MCS@A<%5-2_?RP%,AL
M%@1G%GE*Z[0T#>3BM`OR`:8MO*-4%Y`,H`P!\$EUWV6;>XJP),T:_P`Q<Z(N
MRWM+-C$VQ#4[PP%80X&MVM>QE.69'9P@5R)+-"K!DJ^6Q]$T$HFI<4L2G8-.
M.3EILBX'V7=I=LC*:T_D2@0P9X<Y+NTQI&/6AN02"+A'83-'M%*\JQJ_#X"[
MIAL;B981#FU#+=C4>#1)`"P'!(OE,":Y%7V2D[#-1)..#R977-9]>NQ4!DMD
M*"FX<7:K%E%IZB"8HD;DE8<)%+7AE@3JKQ\)7QG)$QF`FB"6(.`JDOZ'7?KW
MT_T'+9)5M@-4IU]WJFFR]QY(AQDOE-9UFS[0[&6>\7A)(FD,7N<@CK;'GQ"]
MNF24KFH-:EAAYB8P/RY`%6594!M`=IQ>$&MNCLUA:=ZU#V7N,0J^K8M$&^)W
M<_N^KFA=>(K?H^.1N+Q!K_"7PG<5CDA9F!E3`)>$8@"2@4A4AP'4\9#Y\F[9
MZ=>$T*D1U21+K.N"(F66<S*3&0$\?MD-?E*"%N<DPC`@+D2F-PPY>4CP8$TT
MHL\WX\!!YX%><5A5PI>N#KA8"H+,FR4J.URHIQ:C*9!Y1AYC,;4]A%EVC)7Q
M>PI&_+FPQL:[*8S[Y03]@0W*@'FF!39^?`9'LA#[#7NO\DUU30&T%2B7Z/U+
M!*Q+;(VZ/A-DI&O32[CQEU>@.0&))$Z%S&<N#6K2(1'FX6$AQDL)I@?D"#G4
M&CHBP>]?;>X*:GK=,VMHZP=+H@@/C*HT:8E29#*?B4P:9^6O;DSJ.>LBNJ&W
M!H%'PJ4^#A%J"_FQD)8=@G`XW-?+9B<CM='27[M@Z39.0_RE-CK1E5-GRM,1
M:R&K8/"+>-)L@JO#W51*R84;!H<W)@N8DF6DP!^,`,#D81A"QNXB,2U#_)2*
M)6>J$-'QZNCR0C-.,3KT/7&B?G5P++&`";`#6^>)B@EX%D0C4@_?Q@0?(2H;
MEZ$GM"UUAI[@N<#:^ZK;B?DV#Q8\NY$EO_6-D5.+@E."(DI<`4!)$6(!F<^Q
MYF!^,!!G(5TZG-F$^AG\>5K7A$6SSC;MLL-44+/_`-P,5/VO6[%TQ'W/,6.'
MR"`[GI3%(@&9`:$(O3!8!8"`,DV\EZ">:N?R1`E-T>"I@4H,A1*YQCK.]EH3
M$W7]K80O?P)']"K1&OZ),_J\)SL@\E#++R6,(L8%@)M/524Z7VD:[5TNJNHW
M9D0=<.QCLB3+:V@Q[B)>S[!:E,1+@KR)G&>4F+;UIH$P/_I%#/4X+\?(9[!4
M31M4:TRGKSZV)@[ZXZYJW*V^W5_A4C.<ZBKQW6N+.LW@VG-S'6YQ5,'SKV].
MGC*5/@L?L5EH3#+^/``X"$-OV;I/J02J_D(*HWJEJ^Q"K:@X<QUI@NA*IP1`
MY,BT*76&?(HHB!$,HX]\SM-4BG(DH2S35R49H_.?060WC_X^=`4F]>D]'.FD
MVESK%7KKRV:E,ECW_&NFA`D,GBEF:7M;5*GQN.B8A*Q)0R5UPC4GEF'%&KU>
M`F8R:=@04([T45I)$^E74#8",:VZF53+[8[")?2[C>*?7^/KW2"U7)]D-KF9
M<ZH5;&:PR-R:H%&(\0K;$BIV"464V)R2Q`R`KT#9&DM*Z<)=">S.5QF55#LY
MF@8AK,P57MBQP-A8;*:\N]<M3JE9!RR'/4E<8W;C$YR?+7(EC*]C+.=LF#,5
M&YR:=D+REN@6I9_:4BI]34HU57+.OB03T<+,GUHG1X$V!L.QQ0V3*48YJ(D+
MZ='%^4B91G^\`D!V"\A_5Y"M:H-"M/)7J-U<SN35`ZR27WMV$O=76/(E%SWI
M]U((>@D.W)V(^N--L-4H<H>`JLVM.6VF#"0),E)P9D7QYP(,@NSKCT-JN)=Y
M=@PJDI9`97I34X);K],8I>-])I'5\R)T=9KI0RVOC$]J%*65>EGSN%7GVR(!
MPRQA%D1(QDX"S[0YS>&K=&(94FJQ*]A^G;1NW[,$Z_=&/KO:%7RF<P7]U2):
MK/,4N4D=HS/B4*L\X/W`@-)`3!B]`X"%XO`J[TZ`99N\_9W>CVM`\*H%;--:
M9UN(S[)0&(UW4M"5Y<\K9&D\@`SDW[AM_8)Y5N0<FYR::D3`,`$24.,!*5XK
M2,+-SJ]N`V+V49,H_K+<%<(IHD&T8J!%&I7:5(R1SBS^6/R_"L=T=(>E5M.2
MO"3#8C<?E\F9)\!)_@0.R4F#V>%G$H$0E9VAQQ3BYD)0?D2DR?8,@;,@<U@?
M(_LE!JI>8A*'ZX^0M6('M_<]0GCP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*^
M.V=L2N_5[V&(EH?D3_\`#'9!8,O/GU,$V5-*G,HL>,9Q[%F'(PX%C/G&0YSC
M.,X\XR$2M>-<M>'CLLV3/>*'J!Y4M6I'71>4;6OE=Q1\<8M:3H5MM4#A-H\X
MN[4M6LTG65O7#&S&+$AA!@V]K3DY^A?G(6&:8VRBMVGGM4W01BK9#6-Z[*Z]
MM\/B[6!DC3<S:[W]8U,QQ2QM)82BF]`[QJ%HUGPEEE$EF'C"2#!6`<"6'`KA
M[42@KM6XHQE8+-=)+N;UUL#"A/#_`-LZ/*[??7`29N5'""(E,G4$DF9$8;X+
MQ@/C.?KC@>=H5<<&B^@+W>TP<AQ:MX98>]]BRIZ=2QGF,4+AFV6Q;T^O+@4@
M`J-.$A9&DU08`D)@\^N0@P+/C&0C)L%V6Z?WUK18$>N'6;LB,UNLZLBEDMF:
M31O9A@8G&`R<E$L:#D,F11`MQ3E2LD\D"90F#X"$[&3#"`Y]\!_=-:UW7=VC
MBID305?0[V\=G3EN+5\(N!L=H9/62F&?L@2[-_;SIH)R_.T3G\S@J1V-2(Q"
M]RL.*1.JRGP(_!82@L#11VL*:=FYZ^3,**"]@.L-94FE2%`>372-2V.UC>=3
MS"3/R(`TJ-0C71J=1W"8:-0!2:!M,*,P7\9(QAEL%TA!'[3T@O%XGQN)[J1J
MG-]87IE:6<D^)V$UV&RTN!Z=TRAP.*=HZ8T2:FDJI(((31GIE`R3<`\>V0RN
M/:,U`T0W6&'.*Z7/"?4.YI#=M-N`'PYF6)9*\-5M1A&AD^&O!)4E:&V(7"XH
M1DFX"!6844>;CVP(&0R[_AGKB=#+SKMRKPIZ@^R%PJKXN",O+])%[9)[,6&P
M94>]%!,=\',J0:^N6E3]BB&G194$#'DK.3CO<)`E1.+$RI;.28VQ%35RC[9$
MW"7%M*`$F71=E<79X9XXK?0D8<U+$U.S^N5)T@S<D$J%AY@`X&:/(@]PHHH@
MHLD@HLDDH`2RB2@!+**+!C`0`++!C```"''C&,8QC&.!^G`<!P'`A#V7RB/0
MSKMWFDLL/=DL;;=3-@,/"IB"L&[)D2RKY,WF*4?X\TA<`PC*K`\C*&`8`8R+
M&<>//`XP%+9+=D:P_CGH[IW@@%J2V.[#W_=4>OBUY2E<X#:R&*;@ZYPNMX,Z
M'OTNBLE33UIKY7]LFCN`KG`AT$2VJTX0FGJ4P?\`0=X#@.!S@ZNS),__`,FG
MLV8DKJG78BFB&KK`J2%%DX&VJTZN(R,:$9A98!G#*!-,'#R+(Q8RJ"#.?``A
M"'1]P,9%"H<.3%S442C(ID2F,1DRT3"U9DQ20XD*8U*6_92Y=0)C4X`EB!@W
M`1`Q@.<>,>.![@D*(>%@1HTHPN`?1?@2<H6%P/APF]5F,@SA2'[?&"_`_;'I
MCU_I].!^(FAJ$Y%O(FQO$\$MY[02ZB1)LN134I4)U2EL+79*^Z`WJ%20HP9.
M!8+&84`60YR'&<!C*B%5V0""(U,2AI)<'>,+*S2&L3,65$'TN./K&%5"$^4H
M0,#H7$W1R28&AP4;AO4*"O/Q&&!R!?6E<.C?-FES@$)<6JRU&5=C-B^*L2QO
MGZK+0VQ_*F;(U"`Q-*E&6%G2(?=>$\7V:4DGS\90`A#T387$#Y>WV"=%H\;/
M&F-NT.:YF8S-XY4WQ)]<F=Y>HPB?Q)\NB:/NSO'D"I0C`;A.<H1DF"!D98,X
M#7B;7*A$44@\%04_7;?#*TL,JVJ^BS=%6AO88;9Q,C>9>">1UL1IB$C5*12F
M1N#@-84$)QBM:>8(61&CR(/P?=;*(DZ2^&^1U=%'U!L\G1)+_0NR(:]%:B1N
M@S76B%+*DJHXPA4F305E2MH2RPE@^`G&?'OD0LAE9U2UH?8T9MTV$1T=G0R#
MR*M(M.LMQ.)(R5_+'2,O<CB"%S#C!X&%W=X:UJ34^<Y!DY$6+&,9QGR%.'=#
M0]$U'U*6*FA5/99HSK)8=.7O3T5IL:F&RN!V(AV+BSLNEU0GL@R<M=EGBG+X
M<W#R`THYS<<_(69@S.,A@?76PZK;T#WGDK+K*Z5!0VX<4UCM:>4C*F5+6\J<
M9D>[70Q2:23ULKM^$0S3B4.U:(EZ\2=:6L4!P2>JQ\QYF1A><&K8*"U3KK`Q
ME@LM17R:K5$E"J6X-/@J.1JI8C8SD.%/XXPM(_KCU!9N2<G@R<,.!X"+(<AI
MUCTVU_C,'I*N8]$W)GB.O-OK[TJIL1RR4X,8K&=5-BJW-T5KS7<U>]MRXZUG
MWY$"PTY%D"S`,%8`44$`?>]:F4K("MKB71A<E!>Z;$3'+]#A]<B_W$T)ZB1T
M@4E:?0['[=R&OT($_NE]!Y/SD[S[Y\X#3FIV@$2U6G,BLHZ^-B]B)PYUK%J6
MC,BV'E<'D:VN:>ASZ]21FKZ&A@E=5VGPWFO#UDU8L<0.#DL^U3!&H]2<8R$]
M^!39)M:MY:0N?89^TPW`U!B%?[`W(HOZ35;L_0<SG\HA=AR6`0N&S,A@E]=W
M[6`U$1=/V0VNJ1*L:LJDZEP4A$I,*^'@076;.]G:C:W;N$,8>L677;IGII$+
M`/V')@&SC:VR2N;<_=DL/@:"!-]SR="F<T<MI42U5DUXP`03$H2O&/GP$+]=
M2+'L2XM6-<+;MQDCL:M"T:-JNQ)_'HB)Q%&62632$,DD>VMC_+C.<RVY$O<A
MEE@/,--+P'U$89G'N(-*(<Y*[.Y1C.<XPNT.@60X#GZ#RT[!6/\`)DW'TQG)
M6'H/Q_U_WC_I_J$\>`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!!_LU3B5];^_Z
M</I[&Z5;2!Q\G^SZ4A.!?J^@OI]/^G`C=JPI";V)VJHQ[^'KJXZ[',OVSY%@
MLFTMS2LX4Y\_J/SE5CQG]7T\_7@3&U4V3+V23;"F@@"FOAT5M7=NMAR16[I7
M<Z4F5*[-R(,_#]H@0`;$TT(<P+2$8OG-)(,![FB&+.`A*O@5N]GQWO4.N;-D
M'@,D[%.N9K$J"+P-#]EN/4$D`H+*]<X/$::P!(R'V+]0G9'C.<AP`00B5)6^
M)?QVMI%YRAQ.#(]-NP"?O)Q";[@\N16XIOZ?2,IK2HR@C`S))-,5):$.<#-*
M0`+^09@PB&((ZS]1M&\:@PBNGGMMZOFZC7"`:_1<3@]T-,BYLV/#?FM&Z/QT
MAYKS=@HES(535&C"<8)('YR5AA:DL"7VQ@.E.M1RTVO(,;/I!#Y;-S8E'C9;
M*:]:ES%!)'(C&I*-W?8:RNC_`"MQ:HPZKA#/0ISW-P-*3#`$2@[./D$&;<!P
M'`^8Q8C*,-*-5IBS2$V5AQ1AY0#"4>!##E6:`0L"+38$6+'R9Q@/D.?K],\#
M&Q3Z"@S#`BFL2"*QSA)J\"*1L^,SQ0!C6R<9$,QE9YE!P(TVJ7'(4/SBPA3F
M'^/B`(>`TW*MP-8H97EI6P^W9!0UY25G)Z7MN4,[H*3(J]MI3)XG"PUU*"8R
M2[KFR7IY1.FA&H0C*^=*:O+^8)8?86`\.2;CT]'+,V,IT9DE76/K%K]%]D["
M8B&!44G65W,0V7AAS%W51DM(^NQBBJW$H\HOP`@PP@.1Y$(P)85I:A=CN]=O
M6AI"?L)J_K;6>O?8)#K#G5'R"L=@I38]KQIE;:B/OJ`D6''%E=,D.$I60!)]
MJXF-;HJ+_(J`##A.$O)!H2>6]F492T3N)>)=22,U#J)N&Z:?.,>')F<M7.Y`
MV6#4E=BFK:N+1GDL;&:YVN4?]L>6<J"0B'_41@0X"28]KX<7MO-]2#6)X(D=
M?:P1?:21S-0>B*C144E]BSBO&IA3%9'E<<[$JJ]<%:DP6`$$D9)QC(Q#%Z!1
M+VD]F::[.D&%6K6]&2YUD/8[7\FCT*K4R0LYQT6@,=@L\NBX7*4OJ=2V)W(Y
M%1E1OXDJ%&`W+@Y'D)/`RQ#%D,>I7;#1`ZUJ]VKU\HAS:](&'7"[X\Q5NBJM
MEC9"B]+&['=1H[F:0^II`K0EL)RF\Y.<9A2>G;3TAS&)02444%'DP.B4W9*N
MR;]G6N!I4D+G]>4/$]BI`K$T%XC`J^F4OL"%-1;<[_>_.LD!+Q6S@)0E^W"`
MH@1(L&"R9D(`U#$-_P"B9I4^E5R-:2PTT2WVE,2B%%%N,0R2[$.TUK6;VLQY
MGR8AQ5(XDC-B<`79$9E0?_W(BB@8'DSR$/\`9)V!:^1"";IV1)S)ZR130N2.
M42O-8O@SL2>J?FZN8A9Y:&ND?U4S?+M'YXU%(1$!+"J6*RP`SZ#`8(.>#I/E
MQEP=\O>'<CI!Y]6#L]QC74".OKOCY$9NB,L[XSHCBD#VPI71\(84A:6,HQFI
M/NS!%DFH0BP$01``'7WP*Z*?[1]7;NNF.4I#TUVHE%@/D]C%0VK+:(LR*T)=
MTDK1,]N$P8Z@N5V8"85-G!O:(N[+2\$*`@4I6I4,H0\EXP(-^_\`,;6L##><
MI4VFTH8[K9;J"B+I>7%MD"!%"K8=$U>*6Z('#5-!0W96N_RJP%%'(`JDIA[@
M`H)F1@,"`-C*;MJU)/YS5RF7HBI[6M:1RXIQ'1)'3*F/UK+72;LT=E2E2%#E
MO4)'-SKA[*"40<:I!E`/(RPA&5D8:_-V6I!_4:HG,-FLBTK:T\Z2:_83?EL9
MMF.$4](K64N#$6$A/D*%/`"\.P\K@E@"4$(<A^<18>!EAVQE$)HW.I@HMF"$
MQ6LK*(IVP)$;($(&:(VFH?8U%R8`^.`C,)D4I')9BUM_V@A?+A:N*(SC!F?7
M`;"'-(@7*%<('*(^&9-\9(FBZ*"=T&)$BB"IQ6M"64*V;Y_R">/J75M4IBU@
MR\)QGIS`!%D0!8P&+0N[*<L:(UY/H%:E>3&$VV9DBK)7&YC'W>/V,H"WN[L-
M+!W5$O.1RE86UQY>I&2B&<:`A"H&(.`DFY"'LJ++KA(V2EZ5V!"4S-!WS]L3
M5V42MB);(?)<@:3,1Z4KS%X4L??,EOR$7VBL9*CPM(SZ?WB_8,C$],X7;+")
MV;`OF&S+UEF$O2X=L,X5/V8G;+=DW[S#8%9_:R?Z?%@S]/M[?3@5/]RTDK>6
MZ%FU2]V8UPUFVZO75C6F*6*TOS!]PRN%O;"5TV9FD3$XGX9Y*X0MC2K'L*7Y
MBRCD[<8(9I981CP&ONI.`3J@IIMWKG;MJM=P6%KFV:A55+K31L:.(H99AIH-
M,HA2X;"0:84U+$E9KF%`J",8S#UB4T\0AY.]Q!=IY_T_U_KX_P#CY\?_`(?'
M`_S`L"Q@0<X%C/\`3.,XSC/_`,,X^G`_W@.`X%(78-KNID-W?OJ$='&J_8:N
MD<18!2JZ[%MW7NJK!$_(3G%H31=>W6G5TB<GMLCT>;$60.`G3R("DM.61ZIQ
M9P%;NMT9%54B_D&S!)IC$-`91!M#:3*3ZV5E,:SE,'$2#7K9^8H[&6CJAJ)@
MADE?'<D]*`1:8*@*)&')Y.1G9\ATR:JIUZ35_6]*ZE&$NB:A*?3N1)P0A.*7
MDU['2UA1H09R`)A:@(L"QC.<8SCZ<#2;&(..RZSPF>N1BT8HD27WQ@8@!!?N
MQ>%_VPA8SD@)N1IOFP'(?E]"O;V^,'J$Y^`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.!%W>&-`F>E>W\/-.&F+E>KM_QHQ06`!IB<#[4\M:Q'@+-$`HP9057M@(
MA8#G./&<XQP(&:@+<*M]R57RB'E\Z=-`G7(L^WE7DFW]HPY4F^<8S@PO"_&,
M>?&?`\_3^O`L"UTM.H[+7;$ME30\R(#J;9.>59:`A1UGCQ<JMQNCL)ELOF!&
M&A0H$]EO!$R1A$XJ\%K%1I(_D!C`09R$D^!6;VBNC8@KG4A"L5DD.;_V8]=C
M5'$@L&"5NKFFVEKZ0N2-O`66/V.2Q)B<UI^19"$*)(>+.?T^,A"VVUQ1'\:R
MU%`C3,`*ZR[`0Y^,T!!AYH:H>&S[(H9I9H1B6'?V`A]<Y-]\!#]18SP(Z[65
MY3-A4B7!IKT`73%B3@46Z.5D5U4?5^\R#***6)!)2AKUE6+=B$3PO/L!4Q_M
M=0W$$X7"(=QE$D".,++$'2_7RE(M@4(6-\-<*Z0*XA&E**OG9L:F5U@J0]F1
M&IH:YL[$K7LC2X1@D841R9&><E(,(R`HP980BR%=_;U:]RU5IV`NA+(,IZRK
M>V)U1UT;;30(4#G(X$T;`[$US5,GDL/0.R1P:CI4WQV3J<I1*"#0I_(C@XP8
M6#.`KV;-D-J&'KQ@#Z[[&26P[3U1[@8;J-?]KH&EEC4MNJG(+V.)-;7!GDZ=
M.SB84#I,:UEC(-W-2$!";@!N`F8.&(S@97N*@MV=4Y_(?@C59%@,JR(0VM[)
MIL]3+W@M%"DT?TOK&P5B.#9-<2B8Q'W^;P%R^^3)<D)E"H]4,S`A'&Y$&^VY
MJ5.O=;]XN18.C%Z]-A!;[\Z%86F>'2N]ID:?*<Y5D_[0L29GN\P)A"8!9F`*
M,"-SG^SX"#M6%(8'I3_':FC[@^.`UZVRA-"R5*Z+$;,8@4*=?MI-474XPQX.
M)/`U))F%*+))@RU/V(O[@,&AR7@-*;'7!K57^N?\ABH#K[USC$@==I$.QU?1
MN17;731_D%SD&M6I%QJD$/9E+JF6*95(YQ%5B$H:0A28<_'@QC)AX1<#>:GL
MBZ[W7M6NVS4>R$6L*G[,ZU*_I::OE3Q:R;I8QS>&7K:K[B-'N=50Z7(RUHX5
M:Y@B`$C']YD1H,9P8GR#@>-13??]2ZG_`,>F]A4#L1;$'UBK^QHM<-?UG6'Y
MV\(ZVS/5685'3#ZOK1>='GQ.RI<!*3KQY,*^SPL3F*`"SG`@!HFQK^OZ;:E[
MX405UF]D:.Q]BMZ7V]:]4,VHZN.Q$ZK_`/.M.S*/N\I>0S%82EE*F!5X:8Z$
M8^90M<?8/@L1_H4$NUVXGWN^FR>S?_!/LY2Q]VZ_ZOUN@ZO_`()7H>]2&?1V
MX-A9[+&1L94K.>WB2%H9DP#3N*XY,D,,R<6`X(0#$(*U+'MMK<M!NK/6X[3K
ML-A3QJK7:N(WJ[2+KYV^<(G4TFDNA][Z]NTY6*X5BO)--X]%KEG1*E>&,/Z=
M>H:A'*4QOZ<%C#3\5F:N)ZR1.O=@F38]JNYOG3R==#6VZ:[O-C_+H`A[=]9[
MD=[O8D#[2\D>T%>O^NU1*5RPYU6#>C'?Y$ZDHUR5&>P6WHNS'2QK[&-CMG'V
M57U':ZFNAFMU'0.2/VFNX2!-(9U&[3V@L&;1IICRNC")&N=(XRS1@.4"^W)3
M9$NR2$T1I1N"@B9K/OEHQ(=;^AJKV:^VN>ONH\KJZ<[#-D3A-RV@GJ!:AT<V
M*A2']_O4?@;Z1#W5LL^5HFXE*N4$C2'BSX!]LF,-*#2ET[MZZ3G47N_KVO;B
METTMO=#>YC,UVA$CJ^YX9,9Q&G^%Z=ULF"S('V`LKBEBS$XQA\;`?=DI\@0L
M9HC0#*S[&!;'U#.!SGVD?R$3G$1"MS2[6:YH0N(4Z8D[\.CJ24M;.V9R26$>
M0-J!I++SG.<_((.1Y_7D6<AT3\#F=T\6$FTI_'2(<3""FYSG^Q<T>!'#`F$M
MG1.H.U[D=)U"KV+Q@UQ<G]U//*^A9IR[VSC]`<<#5LO-PX:1=[\L$,*E<L[@
MB`*/M<@^Q/10*1Z&L;(!($'R"`,UB92`*#,C,P-3[F!P$(L%A"SJQWECA_85
MO-*Y>[HXS#&GJ5H1_DTN>#,(V.,L[)=&]!SHX.:\[($Q"9$W%&J3!"&'U+*%
MGQXQG.`AK0+TH0OG\8*+XRT.*-QT_MU4I7M;@6ZHRW*+Z#5P@(,;G!(,2%6F
M$!W5%B'C'MY\>HL8]PB#3CP`YEZ]>V(]P3Y1)S^\Z3.;*<L\)2GTH.^6K:T0
MT(C<A">#\FD5(\Y![9R:F,^GD.<8"VPYD<57:W=KD!$=^(4=8E-,BIW"$&2T
MCB=LALJ>A19QD6!C.5)1*30X\>,8(S]?KP*X=>U+CC7G^+NQ-+(D$F6.3&\N
M1)2;X5#>G8NL79'[AT)"`1)198QNHQJ19+$(8C<9\^<YR(/AV!38!I/WA$%D
M?.)'V>1!R+*"3[B6*`L/7E(0%9+`$0A"$>;@G&<8$+P'&<?7Z<";\KC>'3N$
MO>1K!KADQOIYA$=;A$H$1J9N!86S]\+9!Y4A%^6-7.6*U;Q%$!+,)$%*/.<@
M'@&#`YG=_'!^BG2U_'<)<;%;Z03,K+7LXD,J<A0,AW8F&*:L/#D)^AJNP&QZ
M8D-@GQ]T,)8#1$"R4Z.9`\9`8$L00D_3L>>)%U]]A2MHOY5L*=/>U;JW;"]F
MW9R3#4W8H6J^KA.[3!W:F4]:)N:GHA\"+&0*3`+4YOL`HD']K@7ZLB7\GVD;
MT/2>0KVE)%>NS3J*N3@:I4#11=XD5J[PR0MT1,2D_P#%+AE-#>2H,4_%G/L5
M\(AXQY#D(2:E/#R907\9H*Y>O4A?HJH_,#6&KBA/1Y'67?3LWNZ\LTX(E2E0
MH1A5`P=@S'N;[A_5@(L!X=\R*:Q[1'OT?H5+9A"I.^;G6##(Q+"#)*SO[*5)
M*3T]J]6)H7F*6E>SLXE+BN*3N3.?C*=$;]VF$)2'UX$U-.J5J[6SL<W4IRD(
MBGKRLQ:DZ'3T$,:G:0JV+$P<YSN9#'F3DM[T\.:<E\>8_!VA.X+"@EJ%^4)0
MU0S30^^0MYX'.QNAL-UMQK:>R(I?^V':;3MC-*EA)?X]3LC[+(K1:=:N88^F
M9T<"#2\36UFI_,)O0S.60PQ.I<,JO8>5'R!P%9FK=EZ[2N*?RAY3KK:UZW'2
MYNE--@13[8A9;K[;JMY1Z=;*QM\:ERZ\4+?;CBQ,)Z(E,A&\)@&`!@021#2A
M),$'8=2J!P:J;J5K=RR"G9MK.!H',I,<!0F+<$<6:DZTM.>4(99Y`%)8L`&'
M.0B#XSC.<9X$;8)D*WL4V:4$!]BV7473EG6#/#G!I+@XVON>[A+09%C.<HE"
M#!.3A!S@(CB\8SYR#'@)O<!P'`<!P'`<!P'`<!P'`<!P'`<#\Q&E`&64(PL)
MIOODHL0PX&9\>,9,^,&<X$/TQG&<^//C&?KP/TX#@:;V+;C'C7V]6DDK)YSI
M3=G-Q1`3`$B.,6PE\3`*"::,LLK)@C<8P(0@A#Y\YSC'`JMTN-'C>.KA&"!\
MKGTDZ4FFY#D`@'C:[>M[.1)Q%Y$7D!`GP7OD&<AS@T'^GC@6/:Z.FOC@^;-I
M:':0-+PR[,2ELV%P!K?6S\EL$97E7N\D=Q_FO!+B-=!G6.YRJ0?]B;Z^`^30
MFYX$F.!3+W(+7U)CJ^PPD84GY[:-7G-40-3E,0>BB<#O&;J$YXOD``W!X(SZ
MEEYP/(SL@P#'R>@L!#[8M-.6+^+1(A2H9;),W#KI@[Y)?V\J+^V;2YBRQA]>
MBFU6F-4!PA(9GLT&!X&(6"<9\Y]O/`TW<;YU3737L<(8OY#UU01C*FM0RA$C
MD>]T#G;2X.%2VE#[!`H.8+98%LK5R-:NA.!-ZHU5E*C<P%+/LU1)1J0\.IZ)
M*VUPBD87L\BS,&A;'F56U2T2M`O%*&U2VICD,B$N:DZ1K6Y>TPPJ<G)BBDYG
MR^Q8`@SC&`J4[LEB1OUWU?7OSDTL<#0]F?70NLJ1/9Y3<VQN$(=HH(M6ORN1
M*E"9OBB-M=DZ(:EQ5"PG)2_*$>0_)@80KZNC5*57@#<RI*%[;-!*HU/V>V20
M;1XCA5=0^];;B=C+QU7,I`67+''8^-PMF;CK8JS,D1B*9SU(5:HX>#"\YQ@L
M)>,'6?;^P\=?WRS^Z#;"ZX7:,>71:?&ZW1O4&CX7/4&0KV=R:`/=<4W+7HMF
M3MZL]!@D+P>N3EB&7]WXSD/`^"HNK/0N?WI9T>ETQWKONX=2V^'TX]V+=^\6
MR:Q62SV;!(G;".-QP=>6W#$*-IRQ+F4U<D"VMQ!BI(F.R2<,`5`@EA$NFGJY
MAJQF7H-):1?E$?$YFM'^1F1PME.C5O2TQS>'/".TG28(SGEU<C1J%"TPL:LX
M\8C!F9&(6<A(J'Z*:1UZ82=`M.M684>G`F+)4137ZIX^I+"B'DQ)@*EJB24_
MRF-SD0,^WD(\Y%CZY\\"3R)O0-I`$K<A1MZ8L(0%IT28E*06`/GU``D@!980
MA]L^,8QXQYX'V<!P'`JN[NIN_P``ZHMX'F,)1K7IYIL^NTJ4@M2<N-)MJ21Z
MJU^&@A$WNJ]2_!;ID;EO*3IS5!BW!02L?)D.<!7UTP*H'%YMJC3]?6?(;K:(
MGU6.;ZLMF0,,ZBZF62=SW=L-FGK,:Q62T,DW0J*^L)A=FK`'5.G<<)PE".3I
M\CP#(7]W[5)=[T9<M(FRV30(JX*LG]8&3B%K36V7PX$\BKK%Q2>,+R32#4;\
MQ8=/NDA@1@R$\H.?;']>!2ST\4Q="JRK8NJU)+0#$UZX,DRZRHI7&L-:OE:P
MZP#M:;0`AD=_VL2\NZW\G.7QQ8PE,;8G+&BBZ)P<R2%!XEJ@PP.@'@<T'0O(
M13'<OO\`95]J1DA5V7/S"G=D0!G-Z\F)8FC"2E(<A@#]RI1IDI9IY.,YPG&J
MQXQC`\>0Z47-Q2L[:X.RX8BT36A5N*PP`!FC`E1)S%*@82B\"&8())6<X"'&
M<YS],<#E3U'A]6;&4%_'ABUD0B+6G3TO(VZF!4)L*,-4CCC@\1^HK*>8&^+H
MX^)5J+[EB2&*<I\##GX,G^OK_P#*&GY]H?H^BTE[![4/UBITA^9NVA_@\;`1
M'P,R:,14G<N@J.41A@*:E;:CRW.462*3R4`2BTP%+B82$L7ZC3`V9=W7MH0M
MV3[:ZLQJC6T3B]%]:6N]JP11`W.4PQU2R]Q/W)E9\J-7H7D:!$_-KU7[/]N9
ME(>FR2W$84$G@"(L0?#2/6SJXJGG1N2LJ`\4ENC4G9>Y]CUCC9]K,$ID$EF]
M`4C(;$E:95%Y<W(VJ0.MOVF7A4A:A-B,*1P.P07@A*42$(JF:#ZK6EH-LR^Q
MV+6!"7:.]UUBZ[U$F9K,LER8E,)GV\,.U:D#437]F2*;UC('];6,_?RT;TYM
M9SBVOG_>)UI)Y/D06A,VCFO\?[(-D*PC<HV<2M]0=:^NDH8/L=[]P!/WYMZL
M_:)D/_=#H3=/Y[[<QKAK:8C1&GFH0&"4JBB`&J#,B"%E=Z$U+/$'\=R;M]@[
M2-$CN:JHZ"2@0[$6O(<0*/Q'4,.P;T]4I(I?-G:0:YO$AF]?M,==5$(.:1NT
M/=W!J-`$DPL10?W:^JL69]6^SB?N%_;L*UE?]H4.JY"SF;C7>../;.\6EIM'
MD:R3L9\B.;)?(DK/,@D%KG0E4MQ]DEQ@_&4Y1H0DXZZ(MK)VK[B2,S:W=!G0
M1O1*!7JY31EMUW)L$M)84HMZ#_X:6V0YJGW\G2D)%1JJ3QV-99"LMTB?W%2%
M8,GXTW`IBV:,L_771G^/=?=3VSN1;EB6C6\.A$!I1#>5'0:(MHIAJ\CCR]DB
M9L_H&9Q9HR^LLI/;!F/9+H#+6,2<><F9+/+#<%-ZF.T`ZSK+C,`OG8>G%+#V
M;Z#T78]#Q1BA\39V"7`N#2-.?+)@S3:+V,\&;(_BY0TNLA7LKJSQHR1-I!86
M%*F3FH1A9;:.H-X*]F>U.%1;L>V_:Y(AZ^M7YB1-%Y.MYSXX%C?=W#FJ#2U9
M%*#B+JFB#64Q'EE#8CF%^$0\JQB<AFX2#3A&O537*USFC^/@XHMX[SAJ*Y8%
M<EL5'4\=BM$2*':U1%^TVE,W2U]5+A;]8V;9<F8(#$)FGB"9=+GN2J@MPL&%
MY3&#)P4']WW4FPS=I3W(S"4[XW!)H=7>[D@9)/7SM3^K;6UVNI:6C5C)(9/(
M8_4;%)F0V0$.Z-M-_!*VH(<(B322L'#4!4!?C26/G[4=_P`Y7G[I2@U;Z^4#
M2H,_WMC,JD^Z2U2T)\^/HF/=\&*Q?]3#<\"RC@0+M"N>P=\L&4NE2[EZR5Y6
MBIP*S$X;+]-918TJ8$A3>B*7('V:H]M8(A?U>'()IH32VA!Z%'!`(O.0^P@H
M"PRS1H1_RG5FPU\5-;%^IM6:L@,B=JM@;W5[)_C])H_8;U4[P?!G263XAJ7R
M)7/5C2=\;ZX#,<VE2+.""!)B^!U@5V4K(K^"D+TAB!<3#HP4M0G?_61*RV1"
M!2D-\?3Y$QV!`%_ZAX$5:VSZ=@^VP`^!A/UATF.&/&?."329]ND5]N+QYQ@8
MBQA,\9\9P$6,^/&<9R$V^`X#@.`X#@.`X#@.`X#@.`X#@.!_`BRQ#`8(L`C"
MO;!9@@AR,OWQC`_06<>P/?&,>?']>!_?`<#1VSCJ)AULV%?`)PJQ,U'6RZA2
MB'DH*D3=`G]9A.(P(#,EA.R3ZY%@.<X\^?&>!4KHBM$LV^U679```GKHDU86
MF%ASG(21);/P<$!.<^,C!G+T+`LY_P#D#_USP+/M<(]0C,^[0.5'244D=9;L
MY*G^^\?EE+J5'[Z2UU5L6DD9)">F3EM06R'QIA$-(3DTLLXT8O?(QC"$).\"
MFKMS6IB)KU7)G<Q2"-!['VJ1OF$1(3%N<0?3[;N8MPD@Q!$+)H%C/C/PX\94
MA\E^<>?.`T+NRQR%P_CEM42:U#:EDCUIMIA#DN5IIHX^>O?7"AH[^/>Q$A&<
MJC#H);E,X`!C(ST)IH`X\BQP-B[#:[]O-N--<Q](CZHW9BA=Y4O;*Q(NC.R,
M/6JDU+6+';*9T*!:>DM%$@-=72.@2F^J/)B=.<,1)^!_U"\1/@P)!&#@$EFX
M)+P:6G$(1!9F`!P,!`A`*$(D(O.`YR$.<A\?3'].!H3:1;<*"C9L=1%(USL9
M9)A+4E::<M>?E5G!9DWK'EO32!,\2U3"Y^C290L9JA422>VF$JSB0DB,*P/Y
M`AS&;PU+<)^L\G36WT+]=FOU>YDM(,LNN&-WA0]@/<(CK]?=>('L49A[)JY!
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MM."(T"9.&UEO3-HFHDZF9-[+LG&I*L6IG!6Z17>C=MA-4*$28M&A^8M%L$`@
MQ.A3E^I!609**"(00AP'/C@9X[=9M0/"XY8=L#V$)"C<Y$!M;.Q7<QN;DPA#
M&+.2"DMREGX^@O7P,P>,!QCZ>?KP-7.?3S1CLM/5*=I.S@!"@TPX3:3V5;@`
M0`&,8AXR#WM(Q;_:R+P'R=GZ8^OG@8JX=(^NCB-0,S:#LY*^X*)*R$'9'M@>
M$O)0C<C,#]]8JP0QJ`C"$>#,C!@)8?0(<^V1!_3UTQUTMA94*9-Y.SIB1(%\
M?<&43GN?-K+;FHV.2IMF2$HZ(VXVSR$R)/E\:BC?#JW+AE>N,%"+P$&`AH__
M`(]RR8=FED:Z-.^6\\0'7VE-87$ND+&X:Q)9*N.M6\;9C:5E131SUJ>']=&$
M`ZY/5*&XWPF"X*@GX$,T9GJ$K7GK.L-T+`!+VK=H[,(./)AC?:NN'L<;[@S\
MHOGU8-P7Y#@0?0'J5^KSZ^0A\!S4.:=QK4J2UA--K9EL[6;EW/[)ZZ5[H'LO
M-XO22W?.=8:(-%Y5(I+L[2-0MSN?)HAL;:>9$6BD!":(*C$:9*H"0K)(&(+[
M=?-%.T*"T9$(`[=H!U7"1HGD"*#,>O,!V#<*>CCQ('%UC571V_KN<U4WM8JJ
M8NN)8$,CDC8:L<0("E!Y']2A!"S^,?&6U@1]O.6ZP9G982NU>]HV?,K`;X^V
MS"7J8XTQ_*Z=R9+%T3:Q)Y!,71V4*%12-.F2%B!CXB2@BR6$.H)Q;TCLWKVM
M>5\R%R1JF]83[C+^5(L(&G4%>Y8@F`^0DS./(<XSCS],^>!5EJSU20;5B742
MI9MA[XL2IM3DUBHM4J.G@:L#%Z20V>SO<;D*$N712N8W9-BI4D:D*E"@_<KN
MYF)BOC'D9AQ?R9#:<VZX:9G=%W1K^[2NR$T0N[:]/N`_N;<YQTF1,5CIKWA&
MPP6B-*U$:5($T5%.8*07DI0F4JL(5!P,'X,R`T`99/M$:JL6?;A6(]R&<)7C
M=+5Z*:G60F:7%K1HF&O8DVW(V(7B(^S2>I2R\\J[7,0U*HQ20'*=-@!(?4SY
M`R(&JD"8;+U'LE/)GQL%J;4=CT3`F`HAJ`V21FM5IJ&/"-?QE(0FE*FA+4"/
M*4I)A.3DU0/(\>H`!X&A67K4BC)0+M0J:VI=AM<]^3]\RY`6Q,0%B&1';BH]
MP/\`&:=";E03B+_FTGX82S!@5N4Y@E`?4>?BX&YWS4)&\7KM%>N9P:!VV0U?
MK768IC%&&\!4%:JY7WHZ@D:=]3K279^-?G"[3!')#?@`1AL*^,S.3,Y`&"1;
M1M3$P=9:9)9!"XCKTB"^'+E!\5RD56NC5:MN^NH5A!9#V:3#QC7KB'HPG.7`
M&<$_;X%Y\'8#24RZRI4_ZW;K4:1?13P][:[PD;@M4RED#*4`K9M*M"BI\CK$
MIL;WXO\`-?MEIIO\6UO`!HSB<'ISQD"-('DX),+=3WPS:W9+9%%.&X"*]]1J
MEUO01%:TNBO]NR"L9=?\CS+EA^7L*-:T.B>Y4Y/V28E&;@2(T0S19-#D`4,=
ML?6>T-&B73;3,PL=$AA.E=_Z@T-8LLC4A,J-U=")^AA>NX[)A,T?$DS0P`R,
M3%6FD7Q.12LD28K)`C<#P'(@C]K4VV>T;NWCTJ,,TCEY-3KLUKCVHRO?"5V8
M%ZE[^RQJ3ZMVX9"5%:D@.R]6'.D]-GX$\(7M6E\N?WQJ4M.+P`.FU3K))1W9
MNK:)2Z#@;-FM?*3J.-HDZ!S3/J5^K!LV!0NKM.UHP*4;@WK@6VWDHA)0Y,+3
M(C`&%YS@O(PB91G79:E9MG2RGD$P@CDMZV:/FM96T:W*9`+$O>I5JTUT<0KK
M\U2S$C7-"61H!'F8<0H!B1Y`9@&#0?%P/!V&ZZKCL_27M%H2.R*#CLS<38*>
M7O5BUQ6.+?&@!R@I0Z!1J3GD-B@^,K#`U`2V*UB<E:$HT?Y#U,&,9.`WOIC7
MNTKOLIM9M5M!3$)UY<;=@.M5/P:K(A<:6[E0F2BLW-('J;2.6-T-AC6G4/T@
MNDY&B2E)\F`1M@3#L`&9Z\"S#@<^6U.L+#/+TMN8/G\?V`[/*#YD6Z@N\N_-
M68T_W$8V(F7\3*L1Z92../J(U460).N2NPTXQB2`"/"HLS(@!6=6@(7"]8OY
M0M1-6NZ#2ET@5:,,L>=4VDVL'^!UJ@F.DAJAEEK!:%>G&M\A>;=<8RN<53,$
M84+%X2?;@`J7KL<#LCC)N#XW'SL>W@YD:C<>W^[P8@3CQ[?7/ZOK]>!#2HL?
M'V`;KEY\>3J,TD78]?Z>IKEM8AQ@7]/)OLVY\Y_^7U^OT\8"<W`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`C=N4[F1_4':M^)3EJS636V\G<I*<8(DI28VUA*%
M@$YIP`&#*+.$3@(A8"+(<9\XQG^G`J&ZZUN%^T6BP$R5<(*'^/KK"M<E64^?
ML4.))8<*PPI3%F,Y`-<Y8C;B+!>,8R$"00OK[?0)H]9X@JU'8:]XS@(GKLYV
MB"8F#G`P)115KK.O@8"=],FY6DPX*L7D(?C&H$7CVP#`Q!9SP*,NXY4UDV]U
M6Y=78](E:-L[TG"AM1Y+/7+D5?Z"[7254J3MQIY(%848TI9`A_3)?WN,8$'(
M\>0U9V21I3C^.L@BBYE<I*J2Z]]?K2X1F+?=J'J3#06MK.2NC49$C-0+S'B0
M?;C1H1%&$'?<'%Y`(`O&<!`#8UAU7`YTPQUAU4=XL>=$VQM5*;%DB1'O2J;V
MVI6F084V,-*]Q/:"5`<<+FL($X`(_89H3,F$F!&4$80[%4*<E(A1I4P3@)TR
M5.G(`I-4'J`$DD@+*">>K,.5''!`'&!C,&(P0O.19SGSG@0B[&9-2$2U4F;Q
ML/8&R%8U@%]A:=SF&IZR[6^ZV]U42=N#'RH\MU];7:R4Z%6\8)+6?`3E(-/D
M0%.?B%G&0Y9]KMC.N6;4<TU#3._':?9%XS>S=<(]6E+;,2'=X$*E\E<=D*W+
M0(+1,N^J6"''L"LTHT\TQR=/BP66'";`C`$D9#I=ZSG!8XP7;82\\Q4H2=D6
M_3>%2;Z_(-&CV,F)381G`0AQ@MN;,$I2_P"N?C(#G.?/G@0P>MKUFH%\=EW[
M1KI;=>PVQ.[=)U]J50#,\(F=^NJS,:!:GX?Q*G`["D,.JJK6I&)XE\H6E!;F
M5K+%["&J.2)SPFMJ-HLNK>=K=MMK)@BV#WVGD=5,4GM;"96FKZDX4\*P.QNO
MNK4/7B$&O:;CBWR7E8<$R2R8_`UKPK-,-"00%C?`<!P'`<!P*AZ5P0[=W&^S
MD#'Y$V):&:#Q$:_P9XCAKY:.X,J/CF!!P61[.Q&4SAG`\&&>/'J((?8/`MU-
M&(LLP82QG"``8PDEY+P8:((<YP67DT916!F9QXQ[""'SGZYQCZ\#_G=K[%E-
MQVIHA*9'H7LR@%*.^;?+8VJIDTEUFYS/#VKL4UJS6DD:BK81L['*H3?S3'"G
M]:_@;(YALCF`IG`\L"SY`NDK^T^^:M876K/:#=M_<$NB%CQN97$^,6FO728F
ML:&1^9/`IW3\&=VK>:(Y:HS+X4M:TS:[BCOY].YIUBP"G*09:-,%7G3+:&[U
M82G<Z=436VX3K0AW:SLJNO*IH7KOJM8]ER*3'(8V%CKR1RN5[#1MXJV0,3B8
M0FFY[>TO+04E&68U.9!N%(L!.%A[%?Y%%;UK!2=C-*\L\P<KH+5V]-X/J%,+
MP0U#KFC)-<71Y8X_1FQ+LBM>5GI"C/"0D;0K1?&`C(%AIPCTX8U.;UN"<3]U
M;G+;7^0E1A=Q[`R39]33R3KE7IW.':V1K#6ZF4]6\BC[5*98U1Z)F/:5M5+8
MZY/`3!.2,#I'3!EG*,A=@=W1:V-Y20QRU[[)&XA6!U"C4N76YN(G"L4,[;^1
M&E*P*IOE,5+0!$`K]&`>X!",$65C)G`_Q)W<::"^-2]0;>:),0FI(X&RF3]=
MN["*.IEJL!@_V^<M24<O.R\DX!CSD!0T9GOCXCS/U>`AQOOWU06#ZZKI9HO3
MMZ[%[&-L]@146I^?Z9[OU^V2!H.=##9.Y%O+G4$,3?(PM*89N`"6Y"(P0`9*
M,R/`>!&2VOY(=^0"97@EK71E+L'"8%!J'=:\&Q*=G:KGT\FL\A3,ZVTP,T9F
MNKCLCDC;54NPYHU1H5+8<61A#Z`5G*#P)0U^5_*IE+1K:^3^;Z7L\7V05W3#
MJTA.O,AM.?P0S,+?*W>97-+5DS[8%&Q]W,9:HFC-B-O!*!L-).7K"/M%1WMZ
MY#8TW_E45C'A7,WQ.B:TG;E%-L6S62HG7_F%5L&A\X8U*J/(C;]L$V;,33/Z
M[IEQ,?LF-[RW1R2MP24:H3DI;0DA&:$D;^_DZ:&TM75XSB.+&"Z5](6M2599
M9*TO2DGHFW4EI15FE,PGE'*4$M<9#/HA3_Y$YN=SLLZ/(G(@)?\`9+$<:F#[
M:<_D=Z^69;.I-/2JLF"I'79J+26?OT\E^V6KJJH:DAB%.!XBY+I/&J?G9D-D
MOL=<$!BV*Y1-KFV.2HQ`'[LQ&J,*#2G\B>^==-P>NT^EM;+1JC<.PU>RU$X6
MT)KM<T/L2R96B1.D@7N#0GCM;RASDOR`2-QZC.`EXR#[40_IDOR$/#ZQ*^JZ
MM]O3=AG-+KK7^O4$HBHJEHY[OV<M%4[=U<G.T.T%"/#[706AD@K@.PHRC3I'
MY:!;DUK6M!I"<HH"I1\X=5(Y`P`"6(;VT`":4$XH0W)$$)I(\>0FEYR=C`RA
M8_H+'G&>!YALZA!&`B/F,5)P//@&39"T%X%G'C.<!R-9C`LXQG_3@>"Y7)4#
M,D4+WBU:W:D*0(A*UCE.8PA2)0@\^XE"A4Z%$D!!XSYR+./'C@1>V(WWK_7>
MW(G42NKKPMUV=Z:L*_9DOH:"AM=36-8P=P8H\U/4GA$9=%-E/"BQYA("VM@3
MLC,Z&*C$JU09\*-`L4$AM'4#9Y@W)U[K_9"(US:M7P^SD2IYB,=N9C8(U.E<
M;"L.3-,D6,4=E$N3-K;(DQ.%2,!RH"K*<81&DEYSC'`JMV=W,UCADVF%!2+>
MGLQJ"Q6*\Y:^OCW4FHEFSA,T8E:<HU%5+',5>BMHU\[5%%$Q>53*<A,7+/BP
M8,QS5%?0(5/T`"O;?J#^2K(HW<%L;)5?-W?7F$J+#V!C"B$7!+R8CK;'669Y
ME[`"MZ>,;$3=E68U-60L#8I&@;2S<EB$,!YP=HB=.4D3D)2`Y"2F)*3DAR(0
MLA*)`$LL.1"SD0LX`''USG.<\"#%*",,WVWL&HSD9Q-<:9HT@Q>,B*9RV:]%
MB=*#./H$DMX7KS<!S^K`SQY_H+'`G;P'`\QL2N27\A^2=<.GW+FJ5(/"$A#^
M-;3?C^U:L_`,?WF4F0B_OC\#,]OKCZ<#T^`X#@.`X#@.`X#@.`X#@.`X#@.!
M#KL16N#;U_[R.+2<C3N3?I_LJN0GN"<Q6B*4I*9F:@HQ4E*/3&*"0B+\B!@P
M&18^GG'`K%ZST"Y%L/J:WGDF851WH#T';9%X,`<!&O63B8%,Y*E0$7HK,5"8
M7/)0B_DP'!!F19![@]PLJTFNZ/7DU;-N4<IIBIQ+6^Z>RE*.'X`QL/3VJ_57
M+R8R_7.O.:V%@+&]SMT(,RM"=A8I*4)A%FJCQ`R+@2TEDMBL"C+]-9S)H_#(
M;%6I:^R>62IX;H]&HZR-I`U3B\/KX[*$C8TM:!,6(PY0>:644`.1"%C&//`H
M;[G')F6V]UGOR,Y*^@:WK?ZQF@EL7%&`=VN+]:FR#X0Y!7)REA0HF>N,0$JU
M`/8L0%I.,9S\@<\#W>T)I,9.D.,,Z6PTL`(8DG6^@46B]&MK:@B3:U[+:PIE
M4Y>OS!QK&2@8DQ.7!26N,&A^,D6%`LD^^<A%*]-A+$E,WH%@UO\`Y%U"3=*[
M[,P9!:$<8C^N$N3QFK,-TA4NKH$YO<XZ=+FM)*T#:@5-!:8]4N3..?`3<DY"
M8'4D4$8"RPF&?*8$``F&^N`?(/`<8$9Z!_2#W%CSXQ],>>!'G:0-FJ:3D^:;
MV"K;6.;EKF+*2Z+4@#=:$)BR$B0(0/B9QB;G/JV;5:QV0A-0D&'.I04Z@X(O
M08L8#P*2=Y$6[F:.JUIO/>32:VZV6;;Z3LUI5Y5NM,GKFP;.BSGNI0C:P(8I
M)ENUEG)XX\G.1Q*EQ$4T&%_`0:`@9/GY`A:OU],;4T5!;*Y$C+3NDEW5WR?)
M2L+$;G+Q("=P;GCV7,8#!B`4+\*PHD^`EA+!ZI\9]?;(A""%O5[5,%F.U7:M
MMO-&)%+-CP=@%NZS-MI/:5&J?(O0M45[2V8#6,-$!,23&H^D1.17Y$28`%3R
M>E3C7&J?M4OQ!=UP'`<!P'`<!P*GM<F=P([?^SMZ^(`FE=K7UP(PJ?F!@PMR
M29VX$:CRF\Y-R#"0PLWY?H'.1^O]<9X%L/`X_=#]$-OMKJ.OFV*9[)++HF&S
M7L"WT<H?&6!3L8:0UQM-L_9[,I'YB&T56,N#7I]0J78("V<@[`U>?N#CA9$'
M`:/B,CVQ@LXA,65W[NA.+5==D]D-2Z@F,2[9VB$,NR4VUBECE'9=,8GJIMU5
MU\P\AV"N1?8.;8Z2%2VX$'*E(,`#TN,!,G^(RX'RS0C:>SG-P>G61V=V)7_*
MY(X/V&4#@O=%\*J%8>O6)X\G(9DSBM,6B,5`2>4F#\B^#`2O4.`Z4+[ESC`*
M+NF>,[@A:7:$U-8TN:W1S,3DMK:XQN'O+RB<'`Y6$:4I"C4H@F&B-QDL)8<Y
M%C.//`YY.M*NGJ(7+U*7,^V]L[8<ZW*ZR;MO&]VR]M@;5MJ,J+B5,^D4H7S:
M(PJP'QS8JW<UBJQ'9.).RIF](%`<40$G`2@YR$A(WLE>JW3/4V1J[0E9TVLC
MM_<J'EDSRL)"].M5,/8W=L9'"CQ!38+#'W*N:_2QH:<KXOC:A9+"+.`^!!\.
MP^V&Q;&5_(?2Q.R7J,N&H&M=6R'6M440Q'EUK))!IQ*K05R)F).:U!)ZA=.<
MA5F#7A5BP,@(<8^(LL&`ERAN^WT/8=IEK\\3$T^'S3KLV"MZQ(ZG`D-12"U(
M796ID7:)8:X99"%IXFY'-7HHD`%8"A87#&)-@7H/@1!K3>_8R0Z"=>=X.ECM
MSK9>P?95"]=I])"8*QMQ$PJQUW.MVK71B01U&U+6N+FG5E#2"_N`9*4)P)AC
M^YRI%[F!OBV]NKR@B_NS>4<B95#7I)KA#;&UY:#X<SJC(K+#]3YQ;[\Y.ZCV
M2JY@E=Y>WHQX3*S@EE%)1%`$$)@N!_#9L=:#GL)U$5O(R*[<F?<;5/8"VM@\
MEP1F$9)K%K>HM=I:P.$=7*RSE+"UEO\`8+H<-,7["-*R2$0_4GQD(9I=F'6;
M:CQ^X914FJ[C,YAW+XT?ARA=0,;=XXS4F=ON9K>8$QN6#5Y62]76[&L_^Z84
MIB\JSRS/3V!@`PWY=$HJV./O;PT..M.H;K#-&M5ZON6K&B4Z_1%<G76$^4G>
M5G.BVP#U!!:9_CYCC$VE,F)1DHC$Q(%./N!&'9^$*I.W64FZAVMTD2_4S2'5
M7&U=@S1^NI[BT4INI:4?K,>:NKR#J9+3#':9P&Y?6S<^);;D"PDDQ:M$:Z(D
M!7HK-\$J`S:N7N.;'0`S:#:?234Z\;DOKOLSJ4-'>U#0VT%E2T*&1PN@'MAB
M2MX2_DTDDA,:J(PM0H7>Z4UY)5K3$6<&`!@))S*G.OF%*NY)$LZT-#,L/6E7
M$9L:M,K*2B1!LZ62?4!/L*Y$3Q4J1?`C0BDR<+81]AA-C",'G.<G9R+@9TOZ
M\NM!-LQHO4I/6%HRMC^U]$;#V_9C\HJ!G+=(P]U.R4(ZL*2#HCA'MOXQY=+?
M5EJR#2SC@D$$B+&'!9GN$5;BZ_>OM=IILA?4FZLM'66:P#>9XUGHU#%&:55_
M%72%L>\T3U>KR?6OFNGQKD>%);HL/7R9J2FI0O"!*-'C)*=7^D)*=8->ZV::
M]H.[^K+O!*"I_9Z<U)KK-*]!28+-C-<V?32%HFZMW:(1"[1E4YQ#II$I`6<>
M[LK2]'IU[800XIDA6$KD(L.DS@5O6/,]_@V])66I[BZW@05(]8&QPNQV6Z?\
MO)XT6)*!P+DJ^-VP%G3O3=\^<X,)9_MSLB`$0"/;S@*-ZB66N^PG^1;+KDD]
M<2*9.NVU#PF2&584^EP<QEBE346RB3-V)&X.KK^WE<#=4J!26<H'GY4ZSZA`
M(.`AUT\""%#C^ZWGW\4F^`*$3+J-'R2P><!,:T==SI_3*QA%["$H-<I0M*R+
M&<`R60#&`X$$8AA._@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5^=L2;*[JZ['
M$@"Q'F#T8VLR$DL>0F"$&C9R8#QD(@B#^HOSCZX_IP(<Z"H#V'<*L8^H7IG)
M4W='77BWN*Y$$?VJY8RV;L$C^]+",`3$Q*G[@9A(3`EB&`>?&,^@O4+&M/[!
MJFRH+:+W4=7(JF9V;:':2`RUB1-3`T9D5GUM>DW@5D6.K(CH<(U*VRI9'E+V
M-0=D2U1A;@:K/SY,Q@-.=N44=YUU?[]0V/0J26+()/JA=C(P0R'L1TFE+V^.
M$&=T[.6P,*8!JMS=4;B,M0260`P_W)QDH`S,!#D*ZNU*+)H_9G5U%VI(,#<U
M4YV6P5"0824D']F5UBVP6B;#4Q9*,E,(TI@"+(`E%!!DGQC`,?IX&\>P5.HE
M73W6K`UH(5)Y/.EO6PQ0N+6(Y)VF'3R7O&S&L9[)$9"J4-KQX:),>7DA6$"!
M<9E(,W(4Q^<?$((S[`T7V%JK`U?1)>JWJSDL)(V.C8IXX5W-T\L&1"1P"Q!+
M13'_`"9HXF.@4(1OA;>>H>V8M4\X<$Z)(04$I6<<4'2=C_U_K_KX^O\`^GQC
MSP.<76"H')[ZV+TB!VB$;WK>9GV2[S/\VUTO>9Q&"QV1"1;G6^0Q3PMUN2.2
M2,F(X\QQUE-1$X3YR>'&3B!B,\X&$,M@M:H=&7;620NW\?VFM)E!^^.@29^V
MCKBQM07Q=6XC]MZ23J0QE+3RAILQ4BEF!?A`')VY-CPL&8J3`*]LY"Z7JYV(
M)EK+>&N=HQ=-5>T55["[33.?00DQZQ$;&B<]VFM]S17[0*^3&C=I?2,FDBI8
MW94!SD;*^(U+<H"7Z)AGA]?5>Q&HA=C\I$I*R18/:MMV^)&LL`\&,9<0!7=.
MJ$ZA1GP2K->E]8G/&!%X"$HMS"2+R:48(06K\!P'`<!P'`<"KG7.1L3MVN=G
M#.TN)*YPC%"]<;5)DR<!X?PKXH1[;2$EM6C-***&O/C4A;5>/BR8'[=25@0L
M"QD`0M&X%%W2U/ZPJ#2=J9K'M"O8.[VOOMV`1JN667RZ/Q1?,97G=BZV%-#X
M4B?7)"HE<@5J$(1E(T!9J@?W``X+\Y^H5I:NT?;TRVDTWV`B\!:)=KSJ3VF_
MR$7O8V8NRR.G--5`G5HR@%:39`R+7!/(7AQRJ0+TB(QI3*Q(E)OS&EXQ@L60
MD'_%06P5ZTMW%E-1M:IJI67]FNT$EI<E42K1B#5[A'JGQ#T_XYS<WAY;C$#.
M44084L4'*`C!GW,,SY'D+V]WGA-'M+]NWY8L3MR1EUAOQU4KU9B@E*B);ZJE
M:HQ4H-2!&K+)(`5D0LE!$;C&/T8R+QC@4%4M&[BLB>]#C-0-Z1"DK*8.DB=2
MH]TG52++N;!QQS9>O-@6E?LTBR:O(3.#@JQ@);A^2.$6%.87D@7R!&`(U5I6
MN_DXT[TKD##MWJH&LYGVKR2<1'#GIY9#7-!6X=O3L5+"Y$M3+MEFTE?$%T]3
MJ7$V.@1M+DD9O"3[_(TYIR@,3V'@G8I%J_[W;#4[,ZK3Q`5-*D8MSR:LHR25
MU8<LJN+:C5&FDU?TI)[2LJWX%5TD!3<I\"2O#1*B1NZQ2<G4I35>`$!.=MCG
M;>=V(:;LEC7-U\J[XAW71L>YDA;JFO%9"C43M;.GD?L1[D3&SVA$U9\E?'MO
M;L-BEMRULI921?C"$/R)RR0K>:6#LT9>OOJ@3U6;JB[UNY[PM<\JI2S,\Y9)
M:];"R78&YYW4B^TD\OE;TB!K;.'IW<G*3&QH/[O;VI63A,F#@A2+@3$O<[?T
MAA[_`%U?HYI`XGN&ML:BUU*&VU;TCA45BB'1F2*\G0T#K4KVE>Y$GC4N-<`%
M+SFU.<>(I*(\L&?N2P\-K=^U!CWBZHL-FM>J<@9()I/8C%0,,37O*E495UXZ
M5Y2S7?-@VQ<;W7C5-JWL.&B;Z^;&%"RUW*4+N2].Q1BXK&<FI@T:PN>WY6AE
M"QQ-J?0*F()^]Y+(2G:";928#TZ6>R]K\N=LQDIDE6NX4PXN=/4PV`E\/=1*
M`L20#J:@`;G[((9':=E]A\@FG\A<$]U-J9C03+2PJ.6\+&PQS?'J,8(CKC:R
M"I%4'G1T'?L7^Z6-6LM<9*X(\,<()8U*8M"I.">IP/`:X[N[<LXU^T'D%[0A
MRUIA4:U6V)5PV85+V#5Y3]H2:73`O65#&FY`[N-4J'K":)2MK95BMN;RQ`>@
MJ<_(I`A0+BE(>GK//-LBM,M,$.=:6RQSY'W,I[8)N5399%+OE^7:Y6?;]M70
MS.=0V<@>)9`7&#68W2F%#5+G$XM8&*DN"<L:95Y`&W[ZN/;QMB'?=/E>@+M&
MR[O8JWJN^9*_;'4].(]K97C=H_!XA)['>X?71TAF-EDU[7T\.F"ML8$QKBN2
M#"D*!@\G/L$BJTVOVQE>QO62OE/6%=#'942T6V@=(3$U&P&N[(9)FAQQJ%&G
MV4C0RJ<1Y^B2-`6B;@C:Y(A;'LK+Z7C*3)J)6$L-!8O_`&"0:35M`+*T>N>O
MXG8?='%'Q7<#W;FMTK@L==)-W4F3@<*D+/%K8=[+>5K0\)SHV<:E8#6XY61A
M26=E#D!N0V'V<.=R1RI>^6UM=EDZ;MG*VO705IH:55A$U4PM&'KEU":V,:W_
M`!@G;FYVD<:DCW&+IEC6L=6G!:LMH>50`X"$1V30L-TQN57,^Q*SZI*VROVV
M#ZRT"U1?[$IJ>P9I0TZW3BQVAA<F:Y*WFX01Z6*I+-X^TGJ7YM=F;W+7.@QE
M*PX+,;T883>NL5?R"\K7DKM_'NI"_P`UUF3LX8OHN2Z+D2NWE+B84>KF[R@L
M1TC,K0J'DT0QJ<.2@:T9P<"&$?MD80JHUXCCQ46D??K)46K+=JQ`W7=R.1^%
M4FUN,).C\05M""BX3,V9I4UNM=(B,EG=UN%IF6[/V0SU0BRQY]1^@=GG`@AK
MJ$*C<OL17F8_[I/+M9HZ7D.?4'XINUZCS^D"(OZ^RC#G+%V1&^?U`R`'C'Q^
M<A._@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5J=QZ4&>J/LC/)!DI49I-L5\B
ME,'XU1A2*K)6>448<6'Y1D%Y,,_3G/C`3!_T]L\##-,J^0LNV<\E;58T`=T:
M3KFZ[:Q%6+>I>C+1AZ2+NNS3XQRZ9%GMI,>-C$W(DBDAH4(U)AQJAH6A.))P
M66(X)4:6RW7Z>U'*9GK9%W>*0)_V&VA%(4;\A<6QT=;@9]A+'CEWRDY`[.CJ
MO2II5;#,[KTH1B(QE(>5D*9,'.""PJD_DWV7?%1]7+Y-]>[2L&F)@BV"H!L>
M;'K.?.%=2>.Q603++&I-`\M#JS.JQ`H?7!O*.2D'XR+WP:9_9),S@-;]V"IW
M@LWTO4-4@<':60;1GN5=6R0+S<+W@YSC/7YDDJ;J@_W,9=?RF20C6?Z#<!E>
MW_<>!!FW=<M:&;K'U"0'L<T7PM=MSULM;\QTRBDY]FCB"&U(,[G-U/I8&J23
M`$\-+9BD[&%H-"XY5C*`E$$\18L!7W8%H4D3=VG40K"'_P`C&!-I>S:MTOI=
M/!=G/P.%:.-<6A)8\@5%N4LD93JG/N0^*^Q25*,T+"0M"K$$@)N1!=AN9M7>
M]:]F_5%JG5\H1QFN=FB-T93<Z%9&HX]#GR"A:>CLQA<*0/+PB.=(>H4OS@8,
MQ<@.`9@H6<&`-#C`>!!76/?P_:?IDB6QG8YL#<.K[[+K\L"J9+<NF;+8$;EJ
M!U@=RR^-1E$Q+JAAEKN33'7-#%LH')R"E_'*!@&#)Y8SB\""#DIN71Z=6KIU
M":H[C>Q7:^:'[\:.HV_7:_UJ]N@4L`V[&UO(0*)0![U/IQQ>C(@E;BW4'EYR
MJRJ+2F'!-P8`)@6,1*5DT8EZYE=/S#K;?I[8^ZV\%;IG^X)/8<<L1RJ.V-Q)
MW(;BK?4>3.#.S.RRV(@:M3$R-B?"\)')_9R$2;YS1IC!A8!U?E`%6^UKK[#"
MI?.R/L&5K4><8P!`>U;.SV+%$E8SY.Q]TACQ*HS`Q#S@Y0/`<X+]`A"RS@.`
MX#@.`X#@5FZA)Q*M\>V9_"<=@@-Q:IPS[,]0<+XE4;TZJJ0GJR$GL-&0E6D3
MHD(3`YP<:,D>#`X"67G(69<#@CJF)_Y(6?QZECZ/$CD#-W*]H+BJBR+\'B4+
MC&O9FQ;,=IBD*<&M84*)05QB)*U\^WR7X)4%X*R!1D@TD+?-.-([*G&HURS:
M+]B>YNOD7=MK>QI[?JLI]AUE>8*P-B#<'8MKD;+&T$XUVG,^<#WD3>8M&8:]
MJ31*5`BTX2P8*"`/G_B1Q*/QSIQ@3PQ*W16.?7WL!+'G\D86(LAQ13(,%1%-
MI):9/]HC-C<*0'&%YR9G[LT\6!8"+``!??M15CU>>L.QU)QM<WMDBN&A[>JU
MA<G<!@VI`\V!7\AB;8L<P$A$<)O3+78`SL`QD7QXSXQYX%-&@]![J_\`*K3R
M<WGJ&9K!7&EG6Y*=+53\[7=3ED&6Y,WI]UQ-;7>#1VJ7I]5L<,;4M'+3\C>,
MH5'AP3!"1@03L`#W*@T6VMAFE_6]3;U&8QFP=?.R1QV'NQ(?-FUP$S4RKOC:
M"?$O<;?0'B1OLARR62P#.1!&([*90K)Q['%^N0_G8#0G8V:TUWL0ABB;0[*]
MZ;!A<IU^1)Y4QI\R9H2:P:_U?(Q+<K'!N*C#VEE%>N998%QB<)PB2C`F9+,"
M+@3A=->[,5]J-7;+IV8DJF8)U^VS12N49=&L:UULF=7]3LS;8Z<S_?!?"T[;
M&*^4+,*Q)QI1F*<EX,"8'.!!!^N-5-EHUIITZU6YU$L+F.O.YU<SV]V7,AC!
MBRK:_CS!L:F/DV#TKP<V/B),NE;.E&2@4''X2K\B"6+!9@,!DMY:SW'((_\`
MR!VB-5A)7$S:FC6-%2)1)201-L2L>BN*L<&V*"5*\%'.@)<TDM@\'8)`%1DO
M'MZ_7`;H4TK8Y'85UO2LF!2W_%%):&;60AZF)83!MT5L64NNH32P1";N28?P
MG+'N.Q%S-1ISLB`<I;CCB\9$1D00A76.L=T(-&]*8BOJBU&V4(^YQQV/LN'.
M#*,F21>OEN_]\6L@F3ZUM'QE,L,):5[*\F#R+!!:$\)@O8`O40>_M=35V3>/
M_P`CML1U1-U2"X=5JQAE%*VN+N[EFWG)!IC+6U[101&C3*%4LD#5,'S\6,E$
M4:+*C!!&/)OL$(0B[O*SM]5M1TK1*&5#5ETL:N#WA4LB@&Q\<8FVGKCE8HW2
MLGC&OJ^S)A6%HL]<VG<!M<JD[`/X&M9\Z8[PXI"/N3R@WYJ0R6M+M5NM1+/Z
MUDD<EK5W:;<26X82WMB]Q/K1:R6+V)RE(!P<4#:F`W1:/RW#6E&X'$HTRPDT
ML'@/W80"#>&RT<G;;1W\D`MMA<C5J9XTY'"B\1=^5%35(_=;M#PQ>9#"$Z,)
MDK7)7%&J1X^Q^<.'(CX!YR,`P8"8+K6:I/VFZ;28+5)UC)`>N7:Z)D27\>KP
MTHW=PN/3),E;9.YEI!-I+N\-3:I.2)1'%FFB2*#`!$$H>0A6?L(;)V#J$:)K
M9K-)HOFNNW!NMNP5,GC#XP+(]6T5[H'B9N]@NS8M;B'!GB#?7H,/8W`XH"8+
M1C[OW^$6!Y"*/8-N(Z&Z0][&ZVCE_P`H;XHY;`:&IJQV5H%T<"44D%'X+J_6
MUHLE?V0V8*3EB;3A'M3JY(3%!*7)XDYGMG)A>`M4TK:Z^7=R_9+)V6/6&X6,
M@U4Z_6J?6#,9Y%G)CRBD,"DCC%F:*PMMB;7(4ZI^21XY6\.2AP4)C'!!G!2=
M/@[&!!ZNWD8K"@9[('VVNR3MCKA%,EDCM])%*4A3I;-<0!@5/@42QJ;GBO=)
M[<4QV(L[@M+(1M#P\'FIT^0"P#)><&9"K;5N/UG<_6KVF!B=J7?9\#NCMDAT
M<7V_:3HZ,=XS>)K[JTZB"Q;)HH_Q**FP9W$PB.;@%J&-O&L3%A&>A)QGX`AV
M%\"#>MA91VUG8LO&$6%A-RT/'\""+P0)K;M2Z6?$6,E9QG/W@7"4K?D,\^!E
M9*#ZXR#.1!.3@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@54=Y$G<8EU#=ACBU`
MP8N<M8["AH"\DEJ,F$V$B*@2LL!9H@AP8-')#,`%Y]BQ9P(/D6,8X&X=87J+
MH=B=@*?;7YV52>FZ'TL9'V*NM8QB/BB3,ZQBW,QH)%M-V0R:UAO)K0O&H3+B
MP(H\H)$!%Y$L58"&;:*BUG5:[H'S49T<WVE91:VQ4F2/SPLEZYP>[$>-A+/4
M74YFJIS@,C-)/N3\]@CW"%/]N$O[7'VWPYR%6/\`(^;ZVF.GVN]06A_EI&T7
M/OCK1`X\^59&:KD9+?-E+I(%\<03LRWYW`(DPQ)\&C-($N-5F`*58*"<6).(
MT(@Q[N\;D:B>1=X!E2J75SU,]V$E.;$7PDY-1R2H];ZU;,FX,*%[A7OTL(2)
MR2,"-&K-*Q@.0^<9#8';FLS`]0NN*#*K*CM2RUV[`>O"&QFU9&SM3S$8)+H<
M]BFN9B^QV4.C`W.K*SHX&J/RE5+$>!"P#W-!XSG`>,NOC;J'W]J;5S%VX:5W
M9%=A;JF,0=QXUF@`)BULD%JE_LY>P,KI`]H2H^N='U='T[.2(QN)4),O1)W_
M`'0RP$'!GN[E;-UF]PO5NZ)-B:<K294M2V^,E9ZJD14S%<\Y06U3F*X4S2M@
M)6%97SFEKA<@(<E*-Q<6Y6-.G4C*"H``7PA@/3U7FPU;=.FN-7:G7?J;:,S@
M\YM9E17!*G>;W;2DIA9UPV8[OJAH'70*8E".3E/[L$D*%88:-!DDXI2>I-S@
MW`?EN43V+-9VBS/L_-]+936<B[*-(F^0YHBK+T@\Z,<F*UT,RC0FT^>VE94<
M2H5$JBZ4:[)^"181%F)R1B.4%Y+#3U_T_([]O?HJL%P<(!7C54FVFS=KO\(V
MPV*3L-ZS*2*)T%,T16JXLLBK.XVY+FH653^E3EHTP6Y`VI$0SL_=!-."U_K9
M87!BK393[X2813QV'=A#XV_;FC,-PW+=LK1`#"W`BR\%*ONDYOZ0^P?B],^<
MYSG@6(<!P/!E*9[6QB1HXT^)XQ(U;"[IF"2K&;$B21Y[/;U!34^*H^):VA?4
M[2N&6H&CRI3X5!+R7\@/;VP',;T^=@&]VRU+]GEJV7LE76VT'U^;75%JG:D/
MUG<:P52F91J*VLZOY;A4#4CB,Z>FHM4PQ_)+8).-6L/5*$J9Q--`/!03#_C\
M[K[6=@6D+MLCMC-:0ETH>K;>HS#TM(-!;4BC<48X?"5IC7.2BGAT`FG8WY[5
MC4H\A)$E3_#YQG!F/4+S>`X%:^D_E?M?VS/V<X3_`";C5)&/QV<>Y@/VOH;J
M3_\`=LGY]!9+=\.^/4KT\%?!GP,?MGU"R?.<8QG.?Z8QYS_\,<#B`U%K"I+F
MCW0/=:JWX#5DABW8MVF3:#U7.%%F$3FZ?W;M39*TYEAY<(C$FCZ>50M"R-JE
MQ_.&M"`TCU($H"`TP.0OTT+$H'U0V(K&-7EV6R#LG6N"Q.9\+LL>#=K-H_NG
M$:K`!"R\*E(?D&=D.<Y.S[>/].!#K^)@#UZ5J.S]^UK/>T]@1_;MZY.K5-7F
MU'_'V#V00(1C8Z#]?N0D'8P9E&I(.QCT-!G(=*/`IZ[+^X_7OKKE].4XZ.\`
MF&P-M32O@JJWE=B'UHT5K1DFE)T=EVPEDSC$/F#1%(/#,(SS`E*P%*7/X#OM
M0F83'Y"$8*/_`)'6C]GW9M5'IG<.O56T#54V@=<ZU6O*;B,:Y7M')'EC6'31
M[C\`>(FW#9*QC,I3A;2Y.)8:U"$8$PPP!8O<(?#&_P"1YJLY59J5+9&NUYB]
MEW[;\+@UVU&/=2FG$_4>N)FSS>8$VW8TR$W-S1)T[1!H:%4M:&\@HY*ZN*9H
M.4%+S2BS0_!1_(:I!1KK%+)2--)/=W6;L='*WJ36V'[ETR.=2VE)1>"2L(1?
M<G<Y"&-IJZ:9.E$!>K9UY)I[4WJ2U2TXI'E0<F"_.IK?JR^("R6I2UA1"TZV
MDICP5'IU`WYND\4>S(^^.4:>PM;XU'J4"[\7(&=4C.R6,6`*$XP9^H<\#8W`
M<!P'`YWOY%EJ[%U)2NE\GU:LV`4S<+=N3^3BEFV>AB*V&L+J3K+L8QH6QPS-
MTCG'$*B6FR3+60J5)#$Z,:K[@XQ.42,X(;*K7;64:K]76^.X`H>U6+):*V&[
M%YX7%OSAC)')JL@NTEJMQIJ22)$+N`IJ>CF\Q4(](4H*P,8RROIC&`A:YJQ9
M<ZNC6F@[@LR+QV$SZU*AKZQ95$(D_F2F-QMWFD7;)&>S,\B,(3Y>$:##C@O!
M^`Y`/(<^HS`^!B#??`_@PLLXLPDXL!I1H!%FE&!",LPL8<A&68`6,A&`8<YQ
MG&<9QG&>!4OW'!KBJ>MNUYHKU`B&V;)23U5-A0[5]8@>$<&DLA8[3BB=O6/$
M5A:0\<@CL+)=5#XK:1(%R)84@$$],87[9P&L]9-=W&D>WO;;8RP[WJA*L[`-
M=*!6TKK<U?NUHL0+3K%!H?$++DBQFE*9.B`V19ZDA6$Z="88>4F>/*@A,(L?
MR!(.<O\`V%_NZ3$PK:CK4CT7(?G@4?:9E1MT/,O;XV:N.''D<H6MVWL>;E+\
MG:\!`K4)T:4@\\(AEDE`S@`0JGU2(G2G4#L`<[6>H+,)3(.^Z"9ETFK=H<V*
MOI@B1[<:/1=Y4Q2/ODAECXUQU:)K4DEI%3HO'G'L("@TH8#!!U&<"#>KY(SM
ME>QUU&/`,#V1J1C`C#@0L8`S:8ZTK,.`SLY"')BW+YZ9+P'^V%.'.1"]O`0G
M)P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"@7NON60:\3C2^T[1VINO6'0Y9+[$K
M_:"34N=)8VZM\HD#(T+ZA>U,UJYNDUN$JS3VEV0I6XAG4L!N3QGKU"4XE'DP
M-$[N2.QI9_&IO62K=A8YM.^3NMB38?=L>./=44XK&:;-L:"O6M:_OL6A"V12
MMFJYS1,CF\JV9G4JG=*<I-((-R(7`L]U7<UZ_L,[-$2P0#BXZT:,L:8PLA/G
M+?[4K+G]2PK%Q`/*EQ2*G\:T19@S!ED.)(L9P`P'`WKH;!-?*XU4K*,ZLS!?
M/Z*,56'*(5-'-=AS7R,Z=VA-)Q+'%2XX:&(2P8YK(G$.#!I2S!!#CW$8/V,&
M%)_\H']YO-`]>->Q!*E49L#M)UH:UF%KZT1Y,H5MK)8KFQM1KB_*F]H(_)N9
M0<%B.4$X^X++#C.<CQC@;_[7)"JC^R%>J64].)^/ZX]\8XG+&1A8!N-G]_=?
M4(9E[L3_`$2MBQS=LD`/%Y]#<9&#`A%^N0]?O<0GR"%];T,;J]K>Y'R6]J.N
M*%GI>WG83'6MHJ$=<7JX?MZ:NF(I.BTD?1&D%N!HC&9S!D:0&,ICO/ID(V-T
M%>JZVRU?KBT>@WJ^ATFO>W9,H9+6JVWZ8?)-$FVD$Q%AGVPV-#OI_`9&L?(V
M/P[)0ICRU8C?@+,,3*!E^`D+N%1CS(.W[779(5R5&V26D-"]E&?5/6M98*9M
MN^]+_F;;/RYHI9H(G"UO:ZN8]7Z-#A:L*6F"^\&#)`$PDQQX@BWIAK?8\'Z'
M=.*:V+ZP+%VOMUCGTH?9QJM(I;`:QFK7)W^WKCDH;EFSO;4_C:`"@]N?2U9Q
M*A6:XF'NY63$Q00FC3A'&3Z^:]UKLSUQRQ'TI6SHQ,WKL(I-@C]QS"ZJ;D\.
M;W`UDLN7&1U/%:AV2M$Q:N7D1$!B(M2QDH$F0&#`>28466H".+XKMZ0;0]`2
MG_CTODCS!;3[!)GJ\PR/9*N4$JON/HC7RQ766V&-SB8C:X=<(V)O5-J?[YT)
M6"5``>>6H]B@ATR]0.9JLTW62.QVM7'I[,=K=[97+8HOEZ.PEL,>W3=&]@JX
M8IGS<H5-LU'%,IL(<.286$ZD!&,EA"#&`X"T'@.!\ZLS)*52;@Y.FR4G.,PH
M5>?M2,@+$+!RGP:1G[<KQ[#_`%@_3C/ZL?UX'#WT,R^:;2]=_=VKE]M6>LLR
M2I;@KE[MTF:1URAQ*Y95EO+6Z:U*@)3PY>RN24N3X4*E[P[J#%P0HQX7D`+&
M$H+4OXLLQ66)U6,DY,@%>UJU/]XV83'HU6L)9(0Q";HLV0V$K7I:G8#0H7U^
M>Y%&ERA6X93(C31"P4,LS)/W)X='7`<"M71IXAKKLIVL@BKE)7)Q0;MPQ%-/
MSK4WM:!NE"32S55"8UQ@:18H6.K(F:D:865:LI,:-48:``!D@+.-"R)6I(1I
M%2Q4;@A,D3G*5!^<"S@D@@L1IIN<!QD6<%EASGZ8SGZ<#D#ZG-*KHVFU_P"A
M3<Z'6I7S156G<GW\F\_ATC8Y*IEECN5Y7+<<3!*(ZK3&F,JAS4H2@#]UX$AZ
M,1YJ@)RG(_M\!;UUS>A?3ZT%&%+U):.#[>(AEMJ%4Z.JL#?<=ZH\Y1MJ(I0L
M<714$CR`@D`S3CA>H`B%G&,A3C_&FUKM(KJZH78;3>]3:7F$P?;79K_I:WH\
MMN?7*Y9A"K8ES(U6,@C""91"<4G9JJ$(VMC6NK&ZX0KV]M3#6,RLTDA1P+Z)
M$@[C@8+_`&G*^L]1G)*09O[BK[:5'@*@8\X7$%Y;;,7Y,)(+SC)1N?41V<>!
M%EXS[8"N.T-QMK-1]V&UNV_J.KMD)E:%34I6-:1?3*'6"UM)<(MC85QC-CS2
MUV.P$%GS%:36"1C+<0G)5V&@+><>2<4G/4`/$&H6B[9M6E:Z![';'5MKL/6.
M#V)M!/Z4::Y.FJO:F!(*9USW*L@E(\R8B/LE13!K=J[KY8@=8\VML?;0.*Y)
M]J,93<`1H1+LGNSZSGJL=D65BUZ7RH_;F`3"VJK85C?JH^P.(68T:,TG9SA%
M%ZDB)O;7!;23RV7HD+DA6D3U<GER=<I/^(D.$)(2&L#9[6/3G<265EVB:QZ?
M2NVMHV736N8<FUKJ.#3"LGLJ>N>R32U3F[B;PAT9?&21-#A%Q-2M<!R>DRQF
M$V?;-J?)*CW"SG2G:>I:6TNZ:(#6E82)!!]RH]!*KK5N<G.+(EM:MA&M-C7S
M^5EY\5C35')"]&I*Y&@.`@1MH%BY<)5CX\`$6,-AS;M%A-:5#V8W*[TS*#&K
MKIN`^L92R,TIC*Y[ME?BMZDG">1,_GX6^*)%95H)4OQK3C3"BT8S3,@'[$%A
M*(6WL5#O(SZ*CB$E+FSMJ4Z[<!G(SFP,.+C#9;;+40X>3C[G+FMDWY1W^\-$
M67]L0E"#V'D1P,8#1\#[/J9L:I]#KCC<)L<$5W_O)SHFLR'5-&D;M#GYKBMV
M2@QWG9*:0KT*=N.!2"Y,`M$H5J/F6$>0?0S``R5_[(:2CL'WNL%;%K0&P=?$
M^'7%Q_"QQW*V1R`FO8#9*DZO$ILK+RYM"5BL9O"-0XY:\9-";D.!%@P8(*7N
M^+8W0\O>OK9TY[#XMEWUFGD8V2L&P7EZ;'MQB[+(Y7!E=34XY)P1(LZ7II$V
M2<US^)>A"(QJ/5)3O06!Y.2AH^UMEJI8OXWUM)W..V5&(SN<K[,BM?FEN9(V
MG=6N)N=P;5W]$/W:![=BFIA:U-9Q0S(RRA'K3`C"0E!D\18PA=5IWNA4M:]9
MT0LRQ)!(7-MTZJ2DJ8OQ\:X0X)%`[&CE,4LJD1D:C0L$KU3.`ZPT.`FB+(#C
M^Z+UP4#`Q!8R"XX0.[#]?@JU>;(2U8DN,]!A)_V!<(72U;"4JL2[Y/HK.?FX
MX&"O3_87D7G_`$X$6A]D.N2G5FLMN(P79<ZKVZYJ&N*?B<.KUV<K8LJ?#D\K
MBI<1B\`5&-[@<]&+(.ZJ/C/,3X"B0F'"$'&/'`VKJQM97&X,-FDKA41M&$+:
MPM-[J.P(#=U>.-;V)";%C+)&)0I;'B,.XU(R\&1Z9-BY(K(-.(4)U8!EF9^O
M@/SVWU5C&UU<ML=4R9]K&T:]DJ*RJ`O:&`)S/*+N!C2JT\>GL:`H&6B>D&4Z
MX]`]L2[(VJ2,:M6VKBQIU(_`<[S'!:R?;;>]=+S_`(Z^JT[W$A,=17=-G6).
MNF$/@]_)7:2O[>]7509MF.""5S"-*Y.3\CLU.8LJ8LL>$:)T,#E0E/4!_774
MG*3]?6P<=)IU)KQ'`]_;9%A4$W8C^$5,QY%O]K<F#6*11$5CC%P_M%:D"D$:
MSJ#6[Y2Q82#^V^/&`ZQN!##5Q&MS<F_CXH91-"1XVNCJ9O.&ZG.(WTJ.ZEZQ
ML*A]P08244T%&JT0TH4Q8AXQ]IDS.<",SC@3/X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.!SI=O<M42#:BCX-6FHO_*RY:*H*67JI;E.H%2;0+(M&;9M:'4O"'*`
M#MG8&EDC/*$TW9%*EU(0)G,XIC(,7'&HR4N1C#5^Z4JON[/X[-A.VRB]$S7F
M[VA7T+GY31`4%<)X$NB?99#*W)BHH/'Y1*F9.=7C*Q%-BC")X<T3D-",XA6J
M)/`>8%K&I;<Y%[T=K#QE&J"P.-OZLH$+EDH6&Y6_,^GM4?GT1!_^PQQ;4+@V
MY4@Q]2RCR,Y_W8X$@-*:/C&MVKM14I#;!)M2,P5E=4K1/TQ;84DD2=WD[Y(1
MGHBF=<Y-Q:%&H=QIB`EJ#O4H@.!#$+VSP*N.^U!K;)*_T&K_`&8>M@8^QV)V
M+:]Q2L'6@6&GGE6WW:N_<.:^<+!46B4-V:J_1'!4B7&1P8',T'DO.!EB]!!X
M?;,'"?8MM6"Q@&!]:6T2H)@?J9G,8W7ZX'@9GT^ONA+/R83_`*Y,%G`?KP/I
M[\&V$OK5UF,DZEMZP=H,['X>]GRC6!@G4DV$8DT:UMV3=AN]7M]:QB8S4IT1
M.!27[M2@;E9J5O&<=DO(`"$$*^:WM33-3OEHW6-?;D]VT]EUB6%/SVY[V%<M
M@F>.P-RB;5%U#/&W=DV&U(S(7&"W2N7C8W4YC=&="F29,$[*BRL(OC#H8M'0
MV$6AOQJ]O\NF\I;IWK#65Q5:RP,"5I70Z2--N-AC>I=CC5)&'5B?F?*H[/S)
MC!85DB`4,(0@SD85FR_?Z&7QU@ZB[4;-[ZO'5=(;VDS]@4RI%%$7-!(I"P.E
MB1DZN4A5MUU;QXFC*1@"YC.*"D5?.DQ_?"4+)7`A$CN.E-A=M^JBLX9W4*.R
M!WB>\QLY2T^MB^NK(K;TE=ZQ[&R4VRI"_4A6D"E;BIBBE.F1(LKCCV]48Y^#
MBS1X^8L)ZZC]-&G<[A^M6V$T(D)5[DUU9"Q=*=7]M]E6NE7PF]W)V>Y`KK16
MELPIXCD0/+>!*6].P*F=$$PWV,).^,GXPE=TH1)IA'715#`PGO2AD(M3;A2S
MG2!^<96Z&M:S<"^%+<>;*W@U0[RPE4C,`<4ZJS3E+F68%2888,W(\A:SP'`\
MQZ;4+RSNS.YI$S@VNK8O;7%`L"(:1<A7)34JM(J`#&1B3*4YH@#QC&<Y"+/C
M@<S_`$ZS#5[;+3/L/,0:OZVZ::^)G>>ZH3:]]2W&2U/#+EJ.MJ]DA*ZS/N9Y
M"H'-H2YUS"[%/P-Z?"3%HE)YYYP@A*],!;5UBZFZMZ:ZI1NJM-+*<[5U[=GU
MRGT+E"FPX_9K*8;)&UE3O@HA)8NE2L>(^\O+2<[&$)_<H+HY+!@R$!@2BPL)
MX#@55=;DA'(KL[<CCV]"B5M/9B^1T9B$L(<+4C)IYI^D;E*D>0!--5F),!R;
M[9SC!F18#^GQP+,Y>N3M<3E#FL^3[1NCKVN5?"#!IOVZ1M4J#_B+R(&##/C+
MSZA\X\Y^GG'`J-_CWM2MGZ9-`DJS!/R**=7/!7PF9,#E#(+`F;\VB'G(`>IX
MFYR*R:#QGXS,B#Y%X]LAMWIS']SUST"Z^,@S)'2\Y@(C^N$0YIL3;4L&W!,^
MF3RVT;SE.$W(09-"7@>0`R+UP%:.J<17=4?<U,='X](2"=)>SZ(6IM3K/`5J
M\.?\/;1UX:UN5Z5Y%DIN?=)%I7$33'4@O'J2$HA`D)#DQ,H&:'3+P*?;P@&X
M%.]C<CW'I?7-PVIKZ?Z8077%'"(Q>M=5,X0.:02X;`LIQ?Y4V6VN:F=<TRIO
MF:1,C7,AZE60-$>6K1B`(@[`5RP&MNU:(U+UEP*2]:A\R<]([+E]A6DISN!K
M,>GM,<@HC8&ILI&14[O))J,2UWNDA>?E82()Q*504/`1"*,$&O;HJ'L(M[6;
MLDHY^ZC'"-3#=6>6!)JBG*[9#1(3-3D=G%,U)6:!FD;JCL`MV0+T#A5*E4,3
M:A6X486$X&,9F#AA#>@GG<U3M7MK>D_Z9KTF;)(*.U;J^AP.4WT#L-_A<PIL
M[883E/FM+)+U2,@QJ5=NMQI>4!IB@HI&<$_!8/C+X&"P:1[BQICZ4D4KZP]Y
M_O\`0UG5EW:Y-'_%9P:WU2/2B=T`ZK(>R,NSQRDU4?8$K3*DA+LE:1X;<*,E
M^IV,)QAI&R''9U337<+7B3J[[`4<MWUV*2713)C?7U.OL4S%DT%UZKUM23U4
MR7B['Q&6NLGK=X6N!`<+R26]02IR(L.3``"5K;ONNE7;!,+F3:%=B3;':HT1
M+UVE(_\`B"_/<Y8K.L.ZFFVV%"8"-R20LJZ*K80Q85IU2=2(C[G)A9H_.0X"
M$4J@G=L1/7/I8I2R=&^R-IFNC^P++<%^.S3I7.)#&\(6.BMEX4>N:W"%*)*2
MZ+G:>66TARD1%F'93JCU&<``3XR'QVQ=$M7TAVPP5OT<[+D\]WPVW8K=J-E7
M:*76H1/=7Q.L]3XD]8ECK'F)Y0QU"XG5?(4YS<XG!5'(3`9^WSE5DK@:_P"S
MG8Z?WYO96=VZ]ZC;)6E6\2UKD-%SVMM@]']TX%&;DG)5SM$[+K2&N;3KY*)0
MV35K8TB@\2XY$UM1K8H5I@.Z<\T.<!$#8U\B=F]0'7[HM:[SM!K/9]/N]E*;
M_G;UH/N!+X1!&:3UOLK"BFIX<"J34)WXB3S.<M#"LPSJ3UZ0Q>:,HX`B,G8"
M>*G:"G6CK!WDUXE[YL"KOR[[.6*&9[EVENY,2<+C?`0Z@XR=:7X-YI(!K(Q/
M1\%.4'$F"(.2I"@Y.``XT/R!.G_R?:GL7:1.+Z?7^V&N@U'7]5M5--F'ZJ;:
MX2N=K(MC[8E+["B&S%(">!GM$4>6Q<(\*7*80%X<8-R((@A""%`;I:M1W2;J
M&I\B629AG-#[H16W[=CKY3]YLI<"@A&=FGF8S>5/+_7J-G;6\I--BUAG_=>N
M#502R@9QCX\!>+U(V?";K8M^;:KN3(YM#IUV1WXX,$R0EJBB)$TM5?4I&6P\
M):Q,B4A*:6UC);2?8DO.2$1><^V<^X@MMX'(W?DAT^MBT";+*[=NU&+WSKXY
MVA(J!E;SIU,%]?4A-'Y`_P`(>"#T+3UWQ_\`?T&6-PLI7-I6/!I+TSE%F#.R
M,)"HL,3ZC7)[D/68H?));95[RBZ^^EAD<FM@N*K(6HM-W3;ATP^O4^;XLXIF
MQT8A2XF`F2(:)2WH3VY&H-3F)BO@R+@=B'`@EI(+)DDWI-+&(]$9O;9H4"GV
MR8`_"6J:01.@"C,_006^0)EB06,>,%F)Q`_J'.>!.W@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X'-%_(OO[8>D(?KXBI3=,O0=ML9=,XDZ7M)4+P36JR695Q!WCD
M(ETJ@\`M2Q(FO=8\U/9C>N2M"9M39`=E6M`(9)8@^;L`%83YTXT3*8YLA6<C
MK":$:.LTDQ+(#-KK,NF>3[;C7UPC\Y16Q(K7BDO.0C=#C%3D%T1.![RGR<(T
MY*,7N`+3="H_=$;L3L`27J^LTNF"[;J/NJ.9Q:J9#3T/E,=,U%U=;&=;&(O(
MYC8*E6E;"&G\<K7DO*U,J=$2KT^'(1$EAO/2/7TW5/4ZA]=#Y@BGQE0P%NAV
M9BW-@F="_P"$)RHT"U,W#<'4:<OT/P#]2@T0\@]A"\BSC`0Q[3=?-:;PG?6@
MY[!3J7PB0P#L$K%TH9/&(<VS)!/+9_:,VD[?7\N+>4"]JCD;=6Z$'+1NHPX.
M2G-Q82,X.,!G`0P[?)(O#LHYMY.222(_H$V0P9JLKY"_Q>V797I15,O>D02A
MDF&.$,CM?Y6$X.'E.%4>GR(!A?S`$$Q^SX=J)+PZKG&EI;5L%L<K<^QVYED]
MTLKY(JW)2NVD&U9#RSO3-')1#'I6ND346:C;\D.2892TPL?]S&,E##'858VY
M;CMYK1%[.N3KALQ4]Q^[E`7&F*DO%-,6>'1!;4&;9C["^N>T<MC[,_O6'QGR
M48M:5H2Q),>Q00B%C(7$/Z@I(Q/2H]0%(0F:7)0<J&=]N!,42C.,,4"/]@?`
M$D`<BR/SCUQCSYQXX%#_`%?)]G4O2_UMAU@KC7.<24ZDXV[2-LV2F<_KM@)1
M.&'AU1RAC<('5MGN#J_.+HL^Y-&>D(PI+4B4!4B&+]8>-=#CO<+;7JL;ME*)
MT[AS`'=.PW]!)M:K6M"P9AE0PZ*;3+3&0UDL2D*I2)&QQ1J7$M082N6'GG)D
MF"TX<"$,`7#:BV>^W7JYKW;\G9$\9D5G4]7\[>XTF+&25'7241IO>%C%DDQ`
MUC).9SU>4Y@/MR?4PL6,`#C'C@10Z;BQ%=;.M`/7(2`M]F_89\>2C&G-TV.)
MG/2&?4*AO4M623$QP,B+/3B`8`0@BP+(6<<!P-8W7-E-:TY:UAHD3>Z+X/7,
MTE;:U.RD]&VN[FPQQQ<VQH6J4I*A62G=5Z8M.+))9AW@S^V`0_`<AS0_QK:W
M*DW7?M%I7LAK]-ZJ4)+`=V&UZ9LM:C;W20U[L93D9=ESBA'$H/7$A8H9,0KW
ME(V$K7)[?D:1-@!CIGT)`4'2-K_KQ2.JM3Q6C-=JSBU1U+"B59,;A$00Y1-2
M$;@M/<G-:<8:8H7.;L[.2HU0L6JSCU:M08(PXP8Q9%D-S<!P.<K2"Y-P'?O(
M[(:@15U&HMU^M^5TO)D<+@M>)AR':%N@NM,6<WFQYPT$?OM7)92PY<L)PN?J
M!26S9(3F#`VG`P%Z<R=I&DKJ\5\[:HZT,3*T34V,J6)[<Y"H=X(C@Z=:-YDJ
M%7&V7#%(<NXG$@;<D&Z$?:IR#@JA&'C((#G<ZA^U70C6OJLT3K&U+TD35,H[
M0,;0.2(-`;'O"?+\8!8].,=9WB/50^,<D.81.'VHC&Y4J*,P5[@S@(L8P%J_
M3HU/37UFZB#D+*[1MVD5<KYV?''UJ<&1VCY%CS.43]`QK&UU(2N"<;0WR4I.
M')A163`%X'@``BP'`0*_D=5R]Q'5ZE>R*N5QZ:X^KC8&N-C8HTXP'#?-X7()
MW"839D$=C"T:A80@>FM4D..,`867]JE/`/&?DP(`7ZU_-F2RH%"+&C)PE$;G
M\0C4VCYX_7`SV25,R)]:CA8#D0?8Q`O+%GQG./.>!%#>+?VAM"H''9%:K@X2
M&P;+D"2#T314*_'+[9O2Q')6B;VZ(P)D<%S>DP`"MR(RX.:T]*UM9!F#%!X<
MB*`8%"DLV^V:WIKP,C7WGOQ7<5F3:J5Q&D.H/2>YC'LAO=T99D7<);OUMA45
M>Q:5.3:M'C"W,6+A;+@>!$B5*2O*@(:3L'13KOK23:)RB\.IS:Z03"_]H:ZT
MPE,HW+V7&]KYN[6/"CT&=C;F8(5=FRT.D+PB6I%AC8WGJHR8)]7&Y1X!ZDB*
M#/NNOI:K3:%VO6ZMT*^VYILN"['6-4-4:MCG5TZZT^?3U;OX%-9V6PL#-)&N
M:25OL&$O21(O5B?5J52J;SQ)C0%BP44%AES]#'4_#ZTMBQE-"6#@R+5_-I@+
M[O;'<I<VI38]%G=SPJPUAOD[`\$"(^7U+!D>3`!R']6,<"$&J^B>N]FQF\GA
MXE.V,K71?0'1"^F]E3;X[KEG_P"1+-I.U93)A+TD9OQH>!#EPH,U`&@^8(`)
M```CPG"9G@5^:!5S45\T[UKVRMLZ0:RVYV-W_L!%[NJ@_=OM'CE@6=%M>WA\
MA+,DH*6M.Q#VC12J!1A"A-5AG1S@2XB7DID:I.`K[0T+;-^=36C4.*U;&=>]
MN^P"M5LZ:=PI-EO,W:V&G`71WJ/2^Y;CCS@>NL2531:F2L\UKIE,,3%J2"5!
M&32LE#"<;P)1TMUK(KKHRAK4?M_>U9E>9_1U22Z0H(SOE:;2UK)%(8&Q/+R\
MX($%8I1J7->N,--(3GE("Q"\$D%`P$.`KNWPJ..];=YZ6!<=X.[&WDVTMJ3&
MI6=EC.[J6;O,6EJU/%&J%*`Q6T8N5"%4$.=IB%$ZKG10(QNR8E4!$,S`A<#2
M;)IQ-7GKRU+85&_78(C>MDNP4[6U7`RKJ@!<!>8\9NW;JZQ%RI*\5`X/)SE_
MBNKGV0%*!JU&7%Z"'[@LY&>-/P+X'/K;O1:I491=O/9<V(#1E&)T1;IIP><E
MR`A02,.'$>H`%1Q9OW'MZB_H,(<_U#CP%?R)R[7+TGFRE=Z@;3SMUCVJE_K-
M8WZP+WGNIL(>Y5-&&L:VL-WE`HA%^M*S<_MA$39Z1&'PZA7.`V\X_P!2,G!`
M$()1G<[<958!3'>7;T"L*GAVP+WJYL5>-.3;4:?137N\4U:698S,S6.9</5_
M0$::(FN6U.X,'Y%ND+J6%X5IB!9R(7@07?=*KU'9)0>R4BC5["VD1N^]&Q8U
M&RQC;!FLZ\U3;F',89T816:%L@"@L*%J(;"%+2F3(E:5N*.`47[Y!@+B<^?&
M?'CSXSX\_P!//^GGQ]?'G@5&I9?W(_FEZ@Q_ZC'*(94N(&7*62;3-KTK2`6G
M$MQZ]6(#TUI5)1!`L*22@*`Y.]@A,Q@'D05M=?;G)'7KBU-<):.#*)"D[F9=
MEW6UO&GUHA;L[.>[-L`>G"/RE^]3K29C7M[4C124HL`%B(!*4S'W*4\>0ZF.
M!`_10.<9W)$'&1IA[X;!B2*PXSDE7@((<6NR09CR69AO=P*41OKG/HH2F`%X
M&$00A/#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%7F_>J%]7/+(=;^MM==>$LN"
MMJZFL?@4FW6H:9V7)X=*WQQ:G!I70"<1:4IRX>S>$1F59(F9:<8JP28$X)6#
M23`C'V9(+'%UN:A0.\,NTIN>;;A]74+L-(]&0=8;)[#5;94FZS)N?ED`9XG`
MRD*Y0TKL8&TH4:'S@L!180"\\"R^LV^>/$GW30*I);9.'*V2&>N#;#3QHF*1
M1O-UTI\D!E)',"I6O55T&5JUBQ0)U*)<`R4;H'`!)\$"$'H:25+*Z$TYU8I&
M>D,R>=U)K[4-=3@,>4X6LALRA\$8V*4JVQ;]NERM2+GU$H."=DHO)OR>^0XS
MG..!#?LZ*;':W>I&-'OC>VNZKL^@,H;&XX63')W2PC6O9UX=0MR/`@?*2G"8
M2!0;D6,)PGA%X%G.`"""7;BF*4[?HFQ1[922K5[4..N!81?&:<VJ^Y32]G<"
M41F/U%J1H9,;^O&!"*'@L6,?]0DWVU-42FVP'5M6,^U^QMI#))L-L')WK6X;
M-63P":C@VGURJ6Z5_#;+_%8<>?7RUY"I*2JG$@"DQ3C)8#5):8.`BKKI3'75
M']S=;$S5T+7;J3L:-1.YU4=A*JZUGCT-AS3$#X@CFMCR)=5.SCZUF$PU1,&,
MDG!K6XN20YWP%O3Y$)1G`=(LJCY$LB\DBJI:X-J:3,#Q'U#BTFDD.J`AY;E#
M<<M;#U*=6G)<$I:G)A(S"C0!,#C(@"QYQD*0]K=+M1::TPTYU0MZAM^]N:VU
MSAI-?5V7JF?<^)X4D@\(:F$<AM7&O<\J9&I->6I*$I&6JP848J&<%(0'.3.!
M57'HSJ!!M].OIZU[U=[/Z@E##(]JE\J?]W#]QB84UP%HT,V%6R>(5P1M!8,P
MB[C8(G-0U"SEC,P9A.F,$4<<F";D(=-77R[%.77_`*1ON,C&0OT]UN=\""')
MA@BE5+PQ9C/J6(W)AH@&?7`<B\B_IG/`TUTZD'D=86E0C?C^)=2;&\-HBQA'
M\C$^+G-YCQIOKG/Q*CF)>G&<6+P,HW(@"Q@0<XP$?=P.PC;]^M"XM/NK74IP
MO39:GVIKS;=T7R8HJ/5FDUTNC:60Q!M12"1&LCC>,^=VYQ(4$M+&86WIR1_,
MH6B"4<1@(N]0-S;_`*V^KE,W/LK:(-)KH96T-4)]^Z1IO6J3HMYY%)70UYK3
M4_-;.Y\?M.G5,-+,S@X@9A9JO"`+>$S(UF<!T0SR!0BTH;):ZLJ(1J?0&9LZ
MV/RZ%S%D;I'%Y,QN)62%S0^L3NG5MKHWJRA9",HXL8!8_P!.!I?6/3G5S3")
MR"#:K477E%Q65R11+I*T0!C*:BWV1*22TN7)U4B&>M6C3)"0DIBS#1%)"`X+
M)`6#]/`DKP'`<"@KK(T^7M.]G85OVQW%;C;$[CV3VEI>0ZXOV2@52Z2*M;'K
MF+,-UQ5"F=A91OI!M>/[:><L2B4JREP<%B3DDY"J"W';=T5LFJ>S;T@+(-7-
M&O=T.B,I5C.4IBM!7$D5IRU.`FIQ9(&<5C`_!@,^OG]6/Z\#4_6<<2HZX>O]
M21@@)2G2?5=2'"8H!!&?N:,@IXA%%%A``L`Q&9SXQC&/KP)N<"GC^0"K9T73
M1V#'/A91B(=$+$A`3EAB$&'APD\;01XS!Q?ZAFE/ZE,(LG_:H'C!0OTCSP-X
MZM6O%M:>J+6JYKV6)87$J6T-I2<68H:VQU4%L;7#Z)B[F^)FEBP08^KEX`(Q
M$)4`"AK%"G("``$:((<A5A1VU]5TGL1>FQ.[-1S-1V.6UHE.-^T%4-31&)(;
MJ[HG1RIV;8)JG#7^22Q"9%;@<4",^3S#'VS4B?)2YK"QJ1$MJ`H`6GU#V54C
M:?\`Q0-<4N:Q;]M-5I/M;$7*?3FLT*.*Q5@<:;3-\1DQS?+W`G]W21LN9*O2
MEIAG$!3MRP)@PFDC+"$K4>Q.NSR\-$=;[TI9U?WM84F86)'9T&7/#NX8-)`2
M0T-9#V:M7K,'G%X"$D`Q^XPXQCSG'`JOZ-Z8V7UDU9NF+;IN3BR67,MT-AK#
MBC),[.23]8SU:^+8VT0I(UOYTPEP@QY=B.JEK>GRLR,*94$8@8&8(0@LEV:E
ML+4ZZ7^W&RN*>ZVEK3;\$*9$SD`--609]3`3F9.6`"'YAF8#]<X_KP*3.MMB
ML!=3^Z7X2-+'*;O_`%Q];;)7R5_"8R(I"Z$]>ZA.T1L+TXFMB!.F+GSDN*59
MRI+PC4*C<FC+\^<!&_1CJBW"B4*_CORR60J*0XGKK1;B+]F8/:4C`TVHR/>P
M#@])6!/#B(,.8Q63-K&H7C5I\&O"7)J0!`SBPF&F)2PF?W>.$J:IWIV^,C$Y
M/T>:ZA[7G%W"F2.2EE&\)>M&\U<6;GM4A+.3(B'KX%A1`C<>QAF/0K.19]1!
M<+J4R_MO5366._>*'#\#KY3#+]^J3B2*EWXNN(VA^\4I!#,$E4*?@]QEY$+(
M!"SCSGQYX%2_:#5-N79V,=3\?I-'79$XJ9-M1L*0]W-!YC)JR-;(%(M5FQWC
MA3W$5!!T2GB]L?S3FAQ.+6)TJHDO!B8SY@9"'.Z?0A\DB,YFMQG=BL"N&D=[
M>QF;41F#5EV0/7[E@3?$+;KW3EEUIDE-,#MK_7C=';PDQ;DI<3BDAZY&6K2G
M*!(%IH#0M5TUO3N$?NS.LF:]RKD1QM^32]IVAUR?X"Y%ZY4I7J9IL`JO)M4U
MO`I=EBDD5$KHI'#RI`7.GQYFCE(W)O-8F<II-&2$A.OG=K2G66>]J#->.T5%
M57*9+VQ;,2;+5,[!8&)Q4-2V%4XVLR_PN=QX5)5!+0,LLP!9(0C)&5X$(H0Q
M!2[0LAE%RTUN[H'1\HUJL[9/?/M\V&N:KC81?1A-9.-"LL;%L6&W]@3Z^2W&
MMF%`3T-;_LH^%JVYH&X_D<)%AA)AWS##IUZ?POV*-V5',8M%87.C>P[>C,XC
M,(=37^(LTD*OF2)3FN.R%3'HDK?V5J;R$Z1*K.:V\TP@@&!$%YQXX%KXL^`B
MSZY'X#G/ICU\C^G^W'MD(?(OZ?7.,<#G??*QT;<94XJ)5_'.N0]]7!^9:[)-
M3=%GUJ5FE+5Z;&0N#%L.H:\'&DD`4Y%C`1#PIQ[>3,&8P$9.KYQRKZQ^OQ#A
MF=8RQLG;Q9<=;X&[_:@'#H^T[,[)YBD&PVH%[DSH$D&580EDI$IQB-&:A#E.
M+."RQ9#J]X$$="LY_;^TH?47Q@WOVVP4;XS\!^!V:L..$F'_`+#`D*C#"3<A
M_P!J@HP.?U!%P)W<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"FWNSD),>H;4D\
MUBEDER=V?=>2@MF@S(*32U?^U]BHQ.STK!&RSTRA]<UB2)F$E)BC`F#&9C./
M/CQD,0ZR9.1>]+=H]UT.Z/(&S8G>K9R04^K<BW^,2MM?(_1M,4J:)X:I>F:7
MV%O22SJW<!!1JB4^4182\XQ@OU%D++-,8).*NT_U5K:STZY+9D!UQI*'6.G<
MW_\`=;D3/XY6L::)H6X2C[]TQ(UP9*D5?,OPI485F>3<&#P/VR$B53<WK34)
MZU"C5GMBK*YM.5)B5!K>MRF4(\K$)AH!C2*LI%9I7R%Y"/XS!A\^HLXR'-GV
M;+T";L#9UKB4H4+FEGZ5H]%"DJ?"G(E,^[@GI^D91XA^PT)1Z6H$8LFE>H!8
M)\'!,R$G)09=W72**L&W/4XIG>V<PTGBS?*-TI"GV"@J:#'OT4F;=1$>9HTC
M/_R)$)Y%E#!(D$F<FY<D4-2G"P"L(,9)'@)Q88)IQ(]8WO?NGI;'^^RV]M;:
M*B%KPYAUPLU#0Q'^08I8(H[))`T1\AAIJ#.+8SIWRMVQV&)H`6H-RR$EE*"D
MH%1)X=&C?8E?NTD7PQJG4.<Y@U84Y<XHWR=D6R1NPC$4%7E>Q)EQCHCPE$>#
M!GR%!],C#[>/..!6#V'['-$*S1*R(]N6MG7BVSC-DI4#A;%=4Y;L>NL^.K8N
MUK_V](+!L>#M<?55PY*A$*0IE)P3CG#T/!Y(QC`5@MMCR:>[":U2JQ.T74OL
MB%`]8.P2S8250%/UY&#*]E)-+,,<#9\CC5;WW9"&;-8H7*W2/@:UQ#65D3H:
M'!@CA>2@OZT-"D,T6TS"@1HVQ"9J;KO]FWMR,MO0-Z4=/P_[=(A0$^"421*5
MG`"R0_I+`'`<?3'`T9T[BSGJXT2+SCQ]KK?7:#S_`//AO:\(<&YQ_P"T1N$_
MMG'^F<^.!G'8K?FS.N.N#O8FJM.5M:]@E/"="]OUUV[%Z8I*BH%AK>'.4WW<
M$HDCBV'K:\KQ,V`,<$3<:!>86?\`($02RC,\"FOHOK&5[C22Z>P?>&W&_<+9
M&JMEK0I_7JTH78"J6Z;0^OD,-@QRB8Z>US^*CT>CIJA=)W=@52<YNR]G`2JD
MH5/@:P:D.H+@.`X#@.!`#KOF#I-8!LBYNXR1J6S?O>B)I\DI4B3U:X;LE/8N
MSEFE(B2"AG%M342$1H@Y./\`'R&B&8(8Q!G_`&%)OO-!-XDGH:;]UI_LNF^,
MC&1'F?/2\U*]"<8"/.31^W@./&?K_IG@8[UCE)$_6_H&C1/+9($S=ICK&U@>
M6<THYM7C:J7A;<<<E&2H5E^N#TP@B#@P60C#D.<^<9X$XN!S"_RI)7(9?I9K
MYHY6HU*^Y-]]PJ7IZ$Q4L.<()$U1Y_2R1V%(#RPY4IHZVRX<<RJ&3D`P8.",
M0L%`,QD+*>P5A',&_K[U*RG3GM]V[ETD"=L2`G`(TZ5AJQ&91M5+FAR2N93@
M-1%G-UHUJ;\HQ'A/."L`$0S`8.`,(Y=H&C<&C;!V6=F+;*)"=;SIU#;"ZQHH
MF<R19='V)D98G/IP*7L3J>R'RM&_+PJLH3TY:K"$Y/CV-*,&$G)05P=5>@&H
M$@FFDL2M?5G6ZRR;`Z--?K(FY4RJ.KYVV2V=GVTW"-F:H]<QNS<\2`;4_EIS
M7+`C%)Z;X0F&9QX\A?B#J1ZM"C#SDW71I*B/4$?;C4-VL=.-R@L&`*"\#2GH
M8@G.1J0@4C\'$B`;C.<9P+R$/@/,6]/G5BXD')EG7YJ8<2>C5H#`YI.$`SE,
MM``M1ZF%M0#"SQ`+QZG!S@XOZY`(.<Y\AABGH\ZA5:`YM-ZZM4PISR!)QF)J
MJ8D:\)8L>,B)=4A1#HG/_P"AI9P3<?Z"X'@+NAWJ)7(E3;G1NJF]N7#\KV]@
M<I]&D"\GYU2@"!>CCLQ:TRUI)&M'@M&:$:0LOU`$O`"RPA#XUO0EU'N#8O:%
M&FL5"B<RTY*W[2Q;K;UAI*526K3DA<V^RTSF024I*P/`"S@A\^?./KGR&013
MI'ZUH`#Q7='3:O%)2$UN0.$&V=VMB[BSI#DQB(TMC6--W)S6?!B(T9`OM_CP
M(@8BQ8R6(0<AZLHZ=],94>B-4K=N&DE&F.3Y0QSL!WG9$*T1RQ0MPK<2D>PH
M1K%I`E(BRS!"\@(P`K']LL`0A&NSND?KCBREGL.R;OV]KV*L)[P2ZER_L@V:
M98;(@/Y3:E0MDAD,VMX]\1DLYZ'!B(+:[-IAYIP@JQ*@!)`4&N=!.O\`JO9G
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MJWZVF]E)8Y:<L9-1)?%03)<DAY+<UM_QLQJAR`-*64<J7ITX@_%1&>R+K[U(
MTAV-J"W]EKJVZV/V8NRZ;`TRN9KK%DJ6=LVP49M.Z94UW2W0J%P.5Q:VXI%$
M#6:$E*ZG$D3<TY(@;2DX\$E!V1%*O=L+6K,"0>R$"I5@W^V)%[)\&GX,^3']
ML2;SGS[8^F0_7@<P3K)]"S%CY^(_D@;PLCQA0L3GD_\`)^@GM,Q96.9214E"
MQNFLBM,G$F&9]N6,X.34F/(PB#D&1X#6_3\2W$]9'5D\MLK=YJE>>UC8=W'+
M7M:G<U[_`(<)GO$PHGP]<E2(T[@=(D@4ZPXX)>`&*59AH<`#ZX`'6GP*S]1[
MJIZIH-=C?:=LUK6AZ_=W?!2S);`G<7AHW%(CV/L1^=U#27(G5N$O3($[A]RJ
M&3[A(^3.3,A^O`L3C,HC,UC[1+(;(F*6Q60(2'-ADT9=V]^C[VVJ0^Z9P:'E
MJ4*VYR0J`?4!I)@RQX^N,YX'N\!P'`<!P'`<!P'`<!P'`<!P'`<!P*?-X^Y*
MH-%KN-HV9T1>5C/J:#UA-5#_``IYU]B<=,Q;\QF4(A30TFW?>%3.$D-"[P5=
MEW6-I"MN82<DC<#TX#<"P'B]@,B-VQZO:]W3I*.S9&]T\KUI[,JB@TI8"6Z8
MN26BI#&+W6P>41C!SAG#T^5JF=4'VJ509G*\XK)1AP/`30H-TDAFI<EUXVO>
M8CIKV1W`^I-RMRYG4=U:O/-UU_\`G0VDJ;IA4)DACE.[!5^_M$@*@$X9$X\/
M#(<`*9-]UDP)!P2\!L^>TG:\/:M/ZUUMI7M^6/DZ;&TW<:V;MOCM5:4L&<&-
MEKW\F^L""JKE7QM9,WE<XOJK!"8D]IR8VX3)\9R<2$099K,=8"]]V:;MII]W
M4Z5U3&7>O2=>TT4GO8OL?.Y'$"HDF62F5NDYFVLLV9@)7EZ7?;`;@MS>ZMYJ
M<TLPLP."%IP1#OQ5K.=M,SD-/83VXA2/#SUN&N%L7K6=DD/E6C9]F-@I:F!*
M7JX]067]JD,CBB;SH44H2G)G&5N"D@(''(3TZ<-D;?;`RFC[YUSG^L?9MMYN
MI8%,UKMY-'"K["K>FF6X6"NS8!`758173N[Z*KT,ED\C-;$!02WQI/`L(+$2
MF7(#E(`*@PRO-U-P9)O!!E=_]D2W6M&?03D!AV1D%8ZGO<210>V)6S/A-/HH
MO.-8:@E$TM<R?PUI)6(4C/@#$VI%ZL2T:4H0U05IP^=Z85-/>RW=R42UXN^\
MA[C/4"C-H2#7J%BB]JJW>6OS@&P*:20':#75/6$2L&2)RC)*XJ#'-N&S*P)E
M8#"%RHL06+7ANO;6B5?:9:MZT;&]1-[PES0F5Q!:;K>@ZMF"[625/Z*.A0++
MEE+[O:^PI@C,T>Y.\E2.=&.WVQSD1DXW"S[\9H`^+4'=78_9_8^OE;01U.46
M34\.VTBKG<S]3;+6586VL*KNHP2>)2@JN=L#9V8C'$;#2N!AAR!F:V\T"@O.
M5ZA*(L@)5U/VX;Q.6M%:JZVE77["(6Y1:H8#35-1[6:[Y+*7J,3$I'!(JU0,
MV);S.$7*88(`C!+I]V[H7IG1)?G.0!QXX$T^LAH[BV_KCTN1T'-^L!_KL.O\
M15Q=WLR(;/ERL+>L2&*VN.R1-!Y@6RFOK``?V+FX`&$U0L`:88D+-`,)H2[>
M6/OFDS$]QR:Q;I@G$9?F!6P/T0=L[BC890E<C#DSHD>$SPPR%`)C<&12).>@
M/2K0'Y#G(C/0S)80Y63^JGL'ZUMII1L\'9?6;5:NM98S(MY;=L>J6*\:OI.Y
M4,XN*=OANH"P_P#$A8K0=4L2B+FVM+`F:C5#4SNB%,6G4'K"!\#H8U.[$.U?
M>VN%MT:FUSU46-6XEZ=F.1N^Q&V,/L*MI6!,UN[O7]L0QXUL`\L4Q:6IR!CU
M$G2IU11Q"Y,(](<7[AI/=+KG[C-_[7K&<VC/JHH2!0`R`%2BC-:>Q#:.`59<
M,?BL^,FCFAFB5LU,2OK=.EZ98H0)I`A4%F(B<)C"R\FI@"R$A=/-:^T74NVM
MM[TGT"1[932_[`C08.U6#V23-4S5W4\:CK$P-L>)CQ^HL-K0;XD<FQ0J$\)(
M\A<SFPU.E-^50!6>L">[K?'9^F6*B&KKMU\<DI2["-,N.["E2$*I.)0$G#KA
M./3PXXE"`H?S"`+PI]`BP$H0_4(@TT^[6=RR$Y\+:.HRC'HIG5E)D1Z?LQB9
M(962:%*+*^/`<M9VLQ*D39/'@P+KAN/SDD?H6+&2\F!!?KCV,['8;`[J;*_Z
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M*:%#.-N![/<"UD+:W%"<(21&$O[C`\GDAQD>`Y[]<ICVY[Y;9ZJ]D>-<;MVN
MU0TWKBW*;H"9#==6XQ:$YO!XJN15U,MBDL+?;?B]5SY0UWVO$,EV:/C8S6&/
MI""@FK$ZD1@39UPF?>!`^P#0>U>S>";`V56!S'>#"WP."P?4-L:8EL[.:'F[
MT3'XMFJK;"YS2*%U%"UQY"Y_$D4HGD3FD)($'(!C"[+:#:)#LIKU<.O4KT:[
M5&*(WG!YO4,D?:THVOVF:HV*1M(V.1C95K_9#DB:PKVQQ-(*5K$8TBDL9F"L
MC_W8"NO4V]*_U1V\J^E8!I+V=K8YK3UBL%1,:*?T[#I':B*!';!FJXLZN;)#
M9L$J4H'Y3'3T"=8WI@B1&,YA9I`"QY-P%J3MVIH6<.!G=>?:JLQX#D6&G2R1
MNH@8'@W(/($,H.&/.<$"\X!@60_I]L8]R_8-:R/N):2"SF8SK:[D$JM>W*#@
M+&71"2J%"!%D84@W0M67)EZ8DY*:<$6"<EFJOK[83CQC/`WE'NU;7=]C9,D4
M5)OC','"<\"9'_KKW:"^$`:74#.J-/3L]&/"((/NS09#@*@0\@'C/KCP+`0U
M';O<33#9`;#24U5^X4ANTN&S`FI8_*NNK?0B)O=JI8PN70M@DZA/134K3,BM
M_P#M`+Q@/3C`E,'D)@18P+`4X5]W%][,AI:8.4ST1H"$W5)[.K:'U&Q22G-[
MHJ1$(/)'2-#DUR3F.YKV7L,\K1"V/AZ<>4\OC#TUFM:Y7E"XE%E$&A?XY=IF
MF%?)&5FMF[0LDXPQL"B0I4E)[!-Z`UR<D(A&KFEL75VO=$;&YK4BG*'"@TPS
M)1>0Y,&,`\\##7KNIZTXZ4H.>MAW1N)2X*$H-/H79+T*`><8F(.R(%/CQE.<
MH*$`!F/(!"#G&,Y\<"/ED]N725<+E`7>S9]&[7?*RD"J8U4LE6GVQD[6Q"7X
M;CF\V1P8QQU_>`ML@(0G"!]TCQ\Q./KYQD/G`:6ZI^RGKQURZV-.*OL;;BJH
MO(8Q1[,K<FAY<7/"UD3NJ]W?"VQQ4$LH$ZA8R)UWVJ@\("@FG$#'@LK&?C"%
M9.SVT=0[H]BNWKGKIV*Z'513SKJ_H/`G2P;WK1^L4J3R:O+]NF[$$*A$G:IW
M5YT371B5,B)2_)U1ZG*@IP1_&62>EP>0$QIKLGV$7164V;8_WF=,E/QA8XIH
MNLN:!5Z]1.=PAP^\0.Q93`9:6Q3_`!%*^.;6G,*R6K3J_*0X0B18,$6H*""4
MU@>W4S=Z]E=Q_P`E[K.O:053848LZLFJ86'24$@\,G,7.5_9/RFN80L<(+:#
MP0%=D;:HD;.N,CZPD"Q!\2GP8`-)7/+9_,9K248WR[G=7-W:`0(MA+%L.`:M
M;7P6O;9KR90/6ZUI#"[#K:5P6)PD]0[J@!4QALCCJ<-F?5KV`E84>$WU*"^'
M7G^11KILQ'-?"JJU_NYDE>PT];(#$&VQ'VCHY$(LR"8YVX/UG2Z:D6ZO0(X;
M!SJU=P+VW(2Y6<2F+,(:AX6H<*0R%1M]VY(5C:)8[=$I34:\#3N@CMR[[2*!
M-93@41DQ*:?5HB0+%J`8SP!R6=\60^@@"SG@0:Z6%#6IZT.JN(BD$+>UL>[0
MKV22M#"9:SRE/&'A3'=U;<C[`ZK6=8I&TO.$CLT+!H5>"5H$BLL!Q1>3/7`=
M<W`XJMU[7IS7ZRHQ.)=ISKONW-[=LSLL9)%65_W)7]%`CT;UR[%I58U?V*Q6
M!="TFJ"\MLY>$;>O8BBBW^0D?"$KYTJ922(.F'K`%`5N@VLDFK!+7B"#V)`#
M;<96VIFN5L=:-0[DDC[:CLT0=AG&?W4P1II>I@I3)4"P)0T)96"`E%%E@*`$
M].`X#@.`X#@.`X#@.`X#@.`X#@.`X',+VJ0'0NM]R5UV;U0O938R5W!5U<5[
MK#%HA*K+HNF:")87.08E[&Z;-.%X4GKI7:V[IJ2UGJ`/;RA7_*C)#@!_W*8(
MPZ-ZQ0M.:HKUM1LQC<Q9KV)HDL>=).&PC4#3F-H""69QF9KK(03<Q*C\$'.8
MER[#ED.3\GG?)\@@XX]?93*^KN/;+UKK5!E#-<VJ6X^P.J,QK-J@ALA1;(TM
MM!"KNVEZYK54(68:(<AL6I9.M3L"5.D&)8.+FN+29C'NU_:!V/5(ME;C559.
M$[5$+IPOKZ&+9DM2H!M299*U4<;3Y"J3-9A"4QM(4.XSA@3B*+R2'.`9"'QX
MP&I]L=QM:M&JHS>&UEIM505;^Y&B(!E;LT2=])-DK\2O4-+.0V1%CD+T>J6D
M-:@>/1,(`0$BR(0<8X%"G8D@8-DMO9949LCF*6(7:\]'U>-SM$)&OBCNEB3]
ML;O3?1TY@4A2`3NT)F[)_C<E>@7XR$?SHBBLE#$,(<A'F1[1UUMM*NJ]WV5/
M?MXXE6]/]CC+=KYI?`+KGCC+;^H-YUGA$>M9C9J>C<-LICR_1&2C>%29"06S
M-;N]EI@#,.3)30A-;4UATO7=C%56;2E;[]0!870\GC;+7EU4CV6Q^%--@/YG
ML;:<P=KS1'4JQ")KI(XL(5"\[Y%;BY>WL-5\!O`O1F]R:_1`R6,=CVI3L8.A
ML9#.YRS3:<0IF-BL./7)$`)E*VY]<TPV.-'.3@03AP6`*2B//+!@S(QAQD*T
M=ZG+K@:GJJ7:Z;ON.AW&PH([O4.E6HLBV'@*"V(/]PP'MRJ73?5E@5MDT0,I
MR\M1&T[LN,^(+@K/;RA!.4#X%'C^Z=?1&S;Y_P`5+PO':V21[KM[0)?/8SM<
MY6S:**OAL4"H60P9J:&O9FN$P0!>G9C.4#P<-Q%G[+RH`,)WD0=(QFFFES70
MXYW,-5-59/(&ZCD3A*9H\:XU.%9(2V"O,_<+G0":(95A1FI0&_\`;%YR$DDP
M11>,!\8X&']*IR=1U)]=9R8DA.6;J/2XQ$IDX$Q!9XH>WY58*)!C&,!^Z]\^
MV?(AY_5G.<YSG(6?<"!W8MUSZW=GNO)VN6S35)U$422QDGT6D4&>D\?F\+F;
M`2O0I7V,N:]O=VD*A8QO"]M4%+$:I.:C7&X]`FX*.*"FCIMO7N$V)W6V2DVQ
MV*MK?12&K+#AR+7H#)`4MN4/;$:D35&H#24J)0I6VURY*RURD*>5\@>3'1FD
M;<I0K&M4>G6DY3AT+Q;96AYK=MGZW1FT(LYWQ3+;$WJR:K^[-1S"-L<X:2GN
M+OGXQ>0E&\,;DWG@SE8@RJ3)S18).&6=GX^!O'@.`X%4'3HX_F-;+T>#DB)(
MZNG8KV4*GS#>1E.C/=,;LW6GR>2`1A@O3[(@@'G.?/Z/_3@0SWZ.$.4=]I9B
MXHMZ%T[T4UQ<TQ6%.K(;5;'V)*%[.WY]RSA8<747R9+!@>1C%C'GZ^,A:+-=
M^M*M=([$(U:&Q53Q:8#8(\W,M1,\C;Y7;[NN&TDA01V)TS!LR"QY$\J1$?`E
M0MK4H...P$HH`A9"'(<]4MV$W#_D1W5;^HFN9<VTGZPZ%LAQJ/=>U9,2?$MI
M;_7(E3B)RIF+P9\:TTDJEJ?VM`64YH7%,0J2IU8LNHCL9$Q'!U#NE`Q1)KBY
M:S5,Z2#7V&E5(MI^`/E,*4<5E51LF8P;%F%XKA<-$M2,DAB2819[>H$0;\2D
MD)F<"%YSP**;WLB^8[0__'&_EH)]O/UGS+7O=VJI:SJDJ(SL#UQHB6J#)Q8\
M'BISK()J&W'2E&R5Q^<QXG`S$TQ.(4)#CFEV2<#H=@4\AEI0B(V374F9II`9
M['&>70V6QY<2Y,4DC,@0$.C*]-*].(1*I`XH%)9I8PY^H18_IGZ<#G,W=;]H
M**[+]R=EM5KAJ&"O+3U#,EUSYON6EI#<*163KW9%TFQB&L+HUV[76:[;YX(U
M28>=@"LDPYN&<%&<:6:/@=#-.2QUGM157.GU*%`^32N(/+'E"%.:D"C=9'&&
MMX<4H4APS#DH4ZM8,&"QB$('CQG.<XX&Q^`X#@.`X#@><\#/+:'4:8_"52!M
M7#3J18#D*<\*8W)1^<""(.<$F8P+ZXSCZ?TX$#^J5<I=.LW0M:O/`M6*=2Z*
M^^6!$$PIP5!KMB*5+@9P64#)2\X`C0XP$.,!'XQC&/IP*)MG-2>P3>WL![5M
M?JFV#HC5F-!A'6X])[#C,+MIZL)QBD1?]DYY7/N^-$QA2-EGYC@>XI)-@.7)
M`K9_L"B"R1"/%D-]1GKF[.:DG3!<4LM/2O8MCHNFI?!:ZK*[9GN:I@`$"@MN
M5"?79!*IM9S>7(BV9CPW)W)Y*DYK4D/-R3["]/0*\*:ZC.R#;C7B4;.-VTM+
MQV2=B,$@-S95P6>7U3K'2-;6-"6U_3T/!ZW8XU/(*HA[42X%!PYH`,3]DW!F
M<+A$FJ"E08ILOLK9-4Z\4K:5WZKZ@1)97.PFXVBVMT>I>VK46J:^,KZL+IU2
M=K:OF=2FEIG*;`CM2.$;(4)7]"H1.*\]W3G')D:T6,8"4,!ZH.V2AZLT_9?S
MM$[)K-795))I/VH&W-M5RBVH--2SY=7*&T`N>I3M/EC1!7Q^CI:EF.F2E@=F
M*,_8X:R3G`Y26%#J#3J81:$0N&VEJY;=C6'7%BCM.V+IA^NW;!")M?-9'B<E
M"S6I.ZN&H#R95")QBSHCCR1P:EXFX*!'@]41E=_W6`LITJT>V;L_0/K2FS3L
M_+]&6BU;8K"M==X!JT"<D-U=1\57;A/\MO&U8U=B5.&6;,6BY2$*-:_M(4B4
MJ/MZ8MN5GI3R\E!V[UC!<5E7L-K[$PG=@?L^/MS!F;V=(A2VPI4)O("2)\F4
ME$E0_FI`X"#DQ2HP22$9F<^H`A\!P'';8UCU@"VG&7S.9:1Z]LD[>NR:3*-H
M]HZW?=H838&-3^TV;V3%-?8?5JBRZ@9V1T8)?*BI::\92JWMR5EE-[<`9B'.
M1AT9]1TA:)GUN:C3]C@**L6ZS:O#:Q<(:I$YR=D9E-IR)^L-Q,CC@]+'!X0Q
MAW<9*:N;&M4>:H9&]22W&"R)+G/`L:X#@.`X#@.`X#@.`X#@.`X#@.`X#@4*
M[L=1SEN?LY=D_3&U3`([9%<4S"YA,-@=?:IW+0S)!%TTU3_'043G4ACCGK-+
MX`)20>N6G@>F>1+E:)6%"$Y`J^Y"Z*FZQ8Z2J&JJ9C"MR7QNHZW@]8QY<\&)
MC7=:QP*,-<5:5;J:C3(D9CDH0-)8SQ%$E%Y-R+(0!#X#@.=C9^)-KDX_R+KB
M6R.=9DM"-6L%RTN;%B"$THJ&[=7-'V.Z*TL6NU:Q-\JAP',WLK[I*:$]L6I2
M5"883"U:PL07):-[*SZ^:]716^8:VUWM#4+;`6^]HK&SEJ^!.*Z=PQOF41L6
ML7=P)3."R`V`Q*Q'D)5I1+DS.*=:UJP"-1?.>%1_\JUO9'KJO3L#N:I*4R';
M/6)D8LEF,Z9O$ZKYJH*4X?7)[`<C:6D,?^^%]SDLT(%`2L&`R0(W@>-LV`T?
M:2D;2PY4.+?M7TQ,$=*`447\C$S0?L>EKM@S!`"$>2D38-[68-S@'MDOX@>V
M0E%<"OCJW0RPVJ=!I;66UD`U#7O#IW6O,5FEVPBNK&02R(2#<;6E)B*%0Q;9
M%?((R^#=&W[T9!#F)81E$=C!8TJ@`\!=CJE`MGL[V-MS6AV>ZA[3P]UUY55:
MX5?5-/1>O9FY/C9*W^9IAQ=(PWO88T#8RA<0+%:\[+@>I()RFRF(#C[O@4[]
MD<#JG8'9/^0K45-T5%T6T9.C>H<;E5V239%M9"YVHE[K5DE:(>.%V:^1JO:S
M:6AJBS&%0X@7%IAG(4_S"+.7E@,"^--7O8%#]=])X=HK,M.ZW@\`UJK6)3B(
M;2P>R[,>C#V2O(DR19/&I52=KQJ/B0,*%&:%2,H2LE:>`(R50B!>>!5_MH9O
M8=?'V.]#UIZZL49ZK.VN25B\:FH+@97)[=10G7R.3+_(<:M9WE'X=O*8GA*<
MW%-;BK'E0$_)QOH``1!T$V*48U:<3LA_.3(S6W6:3E/:C*D@"1*8CJQ<!R.R
ML"/[8"8@18Q?+@7I@./;SXX&L^L:+-4+ZX="HTS-.&-"W:>:WB_%8PH#E(L7
MU%$G)T",*L9B@!ICFL.&,(\^0C%G'TQCQ@)R<!P*C.UOL4F'6`R:\;`+*0#8
MFK$GN3]@[?SZ.D*G"Q*IC;\P";ZSDL6CJ)8@*?3'*8>J108L$82`!9*,&`'K
MB#2@YGNQ;>/<^+[8Z'=T%P:00W2G7;62UUM11>'7993"P[T['TM>"#$>L)T?
M*R;5)2TF,UZP.*E8@CN<*5C(Y.IJL>%B(Y0<0'=I$Y5')U%HU-X>\H9%$IC'
MV:51:0-9V%#8^QR0MR9W9'EN4!\!/0N;8L*/)'CZ"+'C/^O`R#@.!5?TZ1X3
M5I_)9(-3D0K/W)W^LP;3@KU+BYTDW5O0E3&2%.31C<B6M6VF>%(@EY-R//Z,
M8QC.0JC[6J0I.[I-WE3&PZUK65SZH.LO5J#U9)I7&6.326$RB9F[=R5HD$0>
M%R8YSA[\ND:MN(`4D$4>H&B3CR/U,"'@7U:9Z74?IM2525K7%9U>Q2F#537<
M"EUBQ"MHU#)+8KU#X@UQUSETF7MZ03XXNLC6)#E9XEJQ6HR8H'[FF"R(60Y<
M-J[(W+U!_D?G0_K)5T39K]V6T1''2XZ?MQ]7HJ9B=ET:U29G?YY.\5<O_=D9
MD\6A<`_(97')CUZP;ZM38(4",)P`+ZNK[;+;^_Y)NM3.[L;US8;OU$OJ,U>N
M5:OJIVNK1Y8YM5,1M9D/*76"XK7Q2Z(4$L`F4>Y2,99I8BS"`C#D0@C-<%(2
M)3_(JUBVAE5>.L<I^(Z)2*A(C=#O*(>R1:;;$6!++AE+%5#`T/CLD?I3(&JJ
MF23+U"5H3JEA6#TYIP"TN,C$&Z(FZH>IRWWFN)<7^V^LR\I:;(J4L`0\`@^C
MMWS5T$IEU%SP?QC#!]<;<E:T]]B+\I,)8XL_KU;$H$C1J&?P$?\`L./1/%P=
MH0F]2C<4,B_CZ2=P0J$IY*I`YHT,QV]/3+2U!(C$ZA/@EZ",@S&1!$$X60Y\
M9SG@7GTRJ^^I^J5OR&&_>5M!57RF^WRF?<1=K.^0SVSD7R#]_.?/U\YX&:/Q
MZQ*QO*EN/;TS@F:7$]"I=C<D-2=82C.,3'N9V/J2WE'!"(X7_M+QG/`]$H61
M%%B$(`A"+`(0B\^Q8LY#C.1%Y_U!G/\`3/\`TX'Z<!P'`<#%)XL6M\'F:]M&
M26XH8I(EC>8H+P<0!:F:%AR49Q0L"":2$\`<B#G&<"QYQP(6]4R1$BZRNO\`
M*0`.`G.T[UV7Y">8(T?W3I547<U^<"$(7J4)<K,R`&,^``S@./IC'`KO'N?J
MOHSVV]CI^TFQE?4I'+FI+K]E$1+LB0GI,N<G8F#8B'R),P^$9Q*!K1LC&UG&
M$"&'`E*HPX/M\@_0,XM+?2UMXK??=:^J&[-.Y3$810#A;&Q>QL]02"_(9'U,
MT>7Z%UG2L=A]<3J%?#*IB3'WAX5N:U:I3I&Q`#`$AXSPX$$<M-I+VMP?4+6Z
M#P_:#ILB+3!]=*78FR"3FM+_`&N=0)I3U\Q(&5FL0IIV.;4*"7,J5+DEQ+`U
M(B3G!,<`!1(?/H%2UBH-I;4J'6RTU&Y^M^K5:([^W\[`I>Y12E+`M>:P69UM
M?+NZ6>_F*T;K//WOJLZW*X%BC#HWQY.HS&E[:L6Y<#BQXR'9TT;(5/:[@KKJ
MKK.3)9U(M;HGLA%WXV+NRAL::GMDZ4,5:6<<6_(VEI6IE+Q&%AV6M2>0KP6D
MSA062`819"M-^BNYB$I2L.[W*1:6\EO4B"#&HNK07`3B4@4BR,*URM<Y"-*!
M7@!@4_VN#/C`(`CLY%\@0K=U`LJDD/7C_'#MBSI8\4O6$4V1G![E*[\GJ=M+
M639IUDW?8B)0[S"5N+:UL4&L*<)CG..(C3OM4#.XM[:F]BRR?(=6!5@P(Y[C
M,9)F\0-DDUCKE+X;'RI*S&/<MB3.)F"[RB,M0%N5[]'6H4B;\*5J4LU,1E<G
M]QA^8OV#C:F/^*=98-3]D2#,UB5NV+<?:<G;KBJ[>NL]/9>IJ:1]B%GS(NL5
MS18C-(&2R8"YN($[_P#=X+`I:%0`@`,65.`\#IYZW;!E%KZ)ZN6-,8I,82_3
M"IV%Z-C,_F*BPI@WMJD2G#`8^3E4PQ<^6*'%@`E5`7Y;D>%))X!X*#C.,<";
M?`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`HVS>R'5-^_D!;3*XEB>N-(S6O)MF
M+'.P69-+T5?]=&NTICL/4KU12Y$RI%;J[J"#UOP&Y`4IR,18_C"#(27U26*'
M7?CL9=G)C:&AV-B>BJ,0VQW*=CA->*=G#V0UN`TYHDQ1C,_R!T"3D("LGIC2
MS?7(!@%D(I_R$WFY633FDSZ3C;3*GY9N]K8UR-N?=<6/:9I10Y<X28+I(EE4
MOD3EI:XN-+@)5F#TY:-7Y*^`E44-1C`PT#L-D;CVZ-A+<2<I6(MQ.K"+838*
M"6-0OCNJ':18#\O("6(1);4VPV0_=?KR`>349Y>`^/BR,*^NOJ<6A=E7]?-R
M2CKLJC:^2O\`0_;>R3.@JJB.K=$05$A0;KZTQE98H:]LLZ-U@?(WIZC2EK<B
M4QJ=Q5J#1J#OE`(S(@M4TNI6;-O90XW.X]+T:TBKU1JZPUU'+9:GK2M;F(RU
MEF%C2!_/`W4;(W&3IE\]892VLP\HP'&!*0""I$%+ZY$%.W<=;MY2]T_D?THE
MDK'%JVK6@.N5>R+5%2PN%3AR#:-A5.FER<V<PVNSK8M^LS8VWN[=E:Z+G!,U
MJ3AHRL%DYP(H+VMAH!K)BL=28'LKUEVONZX1+7.'-K/-*<H*&6_$H")KC\<:
M'&%?E'J:0Z1-`G50D^Z2$`0Y1#3%^PQEF9^/(5`2&%ZA(M@M@7'6GKFO/K_>
MDO33VG.DX!;=!XH9):IRD&M[6RIHTB02>41J5)H:%>O$H&@RGRB&O)QD1I9P
M<`#J2V0+PY:17T4/R'"_5:TBQ_%CV$'"JHWT(OCQGSYSCY/IY\\#\-"E(EFC
M.F"P>`A&JU/UT4B"#.<@"(^H(<:+`,YSG.0XR+Z><Y^G`EAP'`C3N'JC4N\.
MM-MZKW@W+G&M;@C7X)Z$U+#&]Y9W%`X(G^+2EC6`SD!+[$)6THG1%DT)J?*I
M&7@XLTK(RQ!0OTK:+UM8T(O"9]A-:V1L/V*5/8UOZF7W9FWI$NG[>J@",;FR
M0T[75LL%%B(QRHK+HU];PFK&(D2EVP<I^Y5&$FEE\"__`%:UIK+3R@JWUJIK
M$J*JZIVA6P0A),Y<^3E^;&)2\.3PF9QR.1*ECJI;&83F)*WD"'\:)`22F*P$
MHH`<!O\`X#@5L=2^,E:8(D6<9#ELV?W]:_B%]#20H-]]EDY92@.?`@J`%@#[
M><8SY^OC'`I[WB-(_?W\E!.F.),.2Z==<K^>46868<G7M\4OQ0`:@L.<C*)+
M2MB8P0!XQ_;S[?[1XSP.J8X\A,0:I4'%)TR<HP\]0<8`H@D@H&3#3C31Y"66
M466'(A"SG&,8QYS].!PQ_P`<31_67;'8_=S?Z?,=@/.PU!]D]RNE7W0TVO+H
MPGES%+"W%Z&RRZ`L#@6Q."$*E[-6J_D/4E.>'#"0[`DI`P*0M&E,U[&NM^_>
MU#8&ONLQAV4H6W[?2[1!MUKW)JBJ7`FN*YUKK2(OK?BNY%&I!+7!W:%,!=7`
MPO)*81AJDPDC"C&"330N7?(#678;I[7HK6ASQ'6"[*YJ>Z&5&W/_`-G8--SI
MP9X_9,%ED'G3.`@]BLJJ9.:F5-KPBP#`5J3`O09`QE##4VFE]RJRAW)I+MN2
MQR#:G6UO:V"USC8XB(A>R-%SHEU05/LJRL`"U<;2LMS,+4L222/XSZ,<L;G=
MO"1]@!$:>'/?MIHF_0/:_M;@<-FLZHW3N']1A5CTY2]#W(_0Y,E7S)\M,AUC
MYL>RVN(HU3>9S#IB<LA*%2EBAY3F`1:/.51X4H=B499D4=C<?C[:$D+<Q,C4
MS-X4Y6"$X438@3HDH2"`B&$DG!!`?4&,YP$/C'G/`^MW-*(:G,\Y80WDDMZT
MTY>J+`<F0E%IC!F+%)1H@%&D)@8R,819P$00YQG.,<#ZDQ@#4Y!I9H#RS"2C
M`'EXQ@LX`P!$$T&`YR'`#`Y\X\?3QG@?MP'`<!P,1L!6@;X%-U[J,);8BB,D
M5N)@@&&!+0)F9:<L&(LH(C1A"G`+.<!QD6?Z8QYX$,>J9.N2]8_7L0XE&D+`
MZ7ZT"-*.]<&!"93\1-)]L!SG&/8@8<X_],\"+>GZY,Z]QG=&R*R3%!37".L<
M1:5PR0L29,.I:Z5!JQ"5DC`4A0PK`EB+'D9F32QC]O480A#X=E7M''-JNQI(
MKPE:(VR]+T)D_NVMP"U!9*>P-XT[RJ,^Q"!0J^P0MB;"8KZ9!Y'@O_>+@5[Z
MVUQ+DNH>KBES_C24G<:UKULIE(3)7.==>8I5(Q!@T7*5O3HAL!(DD"!?)3"P
MNAI2HPU;@1@\*\%J@B`(-]7EIG6=LVOK5'H+K'3&@&VFR.@N]T;`J9:QI:<2
M2FWULB6ME8QUKD3M!V<^!6!'(=$INJ9C$!9AR`;8Y&E)PA&$`RPE9!V*SHYV
M!S5IFX8;<]NMW3?KXQ2UL(&U0.*W!9T>NO8)-(0D-)[>XHXC#9G)E9A8<B0J
M$C8F<,`$4,(?C$$3P47:X6Y[,._C1=>#(8!E<#$9C;?6H:Y4<K`D-$E2_%G4
MYO(!D1V`XR(1OQAS]?KC^H5![/.;0E_CB]*3X^TG46RQ#'8E:DAH>]):_P`,
MB5E."77O:!B01-N<XQ*H=(UDO+>/@_`-R1=C+DZ$IDOP*`FX3C#J4DD3,/[,
M-+)"G;&YD21C0?=%K-:?@^)2VX=;9T.*2-2`L)0\$IVS"$98@Y&'`0XQC'GS
MG@4%6G3.^VT52T)3>G,0D"UAJDIY<I\NFVQ]CU7J].BKIW6VAKQ8TV%44-@1
MZ"^8Y23-6>'V1HD\K:'E,UN2$*-(JR/X#PZ7>OV6ODXTEU<DLGJA+1DF64M!
MTDEJ)O:'B/M5?R)F:"&1\CC(R2$LI^:F!&ZMQOV!"WV5%HQ%8-&,?D8@F!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*/HK9$8KR-=W=U3.M&N[8L1N(1#'JNY
M$8U)V^Q&-@T_T_K=3`WW\^V/#0&/!6.BE/G[I(H(-2F"SD`@B\<#]&CL7UIU
MYVPWA%=\QOR)M14WJ:!1!@5ZK;CR6-M"6M8"7''U5#U44I"10%3&Y%+'!0H1
MN32L.*=BA`,R+)8"<Y"#/:?O9#NP2F:+H;K5LRZYK?>=LZ/G<UC];U_LY2]G
MM%"15Y7)+6D3>1*896+=(D#:D?D(ES2Z+`I5#8>8KP6/X`&%AL:Z%(O_`"MO
M3UG&0N33V+Z'1=OP1C'Q&-Z;JVWK>6<9A(_(CW7,BGJ[!N<"P`U(!.6$.!A'
MD85RZ>;1L%JQ;1Z7=A:BP=3DYVHN]]@F(M+JXV3UA=H],73?>`P=U;I3$M44
M&'YD9GEMKI.[*<N*4M*YOCDJ.-,.49)SP+:>OJU]>)IV(6C!:/VUW=MR&1'6
M"O)'!X%?M@;=R."KI8\SNS4%N.YI%^0]I;5CA%8N&#@;\*'`\S!;H,]*$P0E
M(RPU[W&V:D[!^M[LQI/3FKUMR2.KY+K]3TFL_P#(Q"%UK8,FCEXQ"96S`*^L
MZ021A0RQ50S8V9!(1"4IVU(YN8T:8\]:0L)*"8^ZLYU.IH%#02TNT>3]92B-
M5:D;XI6L*M[7:`-\MAJ8QF;FU0K:KTJZSQN6(N;%1-R)4@,3XP3E04/Y<#%X
M"JJ8WK4#E>.Q$FUP[)YQODVE]1>V*Q,YBN"B)FOH9W>KNUKBZ10PR*D*YASA
M'G&4"5969)>B%2D668/P&%@R+P'3GL2T(7;7.]&)T7/#:VN5*6<TN+G&C24;
M^@0K(*]HU:Y@/4>Z=*\)2#!&)1&>0`."'(O.,9X%7G37M?.)3KMKKJMLU&XM
M7VP\6U%H:U*M40\1Q->;"ZPO==PTJ(V=7!2M&W#02:OA.:6.3R/!*\L3V`A4
M1[-;JVC$%UW`<!P'`<!P'`KMZH7.+ON@U$R2'0HBO&*5G6O+01!/(WJ6EM+E
M*;KL=_?LXDDB$-[=A+WUQ4J<F*<Y&')WIY]0XX%'G89"9FZI_P"3,=`'1LAD
MIF50];T6:IR[EC`D-**KD2>0Q(U4E0N:H!:MA>!)P"^`6"CGG`O(<8R,(;T_
MDBR:R:FZ'I7'I_92Q?:;VHU8JZSI%#"7!G!;<A/F4,S:36ARV',RAE89T6R.
M:DPK(0EFH_9(,K`3LXP%GO6;UMZ[]:M4SZ!:PJK;;:RN:?DW4"N;0EX)8FK9
M[?(C'61:Q14TUJ1/"1(-$QI@J?R*IQ6F&$`P8H'Z8SD(^;N=G^F;-`.U#7:X
M8=><L8M.M>H0EVL;H%&HNH->X#MU&1Q=H:*V<W&8)"EKZ4PRG)B\3B4WD(2\
M#,P(X)><9"%DMB&Z_6%56HVT]77!V/=@]!PJ*$,5MZ=RYJU>C+[75"!H&6/C
M#)9-B.U@R/I\FJ9\:6LA87EU5JSS09)$NR''@\.B*C["8;IJ2K+W86/+&FNF
MK*XLA,E681&O*5FF,60RUE:'9P0^Q2XYG3R$9?D`Q$X,$9DOZ#SY"BGL==G)
MNGO<^^HSOC=XMTQT:C8562"C,HFEXG>]ZU]2Y3C`(A60L/1A$,TT`S"<8S@`
M@XX'1`V#P:VMYN/7P8A2#QZY\A\#3EBQZY\Y\A^OT^N>!\T@,2DL+V<N^Y^R
M*:'(Q9]F+`5?VH$9PE'VHA"`$*GX<9],YSC&!>/KC@?2UG$*&QN4)?DRF/0I
M#D_S9QD[X#4Y8R?ER$0@Y,^,6/;QG.//^O`^[@.`X#@:.V=<UC+K7L*\MQ99
MS@TT;;+F@*-+&<4:L00)_5)2S"2Q`,-+&>4'&0A%C(L9\8SC@:NZ\D"=JT"T
M<;$APU"1NT_UI1)E!HBQF'ITM,0LDDT8B@@*$(PL&,YR'&`Y\_3'`@=HZT25
M3W&]WTS5DMA$8]>NFNVS!2@S+LH=HMK2\2Y>L6HC`B^%$8AL9,62<`6"S1%&
M!P#`BQ"$$2.V:ZF6I-@NPQA<J^MBPEMK=$<E8&Q#6M52ZR6IM&T6#MBA,>+"
M<HV@5-T$AZ`^:D95+W(U.G^`9IGD04YGJ&I=?]@^N:*ZR51F2;Z]M4,5#J6L
M&I[6@+[(7)A0R`4`CY!V((X.%$R&,_B4JXT12/#6(;8:(G.`!,`'/D-B=DVT
M9FK,$U6VUUOF\TM-QJ;K)[!YY5D_MUK>Y)-I,%8ZZ-MT0F%J,DV0PN2'_=/;
MDF-=OR"5M6>N#"\%A/R$K(2LJW;^:2SL#W4H"Z8=&BH37'6WKI=44O.E*[GK
M3L#:\%ES1*E%@KXLY1*4R";8:F:P'![_`&HRL2#+LD<Q&?$>:J]!&A!2<7=U
MQ)80\K72V?Y`:Q*XQ=X4I?RP>XU,BR`Q$X)!*3U#@PM[+\6%*8TH>5!N4OD(
MLBQ\?ZN!6UL+3=96IT!=`L`V$NR-:ZP9WMV$*E%MR&)V)8+.QJG*E=B'F!-6
M8_3[U'IQEVD:LQ`F2J4RU,!`OR`2HS!83,9#IX:MBG47<3%-.'*MX$($#ZX%
M=V1:Z'-_FAED/C!-;HCD#GD68&$+0JBZ9IQ)ZZCZIQRZ.0W`7H0-/D6/N0\#
M*^F=>C=.N*A5[<?A4W*'_8++<HP$T(36\&S%Q%(1@^<`#A%Y2`!ZB%CR(/C/
MU\^>!:#P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`YMIGM'&-<*;[37,RGBMA
MI)<G:9-*EJ6FG)J5KHK*IN/7;5Y"\/5AY3I51[-6E>.$6<GQ[5X!\HTC=D*7
M/S*"!<#):%E6UNM$YM:Q)XZV-L#M$SRZ..G8_KEA:-U9I12;B4X-=7;>=<$7
M*8FQ>=7,`CZ`;<*%)"3W!^"W.K6NR?+V].J=0F:;W==7"56D;W':UE95RU.%
M22CD-:77'5(0"*$=@I40^5JWF(5F,`R#)!^"SPG?VL@P9G`>!3\Z[L4'86VT
MHW#JQ)-W36:9[%L+K&]VYQ6$NC6ES?+(%U^6[K+$VR5V/,$L;%&5YFR-M-D:
M"YGI$S68NP:F_(E')LAR&DNL<RN*<UJT(<Z_[8]%-<]H*AU8V`HF[:JO254I
ML.!P-L79!VO<\XMQ@NS]:EM'[1E97Q)C@KW`)K2J"`SPH]A9#\[*[7)O-+M?
MM>=F=Y:*N?1]1(8S4%M6[UT1Z45?<=B6<PUQ9EL2VFX0A_SE9,K(J%>Q,J<J
M=SR'.63C!F-\;;1I5"M>>$,6[6=^='=D>M25];&DU0WA&3(S*M=F=BI-/J[.
MJV8%E<UW:44L63Q6'R>4-:.,QE[(BD47NP7)>6K*7#0'%B">>M+&,+?&;L*N
M'?*YKCJ+K-J[3VYZZU4C=-D61.=R7R]JS7J+!M=+-ER2+PV%--$R%U2%0N.0
MTDYP6+`E!5'.98$_T*,%D(D;*/&PP`;\2C:Z$Z3UQ,:,ZRYG$'**:@S>S+/E
M"DB[[9C3M%)?/SYE3=8H(`ROAM1J<L3.>M6.I^"52KP(DO`PATG[!.34RT+=
MSP^N;<RLC34-E.3R\O"DI&T-+4@ACTJ<'-U5J/["5N0)"AFGF#_0`H`A9^F.
M!!>K=3:CVBZYM'XH^A?88^0+6G764T1;]=NAD<MBAYJWTW$"(]-ZQEH,*5#<
MX(B`EE*T*K"MH?$/NA=$JU"<<G,#-=/-E+243>4:7[AG,:;<2IHZ?,&^81UF
MS'(+M?013\&-QW9.M6D)RM$Q.@EBA*WSJ+DGF&1.2GA"#&6IP:5"@+$>!\RQ
M8D;DBIP<%29"@0ICUBU:L/*3)$:1,4(Y2J5*3A`)3IDY(!#&,8L!`'&<YSC&
M.!&A7N[I>@R9A=MYJ^CR29\)N%=^U2GR4;Y]?B,^:6`]#/;/CUSXSYX'C']@
M&AR7Y/N=V=1D_P`.`B.^?9&FR?B"+'D.3/DF8?3`L?T\^//`S]KVIU@?$2%S
M9-CZ%>&YT;TKLVN#7<%>N")Q:ERX#8B<T*I)(CB%;>L<C`IRCBQ"+,/%@L.<
MBSXX&PH?9U:V&D5N$`L*#3E`@/"F7+8?+&"3)$:@9BDH"=6I97!:2G/$:C.#
M@`Q8%D10\>/(1>`@!U%M<D@'75KG&+38G.N9TU)+*!)(C-""6&1,JU;<EB.)
M!3DV'C+^T&L1*BU!0<?H$0:`0/(,XSP*N]WW=I<V/^11^*=&UU"U5!I&YKA-
MBY*N"D4(ZI6*C&I5E*:;]JY_;-03/0SU%@I04/./46,Y">7>CH#=_91H/(=:
M]>I56\1LP=GUM8K4NM(;TEC*Y/`W)8XG-1;LPM,@5LCHI//*&4H&WK"!@*&0
M,`,'?,4$*_XV&VFU6U->[X@VULV1V7/:3V]<Z>;3UTBC\EB,<;XQ%6],[,4(
M<66,1PY<V9DY2U5]V=[EJ$RA,$D!6"A?(&.]N/4U'&S6+N<V7JVY$C-=6^D+
MUZ#*U%\SZ`UW3L!BU'2FO`*8FUSB4IFMICY,Z0,`B2U#VOP22M-3$)S4N!#-
M&%M5W,5K+>I>VXTF`@L6[U77;.V,DN%95S)LG=I'ZV.B#!40&V&#6RE%*96+
MU;Q$"$:M`>7D&<B'CR&I>E_;FOME-,*TK>+PFY:XGFH-8T)KC=4)O"N7&LI:
MP6-&J(KY>K3DL3N<)Q4-*EN6D*$RHPI/A20:`P`/C&$60J^[!GNW'>Y/Y`H)
MI&0L\!@W6[H^PU'(42)2B!*X4J?-A9I(/R:TQ:I`Z*U5@.TE:\C++(*"E0X)
M&4/(!&&AU7A"$`0@`$(0!#@(0AQ@(0A#CP$(0X\8P'&,?3'`^%U)-4-;DG)-
M"0<>@6$E'",$2$DTU.8`LT1P,9&4$L0L9R+&/(?'G'`_QI*-(:VTD\P!IY+>
MC*.-+-$H+,-+3E@,,`>,(1G`&/&<X'G&,BQGSG'UX'H<!P'`<"-^Y#S^W-0]
MJ9#]ME;^!UOO%Y^SP;\&5?XNL90N^VP?\9OPY/\`@]??T%Z^?/C/].!XNBC2
M-@TATX8C5!:LUEU5UZ:3%118B2E(VVHX@C&H+)&,P919PB?;`<B%D.,^,YS_
M`%X$'M$WI&Z]H/=XG1?+D+3:^C"%8(XOXQ8<B],88!265CSGY$H2"R1`'],B
M$,6/Z8QP*XNSF!.-E[2=OCR][!WU4\7HGI.KV5IV"I))&F*/RUI=U>]#M(8Q
M/F]W@LO<'V-NJJ,E!-`B-0JLE*#B_F\9+^,+$*V9.R<VF:671+>S0V/M!E/U
MTM/;99IG/UCBA59@[2>4W#=&_>)M1'(!J<@+,.^S),P5D0P`P+U#@*Z>^>H9
ME><=J:G95=&NL!GUJ]>6TT3D-QV;*5U%:YER!/M+UC2!<K&^NCC/7")L,I6(
MS$C6D4KG$TXQ20GRH$,?R\"7FOE63R$]J79[*L6=2[!+;,TYU)1QB2-L[K6=
MN.NQ]<5TYQYO)L.D%LG:;<5,BN4O*U^(<UYD?8WAK2D%"SA08$TL-ISY@WKB
MU9V-*S>VK7U]+1UY+'9B3HM-*O0''K4L6<UR4;>L,V5,2+#C3P`&FP/^U]`X
M,R8'.<Y"B*TX%'B^IC^/(V2*<40B:96F@042[<&%5A8.O3"]V%IA+DK6R26)
MSN658Q.#:3*E@5B8TQ[&_)%/RG-P52@"9!D+=(\Q+0?R771<MD;$C3QOI>C3
M&SQ$260)%#DE<MK%)KTZQ41R<<<+;V!<S)2UB8L_"C`%Z87J/!9N0!/3J7B)
M,(ZY]4F-.K<5R917BJ3IE+IA-]R--.97(YLG"4)*F2DFMQ1,A"!&/TR,Q($L
M0Q#'D0Q!8IP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`Y<F=;48-BK%;KU+&=
M39W;[NFBD2!20^A".4/>L&OK'"#<_@,$OQ9QDMEP0$F%C"3A(J&89Y3XR,(=
M!U]:[QJ^VMD*536TJGE\8=2'2,VG1\U/KZR6<``G%K6$QZ+1N;;(H:]E'Y^^
M8WA$XLZHXLA0--]TE2GDA53;VK=M1?=C3>&-/9GOZD,L:(;5+A-J^;:\K&P)
M4+C5;G`/+A8=;TL-DPD?[DP`)SVWNIZ`0@&HQIS1FC-"&Z&M-K72WU?5XP;8
MM`]?XMO0>_R2]WZIV21;KO4\10%@[4#7-V4+DB'6L42)N>7M#8-47"S`GHAA
M293%XSG(PVAMM!M@5MM6+HHVYM;=8Z>ZSN=GV`C0ZV]?4+"32MI3=_JK,#>[
M`FLTHQ*Z/[D[1A:?C\4TH3TZ9.4I^YRI+!X"&;Q0_:/9FP52LU1:VIX$@U*)
M72XYJNZH>M*"IFUDF=73:JXI#:]6TS-[BR_(7\LQ;G!+FB;&],C1XS]P%4G3
MB-#8+A0G<.E`6Q.'6?U\RZ.`1+CU#[BDM/I3(C9*G$!T0KBHDX7A3L7,:500
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M*VG&-#HNQU;`HLP2C9SK<L.;P$+@V5TA"W)G[9G7W=^3:]Q]PRK:S,*V]^!$
MUI02C"@IP&_%@0;ZF6L.\F\L%K^UX;V.:(2-Z@SFU6%K+L9KWJ-+U#[`'U:6
MWA>WJ+S]#NE,6IVBTU9R%#2^Q]4G<&&1M!F4[@F'D(,E!)0M#WEY(.".3=49
M1Y!"\*8T4*V[6!<SR!%!:C5803QMPS@<2_<:D)>%OV8O`2\J,9R+`1AVYK'^
M0!;&NMOU!'S^IF9)[CKR8U))&QO9MKX$^)(I9D1>(=)'ABD#_.9.R%N[(F>1
M&IP*$H@&^OMG'G'PC#\XMUM;?Q:*0J*D5'T;.C:R5O'88]$/VA-D.3@K4((V
MU-#LG-?B+9;BGYK4+$1X\C-;T7W8%>?<@K)?@P-9VWUU[<,\'?GZO^M7^/C;
M-@1QF<4T.8%FN<GAO[B,<1DIG`!(7R+*6=A^_2"&:)"H=LD#$#X1+PX'D\(>
M3$NL78"55Y!GRQ>IG^/BQ66>U('B718VLY8G0,\H3F*`)4*5;':,EZ`HI"C-
M#DX)2MS3Y/R,L!IH,!.R%?SQKI=;UN(37^D_5'TIV^]:^Q><5MM*KJI,ZQ;7
M6M['M%SJ=PBC3:![S65=D3"W:P0PMU5B:F,$C=F5E>U1*PEM5*TP%@38ISJ7
MNEGJ^'LTNZKNE4$O;D2E"^N%@3ZY[-=E3D!X=U3F^G+3];W(U8VR!0=@]K2&
MNBA4T(#RDQQYPR,AX$9>QZC>R'5/K-V-JS7?K^ZQZ0BNP4QAD>MJ0:?VD_M[
MZB236?PR$-:EQ@=LT95+%+'&7*G`AB+5$/1BIG)=/=*D"(K*@`26F^]78%#-
MDVFLK@L)34^Z3S=^N=<TGH#5-0.5MZG[":]3O,#%;=Y'[)OE--\V0.D0"Z3!
M4\NY#PS((7F*)42AK<`*L*W(*A.J3?:#?QX*&V9JKL(UOWD26M8NZ=EMHY=!
MZ9C;KK[+WV$1Z+,Y:*K;*D,VA;;)7%T1F&N)@B@C)/1#($1YP`S`0Z$_Y!TT
M1RKHQV(L]6G6UQESBVN%EHX)<+<J8W,]:.ZZAEB>G;*AS<<YX4OCY]65P8S#
M34HEPQ$G&X*`,X(7@UCAD#6M>AC+6D8XV&#Q/$?94"0YO0L[)A@;\-+6C0*2
M$RA$D;T'QE%DF%EC+`#`1!#G&<8"K+KVE*F3;_=V0%0U7_V/:W6]B2$*#@GE
MIT+7I523>5A,((08`6H4)#3O3QY!\F`Y$+QP(+]AB47Y?OM6"--^X=M.>NN"
M*!#4'J"$L,D4BV';7;+>B/,$D2O9()$Z')S`AP#!XB1B"+P+R'36$/J$(<9S
MG`0X#Y%GSG/C'CSG/^N<\#X78`#&IS+,*$>68WK`#("(0!'`&F,"(H(P`-$$
M1@<^,9P$6<>?Z9_IP/BBV"L1F.8(3'(B,,31@E&H&88>D*PWI_C3'F&E$&C.
M(!X`+(BP"R+&<Y#C/TX'N\"E:L>Y)FL[MML_JA0ZRV(SR2J6F0/DAO)PE\:.
MAQC2SP>.S-N7IXXA1J'`)4@S*$B4@L:S"DOY@F&%!_6`L+J>`X$5=ZW-*RZ1
M;CO"[!V435JML(Y+/MBP'*/M$-22Y2HR02,T@!IN"2A>H<C#@6?IYQ_7@>UI
MPV+F74359G<R@$.33K?1S8X$E'`4EDKD%8Q=*K*+4%_VSP%J"A8P,/T%C'G'
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MTQDGR/`;CU<C-JB[6N[9BFVI$GN*NW34O3^"TVZ60%("N]AX;7=+/3%FK4,M
ME[%FJG!MN>025::Y"&,Q&C/(/PK*$'!F`!I^\=9G%MI2ZW`[^,II+7R0-+S1
M4MFZ>^M*0G0Q.TPQZ4IW=.0@J),8F<(I@P2@0DIQ0<C(_0H%C`!\#3ITYIID
MZO/X[+5L`\Z_QZHY3`HVQRLS96JI'=-;2$@6KSM&%,'3PN+.;.[DSV:,CXN)
MC;F48:-M?`I1!(49%\0@M5:;,H1V_D%6'7[K6#+_`)PK7K(9)JS7RCM^SE[J
MW0!\N%,FE-0O--&.YE6,P1Y4M[^6K(0@=CBOC-,$:$P&20Y[-UU0XI%M`F]$
MP5Q833</73K?![\36?&;`G8=:X"EC4\65==,1E+?3<S@>L7^279<!GP[#=UZ
MN2/9R,(V/&6S*P8=J6F:)&W:@ZL(6^)3Z`HDNNM+%)8-:SZMD]GPT@-<1SXX
MM8TC<4Z1>_3I@#_VKLL.)),4KRC3!%@R+UP$E.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.!R/4DQUU.]@K8BUZN+G$J[>N\;L0D*9]4N`&!6YNT4C&L\/KMD2G
MMPEF`DOMMNS<WD9SG.59*;X3BPB4C$4'7#P*QME##BNSOK#S@HO)"BNM_40C
MA'9P,)AL'HM=@`"/B\"SG#9Y]OD^F/./7/GV"$,*,&!5VB6BB1F`5JD/89M.
M]*S,F!%D+&FZP]#6AQ_[CVR`P]JD4D;DQ:;&<F`+/-%Z^"QY"'T[NW+K[0/9
M,^3V]-VYSI6!ST$JJ/L<AB#5!7,F4IT^R5R*W03F&>4Q<3:#$?4*T90,@)1Y
MQ^4S[",SZ?&&4=9FU$&V&V?N^.UYVMO^\L/@E705VCU?OB769D<#UDI<W;$Q
MF:R-UCK[5$]0HH::@:4"4>5IB/(G<W[DK(A)1\"]?@<\>WV@NW%I;);I1&#0
M&#R76SL?>]`<67<A]H-L=D-!PO5I_0DW,Q.55NT>6K+,6V-"67"9F"@5EI?E
M<3`+LE%E>3`M"C4%L9\["K2M:2,[PVU77.JE5U/4"Y66GPS2"8619-@SJ]G!
MG&4M./R:W-L#@:-1\I!'@1>,!R/'G/`BUN12M,;9[I::ZBW-5-;WE#(A65Z[
M37"1;E=1"7C>HU$&UHHRK(]EQ7LY0$PG&PKM6O8B$0"RPFQT`Q@#@0,\"L1-
M&$5/Z23S<_5_9[9K59DFFS<TK/4&KXS9+C8^MS35I=P)M?X1)W[7N_H]:S3^
MP2X?`':R'A&SIVI:F9!*\(C4Y11.0A'LM%'6"Z(?.*/J:HMFDUX1#5^;Q/9S
M0233;JFVWGKSMX\V8KJ]FED#CDS'35TOKC`:TDDKD?[A31!*W1Q"-:I*R>(!
M>`G=1?8!L0AL;%*0G8F$3FZ&<]I(?NO[M1C;-J%N^V)S&A*8@:ZUV)IEK>*3
MNX4A1$G.3>L3PYY^^3X^0UQ+`(8R0GP/MBKNNI"=#]L]8=T-1W=M`44[S*=Z
M]2ZU*`^^$C+6#_"[#:[%6Y6RUI]1YP%6N4-GID.0GEIS,"!@/F,[T^H0EN,<
ME78+KDA`428>:WN4O-;9"6`OV_2.+KT">2@.-#CV*+RD^0T`@C`$01!SD,3_
M`/-AKA9(AM&F-+[@;X2HTX3>C*U^UILQBK=*ZF^"T&)3>]WLM3TY&6-2H%X,
M<!/"@HDL(A^H\8Q@0>B[5/V+[:('E9M#=$<ZZ]>3DN!JJ<U/FB&9;'O;*$TD
MY<3:NWLKC2&+5HE-)39`:E@#&6M+*/%@$B_3]0_R(;[]*77[`6C7^`;8:;4E
M#(:O4H4U>PZUHN_N"5Z=4B22N+I("V1WDLF>)#(0.Q:M6[.9BA8Y*3A"-4&G
M^_@)#55VG=;5WKQM-5[UZJ3%W`6B-_#(;O@"5Y&%P`>8F`2TN;XA<3S\@3&>
MY8"A&%9#X,"'/C'`@#W;6TZNN=:].G"\J0T_J/8QR>[>E>X.P1ARBN&62ZD3
MNG+GKJC6DC,QKV.#DUO2%.4J/$Z/:4LZ.,KF4C)4*Q@^(+4]*;REFS&I]"7Y
M.8LTPZ56M7+),'9FCRAV4QDP3D`S*5_B9K^C0/\`B(R]`64[-(%Y):XIN6D@
M48^8(^!R.]]=X8[6NP[2KIMU`0D6/)*5V`2VSME/PPUMG]?U&:T?9QMS125&
MX!4,KJVUA$GIW/E"-<`+>I<5S<S_`"#7".3`"PC7SK&UVV<AO=9H%)$=AUI0
M+CV"U*-J%7,\=`/T?/BE`ZJ7B5F&G3AOFB%@`KF2XQ0H\C6X&6O$4$I,$A/G
M@7D[E7@[Z>Z2;(["QYI+GK[KCKI9-FLK1*%IQ1,I=*U@;F^("9*O:B"5`4[D
MJ:@Y6F)BRQY`(>2\`SX\!$WJ_P!7=C*D>]N-G=HIG23[:6]UF5E=BR):^-,[
M15K`6N+TW%*\9V]O<;'4FREW<W5K923E@C2RR@GA$(O])GQE!4=N3>A-D6?_
M`"+ZX3UY+XXIK:G.M*GDTJ=P_%'9/(7YPECFQOZ3(D1?V!*-PMY-DS/SJ!&M
MJ$"DLKV'DL0=:W`^1>'(T"T&,"SD:12'&`>/?.1$CQC`/;(<>WG/T\YQCSP/
M`@AGS0B&G>YYGRQ6/&?(JP4%29[M",7NH"0:>3@\7GR/`!C#[>?`LX^O`RK@
M<AF@CX[,?\E[L@K60NL\Q8[H585D/T0@-ML[#KTBI0^"ZS%5)-IG1R6L0I)7
M<[LADK<C6/0)3A[(4A4"4HOMA9-.#KSX#@1IW0S'`Z=[89F.2,1'&M5Z_NG*
ME\_;"?$=_P`72G\W\\DPUOF8^3^-^7V7?9+/M,?W?@-]?C$%:_\`'XL_:NW>
MOQ%*MO'"6JK#;+@L2OXJBDR2N?LF.L*R*8('#V*+R*L&%ACDX;6C\"I3+WCT
M,.5/Y3B$62_CP26$8-<]RJ7U)[+N\!NMY'=8BWO876&6)%%5ZU;$7LS(FHC3
M>L,N*Q[=Z3K"?-,<6!R(`AD+S4RDP&<&!`,'D6`CE8]N57LW"OY->S=)K)_A
M`^=>=45XG%-ZWLNDY&%-"=7-C'94?^TK2C<*F2;\B:_&!(5'MH"3R"RQ$&C`
M(>,!M9!N%I_%:\KTN0=TG8S4"Y/74``_1YQH&**1M)(HJV"0H#@R'KB=,M"@
MC[CXQJ"AA-5&Y#@P9@_3@;KW0TY@7:9(*BUZ_P`_3U/!K,ZK;)5Q._\`,4CR
M^<3I!.+UTXEK7.YK%G>-PYL`<ZFUBUKE:%(WL)QF716`G\:,!7H%K4BO:IF%
MJV*H-2LN&)AUAHBNGN?SBMX!)71P:(O8L=FJ..G5*5!F29R"03^/-T!4*C&U
MO9U2E'\Z,19)^#<8P'/IMGMCJ@^ZN;%1:-]B'<0>N%1EJA01-VU.M\I&_P"'
M:).I:!AD4FFG7RD<D\;<0.`2U2M6]HA$-9HSC%A(2\'%A'O96N8%/>H[^.@O
ML:$WF_0*`H-4)X_F:ZQ9F?YA!#&VCXH`-ER%`_%'-2:N(NJ6#5.Z@X(\9,,3
M_)C(!F"P'3&P4WK@C[`=C;2C$7F3=M'(=4J116A*394_XKB1UG(9?<,>KI*7
M#,/YD=/FC&X5.Y`/7F-@5"=`<260?G"A4#(<HFWTZ>YC7F@C)4%!6#?:JH=#
M]0H1LFJHFE$YMVQ)FF=(R.\HM'6G9B<R"54_#D3+#HZ*8Y9G:"*L%F)R,Y>"
M3W%*26':QKY/HY:U"4A:,.&[F1&R:AK6?18R081A?S(Y,88RR%C&]A;RR4`7
M<38XE94X(`$G!WMZ8P'QC@;>X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'%)!'
M^!LFP;U9>P]L_M?3.S.UKLDE$7DD<A);<LI:UZOVHU]`FM:Y;16OD@BRG6N9
MN]<?M,]P`WMI3"\R)N4*59A`C3D(=K!9@#0`-*&`PLP`3"S"Q8&`P`\8$`8!
MASD(@"#GSC./IG'`K(VF#Z=D754?_7WQO(@]?]<944/'5N#?/_R@PUY#X_UR
M9C/^GU"$6KJ(X?:!;"4@(1B;]W.P>2*QBS@H`&T>H/6.W#^/&?89JO#C+D@0
M@\8"(K!IF18R$(!AM65MFWBGMMVY<M90Z\JRDVA>DR!YSL/FU5*!*XK;DW.4
M-;-&2:^4X1MJ!W)1*E#H><2<?DQ.E"64,.3!!"5&H4GV<>+ZV'CE^Q;1YO50
M9KKMH?7W6(=R!L?,I=X\ADC`Q6.*R:]865V92H>Z84H#$#PM,1@.+*&2#Y!>
M@6-<!P'`\/,8CF9`?+<,+,"6*6(J,'RHML0@DAD<3K5+FF81O@2,.8F9,Y+#
M5):7)N2`*#1F8#@8LYR$)ICUV4%,8IJI4JQ$Y%Z]ZHL\W9HW1BA4I=8O-B);
M2$LU^;Q3AY<E1\D=,QJO[!D&"LY4Y,4+7/*@T>3"2\\"E9-UL;S,2?8R+:?Q
MZ%]?KE4UWV%-=8;6D\BBUE5Q)668/D$K&&OM<PMA+LN301BIW2"`NT81M+XU
M$X*D=C/>4!*<H`5``TO95.[?VHBLQTV_=:&5ZW=J+Q7-H1^JK(AL2?[#U"21
M]D8I;?%J)Y&_UC'GQF(UZT3JU8BBSXO7IU[1.UZ,_+>G4JA%X#8VI^W3T78M
M3P?0/92\K#;I7V!/^KMA:G[4PMTG$$@53L$<<;_G<ZK*=S:>NVQ-6D4]K>J0
M-(27F2.K6Y3(C[8+$C^ZSDL.IM5"X<N<RGM=$XTL>2%.%A+NJ8FM0YDJ\(!-
M>%12\Y*-46IPV"RF]\#P+X,Y+\^GTX%9THW)OS:*73FH^M6*P!Z8X([N\'LK
M>BZ0.SEK=!9XU#.0O4)IN$QE<TRC9^PHFL`(MS&@<6B(LZT'VREV4*P'(`!\
MQ'451MHK44KWOLBXNPZ=D93*\IMBY1ANH-E<@)1D*A0K5"LB890#,WFF&F"+
M_)LSXZ`P+&#%YN0!%@)VUGK#K52S::S4[KU1U3M!ZE*M/:ZUJ>!05O/6(3<'
MHEAZ.,,#6G.5)#PX&48(.1@'CV#G&?KP("[/VYU@_P":K4U4V-U[K"T;%I[3
M2;[VRJ,2O6V&V&RBHB+OCE'94JCSF_L"MM6S83@S><-H!%'G@&4/`\Y\^@:I
MHC0O72ZM<*LOK1.8W;IQ7UYU_#K3C-*OBJ+7CKPM:)`D322+"FFJ5M/5S4U'
M3PHU))@LP=?&7$K'I@*\HPO](10[&.Y/;#0%KA^F[]2523OL3V9<6&!:;2NJ
M9>C(H27AE\A(@B*T+%KZ?.Q4]IM=&9(X$$IX\N4O;([JPCPG?C$Z9?A,$[>H
MCJ>B76O6LVE,VEQMY;I;'O(K!VOV0??9<\S.;NRDY[=8U%W%<E(=T\!:Y"XJ
ME)?SX"J=%IPUJH(!"(3I0BEN<Q:U]=/9]JEO'.;FMJCJOV9EFQH=F%+S:-LK
M=;'BS&;6^&PFIE+]630N5P2/2=Y:HWG!"Y0B$!4>U`QX^8!`R@T7JAI]0/<P
MV;\WM8^SF[LRI&9;WW]5E<QVN=O[[A%$3C79CA-:-Z"/(*O-=4L26P!\=7AV
M,$6!O``T!V2,#$G+"#`=2+(SH(ZRM$?:BA$-;&UH&=M(&:8<(E`V)"D2,H1Q
MPAFFB+3D!QD0LY$+./.<YSP.9C?$1A[CWU*`)1%HVF%=6^?O`^@B3GAF<E4C
M5_,(`Q9!E"W*T`C@#P$6"1!%G]`PYX'218\M60&O9W.FZ'RBPG"&0V32M#`H
M.D3.$TFZR/,JUW31&(H%BI"D6R>1G)`HT!)IQ)9BHX`1##C.18#C?VZCW>QM
ML7"=G[FJ^44;J[+X99KQ7NL]1[JI]*9IHK)V,A*Y5;L]NY;C_'"U<^1,;$E7
MNKHQI@'IFK`0E&-B59C*<\.F3K/N:0WUI#K]8$E=93,G#,$9XKFX)5%TD'%L
M-F$(4\36[$Q:&E8(<(Y7=TNS0I?HV4X)&]>>R+$JDU(1@\(,!._@4K4)U=V_
M4G;QL_V<O^QC#*(]L3#EE5_X4*@:THZ/UPT,%2!KP*27.#^M4(7^/R2"N.5P
M""\H%Z9:`P)9!F<EE!=3P'`@'VLR`Z+=8G8:_IT`7,UMTHV>-"B$<).$[!E,
MS(@?L<`!@@8*`;D>?&/.?7QP/,ZN=2VW3'4&#5+'KEMVZ(@\J3+1A[A<S\@D
M\EA#/9+,Q2-9`&I]1-K6-QC#=)#U[@F&H+RI^9S.P(6<>O@-"=<BAZ7[Q]V3
MBXMBA"A-W3I9N;5&$2HEM7?@M+:`9S#4JT_`R%:W"%(E&J`68+XA&!SD!>#`
MXR$2]N)&TD._\D4G[\:,UIT"UW1+%)8#SA-;R]ZX[-%M+@().,G!*3Y5I#1Y
M+\Y``O(O'G^H3[&3VY(B$9#19W6HO9TS6U%DOTDK_9;#RO\`1M284N;BE0VR
M6A^16J]S,8`HP$0!8S[8SG.,!IC:*V]H*%WUT`E,2U>D^R?^8:-G-![#3NK(
M_9*.K:0->K9UO>5UC'O3)"[1-;V/)P7=0WMCV8WA&A1C$:YA^,P>`DI$,2)+
MN'V*9B+[&(G*3:.U)<8W))JTJW^',CX*/["H6M^E+(WR*)+G9A0K6P&5:8ET
M;C3DY`@A4$Y%@S`0]V<=NP<.M6Q(I#OEUH*&T&O]MNSFVMNL%G-QZMB30A__
M`"Q93DJWA?LH$1R4D\C"W[%7]N//ODDW(,EB".G7,[J5<)_C=#&XJE"9=UP[
M$,RD`E!QA"H]NIW5;"9,I(R+)1N4!+.:`L8PYR4$&0!SC`\X$%I,1EIY/9OM
M^VN*<O#9&M$=,'E,%&7G*QP3GV_O,H</N,F'_`,U.8G]",?VOH8+SG/GS@,L
MZZH+&D>ANJ9BF-QHY=-=4J`)ERP+.WF'RMI+J2/(&5ODR@Q($]^3ML<4A0EE
M*\G`)3XR2'^W],A-QF9F>.,[5'H\U-K"P,+:A9F-C9D*5K9V9G:TI2%L:FIL
M0E$(FYM;D1`"2""0`*)*`$``X#C&.!Z7`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP("]E^R,VUFU*FK_`$Z2E<-C[6>HKKQJPQ+"!*$[UL9=[N5"*T&K*P')6&>*
M+5YT@=!FY"24TLZH8\^`^,A1KHKKY!;<UVZH-;I@DC<=C\!I>\)5*E"1%B2L
M%GSJ'7AH/>TH=I>V3#^T[!O-TE+F2_(U(E*42UW,$2$82TX`A=MK4WT]K%?<
MQTMA>T40>T9T!;;?IW3:2OK6YV[0$`_,+&1^3PE<8^"DSAKWE<8E`P-#@A..
MC0@')DJT;8)&C0!EFP\%B;GMGH9:$JM*N((=64HOQKBD2ETO;HY+K4EMHU**
M&M\9KQH<`A%+U[<A&J7+$2<P*@`"BC0A'@`@\"LO3DDX79):^``&<K)W`[1E
MKL:`61F?C15KUHI4*Q2:,6!F)$9*IL18QGS\8LDEA#Z`QD(8EMO6M<W-V<[)
M()OU_7_N:;!M2=,V],[4A>\8J7]EE2.?[>NAB5Z:Y#L5KT!U4O.4V!)E11KJ
M>G"D-!Y3`-\'!)CK'KBEX-<5S*ZRZQ=M=$G][AD=.ED[OFS&*;1&Q\%*T!+8
MPD((_M#>:0F=MZ`HDX2@U`G5`;ROC,58#DLHP++;:V`9J^K%QL"!15]V'?,N
M(6"(UE2[W`'*9SR3?GTD96LT?42R91.*EXC;BL^5Z/4N));0B3J#S\>"1!R%
M4&M?9CN=<.Y#53=O:E0376N5]Z2?6]\K21V(DF^QL%E\<TY:-N2++<Y7`WQZ
MI255^]-SRF9AMS6/+FV'+4IIYPQ&C3E!=''I\WR29V#"D;-)TBJN#XPD=7QS
M9AH8R\K90QAD)22+.IAV<OAC.W'D??B`6$I.<H`5@8QX,"`,Y\X\XQYQYSYS
MC'^N?'CSXQ_Z>>!_O`<"&VUVB-![EN%;NMQEV(G<JQ%*&YL5UW9\UKC,E@=@
M@8R+.J2?)XJ[($4TJNT$490)GYH7%&%K4R;!>!EA$9@81*O6JK9UQWC0[NUG
MJPV[&4^=0:VKY)":-Q!XCL'5$P?)R*5VG<['#)'^W&/8)99D;C\7:E*<MZ0R
M5O3QSXD!*["XXG(:@4V1*.YV9.E5U:X7U1G6]7J!.W[(SE?"[*URO79ZX\K\
M"==3XG^]&^(6/7=/0AE"'_(CXC2)W!Y6+`,3:J)*`X*N!&JJH]+]4JZVYOSK
MCOELU^Z^-4I',H)'-<-I&.=WMK]9<WI)[?4NP\MH&;HYXZW93=>N<W//BC(W
M,.7E"Y3)F<EI+,I"M(`:%GVN?9;#Y_/H;KEM35<ST:W#F3&%WC%%W6L;%$<M
MH!!*=0Z':XW0U9!`KN"S$+4XE[8D,1R9J$=Z+FI/D`L\"S3@4&]E>@D1C+MV
M/=HZ>SI6GGSEU#;&:SHX,-":<SQ<EOADME@IHP/*%Q`M(&O+2DISFP:(XC"D
M/WN#0F>,!".E:]E,"Z@.@#06T+U85<IMQ[USKB`472C`ZLBYWMJ<'Q@2Z)D-
M[W&S'5I*@1<=$C<%SVG^\P6W'D_'A4M4IR#PW;UV=2`9+&[;W&[5(^P;%[W[
MR0M2UW&T3%N3KH;K[34B1EEL6MM4M)>0DQ4$;80)2G-R0B*6A7D8+3J,Y)&L
M6!-ZB+'FFJM\Q+1"_;`>['C=CQJ0R#2*^9VM*53BPF6`)?OIYKA;+V+!/[KN
MVIXMDEW;'T0`JYC$PJ%*L(W-H=%2L)NVC(;*8C*\35S5:*S@2.R8S'YXJ<9H
MSP]'6U=J\JCY39`BG1&N5RU4QI$N"4K.A+PJ6+%16,C)("<<6&T"""$Q>"4Q
M)2<K`C!X*(+`47@9I@SC18`7@(<"--&(0L^/(A9SG/USP/UX'(3>NP=6VS8O
M\A"-5S^17*Z_O?J8-E;Q[)ET;?7Q@EU.PYS`U.B)Q<$HDX54&&@-3^"QARF,
M$,O&1YQD.O;@<\'?)H,IV;J.66_/KFWLF-(UY6R)`=I)JI,*8K^&2J=))$O7
MI[NLJ0VRD(BRR)0=N<`K'LM_,5-Z%O:0JB,%""<$T)/=0'8E0FW>L-%UVFVV
MH6]MM(/2,2-OJ(5HL8XT]-DC9FUH:Y4M;JY2M\<]XM'W=>0W&.K,W!CQRCU$
MD$$@XD/`N!X%>=9]?*>MMU[$W.SMYNO.PS]LDZ4C6>Q+U72/5^#.,K5-9JMT
M@U88:$130%H1M04[6F,4'DH`'G"#@0Q!$`+#.`X$`>UQ$4X]878<A/P9DA3I
M3LX6=@O.0CR5_AJ8B'C`L8SD/D.,^<_Z8^O`E[4J!&U55636WA$!`VU]#$"$
M`C1'B`C1QQM3I@B/'G(SA!)+#C(LY\B_KG@<MUR[UW[U[:U=SVP^OL5@UA6;
M'NZ!K@S*P6NFD+I&,H;5I33^-^%F&24Q%:DP2<[IR41@UI*4D(@8%@0?'`^W
M9-UD"TO^48LL5N96A0@T3TZC[T:0J`G8U\S'I;:C\^MI0E:Q=]FV?F)<G1E^
MYQQ?PB#G)PQ9'D(;?<]"ZT5M+.`K^.#K3)@*6$?L>DV%UD1EE97I#4*A*J6J
M6LA4J^1/CY$QY>5."BC"Q@$6=@02PP'M79W-EW>_CZ0LNK+CK:%++.;HR\QN
MD[!DS;":/'%9CK(I:()-28.V'PN>0L)Y1<>,RL$E2A;P&F)LY"9D&0O"F.J#
M>0^;QV<YMIFT'_*RLJ^B1^LEN*HBV50-JJ>#S".H:N;7DZ)NF$$/LMQEJM4Z
M#>$KOA,M6GFAP(@02"PH)W#TKA==ZF[2NK%_'ETC@(HMK/=+F5;K+:6MSNH@
M8457R-X52YA3`J%JF[NOABP(EA!!>$"A4<D\$FE"&`?`V+UN1@NO(U_'X@Y+
MN%[*AE9=DU9$O0DP$7Y4B*A3-Y9N485"H"1:I!$PFB*P:8(O!9@?.?`L\"^(
M&N1,?V8OS:=1.5:TJVM<*EI!1`5+,@1M\824S);OEP)*DDY:L*M8*1YN0\H]
M,H(P%+]B$8#A8-R`L/.Z]!F&:$:4#.QD)F=3]>L"P(&09Q@-3Q,(?(<XQG'Z
M<8_^/`F%P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*=-NF)+;W93J]7DD-D/[=
MH#2W=+;"(LA1C,**26WW-36&M<?=W!,:2<\X?J[@EMR(:`X`B`$FOF!EB$8`
M7H%=VL56FW^AZQ&A!(FUM;RT<RLA6-0D_*)7)+KY*NL^;RB(JR$II19*N2.E
M2+@D#R(84HS"AF`]@")P$N8[B1__`)RA99*83[F*8Z@J\<7A*6E9L18+V+:>
M5-[`Z+#L/2EUS)<HPN"9*9]HG'E']R6(.2L%FF!\_:C':NDO8[T7IYI9V:\F
M+-L]>$FKUN0Q2P'A\GBQEK./JET122-C6@@,48752!&G=A/"12N5D'EEHC$Y
M.'`0P_75%E_!=F%I'EJ##,26\.S-X/2_#X"V_-%.J%&4FR,(C,F$KLL65OR"
M],8,49+_`/:'&0TU<VPU85)VV;N!MSL+1:!-(=8M"VAE)-(H3!%LA&_[/+#9
M,Y.][US8:9IQ"W&38;A8080D9*7%F*1"R$`L!O30#8FBK-N[>YZH??MSW[=H
MC'8LX3>KF=@U%+S8TH0U1!3VRS8%+J)BD2>9:UKF8"2"%9<L)FU([MRI-G!P
MB2S\!43H5KPJUBBW\>W6G:_1QG@.QDAV@[!+>C$X?+"_`RJD%[.T/]G-:9Y0
M1-OES-,9%;%<K6I.:RN*A!E..*)!#RG4D8"4$P81=L/HWM/VWO2\HC;#1K#6
MU][&IF*\(M6EC6-74.OV=:X];->O[-8R>K&&7NL)&5"*\<SD3J](T[.:G=31
M`4X,`8$L)B=>VQU87E6^R$JIRW]>]D+9V7W@L><S2'4]L3%XW(H10;M.HO2]
M>RU2X152*8)))"M0Z]8'T28E*B<5KL`:(9J18(XPD)<1J?BL7?Z^7A\9(VVU
M-I3KY#X8SV@L`;E0HM"_')UL2]V44C)>/PB)JKRNJF@IBU&H296)CG@1HC"B
MAA"8$9*NV^V.8]+-.;"5B:YULSV*;*M1U11JQD"[$6K*I;TFTWOU.R.2.(88
MW)P:M>]+8\LR2/!Y8W-V:RAFGY+4"SP+.6&_8E)=B+'UM9VJ3JY95-7UI:$V
MDP6]+B#M9%L/T_98A#_S&5_WALV.2URN<CT>$OQD-IR4T1OD\(.!LF%3>'61
M%VB;U_*&&:0Z0$&J6*41AT1O;"\)B5)Z(U0V.K><>B6D`5IC"\C+&(/N#.//
MTX&4\#R7]I_/L3TQ?DG9E_--+DT_F&!;^-?6G\BC.1_DF5QP6=E`[(?F^5,=
MZ"^(X`1>,^/'`I'CJ;06<3BH>NVM]A:/,H_K1:2+0N/7=19,M;;P+LC69ZAR
MRLY!:I8US$QS.H83(W)3*YBI=`N`'&:)F94?^D"CW"#\HOK37>FLMG=V[3:J
MDW;E$NLAKT>Z]M4H3-?OY%%'P^1+'.H,,$S:C6]UJK8'8Z7-X;$?9<SFI'&$
M5\SM@A*2AL+@,82,BNR6[W6G+Z>UDNM]L;M>;RM>AW#>\DJJ!MX-I=88\P+F
M2,KIM(0?DVIHV%JF7R7\NGC"(PE'9BX+(O'C\^),?\`6*;-;"ZAW+UL75><@
MV(C$?U$M+7F9">+V84T4EJ5'")C'%K$X8:8S,V*2L;W-!B7C;2H\XM*I8-X%
MA`:BRJ\D8#E=_C\:$KNP:65GO;LL\V9.]+M"'5UHGJ?I^UFU@:`K(M!I2YKT
MMQV*RQP'[;D,LBRH2%*>L28$2X25KR`1N4K(D2\#NPX$'^PBB)7=^N3TXU*-
ML;=D*'?&;8S5V2.>`%D,]Z5&(]_CC&N7"5(LH8K:K-^0A<CS\H0F1J1KRQ8S
M@7C@;\UVN^([+4+36PD!&,4-NNLH39\<+-/3*5*-KFL>0/Y#:M.1FG)!.+7]
M]E,IP6,0`GE#QC.?'`QO:/9^KM1:C=+>M,][6(BW1FBD-@T+:12:S;9L>5+0
M-4)JJJ(6G.)7S2Q9H[FA3H&\C./I@P\X9*4D\\H(+M&L6U.]+.=(^P"82.@*
M7DV3LMO7]KS8!['E1$5).0IVO;#9*%'H)Q9$E=$RD8':-PMQ88@0$(4QA[T#
MY#S`K*N"FZ?HFONVVH:2J&L*GIJ';>=14/;HC5U?Q2$1T]F=YMI_)IS%'H<;
M:FXV1.KD.<KCU@EYB@_!#V'&18"9]0ZI>!K^UZLK^\:SGU.6O&$,TK.T(D_0
M6>Q)R,6$H)'%),W*&E\:%)[>I1N"<M<@5#!\A!Q1Y><^Q8PCQ@6`XS*#G4@Z
MGMDH%0E:ZH->P78CM%9$DA&M5=V#L&QFME<=-]0LL[L"J8?5U_2-N2I8JI"9
M%'-*-)*RD#JY/3>,YP+.1HFK.0[/JZG+19,(C4V9%#6>D?VM,L.)9Y)')<C:
MW/TP6\,(I'$7-ZC3LL8'0!R-0:B5J$V3R!^@Q!\9R&:\!P'`K_[77(]JZQNP
M96F`28:/378YO]3_`'R7@MWJ:5-1QG@L8!9&42M$(&//C(\8\_3SP)K01L+9
M81#6<DTP\EIBL>;"CC0A":<6@:$:4!IH0?H"88$K&18Q],9S].!Q%=G<M=\]
M:G\A9<D86;#(\]R57Q%U42P:8"`]H:(KHW&7=4T+CD9HTRXMUCI.<J$>0KFU
M.>8<`P)A'MD)<;;/L=40W^4(8].C26W'ZKZ,D/AL<7J7QN3.$CT^5I$[(RN.
M4P%3F6X%*TF4*D101'`7%&"`'SG'`VA(+BTH7'.:,SL^[V*X`U%EKE2I%2NU
M;>SMK:B3#/&T)U;UH*]M?VR5$2$)AF?95G&`BR>(8A"$&<[]R:/N/:UU.FA@
M.L=S-#-51TE0K]MIXPP"TTJ6=VW5+&R3S6&,3V6UNS2/8AB6-1#LX)%+:L<R
M$9.`MZ,MQ$228'0'?66P-+6@-Z>+5CS2"$R`QP?J,;Y([7$RI"V\XPYTK5KA
M[))90Y3%"`/RH4Z%N7J#C@X`%.=Y^,0<I.Y[YKVQ:@[4.3=?7\@Z:N.->+H4
M)62UX-O*P56\&KH@]CQBQ5\RU\C<.9ZZ4N"T!;M]\<E0)F<TTG(2DH?0`3JZ
MUL)TED:HQI0D1END%F/>C%UR$*<KXF1S4;XU+)B@H,A"-,4(IB?"BBQ)A9`%
M,I$7[?[P\"_.R"`J:\GJ86<X"HA<I(%D.,9S@)K&N+SG&,_3.<8%P-!Z%B]]
M&=,!_P#S:GZZB_\`UJ@AV?\`^?`EAP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M*5+[>11[N*C3L82>M2INFK;IP&WEF`*,5?@MDM>W`PA"8(L>`*E(#,`%G.#,
M!_1GU_ZA5EH97\^FKYU=U3"Y&TL^:S6[@WV\NIZAZ:C)#'J]V:TE!,8L4:TG
MC$;AYALQ6"*2G`$G5*`D8/$$C(LY"S.MGMA<_P"0?LG%PTA22=\B?7)44I/V
M"90S#_.BW$LM@QC2UO+3E,U'"<Q;*6.G+"BTL?`MP%*B$<N$')9.`_WL4K/7
MZ;=G_2])+/O\586Y`;%V;>:&J3--2*<I[\=Q0"%FRUH566S.+6VU5B&LJ$"T
MD;B)02O4G%A`0,18@B#[=/LX6[WR-T`+_O5[GVMN+J)1CW/.2)=Q]6JN94^5
M6,^ZM2A34_@?ZP@PF;E").#VP5[9#"&URVC4]GG:RAUQ@&N=GKD51==J!RCN
MQ$[F5?MXBED0OE86VMR^$U19ARMB/)4*SQ"6)A8RM]BP9R'V^$)5Z$G641:>
MY;9.M:M7**EC)85?$S\S7NV+!GPI;8RNC:S<V8ER!,:,J9L9H^W5,JC111C9
M@T@;C]X(:4)V3CSPI?0:,O%![O=%E:;3[NRJ9W_`+D[%[9@,(#!K;M9!;227
M$@G0&L5H2%Y<$]??XL@RAM;#LN6#$@TI`OL\%"]S#PEW.MC'75K53O\`+0@Q
MF%5H0O;VPD==,J%Q2E2`FS;BU6U#@M1J2D8S@+!&.%A2Q&8A*"'!BX1624_L
M9G&.!MM;H7JK);`T1TBL.G:LL)XUTTM*?)C:+Q7135?:6/U236M0UAF$[%U[
M)(A8=3.\AG3@\NZL+:8+#N%N5!"<5C!^#PJ9B>BCU!-/9H5I3N1:51QKM[V%
M7:Z5_6\SIUDFQBVO)'-[W+E%F3J</DS76K)[$4ZV-DD?5,W`]M[@],[4S)#R
M/N2RE6`FC9VW-TZZ;$3.V=F-4T=ET!U/T(X,9LMTDDC0_,L;LV_&6&G(GB45
M?>CW6$BAHH#KHWH@J`LSC+$L?:9:J4JEXR#!X3!X5![PMMI:D;%S;76PJ]D/
M8UV%[I3VF4M5Q^U8=9SAKI,\A4TY$`+I'`G90V.\!URU'I8V=EOJ`0V1_5(S
MS4)QH7`G`@L;KZ-JH+L]JKH#K+)WFOM=-`M<X]9%\H6C#>)1/?W@PR:E]7Z=
MD;H).(XTMT_:TNG4D^,)2A0N9V8PP7HL'@8;0J/L,@$IUELS<RV4R&KM;6Z\
M977U*S-&.23%VM2MFZT&JB*]L?\`;3-&AO"=7<UMC4@CC<A)7_=,JML59-]E
M1@"0L4X'(%UG/\2OCN*[PK-F]G0ZT'QSC5L416T/>WYHF#RST!4=AAA,L:W&
M"!6.TB8(,FG`OQP4[F604[$A")"1]K_4-O?QK:N(FFKT4>+XDTLN&[-*++L2
MOJA>YJ\WDK9JNB-MU?6!R)##(K<=653B+#_QZG(2MQ*<A[/:F1T/"4XEDNQR
M,`2_ET-V+U18IZ0TO\?D>]_8=/IA8FR&X'[=?6G6_2W6ZG8TE9CI4@>9*2I0
MH8GK15+BD00..O:XH^53AX7/"S!:$QWPF#G#IO0YO[V+V?X'J\S6EJYTGTM/
MV7_*%HBES^HDG81?E8-AT3'<C1$9`G)BC;:DO:5RDU_DQ+7_`',J<+G@"MY,
M)2I@[+-*;0H@IVOC2C7FJ7NKX'UW2&K==BB3$;61#',QZIZ(6>@3PM2B='%P
M</PK%+4A;H>XX)7GN)HSC<#R;\HPGAP/Y&`!H!EF`"868$0#`##@0!@'C(1`
M$'.,X$$0<^,XS],XX%5_3\-MCNKUCT2SG-XVC5/<O=+6Q@1M9;@6A8X?`MC)
MZYU]&$V7`@@8R(O7LF:F\OX\")++3!+"(7IG/`QO61D3;Z;-/?8!.T8'"E]?
M99:E"=?L/7DEG-OW,8?G*N-@=P51!N#,&3&SY:PN,4B9V/`6Z$M(E9'@Q_5>
M`MVX'*I/]H8-+]FNS#6F`078NTIM:W9GH4UL;_4NN=QRJK(VZTJQZ.H;8'-+
MB:XLHKF&*Z^65DY_DS%SB0,HI*6>$`B1ECR'57P'`I'[3.L.%]A^JE9G,E45
M#-KWHZ1P&Q8$@GJ4^-AM:'0U>J5S;5YXN*-X:K#KJO[G8UBEO.5MZHLE(N$G
M4&E"+`9P)'=2VE-;:%Z40"EZM8;CA\??WJ46\L@5\N\=>K*K=[L]P"_K:V?5
M<0,4189L"(R2U"-0''D+3DIBSY3!J!"R$SJ7OJG-BHJZS>C[#C=F1)DFDPKM
MU?HNK$L;T,U@+THCTOCQQHRBL_>LCNE&4/QC)8\>IA8AEC`,0;<X#@5[=LZE
M*EZP]_A+#`E%J-1KZ;RA#+&8$2YTKE_;6TK(0`'D.3W%64#`LX]09%["S@.,
MYP$ZXJF5(HO&T:TO)2Q(PLZ964(P!HBU1#>G*4%B-+$,LS(#09QD019QGQYQ
MG/`X\]L-NK/T^T9[NK2H=[;VZP1=V1$`0/PJ]C%OMK8BFD&U!)FI(H3+661Q
M%V6Y8$S@WF%.*7)85QGQ@$%5DH6`VQM\QDRF(?R=VMK"WA<91#=$OMW1T)+9
MTYR9=J-5Q36%X.R)O,;4B52`\TP(C"`)`'BR$9>?800MA12?M$/=7=L;]KNI
MIQ2MRDQ,$L-,;!J7QK*+`8<2!X1D;>B#]Z)O#@XS`AE^/`OZA_7P(E;MUD[V
MYVV=?87#72O=EE%.UE5]KV(^@D,?A4AIL"G8$EH8[JJ5#*&R4/<DCT7FK?AW
M?V=N<T+@)H;$X#5*L@P\@P+U;K?'>-53.GYAL>MZA>6MA4*FVR[?:A/=9PU4
M$PH);Q,VD$VK@:YE*R+U&##XV9R(>,_-CQXR%`&_-[VQ+M`]T4#IV<]9E@QJ
M0:\6NS.,?K.LEC5*79J?HU)$"V&0]_(WFEX")3)FM4-I:CS&Y>+[\!8\I3\B
M,)R&8]>I#,'<ESBZ4\P[_'FQG=(DP3\O_=H7+%ZZ1GMZ=U\E@P9DV(3DHW(<
M!#[F&`-QGUS@/`O5N<]:FIZUU+:K,0.*>M9T>@7$Y\&HEI47=3$JLK./K@Q,
M>$(P_P#J'@:JTB`F+TOU%`B3A2)`:PT'A*E!XP!.GQ544^$@/CZ>I1?@./\`
MX<"3_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`HKOQO`K[L$SF]RD#!$XWTC;-
M'.1RXE>M;V0A[V>JM.\R/"1%\QV?M6]L+,4X)*&>>4E`$.!9"'&`KBT2C]AS
MBZ^OQ1K+.&N7Q^J7C=?%HSJ..*N,Q^6483=NAT=DJYG)E;2@?7)JEJZ)+\$M
MPTB=:,IO#DWX?D#@06=5';GYCONVOITW6RIXZ=$=%ZMD)&TA3',RKJL%"Y2^
M$FXK51(EJTZ$*Z_8%KH:<-(C3D*BUJ8@8QFY^0)0:O[(TS-.>YGHB@3*TJ76
MPH9*=TKD>W,A6X83PRJVFEF9J6K'%I"G`V+BI=*BTJ$A4)1@Y"<G\8*&$_.0
MALW2\L0MVUZXO`3$SB5VWJRA!%@1I"1/V.U2P)SEI6/(D>7)]C[N2GP/Q\Y;
M<(8//@>`!"*]*]H.T>SKLH,M_4W>_8`4<BNCT81234&9VG"DS*K1T_-9H8Q.
MAM6;!TRI=G0Q+)"!%B5IUN4H%8@?*06HQ@T)):`3S0W5"`]@E_5G6G81047J
MI`VV;M.U;LJ+\<C6M]BM5(Y8E:H:DN:=3?\`,V$"KQLHS@HUBEP4(%[.F&>,
MG[,DD/YH7KJOFT]@>N;L9L^;H(/8,%D6Y.S-ZT[,VR0R*9(WS>6O8M$812,?
M>@O2-IB;9K95<=8XZ:7]N>0I<6A2H"7D2P8P!9S;'7=I!>EUQK8RVM9*IG%X
M1-RASNT62[1_`)$:XUZN.<H,I?34)Z1-*\Q1>=\J`+J6M`F&43D&,?`3\8;@
MFE&QIZ=K3L6%8;Z]OVR:7!2I%X)V-')9#'6!D-FKO`A!8GLT;"\H(3+YZX.Q
M:$XL)*TXW):C(R_7``C7'M.'B*W)I&>TO<;*UWTDU[G<-A<.1-@6B3NUVOD7
MA-1Q6;&(&YN+CR"-1^ERI8B^U3FE9^^D&,X+R64'(0KMED'N%QU%B>MLP1OM
M;;2=RFU%DNM[(5XF%UD]24'-"7>7W'&UQ@_N6(+Y5>B=;-=:)#2<GEE2)0C.
M*^3.?;(?G=U+Z?WOL;<MIRE!G7W6SITI5XA26]:)<W6D;`@U\.U?1VT+$Q"9
M[69S:]J8?KKKBG96\3,:%6T+W&9."%0@4"0^F0K\G,E[5=7M<V1#7C@1>-_]
MNKK;U@EK976GW6\M0M3-0J`56ULN#!Y3"*3<G:'TE%&9G5R<U$PLD'EJ\]6<
MW.A9_@06:4'8E1;3[$4=K;1J)[J_4SJCJVM[`MVKK,C[]7-E,VPJJ&/T'UPI
MV>0N7%M+^C8Z&KAH=IB[.(PK69U?E4=4HE:K"0XW`9O6^Z;M&*CV;[3KK>[#
M74#:+K#JWT)UL8FE25()_6;-(7"&TM)HC#E):9>]75O9;<Q$N91*@E!)B"B-
MA.RG`2M,"$'M*=9M(*&V=OTB64#MQ&]]MRM=-EU.Q<)M8FR%=%;.R&4R=!:M
M^591EMR^(1*.V0IKA>^I69N?8Z%L;5C`L+4C$J4F#-+#;O\`&EE^M4MU#O(G
M7'3B<:-%0S91W@=FTK85T36X92?.X]65;"+F+T.P4#!*(D].D77-Z):B,:D!
M`U3<,1&!E8#Z!`GLSWD?NU.QKCTNH":O]5=7.ITG:TG:5N0Q_*E=;25))$%L
M3:BZXED$+W";RRP9*F+84:5"E4G/[XJ3E8*,;?B*>PF]UM;Q,VC%+0G3/<&L
MV_7FL*#0U_5D'OZ.@7/M.UTYV!E;(JYUKW'FK4P(H?4FY;)`'AA<9FM3J%L+
M<G=_`;^42+E04)@2*K&4QO1?MKV<K.TW]IB57]I6:JOO622.2A*VQQ7LM6,!
M04[>M(KW$WXB$L_G4<C<;DT?).R6!X!A>G3F'+"LDY"\+@.!SB5;>S_0/7/W
M1;4U\ZH3Y:[;S]BSQ2[XF;1I"5%A))DWZW5.<H"80G+=<);)B*%/\X,>IY)(
M<9'D?L+(7A:MT4PZPZWT5KQ&AEGM%+U3!JY*<`$%)AO2N+1Y`UNLC6%D@++$
MYR5V(/<%8_&,FJ5)@\_46>!!W>;=>W];]V>K;7J%DUN56>Z5PV[7UJN\C9G5
M_GZ`$!@39+8PB@B1-+HLU-21\7*34KBYJ2G,2/(R,EIABSZ&!X?4WY*D':NC
MSY#A)VZ[0"`5G_<4!RK6@'GVSY^N0J#7(1H?/_M,QC'TQC'`MWX#@897@R3(
M7'Q)P*BR<(L@++6EA*5`P4H.+]#BPM[4$(@Y!X^B<K'C_3_7(4R]A7:???7A
MM=!(1*M3I+>.O&R==Q6M]4'ZJ%+<ADDHWP>)VO:$5(6O,YB]M$*K.*SR..K:
M8U+S25!A7V*U0$*L(%!*((Z]=&JW:!IUO+,;6LZM*#8]5.Q:46#:%^:]ZWR)
MZ?8WI=L4DC13U'+%,>9^YHU\NS<Y+,H;I8JC:;+6*1JTXRTB=&2F,$'2OP'`
MKD[?21']7&_F`!]AE:IW,K!]<8]#$,,<UH#L9SG&/8@9&!X_]0_Z\"PYL."H
M;F]0`7N`]$D."/.,X]PFD%C"+QG&,X]L"\_7@4U]148`CF/;ZH6Y2JT;]W"[
M(.!;8:G":6B,2U;KT+!AGR_(4<8J/"!6'.,8^,0\?^[&?`4?]J=?RP=[=T4\
M20W=*5Q)<[]?C(],M+3NN89JS+FM'4U7ERF/;%M\RF#*ZS7+@U.)3:J0($2K
MU;W)+@_/P'B$4%JTITNU/=6<AI4_QO8B[-R9:I.*)11KK.:'$+@XJDBA0IRM
M2;!(UIJ(Y07C)QHE&1!+!G&"Q`%D/`UKNA*-;:$[E^I]X=-<[&G5ZV55[90E
M;I&"3O,9K'3F!$/DM8PSIP:Z_,=629/C^;9"N-8;5Q7X$EN;A*0*RQDE>P7[
MWVPI914,W8%U)QK8U(YMJ8@^DYAF'XC5@`"YH#?Q3MF?I5L/^W2Y+^[Q]\4,
MK(TX?&/?USP.8CL^KE%'>O\`W(<E_0I1-.-4=H.RUJ.[&>3Z,8<:N/11U:!I
MLF.I(6UJYQAVB2L12]*4W%$KQ")]"C"C,A%@)2:5REZ>.\??""+U98XE`8U(
M9S!6I.B1(@-KI<.NG58MG3FH/2$$JG!3)5["2H."J&=Z*,",#ZB,'G(7M7PZ
MA8J.N9\$CPXA9JHL1U$WY-`1A<%NB#PKRCR<86:`G"G!/I[""+`?;SG&?Z<#
M7^ES;EGTZU.:!*LKA-6M%$MHEN2Q$Y690U;%4N562AC-&5E1DKW]<B%D/GQG
M.?Z\"2_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`HQOF0%1?MQO&4N$F<(23#N
MC.=R!MG2&,M\O60$I-LO)G&3RAFC"X8TLF7H@,K8KRV*`?`N&VDE"SD(A8X$
M`NO"=6U8[SUV3^MY6OFTGLXO=6>W=*&E@8(*[2^FS^Q@AODD[<(&+[5+"XY)
MC$#$<I;$1>!I`_.G*#^D>>!:=KM4=Z-7<AV+W98%=S%EIJ8Z\:>06@[`&^8<
MZ^EA440SEPLQ*D0C<4YC-*T,H=B2C4@4!P`)T_W&50<JPEC"QV9:_4G8=IU-
M=\XJ^&2FW:(#,0TY8KTRI5LKK?%@-B1EFG[3=C`Y4-69(THBTRK(,^1DXR#Z
M8&/`@JDT>&$[<<]T*_\`Q21Q'L^=&_SY";A&1VI/P<?<%YQX*,R<M'C`,9%C
M'@6?/ZN!N6Q=0=X(ILKLAL-I]M1K]`$6RB2G%4HK>_-8)=:Y#)**CAA->DNC
M#,X1L%52XMO?HV06,Y,H;U.2E)0?C'@(A^0K(V@U:WW6:Y;>R>7;7]<EAPUB
MN^+;:[?LT;IC82`?DY)J?"J5L;-121S:]GK(21MEE4$I&-)GQM5M?S9;7$:G
M!>1G%^P7\4QLFQV74>IT_E;"[5_+=KZWADSC<"RB>93B//TAJ+_,#Y$WJ4LC
M,-C;L1MC2K"L+W`2!,M/3A*)SD\XHD0;OC<UATR-DI$1E<;E)T,DRZ%2\J.O
MC8]&1:8MB-O<'**2(#<I4B99(WH79*<>A4_&I**4E"$#&!ASD,FX#@?$>VMR
ME8A<5*!$H<&S"H+:N/2D&K&_"XL!2W"%486(])A846$)OQB#\@0XP+SC&.!7
M9?W7C#K*H-5K+7+B1!*FMS;!)L)M8G=%4@?I)<,7?+=57M;L*(?#G`2M(;:<
MS1-[,K^<0T:>)"4MY)02\$!`&F;4L%XIB_=K=_M@ZFD2.&:UUW&-3M(((A4L
M[I/[WD=H.<5E-B.U;L"=:O*1R#8*X%D-@4=+,&G5B!%CCU!9291G.`A=9^A%
M77E#J5T<NHRP&/L<OB)VMM+L/MWKD[A:9CKRT6/*_P`G;Z%WGRAW8SI93]A.
MZ_%0Q.++B'A$JCZ+[K+?@EE&8`-&Q._]AH_N$PS3?)N)LOKBZW9)=$;KS876
M;6U<S:^QNY*_KR)1"*7W;S%$;!MR1.P:PB#Y8<4=2H]'FZ+UK+$`C3C/410V
MX)GP_8)G+J2T.W.Y5=ADONWD8BVOG772U?(F62W!%ZBGSD:EI"&UFPB*>HLN
MO_:J>Y3SU^$M)4HV-N(:D3J9]E&U9N`JVVW[)NQK0'6U!U^S2KUUY=T.T\*3
MO,2V+UWB4<FS5*ZY>%DG9W"SI'%:N@D/G)-M:_0EC%'$I.(TO;CS&\EY(7*4
MQ1Z$(0`HVKS=8Z&4072NX;3N>%QI[D%KT/&S*<2VQL,]]G$78H'45_[M_P#&
MI[20&>-.N^O28H3+$(9/&A9-@35?B1MK8Z@1)!&!UMZ06.R7$PW!IO<6JSYA
MUC45`Y[/VDX45$H?JSLG:MUMZ.7VH$<<S()`>BM2;M<W1OLRB3RC$H95CNH;
MSCU&4F1C"EQTUAUB@=H[_+]C84BW>Z]&E/4>IR"Q8-?#3?FQW6Y3-/MZNVD:
M:91V`C_R-"J<K*T)^[&-KT4ZNEF1-LC1(G),J:0`/3A9`TZ5]HC+6L8:=+.Z
MQ--*0?6-L65_-MEM8ZEV4LIJA1Z/)D=6QR\HL]0Q%:29P:E91F5[\V+U2@1)
M9H57J,P&0M-<YXNU%U`=;,V<M;-IN&NU$.<TNNX@Q)F@1M@*JWAJAYF$P(A+
M&H4,<95R0QJ..*;DI@R"33@E%YSCQP*7I56,EU]Z&*)9[42*6^7K;3TRO6\F
MQX"$T;3);S["Z=V#M]BD9/@["LAC>+`<$*LH&!?*$C("\9\A#D)Z[-=P^E&I
MY6S^;0D\W/6:A2_7.!7(W1F$+G`U)+MHDJUUK!BC#@YJ65AE*XN.MI[F[@2K
M,Y:D1?DW^Z()0@K\[>\GF]MO\>,XU^9VN-G;%[)CR8M0(E(U+X&N((-B2I',
M@@3R3^>^4:$DLLW"(Q4H(,."+XP""$LNGU:[N$I[<U+J4/`,]Q.TZ5N5Y2_;
M%JV]IKRAV1+\/J$)1X41+8%.(P/U&84+(LY'[<"YK@.!BD(2"01=K1B3O*7)
M`58/@D`T0W<./OU60B6#;_*/.30Y]@>G_P"S$'S^KSP(F]BVD\.["=/KAU:E
MKB5&ELY9"E]>6!AN`XN576M&E);W7=BLP<&)EI*R.2-(5D[[50E4GH#%"<!Q
M>#A"X&\M<(I<4%H6HX7L%/V&U;JBD#CT?LJR8RQ*HTRSF4M*`I"X2=*R+%2P
M]":[Y)"<?CV"`:@0Q@+)`()0`W7P'`K_`.UE'ETZUMY60H.3%LDUBMV*-!6!
M8+`<_P`KB#E'(Z0>>+P6E2GOKHG`<<9D)1)61&#S@`19P$Z(\G6)&!C2N``%
MKTS.V)UP"Q!$6!82B(+4@`(&<@$`)P18QG&<XSC^G`JDZJ\X)GW;6WX_3A+V
MS7DI^(7_`-4&7:@]8G40Q^?U>AXE61E^?IZ9QX^G`K>WJ/3CTW_D#O+Q+G"`
MX-WDUR9)).VQ.)2MAD'::?ZYD)\G3M0$ZK"L<?BRM4K$#X3<JPE^N0#\^N0_
M1WVCU@:$)`7'^1_MY$S7MQ/2-"J6U3JJSX_)IU1/Y5J"5(M"VLW*Q4E<B4Z-
M*(8#`J!!R0`T?]O`2MM&J;=L7N(H6TJ/CU2/;;0>K^NKS=M@VLW2[$ZLFL+=
ML+9V&)#H`YQYR;8/')M6S6W/3P20M8!_E!/YQ)1B/!(,@"UC;;$0_P".-L&3
MZSKCIB&IXV%7(+1U^%*0W#"D"-S0*1/,'_9<4G$FRXEF%!`;A,T+_*09N#"L
ME>^<!R*]A+CI<DTUV=(B_:MV_6H_K*9E3034%T_\@GJI[`<5*UH`2TV(7-]3
MHPT-,56'X^R<S/R[.D`C5F!,-!CUX%KFN$7=8?\`R+=WD9K22RQ:<:&4Q<,2
M,(2J08DBAY5TW3$G<?O%.,E&IV@-"-B,!*;/H3D&1#SD1OJ$+N=A"2U%!7@0
M=@&2CZ?LLDW!A@22\EF0MZ`/`S1#+"4#U%GR+(@X#CZ^<<#$-.3##M1-5SC?
M?Y3=<*/,,^0L11GR#K*,"'[E""`18_;.?(<AQG&?IXQP)'\!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<#G`[PG2TM9I]$-P:^<:J985:^HFU.A5T2.Z4TH<(7&E
MDXC!MR:_#3E11R;U+.Y32=PAXC);@N$!IRY/+:D4F`$I)&`/1C]%L'70]=2<
MUI2P&PVI:W;P=>6W;K)<*96H2-VS#,UW=&)](G)6[JG.N)9+]JVV/%*3'`\Q
M.G33E.6$HE/DH>`M7V<<MJZRGM=7S2ZC-JTC#660,6Q6JJ2/,G[\E,8<5"-S
M3731<K^V*>W2VZR"W&%YAJM4%LE;0K4DI1$/!2'[D-_T?>=2[(U;%+IH^;M%
MAUG-D1RV/2=GPL)+.RC5J&YS;7%L<TJ%Z8)`QNJ0Y&XMB],E<&Y:0:G4DE'E
MC+"%._6[+XU/-D4\JB;J0^Q5VJ[L$61)S3DJ2DQB(SMMOM,[G(B5I"96D+5Y
M0H`C",L`C/MB_./[>/`7P<#GT[-8`HU6ZI.Y5^E]J1->1LQ++BE[6I,)2QQ%
M!V*]X?5=,%04*10<O.D<J0-38H6_`3[+'M<KR!.64,XL!82CI?>G3"76O0=8
MU9<5:)Z]@E`2Y/$W^0W(VU`O4.3$X5["&N$HM>+'1QR?31'^VF]4M)D!8<MS
M/E$--Y-.5>2@T]`IC:S_`*?T8O,AZ!1.NP_?U8^O\:G@TDF;8M1$VN2=VZY9
M;<-88^%V"W:BU``#4:8>(:=2>4?@P_!)9(PLC@$OMJ6;8;#L[@KR@H:K('2L
M-B#/EH9P&/\`<,E3RZP+.DHWO.!2(U"T0=]AZ!,G_0@P>-6(.3#L&8)#/WN^
MJ^8K[@&MAY[PLM2Q:WL.VVML:VA2N;&:OZT>X1&7Z02IX+\)(^0OD5A-R)M"
M;GY%ZC)V"L9P0;D(9K!+$@=H,1THKB8QJ=QLA_E,5-?XD](']F#)(1(W2(3!
MDPYMAZE&-SC,J9%C<N*"/(TRU*:2/&!EB#@,RX'AOL9C<H+;"9-'F.1%,KXT
MR9F*?6E`[EM,D8505S%(6P#@G4!0/C*M!@Y(K*P!0F-Q@98PBQYX$0;1K6WJ
MF#L!=^ND48[WV6O&24_$XZBM1WC<#B%:UDR*F.(E,RN3QYE;Y:[5=4^)'*YX
M8V?,N?'-T=UZ5&:7E01@D(/S>D:GLZRZ]ZTJFA[5!="],DS/>6[;4<)Z2PV8
M/[\<X6C1NM"U^DRY8=+D$IEJT^S[(,5JEN#&Y&UI7$XS#^>'@5#7M?--Z@.C
MEW45PR5]"=*H%94I@VH.H,W>9P@BVX%C6`A>&BT-UM3X@TE/,<UTL^QR,.#1
M'%A484M$DA:=X?EWV(9`6X9";'2?IK<;1(-B.YSLF3)HKMYM^A<9$Q127GK4
M:34K5A('\ZTP@L4E7''PT"]E0(S%2-2()[0S-:,I0(M6:Y%\##*^L69;(W%:
M&_.H50:]H9'V#O=64%H]+;+3UF6-IC&KS;=N)AV078T'N9D^?9843.W*.P^'
MLQ&)(H:VUJ2O0FU.N4&MH7Z:D:MPG4*FFVJ8B[/LP>5SV^S^U[6F1Y2VPKNN
M:;*@NMCW#8KH4$`7"7S9[\FF8#C"=$E`0B3!+2)B"@!#+K=T(E.ALD[()O:$
MWKB0,FW6[MQ[7,"I@)6-Q<1K69E%*T3#/U;VV-"`IU9085#5X(R<WE!$,P)N
M?D'@(5AZ^[ZU[HO=4W=*R@4P!U)7]-Y5+*89XZT2B73"BBHF)>;L1NK6=4QJ
M-.:B`]5$CF2E,$MQ6K4P43ZH/>&%M&P.8/4+$MMIDU]@-P4[H51TGC\WI@M9
M4&T^]T\CYR63P0_6E&\!G%-4(@E;1EQ95,OVGF<<;UAB$)P!FURW.:H0PDKT
M7W(;GVG>=;^PRE-Y.O:J[YJF57TT5,_Q*90:.3!E>9144]<$2A173O*V5`M$
MK;L1NP&M"-4'](T:DC!!V23LA#P*%;HNZR91U_[)]C-2:(5-%[IW3W%U4I!U
MAUU4XU7\OF#;5(8[K/(K'LJM@SIP@2.6PW8=3,FF/*@IDF36Q$WF+2!#5A.+
M"TG?*[X-7_:)TW:\R/6>B+R<+D==CU""P)G4X'ZV-?5E7Q""2.*V'24O.3F-
M,%2ER5,#\R25\AV$Q)!H,D#)),$&GJ%O^9Z9;)]F%F/<((6]>+KV`OZ&TI8Q
MG*W>P-5K?<Z`UYD=F7U8",1)BR5ZV63(9<F-<SD.!J:Z^U,6J"SF4Q6H:@Z(
MD2U$YHDCBW*TK@WN"5.M0+T2@I4B6HE10#TJM(J(&80I2J2#`C+,`(0!@%C.
M,YQG@?5P,0@AWSQE&9]VW+O"U\*RI:LG91#R0_.9.0%_<!";@TG)?H;C./&#
M0BQC.<>,Y#+^`X#@.!!3LWQ_^X#M>;_JEI^1+PX_T&)ORF7`+%G_`$`8)/@.
M<_UQC/G@3KX%2/5%(&F8//:)+&EB7,I2[MEVAC2@YR)++5O:ZL(52E5.;N$T
MD9B=2WFN\)4EI!!S[!2EE@,P$X!@0A6OO$]O3/J1WN2.'IVAT/'V3Z<LK`-^
M$J)8W"0XB?6#&GMI=S$A9C@C;D#NJRG/4%$&C+!Y,+`=ZX"(+754C[C2E"8[
M-(]:+V@+,-.5-8-D]G&M>(25*H4HLHG15JLY(RSSW$DDO&1I?!&!Y,\B]?&0
MVO6XSU_8/LTJ.++3GL^HVES,Z$@&(XDQR76;N@\_(W*!`)$8A)*-R7G)A8#!
M#QY\8QGQP),7`KL9#6DO65([5JQ6,F;,'19VN`A]4UHB7%JDXCS9>5&71E?<
MMF4&#0X$F5%#`;D`L^P<""(.>+LIGO:<ET8VC<+1F_5Z]TF?7.$[^LJ=?L.V
M64OCJJ41YN>DL=1R9[D,/<'5>08H0$ICU."#SC`X&+ZB)R$_#FUP2=[+2ZB1
MFEM#UU)O[:E6BP'"<]PBVXD:4K4:;.!>?E1I9>G&=C./&`GE>,_UX$Z=M$^%
M6JNS*7(1"PIU]N9/D(,>1BP=7,D+R$&/`O(LX%]/IGZ\#T=8E(EFM>O2L>0"
M$JHZIE(A%Y\EB$?`F`W.09\B\@SD7T^N?IP-X\!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<"OOMAC4-EO61OTRSV-H9;&Q:D7PZ&,+@4<:2J>8]73_(8HI(RGQE
M2G<FN5M:)6C/+\&)U9!9H<X$#&<!48.SY5`=B*"IC>.GZ^J)9OK'B]9]LF,+
M,]R/2S<>'E4%/'&L;7K>ZW?]MFU/LE#%<:3P-[ATO`G>I"U/:(#>-Q*:FA<2
M$NM8=UI)5S2[5V$5O[K4[`5OXQIE,<B+^IWWH&-#69:V.#;BZKS!'%;PF(V)
M6D4M[=/V%H<5DB2)"SW!`,X*EW6!H>W>P_2;4N[I7MA1FR$#!&9VZHDV\>FL
MI='2K;(>E;824WI]H:;IFS&B*2Y)L%$FGX2).R%HDN;$C24K)6#7QL;PK@R?
MID+B$B;Z8L2,B<LHY7KAL_.HLI,0N:)O?J_NSL?O.RXM+,X<VI`;E5*FT9#D
M6`>"5`2%OL<0#W+\!T'<#B)KO5LGN'[1]R-9+4C#E+>M#2+>'9JX;C4_NFP8
M4"^-F[=@<#K*,59@+`?'5Q!=!.M?/*L*M&M]Q)E`_8>$[FG",)C[@?Q%^N>^
MX0TLM`RBXM5I9'%9?[<=2IU.+Y@[<R&8'ESCH8#;$W6*D*)>I%A0$;:\-XBU
M&/86#09^/@4@NG11_(UZNS44BZ]=N'BZ84QN!RE%!J@MMPB1.$Q3J%*WG/\`
M0%W+2*J><K$)X3U"5.>\8)Q@T'DS``F&!N^@?Y+79#H@_):M[<]*'-N=Y'-"
M1G6"YU@_:V3.2)5RINC[G)1*2V!744W_`&ZF3X.&>WHFDLY"B`#!YYIV#0!;
M/#/Y!76);[)>FUFN=@H%^[4CIZO:$J77J[V!ZKN3.<J*EDIQ5,-52,3HK@BF
MOWVXK7":^O+:XE92(`!$J,\DI`@"P.LZP>JIF/7MUUTA+G%ABFKU:M>T6V<O
MA3BZMR6;M1""4PRO80[K`'GJ'$O978=ZD$T7`5J#3%B.$+0J!&Y5^PPEL[[K
M5Y`::L_:&QI/$EFN2.>,\0HV0UBBG<PG-HG.+RPU8ECZ6''1=`KD$YF%]GKV
M2-)8]^40O+=E"M)5"+4BR6$V`*"1F8)^0`5&20*,IA##A0`D><A"8,GVR,(/
M?&0^?'CVQG'G@?MP(5]A4"H*P].[OB^T5L+*0UO7M+$[7S.VZ3)H5E36<>E4
M<>I;#':2C(.6)&6S65HS&7`"/PYJT#F8E1BPH-*X'+?J:YUCW/=O-3W[M`R!
MH[6G66BH]9?5%I'9C>ECBO82O"I7)X]G:-/%%!21L4Q]G?X"G7%-"8`QC2HF
M;.,'MB`\Y8%N^Q,T:.SU\M&,LQH'/K*TR43>3;!R\QS=4,*WFORK8^N=T%"1
MMT85*?\`<VK]&R)(-98#@`TU'))2A2LB8!R5`Z#-"D'K;<XE8]H?Q2Q+4#"*
M2-VOO9--A/#(T0Q.ZKY`Q-DJC:Y.^G9=$#Z4WC7"=%IN"DAN%#N$1Q6!9`L$
M2';O8UC0&H8)++/M*8QROJ[@K&NDDQFLN=D;%&XVQ-I.3USH[NS@:0D1I2"\
M?U$+'L+.`AQD6<8R'$SN5:1/<M)4EW'M*./TA2ERAJ[4BOHNV/LVOO86WW4I
MY.A.LEQ4*XS".QT4:V0"QD3>;!FC.WM$)K!L0E@<A&.TA5-H3"U7VFV"U!NC
M:39S<*NX)(-63(/5+/N'L]5E?V)8,;@ES)GBRJZCVO.H7[19GU-.]0M;2F1M
MC+ZB1E*#H_+7E6H5A-7KG<XL/=HT5-SFSYCKIU:]@>MFL^DVX4NE%K6C4S=%
M'"O-T:ML&,0B/+]CX9JG$9N;#GVL6:>56)A=53F_QU437P<G*&(L11I2=`$?
M=6J*VI%JUKO(M=9'KC#%G6?;&SECHNPR<V!(T%'7139LPE3\[Z@,L^##8"]7
M!3DQ0&)VRQK0=$:J,IE\:3/#,I?70H9S>%@VE6_E7P&2DV?#(/::S53L+V0@
MR!#%VJ.?D97H_P!B-Q_CD%VT->T;<#F1\A]<VV\*6F9L4@+3&-BEV>7)0#&$
MKPSC4A?A*:=J:<3BN[,F=9P*66+42A_557.Y'$V)YEU<*94W%M,F40>1."%0
M[1<Y_;"0)U@D1I.5!0`A'[8QC&`@QU_A9Y,_]E65C&CP4\=C%S,4E;E0L.C8
M]`9J2U\AP35"-67E+DAUCK.FPI3_`!_'D8C,"]_(A"#5K4L4]3+S(&N4F.;A
MUB2A\3.T'F'W![F9UZR)_7@2.U>35,H--7@TS?'A84JCCPF^4JMCSE#<O+)C
MWV*IN"WL@\A402J2G%*4RDHL].H(,`<0>0<#!A)Q)Q>1%FE&EBP((@YS@6,^
M<?3@857&568J7A81A.>%_F9>2L$D)\?&7,G\M.9@I.(96,'IPA'C/GV'[>PL
M8%G.,!G7`<!P'`@+VB2HB&Z&;#O2LQ"!&<P16.K2W)$6X(EJ*96'#X>L:CTA
MH#"3,/"5]&DQD>,@`([`A>,8SG@3ZX%4W4\Q+66*[Z'JQD#)?^UGL`?6_)(S
M!""B.N52WY`H",L&"CP+6T[&<!R,.0^HO/D60A"M;;9N9735/N9A$H@$CM)@
MG/;EJ/#WBNXHK:VV1SUHGA/6`@61%B5/R]H9RG)^1*QHBA*5B,C)AV,B/(#Y
M,"&PG#7G2AW?T[D^=#.[&#G-P"G5.645$*6Y"I3F$I$GS,[-O&JP4U'A+"+)
MA23[0(<Y&;Z^1YX%B=3CR/M=VX3M@%/XAET4T3:W(C`AEI&9X-M[=Q<VMIA(
MAY*.6*&,W!F#"_<(2P>N1>?&.!+39V-M$PHBQ8L_ZZH-LV-^:4S:[:].?^-<
MH++0*'5`%0U*<6^[L-<B`@!C[[&'-807[)<?&+YOCQD.6?L`UNHB'Z?W$4C_
M`(_35K`L4-D,;F&^F--H6Y(ZG(=K.AS4Y2Q8OJBZ7:>1QX:$;@(]")K;W4T:
MS.,C+&7@S`@M<L-VRT?R&-:4@W0:8F6=4VQS,6W95#()<5C1LO3D@+!]O@?Q
MK3RDB<XT(<A\@`2(>,_3Z!8_NB:I)TZVQ.1*CT*PK6F]C4BU,,1:A&I+JZ4B
M(5)S`"",!Z<W&!@SC.,X%C'C/`V#1):4FCZ;*0I"&]$555>%HT"4`2TR)*"(
MLX4Z1.6`(`%D)BL8``.,8Q@(<8QC'`VKP'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P*W^X%:-%U=[WY+++,$X:T6:Q?W<BP`D,D8CX^-7G`?J9]D!SR=@'G'OD'
MKG(<9\X#.=L+)K&*.6I^KMMTW'+SB&YEN/&N[DR2Y.RN$8:$D>H:U;@721[B
MT@97MMDZ$:2K1(<H_D3&EC7!/`8/X<EC"+2WIBJ6%R`<EU)VJW@TD.-2MC8=
M&:/O4J95UAD:U*A80Q-L#V.BMX,T99`+%9QX$#1^/;P'FB%]OGVR'(185?Q\
M7]1)&&;9[BNVE3,8@[(7*(+W>^X<[L+60VR-9+4C:Z0M3788Q)&_\\L$::G5
MIQ)#RO*<9.4^<%!#([DZ4]L+N?F=[E'>7V,L0(R)85&FRL<U92;6WMYZE.J3
M)E[/1\=K6//JE&,CT">J0C%@G`"BPEE@]1!KZ<])W8>96==UK4W?#MS%T%3K
M;%<HB^S&&*9'8+VKLLA'^5)LNS8[;L/D5AML;7E*3V`AS*4X9PK!E$YR`)?H
M$=*TZBNTG2K2U;JIKM;%?VR^!N&Q;\37U7&S]RZ4W),++FJ?X`BO%$EK"[FV
MYHQ\:9.,Y(9(V12H.3D%&J<E%B-$&UI!L1O]$M/V*M-[]8.UB@K0ID.5[9?_
M`%I3"BMOY%>3;'8H0VH3+#=3&J6/+6_2%W<E:Q<C<8JB:/D;R#1.)03/M,!.
M_0/M-T<G-%HHG)-LIY&)_5)SE&YTG[(%L`UTVB<EI)@7Q8^2^*.R2NV!W0-I
M;T6A_(,B'+:3E-\`Q_.69G(6AX%2.R%>9R'-5WU5$G+-*%G&8C:5>2$HOW(/
M+SX_.QMV+![B`/']S&/.<9_KG@4Q;2?QO.LV_P#\_)*LKAYTQMEW:5;<78NJ
M+RHK5K/$<N3NQ!,HJA*(RK)2R_EDA1JE(-K3#5!#@&3@Y"6(L*,'BG.S/HT;
M;097G[RT=69_%7F,SC:N!1"P;-J:11Y6WJ(]$L7I2<'E"._M+WNMF1Y/0-,E
MJY>YPYM2Y)__`";<%F1GDA95K+V-Z:[+V=J!')2Y0;6S5?1>N%\CKMRDMOP2
M=ZZVA?#%",UG5*.`WBV.*5O4@HFF29*XA:YL@B,N4.;TB4892U#8<(L)21"[
M;:KR!VMO23`T<JW$[,+7@M.=?NO$Z>GQK1-5'11KD&=>T,U()1JG2#L2*`F2
MVZ[(`F$7E(E<%"#!@%Q"8(@MXB%\PUVMM[UO6/P'V\*VJ2!V?;7[;C+^E@\:
M13I<],<?PI?U>5[0R.LM<HF[+&YD/<#W4#4DRI,QDG)9QH<:W:GN#%^T*ZXO
M'G-TESCU-:W7IB#HX9`&R6!F/:OMU#A??22HJW=T+U%([&J#JA`G$4[V,]N;
M9%XYA68Y"4+#3FT*<++.NO3R4[MU&:5OQIS7\*K(J1N\KM".2U9$YJ[7ULBS
MNR-FJZ44I.ZLD`VN&:D:KT8V)8+!$36N&G=R%"HD81$MXEKP'1)'X-"*(IM'
M`:A@T9AD#JZ!&LL"K^.-1#5%V5FCC.:%H86]J0!)*(0!"G"`00^!C]LBSG(A
M9%D(=];TF:-J=0-)MV[.KJJ!;$V'J_#75;/(Q`F9H<(REL-L;I)+XE"G`T#@
M^QJ(+WL`3#6\I9DHP90<F>XL>>!%@)(>V_9V,R`H@+EUF:4VL\+D!JHPX<>W
MGW%KI>8T(G%,V9"!-*=9=6I*2><D6&9-:Y9/$X1$@4HF;!AP:\LNNJZ[&]Y@
M2S4,^5UY%JM@5W:Y;K;_`-)OS="QVJSRR$.4/0ZFU3)/P3N3;=AUA-5*)_5S
M1,$:>MS&TQL;G#+FXK$J0+DJ`+U\9ZY2U9K8LK4RLJ-6#I8,5K!V9'F/5V\P
MI`W@7U\Y!9E:XILDC"F7IQ+TBH?WQ9I_LHQ\HQ9R%'W?#JM:3E6\LVCI!TH&
M'L3K5Y&O.XJZ7:G*+@M=QUYL*=19A>K0C$\JU0TWLZD4K&G1R.<(>G.6,[]'
M5;@4I2G^@"#`J8GS6LWDZL;G@,M[8*/;Z0U1?('KCJ2[5:CL>$M%D.$;E4:<
MZ=GFP(*WCZB0WW:[[2#9^.BU;05C5H$[T6(YQ3*WY.,MH"2CCM="+0D.VF\4
M^'$1:)/\[B/5OOCKJY0J=5ULRZVQ4S2SEE[;H$RU8&6R"[:HD4RPWHHTRMA<
MI301OPYA5FNK$E0)@F?0\B:8)0\4TNV7[(=CZ#G$6L=]M>H-WW6_*L?$V^]`
M6#*WA;7[S7]^W=!K!@KJ8<WV`U(WR'H_BD$?=4J<U`(QC4H5"@-DZP]5VU57
M!VO0+>R3=&LT]A;6V19U;.\>5ZCS9VE\5E4-K1,GL&QS97K'(3CYHY2!F<4Q
MR,D;>E+1)$V0IBQB&,8;N>NLC8R3L9\=D_<!O^]-+LG?F^3MZB)Z0";9$SNZ
M<E&2RK6I1J4J;A-@40U12PDTLXE>!1@(@`"7ZC#6<,ZQ^PBA(!!:1U9[D[*@
M5'5DR)&&#L-TZ>:];#V4VM"7X\IXZOM)R4P7#E%&;!?V[2D_#E'MK>+"3"@T
MHE/@D/=A&F?<A7T=E;0B[=:8FRA:].3U%#ISUP0X@32-Y=,N#HD7*(;L!&BS
MD1IJE2H+#E,::6J._P#JY3A"0$/D6:Q=[9J<PQ+VH:E$+"TYN2$A?7A@"-2J
M\#R26I6J+^7J$Q(A!#@1@"1Y#@6<_&+(<>0P]1J=_(!.P'!?;?JRDS@9V1"3
M]?<>$+(,&9"GQX56$I#GY"?`QXQ@.0#_`$XR/'ZLA%NW[%[G-6I\=7%F=E^J
M,RPS:V6IM.\2+_Q].JJ0YCM>6;3M<?L_]NQ6Y8PT*D3DZ6<5A,K(4%.```48
M&2;GX32@G"MI/OO^148AWOZ]!!+--RB3G:4VHE)4E%#S]K]V+_D,XGHLK"PA
M^8(!'_#D0L`$/QC.0ISM?>WM"KC;'8?0BX]X])S':(.=1W<=:SAHK:TUBB!K
MDKS12$&L::*IY^Y,;.A/.GK"Y*3%>'Y[+1R81Y3T@/$D^S"WF6H/Y`<<3.T@
M6WYTVQ^%1QJ7OKY)Y+3VVC(D;6EK*.6NCB]F++I.:F1H;&Q,,\]68MR64#`L
MCP$(/?(450[2^[=HZJL';FCMPXMN,;*-J=E+#VDU;TKL[;:$U*YF6\WR%'%`
MLM42?;FD&6QXC$)I]A+QM0R(<NL&/FG91O[@28GRX!/6;:ORS5'HVLU!:CS/
MJ$F4PW&H[8ZPYQ)).*Q+,IAG=]ZM?AMM@/#G(9/=[4D>ZOJJ*MJ_")2\2=$S
M)6X)"Y8X93JE!P9'_DFEGE[0L[-_*ED2(UY0-#@F0.\LZTB#5S&N>AX3A;G4
MZBV`@AS7F%@3EF`SE3C`#/<L8!9`$,%ONU:BN_LY?9S3NSMIJXK6UR=1\.LJ
M6:?3^0R).D=2)WNP4MA6P<2J]JD)$BK*5/TJBC"YJ7@A/'VL$HP;E5A27]J(
M.@W=-S@+3K98JRSK^M'5^%X*82W:\*87%-UE0G(Y*T?9&QI:?"+&)),=EN"T
M*CV9UF!)5)@?`//R!#F%W*M34-RUT?&*$=OV]&Q$HDMKZ\F-](W.NC1D)MPA
MQV1JM&_Q9Q08U,K%Q6152T94?.E;WE"A3@&5DW'PFA+."R_;6*H4O?#UI7(\
MS!HC+/"Z(NVL\-B_*\I9+I#=K78#/%F9`>ES]H,PMVC(18(4A$$P8PB!D(R_
M.0M!WU&:5HQN@808,DXO4[8L9)I8Q%F%&@I^8B+,+,!G`P#`/&,XSC/G&<><
M<#?M;E)"*[@1"!,6C0DPN+%(DA)82B4J0MC0@3)BB@?H++()Q@(0X^F,8\8X
M&:<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`K)W8V5W3IS8K4^J-4J9U[N]NO:/W
M_P#NR,6W;LJIN5-CQ6<>B4B8).QRIH@]A-)<,;"W,Y(ZD9:%[BJ5N*'!.$Y(
M%!^`U)LO$^R7;W5+:'6V<ZKZQU,?<%"V5#XA+8SN5+[+^&9N4?6ABS4\1]RU
M/KH"5K=G,)*90N+<#/LL#$=\)V`X!D//L?L!MFKK(I2/[>Z1Z_U,=(9.^.U8
MO<M[!-4U$J:'IO@LA)$]U_&[:0U.Z.,HPB<U+&O,9U.?M"'08<*CTYQF!!^\
MD[C8A'B!FXHMO<3@?'[(0;W]8#8L+`9@S_NE&'S=)M2%(BQ%^!"P<,S_`%"6
M+QGP&CI/WYQ:-J4J;&JAKQE2G$?\K5V$]3ZHDKU,R7\1AA>[X\!,^GGQGQ^G
M.,\"2U5]L8K7@+#.XMH[M#-4#L%S)6KZ9LS0N[(<U.S0X@1+F+,^A.YAL>7/
M"<A00>-,7G!^"QB\`S\8L\#+V_M0A@R`J9)IMV(Q(O&0B/+SJH\V0M1)P8#A
M<L6M=&22UW5,E;#C`%G"$1Y&,>/AP:'`A!#T0]Q77.A1_?SK87-*)@N"!J-.
MV,JFZ]<2"7%R1#<$:0Q9>5<P!#D1B4H8LC":(H/H+R+Z<"<E77C2MXLQ<CI:
MWZOMZ/FD@4%OE83Z*3UH&08(0"S@N,5=G5'DL8PYQC/OXSG&<?UQP*1>Z#8^
M$LDC9-<'#7[16X5S9KE9^V=J.?8`8VH*Y'1E9R)FC2VJ*<5J6\]<HOVU)$YY
M):%>#RT$>PD^\4EGC-2E9"LJE&:EH$IGE*=4>V5Z])EW6E,XY(46E6WU<P6Y
M*EL!?8%90FQ:[MMNC4D=[6D>MBNTXG]JR_.X2%*I-5H!,PV#\DG*(P%I<*[.
M-H-'Z&-7=O.O\ZD,DCZT2M'M5HE4[S>&L%C5TL4(Q-DP=<Q=Y7S&JWMG9C%*
M]WP^LS*U*4:7Y6P1QII:/(7`ZW[)4=M_2<)V%UUGS1:--V.B<%44E[2G<4B9
MQ"U.R^/O*)6UO2)M>&IR:'MK4HU:18F)4$*"1@&#&<<"H_?#H"U5VKD,^NJB
MG=UTVVBG;*X-DIL6K&EM=JJML"Q*:2:T[":\O/\`_P`TMB/.HQ^7`)B=&L6#
MS@TX\TP`,X"@*,W]OIT#[$U,\=CNL-E[2ZD5;3TNJ&J=C*6EJZT*ZI@B825M
M7R&6U:U2YD9E-2K9^C8&%F=(E)W5(6V)$`RXLI):!B:C`D<S[%/G8O5P^NSK
M/N@FT+WW;<2]FNV7L*A2"6,D!H:LK76IB'BIH:LEY"&6FS)/7[:BKJ)1DTM,
MH;(HQ83GX(4#<%+>&P=INN`>EM@T/I/JJ].6QM*;C157KFW:E6+.U8+NH?7>
M('2:ZM@B*KM\+4ZIJRU)V4L=.PH+DD3BTN$B;,'HDS`)6L4M:-N"=-Y:T=EG
M6KJ%)JSZE1,]_1M7$T*&(UO<DL6N\XU;G`EQ0WJ0ZZ)I6V21EG=+.;9G*9#7
MCN<FQ%E@`*T*M6E/4H2@F=I7V3UEN[&K!H9IDL/7;IU'58S;Z@,+9K-!3C;-
M56%L:&X5W:$KB+8U2ROGU\"0M;S23U#B6SN24P\K`\CQ@*X;<8K+URZ]>J3J
M0L"TH)J%*=E(<V:[;%77FVF@A-"ZIH:N6^0WC$*HF#T6PA76/L"B^*.,QP/C
M_$$O2H90S#B$XQAO"?$RCL&KU5I#UUSQ3J+UKU)!G.I[2W;J=,@;_P!Y)X:Q
MYC+7KWI4M5*"4#G`8M]J$$SL$@0VHQ.F,:&E6>H&N4)PU1K5;]@[K0F+=<%$
M8K_2JCM=8$B8]DKFU^<"T$:V*I]A?GZO#T76:YGE_=ETG8ZU@5?N6S3%!KG"
ME2L+4C$N=3PO906-:BWI64V5Q&DNMFJ*[3Z3T#(E4"G]W-Z%7'*5=P-3#(0+
MH-JD<Q%##=DS:)UAOS)I28/$9+^58$#BZ._SDD!97')-&YBRHI)$9`QRJ/.7
MW&6Y^CCL@?&5?A(J/0JLHG1L4*D*K[9:F,),]#!>AI8@9\"#G&`Y?[\I.U.O
M?L%U@G2S:!B<]2K'V`OV::UT2XZBQ^R9[75WW@X,[C+-1:UMA*>F;:+J78%Z
MD1IS7+%/XY/&'=(2E4#`W*5IB@-@Z96!K9!;5E=\;?0^)P[L>DFR#Q7%?Z#P
M:LH>T3+6)\M]X4I@J*9AS,!M+NAZMJ(JSY1.=@A'&M[\T`6E!<6]H;#D``@O
M`)52MN5P1"-;JP3=AFG^TVUMWT5)^MJPHHRTF=2FQ%:QE3;MQWKH7-I(\N8Z
M$I-@`Z86GL4D>6TML>G-,:R.C8H7!2*`D;"=][3UU5SJ#-.[5S0QFJ)T$P3F
MK.V/0"_;6D]+/+E'(_,T[/)-Y]475HK-[B3#"G(+DG62!8\KC4:D"E2\')C"
MAEAM!?V8;MHWPR/'[W=$2-W$F4.:5E`P[@NTE.9TYI!8W3$=36BF7C:RLK"`
MFK"\#3%C.+#D7DP'D,1!W!;,M[.UK#]Z.BB3I95(`H8=,6U=N0T,DE-++(2*
MH?%F1O,FQ,N?RG,)G_<H'PXP.!?&)![%B%D/"<>\:_T;B^HO^3O1P0G9,J1*
MU:NX=Y\&M!6<84HQRM,5KE]G&,%H3RAJ,J%GJ`O.#O."S`X"$E&WM%V=8G9I
M;YIL)T1OZA2E)-,8H]O#<\-?78@(#S%SVT@=J9FHDZ$@E>@-PGR0K_M^V<J?
M[Y62P^M_[AI@A1E.;/?O2@J93WC+&G>77L'M]$A4NV#!)\,Q1S;J@\(\O?WA
M8R?M`J!G9,#D/K[^0X"K/;+>'.P5C22;2#>#HWA#D\:K6/JXI;R=V[T?A-C?
M8EHU-:9,CR3C7%I/6+$"JLBRR<_$60(HX9@_8/J#`3G%WSNRI^=6>+;#=(<P
M5.K@V(X"T9W_`+]B:L[*HP!!Y;\_..G+K&QB%D>3,'!-1D$!!D!@LYS[X"M&
M[EVX4^M[:[:V+;8]*KY#MGL4U%))1L!W59)A+F)?6KUKJVKWF(71)J3CKVG)
M<"*9+-=F(TLA&6$G*G!1JD@@0@LRV[W^D^T-%W]K#/@=5<?K*\*LE56.+\V]
MU]=L4Q;3)6@<V90L)"9K(<B&$@K):D"8W`BU)6<D*`"`(T'`B]UM7_6/7<V6
M_()+:/3";+;6(JR+DU[J=V25+7]21F,5[B?28A8N.O=<^V$Z6`[SRW)(%0#\
MF<QH&A*VH6E,E3IA!&%GL?[I(A/'$<6BG_CXD<E4IEQ@8@3VR:RN3PH0I2QF
M+#3D;#&)`G,38;\9/%\8SL!(SY,P'.!A"$3-Q>S%_EVH^UT?E>IND:!E,U\O
M-N`F,[--5)G*'1'B"21!EQA$'CL*=3I"X'IUAJEM0"4H5JLT/P9"0>8$.0_6
M`O>SUK=BC#86O<+ABF-5C,M&JBV.=*IVOJQ9(+`HF%U#M6I,679#6`3G,:U-
M@\PN,MX=(:^,HECX)/'R4CB0(M5D@.BJ[U-XI*V>SM<VZI76W<*&<N-(KO?I
M?&JV,*->$)3SE[=H+'I3)BE`&89^48$Z,>#5F"@#$`L0AX"@SM>D79P9HU:I
MEXP+1B*U,1/M85TN<J:NS8B96>U-K=M#3*T[#`T2:@X-'7P2E>02`_"I6A(*
M0"/$9@[QZ"#9/9.E"IWEUYE(RL$EU)/NLM8:^%?VL1]-<>_<DA+@L<UN18RB
M3N3;&CFLHP.2RQ)W):2=D03P8P%J.^ZDE'HQN8I4$C4$%:J[!Y.)!Z9$84*I
MI:`P.,&#`#/Z!9\XSG'G'`D)7J`]J@,':U2DM8J;8A&D"E85@S!2H]&RHDYR
MDO!H0&X+/,+R+'L'`O&?KC&>!E_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*T=E
MU0T_9)UA%>1A+71S>M)G(?C\#,#5E9+BRC,9*R?\>0(1C^@P@]@!]@BSZ9`%
MEW`K?VUK$V1[B]<DP1ULBDS2*S[U@=O2?$&:Y!\%:+]7KDE4:C4T?5+2L4((
M,?;4=9EI"8XXM(-]3HQX#D_!>>!+EQUQUY>`?&[4-3#H7[IS/1QJZ#K0>Z0T
M\]*/U4L9N/=,<J-&7G^H!&"SCQD6?(>./4[5DT#@4;K30!A3NE&@=2QTW70P
M.:$U.>D-1N`!1S(5J4Q*I,*$69[`R68(.<>!9QD->)>O+0)"$8$6CFGR,!IF
M33"TNM%+D%C-%XP(T0"H4``C1XQC&1>/;.,8\Y^F.`BG7UH_7]M1&]ZXU2HB
ML+A@PWD4;L2K*XC=924@F0QQ5$WIO<ET#0Q[]Q,S@PJQ$C0N(5:/`PEG8*P<
M448`);KD"%S2GH')$D<$*D&2E"-<G)5I5!8L>!%GIU`#"30"Q_7`L9QG@0*M
M3JNZ[[B??W?+=1Z?:9[@S)Y=FU>PFTE:I*GV$+"HFT::60.?E*@B%G.#,./M
MCSX\^,YQP(979U,6LX#)55IL@U;&Q!FC4XBD<H'LH@+/L@U1B/V8S9BL];:E
MVV9VY@V^I1P?HD,2'\GE\E8PA"#)J=1@L&`!2A?W6W`H/84M=;BJVW]0I%=6
M$S7<VS6P-GW-OMK8UQMH*J:+,$RCE^IS'(X4GAD0A\J$S%7<S1$AJ72<!K>K
M()2$X)#"X=O?+.LQ^35/0FW+)L["F78"[Z.0:_Q[7OX=,:?J.9PE-L&EV.D"
M[76+6M/X]'V6=SH\N.1I@>7,I57Z?*5,E+-3'J\!.2Z:4UGOBGYA;M*[.R?I
M%[!*PKC6S9#:J.0RT9;6FM%277?J<I77T1V\@0CXS1SS-)`O(6HAX.(22<@E
MR*4NR-6`TE*<$^:Z[84.G\&I&H^V@^1U5<C\Y,U>_P#+]JK]4OT<OQS<D*UQ
MCUGPV^(<C,K^"M<H:4Q9BMKD)<?<6Y0(9HD8$&,*<!=LG41J;QI.K3&LLLB$
MM9"%:4\O*)[CTDCKXA`>G/*%C[EO=F=V;E(1!%CY"3R3,9QY#G@5N31VZ\NH
M&#SB05W4,(JF5[$V#E_8Z#UXA255<NS5R+R$;*U1>IZECOATD+CD1I8?MV].
MF8F,H]0M4Y1DC5*,A%;K`D4E1;*;`RO?^O'FC>S[:,[]S-,)F+FP2&!E:H5_
MC.:RI34BR&)>XQR:1RHVMSPXV`WI#$S]F7NBIS<4?V9C<?@+Z>!SY=N^PCGU
MKR9!N9JNH:)ILQ86&A+<NF3Q.D3:Q;4U.P%LE=H[,0Q16Y@>VBXZJ?7:-,C(
M]1U*K<GTA>2PGH'/(D'X\*K&:\L]AW8@[UOO9'=0*:;KBL6K:%3:S)Y-,=G=
MWXW4T`63RTF[6ZT8''4$[IC79LNF0HTRVT9.VJVM8T)D2:/N@<&K$*U&'0#M
M_0\>>SVUDV-L2I-=NI.A:RCKS+:M87TNKD-SSA*[KFYNK:XEB4MBC\?U?@C"
MA;_MX>U&AS-7AQ`C7ARWHL('$(,;U4QC?FC&_866S=JTMT&UEJ61690R:1UN
MLK6X[6DK0E?8^IC=YQ&:ML=7P[2:=0%@2I`5RB$WNU@MKRG&XX;A(6]*(,+U
M'VAF7;S5R]--B:VZ_P#KYUI@L!QLI6507F@3R^TUDMIR/V6&HY3/&)EK(S6;
M6F!P>4EDRQO`2A?7-<F4-.5B1O2+<J@N'U/V!B=C-[8EU\I-OK[0>%56T)*>
MO-8)+6$4G"Y`^#CC;&Z>IMP86A\25`Q1QJRH32E=AM;7@*I'EF)7HQB6X">?
M`P-75M:+[(9[C6U]"E=MQZ)NT"8K.4Q=E.G[/"'YR0/+U$&R7F(A/Z*,NCLV
M)U)Z$M0%,8>4$8@9%]>!&:HM9'*$[77C>CHW01BA"F%0BJ]=(5`T>&A)%(HI
M+*G-YS"1LJ-H:&=+/+8M$Q"F6G$Y6#.9H@T"&>$>3"0!5=:ZF8PCHP[*;WF&
M)Y'IKL(P[Z[!*D4F;EL=FK!%K/ELX8*D8'1L7IVUW:0,]&MD:0#3*@8.2)"O
M@SCT+"#`3322C"GN#K2*_<+LY2=5D[E`T0P'?B$6'C:"H&X"AO-SG)`UR_\`
M#"`JP'&!A*2ILB\X$'P%4-.N:M#HA_'@/*?/R*5][*V`:TT*="D2O!;[!-Y7
M))@12,HH@O"!2>`9."@@]QE!R+'USC@2<V-=@/U'?R8\?<(\`883(H^/"0T(
M_4+9U;4T\F?D!9.-`4I-R[B*-#D(?4D`?.,\#=TJ-"]]KG5<2262W*V+KVW@
MF#A@!1)Z1:B>G?2B.$M:$\`23B3T*TT)WR9#Z"(!ZX#C.?.`BS"WMY(ZY-<G
M16[Y6J'7O":TKFH/$E4A<TJKNKFC:)(K+&B((0BP>47G!1&,?&:4$(1Y\YQD
M-_3HI*\W-WP(%Z9L5'1W5:C!L*@UK:C5[(6Y:K70?X2FC2"-R'#@6:>6,WW%
M[F##C/H$(0A@U6$J6G<[HTC3BT-K=]WU8[2J'AHRUM@!)Y(AB^A6%@\*2B<G
MFJ2!Y-+$'Y1EXQD0L8\YR+(<N]=NE8/VWU1R![N]6W7S+.Z!8V5=KC'(8(VC
M7ZM`;_1<4O9;&P1035!7S8Z.L[FY/+J_K9>Z24J/_A47P$$'!"$.D;<U=!XY
M47\C(">KH"K<ZOU^8Y4Q.!D6BQBU.?--%2"0?#@^/J\IBVEU:E*\LP6#/90L
M/%CTSD0N!*-NJ*GG#L?TS;5U1U*M;'#K$V!><)%%:P<XC#JPW1I44V+T9AC(
M-1\K8E?#RR,?(("8M0/X\`^4S(P@U&*NJM'URZZNX:MK`;FA[I66+*')77<,
M5+OPX.ZF8Q,3<J5J60Q0F!^'-PBS@L160D9P1CP4+)8@\;8VG*UKVPOY);Q$
MZIJIG:&7K9H-4PMK="H:WX8WM5KMMH>]NK<W-S4E7M!"LO!!^518BRCUA!@O
M(S"!>@3:>ZKHJINT/KGF49C5TU[9=K:W6I7DFL>O6*4)J0O<BO:V7/\``JLV
M!<F)OQ7KK+FIO=)1*FM:Z9(=@K&A&40,XDS("0LOW!9JQD%"2UFN#7*3;6P!
M<J8"WBE(A!V"Q'Z1F%O:(]N7HXO)7N.M:G,><"BUN3LJRC4WP?*7Y&'&.!S!
M[ZT_HP=KW.OV+TS;#ZRR]NN_5AI8MAI1KY5<$C<>&^;*53ARE!$JB]PRB2,S
M'EDPH1J%9C7C!9BTL@P&!&""$)_]J5@+*XN6QW1,)M(2OC1TR1M]7.V/")IC
M:_M3G@7YZ-/&86G1%MK>(61*#A8((^3`Q9\X#P+8=_RPFZ(;J@%C.<9U,V+S
MXQYQGR"H)@,/]/\`^H..!)*%'Y4PV)*<B"/*B,L)^1@\>@\FM20SV#X^GJ+V
M\X\?Z<#)N`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5F;'@"J[.>LE*H\A3(JQ[`
MI$D$#/H(3ZBB.O<?2$C']?D3B9)6Y#$5XQ[&%@'YQ\?@069\"NS:B4OS3N[U
M=1I`L-3,,MM;:$+^068>6%Q-8M1K1<F=(H"6<`DXDL_)I_J8`>,&$A$'(<A^
MH6)\!P(XS_8A!`]EM<]<#XNL<5VPT.OV7():6YD)D$9!1":L5*QL5-8DARES
M528%E!R0,!I($X4!N1^V1@#P)'<!P'`<#^1@`:`91H`&%F`$`PL8<#`,`\9"
M,`P"QD(@"#GQG&?IG'`JZO[JSJ2:&O\`,=97HC42TI&YK'R9!@4,CL@H*[G!
M<:F5.";8C6YT`DKZP_S2I"1E6_-WX";8"4$)#X4''KD*&[/HQWU6BM[5_,Z$
M14O<%XV-`+PE%>/TDD-N:@]B%L:O1&V9C44.JW8:S9*I>D%D[&;%*8<ZRV$6
MTK1/STU-:MJ;QO6#\J1!>9U]Z$4)#NOB$4E9%:!LQJN:N&!??K)>=*JZT763
M(EB,T:EQLK7>5O$H9*\G)92@!;F2EP6(UP3_`'6<_)\>0!2WO7UV;`Z%3Y';
M="6]OW:O75)I'!FBSZ/@/8CL93BO1.!$A<&&:S^''Q]5+G^944P1\YN5!2#`
MJ.B2)G4EC+.1*\+F@+Z-(-/NO^H\&VSJ[^U+HL%[8F`E\V>E%N+]GKMDK([L
M)+FQ8<+QFDGG$K1L3]''0I4G0H%B)J4)#BS"D_Q9!G@2BV*UKJ+::OC*ZMZ/
M*7%$E<4DBB,JCSPYQ&QZQFS7[#8K#JFQ(ZI;Y;7<]8#AY$E<VM4G/P`1A!F3
M$QQQ)@5A&=B\@Z]HC.:8[&?WI,[2K],9_P`7K;@D(_)J^Q2*N+XVQNN(C7D>
MCN/QZ;<HMW?$+-*X9@",!Y^?W$W!PQGJ,MH5<W53.\]5V;J?M=;-XT4]]AW8
M5:=6T<#6RT:4AUJM6D#*YKY\Z0:SM2&^,$)9F_2S0F(6A(#Y.XO[FNBKZ<YK
M%ZTT!Q;;\H=0NN6NE<:P5/%:FKI$H.1L!:Y>^R]^$F<)S8TZD:PUYGUHV'("
MTR8Z1V'9$I6*79[7C"#*I<J'D(0%X`6`-JR:(1.:MY#3,HO'9:U)75H?DK9)
MF5M?F],^1]P(=F%Y(1.J96F)=61U2E*4B@(<')E!83"Q!&'&<!3I?T/JFJ[H
MQLMV86LU[`R/%LR%)USZ7P"!N<M:6`UB,&I@[C6%`ID[W*[\W$<T.2CG27KP
M'-<2$I"%LPR(@J%RD(@[1ZL[&6F,7:#MW6-4M;!4)K<[R_K9P\Q\Z,6AJ3'!
M*G0U)M19BYV:8)<NTM8.RS]X0UJ6B5P-A<$1K$F^Y/=5#T`-^1N;P7L@8"][
MMEGY@K;J9HLP^?Z]59,'A*U-FP3Q!%8<9VBVC:25V2&N"PB0MYJ6!UJYE95A
M=$WY=Z2???BD*,)51K<.]'C5N6W78T(@&O\`8NPMBOM>]>%*7`;,XW,)4IF+
M$8VZU,^P13&GD4@BD^M=];%,C>VUM;0&0>-*/C</)[8X*L!"/5FH-VM`[MH_
M2FA+)7;>1>440OV+W;EFV,BL%W651:ZIB50MCD%,W*62K5G-FT%RL3@:.(N1
M3V*,ML86KTV"\KC/F"7&HNZE\L4UH_2GL`KB5)=Z+`@$SL^0SJD:??5^HV(^
MC=7AX:6E#:#;(98G8W!A8/B9%!KT!K"M?$!@2P^BQN,6ANCM5MM\HOKIW`M.
M+R!UC$IB]+23$6=V2$$6.Z`D[X)+'(ZWI(4L:GQO?!/;T\$(A!5I#T1(%&3E
M(?@+,S@-4)^WW2L2J(Y!&MP`ODE:Q%(4N>NK>8+RV(P("W90WN&2M=?4`"1E
MA`86D,4$X/#C./(,8'P(+WCW'P]FO/1>K-2M9YK8-!26X3D>QKW/-$=TH$NH
M>&K$B%3#;1J5$MHZ/,&34ZMQ=QKU`$ZQ01_:P$D`%!ZDD*UI7WB]J?\`C5>Z
MM'5/3=G"NFT9U$)I^S*3W%E+H17;)(!U@VNMPTB[5-'WR:F2&),XU*<TI_/R
MJ9!IB5#>@'G"?(3'@G=U<K[9FL:29Z6_XZ7-.N$FEVT]CS#6S:Z/2.#27[RS
MFO&N=$1DVK'!]1.\VD,`@KZ24X.BQ(-E=_4\O"M!D90?S4O;Y<TI=]0X;?6G
M=/T[2+O79FQ.VD^>*)VP>8[7UFHWZ(3ML@E:UJU4<]K('<L5L"59<CG22G*D
M*QT9G!:D6@,+3'*@^Z5=[\MDJ"@9/K_HFTR==L%5EP2#9UQG/^6T,2IUUJQG
M3.5<P2:V_'M>%T<FY$XACJH4(C3"_M4I:THHS*<L9AN0VEJ_W:T1:EBV9/-L
MJ1@FI,'I%:I@&L4@>HO:ELW&ZM"Z,QA?:[LVO$$HI;`(C7BS(&YO$6QOZHT]
M6UFIEA&,(RC!A4EL9<,D=++[E-9-4]6R6AB>+.J7=/6S=1F-)@K97^SJ@OKS
MC4>BL*:Y##$D7KN9'6/,ECJZ.^%;>Z#5+5N'`D>0J#0!>!J9L1IS2^ET$J_L
M'M2$_P#(.QJ5C#;MOC991&YW8]JH'EJ<C([B[)6T,S@QV$P+H'(2BFD2L]6G
MPR*"B,#%^OR$@5';!TZMTIC\T,VHUR!,X=#GR%Q:2IDBM3(X[7[XXQ97(X\Q
M.*2.'.+?#W1UBK*8L*($%$:>A1Y,\B+)\!_M<=@?3%9L(6PR"[(:>KX#%K%0
MVB9&G)XC$98$]HJK%47,DG[2VRQ,S$.DM#:A9DB$Y(PGGE/7_<C,"?G`LA2_
MM]:O3?L]L9V83K8._-+I=9<-U[IYEU5E,IO!I_#"7L%368](FI>P,\@1Q:P7
M)@N=V-&K97),^'C(.3$')LD'$D""SW7#M4V@MJO.O_(>K'9TJ0;:-D/=9I+B
MGF*HZ,HRM7$M\R;8<NL<]K0&E.ZN,Q@Q^21H]E:S342Q&F`J^]5)DQP61[K/
M<+8=?9.LGNWKEHS'C7>*I#-C&>0U-%W**K#Y"@RB:$KO=L3FM?$YE9P/QY@5
M+>::,H\6"1%F>HPASD[52^`)X='VM%W^2G<*4M6R>E!JC60Q[T.6L]K9=MNJ
M1))85".F*@BLX4H"4QAB\P+2Z!&2%%DPX)A)9A0@D)W;V`\P5%NT&-QR.2IR
ML32+52ACVZ5.I3.@;PVO?NUBX4C;Q&-SKAT=(Y&X0[KB$WQ@R-8G3!P87[9,
M+"Z/?M<2GT,W,6G`-&0+4[8'(PD8!\WHJJ25E>2\&"P#V#@WS]<^/IP)+PEO
M.:89$6I2:2>H;8PP-Z@Y-@>$YQR-J2)C32,&_P!S!)AA><AP+]7KG'GZ\#)^
M`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5Y7S'OR?8UUZOF%F$^8S5.]1V4XB?D"
MO`ZM&NC8(@)GREY3FDC,";@7@?L`L0?7Z^P0L-X%>&SK@R_\Y^LED<&1,M=#
MYGM=(&!Z-=#TQ[&I9=:)(SKRTK465\3GEU;968`9AAN,)@E_0L8C,#*"P_@.
M!6G=18#>UC0;[H/S%)]4.P56W%GY%DE([8E^E*0:]$#R$`7++4L4$9'^H7VY
MQF/'C.<\"RS@.`X#@.`X&,S.%0ZQXJ_06P8I')S"94VJ&>31"7LC;(XS(6E4
M'U4MCTQ/"98V.B`\./UE'%#`+Q]<<"J!TIJ^NM5>VS350%E[%Z/$+<%6CI:Y
MN"^Q+;H*/K%2L];8^FDJD"\^82B*Q?)Y9B^JG16X?(WE&?M@Y*H`4TJPVE"M
MDXAV$V)$T.J-Q3I)1U`S&$63=%M0`AXB"*>SPDE.]1C4]29+H.;AW;P-BM0N
MM)G+/:)#%E!#.TK"\#<UQ*4(HV'UV1S0?<$CLIT6K21MT:E2,<1W@T_I<[\#
M&+1@KH>((=@:SK%L(+9'NWJA5*!.:B-I@)OW$WY5B;_5XS\#J%C.D6^NLG89
M4BNY=8)V*61MGE<@A$J8WEM4QF>0>41UQ4(CV:<0AT^-_BBYQ2$EKT9:PHHP
M]`I*-P'&<B"$(,Z91I9OMM+:G8G<)^7FM:!N.Z]9NO.L@'&*85#F&JY*[U+=
M6TRD@PO")_MRX9RQ/#.VN(,9+8HHAPD3B&:K5'9"!FOURS372Z]BX[*J;F6X
M'?C9EJSB$`9):N<X]5,>U'6S9RD-+VU6D\4MCK&:(Z](S"ES<)T)1X.DKK/2
M%3.K+6.^$N20N`U_FB+6J?Q#6*_-G9QM+NCLJ_3*YI8A:F1>IC%8QM"PARH/
MC=>,ACHVZWZOQ?\`")&!@,=U0CWM_6>QJM>Z+51@0LAX&/+8C%'*2,,R<8Q'
MG"7Q9"]MD8E2UE;54DCC;)OQO[D;V%\/3&.;0AD'X=']\4G-++5_:D_+@7Q`
M]0K-3:T6GN7>"VWMYX@CB6O%&V"_%:PZ:KGQEED8E;S#WA0@9=N-DU;&M51N
M:29Z)3"60J&*,JVB'H32G!9@]^,#EK"K1TJ"T=O]VHKV04"P,TLZVZ"L0M:.
MG9?-+&@37?ZZK&J]AVGL%0E`@95FM]L-,HLVQ6>41B92(QO=7U^A!9Z)<C3G
MDKS`E?3FS-"7>?L!W96):D2G.L>N]?RJ!Z81Z-/"9U/K^`HV!$NM^R7>-'.?
MWC%LULS,%J6,MS&O0M[^WQQN:V\)6#GE86:&TZUL3;*A:KTK@\M4-DRW4W[V
M@,M"\H[82E\>(_1U3.#:MMR]HM$VMM<VPUE9==Z786:O&(P.?QYLI4H%*H!I
MK@8$T)YN>Y5'1XW;I9+'MQB<.TB0M*^_+$>6P8H:Q@756WW0ZIFA2UF.3L]K
MXI7STWJW$@I'\H!N!!)03C19"$/6MK<+5^A_\.`NR\*]JM3L"^-\<IIOGCX1
M&W.P'QP"TF$(&)L<L$KQC3B?4(5(S"RRD9BP@!XBQFEX$&V@V=7@K'65`&:Q
MH5I-T'1V6X5^%W1BEB&OG%\7QENF2QDP;E<FCB^0-2I&0K&`))JA,:`.<B+'
M@(>`P7O2TIC]52I@M:OW./7H,HNEW8F5LH4EKG'L#E*R4]>".6%"EZDR+LRM
MRP4AP>9E`E-/\?$6,>`_Q=>M/M$>M>6/UDPA@C=%JW=)<3T\2IB1-U9"9&-%
M*%QDZ5&+_BB@01=S2N6`KLD#R@4E'^OQF`$(,C'9$"+G,?K,<M8\3^50R0V)
M'(EA<4)[>(-%'6+,<BE2%&'.1FLC0\3=I3&G_P"S!J\H./.1?0/*+NBGSF&)
M2DJU*Z-C4_EQ5?P20%S6.#99K.U#DZ,Q$,B;F%RRBD<J.=6-:G"WHQG*A'(S
MPX!Y*,P$/56V77#85/3W*P(2WD56G+5V><ME;$D*KA*:PD2HI3/3#UY8(>G,
MC"HIR"-PRG#E`8%1C/Q"P/(>P"51@Q]1Q<N1L(Y,X,)\J01P+NWB?EL82K$3
M<JD:1GPH_(*&%,X.:8@Q8`O*<!R@L&1X$,.,AQ/;-5S7LIJKN_WZKG;I@L2`
M338:9ZS/VJDSG3`U:EV58D6D6I2"N37)[.D\1/9)%^X660)'%>4ZD$NB1TR:
MD4H223E2H.EKJ_FM;MG6_KG)$JZDH+"8W4R9Y>":O2.4`IJ"-*T2R5%Y:&^<
MV+9#K&XKAA=B%Q"E?(%I*M&H`N(-PD4$!"%AV7IAR]$1\3LT9D2AH4O29DRO
M1Y>CV(E4D1*W8AMR;]\:T%+E1!1AX09)":86$0O80<9#Y"G:)".(((<XZ)1G
M(<)B2EC;D[(C%RAL#@@L!GOY,<TIJ?'KCZGEC+_WASC`:@F:[5:-2I5#K#6:
M^Q^;W$)O&MBLS45RU2JTQ!$%B:QJF-\&0[S@01E!1I\C*5>,AP2#^GKP)`\#
M1>QIU_D58["UGA%*V%:PES46VQC8":2V`UJK:AJPX>3W*00JO[,?0+DJ3R-,
M2%K$6<9CP,TO'UR%*N[`^PYTH>,L6Q>MN@D+IYZVQTB;)J^T]L;<<GL%BC*_
M<NBD[<3#V"3ZPUVRN\J4/AZ=/@P;N@+"4H,$`L8\8+&'H]J%DLM=3#=-$\Q4
MF5"M7K[IJJ&42@2+!44?Y`[=ACF@FF`K4JO)BIA"QC^#!&"U&#3<9`:7XSG@
M6=;P_P#>]=^W(P^0?/IK>Y^,"_5D./\`"LH/]<^/ZY\8\?\`QX$L8B=A1$XP
M?@.0X/CK*=@.<XSD.#&U,/`<YQ],YQ@7`R+@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X$&K&)+?.Q'55M,$8#$+U>W"GA>,>@2U"QRGNIL%38]\8$:+[=$^+,B!G
MU!G)@!><Y!C'`G+P*[-GHF].V]?6-*F\M$<V1"8[8EOX3G)"D6ITDBUHD2)$
MN1(%)Y:MU++=$I)!P4X#!$X4A,'C`,"S@+$^`X$(K+)KA=V"ZE%.H%!UILFM
MFYCW#?A6.A)"*)*YGJ,R30Y8C)+RRK`K%ZQJ`6)0+"DH1><D8R`1^<!-W@.`
MX#@.`X#@5I[S["V>IE<!T2U)>$R#;+9!F?7!ZL4L.'%-I_KFWD'MDXVDDS<!
M"XI3I*G<SR62OVA?A.FD,N5`R,8D+<Y>@:Z<-"7?2EH9[AZY$3K^_HH3APO>
M@)=,S3XYOHW>5Z^82"?RJ1B.)8=QWMP7GN;18QHR,.KJ+#;(?F:CBSFP)W:P
M[.53MS4#!<M1N+F)F<S53/)8E*FP<<LBK)XS9+(EU56S"E)IKG!+-@[D/*1V
M:57]P@W&!EB-3F$G&!67N+3]UZ!/=[[\]=5657*GBVP1]UW$U[EC,_MT>F2U
MG=T"46U40<:V8'N>$3Z`Q-6XCEC&@1K"Y:UYRO*3B>D(0.H;4Z,WIAD/5'IN
M\1TQ@,1+8+*35F(RXD.[05(,V;.,R@@MU3E)P.:PF1_=!5*!%$F*%.##!EEB
M%D&`VAV)ZJ6E>%8*+8U(FA=-[\TC%I<JU@N(HEH-3FJ7U.B-E--V"WR!$Y1F
M45;:Q#00E5)7=*K1M;L2@>2@!5-Q0N!65IS9B^Z(8YTGUA5E9='V.LDB1F[*
M]Z-NHN9++TJ.]8PE3M\WJ5_4S=,(_:'<9J1C\)S\Y-K2&,R]"L(PH1J4+*8%
MR^M-Q54^K)3K97]MS:_Y9JPQ0F!V_;LF]))EPGYZ!:0K8)C93(S,L%?KI3DM
M&'"3-#4468R9<$V%*=)E023P)8\#26PU"0W9JK'JFK$=IRVP*5+V$<Q0P"9/
M$#<Y='&A[0N[K`7N01\U*^8A$Y2HA-CZD2J$QK@TJ3TWR@":+/`@?MI&';8J
MVZBZS:]C;[!M;05TAMC<N0QF/N<3AA^LS(N50FM-0X/)&E*A:4*^_P"6,AR5
M_0-QI0T5=1]V2"^#+HCR((RW_J32VXW85_B>G8ZFH1STTKNG[EN78&G6V/(A
MO=ZJG%4OU)UYL:L'J..=26S&JSB4>,GJ](^MZQQ:2S(L%M4-Q:DP8PAYJEN/
MM-!-P]NMKM^JBL^]*GU_CUA:=Q[:#6+7,PVG:?S3=Z3A7:9\2K:/VG:5XSME
MMYF8XNZ321H68U'%GZ-_@C\"3MPEN`_UIV.HNV^K,-8_YWHUQVB[/-IJES?M
M9Q"RHH]6!"2=^MEX(FDL5D,*0N9<K9U]4ZD.Y$>$-4B]4X&#!IV#0`,]@V?V
MM/4:,W#LUS-($:GJSJ"DBE,]E&`<FEL67COC0,>B9:9$46>)(L<E5/K"\JBL
MX"8E+,`;GXP<"QJ+IDXNYG8QQ=VA"A"CZS-6T35(3#!E'N+.JV3VU52,A0<)
M5D@"5L6)$OG.0%Y![^?.<9SG@5CT.A7.^K/\8!>V)C7`UHO%C3*3T@,'@2-J
M30+;A,Y?)DOR5\2<ALS[C^N<8*SG&?ZYX'LW]%U;7JU_*#=EIB-O;'^R9>:T
M"6*"T7PN*#KAU54"6G*G'!+>`M0O7)QD>QHP"%CP(.,9P$065`,..[>:I,-5
MY<DO_B[M$YN6B,3J233SMFZ+_++$!J4.$98G(D*(2@2?`"U`2R/ZA+!ZA3S4
M:I=-.M3HT?0HT+>O/[AH:^'(<JB"$S0`J^-Q\NK:D/7#+^X,1(!'I"0_J//%
MC&`^Q@L>0EYL'"7N517^2K'T;?ZYE])QXEC4+RS"&Q>ZAZW8VB&+"T))@3!I
MCD9`30X]LEXP#(@XP/&1!+-D.*5=IFKCJ7D(_P`SU2WV9A1ZXP:H+3[$:;JB
MLC#X^0H!>'40L><!#D1N<?7./&`XS-2JUU+4[)Z,TU(["MA9*KNWE>'>W=-+
M.#8\MT;O\I+8MEMKS)RX[(JF@E,-UH54VPV(+C"$CQ,Q/#L[%MZM0()/QC#H
M#M"MZXHGKB[Z]>J1B*.#U54]E'U;%HD4XJI"FC\1E&F>H:]\PWJG,Q0>F^Q3
MS5;EN2&#-"VE$)R@AR46`'`D9MI=UPU+VU0-RU[HXZ[Y'6^E-2M]Z,(LJL3!
M-K#<NWPT]BS^G&1"J3*[.L*LF*F7%9^W4X<K%YBD@*0E4,)Q.`KNU4TW;EL<
MZ[^P"P_W4IMMBW_E5$4YEIDCK'H0V:N2K:K9=YC[U)*R4M25P_=<ND,I4'B2
MNRYTRV@7$'$_:G8-)+#>N^=0U?,$O\BZQ)96T%E5D06F==5D$G$FBK(_RR$-
M['J8UR!H%#)"[HECE%,M<GPO<",-YJ81:XP2C']T?OD.I@DP!Q11P,YR`TL!
M@,YQXSD`PX$'.<9^N,YQG^G`BANV*J<Z\2Q-=577M<5=K7".)WF"ZWQVX)/:
MR\TMZ2+&]8S-]$N+39):)L6I0'JSD2DH`"`9P;[`%D`@YF]DHIHLXXHR/T9H
MMV5U!<N=T]#%<3M38:K]]V*GXWG_`)>4DK=5LSEUMSI_KQ-]]&1JTB;#PG4?
M_<3R2@``J^(983E[+YM%8YL'ODRSZ/&RY)*>KFC8O5Z$+4V.^(C:DJEO8XW-
M4_*+7C*-:Q,1*7R>O3?(K2)<F&%A]`G9X%F>\1F7#K!VE.)&/.%>E-JJ,#&(
M0!C*-IMX.,]\^?;R83G.!8_U\^,\">B#X/L$7VI82DWVB;[<H!82@%D?"#XB
MP%`Q@)80%^,8#CZ8QCQP/KX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!".98^+L9
MUW,SX\*]--O$H?7_`'9$GNC2U3GY/Z?HP$7Z?KGZ^?IP)N<"MW9EM<G7L,ZQ
M<%)0*F:/8W3EJ[.!%%G-[HGI&/PYI=/?)A1QR<*.<+D@R0_($0UA9@@9R4$P
ML+(N`X%9UI"(-[<M-2DJ!4H7I-&-ZU#HN(]!)D#0LN'2$EOPN#@?R%`5.24P
M)8LAP'(\>,9SG^@68\!P'`<!P'`AKNQM0OUDKJ-(Z\AV+6V5O28IZ<U9I<*@
MY("Q;?>&ET>"5,G<DX1#C%55S&F9=)9B]C]2VN.M:D8/=4-*0<&=:Z4+_B-E
M52V=JXS.-E+)8H=G8>ZV6-BCRBS93%VY84D(0)%B]X=62O(LL>G`$;8AK5"=
ME1JS"RO`C#1#"2'`K?VBH&QJQGCIO'IFP&+[_;FUC2WY0Z)<G:XMNQ4D4P;C
M]GN1"]0G8F#8N%LQYXH!,19).P=C#(ZF',ZK'V(8;:O:[3S72E'SO7*&2O9J
MWMH8W*WVAJ&CQJ.%/("J]RB16R];`3&2X%&-;X/0TA<2FJ>.DA&$V/NN<H`I
ME*[&$V0K<UMV\;=:B*BW]<,8J?0+=T]47MO23%*8A-JTT0W4LR3-66G9@4Q0
M-+<XM.M>QAC2=EV7&F(6E(Z/S?(\D8`^+#"`Z4XA+XM8$4C4[@\A9Y;#)DPM
M,HB<ICS@F=F&1QQ^0D.;*^,SHB,.2.#6Z-RHL\@XH0@&%#P(.<XSP*8>SO4N
M?QW$PVXUF<[O:$4O+A[5V'T7K1(<1*T]KM<H4$"8]_JUX*1+'>.;'5A&`&)T
MJN/FM$@ET2^YCP7$I2!E/1!C^O,A@&V-<MQNLZY#J#TQZ[$+%3#/8`Y*Z/==
MM3H$L(D<M=6>39!&)'3NJ<&D;<Y$RAZ-4HI%/'A.O+4*$C62M&[A9QJ_M(U;
M.5FJNQ!!Y#6]126:C9Z)EEA*VUG77G7BK#.WQ*X6.-&#`YQB)6=(%QX8LE<L
M@<W=JPC</@)`X$$X"5'`U97%Y4M<+#*)34]M5O9<8A$F?H7,9'`YK')8PQ>6
MQ4E,HDT:?WAC<5S>U/<?3K"AK$QQ@#4P#`Y,"'&<<"+C;43IKWJ!>2G1$M%<
M]VVB3;%WP::V)/61X+N*^K9^Y<V:>3BP2TZ=A=(Z@-.;DZ0"<LI$GC;0D;D@
M2R"2<!")>QU&DZ[Z$ZR];M62)W4279ZTZTU9DDU"Z#1R^8,,T='VZ=X;7<U0
MQ*W,Z0V'5,6G[DX*"<_,6Y/>!A,*^A@`R[<&CJ8NG>/KJU_EE#5'/86RL6R^
MP$W3R^KX1+$I<0I6K8[1]?Q4\Y]:EBI(S%R_9%&N3)P^2?G92<X#Y)#D`4X[
MY4?2%*.?<9#]<*EK*HXTT:O]3M'GP2O"4L29Y#-[MVYLQ0,0V%I&V)(^^+X\
M]MB%":E-2YR/T-SC(\_)P)OSOKMU:M_L<VQI>4P^U%U:2#K8H=QG(&[8W8%O
M=#)*_P![;'M[&-*Z9L\Y>9[-,1&<!(<!4TX5)?E,3",//^<(GT5J)K!8M;]%
M2R=,]E.\SVZ>+*N>R71-LC>$&6NLO<]'KIL>5/<=CU93N#Q>$#S*'!,'!<60
M,*5"G&-,42%.J/*,##+RT+U=:=5NXBX6>/VXUSW4?:Z9NU/N;GL5==H-B!UK
MO6S666Q9PFL`O&8VA5EG-Z>128]6<1*6!Y]TH2B0F@`G2B(":,=ZO-0H-V*4
M-KM%4M\`KVL>L^Q3<$%;:[2L[^2,F^Z7B<)4#D$=MYB7DMZ]`WOAAC6VB3,I
M*M.4=]D2(M%D(5[PC0W6NS=%NJ*2P=3:T=(V`VQ>=>G!LS<TUL-C/H:Q;*NZ
MRY^WPY+:SE,X]4\_$RTFE<$<TB":-RY,XD&&I%P%:K.!A([833_7M'#>^!]4
MJ=B$6-=X>@-BA)6Z>WA2-R/6Z`UC-?R<V2FW&L(G)&'ET^/XGTIU)$E3Y3_1
M/G)0`V<EZY-6U_<#6L(#)-F\DM>ABS9=4W*-D;=4+,2=%8[-0T931>Z5$S/V
M'C4/_:TA=Q/$2:I2BBJY6!J5G(S#DX?(4/Z+I++F]EZ*M"PX]?I0?V+7;740
M'C:_?=LNFI))(;KO=)7BME:06K#:_:VZ1M\+6-:DAF5.ZHI6Y`<GPL(U?H<%
MJD[ZWM<V;7#M[.8[$V8<D--7$?529N%?=DQ84E;T,!IG81R67HX11TCCYLK)
MDDSOAW3$2*P%$D<P1M&W-Y:G"9'C(PU'V`,U5ZT=GSPS7G)]WXG78-*G(RB%
ME?;K;(6CLYNK8KS.F]L;:RI3*2<'/E&A@<EF3N6OPM4FD*4PQ*`%E)E`Q`#,
MJ"U4K66Z.=84WK*Z-M$2.Z>QF`)GV(M5DV/KY$JQ*8G>Z"9.PI*0A;VWQ"G)
M@QMM<")7+$9)"EWF*D]RP,*QUQG`2LV!I*+T'K)_(0CR&;VS.S':CJ[(,D-R
MV-)K7FSDY*-2D+5'\'RR4&KW\].J>5V""RC#LI",XS@L))?OP.F)H"H`TM8%
M8,@5`;D05(,X#C(%`4Q6#@9P'R'&0F8SCZ?3@1LW%?62,T@[ODBW#*T79D#T
MPY6;`J%=&(4C/E2L^R2QY4JV'BDQK@LJ2+%)9.,&),+!F8"$@P&<YP(.?[:&
MQ*Y?X-0#C&^\4G<I0#?30`M-2J.3:!N"*>+B]S:=P<F,04/4L5L,8(^E'^3P
M!`M+!@3;[GX,3Y-!P-T=B9T0+V[W$=K+APW1C.ZZ*;J>HGE(I^X5H]AYBV]F
M$BB[JJ;RUS>H;VEM@3?(4@E7_<DC,7X+$2(7J(L+&=Q%YY_5%>"X@[!GY#3!
MX"I."$/J<W.M7ED.HO&0XP`!S8J.^H<8$'&?(?`L8X%D!)19!11!0?4HDL!1
M8?.<^I98<``'R+.19\!Q_KGSP/TX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!!V3
MB,-[)*3)/_6G2Z1[.*FX(L!S@E4HO74M.Z&%BQCVP(U.!*$7MGQG`<>/Z"X$
MXN!`*YYFZ)^Q31:N$#;'5*%[I'=R?/KBY,Y*B0MJ2&FZSQIO#&7T8\'-A:UR
ML,(5Z8`<_=E!+%G.,$?4)^\!P(,/\:AJWLJJN6GR<2>P8[I%>K&UPXN1,6/R
MD.E5Z:^*WV1*HD)BS)1`9GJ*-R<EQ"YX0X$M,)$FR;D)O`G/P'`<!P'`PJQK
M%A52PB1V-8LA012%1-!^2?W]R^?*-O2B/)2E"&!(0J5GFJ%:@LDHHDHPTTTP
M(`!$(6,9"#FG]!6T_321[I[DLY+;LY8Y*MFKRG"I(1,(9IK1^!A(9JB@SBA-
M,CSK94P*3X>+`E2(L)KPZJ@MA!HVAJ;PY"QC@.`X'/)VDZ*Z_1E[<=D9Q`Q@
MU4LYW4M6\'[%;&9'+Z*.F(4#2Y[MUNL/C4C.84KHB;D<=NE.E2C+=8D--*1`
M`[1@*L\*8]0952_4-9PJFW3F^NE94K?E"30V_J8F\IB%TH'C7>(SV?MT`L9C
MQ!8.[RRQV2WK!M8;36$8<CI?*E]<EN3O*'P`F]M9$P6P:W[95GU0N&L&M!BI
MCG_5-M]8,B'U];FQ&3'/45I'-I*'6Q&?62[ERHEP-6MIDR?%A$*D@UP3!,IN
M$:\L(V=8H`'2OP*%MU>N-P@DC27=K96\OO37IPMS_-&WW5HSSUIB-1;'R,!;
MDX?Y@KE@D($T;_R@Q2PU(_N\"6.+9"+(5MQ(W`D+H4`U8'AU1L'1^UT?FG;/
MLTZ?LC373>2S5CU&H>38`@70.5UNL+@\QO:[ZH3K#E'_`"KD-@%&QFN8>O3_
M`)**-XDQB)+^:?O<@-T2;;S9BE-.FZ9[#L,U?-R-UI=-&[5/4S7N"0UVMJG$
M\KA#M)H5712682*+L,WE%`5K'CI3/W]]<D306^X5H$YN$HFPL\(54]H3K%NT
M71#50C_8,2UKC4"D4&[+G.'2B5:P7GM??E?-T'C1.M>\E"Q/,'7HY)(L/SQ(
MIFZ+$6')6DR!M1J\MKMA5D)H`T4O_0EINZQNN^SIK.X,PTVZL^LW6/83PRI]
M:(E9;M(SGYU>6>=OAQM@L<>"L<#UB-C1N;<03D2A*!1DD]*6B"<&E%]RG;[7
M&JM@+7UBL;5^?NXGA8*H;M9DB:>PIR1'.<;->T`#B271O;9(UFG#1&J$R!<:
MWJLA,)"`S]8;_,JBOC;827B9&DPK505XXU0DF&53A]X37SM)&N7N$:"BPLPU
M93*9&RI563<I\J,#*P'!F`9R'(5K['=5*"_K[L6T46R-@UQ6&P;]K))-I*+:
M8+6TD;KF<=2I*AD=4)VNPY*RJYM6+2>)J2$.Y#68/*L!'R)QI#C3S#0GHWZ^
M1!NV+G^S)+K)3)Q8M*5O1+NT'*V\450Q.L)A:,V8G!I1`;"W(A^6NMM.(%9I
MJLXDPDE/@!18@#$8$:8%URU?7R+KJ0M4YGRL'6XW2]IJPQP%'ACG:"8TA(Z+
M78L#"=E3A&J2L$@RL*,;L(@_>$X]@9*%D&`R"3Z'0:3UEO%5ZB9R0#/O/9#O
M9,X4GM[(N,B*Y[J>I:E<&9@2'I@I')F-::F3J/1:$T>35IP!"$7@&,!N,>NK
M(+;))MEB1NP9"CUU7ZZ@AX4J'\!ED7V4V64*1_=^GY(+L6N;`I<%8%\'PBR+
MQ[8QG@1JJSK9KJIJ"TCU\8[&G3C&](+Q*O*'OCLFCHWV</!35=#=ACE7V;8D
M;DK5DRZ%1ONC)*._[$D/M^HP60S>X-"*QN&`;ZP-SE<YC>.P-E3,EHR2,KF]
M&_19*@HZ)44W!AQIZ!0E`6G8(D!4,"LM1@]0K/`/R2((`AGZ+5")(MNV'<($
MFD8YFQ:K+-4"XJ(#7B+*8DKLUAM#$F,R%'AV+D93JQX3>`G_`&HDQN?)?N'`
MN!R)ZW:BZ/5=LL;#&685XIWQZ\>WR*J($L9HPWM=T3S4S8O86D(7(C-B2TV5
M$5G!*%_V86DQ][+3I75HRW(BT_PXRI"(.J%\T387JNM[J]%8SXG3[RV>ZV:^
M.@6)M,/KM6Z4[4%0":65-E4$M\2$I*B)78,4"*'DU:87]`EA%D-I`UG(#NHH
MW&_?;J-0?JZBUHQ61C.@&R)R4=KN%H_OM*_C/$YI796-?^//2%E!(/))),,$
M(91>`!`^,=,U21&U]?MAFNZ+J<[^IFU$4]EDWE\ZGDMB-Q1O#M:KLZPN45`Z
MSL==-BTY9:QZQ`_$(S71M=6],L`(P63RS@PS?#KZW6MY#O:WZT7AK[^RMVH%
M"T,HK^^*YL)7*8G(ZZ@#;!D;!7%GPJQ&]D8(Q,TK*6H,-=8P[FM+DL4GA`J)
M$%.6$QM*=^X]N%--EZB65%/*1NW4"8PRO[Y@4QD-9S%L:I7.(\ME#.7#IC6D
MSE*&4,@FA%[Y5*$[8:$9GPC(`H*4DD!OK9U!L$YU6K2:S1;7J96>)[9C$[%L
MZYS9HJL]E)/&:Z'JUL`BLSD`'M-D!0T6,(1DY,QGW$#QC/`HKVNA'86A9]=C
MMGJ+ZQ&&IGCL$Z\D\M==<'N^%]II3!;>5*G8QMXII5,-9%P<OIR4!YYRU+DA
M$,\(`'"&$.0WIN@"FGR]-XT=N-6%D@2:Z4`S4#GX'M1E)=J&@>S&5M,A"8U"
M+2I%)$!=).E+ROP8WY'@./&5)A.,!)W:-P"9T^6,<:'(S'O2)N:DXB/'PE.$
MHK!I9F]4;D0LY_')'!T+-/R'.1_;@'Z^1>/(6CX\^,>?'GQCSX_IY_U\>?KX
M\\#_`'@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'.7V]TY;MP=A?50?0^S!%#S"M
M)=)9%8,&6S&T:Y*V'J!XN379?)JM)DM>)%*1X3+$<#685MCGG",9IR,`\X&I
M*]@Z-.!`BTXD%Q[)--)B%X0)#8SJSO,U"93L*\N3PFD<ZTM$8J0YPERWA3,Z
MAG*^XR)0%1Y4E8+*&#Y1E!/?@.!6E(2\%=Q%0G9QD.5O6IL61@6<_0[+=M#J
MX;@!>,_3V("Y9R+Q_H/'G_3@66\!P'`<!P*EJHCLB[!MA6_:.R$<DC6J>JUN
M2UKTUJIQ3/D757';,)"\US.]K;BBSRE1KCV>)RDMU:*O:5))&$Y2=3(S@&F+
MFG*(+:>`X#@.!\;@WH'=`N:G5"C<VMS1J6]R;7!,2M0."!:2-,L0KD:D!B=6
MC5IS!%FE&!$`P`LA%C.,YQP.7G83KXJ#6C=[4Q\O]T:E_6+^\%T=JQED#0M(
M0:_;`NRIH===ZGM"R8_(HI($%"P><LZC-..#X>\LL+<GY;%1I4R9P85:0+^I
M_ISK'9='2O6^4TS"14Q,G]_F#I"&5J+C:!%.9+,E]C.<_C:A@RW+8K/<6&Y'
MOQ#PW&)G!,\&95E&@._7P*]J;MC9K139R+:G;CVG)=A-;KZ.9HII?N!,FV-L
MTF8[`;$B@HO6#9%W861N0OUNREK3C61^6KCTG[P&DRF+(,=C#R\!=#P*PML.
MK:FM@9\QW]63IG7G9N*SF*VFCL2+QQMD=<V=8=>X.-KAYV8HQP/;H5?F8"O-
M^Y9%Z\222L*D(3VIV0G``/`5M2O<N:Z*;"7+L_W"PTM@M"*4TLJ71B6Z[1:Q
MIQJI8<17&-4HL"+P5S7_`)9?5>T-]V4U,J1T;)L:UE"9V)J3M3BL3)W%4<$G
MX['+;U\<=,-/(78&$>U^YMR3O<[?.ZXTRL+DXFPNNTD<F%]JFI&\IWM$R1V6
M35\@]0Q4TPDX;5$#0A2CPI0@.`&^P]DS+%8%V#;%V7#UI&LFG5XYH>`/4%;E
M;_8]Q2J&-L&B]IB:65<XM[,LRFV`F9T+:"RCDY9JUG5#/.P'.,@"PE/:,"4V
M0=3H9*VAM-+`F^SU\$R;\C\WP1U?5T8;Y(M*)P:F);UDA:U2,H63?[IR8WTP
M+!8LX#-TJM*N3DK$2E.L2*"PFIU24XM0G/*%]0F$GE"&4:6+'],ASG&>!]'`
M<!P/A1I5"<UQ,/6FJP+%WW24HP`0!;T_V2--]D3G`LY,*^=,,[SGQGV.SCQ]
M//`^[@.`X#@<48ZY>H[V);Z;,(*)&T0:W.S[0VH&O9@ZPF-Q=G&34OOEJQ'K
M.HDZ#(FMN7QILF:AS;GM&8I.6C6)HSD030^3"2@[7.`X#@.!6'II$-GHSNSV
M?N5T5M%(G3$QLZ@Y%K)-XQ!:GCRBRXMBJEC7-5TJF,)1(+"GLFCK^@(1FBE@
M3CVTGXBD1QA`Q^H;OWQ'6F*!6EVS4FT-U0U1*XT4IA>H6;C#<.5H3E)Z!V3B
MHB:P*PP1Q`<3X79(7_;^#`8/+&#.?`<XE^MFK[(MUT5UMHEVVT_-P;]Z'JV^
MR=GG_:U]I5L;2-P::;U2B7J[,V8M"#IT3VC$(EK3N+::O"X*"!@)(,\&EA9S
MMDQU,Y[,[;XLZ3.$??4U.:QNE)IT9BHM/)+C44AV8,#7&'4"9O7%*F\V%*7U
M;@!YB,D2E*5_>P,("S0W1L`9]WTLOJKQ\61:*0AP]//MXR16$97?#Y_3]!?'
MZ^?'T\^?'^G`MGX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X%*6S&L]+;3]N%%1
M:](2W3ENJC2I;?E4*EGLG>:SMRL=RJ.DK+-82])\@<F!U<SFE(C<\IS"PN+6
M4)&HP8G-,+R%UO`KRLYZ="^T;3Y@PV+,LBC3;>-S&]"$=^."ZE6GI,02U@#@
MK[?#@8C^0WZF>^2@9\!\8%G`6&\!P(=/,':#^P&N+(,=$1C\V:>W1"DS)E.C
M&XIFI[NBAWQ8[@59>"UZ=&K5L))`B\-YQ1PRL9RH*$7@LX)B\!P'`<"%EU+4
M.S$JL#3B.R>\JWQ'XW5\\MFY*M3LK7&3HT]SDTQYUO(LD2Y0_P`8LBPH/'5`
MG@MJ3)'ICC#TD7D+4AR]`,P)GDE%IR2B"L9P426`HO`AC,%@LL.``P(PP0S!
MYP$/UR+.<Y_KG/G@?IP'`<!P'`P>S*T@%RU[,ZHM2(L<]K>PXXZQ&;0R2H2G
M)BDD;>TAB%T:G)&;CU,(4IC<X\XR$98O`P"",(18"K9HG]G]7\CC5:W:[O=I
M=<[XZ,D.J79N1NZEYL+3%2L);6**U1M4].7RK9C1#@[>J*.V>J4"7,9IY#=*
M!&%Y)>QA9G;U057L/5TLJ"XH:P635EA-`6N41-]*$J:'INR>G<$9P#DQI*I(
MM0+TI"M$M2FE*D:LDI0G-+.++,"%#T,IS8;HQ<[$E4!4[3[Z=9DC22"2XHQ@
MRVVULWIM-#W)YE3G(H6F?S6Z47;3$K,5#)<B\.Y3JPJ,A7&I5P!+EN`LYZ^>
MR;5/LOIPFW=9IV6YJ&T"-+8]62/[-HMFGY$JP>']MV/#BUBM0T*!GHSP)5A(
MU#8XX(,$D4G!`/(0FC,H9$+$BL@@L_B\?FT*EC4L8Y/$I6SM\@C<A9G`H1"Y
MJ>F5U3JFYS;U9(LA,).+&`6/ZXX%1B?J:5ZUSYQNCK:OIVUSGJJ$(:Z_Q;?;
M7)=KM;OV"T.JN1-\$AT<FLZ:+:HV-#D*P2DU+#):V,XA@*R-K.R03\85Z.[1
MM%K72VA>HFU>I%H-^OE!;!QV_P#:[;'7`T[;BNKB-J=5,[Q32.35S%8<UWW&
M5MN[;*6:32!,IAK@E;40#L%KU0O<X@-FQ3>37VT6'O(WSI'8&.SC$:IZ)T95
M["TJE3#-F-JH'7*02YC>!P!\+BE@-I\DV"V!D;<C/4IB#59S5DM,9G)>`A"8
MD5J1[I6]>F#5QJ>),V-.ONJVPCM+F^.R%X11&4&T]2E#4(G!+VE#E*EDV<R&
MXA.*(QR(P44K*$<'U4"!C(1:O_8?9%@ZW=\;59KLF37-8KVJ.]65Y.8P[Y'(
MX/3J#L7J2D5T$9CG!K.RC1H(N:[M`DV2%`,$*!X*R(`@9P$KY;:U\#WO[+*O
MC$SF1C!!NM/7BQZ9B2-3\S1&+;EK[N0U+Y+&TYY8T*&3OJF$LY8\CSC)_P"/
M)SD.0@\X#0-5;$W@\-W\:Y<[VU-UN-FZJ>ENP1BEX-QFYI)CK:DMFI5-@%!`
M7^<5ESQL,>@Y&'``N!6#?H+`>!XUV7YL`T=?_=#-H?<4NB]I55N7<,#JV?D*
MRCW>KXTF2:])&)%&Q&ICBD[>P,,D.&26``C`?,/US@WZX"P1NGMJ']M<DJLR
M>.>:49.N2"3TNM!&%X9S+4DNRUAQQ3/"R@H_F$YAB<1*0&",4>N"A`P67YR:
M+@5@4)>NV,FT^Z&)&_759:F<WUN^X,]_R8+FF>7NTJV)K#<RPRHI,S,ISR%D
M67)8(TY/"$`/L2490@9*&0#(0D#?^T=_P*A>\Z:1FRW=NEFKUKLR.D7`Q$QN
M)=91D[3G5*Q#D3$A7M:EN4E&2"9O+ED"LI2/*I<9]?\`8$(3A!:]A![0UM'#
ME"X55"T';;71PG"=N_'8L(O89VB#C*/N_L\.@5PXX:E28+$H^WR#'G!>!X$+
M@<8?7E:>SME/>CQ<QVAB4PTVV$[IE-L2.NGFM'M+L2COX]?=MOM,<DLO//=8
M:^5J;==*&K18:5!RPC[U&M6C1%J2F\(=26RNT%[PG57LGF$7L!2R3NI=OH)2
M5124EGCRK-?1NPDNH;2CP2B4M*A&\$-2BX'%<;E24H5"R>,`1X$$KT"7C#;5
MC.G93:5'8D0S*AA.D-&6@*)C;VDL*.R[(O78*,"D)#IA#A]5Y<8I6($QA&5(
MDA'VH!!*P8:(8@@S1NX=_2W5?INE+]8WO9>W&QC?"KD>W.+Q@A1.(<S4GM!9
M<H:"V8+4D+80N2FK6WX5C8F3FD?&7C(@%&F>P8I;ML[7RW8??R;L>U]L4-5F
MCM\:?US7U71RM:-=*FMUHG=?4-9EF-LXD4\J^2V"]/4L7VNH9,C99$T":"AI
M,@*R=Y$:%^_`@KNC,[_2R#5VFM>;.BU*R782XY7"Y!:LBK1/;:^*QJ%41;%P
M&DQ>&.<EC#`<]O[E7R9$)6O,5$)$AIV0IC#1%C+"/,TZ_-P+F'!X_?\`V4/]
MA59&+7J"W7V`1G4ZD*Y62I]I"THC;L*:_P!YH%CV\L+(9*X4CROPG`-2I(P(
ML!Q01"QD-0371B<PRS[`O/;'><J]U\P:8REU]A+Q3U84NZCMVIZ-W&;6B,_?
MQ`\Q).VDN!7I*G<I`G;DSO@Y!E0<L-2H_A$&TK66$G=&:D\8Q!RZ=<L)2(L&
MX$(P]R?*-CJ!G2YR'WP`Y8YK22L#%G``#'@0Q!#C(L!;[C_X>/\`TS_I_P"G
MT\XX#@.`X#@.`X#@.`X#@.`X#@.`X&F_\[P'_D'_`,9/>0_Y1_PW_G?)?[8>
ML1/$!_>V*_P/]YY28CF9#F1><?B\'Y6X38^?)>"LX%D-R<!P*U'9&K4=PT`7
MED>$+3UJ6^C5*1FDX^17(=HJ/.;R""0F"4&?"3%U(CA""``/D+P'(\B'@`65
M\"#=D)S%G8IJ9@]6I"C:M5MV'5(@(^$)!SN=8NEK3A8N$,H9QH$S6O4`*``8
M,8&=D0O/C'@)R<!P*C[TLF#4?V@-]VV8\@CU>UAU*[4V!.Y!^/7N8V&&5]L5
MKO)I,Z_8-*5<[.`4C2`TW!"8DT\S)7J``Q"QC@6*T/>M4[-5!`KZHZ6D3RI;
M/8P22"R],V/;,0_,IBE0C"M+:Y&VL[XBQE2D,!Z*4I)F,A_V^/&<AMO@.!`_
M=W9^7U"BKFAM?4+/*-R=I'9X@^OD>>TXG&*P9.TMV7"?[$VXA2*TSD53%',)
MF'!QP3G!SRZG-S(G$!4YE&`#:>I.JT&U$J4NN(HZ/4RDTAD#I8ER6_,<I%%C
M7M<\I*18G%OV0YHR$Y+A*Y0<@)!@(`A3H&],F0I@EI4I!8`D[P'`<!P'`<!P
M/&D<<C\PC[[$I8QM$GBTH9W./26-R!N1O##(&!Z1'-SPR/32X$J$#HTNK>I,
M(4)SRQE'$F"`,.0YSC@5,)JSO#JTCW_[N,0G6TNA3&<>H5ZPMRQ3)MD]4H^>
MX&N3JOUH=WA2H=;]J!F)4'F`KMV49E#26$)4?<5J<*=B*"RJE+QJ;8NN6*V:
M3G3)84!D03PH'UE-.")*O1&Y3.S`_-*XE&]Q:5Q]<`:5S:'-,D=&M86-.K()
M/+&6$("W'UB-94WN.^=$KOE?7]LK>3&N16I,JNB,-FU36\_Y)<Q,DUMJB9F@
M.BKU/XZX.ZH])(V<]C?O=6H^X5*0'#!D(BUQO9N_UNP.>LG<O#EUMP*#-:9=
M5N\>F],S6Q8?.F!G:W3#NW;%0>*EJ9#3]F*C&](<2X"8T$/5#7&%"7DB3^YH
M6L::[QZM[_U"FO#4ZV6.UH'E<!F>36\I<V/T0DOXY"ZJ(I-(R\)4+Y&)&C0N
M))@TRH@'N48$PH1A0P&""67`A;LGUSZ*[?\`W)^R.JE*VH]*2#D^9D\PMM;[
M$2@.^WR(;99,?`T3YH4EC2%"+.2N1)I0R@B`((@XS@(ZYZD*N8+'9[5J?:_L
M#I^7QZ'2JOV(UKVNE-Q-C/#)@]1V1N\;:VO:9IOXAJ9S7V)MJG)*3)`31HB?
MF^3!8,!#1,BZ<+?4UL71T6[1MID=(CMK%Z.L)GE2ZH6(^2.TL7TCV<%(I!8N
M:8C$Q<2E5VIA/"A-D\)9H!828]$@?@R&<%=<.[*.SKDN)O[178$^O6&P.L9T
MY+M,:'6(4]:5:HLY=`(_&&Q.[("6MW:U]P/IBQR5"7B7X/)`(DO"<OP&"P?J
M?VU@8=4TS7V9'*VS2R`.D!U^;'#2>BC"8TE7561321Q<CR'].L=%:&"EC+$(
M!B<XY0/(LFA)&>G/##Y-T][C2ZDMAZ/>^TXY8P[3V2[VG<[J+1^G$SD^29Y2
MP!`KRTEMD\;TC`D&@KI"2()(,BSCV'@6#1"&(-OD]<^_)5X3+8S':D65;4@J
M2.4BRO:;1FF@M;37T9ETBGJ%"[L2N=+4;ZX#E,I6&#4I\M@\IL@*_J#Y,AKF
MONI/<"N(%JA6S/V5L2F,:9S-1/J:"OT>@!SD5)%=?6C62D^2K<W%Z.Z848N!
MZP$L!:?(%(B#?;.2<8$'ZV1U1[N6A76S562+M`C_`.T]NI0&1W8%/H;6A3J[
M%F5E"*E7MK(N*N`HID`LB5;LP<'?"<84H(.,#]3\^@;66]?6^"C8?_DZE[+X
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MZD1^2C$N`A*)+&6$0@T'&>L7L%:6'1N/N>[6J*]+H5-TTWJQ67I%80':1K`5
M18--+T$Q7?\`,`!(VYVB%E+Q&EMQ"`05A28P(L!*R`8>[N16%JZ[Z+;@NMG6
MY#+3O?;7;'7YYK\R&4X_0>$--J368:LT'3D%::]!8MA2V0-R%PK5M7.:D3SE
M6J*&I'C!02\9X%C3U7&[JDP.6#:RBF@G`,>0..H$D>SA&^V/;.32=JV8O!7K
MC.`AP7[8SGSD6<?3@0QNUOV*J'9?KJGFQVQ%;6/6BG:V2UR2EA>L[W5ZICL"
MV-7MA(-6Y[C+,W;9Y25E?94ZDLP25"(L!S@Y(P_=`'Z@."XW@5;]M4DJVJ==
MXELE8A\F<I+K993C.J*K"'EIE4COV^+"I6XM=Z_HAJ;Q(7%S7JK"-NI06'"`
MH2LCX/G\")).#D-$7G)\1K^/T@E*A&!:<@Z\*+7%-HUQ3::N<3:PKP*!O2+%
M9`B0.:QP-+*2!-"`)BD18!9!@61!"[E.88:G(-.)$F--)*,-3C$$8B#!@"(9
M(A@SD`Q%"SD.<X^F<X^G`_;@.`X#@.`X#@.`X#@.`X#@.`X'XX*'A0,[)Y@B
MQ$EE!39`3\18PC-&8>`>"L*,F'A&$(L"'D&,%A]0XSD6<A^W`<"!Y.?3LY<L
M9_\`\G0]DR#Q^K_\2V"D'R^W^A?_`/L`>O\`3W^O]?3Z!/#@0?L$\M1V*:M(
M4V?=8W:F;G.KF`.0!$G:EUH:7-Z(XWV&$9A1[D3D`0AP+P(.<Y\8QYX$X.`X
M%-VXL6G)>W5PVRMJ!GNVK()T_P"S47;ZE0DM,EE=US*;VI$9!+*M7P!P<B#)
M&R.\8K5L2("<%E$+53LJ2F&Y&,H(0W'TX%5P#J]TE.J1BE$8KYRHZ//;!'YD
MH3*)"T9?U;B]NR)5]F(:5*D)?'!3A&F+$,*1%\1&!"^/VR%EW`C_`+.;)UQJ
M?4#]<%E#>5B%"L:(W$X9$FI1(K!M*QY6O*9(%5=:11"$;A*I_.Y$J)1-Z,D/
MK@0Q'GC)2DGGE!J_5*I;:P5G8O;)J@1&U]B1LQH=V&#D('F-4'7*U[$_M5#0
M6<JT&)/(4;<!.W&2EPRJ"V2&3(!N"1&D3_;D@":'`<!P'`<!P'`<!P'`K?MW
M162,=KRK9[1:SV75W8J>J"%URLS[#E4^UNV>4($A*1J5WK4S;(HFN33QK((^
M%)-(RXL\D`0:,I:8YIL%I@!Y!O80]Z\A:67L3I5WU@^?/V1VQT+7K[ATJ<59
M0BB/OW.Y&QE:I11J5Q.-#DL%C,$:1@,,P20XKL@$;D+%HU)HI/HPSRR'2&/3
M6&2IJ3.S!)8T[-LCC$D8W,C!R-S9WEK4+&IX:G!,9@11Q!AA)I8O(<YQG@5)
M77TP4L^K+!E>G%Z[(=:MBV@K4.L_=M,+$50&NIX_JS_E52694HH`JKXZ3F`S
MD&'=F(8WCUP$.58B\"+$&H8+"^]O2>HYC#&V0:]=M+J9)'=;64]M>?J-4[CB
MT?'AG2LS!,6=)")%7]AMY*-`I4#4"D+8Z!7K,A&H4$!!DL,Q9NVN[Z;KB5.>
M_?6/N;2-FP_.1%LVLU?/.[-:V`UDLP5QC]%[3J%J!%HF-0N3*P";9&H;QHR2
MRS#50@F9R`/7J/\`D$=5MFP67S>5;'MNN"B#N`&]_KW:-M-I:UA"-0DKRE3!
M7;Z<?(I@B-":(H)C04N\GDF%^/8'`D[37;!UJ7^QN,CJO>#6Y\:6E>G;'$UX
MLZ/0=4E7*D_W2=.-KGBJ,NHLFD8SG&0DB#YQG'GSC.,!FEQ]CV@6OK>@<KGW
M-UHKQ.ZC-+:B7^Y8(6Y.HDZA(E59:V=,]J79Q+1&KR?N!$D#"G"/`S,A#C(L
M!]UB]ANAM1QV'2VS]RM8X'&;"2HET%?91=U=M#;+4+BW)G="OCZI7("RW1"J
M:UA*@!Q61%")-`+V\"#G(?:^[^:-Q>N(C<$FW`UICM63TQ`5"K"?KLKMGB,H
M,=$IBYO`R/KA(4[>O&J1%"-#@L>?[8<BSXQCSP/\/W]T;34[C80_<#6H%&"<
M#6D%M8NJO!U^8ZD.Q#$>V%2@$@$TFN!+PI+3C("9DT)@PXR''G'`^N([VZ53
MVHWN_8?MEKL_TC&G!<TR*VD-PP,5>,3HV9287-[O+3'TMD;E9'WY&<EFG`$+
M!Y><8S@P'D,PA^U^K=A0626A`MDJ$FM:PU/]W,+!B=P5](83$DWV.'/)\HE+
M3(5;''R@MN?N,Y5GDXP3^O/Z?KP/TKC:G6*XV>62&H]C**M%@@1(5,X?:\MJ
M!31FAR8:,UP"IE#I'']Q0L*?*$@9WR*C"@?&6(7GP$6<!RDZWO*^6[+;/636
MVX-`W712;M(K0VP*JB<7:W6;5:9+^T-BF&O$C07[&E2Z.2^`2QCE<Z7J&]6>
M4J0J#D^"0J$P`&D!UHUOL)0=R+Y&UU#=]0VHYPX99<N;JXLJ&3A=%C#<8$4"
M1)(R].9[*(S&?TX4A*\_Z<#\*]V-UZMR1.T0JB]Z9LZ6,"-0XOL7KVT(1-)$
MRMZ5:G;52YV9(V^.3DVHTSBK*3F&G%```\T`,YP(6,9#&YOM[JI6S3,'R>;)
M47%&VOQN1$U->;4A*4^-+6A.O5.+6[(1/65Z9Y3$M:G/V62ONQ"(&$)>1!SC
M@56-5IPSL1W"H"QYY-F*H-2=:+#(G.K%06D^1F"7!NGM`XQZ0LL)NY74TK7M
MUG0RJJFC;DM6P-J<6Y"^2ET7_FS4I*!"@^["X227W1<-EJ*`2^Z*FBL[<U3:
MA;H5)+&A['+7!:\Y)PT(T4;<WA*\JU3KE07A,662(9^1A],"]L>0C7OQ#J-O
M*F)#0-A7W75&68K,AUL4M,9+*8@@E%9VY5\S;YO3-P,\9D3RU*'Q#$+-B:0X
MXC`BB7).0I1"-`$T><!I+3OM4I*^)#*]:[5FU2PW>VG2"&JS*+@]E1&6,]H.
M),;0/Y-A:NO!,B5&696TV0+`*D"(PPJ2,(C?L7M&D4E>YH;PARNS=C*FL2:;
M6437]!1((E$HHR$6B;')_9E7-:&$NB,VT[J6MKL[5S$)T6:\JS26MA7JA,3:
M`8%#J:H4'$I`J@U_=2.RFFM*=2J`=D=E=?NJ#+K$MVPVS!&)-!X)L_8.L#)#
M7V"ZZ:\Q*9-"-]D4256E"VA[G3P<46VMK8D"QIU"E>H5X2!TD\!P'`<!P'`<
M!P'`<!P'`<!P'`<!P'`<""K*/)?9E9)><^H56BE(C#C/_P"TRWW_`+!!'DO.
M?KCX,.0??QX\_('SY\8\!.K@5Q2=L7A[=*2>0(5/XPWKDVA:E3E@D>4?WY6S
M&H:QO0"49Q\8564QBHP(,9]A`P+.?H''@+'>`X'/SV$;(Q"C-WK=B$[V7H:@
MU5T=3TIB5*';-RIU;*036KF\Y.QK'V>($RA*F0,JA/+FHE2<4:4K<$R8PO&#
M`I/7`6*=8LNE4NT.UC%8$@I.0V+&JKC<*G9^O$OA4WJ1$_1!)A@+01)]KU]D
M<3,0%-*!,+!:14(LO(\AP$OQZ!"<;HZ-S(W+7=W7)6UK;4QRQ>O6G%IDB1*0
M#)AQZ@\T02RRRP8\YSG/`K0J:F+$V=VJ0;M;"-I#)5U,I75FZ^:;3NBY2%$R
M3I@-13';RV&A8B;3&^Y+3BCL%FCK$K3@606,Y5DGX"Z.[@6F"S[@.`X#@.`X
M#@.`X#@.`X'X*DJ9:F4(EJ<A6C5D&I5:1446H3*DR@L11Z=00:$91Q!Q0\A&
M`6,A$'.<9QG&>!6?+.LF$0^2/UF:+VI,]`K4DKJC>Y433;8SR37BQG!(>6,8
MK.U7EF1U0YGK2,&%'ND=+BTD&$X><.F,YX'CAOSLUH#."K^T]@6V\-2@-,4V
MGH;.T,;GQ2)-E0#"MYU@V2D<7-&O5`"2/*>.SV0F^PC,`*SZA#D/8CO<%H(H
MD(H5:MPKM4K!`M-;Q0/<V!3C5)\4*BUI;>$+*XW:PQ"(RLE0K-P`HUG<W`HW
MZY"+.,9S@+(&&0,,I:&^01A[:)&PNR4E<U/;"Y(W=H<T2@L)J=6WN3><H1+$
MIY0\"`86,0!!SC.,YQG@>#-JVKJRVPUDL:`PJ?LQ^"PG-$VBS%*FPX)0Q&%8
M-0/J!>D,P4,8A!\@SZYSG./Z\"+$PZT.N>P/@_>VA>F\I$FR(2<U[UHII><3
MD>5`AX+/.AHC@A$-48+./;Q[&"%_7.<\#6A/3?U/D'&'D]<>EX##$Q"4>,:[
M5A\>2DQR<\K."<QS)(3_`)4H,B-P'!IGC.!"S@0O(?TEZ<NJ!$H)5)NN/2TL
MY/\`+\8LZYU::#^Z828+Y238T,D_U$0'T]PB],><!\8$+&0Q0GI"ZA2EXUQ?
M77J<-3@Y><,HVIXXI1A&ZF$*%`<M9Y!K<`H`B`_;%_#@"0&1!(P6$8\"#^E?
M2!U#K585IW73J>`X"8I+@"2I8XWI,E$J1*@"$@0)TR$:D1HLX&<(O)QA?@L0
MLEXP'@?A(>CCJ$DZPU<Z==VK1*@X@2<>&.LVF+)_C'DG.1`11C\0C+/Q\`<!
M-"7@T.,BQ@6,"%Y#Y#^BSJ`4*`J1]>>LY8L`(+$0E@A*)`;A,$021*6Q&I(;
ME1@?;.<C,*$,0L^<YSGZ\#^#.BGJ!&6I*!U\ZY)2U@,%*@M\1.;/G)^,1>2#
M,MS@E$).+`O81?GT$,(1YQD80BP'+4Q4EU<@VED.B+?JU#EEII>V!/&'J&.5
M43))2[1JZ/8,5;X;D,L(D+`@F<V=X\\-*`DI8>_(F3"$\],2C5GJRS@ZB%O0
MYU`+$"UN+T(H]E)<"!IE:B)I)+#'0Q.9\WL2%[B4B9'@DO.3LYQ@!X?`@@SC
MZE@R$,-8/X\G3A%#$Q\6TJCL:6)DBA!^1CUL;`,CHK1*U!:L](Z.C7;"5P>$
MPE))8\`5&'!`(L'KC'H#P'S@_CL]-"=R97M!I)%6E_C[^GE#7(V>S[V:9*G?
MDBC*Q,YBD:"TD[V<K3KO!Y8QJ!"+/`$P.<##@6`V9-.E/K^FJP$A40FZF*Q4
MCFE>F>X(]MKM4FM]@>$@DN"G5FL1PN-SD*5QPE2!3X.$:88!/_;!D&,!]0UZ
M;T']>CC,7BS9.W;*SBW78R#F@N2<;A;+2>UV<RMU^'*%"8YRY66:]MXH^L#@
M286#!")\?HR'@?!-?X_G7)9<LE4ZLQ@V(LR83J-MT3F4DLG;78RP7N2L;&O1
M.\;0.;I,K%>UXDD:>D6%:).686F`<89@91A8Q%\#][$Z">O2UFI+&Y\V;#/\
M10O+7(D$/-VANY+'&Z0,Y0@(7MN1H9>F.;W0HTTP[YB30#^4T8L9QY\<#]WO
MH_Z]FQ`X2BR679&\F"'1U:O:8)>NW6R=X0!I`S(#U0CD=<6=:+]!WTX0$I7J
MD>$B]MR-.5Y(P'`O8+)M5'&./&L&N+S#S7X^)O-$5&\1E1*FV*L\I4,+I`6!
M>TJ9,TP5`U0EMD2A"H`-<0SI4[64J$,*4L!&`!P&^^`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.!`I$?Z]H$F3X+-#\^A<'.$:,(<%&?:;"6"`L"86!Y&(PK[T6
M3L"#C`<"*\9SYSX">O`KIG>'</:_K*-+ER&S&Z%;DENP"S%66DE45?&E8VI0
MI)`+"0*X7R'@*&9C(_3(PA\8R+R%BW`<"LI1`G%\[=)))7V(A=(`/K0CD*+>
M'`EA<6-:\N^S\M=I!&%K<L/-=L&&-;6WJ/HF$B4%^<&#^0HL/`^VS.K+6AV?
M,V9K<D>-%M@499IC3=6H86FJ3G)7E2%>6GM>JFUOS35[QU0X%@$J0RUA<Q&$
M^X"#TPA_)@(@4T3M+V13Q_K'8UWIA]TIU"O\ABE%G4Z4]IV/LEM2ITS2]MK6
MM@KTH=D58TY1]K9*Q+VU,]2-))9Q&QMI)X&E(M(4!?/P'`<!P'`<!P'`<!P'
M`<!P'`<!P,5F<%A-C,"N*6%#HK.XNX8R%?&YG'FB4,"W&2S"<X5L[VD7-RG&
M23A@_66+](\X_IG/`K0DO2OU\*G]5,JFJ^:ZF3E3GSF7Z7W3;NJBLO\`3ZY#
M^W*9F45@2DO/^[(%#0<#(LYSX\YSY#'A=9VRD-"F*H_N&[#(>D"J4'*D%PAU
MFV=(&0>4'&$Z-SMB@U,J3^BG`C,"/<E6`X%D``@!@.`AE16I'9:U)U*5F[;W
M!W`$I#AL5V)HOKM(',D]*G)*48=5$&<ZO1.B-P.",PP!29(H#D6,`/#@.?8/
M?BM,]L+!*5;B_P"^&HD_BYJ9:G21QTT"G$:/2G&'EC1.`G>.;I`4GGIDY60"
M*SC!0\FBS_[0\#/C(/V9G8SG&RNE",0G$)?J3IU=2D);/Z#P-0')^Z8!"=_?
MUS@&?[&,>?.<\#4JVC>W(<K?7MGWMTM9V=R$66F81]?UCN80@2(UR!(O/7F[
MN)5X5XP'D&FE_*8G^5-C`,!+&8$0>SBI^W!&<Y*"=UM)'H/XL>&AO<M#K5:D
MV7DWR1[.*INW:5JPMR4GP>#XO8P9_P"@6/CX!16';NC0"):]Q-$79<4VIA%*
MY#HQ<Z3*MX"C!E44JPR;N$D)FLUPR,(!EE".`1@.<A$/SC@?DCA_<CE`6G<-
M@>MD"[)7QG.2+4_9@S`#,!P'[DE"HW"+*&(60^WQB'@.,B\><XQP,K9X=VM$
MB-&][#:!+,"Q@!1*'4;8)*$K]98LG"-,W--&<+(,##Z>`X^N,^WT\9"I%+I[
MO4Y[=QZO55R]5M@/-:7@R[C6%!DZ;:Z&7PWQA]V,?+6C$^9H0"W9^Q0%/))D
MYO>3R2BQMCTI8D2)8J4$^!H@NIE*'L3(+>CH3)M+W([-FV,KCS;*X1=[*5BF
MS&AO!4C"[O+//GT>+*2OH51DC=24(FQ0E&4!&WDC"(8@U&J,[C!X291).M!,
M(Y+@:\*IPVD78;UGSGXRG2#*;&_+PERF"4+YAA0C]S!!^+P7@1@?`-/W0&)\
MC+=^L%(KSD(<)QQW:QQ3@QD80C-RLQ*&LPW(2\Y%@OX`>PL8#[XQGW"'WU$3
MW&?Y,B`[Z<>M#%.`=O\`\O4U1,NTF;,4L>4ZCZQ!;,GX,61.P57Q9\+4Z@G)
M>!X\XSG&<!(&.*MX\((:9+F'5$QT#!K9.L%)');;Q*`^RRGP[%%MT-<'.%'J
M$L&<(W@L4L6KDQR]&N$(+>E4E!P(0:_6/_9O]N>)!4^B.%6`"$F(6;![`B3B
M'CZA(/5$ZR!,``6?IDT)(LX_K\>?Z<##%D@[>1?!EOJ7K?)^5*2-3A;L-LX?
ME`M%C/SD$93ZQ)\.J4K.,>IHOLQ#\_4L/CSD-?S=9W7N;$X-3!6/5RIR\(%K
M0IPZ7AM<G"C*<$:I,->$2>@AY6!(R8'RGQ\(AX\^#0\"?6N-8N5):\T-3+RZ
MHGYWJ.F*NK%U?&Q.>C;GER@4'8XJN=6](J&:I2HG%4TB.*+,$(P!8\!%G.<9
MSP-S\!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"LV'."%V[A;_19RF.7PKKKU<(
M),39]#T@)YL3M2L=$3KC!AGW(S`0IO.2^0E9(`,WZ#P;C(0LRX$$9`X"5=F]
M1M($IH`,>B>P[BI6F9'@A1F57_K"E1I4N,%9`(Y'^SSQG^1XS@)Y7@/USG@3
MNX#@5LH'IR_\P$ICPU0QL_\`XV8"]$(LED8`F<O^3]DH5:H!N"ON1#7)?@`(
M.3/3&$X<X#YSG/`]'8"S<[/SNRM`J0E,S8GQ'$T)>UMY5\N&Q"U\A$W0$&H*
M\BL[+1N92'9BRHVY`6M3>20(YCC8CG=2>A/.9<+PFY659P"F:\A=3U7$F6!U
MO74::(?"(='48$+)&XTQ(RD#4U-Z8.<Y"2E2DAQD0LB,,%Y&,0AB$+(9SP'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/*2JEICLZI#@(\(DI+:8B&2-2)8
M,2D"K*K[P!A`$Q8`C)#\7QF#SG'M[8#]/(>KP'`<!P(51O3DF*;UV3N@P6U8
M;0V6K2L&K><42D=U:JN9;/(0ZOY;5;3ZG>E3L8C>&2$K4;.V-[,%I;R,X6K%
M!:I4M$8`)J\!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<"B5\
MVCJ&A>Z7:I1<$N>XTB,Z[]0VV.MY%=V3*'![PSW=M&^R=?&FZ$Q.2K)$R1PJ
M6MV'!<27DE$J7!(&+W"9@(3/0]J^@;BR%2%/L$A+:C41CCDU?7ULM:HA"2`9
MIRE:V.<"2.B`L@DL0S/G)+R`O&1"\!^O`A`1V/=?D@[%X%<S5M!!28F;IS9-
M.N,O?SY-%H01,'"]J:D\/BI;S*6!ECXY0_HL.QQ1)2DQ080@,R(``EXR(+,W
M??[0^/JC43_NOJ0QK4^#!'HWC9"G&Q41@D18#LG)ULR(.*P4,T.!>V,>N18Q
MG^N.!A:OM$ZTT`<#5]A&DQ`1>?`A[34AX\!\8$+/K-\^H,9%C&<Y^GG.,?ZX
MX%<-N[4D6-NZ&4=>+K7VRUVW]HNEJ;7^TX>_IIYKM7N(KLO*"+DM>V[!B*IU
MB8(A2V7AM6FM!9YKS('<"=F1%A,6''$!;IJ7JY7^H%*,%.P-2\2%26M<Y;8]
MERU3^3L2ZK;E9P7&P[DLY_,]E,@GL^?<C5+#S!9`07\21.$I(F3DEA)7@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!B;.$2>1OS>6I5#1(VF,_:(CS1F
MD(\#_-%&&$#-R,X9BG"</R"$(619+QP,LX#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.!^?Q%?+\_QE_-\?Q?-Z!^7XO;W^/Y/'O\
M?O\`7QY\>?KP/TX$`E$^<3^T9!5.9:Y&LB301WL%17^%CC^$(='#8EBCJ.8*
M6W[T3.>Z*DK6<C(/RF"I**(-#@T0#,A`$R7.NZ[>#SCGF"PMT4K2SR%!KG&&
M-<>K)/&0<I).&J0FF'EG&)"AF!%G.!9+#G/^W'@,97T%1+J`PMTI6I7(LY&>
MW&EKZXARP!K>I.3*%*$P*AF,"-&H/1$C&5GR`8R@9SC.0AS@(C5%,VYE[%+[
MUKA*=!$ZUJK335^>-M<1AN;V&&,\KL^XMI4+U(&^/M*%$W(75W9H,VD*#`8]
MCBTI6,XQZ><A8GP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#S",>'=
MQS]ZH-\H6O\`[`:4DM*DQ@USQ]P0L"E+/4G+<_0PL9QH2L$@R$)?N+(P]/@.
M`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@10D&].GL3M-=24JV,JN,6
MLWV;!*7.@\BDZ1D>E%LV9%DDV@U=MA;G]JG>9;((JXI5Q:)&8><42K3_`"X+
MR>3@82OX%9%^]P6A&M3_`&5$K1M*7D2ZH)PC@-B1.+4E=<UD<>=%%52.[UCS
MAJC$`<U+Q"6&J(@Z/;D_(,*FA"C0G9-4!&#(>!MO7_L/U5V>N%^H>F9K)))9
M<8IJL;^?FA?6EC1AN;:KN6*PV9UG(#I')HNTQX2F6,$X2&$(`J1.`1D+"S"0
M#1J,%A-S@.`X#@.`X%8]VZ,[!V%NBIV\JG=Y]H+!&LJ779BKYBH"HY^03]Q8
M:BP)!)Y!))XG<5[\F5+4Z#"%`$I-EO.)/$6HR6J4$F!"F_\`I<V,VAO?7/8:
M\^Q;$ZG6K!LR-JD(=6RH2U&FS$@DL2Z7(:OV"@A2Y\CZQ$E7-S@TX9%B=>E+
M,R,18"R0!FVH75YN+HHS7.&BMR*"E<QO^WGBWK,G=X:NWO8LH=5[DF4X;XX4
M^N^]B]X''8RL5'C0X4GJ%F?OE(E*A0:,(\!E&H,-VN9^UW;=TV5N;7>S%Z'1
M[4EI3)Z4I.=5(NPU.]R[0N<0&]IYA:=G@P:PN+;)P&B)7J@KT[DASC[,:0XM
M0%V'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/D`@1E+E+D6G*`O6)
M4:)4J"'&#CTK>:N.1$&#_J(M,:Y'B!C_`$R:+_KP/KX#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X')[OG'=>XAV.2&6V8DZT9BZ3:[]0$F:]L3L1O
M:&;11A^)L'7A>SSQET^98)*8P984M>H+$1K`LQR`B0QB*-070S*?*H8@ZPN!
MR4]NDRL91#9P_6:JH)P(F^QN\FLM1/&M[&.SK.F[)/>MG8^D-0Z0L]#'2'V:
M'WG(MCIG,8\%"F2&`;E(\$@$E`)4(P+.>L6K--8J]UU,*]G4/<-W577+H[7V
MS$-B\X2NCA^R(-63(EK*72R$`.5*(^ZFE'&HDJO.4XE3<60$98_0LS@7.\!P
M'`<!P'`<!P'`K8K;R1VV[<E8QGPNT-T:6BR+'C/LFN_>9'C!7]/8OU_KGZ_J
M_P!>!9/P'`<#\A8/^8K(1E83X+.P<6(H8CAFY$3\`RCL'!`66`.#,##D`LCR
M(.<"#ZYP(/UX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@><602%V5J0E*L*#6
MYN(-/$>(2,9*=2Z&$%$I<J!!*5%#4F9-,P4#)@!EXR,?IC``^Q0=A.0<?DLT
M[!!1AV2DY>33S<%@$/XR2@_J--'Z^`AQ]19SC'`_7'U^O_\`'@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X',]LQ'^V*?[FR^8-.N>ODYT\A>X%.1E!
M$YWK9#9?;JBJJ_>-.GXBYX):.;-8)8Y">76=31U1KDK4K-B2VN@DB`+YP9)#
MIAX''QV:Z=4QUV613UZLENJRT&W'?CIWN]+(A+&9H(+K[,`362_WY(3YDW-Q
MC@IJ>/%OIDA5F+AM:6.(@"`8I/"8/Y@MAZI(CI0F:JRE]9KX,+=Y5H9J01LL
MV,;SD<Y(K^40=KE%5G6!'"C,%-N,$!-"RC/**7_ALI\&^Q.4XLA=-P'`<!P'
M`<!P'`<#73=4M=--JRN[V^*H$UK3>$0RN)3-`FK1N;M!Z]>)C((='#"C51B!
M.A9'F?O"@&222S##%HOE$/`"\`#8O`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P,?*2*PRIP7Y3I`H3H^T)"U82O"XU6E<7PXY.<?\`)GV2$$JP"+!Z
M8]1F#SYSY\8#(.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!1EN?L
MKVE4QO!2E;Z\(-9K8ULN>?UU'U+.JHZ[Y':U6!Q)*O0V;'[+LR$V?FN:])=*
MW>I),HX_R!I;T2DID.:@$J5@DN5(7F\#FT_D<FJD5-0EP1&F)E(M9^U!G^Y)
M'Z&B3.77K;ZI<ASG&?/P+$+29DS']!!+]?/UQC(70:@0N"IJ+H^T&F(15%/Y
M_KC0"*7SY#'&E%,9@U,%<M(XTADTD(1$O;VA8@NBC[(E4<8!)@\S!80>XO(2
MKX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&/@
M=1BE)['\J;)9<?2.N",9(^\P,YQ6HQ&B#][E3]L(*?&`YRF"#WQGP8+/D(0R
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@<N$[NOJ7H/MBN?73;&
MA"+'VQV=V&H_8:I+;/K*$;%+FAQ05Q7-:5M'0KJS2/\`<-)_XSEE;K5Z1&_-
MI0493J:Y`4_CS_8L.H_@<X'\CDH!]$U^07Y-6&4AVC#^V*S[GY;DO5SM4N5J
M\$`\F83)5R5($TWQZ%_*$(LXR8'R%R6CC\VO&GNJ):=T;5CD5K%K^H<4B-6F
M-4)!K:BAB\O*A*4:,U*$].M*-!@>,>2S0"QYP+&<A*W@.`X#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@8G@HS$Z&?]PD^(43**PE^
MOWV#"W@X>5&?KZY29"9@./IYP/'`RS@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@<V=A$[RUEV]+EE0P#9RO-4K)M"J%]O6/$=+]+[@B5PN;BAKMC
M.C2.UXH*#7[5U2-;$E7YD<MEJN3.[<KP>!"D()`088'29P.?;NF98_(=J.E:
M.S!L;9!!YEO#-J_L"*OR8I=&)=`I?1<L32B-2QK4A,0OL8=$2/`5K>J+-1K"
ML9`<`8/.,AN_K4T69JCM:1;ZQB?)7QHW/TLT6C;G`CXT@+,A+M1=+,,09W.&
M2Q*<$P<.F$0PA,4-PTX!`6I0&?*:7\):<+FN`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!A8_.+#3_`/;F>!PM7_W>/'Q>2GQ#
M_P!N+^QY^3.#O8/]W^GG]/\`K@,TX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#
M@.`X#@.`X#@.!0'W7>$^Q'2.X&9_M%=GL60&!QZX'C\I45C%8-P(P19>`$X*
MSD6!"#C/T^N,><X"S;KN5`7:`Z/JRPB"!1J+KB:#`\AR+`!T_#\A]L@$(&<Y
MQ_TSG'_3.<?7@3&X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X&)F@*_?*`SX3_`)LQ-V!A1A,#*?!07AE%DD2SYL&%GY&+`@E8
M+S@8<9%D6,AQC(99P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M"%NYNB=1;Q-M-IK/DMJ0IZH*U4]T55,Z?F"6%R^+6$BC3_%D+RG<UC&_IC<(
MF^1GF%EC(R'YPEBSYP'(1!''2WKEDFF&W>P]E16TETIUDLK7[4^I*;JN22.:
M.TEIE?K=7**IG8D`'->KBKLBG\;CC0X+'4HLAR4.!`BSB\`+":>%L'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`\LS*+#TD")
M.ERXB:W#)"H1B7"T"("MLPJ3DE"%]Z-*:>82(P0`Y*",`,#S@0@>0]3@.`X#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!_(Q8``0Q>?4`1"%ZA$,7@.
M,YSX`#`ABSXQ_3&,YS_IP.7J@.X?8C=77>CTZ.Q=5M&K0ON:;5*I;>-BC/S'
M:-I'7&T([4Q!<!@5O/C:RV7L7.9)*T@D:9V6$,32A)5*UB%2(H"$X-?2+<_>
MV"[)J$-;[_U'MFEK6DW&8/M=UC&Z*G,%OF$UX^IR3+L4QVKBGFS:S?FK$K2L
M=IL,=7B5M`CVR71Q&]-?Y*,-H=,6NMX1'9>AJ=V#@63?V;=%;Q"R8Z6>,LT]
M,V2YD1O)*(\\C_MU!Z'*K)(S2LB)-$7D18A`R$60W-P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#P%"5$*4-*T91N7$I@D*5,?@
MQ'@@M$H<8P:M*,)&<%>,TX],GR`118R0X`+!H@"$5@8>_P`!P'`<!P'`<!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`Y3:'TNV)KZM4$_P!F-:K604&;M%N2
M[V/J-KW;%B0B;UW!+BL^/3"KMK4S!1UUNQVQLG;$;$M#)&(E8%U2H7\9C`SB
M4-YB)Q#147DUS0799ZK/1&A]P=?W&RZ$5JZXJ1<9;\M<\U3-')(VQW8&YW^]
MGF65+1&QUBR-@$5'T#Z,M)6\.*7NL@;WR3+FV*HPZE-.:&5:NZIZ\:[N,C',
M':FJ@@E?ODL,R+.9-(8\P(D4@?P?(0F-P2[O0#SR\#+`/`#,>V/;SP))\!P'
M`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`\%4\A321F
M8<I?<3LT2!R"L^3QE/\`A54?(RG^+XL^^%?YKV]O</K\/CU%[>0A[W`<!P'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`J@O?>/9_6U^I^$V?3&F[=-=A;
M*65%1#8X;FVY'1VA89RI<?'8NV)PZ0R5&R.3PP%$'9$O7E)0+#L)0GB,&3\@
M?,Y;']PY2Y4F;.L#6=4D3FY)*<3NR,91"_'C&<*TI.=0PJRDV?/CU.++-\XS
M^GQXSD/"SL7W8#4*R0=8^H1)20(!EJCNQ]Z-(=?9(:I$2WA*U""I(-`<5A/G
M*HLD'S&!SC.2L#,"'O&[@]I"5S+1'].ZE<A`K2%+'EB[`-;E2,2,XPD*I6TI
MGQDC3FM&C*-$+!2DA#DS)8L8%C]&1AHNU^T7?NDVEE=[9ZKX#3B*7R4J(0=P
MNWM*T]K-JEDM=E(T\5@C0N<$R_#A8DA`E4*2VM*%03A*5@059AF3"R@SI)V)
M[_K+>!1&>J/+1:1M1*;K*C3[O?0819AJ65E0H?RKHY&9.A3N)D@4%EEA&/!!
M@,B$$W.2S`A#/%.V7:V`)PDG41$E&23"@8`=V,5`F$J"8#V$<D]:@4@R41G'
MJ/YLD#]LX]`CQYS@,5%N#W%',PW--TSU\E7`",S$><NS:H_S1V`*,D8(+&WT
M8LCH5!I?@X/LXX+P5]!"P9^C@8VCW4[I`+P#=NDF("9L?J."Q]F5"K'SU'DL
MLLM.G=*X9FPP\LP[W,]U)9?Q%&>HLC^,(P]H_L*[(&5U);9)T>;'C`L9'1S1
MK8/MEII-$H5K>I))*;7-2;9<=0M8E1)N3`^QXU`_I@@@_P`&9+#"'#NHF=<,
MZM[V'ZF^S6FVTN8Q*`M[PFKFF;#8':6SZ2MD(@K`A<V"ZTAZIQETY?6]I0Y3
MISTIJM<3Y/P#(A!#,C>Z6)-AH@2?KD[=8ZG1'*DCZ\%Z(3*91QD6H4A"E67E
M^KF13%"_H`C4@**7M.7!O/%GW+.$5@0PAC+CWW:TLP<!>=2^T1H7#P4H):G/
MKUOM$X'M0RU!ASZ2$]F`F$TH\%`P:/)N#/)X/4`L8,R6'H@_D!]>@#ER)T)V
M^8G5`J&F,9G?0[<`MT&7GT$E5X3HZ<6A(3KRS,#)">(H[(?]Q8?.,9#Z(_\`
MR#NK9Y&X_E+?MJ"IFM,>I5N-AZF[5Q)K#A.K*1&IPN+A3?VHEF%)N0_#[8,\
MEC\X_3P/L_\`SA/J!RM&V$[<&*W(HP\D]M0:_;1.#@F.2A&)24J1(:34*DIJ
M<)0\C"8`(@X`+.<?I%X#"B?Y*W2FH6-J(K=)'@;HI)(3*5-&;*(&TLHU8)`)
MR5NKA3J5N1LZ546()ZPTT*<CT'\@PX`+P&]&SO4Z?7<Q86E[$=82A(<@P=ES
ML)(R%C]Q9"'[,UY)0%..,9Q]?M\F^N/KGQC@94C[H^I1<8841V.Z;@$4C)7"
MRLORO6XO)*C!F0`+.<'M*2:L#\>?=.`0E!?G'N`/L'R&4%=N/5H>6WFD]BFE
M1H70I,>@"7LM40S3RU;N6Q$Y^$,LR<6++J9@H01A"(&/(Q8P#&18#8QG8MU\
MD@`8;O9IL468+(2QF;/4D`!@L8\Y"`0IOC`A8Q_7&.!F</W/T\L),YK(#M?K
M5.$C(I3(WE5#[UJ^2IFE6L`8:D2N1[+*5I2%0J+)&(L!N0B'@`LAQGQGP'N*
M=I]848C`J]CJ&2B)QY-"IM^OB!%8SC&<9,P;(0Y!C.,XS]?'TSP/&.W+U`3&
M`)4;6:VD&F>OH4=>=8%&#]Q>@/0`Y0$0O<>/&/&/KGZ<#(5.SNM:/(,*]A:.
M2Y,]O3"FV8$1D?KX]O3!K^'V]?;'GQ_3SP,?.W)U"38R)1M5K<1@(_C%DZ\J
MQ*Q@S]7Z,Y'*`XP/].?I_7Z9X'@*]]-&F_(PK]S]3T0BQ8"9A7L54";(!"SX
M"$>#I@#(19SGZ8SP/"4]CO7FB]_O-\=,DN2P^YF%&T-(DY`#QG/L+!DX#D(?
M`<_7_P!.!X*CM%ZTDH@`/["-)0"&#)@`_P#*:D!9R#&<8R+]$X%]/.<?_AX&
M,*NW;JM1A")3V.Z0%!&+(0YSL_36?(@X\YQ^F8"S],9X'@J.YOJ82X'DWL>T
MQ%Z#],_;["UHLSG/GQY!A)(#\F`\X_W!\A\?Z\#-$7:SUB.(<#2=ANE!F,IF
MU7X%L[3)`@D.[6H>F\1@#YD4,H2AK2&'>@L8&$(?`L8SG&,AL%A[`M#924L.
MC.[.I$@*;C!E.!C+L?3KF!"8`U02(*L2.9'83?W4AN,>_C`OC%X\XQG@;/8-
MEM<I66@-BU_TG)"G4DY0UFL%JP5X+<DZ;&<J#T`VY^4A6$D8#GW$7D00^/KG
M'`VD7)(Z<0%44_,IJ48L!`I+=$(R!BR'WP$)P3\EB%D&?/C&?Z?7@$TDCJU4
M)"C?V56M`6,T2-,Z(3U02BA%A,,$G*/&;@LL1H,"SG'C&18\_P!<<#[3')O)
MP+)R]$5@(<B%DQ40#`0XQYR(61#QX#C'^O`\LZ711/D.%$GCQ&18SD.#GIM*
MR+&,^,Y#@:D.<XQG@8GB?5\Y36.M2"4LKH^*&.4J49+4[M"\HM`D4QH#D)9E
M.M,4$"R<I38*\!R$?ZO.<9QC&0V04<2H!\A!I1Q>!C+]RC`&`]RAB+,![`R+
M'N68'(18_KC.,XS]>!^O`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*
M\]WKUTOK:R=+*IVPK0RQ9E?.Q$?8]61CI5?::6)7O%7*/N3!*29(E9W$FKWA
MD,<BEI3IDY,:!$D6'>V4Z54(`6$&^?B,]3,$B^,?@W.`BP5GUSX,R$6<!S@&
M?KXS]/IP.,I)VV]@NN[#5YRC:&A=Y6NQK]O2KV^[9#6%,4U04@A-8M%9/S38
ML6FSA=&LBQ&RJ2K+6-(L%)I2D7O\0<B6YQ6E&I_(=(F@6W\NW$A-JRB35VPQ
MANKRV5M>0VR*^>YO):=OR+E1*)RA/9M2OUAUO5DE<HZ0MDI[(L'AM4(,.[4J
MPC7KD^`'Y"O/OYH^W;RBG7(AJUSIU$FK7LLUVN"8I+3LJKJS<7-HA'[@P01!
MUEJO;"TRMW"8ZC^1C0F*'1Q]B@DICPA,#@)DDE_>]R[D:'."OVWUCLA9V,X]
MLK_WMM3(!)LASCQ\6&G_`!^;[>WM\GWN/7U]!>P6<<!P'`<"F3OB6#3Z)1],
M80-:TNFZ?7\WR%I*PLP>]LF=RJ76GM*=0VIU+JD/5JD1/J:D`)3CU\%XSG/C
M(;'Z0"F4KJ=T:Q'OORV4RED:EO1N;J-Z6M)*N0OZK+`8Y&C,..+CQAPD)03!
M"-)*3A+'G(P9SP+5.`X#.//TS]<9^F<9_P!>!_(0`#D0@@"'(\^1Y"'&,BS]
M?J+.,>19^O\`KP//$RLX@8+$TM@B\$C3X+$@2Y!@@P8S#"<!R5ZX),,,$(0?
MZ9R+.<X\YSP-<.%!T4[*BUSI2U2N2THDI.4L<*YAZQ4600$X))):A0S&&@))
M"H,P$.,XP'`Q>,?7/D/)5:RZW+BE9*W7RD%A+@2E3KRE540-04M(0J<K41*L
MLU@&%22C6"R:4$>!8+-S[!Q@7UX&M7KK_P!#Y(H.5R'2C4I\5*,^RA4[ZY4\
MXJ3Q?:FH?8X]7#C33<X1G#*QD6<^"Q9#CZ<#%GCK'ZW9!DP3UU_Z5.8S$J="
M(Q9JY2)QOV:3TPF3!-%"/D`2G"6$(`ASC`0AQC'TQXX'@NO4_P!7SVO+<W7K
MLTB6+BDP$99QFKE*A]$I?MZ$A**A99.`@]L^/T^<<#Y%74CU9K4`FQ1URZ0Y
M1#R#(BRM7J83F>2S0GA\*4\-*5!Q\@<9SC`\8SCZ9\X^G`\@GITZGR/'Q];V
MDF?`L#QDS6BI#Q8%CQG'ZCHJ8+Q]/Z?TX'OI^IOJY2^_P=<VCH/D\>_G5>D1
M^?'GQ_\`4A(_'^[/]/'`_P`>>IKJX?PI`NO7-HZIPAP;A-Z:L4DD^/!^"@F^
MV4<)3Y-]L$A_W^WCQ]/'G/`]-NZL^LUH;5S.V]>NDZ-L<PY`X(RM7:4P4K`+
M)><A/]H4(0P^Q(,^//TR'&?ZXQP/J*ZP.M8A2G6%=?.D@521.%(F/_XKT:(T
MH@`4@``"(4&SGR6!"5@(L_J#@&/&?Z^0_)PZNNM1U3B2N'7WI6J3C6?D!%#U
M?I7`!+?*O/W&?2%!SDSRN-__`%\_^G@*2MB:KUXIKMPI35V&]>ND\>UUF&E>
MPUJ&,3KIKK$)9L1=M>,+Y)6F&U].5<3$KC0HDS-Q*APR^JXZQCQ[ARI-&(/J
M%36KUKK+3UVZ6++DVOW6=)&W;3L&F-(;;6/']&]>TD9C46*D+`FK?6=:V-U.
M"<(_9\O;7!>G0N+&UF(L*R4/W3N41D]4<'MV#?$-6=3?;/LK*]=>O6#;"ZR=
MB#UK_1J%]TAUR5KZ;A2.X*VAJ6`R..N%5OT%G-F((:Z2-;\J95(Q8+4?*(WW
M`$`0NHWPT3ZZ7*HNOJS(3H_J2L;9]N5J+]T?$-:*CC!EBP&QD+NI<(NX(D$,
M8?R#-.$ZA,'\:M`!,:HR0$TO'K@.`K.ZJ]/=:=P[MJ]DW<ZXM78)9;_I]LU,
MYQ5)NFQ>M3HSEM6SM,QVJW%\KM9!ZY0'2QA@DA5H,2IC:RDJ_)IP"%AV2C/4
M+\DW0)TVI2<IRNONB,E9RA%ZGHI,JS[-YXE!`O=5(SAX$8,7@_/GRJ+Q@L[Y
M"\8#@/"'_'DZ9,@P`C0^MFX7I@H1[++;;8E9I6/?.2E"UFL-"K4%"$/V$$P8
M@B&$`LXR(`,A#T7G^/QTWOYB0UST.JH8T29.D)RD>[*;,&$)2P%%!6A:YRC"
MXCR$'D8U&#1FBR(0\B$(6<AYH/X\'2V6:4=C0"H<C*^;TP8[V0:7GYROA'\A
M)LX&2=Z@^H/<(OC%^H'J+Z\#R$O\<;I21#R:ET,@)1F<8#[_`.0;O&+&,9P+
M'KD=GBR'/G&,^<>,_3@9VCZ'>K)GC*R'QC7.2PF/+%"I;^.@VRFU,.3I'!9@
M_*AQ;R8[=K>2B6FFJ,F#&`./D-``0\"R6#U#7QO\=[JT58%^0K._7,9F,!.,
M<-V]SCQJ`!\>`'X_SP$`P8#C`?'K_3@;`!T4=;8$>$/^.[\&06F^S3?-O-O,
M<)$E"5@DI.B^78P84Q!`,?VP!Q@`/],<##3_`./?U?*DR9.LK6^U@DP,@`J4
M[M;GC5CSDX\T1AAH;Z!C)@L'8!G.,8\EE@Q_[<<#&W'^.!U,N27*8RF;D*&)
M;E8)67N+MZ<JSY]_*;.5UW+"/MLX'_\`V_D^G^_SY\A%+:GJ]Z@^K*MV[:L=
M+;A@4GVG5U4(LT7N3M*V3H3W;<V;(<PF_='[%P\H30W.+@48;@2SY,X+#@(1
MF9QP-N:>ZC:/;Y1*Y)M7D[[2XHSTULQ=.M+X&?\`8IN<RK)+)JC=FYND;DRH
MVO8Q[`.%`7N(T:#)^4R[&$YH3RPB#C.0C=8VN_6*U;-[*:RK+#[A2)OJ1KJ_
M;$6,ZQ/;_="1UU(&"'QB%V7*H+!92[6X^*)):Z.#SQB.$SE?:@/(>BP$&Y5!
MSDH-&5E977+5>OVH%Y5;M)WLQBL.Q&XG"KJ<84-Q3Z2O6;%CSREA)I\NQ(#)
M)EB2.JC(SD64+FO`ZI4JA0E)-`E-R4%WR[J<RO4#.%V7]M24DP>1Y1(=QP)4
M^,Y`6'&`&EUM]^6#`P9'ZA.P'V'G'CUP$(0@!V6Z+RO4O3.P[VKGLC[8U4YC
M$SH"-HE[[O!*%+>F06;L/555R!R5,J6+HVE2-NCDT5'%EA(#@1I8<YQG/GR$
M\O\`Q+.8_JI[3.W=4+^F!?\`+.((?`/]0>C32;<7GSGS^K(<F8\_07TQX#^O
M_$6WC_\`QGLF[=5.,?[,?\Z).B],_P"N?+5%$`C?;_H9D>,>/IC'U\A\R;J)
M_$/A,@C/9UV],2HAN4H@(5FZI\^8C5*H)H#'14P6M7L]:#UH"S,8+#\(2"<A
MP(!81_JX&V:RT'N.L&M8T(^T/L%F2=<<G-,5V4OU,GKPF"E)R040W/$BU36+
M41(R_&3?U"$</'N/.19SG@1PU.K/:;9>NK<?9/V2[=1.0P#;/;2B$1L0AFE9
M*,V'T?L!-:VA9ZM&\ZEO(#)"KAT<3"7JBC`%G+#C#`%%>`@"&LM3Z@O[>6CH
M]LI4O;]V-1&MYM(;'8XQ'IK4O7R@EB`-;61+*P>1NHHUK>_-RDI<^PU2>C'\
MX3OLS"\FEE&Y&6$)!R'6_:6+6#5=3*NSOL<?5=EMDW-;YW%=;M'7B`0K-?,S
M8X'CMJ>E:?J6F(*I3^2`2S%*\@,=UI9I96?)8_`0G26)$;"HZ]-F89_($W.*
MJ767+XU;"L@:4TZ36G5LP871S8!1N75>OTP9K0B\G>9"VC1M;,<R!4.Z@&"D
M>#<C\\#6DVMN.QFC-9;O5=OO<A)XUMG:[Y2]4G5_K!KXJE;A:3+)G2%'5+)X
M`7I(0[UU/<2F/N2(A,Y%IU*P]M5Y+"(!!@L!:&FZT[C&Z-;BO[;NSMP;TWXL
M:YB'+=4FE*[`3%DY<2%:EDU.;'5&!X-"/(\ISR3DX3,A),!ZAS@,I+ZVGK\G
M]XL[&.S!>@#'/PH&0S86%-Z(+OD0LCF0EC)3S4\FO^0>H<$"4Y:`^,YPB\YS
MP+!*]AP*^@\5A`)-,9GB+,B!ES+;"?SI3.)&-$0$HQYE4A4%$&.SVX#QDQ0=
M@LH&1BSZ``#`0X#,>`X%&?<-K9>5ZW;U)32C:TLJ;.%!=@U:V1.Y5")?'8['
MJQK,MR8`3Z2S]J=\%.LA8UL21K4H`MYY(R_<PLS!P5`4YH7D'&%%$FFGC++)
M++&8<8<(("@%`#D1@S1C_2$L(,9R+.?IC'`XG=1K=W3LMJ>+!ZL.H7K?@E9.
MTLF%:O.U-(S>@[CF5<O*9]<,OCS%%<@M&HC+0>(VA>TS\V,K@8T-1XEA"8T1
M:;R/(=1>@TTV^F-)+RMTZR45_:$/G<@A,?D+F?72&2737K`D:2X]=$N@%4S&
MQ()4TIF"TY86LCS<_NR,@Q)]RG-+3JBDY(?QNUH33^^"+7-%;;U.H^+639NM
M-J8`O@#HTM#DHGU7`>0LC2\*G5C?/:-+A/(A*RTP4ZH62B_C/+SC.<AB3-&%
M2KM;L6:)AMXD+)U[TU%'@'WJD#J4MDNQUZ/,>S^.RC^S4MYZ>+N7]_!_R$&`
M]?CS@WVP%A?`<!P'`I`[]8\[2G4&BF-CGC_5;NX=ANAR1LL^)MR!YE=<N2O8
M",HVR<QAE=A!:GB015R4%+4B55G[<X\D(3/T9SP)3=1LN;9_ULZ?SIIE<SG*
M"95*BE!,NL."0FLYH_#?GEX=%*]_A5<AQ"VE68J5#P$:$9P5A6`J3#CS3C#A
MA8SP'`<!P'`<!P'`<!P'`<!P'`<!P'`YFMLM5+7EW?E`+?:J^FTJJ:<=9%WU
M/([1/FD*PXU#(7%HMEI;F?7*-.CR!>SS-Y,<"?O3G!AD:`TQ\.-P2$`%`R`J
MFTCTIV78-9?X\&'S6)UBP*4[![9DMC027R9N0(HM%)!*OW=&;N>&9^L1O>W.
MS@ML>4+DH&T].B3#+4E?MT_)I)0P_NS%NX6D72%VS6/FOY!J_:"#MFD=B5+.
MYQ'D;A.K+8YSL?4:$RY'\J9$ND#/,=@.!C<E7LC`R-0DK7@XA-DP0U!@7R=G
M$IFA%<]-13?)6[[R=]G6C3-*E+00B<V>0C55]9<A2KT&4:1*D4,S9+F=$\`P
M0%*4>2C"'&0%BR'@11ZN]4[ZTE[!-?M>MF;J!L)=#+U;;12"5V>4]2^0)EY,
MH["8#+F5K1O$[S^YUJ=L;).`K/S@*`4:`8"@Y!C`Q!U"\!P'`<#Y#C<@5HRO
MNTI.#<*/*0T&,J5F2P!%C*4?W!>083^?8S^V9Y#G'^W^N0^O@.`X#@.!1KW^
M,K,_ZF:]-KU;":H"!=A>ERI$]',4LDZJ0/"&S\+&B*,\>AS'('%W>UB\@"M*
M4<2!)@U%@9I@?0/D/+Z&OMU<([-Y`CF*&9(95W);[OJ!<D6IUAQ"+,JB;60!
M8$G"0Q(:K_%Y/`68B0>Y1@32RQD&%'FA7I*X.U'=T_=ZB%?2*'.=E]6TCPEQ
M#I<T22=0E+FF]?HZ^RJ00!Y?HA#(DZ5R!K2*6(QT6MV7-.]9$<Y%E%^Z8(%5
MCK[.W3K5Z0$L$:-@+80Z>;^VM.'%EA<&J5HG,[B,"OY4B5)#8E&ME6V789CH
MZ\+!#5191-E9322J/<"2TX0YR'>]P*B.\?&3>OA^;SA"_%O.S^@S&_D8%DLI
M;'W?>K75"ZH51X?4Y.F5)CLA$86,LP/TR$8<\"W?@.`X#@42ZZ[D55I5J#,+
MBN)LFSJDN'MLW"I0E%`F9N>%R6Q[;W^NZOXP<L1NSTPI6F-(_P`648N-$H,-
M+Q[9++-&,!60WQT?D2\CK-H?]_L4@C4U433:%;)6:61(,%DZ1T7;:7FK,R_1
M(M"VDL;HH+."8:062`G`A^2_)>0BR$AKM4C'N7IJW?D@(?BC>RKXE2?\MG"J
M,.JE#"XPWBPNU11(3"]K6YN`[!,$L4*"B8(,>%W@1JDK&0Y.-))7*6?J5[M%
M+Z\:'6ZE@,?-LDJ>ZC2(^<S*06.I%8%C26X-B[%GZ1>]V;,&18E:Y.T97'.!
MWA(I;2BBE18T98;"M-I8)]J!T1@Q,HIN)/Y7:UY7D_2)WU'O;;<V^8W(I@&6
MW;:J&E!55%K"C4O-LN7-"PYX<7N%I(X8K.*PJ7H1X,X';#P'`<!P'`<#\S@Y
M&2:`("S,C+&'!9W_`-$>1!SC`#?`19^,6<^!?3/T_P!.!S*Q>#=\$0K&2T95
MNFG6SJ5"9UF=%S>6ZDR!5%94TOTX5+6UWM:FVUPD;!$F:S,L`TZM$N?FI:`M
MV3%&J"32L83@"X'KS3;IM%%N$2WA;&<N>P6>OT-K26!F+)-+`LJDF1"S%0.>
MW6XQ-"WPT-P.N3%1+R-I*3HUIB8*S"9(-0-.6$[>!`2#2!,K[/MEXV44>2I9
M]'=,UZHP[!>"5N'6\=W@IQHLX&(W(4848@G>P0XP(P'CS]>!/O@.`X#@4V]X
MZ]\9-2Z7DL78DLFE$6[#.NR01I@7O2:.-[R_H=NZK"TM#A(5H#4+$A=UIP$I
MRTX!A24!V31!S@'`G?I/:ZR\M3:`MIR'3XG6<ULP/+P7K^^&R:EDCSDD:5X;
MZU?SBB1.\5;7-,:G3GXP(L>"LY`(8/48@E'P'`<!P'`<!P'`<#\<IRLJ`J_`
MOG"0)/@7R&^GQ#,`8+&2??X<B]P8_5D/MC'TQGQG..!^W`<!P'`<!P'`YC]D
M9LQI/Y-VNK5)UT:QF)]1UZ/E=GN+0QKE,2F[G/IXL?G]4N^Z"Y(BCX!'%Q6!
M+1I$V$N5)1(L?='B$'/UHH[8;]*/XRK2I$)$&7]REORPM#A%A*1)<LUK.S"1
M)4WQ8.(&G9SWW",.?F\AR9D`,#P7D00N`ZO-+ZV[)]%>X/6O8B5V.5%[?[F-
ME5DZ=H4],[2]%&5I8%-3]J3QH;DP/#0S)GATCP2E_HB]C23S,EY+,R$P(6E]
MJ&6*OY%TRP1D:Q(65/VOZW1J/)DQPAE-#5':&V)0MZ#`E)AJHXH*$("<9R,0
M\X#^K(LY^H5=?Q\I+L!:FP9UB[?/UJSN]FK7#9YLC4NN5V=%<W9(&Z[\/\!D
ML#-2K5(AE,3++Z$)+2DJ`>[>J(6)R`DIP@P8'7?P'`<!P,4>35@)+#BR,$Y2
M''O@%V1I!G'!P%H--3Y(5!4%@1_W@>!>P#/DQGUQZY^O`RO@.`X#@.!2/WC@
M1J:VZ]&L4/9YD^O/;GH2U0Q-(5\K:F!EERV<OY+3(GAQB*Y$M(1MN!&8R$[!
MZ<X1N"_A&8(O(0_;H@E<NG^KFQ$^FS2W)WJ6=@VZ"LF3(83"H(;8#*TVHHC;
M-*W-KA30QEK',I&RX:CE3BG"Z#$V>IN1@`4,00AVOU"WD-VD[R=A9H@3OVK%
MG]7]H5;K&=8-OIWJ`)GQQI"K\S>+(Z?;W@ET@3:?(*_>E#JZ&#;PK3!D#]5(
M1>Q8564,IB!^EO\`%ODS)`X"VLDL[/9X)!%S6!I2MJ8,IM*S$*&3'(0JD[6;
M.6/*1,J`H3%E$!>"BQ)4Q?H01@.^/@4V][87I3H6WM##CYEK_N1U^,N&[(DY
M1;N)7NO18T;8:I4>`)"SG0A.+)OL#UR#'G.`Y%P+DN`X#@.!R:VXU1-[ZQ=3
M03=\,:P+^^EQ>'!:)@=I$JFLE3=JNPRW+8YE,Q8STR^4EI!)\+3O5,2=DOYL
MX!G.>!;CTB?DL]7>K)CQ8O\`EMS4(+75++*_?CY9V9D:KO6SU.'L<[DA9#S(
MS5`#<8&<:64$`PY+++++```0DY;,=&JVPUBE(8K*7/#+!-BVD,N04Y4\KA$,
M->V2#J`#GEQR81=M540^!9\IT3=%AA2R4\.0.F<%(R,\#B0TN?&^O>DWO(=H
MG,M0#GDV0L$9CJBK:V-.-D\^FLZD06+_`/(5P@$9(>8)94QFX6NESE#>X"2$
M8+3G*#26X!)`6&[27D*24+T@OHES1;/^9SILW29DVFWQN.B6YZ?R)_4J21LS
MF&"1&AY3<5N,DQ6C:F=L6,X6E@^T,2`CK@0(LY.%H?>#>%N-M91+5ZHD-OQ8
MRZDCN_V%>51W-7]2O,%AL2-)-(@18W=JED]<3K?<O9L-,;&]N()0EG_*Z%!$
M84(.=FLF2ZZ4M^J]AH/8EW%/-53%3:SI4<)VSKR+)[O:DH!FGU1/U=BEJH`Z
MQQ4V_=-RM8KP,HL2P]4$]*+!9A0=]$;?$DGCK!)4'KA#(65K?$7HK;UX/M'9
M"0O3^J]I5N#4M#\*C'@Y,>>G,Q^HLP8,X%D/:X#@.`X#@.`X%:\%_L=O&S(,
M?7[_`*]=-5(\B^F090["[L)P!+Q_[@BPISD6<_TSC'`LHX#@.`X%/'>2@.7Z
M21;"="H<SD6ZN@+GAO2D!5&JRD&XU,J%9(4HU2#"O.403,A*^<@1HL8`$81"
MQP-D=+)<6)ZJ=%B83)W":10FA(R0Q2EUB^84XO2`E0X%%+%<6R_2?+*;G(<A
M^+[]3]`^WO\`J\8"S_@.`X#@.`X#@.`X#@.`X#@.`X#@.!RB[CLFK!O\A-DD
M4XV4=8%:2?K%MYI>J;3T`^R1E<XD76NQRI\LA\M]#*$:=-AA@CBM4$M!#8I/
M5C:/@R:6,XC.`KZU+B>E<,U^_C2,A6Y:ZQ&>(;P[(XI>6QO5VP4C1=-E2"Y&
MY`=`%J&7OK2YU&AC\^E+8G"\N24[*LHL2U.F*"7G&`N[_CSL%5QVC]XRZJV:
MBFT:*0=DFR<UDLOB->3N`)(S)I6@@;@HB+D9/V*/N,M>D[?A.L4N2,HULR8K
MRG3GGA(R:,)#]J2%$IMCI_4N"1.J(1=KE7#+RH+"=@A<9K1M1AL.++%YS\Q3
MB`H8!XQGXQ@"+SCQYX$5>M/29UZ_=]7/7!5=DKV!3MFD<\L<N=2IJ-:W1I17
M!O!8$];8JO3FR*5*18*>7![5EJU"S)CHN/<3\`#G!@0AT3\!P'`<##)`$'[G
M@0Q*3"18=7L!1(!B"!6,<8=A9*-!@`L&!++*$9CSD.,"!C/GSXQD,SX#@.`X
M#@4,]^+0KD%>]9S$23-UJ)U[C]#R'UJ@/Y7+ZX1]&]SEW>1@PQ>'@`&AO;#%
MX#4^<&)CDH#L9#\?L$-E=(5-6Q3]!;4J[PI>0T=9]P]C6Z%W2*-/104C8^)I
M[9!8X]+(.V@&,*&!KXVW)$K:+'@*P",2LO(RE!8Q!+KLT?7>-]=>\KNP-ZYV
M?2=3[[3,K8V,\D?EZ]V<ZSDC6W)$K5#_`!)5!IZM8`.!),A,)\_)[!"`0L!3
M1UZ=54]M#4'HJLJ]7!^UPM;K=;[/D[K2+W54:E:R8JIU*T(6])(?\BN,EQ`7
M@;+$DSAAP1I#'-(H<Q'-HFA00G$0'3SP*\.RM%%'BH:'CLQP6<U2/?;0)L(0
MF`.%AQ=2=M:H>&M+@1)9F"_C5M83\Y,]2Q!)R'.?U8QD+#^`X#@.!R;W(XJV
M'KFUP=2X[$)0UQG^01+$DG12V/1J18%'W?M#V*BBMSB2>4(7)(V2TA5(R,H7
M`@DQ4A_6<#Z!%G@6U]&P*^_\3>D:RK&5]CL&?*H5REG89/,PV'(6@^6S:5R=
M[;WF9EQ*"$OK@F?W=4$PPMI1E`%CXP8&`&#1AN>Z&>M7/>K53$AS30K$/I;:
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M);H<[V%6L*C\*O\`''7(JWB@DMK@G>@_AR$N33!D*O82<T.MEK:VQC;&YD9&
MY`SLS.@1M;0TM:1.WMC6V-Z<M(@;FY`D+*2HD")*2`HDDH`2RRPX"'&,8QC@
M??P'`A*^[>60SNJIL2:`[L2(HE[5,B=Y94FJF&A?E.<I**=TXW?:II<2&-8%
M/@PM0H3$>"S`>X0"SD.`UV^;ZVVS(W9:'K!["W4IE=LLZDAI:M1EBY:=A&H7
M??LB(K;<1[TR_&FR7]V1C)?SC`7CR(>.!J0WM%N[!)AR?IU[2SPD@$:8$40U
M+3F?'CQX^$DW;7YE)N?/_P!,L(C/_3@?E_Y/]@2'R/-;GTY=F3>WOKD0F,>R
MF?5-]3,[;E0G+7.CL3&MGW@:+*),?DT*<T0#5'H(!7L+&?`;)QV0R@W"<23K
M5[-5>%>!?;^:1IYNSD0,FX$!0![V%:QMV?).?&56"0"\ASC.<"#G(0YKC;Z:
M.78);^R,FT`['JZKIVTXI2DFG]U:OGO+VZ3:`7-L#8#^%"@K.86"F,:PQ^PT
M'PG#/`,U1@980>?CR,)9O?:M!6`HT]9I;V?J"D^2ON1-G7_?;F(G!YPTY`L%
MHF$XQ2$PTL6/).#?3&,"'ZA$'(@UO(>Z2KXR)"6Z:)=M&#G--A:@(3==5[*#
MCT65)B/"D8`-W_9_]P7Z_$H^)1C`P"^/T,`(0>6P]YFN#FZY97_5?L\@#CGW
M.)2S#KIV8RI5-A*12K4O2='%H=*%PFU*!&:$>1%!.R(L7J6(.,BX&RT'=9UX
MGMASB\65;L,,2KEC:N:)SJ-MW%7UN6HU9B02=P:72C2E20X\8,"*`+&!C",/
MT\Y\<"N3L0[BNMS8.BXW6%6;%XD\R0[2Z4S)W:5]*;#LK2QP^%;;TQ)IK(IF
M\OE5LK5&XW'8DW+%ZLU6J39&0G$`K(C1@#D)&]>>Z?7KHOHSK+JO<W83H8W6
M)1E7LD%F7[0V0B9L4R])SERLQ2S'3-W:Y)A`O"H^4&529/CVR+!0`E!!C`2O
M4]TG4FEP/)O8YIR+XQ>@OMKZK]9G.<Y]?(,)'H_)H?/_`+@^<>/KY\<#Q%/>
M)U")<F8-[%=5!?&'W%]M:C&LQG'CSX+RD,/P:+Q_[0^<^?\`3@>:1WM=/:AP
M0M978?K1]TXJ4Z5.,V<@(0`-5'A3E96.IZ0MK;2,&#QDPU0<444#R,8@@QD6
M`V.D[A>J5<!08G['=)_1+\_SY/V5J5'Z!3+RFPP?A7*B,C+$L.!@L0?(30"P
M8#(B\^W`WLGWITD5-R9W3[B:LG-2Q.F5I'$O8&IA(5*5:4$Y(H)58EOPF$J2
M1X$6+&?`PY\XX'PJ=_-$4>3,*]UM24N2<8R;A3L?3I&2L9]?&3,&S(/IC/MC
M^OC^N.!E\+V\U.L@MS.KS9_7B>DLN2`O)L+NJMI26TB4@,,3!<QL<E7!094%
MDC$#!N0>X0YSCSC&>!GC5=%//JDQ&QVQ6CRK)3Y6&I6J=Q=Q4E)`FE$"5&$)
M'4XT"?!QX`9'G&`^PPX\^<XX&>X<VT62L!<$(LGB``G&%:?.3AF>/C"5C!G]
MP0_/TQCSG/\`IP/LP((L!R$018&'V#G&<9P(/T_4'./ZA_5CZ_\`KP/ZX#@.
M`X#@.`X$,)[U_P"K5E[91?=N8P%>Y[$PZHGVCV&6`F$M1,Y-?R-#-6MT0K(6
MC>"(BZN8VNQ'A,6M5(CE11*S(0#QZ%Y"$;ZSZ9=`*AKG76KH_!YFHC>I&Q9N
MW--&2&WI\N=(S<BAX1O@Y0^JPOR0N4M67!C*$%&[%JD8<$B\!\Y,R().:>:+
M:^:*M%U,.O3)(6)JON]YML7/4C_)G&3!S8L^3,Z1]$QC<<B,:6'!+&1@A&'(
M\%9]L^PO/T"*?:L0H',>IY4E(./.1]M6OPAY)*,/P2D54CLPB6G&@+"+U)`G
M49\CSX"7_NSG'C@9ZRC$5W(667_M`MZS:/'CSC_ZPFO:;80.?CSG^OVV'?'O
MC']/E#Y_TX%F7`<!P'`Q*0'G$OT$++_%?&J?W,@_*Y,8<NR6&(R-4$+*>#]*
M-=DY,')@Q?027!H/ZBQP,MX#@.`X#@0:WEU9MW:AJUM::FV9FNLP*>VMJ:^+
M'7P4#H!UMJLZ_+D/[CI=2X,\@CJMK;)J:ZI_G.,&J2>B?U.2J`Y]>!.7@04[
M/TIR[KGWB0IAMA*A9JS=J4E0\V.3434D-40!\*`M<++4F$I(<E0B'\PEAPRR
M`X!ZF""6(0L!&/H#3-"+I\T<0LRMF<26^M9&V.+E'IR\V,RNDC:K-G+9*W1O
ME;X0G4*27*3)%9XDB<(FYL,,$C0C-1IR#1A</P*U>T+&`57K`MSC&`MW9'UR
M*AF?^\HLW;^J4!HB\?[LB,+6Y+SC'UR`8O\`3SP+*N`X#@.!2OI#2]/7)URL
M3=<T%ADY;:?VVW>MV'AFZ)8N8X=9U3[V[0.T+G*?\;@3B2HBBK&3`&$`&9@G
M(P8`/SZ9#9W1R.+&=2NB8H6B9&^,XI!N`VIHZOE;FT9^)^?2UJE,MG"=')SC
M%S@`T\["DDC`#S!A**+)P6`(2HGITS'M[1Z-$Y2]+`PTW=ZM^:D2C7[,$?GO
M\E7J9J3RE!*?DV//<D))IAR$<3""/XQ\N'D?OE$`8<9>K]C4?,NG?N2MX^WM
M&J.99/9]-,DZ<=;=4[BAU7PH+>YQ/,=K!VK1\B0\J7N3!?PQ]NET=9%3PT/2
MH]U.4N!J%$IX&Y=BK#I`O4;HX*LN\-=I?C_#/Y&GI;*>OXZZU+S)F6U]>84E
M<7TJ=1F/+J#HQD9W<MK>GT);(_.C\4WK2ODP$T&`[@>`X'Y$&Y/().R2:GR<
M46;D@_`0GDY,!@>23@@&8`)I><^!8P(6,9Q],Y_KP/UX#@.`X#@.`X#@.`X#
M@.!_F<8SYQG&,X%CQGSC&?./Z>,_]<?7@8A(J\@$O3NB.6P:'RA(^)0(7M+(
MHRRO:=X0E!-`4C="'-$I*<$I8#QX"6=@8,8&+&,?7/`ULEU8UA0Y+RBUQH9'
MDD.0%92U!7R?)0,XR'("\E1X'H'(<^/&/&/'`R!+0=%(<%X14M4R/!0O<K"6
MN8>GP4/.?.1E_$S`]!9S]?./&?/`_*1:^4)+V@<?EE(5#*&$Q8A<3&215K#'
MMH&X-BDM8VKQMKDRJ48EC>K)`:0;D'N48#`@YP+&,\#!5NEFG+DN/<W'4S6=
M>Y*?'W+@MHBK52Y1X$8/'SJSXJ8>;X$:+/ZA9^HL_P#7/`UJX]8_6Z[OB.2N
M>@&EBY_0J5RQ,[J-7J3,7A5N0<`7*C5&83[J%"G&/U#,]Q>?KY\_7@8<MZA^
MJQP1@0*>N/2/*4L["@!9&L5.I!8-#\G@7S)(@0?G&?F%Y#D7KGS]<<#"EO21
MU%+S1'']<^I)8Q9)SG"*G(HVE8^WP+`/4AN1)2`8%@6??P''R9\9'[9QCP&$
MG]!'3:HQG!G7MK^'V/5*,_`SOB7/R+#<G'!QE,^E9"0`>?!16/!9`?TEA`'Z
M<#$7_P#CK],<C,&<LT<AK>?D:0THZ,V/>$0&C-183X3G-N(M9[06VGXPF#[#
M("6,><BR+.1#'D0>(#^.9U,HE*11'J/MB(`2-QS4!+$=O=NV!,-">J+6F$&!
M1W>$WXQ*B2QY"$80"$4#(L9R'&<!]R+^/CUS,HS_`-JI=L88F7)34+JABV]>
MW[<D>41_T.1NF#+D4GJ4IH/(1%X&$`@Y^N,Y^O`]YIZ.=9XZL)71G93LKC*A
M*WJ&5")D[$]HDF6^.G*R%14:1&"GAIR=C1Y1IP%DX%]0IR\C$,8??(?TIZ1Z
M.5I6Y.;N5VL9&@RHR<K_`/)'LP-0Y_/G]/WX39:8D+^WQC&`?:E)LYQC]?MP
M,0/Z%-?59@!*]T>UM65A;]V8E4]AUX')SP_=IE/VAONMR?\`!\1(R/8(PG_$
M>//R?+@LPL/#._CW:KJAJQ+MKNSUP"K-/,$6MWXN(X!19IP3"4P,_.$PTE&6
M'XR\G"-,R#_>(8_`L!]IW\>311:G>DSM9.][V!W3)TA0G;>O8Q3EH3EEX+5%
M-Y8)F4G5%.8<B^<"\"T'ZQ8+"7CQC`?;_P#F[G6L8H4'+FK:=S*,4(3D:-?N
M_MF8G:2$H"PJD#>(FW"%7VCODOV49/-/.#G/]DPG&,8P'@Y_C9=5IQIPW""[
M$.I)AOS%(W'<?:,U,DS\WR9PG^&U2%&<"*SDK.3##!_&+/U]_P!?`_$/\9_J
M#"K5K/\`!UMY-<$&6MQ\[;[6?_<F\0#`&(G`8;C"<L1G9.&(9(QB*$(P7D/@
M6<<#+/\`\W=ZOTXTBIF@FQ$<=D2G*@E^9-V-P2'K!8BSR3D>%JJ[5F"DIY:@
M6!_&$!F<?3`\8R+R'Z+^@G3YQ>8P^JKS[$#ET"?PR6MQJ-_=D5PZU=R6Y>S)
M5D$5.,R6.$>5HV1S4(2E)1V5>$9YA63<A,'@0?NDZ+*2:)=*I_'-VNU".SF6
M1#,`4S)'OC9KI*VR%%/*B1-T6:9+)TC\_E,30_JC%:=,<I.+^8PS)F#,''8,
M#-DO4W-VL\2AE[;NW%(88@^R&%TV#I>6$>WSH3ONRTTLUP>4Y*KPD&'(PAP+
MU.%C&<8^G`_4WJHLM22J`J[=^V(9R@(@@/37)KTW?!Y+"$O("6[6!*6')9@?
M;R'T]O/C/^OD,)7]/-IK51QP>YOM_2IQGY^)(FOBE2`DHLB\Y3?,3KR4:8?@
M(LXP?G]?],YQG..!@+GTO6K\S>F,[Q.X!`I7*%:=`G.V,K@DYP-`4<N"F1DD
M50@,5*$K<E,,-QCY,Y`6(S&`!P+'`V$IZJ=K0!CA;1W7]B90(D9@YB'(&;56
M3K`FD,N&5&<]+E%!HE,G/PG4J_N1N(E(E?SA$//R@$<8'J&=:>\!Y97W/=WO
M%E04>H7A,25)ILA(RX&D+P`R8G(H3&3FLL]8$7V0QB(]2\!#@`@E#*#V@=<F
MZ*$2-6T]U>\Q;EC[HES,>ZHTBD+4J1G9!@@#>R*]:24S8M(`#'E0,2G(A><A
M"#&<XR'YK^O#?%4,H1/=ON,GP`>,&XSK]HO_`'"/0[W`#"+75O``[)HB\X,%
M@?J$(@^N?;`@!Y0>M'=HY66)?W<[TFMP3A#$F;ZMTX:UPB<C.]2\.)5!'E?(
M$G)>/82<0?8(A8!CWP$`?(CZS-XF=P;WIF[O-W3'9N/$J"5*:HU,E,95'Y(-
M+P!=%SZ<0HEJ+Y#?;)!HQ@\8QX\"P$80R-)I5VJ(?R.`=U$@<ONUX34@GWK[
MU54F-S<%/@O[0O\`#&L!1ZP9X<#$>('QY#D0<$XSG`PAF,AI+N%$M"&*;_Z9
MEM>",%Y,?^O>>&NF3L''XP>+\?NH6A$+*;X\BQ@``Y-P+P$(<X#@,5/UQ[F7
M`@U,O[*M/RTYI8R34Z?K;>U)*LHT.0&E+"G+<=26,L0/IZXQC&<9SY\_3@>A
M5.J/:#523#2V[_:C*8JFPYJVZ"M76B"#15([O#R?('=621!MN&(Y.-[=URHY
M6:'V&:>J-/%@9PLCX&P#&/N&$9X)M#K5(*R65G(S*'VA5&`.^$&3@_$'8U&$
MPO[CVP'/N#/IXSG'GZ<"/-UZP=N6QS#7<7LJ].N6.L<*OJB;P-#"->]EU+F8
MXT)8T4M^.HR5S]L?]NH2O4OB)"!<0).2+\6:8:4H+/\`4(0W]AH[D!B'[6'U
MFI@X%G!>,4WM,M$,/G/@0\YO9OP4+&/'Z<8'C/\`UX'@/3!W;>X0Q^UNK,1>
M"SQ",=:#VQ(&,W&183%?"FV/6!++'CQD9GN+(<YSC`!>/.0U,MCO\B(XU<!%
M:G3FC3X.!EN/S3NY9ZDTG(LY,"K3F6YDE*,(?&,>@S_;_J'@?T*$_P`A(#P4
M8'8#J64,Q:L`S"1:\;6(U2E(2(H62<EXO%=]N-9C`@#S@\62L9]@Y%GZ8#V=
M<J`[4J*IXJGWJ2==4_9E+U9S\Y"2Q39&'8PJMVTIM9$J1^!2:5!=&U&*;G)T
MH1`2'F`*#\QHAB$;P/:UTU\[#M6Z(J_7FEFOK\A=:5''C(="XTL6;2S<QLC;
M>2N/92S9.]NZ!Y=%BEQ-#A2-0`8BRS1C",T180&!A+_5O<>^67';A/K7IF76
MG!6:50R!V2])-M'&9QZ"S)2TK),R-;SAA)<&1-)%4?0C6I2%`R3,IP^1"_IP
M-3H]4^V.,US*ZEA&O?0(QUC8A2LFP:U34[LRU0&6%*1GJ#"I3&&MN`RS$"I2
MH,R/[U,'TR9D6,#S],AMEKA_>^F<8P2X(>ELZ)-):>/KF%IA^X34M20<HYJR
M<R1EQ4.+J@;0*"&XO!:82$2-.-(1G(3<8Q@L-[DK^Y(XXK"B)]9C:1\P0G")
ML':9[.^WR9C`SB@#K*/@^8!7UP7D7J,7T^0./U<#)W1'VO?<I@,LCZ\\H\A6
MY6*'2%[(X4@$%,#+<6F1I)[DHT)RS(@G#$>#XB\8$$)@LY"$)VQ4N4%1E@+F
MZI@73$#.W!E*R*H'%KC*F082%8=CF!M=W)X=$+.8N]\IBE*I0>`KUP,P0O.<
MA[_`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P/X%\?L7[^GO[9^+V]?;W]!>WQ^?K[?'Y\^/KX\_Z<#^^`X#@.`X#@
:.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>g575431exmpg074.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431exmpg074.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#*@)L`P$1``(1`0,1`?_$`'L``0`"`@,!`0$`````
M```````'"`8)!`4*`P(!`0$`````````````````````$```!@,!``$#!`$#
M`P($!@,``P0%!@<!`@@)$1(3%"$5%@H7,4$B(R0843)A0C,9<8&10R4U-"8:
M$0$`````````````````````_]H`#`,!``(1`Q$`/P#W\```````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````,1L"<QFKX'-K+FKANTPVO(
ME))S+70M$M<3&V,Q-G6/[\OT;VU.K<5^Z-K0&F8)3E&GFYU^G33;;.,9#7IQ
MSZL<^]AP==8"2-6#S_&]EE2Z0UZZ)45G#8O:[;>:=_<*Q651.(Y8LQA<T>'=
MNCBG"YA)7Z2)F7ZY0+D)"O&2@$^\R=R<Z]84\\WC6LQU:(/&I9/H;*-K"RW0
MQVC#I7,]D-<OBF0H5[F;HTM"N1QA5A"J--U*5%8QG&<;_7IH$AOO3E&1OH:`
M\J/,^1([]L^"S"RH17V&U\4JWF%P,]L3REXV=TC8?'FS]NW>",ZD*U9"E1IM
MG8DLS77;.`[9=T%339?#!S$OG[,FON45H\W$P5GOHOR_.=9Q]_219XEQ)FJ/
M9LT;D3^N*39UW/U.WWSG.FFVNN^VH<.\NE^>>9&6/2/HF[JLH]AELC1Q"+NU
MISF.0=#(I0OUVW2L+*HD+@@T<G/<K38S8HGZ]BRM=C-_ITUSM@)9*>VW=*S*
MSU.K=A_RF+:DSM__`!:Y4J5(CG$MOT0K?LJ?W/5$G-,W3_3][34K?.=<?1M\
M!U4DG4/AC+(Y--9&TPJ+1(HI1(Y7,EA,5BK4D-*3FX6J9*_[-[)^!I^5IIN?
M@_)19V<E;;8,QG7`8TRW?2\E6G-L<MZKW]Q3N;*RJ&]EG\4=5I#Q)$YZR.M)
MR5"['GE.;^D3&&HB-M<&JBR]MBM=L:YS@,[R]-V'<]CV-/T<$S42]'8W1+M$
M6C<>I4I"S?W7=-JU;'X/2&?41@[)Y>F,;[:8TVUVR'++7(CBTQQ2Q*:2MV^A
M&:6H*W+5[?1N9]*;?7?.I^WVRMMOC7.<_&N<_P"F,@.4````````````````
M````````````````````````````````````````````````````````````
M`````````````@SIV*6A.^<KVA%)/9<9M^8U)8$6K.2F257#?XY-I!%W-ICC
M^3*T,;F"J/*V5S5EJ2%FC4X?8.*UVR09C&=<AY'VCQD]$6B4PF7.W)?`[NLC
M77*OH*702-7DX$<S32)+:B14P]M4?Y.E7-IU9P*UY>@;4TE6S)"K3J293KNI
M3(2$^J=$4$4K/"'L-34-T1.1\T1YS=[=/JM?)8?"[&K$F%V(Z5AV;>O3BC6Z
MI#K<]2S"S&Z:0ZXB8N>K2FQMS1ZLB`]/DK"0K0!@$M\I._5UF]!.KMQ%<[:S
M6?1'3-;0B]FZPN?)[TMI+;;B7/K+6L?LJ5-'812MUI&DE5&[-L6()V.<TL;>
MU92K\E=N:J,#%K!X6]$U,6F#9&>:^T*_MIVI;J&(/L^K)/HT;R-POOO2H^GL
MT]$IOFZ[&<X36ZFF8:X1@MQ*_+T;7(S)IR=:4K4X`7O]*;3N.9\!\M<5QC@S
MJ.[I.UE5K6'0%H=8<N]#2^0-E81]D9"+&1P6]ZWIBV'8BP[6.8BV%7+T*#9>
M6A-.6E)OR#"#DP<CTZZ<-Z`Z:\]+0YF8>T:Z,YL@'=*=;*I#QQWK`ZZIVW9G
MS$HCG.EIOD>44$9M/F"*S](>W*T9"!2H/0..Q)_THSE(#*^,.UJ">O,FXN9/
M32<];O&ETK+>C_[%??./:5\V97]/SYK9V%A;;#MI)SFJ;'R3-LT.<7MM4$JU
M?[.4K1)B5&-T6NI0:FN:CJQJ*9$7A8/8?+^]X:<C1&QB([)J=F]>5>=Z&<70
M&PN=N`'92Z/-<LRQ9%RZ\L/:4RQ:9ML:MF+=KG[29,GRC)"Q%&^G_0-FKZ-A
M-T>G\A@7/JY%U]);4=9C#^6I!>$VB$1B?/9T`JVYTA$`>8K$M+0L939R",&,
M.F7-3$]6_&^-5!A)VH5(YWON[H#2OGK`9?9%&YMOBR8%V=SFP/70_.[9SU!8
MMKP_<A\>C=V/69O'+99[BD/4DX:&6:-SCL8V)TI!6C88G((5&F!-LW[W[DD-
M3SB?3/TZ97.W]?+ZVH]%4T.G7'E:K4?1,]ZA@ITSB.]>U9=DL;\7*RT0D-UA
M;XV*4SD>B;/R$^6U68H3K`L]+O9?L=NE-R1=-Z#\C5I$2>P>:*`I68*(_0%B
M-S)S*Z2/6*3+J=9(5%O;*+,4OT-48D<S:#$R'$6=$FR<A6D3;YUV#V=U4M/<
MJOKAQ56$S6VI7P.(+5%K1Q$TML>LT]5'V\\VP6)N85SHQH&:9F&9<4I*)2H2
M%$*==233"\:[Y#/0````````````````````````````````````````````
M````````````````````````````%<HQV)R--E;H@AG4W.4N7,A;X<](XQ=]
M9ORMH*C'SF2FNB=JDZLY`7'L8_[[8W&F$G_[OT`)R;Y-&W8A$I:I`R.29S1H
M7%N4-[L@6$.#>Z$Y4-BY$:G4&%JD;B1CZR#2\[:':?KIG./U`=V`````````
M`````````````.B/B\95'&J%4=8E*@_?8P\\]H;SCCC-\_.QAIIB?;<S?;/^
MN<YSG(#D886/'QC#,U8QC],8PW(\?'Q_I\?]']/@!USG"H:]$:)GF)1AV3%F
MX.+3N;"U+R-#L:[:8-T*5)#2]3<:;[8^K&/GXSG'^X#OTJ5,A3)T2).0C1HR
M"4J1(E)+3IDJ9.7J40G3D%:Z%$$$%:8UTTUQC777&,8QC&`'W```````````
M````````````````````````````````````````````````````````````
M!^=OCZ=OJQ]6OTY^K7Z<[?5CX_7'TXQG.WSC_;_<!X)[7A7*$HD?ODT[<M**
M5<;WC-8U[YY22;<,W;7T=22"&\FR"I)DD@3@EHS#Q5N[E(%:LA::J2MC6?LH
MPJR::5J:<4&+7?='&\C4\N7&_1YFAC-7W9WF$AF552"'(&NXH-SWP9SS<S=<
M<@5UVPJS'8NMG.=R`N.LS21D[=[V2:J4J10F/1;&A=7M[VS>K>M7E2_.7YLP
M0OE+C^SZ]OKI"'26ZH3#+IZ*B%@69-*3.B<&I=N?54KGVD!I9.Z31P8%&Q*A
M$H>FO\U'A:AP5H%?X[T<U1+T)O2Z+)Z84P>AM?07N-BDELQWHJTI6XJZ1F?)
M#4HH&KWBEFJ4F0A)SE-I<Y.#Q&YM'4;HI:)6S%(=\-YBLA0`KQ7W3=W5_&>-
M$SA?70+?$4?D36!W=*J.=&6PLOJO8Y;?;SG&;(MBF:^7/#RA=.K8E#46Q)OY
M.V)$UQ-P/4M2,Y0@1)M@NIW9TQ/9%.ZIM>INQ+FK6A)9=-E<O<]1F7=:=$\X
MQ*R*'YEX=L5^FEM2V3Q!ND]BR.86=UJM3MS/)7-"N?7_`'8FE.09@ET-.R&,
MPF^.]F^Y>9I!);L[=:62+4?XOROHVQK"G4S:Z]IESM=?/CNBGJZ.7T+/(T$_
M9K2C$68(U(5^JY&5#79[*?78]/\`?4[I@RN8V'T^MHJ5]!1?OSN!%I.?=Y]X
MXCK(P68G5Q%HY1EO2.D>;5<<W>H`_.R`M'396%;,\84E-Q:=1HHP4=]9?UA?
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M7SIWT;[2K+O2ZJ=89'5$#HR,1^9-]!.;M2C_`&Q"[EG4"XYF-[V#74LNJ'62
MWZU+TE"9HB0.26#OC6VIWV#%&J2%N#]RMS0H:T^]GH`KH=^NIJB//CF;5WE?
M3W>UB1JR>;>BJA3S&<67T$L@SI$ZH?WNUM"Y%73579I.&Z2H"'=N=WI-O]HS
M!>^Y9`;#>>/3[NJS[N\\ZZE-;<K*Z[[FE74[\U65'TUY01[S17.$'KF0Y?6R
MK9Z<ME,1GK[)WY]:]4+[OKKDIO3*C"TWWMR-`O?S;W+/+7Z6]*:QM"$5[7-+
M<%3.!Q5LM)ME4@=G"9I)34R2Z'Y]DR1P8&YCCR6(PMY;\J=$RI7O@\TSY^DO
M0O<T-4C'_8%Z'2PJV[9G/`S%I`JJ?N0%:F'0.]I5)KT>:T[`K20WDP25EKQ=
M0[22Z3"O*5:"WMY8=591FV?R"RE&-$VYP"5I![K78<MK"04_Y\H+UH[HWJ5Z
MY4Y6O2&]A0MNC%Y3'1^LY#%'M*UN]2Z+8M'7F/5@I<EZH\U0E:\*BB/O'FZ*
M,$@CWNG?KE9O1-5OOFPN89CRG'GF1WQ#DG8U2R6PJZ:6WG13T"EDT@B;1"=D
MFL`4;*6F,J'Q,XJ4R5^=M",:&[DFZ8#X1_\`L'[NW/,ENX_B*:KGEK:.&Y='
M8-!;\JN:H9)#>_'5WC=.Z*YWLC8&B(66RRAN3HW^*N:<E<VEN*=3DW9-]TPH
M+&-WM/##KBA4=>^<['CG.%@=DO\`YY17JI7+H2XQ=Z[$8"7=O_A+97[.I7S%
M56+U/XXXQA!,MOMH3G9-C8Q.4CVRJT"+J<_L*4!/J]L*S[*YWORF(C`^4K-Z
M^)6+EE4V(KE-;U'>:?G.7M;<T5_/W=WC\F/M)3A.V:/Q#2D7M^AB_P#(+2%&
M&Z!LPK+NFJ9AS58_5UDLDIYVIZJMY0ME,FMM;`U[&MAL68FJ1;6;"9=4\ULR
M$V%7,A;'?3]H<F5R6_N2C3<@DO)VN"\A6_7V,YR9VHEZM"H.NJ1;9)!HU/:B
M.M&@'=*=?J2=S>+5Y7$1IM%$'B8KW^UK#D\S;M&R'KBFR4:I3ME2M`E2E&G:
M!GC?ZN<G+8<XO)^]N-UD-=Z.G-"OFDVHI@Z].[7@T1G:>*H.@IR,(WY\=_FM
MM?Y-JZ)-SV3##\J]EFNNN^-0Z=[]D?/>,P^I9T_W)(FZ.W)&[LE,>-*I>['I
MQC+7S8Z-S)T#_E-ECE?/#Q4RBFG9ST)D.LA(;M6[&AAIFWV-,F@)=1>E7"KC
M;+72*/I*!'6,]E5,<TMWT/Y<?7ZWS$M9U21:>?&LI=?[*;:C&WY$<*_=,&O.
M^-B$NIJC78K`?2*>DW"TULR/TY'NEJ[.LJ6V995,Q6*N1[O'U4GMJGC&HBS:
MXCRR0M34UO<SARA[2%JV],>:IP:HTTTTVVS\`)]KKH2D+:AM96!7=I0N30^Z
M#W-)4KTE>TJ4JQUC,D?W%V10U*X[(US^M;FR*N:HXE.5N:6D0'GYUP45OO@(
M0;_1_P`^W642*$H>V^4S9A$W61LDCC!E]UBF?6ETAY3B?*D:IK528E9C>/%,
MZS99G73;4C"0[Z\X^UO](35GI'G;4^NDNU]TOJIN`LLVI4^;2@V#[1*..RF)
M,KHK+[]R;%FJ,?;URV858VW_`../U_0!(*&:PUSV7:-LMC#ANV2,V'N6J%^:
ME>S?+2,XU/BR[4A69E)(R=ML8W0F?2IUSG]=`&3@````````````````````
M`````````````````````````````````````````#YF%%':_0<66;IG.,YT
M,TUWUSG7/SKGZ=L9Q\XSCYP`PIUJ^M'U3HM>Z\@SPL+*P26K=8DP."DLG7;;
M?4K0]6WG&Z%:[[YSC7&?C&<YS_N`P5SY@YI>U?Y[SSQ1CNN_'V2?FN=2P%>K
M_$VVWVV2_DJH^:=^/ML;MG.GU?3G.V?T_7(#$G;B+B]_-,/?>1.8'H\[/R:>
M[4%5+B<;G[6A'R8:KB9V^^?L%ZZ?.<_^S7&/],8`8+GS2\ZMCOR=N#N.ME/Z
M?"C;FJG-C\?&,:_H=F'9,Q_QQC'Z9_TP`D%/QAR4A9=(VV\X4RT,!*$]M3,S
M)7\<9&Q$@4E;D')&Y&TH$9#<1N5OG7Z2-2\8QG]/@!&#QYG<&OQ6Q+IS#6IY
M>Y>Q6^"4CHBR9KMLFV^3-T+HFWWWTRD+^C?.<[:8U^-<XQG.,AC)_D_YXG2G
M>9D<OPIID1IB0XY9''B;Q=.I-0H"6Q,8J:HY*6MH5;Z(DQ6N<F$;9WR47OM\
M[Z:;8#Y.'E1Q(XL9,6W@EKH(D0@_:B8>Q]7];1Z&EMF<[9W;M(BQ7DW1O5$;
MG?/UE82_1O\`I]6,_&/@,7D7C_P[*%3,XO,<OEP=8Z^-,D8G1V[%Z[D:QI?&
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MB0Q5E*B2:F?8T+W.-VW"$9+_`%P9*^5Y:M6(?1>V6>O;O6U2LM*`(ZR5-D#E
M6::@T2KN%:KH_$;FB*Q;N3%X$S$*]EJU9A?E#J8HU,-V^Y@)ESXP=2MW04IZ
M.8_0F%&2V<W-0%YR>+O?'&VM?Z2OF.K9#3E2,48CD9Z4CFT<@B.#RA42X-I9
M^^5ANA6V#2M=,Z9#$E'C!UPT,/+D&K?J3E.L:[X[Z[FO8U,P^!\I6JPLV)_-
M7J?R5PC3XV.W5,M3IJ\U=K,=R26ENV2?B-I_XZ<\O&NF=`C(KQ-]$6ZQ^K+0
M0]S<YF/?7TQF$QM9I:^<97"&]S,L2%NE;RB*GRALL=]M1PK)JBVK,L:XJID)
MS'E\9$RI:2I_ZN#@B^-_UY.P:\J=AIJJ^P*"K&$%NG($JF['`J3ES#'K"L+C
MV8M;]!;1EL9=YA+6A=93HRL+8B>G1OU9R9*<SHECJD4J]-S]PL`9X[=PE6PA
MEA%V\?KZ7C'7LG[V@7,+O6UU'U5%NNY*0Z;;6_HY8GQD^5MK1)GI9)6V*[.W
M\?;I&L-/T*W3X*2EA"-!>'_H%RW'26N@;9Y3K>22*IU]67K.6M[FZ]RZ9V(M
MYVN>&S*YH\]\^N<8=G^+/4G>F%7J4GUTD4->#F9SV/)+),T"VL:\Q[RAGGY:
MWG.MYUYKF]-=!O-IR&R-XCUY8E0,\$?K2EADT4[47`B>+)3'ZRA$+D:9(LCT
M?(V5HT1A.?O_`).3#]C0PBX^.O8*Y*NJVOK+9.1YZ]\R6ARQ>W,$Q9+SE,!2
M1RV^7CU#@BDEKQC7F)W,LO>S"7)2U/B-`OC+6E2_0<VD)3\;&;!"I'GOZ#1B
M[6[NQ-S-$)7W2GZSL'IQ6NUZ7B!E%.;;..?SN9&ZGSH4X,<6DK'$H?5.Q/X+
MJ6]N;L6[DF'FZJDJC")*%29#Y"=OO4%9(,Y\T7PA?G"#]_NMKV?6?2W.#`HE
M]^]_RBK9;+7-GB9EX1)M4<_,!=1)8\]PEX_)*DL?=U>-CBEFI:C`2FE\_O0B
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MST'6CCR;T!()KU5PGYK<K59.IAR/T,U:>=4EYLK`B$6NDD!)]2*9!K&F2<I5
M4\:7:N='HUQ>#B"5)"8[4M3L%D*(JZ!.OHU6=L-,^LZ).UL^E=E2/KGG:W:,
MLECQ9RZI%<_2\-]30-"\5P5&*YEFS\8DU?3<*D"QP02/*E3H4>C/R8'M:```
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````!"O0O1=(\HU+
M)[VZ)L9@JBHX9NRE2:<R;99AI:39$^ML98R3M&](N7''.;\[IDQ6A1.^V3#<
M?I\?.<!&M1=X\:7X]60Q4QTM3]E*:C?(S&;!<8G,FQTC#%(YBA?7*.,!4R*-
M_B+V\N"",KS<I6]<K.)U2[_=UTSC'R%IDCHV+]-#4+BA6%&DIE)9B16G4:&)
MUA&RE(?IN29OKN2J3:Y,+WQ_QWTQG;7.<?J`YN,XSC&<9QG&<?.,X_7&<9_T
MSC/^^,@/Z``````````````````````````````````````````````````/
M,2Y=%>J)7MTV6,\TO<L2\PU2:[>)HHD=4CAK"&V80"'%6:J[!M",)MM26&NY
M7/HZ8VL<O5F:)S8NFW+)W*-.-*/#7IR![`>XMW<RP6POX=4;]);B[+XVI2FK
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M;F;N+MCCR?\`(=P+T')'+[CTC'K"CKMHH<KK2,T;@<A=F^/0QPC#>G9H@E_F
M:DK>18=EZ8G5B6F;D8SK]O0./6G]DGFNV(SY^+X5SCT>_P`S]"+8LJKH#7K*
MDK]R>(+K4\V9(5+I=*E^DP);U["6:^87)]4&3C]T*-5N9J5DLO4X/1H`@CIC
MI6FN0*2FW1704I40BGZYT83YI+$\=DLJ_84DBDS-$6Y<H98BTOC^H1:O3^FU
M/,(2FX3E;;&F?27IOM@,2YB[4YA[(@K[9'.=K-T]B<7L-RJ:2J5C#+H&[Q^R
MFA"TN:^%O45L>/Q&5-;\4WOJ,[4@]%IDW0_7.GU?K\!*%FW?4]-&UP19\X9H
M>?;MH1JEJU(<]E.YTPM*8%.I\;A;04C3JC-W5S(8UAFN=\:$EZ)C-C-]-=<Y
M`?8^Z:G2W&V\]GV%%2[P=ZY<[=;ZKR[IMILHK!GD3?$7">?L6N^RPJ,$2AT)
M085[ZZE&*MMB],[;:;XU"3@&-R:9P^%)D:R8RN-1)&XKR&IO529]:V%,N=%7
MS^,VHSW54E*5+U'TY^@G3.QF_P`?IC(#)```````````````````````````
M`4%]-^%T7I'QI9?'CK9;G4K-:#Y6"U\F3.QZ2-<2RP&T(?83HSDM1CPQE&&2
M%'%]T6ANY^=$IA^IVQ1V"_M;AH<M;^N'>+)S!6G,'-?6,!55SSIVO..D>;X=
M<]:)$Z.-U;9L0?&B15?9T@;62P6RV)#&Y"_J3VYX=8T?E4A6*DINA!1A.B8)
M(M[P;L*SHK+&F=;T;8)]B=P^>]CJFB,K9W5C%7')W-5/UO0]RP&(%L7X'[:Z
MRZ`,S^F+;6K1O0*4[CKN7E&=@@I(&9<M>6G>M+^A<>N60=()6WB2/]F]B7/%
M^2(Y,7+0B+5[***9:.YH>-GS<G9VES21'F@A$9"56Q3+$]$9*A%N><J5:X"9
M\:]A49[@WY9JSD_H>\N<.HJ0YCINIKEK^<P=15E"ZPG$F768NG\+DTX8#6IJ
MVE#I^><I))RY:EE&_A$+-UV"LAIQH2T?>"0<[7@T,L*[VBO0W.?&#5S62ON)
MI3.L<LGM:Q/0IN>,7%69TL0RS-I,%:<N/VI"F1Y)6-Z6/I3RS/\`AH0I/#F7
MCZF^UE*4S0CET.5*>5[,NSH3NR/N*J+\<XZ(U;$O/564U'N=JBB\$3-K<Z+&
M*_[RUD1B22;F&[*$#E^6F/,0I]?LA(DP]M/0&H.DZ`H2^9W1E27;()WYG5>X
M<=R+EJTU5C7WCIN`T@Z=)6LQW61.6ZN:TC<$G4SE+&D3)T[P:D>&#",XKYVS
MMD)%W_L-W*EA5P$L[73$YN+G"N/52Q>CH"3!;.:-J85<]73'ZGX1C$P..>$Z
M1,1;9TDU/>-B%2H]:21K]!C;MD[<L)NC_N9TN\^U,W\FB:4H'?6)4@Y*D,V=
M)1/V)8]="L7*B"_G)M<'Y"1*&>/5EM+5!S*;G9K4*T;>F,785*#<EH]PVH^2
M?=ME>D7'$+ZSGM*PVE&R?.TM:8<UQ"V%=I%R1)`I?(:^DLD5?E0&%YBB17+H
MLLPWH_O.AAJ#!9YAVF3,%X#9L```````````````````````````````````
M``````XRQ&C<4:IO<$J9<@7)CT:Y"L(*5(UB-45L0I2JDQ^NY*A,H)WVTWTW
MUSKOKG.,XSC(#'()`H-5T0C]?5I#HO7T#B;>6TQ>%PIA:XO%8XUD[;[E-S''
MV5*B:FI"7N9MM@H@K33&=LY^/G.0&3X))UWR9@HK&^=]M\[X+UQOG?;34O;?
M.V,?.=]B],:YS_KG&,8_V`8I+J]@-@;1C:>0>(37:%2MGGD-VEL:9I'M$IQ'
MMS3&"91G9X1+,L,J9-S]\I'!+]I6FSOM]LS7ZL_(0]9G(/,]NY5&3JEX&X+'
M.S:JN%_=FUB1QU]E=ATG*FJ:5B_S!^CQ;6\RS:*R)E3'%$.!ZA.867D@W3<C
M?<O8,@Z`YKHOJ>&-5>=!UNQ6C"F.:Q:Q6J/2'9PU0HYK"EN[A%W\O]M6H#]U
M32K,VVTTVWV)WQMG4S3?7.<`(GG?G]R18TVO>SY-4J?>U.DZK-I"W+4:Y5-F
M2R'BI%")*WK*^CLT:I(E?J]BSDF1E_EI(\<UDK#,9-/U,-VVWR%?\^.'"*6S
M^4+#CU</T-8>*2FQ7SY2,.F+PP43%9FR25_EK-:"Z`)-_E\LU(^R98>H=E*O
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MFC/'3-'9VIUHZ>60Q5*M,8,3)4!6JU;K^WI5>^@:=H[1']EZ'-_`<W<^MI?*
M7Z][KBJGT"K-W@_*LF1<PL3!,E.S1M!53&ACC6ZU+,JZW^W+$3.H4.:!Q2E&
M)351B@S4!EECTE[FRBSMLV%;UI6-356^P$.=*AA<"8JTJM_DG(D-CEFW2SV-
M9EAU\OB[W+:N>95(HS`5T?.*T+U+;E1B@HS;!1A(5`J_KS^P.@317I2\J<Z*
MWLJ/<:7HSNU88Y1E!-7QB8O'<U"0`NQ'.GX))T"ZX9_`J"6.TG:6E.4TO3BW
MM&^B3!Z)0L6&A9Z"^M7K=$[JX31]`4'6T9J:V:HYS3].1F2TQ<L(M./VK?-@
M]>1N/*H<4C42#6-.!T*YX0/;BQNB,_\`!/<B46N^NRHK?`;2_&WT=O3T8X1D
MO7=^4?&:"=4UB66P0UD9CY9E@DT%@[$Q+4TS^N7)TRW"?>0+')M.,3GGIC-V
MS??7<O?.Y)0:C>)_[#'0*IO\V:2NRADW0D]Z[+Y_Q:W2[/9D)JUN@4DZ\OWH
M:(UO&-*6;H,?A=F'1*GU7V_QW`G*Q&A+,.R4<ITV-#8U[$>HEI^;G0?GMB.-
MT<E%*VSGL"0]#P5:YUU#Y=*(E1E,LLV8\0BQ;7ET.A4=>&MR<S5&B#=7HM?S
MRRF])]Q0<42:%)KB_LT1Z7Q*UVCE*DWV-3]AVI]XJ.7]#?L"6,2UJ4]0<XT3
M>;-:E5M$P9K6HQ7'L7G^.R+'THE.[FD&*R?DDK0M0'P7?V)+;>+L[MFE741$
MI+Q/RQS[%[@@[W/EV:^M6PBX?UVR\SWB\I=$4JE1R)"[Z(9>;$6MV8VAT5K8
MZDT4%E87ZZY#UD$'%J225!.<[%'E%G%;;:;EYV+-TQOIG)9FNAFF<Z[8_3;&
M,X_WQ\@/J`````````````````\:7]@'B7J[I_N9$]5=P9;G4;*^<"I*6YKM
MNN+MS4D:YXZM6WS(969;T_<")*P%E$02(J$^Z9,XYU;G/"G8O;;;.N=T@6)F
M=F>UE8>FW*413TS?,QX8I?DUJI*WYY"#F:81NZNB'[F)PE;Q<[VB4+E#ZX?Q
MFY"VIF3K%R8M/HI0*_\`K9V7[%[AGGA1T)[)V=:<XJWU%KR;P]CK'DBB'Z&2
MB0URBCB>T)C9\JF,VS+9/)D3$@2Z6PRP!V;HU((\0:3^T*X_OE6B(7FJ-S0@
MGC[W:AE4^?/:,VZ!NJ5V_P!UTG9/64ZUYJDT&GFTYAB1SOA=7G/E7[;DQ)I1
MJX%H]R./$95$GYRU(G/<C;!>4F2M`C:>^^4O<_+KSW["_9./<]T6Q?3U2+G3
MM[0.1I&9RL:KYAB$V"?$Y\XSB$,O-66Q#(6*0.3](')0VLR5ZT38T,VVQOH&
MP:#>WM=2'U8K#RNEL(JUX>IMS<QO5UV["7XYTK]NZJ65DIN)TJ2*'N2$QOG-
M?J:]2&F-[CNHV5J%RLI-C38S0[`#6%SS_96KNQ6GL7LZ;>:]:(I;S]0L3G<>
MLBOY6DWMNQXW+>F8YS%%ZV<Y]-Z2BSHI0NRN0ENY*AB72!L)1(3DFY>%_P`I
M20]37`L[:K,Y,J.=,%!Q/F*/R5N?'1CI2$:JB8W#V]3*'LS'X:-;65/*F]0]
M*=C5ZDC>/(-M%*DS_P"K\_>,"X@`````````````````````````````````
M`````````````````````````````````_F<8S\?.,9^,XSCYQ\_&<?KC./G
M_?&0'XU**U*P3J67J3C3[>"M=-<%8+^/I^W@O&/IQI]/Z?'Q\?`"+$M#T<B<
M&1V14S5"1UC6T;WCCFEKN()W!@VANTCVB&S(M*9]%+5M%=IB[Y;<D;%Y0Y=5
MGV?H_).^L/I:M&TI>S4T,5W5!6%PLC`](Y&Q-%HP*+3]L99`@,T-1/C2AE34
MZI6YV2F%ZYT4$ZZ&Z_'QC;X`8>LY+Y9<998<\<>;J)<9M;A\356G+5]301;(
M['40-V9GZ%'SAY5,1J^4FQ-]CC<M;MEIAV4BM`G.*^DP@K;4*Y6IY4\(VLEE
MJ)5S_!H"1:5N0:X[WWJ2.QZMEO1;S7\JWGC1%KX=8VSIG:Q*^<9WJ0].;2I/
MU)<7)(4<=MMG[F#`V(``````````````````````#XX3)]=S#-2"=3#=M-C=
M\%:8W,V+V^HO8S;&OU;[:;?KC.?GXS_H`PYVK.MW[3[;Y7T(>B_W-R>OH=HH
MPN.G[P\D:I7=V^E8@.U_<W5-K@M2?_\`5/TQC7?;;'Z`.KQ2].X<=7C%3UIA
MVTF"6PM'3$$BV''6?(6E0PHIQJM_:OR=9@C8E9J(ISQM^:6D-W)U,P7MG7(0
M79?`'$]OPI;7-A<O4N]P9?6#;2IL92PAHCS614K-.V6SV>NVXF,DL^S1$VBP
MXZB>4J-)DDI,X$8.+QKOG;.0FNEZ1JSGBOVJJZ8AZ&!U\QJ7-4SQ=L5.:M`V
MFO"\]S7ZI-W9<X*B4YJU3OMH3@S[1.N<:%ZZ:8UUP$J`````````````````
M`````````````````````````````````````````"CG=_9KAQ9!Z;D<>H"S
M>EIC=O1=:<\0^KJG,;$LH4NL](D+LND&7*0?CQ=N01N.11<JWW=5K6W;F:::
M*%R,K;=06&O#CGWUK#LZ[*HJR'<7]EU]#;;M>VZ#9[QL>-58FK9FNZE*Y>[4
MG5?OY\4M"5.*,YOA["<9JJU+W+-/^=--=M2CS"@VL===957Q9SC;_4%M%RAW
MKRD8^BDDV;:]:$TIF>K<X.[0S)\MS$:Y-9)N^#WHDTS8]2G)*2XW.WWU+TSL
M`EBI[,CER5=6=N1/1S31BV*_B-DQ9*_(]6M^TCLUCS9)FC1V:\'J/P7(IN=B
M<*"<&&8)-SG7ZL_'SD.1:%E0JFJVL"W;)>RXW7M70N3V%.9":E6KBV.(PYE6
MR"1.VZ)M3+'%9JWM+><;]I.2:>9]/TZ:;;9QC(4PHSU4X)Z0LFGZ=J'H!ID=
MIWW3+?T!4\&5Q*P(\\RZJG`F2G_R)$;(8HV-1)[?B'N>JM$:IT7)=T>^IA.N
M?I^0GWH;KSEWDI'"G'IR_:IH9OL60F16$K[3FC+#44B?2$OYJI&A5O2I*G^V
MA2YUV4'[[:)T_P!TO!AFF32\;!\J>['Y'Z&DCA#J$ZAY\NN7-3"FE#I%JHN.
MO;!D3=&UFR;1.^K66*2%U<4K3N8M(TR?N7J7KN<7KMG&=],9"P;DYMK,A4.;
MNX(6IM2:Z[JG!R5D(4*;3;?4O7=0K5&%$$Z[&;ZZXSMMC&=LXQ_KD!SL9^?U
MQ^N,_KC./]P`````````````````````````````````````````````````
M``````````````````````````````````````````8O-W&3-$+E[M"HX7,)
MDV1=_<8E$C7E''"I3)D32K4L,<,D+@0I0,1;VZE%)LK3RS"4N#?N[Z[:ZYQD
M/(%ROY4>@L1\$>_>"K+HB.0SJ:S;&G]IU#N5;E:/[5.%TX505V4IFR3Q=U6)
MH@_)$<26-F-W`Q&2HRM+U^Z6GW.R6%)Y+YO^ELZY9]-Y*LX(L*MIO=?`/FQR
MK6=;:6544DGMSS2BG*IV"Y;6D!,;LAZ2-KLC:ZWP?E(?L0J5,^Q&FV-E>JC0
M!AW5G&?IM)_6^K;HK#E?LANKFG[4\S&J`S-L)5+V2-TK"JJA+3=2%HF3=;C1
M&8"D6.6IQ$JC#,R.;.:M)5&KG%']'PXAD[9Q?8;#R%[2],6<P^K<`Z0H_J#J
M)'R#7<;LKI>$Q%]KBXW@J+4@\0R(,IJM':<?:9,\+%4E,1G+49[*F*PJWRE-
MQN8%,NLK:[O@\^X<G505/V`:XTWXA<KP/JZU6^%3:$79#818EQ,4^N)PH2?:
M-"/$-M#1N6)XP2ZY(4[I46',DQ.9A,>9H&SJZ+7IKK"C^\O123([-=.-O.;S
MQE/!_":?K1IGRR;6-T]T)42-@NRS+$WEZ51/W*R37>4Q6"_N:D\TI4L,-78/
M*SIA1@-0WD!,&V&]*<A6O$+#@$ZVIWR3[:=K`D?/$`2U%(N+54>C=XRELDG4
M$I7-,JCEP3!>Y+?L-RYQT3Z:JGAL.,2F:)"_SPLMU!;GHAT3X.U/TIU]W]6]
M_P!,=B6KSE5,3K%1240B#G`Y]$+ZF6\EUL&<1!LC[Q+RBF2LU6[QL3H4?OLG
MR5H7N7C968%CE'J;T1Q[8/OO:I_;$#>[,CW:M#<J\U5C:\4)>7./ML=LB71.
M1NU64[B8M*-`P5O5.7`A#HI-0,+TXMWYKHOPI,^%`3=5?O7Z+3WF#DUTB4CY
M=D5]6QZ\S'SL=Y59%<KVZ$O4(.BD.,KR:3N)5!9\DQ$W8]_F_P"2KS''A>B.
M3(=-$IZ@O[AYP3Q6WNYZ&V;4?GZC@M<<5/\`?'8'6G:/-+V]RPBZX?2Z5+S1
M_'%49E3#HU2:1S-GTD"%U4Y/T4E.&Y^2R--"D^QAFV@1#6_L5=?<US>`-OS3
M1PH-CNJS/1%WMZ$5+=,O@E62?'.$93(HUI8Q#N<>U2"#E:I,K%)#SDTI%]9^
M^#RR]]_@-@'D_P"[]I]]]JO/)%ETY2#$F<^=I3TA$9_1<_LR6L;$V1NS&RN#
M*Z>G>?US$([:3E]U=NJVE405*8P=G3["<P\W51A.'IG`````````````````
M````````````````````````````````````````````````````````````
M`````````&E[W7FW:T6XS96;SVL)%$NI)K<<9:(M"4+HPM-F7?#6**3B;615
MM+JW[3XTL7>*1@Y\_P"Q-3NNS.RK]$)GY>Q)>X>7"\/57I"V/,'LWHVD;N[/
MI>^Y3Z"\KT;OS?++2<T4RY.F>T5D'\[K:OK+<&1BD;W5EH*XYN7HT[D,SVU.
M*;?#ED_0M0<Y!N+L[^R;)J,XZNN\;AX2=H1?=.]X%^>W^!-.A8Q-&-PMQ%7N
MMAR)]>[6C4&.3M<?8FM,H)V_$:W+\M5]G4DW.-S]DH5_/]E;WZ2ZY\R+4KU]
MMWGBG;]X9]&+6O/D=P0L3R3'Y5S;"NC&Z&S-7,%\/975[4NDK@92QN__`,!/
MJ0A0;;DZ95FZ&!DGGYZ9]^7QQ3XR0Y)=S)976_>?5=R.EL6'*ZXBR?,7XKY/
MFTMVO<HQ`S1QJC>)4N86AH:6YU,1Z&J5CML449]_3"DL.LX,]^+#QQ%TKV-Z
MAL9=CTHV]VH^+X8U\_T>P&;QK3:&K)4Y26<QY\GFILFBSDI7H&_0I/JN<2%.
MNN/M*=3\[$A9;JS^Q-RI3_#=J7M1O+=JS&<QKH]FXEE'-ES5.92CW%[+DL2D
M$J2-UOQE0F>W)NB+I"8XZ:HT1254M6K"_P`$U.F^3=R@MJ\]E^(K/-*S\T9A
M&Z-CLC8GFMYA#N4GOEQY3PBM+6F,:66O7D=4LA=8'5I!+T=D#@I4I&8P]/(3
MG!0:GU*V5FF%;!0:[_4/^N[=M`=LV96\.Y5Z/N685"X]`6C35BTW(JGE-^RF
MCVY&X05FGTPFE5I,'/S<_?B)R?@Q6JU,.-VT+-^H[.0N'4=C>*E?TWY_,%TU
M9Y^\GV?T:52/9%*\]H6NM-4,6O:?1%@51JP(HY-499429R3JEQ;6SR1:0VZ+
M<IRR"=OK+P5H$^POG/Q0C\JKRE(<BXY(FW+MS6V;7M3Z6U&EDGJJ\KQ,;EEG
MHDD&<)PH<R)J_94(RR4:A*:<UZED$H"TN"2]-`^U.^?7CC<;%39?/E>\]69$
M>/%5[PZM6^GK:632*5JKZ$3.S->D8DC?$I\ZM+PHFZ9:J)5)G[5881I^B?!6
MNNOP$@\=>-_G1P-9YMS<J\^_XULPV$/];YE)]FV[-3RX/)9$V2ESCJ=NGD\D
MK.E1Y=V9-N5L6GT.)T*^G7?&-S/K#9V`````````````````````````````
M`````````````````````````````````````````````````````````*>=
MH<,4-WE`X/`KV(GJ4NL+0CERUK,*ML66558<!LB+HG9K:I1%9I#7%M>&Q>6U
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M\%0464D-+1$Z[)B]51OV`E!C_KXRYB]()UW0]W51%TZ69)*QNY],NBC9VMG$
M"Z1JXLE0EE5.M<'NJ(U_'H[(GO)RC39Y3/RQB1Y+1I=3M]=UA@1K5O@U>U-^
M-/3/$3S,>+C^K;+>;!;85T^MBTG1-$7IVWI?6<ELR(/LX<8CO8#.8Z:1UU3E
M%I"C6_;.6_<XO?8LS.H5XZ5_KK]G3PZ=0BK9/R6YQ/I7D7SWYLLBU['>9^?/
M^93.*6:K&F6JJ,;B*Y<<S=%;!U:)%)*DY5'%&A?W2#RROG0[<+$Q;PHER_J?
MV'Z0O#G;G"V9M<JS%F><UANLK<39&PVRCK6S69"NEB!(CCZ6('O<M>65>\F&
M8.3Y=R=E)/W,)DY^H9Y_6<\INF?,V']=J.FJYB]=NUU2>FRH&VDSF'6+/_X[
M7,:EQ+UI+)+`-<Q/9BS()=MLSE%;X6?&5&RDO3.2L[!ZBP``````````````
M````````````````````````````````````````````````````````````
M`````````````?G?7.VNVN-LZYVUSKC;7_W:YSC./JU_^./]@'DB\W477'BW
M%>I.);4\\^JNR\3_`*6G5UT?T)S!%X5.*ZO%EMM+'(Z4W71))C*X@DIY_:<1
MTG=U->LJ$Q12A1GYV((*.6!KW]*N1N\G?I.\:XB7*O3Z>:6E7/!S9Y`'<S2R
M?XY+\^S(*ZP8GJJ*2UZJU_@]65KLRGHU&,.;JPJDRHC!:I/J25N5L4&3SZ`^
MG;IZ3%PR3MG:<@[=1>HM-V)6%Q1^276BX-C_`)<-S&ZN<M;C\,+PWTBB85CL
MDW2.+:M9\OB@PP]'DPQ9N:4<'5UBU^LS_P`J>N?3D,ZO]+T-Z\AW;T#!.=.7
M[,<)?O'93SV\)4Z6/SXMLG4;/E,PGM?P%\?7IB,:W-7ONZ,C?G!1OW"?OAJ1
M?+*JZ5N'J)=$1F?6,U1+_$*IZ?7V[TI'[6D<B?;J<[`Y9B=EL.TXL%N<GMM9
M7=61LB;=%)Q24X@]3A-OA*65G(7'OCN;K.K(Q-8WS9Z!VI358\A^)7G/T)6T
M(K4N`*8M-[/DB?FBNE1;A'GFOU^T>C[TW6?A:N1H3-,;*=T^YYF2334VH2/U
MS[G=XU5W;$XS'.UVYJ@4?6^8L=F$8TC'/;#`RVF_J(C=@=(/KC7,JAKU:ECX
M6/CKJYER./.J)HBZ1:6A,QG)Z`T!6ONJV[.D]-_V#&JUNS5=@.;MZAT;SJP4
M[/%K,N4MU:U?=TB4QF3?MS<>F?897#:P(\M)1#(2F1+,-2K!NII^<F%AN\G'
MKOW?".S90VM,^Y[CM`47Z<\^^7VG&6];[N5S73'[03-)+AT)'YPIEW\L:W$A
MN+.7,+<F29:C$FVQ:K)QB?)IP1_Q3[7>G\ZZ<XACMT/_`![8O-?7G:/5?)C(
M=$:UGL'NTUNYWW9]%%D'$YFSC$FE$L,DJ'*4DHM;\%XW*4X^LPH_4/:8````
M````````````````````````````````````````````````````````````
M```````````````````````````````#K7=G:)`V+61_:FU\9G-/ND<FAW0I
M7)L<$IG_`-1,M0+2CDJM.9\?KH9IMKG_`'P`QEPK&MG8EP3NM>P=S(=X^EB3
MJ0X1-A6DN<50[Z&(HRX%J6\S1;'T9A>NQ2(S&R8O;7&==,9Q@!AK]S9SK*I/
MM-I/0=*R.9[:QS7:7/U609XD^VL/U,TB6NS^X,2AUSK%M#=L-V/N_P#8XVS@
MGZ/G(#H9[R+RI:2>5I;(YLHF<DSN41J;3C645/!7G>93&&;;;1*4RLU<QG'2
M*01KZ]M4*M9L<>FTWVT+VUUVVQD.2MY0Y><KM2]+./.E'+^B$*)*W(KS6U7"
M%5M)$:%/A&B*36">R;RHC*-%K@@K?55C<M/C[6N<%_\`$!%2;SCX/;GFGY"Q
M\F49%7J@;%?+:IIPA4"9H0?7MBR?+1M)I1'_`.)$,I9*R2&,"'9P+,P80NW1
M$;'E[[%%YU"Z@```````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````#7'UEUS:](]H^:/-4!C,#=HCV78W0L<M)^DQ;\HE$7CM+4FKM)"=!D[
M:[-+26L=%B78A6H7?EX)*^C!2;?.^VY8:_>=/=;9]G?+%$=%\]S9-:/1+8GE
M$@N"EF9&JY;J9@L:PNFFNC6J52N4S99*=G^40#G-:N-.(3G(E^VBA2AVV3Z?
M1H$01+^S1SZV/'65K7[5UHTYQY6Z'D]RY3FC[6$L:[IZ58.CD=K$_P"0F>O7
M9:6@-K):X5$[+6)VT/2:*&=/G)^NJS?5+@+X3CWJ\R*TEUG1:>W7+(VAJ-GA
MSU,;#WI2XWNIBB;"KV*V=!F]OLR+PE]B2Z02Z*S%'NVMN%.JY:=G<LDK?.N/
MJ#Z9]^?(TE17A:[L>(MB&U*Z:K4@\A<H5:B6*N,*<YC*Z^.<G63[079CB!S!
M,X6X-SL0]'MQS6I+UU4ZE_<TSD)O8_7?S)D<#;[.9NWN>UD%=%=C($,@_G2%
M.0:NJ./-$ML='LE5ZD.!"J*QB0(%YY9A.FVZ5<G,*QOJ<7G8)*8O1?A&2V!:
M%6,O6M#++"I2'OU@6U%<V)'TKG7L'BQ3>?)I9*<+%:<AJ8(\2[)MERHS?!27
M4_3)N=?JP`X_%'H+S'Z!P&U[1YGF9\L@%/W1.J.D<J7I4[:SNDA@2-F=%LGC
M"S5<K*=X`^LS^E6M;IG).JM+OG?)>F=<XP'8V%Z"<8UG'81+I!T36CI%[!NV
MNN=H\_P.0)K+:B[=MC=RT@,6?UE?9DI,6U?MFD_Z5CEE*B)UT^HTW37.,@+C
M8VUV_P!,XS\?Z_&<9^/_`-/_`,`&+RF<PF#:Q_>;3"+0_262AF@\6WE,@:8_
MK)9K(C#2H_$(_L[*TF'F4/II&^J-O3?<5JMM-L%E[9QD!^VR:0YZDDFAS/+(
MR[2^%Z,QDQBK8_-:^21,N1I#'"/;R9C2JC7-AT?4!.YZ/*HHK"HG7.Y7U:XS
MD!DP#^9SC7'SMG&,?.,?.<XQCYVSC77'Z_[[;9QC'_KD!_0`````````````
M````````````````````````````````````````````````````````````
M```````````%9NG^..:.S8K'89TO5#/9[)#Y#_+(@8J=))&G^)23*!2U&/,6
ME\,>HY+8ZM4MBPU.=LC7$??(WSH9]6OZ`(\+\X.(4\PAD[0\\0MID=>(Z);8
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M-\-ZO9PD^&EP?"/QG@U`5NH*R:$X77XZ>>DLJJ'UXQ^KT3@-W?NEB*;0O:2R
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M][`OJW%EQH44<4%M[*QE,>J`E27O]&RW4+`-']?OK>25!;'-2CM:@WNXH7,.
M)(]E=3UI7-7LSA%%UC:'2=HNT_MEH2$R%43<]M-EN_DM"0U%JT85LF%1"K.Q
M.IF0_4L\-/6PKF^,05;T5*+ME\%GO"_147-EW9DQ=K2KSHBD8=T''KA>.<;5
MLJI'YHJAF_=)G#SFLA2D4:*$K8HQN9@XLG8P):7>?WN-!<W6_02P=6>^KND?
M+*RVNHZ&LJI4\NMTKFSS1GM;&(7I/:L:2*T3.]];,S&A7?6F)4'_`+@H6DDD
M$;FG$AP.$?1_T2FGO:=PQT?>,J9*G@7/=;,DHI(^D(O(D,KO%DY*B<HL=:X6
MS%X0G-A)&]L%R-X_>=G;]H=#49+6A^\2H(SJ'4?VD*P]4^A;4Y7A/(?)UM6O
MS=0A!?0$HEU4/RQS.GELZR+9*3"GZ#1M[1R;7^!1V,E'H#24BA4IWD2C\7;7
M8G;`#:1Z&6MV3:_]?^R+C:X+=%)=JS;GJHYBYUS2C'9,+M^NK(=;`KU5+HK%
MF)C7R*RVS+*E,6)U&N3_`,K=MU-W4?C:;&ZE!J3Z.]6/5Z01GN>ED](V'S7O
MQ==?+.:?O9965ZLSE<=7-W0\4@L\?[REJ2/2U/FNIA!=-Y,^N,80D&:-!IQ9
M>BDG;?!@>C2@^L^I;^\P63KMHYM10OJJ2TI-)['><YZ=+XVR/,PC2V1)XVVE
MGK68N:H([9C:R)W)ERI1%K-DCHE^[KIG.VV`T4/?]D;N"#<OWIUU:ODE,:HJ
MJL#Z*8X4DL6>S^*R"QI!=93<^)W)'A53"A&D@3#"VE[6JW?_`)$D*U+,BW^3
MU1V"@Z*Z/[05D2(VP:WYJYJKV#3V"U;Q%8SU;-\V/('JHXXKZU?.;4CHP/Z2
M*0EBPQ,\#*OHQ*>^N;PB*SLUFJ=41G_%+L&[OSN]8H/Z*7?VC44`IF<P=GX[
MM5=5"VPY1(X>>EG[PT/3S'G)25!2%Z>P(1J:XL2@U#AQ0;$*T>/G)Y2LM0B(
M#;.`````````````````````````````````````````````````````````
M````````````````````````A?H]EIF2<^7C'NBSV)-0#Y4EB-%V*9.X?M,=
M352XQ-V23]0]NGW"<MK81%S56QQ^-]=B=,9WUSC.,9`>5WFRIJD[]@R'BJKO
M4B_KAAG-T<Y\Z.X]A?4?GTRQBK6^EJQL5N::WE$SS8L`JQR[0@VS,G_C!"XQ
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MS#V?!]YQ(+KH*X"H.LKJB7;M&V71WT14SUISA:D`9H5.+FC<HVJ>PCZ2B$U:
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MZU$7,-:Y_P#(_I)LFO*T`/E=(*2:MD1\UM_9ZF;JZ-<9.(9"5+%APVT,3FXP
M5N$K?_=WN.?\1>HMT;T/CG"P//F`=!5W():XREKM2+:=@54ILM$7`X:T*V2+
M(IY%F!D;H8]'NIRE,G6'RO#=HGVV1'&F!0;EOV[ZBUK&XX!>".'=4W89+I'"
MZ\/A3ASA`DD4CM:<+Q[JR[K.GC[%K'F5$3F*1E:]J"&M*SNFRXXM'^.[)VM8
M9E+H$MP/^P#0T41575?4M01%YGUDV)PA1[\Y)9I0#).YRXW=S71EU']&6)03
MW(&M7!JSA,IMUK2IRT*M_0-VQ2G)2XK\+&FX2W7?O;PC%6^P;HUXHZ;J76P)
MJG7R2<0^@JP?)%:L+2PRQ9JAZ&F"BMYPMD;S7;=!ZLD:XYU785G($;8=G;&-
M=M/K"8H3[N<XQ!S11CIITD$5D=A71V!':X5,E1/,7C$5K+F">2V'G&VL\/%A
MS!(W/Y^T)7E:.>AR5"]*B\_BHT^,?0`JA4WKCZQ8NYE<NDN/>5:WY/0<NM/?
M-S*(Y/+`5]`T?QE+%UB%LTCDC(ZNVS3([9BS77ZA6[QYJ;5"@[&F22M2E.^2
M"0N8F]Z.3%5YS./J\NT0Y:J/FF8WA<?4E@L<XB3?$9JR6=1E?,%3M]?+X9_(
MW]<])[S:E.%J78W[JI6F1D$&&[&;:!S+-]Z.-V1\RS4H\$WH;%(!:5L6FD)7
M.M6.[5!*VY;?>H"T%2%V;%V"/7U9[]'R6=.;&6)S_-94CQAQ<=DZ8C;ZPG\C
MUSY.>.1Z_P"P(3M9-CQ*V+7A%`55`(7`W/>R+/OB>KD+:SUE7K=*-HNP2TTM
M2I/,,>DCCO'3$;>K4$+CBR<YR'#4>PW$V>KJDY<:;6AKUI;^;7BD?N5'.8;B
MK#+XJ>>5M`7;FMM<<O.S@_W.J7V8B5?MR8G)9:+<HS4PW!V?M!91-Z`\(*VQ
MC>B>TN4<M,G725KC;D9T+4Q")_<H8>E32UO9U)\M+*<EL9.7$87%$YWW2_?+
MR9C7&^N<AB'2/I1Q5RQR^E[%LN]H<[4`]/2"+PJ;5>X)[63V3+716Y(4$4KC
M2!FO>DP?C5+*NP84DWVT3:(5)A^Y1:<[?0(.@_M+P#-%,^3*+$G<#UK*EG.]
M)@LLFFK2A[>DC,50P59945:EJV+&$2>UZ?/LZ/HI7$VO*Q^9G-U*1FILJ-3B
MR@YDD]L?+J([6QM(.MX>A14A/6FK++>BXC:#A'F2S'G:5?BU^WR%M@RQEE<Q
M3)X2ZJ%C>T'KU*!(A-4*="B=?N`+]5)>5.7TQN<EI6SH/:3"R.Q+"].L&D;9
M(TC,^*&!CE1#,[;MJ@_+:ZF1J3-Z["<_&AWXJTDSZ?I,USD)4```````````
M```````````````````````````````````````````````````````%-O0^
M'TK8/"O6T&Z.L)54M%2V@;-8+3M!$08J65]#G2+N"1UF*5$2A<C%ZB/%F85:
M)\)SOR-B\%_1M]7P`U2RKS7Z1[*YTYGC=E],\AW90];P^K'"%1%)RE:-?QSJ
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M,H+*'.R(H88RN1>[RG0,JG1F2%%F;I#`W<^:;9Z@UW8-B1?OYDGMB8L9,9*S
M+9+M>@Y12$`GL;7+2'N-TI"(7%X#:\4J2Q&R0-^[`WOZ-S<FW=B5_G*=3#RS
M%(:)ZNL?UW],)!55A&([-L3F>NO3$F7U]-#X'S]6#?6SQS1==^M,7=6%3"9F
MUR:XJD30IE0-,NVE+047K+3B2D.3RB#E.0F3_P`S/["+;6,]NB,<:MM;RYF6
MKGR>Q6T^62I#*)^]5E1_+$/.KR)(:4L)!)Y/&[+OJ:V`]1Z1G'K]R69MR3DP
M@E/^-D*=]'='^C*;MRL.R%O%K7T1T$NXONKGZO:U1\U=!L!"F6T?V/TC#+)L
M[EZ;:N$J?.;Y]_AMC:I:6L=G$Y4[M#EJD;]S%*I#]87QM+W2ZTX;<;;CUS<J
M,IU$4ISQE/44GL"0WBT6Q.+@KSGKD&=J(W9]F3IDD3+)SY1).B%39JX8TT>5
MKBQ+?R-<J=#-C`D/T;]M;DK?PYH7L>I8MI6_5'=;#&(_36];JV&XX34<D?OS
MI2_FN$H?&](R+I2FKN/.")N;C$"E=K*CM4F$IVR0_P"`R.N_5OH*>^.W)'5+
M#-XNR7DZ=;\C\N7/-90UL#P3("I%>T"JZUI7.8BGB$>::U>+"CCR<\'M#>2<
MICQ"\O0M7E1IG.@03_\`],\?GLDH"\H5SPE>.>U%G]=4U-X+F<5FX=!'2"K7
MGE)BKBRJM4/3NQM;^KE;=?JO32#,?Y\A>2BS#DAZ@E(9KL%M9OW?PMY&SV.>
M4K9R1TQ+CK7>722U^RD1LJZ&KHMWZ1)LN;&JE<MEDE=U\B?[!O1L5P4Q)(<I
MS"%AVB@W&C(FW5Z!`->>XWC^ZIX_"X]Q,WMLC8NT)SPG7E5Q*K.57!U:GJU6
MAOBDEL-N:6V;(&R,U%=*#*AE6+4>QQ+YJW')3_OEXUUR%J^2>P/*?U!D+-1:
M/AB(N\E>J6AKW,$$UYQIR=U;7[4KK5K=853CY:\<+D,4*G+-4#NAV3M"+?;5
MF2;[-^=TZI*>D)"@?-W7_A_*Z-ATXZ2X8A_+;U.6Z:P64-C;4TJWHYAK9WC7
M6?/D;>VR;-2=F8#X79%85!+XDG,3HB5JIZ5;("D^^YA!^0S?M#FWCFJY1Q!`
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M[`MVMI3Y_2B0/CH\HY<Q+4S;`*V4[PEK4NOYJ=MW+5GIL)U."P%]V7Q_/HWF
M'CFA>>^@;`FR_A7LF!].T2X]/.R&5)DD+2:R"%3ZD71TA449%VL3(JZR)/\`
MQC<I+DYK=C$1>=_P2?M:!`$,_K>4+52-F9ZFZOZ?C+$SS9SG;>FD6:FF3Q&G
MV0=)T3T3(W2`2917;4\1)\>S>>V%E.5[[KOK()_(,+,-^O0P(3J?^JSSM6E6
M7C3+QU!:MIP&RZBMF$UL18=9U"YR*C+/O!UJ-RLN\8O*4K$C=WB4/:6BHVW%
MIC=DV$K:6N*+/QLO,,T"VR[Q<DD(\VZ7\W:(O^M2J_C,TFCO=4BZ(Y8KR]F.
M?L%EJ9U();M`JM7.S#'*KD#!,YCA?&C$"K.S5@C&-SCM_N;G!#]7_P!?)UKY
MVXO@;MVI(9QR?P18DCLFE*->*79&R73]VG<I3VE,VSH:UXU.&4JRF3-Q-#:[
M-R4MA0)M$*7\-:4N,^TL*"&&3Q$[W9K7L#L5@NG@FL.KK7,G4'D=7571EN-/
M',1C=N162P:SNHXM$76<+9:X]LO#*[)CL.WTM+2L2Z*VI;L>2N-6X#9'Y$<0
M6IQR1U2HL=C)A+#/K`I>!TY!M7Z.2!S-J#E'G"L>88=;DQ41(Y8PH)Y>Z>M]
MI&O0Z*EBE`F/2)U1VR@HS30-R0``````````````````````````````````
M````````````````````````````````I'Z4UABZ_/\`[&I_,VJ^MMK0YWM*
M`E6!=3U_&ZJABB5Q9P9$\EG,@^@W+(QLYZW4_=7]!GX^VFN_T;_3]&0T+RKF
MKO>YXSU%UOQ[Z<TQFJ;$JNPZXBJZO.Q;)WYHIJ*0/G/F1KATR@SDPQJ2PFJY
M95UWU=.U[^XHTJ=2N8'W7!QJ;\@[1.$(Q?SL]N*EFD9MCEVSJ2MF,2NZZ2Z-
MN6PR^S[@93NXX^EYZY_@LDCDR8)#6<RB943?54+D&Z9W-4GG*TC_`/?RBVRD
M;<$!:_R\X6[5Y3_F]=L3/R'#9,JH7S7J7H6/2Z2GV4Z.<0J^*])L%N$DH*DE
M#`]1FR%#%*6?2,NK^E,9G9M*QIJ7G\<[[`:1^(J#[X\>J:N[L$VE(K1[M2O)
M1U'LZAZCD2LB*=(=$+^YV)_8JC5,'-UNV),+0D%@5^F/B39.7MOB:R'+EI2(
MQ.<F^5.@;R_2WEWM"Y_/OFF^[.FW5:WLR!2&KS+9JGA"86A5<:3UW>=]5N]7
MI&5=>5FO73&?.-*TF0KCB-VV/-.VPG5.6R7!IWP2%=^C+!]0>8(OTKYA\L4)
MU=(*UK.$/=C<Z=M0^(OKM8*JLEA_/TPCT:Q<#4H<FZPKJ66:]V4Q2/12UI9,
MK9"4+A\F*/S%QH98U^R'L#.[>Z`Y[C/F+((A,$UQ]"8H:?6K6'0=;5YMS345
M=V-(&Q^>IN7#K%CLEN22/T.;4+,6B)PU.KF_)4^B?!&?R`%@O,'T?[EM#M:8
M<>]94A:L5C3S4]>7O65N797;O!7E6V+N9><'*2TRR_PFIH_6;],X]9LCD#Q(
M%ZUT1&EFJ342=`GV3ZI"0WO]%<Z4IUG34WY]Z(K]FM"GK&0HD$OA3YNO(1.A
M;8ZH'YI4%+6I8WNS8Y-#XUIEB16D4$*4RD@LPO?7;7&0&0593=5TE6L&IVIX
M%&8'6%:-2!D@<)C[:2E8HNW-GU[(BFM-M@S8L\LTW<S8_;;8\PXS<S??8S?;
M;(9ZO:VQU*)(=&Y`Y$)UJ)R3DKTB=840XMJHM:W+R2U!9FA2U`M)T.)-UQ@P
MHW3&^N<;8QD!C"*M:Z;2&%,WP&%($T57G.L83HHJQ)2(XZ*==M%#DPE$(-"V
M=>?IMG&YR?!9FV,YQG.0&2+6=H<C$QSBUMR\Y&J1KDAJU"F5&)5S=L?NWK$V
MYY1FQ"I#NJ-R29KG&Y63-LZYQ]6?D*Y[\3<:[V"S6UGDSFK%IQV3&31BLG2C
M*Q+GC1+S<XV,E*"7%QC5^32'8S77?\S51A1]S37?Z_JUUS@.+6G#?&5,6F?=
MU/\`*?/55VXICJ^*'V)7-0P2$RHR/NKAEU=FW9UC;&VJ/MNSA_U%6^,_=4YQ
MC!NVVN,8P%'K.\4>/GXB$QFDH'`N<:R7=65=T_U#`8#730L(ZJWII:_RNOZV
MFCRXN&BZ-0UJLET(>-TR+7=)OH6H3ZIM,*S#,!L,M?F:G[KLOGRV[$87-WF_
M+TVDEATVM2RB2L[;'Y;*X:Z0)X='-A:71&R2??:,O*D@C5R(5:I<F[[$_1G?
M?Z@H-GP[\]";=?+M:*[GS!-Y/;SI<LCT;+AL8Z-.3[(D%S))5&T<5>']U8XK
M!I6JOV3+ES:QDMF-W!;@\O<O8O`"':P_KM^>E,5S9]75DHZ0C$6M*)-$%<$^
M;^EC[B*1-NN*!7DZ,<#0R0IW9(TBF<WK9K_?==4AF75$682=G/W-M@%IN`O+
M^KO.^9]-2ZJ+COB;I.J[/>[EL*$V?(8B[PEFLM_E$H?7260IK887'5S(YN32
M_)6E9L8J4_F)&A'L;\F%XV`;,0``````````````````````````````````
M`````````````````````````````````````````:X?6BGFB_.![OJ:2SVB
MJ[B4O-KE)+7?I1Y=XO33Q'TEH0UQ5PR5S*.O+')82IFAR0IM;'=M.V<$#LI3
M&)RCC,:E;AYQN-/'7J=M9I0VP/K_`)1ZPH^O5?53-%ZWKGHZWVAHIV]9FW36
M'OM>6\MKB-E,?3C]*8XZ,T<DRRPDJ%>Q-;3J2E0;E&&EJ0D.)^5GN[3+1S[4
MM!^IT4J:(UF7'%];4Y.;(D%BK6;6%4Y2$9G3T^.DGK*1OEU4N7-")`C0UR84
MA88AJ[M2A.K-UV^T4$;0ORK]W**DG2?0]9W"=(.D.K7U#6UKK7#LC"]2Y,C3
M235#H1T8=('*A8G&2DE1VYEP=XS%43&D<VR**,1_"@Y/C?)X6^HSFOWFYLN:
MJ:HY^,YC8^12K][GM^YU]LK(RZNU@*K6Z=O*?UVMDZ2,X=IRQ,\CASS'5S07
M%]4BA`L5J=7?7&"=$V`YUJ^5UL6;Z=1#J"6,MU--O-?&4IOQSG-,]`6T@Y.<
M>[X!8T%8J@JI#I,I*1*6:O%,10J%*Z/:)VIN<DAIVQF<:_>+`5<E/57OA.9W
M`^C?_"^_X/8M,\_=71^,46AKYR)J>>6NKH_B8E,YVG%V6XE4>G4=WNAPL5P@
MAV''1W.0MI2<E-N>6M+W":].J_>B_8_R&58?+"CFB,K+1YE1W4Z0%CM6/W8^
MR%V9;Y<[-6*F[0^0PZ(4BV+*N;27EM=2#3<;2EITT79R;GZ`RWA_U![@@7B+
M;W3E]<]V;.^H>2HG"8:FJJTHA>K3<EN/3DJBB)+94\=))7[8HD3?+&^:$/.G
M\>3N):%N2&:+5V#\F[)PB.Z_:;TJ=:;<HLCY17<Q](U$FBER7J_ZPFZ9-5<>
MJUJLOD!V)9W!_F_.[JWI8[9M0WC+-GXUJP[R2)?PQ=OJF,^2S<AF:O\`LWS!
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M`*6@7.7$,'?9%:-HV&P5XA5N4TB$6+F$RJ:/06/6'(Y.IF+$RGE;X4;:89S?
MKQG985KL5DT(FA_]E7B)[<'UOF-6=&U:57RJO6VYI)+$U`N4*J%WN!G<GNH$
MK])(??LDQ*D%E(VWX0N$<(>$",Q21JY&H<[[8T#(*]_L;\6VI#%3]7U'=RS.
M=Q]@>)U8="Q+FXZ2WE5E4H6:NY$QW)/(8SR]4F15=.V&TF=6Q.:-8M_/3FG&
M_;T+3'[Z!*CE_8!\VVR!(;%Q.[6?F)0P'RMS)@E%V99CE%(LUTU2%YRN3S(B
MMV*6)HQ&8'#>AHPG?7)4=HA;'A2<@--P>F.UU#C'_P!AGRP;']QB4DN&V8C,
M6=5&&=UALFY.ZI;I8W2^6GI26J`+(]I3JAT(GF2W!(=LU[%X49)6$[%X,SO\
M8"QT7]9N*)=6/2-Y-,\EIE%\LM=.2"S+@TK*>.,/51B\JZAUJPR4Q!*R,;K+
MY%'T<)GC8M=U&&LK#22=L:HQH068;J$6R/W'\ZD"V*%0JZDUK,[N[6`7,93`
MVIV4QRL8C5D!Z`L&=SN3KG9$U&/#8TMW-DE)3M[$6[/3GN44<B1J$AFJ@!*_
M./JGR-TI;O2-&QV:;0JS.:#UKW)XG8N44;>Y)3R*"5O.S+\CS;NK/4D5?^/9
MB-(:8X81N2%27MJM2)ON%8W",('[3<@3`A!,9(P=`TIS[)(>_3ZONM[[IYSJ
MOF"S(HRNS,RI'&&V4_.>#_RI<M>RMF!`YM[:XO2?'WTA!A)A&YH7&:NZ>*7Q
MS(96?KGFER=E-:;7,2W([PK4]9M4FB5(N,LS9/I),F%P0M$N).V==L81:E;X
MWR9]/Z@.Q9>U..)(E)6QWK/F=^1J-$1A"MFO>K71,=HY*"TC=N4>BE1Y1FJ]
M4=H43G&<X-,WQKK\YSC`#*H5TOSM9"ER10*\ZEEZYHL63U$Y(8_8,6<EJ.TH
M6<B3RRO34:9TW4_S"/&N2;\MOQKE23JI*VVT^DW3.P5]L_T]X"IFTYE2MG=3
MU?$;,KMD='^=QI<O<E'\02LL*=+)=&Z1/+<V+(^TRA'7C(K?=F4Y7H\9:$YB
MS";*?7)@"Z)LLBQ$8VFQ\D84\-T8]I.9+%#N@(C94;T;]G8R0&OAJC1L*92V
MO3*G95L;@C4C&3,[8UQG(#!ZGO>EKW22=QI2U(#;#9#'])%I0[5Y*&B7-#-(
ME\6CDW1LZIV8U2UNRM41&7-CAKKH;M\I5Q._^F^`$L``````````````````
M```````````````````````````````````````````````-<_J5R;:G:?*Y
M-(U`MJU'*-+SYVM)63<2N6(80\1^E;DB%K.L=7JH6T/CZ49(OXB6C^=$^<?:
M.,_Y%[?3OJ&JLCR>]+4?5<_ZJC73M#T\W=`S-KFUS<N\V2GH6@:D:)U$4<9;
M8O<)DYAI1DGZ!G;^W-C@5*FQ^:8VS/\`EPU,/QONG)SJ&MZ^.;_<?A;G/K+I
MRW^B)?<DSWIRW:^I29U]:]CWM:=$/W0757*C>0L;VEXJQ(HBM?1:I:R>G58[
MQDLD]*0XEZ*4>3D"8P@+C\(07W%ER;C3H=9:-\;0E;4%;QB<5WUK*ZQT;Y"Z
M2>L>LW2PKAN:J&=B9;.W0L%S.M8:1M&VO;5*%$1+S^X:Y4_?_%"'K:X"[ZE/
ML,A[.LZN-V1+`;GXFE$DZA@LF00KGQDH*F>>-EG4+S'$$EZ5439A;GBQ"C$F
MD:>(1*=5Z=*7DYS2E9/,.#9EPB7>WHUY_P!ZH^U;.7771,Q>Y)4-,S^@%KM3
M5@=,5ASY9<N;E?2B23U[M!GF-_\`DZX,"-.0PH,)6[#0V9W+,-3/!F,!KJYW
ML'TM\W.*>1;1BE']S=I7CV+`)8FNZG;Z4W'=SOSQ<]>I$Q%'QIK8G%R02NC*
MH?X6N>MY$:KU<-S#(^VXQN4<:9N>&+*O8OU+X6J!GC=G<&=(=,N\@A_3]Y2+
MHJ<UI;666NG?;HWJIBJZKIBP0"-2!*R1E)'8I!""]<KFS5H:'3<[74]-^.?D
M,HM7V/[SHZ[J2-L%F0[-FG<72_+W0D<C=2W`Y<UM];1*J.06I@Z)02A12!MW
MQ6$US:%C.RDEJ^^X&OARQ;K^X_B:I-$P>PL!QUB-(X)%2!>E3+D"Y,>C6HEA
M!2E(L2*2MB5*54F.UW)4)E!.^VF^F^N==]<YQG&<9`8WM`H+NK7N&\+B>Z]U
M0D-;HMVCC/LK<FU,VJ69,W+U.4>3EB%.T+#DNA)FVQ>B8W<K&,:;;:Y#`WCF
M_G>1,C'&I!0M+OL<C!SNHC4?>*M@[FR1Y1(%NSF_'L;4M8CT#2<]N6^5"O9.
M67LI/SDPS.VV?D!U3_RER[*HRQPN3<WT-(8?&$*EKC,6>JAK]SCL;;EAS>H5
M(8^S+(\<WLJ10H:4AFY:8LK78Q*3MG'U%:9U"16RL:U94TK1,U>P=I1SS0O2
M<)&R)L*!-,M"F--&"M)6G2H"BI#H7&D9+=KA7@[&$)6A&/\`I:ZZ8"INGE]Y
MMDDIR$O`W'+?A(QR"-(S6OFZH6M6B8I6@7MDC;4*YNB*5:B(>6]T4E'Y*,TV
MWT/WQ\_\L@/ZV>9/GZRSB+66T\BT>W6!")*1+HE,$D+0D/[`]):_BM6I-FYP
MT^#R6I)`82U-Q+=\Y;BBT6F^A&#L[&;!'L+\>?-&N89):^@'(]=PJ(3*&6Y7
M<K:(LOF;%_(83>^L*+MF..S@VRA,Z+&^8)ZY8B3,;GYV3)VL@E-L25I]&0RU
M;Y:<`N?0CSU4Y\T0QSOY^L:)VZNL-Q=)@N5DV9"&<EBCDU:&15)#8PP/R5M3
M%ZGG(4*?*XPO0U5]XW33?4,BJ;SDXOHV,W#":OI%LC4*OVK('2MO0[>53U\B
MTUK6M*S.IN'QY>PR*5.S8C,0U@;AF4+4A:=P<$A97Y9Y^Y1>^H0JU^,GG%&&
M&.0^`<YL5909@77"Y*X17CS(8S&I<MO3GA[Y:L!5-4Z9S,6R!2JIN1+4"0W<
M_4U"J5'+"=M52A0::'!YJ\>>3N69^FG\!>;QE:C,'O6`OS%;]K.5K-$T9NA]
MZ8TL(R9K)>A7R:1*=VRAX^A28/<,D$HR-M-BS/\`IY+"$W7PHI/:MH%4T0[#
M]!X%`*0L*.V=S/$F7H)@=8YS9*(<[*7*&:UJVRBM7PUY9H<E7J4#4CE1TC*0
M(#\E%?3G0K8L*SS'^L'QY)D;(V-5UWS$TT(FU<S>N'UL35.X6'%5=5TCK64.
M:UU@/5=KWB3L2"P4Q4XW;U6NK:>\FJRC$VQ*@O9.'86O_6FYEN-JG!\TNV<O
M=C3.XJ8N<ZTGBEN7U3OE]K*OY7`Y8ROD);J>9JIDT:M(R<N;PM2',)921XV3
MJ--3=B3/OAT,:_K"<N0WJNE^C(ST3>S?$**OLOH2!T)O'J9V@K!+2YC'['-;
M8VX)*\0.$:9'B=1I*:XEIB_K/:B2VTG9,G))SH&7]$^!3GTATWT_T;+.K6!E
M77A772->PPB,\N01FF3&R=#4K_A9/%[IFK;,$2#H"#5"VGJ5T;U6,[5)RE1N
MFASZ8F)T3Y"`Y=_6`AJV3.;K%^FDBZ-[0/H&'5M7EH4^^R.L^:%5LS"52V%N
MG.]<P"[*NC#*F@.)JXI-T$A+D")1N;JJ3%HC-,%@-QOFOP=(."XKT/%GZRV.
MS"[AOI!:$<7,4./A.C!$V"@J/HR/1]T:S'Q^)4/>B&G<*E2@@W0@S=5_QTU^
M,XP&R8``````````````````````````````````````````````````````
M``````!4_G+M[F;K*4=!0ZA;#/FK[RW93A4-XDGPV<Q1'#+$:EKXWN<<U=)A
M&V%LD![>JCJK!QK::L3EZ:Z;[;XT.)VW"7I5=]/0>PZLJ28V;"(S9]X;RW2G
MH"]R-K;Y79FT#9"Y),\0ID4J"UTA_C#";HK6Y3:&83D;Z[;?&,X`2D`Z]L=F
MIZ2:KV9S;W9#L:H(U6MBQ,O2;'I#S$JLG52E,-)R:E5$[EF:_5\Z&:YUS\9Q
MG`#ID4YA3E$S9XW3"+.$&(;W)U.F:*0-*J)DM;+E5J\.1LB(5F,Y;>T[(3\*
M3LG8+(R3O]>=?HV^`Z]19]:I*^TMI58<&3569'TDL+LQ1+6`FOMXLO3DJT,E
MTF9CAK'-H^M2J"S"EF%/XQA9FNVN^<;8SD.6R6!`Y+^7_')M$7_]O4-Z1?\`
MLDD9G7\)4[H&UU:DRO\`!6G_`(RAS:WE&I3Z;_3L<G5DF:8VT-TSL&5F%Z&Z
M;E&Z:&%F:;%F%F:XWT,TWQG7?3?3;&==M-M<_&<9_3.`'#:FIK8FU`S,C:@9
MV=J2)T#8U-2-.WMK<@2EZDI42!"D+)2HTB8G3&A99>FNFFN,8QC&,`.>````
M````````````````````````````````````````````````````````````
M```````````````````````````#S?S/^O\`K9W$;SA4EZQ0O3+?G</:G:\I
M2N-`)#&Y#).M>8IG0$=82VG2U=2G<^B)'(4<K9%IQI6BAP0:XW3E&8*/*#^S
MKP!=YAU*;TAKVA+\*L4)=='QY2YP-Y5V;6C9:7&Q/)S`W5C.4ULI(U$H)7KJ
M>MFK<V(XXF<OWQ:=@YT/V-RHU"`K3_K_`':MK4I5U9R3TN<#I85U'![:N6:,
M4=MJ'L[C4,!YTK[GIBKZ*1%-<C\K>)!LT0=2N<E:]V0ENZY]5GFY*WQG!P8*
MP^($;XCJCG!PZ;[RC]<<R\C07J`MR-UO2UN88%/KEL3H!PN/F^<3M0WS1&F.
M.BB<PG5W0%.&VRM>V(BTA"C4H[=2$4\N>4?J`VL_!+ASIW=SQ:?`D<X?E=(V
MI64`NJP5-#VPY60S7KI-GZ.QR+P0V#6$BD$@G;:81(E>J9W3K4OW#B<[I,_>
M#?90'G>?IXX5YYH])FQA:Z&\?$<]V4XQLQ3(8ZT2-5%#VW^0QQ2N(8E3D;$'
MXTE<A/SHEVRJ1EF:YT^-=L!YV.!?Z_%Y0#H&A+@E/2U(=%PB`UT@=[A3TN_1
M%-`7>]>-9"SM?`,,,7,;"WS%R;DK,RLT@E#BJQJH5+F$UN6;*"=RS509I`WS
M^W2_P*F(18+,@@\T5=JITEDVPWI>.'-8BYS?6*.*%N7%H;29#'-()#'(QU.)
M4IVY0]*C#"TNV#=2"BS`G;SZFW]C6N.@>*Z#Z3I>4/\`S,5.^C__`"HZ0M"6
M539LTGQ"N>6V]0UY*7,\I+D57PIE8]XXDCS?JWDFJLY-^UI^!E.D3!9[WRH[
MH:6N?(<[Y:F7I@@L:87I65(60S\-V1/8]"(ES;O)7*8W)9DUC,73982)\0U9
M*1,KHYGE$9,P7J9C<M/G38(&F'8WLOP1'>TJG@_'ED=9U#Q75E),?,-T74W6
MK;5Z=?2B56=%FB>V%()C7BK=#.RVF)S)>L/9V]*C<F=.S)]3C-_A9]L-AOD)
MTAZ"=!2GN`GOV,_X\?J_MVL6VI:Q34-*ZF9H?!I/43%*U6[%,']PD*6QD3FZ
M.6=3R\O#HZ-*]*HV5;)TZU"D(#00@[]]V2H-ZR]F+K>41_D3FJ?]-U)1,9GM
M!P=KL]=)GF=P^+\X.\`KQ32<>FBAB@++8B1T7O,A<G!$Y:%:)C$)QJ=9OD/1
M=Y4]:=.]1R#T.9>FFZ+Q]=S7WA9W/%81IHALBB,@1U9#H_%5T3?Y,8\$Z()%
MB;MSN6[)%Z3/P=JJ,V^V4GRETP&W0```````````````````````````````
M`````````````````````````````````````````````````````````!I$
M]=^0)+T]9O",M@#GRC9UAT-8-R2F.</]HR!4WTCU:@EE=HXM)7;1E;6^4N+G
M85&,YN[JR*_X^\I&[9P/W4:%Z;XSN&M&\?+OV88VY7'>&K&HWDMF-K2%2&K(
MC0/3=U4]S]RS/,2*R9?T/2T-H5+53]$[O9K\F4X(>DTND"5J5,:Q/L2F(0H2
M4R78+,<2<8^QU)V)$IAT/U77<A)EU(\N1"[72VK&L6_6)\DT1M"X#[FKN&5L
MX.5>19CGMG0V7QM*BF)9AY*`UO-2:M[EA3L<4'GXX_Y=[;\HZ\[<[+=*]EW&
MID1YADD/@KXU9I2?P?H/KB2=O1JP:`J2J(36'\N76/4-CP9*EA.SNY)"G%M2
MOB@AK6)2/M[$!Z"/0[AWKWH3RBJO-L/%T7GWU#IU6TZ<&;G^R9=2B1J+NWI:
MNGFYZ[;6&"2>,Q68,U*40[.L397E_3KE:9L;SG+7!:M0=G(4Q[(,].>-F_KO
MA+CZFNSW_B.)4+<<GHRZHZF)M!^BL?E_'%J/.T(C-Y.#^IOYUE#'V(])%*`O
M\E?(VMM2_C)]]F[9(4`[N(>@?N/O9IG-D0Y3LVJHI).A>?:<YEO[HWDJT;0A
M#31;56%C%6W->@)[#[2_?W61/<D9HLK;G<_!>RDA4XY7;I%6NQ90??@'N'TQ
M;NS^#:DO)%T>Z4?U3QA1DLMRP[?YCMF7,,<Z50JKVE<TKJ'RUIWB,?JD^7L\
MA:,O#N^Z.W[,2P)D&Z777Y5Z!Z_``!^==--<[[:Z:Z[&;8W,SKKC&3-\::%X
MWWSC'SMM@LO77YS^OQKC'^F`'Z``````````````````````````````````
M```````````````````````````````````````````````````````:&/7+
MC?JN^ND.+^C^8H`SR]XY+HKTJ5MZ[6P&*`3)ONNYN7]()SDBC"]S+(5_<666
M26;A5HIT3MIY!1Y_V\8U-U#5)(^/O?).FYXJ"N9_V!B'-$RZC06=8]A]M0QQ
M='*&2/G&IT]>J)?(DBM?.7$[_/:.4+(QL5E5JU)U6B(_0@K756`PN-5E[]2G
MHRF&OKCDFU'SF)!T%QA;<5;&SI2EKQ*H$KF%?7;G*W=>:W.J"8RN339BA+SN
M;N?OKA2\OVWUFJC_`+1FX<'M2G.W63Q%X"IN?TN493;,O\\D+E6,4H[H"Q^L
M8!-8X]J)';!ER5)#I#%DKI7D>8F8TLMN0+&IW4N*HA%LI0J,DJP$F\56YZA4
MY#_*?E]FLJ1PN>=.65V+#Y_6/3D1<-[8KNB(+T2ANZ(]'HZULY9*;BCD4SSE
M!Y)!61EDKR:G;UTB;\_F*3<)MM`_=[%]WM']@*1N-42'LELH%;V1QL=,V^+M
M/7*BISZ>2\F%N%H'YRG3+^.5M,+9(R8(?]%NI<LV="-]&TPC.QYNH0ZU>F_I
M3!($E[.N#H%T+CUF1?RQD,K45WR7/9!6M/55=4S[@<+1A,3I-YL"0LLVLEV7
M0..,3](VY6U.Y9BM`CSA,:FQDT)8Y5_L1=BV.WURAG,-YR?C8C<4,BO1#QO7
MUX5_,I%`;K[*K_GRH5M=UZM=5'^+Y4LKJ9+I-H3(MW+5:E:M-<::&[[YR&.Q
M3^SA9DL=HS)YS`J2A*B#Q0^YY!7\+MJ<JFYSI>V(92#G63S9>KW5V=T2V)H[
MEW,<L$+$B0EV;OJ+4;I<&_`>HKSK[%;._.,Z1ZV:HZWQ$BWF>1+CXLUR/26H
MV%PC,UDL+<&\I_U;VC=?C59'-]_DQ*F-UQOC7<O3;&<`+K``````````````
M````````````````````````````````````````````````````````````
M````````````````#SM^J%/M-C][\\/]R\;]"]><[1/AOK5*5$:1ATS>2W&_
M'ZP:-_@C$HE,2D<5;X5+#8DV/7[2Y/#BVIT!BG<Y,HP?\[%!J%AMH?V8N8N?
MK&C*F$W>V[55`W"(<_UDBY]K+L)Y31M[_8)=`YS9G2.]CJYA-IE6S`\K8TYD
M(&22&&'M!>V[0;G?)X#,[@]-N^.-HQRY'WQZJWE^\.X>\G%OMJ5]0U3*&DLY
MJB%"\60R;S^31!VG*MKC-;F3MXD2=:LB7XJ'.Z%O3-FI&^ZU48&U'EKT#].)
MI8E[0:Z.0S;&C!+A'G&IWVI:_D7.TM@U72_HCJ*CM)U9"?H2Q=V>;:1Z(4.U
M2\]/&=_WC\.2I]$Z%7KMH:`\]OFKU]V/6<8LCN5R2*^D+AH#S>=IW?4FOJQ)
M)T)81<8B_9C*X6M"WN4RB&02><OSF.T4WR-\C-7IY.O9)`K*R[+-_J*P6`W?
M^A?3W5J/SIY/[I?^D;1X1L2PK@JJ-):CJQ!4Y+(MKWJ7H.)(X49;R&YH+:BT
MVT:LY1RK7N")$HT;4LJV6G;$;I4VA>`AONWV9N'BXNP_/2)VI%Y/V)$9Y$Z;
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M--<?.0'9````````````````````````````````````````````````````
M`````````````````````````````````````````(PGE)4U:;]!I39M35K8
MDEK%T4O=;R"<P:,RQZ@#RMRBV5N\+<WYL7K(PYJ=FU-MN>BW)-VV3E9SM\EZ
M9P$G@(;O3GNE>F8056M^5Q'+5K\N1Q^6;PZ6ISET=6OL66X<6)4Z->AY*5X3
M(EFN-\I56IR0[X^#2M]?T`26\1R/2)(G02!B9GU"D5IUZ1&\-:%S2)5R3&V$
MBU.G6D'DDJTN-]OMF:XQOI\Y^,X^0'12.M*XF"XESEU?PF4N2?1&60X2.*,3
MVN)+;EVKFWZ$JW-`J4%Z('+3"@G&-L8*/Q@S7XVQ\@,'5<S<WKI6MGBWGZD5
MDY<BWTIQF:JJ(&HE:\J4-[LT28M;(C6'=W5%R)I?ER5?@P[;"M.M/+-^O0XS
M78/W%N:^=(/)6.9PN@Z6B,QC#.CCT:EL8JV#,,GC["W1A%"4#(R/[6Q)75J:
M4,-;$S22F(.+)+;$Y:777!&FNF`FL```````````````````````````````
M```````````````````````````````````````````````````````5S[!3
M2-;R7U`AA\<DLPEJ[GFYT,7BD,3862Z22);7,C2LK'&$F5*/\E_='(TLE(7@
MTO.Y^^N,;8SG&0'C?YCX:]HH.[^7]3=522Z9KSCR=WA46\+9JS+F1R^;5%*X
M.MO-YM+I^4[3PU[:(7S],4K-"6-F=VI/HDRI>D9FV2BD7Y`7YIOL/WL613D?
M%[URPUXY7WU!<<3MJ0)N'+DG[Y1$8C2&O2JQJZ40.(S)B);H1.'DR49(M#98
MM8B$:9*:>HVT^HS<*QM74OK[Q]%/4Q1!6"XKB87.1=R='\E-\YYIN"P)]!'A
M@]`(%1C%%U3T_N9C0^05;42UYE+)'TA.N$#&3AR(T4I,9(P'2H/83V:5LO`<
MG=(E6D$WG%!5M=G6<+L#G2PF=[5MTI]+B>1<F14DKZW&(ZN-82]@>U)9NG_0
M:L*%Z?.VQZ;`"3^:_4CT-C%Q<NU(\[,<D@5[],]_V-:-E=,-%H)Y-)*VJ/J:
M7UFS\W<TDQ:*KB&69P6KD!,H0LS@ASA4DTP06>C)USJ<$)\E^X_=7I0DX=>3
M&Q-S5($OL#3]%V@CI9ADO\!M3GB2TS8=@2"(3%-.3)BZ%+B-HJ<G4;Z+$Q'T
MJDZC!11I&#-`W)_V&^ONEN2.1ZP<N0+[@5$7W8%[-+.T*)RC@I1L]A,2@\VG
M4YA4/D]LMRVI(Q+UB=A2FI</IB;+O@K=L0;F."Q.0:&H5G_L%W1R-"[5Z-NZ
M;2#M2OB^7_*9YKVLEC'5'/+_`+V5V!7MZ6+9DM/50:-2LE&K;$=<X)5MV"UJ
M?4_).B?)!.F3C@O!8W]E+6.RCN>&P?B&3R5^XPEW-M;&8F%\PJMFV;61?MCL
M]8*H^\NCU%E:&O&J-2-R._&=U)BQL6I4)AZH]MT,*QL'747_`&AJZORT%%*1
M'A^\SK-@M,=-6E>:-ML.LY)"JW<^<F>?+S&6,V*QGJ8Y:<.FCO!L-9$I;]DS
M>G6N)'T%*B\&;ZAG7._]DB+6]?G#_/-H<'=%<_2?O1JCDKIF72B9U5(J[=X%
M-$R_:(39G?F]Z;7-Z;G1>W;D&I3$"%Q3[;:8PG--,+)V#TR`````````````
M````````````````````````````````````````````````````````````
M````````````````````/+SZ:V_=KKVO=-+6/Z&=%>:%,1_G"J5W&4DIBIG2
M01OH>^YTY3C-A+YG+F>L9T]RI/6+DQ,3<?$VQQ9G(Y,Z:'$;Z_<-V/"K5\_V
M;NF^8)`I:)+YXD6BU.%JV'3D39&:Q+<A]PP%^J6;ZP$TOHEF>^=76(LTKN)!
MJ7*(T@8'%PVPRKBOOYSMG&Y@6.OKUEZC;/+KL&Q72!2CESL2O9!U3K")E5%&
M2:V*,K;/.?06]>IHM+;(F<.4UYI.YE%FK\8@YU(2X=4SF4Y(TQ.N^J<@*P\S
M>T]YMG,5@R;N2F73O.'*^S;'YLJE_P!8'2!CR=;*.@X?:?+]8.L?Y[:+7I.;
M.=_7`ZN$2:)#'URE!&%)2?9P/,,-U+P%X/09K[GSWCQ=4-%'^>M713MQ'N4L
M1W-R\QVG;$,7\@UGO;:QKD4L5/B9!8[9''=]-318MN1HSV)4H^\083IN<=D-
M?O<GH]P%Z%)D/.#K5S)2L>5=K5Z9Z-O4T25='I5(Z2YO-[)F2]@<9U&GM6^?
MS79VXM2F8:WM/HNRP/Z-.E^DQ;H:4$BS?W@\VK8K2KICRUP.XS:>*ZG4PJ,3
M:5\ZT2X0KDFM+.Z(;>7W:)W0<P3P]ZK2"6"[3';4I`W?<1.2=\3Z[E[Z*U.F
M@7B\M+AY;[+Z#M.O';S]K:#W)Y4VC>O+]7VZQU=$DD"I6M*^MMQAE.UO!7:3
M2U[L%'8CU#6U0[JC4#6F:D&=%7V#TYBO*<P/1L``````````````````````
M````````````````````````````````````````````````````````````
M```````````\QG87HUT]Q_VUWBL@C&_7.B;G'RNH&@*:LMXF$+H"/RWJ$^]B
MI]/_`.3,\,?"4B@IU864A<M*,SIG8["<S.QI916H5`2?V0^N++ET9;X3S52%
M>T]#(+P/:745^R=YN.8-=1QWH*>5"P7BW&Q-G@"4]H4P97+7EM++<%'Y2),V
MF.7_`'?TX(P$!V=_9+N#IO>0%4'*X1S4OJF$];IYS'E+<W6K$)<B9[,X^AO/
M5Q*%5TU)`W8EB<$EF3!/JV&-Z';=>W&Y48V+^SC4)H_L#=;R"MK]X8L^@9"\
MULY\@2+O&7E5+=U0LL*K*:6-2M2PE\CEMPJ"WW-*,B]SM+0\R#9N8Y#'5;HN
M(.7JE,;+7N6GXQP;L:5[^KGH3JWFKGFSN6-E'3^E&Q'IZ#6>9'&&0PV(4S:?
M/3$]3B^J<G;XWFOS)#UEO/!E5JDA!R5]/79+-4$[-YF#`'GYHSUFBZNTNAI?
MWKPYR_/N>FU#V[T(9(XAQ='HG.721<CW4UT*W*H?-+$FK_#.G)@],%C_`([L
MXY3L"M@-4J2MU9Q>#BP$\MGH_P"6?.<;MA+T'Y;5E2$0G]G]`5W.HO">=N<X
MJ]G,O&DHYN?JOJ29,+!/WUBO6X39+;$=?4R=H<2T*/[&%196?P33@%C*?]M?
M&*HY1;=Q<V\FVE'W^TZPD'0EJ774O+L"CVMK.Z2'([ZF]?R2Q$\N:E4JN6+H
MIQNN=F92:9JC6'G&?=R7M@[<+(2'^PCS5"(O;UR3&K.D4E0UN52;-O#RZ"E#
M/T!'I3/I?TO&IZXS^'RE^9F9IB$()YY6&G9+/PM2;$G:'E[&')2\AOZ;EQ3F
MWH7(C0XLAP1I5Q.BDK8A1H4K(T/+T/(W_P"9)VNAF,;Z9_77;YQD!S``````
M````````````````````````````````````````````````````````````
M````````````````````````!Y-.V^J.U:SMSVIO>K/1!'4]<\"&<IN]+T3/
MX#1<PI6?3A[YY;+`L:A'A5(HN;:94KGKH6C):-61[0+2WMVQ].IN<9U*#+:\
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M4P<*6]Z^'TQYQ8W_`)[Y:H^-RSH286@M@+79OG[+'>#-TB76''>8+7G]P(::
MA+J=!VB=$/)#!HX'K$QRK=<D)4Z8V^ZGP$[\%5!YC>BS=UY6ES\,\P2:_H?U
MKTJCZ>4POFJ5,T#3S&O>BK;KRN3%5R/;8>U*+A>ZT+2/CFA9G["KZ7HU<8E2
MEK/H`>D=D96J-LS1'6)`F:F-A:T#*S-:/3[21M:FM(4A;D"4O'S@M,C1D:%Z
M:_[:ZXP`[,``````````````````````````````````````````````````
M````````````````````````````````````````46EWF3P#/NDBNO9KR;34
MIZ0*=8[(/\IO<7+<'D^21%*A1164K6Y0=O'G"61M(UIBT#J>C,<$FI&F"CM?
MIQ\!V1_F[P*H>2)%OQ[SQH^D7I_Y,Y=DU715&O5WU]EQ*Q9[FH2-Q!CO)M<N
MR@W7=5DXK509]_&F#M==]0URS/P.YBE7=ZCL*73::**=QRT9QA&N,8;&]8Q5
M,>J"55F\4J]1']\AZTN5:P10SS!P<=4:8MO_`&QR/RLV68((QIJ&Q)9YT<AJ
MJ"Z)YE+J_=!3_4[_`#N4W.P();,"7!_D%CLT;896XMDCW?#7^-_F-D0;2]"4
M"@A,5JDTQJ7C&=L;!5H[QCYJB52TKSK1.QM5\_1+J^N.KK_AC^F>+DEO3DFJ
M7#4[PAAF5DV;*GJ0,:/681"/*%YQ.JG\EI:,-A1:=.>9D!?^V.7J@NNVN<;K
ML%G=G.=\IRZ:3FFU*.1/#6U-$EGD(<*^?G!X94"HAND>?XTYG%I]5>AFJ8S?
M.^GQG.WR%($/A]YFMO14BZH0<]+$MRRR:3R?2)VTMRY]XPZ2&SF.9,,],.KP
MVP#(%HBDA-AOB@TC1MU+)6.JDXC!6QF0&%5IX'^;=+Q&S(%4==6C7T.M=+`D
M,HCS/T!<KBWID-<W.PWS'T49TD\Q?C(ND/GT:2;+BT6Q.JY)IL4;C;[AF^P6
M7Y+\U.<.)KCZ(NBA%MNL[MU%(5\XMR&22UY3+ZV=;'>9=))@_66V1%^4*R&J
M</I\B_!4*]#<Z8;42<@HLOX/W/#8$```````````````````````````````
M```````````````````````````````````````````````````````-5_M7
MUU<?"7FATGU-02F')+6K))7&L84SMA/DL>(S,[:@D"=%)K.2ZM&%2Y&T2@\Y
M+DTPPC107IL:2=IC8O8-4,7]SKNYW<9_`[P,H'N>'UO:[+7FO9'/DC9Z*K*2
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MDPY/N9L>A3_CF_`?9Q_L1UHP&7#=3_1LM2\<P/@WFGL*#2=,]Q<[H>Q)!TQ<
MZRFH97J2HMY"6U)23)*F/2'J]'0Y.VG-VQJ@_)2]%KD+D<S^QU*=-=OG<#M-
M(]#5;=;9S'$.G9*1<<;AL.*BS+,&"NY&1`7IE(F[M*R)\T(;,0:KD^$.4Y!Q
M2C'W<ZEZ[[AMZ```````````````````````````````````````````````
M```````````````````````````````````````````````$,]!\\TKU74$Q
MH3H:O&*U*AGZ9O2RV#R+\W5M=M&EW0/[4;^2V*T#FA6-CVUIE2=0F/)/(/)T
MWTWUSCY`14@X"XE;*.B7,Z+E6B2^?X/+6.?1FGS*WC*B`H9Q'5F%[7,%,>4H
M#D+O)L+,9W4+ENJA2LSOO^1N;C??&P<&Q//'A>V97/YY8W)M#2N>6C7:FII[
M.G&N(YK-I%7"J,H8:9$%$M2HD\A2M!45;$R`G5.I)V3I2"]"MM,::_`6>3P2
M$I8.FK,F)1S%=)(L1!R(*8S-YT2TAJ9JT8B(KF/G$&-9D>+92\)/Q-BLD93X
M^WG7.OZ`/)%9W6O%5!R#LSA>"^7/+=?&6OV-4'+]5*9?66RCF'NAX03FGVBR
MXU('J*5WA-&;;YT:+</=$+.XF_MZ;[.YC:J_(3GI\A9ZH^NO&GI2?4+R]6_G
MY*7'/0D!(Y>K1%8')*2LH@[<5K4MJ7G&9_$ELTPV;2#ER52^F'9>V'-6ABK+
MVEPI.3)S2]-P&9?^;?B1PMT5>UJM_.+S1=PPFQ$'$TNNF%\E3A21,)'7\!89
M"^5G6[I!V%[4N4>K:L(HSN3YNB1)$I322W';['ZF)<[!=^(^T'",R4-N4$LM
M9I8Y*YP5+`9?*J$M^*Q6SV2S&:\'V!3RN')\B"(V5UW*D7.TKPC>B"OPCC$)
M>NN__<D9,"-WKW7X'K]N?9Y9]TL3=4SP_L2.I'V!P+H*PYJZQ\SG2I>AI>^V
MK`F6EL+JO(B\8MQL5[G['+D.C6L3F*E"55^2D3AC[G[T\;3G/,#?R4LD'3[_
M`-(=%4-22]&TQ.RJ^:J4CMU3AZB9,]N%_EU=%-L'<<IXPXG1^.NFR%UE62RS
M$.,HM\K-0NAUOW#MS;9E`4'7U`VATWT'TEBQG2OZQK5U@,62M4*J-'&U=B6!
M/IS94HB\8B478]Y@V)BMMC#U"Q:L+))*VVR`@UH]G^'HTRL27J>P=N*;;-0[
M?S^F.C2#6)ZJ62[Z.:]M@L]GS`2^U(V3F3Q9NUD#,RY?</#I'EB5P)2?9/US
M@)21>M'F^Y,\:D"#KZHE;-+(+)+/:G`AS<S"$U=1!=,VR13>2?2UYWAL8;W&
MNWPG\QXPA(.,;#]2MM\Z_J'#/]>?,XM:RM"3M&CWV12%?6K8UP^)R4R8SHQ5
M;[U&X]77Y4%BJ-XF#8FD;O,&LK4]4B))3?G$[J-RM-\;`.YGGJ)Q)$^;.DNJ
M8A=L6ONL.3T2@^Z=.=W9EMR21MQ*4:)"F#=KCSIE,0ZJE&_Z;*E*5&23H8>>
M>4G)--T"%^>O9[D>^K0K>G7EMM'G:<6]5TPMBL"NCFZO(-';$8H'*'>.2=!7
MTQ8+)F,5GS@B1,:E[*/9E:YL5,)>5A*O?70S30,G<O8;B#:;0&(P">N=WM5C
MJ:521ZSJ.1LUE5-@Z]^AE_+L1U6SAFD/X)>S1;R'5$\Z%Z&F-I*I.;MKM@W7
M`"W<FZ\Y8A=L&T3+^B:8B]SDIH>J-JZ06-%6><ZDV"[88H/_`/ZVO<T[GDZ6
M.^^B=`7@O)BDPS3&FN?N:?4%=8CZQ>>\NM2T*>TZFIZ-2VKF"+S0P^:V'"HM
M'K"KB654TW&CM*HGYTD)2&R*T;88ZYV<'ENR8C0J4B@LW;&"_KV"2F3T4X'D
M>D:V9>T.7EIDQKUWMB+),7E6Y#D_UI'RGDY]G+6UJI$0XJHRRD1MQW5J]2LE
M)]&]3L9G7"<W.@?5P]#N"6J,-DV<NT^5T4.>H0HLIHE2B^ZO+CKG7R26)8$K
MF:%YVD_[>JC:2<K2F8U9H9DDMTWPEVVP?_P`<MK]`.$WN,*)LS]G<KN<,23A
MBK)1+4-_U6JC)=BR=)NX1R#?OI,JW:]I8^H"MSTC?@W*I027N9IIMIIOG`=E
M&NY>-)>\QZ.1SJ:@G.12YVLACB<?TM6&$/DH=*><5C3:2:.-"MW3N#[B!.+<
MH*<S$I9I27).^=]L:Z[9P'.JSM/CZ\WYUB]*]3<]6[(F*'*+!?&:L[CK^<KV
M6#I'/#*LECNGC,@<]VQA1NV<)CE)_P!LHH[.-=\XSG`#&9CWCRO&8DSRN.V[
M#KA.DZ^'((?#Z/E,5M">33>;GQ$UJ4Q*+1U^.7/B)+&YL@?U9A/S@B/;[.&?
ME/C&V0AGEKU7Y2[!NZ44'3BFQ#9I#X!8UEO3A*89F-Q4J*5??,AYRD2HE[4N
MAN35!UD11PU2E?:QMNA3Y4&?:QMIKL$N;>@7(?\`E]AI@J[(>K>Y'1,RZ/:Y
MJC<TJJFS*J@-BLM4RQWWN8D[:M='-FG#Z0C4(,.65B?.?J.++UV+SN$X(+WI
MU[?WB)Q>SZ]F$MC3(FE$GB,4G$4?Y;'8FL296HY.[1AM=U#Z0RK2-B\ISOQ\
MX4?=T^W]6,_("">9O07DSJ_GVN^F*PM^)(*QL]SW8(T;.Y%&X=("I1^^KXZG
MB#RQN+UD]HEZ]P;MOQVLW;"XTLPO."_G?&`';V-W-S35%K6A2LXFSPU6'3/,
M;_V)9+63`)^Y-\<Y[C2]R:W2;_R)NC*J/.Q^'!G5%$MB%4I=3]TYF-$^V=<@
M.4D[8YU<JFA]R,\Q<7R-S9HH]^:XZQQ.4.]H-K3T4NC*"IELKJ9`TGV-#B9"
M=+D.V^71M2?B%;[[G_1J7OG`3B7:U7&Z2@TJR8":7!W'+/-3"YC'=](@[8SG
M&6N4;ZN.=8^XXSC/R0K^R;^G_M`9PF4IUB<A6D/)5)%1)2E*J3&Z'IU*<_34
MTD\@XK;8LXDXO;&VNVN<Z[:YQG&?@!]@````````````````````````````
M````````````````````````````````````%6H;Q7S)"FV6M*6IHU)$4TZ;
MD78KMI/R-K!W1]'R20I9.?:$=-F.SR9%WYH=$)'[7EORFU;"2M2DV"]/G&0B
M>O\`RT\_ZMD;;+H)S)!V.2,-HQBXXJ[97RUT4P>=0O,SVB9M?8>9&XE5]$X[
MO8K[LDC;)J@C9.[LJVU08V.WSD/W97E_PQ<2*8-UG44AF""==&.'6$B2KIG8
MJ'11>SQ6[/4;]+DIK)+FM0@;Y'7C&2V.;*3OHQ.1&QOY*,W)IF=@ILQ^`G!;
M9).CX\NA"]UYBO\`C//)+;SEF7V:A;::G=#2ZZ)-B3T_/$E@ZRVNHY*";=W3
MYC[&8V-J/35=IIC=,XFI]`L:5Y`\')Y;,)4EJIW2IY[7=L53*H8FGTS)@;E`
M[IHJF>;9PQ%QG5YPG;RSJ<H=@:4AB;<DY)C10<7M@X_8S`8Q'/%C@F'V!!K3
MB\1N%KGL&DM?3#$@6=+=`2K::R.H"UI5-NMFMLUL:2L]AJJ<)<#2XILYIS\Q
M\K;[:+[)>,:X"0IUYKUO;U1<NPRWKDZ)D5U\H,!#37_8,+M>057TVK7KXLCB
M<\='BP8BH+/<"+0;D).S^A5:*DB\TDHPS7)I6AF`KM9?@KP?<:8]!9SEU)-6
MQ8[PZ>NC3(.K;J<FM\O>#P=FK5FZ;D*%5)S")!T(9`X^C:CY`MP?@Q(3C7!&
MN<[9R'.>O"CAH\GH!)!E-_TTV=51^Q6+HUBJ2\95%XW=)MBR&S)(>_V+&U6'
M=DD[]%%-LNZ9H-4D;E$-^Q*8\M043KJ`EB:>1''LWG-WV`L16DPO/0-CTS<$
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MR?\`1!D,K^%T<UPJ,)917*8Q@M'GJMO\55O>Y<K_`,7&31?-4,6QDQ2RJG`Z
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MUIS*I=*JX<FRH'E-'VX^Q[<N"MXI4<Y>*Y7V14K5`K.NZ0NB_=K=<&2O"W9,
MZ?<3YR7D+"<C^+W,O'?3<XZ-KDU/NDFO(-9<=J*G35M6$4A&T.@C=%$,BF,A
MWB,9:'&:36R#H>G.=5;EL<89]XTG;<U/JD*2A`-%?UPN$.=<6.MK9^N@F0V%
M(JX?"'5_EK7(T$`2UET3&+Y9F6NHXZ,1S3&T[BT0*/0A8IQJ:NS$V8HD@XA0
M>K//"R?.WCY1_.3O<SU&[,M5]6W9S[:'.\@,=S(@5^T1NV>B^A^D9)(&3\*,
ME8UD264=$+4"3*C[Z8M`UI/K*,-R=ON&NJ*?U9>8(Q0TKYP/ZVZQE%622N'J
MKVYADY%`N&L'CTGORFNAI0KA"HNF$R]I?)!,::2%G*CCE.VA*K;)6"]B]/D+
MY\J>)G,_(_34<Z3@E@W))U-<QRSV&HH).5\!<4$!.NO+7O:;NZ6&T0)DN2V5
M3\8UX_!)F4B?DS'HH-T0EDZX(P0&OF(?U0N)XV]P*3.=T6Y*7NN)`KRP$O%8
M<IJHTX0);*9#*E$8F<=<:#<])[--E4B-+UFCR>MD9!11):<XDDD@DH-N?6'G
M2BZ1M_>[X3T1;7-L]E'.S_R-;3K6+17$AWL/G20RH^9J(FA*LF(RY)`I>U/K
M@NRWR)K)U6IB7$_7;0W;5-NG"FV_@)SLBMU?:<6L1]B&#YO&YLC966!PLMQT
M/A%[\@7A!6Q^F^Q6)7,$</WY._9F_9R//,2(I4X;I\DF8^#0BTG^M1RB?AW;
M9':$NET3=):E=%<8>JLHHG26Q1N=[?E36SW$^,L`:7ZZYVAF5MF+=9E(%"A_
MP0UIT^IFN#%1AX;K>2J$?^8:#KFAGFVGVY&ZJHC#:^ADHDD8BT6>4D(@<'C$
M)C[.O31)&B;W-7H7'=U9RPS3[YQZS?7/P7H7KJ%D@```````````````````
M````````````````````````````````````````:Z/4KT$;_,GD]UZL>:O-
MMEB8I_7T)>H\3-TL"RVI+`?-8XGDIKPICDK-4(VAU4I_R$Z="<HR09N;KC."
MML9"LM'^S,:F:&F91T)1A_+%97!S3T3UHAMB96W')+"4]$T7(:7:&&RVTM+'
M&&6+(9<33="-S8CG-K9'+9.3IIE!L:HTTT"S<`]9O/:SWBEH_"NDHTZ/71K$
MKD]#-:B.3MH6VW'FZP)U6;L[P4AXBR`Q\2,<HK=XRX?;Q];>W)M7!3J4A.)4
M&!%S+[1\1V;MSL;S9,'SIIFZ)ZW;>.&J3U?&GU)&X19)]=GVJ[KIBY31MC&=
M&=C@I>BW?*+168?KOO@K&?QU620Y1GN'Y7D06W++5=<Q1'"*,GD6K6RGQ3";
M7++:9=.7&<-<,1,R/^!;.$T;Y0JK9]_"7LA3B@-+:SS/O8TT^H!L<J>TX+>%
M90*XJP>]Y)75G1-CG$'D&[2],6SW%I(WD.C(Z99I&W-#\V87(%.AF"5B5.HT
MQM\;EZY^<`)!````````````````````````````````````````````````
M```````````````````````````````````````````````!43MSB>FN_*/W
MH*]#YHDAFLX@]BHE\!D),;D;=*Z]>RG^-KB%BQL>FQ4G(7%?]5.K1J4YNN?G
M.F-]=-M0JPN\9^0Y#5R*HYZ[WO9T82T[TI1QRBQ+==)&[K(+U+*JWFL^3EJ#
M$"=&P'QN2U0RJ(R6T)VY"QX3Y+*3[%[?1@)Q@WFOR-!(_P`J,R.!/#VZ<6U/
M8%+<\SF13>6K)_"X':</30.>HLR9&[-RAQ6OD92:)RU!NN3&WX^4'XH"F/-_
M]?WA+E2&PJ$U$]]&MC?7W6]6]J1AP<+C-5.J.YJHCLFAS9C<Q+'D"`V(RN'2
MY:TR!!^/C=V0;Z%F'8^WIG`:@(E2G#4EF=D(:^Y?]*9+QS'.Y8=J]]S2FXZE
M3\\\T._`EAWE8^NM9LLN<W2?LO'%2V'/YL0XO#FR'(=ME2DO]RP>4GUP&_61
M>U?ES%88AG#SV%7"5N=$ED*6IBV0S`N>KSJFCJ"63=J+K@^-$SM*^(HX[(EB
M1$H;R5+FF6IC$>A^AY6VP<CM;U/J7CJC>8+W)KR<W1&^N9S"814*6,O=<5CJ
M:;8-;R"T8P\2N17S,JQBD,;E\=8-M?I<UJ4[12=H5OIKM]6,!D'/WJ[Q9?=3
MT'9AEJ,]0/'145J^5P6H[@<V*-6MA)<MDO\`3]9:+(XWNSRG.3SFRHNN:VE8
ME4GHE^Y6-RS?HVQD!!BWV$1M'6[CRY(>%.UHHR,4JL1-)NC99#:[CE'1BI*S
MDO\`#Y#TJ_.[K8J:0,_/Y;Z0IWTD"M`G(.;2?RB,'8SL66%DGWTQY2CW1Z?G
M=PGS-@@FFK5N65WGK*X%K0==HZ;G==5_.858,_.EI6(G-VMXM-FW,(5IBTI1
M:TG0Q1H<<45L'-M#TDY0@+]$X3%+;JVZ;-E4JKYC)J6L;UY^_P`FE1ZR&@J0
M,$];HG.+5A:N6QPYB6)%A!+-LX.;DG6%;($JO.V-0$G<<]BTEW+1$$Z`HR0%
M+XU.(RPR8Z+N+G&CIW!M9&APZ-;%8C!&G^1$Q22FMV^IV49JC;?[>V-L9VQ^
MH"TX````````````````````````````````````````````````````````
M````````````````````````````````````#S$\YT#QKV'%>@XA$^QNOZ*X
MVOGHWK^C7WSULF34[3K;+[U5R&0M?1.M5.RQC=.@-J\>YC.%+SK$DC\4F3O1
MYN%:/5/MNW@(CM/QN\ZK4ZEKG%V^KM\SKKI=$.AE\O*)N"@F.8SV/-]*1^AY
MF[KXQ#*W1QFK$M>TVR-S,Z;Z(TN[TB;]OR]C3"3S-`_G0=.>>5T755'G95]N
MVE3W6U06UP:](>@5-)1+H>J[]E##Q%T(?2BQ5!9H\R*E%[$XTG&Y`L>5I3`V
M-ICH0GTS^5^FY05Q1LO"?,7L!Y^\;6JVS_,6\KZ%K>HHKT',*GGLBWO#J/K>
M6MROGB&6`^P>*J:W@]8ULX2%P>X<J=#4Z)%*'(]&BSIAM..W#?3VA#N7X\HZ
M<[AN6ZY`MJ&9>=NW*$^AE0,.U@RK%8V):,L+0V;`M8;M))`ZNK^\6":TI/M-
M9Z'4U-@_<[&A)V-0T#<`<S\C^CE`=`5?1'IKTX=(&^EK(ADZM*R.<8U24MEM
M4]*32@,II&JP^J4Z6R*]2F<9;Q-XPW+$2=:D<%*=;E.J-U4*@LWYX^./,UQ4
MO"+2K'LB>7K!XCVIS//8?,I_SA#:]DRB"^6;W85(1BD&K0C=A=2F%S6XV0N,
ML*))6+TR/&-TWU*#@%J/-OGFM/*6TX'P_&>WY[)().I=<ZMAIZR.48]$&*RK
M.152PWQ/9)5O1$=96M(=`*^A3QH>I3*ESX4F<=%#9AP+-2[HR@]%NNVNVN-M
M<XVUVQC;7;7.,Z[:YQ\XSC./TSC.`']`````````````````````````````
M````````````````````````````````````````````````````````````
M``!XJ(OPYQIW_P!!7IR]#O0*L+:Z"Y@E?=-@1QN=^8Y<S*J>D5\=\TUT4]3>
MLY=(I2VL4Y=*1F\-D<*?7:-KC4A1<OUUUU2YV,_+#G.'];[F_H9-V-#>6^[8
M]';M/Z1OF(]2R1-RY'7@N)QZ^RZ#N7//#42HEK`_M6L$_AS<L:GE"^K4^$4D
M>&_))>5:K74+84GY!J>)K(Y38;9]"XRZ.L]FU?T/!$$7HU71,\F$;HG@3JR@
MJVCE92V)6/+G-BN>-0BT7F1;RI2>5C"AL+^C3[VQ))@8+;/DE'Y3ZT5DPD]L
MQ&2.T;AO$G4*:DKD;+@LWJR4U-P>]N$%T?7BR76QV^G[#VMRPWY4B?'B5LCN
M[(2U?RW$I=4QFZ@,EX/E'-GB73TKMGTHES;Q#-NG+2M>`\ET'/I0XWH\T%QO
M5UDS6QJNH!K<J>9)84]-D*F=YO[XM<=3C\9(DK<D/5_=))*T"!VCSB:[\\9N
M,)?#>].5FRL*0Y^[#KNZ^EMZJFLDI:<<PW!=B.>6&M8_Y&\UI8$5?JL=*>1I
M]T[KKJB_/*<-%";7Z2LX#B]`?UY.WKF<JXL6INVN>V8F.4_VM!&TG>'7$PQ9
MY9.W[\Z8M1\D#9_$)L:<V&MM>]$$81;;;K4Y+JSI]32EJ737?8(%4^(\7ZO(
M:*\\]^BN%5U#U->E.=FLM/O:[H.:$):]MWE.LX8FB,WCZMS-?V^K.L)G5LE=
MW5-JO+PXL2_&Y&^/HV1@/<HPD+$K$RI7%(U('!,TMQ"Y"PY-V8T2PE&26J2,
MVQZ=&?LU)C]=M$^=R2M\DZZ_.FN?^.`PFGKEJOH*N8];M)SV-V=6,LV>-8S.
M8@XENT<?/X^_.D7>=FQQ)_Z2K1OD#(K2&;:_.OW2-\8SG&/D!)@#K$#TSNJA
MV1MCLV.*MA7ZM3XE0+TJQ0S.>Z)(YZ-SL0G-,-;E^S<X$*,$G8T,R0>7O\?3
MOKG(?1S=&QD;U;L\N*!H:D!.RA<Y.:Q.@;T9&N<8V.5K%9A29.3KG./G;?;&
M,?\`J`YX``````^!ZE,F^U^2H(3_`'SRTQ'WS2ROO*3LYP4G*^YMK]P\W.,_
M3ICYVV_VP`^VV<:XSMMGXQKC.<Y_],8Q\YS_`/H`JE%>Y.3)P\\X1V)7E#7]
M^ZYCSS+.=&9NV=37.S8RP0I=8SF^MJ'+;JI:&LN%-BAP*.<]46BDHG;4G)AF
M/H`8YUKZ)\2<)&0LCKCI"NJ.6V)EQS"VN6+'`]ZD"=HW3%NCBD9&)N=W;1G;
MSEA19JTTDM)H:9KIDS&^<8`7'0+D;FA1N3>H*5H'!*G7(59&WUDJD:LG10F4
M$[X_]Q1Q)FNVN?\`?&0'*`8ZZR^)L3U&8T]RB.L\CFJER1PU@=7MM;WJ6JV5
MM->7A+&6I6I)7/REI:"-U2G1*6;L0FTV-WQKIC.P").CNIN=.0H`1:?3ER0*
MCZ]5R%LB2.5V$^IV-J729X*6*&UB0[G?)JUS4I&Y2?\`:*TWVT3IC3ML:E%&
M;ZAT'-W9_*G81<[4<N7S7%\(:S=6-DF[K6C\5)65C<Y(RZ2!D2Y>T6N[0X97
M-6^=\;I#CRRS"S"M]M3BC"]0^$J[8Y0@]TH.=);?%?L-WNDFKR&H:V<'7<N1
MG2NVFB5/U9QW8G5/NG(=YRS0AV4MI!AFNZHI`;G3&?I_4+1@````````````
M`````````````````````````````````````````````````````#PSUAPQ
M4'470-[U%6'KIQ0\V=()K/)2^<WU7#)PD@76RY/<#5,)F@Z:IXR[V"-I([('
M2)$MTT9*8_C""3')]5[GE1NC+TP%MNH/"!XKENZ)O.&=,TQSVSV=2DQJVY9]
MJTW?%6>'4:U\O<SU+7->I&U/9TT72&*M5FT0X*E[DZ..[^3'I2H+T5JE97U&
MA\UW];>YI)((BAE_2U&N$6B5/RJ(P:Q4%5W*;?5#.JKFV:47754TM))?>\R:
MBZ%KB728F;:'N/S+7%_U4F&+"\G%[$!7[LWRMM>D:&EEF=:^@7*=`3FVD5@L
M;S9BZQK6HFM)/:]X=WM'7<KH-F?SM9!8[+3TPAK"M+,4(E"AS;%;>6=E)NA)
M4&9#:M?'#-M=`^6^M3<U7K6_6'\ZK[C2,4NHF#O"Y93]>1"L9K6*ZZY;4ES/
M;%.[2GJ6QVZ'G+/F62*0*-=TA))!VFVGVM@UO]D\RU#<?=75=%4=Z&>>D+VO
MV#W_`%I5_'I5DO+%:D8ZSMODR)<F2F!3*#0!Q=(HU0[.\4,DZ@C#5AX-DJT_
M[B$X[78_(2.D\>.KY#V-;5=WIWM%+8J2\>GHOV"^<Z1/ISHJG;B@W-[)7_2M
M<F-$6B<-?2%[7!F&TK5B#<VF(5B-J5ZQC34S<K.F$.H=KSAYP]-<=]E<3]!]
M7=!<I,E70CD[G3FR;U](>B+FA:FQ;3Y1Y_M:0.%Z1=L*(B$&M.;U+&6EQ-3I
MY<2X(]8PH>7?.$"E&1G`<:4>/WI/93A=]YU;V16&\CZ3Z+NV=PYQ5],]>RRL
MH9RY>\0ACI$9-5A+$L;V1KGL0FD52NL?;4J`QO2M2G"'+XJ1EDZZAP8EX2^A
M\)ECFEC/5<&C]!9LJTI#)>>8?TYWE6<,OS-EVE;DZ9+7E"FL9E$SN>934[?8
MC5A-#H*5LPRA7'L9=''7=5E44&;+_$OT:ESJSZ3CO65M34YR=_4=$N%2]-=6
MQ)PZT<73_(SY#[E?V=>[J$'-[_5KNZ1UH(B404.C.\LB(S!RPC\5$0`R15XK
M]FOR.6F/%XP)K>IH1<=RN1\4O+JV!H'[K.8\X\55%6<QMM743[5TQLE@K.05
M)9OXQN78G&Z*3I5!J$TXY4F*"#5?A-Z9W91DWHCL#K.M;>0%4#%:EK23)>D>
MRCXNXZP9XA+\UL5M4BXHT46E"J6O\65.3Q-]G14_D'+RTZ5%^.C2ZE!,M8^*
M_=!TXI%1?G43^^UPUVK1,MZ8C,-[?[.D:Z]'&I(+?ASA<"9UG"9J<*_>'*PI
M9!R"H0U&X934<>,6'N/W]4Y.@25V%Y.]_P!Z]6W/=,'Z59]J]GT]AK@CCSEU
M5U[2JZ5\SM<'C#/*^')#":70F5]7U>OL\:W"0XG[)A5+]S7$PDPGZ3#=\AT*
MWR?]7HQ"VY#4WI`_Q::N57,=+[GJ[COM[A-30!'4%]-JDF*,+_ATUGTW9K/D
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MVQ)ZMZ*Z63O_`'&5K*YT_0F=S^'OY#E%^99'4T.EA,996F+&O"#9/J;DPW4A
M,D+-#N(#_7=[*?(YNS=4]3,=TS*=6+RFHO6[&3H;K.,3"TJ`KB55T[V;1KK`
M\+<P!$NK]B@YR"#2IMU;75R_.W.7Z-QN=\[!@$;_`*VG<4-J=*S,?6D'DMZ1
MV5]=-4<N2U+<OR:800_H:N4=:1RW($S_`,43.E,W8TQ%+LW.J-`XNJ-;L9HN
MV<C3$B1,6%YIOXNWHZ>5?*W":36JI[9-/]`I[HDDXL'IOH)"]5TXMJ.QW9JF
MO/E\-E6NLKC=D-\I?D&B;19#=V!.C6.&N$.3/M'@*^I/Z^O7"=/*7%AZ*K*N
M[;=.4=N5'VYX6]6DR_Y7AIG(M6UXAT?8`QIVIFBCLV=#1>2*UTAUW<7AT8I0
M<KUU3+$Y*+4)%H7Q$Z4IBZ^=7Y$HIY+4M87MPC:DP:7"_+AMF9[MO*D`[E;W
M%(SS.;5:P.S_`+LDDZ2CJ-@2G%-:,QH:=B=RTA1>I>X>JD``````````````
M````````````````````````````````````````````````````>6MX\&NF
MK/I]BYFEW4%+4)4=)]1]$].<W6WS95TO.ZWBC_:MGVI9%?,_^6)5*6-MK>/0
MYPLW?]U1QU%NI=BD92;5>1].5.X8N9_7NZ_W9*;:6;TP=J_35GS1=%(8:XI&
M[V?$S3+K=:Y]NYVA'WZ<=*OLI5RU7,)MJZGKC%*/*/5+LD;DZ1*:46E"&JY\
MH^_;U[N]1FV^VZSX%R_;]T46]U%;<PZ.D3JWV'5E8='P:PK(KUGAM=3]OFK<
MFN>J&Q8B;G!3^)I#$NN6<G4W0_<P@+F7SXS]26[P-R-SR^7G`;FM/GN5<B/<
MBKV\I?/".9]T_,$?F\9<EU;3&OZ];.CV"6V@S/R)*[+E[HLTV3EGX(+3[YUV
MR&(\J>5W5W+MK^67/"&WKD44AS+5E^2OK.6UK*SX=S78A:GHE9?'-U$L<7<Y
M.HG;C+HA:#WDQX=MD"8R11%N_$<C]R51B'4+OVYY8([)[^OOIF.Q:E:JC]O>
M><DYVB]TP1D3M?2%8=12FR)^]K^@(X0EB2-MTEJ2+S%,:FE);X3("UK;H1\9
M)W^YH&N!J\</7`UHZLE,E[;H$OH^ZN?E%)UMT)%7SJ1!/80@=;/YVE2]E_DC
MM)'23Q:*LS+44A<&;1G6Y*1R69N1AB,U,IWUU#OV/Q\],';,<=K^ZQC5Y3I]
MTZ!KZTG1POGIA=6+I4,O\WW?E^N3M:;F>SM!B)Y(.B7%3+),J0-Z?[)3@;NE
M,,USLCP&WGR:YNZJY'XVA7/_`&!8$4MBU*]<5+4ALJ)6%9L]1RF%:M+)B-$J
MB;.;&M7##H@1KNPDM35IAGV1-9"XK0@Y:H(+#96`````````````````````
M````````````````````````````````````````````````````````````
M`````(+OGIFA>7V:#R+H*T(Q4\>L>RXQ3\-?I<>I0LKM8\S+<38S&370M,<A
M:3G4MH4[:J%IB=)I@K/W#=/T^0Z.,=?\QS2^+7YBBMV0-\OFC(RS3"WJV0NO
MW'NOHZ__`(G[8ODA^Q6K4BWWU<$VQQ'Y&RA+HJ(V/++U/*SN'>=#=,T-RA6C
M[<71-GQJJJVC2B.)7R4R(U7NE;SY=(D,3CFAB-L2N#H9AUD+B2F+V+(WUQMM
MG;;.NFF^VH366L2&X2[%*DQFJTO[J+8L\K?"LK[>#?NI<Z[9PH+^UMC;ZM/G
M'TY^?]`$=65=-2TXQMTFM.Q8A`8\[3**5XW/4H?$+4VJIQ.7E/'8A%BU:DW0
MG#S(GQ64E2DYSC8T[?&N/U`2-JK2[X,SHI3[X)482&YU.+VP4JSL7IA,9G&V
M<:*,[FZX^C/QM\[8Q\?K@!%]6WI4-V;V875$_CT[WINU)72-HX85.ZC^$VQ!
MB6P^701[R845@A]CY3RERHTU^K73[V,?5G/SC`5WJ[TIX.NPB'J*HZEJ>=Z6
M!<;MS["M&%\,4J)+<K%'=)<\0!I2;I2E2EZ;HN<6O-SC3[&J4TLS[GTF:9V"
M\`")X[>U.2VVK%H:,V3$7RY:C9XD_P!FUJVO"93+H,S3Q&:X0UQDC07ME0VI
M9&A)V.2[;XQ]POXVQ^FVN<A+````````````````````````````````````
M```````````````````````````````````````````````````````UK>G/
MGNT^DE8TK2,S>V%OJF*7VDL^V&1Y:%CFKEL40T]<4#;FR,J$:I+AID[/,;!;
M'A*I-SDK3+9GY_Y?3C8-+TQ_K8RM]JF^ZA8^AHFTHKXY0XSKJP+`<6RR7B=7
M/TAS9:3[95D6)?JXV8%/<SA%R[R`U'OHC>4+HW)4;425G&K7C96'>V#_`%XK
M,/K/L:H8/>=8SAIZ:Y]Y*J=@MOH)ILV<=`0E;14TH598D")L!9)9!OKSM*8U
M26%S-'CM')4W/BW4O"@M*4;NI#]OO]=ZY"^GN++GK#K^'5'7O%O3-UW1`:ZC
M-8SI0F35G8G42N^HO2;4W&6PE8FV.,L0<U$74X)T)3;(L_1]@TC;!)05EKOR
M)IBN[=FO/\6]%N)'CJ&T+AYXLJ54^M?4[C9\FMOG7MJY.PI0[.%5F6H\S%FE
M*FA9`SQC79,G*,*;V-1J9IH0?NHR$KWY_6TNNPN:'WG2,=QP*N6=S[-E/84T
MOH^IK45W?9"]0VSO2-NENOZKHW^(.<UAQ$SW3&N#0W,"->0C2JCB=%*77)@;
M;^2*EK_S"<>M)'U)U1SW'<=L]D2OH2#ODJE$?IQ.]N;]5%:,4G;OPIN_(T*Z
M5N#Y#5SPJ);E*PHLI=IGZ\YSD!4Z(>.:XWK/U`[`K"PJ.@C!V;1R]BXFEE3&
MREQ7<]VM:%1[P^Y>CBTB;9OC#)8$^D:-"MW?8HYEKEJ'4W38TG)F^#`HGPOY
M73MR_P#".I>A_46DNOF>@9_V?,FYGJ+JJTM;"<VJ?P^F-:A(CVT<FB5[LEOI
M.V*S>'EQ:W$]*UH"W7[/PI+P>28%T?&[S9N[SYZUZ$5=`]4<UW1;%T\[UB?-
MHW`W6S%G04],KZQILFC_`$C;FELS25R1P-D_\L<614N1Z)&;[R!(E2DE?C;_
M`%AOYLV[J>I9&4XV[9T&K1O.8IE)RUTWDK5&D>8Y7;`;*9V^95.JE*1JU1&.
M$[+7`_.V"TJ;'UF9UP`SYD>F>2LS1(X\Z('Q@?VQ`],;TU*R%[6[L[JE*7-C
MHVKDVYB9:@<$1^AI)I>VVAA>^-M<YQG&0'9@````````````````````````
M````````````````````````````````````````````````````````````
M```````_F<XUQG;;.,8QC.<YSGXQC&/USG.<_IC&,`/*W4?F5TL_<X631G--
MP^;[_!6>4='R#GST0@[?*YWV"KFEH3F9O[M&IE-X860D@,N,229;"YE,&:5O
M$@5QU:=A,F2KM-=M0@0O^OCZ&R>?])2^8=EPECJVZ^3>FZEKOE)OM_JNSJHH
MJ?7?"WJ-QV,1]^LMW.6OU<-3FZ;+'!W4-VBS&5)^B5HQ]"<PL)Q]%/*ZT.DV
M3C.NJ[M.C;^L.AY+T`WO]&6]T+FHTM9M-C\O5_7*BIZ`E%<U))+3.JVFE9+8
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MVW"P&/,+T=Z51S2W[5LRH[=G_051>EM)2EUCG7]KVGS97;5<G)4#H;G_`'J&
M$R*-Z1N/H#K6B\B+F!K:TY>4FRG3.YJDLO=.6&Z/R-JVT>9.5XUS9TW9E63O
MIB%R.2,TT>('T18]Y'3?2(,,';$4C/26\8FE5>.R*'+&/1RC#:D3,;3]Y.I3
M$D:.."\!M8``````````````````````````````````````````````````
M`````````````````````````````````````````!_-M==]=M=M<;:[8SKM
MKMC&==M<X^,Z[8S\XSC.,_K@!Y`^7_/'N.#_`/CS&JHMAA@:CCIS+436@N9N
MR]H]7J&>3KU#D]KSEFN^K(JD)B\MU>N"YDH+/V>TVJI4L1DHTI!!A1>=@IJC
M\S_?654Y`R8+TFLE][Z%]*TK<]G$>@DRQ)J/;D?3=5VS$&*-26.NDE+*F<@;
MXPM0KDBI,Y*&QE4[HU.J$[8DD!=F@O,7T,:^H.>;HN*9T90?22JS>QK`>[28
MK3:[\E)#K8/`/'W/#/:<2KN>16':6D^.$WJ-Z,DC4H*+3-I#GLHV5'?"0\T,
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M4S)^=`RFS_*7UH+O>O+<IR4;6DV5;T7U04^R&9=AZP?HV[.*[0B/(I,2K23]
M%UO#V6:IYK/'&MY*80O-,3J6,@L@G"O1)L1IL'M**+U****U^K&I9>A>N-S-
MS=\:Z:XUQ]1IFVQANWQC]=MLYVVS^N<_(`4:4>7H<0:6<29KC<LTK?4PLS7/
M^FVF^F<Z[:Y_]<9^`'T``````````'P.4ID^R?10H((W5G_C)=#C2RME*G[)
MJC\=/KOMKDX_["<S?Z-?G;Z--L_'QC.<!\G!P0M*!<ZN:M,WMK8C4N#BO6'%
MITB%"C)W4JU:I0;MJ40F3)R]M]]]LXUUUUSG.?C`#`6&Y:CE&U<%1VSH$\GW
M%#S[!J=(WRQC4+;*@R5M8'E7+X,AT795RF.(VF5-BDY8BT.()(<$^^^VNIQ>
M=@P.[>N.5N:ET<:^B.DZ(HMSEYI945;+=MF"5VXR/8XXY/INRH98^M2IR(RH
M(W+R83IN7KOKG7.V,X^`%@RC2CRBSB3"SB3B]#2C2M]3"C2C-<;EF%F:9SKN
M7OKG&<9QG.,XR`_8#K%+TSHW-L9%;LV)7EZ*<#V=H4KTI#F[$-.J;=U.;$!I
MNJI>4V:+"<J-BM-\$X-TSO\`'U:_(0'TYUYS1QE!VBR>H[EAE*PA_E"*%L;]
M,EB@@AWE+@A<71.S-J5"E6KUBG5J:%:L[)96VB=*F-.-VT+TVVP&2TET91G2
M+5+'VAK1B5KL4'E94'D[Y"W+5X96^4'Q"*3Y,V%.Q&G[>YX50R<M#D2>D,/3
M&I5Y6VAFWSGX"+5?>G(Z#I))R$LNEC3]'KIGFO4M6FLLNU=CIA_AU)?^&;#I
M_'OXYKOO4*XEYT.V6X3[EF8(U,RJ_P"@`MX`````````````````````````
M````````````````````````````````````````X;AA7E`NP@U3;KLHU.$6
MJPT\E)LKR3OA-JJ.3:[J"DV3OI^O8O&=]=?G.N,Y^`'A9Y-\S?1"HIE94MX'
M=>;JMA\GD\"-Z1KRI^TZ]FG2$V);[%FTCG5?5+UJTT9+ET8K?"^0)G#518S*
MXSLG37]J+=3$VG_4"Y=G><7L56[AV))^2;VC7-\>ZXO>V[3M)E+Z`;VAF82'
MF9\MJHO8U42$RH5BNM;QG\(89XV2B0;:[%."O"13E(GW-383!BBWRC]E9)<#
M-=EF7:;/KYHFOK8UY[OHWKYWUUT8Y.EIDJ%T(9!&3G^MV6(352WP9Z23.P42
M$HB9'N!9BY#LGQ]@L,??_.[V7J5DL:]*^L%MAE_WPBHR,W6^1KIJ)++V?:X@
MO5W7LN,KROKLNZ+F1#^<13GZQ:\1:NCF42B4(6!2A3::_;T)/#91Z#>=-L=-
MUU4KW?E+\[]SV!4W5''!M6EG5FCA%B1+G9';]=XZA3VS,I#/%D2M/6:1)O5*
MWI$TM$:9C2=3MRFLSZ22"PJ_TOPCZ&RBX+6HV*5HDEGGK6TPK^V^<ZZB5[05
MB0+](_<_!<VB-21^J7<B/+*Q*H%+1UBG-IVBPIJ/0RG"5/KL;OO]80%">>?[
M"=RW):M77X\WA!.79#T-UW/6J71WI[G5S?4M7JJ7M=CY_I9<QHV9PE;G!'RU
M6Z,*=$[@VDM2AG6'ZK$97Y&YA83GY5<5>G7/7>[7;%^U\YP[F*Y^;^>7&;1>
MK[6JF#PR%]0UIQ)2M43!SM&BX2WDZ/\`&E4B;'EC96MF4ZL[2[MY;EA%]G"5
M3@,(C_/?]C-J97<B8SF66@N>NF+GK3!*GHNB(\E:^89+;W/$LA]Y:Q@F#)&N
M1)D==02=QC]A/7IG\A-,23TR=)E/@O`194?%/O?S9'8'1M5*+A1\LP%S2PV&
M0&-=F<RL,WB\X9)M)-H39S;.WSFJ?/"+AU)%7)#^\P9PV?)RX;(_N;E:%[;M
M^P36]TE_865P!8W/MH7W%WK#E%EDU=*SNCDR=2F:65#J'ZIDTWEU%[.M20QI
MJSG"T+@3UJQ-T1D):IZ2?=WWVRF+U4*S`Z:[N8/?4E-T^W5'9/1N).E0VW<?
M-TDC76M1&0^P+#NF\ZA6,=9RAEM&*K%M=1SFZE#)`@;HT2:1'W8Y)N>B7(SC
MO@X.XKZC/[%]JP!\6]'K7F'V]$C>=W*/,L`[0KNK*-MJ-5Y+*H_F\+<FFH*F
MDMMPRRYPVL,E=)8__P`L_87(MTU:T#<61]O\8)2Y&Y)]G3KYYS=>G;DZ/C%)
MQ^X45@]",IO7M:3E5*9A&Z1EN\L7QG$0A;2YZ<J6[>N(]AEK\PS55'VPIQU,
M(2:'$F8#G7ER-[8.]^]/OT4MR9RVK9U>#<YQ)TA/:Q=$JR^2EB],^L5-\^52
MHH*<,%'=`5^X(-VR03]R>#-I(Q.*DHC3)YQ9R`(-3\%?V(FTA&[&=KO\IL)V
MD+56=A)5'2&D7IAPY;;>?Z@<EZBNBDM0/\MKOJY]N"+OL<-L8EG-.RH<#7HI
MN2)C]BP&:6)P7[D%,$LB-4=16<AALFK>1SYE<)?W(\3BYX%9TUH!'6SASKI-
M3J%@C3+XK#;3;\REEF6O[*H3X4[8PGRL^XIW#*%7FAZZMT@1ZPONF_E\%@GH
MIK-6YAM7L:6F2BRN'X/`(?K4C&JG4=K&3%L[B98BA_\`Y@S.#,K429NRFV/5
M94IBCS@_5!>9'I9'NJN<;AZ/N5\Z!C-(=#Q"[EZ.Q^GYG+HZB73>`=>U5;"V
MKV%?$\+VLFNH]*JV5LC,HT0(5OPYE9,QON=N8$O7+Y5^B$\ZKNJP6OT>M%)R
M%9TLG4C2<_16S[F@-KQQC>F%CL-FB4$LU!*545A:?:_8HE:,Z$-6NB6OEJU*
M6?C<[*;`4[GOC#Z3OK=%YK#KNCU?7+#ZF;+3BMMP3H&?L%\MW63;Y^\_<OJZ
ML>9`X5L]QG%`2BSJF7.3QNV.*<IT;U96IR'78@C;0-E70_F=)+5[B?.IW_GK
MBOK"&W5S]1O/]AQ#J\Q^*DM#H:QET_E,JDM-+$-4V>QRQ/.M)DF_)0&%QM3J
MXLZ8S5=@DTW!84C?/'7U0EBN0MS[Z*R]FBLE7ZJK"/KWJ3J.,RFXIBRME^'Q
MZ\2%!S4K*YV=E+Q-X>D7US#E&\)-0Q_8S8XW)"5/D,OU\<NYYELB(O3KA]L`
MN5]!U).[GDL0ZQ[2KR6S>ER7]W?;!JUL9&B9E5M`MJVVDJA)&U,9:V0R1HT2
M?=PV;C\F?4%>H3X`>@S16C8VO?>S&9>L0A77\"A71;Y.ND+=M%CQTJR5PT?S
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MFY"WY3?3_P`M,Z!Z00``````````````````````````````````````````
M``````````````````````'\SC&V,Z[8QMKMC.-M<XQG&<9Q\9QG&?TSC.`'
MBAB?CSZ)1BJ.?8CR#R]S1P'U#S%9'3MDE=_N4\KN1VO=,>F$LMU-6].KX_7$
M3E!CNQSB$SEKT=5$SRY)&+]H3_B)?N%8*`6RM3S\]A)"52;/'KWN"P(4IY1=
M(9>D:OOK*'2<YMMY;?RR9,2U$BB-.1"O;7F$?KES_!4.STPEI-T[<B*3GZ'D
M&&+`JU`RO6+K_P!)/0^G8[T'Z"4[44*ZVC2>#N;8K:ZHK*+\ULUE2]@LQ)%)
M#/("_H4DS<8^='%,)3LNYFKY'27%S4Z['YUQN%NO03@_T6ZLX&X.@%Z5^S]5
M6;3]M<LV1=E>01;0\=M,I5#^9+$@EXN#[->@7J2<YW`YOMWRE$N**PPM[=EH
MU.UW3*C<:J-0[?BNI.^Z<Z*\UN()9><CC\5I+@>+V?V5!HHHE$MC[)(ZKMZ=
MM=51E/;#BRHH<\N/07^0M&Z0HT^R@[#76Q^B7!"8Q,H."H<N\J/0V,^FO6?=
M-"U!(8/)G&T^X)U5<\VNFE-HO+8I-N)Y#7U%)XU"23EUE_Y#?.G''5YW125<
MGAJ4G))QZ(H\C[N0F"&<O^P%.RJUY%5:&_;@N*(27EFVC'&[.B(%`X7T/+I]
MYWV13-S,;G8[&S*$U@17FOI(Z./#=&'EN2M^_P"#MA,?OH;@[`8;4,$_M#,=
M1&2B;.,Q77!SO'HC%XG5;Q;/&3G$^Q5TRL>]SK&GTGE.&)[<XNZ5G7+[!RVE
M*M=&LE2H:%&VNIVQV2P'$N.D_>=W;+/A]0%WE(>E:NY;G$"KCK>RC^/H6LGI
M]JW%Q?92Z,0F;Q0]!JTR!K:(O9+3DG=(B(3)FUNV,5[*3$RHT/4/QQMT'MRC
MSKKUBWDMG3*>G8"CO9,0[QU]T,M%#'4".8N&SG$$R6*GGNSR0:K-T;=,H23#
MMBB-MR]-=]@LF```````````````````````````````````````````````
M``````````````````````````````````````Q]_EL5BA9!TIDT?C1*G"C9
M,:_O+:SEJ-49>IRO8C=Q4IM3<)2ML;&9USGZ-<XSM\8`?5IDL<?_`/\`HG]D
M>O\`M$;A_P#Q+JA<O^P<"\FH%O\`V9YW_:+BL?429_[#=?UUSG`#NP'\SG&,
M9SG.,8Q^N<Y_3&/_`,<@/Z`Z<N0L!SZJBY+XSFR9"VI7E;'2W-%N^HVA:>>E
M1.JIHU/RX)VU6J2F%E'[EX*,,+VUUVSG7.,!RBG1M/)6*"'%"<G;CE2=P/*5
MIS"4*A#\_FD+#=#,Z)CD?Q_U==\Z[%__`#8P`^R96E6DE*$:E.K3GDDJ"3TQ
MQ9Y)R=07@U.>4:5MOH82>5MC;3;&<Z[:Y^<9S@!R`'%6KD3:E-6N*Q*@1$:X
MV/5K5!25*3KG.-<;&J#]RRB]<[9QCYSG'ZY`?;0XHW)FI9I9FQ)GVCL:;Z[Y
M*-^G7?[9F-<YSH9]&^,_&?C/QG&?]P'T````````````````````````````
M````````````````````````````````````````````````````````````
M`><'^RGS?<O0?.7)JBAN9%'2DYK7L.,2)]0(J8BU^J(E6#]65EQ&9N"^K9.[
M,">91U4YO+2:H0;+TB7=8B1GJ#2]4VII84;GO(OHSS3$[8L'R7Y&F7.4HD'G
M#Q13-11VP)75,RLZ!N$.ZWOYZL2./ZR5R&5164W$S4O(694MU7GKTK<WN&4B
M52H5(B2\!:+NCGOV7Z)A?IM4J:>V.V)7CEGF<_C0BD'NK:XK"9V5"C*KF-^(
MDE@Z/C9=\1M>7SR/RIK3-[AHECBV..:33=<7]K&,A#?:'%/KCTS3OIXT;67?
M9E3(*AYTKSA'CY>91J-ZF\FCK1S/:$PL9_MB.2#5:LDL/L>#O+69AP7?+D88
MNSHHV3'%E&!G'3+=_82+A?IW):+D-G)[:=;YI!DXHKJ.1_EYRJMKY\2.C/H[
MS&N9U8$G-D&9LZQL]07-&Z0,:/1&O+U-0*5>NYF4H9M0%0>K3+TE<_4IW.M2
M,_;%B>7'"4!=Y/>+\8W<[2?HJ$6M.B>A8\]2"CE\B4%/:F&Z)7)&0UI]D:4_
M\,G8TM-\[&!K$Z+\Q?41Q3^P,!J2+2.+<G]WRKI?H%7!(&UZ_P"2T=[4!.#3
MZK@U?$K)?'BU==]NR!Y;'->O+3J/B+MRM*8G)/3XU6A*,LJ+V,YK0=`N'GS1
M=LUHX3SJKR[*V:BHY`WP\OFJ#>?4:B-K1R.EV*I=8_NQ06V8RD8GK=!G980?
MIG3[F"MS=P&VGAN\O3J$W'U4[=RU]>]I1VP^Y&&B*,JZOZ*AK7#>>Z@<I%8&
ML>OICM9%)&8BS.<E$#PR;R!R4D'2)F=$_P`&IS=U)F-0F+WHYMF_3_G-.8?7
M=3/UYRB$6SS_`'!FIXCKJ;-)Q$JWM^)O%F,,,29<&HQQDR^L-GDM,C)4%J5N
M=LIT_P!1YA>NP:5+ZB?K/M+[ZO[@BN^GN/(KU_>/4W2[VR[\]U_,KND;5SIQ
M9STDI""V=!WQS<E=0*^B[_@TQ;V0@E<4[G8=]CU*4TP\LG(<F[V7UYG'K!/.
MI([2W3^SG2O.?8[#RO`,0J/1_EYF;7;DN/NO/NSC9C9*SVVT+4L&\),^8>6!
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MK28^]J#KWG52J<.CI7`R^*Z$UM"$6+4L#8*7=.B9WY_7S))6XR^9MS$WFQV3
MQ+K6OXVWNZ<@X]&F<7K&B@P@DY.F,"PW];.N.ZH@T=[SCNB(7\PSF[;QK.U#
M'Z_H$35+I)K-D-9ZGWJGA=>HW!:UI8'$YSOHVM;PWEI&][0$D&DI4N2]TI`>
MG,``````````````````````````````````````````````````````````
M``````````````````````````!Q%^%NR%;JV[IRW'9(IPWF+-##$A:W).^$
MNZK0K.INZ?0_Z<[XUSC;.OS\?J`\=M6\S=J4U6VMOQODCL*1>S]8)+.E=Z=9
M3.URY;S5;Y<ME[Q%GG>(Q!9>;1!>CE#-1S]NIJ^#EL3*D87)$D)7'-YY1I*L
M/U_D_P#M#6/)[VB?\3>X/1/^"^B9-1=K;4KSE!;_`).[,32K6T>WR6'Z6S,&
MB"V_-UR+1!HVZ%:D(]U/WE)1.N=#$X9![B4+W_U^W\F21CY'GK.YUXO[;9VL
M^JI3-;Q?$$.E5*UR50\FLQDJN8\WN\&MF;V4W[Z$$)79\C\07-_Y:M0[)L;)
MC`O7PG>??"CMI@X.F$QK*8TGRWQIRG870LK-<%,SO>"6-->>C*[SS;;\N)<7
M!$X7/);=CBVQ]Y"6?\GQ@DDG).V5^JC`5L4\-]`<Z6[Z/]!<[&=X3VY>66&@
M&WB)QMZ\;DN]DM:$2>JHQ(.GTD-B-J2UU@5R2!^=E3Z3AN/(,PBD:-%JWE(U
M&"/D*=RRS_=O%96KVUS?RO>2/K^^6#G"N<%3.IXS'=$M6U_T!Z$J]C7/G.RI
M.?I`).FI_>LM'4PM,H,V5.NIQ6=?R5!H#DV?$O7;K6L;]NZ^8IT5+XQ87,/J
M$AY9Y^1\XO7.EW<L3R,2FE$W-9"MVK68MTOF,JN4ECV-;T3PG6;ZHVA?E.>I
MRK^DT/2KY;6%T_:O$U2S_LMDGL5Z1DFTI669#;"J=%3+C"7323NB=+#V&')7
M-Z6*85'FTDE.T/#@K.<WQ%IHN5_;./V)+#8/OIH9IL69KKOIOKMIOIOKC;3?
M3;&==M=M=L9QMKMC/QG&?TS@!U+%'H_%VXMHC+&SQUI)W,,):V)L1-#<48;G
MZC=RT3>0G3:;F;?KMG&N,YS_`*@.X`8FW21T73*41=1"I,UM,?:(NYML[7FQ
MO:*2]5(#9`6Y,D=*0R!9*"W2'ZLI&[CEP;4*;;5S3?B&J<X48(#+````````
M?G.^FNVNF=M<;[_5]&N=L8VW^G'SM].N<_.WTXS^OQ_H`_0````````#XJ%"
M=&G/5JSR4J5*2:H4J5!NA"=.G(TV-.//.-VU+)))+USMMMMG&NNN,YSGX`?A
M$M1N2-(XMRM,O;UZ8A:A7(CRE2-:C5%:'I5:141N80I3*2#-=RS--MM-]-L9
MQG.,@.2`X;<XM[NA2.C2O1NC:O(+5(7%N5$+4*Q,;K]12A(K3;FIU!!FN?G7
M?3;.N<?Z9`<P``<+1R;C'`]I+7HMW5*D3+U39HJ(V<$R%::J(1K3T6IF5)*1
M6>B.T*,VUQH9N3OC7.<Z;?`<T```````````````````````````````````
M```````````````````````?%05H<G/),^[]!I)I6_V#3"3_`*#--M=OLG$[
MEG%&_&?^.VFVNVN?UQG&?U`>43B:T?47FRB>"*'K_G*V%K<4SR2U^H2^CZ]N
M*RKMDJ2?>A.U.'0E/9DGG\?8*UDD;HB7G6$9^Z8==TS(TE:X(R0;D_8(YF_;
M']B^*T]&;NDG)DX3VI*X!?\`5+%0]/<Z-=F0V/V6CN^J3JNO6W6A-93Y8T59
MTU+N\C(;BV]6Z)G)Q;=<J$.A1NQV0E3G2)^C3WVM0'2-O4M>;9-9+-;AL:9U
M1*WB81;GV.36:>2O,S0W1W^7-[A9;)"89CI"&2E@+PI0+M&QU5&F)B#C\;:&
MA3=12/;-?^^;]8\*YVO2$9N?MSDRSK,FM;&=**JV>><O_%Y!&[Z;9#;Y>K!R
M=/*@A=DJUI6Z5_9R)F:J2_0U%I-5&"M0NK%[[[S[^\L?4.83A5%;-UAU&WIR
M=1"?DQ`XOO\`Y&]'4?(;;3OO5=*.T4*+?M8)8>SO$&MB9T#BZ8*7QAR/US\'
MZE;A3SD9@]7(GRA?M2<_PBWZH9^F;IDK%6\EO.-==WTW5A5<7X&=IY*]JI1]
M#K*QO*"NEF7G"MXF2]2E"A9MGU\+V94YNQ!'WPS=#VM[E<[.G.$.J[E'IBZ:
M1UCGG2<KBCSR`>^+8I0Z/DBO#NI(XY6RJFT/F6M_*;@->DYZ.0I%.R1:W$Z_
MF)=3OQE8=P[>CW]C/?\`8(1".-&!TF4L;K-Z+CTNF/(UWM$88:08F"\7&*<[
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M9]AN[P^6`A9>@#8],)EDZL,(T=9[Z.%<_MY+V9N])E.F$J8Q-]P*!13T,_L'
MF1>-2Q914&L]EL;CRKKIBV*PXFOY*^,4PNQT,.EA*_5XG2F+.<PY-0D;DK(D
MI<6EZF)1B?9O0JL&[*RP[N3^CGL%3%>=3VE<&,QNHZ2I9DB526-:GGW;=32*
MX)K)[/J^/L?3CQ$3).Y12,/QR.<.;*35^SZG>'!<VHSRVTC*S8LL(?LWN/\`
ML;U9#+74-5$]!W!8QLEH9NY\.C'"D6TKR:4<ROML)+-N6QV!KDCK,Z<NFW$D
M;9C%4&7'K]XP0HQG!2/\]*8F"2]K/]4NAI10/3ELTGUEF35GUQ8=GU=R*?R2
MIHMKJQ,GYF[&35E6DCN]KMIT.MBN)A(VB!)9"^R-D;TJ)Z=LDIU6I*C\8L.]
MY.[[]E(?T%1LL[];;$8.+(?1-YV3UA,7+SZD=+XCC@UQ[5PA2%4^%22;OLF?
MV6;N2=F0)8XV-2QP2)MSMVMP(-RZEA=SON:=^0OL2S7#CZ`2./+9?3?#]61[
MH-1S]8%YQ=B1/5N=<2&XTI46;I<WPIUWAL?1LJH\[*(A>C4NB4E6H_&5)=B0
MUGN#]Z[W;U.W=GJN>^G62ZZ%X_C<SJBMGJI(:S<^QR/6F1PQ);/@M7+W96D?
M["ZAL./_`.8VA^:'].0I8-D;>E2:)%!1&VP8:YV7_8)M^37*YGN7H'#J^UIY
MI?D$5B_+5(TO9+`V1CO*&&IT5:O+NZ/L/GMUR3BV1N2TU.28W+5#FA-;%S?]
M"4A0J",+K;/["],UH=;-9-O:U\]D=4\H\YEOUB;5=0A+3RLL9NA;CD4QI=LA
M,>*9X\Q255!#H]LN.RR/:@DQS7;F*4NN2\I@W#<_TQZ)$\`^B'^%VRS*%[!G
M/>=CW]1C+;[C'TATLUPLHB5S"+_NCYN\L#?5-L26.RMG1*TVZ,G+>MPI)V(U
MW^H!4R14Y_9'K.K^-5DBMF:7M=9'6$5/Z!C//<SH1K@AG-%7)]G187)W^X62
MO\KIM>AK\Z%K3BCTS"BT:&Q+EN+-.V48"N<IH#^Q\SQ:IY4K:^@9;T>Y-O8,
M*<K`CO0W-[TOIZJY_=/-4B998H@Q[W!Z4?;*4U&U2IFB4?\`WE=JW.>W[B4Y
M(=22DJ4+U=Q4+ZX.=*><%G4A#[?L;JFE>;.PZVL1"COZIV"6PVWKFI*/0:M+
MSLA^,S%*ALN=PEC:GCY1($:E'_+7,K"17L3C+AN%*YMPA[N75%;&B=AO74MC
M4F5RS&X[75>7EUYS]%K!G-CUYU12EK1;2<(:%6L<=;;-E581!Y:U[H\OK_LG
M(49P<^*#M_P\!;KOI%W;TAZB3+G?DJVNB&!+"N0:"N"R:X07O7D%YUC*>0R6
M\VFR:OF5=RFMI5M:TPO&-MK"T-"]"O+:H^K./7.9AJ?4E,`LSYRUSU+Q%=BF
M$7S1$ZE"GMAYYM:T4_B<^03F,4@V\[^=,`:;-Q9$?C#$AK>KXNWWI"G&/LO[
M,H)2O:E\)U1I2TB)-@\*K6'YW>T%AWY'G%_O3:4U%#>R6R];11S#K28[5YT?
M54?Z=B=B4]!J?I)FJHD[E3_%=,:+6B1HL/;FW2=6CQ\EJMCBU188#2WE5[24
M%0M$TU2'52^N:_A$OI5^E=0_^27[%EL+);+=*M]@@=H)>>K1,A--H)*HBJ]'
M$4S*XZN*50N*PI2G)RC#0GRG/-#UHA/4G#]ORWM6V'.(,=L7Q/N\(>M[5NNP
MJBEK*HL.4R*EH34%0R6$,!.D2,B9[0W'$JE270C4@W50FW^C[JD.NZ$\I_4U
M3UOUU:G-'3,'9J5Z)E/\RJIN?NI^OZXF%`6S(FNM25%[J8#!VY]JRRCZD61!
MV3L,-4;(X^\MCUL4Z8,P23H4$\>B/EMVCTSU4R]!<Q='Q_G*=;<U5'2:?I..
MV-<T%LZN'RL[.M*Q)<M64G7Q2>J^AXA;J">)VC5MD[FB*C'VU"Q+H>;G4LP+
ME>1')/5W&7+#K5/95]K^B[B<;9EDRWGRVU[+N#3,?<V2)M29,DD=J,K#)&DI
MV>V->\[-!1.Z)L-==B2CC\Z[F[AM)```````````````````````````````
M```````````````````````````````%`?4^7W)`_/+K24<^P*26?<B&I'9+
M`X)$8Y+I9(9`ZO*UN9#R6YA@+DSS19^&VN)ZDW9L5$K$Y!.YQ>V,E@/.KT!T
M%[;USU%>ES\Y\G/^[12T)M'G*KJ2QSO<R3G>NJND'4=6N,=Z):T\*EBU%UG8
MTNJZ-[NRI)#D"9QC*)Q/3X1J-TZLK<+$6?W'[>.N;\C4:HY5"DV](N:FG)'7
MO&5P/D^:+>JBH..;1L5S;]K+?W&#2=EM!VMVP6"*,BYI+<S%T4W)*W4JR#2M
M@JC:+5V'/&Z8="O=+]*GU7R=3?3MK5S4&I'<=21VR^JI1ZI39!^?(H5#K*C=
MORYU<^3&M.M2LYZI='&HA_V.1(?VPG=%H$U]<]\>\CO3G6#%`>2L5,2NMB]J
MC@$[K_G/IR<7)2M:QB$VPNKF7-A3`I>&>X)7=REDC:9CG$/2K8U#U[SL:ZIB
M]B],$!N]HWL!+"*.Y?@ES0WIUYO9WJ.F(_811U"VV^/1=@JE]'5%,'R82;^,
M%LJ;72RK:3J5K@<JU+V;TCHYXSLC;U1V@8=X]V'/+-Y<FKO.[`DMV(XAU+U1
M4E2="3=-IF:WI0-87I-V&I)Q('O1$@Q*/QV?<YM3N.A6A2TI#]_7'U&[[;!M
M7```!USLSM#\A,;'QK;GEM.-2GFM[LA3.*$T]"K(7H3C$BPHY/N:C7)BSBML
MZYR6:7KOK\;:XS@.Q```````````````!^?HTQODSZ=?N9UUTSO]./KSIKG;
M;77.WQ]6===M\YQC_3&<Y`?H````````````````````````````````````
M``````````````````````````````,X^<9Q^OZ_I^F<XS_^6<?&<9`>%>FJ
M!]#^86&`VAP!Q3Z`8[NJ&P>C7SL=%U/>+XBXQZ7C3M_EILC"%"RSV\"4UY6"
MD+?XHY1ETAZ!`C/U;3M%2[=7G.V@;$;3LKWDM;_%=3XI5$X0N4<G,MDWC*DE
M-MU0&EWJU=+&F_XZCKL7U8X.[`J<J8;$V-T):S"O0W&%1F,%JS$J,(UIGT!]
M<>V+@[MK;GV<QBO%-$=ENM)UX:=QTX2"%-E+UQ==V06Q9X18TNFB"'V0^I&%
M@B:90TENJ1\U<U2[<IN)1E:*=P[#T_I3T1[;YS\[)?;%"3&OY7$;&JJ>V4U<
MO/\`<TRL]@WF/'\VDUT&SZKH%)*5=(`I@M]L[:P,R9LFST>9LLUS^X$YR8F6
M!8#D.^/3*+6QYC</3&1Q%UD4AXEJV_NU/\LYWF'1=,(JO='Z+V4EL->F>EFB
MITZ1D<LC;3%UBKZ5#>IC;_MG99L09N6$;SG@"_J6[J]%^I.7%';DAG]4\ND7
M=QZPSV\IY*><[DZPMTOI)WM:ML0E\>&^-RN'L^RJ($M\9RJ2I&Q;KIOC/S]G
M.@8Q(NC?:A(;TWUU6?)U_N]H.',T7AU'<]V1"L-M<-[RP=HVEN0_.%(-MWY1
M;V"KY^=V[1U5(7PQ]5D:)U6B;9.7^)J&$W+-O9CK]H?YN]<\V-4S<;7_`*%5
M54T,B%8VU35LP16\>=C:]P2:N<E2]'&L+JYSKIA\50R**7:/':)U+-JX(5"5
M2HTVT#?=YC6'U79_*K')NTH3*JSZ#UEDH9IA6\GKY%!"8*6S&HT+?'8DXH9U
M8I=HPM.05]U!+]W/)[[J;L882GWTV)T#8&222G*T(3E%$$%:XT+))+T**+UQ
M_IKH7IC7337'_IC'P`^H````````````````````````````````````````
M````````````````````````````````````````````````````#KFYH:6?
M"W5I:VYKU<7%8[N&K<B3(L+W9PWP:O=%N$Q16%3BN,Q]1Q^_U&F[?KMMG(#L
M0'"T;F\MP/=BT"+1T5)4R!4Y:)2-7!2A1&J3T:,]9KIA0<E2'+3MRB]MLZ%[
M&[YUQC.VWR'-``````````````````````````````````````'5M3>J;M%N
MBIY<GO96Z.#@28YEM9>[<E6J-CD[,CPU-S;ILVM16<%$;'8.5;:8^33C=_G;
M(=H`````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````Q-TGT%8Y5&((]32)L\WFQ#PJAL-=
M)&SM\JEJ:.D$J9`HC$>5K"7=^(8DR@LQ9NE)-U2Z&:[&9UQMC.0RP```````
M````````````````````````````````````````````````````````````
M```````````````````````````````````0',N7J"L*^*FZ;G%8QV4WE14?
MF49I^?O1:I<X5XVV!JA*EYT90G*=F=O>7E(WZ)MG#"?*\I(8<06=H4>=H8$^
M````````````````````````````````````````````````````````````
M````````````````````````UR^J'6-U\:<CNEL\YUJTVW=[]:U'TW6L$>6U
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M#37.:'/,(4V77,2B$`C!LAFNRJ10E"?N\;J4Q*F-.^FK4J2[K#,:X#3K5_\`
M;$WD%8\UNEF\JF0JP;<Z\;Z6L]YCN]GV!1M74L:UP"5FS=HL&&P!^)L6W7.+
M3??*.',>[@M3;-^ZAP_#U.3IS`ZM)_:CNM77L3G*[BJL(NLF=]+Z]BT.<[RE
MTGE4JC4BA=?S:F8DW-M=U5+-62X['0SHTK!3J8D;T![.J*7Z(3MB"MP]4[]T
M8^LM[3BF-^?KF+C<,H%==Y?1;HV1]MYW?G1&[X:_\1M\S)?7*0D6+HGQNO4$
M',^A1"`K<[&V^/HQN'FFAO\`:2S`:,MB]>M.>*U:$T.L"@X]&ZWYRO9+9TP4
M1;H8BUY#$9$=*7N/L=43HA)!JJ4..V8R_+7#[AV27!M:,D';:AMOXM]CZE[$
MFUBH<U+.:2IYDH^6=.5+T%9<F@.U=7+SO7]IRBH)Q:NF6)]7K*R;&.4Q<T["
M.1?AK]VS;\LPDDO7_D%9*J_L3\[S.R[+KAVK25R?]@NSHF$UQ,*&DM?V=#YW
M55-DV49!K*1+'J70=YD^UN%TM)CRS(J@D4>CJ8E&8\.R(I5J<`X7,_\`9QX*
MZDO+F&A(95O7$5DG5Z1R,K>0S^HXZSPXI8V2.1195AP>FRP7K]P8DSM#W8I4
M[M1;BW(-T!NBHPG<L_4D+;]N^C\[YZZ(;^;*R8.76%[*YF=NIG6U^S>D%'.%
M0/<<:)RI@9E:0%\1P.9'/\Z+5E%N#HL,V*;F%N4)=U.-\K",`,&Y*]I*^ZC]
M#[CX%UJ5UAJF`P,YZKVYB)67*J[N&QZW1Q%+TU5D0>"(ZTLKJZT5,Y?AH-5M
MRYQ)<,M:U1MJE+P1J:&ENT/[?1D+F%U5DQ<#J5]EU#*92T/<:?>A$+,EB+=5
MLELEBME/8+Z;5^C/M,F=M@)#JV-T7/DI+DD=/M%J<JD1Y&P;'NS_`'CG_+D;
MZ*7,7$Q\I>:;N#FF`P#:6]`PR%QZYH1T+4MRWD18Z1>='E2B!_M5?4NJV(97
M33+R<H<"-3DR<S7[!H2QPY[,G=F=_7CRTBKB(1^H8G4*FRZ!G[%))!*IU>B-
MB50365/[E%SV-A,J)C2)YREP@025*WN+ID\LQ-L;J6IT)"Q$Z]*7A-`>(Y7%
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M)A'G*TXHXO\``(XW)*AMJ3M36UQ?+PWZ/+BZ*U*?[!92397L',H?^R879G"T
M3Z$?.;"R[MD701//J?5P>[,ICBE=LH6IOLW`[=F6Q46*YK6O=D!QQ&4+MN>^
M9>$NR,L@S[A9H#K5_P#9A5)Y:HCZCD:&0QJ<.-6#I*.26R^P*QCB-HL!UB=4
M35TK*VD+=&GITJUM9XY:J=6C4+2=WR1)]4F6MH4&N:8G4)JX]_L`OO3W7/+?
M*,IXM<Z96=#5REE+K.GB]F&3H(M*G:OK7M*-QV,LK+`==IJWR&#U;NKU4'K&
M=6B-6;IE24I4A/)V"^'7WJ&Q\V<4]J];Q^C+5>5?(-FJZ73PBVHZ]4HEN.>E
M36`0%$\UD]O+0\KI76+M(+!)*;GQ$@.+>#$9Y:/0S_AOL%.C_?>NN=Y5SE4G
M?]5/U&7/U,FG\Q@#+&DKI'8O`JXC;JXQF(*;J.Z<+Y]F\$DL_E,;<TR#)K)^
MT&%83FY5Z:;F[%!,6ON10-B\45EV9S?6]A62QWGUU6?%=.QJPOP*H(>K:LF7
MM,4+>IA($?\`D':#5\P;*EFYR]0A-4*%*+"<I/\`"E.=N%"K"_M24$T3&[:\
MKGG>1.\YI"P+63O$7NVTFKFAY>Z1I2OD4WEMJ-K?8L*/4$3.<N!QK/!8,;C#
M[(U>FFRC9M^Y]K`2G0/]DNL>DV"YYW7?(MR-E=4=<?+T!E3]/IG!XL_K(!T]
M?\DYP9+!:H>3^\*]Y'&;`8R\*(L>H)6'D&G;:J=-D_TG!^JH_L3I;Y@#=**7
MX[<IQ,W3IJJN7VFI2NA8@DF,KG-OPK>;M2*$+R8,X11Y=ZT:DBP^?E+5[6TQ
M1"A.5_N:PK&OU!V'.7]E/G2\^7>N>G9#SY=5<MO+>&K]M@[>65;DCMS>21&R
MY7%S&0^L6A[1PUE<2JK<BU+X]?C1Q!IK]XQQR7H9]`0CM_9U+CCS3L7L;BO]
MF>YY9CS7S\]P/J6L+@JR2K"TM!N+#&N9;6KR/O,5ORVM6GHMD5/D>4[Q=,QZ
MIE))CB:HQJ5@.BGO]I>+5_2DPN%9R\Q/*Z#]3$U?+*A3=%L3#<<7YPD13,KK
M?H%3"I+`4!\O<)^A=RS"VJ-&O+:TY4IM7)U2&'Z:9#UF)%):U*F6$_7@E6G)
M4E8,USH9@L\O4W3Z],_KIO\`3OCYQ_MD!R``````````````````````````
M````````````````````````````````!QU*1*LU+T5IDZK0E0G5DZ*22S]2
ME20W0]*I+U-UVQHH3'Z:[E[X^-M-\8SC.,X`8[)(+")DV/;+,(;%96S25,@1
MR-IDD>:'ULD"1J4Y6M:5[0.B-4E=4S:LVR:GT/T,U)-S]6F,;?J`[)NCT?9]
MR3&AC9VLQ.TH&!/NW-B)#N0Q-6Z@QK92=DQ!6Q32VF*S=DZ;7X))R;OG37'U
M9^0P@BD:72M3BQ):BK!,R.\F3S5V9R(#%"6ITF20TH]++7%O+:=4BV3)CTY>
MY:\W395IOIKG&^,XP`S5'&XZW.3F\M[`RH7AZ^C]Y=4;6A3.3M]K'P7^YKB2
M-%2_[>,?&OW=]_C'^@#@1Z#0J(M:1CBD/BT89&]P4NR!GCT?:65K1.JS<\Q6
MYI&]M2)DB9P5&*C=C#M--3-\F;9VSG.V?D.KS557Y,)-S6\"R:GEYE@D&9A\
M>R81/3<:8-FY._[=]1<O,P7K]3EK\+<_3CY,_3`#/0$1D4!0Z5E>XVEI.HTT
M=DK\?*9&P$5O#26602=3A3JID;VUELVJ%U?E&JP[&ZP\LQ1O@W?YWS]6WR&;
M-,*AS"A);&*)1EE;4[1^P)V]I86IN0D,.3CU&60E(C2DD%-&5"HTS\;77!/U
MF;;?3\[9SD,9:J6IQBTCY3)4U9LQ<2:'^/Q4MJ@<6;](RPRK;&TH9(_HD:B=
M69HDFVN,KTR;[9*S./\`K:[@,0<N5N9':/)XFOYYI,Z-HH3.*V;F;2KX4F1-
M-?68F6I+$A;,4E92?V:,3E.Y*-79$ER2G7_>WR=KOG;.0'93GF_GJT$M?(K,
MHRH;'2U.L0.%8$SZN8C,M:\<&M.0D;E\+_D;0Y9C2Y$F3%:%'(\E&:8+T^,_
M\=?@)+1Q:,-VZ`QOCC"@,:CWI2UF(VAO2[MJF2+#'"1*$&Q"?39&>_KSMSUN
MY?T[*CML[FYVVSG("+EW,O-SII)"W+GVD'$N93=KLR7Z+JH@:O25V0QJ-%;)
M8$DU4,!FKY-V=47J8E=E7W5Z<S7&Q9NN<8R`S*6U55\_3+$4[K>!35&X.<:>
MG!)+8?'I(F7/,+7:N<.=EA#RW+2E+G$W+3"AL/WQL:@/Q@PC;3;'R`[1I@T)
M8'^02MBAT6993+,(,2J2M,>:6U_DV&HC"5KQ('A&D)<7G#:EQ]LC\DPS[)?_
M`!T^,?H`Q.UZ/J:\T<(06U!&.=)JULZ"W/`</)1^3HE:5:/&C]!YLQJDIZ94
MA>F!RTSMIOKO]!I1AA)NIA)IA>P2.8UMAJC18:W(#%91N#BE1B1/NH+.QKKI
M@W0_8O)NAN-=,8^K&?GXQC_T`1LHHJG%4TB-A'UK#]IC`F^>-D->=&5(5O'4
M]H$QY-8!K:B*TT;B7*5H8LA3*UGV<J]TA>Y&#<$G'Z&!G),5C"=-JB3QQA(1
MZL^T=U2$L[>4FUC^^=L[L6I&B?4K#/MG;/RE^/L9^<_\0'R(A\231M/#4T6C
MB>()$A"!+%2&1L*C:9"EWT-3(D[&6EU;"4B<PO78LO4K&FFVN,XQC.,`,<=J
M>J1^=GI_?*MKEZ?9(T$Q^1/3M"(RXNS^PI\I,IV1Z<5C8<L=&@C+>1]"8_<P
MG7[!?QKCZ-?@/DQTO3L8>H_)(U4]:1Z0Q)B<8O%7YC@D6:7J,QEW7&NCM'8^
MZ(&I.N9F)S<S]U"A(F,+3GG[[&;Z;;YSD!F,@C<>EC4<Q2IA99,R*#V]4H9Y
M`UH7EJ/5-+@E=VM2<WN)"E(:>VNJ$A4GWVTSL2H)T,TSC?37.`Q"=4U4%HJ$
M"NS*JK:Q%;43E.V*IU!HQ+E#<GRN1NF2$!S^UN!B,G+DWIU'TEYUU^^069\?
M7IKG`=98E!TM;%?.]56)6,,E%=/SLS2!UB*UD1DM"F01U[:I(P2#!*+1+NG?
MF60,:-:E6E;:*DZE*49IOKMIKG`=W(:EJN6J%2N5UG7TF5+G5G?5JF0PR./2
MA8^1XM,2P/*HYR;5)BAU8RD1.J-1OG)R;4K3!>VN-=?@,'FG,'/U@+6QPE53
M0Q:J;K3B5UJ-TC00SZR2T(%J[;PJ6S@IFP@+GJZ*+WDU<@T><+B$SD60LTTP
MI3D&EAET)I>G:T1(VVN*GK2OVYN?'F4-Z"$P2+15$@DLC3&HY#(D:5B:D!"5
M\?4:@PI8KTUU4*B]]M3-]M<YQD$)I>GJT32A%7%3UI7Z.;KSW2:)(3!(O%$T
MO<U)1I"EQE!#$U("G]>H(.WTW.5X.,WTWVQG.<9R`Q]NYKYT9T4";6B@:4:F
MZJY`MEE8(&ZJX*A15O*7+_\`L9+`DJ9B*(A\@7__`+ZQOU3J3?\`YM\@.L2\
MH<M(=$NB+FJ@4>B*=.=HHM$M.5VGT268]::EO-BI=2HYIA/.G8O3&JIWT^'`
M_7&,;F[8P`GX````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````!\MR\[[D[X--+P5OMML7
MI]OZ#\;%[EXT.^HO;;Z-,[XWQ].=<_5KCYSG'SC(?4``````````````````
M````````?!0I(2ZE[J#,%:FGITQ>=L9S]1ZH[1.G+Q].,Y^33C,:X_V_7]0'
MW```````````````````````````````````````````````````````````
M```````````````````````````````'RW/)+,)*,,TT,4;;:$:;9QC8W?0O
M<W?73'_S9U*TSMG_`.&`'U``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````!\],'8,-SN87L5MG3[.FI6VFY>,:_!F#3,G;ZG9VW_7'QKI
M]./T_7_4!]``````````````!_-=M=L8VUSC;7;'SC;7.,XSC/\`IG&<?IG&
M0']`````````````````````````````````````````````````````````
M`````````````````````````````````````````````'X***(+T))++)*+
MUQH645IJ667IKCXQKIIIC&NNN,?Z8QCX`?L`````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````````````=<VI5R317JN=#G7<]Q7
MJDYAR5&E_"0J5&YJ-K+U1E%:G$MQ&<%:FF?4<9\?5OMG.0'8@```````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````/EH3H68<;K]?UGYTV,^HPS?7Y+TP7K]!>^^Q96/IU_7&N-<9S^N
M?G/Z@/J`````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>g575431exmpg075.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431exmpg075.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#*@)L`P$1``(1`0,1`?_$`'8``0`"`@,!`0$`````
M```````'"`8)`P4*!`(!`0$`````````````````````$```!@,!``$$`@("
M`@$$``<``P0%!@<!`@@)$Q$2%!46"B$7(B,Q&$$R)"49<5&1,S0G&A$!````
M`````````````````/_:``P#`0`"$0,1`#\`]_``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````````````````````````#6CZD=\2/SSH^`6PQ52BGR2<79`ZD
MDTZF3[(XM2U`QZ9&+2U5QWI)X;"[$EC%73(H2%)3CT;.HQJH6%YWW+QC&I@5
M`N3WBIND.=9%*)+"$;_US`Z,K*YI[S7"I9();6[:;.GFJ]7.'L75D7KE_J>2
MR)F@=M-4J3H4F#'9<PK4BC"(O13KG4+G-WKSYK.3A4K5KV!4[>XWA`+&M&M4
MS\J?8S^[@E2KIFUV&_N!TD8VDJ)DQQSKI^3[$O.6]4I/9U>B<HW8@S&H0;S=
M[C\-7RT77*Y/:$)H^#5KT#<5*U[,;)FJ!K;;OCM*1RK9%+K8B:5R;V9Q9HTE
M(MMKP:G6E?*06;H;G?;7?/QA._.?IOSQ>DHLV"2E[8:%GL-[4OCB2`0JU[`@
MK7);WGU"Z1HY^?JE:R7K*F2MCLFE*;8E*1J:L),S\1FN#-M-<AD<N]$J;@_>
M%6^?4D@=\MUI7)%Y#(*_L]15;BGY[?W2+PUXL)Z@S;:BI<G2NDV;X:P*5RA*
MD2J"4NN-"SCBSC-2P%@T'3?/SG:=JTFCMZ#&6E1S!7\GMZ(&/:=,MKQEM,]W
M3U^HDZM3DEK;E,FW93LDIMC_`,K0LQ/N87IHK2['!BG2'8_/G):^EFR]Y@[Q
M-=T-:3/2E0D-<`L*<9EUH2#[<LD0+W@D6DA;4YNA?W[I_P`[*;0[0D[;3;;!
M)GVA@G.?HMQQUCO6I%"W"7-5MOLUQR&O6XZ$6+%W%]9:`E\:@=NN!B.71%B.
M9R8?+9@VHC,+L)MU)JK'XV#L:&YT"?[QOBGN:JW=[?OBP8]5U9,#C&FEZFLJ
M4F(V)K<)A)6F'QI.M4EDGY(_;25]2)"]LZ_9@P_7.V==?KM@/K+NNISKG5<[
M%3Z-F7BBK-)<JRK]%^NTN358OE"J%(IT>V8Q]Y<>52M$<@+/SG&-E!6VN,?X
MR`D0QQ;RC?@-7(RS\J"4GPF*B-#?RE)>QR=-\>V^-_R%!.N=M-/I]V^N,YQC
M.`'V````````````````````````````````````````````````````````
M````````````````````````````````U;>G'GY;G=K516U*]8+N1)I2TKL%
M[VF[95B6VE,ICUDUN\5E*(,XQE_F\<A*N,/D??5.B\AU;7C4_'QY)PFV+VV-
M#5^D\`NCXNQ6M%:U[NJZN8%;\1YQB$AJ*)<KV&VU0W:<O**K*K28LT8<.NG[
MZ6F5':?9FI7(U>RM4I1I_P#D7\V?FU"-WW^NS?+D[ZNKA>_*$ZW4TWU%1LD,
MEE!6VB=YE#^FK9MBXUJ]ZD9U[RYZ9Y'`9/>$B+9%C":S*"R#2-5QCB5IL1L$
M/VO_`%Y.]K+KHN#/%^<SR)U46?T!;4RL%P>K(C<VLEZZ?JZOJSMF,.2AKIQY
MC$+B!R>I&!6EU;6@Y;@S4_!9R;;[#`$J*?$OL9+U]5W7[K6G$]ERNNNI>A.D
MMH^[7Y9R1H<E%R6%&KAB[4UI9-Q]+2X7(:UL*+D:I'Y`88X*6XTXLS&IV^B@
ML)W>Z"]M)KZ<5?WQ952<QKJ9HVJI97=5<G0[I--('&/.=CLR=OL"7-UHS[FQ
MD2,T@EC@UI-G)T1MQ#KEE3%LZ<[1,<L,-#7MVGYE^D/5UG]T6IIP(P19R["G
MG',V(@:F_><IE7ZE'SM4EFTQ+XK<\B+FU;3!Z:5Y\M99XPD-:%01F5QIOU</
MO**T-*"^_9,:ZSM7@*NN)8MP5Z`*KDHA'S@X4IUZ[R;BF5/<>NGF.11(R.7T
MOUTZX<G1?('0R)*U9I>^ANZPERVTWS]IVWT#6[,N3[]@-&=4P.@N&/524RB\
M>@8._5["[84U,U,A'*YUA0^[^A.<)E<42Z6<)+7I?5%SMLI<94^L.AJLU,J:
M4QVFJ?3.A@0#;7%?:LQJ:[V&>\F>H%FVQM2'FQ5--3M2^&O==(9922:#$==6
M5-:/4=`JH?/G/\.-%$1G1P;GG#N>@).,RF4&JEYH9A+JC]#5;D\RQ'2_H1$+
M:7<UUQ1,XOZNXATLUW1T0>7W1)+MO]X0V!K`I^]<\N-G5>K;')F;]$BR-Q94
M2K9$/WH3L$`,U+C]DQKJ@BV5L#])DZAM[I?^E62<V[SYW5(43HW'><:*HJ3M
M265C%*9VCCLL@O5Y"I&\M9)"!<ZL;AA,4D):=<D%!GOFQT-UK8O27GQ376/7
M_IG"U!-=6).I\FD5.6C&V6V>D?\`?D`=HW0UK2>44&<SJZA7Q0B3;$J<'HSV
M]DP4VJ7%M^TM+L'MV```````````````````````````````````````````
M``````````````````````````````0IT#T-4O+M9N-O77(7&-05L>(U'S5K
M-$)G/7I8^S!^01B,LS/$*^C\HE[ZYO#XYD)RB42$_?Z[_=G&-,;;8"I].^N/
MG#?\UKRNJ@ZM@$VFELJC$59L2%NF2!1.5A)"I2H2QH]YC#:B=%"9.@4[FZ%F
MYV*U2*,[XQ^.=\860J7KOEZ^)$7#Z<OVJ;'F!L,3V-K$(I-&5SEF("K=U#`F
MF9D9*5?O"HR<]I=TFJW8C"?*C'V?=]V<8R$S/4SA\;0R%TD4KC3`V1%O+=Y6
MXO3ZUM2&,-1I1QQ3G(5:Y40G96\PE,9OJ<IV*+SJ7MG&WTUS]`,,TATI94LD
MC$LC4CCJTPXE$_L+ZUO#*K-3&&$J"DKHWJE"%080:5MKOKH9G.NVN<9^F<9`
M=^0H3JB_E3'DJ"ONWT^0@W0TO[R]LZ&:?>7MMK]Q>^N<;8^OUQG'TR`Y@```
M````````````````````````````````````````````````````````````
M````````````````````````````````0'TY9$FJFE)K+H=3MH7O)M$.C.S5
MQ4#9%7>9N2]^,PTI7$I%,9="&79F93U6JIPWROU.+2%[[%%F[XQID/+A2$`Z
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M%8P;KN40'9\Z=9]$4/U%25C7W;/4;XR1_P`4;$[!?^6;#MVVY"?*NK[/[+F5
M?5A3:AAE9R--,+!9$4\00!J+<"=/^Q&A5YUTV)T/P&TGRQ[=Z`GOGETL@[1F
M.L)[KXA7WTR],KI;%M9*X08\QLD]R55/GBOZZRNVD,6(KIY2EI6YDV/-6Z,A
MZ,G.RG3?`#3%6/8O?::OJS3NW5O1TPO57WSYN5=8R>%6QS)8M'WW!^H&J\'M
MZ>N;+,=JO9D-?-MTL+6VJ%4"?D:!=7IS<GVU-R0X%Z%!]4<]!O461L7#[)&^
MI[D73CH;K?U3JJ>1Z-5YQI8-@U]7G,4BB,*K35[U-K/:!R1#3JD\Q]E"]GV6
M+'5K5FY;_FQLCQH&X?BWM:[7?I#T/@/1G:506!5?+U:>?T6K>RV2OJY@-;2:
MX>J:0;'%SFS%(&Q[<SY&US:V$Q1<>9\KS==SGO*0K8[&$F-`CSEWTPZ=<O('
MCR\+,GU76!Z$]TS=KJWG>+R"")X@Q/DLFEX;5PG?W&NH>_,B^0PJH:[U,ELB
M<$1K8FW1$XQMLEPH(SN%0ZZ]TN\8+5-"=*7_`%O2EF\UR2'="2+J2;4U5=AL
M+[S7'J^Z@FW)=2VIAI5VU,EL]BDBL*-D.,H;$*'9Q:6?*@TC.?BQG(6AK;T$
M]@I5T/R-S6\PGSM*L#I?DE5V.M2IV'J%O;X=7;(\U\V.$7>'S>5.Y39,GS$S
M/T3;:I%J%"L1ZE';G8/+W`01`/=?MN=\/75V@@J[D'=AJJ25C7+DT+$_1<8+
MBUEV5T]#*69FE[-D:9/M.H\Y5?,29GHYQS8]*FUV+08W4J=C,$A-<;]UKB51
M_EZ>R6D:=25#9MJ>B;#85RQ^;35UAT\HGSUK)QM:1](\V(5K`V.;I"[.:8J]
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M5K@\1\G8_):<[):?<,M=_9/G+20.[G#(79]A<[5[.J`K*\NJX^CC*2HZBG?4
M*2"**?8%:)[D3=.YGOIO9\=Q*#F=J4E135Z3?EYR9A04G#$8W[D\R/+]:S*]
MT]TS#4E7LO<3P1(WF'UNZ,5@;^=QB'3I]IA^T2M>1NB%QC/[9'^NW?TK(A=]
ME999"C)N<EX#LVSV^Y75P17+G>KNHHA(B)%RJS(ZDE-6QQ)9[\S]K&K$G-<]
MC2%NL%TB3_!+$=D)K?\`F)7@PYM<M-DJXE,?IN7J$R4=ZL\N=#6G(J2KE/9J
MFUX1U787(-@P5TB3<A?*_L:N8=8DX<97*B2Y&J*3U/(&>JWPMG?TVZDAP6HM
MD^NFIN,ZX#*9QZ:\JPZI;.NMH=[$MB!4O>%G<^VPMI.J9W::^OI_2K&\R6W#
MY2VQ=F5J6J'UZQ,*E0X/1F,-WTP7H2:<:>1H:&#P/U\XCGT@KJ/$RRS85M:5
M7V1=L4?;7HNW:HB7^G*HB;'.IG:;]*I_$&!CB]?HX?)FUP)=G`Y,A5$+R,%&
M;;FZZ9#L$'KWY\*(+95DO%[GP>(5*QUW,IHMLFK+AKIR35I;DA11.L+@:8U,
MH"S2>14U.9(X$HT,K0(U#%D_?&#5)?\`Y`7#JSH6GKLDEK12KIFGE[S2DDC,
M3L?"!K?2&QG>YE`(O:47*;GYP:T;%*D3W`)HUNA"MI4KDFR9:5GY<9VQ@!-`
M```````````````````````````,?W=G364IV+$:<-V0^/K';>8:+&K]4F=$
MKBA1EQH]!LMU>_V"U(LV5$G:)]TOQIS-=S-#/LUW#(``````````````````
M``````````````````?&M;F]R).3N*!&O3J"OA/(6I2%1)Y/USGXCBC]-]#"
MOKMG/V[8SC_(#%7*LZX>DVR)XK^$.R/<S0[=(Y11A7)MSB]-RRS=B%2`TK8S
M0LS;7&V<?7&NV<8_QG("-EG)_++@BV;5_-5`+F[9;^SV0+*;KI2BV<OQ\)/V
M&R4Z.;D96_BZX+^7[?D^/'V_7Z?X`8FMX1X?<E9B]QXUY47KS2RB35JWGBHE
M2LPE/C;!!1BD^(&';EDXVS]FN=OIK]<_0!B;OYK^=S_EWV>.$>/%YC_C_P#-
M'G\V4[^0Y;8)PFP:K4Z0[4\T_4C7&F#,[??C7'TQD!PJ/-'SO5'FJ#^&^3C#
M#CDRC;7-`U?J1JH1DEITAY*;6,ZIDYR<DK7738O37;7&N/IG_&`'1G^5_FRJ
M*0E*>%>5U/ZTU4<B4'TI`SEQ!RY*B1KCL.!C+LOV-6IFXC4[;8S.3?BUSOG.
M?\@,>SY%>9^Q>I1O%U&J"M$^$I6BJ,;JM4Z?7.FQ927"E8;A+J1N5IL5\?V_
M%MIKG3[<ZXS@.E7^.'FHXIW5,=RQ&"-'[;.S^:V3.TF98_\`W:&E[Z/S@T3I
M"O>B32S]]=]%1ANAFNV<;8S@!C1GB5YHE$LA##SZ\0C2-V3I<C!K7E[]$P(M
MGMS1I.8L6BW)XG;#2D2V+LSGY3Y?-"\.F2L8Q\__`!Q]`PEZ\$O,I]8X;&5E
M06+_`!V`/LWD\49,]']#K&MID-D'MJF=/*=$ZV<X$%N,L,9TN'$W777=?HG+
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MT$Y?*Q%N?EAN5R6`(V\BC4[:KRV/9*9>6XGD[N.RI&1ML=GX]/M"MK!_7R:8
MS!6*LVGO#I+2OX?BI"*]A*QD@;E%:M;J>M"#7*QM]8MJ]$H4Q`E]LNOF]X=<
M%*#-%*S3_AJ426224':1WP03L-L1>X-^QINX.T0EG2$O:("?3<!WI`M?UU%U
M$2Z*;]:66.J^!((_:#<M..<&Y"E2(#%N^#OA^NN,`,-=O`*9+:TMBH-.Y5[O
M!K#J&.<Q0[,THQW?Y;1G(C/*XY+WOF"H)&U]`QM%'*VFB^,(R'4W=N.=E+>D
M2),J\$(T^I8=;8?A9TC*85;L!BO<%80B&W[*YC(+@K=CY;D6U-RI/:$-BD-M
MG9-4LMZ*G,-8Y//-8,VO.7E.GPO:)1\[NU[H5)QVIH3M=?GAWG8Q'+J.$6KQ
M?6+IP\O;73DZR8U6M_;3"O<M];$5@X1V11^7VW/(G.HK+X.<J8W(I?KNJU(V
M*7$GZJ=-B=P@ZU/)WT*L^:S^=+>BJ`322_N:D_*'64E2Z35ODW15/)3Y`Y:M
MQJY+7NZ&HI:H5R]U;<O,;3$E$QM26BT096)D[F6'2*_(7MK1[L:,,;UQJQ\C
M6=<E$=)3+BYJ?[@2PN1W;03%5C5'MLVXYU?()O'ZND;C3$:<7A@)0J=U:AIU
M++5$$J56A@1!!O#KNJ&,5S.+7/N18Q<O1<`[2J+H"V86^V`C47)6G:E@N5HO
MZ67,,@H1_*3SRHI<\J=8O(4:@E1LV;%(7`E4G3$::!(J?Q][O/UASW-)QS5-
MI[$;IX'EZB3M=C3^#,KG07G*[N\IHKG6*P%)SD[H8%J^S)[5.S_(-G1TW5+S
M\Y)2$$:$$$A("3S=[(B+S!>EF.OJ=QWE5-`]556P79$+L*VCDE<NE+1FDXA[
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MN0DPK4[_`"J2PV<^(_*4VX_I*_*XF5"W%2"*0=%/DVK<F\+0J2UYPNI\R$PN
M%55"U<AJBQ+$2DI:9A$)1QE(2L4%;90(DYA6/MWV+)#=.```````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````#!+1CTSEM;3Z+5S/]ZIG\CATC8X79Q49:YH;7LH=6E6B
M8YH3$7PY.RR8Z,N1Y:S1`LWU2JMB<%F_\-M@'DPX:Z@ZUQ<OJY<*KTCMSIJC
MO*6UK/VD5)6"T<YJFOHNLHMS]:3LM1_[`A%:,+A6;_\`[E@V=VMS;C-VDE$W
M'I34!AFYIF`Z"Y_=WH'INHXX_P#-[I#.:U\6Z5\<F$V80&>Q"]D\]7=WPN16
M!<-#2]$_P5,C9DE6(/@1.64>FKKLX-AY.^4__>44%P:^_LJU98O1/I!031R_
M,--?.ZD>N+J>)MK;D(6MUM(.3)%I'7AHCK<C:3/U&)N;O@Y$J+5.FJ4G_D>7
M]N-MM0_:_P!DNP+`LSRU:6CDATY,BO=,HZ(6K&>[5D4MB1RZIZWYEC%UP6PH
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MM^&XC*I,0F-/4$[X-^`S4W(2S2OH'RG=<CJ&KVRXJ_C70UP4;`;^:.:I!-XI
M_NEGAE@0=NL!`0Z15M=EV375NCKCA2H*3&'Y_$+V5:?<ESJ=D+I@````````
M`````````````#Y5&J[)R'*4U(6GU4F;.6B@@XXX])E&JU*+0F%J2-$JG5PV
M(WVW,T.UR3IOIC3&V^N^@?4`````````````````````````````````````
M``````````````````````````"L_9E[2OF'E+H+H6#58]7;+Z<JN73^/53'
MCE*=UF[G'6LY<G9B3T3<[KB4^V2_D4;)TBI1JG+,R42:9]NFP>6:F_9ZK:@X
M*L#M&+\F\#+X!9-]\HUC="[E%B=8F6__`._$TTVNQ@NVI%D$TL3:V:8;4&Q1
M;>MP[-4H)=]53>N/*.,*P&SE1=7]<ZON?^;W=<V\!US0/2\N:KBY[;U=)Q.$
ML\VF]>2-RC;?8^L9V@38ZLCY`I*_+F[=T>$R/9J,4J2-S"M=C=0%.)5?7FC#
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M'4-<K[24C^R`$3*IS(I')F[ME;2J/';HV=U7F8;CLFE?'H5G!.H9STKYY\8T
MQP3U15]J],7G':*Z![S9>O;3L9"W$VK-&JUK`O\`JV7)X`D0P.NGYU71!UL*
M+MJ3Y%J!8J1849.4*?L*^N`PKM+^N?4/91/1+0\=C=40&#=*=6,/7<TJYH_U
M._5^WV<UU]O7+@J9BW>O]9KKLL8MM=$N#WPU$A*))TPD-^+7<!\W_P#SDTBD
M:J=:6GH6PRRJ:@'$,`8E;U!X4\N)Z'C&WYU<)*O1<3EJ/;M[0>9P80N+*SG5
M$41KG7*C&=="PZ,C^NM$$\VZBL%/T$Q(Y=U177I77\VEJ;G>*:R_&/0*=M<F
M:'=RD6)B6LDIE(L*(]L1D'_&6HU7*=TF6SY]]0&0UK_7NBU9>J-/^FS7U3)W
M-3441B<(:Z.<ZGC_`.E_C<)YA2<S1YI9IDGEA1[`B1M"35QUQAK4&Z[9R1@S
M_.3LAZ,@````````````````````````````````````````````````````
M```````````````````````````````````5E[,@E'67RU=\-Z5FJRMJ)<8*
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MEQNE(W-U7Z%F&DX4ZZ&;9`5<E_F#SC'G7S!K0[T'KN&SCRJOAJZ(M]GE":O/
MYUT):W1%D1R2_P`HL5H66:U.E6OMXV5EP*:3#M'7*LY^P0EU4;E$XW##H-_7
M&8:^Z5EMZM%WPA41:[;Z6M=K&Z4>A9)N](N]$+TT1%N->TDJ6HI*T4DT.^Q*
M=*N*+)4;'*LDZIM%.2M`Z%G_`*Z<I(G/D#)Y'TA$G-F\VH,G@LUBT*A$ZJ)B
MF*B+V&X6?#[1K!OA-D:*XW;[V]GD)Y:YNBY8ED!Y.'(U+C?.R'<,"KWP"M*)
M49VNK@5E5'%NQND/076W2;7K2W[]C$8AO+[1T97-W%TR6EC^Q.L/L%)JP.)G
MWDM:LXO*XE-NOSKC!Y89#-?'GTS>^E_0&V6GK`M)'+ZK;NIEJR1D=*]$)Y;.
M3;[A[45R'64PK<MM35O2$9XXE[8;LB?(LH.7.B95\9B?)&-B=0B6]_&7T4K]
M'Y+LG)5K6Y)S:ZM6`W'Z4.$Z[BMI;%)O:[&V\[M#]*$9<M?$DO?8ANGA$DU3
M(VG4O\=(HP62WZ;FXS@/8>``````````````````````````````````````
M````````````````````````````````````````````````````*9^AG(#9
MWSQ;T)R"ZS1RKM/>$(UCB:;-2(MS41QX;'QHE,?<%#68>DP[-.KZPIM5Z3!Q
M&ZI#L:5H:5MO@S4-<5K<8^HER\7SCEY9.>)J.F45YB8:5HR[J".NQJL)?(VB
M00'62ILO:R-,JCG&K+0KB!X8W9LCG\G<4YBS0\A;]B$DHT->,X\A/5K;GFEX
MO4EQ-U>$MMW==3N3<C1WN[JV'5W4\;NFOXW%>:4T:Z68V1;;ECMW+TWBYDLP
MQK4R5L<%+L<A)TU(^4PT,LB_E]ZN26[>OWV==I=41JSJVY`XY8>,+VB'34BC
M7/=I]4Q'G8R)W:_V11N39.ED,7>K9BZ)2[8>F`G"PM8:HV*4FJM\EA0*K_)K
MT>8*_P"J;KO&A+6>+CO#H_R"=4Q=CW[$.H>AY?\`^MMO,R[IVR9#-XD\*F1D
MKQ0X)"71F:L;?*UQ].G2XU++19QN&Q%L4^Y4<Z\NF9L!_5*NEI[U#Z;0N'U5
M*6GGF459#JVA',A[_P`(3Z&/LA0KYW'&*S+FUV+(-4*_XZG/1IV]6EU,5'F*
M`H15Y/\`96F_)[>J[-3=<'2.*^B_"$P+C],)JDA%Y2GE@TZQ=NB6@HZG=&0M
M?&43EB*GG(7?)1213KONMQ^%HIU+#+7NZ_6/AVM^AGBBZDMJ#[WAZR^J<L/<
MD/(*V[7VRIXZ[U<HXLC)40/=(_O$*,Z-D2-Y:E4W1E*2TIB8DXD[;.^-%`7O
MK3T'])E7K^P\]3>3QDWG%XZ3WYQD-/'<VNS&=']&?A33HN5V/%KTPNPL=VA'
M;9*EF;-CRU25U;B=%7U(T/+UP&Y/U3O&Y.:?.;LF_.?2$YEP5/1$TF<,5JFC
M#\2Q*6I'J8ZRS9IWWT3K=H<P;*W734_!B77='C8\HTG&Y6X:88/Z5=J4G?UV
M<I->D*N2M./N"TW0E>2:Y8_>LVZB]&5J?E=RN!TLJL;>A2;_`$,@94-RGH6%
M>W;DG';IU.26[<P[34H@*H0S^PAZ)R[G:K9I%:UX5GUIS3J.04VB?6W%_LE#
MV=!4?*F>G),[U]+'9S1NC1(^<U251$YI@[1U(6O6Y);?IC&AQNX6CY4]S9K;
M79L!D'2UL\Y<I<8O/E34_7CS`9@[(DCZ=:=NS=J9#5[58\@(0N3XVPLYN5H\
MIT^B5/JF<"L'$'JOM-)#;!R]U18U@^CG?G,3S8,>LZH:OK+D2^*5=6EA9VI?
M!&>_XK.27RNU3XQDZ)9\RJ%,!(D36['YV5:)WS9+MN:627MJ&TD`````````
M````````````````````````````````````````````````````````````
M```````````````````````````!\3DVM[PWKVAW0(G5I=42IM<VQR2D+F]Q
M;UQ&Z9:@7HE.AJ98B6)C=BS2C-=M#--LZ[8SC.<`,=@%?P>JH3%JVK2)1^!U
M_!V-OC,-AD4:D;'&HO'6E/HE:V-A9V\HA"UM3>E+U+)()TT+*TUQKKC&,8P`
M[%5%HPN)1IUL<85A#?\`F_@$*FAO4$H?V9!Z5R_#+-3[Z)OV"9286?\`9C7Y
M=#-M=OKC;.,A@:J@J*6ZXT6TK4JO36$;5EKJJKB'*-=:WW</VV]?8U-9M\8A
M&SI_]SEI_P#\#*C_`+/B^_\`R`Q^JN8Z.I.Q+PMFM8(CCUC]'R&*26Y)=LXO
M+L[RY9!(JDA4(;OE>7%PT98Q#XTD_&;&AOU2MB'!QVQ)&FYQNVX3T```````
M```````````.I4L;8L>&I^4$&;NC*E=$;:HPK6%ED)WK*#+CINC*4:(E6QWZ
MPG[=SBS-ROMS\>=?OW^X.V``````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M```````````<"E4F1D[J5:@A*G+^WY#U)I9!)?W[ZEZ?>:;MKIK]YF^-<?7/
M^<YQ@!\W[=J_/*:_V;?^S/287D-WYJ;\\Y#DS)6%I2/Y/R#$F3<?;\F-<Z?=
M_CZ_4!]9)Q*C3Y"#2CR_O-+^0DS0S3Y"3-R3M/NTSMK]Y1Q>VFV/_.NVN<9_
MS@!R@```````````````````````````````````````````````````````
M````````````````````````````````````````````K#V+R'2_=?/DTYBZ
M";I"[5//UL16R9NB\F<X@\J]X7,&*;LY)#^S&$N*,C9[CR?Y\%;:[&D??I]<
M?=]<!YY[;\=W^X/9RJ9L<@N*#<U<J</\B+*]M5H982]NUSVAR[<+HLC]9J+G
M>4N[W5LE5-)#7L\_J"VU6]MY1WW[%IC,YR%`$O,/MWS9RHTSNE*XZ88[J:/+
M:/TM$8O`[#BSHTP_I:QO2>9RZU]GNEB),]?R"U4O.TV3KT$Q*2[D(""5*A0L
MV/T*U*#?[P9Y^66NEG'?H?UQ:/0&.T8_Q565.6Q4DMFC2XP-'+3(D]:3Q[?V
M%F0)T&\Y=WJ2?DJ=BM\Z(U*?)6N3/KMN`W<`````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````#Y%_P";E`MPV93X<<I%/Z_*O&^4F%OP[_B958*_[,I\
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M`]#)7R%8K!%]J!J;G."=+26R7Z.Y;K::Z^N2J:Z:Z9J:T$+?+7;6)]%(;79)
MXND6BI-H2K:VK4Q.066<3N`\]?G'ZE>FL<*F\CQ:4IZDDKS3+"56U?=#VNEF
M5=[65T#Z$5)S;0KM<1D6J>,3KEISB4&FKNK5,[M(77,M0D:K4YJ`@G4G0+;S
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M::]K.QK)N*C&5)0-.RNJ)]`_/.)R7*/^8P&PW3H#T&Y]M:]HW((RH?)5)8I'
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M5_<463GXS-M`[*NO7O@>35@T3RU.B*HYAEV8!!K"G]&=$VA7->W73B"Q"D!\
M89K1A"F4J%<;D2HEW1[&(\[;FD:K",F8T^73[@R*Z?53B6E.>;AZA76VAL*H
MJ#N>)T%;;Y5FB65;0VRY9)8+&RVEQ,4+FAKW2,>MBMC@O5%*MR"VXS8PK8[?
M&I6P6;B'4W-%@/JF,0;H"F9A($F*YR<TQJRH>]+,YM^/OLLJHL@IO=U'Y1UC
MQ:,.+DR:%??NYH$)ZA/@PHK??`4)ISVNXJNZ^M^?(RGZ#B\A2&O!#W.;8YXL
MVH:CBQJ%M7N[!K*[%L9FCC+'L6(WMA^\;RJ^/#OOKJ47G!QI)9@6VA/<W-$_
MO.\N>V&Q6S2=\]M%*O4^7N9Z)OA1R2_]7W6MR8O,SEN6.1.#DNCQZ,U,29@\
MI;L63C7;??&,!UG1??/,W+&CLIMR7/21LCL3=Y?*'J)0Z3SUDB:-IL*M*NPT
M2QTA[8\)8U*'>96PU)V]M6[$*UQ>BPXK38I$JV*"Y!9I1N-LE&%FXT,W*WR7
MOKOC4TK;.AA>V=<Y^TPO?&<;8S_G&<?3(#D`````````````````````````
M````````````````````````````````````````````819.N^D!G*M*D<E3
MBFA,MPAT8OR=)#N;NR*C,)6(]`G5.)+FJ.(+P1\!9AOS:Z9UTVVQK@!X]N'N
MR?3>B:_X#@RE#,G"B6?D:KL6NQ6_1=Z6Q<4WO>](!W[9[1)7NR-$SG,&"-PJ
M9<]1ID5-F"E!_P"&_)24Y>F5*/7`8.[>ZWJ_6G/,1Z-E]%FR"=VIS?0L\A-%
MG\:WLGIE`Z8N'H9DOF>/EPQI4:[1!>HK^M8[JV,+DZ*C5*J3(E*--\&-ME`7
MNX,[?O22]*RBW)!(.HKIYPF4!]([7AE:1RMK`EBAR:6'T"HV`U,_06)R6.,D
MY5YBE<25U0-#%G0A>GC[<JV2MV=]\X-#6'QIV-UE3WI]WM6E)/CM8;M(.F?6
MRS76B)%)Z.>45QRRC8FYOM`QB>H6ZLB>F:!:L*<HD#9*)'(SHZ[EI2FAJ3)]
M=#?M#91V1ZY]-O7F'3/=%/(#>6V>^^^JLJFIUJN+UQ*[)L'DR2'/S>BF&L5Z
M0+B-;1J:SEU8EKDU8<5J9LT9"4RS]@22I,4%A$G.OMCT[8%2><E:2B"L,OMS
MI%RY+FG076#(554.C4!KCK3O>?T#`H2V43("M5T\EUBQ>LU#)(%\<WRB85:W
M9PT^3)6F,AT4!_L(<<RQWQ'K1X0J>3=55-4\YNV-,]>.U)/J(F[MNDD]&L=,
M0"2RM"1*8M;,Q;"(\^*%.Q)3AN3]/JDS\!/U"3YS[%>:1M7D_P`:X711><%T
M6R]/,<A7\Y<VSRL*EO-36+K(VJ"O9^MAPM2JO:+PJO%>A9!/ZY0I3-):4E67
MMDHK`;'N0;N\\_1'K;O[>O:>E*NY.6[:A--WXMLYL;LP>73N!-UP5=#+8KR.
M$2R1-Q$M:HT5)XS_`"7+>T/YK#N0C-W,2ZD%DA=%%YU\:L$-4PR$T1!H"1KK
M4RN.O\794'\F@\KH"!;UI05APMS?TSZ4S6)2<1R6GC3ODDU2@^`O.<[_`&_3
M(8Q6OFGS+6M63^B2";*F%%65SQ#^9)+34YLJ2.]>YKF-HIPFD;FW-"$]I4-]
MC6VNL1S<)A)-#_W#VXF:'['E[%ZX`09%_!_R3A6$I44XN@;$WDF'&KF)%++3
M_C,EW.CS_%L9F\7.GAL>GGXS%*'`A/EY3+LIL+#MBLZ;&;YR'QQWPI\W(V?;
M2LBK++>7"[ZZ9ZPL5UF'271$V>G2-QN75K-XJJ;'N66:\.\:DT2?:;BN6MU;
MCDJ]"G8$9!1NI16-,A]>?$/@G+.U,>(_=>J!-K*#9-C3HVZ=%5IN[W8MCVY&
MI1<BW6985VM+:EL^VY$_1!R>]UBMC<W+<XO??8LKXPC2U/Z\_F?;,MBE@N4(
MNB'V%"X_`XW'YK6G1]S05W;T=?5O$JB;ER-$RRTN.MC^^UQ!FQJ>'%&A3+G,
ME-C<XW)V=C,AGO47DU".C)'Y\P#,H<XWR+QG`+3K:35`SR>41Z9V#$I#5<*J
MR!1HVPFC8Q]70\F,1E:UR5M-5(S'I"YY,RJP83C0P,5NWP<XTOV&H(!.)ST^
MDB>6!]C,R9HK<A4=16FU._14WZG;O]CIDD4V3/+A$+CL-U7-2Q-HB6$DJ/B-
M-/QCZY"4[&\>>4WZT6Z^:-=;7XSZ!+<[%4R>[^5I2QQ"?V,SVZ;'C[(B]A&3
MF*6+'I*S/RR,)%J7)B#50S.A>5K>:F4;F[F!4;HO^MSQCU`UNL?LZ]>SUL=6
MVB==S:U9MZ&/"QCMY\C<'B<_L0J:2VJY'8T@D5B,L!187X>7ER1I3MC#$!"/
M_KU+"X-B^2E"V3RMTUR8^SVVEL(Z7O!)T2Y/SVNA,GD4$L]J>:WE#.JC^'R$
MJFB3QTB55@@6*F^2IGO1>6H5)3=_Q3"RB0J?R#XW,O._=D7MEQC$:74IS#SL
MQPBBI>J=&/>>7Q?<\F]FSR>7I;L`AD2@U=0R14<GLN21B#)V]M,(;8]+5!*(
MT@DDM*F"X]I^8\)M7;T04.]O6$E6^@9M$+G!3ENBSL71SMSO#8['Z\<*Z0/#
M8L0.6J231PI^W(<RSR<K=MM/M^S.<Y#6!)OZQ-*SVG5M/S[L;H1]2KK1K"RM
MI<T03GZ'R9)I5I/0RAEBR$N.UDEC^C1M)>D'IWTW.1'FD+=-,:YR5@LLD.^L
MW^N9`Y#7$_AL$OO+--;NHSH&L^B;YD]4QQ7<U]6+?O7-)].++DLE^AKC#&5[
M=H*W5HY,#$W?@%IF\MTT,(W*+T.(.#;EY_<G6-Q71K-S]*[HB%R0J!(43%6:
M]@HIGI:2(V9*N?%"UTLE5'YI)6>Q[!D^BY*>[OA2!F,<',I2L.)W.5F;:A>@
M````````````````````````````````````````````````````````````
M````````!#_0N93B@KPS!G-\99MBG[+S#GB,MZAVDC3*<0MZS'G./M20LY6Y
MOB!V^$U(G*TV,./TTTUQG.<8`>(2C>[>W^+ZJY\N3F1]]#>^'VQ>>L(O1>"=
MJQ/HV=<^\:]7J4=>Q\F>&6BZ5'O:L9:(/-,2'>4PU@4NY>[$GT-^5*9E*?L&
MWRLO6[KVWNHF3FZQN:3ZHC*"5>?B-7:\$(O",-S_`#&XV%):]U,9;K<%$HD!
M<!9&:/.:+9I<TC&]K&C0S;1<2>9]Z8*L5Y_9FONU:)F%OUOQ=3<ZD$=NF^D6
M:S9^H229*S\QT95R.P'ZZ9$2E@SXX9^-:Y%(41I"3]?)#B5&C;G/QXWV#&O[
M)?;=V0J+P>D:+4GT]!^AN?\`NX[H=C?&VD:SLRU6NGMZ]A,));7ZX-/WLH@$
MN<90N4)6V&GES*5,QF^6GZ':Z_8&VVC.JH9TM9EX><%Z\/PU"CXTBJ5UF[E*
MV*&SWF1EK5#!*V<^6+$;(Q(6(UN9][O97J2JFB,)]EZ^((8:M(7*ODW*^X-`
M7GQ[/]BR)KW>[UYRA'8TJD4*XT0<S4K%Z?H3FY:995Q75>;)4N]=V:ADD[:D
ME21)MJPQP0*I`W,CTVNZD[;1`B(3;K%83')?4WD2DVQKE_</G/0]IR-^7U#9
MI*]'4G*)EYHI_:G3';3>[.*IF0J%K1+(MS/`N==$VLM9CUA[VOVU6JS46'3Z
MDA9CH7T_\D5D8FB"]O+*>6)':EZ(E":$-K!S1SY.FBQ4%2E])H#^H:V^DX9D
MCM7+&T<NS@M4N-QJJ1%-QQ&Y6Y>VP"YU.=^><M-=JL-0USSP175Z=WW_`''7
M6MBUGS-$ZOV=WBETZ%<[N/0LU2RPQ]F2J7V!('%0Q/&B+/YA;J7DY(GVP:K4
MAT=^^LO7ZB[I/5W%7*E*6E%&GN1M\]8W85T7D^0/68=!QV@9[?UT:Z1Z-PE^
M4,,+KQMBZ=F*7FJ#SESID_[2,%ZXSJ'ZH[WQJ%_/G#SU<P1+D>,TA!I.P=#L
M3S)9I:LZKKIR&=,F\ZO-<1C6O:X71^UJ]<UBAO4M[XPG*EF3UOPJD28O3!Q@
M6]K_`-K_`#`LV*QN;1?JZ*ZQJ:W8R\\PA;(XG9$/6S&UY%%X[,6-CCT?E<-9
MI(L:W5CE2'=.[[(]&@TP[!>JG._TQD.\A_L?YGV`IC""$=:P&3.TRN(B@(VR
M-K3.=GQ=;RE$L<2H<H9C8F6Z-1N$B`S8Q:K)(;B?^.#%&N=],;!C=/\`L;Q!
M,ZS@$IM^[:GY\LB6<_INDI)3TJLZ/R9W@M<*6,N6:K'"51XK^-NZ[$,5)WG"
M--O^QV;#\*<)LDXR9@+#5)Z,<)WS)*XAE-]7TA8\SMV&/MAUO#8M.FERE\LA
M4952!"_R-NBY9N'W1O:5D4<RCLG)RMM=T!^/I]2M_H%<^6_8[CKI6,,TX>)O
M&><XK:$IF#;S3KT39U2U]-ND8/!WI_BCU:\&K8Z;JIHPPI1+8B[(4/[M*@7+
M/P-S-2,8SC&`LVZ>@_"S+5\0NQUZ_P";D%/V#,5]?0.SU=S0!/`IG-VHY8F=
M(Q&):>_%L+R[-I[>?JIT(4;X3_%MDS.N-<Y`8W3WHMR=:,(@,AD5RU32\YG-
M7-MP'TG:MS4TV6M$8,Z,2F4II!)&1BG[\@U8MXLEV==')*J4MQC9G53J?DK/
MW`'8?HSRCP_S`C[`N6P-G6C7EXB3#%)-5B+6S/YNY3?8_:.:0_:-*5#<])%R
M)&H584ZJ=4WXQ&^V#,Y^W78.TDGH'RQ'(%S199=@F2N(];W+6U!TDO@+(ZSC
M=[L^TVMQ>H]'WPB-)G'>(Y;6IH5G.YCE^-JT:IC,*OCVUSJ`GN/WQ1TL2:KX
MK<U429#O,E]=:+(_8D0>4FU@M>FQCG!=5#<\*2=IDW%Z;;'MF,_FDZXSG<K&
M,`,4L'J6B:X943R[6$R/V[FX,#>U1^!*2Y_,7?1^LF*5-EV:8A$=W>1.4>CT
MWFK>G>G`E/NC9BS=CEAA)9>^V`FPI^8SB5JDEY:34[8O-:G)04XHS"6]T(,+
M*/;5INAV=$B\DT[37<DS.IFNVV,9Q]<X`8/_`+HJ;_<>_/?^PXG_`+P+K72X
MMZK_`'"3^;:U89)MX;I/LL7W_F?Q?,J+V0?E?;\?Y6/L^OU`8_?O25#\LUH[
M7)T/:T-J*KV)>Q-;M-IFZEMK(A<9,XIFEA1FGXU-,R>YKE>FI>NNN?\`CG.^
M?IIKMM@/CH'J7FWJN+NLUYIO:I[XB3"ZX8WV0U1.X[.6IE>MD2=RPTNZN/."
MXIL<LH%19WP'YT,^/?&WT^@"0:VLVN[DA##9=3S>+6/7LI(5*8U-H4]M\CB[
M\F1."MJ5J&A[:CU+>X$)W)`<1MN49MK@TK;7Z_7&0'$\6K64>G4,K!]L"&M%
MD6+K)MX%`G&2-"28S(N%M*)^EYL:CARO1W>28NRN294X;D$[ZI"%).YN=<&E
MYV#)6"11^5M1#[%GUFDK(J-6D)7E@<T3PU*3VU<I:W$DAP;CU*0XU`YHCDY^
MNN^<E'E;E[?3?7;&`[D`````````````````````````````````````````
M`````````````````````````?@THLXLPDXO0TDW3<HTHW34PLPLS7.NY9FF
MV,Z[Z;ZYSC.,XSC.,@(+HGE[G/E]E>([SK2%84HR2!:2X/C;6L-8XDF=E24K
M<E'NOU:$:;*HM"4;OJG+WSDLC!F_QZZ_?M]0E=UB<5?G!K=GR-1]Y=&/8S=D
M<G5F;G%P9]SC$YQVS6L6)CE#?L::D*VVR3MIG;8K3.?\ZX^@0[4?+E'T>_WM
M*Z]AQB63=+V(X6C=K_(I%)YN[3F4+V\MG)(5KIH\OQ[=$V-E*PB:F%%E.RM*
M3.Q21*3IOOC8/GCO(/*$.:VYDAO,U!PQF:9W$[0;&J'5#`8HWH;(@BHQ;"YV
MF1Q]@;B"Y;%51YFZ!PQK^2ER9O\`'OKC;;&0P0[SRX+6,T3C[MQ?RW(VB!MC
MTR0I)+:(K*7YBC+(Y4\3E]9X^HD\:=E34U.DQD"YS.3$[Z$[+59IOV_?OMG(
M8,]^5GG)('Z-21QXQH'5SAU7R>EHIHV0)K8FB/59,T\Y22B%-$=8]6Z/H6AZ
M36;(M#L%I<&_:]K?IOC\@S[@[Y1YJ\%*K$A-N'\ITZ9:%<SM-9D'G^8P5K+(
MW.468WNCD#>]ZFZK]3TAL1;C"BM]]TY9J?Y-2\;F&[;A%<Q\DN-[%L.UIO.X
MM+WAIM*[HYT]I!&*Q)Q6C%`>ED%</-2S2[H`]50_P::LLNM>!+$":0E[NAR%
M4I:BEA9!2H]6:>',@\?/.9GQ`26/FJ/,*"L&**Q^"M;')YXU(&)-#K>>[V9U
M^-44H)4.3^9:$D7.2QQ6&*%KAE5N4I--*^FF`P-^\0O.I[_UZ:EJN=Q%QJU9
M6AL'D,#O>[(7+V!LJ>CT'.D4C;7-6">(Y<UL&]2-"-M7%)%R<U=LD+/-,V/S
MN9N&+M'A'P$QVU0%P-C3>*1\YO0P;2!Q]/T#9R2(NLBK4AY00>?SAL1OB9=*
MY^QLK\J;LN1RO7=<W&[)UFJ@K;;78/D,\&^"C&%PAVQ5^[P!QKO2$'5THOV>
MKH'K),4VGYV,NO$9<%BMO.NY31*,F*FO1V#2MVLK3.4WY&/G`2=27CIQ=SYU
MA%^RZU9[(;[?A\6NF),B=PL)R<H20@OBU9W;TV4;1<Y-J5JI3R.R'9.WEEFE
MHTJ`XO3)!AI!)^@1,Y>"W#3FQ0>.&N=_IVN%P&.ULI3([;-3$3J,0*V)W=U4
MESQ&6P_KWAPJ*R+"6+8\I3DHSDQ!1",_*A'J80:$TVMY'<G7'3/$=#RPVTT<
M"X$=:[?*.+BDV311W7N]:1=LB#(X3]Q9&!+_`"%2XM#=M^QV3%H/RSE:C?/V
M_+],!0*W/ZT7)%P2`\EZNJ]&VK2N1:MY$CU=MZ*HU#O&8C2R\MZKEV;;,=*X
M72[9.@E!.CPXM&^<M[VO))+78.;TY"`L)<Z2\`.8.A^:N..6]K>O6"0#C+2:
MM,(<6A573V^2"-V+@@V387)'Z`J8?&ITTKT*<Z,R-F:D*V*:X-+;M"RSLXU"
M:8_X\4XP<Q<D\GYN>['VNN1NB/\`V$C3V\&UXW3Z<.!C#:K&JBLPE,&@D*/R
M0OS;;BK4O:0LB2*EF,'GKS3M]S,A3^,?UJ^7(Q/XM:"?HOH-9-H56D2IB*N#
ME7O%KVU,5:UZR,+#`-F^,2?E*01HJV8NCB[?\<]REVEAVR?.3%F?E-^X,7J/
M^LGSS2314C?!.L.G4#C6UN/$^?9+MK59$GL.%/\`:='7,Z5JY2)K@;:_Q/?_
M`&%0+,M3O[$K;W4G0]61G;=.?\6H8#-OZKW.DZ/U->^FK3=$S56$_JB,LKO6
ME1[,&J"51:>,L8M.P4,;8HJJM?I."/LS3.I5@/*@Q\<3V-OU59WRG+,U"WO?
M_C>CZINJK.CT%@+7HJD^;FFF77GTV/LK8]W@S5M/2K=CT&B/0:Q[2OG/NUS/
M*#^*3)VT1O.%T57')<:$:F*-S0[_`,^O+.4\^>>%I47:\C1;=)]&PI_1RR3O
M#DMN!HHTM-`%=:\\57#W:1'IUDJB'+<#+;D#:?\`(FW6KB%:HO<O\G&=0Z21
M^1=SJJ7X/@=6=9M//DGY@YQK+G>Z2X-5CJ\0NZFF(RSF><R*3QXAOL:NW:%3
M)X>^;B$1;HJ_:G;LCXX(S"\8/WVV"G$L\%.Z6O$024?ZFK8%$FOD%9R8^UCB
MK;'B]=D)94JD:B=V;#(_6M_Q5J8YLK/E:Q0VGFI#C41OQEY-W+*+^P/KFG@W
MU#AYK15375D.KR-\\]6=37'1D4DDBZFG3GB@KHKBBH#%^9I+;N+JCUSQZ)NA
M-8O&TA/:7S;=*6\%X18/P5MKL&W_`,S*+M&D:ANE7;$,:JK>[PZZZ.Z`8:98
MW9.]M52PRQ)K\<;CQ;@@5K&HQUEJ9DVESKHDVP26\R17KG7!F#/J&QD`````
M``````````````````````````````````````````````````````'G6]6'
MOU`C7>7)5H>>D1L>?QN@*VV>[QIAP>9W':(Z39KZN..T\BB"MT1-3M7NDTIA
M*F42IU5JM,.K&Q'E.).II!)NF`UW\%VM[8\[S&,U@OAMH=2NEQ^N74-?]57_
M`-!POH-77$+H"J2*D9XRHH=H.RH755`[6T=)2[QA[.1?P].H2IDAYFA6A^Y8
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M9=JU2S6UA-`K*DDONF,P5=`R9:R.C)HW,C%7;2X.+8Z:.&=UKMN5^442GURH
M#;QR9V/<L(\0JB[DNIBL?J&ZV#D(B\9Y&X\P-+!8EDR0EK6/BQH(:&MI1-K:
M<C)VP4>>0W[[ZI$NZC1,<;]"=PT\N']IJQXTS\NJI'PD@.<K8WLDRQ$3==*E
MM42=#7UW,%1E;\A,[[7Z9ZZ'=Y2DD):YK;2RD2IP6)EB1/@PI(8MR$ZJ/[/\
M>45)9=H,7GGTANK@75UB<XH(5-99$:U?WQBJJGK"O.Q9NY%2UL3*8K,:[KVO
MC%,AB2A.:<V&N"4G5P4'&?8`R^3?V$,43+^HUUQT9.+/B3)<R9HYQAE&((,5
M)DE#QKA6O.U9O9]GRZ<6:RQI;LHKJ4*WI,0@^A^B<G*34G<[3&=PD^T_[)'*
M=,6IVG7\[Y]ZHQ&N)H+7LSG-I1J'PY_AC^ILY?731#(NB59FS>6P/LH<[2:]
M6LMQ-)RK)*6F[8)U2;8W"Z7=WJ/$N-O,PST<;*EG-B,\BKNJYC`*U,+(97;1
M?=3>RJX839#FAW?4L/8V79_)_=*B/S\D9TV*3X/,W*^X-?/@Q[E6UZU32[(9
M8M0UM&R*SAK).-)C4>M@HV:,JWQ__2)*SG#?.]W7\Q_<$NAR]J>42XA.ZIT*
M[3]>FW1[YW"ZU[^Y/"_-=\7G05N_^PS,]<VK:X;[JGS!S=;$]JB`K+?C"*3U
M:2_S*!1^2X;M;`U780-)AZ8LI:YZ&$%[9^S.P#X"O?CRR6'-+4U="NSQ+G+"
M]"X01OIVY=Y=!9>ED*V&(*XMIN.@9*>G;#DLZ0;LC2U2@YI/<G'<K4C[RSR3
M3`D_SC])5O='&TC[?LKG66\CTZF73A^@ZF?S!JFRR=4K"6G5S5W)HFCC*WN+
M&TG&)7%/^"8F/-,V;MSDQJE.:2;N$*+?[#ODJW5!6%[*NEG3-8V]-K/KZ'2!
M'2=Y.>_\EIW>'&6`GD;:UUTM<HBE96FP&5RP>YE)2SFYP+/+SMC!F-`E:N?6
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M-XYI%H6C=#4WX&JE%^_WW.4?#MDW5+MJ248<843N%=^,/=SE3I6$1]WO-`X<
M169..J+"Y-KZC+Y>2<V3)Y]7),.3OJE<V-;43M#T".63`J.JS771*B12'35O
MW595'D%;A8M_]E_+"+M[B[/?=G.Z-J9['=:E=G/2;IUK>V6`RM9KRN85ZU`2
MJ3)-,MZ<W8A89MJ@5[DF%D'F&E[Z:AL;C[^RRMA9)3&G1$^1R2M#:_L#TV*"
MU;<\,KPB)<6IT;U16=BE*)P0J2S2C-<YUW+WQG'^,@.W````````````````
M```````````````````````````````````````````````````````````!
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M?7,]C=;:PR"+RWS9K6'*E\A.3D;_``YW)P%6>5/9WH%11=GHK#A[IW)9:2UW
MV.5(X262\-0&T:Z@L&X":>CND+A.FE9(9)SG82R)H79P):4!1>JLQ.I3M3^I
M)5FGIL!:U/[TTW6?0<8HN^*DI)QA=_=/T=05;RING%61R91*K[1Y*YAGVMT=
M)Q%W.T2;L2[6]"F["M`D;6).@1*6[!V^$6F5`59K#NGP]*O.?]F$^;W4I]L]
M)OBIYO)UG++'K0KUOK)?O7T[;.E9!64CZ$D]7DUVZIW%`Z-J]G9#WI*8E/T2
MI2LFDZJ@V[<O^N_,U^W[3WG+*6^46U9=Z4_==CH)B;3$,@U&.T%K^V+I@9M=
MOD$565.7=I7M##4ZM'\9J=4B<B4Q2G.Q6%F""@W!5)0E&4"SN4?HFF*HI9A>
M7##J\,M35Y$:Z:79TU*P1JY.;?$&AG2+W#4C&-,'&Z;F8TQ]OU^G^`&%2#D+
MEZ6./0#K*J%JZ3.'531$6#HU3(8BU/6URLD`8OXU"&F>:N1"DM[;XFR_4IO*
MWQ]B7;.3"\:FYSOD(5;?+;SM9I33DT9..*&8I'S^0J3U$N8H,W,I$0U5O"Z1
M['Z-;7A(TO2Y+)7-2YI5+B0L4(W-0:K(W+4F;FY"P4-YFH>ON?">4X=6K$Q\
M\)X&_P!8$U408Y'QPN`2A*YH7Z*XRL7J7+]4XHGE25MID_[M"S<ZZ9UQC7&`
MU]&^$'E<76B2H6+EIJA\`1,5NQXMGB4]L]G4G(KS9Z^8[+.6O>LR.?5[@_(*
MK8,84'*=S"-FW3)>=<;FX,"<J8\M^*.?.K[`[3J&K'.'WQ9J2<)Y4YIK"L)=
M#=U%FNT9?K%=VBN'23+8,P/4W>X>@5N2I&@),4*"<[YSC.VWU#@O?RKX8Z7Z
M/0]9773BR:7HV58_4PAE1UDVBUMB:O9-'9A%'EGTAK+,FZ&?.L89VYDY5909
M4XV.U-QO\Q11F@1-)/#;R^E\1,A,BYF2KF,R29E.#4EE6VPR`E>KI>&\^R!O
M3RR-SIGE)$8FE50%K;GYGU68:WO9-@]8G./SDP!<"X>*^;;XHR`<WV;7YKU3
MU6O%3O\``(PBEDR8%,:=J05-BNLE:.1L+^W28[>-F,Y&/^Y8;A3IKG!_R_=M
M]0I+(O#'SZEDL0S:1PFP761(NIK'ZQ.6'6=)2M'V5VS8,7MF>UI+$R8TA/,*
M0>[1A34__P`>=-5>"7)%KN4?IIN;IN&'5-_7V\UJ3LR!VM7U=SI!):TNI-=$
M,3.UA.<F8V;9JC<JCD9JI*VR),Y_#342Q-7-8WLA>^FQ:U5ML8H-*QJ3J&['
M77737733773337&NFFN,:ZZZZX^FNNNN/IC777&/IC&/_`#]````````````
M````````````````````````````````````````````````````````````
M````U6>WEGV)3'E)VU9]236=US941J4M="YM6;@K:9M'WU1+HPW)%C*Z-^FR
M]NP9^;DI2>1G0XI&8;MIN7MC&^H:>+E]Y^R:(3=Q1V)<=-5NH>9VO+-S=(-E
MEIOLNMO>M.AZEYPL]_MUM;6`M1A48?8F[PCRW?C?EX0G;YVV(S@X!6C;^RIV
MO2MH1FE>G.<*Y<9;(+UL9GN5;6T"Z4A2?ERD?U,!(KQ<:KFU=/)4_E!1[P[N
MZI7JG^/\5,0F4)4AAOWZA<?RO]`^DYI1W2^>E9U<=TRMGK+AMCB,OC%3&J%]
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M0FIJF.M^-N!3RI*)^9G280ITY./R/@"ML?\`>;R!E<9?Y`\^/\?DENP&$1J@
M;#AU=UQRE,22Z=;ZSE=E6R7&W5B?E[4]415Y%3*<$?0S=+E"428;E#],E`+R
MU+WGY`MW2S:X\N<9Q?GJU:,LZ0UC$.B93RG$BHG/*H;IW=BWI!+SA(:ZL1%(
MDR;<N'3-.7(#D.6AH5+L:+",)5&Q>`WS^>OH-0/IESNCZ:YPQ,D\`53"408]
MLL%I9F&8-;_$U"<I>0[,S)(I0D0Z*TRPA4F^JK)AB4\O?;33[OH`O&``````
M````````````````````````````````````````````````````````````
M````````````````````````-,'O?=$JI+SS>G:%7E.>;9#.>@.7:LQ==>[J
M2G^`QN<WK"4-@/VYJ1N<%.&Q!71+L:H*UR1^5KIA/G?;!V230T-KO93N/ARS
MYY7])-5]>G?),KN*)/U-]>=45A.J_62)D8V,]5TAS[4\Y@E4P]CMR7.+^H0:
MP5Y3LI;,E-RN3E(W%,43MH$OTK_8GZJF7_OW9E]<6$TVEXSY3N^WZ:;2YW8+
M57]PN3;;-8U^U,LC52A@:F*;*V)S?FS3#NS[%*"=%2P@A+J:X%EEA-'$']@>
MU>J;'YJ8I'R;1F:MNN/0F+7_`&Y4]YD3IRCU\6%4O3EE0*EH_5VD84/,@F[]
M%>=-L'QQ4Y*7-C_=)4B[8L\TDLT*(=:]"SZSO66K^5FG20QCE1LZA\S+!JWA
M%]K"CJ9@CW+;0KE?:\F+Z!B:19%NF?Y,V*HN:O1)LLLBB[-(2$^DERC*T2DY
M#8CT5Z6H>C/+CK[T+D/#=>UC/^.&F*QJ@)=T=#(/>"QEZ<='J'1.W8=%6R:0
M-B<&;6GKJ<D\15N:;.B=V=T!QA6=,I-B]0I#!O87H^`\D=&K;+Y:C72?8"V0
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M3[QC-.]X#5%IWU.:SZ<7\VQFT%5<1:33"3EP^2TY%97:K:@/D+2TYU/;TB`D
MQ.I>/R=,?>%FF'W^YT9V-/-KEKFV(O$+&D\:9J#;ZJK.U+UGDK;55#\P6Y+E
M\_8(7`<(8.J8Y#U.P,:$HE6XEN^QA1R<S;)^I6`E^=^_/EC6Q,7,EW0<@0FR
MRH'.[D2))1E[.[@TPMJD,JB)Y$O1M-<+3H3*#9;"71L+:G;"-9LL2_;G3&#"
M=C`QNRO?/@:/5DR2&`6(N?K6G;;(5M;T[9%8=$U8[NAD,M=93TYUFR[%&2]=
M6I$.ES.X$K=G-!IDO=+KKOC30[0T!)DL]S?,*".3ZV3+HM;'CFI[7L;*>JIF
M]52.S-F643&%2=[I90V5JOUNB(PZ65^\H'AYC&'1K:SD&^5!Y>FQ>^X9DZ>O
M?#ZRL^T['JBS%5X_^A].I;GO)@KF+2LXQ/'WN%/LZB*&/29Z8VF&R!=)V>/G
M;:;)%YY*+7_L5[$EZ[;8"OU;^\O'.M0HIIU2>^<IVJD@RN<SBE7)EG5O&P_;
M5&R2=#7I%EU[7QD#E=U:5O-(Y('6$(#]Y4P)7TDI>A),*/\`L#.NN?;OA[DR
M.P5*]S!^D=T7;0)G0//%&JX%:<*DUJ1]PU,(A;2\.;]79B:HU\Q=B#4Q>9.2
MW[H/Q5!JLLK0G.<AGDN]H?-&N'BU8U9W4$?K:3T?83'4MIL<W@]LQE3'K.D.
M'PQJAC7N^5^W:S5P6I(VL6%&,G[`C=LT+7??A(>0<8&#^BWL71OG3>O&=$SR
M-;S-ZZQF;@A?GAOGD4C*6A*J95C"E?;LL)M><G.F\-;B'=4KQM]B4@Y(R.6V
MJC!J;!)@3O:7H]1U16_4\&EVRA'6%J<N3CJA)>>QRG^.MD4C<]I&O8I'"X@0
MU*)F^R>RWR]6HEG1I$VRY2LV+2%)CE!^NFH=2T>NOFX_H'YT9^M*W7MT1@DE
ML:;K22)5A-7L<AZG5')DMDG;QW32N9FSJ-OM-C;YEOD?TUVSJASKIMG`17I[
M<>?CK?,3HJ)W(S2(QRJ=XOJ>68N4E02KJQI5/4;)<$7L)RE5A_Q9--6Z<,$F
M0%HD\:P[JTVYAVZTM*6G-S@+"0+T]\\[0F-;5S`>QZ`DUBV\H6(JYKU#8;)I
M/)*X-[@Z-2QK)AJH]/)&]V(<6163E(K2IU.=R-L8TS_CZA@$)]:^')):?1]-
M2ZZ(?35A<U]#M'-\@C5O2N)1!YF\MD1$)31U^KIG.?E#K(XJ]RF::,Y1^"=#
M2EB4S8\LDG8HS<.EZP]:>?N5:]J>V4]6]-]-UC<3VX1F-6!R;4.MMPQMDI$]
M::K8XY)9.KDD59&I^F]F/1+"Q(]3SE#DXXWT+T^W3.X#NICZM\L5=RMOU)<>
M\]J`QM;X@HEG-D_8F5LZV@KM-7=C;&6+S"B$LE72)GD.4$B2/)I6^^="H\;A
MSVWPD^IF`G59WSQ$UHIZYOG6G/$9;:NN)?S[8+E+;<A$1;XG=S8EU6KZO=UT
MF>6I(1,DJ;[]MD>-]C,?"=C_`,D'8T"O2;V$X+*VLI-*[=VKYXJVIJNNE\C$
MQ9E),PD$(MNKY%<,<-K>(L.[_([1=6V!Q9:K=4L?3.)C?@O'W_77?7;(;&HA
M+8U/HG%YW#'I#)(?-(ZRRR*2%K-^=M?HW(VU,\,;RWG_`$U^9"Z-BPH\K;Z8
M^XO?&0&1````````````````````````````````````````````````````
M````````````X%!*8\KXU91!Q/R$&?&HT+,*^4DXLY-O]IN,Z?(4HTTVTS_Y
MUWQC./\`.,`.<!#/07/5-=44]/*#OZ"-5D5+9C)F/3.(NQJ](0ZMFK@@=R-2
MG)G6-SRUJT+NU)5:92D4$*$ZI,4:7OJ87KM@.*FN<*(YZK"`4Q2]4PJOJPJ[
MXS(#$61F3Y01M=H0L3F/:10MPK<3Y*L+<5.53H><:XJ]U)VYYYFYIFVP9$[T
M[5CW('^8K:_B9<ZD\9,ASU8;:R(&>QU4:W1KD!33I8+40CF*1,B3.9^$OPK2
M]DNQNVQ.=-L_4!'M2<E<Z4CSQ&.48%5$6*Y_BC0:S(:VE"3:=LKF2K>U$G<U
MTIVFQC^KEST]RE6<Z+EKF8J5*W$[=0;OL;M]P#,/]`T3_#=JYQ2U3Z5_M%97
M!<P<NNXB7$,0F=DDIYO#]8X6T:L^D8F)"<O1T08)PE<-2]<'Z&8UQ]`Q)ZY"
MY.DIY:J1\P\\R%42C;6\I4^TM6[PJT0,S.VQYH1ZJ7&-J3L)6M@9D:%/I]WV
MDI$I).F,%E::ZA%4F\UN`)E*9U-Y1QYSX]3"SEL=<;!DRVLXUN]S!;$7:/OL
M8/?G'1%HI7Y87>*MYZ7&^V=2=TNOVXQC.V,AVU9^>W$-,6JTW?4O+U.5Q:['
M7Z"J6F;PR(((\\(JX:F%OB[=#"OUF$Z7+`BCS2E1ED;%YUU3IBM<?X+T^@5H
MC'BGYV-[!$8_8-",%XD5RRR2OZX5V]NIDRF(T8Z6?++5B?/>223D#=+*@J][
MF"A-'VU\(<]DJ$E.688;L3IO@+&K?.OB%PDS[,57-=:;R22N+F[/3GHVJR-U
MC@\.]*OJY3A.G7%(TV=G/G2$;E:DEEZ)]8XE+*QH7\FA@1=)_(GSKEJ@M4Z<
MU,"4W6N'^I57\<F%DQ'5W@,EL%TM-U99%K%IFSXDIFT[?G)<2J7_`)*Q-AT6
M$E&Z)U1Q6X=:_>._G7)II9EBOM`'.<UMHRWU,N?%MM78KU(<;YEZ.>VN\PUD
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M";CF*8M%-7N$L\;F+$4U)I<VIR$:S0_94;H@2D)$YI"4K0G`=CV/X=^<7=UV
M&](="U!*G6]<1-CB3;9</N*V("],1,5PKS$WQG0168-T=3R6,'*L&I%>Z(W.
M#"2\F:F8U^F0LM:OGMS#=VL,WM*-326NE?TL31,2E*NUK,1S=HBB*?5+:;5)
M")TURE#,,VDRV-1\:>D<KRN_?$."'8W"K[CS_D"KBCPG\T%D?FT065!:*B&V
MDJR]6_#=>L.LT,5N>9&N)CJML6X6)LNU"WV;8CHN.WW5O+SHL6*?N^F^V<:Z
M_:'5I_!CS:1GHM$E8V26P,]=*JWCD+57]=+Q#(LB,C*&&M<LC;`_39T3M-CQ
M:,LK6C9W\O/[)K*9T'XYNFR0K.H=M7?B5QC6=HLMWLCE?3M<1%JTS>,WLR7W
M"[RV87#;=&JK3,B4WM-V>T*HQY6N3?;SFWN:1#AM;%"`A&46F)RETVR$(]W>
M&%0]+,G0,DJ1Z3Q^Y+V<[`<$.MX+9'9U&4W*>@6N!P'HJ]:DJM*J;<L'0,CK
M"&:%,KN<L4)6IVUT.()3XVWVP&PVV//_`)ZMGF:I^2U""35]3U)R>CY;7;75
M#YI"G!B=.?)*QRRO2RUI:%>6:B*>X^G-5Z[E[&J#/J;@S51]IVH4L[%\&N-^
MVK[F_0MH3OIJ*RFQ#X2[RV+5?;B.+5V\RZ`0+-7L,S6Q=?$7[)[[M7Y*5J4Z
M94?A*$J33&R?ZF*,G!U\.\$>0J]Z/?>DHC8?0Q;S+^@Y[U#-:ZE4N@L^K.57
M/.8!;]>:2EQ;YC6SO+-=8PTW@_&(4^CQ@DPXTK*O"GX"OL#`8WX.0NE%L:MO
MF_IRWXGTU77$;5P[!Y7.&FM))3SS6<<KIZA+$19-6-\#;7![(R]K&]_5_@/#
M>J/<V@C'SX3FJR3PW%\R46Q\P<Y4-S?&7IVDD=H2GJWIUCD+_A-J]OK56\0:
M(@A=W;1'H4D+<'),T:G&Z%:X+TWWSKKC[<8`3B``````````````````````
M`````````````````````````````````````#QW==\X^RW_`.[B,7C5TT[5
M5<`,_7W'9^J.&W$D>:_:J_D-?MZ:\TC7SD3*T;,]5"4^M7X,@=G,I.H9,J#U
M!2)PV/R=J%I99W][XI:WZ0DT<\Z*HUEE9VG!V")1E1$+D?5:&(N-A6\Q2TAH
M0-D[1*NI,(X'&H4^:26%[M3<G+EYY.R$U2UK$Z<+$\1R/T=NWTQO:P>I7*W>
M?Z,JWDCDM)&.4=88D5T2^W7=]4M,SO!PCET$-NS78+C2EE-+FS;[IUI[A]ZK
M70S)"4@O12%#_<;H?UGAO?//U2<$N_0Z*M%U0U<\N$8IZF3)(U36RIET`]L3
MTL=K(75/8T%(0P>&Q1&I=FJ1/$+2EM:DTTMPWU..T`3CCU:]5W<J8L9'GHP5
MM8SMZ#5QR#6T8LV%=2.,;KVKIDELG57?%RV=#J[40.>Q+9=$VK<AW@2MQ94B
M=U^Y<81KE*8J#&++]B_6BG'ON5@F7D4ZR)-RO$H-_`K%@;M;ZRK[=E#M.(I#
M9%+XM('FKV\^9UOLV2,]_)1M!>SVUMR#?17@W7\I6B">6GU^Z]1=G53S!._/
M-Q;(2_2_D2I;:N&/S&T5Z2%6?TQ3\TL-^=(BTNM#-33+ZHK*4P5>QKWA2Z-F
MY9FA!IA>N%>FI0>A````````````````````````````````````````````
M```````````````````````````````````````````````````````:>/9&
MZ^HZ<JCG\B@9G*Z0K2R>AH[`.K.J*_J53><^YLH]RCT@5GS2-UTG9)(6FP]R
M5&C;%,D4-Z]+'=%&#MR,[&EFE!JQS[(='<8PETB9"*U_3U@A2!LG$(N&:\U]
M"<WV_P!00Z;6')X&36]'ML/YF>ZQEDCYS;HP2Z2R6/)C2AD2=?G"`O)Q6^^0
MLMQ9[;=$](R:!GV#PO-8W&)=QRJZ/S7]6-%@R^\W"7;]:S/GDZ-11GLN.5!%
M7J+5Y&XNC=9,J_*U68->T9J`I4B^4W0*+4/[>>A$N[&MRLF&)U]T\V1UX])U
M+9SG%6.(1*6-\?XVE+PU5(R()Y!Y38,PA$LM-.CV3_=.HXG0/:T@HMH.VRH^
M\!L)[,]0^J<>4K?ZD<BLU.T=7#>J=)UO'NLHG*YY)K(I1^L5KK*E)"T--<S"
M(HX`Y69E]3/YJ=8L<#$"`],3]^^^QN=0@?I[W`NS@N*61R1?A-569Z(12@9I
M=,/M2,1EPK[FF<1\RH>FKLB\M9(-()F;-I$P0AJHUOCC[A*X)]E4A?"=$WU+
M*/SJ$RM/]B6FGSHR=<30.BY]</6<`MZ!40@B<=FE10.*VY+G6!6#,+$F4$>9
MQ/"#&B`UR;6RHAP,<-?E(W<4.FV?N-S]H=KP-[;+NFNE*5Y/FD-CC]8-Z<@<
M_P#6$2DL*U:ZT;VB.6#')8_6HDE<<L.SGM:YOL./S'R&YDB1\F6J4QSBN.-T
M2(C=R@]#H```````````````````````````````````````````````````
M`````````````````````````````````````````#2MZN=(VAS]??F017M@
MS*-LDQO?H!WLR`QA4W-[=;T-J+E"U;6(A\J7JVUV5Z,ITGC*`O<LDC.<EJ=S
M,;:'$D;X#61"?["W8KR@X^B4@XAKG_:?4EV5?!M76(S&X'NNFBO[IYWI/HNO
MWQ`0IJ]&]JYJ7'KI*;7)`4I5MQ#BT*L:+=BLY,)"!D_]H&478@TYQB1-54ET
MQM6G)TM/MS7:7ZQ=^N6PKWY^8+RY8@%*V]7A<CQ/XQ7E@21$4M6."PC98PJE
M!&?BP4HT":NMO0NXK/\`#SJ]^ED5GD:M691>^E$<Z0@=5RBN:-6P>.>A[QS3
M'F5YLJ*RI,C@5U/4)1$KCT"IT2HE)1VZW=5NERJUU#Z^7O8&R()R%55<SWD&
MIKTBTCZVNKS3HABH]SBS#5J:>U/!*_5<FTY+FJ.2CIRO'!%;Z12X$*9*P21W
MCL>2M&-S?R=M#C`'W=F>EET0+V*4<;26G.4[-H1QG?#E"/F]FT4VR.2MM;=G
M-;E&[(C2^V5UKM[ELGU7;+3FMF)@;\@>=%1B9PRWD:Y/4ARE^JG,<_0MG44X
M\QJ@B=82>6\8$U]8EKNW.$0G!5?=(R[JJO-.BY'9*7]ZGB3!'F7G+=L3QMT-
M:W+4TSXCU9:4_3)01;R_ZZ>,KS)N8[GISS,>X6\I2HK7JFYS:UH3$CY&;(6:
M]4#335)99O.UTACR"1MKRL:VG1(>2<H;E'U,T,_QC4+9O']FSF]`41::VF+N
M@M`16A+`MVQDUE1.)L]VO#R:HY!7T*Q55'6NT7*'/3;9\'ZP;WTP]:Y$&D(B
M]?\`@7OH=K@-_P!S-T'`.L.?*:Z5JS=TS7EXUU%[*B13ZF3HGU$T2EK(<B6Q
M]1(UC@D1OC3N=LF6%%*#RRU)6^NIF^N,;9"<@```````````````````````
M````````````````````````````````````````````````````````````
M``````!HQ]@.E+.HF[?-&&0GLJJN-(?>5XW5%K3GMJU]3DV:4L=B=%/TU:I-
MA?<1K8W1=`W/C65'E9R-S;#U'\M*+^;;;XR3`UB<V?V2YTEELXI"Z*CJBRFR
MH(E>MB1SL!SM&,<30#IZG(;B:XH&RZ(I6[2'9Q?&RUU42RQKUK4]*F9I4*"U
MN#,I,F%%ATB7^Q96YW.MK=\7?Q3'G^,:WOQE`*;I%N?:JD%FQA[LZIK(LI#9
MLFLEYCB%4>XDXABHQE+W;$QZ(GX,DG::GJ3$X7UI;V0I2WK!OOEFZ>&%L`H"
M%QV_4!"B&&13K&.6NLHZ>TM".AH1GGVC8/*GA>DCLLOXD]:K2)GIH7I4:]7\
MNQ9*C<L-,4#ZNM<SOZ,(I=S)3TEHCSN>?7Z8<9\L\WLD>Y_JV6R;C=QCD3CM
MB,Y$4LBQ6^:W:V0\][9DR5VB+&@:#%1JMOW7JE)GXH7^[(Z`I=SK3FGV/Y-X
M-K!XZIZ>[/K/FNC+HNJD)/<-L32EW9CGD8AM[US3;-/:K?M)C(X_7I/\82'+
M4#L8P[Z_:=C523G`0?6?:]#]$4!R5SS)_)NIOUMN-GG;$ND'9OK^%.?.U2IK
M(ZUL^,4-4::K9'9,*MJ6[Y5M$U5M6-#G-%%'!X4*%R=Q0?FZ*`P6J/0[P_KQ
M-(6!P\GVV$77:O.%#].2BF^:X/6=I,TO-)Z'B&G/-.1S6,R2*HE5P)WQUB\A
M6MY30WH\JS#T:@Y4<1J6I#++=Z:\1)FR6U92CRAL5\L&<^>C`_(S9O4J]DII
MRB]'UFP3Y!RRJ=(Y.EK'6D]HMHJ5KT<_U3.D4)4[!OJ0J.R27H:'H0\Y^L^)
M+1>.D^*>*X6=7L?\YYZV4E,XHSPY!%:S0O#\NF*@\RL5"!T</W;-M*XP^%JU
M"@I*I-6E;G[:F:*"SS`V>```````````````````````````````````````
M```````````````````````````````````````````````````"/Y[4U5VH
M4UD6?6E?V.2R&JCV4F>PV.3`IH.7%E%+3FLN0MKCH@-6%$::F[%8TR9KIKC;
MZXQ@!WIT.B*@K)!\6CAY.T>WB6Q)S&V&%;14TO8DR,Y+W2[:9CQA6V==D7T_
M&SKG.,Z?0!1OJ_RSX7[/KV-5?=E%,.(A$9+#I4R(JV6.=1*"W&OH5(ZZ@Z5<
MLK=5&CG=DB,(EB]L;$*O)R1N2J-M$VA6/H`L73O*_-?/K/!V.DJ'J:KT-;1-
M=!H,9#8)'69UCD3=MV0]]94+\G08?,IY(KC3>I=-C%.YKHK1DJ%>QQVFIF`B
MQY\_>4/U5T?ZPJ"#\Z6%?C3*&FQ+VYV@U?U??*[$T5[+94Y);-;XBK>2WA]5
M&&&*%!N#MMSC=CO_`.]]IFH?R?>>7&EL<XTWR5:M#Q"R*`H%)7::J*_EW[-P
M0Q0RJXL9"X0X)5Q2],YGN37&E!R7<XP[?926>;@[[\&;?4,D3<-<?($38W-/
M.-2L*-F<J$=FHJ-Q%NC64"SEQW,?>>OQCF$MN.+25$ZJ#C65-C;\9-^2?K]F
M=#SM=PK5%/%?RG@UFPVXX?PK0<<LJOY.FFD/E+5&5"50RRY#(2Y4V24M#HX?
MJ53VSOY):A"I4)S34.2]-2,EZ::ZX#A3^+?F61%[%AV_+4<6,%IV+/K4ER5P
MF5F+5&TSM!!AHG:V/.1\TW<H:W2%EQ^"<@:#4*'*/_IP5@O.<`)[YB\]^.>,
MYY>%F<RT@QU/->CW]+)KF>&5]F+D7,7A"Z2)Z1GX:9%(WEECR=,Z2UQ.T3M:
M="GQLJVQ]GVZZ8U"Y@``````````````````````````````````````````
M````````````````````````````````````````````\!E0^H/IJ78WL#'K
M2Z9ZF)LOG.#=G23FZGV#EJ+N\=A>D#:;)60.47*Z2"BV\F&QEA1HF8^)[$/"
MO>0*U.^%Q1Q*<LE0&U&?^U_=E2:]EM)7'35.HQQAS+QM.2+;FJ2X(\?:TOO3
M_1Y=@VF]((75KBPH:FB;%/)*]KB&DK#LW$QD[.Z7&NRDEN#I;E]L^WJ(L#LU
ME?J\YFGBFHZV\S'+GJ*1%IO=!!+(D7:+S#&.QIFLN9_8VW=1`8NZR,\ALURT
M(E7V&)?DTW4)UY`#[[Y]I^UN4;_ZSK.X:DY^RX0ZQ//>FJ^U=K$F<>YBH^1]
M)T[>U@S:?VIT*13NTV>HE)Y!73<UMOY<?;"$"Q6648:7H4H.-"JO:_\`91O]
M',?5CDRE:@9Z,M3BJJ'645]T+_($M@;+)17]V497DU3J:YFU?(V`]FD:.?N>
MK.MWW5:;$ZIC\%&8.QOH'LQA;L>_PZ)OJG.V5+U&6%V49WP7KOD]Q:TJPW.V
MI)91.NV3#L_7&FNNN,_^,8Q_@!DP````````````````````````````````
M````````````````````````````````````````````````````````````
M```'TQ]?K]/\Y_\`.?\`YS]/_'_]/J`_F<8VQG7;&-M=L9QMKG&,XSC./IG&
M<9_QG&<`//IZ3V1ZKDJN\MXEEFY1XJYMY)FU_P!(=25&H@MBWW>=V0RL,/S-
M3,@@TY9Y_B(0DR>;K=W%0WQE.Z9(:$>J1UU_/.^$*A]'>H-V><%,T8SV+<+G
MU4DZAYPKZ^Z[OR\:I2$RY#(I'8M`11W@D=)H*FD-?+<U?6,U?;#;OY`T'K5*
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MI0+$SN\%$9W*2:?4!!=._P!G9\Z"HB&W14?`[S)#;!ZF=>.H[%4/0#:[.+;=
M<OK>%S?FALF&B2JDRR.,EY/[\[L!KD:1^N8UL=4[_D+"]\?8%K.VO>UBXDZR
MM3F.647')FOKJ-L<P;$;3>C='[+FD57\LW/T,]R5HA,@@A#&0PQ:1U#K&%B@
MQ[_X&/B)5]OUVPFV"/TW]DJNTMAU%3DBXQO$RT;'D?1$<>$5<6-2MIUVQ[<W
ML'\KFSQ$;?8I8C@UG,*.-ZF*%RI`>GT:MTQY)_U.*SID.YBG]ESF!VZ!KOE>
M9<W](UQ?=SU[2$SI>&/:JDGYNL5[Z3(@;K2<)(ED/MA^8(BY2J*V&B=U2I^-
M;$C4C)4:J-L'ZD$GA,'F![9LG=DO@W.\WHZPXQTR;6;Y9EP/5?1HAUYEK`LZ
M5S'2!PU78[O,3Y$HE\F@;&C7%EEMQR=0H-.P49KH49J4%<JO_L)RU<:R2"UN
M,Y:9!)S$[#M=HWIB6,4OD-:5;&>GYOQE6::<[21QCC=-K)OWHB--S0Q(&;5(
MWHBGHL]0LW3)EBD@.E=?[1=.1J5SFMY'YW>A.]FU!)CZONN-PR!5?.&2M+R2
M)9RZ*JJ731ML],R.RS:/UP].29>1]"%S>W*5!&FY1.^^`NMW/ZC7ISLS<;VQ
MSMRTS=$4;TJ56SX>F46BUQ?H><-]E_JW9+!>>*1T)6+YE8,1K=8IESZJ=5;?
M'FUH0&:G*],_(<0%+D7NEV(_V!"X2Q\4\_HT=N<8O/IK5LDD'6#T61_Z2L#$
M_/9C'-VMKI=<K;^D'G=L2)=&]KV<V-O,7&&FJ3B$*@S(3GR![HKN@X[5%EV;
MS&=6=4WIROVCV-7JZ&V7BT+%;:IXYL"-P5X8)1`$L-8=%$SF>KFK5H<(7$PK
M;<HI+C3)FQNY816E_M4>?[E6-9VDPT9W3+F>QU"M-NAAE!L,D5PPU//R*S2E
MRM>DLG1API?)<XH$K>2@5K3E9[BF(UUPI,^'`70J?W/XVM[H.G^=&2'],Q]^
MO)GI9=`;#E](N+53BA_OZD$_05;5^[V"D>7-&RS]VKX[;;+>>5KC*M.>668;
MH28;J$KW3[`\.4!835%K*L1T35DL=UT'?^J8FRZ6-RI6=T-SWNS+*`N:X*^7
MR9'3EQD:9)6[-TE2MB31$H+WV5Z[??IJ$&]Y^[')?!=]QGG:6L,^LJ:+8`OL
MR>OD%+828!4\:/A$XF\"03*:/SJWM.)G;"*`+BX\T)]C5"O'QF[[%:')\G!#
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M6RJ%9C;(W1@0Q.0K4R&0I%1B5N7JE.J4S8[.GQE&[:!>L```````````````
M````````````````````````````````````````````````````````&O?U
M3[:=/.K@?H7L-A@::RY#4;'&=X]#%ZM<WM+H^S.=1>`M:A\6MJ=0M(8F97*-
M5RS!?Q[FITVY>II6V^#-0\]\"_M1RVUJ9E]DPOC.N8T\Q&)\\-Y<2M[JYE@T
MWDMK6].Z;AS^>P5(UUU*;&SSXD(MTM6R3H\@I`XEH=BS-"U!NB?`6<M[U3[*
M9K4Z'I.X.1H+2C[R]..7VZV+DK>S8I8S`LB/4_1?-$`Y@2U?,KJJ=H97G>8J
M)G.MY;HZQI%^B0QS;9`H(<CBE"8(UGW]E:"U\LBNT1Y1I%_57+T/+X1"&G?M
MVB*_F;3!X>]2U!/;+ZB9)3%FK7F6PCRH"@6(HY)E1ACAJHU*V<-5:/*?8/4!
MJDJ2[(<H6ZI:ZMNOYLV9:U:O!$9GL.EK.VN:K79M4'XU=65^;6]X*/QDG;)I
M12G7?_&-\;`/(FP]*/'3EGM/M5T8^<;U]3?#M@]J\VXX]MR"2UTOZ,U%4I6T
MLD;A7A#[/-&H[M5Z20C8[1JVC;>0B9=OCR?J7L;MH'3R?V+\Z760\4=.6?PU
MTW!I14UGWNI-IFBY-5\CHBH9;`2J<A6+XMF.0V31."6M(X=';]8M8ZYEIE"J
M-GNBY-I]%19>#`[[N;O_`(3[XA?1+>I\O>A;5G[]T:;Y4U%TG7L!YX07M8$L
MD[/:RN>I**L*P4\E=(YI"FF`J]STJM/M\:&0IMS=D6%*C9.%&W7ISSLZ4Z\X
M@O[G/BCK6KO_`$6ZVY]\^XU1CT^4=RU0QC[<"ZZ)S*7EY88VSS/=RGD#=X*Z
MXF493J6_24H5:4M>?J2882I#?YPE8'D%[NL-W]`1_@JMI,954^::`62V_P"A
M*N-ELDC4.B*=7`'>,N"/,A6LC`GCLD,3HD>5"5>W%EZ:;EEZZD8U#SYTC[.5
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MD+<7VX>@BO)L[ETKTGL8:6:/2695%3;)T`LKU4]-K5&#&M?)#,%[)RS%9Y.A
MH8/XX<2>2G>+/TQ97,]0]651!J5Z@KFOXJKG'1MDNBJ<-M%/5?7G5<]:8U*2
M"I#7[-(GQM9W$UF6F*%>FB)-]QI>^OQEAK]X(N2AJ_QW+Z+2;GCKN:U[YE=#
M<J<YT;RZ^="LYBB/FPJ-2'F:$7)<\4?GR/H9_?$.4S(Y"CW5H#$["0[EHFK"
MC9&K5IPW`,J#R*[2]6K5X*B?)[7-CJ(63FV.EX\Z66UU5S(\='O+D8IF$P.Y
M0;W=MUZVN=.[:IVI^DKHT+&UB3I2L:FYUT3;'A3?L/HKP3[LLWTCEG7G"UE-
M"[S$5-49LV_FI3M6<KMN5Q642#GZO*?AZJO9PP/BQ1(9$V[DQQ"[&)B#4C>6
MK/\`Q2$9F"PC.@2_*WL/NJON:53?ZFQNX^Y^+X/;G4DUM#I%.HA-X40\TM&;
MQAM.7?,Y(M43.00R*5Y'6YO)=8-B/9VSDU"H5GD_F_8$V=!S3SCX\?.T.$+:
MA'J+/ZWM/S]/CZCIV2.[*?&EW-/(4,UGT%YWY'FZ]DCS?)8$Q-5I_K#)$K2N
MJ1:].Q:1U7K"SC5)8:TXC)O).H*_SSW:<@]46%^B,C55+U?#[5=N8;(5>?=?
MP^/W%P[$'JRGUDK31L6UNUO7=3DYL>D=3NSLE<4^AVA1>"-"5@;>OZ]D,YJO
MOK7L_K!AQ?+/9E>S!0JH2OK001AIB&O'W3M>5,QTQT(V(TD:*DBFP[NAO+Y.
M7+!KKL@;4Y'Q)DNGY1AQH;P5OLSY=MS/9$A7=I4\EC]0V['Z)LE^.6/NK+$K
M2E2"7N4>CCBZ_H_P#$SLD@#U\3F28:T_(V*"LJL&EYT`?1*_8GS-BU?-ULX[
M5YRD-8'V<VU*]3R+6S#9''HK+G:&RB<MR)].9G1<JT.7LD24_CE$E'''&9Q]
M-?LU-,+#8#`)_"+5A,5LFM98P3J`3AB;9/#YC%71(]QV2Q]W3%K&QW9W5`:<
MD7(5B8W7;3?3;.,XS]/_`#C.`'=,RAV5-Q![XVI6ASWW4X/;T;GEX3D::*CB
MTNVCALA;<G;*$FI9N^/AU^/??.GUW^W[]@[0``1Q'BK=Q8=@G2Q=7&U4;$QD
MNJFZ/-4GTL,I1JVYVF2VP7IR>#(VH)/>-\:-B9M0%;%)B_O//,W,^,H)'```
M```````````````````````````````````````````````````````````'
M6O#,SR%K7L;^U-KXRNJ8U$YL[PA2N;6XHSM?M.2+V]:4>D6)C=?\;%F:;:;8
M_P#.`'B![;_L2QZJ_9)%R#&H+6$GXQI]S9:+NJ(O5*PL^767?<1DYB)G8&B9
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MW*US@HRK_*U.,4'!Z,.=>H/.GS?\GH]Z2M=`%\JTQU$@KCI>S:UJ-$[V$ZG6
MYT&DCY&&5A)7*V]'E$C6K-$J,DK#,SH4"?\`ZDZ77_K`:<V2^/ZU52+VJ$J:
ME[%5EVPS<S]4UC,E31TO8RI7'&M]EU\U'`*L7PZ:2&9UK'J^ER>2JUT?)1LZ
M`U2D7'ZG+BR=%&@2'6;M_6/F/45%\U5U6ULI;%NOE*.\K5K*MD'0K%!G:K>T
MZ^=Y3$:_D4Y?I$F?=+(EM<V*J1-S@NTW.1HEF&\I5K^)H2F#?9.(]Q?XF\D]
M2=-PVN7EGBI*>*3BP&A++'Z22JU[#;HY"Z/JZ-(5\U>W)(W.\I4I&9ITV+^!
M)JH4F*SM,YV-VR'D.IVO.;)CZ&^RM'+_`#UL?2D.?.+&4F0\/QGHAZ0.6+?B
MW2U7W1+I!3<^E,LA)-5UDGL=Y6OZ-:PFM[/AB29<R$GR.>$1@7!HF+>4K,Z^
M?5K4_P":'22-PLSS^ZC[!KF$/'1$W5Q4TGG@NY9CI&)S'GJ3O"NT[!<9-8SD
M3%9*[$$(DZ*8(5!/S9^U.E#E\<*3\UO3]J9FNH.&+F04A4O($RY<O2TK5[)E
M<J_4;VO-9Y-8[S?M7^[$PGVIO"FZ09D;-*$Z9E;HHN/3$H]#U+>F/T#=9S`]
M>7GE#<MI<C1_IFVG6_[KM*H7B?MM[R*U+DF"V<V!5\F*J=`?/MH5NP(R'&LZ
M:7Y)P<MV_&2-9>AQA>/QB\AI73TE_7;9N1^_%,:]4;#:JW[+ZPI.073<\:G#
MO*;)A<I9)-+[GI"IBRW:L9@_'1[$GC$D>"WUQ;3'!=LCSA2Y;Y1X^X.PN^4^
M"#+T7TGT36WJ):G)'H';%:,^7ZWY`U7"@<*RUF+/46T[G$.@)=8P9!FV;4KI
M&G^0A*O.SHH6G*4R+0I.85H$77?SM_7&@G1/_K]F0WCTQ+_5QWBMTSES;KQ4
MXC?+M>/L<6]`QCHUQE3PWQUU8]%3%(E;X4G>SW]TV9%"O*LG1+OJ2K#8!Q5X
MG^&%D0UH]`J5M*U+QYVWY>L"@79;9]RR'-8Z5\S5T^TQ;$CDF\A98Q8]?.Z:
M&$.>BA*2Y-#2RX.W/;T*,C5/@L*YV'R3_7NZUMNL[75^G$TUJR[JI/\`/OE[
MG2,WD?#JC@K;74$KN%ME?01*XQ-/,&@F(O+I'I(4AE"XYI=9.O2J5FJ_4[0C
M8(,LCFK^NZZVD[UPU=B=8=K]&6T1;+]TY4M!S(BU[$[OE-*.KET:]M5H/S-`
M&B+0]V1O4'._3IXB^P@ISU2E)RSCM],'9#T.>,7#/(?-U*&=)<DVM==T0?KV
MMZ4>85*+ND#:[N\-H>`,#[BD:=C[>W,+&:Q--:,\R6H3B5N5;A^5KMH>=G)6
M-<!HR[W\K/,KR)C&O0EQWOV\;#^H/0SG"P7%:Q,=!6,2P617K=?,O1)IIM+H
MY"V=)7KP=/7Y<X+\DKEJ3\9-HG2FYU,VW"G$>\FN9+7Y4H"/\K]`./+54=%=
ME\]2M,9Z1%\R5K+>F:BI*GK!I8R\^1JH2M,N6V,Y621=FJUE;Y&U(379S<$Z
MTS'TW2F[!OEY;]C/);B_SYJ.%U78UV2>"\Z<Z163%5X]UD]*>@4M)-O02+EU
M9;\U:34D?AR)%M9[E^P7$%KR%130=A42BP5DHK(;[8E?U/613Q]]5-843N.I
M\1^02-MFE2R%EL!BD**,%+]G=/'76.N"QL=G%,I;3DV2-#_NU5:9*W^W?&<8
M".^+NO:I[PYMKKJJD$DU259:6DC.B.9_&\Q.2*TL7E;W#5ZT]E_-<<%(E+O'
MU&4QFIV^IY'VF8_QM@!,UBVQ5E0,Z:0VU9=?U<P+%VK8C?+%F4=A+.K<MR3E
M.C>F<Y*Y-B(]=LG3F&8*UWR9G33;;Z?37.<!PIK@J5:LES<CM&NE;A7_`.D_
MGB%--HT>LA/\F2E+HW_+DI3GN?&_Y`B.T.0_F:D_EE;Z[E??KG&0&!W+U)1-
M#0E5/[%L!H2,"1]JN-;%L.398]G/%V3F.UQ5J9/'XUHYO!Q4QE\K0IDI^"?@
MSH;DW.^"M-]]0YVKJGF%].DJ=DZ,HEW/AB)S<I@4V6W`5V\4;F65&P5X7R35
M,_FY8T;5-B=VA0:J^+0ESUREWS@[_@`P^;=K\TU_TQ0W($ALQK_]@^DF:P)#
M5<!:"%;ZK7L=:Q;292%VD"QH)6(8@WJV#Y#6PUS,2Z.VR<[1)D[8DS&H8]TO
MZ#\;\=V%2%5]+7K&:GGG1K^9&:=87UNDRS,K=2G%H9S/F<6-C=6F--VCL_HD
MV5KJ>A1X-4:XR;],;YU"Y8``````````````````````````````````````
M``````````````````"%^C[M8>:N?+QZ(E+.^2&-T54EAVZ_,$93Z*Y$]M%=
M1-VEK@T,:<W<L@QU<4K3L21\F^A6#-\9WVUTQG.`\L,<]B^&+Z_<W/;OE#2*
M&7S2V(E6,PG\_?\`FB?)'_8[DV?=IT^YOUQ%P5S8GAXRPPAO0*&Y6MP;'W1R
M+QL>::CV(R&1]1>[?(72%"SZA[J\\YG;\3EG(L6O7-=V'**VUK]QL!TXK*[[
MCE8+_P`%WQ;,93QBLFI1OK.&Z.83-[HA+^/)!AQ&P"+6+V@X1@5LN>]0>8--
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MVVG75_WE`N=8,A54[/NJF6RJNX]NW;EO?%B1<F5M%*6[8;1'WIGR2@9WQ8<8
MI(3N6^WY1H72['I+R#K'BR.];N/D](+(3>A'1W.K`OIQX99)3-[-,_N*</1C
M.:0WNDI)?:05(G5X=E)T>B1K8A?'=SP6?K@A<>N*")GKT6\FNA>1NNN`?2>@
M%_*5"\.6<[5`P5VRIK?>HBZ5=05SMG.U8SJF9W!8XTRIUDC/8J3=N7-J$E3N
MA**,RI,4I_S,Z!.-H<F^!5#\=TIZ+R-38D:YB8:LHQGI221VT.BTSG-FQNB-
MHPBG$S37^'M),I)8"V.72_DXT4I=#BDQAIBC!*,E3L`UEM-?_P!?"*7[?-HV
M!Z`.9#+`>3^8-^9ZP>(Y?T66\V,]8\H-5.PV9J59V"V+H[I2.1ZU6MT0M&R#
M>2PQ4;\6Z8K?55\(;:N7[J\_?97C&W/**EYOUU,(%0G/_/,2<>I;"K=XB3S(
MET=*BTBJ:T8_,)LD.6K;"R_0IND.Y#PU-9CFFWV.1Z')/D.*"I=D5'_7Y;9W
MZ0VQ;75EP(+-ZN9+,HGK"?M9=RQUYB2SG>S*69>K6RM#&FL%^K0U3FTY7$$\
MB;]-7EH5I]MFYITT;-%B;`2M5,3\`8Y$^&Y#77=,]9XY(>?+]XAY,U<+TLEL
M>)M$K6ESK!K;(_6R>*I9@P3TN:S(A*A4&ELR5N,2-NJ)-HF1)M=`AGSJ5_UT
MN$^JZUF/''I+(")[+X,R\I9J3:1?F0:[7V4RU4\1206BC8J/CVK]8;>[2!(@
M2/9ZU$0CU3$D';8,V48.#/\`I^6>+MM>M%N7+-N@I!%[PY!I2N+ALR[TU]1Q
MIY#B%NUM/7ZB*KJZ<M#7^7)'>XHNZV`?LK0(3RL$D*<D8_\`N]E!>H5'?_ZO
M,TN?S&H:KZ:ZFK%==T_E-(V3=UQ2"7S&V*2LFK:AA5K1:@$5$+FV&QY2P0EE
MA%L[N*5$8T[Y7&+M]#G$S0DHTT,N]?\`G#S6\[.(=*%[J>>S+3?>].C<=)3R
MTN:FVA(FO4WO4%?US'YJTL26=88(I7%1/3:LW5L<7-*>_P`3;[RDY^FZ=.`^
M6P.+_`=LKF']!3[NGH.I8(V\C<Z]'.G&#_>]9,-GRZ#1SE;%/4S/)#4>8LMM
M)PMUUHV0%-FI;.XZEFJ563"\:%J,[[!L+\V]O*<KG.Z/""B[BN#4T^LI`WNO
M^UW1@A=QWE`NNJ?4W$Z6G36S<4D-<V%%6,V(-RHU8F\EOTRG^4@[Y?E."E]_
M>''B[12KE;D_HKOZ25A.5#(LK:+U\^O',L-GM[5Y/[9AB]A9ES*RTLC4,DC6
M32,(F[6<HR$<F=M-%)2IS/*)VT3AU?%/FMX_\4$M73O)?K!&WJU^>T-QS&O9
MS<]YTPEH)"\=9U^^T'7*"V&I`P,BC^(*9+7>^V=FQR;W9S4MQ^,&:E:DE:!L
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M'KE][?+4@5=]A//5[-91C>MD3`\R5K6[(5\46:H#"D*MK2;F&&[;I="R0W`T
M5S]R_P`:>7?1\-K[H=F<.8C(YVA<*RZJU;(2Z1NKX39KA9$^DY5=,L#V=(VY
MME0H'8].VHR]U.QVZ#4G[--<Z)RPHAYD\BVU3%#\[T?S?[-P!=7;!3,-FE&T
MTT<J5.PSU54]S6+'^E'J:V[7DRMN6SMTG,WKIP.9F]=NG:-(\B=U2G5,>I_Y
M@)0]OT_G].)=S`I[(O"N$[=Q`_O7<-G<J/M>H[CE-Z4&2UN-6+T^E=G.2;3=
MFQ-'1)ML<I3K"#$Z19MDG.B<PPL*#0W^N%R3*X??,MI+MF$?POK;J*INC.?D
MV8)')]5:F*5HYR6;M/,UJ5RIM1'#.A*G2N4KWT):41$<7H2&Y/\`D&*,:[$:
M!7;O7S.X%\Y^FY3?_2?H,FI%?W-:O.::H*L0\XS9[CL3B/-]U<X6U8\8:D-9
M2-\V8J_0JJV9VF/;&(TB2,-J],C^J[X<G:AD7</F!Y3[U)[#PQG[WD7/LDA?
M1U']$==R7:JY)/8_SQ75LR61V#!.7([#635BTFD3G=G2M5(4B!B6&*])`0Q%
M*BOJBTP<%AN5_-WEVG;^JKW/K[MZM)?PM640G]SHYR\U).U%K:UUGEUEY=TK
MEXL13-7)675-0;Q!6L:F':*D/K(LV4-RG969C7<@)3]?+!J?L^P?*%@KOO>F
MZRBEN2RN.P:KHR7\G6+=TKZ.C<.4MEG0^7*UD;CSJ_PN!IXTE69RR/:)L2.C
MAI_W[&F(]M$P;AN;_5KBWKB?U%7'/,\E=C/EU5'.+RB2I%6,_:&=MK*"V(_U
M8ID4V6R)@:#(-K)9K$W1*R$N9:<YTU1;F%:_&81L<&QP````````````````
M```````````````````````````````````````'2279MTCC_N\HT#BT:,CK
MLZM[KLAU:US;JA/RN1N6SIG5LU0*DN-M#LJ,X(P7MGY/^'U`>'"F^Z_'>D^>
MD=Y=`^8M@5[S5ZR=4M,F@E03<CFJ_.?B9E3>^];6/<-;50UKV8JL()7[_(]B
M#S?U.75X.4&[(2/Q-"M,AL/L#U:\P*[Z>[$9Y?YMJ-[`Y$IGHRIE]\M].<Y/
M2:TJ]YI0UO"+$HF'2O#_`*21#%2HM;C*C-;G35*U(VI3NE5ZE:%&$8#I^7.W
M_%"R+ZINL$_F4R<Z7OUSSC<[H]NSKS)1#37\?Y7C*"PX))Y-/;?B+OI%EO/U
MDPNJ'71&^-F%K&XLVI6QYNB12488&Z^8>9OFY>5;$1*1\E\\S2KI+_IB3I$3
M1$V=/'GPJEH(=`Z0>43A&-T6B]%#:Q<]V5J,*.V)V8#\H_\`FDV^/(:+NCZU
MB%T=P=K\L<2>8/"\VE/'58MUE73*>F9S-ZXTM^1]BTBPQ615?3<3A&C6R,*:
M=4S7#:RJ9(Z+2(^WN+:7J84G,^BO8)'E?HOY%*^-)1P\^<F7Y.*<IAYIRI&S
MEFGZPD[^IGRYOOA]K.-2'G:0(K`C<@L")P[J:HG%CU>_VJ!V6OC?J:64I*4Z
M'&A6.;=@^`,AE_35D0[B.]I;,9K152>C'25E5A"IC"SE:E`_P#J"$1&0S!/:
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MEB+H:S6P^.2:"LTFGBD@HB59(+R>:>8>MR8%C?`BT^3Y)?<D:N6N3+8YQ;[-
MX*HFV)"KF'4LHM>/*6*K[2GW)U9L3A5KFTMC8AG:F*4KEP,D)FV5^$F_X6R=
M']QFIP5T[MJKPFQ9W:%&Q'N21T5WIT#8[S7KRU+]NF+U;JFMBX^A*9O>T]JL
MHJ/-)\<1RJP)A7;9MNI:C/C*7ZE?<;C"?X]`UKRF$<Y6)UKYG])<Y9M*IZEJ
MQVX>O9'%;4,CUT3NV[`](^X[*@L^L232^5NSAA'<[T=",O!VYQ!A29*UZJ6\
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M%YPM,39+"#NCO`'QDQ9+5"[QOE]K1RN6HJ_I2D:2G705=,KCO,:MJ!MYX@%H
M587/6PZRII8<;A*1`G3-QJ]SCV[QG"DQL,4F%?&$*4?GQ3K;TBNSH^,=@V-*
M+2X9*S>=MWU*I;3"CGO**3\[L/&3;0I]M(T36ME<@2ZMOYZ!C1Y3E:/^IB=/
MMG4O\4!63L64\!]D]*<D>DK'>MW<XKK/L#RVN*RZZNNKXK,H':D`3WE:['3E
M9P8F':2BQ87=Y[K6S@O<"TSNGB6T?+RY*<JC-BL`,QI_R3\4[AK[_2S]VYTR
MT$]&WE/JZYRKNXI]2T-F:I%P]872$&>V"MHF\5R]))S`&"2V',M$KH_I3U!Q
M^R;8G5*X$%Z@)+FGE9X>6=4DF<$?J/&2><8_UES[(4J(F^^6Y55<9NJN*1::
M/TKV1'OT;=8_.Y+;<"C!:E06[ZJSB]DRA0C*T(,<L*0V4^'O+'%G,$P].(YQ
M\LZ`6'-_;<AK:Y-+F20I!$6>:P5C+E+?&J2(A)91"V`,+5:62=%K@60Y*<9+
MP83H665G<-`56<D?UY[RZ=[G*A4FZ%;'BPKLZ/Y&?;A6)*\;^<JTL/IF-6W:
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MS4J;]#7%(L0I=]\ZY4K=SDX>AT``````````````````````````````````
M`````````````````````'$H3D*R#DJHDE2F4DF)U"=07H<0H(.TV+.).),U
MV+-)-+VSKMKMC.-L9SC./H`@=]Y2Y=D\>@$0DO-U"2")U1NM,JZ+O=/UZZQR
MM]W+7&KCM`V1='CVR(97XUQ\WZ\I/\OVX^[Z_3'T")^B//#CSIZ`6_`;+HV"
MD?[PC,YC$ZG4.CC%$K//)L;^$[S!U;YXUMFKVF>WU56L>/5G;[FZ+3&1'A5H
M>63C3(?!SEYS<E<T4C75$1BLD-BQZL8#*:PC\OO/"2W[-.@LYU<2YI%%DYEZ
M)8Z)HI)DSJH3J&1!A$QZ(S/QB492;&I6`N7'(XP0^/,,2BC,V1R+Q9F:XY&X
M\R(D[:S,+`R(2&QG9FEN2%E)4#8UMR4LA.05KJ645IKKKC&,8P`K9=W#/'G2
M4]AUHWUS93]L6'`2<(XO,)K"VEX?$C;JJU7%,B]8>1]S_'D[AIA24W./Y2$E
M3]3="M3,YVR'1(_/+AEN<+,=VWE"BVQWN2<Q^S+/=VRO6!N=IE/XH[JI!&I8
M[.:)(0NR],,@7J'!(:487DA<I.4:?0XTS?8,-??+3SVD4?>XPX<G5,0SR2A&
M'EY^*96I;&EKM0D6.:5$:K=:[QUP:G<]G836%'^(=D_\PC5,7KH=C77Z`,PM
M_P`^>.KXDUBS*TZ.CDDE%MT"X\OV2\%N,D9%,QI%P7)W/2'/>D?>FM,J.95R
M;&[6YYT_;-/WF:HU1&IF^NP9-27%7,'.5D6);M*U.UP.QK:B]<PZRI0WO4J7
MJYHRU,Q:QJ![/J9Z?G)O5O;2R::D'.F2<.;A]N-UBA09C[P%<91X\>=<ULR\
M[<EO/*20S7HM@M6/V:>ZSZSU;&9I>;.T,%R/L+BIDSS&:SF5FLS`B3/#W'4C
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MDVUU(V-,VSC?.=?M"GU1^&WFW02BJE])TF\UB[4O;%BW!`GF,V;8G[1$^6RG
MA[98,;=53M(W/^10*0Q^`M#;EH7ZJ$Z9(CURG^$_<P_</II[Q'\\Z`=*37TY
M5+Y!T-"6#<ECPR.)IN_OC`YNU]5X[U;931,TTK/?EDKBSQ"7HU$6A4GY+3DZ
MZ:%YP7]VFP<==>''FA44RYBGE9\\M\2D'(Q$@35`;H_ODB3%E2*<K+)4'2Q/
M,EDDQ+'=LFR\Y<W.:K.75NVVU+3J2R2B2RP^CNWQAXU]$>@Z$Z:Z`Q:Q%G<[
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MT"DO)G@5PYR+QITCQC$/]BS6-=5(I>BM:T;`<XN\6EC$G@<BK=O/B*Y-$T49
MBZJ&Q>7.A;6<4V;GZFN*G908HU-SI@+5^>/G/!?.&J(Y2U6W?T!8U<12#-T,
MCD+MB31!SB4;4$S6=SQ_EL:8XM!XI^KD\Q>I\=HY&F'*"S$R%)IIIIL69N:&
MP\``````````````````````````````````````````````````````````
M`````````'F8[D]J;E0HH.CXFAKO63PU=/\`0O-US_\`MER%>DUD)SK2O/TZ
MO)!(*BK:J9JQ2V9P][(@)R=0Y$:*,H2')(K5$I"-#,F!]<=]SY_:27CJ-1BB
MI/&GFQ4G!TPZ3NV+LL5LVAHXMZDK_2XCJ$KQ,?94?L-;+)9#F=U1Z/6J!Q(B
MAR??=:4>67E1@,VJG^R3R=-HJOS-:*Z3A%NL7+,)ZN>:?C;)7UIN;K#K'D=7
ML$%C->/49GR3>92Z5$7-'%Z0@]"UZ_C+323MB5R14C)#()U_8AY)3L[#'(%`
M.D,6_8=!6#:479I91#R?'ZLG48)OQF8ZIZ$*CTE.>XC/W&>\[R!LRQH=5:Q2
M8ESH29C;.VQ86]Y(]3J.Z3O">\;DJ'UQZSH3G.G[ONIMC\.<6BM'[_8<#@4H
M=LU$Z2!VW>G1N;G"P6PK4IS*2&::N)&N#3]M#]RP@.A/>WE.]I)R_%B*IZ8A
MBGIDF"MN)0^U?JNK>F+#N!]EK-1=57%/65Y6M3#.+G(@SBL9"D>JY-^-J1LI
M-(_(+`=W9_OMY^5%;%BTE+C>DC;&@MERFEX^SQKEF[)8FNJWX(]H6&=UI1KQ
M'XHX--@2Z'*W5(8N(U.3:82JB3BMS2S-=LA]R#WZ\QUC4@>E=MV/&6Y\C+?-
M(HJG7.]\P!+-X@\P2QY]'9-"5\TKUB;I4QRI-4[XU-"E&<:4[2%+HV)-CE9Y
M!9@05.??NFX>O:HLGC#"]3B0]T(^;#6PM\G+,PTKS\BN*.T[+.D^I91*:RCS
M/1BA!)#79&A8'`W;5S<B"2$JT_&JW=,%P9;ZK53..,K`["X'A;UWXSP>?GUM
MM'*_=M*@9OWC+JV.<T?))8EQ,\>8HM7\*BCCJYK'_8A4VY+V+UU,^W?<TH(_
MMWV]X^H3S]KKO"WE3O%%-I51`;$AW,.CA'EW0SR]V)%R)2RPM%#]G-&;G!+7
MN8M4.Y^$[:4SD;K\[X+SIIN$O49Z=UC:2[M=595<6!S57O#22`.5E6Q<NS(A
M@$D:)C7J^PG9]A;TRKG-.\L42;D.NIBHG8S1=JK3&)L;_-KI@.B0>V_E,N88
M')U';E/1YCLA@7R:,.$U/D<$*T9F]XD,?V42?$RC[%O!3G![B;DE;B'S#<>Z
MG(C<(M%'V@.@G_M[YTQF(T9**]OF-W\MZ,NB(4E4\.IE8DD4QD+Y(K)B]:/L
MB.9G`]H-:(C!'&5$J7%:MRG+-*T^))^0HW*)W#+Y]ZW\=1-_;"HS:E>V7"&B
MJYM>ERS.'V/%#E]44Y&J)>[]CL_10!0JTF=N-DVB;+CX2(HF<U:`M6F4JRRD
MQVF^0RZ4>J/$;!SUTCTDTW`W3V&\F0R/S"]XW`TQKY8,".ES-H\1.'/T4WRC
M/9YL^[&8280+#$_X:W4TI9NGR0?DL,3@_K=QF1#(<IZ@NJEN+;MD,>12B3<S
M7U?=/M]PUDUOR3611/2>M;5*U*5E<G^`.#:_;)M]\&(D;B7J?]F^F_T":T?I
M!Y\.4W8JT;.XN2G6PI/*$T(CL):NA:H<Y2\S!:KRWHHRW,:&5*'!2^+'#'XY
M*;4O)IJC."M<9WSC7(4^N'W(X]HOM5XX8L"+WPBLV/SZJJQ=Y@AA,4<*^+F=
MWP+-A5:W-I1$_P`V7(44F;--TQK@WQM2W-*K3/[$](1G0_8,HC?M7PU(S>(F
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MBTTQ";L46JT)W.*T^0O&Q><;9">````?$X-R%V1G-[BF*6(E.--3TQVOW%&X
MT,T-TQOK]<?7&IFF,_\`\<`/M```````````````````````````````````
M````````````````````````````````!XZ^DO4E?==XSBE.J_,WECH!LJ:1
M^G+9SKO-EL^E2%OG/`]925YE4C=))9=$HJE7L5JHF'*-05%WEP?8]CZE.2,O
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MU3!8WTSO7/0"17=\`J/G"&3B]XANR*X*D_C<ZYZBD9(;'Z*.Y)LJ-T9M%VJ;
M;[M<@,K;K+_K4UM8S3TPUI*!C$[H2G85U='9P175U)D+'6=OV+A76]BQ^/F1
MG^,2^0K++N/XV%(G0N#^Q+E^2$A"+\38M.$&0^%<&<X7TIOZP:L9NL[N[4LV
MRO5SF_H?1&[TEK7$`6]`\TP&E*Q9S;&E9+Q!Y'DV^&PYV,,2,J&0Z%F)79.9
MKL406$H[=!?UHZ<UZ'?5LOJN.)8=U31F+0_=MO0L@0M][UU9UB6=43?4<==V
M][(TKB&VG&Y@H-1P9'K"DBPMU(5EX+/W+-#`^J*U\:J_[6641?'$[O)8,U11
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M&K8J,U*TR&&,M%_UY%<V@-M1GTK;X[+8KI`>CY,XH.T8E%/]LUU%9[7]AP"+
MW>P+4+>D>X7%K)@;8]%,^R9N?D*XTTT[?34W&-0PNL.!OZ_\.F-Z7AKZH-=@
M5VYP2P*!EL&DW:M#.]*U17W3$$L.LH;7<95EM/\`((RU1.IY2X,L13[O9I*8
MMMP;OH:8FWQH%DX7YV^+=$<<]B4[7W<)#+5W?E=*#K:N*6]>06S7)P;:;+;%
M<FL.*/#^L617#[&O]I-RE]6Y3*-B]7-%D_["<D:@.^MCGCRQM2V):O:^\+`E
M]Q=#]<+F25/W._1W/SS,*ZD,WY'WIV?51,RTK&[X:*:EU*T+KA[3."->YDK$
M1!I!J?&AF^H5:B?F1X@T!"ZO>&/TG:U%>40DFEM05"TW?S3/W13$J-Z>:>S9
M6<V*XQ!WZPY<BKI5`<-3EJV&'+-6O19MC!:@X[.0G)+1WCMUEUQ.N[5??$B.
M>;9ZAHLB)1646_2E?5-8-^<ZT_`2JX;ZAUD,%:K5FC7%&:T&Q&X-:)]PE-D!
MQ[>O)-/*P1H%4KQ\BO/2-<V2K3ECU#8FJQ(Q4"CF.!QBPNL:)VYUG?4;CSC(
MN26-9:K<2Q/KFU65+Z4<%$;4,[6I2I2]2-%6&W.Q!WWAL/I;Q`W>O+'G;@CH
M.S%$)<:?Z1;>HV]16C?7MF&Q=U;[)E-DL]:R*0656&D1NPQ`=+E"=U?'J*:D
MO)N/M.0G),9*."W;OXX\P/G`=:>=RN8WDBJ:J9P19,3GT?FL?CUNM\SS-Y3.
MW1Q;7QKAA,3CJ!U7S=V18;VQE1($#4LRE1%)M2RLZ!(G`OF74/GXKLA[@UCV
M[;,MLF)TU6JV56XM@/YS%4W/,>>HK3%<,+56<!KB,E-D.99"LUW7J$*AW<CC
M\F*U1N<:XU#9````````````````````````````````````````````````
M``````````````````````````UD-?CAYO,CQ>DD:N:6<B2]%L]TLEF/ZZ;V
M;(7#9+T00K3W.H@^DHFCV@JYTGY2XS5>JC1#4>:7M\>=OBQC0!%'7GB1Q[T=
M4W4,2K6(QWG:VNKR&E+9=VQZ/.4R6.*+2X:ONB:-:J$.4N96(EKM"3U0W;R#
M5I-9U*]3]RS<_*KZF;!.W/OF1S[2--\-U._*YM<BG@`J2K*-E5A2I\/PDDLP
MB\HASN\N<12.6D5=T;#&)DO:XPB<4[AB+MF224)FIA.#]@PN^/+.IYURK3''
MU'N[E0E-51UA4/1F6!B>YRJ7;1Z$WSM=\TKZ"RU/,&^9U=E]<UZO5D6LZXC$
M;VP26A*)(+TTT!/O%SS>L6+LD#=^?,L5?M,TG]B.$%K^RK6K>.3*:6C5\5IN
M?2&>%P6;,#C+5\MK^&($CGE6IWPYFX/4K,*%"M6:>&`1WP5\Q(M$)'#&JDYN
M8WO\"A]9-[H\]#]"R23U_"Z^L5MMN#,]1R:16<Z/-2EQ2QF=,ZHMH\<W;$J"
M\X^N2S3M#`L597F9RM:TCJ.02IGG^2J1I%'S[`V%!9DP):B*Y;+.IFW&M.\+
M%+DLDSZ](Y?0\?V,7*7`P]P2E'$KLJM3?^(5J5>!_FDME$;GRBK+%*LB";J_
M];V4TWU<T:G59IE]H6S;RQ!!'^+S1E/8T2J7W2^9.UQ@S8].83H;MOL3KOD+
M%WYYG<\=&V?8-O3QTM-LG,ZBG.S(W2"$SM3%7NL9;RU-[2GE/6S5+^C1&/D/
MLAC<[>=TYY^J@YO6HC/B/1[X,49/"/JT\@N2:.Y&ZXXUI(BPH%679D0G+!:S
MBLFSG.9-B2V'4*>G978S6YS/+N;_`"Y_:D93DNR?DU(H=,;&X)+TWR6`BN=>
M%O(=CS`^>2FP.G2I&[T'":(EF(O<Q\28I2;`856\!C]R*&%G82DC%=J>.U)'
MROW+5E`5]&TG_P"W_P"&OT#JMO"7F//62#JLRZ.I7;&EM;W$]T#++'C4QH"0
MR4TVX'M2E61.105=("6I;/[VE,D.*U=L_>ZOJ[?ZXT/QJ6'/5/@YQK4G)EU<
M=,<JOI=7-P6K"[:;)2OGK-K95-OM4N<=<Z93U')DL1)2,Y=5&19)HWJ7)&Z+
M5FGR:KSE>N^=<!@3A_7<XL<8S(8B?;77YS!*IQ.;;D*%PN9A>LN]WVLRXBUN
MW0XK'JNW!R6S6TXD8H;'A*8?M'=DZPXQ.V)U.V#]0S''@=Q7JJ9MBGNV4[6P
MNJE[;F(@^JBV[]AKTW:W5;)HL_\`]4[*%S9&9_;S@A2)C-\Z?I$B-*;DS).Q
MA@0_+?ZXG*;Y6&E8Q:\>AJN2MYS6F9)#7^U0-+NBC*[ERE>4[9C2]M458KB3
MJ5=\1HAD>G];^M)</Y&7LJ3G%:;;E;AUN_\`6FXN7$,[>_6E?+XW%QM7')J;
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MA9(W-DB;<T1EK7.IVF3324"5.ETWVS@LO37Z8P&8@```````````````````
M````````````````````````````````````````````````````A'I.RII3
MM"6S:5=PF/6--X'"'N2QN%RVR(S3T4?7)M39.+)E%HS';$9@L<2Z8V4+G)7]
MQ:9*5OMC7;;[=<AJ3YR]X**G]?<2G=#U)<]!W-V9$87*FF&M=?2ZSJ[A#59E
MWNG/]42N4VM'V0EI8();\\2(L1UP<2$OY!#PBR9KI@[3?8)LX9]98+W[U#=U
M.TW4=AME*5G3-=6S`>@IVR2>$IKL2S6?V-7JUQ@T*E459EQT`2OM;N"9O?-5
M9Q;DI0K-,%%?!GZA7RV_<<VN.X)/R6V<96.[5U6757,O)MP=/S&UJ\K"#0R;
M]3LB>05^ZL<.?R5TKG+5EIU5JMLI<D:92)M#C#"=%27Y0E[?WP\RDT!>[,=+
MAG;1#V:RF^NB%BNA;M4N4A2/5>2&VX_:D8CC3`W*1O-(R&KXB[2!%*]$F&HY
MI;5"GY,%Z8SD+(T+Z><?=,]$3KEVE9K,9O:==M#1)9$>V5+:!M;:1220Z,3V
M)RA+<6D3WJLUGF47ER)4S_<\%J'0O?.Z8HPO&-\A6NQO7IEJWMZW>/))1KRX
ME5_>'G70\;G4=F[0H52)_P"_BY]E%)7V,NS6T%QN.5BIA>I*C0E<XJW'*K78
MO0K.VNF0[/\`_?/Y:-E<S*S9QTEFL&6N+5S1]B-$_K&UFN60:V-W:Q&M-`Y)
M&VR%O#@BDBHNJWM;A+K@PXAN3:*3]22SR<F!9_M[N&,<9<S-/3N(.\V_%WNP
M:'A#8S1=Z:8\N6I+XL:)5\Q2),LD.NB;=.@,EQ"K\?;73<[&,:;;$Z9W.+"`
M97[B>7,(A5S6))NIV)OA]"VJP4Q8+QI![.7%XG<I/FJ./$Q$AOA:M38$;>'"
MM)(F(>V31>S&'Q]?KA5_T;9R'W,/K[RM8/?%8^?U,JWZXY_-HQ8LCF%C0Q`J
M_P!5U>9!:YBEH(F-VEKFC1-,N>I'&9FW[9)85#ALTF*R-%^$^YVFH".?5KW!
MY1\E5]5Q*Z6*PI_9UQD*72'P2`(V5/HCC"%U)95\MEDJE#JS,,?9"'([XM<8
MW4*C<EF;:D_87OO@+P\.=E5IWKSE$ND:I;GYEC<C>)E%UK'(\M"AQ9937\K=
MH9*$!+O''-ZC$D:,/#,:8@=&U8I1+T1A1VFVN=MB]`I]87M)S%5M`63TA,:K
MZM*@%.]0V=R3:2>/4@?-'^`6=5CLG8WAREB>'2)\:6*"O3LX)$K6ZJ%A>BM4
MM((^S0TS&@"1.?/6?E+I7K>P.,:_2W&V6K`RK-P2^SFJWN(UK/7"E).R0NXV
M2NIBXG9TD3U6,KD!"!W(W3IOA4:F8+R9@O;.`BWHCV_XUY8MZV:DNELN6,8H
MV^N;N?;2L,N$L[C`8O(^IJJEMNUK+-CD<L-E3G!$\=AZ@AS4I&H]:E6F::EI
M#B_N-U#.)][0>=D2B=JOL3Z`8;HDE4T-%>B5]<4\B=IC,9)`;$<($PU;I&,E
M(4\=6/UE2JU(TU-:(U>2?E:])\':DZ_)MH&";^['GHYV]0]#UO8<CO*U+UL5
M^K+##2D<+FS74[W"VUM>;'>+?EYCFT1.-1&M61PW<'MP2+''1*V(U*W&FZ4G
M8T!A_3ON!77.=^U_0S#QCVYT?O;[:].E*VESO7U=6!5MXI8=$6^?V*HIQ[)M
M%*[3]%7,/7Y4NIR1#]NAQ!I)6#=M<9V"3IU[;<`1F,Q*0P>R7N\5TIM"%UBI
M@U31=<IL>'[S*]#.;M9I-8)-]X1)&&&,EQEX9%)NR?=:<K-)U2)E.#=-LA,#
M_P"L_FE%V6SI"^=N\ZI&:F)JRUQ:*XNQ6==I"YW(E4K1L<5=RD!BH_5Y=%$%
M><$DEZ&9VU:U6W_TD[YP%?6;W<\\GR<$Q=+8<@3Q0V0]%1?_`'$N96Q-6!CO
MS-&:5E$W3MBG]_O,I&?)$U]L*6-)FMF6KGU=L:201_Q+V,"_O3/8'-'&]3$W
MGT];\7IFJU+RR1U'+)=^S+)7O\B(4JF9D;FMO;U[ZXNRQ&A4'_CD)3#BTZ<X
MW?74LHS;4*!\Y>Z?G[?LCZNA[[:2+GV4\AR^<(K"8[Y6-T&4.550]YC<=17T
MR*E*DQLS7<K>Y2C2I"CCRW<@]01HJ2$;JDV#0^!U]S.0];N::2A+!:=J&R2\
M.'Z4B%D5VA@K[64TV[UBD^E]2V+$WW^=D.3M`(\WUJZ%OQ^$6BQ*<3_T)U!?
MW&:A?;I'MSD[D!5#T/3-[02FEE@,]BR"%IIDM5)3I(S5)'"9;8Z]L+2HU>QY
M43CR@M2IQ_C;.IFFNF-]]M=<A&RSU"\[&Y[L&,N/:/.;=)JJAW^P9_&G&T(T
MAD4<A7\?:Y5F2*&-6M)=5;9K'GM(JVW3%'9U+4:?7&-L_0!'CW[->4\<9HK(
M'KO[E]"S3AH5OT37[VDP&E/C2@=7)A6K4>I!YIN=$CVSJD9FNVNN^BI.85G&
M-]<Z@(/Z,]_O,/G_`)SC?1S=T"SWHSV&[R"-5)`Z3*WDM@6=)XH\QYDE#.T-
M;K^B;XT7'5$H1&*UK^J:4.I1VGQFFF&D%FAL(H_LCF7HV<6I5E-W17L]M2B5
MZ)ENVNHO*&A_DM6R!6>O0FL<GT9U2UORL;WAI6(5&Z0]2G*6I#2<F??IG`"S
M8```````````````````````````````````````````````````````````
M````(1Z,YQI;K2G9=0'0T'2V14$\PS:RZ%+7:0LB-\+C[\UR=I*5.$6=V-ZT
M)3/C,F/SH6ITT-^+[#,;E[;:;!#]<^=O#M1PN*5_6_+]1Q.+PC$%UBZ9MC).
MSHV%UG;Y5_P$C^2JS%,F6IHK=)&LF2%*%AQ>CMCY\XSMG/U#OZ"X9Y(Y;GUI
MVASY1$(JB=W4<2=9C_%2'!.9)<D/TAE!9.$*E>I:V5'F0RMP6;$-Y"0@P]3G
M;;3/VZ?:&E"-]`<=V/9UY]K3'S=?8[Q>[=&LMDSGT@GUNPLZ.2"[^%2IC2E?
M6R=S*HG1]L,J6.SIC<(9&LLS$I<7]S4I<GMFVRC78L(YG.G]92Q(63Q6_,U<
M4L;9]],DT>*RTJR\J1L.#W%'GI+6:$NT%#Y!FMQH9K>FZ2ZQS5OE!C&S*V"1
M:E)RL)G`DS<+9T)W_P"('*A5LVU5-BXHY!TE.E\RF;O)JFZ=C3-,\5!7<`8T
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M`^I3%E<,<@41)ALR,NIR%:G1J#27(U5AL/SKG7;4+1>?[/XO46ZV7[&U1>[W
M4-5=&RF?<]UZ[=068BAE11YV0V#G2U#J(:YXMU=RLWI/:Q_D2T]6O5+E7XIQ
MF"4>GY)&@1/WWR=YFRWT3MR'WWV'=G*'2G7D<YF[0I2UF62P*KZTALOY2CDR
MYU;=:AGLFT4LLUMR;Q";K#5S.I2*ENJ(HM4A-T,TTQD(-(XO\%N#YZ\^FAW7
M$MM:#4?!^:8[2?/\7N./R5$G>H%4=:V%3C;#(LB<&!]O6826/*8Y.6IM<U9S
M>E<%F7(W3[?CRE"?^0_,SQIX431M3*N]HY+'/F^UNBY/8,8OR_\`GN.-K2\=
MR4_$:#F]0]"0`Y,CV;BW.&5\0G);%IB%8>[%JLF_(5C*4L+FS"">3TNDG*_7
M\-ZU@'/U0^.5J6_0$<1UQ85;UOSS#+%G#-#(3-:?L+>6L"AJW-U8\$HM"6M6
MD/4:NIF^BG??.N^H4UUX8\1XO=<931OL>>V19G9%VUG:-.5S`NG:XL91!V-!
M<,H[Q2N,!B34TKWIAYO?[$C2R0OKPZ8=-,EZDYU7$F9U.`<M%>5_B4@NXZR*
MA[_3S:PKN[QJSK6.15/UGSO,RYA?5`2FSY*TUS&(SK'E;I,V`]UNESU<V_?]
M@[FISDN=%1>V?E-"+/2#@SPWW27?-;[[HM")V7S_`-%]#=A36)T1>U:/'2$)
MZ`[`DM*-:,F.P1DAK[8FJB*RBO8ZBB39\&#FTU7K^8JR5\6Y06>]2IOPGVLP
M\`^5O7JON2$S7K-=`;[9&>,PM@8[%CC%6$<D'[#?J)W7-[_'8LC7$_M-G_\`
M4)EYC&M0[."K*)(1J:8&K^>-O]?:91M9+U=]]82BH>R91V3048;V:).#TLLA
M^MZZZ$M*R9Y5*XF!)IX3&J<MFO8_HR9<TZW]B>L,)*2NFGS8`6\FO+7D+PAV
M%6L(L^SNJZV*J%3PU.X)+7.KI2AYN@\X\\*&O:5UXP3OH=/5NT(E,RL^H)/)
M7U_:TZC"E3ND,R48D.S^.`QSTYZ4\@?4\^K(#=%O=_T/.:!,F!SRMK7FRU8%
M):^HKJ:*U[7+S8=WI[(I62MD5YZM9FG#"E2OB@D@PTM5MKC&I9N_U#5IZ(\<
M4-R5#O8V46/*YO8MUPA57U>\H5O%7IXG%8UVS]E596E$,,RM8EJKME9([T_9
MM?5"XJ%"<Y;DHAK)1FX+^Y:@4'A-7`%3\=\,U-8$4]3KEN"O[6;/*FR*/T5I
M^;7>KN=H3RK:]A1V72AGHZ<JJC:9'=O6#%/^@VQ$]O)!:PS=\>/UA.SANDW.
MR&8SCS;\2N=/)#GOJR1WAZ*QSF^:KT:0N5UW)X.^6E9C)=DPK:5+8)9<-B<5
ME->LU>M<QH9OD^6WYDREH<4AA9QQ[IL2C`6TX)Z0\R^"KOZ%NFD(/Z-OLG]&
M;1DTBK.I2:.4V'7$ZM6-R56HN.G^9Y#7"QX@EA2^MI0XN&[RX+9$H:D:%O/*
M;G`PLA5L<&[R)>R7G'*H9!)5OTK$8X^3O>M$&M2/I:XZ\8;)+8F>*ZB4.L:I
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MBC.B;_FI-*)W"K/_`.]+SN*KICMYPG]FM=5OB&+)=;#545;2F(MEE36N4ULQ
M6A'AY:8HY)4=[OL!7)5R6.8SNH/RL3$:;[*%!)6X7?KOL.CYY3D_O)V>WBG(
M54+B^-%S%]`1YRI=[IUUCC$RRIX1V0W3DMK+CVB:+21N<M5633$1R)<2:4=O
MKN`@EW]5.,=/XNK@%GM5Z1Z7.5#-#9+J(D$$LV.)W#I"\S.>*O*=SV698<&H
MAPL9(K*5*#DVJ5*0A4YV,R:3L2`E>,>@O#LX2L:J"=:<^3K^4VFY4?$DL-MF
M$R5?+KC:$3<Y.-8Q5"T/*I5()HD;GA&H,0I=33=$ZP@W;&"S=-M@ESGJ_JLZ
MEI:O.@*4D)LIJ^SV+#_%'E0U.K"N,3EK%38X('5B?$;>\LKTRO#>H1+4:HDH
M],K3F%[ZXVUR`F4`````````````````````````````````````````````
M```````!\#HM,;6QQ<26]<['($"M:4U-F$VSDYF)4YA^C>WZK5*)'LN6[:8+
M*P:<25DS;'W;ZZ_7;`>7>@X+Q7T,]]J12Y>->U^+:!76K*ZKN&-V5ULA_P#4
MDSJVYY=7;4K10>GZDZ+F;)&;SE,MMAB=&=Q:63=C2/A^#TJA.YEZ?<&(1^J_
M!6>.-ODSRT;%>$)4XX]KVZ>D^@+042=@[LD5FO43ZQJ-BG,YDN7[_9K++%M5
M(6E\1J&^/(M$;3JTIB24Q";.@9>XL/BG5KI<D)26O?\`T=#:IY,Z3H2VH2JZ
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MKZ0Q!VLLQ@79==G)G;8\ZEZ;J=M\(U^H67H$GQIY`[-L^[8?VK)I=+>=X_TQ
M*;OG<[Z.@%HU_4;A=UE\[5?,879JAX7.=W.,Q<)S&&S#2OQA8@T-T<BEZW*G
M*8D!`,^Y>\-H'"+&M3/IL]LJ>'WD\>B=H--;7Y4K?(Y_".CY31=Y1.EW:MT4
M>3_L*UFD@IR%+X^@;4;:\'.&J51NI^4[3<!%'5M%>6/-514=+[G=O16RFOMR
MBNA[/H.;,K)5U@%<R\X2.GECFMAKO&UYS(F3Q^@(KTTY2!J((+?WU4Z*UAII
MZ_;1.2`N7)N;/)M#([?*3=^N,%LM;'U'4\\;B)]44:L7GJ)KNE(%Z>(+.7UH
M?'6*60UIC[Q$&I*B3GM2DY$T.16JHC<[?51J%>)7XQ>),"D]E=(.?I6[5M8:
M2T&2?5=.Y9TGSRQ).1;EL*3/5N<_&Q-J6Q>.2N/;1HU2K5L46?W/+8Y)2U"H
MY$8H*U5IPDSL?S4\U+GXLH/S8>^YIU,WJD>SZ]GT^55?+J@L_H>2VUV#94M9
MW-WLF",^4K=`6::RV[UBY.X_J_QV1#C&^J=;IC?4T+2=@>?WFI;#=6_75\=;
M:+N5^<*3JGCJ[4I\BJ2R:WN"*U'>$0D-;0NU)WK$)3(HU*\W;^N32#2,G,SF
M\[*,-Y^Q"<TXHP("CGB!P9)Z^G5;5KZ46.NL/GA]G,)M:RHY:E!3";5!STZP
M"N*_-Y-LUE5,+RS0:N81$:,9"TQKDF1O"3*!7KLHU(--3Z!23G?R3@]I6KV/
M<_2?9_&T.I_I/M6PNRN?K'HVQ^9;L=IC(X/*;L;I@Y&GW%5LF@3C7T=I:Z%Z
M9T97#,B)C\F48=]-$.Y/V*`V,]'<91F.\GG5%QGU_6;LEZ0](JL[Q:YU-YMS
M,J04K6*.YXG/+KLBHD3JV)8;<+)!7J(G+R$3H6XISMSC$/U^`O4C(?.W^,G`
M$"8F9J,[82(8"AC4-MNSS'J6TNQR"743'.8N@N:)1(4U@QTV)K('7=E.?1SS
M(GEZ(T.9,+]2DB8L@G4O)09%YY>7/.4[FG+GI%3O<-[=-,T<B;I7[-([3J+G
ME.T6I7E/2>30FIV^/ZG4-&91`FBO'MM<#$K\U&:/$C393FZ..B'!&FP399O@
M9S?8\XG,L,N"X6QF?+<EM]US`5374<CC5)W%:M\U1?MVS2#N;U7)TW>/]F2&
MI4R+]<_NSNVLZ)S7ZH2"OFTP4%@^W?+AC[DZKX\Z!L*\9@SUSRHHL!8JY];X
MI&3&.P7">QASC*YQ)L9+^IL&(&+T*XE.ZIM5+@@<$2,G0HA&?@Q2:&NEU_JT
M\:2I\*FDXOSHV3V'JDBD*-FVC+S2P.15-0`V*%02`,"=DH!*GA,OC#/"F]*3
M/6/]=-\XP?G]C@L_8G4)OLKQ2L+KZU8#;?=G<5Q6"@9*?M>D)Q0%1$M=>U!*
M(9/YG,3D^61U3MZ62PUP>:Q7L3+*%C<0G>'W]4:3LXZ-ZHU'L&4X\&J7D$_4
MVS:O5G7MIV38*>!Q[IM[=)55T99.HZSJA?#':KZ@L6&Q"JF>/1JO(BY0%!MN
M7&"V5S=RCUQ3BM5:*_H6$*VGXO\`3O0M?].UA;G83=%E/:E?T!)NC;@IN'DL
M#K*>A*A87ZG)XUN]5*$2&)2BDK;H)Q9BM$^5S<K9)5&4[F23ML9C74),DO\`
M7RYW?9UK,4'3W8T;;HE4W,=94;!VRR8JJB-'+N/V1F14-,HTB=X(X*)"?$Y0
MR:R4YE=C54<<Y"J4K%J%1OE-A*&>-OD%8L:KEOYZ@'HAT+6G+F$6Z"7U#"ZQ
MYU(<[*UL5=9<GZ<=I;/7FL7AV022]Y[8ICF4>S$-B&+$E[I6Y%KC*8U('"S>
M"/)4,::K9:ON?LVJ6WFYSDKYR&AA70)N&[DI\G#TN?+!=JC;)%%)`WR)58!K
MNO2NO\Y+F.IC<XJ4A.""-\::AC[1_7LXRCT@LN41FQNCXG(YY7M+UZQRJ*S*
M`L\TKO6G;*9+F,G3+*_]8J7*96E95K,YCU(I#+?Y"XGFKU1"7=(EV))(#NJM
M_K^<-5.P4$RL<@OYR5\V2*0N]921QG4/;'Y,PRUEC3')X([?PVN(HR.,>?D\
M/;352_"(J2FJ$FN^SK_R,QN'Q/?@Q0+CQ?,>)VCHGJ"-0J?ETI%9C.6Z2U^=
M.Y!2="QA5#X+0"\Y77IC%K5Z5M<UKCLG)1DJ?Y$K,<OESL8<2:$_:>-/"S59
M,/NJ%5ZZP&YH90$XYV(LJ,O>Q3W*XM-J<8J+WD]C(UR58S3J?,$`CQ"=$Z+$
M^3-M]MLJ=5&,%:E!R0GS-<8[R@5Q#(^M+GDW-1/&L$X\*B#9'*TA4C(:(JM>
MFV1SU/.V*,[2/1YG]7KD<27H=S#$938BV/)^U:H-4`(^M[PUXNNN>R:1RQWO
M=HK9\F4?M]HYN@5IGP+G^#=%Q:N&BIH]TA#H=&&9O=D5K,<'C;:G2:J7)4P%
M'I=E&S9N<>?L8$07KXD09XY-Z+@E=2=TM;M;I_\`#C=E=N='NNCO:CLQ3>?5
MRCGSPZ:0YMCD7U:(!5$2+)CD8;VM&T;;,R%+OIKJ8>=L$^,/C1S8T-FC>OL*
M]9.:Z.-$2*PULAE,15F6M,Z1Z'LCIA3+IPD)@R=O,<;5L&TW,F0IT!*%#HUZ
M)2&PANV3%FX"-:R\!.'J@<.6'6$/_0*95QI;C_=-%)E]GI=F=JECVRQIC)02
M1M9HPQ9DD<;DD-:\;E[&DKG8M)@ET5KB##2]POUQ5R"U\94W"ZG:K.GMD?QZ
M!Q^.OKE*%"5$Q/\`."I384_L6V&R()-5!,9EUOSVS7)Q?<:+%11F"41)?VZ)
M<9W"X8````````````````````````````````````````````````````#B
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M92ZE'-II_P`Q!BDS"C0.HOSPVJKIGAKF;@FW>INIGBL>7+023.&S5LD<(;+-
MD,*CB&;QJOJUESR9"US*Z)Z^@<O*9F]VPWZ+_A;BS=_J889]0R9I\4*1:KDG
MEU[7ST6YR9\OFM>@JP(=I##7$BB97#;(M^U)PSU^:KAAQRF,W-++\EYC^F<O
MR]M='LW\3=.9J69J$-,_]?6ED:`C\WJ#HA!(7#C6M//R=/T"0U##=)UR+$((
MTQ2=U.YM2VNY4G1FVX_M6'IQD)6^90@.,RE1.)*3&"@$OO'AKRVMAA<'9[#O
M.*LI527?2&Z=BD4/**=JVZ`["C_9=AQ22['P@Y>_L+W*XX7%5:0Q3J6LA*E4
MWF_4X_97@*V9_K;\[XF4MNQ+U/U`T].262/4\;;^84'/3/(X;.)S7)%7VAO&
MFA+2'XFM>3&(X.0(8FK.5,L40GY*8BT!F/GV">>L/$:M.KJHXJJI_ON=1Y'Q
M=S].><F!X4UC2%BFSF)6+5]>U)))0YL-D0621B*V0FBT"QNU/30C3J6A<MW/
M3?;G377(<4X\-*+LN?VI,YO9,E<M+;DMV;R9<EB<:TLU77%T^?\`"N"5=?N5
MLO.S]('L^+-$2-EZ%R5$;Z[/[@;DQ)G.3#C@J2E_K$TJ;)9O*9EV'?EMK;:?
MY1++C16W6W-LN;+"F;M5EU5%$Y^JU3U.RN;?.ZTCE[/*ME6?E'I"7;5.IW2;
MX3DEEA^89_7<F<5EM,SG7M&%M\LA=V1^V+@DL+XVA45D]TMT`M"@+-J]BS)3
M;1>G>'/<$<.?T6B5V^1SV^YQ5[?!]AQQ1P6>J7PZB=#\!]!\'U7T=+FQDN"U
MJROF$V,_5Y%GMWJBYJT,H]])FNC!HXH&Z;:R&PJ*;Y`L1+324N%2Q03IK@C;
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MM=2\K)FF/7%5<A52QC>V.*+:2<XNU44?(M4*D^KDJ0B-K<MQ.J_=;C73[`WF
M\-<D;<24)$.>VVVI/:L1A+7JG85LKC4/C[BE=W9X?I5.G;7$1:VM/LGEDPDB
MI:4CVUW*:R<Z)D^?BTQ]0N.`````````````````````````````````````
M``````````````````````````````````````"J/;/9M*<`<WSSJ;H)3*$U
M85]NPIG?$-C:J4R)8XRA];XTP-S>VDFI$A1CB].A!/Y"U2C0D??]QQY>O^0%
M)><?;OC[HJ8T=7B=KM2LIA>U:=#W`Q_SYEAZF!1JM^:9C*(5.II);@@DXF=4
MGQ-T<H2[FM3JU/#FV'$(-]CU";)R352$TY]6>+7&?TA%X3;\-LN"WA5W4-M-
M=ZU],8=)Z?BD=Y':8"_6RBE4C;GXY6G?FYDGY"W\0A,>80D2'FJ,$Z8+SN&7
M5)Z@>?-\SFM*TIOKBEK'GMR:RK>KHK%924Y.\YT@Z5Z6RPQ@3EDX_++8DD<7
M&'[?7&N-4N^<9S]`%\0`````````````````````````````````````````
M````````````````````````````````````````````````````````!6CK
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M$QUK)QD;+*&N%-R<LE3)'G6015:WI"",9PL5EXU)VVUWTVR&J.@/[`7+-TV;
M.Z]G5!=E\FL]6IF]'95K]84PTU?54"G;T]UNPQVJ99)VZ;RK=ALB1*;:834C
M:J(*WRE7:'&9++SC;(3\R^S_``8\W-*JRVMAK9X!%>82NK3>G)"[1EBYS<8$
M3?3GS8^LB*<.K^D<-)A';:;\-BA*<@+*V4;Y*+-V-U^S(9G>?KYYR4##+"ET
MHZPIZ5+ZWK=CMMVKJL)U%;!M5[KZ3(61V8)/#8`PO)SY+&=R9)$C<<*T>AB4
MEM-_,.-+3:[FZA-'._>'+O4LUM>N*>LQN=Y[35C32KYC#'HDZ,2HV15VWPE?
M-W"-QQ]PB?)-$8V98C2E4O*-.:V86*]"M3MMMM?N"X``````````````````
M````````````````````````````````````````````````````````````
M``````````````/-#SU%.#IO-^Y(W2?<O17-?/#MZ!68DZ:I>9*:YIJM;*ZR
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M`!Q?)W#56H.;TJ=.X?B8T3;AZ$O)7N_SZM#FJ)T)RG*I%$H;R74W/4-5-]OP
M!VIE2;&;&B:S:II@G-DVWZ%Z,MM+&UCH3E(X*U)YIVVYN/N-USN%>9=Y71Q/
MQ1Z@$6]VU*I?$.O>AY)W^NM:JZUBI.*6<:HDT<L>/%Q*/HWN4(K1(9&*FF%$
MM2JC="%^[9MJ220<;DP!YX.6N-?,#UEHY\AM8>I?4%5)^>*!;>?;>=;@JJM:
M3CEA.EZ=CV-ULGDTC+6R8^)/;/,;$*<M4<53/FJI,J;&Y;DW.4QA"@+@\_<"
M>7EI0OJ#FDWOF/SF<7]7<;\N^>I]9E'0!I>&B:>?=:DO5GV10#JDDBI!9$3(
MCDV:BEKPC5M!/V)34NZ]7N>2:`V'<;<&\F<"]YV!Z/(?62L9/$.U&>;Q`F#6
M%(:1;XU:>6=XAZ5>7$+>-LC.DI>J_G2)%H=AJ1ZF%95ZHC]<9W^[8-P]R>E7
M#U'0&XK"E?15=R!#0+RBCUO1:KWM-;%F0=]761&ZBT:7JKZ\WD4]2K4]CRYN
M:5&FS?C\=4JTU,^T!:B,6O6$TD\MA$2L2#R6;P`Q`1/H4Q2MA=I?!5+HF+6-
MZ69QI`O4/,75+4INNY1:XDC??7/UUQG`#/P`````````````````````````
M````````````````````````````````````````````````````````````
M``<9IF2M,[X+,-SC.F/L*QKG?/W;ZZ_7&-MM<?33&WUS_G_QC(#PAU;1'E;Z
M,6/+>0;"ZGZL-F]O]Y>E=S-C!=/*"BO&:Q^D[GI1'64R;JXL4M%*($1(>4BH
M/B3-*54XIE.Z[9/HK18UU)*P&P&P?Z_7"K=:EZ=2.'93:R8L]KY_S59DDB=,
M35IJI#QO(*;DZHMCV=#3O]G'.4?I!&TO1&A"?<Q&N4ZK-%FYOTV#`^>O&[AF
MYIY?G9->>@$F=X]Z5.4"[.-K"PH?`8BY_P"N([V#7?9IS^?#7=PC4PQ$EBZO
M3V7\]0B1D(6YS,4&ZG;EZZ;!M,J'S`KARH2?,U;=MVU*EED2'O:8QZS*KGVA
M-2&K^]SY>X.KG-:9BTK<ZCNA75!\R-61Q2ZZYP4MQE07@C[B]"@\Q],\4\"V
M?S7T5YY<J](Q6]K5NO--Q2^YA<5)2[@RLN9*PX)F"]@L+K".,CG7;BWVUT)$
MWVP"6I_PKE):Y[-?-=UII"#59J:'M>C%`4DJXQ?N-N?)-'8S5L?I&2\L,3G!
MSX_+,UYK_K\^#;;KTB-1EN72]D)="UZU.LV+.5*S,[J/\G;;9#Q%\%\+>5,C
MOA#P`@ZPD;CT74?9E/2BW:SN?B==`*-Z#9/-C6X3;,@VS.KG,QBRV5S)DLQQ
M4/T@>9!C)[6CU_\`PF$JDS10&QRV//\`\T^9+(-K*6>C41YM<XLM]+NG8(D9
M*EB[+7E/<X>EC5">4W6#-DL5J'>L(:ZU18.J-!%%)"E`XJT^VZ35M+)^\[`9
MLD_JX5OMQ]6/,#YVSO.V.DVKJ?2"RN7T!`G=MALNZI54"[+I1'&PV=G&QU;#
MR*@W-;M]G!0NR=)#SRE*?30LO<)WG?@91<OM_J%[UZMB\8L/M.1V'8,F;&JM
MXJEG[G`Y7VOS'U8WID[@EL5ND\E0P4ZAC(H@<M==4R;$CV6%EE'E9(4A)GDG
MP!1=:=:];^I=`=I9Z)K;T<E%RNC)$5=3H8'H@>6^^Y&[R<]CDRIZ3/4H30^5
M-#PU_?JQ-Y:Y/G19OL9]"S3`]$``````````````````````````````````
M```````````````````````````````````````````````````````#0!$/
M"5(FFAQ=F]@6'/Z)2=,=;=:QVH6"M8K6LE07-UO%)O")$ZNUQ,CXY2-Q:(5'
M[$=-VQ$B1-11J\[4U3DTDO5-@*LT7_56YFIAQXG4*[]FD^;^2+2O"TY$V2*N
M(KC2[5]K'Q+$<8'G8QX7I8K'8(AA*+0P@LAP_:'FJCL91Y/UT*#`BOZXMF,?
M>%#6@S632$HY7I'@Y%Q/'WB>I)H=TE'2BJ:L"KS[398PRLJ:G)#/DRB>*,HM
MWDY0T)T&^N-F\Q0F),W#8YREX*<K<GU\LKV$65?S<UO<DY+G<JTK>PEM%I)3
M/.4:]4PA.]OQ-38CKD^-=Q.KBJ?9:V.2U>G7NIA9VF2S"=#`%8V'^OXU46_]
M<]$0.81;ISHWIR$]3Q&40"VV='0='6GIV!.6&0SQONISKEEL64ND.K\ANV51
MUO;4J7=.KUWSJ9H8<4>D#;EYH<-0_P`Y>*:/Y,B:U.^+*]CF5E@S).2J(Q/K
M6DR@Q^L>:X*7'*5I"-[E"T_*(@TS?=(W:)T_US@K`#4;O_6\A2?HWK_HYEZU
ME[))NJ6WN]-C1+34)->XR=W7!3H1(6J6R\]_W<;-@E3_`#[.,;9]BF?8E<8;
MN8JS\N_U"3YM_7;YCD$";ZNA4UWJ>`-_(M4<S?Q>&U7!3VIUF%;].USU&]7Q
M)$;_`)=4LEE=F2RMDK>]H%I9Q)Z!2?KD_;.V,8#%G?\`KL0&865W5-K'ZRM"
MP8MWA==;VU8-7OL#B>L3C[;6=^0^YV6$-FR9RT5J4!L;CRR&&*"\H]=F!QUQ
MN1N:F+SN'#3G]=&LZREW(T_>^CY#,)OQF14S;4<F3U:T1YQ9H]5W8-P=1FQ9
MH-/F<BW9&"7QJV,P5<5IL<;^F;M#ODWW,P24'05#_7':*>Z6X`Z%8NU[*/3\
M$-<L:HW`]*R9&Q#/$TRORZKJD!"YV03/7$=2/K9=*F/N!9:17^4E0EF_73&^
MR?4/3"``````````````````````````````````````````````````````
M`````````````````````````````"F7:?>W.G`L1KF7="O$R3Z6[9K13U91
MBNJZF5J3J;V$^-KHZMT>CT,@C0]/[BI/2M!N,?83G&QVY16OU--+TV#I*F])
M.-[?;WY>SW"T0[,-H^LNB[#1VNE658HK*IKB5/R:N7^R#YL4SML*6R+2.G*,
M-RY04X)DIR4Y0246L2[&A)6W9O,A5LV-2RRWXHV36I:LKVY[%/>%>[/#(I7=
MJ.;XU0![<[#<RTD%T,DA\>4F$)M7#93E-\9V=,%&E[;!D][=%5WS_P`[67U#
M)<OLNJRK:W>K7?%%8MFDY>':%,+5N^.#I%T+<K+3/96K07LIP9J?HGPGTV-V
M,U+UVWP%,>*O8?ASNBO);95<3]WJYDA4^@U9/B/H]G2TBY[36S63615VQ,^T
MI=L,\A<9JTYR:VIT*Q0H5:XQG0O.NY>=PMG=W7_-'.M66]<MMW+!XY`:'9S'
MJV'!*\II"YPXC"\EH2H7*.1W9TD/[IT>U1*!&AT2[*E2X[0@HO8S;&H#"JJ[
MVY?N/H*_N8(=8R#2XN;EL)0V#&I!LECVZ_>=U_BS6Y3!_P!HK(4S-M:(EM@]
MS5(BMTZ'.<??O]N?N`6-:K0K-]C)$U9+$@KQ#525<N32UJEK`X1E0B:W'5H<
MEA#\D<#FHY*W.VV$IYFIN="5&<%[YQO_`,0'UK+!@3=ASRX3>((,,NK7L\Y6
M25F2X:=7S)>K+LYY/6Z?@:O&QNN$N3?L_(SMCX_N^N`&78SC.,9QG&<9Q]<9
MQ_G&<9_\9QG_`.<9`?T`````````````````````````````````````````
M`````````````````````````````````````````````````:SO4WS;8?3Z
MB892$@MIXJ!+#;5:+/*?&J#Q:?Z.1S=%Y9%-VT]GD^Z7"!:G2RXQ:VN2-2G5
MMKFE3GZ_+KIL5N%0;?\`Z^G,ML4O<E';71?4=B]U\L\;\QRAV*7PA]E9Z;B&
M0GOU4V`X2)ZB![DZOKYC)"=_0YW*;EVB<O<HI.:4FW3A@4V_KD<ZSB%UC7SO
M=$^=XI":^X*J^9MLJBL6D6+=A_#,ULB0-Z2;;Z;M/RJ[)B-C;QH[?&-R6EJ;
M4FA11^A>2LAN`Z.Y3AUV\:7#QC#EZ*A8!9E%2NAF177<58DC76D/DD551'1/
M%H<GU:F!,U-#*IR04A*_%)T(Q]A>Q7TUVU#RU1^C_&[I1DX"XVI%#U.36U(]
M8(DS/UK%N;ECQS3UUTC2M5*8S8C5:5M62POT8FDC>HA7:@Q.]:I%#8UI&\Q,
MU*-$A&"B@M?(/#'SA0XZ^OF6]>,#!!>N([V8R67.$#M2<5C[2FO>_(+T+HK3
MSU6:N;W8[GA]KA(C1EN9BLC*7<_YBT^-\Z`,=L_S<\N^AH[T)[*$])6#:-32
M"$=(3&;V=SZQ,2:1.54%\:G\:6E$&-U9V(F1JRX85#'.2(4R9.B*)>S5!.Q!
MB$S<O<-=/!_GUY`^AO++?`^:^_>CH>Q4E9UH5U=,DFM>U?2Z>U&SLYHKTDZJ
M8M"YC$CZRB67]NY]:]6S,:+V=M7=`M7F$?DK"#M0N]UU_74\\I/7W878,@ZR
MZV(I&QE#7TI,H?03U6DRA+A":/C;TL9HC%&='7\D?;)(:F@Y<E8",N>^A)QI
M&/C--)T-`;6^*_8WC3I"<Z<_06(]`4.AAR-IKJ#2?J.K%%"PJ>6%'G32#NM#
M5\Z3I](=9-=$+7)-"'"/_BZ+\;Z&8+U-R49]`MJS^B')SG;M_5`XVBQ0Y5S?
M&Z(E=@6+.W>/1&G%K/T>RR)]JPV'V<\/:>-R4QY115;KM@HS7&#2LZ%Y,SC;
M[0^;IKT<Y`Y2C;\\6)<4-?9+'997L+<*FKV70J57%A\LJ>P.O&+3%=XDZ!Z)
M2H7:R&I2O./P3HD;U&#\_7[BM3`RKE'N#G[L>-*'VI9*>A>DDBM:/+:UG/ZF
M,VNATINTW^G)A(EM?_MU[ZEBN)O'C2$Z[?3!>WR%Z&X*49V(T"W8````````
M````````````````````````````````````````````````````````````
M``````````````````````XCRBCR#B3RL'$G%&%'$[:XWU-*,TSH85MKG_&V
M#-,YQG'_`,_4!Y7^"J[XDM?D:T*B@_:O2W/7F],IYU!RW%>*^D=><Z/DD>EL
MF4.":XXI6]PKVUVN210F/3*SU>[.AT?3%2-TSNE6FJT^FR4P(5M?RX\*^0O_
M`$8JR\>PW5RDM4]Y;R9CK5QF-*2A\NOH.XE=.P?^/6_543KS]7"ZWB:>M8IH
M]81M;"TIFXH_=TW,5N.%&X6:G-&>7W&'&,:Y-C-L6KT*V--E/GEPK?ZRO:OI
M/<W.6GHC,I)$GR/S>+,"AAK%&=$%$G582[2*-N#VAT*-^+!AV#\9#54D\UN*
M9CXFS^_>99M/B.0;!F\#MWK\_HN#19=T'`ZGX`7SR!NS=RS'*.25E4[;T7ML
MUO+.JE;V6NVF"1P-4.2WY-@'H\\MO3GSUZ>Y_;XWRJVR#GFG:$4U50D.AUVL
M<=J='HKD4!42:N(1!E!LPD#7+7E9`V3*_*8A:>Y;$;8/.TSMOOL`P6T/-[D&
M(</2R1R_H'I*45=5W2UH>O#;?$$FT(DUE$6&:DFULJ9+#%J2!/,,G46*9)(M
M.:TBAL7ZK\FEF_-MMMIM@//[4W.W@SZ'<AVLSL/;O2G)]"+)OPW3!Y74$LIR
MI%Q<AY5I&VFJI&:(R2Q6QYC$@-GL)M!S>G4E(KS@A2F+4%)41)VVIX78KB!>
M"?0TGE\16W],+,N+N>3?[.(Z(F4;B+//DK'Y9DP-IF,BC%W9JE+&(95TQ<.>
M%<A<56#M4,D(/<<D;$::$ED!L!X5Y/\`,;@7I"T.J:8[M8GI[]*BCYHWQ.U;
M^H!Y8K3=)9;4IF[3*:46:LD=GSXFTD$R6M!"5&Y."9489G\K0]<6684&PVW?
M1OD.IHDJE1%OP^W#6ZZ:>H%YB-%RZ$VA.6&R;MM5NIZ(L[[&6.486-&Z:6+#
M\K2C\Z*BT[<L^(DX\GX-@MW'YU"9:X2-IBLQBLF=8<Y?II<V1^0M+RX19X^I
MV/U4C1-RM2I8W+ZIS,?`IU*-_P"O;_C_`,<_0.VR],^KQI'<NS9B0&-AKT6Q
M97I</!C.0J)0G.VC9DW\W=L)6J"R=C\:?%J;OKIG;[LXQD.S````````````
M````````````````````````````````````````````````````````````
M```````````````!X1Z5YZ\@>[)BAX>F-^]$I[*CLQ]56^JGF^>9&>M(A-K$
MO"5,<PN"34?+7A+((L7-.5Y#7>'5$5^P0+=2_P`K8Y(5KN9KJ&T1]\I?,B-6
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MG;N<J,Y>?E5;.E^\QU(V1U/$76USS4RF*2IPR\JG1W<Y#\SF;IMDW;`>YRW:
M-BEV<C6ORW5TT0UE%)M24VYR8)3!V]DE!-:-3A#E]:Y):6-0HPTJE$00&9(P
MA-,*^S8GX]MB]L?7`>2#@/A/QJE<S3<$,W;#S?MJ<V=4M-^7K4MI\P,-;4-:
MC[Q[4TPY@GD8:H5*ZU15NI:2FF4ZJI6ZZ/;Z[NS@5JYJ#SS=_P`HL+*3+@OR
M4J6>$<XOO?[M3J"-<_=>1F4,K5K7,0@>:1]5;A?XU&ZZ@EA%Q7>M(*?#+&CK
MB0Q,K?A0O/1:;X5DZMV=]=@F8O\`K;\6QZH:&JI;U'8BYJY*3R:,UW(IL73S
MF[0Y99/6U7],$'[G_P`?:2(_+UKS"W&+E*D_XJE6W253IIC7.,%&!,S-X%<B
M025VQ8Q%W3!F>+3G)-Y6"ZM+#4[.[.AD5[>:.Y(Z]J7%)%C5IV\86,6(H6Y:
MZ_+I'=LZ$Y)QC!0"4O)/BCENAK'Z?[<Y?Z_EW0,*].IH]WQHR/Z2(M$;5N)-
MCV3(E4BAZ8N.L4T<-&=SF3JW_>=J45\.-MS"]]\Z&:!N[RSM.7;5_P`M;=E]
MT;MV?1ZRB39=M6DQ26M,:]7+XOS-6XQ85J;L1C?XLFZXVSK]V,9`=B``````
M````````````````````````````````````````````````````````````
M`````````````````````#SCU%_7P;8\2[PZ\>S;(N&EF22=IR^E:MC-80RJ
M=J[EG<T&F5<VK+91,M'2;/MD/C#%)^ZEL99F&YN2*5.QQJ8_&<%:A$E<_P!5
M_ER!,O+Z`R_+)>77FRDNH:EV>?X3!T6]CNW2FEJE8FDB*/T=%:#6M2K64?JF
MLE3N1DQ`0;\I9IBO=2%3D?\`7YZS2^FD1?GLBC9KQ"V\%QCBQRO%T5EEWBU:
M,W!2+DUSN.)5VMT<DC%<2IV:]]42=0<\1E&UK]C=BS5F,FEAO#XT\9>>>,68
MZ-P>:649&"+.YZO%CB<.D;S2D4;KDHRA(A2+Q,7QAJ%[BJ2P6BXEL2_DTDC\
MA_9L2QZ5F[F)C,?3(#6'%?Z\*GD:GNQ9/`)'IWY;O15/V73IM%V`@KWE2L9N
MV7?;#'.Y/)K"FD=9YU()/+JQ<2S7F+JW!5G=J-2_C-^R+)VAA8;\?/7D9AX3
MXOYYY79#D;@KJFO&IOFLC1X4?9,[0>,FR*TYSN8MV,7&;S"P7=Q<-?FVV,++
M/U+^N-=-<8#2JU_UKH@3)>M9<^]:NSY(>J(!VA%W5Y3<\UQ'7Q)(^V54<<YN
M_3R0-#Z6]VE&J\?(JD<(DP''MB9C6Y.,).QD_?&0EI[_`*ZG,&9^KE]>REGJ
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MUTQ?5<2(=6F^E#9\9>%QJ;1O+-(.+SDO0@/2@```````````````````````
M````````````````````````````````````````````````````````````
M"`>A>I:`Y18(+*>B+.8JKCME6E#Z6A3S("'8U`\V9/<N&(I&<GM3<XZMF7/5
MJ4;;+%GXZ!,63MN>>5K_`)`0LZ^EO#++?DPYB<>B8@5=U?2"K8A-H<2W2M:1
M&)E=DM88-5<+=Y6BCZB&I9G,Y1)4:9,TY</V&F#-C322R2C3-`MJ78D!,+T,
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MQ('N0(4J+4I"9NJ/5E:%8VSOKC(?'S_U_P`Z]0[3HBE+);94Y5O9UH4_,&%8
MWO,6DK7.Z9?6Z-62WEQF6-S(_.#;&'QX2)CG%,G-;MC%)>-#]L[X`0%UCZN\
M$\1SO-8]'WIF(V"1"$UENT1C=:VW:3Q&*Z5KG%L(G$R*JJ"30J&1<QP:C2OR
MW7=(5]WV9^OVF:;;!:9DZ3Y^D$323ENN>M-8LKC\&E.71TF+&Q?KV*S&=+(*
M_7/B)\6-SC'<S!F6E*$!*\E,>HTW_P".F<XSC`1XX=V<8M-F%TZZ=1T4W6.;
M6R6W](XNLJ+)?I6R^5MD&;988['..C$4@=9:\)D*33=5J>K.-Q\)>^N,[8"P
MJ&=0ES6_K6Z81=<X_J#7_P#7I']J4+LL)*LU":^81E*ME&6;1:1N5E5]OP?)
MKG7[OK@!AA5_T8?82NIB;AK,ZSF^N=;@70(J;1W>5HJJW<=VC6QE3)JX97)X
M5ES+V(_9;:82?)CZ?>`D%ND\:=UIC:TR%C='$IJ:'TU`W.R!:M*8W_\`-_0O
M)B5,H-/T:GO]8I_$49UP2I_',^/;;X]OH'R.4VAC,M-;7B71AJ<2/P/F0.3^
MU(5I/[7\K]9\J54K*/+_`&/X)_P?77'S?#O]GU^S;Z!PYGT$P2X*,S6)83M"
M=C5NI^9&SX);$LFP5F-J7`W*S[$2>0X/TRAW,SKJK^_7XL[_`%P`BFO^K^;K
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M^K4"#52ISIG!9>3/OW^F?IC/T`1U,.G^::]-E1$^Z'HV#G05DC,FFY,OMJ`Q
MHV&QR:."-HAT@E1;R_HMX\R2QU<4Z9L5J\$IUR@\LLC????7&0IK%?9OS%FU
MLVQ4$7[!JAW<Z,@Y=@6S81+FJ*H2$,9TB9XH0G=NAU*,BD\OBE^?DJ8E"4^F
M*3S]]RB]=S23]"PLQ(.X^+8FOE[3)^N>9X^[P"+H)O.6AXO2L6]VB$,=4S`L
M:Y=(VQ3)RUS-&7)+*VLPA>>7HE.T<4V=-\X/*^X,-9/2;SXDT/LBP(UVWRM(
MH/3S>T.UIRUAO>M7F/U^V2!XVCS"OECHVR-2D94CX^ZX1H]S]M-52G?0LO[M
MM],;!@\B]2..&3LKGGA5JLYIG]Y])1N:2:(I*T>XE.6>)(HG`V^SVS%F[,<E
M4/L*+L2`JSG.-J3T&Z)U3I#,ZG:_<3\@63GO57,U669':8LSH&FJ^MJ71:13
MF-5O,[(B,:F;U#(DVNCQ)I6ACSP[(W(V/,C2QKU2A9\>""TZ!29G;[$YV=`A
M,GT[\ZSVJJ'W3MWE_1CO-;(6RH'I1=$$2-%A.<3>VZ-R1LC+FJ>B4*]S9GUV
M3)#T^#,':G':Z_:`S51WGQ0F>Y=&M^K^?39'`IXFJV:1]';$+7O<9LI:Q2R3
M)(`\M*%X4+T4R4,,#>U6C;N7A9L6T+/H7]4YN-0@F1>Q7E[%4?YSYV_0B8G$
M%C=F&%II;^T6IX%,&YL=HQ*%;<U)5K@B;'ML>4IZ?8TK3;<L_3/V_P"0'VL_
MK[Y>R`]S2,?>/,;LM98-([*>&]OM2-JG%IA429\2"1O3FWE*MEJ#]4R9RJW3
M&EZ*\D:[;ZE;8TV^@8U)?93SG9T+*HC/1L:M==*:IZ&N&(ME2('N>XD,7Y<@
M;G8UQ(<OK*W&Q2-R:.QIJWWU;GE>W*CC-RM==?\`MTSL&6\Z^J7$_2TQJ:HH
M1;S<W]#6W4U<7$W<\O:%TULZ.Q>RZ6:[[:=I"4VH7"-E$M]?NQ1BM<G<#VO1
M7N6FU4[*#R"S0DSH_P!"N(^09(FAW3W3U149*5T*Q8C:PV-*4L><W>';28F'
MX>&9*JQ@QYQF1'?!^.E^95]"S3?C^$DTS0*F,WM'RT_W2T4^R16YI`5..B:3
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MOX?1D`+G>)%-;24M\"4HJM^-SK1[;4Z!^-0.2IU1?AE)]E!Q!9H8@S^V7GZ\
MI:1QB>V>RR/I=BE4HYY@LLY\O&(S6XXQ%H^BDI<IAK-(X$VZ[1*7('`K5@=U
MIJ-K>3OOT3*-\E&_8'!R;[.<@]1OG)U6'JYI4/2?8-$XZ)K3GN:Q*0/$B3UF
M>9+S&I_>IQ#FI\K5K225EA*UU:\*W5*I5-VQ.VY!)YVA&0QOT(]:=.%>EN:>
M=MZ#<YLBOQZK-O=+CD,Q706L(:=9=QME4-,0*?6Z!SEO-LL]#NYR!*A?U,7:
MEK6RJ=27+=3CX,!!E'?V'^49-S!-^A.F*^N+EI[KN6,L7=JW?H)+IHLG7\YN
MBWJ9K5RH]V;(TU'VTG?WREGXEQ+2(4Y[*XM*],?IG1.6H4!EM>^QCQ8_H7`>
M-&.FF,F"S;HR]*4UL]XE+Q'Y(F:JRX@I/K>++\U^^QYN=T<U?'.RW)G<V1;J
ME/:R6O.^^?R-%!!8;U@`````````````````````````````````````````
M``?C)A>#-2L[Z8-WUWWT+SMK@S?0O.FIF^NGU^[;73)FN,YQ_C&=L?7_`,X`
M:KO5'@V&^@T7YFJ2SY#7+/5$;OQ[F%@MLU7N[9*9"W.'/MVUTT:4XN:W!NU1
M6O$Y!.TTA:E)^^Q2,UG_`"-BS]"MTQP:YO\`]`N8)*;$=:4Z`8-GUZ/\V9JU
M2"R4$A>[1F=L<5]"F719U\7Y-VY\W<I_8-T)7IQ3Z*B4R30DTY,7MMH6F+W`
M1+5O]:^DJ$N=ZZ!L#L1OFAZ'K:>]9NM;VS7;8X4@S0*0R)LEC'EOB"FT65RA
MMS1=SBA?VV,2Z;%'(23$!K2:CV4%'!Z.N<WURE7.M<R!ZO6%=).4SA&D]:+L
M98<U0>&6+%IFH5R:!R=LA;0\NZ-%&-8RZ(""C2U9F5I1'Y&=]3#<XU#23_\`
MIEZ:?_/XKFZ:=A5A".DX;W79/:]2W?65.KMX&S2"TG>PI)(:VE<'F<N6/$DC
MKLZW-*2\;;.&3B$:E%I]%&R7;8X*<=*_UZJ(C_-I?-UB^AL1HEQZ$K_SSY8A
M$BD\#C37O:ER\I[6JD;DR2.2"SF]?,'ZV<V$ET;VEM7%+&O#3IC)BW3?.NH9
MW&?ZU3/,JAZZ275TI3M_=<V]..7S*XZZSSPUM<UY]UYF15JV.#`WMI-A/[LD
M?IK$X?J@=<$NZ353\Y2E01OMG)8"8/.?S[IOE#V)]![ABG?+19EZ6`]V%.^D
MN:%U'M;`J@\0Z:G*"YZ+(36HXG[&-R]JV.7[KB6<_=._Z[)#%*5+NEUQD+.=
M!<:2EZ]`[(N'B#OJE^:^E.J^;X`P=%U38%5POHR8R&FZND/\?C%^5)"'^P6`
MR.+&Q"\8CQNSDV/$1<=C"]SD_P"5KG8P*%WSX"<TQ:2^B/071O7[+':?N!`O
MNYZ;S:;AB=XKB$12YJ.Z@MU79JY`Y'.MQ0UJ545AFC;1A`F0Q:/OBU,B3F&*
M,%[!C\W_`*]5%'4Z[Q:"]CU,RMZ?E#;FM_1SJH8,C:$D+L+N=V[+JR2N3DJE
M^\OKM8U,$SQ$D2(K8C1Z3)TFV=BRL?B8#*;._KAU?8'H+T3T1271==4)2O1O
M*=B4>=SG3U>M#*XP5KLVCG"IG>:PS$>D;9'R(T7.BFY_-1%MI"=Q.5+4^YY/
MWZ[&ATUL>'%5U/SJQ,%H]B\E<W.B'SR8.++`DJBHXE6%>3B2,/5L7Z.B,R?G
M256BW/\`_$)FX,!L;E;1JL*/DQ2TTPH])C.B(L+J<&>)D`Y?ZBAM]SV<P'HI
MQY^YJK.C*2E)K&ZQJ<5=8#/-KZF4]4M<>9I`KB4:@7\/O!''XPS*=W94SQQM
M1)-#M"TVAJD(F]=?+3S%]&ND.>;0Z#ZD-K"Q$<SB_+FT1JQ^B;B=<$[-6.5L
M0:MK#PWHG=[C[VWP)KF&J0Y08A,3HG3)^IY6"-"U(1I=G]<3EJTW'KJ6)NQ%
M=84YTN2G;BV&)1&ND:2#M[M:-(6:1&958BN29UM&)0H^F4;97+4X$(D\*;W-
M04GPLUVQKL%B&/P)KNO_`%+KGTHY^MZ"U+#(9K7S8W\LQ_G&#'UB1"8O3#C5
MSGF*.S=)&I'&YL^FJBEZ%_1-12ALPH5ZXPH_(SG(6:[P\=ZK[LZ"0W\]VQ,Z
M<?U7)5T\BS955L:B*:<RV&6HJ0KV-S(L=Y1N+I'#8,LPOU^!.FWV<T#HJ0&'
ME(E*PA6$@\J>6=7<G>?]H\#Q.PI=*X[<3->9,UGTH9HN1OK(K[97)FE"^*US
M'$#+`H9$V@I=IENCK:F3MI&I6<9^[<TTS<-6U6_U9^9(!#JI8G_HBTYT]U?T
M)1=WZY4P"J(Y5\E:Z)A*B`M4(>J59&`N%K728L:G.[_+565DH=UFFBA4K.-Q
MOL8%U?:_@"X_02.\+0FH]&A(BK/MN%V!;\J=4-:R+:!TPIK>RXC,IDUP2W6Q
M_@4^>&<^0(\I6Q4VN)FY^VF^A&==#-M0KVZ?UH^0MVKK%FC]HVBW).I:.Y@H
M8U1)&*MIZ]5O%N9UE+*DA\<D<CBAC^YXGVM#,7[)`J4_K"S/FV+3_;A+HE"Q
M5J>%W+]M2CI)>MEDNK*%7K9',UNP^!T3%*GK)NHVPN;*LF]2(WJ(Z_P20QV6
M))]&[!<\N:*0-#@D(./^5+H4?J6>6$9N']?#FC_5/3=31^=N36WWT[<DYADP
M?:UKN=V-2,+Y,C-*1%D@$<FDL0.#M(6">,5%M1+OJIV(+WUW,_Z]ONV^X/CD
M?]<7BJ3$V:QJYC:**'V16R.$89VEJIYN<XF_M?8UA]G,TW8W0BL,-;H>TS*Q
ME4?T;'EM=&XZ,)TZ11H=L249H%D8+XQ<WU]UG`^O&:T.@%,N@$V-M1!!'!_K
M+6OW2UU%!L/-"R>.OZFJ&F;ZF.-3,):4]G2O2:/X5;['D(2/_HR$A]"^3/*G
M3'2TCZAL3>RR)?8'-DTY2MJ'QR7(F^N[;J291^5QO"29,JUA='A$_P`8031?
MLV.#(X-"@LW8O)V3]"_LV"INO]=+@9=`]X/+Y#T5/3U3A.GEVF<GLB-ZR]W?
M9V[\W."E[-.8*_8V!J7,37RM%&IOU;6]"GU;\+?G+4*56RC0,IM7P+XQM&,7
MU%"I7>];(;S[!8NWD[C5DX9(A)JCNY*U/C1,%M4RLB)J)(U,MAII@^[+DCBJ
M<BD&[KO^LPAT**UU"2CO$WBO6CNC^>&7%NQBM>GZ.Y@YXGB5DL`G+VRUER2R
MF1^K6R'/[O'W9R0*US6;L6]FKMW'#GC.?KJ7]=L9"5;#\H>*[0L"X+*ED"DQ
MLCZ`YS2\N744TV',6!DLJL6Z+.L):%$H8V9V1-ZN:L<4>3T2%ZUT+7)2_CW+
MVU-**WT#"%'C-PXK>7.0'QBQ,NZ^8=6S),L3V?*$&S0I[0H^(\^WRRH2FY0C
M)61M^@$&;<HTJ_5;^`XD85%;XW^F,!P<@>8;5S!U&_=!NL[8)VUP#E"EN%^1
MV%/`$[!+J?Y?J;4IQ.CEC3\UY>'&W)N^OR%#G+SN2V_$D19T^'/S[8+"U/3W
M"/(/:!L3/ZFH&!7<=!&.?QV'&S5&L5;QQIM!M:VF<DM6R-<CRF4O*)E28U4X
M_P#N49A&AJ8PDW'W@(^D?FIR9+;QD70TBB,L6V0_7!0U])%2&RIW&FF)VISC
M5S_3%;R*(-43?6(IH19K62JVIV:MMCF=X3[_`$5)3,YW^X,HY)X!Y>XC:&IL
MY^@SFPJVJIX32&LAD$RELPD"VLJZE=B3:%1E:KD3PN39(C\BM5\-),*(*.R4
MKU)VVV)(3Z%!P2WSTY,F5LV9=;C7#JT3V[F^)-EY*(79-G0"/W:F@.4/\(,M
MF'PF8L,4G2^+$MQ:=,J7(S56R'8Q&<8:D-,(V#!8_P"4'GK%3[.41[F:(M)E
MO3>!6%,\(WV<E%ZR2L;7-O6$:P\K658+K>.L]R*3Y-LRQW#6SJW=4>>I2G9.
M,QL&%1SR^Y,8[4TT3<BU0P5S&*-L*HX//HO:%GI)XXQ6YY'+7^VJQL&(%_KD
M;Y'7!XL1]<69S5/;LH:C71;JC*;]C\[;!85EX(Y&8'_ER6H*5CF9=QC52FD>
M<)4J6ORI_K^JUD$)K57"37`UVV,E[(=#B?QL%/>''!1FYB@O[%!AANP<]5<$
M\8T;)*RF-0\T5#7DMIF%22N*LDT7B#<W/T&@,ND#_*I'#F!V+TRN21QTD<J<
MEFZ3[]B=3UIVVFNOWY`9/:O'W,%Y697UQV_1]?V)9=6;(-H)*Y2REN:QEV9G
MS63Q_)J4W?\`6O.8M)]<N;1^>2J_4..YBI'\!YAAFP1YGSDX2,KU;5"WE&DG
MFO''5+HOBTBA#7)6]9JWVE.KK;=5.[^6Y*SL-5JV=(7M']QF?Q%CRKR3]FAV
M^F0E11RGS8ILJ%W'FCZU36I7LN?Y[$9^W15K:I2V3.4UF134@DQSLV$)%+L\
M.M6)$[$:<MRHVRW)4Y6/IA.1\86`````````````````````````````````
M```````````!BBZ#Q)RFD=L1<Q(5$WB4>E44CDDWUW_9-,<FZZ*N4K9TQFN^
MNF43XOA#2:=KMKM_S0EYUSCZ9^H:.?=_C2X.W&7@*KJ@IF'6KNU]FI'VQG>T
MHSO,*=K:L%E,6I%I-+[.CC=*X1)'=H0G2!,H0IVYT1*#75*FUU,^7X=-PKU.
M?ZX4"L^&]%Q2;V<SK)S(>/>,.6^7>F$C/+45T52HYDJ4VNYS*YF@9I:PM+ZB
MN!<VMV[F@3+_`(EK9KLD4_=DDLTP+3Q?P]IB.JN.[%5+XR[7/R)QU8_,:,PI
MCF1%9V<^29C5):]E\J99785@24MKJ1\E<K4M*56O=U)>TE,,T/*W2)==`IQ!
M/ZYTJ+?X5*K#ZTRF-SPBQ<@6A'H3$9(K='71MXXQR.JBL,LIZF[<0R<Z[JB$
MT^(BQD4RL)FB?"S5=K]WTU#YF?\`K]WF^2OCF?VWTO4\CF-+=YI^T[D51B!V
MDTHWE.WPN@H_M7=<(7JT'UE6IIF]T$F7O2N2(%AY![J;EKV0IB-D*P-S_;7#
M1/7MA<.V4FG#1#'[B_J^*]((4D@@V)ZRS=G:V!\C\@AF4'\DC.T??%A3H0K:
MGO!BO]2X(BSOQ%'T^W`5A\I?*!U\W9ATA)5]O,TZ07`HBL>C4?B,0<X>0LC,
M!D=BO;-:UUK'23R+-D].SA+8.$DFDB<IM3*B&M-J6G^G_P!`1CT+XZR[I&\>
M])A8ED55(*B[)NGS.L=%`I!!Y8YN$:AG#KD5_LRO'XU/*VY.XD7%'=EB$E2B
M-2:)RG15J:3G[]MMPJ#I_7'G4:IIYK"N>MF:,/CSY^6EQ.98!=<R!)+$'[SL
MY3U-5RIGD+;/"I$V0.)1!T40=:V_EG&+&DDG[\FDYRFT#-H=_7&KI3`;C8+S
MD5-7)8<I\YZ9XOIRV'^IG=Q?JEM&"5Y:\0F]]EH7Z9.NR]VE;Q,F5>7@I60L
MUPR::8-*^FN<AU%S_P!=1XLV2=L3#;HV+O[EU=&H(V)FR9UDJ,-.5H+IYKMF
M5--ORU/)')58L-AJ3G$IGKI&2VH#(NWR!<4;NKQC7.P61X$\1F'@[U"Z_P"W
MZR?*PA%"7=63?5M.<U5W#5R#2MFI095C_)G`][<3L(V1,NF,%7J"VIJ*RCSJ
MY:[9W+P5H1J%:NTOZ^$QZY[T[=[&4VK2C<EOFD>>X903)/*Z>;,-K2SZ@GM`
M3!^E$OCCFH;F)5'I`V4DJ:LDMRK!ZI%)%19N"]-3M5@8H[?U[^AG#H+T`L!V
MZGKB=TQW=T]S?=<WJ!]C-CP\EQA5;=$LEP6/#GI9#Y5G1`K50LIQC;7NDR;L
MO3*=?G4(/^6V`GQO\!F.)W3:;_4,ZJ6D:)5]HU)V12]60NGOS38XXQKD^R>=
MK*K*4%;OS*PXB$FDL[U?D/XI)^A>GY9!Y&V57WZ!J9ZM_K2='0KS_JSF3G!/
M`+V>EMQ\Q61=T08GO>H6+]_3-2W3"K,G3(JEL_C;7+'*YU\[94JXU5NA7-Z5
MH*.3EF&_XT#UD<%51T'3U&1>(WN[P1L2M<(J)AK.C("TJU;7S1$H=4D-AZZF
MS+8=9$^/M[;,LD9%9Q<H7EHE*LL[&NQ6<:Z[9"[@````````````````````
M````````````````````````````````````````````````````````````
M````#^;;8UUSMMGZ:ZXSMMG/_C&,8^N<Y_\`X8`4EY^](N%.J)DEKOG_`*?J
MNRIVXLKO(V:(-+R<@D4B8(^N-;']ZB[2^I&I9*&MB<"-R5I[?HI+2&:;8-SI
M]N?H%POY''OP<N?[YF_6X1DN.7#]HA_!PWJ#-R2%V5?S_!A&><7MIH;]WV;;
M:YQC.<X`?'*)C&(5&WN72AZ1-$<CD?>)4\N9^^QI:2/Q]L4/#PZ8)3:'JE*=
M`V)3#M\$Z&;YTU_QC.?I@!SQ:3L4TC$=F497Z.D:EC"T2>/NFI*E+HXL3\WI
MW5I7ZIUI*98GT6(%19F-#BRS=,;?3;77;&<8#LSUZ%*FW6J5J1.C*T,,-5GJ
M22DQ991>YIN^YYF^I6FA11>VVV<Y^FNNN<Y_QC(")7;H6DF.;LE<NMEQ5'+I
M!`I-:+:W[K_O18KV(*88D?Y:Y/Y)9D>9&9(?8;+@LQ:K3_E8<"]B,&Z_=G4)
M(2RB,K5:EO12)B5KT?X?YB)*[MZA6E_8$X4(/R4Q2C<XC\XC;&Y/W:X^73/U
MU^N/\@.]````````````````````````````````````````````````````
M`````````````````````````````````````````<1^VNI!VV^3,::E&;;9
M)U,W-QKC3.=LE:%:[&[F?3_Z<:XSMG/_`(Q]0'B;_P#2#FZV^&N22[&]7H-/
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M3Y5N6"KGV2NTUAK%M":XJ[E)KKU`FV)RWIVHW)R7"?&-D>X<T]_JW4C-[_E'
M0=5],):LCTMZ+8^@(?$HGSM6#O\`Q.*J)U'+4=H3'+`T>T#P<GTD+:>CC*O&
MF6ICBJW9JRV+2<:&ZAZO````````````````````````````````````````
M`````````````````````````````````````````````````````'&;J9L4
M9J5O@HW8O?4LW.N-\%F9USC3?.F<XQOC3;Z9^G_R`\@?)_BYR7!UTC2L?>**
M76-YZ7ORA:MA(7%RDJ2I.6.J8M+JJO'L&P6-`[3%D8T6>J*Q@S4RYU5J%B"'
M9_8I_KN>6>E3!4QJXUI2+<D5,VPKT/XFSSCUET9':STLYKY]ZZ(Z`ZK_`-7=
MOJK011.%$M_3BU&PHH]:,65)E,LB,69D2)L39<"G5*B-PI`;:^@>??)?K&H^
M9//ZI+GI.L(TP7$Q]F+:15L2FS'23,TSYQN2VCU]NHI?(/W4)<)I"9\;-=WZ
M3K/R#\MF-=L&;G:_:%#V+QLXSZ"M&(])X]5N;.AXIU.^\B0>P(7(8C6#U".D
M3.,3Z69Y9!:O5L=XMSF4[SA;7*9&XM^='\](D>]DZC"DXPE7D*@0[R2FSIWU
MSQRTBZEJ2T^9+1\Z>G>4&3J*H7QEE4\*F],4NJJ>=)4T?0O,E/@2R!-U[LK'
M_$#)(>RK&!&I.,R0Z&_4D))*\8_+ZUN9;7HR4=W4I6LV0P=ACO\`MZT*$AU8
MRRH]N..WN@:TO*TX+F?VTF-C%16?/K#V@25-H])D&^C.C.R8N,S\)(>N2N>N
M.*8TOAG-S1V+S6_6?%6J!UZB@G^\ZI_V*[NA[*@;HPDTA:23_N#7J3D%%FID
MI"?;<_Y=?BUSC.OU#+B.U.0E5=L%NI>G*)553*+&S44?LI-:4-40)UM#!CB5
MM`DTN)=]V',JU-:5.N4>3\'8V)VQ]/K]/J$;V3Z*\KUS#HA89$[Q9L%FT6;)
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MF[U'9`XH7)G4O+3`7T\DE1H69N6S+=L8SA.;G4*S0OU^\Z)<W7RZN/5%0UNA
MYQM-SJJQ][4L&$0=1HL1+HXUM<W8D#C(]G!VK"7N4I2$,S[@HM(XF9V^/_&/
MKD)])[>Y<D+]:4!JRZ*YO6YZCKM^LR2T#2<[A=A78I86-H0NQ9#3`6F0?LCG
M!]R\-Z9!@[)!!ZIR2Z9-UP=IL`I7S;["PBZK"D4'N'DWK7B=N:IA$:K8YWU7
M#H-%8A*+PFI,/71ZB4JR'S^:*6VV'YEGK8X-S8H*U_+1['YR84:1\.X2K`_7
M;@N=$E+C+I0P=E?>@F/FFM9#8*$V.,MQV/*:PJNW8L96:K7=<8Y1J20VY6'=
M(L7Z-N=U*KX=B]=OL^\(TE'MIPTU*27F&V/';=J)+.>?J[F%UUK/ZS=876K_
M`-"V+.:YC[C83>YS%HE4=A<>7PG*E:]Y0F-Z@E9IHA,5'$*BR`G>^?1NG*:6
MT'$HE`[KZ-MWJ&.2V8T92E&05,IL"5PN#LB-[D\W?=K.?:RBE=1!HT=4*<U7
M(7-MWW5KB222C3,[:ZA%K-[/^?J=`<EMZWU/-UDL$"9YQ8],WS$Y-#[&JQ:Y
MHXZL65Q+RT38]153;4=TEK;EQC+2Z.;RE*7)SMD^"3BS-@[=\]E_-6,J3B9!
MT_'&I+^@JV1-KJ?%+#.:Y$GN8VP":^:8NI11%5M(98[&5:_X-9DNACJC_6'_
M`)"<O[-OH'P/OM+YM,<8:I9K?[O)$#KM//\`\7!:*Z(GTP8R*R<F-GFZ^:02
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MJ+*A2HU*`68X>[/9^WX7<=@1RL)_5T>K'HFQJ'945GM#M%)I+4E>MT54&SEU
M@,C96"65WJ]+I`<42SNZ4MR))2ZG':Z?/J7H%U0`````````````````````
M``````````````````````````````````````<"HK=0F4$%J#DAAQ!I1:M/
M@K)Z;<PO;3501@\HXC)Q.VWW:_?IOI]V,?77./\``#1I$O`7DV`PN=P^&V/?
M#,=>$*:DO34Q5RQGE4NZ,NZ&7)$[\JWI^QMIHP2.+'6]7=F,3BH+)):M8X[(
M)`N0N+:J2[:%ZA_67P/YQ:WJ$2%9T)U2\NS(T.R"PU*Y_IG7_<CHOL:[;6;9
M))_@I30Z$.;!,[_D!Q)$,WC3<J)RE*6IE6$^N=@R1[\*>5'N8$OBBRNAM8@X
M\]-W.L[K#6;1LF+SIE8>6%/'T>L)6[H86AF\?LYLIX_"?=4V.B9J4J=/E,;\
MYWW^X.2.^$O':&QYC=\Q?K/LJ_)V[UF^/MS2=/3S;*$3M3EBU1/:\>86QP^I
M(U`:YD:-)3K8RNKHPL[<XR!N4+-W`X]8<6I)#@X'\)N6O.FT8W9%'V[TY(&V
M&K;G>(C5]F3>OW^MX[(;Z;8&Q6+(V]"QU;&)+L\.D=JZ/(==CG0TG4EK+V^/
M)FYN^X=I</A-Q-=;*0PRAXOYM;])5,9DO2QVU"T;9(7F6]-6%ULF_E<:<8V[
M1&4M\.M^TGPUG3+V]022@6_`HU4Y++,T#DU\).$M7N8RK"&S_P":R]1^?I/,
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M6/T?)8%+ZH8*[7P?2;P]GC;?)VV'4-#GZVVO\&O\R`Z7RTGFR*JE#4Y.#E$$
MYZ=260SEIE1I`#OL_P!?WAA(CDZ&.F6!#])M%9'"I8LB3?2\<<G*-O\`0$'H
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M2G'ACYNVI+)+,[7I119;U(K0LNXB#91)G336*3NUK&AEG2ARAIT?RQ+F`C#[
M`T"5.3H=MIJT9/0F?*G4':;A9BAO.GD[F:Q&RT:7@3S%9@V)[M3ZN*R>SB6F
M...@W^JI-91SZJF3^_N3ZI6NM,L.R(Q6H.V;BB#2D^2RSS==@Q:4>8G*\W@O
M0M>2]%:+Y'^E>G4/7\X4Z7#8,>E$<O5GQ!]6&3UA,XB]QZ65TGCI==M1:!.W
M+"M$Q2?X],_'G[<!`6/!KS'-@D"KEPI6<NT:K*X,WG"=E_171&'YDL+2'0"`
M-Z\B4HK11R3=`PQ&K(ZB;$VRK)39HT$;)?BW^_;<,NFWB[P38D41U[+8'/G:
MN$5=<^U1I`%%OV,;'U,#Y?L2Q;+IAC<SSG\V0NVL5>K3>$V#U2XU0:W&ED;&
M?]6F^`G>9^>?.=AQGG=HF>;@=Y?RRPN$:IB\4E]7!&.BH^S/K`AC$L1.=Z0^
M91^QY,GF[,UIBWHMP7J2G(Q.4<=KL<469J$,-?B_YQM3EHX%T2]N)9+R?*TK
M/(;QO^41M%/E^8EE^M)%')%:#HRIK:EV(,V8>Y3J3A^><$;?F*SOG4?*$A(/
M+/AILF,=L)%3)Q4WBTU76`SR;_8EG;.A,F6O]^R318;OM,<DJ-6QQZ=F^B+&
M^F=D:1ZV3%;:IR$Y908347C7YOT;,T=C5SSKLW6`G_+POFCY;EY3.1RLI:XM
M;NH2V`XS*RWXRQD&7-C1'ZIGW]BG+-1$;:::Y)+^T.@;_$+R_:(2[5JT<O-K
M;7KJDEY1<')LBWU$38'6=IHR@E,PAT=<)^M:(9/G1KAK6BR_-9*1V+0(]$I:
MC5/G<O8+1='\(<G];YD)O0-1H9XME52N=$OKMK)IM%7I=4;U,8[/W>"Y>(7)
M8ZY$LKG+HHWK%&I9NNY_X_Q&;;$&&E;A\5A^?/%UKGU<HL3G>OY4934"051`
M=7!*XZD(ZG;=VHU)5,B2I7%.FGM7ZGLB4W>.O^CFS''$X,,3;;YSMD/J8N".
M/HQ%[5@\?H>'L\)NVE(7SG9\-0&/A$3E%)UU'Y;%(37F\<U=_P!,TLL=C4Y=
M$)&R`E*I_%4X+V-VU)(P4$;&^4GG.KB2J%._(5.25G=$VB.1KI>Q*9C+YJG*
M*;B2-+#L"4KG>>6+LET:$N2=GUR<-B=DY>VF==M-<X#)*Y\S_/NHE\M<ZSXX
MYYA*J>0J4UO,\1^L8RB226OYMEB_EL+>&[1#EO61B0:1ANT4HMBLIS"D)!?V
M_85IK@)<HWDSFKF<I01S_2=?5`0L*7EKD\"8$T?(<-G58C7N2EQ)1?84X."]
M6W$;&J3L;J-_ATQG?.NN,`+#````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````^1P2[KD"U$6L6-VZQ(H2Z.#?
ML3HO0[J"=RM5B+=20J3Z*TV=_O+R869IC?7'W:[8^N,ATT21O[='T#?)G/=[
M>$'Y*,Y[-PBT4O*=,K/*;W5<2VMS2W)G%>WZE&J"B$Y9)9^VVNF/MQC.0R0`
M````````````````````````````````````````````````````````````
M```````````!Q:%?8:<;\ANWS?'_`->^_P!Q1?QZ_;_TZ?3Z:??_`.=O_P">
M0'*`````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````#C*TWTUS@PW8[;)AV^-]]2]<ZZ&&[[EE8P7IIKG4@O
M;&F,YQG;.-?KMG.<YR`Y``````!Q'Z&F%YU).R09G;3.#<::&9QKJ9KMOK]F
M_P!=<_)IC.OU_P#CZ_7'^<`.4```````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````'&5IL6467N:8?OH7IIN>;@K4P[;77&-C3-2"R2<;
M[YQ]<XTTUU^N?\8QC_`#D```````!Q_9O\V#/F,^/!6=,I_M*^+.^=L;8.SM
M\?S_`":XQ]OT^_[/IG_Q]?\`(#D`````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````!U*U4[DN;,G1-)
M"UL6&KM7IR,<]4AS,62BW.0&D-^R0[9VRN6ZZD[:X-)R3C;[_P#EC'V@.V``
M````'`J3ZJB-R-C#R==\Z9R8E/,3'Z_89J9C&AQ6VIFF-LZ_3;Z9_P`ZYSC_
M`,9`<X``````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````#@4J24:8]6HWR6G3$F'G;XTW,SH45IG<S;&A>NYF_VZZYS]-<9SG_X
MP`YP````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
:```````````````````````````````?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>g575431exmpg076.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431exmpg076.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@#*@)L`P$1``(1`0,1`?_$`'T``0`!!0$!`0$!````
M```````)!08'"`H$`P(!"P$!`````````````````````!````8#``$$`0,#
M`P,#`P,%`@,$!08'``$("1$2$Q05(18*,2(702,843(D0B4987$S\($UP7(T
M)B@1`0````````````````````#_V@`,`P$``A$#$0`_`._C`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#_]?T__`*_TW@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8+Z/Z)K7E
M6I7BZK:.DI,)9'Z"QA3^T(C(9U(5+_9,YCM;0MK;(Q%4#F]N*E[F<L;T0-%$
MBT`:C0A["#0A:#5N3^5'D&OT36JM!XN"ISWB*W%+4#79?.E[Q!S5):(<OQ%C
M,B$ERKX!+O,$:\U.!M9D1BER?=+$XFTE6$X&]A=8?))R44FT>[RZP8T?KHEC
MY/-:I)0U[-#ZFZ"DE;H[:9JX5,A]<;<T[BL@2\E;]D96D`-F!)&>$X82Q!CZ
M/^8;QN2917!39T_'R4UL1**SR$/CW![6C$460R=3U_JZ%29\F,E@;1%(6SRZ
MQ8PN96P][6-P%S@3HDG8Q&%:&%1DWET\<$+)"?+NK8#&BS9E+:\3?FVV:-IB
MZ;P5]51>5Q=M)5Q<HYS>&B3(%+<(I.$W9J](H3E>\U.<``9HM/N_CRDFFHGV
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M"HH](K6(I&9`"&@X@@\@_P"%P&:`>ME>FP@GM'CGRYS&N*L@Q'&]80PCEU[D
MO17(D>H>QZ/:8%57;R^YW6:PJ</[19=LF.LOI"%UL^/#:I;U2HY>Z/LH<U>T
M8""&@#<%RR3E[NV,W27U:L\>%GRBX57DV%VHX(H/>]/+8^W4>EYJUS\"M&Z(
M*>KD$4/MES<$*=T&[_BQEA2G&E[4!&64'0:`2'@GO0^"4C01W`W1Z%BK7C7D
MSG5VN&.3&%>Z$3ND>JYQT59%J1"H63HDF#WT4N%+&7\-'YFM`ATXHE)H"]`)
M,`:&\[T5V66WTDRN/CMZR^>`^;RT_(I+#-16)2A&9SN_3N]I(R!ARMDLUW2)
MK6-)GZ$(V$XI.D$<:886H"$1AY8;']A]!]*VSTOP!U!SKXU>TY$JXN<^G'"1
MU1;4-4T2H>G^[:12U/#6IC?6G5F0MZ;F<#DXGN"W1GT$Q:<)1"H0E&P["63Q
M<UD\U+Q/5L5E#7+V2:N#_;L_L%FF-?*JI/9[%M6XIY9L]:8O7*IS=M1&NFJ6
M2U6GC28H[X1L924X(0?+L.@D%P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!\=*$^U`TFCR
M=JBR2U!B;1H-J`)SAFEDGC)T+Y`DFF$#"$6]>T0@"UK?KK>!]L!@,!@1;^:.
MSYM3OC3Z0GU<6-(:GF[;_B%M89U$Y;^PY,TCDE[5C&W1.RS+25P'&5CPQNRI
M%M:%,I$F+4",T2;[?C$$'LUOFW(HHY=C48[_`.@WN/I)#8::15E6G1T?NNWW
M^7O?3%9Q"`2*H^C9]S[`:]\@\*AK*E6-4CK1*L129I32148G4N1S6$HH,LW:
MX7E6Q'ED=63R+=MC6<C61RG5\`*>)M5YS6F5=",=!3F2:*2)Z<$48Y+Y992E
MK:C@>S;8E'M$$'UP!]0\/1'D+[^J>L_*-"611)/?%.B;1D_.O39[&VJFBE^6
MZOF=90/H*#F'GQ10PJ;EAZU^2A@"!:6Y*WE1-B%6_<E9U8"@WP:.X[9LSN)_
MIUOD,GA?#_0$`L'E'DWIY@;J^6E.O:-0L\I?K#F,)DCH>_*I2H6H&V3-;5MR
M:MQ\;S6A@B`K`.>OD".!_N'I"/TQ4UBE>1+IB3M<\\O%W\D.Y$WM#F:FO@I/
MG%P["C\>1IK+-IMM9(TZRE+5C$:_+EX5A#R=HD11:0]1K8@]%A];7##7JS;!
MJKR9W-:ULTO5W`KCSCR.6+FF9H>S9G:308VSZ).,:CE:(91:H;=$F)]TIA2E
MF0,AJ@]X2!$B"2'`E7[CO.QP=B4KS"X]2.7`M%2CFZU;M'T:B25BB<+*NV*3
M2'Q.-4>RS>[XI+*J:DD)CS\HE3XT;(V\OZ0:8"<9*-.O&((_X?W%UXXK'J=O
M_:L653>#=8T%PM%^3H[6M6(C.B8+9+#2D<?>SH>D=HPZ6F;-Y@FM-TM>+;1G
M?L))%V(M"N1'DZ<%186(S^4/R>26IJ$AZ)HJ^+=2N/#S[=[FIE['!DE+=4*;
M!MKE.O.>+!I.R'B7PV"-MPR-CM&3)3JW/<&\`;!+1-INP-:]N5'!LW#>L?(U
M,@<1,\&ZAYC<C>GKIZ#HM6KMSBFVHA9C&_<^MG35A2__`"/7R:]84BAD^C*&
MGF:%O+,DT8A`Z&N+DC6*"-)`##5UY\PWD'B=7^1T9*6A["F7'53]`V&QR]3S
MY:%7M:9[J+M5]YUC#>VQIYN9\UT-7DKKBOY([/4CC![>C@[VA*;G,T\\\`-!
M(U</<?7L;Z\)XIK4[FI9/;7'0\7J:QYC$[!%%*U?G"AK_NZ^)':499K%2N,Q
M5.S53!((+%FU>U*1_>..7N0TR0PP06FZ](>9=CZ*I#GAX9_&:CDERQ/IN2LQ
MK>EZ6D",UFYHD-=M`Y@[+TLO1&0Y'9N[,;TX&<*5[.C)^]B4+G`W_P`/08TI
M[RD]R=)0%O#45;<MQZSHSSE:G8MI.5DF68BJ\NLV/H*Y*8IZD(JI2RA&]$6+
M.$-'/BV13)28I9(OLHCU9E6U8`%!;C1YL;NE2=0E:ZIK2)#NJW^&D'%,TF3-
M.S8G;\"ZG0\V32V*3?FM%*$2P'6'/E7=`%/?U2%Z1KE"%,H5H4VBFQQ+`&Y7
M='<'2?/G7O.E.5VV4I$Z3G+/#%TWM:Z6"Q'^.R&<3JZ&>N6JDQ32NWE.V<Z2
MEW@Q;T\1-]F"%6PS.1(BH^G,3J?E,P-49IY+_(>;Q-.O)C6<!X['RLXQ2Q9E
M55:3(BYSKS88I%ITMC-<OEANL?D(([)'^UDK8(#C'FMM;U<16+DQ>SW4:=87
M@6K;_E]ZY0VQ-H12K/S&=$&'H[EWFQHEEPTOV!%Y&)[MCD.V^C;,F;G5*`LJ
MT%C0AD56C;X^@0-!QPT"G9YZDXLHQ2$+\7>5/MZ'?Y0L.4TCRE*Z4YDXZY8Z
M]Z._:EA75"[#65[>9%K+YG):=3V)7*5K,5QJ*U&OD#=$I83'GU0G4D-IIP5O
MO'H,SU]Y4[BG=72"SVWGNNEJ!N\C/1?%S:BW;LB8CSJSHF#VW*T]O+BW.L5"
M\N6RE=6`$I<;+3[V62X@/VJ#L`R@A<=K^3JWZ\XC\?W4S;S]4"N9=Q/=,LJV
M'V%TN;4]74\&YZ5F5TLSK([?>*C>CUB-L;(H!`H!^#(']Y5H!?R!#H0PDDYC
MMM]OKGVHKGDD5CT,=K-@[-,C6"(6&R6U#BTCV1]MJ=8;9D=2-[3.8=(VH9#D
MTN1:5(-4WJR1FIR#=C)`&=<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>;2-(%68X!2I@KSDQ*,U;H@
MK2LU(G-/.3I3%.@_,-,0<J-&`&Q;"$1@MZUK8M^H>G`8#`8&#.B^:J-ZUJUU
MI3HJO6NT*N>W1@>G.(O"QY;T:EUB[NE?H^OTL8'-H=2%+4\(BE!0BSP>AA>O
M7UU^F!IJF\-/C:2#91D<X?K&EQ+G&PFV_?*DN.."9>)U3+(^2HM$TID4)G0>
MU)8DNBMEJ-[,#Z#WO>!<IWBCXC4A-"IA=SJ?G,+-.&I[$[*4&FF%"+$6(PXZ
M_AFC]OQ!UZ;%Z>W7I_3],"T5WAG\>SD)=]ZL+;4)G$\2M8V[["[-+9S5@_U&
MM_#E=`EM@%HMZUO9NBM&>NM;]?76!35OA,\:CB),)=0\P4_3,&>C`;TWUALI
M(J,TH"8N2DZO'12=P&!6:':@&@G["8+7N]-[U@6:A\!OBH;S60\GG"4&J(\Z
MJ7UJ/6=-=8+#2'E2K&M&ZB$IO$WYW$M28(19X_<:#>]^@OUWZA>2?PJ>/)"^
MDR5LKFZ6A]1LK1'FUU:.S>T6QQ:6AC^0#:B:G%%T"2X-Y"9,:).$!9H0:3;^
M+6M`_3`HSQX1^%'Y&J;7??6+HV*E+:N$V/'>O:K^W$N#2H5J4;BG12"^'5.6
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M5E(O?/K!V]=L:K>43)#/9`E)I7DQQDW[O96Y,T1B5QBQE-(EV?"Y9#&A`F0,
M2]O>RS&1L("A0A(2?[.!>T3\0%D5[,:!GT&[QF[=*.8(3:D`I`USYOYZ$S0B
M/W,I9UMA#+8HA'8.CD+Q*%C.6:O6/&W(U6=O[(__`#=?:P,2N/@3*=X!!JM7
M=;+@P2O6NRHXP-;=SM6S:Y*(5<$U5639]92B2)GO3_-ZCG\\4_D'B*O1[@Q+
M1%@+$F"6`.M!G!O\5M_(6MT+UY`U@'MZLR&78M5)N*N3#8XWW%6C#!X;6E@Q
M&)/\/D*:%.\(@]=M+8CTVJ"-!+1@%K8?<<`X+)L#PXWE<-PQ"];<\E]L2JR8
M@CAS&4_-'-',D/T]Q2OY[NT85%Y6RLT.W%IPS1&QAB?FI-(&]W2-[QZ*BB=#
MUO0@QC/_`./<U6,.T0/G?72)+7<!S\IF,;:ZVYJ9HF!PF,G:IW/7^)1-DJ=L
MC-;RZ?SMG)=7MXC*1F<G0_W:4G&Z-.^4*S9_@ZN&Q[F67;_\F]XM$Q>K#K*V
M9$_I*<K%CF#A8=2U+,:,A4C;I;6RVME$=.:ZNFZ]J^-&G`!44I.&K^T:;\@`
MPP/^/1<FYV\2Q3Y'W"5QY]CM:Q:05C8_-KS,:XG;33[_`".65T"WHF1T\P,5
MS',4NEKD\&BDJ9QTO=5ZE0IT;M0:$89-4^&CM4-M3"V47DCK12KFS_,K`<(8
MZ<4R0BLV2Z;#K]754TOR*5Q'^Q&:*,USN]>+U+=IZV0;HK[RM0$C[:DY0,,9
MLG@S[IA41J2%Q+RC(EY?/\DJ:24),9?0UDO3_3J:F8%9%50B#0V).74CQ588
M8WU[:+HB-,5,A[TN,,)-5+CMI$VBPGNY'J.>4/SG5U2VA/"K/L"&M#BCE4_)
M.E9Q4J=%T@=W@QU+#-)%*G]&`TIQ"'27:T21'[?@1%)D1:=,2&QN`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P/.>6>9\'P*-)_8H+,/]20G?.0'0
MM#3Z]P@_%LS>];]^O7>O3^GZX'HP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P/P,TLKV_(8`OWC"4#WC"#WF#WZ`+#[MZ]PQ
M[_IK7Z[P/W@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@6Q+(7%)TWH6F8,#9(FYLD<6E[<D=$P%):"40F0MLLB3\C]W]R=TC\C9
MTRQ,:#>A%G$AW_3UUL+GP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&!1Y"UJ7R/OC*C>W6-*WAG<VM+(V+Z&GM@4N"(](0]LVW5"Z
M-?Y5J-.T>G^RF4)_F+#\A1@/4&P_;"V',K&S,ZAW<W]0TM3<V'OKV-(8\O1R
M!&2E-=W<Q`D0(1N;D,K9RC9)!)6S1BV`L`?0.@JN`P&`P&`P&`P&`P/.L6)&
M](J7KU2="A0ISUBU:L/*3)$:1,4(Y2J5*3A`)3ITY(!#&,8M!`'6][WK6L#Y
MM[@@=T"%U:ER-S:W-&F<&UR;U)*U`X(%I(%*-<A6)AF)U:-6G,"84:6(0#`"
MT(.]ZWK>![,!@,!@,!@,!@,!@,!@,!@,!@,!@?(\W1!)Q^P&FZ)*,-V607LT
MXS18-C]A)0?[C#1^GH$.OUWO],"C15_!*XS'I.4TOS"5(F1K?"V25-*A@DS0
M!U1$+@-DA8UGHK9GM"$_XE24W_<3GA$`7]P=X%>P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&!H;V;Y$>4^(':MXCTXOL-L3W:V3T,6.BE%6U<C`Y`A;<W*'UA>_P#&,*F8
MD3@ZI7DLM(D/)]5>MF;WK18!CT%H6QY1N&^9*[Y=E-S63KGZ+=0P1;+J/:[)
MKJ?PL1<3B$0C<O>V9^8DL25'P"1,T5D*,I*R.!*58H7#`C3E#,T((`_=X^6K
M@3G"*45-[CO!7$8OTM7<EM.DG0RJKC<_WQ#(G'FN4.ZQ.A::_7.3.[?B7M((
MAK<"4CHI-4@*+3B,W[=!Z[*\L7CXI=MI]XN;I*+5`V7Q1CET;5BRT629P(N3
MU:U(&AR4JB]2>-MAB&8G)7HGZ\84!*DJLW0RB4!AH!`P/Q;7EF\>M$(J1>+A
MZ6B-=1KHRFGN_*:ETL:9:S1*;UHQL[*_&KV^0+H^2W%21R:GY.8@8#AEOZ\0
MMED(QFZT#85Z5>4+@B!$\TJY]TM`X"W=>5O([=H!WG@'V%LLQKR*1%OG+W(G
M)XD[0U-L&+(CKH0,I._FMBM4I']4@HQ5K9.@HUU>6;QR\[Q^D9;<W6M70>)]
M(05[LRD)2L.?7.-V'!H^VM;JX2!F?6)E=6LE,:E>DH4A:DT@]P4'!3I0''^I
M>@R/).]^+FJ`4E-G_J^H*YB75<8='OG:<RZ9QV&([&;$S$WO)[W"S9X%$WKC
MVMN?$2C12HG>O>H)`,H6S-%B"V)7Y./'Q6];T=:M@=F4)&*TZ(;I&LI2R9/8
M+`S1.S4\(+3@EZME?CS$K,$;$K4EIUH#!)_@7'`2["%0()6PO0SR`\/)*NJ2
M['?K3GV-5+?1CD33-@S&U(?"XQ92AFVJ`\I8BY2MU9BG98T&HC2U1)?J:G-#
M[#`A'O0=AYY5Y"^%(-4M;7U,NO.=8O2=Q.B]EJNV'ZVH6UU]8#HU*EZ)U21.
M5JW<IF>1M2MJ4EJMDG""G$0/1FP^W>!\`^13@T-,0'HI=V!SJQT5:<E=H;7-
ML2BV(=$X+-)4PN;NSO+!'I!)G5I0N3FV.+"L+.*+%L1?UQ"W_;Z"V'XDOD9X
M(B$(@]FR/L;FYMK.R+#=ZF@]D"M^$J:^D-C1\2D#[$DDW1O"B,%.K,-(/2K1
MRHL"??I[Q!]P?<&4$_5_+BJ!U_:9'2%#CK.V7<;!5MA;MR`EPFR7XM6O;S&2
M!R@Q_`RRYX`N:U).TS>>H/T:G-#[?<`6M!^)IUERW7$(B%FS_HZC(96]@2E)
M!X+8$FM:#,L)F$Q7&KR4L9C4J7OA#$]/9IK6J#]9.>8;K:<WUUKXQ>@>%G[%
MY+?X95MC,_3-"KX#>#HXL5-S(FV8-J-6D^-&G#\LR0%Y,?`()4\M6VI2%2E1
M#./(&G,",`1`%K078OZ+Y\:H7&;)=+VIIMKJ:N`VF&SY?9\)1PN6NI8EX#&R
M,RE0^%L;\X%C:E6A$I3S3-;3&ZWK_;'Z!YG3I?G%CK!JNUZZ`I)GIA\6_C&2
MW72U8(WU@\..UR]LTWM4^5OQ,4<%NW)J5)_B)5C,^=,:#T]Q8]:"W%/9'(B.
MI6^_%O4_.:*BW=]4QAJN=;=M:I*I<Y*C4."15'F^PE,E*B2U\3J6E46-(6K$
M>$:8W6P^I8O0/TFZ/H:SJ6;[CJSIVF1U;*'3\7&+SC\[K^5URO<6A\/1O30U
M24Q[,B3HX[,95R`PH*D1J<TLS?M]Y6]:"JH.A*#+@IESF](5$YT]*'\+=&+#
M,LJMP5F0O2)-,ZJ,Q^=HG$AD>%8W=B7'F%G+52L"G9Y6MA+)"46&.W/L?FD]
M!%+.9>R.4D=)^LT0R.3K;-@+I'I`[-*N-,"5*PV@FL=NB#`IBDDD*8AT2'$N
M!ZDQP3$A^J/>A&!<L;ZRYM.I)#=[OU)SF[U>C<5,/?[R:;+A##32J=L2U0QR
M-K029PFCRP-2@E^;U!04!KNK4$^SV;,-WKWB#P+[BYBM&&POHICZE@AM053.
M5SJ.S*[Z%C2.EGE[41UZ@:F(V9)&"3#@LK9TYDS`>6U.1XPD/1*!2`(5!)6\
M"N;[`Y-U4LIOS73O/IM&P=Y'')G<9%QUZHJZ*2$M<W-@V&13TB0F1=F>PN+P
MD(^HH5%G_,J)![/<:#0@HD([DXQLBIYC?,$ZMYWE-(5Y(SHA.[A:+B@*FL(?
M)R"V@T;)(YYI^#&&A>,J0(!E@/5`^4"TC8/=HT&Q!8CUY)N&6[GVZ.I&#IBK
M;2H[GLT"6W9K1\B2W@1#W$Y2W(TS2L;JIW+G0]T5GNR?XR2B1B$6;\O_`.+0
MAA"D<1>3KB/R+HY4MX\N4=N%04"(4ST77MG1'49,<M^C<E=5,XAL;0E+G#01
MB((`:,TX!)HP!$`HP00WXP&`P&!2&5[2OR92K2)G=*6D=GIF,+>F-XCZDQ2Q
M.JMG5J4R1[1(%2MI5*40C$2TH`TB]*(M0F,-(-+,$%3*.)4`T:0:6<7L0PZ,
M*&$P&Q%C$68'0P;V'8BS`;"+7^@M;UO]=8']^4KY?A^0OYME[-T5[P_+\6A:
M!LSX_7W?'H6_3U]/3UP/PG4IUA!:E(>2J3'!]Q2A.:`\@T/KO7N+-*$(L8?7
M7IZZWO`^V!&=S!Y*-]070=4:#A/R%TFUIB+""JN#HSG=/4U4DN]?O)+88R`=
MW.:*WU8IDJ144J;#T[<:D/"/96S0G%G`+"3'`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$'7E6;O'58MU\WU/V#".O;5MK
M4*M"?5?5_)C;US('&35TTO,(36*9/(SRVK(.=XTD>"F?7N<M:$4,SV$F`T<,
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M-%3*EK)ZH2R"=5NUM\-9#)-8+W5S.\,\HE"L!+>H/7.R(QZ$,P8]:"`X01AC
M/S'5!X:^G*Y\:L-[P[(ORA6UP@TC?^3;$2.TR:)%8\/=(-6*1_66I)IY54T*
M;)2YMY\>4FJ)"4UO1BP]06/^XU2`(?+RIUOXD(7S'X]ZTZM\C?3O.%7,=+6)
M6G/%GU)+I+*9-T-4,KK^LXM,]6+,HM3ME-<E8E[%^!5G#$G;4RHI6,)0-D"$
M`H/OY.^>/&M=W$7C6:+7\I3SS'2T"CZ62\P6Y-WB"R60]$11SJIAC*:2OR&=
MQIK5R)T2PI]3F&K"D*1,G`]&!4I-;/3Z)#)ML,/BD@7CLX/KBU/)BH@-&,<=
MF,>YOZ*8Y;239_G-!'&5R;ILB=V%?4$QJ6:Q=H]2R5;>H8-IAN)*,E0(]>:#
MYPQEUOQ/P!V%PIXUZJ_^4!!7D3,DTJ3\M="S5KH17,^D&JP$S@W32`L;,[Q6
MM&5"H-1N)"$*9H;V\E$-,E*6(5!X"=!#,76_%7&*'BCQ_P!`6)Y+W6@6>J[>
M5L/.O2"5=SHUN%N36;Q^Q((XPU,0E@:*J-F'L$\<$1!C<B2Z2:(T:I$<>$9^
MP^_5G*'%E?\`C2HFB+/\J"RG:@C5YJI/778-LRWF:;SV:.IKW8#PY5Y#YQ)H
M4EB:%S0-;BO0DK(RE1N:9*V#*4[4)A+DR@,*6Y#/&5!O%]S1&TOER45QS$R=
M&/CW5_2+;&N5IFDM&1-S3/8_+Z??(1%.=R*JES,E;G-T$K`JC)AYBDL!KB-8
M$02S`=0<R>.B^?&3X^5\D\DL#A/*]2VU+)C4O3%W59SB[Q>ZGQ^BUX1C]E.E
M>6!6D*IM*U-ST\+=C:-1<DHQL8S"-%%J]$N2<*ZOY@\:\"\3G-577/Y(>8%G
M/M<W/,)+`NJHS4G`*.KYY/I$HLTUQ@L-KB35?<5(I!(]RI9IQ(9D1C\I*;C?
MM*]`&J]0MGJ[ASQOWMXKN2:7>O)W4=:4(PR.PG&D.F%L7XP;&:V2Y7J:,DTB
M,4C#'!:Y@2=4V%R)4C.#$DK6[$J4@1+AG*PC'L+ML;FSQN0GQ(\:T@^^4NNH
M#R_4\B<6"L^G2".-93%;K=%Q$^:GN(#8IC6L\K!\5-XY&M&J$@1C>25#>)6Y
MJCU85*H07-?-,</S;P[4)6FO*]'89S.P6TSCA/;DK;^99K')Y(6F86"D,@"E
M"JA+!4Z1`WO"Q>A*TVI6]6A"SA"J//*TN"I"IEQ3QDQGQB5Q#;=\GL"D7-H>
MBG($)ZQAX>/Z^8G*VCD4M6%UZT-\3IIZHLY6TLY[B>I^1B/7[V0,\]0$(/0(
M6?/N<>(.@?$W`N?X9Y98,DH>U.CECI`.I+BC_)<J:IO*VAPEDB6TFSPY]AE5
M540XMHVE2KT4VMS>\EGMYQN][)-/)&%\RSA+B9Z\4E3\?N7DDK%NJ1DO,UWB
MG3PB>*10J>6\W2.;2\ZO%4/<8F?1<C&F6KEIBEH(*_-G_C1"5*3=?:":%@/O
MC^X&>_#_`"7D2K?)E31-(2&_"ER3KJR=\9VS$&2V@'M14FKMA(0,T"JEJ?7%
MK1*DZ4I"H3R9$2O,UI8<F&(DP/9;_)O`T-\4$"H6S/)/3D/H^L^J(5-XKT[7
MM;\:1Z-*;D@\D,FD;K7=9U[7ZVF)/*`JTVU#@D"TJ'AT+)']_1Z0:D@T+SC%
M(\3V3XCY=7<;\G%<*^8I+?NI+->MGNNN-8I"6E[%:<<D#_5(8&Y57$:"B)ZQ
M]**2-X'!B.6H#UI`B@&IPIDV@\D&C7#E-^,CH[Z_E2KUUYT<[W:G.6=3\YTS
MQ`VQBI9`8JK=$@K+_'E&T#*Z57FK/QB`"I2ZQM8YZ(<0&`.3%@3#+"WX]_\`
M&[?WB=Z1KZ(^5Y:Z<^R"U8S#;`[*L-AYW@::N+-,4UF\ML(1-1]"4S5A+4^)
MRF\.P&MAJW1;L=LER*&$H2<-5>I8W4O)W@%\A#=QEY)(UT@3&5T,:G2Z('8M
M)0-57+P-^K)C55DPR3D"!(?EE<M;QEIR&]Y.&H=`NNDJEP3(S1G:#6[P&S2D
M/_A@[P:;/[`F/'%2QSL04/)ZNJ>QB*H7U\0^L=&R&+F5VL?"I>QUXG>93(OQ
M"I*5I2%<G5FA,,T,T1@0DCJV.\=#\='=,6>O-'VAWW!%ZV`/=U7M1ET+[BO.
MBT$C>4FXG&ZC:Z7C]AR*)M<T4)#"WE"!.N2*F\M4$XI*F*4>T,9\*6#XF(?X
M^O(I(J+[T\CG1E-0N.P.4],V=/+!Z#:^A:LBI+2[DPASI1:?":HDD:;1MK"N
M^9<RIQA4IVP92PX:5,`H`4:D93XGIUPKY&[]@GDO\CW5%$.-'4S%[^<9/<EI
M2/H/G:!1AVE#M%8_5ZZ302)S%K<I*\O3B!TVJ,=D:M,2<0I,$B^;0PMOQ,V[
MXC=\$^36Q.9;.\F[?2$>JY&CZ2L&_I3-'*U8I#$M?V&W,R[G%Z@REY8F:3,3
M/MQWH]HT%V0J`(1K-@2EH]@#[>'._/$BIHWOR9\T]!^2NY?VIST]R[K2>=%R
MFUGRRSX8D2V`N_.5THBIQ;:AMC\8:L`A-CXB7H7L3C"+YM&#T'C\/EK>'?\`
MPQVY6G%[#Y,BZ^8^1'JT;[>K>?;8&M>ZND**8F*5],M<8G1B9JMYZT-W"WKX
MPT-BMP/0FB2*SA$B'L,F^)6^_%YT8AZY9>9+W\G?244K;C9OK.S-]'2:SY'&
M(=0A;:_$-U>U&@CZ1F.2V:4A+<"6\1"84B4!)/\`QRDT.CA;#+GAU@WBXCEX
M@D?#G+GD)I64I.9US6@6])1KJ=MJ-HJQQF4=?7)GC!%M3*30,N5S:6)278);
M4`S2LW2PY-L`A*PB#('`H/&RO[%;YWS7RYY(8E?LM8[B'(K*Z&AO?#/6<21B
M7%+Y<PRQ;T?,5%7HG&2NY(2FI&@2K#"U)&@!TFV`.!"/X#6ZT+E\T5V6+8\5
M=XRGYXA77\/4M3]5$ZA#W'+!D-PUTT(H_*5BN>R]B(ENH`X#5&$*?JA(+4F%
MD$'[&%66'>E@,"$_BOS>U-V_U,^<IP3DOM*OY%&UEO(GVR[0K*'L=1M9M,R%
M;%9*!5*&VPWAPV>=(DY3<`HI"882XJ2TY^B]^X6@FPP&!$Q0GEKKB^?('<?C
MM9*.MLFQJ312!XF%N1UXJ>R:%;6=N5#(CX'V:0*P7IWB,IE'PG$A8W1L3.:!
MP3G)%)98RA"P,E<W^0:2]"=!S>A''@7O6AT<+-FF]7E>=0Q6)4-)$<3?=L3>
M9&YLBL)W7.J^8"")2W)"4!AFT@?F-V6#81;"1W`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`XI?Y6MA-L#Z)\<C_)Z@CURQ&#USV#,CXE
M/)=?U6P]TD!::G5#62@LCGQWC<RU+&YKCR]86V`<4Z<Y.3O:G^P96!D_S=(*
M=DU2>-^*/6X(FE4.YAL"P6:D'[O*4<+LCY"@P:FT86YLM*P*ID<CL-,Q2%J1
M@(9WF71AW-"0$U2!0<(:A"&JO\DN%#F$"\4,S:(DQO#.DI=R99=*;"E%JV@Q
M(:TG$)@C=((^YO[95-K1M(_2)`=L2:Q4BO\`>B58G"M1`&,)2DH+.\T_6]6\
M3W%XSKJ?:_/Z"8IIXPF*!U*ZH^R.IFILA6R'Z)R![G\5GU;!KFV;#=["CJYL
M1AE+H^(U[VF2E*5R-,>0#9X96\]*>(S;J?B]"X596,TF;/P21:D=E%L=_P!@
M<N-%3-<?D[KI[(BP_F;7XV;62<[)4!+NM?E[@^D-@BE))`&T]8:%R_R"VN$1
M[EKAS42F=>-W8L(YAA315]F-/;EC5=TZU05R'6C9-G^!.C+!TM9WQ`98G8U2
M5U<Y`?'E9IRD*QN!HP1J;8:S>=5B?5-!^$N/R[;7M.+C"X$[O*.BK$C'04*2
MO[W157QYE4SA59NZ@@<KN!_>GY":AFY;LD<TJT*E8A:504H`"#<7R;R*A(_S
M+X*+)L.Z9W##F;GZ01E@?>>.C^/W:?OR>0T11XG4YGMKKZ0LD)LV%(I-$4`5
M3\F:%OVEHT1WHD4GH@F!KMY`W0+/XX/!1]R2'4X:VMM\3($D*OH+(2B>:RJU
M58#Y+)8^\YPRRYQ.IY:<0CKZVJGV+'I6EKD4P.5N)@?F3B("H=ZQRJKD\.?A
MKJFV;?=J];;:BB^R6MD=[RX^%$G%J$S,TS:8M8#S?E_<X.-BM\)(D2-J;%[%
M)$II2P`!/9?VCB`:#(/?5*TXX^&WQ14M;TGM.(5&@?'/Z>B.C?&S%&"4*X\S
MR!WB*^R-/UR0V@;31NC&%4X-@H=)5QC;HX7Y$]4N/V:8%G]TRZ&,GA9\-S;"
M+"L.45V\]1LT7#7TFM3DQ38=XQF/.-K)W,K_`)&(V&:\SUL.,C:1+$[@:88V
MH4)@$+DI,7EB/T%'\L2VN9;X/_'C&X$E;8%&U/96GU0L#VCR]9+W$U$&46^7
M)')/.*E3N]5WBZC4.GWSD<9;S36$S18#TH1E#*$%$ZQF5J.?\;WQ212$V!-H
M"CZ&NYHK.R5[U<+4ZQ"40V3J[YE+S";SDM.1AIEKK'9!^W1%F-,?3I'1I.*^
MBX:-6)C0B"R/(VZ1@SP-^'D\+D"<"G?9Z:>ESF`/=64*_P`K>2V3H=Q#8C!+
MY13%>0J$K3)*I1.)RQ[BXE!R4C_W):I4#-<3@SWTCRE35N>$SQ:U)([!M:3T
M\P7/8]IRSH>A[>X=G[G!9FA37,L61M//95:M&U$I:%LME"\H0HZYJ1-)C,,I
M=M4H+^<P-6?*'5U-+O"#X6Z00))2]H9#T[8A4(`]3+F.M)P\PDA%>NW94"W(
M$XR[EJ$A<'!T8E(`%K7,M81\)8SSW`L\W8;.>0"W/^*'\9[@`V@G^YFJM5UU
M0*OI,]5[T;3%@2;=<KS[Z5S*'2.WJIBRJE;`9'Q:V&M6BBV5R;$BK2<M<6J4
M)3!FAE!4FOOLG^/QSQ+N3.8)G:LX;^G))(;7J1%.N.WJT95'F)ZMF*2V3RPM
M-RV.HI5)URE>V?,V)H6V2?Z8B5(CE`RS!JPLCNFK.EX+_'1IZ#="M%?<PW?&
MNAS9V9!KT?.8&%"SP7=D6:EBM/Q-]8JTBM+K+<>:[>$K@C2$,R18>E2K5"HP
M(BCR]ACJ^V1`T_QF^8UK5='/]=2>!=&RB4-$AD-E\I!C%^RR-2Z_6B7-=<26
M*U=,ZBL!W=B33%30A^BT.RIN:-ENRL*DH\"@,,2MLD<H_CD<O&48R16Q9[7G
MDU?5>Y8QR7E]>CESO%)!;T5?9[$$=E5A!8K/=R5D<`D-",UA4OH$)B94K^=`
MF/UH-NJ>IDZ)^!_FEQLJ,R*)S6JO)`+HAL406_O'!SY((9+XA9\XD$"=W6PK
M'$BYYB+UIK+0DJVSV&2=.YC"/28:$K:/88UZ'=:$>_XO?0DI>J_O9UJI1VK*
M7-O7.ER\U6'8*V8BZH1,[M8Z2WJCJ]KJFRHFXV,-Q2#5HD*I4ZI#C=DN8DPB
M5!8:O\_V44R?Q9^[[8J7=@5<GFW;2U8UNQ%]1^`OFU#R1041<6]<YQ.(%F*8
M>(2/Z(XDZ"$H>D8_:)=HHXK>PSE0,7C-G_Q4^ITBZXJ>I25/G2:&2N=F6]:2
M:30']_0&?<^/4>C3%)V",2C\`O=X5#6Z/1QF2)G03/OZZ52=H!2H106A1M,2
M&V?XNO?D+66Y1DOF4BZMK]U:)@_7M6,&@\>/;9)R4\A@5CS:?LU)LD!E<0+$
MX(EC:^E(5"I?O0D0CDZQ`(X+@K:K8S2W\?7R55CSM,N6AVF@ZVI68R2=P3MN
ML9E1<4L$Y\YLL%@55[=,EKZFJH8I#&&R/)$*-G3N+N';L6,.G0T[>D98(L_S
M!O\`!!YI7AXN9DLBXVN:4C)EDZ8^^Z>ZID#0W(U]5FPO>K>I.NXM&F201\;*
MM+0MQ>AKW!8D$F(,1!^N9@7EXJ.IXC>O@7\ETGZ&:X_-ZUKO\)$Y$T7K>_7-
MS.C@S!2M!Z9+:[S!4RNSH?7:=P5DGH4<'$'VD?<.5$DA$:<<&F?BLO=\M?Q.
M>?U7(YQ8Z:&P>*5C+:_B3=T?=)^X;5*!VL-8PPFO5<G8G-ZB]<*F:'?@5+H0
M2)\D;>68D7@3#(+-$$IO@^K*/6[X_/*'5'%J>KG6O;,JB+0:JZVCUY=E,38;
M9TPKVW4,V>))-;QK"!2JM13`IY:VT"J(D*D!@679HS@F>XX89QXEXQ\D_$_&
MODQ?^GVR`Q!N.X9G+;3\2CW7?1%O-1<TA-6V&:O?3VZ7S(3!6A2I`4B+$X,B
M]O6D&!]"1DD`#\8<Z_\`&4D3VNY_\WK-(I6W-L+'X[W)$O7/JR=GNK/I%'+=
M0QLQM-@#DNL-MB#"CD+F)44P-"QPV:K)$E,)/"`E4$TO\?GG*K*D<^K)DR1V
M!PP,RXJ3@LF*4I2'E28#&I>+90G4LQ)UTB8ZPL:0"3H33TJ.-E"D&U2H\A`(
MM"(\1X:Y_P`3NJ*WKKM+I]?13AT'-*XWSE(6.36%=G.VZ>,T^MMTQ`R&,`A1
M^Z[H8$,Q4-`758I95HF9RV@TF4$IU!8CSPA5OXZ#9S8A\JG0"F@+'Z"L-<O@
MUY_NYTNSF"T:F,/:Y3.HA(EK.-U0='6;7T:>6*:LYI12=^BS(YK46M;+.TJV
M:2(-D?!5(H:^^0]+7E647#ZMAM`<]]BMYHY=1EPTMT$P)[.ZRBTI)8):HD?3
M=U-EA?FW41@TZN0H25[0TM)"9`;LL\PLD.T3`_!NC-EF:)$`!NP#T4,P`C2P
M&;#OV",+"84(P`1>F]AT,.]Z_3UU_7`Y`_%+S/%:=\HRRR6:D8NTV).V+IIH
MMRV8!P1Y(:-A[FX+I&U2E:I26QTET#8E`)?SDB2%[T6RMR@M9H02D9Y99@=[
M#K_P&!Q`>,>`P;D#RB]PV;(JPMVP+$K"']I]'W?9"#BN/@:W%AFCTU667&N?
MN@*TZ@M"*2I2]+VUP2,S&X-"%T6`,,0[$B5IUZ<(2X^-;QF6GRGVM<M]2M+Q
M.B@-CL%AOD&04_7TGAU^Z1V'/4+XP.<D1*4S6AB[,3%TH$#ZC7+YD<X/Y6U2
M=>C+#I+@=!V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!
MQI?R:8Q6T\Z]\?4.N295K$8'_AGK63-K-T%;MP5S05P35O202/,]3O:ZKRFY
M57DX</W7I:SRL*Y446H3@2.3>>B&$!H9O\Q_.O==_,WC;9.)&7L,@":B+$9K
M.L#G/JYG88B1$'&N:_?#8//K)>HDXOMBRJ=ZB`4,>DJY.VM;@N4_,KUH1^Q)
M0P3YT>L[PXMM'QT0I):G1;'7DNY8EL5L*JX#WE"^7;29I]$00D]+;4ULO<8G
MH9Z[LD<0/:-2M7(5$54.A03CC@!$("D,(^>?IYLYY<_'G$P1;IF]X`]\91F2
M/C?65S<O2%VU7L1TW!D<]D**1<B7]HR3.4?V`\^>Q]4Q,AHR/5+HH(-CP)0_
M*]PQS;TL/EZXKG\KLN\;S#77-J]AAS*UVU`:LD4T;1"CDG<)0YR%VE\/62P,
M?3)D1*I&A1#+^?XS"AD",]@PO_R/)N"'MLY]LR6>8.:>/VUI)RBYQ:C+@K"Z
MJRA[C;](RS]J2-+*WEJD47<91,XXYO;>VN"<30Z,ARDT(_JJ`&A$86%O=O\`
MF#D_C^K?@F+595$!\A,0Z!Y\4/+9T&HZ+8J\*D*VMH/'EG^9Y#'%T;M1]25*
M\HMB>WR7*U8VMH^P$M2MT;O1HPT4\Y,Q=9/2/B?M&'V`P<71)\JR6R9))J)L
M[BV10R%R.5,-`2^&5O$E5R7ESW$;)K1A?F0E24]17:IN`%O3*]%EEC3[$&&?
M*IR#TQT!XD?$K!><X)U+T=&(2U.$ZMIWJD542V8260'1EG<XW,):Q5V_W*T/
MC]-Y8K=#6]V875]9D/W5(W)484H^<(;8=X5/U-_\>OB,KF5\?='71T-%($PQ
M^W-UIS-Q?V(_55+VFIHRW/6K`5=-0FTXO%G.1R)&$6U[2)O:SQ)E.E:WW$H4
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M=I5.&IS_`,+=(SI6KL%7TJZS.R)Z0%<RT],S'.3N^U;?]]X0ID1;H%.X'F*@
MFF:"1*4\?4E;WB?\;?/M^]YM/&$2BS[)2E"^XZZXRKR=6!9:-OL1.E@;+&S7
MR:4S`WR"R!<H.,2Q]6Y+5C60,M2I"K--/"&7+"X;Y?LOA[C&@DWEBA;+SI$Y
M/T*CK.Q38IQ1*8[T(E4R.3J&F+-)LWASU3RMWH.-I7=H-6L+4%:N++6'G_`/
MY=!"R^B.%N06KQQ\4\N=%^6"NZAY3@C];,7B]@M[=R7#XOT<H?9,_N]4DM<B
ME#"\P>,2BH(.->B-718E*:M7J5"P1B<_1/H&+O)!%Z/K[Q+\'U/&;WC_`&#7
M$A[#C]543<"N-</.=%2Q9)GJ[DD#:[6E5JUQ8-'P>OZRCH%$?42-A93%YJIH
M_P!PLO[2@``TQ[`O>W^:?`'S7(81(>B>7YU87;$F9&MAI2:\Y<H6?)&"026Y
M#-D1TBFZPB\8E]:O+T0F6EGMC.R.BM,-*XKM"2!-T:&Z9G3T-KK^/UR7<?:G
M/-5^0D;A('IOED1[([)YNE#TXO13]<KD1*6Z\[(;7^%SFTFUI9?QZ"/,^A2-
M&C4#0^[9B)6#87?>_<?+[;X:N=+XD7C-X:=*1?;KD%=,G'5M="<TQRDHLZ11
M[MEN*D=*60"NI+3TY?Y`Z0XY<EVB2-@CT#BK4G*=!`<(T-;^G>A1==^&3DJR
M.:^'D5:UNS>1Z)U78?+G*[;SO=:1PI^M)1:<*L);S_.3ZU55X@/E2IF3E-<H
M:VY`;]A0(&E!J%0,U0&PG.;6JY#\/SU=CISES]T;<[;95B,+_5?7$UX[YNT*
M+QVX)9(F.N'V0UD*RJ&<;<B#FB*5EI'$Y$^+WH9PE0D2@HE*$+PD!37W7X/W
M`J`<%2>FHY;MU;<YCRKP\Y\:]%NANFZW-2>9R9O(GP&:D"T\HES7M>M(*(`_
M-AAI:D!7KHS>!&YTIQ+;*?P4].<K5EQIT15KG_SXI9PK^M;*B?,U/S&U&E8Y
MU&B<'R1DT$K<ZC41T&T@DXG]4Y`+/<$Y.OG^-(!,(-R.0M0OE;P?]!1JSZ<Y
M9N'5,=&.33:G//8/9W-4VY\ADC=E=4KVR#+;5@U=2^H:^4,A;^V',<76D+G`
MMX4`$H<@GJ_4H,;=`]P3%#X*^Q[7IKFCEOA1?4'0%9QE$S<KW5R!?5+.*J9;
MI>;/4H]$]9.]33F6(5\_(;'J-?C2G96J1"TC7A$4$S0:35<_SBU_X^?:<C26
M!6#K8/3_`)'J?;'NP8[9W)U>((ZRR&:<OLZ:468Z5DTL5:T0<I96$2Q6U.('
M)?'T2W1JK1R7Y1"#85\>QU'X*?(183-=$'Z$?*YO#FR92*9\_=L\Y='/:I-$
M;%H-*(A]L2I.,Z[CT44)FU!O6FA_8)*M,0E"%I9HCX]8'MI5'4T\\1?F79K!
MOBG)I14DF,*8XW/Z=ZZHQGK)^.<VV"KXJ-O1GTFAC'+;E-Y<YMS,N%*(T)U<
MUA8Q;`FTF2J-!ICX;ZDL2<^,/R^<[<UTTRV/<4G?^2VAMAM(=HT"N;Y*<[?^
MTN<G;+$AS"]1^)-;,TQY4[/"%T&X)Y"$"Q`4$H8E&A!T5(J0['Y?\>?D9D/7
M71BF.21YHA8LK^?1KM2P'-IJ`F'UQ(FTY="9BJY.K-'SV#3LI3#*VP19_,4&
M!#L0-C*)`((OO"$\2JVP^1KGZ-=5BZ\D$YXW@86%[7>2ZX+T_*SU\2VG$I`Y
M(W^64!#9%01JDQ^:$*]R1Q1W,;-ITHB/O`WHL(264;R#Y":VJCMBLWVJV6/F
M3WAR3U]0SK&O(5>70ASM=:Z+2F.1B.A>K?AE0G5$H92U"/6W=M:RR`!^(1:S
M6BM%$AKSX)N'_(MXY*YZRE_?8?=^-IME65N[1J])YT"K=5,6/LV<S1RD52'2
MU1'7>>%%.;4W)UC>H;E*YO:T[<5O0="4F!5O!OYB[S\BG4-OT\^VA7]XU57U
M,.]@N<U;>3ICR_8$2F@K$B<8@[#)$"N\+DAKNFF,77O"K9*8X"A*)I!K1QNM
MFZT%)\=_F]G/379M[5JX7)5MT<]TW4W0]MS0RMN)KYI^T80T5<OB`HN9)'AR
MMFV8A*'J1:6R!*G;&@H]0YA:25!!NCU(T1(:H?QA^5W2OKFFW1LEJVVD)MM4
M[,U%<VO,:%ZAA;%(ZPE=BQ.6L7SV99EK$TF[.;TE+(/0(X[!21J4!6U!:XD.
ME))X=K6`P.#S^+NXK5W=_3[:MKR&1;9,:ON3+I"C:^RT\R>Y$7?3(S&A<QSA
M_2<H,Z,YL?/F^DSM.GP1>D^]:)^%<'0=X>`P.'3^.BQ6'6'D`NU.Y(#$U;7T
M1TW8$0ELCHSI:&2BQ$CY9$$LV)/!4IEJIIYZ;$3_`%]*6YV`E9F9*YGIOB#O
M^TH[>PS?X#J_B$*\A_3KTZT(DJ60R2(W4AIN7K*\\@</G<ZK9QMFN;)7MDU/
MZ8?GNEVXINC4OC#FWLS+HAQ2_DU!X=#*/.&(.QS`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`Y5_Y'8.=0ROF%=:,SEM"W`VPNW5=*=*U
M#VY7?,%P10DAV@:V?5Z7!;-<HY')Q")TT(22QNX'("]I>`(RTY!P3SP[#I+Y
M]>6F14+2,@8)(Z3)B?:BK9Y99>]OZ25O4J:7.&,JUMDCO*&\E,@DCH^(SP*E
M"\@LLE8::(X`0A'K6@]5AT725NKV-TM>GJMLYSC""3M<;<;"K^)S1='VR:LQ
M\<F3:RJY&TN1[6WRV/J3$+F20(!2]&,1)X1E[V'`YA/Y#'C=Y@[7MGD]!/\`
MR8\T>/\`DE55A,HXQU1<#E$&(F?P&1O[&%":PMQ]L54Z-483#BRQN-^'1R4>
MBPEE;*&2/U#7+^1%:,PIFT.*JD3SRZ9-&K8Y+F4,3P*L.@Z!YRH>7*("L9"I
MT\O3Q?[-8&GA5,V.3MA1!>G%,L0H$!(D:I6>:IV6%\>5O=:<TNWC;G&NL'Z@
M+\J3@5UJL+A`F;A*7OUBP\PFH1Q,;M&^M;JAD2:F1'9$&,4MCDSL+MH+F;K:
M-8F.3@"8$?OE^D#DXT/X*$+C9LEHI:U>/MZ<Y;9$%M3G:H75TC=W1/G&DK2B
MK<O!*8]$7!.K;I7LU<ULJ<;*X,ZI9M+OZZ50,@-V?)!R#1WD0\4/A]#8W?E1
M<+1-DJ*-O<-E791E5N<EM=K/I^#A:@'2MIE40BZ21H8^Q%N*Y$UJ-HE.EP2S
M"_<07K`S%V;;M9<;<W^*ZG*B[(O,A]LZH7)L:NO>/+NYDJ2F[(A_)E615"ZR
M"30VW0S"FG2+/&Y.(Q`B9MH24Y@E"I:L5;3?":&?;TMCH]B\>_CDG+AYR*&X
M5LB6Q94^6+=MQQSF6ZVCJ$;ZVM+R5^VWDI[(KUR'7J!=O8S8R:>V+MJR=&*0
MZT2:8&3>S+(?7/ECQ^RR&_R`:AY.BSTWKF";]8K(5SX]I>VG5OC#&V+Y7"R'
ME\006)*V:1LR]2M3-FS&]&-UV6>((TY`3`PSY1KFX!A?CFX,_P"?$7>/,8RV
M':$2A].V]73E"Z\9[5MO4;D90[*7R^%6)":_BC,\MA"I$:E+<U2-1O0OG"/1
M!QY01Z]R$.$W\:?B%NOP_<,=75:RTWT3;L@A)%-P.*]!V3SA!71/8->W&@-B
M2R96HR3T%S2YZ/6-KDX&KVQ2G0C&K-1&*4Y)@;)^2&Y+PA?B3\>-FW3"WMBL
M`%J[:;/C'4O#G&5N3)E&:PV8T,SW,J<D[A"*OJ$:AM2)Q:'%6X;D4VN`"3P$
MF;4"$%J3*`U=%_#_`.*MGF,LAM7PE\N.R9XDK^6\$<3V^[S!_LUPNVQV%!&*
M+M"VI#3E4)&%5(]C`J875U4!*-1DG)TNCC24X?RT9U-)AXOO'G2<O)+<&R];
M,Z>B$@K":\E>-6)0"85U6LKG<LB;I+81+KNJCG.@'^+0MD2N;4EB\E*=53B:
M;\HQ*2]C$'O[_H;H-!XD_'_2O+M9V3<W/1,@L1UZ62\7T#RA*90OKU6VS5XA
M<;2\[0V:VYSM*FAPFSX48^J&=?(P[<V?2\2C[IP]##./5W.+_(?#OP%0R'B7
MJ^2@A\]CDQ7T8T<R<@6I:4"15W&;6?@+K8IX3O5_.;"JD3<K,,+1I6U6)4XK
MR6M2A/<EA@1A&;Y'(I<E7>%'GIOO&"6?&V*M/(W;3:II]#6_+7#4XA,511J^
M?\*NL70P)!/:7C4?B=E(F]_,4Q?["25)UAN]GE@/V>6'QZRH*V[5_C,\'PNH
M>2[3O)S3]B+;$8N?86XI>G7EJIW_`"'T^[L+9,;0H-I;7PUG30]U;VQP?&DQ
MK>MKU6B%9I!QJ@G0>3LCER^R?XMWCSJEJYIM*16%4O0T<E=N4(^P%^B8F%M;
MI+T4HE1%OM*9G@DYB\23.[VG1:="5K8XGC7)C3'14-0)0I#)5N4)UTN_C2\;
M4/#>0>BQ=&0'H1C:I!S=,N38Y9\X6L#!*K3<7X]2Q.-?HS:T@IL06A4-$HVG
M"_&`"F;%+FI5+E*PX*').7ND9!_'1XFC%;<A]$)>FJL[VB]LK(*U\P0]NMEF
M=MV':9LRLR*5(8S(6!!$4K-)!MK6XRIF]C@C+3C<DA1:@)Y02_()SWQ5?A+*
MD=8TEV;"NL@35<VMD"8ZSY3>^HFJ+JK76(S9([0*)4;&J53@>8B3HXTQ##79
MY1)58#QZ6JBS5&!'QU!<G=T6\)%V7EVS*KM9)B\=YP%-(4?0]?\`-[`JBO.1
M$AA4*3+F"KYSSM^(F,'<W@C;ZV-W[`:YCMR'H\M*$"48CPP4IBE@]H?QENHF
MCF*J'RYI#8?802X%#Z!KFCM.-K1.$775F@2U^KVAZ&IAPC2=T:H^8\+TRYH)
MFR,199BI<%*()!05[F918?CE_C=])3/HKQOPD:AD[%5RF0<7]91EUCL(70Z=
M3RFV6(K8VW6"C?IU.4S`\+$0F@QZ6.SN<K0'``K,`F3D`#-?*G?37</AA[0Z
M,1^)SB6-SZENV8PP.W$I$:A=.UH^S)C<>>G1-8MF-,_;FI*GM&,ZD9YR81R8
MI2<-F2E%%^H1@V&:F[I7HOR2>*[OB+1KQYT@T6T+HZLJEA=`\\W+S#<*!V:9
M-)Z<>`6'/I>.+6_3P9!`27)2K<W%>PGDD$-HC0)TQB(P\H+6IRN>YN,_'1Y2
M99W[RY75V*&'5&R>O*!LNUN9VGE.>M,:.:U;V_Q\BMZ;I"`P%/%W)8D<7<"]
M'I4]/+(7H@11PPGG!8];]NL]\^.SRFNCOR5SOP#(JZI;G$IT<^%>WN:F2QW2
MNK5D,Q?F=:_W#7T4DD6J4Z.O;X^&I$CLG-6+1O3BWE$D*A"4F!97BVG<LZ1X
M-\RT$I]^ZVZN7KH#5;/7K3).]V_H2TIK*;"I-^)<X_$+O?*HA$.JQ]6KB2T[
MPG)956FX).BO>=M.1O82D^-'QS]J\2<]]:`GDI3SV[;0J$372T84]A6=8C,R
MRAO(MQWC,86S:2T)"550K6M7,VAJ5/D>`[)7(]$8[[1)U6Q_9#33A#G/RI5!
MSOY)KV\I5@=%-LF2<D22!5C(D'6CNZV0C2PZ+RV92R55ZQTJ5;L/KE4VNY:5
M.Q2Y"@52I:628J5,_O.,),#`_A`OQ1UPY=W452ETW1?RAUX%8$+_`&S:O<'6
MEQ;+ON5.EJQ*/I27"RZ-YZ45(_KFM<7M6Z0Y&$*5$WHQ(CAJ@*A@#;#^/WXB
M.W?'19G0TDZ_24`L;;>IF%PJ%R>BK`D8I9%]1Z=362N43G*0,$A89V_K=S@2
MDF8.2YXD*0*`"0*\U.9H)(6AX)O$/WUX\.I>G+UZ1#3Y,.N>N)PW,8XI=UI6
M),T+Z;9B.:PY%849-9F^.V1ML2+WD8'QP6N4C2!5;3)U6BE)Y6!N7XW^]>T;
M;ZI9*%ZPMKD^:"E5*6I8+7$.;N2>V:E/CBZO)E7+*D<'2T^FRHM'')K6M,T$
M$:!$T&J=*_:'Y2P`"-2'0;@?S>O76]>N]>NMZ]=;]-Z]?T]=;U^NMX$"GC'X
M+[]YZO\`F=H=:6XW2VO#&^W&ZMXHT]E]LW>YMX9;8+2OCATPKB]Y+(::)5ZB
M32(T2YG^):A4G:(*]21G:T$]F`P.6[Q%J?$<@\@-\Q3C.R.OGV[VEONXE/$+
M?%*BZ321EIM9$QVDM@!R>/MH7W\5/$@4;:?-52EX3-VQ$->@I0&:"$LO(_BO
MY^XPO"P[XJVPND)'([$9Y`R+HQ:-T.\W@S2EDDM*EZ]6F9SF]"XR5]2*$Q"!
MO<Y(M?7)L:"=(DAY)`C`C"2S`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8'C6.+>W[2:7KD:':]82W(=+%1";:UP4:&).A2?,,'V%AX2A;`
M4#U&+0=^FM^F\")+R3>+B2>0FS*"F.NFA5#$*09;,"&`'\]4Q<A#S.I<PFI8
M;8")\LYJ<SV<V&2-,WK%K280L;GU&B^J(*01HU.!*K#61?&HA%8XZO7[C=&"
M-L;(Y2'3.U1[\\O:FM*A6/7X!B(2LC'^44$"/^FC++2IOD^,H(2PAUH+DP.6
MGSI=\^.?C_JKGABZ[\:T/[1M5\IN13"+6+/R:(TRPNL(W()"MD4?8?\`,:M2
MF?)2D4M:M8F:AID>EQRLI.B4'*5`R0!:_F;XYZGZ:N#E#JOB])TO`E<`Y%E;
M,%PYPI[F.R'II99A(HC,&J%MCI:73U2Z9I&`AO*`1^VF]Q%I,$>DRPPLTPC8
M:_\`GDD+_!;;X"MTJ]KUY:MQNY(DR-SFZ:I..;.>YNX(9;4]BML)MY@N_I.H
M$8U\%LN&(W98`AI=6)*YJ0F)%`#OD!@?#OOD+O=RK#Q0N_CGB=_/,KC/CN+I
M>23ZNZ]Y%2$D$-S51]I5LSV";/;"W6U6+2IW`T[F2KC9RPIO6)?:TKE)FPZ&
M'Q\UDGMKF7@SPR\H([-#ST8^Q!DA]PQN<57SY?RY*KH:A8`Z)%4J@UB.":HW
MPV!6&D(VJ6('@H"=:H`H0Z6B`46(,?\`FHH?HRZ/'9X:$'*W/MK=C-C36K^^
M393S53S%532O+FO.T9;$,K5HJ0`[OU)I96Y2%<X`8&!3^V'$!:I$O&?[$0=A
MCKS>47_D7B#P=\P7DURVM9$?5UD.+UI95G*E1V+%)15535*\22-N(I5:%6TE
M6A08*2_#,B3.^)BY`_I&A.$&C2"R]!2_)=7L$Z%\6'A$B+$NAR%IGT?NI54Q
M+'S?2%,0]Z+-JX^3M@7`FU;HB$,Y_P!JZZ;W!6,A.ZO:=_DVDQP=J!EIA'!1
M?+(@CE@?Q\_$K9BL#:_U='>BX=+U$J8:,8:VK""T=(B;=:(ZIL'G&L)*N("H
M:8VZL[.K1L3X1I4["4F_:"-5K`W/LGI>5<J^&'Q[0OEB>VWQ-<MR;N4^@%-?
M\V4!0M/2N<Q4,_FR6)]"L_7UV3>,TQ%K7&>8])U_[L4NST:$Q80DT$S34$-A
MKO\`'3VUY8_%/XV*YN6VN<)W<D9GA]P]/6)=#6W3MM=E)L=M6,($D$6\RRPR
M(RD^*FR\A,/35(FE`]?C2#CSB-:/1;"4[E_Q3T5!N.>-.;.MJVH3J&5<=Q23
ML$+DJVHFQK@B1;*Q.B!W>&BNW92]-`71TCBI.4O5JPGG+7(H;AZ%*#/4`8G\
MA7B:<.AZRYKK#CA9R5S+'*+MVS;$61RT./JXZ%K]0FM]+(%$VW&JXEH`0]K7
MN,JDBIW4E;2@TM7"),"I2_6T$X-^N$><I3R7RA4?/TXF,(L*8P%%*-R>;US4
M\:HZ'RE^E<YD\V=7MKJR'"%&8H<O6R09BP"/19*I;LY3\9>SM@"&D_FRM.65
MYS-"V6!73U/SU.)[:"9GA]I\KME$/#RWR=LBDE=6!ALINNZ=P(2RL'9W*)4.
M),?5:=57T0IQ#`G.-"8'.CY%Y%?DX\`_&\^Z$NJ86OU:Q^0",#BG0$\K6N$+
MU7,F:I]:$)8G=?6E?/<X=9LW-4-UH:7]O-$L?EVS25)C<#6AJ$P9Q8>VKBX(
M_C5<$7S![&N>'3:06")FDDKC,"Y6D<P/!.)_=ST\M:F(V8J<H6AC*N1E`*2G
M(T*N4IRP)MN21*<-R^N&1'CO_L:+^"'D;JE_N2WI_<W2O3;ELN2L9?'P;+<*
M:FUCW'NOXL_1^VZED%4.IJ&.-+$0N*C\:,7MZT0#"@@0IU`=!X89V%US)?!3
M`+YO?IOK=NZ?G74EIHHW:E%O'%\0FU:*XB^V637$4NI+9CY4U-RJG$J&(I5D
MD:D"A(YK#%92;W%)`FA"&.NG_(+U93'@8H;K"4=C7C;=C2ONV)QVQ+)B+70_
M/<ZM.G0S":II?4<'>ZLD-CL,&9%D<B1I:&0,IRA\+7%Z/-(+1Z/!H,]0+I?N
M"S_`2U7%7]O=).%^SSJ9WCC1(ZG>JSN&[:QIG733FU**Q>[2MD5<1U4Z0>LF
MLQD5R]Q5+#QNOQ'[4&HSO]H+<0]H%4=XH.T[5ZD@5@^2:`QCMI\A&Z,\AUR<
M6L\IC-:FQB)S"+094_0J<7K!I[,:_:R"7`3;]=')'%R4'J$32F()#[@I<H\G
MZ4K^/I;'9O(5"1GQSA8+KC,;@E?\H7#RH_[3'R-RKY6H?'@`ZS<XJPOLD12C
M0':+CC?[T*((`H^(LL>QA#6)A2>1#R5_QZ>T$(I7='9=U77VS`HK6T8>`LC/
M-6NHX1*^>U+TR?(]5[5#5&VXA8V.BY2J_"-Z=.$S:O9?L$<(08H.Y3ZU\?O\
M9KR`U#TS#IQ6?0L>Z:@MCMJ:1V#5DL8?V@MMFC#F&=P*4LCDM:7DER=&]T*/
M0G*W!_4N*<0BDP234Q6@]/!4GAE8>#'RW79&[ZZ+BRU7U17K9+KLJ"S6NM+=
M420DR@6)1J,/LSHZI'&K6D\^8:;',IP:4YPT0%0$QY(3`#V%VT%T^HMCPL^<
MB7Q"Z>Q+>10F*5C'6:>]>=H5]<KDGG#G"&,V0+JWEK$PQ6*1)@)<W5*>)H+6
MKU#\:`EM"$"SU),#6#PM0OJKJGPD>:6HHJQR:\KHEK56E:U_4SG*6"OY(F)5
ML3R^N!J%:XM@G$Y0>S/0W!,D<?B3R#:(+<G/3[--4`#I-_CK^.J^?&O3?2E+
MWM%0IUCI:4"?(79R9;%2&^UXONJV`P2LJ)LJMSD$86P1X7*8^HV\*S5"W:`)
MA(2R-`UL)B.W53LBXYZD4L;HD8G8N@K7TB?%UO[Y^3LAID)>2MO&[R^@Z:J,
MUK+'L\J1;3FA:32PJ1:UHO>]!RE^+M^3=`Q_R2\P4HRCLHZQ_'PVM8H:K\N$
MNZ_C4HLASC$CK1::.7I:P8&&DI7=CN]+'.1O:42O6W`[YD*<AN,`6`,V>,/Q
MY]G>,:FN_GKH5X@</B3MX_X*\QNPW6T)&AJN!3N*UQ93I(H/)V2KG)3899U#
M)S=)G^?L2Y`X/Y`RE#8`Q0#WI@QWX"5O5I5U]9]`]0W]-)NV,O'T964Q'7(K
MR2J^>H[$'!RU,WN8I'+LFOF\QZ7J0Q]JT$UA>'9S-0_<^(KX_P"X06'X,'+L
M:^^DK(ZVN5ON*/4H?Q==KO7[O*)?Y%5_/TDD]@67%U\*E<'>>F7V5%/K"76;
M(><C-CCB0[IDBPT19`Q!`,@-A_X_<3F,JO1XO4N+&[KF34<H>&>RC*K\IL.9
M9IN8,U#B2'U_:G9]WV/5]PQ`;\ROI8?5M1/8R421U1;`F6K$R8.N/`\;@6K-
M;UQ2`:<M<:C4EHQJ]*-I0*QDC"G&ITD.3JMIPG;UL>BS`&>WU]H@[]-Z#B,\
M!;G5Y/DAD4/:[-(G-DL54WT:\C<ISW[)%;JV)[/1Q_2^-1^]GET@\3;(XN:3
MF[Z\Q2MLF/1[3JDOW-*!J1AV_P"`P.<SQD\E>+7G7R(=/3WD6Y.L);T];#+:
MF[GB%O1JTR:P()56PS2F7?B)7,J$@S(Y/[+,Q%A1!U)7):8A/.,UI06(P_0=
M&>`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!2G1B9'L36
M-Z9FIW&QNJ=]91NC>D7B:'M(2I3I7EK$K)-VWNJ9.L.`6H*]AP`&C#H6M"%K
M857`8#`Y1?+C'NHFCR@,5X<[QFSF1C@/CE6,UAV36O.W+O2[M*5P;TD\GB%7
M-\9Z-LB)HH*L(4)C59[XC1+CB"5P/E3G)O>:G#7WSQ>83MKQ_6%S'&*/L.;U
MBJM'C9CMMV@3E4W-\I1-DWCLI.%-?W2YRUK5+Q.Z:,E&)5C<P'`1IA)PF)"Q
M_*(PH,E^<?C:@N]4/!,LN3RG\H<4VU&*3)?XTV]`Q*ID[C?>I^9!G1:].:>6
MS^#J-USMR8S]'L(FUP83%2H83R?37LT'4;SI&F*%\_49#HO*HM.XW%*?K6-,
M,W@[5'&*%S)G8H8RM;=*XDQP\PV),T:D21*!8A2M8A-Z=,<`M/O9(0;P.5+^
M6;+^<8<C\?[MTHTR*31)%+.A52",,U.16V4+LI'%J[1'EN^W;H_GI_CVRQJ"
M#4PD1SB2I,)%LX)8B2@'A9_D:Z>[7Y*XE\1,?Y6Z6EO+<L>N65CA(8VBK;E)
M1$I+'H_'>?XS%F!_;+WO-\TS2J&%6$CT`AE?Y$A)0Z<UZI5I.B^<(:U>8F]3
M&+GSP07YVTRCZ$:Y?2'0)UD.UQ<K02\D[M:UBP.D'J,O+K4-<=&T95AKPX!3
MG!0!12$P@A`6:J+"H.#Z`#S>0^312AN!_P"/Q,YQ`83:<-*KZXXVQUU/^.HQ
M<K$G*LFL8,^UX9KG&UNB(NQ(G>'L*(EN`F=)<N`B"8:JU[E!!(`AT+\L^.;D
M/LCQH\#PWKSG*"60SUG7@)S`X(MB\NJA@KUQG>EJU4SE5TSVM,?Q1S8TK24*
MA"K?'I,!0F$84(.O9H`0]_R<N,DM/\.</5-PORQ,6F'T_?MNO;.GY_JY[G+?
M5K78%?S9;(V$YN87C4B8VNT9A)=GF"+*-0AVB,$8(O1)"=0'0UX:8O+X7XM>
M'8O/8+)*VES/0L73/<.E[P-]DK:I&:N/+5N[B9Z&B5/R4XMP^$80&)0JM$#`
M`1>P!"3+`8#`Y]OY`U#6]=]9<>CI>K[HL.40'I=XD"ATH>@:4Z`G$"3/%&VE
M%&B3J8Y?3^T0!-%$\R>FL3F6K+V!6G+WH"I`I+3*=!%EY`N6.YK)\(?.]:T_
M0MZ.ET0KNXBP28B;R/S=5MNU%7\7>;6:6!]EU(\]+'*N9",MU7H%BA_AC::8
M^)U05AZ(L@Q1K84GJVO.MZ!\$WB<6,U:V3#>RZCZWB[LE*5UK3S/:U3GSD'2
MG[L<&NFUHG&EU[N\P&0&)$C*[C)),$X$GJ@)G$O99(5+R3R3KVS?"CX[K7BL
M5D#?UQ`^QHXN0R:2*N9ZXM6&&MZ*]V(Z1Q^-5B_L?/#?))/'=IT0H]M(I$!.
MN%]I#I64:<6%P6ZR=F=-^*[@B6,4$ZJM6[*F\@'[HEI=7LGC^N2[X(TM==VY
M"6^1;9H*P1_GZ'HF1QFR39S4[-1S@G(.&6\J$^C"G`D,[WQ2'=MR>+KGJ%6!
M0'5]NW(E\@[8NEE-;B_%U'W('G<"*RHQ*6)]G5/$L5/UW&)C#G)6W'3F/[;'
MOWOH1#W],P[1H;G\O^/R:W=XH2N3[SKU7S#,G"\+)F:./W;5_*G5\FA[.V=`
M2&40`<K;Y+$9K3EMR(5>%HVP,I<DBA[6%Z"N-.V?O^X(\/(KPS6?C6\0K]64
M\Z#?2P3'R)P7H`Z[*DJ'E6BW5BF#TH3&M!315$FD\#I]K*C\:@@"1IX?^(4J
MM%;,TW[1"="CPU2NZ>PM=_'=NRT><+5NHV?P+R(54]4+.>J)[S:IN9DON"V]
M2S(UA;W&E$,6@$*6,[.G5GH&N1!,7MK<$W['M;]HPE!T!>!OHBZ.E.+WJ87I
M.I'84PCUPR*&DR"8=`\Q]$R<3:VQ*#N&TKG*.5H1"H.P%DNCJI^NV.>G!_T0
M(*I2IV2I3E%A\_Y#ET;H#Q.]$V=J/"D@F9\I5.2FTTU,_A0*W&Z8&E;W8QDN
MJN+9@CD!$X#*_M-8E:HD0M')Q$&E!/+#E,I2TGCJWP-><ZT3+&_/2R\NT:Y?
MM2!PL2JJK-E<SEK'S4G<2)>^/M;4K!MH75W^;2E-N/L(GDQ.86F-VJ'I8,-F
M_#P",<%>(GR]LC\V<M]_!I&[(M()+"2;OJ&3<N6VIED(J\;2Z!DDQ8T2%#&4
MPSB/D`\EF;=7=@-3-@0J?3U#==V[]K[IOQC>3>PC(!3WC]L>"M?,SC:D^X3\
M@G,+_8DK7R(Z*1B%&.]^5A%%S/7Z\#/$BXJWH'+[SBX(/E:4)A)^!G#^-=;B
MFS$';"$%N=`V^RL$BYS<V:07YVI_S+<5`I76\D4N[O'W<-65<G@J=Y<VP>E2
M5.4L3'F)@%%&;"B^0X.EV:11MG<0D\*>%;\A:9:P.T<<EL7D3W$9(D0O*$]O
M5*&*4QI<V2"/.Q)*@0DZQ$H(4IS=:&6,(@ZW@0O2CQN\]\*4OY'^D4O1/4SL
M\W%R-)8=-;.OCI*2R&3U#7U91"Q71F!6=V@KV;7!6[<RFRDY0%0`N2&HCDY*
M@A$>:5HL80F^("R&BR8CY#:Z#-+/FL3!XYI&HD%C75U3UQT\S'NHMV-%77<N
MJ_H7F"K&Z/RIM2HQC<R(_%G5/IM"G2$)5)AJLD05C^,(MFM=J>BJKM3I^H.E
M4;7S\3+$1$.D_>-IKX_&F-\2-(V"<HKD98_S_#4[(WN!:-/'H_'@2Y:D'H0M
M;1D[T>%,_C@LMH5CTS)89)>AJ,M"`@YJM5^B\%J)=Y'WQ1%"%5N1I='VPJ#W
MS$(;SE7,,C$<!])M;F=I0OAZ8:8LD)HMKC#`V:\!7EE[V[YZLL^G^F5E`$U'
M6_.2Z>01#1%;J&50I7?YJ/K6/:LP\N6RXRF)*D9HTX[30I\)87XU`(A7]'91
M1AH@ZVL#^;]?3?M]/7TWZ>O]/7_3U]/U]/7`Y6/%CVQ.[J\E-W((Q$$T+K[H
M)XGEA7VX/'*G8E?/<PN6M:XKF$5PD9Y;;CH]5Y6!0*A86Y<L:33"C7(0-&I]
M!VH+()#JHP&!R[^)[JCQ66QY"+WB?'->]^,-]R,R\Y78\XN^P;<=^?):L8)\
MT-D\*9&"0WW-H,H=TLC6E_BA:CY2Q&D":6`T@'J5L.HC`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`Y!?/=4?1EE=P4^FH7@%#T
M-'_^-B=3:MNZ\<E!=9.A[9JRI(WCA#/:-TS2()F^31IM&6I11TLXLS1;L8J`
M(6A"V0&LW\H6/77.;IXJI=$[.$+Y!C%;QZ:KX*"0<HLJ99:Z*5O,?2MQ3';4
M^C2@H3=6!*I&?^7VFABDKU1`-4&G*"=!OAYKI1T4W2*F8K75,,-]0EIYJ0V(
MT166<V\.6TWP&V(=(1JDD^5.]XVK"G)I6-S8E3F[;8\QJ&?1"0X\O9Q!2D@H
M.C_G1M;F;GVBVEH0M#8UME/5FA;FZ/L,7BK$A1)86RDIDC-&(0>IA<=:DY(-
M!3H6@TQL2%:"4E&(@(-[##W47C_X\[3D532WI^C(S;<DHU;)E]5O#RXR9K61
M,^8(D*&1!3F1I\9/OIG`#4D-T2KTH*)5)25!00'%A,T$('F2XZJ&.G<")(IY
M#^9/$W5G+=&].T;5CC/4,5>Y\\L%NU;!:2*@%?ME@R-JVO@3=`2E"=[6Z5GN
M"`X](M+]5@"5:8,8]]TQR+1O*?B2K[K#QY='^6(VDN>1U1#+!X?@C[)*DC9>
MZMJ>&/DI4Q>#RA@CS@EL,E&D<(;I24,K6VT:D@XDX.MB#,W>,>\>=3<Q^,1^
MLCP[=I](0&GXB5*.:ZCJ.FI3-9ORF-+#H$Z-D!Z%84-D)34[K(W$3:0M;GI2
M_$*WEE/-5?,80+9H3?<,1VM(IQ]SG'Z<HJ><RUBWU5%PPR@[2:E3)9%5LZA'
MI6")SML7O4C<$\L1GJ!B7[4KE2DQ2,8SC!&"%@0(_P`I&`WG/Z;XU:J.HI;>
MCHKO]Z87QK(Y$:^K4D<0R2/-Z$E[5$NA2PB#'`"6=\6QD%D.GL&6:K2Z(#\H
M3)^*!@>HOXX>.6*1P]V@#\AI*,_F(@]U.VT6Y,KBJVJ6*B3:A:1"1P`E0<HV
M<0W;T`XH@T&S@`.$8`(2$X#`MLB71Y1+G*"$N.ARMGCC)+7%I^LL")-'I$YO
M[.S..U@D^F\W2UQBZXO10#1'`^#W#`$(R]B"Y,"`3^0M>;A4O,5.Q"-7?=7-
M-@W5<Z^%5??%6]$,?-4-@EAM%56!+XZ&]YJZ,[^X/U6.YC(,!S&WIM+'-842
M62<4HT1HP+#I_C3H'O7Q6^/VO)GW*V6(XQ2W!V'T)>SQ#*>Z=>+\@;',;6C[
MU&H!-+(8K!C$<D3>VO>FIN?EC4L<B$R(2=Q2A-$J3;#+4A\/%AW%P1R[Q/>'
M3L31):5Z#:K7M%ZI+F.FZUC]L5LQR29+F^J&6(L#*QQ>L'PV/2),0IE30VDJ
M5"U,:H.1&_9,#@2`>/7D-QX?YH8*%>K`8[1>VR5SJ3.<Z8JH@%.%O?[IDJYR
M:2W*+URU-+*Y/3+'MHV]4[G@&O=#$OSG"U[@E@#=W`8$<_E'\;]<>5#EL_EF
MT;`FU:1P=A0^Q291`2&%4^%.D/TZ%)D0T\B0."$Q"L3O!P1^@0&!'H`M"]-"
M`(-;X[X;6R*<!&\,M'7_`$0J7N/0H.@Y%T;(EK<[W$_/"NRT4XD;1MV(-;%L
M>4/S,F&@_+M"QO=4K@:)R+-^01I!H;]\?\KI>0:XE%8-=PW#<3`[VG.)_%UE
MTRG<UD-?1>4J$?X&J6&3K"/W&\Q"$-R`!*12\JW)W4&F'&J%0]F!`6&BWGMY
M6OGMCQN6-S'S?`$E@6?:-FT.@2$.,DB\3;8HQLMN1.2R&<N;W)R5&TC;&VQF
M&,_;<6<Z:*&(1!)^M#(-"$_KGF?H_P`;'\=KOA@GJJ2P&U5T]J:5L\NJSIE5
M:#P<HD5J4O%G9\62R,\Y\KJ8L@5D%G)E:#ZCR8I3[UHQ:(`@DEA'7X_K&MQ%
M_'R\K704LF<#:I9:MS\]B%*XO=K)7[V0S'J*&A#L7-98WMT@<8HJ<F$TQ(-$
M:(]T7E'J$A91)X@C-#/GCSA]QW7XK^[8ES[1=^6'9EM7'2L7CK?578;B<<D<
MZ;MR/OPDTGGMQP>$S*AS"Z_>4.G/:)$L.?6!'I0B+:UV][V'2=XBN,.GN06N
M_B>C%B%*CGSM6?\`C6'-?7_0/7R"+L\08)`C?CA2:_X1"G2,+WMT>0",3MA0
MD)Q1!0?85\`=FA,A@:E]Z5E,+JXIZKI^`0AMLN9VC0=HU_'*_>)NOK=KF+G+
MHBZ,1,>73EM,(61M.YZ7;*VHT:2#^[VC-*`(1@0BT\67B2GG)4*N>*WLU4^S
M,]]TJ"N)<T4/>':<F>DHI)^8-E36!XO&YIBUQ@+(GD"A*VNT:);W?8_]X:K8
M@@W@;V<Q>++COD8YP64U#)2TN<AH!EYRFKFKGTHT?8$.:'!S<U$LFR-G7LS.
M^6^_GN>P+Y>),!^-()*)+4E%`]FP^'*7BOXZXDD3!/N>:_?&6Q(S2[S1Q<K>
MI]*G)QE\1=IXJL@Q58@1+/P\UF89$>!.3(G)"K>4K202A*/TD*`3@1,>$7P9
MWGXRNB)E?]NR[F:5KK2HZ30J4EU/'[-+FS',W&=UW)$18IC-7831*H\\M\?7
MGNIR=G8QZ=`$;*($2,7L#J!P+<F+ZW1>(RJ3.Z1Z7M,=CCX^NB&-L[Q(9$M;
MFAL5."U(P,$>3JW]\>E*9.("5&A*-6*3]A+)`(P0=;#F,\%_C0Z?YVLV)]5V
MF^<[.51RWFZP(A7@8[7G2%5=2:0V9>0[CCS?>K-:>XZ5+3V!K<5"(*V6(G23
MH4R="D3J=$EG'J0ZEL!@<\/B>\/W1/CRZ;N"U+$N#G"V819C59S@LE<2JF>P
M^_Y7.;-LMMGBQ9.7=9.'&O\`\(U@1&`]$;=L]0:8#0=)P%"^8.A[`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`M=UG$*8G@F//DPBS,_J(^]
M2U.QNL@:6YX/BL;.;T\BDQ+8K5DK38^P*'9*!:M"#:9*-24$T8=F`UL,76/U
M-S+3K]$8M;?0U)5=(I^SKY!!66Q+2A$*<9DQM8DH7)VBR:2/;:8_($.UQ/RF
MI=&@!HT.][]-ZP,YIU"=6G(5I#R525424H3*4YH#DZA.<`)A)Y!Q8A%FDFEB
MT((@[V$0=ZWK?I@?;`8#`8'!C_)ZN`2SO>NJ.0PR)6&\L_+$(G#$6=0/*<HD
ML.?Y-9MK,C,<LMZWFQ=;2=E->F=`JTRL2UM*`#9PB_\`R%FE)0;/^?'GCI6T
M.M*)?*NXGD74T:6\//D;DMM0O@?FOIEW!:S3-79?7S.KDEU$*!5TS)7)W$X+
M4"=4<(+<X'A0D'#/5'I@ZZZ@9E4=J:KH^N()2KF*NX2S+$R>--,+(3JFR--B
M)003#F`!;%$R23B-A"V(@A2(-:T03K18`X&1,#B1_EWRFS('87CJ?JX-2-*J
M6L78U1.4E*C%7+GM"RVC6D7A$I8TKU8B]`0>GD4.D;@(#<::D3C5(BS"5:9;
M]<S0;!>0#L/OGC&IO$+37C[+9JG@LLYBAQ5@DSNHJ`11WYSVBB:@JR$!469=
MD$A$?DC;/+.0[<F%E>@#;T)YSG]Q<W-JHO`Q;YE?)EY-.9_'OXI+?K^V#N;K
M[O/;Z9TG*9)44*:(GN?LM7HWDB"/D8D3=:NF%*^O(W,326A">F<])BU`C22_
MCT$.F_QV3>W[+X>YCL*_9,]3&Y)M5$?E%A2&10&*U<^+9`]Z/<#B'*!0AYD$
M5CJEL(/+2[+1JS2S=$:.WHL9@BP!I)YH9-Y`6.NZ<;?'S=DYJ2QG^1S$#\VU
M[RI&NE'N9-[.RMSJ00L<),]:)KIK9D9*TWWIF9U5.JHTD@(D^BQ?*&W'C!D_
M0TRX$Y?D76*2P4?1RZN"RK?!:D73PJ?*)@W/;PUK'*0Q1,D0$L1SN0B+5$D?
M`2(*4XO8@!%O8=!OE@,!@,#D]_EJT58'1?+/&=95Y'Y%)7)?V0U+7%OARN*"
MEQ#475EA-ISBP,DNFT(;'A4D.=`:]PU11*?Y-;-4)P#]3`ER\)5>JJG\6?'U
M;.+/MB=H9`Y"S/+>9)(?+%8GD%B3)2Z.CF]P*P+0B1KO(%JD;@K(1O:H"-0J
M&G$6E,*$D("5#`8#`8#`^?RE?+LCY"_FT7HW9/O#\NBA"$`)FR_7WZ+$,.]:
MWZ>F]ZWK`^F!"I_(">T#!XU[$7GWG9G/3MNQJ@21:?5+<^J.EPI(KG#<0D90
M2<I"Y.3TVJD0E!ZAH1$&+%6DVC"]?[&]X$"'+TDXMNOQ/^01-VQUWU-&^*D'
M5/-B)]M29=D/79UGO8X_%Z3L9)#XZ_-U&L[U'8Y84M.3",0HV,Q8`\\\03B0
MHP&:"1>-=[^."DO&#V_TEX_+$7=EP"J+!@C5(H=V5;?1SW6PIV^O<'98I!6!
MYZ08I$H8(\%"XEK&I(W(PHE#H626>>1L0#R0VY\&7E@M/RP4Y;UE6M1<%H=T
MKB91^/M+%$[`<Y6YOK4^H7A0%[>XX],+2Z15'M0SC*0'#.4ENF@'#+T6$G^\
M)RL!@6K.IO%*SA,OL:>/:.,PB`QA^F<QD;A\ND##%XPUJGI_>5OP%G'_`%6Q
MJ1&G&>P`Q["#?M#O?IK`T^YM\EO$W7E&6MTESG=J2RZ:I'4D_P`G2]##+$8O
MVR*)Q;4T?2QLDKB3#('0:2,B"JUI$E4?+H6@`]QG]F!0.6_*7Q5V9*ED)Y\L
M6:RJ2M]1)KR5H9%1%]5FE#6ZIP0-13TC>K.K6(,+P;M>YD`"G0JE)QFA[&6$
M981B"'TY$\HG&'=$D01'FNPI=,I`MJ]7;PTCY35QU\C10Y!)&6(K!GOU@06,
MQU2\$2!^()VB2*U)X@Z&:$.R0_)@;]N"XAL0+G)5I0),WHU*Y0%(C5N"L1"0
MD9YNDJ!`2I7+E&RR]^PDDLPTT7H$`1"WK6PCYY#\HG*W<$V<*]H<-Z'R5DB;
MW+9'JQ.:[UJAACA;!)6N,K(Z[2^PX''8EJ9G*'E.J):2%IZPQ"(1WLUHHW0`
MM+CCRR<P=]K)?'>=D5Z(W^/HIP)$\61SM:\?KUU/@KD"/OI[)9*1D75K)1-+
M^H*),;DCY^4-_719'Z;WH(5/`UY:O([W_P!@V%4O4SC5(H!6M*6._29G@5).
M,-7,TUC=O1FO8;J3R`V=21]@DYD!?[@-61*4-,<<R4#>G4D)30FF&@#KIP/*
MM(&I1*TQ8RRS%"500`PTL9Q0!FE#+",TDHY,8:6$0O400F%B%K]-"#O]=!Q6
M_P`:)"V(>S>EB3(Y(44L2T5^*?E2ZH^R8@VIT#//H<E8G[4MZ.N.51@E391Y
MK@L!&TL>(/:B&\LMO<#DA*L(@[7,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,#03L3Q?<+]]2.&2WK"B45I2.!,;E%H^[`F]E094*)N[JA?'
M*)OPJZF,2#*HNI=VXI3]!STK2@.T(0`!V,>Q!`Q_(9X[DCNOX6=N:.++"Z-?
M*!KZ:UM7$.B]45)TI1M?P3;I4[,<P6/S?96VU_?U:B-M!((X\H'DHA"8W'%+
M"30C`:6'4U3B-S;JAJMO>F`B*/*&MX.C=HLE:&>/IHTYI8PUD+V!.PQUQ>(^
MR$,RH`TX$:%6J1I@EZ+).-+"$8@R1@,!@,#A4_DN4R>O[>06C%[)9X?^3Y(@
ML7L1E04=R]==AKDZF3=%5V2KBS?=-QP:R6@Q\AMM+VG1D>:S$8E!A!PE7WD:
M<:(.WNO2B"(#!R$K$XQ=,3#XT4GC+NF1(G:.D%LJ(!+$Z(VP]4VI'%H+UI.>
M4G-,(+,+$$L0@ZUO87A@,#D)_DK\V=?W_P!"\.KN-J+L2:S*(T]US%9U9;'6
M-<6)`V>`7@S06K'R*RH-K2V.0IL/_".S@J"L/]%326=I>E,`,@9I`1Q>;)FM
MR`\:>`R712DY+/%\6XZMRF)&T(:EKARD;6.<\N5%!%253"WADNNLVI)^WOR3
M@E3IFE8J(`B$<C<T1Y0%``F5F'B,4]\^*7Q:0*KK8A%%S;FZB8`JB\PD%-/;
MVZ"0S6L(S$K(C)NHW=K3,*Z/?FD"H+^V$OSA]MQ+"E5"+^'W%A.CPY0LDY=Y
M+HOGN7&UB>_5)"BH<K/IN(+8'6QJ=N<7#;89&8HYN+NXM18VHTC:K["I2<>M
M^8X9HQ&;%L(7O/WS\X]!3CB)IW1[/:L:BH>D)"_25=R9<_3SE`C@1RNM-)36
M56G0'.\58PRA61[#4$@>@DNPDA8B@F!2GISPEB\9,+CE>\%\QQ"*1QVB;(TU
MV$1+`^P(ZK79$N<7QX=7D:VN%%DV^HA!BYZ7*%&FP<E=QI`FZ+V=ZZ]@`WG-
M^;VA^#XO=\I7O^7W^WX?D#\_M]F];^7XO7V>OZ>[T]?TP/K@,!@<T?\`)QYN
MZ6Z&YBYLWR'2,JN^]Z^Z/)?6%E:Z6J&[(>T1][@,JC<D<+"9+<0O;:TLVPKT
M^TRDIL<"=JRPZ/`5Z$GE!(WXB*`G5+>.KCN!WY794%O*O8G*7>8QA1#ZP@QL
M/GLUEDT=)04WQFFA:KAL2J")(:6G&A"$:A&:`U2`M68>6$)+$;NG6N3NUEIG
M0H]E$A`I4*VAR1-JK;@ETK*VT.BI*4WO(22]^T_:4PW2<W_;,]H_[<"JX#`8
M#`\`6ML"YFO86Y`%Y/0$-9SL%(GTYG-B50H5IFXU?HO[1B!.J6'&ED['LL!A
MHQ:UK8A;V'OP(J_,#2%\]"\OPZL^?(=;,TE;CT)5#A($E-='1GE66,</;!OQ
MZN6K+AD$*GSBS1F-/^VU2X$L;<:_F$@]Z/W;+&48$'THYAMWQH^$+J&$]>/T
ML<G*86G1479V@_NN8RA2G9F5OIRO6E7`[E2\H.4UB[?(I/%#UK=`DT3?BT:`
M)+>2H`2(82@TSH*]Y4Z^$CS)W*ELJZ!3@4\YWGL5?9MTF&[I''Y*X,=#KX$L
MC,@>.=J(W$G!()&WH3'/30K(4";2C4AXP(RU)X3+?QS7V9S>#]:V#9=@RJ;V
M)(+`JIMD*.6=6U+ULHC21H@:Y>SI6J8U+#X&VP]G="I":J"PJFT!Z12,X?RF
MB,'[0Z2\!@:<=SKGLSA3M`_;<4SN!/-_125#I58HZ^*&A3UY+4J)\%8[.A=%
M4""K0ATK"N`0:>V>NA"#[R]^@<^?\/=Q:WOQO6646ZIG<Q->S@UKFU%)UJYD
M;4I,&BQ1*7_&NF]+%:R=U@Q'C<"T)BD^1#V!X7"TH6[#H.M$(```$L`0@+`'
M0`@"'00!`'7M"$(=:T$(0AUZ:UK]-:P```*``LL`2RRPA`66`.@```&M!"``
M0ZT$(0AUZ:UK]-:P/U@?%0<!,G/4&;'HL@DTXS91)J@S0"@"&/99!`##SQ^T
M/Z``$0A;_36M[WZ8'^?OX$ZF>`>7RP;MF%[\N24-DT3T>=!Z7I>J^F:L1-"+
M]S19C>)I"8`=0%04Q'='@8?_`'WZS@:H/6.1F_BVY'?(6&4OXUK132;R(V,M
MIAM96<QJYJNIMLQG3TSVI$'9JD#A<%-N`2BYAT#9MEL#PC7"1EF#+=A-TE`:
M#0"DXR]JC-!U5\A^3.B>T93,X=6E;=7PMXA7[G4*U%V<K715,:>6R,NR-I$X
M,$VD46#"UBE[_($J4#2:X$/YB40AF("MEFA`%PUGWWS]?4ZFU'-4/Z>CTYC]
M82FQ)/%[2Y*Z=IL9D&:'!%'%YC/()]6459GIW=5;KHMO0MBX]R6?&:(@O?PC
MV$($O!+4Z6*]V7=+(O6<$@-5AYF<66K%,"Y.[HYH<'AA=KABH!;M$?7Y$C(D
M$B2MD';P-P&N2*"]F?DU9:79RI>K.#K=P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P-,^JNSV7E1PA;6YT5?UPJYT!=^,'3K/6!S<@/0F%E;
M1/#S:5K5:SIEIXC@;`44>>/0!:&+00?K@:?]O>,W7D-MBK;5F"VDH7"(W1"V
M,HVJR.6X!=-\,DOE\@(?EY"6<R^3NT5AK"VLOL)$0SI!.13L$P\AST2+VB"5
MRO(4SUK`(/74>((2L$!A\:A;(F2I_JID[1%F9$QMI*=+\AWUR"D:$`0@]X_8
M'6M>[?IZX%X8%KIWYW.FCK&3(@]IF)OC+"^)9Z<K8=QUX=G=TD*%?$D"$IV,
MDQ;S'4;,F6*S3T)*$9+FG"0><:%062%T8#`T*Z1\7OC^[`L]+<_3?+%8739Z
M&%--=H9=-T;JX+T,/8Y"OE+2THDY3JG;T8T3VZJC`JBR0K-EJ32=F[(,&7L-
M\PA"`(0`"$``!T$``ZT$(0AUZ!"$.O300AUKTUK7],"D)&!M0O3S($X5NG-_
M3M*9R$<[.RI"(ED"M`W_`$FA4M.:&DS05YOS#2$$#5;]NSMF;++]H5G`A#\K
M7BLL_P`C5C4T\1JQ^7X!":T@-@,;P"ZN2H[TA,GN03!S80ITK([O,FAZZ)18
MMB2*_F"C<"]B6B+&:0IU[-IPTJ\IG*W+<;XYX"K?N7APSK1^YVK1FKU&[\F7
M;`.76"JE+5%Z\A4A989'[/O:K9>XU+-CFQ*G+3)@.@&XAN*$J$B$(D0PG5X#
M6TXY<5<ON//E3/E$TFX4O!UM9U!)D^D\AK^)JF<@]MCKT/3Q(?ON24!FQ'+=
MKUVW`8MJ=J#MF_((-O,#F5_D261544>>*(E:]`\WW@T20?24A3[Z3IY#9;#&
MB(=&*YTXBBSR[]7\LM,:>%QK\D.6$"4.ZA4WHC5119.F\SY0DO\`#*TMS)XQ
M.0VUHC35#VHJOWD]NC;`@6-T?:D2Z>RY<F)CI*^S;E4J(Z:2IT8@5;D[P!:C
M&6H`=H!H2P!)W@,!@,!@,"GNK8G>$![<K,7%)U/Q?(8W.*]I6A^(XL\'PN#6
MI2+D_J,K6A>PP/O#ZA%ZAWO6P\KX_)6`IN-5I'I8%S>FEA("R,+P_F$*GA6!
M&G5N)3,B7&-;*F,'H2M>HT6C1E:V8>86#6Q8%:P&`P+=B<OB<]CK7+X+*([-
M(F^$#5,LHB;VVR..O"8L\U,8H:WMG4K&UP(`I(&7L91HPZ&`0?7UUO6!<6!2
M5:YQ(=&A$F95*Y`OTX;<GDM8WDIF/ZI`#$>E*10I+<%HG0X>RR_K%&Z+V'8C
M-A#Z;V&J/<_&L0[RH<SGJ?3^RZ[AKC8=93>0NE42,Z)RQY;JZFC3+SHD"0I=
M?>:6Z2[:])CE"80%2;W!.)$$TL.\"/'L3QR-%`^-7K"A_'A1EO6#-KK?ZX?C
MJR2]?65'9;(#VJ:UZ5("F&Y+HG,N<X0S:AT;/TM1-ZQ$)>F,4$E&%&G!,`&3
M?$'4?1E2PB\$G1?'Y?);S)9K#GZ/)%';MH]OO<[0BA21(M->YE:LTG#Q%U,,
M-(+;?K)5)")4/0Q%$[`6%2H"87`8&C/DX<%[7XZNXUS:I;T2LCE6]/:N=9F]
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M,)91HCP`$4`P.D)Y<`M+.ZN@]F:`VMJYP'LE`N=3M!1I35`ME-;8`QR<C-:+
M_M3IPB/.W_87K8MZU@<\_B+\F'4W<U_7I4W0#K43G"H5`G(UG!67&_;O/#P"
M1M<G:&)UT_3OH)69#D)JEC?B%(&(.R)!O:@)Q8`%)5/J$F]"^.KC_BIE6/W(
M'--85U:#'5DFK^-S0*%8[3E^;'->1+-L$QL.0.2^:2=`]S-J1JU@U[B::882
M#?R!T`/M"!W^/'Y)_(UWU9<H_P"6=QUU*XA#:XL9!*Z^CG*UBP"0L%H1FT6&
M-,+FYWJV0YMH%].5,HW(D32U.YZWXDQ>]H]&$*U`0ZU<#'5OENAM2VB4R,Z>
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M3F[&)6\!^RR=F[/.)*-"J0]S?GN)1=YE49,A4G=XZR.<CAISNW2`V)/R]L3*
MGB,FOS0(32]F,+@:8E$L2[VG4[*^0O?L$'`XOOY8EC*.?+Q\?]VQ>"\]R:9.
M=8];P(]5TM4->6Q7*AB9TU4S-$ATW6^BF$#+E"%Z#_[820PENZK:\],4YI@J
M-!V'5MPG*`3;BSE"7`:6%B_<G/-1/(V:+5RBJ&--AR^#,B@]%'ZK;GN2(*[9
M2#QB"E925ZLMN(T$@)HM`]<#:W`U&ZPX-Y![G0U\U];4/#;S;:LD#A*(&@F6
MWC:-A>79$2W.AWUVET;"G-&Y)$Q03TBS2A&=LDL0RMB+`((9RJ"HJUH.L(-3
M%.P]I@%75I'&Z)0:&L8#PM<>C[45\*)`E$J.4K#]AUZB,./--/.,$(PP8QB$
M+89'P&`P&`P&!XVY<0Z($;BF`K+3KDQ*LDM>@7-:T!1Y83``5MKFG2."!0$(
MO09)Y19I8O70@ZWK>L#V8#`8#`I3(Q,D9:D3%&V9JC[(W%B);V9D;TC4U("1
M&#-$4B;T!*=(E+$:8(6P@`'6Q"WO^N]X%5P&`P&`P&!07UQ>F_;+IFCILATO
M?D+<[B*<V]L_`LJ@M0)9(C-+Q@VXE-XRBP[2D>J@WY?4&MZ"+`TJ\I2E0C\;
M/>2I(-66K)Y)OT28]#()'%E:91_C.1A)5D/T20.DC;QI#-Z-]4I!@S-`]F_0
M`A"T'+7_`!_6(3C_`!J_(.V*UE@[2?7[5TE_8,REY=@IQ-_/K*[Z305"Y-9C
M#!Y">J'H2(EA-<T*M2;I2H%I8>J3%A</\=V;);IH7M"`RFC^:*&F6^3FV)3)
MPYJYSZEJB\=MI\0?8ZW&W#8MTDCJN7S8AM,^PW$,"M0;M0`T_0]I0A]H4;^)
M_P!#)9]*7"JW"@^=:RE\0Y7*;'.75I4_53!=<D:J^G<'BS4Z7I8%EC=:#<G2
M;:<QN("8ZO&L4&)]>TE,0D$E)#M_P&!3G=O2NS2Z-:XI0<B<FY:WK"4BE0C5
M&I5B8U.H*3+$AZ54D4&%&;T`PHTLPL6]""(.]:WH.8[P\1GQ"4QV;;-/\9<7
M=;\D=:GU)*/W<7T@W6N\-;[7+!+(.HE/X"3N=R6_7+@G2RAZ833%B944)5M2
M6`A09[C@:"2CB&D?+=6DKM7?</:O/'0\%E3-,3JU(KWGXR`RVLYFODB4V(GD
MK$BMG:G^"-L:&JT>UN!2MQ"J^N6%S-++--."M5A3?E/@\K>EEQ=R4)<]<).>
MYXSLY<8Y`45?._\`D(Z&MQ\0G+J@;;*L1`]12&IT)^BV]!M&-RTL$2:D,,"4
MH"&AWA)[B[7Z_FD](Z7LF5RZ'PFNG!F:DLF\<5M\DFR.<Q^P$S*[SK=MO\LD
MM8/ZTO0UC69&D!;8X^P@M28W(34BX!H=&.`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&!"[Y6NJ^IN8#61UI.SRZWA3E6$M=WAW/\;?3?:B%I
MDT:6?:TJ5V)0UCL4=KI8ZM2@!*)#(F8Y&,1!JDU5HG0@E!+/5LLU/*RKF<AV
MX;#,X)$)9K;LRBC;KO4BC[>\:VYQT2MP$PN'HL_WD6SS]I3/4KY!^WW;"^\!
M@,"B)9&R+7]XBR5Q(.D#`W,CN\M8/D^R@;9(<\D,:L[U!HOXG(Z/+0E^T6]^
MJ<7KK7Z>H5O`8#`8#`8$9WDB\2W'WE48JN8NL66>N)=..$J<H$X0&=+X6O;3
MIJ7'"9&!7HA.N;W0I<3%480_83F")T$6RA`V,6]ANW15*UWS?3-6T%4C,;'J
MQIR"1FN((RJ'!<[JFZ+Q)I3,S00K=7,]2XN:WZB0.SE!Y@S3C=B&+>]BW@96
MP&`P&`P&`P&`P&`P&`P/YO>M:WO>]:UK7KO>_P!-:UK^N][_`--:P-">[N7)
M#W[SE'ZSJ#KBRN825]C5Y9`+QYW?%7[N=HM%%RAP61R,R./2M@2$II+HXO85
M9ACBC*,)`,:-1[=:T%Z\0<KR?CZFE]3R[IN^^M'998<SG`+7Z/E1LPLD+?*%
M:8UOBA[N,T1`FJ/)DF@E!(+3)Q'&G&%D$Z,^,(;A8#`8#`8#`T6\GR\]L\<?
M=:],$\1R;DN_3`_5E3Y"%@`[K*2!,-12J--KP^,JTDL6QDFIDQH]FA"'>M!%
ML6@YD_XS"&Q+&\`77]=5,T!E=K+Y'T_%JVB\HM"9B97R;2:IVLF(LI18%=<`
MIZ-.KVJ)3F!8I&#W*=J70:Y&J4#`2&[OB_X$\EG-S-TJKZABE'+7Z?\`'RN%
M5<?3_6O8L\DR.QU`7<]%6LO37Y<DUB47<FX0TY0)-&5#?M)L`0E+#P"$:4'W
M\(G!/DOY=NMXL/M]@J!%#7;GAT@D;_9?6?6-Z3F,RX-BQ1UW'IA&+IM:S*N&
M6N0MB]:%P8!@&WG#&069H"H\H(=+SVB/<69V;TPTY:E>V+T2<Q8!2:D`>J2F
MD%#5%HE2%88G"8/6QA*/)-V'UT$8!>@M!!?XW/'7UIR'U?,[&M1HX(1U`^T4
MXUZD>N7V+IN-6M(Y8GF4*?(THG+-?%HW`Q(V!O:$CP6,36[?;5JS"CU0CABW
ML`3FOZ(MR8GIN..6)R7!I<41I[<H-1N!!:I&<0,Y`K)`:<E6%A,V(HP`1"`/
M6A:UO>O3`X'/XC"?G]FZ8MF-1850/5V-'/%BCE[DQ5-T4W7+%&/5X0(C4?LR
MVK"E*"FG(9PMI0[1,$52+%)B8(Q*]`2'@/#OI)=FI2=M,G<V]0HT1I3L@E:F
M-.TFV$L6E&RBS!#T1L)H=^_T]OH+7Z_KK`M*=2`E-"98>S2IG8GG]BRM\8GI
M0L:3"&T#:UC]LG$6X':0*&EC6JTYAYIO_B@]P=&BT$>O4.4W^,9V3Y+>S'&Y
M;![9Z0?;>KTV`MI\'ATEI%!7@V=_#,!H$,PB,^C-2Q"$SZ,O\?2*-&!0/*H:
M<T10C$W]X30AUWX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8'ST<5LT1&C2]G@+`<,G0P[-"48(8"S1%^OO"6,90M:%O7IO8=ZU_3>
M!],!@,!@,!@,!@6]J0D?NL44_P#%^UJ/`D/_`/($;6_`)R&V[]6KV_9TET8'
M]%'K[-C]0>GKK`N'`L6R%%EIHDJ.J)J@[U.@ND:"A;[%?GV-10QF-DK05+SE
M3O&X]*7<ES1P\:\YN+`B,*4.19!)PR21F'%A4F1?+5;W,4K_`!QJ9V!L=VY-
M"'A#)#'E?+&8Z.LZYT=7IF&Q-A<25H),J6MY24*IR^PG2`5;-+V?]<H+HP&`
MP&`P&`P&`P&!K5U1U_S'Q16I%M=77%#Z5K=QD2"&(9',35NTSM)W=&XKT4>:
MV]L1.3J[N:EM:%:C9*=.:(*9,<:+6BRQBT&.6KN3@:ON7JAZ)2]"4)5G)E@B
M:(E3%@O#\Q595[L8;IX2-$7BI3\7&T;<:G*C*\(4.B"!)RD!VQ%@`2/80S70
M'2_/O5<+7V/S9<M=7E`6R3.<-73*L)2U3"-IY2SI6Y<YL8W=G4*D0EZ-$[I3
MA`"/?^RH+'KU",.]A<C#.7A_LB819"P,:V#Q-J:$YL_:9TSNZPNQ3SE2B0UO
M((0F3!=HPYL$<4-+F!0<>8%60Z@U\96P:V8&3,!@,#%EW776'.-2S^]+IE:>
M#U55T<6RV=RY6@=G1.P1]NT#:MP-;F%`ZO*W1>QAUHM,F.-%O>M!#O`QQRCV
M/S3W%6KC</*EJM%Q5HU3!V@*V6L;7)&IO+EK$WLSJ[-!9,H96)>H&C0R!(/9
MI9(B!?-Z!&+81:T&B<^ZVY_\K7&/D.I3@Z:J[WLB&U_8U"2.-I%5B\]GH+.E
M<<D[*Q,J6R)O#&4A`%0O:U.]+D85:4.B/:?L!1P1""/SQ'\"=E<8>%KK7FKI
M2JRF"[9.W=$JXG`V;HM>I9GF.RJK2&QH+C3U43=*T%#.3@XZ5@&*+$."PUPU
M^7,+&O4F`P-"O`/`:F*L/O.`T;1DHJN1CXC:&6;&3[J?L*5/TIFLN=9@!J$]
MK9SRG0S)#5XS4Q_RO\;9GA<WH=I#&@!IAKGM0%:_C:UC0U>=SWLQU:HDCS+F
M/F!U/G[V9T]T!;L<(>)!=,:.V@_:5J\=\JL2IP5[2#.*="37U2F(!Z>[6UQI
MH@[4'QW2Q]D>'Y:4O/1,C6X.ZLAK;EKNYG)6U(<M4%-S2VD*7%T7F%$[T2G3
MEF''F;T``1"%K6PT%Y)\GO,/:EF22HJ:1WJWSF'UTW63)VZV.=[AIU*SMJ]X
M2,IK"I=+%B4?;C):WF.B%08A*,,V:C6EG)QG@+4[(#?*3^S4:D.S2"U1>F-V
M^1*<6O-)4@^@H]Y!I342I=#"S@_VB"F+,4;UOT+"(?IK8<4?\=]+4\EZ\;$-
M?5E1T1:HIP]:M=3#5;UGW^RO\@W(^BDDV=&>S)QT!7<#JF>OL7=9">T@<78Y
MXDAK:G3I4ZGXTRDHD.EGF/Q%>./CB02J6<X\LPNNY1-X;)Z[E4A_-SJ6O#U`
M9BH9U+_"E3A.)7)5&HNJ&P(P@1`$$A.6G"`H(`['H0?NEO%9X].3;%=;WH7F
MMAJF:$4O(*95G0-VL+\9NKW9<WR&1,K=`$TC6QPQZ>U[$E,/7)F[;PL,(+#L
MX8O36PCD\,==>%J`7_?*#QGT)>=<W&EKID+N*4VU6O6D63M<;>EL5D!5<Z=>
MBB"&QJD.U:IK=#6Q.66J5$""J)$>F+$,`=&^`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&!S[>77@+JWIRXZ]G'+++.3Q/5;CK>VI@P^1J\^/
MCX_#&20.;XGAD/@L#@EE5XZF6%^XE07IW=6%V5""C0EDA2?!L\P)[(LWFM,9
MCC4?I8$]L8FAO."XO*J1N`343>G3&:7R%<$"U^6:&7OY5IVM&JA^IH]:$+>!
M7<!@,!@,!@,!@,!@,!@>`E?\S@O;_IKROHDHCONG)MEMZS[OV?\`;0*O=O2@
MY)];_?#Z:^/W@_K[L#WX#`8#`8#`8#`8%O2F,-LP9C&)V/>4Z$U>RN(S&"0O
MD7<OG87IO?T107B..#6ZEHCUK86!6G"=HE:D$8F/"8G--+&%PX#`Y<OY>DA4
M-?B/4L*9W2MFICTC3#.M3*7B$M_YIM0;DTA/;2VZ3>^3R$12IH(5_5BQ8WP'
MUM'#_P#;2G`(@U,[SMJVHY_&_P#&8XUU<,BJ6RK-/Y2KPJVHV\4#%:[C#I**
MOFQ&W:TK+;B`5]4-/HW1$7Z/K(J;G1K5`0EFF;.VK3FA+-_'1JMTJ;QOM3=)
MK.K:YIQ,;SNBRK`L^K;J@U^QZ9R^</Z1V6O"VPZ]<71B52`U"),%6F,-^X2(
M(=GA`,?MT$ZQ9116S-E%%E[.,V:;LL`0;--V$(=FF;#K7O,V$&M;%OUWZ:U_
MTP/I@6Q+7!V1-(TT>V$J2//V6B.+UD=>),PM3Z>VKU+8Y2I`R+&M67&DZA)K
M2D>UB((O<$H)Y9AH-X%S!]WM#[]AV/VZ]VPZV$.Q>G]VPAV(6PAWO^FO7?I_
MUP(J?.#(G6)^*+M>1LLBD$57M%6(E?YR*RO4&D25$&;Q,#J0SRX3:[E1]:Y-
M8SDH5)B8XH'S?[@?9L6]!@#P/RMP4<B+"4DIG%[,4EZ6ND".W';K:O.SCVAE
M9HS"AMPII<T=CM6$*#'):0-*B:VQ@/.2>X!JOX]G#&$)RTB!`@^S]%$D1?=5
MG+UGU$Q*;[:]1[?L+5/P@!\ZL_V:]Y@_48O37KO?I@:[]E5K,KEY%Z@J.NB]
M&V#9W/MPP*"`%+7.!AW,I;`']BC&Q35E+.=8KH+VN(WM>0`1B7T^36M^WTP.
M=WQ$^+[L?G5=TC*+RYFJWFI-;G*LWK&/QBH^T+YL.9.L_E[@RGGERQYD<NGK
M##5#:%CV)B?V5:K<HZ6M.*+//"/020R/X3?'/UKRK?TON+H?D_GOFUE?*2D4
M":O\9]3WI?UBGNCC(J8"1')8FLV46!'3(Q]2J3WQ(H2O)IZ%V>7'80^QR,)2
M!TS*TI2U(J1';."2K3G)31)U!Z10$I06(HS9"M*82J2G:`/?M,+&`P`O38=Z
MWK6\"/?B[Q9<;<`2"52OF6(V1%Y%.TSRGFZ^57W>-DHY::]OJ60J79]C<_L&
M11-7)"'!+Z$NVD`70!1IX-J!:4'_`"!OR_H#'5A>VLHM,::Y-#D@**6'+$Z0
MPQ8C.3@+5'MQI+@0F&(S6AC(&`X(?78!:%K6\#D=\$GA_P"_>">P;!O+KIDI
M!+7K!S;+Z9ABNKYTMDTGD3P_7(&TRGS;<Q1!B=[!+3-*A6W?F)V>YR\LL*=*
M0>8ET$!(37<G^7OEGLV=3F!TS#>J`J*\@KY.I'))URS<D'B(-1D30!_AB%X>
MXT4-;8S<8]%!"R!)TM6;"9]0)_M_4,HT!Y"^5^QI2?4-9@O0YZ?:]DDM6(K,
MY;Z>HUE/BC<O9HV]IRYC;550*-GN^SY.1HM(C7F+#"MC-+#L)8Q!"D<:>*OB
M+@>4/T\YLJU[CEA2F-*(7(I]+;0L^RY:\PP2R.*FR*KW2P)?(OF9HV3$6U*V
M`]FC$*1($HL>@C-^0)$<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,#4WI7NGCOC\^/H^G.HJ)H1SDQ.G!@9+3L2-QB12%G*7`;5;DPQQ<YIW
MUR0)UQNBS59*<U,0+0MF"UH(MZ#3SR"^<#Q_^,R80VO^GIU.D<SL&OBK/AS'
M`:VDDW`^1%2\.;$C6IWU`21&"%"MQ:%&@$G+BQZ+"$P7M`86(82Q,CJ0^LS0
M]IB5:9,\MB!U3IUY/UEQ!#BE*5E$K$_N']=646=H)@/7?L'K>O7?I@5/`8#`
M8#`8#`8#`8#`8#`8#`8#`8'A)6&FKUJ(3>N(*2$HC2G([Z?T'`2O[/RD(OB6
M&K?F0?7#\WS$D@_W@?&(S^_V![L"VIBHEZ6+OBB`M<>>YF4@.''&J6/;A'(V
MN<]>GP$/+XTL4F<FQ"+]?<:2@5#UZ>F@;]?707+@,!@<N_\`+K5B#XFAM1(T
M!"I^Z-J-L*6+VJOG@*8HY/*@J=DIY8<9,TIX@"U[5,,1.$D*$'01%`;!N)Q0
M:5=^T_&K*_C.>-^!2^V9C$(R-VY3=PV6J9.?QFM[:9#9T>PEREA,Z+J&G=QM
MO1.1!98`R)U4E!2D&*DPE85*E*$QO\>.3N<G\>A(G2\7/H`QBO"T(VCFR^(T
M!!DR-J:BXWIL8&.-<XV9;,';V).B/`K(^T[;=#!+1B,)+3;2^X)T,!@,#7[J
MJ\B^:>=K<O@U+!UP:PB*R3A1639;?3D&6&ISTZ<E)([.=622-T,0J3E(0:6'
M(5(-&""'V?W>N@C>H.UM^<?QDV\T3!5&N=17`XRZF7]RYAZ#AG21T.)9C8P]
M"/0V2@A3/$-2)>@7@)6MP$RP)"4[0M*?>=K1(;:\%<D:X0I=VH]UZ*M3IE^=
M9U-[9-G-RK6QQLQ<FD`6),L0?`TA+^^W-BE$7Z&EDA]ZE9OUUH0]:V&\:%6!
M>B1KBRE1!:U*G5@(7)3T*TD"@H!P2EB)2`M2D5%A'Z&%&!",L>MA%K6];U@:
MA^0]X)CW!/:#^I-=R4S)RW>[NH-C]BN%1/Y9#;6<D6G#8[0:F:1.$!>`ED[^
MJ[%(%@D1_M,^$S0=AV'*+X6%E?/]D=I3.MI..-SR4^/JP?KT?,+O[VL>:"<$
M3NS&K)%*;`ZSY\JB(MB>`/"Y$P'*HPM=!)U2T\>OE*T$8`Q[_%DK!QB'8DRD
M&YC^::G;APW;>5([#O*8K+):E5M5KK_/M)E6?1-5QXND76PFR4Q8\M"L7G)Y
M"PJ=Z-5)34ZHT.[A=M:%$L$VEI37$*51M`4N.-3HC%NBA[2EK#TY"D\A*,_V
MZ,&`LP80;WO01;UZ;"/_`)/F'E`?+(E2+MRF.,ZUJA##1JHM(>=KEM6QI4ZS
M@R0EA(;W%NGM<P=$ACB2+!-$I/W[3MK`D[*",LTT"4(2/!EY:_)IY#.MK<AW
M35=TK&>;(9$+0_;,A@-3VE%WEYF<1G\1CC">W3AWD4LKY_CREK6N@3?KJ_E/
M4I]B)_L*,U@=8.`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&!C67TS3]@O*613VJ*UF\@0MP6=$^R^"Q>2O*-I`J-7!:TKF\M:U:G;@
MK3QG:(`/16C1B'[?=O>\#GD\UOBKZ'Z]Z+J/J'G2G:JMI]JJCSJM41*;W_\`
MX<%)0FS]PF2=H<X\;0TU02IB:U6TRA/L<OCOM&-02(L98][-#I6:D^TC6VI-
MIR$>TJ!&GVD2A`!,EV2G++VG3@+_`-L!!'M]H-!_30=:]/TP/?@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@6I-YS$*VC#E,YY(6R*Q5H$@`YOKPHTE;T0W1R1LS<`
M\[>M^T:UU<"$Y>O3>Q&FA#K]=X'IE*F5)&?9T,:&-\??RD?*TWR)\61ULVSJ
M']L3R=;MT0,<C4Z<&J,FK%2)/]78%JTDI,8:F+-$I*#R,[`_MTIF+XX3=Z?F
M*1?M_<?AB]KC"5I@8FEN-1._X)S:F1!(W0N4*A`5J=.JQ?M.>#84VR2A;*T%
MVX#`Y8/Y?I6__BC95R<EA+<6OJBFUJ-Z<QPHE[8@Z;9NG.60X^1GE2XA^,&>
M6`8HF6>^_1V?\@/QGY$8`I-@O?.,!\!/C:EW1'(,:[]B<*.YO60^FD<[HZK8
MGJP]QR7M#1*U?[!EBZEY,RQQ*M6HEC04-Y3+0JAFNB?8BUYI`2X^(NPZ<M#E
M1REU*\G5EQ<Q+[BL3]QTA4UATC9<213+W,YKK)RWV@')?`DBN2(C4I@D>@)%
M)!8`;V3\`R#30E$P+;E&Y?I$W_LL$;,<=R.,Z==2@UT)1!B6WU!J8F-^VDD\
M\<C+C/VMM@#-!3#7:*T>()6QBT%R8&D7DDDIL0X2ZAD1%@ZJD]OJIZT38PK'
M;*C!#S5AR1`!Z,L=XKBW6V*EIA*M>X\V-NVAAWLK101#T8`(J_XL;]I[\1=5
MDBLL=BJ8_8=EL"A,&>_O='`-$/!+DC@Z%'_CN`!@Q*5`Z%+A,X3'T.AK]K-.
M0M+-(D0=$2%,I++*,<C42US!I24)<D;Q(`[3G*=FED%$FK'`XH(2@%!,_P!X
M6C#"_?Z!]=!"'OP,$=3)Y2KYCZ-2P9_.BDV4T/;R>'RA-]_[$;E)U?2$N/OZ
M?\4C<73YF=V$2H!]9.>H]Q>OC+&/T#L.2/P6QI+'ISU:Q2_H)'8775C<%JG]
MV<E-T=27W)X1'V5_/8U<N>%]]\]5FR0$B6V%(=.P&)LDSR>:,`O<5[$^S"PU
MP_AX-M=D6E<+B&PG.<W`/FY.TNQ"M]O=:W1V!DVXB?VIC9&*;T-#JT84")RD
M>Q&!;YB]*#EIYYZ9*`D]48`.^+`^"@@I6G/3&^\1*DDY.;\1QI!GQFA$4;HL
M].,L\DS6M[UH0!!&'?ZZWK>O7`C6YU\3W+'+'0+/T?4#WT61-&>M9#5H6*P>
ME;BN.$+6"3.;2[.:X]CMR4S=4B>=K&1.(`T*I(F#L&Q;(V,6Q;"0-6W3+<G4
M.B*3-((O^TCVY+$U,;&-7J9;</L)I,HE1;R$P32!NUI,)M"AUO8M[.TH]?0O
M`C1XU:_-0EG<Q,[ME7CR<JR-CCVBAJ;GUBO3]^))NVH8VVQF0+SY6<U1X^"R
M92F<W%P;1Z_*(35!9!"L97Z$AF_GC7DR)MUV2]8F\,.5$EP9>-B>N>$=]LMK
M*[(_-,0&PIWCUDN3_$VZ%ACVG,9XB7%4M$L$F"'T+":(8;V8#`8#`8#`8#`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`A>\B_:/E.YYO>JZ[X:\8Y/9%8
M2>,M;W,;467"QP1&UR)1)'=K=(!M.O,2E1$]O94J)?I[<1*41FEVP!(%]<W>
M@F1:5"]8U-BMT;OP[FJ;T:AQ:?N$N'XM>>F+-6-WWTX0)UWT5`A%?,7K0#?;
M[@Z]-ZP*A@,!@?,XTM.4:></19))8S33!?\`:`LL.QC&+_Z!#K>]X'Q0KDCF
MA1N2!06K0."5.N1*B=^XI2D5D@/3*"A?I[BSB3`B#O\`UUO`]6`P&`P+5=)&
MX-\KBL;(A\E=F^1I)&I<)BW?@OVS#S6(EM-1(I-]U[1OWV90)>8!O^BA6E^]
M(;]@:?7Q;,"ZL!@,!@,!@,!@,!@,!@,#1+R?69;E->/+LJU:$=S(]<L`Y\L>
M3UO("C(T`U@E36P*3VU]*U,"%49/-9QAVI"2L*,*/$5HOVB$(.MAGZ5M5O3'
MG9W:*TL9AKV\I)4HDD.M-TBZ"P8W%;'<HN$#9,5<2TN:FR5M3>^FZ4[2Z.+(
M4%Z]/U!OV[#4YLX)*Z/Y)@5`>6)74/?DYCDI7S9[F)U1H:OBIDD"?(D49<8Y
M%(ZZ:VQNT<B,A-:Q+TIB0Q868:(10/E$'8:-^;R!0"D?&]4U)TC0-4*4#7=E
M65S0<#=X#RBX5?5[NV16?/34][:^L6Q?3D<3H&1A7)2EHB!+Q*UP0>[92A4+
M87Y_'O1V8W\!*T=N!JTR:)^@;?+.<:>24"AAKFR?88AQD0$O,B!KIU.\L[`-
M.V+RFQ.5HE4A&6/6]AT+83D8%MQ291.=-1SY"Y*QRMF3O4CC9[K'G1&[MY,@
MA[^Y125LAJM"<>06ZQN3,RMO7$;%HU*L3&DF:",`@Z"Y,#3KR#R!5$^).GI2
MBFH:Y41NGY:_!G([5<*0!&"VA%^0/=1VLTP*T'*%`((3B]51#`Z&"UOXM$_[
MGO"$3G\6IT6.GB`IU,X62W66<U3FRD.S&^SU-D_LDE:ZIGU)7BY*IAD1%7+A
M'V]Y)-.CP37@!(U>U@5V]+?JI0Z%65F:XZT-;`R(B&UF9&]&TM3<F#L"9"W-
MZ<M(B2$!WL6PDITY00!UO>]^FL"IX&'>B(*_VCS_`'G6<55%H918E.V;!8VM
M-=G)A*1O\NA3W'V=48^,_P#[NS%IW%P+'M6E_P#)3:U\A7]X0X'+9X6/$;Y%
M?'HM[9GW6QE&6&YV)RBGJRNE=97)-&B5RMYAO[G=65ME$I01&#B:C%_Y8PHV
M7K#%,E1C&3L@X!98\"W?XVEQ6??UQ.LY>+!OZ65^U\?HR%4?L>5=NR"O:ZM!
MWN738OK&&2*^)I85+6P;%8?#D*XV1MBEK="1/0D2-.J2%KCB`["G)O3NS<O:
MU?S?4<D2IO5?74')%'UUA!B<[X%2892A,=\9F_:86((P"]-AWK>M;P(K^$O#
M!P_XZK$<[;YV9[?%9#U$9!!7F3V/>-CS\+G&Y%(6:2JDJF,NSV"%:5HUS`F`
MG5EMH%8"M#T(P8C3!B"5W`8'@1NC8XZ")O<4"[0R@'@VC5IU6A$&!+&6<'9!
M@]"*&`T.]"U^F]"UO7]=8'OP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P+:'$F8<Q(G8MN_[@31I7$B@ZD<A"P?AEKHB>#]F1$+
MIJ*'._W6\OV.(T0G$HGW$@/"28,L07+@,!@>%*G6$J7(U2X"5IU2HHYO2B3)
MR=-28"!&F-1@.*#HU8$Y:0:H]YOJ,.S]@U_8`.M![L!@,!@,!@,!@,!@,!@,
M!@6K*9W!X,!M-FLRBL/+>5OXUH,E,A:(^!U<?9LWZ#:-V6)`KEOQ:V+XBO</
MVZ]?3TP/,R6/7DFB1D_C<\AD@@A07,9LU9)0QNT2+`RJE"%X&9(T"Y0S@"TK
M49I*G>SO0@TH8!^T01:T&L/?%6Q+I?A/IFJG.T*VKB'VM1LP:!6_82)AD]70
MYN<F8:I).)(2[N[2P+8TT[`6K&>8M)**`#1P3-;`'>!L2V/"&#PZMFPU,O?B
MW`$/AB)9`XPYO;,6>I:0$IWLXI@2+$\<A0`(]C$O/V4@2%#+"(P/N!ZADC`C
M5\J\?@4AY>3E3[D&C^XTK79D4>V#GZ][:@=-,<@D*%ND0"E\,DMCLCY%W6R$
MS2H6)VMH."G_`"059Q>SRB_D]0M'PX3BM;$X]'*JKX09O'5&5MNV*0?SPS&0
M[8`OB$QH1NTU6I88QQQ$W+'T\G2;2=0C)4E$("O36T^T^]A*Q@4!:XA95T>;
M$D?=5A$A>'!&>N9DB';9'A::'J0FO,C$:L2')F]Q5MWU`FD%*33'%:1H8-`&
M,T`8XZ"Z&I7E2H9E??0]BQZJ:A@"1&LELXDYJ@#6U@<G-$RM28)*).L<7%R=
MWEQ3HT:1*0>J5JCRRB2QF#"'8:"W[VCS;U9XMNGNC>9^AHQ(*C5559,:(M]J
MGS]2R"/OR-$!I<4+C-7FJI_(:_<DQSF26(:B)N)FPJ"__'V`X)F@U&_B_O#0
M[>)FKPQ=Z3N,-;+"LAMB;(.S";0?((VEN210IA4G=4E)4>@:7I&Z*3UPD1*5
MX#HIP`<)R&([:5*'0S@?`2I*!22C&I(`L4DJ%"=((XL*D\A().!4>21L6C32
M4PU96C!!UL(-F@UO>O=KU#`?6AU4)^7.BU%[KY0U4HGI&T#[:<X0KE:"9H*Y
M)A;R9,ED360409FGD:=@">)$)KW]_2C0/@ULSVZP.>WQ%VQXE5\`Z;@/"\X\
MB3LU'<O.\XGTGMQ?U`\+2ZUCXI"PNKA1(Y5I7%45HL;F^&%$!B[>6O5+"B])
M-*=ISM`#=KQ-+>1%*Y2+E>C_`"60UD44I$C2K5[33]<IJSF3`G6MR9*W0@/1
M,[=X<;-U:K7Y!6=&F9(D/($:80>)/OV8$W!@]%EC,WH8M%@$/82P",,%H.MB
MWH!8-"&8/>M?IK6M[WO]-8&G/.O;M<]+SJ65]$ZJZKK]YB#"5)5;E?/*]XT7
M%7AJ/<RFM/N-2RS(9'F%]<%!IP30(R3]K!I=".T5\99@@!N3@?(\@M20<F.U
ML1*@HP@T(1C+$(LT&RQZ"86(!@-["+?IL.];U_76_7`BTX^\,/C\X8LZ1W)S
M]5LP;+*DT0?J[72>9W+;=AFIZ[?A1S0X.WMDPF3LR)6-I21-"E0#^L):E2D_
M$$_8-[U@9BY]\:W'W*]E,EIT%7LIKU]CE?RNLF1B(N2YY)7C5$IH^1212!*T
MUM,I_(H.RK5CM#$)HE*)`G.$((]C$(0O70;W8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`@#\L\K[>(O>LH;S=77DZEE?N=.+UZ];PI.^3
MJRA"JQ!SS90VF=SZ^JBL.1Q5^;(.A4K`&A5I&U7[D:0@O:@]0:`)RZ[6/+A7
M\&7R)L?620+H=&5CZS2A6T+Y,T/*EE1'.;9(ET?(3,*Q]0+1C*5FHBRTAB@`
MQ$A"7L.M!>.`P&`P&`P&`P&`P&`P&`P&`P&`P*,ZNBQN4L)"5A=7HIX>=M:]
M6VF-($\:1_B'9RT_/07-S;U!K5M6W%(?:B+6*_LK2=_#\&CCB@I[/%]-SN[/
MB]W<9`YKUB_;:J=4[,2;'6%?^.-_:;2-F:FH1[(F6MWV`#6[5K=F&B]Z@8-`
M"`+IP-4>B./>6>Y8I6[?U90$7N!@@TA+L.'PVU&PU8ECDI6L"]B..=V!.X[:
M7-06TNYY)J19I8CT9[3/9LPHHP`:`>2WC2EZS\,/2O*'/%$K&:JH]7QBB%T]
M3=7MELNS>J6VPTS]Y<HO7,MG4*1R-R3OZY8\G#.>B3THM&*R-''DE)S`P`SU
M^"+_`,8QTKNP(?.XLG8?&M-&>315TAU;P6PT*%N@+X-6<;$'-[DD":7]6C*^
MX6%4M&><,P)IVR%HQ!+">JHVTEEJBL6=.,XPAIKV%MI`U"9`B4#)0QMM2EC/
M1M0AM:0X0"M;$4FWM.6+U"7O8-:P,A8$67E]C7+,JY1;&SKCHJI^7ZY#<4`5
ML=EW'5-#7/%3)PG+?-M$:*@W1$$L*#JG%U;!+C/LDH2UZ-,F.-T>6F"JT,*!
MX:H%S?7O,M@MO+O7%=]D5T[]"6!(5U@U;75#55#HI*EK%#$CI7Z&%\Z1&$U\
MC-;D3>E<#%(4(#UNW/1^M_7&G"$);,!@0B_R.C-%^%GNL6W9,SZW7T2+^56_
MLT<)7B/M*"D`90K'QC?TZY2\F&:3D-Y!9"YR/,`E2JDJ@TM06$2OB&8XHI_C
M$*I1(9LQ1U=6)_0UK-TN17+*ZJ%3$P@TTD*QG5J[(J>N))8U9/D<9@A,$'35
M*'4!:L(MB.+/*(3A(!_%SD7[@\2E7!U8+5/@,]@6&UE!;;)EUC'0XO2]$NW#
MW<,LA<,U"G9(:M$L,9VX+BW!"M"L"L,.6'EE!T28'\]NM[T+TU[M:WK0O37K
MK0O38M:W_76M^W7K_P#;`UYZZF"BO>4>FYZDD.HBLA?/UR2I'*Q!D8@QA8P5
MW(G1)(1ZAR=7+=%LRA*%2+;848X:T7O:<.S=`U@<NWA:MAPFC3U%)[([#?.D
M;?9>#_SK.QTHX^3YVCT0KESTYN9CU&5_72DVO9).'&0-Y),=7PA`!:::0O`G
M]Q>C`[#"/\3>0,;].+%526>S"Q[P<>;4+Y+7M<X=#."1`PK+E<4X$%AK)F]F
MU*LLK4@)4HR1?CRW_:5J4F)CAMYAVQ!VQ*8ZU*D<B0C)/`1*M*?S6R%RX@\\
M2MI3,AQB904H"<W&?CD98`[3"*]@P_)KT,V(6PC6XB\/W&GC^LA^MVA$5SJ[
M%D<.7UZX2&T;YM&SBPP=4NBBQ!&TK!)Y"IBZ=/'"(2VHVY3I%M>G0)]$;4#!
MO>L"47`\ZM1I&E4JQ%*#PI4YR@1"4D2A4=H@L1NRDR<'J,]09H/H`&OU$+>M
M:_K@11<<^66/]F3N6P6+\/\`D)J?]G5^_3-;-+TYP45E7KK((N7&"WVJ&&3R
M&2IM+;.3NTDVB*0FDIR%!B%08$_X`A-$&;.<.]TG1MH!JC_A_P!WT0]$09[G
M3O(^D.<EU7UVSE-#S'V9+&/\A_N1\B4BF$@$_"4(D3*J<]?50*AJ!D;+"$8;
M\X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`P-9'4_,E-R]
M'7]N]$T;5<Z<(FNGB&'V/:\$@\F60AL4*4KC+TS))GYL<3XTA4(CP&K@E[3%
MB(,UL>OC'[0S:W.+>\-Z%V:5R-T:G1&E<6QS;E1"UO<6]:0!2B7(5J89J96C
M5IC0F%&EB$`P`M"#O>MZW@>S`8#`8#`8#`8#`8#`8%&(<EYK\Y-)D?<TS:B;
M&E<DDYRAE$T.ZQP4.Q*UF0I2'4Z0$KV,IO(.4C4HDZ4P"XG2<XX8%`20K.`P
M&`P&!J/VIVA5G"--ZNVW8O<<PC1LG:(@D8Z/J>5VY+U+R]$+U*/9S-&$AA#*
MU:*;3=#7N2A$AT=LHC1NU!Y!1@:^=(>4ZK><ZDYOMT7.7:ESI>H$[VI@5<TI
MSC(Y#=#"!@A1TX<06!4\F7P^81(Y*W$B*.`<G&(@P`QF>T@&S<#\]4^5&I^3
M*6Y7NR6T/U=8;;U>JBY43@5/4RKG-JPE+)8(5/-J+!@I3L@<6E6RIE9"%6B3
MB5+0KS=EEE#T68((6<F\Q%)N7+-5=3QOG3M2<MEJ21)%RZ<@7/ZJ27K`W!UD
M=A19B/L2$;D2!"P-[X[UJX%$'E."HOWF)M"WK[!>Q!CQ_<$GGF\7T\3UUJ><
MG(;4FEDP%`T7Q5L(L4[2VEK3?8,L26Q4;FO4MK@WF2*)C5:;R71(M:7M$G,V
M><%(,A2&1Y/5,!\>GAGL*K[UBL1ZEK7F/C^S-6I"X]`HY2\1N6)1J,2.02J/
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M[%AR1&WFK)PQ2%J<`."P\LG3:F(+=W40])&U0D7')U)01:^&6T4*+^,I.)XW
MRI!7`X:AZB-4/B:[EE*-T(.:K`>%R`ALM>&0:93>J$Z5H/2Z1FN2&0O&M&EF
M*#SDZD'QANM_&8FC+87BKC:VNG-T;XR@LFS6&*,<KOH[I.15VMT8@<W)EDJ\
M504<GBBDR0/!KR&/D%.)>TKD6KVX[&M$2G"?8+(^!?V-[%)EZ@A,R'LCVP?&
M@21QP/.^)7^YDR(+>J=R9`4N1@(*#MQ^F6A4'A$48=\9@0NS`PETNJJY#SCT
M`MO!S7,M+(Z2M55;[RV"<PN335R>"/QL_<V\3(0J>0KD$3`K-*VD*,5:,!KX
M@B'[=;#GC\8O*_%4>C'33]XL5_:R^Q+&Y6AE=US87=T2ZZA?/#?7+D2H=(2R
M5/-9)`*O?M-9)CN)4'<<7*5;<'VJ6[XR!#$:$A_BZ\/'./C.;W";UVDF(KZM
M&OH]'+X?W"X+"L.'R![0+Q2!7J-MLP$@*`UL[XJ4$M2P]`4YZ;Q>T\8C33QF
M!*%9LH_8];6#-=J?I:B$'EDHVL_!.\H^I^WV%>[?9_;,?"-^D7P?4]WT4.MK
M%?I\1.OD&'`Y^?#KY1.PNU>@7JHNC$4%)CS9R+`+]:'%@XXZ;YT>7IUFLH;4
M:1PU*+BG<F@[Y&5L>>$ZEM&UD>Q^3'Z6)!DZ2+DP`Z/L!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@0U>07Q)J^\+<=+.,Z+8JL2+
M*.AE-(XTX\=\H7^<G%';.D=@N\D42V^:\F<HT%R3O)*1O0(%#<4TJB3E@1G"
M5&DX$ND2CR>(Q2,Q1(:6>EC$>98\F.*;6AF*.3LK:F;232V=@0-;"U%F%IM;
MTF1)DR0C6_82466$(-!<.`P&`P&`P&`P&`P&`P&`P&`P&`P(1/Y!)*13X[WY
M*O<(XV(E-K5XG4*I35W4]K-.@&A?0@`)IY$D$=LEB5B-V'X7)<8>PA,UI*I*
MV>J2F%A&YYD6V'3'BKQ6H)DF5R!\<%+P4PL,6X:Z9MX]Z2-_-3VM=@-7-;C=
MM==&0<+82UI#]I9`^K%S<04,;F,S1!NC0Z..1&#?_'KF:5C7R=":=RS1[`9$
M%;.M@D>0;)A#$Y??'5J]:\JH1)RQ*=I3D9JY4>A(+"D,,-V3HS80?_RD"(JO
MXRYY9;.2;?*BDW74)BLXBD(@K'/>E7M5(X%8K5&%'++/*U)$54VHTKU!IAI*
MS8!F-`U1A!@32=`-#<GQL\Z*V7Q*\Y4?R[;W1W-2!G,/=H7.+CI6E6J_F&+D
M7L^3:21N:5883,ZT1&SMN$N0[4[VI6Z;W("W8@*_[0ALGY:H[()=XO?(3%HI
M'7^72>1\;]$LD>C,6:U3Y(GQY<ZLDR-M;FAG0%G+W-:H5G`T$@@!AYG_`&E@
M&/>@[#:SGQ.Y)*$I!(\(E+:[I:AK5.ZMRQ*<B6('(F&,I:Y$J1J0@4)%*54$
M18RC-:&6(.PBUK>MX&7L"+'R^<5L7=/+,<J]\OVN^:Q0:]JON-GLVU:RKJWH
M*0ZPL3XW_@GN"6HYM4+>2GILD:DL!:L9A1@PZ*-*-(,-+$%6\4G(T*XZYUFL
M(@70\!Z<;)]=\VM!99M;UC3-310+LO8(;"1Q9-$:$T3791T7001,F,&E+3CU
M[=%;)*"4`&@W2IIDO1)4L*;.AIQ!I!=:`PQ1.Y73,4<(=`'X9$D7*T"-CB\V
M=)P\-+>KC/U4:[WK3%`S]'&IS2/<7HL,S8$-/\@\:LGPW=X*$8'4PU-4B4\P
M+.3`#U&D@9G%PK3%15D-CLPC:"D8QB6_6*T]_4T9^),*<_JF@")[P*3`HC^.
MQ/VA&_.T:'"F+IEX9I:JM^M*':#H^@<W4]5(T%[*:Z=HY2K$IDR!T*,5SAN=
MGUJ2@$N6$C:SF\&!M?\`QB9<^./C2J=E;0$2R-)[$O='(7M+TE7%T%5JYHY&
MROS)&3&&%1.+&PE1-#)4O<ALRC[2Y/[=.B@X13RF*("?2"6>?.9?:<5W6=I0
MU'6$A:XV1,YW'$#!$;+4KVH+JL<JM4:>UCU)(ZQA.*3J7`]"B2F*S-E)AJ-E
M'[*#*F!KWUNQI9/RGTW&EL.36(CD//=T,:NOUCRY1Q).DKM7$D0*(<JD++L+
MPQ)I,4HVB&L2;TI2A/V85_>$.!Q7_P`7PF./Y_4ZNNNMW"?LLMX-B(IHT!,M
M^JIERE;_`.5?V1YA[:PNZ%?35ID0M@2MQK?9@WH<B"E(1)0I24XUGL"2S^//
MU(Y7#,)-6%H6[3ET7O"N<8J\RR8U]UIW)TG,5[?^YF9E7KY\BZ%;5=!1MW>'
MW7VE&H0\*0DJC1EE$%)!["`.JC`_(0A`$(`!"```Z"$(=:"$(0Z]`A"'7IH(
M0ZUZ:UK^F!^L!OU]-^G]?]/7^GK_`*>N!H%R^Q>3MIFEGE]@V!Q7+JX<-RY?
M4*BB8+<;!/(XM728PV(,LU*F$E-CC]&F6*"T`X:;Z[B:IUH`CS=!$H,"Y:H8
M?(BFN9G5WK97(#]0B&&R<AV:Z?J>W879K]/5*B-ABJ[YYO:EB1]IC#:E(=1J
M2BC3%!AAQ`/48="&`-V,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@1J]Q>25FX7>C4TKYEZ)N*,$5@"PE,SI4%.O"-"Z+IJ3!6:%K(S,;9
MA4Y$N<796GV8XIFQ2THPJR/G4`]QFR@D0C;SJ1QUAD.FUQ9M/S*UO.FAXTA"
M[M6G1"0NTVN@6Q<YMH7%#\_Q'Z3J5!&C0B^,TP/H/85K`8#`8#`8#`8#`8#`
M8#`8#`8#`MYUD'XIYB[-^#D+E^YUKDB_*M3;]QFCWXUF7/'VY0N^<O\`$HE_
MTOJ)C/:9\JTXHKTU[O=H(2_Y$+LY-/CP7;:+13TTXN%R5NVIK"-8^OGI0R[/
MT^FFE(!<8J"K$;%CJG3C2:.=RE$<-+/$G/+TL/0F`"/WR]L!"WACQ1OKV3%U
MHX\XZVH;=\O]HW1!52AZY@E"4PP-4MLSCW6\<*(,#Z(#)*Z:>4IY@-NX]C"?
MZAN/W]W=9/`7CHX;L6O7YXJ<Z61^EX:]O+WQS*;R0QQ*&G$CJACD[B+KU!5^
MJ03.#F@+1*5+W+7U6BW[R-GG&%'+@A'KV7<DE[2\/O`$KZ=B\;ZZLWH[K:6A
MCT/JCCF?W<MDB5A>^B&Z-R&'4M5?5M,*&!;!JM9-%.9JF6NA9>SC0F!,,T8J
M`$U'@Y96:.>.BJH\QU,^4<E99E<3>HJV1\^2;F-XB;B3:4JVX(%55S"UKMD:
M4.U(Q#+<%4E<3G,L03S-E&"$2`-GO)!-;+K;Q_\`:-A4R_2"+VU!^8KKEE:R
M"*M3<]R)IF[!7[ZZ1E8SM;L6<WJEQ;LE*]GR@'H'K[M!%L.M;#9ZM%CPXUQ`
M'"0Z4Z?U\)BJQ\TL]-*]/"IB0'N>E6@@+#I3I:,?O]`AU[O7]-?TP+M5JTZ$
MH)ZHSXBA*$B4(O:,?J>N5DH4A?H6$0O]U4H`#U]/37N]=[UK6]X$'O\`(0Z%
MY`YGX&26%VIR6D[/J]9>=?Q>-T\M>4\93E6(XL,W<F:6&2@9*I9'@M#"S.A&
MSTA)YYNE?P;!LHXW80N/P5WIS;=O(LC/Y<XS2\45[%KDGC`YU_%7F/3NL)3-
M&TQN:I/,X%:\1""/V$E4+FWZ!RCV$J2OQX-;+TG$F&8$S+F!T,2""S*4"1?\
MZ,03G-$H<$FDP%J<;@6),E7MAVSSV\)I9(_FT$HX0#!`,"'98PU"\ATTDU<\
M0]-SN&RY^@DKB53R)]C\LC%CU%43\T.K>`H](8W65?+'(ZCAQJHT.B!*WI&<
M0$!H@E[`>(HP`<OL5M[H[KK^*OUS9W1LHFMJ6I8,&>%I4QGUY<MR@N1(BGRN
M%*)='SX\PQZ+5.R-IQ1FMP^0!'.259)P4R@*]:W?&$@G\82NT._"K54-=&V.
MK6&3S>XC5>CG&L;!:)C'G^7FFKC'UEC;45MJ"^(C#4BABE>E4C;R=:*6;`5I
M,F("?RHJ4IZ@(6DKBC*MKZGH`@5KEZ.%UG$&&$QA.O<SQ*G%<4R1U"WMX5BY
M0+8S3?C]YF_^[>_36!D[`8&$^E7U)%^=+\DJ]SCK*AC]+V@]+7B7J7M'$VI(
MUPA\6J'*3JXRS2.1I8^B))V:L,;V]>M`G"/9"<XW02Q!RA>#?I`NXK_N5"39
MTHB<5@?`*J10VO#;SZ$/IXN,S*9L"HF[(-!9=S=3,:A[.3^WA$@>M;U(4I)F
MPD)#R##%`0M+^.6DE+'W#:"^\/(%S-V+;<PY+<&"+I*@Z?E?1\S(B\>O4J9.
M+N^N;RSZ^HF3IYBB(.&Z*D3QLP!8-(=EEFGX':.ZH]N#6Y-X1#`)<@6(PC+5
MKD`P[4IS"="`N;#TKDB&'8_71J<TL\O?]Q8@CUK>@@'\7?CB[RY7ZZM.[>G;
M>K^25"]4*DJ:LZL@G4_<-_(XM(`6(7,G.5:0]72&0%HA/R/8RU`A*UZA(:`(
M$(DY)ZW2@.@?`H;\Q@?TZ!.-T?&G2!\8WS1S"Z'M2A6-C<TSH!K7G$>HE;&Z
M"3?`N2B_L5)1C+%^@MX%<P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&!J!TGX_\`B?L21PF7]1\O4Q>TGKK6BH<^V1"&F1.;2W_:-7"8
MS%2HG9CI&#5QXSS&I9M0VF'#$,1&Q;WO`VP:VML8VQN9&1N0,[,SH$C6TM+6
MD3M[8UMC>G+2(&YN0)"R4J%`A2D@*))*`$LHL.@AUK6M:P/?@,!@,!@,!@,!
M@,!@,!@,!@,!@,"!;^1HWMSIX[SD3F;5)!8[HKTY(?;[SUBP1LM<0CDH];2N
MG(&P3U.Y[;_LZU^7&".[(^3Y]Z5?2%H-'/*..LW'A7Q4*I=*.<R:ZVXKFPA\
MGE!^0[H:L%HR>=97MF'#:VK65(>B7@@L#0,Y%^^%QRK0"2U2@P8B#]&!BCS@
M%HJZ\=7A:L@E77<PBU?3^E8C)3+"I.S[`YU?ZXFO)TB0NDBG_*2MY<+-ED>2
MC84*QL9'(U8[M(M_"I.^;9HAAE>TNO\`HQH\/'`SSXZ;(C5#26T+)=Z^,F52
M^-.]#(>V0R%K+-*>6RM^8H7`^A7JM$#G(V9*6F5N:%5I\*T>L*-2B4#"6$U/
MC$O2QK1XM@DWZ)MYUMBRFK_((K"N*4<YS/DMI<TT?GLK;4AYU<6'&(4KCH&6
M.MI`3SS42'2HL'W-DE`.UK09V[(I=7UYQ9TC04(D<:;%O1O/-E5K$Y:_(C7J
M*H#[,@KHQ,DB7HT>AGKVI*)V+4_[.MF;`'0@>HO3`SY!6@J(1*'08YR0+7.+
MPZ/-!VTI8$7VBF5M2,XW).U[4*#T:!0H2[]@=B'HOU]GOWO7K@7C@<S_`/*J
M36$O\==3-U40ILFMC+.V*+!#$T@;*\?(NVR`$;M`:%3)6*TDBV%/36Y>@F[Z
MRTH1!ART&C/4OW`$&3/XT2FTEOCR>UUWP./0&V5]]R-7,$</KBJZVB+NGW55
M.)8*Z,2"FSMPI[VGK-(R(%JSZZ)Q*<42A$N)^TC---#H4P-)?)`D>EW"W3Y$
M>0/SH\!JI[5)&^,V!4-5O2KZ)J1:H*36%?D<EM/18G:5./:A2_MJM%]?1@/9
MHP0!!#FVYRBE@7O_`!7;OCL:I"R;&GUDT\J/9JY@R7DJ8/\`-G]4GK<Q7)JS
MAE+00N/,C(E7(CG?3+(FHRRDGU%&BCM+MM1X`E&_C=U?8]/^*2F(5;-.7!1\
M^(F%GNTAB%W1YBB\Q7+WV6JG55)TS.ACT<E9,=>E2HS:,R4@52,[18C#E)Z4
M206!.[@,!@8NO%BE4HI6X(S!2@GS>15=8#%#B!R5QA@#I4[Q-V;X\4.8-!"E
MVB@3'=03K;DE+,4(=;^<L(A@#K8<J_@"\1G>WC6DMY699U6UE#7RS^5S61'&
MS^I9=8_[QZ29YTX/3*Z6?'V&*[@<<;G=OT`L3BU*'Q6TMYGL).4'K5Y9834^
M/YY\DS_+IDX=O<@<><P1,Z*@51D[G^R%T[L!ZFJ]Z2FN*"4`(:@Q\AE"V%&'
M&G%KCC3%FBO3WAV,0`E"<W%&SMK@[N)WUV]K0JW%<?HHX[9"-"08I5':)3EF
MGF_&04(7M`$0Q>GIK6]^FL"+KC3S0>/WOZVI/3?*UG32QI+%(:[SE<[J*7MV
M(PY4RQ]1&$CZG;I-+X:QH3GUI4R]$`UN'\2T7O%LLL80;W@9FY&\F?"W=*AU
M:N8NBX184O8ELF2/=:K/RT)MIH*B+DE:GIW<JHGC;&K#11XI2O3?&XF-H41N
ME!>@F;'O8=!O;@1]<N>,/DCCJ669-*.8K7:WNWT<F0V"7+^B+ZL=B?"I8ZH'
MEW5ABT\L601EM>]K4&OA=$J0ES)*..*"HT6:,.PO&H_'WS#1MOL]Y5TP68EG
MT?@LEKEB'+>A>@K/C++%I:NBR][3,D*M"SYE$F-8J,AR$'V42-.=HDO8/=L(
MMX&ZF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P(T.RZB\H
M=B6I&#^*NMZ*YYIU7"X^U3(BR*5!:<VCLY9)ZID3K,8NW')R&^9-DTA6R(^I
M:5KLR`;@%FK$YXU)H-D!&WY1.HNZ>2[YY*3UIT(^`,;^8IJ^W7^?YNA,@Y<F
MCS#1LR6R;5="FFY(3:[)/DB<S\DV1T*I2P-[>'>@*1J#3?4.BV%/`Y##8D_F
M*BUXWR,L+P-<4DT@*6#<VI(M$J*0A5KPHBU&S_>$K1YVB];]OR#]/=L+FP&`
MP&`P&`P&!;DQC8)E$I1$37J21LN41YYCPY##GE1'9:Q`>6]0W">(N_I-;5,D
MA;-*/F1JR];&G4``9K6]AP*VC3Z1I$J31RA3I*G(3Z4+#MJ%9^B"@E?,J/%K
M0CU!OM]PQ[_40M[W_K@>C`8#`8#`8$/'G@?VR->-.YG5[##Q,Q<BJ\IR_?-]
MVQS>P:+.L!A`E^6QZ93'S'2L;CL@)#?L9"):8+6CS/:'0!AH+Y/94S;\,''[
MVWV'6]=M*YJH5J1NY_7'=,3A"P)=8K`BCK%>E.Q=SMFSR#0-1@"5]B-X$"PD
MD2Q6(MS^L/03U\;K"73E#G)>2\LTF3FT]`1H9`P2NSYZS.J0,;1$(W)KG%V%
ME6[+4ZI%H.].<C`!Y7:%LU4$)HQ!T$<?F=Y6Z]ZU8N68)R55-#S-Q8[;D,FG
M]C7];%Z5I%Z@828F)O;G5$AYZM2LK#EJR1*EQI&R2-.H"-IP^X@H)HE!81!>
M0:GKBY2\6'CYHCJ5FJ!C=G/K6SXK=CC6\9[@Z@J.$DSIHZ'G]?O2%AC5\,/0
MLZ1.SXG9DZG3@YN1C>>XF"1HQ?5*3FA,#X&&H#WXK*IBDDC#4.!`EG0D1B,>
M>*JL&N=/=4)KIL!K8#Y97=RRVQY029*6S1BL1"QW<R=(51)&S3-ECWL)KL"G
M?B&G\M^>_%MWYW\=^(_-?23?EOQ/V?N_B_R/Q?<_'?<_W?@]_P`7R_W>WW?K
M@5'`YM?Y3D!=[8\;D!JF+Q6<32:65VCS9#H7'8#%Y#.'I>_.CC)QFEBA;$-,
MFE96V).MT4A<52)">KV3K[!:CZ^]AM]X7J'9.0.%G*%.$3<:]2L5D6%+),KD
M/)X^.W-Z++9X\)3+G&J-V?;[BY`VUM@""WH]R+/6D(PDZ2$!3`T(),5-6;63
MB=6$DLVV&]5.ZS8JZ2QQ)+"3H'!OPBR6.)-@P.%.C2X,;39+F;+-!7.2DI8%
M60V("C"=ED;"8&M?D*AX'/Q]]%0QT;IQ9H2Z94MZXIFA-!65/I*)I"W&'/88
M5?Y#/0,@>@C1;<%('<@A"7LLPU,3H\"<K`CV_C/Q`^*>).@3C&F9,Z:4A42I
MN)F534I4ICBB=&9@^-]CB2FU*U7.(H\#)$8CDLN-W+GG6A&J@%)?I%A"?C`8
M#`8%G6)J2[K^=:A:`;K,=PZ3ZB;64_DQ0QRDNV1=^"0%RA0V/1$;&L=/B+TO
M&C5@1[%\VR3=`V`0<P'B2AOF7;YSU!8GD(=>M-,<<Y3DL6K%!;MGU"VQQ%;3
MA)5;N:TP>&UIM\;YL[Q-@C"0M-9+F!N-4_;-+"WB+/V((:V_Q@>ENH^FK(?9
M->%QVI;38T<NIRGAVL'R01'I`:^:JK"C@TSDOY+:DH);23IMM$J*)7O.]K$Q
M99J8U0K^X5\`=H6!;GXR.Q=D>MMZ-IC#8+3P]NAS:E3M"8"I4`U8[/:O:`";
MU6&C]QQZCU^48M;%L6Q?K@<%'\8>Z)]:WDALF63>SAR)HE_/G0R5A(?+@LNT
M)E,I"DNVGW\"N3/LU1%$R5=%(6>68BVJ6+75$SNR8PP!0%FA"#OX&+0`B&+U
M]H`[$+T"(6_0.M[WZ!#K8A;]-?TUK>]X$;/,7EOX6['LYUJ'G:QY_/9JQLTH
M>G8H_GKH6(1]""&#0%29I.E\VJ^.17<F:CG,@`FH*S;@,1FM`)%^N!?%#>2;
MD_I*Z#N>ZND%L[MY)!W>Q7&(V%S/TG30VV*L;FQ,SBL6/%P5/!F#[!;K(DY`
M$Y:HPXTS1GL"+10]Z#?#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`@7\L7BKMKR$7-64XC$8\?[W%ZMJEYCC&HZSJ*[[7F?[RDKZZJWM
M"@25_;%=0QKA(VI,UB(/4I71Q)7[4F@`#0"?<$VE;LSY'*[@4>D^H]J2L,+B
MS-(=1%,K1Q33XUL:%"[:C"1PV)>ECVEY!GTBS][.`F]@1_W:W@7I@,!@,!@,
M!@,!@,!@4UJ4N2M(,UU;`-*O2]U(`C`N*<=#0I718E:E^U!)1(`C=FLDE4(G
MTV)/L[90A"$#8MA4L!@,!@0T>?B8[@OB[OE^#)I-$30/54IR7J'=+%<F24HT
MVSHL,*=JN,^+S`A`:KT3LL;<-$+3H4(1'O+V+0M!I3Y0K^E5>>!WGFW7A_MT
MA<\PCEL^5RNJO(*.G+A7D.\$3+#75IZ905!(]7XZR(8`J'%/I@;POI)A[GO1
M/U?C$$[_`!^H"KY:H!8"1JY>!;5$+6@DZ^Y73H=:^!6,J52%P5WF]QZ)NUK*
M#]&^HWQ0V(3%^_\`<V2#U],"%C^2'7S!->=>='2P7B-H*FAU]'O<_99!UO/^
M21S<!,%D"QHAS?(H13=V?N@QPVW*5!R8;6!P()2BV@-+.-&86&B27MN^N%_#
MEXM=<)BIZ-O/4704VK%@?[\F70'9$3:HZXN-Y3IB`@D,*KJ(W!)#I@NBB5(`
MM%#=@9]+-IP)@%E_;"'0-XJNE;QZQX_8+=Z&45:X67_DBX8$X/=-0JVJ]@$C
M05E8T@@:&0-$0O!N:+(9C';3",TXI>E3["9O>@E@UKVZ"1S`8#`A?\Z_4_3/
M&7&D6OWG&=ZK%NC/1-1-/0]A(J;07M)X7SI*E+S'IS*H?7[\H;HFX/L?>%[6
MKUMW7M:$PDDPC:P@PXO>PR1X<>C)IU?QZ1><OONUNBT\NL:6%1&?V[RU"^37
ML44:4K(@1(6*$U[(99$)E$QKBU"I))4+DK(<!J32-"`)*(L`2L8&C/DR;FUW
MX#ZS;'K[^V9;2\K(>=-5<U5;3F)H$G+_`"@4%=7A((K4TI6"0Z,T62^N*1$6
M/T-V9H98?4(M_P"+5^.*\2=4IFM')"D89=*%('%_K*I*U)=A*$K*7]AI%5<A
MD2R=)22DP2S'Z4C(E"P[0@'D@2$HM8'1=@,!@,##W0ZAX24!>2N/&OY#^EIZ
MS%#&=%'@N.RDEX)A3V8V&QJ0'%*"6-_+6A!M&L&6,*51H!FP[T'TV'$[_&36
MWY:%J],--S=G2+O.NK<\?$%GKE7:OK:6SW5;32S)B]LCO2$]A4_7%RN+VZT,
M[.>D7OC?M,U-*=Q`7I0JVM3F$!*]XF.(^D^3^M$J=@X_O3CKCY%0UILS[&[9
M[R@75<?D5@JIO5&JGC4(KZ&+%&H0V0F/LTF6$.ZKYW%<6]&)U9^@D)2=!TDR
M9]11:-R&3.2A*D;HZQNSZO5+C%)2),B:$"AP5*%9J-(O5EI22$XA&"*(/,T#
M6]A+&+T#L(,_&'YG4?D*Z#EE-*5''2`A-4"^TH>T4-T9:ES6,N1-,V011<HE
M;!-^:*1:XXT&H7(A9[#%&G-.!4D]R48%(C"`G$0PR'M;@%W;8I&FYU"-48%S
M0L36D<`F+F]E:5HPK4Z4M3H:MJCC<F-W[O4Q.@3%B]0$%:"%R8'Y"`(-;T`(
M0ZV(0]Z#K0=;$/>Q#%OTUKU$(6_7>_Z[W@?K`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`A<\HO!W1G9LNBFJU;ZM>:Z8ZS7LZUDG'9'=
M',IJ^?J9FA=T1K_&>6E9D*G4*0,Z'0M[<4I;U]D0BTZM,#V&@"8]C1G-[(SH
M%!9!*A"U-Z,\I*J6K4Q1R9(22:6F6N6]N*L@`P;T`T__`'C`ZT(?]V]X%4P&
M`P&`P&`P&`P&`P&`P&`P&`P(=_/5*5,+\6_14E2R*9Q4QO45@'\W`>CF;E*2
MIA+K2A[<04CNB01*:M#$6K5JRRAI#D`M.FA_4"84(T)@0C9\CEQ2-%_'_P"6
M)!$[FFE?2.R(SSFU([25^01BA+^,AQB2M2O.F?4X:]5-]ZM[HF)V4N*3-C9^
M7/,+6>XH"498PZ'..WDR0<L4"\'+%+@:LJR(B&N6W&/H9<K$2U$)]J%UY&M3
M&;:ZXWXO4Y]&C3C<3=B-$#6Q;P(P?.-R%?G5\#YA!0-`OO13U6MROSS*8:U]
M?OG'Z1HC$H@+Q%C):;+HX>@>'AX8G%808C^`\X20K:D(D*XI486$(F>XN-9'
M6GA?\=G*=NT54//BB-]JQU+,XL[VY>G1/^`F&03VYGTV5U3+J]>6JWI]HN,O
MPEAT?;WU*O):U)B!*L,/3EF;"9OP#6079GC&IQ>-C98VZQ6;7A7\@96-TO)Y
M(3O$-N&9M1B]8X=%R*86F-TD*(!#FH*6.J\E*8L^`D98"M)R0F13?=]ZO[?U
M?C^UOZ'UOE]_TO@(]/M_+KV_:^U\O_9_9\?M_P!?7`]6`P((_P"19SU8/27C
MI-A=4J@)[$8.@Z*G$6(712QIW'7-:R2@Y(I;);"*PKFU))+(ZI;G4[9B`3,I
M2*#PE!-]?[0#"O>!E*%MY>O%J70ZO8A,TO7%IK[+!5'/W2'-%>/=BR6+5U*)
M2Z1>L.G1(YHV-Y"]YVA#MK:H_'0!1Z)0MB711GO";[`TQ\B(G<'$'38V%:B;
MW@%5/XT"EPK"KKI2:/#\`O@,JN[)9!JGG(U@-;)+0OSJD;S##`[,V/VZ*&$9
M'\:%]7RGQ>P"4N1<61JI+,I(]"985S=4?,L78MGHV9,>W,\7J%:<V3=-M:C-
M-W)W%,WN+H,P0-I@$$$"$$VM;V,XV`Y6FB6UM8%?)JXLUQKMI<IVUHVI-9J!
MLC,5?3+%@($R]<<O@"URD2AL2*S]$&J%36IWHK0-`V(,H8#`8'E7(43FB6-K
MDC2N#<X)5"%>@7)RE:)<B5E#(5(UB4\!A"E*I(,$`PL81`&`6];UO6\#%H8A
M7=&5I)-UG6<.B##$HB_N""(P%E8:];#$[6@7N^FE!MC0MR!E`K4Z'[30@"`D
MPS9G]?7>!Q]_Q]>G.A[R\E5SR"5]0'V%S];W,THGU:\L:\A,G[1<.<U;9(>=
MW;:F6D2\H+XW'"66$YLB$Q<$AU;U"5>C.">06G6*0[7]ZT+6PBUH01:WH0=Z
MUO6];UZ;UO6_TWK>L"W&^'1%I=SI`UQ6-MK\I0$-:A[;V-L1NZAL3:*TF;CG
M).E+6FH$^B0:`2(>RP>P/IK7IK`N3`;_`/I_7_3UP(NN7U?F4<KFDQO833X[
MHQ0*9@DC=&$E"+>@)#:;G+"S]"B,F5*)IMLC*2+J2=["X-PPZ6E^@?B/WO>]
MZ#*G/V_)R5<:U)U3_P`%%U`EPAT&VOG/Q5^M=MJ[&T[,1;*2OCMC*GB(ML.$
MR:<C5(BW%6LTI$F+!_8$PPP-\<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@:?]1=T\\<='QM->:VUT)\N1+ET=U77.O0EW$KP-JU"B7)C%
MM+UA/F]L<D^UX#OJK#4Z@:8(S@`$6`0M!MDV.*5W;6]V1;/VB=$*1Q2;5(UC
M<JVE6D%J4^U+>X$)5Z$_91NO>2>46<4+U",(1:WK08LN"\8-1X*R'./W!O\`
MRW<,$HZ'@C\?<9"8.<V(H6IV#\L!N*-VSQ\K3><8L<#_`&IDA0/<8+6O3`S#
M@,!@,!@?+1NMG"(]ANMA*`;\FRQ:)WHP9@-`";_VB-#\?J(/]=:WK?\`KK`^
MN`P&`P&`P&`P&`P(F?-ZY*F7QMWN\)+0?:B$W*($(V5L%Y5ISPI4)ULZ8&HV
M.*K)MR*R^#D()%IPTE&WJ4H!.@QA3`.*$9[L#0GR-6,M:/"7RM/4/2]B1!:O
MCO-9PK28NW:'IN1686X5\-2I*?\`H-UJ::U#:ACZ(G2S934U-B9R6%EKB#BB
M$XR#0FTXB>W"1<D4`^.DC>9@X+ZV9#E4FD%PQ7H%_?#`@-*TO>+IA$=B41LE
MU/"7KYW1`W)$QYOK[0_IL6PYV/Y7<Y$AXCX_?C66RD:N6=70UO/KIIMY;3[\
MYIG*`RQZ51J5)V1LG,:D)@%360D,*/*5@1'G[,3C'ZB]P4?CGI^9\Q^`KBNT
M*$L&O$D\LY7-J]C$9ZD5=/V%#96XR>T[XG;G#&>7TA7D>G[?9;ELW;<CE)R9
M+'$92/T`H,`62J,"=SQ=]26?V+Q["KQN1CK.,6.\R:P&.21VHR;)#"F8V-RY
MT:D2)*MM)G9Y`\NNFTDD:]81I2WG+1F?7/,UH7M"04HT9@E`1)SB-$G?$6,W
M9&PJ@?"2;]A/\)QH]$^\W9?^YHL?O+%_;[?:(0?;`H3".3#+=/W.0Q)S0OKL
M!DTPJW!66;&0J=Z8SW03@B1"(?3D?IM643HQ.69^A9@P_P!V!`M_)J5F,?BL
MFLU31%CG#A`KNH*3-,>?&>6OP53R=8"*,M.VIMB3TS#4/WY"1%A2:<-+&O9H
M]:/2G>H-:"T/XO3DM??&[))&YP5/7SG(^H+8>5S*17LTKHXP:V.UV86>XH97
M]=H?W5,5O2-2YQM&WQTXU*(HE,!20K&8'1@8<24,DLTTHLQ28(E.`PP`!GFA
M)-4"*)"+>MFF!((&/80^N]``+?\`36]X&I7?+.)\XMZ;0EM+&^JBZ<F;HW-$
MDK&MKG9ESLQ-9KXT%*ZLN&012KYP/3HW$B)0/CF@;S#P@V8>5Z:'H(B/XN)Z
M=3XJJ_.*94+4>9-I4:M4H*8JFF"7=6LT@<5*S26L9Q,54[+3J%HTY<@?R&-V
M6EDZ`%N*1$I33@Z,<!@,!@,"W9>22HB<H(4.[K'TY\=>R3WYB/"E>V0DQM4@
M-=V=4)(O"F=6T`MG)S-D'Z`<`._C'Z>W8<2W\<U1XX8IY$)_"^):[LXJ8RCE
M2RI//;3EG:L4O1O7LT;MBG&'<><ZTC-20-*)PD#FL2OZ1X&J^RE,5+TVTP"!
MDZ*#MX>]NFF9WVQD)%3UIL7[9TR]8>WH5#II*;MO(6+TR=8I0I#E?L"8<62:
M,H&]B"`6]:#L(`/&-1OE`@G8-C3?LNJ'6)U@?5#O&6^8./DBO'J9@D<P5R.)
M.R95#*3F;CN(1=*<G0J2_O'LS*O;R"=D$[-`H-V8'0E@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,",3O?QB,G>LI@<J<NR>\.8S8
M0PJHPH8.2^A%50Q29LR]Z)>UVY@P@C[R0ZO!II!9(%GN`,!!8`^T7L#O02*P
MJ+D0>&Q*%IGB1R%-$(PPQ=._S%Z5227/A#`U)&DIXE,B6_\`F/TC<RTFCURT
M[_=5*1C-%_<+>!<NPAWZ;WK6]AW[@^NM;]HO3>O77K_3?IO>O_WP/[@,!@,!
M@,!@,!@,#RKE7TD2Q;]=4L^HE4*OJ(2OG6JOKE#-^NC(V(&CE1_L]I8/77N'
MO6O76`0JMKD*-;M,J1;6)4ZK:-<5HA<DVH)`;]982$9@251'O]A@="%H(];U
MZ[_K@>K`8#`8$8GF3F.Z_P#&[TM,-3Y56NV5CB1NI0CEM+PDW0E5@11`!E$_
M]`1"<U>$N1#5Z0[2+6\9[CL_21*:G4G%'EA')WUT!)M^`*L[LK?I\%>3%TK"
MDM,-Q*+EH7\)+I7MI_#&,$XG[=2D@J:9M[F_)1_?0QUA8-*W!)HI.H0E`-"(
M)D.(I.3='%'/DM=IP]64&<U;''E?/CK/99X]RM0IWM0<\FV?649K%B?3U:DO
M>Q'MC0T$Z#_L_6+T$0,#GR_EK*?_`/DJD$4]KU!9E3*[P:61CKMBZ'?ZILBQ
M+BF]<6]$(L)F@[=6$I;YB54[DO:I`CT8XC"J/$>0H1A3@V)0%4XUEW/Z/PS<
M-0R]KG[7X];9]?UL0:CJRY7NR_[,Z1`[Q*Q;K:BN8A2RH:C.M9\C\!961Q*/
M9]MH1-!3*G*TM$-*7L039>,..QN+\NDMD/MSL2Z8L*T;56L4N[LCUJQ[HA$A
M62U8=^TY"7=$=BE@.S'%E&QI&Q<K0DZ4I0:V#UUKUP)#<!@,")WRG4'Q_(N'
M;58.N6KIJ9T>IMR*6T_(Z1<K?L>WT4Y5SUM5LNH2ECXI,^,,/0.BO1/T""T[
M(SMXA[)"E$`HP`?'P\R#@YSH"U6'QW4S:%+T5#N@I<Q/;59+-8+0GD-I;B4%
M5R]^A?\`DJ5RN1*X[],Y`F-,"-,EVXD*-@*V/9AI@2KKV\2TUL-`L/1B;7$*
M_P#V"&X[[8-)%:0Q$<->A6F)DYP%>]B&F$G4_P!N@Z-T`1@!AJ7VNXHI!RMU
MC&4[2E<'*-4U(W$Y)-Z7CEJ0EW5&QU>^-"1/";>?*_J*V="/;=%FMJV0(V\M
M3LLM:I3:WH6!%#_&(C4LB?C$BK--8.V05^(L.8A/1MU0535!CF40<F0)G-S5
M5A/YLIL=R.3HPZ&^R!.R/(PZ"ETC&B2I%:@.B/`Q]*&RR5DTK)?$I3'6:"-#
MM)3[6C[K'3W5\F+0KB3JABJ&+O9;BE)BZEHF1Z1>J-,(5?:2$#3AT7L?OT&0
M<!@,"W)@825$I2:I4(DB<N./9AZMS&A+;DQ(&Q4(U0X&.81MI:(D&MB-$HUL
MC1>M[,UL/K@<=/\`'.#6U'="MG/T+G:*V5\JYHLE_,DT([RYUZ4KN,,\"LBM
M0%HBJ6HVBXBZU4.3*YEI0SG/4F<#/IDJB-E_($("0[,%JQ.WHU:]6,1:5"F/
M6*3`%&GC`G3%#..&$D@!IYP@E@WO00!$,6_TUK>_TP-$>9O)SQ+U_8G^)*!N
M!?+;.+KO=K+8*]57<->2-H@FWA.Q$O+\AL>`1,3"8M7+"1)4JS9"Q:E-"J3E
M&IM_+H-]\#^;UH6MZW_3>MZW_I^F_P!-_KK]<"-+G#Q"\#<I64_V_3E0R1!8
MLC;9BP+Y#+;INZQ``BLZ+()D$11L,ZL.01I-'!DI]!((TB]R;6Q?&,/NW@9!
MYY\:/%/*5O.MZ<_4V97%C/,&7UNN7(;&M5ZCP8>YO+"_+&QO@TGG#W"&<PUQ
MC*'>E"-O(4`*3!*"/17J#8;VX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`@C\P/E>GGC5DU<H6=]XN9V>S:TF[O%$/2D[Z`CDTDUBQE[9F
MO3=&VJFZ9LUH'%&IODB5:J/<UC7M486-&`X@9I9X0F6IZ:GV34=66*J''S54
M^KF$3529$UR]SBQA\JC+8^G#C3DZ(&MS<(^,Q?O:,]2E3'FIO8(PHL>]@T%#
MN55>J5!7O^!FJN71Q47#6:6T/\D+'Q(F;J+.D1&K:=8<%C$`:RQD<7T9^%)5
M"TA$J%K9WN"'V"#,6`P&`P&`P&`P&`P&`P&!37AY9X\V+'I_=6UC9FXG:AP=
MGA<E;&Q`G#O6A'K%ZTTA*E)#L6M;$,80Z]?ZX&DWD.MB30'@CHBX*:LI[A<D
M8*R')H59U:_X0?WAJ%IS:A%O,<U?3\QTL[%GHC1@WIT7E@-(,%I)L:S:8`@T
MDF]]=0C\)<6O6N[:MO\`Y,+JNKEP#;2-@XHG%G'OCA8+*ROCPZL*^Q8WR*H"
MH;3CBUI29^+&C1['HOW.I6RL"1R@@:N+C>FS>B$A=E'3JC8$ZVN3<43J?TE3
M@OBS6Z2!9/(=`'28TVG/4K]"/5)&A8O9B#-;TG-&6$(L#.+="ZV70%KAC5$H
M0KJ\QD;TC-$D+`Q'0,4<"42H:DK:P$)!,'X8).BQIRRR?@T'0=@UZ>F!>A))
M*8DI.G**3ITY19)!!)8"B222@:`4444#00%E%@#K00ZUK6M:]-8'*#_+F0P:
M?<.<[U:[2-O:I*[]P4.G3GLJAO?+)BR:71VU8X0]QBN=[1.4T5KT('+:9#IV
M8`JC$`Q!6;T087L(O+7.K"N?XPOCB/?V^=Q>/0[M_<<:K@,L1V)E%#3$NW.G
MXD]7]+(@WP%]72J/-#M^5.<:W;C`B^JL"WDO2DPK:P\.H'P2[WOQOU/[9XYV
MJE+E5G(VVU'*R+&L@%G-;7-G5I;[`9_\H1J+22O(W+4J$*UNB.DYI$:1G%H_
MG..`</83"X#`8$/'G75\(H_';8IGD89+9?>;3)I7*9P(I`;@792"8*I$4GB[
MTP[2.C2W[*9QF'J%>G$9J$20!FA$G&_"6(+'\!1OCX<^+Y+)/&W";TB]&/UW
MS$^1R&_R'E-+[)M`AAB6I3-FXMP>7-I,8SDQR1%[V@AO;`K4:@H"<!I1V]A-
M_@:Q=JL^Y!R)TNQEQ)!.U#M2-D($40=*L8+P;7]Q4Q5R+;4*ZGI5(8E&K+2B
M7B+$-E7NC<D7A#LHU22`6S`A$I_&NK"7T]XQXZPV11*.CY^ELNQP2!G2T8P4
MU)I6C:EI"5FD4I)8)G-7"RY"I1EB*"^+OQRD1(2T!23:=$2K5AT!D':4$$GA
M`:6$\HLX)9Y0R#R]&@T/0#B3-!,)-#H7H((M:$'?Z;_7`^N`P&`P+8FQA!,-
MEIJIT6,:4J,/QBE[;E2=$X,Y`&I6(YT0K5:9:D2+&\O6SBC323BRQ@T(0!:U
ML.PX3OXOO3ZFX.][-BTCNGH&:B<.6YK/J^9[+ZN9;7;5<?5W:Q[^E9D0C\/9
MTLGO6/('D&C%XS&H+*RA)`%M]%I8R0[S5Z0#@A6(##5*<M:D4)!GHE!J182!
M22,D1J162()R526$?J68#>A`'K6];]=8$47`/A]I3QWVK8MN5IT/V?;CU9$;
M4Q5SC_1-^*++AC<W'O;4^DN"&/$QN/E*I.@4-?P)W-:-4J)2*5!0=Z^8P0@E
MHP/P8,)18S!^[VE@$,7M`,P7M!K8M^TLL(AC%Z:_30=;WO\`TU@1T41Y2>8^
ME+LDM%5"Q]'O,BB44<Y.]RB1<M7S7D`2K69*B7.<&')+$@D5$38:=$X$F@:3
M4Y9R@(_0C9HM"#H,H4QW13EZ6X;2$6B'2,6GZ>OW2S5*6X>5^A*08RHFUR%E
MC'S%RJV:ZA\;7NCB[/8=)4*54>L.*3*3?CT62(6!N5@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"W'J'1&2+F=TD46CC\Y1XQ0<P.+TR-C
MHN8SE@2@JS6=6N2GJ&PQ4$@&C!$B!L>@!]WKZ:P+A``!0`%%``666`("RP!T
M````UH(```'6@A`$.O36M?IK6!^L!@,!@,!@,!@,!@,!@,#S+%B-N2J%S@J3
M(420H9ZI8L/*3)4Q!>O<8<H4'"`224`.O78A;UK6OZX&EG;M*L?<'$%Q5'"R
MN?[.;KC@:84)77&%YFE"N2PAT;'Z/2E[/KI[;7MQ;&A6W%KT2IK7EC+6$$F!
M'L(=ZV&C'7G-B>A/!58_-6HY`GA-6G.;!''%CIN@&^SJ^6!:9.PO#RNAE&7)
M=#4!S:0&:.7:$Y3/\@AV$3B0>:K())&&)[#ABB4_Q\H-$*_IMOG*MXHZG-H:
MM;.,^<9<@6K!SV,NKV<+DLFYF.@V12!0!2L,TDF`A,JO?Y$HTU>3HH02W<+,
MKQ'.-.8(_(87_CE]9*/KEJ=X+_B^)TH&*N*",MZ96REU)!)5-X=712(XO80-
M#<[N"5$#T+`</6O7`VMP&!SY_P`C'FOLCI;CVMX5Q1"YC+Y9OH2&.URM]=+J
M[12UQJ!JA=D-Q96D-A.+4WR=,T3:2MRL"0HPP\C81G`"'6ACT$8[S&;&\</@
M+\?$`ZRK.RZHGM7]3N0$44JNW.<F^_(PY2N7]%RJK$D4<[,J&[X)*+2?XW)B
MTZA"PI6YW3Z/..+6I=$J4PPFZ\'5PR"^>,'RSI%:%UVBH?N@[@(0G]$67`K/
MN&#-C0M9VE/6TW<:WC,.C$;>8H:C,"<SEMB,:4TX1FP:"<#U"2"7.%MQZQ$D
MK%**<8^;V"%+EM@ERQ+(6R=M[JD$[N;K,"9J)[+A;5$HZRMR0`DBM`$1NE2M
M2:N("D))4!EYN<4#NWH79J7)'-K=$:9Q;7)O4DK$#@@6D@4HUR%8G&8G5)%:
M<T)A1A8A`&`6A!WO6];P/9@1&^<+D>^.W?'E8]!<UH&MYMYYGU,25@CLEDB&
M-0B2-\.M",O\D9I\8ZG@:GF'GQU&J,4MRDI44L,*+#\(Q^W80OCQ3\;ROB^B
MK+BDUKJJZ>D-L=`3Z\#ZCHFS)98])UBGF[5%4P8;5I,IK>K`P.*-ZUE4&%L2
M!M.1)3#AF!5J!'"^,)(W5B;7DYE4.!:DPV/NX'UKVG<7%``MR+0.#8`Q64@5
MIBG--I(Z':^NJ"<FV9L)FR_D++&`-=>V6H+[R%TLR#A+/9&G>E+$;/V#(:RD
M]SL4PVNC3@F#'WBJ(7((G+;`;7,1FBCFMN=&]8J+%L)2@D7H8$(8OXL<>;6?
MQ61MT:H!$(,ED]RVRXZ4Q:GI_5"B9#;'LJ-G222+K`ELL4V6\$'LHVP+TWB1
MMZ=*WE-7P?9;5)I@='V!2VQ0ZJ-N7Y1L3MH2'12G;-IW+\CMQ:BP$[3.:@/T
MT>F]0I,$9K:;U.^/0-;^3?N]`A5,!@,#SK%"9(D5*UAI)*1*F/4*CE)A1*<I
M,24(P\T\XX0"2B2R@[V(0]Z"$.M[WOTP(%?&SY8^:NJ^C`<Q\\<Q02HVE16M
ML7%N702S.=W5C6DQRQ8W$7DYHBU1KUA\E3RV2.IIRE[0&*6[2I#LLX\:GW!*
M">I68H*2*C4:<*M66G.,2I!GZ2@5*`%B$0G&IV6;I.$XW6@['L`O9K?KZ;]/
M3`CPY+Z*\@]MS]8P=3>.EIY(@+=%Y*K'88.NZNO(]ZF:&2-J2-L#!#8%&TSE
MJ.O$74J%AKJO4(CB52;X/I;",!NPTI\9WFS)[NZ+E_*DJI-LB=BQ=EM^;I+.
MJFQT=H4!*H76=@1N"!31:6JVF-RI?+4ZR4IM.A"EH0D)=B+$$8MGA*+">W`8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`TLZNYLZ#O9
MUA#I1G=%Q\@`CS=(V25--;UW2=@M$Z;),%&`UP5D6O!I.J9)@P`1^C2XI3_B
M1;--$)*<,6A!"$#SKV!U%S,_>/Z04%UTZUE,X-%;B;'6=69V%RK1[#83XPUT
MR,09%8_/U\1^.5Y>4EF1;DK3@=D0RD$2=7`LXML")0G$6$[4+C$\O/FWE-]=
M+IF<2F:5OYLN6;S"N'J#K`6DH8&V,RR90J0.D9;E,*?*\M08E"5S&Q!(2*4B
MCWH3`%?'ZAMQ@,!@,!@,!@,!@,!@,"*_S8P)@LOQ?=91&3Q5VFK*LB$7<5<:
M8X%:]FN+EM@L6'/Q&BX724M@MD.J9,H;0G*!H71,2D3EF*%?O1E*"Q!'5+JA
MA&_XS;)6*ZL`G19IYOA(T,!F5*]?HBD2A'9[4Y(G!\J&#S-QZL0ITBL7Y`9B
M9W/`47K[X_<SZ$5@;%'UHG5>`"/UJU5#$9FC2\@P=$EJ1XYMZ`L&+N*-H.8W
M`25-SG95BQ;H=V.1ID8EK>2YR).ZIU91*_WC++"0(,'=*TE'7+^/(R5RX\JM
MKXW,-<UM(]<ZM'(]SQ=.@4I+7;G]P<2N7ZJZ(9[?B:](6K4O*K1<Y4*2CQ&K
MUFC@C.2X$TG#C"FB_&_+T=10\=?(&2BJR;6^"&U_**I.AK>DB;82@BZBMYK.
M;,ET)5,2,($QK<Y2!W6)C"M@-5&BUL6!M1@,"!;^0!TA/^?.;Z915C=5E<X3
MNW+F7P&(WA$KDI"E:]A$G(JZ>2EFU>+_`';&)*A>:Z<CF(7N;FH38Y*%)(/B
M6A-T4E5A$SUG6O<G>/\`'5J.#@N9O\@]]N_3,9#T'/Z'L.E6F/+H#%["F:=[
MC**=N[/$X5)BX:(3.A$K2$A5:=/C-.VI3IU030GH\)U#=1<R\"06D>O8^7&K
M:@D_MEK2-Y$B@,F2CKK]].QM;J$B^M&]IBP"-Q(:8O00)$IY@B]G'$DF&[+"
M$L1Y!"H@Y,I)*4)E!1A"A.>6`T@\@T&RS23BC-"+-*-+%L(@BUO0M;]-X']*
M**(*+((++)))+`4224`)91118=`++++!K0`%@!K6M:UK6M:UZ:P/&UMJ=G0$
M-R4Q><G3_+\9CFZ.3RN%\IQAXOG<G=4M<5/M&;O0?D-'[`:T$/H$.M:"H8#`
M8&JG<\.06!QMT]"W*$I+(22.C[&;10%?#;'L1'+SS8RX"1L"F"4^]1RU)<2Y
M+`%E[;X\X(GA5K?QI3BS1!%H(B_XR9#3KQMHW*-4K#:)C+];4X=FZ'0F#=,Q
M%L.<0_CF=_<#';IN6S9YG2DES:1(C7./KS&$LY&8CUK2U*LU@=`K`PH(TVZ:
MFTQS-2Z7O#E[W=Z=W];]E\>%[XN!^2?%SBX;2%KG$P*9/\OP(TVBTY`"R"BR
MP!6L!@,!@>)R/VF;UZD*;2P2=$J/"DV823I5LH@9FDVSE&PIRM'[#[?<9O0`
M^OJ+]/7`YD_"OY,>7>R.E;)B5-^-"FN))>\5_-I<Z6-$+%Y@7S:P`0B>QZ)O
MS&NA=<-$5M!4Q*GIP$L+=@)%;"J.1&&_.(PPHPT.EYE7O"_\O^881,7TGM<@
M:]B<T3E^:9T^B=HGX/T__P"/"X;,'KZQO^\5[/[OZZP*HJ)$H3*$X#SDPCR#
M20J4^PZ/3B-+$#1Y&QA&#1Q6Q>X.]AWKW:UZZW@<Z7C3X;N'DSL;2F4<,R1D
M:5E5VFWS3R"3KR$2CH>PKFF3M,HR\'FS&A!!AD)A#A:2PD3P:-O8U0$!J31(
M3P[]PQAT8';-T4;L@)8S]%CV2`X8BRAFZ#OXPFF`+-&66(?IH0M!%O6OUUK?
M],".+F&Q_*C+I\ZM767,?(]-UTV1N9@0S&JNC)W:DADTT`]IA0$2&(.54Q(A
MFAHH\::6YFJW';@:K)"<4G(`;]<H,ET/*?(4X6(C8NFZ9Y+B=:IH(Y+'&PZ+
MOJU)\^O%B%KH^G:6=OKV>T37&H_&U*`QS4GJ#7AR.*$6G)#H6Q#,P-UL!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@4MU?&5A3#6/CNULR,
MLLTT:IU<$C<F`40#Y#S1GK#22@EDE_W#%O?H'7Z[_3`T:["X@*ZM<H=8L"OB
M3\Z7!"X5,85$+>@54<VV@\EQ:?+XN\.K?M3>-060[M[8:KBR8T'X!R8S#!"V
M,9HQ!*$6&T32Z,%)5O64?M*TF8Q:D3UO4Y4\FRN/PPVQ;$="VJ',12=#HY$T
M`EMAR40-)&I#K>S5BK1"8L7]H<#*^`P&`P&`P&`P&`P&`P(N/-0Y-#3XO>O%
M;XC*<&_<!9TPT:D%["2'G+)U%$R4M8=S6$5PH4NU)H/<H;O_`!"/^]Q]6W2L
M.PT4F"Z/PC^-NE<6:8JJ?:TO)L34HY6@<^W48(ZYOTJ:=G@`O2`'V06TN;RZ
M&)?0X&]:3J-!-!^%]P<#-=*<YD=?^!ZN.;H6NJR4$V_S`R19H66(AZLU5+@+
M;T6O%IV3S.;0'J<IG).0"`F.4O"98`P!1I83T&@)S0QMW;S.R<N_Q]YUR_(H
M]6BULJNEJWBKZP0:M^G)W5[BY(K5B#TY;:X=!;45]%C9'!^,$H.7G2<[:(0Q
MKG`0D)9Z?`DY\;K<U-'`O'K4QMI30SMW/-7(FYO(B-EP),G2)HJW%$Z20^Y'
MV36DPHS0A]Y)+ZX+''XA!$::+8O7`W7P&!RS_P`MNHKEN/QX4NQ476=@65.&
M?L2MW\">K8K^[)RR(4]>6NB$Y,B%N-U+"CAN"].#W-11AVQ^W1NP$^\>@PUS
M8S>3CEWP!U6W<>P7H!KZY:.BY4\RHB>5?74[NYPKR<V--I5.9U.ZGFT[LY2I
M7''OQ"@QN0&&2A5HLKXT9/V#E.@FC\-ZOOMUY!5R#R/*;!.OJ27-9;Y'B+-9
M*HC,K04VJ4-)5:)5T:J)M96:.F&-R<X\]"XHD;NF6'G%G$EE:3AT$K6`P&`P
M&!:<Y<)FUQ9T75]&6282\GZ6FB.R.4J(4S.'S.*0A>);)4L;ERANTA;#3E`-
M!;U&SS2@D_[>C/E`&#NUF!'*>0.GXZXI=KFYYH6U4#BB"R6G)1K&\^%/(5R4
MJ.4<[,5QR`]0E]X"T,76)GY6/>BD1@5`@;P(C?XU-?@K?QY*X\D(3IF<-V3Y
M0SIT<"Z_KU(2E&0RZ-`D:>P'!8_*B!*M#&(Z+E)8WH\1A>P#=`.)QH=!^`P&
M`P&!\E!6CB#B=A)'HTDPK8%!?S$#T8`0=A.*]0_*2+U]!!]=>[7KK`@[\67B
M*M7Q[RM%(+&Z]8>A([$JJDU,5'7J'E>IZU_P_7C]9JNST\4CER;5S"]'F+MC
MVZ+1`:EK[MO,,5_(:48,A.(L)Q3??LHS1?K\FRQ^SV["$7O]N_;[1#",`=^O
M]-[#O6O]=;P.>CQ?0#RVM?7=F2/N=FZ59J420:<-,17VAV!R[<$&>9$*>M1T
M22H:FI"A*[<=+3(8H,4DR'1[+I,(DU"I1J!#`8`.AO`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$,/EL\6]C^1Y50RROKEY^JH50
M*)P!W27KQ74_7"61()FD9P#+:MV8O2CBY250Q$[.2IM!+7;$`TTS0DQ0!A++
M6$/,KRM:\@!RMH7G0>#1.'FKH_&&^$L*TR,L#>RF*V2&M!I[5$FA2)%L:9L2
MC&G0$B"06+8"P[P/O-*[@EC)X\DGT/CDQ31*91>PXN1)&A$[EQZ=PES*>HA+
MV8*TD[3=(XVZDA4(E97M.3FZ]0"U^N!>6`P&`P&`P&`P*::[MA#LB8CER<MX
M<4+BYH6X1FM*E3>TGMR9R5DE_P!1DHCW=,$S?_IV>#_K@5+`8#`C;\OI+:;X
MU^MQNT^2U<A1UJ6X&3QPLVU*>;8Z8WR9@6)U+G8-+1V6V.RMRA02$@XM"V+2
MUP#=I516TAQ^]!'@99\;5?QP3K#)O!A3L3=S:H1D71&>F>JSV(9\?LHR,D&[
MZ.)K0CIP85C@@"VKA?ML`='#-;=ATTZ^?028>*N:-]B>/+E.9-<VU8Z![K,H
MPB:ZM&V;IV_?4?7IO-4&6?>43@MJ2TT@Y((@9SLTHADC*V00#:8HD8@L3S-S
M0,`\9G6$C%HD6BH0SMWM4'W^B)%MYFD9:O8-TY@`*Z&;8_M^@5;;L*5./>A.
M._QWVM;#*GC'.0*?'WR(K;-'Z2K:.A:X7V%]T.@_N+D'VW+8'#H@(;H5)MN)
MQOPB?]:5?%[=`UHC16L#>K`8'-A_*%@KS+.'J.>HC7<WLJ=P?KN!/$1C\)YE
M0]7#.6/%:VU$EFGZLG=U:V4ML"C?MG)5RS9I('@A$1H(3#RS2PA425S*N5O#
MS1_7U(-/1'#/D/D'9+3S^7)&FH-\N1.=S"63&65RU&6CR(IM]9R\9#G1@(2M
MJR7+&)>J$J;?G"FV,&AA#J'\*+]V>^<9+R^]II-[$Z(C=\W/#7Z:2]E@3.U2
M-IB<A(9$#M6!T!3-J:05*O6)%1S$Z."%N7KDXQ&:3`1_4$,)<\!@,!@4I2Q,
MJQX:Y"J:D"A]9$CJ@9W<Y*28XMB)\$W#>$J%6(&SDQ#H)I2[/"#>M&[3E^[U
M]NO0*K@:]]:J%*3ESHE6C=7%B5HZ4LQ6F>FAZM*..C2<EA[N>6XM[]2#8]7(
MT*T8B]&%J(JC52`H0="0%&*=%@V$"_\`%>FTPGO!=DNUB3"=3";MO0\_C3BJ
MG4NZHES@A9693O481%J>CS]L:#06I5K8"(B0F3Z1_6V[E@>?MEEATV8&.:F@
M"VKX"RP=QL.?VJL:%#\>9.[0<VQYF[P%[D3L_D)G9R9V=A0*$["0Z!;D/M2@
M&!O2$`,$:8$9HPR-@4=Y=%344@,2,+N_B6O#6UGE,XF@)C8E<59:90_+_P`N
MZM)8FAF+'\RK1`CU>R@[^$@X?H#85C`8#`8&N$"[%Y(M2R5--U?U%SS9%MHD
M3TXK:Q@-SUU,9\B0QQ60AD"E9$H[(W%]2E,BQ264KV80'ZXQ:T/V[P-C\#^;
MUZZWKUWKUUO7KK^NO77IZZ_K^NL"(;F+Q#1KF_H!5T<Y=P^02^IE^#G4/:H_
M=70"=\@;?"9T-S5',2J.,<08#'A>Q.[J->@<CU'W"%I)!FA>A(`Z#/7//!*O
MGNU6^R`]L][7<Q-,1D\6:ZBZ'OQ#9U:I5$G7L"PR4JP#A#/-)-)6<EC$G;CW
MIY<P(2EBCX0`$9L6!(!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,#2[J_N*!\D*HLSR"F>M+ME,S;G5TC\5Y<Y?MR_G`U*S*$B=:%V>(3'
ME,.C"K?VOD*(='1$<>448(L(M!_4-JX5*$\XAT3FB-HDK`DET:8I.E8IG'W&
M)R]E3OS8E=26F519X)3NT;D;<6JT2N0*BP*$:D`RC`Z&#>L#']WW0WT>P0Q_
M<89/9P7-;AJ"G4R"O8^*1.#(ON"P6&OD4QD1`3T_XR"Q!0^A7O2_>Q:1-Y!A
MGM%Z>F!F;`8#`8#`8#`8#`8#`U8[=Z$>^4.3+[Z-C<6B4W?Z?KUVF3/$)U9D
M=IZ*R1P0C(*3,[I8\KUM@C7WC3]`($?_`/Y*G9:<&]&'`W@1P7'V++.CO!M<
M/64D)KSFV56+1,W$C%!^S:[=(1$G!7+5<#81M'6L.C$E@2=>\*PDE"+"W'Z)
M<E`F=3L!NC30!=/CLJL/2GA?HZH55J3FO$EDT\_Q?=KT%TNV7/8#,@%/Y(`3
ME%>A380D:'A[-)2B2+ROPYA#;[U#7K9H4^CA!)US[3P.?Z9KZFBK'LZW"J^8
M],15BW-(6^569*"@K%2LM7*WYJ98ZW+U28"K2<GX42<LI*247H/]GKL*)U%S
MM%NL*(L#GZ:3&U8!&;%0-R!SEU*3]VK"RV<#8]-KZ09')DS:,5-VU"EK`2J*
M,+/3+$9AJ<\HPDT8-A<U%5`R4#3]=4O&Y-8$R8:UB[=%&J46I,G6PK#>T3:#
M99*Z63)Z&)R?748=^FS1^T(`:"66`!8``"&6,!@0^>:OJOJ+DWE^!2CC@#JN
MOVP;UBE8Q".M?.,JZ3'*PO44G#NK8=QN*/[$LBYP_P`$!42Z""X^\Q-I$6C-
M,5A,*#&G$4*?_*UXV"8#Y68(XVE(%%QN22QH/*ZGEG,1*U?5,J9GZ%`50YCE
MI+PX-.E"9.K,.&8B(7C,&0:B+T4(&PE5YTY>YXY&KW_%',M.P2D:YV\JY$=$
MJ^8TS&U*Y`O2-Z!<^KP$:V<XO*U$U)BCE1XS#S`$`T(6_;K`R?+Y8GAS<WN2
MEEE+\!QD\1BQ:.(QUQDSBF43"3-<83/#@B;"C34,98SW4*QV<#?:F;6T@]4<
M()10MZ#Q&PU698Z*P=3>:%(4D(=(:.N"US5JNUJMQ?FA[*FZML$S"?!S1L):
MQH$YX7$*0*%6>`2<1@@&@"]\"AR>-,<SC<@B$G;B7B-2ID=8Y(&E2(T*=T9'
MM">VNK>>(@PH\)*Q"I,+%L`PBUH7Z;UO]<"KDDE)R2DY`-%DD%%DDEA_[2RB
M@:`6`/KZ[]`@#K6L"QIK#GJ5N5>K6FQ)A!$L+G!$M?FJ*EQH2*RF@B.R)F_8
M4Q,?X^]KB(H<Y/2=S,VUFMS@)6V)P?9T0(\HT,;=<N;LR\J])/+"[%,+TTT3
M;#FU/ATFL&%E,R]!!7Q4E=3)?4S2_6E&`MYQ6C?OQQ$K?$GL^1"28I"6#80I
M_P`;^YS;=YNNKY.B$G1@8]:*;8)#KI#KCI!RC'YTEY7_`+55O/5-05`IB#>B
M+*`)"VM!#DH,(%M2ZK#%)Q>!T4FHDQZI(M-+]RE#I1I*9[S`_%I4`)9_]@1Z
M+,]X`:U_=K?IZ?IZ8'JP&`P&`P&`P(H:%\:4LH/JIMZ`9NEV!\@1)=@C>:E!
MQ)Q17,F?%DU2KRD`CK[I>G*ULLEO8E:_[)Q(MG&NQQ)>U9P];-T:$KV`P(M8
M!Y:/'_TW?RCCRB>L3E'0[3)'K3K'HQ6LYV>E/IR4/SA8\'<Y'-*R50%M4NS+
M6KTF.+,4%+SV@8U;89HP253H,FT+Y1N#>H;B04%0'0T<M"VE\3F<W'$(^P38
MI6U1R`/#`PR95(5+M&6U!'5*9UDJ4HE,M-(4J_48B"S`%C$$-_<!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@8#OCF:HNDF^/M]K-\U4ABB
MM<NCR^"6[;M//C6J<BDQ*TPJ04_.8(^'!4%)"PB`:H,+]NMZ]OH(7J&4(%"(
M[6<'AU<Q!,M1Q2!1=AAT:2.3R\R)Q3,,::TK,T$+Y!(E[K('Q:4@1EA-6+E2
MA6I'K9AQIA@A"V%V8#`8#`8#`8#`8#`8#`T-\H3#J3^/;KM@$08J*<Z3EA"E
M.7.Z@K'YD>B"C5H#I]?C%)*>BZ3:0L?S*7Y&-%HGW!]Y)@BSRPB3@S["FO\`
MC+RE;&W9G0Q-OY9MYA0N"CH*@DS6C5!GTM8!I3[SYWK;_!A7Q/9@D_HVL(P&
MB]$*TX:L:E=L)%_"P8$SQA<E?'(F:4DDP9Z2$O,?N^.=$LYH$$WE"$2)':T2
MA5?QQX"SFIA(Q(DK8`#*,C;<(]48E&I-"4?`8#`8#`YQOY0TRI.%>.6(.%[)
M'%;%CNIJFTT)VV#V/-CS9,ACUA.J$HL-;7QSFX1\\Q"A4^Q:LD7U?30B0)AJ
MC4YZ<,W_`,>3_&!WCH;%]109BKJ(KKUO`!L4C<`EU>M3;)625ZB\L)3H9ET;
MU*M?=$2%A4$Z<DLJ,;S@E:*(3%:)V,T)RL!@,!@,!@,#5CJW=HIJQL5XBTUC
MD%@4<I6X)!+W4P-BIYHH>&V)*1Q]&SO]9I'*:Q"/E(QKE:UVCJ19+$:I(DVT
MD&G"$'`@G_BO69%9OQ;;S!%)P[RI)%^@+&6G,2V2=&S)N@XY3.ILY`;VN27I
M`X<U&:E8"=2$Y.TFJG+1CO\`8?2TSBH$7L.G_`8#`8#`8#`_@M[T$6PZ]PM:
MWL(?7T]V]:_37KO]->N_]<"%GCKRTRSJ+KUWY(DG.M4UG(H;'+$<+)<(IWES
M1>TH@$IAL@3M#/"'FJ8"N36`<[/2$"E6N.(2FI&78"R%!HC_`+`$P33X#`M9
MF@T*CCY*)/'H?%F&2SA6WKYK(6:/M+6^2]<T(MMK4ME#LA2$+Y`K;&X6R$YB
MLPX9)._8#>@_I@7)LDG9H#]E%;/+`84`[98/E`6<(L9I8#/3WA`:,H.Q:UOT
M%L.M[_IK`^N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!\CR
MQ'$G%!.-3B-*,+">1\?S$"&#8='$_*6:5\I>]^X/N`(/KK]=;U^F!"AY<NX.
MC^'@4NMJ&RZ$B+%9K%8\3)U<?,G5_0;XNL]C9D#I'G]:NY>^R7"*^96<:M8[
M'J6AQ6'*BB"TR,:4:U2W!+#1<GD<VI.GYE,'&-/$NEE70"22EVAC/*8]#W22
M/D4:7-\<8HP3E*AFK)&EKHI-,0I'@@ET3)1`+5`">$P.@IMZQ^ZY+"VINH2?
M1VMYL59-3.CQ(9/'B),WJJP9[*B[G<$82-ZE(N))?Y=5Z5V;6U5LO_Q%ZDDW
MW%^SY`!F7`8#`8#`8#`8#`8#`T(\I*TEN\>'8"M0H1)4Y5(2\)Y[C,*>@*$!
M)R<L@W2B6W\PR:GF@`P&;#ZOJ$]*=O>B0^PXPHP`8"\,>FRRO%M037+8Y&GZ
M)O,=E[,-L5R[F:X(U*8VHE;[\Z=P7\Q1"+4.K(+.4'MZEM3-NU*8Q*,IQ,4+
M=*#S`E5BT4BT'8&R*0J-,$/BS*1M*S1J+,[='V!I2[,&=M,V,[2F2-R`C9IH
MA>PHL`?<+>_3UWO`K^`P&`P&!%5YCJFY$N7CH<3[:K3H.V:23VO7CT;#N:HU
M/I182F5I3W1''U*Q%79)CLCB1.G`\*]6I,3(B/D+V,XLW9.\#'W@V7<H).1)
MW6W%U(W[0U&4ITO;U7MT4Z-,.%/'24HRXQ*9A(4I2Q\D#FDCQKY*S$:<E6HV
MH+-1&^X.O76L"8M>A2.B%:V+R`J4+BD4H5J8>Q:`H2*R1IU)`]@$$>@FDF"#
MOTWK?IO]-X'D8&)IB[$RQE@0E-C%'6EN8F5M(V9LAO:6A&2WMJ$G9HS#=E)$
M:<!8?<(0O0/Z[WO]<"K8#`8#`QE#K?@=@S"P(9"W?]R+JN7(6*;NS04)=&&.
M8*MKAKH`HD2;9C9J?QM$F3JG9G]_W6U(YH#3P`"K)]P6O;4B233G"U9%64M9
M'4A[J.P3XE,XY,Y,A9A'CB[R2D>6J=U(DD4T;`(E8/>!PCI"QV2F%^]&68I`
M6#8<^W\6>Q&27<A7G%H6X1LV$P#H>>("&A!8G2\^D#7*'62R13('-P*Z#B$4
M3Q%BG1"5+($#:U?8</D<U*A\TG=#S4Y8=/V`P&`P&`P&`P-<H%Q[R95DX76=
M6G,7/T`LESD$CEB^PH;3M?1N<*I-,"U1,L?C98TQY(_[=9*4N/`N/^Q[U03C
M-&;%H8O4-C<!@1NU#:?E(E'2CM&+=Y,YCK#E:/RRP6;=J-_2<AF%K3N,%K9.
M?5LTA-<M5;":&LM2V)6E,^MSZY-RHM2K//2[$62$@892K>:]]J[G9XU<7/\`
MS-'*/4,\L7NUHU?T=/IY+$;HB$E(A[#JNY=0-9:"<]"$:>J4EN2DA*4'1>O<
M9K6QANA@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#SJ
M5:5$5\ZQ2G2$?(03\RDXL@KYE1Y:5,5\AH@`^10I.`66'U]1C'H.O7>]:P/1
M@,!@,!@,!@,!@,!@:M]N0N4V)R'T?"8/&Y9,9G(J@FR")Q6!O%<QZ:2&1[9E
M)S*T15]MUAD]9-#\N<2BRTJA[0*6\DW81&AUK7NT&OOB-JN>TGP#1E8655MF
MTS+(J&=)EE=V_(Z0E,]9$JRPI0Y-YKJ[<[Q.$U8).[(U@%:4I&W%*B4IY85H
MSEFCSAAO])HHEE!L8.5.\H:MQ64(96E!&I*[QPIV5($3DA+:),6TJDP)'%U`
M',1A[:K^5&><428,&Q%`WH/;(I"VQ9I/>W?\CM`F/;TQOXED>I$N^5S<4C4D
M^)ICS>Z.QY?W%I?RC`0("<KW'&[`46,80^$ADR*-[80K$+^NW(9$W1E)^!CS
MS(-(UKD6I,)7/8F=$L"Q,!`4@OL.*OX4:?8@:,,#L8-;"XL!@,")#S9J^4DW
M"[XG[&YUL3IZIGJU*GC+;6];/*J'NJ:Q)1)RX_!I4]6,&6P9FK&+,KJX^U8^
M.SHF:D^CP$G_`";/`6,+:\+L@Y$C_'L\9N:.?9SQ]!*WZDN6KK1@-Q3=OF2D
M?0,=DS+$;"=FJTDT\GD3GK2YR;29I3+FES$WF+THTJ<O0B_[PF4P&`P*2].P
M65(2L&WNSGHYT96O2=E;S7)66)[>$+.%><G)_O+:VP2[2E:?O^U,C*-.%_:#
M>!5L#X*DJ=:E4HE90#TJL@Y*I(,UZ@.3J"Q%'%#UKTWL!A8]ZW_]-X%O"2,D
M&BSB)E1,C`UL;0I6!`9K38SIBFILT`L]R4)4YQI25.D1%A-.]AI@22_Z"]NM
M8$+GAL[^L[R8TYTH.X6[DR.M$%F^JUB[?QK<TAEII,0DC"Z&'N<A7D*4SK#5
MZO6][9EZ4UN6*1%GG:2(Q$%C-#?#A_@*B?'U#K"@5`NEP*XO9%C/EH/#=:]P
MSJV0M<FD:@Y8\F1L<S=7$3.!V7*3%*X\/O7NBH?SKU"H[03-!L>_6`[M3@P(
M6RLI[)"W:S$=?NC@VIV!(AC30IC"Z1'V:XC=GY`<L@2%4F*:S#$@#U^W%0$(
M$HB@C-"&3,!@,!@?@P>BP#,V$8M``(>PEAV,8M!UL7M``.MB&/?I^FM?KO>!
MXVIP`[-;:ZEI5Z(MS0(W`")U1'MKHD`M3EJ0I7)N5!`I0+TX3/8<08'1A1FM
MA%K6];P/?@<W?"E7>8Z+]_)C>F".E#>58VHO[4BEMC=B\N6355@[D;[+3Z<>
MH94$!H%CN%H);V(36F_$KGQ$!L-*"J$?O6ST"H.D3`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8$#WF.\>O0W9$IIF8\Y5Y3$XD<8
MJ^\JLD+A<?4/5/.((4CLC<(-:9!$=\T*B#Y.M5)6AU;G).Z:$0>WKMIQA&4:
M/8`ELY?KF24]S=0E3S$J.$RNLZ>KF!R,F(2"<2N*E/43B;4Q.)<=D]F+7&Q)
M"R@5(1:3+7P\YU4E>TQ4,1PA[P+AN2DJNZ`AI-?6_$TLSB":8U]/R&=6M=6X
M!,OJR<,%D0)Z+5LJ]M7A/C\TBZ%:`&C?B.V1\9P#"1C+$&5,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,",/S`<237R#<+V)S56S91[C/Y!)(!(HJ9T("=_P".FM7%
MY4WN+DXG**X-!*$3W^WON)T9I0#BM&'["8#VBV((6SXRN,K(\?W)MBU=;T=Y
MQEK@99DEMEHA/'-.N=<0]:E'$X40G;TL.FLG6(W*?JWR(C&6>68W)1?^+^@3
M0F&["5A*2<3H_9RQ0K^92:>5]@M*7M(29[?8B*TE3I_>21Z;]HC/>;OU_N'O
M],"T(?/4$R4/"-,P39@5L9HRU94OAK]&2E)?YV1L*=2TKW-&4UO1"PR,FJ@?
M4/.&!"I2'FA+`K(]X7S@,!@,"WU[2W%.)LI/4KB%:./KVD7O?G5*QE-QQY#B
MH4J6C2O;'I<48B#[5XTPU1!/O``S18Q@$'-/_&3LJ96#4?8!,SMMMM9:S7Z6
MH2+&CKV+=1-B)&^&RY2G7-K5&HQ'AUN@>DJ4KXU"P:A3)=IA*AZ)&0,O`Z>,
M"CM3(E9SGH],I=U`GUX&]JP.CV[/!*548@;VX29F(=%BLIB:-$MH!A1(]$I`
MGC--T7HPXT0PJ^]^FM[]-[]-;WZ:_7>_3_36O^N!\DQWV4Y"CXCB/G)*.^!2
M7\2@GY0!'\1Y7KOXSB_=Z"#Z[]!:WK`^V`P&`P&!@-BZLY=E$Z_Q=&>DJ#D5
MF?N)XA_^.V*X:\=YU^[8Z2M42"+_`+1;Y$H?_P!Q,2=M4C6(OK_92@3F",`'
M0!;T%K0;N'CBS+BD//$!ZBH:67W%)#)XI(:59K1AZJU6N0PHM4=+FHZ`:=M2
MD:B-%(3Q+?8E&%.$@S8]Z^,?H&TN!&K6?C%KVLNEUO3I/47>TT?3)I,IHT53
M/^M[%?Z$CPYRK?W)XC**K"1MS2\0]*\2,]6@0/!CD!`:6GT1L!:<H`0R3$.$
M(3#;N@MX);\[*D*VO54O7,=;3WJJV+"I]4LF4:=(LK4OT%F;T]DO@V9O>E)C
M9I0>("%08$PO7^T3HL-X<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@:S=%=@<^\GZB!M^S)W@S=.=2+\$^$UW9<PCA6XJ4TJ'@,AD,&A\F
M9H?\:9Y*,)$[GH@JBP'")V9I.=[`URNGRJ<PTS67,]S`9;]M^L.LW)8VT_)Z
M)H.QK+5N`DS,=(4ZMWA3<T);$;TCJRHU2I)[&@XPY.D.,T#18="$&QDGZUJ:
M+\]QKIL\BP7&M)>Y5<TL"=%6LS2SE2NN"Q(M5T-+6U^_-#+*V,(I5+T>EHEZ
M5+I`D^10=[2B]BP-FL!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#RK
M@&&(E@"0F#-&E4`*`2HVD.$8(H>@!*5:UO:8P0MZT$S_`-&_U_TP.8S^-#:*
MR?Q3OAI<G2=/"V,],(S`*[$[1IOL>0I&]R:WQL1L@7NJXE%%D;;FD49,T4I<
M0GD/>S1#1BUI,H]P=,<D92Y+'GZ.&N3TSE/[*Z,ICO&W12R2%J+=4)Z$;DPO
M2,05;0](0G_*E5%;T8G/"$P._<'6!8<3F;NNF*R"IJ]L`B(QJ+%"!:TK$@1M
M;Y)&V2O,5611,@=G(N=/#F!"R%NVW@3?^'7HEQ`R%9Q@Q@`&179J1O:`]L<-
M*1)%&R1&Z2+ES:HWM.H*4E>Q:VJ4BTG7S$A]V@&!T,/J$7J'>];"HX#`8#`8
M#`Q?_A&E_P![MMF?XAJ__)#.:X'M%@_L"*?O=J/=B%"5U.;97^)_/(37-,K-
M+4"*4!V<6:,(_70MZV'&QXYN;O(Y6'GSZ-M47/?3T`X,LKKWK5]D"2=NJ5FB
MXY7)80ZNK9>:MQ0LD:9)Q`)>Z!2IV),BVN]FEJ8@PQ4>A4*A!V[X&A:+R@^/
MUSZ5:N/&CJRJGSIEXEDM@A%/,#HN?92@F<%&J+E,8D/XAN6MD4>VTQ">$*=S
M4(S%(B1Z(T9L(O0+M@7D)XFM&WF&@*_Z8JF4W=)PRPQCJELD0!3Q>3!RG,^5
M*M1HXHES3HVDEE5C$<:6`HT*8S90AZ!OT#<?`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`@7\Y?"G1?;S1Q^T\[4I3-JK:ZN&5+9Z^6]:
M<ZK])7\&E\431]U6HX_$G]@23II=BBQ?=)%LUV1J$B(;;HH1BE02$G7"]932
MF>.^;:KL:$0NMIW`ZBAT<EL!KM[<))"(@_(&PH#BPQI]=1&+W-L;E&]@":,P
MW6]ZWH)IH=!,$&UV`P&`P&!\CROG(.(^0TKYBC"OE('LL\KY`;!\A)FO799H
M/7U"+_3>O7`M*NX817,#AT"2R&82U/#8VSQHF4V%)%\QG4B+9T)*$+U+Y6Z"
M$XR*1N6B?F6+#M_(H/&(>_3U],"\L!@,!@,!@,!@,!@,!@,!@,!@,!@,#^;W
MH.MB%O00AUO8A;WK6M:UKUWO>]_IK6M8&*+48[CD*5O::HGL2KDE>WS1!)92
M]0M1-92S*'&&O"&"OT%0*'ULBWY&-SD]$O6D/"5P2+T"<Q-H!0S='`""KP)J
M4ALR\C8"UEZ/;B#HQJ3/$HNJ\.0K8'(5K,&8Q\M9'63E=G8]PW6DK4#2D3N4
M8D5E[3D-YHA(ENM!T6X#`M2<P:)V5$WJ#3IC222)2),6C>V-?L[2-R2EJ258
M"%'US2#=E:4)P"WK0M>OM]-^NO76!6TB_:M4ZI?HN"7\6L)1Z4JT^B4KE\S<
MA<?M-1NC![5(RMK?@&/>@>U22:#TW[?785#`8#`8#`C-A7DN9)OV=_PI)YBZ
M#C,S;7V:-4NG\K>^;2X-%FV,111*V&3JFJ+]`2NT36.Q$WU0LOR1U.I,`O(-
M/*)#\GQA)E@,"R&>LJVCLNDM@1^OH.Q3R::1:F,V9XFPMDNEFFTGZS=J2R1$
M@(>7W2!/_MD_:.-^(']H?37Z8%W"1(QJP+Q)$PEQ16R"U@B"MJRR!;$(1(%&
MP?,`K8A[WL.M^GKO>!Z<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@1C>3_`,D35XUZUK:Q':!0:?EV3.5$`0H)OT;67.Z5`[?ASG9$M_*V
M,2KV]-?HF&%<-O3J3FX&P&F%B`/6]!N+S)<P^B.?:>O(UFCD=.M.`Q^9J(_$
M;(BUP1IC4O*("E2T,]GPG_\`U2<)&Y1L1.G!!H*<\0-[#H/ZZT#I1]Z`C5+R
MUYY<@T)LB\TJF)%0R'6*_&QF&N:9=-8X@F"IX>2%:$Y-^$@RIS7IP!-`)0J2
ME$Z]?D]-AG3`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`H\@8FZ3LCI'G;[_P",
M>41[>N_%N[NP./UE`-@-^F],*YL>FQ1[=_VG)5!)P-_J$6M_K@?HA$XEO;BX
MFO1ZAI5-K2D0Q\2)`6F:UZ%2\&N3L2X%D!<U1SV0O3%&%'&#))TA`(H(1&F[
M&%6P&`P/P846<682<6`THT`BS2C`!,+,+&'81EF`%K81@&'?IO6];UO6!^\#
MG`\$48U%KT\I(=--C-Q;]TL%T3JYN3Q:B;'H)4BLKYEL;3<M>DG5B#]TL2E2
M_?\`MFRSDP&[05(73W!T?X&-9\^3P*1VCE8-#6.?&1S;W''N=H'P-6@4D/+>
M@4-3^\1[Y'4MS,1*#3B4Q`-F#"#W[WH.A8&2L!@,!@,!@,#5V/<1<;Q.XWKH
MB-<J\],M]R&1+)<\W2WT_`B+372IQ(<4KC(S)Z%B_<Y;TX)G=46H4@4A..+4
M&!&(6ABUL-HL!@16&=5>2MWZ]+I./>,U$Q\V,-JJF:6=93GJ2N2F9^IO[D?(
M;)_7%;1]K<9HOEZQ&K<5)S"X%I=)=)22A*A&&C^(+_C/1GD&6=3ME2S#QQ,<
M;YH<9/,&PSK%D[+KB6`:HPS-D@7Q.2NM'F5Y')X6MF)[:A2";TYZG3<H</[U
M)A1(C1!(I@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"VI#
M#(?+A-@Y7%(U)QLBS;@S"D+$UO0FA?L.@;7-@G)*IV@6;"'6OE*]@_37]<"O
M)DR9&06E1IR$J8D/M)3IBBR""@^N]^TLHH(2P!]=[WZ:UK`^^`P&`P&`P&`P
M&`P&!^##"R2S#33`%%%`$8::8(("RRP!V(9A@Q;T$``!UO>][WZ:U@4]I>F=
M_1A<6)V;'IO$8:2%<TKTKBC$<0/99Y052,TXC9A)FMA&'W>H1:]-_K@5/`8#
M`8#`8#`8%LS&6L\&C;E*'T\)#>VA2E^FSDQ`UB]Q6IFMG:TQJT]*C`M>'=:0
MD(^4THK9QP="&$/J+07"08,TDDTPDQ,88468-.;LH1I`Q@T(1)HB##21&%;W
M[1;`,0=[U^F]Z_7`^N`P&`P+9224:J7O<2W'),E`S,,??02I6W$EQ!Y$_K9`
MB&RLCJ!88>K?F'\#HYP(&04$@E<D$$9GRBT6%S8',9X(*PFL)Z[\LSC):J<*
MS8C.D7Y##/O\6<^<XDO4?6V#8*YL&SVA4TH>)99R5(TIDVSDB](G;$^S2EB<
MPU4K6!+#ISP-:K`I"Q)%:5"R^ON@IG4U<5I-[#FMO5"R,#%(V[H@<Q:#RF)D
MDLPDVULFA3)#I.J,<RTS2()"L(_K"++++($4&RN`P&`P&`P&!STIIGY)&SR8
M1>`NG2G5KMSHY]-6"[N<2;_%[&3.;$%*'1]_70FKC^OP2%#+$1+2G*0D*)&>
MUC(4NZC>R5)@"1%B#H6P&`P&`P*6G>VE4[N3`F<$QSTSHVMP=&TLS0E:!$]C
M<BVE2I*_J64X&-"K16]_]VR!_P#3`JF`P&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P(H/*=#NK'1BHV<\M7%V=7;K"95,D<HB?&M6<UVT]S/4FC
M:<R//=D1GINPZ]AZN&PM5'E!0"$QJM2>K>0>A98BRSR@W7Y*9K.C_-5+,]SR
M.S)9::*!,P)S(+D;ZT:K2<'XTL9ZK<Y;J==G^LDC^F":$DX+.O6I?]O7J><9
M[S!!].KJ4DW1W.EN4;#;EG?/4GLR(JHRS7169QB>=5\J4J$QVWN.G$KVH\"L
M11`B!_$J3&_"</V&EC]!Z#/J4C:5*F3;./4[3D$D;4*AZ,4J-E%A+V<H,T$.
MC#S?;[AB]->HM[WZ8'WP&`P&`P&`P&`P-4N[&N-O7%76;5,&,B3Q==SG<A#Y
M'5;393^C>V_<`?MG-:YCIM0DMAW0+=!^,]-'#2GH\H0@)!A.V`6@C7_CH-$3
M:?&5!A0>#U+`XRZV=:#NUM]+Q7IV(PYW3*G9(43(Q-W61JNS5#PZ$IP_.H3*
MEK&,)8`(SQ[`;H(3JX#`8#`8#`8#`8%*;'QH>378EJ<4J\UA=3&-Y+3&A-$V
MNY*-$O-;E>@__B5%HG$@S8=_KH!H=_ZX%5P&`P&`P&!S$^$"&R&(]^>6U<YU
M([P%FFUDQB1L<E<N'99RD?,`CGEN+%S@X2*4/SQN7F'+'L?U_K^TASV2H<0`
M)T9L`@Z=L"V?VSK]Y;F/Y^3>NXSJ,[BWY86X;Z:==NFG_3%LG80R;7NVG^WH
MS6]I?]O8=^FMZ"YL!@,!@,!@,"F$/;,J/4)DSNV*%*1P$TJDY"]*:>F=0)0+
MA-B@HLT1A+@%$8$[9(M:,T4+0_3V[UO`J>`P(GIWQ'WE-.PAWHF\JMG0'FUB
MLV"V!$.3X=0]6IVD<>:2(DEL2L)Y9"Y0<^2V&S%%&56DA@TQ:MJ/>5*@`QF`
M!ZAE_P#XH]&J.EHE=[9Y%KX7T4AL.06*[\K.M?T.LKU]:GZ*2)F980SV3%8%
M$;420B/.+XF<DJ=Q=7P)PT1>C-C'L!Q02!8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`M>13B%0]0S));,(M%E4B5*44?32*0-+(H?5B)*
M-<L2,Q+FK3&.BI(B+$<:61H8RR@[&+6@ZWO`]L;DT;F3$URF(2!DE49?$@%[
M+(HVZH'QB>$)OKHI:UN[6H5-[@D,V'?M,*,&#?I^F\#Q36;PVMHG()[8<KCD
M%@\3;%+W*)A+GINCL9CK.C![U;H]OCLH2-K6WI@?J8<>:`L.OZ[P+F`,!@`&
M%C"868$(P#`+0@#`+6A!&`0=["((@[]=;U^F]8'ZP&`P&`P&`P&!CRW+6@=%
M5;8=T6D^?MBMJJALBL"=R+\<ZN_X2)Q-J5/3\Z::F)"YO+CM$VHS#/@2ISU!
MOM]I8!"WK6PT2<>GZ2\B'CGN&ZN5Y>BL.GIU7%LQU4OE\+Z`A0)*Q1QN>&>R
M8F6VPY%#;WC[FZM:=8@1NL>2+7)&I-`H1)5YQ84IH:O?QU8JAB'C.AC>TE(T
M3*NMJXGU@96S?1YC/'&!ZE0ES+'V=3U'"X%92YM:VPTH`%`&_3:<+W#*--.V
MH'L)T<!@,"UY/%BY1N.;,?90Q_MR4-<I!J,/BICT\F-0%0`,4C^K^KQ%UVU7
MJJ0F>A2C98/=_P!OI@71@,!@,#$MCPZ'J7V#7#,95*HVCH3<YFI0$$V?(W!3
MT[M!WF-/SG8T=;UB=FF3='HVXJU"(#D6>2W*M_:*"$X`!A#)K:Y('AN;W=K5
M$KFQU1)7)N6IQ_(G6(%Q!:I(J('K]!DJ$YH1AW_J'>L#VX#`8%OQ9;)'%A0+
M)<PM\8D)VE/Y%C:WX4G0(=EK%!2;Z[X-G81KPJ48"SA;VD)V6(S8/07M]P@N
M#`8'-?X:H-*8-Y'/,V2IK9@A$>>.@"W8]_2T#9]>O<W<7*P+3D$>5FV9/[0F
M3?,FE"RR%2I`0U($R$\QT^VG^J2("7`Z4,!@,!@,"WW2,,[R\1E^7EKAN406
MN+@Q"3/+TWHRE3JSK6%:-Q:V]P2M;\7ML<30EEKR5)9!HM'%!`<`!@0N#`8#
M`Y6&7P7]3HO,&Y]YN$NXD<:',ZU?.EVE`Z0BWW6_T1#R@9$WXG0$CA'82.5-
M@&LPML<UKDYIFA2I-6$(Q%F;;PAU3X#`P?,>C.;8A*DE96!>](1>;R!S;8LA
MKZ86A`V25/;S)`%%M$<211Z?$KNY.;^6K!I,D`G&:JT:'0`"]VO4/!'KVY:C
MBR.U'%KFH)C<6E^3TW%*S8K&KQO7M\ICB$Y&FJQ@AR%Y*4II"QMK,84!D3I]
M*4Q*40=$A"7O00S_`(#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`AR\RGCCL?R.U-2\#JH7+37)H#:BQ^>I5T]4RRW4;'`'Z(/+%*$]>L2<
M(TQ$K=%PF[>QG;2B"4GT:G6)%)))FPVIXEHRW>5:IIGF-Y;:6<:LJ*AV1DU/
M*L876M"7&T?W?(!N4>8*>4K94ECD(;HH8D/TXFORQ:XN1YPS"2?U]0V>MVHZ
MVOJLYK3EP1!JGU86*Q*XS-H:^!/&TR)A7>W[3:O"F.3*/@.]FM[V`P`M;UK>
MMZW@9#++`46`HH`"RBP!+++`'0`%@!K00``$.M!"`(=>FM:_36L#]X#`8#`8
M#`8#`UB[8D!,4XYZLDJAV`PIV+G2Z'10^F3MYJ[3(G1UW(CCW<-E1R+3=_@!
MK84'9X'E$S.JIM&#2@I(>,O10@AG\05P(K(\'=E3A19L^LDN/,/7D=<9/:G3
MM@W*](4\(32IJ2)RKWAU4UU:+#%S6)$F<4!K0P&/K2D6A/2:-5?&4$,F?QOI
M;'9GXSHT[1@TL]K*N"TF\!P;0O2VS#!)%3/H'V)1?T0A,E),`F,+"%(V(OPA
M1(0#*'M28K"`)Z<!@,!@,!@,!@6A/YLSUM")7/Y`ED:YCAS"YR)U1Q"*R.<R
MA4A:DIBM0GC\.B#8]2B2NQI9>PD(D"10J4&;T$L`A;UK`NLDS1Q11P0F`":6
M`P(#BQDFAT,.A:":2:$)A1@=;]!!%K0@[_3>O7`^F`P&`P&`P.8GP\5HZ,'E
M/\NDU7U)6L$-<;,D;>XR>)\P]+52_2E8\VK()(C7+K2N)Y<J^E93X@W]]61'
M`EE.RHP#D2`M#I-\@=,R1U;EZMU0HU9*A6R*R$#L07O>S$"Q2WHW8A.HUO6M
M!,-;G`@[6OU_L-#O_7`J&`P*.RM1[0G6$'O;P^B5O#PZ@4O0V\:A$0ZN2EP(
M94>VUN;"@L[(4HTE1Z,`8HTF*!HXXXSW&""L8#`8#`8&@;QY*.:F7L(GAPY'
M>Z^[]K8XW+53+S;>3S5K.MEK(9(&$+Q;;=!5$"0MRQM+WL;CM;MK3FA,*.4E
MF$*`E!CR1>6WF&/]?.O$@(9U%);CCMAU_64K<X7S%;<LK"(2.SVMG>X>IE%D
M,L?51UFCJ]H>BU0W(T>D9*4H\\8]$DF&!"3_``-)'_B;B>3=-EW/)>&Z/DMZ
M*$*.P#.F'NCJG=WDJ4QER8VMA)/G#BF/FNK$;R$*94WJPIA?72HO4"LLP`"Q
M!DT[CODD^R$%R&\N\\"MUKEAT];K4U2]<AL=%-U.U(E,O3S<$<#)BY,I&L-$
M8NTJ^R8(P6Q#WO?K@;'8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`TK[J[C@?`U3QNV[`JGH2X6V567$ZM:XIS=5+E;<W"^2[:X2%<N94*
MQM(0,Y8&XPO1IR@`E"PPA(0$U2H*+$&(+^\EK93O+M-]2POD?LB\6:Y;%9:^
M0U3$Z:6P2[85^8U*2?W)8E=7"M@#K$&%.YQCZOSK/B),VN2GZ,^H;I1@5VI/
M(`LLW@"2]V+N7[RBQ\8BUIR<[G,D$3E]QOP*O>Y`S'-\2+C;XI87Y7)],`CF
MW05!>SRS`^@=ZV`0PD2),^8DHWV#+^4L!GQCU[1@]X="]@]?Z##Z^F]?]<#Z
M8#`8#`8#`8#`UVZ]>C8YRCTO($\W%6JEEH2W'1+809=%H`.$JD,"?E*64@G,
MX9I'#8<-C4%A4!='5O6MZ'9?S'D&E`$`01`>(F<R&:^%)^>;7N`Z5*6J'])-
MSY;4>ZBKR3+432WH9`L7/#;>5%0Q&@J99'@J#Q$GZ0.;VR;)"XFB4&&`+T%]
M?QXK&9;,\=B!Y8)N^3AL;;NMID3*))U%+.MWF/DE+FES3QE59TPK6K')`4@2
MNH#2&DMO.()3J"U.E`S%9A903G8&,+?DR:#PA;/'>R&*J8C`UC;,[`E\E:TC
MDRDU]'%9;E,6U:<L7MY3&6[,I!I'Y+0C!H-B^4)1FP^S89+)-*4%%'DC"82<
M6`THP&_4)A1@=#+&'?\`J$81:WK_`.F!],!@,!@,!@>%M$YC1@$[DH4Z_9BG
M1I3:J4+$82M*3M(Q`4*DB$X1AB/18C-;*UH!NQ!#L0=:$(/=@,!@6'9L](K"
M#ODY4Q6>38ABTW",C%91-QG,X<].+L@:=?@XJTZ$XNVT0E^E"C16M[*2%&F[
MUO0-X%^8%M&1D!DQ2S+\Y)0&)8TX1G4;+>E`8<H`X.C:Z[?%4=]/JGR5&)M^
MNG6[WHPI*><5KUT9OT#FJ\25=-\,\R7FC>F^)QY@!,++-=Q*DM=]@,;XI^67
M>X\XV7W#I/1;@B?7G:US,U'=*S'(]5H]K.*8TY1&!T]8'Y&,!0!FFC`666`0
MS#!BT````UL0QC&+>@A`$.O7>]_IK6!X5KNU-B'\HXN;>WMGN2!_(K5J9*A]
MR]00D0A^V>86G]RU4I+**U[O]PPP(0^NQ:UL*.\S.-,#_$(N[N6DC]/%SNW1
M-!]1<?MV6,3&MD;J5]A,E.2(0I&9N..V-282`>PZ`'8C!!`(+HP&`P&`P&!P
M]=RT@T<_^>BE[ABE?T1.FRTNJN?7*=*G.MN]6RXJZG=J6/SLE;)V@M6.B=*$
MD6VM#"#`($B%P2LB=O=GQO<VT8E(MA#N%P-!;3\A4!J;JJ+<G/'/O9\ID$J1
M1!87<%;<NV-8?/+$.:/`65N32BU8ND<$3)^,4&`,=%)B;:!K(%[U*@O01Z"'
M])[[;#+O9*+/Y&[S0N3W;CO4Q5DK.89(&DD`6DEW.U9CI:Y#H?%4E4NNVCVH
MW/Y1*#MJ2=_6"`0Q`#?G`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`AF\XM+59=/*,)16?'WB0BA]T(I/!TJ?D&W.WH@&9+JJM>%)@V91
M]**$DX'"U#3+E8`/9!@!,KSM`H*WM1HD(@J?@WCC7$>'38ZU1@,3*0W[>ZI6
MV-_*MC<9Q/;@_P`V42589`:)M-S<I='(2F,>?JHQ&A2%:$F,(+3$:(V'`F&P
M&!2WIH3/S2X,RPYR3I7),8D4'L[LYL3F44;KVC$A>&96A=6Y1K7_`&FISBS0
M_P"@M8%4P&`P&`P&!@[IP997-O0)AJXEL`"E+2WMQ4N]?Q\A#O4'?/:J-?K9
M0N=6LH"!^@MJY(F4,*?T^1>6-*$T.PAO\)+B]/7B)D(Y3;Q#BM+7]`H395%;
M=Y17!JU`!M,^JB9[*YE;':EH<L84AFG@*A<0O6-:A9L]6`:?1)`0]/\`'(L%
MRG'"$H1NEEJ;441'H&P68$@<.HJJZG7H2%;1$WDMEW)ZCA$$C\.;R-N&U!#.
M<G4*!"5&+@G[(6$EEA/Q@-ZUO6];UZZW^F];_76];_KK>L!@,!@,!@,!@,!@
M,"G@=FHUT4L9;FWF/2-`C=%C.!8F&Z)6QQ/6I6]Q4MX3-JR$"Y4V*2R3A`T6
M:8G,"'>]EBUH*A@,!@0^\1\7W50_>?>=_P`[A$19*ZZ`DBATKN4-7670MQ2%
M]1J9*)X+*=*7L9F15O5P=D"&<:%K5*?QI@@-S=[6T(M["8+`^1Y!*DDY,I)*
M4)U!1A!Y!Y8#23R30;+-).*,T(!I1H!;"((M;T+6_3>!^2DJ4E,2C)3$%)$Y
M11)"4HDLM,02GT$)!1)``Z*+*)"`.@!#K6@ZUKT]/3`^^`P&`P&`P(=>@?*8
M"E.[:\X\TKY"^M,)U5D(7ERWHZVVZ_4:FQBVA9H::FX?RI.(>B5#0.Y?XD#I
M-&]*YC&3\JE'H[T+"8K`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8#`8#`8#`8&D?D!ZF5<>\^GW(EDM2Q'2:9QF/JGZZVRZ'6"I$3O]\U26>G
MHB`6/-P.RL"'X40Q(`(OG'H)ANAB**-#(/&UX+ND.::KNIS>(8_N,Y:G98M=
MJ^BUK0J'*E#;)'IC,TR1>\(W$+4:24_XSXC`/#:D/&<`8P`V2(L6PR_:9=G&
MUK/BZ54P=';YD/D0*O56:F?5M=)Y\)J5:B9TZ21=0DD:B)EO>R=N`$!@%8DN
MAZ*W[_3`NYLTY:;6_3R)"-WTA2:=1M@#RVT3EH@O[PF\M4,U4!")5[ME:,$(
MS1?IH6][]=X'NP&`P&`P&`P&!A3I-A;)1SM?,;>6]H=FE]INS6IP;7]%`G)C
M7)5T+>DYR9V06J(%8+&XP(_0XN1["Q"!ZZ7[TE^7>!#_`/QW()+8SXYE<7LQ
MGA85#A=MI"&VQ2(<?QR(K6-Q;(JF,(`T\:22652YEG&`/*4'.0R7PX6A`/(T
MC"B$8$U-9U'5-+1S</IRL:]J:(B7J'446K.%QN"1P3HK`24K<MLD6;6ILVO5
M%IBPF'?%\@PEAUO>]!UZ!=".2QUQ>WJ,M[^RKI)&B&E5(X^C=4*I[8$K^!8:
MQ*7IJ(/&O:B'HMN4"2#/++"I"09LO8M`%Z!6L!@,!@,!@,!@,"S)CJPQ&1#5
M?F0PHG]YM.YZ.8$OAYG^/`)7(;X7$"F4],']YGK@HRT@UH_HE%#.,,"8(`"A
MA>>!X0-C:6Y'O(&]"!W5(DK:I=0)"`N2AN0GJU2)O/7:+TJ.1(U+@H,**$+9
M98SS!!UK8Q;V'NP/$K_)?.V_1VATFTM'^7TK"?L\3=^/7?'IMV2()85OY3ZV
M][-]2_KZ-UK7OV#>@]N!34Z%22Y.2XUW<%:9<6@`E:#RVP+>T"2`/"H-;S$S
M<G<S3',1P1'_`&E"@(=E!^+16O=H05+`8#`8#`8#`8'A3-R5(J<5A/V/G=5!
M*E9\JU8I)V:G1IT!7U4RA0:F;R_K)0>XM.`H`S/<8+6S!C$(/=@,!@1O7PE\
MN:Z_4*?FAW\=\=Y<+<X@H7N=T,_1LFOP]J)+1;G;<4SPQSCU>%J5AXE&FL[[
MGH46$O9VA"$+6@J\M:/*@JZ%8APZ:\(M_*)-MQMR?T[E";V_Y#*:33B]THBZ
M9=^ZW2MC9^NUK84SEI,E1@UO6]D!V'?N"0K`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`_!AA9)8S31@***`(PPPP0
M0%EE@#L0QC&+>@@``.M[WO>_36L#7U):=(=-T_9XJ;GM6]&1-2PS*"/R:LY5
M6=LL#B[*8\I3.$'=2S7AR@BEQ<$J\!1K<\FEHS2E`=*M:3F"WL-'O#)1D_Y^
MX^%"+%J20T:]GV?,7@%<R&F^3J.,1D*2&9,-\00SCYT?J\$WOBE(/8%;BO4O
M9_P[^384@48=!+-@4U.S-"-R<GE(U-J5W>2T!3PZIT*4AR=2FL!Y386Y+BB@
MJEQ;<6I,"1HT0]$A,%H'IH6_4*E@,!@,!@,!@,#Y?[_S[_4KZWQ:]->T?S_/
M[Q>[>Q>[X_B^/T]->GKZ^OZ^F!]<!@,!@,!@8_D,`_<,\KJ=;FL_9/\`'89?
MK4-CTDVV02<"ES0F:-#L2/!2&[E`HN%/M2T:V<2%$K-&;Z#%L/M#(&`P+?E<
MG:(5&9!+W\3@!CC#.X/KN-I9'N2N@6YK2FK%@F^/QMO=I`]K-$$B^-*B2J%1
MXO0!98Q[T'85\(M#"$6O7T$'0M>H=AWZ;UZZ]0BUH0=^F_Z;UK>L#S+$A:U.
M),88J*`(9(]C1JU")1K9!Q9X=!4I#23P@&(O6AAT+6A@WL(O4.]ZV'JP&`P&
M!SX=,0KS`RKRC1-34T?N)1X_(K)Z&EIZN.]?\[TQ"7@:4:,FT$;U#"^<)I?<
MJCB+19QBR,*'PHAU&4,13@24L((1!T'X#`8#`8#`8#`8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`CK\GK/UW(.;D+'Q?7+Q9EH.=H0E,_,\<Z;<
M.3I`V0#>W,;Z^-UI-;2Y+Q)TCB%$4O;R#$BH]M.4&IS=GDEE&!>'CFA_1<!Y
M-K^(=3QQSBUP,KC+R75L?NBY;U9(Q-"F4.BYB62"[9JB1/LF<5*!4'821:&4
M@3:*3%BT$O0`!LO=-4QZ]J@M&E9:XR=GBUM5_+JXD3M"G]7%I>V,LS8ET?<E
M\8D:'0E3(_)$C@,Q*I"$?Q'!"+81:UL.PU4[2A,.KKQK="U^?(],<'KGDZ71
MM/+)P]VZ9IK8X+71R)M?9<_48J;KI6?6(:"CUY\<&%Y4>@]D!$,?L$&%/"!)
MHO+_`!F<XOD.ED9F[`H23@I+)8>^=.R2.+ST]@R<I>6V//8`"[T5E(%X3$XM
M+]:;RQE;+;-:;PIM:"6/`8#`8#`8%'D*<Q8P/B0HLPXU4SN2<LHE,WK#33#T
M1Q0"RD;M_P"U*C!B%Z!+4_\`CCWOVF?V;W@0,?QWJ+G7/W*]XPJ>U+8%0N2K
MIJ7O:5DL;G[FWGEY7IE42AB0:TF-\UR*1QZ0)2%*(:<+@N&2:'XOJI2PHTY.
MM!/_`(#`8#`8#`8#`8#`IY2XPUS7-^VYP)*1I&]4!T-`FTV+QKC'`LQ&A&!4
M8K$K;=(0B4:,)+!H*DKV",WL>@!4,"GIEQRA<Y(QMC@D*0#2A(<%/TOI.VE*
M8)YAC;]=:H5^Q&8+91OV"4XODUOV:&#T'L*A@,!@,!@6])FAX>F](D9)4YP]
M60_1MT/<VIO8G)2M:F=_;G5ZC1Q$A:W9"4WRUI1G-BH\HH"U.G5C-2G$*0%'
M`"X<#XJ-J-)S]I`$F*M$F[3`4&#)3C4:`+9(#S2BCC"B1&>FA""`8@A]=Z#O
M?Z8'Z*V;LHK9X2PG[+!LX)0A#*";[=?($H8P%C&7H?K[=["'>]?UUK^F!],!
M@,#QI'!`OVK"A7(UHD"PUO7:2*25.T2\D!9AR%7HD8]IEA19P!"*'[1AT/6]
MZ]-ZP/9@,#5V9=O<;US8S]3]A=4<^02U8PN@;8_US,K=@D7FK6X6@-,"O$2F
M-O;XA=M*ICM:3M``)6Q'A.+%K7M&'>PVBP&!%+V-X>.8NY[J(NF\K%ZM*-(B
M4<C6JPK?I&?5I4(G>&K'Y9#[$U#XFH0'D6%&129:%*M*6%I_:<+9B<8Q#$(,
MNV-XY*8LBZFB]U5I]>165MMC5Y9B^+0WK[H!KIV3/%:/3$^,3-(J/7SIUJ53
M$5ZE@`!P;4[.F(6`4'[%Z&F?($-[6UU;W@D]0W*-*24SBYM1X]%FE_&X,Z]0
MUN2?T.++$+:9>D,+V+6M@%[?4.]AWK>PJ&`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&!BZX;OIKGN%GV/>]JUY35?IG1I9%$UL^8,$'BQ+P_
M+`-[*UF/LD7MS:%>Z+3-%D%;,]Y@O7TUOTWZ!]*DNJGK]AX+"HVTZ]N*!F.[
MTP%32L9C'YS%C7N.N!K6^M13]&E[DUF+VIP($4>6$W8BQ:_77IO6]A=DNED;
M@44D\YF3T@CD0AD>>I9*I"ZG:3-C#&XZVJ7A\>G%0+U"0@:VM&:></?Z!++W
MO_3`UJO"U(1/^%[8NJ#RJ,+:VG/+,TLJ)3>4SB<TM#UD&E%6.$D8Y4]V/&F4
M^R*NCZI@7E*S7E`WB>6@@6U!)/V"@@P-._!JZQET\=U7_M.:0B>-+?)9TW:?
M*_Z<L_K-A"I+?1J#T.[2MJ,1&4I%J;[.MC8PH@)&D(PEEB&+9F\"7K`8&'>@
M;KCW.5+V-><LC5@2^,UC'%,J?X]5D/<9_/E[2B-)"N''8@U;"O>3D*<T2@X)
M>]?$F*,-%O00"W@8XXR[+HSO6AHYT=SPZ29UK>2.+RRD"F$,D4$D#>_1Q7^/
MD#,XL<E0HE&U#0XZ$0,]-M0B-,`+X3S0Z]V!M3@4B0/22-,+W(EY+FI0L#0Y
M/2U.RM+D_O"A(U(SERDEI8F9*N>'IS-)($$A(D).4J3=A+*`,8@AV&J7&?;=
M-=]U'(+?Y^*LUMBC-,WVNC%-JU/,ZN=_W,R-3.Y+%+<P3=M:%3VS)@/Q`/M)
M_>GVI+.3B$$XDT``UF\3GCDD7CEK>[HC,)K2U@2:XKI=;36R.EZ$(H-N&F6M
M*!$2B?6$B93(IQ7E+BU1Q7PF)TJ(E1\!)?MUL6PE=P&`P&`P&`P&`P&`P/"V
M.C8]MZ-V9G%`[M3@06J0.;8K3KV]<F-U[BE*-:E,-3*2#`_J$8!"#O7]-X'N
MP&`P&!;LLE;!!XZZRR4N&FJ/LB?2IS<-IEBS28@1I9`1_5;TZM:?L1QP0Z"6
M6,6][_I@7%@,#&E@6Q#ZI0O<ELM>G@E=QQC;WA[M&4.;$T01L/<WXB.I&1:X
M*W8#BD=#5RQ/O0C$H$@@J"PA.$9L180R7@,"TG5K<9"KD4<?FUC65V]1(MK,
MT%Q=`2!>XNICVADS:N1E(TZ-*Q[8S$?UE!"W:H9YIX1%E!++&8%U@`$L`0`U
M[0`"$`0Z_IH(=:T'6O\`[:U@?K`_(0`![O8`(/>+8Q^T.@^\>_36QB]-:]PM
MZUKUWO\`7`_6`P(`N[O"S+NR.S&+I6/W!S%54<;GJE9VX'2+@>F;NO==-Z6)
M>&M$UG6[.G0@]?!92SKD6E!"E,8I0F,R,"86BP"UL)_<!@:B="=^<2\G/B>,
M=+=5T/1TH5-30_)8Q9-E1B,252QOZ]Y:V=Z(8'%P*=SFAP<(ZO)+4A)V1L:,
M[6Q:]@O0/K+>^N&X#/T]4SCL/F.(6BL<8FT(:XDMYUJRSQP<IXD8U\*1MT1<
M)(G?W`V6(9,WGM_PIQZ5DK"AE;$$>MX&VV`P&`P&`P&`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P&`P&`P&`P-1>V.77CKFEBZPC5R/E"2MJG<*L*+6<P0*N+-5L
M;W#'3:TDE1"[4C\CB+R@<4IQQ!H#2`BUH>O[A%_(4:'FX8XZCW"M`M'/L4LV
MP[68&5Z<WQ#(+*15PWO2$QZ3M^W%G;4=7P*O(\ECX75*>K3%&(SU1`E8RMJ#
M"@$A+#;1T:VQ\;'%D>VY`\,SP@6-;NT.B-.X-CHV."<Q(O;G%`K+.2KD"Y*<
M,HXDT`BS2Q;"+6];WK`P5?Y+-77*=UIXRS)&"/03GNR"8_'XO+&RED+*S1BN
M'D#2S1V=`;U#-4R1M1(2R$CMI(-*P@`!1HK8"/9L(]?`S/$=E^-:FYFBDDOD
M)+RZ2T\),^ZL@G8LQCA6W36T<=D5L5W#X)'VYW3M^R5*B.C;2%[&<J$0K]5'
MR;P)CL!@80Z9T+?-_0'L5M"`7^$[4V%<_P`PEU>L*/>H*^[TK>Y[``&3N$M"
M?T]ZEW90B=FXG0E"36U!9>L"+[^/Y,DLS\;\".)L2N;*5,,\GD><WFLKYN;H
MME;UJ92W+PL[C/KR,-ER1\+0N1*DUI3"VUMY*HH*?V[$8'0388%$DJ3:^./Z
M'6TX=K61U2:VK&O+2ZVI0GDZVI,:U"1S`GU[_P"_:8TH_0?798PC]-Z#GX_C
M?2U@>>5;VB\9G_.4]9H1TE(T"([G"9=HSN/M!2^+1@X*"2/?;*E7.4[[O2;U
M`B:!Z:DJ71?OUM6)0,8=$6`P&!1&%@11U,M2H5#PI+7O;X_'C>GYZD*@M:_N
MBIW6IT:E\7."A`SIE*L1:-`0(M&@3!`0G**)``&@K>`P&`P&`P&`P*:SLS1'
MFM`QL#4VL;*UIBT;8T,Z%*V-;<C)#[24B!O1%$)$B8H/Z!++`$(=?TU@?/T?
M?SNQ;,:?VS^)#H)7PK/SOYW[@MB,VH^?\?\`B?Q_IK0/B^;YO7?N]OZ8%6P&
M`P&`P&!0T[&6)G$SORLR6E&FJAJ3I`A9C-JRCUYRY,E4(V]L;VL9#:`99!/_
M`(_OV62`1@C#?>8(*Y@?(D)P2PZ/,+--UL7N,**$0`6MBWL/H4(T_8=A!Z:W
M_=OUWKU_3U]-!]<!@,!@,!@1%]<^7:*\CW).*:<>(?(7>:N$M%6K1S_G?G$R
MR:P>'BVC'/4=C*"5@E+6(MR3%,ZC[)QJ<",M02)-\VU&RRC`Q]W=YLJ\X7Z\
MHKCM_P"9[YLJ<WN@@CE$GV,%1EJ99`&=3Y-`-,=>DNSEM7/)?$E9_P!U[0ZT
MWE(47L'I08(>@:";7`P/.>6N9[/LJ/W+9//=)V!;448SHS&;+FM70F4SI@CQ
MZO:\;*T2E\9%STWMH5HQF@**."`L9IFP:#LTSW!=DJI:G)TO8W6;U-6<R=(P
MYL[W&G*502+2%?'GF/'%*&!W8UCNU+%#2YL9Y`!HU"<19J88`[+$'>M;P,F8
M#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`UKZMOR5\WU638
M<*YXN+J"1JYO!X4@JJC4<>5S52.:/Z5B_<!YTK>X['6J-Q_:G1[@N6+$Z5(1
M_N'F%$A,-+#3&P/)I.HEP7T-VL5PCTG$7ND)DY1ADY\Z+4P/GN>V*QHI/$V$
MBR$CN^OTD98_!EB*3C5%&':.6J3&X].E3J!"3C."Y/&CY#)5WWS_`&==<GY_
M#3SC7=BR>#H(;&K0;;7639%'HXS/I+ZUDJ(O7<JC"EW5N9J),W/S,V*CA)]*
M"_>F.+,P-F5MAJ[=XM=;4D%>S^K%5D<TNTZ=:NE:V%0^T8'N5UFJ?%$,D2^<
MZ6UY$YVP`7;2*C'K1K.WKRQ;6:$G+-]0CB_CV.K<[>.6-'M+5-&AM+M2QP)$
M\\M?G2WWTT"@UG<3%.G[F.*PR`M#<8>N'I.WJT!3Q\8?M';$0J3;P)PL!@6%
M:JD2.K[(6!.TF$D@4P4A4"EW[`"0(B/.)NCMSS1"G<)T5L/N_+_&9^-]/L>T
M7Q^FPB(\!$P4S#A`TT]\62`MCNB?,*-P7]W0CR%J_J)FN)K"R1W7`(U%6*/E
M@,7"V"-B3;4(PB^Z8,7W]:"$VF!XW$P9+>N-+^/Y"D:DP'S'G)2O>`D8@_*I
M3DJ5"<OW:_N&`LP8-?J$(MZUK8<]_P#'4LE19E`=/NYTG%)RR>IYB6$Y9VI8
M79KNB/\`QC<F5I5;Q8T4A[U7S=\B'0D"(Q$0I<4N]*U!81CT(P.AS`8#`8#`
M8#`8#`8#`8#`8#`8#`8%%0-*A$[/KF8^O+@0\F-PTS,N$W;:H]I`B"C-+8PI
M6U*O`6YF!^=1]H]4+9^][+V6#T!H*U@,!@,!@,!@,!@,!@0:>1KPYF]S7#+K
MH9IQSG&GR1TY5M5_1N'EU]NQR&*J[3=;595Y$O*OZ!ZB:?;RL**UMF:4JTTC
MYR%JA>C.VDT$V;WI^TTG!C0FC\UH2/283X%9MK^/2M/I=L\+>+2OW_0^7XM!
MWZ?-[/=OV^N!'KVSV=U#S9,(C".>/'%>?;"^;1<;PUR6NY_7E>UZR2%%(-(7
M:(3R7S(Q0"$*R(WO\FD6*TWTG`8@I"1_-HS987/:'5/55?.I*>/>-Z\[<87!
M@KY<@D5=W/R^7]"12Q&F'*HQ*X_.;:ADA:O\=N)HR%C@WIW=$K`7\R<0@[WH
M(;]X#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8&`>IJ"9.
MI.>[7Y]D:IE0LMJ18^,K5\A@4.M!H;]&*DJU.O4P.P&UVB$A,0JD8#22UJ<8
M2CP`.![32P#"&(>0>29ES%(^AI',>@%M]+K^G\=L9>YO%)4?4<C02-IA[?#7
MASDSO2</A"*QGF0-K(W`VO<D0529.@*(`+8-8&RUPH372IK.:D[HN953M7TS
M:T;LUZAXG1M5N$<<DB9<U@L(LZ!&.24XW1A`7L`VD1H0Z6!VG^36!#'_`!VE
M30#@=SCS*MD[HCC%ZS]O$Y2A=Q\J-4'JVF).@RFM-QE)91!4+6F+6!U[7M2*
M0FJ!&F"W^.$WZ"$\6`P+0L+1`H#.`JG,QD3"B$ETH>2GANCQK01ME6Z.<RW]
MW3+6EC,0%^INEBHDU.FV#Y#`"`$0=A"?_'K<WIRXKFPW!_>I>V$]`S@IDE+Q
MU1S)UL%>07'H<2<A;9[RM$XE!61$W:)+%ML7DFNX#SS#QB"F/2E`"=_`_!I>
MC2C"MB&#1@!E[&4,11H=##L.Q%F`WH98PZWZZ%K>MZW^NL#FO_C:OZ5XK#N!
M(@DKM)T;7UW*@C<'OKN7]9.1[@L(5'*EISE):^@*:([6I@)_?LLHQ>['@,.7
M`3F%%E[#I3P&`P&`P*.])GU24@"PNS>T'%/#2I<37%F->BUK$G6E&O32F))=
MV?:!P<T`1DD+!#/`D,%HP2<_0?C$%8P&`P*:V.J1W+5&H]+=`1.3@U'_`'FQ
MS:Q[5MBHQ&KVG+=$B,Q8BV>5OX51.AIE(/09)@P;T+85+`\I2K1JI4D^NJ+V
MD`F'M0:0("51]D)@M!2G[_M/&3\?H9K7_9L6O7^N!ZL!@,!@,!@,!@6A`VJ9
M,L6;VV?RYNG4K(/=AN,H:HJ"%('`A4\."MH()C8'J0A0":F4].C,']PW[)B<
M1^]%[-^,`7?@,!@,"WG=S?$3O%4+9&3WIL>'->DD;V6ZMB$F'MR9A=7%&ZJ$
M*PX"YZ"Y/21,W!(1@&86)9H\?H44/>!<.`P&!'+VY67D]G\CA@.#NH>:^?H4
M-N1([$W<E#OEK39.YI9`)Q/?X2X)Y2DC:E,XL82VXYK7MQ>PA^0XE<4:,L1`
M2)I@*"TR<M6<6I5`(*`I4%$[3%'J`EAT<<6GV:?M.6:9K8M`]X_9K?I[M^GK
M@??`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`P!U+6
M]QV[05D5WS[>BOFFY9&UMX(!=Z.&L]@F01Z;7YI>1*3X:_'I6M^;WE"W'-JH
MHPP`@IEA@R]Z,"#`U]\=U"]MT#5DX8^[.QD'95HRJS'N7L,L::P9*R:()$5R
M)O2(X0THV<*?\BWA5HC5P?E(*TB&K$F*V846$P0;^'@-,(.+).VG.,*,`4HT
M`!NR#1`V$L[11GJ69LH6]"]HOTWZ>F\#5>@H!>M8\F1NO^FKG9[TO&)0F6-T
MVO!#%&:*(IHI3KI"='I4LBKRL!&FUV)C)B'3@`TTEL&N).'KX4XM!`$6'\<Q
MR,4\/S!K-ESI,C([>4E9S'5UKOC2N#3#$D2A9)@RV_C"Q+-BT@`,96P_EY(Y
M#D2SV>F]C0EHS!!/BX`V8@7%Z7&->QHU(-.1/UM'-VQ$CUI<5M:2H1Z,2>OR
M!^8LPKU#_<$0?76P@^\&5Z3VZZOZ<U.>A.C^F-P7HQ]BS#9'0J/EQ*9^*1MJ
M='MF@AO,5C6&T.$?*4-XE8U*\:(LT2P&T)/Q?)Z!,U8R,YQKV=MZ=U<&)0NA
MLG1D/;0XM30ZLYRID7$%.K8[/R5<QM;@WC'HXE0M(.2$&`T,X`RPB#L(/_`,
M?O?!MEH$MA6!+]MEVV:0G>ICU-R;T^Y,YRN,Q=R,#'[`Y<TMK>*MYBY:8N`W
M//RN9:E08L.U]-2F+"'I_C_V)9=J\OW>_P!I]!VET"_)>BI;&4CY9/5_.76"
MV/M37&HR(A`PSGFPQ2QQ9O7FKC%0&Q>?]G0!EJB"2$Z@O0PUY_C=/9SXA\@A
MCU<\^M:5MW2B=M=$,W[E+[0U&&TC<Q"VFMHT\'@Y4`"\+RUQ9AII2E4]Z0@&
M,80)0!V&3_!?*]N=M>3R(J9=:4H=8?TZ`MU*LKR'P?N8+4L6/UGH#T\>C,+B
M,5W0:7:EC,`<A<=JG%P^(L@X>A->_<'1!@,!@,!@,"UXGLHI`M;$T9=XNA9'
M=Q:6\AV-;#M.J0@P)P'YJ&W/+T9^'<S%`]D:5B3K->T7R$%?VZV%T8#`8#`_
M/O!H>B]B#[Q!$,(/=KW[`'80B%H/KZ["'8]:WO\`IK>]?]<#X+59:!&K7'`4
M&%(TQZLTM(F/6*C"TY0SA@3)$P#5*I0((-Z`66$0QB]`AUO>]:P+/K^<%V)'
M&:7M\<E##'I-'(Q*(\*8LBZ)2-0WR=E3O(4CW"7XE#+H<^,X504ZYO=D:-:F
M4Z$6,O0@"UH+XWO6OZ[UK]=:_7]/UW^FM?\`WWO`_N!9K]*U[-*H+'$T,E+\
MAF2Q_2.,K9R6LR.P0+*PJGI*KF!BMS2.)"20*$WT$8DB=7O:TP`3-%@W\F@O
M+`8%JO*MLAJ"635R/D:I"F;=N[FB0)I#*CB$C&@,V8"-1-F3.KD>M4DE[WM*
MW)3%"P_T]`#,WK6PNK`8#`8#`IJ1Y:'!<ZMB!U;5KDPGI4SXWI%R52N9E*Y$
M0Y(D[JD)-&H;CUC<I+4%`."`1A)@1AUL(M;V%2P&`P&`P&!'WUWRIU??<\AD
MBH'R*6OQS#6N-#C\Z@4`IJE[(#,%A4D2R)!*V6266R.:Z&R8LI-^.4[$2YH%
M3<+9>DI8Q&F&!2;JXDZ$LQ/&E,$\FO85(/[5#(3%)$9#([S$\Q69N,8;R$#[
M.7"-RJAG1S8I=.3`FJEVVEU0MY*DS6TZ0LH&BMA(<8A)-5(EAABO9Z$"@!.@
M+5A"8S[0"P&B5H2#RD*X>M%:^/9Q9FR=[WLOV[$+U#V8#`8#`8#`8#`8#`8#
M`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'P4JDR).<K6*"$B5,6,Y0I4FED)R"2]
M;$8:<<:(!918`Z]=B%O6M:P*2QRB,R<*\4;D3%(0M2S;<YB8W=O=@MSAHDI3
MM"OV@4*-(UFDYY9GQ&>T?L&$7IZ;UO`\\PF</KR,O$UG\KC4&AT>2_>?Y;,'
MUKC,98T7RED_<>'YZ5(FIL2_,:`'R'&@![A:UZ^N]8%FQ6W*DN%DE>ZJLRM[
M5(94QK>_!@,NB$_3M:IP1*AI$#T0T/*I"G-7E%#V`A680$\`1>N]!]V]!"S_
M`!Y=605RS>([.:XO'U>NDYF)E;8IS5R-S"S@826*.D@<#(MR'85A0Z1K5"LD
MXLYS=%):_7U])B]GIDY2@P)V&J41F6LRURBKTR3%M+^VC,-CCHTOB0Y641H9
MK;M0G6&-_P!H0#0ZV6:8#6M#U[O0._7`@C_C^U]?%>5+U8WWI4-JTVK<>F7Y
MSAL=L_COFSCTQ9%U#6G&G7LK'SDI5M=ADEB'I.<\+35!`/A+(0'FD`'[0GGD
MJ-8XQQ_;VY<H;'!>R.J-"Y)$K6N5MZQ4A/(3+DJ)\`8RK%"0X83`%+`B2F"#
MH)NME[%K`Y]OX^Z*1-_*72Z!WF=C/&TM\S%*4Y3(OB9(!D=DT4:TCR*/IN3)
MK/((6H`I(+4+!OYI7JHV$)0#$I8CC0K'\=8$[+Y;O0,[FQLR6&=*2Y2A,^'B
MPM.C)/8H_I:<49Q1-YO#5A[FZ%G&J%#N8E7GG:$,DK:011@@]/@QE[F\/WD%
MBSQ9%V6`X13J.1"6%W)U?R7TF:RN#K*[#_*%1]CYG&)ZJW2E>A'I8GDNB]*Q
ME%E-Y1042HL(?'PHVD3.KX\J3"*X+EM)=%^KU81M]L=&\V7B@AB#<@LEF0-\
M)8*+?G220%L4A9!%&:D9",9Y")*D)+T>W+=[#H(P&`P&`P&`P&`P&!Y3UR),
M>C3*5:5.I<3C$S>G/4%%'KU!*4]:<0C*,&$Q4<4C2FG""#0A!*+$+>O:'>]!
M\A-38-T(>QMR`;RE0*VI,[B2)Q.:=L7J$:M<W$+]E[5$H%BMN3FFDA'HLPP@
ML0M;V`.]!K$F='VNE]W2Q15Z57;<I?VYFA:?5BL<5:NEG"-P$Z0Q%HKUOEDY
M?T\.7L,=VK:7#2HAM-5K69>X_6VBV2=L,QPA=)Y:%P>YW`55?.\;G-A1^+MV
MY>2_Z?8<V/ZYBC4Z5A9!)VH@,]CZ$AU(;E(5"EK+5!*,$%0$W6@JZ1B4R!J;
M=6.RQ-R=VB3*WYL+;R%#DU-QS4^N)D,=T(WE,6J3R%$Q[3#/-"`.B5VS?A%L
MO0!;"\L!@,!@,!@4E]2NRYH<$C$[%,3PH3B+;W@]M+>"F]1O>O:H&V&J49:W
M0=>O]@C0:WO?]?\`3`JV`P&!XTB(E+\INBT^UJK1`G%<6F)3GN!Z<@M,!0JV
M2'6S!A)+T$/KO?L!K0=?IK6!XI'(6:),#W*9$N+;&".-2]\>G$TLXTM`U-:4
MU:O6&%)BCE!@$R4D0]A``0]ZU^FM[_3`K`1:&$(P[]0BUH0=_P#70M>NM_\`
M[ZW@?W`@6\PGCO[0[DGU(BYL<N(FVNV.,R:.6FIZB@$]F,R3@=%OVR2H>7&0
M*VAQC[HFT$I0D,_&JR5`-&`5B`/8"PF]@3"KBL&A<87_`(72Z-Q..L*S4;0*
MVJ.Z5L[.C;U'X%K7KW5<VLOS)]_5(.5*322/:`9I@M;'L+LP,<3RXJBJSXM6
M=:=<5SL]N5O!.IY.(S$/F:4"I$A7NA7[@=&_Y&Y$M<TQ)Q^O4HLU06`0M",#
MK86@X]2<R,Z@M([]%T2U*CH<SV(2F<;=K]"H-K^0D+%3!.BR5,A*,'#GQ,WJ
M#$;GK6T2DL@P19HM`%O09S*-*/*+.),+.).+`:4:4,)A1I1@=#+,+,!O81EC
M#O6];UO>MZW@?O`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
MP#U55$GO7FR\Z:A;M!F&6V=5\QA4<>+-KYHM:O6]X?V94WH3YG7+^$QEF,=T
M>=K2I"J`:2:5O?N+,UKV""/GPW<*](\%4K95=](.?';H_3*=-,U:U'(%#L5%
M,@SA1-K97X<X;XS#H"R29Z"K;"BDBPMJ3F?5*]3-^IFBR@R'YIX\V2OQ6]O1
MQ\7.S6Q/%*.B)_<H_7.K:D3>P&/#-M[61NOQ.K$%]DJ9J"<-N%M:DTB6Z*5;
M.*T1[]!%S_&@H<_GJDND:R+K>UX$D0[II60IO7D.L>;[9E!C_'9](FESD#]`
M)U-BK:0_L9[8Q@3OJ@#S&G,]P1JQ#V=_8&</X_\`##(U176[8H:U:>.+>CY&
M6ACSUR!R)RNZ"V.*M@G[;I&N2+,LJ(V"%<L5"()6.AJ106D(+3D%B3Z#[0J?
M\?!A41:B^E(\3`45<L:'H][$UL*'@LO@\LU1IB;6]8Y'Q=-.9RCL!6H1MJ0&
MUQ1X0-Y)1:70C`Z#HL.@3`_!N]Z+,V$(A"T`>PA![/>+?MWZ!!\H@E^[>_Z>
M[>@^O]=^F!SL?QXT[P&BNLFB1.[S(GD?1TA4/;D_5QQ7"53BXKF4MO\`G5ZY
M(L.PD\R6F-+8D+/72H\H_>BP)D6S4A(A!"J?QX6*:1FDNK6*<IVIO<T?5<PV
MWM;=2?%U&FIV43<B)1J7"/<:3&7L3RJ4')SB_OO8RCA!(T4AV:D*T+06[X)'
M-U5WKY8"G`<T5IE'6JAS:E4OF_)4H^%.>^604H0HD'-KBI?T"D!Y?O4*'\H"
M8\O9!2(6U*=SWL+Z\.5HK)ST[Y1XU_F&S[.:H1T1I"C0V`Q<4M+8Q*U,ILS2
ML42<>8YE);'DS<:F3IR?NS).BU]<A.4066N+="2@G^P&!X7!.K5)P%(W`UL.
M"K0'B4DITJD8TR5<G4K$6RUA1Q6BW)(4-,,>M:,+`;L9>PC"$6@]V`P&!18Y
M'VR*,+1&F8*X+2Q-Z5K;@N;N[O[@%&C*"21I8]/ZYS>G11HL.O>>J4''F;_4
M8Q;WO>!6L"RWRQH#&9=!H!(IG&6.<6:.2%UU$G5Y0(9%.#(<T:?Y6"*M"@\M
M:^#CC(+2M;I.`S:9/OY!^T/ZX%Z8'S&228,HPPHL9B<8C"!C`$0R3!EC)$,H
M0M;$6,11@@[WKTWL(MZ_IO>!],"VI<Z-\>8'.5N#(ZR`,3;W&0D-T>8%4GDY
MYJ%N5Z,(C#(WD*7-Q?5B0TU.02F#L\_9VRP^OOWK87&`7O`$?M$'W!"+VCU[
M1A]VM;]H@_\`I%KU_77^F\"EO(7P:,K4>.:2%_Y-E$<-Y3+%:/;,%W0BD)11
M2%6B."YGL&E($1FQ[**6"*&:`PL(BQ!5L#^;UZZWK]?UUZ?IO>M_K_TWKTWK
M>!:T'B22!Q&/0U`\2I_1QML3M29ZF\G>9I+7(E,'80*I!*Y$K7/C^YF:_P#R
M*51QIQF_U$+>\#]R6-G2,R-C*D\GC6H[)V^2&EQI:A1ER0E`G7)Q1B2:6MKC
MM9&'#:W1B@DC:<\9A!6PG!UH6A!<^`P&`P&`P&`P&`P-#NPO)+RCP@N:T/2D
MDL**:>H2_P`Z:W.-4E<5CQU0@871N9-LZJ3U[")+'663/+NZD)F]$O5)3%1Q
M@`ZWK9A?O#<F#S*/V+"XA8,25J%\5G<7C\RC*Y6W.3.J61^3M*1[9E:EH>4B
M!W:E"AN7%C&F5$$J2!;V`TL`PB#H+HP-9;^XNY&ZK=H0_=+\TTC?+S6QRTZ"
M.5LUM%)VKB^G(Q(>XIFHZ1-B\1+>X*&].8>FWZISC2"QC!L0`[T']FO%?'-D
MLC!&K#Y/YKG4>B<>:(C%6.7T96,C:HQ%(_L[;#&8X@=XNK2L3`R;4&;1HTH2
MDZ;Y!?&`/NWZALL66`H`"B@`+++`$LLLL.@`+`#6@@```=:"$`0Z]-:U^FM8
M'[P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P,3WK;2&AJ>L:
MY'.%618[?6T4=)8L@M01,Z=V=*4[43\QK1"(>G5(CI"_J0Z_V4P3B]CWK?\`
M=KTP,+<G]F17KG_(^HS275=-&5BZL#*]D=.\[SZ@SG=S?6LQU&EB)<Y1)-R?
M;$46$#@)+[@)Q'$"UL9*@@TP+I[,IN2]#<I]`4A#$]6J9?:%6RN'Q4-V1,F=
M501(G9N-)95\ZB"A`Z$/[$VN7QJ!IQIE`1#*#O98]:]NPCC\-/C]Z'X+CO0#
M#TC)N,9;+[(=:U<43IR70\6I%8-#&&22M9H;13QF"P,N5*31KPFMAYZ88B?D
M6:"+03/;H+`\$4,E,`CW:$;?ZJ>*I0%=).:YE;E_#%#\2(7@"D;Z2>YMJ"C[
M<M)-:?HD2)2]N:T+:4C3A3DI`F@$;\04WP%P"%P&'=G(XC5<:K`X_IMT3/A,
M:Y"OCDI.[.#0C5H1_8:KNM>U-3`UK4:.+][&:C;VT0Q%;`/9@1!"=:!SJ.65
M$VF;1(YU41Y\"L$W'/<:DL0<QZ0."MK4_:CLP:&&1MVPK$)F@:4I"MFEZ"8#
MW%C`,07?@0+^#1%)T+;VVED;>>VF)NE5Z0C1W!7/O#>E*A,4[A6K3TM"3N:)
MKD<CAB!]A[==IE!>M`T7\FCC/8%E^`R&3N&F=^)Y[3;!5CD?TML@AU:..J;Y
M&734+<9+B%RET0T[;UK-\UTT.IAX2!*1)MMP5(O8:H&J/+2A0O!]&'^.=0>5
ML;RJEIY;AT0G&D*?J#XQI]O)+*F]Q'%'HI'S!/)5,;`6K4JTOY3I2B;0DEE%
MFI]"4*5Q9(?WPR3I0\=W^8VN3)`-X'6/1R9&M3G<E<F\['MZI[FUMFDIS)Y0
M4O>K%N\HHANV`ETEZ%*IV0$*K>P+%JPD(='&`P&`P&`P&`P/&>W-ZE6A<%*!
M&H7MGV=MJT]*0:K;_N%:(6?14F`$<D^T1K0#/C$'W@_07KK`]F`P/*8M2E*T
MR$P\`%:PI2<E(WZ^\XI'\&E0P?IZ>A/V2_7_`/NU@>K`8#`8#`8#`8#`8'G&
M2:)40>%6>6242I*,1!`EVF4F'C3"*4G#&G&L":C"0,)>BS2R]Z.'[PCWHO8`
M^)7Y+\@L^;2'\3]5#]#96S_R&UOR+OR>E@1A^MI+HKZWP;!O8]BV;[]:UH'J
M'\^RM_*:2?C1?C?Q^U.W?[2?V:6_8T5IM^EZ_:]VR-_+\OI\?IKV_P!<#WX#
M`8#`T$[)\=-0=M22OI;8-H]15<^UW'IC$4"SG#HBP:,U((K/#F0^31Z7DPU<
MG*?FU?MA)#O0M`,]FQ!V/>O9[`W&K>`Q^J:\@M81,3R.+UU$(W!XX.1R%[EL
M@&QQ5G1L;4-\E,E7.DBDCN)"A!M2N7*5"M6=[C3C!F"$+87K@:+=F^0>F.&%
M%<I+;@O1DP46L&4)X670_/=F7@%:_P`8_!"U$7`^OV1V3L<HD9+YLUJ3+1D!
M6E(E8M##HC?J%M33R/02#1V"3%PYB[Y>XC8%8-MG-[U"N,KGFRR/Z=G!Q;T4
M`F\+B[&YV+#;(W^.V<<W+V8DE*0>0(]05LT`=AOZSN07EH:W<"-Q;@.K<A<@
M-[PB.;7="%<F*5!1NC<HUH]O<4VC?8>0/6AE&A$'?ZZW@5'`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`L"UJSB=T5C850SPAT4PFT(7)8#+
M4[&_O<5>3HY+6=6QO)35)8VO:Y`PN`V]<9HE6B4D*4YGH,L81:UO`U6X_P"!
M:2X5+G"BG7*^9V_VJ=!T4[E=XW]9%VR-6@@J%S:8P,E39DI<D+(A8VUV-*V4
MUITXSB=%%B"8`@@)84CRLJG)!XTN[W!JCS!*E+;RI=KF='Y0J>T;"YMC=`WI
M:]%.!T;?HL^B"6S$'F`+2N2`TXT`2]'E>[WZ"$7^-,?4S_(NN9C43#7FV5YA
M?-@U5AQ3D[H?F9QGJ4P%L%Q900JO"_KM:YS'4D90$'^]D`UD(URTT&M*4VTB
M@P-D_`O5,KJZ:^2=+(^<F*B$J_J#2=G>F;E.R>:=6>G;'.Q#_P`X%7/+*GC5
M/VEM2.R?Z0F,A"@0`5C&(Q4-;_L!\_`C%817<I\C4"C='PVFW]OZ=&[2<R!T
MSV36#)*]JUTW;42TYWZPD,F;Y`L3*6E68!)$CRVYO)5!-,+]BQ,,0=%6`P.?
M#P;-;JUV+Y("2J:8Z5B`>DB@LS&@X(>^+W9Y<_RE@_D'%XD3K.9>CN0:1L"A
M*`-"!,D:Q#$H!ZZ=?86%B?Q]8F\Q^8^3AT>>6F7FHV0]:N8B=M/-EY4,.;)6
MJ36@G;E"EYN.P)DAFI:)E4)7$"1C3-R5D-?#=&;/^V7\07IXA80377;WE2CX
M:C1PA2ON8AP/ES!PBU<M1^3)")?/E#5HNUFBY;$27,%42^F*DHOQ#&,>A*'$
M8=[7?`G"M>*Z.2:/^07RQC>JF2PE([7,2YIIVEX!/Y:W9(ULTL!>4YG7LNFL
MA7]#A`A7%'!7!1(T:\Q0:[DZ"-><#03^8#`8#`8#`8#`I9+,@3O#@_%`4:<W
M1O:VM88-<N-3"1,Q[LI;P$MQJD;:C.`<]J-F&DDEG'Z$`)HAA**T`*I@,#S+
M$XE:-4E`J4HAJ4QZ<*Q&(H*Q((XH185241Y*@@*DC8O>#8RQ@T+6O4.]?IL/
MZD($E2)4HU*A8),G)($L5B*$K5")+"7M2J$2402)0?L/N'L``!V+>_0.M?I@
M>C`8#`8#`8#`8%MMJI<9(Y*C4/34N1IBF,YN9T34I3.3&6J3*M*?S+L-S5I7
M0US4IQ&D`+3I!IB=:T/1GR!,V%R8#`8#`8#`8$!OF?\`-\W>'Z>\LM,BHQ;<
M</ON.="O#\;'92W-$O8W&J(U%3H<A:FQS&0@_"OLHEY&GAR/,'MO;4YPTZ96
MH]I6!+[S!<)_0G.%$WLJ0Q1L57#4D`LI4VP:9`L.'-RF9QAM?U""-3DMH8`R
MQF1'+MED+_I)?L@#H?Q`WOVZ#.N`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&!@;J2VG&A>;KUNQIU$]NE451.K`0;G9TQ(A05<4CJ]
MY(,EAU>Q.=3DN/%F)-"6;:69R<-$:%\*<P?IK`CC\1?E,<O)H@O!R<VGG^,G
M5*GI[V1JF+3LRTWI.&QH[(GC;Y,W*;TE43`UM<ETR!4L25L.=E927YBW+ZQX
M"PFAO-WE&7>:\/\`8L-8'A''WN6\N7Y&&E\<6)XE#>TN+_5DJ:D;@OCD>99(
M_OJ)*>K",U(A;EZL\O6P$ISC-A+$'/)_&W:8!%6VT.<R4U;.RZO:ZYUM0AWK
MN?=^3`S3Z0.Q8D<GE976,(K&NH:[L1B4(2V>"M)#?LM0,"L)OUB-A#8CP5,%
M?0SHWRQ1F)PUBCKZ9U#MRDKM':Q[/AQ#R<"46F'1#I).J91(X\\+TJU:>H`D
MBP$A).EIBDSY4RI#H@*CX*$1D?N[RHQ=.Z/[BP(^J!KHZ7*C^WEL@0M:I^LO
M1*9:JZQB$:AX-_*$S8PQ(]P..4?(<X'C3#:1;#HQP(E_%/W!?W9[;U23T/$:
MYA$LH;H)VJID9*^KCH>O='11*WA6,S\_`Z!C\?7/"]_*W]@DQK+T06F$#Y2R
M]C+$8&HG@HI6'U79GDO<X]7C'#'*2]0KRG%Q;*7[AJQP?$3=*;..;`O+QUU*
M9+%9@J2%.&S-:@^RTJ32CY5NQ!6(`EA;G@=B$#8[R\H;Q&XY`V61.?1I2>1*
MH>C[^;7%P`3*K44I?W.A[/:FZ)$+2E*D_8`PHU4`.QF:6C"1^-]P2]\]>/GC
MOE2X+VOV@*29*[M[I=]6R2[9JB?ID\KYL\.4B=9:X*1HY+(WIJ8BETD>U2PT
MAL3HB!FF:]0>T!80!]:"X,YHYFO7I?I&HH@_,MN]<2-OE-WR%VGLVE"-_=6Q
MQD#LCTSL$B?G)BBJ(IRE"XW1#<G3%AT=H`=:+```0W&P&`P&`P&`P&!\=%&:
M4&';4G"*&224%)L*?ZY1A8SQC4@&$C2K9R@)H0BT(P1>@EA]H0[V/8@^V`P&
M!2EQ+T:O93&YQ;D;:G6*C)`D5M*A>M=4(VQ:2C2-2\IW;R6-00[FIU!AYJ=>
M$T@D9&BRQ&Z/*"D,[H89)Y@QJGLMR4H3&%Z1-A3`M;/V]'WIL_'HT*AZ-./;
MY(L6OT<=%>S"=DFIB3RB32=:"6<>%V8#`8#`8#`8'@1M36W*'58@;D*)6^KR
MW1Z4I$I"=0[N1+8WLI3@Y'%``8N6E,[0E2A--V(>DZ8HO6_86'6@]^`P&`P&
M`P&!9[S%(;/2"0R^%,<B*:UJ\E"1+XVUNWUC"S_K'+&\MT3+`DD+M)@C`8#V
M[-+T'>_]-:"ZDZ=.C3DI$A!*5*F*+(3IDY0"$Z<@H.@%$DDE!"6446`.M!"'
M6M:UKTU@?;`T4[MGGD'@$(BCEX^:%H:_IJN='ILF<?O"T7:LR8\C6-/PQ24,
M1B)*6WR-O9W\S9[RA-<$"L]"5HE&+YCOE(#'$ME7F`;JHJQ;":8\>TLN537+
MW_FQID%Z7_"82RVQI:M#'QU<8CI6;.,E@7XTH@Q42[*FI>-2:(H!Y99>CQA(
M#79L\/K^"GVFEC*&SCH=&#;&0PL]P4PY'/#&1".7I8FI=O\`W51&4\@VH`@&
MI_\`(&ET#9G]^]X%XX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8
M#`8'\$$(PB`,(1`$'81!%K0@B"+7H((@[]=;#O6_UU@6K$8)!Z_;S6B!PV*0
MEJ/4G+3VR(QYHC;><L4&F'*%9J)F1HDQBD\XT0QF;#L8A"WO>][WO`L?HBS5
MU*T#=UQMJ2.KU]3U+8EDI44O>7*.Q54=!HB[R8*>1/S.QR=V9V4W\9[5*E,W
M+CR2MB$60:+6@;"&'PW>;)7Y9+0O2(LU>51&HE1M:59)'B20&>6Q)UJZ;6*X
M2)(<P`;K,HZG30,S47%E?JI+`=O9GQZ#[PCV,(4GPHH8NV]%^4M!'69N9C4'
M2REN=26N<]XRHHU>EF=K'J#UC1UM`(A6\;7J#UPSA@@:QV).^7U4G[1!:1C"
M@>#V;)95U5YA$S'+7>:1Q-U>B=4[DONCI:S6EM7.;S:*0]DCD>OBHZZ8(;I$
M%I]K@%@7O@?GT6C$I&A0MA@PZ-L#G&\`$F=GN4^31(Y2:228!?8;X]$"D=F]
M6V*-G$[N4R1FLS<'I6EJG1LK>E`R@]OX92\+%'KZ.0R=$H=G!6_"T"0K>K/+
M0\2:&V3%#0=3OS3%S)P]]GK6YVA26S+F"Q.;$U])-Y=6MQ+PD(+<2PP=:K`!
M&M(`I*1I](21!0?"W+)`X=O>7>-/UJ2B9E--YQPAGA+U;/7]H-<`TRRNWF]U
MTRE=,U#`F"*ENP%B(DQ/''=Z2&"0>P@6FY.A,&'1Y@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,#P(75L=-K=-CB@<=MJ\]J<=(5B=7M`YI0EB4MRW2<PSZ
MJ].$X&S"3/:8#0M>NM>NL#WX#`8#`8#`BK\G_"W6W;3'4C9ROY&;=X!40-UE
M"F;F5='USJ"T$+\2Q!:/RSA'YU7DE;5L-/9SA(P`7&HE&G`[2@@>PE[T$(_\
MBB1^2/BCC_@YUYB[1O$N0U`T6I&.B[M+<8K%G.WMLM=15P8IA8;"VG'+'>0K
M%L>7EH4Z)K<DY!S@:H6J2-EZ4&AT;>-N:S*R/'SQ+/K&DR^:6#,.5Z)D,ZE[
MH]MLD<Y/,72MHZJDS\X/[.L<&QX6NKT8>>:H(.,+-&/>];_7TT&ZV`P/.,\8
M51";250,LXA2<)8#X/JIQ)QI0`3G^X\*GYU>E`A%>PL8/:2/WB!OV:&'HP&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P+2GT>>9;!IE%8[,7F
MNY!)8K(&%CG\<2,ZZ00AW=VI6WMTM8T4A0.K"K=XZK4`5IBEJ90E&<2'1I8P
M;$'810\Z\`=)<E<[=>,-B>2SIOK^9VQ5LZ)A,JOR4)(:V4Q(AQ:9DI)'#9,E
M'+9/!][-=$!BA6!:<C;A-OVDJ(L0A`P.;7P$*I^FCGE1B_2W73%WW#$W#"%Z
MFK-).G9O;-41DMP07&1.82Y3M#)9G&&2+SB/)"RU3P4K0/@$J8X04(`$B'L,
MK_Q)`JE5O=S/+?!3^?*GD\1IVRJ!Y;56G,YV.O*[M=4_/BN8-6Y`SD"D\0F:
MIE2%M+T[K3WHHE"--H(RQ'*3PE,\)[4P-/7WE]3)K+DTSD0.HM">(TLL#K";
MQV%?/*;0/$C2E7_253P5G=QB$!,(N+KI+H2-$1L2T2#\<8<'1CH(0^OMUH/K
MO8M^FM:]1"WZ[WOT_KO>_P"N!_<#GU\)%NN-G7!Y,4CI?!MR*(UTF%,2RBZ\
MOKII)6:4Q]LA&&+LT7N.GJN9Z=90&-H@$(V8]S$ITGV0HT06WI-G!T%8#`8#
M`8#`8#`\)P7+:]"-.>A`V!*6:<B#DJ@U>><+1'X\2%6!84G2E$BT;\P3"3MF
M:$'V[+]N_<'NP&`P&`P&`P&`P&!:$+FK7.V]V<VEODS<F9Y;,(8>"4Q=^B2Q
M4Y0B2.46=G!L0R%`W+'*-KG)J-,;7,D`T+HBV6J2F&IS2S!!=^`P&!:T-CSE
M%V$MG=I?(ITM`Z2)P%(Y2!B+>#4[Y(G5\0M`@1MEC[3IMC"%Q+:T'HFT?M`C
M)VH,/4?*>:%TX#`H$=11XA&H<8XT)&@B1KCI$X;3LFV!4Z.K@`D*IW=T1R)`
MN,=U9:<O1IJDO[`M`#H6_P!-8%?P&`P&`P&`P,"WOR]S3U5'6^,](4+3E^1U
MKTXF,2"V*[B5@IV(UY3DI7-9&S9(UN1T?7+TR<L!BA",@X6BP?W_`-H?0,A5
MI6L"IROX?556Q1G@M<U^P-T5A4.CR72)BC,<:$X4K6RM*,.Q!2MZ!,`)91>M
M^@`:UK7Z:P-6^YN>.G.CH##8IR]VG*N)9$US,:^;S>)U?#K/<IC`'2./<<>X
MHC2RU2AU&'Q/MW`X-;LF-V8A<4A1FRC/:'V!A1RX%Z:5\Y5=3C9Y4^PXU9U:
M)K`;U_0#5&N?G256L@E4D<WB*!M9DFE62TMV<J\95"5K2KFA<R*EA*<9J@8C
MC="*#>N@J]EU2TA4E83^T9#=TXK^NHA#Y?<,M3!1R:SY+'V-$V/4Z?48%CCI
M*YR=P3&*S2]J5(@"-]HC31:V,09<P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&
M`P&`P&`P&`P&`P/F<<2F)-4*#2B$Y!1AQYYQ@2B222@[&::::/80%E%@#O8A
M;WK6M:]=X&&J[Z0YWN"3/D)J>^*8M&81IF;I!)(G7EGPB;2-A8'@?Q-3T],D
M;>W-Q;&ES'O02%!Y0"CM[U[1;]=>H6];T7CU855T'9]7UW`FNT#:@G#E^71)
MHQ`'"5ND8BDA=8PW2B?"C+U]-N3NIHO:K7I'%,W_`#&';3FA]X!AS'_QLY\F
M?K[ZE:X?9V[5A\@JJ`RV5+&'I:+W7"(E8:*1J"MD)(I!./N687#W^::D[FH/
MVD&[F:(;"P&_'H99AH2`>+VU!3OR*>5.)H[FGUDM%=6E^,_:\G[>L'HB.P%<
MKF\Q1;;(Q14JHVO&2@R2P,(DHD**02`*+232$DPY*62I&$_6`P.?'PRW,197
M4OE;CNKF>+(W#NF#DJ"+/G9TDZ8-A*`N66<U'ELE;/5,5<CHN/*5S8(@I,2M
M>3%)B42,1NR6Q.H5!T'8#`8#`H*241Y=(WJ((W=$HDT=;&-Y?&0LWW+VMJDQ
MSRG8%ZLGT]2TSL?'EP21?^L24S7_`*<"O8#`8#`8#`8#`8#`8#`8#`M&311B
MDCG!W!Y8AO"J&RLR41U8%<:D!''O]K2:/:>S2"UR0+D`34_JD6B1@4A"-8$W
MX];+T:6%W8#`8#`8#`8#`8#`H\AD+!$6%ZE4K?&>,QB-M2]]D4CD#DB9F%A9
M&I*:N='AY=W$Y,WM;6VHB!G'J#S`%$E`$(8M!UO>!5"3BE!11Y!I9Y!Y8#B3
MB1A,*.*,#H99I1@-B`868`6MA%K>];UOUU@?3`BJ\JG$MP=M06EXQ4B'EAY_
M8-DKY/-8[U3';?=HO)8LY1=QCYS.S.M+3.%RYG/TJ7`5J"@J``7[2DE".**T
M:$X-L^*Z3F?./*])T=8+A5KI,:UAQ<;>EM*U_NK*N-,(<5ZA*7$(&)P<]L*!
M,@4%%&:^76E*D!BC19.C?A+#:+`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`I3ZWGN[&\M298!O4N;4XMZ=>8A2.@$)ZU(<F*6#;'`
M!B!Q`F,-T/9!X1$G:#[!ZV'>]8$:O`_CXEW&$NFTD>[3Y]FB6:0.)Q5R;J0X
M,H?C]<^26,.+BL.L:>2"I5[@OF<A>DKCL@Q'[4+,D]FC$J,D8C-C#?*ZHXJF
M%-VU$D*I6@6RFLIY'$BY`8U$KD:I[BKJV)U2(U]2KV0I6G-5:&6)80<E"/6M
MF@&7[@[#D:_CLU/7%']E2^)LO/=@45+Y!Q)]@.IEUSQ??HWYDA%G50QO0W&O
M.6ZSB\J@;D<_O1:U,Y2QT4K',E4<``#0D@,)"4/@.72DCRR^32KG.W'F=L[4
MH;I<1#I%WPSWPI@@GES85#4F9.6$5.0]SI)L_$N84HAJI"["9R$R1MU\X3@*
M-!/?@,#GH\2TOE+SY!?+9&'2Z6ZQ&B*WD<43"$W4D/N%97BPV;3IM*1K*J8.
M=ZH=ZW.$2S&I3/NOS\)(-)]`6SC21KE`="^`P&`P&`P&`P&!1Y"S`D4??(^8
MXO#06^L[FS&.T><CV:0-8'-$>B$XL;PEWI4U/"()_P`J927OY"#PA&']0ZP/
MTPM(6%C9F(#@[.P65I;FD+J_+S'5\<PMR,E'IP>7,[6CG%V6Z)^10>/6A''"
M$/?Z[P*M@,!@,!@,!@,"W4DAVID;_'S&-_0DL+8PN>I(O1IR(R\_G!O0#$+&
MXA6&'JW!ATS:$X`,)*"0%6GV$0_D%[`K:92F6IDZQ&H(5HU9!2E*J3&EGIE*
M8\L)I"A.>4(91Q!Q0]"`,.]A$'>MZWZ8'WP*!*GPZ,QB1R1-'W^6*(^Q.ST1
M%HJ0@52>2'-:!0N+88XF=7%G:U#Z[C(TG2%J5:4@:@P&C#2P[V/051`J&M0H
MEIB-6WC5I$RH:!>$D"Y"-02`T2-:!,>J3A5IMC]AFBS3`:&'?M$+7IO8>O`8
M#`8#`8'Q4IDZQ.>D5D$JDJHDQ.I3*2@'IU"<X&RSB#R30B+-)-+%L(@BUL(M
M;]-Z],#ZZUH.M!#K00AUK00ZUK6M:UKTUK6M?IK6M8']P-1^N^S:UXMBT1F5
MH0B]IE'Y7('-F4*:,I6<W2IAK:Q1AWES_,IRVP5M<W%@AS*RLIPSE7Q&FB'L
M("BC-^[VA?/+?1D1ZTH:O>AH%%;.A<0LI`Y.;%';B@CI6UA)$3<^.C%I0]1!
MX$-8WIW0QK$J0FZ&82L0'$J2AB*-!O89_P`!@63*K+KB"Z2"FU@0F'!<$SRL
M0"E4K8H]I:CCJ;:V0*DFW=>DTI3,2,.S5@P>X*4K7N,V$/ZX%QLKTS21G:Y#
M'79L?V!\;TCLROC*O2NC.[M3@06J0.;6YH33T3@WK4IH3"3BAC+,+%H0=[UO
M6\"IX#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'@=%2I"V.*
MU"WG.ZU&@5JDC4G.3)E#FJ3IS#4[>0H6&DI"#EIH-%A&:,!81"UL0M!UO>!%
MQP?Y.5W:=I3&GWSE*T>>I=75;H)I-U,RLR@[!CK?)%TFVR?L!I7519$K=W-U
M2MII2Q2>>@1!0G!/1+"TRLH!9P2B/#>)V:'5K`J&A&Y-JYO"M+3HU9B,2Q*:
MG"J`E<$ZI`I&GV9[]%GE&$CWKT&`0=[UL(!?$IXP)GQST1T%/[!FDLDSA!]/
M=*1.1.7-_(=(PNZF2?HZIMY]N2`)Z+K1FGT9:$,G+41L]J<)`X$+5S6>N-``
M0R$R,)-J3XFC])=0](=2H;JO&=2#I,;4)\KR>NT`75S!@,^TH6\F#E,->1Z9
MZ*;T:0"-)IV>7725`'1`/[0@V$-UL!@:84/QHWT7T1TKT03>MX6.Y])/#<XN
M%?V$XP!9`JW1M2A6M;&2!`CU?QZ7!:VDUT5%(BW1V<0I4AX@!#\HS3S0W/P&
M`P&`P&`P&`P&`P&`P*:O=DC>C<%@M*5@6P/JK2M2-4[N01;++."26V-I2E>>
MI&2<`82P%B&(`M;UKTWK`J6`P&`P&!_-ZT+6PBUH01:WH0=ZUO6];UZ;UO6_
MTWK>L#YD$$)2"4J4DI,F3%%D)TY!8"2"""0:+*))*+T$LHHHL.@A"'6M!UKT
MU^F!2T#`TMCJ^O2),,IRDAR!0\J!*EAP59K8@*;$.P)SU!J9&$E$2$.PD`*"
M/?J(6MCWL6PK.`P&`P/"K6Z3*&U-M*N/_)JS4>CDB89R=#LMO6K]J'(\&]:1
M)#-(MD@,W^FU!I8-?J/6!XTS(4A2Q]`@<'=,BCVB2BB3'`UT.=4:9I5-1"-\
M<GO3F[N00?8`I$>)1I6:J(+&8</6S`F!6L!@,!@,#2?N[@.@?(K4L>IKH@,]
MU%8I83!:$?45]-W.&.B*7QQ&ZMS>I6A3A6,DB;1-SVJ),0NJ)<C%HWWZ+":`
MLP`92Y2Y>J7C&@:\YIHU#(&ZKZQ0NJ*-)Y5*7N:2`>WU_=I0\JW21R%6L<EZ
ME>^O:H_V^X)!`3-%$%E$@++"&PV!`O\`R#A*$'*5./9,&)F*5/TG$F9]<3Z'
MZ"OI+`8W((;.R76?NS-S/;M16?'&*-#2$GJ5B<]T)5""6A$A,$J`(`0!].\_
M[G7CZ\;C*W\?3B[&Y.+L2EX='DGB7Z)F,WC#"ZW&T/\`')PCK9Q[,BDAH!GD
M2^+&/:-T>9*ND,E;E/KI&4D$Z(]AV.>/^,AKGAKE:%+&5WB6H)15=P\]ED]5
MK:*=VH478$;"(EQJ1V?Y0XUZ8(:'W!;E#DM/)`(/O.&+>][#<C`8#`8#`8#`
M8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8#`8'F(VKV8KTI+3`*"IUI`(@XTTPU
M)]9-O9BL)A!(2%/W-G!T`&S`_$$`O=[A""$/J<44H*-(/++.(.+&4<2:`)A1
MI1@=@,+,`+6PC+&`6];UO7IO6\#1[F?QH\&\;V#)K5Y@Y>J^E[!ES&XQ=YD\
M.;5R=:&*NSTW2-RBC(2M<%J*+Q5:_M*9:8V-92-#M22$SXO?KUP-Y<#"U:5K
M.H5/;VE4JN6363'+3G;%*Z]@SZTMC>VT?'VR`1:)N4%BRYO,^9Y9GF1L2M]$
M<I++/+4N9A>_?H&C!!FG`8#`IC>S-+2<[*&QM1-Y[ZY[>7HY(F*3F.KL)"A:
M]N2\980B5+=MS6F(^0?J/XB`!]?0.M:"IX#`8#`8'Q`I3F''IRSR3%";XMJ2
M`&@&<GT>'8R=GE!%L97S`#O8?=K7NUKUU@4&9'2]-$I,HK]NCKQ.26)U-A[5
M+WARCT5<9*!$<)D1R-]9V22.S0R*''1852A,WK3R2=B$`DP6M!V%>3[4;3D;
M5!)"JV25M2%.(8TX5'L#\P2!F`+,&3HSU]NQ!"+8?3UUK?Z8'VP+6,6S'4V1
M-Q3`Q#K\R*N:U?*!R)47)4TQ)=FDAI8$T2TP#0JF)<R'K5!SB)T*-3J$Y1(4
MIH3A'$A=.`P&!Y$Z!`D/7*DJ)(F4NB@I6YJ4Z8DD]Q5$HTS>2I7'%@"8K4%(
M$9)`1F;$())0`:W[0AUH/7@,!@8TKZXJTM5VLYDKR6()4X4U82FJ++`VDKMI
MHM8J&-QN6N,24.!Z0AO7NS6PRYN-5A2&J`)35'P&B`>6:4`,EX%/=F_3LU.;
M5M8X-VG)O6-^W!I5"0NJ#2Q,8GVL;%H0C$C<$OR>\DW6M[+,#H7I^F!YXZSZ
MCT?8F#3F\/>F-G;&?3S(EXG20.^FQ$0BTYOKF,!0W%X7_!\JH_80[./&(>]:
M]?3`K&`P/.K3_;2*DOSJ$OV4YR?[*0S1*M/\Q8B_G2F["/12@GW>X`O3?M%K
M6_3>!CBI%%BF150DLN+H8JZLDEDT<CQ2:>&V*X2*!QYX5,\'G,F?S(S%@I9;
M.(ZC(='%N`2H`W*50D_VE(@"-$&3\"RW^4.S8_M$;:(:^OJAY9GYW`_A$C0P
MMG-85L=2Z9I$]B.4N;>\/Y#Z8<VEDMZHH\#<JT:81L)?R!5TJB2#D3RE6-30
M1%2&QC.87E.]JE+XY/"@]Z#(T+HP&,B9&TM[4G3MXDBDMP5F+1JCPC)3:3@$
MH"NX%IPF$Q^O(\5%XP!W+9R721/!87R2R67..ETJD3K*GC8WR6NSX]FI1/+T
MHVF3B4;3H4^P)DP"DQ))(`N`+BWB<#6D*Y&)T(1D.)S:%23MP);U1RE,E7&H
M]#^P6C4J$9Q99NPZ`,90PZWO81:T'LP&!')Y,+YZAYPJ"OK,YD35VK/3VRV,
M]K%6%172W0"0BN'"(S$_:]NB7*K3(;,9QII8A;`JG83<L0H4AI@C2Q"V``PN
M+QF]/6-V!Q]`+PMM+#TMBO$@LB-2D-?P"V:RA!SA!;"DD/THC$1O,I):J)L,
M(9@>AKPE0J5!NAF?53!$$D`;\X$*'GG[AOG@CC&(VOS;,:^@ML33HFL*A9'Z
MV8>CD-9`(FB"5G+"9I)7>4Q2.5:S%:9PJC)$Y&*DB8";:<1.A*0J"`@0GWF$
M\H31PAXDKA7W4_1Z>]?6?V)'+XDE0<C5=;MBO*6LI`[CI1;3U?2]1"*N>JM/
MBZ=,K6K0KT:]S;#=N*1P-`6,O8=?W%<HMV;\H4%,;Z<S7BX936S`_P`^<3X&
MUUBI4/CJ2):/2J!,DPGS/&E9*4XLLTA,[K"=F`$,.P:'\0`V@P&`P&`P&`P&
M`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&!!;QS8O=Z;M)-7W15Q]B6!`G
M"+VYK<)G_CBJ*G:>8G1MD6G)@FJWK*K+%F$86,9C2`EKB;`G.4OZP!IQSR46
M/XQE!.E@,#6"&]L<@6),XA74!Z:HZ:SV?OMDQB%PV*V7$W^2R9_IX3@&T&MH
M9FMT5+U:F#?BE&W#V@]I`"MBWOV^F]A0Z^[LX_M*TRJBKWJOFR=S]W>Y1$8W
M7,+N*'2.S5\QKA(^N-GL:B%MSH>[%'0YM9Q'J-!+$(HLH\1N@!`'8@I$1\BW
M#D\L]DI6)=/5.]6Y)+4M>DV*MR)!HF9NEH4>!49:D421]60G<3#X@%&;\JGV
M:1'^WT3G';WKU"KU=WYQ+=<Y8*PJCJJB9W9LJ5V&CC=;L%D1E38#V;5#V^1Z
MP36R%C7ER56BC;I&7#1BD"7:<XA(:H)&8G#LW`Q57?EF\<5MWK'>9:TZZJB;
M7W*IE9%?LM6Q]:\+I2;+:E3+5DZ:EZ8#1HAE"WI6Q48D4K3$Z1W"E.VWFJOA
M,]H7I7WDDX0M2SVZE8#U/44AMUXM&U:7::U)D844U<[+I(A2IL^-((ZYD(G-
M9^V4Z,T?W"RQ(%H2][2'GZU@82@'FC\:MF=`:Y9B?2C:JOQ1=TGY[:JY702S
MFIU?K*AVG@J1)6)4XPQ.U.,;;7./K4`WH"C\3^03[(TH]XRM&!D>&>5/QY6#
M?`.8(AU?5KOT&.T9S2P:B^V[H)KNS*V)=SII&?Q+FTHAZ$SZ8E0-*][^BJ.+
MT4G/-,,+",*0L\M?CN;.F7+CAWZ;B;-TPVVS%:/_`,3.[!.FY_=+-FB!M<(]
M'H^I4Q4MFD!:DMW3%G+4:HY"C//*+4'%"-*T,+:0^2GQ50WJB9T8V=%4)'>N
M[%N:*T3/H6WH%""TIK<#&W)XO#HM*%*6/@5OIS*D.+:$*Y2>8W)3A?1`H"=Z
MDX'EDGF?\;\/Z;,XZE/0FF#HG5WQ7G=/7[I6ML)1N-IS-.F&PM#3(#(/J,NK
M6<M7)D9SFG6&-R56K3@..`$\H0PR,Y^53QY,?1CIR.^]75>Q=)--E0NGSJ@?
M%+RSRQ;9%A%-QL1BS"2Y-"9')E;IMW2%B-;CE29*>I*)4&%&F``(,26_YJO'
MW1W4B/C6?63/$W0"ZWJ[I!/%FJD;>>&4V>66T1E\9DJ:<HH:.$.")I;9LS&.
MIB9P/&W!="-F`]-CV`+KF7F*\;]>]&CY)FW2[3&^A]6U%*.3UJY5_;('%RLR
M;::PQQA9W4J!&QUX2*E#VD(.<4RPUL1'J2@*5!.S`>X*7:OF`X[IOI+7*DT!
M?NK3-N.NZ+1*6#FZY9)7[K/;$BS7,BDS18[-$E</<TD.CS\@4/VR58U#>4L`
M9HDTH!QA04E=YE^-FSK:/<4.*+HE!>$IO1YY]8BEG-5P)H(Z3)C2:/7/+;89
MT9!$W:$`4"T4-T1J5!:<K?W5`26S_P`[`RE<WD0CE-=!Q[G@WE/N6Q'1^E4)
MBIEJ5SS<^.%#-ITX(1GIW$NVI,\16-RI)'`+P">"&`3NO;P%*1"3BTD4?&'E
ML7R$G5]T^U<SZXQ[,E9"^:P>(+;^CD*JC_C^TI)LE:S_`-X*).\7*U2\^,1<
MYW+*=!EL6U)0R3_A)/\`C#\@8QZ'\C%Q4=>\@JQ'R5"G.O8M(JZ0O%U61WCR
M+2+=^UIWMG(.F*6MI9,G"S$R=O<W,U"B2.3>VGO2Q*("7>PF%#&%@]/>6A_Y
MU[)B?(X:+I)U/E\VJ>-M$LL+R#<N4U+G=AL=6UHW63QVB)&Y.UL.1T2&O&(+
M>I1H#WD)0?H".$:6'88E\F/F+?N&;P4U"RS#QS1\M#%Z\D:H'2O55O0JV=?O
M-^.;U0=4U6?-MB'`9R6M.8J(</S8P:()$:>67[B23@N'KWRE7#S_`-<D<IUX
MF\:!#E,6*O9G!W7H?OP^CY^M996I:&UW,>JF4TDXIU+TM<=KOPB5))3%CHA)
M+4EDF"]Z?0>CR4^4BP.1[QU355VMXR(4M8:+;KKG"3N'HBYZ?FB-I<9JZQ=,
MIB<;@%,35GES:M"@++2IDCL:_*%8S=A;O@)"8>'A[;\IMJT'/H_6M<V;XFX$
M\'4NU7K(W3KGM*R*_4[ACW+I`V,"N(0N,42H5R9GD\=;41J5>4Y[4%K5AP?H
M&ID@#U87GW]Y(K&YSD,1BU/7CXF8>XOM%)KA<==G=@3*KWT].XN2E$R/<&AT
M/KIWW,ZSD.T@R4+S^41F'J`F?[`0%>XP,&^2/S1R#AI=1\8;9UXZ"Y!;M`QR
MVDZ^YK]Z*8?RKD[*A)1N4*B54<QVII95K\(DP3$\.[ZT&+_B/",LKZ^QFA/E
M`I&&8P6%RX"YB=`2F)QR1@<HNJ5KHRXA>V=&YA71U:O3(ERQB5Z5?(D-.)*-
M,3B`(8`BWL.@CV[R\O\`P5XU9/#X=U_;3Q74CG\,>9U#F]LKBP9MM]9V.1,T
M95ITRB'1QZ2DNIBYXV8`@X9?_C)#S![!H)>C`M#K#S*\I\D5AS+<,AA?35O0
M+K.*%3FIG>A:$E,ZWJ(J6&.R1$\2\ET-BXHH<O:Y2D&2W*?_`'86]F?^+H))
MH@!?+YY0ZGCE)<\WZ[<[]T&P7HJ*/DP:TT6Y`MVQ995K4R)2E6@7;%*V:)>\
M5^J>RS=;;-"+4EKR];.*'L@(C=!:G1'DHL>K:`YLZ%H[QW]G=3,70OQKED`@
M,(1Q^W*A8'!`@71]TLNOW8Y:[,Q\@`N]"R1_&4ET6+[9Z<6P!$%'O/O3HVDH
M7S/;;'XONSKKE72$!*+L*J:LDD.D3IS3*6Q(G>XM$K'9%#^3&VEPD2Z8+$SG
M(2PI4R4EJ`6L.&,E.F"%W6]UQW\R\QT7:U%^,*4V7?UIR<EGL3F^;=*T_6A]
M!,OY!R)W()K8IVGUBD2=8C0%&%@:"%`T^E@!'Z#LL18@IUN]7^3&#UQ3\UK[
MQ5)[8E4LCD\.N*I63M:FF:5U!,&I<J25\V-T@D<;:879$6ER9.6K6.*)8G6-
MA2C0/HFFEB`(+PLR2>1]1#.<[*H?EKD%IO.61S1?6,*O"ZI62*#-+0SC?F>L
MJWN.LJS?U$J$;,')P3DN"IH-;41A_P!C20>CC1A"]'.6^2;="5<MC](\>#Z<
M?#'P-NL,EOZV6JD:_)3JW$R/*(A(&2BI--K`.=&TI*6J(.0LP4:HX>P''E%Z
MV,-I*>/MY35\&/OQMKMHN8V/HAV0V5*[2-\K5'*=AW^0)ACM+FECDJUDT+TV
M4):E).UZ[UO0O30A!DG`8#`AK\U_C"E/E6H&C:2C,QK>($5MTW#+IE?^4FJ?
MO<:DD08838<2>(SILKB60B0J5J\<S*-#H#JW;V60,(%2<8@F:#G:\BO,2/Q4
M<[^*NO'^`T;:[Y7$C[EAB*JHEQ'9G95)25=?<ZJ!]!.$=77IT&C#&I1%X*U[
M2@$\2MT.&O<%`&Q+M']HU*'65XQ%[BY\!\L+G./(8F-15C:)NC+=0P.8$C%'
M0KW$N*-8*#)D,K3UD8CC($@#&\EQ5D;,T(XH?QFAUH-[\!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,"%;EWPO0KF;KMTZX3]+VA-WD
MR=VY-6>OU51\L0Z/[W<1LJ52$B9RV&4<U6?,'A(NE9@B70MZ;51B=&D2'Z-1
MD!(V'HX]\/J?DSL:VNP`]+N-CN]NSVT)H\0!9S5S'"VMM+L;1NR4#1.8K79-
MGLJQC,$#9Q[8[MR5XT`6UJ0TPTXP87!57B%B%6]L2WM%)T?;#J\R;H6RNB/\
M>BK_`)Y;$AKS9]>J*[=8+)K315'_`)NE-:1]L.`:SLHI$F0HCTQ)HBSE/S*#
M@MOCSPNP+CSHUEZ1C73MY3A\2N%X/LDA4FB//3;$I;(+T?'EX?G%R>(Q3C19
M^B6G[R3ZA`Y$?H)[>`6A!(-/2F!FNN_%Q7M>]*I>I"^ENNY+-TD[FDY!%'BQ
M*]9ZU6;FXW?2R*/D8@=30U7)XDUIG;XD:=S6JSR])RAC.,,]XQAK]3/@YI^D
M/)).O)1&>E>F'*?V%*IE+I)6C\\P!;"'91,VM>VBC#PX@@I,F<8)%MNAIC*W
MZ4E*$6RTX1*C@$^@PS\Q>+^.,W8)77JCL3NU[-;+*G-HQKG1TOI&+F:-/-AM
M?XZ2,K=7B6%IG<R(FF&&*2FTUV&F*/V'?IO6A:&%@M7B+8FSR"+>^_\`FEVD
MN7&S)PFS5SRYV-%'BBF!6^-(FN0QMD97N#NCXPPMW#H&QHVQ8@4[+#\`U1A.
M]`T&P%H^/.N[5NU%>[C>?6D3D3=9M<VFBA]?W](HI59+Q7>HR#;**N$J,Z.*
M8U/"(DD*D9)I1BAS*T,.CRM"UZ!C!X\5-=R+NV/=Y2'IKL%ZD\+F@K`@E$.%
MI1=3SI"Y*L@:^N'P<>@Y]>FOK<UO\97CTI3DNQ>QJ1#-V9OW[#H*I;_C!B-T
M]1INGI)USWBQ!;9+`IHRT'!>CET3YW8Y9`R(XB+=6R`H(X)<21*6Z,E$O"/;
MB)*MTI5#]@!G[$$*BZ>,RO'/MQ5W-_R!ZB02]:[0]Y4TNAG,$'SN>KB#`7'2
MMCKQRK)Q7$'O*5&D.6+T[D0\&*$A?M6A*"$D(4NR_%_%+/ZH=NH7#L#OF*%/
M4PJ">.'/D`Z1613G(^24V!F*9A!@::,G.R)GDI4>2:>T*1T3$.>]&[-]=&^@
M0]<M\7];R[J(GJH[I?N%CD0+ABMSG51&^FI0V4$I?(C%F:+(HU_B[:!0WH84
MZDL@%#FB2')QN1IQI9YHTH@IP!E^V>&ZWN2VF:X9';?73`\,CW')$FAE==?]
M$5S4IKK%=-P&LX^JH?833!PISRF[V+DY2,I.Y!4J/M@.V>9O88@4^)SDM=VM
MKOE>9>2Z_")8@G#6%1T#:_\`CQCE"",F0W:UH@!4E*9$S<OC!HD*IJ%H;.<F
MW\>TOL_3`]-Q>(SQ_7_U!'NQ;>HU5-;YB\DB$S9WYQM.X"(L1,8`0Q)87*A5
MH@GJ2N!/D?2QM$66;IJUH\).OL:.]=^H>:RO#UXWKBZM-[:L[E^+3+I@Q_KJ
M5_Y%=9+8`-`E%4D($L(D/[50RU)#3G-K2,Z`H8C6\P"D"`CY@CV#>]AL7:W#
M_&-ZS0FR+HY-YOM:QTQC(:GL.P:3KB6ST@<;/2*(_LF9/<<6R0O3,:A)VFUI
M5K1.B]!#K0?TP*')>'N&+.NR0WY,^5^<9_?H%<022&TY74L%E%@IW.&)&)WA
M1I\C>65:YI7B/MZ9L,1J0&!4E$$)@A'["B@A#.[Q3=0R&;);+?ZJK=\L9`RC
MC:&?O$'C#G-D<=,.&I&PI94M:SWU.RC4&",VE`?HC8Q;%[?7>]X'E?*-I23S
M!/8<EI^K9#/T:5(A23E\K^)NTP2HD`]F(4:>3+VA0]$)41F]B*+"?H!8OU#K
M6\#V3.GJDL=Q;'BPJMKF>.S*7HIF=)G"(S*'%I*T=M1HML6OC8N4H"]*-[,]
M"A`U[]^[^OZX'DF-'TK8BA:KL"H*NG2MR:FEB<54QK^)R90O9&%4YKF-F6G/
M;2M,5-3*M>UIR1.9L1*8U6<,L(1&CV(+F5P.#.&R-KX9%%NTK05'TVU<=:%.
MT["0/1A#(1LY&/XF@D8="`F#Z$AWKUT'`H4SINH;&6,+A8555O/'"*C^6,+I
MG!HQ*%D<,]HP?(PJ7MK7',X_88+7JG$7OT%O7^N\#(P`!+"$``A```=```&M
M!"`(=:T$(0ZUK00AUKTUK7Z:U@6Y)(7#IB6E)E\3C,J*0G!4(BI(Q-;X6C4`
M/3J0'I0.:54%.<!2D*,T(&M"T,H`O7U#K>@N0(=!UH(=:"$.M!"$.M:T'6M>
MFM:UK]-:UK`\2US;VX:$M>M2HQN:X#8W`4G%DB7.!I"A26B2Z&(.SU0TZ4T>
M@!]1;"6+?IZ:W@?58>8F2*E)*4Y<<G3'GE(D^R0J%AA10C`)2!*#"2`G*!!T
M`.QC`#0MZ]=ZUZ[P+1K232.:5Y")?,($\U9*I/%6)^D5:R-S87J00)X=6U.M
M<(B]NT77NL;<7:/J3A)5!R!4H2#-+%LHP8/06P]<+>)2^,ABZ80_<&>0/TI;
MRV+<@;I-\K(TR9V:XS(=.C464E`&6QU&E==)=AT<@TL^L=ZFE#WL+LP*"AC+
M&VOS])T2'1#Y)B&9*^+]'JA[7D1\M:2T`$G-/&E(^F6X':ULH`-C]_\`?L7H
M'T"O8#`MF7QO<NCZQ@U(9-%ON'MA^WN(.8&>0)@MKJA=!IT;B-*LTG(<PHMI
M56M%^X:0XT`1`$+0PA<V`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`
MP&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P&`P*#(HO')<A3-DG9
M&U^;T;RPR)*C=4A2Q.G?8N\H9#'78HHX(@@7LKXVIU:8S7]Q1Y(!A]-ZU@5[
M`\:Y*:L)+**7K&X0%C>JV>A^I\QI:)<G6'(#/NI%A/TW,H@291[0!-^`T?Q#
M*,]A@0]F`P&`P&`P&`P&`P&`P&!\`)DY9YRHL@D"E2`DM0H"6`)QY:?Y/K@.
M-UK0S`$?,/V:WO>@^[?I_7>!]\!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#YZ^;YC/=H
MKZ_QE?%O6Q?-L[W'?/HP.PZ!HO0/C]F];WO>]B]?3TUZA],!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!
K@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>g575431g01t77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g01t77.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1@!^`P$1``(1`0,1`?_$`*L```$$`@,!````````
M```````%!@<(`0(#!`D*`0$``04!`0``````````````!P$"`P4&!`@0```&
M`@$#`@0$`P8'``````$"`P0%!A$'`"$2"#$302(4%5%A,@FQ(Q9QD:'!0A=2
M8C-CLW<X$0`!`@4#`@0%``<%"0`````!`@,`$00%!B$2!S$B05%A$W&!,A0(
MD;%"8B,5%O#ALC-U4G*"0V,E%S<X_]H`#`,!``(1`Q$`/P#[^.(0<0C!A`H9
M'./R`1_AQ"*;;XM<[M*WM_&#6D@NQ=3#%.1W3<V1?<+1-?+CA6$07`0*E:+F
MEW-VY0$3(HF,H(8$!!"+:0L0T@8J*A8\BA(Z%C6<4P*LL==<C./;),VI%%5.
M]18P()!DYC=QA]>(0K<0C!C%*&3"!0R`9$<!D1P']XCQ",_C^7K_`!_@/$(.
M(0<0@XA!Q"#B$'$(.(0<0A+B9>-G6:,G#24?+1C@#@@^BW;9^S6,F<4E/:>-
M%UVZGM*D,4P%$<&#UXA"IQ"("\@-Q*:JJS5O7X[^HMF75^6L:RJ9"]RTU979
M`*1TL0O<9*'A2F^H=K&`"%(7MSD0XA'/H73J>J*DY3EY%2Q;"M\@I9]DW!81
M^JL-I>E[EA3,(B9&*BDC`W9HE$")I$R`9,(\0B=N(0<0C10A5""F<`,4X8,4
M?00^(?CZ<0A$(]-'/4(YT8QF[H,1SU0<E%4O06#A0?1QCYD_^,N0]0XA"]Q"
M#B$'$(.(0<0@XA!Q"#B$4-FF3KP_M[NYUQJ[=>-5SDBKWVMLT55_]G["_4[#
M7>#;(E.*5/D#]I7S<A1*W/E0,!S(TTMYP--B:RJ7S_L8QK<2VW[JP0@^D6YL
M.P:?6*7);#EYMBE4(^%"PJS)7":C5Q&_3@Y;*LU@.)7/UA,`B0G50Y@``R/,
M39#I"6^Y9Z`=?+I\HOGW;?2?I%;M`U&>V':I#R<V;'+L9RS,?MVIZ@_(&==Z
MX4,*K9<Z!B@9*RVLI@<.SB!3$3$I,!DW*N?P5%#FBP#IXZ=8J=(N(F=,``H#
MUZ],]PY$<]1^/,":AE12$G573^_RBFY.NHTC?W"=/F#KT#\^95+0A6U9`5Y$
MQ<009'K&0.4>H#G`XZ=>OX<J3M,E:110*>H,:BJ0!P(X'\!]?[N7*"@)R)'I
MK%$[E"82J7P,(T]&I3,8Z8F/[*AB@HT<>AF;]$149NB_FBN`#^8<QAQ"M$'<
MKR&I@DE1V@&?PA.I=@&P02+IP4$Y)HLO&RZ```&1DF2@HN<E#J`*B`'#\C<N
M)*4A1!D?2+E#:K82-P]8=8'*(B`9Z#CT'&?[>%'9*?C&-#B7"0G]F,B<`QG/
M7\O3T]?P]>)B1)($C%2J1`D9GT@$P`./CQN2#M)&[RBL_0R^$9$P!_C_`(<M
M+B0I*3U5TBX`F-?<+^/*!Q!)$]4F1@4D:R@!0HYZ]`'&?AG\A^/*AQ!$YZ3@
M4D1MGE=P]8I%2]\>2^NM.24=3;O`3=@1M$&Y=O4F+"->L"0YUS1SXL@@\>-S
M*)*E`YC)D(8#$`0]1#GS?S#^3&'<*7JGL=]I*RIK'TA86T.T;B4S.A\M8E3`
M>)LEY,M;]RLZ6PQ3_5N)&LI@"0.LOG%<YG2Z%&BVTU9;P$[X9TQ9OM:HZ[[U
M7LVXFGOM+0%)<'<""<E38V1=@Y9(*+"'>8$S`!0$>2KE/)6,XK@JL]N+3BK0
MBE2Y_#U4)C=*0\9'Y&.3LV+7B^9$G$Z=`-T4^6QU_9T,S(Z`@^&ND7&T7O6M
M;SA)J:K<3,0B4!+!"O64VBS0<"L+-)RDHF5DX=)&2%`P8^?H`8].<?PAS5C7
M-^/5-]QEI]NB8?\`;/N_5,B?D.D;3D#CZ]\>79FU7KV_==:]P;9D$$R&IEXQ
M*$1:ZY-O7K*&L,)+NX\P)R#6-DV3]=B<3&)V.D&JRJK4PG(8/G`.H"'PY)=N
MR6QW6O=MMOKZ.HK6/J;;4"XGXR6?U1R#]MN5*T'ZRE<8IU=%J!`5\"4@'ST,
M<$]=J=6%FZ%CM->@EW09;(S4Q'QJZX9P!DDW;A$YTQ'ID`QSSWG-<5QJJ11W
M^XT=)5N?2AQ:4K5/R!4"9_"%#8KM=&E5%OHJBI:3,J4E*B`!YD)($HUDKO4(
M51N66M=<B_K&H/&A9*:C61W3<Q^PKIL#ARF*[8QA`H'+DHB/KRVX9QBUL6@W
M*Y4=,EQ`4E#BTI6I))DL34.TR(&G4'6+Z*T7JK!^SI*EUA"MJE!*E;5#JG1)
MZ"1ZPLL)>-EVB,A&2+"19*`8Q'K%VW=M3@4!$1(LW.HB;&.OS<W5-6TETH?O
MK74I72'7>DA29>)F#*4HP5--54M2&'FW4+\B"#\P1.&Y';'H<Q*'@XVZ520F
M0.9(8IG.Q;I^90@B4Q$VB+H5CJ%,`@)0`3`(=0YS-OY!PZLN*K/07B@JKJ@R
M+3:TEP'R("R9_*-C4X[D5#2BOK:"J8HU#1PH4$GYE($59VSY&T#Q1FM@6793
MJ01K]B=UY:IQ,0P4DYVT6MZQ6+(1%>BTC%.Z6("29UU<E10[R]Y@$Q0&G('(
M>-X!:DW/(%K54*T0T@=RO*7J8WF$<?9-R!</Y;CB&PRD36ZX9(2/$J5X#]?R
MAFZ^_<)B+7=J74+=X^;^U4CL6::UZF6BZ5`"5J1DY!04HU-X]:JF/&E>K?(4
MQP$H"(=1Y'N,\W-WF[T]OK[+=J!%8H!I3C:BV4DR"RK8D"<^GA*.TR'A1^SV
M>INE!>[+7KI$%3J&GTEU)`FI*4;B52'C(3G*+BR>XM50D@XBYO9VO8B58*^S
M(Q<I<:\R?L%P*4_L/&KJ01<-%0`Y1$IR=V.2O493B[5<:%=PHDUC:@DM^XCW
M`H])IW3'S$1738WDKE(BM105RZ9U)4%AI?M2'4A6V7Z#"LYV)1F4Q%5YY<:B
MUG9Q%!>$B'%BBT)260>`(LUHV.5<E=OTGG8;VS)%,4^!P(\SNWVR-5J*%^LI
MTW-8[$S$S/TW3C"U9[P[2KJV*.H5;FR0M82HI21U!(3($>,S'>/;JV24=P*U
MB@D9UA%!-OX)249$F&,,)SI_=G;`RX/&\6)RB`+G3!,1*/7GO-QH6JI5$NH9
M^Y;3N()$P/,B?I'A31UM10)J4T[P2I6T&1D3TE/;U](TB+C5YR'5LL)98"6K
M297(GGXZ58/X4H,3"#TQY1LZ.P*FU$H@H83@!!#KSS4]YHJUARL8?85;VR0I
M<Q(*3JH3G+0$?IC._;*J@?;IGF7TUS@$D%)F0KH92GKX>?A"15MIZ\O2KXE+
MO=-M9XH!^YI5RQ1$RM'E#H=1ZDQ>KF:I`<!*!S8*(@/7GAM>3V6_AQ5EK:9\
M-$[P"#*74F2O"/5=K%>;&IL7BBJF"\.U2T*3.?0":1.<)3;=VG'JTDFSVKKA
MR,.LW0EP0NM=6^VJ.GR$6V(^,21$&IEY5TDW)WX[EE"IA\Q@#F%&<XJZZMAJ
MY4BG6B`L;DS220D`]WBH@?.+EXADS*$/NVRK2RZDE"BA?>$@J41VZR2"K3P!
M,4V\BJHSO7E9JZG.Q3*UL>J+O$F[\9*J\:316ZA0$!'N1<^V<#8^42YY\.?D
M!B+.=?DO8\;J1*GNN.5=,J?@.Z2OC-PR/I'T/Q=?:C%.';MD5"2*EN]TB_\`
MA!22/@0""/&<H@>IVZ:VI6=*>+$B#HDS6MD2,;L$HI*`)JC0G/OQIU3&`J8E
M.4#D'`C@4"#_`*N0EBN97?DJR8G^,=:TX*RAR`M7$]VX4%"ME;9/^\'7AJ9'
M:(DZZXY;L2N61<U!:?Y?76M+U'*4C4U84A0'JA2$*F/!?I$B:AV"CJS3OEE;
MD#`V=1^RK`PKR91(GW3#XBD?#$1[_E[$5UBGQC]"8\D+B?.K;Q?PYR5E-"H-
M(9R&IIZ,>;OL-I9D-)]Y\/+UCE,RQ1S-.0\*L-27%,5%JI7:A2=2ECW5J>*O
M(;$F?E.(?\=+52M8[ET\O7;,A.#L>J(UW:A").D2QE[E'ZCQNL=1VBW*HD#Q
M9L7Y1,4I@..0SR*.`\TPOC+F?$TVB\(JGLEI%L7%M2%)+=:\L!O<M3B@-5C3
M:.ACON5;)=LVXYR!BYT:&TV&N#]O*-NY=(VGO,D$DZ(402!.8B9M`T.G;RVK
MY!3NXHEI;K%$6D\%'0EA!9<D'"%>R2*)F3,5$S-"(IM$T2JEZ%$!ZY-R6."\
M6PWFKDK/;]RDEBX5U)5_;H9?<*%4S/\`$[P-TQZ&0&D1KR??<AXUP;%;+A+B
MZ.V/L"H]YE`4''2$$[E2E^\03U.L(F]ZG6X/R+TQ4H;6H;/KL)JA=E&4`7J"
MQG\<R=3JC<$GTB94BWV\""<G<(B8<!UYX><K-9K#S]C%ALEE_GV.4F/)2BW(
M6HAQI+KQ2L*`42=2.A^GUE&[XWO%QN'$E_O-=<S:;R[>$'[PHU2XI+87-.FB
MQM!,QYQ%L-(2E;\4-Z66GRH0"%OV7$0*E-BUY/W]?Q9GRJ3V,567]I1-=^T6
M20.8G:0S<GS#D1Y%5NO.0XS^)V7Y9C;PHW+C>VZ9RWA:E&VT[DTN!1)W).T]
M2$Z),=M74;-[YQQ['[TDU]5;;.MX5JTI2*UU`WH<"0"E24J!(`GW3\`(E[?N
ME]0:_P#&&"O-1AHN#ML6WIC^$M[!PNWG)>2DSM#/E%7R*XG>+KE4,J`%$WM'
M*`EZ<F#GWBCC#CC\=*+,\/8I*7+V#2_;5[3I+E0MT@KU"NZ9\)F4OT\!Q7GN
M>YAS34XYDSSM;CS@?0XPXV`VAL%2?*0```Z>.LXA;>4ZT-YW^!T]N1TR2J3C
M6C)PBXF110A&.RG+1V\['AG1BH-WJ,J[C%3`H("43I&'H(<EF^U>_ES![SG2
MD&C=M8F5Z(2^0D@JF93*B#K&/$:5T\,YI;\(0I%U1<-4H$UFE!4"!(3D$!8$
MOUZQ-6RM_>6>H?*/1^M[HKI.4U7OG:CJ`JZ4%"6!:VQU10D&1$!EWSR1;LD)
MU-G(D,"J":J0G(80`,<D+(L_Y1Q7D&QVNO-K?Q>\W%#+6S_-;;*T)"OJ.DE:
M$"6A\HXG%N/^*<JXWO5SH$W1C*[1:U//%9'LNN;%DI3(:":);29ZSBD%=UM)
M7_S)\T46/BIKOR9;Q^UF*<G_`%_:(^O_`-#LGRKU,ZT45V@O]S&61(*BA,9(
M+<`R&>1%0V)R\\KY<ENP4%\;I+BA2G'GE-E!(G-.T]4RZ?&)AN&2)LG$>'E>
M05]B%3;%@-M,!U+@3(=QT(!GUU^<+WG-IN7V#Y=3D?KI-2(N>HO$FK[-UTWB
MP3[FTAKNX.'"<2Q1[A/TBSJE0*`!E9)/`#GF7F;'KK>.7G:'''5TMPM6-IJ6
M&43*2L>Z9`]3+8!&#A?(;59>'6*W(6FZJU7;)54U2\OM4&U>T"HC4"?N$F?F
M8=.A=R1_D)Y-[3VVU^D![9?V_O8L35N)14B[5%G-'V:+5*&3D!O)H"<A1#JD
MH00SS?89EM%F^?7&_,A0JG,8<#R9GM6A#H.GF=3'-Y[A]=@>`4N//E)IF\GW
M,J`^IM>U23/T$AUBJ:UDEX[]M?QHI"$JZ@*-L;R,M4!L208KG9E&`;3"[DK)
MXJCV@#158YECD.)2F,W`39*`\BHU5W5P-8<=;>336VZ7EUJK=6HC^$%-=NZ8
ME,+5U/A$M4UNM3G.=^R-3:7KK:K&V]1M2$E.['-0F6LE(2-!^T8]E;9X+:&B
MM;7F*T-#UW4>P;GJ*=UM!W:&D'S7[A%3)8I8JT\9%\8LP1^Z9HE5=B0ZI4ES
M=H_-@?K2X\.X738W4VW!T4ENO-5:G&/<2LDN(<1)1/<-%#JH3E./DFT\NYH]
ME-)7YHNIK[3279NH6S[:>WVU3D.W0ID9`^6OC'D^EK*6AX-;PHMOAUKFN^5-
MKHBU?U3MB.EDR0%_AFD[&3MIL5AE$EDSN'\3"P+R50=*G4%-_')X;D,8I#?-
M`QA^W4W_`(3N>.T+?)%PH2*.L#RMKK33H=>4LSD%):;<4)*^I('C'U0J_6NN
MN*>9+?DU<[Q515^^JI"R/<8<<94TVA"9&86XMM!!2.Q95/01[HVZ'H+GR0U4
MZF$+(;8)*?:W5;=,G14JRC&Q9TRR"4JT-E19ZN,B/LB4<``#GGT9F-JP57/N
M/7*M76?ULW::TTR$N)#'M,!*U%:/;*E*)61,+`T`E'Q]8ZO*$<:7NBM_VO\`
M2IJJ4/;T$O!2RH)V+"@D?3K-.GA#SJ^AM>5?9MHV[$,WZ=OM::K>1,L]*M&-
MQ7%L9ZO&L/8*5DX?';%%8P&'OR/IGG48]PC@N,\C5_*=K;?&2W-$G`I:2RF<
MYEM`0%))GJ2M4X\%XY$R:\8A1817+:-EH=4;4D+4/!*U;B%!,NWM$O,PR7/B
M)J5W$2<$N>V'BIG82>S)1G]^`$GMC2!0"$7*#+!XL!5$?8_''S<XA_\`%3C"
MILM1C[J[H;74W9-Q6CWV]:A)!'_(_P`O03203^]&\I^9\RI;BW=J?[1->U:S
M;T*#:II85,&7?HLS^KI^[#XV9H'7.U8N%B[!'NHXM>EVTW$OJTLWA9)H]:AA
M("NDFBF4!$"B8@EP(E`?ASN>0N$L"Y)L]-9[RPNF125#3S3M)[;+R5LD%$G"
MVO28$Q+6741H<2Y'RK#:RHK+<^'C5,+9=14;G4*0YHH%.Y.LB0#/29ADWKQ'
MU->;0YN;A6XUFP2"94Y=[3+,XKWW@0(1,ZDBF@@J115<$RBH)/;]PP=QLFR/
M.)S#\5N+LPO[F2J-RMMVJ&PA]5"^E@5``D"\%-.;CJ=1MCH<9YJS#&;'_3K:
M*&MM07N0FK9+I:/_`$R%H*1Y3G*'3%>.VN8BVT.Z1R<XWEM;U<]/K*0S"BS%
M.(.FZ(<7R*Z2JKYZ;ZPXBL93NR/.HH.!L(MV76C-:5=>+S9:`4C$W4EM;*5*
M5_&26IK42M4R%)'I'/5O(N15^.UV,/\`L?RZX5GW+I2@A8<DD`((5)*0$B0*
M2?6.G%>,>JHI/9S,C"5>0^VW0OK=`OY,7$.+OWW#D',6W*@FK'+%7<F,!BJ"
M("`8]`Y@MWX\<:6YK(J5-.\[;\H4I5:RXM*FMR@05,I"$EL@$R)*I1[[ARQF
M%P39E+<:;K+$@(IGD((=*!+L=45*"TF6HVB<,*(\)-*Q$C%/'2UWL,=`N"/8
MFLV:VNY2KLEDC]Y#%BS())&31$"]A3&$"]OQ#G#VC\/N*;764[U2_>KA;:18
M4U1U=4AVD009C:T&$*T/[\=%<>>\WKZ1VF:;MU+4/M[%OL,%#Z@1(S67%"9'
MB$@CPE%5J+J:A^;MZ\G7>T(U6Q:H0N<'#4,K=V9F[BIFML%(L+%6)1J!7,4X
M/"-4"'!,?;727+[A3B4!">LXX]Q3.+0U9[]2I+3('MN-]CJ)`2VJU``E_LQP
M.&9SE&!WI5[QZJ6AY:-JVUR6RL:SWH,B29ZG<#Y$1+^N/VT_'G7EYJ>PTY?;
M=OGZ'+(3-/3O&PY";BZ^^:'*HS48QX-&90(U,'RD,8R8A@#%''(RQ[\>,"LE
MZILA0[<ZFX4;H6S]P^E:4%)!``#2>T$3E/YQWU]Y\SF^6*HQU2+?2V^K;*'O
MMV"VI:5`A6XJ<7J093E\([UQ_;AT)<KY>=C'L6Z*O8]BS*D]:1H^TIFIL7L@
MH4"]P-8I%(123ZB0ASG`HF''KS-=?Q[PFYWRNOZ*FZTE9<5[WTT]0A"%*E('
M:65'3P[C%;3SUF-JL=#CZJ:U55%;4;&#4,+<6A/E,.I$CX]HB?XCQOUY"[>C
MMW-E;,XO,;JQEI]-5_-F>1KJIL'1':*T@S6;"=[-G6)_,='4$3@(Y+UYW5-Q
MW8J;*F<P"ZE=W9H12=ZTE"FA/ZT[`5*[CKN`](X:HSN]U&*.X;M81:':Y56=
MJ"%I=5*80K<0E`D)#;/3K$8:Q\#M`:@N>Q[Q1F%GC93:%?LE8GV2MA,XAF,/
M:GA'TJVK\<9H4L2`+IE]GM,8$BE`H!C.='CO#.'8O=+E=K5]T*BZ,J:="G$E
M"$*W3#0#8*?J,IE7A&]R;E[+LLM-!9[P:95/;W$N-J2A06M:0D`NDK(5](G)
M*?&.[%>#?C_'>/@^,KN#F;!J\LB_F&Z,_,G=V!C+OWQY'[HPG6[=FY9OF;DX
MBBHF`"4HB4W<41`;D<,X1_13F!U+;S]C6M2P7%@NMK4);VUA"0E0D)=IZ:@Q
MYG>5LO7FK6>,N-,WMI"420@AI:$_LK0I2BH'Q[AZ$0P*A^VYX^5*,MD2>6VY
M:&EMJ+ND*_U5LN8D58"ONWT?)&1JAF:4<6!=)/8M`Z:Z1?<+[>,B`B'-)8^`
M,,L*:C[>JNSSS].IC>]4)6MI"@0?:(:2$G70D*\(WU\YSR^^N4ZWJ:UL)IZE
M+^UFG4E+BT]`Z%.K*DGQ`*9SZPF,?VTM$M1FI)U=-[S-MDHIM`QE_FMI2SZ[
M4^'1E&,DZ94V:.T(I"!*HM#,W2A2'.JQ<KI9`%##SRL_CMA;3SU:Y6WIVZNL
MI:14KJ4%]A"5A1#"PP`C>)H7-*IMJ4D2)F/8[S_F#E*U;FZ.SM69NH4\JF13
M*##RU)V@O)+Q4H(,EHDI,G$I49RD9CN0''RVTH!@^;_;/9PC@?\`NP_QQZ].
M:',$L)_*'#Z@";IL-W`GY!+!C68\VE7#.2S4H?\`<[=(#R)>G%JDN[`]Q0+D
MPB&!SD,!U'\QY],">H/0'3X1#P453G],]/A')RL70<0@XA!Q"#TXA%-?,W=J
M^M-?DIE0$SW:FTS&JE.BF>%I%%&24*P?S!6Y<J%%(BXHMC#@#N%`P/R&PA$G
M^-.G4M&Z@J]%/[*LRBW/*6=XEVB5Y8Y02N9(2'+^INS-VMDOQ21*/+W5;^GE
M")Z#IS`VDI3(]9Q4QGF2*0<0@XA!Q"#B$'$(JK<__KG2G_K'9W_EA^?,F8?_
M`$YAO^A7C_`Q$PX[_P"FLC_U&W?XG8M07TY]-Q#:/IC;B+X.(0<0@XA%:-_^
M3E&T9&_0N#&M.PY5,J58UW!B9Y/2KQP)$VIG3=J"SA@P,H?(G,3O4*&$RF'B
M$0_XZZ!NDQ=G/DIY%=CS:DNF8*G5#848:\AE`.#9))N83E0DBMU>U-+)OI@,
M)C?SSF$J$7WXA!Q"#B$'$(.(0<0@XA!Q"(8G2:T':M(/,K$#:!:W:`J*)?N?
M>>!,=C_4ABF00&+[2+`C_P!<Q5,C_+`>O(WO:,&/)=G5=5H&?IM]<*,$*WKI
ME):^[5HDI`0D-F2E`F?:%:RZ>D_J<XM<D4/N#$R^T:I0E)+DC[0(GN)ZRV@C
MSB9">@_V_P"0<DB.8A&ERSXHD4@%8H'29CBJVEDG@M'/3]`.FA_J&@_@8$E0
M_P"4>(0PU+AL=B<$'FH9.4*'0SVK7&FNFI@`.AB)VF2J+PO>(?I%,1#IUXA#
M>F=E;2:HF^Q^.=ZEU_\`060O6G89L*F.@'<(WN67(7'Q!$P_EQ"(3GT/,C83
M)T5R\I/CU5RD$SXU7^[;2V0HT']:<>>.8?1IO2AC`M4C'R`X$>9VR@#N$S/^
MW6*PW?&>%\2H*\2+"I6]W=]YIJK_`'R=VC'VB+V$Y=_,#T8UC=86#5;@)\B<
MK-,Q@#]1A#'+G2LIU$D_*!E'H(3..N/4V,"(CVYZ"/<`#W#\>>:*1OQ"#B$'
/$(.(0<0@XA!Q"#B$?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>g575431g21p84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g21p84.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X010:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;6QN<SID
M8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM<$U-.D1O
M8W5M96YT240](GAM<"YD:60Z0T(P,$(U-S=&04)%,3%%,CE$-3!".$5&,T4P
M03`Q,#DB('AM<$U-.DEN<W1A;F-E240](GAM<"YI:60Z0T(P,$(U-S9&04)%
M,3%%,CE$-3!".$5&,T4P03`Q,#DB('AM<#I#<F5A=&]R5&]O;#TB4%-C<FEP
M=#4N9&QL(%9E<G-I;VX@-2XR+C(B/B`\>&UP34TZ1&5R:79E9$9R;VT@<W12
M968Z:6YS=&%N8V5)1#TB=75I9#HS9C(Y-35F,2TU.3EB+31F,S<M8CAF-RUC
M.60V-#ED9C,S9&0B('-T4F5F.F1O8W5M96YT240](G5U:60Z,3=E.#`Q-S,M
M-C8Q8BTT,#4P+6(T-3DM9#$S.3DP-&,P,CED(B\^(#QD8SIC<F5A=&]R/B`\
M<F1F.E-E<3X@/')D9CIL:3YR<C4P,3@U,#PO<F1F.FQI/B`\+W)D9CI397$^
M(#PO9&,Z8W)E871O<CX@/&1C.G1I=&QE/B`\<F1F.D%L=#X@/')D9CIL:2!X
M;6PZ;&%N9STB>"UD969A=6QT(CY-:6-R;W-O9G0@5V]R9"`M($58,3!?,C(@
M0U12("T@4&9I>F5R($%G<F5E;65N="!?4F5D86-T960@('=I=&@@07-T97)I
M<VM?14%35%\V,S4R.38Y,5\Q+D1/0U@\+W)D9CIL:3X@/"]R9&8Z06QT/B`\
M+V1C.G1I=&QE/B`\+W)D9CI$97-C<FEP=&EO;CX@/"]R9&8Z4D1&/B`\+W@Z
M>&UP;65T83X@/#]X<&%C:V5T(&5N9#TB<B(_/O_M`$A0:&]T;W-H;W`@,RXP
M`#A"24T$!```````#QP!6@`#&R5''`(```(``@`X0DE-!"4``````!#\X1^)
MR+?)>"\T8C0'6'?K_^X`#D%D;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#
M`P,#`P,#`P$!`0$!`0$"`0$"`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@#*@(*`P$1``(1`0,1
M`?_$`1H```("`P$!`0$!```````````(!PD%!@H$`@,+`0$``00#`0$!`0``
M``````````<("0H$!08#`@$+$```!@(!``0%"@X,"@0+`1$!`@,$!08`!P@1
M$C8)(1,4M'4QL;-T%36U%G8X<2)RLC-S-(75MA=W>+A!46$C0Y0WE[<8.0HR
M)-255M;76!E98],E18'10E)3DT15)B<HD<%B5&26H65'5Z.E9H:F9T@I$0`!
M`P(#`@02`PD*"@D"``\!`@,$``41$@8A!S$3"#A!<;$B,K)SLQ1TM#5UM39V
M-PE1PA5A@<%R(S.3TS21T4)2@U25%M878H+#)-56MG<8"J&20U-C)657.=*4
M562$1?!$HJ.DY*5&A28H_]H`#`,!``(1`Q$`/P#L==KK>5NOWY7[H6_A#_\`
MI#?NY0]UC?KXG5UU2F;+"1<I/_;.?]^O_"ISD=IKP='6I[!/0'T"O/X]?_TR
MO_K#_P#CSF_M^^_SV7^F<_\`JKVXIK^*G]P4>/7_`/3*_P#K#_\`CP^W[[_/
M9?Z9S_ZJ.*:_BI_<%5^<O[CO)QO/ASH[4.\K'HEGNNP;Q^.UNJU.UM=;`X8Z
MXU4O;H.,9-MI5*YP3%NM,`4RZB;4JYTR]0#E`1'')[DY%@;W?:XW@:UMR]0O
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MW"+.<6]$ONIN/28L-Z2C(7KLXW@I302K%!V$X8&L'47VC9[2Y/8E*4ZA20`I
MIG#KE`=!L'H_36VQ-*YGR,S&QA^\DW81-])-6)SDX^\0"G*1PX(@)BF'2YRE
M,`&Z0$2B`?M#DMN^'Y>_)'W<[I=4;P;7IZZOW.Q:?N$]IMV_WOBG'(D5U]"'
M,DU*\BE(`5E4E64G`@[:X2WZKOTN>S$6Z@(==0@D--X@*4`2.MX=M,)_5EY=
M_P#,TW[_`#$<./\`8'E>?^_K=O\`^V]H_IW57^FJ5?[+F?SQS]$Q^KH_JR\N
M_P#F:;]_F(X<?[`\/[^MV_\`[;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O_`)FF
M_?YB.''^P/#^_K=O_P"V]H_IW57^FJ/LN9_/'/T3'ZNC^K+R[_YFF_?YB.''
M^P/#^_K=O_[;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O_F:;]_F(X<?[`\/[^MV
M_P#[;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O\`YFF_?YB.''^P/#^_K=O_`.V]
MH_IW57^FJ/LN9_/'/T3'ZNC^K+R[_P"9IOW^8CAQ_L#P_OZW;_\`MO:/Z=U5
M_IJC[+F?SQS]$Q^KH_JR\N_^9IOW^8CAQ_L#P_OZW;_^V]H_IW57^FJ/LN9_
M/'/T3'ZNC^K+R[_YFF_?YB.''^P/#^_K=O\`^V]H_IW57^FJ/LN9_/'/T3'Z
MNC^K+R[_`.9IOW^8CAQ_L#P_OZW;_P#MO:/Z=U5_IJC[+F?SQS]$Q^KH_JR\
MN_\`F:;]_F(X<?[`\/[^MV__`+;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O_F:;
M]_F(X<?[`\/[^MV__MO:/Z=U5_IJC[+F?SQS]$Q^KK6[?H'F!6Z[)32'>7[X
M658D0,1-;0O#I1,WC72+<>L0FB$##T`KTAT'#PXY+DB7'<QRA^41IS<[J?04
M2%8[R[*2Z_%ONI@^@,0I,I);XV[.-XE;*4JS(5UI.&!P(T]^1<;3:7K@S*4I
MUL)P"FF<#BH)VX-@]'Z:BFKT+F;.V"*AU^\EW:FD_<BBH='C_P`/R*E*"*JG
M20Y]*KE*(BGT=(D-]#)5N4YR&N2CN/W`ZIWMZ>TU<9=[L5N3(99D7Z^%AQ1D
M,,Y7.*GMN9<KI/6K2<0-N&-</9M2WRY75B`Z\A+;J\"0TUB-A.S%)'0J>OZL
MO+O_`)FF_?YB.''^P/(%_P"_K=O_`.V]H_IW57^FJ5#[+F?SQS]$Q^KH_JR\
MN_\`F:;]_F(X<?[`\/[^MV__`+;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O_F:;
M]_F(X<?[`\/[^MV__MO:/Z=U5_IJC[+F?SQS]$Q^KH_JR\N_^9IOW^8CAQ_L
M#P_OZW;_`/MO:/Z=U5_IJC[+F?SQS]$Q^KK3+WHSF%4H+W6;=Y;O9=7RUJU`
MCC0G#M5/JK^,ZP]5/138W6#J>`>M_P"`<>9R$K-N-Y5>_3^ZS6.AF;=9_L2;
M-XZ%?M2![C(W%9$?E[JZC(KC#FZS-L&!'1YW4[ESL=L\.CR2MSC$IP4TSA@<
M?H0#T*TBD:VYEVFP(P[GO)]WHI*M7:XJ-]`</DE`,W(!R@!U-)N2@41'P_2#
MT_MACW>6WR1N2]R8N3_-WN:1TM,N%[C7.#&2S,OU^+!1*<4A:CQ-P:<S)`Q3
M@L#'A!KG--WZ]7JZI@/OI0VI"CBEIK'K1CT4$5-7]67EW_S--^_S$<./]@>0
MK?W];M__`&WM'].ZJ_TU2B_9<S^>.?HF/U=']67EW_S--^_S$<./]@>']_6[
M?_VWM'].ZJ_TU1]ES/YXY^B8_5T?U9>7?_,TW[_,1PX_V!X?W];M_P#VWM']
M.ZJ_TU1]ES/YXY^B8_5UH>P=)\Q*=%LW[7O+-ZKJ.7X-#%<:#X=JD`@MUUNL
M4$]&-3%,!DOVQ#H'U,?I\OS1.X3E=[S;SHC6VB46RWVVPJG-N0;]J,.*<$N-
M'R+X^Z/)R97U*V)"LP&W#$5R^JI-TL,)N3&DYUK=RD*:9PPRD]!`V[*U2BZT
MYE6N>+$.>\GW@@D9DZ<]=OH#A\DIUT/%`4.NII)R4"CXSPAU>D?VPQU7+DY)
MW)AY+>X5W>QH_2LNX7EN\0H89F7Z_%C))#V=7Y"X-+SIXH9>OPVG$'96CTU?
M;U>[H(,A]*&RVI6*6FL<1A]*".C4S_U9>7?_`#--^_S$<./]@>0P_P!_6[?_
M`-M[1_3NJO\`35*)]ES/YXY^B8_5T?U9>7?_`#--^_S$<./]@>']_6[?_P!M
M[1_3NJO]-4?9<S^>.?HF/U=>.1XW<O&4>^>%[S+?9C-&;IR4IM#\.!*8R""B
MI0,`:%*(E$2>$.D.D/V0SL=W>];=;K+>#8M(3MW=L:A76\PH;BV[[JG.A$F2
MTRM2,UY4G.E*R4Y@1B!B"-E8\N#-CQ79"9:RI#:E`%IC#%()V_D_N4N9:SS2
M-U?_`/I%NGZ;J_\`^OG$']D0_P#\-?NY8ND_+$Y'#)=";'>CDSX8W^\_P<<,
M?\\^Y22#6>H#A^5;V_\`A-__`$TRQ>,W+LQ2F_XF>_?IBE'^0CAQ^R`#_P#L
M#RM/*WZ[MF)+C"=W%I*4.*2/_/=5=`D?_AJEB3;)A`/ACG!_W3'ZNOK^K+R[
M_P"9IOW^8CAQ_L#SP_OZW;_^V]H_IW57^FJ_?LN9_/'/T3'ZNC^K+R[_`.9I
MOW^8CAQ_L#P_OZW;_P#MO:/Z=U5_IJC[+F?SQS]$Q^KI?)VD\SXF:EHM+O)-
MV'3CI%VR(=3C]Q`,<Y6ZQDP,<Q=+IE,80+X1`I>G]H,L%[C>0!R2MZ6Y?2>\
MN\:=ND>[7_3T&X/-,W^]\2VY*CH=6AK/.6O(E2B$YE*5APDG;257+5-]A7%^
M&V\@MM.J0"6F\2$G#$X)X:FBM\>N7TY`Q,NKWF&^DU9!DDY4(GH;AR1,IE.D
M1`A#:'5,4H?NF,/[N0Q<I/56Z#<KOYU7NHL.[^#+LU@O#T-EZ1?=3\>XAH@!
M3O%W=",YQVY$)'T"E#L[$^XVMB<[*4EQUL*(#3.`)^C%LFLW_5EY=_\`,TW[
M_,1PX_V!XB/]_6[?_P!M[1_3NJO]-5LOLN9_/'/T3'ZNC^K+R[_YFF_?YB.'
M'^P/#^_K=O\`^V]H_IW57^FJ/LN9_/'/T3'ZNC^K+R[_`.9IOW^8CAQ_L#P_
MOZW;_P#MO:/Z=U5_IJC[+F?SQS]$Q^KH_JR\N_\`F:;]_F(X<?[`\/[^MV__
M`+;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O_F:;]_F(X<?[`\/[^MV__MO:/Z=U
M5_IJC[+F?SQS]$Q^KH_JR\N_^9IOW^8CAQ_L#P_OZW;_`/MO:/Z=U5_IJC[+
MF?SQS]$Q^KH_JR\N_P#F:;]_F(X<?[`\/[^MV_\`[;VC^G=5?Z:H^RYG\\<_
M1,?JZ/ZLO+O_`)FF_?YB.''^P/#^_K=O_P"V]H_IW57^FJ/LN9_/'/T3'ZNC
M^K+R[_YFF_?YB.''^P/#^_K=O_[;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O_F:
M;]_F(X<?[`\/[^MV_P#[;VC^G=5?Z:H^RYG\\<_1,?JZ/ZLO+O\`YFF_?YB.
M''^P/#^_K=O_`.V]H_IW57^FJ/LN9_/'/T3'ZNM7N6@^8-9KK^:;]Y?OA99H
M+8")K:%X=*)&\>Z1;FZQ":);F'H*KTAT'#P_MXY[D<2-RW*/Y0UBW/:IT'%@
MV.ZIF%QZ)?M3!]'@T*1*1DXZ[.M]<ME*59D'K2<,#@1I=0"XVBTNW!B4I3J,
MN`4TSAM4$[<&P>C]-)EOZ=YS:DTEM'9\)WB>V927HE/D;''1TKQ]XE!&O73,
MZ!2-WHL]/H.@;G!4>GQ9RF_:')G-7_+=Y(.GM+SKY$L%W7)BQRXE*[_>LI((
M&"L)@.&WH$4ANM]Z.J-+:/N6HXACNR8453J4+:1D44D;%90#AMZ!QJC(O>U]
MZ.8P!_7+>ATCT?R`<=?]G.-4/)6Y-`&/]59/]/W_`/TA3+O^.W>B?_S=9_\`
MJ.?OU\_\6SO1_P#?*>_S`<=?]G.?O_"KR9_]59/]/W__`$A7Y_QV[T?_`,&V
M?_J.?OU\*][=WI":2R@<RG@BFBJH`#H#CKT"*:9C@`__`"Y]01#/I')4Y,ZE
MI2=*R<"H#S_?^B</_P`(5]M\NS>BMQ*#;K/@5`=@YT3A]-7&\:[KWI.Y-:\6
M]ESG*2Z1NL]VZ*XY;2MVZY)UPWHE;BK/NA:+C;%0*G0I+AY;I>0M-<E99L6+
M9/)E!.=\N:HHNRN3*I),>WJ.\F;0VJM7:5M]@2[JNP:AO=OC6M#NJI;[C%K#
MBV9DB6C4\9M$=]MM9D.M1EJB<4ZM;):"%KD\MQO,R+%E+=P9>89<4O!A(!<`
MQ2E)9))!.P%778@8XU;)W?VR]F[3XI4&W[:NSR_[`&T;IJT]<W4-`5IW8B:^
MWGLG7\/)/(*IQL+7(YXK`UAJ"I&C5!(5`,8"@(CC-N4BQ%TAOBN5DT9X3;=-
M^"6N0S%3+E/I9,RTP9CJ$NR'G7UI#S[F4N.+5E(&.`%='9RJ1;T.2,JWLRP5
M94C'*XI(.```V`<`IS/'K_\`IE?_`%A__'B&?;]]_GLO],Y_]5;+BFOXJ?W!
M1X]?_P!,K_ZP_P#X\/M^^_SV7^F<_P#JHXIK^*G]P4>/7_\`3*_^L/\`^/#[
M?OO\]E_IG/\`ZJ.*:_BI_<%'CU__`$RO_K#_`/CP^W[[_/9?Z9S_`.JCBFOX
MJ?W!1X]?_P!,K_ZP_P#X\/M^^_SV7^F<_P#JHXIK^*G]P4>/7_\`3*_^L/\`
M^/#[?OO\]E_IG/\`ZJ.*:_BI_<%9+QRW_I5/>S_SS?\`CQ3_`+;O/\[E>RW_
M`'KG_P!587%M_P`5/Y_Z!7@>?=;KVPO[*;$^UG[877TE*[^NLN/^SH_$3U!7
MFSFZ]J,**K[Y(_/F[MSTWRQ_H#7QR>ZWF^[TO%]/>MQ6GF^=873=[W7Z<ZES
MM;?P`=I-7#]5ISLK;I-@S\G\L?J-N,_*!<C%EY6X:-/+'ATP22\:JDEXPP=<
MY"])@^>3VVEZR;R&5K2VA>[Q])6K'*@*OMA!6K*%*RIQS*RI4K*#E2HX`EU.
M#D,\/^=CO3M5_P#)WFO!<O-%2,3":/WWIE?3?.7NZX.R-=\UFJ4R=/8[)R?U
ME*+UL:Q#76TST3-0+%!%PY3?HMDU&KYJN@=5-8HY(-R!MPUPW*\M+=_,GZ@T
MY?6[Y:[^ZPJT/R)3088MTEL/\>[%CLN-/+*D(+*ED.-.MN)0I!%<KJBZ(N.G
M924M/-%I;0/&`).)6#A@%$@CHXX;"".&K$ZQVMK_`,H(SS]')[^5'S9]X?N3
M>O5TBDNLOGF)XRWVXI[<H\TY.C"BC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BH^
MVIV"L'VIG\(L\?K\L3GR:$\8N'JF?7+ZS]FI721WQ-+-KGMQ6_;YO-7&60/F
M#\RO>+Z#1Y=$I(=*>T43NOU54[64RJ<-1A11A11A142;J[%_?B/]9?)6/DW\
M\(^Z5UZL:N'W@^S_`/+H_#4.:=[<L_1\E["7)=?FX<RB[>G[1W]=<%H/VC;[
MDYU!3?94RI=:,**,**A+>?9V)]-%\Q>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'U%
MU&FF>VR?HF0]=ODCWS?^9E)]Z;5U)=<AH'VA'<%_5IN,JBTN5&%%8F>]XIKT
M3(^9K8J>XOXVZ.]ZK3Y?'K!N?FV1W!SM32#)_P`']$GKAEZR?V4CI.=15-G3
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MB59F.3DVWD7E#`SD@.DAD5VS9B4Z73UNNY7>HE*4.D0\<F(@`'*(^:;7<EQD
MS$,.F(O-@O*<IR!2E[?H2$J)/!UJL,2DX8R++=W(:;@W&>,%>?*X$G*>+2I2
M\#]"4H62>#K%X8E*@/Q?V2OMUY")7F8Y&3;,R'78*.2%=)%?BDU9==(1ZW6<
M+O$2E*'TP>-((@`'*(_<>UW)UMN8VPZJ(I9`6$G*<F*E;?\`!"5$G@ZU0&T$
M#TBV:[O-,SVHSRH*W"$N!)RGB\5+P/\`@I0LD\'6J`)*2!UZ<#>&D[M3C-W5
MG(&-Y+[\I==H'&WBW.7'0<5L"WHZ;O`T;6#=6O.6=4AK+`1\!,O9AZV--F<I
M2T=,,FH(G9)+G,Z&%3E$[\[?H_>MO@W;2M*Z<GW.Y:IO[4:[N0XQN<3PN>0\
ME4AUAY;S26D+$4(5'>C.N9TOK;2&:L%V*VJD6JV3$OO)0B*P2V%'(K*V,-@(
M`..&;'$*`PPQVT]/=CCT\-Z4/@\.TN4@^`.@/#RKW6/@`/4#&^<K`8;\9X_]
M(L'^S]KK=6+S:GNCO?5T_.-RK;T844844844844845D_P9BI?V6K"_7UY7GW
M6Z]L+^RFSD=9^V%U])2N_KKWC_LZ/Q$]05YLYNO:C"BJ^^2/SYN[<]-\L?Z`
MU\<GNMYON]+Q?3WK<5IYOG6%TW>]U^7/>.]V+%P-A@?R44,SS?AH?W6AG7D,
MS%>ZO%_E+'^ZD,^\6KY%+QWE'CFJW5-XI<A#]`]'1GWR=)7@-LWB3N+:>XC0
M#KG%NISM.<7?K`OBW48C.VO+E<3B,R"1B,:+NG,N(G$C&4!B.$8M.[1]T="D
M2Y:\-XCBUI2K2-8VML^VU>P\D>[;J+;7EUG%IVITZR5WEUK>0N5RH@R:S^<K
MR&S)9Z5\]A3/',9'/`5-'D;).%$<?Y\OC?C-WN\LS1\6[6>TPKM&<U%)5-BM
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MNWR1[YO_`#,I/O3:NI+KD-`^T([@OZM-QE46ERHPHK$SWO%->B9'S-;%3W%_
M&W1WO5:?+X]8-S\VR.X.=J:09/\`@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?
MU!/K0R@9<?.#_=E]L:=(CL!TA7WF'7U1A12*W/M?:/3TGYVIEW'D@<U#=M[D
M6?R)JFX7_P`^3/&7.V--SKWL36?13?UARJ1R^.>7O(]Z9?5%+CI?V>A]P36X
MXT6M]1A11A11A11A11A11A11A11A11A11A14<;9[!S7U4=\)-,D+^5ASXM']
MSNOJB=7)ZV]FI'31WQ-5-<U/FD<B?S7SOLC3+6^\[X>WCQ)7;)IG^][X77[T
M<YU4UQ:MJM90MJ<PXL8.(I.:>21&BCF854-'KLW39G!%AUG1ZXS3CU'!3%>H
MI`[."7AZ!4.(L*=N]J-E,%N+EF%A*"H):`SA25*=XT)X]16$D%I2N+&;9L2D
M5&2N_64V+[.9A9)ZHR&RL)9`XQ*TJ6_QP2)"RX$D%E:BT,VS$(2!L+RK5^06
M%P\BT5UQFHRQ`H91P4Q)R'2;(,))+J+%!)PFW9I)GZH`5=-,I50.`9K6+O<H
MR.*8>4EOB'&<,!M:<*BM!Q&T$J4H8XE))*"DFM+&OMWB-\3&?4AKP9R/A@G:
MP\5*<;.(.*2I:E)QQ*%*)04DU^,O5J_)IO5GT6@X55>L9XRACN"F"8@VQ$XR
M13ZBQ01<H(MDTS"0"@LD0I%0.4.C/N%=[E%4VW'>4E`;6SA@/S3JB7$'$;4D
MJ4H8XY5$J1E)QKTM]]N\);345]2&TM+8``3^9?42XV<0<4J*E*&.)0I14@I4
M<:[WNZG_`+-#@5^B5H?^CF`RNARPN=7O%]\[OY:]5AS3/LY`\39[VFOONQOF
M;4G\Z/*/]:K=>?/*Q^.,_P!$6#_9^UUZV+S:GNCO?5T_6-RK;T8448448448
M44845D_P9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_LZ/Q$]05YLY
MNO:C"BJ^^2/SYN[<]-\L?Z`U\<GNMYON]+Q?3WK<5IYOG6%TW>]U[.;W;ON]
M/T^*C^K?R<SPW!>SN\O_`'<R?7=BK]NGYV'XV.]NUIG>J_-SUG^FIP4_6PU/
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MF:V*GN+^-NCO>JT^7QZP;GYMD=P<[4T@R?\`!_1)ZX9>LG]E(Z3G4539T]#[
MU6&)?8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.OJC"BD5N?:^T>GI/SM3+N/)
M`YJ&[;W(L_D35-PO_GR9XRYVQIN=>]B:SZ*;^L.52.7QSR]Y'O3+ZHI<=+^S
MT/N":W'&BUOJ,**,**,**,**,**,**,**,**,**,**CC;/8.:^JCOA)IDA?R
ML.?%H_N=U]43JY/6WLU(Z:.^)JIKFI\TCD3^:^=]D:9:WWG?#V\>)*[9-,_W
MO?"Z_>CG.JFN/A/_``R_1R.178FHF1PU\9]5^5^+G[F<^UG'L)\^VOSJ/QT]
M45Z,_GD?CI[85W?=U0(!W:'`GI$`Z>)6A^CP^K_\N:_ZF5XN6$/_`/JO>+[Y
MW?RUZK&>F?9V!XFSWM-?IW8WS-J3^='E'^M5NO/GE8_'&?Z(L'^S]KKUL7FU
M/='>^KI^L;E6WHPHHPHHPHHPHHPHK)_@S%2_LM6%^OKRO/NMU[87]E-G(ZS]
ML+KZ2E=_77O'_9T?B)Z@KS9S=>U&%%5]\D?GS=VYZ;Y8_P!`:^.3W6\WW>EX
MOI[UN*T\WSK"Z;O>Z]G-[MWW>GZ?%1_5OY.9X;@O9W>7_NYD^N[%7[=/SL/Q
ML=[=K3.]5^;GK/\`34X*?K8:GQR?RGN>]IGQ"\>JI=:?7/LV]^,WVZ:WZL=K
M:_\`*",\_1RS/RH^;/O#]R;UZND4C=E\\Q/&6^W%/;E'FG)T844844844844
M844844844844844844845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?LU*Z
M2.^)I9M<]N*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG:RF53AJ,**,*
M*,**B3=78O[\1_K+Y*Q\F_GA'W2NO5C5P^\'V?\`Y='X:AS3O;EGZ/DO82Y+
MK\W#F47;T_:._KK@M!^T;?<G.H*;[*F5+K1A11A14);S[.Q/IHOF+S)G/DE\
MX+5?N8OUE;Z3S>/YJ8\8^HNHTTSVV3]$R'KM\D>^;_S,I/O3:NI+KD-`^T([
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MU\[[(TRUOO.^'MX\25VR:9_O>^%U^]'.=5-<?1"'`Q3"4P%Z0'K"4>KT?M]/
M1T9'&I2<",1C43`4G-EQ&-?EGW17XN?N9S[6<>PGS[:_.H_'3U17HS^>1^.G
MMA71GQ(E^.%9J7=/H3W#?8-WY)[2XP\%:A1>0TWKJJV722$-5H%I<WTI!2TM
MM*K.T]H:LK4;)&<KLV7NS&M1:N3(23%LBV4C!WSPMZ%VO.^-RW:XML#=9:-6
MZLDR[,U-D,70NR'E14-O-MP)"3`N#ZV`A#KO@S[G&M!R+(=6ZFP?:%0FXEK"
MXRUSG(D8)<*048!`5B"5CKD`''`9@,#@H`"KD>[)\/#FECT]/3M/E+X>GIZ?
M_JLW7X>GH+T]/T`QCO*O^.$_T18/]G[774V/S:GNCO?5T_&-SK;T84484484
M4844845D_P`&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24KOZZ]X_[.C\1/4%
M>;.;KVHPHJOODC\^;NW/3?+'^@-?')[K>;[O2\7T]ZW%:>;YUA=-WO=8GO#S
M+$=<)CMS6`CA/F0DHV/4D&[JVD<$XH<K3(&J;5V`M'-I*J`#&IJ@*2CWQ13_
M`$HCF9R9@A36O4N^#%HZ'(5X05)CY3J'3V/A"D]<F/ACQZD]<&LY&W"OF\XX
MQ<,<?">AP_FG>#[OT?=JFZ?">C-3D@;-4N4E0L"VX>ZCM,\7?E[ONU*A;W4U
MS(KJ\%L'7>QKO/3H/W4]5'31D]A$$XF0J_N4+&4:++>3.SRL<DTVZ7RP="W&
MU3=(S;:FXZMCL_9$2);Y,9+5F(=AS845EK(EF0EQUJ4M4AF?X1X1#>;1QK*>
M'ON=-@DH6F0E>1@GC%*6#BYL4E2B>$8`IV%.&"@3@:N^K':VO_*",\_1R8_E
M1\V?>'[DWKU=(I/K+YYB>,M]N*>W*/-.3HPHHPHHPHHPHHPHHPHHPHHPHHPH
MHPHHPHJ/MJ=@K!]J9_"+/'Z_+$Y\FA/&+AZIGUR^L_9J5TD=\32S:Y[<5OV^
M;S5QED#Y@_,KWB^@T>71*2'2GM%$[K]55.UE,JG#4844844845$FZNQ?WXC_
M`%E\E8^3?SPC[I77JQJX?>#[/_RZ/PU#FG>W+/T?)>PER77YN',HNWI^T=_7
M7!:#]HV^Y.=04WV5,J76C"BC"BH2WGV=B?31?,7F3.?)+YP6J_<Q?K*WTGF\
M?S4QXQ]1=1IIGMLGZ)D/7;Y(]\W_`)F4GWIM74EUR&@?:$=P7]6FXRJ+2Y48
M45B9[WBFO1,CYFMBI[B_C;H[WJM/E\>L&Y^;9'<'.U-(,G_!_1)ZX9>LG]E(
MZ3G4539T]#[U6&)?8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.OJC"BD5N?:^T
M>GI/SM3+N/)`YJ&[;W(L_D35-PO_`)\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>
M1[TR^J*7'2_L]#[@FMQQHM;ZC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BHXVSV#
MFOJH[X2:9(7\K#GQ:/[G=?5$ZN3UM[-2.FCOB:J:YJ?-(Y$_FOG?9&F6M]YW
MP]O'B2NV33/][WPNOWHYSJIKB482%))L$P,HIW[OOK4_C5I5Y)IK)$EF4.Y"
M2080Q)]658-SHL#""JL>1D<XF.4P>,(8S')$:_JTT./>1]FMPT+#:4$$MJ<3
MD*W2R&UJ!6.M2\70`$D=:H".!^'J=6E$F3(;^R6H+;@:0V02TMY/%J<>+`:6
MH%8!2F07@`E)!R*`VB05V`G+.%(Y"'<PHS5?9H-52IHNTH)4T<I/397AWG^,
M/&PB[2%H=)/][\4HB8YP.0VIC(TVJ&E,I3Z9_$/**AB4ET9PRUE"=B5?DU<8
M%';G2L)!"AH(:-(KMZ$3%247(1I"U*&)07QQ@89R!'6H5^26'0I77<8AQ*4E
M*D_C.J;`2>2BD2A#N8?RJ&:-6BQ4DG81"X-#6"9!Z=V'C7C(/*4_)#I$`R7B
MU$3F4`Q#?=O3IM;#*9BGT3LCJE*&)3Q@S<2UE"=B5=8KC`HD*SI6D)(4/2UH
MTBN.PB>J0BX\6\M2QB4<:G/X.SD"-B%_DU<:%J(5G0XE*"E0[]NZI(0W=H\"
M!,4INIQ-T.<@F*`B0WY.($H&+TA]*;JF$.D/#T".5P^6"I0Y5>\;`D8ZRNX/
M_P!Z]5@K3/LY`Q_F;/>TU^O=C?,VI/YT>4?ZU6Z\^.5C\<9_HBP?[/VNO6Q>
M;4]T=[ZNGZQN5;>C"BC"BC"BC"BC"BLG^#,5+^RU87Z^O*\^ZW7MA?V4V<CK
M/VPNOI*5W]=>\?\`9T?B)Z@KS9S=>U&%%5]\D?GS=VYZ;Y8_T!KXY/=;S?=Z
M7B^GO6XK3S?.L+IN][KV<WNW?=Z?I\5']6_DYGAN"]G=Y?\`NYD^N[%7[=/S
ML/QL=[=K3.]5^;GK/]-3@I^MAJ?')_*>Y[VF?$+QZJEUI]<^S;WXS?;IK?JQ
MVMK_`,H(SS]'+,_*CYL^\/W)O7JZ12-V7SS$\9;[<4]N4>:<G1A11A11A11A
M11A11A11A11A11A11A11A14?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]9^S4
MKI([XFEFUSVXK?M\WFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJ=K*95.&HPHH
MPHHPHJ)-U=B_OQ'^LODK'R;^>$?=*Z]6-7#[P?9_^71^&H<T[VY9^CY+V$N2
MZ_-PYE%V]/VCOZZX+0?M&WW)SJ"F^RIE2ZT844845"6\^SL3Z:+YB\R9SY)?
M."U7[F+]96^D\WC^:F/&/J+J--,]MD_1,AZ[?)'OF_\`,RD^]-JZDNN0T#[0
MCN"_JTW&51:7*C"BL3/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVII!D
M_P"#^B3UPR]9/[*1TG.HJFSIZ'WJL,2^QI_4$^M#*!EQ\X/]V7VQITB.P'2%
M?>8=?5&%%(K<^U]H]/2?G:F7<>2!S4-VWN19_(FJ;A?_`#Y,\9<[8TW.O>Q-
M9]%-_6'*I'+XYY>\CWIE]44N.E_9Z'W!-;CC1:WU&%%&%%&%%&%%&%%&%%&%
M%&%%&%%&%%1QMGL'-?51WPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'?$U4US4^:
M1R)_-?.^R-,M;[SOA[>/$E=LFF?[WOA=?O1SG537'BDU:@[\K!JV!V<H)'=@
MW1!T=(.@`2,Y`GCS)@`!]*)NCP9'0MYXL\25KXD'$)S'*#].7'#'[N%1/<>^
M6A'+B_!P<0C,<H/TA..7'[N&-?IGS7C7XN?N9S[6<>PGS[:_.H_'3U17HS^>
M1^.GMA7=_P!U/_9H<"OT2M#_`-',!E>+EA<ZO>+[YW?RUZK&>F?9V!XFSWM-
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M>2!S4-VWN19_(FJ;A?\`SY,\9<[8TW.O>Q-9]%-_6'*I'+XYY>\CWIE]44N.
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M-/R)C=GM[:6F_`_`X_Y13F7:I*4E(3D/7#9@,0%8@8@[*;#NR`ZO#BEAX?!M
M+E('TP=`^#E7NL/"'2/0.(YRKSCOPGG_`-(L'^S]KK:6+S:GNCO?5T_.-RK;
MT844844844844845D_P9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_
M`+.C\1/4%>;.;KVHPHJOODC\^;NW/3?+'^@-?')[K>;[O2\7T]ZW%:>;YUA=
M-WO=?CSXDTX.P\#IQ9J_?(P?-^'FUF,4T4D)5\C$<7^4LBJRBH]']^?RCM-L
M*;=`GTRRQBD#PFS[Y.<1=PMF\2WMK;;<D:`=:"W%!#:"Y?K`@*<6=B&TE69:
MSL2D%1V"OR[JR+B+.)`E`[.'8TZ=GW?HI%>6_,:*Y)Z5K-)6U#M;4%UJ')3N
MV]F2\/L6,ASQ,A3]F\NM<?$"=IUUJTO/4V[Q=DBHT[GQD:]7/'JIK,WZ;5XB
M='']_+WW'S-UG++T??F[U9[W89J]106W83CH<1)@VE_PQJ3%D-LR8KC#BPC*
M^T@/)*'XZGF'$N5R^J[DF;IZ0T6W&W4\2HA0&&"G!E(4"4J!`QV'9M!P(PJP
M>L=K:_\`*",\_1R?7E1\V?>'[DWKU=(I+;+YYB>,M]N*>W*/-.3HPHHPHHPH
MHPHHPHHPHHPHHPHHPHHPHHPHJ/MJ=@K!]J9_"+/'Z_+$Y\FA/&+AZIGUR^L_
M9J5TD=\32S:Y[<5OV^;S5QED#Y@_,KWB^@T>71*2'2GM%$[K]55.UE,JG#48
M44844845$FZNQ?WXC_67R5CY-_/"/NE=>K&KA]X/L_\`RZ/PU#FG>W+/T?)>
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M$#!05@4D*2`<3@/W5L]>0D5HA:98)RC<S(BS$ZO0X3/(+-$&:?5ZO5,JLJ_0
M#J%$3$!=,Q@*4Y1'S1:;FY%3-0PX8BLQ"\-A"`HJ/2`0O:=ARJ`)*2!X-V2\
M.PTW%N,ZJ"L+*5@=:0V%J6?N!(;7M(`)0L))*2!^+^SUYLXD(AQ,L$9-NU(*
MS%142KI^7^);LR='5ZIE5E7J/T@")RE5(8P`4Q3#]QK3<W6VYK3#BHBEG!8&
MPY,2H](!*MIV$I4`2017I$L=X?99N#,9U4%;ARK`ZT\7BI9X>!(0OKB,"4*2
M"5)('7WP+X7+;7XR=U;R&;<AM_T^.UYQKXO3=HT?#[2V"WTM>5*/JY,U:=)4
M6'N,!!5V<5EI-`\NL9O(,)MBV%NY9"HJ=SD*'**W[(T=O7WO[LW=,Z;G2KGJ
MJ_-1[J[`AFZ1!*GGCTF6[&>=>:#;:Q&2%LO177.-:?"4):JP58K9X1:K9-#S
MR4HBL$H"E9%96QAUH4`#B=NPA0&!'1IY.[''IX;TH1Z.D=I<I!'H``#P\J]U
MCX`#H``QO_*P&&_&>/\`TBP?[/VNMS8O-J>Z.]]73\XW*MO1A11A11A11A11
MA163_!F*E_9:L+]?7E>?=;KVPO[*;.1UG[877TE*[^NO>/\`LZ/Q$]05YLYN
MO:C"BJ^^2/SYN[<]-\L?Z`U\<GNMYON]+Q?3WK<5IYOG6%TW>]U^7/>."9L7
M`V&%])1837."&AC2D,[-'S,865XP<I8\TE#2!"G/'R[`'/CFJX`(HKD(<`'J
M]&??)TE&#;-XDX-M/%C0#KO%NISM.<7?K`O(Z@X!;:\N5Q!(S()3T:+NG,N(
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MED#Y@_,KWB^@T>71*2'2GM%$[K]55.UE,JG#4844844845$FZNQ?WXC_`%E\
ME8^3?SPC[I77JQJX?>#[/_RZ/PU#FG>W+/T?)>PER77YN',HNWI^T=_77!:#
M]HV^Y.=04WV5,J76C"BC"BH2WGV=B?31?,7F3.?)+YP6J_<Q?K*WTGF\?S4Q
MXQ]1=1IIGMLGZ)D/7;Y(]\W_`)F4GWIM74EUR&@?:$=P7]6FXRJ+2Y4845B9
M[WBFO1,CYFMBI[B_C;H[WJM/E\>L&Y^;9'<'.U-(,G_!_1)ZX9>LG]E(Z3G4
M539T]#[U6&)?8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.OJC"BD5N?:^T>GI/
MSM3+N/)`YJ&[;W(L_D35-PO_`)\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR
M^J*7'2_L]#[@FMQQHM;ZC"BC"BC"BC"BC"BC"BO*^?,HQD\DI)XUCXZ/:N'S
M]^^<)-&3%DT2.X=/'CIP=-!LU;()F.HH<Q2$(41$0`!'/:/'?EOHBQ4+=E.K
M"$(0"I2U*("4I2`2I2B0``"22`!C7X2$@J4<$BH6U9R=XY[QF)BO:<WIJ?:$
M_`)*N9>%HM]K5FE6+)%PDT5DE(^)D73HT45TN1+RLA#-A4.4H'Z1`,[O5^Z;
M>?N_@L7/7&GKS:;=)4$MNRXC[#:U$%00%N(2GC,H*N+)"\`3EP%8L>="E**(
MSK;BQPA*@3T]AX/N\%3GB?5ET845'&V>P<U]5'?"33)"_E8<^+1_<[KZHG5R
M>MO9J1TT=\3537-3YI'(G\U\[[(TRUOO.^'MX\25VR:9_O>^%U^]'.=5-<6S
M6ISY;:2;6L8K1Q)AY)%:G6G%%U&3AHZ;MH$8Y654K+9G'J."G(Y1:%=&\4'2
M(&.H8S"7;S;C9C`1%RRBPE&8!H`*"DJ4]G#8?4I8206U.%L9CLP2D",A=_M*
MK%]F-P@F88Z&\P#`2%I6E2G^,#0DJ6X$D*;6Z6AF.`(2A(V-W68!^J*[R+;.
M%AF(RP>,/XT#%FX=-!&.E"=50H)NVZ#9-,3%Z/&ID`J@&*'1FL9NMQCHXMAY
M:4<0XS@,/S3I)6V=FU)*E'`]B22G`[:T<>]W:(WQ49]:&_!W(^`P_,O%1<:.
M(VH4I2E`''*I14C*3C7XRU9@)%)\J^BFSE15VRFU#G\:!AF(-N4D5)%ZJA03
M=M$D")]<O1XQ,@$/UB!T9]P[K<8JVT1WEI2$*:`&'YMT_E$<&U*B2<#C@HE2
M<#MKU@7N[0W&FXKZT(2VM@`8?F7U8NMG$;4+*E*P..51*DY5'&N]ONI_[-#@
M5^B5H?\`HY@,KI<L+G5[Q??.[^6O58>TS[.0/$V>]IK[[L;YFU)_.CRC_6JW
M7GSRL?CC/]$6#_9^UUZV+S:GNCO?5T_6-RK;T844844844844845D_P9BI?V
M6K"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_`+.C\1/4%>;.;KVHPHJOODC\
M^;NW/3?+'^@-?')[K>;[O2\7T]ZW%:>;YUA=-WO=>SF]V[[O3]/BH_JW\G,\
M-P7L[O+_`-W,GUW8J_;I^=A^-CO;M:9WJOS<]9_IJ<%/UL-3XY/Y3W/>TSXA
M>/54NM/KGV;>_&;[=-;]6.UM?^4$9Y^CEF?E1\V?>'[DWKU=(I&[+YYB>,M]
MN*>W*/-.3HPHHPHHPHHPHHPHHPHHPHHPHHPHHPHHPHJ/MJ=@K!]J9_"+/'Z_
M+$Y\FA/&+AZIGUR^L_9J5TD=\32S:Y[<5OV^;S5QED#Y@_,KWB^@T>71*2'2
MGM%$[K]55.UE,JG#4844844845$FZNQ?WXC_`%E\E8^3?SPC[I77JQJX?>#[
M/_RZ/PU#FG>W+/T?)>PER77YN',HNWI^T=_77!:#]HV^Y.=04WV5,J76C"BC
M"BH2WGV=B?31?,7F3.?)+YP6J_<Q?K*WTGF\?S4QXQ]1=1IIGMLGZ)D/7;Y(
M]\W_`)F4GWIM74EUR&@?:$=P7]6FXRJ+2Y4845B9[WBFO1,CYFMBI[B_C;H[
MWJM/E\>L&Y^;9'<'.U-(,G_!_1)ZX9>LG]E(Z3G4539T]#[U6&)?8T_J"?6A
ME`RX^<'^[+[8TZ1'8#I"OO,.OJC"BD5N?:^T>GI/SM3+N/)`YJ&[;W(L_D35
M-PO_`)\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR^J*7'2_L]#[@FMQQHM;Z
MC"BC"BC"BC"BC"BC"BHXW'7YRV:BVG5:PY=L[+9=<7>OUYVP-'E?-9R9K,G'
M1+AD:650BRNT7[E,R8N3D;@<`\88"=(AU&A[E;[-K2SWB[)0NU1+I%>>2O/D
M4TT^VMQ*N+!<RE"2%9`5X8Y058"O"2A;D9QMO$+4A0'3(('#L_=JOG@A0-WT
M?9-^0O\`4>3+;6Q*/48372?)>>U'9WVI)*#?3SVZ4S7UTJF]MU;%V'4+E+68
MKED\GSE>QD;$-F"TE()HLRMG*<H?4F@=0:6MKFG)NE%:I-PDNS38V;BPBXH=
M0RB+*F19%IM<*%)C-L%#K4,%I]^2[);BQE+?+NGM+,II]8>2_P`1D`3QI0<A
M&.9*5!Q:E!1.(*MH``*E8#"S"S6>`ID#)VBTRK6$K\,W\JE)5Z8Q&K)OXPB7
MCES%*<P$\8H4/``^$<:I:;3<;[<6K3:&5R+D^K*VVG:I:L"<!P;<`37:62QW
M;4EV8L=B8<E7>2O*TT@8J6K`G!()&W`$\/0I>IOFMQ4KD6[FIS>-(C8IB5,[
MMZX=N_$H%56303,?J,SFZ#+*E*'0`^$<4N!N&WPW26B!;]/SW9CA(2D)3B<`
M2<,5#H`G[U;[>!N[UMNKTC,U[O#MLFTZ.MZ4&1+?2`TT''4,ME125'KG7$(&
M`/7*%1>\YP\2]S-U==ZNWM1KK=IP`4B:W#.GRDB_)%G+*2!D"+,44Q!K'M%5
M3=)@^D(.2(?+<W`;Y="\L72NIM7:>N$"P1T7(./NI0$(+EKF-HQ(63URU)2-
MG"134+EOJW5ZPA+T_IF]PYEY>P*&FRO,K(0M6&*`-B$J4=O`#2B\U/FD<B?S
M7SOLC3+*V\[X>WCQ)7;)I#][WPNOWHYSJIKCX3_PR_1R.178FHF1PU\9]5^5
M^+G[F<^UG'L)\^VOSJ/QT]45Z,_GD?CI[85W;]U6\:(]VKP&05=-TEU>)>A0
M31472(JH)]=5\I`(F8P'.)C>`.@/".5Y^6`P\OE4;QG$(46QK.[XD`D#":]C
MB>`58STT0-.P!T?`V>]IKU]V-\S:D_G1Y1_K5;KSPY6'QQG^B+!_L_:Z];%Y
MM3W1WOJZ?K&Y5MZ,**,**,**,**,**R?X,Q4O[+5A?KZ\KS[K=>V%_939R.L
M_;"Z^DI7?UU[Q_V='XB>H*\V<W7M1A15??)'Y\W=N>F^6/\`0&OCD]UO-]WI
M>+Z>];BM/-\ZPNF[WNO9S>[=]WI^GQ4?U;^3F>&X+V=WE_[N9/KNQ5^W3\[#
M\;'>W:TSO5?FYZS_`$U."GZV&I\<G\I[GO:9\0O'JJ76GUS[-O?C-]NFM^K'
M:VO_`"@C//T<LS\J/FS[P_<F]>KI%(W9?/,3QEOMQ3VY1YIR=&%%&%%&%%&%
M%&%%&%%&%%&%%&%%&%%&%%1]M3L%8/M3/X19X_7Y8G/DT)XQ</5,^N7UG[-2
MNDCOB:6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJIVLIE4X:C"BC
M"BC"BHDW5V+^_$?ZR^2L?)OYX1]TKKU8U</O!]G_`.71^&H<T[VY9^CY+V$N
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MJZ3*MNXAHJQ6<-U"O4"-7P<L>)':AZ/E0X[42,Y;7$AEI$=MA)2Q`)7!XJT6
MQ<JW+S#P>>IV<W)<3(0VZDL.*>YO3ZB52$J)40L;3B3PJ[+%Q>5?TIP20,"1
MM&#[\Q/FR[A^2P?"D=C<]R'Q7LGC?^373C^3G\;M.>/?Y)RN5CD=_(M>O:49
M\/Q.3`;K_;NW]T7WERG)?--YAFOO%[;ZXM]+_P!V-\]#5GH^_?B%8\DKW)_$
MNV]-[R=VJD?)P^+MM_$D^2O5T(<U/FD<B?S7SOLC3'A[SOA[>/$E=LFGY[WO
MA=?O1SG537'T0AP,4PE,!>D!ZPE'J]'[?3T=&1QJ4G`C$8U$P%)S9<1C7Y9]
MT5^+G[F<^UG'L)\^VOSJ/QT]45Z,_GD?CI[85T,<0;]QDKT/W8\/(<066PN1
M\SQ&X!0+WD#-5*A71O1ZR)J0[I]HBZ%+7&$OKE6OKV56+0NT4S$(>15*WZ\A
M[F'C@C1WUZ<WKW.=O8G1M;.6S=<QK36#R;.U(EQ52W_\Z3)8<EMQG8:0\&$R
M%VN0[_G+*2YEC>%B2;!EG>@HC6U)C!<TPXHXPA*LHRHP(25!6S'#.!UIV;<N
M6KK>[*^9U3/#T_\`S4Y2^'K`?I_^JS=GAZX>`W3^W^SC#>5=\;YWH>P?<_\`
M[?M==98_-J>Z.]]73[XW.MO1A11A11A11A11A163_!F*E_9:L+]?7E>?=;KV
MPO[*;.1UG[877TE*[^NO>/\`LZ/Q$]05YLYNO:C"BJ^^2/SYN[<]-\L?Z`U\
M<GNMYON]+Q?3WK<5IYOG6%TW>]UXN\"<"SEN#3P&,O*&:<U&#HL77CG3L4F9
MMQ8Y4KECJ\HFX9J)3[\2>*8F*LD8KHZ8@<@AU@]^3:T'X>\%@N,,A>@UIXQX
M`LMYK_I\9W@4J!91CF=!2H%L*!2>`_EX."HAP)PE<`X3^2=V#[OT?=JH6S26
MP8[CU#Z_VC6^8:5UC>1'=FW61OG)?;EOV]2[G#6_F13'5-7U?-34)6H-E8RU
MXX)VAF2)@IF/D&@(/HU(GDKAS*7R28NFI7+:T7J32,K1"K"Z_J6*B)8[=&ML
MJ*[&LSB9(GM-.ONJ8X[%4!TR)<9YEPN1Y2U<:TUQ-^4\G3DAE],GC0&5%3JR
MM*@7!ERD@#'#LA@E0(P*>`FYZL=K:_\`*",\_1R:'E1\V?>'[DWKU=(I.[+Y
MYB>,M]N*>W*/-.3HPHHPHHPHHPHHPHHPHHPHHPHHPHHPHHPHJ/MJ=@K!]J9_
M"+/'Z_+$Y\FA/&+AZIGUR^L_9J5TD=\32S:Y[<5OV^;S5QED#Y@_,KWB^@T>
M71*2'2GM%$[K]55.UE,JG#4844844845$FZNQ?WXC_67R5CY-_/"/NE=>K&K
MA]X/L_\`RZ/PU#FG>W+/T?)>PER77YN',HNWI^T=_77!:#]HV^Y.=04WV5,J
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M4VF-)9EF.V$0`F,7F8%O#C3"N,:0XMIQ:WD2<7E``#F=.*=*Y"7@L+"DXXI*
M<3UVW`J7@3L.&(V$;*L>YA]']6;<'3T]'Q7+T]'J]'NI'=/1^[T8U[<CC_>M
M9,.'PO\`R:Z<ER=,?[[=.X</AW^2<KCMV<AO9/6US=;'DJB[@7]?='>14#%I
ML"5Z2;VVIEK[=C(>Z#^1G#/D59$RZRP(I%9I-/WI-T*X&F[TFYN]5JF"UI=J
M:BXMR4A+CSA7QR#&D<<I:,B$-9"&0E*2I1<4]UZF0W@IGS)&MY2>1#KY_5;L
M-=M=@0\S;+>0,K3>[5Q(0LN+6Z5@OYE+R)XI+/6)=XS-%_=2_E!)S>TX2R^Y
M"\>K6-FN9%PQ(BW<,YTU,DB-(E-!-54'4:BW!RHBZ*('4(8I%R@H4#'D0W2_
MU:5O#A*M7'IDID+2@+)4%->"R"IPD@95DY`ILC`$$MDI.":R>X?^J*MZ<)5D
M\(1,2ZZEM*RI25L"'**W2H@97%*XM*VB,$J!4THH5@GI*YJ?-(Y$_FOG?9&F
M.CWG?#V\>)*[9-/*WO?"Z_>CG.JFN)%A(TDNQ#E8P0EL3VTOH]Q,.G[%PN$F
MRAW)7_D<*2>/.1C)9!B/5<J,2LU#&$_@\:0YF/2(U_.F09$C&V-Q$+2VE"P.
M+4ZG)F=+(:<4"O:@.EP`!/\``4D1Q/P]3JTDE4J5C9VH+;B64H6E/%+>3Q>=
MXL!AQ84O:VE\O)`"?^S4D;7(?E!)+.%8WW'6AC34`U09+$12<I0!QC5)Z7(\
M,H)UI)`P.TA:J$*0R0I'1-XPIBGT\;^K:H242N/3.##RBH$E)>&<,ME.&`0?
MR:N,!)"@M*QE(*>>A_U15;T-S?"4W(1GU*6"2DOCC`PT4`8!M7Y)7&I)(4'$
MN)R*24_C._E!(\E%8GW'6B/*H9LU9."(I."PRH-#V&6*],H)SR+3H<I@U4(5
M-1$R9TC`J4Q3?=O_`*MJ891,X],W(ZI2QB1QHS<2WEPP"%?DSQ@)4E04E8R$
M$>EK_JBJ,PW</"4W'BWE*6DDIXX9Q':R`8!M?Y-7&I)4E86EQ/%D%/?QW5']
MFAP*Z/4_JEZ'Z/YN8#*X7+"YU>\7WSN_EKU6"M,^SD#Q-GO::^^[&^9M2?SH
M\H_UJMUY\\K'XXS_`$18/]G[77K8O-J>Z.]]73]8W*MO1A11A11A11A11A16
M3_!F*E_9:L+]?7E>?=;KVPO[*;.1UG[877TE*[^NO>/^SH_$3U!7FSFZ]J,*
M*K[Y(_/F[MSTWRQ_H#7QR>ZWF^[TO%]/>MQ6GF^=873=[W7LYO=N^[T_3XJ/
MZM_)S/#<%[.[R_\`=S)]=V*OVZ?G8?C8[V[6F=ZK\W/6?Z:G!3];#4^.3^4]
MSWM,^(7CU5+K3ZY]FWOQF^W36_5CM;7_`)01GGZ.69^5'S9]X?N3>O5TBD;L
MOGF)XRWVXI[<H\TY.C"BC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BH^VIV"L'VI
MG\(L\?K\L3GR:$\8N'JF?7+ZS]FI721WQ-+-KGMQ6_;YO-7&60/F#\RO>+Z#
M1Y=$I(=*>T43NOU54[64RJ<-1A11A11A142;J[%_?B/]9?)6/DW\\(^Z5UZL
M:N'W@^S_`/+H_#4.:=[<L_1\E["7)=?FX<RB[>G[1W]=<%H/VC;[DYU!3?94
MRI=:,**,**A+>?9V)]-%\Q>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>VR?
MHF0]=ODCWS?^9E)]Z;5U)=<AH'VA'<%_5IN,JBTN5&%%8F>]XIKT3(^9K8J>
MXOXVZ.]ZK3Y?'K!N?FV1W!SM32#)_P`']$GKAEZR?V4CI.=15-G3T/O588E]
MC3^H)]:&4#+CYP?[LOMC3I$=@.D*^\PZ^J,**16Y]K[1Z>D_.U,NX\D#FH;M
MO<BS^1-4W"_^?)GC+G;&FYU[V)K/HIOZPY5(Y?'/+WD>],OJBEQTO[/0^X)K
M<<:+6^HPHHPHHPHHPHHPHHPHKP2JTBVBY%Q$,$)2508NUHR,<OO<MM(R"2"A
MV;%>2\E?>YZ+IP4J9E_$+>**83=0W1U1R8;<9V6TU-<4S#4XD..)1QBD()`4
ML(S(SE(Q(3F3F(PS#'&OE14$DI&*L-@X,?OU3[W247(QRW*(Z\8NK$.]A1:T
M%>W-1M$2OL5J-@V8HM.JW:QZOUVELLR:JO5]TFJTL0>OTF7_`'PIUGL\LZ7%
ME(TBEMU(FHMC@=B)DQW!"5Q,$!D16)\TP<0,>(<3'.S`-]:4HYS3R5)+^(ZT
MK&"L",VU6W,4IS=,8]/Z7\YB?-EW#\E@^%([&X[D/BO9/&_\FNG(<G/XW:<\
M>_R3E<K'([^1:]>THSX?B<F`W7^W=O[HOO+E.2^:;S#-?>+VWUQ;Z7_NQOGH
M:L]'W[\0K'DE>Y/XEVWIO>3NU4CY.'Q=MOXDGR5ZNA#FI\TCD3^:^=]D:8\/
M>=\/;QXDKMDT_/>]\+K]Z.<ZJ:X]$TDO*`7!%(%S%!,RX))@N9,/43,MU?&&
M3#H\`"/1D<REKXOB\RN+&W#$X8_3AP8_=J)P..90UF5Q0..7$Y<?IPX,?NX8
MU_N%>=?BY^YG/M9Q["?/MK\ZC\=/5%>C/YY'XZ>V%=W_`'4_]FAP*_1*T/\`
MT<P&5XN6%SJ]XOOG=_+7JL9Z9]G8'B;/>TU]]V-\S:D_G1Y1_K5;KSYY6/QQ
MG^B+!_L_:Z];%YM3W1WOJZ?K&Y5MZ,**,**,**,**,**R?X,Q4O[+5A?KZ\K
MS[K=>V%_939R.L_;"Z^DI7?UU[Q_V='XB>H*\V<W7M1A15??)'Y\W=N>F^6/
M]`:^.3W6\WW>EXOI[UN*T\WSK"Z;O>Z]G-[MWW>GZ?%1_5OY.9X;@O9W>7_N
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MOF+S)G/DE\X+5?N8OUE;Z3S>/YJ8\8^HNHTTSVV3]$R'KM\D>^;_`,S*3[TV
MKJ2ZY#0/M".X+^K3<95%I<J,**Q,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-
MLCN#G:FD&3_@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@9<?.#_`'9?
M;&G2([`=(5]YAU]4844BMS[7VCT])^=J9=QY('-0W;>Y%G\B:IN%_P#/DSQE
MSMC3<Z][$UGT4W]8<JD<OCGE[R/>F7U12XZ7]GH?<$UN.-%K?48448448448
M44844845\*JI()*+KJ)HHHIG5665.5-))),HG4444.($(F0@"(B(@``'2.?2
M$+<6&VP5.*(``&)).P``<)/0%'!M/!5-/=(4]2ER/*Z,3J,C7X];8T6[;O9.
MBUVK2Q'#BQ;.=.JE;K1&:$TM([/OM>*Z3>2$X1_<H9PWEFOD4NLKY:95\O+/
MO:;[%T=+5-:DR4VMQ*DMRWI#92&8"4R(S#EWNB($1[*IMF*6;9)0N.]Q\)".
M(".9TZWQ2I"<I`SCA2`>%6PD-H*E#A*L5IVC!1VU8)S$^;+N'Y+!\*1V-LW(
M?%>R>-_Y-=.1Y.?QNTYX]_DG*Y6.1W\BUZ]I1GP_$Y,!NO\`;NW]T7WERG)?
M--YAFOO%[;ZXM]+_`-V-\]#5GH^_?B%8\DKW)_$NV]-[R=VJD?)P^+MM_$D^
M2O5T(<U/FD<B?S7SOLC3'A[SOA[>/$E=LFGY[WOA=?O1SG537'PG_AE^CD<B
MNQ-1,CAKXSZK\K\7/W,Y]K./83Y]M?G4?CIZHKT9_/(_'3VPKL1[NG9_)&J\
M/>[Y@(O56E6_'(_$/AY[H;OOV\IJJV!6=N<97*;-4>%UY':KL:*]P:.WC(8<
MKF6;1\RK((H>5-E@.F6$3E.Z2W6WC?=O*N4N\7Y6]`:UU+DM4.TM2&0U%<?D
MM2W9J[@P1&4E+OA)1'6]&2RMSB76\JC8CT^_-;L]O0EMKP+P./BM2R#BI*4E
M(2$';P88D!6(&(--EW9`=7AQ2B^$.C:7*0.@P=!O!RKW6'A#I'H'$;Y5YQWX
M3S_Z18/]G[76UL7FU/='>^KI^<;E6WHPHHPHHPHHPHHPHK)_@S%2_LM6%^OK
MRO/NMU[87]E-G(ZS]L+KZ2E=_77O'_9T?B)Z@KS9S=>U&%%5]\D?GS=VYZ;Y
M8_T!KXY/=;S?=Z7B^GO6XK3S?.L+IN][KXYZ2`1-EX%RXLY"1"(YQ0DL,;$-
M#/Y>2",XP\I'PQT0P()3OY5\#?Q39`H@99<Y2`(";/KDZQC-M6\6$%M-%[=^
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M45$FZNQ?WXC_`%E\E8^3?SPC[I77JQJX?>#[/_RZ/PU#FG>W+/T?)>PER77Y
MN',HNWI^T=_77!:#]HV^Y.=04WV5,J76C"BC"BH2WGV=B?31?,7F3.?)+YP6
MJ_<Q?K*WTGF\?S4QXQ]1=1IIGMLGZ)D/7;Y(]\W_`)F4GWIM74EUR&@?:$=P
M7]6FXRJ+2Y4845B9[WBFO1,CYFMBI[B_C;H[WJM/E\>L&Y^;9'<'.U-(,G_!
M_1)ZX9>LG]E(Z3G4539T]#[U6&)?8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.
MOJC"BD5N?:^T>GI/SM3+N/)`YJ&[;W(L_D35-PO_`)\F>,N=L:;G7O8FL^BF
M_K#E4CE\<\O>1[TR^J*7'2_L]#[@FMQQHM;ZC"BC"BC"BC"BC"BC"BM0V%5U
M;O0;Q2T'<4P7M]0LM71?3M:C;G",U9^%>Q2;N8I\R8D/:XIN=V!W$:[$&SY$
M#(*B!#FS=Z:NR+!J.WWUQ#SC<*:P^4-/KBNJ#+J7"EJ2UBY'<4$X(?;Z]I1#
MB.N2*\WF^-96T,`5)(V@*&T8;0=A'W#L/!54_='Z7X_:1AM_U[2VZ]:;SL,C
M<(%SM*Y4SCR?0MCDK%#NKG6TY&P%0EG-9M586>Q+YM`!6V,;6(Y!FX)')&(L
M<XO"Y:&N]Y.OIVF[GKNPW73UL:@O)@1I-Y%W80RXF*^4,XMI?COA+C2YGAKK
M\]]3K2I*PI"17/Z=BPXJ7D174.K*AF4EOBR2,PQ.W`C80G*`D8'+PT^7,,!'
MC-N``\(C5P``_=&4CL;MN1V;UK(?_P`;_P`FNG'<G39OMTZ3P>'?Y)RN1;<V
MV-<7;5^Q*_4[?$S\LRC6ZR[>.,Y51ZK&QU]-\5!^9N2.>+L@?ME%4T55%$V[
MI!8Q0172.>:70VC=46'5MLN5YA/1H;CJ@%+R@]>P\48HQ*TA61:4J4D)*VW$
M`YVUI2L_S--<Z3U%R'-X5KLDYF3,:BV\J",2.LO-M"PE>&1:DYVU*2E14E#C
M3A`0XA2HB[K&U5R<YJ:I2B)AH_54C=D*$20\:"AT6=#EP77*15),PMNA^B9-
M3[&L14IDQ.7PY(ON?L]TM^\FW+FL+;0%.`DX88JCOX#$$]=UB@4\*2DA02=E
M59>3_8;S:][5N<N,=QEL)?!*L,`5Q9.5.()Z[\FL*3V2"DI6$JV5T7\U/FD<
MB?S7SOLC3'9;SOA[>/$E=LFGN[WOA=?O1SG537&DVEK`:<59.:RW8PR;\6;6
M<7L;859$@LP=(N&4.6.\8H*AQ,D9(5RJ$,F<W0)2@(Q].P[:+>'VI:G)Q;S*
M:#"L$'-E*5.Y\!@,%!004D%(V$[(M%V^T"W(DLS5NW(M!:F$QU8-G/E*5O%S
M`8#!04$%)"DC$$D#]%K57&\DM#KS#1*3;J,DEF9Q5!0JTBJS19MRG\5XE5RJ
M>0;]*9#&.F1=,YP*0Y3#\(M%T<BIFML+,1040H888("BH\.(2`A>"B`%%"@D
ME0(KQ;L-Y>A)N+4=Q4%860L8896PLK5ACB$@-N8*("5%"TI*E)('XR%JKC1Q
M(1#F8:(R3=LF59F?QH*%4D`019H@?Q0HJ.53/D!%(IC*$36(<Y2D,!A](UHN
M;S3<UIA:HJE'!0PPP1B5'#'$)&177$!)*5)!*@17K#L-YD,LW!F.XJ$M9P6,
M,"&\Q6<,<0D!"QF("5*0I*25`BNMC@-P0=;:T%W:?)];?NR*LG0>*'$A]`T"
M!=V!LQ:O*;4*6ZEHA-PA<VM6/2;O%L7"4E'.*^X=+/)!PNH]41\4S3ADY1G*
M'9T9O'WJ[I6].6N6JXZQU$AZ8\EE2U)DR926W"DQ52!*BN+0IA]$Q#:6F6VT
ML)<SOJL"6*TF3;;=/XY:0B''(2,>@A.([+#*H<(RXXDG'#95A7=D#UN'%*-T
M`7IVERD'JE]0O3RKW6/0'3T^`,;3RKQAOPGCA_\`*+!_L_:ZWMB\VI[H[WU=
M/SC<JV]&%%&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24K
MOZZ]X_[.C\1/4%>;.;KVHPHJOODC\^;NW/3?+'^@-?')[K>;[O2\7T]ZW%:>
M;YUA=-WO=?CSXC$YNP\#H-9U(,$9SF_#PBS^)>*1\LQ1E^+_`"EC57L3((_O
MK"4:)N14;KD^F16*4X>$N??)SEJ@6S>)<$(;<7'T`ZZ$.)"VUEN_6!80X@[%
MMJ*<JT'8I)*3L-?EW3G7$0<0#*`V<.UIT;/N_12,<N^%E`XJZ7J\WKRX[$?0
MUFY)]VY2C4"Q3C5]0:S*U?EYKB2LEUHE>1CVR=)D]G2[\'\W'1YT8/W0(=RT
M9-57+H5G\_+UW[ZDWP<LK1\#4T&V-SHB]12O#&6E(F/MR+0^AB++>*U&4W`;
M1Q,5YX*E\24M//O(::".7U7;&;?IZ0IE2RE093E)ZT$.`E21AUI4=J@.MQV@
M#$XV"5CM;7_E!&>?HY/ORH^;/O#]R;UZND4EME\\Q/&6^W%/;E'FG)T84484
M4844844844844844844844844845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY
M?6?LU*Z2.^)I9M<]N*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG:RF53
MAJ,**,**,**B3=78O[\1_K+Y*Q\F_GA'W2NO5C5P^\'V?_ET?AJ'-.]N6?H^
M2]A+DNOS<.91=O3]H[^NN"T'[1M]R<Z@IOLJ94NM&%%&%%0EO/L[$^FB^8O,
MF<^27S@M5^YB_65OI/-X_FICQCZBZC33/;9/T3(>NWR1[YO_`#,I/O3:NI+K
MD-`^T([@OZM-QE46ERHPHK$SWO%->B9'S-;%3W%_&W1WO5:?+X]8-S\VR.X.
M=J:09/\`@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@9<?.#_=E]L:=(
MCL!TA7WF'7U1A12*W/M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_P`^3/&7.V--
MSKWL36?13?UARJ1R^.>7O(]Z9?5%+CI?V>A]P36XXT6M]1A11A11A11A11A1
M1A17AE'+9G&2+Q[))0[-HQ=N7<NLLT;HQ39!NHJO)*KOR*,4$F*115,=<ID2
M@7I.`E`<R(C3K\IIAAHOOK<2E+8"B7%$@!`""%DK/6@)(4<<$G'"OQ1`223@
M,.'Z/NU1[W,:4PTG>8S*<J_N1*)7JC.I:RDA-8P?Q^EG[O9KA6W2Z&K=,:PK
MRMHGXP6DB^\GD[*S2*^223<(+$<E6?\`<NE<%ZWZ'D6^7Q\0V^6EM@NSW?`V
MT)@)$9LS[G/>$=E?&,M9V(+JBTM:FW&U-%'*Z9S!<D+3@K.G$X)&8]=M.1"1
MB1@3@5#;P@XXV=\PQ$.,VX!#P"%7`0']T)2.QINY';O6L@__`!O_`":Z<KR=
M-N^W3H/!X=_DG*Y,-[TJI0&G+.XA:_&1BT-!^YD09HW!,(R/F;377LHS8DZ1
M3;(/5XYOU@*`=":":8="9"D"9;=Y?KS<=<1&I\EUU#\CC',QQSK:CO);4L\*
MBD+7@3T5J4<5*)*[_,^TW8K7R$-<NV^*TRMB%!;;RC#BT.WJV+<2@<"0HMHQ
M"<-B$I'6I`$&]UW7(%AS;T\^913-J\C:WL.#8.42&*JUAEJ7//#Q:1A,/^)`
MZ1*<A!Z03Z.@G5`1`9(]S-TN,G>+!CR'EK8=?==6DG8IT1GDAP_X64D$_P`+
MA5B=M54N3Q>;K+WK08LJ0XY'><D/K23L4\(;Z`Z1AV>4D%0PS8XJQ.!KHJYJ
M?-(Y$_FOG?9&F.UWG?#V\>)*[9-/@WO?"Z_>CG.JFN+9K3YA.VDG5;&HLQ++
MO9(&ICSIG2C1TT<MF\`HW5GE:TE&1YW!3IJI1Y'`^*+TF`QCG,PEZ]P568VY
M$4)D%A*,V#64*2I*B\%!D/EQ8!"DJ>*.N.S`)2(R%ZBMR[%]E(A!,HQT-Y@&
M`D+2M*E/A08$DNN!)"DJD*;ZX["D)2G975<@7RAEGD2S<*FEHV>%11,1-[M0
MZ:249*%$#!U'K1%`A`.'0)DR@4W6*'1FJ9NEQCHR,/+2@,K9P!_[)TDN-_=2
MHDG`\!)(P.VM$Q>;K%0&X\AQ#8CN,8`[.)>)+C7!M0LJ*BD\"B5)P)QK\96N
M0,@B^5?1+-THJY93*AU4S"8TO!H`$1)`(&#J/6)$2D*H7H,*90(;K%#HSTAW
M2XQEMHCO+0E*%-``_P#9NG\HC\59))!V`DD8';7I`O-UAN-(BR'$(2A;(`/_
M`&3ZORK?!M0LDDI.P*)4G!6VN]GNI_[-#@5^B5H?^CF`RNGRPN=7O%]\[OY:
M]5B#3/LY`\39[VFOONQOF;4G\Z/*/]:K=>?/*Q^.,_T18/\`9^UUZV+S:GNC
MO?5T_6-RK;T844844844844845D_P9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U
M])2N_KKWC_LZ/Q$]05YLYNO:C"BJ^^2/SYN[<]-\L?Z`U\<GNMYON]+Q?3WK
M<5IYOG6%TW>]U[.;W;ON]/T^*C^K?R<SPW!>SN\O_=S)]=V*OVZ?G8?C8[V[
M6F=ZK\W/6?Z:G!3];#4^.3^4]SWM,^(7CU5+K3ZY]FWOQF^W36_5CM;7_E!&
M>?HY9GY4?-GWA^Y-Z]72*1NR^>8GC+?;BGMRCS3DZ,**,**,**,**,**,**,
M**,**,**,**,**C[:G8*P?:F?PBSQ^ORQ.?)H3QBX>J9]<OK/V:E=)'?$TLV
MN>W%;]OF\U<99`^8/S*]XOH-'ET2DATI[11.Z_553M93*IPU&%%&%%&%%1)N
MKL7]^(_UE\E8^3?SPC[I77JQJX?>#[/_`,NC\-0YIWMRS]'R7L)<EU^;AS*+
MMZ?M'?UUP6@_:-ON3G4%-]E3*EUHPHHPHJ$MY]G8GTT7S%YDSGR2^<%JOW,7
MZRM])YO'\U,>,?474::9[;)^B9#UV^2/?-_YF4GWIM74EUR&@?:$=P7]6FXR
MJ+2Y4845B9[WBFO1,CYFMBI[B_C;H[WJM/E\>L&Y^;9'<'.U-(,G_!_1)ZX9
M>LG]E(Z3G4539T]#[U6&)?8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.OJC"BD
M5N?:^T>GI/SM3+N/)`YJ&[;W(L_D35-PO_GR9XRYVQIN=>]B:SZ*;^L.52.7
MQSR]Y'O3+ZHI<=+^ST/N":W'&BUOJ,**,**,**,**,**,**TW8QSIZ]O:B=7
M1NYR4VSG+2W$>E+-[<8L*]$*PM%+]*,FE/\`1Y(9N?Z18%>H/@,.;W2Z4JU+
M;DJEJMZ3.8'A25ELQORJ/RX<&ULL_G`L;4Y<PVBO)[\ROK<_6GK>''9P8=''
M@JF+N86]30><EE*Q2%:$PD"ZIDZ?#+U:K5%9+4KR>W=\0V:[:JT6F!87$3*I
M33<\M+*S$XX$OB7+U1)!L(OIY=+EY<8TJF[7!-QDMFX-R71(D20;BEFU>%J"
MI$N5Q(<;,58CQTQHB,<[3"5N.@<SID-@O\6C(#D(&`'68KR\"4XX',,3BKH$
M[!5G7,3YLNX?DL'PI'8TW<A\5[)XW_DUTY;DY_&[3GCW^2<KE8Y'?R+7KVE&
M?#\3DP&Z_P!N[?W1?>7*<E\TWF&:^\7MOKBWTO\`W8WST-6>C[]^(5CR2O<G
M\2[;TWO)W:J1\G#XNVW\23Y*]70AS4^:1R)_-?.^R-,>'O.^'MX\25VR:?GO
M>^%U^]'.=5-<?"?^&7Z.1R*[$U$R.&OC/JOROQ<_<SGVLX]A/GVU^=1^.GJB
MO1G\\C\=/;"NZONKYR%:=VYP$C7<Q%M9%QQ-T"FW8.)!HB]7.OKJO%0(BU46
M*NJ=8Q@`@%*(F$?!E>WE>V^>]RI-X\IEAY<9.LKP2M*%%(`FO8DJ`P&'1Q.S
MHU8RTTM(T]`22,W@;/>TUE^[&^9M2?SH\H_UJMUYA<K#XXS_`$18/]G[77M8
MO-J>Z.]]73]8W*MO1A11A11A11A11A163_!F*E_9:L+]?7E>?=;KVPO[*;.1
MUG[877TE*[^NO>/^SH_$3U!7FSFZ]J,**K[Y(_/F[MSTWRQ_H#7QR>ZWF^[T
MO%]/>MQ6GF^=873=[W7LYO=N^[T_3XJ/ZM_)S/#<%[.[R_\`=S)]=V*OVZ?G
M8?C8[V[6F=ZK\W/6?Z:G!3];#4^.3^4]SWM,^(7CU5+K3ZY]FWOQF^W36_5C
MM;7_`)01GGZ.69^5'S9]X?N3>O5TBD;LOGF)XRWVXI[<H\TY.C"BC"BC"BC"
MBC"BC"BC"BC"BC"BC"BC"BH^VIV"L'VIG\(L\?K\L3GR:$\8N'JF?7+ZS]FI
M721WQ-+-KGMQ6_;YO-7&60/F#\RO>+Z#1Y=$I(=*>T43NOU54[64RJ<-1A11
MA11A142;J[%_?B/]9?)6/DW\\(^Z5UZL:N'W@^S_`/+H_#4.:=[<L_1\E["7
M)=?FX<RB[>G[1W]=<%H/VC;[DYU!3?94RI=:,**,**A+>?9V)]-%\Q>9,Y\D
MOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>VR?HF0]=ODCWS?^9E)]Z;5U)=<AH'VA
M'<%_5IN,JBTN5&%%8F>]XIKT3(^9K8J>XOXVZ.]ZK3Y?'K!N?FV1W!SM32#)
M_P`']$GKAEZR?V4CI.=15-G3T/O588E]C3^H)]:&4#+CYP?[LOMC3I$=@.D*
M^\PZ^J,**16Y]K[1Z>D_.U,NX\D#FH;MO<BS^1-4W"_^?)GC+G;&FYU[V)K/
MHIOZPY5(Y?'/+WD>],OJBEQTO[/0^X)K<<:+6^HPHHPHHPHHPHHPHHPHHPHJ
MC_N<KS#VNQ<TF+1<)*>9[9BYZW65(JL2WN<U8;'M5F:VA35JC45*HO+(UPO2
M0R)SN$4TE.D$_%B9_O+@T_.L]LT)(>3Q5N79G&8S!P<,5IEBWJ\'\)$F2)`;
M+YVA0"%*6G:K.!RVFW4N+E`;5AP$G@S$E>W+@,,</OU97S$^;+N'Y+!\*1V-
M6W(?%>R>-_Y-=.4Y.?QNTYX]_DG*Y6.1W\BUZ]I1GP_$Y,!NO]N[?W1?>7*<
ME\TWF&:^\7MOKBWTO_=C?/0U9Z/OWXA6/)*]R?Q+MO3>\G=JI'R</B[;?Q)/
MDKU="'-3YI'(G\U\[[(TQX>\[X>WCQ)7;)I^>][X77[T<YU4UQ]$*8#%,)3`
M7I`>MT#T='J=/3ZGJY'&HC`C';43`4G-AB,:_+/NBOQ<_<SGVLX]A/GVU^=1
M^.GJBO1G\\C\=/;"NASB#?-`P$%W8\*?A3&[%W],<2.`4++<EI>C4^ZNZ34P
M&DNZK8H6H2SQK9';*LN+&M%EN3$[9:"D%3II^6^YOD8QG;Z].[Q[C<-[$].O
M';7NX8UIK!UNQMRY,5,J1_G29#+LEM*F$J?2PE\VQT+3+92E2N(\*X^K!MG=
MAHC6U/@H7,,.*"Z4A64948$`[=F.&<893].7"KJ.[*^9U3/#T_\`S3Y2^'K=
M?I_^JS=GAZ__`)73^W^SC$.5=\;YWH>P?<__`+?M?0KJ['YM3W1WOJZ?C&YU
MMZ,**,**,**,**,**R?X,Q4O[+5A?KZ\KS[K=>V%_939R.L_;"Z^DI7?UU[Q
M_P!G1^(GJ"O-G-U[48457WR1^?-W;GIOEC_0&OCD]UO-]WI>+Z>];BM/-\ZP
MNF[WNO)S_:K/YG@LP;JRJ#E_S7CF+9>"=MH^>0<O.+7*ALW6@I%Y_B4=.)+*
ME,S<+?O*#D"'/](4<]N3>\B/!WA270RIIO02UJ#R5+9*4W_3ZB'D)ZY;1`(=
M0GKEHS)3M(K\NX)5$`QQ,H<'#^:=X#T#]'W:IB9:#MNHN+A[99]><D]:FV3S
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M4:1;G&O[I:J';ZY4;XS;^5NZ3:)ROR$9`6YJU%1('+BMRKI)Z1/K%ZYD0#I#
MIZ<Z+2%TM-CU9:[U?X2;E8H=QC/R8BCE3*8:>0X]&4K`Y4OMI4T3@<`K'`UX
MR$..L+;:5D=4@@*_BD@@'[QVTI?#36&YZ?8=OW';DQKA%6R16G:$WI&M-FVG
M<,='VG3E5EZS<MA66\7*F46>)==D%D8XKZ+59K'9$B$5EG;EV[<'!9=^6K="
MWNV62QZ+8NBD17KE+5*G0(]M6N/<Y#;\:&Q%C2I;)BP<CQ:D)<2'3)6AMEIE
MEI-:^V,26UN.2"CK@A.5*BL8H!"E%2DI.96(Q&&S`$DDFI;YA]']6?<'6]3X
ML%Z>CU>CW4CNGH_\&<9N1Q_O6LF'#X7_`)-=.`Y.F/\`?;IW#A\._P`DY7';
ML]AO-OK:Y.]C3]7DX-]7W9G\1"Q3:/;P$DE;JF%=0B7A#+RTR#I$\B===R=)
M,K0K0GB0=`NHI-WI.1N^=U3!9TQ&EM7!N2G(XZXI9>08TCCBXDX-M92&0A"`
MHEPO*SEHMI2IGS)(V\AKD0:^?U7)B.V]R#$S---A"67!>[5Q`:5BIQS,"^5K
M<*0&@PD-AT.+7%_=2I[!2YOZ<+97$0[CE*QLU>259IH-W+6?/3)(K6-121(!
M'42BW(Y40<`)51(<I%RF4*"AI$-TJM-+WAPC:DO(DB0L("B2E3(BR,RR2<4N
M%10%HVIQ!4V0DE(K)[AUZ17O3A&RHD-S`Z\EL+*E)4P(<HJ<45'%+I46TK;V
MIQ25-$(44#I*YJ?-(Y$_FOG?9&F.CWG?#V\>)*[9-/*WO?"Z_>CG.JFN)"/D
M*478JB;&M-DK&]M#YDZFG"\4YDAD&<.Y(^7;PY)<9^)CG2#'Z5X=L#543=;J
M_OQ5!8_)C7XZ8"I$M2K6W$0I+0#B49%.I*`7>+XEQ:2O:V'.,3AAC^3*1'&_
M$U,K2*%2IJU69J$VM+*4NI;XM;R2A*GBUQ#KB5+VLAWC4@9<?R10-LD$]@%E
MG"T:XB%(<TU`-T&"Z:":R5>$8U2>DDG?4,L>63.5VEY.KTI*('2.B8BI#`?3
M1E:;,)+<I+XG!AXE8)(+W7AE!3C@&R.+5G3UP4%A84A0R\[#7I$V]#4U$@7$
M1GU*<25$&1^4##91CE#1'%*XQ/7)6%I<"D*!3^,XGL`'DHO$N(A2)%U#-VL>
MX3035+"F*T/8I(KP2&6&60$KDA6ZG2BJ@=,4C$6(/7^[>K3989;FI>$W(Z5+
M221QO7!E&7'#BSUA*T]<E84%A2",/2UKTB8[#5P1(%PXMY2G$E1!>&<1VRC$
M#BE8MJ+B>O0L+"PIM0R]_'=4?V:'`KH]3^J7H?H_FY@,KA<L+G5[Q??.[^6O
M58*TS[.0/$V>]IK[[L;YFU)_.CRC_6JW7GSRL?CC/]$6#_9^UUZV+S:GNCO?
M5T_6-RK;T844844844844845D_P9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U])
M2N_KKWC_`+.C\1/4%>;.;KVHPHJOODC\^;NW/3?+'^@-?')[K>;[O2\7T]ZW
M%:>;YUA=-WO=>SF]V[[O3]/BH_JW\G,\-P7L[O+_`-W,GUW8J_;I^=A^-CO;
MM:9WJOS<]9_IJ<%/UL-3XY/Y3W/>TSXA>/54NM/KGV;>_&;[=-;]6.UM?^4$
M9Y^CEF?E1\V?>'[DWKU=(I&[+YYB>,M]N*>W*/-.3HPHHPHHPHHPHHPHHPHH
MPHHPHHPHHPHHPHJ/MJ=@K!]J9_"+/'Z_+$Y\FA/&+AZIGUR^L_9J5TD=\32S
M:Y[<5OV^;S5QED#Y@_,KWB^@T>71*2'2GM%$[K]55.UE,JG#4844844845$F
MZNQ?WXC_`%E\E8^3?SPC[I77JQJX?>#[/_RZ/PU#FG>W+/T?)>PER77YN',H
MNWI^T=_77!:#]HV^Y.=04WV5,J76C"BC"BH2WGV=B?31?,7F3.?)+YP6J_<Q
M?K*WTGF\?S4QXQ]1=1IIGMLGZ)D/7;Y(]\W_`)F4GWIM74EUR&@?:$=P7]6F
MXRJ+2Y4845B9[WBFO1,CYFMBI[B_C;H[WJM/E\>L&Y^;9'<'.U-(,G_!_1)Z
MX9>LG]E(Z3G4539T]#[U6&)?8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.OJC"
MBD5N?:^T>GI/SM3+N/)`YJ&[;W(L_D35-PO_`)\F>,N=L:;G7O8FL^BF_K#E
M4CE\<\O>1[TR^J*7'2_L]#[@FMQQHM;ZC"BC"BC"BC"BC"BC"BEYOMQLEXL[
MW3&J)-6*E6:;4VUMF,TT7">K861;INF\'!"X379/MMV:.6*HP;*$41AF2I9-
MZ0Q3,&D@IFG+):[!:6]=:Q:#T-95]GP5$@SW4$I4Z]@0I%N86"EY:2E4EU)B
M,*!$AZ-AO.+=<,:.<%#LU?Q`>@/\,C@'\$=<>@%:](Z>-I+R*\<>ZX4GN5'M
M6%_U8S=`1/;4"Q`PFFT7\FYZ#[MC"G46;3+Y<5)_K'92BX]=J]C]E&UN->\9
MI_>5*QXYU2X=P4G$VYY?_9%#:?-;F`2N,TC"'@E^&V,KT>3\*C>"X.PT\`ZY
M'\<?3M_ACH*/9<"CP$8CDA<ZWL'A_LRWU*1)*04Q43J-G'B5VKE!=M-LV<A&
M2<>[30?Q,U$2#=5J]9.4TG3-VBHBL0BI#%#-W76*Z::WV6JR7EHLW!B:`H8A
M22%-*4AQM:24.-.(4EQIU"E-NMJ2XA2D*!*[<FYU#V^K3CC9Q09W^3<V'Z"#
ML(.T'8:Y@>1W\BUZ]I1GP_$Y+3NO]N[?W1?>7*<M\TWF&:^\7MOKBWTO_=C?
M/0U9Z/OWXA6/)*]R?Q+MO3>\G=JI'R</B[;?Q)/DKU="'-3YI'(G\U\[[(TQ
MX>\[X>WCQ)7;)I^>][X77[T<YU4UQ[IE+XX#]4OC!`""IU2]<2!X0()^CK"0
M!_8Z>C(Y5$Y,N)R\.'0Q^G#Z:B:"E8!.)R8XX8[,?IPX,?NU\Y^U\U^+G[F<
M^UG'L)\^VOSJ/QT]45Z,_GD?CI[85W?]U/\`V:'`K]$K0_\`1S`97BY87.KW
MB^^=W\M>JQGIGV=@>)L][37WW8WS-J3^='E'^M5NO/GE8_'&?Z(L'^S]KKUL
M7FU/='>^KI^L;E6WHPHHPHHPHHPHHPHK)_@S%2_LM6%^OKRO/NMU[87]E-G(
MZS]L+KZ2E=_77O'_`&='XB>H*\V<W7M1A15??)'Y\W=N>F^6/]`:^.3W6\WW
M>EXOI[UN*T\WSK"Z;O>Z]G-[MWW>GZ?%1_5OY.9X;@O9W>7_`+N9/KNQ5^W3
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M7S@M5^YB_65OI/-X_FICQCZBZC33/;9/T3(>NWR1[YO_`#,I/O3:NI+KD-`^
MT([@OZM-QE46ERHPHK$SWO%->B9'S-;%3W%_&W1WO5:?+X]8-S\VR.X.=J:0
M9/\`@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@9<?.#_=E]L:=(CL!T
MA7WF'7U1A12*W/M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_P`^3/&7.V--SKWL
M36?13?UARJ1R^.>7O(]Z9?5%+CI?V>A]P36XXT6M]1A11A11A11A11A11A12
MJG6#C+8IB0D%"FT!?[;*V.6GG(E\JTYL&Z3"LA,R-ED%/WY]JZZ6&0,J9^X.
M=2MR"_45/[DJIC%+`E']Z]L8C1@?[R+;";8;93V-SAQ6@AI#"!L1/BLH"0R@
M!,YE&9"?#4*$S!2E41TA(*HJU$[!B4*.TD]$H)VX_P``\/6]CO\`N?=4)J5K
M58A--M.[*V;/%I^IZ%Y<#)W;K.JF5199TY*BZ4AZC6VIP=S,H9%1-BU`"E(L
MZ6:ME^;T+H.?K-V9-451]*VF/X3<9F3.F,P#@`E.*0[)?4.+BL!22ZYB2I#+
M;SK>VC0+C<`\FUL.2'6(ZWUA(V(:;PSNN*X$-I)2"H\*E)2D*6I*3`&Z=;*:
MYXE[[-*RQ;#=+PF[O6P[`@T]RXV7N,FI6XMTI"01%5D(*"CXN&:,F;<#*+F;
MM2*NEG+Q1PY64C0FJ4ZHWS:<$-GP:Q6\IB0F2KC%MQFP^XD.ND`NNK<=<==7
M@E`6X4,H:82VTA6^36QQ.^O3V8XNKN!4H\`*BTL;!T!@`!TMI)Q)YK>1W\BU
MZ]I1GP_$Y*ANO]N[?W1?>7*<U\TWF&:^\7MOKBWTO_=C?/0U9Z/OWXA6/)*]
MR?Q+MO3>\G=JI'R</B[;?Q)/DKU="'-3YI'(G\U\[[(TQX>\[X>WCQ)7;)I^
M>][X77[T<YU4UR?::KL5<-PZFJ,Z@=S!VK9M!K4TV275;*.(B>MD3%2:";E`
MY%VZBS)V<H*$,4Y!'I*("`#D7NN;G,LFB+S>K<H(N$.TS'VE$!02XS'<<02D
MXA0"D@D$$'@(PJ+_`$5;8EYUC:;1/25095RC-.`$I)0X\A"P",""4DC$'$<(
MKL6'N6^[\$1$-76D`$1'H#:6PN@/W`Z;`(]`?NB.0@CEV\I+#SO$_P#L(?ZF
MIA3R,]P/_P""Y/\`][*_6UCY;N8.[_;Q4HNGJ^T^,2CGRA!':.P!`#E:JB4>
MCW?Z!Z!#I\/@S)A\NKE(.3&6U7>)E+J`?\PA_P`8?^#1_P`&NX-'7IMDG,-H
M_P`\E<(VC_M:CSN]]A<G*AQ)X!0L)KW1+/C(7BKQ#9OMN7O;-HAKHM.6UK7:
M5-4F'HD30)IH:RMUWK$895S()L)-5\FDJNV4*<,Z;E*Z:W3WK?/O'GS[GJ%S
M>N=8:C4BW1+='=BAJ.IZ4U*<EN3&E<00EWPE*&5/,):4M#;J2DTO]E=FLVV$
MTVAH6\1F1G4LA6T!.4)"3MX,,3@<=I%-CW9`=7AQ2P\/@VERD#Z8.@?!RKW6
M'A`.D`'$;Y5YQWX3S_Z18/\`9^UUL;%YM3W1WOJZ?G&Y5MZ,**,**,**,**,
M**R?X,Q4O[+5A?KZ\KS[K=>V%_939R.L_;"Z^DI7?UU[Q_V='XB>H*\V<W7M
M1A15??)'Y\W=N>F^6/\`0&OCD]UO-]WI>+Z>];BM/-\ZPNF[WNOSY[2'N18^
M!DQY#(RON/S@A9<(J&;`]F948OC!RD?A%P[(5$0>R\B+?Q+5'KD\:N<A>L'3
MTY]<G2-X;:]XD+C&F>/T`ZWQCJLC3?&7ZP(XQU6!RMHS9G%8'*@$X'#"B[JR
MKB*P)PE`X#A.#3NP?=/0JNOD)S8D>7G'UBVD-`[)TE\2>7W=SRJ2E^1?)A,_
M&;EQ0VIF:97U>@!:NTO<0'S0I/*/*XAXV=G\G,KX@)$N0IN%B[E>6SHAV-J2
MU7_P^-J!LB&4'BN(M+JLQR//9DGC>*<)R<7);=93Q@1QAY+4UT5<=.2065M9
M2T>NZ.+@^X/HQ'T@@[."K+ZQVMK_`,H(SS]')W^5'S9]X?N3>O5TBDQLOGF)
MXRWVXI[<H\TY.C"BC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BH^VIV"L'VIG\(L
M\?K\L3GR:$\8N'JF?7+ZS]FI721WQ-+-KGMQ6_;YO-7&60/F#\RO>+Z#1Y=$
MI(=*>T43NOU54[64RJ<-1A11A11A142;J[%_?B/]9?)6/DW\\(^Z5UZL:N'W
M@^S_`/+H_#4.:=[<L_1\E["7)=?FX<RB[>G[1W]=<%H/VC;[DYU!3?94RI=:
M,**,**A+>?9V)]-%\Q>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>VR?HF0]
M=ODCWS?^9E)]Z;5U)=<AH'VA'<%_5IN,JBTN5&%%8F>]XIKT3(^9K8J>XOXV
MZ.]ZK3Y?'K!N?FV1W!SM32#)_P`']$GKAEZR?V4CI.=15-G3T/O588E]C3^H
M)]:&4#+CYP?[LOMC3I$=@.D*^\PZ^J,**16Y]K[1Z>D_.U,NX\D#FH;MO<BS
M^1-4W"_^?)GC+G;&FYU[V)K/HIOZPY5(Y?'/+WD>],OJBEQTO[/0^X)K<<:+
M6^HPHHPHHPHHPHHPHHPHJ".4+=%WQTW6U<H).6SK6ML;.&RZ1%T'""\2Y26;
MKHJ%,FLBLF<2F(8!*8HB`@(#BB;I''&=YUA>:44.HNL=25`D%)#B2""-H(.T
M$;0=HI3MRS;;V]K3K3R4J95=XP4"`007`""#L((X0:YUN'NSJ;:.5.B8O\I4
MS>;%%VMAKVK)6F3F)=_!5&H(3CAM4:DXE&:/32(52/>`BY1.NBZ<-U"&=.%4
M`!.3??;I.^6G=!J&7]E,6^V/0US)!CMM-H=DR2TE4F2EM1_SIT+;S(4$*;0M
M)#+:',5/LU38-SNB=UNL8&@0RS<[BQ)SC!PJ);426F"M/[&T4.AGBR8X4EU+
M:BH*`Z"^88"/&;<`!X1&K@`!^Z,I'9&QN1V;UK(?_P`;_P`FNF7\G39OMTZ3
MP>'?Y)RN1+<>V]<WC5^PX"IVEG-R;2-0643:M9,C14K"PUP'Q64HY8H1<BLS
M2DVBZB;=950K5XW<"'B%TE#S3Z'T7JC3^K;9<KS#7'B+=(!4ILJ&=E_)F;2L
MN("BVXE)6E(+C;C>/&-K2E9?F9:ZTIJ/D.;PK99)B)$MN+`)"4KRG)>;9G"'
M"D-N%(<;64H4I0;=:=(XMQM2HC[K"VUR=YK:H;Q,J@]75BMD.$T2).4E3MFE
M#EO&.BIN4$3BT4+((F16Z/%."*`=(QR](A(ON?LUTM^\BWN365-MA3@))20%
M*COX)Q22,PR*"D]D@C!82<!56GD_Z?O-KWLVYVX1U--)#Z224D!2XLG!.*5$
M9QQ:PM'9-J24N!*L`>C+FI\TCD3^:^=]D:8[#>=\/;QXDKMDT]O>]\+K]Z.<
MZJ:Y-.-LG8QY/Z*:NZ]',8,N^]5,V<RK9"F=R1#7"OND5V<.$.`"H=0#)&1,
MY!0@I','6*`":,+>E$M?]TNH7F9+KEP.G+@I308ZU!\&>20IWC.`#!04&\#F
M2-A)PCIW<P;-_7+3[\>8\[=#<X2ULB-@AL^%MI4E;W'<`&"@L-E)S)2<"3A_
M1WRKU5@*L7.>\DQZ+D/-%LR[?^WL=V1VPKY7V)Z54]]V5Q<9/>*7#3?D-N7>
M-(L]@X[<7'L[7*A=4"Z[L=<HNI*3`MZ58M>VJ)M=.7C)<(IPJYDF#&.L1?=!
M8B4BF4J7BWM\J[>X^QOBUSNYG6/3\^TQM3W]+3\F*?#6'Y=QE/*E,S([D>2'
M&^,0E##KK\(\2A2XJB5YN;L<`&WQI:774.%EK$!76D)0D92D@IP.&T@!6T]=
M3/\`=CCT\-Z4(```.TN4@@`=/0'3RKW7X`Z1$>@,2;E8;-^,\?\`I%@_V?M=
M9]B\VI[H[WU=/SC<JV]&%%&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LI
MLY'6?MA=?24KOZZ]X_[.C\1/4%>;.;KVHPHJOODC\^;NW/3?+'^@-?')[K>;
M[O2\7T]ZW%:>;YUA=-WO=?KSI:HOKAW?[%P"@MGW.VM,7()++-E1;O.-'*!L
MX!)RV41<ME115-U5$CD53-T&(8I@`0^.3XZN/9-Y$AK#C6]WCZTX@*&9-\L*
MABE0*5#$#%*@4D;"""11=0"Y#!X#+'>G:4/F3Q9UKQAXKZ_AZ%,;4LCN5YD\
M!V,U8]K[?V1M>P2[>+Y?:Z>10N%[S9)F/9NV1)4Z)G#-LU<.TB$%T=<Y>OCX
M/EV[WM5;V>7=I:;J-BSQ668=Z6TQ;[;!M[+:G+0^ES`1&&EJ2HMA00ZMQ#:B
MKBDMI.6N;U;`8@:8?2R7%$J;Q*UJ63@X,.R)^GH`8]'&G.K':VO_`"@C//T<
ML+<J/FS[P_<F]>KI%)19?/,3QEOMQ3VY1YIR=&%%&%%&%%&%%&%%&%%&%%&%
M%&%%&%%&%%1]M3L%8/M3/X19X_7Y8G/DT)XQ</5,^N7UG[-2NDCOB:6;7/;B
MM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJIVLIE4X:C"BC"BC"BHDW5V+^
M_$?ZR^2L?)OYX1]TKKU8U</O!]G_`.71^&H<T[VY9^CY+V$N2Z_-PYE%V]/V
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M4'=1\2['Z38[X*5+<C\7M-^F(W?$USW<4:#2F7)WC],LZO"M96MWN3-`2"#)
M))U#_')5X_M2<>J4`%LA//3BLY3+T)G4'K=4!\.25;XM1WY_=-J2"_+?7#E6
MYOCD%1*7/!@E$<K'\(LH&5"CM"=F.%2<;\-*Z<C[J+[<&(4=$V);)A96$`*:
M\*<2N1D([$.KZY8&PJVD8BK[N88B'&;<`AX!"K@(#^[[J1V1T;D?BM9/&_\`
M)KJ-_DZ;=]NG0?Y]_DG*Y-=\T^K0FG+0XAZ_%1JT/"!&1)V;-)'W,CIBUP$A
M*,F!2AU&C9^\9(G4(0"@;Q)"_P""0I0F4W=7N[S]<1&ILEYU#\CC'`I1/&+;
MCO(;4OHJ4A*E!)..&91X225[^:!I^R6WD(:Z=@166ELPH+;>5('%H=O=M6XE
M&'8I6I""H)P!RI'`!A!7==U^#8\V=/O&42Q:NHZN[$AF#A!`J:S2(7I<\]5C
M$3AX2L3.T2J`G_@D,'TO0'2&22;F;E<)&\:"P^\XMEUYUU:2<0IP1GDAPC^/
ME)&;A(.W&JIG)WN]TE;UX,>3(=<8><D/+2I6(6\F&^@.J'17D)25<)!VXUT4
M<U/FD<B?S7SOLC3';;SOA[>/$E=LFGQ;WOA=?O1SG537(QQKI<DERQT)83V)
M55M_6!UK)^3"$R+Q5LZN40V1@%A5L*M?"&8&<%.EXJ-37Z4B?3]83G-&EO3O
ML5>YO4=M3%2'?ZMSD9OR64*3&<47A@R'N-7@0K,^4=<KK<,J1'[NZU+"<U-8
M;0F&E+WVC`;S?D<@4F6RHOIPCB1QS@20K-(4CKU=;ERI3_23RK54]U8N<]Y)
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MQ?WXC_67R5CY-_/"/NE=>K&KA]X/L_\`RZ/PU#FG>W+/T?)>PER77YN',HNW
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M;8%E6;D44G`)'5:Q"[<X^)7(;I(<P>'U>G%*M&Y_>3?K8S>;1:G7K9(1F;<"
MV0%)Q(Q`4X%#:"-H'!2O6+<+O<U-9X]_L5E?D6>4C.TX'(X"TXE.("GDJ&U)
M&T`[*F6KV>"NE>B+56)%.6K\\R2D8F213712>LEND4ER).DD'!"GZ/4.0IOW
M,X:[VFXV*Y/6>[-%FY1W"AQ!()2H<()22DX?<)%)M?+'==-7>18;XRJ/=XCI
M;=;)22A:>%)*2I)P^X2/NUGLUU:JO,]>M8YD[D'JH-V;!JX>NUS`8Q46K5(Z
MZZIBD*8Y@32((B``(CT>`,]8[#LI]$9A.9]Q82D?2I1``V[-I.&VO>+&?F26
MX<9)7)=6E"$[.N4HA*1MP&TD#:<*5:2YS\4(B,>S,CN.%;1L<S7D'KHT-;#E
M09MD3.%US$2KYU3%31()N@I1,/1X`Z<6"+R?=\4V6W!BV-]<IU80E/&QQBI1
MP`Q+P&TG#:<*4W5VY+>GH/3%QUGJVSO0M,VF&]+EOJ<84EF/'0IQYPI;=6M0
M0A*E$(2I1PP2DG92N[?[R3A'L[5M_P!?43?D!8;C<:G-P%:@V]=O39>4EY!@
MLBS9).']6:,D3KJ#T`955,@#ZHABMZ*Y+6_S2>KK;J74.G),:QP9K3S[JGHB
M@VVA8*E$(D*40!MP2DGZ!2'\G7E';E=2;]M)6&R7UE^[S+]$:9;#$I)6XIT9
M4XJ82E./TJ4!]VJ_^+7SB],_+F-]A=8Y'>[\,+[Z/7U4U.-OV^#FI?1;G535
MW_,3YLNX?DL'PI'8P+<A\5[)XW_DUU&!R<_C=ISQ[_).5RL<COY%KU[2C/A^
M)R8#=?[=V_NB^\N4Y+YIO,,U]XO;?7%OI?\`NQOGH:L]'W[\0K'DE>Y/XEVW
MIO>3NU4CY.'Q=MOXDGR5ZNA#FI\TCD3^:^=]D:8\/>=\/;QXDKMDT_/>]\+K
M]Z.<ZJ:Y6N.7SAM!_GLU1^/M?R*W>?\`#/4?H&X>2/5&=NU^(EA],0_*&Z_H
MHY6/JP[6+G/>28]%R'FBV9=O_;V.[([85\K[$]*JL>[DY)Z#H7!_N^M57#;=
M&@-D6GCQQ^K4)2GTZU"Q.9RQ:]K#F`8+QJ1E5XT\TG*LRM3N@1375?-4B&%1
MR@11WO*@W6;QM1[_`/>5K"R66X2=+P]37A]V4AI7$I:9F/I>6%G`+#1;<+@;
MS%"6G5J`2TX4Z"RSHC-JAQW'$!]3+8"<=N)2,-G0QQ&&/TCZ14T=V.`APWI(
M"`@(;1Y1@(#X!`0Y5[KZ0$/V!#.$Y6&W?C/(X/LBP?[/VNLJQ>;4]T=[ZNGZ
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M'^LODK'R;^>$?=*Z]6-7#[P?9_\`ET?AJ'-.]N6?H^2]A+DNOS<.91=O3]H[
M^NN"T'[1M]R<Z@IOLJ94NM&%%&%%0EO/L[$^FB^8O,F<^27S@M5^YB_65OI/
M-X_FICQCZBZC33/;9/T3(>NWR1[YO_,RD^]-JZDNN0T#[0CN"_JTW&51:7*C
M"BL3/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVII!D_X/Z)/7#+UD_LI
M'2<ZBJ;.GH?>JPQ+[&G]03ZT,H&7'S@_W9?;&G2([`=(5]YAU]4844BMS[7V
MCT])^=J9=QY('-0W;>Y%G\B:IN%_\^3/&7.V--SKWL36?13?UARJ1R^.>7O(
M]Z9?5%+CI?V>A]P36XXT6M]1A17-URW^<KN+Y5)_`D1DI&YCX5V/Q,]]<J9[
MD^_!73GB![\[5X'$[YMVFOD-$_6J8P+?)\4K[Z0<_!48&_[XSZD]*._@IA<3
M2D@K5;WV'N7R4L7P0\S<:=]H(/CC/?$UOM*^U%M\?C]^17'[LVPU]77UV@4I
MV%4G%M=VF01A4Y5@>758,H]ZP>/4HTK@7JC1H^3,BJJ!!(FJ42&$#`(9-GI2
MV7)&I8%Q7'?%O3<XZ"Z6UAL+4M*TH*\,H4I!"DIQQ4DA0!!QJ4/EFW:U.<E[
M>9;$26#<E:$ORPT'$EPH1"DH6L(QS%*5@H4K#`*!23CLJLO1O\KNO?E,P^N-
MCKMX'L5<_%%U3]Y"//*W9^^-M[^FN@SBW\XS3/RZC?8761K[W?AA??1Z^JFK
MI6_7X-ZD]%.=5-7?\Q/FR[A^2P?"D=C`MR'Q7LGC?^3748/)S^-VG/'O\DY7
M*QR._D6O7M*,^'XG)@-U_MW;^Z+[RY3DOFF\PS7WB]M]<6^E_P"[&^>AJST?
M?OQ"L>25[D_B7;>F]Y.[52/DX?%VV_B2?)7JZ$.:GS2.1/YKYWV1ICP]YWP]
MO'B2NV33\][WPNOWHYSJIKE:XY_.'T'X0_ELU1X.D.GM[`?L>KD5N\_X9ZC]
M`W#R-ZHSMVOQ$L/IB'Y0W7]%'*Q]6':Q<Y[R3'HN0\T6S+M_[>QW9';"OE?8
MGI5S'\8*A6'.JN[PV&OP?V5>IN!TCW>U.2Y*T.PWE^U2E9U?5\U&/+UI5@@S
MH5PU55XZ)49/;<J:=D*O,1+55ZQCVK6.E$Y8-[5ZNS6L-YNF6]?VJWP)%_UE
M)-CELQ$*+;0GM.)B7195,C7"0MP.M6Y(B,SXTAY#$B2\])AJX:`VV8\-XQ5K
M6&HXXU)5PG*1F1V)0`,"OKBD@8@`)55QW=F!T<.Z:'3UNC:O*8.MT]/6_P#J
MMW9X>D1'IZ<8_P`JWXW3NA_Y/8/]G[7726/S:GNCO?5T^V-TK;T844844844
M844845D_P9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_LZ/Q$]05YL
MYNO:C"BJ^^2/SYN[<]-\L?Z`U\<GNMYON]+Q?3WK<5IYOG6%TW>]UA^\2A0L
MB_"FM"+TH63F,2NB,:NV:R0>[O$_E;$_]FNGA3LFLC_CG[PJL`HIJ]4QPZH#
MF;R99WV6WKVZCB_\UT.7NO"E(_(ZAT\YUZ4X*4CK>O2GKE)Q"=I%?-Y3G,5&
MWKI.&SAVM.C9]VJU-CUS8M>XE5(EDU1R=TE0QY8=W!&T'6O([=]-W*I63P/+
M2A1$PPJZ;)U8MA5$4R-4!6;R<Y(1"C8S?W+(DB3Z:1_D;733%RY>VD56J\Z3
MO^HN*U"N9.LEJDVP/AZU/.-K?*DLPY.)4O*MB*S)2L.>%J6XK9R&H4/(TO(S
MMOM-8M!*7%I7A@L`X<*ATBHC##+LJUJL=K:_\H(SS]')Q^5'S9]X?N3>O5TB
MDULOGF)XRWVXI[<H\TY.C"BC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BH^VIV"L
M'VIG\(L\?K\L3GR:$\8N'JF?7+ZS]FI721WQ-+-KGMQ6_;YO-7&60/F#\RO>
M+Z#1Y=$I(=*>T43NOU54[64RJ<-1A11A11A142;J[%_?B/\`67R5CY-_/"/N
ME=>K&KA]X/L__+H_#4.:=[<L_1\E["7)=?FX<RB[>G[1W]=<%H/VC;[DYU!3
M?94RI=:,**,**A+>?9V)]-%\Q>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>
MVR?HF0]=ODCWS?\`F92?>FU=277(:!]H1W!?U:;C*HM+E1A16)GO>*:]$R/F
M:V*GN+^-NCO>JT^7QZP;GYMD=P<[4T@R?\']$GKAEZR?V4CI.=15-G3T/O58
M8E]C3^H)]:&4#+CYP?[LOMC3I$=@.D*^\PZ^J,**16Y]K[1Z>D_.U,NX\D#F
MH;MO<BS^1-4W"_\`GR9XRYVQIN=>]B:SZ*;^L.52.7QSR]Y'O3+ZHI<=+^ST
M/N":W'&BUOJ,**Y5>\!B=TR?*7<1M;VR&K40T.[73;KQ48_DIFX$AV8QL>\=
MS+&0;1,"J?R055T4E5?)RNT^H"JK9=O,#R;IN@XFZ*QC5,-^5-6$@D..(0U&
M+BLZTI:6A3CP'&94*4E.<LJS9$.MN2M;K(.\.9NATXK2<UB)`;LCB@DMH6X[
M)#[_`!:%J=0M+;1/%YEI2I?%A](2%K:=:Z(>)'C@XT:4!P*1G'Q!A?*#(%.5
M`5_%&\<*)5#&4*B*G3U0,(F`O1TCTY&9OGR?WJW[BL>*^T7<,<,<,=F.&S'#
MAPV8TP#?SQO]\>HN.R\=]IN9L,<,=F.&.)PQX,2:8G$QI)*U6]]A[E\E+%\$
M/,W&GO/\'QQGOB:WVE?:BV^/Q^^HKAQGJS0DC[1<5RC;2C92.7V%+S4]8XN5
M-2!L"E$M:+M>OR+Z;`[>/D4KLY6:>*16CE#/%`(D53JG1L`VZZZB6FT-W2X6
MAV(ZF&VTRPXWX5Q(EQRD/(0U@I:#%0ES,I+P#2<RRG%+CY^5;:M-HW$[UEVJ
MW7=F6WIK4;KKSZ'?!2^;3."E,K6Z,J%B6XMO*E3!+B@E`7@IM-./C>VEWE2%
M9:5KZT+\<4P8L(^$?H20L#&Z6!G4HXG'#<':/2(+`5KU%.KTE$G6Z"KGO*<L
MQW?W!$)F2F=X"<ZUNH*,_P##RMAH'*>%.+F(QP(.&)JY<AUW3ZN5WNP;M[$M
M-R_K;:\[CC[:F^,\(3QF5I+"59#L*"7<4XX$*PQ-X/#=AO9IRUX^*66;K4M4
MGFS+*ZLS=NV:-)"&0(,XA18V`,WCD324(]8G:+KBY,609NDE2*+.DEB^(8%O
MQD;O7MS.I4VJ/+9O*+4PE@J4I2'2>*,M;V99R.I6'$(R`LN-J0I*&5H/&6Z-
M\$;>6QNWOBKK(B/6-R#/5(`"4K:2'"(C;.#8*VE-EM:N,/'-N)4E3CR%CB^B
M[F'T?U9MP=/3T?%<O3T>KT>ZD=T]'[O1D8FY''^]:R8</A?^373">3IC_?;I
MW#A\._R3E<=VT(G=[+6]R?;#ML!-PKVONQDH:*B(^/9P<D2VU+XNI0;ANS),
M29%4?=$[A=XN4I6HM$?$BY37<K3=Z2FZ!?U3!CZ9A28\]N2G(ZXXM:G4&/(X
MXNI*BVV0>)"$-H)+G'+SAI3;2%.^9+`WBQN1!KV1JB;'D0'(,3.TVVA"&7/M
MNU<0&5!/&N`CCRM3J@`WQ*`V7$N/.1=W4S>_M^;^G`L;^+D(X]8V:M)G;)-T
M'3>P*4R2*V9-B-VJ*;F%2;$<G06^D7*"@)K@H8I5!D0W2NZ;<WAPC:VWFY0D
M+#845%*F1%D9E*S*)2Z5%`6G:@E)4V4@E-5D=P[VDGMZ<(V9I]F8'70V%%2D
MJCB'*S+45*)2\5%M*T;4$I*VBA*BBNDKFI\TCD3^:^=]D:8Z/>=\/;QXDKMD
MT\K>]\+K]Z.<ZJ:X\N,TE32\R=%(,:DP;V-YR2UNU>3:HP[F;,\9V6'(\?DB
MRO?=Z(B7K=D!2/A3\0MU@,)/W\#C'1O6BWP[C=0N2)KBK6C2TY26AQJ6LJF'
M,J.,R\2XXDK)+6.=.&`5^3RTQC=]"U(JZ:?=E7!U=F;EV]2&1QR6<BYS)0V7
M<G$.NH4LDLA6=&!`5^2*:_I<Y54J=.L7.>\DQZ+D/-%LR[?^WL=V1VPKY7V)
MZ55!=V]P\T#=N+O`KDO:J@[F]JQ'$7C+&Q3YW8[`$%&NJ#78^:JUA95E&12A
M6]E8+N?$J.RI`9VU322<`J5%+JO7Y4>^[>/8=[>\7=59YJ(^CWM:7U;B$L,\
M<M,QY;4AE;Y075,+"<P;*L&W%+6V4%:\><LMMANP(DYQ.,@1F@-IP&4`@X8X
M8_=Z(X>"F7[L<1'AO2A'PB.T>4@B/[8CRKW6(XE7*P&&_&>!P?9%@_V?M=9U
MB\VI[H[WU=/UC<JV]&%%&%%&%%&%%&%%9/\`!F*E_9:L+]?7E>?=;KVPO[*;
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M44845$FZNQ?WXC_67R5CY-_/"/NE=>K&KA]X/L__`"Z/PU#FG>W+/T?)>PER
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MW,?"NQ^)GOKE3/<GWX*Z<\0/?G:O`XG?-NTU\AHGZU3&!;Y/BE??2#GX*C`W
M_?&?4GI1W\%,+B:4D%:K>^P]R^2EB^"'F;C3OM!!\<9[XFM]I7VHMOC\?OR*
MY%-H?R4WKY#6#X%=9-+I+VQM_I!GOJ:E3Y9_-0WG>Y%\]7R*JTT;_*[KWY3,
M/KC8[S>![%7/Q1=4[>0CSRMV?OC;>_IKH,XM_.,TS\NHWV%UD:^]WX87WT>O
MJIJZ5OU^#>I/13G535W_`#$^;+N'Y+!\*1V,"W(?%>R>-_Y-=1@\G/XW:<\>
M_P`DY7*QR._D6O7M*,^'XG)@-U_MW;^Z+[RY3DOFF\PS7WB]M]<6^E_[L;YZ
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M\F_GA'W2NO5C5P^\'V?_`)='X:AS3O;EGZ/DO82Y+K\W#F47;T_:._KK@M!^
MT;?<G.H*;[*F5+K1A11A14);S[.Q/IHOF+S)G/DE\X+5?N8OUE;Z3S>/YJ8\
M8^HNHTTSVV3]$R'KM\D>^;_S,I/O3:NI+KD-`^T([@OZM-QE46ERHPHK$SWO
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MMC;_`$@SWU-2I\L_FG[SO<>^>KY%5::-_E=U[\IF'UQL=YO`]BKGXHNJ=O(1
MYY6[/WQMO?TUT&<6_G&:9^74;["ZR-?>[\,+[Z/7U4U=*WZ_!O4GHISJIJ[_
M`)B?-EW#\E@^%([&!;D/BO9/&_\`)KJ,'DY_&[3GCW^2<KE8Y'?R+7KVE&?#
M\3DP&Z_V[M_=%]Y<IR7S3>89K[Q>V^N+?2_]V-\]#5GH^_?B%8\DKW)_$NV]
M-[R=VJD?)P^+MM_$D^2O5T(<U/FD<B?S7SOLC3'A[SOA[>/$E=LFGY[WOA=?
MO1SG537*UQR^<-H/\]FJ/Q]K^16[S_AGJ/T#</)'JC.W:_$2P^F(?E#=?T4<
MK'U8=K%SGO),>BY#S1;,NW_M['=D=L*^5]B>E7/]PUOO/RK<?N[8CM:4NBJ\
M3G>B>'S>R7TQ(*0FDVEHB-;U*X5:V1CZUHW5HL"LE*.(U]`0;U)-PI%>5JIM
M"RBB<D6_+3G)QN^\G>G*U5/N"=\B-0ZD+$/%U#14PY.DQI$=Q$<Q5#!$=#[4
MR4TI2!,XE"GC$2KD+8]=VX<%+"4?9Y:9Q5LQVA(((QS=$D%*3MRX[,U6.]V2
M`%X<TL`Z>@-I\I0#IZ.GH#E9NL`Z>CP=/1^UC7N5>2=^$\GA^R+!_L_:ZW5C
M\VI[H[WU=/QC<ZV]&%%&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'
M6?MA=?24KOZZ]X_[.C\1/4%>;.;KVHPHJOODC\^;NW/3?+'^@-?')[K>;[O2
M\7T]ZW%:>;YUA=-WO=>;GXZDF$YP3?PS%O*3,?S:BG\-%NWR<8TE)=EQ<Y3.
MHN-=R:I%$HQK(/TDT5')RF*@0XJ"`@4<]>3BS%D6_>'&G.*9@N:!<0ZXE!<4
MVVJ_V!+BTM@@N*0@E24`@K("0<37Y=RH+B%(Q4)0P'!B>*=P&/0Z=5H[LY1<
MB.2.BWP;LT@RT["5/F=W=9JDB"[(9=:1?\OJ5'S42^,TO%O3L;,6<.UE&\L@
MWBFB99#R`I':K95V:2#D1;H]V6ZWEHZ`.@K^Y?)\V%?_``DX*XL(1:'%M.(S
M18Q85F=<87'6N0XHL^$E3*'4,CD-23YDW3LKPIH-)2IK#Z<>,&([(X\`..P;
M<-N&-6G5CM;7_E!&>?HY.=RH^;/O#]R;UZND4FEE\\Q/&6^W%/;E'FG)T844
M844844844844844844844844844845'VU.P5@^U,_A%GC]?EB<^30GC%P]4S
MZY?6?LU*Z2.^)I9M<]N*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG:RF
M53AJ,**,**,**B3=78O[\1_K+Y*Q\F_GA'W2NO5C5P^\'V?_`)='X:AS3O;E
MGZ/DO82Y+K\W#F47;T_:._KK@M!^T;?<G.H*;[*F5+K1A11A14);S[.Q/IHO
MF+S)G/DE\X+5?N8OUE;Z3S>/YJ8\8^HNHTTSVV3]$R'KM\D>^;_S,I/O3:NI
M+KD-`^T([@OZM-QE46ERHPHK$SWO%->B9'S-;%3W%_&W1WO5:?+X]8-S\VR.
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MMRP;I]XEGTENATY`F,39$E-F7)7Q#04EIA#T@J==6M2$(2$MN'$JVE`0`77&
M4.=#7$A9-QQHTHX1,)D5Z#"KI&$IR"9)9(RB9A(H4BA!,0P#T&`#!Z@@`Y&A
MOG0IK>K?FU[%IN3H/`=H.!VC8=O1&SZ*CZW\N(>WQZB>;VMJN;A&PC8<"-AP
M(Z1VTQ.)C225JM[[#W+Y*6+X(>9N-/>?X/CC/?$UOM*^U%M\?C]]17$_=AWP
ME&W<]I4KR5"4AKW%L6T0D5Z1_6E*O=9>%FWZQ8=.6A[.W63B61DU%RQ8I)N1
M$5'"S<1GHL/]W:Y4!-H$DZC#\1Q:G#E*'P_%;=:0.,+;K!!D.@A!?"E-`!+:
M'*D%Y7B]XZ>3YO/-Y5%&G/ZHZA;0EH9PN.;=<'&G5GBPXW(2?!F2"L1\J7<2
MIU;6*#<?+5$RN\:/#LB3!G;*XD8.E5J]/-(Y)VP,/E*`RSJ.1C#'`#`).A40
M5`P"3K`("+C-Y5GF0]W]PFOE@,N02M(#S*EE*^Q/%I67/IQZWK<"%88&JJG(
M=L,^!RO-V%QDF,([NK;4M(3(86X4./IRJXI+A=PX<<4=:00K`@U>7PXWI2+-
MRQT%5&:4\TEK%LB<;5SW3C$VC6?94?W:9V*;BURO%Q4C&,E&*M5"*%3>(+BE
MX]ND1=$ZD?F_#=]?[5N;U'>'S'7#BVMI3_%N%2F52N*4RTX,HP<6AQ+B2"II
M:,_%N+4VXE-N_?!O+T[=MV=^L;*9+<V5`FH8SH"4O)B+R/.MG,?R:'$%M04$
MNH44<8VA+C:E]$G,,!-QFW``>J-7*`?1&4C@R,K<B<-ZUD/_`.-_Y-=,"Y.A
MPWVZ=)X/#O\`).5QZ;9WG2;WK*PUV)3G6<K8JV]LD$A,1J3():K5^U5E@O96
M)TGKH%8IV\DB(D#P.4%B'2=(MU>J0TW&C=WU_P!/:KC7.88ZX<:4EATM+*N+
MD/1WUAA>*4X.)2@J/_9K20ME;J,5!4OF5[RM/:FY#VN+3"3(;FR8$1]I+B$I
MXR.Q>K6@OI(6KK%*<2D`X.(5BAY#2\$F+>ZGOT#8^;NGH]B210>2-:V3/,D7
M[0C<SF$;4F4;IRJ(D<+D49O%9`A4^@1.0Y#D6*DH7J9(ANDTY<;7O$@R9!:4
MPT^XRLH459751I"BV<0"%)""5=`@I4@K2<U5BMPVD[K9MZD&9*+*H[+KS"U-
MK*LKRHDE1:.*4D+0&R58C*04J;4M"LU=(O-3YI'(G\U\[[(TQTV\[X>WCQ)7
M;)IYN][X77[T<YU4UR6\;G-D)RHT4W>2U6]R#;XU05A%LXR26L1V*EOKZJ2C
M]R$P=LQ.F[*<#*BT\0=,I?"4Z@`$8V])JUJW0:A<89F>&C3MPSN*<0&0L1G@
M0A/%9E@IPP2',X43L(228[MW+-E5JS3[L://^T1=(>=U;C8CA8EM@AM/$A2P
M492$AW.%%6Q24DG^C]E7:I_:Q<Y[R3'HN0\T6S+M_P"WL=V1VPKY7V)Z5<\_
M`?5%WGZQW?MX8\>]NW"JL.%_#)R;:I>9-XUOI:&7A&B0RTE'Z#KJ9F$[L.HM
M1*:38NSIQEFB_)2J%54!<4Y+^49K&P6Z[;R=/R-2V6%=W-=ZG3]G_P!68DZZ
M.AU1XM"[N\<[4*2K$,.MA3\%_C2DH26PKCK1'=6W#=#+BFQ%9Z_CE)0,.$AL
M<*AT0=BAA]VK,^[)'IX<4L>GIZ=I<I!Z>CJ]/_U5[K\/5#P%Z?VOV,:ERK_C
MA/\`1%@_V?M=;RQ^;4]T=[ZNGYQN5;>C"BC"BC"BC"BC"BLG^#,5+^RU87Z^
MO*\^ZW7MA?V4V<CK/VPNOI*5W]=>\?\`9T?B)Z@KS9S=>U&%%5]\D?GS=VYZ
M;Y8_T!KXY/=;S?=Z7B^GO6XK3S?.L+IN][K]^<S=N[N?=^,W:"+IH\YX5AH[
M:N$B+-W31UQJY/H.6KE!0IDEV[A!0Q%"&`2G(80$!`1SSY/KKC-BWDOLJ4AY
M&[M]25))"DJ3?+"4J21M"DD`@C:"`1MK]NH!=A@\!ECO3M*]SBXR\?.,W%76
MM:T%IS7NIHE;F5P,8.R4JL1D.^DF#+E[K9_&L)>700"7F&40O*+@R2=+K$9I
MJ"FB!"`!0>C\M_>OO*WK<N_3-UWCWRYWF:F'>5I,I]QU"%KM$A"UMMD\6TIP
M-HXU3:$EQ0S+*E8FN=U?!AP=,/(AM(;3F;[$`8_E!AB>$X8[,>#H4V-8[6U_
MY01GGZ.6)N5'S9]X?N3>O5TBDELOGF)XRWVXI[<H\TY.C"BC"BC"BC"BC"BC
M"BC"BC"BC"BC"BC"BH^VIV"L'VIG\(L\?K\L3GR:$\8N'JF?7+ZS]FI721WQ
M-+-KGMQ6_;YO-7&60/F#\RO>+Z#1Y=$I(=*>T43NOU54[64RJ<-1A11A11A1
M42;J[%_?B/\`67R5CY-_/"/NE=>K&KA]X/L__+H_#4.:=[<L_1\E["7)=?FX
M<RB[>G[1W]=<%H/VC;[DYU!3?94RI=:,**,**A+>?9V)]-%\Q>9,Y\DOG!:K
M]S%^LK?2>;Q_-3'C'U%U&FF>VR?HF0]=ODCWS?\`F92?>FU=277(:!]H1W!?
MU:;C*HM+E1A16)GO>*:]$R/F:V*GN+^-NCO>JT^7QZP;GYMD=P<[4T@R?\']
M$GKAEZR?V4CI.=15-G3T/O588E]C3^H)]:&4#+CYP?[LOMC3I$=@.D*^\PZ^
MJ,**16Y]K[1Z>D_.U,NX\D#FH;MO<BS^1-4W"_\`GR9XRYVQIN=>]B:SZ*;^
ML.52.7QSR]Y'O3+ZHI<=+^ST/N":W'&BUOJ,**YL^7K1JYY*;D!RU;.`-90;
MF!=!);K-U8:$.J@;QA#=9!0Z1!,0?I3"4!$.D`R4S<H\\UNKL?%+4G"+CL)&
MT.N@'8>$`D`\(Q/TU,QN"CQW]RNG..0A>-N4G:`>M+[N(V]`X#$='`5>/Q/^
M;=IKY#1/UJF1_;Y/BE??2#GX*C&W_?&?4GI1W\%,+B:4D%:K>^P]R^2EB^"'
MF;C3OM!!\<9[XFM]I7VHMOC\?OR*XSKMJ>B0%5V?>(Z(<!:)BMW&7<R;J9FG
MOB',M6U&L@BP9NI!5@R8N`2,H"!$@33554,0"];H"<VP:RU%<KQ:=/RGT_9#
M$J,VEM+32,4MOA2"M24!:EC$#.59BE*0HG"I)>5]H?3EJY->]74<1E?VO(T;
M?W%+4ZZO!3MN?2L(2I92E!PS9$@)"E**0,:KZT;_`"NZ^_=LS#I_=^F$/#^W
MX`QR>\#V*N7BBZJ-\A'GE;L_?&V^4)KH"XM,6)>2&E%BLF95D+\W605*V0*J
M@L^2=B^614!,#I*O1$16,40%41^F$<C=WNR)!W77Y!<7D5;5`C,<"$%.0$8X
M$)_@@[$]#"KH6_2)%3N?U&Z&VPXFV/$'*,05J25D'#85':HCAZ-7D\Q/FR[A
M^2X?"D=D?NY#XKV3QO\`R:ZC)Y.?QNT[X]_DG*Y3N13)DEIJZ*I,VB2K=BV*
MW53;($40*^LD.N]*BH4@'2*]7(4ZP%$/&G*!C=(@`Y,+NQD/KUS`0M:RA3BL
M05$@Y&'0C$8[<H)"<>Q!(&`IQ7S2XL5OD'Z]<0V@+3&MX!"0"`N\VY2P#ALS
M$`J^DC$U`G=B(($YI:I,1!$ADXW81$S$13*9,BM%L*BR:9BE`4TUE"@8Y0Z`
M,8`$>D0R2C<HXX=Y5N"E*(*G2<2=I$=T`GZ2!L!/`-@JI=R<775;W+<%*40I
M,@G$DXD17@"=NT@$@$[0"0-E="O-3YI'(G\U\[[(TQX.\[X>WCQ)7;)I^&][
MX77[T<YU4UR0<;-?0S?E3H.R$7>"Y+R#UM/$;"C#E*64D;G$-'2AY-.))87#
M,4G9^HU4>';D'J@!>J0A2QG;T]2SG-T&H[6I*.*_JU.9*L7?S:(KBD@-EPLA
M6*1BXEH+.TXXJ43'QNZU=<GM5V&RJ0WQ)N%O8*LSV/%-RF5I`:+ICI7BA.+J
M60X=I*LRE$_TB\JW5/G6+G/>28]%R'FBV9=O_;V.[([85\K[$]*D@[K7^S?X
M-?HMZ6_$6&Q?N5USHMX/O==/*W:U=A\RQ?%T=J*_#NQOF;4G\Z/*/]:K=>>G
M*Q^.,_T18/\`9^UU^6+S:GNCO?5T_6-RK;T844844844844845D_P9BI?V6K
M"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_LZ/Q$]04CW+CF?%\4'U%8R.OY.
M[C=VL^Z24CY]E"A'!`JQ*1R*E=Q[T7`N?=4!`2]7J]0>GIZ?`\GD;<AZZ\K^
MWZ@GVW4<6PBPO1&U)>B.RN.\+3(4"DMO-9,G@Y!!S9LPPPPVM^WY<H"'N3DV
MV-*M;UQ-Q0\H%#R&N+XDM`@YD+S9N,V8888?=K&<2^<$5RKLUOK4?KF5I1ZE
M!1TXH[D+"QF2/B2$@JP!LFDUCF1D#I"EUA,(F`0'HZ,VG+%Y!=WY(FE;+JBY
M:FB7UN\W!Z*EMF&[&+1992\5E3CSH4%9LH2`"",<:Q-Q_*+A;ZKQ/M$6TO6Y
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MQ?WXC_67R5CY-_/"/NE=>K&KA]X/L_\`RZ/PU#FG>W+/T?)>PER77YN',HNW
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M/+WD>],OJBEQTO[/0^X)K<<:+6^HPHKFZY;_`#E=Q?*I/X$B,E(W,?"NQ^)G
MOKE3/<GWX*Z<\0/?G:O`XG?-NTU\AHGZU3&!;Y/BE??2#GX*C`W_`'QGU)Z4
M=_!3"XFE)!6JWOL/<ODI8O@AYFXT[[00?'&>^)K?:5]J+;X_'[\BN13:'\E-
MZ^0]@^!'632Z2]L;?Z09[ZFI4^6?S3]YWN/?/5\BJM-&_P`KNO?E,P^N-CO-
MX'L5<_%%U3MY"//*W9^^-M[^FN@SBW\XS3/RZC?8761K[W?AA??1Z^JFKI6_
M7X-ZD]%.=5-7?\Q/FR[A^2P?"D=C`MR'Q7LGC?\`DUU&#R<_C=ISQ[_).5RL
M<COY%KU[2C/A^)R8#=?[=V_NB^\N4Y+YIO,,U]XO;?7%OI?^[&^>AJST??OQ
M"L>25[D_B7;>F]Y.[52/DX?%VV_B2?)7JZ;-L:F=;XUI>-+L9MO6WFSJ^ZJ#
M:?=LE9)M$*R1T1*^78(N&BKQ-+Q7A(55,1Z?\(,<IRCM6M:!W":OUN^PJ2S:
M;%(E*:2H(4X&0E90%D*"2K#`**3A]!J2#46E'=<V*5HYEY,=VY,E@.J25!!6
M1UQ2""H##@!%5]ZS[A6]4'9&O+XOR2J<DA2+U4+@M&I:WF&RL@C6;#'3:K%)
MR>W+$;J.R,13*<2&`@FZ1`>CHRM[JOYBNGM1Z6N>G6]+3&G)]ODQ@LSFU!!?
M96T%E(C`D)*\2,1CAAB*1W3'(0O&GM26^_+U%&=1"FL/E`B+!4&G$N%(/''`
MG+AC@<*Z5,BNJ2&L7.>\DQZ+D/-%LR[?^WL=V1VPKY7V)Z54B<`^<=-UMQBX
M`<=/R;[+LUJ<<<^+2%HFXIC`L:[5ZILFNZEJ54O#16;G8V1N\4O>=D-(IRT@
MV[Z29F82+A5N"#3KJO[Y1W)_OFJ=[.\C>=]J6J)9TZGOY8:<6\MY^1!>N,F1
M%4&FEHBN")!<D-N2EM,.AZ*VAPN/94<M:+JTQ!APLBU.<2UB1A@`H(`5M(*A
MF4`0G$C!1PP%.MW9`=7AQ2BB(")=I<I`Z0$!`>CE7NL.D!#P"&(-RL#COPGG
M_P!(L'^S]KK:6+S:GNCO?5T_.-RK;T844844844844845D_P9BI?V6K"_7UY
M7GW6Z]L+^RFSD=9^V%U])2N_KKWC_LZ/Q$]0515WPWO_`*%]$[#\[J&3I_)5
M]GMX?CEG[W<:CGY>/G33/<)W;Q:UCN@?Y4MR_(&N?C$[SJOG0_";1'O%-\C;
MK4<A+VSO_HQCOZJ>_DC\^;NW/3?+'^@-?(<=UO-]WI>+Z>];BI'9OG6%TW>]
MU[.;W;ON]/T^*C^K?R<SPW!>SN\O_=S)]=V*OVZ?G8?C8[V[6B]ZBY;+\=]=
M(HN$%E6O-?@BFZ225344;*'Y6:D6(FN0AA,B<Z)RF`#``B40'U!QR_RH&G6^
M6YI=:TJ2A=OO!22"`H"URP2#T0""-G1&%:?7)!TV\!_';[=-2+6.UM?^4$9Y
M^CEF/E1\V?>'[DWKU=(I&[+YYB>,M]N*>W*/-.3HPHHPHHPHHPHHPHHPHHPH
MHPHHPHHPHHPHJ/MJ=@K!]J9_"+/'Z_+$Y\FA/&+AZIGUR^L_9J5TD=\32S:Y
M[<5OV^;S5QED#Y@_,KWB^@T>71*2'2GM%$[K]55.UE,JG#4844844845$FZN
MQ?WXC_67R5CY-_/"/NE=>K&KA]X/L_\`RZ/PU#FG>W+/T?)>PER77YN',HNW
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M/+WD>],OJBEQTO[/0^X)K<<:+6^HPHKFZY;_`#E=Q?*I/X$B,E(W,?"NQ^)G
MOKE3/<GWX*Z<\0/?G:O`XG?-NTU\AHGZU3&!;Y/BE??2#GX*C`W_`'QGU)Z4
M=_!3"XFE)!6JWOL/<ODI8O@AYFXT][00?'&>^)K?:5]J+;X_'[\BN/#95RJ+
MFBW:L-K17G%D7U[:WJ,"A,QZTNJTCV$FP?N$X]-P9T=-D]9K(JB!?WM1%0IN
M@2&Z)NM*V.]-:@@79V))3:TW..DO%I8;"EK0M`*R,H*D*2I.W:E22-BAC)WR
MR]06)[DQ;S+,S,BKNRM"7Y89#J"Z4HA2D+4$`YL$+2I*CAUJDJ!P*3A6QHW^
M5W7ORF8?7&QT^\#V*N?BBZJ"\A'GE;L_?&V]_3709Q;^<9IGY=1OL+K(U][O
MPPOOH]?535TK?K\&]2>BG.JFKO\`F)\V7</R6#X4CL8%N0^*]D\;_P`FNHP>
M3G\;M.>/?Y)RN5CD=_(M>O:49\/Q.3`;K_;NW]T7WERG)?--YAFOO%[;ZXM]
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M<Q08APU/LI:\'8.0H67"3AT0H)`.`RJPV'$$$59IW97S.J9T@(#^5/E+X!$!
M$/\`ZK-V>`1```1#]SP8U'E7_&^=Z(L'^S]KK>6/S:GNCO?5T_&-SK;T8448
M44844844845D_P`&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24KOZZ]X_[.C\
M1/4%45=\-[_Z%]$[#\[J&3I_)5]GMX?CEG[W<:CGY>/G33/<)W;Q:UCN@?Y4
MMR_(&N?C$[SJOG0_";1'O%-\C;K4<A+VSO\`Z,8[^JGOY(_/F[MSTWRQ_H#7
MR''=;S?=Z7B^GO6XJ1V;YUA=-WO=8WO"8=&Q2'!^N.&XO&]BYG-:^X9E>JQA
MGB$WQ4Y5Q:K,LFBBX6C#.DW8I@Y(FH9N)O&`0PEZHY7)JG+MD;7]T:5D=BZ%
M4\%9`YE+6H-/N!7%DI#F4IQR%20O#*2,<1\WA(68J#M"I.'T<+3HX>ATZJ=M
M.A[EJWC/'7F]Z*N&E;-L'EAW>3*><["W%KW:>QK]/1?.YK89&:V>KKG3VKHY
M_<(<MK3CF<PZ=3/C:ZUCVC0S=%!47$GW)'WB6/5W+ET3I_3VH8-^M5M:ORF4
MP[9,M\*&RYI]ME#4`3;E/6B,[X.I]V,VW&RS7)+SP<6X@-\9?HCL?34EUUI3
M2UEK',M*U*(=))5E0D8C'`$E76@`8`;;BZQVMK_R@C//T<FKY4?-GWA^Y-Z]
M72*3FR^>8GC+?;BGMRCS3DZ,**,**,**,**,**,**,**,**,**,**,**C[:G
M8*P?:F?PBSQ^ORQ.?)H3QBX>J9]<OK/V:E=)'?$TLVN>W%;]OF\U<99`^8/S
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M]5AB7V-/Z@GUH90,N/G!_NR^V-.D1V`Z0K[S#KZHPHI%;GVOM'IZ3\[4R[CR
M0.:ANV]R+/Y$U3<+_P"?)GC+G;&FYU[V)K/HIOZPY5(Y?'/+WD>],OJBEQTO
M[/0^X)K<<:+6^HPHKE5[P&J[:L7*3<2M#V(%,BVJKGR:/:LH<SB4N(0[,T8>
M7D)6M6%9M`%4,T.H+7J*>*;KH&25\K(JUF!Y-UXT9;-T5C1J*V>'2UA.9:E.
M96XW&*XSBT-OLA3V'&!/&8IS+;<"T<24/2M[K;)KF[;G].+TU=1`A(LKF5"4
M-9G)/'R.+XU;C#Y#.;BRKB\JLJ'&RE?')6ST0\2`5+QHTH5<Y%5RT&%*NJFF
M*2:BP)&!51-(3J"DF=3I$"B8W5`>CI'U<C,WSE!WJWXM@AO[1=P!.)`QV`G`
M8D#A.`Q^BH_]_(<3OCU$'2%.BYN8D#`$[,2!B<`3T,3A])IB<3&DDK5;WV'N
M7R4L7P0\S<:>]H(/CC/?$UOM*^U%M\?C]^17$#8ZW54D=H+P6J]D5UPQ5OTW
M,VJ>716I,E/J4*SM5)FOM'6P'3ULUE6]Q<"V6;11FH'=+D%)%43G1GYM=UO"
MUVANXWBUR6W$PVFH[((E(9$QA0:>4F&E*E-F,CC$KD!S!MM06M`2E;\^5E:K
M,C<%O5=MMENL5UO36HG79+Z@8JWC:9J2ZPA4U2DI<$I>13<;B\7'4E"%YE(2
M3CXPLZ6\J0ZE+(S>Q)KB0640UKS=FHDP5'I8IN907BJZCMH(B!S%)U%0`!Z"
M](@"][RI%I7N_N#42*MN8()SN*>*@5CLREO*`$JV8`G%.)&W`$U9N0[*L;G*
M[W8,083C4\:MM>=Y4A2P5B0G.4M9`D(7L(!5BC$C;@";P.'%:W5&\M>/CV=O
M<7/5979ME?6N+5:-6[QN1Q[MHT5G6%64"R'W$2CUVQWC9VH=TU=MA$CMTFJ8
M"L"WX770<K<SJ5BWVYZ/=Q:6$1W`I122.*,M3X4\K\J5AP-N-@-N-K`4RRI`
M)MT;W[-O$B;MKY(N%S9DV54&>N0V4I2I(*R(B(Y2RG\EQ907$.*+C;B-C[R5
MG#HOYA]`<9]OB(=(?%@O2'[8>ZD=TA_]F1B;D<?[UK)AP^%_Y-=,)Y.F/]]N
MG<.'P[_).5QU[6K>YX?6TVM<+U%V>MC69=:T-3-6J$B2V/+?5BP!8(["`B$3
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M//\`#\83U:>3*4=.,HPHK%SGO),>BY#S1;,NW_M['=D=L*^5]B>E2&]UK#0X
M=WOP<L(1,:$^?B3I.&/.`Q:A,&ATZ?%/DXDTGXKRTT:1ZJ98$!/XH%3"<"]8
M1''$\KJ=./*5W@6SCG?LT:SNCO%9U<5QIDN(+G%XY<Y2`DKPS90!CALK4V%*
M?L>*O`9_!T#'HX8#9C]%>SNQOF;4G\Z/*/\`6JW7GARL?CC/]$6#_9^UU^V+
MS:GNCO?5T_6-RK;T844844844844845D_P`&8J7]EJPOU]>5Y]UNO;"_LILY
M'6?MA=?24KOZZ]X_[.C\1/4%45=\-[_Z%]$[#\[J&3I_)5]GMX?CEG[W<:CG
MY>/G33/<)W;Q:UCN@?Y4MR_(&N?C$[SJOG0_";1'O%-\C;K4<A+VSO\`Z,8[
M^JGOY(_/F[MSTWRQ_H#7R''=;S?=Z7B^GO6XJ1V;YUA=-WO=>SF]V[[O3]/B
MH_JW\G,\-P7L[O+_`-W,GUW8J_;I^=A^-CO;M:9WJOS<]9_IJ<%/UL-3XY/Y
M3W/>TSXA>/54NM/KGV;>_&;[=-;]6.UM?^4$9Y^CEF?E1\V?>'[DWKU=(I&[
M+YYB>,M]N*>W*/-.3HPHHPHHPHHPHHPHHPHHPHHPHHPHHPHHPHJ/MJ=@K!]J
M9_"+/'Z_+$Y\FA/&+AZIGUR^L_9J5TD=\32S:Y[<5OV^;S5QED#Y@_,KWB^@
MT>71*2'2GM%$[K]55.UE,JG#4844844845$FZNQ?WXC_`%E\E8^3?SPC[I77
MJQJX?>#[/_RZ/PU#FG>W+/T?)>PER77YN',HNWI^T=_77!:#]HV^Y.=04WV5
M,J76C"BC"BH2WGV=B?31?,7F3.?)+YP6J_<Q?K*WTGF\?S4QXQ]1=1IIGMLG
MZ)D/7;Y(]\W_`)F4GWIM74EUR&@?:$=P7]6FXRJ+2Y4845B9[WBFO1,CYFMB
MI[B_C;H[WJM/E\>L&Y^;9'<'.U-(,G_!_1)ZX9>LG]E(Z3G4539T]#[U6&)?
M8T_J"?6AE`RX^<'^[+[8TZ1'8#I"OO,.OJC"BD5N?:^T>GI/SM3+N/)`YJ&[
M;W(L_D35-PO_`)\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR^J*7'2_L]#[@
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M\*1V,"W(?%>R>-_Y-=1@\G/XW:<\>_R3E<K'([^1:]>THSX?B<F`W7^W=O[H
MOO+E.2^:;S#-?>+VWUQ;Z7_NQOGH:L]'W[\0K'DE>Y/XEVWIO>3NU4CY.'Q=
MMOXDGR5ZNMBB]LZQZ99_7CBN\MGF@;RO<^?WL5*GISS_``_&$]6GDRE'3C*,
M**Q<Y[R3'HN0\T6S+M_[>QW9';"OE?8GI4D'=:_V;_!K]%O2WXBPV+]RNN=%
MO!][KIY6[6KL/F6+XNCM17X=V-\S:D_G1Y1_K5;KSTY6/QQG^B+!_L_:Z_+%
MYM3W1WOJZ?K&Y5MZ,**,**,**,**,**R?X,Q4O[+5A?KZ\KS[K=>V%_939R.
ML_;"Z^DI7?UU[Q_V='XB>H*HJ[X;W_T+Z)V'YW4,G3^2K[/;P_'+/WNXU'/R
M\?.FF>X3NWBUK'=`_P`J6Y?D#7/QB=YU7SH?A-HCWBF^1MUJ.0E[9W_T8QW]
M5/?R1^?-W;GIOEC_`$!KY#CNMYON]+Q?3WK<5([-\ZPNF[WNO9S>[=]WI^GQ
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MN19_(FJ;A?\`SY,\9<[8TW.O>Q-9]%-_6'*I'+XYY>\CWIE]44N.E_9Z'W!-
M;CC1:WU5!["[Q/:%/OUWJ3&AT)TRJ]ML-?:.G:UA!TY;0\JZ8(+N01?D2!=5
M)`#'ZH`7K"/0'1CU]-<F325[TY`O,BXW%#\N$R\I*0SE2IUM*R$XH)P!.`QV
MX<-2'Z0Y'>AM1:3MFH)5UNS<F=;X\A:4"/E2IYI+BDIQ;)R@J(&))PX:KFV9
M>I'9M]L^P)9DRCI*UOTY1XQCA7,Q:K>1M6GBVIG)U'`I]1L`_3F$>D1QSVE-
M/1M)Z=B:;AN..Q8;9;2M>&=0S*5BK*`,<5'@%/(T3I:'HC2D'25O==>A0&BT
MA;F7.H9U+Q5E`3CBHC8,,*Z$.)WS;M-?(:)^M4R-7?)\4K[Z0<_!40^_[XSZ
MD]*._@IA<32D@JDNR=X[M*0;6*O*T"@$:O$YF#4736L7CRMU@=1YEB@:0%/Q
MP)FZP=(=7K?N8_:U\E[2,9V-<T7*Y%Y!:=`(9PQ&5>'88X8[/IPJ3>R\C30D
M-^'>&[M=B^VIE\)*8^4J&5S`_D\<,=GTX55%M4@)ZMOQ`$1`E*L1`$?5$"PS
ML`$?W?!CQ='G-JZVJ/"9[/?4UV_+,45\DS>8H\)T->S_`/T^156&C?Y7=>_*
M9A]<;'?;P/8JY^*+JGAR$>>5NS]\;;W]-=!G%OYQFF?EU&^PNLC7WN_#"^^C
MU]5-72M^OP;U)Z*<ZJ:N_P"8GS9=P_)8/A2.Q@6Y#XKV3QO_`":ZC!Y.?QNT
MYX]_DG*Y6.1W\BUZ]I1GP_$Y,!NO]N[?W1?>7*<E\TWF&:^\7MOKBWTO_=C?
M/0U9Z/OWXA6/)*]R?Q+MO3>\G=JI'R</B[;?Q)/DKU=;%%[9UCTRS^O'%=Y;
M/-`WE>Y\_O8J5/3GG^'XPGJT\F4HZ<91A16+G/>28]%R'FBV9=O_`&]CNR.V
M%?*^Q/2JCO@?R:WC1^+G=_:MJW&B;L&ND^/G$Y.S;DE92<CZQ)UC8\3IZB)H
MT)W%U&9@7%^JUIO$@YD8N:D(E'W'KZBR;@RCQ$B<@'*(W4;O]0;W-Y&KKOJN
M/&U.=2ZA+%L;;:6^V_"<N4LF6ER2T\(<B/$9;9D169"O"9B4*:"6'%*Y6TSI
M34"'';8)9XEK%9)P(4$)ZW`$9@5$D*(V)QQVBG?[L@.KPXI9>GIZNTN4@=/0
M(=/1RKW6'3T#T"'3^[B`\J\X[\)Y_P#2+!_L_:ZVMB\VI[H[WU=/SC<JV]&%
M%&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24KOZZ]X_P"S
MH_$3U!5%7?#>_P#H7T3L/SNH9.G\E7V>WA^.6?O=QJ.?EX^=-,]PG=O%K6.Z
M!_E2W+\@:Y^,3O.J^=#\)M$>\4WR-NM1R$O;._\`HQCOZJ>_DC\^;NW/3?+'
M^@-?(<=UO-]WI>+Z>];BI'9OG6%TW>]U^G.H[I*W\`56+=)V^2YV5Q5BS7<"
MS0>/DN,_*$[-FN\*@Z%FBZ<E*F=8$E?%%,)^H?HZH_/)[2TNR[R$2%%$<[O7
MPM03F*4&^V$*4$XIS%*<2$YDYB,,PQQ!=<>,AX;3X6.].U7WR9Y$<C-[Z+E8
M[?O$N3XKCK7G1W=D%!M)G8)]@N;A,27*#6<A8S1<NQHU9J4Q785$&9F\K#R$
MJS=F=BB84EVZZ9)".01NRW8;O.6CN^E;N-9M:O%UM5_>=4U#$-,9M%NDH8XQ
MM<M^0V\Z>,"X\EF.XV&PL!;;C:CRFJ)LV7IV6F7',?(MH#%6;$E8QP.4`@;-
MH)!QPX0:L7K':VO_`"@C//T<GMY4?-GWA^Y-Z]72*2^R^>8GC+?;BGMRCS3D
MZ,**,**,**,**,**,**,**,**,**,**,**C[:G8*P?:F?PBSQ^ORQ.?)H3QB
MX>J9]<OK/V:E=)'?$TLVN>W%;]OF\U<99`^8/S*]XOH-'ET2DATI[11.Z_55
M3M93*IPU&%%&%%&%%1)NKL7]^(_UE\E8^3?SPC[I77JQJX?>#[/_`,NC\-0Y
MIWMRS]'R7L)<EU^;AS*+MZ?M'?UUP6@_:-ON3G4%-]E3*EUHPHHPHJ$MY]G8
MGTT7S%YDSGR2^<%JOW,7ZRM])YO'\U,>,?474::9[;)^B9#UV^2/?-_YF4GW
MIM74EUR&@?:$=P7]6FXRJ+2Y4845B9[WBFO1,CYFMBI[B_C;H[WJM/E\>L&Y
M^;9'<'.U-(,G_!_1)ZX9>LG]E(Z3G4539T]#[U6&)?8T_J"?6AE`RX^<'^[+
M[8TZ1'8#I"OO,.OJC"BD5N?:^T>GI/SM3+N/)`YJ&[;W(L_D35-PO_GR9XRY
MVQIN=>]B:SZ*;^L.52.7QSR]Y'O3+ZHI<=+^ST/N":W'&BUOJY/.4&UJ/0M[
M[6CK5*N(Y4]RV'8'+DL5*.XR)AFMKD&99"=E6C1:.@V[Z0,#5J9THD#ER/BB
M=)O!DQ^Z71^H-1[O+/*M#*74"#"92GC&TN..JCH5D:;4H+=4A'Y1P-I5D;Z]
M6`J9G2&N=-Z8T!IV'>7E-.'3L1Y2@VXIMMI+#2<[SB4E#25K(0V7%)XQ?6(Q
M5LJ&[;O'75.]Q@F9&8.M-UMM:V3:(JUEG%TZXLS=/@EY+W)BW:40U)'1KQR/
ME1TCBBR<&*4PI&#.XLV[_4]\X_P%I@(CRE1U*<D,-`OA24<6CC'$EQ16MM`X
ML*&9UH$C.#747?>5I.Q)9\-=?4M^/X0E+<>0Z0R0I?&.<6VH-)"&W5_E"DE+
M3I`.10'4]Q)52<<:=*KH*$507H4*LBJF(&35253,HFH0P>`Q%"&`0']D!R(7
M?.A;>]6_-N`I<3<700>$$'`@_=!J)K?TXA[?'J)UHA3:KFZ01P$'`@CITQ.)
ME21UQ_2&U]=K['G]?HVEDM<F5DD(Q[`I-I)1TSD%"'ETVCI8C$63996+6(N4
M#JE`R9RB'3U@Z9LHVCM3-Z7C:D<AN)L;D5#B7BI`2I`P;*DC/F4`X"@X)."@
M0>`U.3;==:5=GM:7:F(5?6T--K:"5DI66$.A*B$Y4DMD+&)&*2".$4O=^LFZ
M3M;Y'V>L0,+1U8V_P+%PDHP<.9N-2K=WF8>T,9%"U.WK9V9M&QK52,6C"&.9
M9TN*B9$B$%2].6O0B7K=)M,N2_J!+L-Y8(6$M++\5IUA:#'2E2<RWW$OI?(`
M2RWE4I:C35N5Q=]X*^3MO+C7B)&CZ;.C]0,H(*"IUL6VX.M2$+$A2PK*AAM3
M"XX)*GG,Z$H2*0'C];JU*[RHL)'3#=Y+-;:FT<LD4G?70=,#F*];JJG;%;%6
M;#_A%Z_3^UTXX_>39;K#W?W"X2F%(AKA%25$IP*5CK5`9LV"N@<*JK\AS3U[
M@<KO=C=)D9;<!S5UK6E9*,%)<?3D4`%%1"N@<,*O>X>[EU[9>56C:S$S#E2:
MDMC.FD4S=P\O'>["5<1FBRTM#K/V3=&4@$'$2Y0!^@8[4[A$4P/UQ*!H\=]V
MAM2VK<_J"[3&$"`U:TJ<4EUM?%E\M<6VX$*46WBEQ"RRL!P(4%%.`)%OO?%O
M#TK=]U^H;/"D*-P=M\I#:5-.HXSB%8..-E:$AQD*;6CCDDME:<H420#T(\PP
M$>,VX`#U1JY0#Z(RD<`9&KN1.&]:R'_\;_R:ZCVY.APWVZ=)X/#O\DY7(1N+
M<6OKKJNUPE?F'*TK*PAY:,9/H:7B%I&"B+%74E;&Q+*,F@NJZ^._3!F^)UFS
ML0."1S&34`LUFB-#ZEL.KX<^Y,(3#9?#;BD.MN!#KC+Q#"^+4K*\@(/&M'!;
M?6E8`4DE7_F8Z_TQJ+D-:[MUK?6J8]#A.MI4TZV7&6KS;`7T!Q"<S*RL<6Z.
ML=.8(4HI4$Q)W5MUKD_S:U(RC'JRCMU!['DV[9PQ>L5EHMO1)4A9---X@B<\
M<\"12,V6`/%N"B;J"(D.!9%MT-ANEMWBP'Y;:0RAUQM2DK2L!PQY'Y,E)(SI
MR*"T\*#AF'7)QJZ[@M,WFT[UK?)G-)3';4^VI25H6`ZJ+)/%$H4H!Q'%J#B.
MR;.&8`*23V!47MG6/3+/Z\<4;EL\T#>5[GS^]BI-=.>?X?C">K3R92CIQE&%
M%8N<]Y)CT7(>:+9EV_\`;V.[([85\K[$]*N9CB8VN%HB^ZPJT#MSF<RJU<XY
M<+-@;%TM3M1IV'C7-0C6OE;5BSI[&1BT`C$4KHR;&MS=\M*(M$617"!(YT#=
M925S?*[9+1+WOW>XV70KEWE:HU1#A723<2S?&G5/9GV#"+AXPF*IP6Y;28ZG
M%.EIPR6BZVGA[>''$P&T.20VEEE2D!&+1&&PYL-G789P<<,,1E.!JX/NR1$>
M'-+$>CI':?*41ZH])>D>5FZ_4$>D1#&2<J_9OPG^B+!_L_:ZZ.Q^;4]T=[ZN
MGXQN=;>C"BC"BC"BC"BC"BLG^#,5+^RU87Z^O*\^ZW7MA?V4V<CK/VPNOI*5
MW]=>\?\`9T?B)Z@JBKOAO?\`T+Z)V'YW4,G3^2K[/;P_'+/WNXU'/R\?.FF>
MX3NWBUK'=`_RI;E^0-<_&)WG5?.A^$VB/>*;Y&W6HY"7MG?_`$8QW]5.'S.O
M-3UAROX%[(ODRWKM)H3;F1;K;/.DG*Z$17X+CL\?R;\[=D@Z?.C(MD1ZB*"2
MJZQQ*FD0ZABE&(K<7I^\ZMW.[Q=+:=85*O\`<5Z9C1V4E(+CSUZ2AM`4LI0G
M%1&*EJ2A(Q4M24@D2,W-UMBX1'W3E:1QQ)^@!O;4:[UY):/Y.73A[':NL*ML
M;T#O&*[0;Y&S-3LU<ZKEWQEY2(+$3C[A"0ZD]6Y0B;IJ1\V(NP<K-72!5#*(
M+$)U6[W=9K_=/8M;RM71A#<N6[!Z9$6U(8?ZU-]L!&*XSKH9?;);<+2RAY"7
M&G"D)<03X2YL6<[&2PK,$30E0((_[)WZ0,0=HQ&PX$=`U'O,?B-QZXF<5=?5
M_0VMX>CHR7,C@/'3$H@+B0L<]'Q7+_7DA"LY^Q2*KF8FTX4\RNFV,Y654(B)
M2B8W5`<<W\N[?1O+WR\N_2URWB71^X.-0[TMILY4,,K<M#Z'5,LH"6VBZ&D*
M6&TI258D`8X5IM66Z';],/HB("`5-@GHG!P88D[3ACLQISZQVMK_`,H(SS]'
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M\WC^:F/&/J+J--,]MD_1,AZ[?)'OF_\`,RD^]-JZDNN0T#[0CN"_JTW&51:7
M*C"BL3/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVII!D_P"#^B3UPR]9
M/[*1TG.HJFSIZ'WJL,2^QI_4$^M#*!EQ\X/]V7VQITB.P'2%?>8=?5&%%(K<
M^U]H]/2?G:F7<>2!S4-VWN19_(FJ;A?_`#Y,\9<[8TW.O>Q-9]%-_6'*I'+X
MYY>\CWIE]44N.E_9Z'W!-;CC1:WU<M/(*NU^;W/N0)F#AY<'ESV37G@2<:S?
M@[@)>R.QEH-R#I%4%XB3%LF+AL?I16$A>L4>@,EVW;7.Y0-"V,P9#[)1`@O)
MXM:D97FV$\6ZG*1@XWF5D6.N3B<",:FWW>VBU7+=K8?M",P^'-.Q6%<8VE>9
MEV.SQC2LP.+;F5.=!ZU6`S`X"HN>5FN/$O)W<!"ND#0?Q<,DXBV2R9Z\H#<R
MD"<JB!@-#*&;)B9J/[P(D+TE\`9UK%UNC"^,9DOH<\(X_%+B@>.&.#PP/YT9
MC@YV0Q.W;7:+LMGD(+;\6.M'$J8P4V@CB21BU@1^;.`Q1V)P&S973%Q.^;=I
MD`\`!1HD``/4`.JIX`_<R*??)\4K[Z0<_!4.>_X8;Y]2`<'VH[^"F%Q-*2"N
M3R2223F9U5----5S+/Q<J$(4BC@47:Z:0KG*`&6%),.J7K"/5+X`\&3'Q5K5
M!CH424)91E!.Q.*03@.AB=IPX3MJ?&W,,HALNH0D.+8:S$`8G!M(&)X3@-E+
ME?\`7$7"UC:]M)8+[(R$I`722)'R]_MTA6HLDE7E4%XR-JJTN-<2C$%2'6;I
MG:G%LHJ/BS%*5,"*AIS5$N?=K/9E1K<U&9DQ4%;<.,A]PH>!#BY`;X\N$$)6
MH.#.E(S`DJ*FH\KG24.W<F+>E>Q*N;TI[1=^<"'9LI;#8<MKP+;<8N^#AL$%
M2$EL\65'(4@(":[M%_2;=H`$`"`I:6"J@$`"@HKX"^-4ZO1UU!*0H=8>D>@`
M#]@,<UO!Z[1=R*MI$-8&/0'T#Z!M.S[M5&^0EUW+*W9%6TIUA;0,=N`\(2<!
M]`Q).`V;3]-7W\5:M64.2^B)!"NP:+^'V`Z<1+U**8INXM>S>5.+(M'N"(`L
MS4L#C]\>BF)1='^F4ZP^'(Y]\%WNSFZK449R5(5'?MJ4N(+BREP,94L!:2<%
M!E.QK,#Q8V(P%7-M^5DLS>Z._P`MN)&$IBV2E-K#:`IM4A:5/E"L,4%Y77.E
M)'&*VKQ-7N\Q/!QFW`(>K\5P^%([(\MR/Q7LGC?^374:G)S^-NG?'O\`).5R
M=\@JM68_4-I?L*[!L7T1#FCXIZSB6#9W&,)RUP4E-,8]PB@19FREY%LFNY23
M$J:ZR93G`3%`0F0W;7>ZR=:PXTF5(<COOYW$J<6I+BVH[J&EK220I3:%*0A2
M@2E)*4D`D4OWS1;'98G(3UU*BQ(S<EF'!0VM+2$J0AZ]VU;J$*"04I<6E*W$
M@@+4E*E`D`U!G=?Q,4VYK:C7;1K!NNSA-C,&:R#-NBJU8.J5/NW+)LHFF4R+
M-=TD54Z11`AE"@80Z0Z<DCW+S)CN\B`VZZXIMQQU:@5$A2TQGDI6H$[5!)*0
MH[0"1CA54/DZSY[^]F`T\^\MIPON+"EJ(4M,1]"5J!."EI22D*.*@DD8X5UT
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M"%W."=.4UMSP0LQQ84R5$(5SQBDVSTI(K8TE#4"36.FMU4V\T[:QJIQ`JZJ9
M1ZP1;\DW[7_JMJTV`8WL77218&>4W^53?FU)Q<A(=F-@$8E<5MQ](Q+:%$8&
M1*^\7Q['&_F\C^/8G9Q1Z"B$G_&('TTFG'_4>T=35KA<UW)JVR:KOTQWE%%3
M=P\Y0=&TI@O7*KQ:Y-4^@!6U]*W6[DF8YGK^%BRNO=19!9M*'=`B0Y3G647+
M>1K32.LKKKM[0UWBWC3C&ZR64N-3+M*6'Y%_L4F9QXND6*6EJF.OEOP=*TKC
MADK4DI2VC60X[\=$426U-O&<G84MIV!IT)PR*5B,H&./`<</IJQ_O5?FYZS_
M`$U."GZV&I\Y/Y3W/>TSXA>/54NO?7/LV]^,WVZ:WZL=K:_\H(SS]'+,_*CY
ML^\/W)O7JZ12-V7SS$\9;[<4]N4>:<G1A11A11A11A11A11A11A11A11A11A
M11A14?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]9^S4KI([XFEFUSVXK?M\WF
MKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJ=K*95.&HPHHPHHPHJ)-U=B_OQ'^LO
MDK'R;^>$?=*Z]6-7#[P?9_\`ET?AJ'-.]N6?H^2]A+DNOS<.91=O3]H[^NN"
MT'[1M]R<Z@IOLJ94NM&%%&%%0EO/L[$^FB^8O,F<^27S@M5^YB_65OI/-X_F
MICQCZBZC33/;9/T3(>NWR1[YO_,RD^]-JZDNN0T#[0CN"_JTW&51:7*C"BL3
M/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVII!D_X/Z)/7#+UD_LI'2<Z
MBJ;.GH?>JPQ+[&G]03ZT,H&7'S@_W9?;&G2([`=(5]YAU]4844BMS[7VCT])
M^=J9=QY('-0W;>Y%G\B:IN%_\^3/&7.V--SKWL36?13?UARJ1R^.>7O(]Z9?
M5%+CI?V>A]P36XXT6M]7,#N_^6C;GYR[Q^,DCDM&@?82R^BHO>$5./NP^&NG
MO0D+R9NHR/ZH?4$^M#.L3P??-=NG@/3/5KI&XG?-NTU\AHGZU3(MM\GQ2OOI
M!S\%0P;_`+XSZD]*._@IA<32D@KE`E??:6]+2?GSC)C8?[&SW%OM!4^T#S?'
M\7:[1-1?MC^3#8/R-LGP0[SK=&^UEM\>8[XFF[<LKFE;R_<6]^KY%57:-_E=
MU[\IF'UQL=_O`]BKGXHNJ>/(1YY6[/WQMO?TUT&<6_G&:9^74;["ZR-?>[\,
M+[Z/7U4U=*WZ_!O4GHISJIJ[_F)\V7</R6#X4CL8%N0^*]D\;_R:ZC!Y.?QN
MTYX]_DG*Y6.1W\BUZ]I1GP_$Y,!NO]N[?W1?>7*<E\TWF&:^\7MOKBWTO_=C
M?/0U9Z/OWXA6/)*]R?Q+MO3>\G=JI'R</B[;?Q)/DKU=;%%[9UCTRS^O'%=Y
M;/-`WE>Y\_O8J5/3GG^'XPGJT\F4HZ<91A16+G/>28]%R'FBV9=O_;V.[([8
M5\K[$]*J0N`G-^L:WXQ<`..Q-6[.L]D7XZ<64;18HUA$1]:K=2V37M25&KW:
M-<3$HR=WM@-XV.WC7C*%2=R+$L;).5D2H-2F6?WRCMP-VU1O8WD;S57>TQ+6
MG4]_,=E:W%OOR(+UQDR(JPTVI,1?@D);[3LI3;+I?BM(<+CQ".6M%T;8@PX7
M%N*7Q+6)&&`"@@!0Q/7=<H`A.)&"B1@-KL=V0'5X<4HO2`]7:7*0.DH](#T<
MJ]UAT@(>J`X@W*O.._">?_2+!_L_:ZVEB\VI[H[WU=/SC<JV]&%%&%%&%%&%
M%&%%9/\`!F*E_9:L+]?7E>?=;KVPO[*;.1UG[877TE*[^NO>/^SH_$3U!5%7
M?#>_^A?1.P_.ZADZ?R5?9[>'XY9^]W&HY^7CYTTSW"=V\6M8[H'^5+<OR!KG
MXQ.\ZKYT/PFT1[Q3?(VZU'(2]L[_`.C&._JJ7N]9J,5?[?QWI$['3DQ#6K4_
M/F%DXBL4^8V%8Y9HZXOR@J1<%0J],5V=NLK(]0$48MI(,5GIS@D5PCUA4+&'
MR/+U,TW9=37^WNQV)T.\Z0=;<?DM0V&U)OS>#CLQYIYJ*VC',J0XRZEH#.6U
MX93(AJ!M+SC+2P2E3<@$`%1/Y([`D$%1/T`C'Z12(\;;6N\USQ9V5+Z8T]II
M@MWE$+86].T)QSVUIU9>!KG$CDXL"=I;W>R7*)V)LLB;)1!=&IO9"+CE^I'E
M=O%RF5%PV]*SML:HU?I6%?;W?)*=U;K*I-WO5NN0#S^HK$,8YBL1G(4'%25H
M5<&F7WTYI)99;(16IA.$LQWU--M#PX'*VVM&P,N\.8J"E?B$@<&)--%R_P"6
M"')#0U7C/R+;;T^K#\G^[8V)#%VDG0?&VFF[`Y>TV*AIE@77]YO;6-(M)U%[
MY.F]6;GD&12/&@+-S&.3=?+SW..;KN6GH^7]O66]H?\`ZQPG?`#,PCR8=H<<
M=:7X9$B*60W):SEI*PRZ5,/%#@"5>>K+@)NG9">*<;PXE0SY=J5.``]:I6&T
M'#'A&T8BGTK':VO_`"@C//T<L`\J/FS[P_<F]>KI%)79?/,3QEOMQ3VY1YIR
M=&%%&%%&%%&%%&%%&%%&%%&%%&%%&%%&%%1]M3L%8/M3/X19X_7Y8G/DT)XQ
M</5,^N7UG[-2NDCOB:6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJ
MIVLIE4X:C"BC"BC"BHDW5V+^_$?ZR^2L?)OYX1]TKKU8U</O!]G_`.71^&H<
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MV5#6*SPL+*R^PMBO8QA(OD6SEXTC;#('>N$4U#`/BD0'H`1Z.N?Z4G6-X,F!
MW8:>OMVW=6J=;(C[\-FV0DN+0@J2E2V4!*21T3_T#:<!MJ:K0>I]/670.F8%
MUF1X\U^PQ5(0M82I26XS140">`8\/1.P8FHHEMD4&%<Q+27N%?C74W!*V*)0
M>2*"*C^":LQ>K2C<IA#K,_)2&.0P]'C`(?J=82&`.QA:6U'/:>>A09+K,>0&
M7"E!(0ZI64-J_P`+,0"/X.(S88C'L)6L=+VYQIB=/C-.R&5O-A3B05M)!47!
MM['*"0>B`K#'*<.GCB0LDXXT:4<(*%50<4&%715(/6(JBLD91)0AOV2*$,`@
M/[(#D3>^="VMZM^:<!2XFXN@@\((.!!^Z#40._IQ#V^/43K1"FU7-T@C@(.!
M!'3IB<3&DCKD=E;C3QN$M6_C;6/C'[N2C;XO_&"(]W?*`<N'`M_<?RSW1\>#
M?]\ZGB^MU/INCH\.30P['>_L1FZ>!2_LOP=M7'<2YQ67*$X\9ER88[,<V&.S
MAJ=V!J/3^,>S^'1/M;B6T\3QS?&YN*2K#B\V;'+UV&&.&W@I8+ULV]2S+8E8
MD=8R-?K:41?ZZ:>DCRB2SU9A`W*3C;)#JJ1",#)5E_%PC0A@([%V#N2*4I#$
M;JF%6M/Z4T]#?MEVBW9J3=%/0WN)0&R$A;T9M;#@#A>0^AQUPC%OBRVP25!3
MB!31.5KK'4L_DZ;S;/*M#L:SHT=J!@O+*P5*1;IZVWVR6@TMA;;38(2[Q@<?
M`"2&EDH=H>9AG.Z=?QS:8B',B2SM2GCV\FQ7?D,@<X+E.R2<'<E,@(#UP$O2
M3H\/1CA]XD&<UH2Y2G6'DQC$5@M3:P@X@88*(R[>AMV]"JI/(5MMR9Y8.[.8
M]&D(AG6-LP<4TM+9S/IRX+*0DYNAMV]"KZ^(FQ:)/\G=/1$);H&5E$=G%A%6
M#&00<.BRL4SDW$BS\20PF,=HBR7$Q@Z2=*"@`813.`1U;ZM,:BMNZ>]S9\*2
MS$5:>-"UH(3Q;BFTH5B>@HJ1@.'KTDC!22;C>^?5NF;GNGU-`M\Z,]-3!?9*
M$K25<8W@5IP!QQ2$KQZ&*5#A2<+\N88"/&;<`!X1&K@`!^[[J1V1S;D?BM9/
M&_\`)KJ.+DZ;-]NG2?Y]_DG*Y)MV[#HMLT_>6=9ML#.NQ2,U*WC)!!VJ9>$G
MZ][JE*1,PB8C,'Z)A.'TABJE,03%'IR9S0.F=0V;6UO?NL*1'9QS9G$%(P=9
M>XO:>BK(H8<(*2"`1A2X_,YU9IJ]\A+7\>T3HTA[B82<K:TJ.+-YMO&88':$
MYTDD;,%)()!!J%NZSLE?F>:>JB1$S'21SL-E=4K-R18Q@8428*[,!2CT]1$7
MR(];_!,54IBB)3`.2/;G;5<H.\FW*FL.M)!<[))'9QW\OWSD5LX04D'`@BJK
M')]LMWMN]RVJN$9YE(0]B5I([.+(*/OJR+V<(*5`X$$5UYT7MG6/3+/Z\<4[
MEL\T#>5[GS^]BI0-.>?X?C">K3R92CIQE&%%8N<]Y)CT7(>:+9EV_P#;V.[(
M[85\K[$]*N;3B%N"W*:H[OS2:/*NA55DWT3W=UA@^,GY,IF8G;1#RZ](=35D
MOFP&]#GW<`V?O(J3-"(L'[-K(2+..37?1J+253DI3-]6B;*G6.\G7J]'W&8^
MK4.LV7;[X<TTS'=;$I+3$2&9;*7E(2XP)2GF77&6'9*FX\I;T-47B;=)<\'A
MQ1(0D<5'(:RDD@Y<2I64X<!RX$`D)Q*0%9K:.[*^9U3/5#_YJ<I?`80$WSK-
MV>J(>`1^AX,9IRKOC?.]#V#_`&?M==#8_-J>Z.]]73[XW.MO1A11A11A11A1
M1A163_!F*E_9:L+]?7E>?=;KVPO[*;.1UG[877TE*[^NO>/^SH_$3U!5%7?#
M>_\`H7T3L/SNH9.G\E7V>WA^.6?O=QJ.?EX^=-,]PG=O%K6.Z!_E2W+\@:Y^
M,3O.J^=#\)M$>\4WR-NM1R$O;._^C&._JJ9.]2K)KI<^.]0)'W26-9]1=X%!
MA$ZX]P1O\H$CQ5FFPQU/3M4S7:RYGGI3BFBA(/V;-SUA265(0XCD8')`NPL-
MBU/>RY`9$2]:.=XR;QW@;>34#2L\DQVGGTLIPS*6RRXZC`+0A2D@5(A?V^-=
M9;P4<S<@8)PS'%H[!B0,>F0#T:KLXFVJ!VH?2MX1JT?KJ?M?>E:QK]XUU0:5
M5=+Z_I<G5^#N^J:FC4]?T#:&SW%6MSR,8$7F),\T#EP\\2#8$T6B!L<WODM%
MQT>F_:?7,<NENA[HI[T2;,E2+I,E-R-5VB23(F3($!,B,EQ93&8$7(AOC.-S
M./."M-;W$2.*="0A:IZ0I*4A"4D,.)V)2I6!PX3FQQPPV`4\_,CC;&\=>*NO
MHM+;6_\`<<Q)\R.`S&5M6^=U;#VO)NTXOE]KMS'N6<=;)^1KE<DC-9(K=XO%
M,F(ORMTC+`8Q0S"^7;O2E;SN7?I:6NRZ;L<%J'>EMQ[1:X5O;27+0^E:5+CL
MH>?1F05MHD.N\25K""`:^M60DPM,/IXQYU14WB7%J6=C@Z!)`.W;@!CAMISJ
MQVMK_P`H(SS]'+"W*CYL^\/W)O7JZ12467SS$\9;[<4]N4>:<G1A11A11A11
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MD_X/Z)/7#+UD_LI'2<ZBJ;.GH?>JPQ+[&G]03ZT,H&7'S@_W9?;&G2([`=(5
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MC&$9A-U6I;[8M#6!5HDK84Q%A26\H2<CZ(R4!8Q!X4**%I[!Q."7$J``$TNB
MM)Z=U#NTL@O,5N0)&F8L5S-CU["V&5%!P(VA20I"^S;5B6U)*E8Q+8-6T"RQ
MSR'GJRSDXV2I;:@/VJZ[\I'=2:JD=,8M8R+M)03QKLHJM'/3Y6T5,<Z*I#'.
M)NSMNKM26J4B;;I:VI34]4Q"@$8ID*!2MP8I(P6GK7$?FW$A*5H4$I`ZZX:'
MTK=X;L&XPT.Q'H7@:TE2\%1PK,ELX*!)0KKFUX\8VHJ4VI)42>H#B.@DVXSZ
M3;($!-!M0(1NBF`B($112,DD0!,(F$"$*`=(B(Y$MOH<6[O6OSKAQ<5<G23]
M))Q)_=J(??RTVQOBU$RT,&D7-P`?0!@`*8K$QI)*Y'7M0J;2X6>R-JU`H6&6
MGW;V2G$XEB66>O&@&BVSI=_XGRDSE&-0(@!^MUO%$*41Z``,FA8O=Y>LD2UN
MRY"K8S&2E#1<7Q:4J_**2$8Y<I62O###,2>$FIWK7IZQ,*1=V8D=-T?:96XZ
M&T\8I26$-I45X9BH-I"`<<<H">`5!NPJ38&=;VC8I;9=LL,<I!W5_"U![&4A
MO7X-D^K3EJC')+LZFE9'*D6LHN9!R,@18R2A4U?&@4XJ*!IJ_6U^Z6BV0[5#
MC2A(BH=DI7*4\ZM#Z5%9"I!82'`$!:.)*0I)4C(2`EL/*ZTY=(W)DWHW:==Y
MLJ*K1E^6U&6W#2PRA=L?2$!2(P?46R5E"^."BE00O.`HJKAT'#Q##<U&>,8J
M.:/'EO;O73MNR;I.5W;D0*Y<J+D3!457`)AUQZ?IQ#I'I$1$70[QITV1H6X,
M2'G5L(A*2E*E**0E/8I`)PP3B</HZ&RJE?(8N-PE\L3=A&E/O.1V]76Q"4*6
MHI2A,@94A).&"<3E&&S@&P"KXN)VL*%'<I>/%A85IDUF:I>)9.O/TE7@+1C>
MY+2,A8V:("Z%,[!\]=*JD;G*=%J90WB"I`80&/#?)JS44K=%J:VR)3BX,RWM
MEY!"<'#&"$,*/6XA:$)2DK!"G`!QA7@*N*[[=%:7B;K+W=8T-M%PAVN9Q*P5
M`H$IP./)`S8%*EDD((*6\2&P@5?WS#$0XS;@$/`(5<!#Z(2D=D<&Y';O6L@_
M_&_\FNHZ.3H,=]NG0>#P[_).5R/;VUG1(#5LY/0];9L)>L5(:G!/DEGIE8^M
M3%O@I5Y!D!5THFM'$?-B&;IJE.#,G2FW\4F8Q!F@W>:KU#<=71[=.E+<A2YO
MA#J"$X+?:C.MI=."00LH40M22.-."G,Z@"%L^9]HW35KY#>MKG`BH;G1+;!C
M-+"EXH8=OEM<4T,5$%`6D%"2"&ABEK(DD&&NZXJU?C>;NG9!A&(MGL;5]A5]
MDX(HX%1&%4I4XZ"-_?%C@JW16;D\5UP,9$@=1,2D$2C(YN;N]RE;Q(4:0ZI;
M#LAUY:2!@71&>3GV`8*(4<V&`43F4"K;56#D]7V[S=ZD*)*?4N,^](D+20G!
M3PAOIXS8!@HA1S9<`LG,L%6!KKWHO;.L>F6?UXXIG+9YH&\KW/G][%2>Z<\_
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M2N_KKWC_`+.C\1/4%45=\-[_`.A?1.P_.ZADZ?R5?9[>'XY9^]W&HY^7CYTT
MSW"=V\6M8[H'^5+<OR!KGXQ.\ZKYT/PFT1[Q3?(VZU'(2]L[_P"C&._JIP^9
MU$I^T>5W`S6FPZ[&6^A;`:\R*?=*I-(`ZB+'6)_CN[CYB%DVXB7QS*09K&34
M+T@(E'P"`Y$5N+U#>]([G=XFJM,RG86H[:O3,F+(:.5QA]F])6TZVKH+0H`@
M_2*D9N;3;]PB,/)"F5\<%`\!!;V@UHNY^-6C.,<SP$J&AM=0^M*O*=X)2'[N
M`@7$J>+!TTXR<F6#<S1G)2#Y&.22:)%(";<$DN@.GJ]/ASH-"[U-X.]B#O'O
M6\6YOW6[L[MI2$O/!L.957VQ+5F4A""LE1)S+S*^[A7E)@Q(*H;<1`0V9B=@
MQP_-._3P5O\`WJOS<]9_IJ<%/UL-3XJ?RGN>]IGQ"\>JI=8.N?9M[\9OMTUO
MU8[6U_Y01GGZ.69^5'S9]X?N3>O5TBD;LOGF)XRWVXI[<H\TY.C"BC"BC"BC
M"BC"BC"BC"BC"BC"BC"BC"BH^VIV"L'VIG\(L\?K\L3GR:$\8N'JF?7+ZS]F
MI721WQ-+-KGMQ6_;YO-7&60/F#\RO>+Z#1Y=$I(=*>T43NOU54[64RJ<-1A1
M1A11A142;J[%_?B/]9?)6/DW\\(^Z5UZL:N'W@^S_P#+H_#4.:=[<L_1\E["
M7)=?FX<RB[>G[1W]=<%H/VC;[DYU!3?94RI=:,**,**A+>?9V)]-%\Q>9,Y\
MDOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>VR?HF0]=ODCWS?^9E)]Z;5U)=<AH'V
MA'<%_5IN,JBTN5&%%8F>]XIKT3(^9K8J>XOXVZ.]ZK3Y?'K!N?FV1W!SM32#
M)_P?T2>N&7K)_92.DYU%4V=/0^]5AB7V-/Z@GUH90,N/G!_NR^V-.D1V`Z0K
M[S#KZHPHI%;GVOM'IZ3\[4R[CR0.:ANV]R+/Y$U3<+_Y\F>,N=L:1:[Z]&/[
MPSC?.@RL<BE98C4]GK45!Z6KLF5-Q&J[;:[4G&^YC:\L"E?C*\HC!OK&UDIN
M&=KM91!*+,JH/BCP:<K34HDW;?-;BY%:7%U3>F'W';H\WBE?V:JWM&V>&LAY
MQX&6U"<8BR6T.,.+EA">O2I5B9P;MR\%',PV0`@'@SYSGRG`#K2H%23@1EJ]
M/(6:46N8'=_\M&W/SEWC\9)'):-`^PEE]%1>\(J<?=A\-=/>A(7DS=1D?U0^
MH)]:&=8G@^^:[=/`>F>K72-Q.^;=IKY#1/UJF1;;Y/BE??2#GX*A@W_?&?4G
MI1W\%0E8.\.TI7+#.UM]`;'4?5^:E()ZHVA(11LH\B7R\>Y.W44LB2AVYUVY
MA(8Q2F$O0(@`^#.^MO)GU[=+;'ND>3:Q'DL-NI"G70H)<0%I"@&"`<",0"1C
MT32G6CD?;S;S:(MZBR[,(LN,T^@*>>"@AU"7$A0$8@*"5#$`D8\!/#5'/DYY
M>P"T:B4BDQ/"U:BL(E(124E!1;BL)`.)2%.X+U^@#"`=/1TY(!QB85MXYW$I
M8C9E8<)#;>*L.#;UIPX*E$XY-NM'A#^)1&B9E8;20TUBK#'#$D).&.'WJ<:\
M]U_R"L=.M5>8635A'LU`2\4T4<3ED(V*X?L5VJ)UCDJBBA$045`3"!!$`_8'
MU,0_3_*UW;6N^0[E(BW<L,26W%!+3!5@A840`9`&.`V;0,>C4>W*`Y2N@MZ>
MXS6&[73T:YM7Z_Z:N-OCJ?;92REZ7%=8;4ZI#[BDMA:P5E*%J"<2$J.RDHUO
MW&W+JHWNJ6:2N.B56$),-7[Q-G:KDHZ,@B)A,"":M`13.H(B'0!CE#]W%ZU3
M\P+<M>M/3+5%@ZA$E]A2$E4>,$XGZ2)A('2!J`[DT<E;>+N>Y0&CMZ6IY%I=
MT]8+_$FR41WGEOJ98<"UAE"XS:%.$#!(4X@'HJ%6G:6X%[CUYMG7UYFYN@+Q
M%5LK.8D48Z6FUGZK5!-8IR-$EZ\V146$5`Z`,H0/W<:%KOE$Z'U-HVY:?@1[
MDF;,BJ;05MM!`42,,Q#RB!LZ`)^Y5AC>7RKMW&L-`7?2ULBW9%QGPELMEQID
M("E$$%93(40-G023]RK'-^T*9VAIV_4"O+Q[:9M$*$='KRJJZ$>FOY:T<=9T
MLV;NUR)]1`?"5,X]/1X,:_NYU'!TEK>W:CN27%P8C^=8;`*R,JD]:%*2"<2.
M%0IFFZ;5EMT-O&M.K;NEY=M@R>,<2T$J<*<BT]:%*0DG%0X5#95)^V^ZMY%7
MK7EEJD/9=4(R4PW9I-5'\_946A3-Y-B\/XY1&HN%2%%)L8`Z"&\(AC]-&<K_
M`'8Z?U-%O$Z+>516%**@AE@JVMK2,`9*1PJ'"1LI7>6IOHTKRB.3)JC<YH=F
M:QJF\M1$L+F(;;C)+$^+*7QJVG'W$@ML+"<K2^O*00`21"G%GNEN2?%O=]3W
M=L*SZBDJE4FUB0DF=5L-H?SJI[!7Y*OLA9M9*G1+-0I'LFF93KN"=5,!$.L/
M0`R/\D#EF;K-[O*"L6@=-1+TU>9HEE"I#+"&@&84AY>92)+BABE!"<$'%6`.
M`VU`]NXY)V\?==JZ-K74$FTN6F(ET+2P\\MTEUI;2<J5QFTGKE@G%8P`.&)V
M5<M1>V=8],L_KQR1/EL\T#>5[GS^]BG::<\_P_&$]6GDRE'3C*,**Q<Y[R3'
MHN0\T6S+M_[>QW9';"OE?8GI54=W;/+GCY4^''`G1\W?%$MER.@-`U`T(RJ5
MVEV$/89_7.OG=>C[3:8BN/JG4OC">[1#5@K)OFB+R0D$6:)SNC>)!Z'*FW+[
MRKSOPWBZ_@6X*TJUJ2\2>-5(BMK=99FS$O+CQW'T2)/$B+(<>2PTXIIEE;ZT
MI9&>N=LEQAMVV)%4O\N66QA@HX$I3AB0,!CF`&)&)(`V[*8ONQOF;4G\Z/*/
M]:K=>)CRL/CC/]$6#_9^UUFV+S:GNCO?5T_6-RK;T844844844844845D_P9
MBI?V6K"_7U5_W@.^]XZTV/J'7^L[I9M+4NY0&U+9=-X5KAON3F>\93].F->1
M5-UDE3-4LW36H?&UM;Y237DY0#^-;P9F[4I%5#*D<#NGW=;O]53M9ZDU7`B7
MZ^P;ZU'BVI_4ULTPE3,E=P<DSS*N"DJD^#JC1V$,1R,JY8=>*D)"%:F=+E,)
MCLL*4TTIHE2PRM[:,@2G*C@QQ)Q/03@*K-YC[0V+N?1'"C9FVZJXIFQ[31-C
MKVR#=5&U:_4]THZPP4,$TG1+P0EPIC6TM8Y.40BI/KO8]%X1!4ZAR"H:7;Y8
M.DM,:%UGO=TIHR8F=I>)=K,([J9,>8,BX\YWBC+B$QI2HZEJCKD,8-/*:+B$
MI"@D1[\N!]Z2]I5^0G*^J-.Q&!3M"XPQRJVIQPQP.T8X5-G=`_RI;E^0-<_&
M)WG+_.A^$VB/>*;Y&W6+R$O;._\`HQCOZJ>_DC\^;NW/3?+'^@-?(<=UO-]W
MI>+Z>];BI'9OG6%TW>]U^?/:6CH"Q\#+!,.DV$/`<X82>F'ZH'%)C$0O&'E)
M)RCU4J93JF3:,6JBA@*4QA`O@`1Z`SZY.D.5<K7O%ML%!<G2=W[K+2!ABMQV
M_6!MM`QP&*EJ"1B0-NT@47=24+B+5L2)0)Z0:=)I..:',?17)[1%8K>K9RP?
M'&E<MN[WLUUHURIUEHEVJ$+:^7&K25%_8:Q:HV,E8]E<(](LA#N!3%M*1JI'
M+515+K&*^?Y=.X_>%NFY:6C[IJZ/&^Q)[-]8BRXTEB7%DNQ[3*\)0R_'6XVM
M499+,E&(7'?2IIY*%X`\SJVY1)VG9"&">,26BI*@4J`+B<,00#MX0>`C:*>*
ML=K:_P#*",\_1RP5RH^;/O#]R;UZND4E5E\\Q/&6^W%/;E'FG)T844844844
M844844844844844844844845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?L
MU*Z2.^)I9M<]N*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG:RF53AJ,*
M*,**,**B3=78O[\1_K+Y*Q\F_GA'W2NO5C5P^\'V?_ET?AJ'-.]N6?H^2]A+
MDNOS<.91=O3]H[^NN"T'[1M]R<Z@IOLJ94NM&%%&%%0EO/L[$^FB^8O,F<^2
M7S@M5^YB_65OI/-X_FICQCZBZC33/;9/T3(>NWR1[YO_`#,I/O3:NI+KD-`^
MT([@OZM-QE46ERHPHK$SWO%->B9'S-;%3W%_&W1WO5:?+X]8-S\VR.X.=J:0
M9/\`@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@9<?.#_=E]L:=(CL!T
MA7WF'7U1A12*W/M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_P`^3/&7.V-5C;;&
M+_XKW"@-@RU78S7Q$B?R;Q<,M8`F)ND^ZTS[C$GB+L59`;"POP2"QPKJR45[
MF@49T1;])1ABY3_A?V-OZ_JTS+<@?USF^'..AGBFI61GC2R0L(XE</B4@S4J
MD<>3]GX.X&E#LN7C+7QQ2%>#IR@8XE.W#'[N;'L=F'9[*Z(\@KI3*Y<]\2<:
MRW?M-J\D6#-R\V1L)1FV=/&S=P[383TBX?*-45E2*N",F_[XL)`,"1/IC=`>
M')<-W<24_H&T.L-.+:1:X84I*5*"2ME"4!1`(25JV)!PS'8,34WN[>="B[NM
M-L276VWG+'$*$J4$E01%;4LI!.)"1M5AP#::B]S,1#=5HDXEHQNJ]9+/F22\
M@T14>,63=-P\>M$U%BG<M&;=0JBJI`,1,A@,80`0'.M:A374+6TRZI#;@0HA
M"B$K4HI2E1`ZU2E`A*3@5$$`$UVB[E;F%(0\^RA;B5K0"M(*D(VK4G$[4I!!
M41L`()KI6XF&*?C9I@Y#%.0]$B#$,40,4Q3$.)3%,'2!BF`>D!#P"&17;Y04
M[T[ZE0P4+BYU14-F_P`4E6^;4:DD%)NCN!_<KGYVJ4?RK;-'H'H_*-=O#T#T
M=IY/]G))-'D?U.M(Z/V7%[PW4NF@B/Z@V0='[&A>3-U@*V4?C?6AZ!Z/C;`^
M'H'H]_6?[.;*Z$?8DH='P)[O2JVUZ(_J[-'1^SW^\+KJKR'VH%Z,**,**,**
M,**CC;/8.:^JCOA)IDA?RL.?%H_N=U]43JY/6WLU(Z:.^)I8J+VSK'IEG]>.
M64>6SS0-Y7N?/[V*1_3GG^'XPGJT\F4HZ<91A16+G/>28]%R'FBV9=O_`&]C
MNR.V%?*^Q/2JJ7NU.+/&ZT\0^`/(:QZ,U;-[RKO%?0Z<+M:2I<$[O,>,5KZ)
M:Q2Z-@59F?"\BFQO%M5S&,LW(4I4S%`A`!XG*IWO;TK1OJWD;L[7J"[Q]WTG
M5]W+MO1*=3$7QDQQ3@+(5DRN*ZYQ``2LDE0)4<>?LD"$Y;H<Q;39E)CMX+*1
MFV)&&W[G0^BIT[L;YFU)_.CRC_6JW7B>\K#XXS_1%@_V?M=9=B\VI[H[WU=/
MUC<JV]&%%&%%&%%&%%&%%9/\&8J7]EJPOU]<^7?O5>ZW5/0-9IT*T(E(R.R/
MC5=XZ(YH2>QZ]64G5*,]A]8R'%W3FZ*13['9!Z"&F;A$2!V2273%LU%1760?
MKR*[O8;#KC7EVOCZRMJX(\'BK<TPW">?+T[*[/1?KG;)4EACA$:VR60ZI6$M
M]".+0YR^HVW78T5MH#:C:H!XJ`P3L26D+2"?XRP</X(X2%\Y.M8]CQBX#LHN
MM2%/CVNJ;FW;5N6G]OVJ4BR)2E<(*4C8M^4_7^X9=ZL<HJJK3T+&/3'4']X(
MF"89(G\MAZ3(WD[YGYDMJ=)7?K45/MLVV.VX2S/.*&;1)F6UM`'6I3$E/M``
M?E%*S4P;EN`!6E`E)2/!9NPE9(Z^-PEP)6?\9(/W*8KN@?Y4MR_(&N?C$[SA
MOG0_";1'O%-\C;KPY"7MG?\`T8QW]5/?R1^?-W;GIOEC_0&OD..ZWF^[TO%]
M/>MQ4CLWSK"Z;O>Z_3G4@9W;^`+0KA5H9YSKKC,KMN1JJX:&=<9^4+<KMND_
M;/6"J[85.N0JZ*R!C%`%$SD$Q!^>3VX&;+O(>*4K"-WKZLI*@%9;[83E)0I*
MP%88$H4E8!Q2I*L""ZC%R&.#&6.].TD/+#C=<-#<7M<N-C;RGM\7E[RF[NZC
M.+'+ZRT;K:-BJU2^8='<UN(JT7J765*E8V"19S0![EOI&3CF2Y5#L4FI53E%
M^?R^]Z5DWB<NK3#6E]/QM.Z?;3?Y88;G76<MQ^59W4ON2'+C/E-K=*FOVAIA
MAYU!2F0MXH21S&JH3D33+Q>=+SIXI.)2A(`2X,``A*2!MX"2!T,*?&L=K:_\
MH(SS]'+`7*CYL^\/W)O7JZ125V7SS$\9;[<4]N4>:<G1A11A11A11A11A11A
M11A11A11A11A11A14?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]9^S4KI([XF
MEFUSVXK?M\WFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJ=K*95.&HPHHPHHPHJ
M)-U=B_OQ'^LODK'R;^>$?=*Z]6-7#[P?9_\`ET?AJ'-.]N6?H^2]A+DNOS<.
M91=O3]H[^NN"T'[1M]R<Z@IOLJ94NM&%%&%%0EO/L[$^FB^8O,F<^27S@M5^
MYB_65OI/-X_FICQCZBZC33/;9/T3(>NWR1[YO_,RD^]-JZDNN0T#[0CN"_JT
MW&51:7*C"BL3/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVII!D_X/Z)/
M7#+UD_LI'2<ZBJ;.GH?>JPQ+[&G]03ZT,H&7'S@_W9?;&G2([`=(5]YAU]48
M44BMS[7VCT])^=J9=QY('-0W;>Y%G\B:IN%_\^3/&7.V-)XOQYN(<TM*[8N/
M-JJ5]FYV/"6K26AYJTS4->!JDIJ1_`;#UG6*JO>4:Y9XNSKZZ,JV*C$`1-HO
M-O52+R1$'",#_+/WF6/^N^]O1MCT%,DOHGSH]UNS4=IV+X0W<FWH4Y^0(A?8
M<8$T)652<2XB`PA3<53C:U.T[#=\&@2'920,J2ALDA6!00I(&;`@Y=FS@S':
MK`BZW(;J4&N3#E5IZD;'WCN9[9FCU1\YGME4U)^P?&8OHQA(W)U(EDH1ZFF9
MU#3\>\0$R#MN=,W54.14%2"!2S+;G];W_2^[^Q,6I;8CHCP9)0M&=#BT1DHR
M.I)RNLK2<%MK!&("D%"L29D=+[O].:MW=V*3=T.&2O2\:*%H64+;2XPRL.-*
M'7-O(4G%#B"#M(6%#`"'K=H?7MR9BSFVLD8X:[:ZW:R+.0\CEHR$:"91B_AI
M%)#RB(GV@KK%!RW%,JR2YTER*I"4A>WLN\34MC?X^`MK+]IJG*0I&9MQU6Q:
M'4$Y7&58).1>)2I*5MJ0O%1ZF\;K]*WZ,IB>A[-]G>`I6E>5QMH$Y5MK`Q;=
M3F4,Z,H4E:DN)6C!(ZH^(;9)EQCT@R0`009Z]@FB(&$!,"+9`44@,(``";J$
M#I\`>'(@M]3JW][%_?<_.+N;RCTU'$_])J)[?LPB-O@U#&:_-MW)Q(Z0P`KF
MYV]J77#SD;M/8KVI1;VYK;(FU`G'A%'+ELXKUCF$HMVQ(LH9%@[115`AU$BD
M,J5)/K];Q9>B4C16L]4,;L+1IAB:\W8DVMH<4DA*5)>8:+B5D#%:21B`HD)*
ME9<,QJ4S0^A=)OV.S:KD0F7+\JSVT\:H%2DJ9BH#:D8DA"@#@2D`J"4YL<J<
M,!4]2:X:[DB]AIU**-=).^UJ47L"Z9W#Y%^W<1T*#A@98YR1XJQR)2*E1`A5
M#=)S`)S&,.RO.L]4.Z'>TRJ:\+$U;GVPR"`@H*5NY5X`9\%DE)5B4C!(.4`#
M;730FDV4W+5*83)OST1YPO$9E!:8BFL48XY,4`!01@%'%1!423UY9"K4(E&%
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MVMTIU%VN$B!`8,?%(44A2\&R$IR\`#CC8*B<,!B=@5T<*479]*V]SWT%Q8V=
MJ:;C=[2,/6+K&;&MHSFCZQ((6QS(P)C1TY":RV?L+7,/.(H,_P!_91,[)I-P
MZ@F4`Q^C'Z<CK?;N4Y&&N]X^CM\+C^E&;C/MCMMC")>YB%QF6I@4XT[*ML6:
MMK,ZG(Y*B1U.8JRI(2330.4_NJU_O:-@FZ)BHGIALRDOJ+\9DI4XI@H&"G<I
M)"%8A"E`8;3M%,3W<G%O>&@;YLJ;VM46U<C;#486*B'"%CKTV9R^9S+AVX1,
MC#23Y5`"-U`-UC@4H^H`].<!\S7E9[A.43N]TM8MT-Y=N=TMMYDOR$*A3(H0
MTY&0VA05)9:2O%8(RI)4.$C"OGDH;F=XN['4UWN.M8*(D25!:;:4'V'<RTNJ
M4H8-.+(P20<2`#T#4V\D?GS=VYZ;Y8_T!KY'_NMYON]+Q?3WK<4\V;YUA=-W
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M4V=/0^]5AB7V-/Z@GUH90,N/G!_NR^V-.D1V`Z0K[S#KZHPHI%;GVOM'IZ3\
M[4R[CR0.:ANV]R+/Y$U3<+_Y\F>,N=L:K)VTS6B.])XCFL]SUQ-2MRJ^L3ZY
MKDE7J^SG:Y0HBP7M]9H:9?&W$PLPS!+5$,WU6E6M-DRR;E9XP=.&B#(%!A@Y
M4#Z)L+?B+3`NC$.#JZ\":^AYY33\MQJ&AAUI'V:MCBO!W'&I\=RYL%A"6)#+
M;SCY2%#LH*56WC%(*E,-Y00,0D%6(/7XXX@%)"#B<02`*Z(,@MI3*Y@=W_RT
M;<_.7>/QDD<EHT#["67T5%[PBIQ]V'PUT]Z$A>3-U(U/XB[_`-@U>$N=3I;6
M2KE@9%>Q+X]GK+([AL"BC<3F:/95!T@/C43!U3D*/@Z>CH$,YB][Z=V^FKM(
ML5YGK:ND9S*X@,/K"58`X9DME)V$;02*XW47*%W2Z1ODK3>H+FMB\Q'2AU`C
M25A*L`K`+0TI*MA&U)(Z%7K<?*G/472FM*?:&98^P5ZJQ\9+LB.6SPK9Z@!P
M52*Z9JK-5P+T_P"$0YBC^WD>V\J\V[4.O;K>[2LNVV3,6XVLI4G,DX8'*H!0
MZ1`-18;W;_:M4[S+WJ*QN%ZT3)[CC2RE2"I"L,#E6$J3TE`'[E<ZFUOY5]F_
MG&NOXSR>2<Z/]CK3Z+B]X;J8S07L#9/0T+R9NM?K?;"M_*V!^'6>;*Z>9)7B
M3W>E5MKU[.S?1[_>%UU6Y#Y4"]&%%&%%&%%&%%1QMGL'-?51WPDTR0OY6'/B
MT?W.Z^J)U<GK;V:D=-'?$TL5%[9UCTRS^O'+*/+9YH&\KW/G][%(_ISS_#\8
M3U:>3*4=.,HPHK%SGO),>BY#S1;,NW_M['=D=L*^5]B>E59W=G;QTM7>"O`7
M6D_MW64+L:=XXZ*@86@RM[J["Z2LW(ZSBY>.B6%7=2B4VZD7\4@9P@B1`5%4
M0ZY`$.@<=;RK-W^N[GRA-X^JK=9;L_IB/JB[/.S&XDA<5MI$YQM;BY"6RTE"
M'"$+45X)5L)!K1V.5%1:HC"W&P\6&P$E0S$E((&&...&VI+[L;YFU)_.CRC_
M`%JMUYRG*P^.,_T18/\`9^UU[V+S:GNCO?5T_6-RK;T844844844844845D_
MP9BI?V6K"_7U5OWMRD2QT%3K"[N5/U[/U/D%3+'1+I>-F0>M(*O7)I!7ELT>
M'5MG'OD[3KBX5AWKU$L+*U1=JH54SLCALY9MSBX;DU)F2-_NIK8S!G7.W3+?
M=&)<6)!=G.O1E36%*3A'O-ADQDAQ+2C*CW!#B2D,J:=:?<36IO&46ME94E"T
MK04J4H)`5E/TMNA6S'K2C#HX@@5^W=-ZHUU0.'E$N^OJC;Z,.]6<)LZT5NYV
M$EFDFD\UJ5=UZ1TVE4:#J]N\CYJ)H[:0373@8Y)QY6)T44VHMTD^2Y9.L=3Z
MDWW7&P:EFPKA_5Y;L"._%9+"%,JDO3,JFS,GJ2MIR4ME2#+>4CB\KBU.AQ:O
M?3T=EFVH=92I'&@*(4<3C@$\.5/"$@]B.'8,,*LOQJE;RJ^^2/SYN[<]-\L?
MZ`U\<GNMYON]+Q?3WK<5IYOG6%TW>]U^W.=RV97+N_7KQP@T9LN=]9>O7;E5
M-!JT9M.-/)]PZ=NG"IB)-VS9NF9110X@4A"B81``$<^.3ZTZ_8]Y+#"5+?<W
M>/I2E()4I2KY84I2D#:5*)`2!M)(`VU^W4@.PR=@$L=Z=I?.\*WOH_='':DI
MZ=W+JG;"D!S,X!NYTFM-AU&]GA6LORRU>6)<RQ:M,2IHYO)F:*@W.MU"K"D?
MJ";JCT._^61N\U_H3ENZ35K>QWBS)DPKVEHSH4F('5-VJ3QB6_"&V\Y;S)SA
M.)3F3FPQ%<_K.7%E:;?\&=;<P4WCE4%88K3AC@3ACT*92L=K:_\`*",\_1RQ
MORH^;/O#]R;UZND4D=E\\Q/&6^W%/;E'FG)T844844844844844844844844
M844844845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?LU*Z2.^)I9M<]N*W
M[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG:RF53AJ,**,**,**B3=78O[\
M1_K+Y*Q\F_GA'W2NO5C5P^\'V?\`Y='X:AS3O;EGZ/DO82Y+K\W#F47;T_:.
M_KK@M!^T;?<G.H*;[*F5+K1A11A14);S[.Q/IHOF+S)G/DE\X+5?N8OUE;Z3
MS>/YJ8\8^HNHTTSVV3]$R'KM\D>^;_S,I/O3:NI+KD-`^T([@OZM-QE46ERH
MPHK$SWO%->B9'S-;%3W%_&W1WO5:?+X]8-S\VR.X.=J:09/^#^B3UPR]9/[*
M1TG.HJFSIZ'WJL,2^QI_4$^M#*!EQ\X/]V7VQITB.P'2%?>8=?5&%%(K<^U]
MH]/2?G:F7<>2!S4-VWN19_(FJ;A?_/DSQESMC2><@-?VYGS)X$[R<ET^;4K:
M0I.HWSJ9:K.MEMMI3LE<GE6:>YL94WTC/1+J.>+!$*+S<='P,GUWZS9P<B.0
M/\HO4EE?UYR@MW[1O?\`7-5^N=Q0EI03!5`93$3(5G<D(0RXE:4^$I1%>>EL
M98[;K25+I3K0RX(MJE'B_!^*0C;V6<YL-@&)&'!UP"3M(.RKK<ANI0:Y@MW`
M([GVX(`(@&R[OTB`#T!TV21Z.GZ.2T:!(_J+9?147O"*G'W8$#=KIX'A^Q(7
MDS=7T<._FRZ>^2X_"DCD=>^_XKWOQO\`R:*BCY1GQNU%X]_DFZ97$KI%*Y<M
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MJC>$+9;\)2R4)DI&5Y*ZYVRVV$[`A3UMI\+0PC!71/68#'Z<`3ACP=#"F.[L
M;YFU)_.CRC_6JW7B7\K#XXS_`$18/]G[76;8O-J>Z.]]73]8W*MO1A11A11A
M11A11A163_!F*E_9:L+]?54_>_R#%EQ^HS:8MIZQ7YCD52XVP,95MN'\FUWC
M"US8$E\2=QS.@Y!GMJK:YDG\<@Y&1BD9`B<TSCDGK56/6=B5Q_)@C2']_P!J
MAV#"$NY,6VZK96VJV^'17/#HZ/"K8U=T*MTB:A"UM\3(4R3%=DKCO(DH9QT]
MZ4!:F`I65!6@''/E4,I.59;.<).&.(QZX)Q&!-,YP?9FC^).@V)]LO-YF::]
MBD!VJ]:VIHI;?%J."@N@E>UW=W/'18!Y"T5F5W$LNU:IJ.UE7!U%#-^W_/B3
MOGU'(39D:?"[FX?L]*HZA'Q"=A,0)BA;GYUQ,9*(Z''%(90AM*4C:VH86YD<
M87>L'7[=O_6Z[`<`S;<!M.-3KL==%O0+H99=V@"M8FFB)H^=95>34>/X]=DP
M;1-BDE$F$),/'KA-%FY5,!$7)R&'U,3S2[:W=20`VE"B);2CG94^V$H6%K4X
MR@%;K24@J<;2,5("A66^0&58_P`4]'`_>)X#]!^FN>KA$_=2VSN[]EY%.[#+
MR.[.8*M@?7JT.K3)REH0XFTYG:9%HX?1$"[CVCJ>;KF,D+1)!943+MNELHD`
M26[_`&.S"TGO)A1C`\":L&FPRB)'3'0W'.H9*HZ%!#CR5J2R4`*XQ2TIP;=P
M=2O'CK62I^&I6;,77L<QQ)/%#$\`Z/W/NC95I/.DCE6W\`$F:R39XMSLK:+-
MRX;F>-VSM7C/R@3:N'#,J[4SQN@N8IU$052%4@"3KDZ>L#1>3VII%DWD+?2I
M;"=WCY4D*RJ4D7VPE24JP5E41B`K*K*2%9588'?77'C(>'#X6.].T@W(316X
M]#\-];5S;,SQT.)N8?`9G$T_C?HR2T_3JDNSYD4=X^%H^E=@6]]88B83DTUV
M[-1HP]RE3*ID.N0P&"0/D*;PM#[Q/F`:8NFC6-3@>"WI3DF]W9%RDR`JS.I1
MF0W#C(9<;+:D+<2X]X0D(4I+:@17*ZFB28FE7D2"SV3>`;;*$C\H/I4<0<>#
M`8?=JPRL=K:_\H(SS]')\^5'S9]X?N3>O5TBDNLOGF)XRWVXI[<H\TY.C"BC
M"BC"BC"BC"BC"BC"BC"BC"BC"BC"BH^VIV"L'VIG\(L\?K\L3GR:$\8N'JF?
M7+ZS]FI721WQ-+-KGMQ6_;YO-7&60/F#\RO>+Z#1Y=$I(=*>T43NOU54[64R
MJ<-1A11A11A142;J[%_?B/\`67R5CY-_/"/NE=>K&KA]X/L__+H_#4.:=[<L
M_1\E["7)=?FX<RB[>G[1W]=<%H/VC;[DYU!3?94RI=:,**,**A+>?9V)]-%\
MQ>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>VR?HF0]=ODCWS?\`F92?>FU=
M277(:!]H1W!?U:;C*HM+E1A16)GO>*:]$R/F:V*GN+^-NCO>JT^7QZP;GYMD
M=P<[4T@R?\']$GKAEZR?V4CI.=15-G3T/O588E]C3^H)]:&4#+CYP?[LOMC3
MI$=@.D*^\PZ^J,**16Y]K[1Z>D_.U,NX\D#FH;MO<BS^1-4W"_\`GR9XRYVQ
MK#4^D<,W6W:I<I30FK'F\49&+03Y!O-24]R_;;8:PQ6T?3AVTK&'F4-H-ZP0
MI4DO'`=-`"M`6*X$C8:W_+NO^_-G?SO)L4345X;T`J_32;,FXR4H5;U/!2Y/
MV<'`T8!D8YE9<"O%[(6PIT*[IAJV&UPW5,MF5Q2?RF0=GAL&?#'-A^]CCLJP
M/(SJ[*N2+EIJ-#86^-NRPVRRUN2;3>U*S!NX1R)!KTG,VQRJ%ICVYU`9KORM
MDU&CINY36;O6B@)G`O5Z1F>W,ZT<TUN[LL(0HLJ*MBWONI=3CQS;4=(\'60,
MP1F(<;6A25M.#,DG'`3$:=T&C56@-/SO#ID26C2S##*FE8<2X['9PD(2>M*L
MH*'$+"D.MD)4`!MZ-^$<?[D\3M$Q7CU'7N70V$;Y4MT^.=>0.';3RE;I,<?&
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MW+A[?*R_;U]:]V4*=%F2<1T8LT951&02A5(]V9(7)T5T52E=',<G5#H`-C>=
M4/N:'>L28=L0TW;GT*>$1CPES%*W`I4@H+H6G'(%(4DEL!*L=I.VNFD8[:+E
MJ!4VZ+=<ANK2R9DCP9O"(ILI1'#@:*%8<84K2H!PE2<NP#KOR%>H0Z,**,**
M,**,**CC;/8.:^JCOA)IDA?RL.?%H_N=U]43JY/6WLU(Z:.^)I8J+VSK'IEG
M]>.64>6SS0-Y7N?/[V*1_3GG^'XPGJT\F4HZ<91A16+G/>28]%R'FBV9=O\`
MV]CNR.V%?*^Q/2I(.ZU_LW^#7Z+>EOQ%AL7[E=<Z+>#[W73RMVM78?,L7Q='
M:BOP[L;YFU)_.CRC_6JW7GIRL?CC/]$6#_9^UU^6+S:GNCO?5T_6-RK;T844
M844844844845D_P9BI?V6K"_7U3%WQB>U9Z*XXT*G#<'%%M>[))Y?8BE<?>4
MN\#SJU7J4_)P$1>UN+&U]76^`URL99PLLU%1PXD9=O'JH@"+)V4[MN2RK1]N
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MN169DIAOCELM"8T6'U--_EG&W$ELMI/&8(S$>T/4NF]1MO1;1.CR%I;Q6&W`
MHI23@"<IQ&)V`C;CP;:K2XLL63/<'=['9-W(>5;CY@`O*N+$SLJ=D"+XGT^#
M83L<Y&V66TQL2ZBXQ`C=E8VM?GT"I]+B*0(9)=RH.]V1(?T3O+2^I/66/3>#
M894P6.,U#)=6RM/@[$=;B7'%E;L)R9#63^2F.*"VVL2``),/#_O7MN...#0&
M(VD@8#@4$J^E(X38[S>[=]WI^GQ4?U;^3F->W!>SN\O_`'<R?7=BK=73\[#\
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M5^YB_65OI/-X_FICQCZBZC33/;9/T3(>NWR1[YO_`#,I/O3:NI+KD-`^T([@
MOZM-QE46ERHPHK$SWO%->B9'S-;%3W%_&W1WO5:?+X]8-S\VR.X.=J:09/\`
M@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@9<?.#_=E]L:=(CL!TA7WF
M'7U1A15?EEBYW9&Z+)JBIRBE<=$.O:;W<$S($DJM2Y":DHMH2G-G93ED[I8W
ML8Y;MG`)JLX1-,SMSUEA9M75H/6W++B<D3D"[L)5HBJF[S[]H>VLVE"VEJB,
MJ;@L<;,E.8!M28_&(+<4*XQ]PIS!+(6JD6C:>5?M4S4N*RPFI*RX0>N.*C@E
M(X=N&U7`!]W"G#0U5KUMKM/5"-6CB:_2B_<@E=#RCQ/D_CO*Q=B]\?[IC-FD
MA\M&1\?[H#(#Y6*WE/[[E:Z[;PM:W[6\C>1>KE*E:XERUR7ICJL[KKSA.=2\
MP*5)4"4*:*2T6CQ11Q?64L+<2,U&$-M"4QDIRA(V``<&'5QX<=O#6DT*R6"J
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MB(VXVN0@*0M#"$J0H=!25`@CH$5<_P`68"<JW'W5M?LD2_@IR+KHMY*)DVYV
MK]BO[HOE/$NFY_ITE/%J%'H']@0QBN]ZY6^[[RKO<K6\W(M[TK,AQLYD+&1`
MQ21L(Q!%1K[][M:[[O=OMWLLAJ5:WYF9MUI04VM/%H&*5#81B",?N5/V)O22
MUSJ[)X[[XDME;!DH_4&P'L?(7RVOV+UO7G:K9VR=V&0<-72"A0ZJB#A!0IR&
M#P"40').=+;S=W<72MMBR;W;6Y+=NC(6E3R0I*DLH2I)'0((((Z!%3%Z+WP[
MJ86BK1"EZBM#<MFU1$+0J0@*0M$=M*DJ'04E0((Z!&%86`XX[^0M,`Z7TWL-
M)LWLT,Y774KCPJ23=&9:K++J'$.@J::1!,(_L`&9]QWH;N'+1)9;OEL+JHCJ
M0`^G$J+2@`/ND[!]VMG=M\NZ5VQ2V&M26=3RX+R4I$A&)4IE0"0/I)(`'TUT
MB9%O4,-&%%&%%&%%&%%1QMGL'-?51WPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'
M?$TL5%[9UCTRS^O'+*/+9YH&\KW/G][%(_ISS_#\83U:>3*4=.,HPHK%SGO)
M,>BY#S1;,NW_`+>QW9';"OE?8GI4D'=:_P!F_P`&OT6]+?B+#8OW*ZYT6\'W
MNNGE;M:NP^98OBZ.U%)/P6[P7BKISCC%:UV#<KY&7"K;:Y.-)MC$\?\`D1<(
MYNNXY/;B?I%:V2F:JL%9E2"U=D$3M'BY"F$2"('*8H+URA.39O@UQO0>U5IJ
M#;G;),LUB4TMR\66,LA-AMJ#F8E7!E]LYDG8XT@D8*`RD$ZNU7BWQH08>4L.
M)<=QP;<(_.KZ*4$'[QJUK07)#37)ZJ3EUTE;'5MKU9M\G0;"M(5*ZTB3A;A#
MQT/+R4#)5Z_5VKV)H[;1E@9K=)V@)G3<%$IC>'H9YO&W7:YW37B/8=?0T0KE
M+A-S&0B1%E-NQG5NMH>0]#>D,J2I;+J=CF(*#B!LK?Q)L:<V78JLR$J*3L4D
M@@`D$*`/`1T*G'$_K+HPHHPHHPHHPHK)_@S%2_LM6%^OI`^=FU=Y5\M`T_Q1
MGZLQY+;6GK:O6(>VQPJQBE#@*U*Q-KN9I:2A).KLTM9VFV5Z<=,W*J+V68,G
M#-B19PJ"8JWNST?N^N6M]5:VWQ1I;FZNSS%!]V.O!P2WIW&1XO%H=;D*,Z/'
MF1&W6TJ:CO.MOR%-MH*JP)DB4B,Q&MY2)SB=@(V90G`JQ((ZTE*B#M(!`Q-<
MI']X\9;=C*CW=$;OB61G]LQ^O]^,;?.IIP**TVX:6C7#>,EY1&JL(JK)3\E!
MIM5I$L8U;1Q7YU@;))H=0@7O?^2[D:+EP>4]*W=LJC:-=U#HM<9HEXAH*A:B
M+C;9D+<D%E#I<2P7W%O%D(+JU.9E%L?*($E*K*F6<9`:D8G9MZYG`G#`8D88
MX`#''#96J_W<&"B;+/\`/^"G7X1,1(\6TD7\J:9L]>3BD"S<@L,FM.4M_%6Z
M+0CS)@LHM&N47I"$$43@?HQ0O^<YN$RU;CN3Q<+>WQTUK>G-*&^*8>+A^S6Q
MQ8:E(<C.%>.4)?0IHDC."G&L3D\H2NY79"S@DPD[<2,.O.W%.!'WCC]%7#\+
M[5$V_<W!>2AV\FQ0:;RY2PCME/N]BR-B+*07![5<1+2$I([,81<VZ9SDJR7>
MQA$$"M6L6N@W.(O$G124FM^UGFV30N\&+.4TXXO3]@=2IE,)#/%NZJN#C:&T
M05N-)4TVI#3Y6LN./H<<2`PMDEQUL<2Y)B*3B`'71MS$XAA`.)5@=IVCH`8#
MAQJTOF]V\[O3]/BH_JW\G,:)N"]G=Y?^[F3Z[L5;ZZ?G8?C8[V[4+]Y'LG76
MQN-](5U[?J7>TH'G'P5BIQ6FVF#M"<-*%Y8:I$T;*GA'SXL<_*!!Z45A(H'0
M/@\&.Q^5UI;4^F.7!I-&I;=/MRY%LN[C0DQW6"ZW]ERNO;#J$9T;1UR<4_=K
M1:U?9>TT_P`2M*\%M@Y2#@<Z=APX*G.L=K:_\H(SS]'+)/*CYL^\/W)O7JZ1
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MLLV]J%I(W%T$>NZ<`20B)EB55`9NGV)%`B,I'&.0%TRD52.B[0;.$;BN['<?
MN^Y0_()T'NOWDQ?"+%,T-9U-N)`$B')3!;#4R*L@\6^T3L_@N(*FG`IM:A3?
MIMREVG5$J;#5@ZF2YB.@H9CBE0Z(/_0=HVBO98N\$U?5-53MAEVZ)]SUZ;<T
M)WHME+(GL+O8C=L9<@,7JC<IC:U=-2^Z!;*9N#5.-Z0.F$@46&5L-;\C'>#H
MC?A<=U$UYMW35NE.Y[RA"O!#%:=+16$G`^&%0XL02H.EXC;X.?"*=9HO0>L]
M<W:UV*TP'47.[0VI;7&#!I,1T`B6IP8CP=(Q"E#%6<<2$\<0BIUXT1Z\GK:`
MVK95D9;9.VX""M=XGR)J$1%5PT.YC*O7T%U%E8FE5-%Z=O&,@,/5`RCA8RKQ
MRZ760;>K);B:IDZ/M25,Z6LLEV/%9)!."595OO$`!R5(*0M]W#;@AIL(8::;
M1X:STLC1>L+GI@/&0N#,<8+I`27.*44YLHQ"4G`D)!.&.TJ.*BQ&)E7-T844
M844844844844844844844845'&V>P<U]5'?"33)"_E8<^+1_<[KZHG5R>MO9
MJ1TT=\32Q47MG6/3+/Z\<LH\MGF@;RO<^?WL4C^G//\`#\83U:>3*4=.,HPH
MK%SGO),>BY#S1;,NW_M['=D=L*^5]B>E50/=F<0M-3W%_A!R3F2;!?;"'BGQ
MA\BCAVOL=G0(B6HM&;$C+%&:^CK,SJJ,K)LWB+>2(=LHQ?D8MSJMQ6!959['
M*MWUZYMV]K7^ZR";:WIK^N%^S+^SX2ICC<N6HN,N3%L*D%MM25+8(6EUDNN)
M0YDR(1SECMT9<"+-5G+W@[6S.K*"E.PA(.&)Z.S`X#9CCBS'=C^'AM2?SH\H
M_P!:K=>)3RL/CC/]$6#_`&?M=9UB\VI[H[WU='!WMQWA7Z?=U_5XXTX;_P#V
M?W:?[N(OKF^46K\[,\<5WMJGZQN5;>C"BC"BC"BC"BLG^#,5+^RU87Z^J/N]
M&MNO]<<F>.5]OFY.7FIHQMJ7>]6EY'AY7XF7M<7#7';?&:"B[)?32<'<922J
M#G83N#KS*)K\%+S[Z=GF9TTB-4')\>5N`LNI-4:>W@:=T[8]%7F6O5T.0VC4
MKSC<=QV-%U"ZXQ$XMV,VB2F&F7,=D3)<:&U$B/I4M3SC2:YZZN,LNQ7G79+:
M>(4"60"0%*:`*L021FRI`2DJ*E#H`USZ_P!X<7FG>M.[/=V%EO".EG6J]VNG
M#/DHO55]\I).)_6BS(VU?B4!:RVMZS$Z1W+9L4@M1,"*I2K)J%"ZW_R9K<!E
M?*E9MCE@=A(U/HY*56,2!:"4Q-1A7V?X5^75&"PH(6LGC,"X@E"DDMSY0I4?
ML0K#H5Q,C\[AQG9,]GEV8_2!P<'#6P?W7]X>.VQS2D$V<7(J,>/40\)'SC]M
M%PKX[6R/%RLY>3>)JM(Z+<B3J.%U2F312,8Y@$H"&;K_`)U]A,KDV[A8REO-
M)<WE7!)6TA3CJ`JUH&9MM)"EN)QQ0A)"E*``()KSY.9RWBZ'`'"&CAV#L^B>
M@*N/XV[4<;@WOP,M,AJ_5&IYYMO7F=!6R!U"RK<=!2ENC.+E73GIV695:TW5
M@6767,5NDNK)N'#J-;ME>@J0I">DIO3T@WHG=YO%M$:[WF\VY>GM,.QWKDI]
M;K<9R_OEEEM4B/%7Q8&*U)2PA#;ZW48E86`XZ%(,F7$<+;;:^->!",`"0T,2
M<"K;]_:`*?KG_&)3DSP6@UVC>00G.:\;"+Q[QRZ9,Y!&7XM<J(Y5@\>L2F?,
MF;U-R*2JR`"NDF<3I@)P*&-RY-\M=O@[PK@VM3;D?02W0M*4J4@MW_3ZPM*5
M]8I22G,E*R$*("5$))K;W=.=41!&(,H#]UIT551>.+NQM`\9(>R[1U73M76&
MX<JN[=JC"&K^];'NV6A("C<Q*B+&G/'S_5^N*^WKT0$MY3'/$#2,F]([,#U0
MADR$+)QR/][>F-X_+GT7:M(WB==[9!1J*0MUZTL6MMUZ79UYY*4(GS7E/.<7
MQ;[2PRPT6P8Z5!94>,O\!Z'IF2M]M+:U%D8!PK("7.Q[%(P&.(.TG';5O-8[
M6U_Y01GGZ.3:\J/FS[P_<F]>KI%)Q9?/,3QEOMQ3VY1YIR=&%%&%%&%%&%%&
M%%&%%&%%&%%&%%&%%&%%1]M3L%8/M3/X19X_7Y8G/DT)XQ</5,^N7UG[-2ND
MCOB:6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJIVLIE4X:C"BC"B
MC"BHDW5V+^_$?ZR^2L?)OYX1]TKKU8U</O!]G_Y='X:AS3O;EGZ/DO82Y+K\
MW#F47;T_:._KK@M!^T;?<G.H*;[*F5+K1A11A14);S[.Q/IHOF+S)G/DE\X+
M5?N8OUE;Z3S>/YJ8\8^HNHTTSVV3]$R'KM\D>^;_`,S*3[TVKJ2ZY#0/M".X
M+^K3<95%I<J,**Q,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FD&3_@
M_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@9<?.#_`'9?;&G2([`=(5]Y
MAU]4844BMS[7VCT])^=J9=QY'_-1W:^Y%G\B:IN%_P#/DSQESMC5#O)&D6&P
M;ZN$U#['L5)9M)"PQ<@PKL%0WCN466D6+U@Z-,VJIV1^T;M"IKD4:IB5%85"
M'Z"'3$3Q8[[K_;+;O>UA`G6N-/?7J22XA;SLM*6P%NI6GBH\AA"BK%!2XK%2
M<JD[4JP3/CN"TY=;IN4T/<(%VE6^,C3$=M:&&82E.*(0I"N-DQ9"TA("PIM/
M6JS)5UI1UW2UQE#HX]Z8`1$PAKBJ`)AZ.DPA$M@$P]4`+TCZH]``&0.;U]N\
MN^G@_P#-)'?%5';OL&&]W4@X?_.97?55.6)_27T844844844844844844844
M844845'&V>P<U]5'?"33)"_E8<^+1_<[KZHG5R>MO9J1TT=\32Q47MG6/3+/
MZ\<LH\MGF@;RO<^?WL4C^G//\/QA/5IY,I1TXRC"BL7.>\DQZ+D/-%LR[?\`
MM['=D=L*^5]B>E20=UK_`&;_``:_1;TM^(L-B_<KKG1;P?>ZZ>5NUJ[#YEB^
M+H[45^'=C?,VI/YT>4?ZU6Z\].5C\<9_HBP?[/VNORQ>;4]T=[ZNC@[VX[PK
M]/NZ_J\<:<-__L_NT_W<1?7-\HM7YV9XXKO;5/UC<JV]&%%&%%&%%&%%9/\`
M!F*E_9:L+]?5&'?5ZOO=UA=>6>B<(8+E&]ID#N!V?8[X-CW:8U%+H(5:QTVO
M1>B=2;*U3?\`9*6R;?6F8FD&LFJE6W,2@[4:K")`!Z7)'U;IZP[Q=5VG4.OY
M&D6)U]83X$CP**U<FS)EL27G+M<8-PAP3!C/N8,N,)5-1(<92\V`K'G+\PZ[
M$8<:BA\I:/7=<HH."2D!M"D*5F(&T'K2`<#7.-WY43%07&_NGHJ&G)>QLFFC
M=P%/*SU/L.OY<\BK-ZT7F6+VE6U%O9ZRI#S"J[,&<@47:14`!4QS])S7=O\`
MD^YDRX:IY6<R='9BOKU?I#!MF2S,;R")J,-+1*CDL/AQL(<XQD\6HK)0$IP2
M&W[_`%*4,6)*25`1Y&T@I..9G'K3M&!V8';4D?W9MRQ9W[G2[E'4(QC6W&=L
MN_>6:.5EZXU9I3<B=RXGXE#]_E89%$!,Z;$^G70`Q"^$P9]?\Z>U(?Y/G)^9
MB(D.2E[T)P0EA8;?4HVUL)2RX=C;I.`;6=B%8*.P4<G4@76ZE6`3X$GA&([,
M\(Z(^D5;UPSK%QK&P>[90N=;AZT[>[&Y5N80L179"NDGJLAQ(J+&`M*X2--H
M*\F%@8MBN$5?<TAD4C@BJJHL17JTH=^=VLEVTUO3<L4I^4RW:]/I=XQY#Q9D
M'44E;T<9),P-\2M10I/'D*4,Z$);4C%QEL;<;>A!U(22MW#`88CB1@=J4XX\
M/!]SAJSOF]V[[O3]/BH_JW\G,:;N"]G=Y?\`NYD^N[%6]NGYV'XV.]NUIG>J
M_-SUG^FIP4_6PU/CD_E/<][3/B%X]52ZT^N?9M[\9OMTUOU8[6U_Y01GGZ.6
M9^5'S9]X?N3>O5TBD;LOGF)XRWVXI[<H\TY.C"BC"BC"BC"BC"BC"BC"BC"B
MOR770;(J.'*R3=NB0RBRZZA$D4DRATF.HJH)2$(4/5$1``S[;;<=6&FDE3BC
M@``22?H`&TFOMIIU]Q++*5+=4<`E()))Z``VD_<%8;XUU?\`TD@/\\1W['A'
M_P!H_:S.^Q[O_-9/Z)?_`--;/[!OO\RE_H7/_IKZ):*RH8I$[%!'.8>@I"2\
M>8QA_:*4K@1$<_%6BZI&9460$CHEM?\`]->3]GNT9I3\F+);82,2I3:TI`^Z
M2D`??K2-I3,.:ASX!+1@B*3/H_[0:!_WBS_9%;H_8Q]WRR(<MOEQ:%6XTXE`
MD7#$E)`\TS^B17"ZS4DZ:D@$<".^)I:==2L4%XK8C*Q?W>;_`+Q9#_[*X_8!
M?I'+'/S!$+<Y%N\1"`5+-C1@`,3^VQ.A21:5V:BB8_\`>_553K>[<-_[WC/X
M^T_ZW*:?@$[_`+E[_J*_>IPF9/TBCW;AO_>\9_'VG_6X>`3O^Y>_ZBOWJ,R?
MI%'NW#?^]XS^/M/^MP\`G?\`<O?]17[U&9/TBCW;AO\`WO&?Q]I_UN'@$[_N
M7O\`J*_>HS)^D5$VZ)B(/3.@LM&#_P!L1W_>#0`]1Q^R*P!DJOR=(LEGE@%;
MS;B$_P!4[KM*2!PQOI%<1O`4DV#81^?1^&H>T_+1);PT$96+Z/<^2]219C_`
M!^P"PCDN'S;&W'>15=D-)4I?V_:-@!)_/KZ`K@]"$#4;>/\`W3G4IJ92Y5"#
M:^735KK<0R\:FAY9*3L7'M?'*];Q2/E#MTDCXU3JCU2]/2/0/1E5"RZ1U7J2
M;]FZ=MEQGW'(5\5&C//N9$X9E9&D*5E3B,588#$8FEO<?893G=6A*/I)`'[I
MK!);;U2N82H;-UZL8`ZPE2NE;4,!0$`ZP@22$0#I'U<WERW5;T+,P)5WTW?X
MD4J"0MZWRVDE1!(2%+92,Q`)`QQP!^BL5=UM;2<SDF.E/TEQ`'_2:RL??:-+
MK&;15TJ<FX(F*QT(^QP[U8B)3%*94R39XH<J8&.`"80Z.D0_;SFY.G=00FP[
M,@3&FB<`5LN)&/T8J2!CLX*^H]SMLM?%Q9##K@&."'$J.'TX`DX;>&HMWC,1
M!Z[$]66BQ_[:+_W@S#_V%W^VL'[>3$_)0C2&.4!JI3S:T).C5]DDC_\`.4#Z
M17$[QB#:F,"/VCZBJC734M$ENJ8C*QG1[E2/J2+,?V6X^H"PCZ@9(W\WMIQW
MD:24-)4I?]:+5L`)/!*Z`KD=`D#4(Q_[A?U:;7W;AO\`WO&?Q]I_UN53?`)W
M_<O?]17[U+AF3](H]VX;_P![QG\?:?\`6X>`3O\`N7O^HK]ZC,GZ16*GIJ&&
M#F0"6C!'W)D?_;VG_P"!K?\`2XJ6XV#-3OLT<I3+H2-4VG^`K^?Q_N5A7-2?
MLV1M'YASM32%)RD5^]_]JQ?JD_[R9?MA_P!/EZ*?V4CI.=15-H3T/O58.G-0
MWBTP]UXSIZA/_;VG_FA_TN4%[A`G>'OGB7<..7_`5_&/W*=$E:<@VC@K&GO%
M*3.9,]PJY#D,8AR'L$24Y#E$2F*8HNP$IBF#H$!\(#@G3]^4`I,*64D8@AES
M:/\`JUL4VVXK2%ICOE)&((0K`@\!&RLBC8(%PFFLA-Q"R*I0.DJC),E$U"#Z
MADU"+&*<H_M@/1F*NVW%M90Y'?2L'`@H4".F"-E8;@+2RTZ"EQ)P(.P@_00=
MHJO?;.RM<4JV.U;EL"DU-&S7U:JUY>R6F$A&TS9I([]U&U^/<R+UNW7F)!NP
M6,@W`WC%O%&`@";H`;LW)!2I')3W;(6"%#1-G!!V$'P-KA%-NO\`Y\F'_P#&
M7.V-5,[E$!VOL,0$!`;3)"`AX0$!,40$!]00$,B'Y0WQRU5Z=E]^75B'DS\W
MW1ON_$[2NA3C-\WS3/YN:K\%-\A$WK?$J^^E)'?%5%_OM^+VI/3,KOJJG'$_
MI+J,**,**,**,**,**,**,**,**,**CC;/8.:^JCOA)IDA?RL.?%H_N=U]43
MJY/6WLU(Z:.^)I8J+VSK'IEG]>.64>6SS0-Y7N?/[V*1_3GG^'XPGJT\F4HZ
M<91A16+G/>28]%R'FBV9=O\`V]CNR.V%?*^Q/2I(.ZU_LW^#7Z+>EOQ%AL7[
ME=<Z+>#[W73RMVM78?,L7Q=':BDUT1R0V3QWX*:04U+H.?Y"WG8&]^65<BJG
M!2K^+)&)Q7(O?=ED)J:6AJO<9A&(0CHM4IEDV!TRKBDB)O'+H)JKEO#W7:6W
MF\H6_IUGJ.-IK3]MT[IU]R0ZVAPN%RRVAA#30=?C-%PK<20E3P449U@9&W%(
MUD2:_#M+7@[)>=6ZZ``<,,''#B<`3A@/H^YPD4WW!=0RMQ[P)8Z*C<ZW/.W+
M*-EA3%9LHMQRXRJ*-EA1461%9L<PD,)#F()BCU1$.@<13E!I"+'NV0E04E.[
MN,`H8X*`O=]`4,0#@H;1B`<#M`-;&U?G)A__`!L][:I_\;?6XHPHHPHHPHHP
MHK)_@S%2_LM6%^OJJWO%.(]_Y(7_`%';651XO[;U=K&N[896G4?+.Q;&AM:'
MM]RE=?&J^S&D?2*]8XF5LU2@ZY,1K9650$&*<VJHV$JIC&QQ>YS?1IS==<M9
M65^;JVRZNNU^95'N.G683L[P:,Y</"(*ERGF'&V)#K\9]:8Z_P`JJ*A+H*`!
M6HN%N>FHCN!+#C#;1Q0Z5!.*@C!76@@D`$#'@S;*Y;._ZU7L/2&G.[$U-M6T
M1EQO5$U9O>#F)V$F;)884S=*U:[6@HF&G;@FE:9>)K=>6:1K9Q(%\K50:%,H
M(F$1&]3_`,G!K#3.O[ARJ-9:/B.P=/7'4^C'6FG6F&7<QA:A#KCK48F.VX^\
M''UH9/%I6X0G`;*;-R@H[T5%DCR%!3J&9`)!)'9-8`$[2`,`"=NRL)_=\(FO
M3:7>*1UK@+5:*VIQ30<3,#1E:PA<Y!A'V%W(+$JCBZ.&E6;V%`&OC6:CU0J*
M:Y"F'I$``>Z_YQ^9<H&Z+DY2K/)AQ+H-ZLU+3TL/F*A:[6A`\($5*I"F3FRN
M):25%!(X":QN3ZE"I]W2X%*1X"G$)PS=GT,VS'Z,:Z"-(0NL(?>_=U*ZBK5K
MK5/F]A\H)QN2WW/4-TDIA9YP[HY$IA-;25GM%+A$5(U%N@=H8[9\HN@HZ61`
MKA-0]%'7T[5LW=YO.1K25#E7N/;+"T3&BW**AH)U+*Q:(NK#$ITA96L.`+:2
MA:64.8M*2ES,5+"9<+P9*DME;IVJ0HG\BG;UA*1LZ&P]$C;3V\WNW?=Z?I\5
M']6_DYC>=P7L[O+_`-W,GUW8JVUT_.P_&QWMVM,[U7YN>L_TU."GZV&I\<G\
MI[GO:9\0O'JJ76GUS[-O?C-]NFM^K':VO_*",\_1RS/RH^;/O#]R;UZND4C=
ME\\Q/&6^W%/;E'FG)T844844844844844844844845`_*$`-QWW,!@`0'7ED
M`0$.D!#W/5\`@/@'%$W2$C>;8B.'[38[<4JNXPD;X=-$</VQ&[X*YJ6Z"'6'
M]Y2^P./X,G_X.K^YDJ+CCF'9'LAT3_&%35O.NY>R5V2>B?XPJ;.-%0J=SWUK
M"KW"L5ZUUJ7L"J$M7K+"QL[!RB"41)NDD9&)E&SI@]23<H$4*55,P`<A3!X0
M`<X+>K>KS8MW5VNUDER8=U8C`MO,.K:=;)<;22AQM25I)22DE)!P)'`32,\H
MQ*9.X_4;,@!QDPDXI5UP.$ADC$'$<.VKG-F\1>*+:CSJS?C'Q\06(DS$BJ.F
M==)*$$9!H4>JHG7"G+TE$0'H'PAG,?+<WI[S=0\M/1-GO^H[[.M#TB>'&)$^
M4\RX$VJ<I(6VXZI"L%)2H9DG!0!&T"H,]7PH36G9+C3+27`$X$)2".O3T0*7
M+7W%?C`O=*ZBMQPT,LDH^,!TE=14!1,X>3.!Z#D/7S$,'2'3T"`Y84Y>=UNE
MCY'>\"[663(AW5BRH4T\PXMIUM7AD5.9#C92M!P)&*2#@2.`TE.F$(=U!%;<
M`4@N;01B#UJN$&G(_J?<2_\`=>X[_P`RVM_]6\J$?WV[YO\`6W4W]*3OU]+W
M]FV[_N&?^HG]ZC^I]Q+_`-U[CO\`S+:W_P!6\/[[=\W^MNIOZ4G?KZ/LVW?]
MPS_U$_O4?U/N)?\`NO<=_P"9;6_^K>']]N^;_6W4W]*3OU]'V;;O^X9_ZB?W
MJ/ZGW$O_`'7N._\`,MK?_5O#^^W?-_K;J;^E)WZ^C[-MW_<,_P#43^]46;AX
MD\5&=/\`&M>,W'YLK[K,"^,0TWKM%3JB"_27KI5TINJ/[(=/0.2??*.WD;P]
M5\K,VO5%^O-RMG]5KFOB94V3(:SI,;*OBW75HS)Q.56&(Q.!VUQ>O(<1BQ9V
M6FT+X]`Q2D`]'H@5$FI>*G%YU=&J+GC=H1PD9A(B*2^H-?K)B((AT")%*^8@
MB'[`]'@R5CYJFH+]ICD<W2[Z:FR[?=4WVTI#T9YQAT)4^L*2'&E(6$J&Q0!P
M(X<:XC1#33VH$-O)2M'%.;"`1P?0:K0_O%?'?0&ON[M5GZ%HW3])G?RYZQ9^
M[51UI3*W+^1N&=K\H:>Z4/"LWGDR_4+UT^OU#=4.D!Z`SE_^4LU3J;>?\V5&
MF=Y5QG:ATW_=IJ)WP2YONSHW&H=MH0YQ$I;K7&("E!*\N9.8X$8FO;?LPS"T
M+QT-"6GO#&1F0`DX$+Q&*<#A7%AQTK-5D+A,$F*_7WK1"KOG'5DXN.<-D#$?
MQH"X'RI`R20D3,;Z?P=`"/AZ,N7?/^T;I31/(MLUTT1:K?:;PYO"MK1>@QF8
MKRFU6Z[J+1<80A:D*4A!*,2DJ2DX8@5'!O=O-\BZ40NWRY;<E4UI(+;CB5'$
M.=:,IQ.)PV='973+W%&F]";`Y:;&B;%JS4%V81>D+,9>,F*53+*TC99*ZT!(
M!69/8UZBRD4D'!R_3%*J4IS!Z@CG\_7YA6N-XNF]S5KFVR\7N!(>O[&#C4J4
MPI;9BS#L4E:"I!(!V$I)`/0%=MR)9NH;EO3EQ]2.S7X:[`\ZVF2IU:%?YS$`
M<0'24G82`M..PD8[:Z9-U<2^*S*OQ9VG&?C^V.:8*4QV^G-=H&,463L>J8R5
M=(8Q>DH#T#X.D,U7R;-X.O=7;^-40M5WN[W.$WI!:T-RYDB0A*_M&"G.E#SB
MTI7E4I.8`'`D8X$U(AO!B18]K94PVVA1D88I2`<,BOH%1SJ'BGQ==W$B+KC;
MH1PE[ER!A37U!KY9,3!X@`-U%:^<O2'3X!Z.D,D(^;%J+4&EN2%(NVF9TRW7
M0:EM:`]%><8="%"5F3QC2D+RJP&9..!P&(V5RFA66G[^&WDI6CB5[%`$?P>@
M::G^I]Q+_P!U[CO_`#+:W_U;RKU_?;OF_P!;=3?TI._7TM/V;;O^X9_ZB?WJ
M/ZGW$O\`W7N._P#,MK?_`%;P_OMWS?ZVZF_I2=^OH^S;=_W#/_43^]6+G.(/
M$U.%F#DXP<>2')%2!BF+I?7!3%,#180,4P5L!*8!]00\(8INY3?'O=F[Y-)0
MYFJM1NQ'=3VM"T+N4Q2%H5.82I*DJ>(4E0)"DD$$$@@BL.XV^`FWOJ2PR%!E
M>!R)_BG[E(T3BYQE^D_^G317JD__`%2T+]L/_P!`Y=CG;%/X;,`YA^XJFY)Z
M'WJ?=/B!Q,ZB8_U7^/'3U"#T_D6UOZO5#_\`EO*+4_?7OD3.?2G5NI@D.KV?
M:DW^,?\`QZ<NFVVXH&+#/!_$3^]7,%N'47&2L[(V`C+:RT17FQ=B62.9I25/
MH$0B"CZT3+2)8MB.H]N0#O#M%$VR90Z5!2,4@#U1`)7M$:UWL7;2UM7#NVHI
M+IMC"U%$F8X<$1VE.+44K4<$A04M1X,P*B,1C-/IC3&ZZ#HJS/7BWV%EQRV0
M`5/1XB2I;K",@Q6@$K<4E67A*U!6&)!KH(XP<3.*\CQ[U"]D.-&@'SUS2(A5
MR[>:<UXY<KJF3,)E%UUZZ=550P^J)A$1R-K>UOEWOQMY5[CQM5ZD;83/<"4I
MN<U*0,>``/``?<%17[\;)9H>][44:)$C-1D71T)0AI"4I`(P"4I2`!]P#"EM
MW)P9X<7Z??0]JXRZ6?0\#>QL;2(94*!@(QY(0Z[PD<WGF=>:125D@FZCCQPQ
M;\'$:LNDDHJ@<R*8EMU<DZ?.NO)>W=W.YO.R;C(T9:7'775J<<<<7#:*EN+6
M2I:U$DJ4HDD[22:9-?4I1>I:$`!`D.``;`!F.P"D*V^@@UVA?6K5%%LU:V-Z
MV;-FZ1$&[9LW*FBW;MT$BD20001(!"$*`%(4`````R'[E#?'+57IV7WY=6(N
M3/S?=&^[\3M*Z&.,WS?-,_FYJOP4WR$3>M\2K[Z4D=\547^^WXO:D],RN^JJ
M<<3^DNHPHHPHHPHHPHHPHHPHHPHHPHHPHJ.-L]@YKZJ.^$FF2%_*PY\6C^YW
M7U1.KD];>S4CIH[XFEBHO;.L>F6?UXY91Y;/-`WE>Y\_O8I'].>?X?C">K3R
M92CIQE&%%8N<]Y)CT7(>:+9EV_\`;V.[([85\K[$]*J$N[YX4[1O&G>[NY'-
M.5][@=;UGC]QRM9-%)QML7:M92&UA0(B;CZY8X_:L)4XRL79E54T)-C(527$
MS>0DO$JI+NRN4)%^4IOYTEI_6^\W=>]HZW2=4R]27N.;L5QPI3;L^8XTM]A=
MO=D./Q52%+8=9N$;!;,7.A;;):<Y*SVM]V-"FB0L,)9;/%X'A"4@X'.``K#:
M"@\*L-IQ"C<EDXY7NPN+PN+;4ZE*)<LN5ZD&YL%45GI)=V;=')ANY&'F0H&R
MF]09L62ZB\@Z&,.NY;D!JB<#K=4RT;JERD<K/5H:A39L0Z-T\'4LR`R@)^R[
M$4\:UX9!,E2U`)9;X\(0LEYP%+>(UT[+]A,8J2E7A#N&(Q/9N\!RJP^Z<-HV
M#AJ[7@:<%+-SV."J;@#\YK$<'"("5%P!N-/&`0<(E,(F*BN`]<@#X0*(=/AQ
MA/*)&6T[NDD%)&[YD8'A3_YY?MA^Z.`X;,1LKJ+3V<OQL]Z:JP7&UUN*,**,
M**,**,**R?X,Q4O[+5A?KZJ/[YY]18?C-5)[83NJ#!P'(O7TJWK-_KVN=AT"
M_2Z4=<V\?2[CI39>R]11F^(Y^9R9RTJT?/-)E:69M'S0JQV`I'<YR3X^H9O*
M,U);M-(F?:$FV7=M3\-Z;"F0VS+9*Y4:Z08-Q<M"T90VY/>B.1DQW'H[Q0)`
M6G2WTM)M#*WBG(%MG!02I*CE."5(4I`<'1"0H*Q`(QPKEJ[\ZMP]1XX=TW6Z
M^[V6\A8K1&V4(U;;]&E=8[!(U/*:P7(TFM;S8GDZ"U8>-%".AE#K!&1B;=N1
M59-,JI[U7_)\W2;>M4\K2Z7)%J;GO:QTB5BVRVY\,J$;48*FIS6#<Q2\,[TD
M!/'OJ==4A"E%"6S[_D);8L2$9RD1W\,Z2E79,\*3M3]Q/0&`VU)?]V47\EV)
MSD<^43;/R?C6S7\KK+5J^LC7Q4Y(*>45]D^`6+R;0ZO6:)+`*2BX$*?Z41S]
M_P"=3;XWD\[@&LL=>;>?.&5]2D,*QMC8RO+1UZ6CP.*3UR48E.T"OSDZG"[7
M4[1_F2>#A[,\'W?HJT[A59ZP^W]P9J\3,PRTS';6Y/V1]7H!W*OH.*C+#PWH
M)FLG$/IV?LLR[>3C])=:QD6=B1A<32S)$@(MB*K4N=_%INT?=QO!N\QA],%V
MSV%A#SR6T.N.,ZFF9FW$,LL-)2T@H3"*6\7K:(<AQ6=U2$.)M;C9F1&TD9@X
MZ<!C@`64[1B2=O\`"V[%Y@-@VV@]X8G:%G_!Y&CN85G=E>:3!*F/+(B[<5UI
M;5.+/*@E:=3[>/$K]>$;S0H'=D1_?3(`8"=)N@,:5R:%6A$?7Z]0)?78$Z$6
M926"E+RHPO\`I\OI9*^L#I:SALJZT+(QV5O;SQA,4-8!WPKK<>#'BG<,?N8\
M-(5O^J<W*OQ?8&YE;&K]^5F.;_=\R.NVS(](=V.H)CR\IZ5B@)^6UYJ74%7E
MV81Q895JL2/57\H.[*93Q8)!D@'(6O&X.[<NK1`W&VN3;D,6V^HFJ4)26))^
MR%EEYEN;<;D^VK/X2EQ)>2C(&2$YBLURNIF[HWIF3]IK"\5M%/8XC\H,02E"
M`=F7#9]-605CM;7_`)01GGZ.3T<J/FS[P_<F]>KI%)A9?/,3QEOMQ3VY1YIR
M=&%%&%%&%%&%%&%%&%%&%%&%%03R?^;QN7\WMD^#U<4/=+\3+%Z38[<4JNXW
MXP:;],1N^"N6JIQNT4+%)N[;;J=(UH74^$1!05*DHR4)$J"H>!/(6%Y;GZ1Y
M%HT'J.BIL0274#KD,F`]0)=;S*TDY;&F;+"G-77(SQCKTI#C9<&''!#*8R"$
M*5M;)=S)'6J"B,3+U;H>MF[B\_>YUO=M1?7Q3+,5Q#@;+@+)6\N2L%:4[',K
M(2M77)R#K:ES@M%;T8\NM`*6VRUR;J[BQ7QW:46[=FUD(Z3/'2R%/C8`6D*R
M![6#QO0N/E!BR+-<#)++/2*%.CQ?*#F;O9&Y;4B;+%E1[LF+$3')4I2%MA;9
MDK>S.KROA?6=8"RZ@A:&XY24K0'?3"WEQMU=Y5>Y<619EP9"I``2%H7X6P(S
M;.5E&:.6^OZ\\>VO%*W9`4%-]-VU.P5@^U,_A%GC</EB<^30GC%P]4SZB&UG
M[-2NDCOB:6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJIVLIE4X:C
M"BC"BC"BHDW5V+^_$?ZR^2L?)OYX1]TKKU8U</O!]G_Y='X:AS3O;EGZ/DO8
M2Y+K\W#F47;T_:._KK@M!^T;?<G.H*JW_O+7]FNK^?S5?F=NSD?^3S_^8!'^
MZ[4G?;761O\`_8$^.L]1=<*NA?(0E[L,HU=/HT->6`T@R8E5,]=LBJL3.FS0
M$5$E1=+H`8J?5.4W7$.@0]7+OG_,*>$?\%NG/!%H;E?WFVC(I>&5*OL^[Y5*
MQ!&4'`G$$88[#4:^]#PK[%A""XVU-^UHO%K7AD0O%>52\01E2K`JQ!&&.(/!
M73!_=OEH)7F-MLD(S7;E:<;W#958\ZTM":R2FQ:Z_13&=CWCAJJ]37>K'<(G
M*#A,52F,=0AT^I_/#^:,W<$;C[*J>M*BO5(4`&5,$$0GD$\4M*5!!"$A"@<B
MLI`2E258K%R0FKJWO7>5<W$K4Y9IR@`PN,00_:VR>(<0E004H0&U@\6H)(2E
M"DKS=<>\^SL3Z:+YB\Q//DE\X+5?N8OUE;Z?AO'\U,>,?474::9[;)^B9#UV
M^2/?-_YF4GWIM74EUR&@?:$=P7]6FXRJ+2Y4845B9[WBFO1,CYFMBI[B_C;H
M[WJM/E\>L&Y^;9'<'.U-(,G_``?T2>N&7K)_92.DYU%4V=/0^]5AB7V-/Z@G
MUH90,N/G!_NR^V-.D1V`Z0KC+Y>UJCS._KW[K4/:=EM<J?;,,SDZ6QD)"L)P
M3F>M==>-)]N%AA8L\@S2N[H4@**3\&[Q0R*Q>J)DYQ-REUU!!W<6[P*XV>+9
MV1;G5-REH0^74LQWDJ9/$NN!"C%;S8A3.=I(<0<0%2VS+3IV=9[`9EMN\J]/
M:59:2[&2XN.&51.(4EY/'LME:1+<RX%+V1U9;6,"4=67$XH$XV:5(``4"4""
M(!2@)2E`K?J@4"F,<Q0``Z.@3"(?MCZN0];Y#FWIWY7TW)T_]/WNH*CMW[I"
M-\6HDC@%T='_`$CI]6H:N?:^T>GI/SM3+DW(_P":CNU]R+/Y$U3%[_Y\F>,N
M=L:HCY)1NT'V\;@:E6ZGUROEF+"692GJ7)6F76E@>,C1JL<JUMM;:(QYV1G!
M5R*%,H50J9B"8#'*6*[?;*TE'WQZP%^A3I5R.HI/%%F4B.V&^,=SA85&?45A
M60H((24E0(!`)GTW!P]9R=QNASIZ=`B6L::C\:'HKDATN94<64%,IA(04YPL
M*!4%!!!(*@.E3C+T_P!7O3'2("/Y.*ITB`=4!'W);=(@7I'J@(_L=(]&0/[U
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M2`:PNLXA^^"A\:(Z88M2IK+M6:SI`HINSN,_5ND=^VK==6C2MYU-8$:8T_`D
M-PU.QF09=DLZ0B5<(J/#XK1V9_`'XSKA4AMU]#+AS:%"6'[8Q&<?;9=XYU0*
ML">M<<[%"NM4?Q@0-I`)%6"]VVRM,<7F^QNUMC[]:FW.&V)S-XBX-O6F-N4'
MCUQM.SL"4`S>2#&*5DXPZ"BR3=4S;QXG,B5-(Q$R-LY4K]HE'0$BPPG+=9U[
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MJXECHGXQ-D""!_*1;)&.90>D!'I$;R/_`"96H'=5GE2ZC?ODG4KTS5&CG57.
M1'\$>FE474>+SD;.YQ*B=G%YU``#`X;*;5RA6@Q]B,AH,A+,@9`<P3US.P'`
M8]/"LG_=B68R.SN;<>5X[CA?<<HUF$A'K/6[]B+JP/D`>,G$:DM(H.VHGZZ9
MVY#KE.4!(43``9T'_.LOB+R<]P4DH0Z&]YD]6180I"\ML0<JPLA!2K#!060@
M@D*(&->7)T&:[W08D8PT]N?HVU:QQ%K5AK_)WAPG(70]D@V.[>4]9AV3*J1U
M.K?EE=X:Z\:3%@C*X;6NK;-79I^_!1M--7\8F#R7;N)$IE#/#*#2TWTW6VW+
M=-KA4:`(MP<L%@?<4N0N2_E>U--4VRX_X=/8>:0C*N*XT^2W&6U%(2&`D.)M
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M^JJG:RF53AJ,**,**,**B?<R:BM-ZJ29U#>Z\>/53(8YN@`7`1Z"@(]`".2L
M?)OYX1]TKKU8U</O!]G_`.71^&H?U`V<)W=H=1NLF0(^1Z3'24*4.E$H!TF,
M4`\(Y+K\W#F47;T_:._KK@M!^T;?<G.H*JR_O+7]FLK^?S5?FEMSD?\`D\__
M`)@$?[K]2=]M=9&__P!@3XZSU%UPW\8`,-YF.J!A$*J]'Z4!$0Z)**\/@\/@
M'+MG_,4D#D-67'@_O&MGJV\U&)OK(&C4YL,/#FNU<KJC[@XBA>7VP>L0Q2_D
M`L_JE$`Z37O78C^P`=(]&?SGOF,*2=REMP()_K(QY)-KLN02I)WNW#`@G[`?
M\IAUU$[O155KL4"22BHA,E$03(8X@'D+SPB!0'H#,'Y)?."U7[F+]96^I,]X
M_FICQ@=HNHVTXV<)W0AU$%DRA%2`"8Z1R%`1%OT>$Q0#PY(]\W_F92?>FU=2
M77(:!]H1W!?U:;+*HM+E1A16*G0$T',E*`B(Q4B```=(B(M%@```/"(B.*GN
M+^-NCO>JT^7QZP;GYMD=P<[4TAR;-Y^]_P"*.?5)_`*_MA_][EZR?V4CI.=1
M5-G3T/O58&G]C3^H+]:&4#+CYP?[LOMC3I$=@.D*Y<=HIJ?E.V5](?\`E!NH
M_P"";_2:4Z/V/W<EGTBI/]4[5M'FV+WANIU]"K1_4>R[1YHA='_\6:KH1XJ`
M(<<M-@("`_$2&\`AT#]B-^QD:N^`X[T+YA_^$7>K40V_H@[Y=2$<'VJ]U:@F
M\R4:VV),03F2CFTY+2%AE(F$</FJ$Q*QD8]23DY&,BU5B/Y!A&G>H@X613.F
M@*R?7$O7+TW*.1_S4=VON19_(FJ8I?\`SY,\9<[8U39N=9$NV-B@95,!"U28
M"`G*`@/7+ZH"/2&1%\H5"SOQU40"1]NR^A_XRZL1\F9MP\GW1I"58?U?B=`_
MQ*Z%^,H@;CWID0$!`=<U40$!Z0$/<IOX0$/`(9"%O7!&\N^@\/VI([XJHO-]
MP(WO:E!X?MF5WU53EB?TEU&%%&%%&%%&%%&%%&%%&%%&%%&%%1QMGL'-?51W
MPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'?$TL5%[9UCTRS^O'+*/+9YH&\KW/G]
M[%(_ISS_``_&$]6GDRE'3C*,**Q<Y[R3'HN0\T6S+M_[>QW9';"OE?8GI4D'
M=:_V;_!K]%O2WXBPV+]RNN=%O!][KIY6[6KL/F6+XNCM159L"RH$;W?%-D+1
MPHL7-,NS[7R_U'=*/44)IU(-:)&<G]];(BYJPMF,:^9$KU8ND$W73D$#!9HA
M=T96`;OI!7R%PZVXOZDE<I2=&M&O8NA#:8>F[C%ER2TE"I;EAM$)QIE2UH47
MGXKJT%E8\!DH;"+DY'C(\(:T2`RFSI+D54KC%/(4D8]B'7%`G9P!0X>R&/6`
MG8;(>!Y")6GGRDFD5!-+G394TFY3*G(W23XU\8B)-R'<)HN#D03*!`%0A%!`
M.DY2FZ0!KG*'45VC=RM1S*.[U@D[`23?+\22`2D$G:0DE.W82,#6[M/YR7XV
M>]-58)C;*W%&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24
MKOZZ]X_[.C\1/4%<7/\`>ONVW"7Y*[V^%]5Y_0._Y'+X<<HWTWHSR74E-6Y2
MG[7:.YR.V9J'/[L46+/LWFX2;A']EA3\<HXLO7(M`SJ3L$6:P/@?PD<U*NU,
MY?RK03H(I@JF)U%`#K%Z>D%C_P"=8,M/)SW!*@2&XDX;S9_%ON'*VRY]F(R.
MK5@K*AM6"U'*K``G`\%:_DZ9?M>Z9@5)\#3B!PD9SL'3JZ3CV75R>^^[^;:F
MU6KJB`:;3Y2(R,::[3^Q4+!+K<.*)(A,DN%GC8B:E)B/BY!O%3R:J`"TLL?(
MHBJY.0[E6D3O*.KE;NMY+NLKP+S<5VBP%"_!6819;&I9:.*,9A;C3;2W$+D1
M"E?Y2"]&<R-!26D.0A\1X7#$=OBT!QW$9BK$\2DXXD`DX8!7T*"AMX:L$YO=
MN^[T_3XJ/ZM_)S&V;@O9W>7_`+N9/KNQ5N+I^=A^-CO;M:9WJOS<]9_IJ<%/
MUL-3XY/Y3W/>TSXA>/54NM/KGV;>_&;[=-;]6.UM?^4$9Y^CEF?E1\V?>'[D
MWKU=(I&[+YYB>,M]N*>W*/-.3HPHHPHHPHHPHJ!.4CITRX\;@=LG3ED[;T>7
M4;NV;A9JZ;JE3+U5$'"!TUD5"_L&*8!#%&W1LLR-YED9D(0XRJX-@I4`I)&/
M`4D$$?<(I6-Q3#$K?!IV/*0AV.NZ,A2%I"DJ&/`I*@01]P@BJ!-=W2Z*[#H"
M2MRMRJ2MYIZ2J2MGG5$E4E+%&D4253._,11-0@B!BB`@(#T#X,D>U-8K$C3-
MR6B#"2L6^200PT""&5D$$(Q!!V@C@J6K6&FM--Z0N[C=MMR7$VN601&8!!$=
MP@@AO$$':"-H/!73MD3=0>T845!'*#YO&YOS>V3X/5Q0]TOQ,L7I-CMQ2J[C
M?C#IOTQ&[X*YK6_^$/VEQYNIDI[G!_C#MA4U#W8_XR>V%,3Q#^<MI_Y3.?@&
M8Q,M]7PJO?BB>_-4CO*&^"FHO$D]_9J__:G8*P?:F?PBSQ+_`)8G/DT)XQ</
M5,^H/-9^S4KI([XFEFUSVXK?M\WFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJ=
MK*95.&I3.<#]_&<:;^\C7SV->)+U4$GD>[<,7:0*6V$3."3EJHDNF!TS"4W0
M8.DHB`^`<67<!'CRMZMM8E-MNL%,C%*TI6DX1W2,4J!!P.T8CAVTX#DOQ(LW
M?7:8TUIIZ,I$K%#B$K0<(CQ&*5`I.!`(Q&P[:H+^/%W_`--KE_\`E5/_`(0R
M1K[`L'\P@_\`V[/_`-%2R?U7TO\`_@RV_P#VK'ZNF`XHT*K;SY"5>&W`P=;%
MBF%5N:K./M,U.R3-NH=JR4,HFV4DP1\9UT2B!A*(E$H"'1B;[XM17?=]NTES
MM$N(MDQR9%"EQVF4*4`I8P*@WCA@3LQVX[::URN]$Z0.Z5R\(MD%NZ1YL9#;
MK;#;:TI<6<Z0I"4G!65.(QVX593MWA1Q2CZCX]MHVED4]U6!.GJ2H?2F!?I\
M)),AOV/V\6+Y2V]7>)K/E8&SZHNTJ;;/ZK7-SBW"G+G08^56Q(.(Q.&WHU#[
MKN#$CV+C&&TI7QZ!B/OU%.J>&_%M]<FK=QH^EF2,PD1$.K,#X2HE$/`>6.7_
M`/-DJ/S3=37[2/(]NE[TU*<AW5%\M20ZWAF"5OK"AM!&!'#LKB=$LM2-0(;>
M2%(XI>P]*JT_[P_Q>X_ZR[O%:QT+5E9K$X.\M8L1DXY-X#GR1RSM?CT`,L[6
M*":O4#I#H_8SEO\`E/=6:CWQ?-=1I'>;+=O.FO[M=1/>#R,"WQK;EM"%X)"3
MF2%*PV]$U[;\V&;?H8R(20V]X8T,1PX$+V5QB\<*A69.Z2R$A"LWB)*R\5(D
MJ"W5!4)",*4X>+5(/6`IQ#U?V<N,?/TW>:*W<\C"SWW1%NCVV[KU_;F5.M`Y
MBTJWW92D',5#`J0@G9PI%1Q[X-07J%I)+T22XV[X8T,1AC@4N8C:#]%=,7<?
M<?-*W_E9>X:XZYK\]&-]&6-^BS?%>F22>I72A-R+E`CP@@H5!T<OT#90)Y?V
M\K7FF]SUNG6.Z28TI6H&$%2,N)28LPD;4G9BD'[U==R(+U=;]O4G1+S(<D1D
MV-Y82O#`*$F*`=@'0)'WS727N7A7Q3CH",4:Z-I1#GERD,/4E@'JBR=&$.E.
M4(/A$H>KF%\G7>;KW6^_;4]OU9=),Z$UI%;B$.%."5_:$%.88)&W*I0Z1J13
M>!"BQK8RMA`2HOX;/HR*J/=2\-N+3^WD;N-'TLZ8Q;\W1U9@WA`4``>@\L<O
MJ"/[&2!_-:U1J#1_)&D7K3,IV'=!J6UH#C>&;(L2LR=H(P.`QV="N5T.PU(O
MP;>2%(XE9P/^+7MY?</.,U3XZ['GZUJ"LPDU'MH`S&4C%9AF^:&7M4&U6,@Y
M0E$U4A4;KG(;H'PE,(#X!RNYN4WW;UKSO.M=MNM[ER(#BGL[;@:4A6$=U0Q2
M6R#@H`C[HIZ/)WTCIJ_[X[-:;U"CRK8\M_.TXD+0O+%?4,R58@X*2",1L(!J
MHK0&D=73F\=2PTQ5O=.)E+[7F,C'O9VS.&;UFN\*19LY;JS1DED52^`Q3`("
M'JX]+>/K[5UOW?WF=!E\5,9MSRT+2TPE25!.Q22&L01T"-M2$[VMRNZ>U[K]
M07*W:?M3$]BTR%MN(CMI6A:4$A25!(((/`0<15^TUP>XF)0TNJ31=+`Z<9('
M*/BY/P"5HL(>I(@(?^#&2[E]^V]Z?OBTG!F7Z<Y$>U-:T+22C!2%SF$J2>LX
M""0:B`N-L@(M[ZDM)"@RLCA_BFDE)Q#XP_O?_P`D:7ZI/V)O]L/_`-,9=0G=
M:I_#H!S_`*`JFZIZ'WJ>M+@YQ+ZB9OR%TOI`I!^Q27J@`='@&1RC=/W_`.^5
M,Y]`U!/RAU8X4?QC_@4Y1-JMQ0`6D[1]W]^N:_97&_1;38^PFS?65<1;MKY;
MVK=,I7X$321L<BBBD3I?>H4@%*`>KDHNE=Z.\)[2]L=<NTI3JK=&43UF))80
M2>PZ9J:G1>Z[=^]HRSOOVR,7EVJ&I1..)4J.V2>'HDFKW^,O"SBO+\?]1R4C
MI*G.GSRDQ*[EPHG(BHLJ<AC'.<0D``3&$<CQWK[]][\+>1>HL6_SD1T3W`E(
M*,``=@'65%5ONT[9;?O;U#"AQVVXK=S=2E(QP`!&`&VEUO?`3B$XWE5]HFTM
M"(V[35FL,AKQ9I+6-I%0LV]=MP+85X9"8(RE9J-39`1H=R"J+<JJG0D)C`8M
MMKDI7*=>.3#N]N]S<4]<I.CK4ZZXKLEN+B-*4HX8#%1))P`IE=\0EN]2VT#!
M"9"P!]`S&K3J70J+)U6"D)&EU-^_>1Z*[MZ]KD.Z=NES](G6<.%V9UEE3CZI
MC"(CE53EWZAO\/EB[Q8T2=,:C(U1+"4(><2E(S#8$I4`!TA3E-':MU5#TO!B
MQ+G<&HS<=*4H1)>2E*1P!*0L``=``8"I5:,VD>U;L6#5NR9-$B(-6;1!)LU;
M()E`J:+=NB4B2*290Z"E*```>IC,7GWI+RI$A:G'UDE2E$J4HGA))Q))Z))Q
MKTD2)$M]<J6XMV2XHJ4M:BI2E':2I1)))Z))Q->C/*O&C"BC"BC"BC"BC"BC
M"BC"BC"BC"BHXVSV#FOJH[X2:9(7\K#GQ:/[G=?5$ZN3UM[-2.FCOB:6*B]L
MZQZ99_7CEE'EL\T#>5[GS^]BD?TYY_A^,)ZM/)E*.G&4845BYSWDF/1<AYHM
MF7;_`-O8[LCMA7ROL3TJY[N`VU;PQJ/`#5T;R`Y)PU7'A?PRL+G1^M^(\5>*
M!TS;5.)D[-:N04CJ"UF8:[MK=F#&7\GEV3NM.FRZWE:!%4R(R5\HS1]@D7K>
M1JZ5IO2K]V_KWJ=E-UG:C<BS/R2BXVQ'LZ+E'SS8Q5QL;/&=;G-N-HXEQ2%*
M7QUHD.AN&PEY\-^"LG(ED*3MV$EPH/6G@.!!203B.A%+#EONCC1QHU(.K=KT
M6HI^-Y=S3*C674&S=F0MLM\ES,W96XM/:-QUK0;M(Z2J2C-0ZU=L:P^0&FHU
MTA(,G[0PBU[&1N7T)O5WJWK^MUFN$U6&G&ERV+E`@NQXR-,VM]PP(TZ9%1=)
M`4`F;"3^6$5]IR-(CO`![P%QE08+?$.(3^>.4H4H$EY8&8I2HH'\57!F!!!'
M!;IP+.JK9.>JJ[AN[<+<Y;$LX=M!(9H[<K<:>,"KAVT,F(IF:.5C&.D)1ZHI
MF`0\&,MY124(M>[I#:5(;3N^9"4J[)*1?+\`E6.W,D8!6.W$'&NBM/9RR=I\
M+/>FJL'QM5;BC"BC"BC"BC"BLG^#,5+^RU87Z^O*\^ZW7MA?V4V<CK/VPNOI
M*5W]=>\?]G1^(GJ"N+G^]?=MN$OR5WM\+ZKS^@=_R.7PXY1OIO1GDNI*:MRE
M/VNT=SD=LS2U?W<P]!3E^\"4VG'UF6UTEQ<;JW&)N<U'URJRL$G/O3O8R>L$
MLNVC86-?D+XE1TLH1-`#]<1#HQ?_`/G,TZC5N2Y.Z=(.2V=3G>G.$9R*TM^0
MVZ;8@)6RRV%+=6@]<&T@E>&4#;6KY/7$_:5V\("2SX$G,%'`$9SL).P#[M7F
M\<[Y6-A[[X#352T]KG2<.CM[E8U:U77%PA[PV>,77#NBS,%)VN;A3JMRW-M6
MI1FQ=MS**BW2:))@?H+U2T<MY^G;MIG=UO&@7F]W2_3E633ZE2)L9V(I*TZE
MEM/(CM.@*\%4^VZZVL)3G4XM13B<2Y.$ZV]+B*;;0TGC'=B2%?\`8I()(_A8
M$`_1A3T]X@\LT<[X12-*AFECN<?S/9/J?7I!^G%,)^U-.+'*AQ781]**B5*.
M9RTPFBW57,)2I$4$PF*`"(-[Y,K%JE,Z^C7Y]<6Q.:%4B2\A!<6S'5?]/I>=
M0V-JU-M%2TH&)40``2<*VUY*TF*IH!3HE;!P8GBG<!CT,32(\AMG<R=D<:6A
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M5LH`D`%`Z#C+K>8ND6+8TNT3)\B[J0RI:'(S;3*%JPXUL."2M:BVK8E0:"7!
M@K%)ZT2]6Z9K:1<7D7B#`CV=#ZTMK1*<=><2EP<4LM>#(0@.)VK27B6U=:,X
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M1)554H'`IDRF`W1*C?HND(I2C3DV?+.89E/16V$Y2D$Y,LEU16E1*2%)2DX$
MA1&&,IFG9FMI:5N:F@V^&G*K(EF4Y(7F"B!FS164A"D@*!"E*&(!2#C3L]V!
M);0D^2,,OL2ITVJ">D6XS9E6KC*VMXF\!%--=%\H\J=>8E;>((51-1%54QNM
MT&(00'$$Y6D7247=:^WIB9.F`3XV93\9N.DIQ)!0$R'EYL<0I*DI`PQ"E4VG
ME*3-9S-R,QS54&!"!G0\J6)3DE85QBP0K-&80$X8%*DJ43C@4IPJ][=78O[\
M1_K+YM_DW\\(^Z5UZL:HB]X/L_\`RZ/PU#FG>W+/T?)>PER77YN',HNWI^T=
M_77!:#]HV^Y.=055O_>6O[-=7\_FJ_,[=G(_\GG_`/,`C_==J3OMKK(W_P#L
M"?'6>HNN%/0_N?[K7<99RNRBPUW8323QKT^5-&!5&)G;EMU4ES>4((`8Q.@A
M_I@#P#ZF7?/^83\)_P""[3G@:$N2_P"\VT9$J[%2_L^[Y4JVC83@#M&SHBHV
M-Y_A?V-"%O0AV?\`:\7BT*[%:\5Y$JVIZU2L`=HV$[1PUTS_`-W%;Q#3F9N!
MO'J3@O!XYNG<H$^T9L)%XH]V/77*,TZ1C408N7,D*BA#./&"L)&Y$S)IE3)U
M_P">!\T)R:]N,LCDD1^(_K0E+?$J4M"0B$\DM)*SG2E&`(1ER@K4H*45*P5[
MD>NW"1O3<=F)B^#?8LU#7$+6MM`0_:TEE)<.=*6\$J#>4(!<4M*UJ6K+UO;S
M[.Q/IHOF+S$_^27S@M5^YB_65OI^>\?S4QXQ]1=1IIGMLGZ)D/7;Y(]\W_F9
M2?>FU=277(:!]H1W!?U:]7-_YKVTNGP?XK6OQRKN5I]P/Q;M'X[_`),]3[N3
M!\<[%^/)\CD5SO<3[)NE3EAQ]8V"DPB53F-U2*+V6C51(\J<%`O)Q&KDE"+S
MCH)E:WF;1SIN_:I)D(5PNW79MCI)JJR:;X[7H1.YS4LBVSY!O+%A04-K&*9#
MSR6C(+9#2>*$;,\VMEQ1)*&W6WW4K4A#[][-XWAJW?7V+<[='%DD0;H%N(."
MHS+*'TQPX"\KC3)RL.(>;2``MQIR.TI"7%]7,][Q37HF1\S6R+S<7\;='>]5
MI\OCU$-<_-LCN#G:FD&3_@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?U!/K0R@
M9<?.#_=E]L:=(CL!TA7%MS1@=93&^KTA;[E;(ZQ/W>R`B*?&UN7L<#(EC['<
MXB,MIPBJ-:UXB=JLK=3G;ODS@=FN=LMXDQDTA&='<3<=60MW5O<LL&$[;&T0
M>,DK?;8>1G8BN.1_RDN.'&I#<4!;2A@Z@.MYP%+`E@O%MTA.L=@:O<Z>W=7=
M,1N+BML./,KXN,6FY)XN)(4V]'<EDH>2<6EEI90HI1CUD<3@$.-FE0'IZ0H$
M$`]8YU3=((='TRB@%44-^V8P`81\(^'(;=\AQWIWX_\`J3O0`Z/T#8.D-@Z%
M1];]AAOAU$/_`%1WHD]$=$[3TSMJ&;GVOM'IZ3\[4RY-R0.:ANV]R+/Y$U3%
M[_Y\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR^J*7'2_L]#[@FMQQHM;ZC"B
MC"BC"BC"BC"BC"BC"BC"BC"BC"BHXVSV#FOJH[X2:9(7\K#GQ:/[G=?5$ZN3
MUM[-2.FCOB:6*B]LZQZ99_7CEE'EL\T#>5[GS^]BD?TYY_A^,)ZM/)E*.G&4
M845BYSWDF/1<AYHMF7;_`-O8[LCMA7ROL3TJ1_NMBA_PX>#1N@.M_5:TN7K=
M`=/0-%AA$.GU>@1#%_Y71/\`Q1;P1T/ZWW3RMVM58?,L3Q=':BJ6M=&I?N!I
M.8O%LK]8;T:J<I7\+*[6X?-.46@(%6[<X>2-?GAV5*Q+>/OFLGMNC(E-FP?M
MIZ"BSH-':3M1R=5%`7VZG%]^T;_!L$.3+=N$RP(=;M^I%6"\/"+I6R/,^`MN
M%<2>F,XXIQYE<27("W&5LI:"''!S+/%9&E.J"0A+N!6SQK8S/N`YB.N3B!@"
M%)&PXX[!5SO!H>M=.\$,)R*]?GI;S^-3^Q*];CEQF-XU$.NIU45.GK$#K&Z"
MB`=(^J+%^4",+%NV&!&&[J,,#PC_`,ZONP[!M'`=@V]`<%=-:OSLSQL][:I_
M,;A6WHPHHPHHPHHPHK)_@S%2_LM6%^OKRO/NMU[87]E-G(ZS]L+KZ2E=_77O
M'_9T?B)Z@KBY_O7W;;A+\E=[?"^J\_H'?\CE\..4;Z;T9Y+J2FK<I3]KM'<Y
M';,U"?\`=E6GNAL/G*Q\BEY'RSC6S:A'U_R#W??"O.R"96D'[JE-&!,.!-U&
MHN`%`%Q+XSZ7IQ:/^=2>\&Y/.X"1QC#63>?.5G>S\2C"V-G,[Q?Y3BD\+F3K
M\F.7;A6NY.HQNUU&!.,)/!P]F>#'9C]&-6Y\.U))3<?`H96=L]G>FW;RU<.I
M^QS5BF6\E(O^'5`DY<:\2V5:FSD(Q82CY5J\8>0$8MI1!R#-19OU53TI=]Z8
MJ=#[Q1#CQ(C`L&G0EEAIEI2$(U+,;;XXQY$EIU:VT)<:>XXNKCK:+Z6W,4!Q
MEMS>$Q,Q4H\:]M))Q/$I)PQ"2-NPC#`''#$59]S>[=]WI^GQ4?U;^3F-+W!>
MSN\O_=S)]=V*M[=/SL/QL=[=K3.]5^;GK/\`34X*?K8:GQR?RGN>]IGQ"\>J
MI=:?7/LV]^,WVZ:WZL=K:_\`*",\_1RS/RH^;/O#]R;UZND4C=E\\Q/&6^W%
M/;E'FG)T844844844844OO*WYN&Y?D),^QEQ2MSOQ1L7I%KJTKNX/XS:;]*L
M]6N>;6_\HVO/EY3?QDC,DOU3[+W/T=)[PY4O^L_8V\>B9GDSM=3>1#5!'1A1
M4$<H/F\;F_-[9/@]7%#W2_$RQ>DV.W%*KN-^,.F_3$;O@KFM;_X0_:7'FZF2
MGN<'^,.V%34/=C_C)[84Q/$/YRVG_E,Y^`9C$RWU?"J]^*)[\U2.\H;X*:B\
M23W]FK_]J=@K!]J9_"+/$O\`EB<^30GC%P]4SZ@\UG[-2NDCOB:6;7/;BM^W
MS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJIVLIE4X:E"YV_-@V%[8J7XWP>+7
MR>?BU;/Q9'DSM.'Y*WQQL_XDOR1^N>[)*JEYIU^[Z^<O!?)&X^9-L0;E)_"J
M1X[&[95-FY77P3E>D(?;JJYS=78O[\1_K+YWGR;^>$?=*Z]6-4,&\'V?_ET?
MAJ'-.]N6?H^2]A+DNOS<.91=O3]H[^NN"T'[1M]R<Z@JK?\`O+7]FNK^?S5?
MF=NSD?\`D\__`)@$?[KM2=]M=9&__P!@3XZSU%UPV\9"E/=IHARE.0]3?E.0
MY0,0Y32$6!BF*8!*8I@'H$!\`AEV[_F)R1R'+(4G!0WCVS;_`/XV\U&-OH)3
MH]"DDA0G,D$;"#E<V@]`UU*?W?V)BHCEWL5&)BXV*15T'9E54HQ@TCTE5?CU
MKLOC%4VB*)%%`+X`$0$0#P9_.F^9%,F3=RUL<FO.O+3J-@`N+4L@>"3=@*B<
M!]P5WO(5GS[AO?G.W!]Y]Q.GWP"XXMP@>%0]@*R2!]P5U+[S[.Q/IHOF+S-/
M\DOG!:K]S%^LK?4DV\?S4QXQ]1=1IIGMLGZ)D/7;Y(]\W_F92?>FU=277(:!
M]H1W!?U:]7-_YKNTO:M:_'*O96GW`_%NT?CO^3/4^[DP?'.Q=TD^1R*I+XU_
M.$TM^<BL^?%Q^^]/X:W[T6_VE2;[Z?A#J;T+)[0UTF3WO%->B9'S-;(^=Q?Q
MMT=[U6GR^/4'US\VR.X.=J:09/\`@_HD]<,O63^RD=)SJ*ILZ>A]ZK#$OL:?
MU!/K0R@9<?.#_=E]L:=(CL!TA7+;M$I?RI;'4ZI?&$V!>"D4ZH=<A5+-(^,*
M4_1UBE4\67K``]`]4.GU`R6K2)/]4;6G$Y3;8F(Z!P81AL^YB<.F:G6T,A"M
M$V1:@"L6>&`<-H!C-8_NX#]RNA3BG\W'37R$AO8C9&EOA^*%\](N]6HA]_7Q
MEU)Z5>ZM0M<^U]H]/2?G:F7*.2!S4-VWN19_(FJ8I?\`SY,\9<[8TW.O>Q-9
M]%-_6'*I'+XYY>\CWIE]44N.E_9Z'W!-;CC1:WU&%%&%%&%%&%%&%%&%%&%%
M&%%&%%&%%1QMGL'-?51WPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'?$TL5%[9UC
MTRS^O'+*/+9YH&\KW/G][%(_ISS_``_&$]6GDRE'3C*,**Q<Y[R3'HN0\T6S
M+M_[>QW9';"OE?8GI4D'=:_V;_!K]%O2WXBPV+]RNN=%O!][KIY6[6KL/F6+
MXNCM15;&JF/>!R?$[5L/Q!A=;/*%8)7F)"[#D)E\A#WU&:><M-V-XQ&&G%KA
M3'D*P!%TD(.HYR#YJS4DUT%$Y%***LZ?6$CDVQ-\EWG;ZW[HC449G33L)#2"
MY#+2=.VM3A=:$:4EU>*5?DWD%IQT1&W$JBKF%&CCB\*M[:;<$%DEX*QV*QXY
M>&!Q3ATP<0,Q'7!.-C/!,BJ=MY_IK]7QZ?.^U)N.HJLN3QZ?&_C(1?J+N.ER
MN3QI1ZIU>E4X?3'$3".-@Y0I0JR[MU-X\6=WD<C$`'`WN^D8A/6@X88A/6C@
M3LPK=6G\Y,QX?"SWMJK`<;=6XHPHHPHHPHHPHK)_@S%2_LM6%^OKRO/NMU[8
M7]E-G(ZS]L+KZ2E=_77O'_9T?B)Z@KBY_O7W;;A+\E=[?"^J\_H'?\CE\..4
M;Z;T9Y+J2FK<I3]KM'<Y';,U#_\`=A6\0[VES8:6!!DZ@77'6+;S;62?J1<<
MYB%K$]3DD'\FB!EHYDLR,<JJY0$R*8B</"&+#_SK;LUGDX[@WK:IQ%Q1O,N"
MFE(0'%I<%K04%#9V+4%8%*#L4<`>&M?R<PDW>Z!>&3P-&..P89SCMZ%74:?D
M-?M.6/`&JTRB[RICP]JY-VB3=[H0D97XVQS/BS7:!5Y:DW@S=&.G*;%TZJ14
M=%)*HQLDI&MD7BK,2N/*EZ0^MHVI'MS>\B\7VX:?G,"'8F&TVLH;\'6J_O3)
M#<J+B5M27),B0](4E3["7UN,(?Q:XEMR,93(N$-MI#J3F=)SXG$<4$@I5P%(
M2`!P'``X;<2_O-[MWW>GZ?%1_5OY.8W#<%[.[R_]W,GUW8JV]T_.P_&QWMVM
M,[U7YN>L_P!-3@I^MAJ?')_*>Y[VF?$+QZJEUI]<^S;WXS?;IK?JQVMK_P`H
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M/VCOZZX+0?M&WW)SJ"JM_P"\M?V:ZOY_-5^9V[.1_P"3S_\`F`1_NNU)WVUU
MD;__`&!/CK/477#=QB[<3/R5>_",5EVW_F*.8W9?]XUL]6WFHQ=]/L:GQYKM
M7*ZHNX-^=_L']'^S?CWKO/YSWS&?@G;?>1CR2;79\@KXN7#T`_Y3#KJ(WGV=
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MZ\<LH\MGF@;RO<^?WL4C^G//\/QA/5IY,I1TXRC"BL7.>\DQZ+D/-%LR[?\`
MM['=D=L*^5]B>E5`'`GE#:JEKCN^M"H\EN*](JDAQ#X;/`U'9]9[,MG(F9G+
MQ&-8IY#DEH;9->I=>KUUC6R85^<68."MW_E"#AHN5OXU22'E%[I+/>=4;RMX
MKFE=7W"\-:UU,G[18G08]E::BN*<2X6W8+TIYZ*M2O#(J7D%;/%N-/-ES(GD
M+1/<;9AQ`_'0V8S/6%*BX2H888A02`H=BK#8<00<*F#@CPCTQM3C;#7VSV+D
M@PG;!MGD\XD&E*Y?<J-=5=%1#E#N1F0L32J#N&MTZ`1\2W*)TV#%LD=03*&*
M*ASF-Q/*&W^:ZTAO3?T[:8NEG+?&LUA"%2M-Z?FOD&PVQ1XR5,MK\EXXJ."G
MG5J"<$@A*4@9-IM<:1"#SBGPLN.]B\ZD?G5\"4K`'W@*M$T-QWU=QMK5CJNJ
MV%G;,;A=978EKD;IL*_[1M5CN<U&0L-(3LU<MF66VVN2=*Q5=9-RE5>&332;
M$*0I0Z>EI&\3>;J[>G=8MWU>Y$5(A0&X4=$6'#@1V(K3CKJ&FHT%B/'0D./.
MK)2T"I2U%1-;Z)#8A(4W'"L%**B5*4HE1`!)4HDG8!T>A4WYP%95&%%&%%&%
M%&%%9/\`!F*E_9:L+]?7E>?=;KVPO[*;.1UG[877TE*[^NO>/^SH_$3U!7%S
M_>ONVW"7Y*[V^%]5Y_0._P"1R^''*-]-Z,\EU)35N4I^UVCN<CMF:7C^[=5.
M'OEDY^4R?K9[C#V?BV2$D*JDBQ<.;`@_F9%O[E,DY-):/]T'AS@1N98IDR+B
M0P^IB[_\Y[>9NG=Q?)YOMNE"#.B;TYKJ)!*PEDHMK9XQ1;(7D2!BL)()1B!P
MUK.3PVEVYW9I:<R50DC#Z>O.S;5PW"^9F);;/`IO.4>ETEU7-\<Q*HD>B159
MCH>UH5SB)1(PUC>O*I0M=15AGR.D%&+Q\5@KTG9@B"YO$BBA2:W[08,/1N\5
MVWW"?/9E:=TU((EN/K<CE_4<MSB$ID2YKC+)20ZTT7DX!SC.+&?.XXVV*4J1
M$"T)24O/#K0`#@RD8[$I!/0)PZ&&.S`6+=Y#8IFH)<+[;7*P[N]BJW,9"QP%
M*8+.&[ZX3<)Q4Y52435F;EG&S+MNZL+]LFT3429NU"&6`Q4%3`"9FQ<ERV0;
MVO7=FNDM%OMDS0Y8>E+"5(C-.Z@T^AR0I*EM)4EE"BX0IUM)"<"X@=<-U>UJ
M;\%<0G.M,G$)^DAIT@<!X>#@/2J">=.V;GLSC53V6P-$;*T7;:KS0[OA.9C;
MHYI\]5IMY+\J=:*++:ZO%*L<['7"%8*,!!15PA%ODB+(^4,VZB@I$=S\MO1M
MBTIRX](OZ;U%:M0V:9!OI:7%3)9D-);MD@`38DIAI<9U86,$H7(:44N<6^XE
M(6K0ZPD.OZ:?#S2VG$J:Q"L"#BL=BI)((_</!B!38UCM;7_E!&>?HY8FY4?-
MGWA^Y-Z]72*26R^>8GC+?;BGMRCS3DZ,**,**,**,**7WE;\W#<OR$F?8RXI
M6YWXHV+TBUU:5W<'\9M-^E6>K7+SKC9]Q1WMK.!<ZMFBP4ER`JM%CK*U7?NR
MM&D>\:RKJT6-G[A(H1$))D2)[F.4G+MFXZXHKKMG0%;GELU1I*R+W>W6XM7=
M@W%K3<B6MA00G,I:5-I885QQ+CJ"3QZ%(;<1AG;;=9Q=3)KK/6M_1:KK;7K+
M(%N>3.B(?25JRI1!?=4^^GB0EMI>`#"TN.MKQR..,O96E]A&0DU#;1A14$\G
M_F\;E_8_^7MD\/WO5Q0]TOQ,L7I-CMQ2J[C?C!IOTQ&[X*Y:*E;[;.V.2BY/
M5UAJL*P=6"/2M$O/5-=I(^Y@J(LWS*)C99W,&CIQ$06;*F2+U2#T*@0X&*$N
MUZLEEM]K:EQ+O&F3W$,K,=MF0%(XS`J0MQ;:6L[1ZU:0HXG:@J3@3+M;=17Z
MXW-Z'+LLN);VGUH$AQV.4N<6X`A:$(=4YD>'7H)2"!L6$JQ34O\`!?:%QF^7
M>@(&>U9-5MI8[%?7S:;%P_?,(F/JL?+QK9A8SJP4:2'M$HX'KD:B8[5=L<JS
M-T[(57Q?%<H/25C@;E=27&W7=B4]%BPT*:P0A;BY"VUJ6P`\LN1VT["Y@'$+
M!0^RR2C,@V^K6M_N&ZN\VRY661%8EP9"TNXK4AM$>6RVE+Y+*`V^X3F#>*FU
MH(6P^^`O)TV[4[!6#[4S^$6>-P^6)SY-">,7#U3/J(76?LU*Z2.^)I9M<]N*
MW[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG:RF53AJ4+G=T_U8-A]'A'Q]
M3Z`$>@!'XWP?0`C^QTCBU\GGXM6SZ,LCR9VG#\E;XXVC\27Y(_7-12+A;[25
MRM/:KL=`0(W74:#89^I/G+QT@\5:"Q,R@9>279F4!(52+*?O)TA*8IAZP9*E
M?[)9;04HMUXBW)PJ`5Q+,E"4I*0K/F>;0%88Y2E/7!0((V&I2--ZBO\`>LZ[
MG99=M:2@E/'.QU*4H**<F5EUPC'#,%'K2D@@[:=KNO[?;+9R1AG-BUA8M=(?
M$BVKM2V*<JLB\77%%)%9DJQKTM)K,ED`3Z_64_>CE,`D,;IQ!.5K9;-9MUK[
M5LNT6YN?:$8*XEJ0A(&)(4%O-MA0..&`ZX$',!3:.4EJ"^WW<C,<NUFEVIKP
MV$4\>Y'6HGC%@I*677"DC#'$]:01@35[^ZNQ?WXC_67S;?)OYX1]TKKU8U1'
M[P?9_P#ET?AJ'-.]N6?H^2]A+DNOS<.91=O3]H[^NN"T'[1M]R<Z@JK?^\M?
MV:ZOY_-5^9V[.1_Y//\`^8!'^Z[4G?;761O_`/8$^.L]1=<+7'X`&>N`&E/<
M,OQ!G.M-=8"^Y``XCQ&3$QE$0`&(!XT>DY?`7U0]7+O/_,,8_P#!5I[!GP@_
MWF6G\E_WG_E]X_)\![/L>`\/`:C4WJDBP1,&/"C]JQOR/#QNU?Y/@/9]CP'A
MX#P5TU?W<M43\QMM@:TN+*J;CQ).7@K-Y=@5)^[V-5UE'C>+GG:[^.:O6OB4
MDB(D(R\6U#Q8G/XWH_G>_,^0$[C[*1#3%0-3(2G!3:\4)A/@)4XRD(6I"LRE
M%1+N+AS`)R8JWR.4!.]=XB`B$V+',2C*IIPE"'[:`A3K"$MN*0K.I2EE3V9T
MYPE.3'K4WGV=B?31?,7F<+\DOG!:K]S%^LK?3^MX_FICQCZBZC33/;9/T3(>
MNWR1[YO_`#,I/O3:NI+KD-`^T([@OZM>KF_\U[:7['^*UKP__P!95W*T^X'X
MMVC\=_R9ZGW<F#XYV+\>3Y'(KG>XH;0N#_ECQ]KTOJV:AXNP;KD8IC8R.'SU
MG&1=,=S297EH(>#9I0<C87,6V4CTP578O&C\AT':JJ2B.2:;X])62/N;U+<X
M5W8?EQK"AQ;!2A"EN2DM'+'/&J+J&4N+#QRH=:<94EQE"%I73[M[&M;_`"=W
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MU;-+=8QC&^($%UC'\7US#XCPF-XK]ZZQA\(]3Z7I]3P9#SODP_O3OV&`'VD[
MP8_3]W;^[M^FH[=^^/\`?%J/$DG[4=VG#'A'#AL_<V5#-S[7VCT])^=J9<FY
M('-0W;>Y%G\B:IB]_P#/DSQESMC3<Z][$UGT4W]8<JD<OCGE[R/>F7U12XZ7
M]GH?<$UN.-%K?4844844844844844844844844844845'&V>P<U]5'?"33)"
M_E8<^+1_<[KZHG5R>MO9J1TT=\32Q47MG6/3+/Z\<LH\MGF@;RO<^?WL4C^G
M//\`#\83U:>3*4=.,HPHK%SGO),>BY#S1;,NW_M['=D=L*^5]B>E2&=UK!PH
M=WSP=L@1$8%B4XCZ2@U)X&#4)D\*E4(M^E$'E`2\N-&)/ECK%;B?Q153F.!>
ML(B+BN5U<)YY2F\"UE][[,&M+HZ&<ZN*#IDN(+@;QR<84`)*\,Q2`G'``5J;
M"A/V/%7@,_@Z!CT<,!LQ^BOW[L=PW#A[2&HKH@Y-LWE&J#<52`N*7]:S=I?&
M@CUO&"GUB"'6Z.CI`?VL\^5@TX=]MP>"5<5]DV`9L#AC_5^U[,>#':-E%B(^
MS4#H\8[WU=6`8VZMQ1A11A11A11A11A163_!F*E_9:L+]?7E>?=;KVPO[*;.
M1UG[877TE*[^NO>/^SH_$3U!7%S_`'K[MMPE^2N]OA?5>?T#O^1R^''*-]-Z
M,\EU)35N4I^UVCN<CMF:7O\`NVCYM'6SGB[?56R7>.3XTQQ)6IT]6)1M$Y#N
M+([;R[."/.2L)&#)>YBJITBJ.DA.8O5)UE!*4RZ_\Z!'=E;AN3XS'F1;?*.\
M^>6Y$D.&.TX+6A3:G@TVZYDSA(40VH`'%6"02-9R>"$W2ZDI4M/@2<0,,2,^
MW#$@8X?=JZ/CBUU4[Y2<&[-J*1W1[@N=A<A*[+0VVK?J>YHA)P7"/7!8&7K\
MIIY].U454=>K0T4^)[H'=H/(Y5)T@1R4ZBM(K>@[K!G=%O`M6M&K%]HHMEF>
M;=MT:XQ3Q;NJ9O'-O-W)#4C`S!*D-'B0VIIY"V7%-%*4.0A".9\5<8NY,[@(
M64*VAA.!!1B.QR@[<<1M&-63<WNW?=Z?I\5']6_DYC6=P7L[O+_W<R?7=BK=
MW3\[#\;'>W:TSO5?FYZS_34X*?K8:GQR?RGN>]IGQ"\>JI=:?7/LV]^,WVZ:
MWZL=K:_\H(SS]'+,_*CYL^\/W)O7JZ12-V7SS$\9;[<4]N4>:<G1A11A11A1
M1A12^\K?FX;E^0DS[&7%*W._%&Q>D6NK2N[@_C-IOTJSU:YYM;C_`/,;7GR\
MIH?_`-RQF27:I]E[GZ.D]X<J7_6?L;>/14SR9VNIO(AZ@CHPHJ".4'S>-S?F
M]LGP>KBA[I?B98O2;';BE5W&_&'3?IB-WP5S6M_\(?M+CS=3)3W.#_&';"IJ
M'NQ_QD]L*8GB'\Y;3_RE<?`$QB9;ZOA5>_%$]^:I'>4-\%-1>))[^S5_^U.P
M5@^U,_A%GB7_`"Q.?)H3QBX>J9]0>:S]FI721WQ-+-KGMQ6_;YO-7&60/F#\
MRO>+Z#1Y=$I(=*>T43NOU54[64RJ<-2A<[?FP;"]L5+\;X/%KY//Q:MGXLCR
M9VG#\E;XXV?\27Y(_7/=DE52\TZ_=]?.7@ODC<?,FV(-RD_A5(\=C=LJFS<K
MKX)RO2$/MU5<YNKL7]^(_P!9?.\^3?SPC[I77JQJA@W@^S_\NC\-0YIWMRS]
M'R7L)<EU^;AS*+MZ?M'?UUP6@_:-ON3G4%5;_P!Y:_LUU?S^:K\SMV<C_P`G
MG_\`,`C_`'7:D[[:ZR-__L"?'6>HNN&?C8U;/K?863Q!)TS>4Z3:NFRY"J(.
M&SA]&)+H+)F`2G252.)3`/J@.7<?^8C>=C\B"Q/L**'T;R+6I*@<"E0MUX((
M/0((Q%1E;XGWHNE&I,9:FY#=P84E23@I*DAPI4#T""`0?IKJ0_N^]>AX+F#L
MH\6S,@J\X^SY'2ZSR0D'2R;2]T'R1`[N3=O'(-FOE"GBT@."9!.80*`F'I_G
M4_,FN4ZX;DK4F6L*0C4K)2`E"$@JB3,QRMI2G,K`9E88G`8G8*4#D-7>XW3>
MW,3.<"T-V&24I2AMM*2N5"SJ"&T(3F5E3F41F5E&).`KJAWGV=B?31?,7F:'
MY)?."U7[F+]96^I']X_FICQCZBZC33/;9/T3(>NWR1[YO_,RD^]-JZDNN0T#
M[0CN"_JUZN;_`,UW:7M6M?CE7LK3[@?BW:/QW_)GJ?=R8/CG8NZ2?(Y%4E\:
MQ'^L'I;P_P#ZQZQY\3'[;T_AK?O1;_:5)OOI^$.I?0TGM#729/>\4UZ)D?,U
MLCZW%_&W1WO5:?+X]0?7/S;([@YVII!D_P"#^B3UPR]9/[*1TG.HJFSIZ'WJ
ML,2^QI_4$^M#*!EQ\X/]V7VQITB.P'2%<K.VX&$?;@V!+O8>,>2K*Z[`CFDB
MZ8MEWK9@^MCEP\9(N%4S*IM7+A@BH=,!ZICI%-T=(`.2ZZ+N,^/HFVPF'W40
MW($-:D)6H)4M$=*4J*0<"I*5J`/"`HC@-3E:,M=MDZ2L4^0PTN:W9(C:7%)2
M5I0N.PI20HC$)4I""1P$I!Z`KHHXI_-QTU\A(;V(V1C[X?BA?/2+O5J)/?U\
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M0K4EKE:^)L#6,OC%[`UB%')H,@/5#=9XKN^RV[M=^FJ--ZNO#L#1MPLFFGN)
M4PM]A<AJRV<..)#,:2^B:(A>$(Y40W)(:%P46$C#GQ;5S+8P]';"Y"''ACC@
M<"XY@-I`*<V&;^$!CDVUTA1:+AM&1S=V5L1T@Q:(N2,CKG9D<)-TR+%:'="+
MH[8JA1!,5/WP2]'6\/3D7,M;;LMUUDK+*G%%)5@%$$DC,$]:%8<.79CP;*[5
M((2`>'"O=F/7[1A11A11A11A163_``9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%
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M]WM&G-0JGVQ,:V6ZS!J8^R&%.OR&6DI6TA`"RVX%!64I`*E"L/3^[_2^B!)F
MV-MUMQYK*O%:W,4@XX`$["?I%+!QK5LAMM]V\C:;7)VA^UV/RM*T1FWFSW<W
M4XAUQ(I\A'5*8_*U7*S9T))@F[%94J23ADH=P*J;E8ZBA@1C>HBU#1F])=HA
MM1(Z[7I[,6DP$M2'$ZBDH7(:^SGWV"A93E25*0ZD("%-(2E(K8P<_A$(.**C
MG=X<V('$C`'.`<?W1]TU83S>[=]WI^GQ4?U;^3F-IW!>SN\O_=S)]=V*MQ=/
MSL/QL=[=K3.]5^;GK/\`34X*?K8:GQR?RGN>]IGQ"\>JI=:?7/LV]^,WVZ:W
MZL=K:_\`*",\_1RS/RH^;/O#]R;UZND4C=E\\Q/&6^W%/;E'FG)T84484484
M4OO*6_VC6&B[M>*:\0C['"E@ACG;EDWD$$A?6.(CG/79NR';K==H[.4.L`]`
MCTAX0#%)W1:<M.K=X,"P7Q"G+6_QN=*5*03D8<6G!22",%)!V</!2N[B=)6/
M7.]*V:7U(VMZS22_QB$K4VHY([KB<%H(4,%H2=AVX8<!JEBX<S.0-\J\[3K-
M:(=Y`6..7BI9JA5(1FLNR<@`*IINF[<BZ!S`'@,40$,?A9-QF[;3MWCWRU1'
MT7**Z'&U&0ZH!2>`E*E$'I'94EVG>3=NCTI?(NH[)!DMW:$\EUI2I3RPE:>`
ME*E%*A]P[*@W6_\`*-KSY>4W\9(S%`U3[+W/T=)[PY2HZS]C;QZ)F>3.UU-Y
M$-4$=&%%01R@^;QN;\WMD^#U<4/=+\3+%Z38[<4JNXWXPZ;],1N^"N:UO_A#
M]I<>;J9*>YP?XP[85-0]V/\`C)[84Q/$/YRVG_E,Y^`9C$RWU?"J]^*)[\U2
M.\H;X*:B\23W]FK_`/:G8*P?:F?PBSQ+_EB<^30GC%P]4SZ@\UG[-2NDCOB:
M6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJIVLIE4X:E"YV_-@V%[
M8J7XWP>+7R>?BU;/Q9'DSM.'Y*WQQL_XDOR1^N>[)*JEYIU^[Z^<O!?)&X^9
M-L0;E)_"J1X[&[95-FY77P3E>D(?;JJYS=78O[\1_K+YWGR;^>$?=*Z]6-4,
M&\'V?_ET?AJDSO-N46Y.'7$JR;ST-/Q]9V-$7:AUYC+2<!#69HG%622<M)=`
MT3/,WT<H=P@B4H'%,3I^J40'PY<DY,7(NY/_`"_M[\/DT\IRURKQNCN$.7.?
MC1YLJWNJDV]KC8JQ)ANLOI"'%$E`6$KX%@C93?+SJ*ZZ6@*O%F6EN>A24A12
ME8P6<%=:H$;1]S97(YRF[VSF]S4U*\TUR!V'6K/0B3\';BQL5KJEU=V$Y!J.
M&\<X]TX"(8OO%))2:P&3Z_4/TATAX`R>OD4?(H^7!\NS?K'Y07)8TI>+-O/5
M:YEK,B3?KM<6O`YB4+?1X/-E/,YE*CM$.9,Z<"$D8FDOU'O-U?JVV&U7M]MR
M%G2O`--H.9.(!Q2D'HG92L\8NW$S\E7OPC%8DG_,4<QNR_[QK9ZMO--CWT^Q
MJ?'FNU<KJB[@WYW^P?T?[-^/>N\_G/?,9^"=M]Y&/))M=GR"OBY</0#_`)3#
MKJ(WGV=B?31?,7F8'R2^<%JOW,7ZRM]28[Q_-3'C'U%U&FF>VR?HF0]=ODCW
MS?\`F92?>FU=277(:!]H1W!?U:]7-_YKNTO:M:_'*O96GW`_%NT?CO\`DSU/
MNY,'QSL7=)/D<BJ2^-?SA-+?G(K/GQ<?OO3^&M^]%O\`:5)OOI^$.IO0LGM#
M729/>\4UZ)D?,ULCYW%_&W1WO5:?+X]0?7/S;([@YVII`^D2IB8/5*F)P^B4
M@F#_`/.&7K)_9O\`\I^&FTL@*6A)X"I(_=(I#3\]^3B9U"%N$%U4SG(4!IE>
M'Z4AA*4!'R7I'P!E2V7R=-TZY;BE09&8N*/[4]T2?\*K"#')/W'K80HVZ5B4
M)/[9(Z('^%2DSDD\FIN8F9!0JLA,2LC*OU2)E2(J]D7BSUVH1(@`1(IW"YA`
MI?`4!Z`\&*[;XK$&`Q!C`B,PRAM`)Q(0A(2D$G:<`!M.TTX:UPH]MMD:VPP4
MQ(\=MIL$DD(;0$(!)VDA*0,3M/":Z.>*?S<=-?(2&]B-D7V^'XH7STB[U:AI
MW]?&74GI5[JU"US[7VCT])^=J9<HY('-0W;>Y%G\B:IBE_\`/DSQESMC3<Z]
M[$UGT4W]8<JD<OCGE[R/>F7U12XZ7]GH?<$UN.-%K?484484484484484484
M4844844844845'&V>P<U]5'?"33)"_E8<^+1_<[KZHG5R>MO9J1TT=\32Q47
MMG6/3+/Z\<LH\MGF@;RO<^?WL4C^G//\/QA/5IY,I1TXRC"BL7.>\DQZ+D/-
M%LR[?^WL=V1VPKY7V)Z546<'[[S2K?%7N^FU)J^L8WC<QT1P^(^N<QY/,6&[
MM;ZWTMKVR4!TS/=(.7HDM6CV"PS;69;1<TW>`WCF8MRB9T<TA&__`$[N)NF^
M#>4[?I=V=WI.:AU(416\S3,54,W28Q,2H176Y;;_`!,**Y&7(BK:SRGPX0&D
MCE+4]<T6^&&DMB$&F>N.TJS9$E/9`I(Q4H*`5C@D8<-*7ORO2\_W9G&%&(C[
M2L,5RZY2S(2<)+V6-8MGT=N_DR:)@'K>LZ)Y!'&Q7IV8(:#>K13%*-DGA5?=
M!#I$BRS;N;E"MW*MU:Y-=AI#VBK`UQ;K;"UJ0NU6+C'DE^[6<<3$3_G,MI,A
MU3[#91X,YV2-?+0I=C8"0K9)=.()'`MW`;&W-JNQ2<!@3PCH]'V@[O/;(TSK
M:\6BCSNMK%8JK&O9FCV5Y(R4W79`A#-G#-[)2\5`R\F!SH>-2<NF+-RX14(H
MJ@DH8R98N]XU@MVEM=733]HN$>ZVR+,6EJ6PE"&GD$Y@I*&W'FV\`<JD-NNH
M0H%*'%I`4>TB.K?C(=<04+4D8I.)(^^0">F0#]RI=SBJR:,**,**,**,**R?
MX,Q4O[+5A?KZ\KS[K=>V%_939R.L_;"Z^DI7?UU[Q_V='XB>H*\V<W7M43[W
MBT9G36S8QU`5.TL75,G0E*W>*V\N%4G8A-DJM+Q4Q5H]=J]GD7T8FJF1JDH4
MRJIB``YV6[R6N#KFTRV9,R'(1.:XM^(^F-(:<*P&W&I"PI+)0X4J+B@0E()K
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M^L+#K##\[0JHZ7'E\6RVI_4&GVDK>7@<C2"L*<5@<J`2`<,*VUY<#1BND$A,
MG'`;2<&G3@!]/T4AW(;GEJWG%QQ6>:JA)UG":SYV=WW'>[TA+TN;C+$WG.7%
M+9-CMUJ99K(6#FF[BJ.%7$3(BVD4(]U'O#)^(?H"+_>0GR=M7;@.6_H)C6$B
M.N?=;3?%\2AN4TMDM6EQ2@H2F&.-:4F0A*)#.=E;S<E@+XR.X*Y74UVCW73<
MHQP0A#C0QQ20<7!_%)P.PX@X'`@\!%605CM;7_E!&>?HY/1RH^;/O#]R;UZN
MD4F%E\\Q/&6^W%/;E'FG)T844844844I?.7YK^R_J:O^.,!BS<G[XM6KIR/)
MGJ<#R7/CE9.G*\C?KEXB=Y0<G<(JFJ5RT1CNP6ZY5&NR3YO'#%S"]!:6-:S/
M2JLY!TO&`R<ULZ96KU-N]61=-G!$C('.=.6V9N_N$2R/7Q,J(ZS&A1I+R$*7
MQC0F*8#"<%(2',R7P2XT5M)4VZTI8<2E*I.(.\JVS=0,Z>7%F,OR9\J,PXM*
M.+=,-+Y?7BE:B@)5'*0AU*'5I<:<2@ME2D;GK?>4&3>VM*@YK=H:'DM_U;6D
M)-+-XX\3+6*,?-9F9+_B\@N]BDF#%MXY(KY%LH_;'!=J59(#F+HM4[O[@K=Y
M=;TU*B+2UIN1.=:!6'&V7$*::[)`0X5K5E46E+#*P6WBA92#S&L]YEN3:KK8
MW8DQ!=3.@M.E*.+<>;@ONN\"RML(0G,GC4MEY!#C(<0%*3V$9"34-M&%%03R
M?^;QN7\WMD^#U<4/=+\3+%Z38[<4JNXWXP:;],1N^"N6>I;)96FR2==9U+84
M<:*=V"*=3D]47D/6SOH3KMG*;66<K=5TFZ$P':JD(*3E(0.0PE$!R7:]:6?M
M%K:N;\VV.AY#+B6F9*7'\CN"DE3:1UI3P.))S(4"E0!J7:W:SCWBYO6IB#<V
MN(?6VIUV.IMDJ9<"595JPS!7"VH`I<3UR214O\%MZ0=LY=Z`JY:U:85]:K#?
M']>7EV\<#.2A:1'R\7*R@+L)!Z5FN64'R=5@X\5(M%!)X]!,JA##Q7*#W?7"
MS;EM27<RH;\>'&B(>#:EYD.REMN-MX+0C,.+Z]+R,S+@S<6XHI4`@V^K>7;K
MWNKO-F$.9'D3(,A3!<2C*MJ++8:<<Q0M64APY%,KROMDCC&T!22>F[:G8*P?
M:F?PBSQN'RQ.?)H3QBX>J9]1"ZS]FI721WQ-+-KGMQ6_;YO-7&60/F#\RO>+
MZ#1Y=$I(=*>T43NOU54[64RJ<-2A<[NG^K!L+H#I'Q]3Z`#HZ1'XWP?@#I$`
MZ1Q:^3S\6K9^+(\F=IP_)7.&_&T'_`E^2/US3T?93*^@Y4CJCL2$;-V[A<CN
MWU!Y6F[U1J]5CUV3+R]8%E'R;E`X>+,0GTI>MT]'0(RIW_2K^G2A,F;;)#JE
M`%,:2E\I"DA84K(,`@I(ZX$[3APU*1IO64?4V=4:#<X[2$$YI,=;`44J*"E.
M?`Y@H'80-FW@P-.UW7VR&6P>24.YCJIL"`:$I%N=(N[I4GE81>`9)-L=!H5\
MJ+@SMNJB;QB1TR&('A'$$Y6NEY&FMUK[4F9;9+QN$9)3%DI?*=I4"K(,N4@C
M*H$@TVCE):PCZJW)3%QH5RBLB=#4%2HZV`K%Q8P`7@K,"#BDI!&SZ:O@W5V+
M^_$?ZR^;7Y-_/"/NE=>K&J(_>#[/_P`NC\-<X_?K_P!G9=_SHZF^&GV7S_E)
M<]JS>@KQY,FFP:[]G'.ZM]6N'=O]SO\`[0EYVWRV%*_:HO=5=Z72&I[%72_"
M*G7CN1ZI9+42-=H,)$U&F`8OG10,U9NQ=1WD[IR4Q%"BW05Z#'Z2F#J@/@'U
M,@K_`.8<4PGD36!4I"G(PWE6K.A/9*3]G7C,E.T;2-@VC;T:2S>TJ,C3D=4U
MM3L,7./G0G8I:.OS)3M'7*&(3M&TC:*Z;_[NB]F'W,':RLG9(BQ$-Q]F5>M!
MOV<K&QT@ML6I"[9,GS./C^HS38E:%(@L"BY3%,H8W0J`9_.[^9W'@Q]R5G1$
MBOQ5#4K0_*H4VM:!"D95J0I:\5%?&$K3E000D#%!-*QR-(MNB[VY"(,*1#4+
M#*'Y=M;3CC8?MV1:T+<<Q65ETJ6C*@@I0$XH)KK*WGV=B?31?,7F<5\DOG!:
MK]S%^LK?4@.\?S4QXQ]1=1IIGMLGZ)D/7;Y(]\W_`)F4GWIM74EUR&@?:$=P
M7]6O5S?\/%[:0?\`XK6OQRKN5I]P/Q;M'X[_`),]3[N3!\<[%^/)\CD5SO<3
M]YP4URQX_4\];M,4\LFZI"`KC^1;1_N;+DU\\FD[)(E59R#M6.%H_@3H^1NR
M(/\`J.6ZWB?$J&,233?'N^N$#<WJ6]B5#>8BV%#SZ$*7G;,Q+181@I"0O,AX
M*XULK9Q0ZWGSI`4^[>QO,MMPW?WZP*B36)$J#=&&%N)1D<$-MX/N`I6HHRK9
M*>+<"'L%MKXO(HE/5S/>\4UZ)D?,ULB\W%_&W1WO5:?+X]1#W/S;([@YVII`
MC?83_:3^QFR]9.[-_P#Q_P`--J8_.M_CIZHKFUVRYV>A<WP5O9=2KD`Q@`LZ
M%?4>QQ+?Y9&29&3UV_A'5:EUYRAJH.%#N?$N6BYG*::)%40$RF5[],M:2<MQ
M-UM4V5<G)JV"\$K,;*XDJ0E#J7VPU+!"0C,AQ`0I2U(<V)JQ[JM[63=V0BU7
M>#$MC<!N0EDJ0).9M24K4MI3#A=B%))7E<:67$H0E:,2JL[N"'W4]F7#K7EM
MBH&LM8%ZZ5:%*D-E^-<6UM"T65LBO4K*C+P,N_=QH/6H'1<G28&30$#+F-FF
MT3-T&Q!2UJ:$](NJY"4A6WB/!W%,!S,1(8+;S:$O\4Y@I`4\%.`AL"MEK.!O
M%E.I>TM/8C6E$/,4Y<7_``AM#Y0$I,9\.,NK4QQJ,4+RLE+>UQ5=7G$\3#QM
MTL)Q`3C08,3B!#)`)Q0$3""1C',F`F_\D3")?4Z1R'/?&`-Z5^">Q^TG<-N/
M1^G9CT\!C45N_<D[XM1E79?:CW0PZ(Z!Q(Z6)J&;GVOM'IZ3\[4RY/R0.:AN
MV]R+/Y$U3%K_`.?)GC+G;&FYU[V)K/HIOZPY5(Y?'/+WD>],OJBEQTO[/0^X
M)K<<:+6^HPHHPHHPHHPHHPHHPHHPHHPHHPHHPHJ.-L]@YKZJ.^$FF2%_*PY\
M6C^YW7U1.KD];>S4CIH[XFEBHO;.L>F6?UXY91Y;/-`WE>Y\_O8I'].>?X?C
M">K3R92CIQE&%%8N<]Y)CT7(>:+9EV_]O8[LCMA7ROL3TJYK>%.A+??JQW>M
MH2TOO:V52#XO\*M@1FS4]GZ=AM-4"<BVNJ&MPL%"@IRH.]FQ6QOBMJEK#V1N
MWE$S2E8DW:4<"1WSE0)4-_.\:RZ<NV\NTKONGH=XD:MU1#<@F!<G;G,:<5<%
M1F9CS4E,%R%X1<'),):XZ@Q/897)*TQVDGB;7$<>;AN<4ZIL,,*"LR`A)&3$
MI!&8*P0`K`[4DY>$UH>^HC6T[W</%1AM"KL+A7'7*[EXW3BBVY:ISL>\=;GY
M*IA9X--UI;?E7>-X9H*J;X\K7Q19M70J(ND7'BR*]%NZFZIM_*BUA(TE+<@W
M1&CM.*+G@PD-+2FV6,\0Z4W2T2$EU64M"/,S.N-A+C3C6<H\9:6%V6.'TA2/
M"'MF.!'7N[1UC@V='%.P'80:ZC(`&H04*#$Z:C$(F-!F=)V,@D=J#-$&YTGX
ME*+U,R/0)5N@/&!]-T>'(C[D7C<7S(!$CCEY@4Y"%9CFQ1_`...*?X/!T*[Q
M&&08<&`K+9A5]4844844844845D_P9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U
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MG,JE%(Y&W*)D0PK#$..C$`C'\BG;MVDC@4<.R!PJRWF]V[[O3]/BH_JW\G,:
MKN"]G=Y?^[F3Z[L5;RZ?G8?C8[V[6E=ZF0A..6LP(4I`'FKP5,(%*!0$QN6.
MIQ$P@`!TB(^J..4^4^HJY;^F2HDGP"[^JI=:?7/LV]^.WVZ:D"L=K:_\H(SS
M]'+,W*CYL^\/W)O7JZ12-V7SS$\9;[<4]N4>:<G1A11A11A12E\Y?FO[+^IJ
M_P".,!BS<G[XM6KIR/)GJ<#R7/CE9.G*\C?KGEZ`_:#U>GU/V>CJ]/T>J/1]
M#),*E^RCAPK<]<``[&UYT@`__'M,'P@`^$+)&``_1`/4'-%JCV7N?HZ5WARN
M;UHD?U-O&S_\U3#_`/PSE=3>1#5!)1A14$<H/F\;F_-[9/@]7%#W2_$RQ>DV
M.W%*KN-^,.F_3$;O@KFN0_PA^T./-U<E/<X/\8=L*FG=['_&3VPIA^(@!_66
MT_X`[3.A`>@.D!&`F.D0_:$?V?V\3/?5\*KWXHGOS5([RA4C^Y341PV^!)[^
MS70!M3L%8/M3/X19XEWRQ.?)H3QBX>J9]0>ZS]FI721WQ-+-KGMQ6_;YO-7&
M60/F#\RO>+Z#1Y=$I(=*>T43NOU54[64RJ<-2A<[?FP;"]L5+\;X/%KY//Q:
MMGXLCR9VG#\E;XXV?\27Y(_7/=ZN255+S3K]WWX>2\%\D;CYDVQ!N4G\*I'C
ML;ME4V;E=?!.5Z0A]NJKG-U=B_OQ'^LOG>?)OYX1]TKKU8U0P;P?9_\`ET?A
MKG'[]?\`L[+O^='4WPT^R^?\I+GM6;T%>/)DTV#7?LXYW5OJUP[M_N=_]H2\
M[;Y;"E?M47NJN]+I#4]BKI?A%3QQSCVDM:+/%OTO'L9*DR[!ZCUSI^-:O'<<
MW<)@HF8BB8G24$.L40$/5`>G(*?^8?DO0^1)89<8Y9#6\FU+2<`<%)MUX4DX
M'$'`@;#LI*M[LN1`TRQ.B*R2F;E'<0K`'!2,ZDG`X@X$#81@>C747_=\*O'P
M',;9[ILXDGKR0X\S#9R\E'972XM(R]T46#1,$D&R":+87RHAT$ZYA./6,;H#
MH_G5_,INTFY;C[2RZEIMAK4S2DI;3E&9R)+SJ.)4259$]'`8;`-N*A\AZ^3+
MMO7EL/(9:C,V*4I*&D94YW9,'C%G%2E%2LB/X6`">M`VX]5>\^SL3Z:+YB\S
MG/DE\X+5?N8OUE;ZD8WC^:F/&/J+J--,]MD_1,AZ[?)'OF_\S*3[TVKJ2ZY#
M0/M".X+^K7JYO_-=VE[5K7XY5[*T^X'XMVC\=_R9ZGW<F#XYV+NDGR.15)7&
MP`_K":6\`?RDUD?4#U?+2AT_1Z/!T_M8_?>G\-;]Z+?[6I-M]*4_W1:E.`Q^
MQI/:&NDV>]XIKT3(^9K9'SN+^-NCO>JT^7QZ@_N?FV1W!SM32!&^PG^TG]C-
MEZR=V;_^/^&FU,?G6_QT]45SXWO2NOM@/+(ZLD8[6>6%""9/GK.1<L'J!*J]
MF5XI>,=MS`O&KG1G7;9UXHQ4WK-8R"Y%$Q$!KFVK7FI--NM,VMU"6(S\A:$J
M0E:3X0&PX%I.Q8!:;<;S`EIU(<;*5#&K,EXW=Z8U0VZ]=6EE^4Q%2M25J0H>
M#\8ILH4D@H)#SC;F4@.M*+;@4@D5FKCJO7%XL;.R7&DURSS,2R?Q$>[G(MM)
M@VCW[UL_7;E;NR*MC=5VS(=,YB"HB)C]0Q044`VHL>K]4:?M:[78Y\J)!><0
MXM+3BF\RT)4@',DA78J(4`<%8)S`Y4X;*YZ(TEJ&9'NM]MT29.884TA3S:7,
MJ%J0LC!8*3UR`4DC%/792,ZL>H;BD`!QPTR`!T`%#A0``]0`!(P``?N`&1);
MX3CO1OI/#]HN]6HB-_0`WRZD`X/M5[JU"US[7VCT])^=J9<HY('-0W;>Y%G\
MB:IBE_\`/DSQESMC3<Z][$UGT4W]8<JD<OCGE[R/>F7U12XZ7]GH?<$UN.-%
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MEY;C;=B8+F`'A+AQ*$K`P<<.)0O!)^YBI.!X#CLKJ,B'17T3&/2&,<CR.9.B
M',B5N8Y7#9)8IC($45(@8P'Z1(!C`7U`$>CIR(^:R8\QV.H8*0ZI)&..&51'
M"0">#A(&/#@*[Q)Q2#](K(9C5]4844844844845D_P`&8J7]EJPOU]>5Y]UN
MO;"_LILY'6?MA=?24KOZZ]X_[.C\1/4%(=S%Y07?CP_H+6H0=6F$[4TL+A^:
MQ(RJIT#Q"T0FW!I[FR3`"E4"0/U^N!O4#HZ/#TJ_N0W2V#>9&N+UZD2V%0UL
MA'$EL8\8'"<V="^#(,,,.$XTZSDY[C=,;X8EV?U#*G1UP'(Z4>#EH!0=#Q5G
MXQMS@XL888<)QQV4N==Y);6Y4ZEY'TAY2H-5_%ZK/)0\=1'D]!V64<.'YTGC
M:$EG$G(*L+$FQ;'/%*HD!1.1!(0Z>@`Q3[GNMT?N@UGI>_L3Y"8[UXR.KEI9
M=8;"4`I4ZV$("V2M0$A*CE+.<;.&OOE,;@=+[H]+0;EIN5<)4F;)=:6E]36`
M2AL+!1Q;39"L2=I)Z&`I0N('7+N;@812)0CE2[KY4B9XP>/)"*F@/PGUDJ5P
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M.JT,Y1<-RKAXOP"<AR_N#DD^N[[)TQH^XZAAH0Y*AQRZA*\<BE)4G`*RD'#;
MT"#]VI==Y6I)>CM!7;54!#;LVWQ"\A#F;(I25)P"\I2K+MVX*!^[5S&L^!&M
MM7WVL;`A[C>9"3JS\\@S922L"+!PJHS=,A(Y!K#-W`I@FZ,/TIRCT@'AZ,8S
MJOE%ZIU;IV7IN;!M[<28V$*4@/9T@*2K%.9U0QQ2.$'94;FMN5AK37.E)VD;
MC;K6S"GM!M:VP_G2`M*\4YGE)QQ2!M2=F--1M3L%8/M3/X19XN/RQ.?)H3QB
MX>J9],PUG[-2NDCOB:6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJ
MJ<>0^R9G46G+IL2OLHV0EZXWBUF;.8*Z/'+&?3D9&*@Y*S<-'(@5!Z8Q>JH7
MZ8`Z>D.D,J"[L]+0=:ZX@:9N3CK4*4IP*4WE"QD:<<&7,E2>%(!Q!V8T]'<_
MHNV[P]XUMT?=W7V;=-6Z%K9*0X,C#KHRE:5)VJ0`<4G83T=M4T;:YO;-W+09
MS7ECJ]&C8B;&.5<O(5O/$D4C1<FTE$`0,]F7;8"J+M"E/UDS#U1'HZ!\./FT
M9N"TIH;4<?4UKEW!V;'SA*72R4'C$*;..5I*M@42,"-O#4D6[_DP:(W;ZLBZ
MPLTZZ/7"+Q@2AY3!;/&MK:5FR,H5L2LD8*&W#'$;*3'%TIR=.OW?7SEX+Y(W
M'S)MB#<I/X52/'8W;*ILW*Z^"<KTA#[=57.;J[%_?B/]9?.\^3?SPC[I77JQ
MJA@W@^S_`/+H_#7./WZ_]G9=_P`Z.IOAI]E\_P"4ESVK-Z"O'DR:;!KOV<<[
MJWU:YI.Z5X4Z^Y^<K_ZOFS+3<:?6'>L[E<#S-%4A$IXLA65X0638IY^(FX_R
M-8SXWC0%#KB!0`IB^KDGOSU/F*[U/E<\AS_BIW.V33]_UFQK&TVH1+RF8J$6
M+@B8'G"(,J&_QJ`R.+/'9`22I"]@KC-V>DH.M=2_8=P<=:CF.XO,WES8H*<!
MUR5##;MV5U5T#^[.<3->R[J8B]\<BGB[J.6C3I/W.M!2*DLNW7$Y?)Z"@?Q@
M&;``=(]'0(^#*!O+?_YI7EA<NO=%$W.[QMWV[6T6.)?(]T2];47L/EZ.Q*CI
M;5X5=I#?%J3+658("LR4X*`Q!5_57)+T5JVUBU3;E=&V0ZES%!8S8I"@!US*
MAAUVW95B/#7NN]0<*MG36TJ#L#9-JF)REOZ0XC[@K6#QJ,?(3$',JNT0A:_%
M.O+"+P29"]902=0YNDHCT"$'6_+E;ZUW\:38TCJ.VVJ'"CST2@N,'PLK0TZT
M$GC7G$Y2'5$X)QQ`VX8X[7<YR8=(;E]2O:GL$^Y2IC\-<8HD%DH"%N-.%0XM
MIM68%I(&)PP)V<&#B[S[.Q/IHOF+S'W_`"2^<%JOW,7ZRM]*GO'\U,>,?472
M3[!W#8=&5P]^J\=#2LJD_90Q6DZ1ZI'BVE3*`NJ)6#MDX\>GY.7J?OG5\(](
M#DM/S)-%VW7_`"9W--W9U]F$O4$!PJ:*0O%M$H@#.E2<#T=F/T85W')(W<V?
M>GO@1I2^O26(!M<I[.P4!S,T6LHQ<0M.4YCCUN/!@12D[6YS;/V]0+!KNPU:
MB1T18TV*;QY#MYXDBB5A)LI5(6QGDT[;`)W#$A3=9,WT@CT=`]`Y`SH[D^Z2
MT5J.-J>VR[B[-BE92EQ3)0<[:FSFRM)5L"R1@1MPJ7707);T-N\U;$UC:)UU
M>N,(K*$/*8+:N,:6T<P0RA6Q*R1@H;0,=FRH8XU_.$TM^<BL^?%SNMZ?PUOW
MHM_M*4G?3\(=3>A9/:&NDR>]XIKT3(^9K9'SN+^-NCO>JT^7QZ@^N?FV1W!S
MM32!&^PG^TG]C-EZR=V;_P#C_AIM3'YUO\=/5%4BN1ZIG)@]4IW`AT_N'..5
MGGQC*6/_`!#U:M/PQBRT/I0CJ"KAZ=W=.K;34:K9G=WV`W=V*MP4ZZ;MEJ[Y
M.@YEHMJ_72;@K!**`@FJX$"`8QC`4`Z1$?#C&;YRG=7VB]3+2S`MJF8LIUI)
M4'LQ2VXI`)P=`Q(&)P`&/`!4=FH^6-KNQ:AGV2/:[0N/#FOL)4H2,RDM.J;2
M58/@9B$@G``8\`'!5B6N:1'ZVHU6H42[>OXVJ0[6&9/)$4!?.4&A1*15T+9%
M!`5C`/AZA"E_<QLNI[_)U3J"9J*8AMN5,?4ZI*,<B2KA"<Q)PZ9)IG>LM3S-
M::IGZKGMMM39\E3RT-YLB5+VD)S%2L!T,23]VE)N?:^T>GI/SM3+J?)`YJ&[
M;W(L_D35-+O_`)\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR^J*7'2_L]#[@
MFMQQHM;ZC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BHXVSV#FOJH[X2:9(7\K#GQ
M:/[G=?5$ZN3UM[-2.FCOB:6*B]LZQZ99_7CEE'EL\T#>5[GS^]BD?TYY_A^,
M)ZM/)E*.G&4845BYSWDF/1<AYHMF7;_V]CNR.V%?*^Q/2JC3@KR/Y#47BUW?
MNNJMQU&2U,CQ_P")1+)N>Q3J[*OS]<V1&Z:U^,31%XUJ[8L=AU2T7:4>O&4Z
MHP;.(J"`K515Q((@E()RA-UV[/4.]W>3J>[ZGXK62M2:B+%L9:"WF7X*[G,X
MR6%J2M<*1'BL--NQ$NK1(EDO)0W&65\K:ILQJ!#9;9QC\2SBLG80H(3@G#^$
M"HDA6`(3LVD5%$AR4M/&?NZ^/,Q!SU'K\%<.37*^KVR1ME8UG=Y-1BTWMR1L
M$6UK%+VKNG2$#,+KR\.D9X=.0=NFC,AE"MQ`#')V,;=7:-ZW*<U-!N$>X2;A
M!TGIY^.B._.BMA:K39&7%/RK?:[J\T`VXH-!3+;;CA"2Z#@E6.9SD&S,J04!
M"GW020E1_..$8)6M`.T;=I('0KHHBW)GD9'.S'\89TP9N3*>+(EUS+MTU1/X
MI-5=-/K";IZI3G`OJ`8?5R,>8T&);K(&`0XI.&).&!(PQ(!/3(!/T#@KLTG%
M(/W*]V8]?M&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24K
MOZZ]X_[.C\1/4%4^=Z#[\Z;]&W;SFLX[+DE?L-\[K%[5^I%.0UYMU)W:%VLF
MH9X1U6(N\?R6J<[4DK[%SNFCLG%-5,R2&R*&<R2C2*;.9%!RS8R#EXFF#9R=
M,P-7'45`.D@9W._R\3;!)TK>;=--NEQ[X%B2,QX@94!3BDH*5+0E).=`(XQ&
M9'`JMCRZ6TNZ'LK:TYTFX2.M^G\@G9M_Z#T*C#B/1=EZ^WOPC@MKZM_)-:/Z
MP'+GQ4*VCD(B'F86)X8ZWK,588B/9TG7\</CVT$"#UXWCQ3DI%!=T9<ZJJB:
M/6[Z-0Z5U+N\U]<-'7?[9M']6].8NJ67'&G7-3S7W&7%JE3%[%/9VFEO8L,K
M;9#:4(0I<5EN:?9EQ42&^+<XY[9A@"`RD`CK4CH;3AM.)Q^BQ7O#K7!4-]P=
MO-H>^YM8I?-6,MMCD?$K.`CX&N<7.4TQ,/A0;IJN%@:1[-102D*8Y@+T``CC
M8N3/9[AJ*/O`T_:&^-NT_0:X[",0G.\_?[`TTC%1`&9:DC$D`8[36ZO+B&3%
M=<.#:90)/W`TZ3_T4KW-CE7J#DMH",:ZID)V4;T7FWP!5/,2=<DH>!M];G.8
MU3K\%>]?S#Q,K*X46;L%"FV322:F%)=:,6,4/%&145>C\N3<]K;=5RU]$O:Q
M:CLN7"W7L!IM]#KT9]JS*>=B3&DG-&EM,S(KKC#@S(2^@'KPM*.=U=<(T[3D
MD1R2$+;VD$`@N8!23T4DI4`1]!^Y3G5CM;7_`)01GGZ.6%N5'S9]X?N3>O5T
MBDHLOGF)XRWVXI[<H\TY.C"BC"BC"BE+YR_-?V7]35_QQ@,6;D_?%JU=.1Y,
M]3@>2Y\<K)TY7D;]<R$5NB@S%F:U%H_D4YN1L%BK<,B^AI%@VGWM22GALSJ!
M>.D$V\M%0;NM/&KEPB8Q471"$-T`L@926"9H34<&TKO3S;1@-1F7W2AU"U,I
MD%GB$O)22IMQU+[;B$*`*FRI0Q+;@3*/!WAZ9GWE%A9<=3<793\=H+:<0EY<
M8/<>IE2DA+C;2F'6W%I)"7`D'\XV5^W6<WO%+D;K=M+0M;CM=_EFIL*Q=HF:
MNEK#!24[-OT)<SHDTI+0\Q"HQD4V\F,P%%VN[<&$Y4RD.GCZK@;OU[K[H["?
ME.ZF^PI+JTG,D,NH9:06\I:#;K3I<D+XP/9FT-M``J*DJ3_6%TWDI:NS,Z/#
M:TN(LQI*@0HOM+BS5AS'C2XVXT&X[906<JUN.'$(`4CL6R$&H=Z,**@GD_X>
M/&Y0_;U[9/@]7%#W2_$RQ>DV.W%*KN-^,&F_3$;O@KG@X:[7H-LY6ZHJ]>G%
MI*:BMA.XZ1;D@;(W:M)"O@^93+)26>0[:'\K8.@$ATP<"81#Z4#!DF6_+1VH
M[-N>O%VN<=+4!ZV)6A1>84I2'LBFEAM+JG,JT[0<F'TX5)+OCUSIF^;K]566
MUOK=N#$"0VL<2^$I6PZA#J"XIL-YD*V%.?'Z`:ZE<B*J(6H^VIV"L'VIG\(L
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M>,XPX0VWE5D6R8Z`M"TO.%:'RX\LI<0A3:4LI&91<PW"E[8H&P_*?B9.+S9&
MC11\JN2`LK%H9LDY.S5.V>2D,Q:OE$W29DS)H'44`Q1`2^`<T=]T;J/3.3[=
MCICJ6L(`+S"U9BD*&9+;JU(!2005!*<"-NVNDT]KK3&JRO[!?6^E""LJXE]"
M2D**3E6MM*5D*!!"22"#LV4[7=A;4H>RN2L0I29Q6<01H]K?"Z"#L4:S5:+M
MT4$EFKV8B(YH]`RJ9BB")U#%Z/"`8@G*STAJ+2NZM]-_CB.XJX1T9>-96H*!
M)(4EIQ:D["#UP`/0IM'*5UOIK5^Y.8K3SZWVTS82\W$O(04EQ8!2MQM"5[01
MUI.&&VKWMU=B_OQ'^LOFW^3?SPC[I77JQJB,W@^S_P#+H_#7./WZ_P#9V7?\
MZ.IOAI]E\_Y27/:LWH*\>3)IL&N_9QSNK?5JF[^[4?VE;7\P^U?9ZMG;_P#.
M$?\`P^/_`.\[37:7*L;<#[?CQ)[ZE?T),_E0T^"C"BH2WGV=B?31?,7F3.?)
M+YP6J_<Q?K*WTGF\?S4QXQ]1=5G<J^C\D;CI$``+-7A$1\``'7=](B/[09,S
MRZO@0?3</O<JEX^7X<.4.@_^A3^JQ5/=+W/0K_)Q\-7GTD,K*P+ZU1T?*PLE
M#.WE5:.(9LWLS="10045@ID9YN9BY*`IN0\84!!1%4A(C[]H746G(CLZYMM>
M!LR$1UK;=0ZE,A275*8)02`ZUQ*PZ@[4=:3BE:%*F4T]O"TUJ>8W`MCCOAKT
M9<E"'&G&E*C)4TE,A(6E)++O'(+2QL7UX'7-K2F:>*.ZM?S_`"GT35&$A($F
MY3<!(:%;OH:1CT9X]2>2Y;#)0;EV@DC*0L8\K[MJJZ2$Q".2%(;H\<B*G![X
MM!ZDMNZ'4-YDM-&`S9"ZZ4.H661(2WQ*'4I)+;KB7FW$MJP)02H8Y'`E+][&
M\;2]SW<:BL<=UT7!ZW7!EI*VEH#QC-N\<MI2D@.--J9<;4M)("PD'\XV5=4<
M][Q37HF1\S6R,G<7\;='>]5I\OCU#Q<_-LCN#G:FD"-]A/\`:3^QFR]9.[-_
M_'_#3:F/SK?XZ>J*YR-ISF\HJPR(TV%K8TEC&DF!GGXM'2[J00=@U?U>5:+S
MD>_CF#M)SY3[HM&[I1!)N)2IG4.!#5Y-.V_=_,8(OC\K[?<E+:XE&9(2@XJ1
M(;4&EH6M)3DXEQ;86I8)4E(*A9.U!<]X\.Y-"PL1/ZO-QVG>.7E45+!"5QW$
MEY"T(4E7&<<VAPI2@@)4HA)[#=4@`:NUL`=/0%!IP!T^KT?%V.Z.G]W(/M8>
MUUUQX?M&3WY=1`:]Q.NKT3P_:TSRARM]SG*Y.D5N?:^T>GI/SM3+N/)`YJ&[
M;W(L_D35-PO_`)\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR^J*7'2_L]#[@
MFMQQHM;ZC"BC"BC"BC"BC"BC"BC"BC"BC"BC"BHXVSV#FOJH[X2:9(7\K#GQ
M:/[G=?5$ZN3UM[-2.FCOB:6*B]LZQZ99_7CEE'EL\T#>5[GS^]BD?TYY_A^,
M)ZM/)E*.G&4845BYSWDF/1<AYHMF7;_V]CNR.V%?*^Q/2KFPX9,;'8Z/P`J[
M2P\VW+IAQL[OV^0$30*ZO_53J=4BQJ:=KDK0?\IE7@[M*2*L))H/U',<^4KW
MNH+QTPDQ:P1F<IV_21:[7J#>1=WHV@4,N:IUC$><F/#^L$B0YX08Z(X\!?=B
MMH#K"V0V^TF9X/Q#4F)QUP#_`!-L"UM0VPJ5B&(Z@$C\D`,,2>N`43@<<0<N
M.)"L$82,68HD3W<6E?CYQM8<C(U_R&Y9-T(U_);%A$ZT+?D%R&E%R1$_JJC;
M`N[*U75%A[BQ"8M&<4[>O")/Y!HD8OC.8,'44SE0W[^KNJ7-+RF],Z>)6A$)
MTOYK/9FQQC-PEPXJX\4K\*DJXQV0VTVI<:,\L')[9FDV5KCF`\DO.[,5##\H
MX=A0E2L5=B-@!)VD5T'17B1BXT6[`\6@+!GXB,43;HJ1R/DZ?BV!TFBJS1([
M,G0F)4CG3*)>@IA#H'(U9F?PMWC'`\YQBL7`5$+.8XK!4`HA1Z[%0"CCM`-=
MBG#*,!@,.#Z*]^8]?M&%%&%%&%%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6
M?MA=?24KOZZ]X_[.C\1/4%4^=Z#[\Z;]&W;SFLX[+DE?L-\[K%[5^I%.0UYM
MU)W:%VLFH:X07&(U^TY(7.>*^4BJ]J))^Z0C(R3F9%T(2#Y)NR814,NUE'[Q
MZZ5(BDF@L@H8YPZ%4OLA>XW_`%CFZD>TM8K<6Q,DWHH27%MM(3UB"5+<="FT
M)0D%2E+2L``]8OL3L>72XEG1%D=7CE3<9'`"3^83T!MK1>.TY>K9R?X#V"TW
M[9-ECFMZY30:%<V!Y=*QL%*O>+%7NXCKNSVZF5':9ZQ#1ML)!O8VPKSZS&:C
M72:,HY*F917HMYMOT]9MTN\:VVBVVJ+)7;[`Z7X>1M;S:;_(B_YZQ&E2;>'W
M5QS*:?A(AI=BOLJ7$:*@A$5\);KD^(MQ:U)SNC!6T`\4%=:2D+P`.4A6;!0.
M"C5CW.)--:[]WPBLF15%;GI5$5DE2%42525XV\G4U4E$S`)3IJ$,)3%$!`0'
MH'&N\G]:F[!O*<02E:=W4@@C801>["00>@0=H/0K=77:[#!X/"QWMVHE[RZB
MTBD<;=;MZ73JK4&ZW,W@2U60J]>B(!%5JPY::S58ME4HEFT(H@R5D'!DB"`E
M3,NH)0`3FZ74_*TU#?[_`,N+3#M]G3)KB85Z4"^\X\0I=JDA:@7%*(*@A`4>
M%00D''*,-'K9IIK33P:2E(S-\``_ACZ.G4T5CM;7_E!&>?HY9/Y4?-GWA^Y-
MZ]72*1^R^>8GC+?;BGMRCS3DZ,**,**,**4OG+\U_9?U-7_'&`Q9N3]\6K5T
MY'DSU.!Y+GQRLG3E>1OUSG!7X`'+5Z$'#%>L'\C*L781;$'3*4F$%6LO)-'`
M(`LVD)5LL=-RL02J+D.8IS&`1#)/#<KB6EL&0_Q#C:&UIXQ>53;9"FT*&."D
M-J`*$D%*"`4@$5+>+1:4OHE)BQQ):<6XA?%HS(<=!2XM*L,4K<2I06H$%0)"
MB037[ZJUE7F6]Z=>`D;FYF)'9M,DB-'E^NBU;C532$+%+-8ZI^[I:TE'+E1%
M<4%&JB9'2AU"`41+U?C6&K+F_N\G:?+4!$%JTRD%28<4/K&1UP*7(XKCRL8Y
M,X<2HMI2E6(QQ3_56C;7&M=]U$'KBN<[;IBPA4V66$'P);92B-QW$!!`*\A;
M*0XI2T@'##K>R&"H3Z,**@CE!\WC<WYO;)\'JXH>Z7XF6+TFQVXI5=QOQATW
MZ8C=\%41<4R$3Y&Z<!,A$P5O3-94"%*3QBQF;L#*J=4`ZZI@*`"8>D1Z`R0[
M?"I2MU]\S$G"WJ`QVX#,G8/H'W."I3]^K33>YO4Q;2E)5;7"<`!B2M&)/W:Z
M5,BNJ%NH^VIV"L'VIG\(L\?K\L3GR:$\8N'JF?7+ZS]FI721WQ-+-KGMQ6_;
MYO-7&60/F#\RO>+Z#1Y=$I(=*>T43NOU55MW-WYKVU/5^X:_Z@B`]K8#U!#H
M$!_=#*E>X+XMV?NCWDSU2`<F,8[\K"/_`!9'DC]<M&K-#0VKIU><CIY[(G"N
MN:XBD:$K<,L_:.9&.D32MPDH.-9/[Q:4U(TI4Y%^8RQ"K.!Z.NX4,,N^K]XD
M[5UO3;Y49MI/A27R>-?="%)0M'%QD.K4B)'(626&0$DI;&.5M`$F^CMV4'1M
MS-RC25NGP<L`<4PT5I4M"^,E.--H7+D`M@!]XE0"W3AF=63.:9")$!-(A$DP
M,<X$3*5,@'4.950X$(`%`ZBIQ,8?5$PB(^$<3Y2E+5F6258`8G:<`,`-OT``
M#Z`,*4Q#3;2<K:4I3MV``<)Q/[I.)^[3K=WN0B7).!22(1)(M2N8E23(5-,H
MG:-SG$I"`!2B<YA$>@/"(B.(-RE5*7NLDK625F;%VG:=BB!M/W-E-FY6S3;6
MY&4AI*4I^T8FP#`=FH]"KG]U=B_OQ'^LOG=?)OYX1]TKKU8U0Q[P?9_^71^&
MN<?OU_[.R[_G1U-\-/LOG_*2Y[5F]!7CR9--@UW[..=U;ZM4W?W:C^TK:_F'
MVK[/5L[?_G"/_A\?_P!YVFNTN58VX'V_'B3WU*_H29_*AI\%&%%0EO/L[$^F
MB^8O,F<^27S@M5^YB_65OI/-X_FICQCZBZK.Y5?R1N/E-7O9'>3,\NKX$'TW
M#[W*I>/E^<X=OT%/ZK%5<-*_`,'#1VQ@X9D[CV#J*8.FD6Q;.&,6^=HOWL8S
M710(JVCWC]NFNJ@02I*+$*<Q1,4!"&UZY7&0TMF1(?<9<<2XM*G%J2MQ"2A+
MB@20I:4**$J.*@DE(.!(J;N/:+5$>1(BQH[<AMI3:%);0E26UJ2M2$D`$(4M
M*5*2"`I24J()`-39QIK\`3D;HMZ2#AR/8_:<;(,'A8MB5TQ?SCWJS;YFX!`%
MFKR9*H8':I!*=SUA\8)NG.!WJW*XJW7ZACJD/EART+0M/&+RK0TG\DA2<<%)
M:P'%I((1@,H%)EOHM%J3NHU%*3&CB2U:9JT+XM&9"WD'C5I5ABE3N)XQ0(*\
M3F)QKICGO>*:]$R/F:V1V[B_C;H[WJM/E\>H3KGYMD=P<[4T@1OL)_M)_8S9
M>LG=F_\`X_X:;4Q^=;_'3U17.MLS1=?V#)VJ;=SMBA9N:@XJNMY>&<-DWT''
M0\A,NG[.+4<-U@]R[4WESH2;-4%&Z_BD5R%3<I)K%KNV'>#<M-%B`S'BOP&)
MCSRFW4J*'5NAM*%.`*'Y2.IL+8=3E6G,MM14TM2#99OF[:VZH?7<7I,J/<)$
M2,REQI20ME#2G%+0V5)5^3D!TH?:5F0O*VXE*74)<'7_`*I'K:NUL;HZ.M0:
M</0'J!TUV.'H#(1=8##5UU'_`*C)[\NH==>C#75Z'T7:9Y0Y6^YSE<G2*W/M
M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_SY,\9<[8TW.O>Q-9]%-_6'*I'+XYY>
M\CWIE]44N.E_9Z'W!-;CC1:WU&%%&%%&%%&%%&%%&%%&%%&%%&%%&%%1QMGL
M'-?51WPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'?$TL5%[9UCTRS^O'+*/+9YH&
M\KW/G][%(_ISS_#\83U:>3*4=.,HPHK%SGO),>BY#S1;,NW_`+>QW9';"OE?
M8GI4D'=:_P!F_P`&OT6]+?B+#8OW*ZYT6\'WNNGE;M:NP^98OBZ.U%5+.7FN
MHGAOQ,D]@<6*ER8%QN/GI7:ZC/7G8<!)563E]];@>.F[6F:RH6Q+)>:W9HV'
M5),B,<LWCFC0#'*85BE%YC3&IYF_'6<33>KYNE`FQZ1>>+,2$\B0VW:+:E*E
M2ITR$Q$?86ZDQORR5O..$)(#9(YTEE-MCJ>CI?\`RKX&*E`@EQ?\%*5%0('7
M;,`!]VNDR(`"Q,6!6S9F4(YD!6C(BJ;-J`-D@!LT37;M%DVR`?2IE.DD8"@`
M"0H^`(LYI)F/$J6L\:KKE$%2NN/7*(4H%1X20I0QX%'AKMD]B.ALK(9C5]48
M44844844845D_P`&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24KOZZ]X_[.C\
M1/4%4^=Z#[\Z;]&W;SFLX[+DE?L-\[K%[5^I%.0UYMU)W:%VLFH:X0L74BRY
M(MF5SG-=O`U`1TVO-;:E?S=578/G[Y.:8QXLI$9([(S;K':E04.Y3ZR10ZQP
M$.YW^R&8K^EG7X,>YL?;92J(^K(U("T(06EKSHR9LV`<*@$*P6=@(K8\ND%6
MB+(`HH/VA(ZX<(_()VX;<>ET:T/BOMZP[NW1W?MWL6R9S9BZNW.5C!H]L4G$
MSTI746_#JAGD(->P0-1I4/(#)3JKN;\F29&/$>ZWD!UEO)RG'H=[^BK9H'0F
M\FP6RU1[4V++I]:DLH<9;>*M2RPAT,O293B,C0;BYU.@2?!_"4MHXTIJ*Z!)
M7*E0W5K*SQCO"02/R*=F("1M.*L,-F.&)PJR/F]V[[O3]/BH_JW\G,:WN"]G
M=Y?^[F3Z[L5;NZ?G8?C8[V[6F=ZK\W/6?Z:G!3];#4^.3^4]SWM,^(7CU5+K
M3ZY]FWOQF^W36_5CM;7_`)01GGZ.69^5'S9]X?N3>O5TBD;LOGF)XRWVXI[<
MH\TY.C"BC"BC"BE+YR_-?V7]35_QQ@,6;D_?%JU=.1Y,]3@>2Y\<K)TY7D;]
M<\N27U+_`%N>M_Y1M>?+RF_C)&9H]4^R]S]'2>\.5S>L_8V\>B9GDSM=3>1#
M5!'6F[%MHT*A7*[`P]U!J=:F;"$:+CR3RX8A@N]\D\J\2X\G\?XGJ]?Q9^KT
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M,'YE>\7T&CRZ)20Z4]HHG=?JJK;N;OS7MJ>T:_\`C=`94KW!?%NS]T>\F>J0
M'DQ?'.P]UD>2/U1KH_6)MR;/K>MRS05X;($L4)@6'NF#/W,AWTN(^0^5L?'^
M.!CXO[*3J];I\/1T#('K_5@T/I*5JDL>$B+Q?Y//Q>;C'$-]GE7AAGQ[$XX8
M='&I1]Z&MQNXT/-UH8WA@A<5^1XSBL_&/(:[/(O+AGS=B<<,-F.-6$_\+QQ_
M^VE/_P#((?\`6W&T_P#%LW_^`3_]W_\`R]-"_P".9K_5D_\`WW_\I4V\>N#J
MNBMFL-B'V42S%91$S%>Y(508D5/=9!)'Q_EON_(=7Q'B^GJ^*'K=/JAG!;R^
M4`C>%I1S3*;48A<?:<XSPCC,.+).&7B4<./#FV?0:3'>_P`J%O>GHAW1Z;*8
M)=D,N\;X5QN'%*)RY.(;QS8\.;9]!II=U=B_OQ'^LOCQ_DW\\(^Z5UZL:F(;
MP?9_^71^&N<?OU_[.R[_`)T=3?#3[+Y_RDN>U9O05X\F338-=^SCG=6^K5-W
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M3CAAT<:M%UIW=JVO=ATJ]FVR26"H62+L`Q@4L60OPCEP6\E!W\9G/DWCNCHZ
M_BS]7]H<:/JKE-MZETS/T\+,63-BN,\9X5FR9QAFR\0G-A]&88_33&-;<L1K
M5^C[GI4:?,<W&$['XWPS/Q?&)RYLG@R<V'#AF3C](JR">]XIKT3(^9K8D>XO
MXVZ.]ZK3Y?'IB=S\VR.X.=J:0(WV$_VD_L9LO63NS?\`\?\`#3:F/SK?XZ>J
M*I$=^J[^J<_7'RL^]^UJ[H>K5J"%^:9_$1U!74?J?^2S6GR`IOXNQV1":R]K
M[KZ2D]^74%^O_;N]^EYGE#E;_G-UR5(K<^U]H]/2?G:F7<>2!S4-VWN19_(F
MJ;A?_/DSQESMC3<Z][$UGT4W]8<JD<OCGE[R/>F7U12XZ7]GH?<$UN.-%K?4
M844844844844844844844844844845'&V>P<U]5'?"33)"_E8<^+1_<[KZHG
M5R>MO9J1TT=\32Q47MG6/3+/Z\<LH\MGF@;RO<^?WL4C^G//\/QA/5IY,I1T
MXRC"BL7.>\DQZ+D/-%LR[?\`M['=D=L*^5]B>E5''`GGQK'4W'7N\>,<Y4K@
M_M=FXV<48DDTQFM6,42/-HU*O,*VM`T6Q[&@]O;#A8]9R49B1K5=EV,20B_C
ME>LU=E0D!Y1?)SU9K+>=O,WL6^;!;L\35.H7"TMJX+)3`D/+?#TMB$[;83JP
MDB,S.FQG9!+?%HP>9+G*VB[L1X4."M*BXIAH8XH_A`88)*@M0'1*4D#;CP'!
M)MYR$DOW>_%R!A*Z#V4@^4')NWNYZ<UQLB:J3"%5Y'\BZN_:H;%J.O-@04'-
MB63%=>'43:R4O&I*E;.$2@IXQ>]WT:*WRE=77&?)XN)(TE8HR66IL%J0MT62
MRR$*,*3-ANNM?D\B)*2XQ&?4@NMK)3EU<LJ-G80E.*@^Z<2E1&'&.#L@E0!V
M\&PD<!%=44*/3#Q(B=!01C&`^,:H.&K93I:I?3MVSM9PZ;H&]4A%%#J$+T`8
MPB`B,0<_9.>&"A^57L40I0ZX[%*2`E1^DI`!.T`#97?)[$=*LEF)7U1A11A1
M1A11A163_!F*E_9:L+]?7E>?=;KVPO[*;.1UG[877TE*[^NO>/\`LZ/Q$]05
M3YWH/OSIOT;=O.:SCLN25^PWSNL7M7ZD4Y#7FW4G=H7:R:A7A5%%G(?E!$F?
MN(OR[1[Y$DBUM\WK]9BK_P!KG1=?'>N2T%.51)!4I3*/VKQLJV3`QP4+T=.=
MYOXF&WSM)3`VE[B]0()0J,U,"Q^3!3X*^VZU()&(#+C2TK."2DXX5L.74G/H
M:RIQPQN$C;B4_P#8)_A`@CI@C"H\XA/8*0V;W<;R%>3;I=[L[E8_GB3SE)=T
MVFWO$*E*.09IDV+LM=&(<E*"K<[AVS=.P,9PLU*HH99;I=];%PC:4WH,3D1T
M-MVG3Z&2RDA*FDZDE!.8^!007$]BL(;<;;P#:'BE(;1%=;B@OPBDG$N.XX_3
MQ*?\)6SZ-H)X2.B;'^>LO%5^R\"9^>DX^%@H'G+`34W-2SQO'14/#Q7&7E$_
ME)64D':B+1A&QS%NHLNNJ<B2*1#'.8"@(XUWDZPIERM6\6VVYIQ^XR-WSS33
M3:5+<==<OMA0VVVA(*EK6LA*$)!4I1``)(%;N[J2A<1:R`@2P23L``:=Q)/T
M"EIYV<F^/'(_CG7#:!W9K'<R-)YL]WLC:G6L[E!W-C"FM')W5$Q73NG\"\>L
MA;S4<0ZC94BATE?%*%*83I*%*\OY;.ZC>9NNY;^CAO'L-VL2Y]NOICIG1G8J
MW>(MTIIX)0\E"L6ED)6D@*3F22,JTD\]K"=#FZ;D>!NMNA*VL<J@K#%:2.#Z
M1P4V-8[6U_Y01GGZ.6)N5'S9]X?N3>O5TBDELOGF)XRWVXI[<H\TY.C"BC"B
MC"BE,YR=`\8-E`(]`"%6Z1_:#XXP'2/_`(,6;D_?%JU8</\`G'DSU.`Y+F/]
M^5EPX<97D;]<M5.V5LB=NR<'9-9*5"!5<V&)(ZD7+KW14>0+)I))SK%R=$D-
M+UV9(]!LW3;F,[*JBJL8/%$."<NM\TKI:WV`W"U783;B$,N94)3D"7EJ06EI
MQ+K;S13G6I8#92I"!UZDE4EU@UCJVY:C%NNMH,&VEQYK%:SGSLI2L/(5@&W6
M70O(A*"7`I"UGK$JR[GK#96R%.1VNZP\UFK$5)'<E.K9K'(.'11FVSV>FGT7
M9*\^*D$*=@T85UIY8T5/Y69Q*$32`#(B"NBU;I72R=U]SNS%V#UY58Y+_$(2
MG\DI#+2'&'D8\:%J6\YQ;B1Q80PI2]BP4<SJ[66KEM7>SR+06+*F),8+RUG\
MJ%Q9JVWV5X!O*E##8<;4>,*Y"4IVHP7V*Y"#4.]0YR'_`)!]Q?FUN7P"^SN-
MV?Q$L?I6-WY%*/N>^*VG/34/OZ*Y<(B\TF4G3UN,N53D;$@$BBO`,+'#/)M!
M6/16*_26B6SU1^DHQ,0P+%,F`I"`@;HZ,ERFZ?O\2WBZ2X,QJV*R$/+8=2T0
MLC(0XI(00O$92%==CLQJ9I.IM-S)R[1$N$)VZH60IE#[:G04*`6"V%%8*""%
M`CK2-N%3QQ&O5(F.4NH("(N=3EIYM>"E<0D98X9_,-S,$'R+XJ\8T>K/DA9+
M!U%@,0/%&\!N@<3O?3I^_P`'=%>[E-@S&;<JW]:ZXPZALYR@HP<4D(.<;4X'
MKAM&-)3OLU-INX;J-36N!<(3US1;'0IE#[:W04.(2O%"5%0R'8K$=:=AP-=/
M61,U#I4?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]9^S4KI([XFEFUSVXK?M\
MWFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJVWF]TAQ<VL)0`Q@80`E*(]4!,%M
M@>J`C^P`CE2S<%A_>Y9\>#C'O)WJ?_R8R1OQL1&T\9(\D?JACNTMD;&MO+_6
M;&YZU6H3!S"WUZU;R*SP)IG)0-2:LY!%T9=%.-EXV7?3SD62[$QP20C^LO\`
M=*71(GRJM+Z8LNY.ZR+%=4W&0A^(E2D!/%*0](4I!3@2MM;:&4<:ET#,M[!O
M\TO%W>^[5^J[]NAOD>_6HVV*N.PI*5J5QJ'&9L!*PHE(0ZAU;SG%+:)"4,XN
M?GFZZE,B*J,NC"BHDW5V+^_$?ZR^2L?)OYX1]TKKU8U</O!]G_Y='X:YQ^_7
M_L[+O^='4WPT^R^?\I+GM6;T%>/)DTV#7?LXYW5OJU3=_=J/[2MK^8?:OL]6
MSM_^<(_^'Q__`'G::[2Y5C;@?;\>)/?4K^A)G\J&GP4845"6\^SL3Z:+YB\R
M9SY)?."U7[F+]96^D\WC^:F/&/J+JL[E5_)&X^4U>]D=Y,SRZO@0?3</O<JE
MX^7YSAV_04_JL4H7`#8]#N7*75"%5MD+/+++WHZ24:Z!=0Z4-4'J<BN4G5*8
M6R`S;,Q5?L:R;E-1,3IG`PP/<I#2^HK'NBO#EXAOQD)3$!*TX`%V2DH&/\8\
M4X"GA2IM:5!*DD5)AR@]7Z:U!N1OC5EFL275-M$!"@20U-AA:A_@CCFB%<"D
MN(4DE*@3TMY%74358F>]XIKT3(^9K8J>XOXVZ.]ZK3Y?'K!N?FV1W!SM32!&
M^PG^TG]C-EZR=V;_`/C_`(:;4Q^=;_'3U17.5L_96R*M9GT37=9*S4"TCDIQ
M:UNW#M.'?M_*P9R5<;NVB*C>$L0+.4U$5WYBLB-R***#U0$2UX]/Z5TM=XIF
M7.[!BXKDK:$=*4EU!VJ0^4J(+K."2%(:!=*RE*=IP-D^_:PU;9KJS;[5:"_;
MD1V7C(4HAM:<0A;`4E)#3V*DJ2MXAH("E*.`)'85JD.C5VM@`>D`H-.`!]3I
MZ*['>'H_8R#_`%B<=774_P#J4GORZA_UZ<==7H_^K3/*'*W[.<KDZ16Y]K[1
MZ>D_.U,NX\D#FH;MO<BS^1-4W"_^?)GC+G;&FYU[V)K/HIOZPY5(Y?'/+WD>
M],OJBEQTO[/0^X)K<<:+6^HPHHPHHPHHPHHPHHPHHPHHPHHPHHPHJ.-L]@YK
MZJ.^$FF2%_*PY\6C^YW7U1.KD];>S4CIH[XFEBHO;.L>F6?UXY91Y;/-`WE>
MY\_O8I'].>?X?C">K3R92CIQE&%%8N<]Y)CT7(>:+9EV_P#;V.[([85\K[$]
M*J@N[>XQL[;Q>X%[V?[GY!QK:,XA<96;+4-9W%=ZMJ(D[3J\PD@LCFFP$Q'Q
MTD>TL5DV,VP=D7CI)!LF8Z(*&6.L]CE1[V'[+O;WB[O(]BTTZZ[K6^J5<G[;
M%D7(M27EHXA,EYI:T".L*=BO-E#["UJ"5Y0V$<Y98(<@1)9=>`$9KK`M01B!
MCCE!P./`H'8<.#AQKRW*QUA:N[NXQU:YP^M[=.I<H>3TA&UC8>SX/3$6RC9G
MD'R4B9&?/M>P3AXK6YBQK9ZDW?*5>XJNC$5:MXT#G,Y0<QH:1JRS\IK5EWL3
M]TA6\Z1L*%OPH#MS<4MJS6-Q#(M[+0<F]>II2VDS[:EL%#SDHI2&G--)##EF
M8;="%+X]W`*4$#`N.@G.3@G9C@<J\>`)Z(ZCHA)!&)BT6I4R-DHYDDW(DZ5?
M)$03;)%1*F^6`%GB94P``5.'64#Z8?".1&S5N.3'EO$EU3JBHE(0<2HXXH&Q
M)QX4C8G@'!7>)P"0!P85D,QJ^J,**,**,**,**R?X,Q4O[+5A?KZKT[Q#6'.
MC8-`,\X+<@V6HKS!QU^;SM'D:Q05D]I>[<,9K6B1&R+C4+FXUC8ZI,H@NW<(
MLE&[Y-=1%4[0X(O6ZR;GM6\GS36]J\,<H333EZT_(O(4U+0_,!@<5,6I\N08
MTF*F>Q(:.1:%.I6TI"5H2\G.PYKK@Q=7H#9M3P;=#>U)">OQ2,,%$*RD'[F!
MX-FPA,.;5<O=0H'%BL[0O,CLO8D+0)UC=+Y+1U>B9&SV-(E5]U))U'U2-B*\
MW,9T)B!Y*V2(8I`,("83&%2]PETT]>M2:ONNDK>U:M,OW)I<6(VMYQ##!\(X
MM"5R%N/*ZW`_E%J()(V``"27D(H=;LNH4/K*W@Y!S*(`).23B=@`_<%?'`<)
M$5>181#().6'3C@(N-&-;3(2$B)I?R)D,.].1G*@[<]5/R94P)+];J&$"F'/
MKE&>#!&F#-<XJ']N)XQ>=361'Y/,OC$XJ;RIQ.=(*D89AM%;KES9OZDV3*,5
M?:$C`88[>(3T.CTJBOB/78"M["[M)"OPJ$"G)[(Y;SLNQ;1[R-;A8Y3BE4UI
MX4&[S1N@Q!!&1`Z"9$8R3:MDTBMT)-=)$B#;K]]%SN-TTUO5<N3ZI*FK7IUI
MM:EI6>(;U#(#.)3=;OM*,%**GV'%J477(C:UJ<=BLMR$(>@A`PQ6\3T-I:&/
M\!OH_<('`%'#`62\X"@:]=WL4P`8I^>U2(<I@`2F(?C=R=*8I@'P&*8HB`@/
M@$,:UN!)&GMY9&PC=U(/_P#6[#6[NOYV'XV.]NTNO/[1>HM%\::\PU#0H+7T
M;=N?O!JZ6*)K:2[.'<6)?DWI*$4=1\.*YXR`9A&PK=,C*/2:LDQ(8Y40444,
M=XGRS]X6M-X/+DT;(UK<9%RE0+)=HK+CY"G0R+=/="5N8!QY6=U9+KRG'2"$
ME92E(3S^L8D:)IJ0(R`A*G&U$#@QSI'!P#8!L&`^Y3+5CM;7_E!&>?HY8UY4
M?-GWA^Y-Z]72*2.R^>8GC+?;BGMRCS3DZ,**,**,**4OG+\U_9?U-7_'&`Q9
MN3]\6K5TY'DSU.!Y+GQRLG3E>1OUS.URA2T-89"?E-DWBU)N)":<QT!-#620
M$,QE5_&M(]HC'UUI)J#"HB*""YG?741Z/&@H;I,,K%TU%#G6QJVQ+5;X:DM-
M)6\UQY>=6V,%+45O*;'&GKUH#>`5V&48`2GVC2T^WW9VZ3;O<)J5NNJ0RZ(X
M9:0XK%*$A#"7#Q0ZQ"BYF*>SS'KCNFK:%+)[XI5J>[)O$C&J[0I<C%TE8:R2
MJQ"7E\.P4CRE)71FG:`/`5=I*&>%6345ZG7,F4`S1:NU%#5N[GV=BUV]J4+1
M*0Y*''F0X<CBPO:]Q23ERMJ`;*5!.;`*)-<WJS2T]%MOE[D7>X.Q%6^8MN(1
M'$=L>!+04;&.-4,^9P$N9@I67,4`"NN+(7JA3J'.1'\@^X_S:W+X!?9W&[+X
MB6/TK&[\BE'W/?%;3GIJ'W]%<OL+6:Y$/WDA%0$-'/Y1W(2LB]91K-L[>R;]
MH";Y^X<)(E64=/2H%\:<1Z5!#I-TCTCDM<^[72;'1&F27W8[*$-H2I:E)2VA
M6*$)23@$IQ.488)QV85-$U9+1`==E0HS#4EY\N+4E"4J4XLI"UJ(&)4K`9CP
MJPVXU/'$2L5R%Y+:F=Q$!#1CN1V,:4?NF$:T:N7<C*(O%Y)ZX712(JHYD%PZ
MZQA'I4/TF-TB(CB=[Z;M=)^ZJ\LS9+[K+5KXM"5K4I*4-E(0@`G`)0-B1_!&
MP8"DJWUV6T6[=!JB1`C,,ONP'G%J0A*5*<<<07%D@8E2SM6>%1VG$UTVY%!4
M-=1]M3L%8/M3/X19X_7Y8G/DT)XQ</5,^N7UG[-2NDCOB:6;7/;BM^WS>:N,
ML@?,'YE>\7T&CRZ)20Z4]HHG=?JJK;^;OS7MJ?L?XC7_``AT"(?_`!;`>$.L
M`EZ0_=`0RI7N#^+=G[H]Y,]4@')C&._*P@;/RLCR1^J$N[/U3;Z1S!UQ,6'8
M"]I0"`NT,HFHO<W3FP2+JNNG@6N=+:KI9XJ*ET48XZ0-X9LP:&!T?I+XM-ND
ME(MRK-8V2_[DKI!MEM3#<\)BN@@14I90EY*?!VO!XK#CC9*PK/)6\X.+3@<R
MG%K=SOMT/?\`3FZ*^S[K=%S6?!H[1!,I1>6J=$5X0Z)$J0VVX`@IR1FV6SQB
ML1E2TAOJ8R(BHS*,**B3=78O[\1_K+Y*Q\F_GA'W2NO5C5P^\'V?_ET?AKG'
M[]?^SLN_YT=3?#3[+Y_RDN>U9O05X\F338-=^SCG=6^K5-W]VH_M*VOYA]J^
MSU;.W_YPC_X?'_\`>=IKM+E6-N!]OQXD]]2OZ$F?RH:?!1A14);S[.Q/IHOF
M+S)G/DE\X+5?N8OUE;Z3S>/YJ8\8^HNJSN5?\D;C]G_XFKW@$.D!^G=^`0'P
M"&3,\NKX$'TW#[W*I>/E^#'E#H!X/L*?U6*4#@9K:C5WEKI6<A*VQCI>!KEK
MHL0_0.[%PSJ"E;EI,M>*95RH56.;/&"1FY5`.+8I.HD)$Q,48(.43JG4%SW,
MWZWSY3CL*1*CRW$$)P5)#[;?';$C!:DK4%D89R<RPI0!$EW**T?INT;F[O<K
M=$;:G1K?'AMK!5BF,9\1SB1B2"A*FTE`..0#*C*DD'I=R*FHG*Q,][Q37HF1
M\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FD"-]A/]I/[&;+UD[LW_\`'_#3:F/S
MK?XZ>J*YTMHZIM5S?VV2@MG3U3<24#%P<,T0]T'4)$E;2$PI9S/().79Q4H-
ME8/D`3=>*2DH]RS342<F1$[<U=_3VL;/8EL1;A:8\QIJ:\ZZHY$NN9@V&,KI
M;4XWQ"T+*F\RF'FW5)6T%X.BRK?]$7N_O.3;;>),)UV'&9:2G.IIL)4LR,S(
M=0VX7T+0$N94OLK:2I#I;*FCV!ZI$#:NUL(!T`-!IP@'[0#7HX0#_P`&0AZP
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M646)D#HO/;<<,.O=.P\8V,W\4$G$[`DUTF:LE;#.:XH\O:ZI*4:QR%9B'$Q4
M9R5BIR9@'IF:0*1TK+08C$OI!(`#QQV_[WXP1``#HZ,BSU?#MMOU1<(5GF,W
M"UMRW$M26FW&FGDYC@MMMW\HA!_@A?7888UVT=2UL(4XDH64C$$@D?<)&RM]
MSG*]J,**,**,**,**R?X,Q4O[+5A?KZJ-[Y>ON;9H+5E6B2M9NT3_*?7K&GZ
MSF8%O/T_<MB)6=CO4];WE*4WOQPKD=65HQHZEQ=25I;-R/8AL1)!R\.U2,YW
MDIW)JS;_`#6%WF%<>T1K)=UR9S3RF9-L9,^*DS8A;M-[>6^'%-QN+8@.++4E
MTK<:82\L:6^(+EKCMIVN%QO!)&(6<JNM5BXV`,,3B5@8@;"<*1Z^3%8G^)'!
M*7IJ%?:5UYJNUBQ8U6FR6OZ]&JHS,2WD8J+J,KL':[F);Q<HBLW^DLLXV<&2
M%=L]7;J)'%5M.P;M;=\^\.%?%25W-%XCYUR)*)CRP6G%(<<DMP[>EQ3C92O;
M!B+0%!MUAMU*TB2/D!*;7IJ_*:PR%<+@24@=;*Q`!4O#`[.R4.B"14O<)DGZ
MT;R83C@:'<FTRIUT'L%)V9%XR*YDC2<>2!A;52)63=2,:"J"":$LP4\>H005
M+T>'BM_2X[<K2BI6<-"^C`I>;8*594<6OCG8\IM"4+RK65QWAD2H%!QKHN73
MB=#V7+AC]H2.@3_V"<=@*2<1]T4O/!=U2(K>'!&@UM^1>9AMK\J+'(-2N)1V
MF2OV/B+3%JLFS>20E*NE6H[JP+M-))N#&5BW310'*J"CYTIG*#9O\S0&\/4=
MU;*8+]GT^PA6#:27F-1RA(*DHX"^O&6VI2E\;'D,O)XI#B8[,5%J+2941E!Z
MX..GH\!93AP_0.M/T$$;<,3;AS>[=]WI^GQ4?U;^3F,OW!>SN\O_`'<R?7=B
MKHKI^=A^-CO;M:9WJOS<]9_IJ<%/UL-3XY/Y3W/>TSXA>/54NM/KGV;>_&;[
M=-;]6.UM?^4$9Y^CEF?E1\V?>'[DWKU=(I&[+YYB>,M]N*>W*/-.3HPHHPHH
MPHI2^<OS7]E_4U?\<8#%FY/WQ:M73D>3/4X'DN?'*R=.5Y&_7/+DE]2_UN>M
M_P"4;7GR\IOXR1F:/5/LO<_1TGO#E<WK/V-O'HF9Y,[74WD0U01U#G(C^0?<
M?YM;E\`OL[C=E\1+'Z5C=^12C[GOBMISTU#[^BN<"@5.0OETJM)B5V;:4M<N
MU@8]Q('638H.Y$#((JNSMT7"Y&Y#FZ3"1,YNCU`')1-27F-IVQ3+],2M<2&R
MIY:4`%92C:0D$I&8C@Q('W:F:U;?X>E--3]37!+BX,".I]Q+8!6I#>"E!`44
MI*B.#%0'TD59AI;@1MW7.V:!>YJR:_=1-5L3>7D&\;(3ZC]9LD@X2,1HFYK[
M9`ZPF6#H`ZA`Z/V<:IKOE%Z+U/HVY:>@1;DB9,BJ;0I:&0@*)2<5%+RB!LZ`
M)^Y3)MY?*PW>ZRT!=]*VR%=V[A/AJ:;4XVP&TJ*DD%93(4H#9T$D_<JW+&75
M'O4?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]9^S4KI([XFEFUSVXK?M\WFKC
M+('S!^97O%]!H\NB4D.E/:*)W7ZJJV[F[\U[:GM&O_C=`94KW!?%NS]T>\F>
MJ0'DQ?'.P]UD>2/U49P>^=#K/Z-K_$Z>QZ.__P"$EV__`"?REFI".5!\#+W_
M`/DOEC%=#^1FU#Y1A142;J[%_?B/]9?)6/DW\\(^Z5UZL:N'W@^S_P#+H_#7
M./WZ_P#9V7?\Z.IOAI]E\_Y27/:LWH*\>3)IL&N_9QSNK?5JF[^[4?VE;7\P
M^U?9ZMG;_P#.$?\`P^/_`.\[37:7*L;<#[?CQ)[ZE?T),_E0T^"C"BH2WGV=
MB?31?,7F3.?)+YP6J_<Q?K*WTGF\?S4QXQ]1=5G<J_Y(W'RFKWU[O)F>75\"
M#Z;A][E4O'R_.<0WZ"G]5BEWX3?.@U9[9L_XFV'(`-_?PEN_XK'E+-2I\IOX
M&WW\2-Y9'KHFR,FH=ZQ,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FD
M"-]A/]I/[&;+UD[LW_\`'_#3:F/SK?XZ>J*I$=^J[^J<_7'RL^]^UJ[H>K5J
M"%^:9_$1U!74?J?^2S6GR`IOXNQV1":R]K[KZ2D]^74%^O\`V[O?I>9Y0Y6_
MYS=<E2*W/M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_`,^3/&7.V--SKWL36?13
M?UARJ1R^.>7O(]Z9?5%+CI?V>A]P36XXT6M]1A11A11A11A11A11A11A11A1
M1A11A14<;9[!S7U4=\)-,D+^5ASXM']SNOJB=7)ZV]FI'31WQ-+%1>V=8],L
M_KQRRCRV>:!O*]SY_>Q2/Z<\_P`/QA/5IY,I1TXRC"BL7.>\DQZ+D/-%LR[?
M^WL=V1VPKY7V)Z54V]WKS7T'KCB'P&T+.3LX^V4[X]<:H.<AZ]6)>;;T-"^4
MO5<=2[/?W[-`6U8I]HL>S8*(922HB@M)OO$@/^+NC(/CY2VX;>-JC?5O&WBV
M^/';TJC4U\=:<>?;:,LQ)5P7*8AH4<S\F.Q`ER76$X+2PUG_`.T9#G-6>Z1&
M+=$B+)+_`!+0(`)RYDH"2KZ`2I(!^DX=`X0_&::J^U^[/U8]M_(RR<;X_5G(
M/E#L;W<K\G%,UK4K"\CN0;52KM6<O9Z>U>VIPB\,:#5%]_B<H"2OB51``#MY
M>N;MH[E67ABRZ8BZHDW?35AA<4\VXH1P[9+,H2%*;8DJ3'!2!+3Q7Y2/G1G0
M"2<9,9N18VRX\I@-O.JQ!&W!QS9M(V_Q=NP]"KZZRZ\MKD`\\1-M?*H:,7%M
M94?)[&W%5DB<4)Y`!$$IE(1ZKHH"(`L!N@1#PY'3=6?![I)8S1UY'W!F8.9E
M6"B,63T6CPMGARX8UUJ#B@';P#AX?O\`W?IK-Y@5]T844844844845D_P9BI
M?V6K"_7U5'WO+)FYX_),YF)VY>82WWII11U?J^#U99R7"RO8JRV2B,)F!VAH
M7?L:[+/7FM1L*BL$:@DQ7E$W2KA$B)E,<CR8WWVM_P#>GX+UEM\^$Y-E^'SW
M;@P8S"):&):VGH%WLZT\3$??E*3QZU.H84TAMQ3@36GO(!M384'%I4$IRI"#
MB<I*<0IMP;5`)X-F..(PI*-S*S:G&GA0A8XZ?B9R+UK;("2C[)[BB_;.*Y+0
MT!T,SUW7&GX96N*$C0/#J(5:`!2),V,9BW.)B`J&A40$[U->N6MV,];WKK'>
M0MCC<B@^VZ]UP>FW)T/@K(DA<^9A(#H$AP`*,DG(&S?U=OX6"%AR$"#AT$R1
MT$H&&S9UJ=F&P5+O=^,C23_D%'$>/8X[_49F1)"-6?-Y%@9TM*H%>,'$6BYD
MT'K43]=([=-1<IR@*93'``'B^4D^(L?34E2&W4MWK-D6$*0O*&SE6'"ELI5A
M@H+4$$$A1`Q-=%RY1FT59$XD8W&1P</YA/T;?W*7OB/6;#7N3_#E*0MYY^#9
M;MY35J'8,JJTI];,\K_#/7;27L<7776KM2VNN3,B^!1M--7\40'DPW<R1#JF
M>F.*E;Z+K;+ENEUPN-"$:X.6"P/N+7(5)?RO:FFJ;8<>3/N,=]I",%Q7&9!+
M<9;44A`8":BHMR%HGQLRL4!UT#9@-C*<2!E003P*!&T@JZ-6G<X#%+>N[V.8
M0*0G/:I'.8P@!2D)QNY.F.8QA\!2E*`B(CX`#&A[@03I_>6D;2=W4@#IF]V&
MM_=?SL/QL=[=J).\PO%*NG'2CEIUPJUL-!\W>!+.:"M6")G1B';_`)/Z<F&+
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M2%E;&`4AM/&$\*1)GI[>0G4.H#9FK=,992MYI3CB<JDO,!"G`MLC%+.1Q`0_
MB4K<5D`X%'=-5;Q;R'(V@Z];TFT%%CMVH5B6FG:/DB3207L$P[B'[%@HW\;,
M5U_&U%9RL_25*FT(Z:@('%4WB]%K#=^Y&W7W+4KL^(0Y99+[;23F*D!EM+B%
MK!P;>0N2E"65)*G"V]@4A`S\SJK>2F6S>=,-6Z:`W#FL.NK3ERK5%FJ:6A!&
M+C*VXRUJ=!`;#C(P5G5D[$,A$J'*H<Y$?R#[C_-K<O@%]G<;LOB)8_2L;OR*
M4?<]\5M.>FH??T50%QG`0Y!Z5'H'H_*)6_V/_P`:#)']ZQ']VM^]&/\`:U+7
MOL(_NBU-Z'D]K73!D5%0FT845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?
MLU*Z2.^)I9M<]N*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJMMYO#T<7=
MK"`"8080`@4O^$;HML"/5#I\'2/1E2S<%MWN6<<'Y1[R=ZG_`/)C.&_&Q'A_
M*2/)'ZH;[M#=S?9_+C7#!G3++`,1BKO(-9"<2\E<E>1%0(WG(F9AU&Z+J"<M
MG]B*@T,H8X/Q9.S$`A40Z\B/*KT"[I/<O=)+\Z))D<=%0I#1S)RN226G&G02
MEU*D,E3@2!Q/&L@E1<ZUW^^[>,G6.YV^Q6;?+BQ2Q'6E;PRJ"VID%+S;K1`4
MTH+?"6L2>-XI\C`-]=U(Y$948]&%%1)NKL7]^(_UE\E8^3?SPC[I77JQJX?>
M#[/_`,NC\-<X_?K_`-G9=_SHZF^&GV7S_E)<]JS>@KQY,FFP:[]G'.ZM]6J;
MO[M1_:5M?S#[5]GJV=O_`,X1_P##X_\`[SM-=I<JQMP/M^/$GOJ5_0DS^5#3
MX*,**A+>?9V)]-%\Q>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'U%U6;RL'HU$Y$`$
M1"RU\0`/5'H.['H#]T<F9Y=.W<3A_P"MP^]R:7?Y?IPY0Z#_`.@S^JQ2#=VO
MN]OL[ESK&/9TRRP#$6=S?MI"<2\E=$>P].*A.Q,S#J-TG4&Y;/[(5!H90QP?
MF9.S$`A40$\(/*GT"[I/<O=I+\Z))D9XJ%(:.9.5V3BTXTZ"4NI4A@K<"0.)
M#K(45%SK9"=].\9.L=SM_BM6^7%BF*PM*WAE5G:F0`\VZT0%-*2M\):))XWB
MGR,H;Z[J8R(BHPJQ,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FD"-]
MA/\`:3^QFR]9.[-__'_#3:F/SK?XZ>J*YSMD;Q0I%M=4\E)M$\_38H3J[IDC
MY.Q7@7+SR!VK".%4%4IV?:2#E!$D8F9-9<R@CUR``=:O#8]W[E_@JO:I\2/'
M,EQH)4<RP\D%:0ZD$%IE2$K47R"E`3P*).%E.\[R$Z>O#%A1;IDF0&&7E*2G
M!"F5$-K+*B"'GTK4A*6!@I95PC`8]@VJ0ZNKM;!T@/10:<'2'J#T5V.#I#]S
M(0=8G'5UU/\`ZE)[\NH>]?''75Z/_JTSRARM^SG*Y.D5N?:^T>GI/SM3+N/)
M`YJ&[;W(L_D35-PO_GR9XRYVQIN=>]B:SZ*;^L.52.7QSR]Y'O3+ZHI<=+^S
MT/N":W'&BUOJ,**,**,**,**,**,**,**,**,**,**CC;/8.:^JCOA)IDA?R
ML.?%H_N=U]43JY/6WLU(Z:.^)I8J+VSK'IEG]>.64>6SS0-Y7N?/[V*1_3GG
M^'XPGJT\F4HZ<91A16+G/>28]%R'FBV9=O\`V]CNR.V%?*^Q/2KG>X=DY<RN
MF.[CBJ)QBUQ9]$AQ[X/J2N^!8U;\I#:+AAHMOM\8YMCG;M6M=:@*^XB73DR+
M>L31/^SVR":;TTTH>&DTWW*W+P]=;T)FH=672)O#_K+JH-VC/(\!4X[X7&C.
M)CIMLB.^\\EQM`4N?%/Y9UQ2F!`2F=QMM^T51H26F$*B<2QBYLS8#*2,<X(`
MP)[%7`!MS=:NVYK+2E>%_$&AWBN0!8A7>W.+8A;S;+%J]C&LF=2WER"924'"
M4V\<N^*CRZ2WCYMB\71%W(-&9$D%TD57I$"%4W0MJOR-^NMM16"5)\-3I[2L
M+P2.S/6M2I%JLZT.NR8FG-0)BMX-.M(5Q;+CI4XVM:&%.*.%)6U]F1FG4C+Q
MKZLQ*<-BW,0$J>:S':#PD#8<"<*ZI:X5J6O0)6)")L2PT65FFFF*2:;4&*`-
MR)I"X=BF0J/0`%\:KT!X.N;U1B!NA>-SD&029!?<S$G$E6<YB3@G$XX[<J<?
MH'!7?HPR##@P%9G,&OJC"BC"BC"BC"BLG^#,5+^RU87Z^JF>]^/.O=*T:.U[
M4;Y?=J0&ZX+8M;AM.6_:4)N>J05<A+;!6C8](JVB[)6MQ7A)FVMB5>=-HE8S
M9I\9"/'Y%6399%1R_)A%N8WY:HE:EFVZW:0DQ;A"?=N<:`[;)#K\QIZ/"E2+
MLP_;(A4J.J8VN0D+<\"4Q&4A]UM:-->LYMK"64K7("D*`05A8`205)#9"U<.
M4@;!FQ.P$4H6_!NAN/G#<^PJS?J?;E*#=%9.N[3N5FO^QX])6:B%(DUVM-S>
M2%N>V1[#&;N'2,FLH^8JJBU6'QB)L4'=R+$-Y6N$Z:EVZ=91<HH;>M\9B'"6
M0TX'/!8\5*(R&$NYT-J82&G4I#S8RN"I)N01QO\`5^_\<E:7.,A8A:BI78RL
M,Q5MQPX<=HX#P5)_=\HQKF2Y`-YF$?V6(7U**,K7(I`[J4L$:JO*$?0D:U26
M;*.7\JU,9!%,JB9CJ*``&*(](<ERE')3473;L&0W%FIO.+;[A"6V5@-E#JU$
M*"4-JP6HE)`2"<#P5T/+E"3HJQA0*D_:,C$#A(XA.P=.HOXO36G+!N#NZY32
M.H;5IFL'VERW83%>M\W.V63D[7#<5JW$S$D-BL?1*33I@9H6.D5C@'3+LW?6
M$ZWC3#UV]N#KBVZ)WG1-?7J'?;L+1IU;3T9IIAMN.[J!]QI'$L?DVDKS%YE(
M/[,XS@$HR"HK8"HRY,)45M33?&/8@DDDAH`G$[3]!^Z#T:?CO#:K"7I]P?HU
MF:J/:W=>:4?4+$R2=.F*KN"LW%KE/"S#5)ZQ6;O6:KB/?*$*JBH15,1`Q3`8
M`'&Y\F>[S]/1]?Z@M2PW=(&A%R65%*5A+S%_L#K:BA8*5`+0DE*@4J&P@@UM
M[RVETQ6E[4*E8'I%IT&EJYS<7-)<<M`UAYINDQ5%2MG+;NXJ],1->8QL-!*-
M*1R\J\G&.T82'8Q\<E+R$O?95V_=^+%=XLY#KFZB:1"/*^6[O<U]O/Y:^CV-
M<SWK@N&QJ%YIQY:W7@J5:%-N)+KJUK+:&XD=MEO'(VE'6C,M:E<]J^!%A:<D
M&,D(S%H$#`#K7,1L&`QQ423T<:<&L=K:_P#*",\_1RP[RH^;/O#]R;UZND4D
M]E\\Q/&6^W%/;E'FG)T844844844I?.7YK^R_J:O^.,!BS<G[XM6KIR/)GJ<
M#R7/CE9.G*\C?KF8@*WL9.RN9>XWBO3\,UD9\]<@XVCEB7<;&/SF3A_*)Y2>
M>K*R3*.4%!T)$`2<F^G*"8#U`E;N5TTPJU)A6.WR8TY;3(?=7+XQ*W$#%S*R
M&4@(4L!3>*\R!UIS89C*3:;+JQN].7"_7"))MZ77BPTW$XM:$+/Y+,\7E$K2
MV<CA"`EP]<`C'*-TUE6]BN=\T63F;Q7GE(:;7I,C7:FC1RDE6S0'L2W!-]9E
M9XYO=!M+++J$72:@4[82D,0INL8=%JNZ:8:W=W")!M\E%_79I2'I!EXMJ5E<
M.*&`R.L4V$`H4YB%XJ"B,`.:U?9=6.V^]SKA<(CFGD09BV8XB8.I3X"XG!3Y
M>/7I<*U!:6P"@A)3CBH]<^0MU"U4.<A_Y!]Q?FUN7P"^SN-V?Q$L?I6-WY%*
M/N>^*VG/34/OZ*YO>)&I=:UCE1JJXP5,@F%JF=L,9A_82,DU)@[Z=<I^ZXHO
MU0.Y;-GYR"<Z*9BH]<YQ`H"8W3*-OGUGJF[;H+Q8[A.D.6=BS+:0R5$-A#23
MQ>*!@E2D#8%$%6`2"=@J3_>SH72-FW;ZLOUN@1F[S(MLUU;^0%TK>0.,P6<5
M)2LC$I20G$DX8DX]4N1`U#S1A14?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]
M9^S4KI([XFEFUSVXK?M\WFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJV_FY\U[
M:GJ?<-?]4.D.GXVP'1T@`E$0_P#"&5*]P?Q;L_='O)GJD`Y,>/\`?E8L.'C)
M'DC]4&]VA5]SQO,C6<ILNQLIMFA6[W&K'"7BY;RZQ/8!5P$I6F,?KNF.*?7A
M9QZQ5&#EY*G.8Z`=?K('67D9Y5=WT+*W'76)I6*Y'?5*B+`XMQO(REX)XM]:
MYLI,E[,M)2\AJ.``X<N#@0V[3?;8]X$+=-?)FK934B,F(P@D+;7G>7/AJXQA
M*(454=DI0K,TMV022V,V+1<=ZG<B%J-&C"BHDW5V+^_$?ZR^2L?)OYX1]TKK
MU8U</O!]G_Y='X:YQ^_7_L[+O^='4WPT^R^?\I+GM6;T%>/)DTV#7?LXYW5O
MJU3=_=J/[2MK^8?:OL]6SM_^<(_^'Q__`'G::[2Y5C;@?;\>)/?4K^A)G\J&
MGP4845"6\^SL3Z:+YB\R9SY)?."U7[F+]96^D\WC^:F/&/J+JL[E5_)&XZ?4
M^,U>]D=Y,SRZO@0?3</O<JEX^7YSAV_04_JL4EG=YUS8S'ECK&4V#>*];54Q
MOK*.;0M'+6@8-G<%.+M50D%)^6<K&5BV+<KE$2`07!1,4_5*4!@KY2]TTQ(W
M-W:)IJWR82#X(I:G9?'YU)=:"AD#+:1@XM90H''(<",234C^_BS:KB;F;_-U
M/<(DU09;0VEJ)Q&0*N,923G+SA.+:$!Q.&!6,0<`!73CD3U15UB9[WBFO1,C
MYFMBI[B_C;H[WJM/E\>L&Y^;9'<'.U-($;["?[2?V,V7K)W9O_X_X:;4Q^=;
M_'3U17.=MBJ;EG7%Q4H]QA&$8YKT;&059FFC4\*Y?+OY@EM>3*P0+^60DDF"
MC):+<).%&O714;KLQ*H*X5X=-7C0UN?C)O\`!?<EHG/..OM*4'4H`;,9+0XY
M#905AU+Z%(2Y@I+C;^*>+JRCJ2Q:_N:W7=.SHS<14*.VRPZA):4M2E^$K=/$
MK<"P@M*84E:FRI*FW&,%<;78/JH0'5^MQ+T]4:#3Q#I]7H&O1W1T^KX>C(0=
M88C5MT!X?M&3WY=0^Z]!&N;T#P_:TSRARM]SG*Y.D5N?:^T>GI/SM3+N/)`Y
MJ&[;W(L_D35-PO\`Y\F>,N=L:;G7O8FL^BF_K#E4CE\<\O>1[TR^J*7'2_L]
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M3SDIA)(<YI]62S1UXX8/O=$IQ&=TGK@XV<1P@!6*B,`D]#IRB%2KQ,6L1114
MJT<R5*JLD]065*HV2."BJ$F)I)%0X#TF(X$5RB/0I]-TY$]-06YCS9`24NJ&
M`*"!@H[`6^L('0*.L/"G9A7<IVI!^Y_^G#MK(9C5]4844844844845D_P9BI
M?V6K"_7U7ASYX32?-<:/45;/JNAU*N.K0\FKW*:0B-D\A*V_D%X8D:XX];(L
M%@8QFC9HR+-P9Y,IQDL].H1J")$@3,8RS;K-_47<-K75%Z1$O%QO,JY+2U$;
MNKD&S/H0])*TWF"RRMRZM8J0&HRGX[0!>SJ7F`&NG6M5TC,MYFT-I0,5%`4X
M-@PXM1."#]*L">#"DSYM:Q;Z7H?%_5+6[;&V.VH5*M%<1O6W;8XO6S+0FP7K
M1"RUTMSINT7GYQP`_OC@R2?6```"@``&*3N$U8YKO46K=8/0+7:W;C/COF);
M8XB08Y6'_P`G%C)*@RT/X*`HX;222:DEY"+`BV74,<*6L(=A#,LYE'K9.U1Z
M)K'<&8%[:$N15>C[5.TAU+ZF;L0M=8&!)881%:2>@[=PJ]G34@&DB+3KD27=
M=5)N<P*=<@E`Y<KE!7%BT+TQ<Y,.//:8O)7X._QQ9=(0G*ET,$/*1FP*D-XJ
M6!EP5CE.XY=""YHBR("B@FXR-HPQ'Y!/!CLQZ=:5H)734+RCX#TK5EOOE@=F
MO7*BW2\;L&@UW7SIBV:\7X#7!'M/2H59KVK+M57KJE>.>6&KKS$;)3CEVJH^
M474$I=]O'1KF?NCWC7[5\*W1F1;]/QFUPYCTQ*U*OSTTIDF6^]<(LA*965N%
M/1&?8B(90F.AM()BPB>#)GQ&HZEDYW20I(3_`-D$[,H"%#K=JDX@J)VXU8MS
M>[=]WI^GQ4?U;^3F-BW!>SN\O_=S)]=V*MS=/SL/QL=[=K3.]5^;GK/]-3@I
M^MAJ?')_*>Y[VF?$+QZJEUI]<^S;WXS?;IK?JQVMK_R@C//T<LS\J/FS[P_<
MF]>KI%(W9?/,3QEOMQ3F6ZTPU(K$];["NJU@JW%NYB6<(MUW:R+!BD9=PHFU
M;$477.5,HB!2%$P_L!E(RRVB=?[M'LEL2%W"4\EIM)4$@K6<$@J40`,>B3@*
M=7I^Q7+5%\B:=LZ$KNDU]#+25*2@%:SE2"I1"4@D\)(`Z-*@'/[C*;P!;)[U
M!'L7:/4`!$?^[/V@Q8SR<-ZXX8<?_P"ZC_K*7T\DK?<.&WQ/_O(OZRO\_K_\
M9?\`2R>__(JT?@S#_AOWK_S./_\`=1_UE'_"3ON__!\3_P"]B_K*VZA\R-#;
M)ML+2*G8I=Y8;`LX;QC5S5I]@@JJV9N7ZP*.WC!)LB!6S0X@)C``B'1ZHAFE
MU%N.WB:6LK]_O,5ANV1D@N*3(960%*2@8)2LJ/7*'`/NUS^J^3CO6T7I^3JB
M_P`..W9XB4J=4F4PXH!2TMC!"%E2NN6D;`?IX!6P<IZ%:-G:*N])IC%&2LDT
M6"".9+O6D<DL+&R1$@YZSQZJBV1ZC1H<P=8P=(AT!X1#-;NAU':-)[PH%_OK
MBFK6QQV=02I9&=AQ">M0"HXJ4!L&SAX*U&XC5EBT/O3M>I]2.J8LL8O\8M*%
MN$9X[K:<$(!4<5J2-@V8XG8*IW_J%\H/]!8G_P#+6J_A/'N_\16Z3_\`"#W_
M`-K(_5U(O_Q7;C?_`,*R/_LI7ZNMEI?!SDK#W.G3$A2HI&/B+96I5^L6XUA4
MR3*.FF+QVJ5).2,HJ9-NB80*4!,80Z`#IS57[E`;JYUBG0HT]Y4EZ&^V@>#/
MC%:VEI2,2C`8J(&)V#HUI=2\J+<K<=-7&W1+F^J7(M\EIL&')`*W&5H0"2W@
M,5*`Q.P<)J\^P3L=6(&:LDPJ=")K\5(34FLDBHX42CXMHJ]>*)H(E.LN<C=`
MP@0@"8PAT`'3D?5MM\J[7%BU0@%3)+R&FP2$@K<4$I!)P`!)&T[!PFHM;1:Y
ME\NL:RVY(5<)<AMEH$A(+CJPA`*C@$@J4`22`.$[*0#;G-KCW==5;$J=?LTR
MYFK+2;)#1#=:I6-HDN_D8ATV:I*.7$>F@W(=50.DYS%*4/"(XY#1>X3>78=8
M6R\W*(PF!%GL.N$2&%$(0XE2B$I62<`.``DT[;=[R8][VF=>6>_W>#&1;(5S
MC/.J$N.LI;;=2I1"4N%2B`#L2"3T!56G&?YPFE?SB5OSH,=WO6^&M^]&/]K3
MZ]]GPAU-Z'D]K73#D4]0FT845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?
MLU*Z2.^)I9M<]N*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJMNYN_->VI
M[1K_`.-T!E2O<%\6[/W1[R9ZI`>3%\<[#W61Y(_51G![YT.L_HVO\3I['H[_
M`/X27;_\G\I9J0CE0?`R]_\`Y+Y8Q70_D9M0^4845$FZNQ?WXC_67R5CY-_/
M"/NE=>K&KA]X/L__`"Z/PUSC]^O_`&=EW_.CJ;X:?9?/^4ESVK-Z"O'DR:;!
MKOV<<[JWU:IN_NU']I6U_,/M7V>K9V__`#A'_P`/C_\`O.TUVERK&W`^WX\2
M>^I7]"3/Y4-/@HPHJ$MY]G8GTT7S%YDSGR2^<%JOW,7ZRM])YO'\U,>,?475
M9W*O^2-Q\IJ]]>[R9GEU?`@^FX?>Y5+Q\OSG$-^@I_58I=^$WSH-6>V;/^)M
MAR`#?W\);O\`BL>4LU*GRF_@;??Q(WED>NB;(R:AWK$SWO%->B9'S-;%3W%_
M&W1WO5:?+X]8-S\VR.X.=J:0(WV$_P!I/[&;+UD[LW_\?\--J8_.M_CIZHJD
M1WZKOZIS]<?*S[W[6KNAZM6H(7YIG\1'4%=1^I_Y+-:?("F_B['9$)K+VONO
MI*3WY=07Z_\`;N]^EYGE#E;_`)S=<E2*W/M?:/3TGYVIEW'D@<U#=M[D6?R)
MJFX7_P`^3/&7.V--SKWL36?13?UARJ1R^.>7O(]Z9?5%+CI?V>A]P36XXT6M
M]1A11A11A11A11A11A11A11A11A11A14<;9[!S7U4=\)-,D+^5ASXM']SNOJ
MB=7)ZV]FI'31WQ-+%1>V=8],L_KQRRCRV>:!O*]SY_>Q2/Z<\_P_&$]6GDRE
M'3C*,**Q<Y[R3'HN0\T6S+M_[>QW9';"OE?8GI54YW=7++C%KKAAW?FD+UO[
M456W)9^-_&J%@M5S-]KC384A)7RCQY*4@2H'D/=Y(EK5:'3CU5$").U.@B9C
M&,4!>3RG=S6]G4^_7>3K[3^F[U,T/$U3?'7;@U$?5#0B)+691,D(XDF.%`O)
M2LJ;3BI0`!(YZS7""S;(<5UYM,E3#0""H9L5)ZW9P[>A]-*`KJK=NU^`?%Z%
MU)2KS?(V&Y2\KY_8%?H\JJQ>ECV&\^2!:K*/&+3DWQ)DWY8BZJLET#M[<!F;
MDA%A8N>J!D5L1K#06CN4=JV=K.?;[=*?TAIYF&]+;"TYUVFR>$-I6JQ:B;1Q
MD4.H6%V[!QLJ0)#6."]=X/*D6AA,=*UI$ATJ"3_XCF!_.LG8K#^'L.W`]#HJ
MC2JDCF!%P5*N5DU*L58QCK`J5!,%`5,=T^.94#@/6$5UA$?5.?\`PAC&E%"I
M+BF\.++BL,.##$X88)0,,.#K$_BIX!V:>Q&/#A7LSPK]I)N\$O#/7O&^6L<G
M)OH2(3NFOV<S-5^8-!WJ'B7MH8)/Y;6SP).*3&_1C?I78%4.HB`IG.HDJ0AB
M"O?)LL#^I=Z+-KB--R)I@3%--/-<;$=<2PLH;G)XMP^!N'!#Q2`K:E*5H40H
M:N\.AF$5J)"<R<2#@H#'A3M'7#H5*G%5U[J:&UW8F^PK[LR%MM?CK96+%L]2
M`=WU&MS[%K(1<+9I:N1D2QG9.*(J9,[Q1$'*OJ+&.<HG'D-\#/@>\2YVQRV6
MZU3X4E<=]F`'DQ"^RM2''6&WUN+:;<(!#85D3_`"4G*,BWG-$0L+6M*@""K#
M-@>`$@#$CZ>'Z:87$SK,HPHK)_@S%2_LM6%^OKRO/NMU[87]E-G(ZS]L+KZ2
ME=_77O'_`&='XB>H*I\[T'WYTWZ-NWG-9QV7)*_8;YW6+VK]2*<AKS;J3NT+
MM9-1/P16;MTN2B[MU),6J&E'RSE[#.V#"89MTRS)UG44^E56\6SDFZ91.@JY
M4(W35`IE#`0!'.QY0R''%Z5;90TX\J_("4NI6MM1/%`)<0V"XI!.Q:4`K4DD
M)!40*V7+G(&B+(3B!]H2.#A_9T\&.S'IU%O$JHJU7;O=\N0FKI+1EOW!RTN%
M>:WN8V+/3=?@)?A_1"L(3W5V;!0$XY21(VZYQ:)*17C3&\G4,/C!'KM\UZ1>
M-%;RFBQ`9EPK)IV,\J(U"9:>>;U)+SN\7`=>:2258#C%)D90.-2!E`BMMS?%
MR89Q44J<>(S%1(!93LQ4`?W-GT599S>[=]WI^GQ4?U;^3F-6W!>SN\O_`'<R
M?7=BK=W3\[#\;'>W:TSO5?FYZS_34X*?K8:GQR?RGN>]IGQ"\>JI=:?7/LV]
M^,WVZ:WZL=K:_P#*",\_1RS/RH^;/O#]R;UZND4C=E\\Q/&6^W%3UR<#IX];
ME`/5'7=G#_\`AJV4NMT_Q+L7I-CMQ3Y=R&S>_IL_^L1N^)KE&JV[Z;:K@E3X
MIG:2N'+VS0\?-R%?7CZY+2]4&13FH^)D7*I%WZC4L4Y,94B'DY/$B0ZA%3I)
MGF*N^@+Y9[(;W,7#+:&V'%M(>"WVVY&0M+<0D$("N,0`DJSG-F2E2$K4F6NV
M[R;!>+W]AQ6YB5J>>:0\ME2&''8ZE!U#:S@5E/%N$J2DMC+E4L+4A*OBI;PI
MMTM"56AFEI(J\4L+>)FI.ON(ROSCJK."HS3:%>NE2N7WDA#`H*P(`V`/WLRA
M5_WG/V\Z`OEAM"KO.7$*$!DN--O!QYI,@8M*=2D949CL"<Y7_""2WU]?=EWD
MV"_7@6>$W,25E]+;SC*D,O*CJ"74M*5@I>4',5!/%CL"L.8HIG.[_P!XTR^<
MO-0U^#:6E(7KV[.H>8EZ^XB82P$KE<>I3'N(Y=*@[>IM4I=JKX[Q!&X@MXOQ
MGE":J*:3\I#=_?=.[E;W<K@N&0VW%2ZTV\''62^^DM\:E(RI*BVXG+G*^MSY
M>+4AQ2'[\=Y-AU+NEOUKM[<Q/&10IIUQE3;3W$3(@<XHJP4H)#K:LV0(Z_)F
MXU*T(ZD\B+J*^C"BC"BHOW?_`",[9_-M>/Q:DLZW0'MU9O2L7OZ*[G=A\2=/
M^FH7E+=<PK,/ID/M8^PFR69_@5T_PU.+)[%73_"*FKC0'_U":6_.+6_.PS@]
MZOPUOWHQ_M:3/?9\(=3>AY/:5TP9%14)M&%%1]M3L%8/M3/X19X_7Y8G/DT)
MXQ</5,^N7UG[-2NDCOB:6;7/;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?
MJJK;>;P@7BYM8P]/05A`&'H#I'H+;8$1Z`#PB/0&5+-P0QWN6<#A+CWD[U/_
M`.3&<N_&Q$\`<D>2/U17W;>]*%M'EKK.,J"\D\35B;I,1\JLU;IQ4LA&TQ,)
MYLQ52>N':;VNN+6P0=D<(H%\>L)43*^*5$DA'*EW>ZCTCN9NLN]):0H/16EM
MA2BXV5RCQ*E@I"2EY,=Y;90I9RI!6$9T9GE;]=Y6FM9[FKW#L:G5H4Q'=0Z4
M@-N!N7!XY*2%%04PJ2RAP+0@9UD-E>193U`Y$K47E&%%1)NKL7]^(_UE\E8^
M3?SPC[I77JQJX?>#[/\`\NC\-<X_?K_V=EW_`#HZF^&GV7S_`)27/:LWH*\>
M3)IL&N_9QSNK?5JF[^[4?VE;7\P^U?9ZMG;_`/.$?_#X_P#[SM-=I<JQMP/M
M^/$GOJ5_0DS^5#3X*,**A+>?9V)]-%\Q>9,Y\DOG!:K]S%^LK?2>;Q_-3'C'
MU%U6;RL'HU$Y'P]`66OB/0'2/0!W8CT`'A$<F9Y=(QW$X?\`K</O<FEW^7Z<
M.4.@_P#H,_JL4BW=Q[UH.T.6NK(RHKR3PBK*X2\?*K-6Z<5*HQE*+[O-62J3
MU=VF^KJ]MCT79'"*!?'+"1(ROBE>I!QRH-WNH]);F;O+O26D*2Y&;6V%*+C9
M<E?D5*!2$E#PCO*;*%+.5(*PC.C-(IOQWE::UGN:OL.QEU:%16'4.%(#;@;E
MP..2DA14%L*DLH<"T(&=>""O(O+U$9$C46]8F>]XIKT3(^9K8J>XOXVZ.]ZK
M3Y?'K!N?FV1W!SM32!&^PG^TG]C-EZR=V;_^/^&FU,?G6_QT]45SN[`WSK^A
MV5_4IIQ)K3K5FG-23..9H.#Q5:>+*(GL[LJ[UJJM#,7)B)+>3%<.155*5-%0
M>MU:[%GW=ZDU%&-Y@):3;UR%M(4M1`<?2<0PG!*@'5IQ4G.4(RI)6M(PQLO7
M3>;IC3=R:L<]3RKBAAIUQ*$@EN.K!)D*Q4DEI"L$JXL+<*E`(;4<<.O?5`"7
M5VMBCZH4&G`/T0KL<`Y"5K$XZNNI'!]I2>_+J'#7Q!UU>B.`W:9Y0Y6_9SE<
MG2*W/M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_`,^3/&7.V--SKWL36?13?UAR
MJ1R^.>7O(]Z9?5%+CI?V>A]P36XXT6M]1A11A11A11A11A11A11A11A11A11
MA14<;9[!S7U4=\)-,D+^5ASXM']SNOJB=7)ZV]FI'31WQ-+%1>V=8],L_KQR
MRCRV>:!O*]SY_>Q2/Z<\_P`/QA/5IY,I1TXRC"BL7.>\DQZ+D/-%LR[?^WL=
MV1VPKY7V)Z54$\%V?QOT-W=[VQ<0+[(+:GTQP]C=4\O*`G3;#(1JMDUO4):[
MP]SJT^_JUD0U:SC+:_B59!FE;&#!R=X]!*-D6;<^2.<H-_[%WB;S6+9K:W-(
MO-]U*NX:<F&2RA88G26XKL60RB0P;@IR.S(2RZJW//(#$?/*BON)KD;4.,B0
MRN,LEMID(>3E.&*05!0.!R8$C$9P#B>M4!6LO66E'O=Q:3+NKDSMSC)$I;[Y
M?!!3VCD;.ZO-TDY'D!R`@STMPUJ<1.S,W27B,L"LQ&$;E&2;IE2!PW-T*!M6
M']>L<J&_'0>E++JR8K3FF^-9NI83$BMHL]G=$H*D.,M-2DEO+&?*SQ"U%9;=
M&**\R(ILK7A3[C">.>P*,<RB7'!EV`DIV[1T?I%=#L(+8T+$&9+M73,T6P%H
MZ8I^)9.6PM$A079H^-7\4U62Z#)EZY^J00#K#ZN1G3PZ)SX?2M#_`!R\R5G%
M259CB%'`8J!V$X#$X[!79)PRC#@PK)YB5]57WWD-PCJ[HR%B#B7W=LVR:.W@
M@DZ!-;!I2*;">8JSKS8\?"4N\/&-&0AG"I7JR#4KP?&%*W.0XB<KD^2Y9)-S
MW@OS4X_9T2U2U.\7,:ARB5LK#*82W941*Y9=2DM)4X6NM)=2I(RG3WIQ*(@3
M_#4M.&*2I/#MS8)5UN'#LQ^BF'XK.F;[C7HEY'UE.FLG.JJ0NWJR,(6MHP2:
MD`R,$<C!`1-2*10$>@B*I$UR%Z/&D(IUR@F>^!E^/O4U"Q)EF<^B\2@J07>/
M+I#R^O+VT.$]%224$]@I2,"<RWD&"T0G*.+3LPPPV<&'0J?<3BLRC"BLG^#,
M5+^RU87Z^O*\^ZW7MA?V4V<CK/VPNOI*5W]=>\?]G1^(GJ"J?.]!]^=-^C;M
MYS6<=ER2OV&^=UB]J_4BG(:\VZD[M"[634.\'K57J.RY+7"V*5Y.M5O2[B8F
MOC9+L8"LK1[)656<-)Z:D@%A%Q;TI?$K+K`9-,AQ$0'U![??_9[GJ!_2MDLP
MDFZRKZ&VO!VUO/A:@V`IEI'7N.)[)*$X$D8`CAK8\NEQ#6A[*XYER)N$@G$X
M#\PGA)X!6K<;[U%[`WEW?LM!:LUCIZ!:[<Y8-H6G:IL\;:X%M%2'$"CV&+"6
MD861E(9&SL(F:;LGB#186Z!FQ4RE*)1`=OO1T]+TWN_WDP[A>+M>[BNRZ>4[
M)N#"X[RG$:DELN<6AU#;I86XTMUI;B<ZPLJ).(J+"$ZEZ5#4AMMM'&.X)001
MAQ*2,2"1C@<#A]%/1WB5:3NCGA)3%9:9@$KAS-:516>KCP(ZQ0B=CXK\J892
M8@9`4EBL9J,(]%=JL)#@FN0IA*(!T"WSDR755B:U]?4,L25PM"JD!E].=ETL
M:@T^Z&WD8C.TYERN)Q&9!(Q'#6VO*.-,5K$C-)PQ&PC%IT8C[HZ%)QRZX@5+
MBOHM@O1+O?Y6HW3EIW:$-$:VLTP$M2]8+4OEK6I"=-J]LY35E*Q7[U8;LYDW
M$*+I>-C'0F)&IM&ABMDWS?+UWV7G>_RT=$-ZAM]M9O4!G4CKDYAKBY4\2K24
M->'J20V^]$9BML(E<6A]]O!4I3SP+JN9U7;FX&G9):6LMJ+("2<4IRN;<O1`
M45$E..`/8X#93[UCM;7_`)01GGZ.3_\`*CYL^\/W)O7JZ12667SS$\9;[<5/
M7)OH_J];EZ?4_)W9^GH_:]S5LI=;I_B78O2;';BGR[D/B_IO#A^V(W?$UR.4
M]/<KC9K12TUN-851E(WY19TR8P$?&M(YX9VG6G4!+1=WD;'9I"?0(V5E$96&
M9(E7ZRI1(H@B"DT-[5H9K2BTVB4ZY>'&H8"5+>6M2TY2^EYMR*AAA#)*TL*C
MR75%&"#F2XLIE-M#>\!S5X<N\-ENSMORSF2EI#:6U+(84RXW+6^^MY(0I],B
M*TC-F6G*IM`7\4<FYG.Q&JUSK<;&UMD:\>4N&+*!CHQB5_)I&@/BS(Q%WEYZ
MTC.-TRN)$)>)8`1P'CB^+5*5,WUJ!6A6M,+;L4IUVZ.")E2M3RW%Y&SQW'H<
MBMLQ^*42AGP:0]B@Y#F02H?6G&]X3FJP[?8;+5J09>*DAIMM.=P%GB%M2W'7
M^-2`M[PF,R,XSC(H!!9ON\";G<<U]/N+U6HR*@V:FRDW*K%E`Q<8P>OXYZO#
MM:L\A+O.R]J82K=-9P\4F(R/43<%*J4$U#F2Q)^4RK0K>X:]M:>E.O7!8@E(
M6MYQQ:$+2'%2$NQ6FXZVR4H:3&?>!02@E2`%TB&^9O>`YNWOSVHX;3-N1"7F
M4A+3;:%KN$13:8ZFI;SCZ7$A2W%2H[*@H!:0A1+==7V0YU&;1A11A147[O\`
MY&=L_FVO'XM26=;H#VZLWI6+W]%=SNP^).G_`$U"\I;KE"K6M86&M;ZW)S-Y
MD).3D9&4(SEK_<9&NQ@2<<1LXC8RJKS0UM"+2.4ZK=(S4XME%3>*$I2IE),9
M==53YUG;LJF+>W$::0V5-PXR'G.+7F2M<@-<>7",$K4'!G2D9P25%4S3&D+?
M;[M(OB9%R=EO2%N!+LV4MAOC`E);;C%[P<-@@J0DMG(I1R%("0F:N)6M86O\
MI]56E&9O4E)R>V&,D#>;O]QEH*.),.B>/C(VLNYH]<;QK10#&:D%J8S7KB5,
MQ2E(!>#WS:JGW+=#>+0MBWM16K,M&9J'&;=66TG!:WTM!]2U#`.'C`',,5`D
MJ)3/>SI"!;-VVK+RB3<GI;UMFN97ILIQE`=1M;;CJ=XA+:3B6T\62WC@@A(2
M!U1Y$%4/%&%%1]M3L%8/M3/X19X_7Y8G/DT)XQ</5,^N7UG[-2NDCOB:6;7/
M;BM^WS>:N,L@?,'YE>\7T&CRZ)20Z4]HHG=?JJK;^;GS7MJ>I]PU_HZ1$`Z?
MC;`='2(`80#I_<'*E>X/XMV?NCWDSU2`<F/'^_*PX</&R/)'ZY_N[&;;='F;
MKA]L"K14&R-6[^$BM'15;A&B-I>PJBY6%=4KEXLSNUP*K5!RH+Z89L'J1DTQ
M(`"X723DAY6#NBAN+ND?3<QZ0^)4/(%N/NJ,=+H&=X/Q&$QW@HH'%1G'FE`J
M"B0TVM3JM\[&NO[JK[)U/"9CQS$9XPH0RTD2%W"&<C'$S)"GV2D.'C9+3+R2
M$%('&NH1U69#[4;=&%%1)NKL7]^(_P!9?)6/DW\\(^Z5UZL:N'W@^S_\NC\-
M<X_?K_V=EW_.CJ;X:?9?/^4ESVK-Z"O'DR:;!KOV<<[JWU:IN_NU']I6U_,/
MM7V>K9V__.$?_#X__O.TUVERK&W`^WX\2>^I7]"3/Y4-/@HPHJ$MY]G8GTT7
MS%YDSGR2^<%JOW,7ZRM])YO'\U,>,?4759W*K^2-Q\IJ]ZGVQWDS/+J^!!]-
MP^]RJ7CY?G.';]!3^JQ2.=W1#[$2Y;ZVEKS"ZRA`ZVP6C9"A'L/E;@SF&FSH
MO)91\5M'/ROF#!-QTF1\H;JJF3`W0*@G@TY3LW3*]S%UA:??NT@_YFI1F!G*
M,KK0*6PC,M&1:RC`*R+2D*(V)`D5WXV[5;>YS4,[4D>U1QQ+:4B(7LQ*KC&(
M4YGRH7G0A*\2C.A2BD'`J*NH'(E:BUK$SWO%->B9'S-;%3W%_&W1WO5:?+X]
M8-S\VR.X.=J:0(WV$_VD_L9LO63NS?\`\?\`#3:F/SK?XZ>J*YOMQ,=PNY"V
M.*75Z;/1K*N1C:O-I(C=G8)"8DY:2]W7C*T'FF*\*M5/(V#M)H**:+](RG4=
MD<E3*6O5I21HAE;#5^ESHTIR<\IY2"5,H:;0CBDJ8#2PZ)&9YM3F92FE!.9E
M31439'U5%U\_)6]I^%`E0VX,=+*5X(>6ZXXKC5)?+J"T8^1ET-Y4I=!5E>2X
M`$]B^JNC\E^M^@>D/B%3^@?VP^+T=T#^Q^QD'&L,?ZVW3'A^T9/?EU$/KW'^
MO-ZQX?M:7Y0Y6^YSE<G2*W/M?:/3TGYVIEW'D@<U#=M[D6?R)JFX7_SY,\9<
M[8TW.O>Q-9]%-_6'*I'+XYY>\CWIE]44N.E_9Z'W!-;CC1:WU&%%&%%&%%&%
M%&%%&%%&%%&%%&%%&%%1QMGL'-?51WPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'
M?$TL5%[9UCTRS^O'+*/+9YH&\KW/G][%(_ISS_#\83U:>3*4=.,HPHK%SGO)
M,>BY#S1;,NW_`+>QW9';"OE?8GI4D'=:_P!F_P`&OT6]+?B+#8OW*ZYT6\'W
MNNGE;M:NP^98OBZ.U%<_=EM=W?ZPTOJJO[\XAZR:+5GEQ>HF#Y;;'B]8QT19
M7?*WF%JT+]K>7LFGMCQ,A:41OC(7(,WC"2;-(KQ0@*#TYPDDM5GL$;5M]UA<
MM.:UNSR9>G(CCNG83D];C"=/::G^!SFV+E"<1'/@CN3C6GF%N2,^/&1TIKCU
MN.EAJ.AZ,V,KR@'E!(!XUY&9)*%#'KAC@00!]!KK>KB+AO7H%!V\0D72$-%H
MN9!L8#MGSA-B@19XW.4I"G0<J%$Y!```2F#P!D,%T6VY<Y#C*%-,J?<*4*V*
M0"LD)(VX%(V';PBE$0"$`$XG`5F<P:^JKF[PS8VDJ9#:HKVXZ5)W;X[65Y&U
MIBEMUMIFO-W2DI4*[X^RV-W:*XA(1Z<_;(I95L";Y1LR0=2)4#>0B4SG^31I
M?7U]G7BY:'GM0/`(B5OK-M5<WE)#<E[!AA,=\H668\A*5XM)<=6S&+@\(!&E
MO+T5I+:)*2K,K`=?D'"!M.(Z)&S;@,58;*:[C=8JG;=!Z@L=$AGU=ITMKZLN
MJY`R,F,V\AXKW,03:QRTV+M][M`T(GU"O`64!T0`5`P@<,1W>E;+S9MXU[M>
MH7VY-\9N3Z7WD-\4EQSC"5+#65'%9B<2WE26R2@@$5L(2VW(C:V@4M%`P!..
M`PX,>CT^C4UYP595&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24KOZZ
M]X_[.C\1/4%4^=Z#[\Z;]&W;SFLX[+DE?L-\[K%[5^I%.0UYMU)W:%VLFHPX
M"H*NE^1+9!M+O5W&G5T$6<`_9Q<\[56/+)IMH23D/\0CI=<Y@(V77_>45A*<
M_P!*`YUG*-<0RWIAUQ;+;:;X"5/(4XRD`-DJ=;1UZVP-JT(ZY2<0G:16SY<P
MQT39`,2?M"1P;#^83P'H'Z*A#AT61+N7@;[JSELM$@INWE@[?66V2MGD59N2
MDN&>NY:6<QK2XUJHST(W0DWZJ#A#R!*/7>)*.H\QV2Z(AW^^\Q3H;>)X''AQ
M(PL&GDH8CML(#2$:FFMMI6J,_)9=);0E:%\<IY#2D-20E]MS&*JVYO"8F8J4
M>-=VDDXDLI)PS`$;>'9ACM&PBK0.;W;ON]/T^*C^K?R<QI6X+V=WE_[N9/KN
MQ5O;I^=A^-CO;M:9WJOS<]9_IJ<%/UL-3XY/Y3W/>TSXA>/54NM/KGV;>_&;
M[=-;]6.UM?\`E!&>?HY9GY4?-GWA^Y-Z]72*1NR^>8GC+?;BIYY.?-ZW-^;N
MS_!JV4N]T_Q+L7I-CMQ3YMR'Q?TWZ8C=\37-0E_A!]0?V,V2I+X/OCJU-6YP
M??'5KXS]KZIG>&?SG-3>EIK\59[$GWY_">\]Q:\H9I$.4E\$-0>+L^5,5T8Y
M&%4-U&%%&%%1?N_^1G;/YMKQ^+4EG6Z`]NK-Z5B]_17<[L/B3I_TU"\I;KF3
MK\7(S<K$PT.R<24M*N4(Z,CFA/&NGS]X'B&K1LGTAXQ=PL<"E#]D1R5ZY2XL
M"&].FN):ALI*W%J."4(3M4I1Z``!)/T5-W=YT.V0)%RN+J&8$="G''%G!*$(
MZY2U'H)2`23]`IOM`<>MZ5[=^IYV=U/=HF&B+U`OY23>Q!D6;!DW<@9=TY5\
M8()HI%\)A_8Q%-Y&\O=]<]`7FWV^\P'ISUO>0VVAS%2U%.Q*1AM)Z`IN^]K>
M_NMO&["_VNU7^V2+E(M3[;32'05N+4G!*4C#:3T!5_V1OU$G1A14?;4[!6#[
M4S^$6>/U^6)SY-">,7#U3/KE]9^S4KI([XFEFUSVXK?M\WFKC+('S!^97O%]
M!H\NB4D.E/:*)W7ZJJV[F[\U[:GM&O\`XW0&5*]P7Q;L_='O)GJD!Y,7QSL/
M=9'DC]5&<'OG0ZS^C:_Q.GL>CO\`_A)=O_R?REFI".5!\#+W_P#DOEC%=#^1
MFU#Y1A142;J[%_?B/]9?)6/DW\\(^Z5UZL:N'W@^S_\`+H_#7./WZ_\`9V7?
M\Z.IOAI]E\_Y27/:LWH*\>3)IL&N_9QSNK?5JF[^[4?VE;7\P^U?9ZMG;_\`
M.$?_``^/_P"\[37:7*L;<#[?CQ)[ZE?T),_E0T^"C"BH2WGV=B?31?,7F3.?
M)+YP6J_<Q?K*WTGF\?S4QXQ]1=5G<J_Y(W'RFKWU[O)F>75\"#Z;A][E4O'R
M_.<0WZ"G]5BEWX3?.@U9[9L_XFV'(`-_?PEN_P"*QY2S4J?*;^!M]_$C>61Z
MZ)LC)J'>L3/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVII`C?83_`&D_
ML9LO63NS?_Q_PTVIC\ZW^.GJBJ1'?JN_JG/UQ\K/O?M:NZ'JU:@A?FF?Q$=0
M5U'ZG_DLUI\@*;^+L=D0FLO:^Z^DI/?EU!?K_P!N[WZ7F>4.5O\`G-UR5(K<
M^U]H]/2?G:F7<>2!S4-VWN19_(FJ;A?_`#Y,\9<[8TW.O>Q-9]%-_6'*I'+X
MYY>\CWIE]44N.E_9Z'W!-;CC1:WU&%%&%%&%%&%%&%%&%%&%%&%%&%%&%%1Q
MMGL'-?51WPDTR0OY6'/BT?W.Z^J)U<GK;V:D=-'?$TL5%[9UCTRS^O'+*/+9
MYH&\KW/G][%(_ISS_#\83U:>3*4=.,HPHK%SGO),>BY#S1;,NW_M['=D=L*^
M5]B>E5??=DW.GPG=Y<"H6:M=:B)B7XU:+BXF)E)V+CY*4DY"A1:C".CF+MTD
MZ>OWR:!S(HI$,HJ4AA*`@`XY/E7V*]S^4QO%G0(<I^"QJJ[...-M.+0VVB8X
M%K6M*2E*$$@*4H@))&)&(K3V-UM%FB)4I(46&P`2,2<HV"J^N+&H^7BE?T/O
M'CI6=!VZGMWG(>@;/@-J6UQ2K-,04-S8Y-69]6H29;Z5VLHA'3SF=CE_*`4;
M'9K19@*F<'!C%<IO>UIN53<M1;O]YTO4<*]J19ID!ZWQQ*8;==TM8F$/NM*N
MEO!6REIY&0I6'$O@E2>*`.G@1[CD:E0DLJ;Q<2H+.4D!]TX`Y%[#B-NS##[M
M=#"`J"@B*R::*PI)BJBDH*J22G4#KIIJBFB*J:9ND`-U"=8`Z>@/4R-!S+QB
MLA*D8G`D8$C'82,3@3T1B</I-=B.#;PU^N?%?M5[=Y6SF3<>%)&*W9<]*IDL
ML/6UWU29U--I8WE[<I5"#BK3:[%<-8/J+7V\S*HK*R3.VP!2B'BW!G:1_(U7
M+<E9^"-Y@C3+!`ORC$=?")"I!4PF(DR77(\=F-/1+>4TVI*6';=,)[)L,K3Q
MZ-/>PKP/,EU377`;,-N;8`22G*,3PA:?NX\%-?H1=@ZTGJ=Q%UV!J4:MKZJ*
M,:S5I]A:JY!-30S048R$LT6Y>Q\_&-"=!47:*RQ'!``X*'Z>L*.;Q6Y#.O;R
MU+DR9LI-RD!;\AE<=]U7&JQ<=8<2E;+BCM4VI*2@];E3A@-A$(,5LI2$IR#8
M#B!LX`1L(^[4M9QE9%&%%9/\&8J7]EJPOU]>5Y]UNO;"_LILY'6?MA=?24KO
MZZ]X_P"SH_$3U!5/G>@^_.F_1MV\YK..RY)7[#?.ZQ>U?J13D->;=2=VA=K)
MJ.>[X2C%Y/?Z,W"/;-#+:F\5+UN-:&?R%@C%'$H1_",&!%$3O7LLU$Z"2('(
M*AU`*`AT].=/RE%RVXFFW($AN).3><6WUJR(9<`;R.K600E+:L%J40<H!.!P
MK:<N7*=%6,*!4G[1D8@<)'$)V??J.>-]JU?==X=WM9-6478U$C'>U>6+&>9[
M1MDW>+*]G('B74:^@T2LU@<+OG<;2:Y%L*X1`O429*1!T>@RA5%#]/O2L^K;
M#H#>7:]7W"UW&6BSZ>6RJ!':B,):>U%)>*BPR`A*Y3[CTTK.*G4R4N8A)2E,
M5L)QAV5#7'0M"2X[CF)4<0R!PGH)`"?N8858=S>[=]WI^GQ4?U;^3F-GW!>S
MN\O_`'<R?7=BK<W3\[#\;'>W:TSO5?FYZS_34X*?K8:GQR?RGN>]IGQ"\>JI
M=:?7/LV]^,WVZ:WZL=K:_P#*",\_1RS/RH^;/O#]R;UZND4C=E\\Q/&6^W%3
MSR<^;UN7\W=G^#5LI=;I_B78O2;';BGS;D/B_IOTQ&[XFN6"O[=UQ9+4O38*
MSMY.PME91DJU;L)<&GE\41YY=')3"L>G"N)%%-BX4!!-P=51%NJJ0IDTE#%E
M[N6BM46NT)OEPB*:MBTMJ"E+;S9'"G(LM!9=2@E:$E:D!*5+0A1"EI!E[A:]
MTE=;NNPV^8ERYH<6@I"',F=LG.@.E`:4L!"U!`65J2A:T@I0HCXKNWM<6VQK
MU.N6AM+3C8\@BH@W8RQ69W,48`?LVLPO'HPSU\W2,"WB$7"BIVP^/*4R/T^?
M5ST5JBS6M-YND13-O4$$%2V\P2YV"E-A9=2@GK<RD!(<_)DA?6U]VO7NDKU=
M5V6US$NW!!6"`AP(*FSUZ4NE`:6L`YLB5E1;_*`%OKJ9S@7M[7%TY<:OKE7M
M#:9EFLG:#'3;L9=)FJ:,JTGY>BREG4>A$2+EJC(-US)-UU5/)'*3@"B@JFH9
M)^43HK5%BW+W>Z7>(MB&MIC`J6V5#C)#>0J;2LN(2HH6@*6A*>,0MHGC$*2$
M/W\Z]TGJ#=%J*TV>8E^:B.C$!#@0>+EQLX0ZI`:6I(6VLI0M2N+<0[AQ:TJ/
M3UD3-1/4844845%^[_Y&=L_FVO'XM26=;H#VZLWI6+W]%=SNP^).G_34+REN
MN=WCQ_+II?\`.32OAIGDFF\SX?7WT5*[TJIAM\'PLU+Z%F]Y773ED3U0@484
M4845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?LU*Z2.^)I9M<]N*W[?-YJ
MXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJMNYO"!>+NU3&'H*5A`&$1]0`"VP`B/
M_@`,J6;@@3O<LX'#QCWD[U2`<F,A._&Q*/`')'DC]4G]WQL^B7+EIK>(K,^2
M5>DCK/+IBE'RR#)Y'FHSARLM&2CM@WBY52/2GF/EB39955D9XB5<J9E"@+\^
M4KI+4-CW-72;=HQ98+K#9Q6V5I7X6$@.-I67&PLLN\6I:4I=#:RV5!)-/AY1
M&L]-Z@W,WR!:)(>?#,1T$(<"%H\*AJ);<4@-N%`>9XU+:E*:+K:70@K2#TN9
M%544E&%%1)NKL7]^(_UE\E8^3?SPC[I77JQJX?>#[/\`\NC\-<X_?K_V=EW_
M`#HZF^&GV7S_`)27/:LWH*\>3)IL&N_9QSNK?5JF[^[4?VE;7\P^U?9ZMG;_
M`/.$?_#X_P#[SM-=I<JQMP/M^/$GOJ5_0DS^5#3X*,**A+>?9V)]-%\Q>9,Y
M\DOG!:K]S%^LK?2>;Q_-3'C'U%U6;RL$"ZB<F$>@"V6OB(_M`!W8B/\`X`R9
MGEU`G<3@.'[;A][E4N_R_2!RAT$\'V%/ZK%)WW?^T*)<N6FL(>LSY)5Z1M8Y
M=,4H^608O&!J*Z<K*QDJ[8-XN54CT9]B+Q)LLJLR%XB5<J9E"@,$?*0TEJ&Q
M[FKM-NL8LL%;#9Q6V5I7X6E(#C:5EQL+++O%J6E*7>*66RH))J2SE!:TTUJ#
M<S?H%GDAY_P:*Z"$.!"D>%0E$MN*0&W"@/,\:EM2E-%UL.A!6D'ICR*:HGZQ
M,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FD"-]A/\`:3^QFR]9.[-_
M_'_#3:F/SK?XZ>J*H$M^TZ#49)W$6"PI,9(JA17:$82S\[%L]!91*3E#1S!V
MG%0B1"=*[]R9)FVZQ/'*DZY.M7#@Z0U'>E*FVV,7(O&+P45MH"U)5@6V\ZTE
MQTD]8T@*=7@<B%93A9VDZUTQ8WF8%SE!N6$M9DA#BRA*AL<<R(4&F1AU[SA2
MTWBG.M.9./6AJ@!#5NM0'P"%`IP"'[0A78[IR%_6.W5UU(X/M*3WY=0LZ^..
MNKT1P?:TSRARM^SG*Y*D5N?:^T>GI/SM3+N/)`YJ&[;W(L_D35-PO_GR9XRY
MVQIN=>]B:SZ*;^L.52.7QSR]Y'O3+ZHI<=+^ST/N":W'&BUOJ,**,**,**,*
M*,**,**,**,**,**,**CC;/8.:^JCOA)IDA?RL.?%H_N=U]43JY/6WLU(Z:.
M^)I8J+VSK'IEG]>.64>6SS0-Y7N?/[V*1_3GG^'XPGJT\F4HZ<91A16+G/>2
M8]%R'FBV9=O_`&]CNR.V%?*^Q/2KE(T%:^$2)>Z-BK7HXK_F;"Z;X2GKVR'\
M/2?([!392N4V*@)`]<E+="V[;(456\.#13F)9N)&M246YD"^.8P[QJM,3O'L
M^_U9WT3+/J#B]Q;]\U3QT%#LK,S);?DN/(#[<9V-;O"Q%0)")#B&9S$AJ,<D
MB<PZA/XCEK'V<EQK&YAIC!6"=J2$@;"05Y<VP@8I()VA)!L)XESW*ND\<*=>
M=4V31YM2UYYRE6F->;7C[D65NUP0YA<AY&9=5>X:WCK3=(:3B*LP:@V9MZS9
MO==1P=))JDN0BAVT[Y;=N?OV]"=I_6,74`UG)18`W-MZXW%Q8QTU9D-)D1IR
MX\5UMR0MS.ZN=!\&2A*UO+;*DIW-O7<&H278ZFO!TEW%*PK%1XYPG`I!4"!A
M@,JL<>#&KN62YG3-HY.0$SN&J"YR`5P4"&62(H8@%=-VCHH%$W1T*))J!_Y1
M"CT@#!GVPR^MI)Q2E9&.S;@<,>M*D_\`54H?02-M=0#B`:].>5?M5^\_=VZE
MU?6]85;;-(MMTC;K>8F9B_B3LAAJRT5^4IUJI;"%G*Q97-RH;I>R-K?=8D$V
M:,HR(=@9XNNL5NW4(HY+DX:"UGJVZ7:[Z-GPH$J!;W&G/"H*[A'>;DQY2W6G
MV$QI:0PJ-%D%3BF'2'@PVVV7'4J3I[O*CL(;;D(4I*E@C*K(004X$',G;BH;
M,1LQ).`IP=3*BOK#7ZQFWD0K5"`5\C^/2^SC-04C6YRMU-B.3JK799$!ZIY,
MQU/+#@*@'.!@.*):R0&]67)L+XS+->&;P00,V"U=<(20!%!X0P`GBA@C*DC`
M;*/M80>#K1_"S=#^-_"Z?1J0<YJO:C"BLG^#,5+^RU87Z^O*\^ZW7MA?V4V<
MCK/VPNOI*5W]=>\?]G1^(GJ"J?.]!]^=-^C;MYS6<=ER2OV&^=UB]J_4BG(:
M\VZD[M"[6348\!$1<N.1+<K=1V9?3RR(-49TE76<BJ>6(#=*S*""==46$W5*
M^-X&@CXT?`3.LY1S@:;TPZ5!`3>P<Q:,@)P#9Q+`VO`<):&USL.C6SY<PQT3
M9!P_^82.CA_V">CT.GT*73@J[2DMC]WY*!%O8]\_W=R_&?>2-M8VYW8;.UXD
M4IG8+&LYC7#EHS-*R*!E`$#]#X@E=HE*T6;%!3N4(RN+I?>3$+S;L=NP:;XE
M*(ZXR66%:BE*98"5A*E<6@A/!BT<65DO(=)BGM1S/0U8$$NO8XG'$\2G$[/I
M/[O"-A%6E\]63B3LO`F-:2LA`NY'G+`L&D]$$C5):#=/.,G*)LVF8M.:CIB&
M5D8I94JZ!7C1TU,JF4%D54Q,0S1.3J^W$M6\64\RU)9:W?/+4RX5AMU*;[85
M*:<+2VW0AP`H66W&W`DDH6A6"AO[L"I<1()!,H;1AB/R3NT8@C$?=!'TBE6Y
MEZBVEJ7B3K5AMWDILGDI<)#F)W>R4M8KU7=55.)8RL5RJUFE)OZ=7M9:^IBD
M.RLBKDBKAK(.Y@4#(D*@J0O7\8];Y=FM-(ZSY>VF9&BM*VK2MD:BWTMLQ'KA
M(<6VY;)!;1)>G3)0=6P$E*'&6XP6%*+B%'+EYS5L:1'TN\)+ZWW"IK$J"`,0
ML8X!*4X8_02?N4XE8[6U_P"4$9Y^CEAOE1\V?>'[DWKU=(I)[+YYB>,M]N*G
MKDW\WK<OAZ/_`)=V?P_M?]FK>'*76Z?XEV+TFQVXI\NY#XOZ;],1N^)KD%HT
MC9GVT8F.=ZG:U:&AYK:2Y'K.O3[(U<*_7D`)..K++0*=0L([#5ZCL4X!T5T@
MHYZ%3*)@Y`9KM01;3'TB]*9O*YDY]B`"E3S*N.R!'Y)+#;QDL^!#%O-+;+:T
MHZP)46B)/K')O#^L&8SUE1%@L2IZ@4L.HXC,XK\LJ0ZP(S_AIP<*8;O&(4O\
MHI:0[7YZ\D;._P!CQ#%_J9K3HB%4V69-PRKT['!5/=&91.4[FQ3$"A5[,-Z4
M3*]_^'70"B?P*BHEU\^M31;3&TN_(CWE<Z:^(.(6\ROPC(T1@EEIXR&/!`2U
M_GK9"AV&1>6OK2\J\2=5LQY%D1#A1S/PR,.(\'SO)VJ?=8$>1X80'?\`,G<4
M'8LK3F-,YW<DE9Y#FQI!K(ZE:4F+A"[921%C7IZ+)4#2#1=4L.XG9V!:UZT#
M;#HB[!2MN002,WZ%052%,2I1RH(MIC;A;^]%O*Y\N0;<3G>9<,G(H#C`TT\I
MZ/X.#Q>6:C.H+ZS(O,"B&]^3>).[>\M2K*B!#8@/@!##K8BY[C#/%EYYA+,C
MPC#C,T%S(GB^O"TE*AUJY#+4;E&%%&%%1?N_^1G;/YMKQ^+4EG6Z`]NK-Z5B
M]_17<[L/B3I_TU"\I;KF<XPTZR,.3FJ[!);0N$W%NMO5IW&4URPI;2N14:\?
MQJ2$299E5DK&_"+>>-507,_*H)3$(J"G4,925G>S>[5(W3WBVQ;3!CRT65]+
MDE*Y2GW%I0LES!4@L(XQ.5*T!D@$*4C+F`3*UO0T_=XNA=5W29>9TB(NUW!3
M<4HB(8;;5'4`V2B,'U\6K,I"R\#@4I7GRDJZL\AYJ&RC"BC"BH^VIV"L'VIG
M\(L\?K\L3GR:$\8N'JF?7+ZS]FI721WQ-+-KGMQ6_;YO-7&60/F#\RO>+Z#1
MY=$I(=*>T43NOU55M_-SYKVU/!T_XC7_``>#P_\`Q;`>#P]`>']WP94KW!_%
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MCQCZBZK.Y5B`:C<B80*4++7Q,(^H``=V(B/J^``R9GEU8G<00.'[;A][DTN_
MR_2!RAD$\'V#/ZK%4X=SS;+7=^:FNY2.TW5]84F*;[%3?$B*R6*9M7-HJ:5@
MAV<9,E<=$F_L\![G30@U;IMQ8JI^6D;.@;MR1*\MRS6>P;A[G$E7R7=K\\J$
M4%Q_C%*2Q(++BG&LOY-##W'Q?RBROC4JXA3K)<<4ZO5U^O&H]U^H9<.Q0K18
M&8Z`L-,!M*3(FP'FDH="ORBY#/$2CQ3:4<4I`D)9>#32>RW(-*9!6)GO>*:]
M$R/F:V*GN+^-NCO>JT^7QZP;GYMD=P<[4T@1OL)_M)_8S9>LG=F__C_AIM3'
MYUO\=/5%<S6[V<M\9+A-QVB(B\*1=,BH]M:6S-%Q=98\W.R*GN;&%6B'L?*0
M%6D(=HO(,5U%'`).@<)(*$3$BM?[1K\/P:/`DZA>MZ7KF\M4=2BF*V&FTC.Y
M@XE;;TA#CB&74`(*FRTMQ*E!2+%^LV)XNCEQBZ;9N)9ML9`D)0E4IPO.J(0C
M%I:7&6%M-K>:6HJRN<8EM03E<[.]5='Y+];]`](?$*G]`^KTA\7H[P_L^KD$
MFL/:VZ>D9/?EU$_KWVYO7I:7Y0Y6^YSE<G2*W/M?:/3TGYVIEW'D@<U#=M[D
M6?R)JFX7_P`^3/&7.V--SKWL36?13?UARJ1R^.>7O(]Z9?5%+CI?V>A]P36X
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M)D.3H$'!Q$RP?3B/2.1`S0X)CP=!#H=5B"@-D',<06QL;./"@;$]B."N^3AE
M&'!AT_\`IZ-9#,:OJJW.\!3OBLAIC\F2@3]R:C=I9KJ_\G[C8"EYAX&9UA.3
M9V;(UBK40P>>3QQ*^99TL($9VAP<.HDFNH1TG)N5IU$:^_UK'@UC7X*VJ?X8
MF&(CCS4]IH*5Q+[BTYEF8$MIVN0&T]<M3:%:2\<;BUQ&UWKCERYLP!23T0.A
MEV]!1^[3F:*MS&^Z:UA<XUK$L6=DI->E4X^"C%(6'C3N8Y`SB,CHE59R:/:Q
MK@#H%2!54I/%]!3G+T&%#-X5ED:<US=K%*6\X_%GO-E;K@==6$K.#BW`$YU+
M3@LJRI)QVI2<0-G$<#T9MU.`"D@[!@!LX`/N5*^<=611A163_!F*E_9:L+]?
M7E>?=;KVPO[*;.1UG[877TE*[^NO>/\`LZ/Q$]0543WF\9)O9/4CEC&23ULR
MB;NJ]<,F#MVW9)`M7%!5>+-T5$FJ8)I&,)E!*`%*(^H`XZKDGRXD>)>FI#K3
M;KCT4)2I:4E1P?&"0H@J.)`P&.T@=&I!^1-<[9;K;J/[0DQX^9Z&1QKJ&\<$
MR<<,ZACAB,<,>$?32K\<JALFS4GD-6M?U=U-V&RUW5584B7LY8:(QDJ[.[0K
M)+W'O+A!$)-U]NMK63>KK+LBK/$V:@*)(+B8B:BO[S[UI:U7_3-UU)+1'MD2
M5<'PXEIF6M#S4!\Q%IC.DM/*$YMI"4.E+9=3D6XW@I2<GER7*!==#65BT28T
ME\7)W,EMY"B$J:;QS<6HJ2"DG;ATL3LJ7]HOJEQ(WIW=$AOJU4325#KM[Y1Q
MC*=N_)&\;)I\+&.N-S"'K$.;9N^F-3E(=9RI&J(-8@@&;`*?C$C'675*'%:1
MCWG?1N^WGQMW4.XW_44JW6!Q346R18,EUQ-[6Z^YX!:%R&W0D+"W))P<P.58
M2AM!,9KY;MTN$9:D--)6Z,5.*4`.+P`S.8$<&P<'T;37IY?\^.#MJNO!5S6N
M8'&>=;5'FU5;5:G$5N_7#Y"MUA#0?(>%7L,ZLWL2B<3"(R\XR;'=+BF@5=TD
M03`90H#X[D^3GO\`[18=X35UT3JN.[-T%(CQTN6J:@OOF[V9T,M!3(+CI;:=
M<#:,5E#:U`8))!<KO:G'8A1)8(3*!."T[!Q;@Q.W8,2!C]VM1[RGGCPDOFA-
M>Q%*Y=<;+9*,>77#&R/8ZN[JUY,OVE=J_)G6E@LLZX9Q]@<.4X>OP<<N\>N!
M+XILV1.HH8I2B..#^63N)WUZ$Y8NG=1ZUTEJ2TZ?:A75*Y,RW2X["%.6V2VV
ME3SK26TE:U)0@%0*E$`8FM5K*YVZ5I]UF,^RXZ5(P2E:2=BP3L!QV"MWKO/W
M@LA9H-PKS(XQIHHSD>LHJ?=FOB)D2(]2.<YU#SI2%(4H=(B(@`!EB#E'VRXW
MOD\Z[LUG8>E7>7H^[LL,M(4XZ\ZY`?0VVVVD%2UK40E*$@J4H@`$FDGM"T-W
M:*XX0EM,ALDG8``H8DGH`5-'(CO$N`\WHK;41#\TN+4I*2%#L31A'1^]]:/'
MSUTNP531;,VK>R*+N5U3F`"D(4QC#Z@94<W9<F7E&0-X5FFSM":O9AM7%E2U
MKM,Y*$)"P2I2E,`)`'"20!3R=SVJM-6S>II^X7&X0V(+-UCK<<<>;0A"4N`E
M2UJ4$I2!M))`'TUSY)\K>,0#X>0FF0^D.'AV/5/V2&`/^]/V\DI7N>WL8>S5
M]X1_^I2/I[G4NZ]^6Y@C9JO3G"/_`,XQ/I[M7Q_6LXQ_[PFF?YQZI^%,_?[G
MM['^K5]_^RD?JZ^O[\MS'^MFG/Z1B?KJ8KB7S&XEUWD3K&:G^3&B82'8R<L=
M[*2VU*7'1S,BM:FD$SNGKN81;-RJ+JE(`G,`"8P!ZHXF6^7<?OFN>[*[0+=I
M34,B:XTV$MMV^4M:B'VB0E*6BHX`$[`=@)I'.4!O@W4WC<[?+;:=26*5<76&
M@AIJ=&<<61)940E"'2I1"020`=@)Z%7U_P#$G[O7_?AXG_S_`.KO]9\CI_X6
M>4M_J!K+^AY_ZBHH?MNS_P`ZC_I$_OT?\2?N]?\`?AXG_P`_^KO]9\/^%GE+
M?Z@:R_H>?^HH^V[/_.H_Z1/[]'_$G[O7_?AXG_S_`.KO]9\/^%GE+?Z@:R_H
M>?\`J*/MNS_SJ/\`I$_OU'.X>\9X`R>I=G1T=S7XKOI!_K^XLV+)IOG6;AV\
M=N:_((MFK5NC93K+N%UC@4A"`)C&$``.G.HT1R8>4?$UG:94K06KVXS=RC*6
MI5HG)2E*7D%2E*+````)))P`VFNRW=:ET]!W@6.9,G1&HC5WAK6M;J$H0A,A
MM2E*45`)2D`DDD``8FJ(=$\N^*L1N;4DI*\D-(1L;&[`J+R0?OMG4]HS8M&T
MNT5<.G;E>6(BW;H)E$QSG,!2@'2(Y(=O#W*[X)NAKU$AZ6O[LIVVR4H0B!)4
MI:E-J"4I2&R5$G8``23P5*KO4WS[HKANWU#!@:GL#TUZT2T-MHGQ5+6M32PE
M*$I=)4I1.``!)/!71)_Q)N[U_P!^'B?_`#_ZN_UGR,G_`(6>4M_J!K+^AY_Z
MBH>/MNS?SJ/^D3^_1_Q)^[U_WX>)_P#/_J[_`%GP_P"%GE+?Z@:R_H>?^HH^
MV[/_`#J/^D3^_1_Q)^[U_P!^'B?_`#_ZN_UGP_X6>4M_J!K+^AY_ZBC[;L_\
MZC_I$_OUH^R.\;[OY_2IQJSYM<5'+E9-H":"&^M9KJG$K]J<W421LAU#]!2B
M(]`#T`&/9^75N!WY:,Y9.B]2ZNT?J:UZ=BOSB])E6V8PPT%VN:VDN.NLI0C,
MM24)S*&*E!(VD5SFK;K;)&GI#,>0RMU03@E*TDGKTG8`<>"EZH7>`<%&=QK[
MEUS*XPMVZ+TQE5EMW:]123*+9<O6455GB)D+UC`'2(@'AR?OET:?ONJ^2)KW
M3NF(<JX7^79D(8C1FEO/O+$R*K*TTV%+6K*E2L$I)P!/`*2S3+K3%^BO/*2A
MI+FTDX`=:KA)V"MGY@]X3P/LW'+94)7>9?&"<F7S.#*RBHC>6MY&1=F2M$(X
M5*V9,[$LY7%-!(QS=4H]!2B(^`,K`;DN35RA[5O/M4^YZ&U;'@MK=S..6J:A
M"<8[H&92F0D8D@#$[20*?#R=M8:4LF^2RW.\7*#%MK3CY6ZZ^TVV@&,\D9EK
M4$IQ40!B1B2!PFJNN'7,GB16>1NO)NQ<F]#P4,R&S>62LQM6EQL<U\?5)ILA
MY0]>3"+9'QSA4I"]8P=8Q@`/"..WWW[C=\]UW87.!;-)ZBD3G.(RMMV^4M:L
M)#2CE2EHJ.`!)P&P`FGT<HW>[NKO>YN\6RSZCL<JXN^#9&F9T9QQ664RI65"
M'2HX)!)P!P`)X!5[?_$G[O7_`'X>)_\`/_J[_6?(\_\`A9Y2W^H&LOZ'G_J*
MBL^V[/\`SJ/^D3^_1_Q)^[U_WX>)_P#/_J[_`%GP_P"%GE+?Z@:R_H>?^HH^
MV[/_`#J/^D3^_48;<[Q;@%)U+R=AS7XK.U_=5@IXEMOC6CA7J%!?K'\4A8U%
M.J7I\(]'0'[.28?*?W([X]WW*K-_UWI74-FL7]6+DUX1-M\J,SQBS'R-\:\T
MA&=>!RIQQ5@<`<#7':YN5OEV/BHK[3CO'(."5I4<!CMP!J@_OG>6O%C:'`ZX
M5#6O)#1^P+6ZV/K%ZVK5-V;4;%.KLV$N\5?.T8N+E'+Q1NS3,!E3@02D`0$>
MC+K'RP-::/W?\KZTZFUU=;=9M.-V6ZH7*FR&HL=*W(X#:%//K0V%+.Q"2K%1
MV`$TW36D>1*L#C,9"W'BX@Y4@J.P[=@Q.RJG_P"[X[OTSIOO!F]RVYM?76L*
MB72FS8PUGO\`<J_4(`))XI7%&<?[KST@P8>6NRME/%)>,ZZ@D$"@(^#.M_YJ
MG>%H+E!?*J>T!N(O=IUGKH[Q=/2!;K)+8NDXQVDW`.OB+"<>?XEHK1QCN3(W
MF3G4,16/N0B2K5K<2KFVY'B^".C.XDH3B<F`S*`&)Z`QQ-=S_P#Q)^[U_P!^
M'B?_`#_ZN_UGS^:5_P`+/*6_U`UE_0\_]13Q/MNS_P`ZC_I$_OT?\2;N]?\`
M?AXG_P`_^K_]9\/^%GE+?Z@:R_H>?^HH^V[/_.H_Z1/[]1#N3O$^`DI`QB,?
MS6XL/%4Y<JATVN]];.3E3!FZ*)S$;V)4Q2=8P!TB`!TCDM?R?]SF]K=QORU-
M==X&F;]9+8_I);3;LZ#)BMN.FX05AM"WFT)4O(A2LH).5).&`-<)KZX0)EL9
M1%>:<6'\2$J"B!D5MP!.RJ].2W-_AE.ZN7CX3E?QVF7QK#!K`RB]OT9ZZ%!$
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M_J[_`%GR&[_A9Y2W^H&LOZ'G_J*9S]MV?^=1_P!(G]^L9-=Y%W?"T-+))\W^
M*!U%(Q^1,A=_:P,8YS-%2E*4I;,)C&,(]```"(CX`Q2MS/)GY15LWP:4N5QT
M+JYBWQ]2VQQUQRTSD-MMHFL*6M:U,!*4(2"I2E$!*022`*P[C>;2NWOH1)8*
MRRL`!Q.))2<`-M)(//;@WXHP?UP^,W2*)PZ/RTT'IZ13$`#W\]7IRYW-.93Q
M3M!SX8='''"F]LG!QLG8`M/5%4\.N5G&,WE75Y":9-UC.!+T;'J@]8#&.(='
M1*>'IZ<KRN[G]ZYE*4--7S+QA_\`U*1]/<ZLG1-^6YE+;05JO3@(2C'_`,QB
M;-@_\:NC[6?>-]W_`!^M]?,7W-GBJT>LJ/4VKMHYWUK%%PU=-X&/27;N$5+*
M51%=!4@E.0P`8I@$!`!#(M-5\E_E(R=4W*1'T%K!;#EPD*2I-HGE*DEY9"@0
MQ@00<01L(VBH:-;ZCT_+UG=Y46;%<C.W24I"TNH*5)4^X4J20K`I4"""-A!Q
M&RMW_P")-W>O^_#Q/_G_`-7?ZSYS_P#PL\I;_4#67]#S_P!17,?;=G_G4?\`
M2)_?I-+;S]X+.;38G"',CC&L@O-2*J*J6[=?*)J)J.5#$.10DZ8ARF`?`("(
M#EPGDKVBZ6#DR[OK%?(S\.]0]'VIE]AY"FWF76XC:7&G6U@+0XA0*5(4`I)&
M!&-(#>W$.WF6ZT0IM4A9!!Q!!4<"#T130T;O'>[\9U"O-G/-SBF@X1C$"*HK
M;[UBDJF<.D!*HDI92*)F#]HP`.5F^6UR=]_>J>5GK_4.FM%ZIGV&9J24XQ(C
MVN8\P\VHC*MIUME2%H/04DD'Z:6/3EVM;%BBM/2&$.I92""M((/T$$XBMJ_X
MD_=Z_P"_#Q/_`)_]7?ZSXUK_`(6>4M_J!K+^AY_ZBMW]MV?^=1_TB?WZ/^)/
MW>O^_#Q/_G_U=_K/A_PL\I;_`%`UE_0\_P#44?;=G_G4?](G]^C_`(D_=Z_[
M\/$_^?\`U=_K/A_PL\I;_4#67]#S_P!11]MV?^=1_P!(G]^C_B3]WK_OP\3_
M`.?_`%=_K/A_PL\I;_4#67]#S_U%'VW9_P"=1_TB?WZ/^)/W>O\`OP\3_P"?
M_5W^L^'_``L\I;_4#67]#S_U%'VW9_YU'_2)_?H_XD_=Z_[\/$_^?_5W^L^'
M_"SREO\`4#67]#S_`-11]MV?^=1_TB?WZ/\`B3]WK_OP\3_Y_P#5W^L^'_"S
MREO]0-9?T//_`%%'VW9_YU'_`$B?WZ/^)/W>O^_#Q/\`Y_\`5W^L^'_"SREO
M]0-9?T//_44?;=G_`)U'_2)_?H_XD_=Z_P"_#Q/_`)_]7?ZSX?\`"SREO]0-
M9?T//_44?;=G_G4?](G]^C_B3]WK_OP\3_Y_]7?ZSX?\+/*6_P!0-9?T//\`
MU%'VW9_YU'_2)_?H_P")/W>O^_#Q/_G_`-7?ZSX?\+/*6_U`UE_0\_\`44?;
M=G_G4?\`2)_?K0MF]XUW?\A2Y9JRYM<5'+A0S#Q:"&^M9KJGZC]L<W421LBB
MANJ0HB/0`]`!CZ_EL;A=]^B.61I34NL=(:EM6GH[=RXV3+MLN.PWGM<QM&=U
MUI*$YUJ2A.*AF4H)&TBN9UA=+;)T^^S'D,K=)1@E*TDG!:3L`./!2[4SG]P5
M;6RNN'',GC$B@A+-5%5E=VZ^2233*81,=112=*F0H?LB80`,L%\L"RW?4?)7
MW@V#3\61.ODS2LUIB.PVIUYYU2`$MM-("EN+4>!*02>@*2JP.-LWN(ZZH):2
M^DDDX`#'A)/`*<;_`(D_=Z_[\/$_^?\`U=_K/E0G_A9Y2W^H&LOZ'G_J*7O[
M;L_\ZC_I$_OT?\2?N]?]^'B?_/\`ZN_UGP_X6>4M_J!K+^AY_P"HH^V[/_.H
M_P"D3^_6.F.\B[OA:(E4DN;W%!152-?D33+O[5XF.<S54"D('QGZ3',(]``'
MA$?`&94+DM\I1$UE:]`:Q"`Z@D_8\_8,PV_F*_%7NSE)_P`ZC\'_`'B?WZIE
MXP=Z71=1\<.[,T[K_?W#-G6(K2FA*_R6?;)W+4&-TU\H@375<FJ:SK(W^ORL
M?85XJT&<>6@PE4(LS!T+U(@I$26?1O:Y(FH-:;T=Z^M]2:;UTN[/7Z[O6-$&
MV25Q9@)FOM25/^!O-K9#D<(XKCHZY`>:XA:@M2V^9@7YJ/"@QF7HP;#38=S+
M&9/8@IPS`XX'AP.&!Q^@[I!27!=CW>.JKUR8UE9=WP>]K5R5U;2$=:NW#N2M
M4,KRIW=M>K2]1EVMTJ$3#3\*U;.9J%L#)^WE&311VJU<%;G<#FAN$7E!R.4Q
M>-/;J;M%L%PT]#L<^49R0E$=T:?M5OD-R6U19+CK+JE(BRH;K*V'7`RAYHNI
M:KU0JU"S-NSFU.H=4ZA.7A(XU:P0<P`(VJ2H$$#'`X8UT<0!(]."A4XDBJ<6
M2)CB1J;A-=%=./*S1*S(LDY*1RDJ5N!0,50`.4?`8`'IR+^XJDJN#ZIA29A>
M65D$$%>8YB"G%)&;'`@D$<&RNT1AD&7L<!A66S"KZI&.:-"VA>5M1DHVH4-P
M5V'L#MY;XIK8*I4;-")KV"AMWDE7[//VNE2D=[K:R-;8A5./D""X5D4"N2&0
MZQDW![B=1:2T^W>E:@O2K)<WXR4QG%,R)+#I#,M24/,,QY3:^+G?9TE)>9.1
M+#A:4',`K57-E]TM\4WQB`=HQ`(VIV@DI(Q3G&P]$8[*87CW#7*NZ/U9`;`A
MHNMW"%I4'%S=<A4*^UB:ZLQ:$;-Z_'MJH4E90:PC)-)J0K#I:`"70D(DZ!%-
M-Y<ZQW/7]WN.FWWI5D?GNN-/NEY3CP6HJ4\M4C\N5.J*G"7ORAS=>`K$5F0T
MNHBMH>`2X$@$##`?<&&S9P;-E3%G#UDT845D_P`&8J7]EJPOU]>5Y]UNO;"_
MLILY'6?MA=?24KOZZ]X_[.C\1/4%1IMP2!JC9PJ/&L>0->W03OWU>"VLF)`K
M<EUGCRJ&;NPLS5L'TZD>*2@/2%%'J&Z_0/UHO$ZQM.5"W5?:<7!"'O!E+_+H
MZU,C%/$*5P![,GBB0O$9<:).'@[F.`&17",>@>AT>ET>"JYNYZV;);AXO6'8
M<UL9ILZ<L.TWB\U.,Z?4JFUB9%/7.M4CT]D>DH)P<W#U)N5-C&JBHN[9QJ+=
M@N8BC3R=%SW+;TI%T3O;C:9@6M=IM\:T)#32I,B0IQ!FSB)*A*)=:=DG,Z^D
M!#;KZG)#84E[C'-+IMXR("GE+"UJ<VD)`P.5.SK=A`X!T0``>#`6H/(]A(D(
MG(,6;Y-,W7(1XV1=$(<0Z.L0JY#E*;H'HZ0\/1C0F),F*HJC.+;41@2E122/
MO$5ORD*X0#6/"LUL.GHKT&'2'0/1$L/"'[0_XOX0S)^UKI_.9'Z1?[]?/%H^
M@?N5I&QZW74Z/8S$K\&4WD(!T^Y$>/@%R@`@("W$!#'J?+JN-P?Y;&[QIY]Y
M;9O:L0I:B#_FDGA!.%<[JU"!IR60!CQ?T?X0I3:K!P1K/7"C`P0@,Y%`(>XL
M9Z@O40'_`-E_:RU)RH%*1R:=X2T$I6-%7H@@X$$6^1@01P$4B-EVWB(#P>$M
M]N*>GXL5OIZ?B]!]/J]/N2PZ?-\I#_:UU_G,C](O]^G(<6W_`!1^X*_WXM5S
M_P!P0G^:F/\`U&?GVK=/YS(_2+_?K\XIK^*G]P4?%JN?^X(3_-3'_J,/M6Z?
MSF1^D7^_1Q37\5/[@K_/BU7!\`U^$'[U,/\`J,/M6Z?SF1^D7^_1Q37\5/[@
MK_/BQ6O]'H/_`#2P_P`GS]^UKK_.9'Z1?[]?O%H_BC]RCXL5K_1Z#_S2P_R?
M#[6NO\YD?I%_OT<6C^*/W*/BQ6O]'H/_`#2P_P`GP^UKK_.9'Z1?[]'%H_BC
M]RCXL5K_`$>@_P#-+#_)\/M:Z_SF1^D7^_1Q;?\`%'[E?7Q:KG^C\)_FIA_U
M&?GVK=/YS(_2+_?K\XIK^*G]P5\_%BM?Z/0?^:6'^3Y^_:UU_G,C](O]^OWB
MT?Q1^Y1\6*U_H]!_YI8?Y/A]K77^<R/TB_WZ.+1_%'[E'Q8K7^CT'_FEA_D^
M'VM=?YS(_2+_`'Z.+1_%'[E:!M&MUQ.B3YR5^#`Q4F8@/N1'CT?]HM`]06XA
MZ@X_+Y9-QN#_`"X="M//O+:,BX8A2U$'_P`IG\()P-<QK)"!IJ20!C@CH?\`
MB)I:]=P4":[ULIH&"$!?FZ?^QHP!^Y7'J"#4!`<L;?,#<<:Y%V\1QI2DN"QH
MP()!'^>Q.`C:*2/2H!U%$!X.-^JJG4"L5L/"%>@P']R)8?Y/E-?[6NO\YD?I
M%_OTX/BVSPI'[@H&M5P?`-?A!#]V*8?]1GY]JW3^<R/TB_WZ_.*:'`E/[@K_
M`#XL5K_1Z#_S2P_R?/W[6NO\YD?I%_OU^\6C^*/W*/BQ6O\`1Z#_`,TL/\GP
M^UKK_.9'Z1?[]'%H_BC]RHGW-7*ZE3>L2OP8#[KQX>]$</["_P"P9L(9*G\G
M:=.D\K\MR'G7&_ZIW4X*6I0QQC=`DBN(W@)2+!B``>/1^&HAT]!P0WAH'N%"
M!TQ\D'26(CB#T>(#I#K$;%-T"&2W?-L==9Y%=V<94I#@O]HVI)!_/KZ(KA-"
M`'4;8/!Q3G4IN35RO&#H-`PQ@_:-%L1#_P"P4,J>"Z7,;1(?![HO]^ESR(^@
M?N5%.\A+2-*[=N=.I+*<MM2UG>K+6(6*A(U>4EK!!UB3DX>-C45(U\DK(/I!
MLFDB4Z*I!4,'6(8O2`]CN_QO^O++8KW/<CV:;=HC#[KCJPVVRZ^VAQ:R%H(0
MA"BI1"DG*#@H'`UCROR45QUM(+B6U$``8D@$@#941<=*DR<R,](R-<W%7A]R
M(=Z>O;CVKJ[<+&R)6$SI=E<85.IW79"]63+[E+))E;+Q,8Z*J;Q39;Q(&0[3
M>?>GVHL>+%E6.3^6=3QULM\^VK8+.4*C.F1%@B0?RB5$K1(?;*1G=1GP<QH3
M8*BI27!L&Q:TKQQZ(P4K#@Z&`/T'#9(^[Z[7DJ[%"G7X(!&:*`_]CQQO_87?
M_G-AZ/4R3+Y*4V9)Y0&JDR7G7$C1JR`I2E`'[2@;<"3MKC=XR4IM3&``_P`X
M^HJHWTW!0)KJF`P4'[U2`_2P\:4?5;^H8K8!#)&?F]//,<C62XPM2'/ZT6H8
MI)!PPE=$5R.@DI5J$!0!'$K^K5=?#9.P0/+:Y4332D'?]%2-SVE/[$:6B?LE
MG?LH&9>-WM-VE$V^X[BM$K>[M)3#<K&?%]66;J-*NW8-CF:%\H3A1WXJMMQW
M,0=1:Y$BV[PFH,!F$J.RPPA;S25)DP'(T:VQVXD5#1+L/BISK;Y0Y(=2'CQ:
ME&MH6BXJ:C8+B%2BK$DX`]BL$K)4HG8K%((V`;-M7B_%BM?Z/0?^:6'^3Y'_
M`/:UU_G,C](O]^NJXM'\4?N5BIVLULL),F"O08"$5(B`^Y,?_P#@:W_XOT#B
MI;C;I<U[Z]'H7)?*3JFT@@N+P(\/C_=K"N2$?9TC8/S#G0_P32')PD%^]_\`
M8,%ZI/\`N6+_`&P__%,O.S^RD=)SJ*IM*>A]ZK!4ZW7133_[`A/\`G_=3'_S
M0_Z#*#=PNES$]_\`SE_\\O\`[1?\8_=IT"&FLHZU/`.@*_WXL5K_`$>@_P#-
M+#_)\Q/M:Z_SF1^D7^_7WQ;?\4?N4?%BM?Z/0?\`FEA_D^'VM=?YS(_2+_?H
MXM'\4?N4CMR@H$MNLQ2P,$`%G9,`#W&C!Z`!TH`>$6O2/@R['R0UK<Y*>[=Q
MPE3BM$V@DDXDGP-K:2>$TW*_[+Y,`X/"7.V--G0*U7#TNM&-7X,1&*;^'W(C
MP_8'U`!N`!E5/EYW*XL\LC>.VU(>2V-42\`%J`&T<`!P%+?I="#IZ(2!CQ">
MA6W_`!8K7^CT'_FEA_D^-(^UKK_.9'Z1?[];[BT?Q1^Y1\6*U_H]!_YI8?Y/
MA]K77^<R/TB_WZ.+1_%'[E'Q8K7^CT'_`)I8?Y/A]K77^<R/TB_WZ.+1_%'[
ME'Q8K7^CT'_FEA_D^'VM=?YS(_2+_?HXM'\4?N4?%BM?Z/0?^:6'^3X?:UU_
MG,C](O\`?HXM'\4?N4?%BM?Z/0?^:6'^3X?:UU_G,C](O]^CBT?Q1^Y1\6*U
M_H]!_P":6'^3X?:UU_G,C](O]^CBT?Q1^Y1\6*U_H]!_YI8?Y/A]K77^<R/T
MB_WZ.+1_%'[E'Q8K7^CT'_FEA_D^'VM=?YS(_2+_`'Z.+1_%'[E'Q8K7^CT'
M_FEA_D^'VM=?YS(_2+_?HXM'\4?N4ENK^2U,V?R.N6AXJA48[:H'V05Q9(N8
MA9DJJ-&<:P8QCE`[6-+"RCJ;DKE+(/X]@\=/ZXI$)$DDT5'J9"+OJW=5?=);
MKX.\29<;@'9H@Y6'&G6L#+$]:TD*7QK:6D1HZV7GFVV9J9*U15.)84I6L8G-
M/S51$H1@G-M!!['+AT,#B5'$`DIPZ[#&F.VM6ZZG19DQ*_!@(&C^@?<B/'_O
M%J'J"W$/4''(?*UN$]_EOZ/:??>6V6[IB%+40?\`RF:>`G#AK4:V0D:;D$``
MXHZ'_B)I9J/!0)KC62C`P70,RS`?^QHP/!UQ_9!J`AED?EK+6WR0]Y+C9*7!
MI">00<"#Q8V@C:*2#3@!O\,'@\(3U:=WXL5K_1Z#_P`TL/\`)\I8_:UU_G,C
M](O]^G$\6C^*/W*/BQ6O]'H/_-+#_)\/M:Z_SF1^D7^_1Q:/XH_<H^+%:_T>
M@_\`-+#_`"?#[6NO\YD?I%_OT<6C^*/W*YJ.>.@(79>_.>]H-HS6-BE=;:UK
MEDJ%P3YF;;T;?8L],T)1-@3]G8:%HT+:ZILQU0I:`KC_`*[L\$#CR..;N/WH
M$W9Y4N3OO(GZ5W<[N;0-07:+#NMU?8DQCIFW76(X)5WEPV6%W>6['D04RVWI
MK6#8EY.,E.M]>5,IXB[0TORY;G%-J4A`(/'+0H96TJ)XM((5E(2=N7'!(/TU
M,'>5*6.>Y#4W5U4Y+7C02$WQ-5F9:/@..?('?5=D&$C,;-UR,FU8\>[;'OJK
M/)#L%1P=23C#-G*L<Q%)R)D5$@XGDKIM=NW:3M77C2MOU&Y'UD&FUO7JSVAY
M"T-P9O%J7>8RT2&3X&$`,/A:$O2,[0"TKK)O>=<Q+#;ZV08^)`;<<&TJ3C^3
M.P]=CM&!P&W95LG`]U)O>%'$MU,S,I8Y=;CIITTG89QP]=S,Z^"A017,S+.9
M)5>16D9-8HK+&<',OXPX]<1-TCC-N4.S$8W]:S:@L,Q82=3W/(RTE*6FD>&.
MY6FTH`0$-CK4A`"<H&4885T-I*C:XY42I7$HQ)X3UHVG';B::_$<K84@W>`R
MDK):YJ>H(V#V29?<]QKE7AKIKRRV.I$JUO:7.EN8%C:YZJ5JTS$569B/7D7;
MMR1HL"36)6`$SJ'3ZKC>3=$AQ=3S-;2I%K#=B@OR'8LUAB09$9464EY<=F0_
M':<?:6&6VT%Q.9R0@E24A6.HO"E*93&2%XNJ`"DDC`YDX8D`D`[23AP`U-"/
M(_7U*X_4/=NWW;O5,#8*U77*\?:#R<_.L)>3A%)$E?.$?&JS<[.'29+"0OD:
M;UP)!\8W26$R)>$<W7:EOV\FXZ"T2A%XN,:4\D+CAMEI;:'0@O#.L---`J3B
M>-4T@'K7%H`6<H366H:)4DEM!2-AQ)Q(QPX,2?O8_<QV5.%2M<!>JM7+K5)$
MDO6;9"1=C@)--)PW*_AYEDC(1[KR9VBW>-3+-5RB9)9--9(PB4Y2F`0#@+U9
M[EIZ[RK#>&BS=8<AQAYLE)R.-**%IS))2K!0("DDI4-J200:RFW$.MI=;.*%
M`$'[AX*V'-97W63_``9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_L
MZ/Q$]05`_):0KL;Q^W*O:K4UI4*OKFUQBUG>;.2TNG&/9J)<P\.*.UUGL<GK
M]\\F7S=NVE/'%%JX5(<`,(`4=WNKC7.5O)L;=GAKGSTW2.X&$P#="XEIQ+KN
M-O"5F8A+2%K7'RGC$)4#@-H\YQ0F&Z7%94Y",<V3#$8#K]F7;P'H&D@[HB91
MF^,ME<(6`ML*VV]/L5K(K<EK/*2<@A3J&:51EX@^Y]\I4AW"2BBT<FR3G@+)
MM6:4T+1L,J)3+]RU(*X&]>(TY&\#*K*RL,",&&T(,F7Q9;<%LM!E)=;"7E.J
MB8L..+@<<Z(8(U6G5!4%1!S?E#MS8D]:G'$9W,N!V89MH&;`9JM.QH5;^C"B
MM'V5V%LGM$OG*&/7^7+SW-W?IM7DDFN<U=[-R^Y_6%*/5.U-;].Q/GR&6K^5
M'S9]X?N3>O5TBD/LOGF)XRWVXI\,H\TY.C"BC"BC"BC"BC"BC"BC"BM77O-*
M:V-&GNKA5FUM<%2.WJR]@B4;&N19,RJ)T811V635*JD03%$J0@8H"(>`,V[>
MG[\]:U7MJ#,59DD@R`RX6`0<""Z$\6,"<#BK8=E>9=:"^+*D\9]&(Q_<X:VC
M-17I1A11A14?;4[!6#[4S^$6>/U^6)SY-">,7#U3/KE]9^S4KI([XFEFUSVX
MK?M\WFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJ=K*95.&HPHHPHHPHJ)-U=B_
MOQ'^LODK'R;^>$?=*Z]6-7#[P?9_^71^&H<T[VY9^CY+V$N2Z_-PYE%V]/VC
MOZZX+0?M&WW)SJ"F^RIE2ZU%&^:ZWM^CMR51XO8&S2RZKV#`NG%3@W-HM*+>
M7J<LP64KE99B#NQSA4UQ\DCTOWQZOU42^$X9V.[NYNV3>!8[PPF,MZ)>(;R1
M(=2Q'*FY#:P'WU=:PUB/RCRNM:1BL[$UCRT!R*ZV<<%-J&P8G:#P#HGZ!T>"
MJ_.ZK2B4J=N]*`A:W`0[3:<FT&.=T2$UEN5.87F+//RJ>S*%"6.WDIU7C"3Z
M$=38I60%2.A&(H>3-BD`@N3Y8"YB[Y8%W)^5)FKM#:LZ9;LZV%H-,,MF#+=8
MC&2^YQ*WKG(2S@]*=XSC72HJ&GL&7BG<@2$AP[,H2O'$DYD@G`#'!`QV)&&`
MI[=Y]G8GTT7S%YCV/DE\X+5?N8OUE;ZYS>/YJ8\8^HNHRTV;JW0IA`1`L1)&
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M``?T2>N&7K)_92.DYU%4V=/0^]5AB7V-/Z@GUH90,N/G!_NR^V-.D1V`Z0K[
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M:^4@V;^6"@+SQ"7E8M2J%;"Y\67QXMRJF.J5`5>GJ`81,!>CI'IQJ#O%<:KB
M,W$9CES89LN.S-ALQPX<-F/!6\&.&WAK]L\Z_:,**,**,**0/5_&Z1TOS!V7
MMESMV,5J>]TII>HZDCJ,YA7;2=(SKCZPJ2,^SF'59<L(U*!,Y0\3%QCQVX>J
MJNEW*_C#KN.U;O2C:[W)6K1K5E=%YT\6A)N*Y:74J9*GT,A#*FDOI6LO!"\T
MA]MM#2$--M-Y4MZAB$J+<ER"X.+=QP0$X;=F.)QPV88\`))VDGA;7;/8.:^J
MCOA)IB^_*PY\6C^YW7U1.K5:V]FI'31WQ-+%1>V=8],L_KQRRCRV>:!O*]SY
M_>Q2/Z<\_P`/QA/5IY,I1TXRC"BC"BN>CO#67#ION3E@-KJ?)*#Y/CQ:L]H@
M;MIB\[[M=!GHF:UJA32([/HNA;'.P^IXYX:K1L?)*WR%AH*PQ,<14KQX@V=%
M;27<F>1OO<T/HT6>9I:1NE_K>Q'>BW.):(\QEQJ<9),"7=V&G;BM/A#[S";1
M*DRX<AY2"PPXZR7>.O(MHDR.,2^)_@Y(4A3A204Y>N2V2$#8`>,2E*@.$@'!
MH^9$=.4#>&G>0,+SFT+Q7)#Z^J%=G:-NV(DI*+V'&QMTD6$:FN>$W%K%T6HR
MUIV@P9/4S).$CR",=U54Q^D.D>XZ5;]2:`OF[:=N^U%J]3]RDO,R[6XA#D):
MXJ%K(#MMGI\);CP'G6B%(4&52<4*&U.?<DK9E-S$RV8^"`"E8)"@%'#@6G82
MH`_=R[:<G@L"I>&'%<%S)F7#06JP7.D42(G6^)L3XTZ)#'5,1$ZG2)`$QQ`H
M@`F'U10[E"%!WZZO+>(;_K'<,`=I`\)<P!.`Q('"<!MZ`X*V5J\V1\>'B4=J
M*:O$>K84G',=IHJ`J]0VYO2NRUEBZ)/&J<$QCY"J1;8DGM]>+I2+M[,WF>JE
M7J2L?*&9.FD\I+P[J*=-R&;O""H=%=<-Q[V\*XW:;HO=])9BR[C'\(=6M$AQ
M1;MH<E%*&HC,B1("V^-;<B)C26Y#:U!QA00%MZVY"(AM,B6DJ2@X#@&U>">%
M1`&W`A6((/`>@4:Y@6+7VI>%G%^BPEB1#7#YY1)"(B-@N'UUOVQF=.3B;#7J
M^QVCJE=[2JY;W\VZ:NU[,C8(]'QJ/69NUBJ*`9P6Y.V:EUGOWU;J&?%5_6AM
M$M#CD-*(L.$J27&7GEP+@$RGXR&DN-I@JAO*RJP?904I(U5R6S'MC#2%?D"4
MX!77*5EP(&9'6@XX'-F'W":M3T)`6ZJ:.T[5[^5J2\UW5]#@[B1DG%I,T[/%
M5B,8SB35.$(G#D;IR2"A2`U#R<"@'B^DG0.,_P!XMRLMXW@7R[:;SG3\J[2W
M8Q67"HL./N+:*BZ2Z24%)/&=?CV778UOXB'&XK;;WYU+:0>#A`&/!LX?HV5+
M.<;6163_``9BI?V6K"_7UY7GW6Z]L+^RFSD=9^V%U])2N_KKWC_LZ/Q$]05$
M6[]7#NO4]XU4%^OVKBWB&-"*WW5TA"1.P*XW5<MUG+JK2MB@+/%1DFX;HF0!
MP9DJJ@14QT127*FJ3,T#JX:#UC;]8&VVZ[FWO\:(<]#KD-]02H)3(;9>8<<;
M!(7D#J4K*0EP+;*D*^93'A4=<?.MO.,,R<`H=(D$`_=PZ6VM`XI<8ZEQ'U,V
MT[1I^9L-98S<G-L'4]7=95V304EDV?EJ;O\`)=0=>QD\\=O6RCMS*239Y-/G
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M,<P[Q!([OZ1ZY%RV?A9=3:NT/R4Q-LKJ5*?8EP9`<>>0&(D^6"8P@^#JB2TO
MAQ$Q,U;Z)+2U)9ZYAH-.\PXRQ)OF5P<!2H8`'%24\.;',G#`IRX$'AX3B+JL
M8?73T844845'VU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?LU*Z2.^)I9M<]N
M*W[?-YJXRR!\P?F5[Q?0:/+HE)#I3VBB=U^JJG9*8INGJF*;H,)1ZH@/08H]
M!BCT>H8!]4,IED$<(PIPU?[GY11A11A142;J[%_?B/\`67R5CY-_/"/NE=>K
M&KA]X/L__+H_#4.:=[<L_1\E["7)=?FX<RB[>G[1W]=<%H/VC;[DYU!3?94R
MI=:CK<$79IS4VSX6EV=M2;A+:^N4;5;D]>+1S.J6)]79%M"V-W(-TEG$>VA)
M%5-R==,AU$2IB<I1$H`/3Z)EVJWZRM,^^Q%S[(S<HRY$9*0M4AE#R%.L)0HA
M*U.H"D!!("BK*2`<:\9*5KCN):5E<*%`*X,#@<#C]P[:4KA-79MI,;HLODU;
MA*>XD*G0HVO5W:6R-P(+W'7BMN3N-U2N&S8.(EUHVUQUBATVX-S+-G)H]5V;
MJKN%3*+-OZN<!Z#8K5GE2+VEN1,6\]`@VTB--$8QHIC0'7&PN.MF2I><)6@/
M(9&+;2`G76M"@IU?6AO$)`"E+VIQS*Q4`<""/N'#'A-,;O/L[$^FB^8O,D/^
M27S@M5^YB_65OKD]X_FICQCZBZC+38"-T*!3"41B)(`,``(E$?)^@P`("`B`
M_M^#)'_F_$#D9R"=H_K3:>I*KD-`^T([@Y]6D![M,D]-;YVM(Q6WYS<E4HM0
M=5"\W621V?!I2]]GPU<Y@HM2K[;V?9[2B>*4IUGG"K$@HEHB\MCY!NH=`$RC
M!YRJ56Z!N[L\699(]CO%PFIDQ(J#`=+<-GP]+S@?MT!B.0X),"*4F7(<4U;H
M[CJ4N9C2DV/.J6XI+A=;0G!2CF&*CEP&"U$[,%*[$#%9`V5=QC!ZZFL3/>\4
MUZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@YVIKF_EMD\H5.9S.+;[IUY&<?(7D
MQ3]3!4FCJLF4F@M>CF=\D-86A)S1%[*VV#&-XE=_'D0FR"ZD9YJ(J$;M19*7
MJ[AV4CI.=15-G1T/O5TII?8T_J"?6AE`VX^<'^[+[8TZ1'8#I"OO,.OJC"BJ
M=.8O*2$XW7BO,)'7&Q]C26S;K:(R)9T".9.21C>O/8AQ89"7>2#EN@B9A!2R
MSY!L7I6?`Q402_?CI@:[CR/^:ANV]R+/Y$U3<+_Y\F>,N=L:M=H1!2IM=2$0
M,*<:B03%_P`$PD$Q1$O3X>@>CP95)Y?'/,WD>],OJBEQTO[/0^X)K;L:)6^H
MPHHPHHPHJHKE#'U+_B&<7S65<B#LD96['6GZ)JW-2I9<VSHFM*0DLG8]G5!Y
M3*<N\6C?<X\=%3"TE*NW8)HG41,07I[I)-Y_X:-6BU)*F2Z^P^@\>TWQ?@#C
MX=;+$"2F5)"0_P`<'I$9+$=MDJ<2E84.=GI;^V6,_#@".`G',!@<5#*.##`'
M$D[-E6ZXRRNBHPHHPHHPHHPHJI/CHRA7/>3<I'CN6L+:ZPD=/,TJI+2L].%;
MT:72U3)QLLQEBH,Z\TK4I-*N7;:&,5=W'K.AZRHI%;%(\[>?(GM<EG2+#+,9
M5AD.LJ,AMMEK&6V;@VMM;>*GE/MM!#:Y(*&WDM[$!9=*N=A!)O<@DJXT`["2
M>M.0@X\&!.)">$8]*K)=L]@YKZJ.^$FF=[\K#GQ:/[G=?5$ZL76WLU(Z:.^)
MI8J+VSK'IEG]>.64>6SS0-Y7N?/[V*1_3GG^'XPGJT\F4HZ<91A121[OY8W'
M2^Z*?K1?4=?L$!>$$#U"55VR2HW>_2"7BPFZOK.MVR@QNL;=?(GQGC4JZM>8
MZ=D6A#N&C15,ANA?-`;F[)KO0DW5;=ZDQKC;U$26Q;O"8L-!QXJ1.?CS%SXT
M1S#*J:FTOQ&'"EMYY"E"M7*N#D64E@M@H7P'/@I7TA(*0DJ'\7C`HC:!54W>
M?\A;C=H[F[QFI%^A=*1D+1M72URFX+B_R0M.TKIY13(#:)H!SNO4\^MKBKL+
M1`0X5AZ%H9M`91+IP5P55F(*&>'R2]VECL,G0.]:_P!N?OTM^X3VXS3M^LD>
MWQ<LIZ!QR;7<61-?6P\YX>T8#KG&R&VBV4/C*.?OLQUU,J"TL-)"$E1#3A6K
MK0K#.@Y1B!E.8#`$X[*Q7?-7>`I6S](1KNKQ,NEMW2LIK/8+"%W?0XO9%QUT
MXMT>\3JL9HB2X^[^VJ[BHV0=.5DKU2VK"4@3/'*7CR&,BJCF<A>P7&_:3O\`
M*9EO,+LM^;G0UNVJ6Y"C31&6DR'+LB\6>WI<6A*$JM-T<>8EAII?%J`<0OYU
M,ZAI]I)2#QC12K!:0HIQX`V6W%X#;^40`4XG;P$7*<!DT4>$'$9%LV39MDN.
M.G$FK-(RQTF;9.A01&[-([@I7!TVJ)2IE%0`4$"])@`W2&,;Y1JG%[_M:+=4
M5NJU1<RI1P!4HRW25$)ZT%1Q)"<4[=A(PKI;1@+7'`V#B$=J*;;$8K8TB?>)
M*LB<?6)'DL]K_7VYI\Z5B@IY.K7*N"C?88QYVAVB0D(FKURX,2CU63R><HP2
M9U.J\-U#@`N%Y,J'SO)<4PRW)PLMR!9=9,B,_C$=P9EL(0X^_&7PNM1$*EJ"
M<6!F3B-3></`QB2/RB-H."AUPVI.(`/T%1R_34>[8A=WV;@QI&"KZ3O8-NET
M=-,]JAKV7<71K:*4LR2"\."2DO/,YZV0[\H)J.%&LN@[<](G(LLCUT%^FT;.
MT!:N4%?[A<BBVV5E5S5;_#&TQ51Y04?!06VV5,QW4;0@.1EMHV)4A"\'&_&0
MF4NU-(1U[AR9\IS8I_A;2<2/IP.)^DC87IU!##7=3ZS@!C7$,,)0:A$^Y#M-
MTBZBO<Z`8-/<YPB^D)9XBLR\5XLQ%73A0HEZ#*'$!,+>];3OM/65VN7&I?\`
M"+E)<XQ)24N9WEJSI*$-I(5CF!2V@$'$(2-@VT9.2.A&&&"`,/HP'!T>J:D7
M.8KVK)_@S%2_LM6%^OJN[O&]];TT-3-8/]&(.&+J\;G)3K[>F?&7='+AUKFE
M!2+W8PL2>E]'2E?M,JG)6J`C(E1\M((-8\D@*HIKGZA,6?<QNZW>[Q-Z6KX^
M\%27&;?'ER8D15]M>G$S97VDPQQ)NEU;>CME$=Y^0EI+*W'BR$!3:<RJUUQE
MRXD*.8FPK*0I7%+>RIR$XY$$$XD`8XX#'HU/7%.[6[8W'_7-SOEE4N%MFV,R
MI-6-71>P>-*LDNSLTU'(F4T=M65F]@4`S9HT31%"2=*J.O%^5)B"*Z901'?#
M8++IC>1=+%IV*(5ECN-!I@7:'?`@*8:6<+K;VVH<S,I2E9V&TI;S<2K%;:B=
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MX;#B4%*1A@03@I1`Z!P.#X8W>MM1A11A11A11A11A11A152S>2GX[O:9F`"I
M2KZ)GM;56SA8Y6$J4TG#1I-=72!=/JW;75+6L=)K*TY`MF`PC>?1<24JX?/0
M:>2@X.H\QR+;97(S8N1FLMS(]UD,<0V[(:+JS-BO)0_&3*#$I\-/+=\*7#4A
MB.B.QQW'%M*>>"EIU"4924E`.)`.`RJ&PY<4C$`9<VTDG##&K:<9G70U#3+D
M%J&0N7Q#:6X%)\TLM7T%S05F1J[RQ-SK)+UN.O:\,G1Y*R)+MU$C1[>14>`J
MF=/Q?7*8H=R_NVUK&L?]8GH6%N#(>(XY@R$LD`A]<0.F6A@A25!Y;*6LJ@K-
ME(-8PF1E.\4%=?CAP'#'Z`K#*3]S'&O]B]_ZGF;82EQUE=JRR\FZ@V+]6JW%
MG3I><9>/!U!P.PGL`WH,_-HF:JE%FRDUW/72.7J=8A@#\E[M]90;,;[)BH$)
M+275H$B,J2VTK#*Z]#2\J8RT<R3QCK"$8*2<V"@2)F1U.<4E1S8X<!P)^@*P
MRD_<!QK8]J=@K!]J9_"+/'>_+$Y\FA/&+AZIGUH-9^S4KI([XFEFUSVXK?M\
MWFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJKDT/JB*OO>H;GV'6YR4U^%)NULO
M:9HIT\92VX8Z2K-`K$\6RN4:72H;8NL7RCUJI7ED9.UI0(H.T%5$W+A`&->7
M>)K&9ISD@V+3-TCLW(SX$>(>,2E3=M6A^8^SQ"3*E.PIZ`EP3$J8MZI>9EQ"
M5--N&0K$2.EZ_NO()1E45;.%8(2#CUJ0I/!EVKR[1PD87ZY')774844845$F
MZNQ?WXC_`%E\E8^3?SPC[I77JQJX?>#[/_RZ/PU#FG>W+/T?)>PER77YN',H
MNWI^T=_77!:#]HV^Y.=04WV5,J76L'9XE6?K5A@D%8Y!>:@Y:)17EX="PQ**
MLBP<,TU92`<KM6TY')G6`5V:BJ9'*8&3,8H&$0V%IFHMUUC7!P.J;8D-N$-N
M%EPA"PHAMY(4II9`P2X$J+:L%`$C"OAQ.="D##$@C:,1M^D=$?<Z-*UQ=T[!
M:WFM@6=I:H&Q3][@-<DDVM)TPST=2XN'K@W,:^;XI1X.BJ75\I///=-1X[4D
M4V:+!(Z#=$B'C5=WMZWN&J8%MM+T.1%MUNDS2VJ5<U764XZ_X+QW^<+RX14!
MEOB$M-I9+BI*TN.N%S)@0(R&%+<"@I:PG'*C(D`9L-G\;:<<3CAAL`PJ5-Y]
MG8GTT7S%YDE_R2^<%JOW,7ZRM]<=O'\U,>,?4749Z:$"W0AA'H`L1(B(_M``
MMQ$?_LR1_P";\">1G(`X?ZTVGJ2JY#0/M".X.?5K5]2[RINW=ZUV5JNGY*D+
M7'33RZ1.U+K0:XTF]N:[%+6DPT:4ZWP5P=3;:'K2^PX59ZWE&"K=5P[,W1,B
M[8/4B5P]9[OKYHK=[*AW>]M3VX-]3%<M\68^IJW3<9S2E28SL9+2G7Q"E):7
M'>2M*&PZX'&9$=:E=CRFI,M*FVR@J:S!:DC%:>M/6D''`9DXXCA.`P(-/#B`
M5M:Q,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FN1W:U^O-,YQW*9C>
M/EDM];UQR)U->+FZKMZEU-<1<7;&&L]=UW>URUJEMM6M0^ST:E+2[=G.O*N1
M156,:"FDHL!7.7JY_92.DYU%4V='0^]77QU/%_O?3T]3Z3I]3IZOTO3T>'HZ
M>C*!MQV7!\?^,OMC3I$=@.D*,PZ^J,**Y9.<N[Z?J?O*[)6G=_W17;7M*A:2
M@XR)HW)?6/'.@)/X*X<@;#'R.QE+XNX=S]//`L)8TA(MT`,R71:1C=!\[ET0
M1NX\C_FH[MO<BS^1-4W"_P#GR9XRYVQKICUH^8R>OZ?)Q;MK(1<G`1TC&2#%
M0BK%_'/T"NV#YDJD=1)5F\:+$42.4QBF3,`@(@/3E4GE\<\S>1[TR^J*7'2_
ML]#[@FMXQHE;ZC"BO!)2L7"M%'\Q),(EBEU05>R3QNQ:)B80*4%'+I1)$G6,
M(`'28.D<R8L.7.>$:"TX](/`E"5+4>DE()/[E?*E)2,5$`?=KWYC5]541RXK
M3V>[P_AK)E'7[)G6(E@Y1>W&F6AU)/7LCLV.67:5NQ0NN;9"6";;1\$9%E'R
MDQ7T:^[D22Z9W"G0+9ZFY>ZL6[DS:YBG[2<?EO+24QI4=*$H1!6`I]EV;'=9
M:4MT*=>8C3%3&V%0E):3B'><N*"N\QE=8`D=%)QVJ'`0D@G9L!*<I.;;T+=\
M9771U#:G('42-T-0%+;U;"283KBBWN#9C5=*RJK`V3K"U\+"C1D;.=V/B`C3
MR(/A<#XKQ7C/I<[E.[;6J[#_`%C3"_\`+"P7P..8\(+`&8OB)QOA98">OX\,
M%K)U^?+MK&\,C!WB<W7XX<!PQ^C-AEQ^YCC4R9PU9-0XSW]J=_;BTEK9'AYA
M286KK9^I5+BWIKZQH**HK5R-V(XKZ6OY.PD<(*)"Q;R:KOQR9D_%]<HE#N']
MW&L8UE^WWHJ!"#`>4@2(QDH8(!#ZX27C,;9*2%<:MA+>4A6;*0:QA,CESB@H
MYL<.!67'Z`K#*3]S'&ICSAZR:IRXL?&);GGME_<$Z\Q74<<@86%A6%KFYN-2
MG*[)\?B7>U5:"]Q&,-7IZZ,).$=6(IU`*#D"(M!6,F^4%\&][[,1R=K-'LAD
MN-A-G===7'::66GF[QX+'D.\:MUYF*MN4W"(3CDS+>"`J.D<U`SF[.%S*#^4
M`&)(Q!;S$##`%6*2K[NP8[:M&VSV#FOJH[X2:9U?RL.?%H_N=U]43J\-;>S4
MCIH[XFEBHO;.L>F6?UXY91Y;/-`WE>Y\_O8I'].>?X?C">K3R92CIQE&%%44
M\W[+-+]Y=P]:?$1$:[10IA)NW7_4=?V)2X=ML'<5#B:O?ZG.0E?V59JQ:/C>
MF:IL7<L2D)P\G(B^1?.4C%42D*W`VJ`WR5=;O?:*OM.X>%%J-#N+T*4XJ';9
M;DB'(:=>@L/L>#$7%UN.;JJ2PSX.N.TL%*^4NBU&^1ADZQ&7$J0%)&9:0%`@
M*(./6`G)@3B":3;O;Y:YLN1&\GL)=[94-.0.GJVSV^KK+=W+2@5F0V/>*5+U
MO6]>Y+C4->7'0S6-GVRC)I"UY,\8M.G=,RSTNS8OFR*BX\C"%8G]V6GV)]OA
M3=<2+V^JVB?:M.S'T0HDIM^<]8_"9L:[J6RH.N2IB@^F(&WS;H3\B.ZXG6:B
M4Z)CI2M28P;&?*MY(S*20D.X)4W@=@2G9FQ&=0!`JTSO&MQZ@T=J-_=]@\4X
M'=MOC]06<=9WV_T#2,]K*NWGW)=&IM)MM@VE?*9,,6L]:2-U%F$4"RR[;KBF
M/C0*&-$Y,&A]:[P-:-V#36L9%@LKE[8\.APYEU9G/1.,3X3*C,P(DII:F8Y6
ME+TC*E"\H5UF-;^]28T6.77HX=<#9RJ4E!2%8=:DE:DG:>@.A3*]WVLNYX*\
M/'3I%!LZ=<:-*.G39L04VK5RXUY7UG#9JF(F%-LW6.8B9>D>J0H!TCT=.)5R
MDVVVN4)K=IE2ELHU7=$I4HXJ4E,UX!2CT5*`!4>B236;9R3:HQ/#Q".U%-]B
M*5LJ1;O`6FK8;34=MK9&EV^XW.I;?`RU30-=W6MG-3F++(-:L6P*W5@_CWD7
M!$<R+<L@03*MSI`559,2(==-PG)N>U=.UR[HS2U]58VKS">;D'P5,Y,AMA"I
M'$B*M"TN/%*%EDX)6%8H0K,YE5J;P(Z8PD/M<:6U`CKLN!.S'-LP&W;_`-/!
M2E<EI2T6O7_!Q*MW3^KPZL54CI=.K$W3LVO,4E9/87&BH-8V-V30V$S(6-1]
M%WQS76SV59*`WB[.YENA!TR+U5FW50[19M2;P%W2!_69F+,6V9!M<!Y9#<.^
M25+7!EK:0P$.1$35M1W4E<B`U"Q<9D''7SE..,Q<BN)*D@X9U#A4T,`I...Q
M12"1L"BK815M^O8HD%0Z5")MHUF2(JE?C"M8><EK/%-P8Q31MXJ.LL\4D[86
M1/%]";YZ`.W9.A5;]\.;&8:EF*N.HI\]2G5J?F/.9G6FV'#G<4K%;#.+3*CC
MUS37Y-L]8CK4BNA93D92G8,$@;"2.#H$[3TSM/1K;\TE>M9/\&8J7]EJPOU]
M4J=\(UJNT&6KM$VJC\K;(Q-9)_9O4T7H38FX:-:WK>D;'I5<K5I7U[?*!)>[
MU/MT]'VE)CY2X3.E%D\:W,58JJ+ON2Z]>-):]U?O#L]PT=%D"6[`QNUWA6V7
M'2JY193[\<3(DQ'$R8S+UO4[D00I\Y'`6RA>@O0;?BQXCB)"AE"OR;:EI/6*
M2`<JDG$$A>&)X.#;L:SNSJ"_UAP>T3292-L<+(14?=G3J$M6M;AJ"8@U9W9E
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M>.B3$U!;VULP'VS<`AA$J1=9;4LJA(%]?2Y;GXL4.LMBQ1WY"X:9RI65IQHK
M*P_QVHSE4TLXJ!R;2D(24]=^2&"PI6!/&D#-ER[0:OPR.>NNHPHI"8+DA?6W
M)%_J.Y3E:08I6%G"E8P^G;O)51`)IFH\K\4KOZL[`N=5KE^=D.GU(2V057>2
M?08620IF155<7<-UVG'=UK>M+''E*D&,IW.[<XJ)!XI02\X+._#BR'X:2%8R
MK=+GML;`^O,%H1J$37A-,=TIPS8;$*(V\`XP*4`K_!6E)/0Z%/MC=*V]&%%0
M]+;XUM"6@]3D7EI(\0D6T.]G&VN-CR%"BY=XJW0;Q<QLN/JCK7L._,X=IIF2
M<R:1DE#E(IU3&`![>'N[U3/M`O,9$,L*:4ZAI4V$B6XVD*)<:@KD)F.(P2I0
M4VPH*2"I.(!-8RI;"7.+458XX8Y590?H*L,H^^:F'.(K)JHXD-2D.]=>V!]$
M,'EO?1<)$11FUKL,5-1QVNA;*\3N4CK<PNV=J@&\2:0A$K40S2'9O),(LR2L
MF0BH/15.OSG(Z;ML=YQ%D;>=<<S1V7&EA5W828R)W6JCO*<XF4JWD.27&V/"
MPM$4E%<[E:&H"L@%P@`;2"/R9ZXIZ(PQ3GV`$Y>RJW'&75T55&H3$A!=Y]92
M%N%WV$5Q%P;%IKJ)W338='64)8Z=2XR955T%99UA:+S3"R8-+!(3L2@9**,1
M/J$45*N59Z+D&-<.29%485OMA2\ZM4URUR7#/=8DREM`7AAE;$25Q?&0V8DA
M85(!5BI*"V4<Z%*1?5=<M>P=:%I&4%*0?R9.*DXX**AP?NXX;1=J)+=YQNN$
MLM[LZ]T@H289HT5OLRT6"DPL,^@:1()1<+4I'7M:30B2I-4I%PZ<JE01E5RM
MVBSDA"'4SMX5G,/DGV&?:K=$38I$AI1EJ@QV93KJ'I2"X[)1,?)<Q4IE#:$E
M:HZ"Z\VTI12GYB.9KZZE:U<:`>MS$I`P3L`*1LZ))Z.P$U:5M3L%8/M3/X19
MYMOEB<^30GC%P]4SZ\]9^S4KI([XFEFUSVXK?M\WFKC+('S!^97O%]!H\NB4
MD.E/:*)W7ZJJ2'ARUI</WF?+^%@$:G'+1*=GK\:RI,74*=`)Q<>WTW)G@E*G
M':#UW89.?K"DJ"3V6^-=I8+*JB0OB5"F*2N%OP>OL[DI:)GW%4QU#Q8>6J4Y
M)DO%Q9N;8=$A=WFLMLOAO,U'^S[>\E*0HYTD%2NVT-)ODE*,H(Q`R@)&'6'#
M`-I)(QVG.L=*G6T1R:MFS>2>^]*V=*!BT=725D2@(J*K+43/X")GH6+BIX=C
M);>GBV:0<M)0II2,2J44>"=KD;.G`*%2\K0?>'NHLVE-UFG->6DR'EW=I@O.
M./JZQYQEUQQGP(VUGB$)4V0P^JXR!+;0IUEO*5\3M(DYQ^<]%<P`;)P`'0!`
M!S9SCP[1D&4["?I>+&_UM:,**B3=78O[\1_K+Y*Q\F_GA'W2NO5C5P^\'V?_
M`)='X:AS3O;EGZ/DO82Y+K\W#F47;T_:._KK@M!^T;?<G.H*USB=R8MN];QO
M2IW%*!BY+5MNEH-&`A*TU9MVD8VO-YK,1(-+REMV[!LAI)1U5(99ZA`U]NTD
M"N&AR"X160;UL=\FZFR[O;!IZ\V0R7HMWA-NEYU]2E*<5$B/N(5$-MB^`J0N
M00EI<N8MQDM/!7%+0XXL%OG.2W76W,`IM1&`'0S*`Z[.K-B!PY4X'$<((#([
MP@7-ITOMVLLTK0N\L6L;[!M$*0,6%S7<RM5E6*"-2]W)>O0OQF657`K'RQ^Q
M:^5"3QKA%/K*%2W0%Q:M&N[+=GS$2Q&NT1U1E<9X*$MR&UDR>*;>=X@`8N\6
MRZYQ>;(VXK!)S92"Y%<;&;%3:AUN&;:#P8D#'Z,2!CT15?\`W;3AE+3W(R><
MT&(T_>7,K0&.P-4PL1#U@T%/E&^6%:QVJK(;)V'8(FZ6AU9ER*%=&;L&T.PC
M6$:H[;,?'8Y'E2MR(=NTO;FKD_>]/H9F+AW!UQU_C6?\T9#$>08,)ER+'2P@
MI+86\N2]*D2DLNR,E:BR$*6\LH#;N*<R``,#UQQ(S*(4<>C@``D)Q`QIX]Y]
MG8GTT7S%YCWODE\X+5?N8OUE;ZYO>/YJ8\8^HNHPT[UOCC]*8"&]QI/JG-T=
M4ANA#H,;IZ0Z"CX1R2#YOF'_``:R,1B/ZTVG9].R57(:!]H1W!SZM)MW<(WF
MTW*;OI]?4*M5E.MSE=NUOJR=0:GM=P?5W0%CK80\+'Q<9-0%5FIMU=K<S,Q;
M,8&4C+7'.D2N.LD9"!_E0_U?M%CCZ=3<KC*NQE-/18T@R5"/&0]>&'^-=6XX
MT](::3:[<Z'5NRV'[?)966\%AQ3K+QKCI>R(2WE(41AM.#9&`P!`)SK&`"2%
MI(QZ%PN,CKI*Q,][Q37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FN,?D_#W
M*G<R-O6BBZ\W]#QUSW1J:G[2L`/4R:WMM0N3C1]C0G8LBF@W3-[4DYG7RCF1
M3&Y>,CD8/J%<M7<BDP4O63^RD=)SJ*ILZ.A]ZNU%3[(?ZLWUPY0-N7G&1W=?
M;&G2([`=(5\9A5]4845RM][HC,2^[I46NSY]W0M<1M+N^[]/MM:WZ,U[!T9]
MLFQ-F=GVUR0U5"RUDI\)LH\0YBD(N41=Q38D:J],1NF99P%W'D?\U'=M[D6?
MR)JFX7_SY,\9<[8UT/\`$8#EXI<9BJ=83EX_Z=`XF*4INN&O*Z!NL4@B0ING
MU0`1`/V,JD<O?GF;R/>F7VPI<=+^ST/N":87&BUOJ,**JCYZ0]=V;LRNZRVS
M3M93^K*OK5?;40YO7(5#0KA>>;/;A7;ZFX*\A;0UNE4K-;/$2;H#LT$XEV#9
M918Y5@3!XO)UFW/2FE)6K-&SKM&U?+NHMSB8EF-W`94F,]$(RNL*BR'WQ(8;
MP<69#?&H2VDMYCS]V2A]]+$A+9CI1G&9SB]NT*Z!S`#`G9L.!QVU:;%)-D(N
M-09E*1HBP9I-2D<*.R%;)MTR(%*Z6$5G)02`.A0_TQP\(^$<:',6ZY+=<?)+
MRG%%6(">N*B3UHV)V]`;!P"M\G`)`'!A5>')72.X[[RRT!>J)0XV3UU65==.
M]IVAU>BQ99)A1]KIVN*K+NJ^ZK*04>TZ0?I6F*=LB"D[68N&,@5PDJV0%S.Z
MO7VA].[F]2:>U#<76M3RTS4V]A,3C,BY5O,=Q],CBU("9*$*@2&W3F;2ZU(C
M%M:'7*T\Z+)>N#+K2`64Y<YS88Y5X@88_P`'L@1PX$''8*L>QKM;JJB[K-25
M<[SF#<)7"Z7PBD#7PC]00VYZA5R4MG8Z@[JUIDVFDK9.QTSMJN.T`:V62<PR
M9A@Q@E5P!58ZJ*CTK#`BW/DG2&UP8%N(DO9[D[;),CPI3$E,B.VJZ1VEM6Y]
M)XR"PB4H>%^%H;)0VE"T\ZZI2+Z#F4O8,$!8&7$8$Y"05C@42GL<N/#LJW3&
M6UT54Z:SM19'O3]DP%HO5G+;X2#71C*"QV99YJCQ<)+T&+>(1\737NOH!!-A
M)14$TF9-=9P+)G-B@@T<N#B(*/?U79S%Y(5JN5IM\3[$D2`7)BX+#4IQUN8X
MDK<DIF/$K0XZY&80E'&N1>,<>::`!3S;#F:_K0XM7&`;$YB4@%(X$Y1P@!1Z
M`5@`35Q>,@KI*JPT<+R%[QSD&SEV=:L4M=*Y9)AK>H.S)2EGA*I5OR21T%KN
M_5BO[+EHRLMHM2954AEY2LQKUZGXX"N#F(J*SO=X`8G<E_33\)R5%A0)3#:H
MCK!;8=D2/M%;LV&^]!;<?4X&DIDH8G/M-*XO%M(4@-Z"+BF]/!02I2DDY@<2
M`,@"5`*(&&/6XI!.W;]-A&V>P<U]5'?"33%.^5ASXM']SNOJB=6%K;V:D=-'
M?$TL5%[9UCTRS^O'+*/+9YH&\KW/G][%(_ISS_#\83U:>3*4=.,HPHJI;GEO
M&.U1R9XILW/'C2_)"95"<L%2K5QF-%4S=]3FF,Q%-_C5QQLVVMDQ$O:[_P".
M,V22J<5`E7EG!6ZB4PU71*@H\SD[[OY.L=U&L7VM37W2T$<4S(?C-W:5:I#2
MVG#X/>V+=!<;CP\,ZE7&1+*(Z"XE<%UM9<3SUVE)CSHX++3ZMI`);2L'$;6R
MM0)5P=8$[3AUP(PJG?OAMA/$.5.Q*U'1E6EZY;]+TJ6N]-5H'(BM.VTI$TV9
MDJ3;-PO);:^ON,&V[+37KPJM<\5'3T_7ER(`LT7.S0(1[O(CTTPYN@MEUDNS
M&;I"OLIN+)$RROI4VY):1*CVU+=OF7ZW,24I*9N9Z)#F(+A0\VE]Q2N;U(\1
M/6A(24*:25)RN#:$DI*\5I:64_P=BE)V8@X"K&^\,UC2MN<C],URS<<]RV^T
MP&E:U8]6;^TMM34.N+95[PUW!$ST=KI!CR/OM0TW>%G,Q3(V9+'IL9J7.9J!
M544FBO2HU_DT:LOVB]UU]NEJU/8H5HDWY]BX6>Z6^Y38\B(JVN,KFE=DB2;G
M$"6I3\4O*=BQ@',4+6\C!.ZO+#4B:TA;+JG`T"AQ"T)(5G!"?RB@A6U(5A@H
M[.#"K*>"9W"G"[BH=V*HNS\?]4'=BN5N1<71J7#BY%P1I_BA7`K";K@C^]`?
MIZGTO1C6.4*EM._;6"6<.)&I+AEPQ(R^%.9<,W788889NNPPS;<:W=IQ^S(^
M/#Q*.U%-;B.UL*K<[SEE?2:3K]KHE>1EW=!N#2WA+N]YJ:::5"=BT@/3K&+$
MUBHC'8KU*QBB@VBEK'$""RX'(#PP^2*.EY)S^G%:]DV?4,E3+-RA*C<6FTBY
MJDM.'"2QGXF6N$DL9EN2$PI/6H*5<0/RR-)?0]X*'&AB4*QQXS)@1P'A3FV\
M`S#[_!4);<UY19'0?#77M>?.-J:U_)6I#0";<NLJAMRUN95UINKTNZ5QWN!*
M.90*4K-6%.#DTF\HSE$'UI8.DR/5&G4SO=%ZFU#%WC:YU+<VTV?57VP'7BKP
MZ3;HZ6TW-^5%?3;2M3Q;:95*84N.['6U`D-*4PE[-6+(9:5$C,H/&,<7@.Q"
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MU[$U*ZQ==2W=V4BU^!>#W"'-M<FTIB7%,I:2\B$Z^Y<(B,%-HE)0O`'$CG;E
M9)MP>8EQ5,@H9;"<^;%"DK#F9&7@S`!"CPY:MUU,.VC:]K8[T)KI+:XH/?C>
MGJ96RKZ]*Z]U'WN<%;5N"+>R'0]QO)O'"Z(4WE7C>J'B^KC!-9#1@U+*&[XW
M,Z.S)\&-Q#`F9>+1GX\1BI@'C<^7BR1Q>3'KL:ZF/X1Q*?"\GA'1R8Y>'9AC
MMX,.'HU(F<Q7M1A11A16C[*["V3VB7SE#'K_`"Y>>YN[]-J\DDUSFKO9N7W/
MZPI1ZIVIK?IV)\^0RU?RH^;/O#]R;UZND4A]E\\Q/&6^W%*%#O(4.^BGF:,%
M1Z;.1>N#Q3>4K\/4Z;=MH5RRZMBK?/$M[DNZJS:-K1$;:XYLJFZ"D69./<1R
M*0N8[R<ZZU6R:Q//(3C/N2+A.M[UT#BFWG)$F+`?8GN1F3&3]EOQ[>XN.M:2
MW]JP2\A]:PU*XQ+:%K24_P!9B`$)6$88@!*E`H!./7@K`(&W(K#`;4X8FZW&
M&5U%&%%4FT>E)7WO-KJ\B['<X-O1[19-EHO*Y.6$).6_^$M/UR5A-B?8]=2F
MF+63KMZJVCS.99L]:S7EI044`S1^NH+\O3O)0@,2XL&0[<(C$$I?:9XMO_.+
MD^V["X9K=SC[%W!;P1'<:<@<0<J2'N7::XZ^**5*`0HJV$XG8@$*_@E!_@`8
MD$*Q^Y=EC"JZBJZ^-7,'96\MX7C6=FH]/U_"4Y[:3M@<AL@]ULC1M)KQT1%M
M8^:I\%6V+FL),#+34B$@Z;NE'K=!DWZ"JN,<YO4W):5W?Z`M^J[3<)URGSFX
MX5E\!$5A2D!;CBEM27GUI?*PF*QQ+:VTM.N/NXE#5::#<GY4I;#B$H0DG^-F
M.W`#:`-G\(XG'$`#HU`U`JLO!<T)7;D_<#W;75SY)7K4%>;2R^R4T*YM:#K-
M_L+66+5UMA.JH]DX>N.EJ5&RRD$"3-I!F%$B";HCM11-27B%<-Q+.B[="$#4
M\'2T2Y/*;$$E^WNOPV5-\>(29"6W'TINC\<2\SCDH9U.*94RG#9;4BYF0M69
ME3ZD#'-L6`HXX9L,0.L!R[`G9ACC5QN,?KI:KAHZ7'#:O,53<M>Y(VN2VQ69
M6_ZZ::#>76,1B("0U^WMFK=DM6M)*D:6)'33RN-Y=5-14R1G,4V>IE3%58%'
M1:@7O1T?N0&AKGI:&UHV6S#FJNZ8KA<>1,,>?!4J5CQ96TE]<9)"0H(D.L**
MLB"G2M>!2+EX2A]1D)*D\7F&`RXH5UO#@<,>F`?IJQ[&NUNJIQK(P*_>XV7J
M?DG:R496+$0K>&=;&<7B6>RVK-?**R=F4!4=>Q]IBF48HWCV"A`,[AW$BY2_
M?FJIC/ANOVBWR+XN;[97%=ELG,ZF$(K:6[A,`;8&'ABX[BG`MYY)P;DHBM+_
M`";R`.:1D.HE?F\P2>#-F.*$[3_!!&&P=$9CPBO1HVIJ5?O--O)L#W<8H\%>
M$R*3-GV/8[,HS<0>F)E%K<F=JLLO5XW23:8E'AJ&^9)@\<S`S302H(-/W_RW
M@WE-VY*-D5(%O\,$B*2&F(3#`4EVYM%494=AM]=U4TVV+NTZKBT1O`'@7''O
MR?[%;XN^.89\N"N$J)X$'KL20$8D\61M)S#8!MM%VIV"L'VIG\(L\W/RQ.?)
MH3QBX>J9]>>L_9J5TD=\32S:Y[<5OV^;S5QED#Y@_,KWB^@T>71*2'2GM%$[
MK]55*)Q5KL\EWHG.6W3DB#!U-)$A6+&:TE98^UV2LU^`U"G7W4;O#XK%UY(:
M^JJ3SQ;.%9S'NRJZ?*.'[(`22=+UK]\%SMR^21N^LMO:XQE@EU:VKJPN.P^\
M]<B\E=J\(\-1,D%.+LIV-X,EMI+<=\E:VFUAMZ%_;TIQ9P)V;4'$@!&&"\,I
M2.@D''$XD=$Y/AD]F7',W=A;8]K(3AFF^F+>`A;M(6IK$.ZQMK6T1=)R!KA]
M:T2/UZM>Y)RPD;&)03"P2XIKH@[(S4<DQ-^D>"UN+L!LS<O[/SVA:GG8J(ZG
M$OVZ<Y%:>?$Z6N8(B$O,0L<QAQLS:RRI]+2OVV%1N;O&%.?!S8%8X8+2%$#*
MD)S'`J_C':,<,:N"QDM=)49TC<&O]C3=G@*9*R4T[I\C)P\X^+5+<QK82D)-
M/J[-,(BWR<$RJ=E=0\]%N6CHD:]=BW<('(IU3%$`ZN_Z)U)I>!$N-]9:89G-
M-N-(\(C+?XMUI#S2W(S;JI#"7&7$.-E]IL+0M*DX@BO!J2R\I2&B24D@[#AB
M#@<"1@<""#@3A7@W5V+^_$?ZR^26_)OYX1]TKKU8U<=O!]G_`.71^&H/U<F\
M6M!T8]?R5^K!SB;%T/B^AL\.R,5LN/CFSQ']Y6$IOIT52^#PD,'THR^?-F4P
MCD8W)<E.>,-1V8K3MZY(DJS#8I)VC$;%)/T*'#7`Z%Q.H4`</$N=2E.[N!\]
M>[8WRYGSU5"PR<6:3-7Z_;I*ZM*BU0WKO2N2\%53.]<T%O1:@M;Z_(/?<@$4
M#NG;HSX&Q"*E-D`7*BCL,:-TZU;A,5;&GN+XYZ,B*J2HVFTOMO2,LV89<D1G
MF6O"<RPVVV(_&E2"*5.RDF0\5Y<Y&.`)5A^4<!`ZU.48@G#HDXX5:I=ZG&WV
MEV^C3`JA$7.KS]3E11.HFL$;8HIW#OO%*(J(JIJ>2O#=4Q3D,`^$!`?#C/[!
M>96G;["U!!P\-@RV9#>(!&=EQ+B,0001F2,001](-;]UM+S2FE=BI)!Z1&%(
MSP.UQ0*%&6=GIV[P\MK)F1G'LH2GZRW?2Z4^<).'C=C8X.<W/LC9459$139.
M2"O4%6<6X%3QK@5^EJ*;@N41JC4>HY<1_6\!]G5:RI:G9,ZU2I2`0DK8=:MD
M&"XP<5H.2Y)=D(RY&^+P>S:JTL,LI4(RP6!T`E:4],%:E`]'L,`>CCLIH=Y]
MG8GTT7S%YD@?R2^<%JOW,7ZRM]<KO'\U,>,?4749::*!KH4I@`Q31$B4P"'2
M`@/DX"`@/@$!#)'_`)OQ(Y&<@CA&J;3U)5<AH'VA'<'/JUINA(+CAJ_;;J@:
M":V]1]+1MXA[?[L[3W/8:Y%_D+-KG73QC!5_8\Y.U:8=4X7D+7SKQ9DU8ILB
MBU*8R/7(2N3O%N&]'5NBT:CWCKA".R[$=C<5;[8R^Y]K>&S4K=>A-,R&TR<L
MJ8$/@ID+4MX@+RJ4KD1$)B1Q,/-B0H'%:R!Q>5.P*)!R]:G9P#`<%/9C>JVU
M8F>]XIKT3(^9K8J>XOXVZ.]ZK3Y?'K!N?FV1W!SM37(AR[W%RJ2WG>M-.]K4
M>GZB=[VU+(5RKWBRNJ);;]K4MZT;/R=5U7#634L=&[8$@1DPW5;P-GD%B&>&
M56\49L*9+U<_LI'2<ZBJ;.GH?>KL(4^R'^K-]<.4#KEYQD=W7VQITB.P'2%?
M&85?5&%%<T?>!1'';9'*'9U&OFC=N6B\4JKZTN=ONVM]8[0VI7[_`*QFY'>[
M6&U)L!E1)!E"4^+BK+!J2:<G))N%.H94$B@D5QTW<>1_S4=VWN19_(FJ;A?_
M`#Y,\9<[8U>IQ#,<W$_C&90X**&X^Z;,<X&`P'..NZZ)C@8O@,!A\/2'@'*I
M'+WYYF\CWIE]L*7'2_L]#[@FF(QHM;ZC"BJ<>\DJX,=L:2V1&UG9ON\C+4)@
MRV8M#:QEN.&LIB!LMOB:M<=K*V75>VK@R>5!/;$O*%!)K$1)D$"+J2;=TU;C
MCX>2U=S(T;?]+RI=I^SE,S%J@AV>W>YS;S$9R1&MX8N%NC*3)-NC,',Y)D!:
MRVB(ZR\Y7-7MO"0T^E+F?%/78)+:2"0"O%"SLSD\`'1S`@5<,T$YFC4RBZ;H
MXMT1.Z1`I4G)Q3*)ET@()B`FL/TQ0`1#H'P8R-X)#RPE)0G,<$GA2,>`X]$<
M!KI!P54"EM"`A^\-V-J:-L%_&S6K;%/N+B/_`*QE8UWKU@WK^HN/$/964QJI
MRJZL=F<2<988<T*W:-G*MH?J/VZH1S6.%\N]=>DKE-Y,]KUE*C6W[)AV:3&"
M_L5^;-6IZXWEUA35P2$L,);6S)$I;BT)@,B,X@RGI/@[?.!]";RN.DKXQ3@/
MYP)3L0V#BCA.((RX`YCB#E"<3<-C(ZZ2J<I@8-;O=ZDGTZJ:2D=$3#GJQ[C8
MZ^QII_+<?E6JBEG*@J-`B).OP\4F6,0<D`DE#R+E5#I=L5A!\$(7!'(KFJ_\
MX7$=?;3UZ80A-(;O`4`QB/#'&WG'"7UH.+$EEI#GY&0C'FE9#J)/YO,`?XV8
MXM]'^""`-F/""<-H-7&XQ^NEJGO6=44K7>CW_P!SAN_N8O#VM3QTE:-DV*Q'
M:25`UC.*L9Z.LMGDZ='\<$;').E:N_:(%>A<QDHTB:+1J`J/;U7>$W7DC6WP
MGP#PM+\<8(8@LLA2)D]H+96PPW)7>RPAM,]EQ9:^S/!914X\Z0GFV&\E^7ES
MY<#PE1.U*3M!)'%XDY2-N?,G8!5PF,DKI*K.TTCKJ_\`+7:<<UT_6*POI:WR
MD;#7:!E]F)V24GJU7Z<S\?*2*2$/2UHYW%7!5!:(%1X'0B05`5Z!,5UNN5ZG
MTWN9L\EZ]RY;=^A-K=BO-P2PVR^])5@V@EV4%I<C)6F3E;VJ4$E&.!T<8,O7
M%Q(;2DM*("@58D@)X3L3A@>#;3U;9[!S7U4=\)-,5[Y6'/BT?W.Z^J)U:_6W
MLU(Z:.^)I8J+VSK'IEG]>.64>6SS0-Y7N?/[V*1_3GG^'XPGJT\F4HZ<91A1
M5+/>!A%.N;'"%B_<Z,:G2OVJY=+XW/[]%;8DI!AMI).(K]?6J[V*K[JLNTW+
MZ33/*+KM6[^%,@=FY/((`5]W)M,QG<+K^1'1J%:3;K@V?!D0W+<A"[<2X\\'
MT./)?24M,$1TH<6U*#B7VA&<)YB\93=(H/%=F@[<P6>OV`88##A.W8"G#`XB
ME*[V[E7RRUY8N1FCJ?L_3<)J^_TF-J]=:S5UUBRN,,G<J/2I2=JCRO24"_LJ
M,E9ZY2KZ5B#M9([X9MF5HH51-#JK/R,=S^YO4ULTOO`O=IODC5MMGKD/*:BS
MU1G3&ERFV9"7D/(8*&'Y5H+O%I4&O!7R\DI4YCKM17"X,K>BMN-!A:0!BI.(
MS)22,",<2$N88\.88="IJ[QVK:\V?R&K6KK`XM+>3GN%UAAY1ZGPVVAS+;U*
MB7?94=#O+AJ"/U.HI,Z)WY&/X4#,[-*-7D6Y!-F((J.(TA#<'R7KOJ;26[25
MJVVIAJB1M=LNMI.IH&F52)<6"MQ,:Y+N(#5VM#B'<'8+#C3Z"I_%:6Y2B,J]
M-LOS$L+S9C%(/Y%3V"5*`Q1DVMN##8H@@[-F*:L^X%E33X2\3$T57BZ*?'?4
M*:*\BHHK(KHIT:%(DO(J+$264D5DR@9<3E*<51-U@`W2`-+Y114K?WK-2PA*
MSJ:Y$A``0"9;I(0`2`@'8@`D9<,"1MK>VGS7'PQPXE'#P]B.'[M-GB-5L:27
MG<I07NJJS7;EN.MZ;E'FS:'9J=*3;>SOW\]-42R1MA^+U?84*P5;89I:9%--
MD@K!OVTAY4[003%4[@K9=>^3RG4;&L)=SL=CE7R(BTRV)+;2F$(9:EL+9XYY
M<MF1"XMK%3JTRV5L\6VXXK(&BZWJ[MQ)CI0ZZEI1<203CM*2#@,I"L3P=:0<
M2!T<#`W)U;3T9Q_XW[3OD;+;>B*ZC486I[`UYO/;VK'KN9M$K0)FM.XA:OV*
M<O5Q"7M])BI4J<FZ?KQBD,#MPL`HJJ8HNZ9&MY>\C5.D-.NLV2;*5)=D0YMI
MMMP0EIAN8T^EP/,M1(W%QI4B.2PVRA\22RTCKT)K$G&,F&Q(>!<2G`!27%HV
MDI(PP)4<2D':3AEQ)V4_6A4J>CI'4:6OF"451B:WIA:E%HS<A9"1U?"OL/<I
MC\898QI6<4:-.JF=VZ$7#@Y1.K].8V-QWBKO:]?7I>I7"]J`W25X0X6D,%;W
M'+XQ?$M_DV@I6)#;?6(!"4=:!6WB<6(K?$C!K(G`8XX##9M.T],[:EG.-K(K
M)_@S%2_LM6%^OJF[O6->;ZW!;>-6JZ4^T(.L;=MQ=%2B[,WARHT_9MR[)8T+
M:LFA05E^,=+DYHM$@*JQ5LYGSJ7:-&\G"I%=H*I"F!W7\G;4V[K1-\WA:OOS
M>H_ZV0FI1$N#:M/W)BV05W.&V9@%]E-M>%O2%I@!IN,XXMB4LLN(6%$:*[,R
MY+42.T6>(44]:I;J"M611R_DDDY0.NQ)`Q3M%-GW?1H<.(6H6T$TI\<QC4[S
M"JQE#N.YK]5XF6@ME7*&GXAE:^0D;#[ED7D3/,7+=\G/-D731^DLW(7Q"20B
MW'E)B=_?7>W;@N<[(=,1T.2XULAON-NP8SK+BH]F6Y;$)<96A;1B.*;<94VZ
MH\8M=;>SY?LYL("0!F&"2M0!"E`C%P!9P.(.88@XC@IR\0RMG1A11A16C[*[
M"V3VB7SE#'K_`"Y>>YN[]-J\DDUSFKO9N7W/ZPI2*GT?&FM=/J>[T3T_0\N0
M_<'+5_*CYLV\/W)O?JZ12'V3SS$\9;[<5"%,W'NJI<O4*7M'?4G+0-GVCM"*
M;Z2MN@)"N$@J5(OIYMI^:U)L6KZW5^/:2Z0PR+QPO.NF<:V&55D7`N%FS:-J
M?WW0^@[SN45?=(Z<:9N,2T0'%72/>$/EZ4A#*KDU<83\X>"$'PE32$1&W7W/
M`T16@VAUV4N;4F4W<>*?>)0IQ0R%O#!)QR%"@GKOX./7$`9LQQ(";7L9S704
M8454?QXB(Q#O%N00UQS5X>)KK>W0CR':OJ5"6F2<2$1IN82C`U>TMZTC$TRL
M/'#IVTLS*`8N9YY+KDD%S@@DHZ>AO,FRW.3%IK[43+?FRE1G4NJ1*=CH"'+F
MT7/#U1@AR4^E+;;D%V8ZB(W&;5&;27%I9YV&E(O3V3*$IQ&'6@G$(.&7'$)&
MTA02"HDXG9MMPQE]=%55G$L4;SLRJV=M:K@>`I,IR46J:<GHC<=9LUI^/NSI
M0UJ8[/WA,>6ZCO47"S<4*K`D4J3W4<-VCH@(^2'0.\#?+GT_I29:78<$7*>S
M8Q(*+M;'V(_@D!OP=<"U-9;C$<=:<RO&0D^#H6\RK/QP<3H+?@Z^EP*5D27<
M,6U@G,HXYEGK%`$;,.'8=F&%9G6L&YA^95R-:F^KK!L<UWM4^:8@>,=SGKS4
M-871K96NKV5JY%Q=SCZ#69Z2JE;,V)Y1!JOQBFZ;!90X*)+&P-57!J;N-@BS
MJN\;2XM\=GBWK[%9B29\53"IZH]E<BKF/LHD/APY):6?"%JD(2G*M`^F$%-S
M5QG%E_.3B&E%02K'+BX%902!AV..&P_34JQ/*3:ELY2):JH>CRW'CRPFI^F6
M[D7%6DRS*MW^LQ=P2L-17KK>)<"C)5:YTQ>*E?+7#!)`7;$S=1TJ[(@7CYNZ
M/2%FW1JUAJ+4!@[RW&&94:RN1\%/PWW(Q9DAXN)Q1(BRD2(_%(=4OBY`<2RA
ME3AR$SY#D_P=EK-#!*2X#P*`.(PPX0I.!QPX1ACCA2X\?+=M.$YL7S3ULN\J
M_J06S;-_K6L]<V;3DS5ZF%AN>V9)Q:=HPU+AS[#IE6FX"2@$XMC-KM1=71>4
M=N#NEE$`25#>59=(3]PMNUO9H#+=Y\"MT-^=-8N;4B1Q,6W(3'@.RG1"E2&G
MD3"^[%0X&[8B(RVEE"7"O"AN2$W1<9Q9+>9:@E)00,5+.*@D9D@@IP"L,5YB
M<3A5N(G(!RIB8H',4QBD$P`<Q2"4#F*7IZ1*03EZ1_8Z0_;QE^51!4`<HZ/3
MX/W<#^Y71563#:YK;'O+)F_MN4=5?6>=IT^>6XWIJ(IV)!G$T?7T%&.%&+&2
M(R4<Q:#DT@HZ=MS20M'"*:72W!<Y77SM3W21R5F--NZ1F-VF/.9#=[()9*G)
M4QUQ(6M!4$N%(9#;:PQQB%J7^5XM)T264"]EX/I+A2<6^CL2D#H]#AQ(QP(Z
M&-;MJS54M4^;&Z[I,SNL)'X]A)66N1C&W4I[LV,K9*IJBM*MI"K/]0_E181+
M69AE#JG2O*\$GY:W$D<DHL!2:'5^L(5YW"V&PP8]V:^SLC#ZUQI28+C_`(1<
M'PI$A%R\`6XIIT!(5:DRSQ3N:4M+>*O6/'4W='75%LY\2!BG,!@@<&3-AB/X
M^7:.MVTX.U.P5@^U,_A%GBQ_+$Y\FA/&+AZIGUK]9^S4KI([XFEFUSVXK?M\
MWFKC+('S!^97O%]!H\NB4D.E/:*)W7ZJJ@S1.G-PU;O#-[;$L>HI*JZAGX38
M8T*W-]A,9FM2<]:)'3,C:;,QJK0',K$.-C-J['D=-Y-T7Q,I7GBC-D@W/Y2]
MK#;P]<:(N_)HT]IBUWIJ9K6-(A>&1C#6T^VRPBYHCL+D*RMN"$IYXMK8;.:/
M,82_(<=3Q3"SQ(TEN\NO+;*8Q"LIS8@DE!)PX1FP&.)X4G``;3''"N1?2?/[
MF%+RUI?%E)T9SW2I+IV655CINN.-714M"KV=!P,/:8K6C-RP817N<T9IQ?ND
M];N#.71E5"]1OXC1XG)OT1"A1&S$C\5DE)3Q86T^F>XVZ&".,CN3E)>>D<<X
MXI_B&'6@TR$(/C;%%5WDJ4HYCCBGAP(R@C'@(3L`P`PQ(.)JXYRN#5LX<F35
M5!N@JN*2)0.LH"29E!32()B@94X%Z"@(ATB/JXQ]ILNNI:!`*E`8G8!B<,2?
MH'1KI"<!C5._=[62LV3D_P`IYFF6:MR]?M,A;[60*Y,P<Q#SKB2W+<5@G:[$
M5]HDAK]*(2<^YDTV</)96>G4EY(JR72H"SW>4K:KM:]TND(-]B2F;E#;C1SQ
M[3K;K01;(PXIYQY1,PN%/'Q7$-1TQ(BFXI;7@DHYNSK;7/D*:4DH42=A!!Q6
MK:`.QPX%#$YE8JQ^FS/=78O[\1_K+XN_R;^>$?=*Z]6-6LW@^S_\NC\-0EJI
M5RA;/'LVOESM&&FE6K'QZ;7RQRFT$Z#7RE4!2;^4*@!.N8!*3IZ1\`9+U\VE
M#3G(ON;;Z^+95J*S!2\"K*DR%@JRC:K*-N`VG#`5P.A,1J)!&T\4YU*3ONSW
MJCS=7,A^[N;V7=V'9$A/*P+I8CI=*1&R3C.PN).;(LJRN;BO2*9(MG*1B,?&
M"P(F1)`Q?%F+`;RK&$L:#T/&9@MLLQK6AD/)!2"CB&E,AMK`+BAY!+[K#ZGG
M^.*E+<!S`JC8SC*DDJ)*EXX?=Q..)_A8'8",!AT*MXG)=I7X67GI`3@PA8Q]
M+/1(*0'*TCFJKMR8IEU4$"B5%$P])SD('[)@#I'&56^$]<I[-NC8>$/NH;1C
MCAF6H)3P`GA(X`3]`)KHUJ"$E9X`,?W*J1[J&5K\D/(,]1L$%-5IQ*TJ:8GK
M<I&2U<DU9R6V<[/<Z8C"P\3'4FA6QH5`8RL"I(N(H[1=91ZN#P@@\_EC0[E%
M&FA>HTABZI9E-+#[;C;[8:;@)$64777%RI<=6?CY^#*)`<;;2PV6%"N=T^I"
MN.XL@HQ2=A!!Q*NN3@`$I/03M(P)Q.-6*[S[.Q/IHOF+S'A?)+YP6J_<Q?K*
MWUH-X_FICQCZBZC'3A1-<@*4PD,:'DRE.'A$HCY.`&#PAX2CX<D?^;Z0.1I(
M)&(&J;3L^]*KD-`^T([@Y]6ETX5)7ZJ;(N,?MC7%>DMG6II!,++M^`U/LVN7
M1TG4*+3J\+;9%]MVDJ#5+-'34[5Y*83=-K//.%7LNF@W(LV1\I)7\W\+TY>-
M+09.CKI):TG#6ZMBVO7&`_%29,N2]F@PXUUF2&%M-/L1BVN!$0EJ,IQU3;J^
M*4JEKXYM]0D(27U`8K"%!6Q('7**$@@D$XA2MIP&(&-6C8T>M]6)GO>*:]$R
M/F:V*GN+^-NCO>JT^7QZP;GYMD=P<[4UR&;YK+FV;_Y%7YQ4MPRJE&Y":XHS
M"S27&^K[3UG7XJ.+HF274K&^+?;S3FCV2R]E.F\^+L.B=)<1`RJPN3]6]9/[
M*1TG.HJFSHZ'WJZ^9*;AHQ5T$E+QD>+9LI(N`?/VK04(\BY6YGRP.%4_%,RN
M%"D%4W00#F`O3TCT908E0)TNXO&*RZZ%2EH3D0I6*\5*R#`'%6`)RC;@,<,*
M=$E24H&8@=;C60S3UZ4845S&=YIRWV[H_?&U:=3+7!5ELCK*O3U#K#IEQ]6C
M=NVZTW.]0ESKNU;#M#:5-V)1ZI%UN.9I0SFN,C*J/GSA0%'!DO)1NX\C_FH[
MMO<BS^1-4W"_^?)GC+G;&K[N(Q")<4^,R:8F%-/C_ITA!.`@<2$UY72E$P"!
M1`PE#P](!X<JD<O?GE[R/>F7VPI<=+^ST/N":87&BUOJ,**K>Y@:*GMO[".-
M4GM;3U@>ZOKVN$ZA<M=/=AVK3+38-WGXL_(W7QVVTJ)\3I.,.'C'#]%`[X_Q
M;2!NX*9(28Z/<GO"MVB=,@7B/=8UM;N[TTR8TU,*/<U0XK+@LLS-`E^$MN#K
M4,J6&AX<OC&R%YJTERB+DO?DR@K+83@I.8HS*(XQ/7IRD?3P]:,#5B<6U78Q
MD<Q=/59)RS8M&KB1<!U5WZ[=NFBJ]6+UC]"KI0@G,'2/A-ZN-DEO-R);LAIM
M+32W%*2@<"`HDA(^XD'`?<%;I((2`3B0.&JI-QHS,GS?I5V=62Z733NN-IZT
MH5NI\A5D:MJS7NW+Q!TS\G;TEXITHG;=@6B/DK1%/T&TY7Y>$9OIU!N,M&='
M0B\30ZX,3<#/L+,6!`UO=+1.F1I*)!D7"9;HCLKPU)B26S'AQUHCR&5KB3(T
MIUJ(XZ(<OA<Y^2%*NB72I2HR'$I(PP0E:@G+UP.*CB0<%)*05`9D]"V<QR%,
M0ICE*901*F4Q@`QS%*)Q`@"/280(41'H_8#IQF@2H@D`D#A^YT-M=#59,QKF
MM%[RVH;$+R@JK>U/:],M''&SQB2%CDXJNZF<1T:'DL?($3>NHE6YO9_RF10.
M[39.O%-OW@#F*Z^#J>ZGDJS=,'24Q5G;DM*3?,"6&W'KB%KZY:"4I<$5J'D9
M6&RZWG=_*90=$IE'VXE[CT\80?R71(",!^YF*L3MP.S95G&-/K>U7]1]5RM<
MYU[4O\O.ZP>HWMH:;K$0C;J2XV?&P47KC5E0DD%:G*:@<[-:Q;><CA7648WD
MD&1.0;'&-(LN<3N1O^KX=TY/=GTY"CW9M=N7Q3[AC2DP%NN3;A)01(;N28*G
M"TO(D.VHRB670)2D-IRZ=J.I%V<>46R%[0,4Y@`E`.PHS88CH+R[1UN)I^6[
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M]TLB4D_D*K#IQD3'R5>*M*HHJF=BH"8`Z/<GO/T?IK=QJS=_>K7>)FH;S"DK
MAO0GY92T^B!(CM<;$8FQ6"A")$E3\AYB84QU+0&<I43I+E"D/3&)3:VTM-J`
M4%!.T9@3@HI4<=@P`*=N&VJF^^<K]H9;#V(FVT'M.&U!LFMTZ2VQNN1?S]OX
M\W&R4*A762H\[.TO7=0F+!2K+3I^O0==%[-6VG1$H]=Q)W4?.LF"A`>1R%[E
M:7],VQ;NH[0_K:URI*+=:T(9C7F,Q,F142V6I4V2VS*8DLO2YO%1;=<Y+#3<
MP,R;>_(2H\_J9#@>7@RX(RT@K6<2VHI2HI)2D$I((2G%2T`DIQ"P*Z:XIBR\
M3'R@LFP2AH5BQ/(&;HC("R*4K@K([P$P7,V*X.8_B^GJ=<1-T=(Y%%,D/YW8
M@<7X('UK",3DS=CF"<<,V4`8X8X;,<*[E(&`5AUV%9%FS:1[5NQ8-6S%BS13
M;-&;-!)LU:MT2@1)!NW1*1%!%(A0`I2@!2@'0`9C/OO27E2)*U.2%J*E*42I
M2E':2I1Q)).TDG$U^@`#`;`*]&>5?M*?RZN4'JZD5[:*M*K-LN=>M<57:6]L
M)IKIJ_QZ>-(.Q3B+.HQ<[>YYI'Q90=KQL*P>OG"C1%8J:?D_E+=9-RUCN&KK
M_)TBB?+A6*3#<>E(9XK\OX(E3K+15)<9B,J6Y^30_*>::0'%H*E<;Q3FON+J
M&&DOY4J=2H!...S-L)V`J.`VX)!.P'H8A2N3#ZFW'NX=8-QUM5ZA7KZPTQ&P
ME#D5:A,T>AN9`6;V-)+/+T_KNNGL/7E6G23XS.8]F[<%20=`1XJ5`5FW4Q[Y
M8^5#=G1=9<VYVYRYK=EH$EJ7+2C,E9;3$0]-2Z\%8'P%#SK:"MQK,P@N#73B
MT[96QD2E"P@!)P*4X\&.;!.`_P`(@'@.W95A6@9-E,Z*TQ+1IG1XZ2U5KYZQ
M.]J<70W9VCBIQ*K<Z])@S*0514,D8!&-8F.R9?8FYC(D(86T[QXC\'>%?8<H
M($EJ\3$K"9#DM(4F0X%`2G<'9(Q_[=T!UWLW`%E0&XAJ"HC2D]B6T]`)Z`_@
MC8.D-@Z&RI;SBZR:R?X,Q4O[+5A?KZI][Y6T0E&U'IZYVJ)I#RJP/(%'W7EY
M_E>IPGOE87E-<[)BH>:TUR$96>MRU=O?NF[(@YCF_E19BOK2+99,B(G62=-R
M4[1/U!OJUI8K.]<&[Q(M\SBVV=/#5,1\-W6*XXU<[,IA]MZ)D25H>7Q9C3$Q
MG6U%8#:]'?'$M6Z.ZX$%L+3B2[Q"ABA0!0YB"%8\(VXIS`[-M-'W>T]KFS\.
M=(SFIJ?`T2@/X:Q&@JW6ML(;WBTCH7:S-I>6'<K==V&S)6SSJ+F3D)A1=PX>
MR#Q<ZRRRPJ*&;WREK=J>T[\+_;]93I-QU(V^SQS[]N-I<.,5A3;?V80GP%MA
MHML,Q@A"&F6FTMH0C*D;:SK9<MK2XZ0AD@X`+XP=D<3G_A$G$D[<23B2:<S$
M+K9T844845H^RNPMD]HE\Y0QZ_RY>>YN[]-J\DDUSFKO9N7W/ZPI1ZIVIK?I
MV)\^0RU?RH^;/O#]R;UZND4A]E\\Q/&6^W%07,[8Y/-N\BL>M*+<HF#UC[F:
MV</-2;;I.U9F"VW7W=?B7MTONBMNQ=0C:)JJTT..1D4W<&O+6!O./(\!48QZ
MKHSXM4*#HW=,[R7(NJ]007I&K.-G)3<;=*M[3UN>2\XB+$NUN<DKEW"/+665
M-RT1X:XK;V"9$E#(CE<E2)XO:F&E`,8)ZQ:5D+&`S*;6`$H*1CBG%68C@3CC
M5LF,VKH:,**J;XYM;)!\_-]0%@>K76P&/=9BQ6.9K4$VG:O6Y&!TBYUJA'VQ
MFF*0U"QMEY-NTKC9RX>Q@Q7ECPB17I"E>3O/=M5PY..G;E;6TP+:!%:98:?=
M4R^^AZZIG%<=1Q\)84&%N37$(:?$CB&%+,=1//0@M%W>0LYE]<22!B`0C+M^
M@[<$@XC#$\-6%5S?.F;?LFQZ>K&S:;.;3J,>[EK-08V;9N;3"Q;"63@7T@_B
M2'\J19M)I4K113JB4C@?%B(&`0QM-TW=ZZLNEHNM[M:9T?2$UU+;$Q;2DQW7
M%MEY"$.$92I30+B4XXE'7#9MK<HEQG'U1FW$F0D8E(.T#'#@Z>RDNTF/D7-#
M9[&2W%"V\DA#%L%3K,=7-KU6+KB$@U-%2&LZO"N=W36KT34N,K+*?E'1JL1[
M)/;2JNDLB'C4RKMKW\ON)M,B+8WX1;?XF0^M^WR''RA7&(G2'4VIJ>?"G'W8
MC#8N!:8:@(;6A?6*.KB[+FX%.!6(Q``6`.AE`SE/6@!1.3$E>.(KR6V\ZUJ/
M-2$1B]6\46OE4K%M+IM:00H<9R?8727AK0S3BZ_3Q=-M@7&.FCN(U(\\D*:C
M-%V=%!A*-UG#V-]K+I_5-ZW$2%R[OK%>1EQ46WH,MRPKBMNL*+CTG*J'&6T`
M^H1%8I<4VE;DB(XVTQ*_''6&[F`EN/PC,OK0[F(.P#LE`[.NZ&.`"@24I=QL
MB7M5[SW:4)8N)E;U`%@W/N^^U+?SVA\G:I8-HC8E=EH24$SOJ)9G1^ZGMCAH
MUA:2+RLE%,*U'2/N5'QCEXW(X;+MO3F1[QR3+1/MFLY5[\&L5JB2+.F78I#,
M#B1!*'50SQ5UM:6'5O0"B.Q(>G/,^&29;3#JFW=9!26[ZXE<=+>+JU!S*Z"K
M'-B,VU"\0`K:0$@Y0DD8AH=4U>QQW-(=BL-4V6B25QV3O*E[)C:SI'8NN]>J
M4&'_`"A2%'VG:-FDE`UKM:S7J8K\6]5<*,O*UG5C+XE4@LU@<))K&[VN3N)_
MJQ)O$2XQ8-JM4J"M^ZPILP3'?`T2K?'@\7X=;V(C3S[24)=XM+<(YT*X]'%9
M\=M:;GQP;4A2EK2H!"DIRC-E658Y5E1`..&.*MG`<=*JH,C=[G:6EI2EW]Z8
M59.8@W<?&3C>`85:<UK+QQ%8M!Y;I!5K6SQ$#&-+!("S+%/[4FQ20(DX1S?7
M@OCD71'K06&]/.2RVZE;C2GER&IS:R'"F,@*?#CS[D-GC3(9MZI"W%+;77DW
MA_6)0<Q+H3B-APP*2-FW@P`"CA@5X88$5N\`C70[T:P24)&(0YGC&?A;18'I
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M_&$-B_+4@;2DXDCHX(V).)Q(!Q4G`88XU9;M3L%8/M3/X19YTWRQ.?)H3QBX
M>J9]>.L_9J5TD=\32S:Y[<5OV^;S5QED#Y@_,KWB^@T>71*2'2GM%$[K]55(
MIPFJ]:I/>1\L*7KI\[J-!K*%_%/6)+O'MB.9RP2NH)>0EEM0#OZ43AJ=77AW
M`5>6B];1)%D9AZD^EE%A21<5RM_5WNM_Y+>C;[J=M$W4<M4/&>8JU%+3+=R;
M0V+E]CMEV2\D(\/CR+W(*51HZX\-+>=;:N6MM#5[D-,G*RG-UN;HDH..3C#@
M!MRD-CA.*L=A9WC]K"KU;G)R#V$AR"U!>+KLZG.I]WJBDU2E0]XB-=&ML,TH
M5LN4M`J*SDX>&DF$S`^Z;CH3E4T6Y#=*\>KT)-O)U;=[OR?]-::<TU>[?8;3
M.2RFX2I$IV(Y-\'=5,CQFW@&F@ZA<67Q",51RIQ0P;DHQSX;#;=U>>#S:W7$
MXY$A(4$XC*5$;3@<R<3P[.B*LF.<B1#J*'*FFF4QU%#F`A"$(`F.<YS"!2E*
M4.D1'P`&-92E2U!*02HG``<)/T"MW5,?`](6'-?E$4%MM,1LL?L2R'KEMFW\
M]0D(EKR&M\)4K/4G+:>?U**+:8ENJ="&;1D'(QB""BKI-XU>QSK'T\H=8D;A
MM(DILS@BN0F`_':0S,+BK-&=DL2$J91(<\'<*0N2M^6P^M:4-*8=CR6JYFT[
M+H_^<&8*.!.*<.,(!&W`8C^"`DCHX@I-6A[J[%_?B/\`67Q;ODW\\(^Z5UZL
M:M;O!]G_`.71^&H:U`<J=V;'.8I"$C90YSG$"E(4J`"8QC"(`4I0#I$1\`!D
MNWS;P5<BFZI2"5'4%GP'\NNN"T'[1H[DYU*ASAGJVNZ]WWRKF([D#J3:MMV!
M+UR[WFEZSJ%+K<C4FEGDK7.:UL-S-5E%G2LM:J2^(8'3D0++G24<I])"@8:Z
MV_/5USU+NYT?"DZ;O5GLUM9?BQ)4Z3*?1(4PB.U.9B^$`)#<>4@CBT#&,%(:
M5@HD!6K9'0S+D*2\VXXLA2DI"01B24E6'1*>B>'AJQY=9!N@LNZ520;(I**N
M%ESD3021(43*J+**"5,B1"`(F$P@`!ZN-=;0XXXEMH*4ZH@``$DD\``&TDG@
M`K=$@#$\%4X=U,V-&VSDPP5_+`QD'K'3EHFZWM.<?69K7)2PR&X@2)6Y\9J4
M@'RDY%1S>0?MX]M#FB%7"<8[CF[AF)E'P\L-T2K-I20C[$<C-N7..T_;VD,*
M?;91;<2^SQ3;R`TXM;+*WER1)2A4MF2XV_@GF]/C*X^/R@40@D+..!.?@.)&
MT`$X`88Y2D$59/O/L[$^FB^8O,=Q\DOG!:K]S%^LK?6AWC^:F/&/J+J,=.'\
M7<NN(=/4AY,_1T@7IZODX]'280*'3T>J/@R2#YOJ<W(TD)^G5-I'_1*KD-`^
MT([@Y]6H9X?VB[;8VA8-XOMQ;MG:#LW7Y;52]-WS1&R=;TJ@5ZUNZE9JRTC[
MO8X*/HUUL]9\ODV/ET4LH:6BW#94.NFT,LI7FWVVBP:.TE&W?Q['8(^H[3<O
M!Y5SB7:#-E3'HZ9##ZEQ6'5RXK#^1AWBI"0(\A#J#E4\$)5>VN.R'S*+KI9<
M1BE"FU)2D'`CKB,JB-HQ'",/HQJR'&N5NZQ,][Q37HF1\S6Q4]Q?QMT=[U6G
MR^/6#<_-LCN#G:FN.3F/L=DXY1V#CY4]BS%J?2G)K4V_;K#)5F=KMIUS*4:A
MZ_@WVO"WRU;,@ZS9],/::<DBHR@JK+*K.'R[(7`.A,NC>LN'92.DYU%4V='0
M^]5QO,:HTI+EM+[EF9.JNY33-0T-8UJ+?*-5[*[N[*UW>^TIE'ZZ;2]XK,E;
M%ZXNNK,-HL[=5D>U-X\S;QDD1,4*?FZ2]7Y>ZM6AH+4Q$.^W6]L"7$ER&$Q5
MQX\64I<U3<1]$</@)C+D!:71;UR0[EBJ5QB^SVVO#O"5%.9I#9RJ2#FQ*D];
MBH$X<('!G`PZ[@NDQ@==31A17(OWO4W()<L9UR-.WY=)#76O&]DUA!U"DLK_
M`*@5N,PANI^O.S,))\>-JPK&[-)JIP\,G)N)1L[C&\V5PT\C\6JLK=QY('-1
MW:^Y%G\B:IN%_P#/DSQESMC73)Q(*4G%3C04A@.0N@=/%(<!$P'*&O:\!3`8
M3'$0,`=/3TC]$<JD<O?GF;R/>F7VPI<=+^ST/N":83&BUOJ,**K+Y63?&J(Y
M&5)ALCCG9=_;7N6NJ]3*P@TCJ#*0<8F\FMGV2FP71<[/`&@W%F>56Q+/I?JC
M%QS2,2,^70`Z`*.NW/0-ZDW=A-D:6U1$TWHZ#<WI3Y4N8VZX4M0&)+O^:L/<
M:EA,B$EJ-CQ[SCZQ';<RN9='<%04S4A]E3TA2`D;$D#:HI'7$88X*Q/``-I&
MRK+6H=5LW#Q)&W0@B'DZ9BG(AT)E#Q)#D`"G(E_@@(``"`8U5XXNJ.8JZX]<
M=A.WA(Z&/#6['!59^V8N%@^0K_8$[PYK5D:'W[QPIL3MWRN5+8G5JL<AJJ+C
M-R3<2K"H5AY6:4#_`-RF3UL]?2K*9KK8CE!%LX0<-G6:-ES[ANT;TW;]<2HK
MPTY>Y+EMRM\2F.PBX..6QIP.E]+\K)X0ZTMIJ.[%FNJ:<<=;<;=T<A*43"\N
M,E0XYM(7MQQ.0!9&&&">`$$D*2,0`01#>WO(S=ZQI1A<49F0F#UB)GM>EAXN
MPIQC&,8&N$8X<,4U[>87DVU"3<?&&28L"QK:%,5!9,#+NC*=QHKCQR/;](LB
MF&H(EN,S.-<9+BW%^#.!*R(W6M*XM'@;#KI?7*!<0K!MD(QI.']8&@YB5904
MX`X8;1]/#MZX@8!.P\)K>9A&MF[TFM24-%)QTEXMM7;K:W(UR0CK#:&G'N_S
MM7H+&-#4S:Y0=UCZ;*KS(2WQJ<1*L,FLR4#RE5!HCS\%=T')%EQ9SQ=BXJ>B
MQT\>A;+"KS#:?F+7]HJC.Q5R6T1O!_L]$A,E3<A)XI#CSGJH(^WDJ2,%<"CL
MP)XM1"<,F8*RG-CGPRXCAP`MBQF]=#525>KE31[U&QV&!C$PDGT+-)VV?GXD
MZ$0I:8O4=$;L:WK2VL[9)-9"[LZU-`^GH%>,8KI1;M-^/6*5(ZKSKE=+ROD@
MQ;9<73X*V^T8[++F+@CN7&6I;\Z.J.A2(JGVN*B2T/NH4^VJ.,"5I1SJ$-B_
MJ6@=<0<21LQ"$[$G$]=@<5)P&PXU#'$2]2MZ[T7E'8XED_HM4LC-X,I3[:_V
MSK.U2MCH]:U_1I-:2TA/ND*5;[$P6C$%?C@@D_;*PIFA&+HJ:PI!W6^K3T/3
MW)(TC:YKC=PO$5:>+DQD6Z=';8E/S);81=64F5&96'%I^S5J96F4'E2&2I`7
M6-;G5.WZ0M(*&U#:#G224A*3B@]:3L[/:,N&!VU,/&;4NYZWW@F_ME7^H3D?
M#W2,N(+OF"UG-0FCEB?5+.GV&(L4W4V#6V_E"@$G29(A&=E358\$JFHW:D<-
MRI\1O6UGH6Z<FS3>E=.38[DV`[&P0L,>&*2L7!4EEQEJ0M4;P-XMDR51(XGB
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MHK.<AM79))3E4,Z>`*6D%6(V]:LA/8C&JE.]\LFL*QRLY/V>R;DCE[!&:Q@:
MR;0-KHLS*(VLDO1M'PM43CY:(Y1Z^9S<'4+1LI&TUYG)5*28L+*E,R`M7ZK-
MN`/-Y%-JU;=MSVDK3:[&ZFVNW9Y_[8CRVFS'+<NZNR"MMRP3%-.R6(*H$QQB
MXL.O0508P>C(><-<[J-;#=P?<6Z,X;`XLI)QQ2@#:'4X@%69(*"`K,<#@*Z_
M(P!+&QY1$1$K%H`B(](B(()@(B/0'2(C^ST!D*$L@RG2.#C%=4THZ>Q'2KVY
MCU^T844E//>4AJUHI.WRNK]=[/4K5^HJS-/8^OH#9["EEEIYM!RE[A*;8;%3
M&DS8("'D5S((DFHI0X'-T+&Z/$JKSR=(DZZ[PC9(=WN=I3*MLL*,*8]`7*XM
ME3K<1V2RS*4TR\XA`6HQ9"1@,6QCQB-7=U)1$XQ3:',JT]DD*RXG`J"24XD`
M_P`8=/H4OM\MU1W=P*T=:-G.6G&NHV.6U.YDF;.H-[EJ)5FW2,K&Q,U7:!=#
M1)M'6A1)([45)<K5J`M/&G-U2B92=.V6]:!Y16H+1I-"]57J*S<$H4J28UR"
ME'!;C3TR+QGVK'!4'`F,7'/RV1(Q(&&ZXW*M+3C_`.0;448[,R/N`A*L,AZ&
MW`;*LAUFA'M=<4%M$RC"<BV],K*$;,Q3!Q%QDLP1A62;22CHQV^DW4<Q>MRE
M4204<N#I)F`IE#B`F%KFJW)+VJ+B[,9<CRU3GRMIQ:7'&UEU14A;B4-I6M)Q
M2I:4("B"0E(.`W;``90$D%.48$;`=G"!MP_=K=\T%>M9/\&8J7]EJPOU]4T]
M]I?:AJK06O=E6W6KV\)5C<S]HVL0W"T4BO:X9V[5.TJ99+#/S%2K5K?K/9FL
MSSN(@&SA!HP/9WT<==\U!,HJ.RY(6G;WK#?YJO2MFNK=O7+CR%*9\&CRGIJH
MUXARF&66I#\=`0T^RW)F+0MQX0&I26X[Q4<NBO[S<>UL/N(*\I&W$I"<6U))
M)`/""0D;!F*<2*:7NXT*ZAPWU,6I-[^%85?[3=P,SL^67F[O>8I_N+8#UGM2
M6D5ZG1.NWVZBX"T,DDH:,;-F$N@B@V2133*#>>5`Y<W-^-Y-Z5;?M8-V]+S4
M!L-18CB+9#0JWMH$B7@;<1X`ZI4I]:WHSBW'5N*4:VME"!;6^+S\7BO`J.*E
M#.KKR<$]GV0ZT``@`84[V(#6UHPHHPHK1]E=A;)[1+YRACU_ER\]S=WZ;5Y)
M)KG-7>S<ON?UA2CU3M36_3L3Y\AEJ_E1\V?>'[DWKU=(I#[+YYB>,M]N*3B.
MK-,<]]',7)Y`2Q["A4B0M>V)5I-=M57,O^0EF69U-LL]IUL1C*VV#@4%)Z)B
M*K;E5TV3\[Z1BR%0.XRKC*NM]:Y";%C8DLBV*FEUZ%(;"I"6_M97%7&"(\XK
M;C.O$1)$FX6Y*"ZRF/%EDN):I:TH:.IBZ0<^7`*!V8\7M0K%.T@=<`A?`<5)
MV8U=OC!ZZBC"BJT>-O'V!7Y,7OE['[BU9>R[6:6=S$5ZAUBYP?BX205KL="3
MKAO8MOVR-:65I&01FLLZ;PC,9!54#%!J'724=5O2WDW%O=3;MRDFQW>W&SK8
M2X]+?BNXNH#RW6@IFVQUJ84XZ'([:Y3G$I3@2\<JTZ.%#09R[B'&U\8#@$A0
MV;`#M61C@,"0D8_<J!N*ONH'>F<QQ<1%()5WY+?)52ZLZ!,U27MDZR8:"K5^
MJL-*%U]7H.RR&LUH>.3L4BYG9QZY<RK<S0J+8[A-!1=\'@AY(>APV]/-W;,9
M$B*J8U(;CLJ7=WX<AUOPQYUA$X.O&$RB)%:0B.Z'BMU+2G,2WYOMZ3B$<6<2
M%92"3^3"@#E`.7`9B5*))&&`QP]&HW^KZGWK6Y*(PJ[-O:+$I8K;$3D+&M8>
M$9R$MJS64G;X^0;/=,)OIB\2CQ!R^=R;.['14:+I(G:`*1R%\M:1]6WGD>6/
M4,B6M5IC!F.XTZM3KJD-W"<W&6A2;F4-Q&TE#3;#MK"DN(6XE[!:5']CEAO4
M#K02.,5B00,!M0DG^!M4=I)"^#9A3':MY.6>=Y"VO4EPGN.[N7B=S;(ID##,
MKG,.MYHT9FG-3=852I$#1I&&\@;148!7[U693;MNKXMZ=!__`(H*7ZNW3VFW
M[M(>L[)'U,B$]8H4IYU45I-I,M1::?!E/2T.YU..8LM)C%:\<S"7(WY:LV/.
M<7,5'<+)4'5)`S'C,NTCK0DC@&TYMG1P.RJU]6/=/ON^%+L>H/9\ZC_<7)70
MDI#;+V=3-L2+7<4;KP]@LLO2*&6TEVWQ[@%6&K99.N'?(3%==1:\F1LVA?=5
MH9RZC5\?6T?D2'2]Z;C!+=CL=W;=@P)5N0JVKF\2PW*E^#_9UY>"[A',T-+C
M36Y"(BG79_@;P:TD<QCJ3CFR=KCK9"E)6<X3B2E..=L=8<N.*2,V`3F&+S\8
M0W;:N56VYVR[(D[SK&OVS8;J'K;?=-O(PJ+MUM;?NOXV8DM826JH5!ZQ4@Z,
MTKC"%2L;B#C'<"\F4VRKUZF\4;YO9.@;/N?LMOM5K:M^K),.$EU]5KC%<E*;
M?:)BVD3T7!TI6'9;DUZ4J$B6^W+8@J=0PPIA.U@>%.7!Q:UE;`4K`9SLZ]Q(
M)24#H)"0G-E!2588G&M'K-&C*MWJTN$+72PS"1;3]T,T9H2+2=<O+#J"';35
MX7GU(,M6?:9E[`#AB6M)/C3Z=X(YF3E&//U2=!=M02[OR/F3/E%^0TMF+F44
M*92EFY.J:B!D.^$(N;;.1TSE-"&;46H*3X2G%7DVTEN_G*G`'%71QVH&*L<,
M,A.(RXYL^*N"O7KRR,J[WJNP:4XH4X]D+#3Y1O`;8F5+<G()U^$H.N;!(T1-
M1]N&58VFLQ<U)BY3D%ZHW(U</D6I7'6!N=?PU-:W[GR/[;?FKC';C1IS:GK<
MT(Q07G9DUE$LA%M;7'?<:;R%E%P67$-+>+6!<2W^LK"+^MHH)*DG!9QX`E)*
M>S.(!...088@8\&/DT=:Z<S[T'=E'?I3$W?35R=&,NBB4?'P+F*9UC4YI.+<
M1`Z6@2+7U,[8B3^6CK*L5^R8MTETE`;)D;^^\"S7Q_DE6'4$<L1].^%,\9%!
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MOF1*4AA?%IR,A2DKI:(C,?[8>?:==4X4D*0I*\@.*>Q4>L.`P&"=NWAHX<T3
MBM2^1VZX/0.N96@S-%3N-'FVLEM"K3":CQC8J5'V^2CM;*72P[1AXVP.ZU#@
MTD)=LC'BSC4?(2-RNC@Z-^&H=[]]W7V&X;Q[HS<8-P,:6TI$"0T0E;,I<9"Y
MPBLP'%LI?D\8S&6IX.ON>$*=+*>*+:U;VIKJ(:"A2,R3BH'HIQ(3F*@#@,"1
MA@!AACMM`7*B=%8CDJ1VYTE"KD6*4R)T3$$%2JE.`D,D8@B!@'P"'JXTMLN)
M<2IHD.@C`CAQZ&&&W''@PK>G##;P53QW=^QFEHY(<L*_6355_06=NO$U3)FL
M6O55LC7]?>[)D!9+PTY3&CBXS<<O,.90IBR[I%&'(@W8-D#@0QR/<Y36F'K1
MNNT;<KJ)C>HUPHC4II^/<(ZT/)@HSAUJ4H1FEAI,<@QFU*DE;DAUQ)4$JYRS
M/!R;(0C*60I1204$89CP%.TC''A.S8`*LPW5V+^_$?ZR^+S\F_GA'W2NO5C5
MJ]X/L_\`RZ/PU!.N(:+L=@=UZ;9)2,+/5RPPTO'N.MXA_%RD<HQD&2W4,0_B
MG31<Y#=`@/0;P"&3`?-AG2[7R-KA<X#BFI\?4EE=;6.%#C<E2T*&.(Q2H`C'
MHBN!T,E*]0H0L8I++@(^X4U#?`6L\98.W;I+QWH4S1&D-(+4Q]%SNSZK;7S1
M*L7N]Q<F`TUA<K1?J?[M6YG(2/C+,!'SI-PF"(IHI@V1KK<HV[;U[A9;"=YM
MQ8N+S[8E(<:@2(R%%^)$<;_SE<:/#D\5&4RSA!):;4A17F<475JS:&X*''?`
MT%`!RX%0/`I0/6YBH8G$]=M..S9L%DLNK%(14FM/*1Z,&C'O%IA:7.V3BDHM
M)NHI(*R:CP0:)QZ;0IS+&5$$P3`1-X.G&LPD3')C3=N#JK@IQ(:#>8N%PJ`0
M&PGKBLJP"0GKBK##;6[5E"25X9,-N/!A]VJD>Z;OJMPC-]1S=.$/78&SP:U6
M?PMHUC<6\A79J?V4K77#6T:^:C*VZ,4K3)D=*9G')WL@J=82(-RIF*9Y_+)T
MXBR2].RG3(%SDQ'1(0['GQE(>:9@AX*CS%<7&<#ZG0J-$0&F4A&9QTJ!'/:>
M>XQ+R1AD"AA@4G82K#:G:1AAURCB=NP58CO/L[$^FB^8O,>)\DOG!:K]S%^L
MK?7/[Q_-3'C'U%U&6FP,:Y@4INH88>2`I^@#=4P^3@!NJ/@-U1\/0/JY(_\`
M-]('(TD$C$?UIM/4E5R&@?:$=P<^K22=V1,RLM?MHQ)K\XWI"T>`C89':L#M
M?;]OUA5Y.0CZ2E,4FH06S:[5XZ4?7JTUZ8M3N5B/=AC&`Y)$-W3=J@@V&"GE
M7P8</3EHF"VIT]/N$E;IM[UOML:>^VA<HMRI+L%Z0MM$2.]&M[<>3X,Z_D5-
M=9<><<=I3;$I2GG$Y^-2@`9PM92#UN*0%``YB"LD8@8Y00`!5RN,:KI:Q,][
MQ37HF1\S6Q4]Q?QMT=[U6GR^/6#<_-LCN#G:FN+[FUL;:%PY22^J9"[:DMM<
MH/);3$W48-S%V";VM3:JC<=&V.Q155$=`/6,<RJD>9\A8';.XIL8DEE:#(+H
M+N&S92]9/[*1TG.HJFSIZ'WJZ$.0LPUI'+IC/7W<K:H0TY'Z?9ZLA$X;2&P9
MB`GSV"Z0]C>L*O?EWVU*@E<W3IDT/)UJ-49J@U$7"Q%40Z*8^B(+U_W4S;=I
MVQ*FSH\R[*N#I=NL-MYD(CNL)7(AA%ODF*E+K@8G/AQ/&`-MJ0LXN%DJ#4Y*
MWG<J2EO(,$*(.)!V*Z\9M@Q2,-FT[*M'QG%=#1A17++WC-M;ZPY@[KL?N-RB
ME%KQI[5<"M:-+[@O^I=$:N)#7[;\6WF.4\Y2HYVI%UV8-<CGCE?)9HSE)HX;
MJ(L45#NANX\C_FH[MO<BS^1-4W"_^?)GC+G;&NA/B(7J\4>,I>CHZO'[3A>C
MJ`GT=&O*Z'1XLHF*3H_:`1`/4RJ1R]^>9O(]Z9?;"EQTO[/0^X)IA\:+6^HP
MHJI+O'*'+S]XU9*1#.E2+J7KE@K#>K2>H$=R;(V4$4N>US%2U:L75UZ<:(FV
M%9:O55+TL,FR:&=I-SPZJQD)!B\[DO:BA6ZP7>)-<GM,LRF7U2$7(VR#!XP"
M.U(N`\/B"[-+?4TD6E/$.N!M;J9R&PY&D<[>F5+=;4D))*2,"C.I6&TA'6JX
MLX8_E-H&.&7'`BV&.*4L>P*5!5J4K)J4K9P<5%VY00(`(+'$QQ.JB'TIAZ1Z
M1#U1QG$HDR7"5)62XKK@,`K:=H&S`'A`PX*Z%/8CI53AN2R7NX<XG=5"1EYG
M5>L]O\:'5KB([;IRTF`FI6=TY)41IL&E$VM`3%3FG-EDSRT01M5IB/G9%M'M
M5S$*Z=KMWPZ&M6GK)R?T7@M,,:ONMDOB8[B[</"GFFVKFB6J'*-O>:D-)8;$
M>25SXST1E<EYL$LLMN<U)6ZY=>+Q)CH<:Q`7UH)*"G,G."#B<1@DA1`!X21[
MMNT:.A.\_P!-R<161CPMY:9;95RV0=(S]DFH:`W1#R5AJUC2BUZW`U."8K,D
M;G%R#M&2L9EH@S$I?(3$>8^B]02I_)+OD2;+XTPC*CMI44EEAIUZUN(9D,%P
M/O2'5AU5LD,MJ8A!,T2"?"`6/V2TE-]:4E.&;*3])("P2#A@`-F<$XJZW#@V
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M0Y]J.%$0J.*8ST`!$E3SS2DEW.KFV'&DW];2L2]E.!V8=BDX$9!UWW0KL<`>
M"OTTU&/Q[UCD#(/2['@R-H"50BX^Q7;9ZM9GX9]2=+N3RE4JC[1\)JE:LO9H
MBQSJ-KO-3"$@Q!,4&[9(J!/G7,N-_P`'NFHS!M<A2Y+9<6S%@!]EU$JZ)#<B
M0BZNW`/I:*0$KM46,MEW,''75EQ1&2?ZP/$YQL.&*E8$94;0,@1AC]"U'$<`
M&RF(U)NFY[0Y;[<U_9Y9C'P>F9JW1=0K,(Y80+N18EB*`5.>M4:ENMU:K6DI
M\97(('?T=O$)*@55H\ZX%,LF6L]"6+26Y>RZDM++CMPOK$9R2^ZE;R4+XR9B
MS'6;6F/'(XA!4&;JN2I.*'F,I(;S8\IU^XN,N$!#1(`&S'8G:1GQ/">%&'T'
MZ6VVSV#FOJH[X2:8OGRL.?%H_N=U]43JU6MO9J1TT=\32Q47MG6/3+/Z\<LH
M\MGF@;RO<^?WL4C^G//\/QA/5I1YK:G+BM]X^VTFXOTR-0NTVPLU+CV[<T]2
MRZ?7K]OFY)6=H27'=NW:L:Y)4KW!=3J6U8B20FIE@J,>^;F\G6K%P-(;E[IR
M75:]:MK'VW`CK8E+)XF5]I!Z,T@,S#>B5+?1*\+;B*T_(87%BR$"3'='&H69
M4BXHO7@I6>+6<4]%.3`DXIXOH%.4JXT',H;"-A\_-4)^%YT\<8NGSS."';'Q
M-A;784=V;JJNR:(J[NR%8C+%K.G0EF#1L@RE(Q%9L[B+HW:1DPY3\;',[!()
M/HI?UW#_`&=/Y/>J)=[CKD"S>$NQV3:[7(@RPF*7W&9TEUC[50IMPI<;DVQ;
MC\9"LDI^VQEQYC?Y=,Z;JPEL@<9E!.=84GKL`4@')M&PA8`)[$+.*3\[NK.G
M97O"J@[=;YVG2ME0UWTL_D*)^0O8DUK.WOO)*P6(CQVIIP],CXV0L3&.:H*_
M'>0EHQFJ``1D+7I1-^Z!NVMX?)IFLLZ=M$_2K]ONB$2_M:$U.C(S/\8O[/N8
ME+6AE:W%)^RF8[[B>R?#W7@E-QE7A)+SB7PM&*>+44G@PZ]&7#'`=F2!]&&R
MDM[VVVQ,?O3:=>I>UJM4[U,ZI:0UQUW6JA/\HK[LAJ^U;>9R,A[91+94(C4O
M#MH-0J\J]9VYM;T[!(1\6Y=-XUT=,J9UWY&-FF2=WUHN=]L\N9IYB\*=C37Y
M+-AB0E(GQ&G'8\N/)<N.I5>$OQVG+<Y;50V7I#3+LIE*BI.LU"XE,MQ#3B4N
MEO`I`+JE=8H@%)`0SL!(6%YB`2$FNFF)Z/<J,Z/4]SV?1X1'P>3)]'A$`$?H
M]&11S/VQW'AXQ7;&NX3V(Z5>_,:OJC"BE"YG[?J6J=:02%FAK5/NK[?*I3X"
M-JMOVQKM8D@\EFJB\M+7W3$+/WJO0L(S*=RX!FT<JNR)BD"*A#*"5:]Q6BKS
MK'54ARU/PXS-NMTB2\N1&MTT%"6U`-MQ+FZS$>==5@VCC'$);)SYTD)QUMSD
MMQV`%A1*U@``K3T>$J0"H`<)P!QX,*7+?]/EK]Q0X\1>FR<=Z=IA$]`DYT-B
M[+DHNA048W1BT*$PC)"^:HM,%M&$>SCD6#B-M%?:N9!VY:NB`D^0`AE/W;WN
M%IS?'J:7K@ZFG:Z4)C;7@4%#DMU9+AEK<1$N$=V`ZEI/'(?@3'$,MH>95GCN
M$C#F-J>M[*8W$IC=:3F40D#9EPS((4,=F"D@DD'A%8KF$\E-7\0-`:IJFPMB
MU>><I4*NJ6RA638=A;/*+4*$X1O;BY[>U[KV1LT9596%.5)O/M85LN,NY8N$
MVJ*)5?$9FY)B)JW?9J36%XMELEVY)EO"/+8A,J3+DRTF(F+;9DQ##DAMT%2X
M;DI:!'1(:6\XLHXSYN14Q;68[:UI7UHQ25'K0GKLRTI)`(_A!(VD'`#@L"X_
M2XS^A=(SPR%@EAF]1:VEQE+8HDM:9(9*FPKP7]E617<HJS[SQWC'AB**%,X,
M<0,8/"+;MY,(6W>+?[<&XS(CWJ<WQ<<$1T9)+J<C`(20RG#*T"D$("<0."MO
M#5GB-+Q)Q;2<3PG%(X?N_3]VIP_!F;W^RU>?Z^JB.^2GK%7]'Z^4KW):7XV>
M[.Z35&>F*['[2EK'9*G<]=[&JEI/!1FH63ZQO)374#,.+8W&1\GK;9Q")NI)
MRV3036*Z#DJVZV7+?KJM-STJSJKB(TJ2RT\N`VPQ(BW2-(CAURY+0PEN:\TB
MW+XG/-6B4IJ*TZIQ2#I+XM:+8QD?+&)2"1G)(4A0.`1MQ2#GVX)&7%1&&--%
MP)AU:WQ6UY5UMDJ;8-4IS;-0);5IB\V)9LWJ>Y-@UQK15K#LS_X_GUM5-HPE
M6.^EA,]>&AA64,83]86]\HN<BZ;W[G=T6H6838]NDF,&XC(49%LAOJEAF#_F
M;(N"G#/#4?!IL2<B0,N`VUH3D@(;*^,RE8QQ4>!:AEQ5UQR89<3M.7&G"Q$:
MV5&%%&%%:/LKL+9/:)?.4,>O\N7GN;N_3:O))-<YJ[V;E]S^L*4BI#T6JM#^
MU/1(_P#V/D,M7\J3;R9MX?N1>_5TBD/LGGF)XRWVXI1=1\0Y.@]YG8]Q*R''
M)R#Z7VM<WT+3KG4H_<D:SV.PL)H*P7+7:.F(2WR$A)-Y(6RLDXMTBB*1!%)$
M"`.5:=:;ZHFH^2E%T0AK5"2VS;XJ'9,60NV+5"6SQK,::;F[&0A!1QB6$6YA
M68]>LJPI;(]N4S?%2<6=I6K!*AG&;'`J3D!VXX8YSTJNIQA]=/1A15,G`#W6
MJF[YG65YU=0-,V*$J%GD:?7(C0T=5-AVBM/WU/?6&0L^TG=HL<_,UNHVJ07C
M(]8Q$UK((>Z#I<XE23Q]'*0\"O&@&-5Z?N]ROMLD36$27W+NN1"COH1)0RAB
M`F.PRT_)CH0^\D%286/@S3:05JKF;1F;E%AUM#2PDD`-@*(V8XKQ)(!V#^-P
MDU"^@:1+WCO3-M[,C=/UFIOZU>;4\N$)L?4=AA=O5F!1BD:<SV3!\E*1)HUJ
M4AMI*BS>15!F@LS&0BFRL@V<19VI4S=WO'O\+3_)$LNE)5[ES(\JWQTQG85Q
M9=MK[Q<,E4%VQRFR^V[`'&-R+O%\!=9D+1&=:F)>*AC0VE.WYQ]+:4E*SB%(
M(6!AAF#J3@0O80VK,"!B"G"G5UWLK;<CSQN.L[*UT_:(.HH6X#7:MZ@4AK/"
M5B:I^N+'6ZZ[VB79EK7"\B^>%;S$"O#1Y%XAG'2)5B@J@@9!]3:5T9%Y.\'5
M=J7>XEPFJC?YJ_<@ZPZ^U)FL/O)@>`QQX)D25QI:)+Q1)=DQ2@E#C@V;+\A5
MV4POBU(3CUP1@0"$D#-F/7?2G*-@2K'@%1%3H=Q4.\REH..B;7JYC96UQLKN
M6=;$+M)EMUJNY=VUO5FU(K`>+T769&SWR=L!%I]511T[CA222(#EJ8O:7R<W
M>^2DS<)+T.[R(JXS"6TPO`%6Y02F.9"I3^V[/H8B1(93#2E+;;V=:U<4Z#CM
M)+=\*$A385F..;-GZ.&4?FP2I2NNX2/NBI(U-7]UV_F"_P!G;RXD^0H4BX\A
MM::CWC!3VGSP:6M75H*YH&P[?1[`5OMJ*NS^IP/N"PE8%[((N8^9="Z:-TG)
M_)^6UE<M!63<DWI/=_K/C'+A!LTZXVIUFY!TSDQ\LR%&ELXVYR*B0]X6]'EM
M,J0]%9#+SJVD\;[1T2G+D7Y4?`(4XE"P489<>M44GKPK`904DXA1Q`QV1KJ*
MAMX[G*WO<?#U&#G7^R=WP]UD86L:!C:99X.5DN0$G49"M6^M.E-K67;,HG#M
MVS^/=)(K,'%;N"STRGCD^CJM:ZB=E<GY6GI+\V1;F[5:G8J'7[PN4PZVBSMR
M4/QGTBWL6YLN+6R\VI2743;(A@)R*Q\(S03=>-`2%E:PH@-A)!+A&!'7E9PP
M(/!E<)X:GBKU6O0?>$;)F@VMK%Y8+K%1%B'6*,LHTV)$IQ>J:E4#D<Q1855C
M*NEFT(G)"/N@D]3C'"1C("W33.*=W>\7.X<FJU0#9[LBVP'G&?#RV%0G"Y<)
M,G%+G&A;:0ITL#\BIHOH6`X'%*2,MMM"+PM7&-E:@#EQZX8(`X,-O!CPXX=#
M"LS6Z5=6W,FSW!1>G)SCN$2]V8:#WVI&1IM=*GBXN/LTYQ_K^NHF6ME[53B$
MF[>8LTM(-XP%#HL'140\F/@W6_6%W<;$LB4SC;T2#Q3KMH#B_#1QCBV&KP]-
M<;CQ`7%+7&@QV5OX)7)9*_RJ?M#3HN2G.MSD;0',!EV#$MA()5LPQ43AP`X;
M*]%'U_M1ARRMFU92AW:+B[`T?5DZ9)O5*^I4(15.OE6N2,S)6JZ[I?W*2+4V
M:2<?$P]*@SI"`2#9TX;HOA\]0:DT?)W-0]'Q+C`>EQEH?!+5P%Q+H+V$8M(C
MQ;6B,CPAQ1>D2;I+"AC&=9;<<CT-,R!<%2%(6$G9PHR8;.NQ)4O,<!L`0GZ0
M2`:;/:G8*P?:F?PBSQ:_EB<^30GC%P]4SZUVL_9J5TD=\32S:Y[<5OV^;S5Q
MED#Y@_,KWB^@T>71*2'2GM%$[K]55)%PYD36;O(>2^P(^KN:S&W:K6M9=Y)T
M!Y1FUG6A9+4\3'LHM2(U17X6>O%)4:O65PD).XV]RZ5/'>0$8I)NVZ5<+?A&
M%IY+FE--R9:)<J!,C@);F)EJ8#J+BXM3@<N#SK,24%-.VUEBV6U#:1*\(5(6
MIEU:O6U7&7M]Y*<J5)/"G+C@4#9@@`J3M"R5K)ZW##:*VGA=;UK;SHY'NW19
M2)D/<C8RDG79MS*L[FU<#L*B-B([`9V"#@)&QP,(+4Z6OETFR)(>LNET5.OY
M<B8-1OVLJ+-R?-+LLEEZ-Q\(-O-);5%4GP.6HF&IEUY##SN8*O"%.*,F<VVM
M.7P=8K[MCA<NKY.(5@K$''-V2>RQ`)`_[/9L22.B*N.QCU=+53?"@FU"\M>4
M1+)2[S$ZM1<7O\F%J?R[F3JTTW?[^V))SC23D&E$@Z[/V5"S.I'W+*E,RKN!
M@R`Q5*0IB.'3R=_*M'G<SI$VJ?;WM7*3$\/CH;2W(:*+/";:4A"I;KS+!82S
MQY5&CMRY1,A!40IMKGK7X1]HOYTK$?KLIQQ!_**)QZT`G''#KB4IV?=-A.ZN
MQ?WXC_67QQ_R;^>$?=*Z]6-6HW@^S_\`+H_#4(:N7<MK2=RS;E>/&\'.+M6A
MU%4B.G*3(RB#<ZJ#9XNF5=4H%$Q$53@`]($,/THR^?-G;:=Y&-R:?44,JU%9
M@I0`)2DR5`J`*D@X#;@5)!Z*@-M<#H4D:B01M/$N=2E$[MFT?&S<_)^4Z\LT
M57<MW#V$F7+]C;V#M]M3;LAT;D@YR*AYF0VFQ([]SD)+R=!)&NL&#`Q/&-1,
M:`?E36C[&T+I*)@RM"4%*76DH7&6E%OMR/\`RQUIQUI%O7EXY3&=:E379$D*
MRN@!4K(YQDE]6WI'A[-?9@@$KZ&.'8@#H5<+C(ZZ2JF^[%)M,)7D#\?Z9>*S
M6$#ZU:ZIE;++.)F)L=%6>;-G8]9*72H5/@+3>&*,\F2=FF#J6([(=DW453\B
M)XUY/*Q5I`P]-_U;G6^7=E"<JX-L-I:<8EA,%I8+9ER7H\59948D5YN.6R'W
M4H5QZLG/6+PC,]QR5I;ZW(2<04]<>'*`5;>N4"<=@Z%/OO/L[$^FB^8O,>G\
MDOG!:K]S%^LK?7.[Q_-3'C'U%U&6F^M\="]3J]?W(DNKUNGJ];_%^KUNCP]7
MI]7)'_F_8?\`!G(S<']:;3U)5<AH'VA'<'/JTMW#ZK;):<AK19;Y3K#$;$<:
M@09<F9VR.M#';.MLRLE29^C-*0EI]S[N+596#5L'B1G"N54&#9@7QJ;H[KQ]
M?_?;=]+/;LXEJT[.C/Z93>RJQ-,)NX4FW-HE,RU2C<D\4)`=$/-X*4)4\N0<
MBFDL\6J=M;?$Q2W4J#W%_E2>+[,E)3ER;<,,W98[`.CCC:7C1*W]8F>]XIKT
M3(^9K8J>XOXVZ.]ZK3Y?'K!N?FV1W!SM37'-S"N'%J'Y;RY:I6=H,-P*[1K&
MN=RRT1=K&TK$ML.]2W':>UE*R53)N)@@2G.$X`R#EH2K.6DVXCU)!5(6T0+S
M+UD_LI'2<ZBJ;.GH?>JZKFB1ZEOB^JI49P^</=?Z-BX6-::^5LT9N=>5V);X
MAW3;G?4[%&.=6Q4@=ZG`)*LO<]62]TS)/%9-J4D>G3KW.JCKT?&0NX);;;O-
MY<=6J8&'+8&XK#B9,6&67$SW$!"IBDN\<ECB`MA$1XJDJ<!<,1()R8DMM@#+
MB%XJ(RJ5B,H_@[,,<=N8=;5PN,4KIJ,**YD^\KVKR?'D%<=0Z5UI7-DMZ]'1
M&TJ"(V+6C&=J.SEJ/R79GF9"!LNTZ;9)QDBC$-'@-_<J49*PS&64*FHJAT$N
MX\C_`)J.[;W(L_D35-PO_GR9XRYVQJP>1Y+2'&SB)PSE&UG@Z[#V?1&K8^(1
M6U/:-OV>T2L3K2O2SR*C8>+V-JF(A6D?66ZS]=RXDW#A1!!<R;<I6ZB@UQN4
M)NJA[TN6GO6AF)(E2HFII"UD7%BVL,-.+2VAQQQR%<'75+?*6DH0PA"5K;"G
M"7$II7+3.5"T[!5F"4J9&'6%9)&W``*0!@-N./T[-E6DUES+O*]".Y\(L)IS
M%LEY/W%]T`B3/%4"'64CB2R#:31:*F'K$3<$!9,!ZIQ$P"88U[JU"8N<AFV\
M=X`AY0;XW)QF4$@!9;*FRH<!4@Y5':,`<!V""HH!7AFPVX<'WL=M0GR1Y.ZT
MXM5*&MVR4[,\0LLZ:L5N'J4*$U-3M@"(DIM.)8IN'<;&INEX^)7.3RARB00(
M8PB!"',7O=UNZ;56]V\OV72QB(<BQ^/?<D.\4TTSQB&BXLA*UE(6X@'(VH[0
M,,Q2#BS9S$!L./YB%'``#$DX$X=`=#Z:BCE+49+8M6U]>]8\8-'\D[.Y;JJM
MORV5FL%6K5-E*^[E6\I"2=K2"31F"2"R`HP7BFR4LJH9LYD(<@G?I=CNBO47
M3%WN6G=6:MU!I6TI4`K[+??P?DMO);+;K<<\66B@+S2\RU1TI#K4:<H",O'G
MMJ>;0ZPPT^Y_A@;$D8X@G;C_`(.S'@)3PTZS(#%9M"G3*D<&R`'2*B5L5(P)
M$`R96Y%G!$"D'P`0%%`+T=`&-T=(H,^07UE)*DYSMQS8[>',0DG'Z<!CPX#@
MK:#@%4N;UD4W',.,H4OJ2`!S(\I-,VRB[097*H0<P]GF"_#V=>Q$P8=P1-M?
M1QM?46TN'M?5A%&;YW$0"Y&BZYVRJ[[=WL53>Y%W44*]2>*:TC<X\N`J-)=:
M2RL:D:2XU_Y:Y&0OPR7`0U,3*#K3<FXMJ>;;2ZAOF9:L;D&5-C$R$%*LP!Q_
M(G`]>#AE2K%.7`D(.!.&++W:IUYAW@E-MSK:FLHZ<M-!I,4SUG)R:D9?GA:@
M;<#E)^Q;)0CYI,>[:5A<"R2</&2XIQ+T4`6(DJ":56"\W*3R;)UE:L]V=M\.
MY2G%3FVPY#3X3]FI*%J+J%-<464<:I#;J,TA@.9%+059KK:!>$N%QL+4A(RD
MX*V9_N;<<3AB1P'#&LRO2KH'-!*Y%7IZ$V:!'R:(BM]#5D9'6@*%AE[#<]'0
M&N65EVA9V"(G1CW$[-/H:*<B4[-9L8!3-@-WZPG<2;&4SE0!(ZYQRT>$%$[#
MC0S%NKTU3$!A9P4\B)%:DR&\0^AT$*'V6G?M/C>MS8<`<PQ3P8J0$XJ/T9E%
M(/`13^8W&MO2%U[7^TT.7LYME]1+O'Q$BT=U8I6LUJA?4ZD"X:5YDYN[N9G+
M3;]QJ7%PTJC1-"-@("FQ:I0(G)@_.@B_!Q5SU)I!S<K'T;'N-O<FM+3(ZYJX
M"XAX*>4F*EIJ/&M@C)5(<*GY<RYOI.9<3P<.+CUJ$,R!<3(*%A)V<*,F&SKL
M22O-L&Q*4#^-C@#22<;6%&F.]IY%;`)KRY05SD&NP:Y&6HT+<:JVG(*LP6F(
M:7-?X*^Z6AWLEY-/LERUN8K]UD:[(1JY!%@FLFDKB][TI.H(/(STQILW.#(L
M3:X;ZX_&QI"FG7WKFZWX&[#NCJ49F5H,Z-,M;,UE]"O\Y4VI:*U<(-*U"\]D
M4'3F`.!&(`0#F"D#';V)2LI(Z&-3YQGT_MG7G.#>3N;UE9F>KTZTZ8TW:TX^
MH2S"QQD@>F.(QHU=5R+C)F4E1<Q[Q,[15FR3BVC1)-4[E02+KIUO6UMHW4VX
M#3[,"[1%ZM,M*Y-O:1+"V'$>%)<4I+[BVFV\JVE!Q+CJI#CBU(2TD*;;S(,:
M0S=72IM08R]:LY=HZW#@`)/#LP&`'1X38AM0@*4B53$X)@HM&$$YO\$@&E&9
M1./2(!T%`>GU<4OY6'/BT?W.Z^J)U86MO9J1TT=\35+O"SF)M+?7(^,HUHXX
MSNIZ>WB+5,L[%/J75*=;62C7:MUM]"33*Q42L01X^40M/D[-RP>.O'RT%+@C
MX]@FV>K64>6US0-Y7NA/[04C^G//\/QA/5KU3U0O+/OK:C/V%O&3I)2C1:T4
MUHK"XUQT&LD:;N0("Z[,=^1;%KKLNNK6V7@$VJT_24YQQ-)O&T0\,U7$]:^W
M7K3[_(-FVVVJ=CJ9N#@<5+7&?3X<9-LXZ+!3FA/)\-CJ1,+B8=T5%1%4P[-8
M#S82L"VW1J=*UX'%`PRYAUN5>"E=D.M/6X9D9LV(2<#3/VCC!R&N?,Z5W/;8
MO1UZTU`;-UJ_U:QLMPW#3MDTZBP-'UL^GQ*GK]X;76RVD#N:#E+#7Z[;XAXB
MPF5!?MY!J=8@-TFM.]K=I8MQ;.A;,]J"WZYDVF<B>MB-;9,&3+>ESD,[9B?#
M8*GK8['AS)MMDMJ>C`1G8SR4*XS/<@3';F9+@:7&#B<N)6E02$IQ['K58+!4
ME*P<%;0H8[%\YX5NKMN\*X46HTWJ6K2`/ZH>92NM`JZ]NM+Y]NW6=7J[K6LZ
M$6YN=]O3)PY+&K,T54VM3A7BDJJJ0%"IK*3R>+I=G>33KVSB/>9D;BY`:,69
M($:.A%JG2)"9S7&)BPXBDI+Z75)+EQE-(AH0HI*D8=V0V+Q%<Q;2<1CF2,3U
MZ0,IPS*5T,.!"3FZ=EV].'W&/DJK'O-WZ5H]\FXD!3B+:[CE(B]PZ!V[EFNS
MB+_77$/=8J/>L7J[=RV;OTT'+9=5%4ATE#E,U7=]OMWL;JT.,:`OUPMT![:Y
M'2L.1'2"E04Y#>#D5Q:5H0M"ULJ6A:$+0I*TI(W<NVP9V!E-(6H<!PP4.DH8
M*'T$8[1LICDDR(IIHI%`B:1")ID#U"$(4"D*'3TCT%*'1B7K4I:BM9Q63B3]
MT\-9W!LK[SYHHPHI$^\-UA';&T`Z=#75[;;*78Z]8=>UYM"Q\^YD;A[L,&C1
M!A'NZ_87A9!RQ57;E58D0>E;KK$363\8)@<+R9]6RM+[R$,B4F%9I\5YF8\I
MU;*41N*6I16M+S*<B5A"RETK:*T(4I"LH!U-Y82]#QRYG$J!2,,<3CTCMZ&S
M;P[:7_FA4"FX+:4I4C7&L*A!/=-3UCC)9'8T"M4XFFL&:\G'15CUQ$R,G1;:
MXEG+6&8O'+!^W9'>G768.D6ZY"J3N)O9'*#OU^BREON2&[FRPXV83PD.25J#
M:W&)KB&Y<9+:7)3K2'65NAI+;<AE;K:CAW-O_P`J::4G``H)!S#`)X0"D$I.
M."02#ACB00#4?\BJ6QM?`?AJE9H^^5FP/X73%7A]>T>RSSJCEL$U2HRUDC]F
M4%G5MP/-NUZ`^(XHG;IQ,I($*LX53=-$%';U+I-V-^D6?E&:Y7:G+=+MK;]S
M?<F2F&4R^):E.1RN#,5(MJ;<\]X7F"S(89)2TA33SB66%^4UH.6B-G"TK(0`
ME).7$I!P4G!><#+]!/"<0,35ONO7#YW0:.ZE&D6PDW-0K3B18P<9)PL(R?+0
MK)1VTAX>:;M9F)BV[@QB-VSM)-R@B!2*D*<I@!E&I6X[.H[@S$6\Y%1-?"%N
MN-NNJ0'5!*G76BIIQQ0P*W&U*;6HE2"4D&NC9)+*"K`*RC'`$#@Z`.T#[AVU
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M?EI%Q*3LNBZ?N_%N'"B2<>_*6F3IV_"_R;C#U%`EF0R"Q?668]U0E,5A*#+B
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MC+2$O;)J-OTG;R:_C2O->[&2ITA>5*]`VDM0:;*&ICKI6P^X=ICE?)0E?&^,
M>)(]'CS>+Q5(FY7>-/T6YK^%#8=TXU",Q>69",E$0//1_"50?"/#0SQL=Y/&
M>#Y<&EKQXL9JP57&(F0(JE$/%64=:K#-@#AFPRXX$;,>CAPU7IP9EZ)%<FK/
M*:U8Q578<AZQ?+1=]9P%MG[M/TJQ:WNH*P;W;:]XK9[%!V252V#)B"+&8)&-
MG2BC)-HX200=).7Y04+4,S=1$B:J<>ER-,RXD>+.>CLQ693,Z+@ZFW"(^&76
M&S#8ZYV,7W&TI?4\VMQQE>GM2FDSE*8`2'DJ*D@E124JV9\PQ!.8\!P!V8'`
M&L#PWB)QKWDW)B0MJE-4?K)[Q3A)FH0MRKT!85U+KI@;9&P;RR:J:/[7/59J
MT@_C0V>W^P1T+*NR^X4<T:NG9R;'?C-M[W)9TI&LPG",DVHNM278SSS($6Y^
M#K=2Q<%(CLR%*E^`+:L\-Z5';/VA)>>992KXMJ5B]OES+CU^!`4`>N1B!BC:
M1UN8%Q023UB0":9"JZ7V1%=X79=Y1NU==*:BN[2TPDIKF&M+9O-N[?6-?Z\K
MAEG]60AE%IFZQZL4(OW!I/\`Q"-:H%.WZ5DP12Z[ZZTM,Y-$7=_*L]S&M;>N
M.ZW-=CJ4TF,_,FOX(D%T!J*L.?D4!C\L^XX4N8(5QF:W&?3>%2DN(\&6""D'
M;B$I'!AM5LVG'8`-FW9B:?J6M3')]O*UC<M5FZQ!;WV]MR;9)0=#BMD1.Z&:
M*U(D-4NYAPX0V!.5X\)8Y(_E";844XV%09BH=N=,<S+WK.ZP=TJH=VL4R/=I
M&G;;;FEEV6Y!<MBB)2+@EI(,-IX.L,#(I>93\IQ\)2XE8KY;CH5/S-NI+8=6
ML[$A07V.3'LB,">AP)`X*6'B7:.1UN[R/D,Q7W3;MCZ*K^P-E2DK1V&VI--E
M0WD=L;?6KZJI:M<WW6)@85.,)3BU]A#4FU(,W3Z'2GY-HL=P02*SOEM&Z^R\
MEO3,ANPPK7O"DVV"VW+7;FRJ6E<*T3Y`CS8D_KY#ADF8])NEO6XVU)7;8CS:
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M.H7`1)*E%M4YUHH83X1G&W+VX<IQ"E8'$#^`A).&&)!PP&"L.CE!Q-;CJ%&%
M?]X[N"6BYTT^B>JS$JC.0MFIY1$\M7M1Q;BC6Q"8=P^QKE6(`M>+(UY"%8R]
M9@G3]^9Q((O'9&I='K5<Z-R7K)"EQQ&6)C;9:=8D\#;UQ<$N.6TNPHS[W'%B
M:N4[&G2VV8X;C+894\?6,$F].*2<1E)Q!'1"!E.."E`88IR@I22<2"<*L0VI
MV"L'VIG\(L\[?Y8G/DT)XQ</5,^L;6?LU*Z2.^)I9M<]N*W[?-YJXRR!\P?F
M5[Q?0:/+HE)#I3VBB=U^JJD$XBQM+KW>L\H6-5E=.QR4M`;<6-0HK2<%K#9K
M"5C;MJ@]GLD1.1NJHA_L2A3$K)@65L9[5*H/K&11L9!!=J**-=/?3*OMSY'N
MDI%X9OCJV9-N'A;ET=GP5MKBW`,,.-+N#B(4MMMO&/"%OCK:A%+H<<;="UJW
M;DM(U`^&RT,0OK0@)5B%(Q((0,R23M5G.*MF`(P$I\0G^JW/>#\NHV'K4`TV
M;77.RXZ6LD,^M;*0E(*8OU(M[_XQ4V2>R,7'O#2]A0;)2QS-1F0C#J,4`:%,
M<W(;ZX^L&N37HN5.E25Z3E(@K;8=1'4AMUN'*C(XF2A"'%IXME;BHX#G@W'I
M1(<+Q"1[VXQS>)*4I`?3F!(QV@J2=J3B.$X8[,<-@PJX`YR)$.HH<J::93'4
M4.8"$(0@"8YSG,(%*4I0Z1$?``8R9*5+4$I!*B<`!PD_0*Z2J>^`<"Z=<K^7
M6RJY=H*W:PN4]<BQ2T#`ZRK\<K:&FYKHWFCQ;&H,&5O4:L!9&(XDIQ1V>;=K
M'=)'Z@`X>/;Y1UQ99W.:*TK=($B%JV#'C<8'GI[RQ'5;(JF@XN2M48*7F!0Q
M%2V(K:0RM.;%MCF[0@FX27T*"F%%6&`2!CG5CAAM^^K',=OW397NKL7]^(_U
ME\7SY-_/"/NE=>K&K5[P?9_^71^&H<T[VY9^CY+V$N2Z_-PYE%V]/VCOZZX+
M0?M&WW)SJ"D[[MY[JE_O+ER2GUB`BKK`7*4JULF*\\MZ"<RTBMD[!<1KR8IL
MV\DV-(F'23\@&257*\?^3F6*@BD44P@,Y4<?6,?=_HM5[ER7K#)@MR([3R8Q
M+2G(,,+2U):2A<IM)0<%)06F<X07'%D**HV0QS*D\6D!T*()&.W!2L,4G'*?
M^D\.`JWMV[:L&KE\^<MV3)DW6=O'CM9-LU:-6R9EG#ERX6,1%!N@B03G.<0*
M4H"(B`!C*667I+R(\="G)#B@E*4@J4I2C@E*4C$DDD``#$G8*Z,D`8G8!50W
M=15F1CC\B[:SMT1;]>7RPTV:HDA"5O6M0C5_\;V"O8I"*J]`BHB0KT&_DGY0
M9M)LAY(J*0'4,"AU2`]7EBW6+*&F+,_"?A:FMT:2U+0Z_.DK'6PPRAR1,<<0
M\ZA"#QCD4A@J5E2"E*">=T^A2>.<"@IE:DE.`2!_"Q("0,!CP!6VK".0DA'Q
M%.;2LL_8Q45&/UI"2E)-VWCXV-8,XM^X>/Y!^[41:,6+1NF91594Y$TR%$QA
M``$<>'\DOG!:K]S%^LK?7/[Q_-3'C'U%U!G&_8.O=AVUXIK_`&!1;VE'Q#E.
M17I%PKMN1C#OR%.Q+(J5R4D`8F>$04,B"IDQ5*F82=/5$0D@^;Z<O(TD*/`-
M4VGJ2JY#0/M".X.?5K`\+;3K9L:+U;`<K]C;ZO%)UJVKEAKURK$/7HM)UKM>
MLU&TSL4K^2:FVEX[@)QVW8K(OIJ6<,R/B$===8Q5LKL[]K1JET/:NN.CK7IW
M3\^ZJ?9>C/NO.%,T/R8[3@^T9,=*7FDK=2IJ+'0Z6E*:RM@HI6K8XP,(Z)"W
MG4HP(4`!UN`)'6).P[-JCACMV[:L)QM-;BL3/>\4UZ)D?,UL5/<7\;='>]5I
M\OCU@W/S;([@YVIKCCYD2&R7/)FWR:NT[4EJZ&Y0Z'I,?+1M+LK?6K"WS%8U
M\ZD>.=LL+>*)!R][=P?4)#K*G78-?C.].H]0DRMF"MZR?V4CI.=15-G3T/O5
M?SS&C=71FUXIO9=BVJK1&[PH]-W]58VHN)MC,ZOUX\ML_6;,VL1=?VI_5@:7
M&R-H5^LS>LTTVLOY011H[0!T-,#=)*U=+L,]RU6R',FV"1.DV>0N2EI;4^;Q
M#+["F?#(Z)&:,PY*92XTX5.1N**7F7"U3AYZ6$NI"UJ2ET)2X`,<4IQ(..4X
M=<0DX$;#CL(QJSG&?UOZ,**Y3N]SA=44W=]]W[(<@=;4';5)UVDX@=2&G]MQ
M&Z-@(L9/8-<C?B>VHO(_5<"[&7B[Y,QC87$$^4,BN]254714%`MW'D?\U'=M
M[D6?R)JFX7_SY,\9<[8T[6^8NTVCB=P#IU7O[S64E&ZST_9(R6]TMAL8FW";
M41JY/5IBWH.O[.9]<XN(?@XB4U'`=0SE1;R)R"70$`^\R3:+-RS]\EYNUM;N
MT1R]RV'&\D);D;!^.\R^HRYD<(BN.(R2"E&T(2CCV2O&E2AI<<T[;VVUEM0;
M20<58'801UJ3UP'!MZ..!PJ[NL2*<M782212F4$GL6R<)I6*/?1,\4AT""49
M>,E&<?),)`Y?IE4G#=!8AQ$#ID-TE"):[1E0KG(BK4PI;;R@2RM#C.()_-N-
MJ6A:!P)4A:TD;4J4,">Z;5F0%#':.CL/WP=N-5E\PMC.*!R8H#9A;-^HR%VU
M2E2XNG:6#1B2+NTREOG'U1>SSG>C69B6Q)A2(?-#OV;1!"';(J+23HK91(H.
MNW(Z7:U)NIN3LF'IQ4:!>#*<DW3[6)3';C-(DI93:5-.*+8<:<#+CBUR7%);
MBM%U*R='<GBS.0`I[%3>4!'%\))PQXS$;<",0-@VJ.%?7.R.U6RB):UWRX;H
M@-JR7&^V4K6!=?56WV;W&M\J+A!F[KMNJNO[%4H:V7:7ER0$@U>I^0SS5PT(
MJT$B*`A^<GJ5J^1-9L^G8-BDZ/:U3'E3_#)$9CC8S>!4EZ-(F,R'8\5MLS&7
M&CQL1Q#RD/!3CF)=DQPDN/*=$@L%*<H)P)^@A)`*B<I!V*&&S8*LMJ*"[6IU
MALY;KM7+>O0J#AJZ,)W+9=*-;)JMW!S`4QUT5"B4XB`")@'&JWIQMV\RW6E)
M6TJ2Z0I.Q*@5J(*1T`1M'W*WC8(;2#PY1U*K[VS!\;*MS!ID3>V6TF>Q=XR]
M`NU27BYE1UKNQ7"@3]4Z\2>'175>0+A-YJNERLRH":#:0)`QQ?&B!'J#AR>C
M;AO3N^Y*=,T\Y:'-,:?8F19(<:"9K,:8S(P<#I`2\DIN%SCQDYEK9,N2<@*F
M'&M/(1";N24NAP/.E*A@>M)21LPZ'8(*N@<J?N@X2_LFMF[Q768Q<.N(0%5A
M96[LK!#WY]'2AH(-GQ](MT+!U-:"K#:8K$A,.TVMCMAYEB@@\,A'-D'1BN"Y
M^FY#UJY,5U\+?3_G,QUN*IEV&A;?&^`+E1G79`>?4V^AMM3D*W",ZM;8<E.N
M-`M'Y>`7>491P)!5B%8'#-E(`P&(Q."EYAMP2`=M1[5[)6;)WH%F;FJSQ5S'
M6)56$E%IV/@12GZWQ_DJ=,71.%>U:0F+K#^Y[AY`HA'V1G&I+K'66A3O&2D@
M/2W>UW6U\DJ(X):`T[%`=;#2WL67[PB2W%+J)"&HKF=+<M1>@NOJ0E*&YX8?
M3&KP;6A=]4,IQ"MAQPVAL@JPPQ4,,4[%`=$IQ&-7!8R6NDJJ^AHPDAWEU^E8
MR<-.IFJ;^53EX.S4U%9FY<477%==:_M*<XZAK_;Z0Q]Q!F(B-KK6;@8:;=/'
M3YXU>+E:@[[42Y\;DJ6V'+C^#J$U#9;=8DD*2)<UY,R.6DNPXTI?&^#2'YKD
M67)BML,QV'F&R[6@:"57Q:DG'K<<04_Q4C*<<%%.S$!(4E*B22"<*_WCYN3D
MC-<W-OT#<%Y@EZ&28V'"T.DTF=KDM1(E>C5G2\X:%15LF@-8[2<7F,A-BMI*
M4,A9+'$"I**()E)Y"<Y?S>5H;=;`W!V34FB;?(3J(L0G9<J4T^W+<$M^Z-<:
M0Q>)\`1%NPEL1PN%"DX1TN**O"$@D.3-5='&9*QQ6*@E*2"D90@X;6TKS`*!
M/7*&W#H5IG%B2VA,=X/R$E+>]V/7H&<A;7-Q&NK=.V9Y'MXID_UW7:Y8XI-Y
M`L8):"DHQJ*C6/*A&N8)955%55^NHN9/>[WHNDH7)KTU$LK=KDW&._':<FQF
MF$K4XI$UY]EPI>6Z'4+5@X\5OHEI2A:$1VT-A7E`4^J\/*<*TH()"23P=:`1
MLPP(X!L*>`XG&K0]G=(4V0$H=8WE41U0$.D!'W69=`"'2'3TCG8_*PY\6C^Y
MW7U1.K'UM[-2.FCOB:Y)N[@@+C7>8W%:WQ&X(&U:ZLMAOM(@X./W#IRY6->G
MOM2(-&;:QT&MQS+8U;*V2X^5]155^@U%N_15!</&.^J-E'EL\T#>5[GS^T%(
M_ISS_#\83U:M1V(A"%[[W5(.(BJ+R#[2$6X:.&&UXJ$>>Z<7!;3Z\M=J$\O;
M>:LEP8Q"XMZ\PCZ\ND,8JZ?.7)P1)Y#6DTRY//($O!;?F)C-W]Q*@NWN.IR.
M.V_!N++3$4TQ&6X,\QYZ:A7'I9CM-)+BO"%B>"?ZTMXA.):'\,#:`O:I.;$G
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M:83!Q2RY(B+7G2KFAN<(^11"7$(S9`4I4O`@DY@1BDA(.&&8]$!0%F6-2K>4
M8448448457YS4V_9M/7?04Q%[7E-:UR4_*-$VQ&+U/:-TC)>Z;K7$%5Y9_1Z
MP\C7:S*'M$VV8D<)*N'I'DRW10:+E774;N2W#Z)M6M[!J.#,L[-UNC/@3D<N
M7&/:\G%IFNR&T2WTK2%N1VENE"DH:+49Q;CS9;;2YI[G)7&=94EPH0<P.""O
M''*`<HPX"0,>'%0`!Q.&M<TA)8^'%%LNQ+++T:QQUEU1<$I:;UUK]>81NJ1A
M%JTE]57C8;.E@\>K/%"+1*TM(&:&$0*555(#%VNX@*M>_"X6K3$1FX6MV)<(
MQ;:FS`T8I[)3=PBPE2LJ0D%,A,=D.`#$H0O`_%SZ^VH6\HH6%(.)2G'-]U"E
M9?O8G"O3/?'RZ:$XMUZR<<Z#O:#=Z<B-E[,BY<\(ZB65JI=2I)V%:UX:O1SR
MBL[O82V66<PCI11I!&]R3LB.40>).$O*W?U=L.\;5USM>J+EIZX(OCD&"XWQ
MJ7%1Y4B4%OS>.6F6J*SQ$=$IM*7)8\(#ZFEEA;2_U?'.Q(Z%LH=06@I0.&&*
M0G8G`9<QQ)2=B=F&(QQIR=#V0ERT?IJWIU]I4B6K5.O+(2JQX@9A623E1B),
MM>9"`B`M(4KKR9,>D?I$@Q#MX=K-CU_?+*J2N:J'>)K!D+[-\M27&^.5_A.Y
M<ZONJ-;*(OC8K3F`3F;2</HQ`.'WN"II_!F=#_9:O+]?5=O>,<K-:\.J14]E
M7O2B&Y7]RN\KK6K1@I5ULY4LZU&O5PJE8:2L]&R9E9B_6>L-H"*CVZ9W#N1E
M2"F0_BS$,M&YK<]JK??O5U+I73M^58X\%U^=(<Q>4D,"Y,1I#ZFV5MX-0V'U
MS)#RR$-LQU!2AF!&NN%P8ML%E]UKC2H!(&SAR$@8D':H@)`Z)-31P]W$AOSC
MGKS:2.O8O5:LX:WQ$G08&9866N5^?I-\M%$LA*O9HR(K["T520GZTY=Q4HDQ
M9ED8]PBY\2F*HE!&]]VB'-W.\^YZ17<GKPB/X,XW,>:6P^\S*B,2V#(8<<>6
MQ(0R^AN0PIUPL/(6UG5DQ.PMLD2X2)`0&\<04@X@%*BDX$`8C$$@X#$8'"F7
MQ*:SJ,**,**T?9786R>T2^<H8]?Y<O/<W=^FU>22:YS5WLW+[G]84I%3Z/C3
M6^GU/=Z)Z>CU>CRY#U,M7\J/FS;P_<F]>KI%(?9//,3QEOMQ4,:MT;R)AN\3
MV=N^^,];O:K:$I"#9S%+N-#E9-KK*/K)6FN4YJC773*^Y-?2KMVW30E@KNP#
MUZ6D&0.SQ9`,8V5.M7;P-V4[DR6G0&G5W1N\1%(=4W*C2VVU3EOYII:EQ;F+
M9,;2E17'\-LXF1V72RF6H@"ESCQ9J;RY*=""VK$8I*2<H'6XI4C.D_3E<RDC
M'+7HA=V7V1[T2W:6<[DM7Q.K50AY&+TVE2JZC7EXZS:R4EI.6D)@K]2V.6D1
M9:XW<-9Q1LBP2>2*L44ZIW`>*\Y^@M.1>21"UVU8X?VY+FNH<N9E/%X+8G!M
MMM#601TJ<8?6AR*%J=4VRB80A+9S_J93RK\J*75<4E((1E&&!3B3CP["!@K#
M#$Y>C6N:\KD38.\?V7-7>A0LD^?%5EZ7)R=EUNM)U?XETG4OB6\CJV'BY:PM
MK+&S"@/$;4XD"*JMG3)N!A(@U33VFIKI,MO)=M4&P7%]J.V0W*;;8FAN1X5*
MN.*D3W'&V5,+;'%*MZ&2E+C<AW`*<=6KX90E=Z6IU`).U))3B,J4<*`"<0=N
M<G@('0%29HO8-T>\DIB9>S\_.T?84+-U*9LFQJ-6M8H%L6O;&Z'656UBXCKJ
M]"\NUFEDL?EQ$8L5A0:IK.'")DTT%N4WA::L3&ZQB"Q&C1]06Q]J2TQ"EOSS
MQ,QA/ATB>E<5/@B0IB%Q15(RA;BFVVUA2G$>\1YTS2HDEI8()4D)VI/6A."N
MNX58[.AB2.`K%QOO=.H?>L<H:G85JU6I[=3JUA43WFGUZ.VU89>E1VJ_'04'
MLI[KVASLQK*<ARKR59@6DU=B*DC9%916,%B5H*L;T=.WS47(]TE>;8F5*MUA
M1'\)\$DO+MS+<I=PP>=@IF2VFI[3F1B=+<BVLI+\9"42Q(+U8,)UIK4#[:\J
M5NXX9@`LE(1L"LJ24D;4I"E\"CUN&%9;A=4Z'KKE"[E:O,05@G=QO.0<38:^
MXK.OQV_JQ/4^PGK1D78*L)XNQU>,NIGIW#]=8/&NI+W-0>>.4.BHCA[]KSJ+
M4^Z1$.[,2(UNL:+,XR\E^9]FW`W&&E2O`P[BQ(<BY0AE">M;8\*<8R)"TK^K
M8VTS/*FR"MTN`C!.=&17\+#:`KH_2<H..S"6]1;ST1(\P[YI2CZ"U="7Z,V3
M>++8=ISVP==?'AX_>2-UB+7(L(!XW?;-&ZS5IK3KR"&:@=B%64+(+/&1#(1Z
MW&:UW?;PXVY&W:\U!J.[R-..VJ(PS;V8<WP5*$HBN1T+>2I$'P5J.^WQTES!
MTSP8R&'U!R2C(C2XBKDN*TRV'@M1*RI.;A4"<.RS$@X)&S+M)&P%,M3TV35[
MV,-AQD5JQP^_+'R&AKS;*O7>/%9BYJANJUL2)H)4[E6+!`;_`+)N*IVBC/J_
M*5R;@Y)LZ=,[',>7*-T6ODBYZROD1'(W_JS+>O"8_P!AV9V)'?>O+[C4M+\)
MR9C&?9>L[%LD1Y;4QB;%EL+;;=M<'P=+JW>.UD=I7]8>.2&\>-<"B`V`4X*"
M>N!#A6"DI*5)()"U8X`8.W6*97(/GW(O+YR3UQ;+[.VBRW*C:1C:C=H&T17D
MNI5("*E;`K&[0=Z]=7ZL:OL*L<C).8!%Q)UL.DJ(."'<IH'=K[=+AR<6F-.Z
M5ND/3D>(Q&EW5<F*\PYFN(><;9"X"9B8;\]E+RF&Y:D,3=A<+:DM+VC;2$7<
MEU]"GBHJ2@!0(ZS`$X*RY@DX8E.U/0QVU(,1<M3V#GS8X!WK.)7VS1ZT6$@=
MFW"W6Z1LC.!FJ%7;1,M].U!Y4I2E5ZH2)7:;*8<L9J,=O)-HY!RV6\6F93FY
MMCUE;>3E%N3-V>3HVX2N->@1HT9#"GFI;S#2KE)3(;E/2492[&0[%?;:8<:X
MIU&903[)=CKNZD%L>$(3@%$DG`I!.08%(!X"0H$D'$&MBI,3077,O9]AKMLV
MRM9HJ.1JMMJ==I<]":%9S)J;1YPAKI95HAS`VS:3:OR+!=HX0?-A;,7WDQD5
M%"&,&LO\S4;.XRTVRYP[,FU/.F1'D/2F7;NIKPF6U_FK`<2]'@*>0\EQ"VEY
MW6N-#B4J`/VTEDW-Q:%.9P,"`DAO'*D]<<,"O`C#:,`<,*_'5\+KI;E]N2T5
M2S[3=6)J@M4K;6H2C3==T$PG6D!09-P,W87$.M"VW;+.*=L1*[;R"()L71FX
MMS'2.</O5L_4[>Y2QVB\1+0BV+4),=]V6T]=UM*>F-CBF0X'8]N4XEW%M;*L
M76PZ'`E:4D82R;BZXVIS/P$!)#>."3M.&!7AAMQX#AA32[4[!6#[4S^$6>+G
M\L3GR:$\8N'JF?6LUG[-2NDCOB:INXL;XV[;.\$VAJ*Z677:.M*@YN,;K:LQ
ME9LT99)IW59"M'>2[2YS,,P@;A+UMC:%8NS146\?C"/&J*JQ4?*B!ED'Y@_,
MKWB^@T>71*2'2GM'$[K]55;1Q`;Q=>[R#DQKUM)^Y+6C5NV-J3K=K:)&;A(>
MF2$AJ-<;)'0]DY,VZ=@)29D>@DF+?7$+'.%2)&)*'Z"(*5NM]CLNY\ES2FI7
M6N.>N$J.J5-5'0TZ[*0BXCB%N,6*,R\VTC:QGO<IY"2L*B)ZYQ*OVT)1>GV0
M<`A)RIQ)`3UFT`ND@D\.#:1_A="I"XD69TMSZYG5*0@K"I*1TM8GZ]MLE>NC
M::5K[B6I+JG1+VP2-\DZ0YJA4)1^A5&T?#(.1B(Q1515$150/S.^>TLM\G+0
MMYC2(PB.LLH$=AZ*IH/!N4F2XEE$1N4F1BVRNX+>DJ1X0^E"4+`0XGVMSA-W
MDMD*S`G:0K'#%.`Q*BG#:<@"<<!T."K872C5)JY5?';ILDVZRCQ1T9,C5-J1
M,QG!W)UA!(K<J0")Q-]*!>GI\&,X92\MY*(X47RH!(3B5%1.P)`VXXX88;<>
M"N@.&&W@JM/AZQT`TY$;O#4&_JMM.36JS"QJU2C4X(N(@*9L6^VN_5Q>P7V.
MD).I;#D(1:96B(4(DD6$-!-DFCILHJ!%\=3OMD;QWMV5@.MM-S+1%3,6P)$N
M3QCCTJ%$CPWPS$6AN1"0Z&DR97A!?\)EK6\RZE!4W6DMHAB8[X,\EQ67'!(P
M`2I14,5#$*PQP3AAE2,".C3L;J[%_?B/]9?'5_)OYX1]TKKU8U:/>#[/_P`N
MC\-0YIWMRS]'R7L)<EU^;AS*+MZ?M'?UUP6@_:-ON3G4%*MW=5F=2.Y>8]<?
MP-B1F*]M6PH3MGLU=N4799I=6]71Y!IW.6G[]8ZU*33>MR#9*/3AHUFBA#MT
M.NH8ID2%K^\IRTLQ=#:'ND:1&5"DV=DM,,/1G&&@(D5+IBMLPV'VVB^A:GC)
M?=4N2MS*D$+454LRRJ3)00K,EPXDA0)ZY6&8E1!.&&&4#9A]RK3K(]KT=79Z
M0MKF(9U1A"RCVS.Y]1HE`M:\U8KKS3F;5?B#%.(0C2*&<F6'Q0(@83_2].-#
MM;%RE7.-&LJ7EWAQ]M+"60HO*>4L!I+01UY<*RD(">N*L,NW"M\LH2@J<P#8
M!QQX,.CC]S#AJOG@5#Z8@;/R`A-3[XAMUNX!YKV&L_Q;IKBMQ<&V4)=[-5I"
M8L)9"5@=D7NPQMG53E)N(4:QJB$<S;D8M%$%"G<GRBIVNKC:=-S]9:=?L+,E
M$QUCCY*7W'5`Q6)"&F<C;T&(RMA*F(LD./I6\^XJ0\EQ)&HM*8R''DQW0Z04
M@X)P`[(C$[0I1!VJ&`V`8#"I8YXS2-:XR[6L;D)X6]>U[L:<<!5H>"L-F\3$
MT"ROU/B]`VB/EJS,38$;CY*VD6CI@JMU2N$5$A.07]_)*YP6J_<Q?K*!7+;Q
M_-3'C`[1=4R=R)+5W7NZ-L<>6KJH7.U/]>5_?,_M37%HU%L:IV1*R(P*3>/L
MNU-;:MU?,7#:C8MK(:49RJ+I&':D:FCS)M'Q$PD=^;_S,I/O1:>I*KD-`^T(
M[@Y]6G,X8V2;LG/?DU-/&!(VHV1#:CS79)2AW>I2/17KGJ>O[)A(9C8*;#P%
M>DJ[;B(GMRC*4?K6:8D&SQ4`*T(5""O?I:H%KY.FE(##A=O455O3-+<N+(1^
M6BW%Z"ZZMF2Z\\AZ,5"W)=893!C,NL(VO*+BFVQ:EW=]1&#:L^7%*@=BD!0&
M*0`0>SP)S$@]#9<MC&:Z6L3/>\4UZ)D?,UL5/<7\;='>]5I\OCU@W/S;([@Y
MVIKC0Y5P^PW_`#(V7(SVJ4X36S;<NI%8.^1E1>341*W.&8ZF3J\B];FWDQI+
M785QI<A-&?VEY3'-E@X.`;H1Q3INS/6UZN?V4CI.=15-G3T/O5=CWHTM0M?[
M=XK[)L]$8VI;RRWUF2<(5Z':S#:.4N^H7$')N]@+O8F71B*]-NSD1@4UG*4D
M\E"J%;'712$:>G)<AZBU)I[7&EK3<7(:.,:?0"\XII2Q'N8=0F&$N-EQYI(*
MI:DH4PTP4ET-K7@OU[4RR[&?<0%'`@[!CABC`YMAP!_@[<2>#$5<IC#*ZBC"
MBN:/O$.2_*BD<DMHZ)T'6Z'97%FU6K9:NWFI_3$39FDA(QFZ8FPOVD1LC8-3
ML=E9,K$PK:RA(V/DRHL4GH%*"QR%-=QY'_-1W;>Y%G\B:IN%_P#/DSQESMC4
MS[\LLN?C#P0I"<;7YO7H\?-9V6P0\Q!3*DD]E_R<PD?2Y)A:X+9^J9V'CJ^[
M;JK/VC&7C7K_`,:B0%S(>4D+`OO(M5O3RP]\%^2[)8U$-5/L,.MNMA"6LR%R
M4+CO0+@TZMY"DI:<=C/M,Y5JXL.<42I\-:_ZOV]K!):X@$@@XX]`XA2"`.B`
M03LVX8U>31*TWIU-K57:2D[--8.(9Q[:4LTP_L$\[013#Q)Y.;E73^3DW!$Q
M`OCG"ZZYRE#KJ*&Z3C$?J&ZNWR^2KN\S'8>D/*6IMAI#+*23M#;3:4-MI)VY
M4(0@$G*E(P2.\:0&VDM@D@#A)Q/WR=I^_57?>901K/*:^:1RD!8?BQ!O+ELC
M7C?2YK1=973L7;:VO='Q-Z,*E?;!I.O2$(S?1H#&1R$F]<N1<MG:8,%BB[?D
MIW`6F)<GI(DQO"Y"8T&:;IX/%;N3D9\14&TKD1&;H\AU33_Y=Y;#3:`TZRKP
ME!&AOB.,4@)P5E&92<F*B@$9ORF"B@88C8,23B#L-1WSPU^6WVEKL&)IAI^E
M:YXF/)!F2@7B'_*!9OC-7-RLF5<:0=B/*Q=\U]&5%K(*21(HT+93,)!P_BY%
MPY8)-2]-R=]2&RVA>FILX1K]=-9)0KPR([X&QQ#]L4I]3K(;<B3')*F0P9`E
M00\RU&EQ6FI*W3XW9GC'..2G%I$?^"H9CB%[,#B%)`QQPRJP)*5$C"KDZBJ9
MQ4ZPN=%!L=:O0JIV[9155L@92-;',BW576<KJ()";JD,=10XE`!$QA\(L<O2
M`W>9;:5*4E,ET!2@`HX+4,2`$@$\)`2`#P`#972MG%M)_P`$=2JWMZ4RN)<T
MM<6/9O)37$&QLTKIECK_`$9(5&ZM;C9'=8M\C9*K%S<Y4MH0D#8(=OLJ&7E:
MV[F815*/FE56Z@NB"DB9T>[Z^W1>XFZ6O2FE;I(D1&;FN9=D28JHS"7XR&)#
MC34B`Z\RXJ"ZB/.;C2DJ>BI0XGB5!;@TDMI'VFA;[Z`%%&5O!68X$D`D*`(S
M#%)4G8K9MX*D#8%RU/(<Y]9TNT:SB[!L*KUB'FZ#?+S;K9Y)6'MK;;'CI%QI
MVD(52RT<;BVBX!=M-R2KZ#E`9/T$?&+(]4H\WINQZRC<GR[7VTW9Z-IJ7+=:
MF1(D:/F?3'5"6@7.49#$KP93CR5Q6$M2V.-9<7E0YB1[/.QS=6VG$`O)2"E2
MB=F.8'(G`IQP&"CBDX$#:*V"/BZ!(<W9V;A[=MCXZ5JNQ\%::E3:7/QFF2N9
M6E^[$;^5ZXFB7M?LMO3@W*3N&*1VQ.R(X23,18QPS6R9>I(VX./`FPK-]A2I
M2W8\B3*9<N>5N5Q:_LV-QB7F(Q=2IN22VZ'2A:@4!)K["63="I*G.-2G`A*2
M$;4XC.<,"<-J=HP^[44L^1&P7G>63?'Y7<40A0J_7X=PTU&WI;,9"54L^II*
MV.5I*SJQAILCRO2E83D&SQ%R2+%M**LEA4=B@FCV#^[+33')6C[R46-Y6HI,
MEU*KBJ4K(V&+BB.D(8#G%%+S;Y96VI!D9XZ'T!+/&*<QQ,>-\,/C!Q(`ZS+P
MXH)VG#'81B#CA@<#MPPE.CP>NG',[9]FK=FVHK:HN-1J=MJ];H\U!:(:3!J;
M1IPHW6T*P[F#MFT6T!(,%FBZ#]L+9B^!L9!10AC!R&H+AJ=O<7:;5=(EG%G>
M=,B,^_+:=NRFO"9;7^:QPZEV/`4\AY+B%LKSNM<:'$I4`<AI#)N;BT*<XP#`
M@)(;QRI/7'#`JPPPVC`'#"E(X_U+;;OO4^1.W+/JV_5.GV>LR%1A;5=]'PK5
MV]B*#'4J"C8Z"W+`.)BM_D\L+SQDI%II28STFHF)'\>@5F)DUHWD7K1;/)`T
MQHNTW>W3;W$EHDNQXMU=4E+DQ<IU:W;8\&G_``UE.$=\J8\$8!S1Y+A?P5KH
M;<@W]Z0XVM+:DX`J0.!(2``L8C*>$;<QZ(&%2=QC-K26YE[BFWG&NQ:7WT_B
M+7.6>8L>V8G8*DE#NYBH0BBT7&4V6LU/@8FPGB6\B1IY<@[;N'"YE&::JZO5
MY/>P-50]QMC@,:JBWW=TV_':8;8MSD,(=2U)=`<<DML27G&0XMDN<4MM:$-A
M+ZD-HQ]X/$*N;BBPIJ60225A6(Q`V!)(`.&.&.(V[-M6&[1,)*7)F`#")7$4
M8`*'281"59B`%`1+TF$0\'A#%.^5ASXM']SNOJB=6%K;V:D=-'?$URH\#&SV
M"Y=\:*,RBYR<IU$W-;8:!VE1-/:C+QRF2#K#=GBJ_"<BHG3FI=NVS8#$A#F<
MQ+XTVP,0BJJK]==!(V64>6SS0-Y7N?/[04C^G//\/QA/5J\>UVC7T/WB=-@4
M])\D6E_LE<@T)?=-9N5]B>/DW'(TO9;NI1=XI"=G;Z[NLG&ECYINW5)%NI6,
M73\<X,@V!NHI5*L]IU)-Y,DZXJOVEEZ;BRG2W:WXT-R\M+,J"F2Y%E%A4V*V
MO/%6M)D-QWTGBVPX[QJ4KBXXRF\I1Q3X>4D8K"E!LC*K`*3CE41UW0)'"<!A
M6)V[K_AQ"\GPY`,9K9R?)ZE;0UA5[/7M2;=LD6$_;-IU&L1L15[/K.RW.+U+
M//[1J+6<:YE6;1J%B>UV%;&3*JJ+(BN;HK4F_"=NE_NWD,6D[II]HGOL/7&W
M,.<3'M\E];C[$YB*Y<64,7&<^B.ZXX834V4Z%%"./*/F2S;4S_#`7/#TN)!"
M%D8E8``*2H(.*$@D`9BE(^Y22\IM1<BWO>YZ-VW`:4V7:M/L;1I>)?[&M-.U
M/>=9UN,;&;!*O];2=5T[M';=&>P<@_<F>%M?N2Q;OEG#^,G(D%!4Q>]T.M=V
M+'(NU!HRY7ZU0];.1+HXB%'DW").?6K-Q:)S<BYP+=+2ZA"`V;?X0ZMI+4>7
M;YA3EK5SXTTZB:D(:6J,%(&8A"D@='*0A2TX'''/@,<2E::Z&,C0KL:,**,*
M*,**K"[T*ONIW6E%"OP^DIR\(SEA"J,=GUJW6V[F61@RS;A?4$)5(R=1//QC
MN!:OGCB68N(=FBT376%)1-%4KL^23<F;?JNX&Y/W^/8%1V?"%P'XT:+@7>*`
MN3LAQHAE:7G&FD1W4275.*;;"TJ6@Z*_(*V$9`T7<3AF!*N#'K``=HP!.((&
M&)Z%8/D^:!)PBXX*:_E;6LQ^.?'M;7$A,3C^5GY$QVPJPBEKL&C;`A9W@N8X
MQCO'%,=+K"<.LF!F'E!B[#=,+BK?[JA.I&8:9'@-Y$U#;2&V48*P=$=FZLEA
M.5>`:1<VT)PV*(D<4#\3\GV6QQ)5AF;RXG$GZ,2@X\'"4'_HQK6^5UCVBI5>
M&FN*-8;$RN^Q*/*E=Q%"VQ<J'?9@T3%:O]W).MQM\W9I0M]]PHV4=G%G89IS
M/"LND8B)C"].&TW.VO2*;OKG5&H(T5RP6RX-Y7)=NC2X;?&.3^*;?7$M=T\#
MXY;;8XR'%;B94+"E@<0D_%P6_P`7&8:*@ZM!V)6I*C@$XD!2T9L`3L4HJX-G
M#5B_'%..2X]:'2AV\0SB4],ZO3BVE?DIF9@6L<2D0963>$E[$=6P2L0@V`I6
MSE^8SQ=$"G6$5#&'&Q;T%2E[R]1+FJ?7--]GEQ3R&FGE+,IW,IUMD!EMPJQ*
MT-`-(5BEL!`%;F%E\#:RX!/%)PP)(PRC@)VD?03M^FIY_!F;C^RU?'Z^JI.\
MXY"OM)K::GZA8Q6MVL=OPFS)K4<O`<A6M/W#6)FH;=I\+7IK8NB=';Q>0*D!
M9D1L"+9S%.F:SJ%;IO"H`X:*F<CN(W:1]>ZSUK;;W%RV6[,W""U<6WK,J3;7
MVKA!DNO-0KM=;4EX/,'P-3B)#;J6Y3JF"X6WD#3W.88L>,MM7Y1LH44$.8+!
M0H`%3:%X8'KL"",4C'#$5/'=YO)J1X=Z;E+!=75_EI=M=9AQ/.F&S(_R1*7V
M1<9)E3V8;EK%+VC(Q.NV#I*OL9&;B8]]*,XQ)X9`@+E#$2Y2[$&+OOOD2VP$
M6V&RJ*T&4K@KS%N#&0N2K[,?E0$.35I5,=9BR'FH[KZV`XHMDULK,5*MK2EJ
MSJ.8X]=T5$X=>$J(3V(*@"0,<-M.AB$ULZ,**,**T?9786R>T2^<H8]?Y<O/
M<W=^FU>22:YS5WLW+[G]84H]3[4UOT[$^?(9:OY4?-GWA^Y-Z]72*0^R>>8G
MC+?;BE"K9*_)=\98K'58&,GRO*>JQLEECZS5+G(1<C7-7*55Y94=E-]$+.]<
MU!E+Q!JC(P!=E%F%;*W*HK!`R<"X)5LNBKE%Y$$6UWB2[&*)P6PPM^1%0XA^
M>)"6#!5=@F;)4VX+BS,-C,9,%92BX<>V&U+6C(K4BEM@'%.T@!1!"<,<W%]:
M,1D*>-QS?P,#C6XL)99QWET]=JU:[7MN"23C:7[AU#<U(91&L/+:S7:?=X1S
MJ::FD)S85<86-NWGIQY$CT0#R/$!14=$<)*Z.3#0UR58]ANL.'9;@2N5QLFV
M2E.3\K[TF*ZFXM-%J&^MA2XD1N1^V-/`A:65-+1ZA1-\+J%*<1L3@%IP3L`4
M,A.*ACURB.Q(X,<:\&G*]5*CWGNTT*XQBXDTLQN,6^M*3U^^F[BX94/4%Q-J
M:6KSQXYGHUGK1]<'EE969ZJI$/?C2O%,4T3H&`,C7%RO%ZY)EH<NCCSP9<C.
M(CE*$-1DJEW*-]HMO)2EE:IR(S4%V"TE,EK[/;F2%+2X"?R,AMN^N!``Q"AC
MT3UJ#D(X1EQ*@H[#G*1AA6>@=L;#4[P2S4.B:7XY2[:*N4A'[)N$'0HB(VQ#
M:Z=U2CO&-H>;C;;(=_&*S^[-@=C+5]:N-GC-DDS*83>5I.3ZZXZ-TRGDV1-1
M:AONJ&77H*%P8SLMQRW.S4R):5L)MBH*>)8XIEL1YB9KC;CJGR`.)6TGZ1(>
M^V%,M-,D!77$)`6$X)VY\VTXDXIR@@8?3C6N]U]R=O.W&S/5=QY*Z]Y$O:!1
MI%U/K(:)WS0]L1$FE.0QZK8[+L'84W(U.\TRX5&P)NH*74BZX_L38WE31LJD
MW>"EM.5KNGT_HMU>K['I6YZ88N5P0ED&[6B7;G&RT[X0PQ#AM(D1)4:2RIN7
M&3(FLPECB7G4+<8S_%BG.R`([KZ'BA!Q_)N)6#B,"5*)"DD'%)P25#:!L-2O
MQAG%:;R*N^B9S;%WO%]J0V,]T3FQXVL(>1]VRQ^QZJC'(HE;<H['$5.H7QC'
MM'\@5Q'@J@NF98Y")CG&[V;>B^;L8&\*WV:WV_3LWB!%+7VVMQ'%9X4@K)S6
M!AR1)B.O.,LE#Q2IM00E2E"LB"OBIJXBW%K>3CFQXO`X]<,/^U(`4`"=G#MK
M1-;W6_TWF5+MUI9>Y:7V)N#9&O&-FF=6KD;TW8<9*[`MBE6C+BXW&[?GG73M
MZX@DW"59*D$/7$#'11:G1=FZ+5-ATW?-QK+C;*8.N[99(4U;#4\$R83C<..)
M#D9-L2@-)2E$M2%3BKPF:X`M;R7&1Y,.O-7,@G-%6XI.)1V*@5'`*S\/\'L>
M!(V`8&HBUUJKC-'=Z!*EDJ#RFU!R$C;_`'G;E7@G5]A]@\>]OQ,M7]PH?E=C
MXM!W;I[7]=>'W)9U_)3!7&;:S2BS50%E?%D/VFI]8;UI7)*9,6Y:0O>[1VVQ
M+=(=3$<AWFVN-O6T_9RW"F,S,>2+9`1Q@\-<7!CH=26T9E)QF8\%-].9$AN8
M%J6!F"FU@A?7X;2D=>K9UH"B1MJ6[:?QW><MV=#9R-9NZT32#6JPO])PUTIL
M_'Q=(FY)E[N;%G9Z*M=(=R-!7L\-#+U9,S8LFFH65,J0P-5>,LR>+Y)RG]1+
M:EV!+TKP=E%T=BR65N2FD*XJ$TRY'E)1,$"3)1/4%E@I,,(4"\C)<VWW!H%+
MN"<3D"DG!).U1(*<4YDIR;,>R^BMDIV^:Y)=X[:=+U357')W%0<>K&*;<JGQ
M&<;8C;$RHLG9;_6;!(15A7M#.>:3+Z/;*1*L0W(FQ46<K/3G.1L&JOF[NZ1>
M2]#UW>+QJA$R0X'!;I'A8MRV52VV(;[*'&0PIE32'EB0F2LJ=2VTAA*4J=/V
MU+0J]*BMMLY0,,XRYP<I*@2#CCC@,,.#$D]"L]14=2-.\$MA8#2>[UMADK+R
M/LN_9DZSG63]5Q4*Q*1<<T=N%#J32#B";F8%?%.8C%XP3:&*'CDNKK]0N:S>
MY-D,W&_6!.F3+2MBSM`)GH`DOMN+4D`!HAXATM$`NMO*>!ZQ>/VT(XO"LC3O
M'9=KA['@!`^[LV8]`C#HT:E1U(UYY[(+5])[P0O9:O(QUIWS9#++ZYGW9(2@
MO&S"/<N%5%9DK^`*T*E)`<Y$U&Q6X@!E``GYK-S6;W)VM9N]^T^K3QEH7'M#
M&`FLI+LQ*EK2D`-9'N,*F"`2EPN@X).8CB.+LOBVG>-RD%P]B=B?W=F&W[F%
M/IM$0"BSPF$0`",1$2]'6``DV?2(=/@Z>C%)^6)SY-">,7#U3/K#UG[-2NDC
MOB:Y/^!%#>T+O>Z7`W6.TE!W6&:;=;1U>XZW2+M%(AU)6DW^1OY+FSM=HG=X
MQER=M2550GNN@T;&7]T0,4.JT#+('S!^97O%]!H\NB4D.E/:.)W7ZJJM@XMR
MR\]WH_+49Q=9%_5HZ[0E6@7]EE!!A7G;K2R\C88.CSG)"=<13>T/&K?RN18:
MX9QKX[1(22B!^LS6K9[W(;=NY(^C/L]*51Y;L5V0\AAOKWDIN@0R[*:LC27%
M1TJ7Q;+M[=?:#BPJ&XG!]M8("BN_2,_"D*`&)X.LQ(27#ACT2&P#AV0X#F]#
M4KA]LWG!;-A:TL5ME]FT6T[HN\7,1BVD#5F5?O9:%I.Z6*UBHR;O<\S7DK/8
MXTK!O<%&S8Z2/1"&<1R:X!@;Q;]OMTIN!AZ:U5%A,:3N$.UQ7&G!=>/;0EMV
M5:UAF64VQIXL,/EY=M2M84K_`#\-RE-U]1&K:_=5/,*47T*6H$9,#M"5[4]>
M1B1AGP'\7%.-6_.&[=XW7:.T$735TBJW<MG"1%V[ANN0R2R"Z*I3)K(K)F$I
MBF`2F*(@(=&,G:=<8<2\RI2'D*"DJ22"D@X@@C:"#M!&T&NC(!&!X*J8XN7K
M6E0Y76W3NL>'K/5;0[C8=1FKK2+1;)*,HY:;9+*>&+=-<R5`K5,U>7=$=4TK
M`BYA)!_[L@\C%7JKA4Z2B;R][FGM57O<["UOJS6Z[P\$PI+465'CH<E^$L,!
MWP6:B8_*G_9:Y"H:D2F6?!>+EH80VA*TJYZ`ZPW<%1F(P;'7`J220G*3AF24
MA*<X&;%).;%..-6);J[%_?B/]9?'%?)OYX1]TKKU8U:G>#[/_P`NC\-0MJ9P
MW9W%-V[71:M6L3+N'+EPJ1!NW;H-?&K+KK*F*FBBBF43&,80*4H"(CT9+Q\V
MMIQ_D6W1EE*EO+U#9TI2D$E1,A8``&TDG8`-I-<%H0@:B03P<4YU*3WA/0>(
M%OY*;"VYHV>O$G<ZFE=E6<DJ;3J=8LE+V#M#9R4RNM*:P;N+A9&8[(832K,+
MNNWGS(I-%P250326R`O?UJ/?99-U=LT7O`C6]JQ3#%"D#[3+[$J'`@%H!N>4
MQF%>`KBI<^RD+AA2GFRM#BEHI4;6S;7)RY$4K+J<VWK,"E2E8[4[3UV;#/UW
M`>#;5N<Y"0]EA9>N6&,8S4!8(N0A)R&DVR3R-EH>5:*L).,D&:Y3H.F+]DN=
M)5,X"11,XE$!`<9=;Y\VU3V+I;'7&+C&>0ZTZVHI6VXVH+0XA0P*5H4`I*@<
M00"-M=$M*5I*%@%!&!!X"#PBJL^".T:0OMF_ZVU[Q)#1D4YKJ\E.V"K6^X6B
MN56=J=PG4#Z@M=<LM!I,1JBU,G-L=SRD/"'=QJKZ<=N@.LY<.G!W=\H?2-_;
MT;;=4ZEUG_6"8B4$-,R(T:._(:D1F2+E'?8F2G+A'4F.W$3)E!M]+41EG!#3
M3+2=#:7VC(6PS'XI.7$D$D`@GK""E(0=I5@G$8J)VDDTSW.F0F(CC=LZ6KR/
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M!PQ3@",<,!C@#@"K`G;PER&/)28?\I9?CLAK-\K$PS8!?7=M(3KAXP%2BP]W
M:625ARTLM3C]?RB\L,"U>C8SRJL^V41]S`;!Y5B'2-U<*/NB9WFN75M,Q]76
M15(:2E>$MR*IAMWPKPA<QL-^%N->!".F&M*_"R[^1K9B<HSS""#E'\+;_%"L
M2,N`2<<H.;',,,N&VF9GO>*:]$R/F:V:_<7\;='>]5I\OCU]7/S;([@YVIKD
MUY7_`-6B5VULJC1VT=V26P6_(?3F[IK0\)J@9'73G?%5_)/4'>U%MM%UR>?9
M4_75)DH;XQ-2V1*$824@Q14*)GH,U;UD_LI'2<ZBJ;.GH?>J\[GQN7=&G[!Q
MV4UP]UC"TJX;$DJOL&P[6;H-:I&RTD,(PULE)6B2;*1<&V<6A\*A4$54I>1=
M-T46/7,"A<I4[B-#:$UL=7IU0W=G[]!AF1#9MZBJ0MM"GUSBAA"@XZI,=&4K
M4E49AM:UR,H*33BKG)E1O!^)+8:4K!17P`G#+B3L&W[Y.`%6)8U:MY1A17*U
MWFBE9V-R[O&LM@6.+F:EK?7]&V)$ZHV/J+E)MC6+BV6JT;508W-G'<=)R.KK
M2WL#TLA2+7!)1FW$B*J!5$R.>I=QY'_-1W;>Y%G\B:IN%_\`/DSQESMC4]\U
MJX2R<%N"C:W1U)>T9UI*C1D2]LCIXM,M-L/=+1CRGQC..*SFX`Q+<:--'%G'
MC$&%<\:L[>N4&9U!&#6ZW55KY=N]]ZS.W!&H4:D6XXED(#:K>F2VF2XMS,T[
MC'XP/F*T[QL[*AF.TX^$@*4A&?3$`.!!:XD`8\.?`X##:-N&&8C!.TD@5T.Q
MJ1D(Z/1.DHB=%DU2,BJOY4JD9-!,ADE'/6-Y0HF(=`J=(]<0Z>GPY"_*6')3
MCB2%!3BCB!E!Q)VA/\$'H#H<%*(G8D#[E5V\M4=/VO;L/0K=2=P.[DIK&%GG
MMOU/`;QMA9;4YMI,VEYU998+2DBP631MT0T>MVCR3\8FU4>*+-RG42.0SF]S
M*];6?13^H[+/LB+&+LZRF-<'K5'XNX^`*5$N##MT0L$QG%-+<;8P+@;2ATI2
MM*AIKB(SDD,N)<XWBP<4!9Q1GZY!"#T1B`3P8XBE]Y\Z^D'5PK?Y/J+N)O[G
M\?UFD.[I24RE3WL%7J_MROO:5,-6FI=@/8NR-J/L"2@8Y`735\[E+E'F2;+D
M8.E$%)Y.6I8S-DE?UEN%C5QNI`IQ,HM&2AUYZW/(E-*5<8:7&%2X;$MY?%N-
M-Q[9)"W6U2&4N8=W9)<3Q*'=C.S+CA@`L93UBL#E44C:"2L;#@<+B:ZU(PK\
M$Q39+1I&<-&-21SE=-RX8$;LD$2LEW*(F2<+-0)U#'*(E.8HB'@'&17-XR+E
M(D*<2ZI;[BBM(*4KS+)S!)V@*QQ`.T`X&ND0,$`888`;*JEYK'1-S"XXM*NR
MEH;:;RO1<?`WE'2L)MZO-(^2V2T+"DMHVR;@V-;J%:V0TA'<F[@#_&E`';=1
M!1ND4RQ7A[ADK&Y+5#UW<9?T@B2XMZ(;H[;7E+1!5QIC>#M.K?DOP52FV&Y@
M\`66W$N)=60@\_=,/M)@-@B04C!60+&U6S'$C`!64DIZ_:,,!MK.W??,!$]X
M=KG2\)JOC;:7BT-"?&O8R7Q)7W!1;Y8$K-,NF+E;W?)<JTL_JK91TP:!$O3O
MP<'.H[03.<2:^P;N[E-Y,]TUW/O&J8;"7W?!X1\*%MEQ&2PTE:1Q)C/A$A0;
M><\(:#.1*4LN*2D*^W9:$WE$5#;"C@,5=;G2HXGZ<PV;0,#C](K9&Z6I6_>)
MLO<_26[)39Q(*0:S&^7)UE-4QS>4H]CF(2-!VL=3W8:J,VDO"D,0P%BI!DFU
M.0H*HB.K=7K-SDR.>$W^PLZ3,A"F[0D`7!9;E,-NKR@#BU!2HTH@C&0RZIX$
ME#F'V/!Q>1@TZ7\-KG\`8I)`^[T4_<(P^BH[-)227>:2EYCK!=]CUMK&0M"3
MC-<255=PVO$9RO0E;LM7OL%-S-:L=JA&]Q*SL3A:LM[,-94:+JORL"K.^GIA
M%BKY*+.GY,:!:[HMUV85S42$NS2T\Z^P_$>::?8CNJC<9"0F<N#X<'&T1S)*
M&:\<ROMPNI*UHP"<$D8)Q`!"@2"1C@KK0K+@<<,34@T1'4C3O!+86`TGN];8
M9*R\C[)OV9.LYUD_5<5"L2D7'M7;A112:0<03<S$KXIS%9.V";0Q0\<EU>:U
M"YK-[DV0S<;]8$Z9,M*V+.T`F>@"2^VXM20`&BEXATM$`NMO*>!.1>/LT(XO
M"LC3O'9=KA['@!`^[LV8]`C#HUY-#:BYJ5?F9:9[;G+:"W=I.#IM[90U)BE8
MNE2=?4O-NBK/4HF[ZH@XIVWE+94X]%5./M1Y9JD:$<@Q]RSJ=#X/;>)K7</=
M]QD.W:+T9(L&O9$Z(IV4X')3;PB1G&)+D6X.N)4W'D+*5/6\1W%"4CPCPM*<
M8Y_(D:YMW-2Y$@.Q0E6"1@DC,00%(`VD=!>(ZTX9>C6I]V7K.L0L2]M];C=#
M1\DWB'$/L'\FFH=AZPM,C<K2I#7,UF?NIVT%I=Q@;@P=%D4IR(@F[&:,L5PT
M6*D!TQW/*NU7=I\QNR71W43L53X<A^'7*%/CHC1P[%XA"68_A49Z,M)95$DR
MUNQ0DMO-E92JO.QL-I27$!D*PP5E0I)*C@K':<I!X<P3@KA!JRS9X`--D0$!
M$!=1("!>GK"'NLRZ0+T>'I$/4SOOE8<^+1_<[KZHG5B:V]FI'31WQ-<MO!NG
MH5KD%P!GK,;C%\?]B6_8]@;R.KUMQK[+MT37J?NFL6J8?2%@LLCIB6@XNQD0
M0D#UQF@07*K55KT,U>NI91Y;7-`WE>Z$_O8I'].>?X?C">K5N&PN,FR7G>#Z
M\Y.M*?%623K)U(9C/5S=L?3VI]>/H"8KZ4%?]:6F@V6PE5K*<Z]D$U*]-*LY
MMXB111K'&,J(U:]-;V-+,<FNY[IGIKT6)+`=6R_:ER5":AYMXNPYT>8PS@^6
MFF5"9%2Y%:4I*7I0"*6MZ"^;PB<$A2D[,0O#K<",%)*2=F)/6JP4>@FH=Y)Q
ME,D>\NU%3*"PE[I+2]BTCN;D)JRE;!NDE'R5LH=GA(#6VVMH4FHK2,+JEUI2
MK,XB?1D[$E&QMV:1[&+*JJZ9LDU>WW62[[&Y*EZONHW&($)F+=;99KA*AQ4+
M1'EL.O3K=`E20AVX)NDA4F&IB$I]^UN/2)90AE]]2,::EI5\;:9!4HJ0MQ"5
M*.)20$K4D8A&08*Q5@%@!/"!4H\L^6<I5^8>I>-&N[/#1-AOI=;0UX>CO&&H
M-XK49)[0K#CJ:[U;>R2E<OUFF8N;;J"[90DD"T,A*,G#MFLFU35Y'<UN:B7;
M<C>=ZNIHC[UMMWASL1/V4[,B/N-P'TXS9\0MOPV&G&E@-NRF,LE<1]IE]"GE
M(R+A<%-W)N"RH!:\H5UX2H`J'8H5B%$@\(2>MS`D'#&W+&75T5&%%&%%&%%(
M%S<F-=14IJXLQL*W:IV^ZKNWPTO>8)]9&=;:O4(^FJ6:&O!:JREY=U#2G3'+
M%339J#TLS="B9N@%''[@X.IYD2[F#;(5XT2B3;?M2(ZAA3ZDE<D,.Q/"%-MI
M=;_+))+J?S@Q2L8E.HNBF4J;S+4W)RKR*&.'\'$*PQ.!V=#H5@M]:YT/'\/-
M=P`ALVR:8JZ-%^*4;2G]6?;%GR^5L'E:F89ILZ+7?VJ\$52%1NR:E)+NSN5B
MH(J+BF0NPW=:GWB2=]USN7_E,774M4OPE<I$A$)GK5I?:=5`<"(\0@X+=<)C
M-AM!<6EO,H_$MF(+:A'Y149.7`)PS'Z",PVJ^@#:<3@,:@/D+LRAQNO]"R\3
MK)_?]/L=8V?6]Z9[09UG6^W:=5Z7M3CFG<BO:MM6X:;L$/;8V$K[D[9Y$LS.
MV=G1B56ID!6:F54?=II344K4FHH4R[-VW6SEV8G1%0%/S;;)D2K?>C&RR+?&
MN;+D=;KR`MN0X&W("IB'@X&W@C$F/M)994ELKC!LI5FP2L!*V\VQ9000`<"!
MB%9<,,15DO&&+=0?&OCU"OD63=[$:.U-%NT(V7;6".1=,*%`-%TF$\RDIIG-
MLTU4A!)VD\=I.2`"A5E2F`YFL[V9;-PWJ:FGQU.*8?U!<7$E;:F5E*Y;R@5L
MJ0TII1!Q4VIIM2#BDH01E&Z@I*(+*3AB&D#8<1V(Z.)QZ>)Q^FF$_!F;+^RU
M?/Z^JA^^.EY>OZ@T_-H;%KM+J[+D7#-[K6+'R4W[Q91VS%R])V#"PU%8;&XR
M4F[[@7D&=LD&$YY&T02C_$0ZJ\@;R5`_0Z'DKPH5RWUZS@.6N5/NSELGF*^Q
M8[1?S;G&[E'==EKA7V5%MH0J.AZ)QKBE/9Y*&XPXYQ-:2]J4BW1UA:4MA:,P
M+KC6<%!`3F:2I?#@K`;-F)V"F]X3H"SXR:UC5"PB;J&/=H&2;5W?.SN3D4PF
M('8=LAIJ+3WEN6+A=F7MW%2S%9LZ/+-4EF#I)1BF`HMDC"VO?TX'][%UE)\(
M++XBO(4]:(%B<6T]"CNM.&TVQQV#$2XVM*VQ'<4EYM29"L''5@;BUC""A.S$
M9@<'%.C$*((SK`4K`[#B-AV<`IJ,2"MA1A11A16C[*["V3VB7SE#'K_+EY[F
M[OTVKR237.:N]FY?<_K"E'JG:FM^G8GSY#+5_*CYL^\/W)O7JZ12'V7SS$\9
M;[<4GU5H59KW>[67R=E>)NV*'=;(*Y5)JV;@:C2+UI"4AC23RX?DD5V558.3
MOL+)1S"FFN#4Z[KIF$V;ID"PMJMUXU%=;GR+(G&.6^/9@$P<H,]IZ3*B75MW
M(F-]HB#(=;B.L//7,6UP(;P@J?:?*`ZM;;*$:B5@%ESLOX!`2I!&..3,`5`@
M(SC;UV!&.$C0]-;..]7GKJZL5VKSJ-@).%C:W:;!L5&`V`@MIJAN/*=9U_XG
M#JES4:V>0=GD#IS1I@9TBYCI(IH]5UR\Z^.M\CZ/868L"2R[);=6_'9A%Z&1
M<Y:<LY[PG[03)?R-AD&*(W@A;"5K4O%GW2T#?RZ5*20"`"58*ZQ/8C+DP&W'
MKL<V/!AM\W&#5W)B$Y<6+9FR]3SE>B;`EL"!F+5)6&+E(DM45<H3=4:1;_\`
M+WL"U2XM;&4S6/;.8AHQ1BC>.\G:.0Z!]=[6KMU,_<O%TII6\QY,V,8;S<=#
M+C;GA`26I"G$?9$..WF8P<>6B2XZJ0,G&O-'9^0&)R;BI]]LI2<P))!&'",/
MRBB=NP`@##;@#6R\=6<ZPYZ\CF#BQ6IDR:#(.).FR)MEI0]DEGU8U,=':A(U
MG3H[1T<I/M4_)D@;R2LP<K8YC$$!5\7JMYS]ND<G72\EJ+#<D+R!N2CP$N,-
MH?N.-O*U25W5894<ZL["8P*P`K8C-]P@L79\%2@.BDYL"<$=?A@$#'@X<=E*
M3W8,'-U#FURAI)*EI#65:K]2=JR%8XK[`V=L[2UIO:NPG%?>/[(Z>[TNU&H%
M_H])JT(U)&2M)I%B5"3>-6:"T=$JJJK/RM+A`O>X325_,V_W:ZR9J0A_4$.!
M`ND>((8>2AA*+3%ES(<J5(E.%^/=+K"3Q##K[B),Q"$:ZQ(6W='VLK3:`G@:
M4I2"K-AM_**2E24A(P*$*VD`%*:<C3VRZS.<]-N1$10MD5]])1YXRQ'<2FXX
MNGAL*D0C-A:;N^J\RVBM93+2VT]2M1$=)MFRG2K!'4;K+>4*'!#M;Z4NUOY.
MMEFS;C:Y,=ISC&0&[8Y)\#E.J7'BHD-*<G-*C21.DO,+6.MEI2XVCBDI.SC/
MMKNSB4H6"1@=JP,R1M5@<$G$90"!_!V$XU^,)J?D4CRZ<W]YI*CLX$^T%7OY
M;6SC5@2CC7AORIL7HGAD>FTIV*7HCVG5\7Y6A)<4XMRFJZ\E./CON?K+=BO<
MLC3;%_N"[B+2$_92A<.+3-_\O6G!T_YN66Y:;E,XDN&,%/M*0UQR1D_$QYHN
M/'%I`1QG9]9CEZ_H<.)3D3CACL.W#A_*87X\3/><1,*6,V]^7"JU>MVV3)&V
MC4">HEY=YK;9E?JUOG*E(VK\O(R["@24M$E>14:G5UU%D2//'NFR:C?[@M[S
M(/)/>GEVR?U`F2WX[>>/<C<@VF=!>D1FI"(_V1Q:YB(\@MR'U3T)2M3'%LNJ
M2X*,-5]"<'/"DI!.!1DQRJ`)!/&8Y21B!EX,<2-F,F-9;E_XIM3V8.LK4]TZ
M>OR3%OL56XR<A`UUXWTR_CYA5C7$&*4778FV3CR,CG#-PY54>24.F]2(3H4$
MV7"U9H;_`(0YFE!=H;>MQ)0M4(1FT//)5<T+:"WRLN/.1VDOO(<0A(;8DJ86
MI76X?*F)/V^E_BU&-@>NQ.`ZS;LX`"<!@3M(QK$URLO);O4)RTN;=9:]*U^M
MR)I?7#J[;.>05C@WNJZS#UR=K-5^)L=JY2JMU#JK.WQGJD@%@!5L!R^2B1SF
M72ZL0N2%'M#4*))AR92.+FIBP$NL.IN#[K[3\CPE<\2%`)2VT&@SX'D=*3QV
M9KY0@JOY<*E)4$G%.96!&0`$#*$X?2<<<VSH;=>X"[(J,QN*U:PJ3B;2'7TE
MM%>4-:>6\]:BRB5FO=CEF+"O\;TW)X6"LD$Y\I";0\D;L*V@9FFU=OEW3DC/
M9\HW2UZ@Z(AZMO*8Y%R:@!OP?3K,?BRQ$8;6MZ]E(==8>3D\%7QBWIRP^IYF
M.VRTI_XM#[:I*F&\>L*L<7B<<5$[&^`$;<VS!.S`DDX'=R[(J-@O,QKFH.)M
M-'6L596+_P"-?+>=OBTJE.2C"PQ*->X]>5'AJQ+5Y"2.VL1?)&C*L/`2CV#B
M0%5R9J<I_2UZMNGV-47I,<KNKS"T>#Z=:B!LM-K9<+UYRAU]MXH"X1XQQV>W
MGDR&XV1H.EE?;6Z66\<$`\+Q5CB<1@WP`C'!6P!)V`G;A:GM(HFHD\4H=)C)
MLBE#]L1DF8`'A\'A'-G\L3GR:$\8N'JF?7QK/V:E=)'?$USF<5'VH)SO+M=7
M/5O*B@[I1V-L_DE=3ZSJ!]IN)2@I.]73S1^^G"R&UIS4[2/+((E0CW;6HP3V
M;36%PV=.T2.E5;('S!^97O%]!H\NB4D.E/:.)W4]JJFRX3V5[/\`>/<KI23B
M]@PGQM8W.S5EA?J/L^A/AJK:6U9`MB%B=D2%.=J"U?1ZW4,A7)MF"*A3LYAH
MV4*Q4KC;^K4Q;N2]HZ)$>MLCP)R*P^N'*@3$>$*;N#RCQD%$E(S(6G$+FQ7<
MR2E^$\Z@R$J[:UE=ZD*4%C,%$9DJ3LQ0.!67Z/XJA]"@-E2QPFB#0?++DK$R
M]U'<,Y!LG55;W^8:TW7,_3$:S.PC:P:[8:9J5H=M$:W+2;MM(DL*,!747QFQ
M!!)RFLW<GXW?W-%PW-Z5F0H'V);Y#B9!AMJDS691?:=4S-7<Y#"5%]MM*V3#
M5,FJ:"U=>TI#C2<BUIR7!]*E<8L##,<J2G`C%.0'@)P.;*G'#HX@U;&X\H\G
M7\D%$'7B5?)A<`<S<''4-XD5RIB50404Z.L!1`W5Z>CPXS=KB^,3QV;B<PS9
M<,<,=N&.S'#@QV8UT!QPV<-53\"%E#;[Y6-VLG37<0WV!L?_`!1FKILE]:V1
M3<UY-<1L+"MK.-V-*\I:/+!A_C:<>M'^)%#H()`!X7*,0D;NM'.NM3D356V%
MURA<S$4P+9$\&XE;X3:U/"/Q?A/V<-CW&!S%68UH+0?\[D`%)3G5_$S8YU8X
MX=?ACCAGZ&&%6![H*8]-*0H")C3,:4H!ZHF-X\``/W1$<<G\F_GA'W2NO5C5
MI]X/L_\`RZ/PTF_&K<6IMZ6ZZP&IMFUVVOZE&NZ_:G5=*G+%K$C98%1Y#*JI
M2K`8B6(LT$RI.J#IH<Z1T5!ZQ5$PE^^;&^F+R-+C*6CC$-ZDLJBG,I&8)DJ)
M3F04K3FPPS)(4.%)!`-<#H49M0H2-A++G4K1^[D9D8WKDLVD+5^5B?;VQE$*
M[?E2U>FVEY'5%]-T9S0G^DZS;9]KK>*K]NJ\K(M5",*^E(>ZQ^K&H$03ZU>S
ME0/F1I[2KL:']C6U4-3@MK?A$F.E<E#4M,M%T?CLJG./1GX[+B2],4SX.G&4
MXIQ6"K648.O@JXQ>;#.<$G`8IRY`3E`()&Q../8C"K3Y`'XL7@11F99,6JX1
MYI`BRC$KWQ1O)3/"-CIN#M06ZOC`(8IQ+T]`@.-"C>#^$-^&9S$SC/DP"\N/
M792H$!6&.&((QX16_..!RX9JJQ[K1=NK6MQ)1$C5WU5:V:+1JJ<>KIH;JTBO
M=>\F*CL=OK91:ZM+`)Q\!+B<\P'0H`CXP'..]Y7;;J+K8US6I;=X7$<,@K%S
M\%4YQ<3;"5.`BJ9PZ-M`C=C@,O%5H+"1D<RE);S##L,V&*NRR]=C^/M_Z:87
MO`IR2K/%?<-DAF<K(R\!K;9,S%L(%K&OIQY(1M`LCMFVA64S`VJ(=RRSA(I6
MZ3J+D6YUA*"C5<@BD9[7R2N<%JOW,7ZR@5SF\?S4QXP.T75#?<C_`!6C>:>P
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MEVQL*(#K,Y0XTY"$+^VBM8)`1L4$D)&P;%',!B>ABE9^@IX*L2GO>*:]$R/F
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M5$YL4;`0H`%0)P!&!P.)K$]YY=[VQM.C]>TW85CH[ZZ/'4'6A+5+[6-?DOUR
M<FJ57MUQY!0NY]85V">4)VX+(1T$G&V=^9<OE2T:X;BGXOYY)M@T](M%_P!2
MWRV1;A'@(2Z__G$-^88<9/A#\:-9W;9/>=3,2"R]+4_`9"#Q+<IIT*S%]==#
MC3+2U(*C@-B@G,K8"7`M(&7A"<%'HE)%6^H%4(BB14XJ*E23*JH/5Z5%"D`#
MG'JD3+TF,`CX"E#]P/4QE#A2IQ2D#!!)P'T#H#A/5/3KHQP;:YA^\WVU:-:;
M]VM3-?[88LKOR!U_JK7</3:5);!-N;5<C%;DN3R,V/'TBBT:<KUVA]H*2YH%
MN-LGJS'@9DX9@X6:N7267;N1_P`U#=M[D6?R)JFXW_SY,\9<[8TU>_@8N^(?
M=U0[LIHJ)L>K:[!3%E8O/<EVRK4AQT:DF*@K//-B:W@$ZU?FA0CY)D\<K&D$
M`*5N0JR95"P![QR\URU-]<Z-@[*BWP/-,*3QB%/(GLEJ0&DPIKQ?AJ_+,.MM
MI#*\2XHH44E4H>!T[;DG8E36!/!LRG$8YDC!7`03MZ&VKR&*:23)FD@FDB@F
MU;IHHH$(FBDD1(A4TT4TQ,1-(A``"@41``#H#(D)"EK?6MPE3A6223B223B2
M3M))X2:[P<`PX*K;YG[OY$:RVI2HG4(1\92S4"7L6R[02B5>_257JJ;Z396*
M[/6,OL.DR+!M0$DF*\<(@>)7>OS^7BHDCXDSI-Q6@-V6K-(3YFM>,=OPN3;,
M&.9;\-#\@H;4S%2MN%*0M4PEU#W!(0TRGP<)6O.-)<Y4UB0E,;`-9"5'*%$#
M;BK:I)ZW9AT,3MX,*C_O!=G[%J;'4\AJ[:&Y:L]EJL_2?NJD\HD3690+-`RK
M>J6B84D(:==+6:MSS8LJ,8TCT6$NT;J-3/&8"43])R;-):8O,B\QM76BQS&&
M9B"A,A,MQ]OB'FS(CM!#K*0P^RHQ^/<>4]&<6EX,/X'+XWA]YL-J8<=22GH9
M0#B#@3L.T';@!@1LQ%-UO#EK2..<WHZDW*#N=PL^[!FF=;"I?D^9K":I)U-.
M?DWD==-@U)[(&*I;VJH,(,DS)"D"RA6YDD#J`BV@-S-_WGV_4%^L<B#!M-AX
MI3_A'ABA_G!D%EM*XL.2A&R,XDO2C&8S9$ET+<2FMC*N+4);33H4IQW'##+T
M,,3@I0QX1L3F/#LV4J_,'66Y+-S0XE7>G:QM=RUQ6+%KE&WV!A<9-O!U5^GL
MA[)K6A.I1[(R3:0JE51?)/I!RY3;/HV:%F)#J%3$JO[DM6:&M6XK6=@OEVAP
M=42XLTQF5QFU.R$&"AL1S(6K%2)$@M*:9;0I;3\4/A24E0.!<F)*[G'=;;4I
MA*DXG,<!UV..`^@8XDG`A6%8K;%8>6+O--+2+BWV>F2=;AH.5;5L+MLU.N;!
MJ2#':C<Y:_5H6E%US+O&CXZ)IPTN_46CDU$RD$#+M%D\S1UV8MG)1OT9N%$G
M1)3[K:G_``6"7X<@KMZAQTAV5X:VE2,PBB,RE+RDK*@0V\VKYD-E=\:45*2I
M(!PS*P4.OX`$Y3_A8G9]\&L1Q*V357O*W96IJZYFD9"J;3Y"6F7-8N7$^]C'
MB=OV_N\KB!@.,:+@(9*WQUDK[]\NR!F#"*K2\?+&?*2#TS1'-WS:6O$?<[:M
M97-+"HTRT6:.WQ.G&4N),:VVK!YZ^D<:8RV'FFD.\:7I$Y$F&(Z8S`>7\VY]
MLW!<=&.*7'"<7CAM6O8&N#$$$X88!."L<QP'Z0=+KRG>R35FB[7*0#VMP\DP
MD:3*V1"&B[,O/Z6J\N16AT)O8R,YV&;+2[N1E9@T6+\\R*R7C"HMCJ+_`#<+
M[<D\C9BU2X;,EB4^A:)3;!=<8#-T?;(ERU,%33J@VVS'C"1Q(C9%Y2MU*6Q#
M2/ZPE:5$%(.*2<`<4`]:G':-I).&.;'H#;X.`NR*C,;BM6L*DXFTAU]);17D
MS6CEO/6HLHE9KW8Y9BPK_&]-R>%@;'`N?*2S:'DC=A6T!9IM';Y=TY(SR.4;
MI:]0=$0]6WE,<BY-0`WX/IUF/Q98B,MK6]>RGC7F'DY#%7QBWIRP^IYF.VRT
M7_RT/MJDJ8;QZPJQQ>)QQ43L;X`1MS;,$[,"23A@..*]<F>]9Y&V2E0T/.P4
MU6IB0D+?`0=(MP,I`E8TS"!/+;C9:8;/&%<N2\.O'-ZM'[#DG3.3@72[^)2!
M4JC;9;T&[G!Y'FE[5?GWX]Q8E-(1&>=E1LR"_<W>)%L5<U)6_&#B'USWK,PV
MXQ+9;CS%E!2[\0BA6H'EM`%!2=H"3T$#'/DX%88!(<)!224_1(?#79O'U[R;
MMNN=)<<-M:D.&N;`_L-EV/;;I&.5']+LU7K:%:+IJPVBPA'UQ*&E&9H>Q@FC
M&%\0YAFIRO&,@S;<SORTGO)8W3PM3Z^U19KTG[490RQ"CQ5I")3$A\O_`&FR
MPSG?+K;@DPBI3YS-3GDEB1&?=]K8_#,Y3,5AQOK#B5%0[$@89"3LP(P5P<*1
MM!`LLVF;J4B5-UQ3ZJT6;Q@%ZPI]$HS'K@7_`,H2]'3T?LYWGRL.?%H_N=U]
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M#6B`U`BLJ0F0;0_-<3Q<N=-BN1YD.[6WBG(TBYRE"//C2XZR\2MX-J2RWE2;
M>^W=1/C'%2CP<8$C:E*5`I4VO$*"$[4E)&'!CM.A<_BSZW.?@LQAUZ"JTDK%
M2%KU4W-XL$#;+)6*_NVES+"8EV">QJ-67-0US<BQ[^(!=C*R$E..!:H-ED?*
M6ZO1<G`VU')]WA2)R;B'FHLH1)"8C+T=A]ZURFEMMK,*6^F3-C<<S)R.QV6(
MB..<=0YQ3J/&[YS=8@3DP*DYAF()`6DXGKDC!*L"-A)5L`(Q%76XPVNHHPHH
MPHK`S]H@*N6'-/R:$86?GXNKPXKE5,#Z?FE#HQ<8EXI-3JKO%$Q`HFZI.D/"
M(9L;=:+C=R^+<TITQHSDAS##K&6@"XX<2-B003AB?H%?"W$-X9SAB0!TSP"D
M2Y7\E[7KJ/T+L;1FM('<`7A*5=QMB<4+:-O60J<R]U\U6:1,AK&J6FST9I-1
M<^,X\DG$:];"RKAVHM%7*[<R+AMSFZJSZGDZBTQO!NLBR&WEM*V4RX$8&0TB
M8H*<1/D1V):FG&?!6V$/M+#LU+H>0TVX%ZFX3G&0R]$0',^.!RJ.PY>`I!*<
M0<Q.!&"<,,2,(E[P!$LWQ;TAMJZV9DTD*O<Z$^L]P3HD56*FTCKU''A;%*S>
MOMO4_8%VBJT#MR@)88BC:8*MXDKA8X)*)F[/DWK,#>Y?]&6&(XN-+@RT,1C+
M<?D*7$7QK+;4RVR8<5Q_*E>,DAR,4\86D`K2H8]W&:`U(=4`4J3B<H`P4,"2
ME84H#_!V'@Q->_>,KQWUGQ4XN;UV9^4"TP5)K.K*;2[IKVS%K`-FFQF%,6C;
MM:7\K)52LI5J`FJK$V)HM)$!-K+QK(6Z`KF304QMW\/>;JO?!J[=[I3[-B7&
M?+N$F5%F,<?F5"7*"XL=#:)#Y?>:D2(3B6"2Y&?D<:X&PIQ/[*5#8M[$M_.I
M"4H2E23AV67!1Q(&`("ACP$#`8[*L.TT6K$U!JHE&AI2NTDNMZ,6GU^<2<H3
M<%5@K$6%?AYA%XNZ=HRL9$^)0<%5544*L0P&,8W2(MGUR;NK6MX.H'V95^-T
ME^$O-%):=D<>YQSK12$I+;CF92"E*4E)&``V5N8W%^#-\4"EK(G`'A`P&`/W
M0*EO\&9U/]EJ\?U]49=[&X?\A[H_X1U+2*FRMCP_'FT<K*),-MUS&DK(>S%V
M3#Z(:5:H3$)Y*K*PAZI<[`YN0.716C:',U(*#A9TB!'H\G!J/NSO%TW^7F_B
MU:7?UTO3\MI5K:NK`8XF1=E2)+3N8-NB1%AHMF1LN+DAY7&-H97FYV[DS&T6
MMMK.^(P=2<Y0<<0W@".$8*45XG`##8213A=U_:JO=>"FAK)4JP-3CGK._-Y-
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M([[B?3M;^3L5I>T'XQ03EQ0[+6(]>N2=$V`A!V".4@-K+TNP$UC`%^)SBRR5
M935=+296/05T4C@U8J[W`3>0/&59VV8MH;N7$O)3+8?6'VY<,NLK#UO$IDSW
MO_,D06)RDMI8,C:T5-!9FT9=4'C"5.%&(ZTC84JP(P7E.4=9F*=N.'#MIR=2
M:ZTW5N5K[<U-V[;+C+[U2VG248W:%?F[LD68U1<9Y[;('2^VYEM'/JC#P\K*
MO4O<0[B5CI*)B/\`LLJ;:+4.FAVL]3ZYN^YUO0M\LL.#"T\;?**X#S44\7<(
MS*8[UTMS2EHDNNMMM*\*"([S$B1_G94[+2E6SCLQF[@9+3BE*=SIP4"K:A1Q
M"%G#``D];B00.MV)J+]+;`>SO>-[HBZE:[%(4Y:0N#.U55"7OIM>QTS5Z'J2
M'3GD(%Y-':1^R%K`U?,I$[F'9UQ6/1;*1KM>1.\!7K==Z;8M_)?L4N\PXK=\
M2W&5'D%N)X:MJ1+N+A9+R6@I<$,J:=9")+LU+RG4RF6XJ6,F/%>*[TZEM2BW
MB<1BK*"$H&.&/98X@X@)PPRDJQK7>/E:\=WI7*>V,JM7T8A%D>,-,L]G0D@9
MO84ZOK\LTY^(8W!U=4;9+(N&X/?*H)E$,V()>2.%#*==UL]Y5UR<D72%F?F2
M535.<9Q2H#J,S)?F<4GPOP9,4QVR%\5Q<MV2X[GXYM(3E9^(:,;](<"1EPPQ
MS#AP3CUN.;$]'%(`'`?IC_NTZ%H^:W:WVAQ^Y%?E.T_KKC@YUMJJFS,YQ_>;
M.@HW96RV]NV!4-G1.L*?4-GQJFH[)06"<>%N/*K'6LKPQ'`+>/,MTG*JU%K^
M!H)6DMY.F/LG6UTU0F=<)+35X3`=7!@JC0Y,!R?)DP%BXL3'E/?9PCI"8+`4
MWQ?%A'E8V8JI7'PWN,C(8RH22WF`4K%04$@*&0I&&?'LCMQQQ86F43>-:[R[
M85L#5`M]&[`AY*47V0X84:8='GX?66L*ZBNC:CTA&\UR(D'$6FR0A"SRJ*KA
MNY<E;]0%O%IK?=0[O[KR5;99C>,V\"VOH;$(+EM)#+LZ>\08XE&(^XA+A=7*
M,1*DH6TT7,Q1FS&FI2+XMSB_\U6"<W6G:$I'#ES`;,,N;Z3APU$U^J]:BN]A
MH:D-K`B!)&(H]XLUX@V]71,E>759W+5XE>=LZ567>U!E8(!=Z"L*[EVCZXO(
MY-9LBJ2/5!?LM.7>ZS.1Q<4SKL5%IZ7%8B.JD'&(E^V/N!I@R`B2MEX-%,IN
M,XU;6WE(=6A4E'%X[S:$Z@1E;X0E14,.RP6!B<-F(QZTD%9&(&S;IJNT6=W[
MX2M0KNQ1K5]0%I:A)0CB^TZS2T*Z;ZKV5,EJ<5KIKM]!Y`1FPH%XRM3F>6HZ
MLY'KL@C"RAF+I5-#>(TB_8.1)*GLQ75Q[DEN674Q)+#;J3<(+7A#DU5M*7G(
M;R7;>B(FZIB/(=\+,02&4*<\N/#NI$I*ABC%.&8$CK%'`)S[`H8+*LF889<V
M!.$VP>QHZS]YU8JZQV+='`5-VE60@(AXO,UDSAMHIW+S5%G46NV&D95JPRDG
MP3BI'-&=OE;$DT$DX5!8&*?`W#3$FT\DZ+<Y%L@),Q!?XYQ(:?RJNR6VI;15
M;E+D/J0CP5)1=6VDPE/!5O+C?A"\I#R7+ZI`6KK=F`VC\WB4GK\`,>NVH)S8
M=?@<*\*=$L]A[SR?LT"YM\?`U:PQCVT.H!A2'#%JN7CO24`7L%XE]=RLB2KV
MIF\;PAZ$G+I2B#OHL[?Q":I%"Y"M0VFV<DV-:;BB$[<9D9Q+"7ER@M0^VI1P
M9B-S6T%^.I*Y0NZHRF%MXVESC%(4D_G%.+OI<1F"$J&.&7_NT\*BDG`]CQ>.
M./Y088U^W']S87/,YYLVRV38^RM=[A8[2JNA[9MSW%9C5)'7=LLSJX0NK*W1
M[8]@(6O3T.3R5-U)U6LRSZ*KK=1TZ>.E#^4?&\AJV-;BV]*6J+:[5J:R.0)%
MVCV[C5>$(FQV$QG;@_*CH>=>9</&%MBX3H[4B:ZEEEAE*>+(96;F7UJ6MEP+
M#97AL*2<0@).`!&S$H22$C$D\/UQ?<3SCEQ,;'M-HV;LRE[OJ%\)H&[[D0A&
M#V'C:)<W#FV1&LJ_1K?*5F`K5CC)MAT&?U:G2CZ-@VBJYGSH7)A_-[3=N;W+
ML:7M$2TVJ^V";$-XBVPNK2XN7%2F.Y/>EQFWWGV'&G<0S/N3#3\MY#8CL\4`
M0"LW$ON*<6TZE7%J7AL"5;0D))`!!'"A!(2,<3C5E^S^D:-.`'JB5@`=`=8>
MGW39='0``(B/[F=1\L3GR:$\8N'JF?7CK/V:E=)'?$URI=U7&0-3Y=::I:U#
MVQK38K.P3<A:JQ*[JBMD:T>149Q1=TME+$KB6S[S-P,I"6*NR=?K2B[=-`M8
MB"D!4%CK)C9`^8/S*]XOH-'ET2DATI[1Q.ZGM559/W36V.6^U;1M-YO?:5JV
MOKMB@VDZ58(M[IZ9H!96[P%!NKA*??DAZ3O."E'S.<&1JD"I7T(>(KK]1%Z^
M=O"M2-ZX_+*T;N8T?:+0QN\M$.S:G<4IN4RXFY-3.+BO3(H+*"[*M+S:%-<3
M<)8F+DR9K*7&([+!=4ZKFGI%QD..&6XIQD;4D9"G%02K;L2X#MQ0G+@$G`DG
M#!X=22O'.#Y.;&I>G;++V+8T^-^N>WZZCL.?DZO1Y=6U1S:>?-ZA-/%()M,2
MMO2,@\3B`%:/5-UG"21'9#J(#K.'O/N&Z>UWW7$1F+IB-X'%MKQA,MR)38CK
M4R@R6DAU33<8A;:I/6O)&#2UJ94$[6.J$B<MJ,HJ>.92QF)"3B,=AV8D\.'!
MT>&F(@]^:,LU_D]45S<FK9[:$,K+(2^N8>_5:2O,:M`J^(G$GU4:2JTZV4A5
MQZCLIT`%L?P*=4?!B97#=SO!M.FVM8W2QW>/I)\-EN:[#D(B+#PQ:*)"FPTH
M.C:V0OKQM3B*S42XCCQCH=;+XQQ2%`J&'#LQQV='Z*KAX(Q]L3Y><WI&59;N
M+6W&S+I\7WEW;R`40Y%;)%(*J1EB<0S*$NCUZO%K)Q`1+MZC`Q+%1HY/X]8!
M%T/*'DV96Y70$6&Y8#=$VJ+QR8JD>%C!AP@.,I=6[%2D.)5)\(;:5+D.I>:3
MQ:#AI+2ES[1E*4'<F=6&;L>$<!PP5P;,"<H&!VFG[Y-64M,T]:+B<L.8E3:N
M;*<MBLK&EU\20<;(29PG+C)HN8VIPXE;?XS).$U$&*/66.4Q2"`N%^3?SPC[
MI77JQJU6\'V?_ET?AKGB[E.[V-SRGOE1CT:TUU\]U_?IV6<T5K7W]!G-H-K/
M1K9,(4BWPNG-2%DZA7(W<)74<S`TZ#9.?.L:3<D=(`E+I\W#F47;T_:._KK@
MM!^T;?<G.H*NWXT2W'2,VKM77_'VS2MK]S_=&R;!2-L:<LM:IEDG[M8Y5S"5
MROV)\LDR))3DK).%S0X*,V8@DBKXH#MBFK9;U86\^7H^SZDWDQ&8?&9&(9\"
M:8?E,,Q6&TNOO,H!44--L(0).5UW%;B,^5TA8(*H29#C,-15AB5=<2$DJ)P`
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MUQ<1A*FE-1HCX;D-J:D..H3QP0C26`.`OE8=P+FS/CP9EG8<!F.W$J&(.(`X
M*9'O'(;XQ\/M[5_W32A?=S4NUHD9A>02B4HH'^M[0V&0-*+@*$<+0%.N"Y_I
M4A`##X`QY'R2N<%JOW,7ZR@5S^\?S4QXP.T754O=8;:2VGS+>`W_`*VC!"K\
M6[(S"O\`-&[K2FXF"LS:M'S`RC'7+F):N:%09E!=,(M^9X[)8S-EE4R($:AX
MR1[YO_,RD^]-IZDNN0T#[0CN#GU:L5X_;CD[9SIY&T-S5^.<,E$P,V5>?U]%
M"IN*WI4JX0E=@)38%Q06.WE$V#&8<1KJ&<$(]AG\>"GW*\;"I7OWDZ'B6;D]
MZ7U$U+U0^MZ2U@S,<PML8RHSKSS<.,0%-E:VT/MR4$M26GBG\\PZ$JM#DJ<N
MKS)2R,`=J1UYRD`%2NCPX%/"DCZ"*D2JFY(..9-M?6&`V&&@GD<7XFOW-QJL
M93JXFRI<-&NXA]08N,D)2P24O<VC^1;RBTH51)%ZFD9$I42D#F+P-US>XV%'
MMDFV?WC(=_SE"8TA<E\JE.K2XB8XM#;*&XJF65L)8(4II2PLEPFO=OPTW)16
M%^"$=;UP"1UH&&4#$DJQ../1X-E.E/>\4UZ)D?,ULX_<7\;='>]5I\OCU[W/
MS;([@YVIKC_Y/5NEU#?.X+2PX]JW,UVY1Z@8V+?MOI*L,YUWLV=::;2BX375
MLC]L.G%R8-X2!05\0XIK8&:"[IZ=VHR)X\MZR?V4CI.=15-G1T/O5<EWI]`0
MV5?>)M83U*ZVI**6J\R#?W*L4#&S55:1DGK5Y[JLV5@8R3.'CY*=3CF+^RBD
M(0+1P;JF3<N&JJ5.KDK:C<TK`UW=E7E%GB!MA"N,9>6U(4X)Z>+4IE:%.K0T
M7G68.;_.W$#$*::>0MP%[9#ZHK?%\8K$G80",,NW;CAB<`5?P1]TBF3YP:QV
M[L\FHHS7T#,6NELYZWCM:LQTX#./EH=[5E&U>">KI]Z\>D;/&MYKZ;J*3CA-
ML?H.9@YZW611W<#JS16DU7J5J62Q#ORX\;[/?6UF6VXB0%/<2]]DWDL+4ULQ
M3$05CK1):PP7L+JQ)?XM+(*F@3G`/",-F(XQO$8_X1P^@]![42@5%(H`!0*F
M0H%#HZ"@!0#H#H,<.@/JA^B.-Y6<5D\.)/\`^G0Z@K:C@KDG[Y"\SK??%YHJ
MFO\`C_9B,-<M-@:XN-UM6C:EMC7-B1>;5@U[%6I2T;`INX$T6^QEJB=FE$HN
MR.R)ODFJ2S@RB8W;^1_S4=VWN19_(FJ;C?\`SY,\9<[8U8AO?;^P-'<1>"=D
MH6_+'J4;?I.FTDT$RC*0M#N'R>CV\[#WV5>V;3&U'I(^D/VB2LE'(&9JRK4Q
M6[8Q%Q$3P!;SM$Z9U_RU=\%JU#IR+>4PM2*E!U:Y0=2@RF67(;:&+G;TYY2%
M*2P\L.)CN`N.A3>`"I0I+T73EO6T\IO,SEPP3AV)(4<4+V)Z(V8C8-M6Q7_D
M-HS3*=&0W-NG6.L76P$'1*<XV+<("@M[>ZB6T8M+%@S6B1CTG#AL66;'.@4Y
ME2`X(`@(CD8^G-V>\'72K@YH6PW:[-6U23)3"C/3%1DN*<#?&\0A92%<6L!9
M`2<BCCLKLWID2-D$EUMLKX,Q"<<,,<,2/I%)#WANN?RIR6C%(O6-_P!G.X>1
MG)ZNVVM0D]::9IQ^E%'E8;9R,'37$4_N=U<S\9&,8]C(NWT"5JNLX<1SDI#=
M*^\F?5']4(NH4R[M;;2R^TTR]'?=9CRKF@N!MV`79(<1%BI9<?=>=9;:EEQ"
M&FI+14*U=Y9\(4UE;6X0200"4HV8A6"<,RL0``24X8DI-8WO(OCE:=5:]UG"
M:UO.RIJ=B+1,VF9AM"3.QDF#%AK^9;GC8R2CM/;29:ZV7>9I8C"&?H%:*0KI
M8'2XBV3ZA\KDM_8=HUA<]5S[K;[5`COQVH[3MW:A%:US&E!:T+N4!4V#$:!>
ME-*+@E-I++8XU69/S>^-<CH82A:U$$DALJ_@G8"$+RJ4=B3LRG:=E+GWINR6
M#>^\7=32LNTK!(MLQV&=G9KO1S'1:?&&JQ`;%6UU*;3HLSLV;U0]BQ:DA'D7
M/P$V6?<F6;D69)+)J?R0]+2'-.:NUE#87++REP@IB++P*N)D.>!":W;Y;4!J
MX)<XPRFI$.9%,-H-N*0^M"L*_O@/,1U'+AUVU2?I`S92M)448892%)5F.(Q&
M-,'R3V'&*\^=%4-+9MFA7,'':E?.Z_59M%ZK&REFVK*)HLG54:[@HB\>VV1$
M1Y(N:?/JW=$%*^"ODZ,8LB9RNFNZS3,M')SU#J)=IB/M2';BA+TAHH"VV+>V
M2M,A5MEA:H+BR_%::G6Q0F9.-7+0L--YDYY/VNTSQB@0$;`>`E9Z&=/9#8HE
M*^MX`DC$XO>U!LUV[Q;73JJ/+E&!7HC3$E8W]2;4J1<Q[!H3D&NA8E[79M?6
MM/74/$@J=B_@%WC92[I2Y3,R`I&*G-F;O-1VFP\F*Z-7A$%TR7KFAA$E4I"5
MK4;,"R([$R.9KCF`=9F(:6FU*C$/J*9:$CYELN.WE!;*AE""<,I_[S;B4G*!
MP%.(SX[.QKWZ[&TO.=S/:4[8]D["U1<K1NC3FJ7FSCU]G7M>[(HHWU>V1VHZ
M[2[@HW;QQXZ@SL*G*3M3C)5\PC%16EW@K-@>8VIA:&.3RO2-OBVJV:Q@Q+9<
M[@F`'E/3(4OP01UW%Z5&!4L+F1)2H\2XOQVGGT!$)@(=+'TSQANPD+4M<=2E
MH1FPP2I.;$("3P8)4G%2`2!M4<1C(.L*GJR+YER5_@.2"NX+;?6>RZ]^2W8K
M63O=WU`I2;38%+BAKF59.6*6EZ;'3<L2&>M92)33D446#=-ZHKXH%^;U9>=7
MR]QC6F[CI862RVY<%[P^$IN)%N0E1V1&,UM25FZ25M-F2TXQ()94J0XIA*,Y
M;]F&XZ;F7D/\8XL*&16*E(RDYLI_@)!.4@C;L&/TQUQ_<3SGF:^V99+-LO9>
MOMO,-HU;1%MV\A#,4JO(:]MME<W"$U-`T>WOX.'@9R(+Y*1S+5*K2LA$UU!5
M=V_<G4%QT^\ANW-;BV]*6N):K5J2R.0)%VCVTNK+Z)D=A,9VXO2XR'7'FG/R
MA1'N-PCLR)KB&V8[24AOPAE9N9?6I:V7`H-E>&S*3B$!)P`(V8E""0D8DGAB
M3CK192K=Z]O%1K4I:8I)&6SU(O9:]^HMY7@K)88K3UEG-=V)\QU&2\UE%NVE
M$%X.JR-W.HPC!*Z)%JH"1TAV>\[4,2[\CK3Z7IK+%_+D`.01#EQ`ZPRY<F&I
MK*%W$Q'RI3:T2K@S:@EY\%E4M#@+3F/":4WJ!W!)+6"L%9DJP)""4GK,PX>M
M05[!MRX;0Q&G.2VZ[_S.NU"9%96[3:06HR2Z"3*$CZU5H]G0_B9-PHO:'$V-
M_8DYM[-L[&S>SLD0ZJS4[%LT!!VF"9:XW5:#TWN+@:CD%R%K@^#X@E3JWY"U
M2_"FG<DMQA#):3%<A.-1&"$I>3(=>+C*CFQITIZYJ9&"HVW[F`ZW*1UH...8
M*!4>A@!@:?+8K^-DJ/-'9O&DBW;R;6/>"R<HN2I/&$XV:R,>L=%0Q4GC1PF9
M)5,PE.FH42F`!`<5WY6\:1%Y<FC4R6UMJ6Q<UI"DE)*%V>:I"QB!BE22%)4-
MB@002*U^M2%::D8$':COB:Y6>(6^-D[&[Q?C/0KKR$DKW(U"UW`M^U_+V:#?
MP<[:&--W(VJFU=0TF,K4'8*74#P+QXWD%9U./=',Z9L$4'@,E'QK)?+9YH&\
MKW/G][%)!ISS_#\83U:L>N5;I=`[Y#5K>"F@K+G9B1+C+U^*OA%G\[<#:FW,
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MZ*95?8J2E*E@@8YL"%!25#82`<$DX8!1.8IQ'1F7E-K'1<USWXQ6+:F[+C4-
M@-GD+:=.UB]:^HDUH^>>PUGKL1(ZTK-V2K\!;8[8MDE"-)-E&2L[(-RO@"0C
MF8K('(7AMT.K-X,#DZ:LMFC[#!FZ;6AV/<GXDR6U=64NL/.(G/Q2\]&7"8;+
MC#K\>(RLM8QI+X0XE1R9[$15W87(=4E[$%`4E)0<"`4A6`(43@0"H[=J1B*M
MSQEM=%1A11A15*W?/3;FLT;0\TO;MIL:TYN=PJEAUEJN7K"<]N<EIKK)NUHD
M559#?VC+C;K),I-%XY).#)8%FD+)RRQFS1<&DBT?AR%H#5VU!J*`W"M#EU1!
MC2&9]P;?+-L,=Y2E2W)"+/=HT9AHJ0\I4HPTN2F(;8=>;+T5[F-3*+;32BIP
M(S$%*",5XCL0.,;42>#K<V"2HX`X*$,'"^S/$'AL%JV1>XC<=._+%3(C9&U+
MSJ'7+9P[U'L6OR4/5=O6F<KFZ:::V.'FIHET=)C*.5G;"#E1]TI%0!\J[I)T
MY!WUZY^Q[7;GM#SOLV4Y"M\2Y35)3<83R'9%MCM/VN3X.E-QD-A3L=M+;TJ'
M_FL5.'$XOY95NC<8M8DISI"EJ0GL%`@+)"TX]8#L)Q"5=<KHLKRRFKIMSA9Q
MRL;R'C)]2YO=>2]G@+S3[+:;=<)^PUAS&1\92XW5#G7TLVLDHM-.I)L\9Q1$
MO(&IA%HU\8`I)7N:@6+1>_?5%K8?=C)@MS6V'HDEB/&C,LOI<6Y*7<$S&U,-
MAIMA;3L@JXYP`//9>OSK@IV1;&5D`YBDD*!))(P`2$93B<200.`<`K!\O=;O
MXO@CQ7AX2QGUU:Z(CK*`AK#:'.R*K'0KH^GY^-7C[3'1$B@WBEIIZR1CO&V=
M-PTCEG0]82.S)'S8;E-4QI?*&U?-GQ1<[/<53WG68Z8,A;J1<F5A<=;B"7`T
ME2G\L!2''DMC#,R%IKYN+!3:8Z4JR.(R@$Y@!UA&T`[,>#KM@Q^FK0M$,9&,
MT?IJ-F%XAU+Q^JM>,91S`*G7@7$BTJ,.W?+PBZB:*BT0JY3,9L<Q"F,B)1$`
M'P8TG>'(BR]?WR5!2\B$[>)JVTO`!Y*%27"@.@$@.!)`6`2`K$8FM[$"DQ6D
MJPS!M..'!C@.#[GT5-'X,SHO[+5Y?KZIM[Y?5%&VAKC332YZDJES8#NAW#SV
MSU^-+WEGLO2='>TJW3,U/ZVTC7A&WVX+/8JY#Q$UY&A)M6$4Z5?.XYRBVZZ#
MK^2EK'4&DM[VM7K%>ID"3X-)<9@"^)T[!NDM-Q:::9G75[_-HW$,OR9,7C%L
M./2&T1V9+2W<KFBOD=I^!&#K:5#$`JXKC5(3D))2@;3B0`K#$`'$I(&QS."C
MZ^/^)&CS[(U[&:LL[*J+PJ=)A]=?D>8QU4K\[+P6OY(NH1>/S:G<V>@QT9*N
M*P*IS5]P]/'CT"W$`;'RA8^G8V^?4"=+7-V[VER8'3*<F_:2UR'FFW9B/M+*
MC[12Q,6_'1/"0)B&DR1L=QK<VDNFW-<>@-N!.&4)R8`$A)R?P,4@'+_!QPZ%
M-GB-5L:,**,**TW80]%-G!Z@*]#=`?%F,4I5.AXV^D,8_P!*4#^H(CX`Q['R
MY>>YN[]-J\DDUSFKO9N7W/ZPKC,X?$AV_>.4^N5N^ANM"`Y/P5ALENLM-NNO
MY;7LY+;%OE<ET*S7KMOFRR,G9+]-1P-K),FH\3[ILX1@JT<E8&3(M:OY47-H
MWA>Y-Z]7R*0^R^>8GC+?;BNAN-1T5-]Y.\M$%N[>[K9D4W<U*0HB4?9W?&@;
M.CJ-<UEUQ&VJ/BV]-#9"U181-FD8E\]>N6YX$BK0C909(JM3.4O>%`Y+"+1<
M+!IU&E'E)D(EE;";YQ!N(XB:N.MPR?`1)7(@L2&FFD+$M2'E.I$4H75(B+O9
M<0Z[QXV9=O%8Y-J0<,N;#!1!)/6[,.NK1^-IX1;G7M6'^-:TA!U68O3S5U26
MHUW8UZ$F;0YF'VW'M5++[/GZ?391O.G%)T\80;$\R#QR9($TW#@#[_>FF>CD
M]V>;X&EJX3&(B9\D2XJWG6HZ6D6Y$CBX#,F2V6AF;:>ENB-Q307F4TV4^,+*
M;LXG-BA)5E&56`)QSX8J(2<>$A(S8GZ36'J<3;GO>R[);LS7VLQT:S1MBDR1
M"BNX6V0+G5NMHFQ5B2LKR@C8']9:/6<*JTK:-A</85W)&D_)FZ+I,Q<V\S+*
MQR-K4X^+=+E.K,<-$RTNQWDSYSC+Z&$S.)0^I*I27)RH:&I3;`B<:XMI0/RV
MEPZA6!G2D#''K<",B003EQP['!.;%).;``UEN,5P5V)S<L.Q$&EH90MPK6WU
MV\3)>(-9JU:HD^CX"Y5:\+C'-57%%J[&$A$8E$OB1AK:YG(X3/?%&=9A[V;(
MC3&X.-IEQ<1R?!E6T%Q&/$/QW!=7HTB(,Z@F7(6[*5(4<WA-N;M\H!C.&J^H
M+G'713PS!*DKV'A!&0*"MG8C!.'\596G;PUK_=F\O-=\BMB7*@PW%G2/'FW:
M<JLC"(%KULK3?8K.B/G]1EH6FQ>O)*BU':"4)7U9?R.U.S(H5IC8V*39BO(F
M4,9ILN5;N5U-NQTS!U'.U??]366^3$.GCH[ZH2I:$26W9+DU$N3`+KP;XRWM
MA2YSL)U;LAN*$@/?%CN+,UY3*8[3+C22-A&;+L(2$E(5@,<%GL0H8`JZ#*:K
MNFJMD<O+79*!R&VI=I9BULD=.:--6;VEJ&DMV$;`UI&^MG#Z-81D9(6:5K;Q
M&-EUGCF$L*8/21#3RAK(/C)7J^PZPTMN5AVO4FF;/`AN+86U=>/B&Y2E+6\^
M8:@A:W'$,-OM*?C);1*A$L&:]Q3L:.,Z.['?N*ELO.*4,048*R)V`9N#`$D'
M`XE*MN48@FH+V%3J[)=Z'K)>P>Y$5/Q;:LW6'FI"(O<-8+_U*EN2&BJO7YNL
MU.8IT_6:0R.*SV/G9B/2]TRHO4FWE)45%5"TS?+G%Y)-V;MO'O6UY;\5UI#D
M1UF'C(MCKDAYI^0U)9?E*&5IZ)&>5Q!6PMWBBM*,1YM"K\V5X!8P4"0H%6Q8
M`!`((3T0HC;@<,<*UNS23R3[VZ@6*(LV\TZW'JGUD[1AF#NW\?[+.DTIL>;F
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M=HX"G_\`:S?<I1Y^PH0/>U`\0L>J8"1E)VM45>3MC9DC>)>+DM%U>3-K&+CB
M7]LLG$2*S@9*&M8P(NG5A5/7C.5&Q2H&6BW6URX\C/B'(MXDQ68[\L(CJ48K
M;B+M(;\/<68:@7$!/$2;?X7Q;<-*;F&DNDN#7K6$:AQ"FPHD)Q/9$%L'*!FX
M#PI7EQ*NLQPV5-NM;G4(KO!MAZEJ_&'0=5CJX!D$MWU&)HL=>E+-9]?H[*MT
M-+RD4<LH2W3WNNU<K08MT9!2*.>57.JW,41X'55BO<SDUVS6=WU;J.9*E;3:
MI+DM<0,,3#!C.MMN#BS&9XMQ"96=3*9`3#;2AT$#*8=;3>%QVV&4I3_#`2%8
ME.8@D;<3B#EPQPZX[*_/2-SH4?SRVWJ.H\7-&T1E32R\5';GI$738^T/9:0J
MU-OMNKTA)PZ!%/C+*J6AH\?02147[=B=!Z[`R:B9C?>OK%J.3R=K+K2]:NU!
M<7YW%N+MDIR2MA#:)$F)&>0VX2.(;##C34M14RMT.1V<%)4!^1761=G([;#2
M`G$!:0G''!*B,1T3B"4\(&!-6([.$0H\X(=`B!6`@`]/0(A)LAZ!ZHE-T?0$
M!SN?EB<^30GC%P]4SZQM9^S4KI([XFN0GNQ+5J:P=XQQ'9T>.M(R=>UYO2M1
M:$U!U*#=Z]I;325!L:=/O$[6Z3797;EL;2MJ^+36;EUT5VI*.\*#51=VY<Y9
M`^8-S*]XOH-'ET2DATI[1Q.ZGM559'W6-8L]9Y2[">1&MJW3*1<-46R7V,EK
M"'O]0T_$[=8[$JR=?=4=VTV#-:"W37KOKN036@9>OQSB6B(&-;C).V:TH:/&
MOGRO;M:;KNBMC$VZRIU_A7F.W",]V')N3EN7"D%Y,I*H;5XM;T6:A29<:8\B
M/)EON^"LOMQ!)I5;`VXB>LI0E+2FR590H("\PPR]<6UA23UI2"0D#,0584U_
M%%]$M.;?*A)VRBEY67F]PS43:8=Q",S2\;7;GK:NVN)>T*&JK*=@9BJ+$AH]
MS*RSH%+2+<CMD#U$BCA%'-\4>:]N#T>MEQY,-B/;6G([B75<6MZ+.>CN(ENR
M%M/-2`9+R(\=O+`SJ9D&.LH;7L+>4BZ2,0,Q*R",-H"D@C*!B".M!)/7<(Q&
MT:]Q2JM3N7-'>%AM479E+7K2Y[/N.L8MZ2894FD0^Q+9.I+3=38R]O=S;.=V
M/!6HTG86CR*:M!F'*BK<B14FY2[/?%>+S8]Q.G[;:'H@L]U@P(T]Q'%*E2G(
M4=HAJ0MN,EI34)V.&(3C4AQSP9"4.J65N$_%O;;=N;JW`KC$*4I(VY4A1.T8
MG'%0.*@0!B=G`*]W!R4BEN7O+:'A>H1G%SFPTY%]'TMW`1MJL[G>UWGIQ5Z5
M<C1O6[%1FUC9Q3A)!-=.QIG3E%%_*RND$,?E`1)B-RFC)T_$OO1X10A<I+RX
M[";3%9:"<"HOLRU,.R$*6I*H2@J(EOB2RXY]6I23<9"4\`*L>MP!/&*)Z13B
M!_A=ECCB!8EO2)BYZA.(*<CF$Q"S4@TB9B)E6;61BY2+D4G+.0CI*/>I+LGS
M!ZT6.FLBL0Z2J9A*8HE$0QPWR;^>$?=*Z]6-6IW@^S_\NC\-<WG<S.H60YB6
M*5A(VK55.:UENV3E*#1$H*$IU6ET[EI>$$8^CPFP[Q\3Y!W#0C)NX3=-HATJ
MDQ0(=%3Q`"G+K\W#F47;T_:._KK@M!^T;?<G.H*L\X`34%&[+Y3D>,F`2B5C
MN%Q/98$K`Z%NJ[C=>Z&:LNUH-8IT8^HCUE-0KQBO&OU3S$FY:"\*W.FJ18]?
M[E(0+A*TKI!3#CG@ABQHP8>S@QI`M=K4&U3'Y*T2T*:=:=0^RD1F&W`P7$J0
MI"54M"D)?D8@9LQ5B.B,Z]N4)&7:",#M)&.'1K$=WE1:I,;8W'<[)#3I-HZP
MF)VHPK5^:31J6N:O:;QL%\-/UHC(7&=EQJBJ:0NP0E&K9=HY>+@B!4U?%IYO
M*8U#>(6CK'8K6_'.D;LPS)=4C(9$V1'B0T>$SBB,TWX0">+SQW%H<0TWG)4C
M,KYLS3:I#KJP>/;)`X<$@J5L3UQ.'1V@8$G"O7W6<I$O9'D4R@.H6#AI2EQC
M-PPISFH0UF>-K#MLLY=6<6N1NG5Y%]->/AG]<01\EAGD`<Z2[CRLYR^/*[B3
M&(NF)%RQ-P?9E.*2N2F2ZPE3-NXJ*IP%1?0AK+)9FK5QDIN6E*VV^)2D_MA4
MDJ>".P!2.QP!VKQ5AT#CUI3P)*>$XTU?/6(:V#C)M2!?7U#5;*:H5_BG>SW1
MU4FNN&S^CV!JM>G*B#Z+730J9%1?'$CIL<"H#T*IC],#R?DE\X+5?N8OUE`K
MGMX_FICQ@=HNJD^[7H$Y3.\)MKVV\JJ5R8M4YQ8V05VVI<78HMMKR-;<HG,P
M5D]3L6Q=CK*"XM5EF81N1-PV!HVJY&IR&40,;)'OF_\`,RD^]%JZDNN0T#[0
MCN"_JTYO$AA)$Y\\SEWMM@#BC/6I\I1$M:+5^V1Z=B=ZSCXB=F+4SKZ-:5B'
MD%1FYV)F\L]D)\CH73]%LLS!,($=\\B*>3EH5MB%)`5'CH$LS@]'664SEN--
M1U/%\.)=EK#H7':9AEL,QG'6W\Q5&W!7VO))4.$];EP.W+@2<,,,$[-I*L<2
M`16P4C6*D'SY+*V;F=,[(L<.TV3)0^D[`E-QYJS#7EJO8$=?L48R82UY-.8&
M%FV,NFH\:+66.C&B/D*3**?O?*-;?]6)N')S,.U:%8M=K?7!0[=&2TOCW8B@
MR9BRXV9K27G6G8Q#;B8+S[B_"%R)D9CB_MIC)=\RY)6L9B$''8%;<NPY3@"#
MM&8`##!).-F<][Q37HF1\S6Q&-Q?QMT=[U6GR^/6PN?FV1W!SM37'IS`A;`;
M:VQ-F%V'%A%,>?7'O3@VHZ6ZOCK#HR=*U;/FXPL8U*ZIZD4U7/(+F7<OQ@S]
M6<DP.8143\K3O63^RD=)SJ*ILZ>A]ZKX>\?OJ5(L_%YPK0=-6\6VS)6?;26W
M++4H9K&NFAJ]5TX%M&V`Q)2296L;D`%<L>LC$S;.+?/0%JV,4],3DXZ<7?T:
MV:1<KY""X/$J1;F)#JEI4J0^7E+9Q;0J/X-M0[@J1%=EQXY#KH*7#7=[BO!C
MD:5UV.*R!AP##`[3CFX1P*"2=@J"^\::0##DQIJ9LED:**S=.A8.GZTEJ?9+
M-!;,DVEAOL'+:\L\[6-W:RC*!0;K*;)@'4TO<46E.EW-<C&KA\X63+'J=ER8
M'KE(W4WR#:XJPB/.==DSFY+##L%M3,-UN:PT_:ISDR9%;@S&XJ+:IRY1D39;
MS<=M"C)3CWH($YI2U#:D`)()"CBH%)(6D)2HJ259\$$I2"2>MJ[!$!*DD!B$
M3,"9`%-/HZB8@4`$A.@`#J%'P!^YC"UD%9()(Q.T\)^Z?NUU`KEU[SV'XZ1O
M+FK6JQ;,VW1^1[F6KKNDTFIMI%S^5>J0C/=5,,.DHM+7]JBK!NBK*[->-7PN
M7S%O$P4LJZ7,B'BG!+M_(_YJ.[;W(L_D35-PO_GR9XRYVQIL.0EQKU&XB]VE
M-VB1CR12%'H9AAW#B(2;N7;+0+"396!$MNTOO>E*?%1=@"R)W,,222662/'N
M4U04*I`3O#L=SU!RT=^-OM#3AF*NCGY5(<)2E4UIM3.,>Z6F4!("\J@B46%(
M2H26E(RE*HQ'$-:=MJW",N0;-G\4G':AQ.S[J<?H-9'O5+13++L+BUKN:G&C
M"&G!GXK8*BKI_&NK!5MB36M20=`?MG6^^.[6U4F^NZRY7DV[)*U/VCZ(CC'B
MTTU3`LA/(_M%]M6FM7ZG@QUN3H_$N0P$H6EF1":G%V8A2;1>E1Y41+Z$,+=5
M;V7&I,D)EJ4@%O9W]QI;T=E1P2<0KH8A13@G\XWBE6!QPSD$)ZWZ6GY3JZ0U
MMKC3?'%[R%VQQ[5KE>BXVB2.K8NY6&]SD+7*D_H54I+N2KL'--'3N[.BE;-8
MQ5$)BQNFBB$,9&0(1RW2#="C7^J=47S>@QIFS:E1*DN+EHGN1F8C3K\A$N1*
M2AYUI24Q4XN./I5X-";<2Y."XRBTYL)_@K##4(O.,Y4@)*`HJ(`RA.(![+@`
MX5$8)P.T83FTRW=)1-0KVL>8^L>-D)+:^;M)2I6ZR16I-@3$ND]15CK15K[.
MH6ZR5A!@Y2;I/VAF3[Q[!!XP$Y';Y&3C,_<(_H&+,FW/5FA[MJJ>S<BIN1&8
M<N,-MLI(7'D1&C&8?*TE:FG`ZUD>6Q)RJ9CKB2_BZ"4I*4,26V$E&T$A"B>@
M0HXD=#$8'9B.$A28-[UMU).'O&YO$VW<L7*4`+!?[78=)59[?XB":-[)J6-A
MW6SJ%`WB!MZL%=9!1TS@W2GNI$L'I5'DFF5DT7?-5!Y';,5J/JEV9"L;T.Y<
M3#CLW20F&X\HL7%;J8$MZ(]&#T5`;=E-CB)#S12Q$47WFX[V+J`J)8"5.A2,
M5$H&8#:@#,D*!P5M"3M`.U6P$ALMYT*HN.6F@;6?;>I];V,CID[6J-TG22]Q
MVH1M,-VK:%I.OUI"MJQ$F*Z:":-B0D'H)J_XN>*<=/7Q&]WVH[TUN9U)9TV6
M\W2UE"DB3%9XN-;RIHJ4[*F!#X<;P*U*A+9:)3^53,;PRUL);+9N++G&-H7]
M"CB5[>!*=F!_PL3]&4TH?+&R(UGO)M+3Z=HU95Y2)A=01+6Q[(8,DGT"UM;[
M>;-Y`0K0+Q`N+'7[T#4$7LT>+?*U60;LBH+$+(+>)6G<W:UW7DLWZVJB7B7$
M>?N3BF(*UE#RHZ+2I+SJO!'DL/1,V9J*)#2;@RM\N-J,9&?77!81>VEYFTJ`
M0,5=#'C-@ZX8A715@<APP/7'"=HFZU*$[QV1U77>,>AH])!!A+2.^H.)HS?9
M3"[7_6^R+W/!.2S%1.;C;9<&\0*:$4JW+*2L5[I2@K*M"*@FGLRPWF?R7FM7
MW/5FHG5J4MM%H=<EF"N+#G0HC/%-K!:7'C*<S+D)66(\CP6&$(>4@JRTNMIO
M1CH89'1+@"<V925*.)X03AP<)&96.%8SB=K2YUOEWR(V1L?3>X:Y9MH2ZZ[;
M99[)8BZ]EXJIVK:U?K=6L$<&Z;/#VV)@]<A`/:V_>0"#EFO-O6:(-D&J*"&7
MODU58KIN5TQI;2]\LDJU6A@!4$,,^&-N2(]O>?D,K^RV'8SCLWPQJ:TW+6AU
M$5A]9=<><<<^;>PZBXO/O-.)6X>RQ.4@%8`(SD$!.4I)3B,Q`P``'KUE<Z%$
M=X/L34-4XN:-JB%:!1%'>-3B:='W$]EM=`0V;<(F3DXU`CA"V3P3#9=:#*5*
M45C5#RJXG;&`P^&J[%J*;R:K9K6\:NU!,<EX$VJ0Y)7&#$>88,9QMM9*3'9X
MM:$RR5,)?"8;>5T$5^L.LIO"XS<=I(3_``P!FQ*<Q!(Z)Q'6\.'7'94`\<ZM
M$I][#NUPY3:S,]2H2^12U]F*_!5^\6V4L=9TG.29I*5I<70:M=(B`CI)LQ8I
MJLK'(0A2JD,O&>5+).E'WGW>8KD<6!IHK8MT^1$<$-IYUZ)';8?NC3>1N4Y,
MD17'EH<==*783,HE"@W+XE"V<2$VG^L#I.U:0H9B`%$D()Q*0D*`!`&Q13]*
M<3B\]`TA3-8<J9^\,=G)/G]\;[`)#:TAJ7XMY#J61KKB4GVMQMT*[?1A*U7R
MZ]14K;-TPAC-E9-\'E#]9P(@WW4FOK[JW<_&T_(M);C6Y4/C9SLK%+H85-;9
M5&C.I0X7WO#%)FN-O2@M+$<\7'0V,=JS%:8N!=#F)7FP2$\&.4G,1LP&7K00
MG#$[232(<;5YB?Y2<P+R[AUZ2RM@RL^WUY:=6*T39305KWK^N+GL*+>O%KIF
ML?+U)X!91I/6`MJ6?"[Z4")%3++9R,FX-MWS;GK`P\FX2(2)K)F1YXF05X6&
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MBRDA%S,`SEA_.Z4`3F^*##P.+2FFG5M,.0+T)+2/\T)Q4>,7V652>PSY=FS^
M"<<1T<2%_P";E>IE-[R+B#;FDNE4Y_:5JU!'6<T7=C1=@L,I7MJ14;6W$?KH
MF]]3MKLG-QX)P$\]<5^^'C('J+(1[4S8RRJD;@[E?;YR6];65Y@S+=:(=R6Q
MQD7C&66WK>XM\+F_9-P5%+2\TR(TB9:`_+S-N27@Z&T8=T0TU>XS@.5;BD`X
M*P)(6`.MXQ&;'L5'*Y@G:`,,:]7.&TQCGO$^(Y8B=MRDA0G-(JMDA];;2UNW
ML+B0V1N+74BTK]BU7:3(WA"DM8EBSE['/5CRQX$6=LT>-"M%PD8_RW`6B4UR
M9-:&;'A"-<42I##DZWSE,A$*VS4*>9N$?&(92G%NQH42?Q31?#KS#Q>;\%D_
MMU<2;S'RE6*,H(2M./7+2<"@]=EPP*E)Q.&`(P.87D9'[7548448452KWR*U
M!:PG'9WMIJUEM9)V#:B,Q!5Q32\5N)]:'-';)41[1;/O&)=U>+J$5._3V=LW
M=M';Q([,QTWS-N[8KOQY#J-1O3]3LZ,6MG5AC6\M.OBZ.6U#"92C+3+8M3B9
M#DEQK9`6MMQMM0?`7'?<9D-\QJ4LA+)D;6,5X@9`O'+UN4K&``/9#$$[.$`@
MQ?I[XTQW!_B-/2O(WC#JI6.N.S&UO1M4D6BZ)VA,-.0<7<E4:!"P_P`6($8Y
M92CNXUDV2CDD$8N><"U;HD$J!NMUM]D2=_VM+=#TOJV\(=@P51C'1X7=H#2K
M,Y&!F.N\>]G`EMONK4\I:I$1OC7%G%P8\;C$VJ,M3S#9"E8XG*VH\8%=:!@,
M.M(`PX%'`#@ID^357</.`NDHJ4OD1M5TG:])RBFV(2.9;>J\TY<2GES2Z1^N
MYR/NSO>U><KNTRLX1NDZ?.R*HNTC%%J)RI9NHN[;'*-O\R);GK.R8=T;%N=6
MJVR&DI;R*BKFM+BIM+R0DEV4M3;392ME8/'`'.G-DVAI*EAPYD'.!G!V]D$G
M-Q@^A.TG8>A6`Y>MY"Z]W;QP$Y)*BNIF0XURJTW5A93T'KA_[@(2T1)RM?UM
MK>U0EYK*=A3:1K5A%0*3([]ZS<-RH%03`NQW*.QK#RF]4!):N#+#5\;#4C,R
M[-1QQ;<;;>G38[L1\LEQ]QZ1+4Z&6GVW2X7%8_%Q!=LS'"@DM'$;0G9B"0E)
M"AC@``G#$@C#"K0-/1Z,3J/5D4W=/7S>,US2(]![)+2CB1>(LJS&-DG3]><8
M14TN]<$3`ZIWC5LZ,H(BJDFH)B`TO6\E<W6EWF.H;;<=NDI92@-A"2I]Q12@
M-+<:"03@D-N+;``"%J3@H[V,`F.VD8D!">'''@'TX']T`U+/X,SJO[+5X_KZ
MJL[U..H:D#QPG]HAN>L:XJO))63N.[M$V_=M.O.AHMWJ#;D0A<DGW'V+E]AJ
MLK/*R#>L*==,D.G[N`9\H4G4`SC.3S*U$G>/O!MVD?L*7JB9:I3<:U7:-:Y,
M2[N)O,)PQBB\.-P@IAM"YZ<%&2?!,(Z2K-AJ+LEKP2*M_C4LI6DE;96%-CBU
M#-^3!5M/6_1UVVIW[OR2LLOQ"T_)6QELII*NF]T.V6V_9-E6O8DY7"[&MZ=.
MMU@F=QI-]I=6[5`C&89M)U-*1CF#Y!HJ0@H=4$3Y246U0M]=[BV9RU+AH5%"
MA;6(,>$T_P"!1C)C,M6PF!_FLDNQG7(BE,O/-./(4H.8G8V=2U6YM3@6%==V
M945$9CE)*^NZX8$!6T`@="G)Q#:V=&%%&%%:5L7Q7Q*G_'](H^2I>.ZO^%XK
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M,&X\BVQ1'93)98DS7$A2%E89+>ICQI942%D9$(2H%0!`6<N976XXD+5B<I*4
MCA;B@[-MT;SYM>DGL?QT6:1Z\U..96KZUAJEL-&J6RB-[=4P=W`=OSTU+[`>
M3[>40DXGXM-RN(5B68%PB1<C<R,:CTI997)RAZ^8=U.EYU+326Y$YV1",B/+
M,:1EC?9K+3<-+)CK8D>'+*)3IA!I:FU.#8LON)NZHI#.`Q.(2`K`IQ&W.258
MXXC+V(S8C'"HBT9:6M^[SS;<W47-#M%!1B)B2CG<#8;?(+5^=9U2JT*X6=U1
MSRIHRM6^WOZ\PCBV5S$M(B>A8P48I\]7(\#.TW@VA[3G)-LL"])N,34:GVD+
M2\S&0'F52)$N,PF6&^,?C1D///&"W(<DQ)3X<F1V&U,5C1'`]?7%-Y%,X$C`
MG8<`DG+C@"<`,Q`"DC!))QJ6M/;OY$J<_-B\>[O-HV+5<'2[38(%P\DM<&M*
M1VCJC.(E],0M0U_77<+&.$;,LDQ27E'3I9OXM55(Y@6.AQFM]`[LD\G&V;RK
M!'5%U?(GQV7DI1-\'(4F6'$-NR9CR77`6$J=4AAMM*\R$+2,B7,B-*F_:ZX;
MIS1PDD;4X_P<,0$C`;=FTG_IP3[NF+Q,US<-AU`G:+_;=4;!U3)[8TG-;:UM
M`1UI+`ZOF=?Z0EZ?`WVI[=L<4D:F1S*'4M$.XJ\<Y2L,H<JCORQL]:D6WEEZ
M?@W31$;6JHEMA:QMMX;MUT:MTYY<?CI[4RZMR7HDBVL.'PI:Y(@243WD*A1T
ME#/$.QWE:[3SJD251LRU1UME:"M(!P24H("@LCK1AF!2#F/#B"*GS@Y,U"O\
MC=F:\D:?*579#PEHFT7-?Y`)VVBV&*@+A9JY/O76N4N0ET8-3QM@059Q:#>M
MM5HDB3E)5-F8IRBG/*`@WJY;L+5J:+-9F:708[12]9S'ELN/1F'V4IFFS15J
M"V2EU]:YSB9!4TM"GP4FLNU*;1-6RI)2^<3L<Q20"0>MXQ7`=@ZT8;>"LG?Z
M=KNV]ZC09A[7HEG>-<5&D3C2R$<12\_-EL-5W+%MXTYIJZUV<AX>)1CS*`C!
MQ$T@[4.;RE9$#.$38NF[YJ:S<D&XP6)+R]/W2;*:4P4N!EKB9%L<4L<5%>:<
M<<*P,TJ3%6VD#BD+P;6/IYIER_H44@.H2DX[,3B%C#:H$`8?P0K'HD;16@.$
M8R*[YAHG`ZX8/VD[K>#<R%S'2\%:AA+*TIVUE+,\KNZ8*.AGNIUED73%&;C9
M>7DU9QP\2,E$M^LF_7Z-MR7,Y#*U7&Z.-O1[HZE$7[4=C\:PJ3;PPEZUO+=1
M<`"EU45^-&83%0VL+FN8*CM^)"4ZEZQ`(*!UV0'`X+QP6`,G0S`DYB>Q'"6L
MK-4@&_.BXV&"VQMM_8C-67Y3M>0-&V0WTP276U^H2G&NUJ:2`ZM3M[*BJ1IF
MX*H&>K$1:=804.D`(]=;S<G>3Y!MMPLUE;M@6KP":]+@JN?%B8#)\%CJ1X>8
MRI8?"\J@TDJ>PQ2E>.P0V@752T..%?\`"2$JR8Y>MS'L<<N'W>"L*QU)JN=[
MQ&3W'!WS<TGLFEQ+JNW.L(U"Y/M-PCB5U36$(6L.+RI&EI4(]0KD@6<&.274
M<N'\J0YCD$!2/G2-::PM_)E:T/<+=8FM+3WDO17S)C(N;H;N#Y=?$0+\*=27
MT&+QRD!"&8ZD@*'7I^!'CKO)DH6Z7TC!0P5D&*!@,V&4;.NPX<34-ZXC-?G[
MT*_DG!:OME5!.64@;-$FA(U&83ONHJ2X7B;:FSI\7)3MOB(BJ/0;M1E'S*+C
MT_'HIMUWSPA^YU1+U(GDE6TV_.WI6:6P\PYQJRV8ERE`.1BJ2XAJ,XY(:SN>
M#M.R'CQ:U.MQV%)QF$L_;R\^U]..!&`QS(3L.P$D`'9B0!M&!)K_`#1\9K\_
M>6;>]U#,WNS*>WM[",LL.>%CF5@9W.H:NEY)K9D6-.AI">NL42%7+XH\C(,X
MAOXWR4&YW;M$/W7\O4@Y*UE\$SMZ4G*C+<8<#JULJBR9[:%,%<EU#,5SC4',
M&&79*\G&EP,LKHBI9^W',V!?3C@1@,<P23CL&*AA])`'!AB15I&SP*:CS@'_
M`,`2L`/X1#Z49-D!O"!3"'@_9Z!^AFZ^6)SY-">,7#U3/KSUG[-2NDCOB:YT
MN%>^.1^Z^7_$V2OTK,6[7;I;>DC<WZNL:W4=<:QW8PH=^B8#6>C-GUN5D6^]
MZ2]HHOW3N447DCH'9-5C.T5'QV*-D#Y@_,JWB^@T>71*2'2GM'$[J>U53@<+
M>-/&#1W-*^1>H]R\B;+/TBD[(IK&B;4J,8&L2'6#CS7[\VU9M=CK6H+7%WJV
M'US3H9]'*2DFK'@X`YQ.JHLKE;K?MO5WM;P-Q-NF:TL>F(MMGSX,E<NWR7/#
MR!]LO0U7"WKG21&3/<FW*4T^(["7LA2D)0E"*5^V08$6YK3'=>4M"5)RK`R_
M]F%9%Y1CE"4)(Q.'[M>OA2E<(+GOR0KMG@I9R1:N;(\CV>LU78(7UA3MI4^M
MP49,-S$F6:K^D1#HK.-$DNH\]SE!7>-R*.R`GX;^5V2X\G32USM,AE*DRH.:
M`%!9AKDP)+[KC2L6E!$IQ)<?!C):XX!MAQ265%7[:^,1=WT.`]BKKOXV58`!
MX>Q&P;<<-I&VMJX72TL'-#F_1D()&&B86_['D"2Y)/4<NY)(6FT5JVMSHR4'
M5VVQ)YU*+VIX_<LI.0<M*PB9C'JI"LHF8-1OVA0SN*T!J!R0I^8_;82"V6[B
MVDHCL/QE`H=D*A,I;$=IE#K#*')ZA(DH7D2H5Z6Q2OM.4T!@D+5MQ0>$@\(&
M8XXDD$D)V#AK=^'N\>0=PY0<D--[9EFM@J>L&1@JLJ,GKQW8.LVO$Y6VCBUL
MJ)0:>UB)BQ1D8+TK(KA]Y(B)?&@D*J!U]!ONW?[M;)NETMKG1K*XUYNSG^<-
MY)J6>NB-/J3'7+F25.-,N.<472AKC%8Y"O(XEOUMLJ8Y/?C2#BVV-AQ3CV1&
MW*D8$@8X;</W,68YIO=D1W&K:LAIR.2F-NL:C9'FK8E=!FY0E-AMJ[,+4V.7
M;R*J$>NB]L)&Z9B+G(D8#=!Q`O2..E^3?SPC[I77JQJTF\'V?_ET?AJN'BG4
M-LQO+Z#9[<HFK=?2=]TUR>NCPNJ]E[(V`68M=PL?&EI=9F95N]*H+BL._&1S
M(K=I%"HU*4#F(*)@`5)>_FS/F-R,;E)2`5-ZBLRL"`0<LE1P((((V<!!'T@C
M97`Z%&;4*!]++G4K;N[06N+#>?*:`N4!,-9,QXV7=7EPT-&,]K.D-C[0KJES
MDHTJ#^-0L:7N.,>H1E+R*3<C,R"G44(!E($.56BQR=WVD+E8Y+"X@"VTQ`KC
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MEH#Y-,'J*+HZB1%"BF<H\ERE=W>[K1-KTO=-`)=0+K&E+?"FI325<5X+Q;C*
M9<N4X6%\8YQ2CQ2E-A*U)(4DU[V>7+DK>1*PZPI`VI/#FQ!RI2,1@,>';4B]
MY(T,_P"&^_&1(J,GC.]0;9;!!S<P%>AYD5M;6DGN7*V`9BO!!1S_`*?%+//=
M!CY,F85/*$>KXPK\/DE\X+5?N8OUE`KF-X_FICQ@=HNJ5^Y9>Z2FN6-@L&L*
M_;X2WO=$;N9[!5M&[H;>#9_#?UC:[9M;.8J9BMK;25A7TK%VQ_+S3991D4TW
M+.A2*JF7K$D>^;_S,I/O1:>I+KD-`^T([@Y]6K$N-]?@I/O"-YN6%M%-"ARV
M['4-!5[8=P>"ZFKG9-:2>SXZU4N83^)<?%IRSV)=%"ONY7QTBD!I'W'>("P<
M0/[T;E<(G)JT\U)A8N7%FUI==>A1DY6HK$YN`N/*:/A2W"VB0V?#&X^5E1$7
MPYAP2&E.A(0J\.D*V(*\`%'A44E0*3UN&.!ZTG;V64C`Y754O8[/WCVUW3K7
MJ"<)%V&25;RTLPNSE6O)-=,TZIQ]QBUHF<)KB(LMW1B1:%5F8%O930@F;DDU
M6/DK3,/6$*UVGDO6=EJYJ,]Z,@%MM<5(>*KG)D+C.!QKPUQB*7.,*8LM<$2L
M'51$2.->KZCJ6Y>G"4=:%':<VSK`,1@<H*L,.N3FR[,V&`JU>>]XIKT3(^9K
M8@FXOXVZ.]ZK3Y?'K:7/S;([@YVIKF%Y(RE4FMG;P<K\,FEHM=,L.FJPPYC5
M*OUUNPK)9>R4+RFMWR7V(-*G7U[K,4Y%JJXI@6Y,D0_;MSK-%/'LRWK)_92.
MDYU%4V='0^]5GO>,58UMV;QC:)-8L';)]?ABIR7H,_<(F"G)NP:J@6:5@5KV
MI=LJ/(2PP[V29&KKGXMHV!0X&+,-SL0*-,[DZW<6:SZU>6M[B7%Q^,:;F,QG
M'6FD7%Y19#UQMP2ZRZEAT34>'*A@$&"ZF1B'"79OC'(PV8@'`E)(!)0-N"%[
M",1E.7-_&&%;7WB7("QZ`C=7)TVD:AN<CN"5M]-N<1LMO!*+6'7]0H=GN,A$
MH)S]II<;(P<885GC])1V_<E:^-291CQPZ_>^9Y,F[>U[R)5W5?+A>X$:R,QI
M,5R"70&9DF6Q&0X2S'E+0ZOK6V5!ME!<R+?EL-M==[WF8N&EOBD-J4X2E05A
MM2$DD;2D$#A.TG#@22:L>8*D78LEDP0!-9HW5(#8QC-@(HB0Y0;F.DB8R`%'
MZ01(01+T?2AZF-=D(4W(<;5FS)6H'-V6()X=IV_3M.WHFMT-H!J@?FG.UQQR
M`W#K:8X:-N2D;<-1#)W*\U2OUEQ9]>LZ]9;2XI[/9,]M+XFTA*KDF#+2E=3@
M[,O8FK]H\7-%`44'0W:^1_S4=VWN19_(FJ;C?_/DSQESMC7AY(5U^GQP[M2X
MUK_MJV/M5ZPKKBLS^X8^B4V6C(34#&RL+`6M7J\T/7SBT5287%VG,D<&GV#$
MRX-FKL!Z6D$NN[HPOE<[\+)=CQ-G;OC[XD,VU<N2AQU]IA;7'Q(DN:F/);'%
MF,4"(\Z&RZZR1@\IL5!%AMKC>UPM`8%82D@`G'!2DIQ!VYL<P&.`/0FOO1@?
M.-J<!FSN[6^FQ3RY;3).CKFP45_.OC#6Z6F],QIVP-DZR).L8^N+RRAK$U),
M.ZYTD4]S'/E@$QJW)',=O1^\9UF!"G3$0;>6O#69:&4?EY13GDPX,\M+6^(X
M$)PQFYO7)\+:XC-6[OV)D1`5*2DJ7CE*<>!/04I..S'KAB4_Q3C6U=X!-52C
M;WU#?M@TV6G*=$UV,</;!2MUN-4WFM-H^SSD5(RK)E&[UU#(2KAK)76(;QSQ
M1!\T8^7O@.JAXSI'3\FZ!>-0;O+UIS34YF/>WI3@2S*M8N$1]2V&G$-J4NTW
M)#84B+(6\V%M..\3'RH<RX#TO"FVI;;SR26PD;4KR*&T@G8XC':H8':!B>"L
M5WK[^-;Z]XYJ1U>KTU-6>UV^KHA-6B`9V5]K^9TY;U-AUR,EK#:(>OR+.;J"
M:P23I.2<2Q$4^M$$6?JI*IYG(YC2G-2ZG3*DR6($2'&?/%1WE,(F-7.,(3[C
M;,=QY"FI)3Q#:F$1RHX35(CH6A7SJ`I#+.4)*E*(VD8Y2@Y@"2`<1PG''^+B
M:COO.&T`WV'P1M4-K2&OM@&3L4?(M&>H&F\V)8!Q"U=]3TGD.2,97Z(=+6ID
M1K6[*6:K;6%4=/%'+HP+F:..FY)[MQ=TSO#L\ZZOVZV\4RM"E7)5I7QR79")
M)2Z7%0W$B.HN38)BSG)26V$M,@MAYOQOH0'HCB4!:\3CUG&;,!ALPS#;L2K,
MD)Q.)VX%SMN52`>\S-5SK3;&VX38+6!JRLK1-:T?9$G6I?6*-Q?#!--M6*H2
M"%0CZNYMA)@$%YQ)0"`LZ`"^)(?I0O1=YN3&XR\6YZS661II<F0&Y<Z7!;?;
MGF,CC56YF2@R5R$QS&SIBJ&)2SB<Y3ALY#:#<VUAQP/8#%*4J(*<=F<C8!CC
MV7W>A6%VGJ35-\YYZFO0W[<X[7U7$UB3?5"L5.X6+6$17)5CLMO`(VJR,XQ6
MFT<]K?$=JG%TL9PX(PZ@%3%=%4N?I#6>L=.\G:\Z>%ML7]3KP\^VB2_(C,SW
M'VUP5/&.PI8DRQ'06TCBTA""]F)5Q:T'XD1X[UV;=SN^$-@'``E(!S88G#*G
M';P[3A]T5#C6/H*_>L"A8BM7M_K(%LE3L$0>'CECN;MH>R0YZS=U$:<SE9>4
MC:?6G1F$:67<,V\>BVD#H)/'"JCGMW9.HV^1[QELSMZ<E_D)#+@=6`F+=V'.
M/B@R5-MMKDOMAY\QD.K>4[&2XMAM"6L8!DZ@P7M>3M!&`[)LC!76XD@`X#$@
M#`X8G;*U-U=LJ'YKM+/<^:S/8D=&NMEA!Z&5DPK$Q!1%MC7]BC*@^UO!2IX2
MW#68>7CWS2U2")'T>S:>1MVX)23A8./OFKM*SMPR[38M!KMDIU$'C;N&^/:>
M<C+0RY)1.=;#L;CW6WFG+>RHM/.N<>ZZ5Q6VSD-,/IN@<=E!:1FP;QP(!&(&
M4'`X`@A9V@#`#KB:B?6\9K\_>A7\LX9J^V54"2QX&S1)H2-0F$[[J*DN'$3;
M4V=.BY*=MT1$51Z#=J,H^91<>3QZ*;==\\(?LM42]2)Y)5M-OSMZ5FEL/,.<
M:LMF)<I0#D<JDN(:C..2&L[G@[3LAX\6M3K<=A2<=A+/V\O/M?3C@1@,<R$[
M#L!)`!V8D`;1@2:C/BC`6FM=Y[OAM8'29W;EKLAI(V(U@E'<9?48UEJ5U6&Z
M4F7COJN*NFT:I4I9@$^T4LUK7@&*S9$BA$P`<ZO?%<K1=>29IUVVH(92N"I#
M/$MI<B%:KBE\EO[:N#D6!(D-O>!N)@V]$QU+JU)4O$5X6]#B+Z\%\/78G$X*
MPR8;>+0%*`(S#,O*,!6;TOJO56S^\=VI>7GDK"QZZN-IV10$*Y&4UR\E!F*[
MK&$EKD_VY#2:ERL%?NC444QKDBU\1%$:`DV6*V4.1?7ZZUAK#2?)>L^GV,[E
MLN<&/!F%]R2E+?%/3W6XR+<ZV(S+T5697AK+F>07,[K9=2E3?W%CQW[TXZ=B
MT**DX!.W$)!5G!S$*_BD;,-APX<3I&2UN?F_S1BF\.=#9*,K>9%=>'A7"M2>
M5E;86IV;\(^V25DDGKJT+231`\M&(-6[!I*JO3)%3.HKXQ^?(<BZH3O'W,S'
MGL^E51WD!+CJ1)2^+!?%(SQD,(2E@-J6F,^MQ;SD=+`65!*,O+ZE4SX'<4@8
M/X@[!LPXUKHDG;CPC#`''[M5$\"I?:<KWD_'UE+;XC-\UB$OEW=6RS42W[7N
MVM#2\SK794)52QTE<]9T/7C=]\=*3>E4BUAU+$:@X7BCK`WBVY0ERY;7-`WE
M>Z$_M!7!Z<\_P_&$]6K@[)K8(WOCJ)8]8P\%'Q:=;&:W6E3]'S<$BVDK9KS8
MPQ4_L+;50UHZ86>V7)_&E!(9^PM61$&J:92'>`0%:T%KU297(?N-KU8_(=EF
M5Q5K,FZM.E2(\V%QC,.W29R5L1XR%G-X'#<=*W%**DL$E"QK8RZD0M@`)RXK
MP01M*58%2PG:58?PE`;/IJ<^2''7<,QS9T?N?5M";2E'5=:I-N6R)[NVW4GR
MC?7VQ%Q;,5=75W:E3U]9DXJ%M!)DCM_#RQ%$85RP<(+"\:E!/MUV\[1$'<)J
M#0NKKBIF_A%P^S&#:K=(0#,A#,L3WK?(F,%QV.8Q;9DQR%2FI#;B`P\:RIL*
M2JZ-28Z,6NLSG.L=BK^*%A)P!S8D'L2"#B*57;E;L<5WN#&X[*INWJOI"P*Z
MO85V]4J%M=MUG(W:GU^CS5.N6PTUI'9M)K2TY:W$E47Z@U:K+Q<=#,9,9LO7
M,J18-%W2US.1>Y8]*SK)+U_&3/6]$E.QX\Y$62]+:DQH1"(,I\-1TL7%E/VA
M<$R'I,B((!RA"L"0A:=1!Q]+B8IRX*2"4E0"2%*VJ2,3B@]8C`)"LU7Z$.14
MA%$SE434*4Z:A#`<AR'`#$.0Y1$IBF*/2`AX!#(Y%)4A12H$*!P(/"#]!KKJ
M^L_**,**I2[V#:E=T]M_@S:[7M3;FI*X_LVVZ;8K-J>\TW7CV.@+NYT[67]@
MD)J\0UFB)LM1<2*$B:&3CP<N(Q!^]([;%CSINGY<CC2%SUOHG>#9[/9[+>KH
MW$MTEEBXQ),U*WHJ;D^AE#41UAQKPD(6R))>R(?5'84RZ9*5M<OJ"0B-)B..
M..-H*EI)0I*<`K(,<5`@X8XY<,<,3B,-OKL,):[-P:B'NG+V^V/#1&_=OV&&
MV"6T1I[U=E6W(^XGI&Q("^0T:SBTYQ90YI-619$01==84RH'17,4GC;9]GM/
M*!>CZXMS=KG/:<MK+L/B%^"10JR1A*A/1'5J<+0`#"672M3>&8N!;8*OI:7'
M+4#&65I#RR%8C,K\H<J@H##'HXCA^C`UG]R2*$CW<?&)WKZ+DW(2J_'X:PPU
MRYL+#;93*Q_CUE-'RC1H:>8[43;)KG*Y52ZQF'E_CQ(4YSEUVAHSD7E0ZL9U
M*\TGB4WCCUS4LKMVQ>`%U;4KB5V\J*`4)5@'O!N+Q*4I/U)4%65@L@[>+PRX
MY_\`$/#G^[]&.-;3R/TX[WUP(X\U/3-=?3$*U+HRVPSNFMHE]:ZC6(.G+N(J
MR4J$^.^GZW,SK-XNS:*MUGS5NDS=.5RMSJHII9J-UVN&=W7*+U->=<RFV)ZS
M=HSJ9*G$1Y+[LD!QB4[X+<GVFE)#KB5I:<6IUMILNI0XI=>DV,9=H9;C))3^
M3(RX8@`;"D9D`G@'"!@2<-E.AQ-CMI0?'C5U9W)2JUKZ^5"N(TQ[5ZA(.9*N
MLHBHK+5VL+1B[VP6Q\1![6XUJKU%Y1\N`G$5%>N(D*A.^63I&X;S+O==#SY5
MRT[-E&4B1)0E#RW)(#SX<"68Z"4OK<3BAAI.SK490"=G;TOHAMHDI2AY*<N`
MVC`;!AM/0`Z)IG?P9GI_9:C]?5"O?1<B./L;.:8XL[%Y"[9T[L.TRT_MZ*IV
MJZ1R>FY+:-?:5+95#K$:>?XQFC;<F2N;3D(N96CO+#).T(P2+-S>,0.5\/),
MW9;R96IM:[WM,::LU\TS$G.VUR3<)5A:1`>5<(LM]89ON>,>/MZ'XR7^*"FU
MOA2'!E<2>:OLR&EF-`>><;>4D+`0ETE0R*2!BU@=BR%88[<-HX*>SNT(":K7
M"#14787M@?3(L+M*/3VB`W56YQF,]LNZ3J$,[8<C&<?O%VE7VLD1BWD;,@E)
MR[9LF^.4"N2AC4>57<8%UW_:AEVQN,W!XR*VD1WK6^TKB8,5HNI795+M22\I
M!=6S!6IB,M:HZ22T:WEC0I%K:2LDJP4=H6#M4HX?E.OV8X8JVD#'HT]>-ZK;
M4844845INP3&)3IPY4Q5,1!`Q4@]50Q7C803#P#X3B'1Z@^KCV/ER\]S=WZ;
M5Y))KG-7>S<ON?UA7,MH)_HNN[9XOZLH'-/:&_[M6^8C<\SJUS*N%=:U=%2]
M[`F9:6:U52EE=UV*A)"?)%PTDXGG+&772=`Q4<BDLFVM7\J+FT;PO<F]>KY%
M(?9?/,3QEOMQ5B>IK+QOV)WF6R;SKCD%.OMJ(K3M&N^C9K5VT8ORH^K:Y.:L
MD[53[JREJU4976<7:J=*,#2$Q&3\.>RL'K2-<MGY_IJJVLK5O1TSR4[5I_5&
MFH[>CU):EQ;LU/@.91/?:N#<>3%4V_);G.1Y,=X,QGX<D07F'I33L<;%OCKA
M/7Q;K#Q,C:E2"E0[`%!(5B`4@I(Q(4,P(20:]FN]8SR?>A;&O::\O<DH9.0C
M+/>'=';HUF$C9/4M/E*EKI64@=5PD&UVU6SV0YRS2DVNX<TYXUCUC*NC+E#'
MU-JRW*Y)-KT\I+,%;Y0XQ$3+47W5MW&2W(FAMZX.NJMSX8`,414H;N33TE`0
MR&R?UEA?V\MW:K#$%678`4`A.(0!G&/99MJ"$G;C6'XE(M]6\T=EZCC:3L>'
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MR9\F'Q7%R+7$9*8\=P,P\Z$-I=6@XUEB3F9JGG2PME2""X@I4I:NL`S'*%8X
MA:CM(Q5T<!6V<6['$RG)FN0*%%V_&FJMBV^UAJU;*M,QM-U:VF&]OG[%+QUP
M4U!47]O;(6607A8=*8GY5%@TG7!676`Q3ETV]RUS(FZF5<7+A9'1,BVU3K\>
M0TN3/4TJ,RRVN,+E)1&46$(E251H<=3SD1LOX$%)]("TJG)0$.#*I>`((2C'
M$D@Y!CMZT8J.`4<*WZY2L+L3O(M?LX8&T2OJ,D06;L2S79D+.6F5>4S:B+BE
M0;OW7?ZOM59B$I%!S*%7B6CUNZ,W\2[,/5$O-V.'/TQR6[D_.SO-WHN<4R%0
M76H[:95O*93J>+1/CON%"VXY3(<:6V'<[(V@^SJDO7M`3L+>&)ZX$G*OK1MR
MD#'$[`<<,#416`VK:YWQ]4K\56=6-[S=8F)O4S;5-6V%E:FLG%Z3VM7GU42M
MD/J9S69V[6>*=QDH6<D[DS58P\>I&)L53KE%7M;:-773D/3+E,EW=6GX#SD1
MJ,)[*HZFW+I;WD2#'=N*7V8K#B7XYB,6QU+LEY,M4A"6R$8R_!T:E2A*6^-4
M`HG(<<0A8PQ","HC`YBL8`9<-M9VIUQNOWJZT_"0GQ29I1]PD740UTW6JLXE
MU#5"RUFX6.>NH1#&RVZ.GK4TCI"+F>NJD59T]:`NJ5UU2:^\W1UOD>IML^1X
M:^IR,A+BKF_(2V/"6'XS#,7C%L1ELQU/,OQL$J*6V'BV@LXJ^VT`Z@SI&48$
MX9`,=A!)5AB03@0K[I&.VOC6=<;K]Z79+#`0(TR-3AK9(KUYIIFM5%5X1Q6E
M*Y;YVQ6PL1'V2TH6.]1K:2BYPPG2,9=VU3663=CU?W5=T=;Y(D6V7*1X=*+\
M=`>5<WY(24OA^,TS'XQ;$<L1%K8?B#!0"&75-H4R,1A`-^4M`RIP)PR`=#`D
MG#$XJ`(5TQB<:-9#4H3O9]FP"UE"R[1D(FTR[IQ+V#5BLM'ZN?ZWU;)5BN-W
M%:B(O8CX]>M*LJDC799`S=A$G;2/EJRATP6-6"]3^1I:;BB+X+I%MZ.VD-LW
M`-KGHFST/O$/N.0D!Z.(ZE38ZPMZ0'8O$-I"B@8XM&H7$%69\@G:48A.5!`V
M`*V''K3P#!6)Z/\`FAS52&[U/>5<-926?9ZT+>Y6<?RMBU:YFD-=O8/2C^CP
M)'%1A8F]2YZW+.Y9M[BS*!4H:.\C6!TNH<IW'[O$%XG<D#3]T$4Q-)I?B-M(
M;9GI:,U#MT1+>(DNN1&^/;3'7X5&6527N/;++:4E+9$XM-_=1FS/X*)Q*,<N
M",HV`*.!Q&578C`XGHVR;-+UJ1-E\/TP1Y?``B/AE&0>``,01']SI#Z(9E_+
M$Y\FA/&+AZIGU\ZS]FI721WQ-<HO=S/ZC,=X[H.[*L8F?VKMN'WE=+19JYL=
MDXGM:1%?K%YK*.I>1.C*#K;5>J=6;@D7BP/&BI&<E,JDC9%JJ]63;BX<60/F
M#\RO>+Z#1Y=$I(=*>T<3NI[556W<8UXHO>?<PY!H%+;%M<+)1,<\=:T;R-_G
MIW7`ZK97E&)W<+R&L<75JR2S0R4A4)6)=-E5UV3V'DU6:"J1*T^]AN8>29HB
M,]X>HPWT.+2F<I$-EJ;]H*B%RU976')#Y8E*9N4>0VM*$OL38B'W$+*Q02G[
M=DD9>N!`ZW%1*<F;!>P@#%.*"".`I5@*_3AU3J^CSNY+6=DYAXF:A";?K\Y6
MF3>[5Z6L=EM6S:'/6W:E@JLF,Q2536-Y!-F\5*,),[]6`19-')#%:ID;?&^^
M^7)?)YTK:7TOO0)!MKS3ZE17FV&(\&6S&M[,AOBI0XA+KBY$=Y@,IF*D/-*!
M=472VM(%V?<&`4,X(ZX$DJ22L@XIVX``@XY<`>#9F.($=6J]S,Y<O`JB3:P/
MIG:]AG[&6(V7'25=9*;8*V91L["SE]L>OJ^.Q(:*9R\8Z@(F.5ML=&%DG)"*
MIB4^%OLE76Y[C-%L>&%=M;8M[++'&05H>4+=F4MIUJ(Q,>\"=<<C/MS)#R;<
M\^8K14A0*?JW)0BYR#EZ\E9)P4".OX""HI&8`$%(&<#,:]G!69F@Y)\I:VW?
M2GQ'-9;W;(>`>O93XN04A9=SW66.XUV>1GY96U1%F9R82<RY490PPDTY/&I(
M*)%_>/#E"08)W6:0NCK;/V_X+$CN/)2WQ[J&+9%;`FA#+8CN,*;XB*V'97A4
M5"92W$K/Y3ZM2E>&R$`GBLRB!MP&*U'K<2<0<<5'!.51RX?0XO,2/BY?COLR
M)F[!/U.%E*O88Z7M540?NK/6HQ[7IAL^GZZTBV<A).YJ(;*F7;)-VZRRJJ92
M$(8P@`N2^3?SPC[I77JQJT^\'V?_`)='X:HS[N!&B(]X[<X31-KVK-ZGB.)4
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MM`TBQ0L5$-YE6"K+9A'`UG&SH$O\8221Q^5`]>+[:M(YY:I##C!9C,EV"XA:
M1#MA$IE^/$BO2F77'%QDRYRWGN,B.LY_R2UK_;*&VEO];@0<2<%##KE]:05*
M"2`,V5(`P4#T=F9[L)[.MT=Y4]T[EQK-2F:RA7(.5>2"T?4%'LSL<)&KT%20
MLUF<676+!NS:&B;$J$:XEE%'*1V+<K,@#@\K-BWNN:?O;2&?M6:P^7W6TH"Y
M(2U"R/S`AAA+$]:E."1"3QZ(Z4M+3(<+ZC7U8BL!ULDY$D8`]#:K$)VG%/!@
MK9CMV#"G!Y822<-J2;EUK!5ZFC%,)V15M-W:`_I=;39UV6<&GK<P&4@P>UF)
M!/Q[Y$7K3QC8AR^.2Z>N5[7R2N<%JOW,7ZR@5SF\?S4QXP.T752/`&I[1)WA
MEXV?LVWT2Q?&?CULK5]39:MH_P`0]>K0FDMN:V9N[Y`Q9=G[/2.[NDY=G+-X
M"CAF[;JP0(N$NN0.K([\W_F92?>FT]277(:!]H1W!SZM-[Q0V9&;`Y;;8E&_
M"1WQTL-FUJ:=N^S+E`NH/:5KGXJQUF.;1D^P2KJ$*C5IZ-D2+Q\D235=3K^&
MD"&:@C%(O7=?_?%I25IO<S9HCNOD:GML2Z\5%@QGDNP([+C#ZU.,K+Q=,AE:
M"AY@L);B,R8R@\5S%L,JI;WTO7%Q0BEE:D8J4H8+)!`P.S#`@[#CBHI.S!()
MDF%FM/3O/JW-34Z37W)2*RWK*%TG]C0$8FPA)F@U>VO(^BZL:3+:<LE<?,Y)
MN5W,.V#D4)-)RDDJFDCT9RL^!K>W\G*$Z)S2=#W"67S%9A/.%;K4R1'2N7<%
M-*:8?0I"RW&;=1F84TM:%+7C7LE49=W4,I\)0G#,5`;"D'K48XD;=I(.W'Z*
M>J>]XIKT3(^9K9P6XOXVZ.]ZK3Y?'K*N?FV1W!SM37$[S'CZJ]YGV^BH[8LI
M+NGOK3NZ7^JI60TI&44E,:WG0SM&:@K>[OZNP9ZV/+15VS<M*:5\;`W*"SA;
MQ,6X0>*WK)_92.DYU%4V='0^]71[RXCM5-]T/ZY;]NR]/>;UHNMXRSU!IH&^
M[4LDQ7-4;17D:V;4^PZVW6A]<6QW:;F5,R;EM+K)+^)D&;9LX2,Y-3!W62M8
M.:8<NEELK,YC3UXN+C$E5XB6]AI^X0LC_P!HPGR')L=,>*5`H<C)4C/&?==:
M6&@X><F.'@AQPI+K:`1Q:EDA"L1D4-B3BKH@]`@`[:CKO:GM#C:MJ=OM*<BX
M'75ZE;50[9*3<;K6S-FL6X@3S!H-C4;W9*.\D2W*08-2O7C&5%:.&,:J%;B8
M?&DW'(S8U%*N]Y=TA'>D:GM[,>7';:7.84IP/!KC5R8C$M*/!D+<+3;L?*]Q
M[R2Z`,BO/4):2VV)!`962DDA)V88X8**<<VS$@[,!LJWEJ4A&S<J8`"94$2I
M@!>J`$!,H%`"](]4`*'J?L8RIXJ+JBKLBHX]/&NB'!7(AWPT957_`"LLM+E-
MLV6EVO=.NVM<J%,3D])Q5!N!8"/WG!6I6XW?8=_K\OJE2)J-^?+-Q/$R)["N
M"!(=-V^9KMT[MO)`YJ.[;W(L_D35-QO_`)\F>,N=L:L[W0AKVV\1>"]+N>Z9
M344FXT+7K57T$]([=V_'3;UGH^(B6LPS;:PGJF:(OM"D9A&4KX/'RX*/DN@&
M+GH^DK\;UGM36CEJ;W]06.PLWJ(-4!AXFZ6ZVK:2N4AQ32C/9D<9$EH;5'F<
M6T@I:5MD-?PE4@AES3D!IUTMJXG$=8M8/6D8]:1@I).*<3P]`UC.]`K-OF+-
MW>T;)L:EM"QQ%ZMLG;2KTC<4&Q>M2PM-K;VZV2/UNSODK$:CB9ZRL5;#7I23
M3:RBRS)!51PBFNF"-<DJZV2#:MY<J(Y-M-K>M\=$;"5;75I5QLE],5A<Y41M
MRXN,L.IAS&&%.1TI?<0EI:FU'87U#BEPTJ"7%A9)ZU8Z"1F.7,0@$C,DG`[!
MM&-3;SXL\/7=FP#60K^X&7QGU).5N5MVKZY*6=K8JRX4MLN[I\PB346T&=?D
MHJ;A(\D?*QZD5.LS6)0S9P'0`AP/)SM,VYZ4DO1I-D<\$O33[<:>^VPIE\",
MVF2V?M&`IY#C3KQ>CO)D1'!"2'6ST<J[N)0^`0X,S9!*03B-IP/6*P((&!&"
MAFV&HV[R=]1XSCUQZ'9H1VM]<W6)"@6^-G([7]E:TR"E=72<@YIS.H;*L%%D
M9@\TZ9MHUXX;RQ';`C)%8&XG`RA.IY+,?4$O>7J;^JG&W35$![PR,MI<QA4I
MUN>VA,E4F"S+0T&DJ6^TA<<MO%UQOC`DA*O&]EI,-GC\$,J&4@A)R@I/6X**
M2<=@.W$8`X5KO>L%U/5;'Q`M5AJNJ9:P39;-KB#E[]JRPVP:]!K3&JIMO<)*
M;IFIMI3H4RE.VHHNJZJX@V<H>>!89%#R0YC;3D>G65XM>MK/;)EX9ML<L376
MX=P9C\<Z&K@T8R&I5Q@->%2DJS-S4HE.1Q$R>#.<<D#XU!X.VN,XM+96<4@J
M03@,4'$E*%G*GHIQ2#FQS#"MPY.5QO,=XIQUD(>#&NOFMGH9I66;:;K2TI=I
MFNR\/+J2`;/D8A.;GJTUU_)N6#]JT<.`AW+!FZ$R)D!*;2;I[H["Y,>IXTV1
MX5'7$E\6VJYOAN*T\VZV$>`(<+3+ZIC:'F7'$(\)0\^S@X',1Z3D!5Y9*1E.
M9.)R#%1!![(C$C*2"`=A`.S"OSO-<;2?>C:PEX*`-4E&R@.Y$6FEZPPD;=,0
ML+<FMDLTEL)U#MI^WUIU69)BW(X15<(QCPW3XXJR14R_6G[H[$Y(]VA7&3X:
ME8RHS71]:(S;KL93#"(:75,QGTOH=64*2A3[8PR%M941U`5?FU(&7Z>L&)("
ML2588D8$;>@>CB*_UL-1A.]Y)%R-E+/[/G8YU*P:,M-ZH5>P.JG&D)YP[K;%
M:(C(S:+92/NC3Q[.M/4W30T:X6F3/3&!-N7\=^VI_(J,N+$,;24=U+;I;:N`
M2]<$W5E*7UAQQR`H+BJR.3FBVX'T(@B.`5.$'%IU'E4K%\C$8E&Q&0[-@"NR
MX$G$88JQZ%;[K.4K.SN\$D]MTB_:2E6Q6EVHSUBA<Z8CN`D#1(,M#L5"D**6
M`1VZG+0FX*N^E%/*9E2G!"^)72BBRYS/QYW5<2ZZ3Y-C6C+_`&V_LNYXLM*S
M%E&VEZ6[X6S+1+XXVTMNVV0U'&2,FYF5G;7,,)(CUZL*0_>#(:6T1UR>R3GP
M2,I3EPSXA8)VJR9<#ES;:T+60U*$[V?9L`M90LFT7\3:I=TXE[!JQ66C]7/]
M<:MDJO76[BM0\5L1^>O6E6521KLL@9NPB3MI'RU90Z8+=%JP7F?R-+3<6XO@
MND6WH[:0VS<`VN>B;/0^\0^XY"0'HXCJ5-CK"WI`=B\0VD**/)CBT:A<059G
MR"=I1CERH(&P!6PX]:>`8*Q/1TKC5QCV^MS\DMR[PU+>`NC8NZ;#L;<*Z5%H
M&M23Z-UKD!Q_1T18M,SU<N&T*;<-)M_)++!["8S#ELK",SNU47"22;G?;U-[
M&B6^3BUH;0%YM_V$HVMF%;09<R<63%?>O!NS-S9?C0),:Z*XR#*LSL9"TRGT
MLH6VM:FO*#!DF[F3*;7QO7E2^M2G',`WQ9005)*-BDN`D91C@>%AM'*+0_>#
M[Q9-I*%ND7;HO8<^>Q%B[$[LM+D8)73D6I0']SG=>U^*=P1/*E%&<7#SLV6.
M,BH58B(=0"IGO`2B=R:]/ONM/P)<)Z$R&>,92Q*0\+FX)B(K4QYQ+IR@.R),
M2*7@I)0I?7$YD7%-X=`(4E04<<#BDC(,N8I`P^@!2L.CA6#T!!R]J7M^_P"P
MZKV'1Y;;U(CK6FXO^N])1QJ\E?K34[A(4*O[,H\TMM6QP#.6557:-YN,:*F1
M#KK]19))$K]N1-/A6GE@:'W;6R\6RX0[+-ND<B'-NJ^.,2RW2,B6]!E-"`P\
MIL)0XN(^X`K8UF0M:SR^HTJ<L$F8MM:%.)0>N2C9F<0<H4DYB,>#,!]W;LJE
M?AJ%CF^\TTGL2SP4144;CM6[,*46)UCQOI<ILJN0^I=B3`W2[67C]M*08V)\
MW9V=DXC&;FNOUVS*7\J<3)%78-UIJN6US0-Y7NA/[04G6G//\/QA/5JTR8FV
M=X[X.DSK6%9HGUZQ=:W?6.4J57EA@GJ6O-I/5:6K-4>A7B0862](/F4]"R%B
MNM4<,8A!RR]QG`NP!:M)!@/Z?Y$L^W.OK4+FXF<AAN3(;XU)FP$B4&I4R(A;
M$0H=B2F85KN"'9*FG_#FPR2VL2E!W4:5@#K!EQ(!PZU?6XI2K:K8I)4M!`Q&
M4X[<5S3=.6_>G<-%9N?CJX06=#@Z@2O72XQT[9(6>VW&2-B@[RP)Q_OM;K\:
M[L]59#'D:6RNK6CQ!V#PWB$05;Y>XAEIWDAZY1`C.RE9Y;LDO18RVF'6;<XA
MEV(LWB(^\M+$AWCBY;YJ8&9,A@<8LH=^;F2+_&S$)V)`P4H$@K!(5^34`,0,
M,%IS<!V#9XM_Z$GZCWBL_O6[:CJNY]*;-3@64M4K9Q<V7N51\T=T73M&E'=<
MNFK*9O%HUL%$)J]XXB(6SP569N%[`_%.3.FL91+WW;[Q;=>N3'&W>V"]3+%K
MVTEY3<B/?X-L"%)EW*6VEZ+<)5J4IF69[:),J!+GN(1#CA41*D!*_P`F1%MW
MDRW6TNQ7,,06E+_@H2<%(2O:G*<$J2D=<>NVU>W&MV3..CVD:R2C8YJR:MV$
M<@T(P0CV2"":35DBQ3(DFR2:H%*F5(I2@F!>J```=&1YRG7WY3CTIPNREN*4
MM945E:B25+*R25%1Q)422HG'';76)`"0$C!.'!7MSPK]HPHJCGOO&VP76NM$
MIZX>W^!G27"Y.#VRE[FW+K9A7&:$#&'7<6FDZEJ\HCMF/6)TBFREI:`08F3,
MHDY,90X%D`Y`CNFV=3ZA5JANVR+<8,9(CRK9;)RWE%YS`1Y5QD-FW+'\)V/'
MF+="@E;0"4D\KJD/%EKB"L+S*VI6M.&P<*4`Y^D2G#Z:\FOX%[=^[(U$Q?[5
MUE'4>0V?97E^G+,RO>T6FUV*F]K.XB:Q2976][<7B8?7^9,D1)W%2<I*.4E0
M%%583'$_OJ2XL6#E87J1&L]V=U`W:6$PVF%Q("K>L6E@./RFYT1,1I$-K,5-
MR&&([:D_E$(P2$_C*"[8FP7&PT7#F)S*S_E#@$E*LQS'H@DGH8TS^XZQ`S/`
MO3\'9=SZVMT.R8Z55^.%BIT[9:/N_P!RR1YXVOQM<IJ[S8B1;49)-=H:$57F
MT0;!US*$\J$R2Z'NUQ@\HJ]W"U6*ZPIKCET'@S,EIB7:N,SYWEOR0F$?!\2A
MP2DHBJS]:$JXD#/DMH5:6T+=0I("-I22E>'``$]=MZ&7KMG3KS;QU7>;]Q2X
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MA*@`TEUQ+8&0.+`S';QT*:CH;7M6E"0=N.T``[<!CT\!C]%2E^#,Z[^RU>'Z
M^N?/OG]*<H-Z;#UM1ZQ>+;&\5YJI2S"]Z^KG'&H[];7782<U-2#D)!C5-V:M
MY4`#*FM$U3-J8V=IE;HJK'.!P,!'Z<D[7NZ7=[<-6W^[6^$[O?8U"^N),?O<
MFT*BPRL(3D7(M<_3_725%(7<UMDK4A"4Y2,W+WV+/EH8:;6H0"T,R0V',ROO
M+0[V/00#]-67]WS0HC5W#G1^OH(8P8FIP,Y$LBP^M]U:A8))HW*R',W)KCD5
M:;INBK+MU5#)KHSLFZ757*=9(2-E$$R,KY2FHYNKM^&H-2W'C?#)DAIQ7&3K
M7<EDF,P,3-LL>+:Y`4`"A41AM"4%*%A3J7%*Z*SLI8MK3*,,J01L2M'\(_P7
M"I8_QB?IX,*<K$-K9T844845IVP#%)3YLYC"0I46YC'*'28A2O6PB8H=4W2)
M0#I`.@?H8]CY<O/<W=^FU>22:YS5WLW+[G]85R*\-V]?J?+JCT>4U[9J!LU?
ME=J^==)0?).)V!KZ>K,-=MQUU[*3&IR<A-ARL*G$6591A7U2P#5**4-(-E19
MK&%$;5_*BYM&\+W)O7J^12'V7SS$\9;[<58?PB3K5/[S/DA69JO1T;>KI:-R
M3]>L>E^0E?=5"[1L!NWD%)69UNK13';[%PJ\J<9L"`BVZB5*=&BKH6;4=.DG
M+I916M!O]5=;WR4=+76!)==T]`B6QEYBYV9Y,F*MZUV=#";7=EVU8"9#D.9(
M6E5T;$BUF`EIE;3*$(6.UY&[X^A20'5*604.#!0"W"<[>?H!20.L."\V)Q)J
M62+4J&[XM[8W^T8.'E).+7H2U4E$=;1$A*61UI'7\C6JRP9-II+94F#Z.DCO
M4K!(,@CG#E-.%:**K$ZB?&E%^G<B!NUQK1(?B-/"8)#9G.(;83=9B'WUJ4T8
M+>1:`TJ&R[QR$%4]Y*$*S*R,6DZD*RX`HC+@<HQ.1)`X<QV'',1ACUHVUO&O
MYRW0G>M;1KSVIQZ]5N5<E9./N<VI%RMSCE8;7.JT/<*'DDZX1Y`:]7<)'6:1
MBDNJHH^<.5TVW5%SY/S^I+?99_([M%S8FN)O$&4VVN*T'&XJP[-N!XUQ!?*7
MI@20EQ\1DA+2&FU.X\5QOJRMQ.H'$%(XM220HX%0P2C8#AL3]`QX23APX'&Z
MKUB+[P_D(C2X[6\/%5^8V@\FE8F/U?"WR5LU]A=#S,O#OJFG:#;'80,`_CU9
M$EB1BBH3[J<6(Y.0B#8[@WI7:[3.3-II=]=NC\R2Q`2T'%SW8C;$1V[M-NHD
M%CP);SR%I9,)4@KAMQ4%I*E..ALA-MIO+P:"`D%6.&4*)4&R1ACFP'#FPZXJ
M./`,5Z[O&IK-N\0Y)6.=UQ4*#;OBKL!:QLJ%58:$;1]@N%JU1(SD7<)R$UC(
MNI9^NC`,7;"+D]D3!H111]Y&Q\F<@9HI?*8O*'>3-I:UV^Z3;C9?#(885+D.
MNJ6S&CW!#3D9IV>A+:`7G6WI#%DC"4$Q^/D<:U@]AV9LB\OK6A*',JL<H`VD
MH)!(2<>`$`N'+MP&!V,WHS;6TK!SIN-!5V_L6<UDS'8$Y'U*[*:K,U-%^YE8
M9Q=?CX2K4]A:6*=?LZ<E),)I><=%>Q#UNT79%63%<B4;P=&:1MO)[@ZC19+9
M'U6OP-I<B*+AFXSC'U./+=D25QUEY@L,/1416RU):<>;?*%<6K.B2)"[JIGC
M%E@9C@K)P8#`8`8[#B0K,<00",=M#G;6U/\`B&0FN(?<&Q":VD[$=P^I-A-J
MPM822A*??V]CK4)#LZBK>IF&FI]&-=L90TXT6C5XIT@JV7(I^^#6C-(?\-$C
M5$ZR6PZI:BX(E,_:''DNR898?==5)$1IUIDOMNQQ$<2^B0TXAUM2>M#(D?;(
M82XOB"KL3DPV!6(`PS$$X$',,,",#6C7)Y;XCOD]:,VM8+)5*VZW\:ZD)&2U
MU<UZ^]@=:["(M;*S!.-1R^PM,LY4CE&'>OT;C#H6%1$$3-'1$RD'H+&Q9)O(
M<NK[TLM7F%=,$H0B;%#R7IT/".^Z+BW"N:F\JI+32K9)5""LX>94HFO)TN)U
M*@!.+:D=$I5A@E6T#(5(QX"<XS<&!K5(<ZH][L@A"W:LWJN'N=J=V-`;UK6>
MNU0OD?QGG&J,2]@Z\VB+C5X"%KLW[E,XETD[3."!GSI4[H2*!N)R4?\`!8IR
M=`EV^Z"#'2P?!)S,63$7?6E%Q#KRG(TAYUYKPAR0VILC.([*$L@I/FGVBP2I
M*T9CCUR2H*XH[,!@H``X`''Z3MKXI!E/^+=*-H:[UO857^->PWDPM\>];3]W
MJNP&O'VNQTC$S,566\/;*Y#P$(NW@V,*\0<)`1D=XNH9YUE3?5_"/^#%EV=;
MY5LN_@<)+8\$G,Q9$-5X>6AQIQ\NQWG7G0N4[*;6A6+J6&TAC!`&O:(A*TK;
MS*QZY)4%<6`00,"`!UH2<>#$[:EFJR[MGWJUKKDGIPJC&3@+//U3;C^HR,7)
M-%4M6:H86%E&RD5;0K\]7^N@FW)*2,*,@@Y?+,DG($5,53C+O"9?Y'T.Z1+X
M1(:DL,R+<B2AQ"@;A<%LJ6VY'XYE[`J68[,KB5H:0^MHJ0"G(;41?U(4UL()
M"\"#V",<"#@1]TIQQ)&-?[JZ4>-.]$VC6I33GB&SJM7:Q5/;4C3Y"%EQ;*06
MHFD[&M'L7;5*U,U]61`P-Y5["IR9C.3(%<]18Y535L-A[DD6BZQ+YF=1+BLR
M+<B2AUO,'KDII:DN1P^T\$89X[4HL`(#A:Q0DH&%$7YQ"FMF51"R,#P(Q&PX
M$8]$IQVX8[:LTV@(!19X1`1`",1$`Z.D0]TV?2`=("'2/[H9TORQ.?)H3QBX
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MY)2<PP&5><`8@I"LXXW-A_AY`-@3P5OO&9['63FKRBV(^3BF*]+/M'7#<D56
M*5%K^Y,3=Z8YF)"<G:M6*S:KB]=.H-%1()M.07C_`-]3;.ER+'7<<YO68E6O
M</I'3,<O.-SQ`FJ+C\IP<8Y%E):0TU(??CQDI2ZH*\%+*'NL4ZRVI"6VO:"4
MKNC[QP!3F3L"1L"DXXD`$\'\+'#H$XXG?.-%5T2UWU*;8IC?<*=ZY.:;D-\Q
MKC84M`2-?<ZWN5V@Y9U78IC#.WKR$"KS$RQD&C!^8Y6J%F6(W544%\@TYW>K
M>-X;V[IG1U]59#I[2=\1:%IAMO(>3.C176TO.+=2E+OA#33K+CS(!<7!;4ZA
M*?!W'O6"W$$LR&N,XU]KC!F((RJ4#@,.#`D$`\&8X=$"'>[\JU:@>0?)=O2(
M_6T'3ZO/[*ID6RJ++5L99Y-9OR"V1*/%;15("U2.P->MZB\=*PK%N\C6;2?:
M-DI102KJ)HE[?E)7>ZW'=KI1R_NW61>Y<:#*<5)5/<8;"K/!;2&)#T=$.89*
M4IE.K;?<<AN.+B)!;2I9QK.VA$Q\-!`;25)&&0$_E%':`2I.'8C$`*`S<.RF
MI[PI5XAPUY#+1\&_L\@EJ?89V-:BWCV.D[`\"CV+R6&CW\<W>/V;R27ZJ*:B
M**RA#G`034_P#.%^3?SPC[I77JQJU6\'V?\`Y='X:HJ[H:L2>O>\'NNN;%6M
MH05R@N-4[.WY[LOXB+A,WBV7NHO)UQ3K%K&E4>F[*J@^1I.&MI4;*3KU)V1A
M)`U6C"L6TNGS<.91=O3]H[^NN"T'[1M]R<Z@JS3AW;JS%W#F1R*LWD,:PA`N
M:<X2NU6H10,:=J796YU7:[@E%K51=W>;5*R=./+9:.&7-UP0%13Z8ZL`6^^R
MW679-#[L;5QCLB1X*6B](DN9Y-Q@VP)`,M^2F*T,S:.*CO>###C`E.Q*%3MK
MB$N29J\`!FQP`'6H4O\`B@9CP[2,>A4X<5]2Z3U_?MS5ZLQ6UC6K9E!UKLV[
M-=NS=<M+6:I.QY#92M;C6RT`]DFJPU5RE*UUP@^.JJ5M'(BFJ[35.\<\!O?U
MGKW4FG+%<[L]9_L>TW*=`BJMS3\=34J$B"'UJ#R4*'A"3'FH6T$I*WEA2&5H
M2PUE0(\5EYU#8<XQQ"5*SD'%*LV`V8\&U.WH`</"8/[J:%A(Z$V^XJB&OV50
M;C1JG6F]*;ZSCY&3C:G+;.3;6FXURDVNPV+7DY+,Y1%G\5Y9!FE#DC>LWZZ[
ME\5'O^6'/GRI]D;O"KDY>E>%R'U2E3EH;7(;@%4>,_*CLLS6FU-J<\/CK=5)
M+^#N5MJ.5XNGTI2EPMY`WUH&7+B0"K:H))*2<<,IPPPV;2<'$YF5F"NFBKG3
MK16YNYUFUURV5RPT^LNDV-DM4)-5*;CI2N5]ZM*0B3.;FF3@[=JJ9ZT*FNH4
MPK)`'7*\SY)?."U7[F+]96^N>WC^:F/&!VBZHZ[J.=IO_$1VK0]6Q6SJ[JR@
M\9;(LUKFW-R1VX;=";3NVY:]:MOE=.H+;NW8.LA*2;E@^6:@X8O%GCE=5PD?
MI3,$C_S?L3R,Y('^M-IZDJN0T#[0CN#GU:L3X7[8VE=>3&UZG8MM;$NE&KM9
MMTI#06PU]6'?';3%QIZ])6+#4.EP<I69&EUY5XP=*N9:70G2R"3HI&8I`D,!
M6_71ND;#NIL]YMEEMD#4$J7&;==A"X!`4U&DB4.-ERG6WT2G@VZVE$>,N(65
MLE3X7G"I6R1(=G.-K<6II*20%9.B1EV)2""D8@XDYL<=E>RB;(C&G>%V;4K[
M4ND(BR1CRQ%:;&I]6N[V]%J\KKF-NE7A;-89"*AH&&L5H2<23I55LI(1YF\:
MJTZQ7)TSG\-0Z6EO<FB)K./>;^]:W4,YH4F1%3$X]N:N+(=890XZ\ZS'*6&T
MI6&7@M]#V!:2I*?UI](O*HY;:"P3UP"LV!2%`$D``G:=F(P&'#5GD][Q37HF
M1\S6Q$]Q?QMT=[U6GR^/6QN?FV1W!SM37&5S$)/NN9]LG7LS,,=7P^V=,TED
MO6]A[]94&2W'*&US/I4_9BDAJJP::<["+`'(O$TV)G(-F<JB:KY\X?+ILBWK
M)_92.DYU%4V='0^]5Y/><60?RG\9ZM!,6-DD7\Y9:]?8-KL&JUB5)2;G(U%]
M!0TXSL,BT>UZHW.]41AY39HLONM&)Q2B+51,71^O3IY,=K'V-K2[W%QR+&;"
M'HCJH<A]OPJ*)2'76E,H4EZ3%B2WLD&0?!WS(2X\A093@X"\K_*1VT`*4<0H
M9@#E5EP!Q.P*4D8J&T88#AK<^\Z:Q$NQT/6;%#1[BN6>T7>*F[`NR<)2$,U2
MK#>5;1K"T)(R*5?3L4E'()K)F9G,^!`I"+H&)U5N3Y)STV%(U%=;8^XFZ1(D
M5QID*24.J+Y;4M;!*"\64+64J#@#6<J4VX%8M^]]"5!E"P,BE*!/T;,<,=N&
M)'T;?I'1M);$(FW032(1-,B*1$TTR@1,A"D*4A"$*`%*0I0Z`````#&C.J4I
MU2EDE1422=I)QX3]VM\."N3WO;BSSSEB55K-3$/KVETF,LNX96F[&W]5'=>B
MYF\6N%IA]MR5(U3LK5.MM73LPV73!\Z32FYDZ"Q%'4;'M3N37;>1_P`U'=M[
MD6?R)JFXW_SY,\9<[8TY7*BS"PX8<`8"'9-9>QO-44!A8XAI=JA6[&GK6\Z)
M"AV=J6!MTDUCRUVVFDPC'T\@!W]>1,=1HHBHJ*Z<#NL+3X1RW]\EQGK6Q;&[
M\XMEQ422\SX=$EL2V%<;&0I?'1N+X]J&LAF8H)0\EQ"`VM3H[F&F[>A(Q66A
MB,P!RJ24G8>@<<"KA3T,.&ME[V&N66'M?%O8M;JMGN\O$NI=2!KK-=>::1]G
MKKFDNF%,U_*QG'/==HKUMV='O78NY%23J4:Z8UX#.I`#II)';WR.+I:IUFU=
MIBZS(D"$\AL//*`:4MAY,I*Y4QMR]6MAZ/`6EL-LABXOMNS"&HQ2I:T[74"%
MI<CO(2I:AC@.':,O6I(;605;<3B@$)VFI?YP<A-C,M;Z'V)J^\[9T[*WVDIV
MB5J;1;5T$S:,[O2G;JOH6J2OM+O#UC<*5:735T=BW9`C)-(]ZU,JB<Q3#Q.X
M'=II=_5&HM,ZMM]FOD.W3RPW(4)[JE*BRDI>,=$.5$2N-*CI<;#JW2IAQYAX
M(6D$#)NLQX,,O,+<:4M.)'6CLD[,2I*MJ3@<,-H!&RLOWBR;:7UCQR@;>V83
MD=;)N5B;5<U(E6.?LBFUA*2QG$7.-?=="G_&>;C4"G(+9QX[Z1))PBH4AE,+
MDQ*=A:LU1<;(MR/*AQVW(\4.!:%_Y^VWE<:5Q9D\0TM9!SHR]<M;:TE03]7K
M!3#*',"E1(*L,/X).P[<,2/H^^*C+O77%IK;OA=-TFJH6=&/O,C`/JTZ>:ZE
MH"7C9>6U0,9!AJ*]Z@VT;8$TC,Q+20C7<<A#KUP8Q1T:0:D/XTG6<CINT71G
M7<"_3%1%NV]#R'TIFMO-K;;N'&._:42Y6[P-HM..,OMOJDHF\>AD1GE)R*\-
M0%Q!BJ:3F`61AUI!!*,!D4A>8X@$$89<,<16&YAG4#O&>/B4%=JQ83.K-QF;
M7^BRUZUJ:TU2+2W"ZEJE\6*8=M%[`@8DDO$GE73Q-P]6EUGP-C`#),$LSMR*
M4'DP:E7<8$N,$1+ZJ'+;B3O!Y#AMJ6Y''R@IR&\X6W!';;*&DQDM%T$OJSU\
MW+STSD4D]<UF25)Q`SXC!.Q0&(Q)VXXX<%?GMXZI>]6U>A!W>MW*/7MVJQOE
M9>WW6SZZ4F=C:-NIU3HUA6&#6&OE2K$9$SSYV*)S/O=1>0*+DYTS-@1^M%)0
M>1]=W+A;Y4&2F%</!'TQ)R(LII<NUIDK6^M3L20^XXRTWF`:XA+)#20H.E9)
M\_MA"TJ3F1F&9.9)"5Y1AL4``2>CCCMZ&$M2$J\CN]>K\)(:?]T8FPQLM*5W
M;,C4I".=04W'Z#0:V!.!GXBW-HNR0J\8U9QZCR7AG*[-XZ<,FZQ"]7HXV-#8
ME<CJ3/C7OBID9UMMZW(D(6EYI=W*F2\RY&4XPZ'%./!J-)0AQIMM]UM1QQR"
MHIU`$%O%*@2%D$8'B]N!!P(PP&)2<"2`:ES7&][#6^6$YQ>'7.I:A18Z[W1"
MNV:KS-GEIR7?3.OVF\7%??0[RNPX0=UDPMSB>DG0'=P`-51:HO%9$QDB<7JC
M=Y;+IN;C[VQ=+S-U"[`BEYB0TPVTVAJ8JU)>0ZEYSC8K?@R(C#>#<SC$\<MA
M$8!:LAB6M%P,#(VEH+5@022<4Y\,,!@HXYB=J<-@.:HCJLN[9]ZM:ZY)Z<*H
MRDX&T3]4VX_J,C%R315+5FJ&%B91LI$VT*].P'703;DE)&%&00<OEF23D"*F
M*IV=XA,O\CZ'=(E\(D-26&9%N1)0XA0-PN"V5+;<C\<R]@5+,=F5Q*T--OK:
M*D`IQVU$7]2%-;""0O`@]@C'`@X$?=*<<21C4><=&EFHG>H;HUK4;0U+I).G
MW*7+0XJ\[[>P\!;W*6M+!(`\A]A;,DM92UN=/K:N\73K=>!*':N2IG=H"<&Z
MW3[SGK5J'DA6+55ZB+.O3.C-^%N1+0EQZ,DSF4978<%$YN,E$=+:%39F:2X@
MJ2RX$\:CQA!;5_=8;5_FN51RA3F`/6G@4HI)VX]:G8#PC@,N<<;'4H;O#N4F
MK*_H'7.O'#*#:3Y;35F]'CY1TT=_%^6EK&N$)`1\B\EMJS]E,ZF&X/'*S;W*
M8*/2D55+T\7O0M=YG<F?2.K[EJ2Z7-MR0IGP>0J6MM*D\<VVP.->6A+=O98#
M<99;;2OPB0A@J0@X9$);:;S(CH90@@8XC+CT"3L&.*R<3M.&`QK#ZFV_M"T[
MQY#4'95P;SLY&2-Y=1-7@;S[JURAQ%3V'K6'AH5]KU;6E1GJP"C2R$"*GI1V
M'QI11>.6B2J1?&E?GR$-%:4M'*%W7:CTE!5'A.L/)7(>B<6]+=D6"\N..IF"
M=(9?P4P?"(D=O_,%*8:>6A9R'E]3R7W+3-9?5BH$8`*Q"0'6P!ER@CAV*)Z[
M:153/$?7_%6K\V.$]CT^QY6L)"XW[:4KIV9WC+5U[K'8>K(;3L_0[M8]5L88
M3S\8C$!4JBS;ISZ,:]5ARMEDD%0,JH$TO+:YH&\KW0G]H*3O3GG^'XPGJTX=
M<9M4^^;6/"V#6.SGIK1./)-:LQ,=8+W1XY?5^RF\XVNEHG(G;;FEO]<2;6.@
MO($9^@OGK*8:^11R[%)=%6NA='W5<A=*9T:[6E@1&DMA]Q;,24L3X):5%CM.
M6Y,I$UM3TOCE0[NTT[&=X^4W(6VM"MH`_K-UI;<.8XX`%21E5CF)"\N4X)PS
M-D@C!)&(J9N7ME;V7O*N(M-"2AIV!ICNDRKV%00@+"XKFRS7@CUH>7:LM`;I
ML5:ET*5.M7C920E*6U*W>)N&LLT4$ZI^%W*6IRU<E?6M\+3\>XST2FTNDO,I
M?@^"%*@VI=XM;+[9E-.-+2S'N;A6TIMV&\D)0G)N*PN]QFL04)RG#8<%9NC^
M360<I!&)0,#B%"L#N_D;MBF]Y`3CI`WJZ0S;:6S.)]R@)FRQ>[XVI5?7]0(F
MSVEJV@UV)U1<=7[8A-K,95^21F6\W!+04W(`,NN1&&CS9LM`;K]&WSDN'>=<
M;?`?=M%JU#&>:8<M2Y$B9))5;Y\QYRX1I]N=MZVV2S&7%EIEQ62(3:ESI(KX
ME39#5Z\"0M0#BVE`D+`"1V:$@(4E87B<59DY5'KC@D5>;D?5=71A11A153/>
MMS>VX>GZE)K=K;XN$DI+8C6Z;'K>Z=EZGA]<-T*BE(-;#>([66X-,REMJL/#
M,Y6:7*K(+=4(3R!`K=Q*)O&SRN1W`T9.O=Y5JA<)Z>TU"5%A/VN#<79JC)*%
M,Q5SK;<VX\AQU4>*@I93CX5X0X7&HBV'>>U`J0EMOB,P22K,H+4@)V<*@E:"
M0!BKA_@X#`JQ$`:ECZV7NXN.%,NT]-\9'T7=;_=OR8Z4I3O:TY%EUIM&TR+B
MG4-_&%M-MKY*O.2$:BRGHV5+)E>*MFY7ZZKOI74C6<FZ'E0ZHOMACQ]61WH$
M.+X?=)2;>TYX=`CH$F6ASP>.]X0TA]3L1^.6"VEUTQVT,X-X<<(^Q6&G26"%
M*5E0G.1E43E3AB1@<,%`XXX#$X[6-W/%Z=5XJ\9J?#;RV)6:9!P=7N]->Z\U
M"2R;+OL#2HV"KK-:.AZG56-@UK8FEFN\0@HYB2Q$@G(OB1YQ$7*J1TOT++UN
MC?!JN]SM/VR7?9$B1%DIFW(L08;TI;KR@MR1(6S.94Q%DK")!DLJ9:,E(`:0
ML9LE,;[/8;2ZM+0`4G*C%2@D`;`!BDXJ&T8'$X=&M&YRMJNSX"\:H?6LI%V.
MI%N&@$Z9:;!2D_<T:96Z=+6)W;9XE7H5@>:MB6M#K[QU,2D76EUHF.!TEY.V
M2.JNWZ#D_.W=_E&ZJG:J9>BWDPKP94=F4<_A3\EME,=DOS&4SW%2WFVXT=^<
MA,A[B5\:ZM*&W/*ZAL6AA+!"F\S>4E.S*$DXG!)RC*"20G8,=@X195QPF4K'
MQXT-8&\@WET)W3&KIE&5:,D(UK)I2='@WJ<BVCFJ[ILP;O2+@J1%-50B13`4
MIC``"+5]Z,%=KWF:BMKC2F7(]]GM%M2BM39;E.I*%+4$J6I)&4J4E)41B0"<
M*W<)6>&RL'$%I)QX,<4C;A4]?@S-Q_9:OC]?5+??B/7-=X]ZWO["@[(L[_7V
M^F%A0N>L[KOJCS.IT5:1?HB2LZTEQN<LME*?&:*D5ZTTZ[AK!HOYM%626!`@
M)*NZY'+#5SY0&K=.2+C:XD>Y09S)BSHMHEM7`BY1W$,!%[2N".(<0B<Y@AR4
MIF*XB*@N*SHT&H"46IAX(6HH4DYDJ<24=803BWUVT'*.!.*AF.%.QP1E%YKB
MKJ^3/&;1BV+I6^C6AW1;-E7;9LU2$MF7)&@W"TV+<)$MG++7JDIQ\TV;32:3
MZ.9/T6ADTP0`A6N<H:(W`WP7>(EVT/2$"'Q_V7'@Q8+4HP8QF1H[-M)@`1)1
M>BK7%*FGG65O!2BX5'=VE15;VU8.`==AG*E**<RLI)7UW7)P4`K:`0.A3<XB
MU;&C"BC"BM.V!TC3YL"G!,WB6_54,`"5,?+6W0<0$0`0*/AZ.G'L?+EY[F[O
MTVKR237.:N]FY?<_K"N.+C-8:1,<]>*41!4?948]J_)JQ1T/&V:O1T;%ZIBY
MFUVFW6.,=W5AI^G6+:23VSRCIE#FGII\,.V<+E;`X,J9QEJ_E1<VC>%[DWKU
M?(I#[+YYB>,M]N*L=X^2#9GWHS"KVO2N\*A,,]Q<GY:@H3=6F:WJ6"5MDGRP
MF+5LNIW*>TNG8KU6K=7HZ*EDH<E]>5=E/[4D'D>Q053!!.MKO*C.O\D=R[6:
M_:?FP5V.PMS"U(:?N+HCMZ>:CP9$9FZ%F(_&>7(CJDFT-3W8=@C,29#B%EQ2
MOPR!?@VXTZE0==*<00@8ETE0448J!`!PXPI"G20!P4U&I-I5G:'.E&P(DV2T
MMZUDN51GM93#Z0>:UJ+6K4FW0R^PHN&<U&-(TNA9'6D:R7DQ>F3.VL2;=-+I
M`JJJ0:STC==)<GM5M6;4NRIBQI+,YI"$SI*I$J,Z(;CJ9*RJ+DG/NH8#0(7"
M4ZI>!*$;"/(0_=<XSAS,H%)[$8)(S`8#KL4@8X\"L*P4?K/26R>\`JML_*%3
M-EV12[VG8QJ]KZG.X6;UALK6M5H];?6BS7I[-S$^ZB)]C2&$(K$**>Y?6*;R
M=)(ZSDRNPDZKU[I;DW3+-]F3K5:Q;X\+CIDE+K4^#.D2WT,,1$M-LI<97*=E
M)DI''X$<:M:4-!'P&(K]X2YG2M><JP2G`I4D)&)5B3@<H3AP?1PFI)XIVK7.
M\>55UW6PE%J/L)E5I6!EM3FK%DBI253G835CZ:D;'99B><Q-J3H$Q&#$I&:0
ML,J@_%T0QE2!]/RV^&T:GW?[GX&@Y#*;AIER8V\W<./8<;;+3MP0TAAAIE+D
M<S&G/"%!R5)2MD,J`0H];[V]QF5<%2@<CP2048$$XA&)))P.4C#8E.W&DX[O
M+:VR]L=Y+M:T[KTE>-6W^6TEL<Z#.PUO9-<9UMJG;]"OY&'1/L[4]?E):&>F
MEVT8S-'6B3A32M6EWS)DBVD4!27'E,:/TKHWDM6>T:#O]ON^FV;_``@5,OP7
MU/J,:[H0Z?`+B\VVZGBUON!^`Q*$>?"COON.Q7,^MLTA^1>W')32VWBTKA"A
MAM;Q'7(!(V@#!13BA1``4*G_`$;M9KN+O#%K<O4DZLX8(;.J+!A#"S3LYQC8
M*/CAEMH+_DUAWTC`DCZ@")&QYIS[ESCI!%(SE'H4*F^\#1SVB.30FRMS3+:<
M5`DK6[F+`SO+7Q<`>'.H0\5R<Q6(J/"(C;BUAISK3EQ9`DWGC"G*1F&SAV##
M%76C$;.#,<%$#:*_V=VLVV7WCE!8NJDE!?DQV,I36;B-!F784^X:UK<]=1DY
M-VKK47@4!$[%P_?QH3_B?<^1A7R9Q566:%_+=HYW2O)?N,AF:J1]K6L25!>;
MP-D*?MCQ;;2)V7PPA:&67_`\W',3HZDY$-O$7(#]Z0"G#BUY=G9'8L8GK>QZ
M)&;@*3T2*U'74*Y9=YF[L$K0MQ-]F67?>X&%EBI>NV^XZ_@-"UW2LW^1_=\'
MM39&N;A5X.%M4PJK$K15-MM8.Q=3;6*,Q<>YSXCC=:GGM/\`)21;8=QL:M*1
M=.6U;#C;T:-,>N[UT:^TK4[;X,V,^Z[';"9"9%SMT\.MQ7I@D-^$QU->;*2+
MX5J0[QZGEX@@J2&P@Y%A:DD`$[,$+3@5!.!RG'?*/?*_?N\5:V)*9W!'W&.O
M%IUZ[UBM/2J6MH:+K],Y)4RSVHT86JQS23:S:&EJ;**)N7"A&KRP1QVZX]80
M=<[?].W+3G)C7;%L61VR.V^/,3/#+9G.N/2K)*8C\9X0M2%-&Z7-A*FT)+C4
M.2EQO8"U[-/(>O.?%P.!93EQ.4`)<23A@,<<B#MX"I.!^G\]5;`@-B]X,%P;
M3&XHZX*6JV4:4U<ZG99/7%5B*[0-JU6SSWN6%4C64FSG)/4-6>+E<K&%"2EF
M1VZXEZY'/WK#3=QTQR:_L1UBQNV00X\MN>EILS9#CTRWR&&>,\(6IM33=RGM
M(+:1G8CR$N-XX%K\CO(>O'&`N!S,4E.)R@!*P3A@,<2A)V]$C`_3LG'!87/,
M&6MBS^1LVP-B3V_S[<JD]4M>+7713*B2=>HVIPEKJQTY7[?&4RVTFM-2M8SW
M;39NWKHCQE[I('>.\U6]!OBMR3-F0VU$TW;(UG^SI#,B:(MV5+0]+N/%Q5W-
MZ,Y*C2GW"X_X*7&VFU,/^"N)89KTA'&Y%PDJ>67,X(3F;RD)1BK("$E(&`S8
M$G$9AB:^>)RGCN5,S:5'\E9[WLQOO*;W1`3]4U\:[Z'F:M;JC3=>5NRW2.T[
M5;8T@+)1X-`K.*-+E:K/$%';%.19&,[2_=\B>+W0,6A+;433UJ5:FK6\S(F>
M"W=J1&DR9K[$5=RD1U/,2W5ER0(Q<2TM+,A49\!E?Y;]MP+F)4ZO.5@A.9L@
MA*05!`.!2-@QPQVC,-M6=[.Z/B/.=(]`=5ATB``/0'NFRZ1Z!$H#T!^Z&=%\
ML3GR:$\8N'JF?7EK/V:E=)'?$UR!=UO`4Z+[P_B1(0:US?J3E$Y"3$%7Y:U6
M&>7T9"L]552@CK/:S>9T5JZ+'8TM4J%6"M'$3)R+--*!>HF34/T/5[('S!^9
M7O%]!H\NB4D.E/:.)W4]JJK,.[VE)*9[PS;VP+U1;=1-B[]U5L79=BUHM0]Q
MZ[B=&V.L7O5]*EJ_;EMI46*9[:LFQ:P$(\9V2$FU84AXB009QC=L9!<U?#E+
M1(L'DT673>GKA"N.F-.7B%!9G"7;)KEU8?B3Y3;T80);BK<Q"?\`"FW84J*F
M41)C./RW70XV%6LZE*O+CSJ%(>>;4HIRK2$$*2D@YTC.5#*0I*LNP@)`P--#
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MI%>5G4VVX^M"5YMI`.3:D<`ZP`XXX_<V_34K\%Y/6FS=M[GWI4+*,?8[>R+'
MSFKV]8L5<!BV>6%>U$M\VXL%DG"6634>S"D:W?M&D(FHFV5Z[3PIE0X[E!Q-
M5:4T98MWMZB\;:X3F=J>7V7\ZDLB.8S266&BPV$-)?6RXY*4E2T97MBBYD6I
M3#\AV6VK!:AM3@1T<<3B3B=N&(">`[/HG3O"XAC/\-.1$))Q5JG8Z6U+L:/?
MP=%(T4NTPS=46R).(NH$?M)!D:ROTC"DR\<W<)^4&)UDE`Z2&=%\F_GA'W2N
MO5C5I=X/L_\`RZ/PU0/W-S8(?FQ>[C,$V<HQ?\>=ESK6V[`)#&:2M5F=IP6S
MO&Q[&O:DU4>,E'=@O4Q/"T.V?*_%Z=A3]9NHH=FC+U\VB.[+Y&%RBQQF?<U%
M9DI&(&*E2%@#$D`8DX8D@?37`Z$(3J)"CP!ESJ5:)P?G8QZ3EY9'I9-U)OU+
MQ992Q,F3WW3FZY)W/:LS5'$=)V[:MUKDD\2J;AL"!%*?4D&YNJDX:K`4P$@&
MW_V^6PK15K8+2(C8BL-LJ4GBVGVXMO:D)6W&M\5]"3(2LK(N5Q6L8K:>02"I
M4K4M)\)6<<QS$GHD%2R,"5J!V8?P$?=!K&\#+?6M2Z1Y1W6MU"[RLE16]NV*
MO6GK?4+$;#689YL:7UG7X4^I*?&NR3R>O8MA'O2.D'2"+TH@Q2!,3E/E\HFR
MW76>OM(V&Z3;>S%N"HT(/H5<E\2^ZF$W.>=%QDK3Q)F.//-%M;:U-'_.%Y@D
MI_+2XB/%?=0E94C%6'6;0,Q2!D`VY0`<<=O!4\]W_'ZVD'.\MC:^N3>54NUJ
M;1\W2XZJV&H1U8+3;;LR*A;,>.L=LN#EU);)8.32'E:*S5!Q&I,3`U3.!SJ)
MURD).J8S6G]+ZD@J93`AJ6U*7(9DK?\`"8\%QUC.Q'C)2B"M(9XM27%H?5('
M'+3E"<NT!@EUYE6.96U(!`&4J`.!)VJX<=F(PV5-/-5E"R6@;Y'61C7Y2NR%
M4N;&?C+8O86U5D85W3IUO*,;*YJ#1_;&\`[9*'3>'BT%I$C<QQ;D.L!"B_SY
M)?."U7[F+]90*Y;>/YJ8\8':+JA/N2&L1'\H+D%4:QE8J#C56[G,=JZ&L>T;
M<TISR!V?IO6Z,_'2^V]4ZZM"=?V33M=PLA#-3OILR46D@*IFBYE4U)'_`)OP
MQY&<@<'_`/M-IZDJN0T#[0CN#GU:L#X/;0;[FY@[%V<I5&=2>VC6-Q,C"0)F
M95HUNO+Z+M;HVS5$]:5!Y,V'_P"+&T9&.%G[I1I)PUD:"55,B+@T%N__`$DY
MH7<E;-)IF+FL1+M&Q=>S8+(;NT=/@`,Z2EIG_-UOOH2RVEQB3:G@4*4MH*9:
MGQ)N2W\H25-JV#H;6SUW6C$[0`<3@4K'T&I$T5#S>T^9<]R4./(FIPDNC;J2
MK1I>MM%=0'DM0R5WU*QE&5_"QMW#BKV1HBXF6\1[@)'&:<$<&>'*D4AN8WA3
MH&D-QL?=6G^K$R>PJ-*$MM]0N01<D1;BMM4/B"!(8441ER?#%#P5"F@PDK*A
M[1$JD7,SORR4'%.4CK,4%2,<V/`>RPR]EMQJT*>]XIKT3(^9K8B&XOXVZ.]Z
MK3Y?'K97/S;([@YVIKB/YAVZ3'O`+;1&P0<Y4%]Q:8LTE7XZK;PK\/7-A-FV
MNHAC>;(WN&QJ]I#8&UP@A*U:6*KP<RNS:`B1=(':`K)WK)_92.DYU%4V=/0^
M]5^?>-/9:Y[GU36HEGM6'?Z6>P.P3NJ;)OHUML"G[*?RU&N$17C)TNQ,FVP&
M3]C$0M<=)NDG?NK9%"'(V;IF=FIY<G1B'8M,:ANLU=G?C7YR5#"9+:%JAR8.
M27&<>QE,J5#4A<F5-;+:F_!X22DNNJ#(7Z[E3KS2$AP%H)5UIPS!76D#K3UW
M`E)QQQ5T!MK;N\METK!*Z>TS+S>JXJJ;!>SC*S.[E!MY:Q5R*>5*Z*N+*T?R
M>HMH-JM&.EX%"':R4:K%2[>7DFYTW``4H&Y?DJPEVV'>]=0H]X>O%M;:4PF,
MZ6V7W$R(H#"D-W&`J0XD/+DN,/ID1EQF'`ILDDCWOBLZFXRBV&UDXYAB0,%;
M=J%8#9@",""1MJV!`I2((D)TB4J292B)SJ")2D``Z5%1%10>@/\`",/6'U1\
M.,X<)4XHGA)/0`Z/T#8.D-E=`."N/[OC;?)0?-!C7(P("6B;A1("/V%2253>
M+-6V5^-V'<).!4VC:(W9.N>/.Q*3`3`J.(VO2JCR99N#.3&07:NBH*7;N1_S
M4=VWN19_(FJ;C?\`SY,\9<[8T_7)%Y,VKBWPNU[$I;*@YF@\<-2[OB['6)&0
M8P]D:1FKY"'O%:4*G1K4R"U1U<CP91+H1(\;V6TPC=%!1-\X.C!-KZ/"L_+(
MWL:DG&UR(5QU=*M3C,A"%NL*6Y$<BO[94=?$+?7QLEO`MK@P)[BW$*CM)6IL
M4J<T_!93G"D,)6"#L.`4%#L3M`V`\.920!M.&-[T;8DU&;]THVM.A]D62M:R
MK]9F=5W=+3#39]/F9[8BTHXNE.OEBNNE=RTF"M+.TZJIK-BZ8OZY.,33:[D'
M:J(_2(SR1],09>[B_.VC45KBW6[27VKA%-S5`DM,P@VF+)B,Q;I;)3L=4>X7
M-QUMUF;$=$5MHLH7V6POSRDRV@XRM2&P"A63,"58Y@HJ0M(.*$`$%*AF)QPI
MJ.]*VBFA$U?22U8@UF]IA)^SN+?:"MC-8PI8*UQ'DM7!UKG8)&ME2;(+`203
M*V<1S]Y&@0JZ;E;Q*0\D72*G)DO7S<N0ER'(98$9C-F<_*QW,S^6;#*F"HIQ
M945H>9:E%1;4TC/GWY_!*8I2,%`G$]#81LZU6W[NP@E/#B<,/SVL#>P4'C?J
M5W)T2"I^S(=JRL!MK0C2<OE5@I'6MG%6QR+J2U#LV-KPI>YZ,2M)1Y8N5;S4
MBB9)<A`ZA\WDZ6UVVZCU3K-EJXR+W:7U*9^SW5-1)#J)S&#"$HN4!;V.=4A+
M#Q?CKBL.!;95UR?F[K"V6(Y*`VX-N<8J`*3M.*%`?1B,#F(VU%O>$P*AN0M&
MF9.B[HL3JHZIT]&\=8^DU^Y[3INX+G:MVIL]TZ_DHJQZYW%HZ@V*OZ^KT+(M
MY&;A8Y_)*+H.CRJ#2)7,AUW)JN*1NTN$&)<+%%9FWBY+O2Y3T6WR;;%CVHJM
M<Q#C$VVW68R],>E,K9BRGF6$I<93#<>F-ASPO"/\\0I2'5%+:`WE"EI6HKZ]
M)!2M"2$A)Q4D$[#F`2<)*Y#7R`M'.G7T0]F=P5RU:JOFIJY7Z96)V5CJ1?UG
MNQM`OF=METFE5,#@A:=O2WH.FAWB[)S%UMZ*@I*%!1MRV[33MRM')\N4UABR
M2K/>+=<7WI3[+:Y4,)A7A"H[95(ZT^$VFVK;<#:'4/SH^4+22EWWF/(<NJ$D
MN)<;6@!()"5=<WM.SZ'%XC'`A)^]Y[9L."NW>!U-T:6W)!76A;!K.NF.N(F>
MEF-"EFZ$IL^*EKX^;-ZDBC(%<41P@Z=-G#E=J$<]*!%2*'*H7TLVF;C8>3;,
M9#-CD6&XVU^:N:XRVN8V2W`<;B(4J02C++"VVUH0ASCFCF0I*2D_CCR';PDX
MNAU"PG*"<IVJ!5P?Q=I!.&!K;-6B#CG2_N*\F[G]AVW:NZZE>=?SE3I#ZVZA
MUIKNIS$%J6]-K7^1>.MM8UU=&$2@"+=&PD9R2MD8*)N'R_NJ"^FU<"WR?&[(
MVTB-IF%9[7(B3&I$I$>Y3ILAIVXQ%1_M-<=^;%6XK,M4(N,)A2$J;CM^!\7Z
M1]MU+A.+RG%A22$XH2D$(5CD!"58<&;`YAM)S8X3BO*5B\\Y=MVZ;MDK#;`A
M372!K52E9JWV*3L%0"][)K4A!R[ZRH,TH!Y6'M#3G"P4>9Y#LHR;C#MS%.8V
M9^]^)=M/\GZRV6!#9?TV^(KS\EMJ,RVS)\$@OH=;0P5%Y+Z9:HAEO!N2Z_%E
MI=!2!7Q`4V[=7'%*(>&8`$DDC,H$''@PRYLHQ`"DX5E^."XN>8,M;%G\C9=@
M;$GM_&VY59ZI:\6NNBV=$DZ]1M3A+75CIROVZ,IEMI-9:E:Q@3:;-V]=$>,O
M=-`[QWF%O1;#6Y)FS(;:B:;MD>S_`&=(9D31%NRI;;TNX<7%7<WHSDJ/*?<+
MC_@I<;:;+#_@KB6&:^X1QN1<)*GEES."$YF\I"48JR`A)2!@,V!)Q&88FH1[
MO.;E[1S5WK8=E*[<U=MI[$RGN[J[9VMK?2FVT3ME8.$=;`KL^WJ.L*1=V5(C
M8"-C$G[AC8WJ[5RD+:020*)3]_REX$*T;A]/6S2HLMWT8V\WQ4^!.C2E0`H.
MNIAO,F3/E15REO/OJ90[":0XA8=C+<(*<2S*4Y='5O\`&-R"#BE22G-P#,#@
ME*LH`&)"C@=APJ>^"-J@K]NW<%]C]G6F,E[412R6GCY,P-FAH2,N%AJNJ9.W
MW2%/*6)Y&&&&FQ/!O02CFQO=-NZZ/4,*B<\H:SW'3F@;)IR3:8;L*&0Q'O+3
MS#KKD9F1<&XT5T-LI<_*M82VLSRQQ"V<>$!.9:7$/2G'@XH*5M+9!`!(02H8
MG#8>M.P;<:U?CC`35NO&VN3SH_(NO1W(*D5&]MZ%LZM-F=(K,A9%M;G5C(R[
MH65PYN[>O,X))O6TO<:&]SXQ5UT^,.L/5?[R+KC!LO*EW=[IF/ZL296FIUYB
M&9`?4J4^ABUWD!QR*6$B*IY3JES5>%2>.?2SAE"!CRVHD*<LDN>>."7DMJRJ
M'6C%;>P*QZ[##K>M&`Q^FJ,^[KAZZ3O*]3R\?"MJUXO<>QXRHU>,@>/SI.(K
M!*!M@9*6L%]UUJ_7=U?3EB?$;']RTVZ$,P3(!5E)%T";DLR?+:YH&\KW0G]H
M*3W3GG^'XPGJU<3/IW.:[X75;G8/&U_J:"\;?'5,W++W-M:JENA?6NKK!7J#
M)5I^PTPO\2+[+UO:%A3-4@O4<JO'03IX^BWGBF;@]:NW*L4#D27AK36J6[S<
M<(B95L;BJCR+8)T]EZ8A]"[F/"H;;\"&1<?LEY*'I;3$>6QG?;2L*^-5J1LO
M,%M'795E6(7E20DCK.M40I76<8-B22D[#7GW-8)>P=[MK*.V=5K#K^@55K6J
M9J>\OM&.;W1-C61BGJ_9<(J_OMZT[:*-4YRQ6R[SU;A)"K6>#LL*_K2YG0K(
MO&Y$O70MMA6WD67:3I.7&N6I)BWY5PB(NR8DN$PLSX+H1$B7*/+D-,QXL2=*
M9N$"7!E,SFPSD6PZI?Y)6I>HFTOI*&4X)0KB\R5'K5#KE(*025*2DH4E22DX
MX@BM6Y/:AILOWE=1V1:]-;5F-FQ&\N(#C21HR*V;?M?7FF$!",VOMILZLU/V
M9H34]@TPIT"^18EI\X$3#N'9Y%1Q+,#I;?=-K6^0N2O-TM9[Y9V-*/Z?U(+K
MQCD&',B2CBY;[<I+$F#=[@S<Q^:4Z;E$\(DMLB,EN%(2OSG1FE7M+[C3A?#K
M.3`*4E2>!:]H4V@HZ.&16`)S8J%=`N1MUV%&%%&%%4O]\W!QR6M-5[--QWWK
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MLV!+8?\`#'&EE24,VXB2T2O#CVENH<UP*8UFC!IQ*%)6L)("R5#%6Q*DD901
MPE?6G9P$`AB>6UH0H_&7A3,U"_1&G[)\2E8ZM1U:INSWEKL$+(46L&L-.I^R
M]0[05INMHY8J3920<V66E(>162;+)2"+MLD\Q,=S%H<O^]?7D&]VY^]VOP\+
M?6_)@)CLNHEO\3)DP;E`$F<L8K2RB#'CR64J=0N,MEU;%9MQ<#4&*IM8;7EP
M`"58D91BD*0K*D<&)42#L.((QK[Y>/V#'7_`.'"SRNL==.*7$*71G6_<P:D[
MI3PNEZ,6$CH1E&;(C'L]35[VE8D3I3Z;9.O0,L3RMZ58%"?.Y6-(D:DWCSC$
M9NVITSW!%4_QGA"92?M.7QJW5.07$,R1$5"4%0U+,V7"5Q+!04J+B0&8:<Q;
M9RC-AAAEZQ.`&"ABG-F[+#*E6TXU<MKMC#1>OZ-&UU\A)U^.IU98P4DU;HLV
MTA#-(5DWC'S=HV(DW:H.V29%")IE*0A3`4H```&,:U-(G2]27"5<VU-7)V<^
MMU"E%2D.J=67$*4HE2BE9(*B221B2372LA*64)0<4!(P/TC#94A_@S.W_LM6
M/^OJE'O6;#&W/8^@].U^7Y816TZ#=5-Y5U'AZ[UJEM]^K,Z[W[3*J^A&5\VS
M0VDU$U&P5Y>4G(V1CI:&E8M`S19!5-5P9L\#DZVR58IVN];W)C1KVD+D]*M3
MQU*F<;:@-72URI"'51+=+4TY)9>3'B/LO1Y,>0L/-N(4AL.\_=EI=3%C(,@2
M$!*QQ.7/M0M(PS+3B`1BH$%)&P@XG!O.[DJNS:?P[U=%[F6MKC:<A-[@N%X<
M7JEQ&NK6XG-@;NV/?%UY:BU^Y;!@JH99.R$,DR9S+YL@W$A4SE)T)D;7RH+Q
MI.][[KO+T*F$G2#4>VQHJ8DIR;'2U#M4*(`W+>C0W9&!8(4Z[&:<6O,5I*L5
M'<65M]NVMIDYO""5E69(2<5+4K:D*4!P\`413OX@-;6C"BC"BM&V7V%LGM$O
MG*&/7^7+SW-W?IM7DDFN<U=[-R^Y_6%*=6'"ZUEK*2RRJJ99Z($B:JAE"$,1
MZB!#$*<1*4Q`'H`0Z!#]C+5_*CYL^\/W)O7JZ12'V7SS$\9;[<4]64>:<G4'
M4B&Y&HW:PR.Q=@ZBD->^[UE)5JG4-66N*M7Q866*I4%IV\R^UI:-]W8]L<4I
M$B$$#=VHGXQ$R!3^+(H%_G;L'+!&BZ8MMZ:U+X.QX1(DW".Y'X\#"2&HC=O;
M7Q2U#,R5R\[8.58<*<RL1I,T.E3RVRSB<`$$'#H8J*R,?IZW;T,*C/7T+S&C
M-AT]785OH=EUQ)26V9/8#9BRCHZ8K1R2CYGJBO4WR.O,SS-,?01VKQ8[Y4LW
M&OD5D7#J21<)BTZO4L_<?+TS.1IJ%<8NJ&FK<W#4M2UM/CBT*N#TG,\H-2D.
MAQI(:28K[2D+;9BK:4'O!E-R2\GCE(4P2LJX`1MZP)V;4X8';UP.()4#L_?4
M%8Y=Q5[93.X]ETZU5&5CK[[NU*!K</#Q=3>I3<!^3U.IR#:)2M,\L\9#+*/'
M,D\(BWCQ9-1:+/4W$BOYZVNVY:9IYR#H>U3H=Z9=A\5)>?=<<D)+3WAAD(4X
M8[(2KP=+;;#14M[CWN.0PIN*W^QF[BET*DK2ILA6(```VC+ALQ/1Q)/!@,"<
M5%ML1BMC2F5.#Y@->3-@=72_Z[F.,05RPOZK%0-$1AK4,S)S,<6MUN?D7=HE
M),9.IQA'0KR3=,&$JF=+_%6JW6*19;S<-R;VZF,S8K;<V-[/A3*)#CTLNQ^*
M;:7Q[[*$QVV^+D.%L(86>.CJ"_RKR,"=<VBY"<2ZM!@Y3@`G`XDC`$XDX@8[
M>`_0#6/BX?F:.\59"<L^OT]*QUT.E%1$.LP75L&MY9OLE^]<VMF^HK:RQM]J
M[OXIQ\66,FBQJR99%R]\H$Z*2>3,G;BQN_$:WQ+D=>.P`7''`L!F<VJ"A*8Z
MD2U,+AR$_:#T@OQ2^E1BM,<4$K6K\2FY^%8K4CP4*V`=%)S</6XA0ZP#!6'9
M$X[*</$1K94D](8<W2<CYHU[E:4KQZ:SME<0RT4_KP#*4V02MZM:BC5TM()=
MF=]@WSFOIJO5)X(@[-I)`9NNNX:*H+U?Y&X([KF!IYF>-Y:X["70XA[\G)08
MP?<X[PHQ51'4)F*2TF)X0''(N#K;;;R'-6T+IX:>-*?`\3AAAM3MP&&7-F'6
M[<V&`5L)(PDG4L;RDB9IR3;5EU=;ZE)3^P7Z!HV)E*[>*E$+V^>6U]`I+QH.
M:K=&*%2/'I+.%&T,\;G*<%#/E.E8W+:SE;HYL!!T9%N\*]-1H:#G<;>B2'!&
M9$QXA>61%69/'*2A*Y+2P4E(CIP0/>.F>E7^<*;4V2K@!"@,3E&S8K9AT$GI
M\-1GJ:'YQM-Y3#O;UGU]):54=712-8U]6($R<2L_5^)K9I'I42'M3.P-RBB8
MRCJ:?,DX\JR2I7+PZ3E/J]93N3^]N_89T5$N36O`B*%K>#FUP('A*E+,MR.I
MD]<`EN*TZ7BA:"TPE;2O".FZB43)4@Q>NPPPX/X.S*#CTU$88\)VU]:2A>;C
M3<=AE-TVJF2&H7;.P-$*ZT5K;I9E--9?QE?F*$,!0*Q88ZLRL.Y3(HTL<K,O
MVRK9<#**>-14+^:]G[@WM#QH>A(<YK6J%LJ+R@^D+:4W@\U,XZ8^RM]MU)(<
MA1XS*TK;P2G(M)(J;H)*E2E),;`[-G#CL*<$@@$=!141@?N4S&U.P5@^U,_A
M%GB]?+$Y\FA/&+AZIGUJ]9^S4KI([XFELU\X<+W>L%7756*20,8@*J'4`AO(
MW).L3KB;J#U!$.D.CP#T99!^8/S*]XOH-'ET2DATI[11.Z_553ICT]`]40`W
M0/5$0$P`/1X!$H"41`!_8Z0RF4,,=O!3AJK$X2[2V[L2^S8VW<+_`&-6V-(L
M2,^=6LW!O!S>Q(BXQ$"O8*&I,\7='QU'AH19C+L7->/.6AX*RJ11-UF*[IT[
M+?WI'1>F-.1_L:R-VNZ.7!DL@/QBZU"<C./!F6&K]=5RW70N,ZB8(D!K*E9`
MPD-LLZ*UR)+SQXQPK0$''8<"H*`Q3BT@)`V@IS*/[A)D+BOMZZ;2C[2X=\AF
M&WI!.L3BT2M%<5MG:CI\;(LY^1B64NQF;:0@VQ5J=J5N]B6SA1PFY36`I^@H
M"'-;W]%6+2,F&TSIERRQC+:#@<U!`N,E:%,H<4VMJ,?\W"LQ6U(6A*"V4$C$
MX5[0)+L@*)>#ARG#!I2`#B1CB>'[H&W'&M>X8[1V9LNR1Z[W>([EUJSTK#/Y
M"5D]7W:C33S;DQ.M$[*M'STUIC5]2MU%B#Q3Q*(68@TD$478MW[$YVZ;Q79;
M]-(Z4TK:W6V-/_86JEWYU"&VY\66TFW-M*+`6RU<Y\B-+<#C2I*7>,94IL.Q
MY`2ZIA'Q;'WWU@EWC6`T-I2I)SD[<"4)!2,#AA@=N!&S&G!W2(A3`$!$!"8C
MA`0'H$!#QX@(#^P(#CN?DW\\(^Z5UZL:M#O!]G_Y='X:7RH.)H'\VYA)!!E8
M4:;;U(.4D8U[/-HZ6]R%U6#QU$L.M)2K5!^5-55JW_?G)2]0GTXADP_S5D0E
M\D&6BY-K=MQU38PZA+B6E+;,LYTI=7UC:E)Q`<7UJ"0I6P&D_P!#YA?TE!P7
MQ#N!PQVY=FP;3TJCKB?LN[7FO;`M#[DK9]M5ISJ"MV1I:Y32=AK@5NW/@N+A
M[,4!DMI/5L5=:O&P#>-*F1!&1=3+YNHX,SC"K%:K5P]\>E;#I^YVVT1]*Q+-
M=47M]A4=NZ,O\?&1X,$MS%"Z3W(KZWB^25J9;C-+2V'Y907D*[;WW74+<+ZG
M$<6#B4$8';M3UB`H`8?25';@G'`ZYQ>VINR\:1Y+VVQ\DDME32,"XL.F=@%T
M):J+3H*J*:N;N*Y?&,`_U+796R!/6QB_DG$,U^-"C)L1!))PY\>0%-IO;TAH
M*P:^TK9K7I95J@*D)9N</[7CRY+L@3U!^(MY%Q>;8XF.MEA$ESP`.K+BUMM<
M6K+\0)$IV*^XM_.K#%"N+*4@9=BL,@)Q.)*1FP&&TXU*O"'8VPMGQ]UM=PV@
M78\3-Q].L<21M3;S7*_!REE>W65>)Z_EKOIK3SR<URYJ)X!*.`22SHB[5RX7
M<E\K2(/';_=,::TE)@6>R6C[+F1W)+#A5)B/O.ML)BMI,QN+<[DEJ:F2)BGM
ML=LH<:;;:/$K561:WGGTJ<<<SI(!'6J`!.8]:5(1BG#+APG823MIA=Y&$M>A
MS%$2F+-D,4Q1$#%,#%X(&*(>$!`?V<D5^27S@M5^YB_65OKDMX_FICQCZBZC
M73ZRSB[)&65.J<D1)E3.L8RHD`PMA,4!,;K`0QB@(@`@`]`9(]\W[F9R<>#^
MM-IZDJN0T#[0CN#GU:7#@YM;>FR=E7,-A[CC]F5.,@K$P9*1-)O\!#3,I`6*
MLUM*7CB6?CGJ.)J,K!S,;8&TK&IV*S*N57B!"E0"-557K^<H#1^[W2VE8/\`
M5FQNVJ\NR&5J#DJ&\ZTV\R^^6U\1>KBY);=:7#7'?5"@I0EIQ1+AE(0VJEJD
M2WWU<<Z%M@'@2H`D$#$8MH`((4",RL<1P9=LB<=-R7R9VE9-;63=41M4T7>M
MQ1MBC#:$VI6I&C2,';)=U"4N,V\E5ZKJR<85JL.X]N=!VQ+)'$!.1_(@HFL;
MF=Y^A].P=(1=4VNPOV</6^VK97]KV]]$M#L=M+LIRVE^1<&EOOI>6%MNE@=B
MJ-%*5('M"DO*D*86Z',%K!'%K!203@D+P"#@,.$8_=5PT]4][Q37HF1\S6S@
M=Q?QMT=[U6GR^/65<_-LCN#G:FD+(NL*1$!64,@($**!CF,B)>L!N@4A$2='
M6\/J>KX<O63^RD=)SJ*ILZ>A]ZH^Y5;/WK`<C*C1];;W94V*>4^DV`VOV^N+
MW8WX%=VV;A'=IFGM<X[;79RU<6D$VR+AO\8J_P",21,U.=@98DD-,7=;I+=[
M<=WMSU!JG3KDZ8BYS6?#%38C".M8;=3':2_>K>IM\(*U(7X%,RJ4'@F0$*BT
MX::_+1+0TPZ$I*$G+E4>B1B<&UXC@QZY/T;,<U>KF[LO=-7VWKZJ:MWB.LE7
M]+<6Z.K[*B7FXK2KJOS4A&SKRR156XZ[F+9JF^=3D`U430EJZYAQ(HH<'0/T
M/$:_<%I70EVT9<KQJ[3_`-K(;GB,MY4N)&#:7FD+92PY(O5LXB0A+4MP%<>:
MB3BE*>),=SC/JZ/RFY"&X[O%XIQ`RJ..!(.(#:\1M2.%)'W<1A9ZB)Q22%0Q
M3J"F05#D3.B0Y^J'6,1%0ZITBF-X0*8QA*'@$1]7&F+RYSE!"<3@"<2!TP`#
MTP!C]%;X4C]P<.$[9:4TUUB)FGI43)D5.4ANLY4`W20#`4>L'@']L,NW\D#F
MH;MO<BS^1-4W"_\`GR9XRYVQI6.5V\]HZP<UQC2=J/M?UJM<=U[]-234(^'J
MFMI@)BSLJ]>-J2<GI/;"=HJEG<0GN7&0K9S!%,_9JHN'29I!DNA`7OPW?:1U
M9RJ-XS]^L[=QNDK>3(AM-JSN2)S7%QE/1+>VW=+=X/(CI=X]^4MN60RZA;3*
MA&?;<5&VRY#%DB!IPH0F&%$\`2<3@I9*%X@X8!(*=HP)V@BWR*=>71<:]\8"
MWEC!FZ\<#<[0%?*&Z:WC`:**KJ-@/U^GQ9CG,3IZ!,(ATY$5,9\'ENQ\,N1Q
M2<,P5AE41AF``5AAV0`!X<!P5WB3BD'Z12)\MM[3^K[S58F)WBRU#68_6UWO
M^RWSS1SG:#:#@HV0AXZM6R8LZEHK\13X%25,ZCE0<)+D5<+HJ*+-$DS'5<-N
M8W>6W5NGYDR9I]R]75RZQ8<%";JF`IUU:'%OQVV`P\Y)>#?%O)R*04H0XE*'
MEJ`1JKC+6PZE*70V@(4I769L`,`"3B`!CB.GAM%1#RSY(WVE+FL-!W0>DQS3
MB9)[6C/=FB$6U]'6.:5D&E=LV[)0:E8I6LP5G30%K`K,'R)(>>9=$@V?MW:2
M!NUW-;K=.WYO[-U'8A/E+UFW;W.*ED3%L-!"GF+6WX2RV^\P3QDM+S2C)B._
MYL[&<96X,:X37FCG9=RI$<K&*>M!/`5G`D`\"<#L4.N!!PJSNJ.W$A5ZV_=N
M!=NGL!#NW+LR0(&=.',<W66<&0!-($164.)A(!2@7IZ.@/4QIMX9;C7>5'93
MD9;DNI2G''*$K4`G'$XX`88XG'AQ-;ULDMI)VD@=2JTMF;OV!"\I9*%/O^8J
MU,A-YZ$UC7J(&O8A/7\_*;#0U"M8M>R-V=4:0GIO9+F`N;U^A'(RS5N9G,,W
M[=8@P,HS<.JTIH#3<_=$U/&FV)E]D:>N\]Z7X8X9C+<(W(,S$14RT,M04O16
MF5/*CN+#D9^,XVH7&(^WHWY3R9Y3QQ2T'6TA.49259,4E64DJP43AB-A!!ZQ
M0/XN.0&PVW.**K3CD&Z+H5S>[#JQCKYQJB$A%;!MP:]45$=<5^X/(!\_N;*H
M#[I2\G(MY&+>,TUB(^1O&I#OB?;6[?3+O)_>NK>FD'>*BW,W!<P7!UT,V[CI
M(,UZ,EY"(JI/Y",PPME]ITI4YQ[#RDQU!F/"ZA!>_P`TSE&7(!BO`=:#AUV&
MTDX@C@P(VU^>K]][3F>6+*J6W<:"M4E]S[FUCK^G)U=:'AMC5+7\?NZ6L:\6
M5]KR/<2%OUA:ZO'PDA(LYX[5NUANE5LM[LMG:GUJW=UI"#N;<O%FL:A>&;%;
M)\R29`==A29B[4VP',DU:41I\>0]*98<B!Q;DGK'4>`NLI&)<A5P#;COY,NK
M2D88!03G)PZWA20$DA6&">`Y@:PND.06Z+!S`/4+GMMB]UM9-@[JJFLH1:&&
M'_*1!4-38QY;XLUI75D0X03UG8JL:,?3_P`;I`0&/3;+1Y@E6<B?/U_NVT);
M=R8O5BLKC>J8MMM<B>Z'>,\"=EB$&^/?%P<23.9D!]J']G,_GE.MR08;\5/Q
M%F2EW+BW7`6%+6$C##,$YL<!D'8D8%6<\&!3UP54@<8>2=PF-A0.M-@[BAKZ
M\N]BW66KL975$M4+3)LZ+:;,163HUO8N8*KW'6%80B#Q!UUX!K+-7B*1'BRX
MNFRZ_-[V=UEDA::D:KTU8W[<Q;XMK\(6W<&Y,=M4N.P0W+C+2[(C3WRX)(0B
M8Y'<:4M3#;89=;;]H$UQ3P8><"RM2\,4$$Y2=J3L!2,,.Q!!X2<039?C5*WE
M5I\-N2%QN$Q2=<;$W!%;)G[;KRT7B'&4U-*4"ZS#&MRU<8/KG"S35W$52XZE
M>NY\6\2^3KT1(`8@-WI?*TENLZK?ENNL=D@S]4:8LCUJMT*YL17>+N+<R*VM
M]M]:(KK2DN2(UQ2EG/(:,R2S@2XP>)6C#1VV:ZXI+#S@6M2"H8H*5'`CK@=@
M*-NPY0>@=N-+]QTWMN?8%DFX7:FZF]XC[EJF9V'2ZNYK1*X]EZE&W#4[&O;+
M@83\DVOW,/39A:R22S)VI*SGEC>20BUR(/X%XZ>R5\C'=[H73?*LT=/T?856
M^3!NLV%*D)?+Z&Y"['?%O07G?M&8EV2T&&$NMB/$XI;#DMM3D:XL-,<?J*7)
M>L<A,AW.%(2I(PPQ`=:P4!D3@DXG`XJQQ"3@4$ESJ4NNM<:L59958I)MD8A5
M3F4`A@$Q0,0#B(%,!3"'2'AZ!$/4')A^6SS0-Y7N?/[V*3_3GG^'XPGJTME4
MWSMYQS;)!3.Z!1U9+;DONH:W2).OI%KFQ'%;@KO*OV&NVY]81$PPL^IG=?0C
M[`Y4M;\CE8AWZ:!6;A%$U72\;N]%-;A#<(-BS:O9L<.Y/RFWCQ\)+[L5M"YI
M$]QI;%Q2\MZ&A-O9+:2F.IPOMN.!:FY<DW3(IW_-RZI`21L5@%'K>M!Q1A@H
MYSCPX8$"O;M'?>W(;FB2@PFP;42CL=KZ5K4DK'0I`U=1H"V-M6-IO7UZ:.](
MRCFS7R_R]\:IQK^/NS92.&RQRIVJ36.D#*>&D=W.BYVXDZCGVV&=0.6:Z/H"
MW3X?+>CJN"FID12;JVEB)#;B.*?9>M:TOB#)0EY;LJ,$_K\N0FY\2A:N*#B`
M<!UJ0<F*5=8<5**A@0L89D[,$FI0V)R(LM<Y5*T)+<4@PH,78-0UV<JL1QOF
M+#'UN>N;ZML'$+<MUO+*Q@686]UL&K),",6J\@Q/-BHH@JV077;<EIG=E:KI
MN?&HEV-MS4;T:Y/-2'+VVRM]F*A]:78UK2PMY7@R8<]3Q=<0RZ(N5+B'7&VW
M?=Z8M%PXGC"&04`@-DX%6&Q2\<-N9&&`Q&;@P!(L5QL5;JC"BC"BC"BHDVI%
M[ND$ZFCI.VZSII@GW'QX>;$H-BO@'K2L/)&04J\?7K_K\J4XC8BM/&`Z<'05
M9J+"`D5(3K]GI"7H&,N8O7L*ZSAX,/!$PIC,3!\.(Q$A;T.9BT6>,R\6@*2Z
MEO$*0I67'D)E'*(JD)V]=F25;,#P`*3MQPX>AC6E;"@.33H^K4Z!?Z2R6A(B
MR/-E2"U52CX>[7!E'PAZA&'@)16X2\!KN>>)RB4D2.EBS;!1=DJB[730<H.-
M]IJX[J&4W=6I+;/<1(?83!0)!6[%C*6Z)+@>;$9MZ:RDQU,%Z.8KH2^AQEM;
MC3C7D\B<>+XE:00#FV;%'9@,#B0D[<<#F&S`G`@Z%-5GF;8:%HMFTV-5M>V]
MOKUPYY!25?AJO9Y>2V*G'5%1*%H;FSUM2ILXEZX+/($E%8L2M71F#D[!PW*X
M:&Z.!==Q=LU%J%]ZUS+G9%7-*;.AYV0PVB$5R079:6'Q(4XD>"++"9&+C8D-
M"2TZ6WAXJ1<ULM`+2AS)^4(`)*L!L3B,,.RVX;#@<",13245.WI4FG);"7B'
M5^3JM>3O#FOD63@'%O)$M"V5>$3<$37)$*S0+F;`<I3@B)0$`'I#$BU"JR+O
M\Y>FDOHTX9CQBI>(+R8Q<5Q`=()!<#64+()&;'`X5GM<9Q2>.PX[*,V'!CAM
MP^YCP5OGX,SN_P"RU8WZ^N7SON+#46_,GCX?8_&S4VWJ9K&A5*\**7?BKL[>
M]BVO';#Y!L]4;3U5&7Z@^-8:U9ZLT^_E[XV+(M)(KJ3;(@DV,KU.M)OR0+9>
MG-!Z]3I?5-YLM]NVIKG$`BZ@@6EFWKA6YZX6^X.0YF"YRKA<D1K2LLN,%MA:
M\[H1FPXR_K;$J+Q[#;C3;*%=<TIPK"EA"T!2>QR(Q<&(.)`V5?=Q6#0`:!UR
M'%NMQ]0T(#"7_)W7(JC6/6K",8_&29]UDVU(MT'6K%`E7L?EBHD<L4#*F4%4
MH&(H4YHP-[YWD'>/=#O=E.S=XO&-^&ON2V)RW%\0UQ95*C.OLO8,<4G%MU82
M`$$A22D=I;_`_`T>`)"8F!R@)*<-IQZT@$;<>$4P6)K691A11A16C[*["V3V
MB7SE#'K_`"Y>>YN[]-J\DDUSFKO9N7W/ZPI1ZIVIK?IV)\^0RU?RH^;/O#]R
M;UZND4A]E\\Q/&6^W%/AE'FG)T844844844844844844844844844844845'
MVU.P5@^U,_A%GC]?EB<^30GC%P]4SZY?6?LU*Z2.^)I9M<]N*W[?-YJXRR!\
MP?F5[Q?0:/+HE)#I3VBB=U^JJG:RF53AJ^$TTTBB5),B91.HH)4R%(45%E#*
MJJ"!0`!.JJ<3&'U3&$1'PCGTI:EG%9).`&W;L`P`Z0``'T#910FDFB7J))D2
M)UCGZB9"D+UU3F54-U2@`=910XF,/JB81$?"."EK6<RR2K`#$G'8!@/W`,!]
MRC@X*$DDD2`FBFFDF`F$$TB%3(`G,)SB!2@!0$YS"(_MB/3@M:W%9EDJ5]).
M)V;!_P!&RC@X*B?=78O[\1_K+Y*M\F_GA'W2NO5C5P^\'V?_`)='X:AS3O;E
MGZ/DO82Y+K\W#F47;T_:._KK@M!^T;?<G.H*;M)))!,J2*::*1`Z")I$*FF0
M.D1Z"D(`%*'2/[`94T6M;BBMPE2SPDG$_NTNO!P4)I)(ID1133223*!$TDR%
M33(0H=!2$(4`*4H!Z@`'1@M:UJ*UDE9.)).))^Z:.#8*$TTT4R(HID222(5-
M)),I2)IID`"D(0A0`I"$*'0``'0`8*4I:BM9)63B2=I)/"2>B:.#8*A7>?9V
M)]-%\Q>9,U\DOG!:K]S%^LK?2>;Q_-3'C'U%U&FF>VR?HF0]=ODCWS?^9E)]
MZ;5U)=<AH'VA'<%_5IM4TDTBB5),B11.HH)4R%(45%E#*JJ"!0`!.JJ<3&'U
M3&$1'PCE4=2U+.*R2<`-NW8!@!T@``/H&RERH(DFF*@IID3%4_C51(0I154Z
MI">,4$H`)S]0A0Z1Z1Z``/V,%+6H`*)(2,!B>`<.`^@8DG#[M%8R>]XIKT3(
M^9K8J.XOXVZ.]ZK3Y?'K!N?FV1W!SM32#)_P?T2>N&7K)_92.DYU%4V=/0^]
M5A*:20^*6%-,5BH`D57J%\:"1^H<R8*='7!,QR`(AT]`B`#^QE`ZX+7X:^WB
M<G'K.&.S',H8X?3M.VG2([$'HX5]BDF90BQDR"JF50B:HD**B9%1(*I"'$.L
M4J@I%ZP`/0/5#I]0,PPM824`G(2"1CL)&.!(^YB</HQ-?7W:^\^:*16Y]K[1
MZ>D_.U,NX\D#FH;MO<BS^1-4W"_^?)GC+G;&F<JE6K-@I$,6>KD%-EDJ>M6I
M$LO$1\D5_7)02FDX!Z#QNL#J$D3)%%=J?K(+"4.N4>@,JL\NN[W:V\LS>(;=
M*D1RUK"0^CBW%HR/MD<6\G*H9748G(X,%IQ.!&-+=IEMM>GHF=(.,<`XC'8>
M$=(_14F$(1(A$TR%333*4B:9"@0A"$`"D(0A0`I2E*'0`!X`#&:J4I:BI1)4
M3B2>$GZ370UB)2N5Z<\?[M0,-,>4P\K77/NI%L9#RBOSODP3<$OY6@MXV'F`
M9(^5-3=*#CQ1/&%-U2]&;$NESM^7P"0^QD?;>3Q;BT97FLW%.C*1@ZUF5Q;@
MZY&964C$U\J0A?9`'81M'0/".D>B*\SVGU*2;*,I&K5R09JUYY456CV$C'39
M6J2)$$Y"L*(+M5$CUY\1JD59D("V5!,H&(/5#H]6+W>8KH?BRY3;Z9*9(4EU
MQ*A(1B4/@A0(>05**7>S3F."AB:_"VVH8*2DC+AP#@/0Z7W."L^DDFBFFBBF
M1)%(A$DDDB%33233*!2)ID*`%(0A0```````,URUJ<45K)4M1Q).TDGA)/1)
MK[X-@X*P3RI560<+.G]9K[YTXE(2;7<O(:.<N%YJLJHKUN7666;'44E*^NW3
M.Q<&$56AR%%(Q1*'1L&+S>(S:68TN2VREEUH)2ZM(#3X(?;`"@`V\"0Z@=:X
M"0L$$U\%MLG$I!.(/`.$<!Z8Z'T5_J]3JSIR1XYK5?<.TY]"UINEX:.5<IVA
MK&%A&UD(NHV,J6?;PQ0:$>`/E!&H`D!P3^EP;O-W::+#4J2EDQC'*0ZL),=3
MG&J8("L.)4[^4+78%SKRG-MH+;9.)2,<<>`<.&&/3PV8\.%?X6I54CQI(DK-
M?)(1\O)6!@_+#1Q7C*>F6+F,EYMHZ!L"[:7E8UXLW<N2&*LN@J=,YC%,8!#>
M;PIA<54N28SC"&5HXU>5;+2TN-M*3FP4VVM*5H004H6E*D@$`T<6WB%91B"3
MP#A.PGID<)H)4JHF]8R2=9KR<C&24Q,QK\D+&D>Q\O8DUDK!*L716P+M)*<2
M<J%>+IF*JZ*H8%#&`P](J\WA3#D54N28SK332T%U>5;;)!9;6G-@I#12DM((
M*6R`4@8"CBV\0K*,P)(V#83PGIGH_30E4JJ@]CY)&LU]&1B74Z^BWZ4-')O8
MU[:%C.+,\CW1&P+LW5B<'$[Y1,Q3NSB)E1.(]."[S>'&'(KDN2J*\AI#B"ZL
MI6B.,K"5IS8*2R``TE0(;&Q``HXML$*"1F&.&P;,>']WH_36P9K:^ZP#2IU6
M/=Q[]A6J^R?1#>::13UI#1S9W&-;(_;2MA;1[A%L19DWGI-FBY>D3$I72Z1%
M%0,<I1#9/7F[R678\B7)<CO*:4XE3JU)<4PA3;*EI*B%%EM2D-%0);0I248)
M)%?`;;!!"0",<-@V8[3ATSM/TU'&RJG5HJFNWT96J_&O8IB,1&/&$-',W4=%
M3%@BI27C&#ANV369Q\K)LD7#E%,2IKKHD4.4QR%$)"_E<7F[S.6[I./+ER78
M[QN+CB5NK4E;C5FN#;;BTJ40I;:%J0A2@5(0I24D`D'E-:MMITV^4I`(R`;!
ML!<02.D3M-0#1>V=8],L_KQRQ_RV>:!O*]SY_>Q20Z<\_P`/QA/5IQ35.JG=
MH/SUFOG?-9U6TMGIH:.,[;V9>*5@EK&@X%L*R,ZM!KG9F>%$'!FAS(B?Q8B7
M*6HO-X2RJ.F7)$=<<1U)XU>53`<#P8*<V!9#H#H;(R!P!>7,`:<3Q;>..48X
MX\`X<,,>GALQ^C97[+5NNN7AI!Q`PKA^=['R9WRT6Q5>&DHE)1O%2!G)T#+&
M>QB"QR-U1-XQ$AQ`@@`B&?#=TN;3`C-27TQ@VM&0.+"<CA!<1E!PR.$`K3A@
MH@%0)%?I0@G$@8XX\'1'!^Y0XKE>=NSOW4#"N7RCJ+?*/7$6Q6=G>P9E30KP
M[E1`RQG409<XM5!-UVXG-XL2](Y^-W2YLLB,S(?1'"'$!(<6$A#N'&I"0<,K
MF`XQ.&"\!F!P%!0@G$@8[.A]'!^YT*S.8-?5&%%&%%&%%&%%&%%&%%&%%9/\
M&8J7]EJPOU]?3O[J<_<?W0OZOJ_939DZN]K+IYD\Y2N'A_/KX:^8_P"81^<[
M!/4%?A_$LY[^@J]?TM'\2P_H*C]+1_$L/Z"H_2T?Q+#^@J/TM:9L+L9/^]'W
M&'W;]R_9TOL__P!Y_P#=Z,=QR#>=_H/]C\\*_8/VO]ED?F?\+\&-:'4_F"5V
M7YO^%V/9#AI7JSVD@.Q7OS&_8?LWW6E]B_Z7_P`W]W+*G*-YO>NO:GV0N_[1
M^S_L+_Y__P`'_O/\#&D?M'G6-^8_:&^#A[(<'W?HIT_XEE/(<`\Q4O\`^EK_
M`'^)9^_T%7Y^EH_B6']!4?I:/XEA_05'Z6C^)8?T%1^EH_B6']!4?I:/XEA_
M05'Z6C^)8?T%1^EH_B6']!4?I:/XEA_05'Z6C^)8?T%1^EH_B6']!4?I:T79
M/8F<]Y_L;3[N^Y??!I]E_<_:_=QZGR[^>-HS]E_/SO-_[9YLF_F?N_QO_#SU
MSNK/9^1V7`GL^Q[-/#_^G#2\T'MC`=C_`+L/]Q_=7W*X^P__`'__`-S)\.7-
MS1=>^TGF9/[;^R_M<;\]_@_1_A9:2[37GZ+^9_.?P>R[%7!3@?Q+*G?]!4N?
MZ6C^)8?T%1^EH_B6']!4?I:/XEA_05'Z6HNV[V2_[C]]&/OC]S?PW_[S_P`W
M_P`.24?*FYU7\'V8N?FK]IX8W_[O^/\`>KC]<>8_Y9'9]CT?^FHHU3VR:]D_
MN&0][_NK[&3_``?_`+S_`,[]S)0OF@\T2Y^?//EJ\Y?LGY]79_X?\3[]<7HO
MS\C\U^:7V'9<%-1_$LK*_P!!4LGZ6C^)8?T%1^EH_B6']!4?I:A_<OO#&>\/
MON7WS^P_<3O['_TO_P!SIR6/Y0WQRU+V?LFKS3^>\X0OSG_A?3_AY*X;7OFQ
MG@_/_P#:<'8*X/NU'>INV"?93WM?>]WW5ZK?U/\`H_\`SO\`P8_;YIW--?\`
M/7M):_.?[+_^L\/_`(G\7[F:N7T3Y]'YO\ROL.RZ'_132?Q+*TW]!4L/Z6C^
M)8?T%1^EK%S?O-+>]_O8^^R_8_N57[)_T?\`YW[F*-N>^+NE?-/M+:_S'Y[]
MN8_-?^)_$_PL*Q+A^P/_`)S\ROAX.Q/#]RDC)_Y'8;U2>I]$/4RY=-[)[VRX
M'.'I'A_#3>T]#]GZ%/:G]C)]P_X)?4]3U`]3]S*2DW]M>\Q_GE\/#V1X:<<G
ML1^=X*^_XEF-_05?OZ6C^)9^'@__`#%7[^EI,+;VIL78OWYD?L_V?[I4^S?]
M+_YW[N6^^2US:-`>U'LA:_V7]F_9&_V?_P`'_N_\'"D#O?GB5^9_:%]EP]D>
M'[OTTT=%[(5[WJ][6_W)]S?X/\!_T>5I.6ISL=?_`+#[22?VW]J_@_GO_$_C
M?=QI8M.>8HO9?F1V/8_>^Y6V?Q+&P?T%6Y_2T?Q+#^@J/TM'\2P_H*C]+1_$
ML/Z"H_2T?Q+#^@J/TM'\2P_H*C]+1_$L/Z"H_2T?Q+#^@J/TM'\2P_H*C]+1
M_$L/Z"H_2T?Q+#^@J/TM:!L_L5+^\WJL/N[[E]\6OV3]W]K]W'R_+>YXNE?V
M?\W<O-W[7YLE_FOK_P#AYZYK5_L^_P`/"CL^Q[-/#_\`IPTNE,[65WL;[[-?
MN7[H_P`(?L'_`$G[66`>5]S6-X/M-[*S?VO]F[`?G_\`POXU)98//<7\S^?3
MV/9?>^[3E?Q+*C/]!4O'Z6C^)8?T%1^EH_B6']!4?I:/XEA_05'Z6C^)8?T%
M1^EH_B6']!4?I:/XEA_05'Z6C^)8?T%1^EH_B6']!4?I:/XEA_05'Z6C^)8?
6T%1^EK(?Q3WLQ1_Z']E:Q/TGY^O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>g575431g33s01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g33s01.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,9:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;7!-33I$
M;V-U;65N=$E$/2)X;7`N9&ED.C@Y-#$Y03DV1D$V1#$Q13(X0D1#1D8P,$9&
M13`T0C8X(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.C@Y-#$Y03DU1D$V
M1#$Q13(X0D1#1D8P,$9&13`T0C8X(B!X;7`Z0W)E871O<E1O;VP](D%D;V)E
M(%!H;W1O<VAO<"!#4S8@5VEN9&]W<R(^(#QX;7!-33I$97)I=F5D1G)O;2!S
M=%)E9CII;G-T86YC94E$/2(T04)"1#,W-C-!-#@X-30Y,CDW-$$T1#(Q,S`T
M-41&."(@<W12968Z9&]C=6UE;G1)1#TB-$%"0D0S-S8S030X.#4T.3(Y-S1!
M-$0R,3,P-#5$1C@B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@`.061O8F4`9,``
M```!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("`@$"`@,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P/_P``1"`#T`?D#`1$``A$!`Q$!_\0`L@`!```%!0$```````````````$&
M!P@)`@0%"@L#`0$!`0$!`0```````````````0(#!`40```&`@$"!`(&!@4*
M`P8'``$"`P0%!@<(`!$2(3$3"4$446$B%187\'&!(Q@*D:'!,B2QT>%"4B6V
M.'@9\3-#8I)C)B<:HN)3-#4V*!$!`0`"`@$#`P,$`0('``````$1`B$Q05$2
M`V%Q@2(R$_"1<@2QT3/!X?%2@B,4_]H`#`,!``(1`Q$`/P#O\<!P'`<!P'`<
M!P'`<!Y\#:NWK5@V<O'KA%FS9IF6=.W:J;5J@B0O<HLJX<'31313+XF,)@`.
M!8CFCW3O;?UZ%1#,.\&LM,D$C"16$5R[3YFRI&#OZE4K%=DIBPD'JF8`ZM@Z
MB`@'CP,<E_\`YI+V4:&X4;)[62EY63`_3\`88S%.H*F(7J)"/75*BV`B8?`#
M"H4@C_K=/'@6T37\XC[1$88P1R.TMA$#E*4\=AB)9H*$$1*90AIJ^QBW:4``
M>ADRB/7]?`X)/^<D]ILZB9%*MMJB0YR%.L.)J><$B]?M*"0F3S',!0\P*`B/
M`J[4/YN#V9K.L5&6R;FV@"8R9`/<,$6]=/J<P%$3*TLUQ!,"`/4QC=``.!D!
MQ%[[7M"YN>,(VC;]8!;R<DH1%K&W^Q/<3NS.%`((-Q+E&,IZ7?W'`H"!A*)O
M`!'IP,GU1O-,O\,A8Z':ZU=J\Y'HVG:C/Q%FAW`B!3!Z$G"/'S)4.PX&^R<?
MLB`\":@_3_3]?`CP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P-NZ=MV35R]=KH-6C1!5
MRZ<N5DV[9LW03%9=PX<*F*D@@BD43'.80*4H"(^'`Z^6]/\`,V>UKI2>:JK'
M*SK:#+D2=9HICC6XK"Z,&<DD;TE&M@RBL\88UBBM5NI'!&\B^?H&*(?*F,`@
M`=1G;O\`G(O<'RZXDX35O'6*-3*@N+I%C,F9$S1E;Y50RB3=5>QW%BTHK1Q\
MOT,)4:YZB:@CT6-T`>!UQ=A_<%W=VQ=/'.QNUF><O(O0,52%MN2;(XJ21#F.
M8Z;.DM'K2HQZ)Q/T[&[)(H``!TZ```%GO7ZO\_`=1_R?3\/+ZN`ZCY=1Z>7G
M\.!#@1ZCX^(^/GXCX_KX$>OZ#Y_'^T>!67#.QF?==)]&TX$S7E;#-B0<).RR
M^,+_`&BCO%'"/3L,Z/79./*]3$I0*8BP'(8OV3`(>'`[$NH/\VW[I6NRD7"9
MDEZ#N'16G1%=AEV"1K>0@:]Q>A(_)U$1B'AWH$`2@XEV$R8>O4P"/`[=^C/\
MV#[9FUJL14LS3%ATNRA(J)M1BLTK-9'%CM\?TB@2+S1!(A`LVGJ'$HK3[.`+
M]D?`?`>!V=&CML]:M7K1P@Y:/4$7+1TV72<-G+=PF"R"[9PD8R2Z"Z1@,0Y1
M$#%$!#PX&XZ_IT'@.O\`9_7_`)N!#O+X?:#Q\O$/@/0?C\!X$>X.O01`/VA^
MO@.X!\A_3IU#^D.!'@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.`X#@:1,`=`^D>@!\1'Z@X'7C]UC^9#T<]M<;
M)C"!DT=G]IHHKI@IA+&4^S)#TB:2*(`AF')"2,I$4=5LMT!:,;HR$Z00#U&:
M)#@J`>=G[BWOK>X?[E,A-0V7\OO:#A&076!CKKAMS)4C%";$5#F;M;2V:O59
M[)+A(ABB96P/)!,JH"9!)`![`##EU\>H``?5_D_HX$.`X#@.`X#@.`X#@.!F
MI]@;V_Q]P[W*\'XTL$",YAW&#\<Z9X(NV,XBC8[QV^8NVU<E@.U<-EF]^N#B
M,A#HG``40>JCY%,(!ZFWN;9XN^$-6UZ9@=9HTV;V9N55U.U8:=I"!%Y=S$+F
M%;W0K=%TR.C$X:H;:8N#U0G<1NQ@%#&*8O4HAC;D-(]K=<YW#=IU(W4S=L!3
M=>IIY98K4G<?/E[AJMD^<7A"0<^#3:2ELY&^GAK,1J=['U?(<=;*?&2CH1;%
M8(`5,FO;MZ)F*KZU9>QCEV6@-3[OL[O_`*;[A0NPKG9":UXV:R31%<PWZOHN
M7#V<POB;),S3[?C78C3EP5-<&I:+)OI-BQ1[EG,<<HI$RK(Q:M<<\/(;-J-&
MW@S33;!D_)=:O5"GG]`P9>&N!:[#/&2LWBW']?G<=),IBD6MHU.W<FG#R4HW
M!4QV[I-0.[@;R^XBVQE978"1QSMS$4QCD"E5.&U^K=AURI]TC-=+K#I$3MER
MDGZ-KK,WF)A=!`3_`'5)+LB1YS?N5S%Z%`-W^#MRF%G>O&&:L)S%12UY&L1,
M#/81L<?,.-H&K/L1R_+ST+E$R!,42CW[3BIMV:;U!(>U&4[O'@?*H);WM)S!
M"-\DM3INL(8YM"6S3ZJPF8*[8I/+969_P2[P5'2LY8XJ*QVJ_P"S[V1GW#J2
M(EW"W4,;H'`XVIV/?UI#8%2R%B_567LLO?++'[+.L=Y8R@SK='QP"[HU-LN(
M$K;C`DO?+.JT!$).-DPAT4U1/Z#E0O0>!M"9BW<9T\).1TRI,K<E-D2X\3JM
M9VAK_P!WI:V+/#)$V1=62Q8ZA4BS[-GT57HR3=5\8>I4WYQX&[N.Q.QE.@\]
M3H:,Y6NOY8WJKU_$D#CW*6"Y>S;&4N<<LVTUD.K,;%>ZG'4!O4"+JK.HJQ/&
M4@X21_PQ53F*3@<K<]I+51YK/3%[J7M'9H7"6.ZU?X:ST&J4.W-,[NI]FFX>
MX^PA#M<BM[)/9!JS@YD'[249Q#;U$Q,@X63,4XA`-OH-"T-ZK+8.VFA7*NN"
MFRKB8=X!N3ZKQL,V8D?/\1/K'`)R\6?8B.(?L/3FZBTDLJ`D;^L/CP/G2MVL
M,WB8P'7&T?F.LV+9&D6V_P".(:\:_9IJ*[*#HZ*[BRM<COYFE-X7$UB9(MC&
M2C;&YCGKT.WY5-;O+U#BJC[ANG-VB<&SD%FR,"/V6R59L08-+/5._P!0D,@9
M)IYG9;%4HV'MM4A9AA(LOD51*9\@U1<$*!D3J%,41":(W>73N5KDI;VNS&%D
MZK"YQ4UHE+#(7Z`B(AEL$D[%B.&UGTL\9-PR(J\**246!A=*GZ`0INH<"HKO
M8S7QB7(YWV=L-,B8=FX:LY<.[RA2&Y<66.QF;EKT!D<5IP@4>;GC.D@9-),6
MJ[H5">F0W<'`J$G<:DM(2D2C:*ZK*PC)I)3,8G-1IY"(CGZ8+,I"49%<BYCV
M+Q$P'266*1-4H@)3"`]>!SJ3A!8I#)+(JE4(10ADU"'`Y%/[AR"41`R9^O@8
M.H#P/KW?:$`\>G@/3J(@/AYB'4`_J'@0[PZB`B'ATZ]`'J'7KTZE\1`/#S\N
M!#U2=0+W%ZF\@\>HB(]`^'QX'TX#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.
M`X#@.`X#@.!2_,F:L4:]8SN69,W7^LXOQ;C^(6G+A>+A)HQ,#"1Z0D3**SE8
M>]R]>.%2(-6J!5'3QRHF@@FHLH0A@\W?WF_YJ[,NU#NVZ\>WQ*VG`6M:I'T#
M8LSI%7@,ZYH8*AZ#D81T7LD,/49\`&[$6AR6%ZWZ"Y<-"*KQX!TYG#E=TNJX
M<JG7<+'.JNNJ83K+K*G,HJLNJ8146744.)C'.(F,/B(\#X=>O[/#@.`X#@.`
MX#@.`X#@.!$H=3`'7H`B'4?H#XC^H.!ZCW\H=H*76W0:9VSN4"1ED[=&P(V&
M$7<MBA)1>"*.XD(?'S0AO76410M4XK*38]`3^89NF1C@;TTQ`,C;ZP.-I_<T
MR9D5!0SG"_MK4MYKSC1T0R_R,UNGL17HJRY^LS)9,[9-R[PMKXI"UM,QB.2L
MY*UR!4U$U"KDYO29V9VZ7I@'0"@````````/EV]`^OZ1YWMEZC"E.<<$85V:
MQZ?%6PF-X#*M#3>(2L7&3GSC">I\ZT5*LPMN,;[!KQ]WQ5>HM8H*-)JOOF+]
M`X!]LP?9YFZR_=9<+;:_F?;?V\2JCD^5R1OOH="()*.\L-(-:V[\ZI5L@_+J
M2F8JI7&H?QAX8K214E'MJKS)/(,4S%=S)QLN5,[L.-TLOT;S&9#%&6,:9RQY
M4LLX=O57R;C.]0R$[3[Y3)EC/UFQQ2YU$OFHV4CU5FZID'*)T5TQ$JK=PF=)
M0I5"&*&55#Z=>`Z<!T_3]?GP'3@.`X'S],H^/VP\_(YP\>O7KT`W@/U\`"1`
M`P#U,!QZF`PB("/[?+@:3-T3F[SID.8!*(&.4#"42]0*8@B`B0P`/F'0>!+,
MG0Z/-MBLIFG5:79DFVMF(TE*_$R#4ED8G*HRL)6SMHLB$ZS4(!DGG;\PF8`$
MIPX$AV/6_7BX1F182W8&PS:87+[^(ELM1%CQ=1YN+RE*U]5%>!D\C1\G!.6E
MWD81=NF=FM)D=*-CD**8E$`'@2Q<]0-7,A/,M25RP%BJ?E<\8\B\2YFF'=.A
MR363L90B)F\-1;G,MFR,I.5F*0-Z;=JLJ9-$@`4@````!+PZ.:HEN4'D%OAF
MO,;C6=>5]4:_-1DE98E6&UX6:@R-B^.:QLXT8-8-!H'8BJ5('K<`#TER#X\#
MCJ9HOKICF5UTE:)!Y#KA=5JQ::?AN%;YQS:^K,=7[BDLC+M+I7YG(,E%9470
M!P<[%S:$IAS'*"!FRB0E+T#A:SH[4:;#X7@:WG+;MG&8/RO8,MQ23[9S)EE=
MY%>V-PY<OJ'F:7MDG.R^3,5MSNA!G`R"PM&1"E*CV@4.@?22U$N"M<L<!!;F
M;=U]W8]B&^>C6<;AC>PV&`@`<@X=ZZUA6PXND647@%R("4(\R*TNB0>U.1`/
M#@<C;<!;&R##8DM'W;R12YO+L]3IG$,E(XGPA=(W6-I71;A8:Y1X&4IS1.]0
MEZ12,5W^)5Y!VT$XG:+HFZ"`;JS8LV^<V/,DO3]LJE$0-KPY`U/"U1L6N4%/
MH8AS+&H'3FLP6&>C;[793*$+95>U0U84+%(-!ZE2=]!\`W#*K[K1UFJ`JY=P
M#9*;&8`=5^Z)2.(;C!6FU;,(M1"/R5%.HK)#R(K.)WCX`%U6A0>2":(B"4D)
MN@\#C*27W`D7&MJ61E]/))G]TVX-P']);9IAG1IT$U_P&;6N(G7,ZDG$'5](
M)<MI?&6('>+<P_9*`;&NV_?MK#8C&[X0UJD['-YBF8/-A:)G:]H0%"P8+Y=.
MN9"HJMHQ"UDKU?ACP25?U]RG%M2J=Q$7Y@Z&X'&6C/VW=.I&1;=+Z;U=V[JN
M?@H]4AV>U>.XEC:=<A>MR*[*SMIN57K,)1W<=''47<4Y8SI_^Z$A'A^X!X%G
M.:/?(U1P.7/RENDJG<%L7/X%OAFJX/S_`*]YNRAM4S>(,SVQ?&V,J#D.3LU-
MDZ,Y<'2<,+42'</?2$S3U0$O6R6]&9.VQ:^_;I_+3LK&4[#F_F2(9E6(B<A;
MMC[1?8*SU&Z3<DW2</L?U=TTJ*4HK<JV"O8^%XT9Q0*)*%1>JB4>7V;)F-K<
M/Y@723&K^O0N4\6[XXMLUMB9.=K%4OVB^PT#8[!$02K5M89*&CC5!<9)A7G;
MYNB]71,=%!1=,!/T.4173:&8^4+_`#%_M7R#KY>>RIF?'H``"LYR'J=LW6F#
M7R[A<OCXJ<MD@)X]P]P@'01\O'F3,\+HL6>\9[6F9W*;&@[Z:SN)%7M!*)M&
M3(3'4PH=3IV(%A\BJ564%T<1\$O2]0?]GA9<],AE>LU>ML.SL-5GH:T0,BF"
MT?-UR48S<0_1$?\`S64E&KN6;E(?]HBA@X'.\!P'`<!P'`<!P'`<!P'`<!P+
M6=R-R-?M$,`W79#9:]-J'C2FMDB"X*";VP6NPO2K?<M'HL%ZR3JRW2PJ-SD9
MLT1#H4AUUCHMD5EDP\E;WB?>RV5]VC++E6T/9+&6L=/FEU\.:Z0\JH>#A44C
M+MVEQR(Y;^BG=\GOV*G[YZL46L<10[=@DB0ZYUPPKB/4>O41^L?/Q\1_KX$.
M`X#@.`X#@.`X#@.`X#@7K>W9IU;-^MTM>-3JD1X17+>0XJ,M,LS164/5\<1(
M*V#)5N,HDU>%1_#='BGSI/U">F=<B9!$.\!X'LC[/9CQ[[=&CETO]:JR`5C7
MO$L#2<+XQC4UU#V>UM6<3C?`V(:^R:_[P>/K?<G</!M4D`.N8SD.P#"'3@6M
M:=X!EM8M;<:8BML@E/95(A/Y,V%N!/E3+WW9O,TZ\R5G^XO'+5DP*]%UD2?=
M,FJADR=(]B@4I2E`"AVTUNO.9RQM<\+E^;9.!J;K+M5DW#991JX2/ZB3A!4R
M*J*@!V@HFJ3H=,P@/3J`@/3E^XL*L>!LLZN9#LVS/MVPL(C.W&97M6R&A[F5
M:TO!&US\_I*3-]PZ90Y*QKEN'*-$!`)5NFVJMX=@FG/(D=')))<=OCLYF,-S
M:5E*U6VNPYN+BIOEC#<M+'8M9J5IUZH]QA7=1REB#)5;4(WN&)\OT&5[9NA9
M(I[U0$GT:[+U[3)N$%%VB[=PKS:7)<!P'`<!P'`<!P'`<!P'`<!P'`<!P-/4
M!Z@'B(?IY^77@8O<Q^[!KQ4KY,X*UYKV2=Z-E(50[2;POJ3#1U];T![T6*`Y
MLS3)2D'@?!S1JJ@8');%8VDBD`#Z;-8_:0R<W$[%KM@MWNF[!**!>\YX1]OB
MAO04$<?ZO5R/VOV,29.42%,PL&PF78N#P/7)=L(&ZJ5^GS7HF,/8Y,)2GYU_
MBOJS[HITG[<.H4S*-;/FZJ93W/O;98'(7G>/.62-B#%==H`*T7C21F:_A2MM
MQ\RMF%;1;$`>T"=H<G\?U/<NTHV/L<XL:)Q^*\98PQ:P1*4B33&6-*)CY!,A
M">F4"!3Z_#*="I_9#J8PB'QYTUU]O#-N513V*PJ@)5)V:,02]@E&4?"02^``
M7M^8Z=GTAY<U,>4=>KWDW[]3;+0HYW[U14-<-QR@=1VNH<I37W$/4A3&4$P$
M'H'4.O0>G))<\]8I>O\`Y1C]"2D2AVED7Q2]?$I';@"C\.O0%0Z]`#I^KG?^
M/XO2,3I+-@K=8M[<S2W5>KVQJ<.AVULK,#9T#`'D!DIV.?EZ`'+[/B](U+A*
M-7Q/4,<3`V;"TADC6^V`LDY+:]8LLY!P7(BL@/4@.8:G3B5,E6_^TB[BED#A
MU*8ABB(#S^3XM=I)IB7+?O\`HR*87]U/W1]>U&C$F;L9[F4=J5)/\([54U''
M.3RLDU#'5;Q.?\(1S.,7DE$NU,KF?JCTOF8Z@^`AR_\`SW_W0]_T9K-<OY@#
M4'(LQ7\>[10=RT.RQ87"$=$L\^+P[[!ELEEP*!6E!V>J:S[$\FFH(]$4YM>N
MR*HAT^3`1`!X[:W6^V]M2R\SIG1CY!C*L&4I&/&LA&R31N_CW[%R@\9/F+M(
MB[1XS=ME%6SIJZ04*=-1,QB'(8!`1`0YE6\Z\!P'`<!P'`<!P'`<"@6SNS&&
MM0,%Y(V-S_<&5&Q-BVO.;!:9UW^]<*`4Q&T;!0<<4Q7$W9K))KI,8UBAW+/'
MJZ:1`[C<#R`?>(]WW.?NU;#.K]<3OZ5@6D.I*,U]P0WD3+0V/ZVLL"0V"P%;
M'!E/9/M+9!-67DA`P%$2M6W8U02(`8@A'K^G^7Z^`X#@.`X#@.`X#@.`X#@.
M!'H/3K^GAX\#T'/Y+[V_R1M=SM[D%XA"_-6)9SKS@)=^U;**(PD8O'S68KC'
M',=15+[RETHZ#;KD*F<OR,BB(F(H8.!V--M9IMM%[AN`M9$!)*XET9@H3>[8
MAD58CB)G<Y3CV9H^D.++$W0?)G$T5.M+#D19HY;JIF&N1;DIDSIIB;6LS4MQ
M%WXF4.8RBRAEE5#&.JJH/<HJH<PG45.8?$3J',)A^L1YZ+CPYH<@<!P-(E`0
MZ"`"`@`"`_'IY^/ARRBS+.6%LJ4S*:F[FEK>-0VRC8N*B,Q8>DY1*N8X]P/$
MU:1%-CBG),@8@Q]9V,IL<*A<;9#63,LU7,$-+G7B'`@CQV^/$S&YMFX9+M6-
MI,3;A87K>;\/R,FK`S+B3@K%5K/%KUS(6+\A5EV>*O6)\J4YZ/WG2<F8^GT%
M6$O%N0[T5T^],RK=1%93FTN*X#@.`X#@.`X#@.`X#@.`X#@0,8"@)C#T*`=1
M$?(.!9OMIO5@C3QE4XV^OK#=\P907>1N#M:L10IK]L/G:>9H'77B\9XW8.4'
MKMBQ(7ND9J05CZ]#)#ZL@_:IB!A#%O<\=[7[L.G#O>V_/<$X%>%/\M[>6K&2
M'C(;)&N"'`8S<O;RJ'C+??W*B"YDI&G8Y6A*U]GT'4G)@!^O2?'QRS[ET-!I
M%$Q/1XO&&(Z'2,2XQA">G#8XQA6(FCTB,`H^*J%>@6[1FZ?*C]I9XZ^8?.%!
M$ZRRAQ$W-322YS4NW"9>WX>'3R_9\0\O`.=+;>V6K_3_`*/ZN0.`X'7W]Y#_
M`)L="_\`IRW%_P"/,1<>?Q3T_P`HQ]<]#$ZB'"G`C\.GU]?VAY#P-N\;-I&.
M?PTDT92L+*-SM)2$EF3.6A)1JJ`E7:R</)(.HR1;+%'H8BR1RB'PY?TXYG+4
MVLF..U1M;-@=HM%)%N^TORHWK>/DWAWD_J)F1:<NFJEE]9959^%(0^9=WO6R
M=>J.#*`ZJ[A6%%<J?S$4HF!N<=O@UVMNO&U\>#WWSC#M<:#^[IK_`+N2I<12
MT;)ZZ;;Q,0:8LNL.4I-@I/RD.W3$SFY86O#`J52SMCH134$LE"'^;:D3$9!D
MQ-T(/EVUNO;JROE,4P=2B!@^D/$.9$>`X#@.`X#@.!M'SYC&-'4C).VL?'L6
MSAX^?O5TFK-DR:HJ.'3MX[7.F@U:-D$C'44.8I"%*(B(`'`\GG^9`]ZR8]RG
M81?!.#[0N72'`-C?LZ,G&K*H,<W9#C_F8J9S/,%+Z8/H1,IUF5615`00C3*N
M^A%I!4B8=9C@.`X#@.`X#@.`X#@.`X#@.!4G#F*+OG?*V.<*XSAE;#D3+%VJ
M^.Z1"I=X#(6>WS3*#B$%5$TU1;M/FWI166$HD12`QS="E$>![9>NF(,.>V)H
M-0\7+R3:!P]J+@)P_NMK%!90'C:E5Q];LI7QTU3!5P=Y8IHLE*J(D`QSK.!(
MF']TO`L7]OFIW0F#Y_8K+T6K&9_WPR');A9=CWAC*OJ77KW%1\3K=AGU%F[=
M=!MAO7*+K\:J@*:0EDUGBBA`746$W;323F_AB[>%\?-LG`<!P'`"'7^WZP^@
M?JY?%GJ96`YN1MNE.89KW$<)1$Q.T*6:LTO<HP-6F:CMSE#$E<C2L8O<G&D`
MS14%WL5KE$HE_$S1%,%KO1$54Q$\E&,.[COIB>Z=-ZW/#-Y1[Q4<E4^JY`H%
MDA[E1[Q6H*XTZVUUZC)5^SU6S1K>8@+!!R;8ZC60BI>+=I+H*IF,0Z:@"`CU
MYS:37P'`<!P'`<!P'`<!P'`<"`C^G3K_`$<#%3M?O?>2Y)L6G^B\+5\F;41$
M5$R68,D75)\YUNTBJ5@2,M%7#8*9@ETI&R9/LS(04J6-(A0;#.B8CIT,?%_X
MM2R6BA>"-;J=@63ME\/:+CFS8_*+5`F<]M<Q&CGV;\MG3`@DKC,T8DE!8@PQ
M!@`(P="JR;&"C6Q"&6*[==[@W6::L7;%7`@4`\.GATZ`'P`.G0/+IY!SIX91
MZ<@<!P'`<#K[^\A_S8Z%_P#3EN+_`,>8BX\_BGI_E&/KGH8G40X4X#@.`_3_
M`$?JX$O6>J0-R9P[2?0D"N:S,L[/2[/7IB1JU_QQ<(Q8CJ(O&,;Y"*MK%0[E
M$.TB*H/62I2G$H$7362$2"V_5KC;EKW;,]_MR^\_:JA8*;K%[B5KCI)&R2[2
MGX+WA48Q]9KEZEW?8A`8MVBB6H-H7%V9WXB"498FI4ZM;!*!.K&2_<NO#M\>
M^LSM.&Y<NT.4>H`/V@Z]?[P"`^?Q`>8::N`X#@.`X$!_3].@\#ID_P`VO[N:
M^MV$V7MVX,M*C'-.Q]9/+9UFH-XB$A0-?7ZKF._"!UDCG7C9_,CEJNV5)]E5
M.OH.>XH%?MU!#S0!,(^`"(%`1$H=1\`$>!IX#@.`X#@.`X#@.`X#@.`X#@=Q
MO^3MT!'.FX]^W:NT%\UCW4B!"&Q^Y>M4U6,GGK(L:[8LU6PKIG(NO0J*9Z\5
M[>T[5W(QZA?/KP.Z?[GTJUV$O>LOMKLERN8+8JR/,Y[;$0%!P,1I'K=+P-FN
ML!,(@59=BCL%EES6:,W$Z8(O6+^52`X&3'B2VXG8NM>NSOWCEX=%-N9RL=;Y
M=`.B#8AA_=MD"]?L(-B`"9"_`A`#R`.>GF3V^')M^`X#@.`X#@:T7"S5R@Z;
MG`B[<X*I'$A5`*8.H&`R9P,15-1,1(<A@$AR&$I@$IA`5YGMO1UTLAU&L+70
M/9]EI"Y24B=/-I7MWR#H2Y7.D6$P?F&*25N.>M&T5R`8K"M.F[MS?,:(K>DF
M$.K+Q#<3!&-4"\-IBX=)<S+.)^G]7]7,J<!P'`<!P'`<!P'`<!^GZ?KX&(S=
M/;;*MORA(:+:5SS2NYH2KT78-I-G5XUM9:CHWB:VE$(-ZC"K]\9=MK,K,2JA
MC^H+B*2"8#.S!212!$WNM-;M<1+<):PKA;&&NN-8O$.&8%_7J-%RTK97R\Y+
MN;+><@7ZQ*B[N66LNW=^)YG(^7+Y)G.[EYJ0456.8X((>BT211)WFLUF(QFU
M4\?'S_3_`$<(<!P'`<!P'`Z^_O(?\V.A?_3EN+_QYB+CS^*>G^48^N>AB=1#
MA3@1X#R\_#@.!#E&QEXF(L$+,URQ1$;8JW88Y:(L-<FFJ;Z&GHEST%:.DV:O
MV'#<QR@<H@)5$52E42,10I3`[XJLT'M-^Z!8,$6['^D&V%RE;/ARZRD=0]/=
MC+G)G?V*I65=(4Z_JKGRQO#`,C(.DTOEZ!:G1@/,I)EBGIQ?E0%7Y^\]N]UG
MAO7;/%[=L0!Z\RVCP'`<!P*`[3[&XWU&UTS+LQEN0^[\>X4H4[?+$*9RE=R!
M(AL(QE?C"F`Q59JT3*C>-8ICX*O'29/];@>(]N)M5E'=C9?,VT.89)20O>9+
MO*6M^@*WJLZ]$*G^5J],A@])$$X"EUMNUC&)>T#?+-2"<3*"8PA;-P'`<!P'
M`<!P'`<!P'`<!P'`^[5LN\<H-&J"SETZ53;M6S9([APY<K&!-NW003`RBRRZ
MQBE*4H"8PCT`!'@>T%[)&AS;VY/;@P%@J8CVT5DN5KWYLYU7'L*JIEG(39K-
MV-@^=?8]3\%1A6D$0W7L%*+`P"(#U$*(:931=D+MLE[BTJHH\9;27!+$FKGK
MK++)0FC6M<_8:Q0)F):N'3HT.78',:EDO*Q4P0%RQ7C#*)]4B=.NGK>F;9TO
MUYT8.`X#@.`X#@.!0/9_7YMM#@^TX?+8UZ%=%)"NY`P9E9@9)&7PEL?C:1"S
M8/S!$.!;.3D+4[LV0+)H=HI2$(Y>-%RJ(K&(.?ES9,>(UK9%R6@6TCS;?6NK
MY(MM>"BYFK$U9<.[(XR,':KC'8W$THK4,NTPI17=":+3LC`[^)5!54'<(^9N
M"G,54!'@VO3X#@.`X#@.`X#@.`X&.?W`]LKCA.#H&"=>&,!:=T=G9.9J>O->
ML1%%ZCCZ-K[)-]DK9K,!4C=['#.`:^Y"3D`'HI,2:C&(;_OGP'326\3L6WX&
MP=4-<L:-L84Z;L%R6>V*:R'E'*]T.5?(^P&;+>H1UD'.F4I(!,K(VZXR`=K9
M`3"WA(A)K&M"IMVY2CU^.69MCGM<WA5_G1#@.`X#@.`X#@=??WD/^;'0O_IR
MW%_X\Q%QY_%/3_*,?7/0Q.HA^OP_5RJNHPEKS!YCP7L%=U;M1\>W/&5\P+!5
M6P95R`3'N,30N1I":2MK&9>KQDBG(65\C%IEB$_L"5;J`=0$0'E\NV))]VI)
MA<MG;6'6O!V.=F[4O_C)G&^PN3L+XO99$V1>8R?/8^H88I5]B%*G`-J?-$S=
M>!LMF65/&++1H.8XJ9!5#KUYRFUS+?1J<6]-[L[J9KY@2OUB>C:GE:V+AF+%
M.-&]1I.82W:Y9I"Z8?B,@V.LS<,2FN":UY*1L,R@C$QJCA\ZEXU05FZ(]Q3)
MM;MMQ_4-L)9L>CU9R)L#DC&^O=A@ZI`XJP8E<LFUJ\YDHUHE<;;"MJ6YMLY@
M)I:)F2@5;C785R1%E-V9,JK:M.#G^<,7M%(FIOM)G&;U&;&.1\Q>13Y[%216
M19*,=.(V2+&R+.9C22#!4S9ZG&S<:JM&S<>5P0WHO&QSH.4^BB9A*8!YZ&6U
MY!P]CKL!<:[.T^V12,[5K-'FBI^&7.=)-^Q.H54IT'*0@XCI6/<ID<LGJ(D<
M,GB2:Z1BG(`\N)>+UA=/W_AV9_97]PZT99C93239JY*6?97#E51L>*\J3PI(
M2>TVN+)TE#1EW?*D%-%]F7%CHZ,)>$"E%9986DK^\*_4,G\ZZW7BS#L[`_AU
M'Z?C^GQY!'@.!`?(?/Z?#ZO'R^/`Z'G\Z%O\I`TK!7MS4.;3(^O2C383/K=D
MX:*G_"<!(O8?$-1E4R^NLFC,6MF_FE4#^D<!B6"H=R:OB'GFG,)S"8?,?/X?
MU?#@:>`X#@.`X#@.`X#@.`X#@.`X'89_EE]`_P".7W.<:2]I@OO;#6JZ2&Q&
M3C.4N^->R=8DFZ6*ZHY[E$B++SV0C-7)FXB;UXZ.>=2F(0X<#TF/=>R1<$<!
M5G4_#TNO#Y_W]OK35''4LR3*X?T2EVZ*D9;8G,WI&:NP1C\08"BI^3*Y,"9$
MY,6*0*%562ZA/]4IE.QS4JAC?'<2G`X\QO4:QCJ@0B/>"</1Z-",JS58XO>8
MQQ,A#1J7J"81$ZHF,;J)A'GIF).'.]N?X0X#@.`X#@.`X$!Z=!Z^0^?P_K^C
MZ>6"RZM6(VJ?N9U2R*'+&80]SZ!-CRYD,+1K#P&_&O5-6E:+:>]=TT1:/]C]
M:HAU&.2HI+KR,S1VH&[!'[?GWEEPWKTS=!T$.H?'ZA#ZO(?'X<RTCP'`<!P'
M`<!P'`IWEK*M`P?C+(.8<J6:/IF.,74ZP7Z]6F4,8C&"JM7C',O-22P$*=5<
M6[%H?L23*=593M33(8YBE$,'VKD+>LD2M\WLS_`24#L1MQ#0A*S1I],WWAJ_
MIG%OU;)@'6UBU7.?[GM=D0D"WC(8I@D=[:)5-LJ4$XU%)+M\>FVMS9X8VLZ7
M>?$1^G]/V<ZVY8.94X#@.`X#@.`X'7W]Y#_FQT+_`.G+<7_CS$7'G\4]/\HQ
M]<]#$ZC4JFJ@R))*H."1JCX8I.1.V7"/6E"HI.#Q2#T4_EG$J1!=,YFQ#&7*
M10IA+T,41MXYO2N=;7&S1].M&/64VX;T>[S56L=NJORS4[*?G:*JNXI\FY45
M;G?-W5<<.E#ID1.F0YC?O2G[0`.>UTN+WA58E]I=F7<!D!A(9(D9:KY:LDQ-
M9$-.4.D3L;9KA-U9A59U\WEI6JNR5RQ/J<P;-5"Q:S1<C9(J@%*;[8\L3\KG
MPXV+V:V(A[3,7:)RO,-[=8K%1KA.3J\-5Y!>1MF,*[^$,>V15G(PKJ/3EJM5
M/]WIJD3*+AMX+^J(`(;FDVG7&#.$OW7.&7<E6@EUNMZD9&XI5&?Q^,_$0%>I
M;IQ1+,HN:U5*20J4%",I..M)GBH2!5TSKOTE!*8YB"'.D]NL]K-SCCM2IND1
M-!8K1JH5I%MVIG!6C%Q\I#LUA]%E\\*2/H0Z"I@[$OF!2`PAT`1$.7W:]2G+
M>.FKIBY<,7[1VP?,U3-WC%^V79/F3D@`)VSQHY(FX:N4P,`F(<H&`!`>G00Y
M1\.0CCEW^0ZE9<?9BPE+MZUL-@6W%R9@BQ.53(L#VQ!BI&V#&]F.0Z7JX[S;
M555ZU/H'-Z1D'2*XAWMDS%X_[$VVQB>K?Q\3GMWO]*ML\>;OZR8FV;QH5XQ@
M\E5X',M5I8GI6+'MWAW+B#OV-K4U$B:C6RT*X1SR,=@)0*H=N"J0F143.;R6
M8[=%U`#UX$>!MW3ELR;.'CQ=%JS:(+.7;EPH5)!NV03,JNNLJ<2D2112*)C&
M$0`I0$1X'B3>[+N+(;X^X9M+LL=^X>5BY9.EX;&I%'1W"33%%&.%-QLB@!BD
M*B5S5(1N[53*':5RY5$!'J)A#'1P'`<!P'`<!P'`<!P'`<!P'`U%Z=P=?+KX
M_'P^/AU#KX?#X\#UC_Y5G0133?VU*WENXP(Q>8-SY%CG*R?--S(R<?C([)5C
MA&NK>NS:N$VJE4=*SY2&$X$4L!P[O@`7,46=_BP]P/9/:,ZJ<CB'3Z-F]`-:
M%#"BY82.5Y!Y"W'>;*4%U%T3YAE)L*WC@';=1(>^#E4#DZE$1UKI=OI$MD7S
M!Y<[N9P'`<!P'`<!P'`#Y#P+4-Y,/VO-^J66:IC4YF><J(A`["ZT3;<AE'D'
MLGKI+)98Q*9GZ;EBJ!;-+U]6!=$*J4'+*750-U*H/)\FEVGOUZ:EQQ61[5K/
ME6VFUPP=L=3`*C7,V8OIF2&3#YE!VO"+VB#9R4I6Y!9LJN@$M6)99>.>$*<P
M).FJA.OV>>?&.VU>N`X#@.`X#@.!`1Z?UC_1P,)/N%VEML]M%A'V_$`4D\/T
M.&A-U-Z&""J1HZRX\IMN".U>UQGU4?F>QIG#.D,,U,,EOEU%ZU3UR_OF[I9/
MFM9G9+TKJ\>NI%XY?OE?6>/5UG;E4"E3*HX7.918Q4R@4J1!.8>TH`!2E\`\
M`YZ,^/#F^'('`<!P'`<!P'`<#K[^\A_S8Z%_].6XO_'F(N//XIZ?Y1C[#S#P
M$?'^W^SGH8G47]XAD++7W7MCRV/I2'@HQ*U9>F[O/6!U4XZ%BK(RSQ%$S').
MI6Z=8")LC3%#.+316-_O,D:8I6GVC@(RS.MC2G4E#8(@%]LXW*:5L/DHMY-)
M8Q/CZ>Q;.5]:+FLLR,RS7HDRZ6?D>O'%0?)+6`WJG1+!G[&P%>`)0Y^R^,&5
M3-88_']MP'$4C)D;A^8IS?:NX6G+[R^Y"-3;=B+#K_!#2*?9FQ;$%GXB0F;`
MSL[1NU;+I-Y53YHJ;4K4X.%#%SM,<*HIF^I8B@\$X[R+2(0C2;V2C6-IIL$*
MTU]Y8GJV+JV]H688Q1N]6'YDV2\V)&=-55!<&18I&12%,0$O.GQ6_P!JE787
MJ^8&4)8SW%,M_9K[/:+2\`RQ]DR%I#Z.3K6K-1A+-;9)Z6`L/WS2ZW,H*,)5
ML1-%%)^F8JRH*=0Y/;MFV<0<'G*QW6>I%G7UPRY3*S3(G)FY4AM<P891H]`_
M%D[;,E3[NHW2QP<TX3D<L8[N&%E6D7621J;]NDZ27001174!0V)/U8JK6MJ"
M"3+L89TDNA8G&"=;GE^1=)G2>IY!=8?KIIW[R34ZK$ESQA8\SHJG[X%1_>?:
M$>>AE;OR`/40Z>/U=/,!\/']G3BSW<164;V2MG0U[W-M&K,^^%EB'>-&>RCC
M5LLHH2-J>W6.8)LME*"9D$I6,<VSQBR/;SQ`,)3+S<`[!,IU7)A#R?+\>VN-
MO%=-+G5W$`YQ:1X&(+WX]H5=1O:=W*RG&R`QMKFL7NL/TAP3O!PG:LT/6F-&
MCIF8G[PCR)8V-R^(<O02"U[NI>G4`\88W0>G0.G0``?'KU'IXCX^7CP-/`<!
MP'`<!P'`<!P'`<!P'`<#)1[1>C$E[BON":ZZPD:N5*98K@C:LOOFWV?NC#5$
M`+-D5R=Q\TS,U<2L,R&+9J%/W!(/T`*!A$"B'KO;\[#'TGTRO5TQ=7&+S)"4
M94L':N8W8-$"-K-GG*,I%XIP#18R*^PU-%IW*<8&<I=4T48QHNH8R::9CE"C
M&M>`XO5;7W$&ND1++6(<34Y"&LUK=KN7#R]Y-F7CJTY@R/)+O7#QVXD\@92F
MI:3654555,1=,HF'MZ\]&DQI+ZN>W:N`>7^?E0X#@.`X#@.`X#@.!N&;L\>\
M:/D@`RK-VW>)%,'<4RK58CA,!`>H=!.F'+]/46O^U.N7$ECWLT8]<"QFJFUM
MBNN(6`N&IR-=:MP8M/9/%39BW;MVPM8FMVNVVFOMRB`]I(7M$>H"`>?:6;67
MMTG3,#^GZ>7,J<!P'`<!P'`X>P3T+58.9LUDE6,)7Z[$24[.S$DX3:Q\3"P[
M-:1E91\Y4$I&[-@Q;G554,(%(F03#X!P.OKHB\ELFXSR)N=<6;IMD7W!\JRN
MR2Z$B4II*LZ\122^/=-\:`H5X^2195_!L.WG%TD%?05D[*Y<`4IEC%#M\>G,
MO=8VOA>ST#^OK^WFV3@.`X#@.`X#@.`X'7W]Y#_FQT+_`.G+<7_CS$7'G\4]
M/\HQ]?']7E]7[/+GH8G4?=5V\=12%?</';B`;R;J:;P"[@ZD(WFW[=NTD)I"
M,4$[=&8D&;-%%=<I046213*81`A>E5,5&IB%PE1A/QKC+&S-JU!T>R91L2E3
MJC45WC:.9QZ+EA&2S]S*R3]XF1-%!N?M()UE#$23.8,[7$SV)SL>NV2Z_7\I
MVRTPE7C6>#+S'XYOS%U:()_:V=ID9[\.-E:_7F2CN2DJLWFU"$-+CZ+-3UB"
M@*H@H!.6VWNQB=J^%0QYE3,<+>)B!$TU7M>L4R%HGWMCG%&[&IX]@AE;`%.I
MY7)%4W$Q('2D9!E#-P(=7TW+@YBE^T.I\F)-<<&',6G7*_T>+<S]@=4AG7(N
MJR\Y8[`C,+A'566C',`U<XLEA7CT%763)J6MT:VC6+$KEK)KNCF27$C9R=._
MR_19HH.=BS6,@==H@=1L4A$"KH(',U`/M`F3N*?TP(/AT`>WPYOV\^Y'+R,G
M)34@^EYF1?R\M).3O)*5E7B\A)R+PY")G=OWSDZB[IP9-(A.XPB($(4H="E`
M`J-ER!X?'KT^KS_JX$E9`_&$=!,;[C-8&>8L)VRK;`X4D"=Q54<I8;D/Q="1
M(+)!\P1I<XEN_@'9$Q[EVDHHD/4#=!S\W/PUK7;'Z<</0AUOSG3=FL!89V%Q
M^N9:G9KQE3,FUXBH@5VTC[?`LIH(Q^EU$[>3AUG9FKM(W0R+E$Z9@`Q1#G@=
M5:NH?2'](<#I2?SL&=5ZOI[J;KW'R94%<P9WL>09R/35`JSZOX=IPL$4G"(&
M`1:#8,DM%0$0$/5;!T'P$.!YL?`<!P'`<"OL)JKLM9+-ANEU_`V69JW;$5X;
M9@>M1=$L3V;S#6"N9IF:?QO&MV"CJX1)7=<?I"NQ*LF"C-8O7JF;H$Z0.B.Z
M-HPJ^V0KFK.>9O`$;"V.Q2&9HS&-L=XU:0%0=N6-JF5K@C&'A"Q=>>,EDGBW
MK>F@=(P'$!*/`T9%T2W3Q%CJOY>RAJEL'0L66M6N(5S(=JQ+=H:FS"UP:HO:
MDBRL3R&2BU5;0U<)GCB^J!GH'#T0.(\#A\[Z:;::O1M-F-D-;,W8*B\A-5G=
M)D,L8UME#:68C9--9VA%+V2+CTW$@S05(=9KU!RB0Y3'3*!@$0MIX#@.`X#@
M.G`])+^34T`'%VN>6O<$N\"=O;]C)5?%.'UWJ2Z2[#"E!EBJ6V=9^NV1_P`-
M>\EL10,)3*%,G6T3E$`4-U#-MFV>#:/W.:=1D>R2P][8%+99HM95$07B)K>+
M8BN3%7P9".2NF!VCN2P9@-U8+48J3@3MG5HCA62[A;J%WIK-KSTEN%XQ?(`Z
M]>GF(^8]?'J81\1$>O._$DDZCG;FY1Y`ZA_D^GX\!P'`<!P'`<!P'`@/D/ZA
MZ?7X#X?5X<UKW^$6>5R5#%GN_8:F#+(LX3<G0W(>)I)N@B"9IC*FFF5HV_TY
MW(J^!%G#/#^<9E)/J/?Z2/3R*///\DQO?PZSIFL`0$`$!Z@(>?\`X>',*CP'
M`<!P'`<#%%[S-NL2>ES_`%]H<HZBLE[SY6Q/H[1W<>]28R3%ML+:VT!E.=8J
MG17-ZM6P8RM$H/0H@4K/J/T"G8Y$L17JZBRK-/CT(JG52,B:A4(MHF1)K'U.
MI1C6N5ID@D0`(1%K!1:"9`#H``4`Z=.>KZ.37R!P'`<!P'`<!P'`<#K[^\A_
MS8Z%_P#3EN+_`,>8BX\_BGI_E&/KGH8G40_7XAPJJ^$[3C.CY`87/*%0G[PT
MK#1>7I$+$)5Y[&,\E-E$E*E:;C!V5PSC[96Z>Y`9!.),L1%X_10!R"C8JB1\
M?)U^5B=8_)F,T*%L]`3CC.MLO6>I6IR$7?)D,:G447HES>Y%B9O)92+%>O9N
MVV:4<)2Z<7T;-&O:+,!/U*'//$PJ;L:[*4C%D3;:'&X/A[QC>4KN9V]=>7N8
MD4,HC:<RXO88]DW%\E:I+1%1LM4AP06;LTB,PD&4*L9%!0CA190W2:^Z>Z]H
MY''^T,+5Z?6\?W2`MV3ZM`TZN!(N;<O7;+-W"^1YW[6=K\@E9".V=<PPI3G*
M%<AB,^Z;B&J"SXAS.W9^V^S59M9,++6R1T$$D5#^H9(@$$_<<X#T\@*=015.
M4A?L@8WVA`.H^/-YXPR^_('`<#ZHK';+H.""('06173$.@]#HJ%5((]?#M[B
M>/)MK-];K>J.QC_+DY2.OK+GO4]^Y.9QI[L?;X*E-11203:X,SHV2SGBI%J)
M3G4<,HQS;9F,24-TZ?=HD#IV=I?%\FLTWNLZCMK<ZRWMV'>\?I+_`$&_S<PK
MS3/YUW)8SF\^JN*T%S';8[U@=6I=#J40;RV2<E6ANZ^SW";N5C*,R$1,`?5Y
M=>!TON`X#@.!$/C^H?Z_#@=\71?:'2BG9[_ET*MDG$>.KAE^-TP78QNU4CM!
M-TEAK8JG8=B?_EFWXLCE#8_EI`J@JJ)??SAJN<\L4@E$$D>H6:Y<CV>3?8,T
M]3I&*H/,]AQ3KWM^G=\F1'N!5O"+_7!);::T6A1C9]45;.Q>;`O+14057;M!
M;'7.@X*4I%`(B4P7F;Z;)8ER7A+W`<.ZQ9)@X+:1;2GVMWEIL-LV*2G\5YKP
MS7Z]BU>VQN`Z,#J'HN&\\8?N[R!7>O'+F4?&8@^<-1CEQ<FX%JON1X\EL!Z@
M:DZE[5YGN6S^F%,V&/L-N=N3B#9?7O/6PF4-G<P8]M#).FZO8WR!EI_>XW$F
M*6[A1E*2]F;,26*;=NWPIM?W17`=3'-),,)Y4O">N[G)SS"1)Q8N-W69V56C
MLIKUL$D?EU+NQI#^3J;:;,MZG>1@X50`G;T'KUX%+^`X#@.!7W5O7>^;:[%8
M6UIQBS,\O6;,B5G'T"8$C+HQQYV220D9]^F4R8_=-:B?F)!X;N#TVK50W4.G
M`]J;K@;VO=#S!VI5S`6F.O'V"%/&L'SZN8OJ8=$P.X49,7=PO$FU[2]3%%]+
MOP`1[U?$+)]#L2WO%&N$1+9F;>ALCL?<+1MQM,<Q%$W"&;L\G:V,:.H59=RL
M2-PCCPD'2HY`550:-H,4B*&(`"/;XY/;GRQMW]%X8!T_IYME'@:!.FF`&6<,
MVA#&*3UWKQJQ;BJ8P$20*L\602,Y7.(%23`PJ+&'M(4QO#EHT*+-$07,N_BF
MWRJ8*O1>R\6P^[TA_P#+6DP?O&PQ"#@0$$5'7HIK&#H0QAXQX&U^]X+Y4TA^
M**<,:0X(C)%N56^ZA<]H'%HG*_?`1AWA"&`QD05%4A1`3%`!`>!R#P48PB"L
MJ^BX=!VX:-&3J;F8>$9/W;](%V+6.?RKYFRD7+Y(P&03044.L40$@&#QY!]#
MHK)'6250625;&$CA-1,Q%$#@;L$JQ3``I&[O#H;IX\#Y=>H]/'RZ_5P(\!P'
M`#^GT?MY9Y%B6X[AS2\U^UAFN/`B3BC^XE"X@F7G:F!B5+;'!.5,0OF:BA_W
M@(/;6VA`[0'H*A2"/B`<X?)^^NDZ9U2AT*`>`=``/#R\/#PYA4>`X#@.`X#@
M84-XIO\`'_N9>W_BI!<RC+7O#FV.Z%EBU4B+M`L3B`K>L^%I@#=#`C(1<SE2
MQ*(&'IXE'H/@/$[+Q,JRD``*4`\@``#KY]`\NO@'CSU7NN2/('`=?'I]77]/
MCP(=P?7X]>GAY]//E@AWA_5U^'[/C\>G(`'`>O3X>(^7V?U^/AR@!@$.H>(?
M2'B'T>8=0\^!JY`X#@=??WD/^;'0O_IRW%_X\Q%QY_%/3_*,?7/0Q.HAPIQC
M/8<F)Z*<O2'+B@(@'F8`_7X?3]/ZN,6&7W,U<$;*/%$5$F:1>]5XL'H,T4^O
M05%G:_IM44P'S,<Y2AR7B9%%IC83!<')?<CK+-0EK$90R"54H:[W*5Q<NDQ#
MO9M*MC9C:991V`F`!(<B8@(AUYR]^S6%4*Q7-H,G(IN,.Z3[!3L4X2*HVNV:
MPJFL%%.4XB":X'RA*_CA=F(=#&,C"&/V^(%Y/?M>NC"NM<T2W5LW8>\YAU?P
M&R6*EZK'&]/NNR%Z:)^`JE3L-T<4+&I9`A?L]Y62Z1>G4`-U#EEWO$J<>62_
MVH,6JZ7^Y86A.LTY*S0PW5TVLSZ<M&4&%(AGXY=U(R=$!!U^JP-"A(.)AJ\A
MB3,;Q8J"@.EQ.B)A6$.A>>?Y,^^VNLZ=KSUTOI#_`-P?\_.:O*2_F]+">8]X
M^WQAE?4)4M?,%U]-,#@;T"NH>7M(IB7J(D,8]C[^@^(@8!\A#@=7W@.`X'*0
MD5)STS$P4*S6D)B;DF,1$L&Y#*.'LE)N4F3%H@F4!,HLY=+E(4H`(B8P!P,W
M=Q]J#!]`R%GHN6-R$,.:\X,V#Q[I*WS0^Q;*Y4?Y"W$DZ`TLF68*,J%1E:\I
M6,-8EEVDHK*3[URH^3C$V@-V;YZY,V1"WK"OMD9#O6Y^T6C%YD)2+S/KUC':
M.?CXBA0X6P^1\E:^U&;L5:JE<3?J0RYJ[D9Q&)G2?J$26;QRX.#HE$IB@%M^
M9M$-N=>_QXIF3!5XI;/&+K%3:]3"R$;-0$&3.,3.3>'Y-.PUR2F829KV1HZL
MOQB91@NYCG:S-9`BPKIF3`)YP_[?^7+]L#G;6C)/S."LHZ^8!V+SG>:W=H-P
M]F&*NO.&I[,DI1GD:P?IC&3=BBX,&I%5#F*S46`RB9A(*8A7:"]I[(,WFC&>
M)T,EL4HS)'M\-M_4\C?@&TGJL%`N-5[!L^IC*0<>L1JI,MF5?4@SR8.",OG3
M^IV#T]$0EF>T)POB#!&/KKLGN%!X<V*S5@<VR6&]=&^&;QD!@OC.;BI"9Q&E
ME[*==D$VV,;7GN-CA=5IDWAIQ)&.>,'DHNP;O"F3"@>\.M,'K#E^N5ZDV27N
M&+,IX0P9L-B"T6%M&L;'+8[S?C2!O#%M8F4,JXB6U@JDV^?PC\K90Z!G4:<Y
M![3!P+..`X#@=X[^3'T"_'6:,U>X;>((%:UA>,6PKA!T[3.!'&4KG&(.\B6.
M/*?H0RU2H3M"/*IU,4QK"IV]#H#T#MJ>X-,);';1ZH:")D4=X\BG"&]VX;-/
MY@&LAA?`UN8-,`8HE#]$FCIMF[9T(Q59OZ@G4BJD_*HD=!0_-:S*6X79NG;A
M^Z</79P.Z>*JN7)P*!`.NLH954P$*`%(43G'H`=`#X<]'C$Z<WQY`X&'/WX#
M68N@-+&DJUYO=!W\T8+3%K@22/4"6HN72G@#6Q.&.G,K5E*3],STC0P.A;@?
MTA`_:/)O9B>O_G%C"![AO\3Y$_YA!/<UYK4ZS9^5/LVHV)3`Z64H?`9H%7/1
M_N%&5)D62>WI*.-"J%">'UQ(*)E10[?#IRF/'37.>%4<\8<H^0Z7[3N(<#XD
M]HS-\C;M^]M1E<+ZMV^^RGM_9#N,?K*R?PT+D^<=LK';FF1_P^S:>H!FBS9)
M[\L':#<5#<OC'.,7_P`4G:A]RDM!I+V<-/,`9=:T7(.[N;G>T>O>N\?LG?[#
MB3&OMW6E;+JZN?%;).V^Y2$-CO&>HSEDU1K+UZXE;-8$_09,4P;+N&Z;QBJR
M[Y)R]OKBC(/M#XITV_*W:S7"5J(T6NYTF-G;!#1N\:6/]5G#>:F<\+PF+;Q'
M4JHQ%I@G$M7Y4CN8-)/VZ*9B)G,*H:YQQWA,1GL:F6,U9G=$32>*,F2CY%%4
M7#=O(J-$#R35HZ,4AWC)I('4217$I!72(502E$_:'3QBR,_9]^0.`X#@8^_=
M('[LTY0O:11!]A_<?V\\M1SCN$IF:E:W(Q1&2+@I_(H_<M@<D$3?9`IO'PYR
M^3]_X=->F>WG-3@.`X#@.!`?[?T\_#@8&95VK=O=VW@L"_8JG@_3/2W!D.<2
M?:9+Y.R%G#-UF3*J)>TQW*$9%&.'][M`@^70.)V7K"Y_KU\O\W/7MWPY(<R'
M`=/'K]73]/CP,=6VFWV3=;]M=&,8U7$V6,\8XS_1=N9C)^(<`T*IW?-=BE\0
MP5)<XYGJHI;;33$(2O5:1L"ZLP*4B4SE(Y"BBMT*4&V9CZK)*QZZB;W[\;6Y
M;]NRDDNE[3KN?-0*!L7L*^U\U7P/D.);SE@W&ROAJ:?Y5DLDVFLRV&<7,\<4
M5I&NG=53DY-I)@NY2:F,`F&9O!)&[TUWZW6V,S1DB@7'...<94M]AW=C)3'(
M^<-=,?4;%F`X?`.?Y/$>.,MX"MS6U0;W;3'E2C8MS^/T;($>A"KH$676Z!V*
MO=BV>.4QPG>G^YQG;`VDM1V%V;HV4=G'67=NPQMK+E^EZRVG'ILT:=S^4*AC
M^H;`9.H&-HAY!8LOM^92\H^QW!+_`"CN])M6:3=N<7(*\>ZV>IPSD0DRTL4+
M$6&.C[1$L)Z,:3+&*O-:DJ9=HUH_3]9%A<*=-)-YBIV=H4>U[&NTR.&:W5-0
M"F`0"CE>`X'7W]Y#_FQT+_Z<MQ?^/,1<>?Q3T_RC'UST,3J(?I_EX5$H"<W8
MF`J*#T[2$^V8W=TZ="E`1\?A\1XX\8&RGI**JK$\G:YB%J<8F7N4DK7,1=9C
MR%Z?ZSR<>,&_@/\`[77I\.#SB=J5Q6>\7VJ24@L8N[SGNQ)JD;A`:Z8LO^9G
M`N#?^DK-U>$&HLR@/FHM(E3*`"(CT#G/?;GC.,>%DN.>U=J_@G>[(*9'%8U&
M:8DAW)1,C8ML,U4['[HB8E`2.?RSQF&0[XKW`/@F8[90!*(#T'IS%M\9[57&
MN^W=L'/@BKE?<NNX^:JHE%W7]5\&1J;T#`;]X5'*.=WUGF2G(7[/K(PZ8?ZW
M;X\LM\VBN==]K[26-=)25^H>1-D[`04ECS&SV9;YDV/.X(`""R>/V4A6<=-P
M`P]Q4PBS)%ZAX#T#EDEW[MQ_72+VJ)2:'BM@6)Q3C^@8KB2$`A(W&E&JE#;%
M*'=T*;\+Q,8NN`]WB*IU##\1YUQ/2(FE=9=T<572ZSI81$16<JJ+J]1\Q]14
MQC]1_7QQX)]>7SZCX?'Q#SZ#X?MZ?#Z^.A21]-C1-W?:PR20@"9MMQD+"CU4
MP_8"+V*UKR57R(G+X=_J3M+8B'P!0A!\1#G+_8D]DN.<NVO4KM8>F7_9)_\`
MAYY%>2__`#9H=/>KSJ/3IUQ=KX/B'3K_`/2:N%ZA_M>7(.MAP'`<"?<5W=?&
M63\<9):LTY!SCV]U&\MV"H]$GJU2L$?/IM%1^";@\>!#?4/`[#&Q^T>A;_*>
MY&N>P=@RQD#7#)/N$,?=`P/F?54N/[5.VI+--)/*W?!EVBKE:8&-J0S53M+6
M+^\TE'$C5;+$KD=Q[Q/N2*%F^-_<KI,S[A.X.Y&PE/R"A4MOL:;98TFZUAR6
MA"WBAP^QE&FJ!7"P,U/&A(N05HL%(-TUU3E1"0*V.`I%*L8@!D*U5W_U7L.>
MZMB)=E/2?M\ZL^VY,T":?;&3]7HN3<P7'6C,%DWAQ1<F=4AYVUU]C=Y_:%\S
MJ-:JL<\FG05.5=ME%SE<NC)!B*U@WG#&^S>TVRF<H^QWFU;,:^;P8\FW%6)%
MI.OS0VYQ+D"FMK([0E7K%NA78JTW?YEZ1(YEDFA#`BFJ8I4S!?57?>C6@LC8
MCCU9O97^%FD>U>31"TZ\M+Z0E#GLJK:96K7R5R(UQY^)T:.K5'^4K`G8!7<)
M$ES($]8Q#."E2$+:LS;*Z,[9X=Q!<,^,MI*GMU@K5.G:N,:_B2,Q9*X0S..$
M:8>B:[9!F+C;9MO<<7N(RM,HYA<(YO!3H2I6`.6"[-9RJ5,*?>Z7?:/8,M:\
MXIH=L@+Y&ZK:0ZL:U3]UJDO&3]4L.1*A1#6_*(UB>B'CYA.0=?R'?9.'2=)J
M"17[O$2?8[>H8R>`X&HO3QZB`>`^(^/B`"(``?6/`]F;^7_Q?C7%?M`Z+QV+
MXX6,3<\*0F3[,Y5*B+V:R%D)5Q8[Q*OUDBE]949YTJW1`?%)FW12'^YP*7:&
M.%LM);6;L6I)#\RMK=J<LT51D!2&<XVPEI;>;7KAAC#BBI&S4!=,%X*;M$H)
M0$AYBRK&*8P%*/.WQ3BUC9?P``'ES;)P*(;&9T@=;\3N\HSD#+W)Z\OF*,34
M''U=>,8^Q9(RQFW(4%C7'='A7\D51C&J/IB<%VZ=K$42:,&:ZAB^`<9$KEV;
MP3:MJ+%I&@TL]MR[2J'.Y:G7DYB21'"J"%`L5:AYF&K5]N4>E"W#)=1E;;&.
M%0AFSM*)%<"F>).BF2+,Y%:2JX]MDUD6MBWQ[;[+67->K.9()]`UJR3L*^DH
M=O:J=7,KM):+>+.%UZ](I2<2TD_F"I-'!%D"I]P#R_04\R%,5+`5,86.EZQV
MW*4DG;FS&HXLU6POCIQ>SVR<9.DU[,P146H=0QY&H1+$Z,I9WDC'E(D*38ZQ
MQ533%/TSCH[25CW+FJ>>,%5+8U&M8WB<4Y!N3ZG)*9VP[1*Q8H#-3K(:^*[#
MBR\UVRUZ3-"9D<9=8&@7*'>LI+2Q$S%7<`=-09Q;F]KS%RJOW-1X&5(X_#="
MJ-1AG"\V#HT%1Z32ZY!E%=XN_%48BKU"!B!ZG5,86S5`1^`CXU$H$RUB%2B,
MLJDS'A\<5R;&1E(W*?YKX_+C*3CX?U1F'<=?U+$6J/20X('%X5-T95H4AA5*
M0`'B69$^(+).$$'3=9)RU=MT'C1TW537;.FCM%-PT=-ET3'1<-7394JB2A!,
M11,Y3E$2F`1H^G('`<#'Q[LYA)[:NU2Y1[56!-?Y5L<0Z@D\B]H<,/&BYBC]
ME0B*R8&,0W4AP#H8.G.7R_O_`!&]>F?#G-HX#@.`X#@0'R_:']?A_;P,!&('
M8S&_'O'31C%5%CG[3*BI+`F*8D0K>F=7F#,NTXF.8J#BSG4$X=$SF5'H`"`\
M[:3&OW2KKP\0#]7-N8/EP)8F+K2:XXDVMEO%)K#J#KK.X3R-IM]>JX0-1D9)
M>%C;9/.[!(QL?!UF5F6:K-J]=K(H.7:*B21C&*8`"9$CE<().VJJ#QDLW:O$
M'S!PWD(]TR>I$79O6D@R479/&+U!4AT5TCG25*8!(80$!X$B/:WB^8RQ2+1)
M1=-DL\8GIMQD\<2CAVFIDO'N.,F.&M4O\W!1A'A73&E7I['(Q3U^JW404<H`
M@FH13N`1FJ$KZ!:0.93$,T.J&*VLUKW%QL'@R1B$[G`.L40D/=GV3(6$K1(&
MU1J:T3'Y%EG4XBVD"O$C/W*AC%,4W9P.:F]2M.;A782DV#`N%++5*^VS0%?K
M!E`7:1<7G:7));%(,RQ5B1?'ALFV)N5:S%,H9NW?IE#_``BI`*#`^>.=<],-
M=ZJWQCC+&.`\6TG+-^@,B1./GMMCI&*R9D_'Y8E6GW.C1.1[K.OK9:**,3'K
M1:E?%<K!9JW62("A"&X%T:ZCMTHY=NCN72QU3JO7B_J+*G<KF$5%'3A3J85U
M5!$3"<W<8W7@:117[B$]%4IU1[4BF(<!4-U[.B8"'[P>X0``*`]3>'GP.(BY
MN&G"R2D',Q$X2$GI6J3AX:1:R1(2V01TDY^IS!FBBH1MG@55B%>L5NURU%0H
M*%*(ARRS[CKP^][>:30-FM$)Z^W.KTF%0UTW`(I*V>7;QC83.<@8F3:I(%/Z
MCMXX<G1."2:*2BB@D,!0'M'I)B7-Z/#'%5[W.Y0_=X!P!L_L0<_9Z$OCS"M@
MK%`5!4>TBJF3LM#0Z@1IU`>JR2BQ0`.O0>=[OK;C7FX9FMG%PK_`ZC;^V\Y5
M)"CZTZX1IE2=393RM/9QOB#40'J8]*PK&Q]80>A_^DM.'3`?`QN@\Q[;?'/W
M7,]5=(#VR7\TF0<Y[I9ZMB2@B5U4M?:S0M9*<J"@!_AQEXME=,DK-TP#H!OO
M5!3M^UU*;KS/\>V<9N?Z]%S/*O\`0O;PT7QN\3EX/6#'MHLR)B&_'&:%Y_/U
MW542-ZA7!YS+4K9VR:P*AW]46J0%'^Z```!SIKK[9SVF:NPL$M(5;'5\4K#A
M"LDKN.<@3\*VAV3.)A8V4KM*G9B'>?<<4@RB3MX^18I+"D*($,4@E$.T1#F\
MU&`I_P"XMN&[P!0;X^J.0L+V-][2F9=HS9&R!%X<FH'/V<*A:\:0]>SGCF(J
MRL\X@ZNT:V5T@6)EF<<BHNY*=5F<"?9\UNUF>.L_VQ_7V;QRFS9;9G=W!F/]
M?O0R3M\C<+QB'<G.5]:*XWTKR5FY@RPGCFB6''3NSQU%3DL1):X0<O,NI6P'
MC#JV]""6<&.@=5)-,MLVG/W/^%T$7F?8R2V8U%K$'LM3,I(6S#58S3N1K]B.
ME8^=8!QIB&1Q%$R[.[T#*+]9+*%GS)G_`"B\../(%-R5=XR.B!VB+(/5--+G
M>3U2\17G4G;.1V@>YZ82>!LV8?-B#-]\QM%RF2*`>I0TE!U<*\FPKME>JV*:
M^1S]'GESK3\"@0&C%H**B:IQ,8.>CNIC"\?A#@6Z;%.TH:7TMMRG]^G^Y?HE
M()'[#G$GW_E9:D.NA4S%4/ZK&T*IB!1Z]IQ$?#KSE_L?LGW=M?VNW5SQJ\IO
M^<!K2T)[P<Q+J)'(C<M;L(SR"@_W5A8I6:K*B3KX@!#UWM'Z^!U:^`X#@:B&
M$I@$H]HAY#^S^W@1$YS`!1,(E`1,`?#J/F/0/B/`NFT>6UY:[=ZY/-M$$'&L
MK3+](7SFBZ2L#AHKC<DP@:R)/&]4,2S+LE&(&!8C`?FC)]P)_:$.!V`*;J9C
MF\;05'--HUZ]OR5U;NNHNQUYUNS;@-#8&']O>L9)Q!<6D$3(V_$5DRUM\X56
MNX[F;3'P,TR*FD1>8FJ\#=C-(KK-G03O-ZR^WJ&RF?<"?D3BZ*R7F['>#Y[&
M$,U2RC,8ER'3;?JC;)2[Y_\`;QO,#+S<52,:N=IDHRWDE[S)I1L+BJ)EA=>B
MHW=PQ0Q`^YEK`I@6+P*;'6)J]7M?Z[4$,6QV8V$U"3.1LUY>1BXW(UVO^>8>
M-G)B:Q+9<@0MVCIVE5"81CWL=C5Y"F.B=V9^L8,3Y1$OB`B!@$!*(>8"`]>O
M7ZN!`PB81$>G7Z@``_8```!P(<!P'`]CW^7&M06_V6-#GXJ^HM$XXMM2<=!`
M>P:EE:^0#5(1#J'V&,>EY]!#KP);]NA!:)QCMG2%>X/RT]TGW#ZTF03=P$;6
MC,Y,J,NP!Z]B2C*^$.`?0;K\>=OB_;M^&-_"_;FV3@6`>Y"*T'B/6S,BY'BU
M/UA]Q+2[/^64V:8K&8XFB[^\QW:;8X;$(HJXCJ([R(TEW@E`PH-6JBPAT)U"
M;<K&QOE/V<>^Z/CO+[35JY/M=:'K3FG5*5SBVRUA9JT%?+N3*-D%#+4;1%KF
MID):GU-O5EV2R1&(2PR!D5$&ZR!?4,QGGB9,^%(Z3JP?V^;COINU-9KVNV#A
M)%*#NV*\06'-USRE.9B?1V(J?BZ,J>5*LI67`VC,,]DEJE$TV0(F\^YXA=L=
M0`(V.472+R-IK'N+#:[N%=0\2)3VT5O)38!Q"O[KC]JI@*/LD<BZR7?F2MXF
MJW2<HWS$ASJLH*+5=H1LA.@@\<%.R141/KO7'U68SRL*OWMSS>==+]<,'U9#
M9K2&3P'E?&3]'#UFVBAYES;:M3L\U[*^1<[Y3M6(75WIUWV-R(HVDI^OR:;@
M%8RRNN\Y6Y0*`9FM\);%TNZ.MUUR1JWC/$N+&D[L4MA?8'7#,%CQ5G._LE;+
MN+C+!]Y7M%HQ)E#)%J!.O3=UM)'",FU//>G$2<G$MFKTY43B?C:<?I]&I>>5
MF]8T'OV0,_TS+F4=8<>XZP/:/<VD=P[+J)9I;&]HC,'8WA=(;%KY%9"NM4K$
MC.8TD\P9CS3\E8I:O5U65:,!%NZ=*+.2.%"3'&/"9X9M$$R(H(())I(HMT$6
MZ"""::*#=!NB1!!LW12*1%!LW13*1),@%333*!2@!0``TCZ\!P'`Q^>ZN`N]
M!,HUTA0.XOF;](,<,R"'457=TW/PC&$23`P]AE#)E/T*8#D$`^T40Z\Y?)^_
M\1TUZ9[.<U.`X#@.`X`>!@'P^T&%WU]XZ&.8"F?["Z;7A-$3`<_R]CTOJ41\
MT!Q[3>DLO63D[/[I#)CT$1$0#MIS$JZ\/(.=.G-`W]TWAU\!\`\Q\.)B7GH8
MKLKW")H>:O=*F[3K4KMWD1JI[>DS@W!2N.@R9'6+'CW#T[7\86VTU\T;-*H8
M8QEF@UKD[%(,V#Y=AZ2R2")I!=#I+]"/CA[#NS^/,?>W31M7;_6V>OF)X;)D
M3F%;..#,J46UOI>5A[J^E9&VXLD;A59ZO8GD+W8%&6.:V=D9W6@28.EU5VA.
MT4R)%]P."S[%;6)Y7U\K^VZ-U-H+'8RU\M.O5;-.TFP[6,-IU[Q1<0;(S3=@
MO$M<9.*ZJI(2Z$^+&KJ0BK\[I?YHC(@K+QC`N8U7M&Q$OM_GK$.4,BO[!C[1
MJ=DJ7,6YK(QS^'SU;-H)VOYLPK^)5VQ1>%D-6L#G=08(+E;+^N\:.%"'*8@F
M>3PLBQMK5M@%CJ(T.2M.MSZ,UR]V>"L-ML>#*UE-E/GS!O-8LAXTQD$?:YV'
M3JT[E.GN23<0\;&5<OHY0`[/2./,W-MOC@;W5W%,7B:SU)KMOIAE?+MGR3J]
M[<=$U8L;77H<VQ^#XS"&&H6NY1UYGYUP*C#5:Z8OSR9Y<YN5=KQ"<NW62<$<
MNU&9$@UBYSX/"Y[9&T[/I;^:V0>+H/8!OCF(R1KBMDBX04K<K/K;EC"-YL%N
MB]FT)RGQ$`?&==<8QCT8X\S-6V0"Q*.7+-:";IH$5.=R+1F0^Y?3L6L)F3M>
MZ%J<Y)UVQ_=MCWAF$58LIXGEH3>MA4LMQ^LL"T9IC0,UH:0/'KEG#PK=21D8
MULG*MTEI8A%59R<+_/;OI$]1<(YK;ST%F&%;73>3:K*5$=;`QSR(S-<\47F=
MK+K'61KZSDV[*86DK;#,^Y->001E%T$2&>IE<^J'+.N>Q-VWFJ3?92L4^T4-
MQ4:9MIKY-2.0M2\OVZ!9SE>KEY=QRD=8,5Y,9.D%?O3!&<(8YH6R-P^W''50
MEFW:Y9@86W,EG<)]5K^(\UGSK2%;,O!63']MJEFE\:YGPI;Y!5W;\"YMJ942
M77$EK2,?]X>+,<CN%D2%!M.5]RT?(&,"A^S6EEV+,*B@``'AT`/AT\N=F7$6
M*PUZH0$O;+=.1=8JM?:D?3UCG'96$/#LU73=BBX?.S`;TP7?O$4$BE*8ZJRI
M"$*8Q@#BV3M6RCKK2)JR6:EPEXI,U<Z0"'XVI<+;J]+6^F?-*"DW_%E9CY%Q
M,U_U5OL?XE%/L.($/VG$"\S[]1N;5*UVMUNTS-ZD8F`ID)`2[J\2]H5(QKD/
M4P8J(V%U:'#@`2:P'W:Y,F\%0.P4%!`W@/'OU2^['Z>*D][@W"[V"A:Y(88Q
MN^JL1C-SB2M0+VGM%X&-PI;`8OWV,81FJ0$VV,K0#)JNI&E_<.103/YEZ\>[
M2_\`HO*5JM@S5_"S:-CJ=B/!>)6D2QR8\AH]C$0E:2CHBWUYG%9J=1Q)9Z/I
M0=DJ+5NVM1P'Y4T:F0'78E]KFL3%Z$N1^L.F<!;8&\1FO^MD!>\;P%<N=9N+
M:O5R%L="J-,8"QI]T82IY)N$%3ZA&,O0C)5<`CVB2/8FJ';T#EK[?=,1<V=*
MW4>T4*^0BEGQ=:*'=ZU8)N1>N;-C&:KED@)ZTJF3+,OY"6J2[EC*6I8Q4P>+
M+G,_4*"8J")>P>=68G'Y5UWJ)@U<BHCU]9,$%141[2]YO5)V]R7:3Q'NZ=`\
M>+9!P<C.0<0ZK+"7F8V*?W>;<5FDL9!P#=S<;(SBGDZ\K];3,'25EVL''.'B
MB!![RMFZB@^!1X%`-G&RTFSU2AVHE%Y+^Y%[?;5D4WV@.JWV`AY50.T/M'Z,
MX]0?L^(=.H^'7G/_`&)^B.NO[8[>7/$T\W#^=KQB:*VZTUR\@S%-O?-=[;0U
MWA4S@1P_QCD-Y-B513^X*R;')20=`\>P`^'3@=);@.`X#@.!4C$.4;%A3)5.
MRI4X^HRUBI,PE,QD7?J75\BTJ3.1)5NO&VBC72+FJO9X5^T<*)+M7C95(Y#]
M0`#`4P!?6X]VC;57(;"X-@PI$T2.P].:^HZRPF"<9Q&IJN%;18TKM9J"\P`Q
M@4:6]0L-^;(3[N45(:=4FFK=Y\Z"S9`R84ZO'N,[,WZ:RW/R4Y4(-_F#!E<U
MA?ITC'M.I$;CG7"L+L#-<'81B:U$Q\7B7'<PQC4V4NUB4459=BJY1=JK%?/O
MF0E/8W>K8G:BDX^H&7;+"2-?Q\JE*B,%4X"L2E^N;>IU['[;)>5I2$9M'60\
ME(8\J$1`EF)`3N0C(U(G_F'746"SW@.`X#@.!ZS_`/*76H;)[+V&H\RQEE*3
MEG/545`1#]UWY#?VI!$`#_5(TLR?3X^/`N(T[*:&SY[N=!$/22KON/QUZ9H&
M$>XB&9=1-?[:Z6*`@'[M[)L5U`$`Z=PCXB(#SM\759V7T<VP"/3@8T?<^V3R
MWJKA,,L8NS9CK%SR+@;:XAL?WC5>W;'_`,0>1(KY%U`XOG+1"S437,!8GDXQ
M8R$Y9)-1H#8ZY78O46S14AI<B9<H^Y?JQ@[-V`M?,O9/Q52LBY7IZMBR4F3(
MS60@<!RXXNJU_J\5)/4(]T%PALF2MB-'5Q^Q7,FY;I)NNY0%BDXRN,-WM9LC
MGC!&U&EF/</8SO>=&F9J3N`]M&`<;'QS!VO(-HQ92\<SV.YM3).39RLUK&D%
M3#3DB8[I1^0CYT];MQ0<F.F0&UQ,I.:DYI[K>KTCBZ]9=:UW+IZS3]8\8;3U
MF&=5V&:W?+U?R=DR>P/^4V/JP:85=M\S8]V*@AH<\QD!0:$FG[)5NLLU<$4X
M]VJXXRJYLIL#E##>P&FF*:Q%U9"+V`@-U9#(L?9(PLI-Q$WKWK&7,-"B8:8;
M2#9E'&:W81;39B@JD];I"B4Q"_O!NV?;[IT3M8?@#W>JSFP/:^AF4\A(W/8O
M'>6+]NS&!K[EVC1=;8XLU9MF:)D,(6B[5N#I"IV]WK?I$3B)*9!VR,()CZ(B
ML&/=?[+B97#Z[67W`-HL`UG9)?..#,05/9S`=\R5BO!%,P:J_O&ND7=Z389C
M6.Z5;820L\F[R#E2.>MHA];V]@@"U]\B\=-&:+<Z21U-8V_=(G$78:>9N=;+
MZD:P[#231JQG,T8*Q[?;0S8I"BQ;7-[$_==X38(&$108'N<1(*-T_P#TT%"$
M_P!7EY\]HN,X#@!\O\OZO\G+X%@WN`%)8DO;\P\*:C@<R>Z1J65TR2/XN:_@
MLM[V+L)UD@#N4:M4L:(>H(@)2B8HB`>?./R_]RNFO49X0_S_`.7G-4>`X#@.
M`X$!_3Z_Z.!@<DFAZ5[N&]-==]$4<UZ?:4YTB1$X`+M3'%XSE@^PBDEYG%N#
MN+!00Z#VF*'ES>N^)C'E%S0>7.][<T>)Q1\"-VZ#_P"]T&S5&8^[@AS32+9!
M*:-#%='?DA3S":99(\*D_4,X(T%7Y9-<YE"D`YC"+C'U%"MDMF\::N4VMY$R
MZK:W\1;<BUK'31"HQH6&P,3S?K.)[(4VQ7=-3-\9XIKK56:M<GW&&+B$Q6`I
MQ[2C!SU\V2UWQ%=Y/%F2=D<,8_R$R8.9&1HMCR(PB;",.G#+6`DFI#F-ZJK&
M7K;8[^,(IT7F&Q!^12<G*9,-36T2XGLCJ+`GHS@VQ6N=7+L.O7KIC^2_&M;B
M"9K"\/4*96<A,WC=-$]E0L,G&IP:4Y)&23([:IQRRZ2Q$T.9%O.0_<AQ?C##
M.8<UW*D6B'@<0.L^PBL'*WNB1\[;[U@38"$UI8U**BG#Y2=CT,E7F>1=,YU1
MBK$04:DJF^6!V":*CSCR*UTC<?",]C8V2KEE#&F*ZQ)Y'G\4,I22R[6;?4[I
M;:E'0CVSK5NRU0%>^"AWTW\LZ4FFD6O&D2!S(ILD'*!CAO[=MIB&G;"8AU.2
MN$'9LUY?R(O0I/'E7N$,ZL.)TRXOM&5&5RR-`)JK'-"25?K1$2-FRAWZ02;1
MRJF5LH4QGG`N/(Y7ZD5*LX(?U"."&!=4#D7*0"D5`Q3?96*7P[P\0#R'@04.
MJJ83JJG5./F=0QE#C\0ZF.)A'H(\#2("(=!Z#\!#IT`0^OSZ^?ZN!CDW1PW:
MZ9;7F^&#*Q,7"[U>HQ=:W'PC4T2J3^TFM=,*JO&Y`J$9U].7VFU:CE7$A7E0
M+\U9JN1W"*&4,5L47.EFWA>YAQ=:M-4O%9K-YH5EC+K0KQ`QENI%RA3&/$6F
MJS2'S$3,L1']XD5RD(D50/T5:N2*(*@55,Y0[S:7KIG']UM>ZAR-<)U.:E.S
M\#U/:;4>W98%4AE6;;%L)G*L&G927*0#&""A)IS&OGQA`2)MD#'.':4>9WZ(
ME)K`6ZX[GY%O!,/6?7I_BRN93Q;@')LO@2NS]!R#(Y"LU?LV9-A,RR\5-025
M[B;HK7VL;0ZLNX.LLD1S+O7"3I9-$F==9M.52JIAS94_MK9HP=DJ19Y0V$L^
MMF3*/6J_$P<5%S!K).C,?<E+DK">R6**OMF>*NDED)ERNW1(11)NJGV-Q,._
MXYCCM,K<K,YVAQ)7Y:Y8N7V2JM*M^4\:ZLX#PYM+<%+#E1Y>]C\#M,79$RTT
M;/Y&QRZU1PILI#M[554%G'IE:-YA=@1&+.F`<K,6Q5RNX.";Y9XFDU>@UVR9
M>_!NH.^>''=F>OFKV=L=TR/KG5\>T#[[DY)RT6=V#+ULBERD5\"*.C&%82$$
M!YW\<^B+>\MZI[*S*]@^^)6Z[6QI=5-%8B=KUKK6*\<N<D0>!MD6>2LV:80+
M>GH04#/2DI2V7S2:<T(-I95$C)9P*:PEYSNF++)U_7]>"?5?%D"U2%BUVS5;
M,*:Q94J$M/RQ5(/#\G`,-9\J7AB[F:^QLV1&,)BY\%EKXP%34<"5HT79V:=;
MQ)V;(Z8+-U>=;]$6'_E5NM/88D8IW+[1Q\_0,&[RRV$?N3)%@H5IF<OQ><*O
M,Z),;FG+62:M]K<JXV5?FB(JTR#XQXOO9S2RIR=G,;:^Z>5588X]SG9MP\/7
M[)-)V`DIW'NVMVODO>/OU(FH%7U=G=7W]1Q.VH5-1FPAHK(T3DB7DF4U\E'_
M`'RA)KN#O%E&:S7M:RSCZI<8Y]%XMZC75KV7]L/'S-$SAQ.^X/0+RY1(?Q3A
M\$8<R]E"4<JI!]LR;1VR9FZ].TIA`1YG_8O_`-<==.=)7;+]3_XB/]/_`.;G
MB:=-_P#G2\$.KOH-KWGJ.:E77P+L.$'-+]HB=G5,PU1]%.G`G+]HJ9K74X9+
MH/V1%8/'KT`0\RW@.`X#@.`X#@.`X#@.`X#@.!Z@G\F!<?OWVP<O50RP'&C[
M>WQN5$/[R*5AQMBF:*/3S[%553B`^74!^O@9-,3*#$^YA[ME7[2)EG$O;ZRZ
M@F7J!CDF,%WO&+UP8O0/M'=8Y2*(AU'P\?HYV^+/-8V7K`/7]7P^G_+S;()0
M']`_M#KP+9=C]?+YL!%.ZO6]N<ZZY4BU42T8MRY1\5T_"]P@LJT.Y`9O/F67
MRO3+/)T+(`0KA>,:S\.J4[9DX$?ES+)IJEEDO8FJ#UOPI5G6LSBLU)Q#ETZH
M,WB[75H2:>O6E0HMCQU!XFEHBQ$?`LM>'!Z+7&C=%S('.HBY!1<OVE!+RS$@
MDG8+5E?.EWPUEVG["99UDS+KQ#9>C<8Y,QA&XRLC)BPS3#UVOWK\=U3+<#/4
MRS12,77$!8INBH$:/C)NBJ>HDF`RS,P+2K-[;V,8W+?M1T;'E<3)A329_F6W
MV=_;LGI.,EY>1@V\)D6@4^Q4XY0>YK4LVSZ)<BSL@9'[LK\A%]Z21?7)Z;VS
M,G4JRKWLN:\TK.F5<-9/M5LG6UPUT9Y_9Q4+796NG;.2[3X;7QK<'.0F;HCR
M4A%HZE"I+PAU/DR*J`993U6W40WMBWGI(D2F:@XMK]6]OV$B[E;+56_;UKDQ
M#X65D'58FHS*T#:<)2N"W*F3U&;56)EHUW1YM5RD,09%NLN<``3-S"`\_;%R
MIIC[33).KU'GZQK)M3GJ?Q?C?'>76NJ&E>17.)VF(*E=[O6;$QH]*O6>%*<;
M--QP_CBRV`SN`82\B;[F133(=5X5N@D#&.NR7E<?JYA-GK3K+KQKLQD4IA'!
MV%\?XT=3*"9DD9N=@81%2VS:"9_WA&TQ<'L@Y0`WV@05(`^(#S7W[177@.`'
MQ\/K_H^OEG5%EEL;JY(]U#V],9M54'#/`V$]PMR;6P6("A4%;0UI6J6-'?0Y
M!*#OYNV6)5`0'N[2','42&$O'Y?^Y72?MC-V'@`=/+ISFJ/`<!P'`<!P,)^[
MD&G0?<[T)RBFBX!KL3@O;+3F=?&5(BR)9H.*JNSV&X\PF$`6?R<EC6QIH$Z=
MWB;MZ]3=+.Q68I@,4#!Y&`!#]0^(#^WGIO=<D>00'R']7A^OX<"S[8G3FK;4
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M@3)]'ZOT\?+@.!]F[A=HX0>-%E&SMHLDY:N4A[5FSA`X*(K)&_U3IJ%`0\_$
M.:S_`,##QF&B,-%LI+7"#;(5[0G9#)"06!H`^E5M'=N<FR0$))MA#[-7U/VU
MM"@$.0?\!3;^L)A]%E(D`,ZVS;Z?]5O/W;7+>P-'PSE[7S"62(>=8.-FK?9,
M<1=P<,X]?'N/9R,6K\5&-<N%=F4690EUM-J80C-P1)5H20<I>N)2*$$=[6]6
M,I7KFX^O\K5<1SUPR!&8DE,VI2:]&H61W*R%G10C,ESF(6[NSKPS62KU-AYF
M]P!H^/DI9RPCG3QPDU25,OW%":[8^PJ55LXX7NV1IC#M-RC4[/E>N'M"$[CZ
M(5DSST:ZH\FC#7F,]16-0AWTY1Y1RDE,Q[1TX>QI5DE5TB)*$./?6YYGJS<2
M6X<3;<W4^K;$8;UPEZW99/(.5HZ0FJ_8T(EF\J>/[`*-A:X[KUKE'Q#+5^ZY
MB&L3;:J@@)%U_NUR7N`A_'COGW5J<1)<CNSIY#.9=E*;,8LCW5?<"UFT57%D
M,2.7;V%:IR1C.6]>59NV58M"!F,Z[0449UM;M&35:$.0QGOIA-4]LK@R%L]X
MQNCE"H368*)6\DSK_$S&1=EL;R8Q?1'N0Y^DIRQHXU7;W$]::$>$8?.'>FCE
MOG4T56Y#'X_DOT,+<K![A6/Z_$8CD9F'AX&6RW<Z+!(LYN\O)5I2J_/:[QFR
M%HLMZ=46G6J7K<[7:Y*-XJ,AUVOKR[EPC(=Z$>*BB=_DIA<C4]C<2V8^)HAY
M>:G`Y`S15:9;:;0D[$2UG<(Y!;/7M*8?CR`8J4/YVXH1SD8'YEXQ4L`-EC,$
ME0((\?R4PH98]^L.H2>1D\:.6.9ZAAS%E%S'D^Z4Z<<LHVNU.TYX3PA;#1S.
M:AF?XB&CM_4L)7[)1:+F&+59%LN*A.[D_DN?"77./NO@UWIYKS[MVKE=ZG<-
MM8M6-FMD)=^V`18!-YJLM1UPQV13Q$45I:I1]F=M2F_O(D4,`#YAQ^7Y+M^B
MR8E==>-<3IV7/3'_`&Q_H#G%IC,]Y35Q3<CVQMR<#L(TDG9IO#,_;J&T%`'#
MA7(6,3-\CTIHQ(!1,#R3GZLBT((=/_W`AU*`B/`\4$Q!+X&`0'J("`@("`@(
M@8!`?$!`0Z?LX&G@.`X#@.`X#@.`X#@.`X#@>C;_`"0UF!QK5O33O4\83..+
M[.5(.H]H6>@RL6<_4/#[7X1*`A]7`SP2K9O6_>#V?9$,4#Y0]N;57(*Z?9X&
M<8[V2SEC\Z@&Z].]%K:4`'X]I@#G7X]L9GJSM.%X(=?,0\>GC^SRYT81X`?'
M]GZ?MX`0#Z/T^/`P,>_)9+_,:VY$P_(X4V(MNKJ&L&<,[Y>R3ANJNIBF6#,E
M*:C&:\X3RS9XFRPLM2<9TBQBID2S+@DHE+EBXR/^TD9T7F=N_'Y.NFTV?L6G
M>=;7I31DX?%V(=WKK!:69^OFRN?YBNXES;I/KEA28K5CCE'DY8+@R6A,S9UF
M6CRJU6B0BQS2S:;=2DV46")14S>;)._ZZ:DQS5"]K,82>`L][6,F%Y:W:DY(
MEV#;<&3I[Z4Q-=_R6WIVJB+?BC`.U^<G$C/0%6N-XL,^-.2L:+$%*#K^RD7:
M:*;J7BT3:LF<9O!]6>_5_+4+GC77#^7:Y1V&,X&TUN0B(S'<*[C)*M4Q+&UG
MG<5K0M&EX5G'0U@QDDXI9CUB3:-V[:1@3M5R)$[NT-YMF/$95WZ!_2'3]G('
MEP'`<"(%,<2D(`F.<Q2$*'7[2AA[2!X`(^)A_IY9U1;!H4V#+^]'N1[-%5^\
MJECZT8B]O;$$D)VBK<T5K!57ERSH[B?1`RB2$CGS,,G'.^IA`[JO]!$3)B!?
M/M<[9=9TS#AS(<!P'`<!P'`Q/>\U5)\FFIMC*/$.YC(^B.8L1[P4]G&,`D)5
MW%8&M2$CE^'CT2J)*"I8\!RUKCS%`?MD<B4?I!.QS`R<!.D;6"I/T)6I65C'
M6BI2;10%&LE5;1'M9^LOVQP_OH.X*105*(#X@<!#GJ<@?`.043S_`)E_(VAU
M^R,*>\R+=LBY<Q3K_B''C:=85)M<<OYGL1J[3(^PW.5;O6%-I\>*#A]*2(MW
M;@C5L*39NNY512,S)S>A;KCG=2TY+RECC"$5KW\ADAQ:MDZEL3\]F&O_`(5P
M,ZU+R)4,=97?5&6)72O\X(61W?XA[5V[=M#N5T7"J$@5HLW4#C.>?!AJR[FG
M-N*MW]:Z,\L-G1U?SC-66J2Z$[@VJH8K&89XHMMIJ./\39QAI&1R[>=P[A=:
MFHHQK;I@UKCN(!PQ2,+M)`5ELEXZ)%0-:]L:OM)2<RV6JU+)=#>8NM&<:;UR
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MF@DK."C*/45@4U%`^T'3DS]C"_F]RNU6M=+P#D#,>S\'L"SMFT>IE,O4;6<#
MT+$L%-T#8UTZQE<*S4#4]Y(KSM"AKK;(:?J+]QTF&J42HFY>/DW"G1+F*O\`
M738S)X[9G."AF;EPT.H7^ZH=NL=$RA0Z]`*<2=0_7RH^'`<"7[55*E?ZE;,>
MY#K$3>L=9!K4O2L@T:P(?-0-SI=A;&93M;ET0[3%;OVIOW:Z9B+M%RIN$#E6
M2(8%DO8P&6;6Q*H9ZIFGVRETL=^JC#!>RM+TTR!/ID4E]H]:KZQI`2U(N-N,
M<%XK<C0Q:G1CCU$2G<6B!18SI`*=NY$TSXO2WU<+&Z!R,5CH<4L-@7SBFY(U
M]QYK+M%)3F-(B<N>8\<XRS!;,Q0D]C^9=3YT,37RQ.KJ]BIATLG--CIB61;I
M)ORE/SKI)9RRJ^TU!J*CZHIV:Q/+74JSDC=O(<E2EX]:&;69ONJ]A'<Q6'=@
M@Y=A8XTF.DX%!)"0:N$WDN4`^8,GTZ#TF),3I$MV'1G'\[8;CD%I?<DU?)QL
MCZ_WG"$_7;?:FM)P3!:MFA5,(4%7%RUA<5W+C.NN$)M1Q+6`ZDFN%D=E*H7T
MR",NNM[BY?-]I+#OZ.[HY,FR;)J]P;O#@[YUM48M4&3'>++B>7+58VK55\)?
M4HS\GR"3+O\`2ET.AW)B"4"\GLU]#-2K5-1,DR5KRJGD'(<7!8C+M-E'/&(J
M+#TV#D;3-3UHU:CM:JEDZP9`;2Q%VM>;M).5D5ZHX9%>&>-T4#.RLC=O'LU]
M!/F,M-V&,IRJSD;E.>D%ZM?*Y>R)_AQA&&E%J[I&CI*2,<+-)#O;I.X)(UC,
MJ`&.1R86(!Z/[WE]NOH)!HGM\5&AV.INS62KWZIDHN!*GD>#R#0YEW.RDWKS
M1'F-JK?,4RM>OT'7<>SDI672:X$DHJ=^Y)=N5Y'F*910@O;KZ)G'+@[-I)E1
M3$-UQS&Y7B<J6"UZL8J]ORC(O*)"8Q8476F!S5'VV=N]GDVDM,N+WDZ.HRSI
M!1)%-JA(/TTCM$$A55#G/?7VW'T5FS]GZKM,AY?]PC<=NB*E8OF:JKJ/@]ZL
MD^3<+X4THK"U$>R3?YDA6QV5BS=:+<J"J!C$<?+%,(CT`1\N_P"ZNLZ9U.95
MI/V]ANX`,42B!BB`"!@$.@@(#X"`A\.!XM?O=Z8+:)>YMM)@YE''C:*_O+O*
M^)"]J0-%,6Y7.K<JTTCC)`4@LZTK(N8;Z05C3@;J8!'@8G>`X#@.`X#@.`X#
M@.`X#@.!WQOY'FXN4<D>X/CX[C_"2%(P#<D&G7S<0\[DN%=..G7Q[4IU`OEX
M=?KX':1S@S5AO>/Q:_$>UOD;VP<Z5L@]>TKIYBG9?#EU*GX]0,9HSMZQ^@]>
MG?X=.=?CZK.R[8O[0_7X>'7P\`\/+G1AJX#@.!\'*"#QD\C7K9L_C))!1I)Q
M4BT;2,3*,E2>FLSE8E\DXCI1BN0>U1!PDHDH4>ABB'`DJR8LQ3=)!*6NN),1
MW:60*Q30F+KBC'-QFFZ460J<4BA,V>L2LH@A$IE*5HF58"-2%`J12%``"8F<
MTS9,1,#FM5AZQMT6^JM6D(K(*SASD.*DJU"247D5T[BVD&Y=9"C9%@Z97I=:
M#CV[$32I'71FW21#HFF0I=7%O'0Y)FR91S1E&QC!A%QD8S:1D7%13!G%1$3&
M,&Y&S",B(J/0;1\5&,&R94D&[=--%),H%(4`\H-UP'`<`/EP*29[SE7M8L$Y
MHV3M@$-7\"XOM^4G#,PJ@,Y,5N-54IU2:@@DX77D;E=EH^*;I$(8ZJKL`+Y]
M06R:WU(JO[9^O%AU@TAP+C&^_O<NOJR]REGA^JDP![)Y\S7.2F6\S.7[N.22
M0E%FV0[F_:INA#O6:MDA'H```>?:YKJOMY`X#@.`X#@.!P=EKD#;Z[/52TQ+
M*=K-GA)6NV.$DD"N8Z8@9M@XC)B*?MS@)'#*0CW*B*I!\#)G$/CP.O\`Z(-I
MK'6*+WIS=G;ESDOV]\IRFK\BN_#MD;1@59NI?-.LG`0&K-%1E:\!3+&*5.B7
MT4I&ON4`,)D3#SOK<S+-7I=>H#T\?A^GES;"2LB8VQ[F"D3.-<KTZ*OM!L"T
M4ZE:U+F>H)C(U^3;3E;G8F5BG;"<K5IJ\ZR0?Q4M'.6TA'/42*H*D,7D$M4C
M`F$,8*T]QCK%E8J#O'U7N=)IDG'_`'F[FX:KY)M+6\Y*8.)R5D'\M/OLBW=D
MC,3DE)K/).2DD@657$1$.!L76`L`M,JJ;*2>/Z\URU7E%K0.4;%;+$WA:C+(
MP1:LYR(T@9^T)XMI-T3JYPC#V9-BTD$V)A2!P3U#":WOGD5,C351LU:14$ZI
MK-G?7=OLL7%0TW7D4\@R5C24>Y"M%=8-I(RMX>SR+DSB7D(PKLRH']58X?WN
M))D6;7#1'3QM@?..N=$J&/==*_M/CZ&PQ<9"$EX]_:7>.8J;1E&U"Q?"91M4
M@,+!()N'Q(Z-@4TFL;*2SB201,_,4W&)897:SM;QE9T*J:4BJ/(Q>$,@5":H
M[=>;C'3'$.5,>QWX9Q_Z2R$F"<)?JK%S8,V4>_$KT?G"D%L<ZA`Y,<&>4K1N
M`L&0<5CVNQF':&TKV(*CD#'>+ZVX@PD(*C4'*\;]RY5I49#2ZCQHXKV0X@/E
MI5L[(N"R(B3[(^/+9ZBD==T;UGH!,9QF)\?DQ74,;YKQ[GES2H"9L]DBK[:\
M.0-CB,*U2??WVPV:4@L88EE+.I*PT#$*-&+=TT;I@F5(HAR"[81.8QSJ&,HH
M<QCJ*F'J=0YA[C*''J/4QS&$1'Z>`X#@!\A_3]`X%!MDM=Z=M'B=YBZV3$G2
M)R*L$1DC"^9JTW16O.O.>*>5=7'F;**93L,L_KKM8S>6C@.FC/0+AU'K=2+%
M[6/=QY,X8^\,9(NUO)>L;9QK\!0-KL!S$=4ME<<UHZAJP>5F$5'5)SGB<7`$
M=2NO^?H5+[XK;P`-\@L=Q%..URT$#=/BN99YB56DHD*H4QP,*8'`3@42@8Q.
M[J8""8HD*;M\NH#T$?+X<Z(QUY.S3L/CYA[BL<KE2EKV?#3K3_\`AR71QS&P
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M3(<P<_EX^*WR:\UV%=&]9HC3C477_6>(=A*'Q)CF'@;'/?;`UJO[X5I_)ER5
M*HHL9-Q<\AR\I*JE[A`JCPP!X`'/"ZQ=;PIP.E'_`#E/M]+Y8UPQ7[@5!A%7
MMQUJ>HXRS(=FBX5<.\(WV9$]:G7)$4%P%O0LE2)4A$13*1"Q+J'-VH@`!YLI
M@$HB4P"!B_9,`_`0'Q#S'X\#3P'`<!P'`<!P'`<!P'`<#N7_`,E+;T8S?_9Z
MFJB8/Q9J2\DT"!XE4<5/*^//`2B/VC_*SJO3I\.O`[HVYJ81'N@>U_,)D."E
MVQ'[C>)7"P!]C_%XEQ9DN/36'^[U*ICI<2!YB(C]'.FG_1G9<P4>O0?I`1^O
MQZ?U<ZL-7`<!P'`<!P'`<!P'`#Y?^/\`9X\"PS8NOGVBVNU#T2;I'=T6'L41
MO_MRB`+E:#B+`%H3;:P8[ES&22;*CEK9U)O,"T!<JSB'IC@PIJ-S*ASE\EYX
MZ;UZ9VBAT#]8]>H^8]?']G3RYS::N`X#@.`X#@.!`0`0$!\A`0']0^`\#"3[
M@U9;:N[3X/WY;B>*PWDV+KVE.\S]NW;EC*S3K5:SR&J&R%C%$&IRM,+YQFSU
MV8?KF<F1KER4$?1;M%5`NMQM+]4O,5V>LW<<[<,'J`MWC)PJU=HB)3>DN@H*
M2Q"G*(D4(4Y1Z&`1*8/$/`>O/1VYX;?@!_R^'Z!P,=_N152TV>AZUG3-,AA.
MK;40%LV9<PN%W^RB,#0&F-[\QQW<+9KQ&)NW^7*54\POHEP]9`RE6[%T=H^7
M8N2-NA%EP,=\S0-@,A$9HY9U9FZCN#F2E>V$[TAL-`P](UW&^L33`^?+!/[&
M!&62$+(5?2]>(I(#;KO6W+YB9^VL1(L@28)?+I3^OZ]1=;N*^CKMLS@;;/7_
M`!;?<A[+L8^IXLPQK1G?1:<N&/KK18G;*3E;I<5LM6!DQ:Z=WZG-6LG.H6A:
M49+DKC:,?E:NTG**7%SX684)M&&LDZUYGM&0,$XXO&?<14S/[F#Q_$Y*H-@?
M)9GV#QZQMD_CVZ2E=HZ+"0L9*])Y+E:C4\M6`@QSRWI&G'Z2C2(C5%",^3LB
M:;E8B2BBA`/_`'E5B.5>\P`90BKE+]TZ524$2F5+]E0P"8/`0YH;;D#@.`X#
M@!\>GZ_'ZP^C]O+!9'N1K9<LFEIVQ&O+&(6W)U\@)N(QS#33LL17-F<+S3DD
MK?\`3/)4QT[6T1=7#?[PH\JL!C5:YE162,DBZ<=9M;G.MZ)CJJ#XHRI2LV8\
MK.6<;K3):G91D4DXVRQYXBYTJU5U^I$7/&N08-<I'->R/C>S-UHR98+%*=-R
MB"I`,@LB<W;3:6=I>TG#K'K4>0R#+KX!Q:[E\M-%F&59-[!O'KK)#)P_0E3H
M6X7<FNE(&;2C9-TT5(5)>/<IE4:'0$`YH<W#8)P?7(F)@:_B&A0T-`1UYB(-
MFPBW::\9&92;LVF4D$YA215GG;K)36/02FWCEVL^>IH)@*P`F3H1IH.!<%XH
M:5^.Q;AZA8[C*E=3Y*JD75HMVUC*UD92)<P!KY"L'<@];L;6$(^<-B.RAW)E
M<**%`%CF4$)FI6/,?XUCY6)QO1ZQ08J<FG5DFHZJQP1[25L#WK\Q+/2F574.
ML)1[4DBF*V;)_NT$TB")>!.`B``(CTZ`!A'KU'P`!Z^77A7SU2Q*3;3W!*\L
M[1+)8*]MMTG>[HX5317B;;OCDJH&;8YI:(+(J$>*ZOX7L3F:?*)'*9E9;4S)
M]HR"A4_)\VTVW_3Z.FO3LPE#H'3KU'XC](_$?V\XM-7`<"F69\08_P`_XFR1
MA+*M?:VK'&6:58\>W>OO2D,C)UJU1;B(E$4S*$4!L\3;.A4;KE#U$%R$4(('
M*40#Q-?<9T?R+[=NX^:]4,CIN'"^.K.X-2[.L@=!O?<93)U)''MZ8]R**9TI
M^MJ(F<E3`Q&K\B[83"9$W`L>X#@.`X#@.`X#@.`X#@.!VC/Y02TG@/>'KL*"
M_I)WG77.%<,D!P+\P=BQ@K@0@`/]XZ85<QP#Z"B/PX'?X]QL25_;+V<[T)Q1
M*CO'?,6N%_(/D\NZ@["Q0M3F'P`KV0@VQ`#_`%C]H<WKM-<Y2RV<+B2@(``&
M`0'IXA]`^`"`A\!#ISM++,QSLLN*U<!P'`<!P'`<!P'`<"6+K>:5C"DW7*&3
M)YM4\:8RJ-BR'D6U/.\&E;I%.C'$W9)=8"$44450CFIBH)%*91PY.FD0HG.4
M!ELG-)+>D@>UKB2Z&H.3MV,XUES5MB=^;9$YEL-3E$0)+8>P+"Q/W#JMKT8#
M***L28UQ&=!]*-!*W$EKGYE0Z*:BIRAPMS<NLZ93@#I](_KY!'@.`X#@.`X#
M@.!3C+V)Z!G;%V0\,Y4K3&X8WRG3+!0+S6)$HBSFZM:8US$3+`YRB55NJHR=
MG%)9,Q%4%0*HF8IRE,`80=6K#?J!(W_1C8.?D)S8[4*+@$(>[SHJ@ZV9TZDW
MBU<U\V<8.W!")REEC&4<6EY"(D=<["V117"INR1156[:;9XK&W2[SZA\_'KX
M"'3H/3IX_'FV3@?5!99JL1RV66;N$A$4UD%3HJI]0[1[%$S%.7J'T#RC5\RZ
M!)P@#IR"#LX*.T`75!%T<INX#N$N_L6.!O'J8!$1Y!]/GWXIKHB^>"BY`H.4
MOF5@3<]A"I$^8)W]JXD3(!0[P'H4`#X<#YE=.BB(E=."&%O\IW$64(?Y3M[0
M:]Y3`86X!Y$_N]/AP/@`=```\@\`^H/@'[.`X#@.`X#@.`Z>(#X@(>("`B40
M$/$!`P"!@$!\0$!Z@/+GC`Q7[?8^>:S9"M^\U"BY1Q@F_+Q;KW%<;5>-4DU:
MV[C&S6OUKW!Z!6&:?JJ6*D1HH1>6F;(@JS59(E,=AW3!0_,\:W./TKW]T\IF
M;K-FCMD_CY:.?LF,G%S$.\1D(>:AY5HC(0\Y#2"!C(2$-,QSA-PU7((D514*
M8//GIF+K+&$>`X#@4DS+DNS8^K];A,65MK?MC\TW)CA_5?&+TQB,+KFJ;:J/
MF\W:U"IJ@QQ-AZOHKVNX/U`]!M$QX(&'U7:)#X^7;772R]V<+-;;]'8!T=U)
MJFD^M]%P/7I9U;9N,/,W#*>3)5%-*R9BS3?I5S;,L99M2A.Y9>9NMTDW3@I%
M5%S,V0-VA5#)-T^GAZF':+N>`X#@.!U6OYI#VB5-\=6D=I<*5@)7:K4^`EI-
M*-C6ZBLSEC!2:CB;N6/T4$"&5D[#3UE%YV!2`#*'-\^T1*99\3H'E6#X\!P'
M`<!P'`<!P'`<!P'`SY?RQ=Q_!WO9::'%3TPLKW+=.$?'[7X@PID-N5,W3P_>
M'(`!U\.HAP/26]W4B,75M`LA+$Z)XS]U+1^:76`3`=!I<[U+8>="7H'VO52R
M5V"`^'0W7X<"Y.10%M(R#<0$OH/G:/3X`"3A1,`_9V].=_C_`&?EC;ML^:9.
M`X#@.`X#@.`X$.H``B/D`^(_#H!>H_U<MLUUS923-6$9/K:V].U\!HW'E7?:
MV:W2]"SU[A$JWZIPUUO#55"Y:Q:/NW2I#DDS/Y%HTR-D!@D403A6D/'.U2%D
MQ15X;[>Z\=.DF/NSO@``(]`\^@B/D`CT`/I^@`YA6K@.`X#@.`X#@.`X#@8Y
M/<#U.N^9X:AY]UQ<0%>W3UAD)FT8#F+"H+:HY.@)YDFUR=J]F%0HE^;P[GNO
MM0CG1S#W0LPFPET!!1D)%;+CD[6YX(S?3MC,8,<J4B*L-332GYRA9&Q?<T@:
M9'P+F>G*@PR+@G*T6(@K$WBB2P]A%#%!"7C5&TBT,HV<D-SOKM-IURYW7"KP
M?MZ_'KX#_1\.5#@.`X#@.`X#@.`X#@.`X&I-3TCB;L;K$.DNV<-W;9)ZR>,G
MB"K5]'R#%T4[1_&R+1<Z#ENJ4R3ANH=,X&*80XO0PUN\?):,Y6K.`TRN2:;Y
MWM4@PTLL\HZ5<!KSF*5*[LMCT/N4V\.(!1[.<'<QAV0=J^*?S-=$PJH-P'>N
MTTOLO[?%+SSY5]$IB"8IRG(<IC$.FH0R:J9R&$IR*)G`ITU"&`2F*(=0$!#P
MZ<[,H<@E>\WJDXMI%MR=DRRLZ9CFA1!Y^YVM^FJX2B8PJI&S=NPCFQ5'T[9)
MR0528Q$6U(H\E))=%L@0QU`Z9WWGQZS;:6RW!,[;8XZ7N>V7J/?W5ID-]]I*
M2[HV:[[3S4G7#`UB^7=/=0=:95XE,DK\VB@=9LEL7FY\BC.9!?$,*K/HS@TQ
M328+`MY/D^2_)?I';68C-5]7C]/7X>?ESFJ/`<!P'`T'*8W;T,)>T0'J`=>O
MF'3Q'RZ#P/,9_FB/8_<:C94F]_-9JH=/5G,]H,KEJHP4<8C'`>8;$[,=5\DS
M:H@E'8LR;**^HR4`"MXN;648B*23B/2$.GD8IBCT,`E$/,!\!_H'QX&G@.`X
M#@.`X#@.`X#@96O8TM@TKW>?;TG?6%N4^S=`@%E0Z=?EK@Z7J+I/Q$.H+-YL
MQ!^HW`]2_P![UO\`*^WW;+R0X).<19^TRR\U5'K^X/0-O<)S#A<.GA^Z8`L;
MQ\.@#UZ^7`NBM!2EL]A[0``^^9/ITZ=O;\ZL)>G0P]>I>@\[?'/T_EC;MP?-
MLG`<!P'`<!P'`?V>(_4'TC]7+XSX.UJNU.P=GP_$T7&6#8**R#N7LG*R]$U0
MQ?+J&""&?B4$5[QGK*?HE4=1N`M=X9T6;L3HI!-(.B-(=MWO'R:0\_DV_3[?
MJU-<7*^G3352JZ=X+@<1P,[+7JR.Y:>R#E_+=G31_&N;LW7U\>=R?F"ZN$A.
M9:P7.PKG.5,3JE81Z;9BB;T&R0!Q;75<!P'`<!P'`<!P'`<!P`^7`Q![J:FY
M8Q_DZ9WMTIKB5KRQ(PD/";9:M_>#6NU_=?%U/24"OO8.45($;4-M<2QHG+2+
M,N!49)IU@I8RC!5`S76NWMN4LSVX7#&9\8;$8SA<Q89L3BSX_G'\C"&4DXQ>
M`ME-N4$H#:V8NRC4'H$EL>Y8HDCW-)F#D").6ZI`53!5LHBL?MIM=Y]6-IBJ
MF]?+Z_+]/AS2'('`<!P'`<!P'`<!P'`<"G67,1XUS]BV]80S+6QMN*LEPZ4-
M;X1)?Y&5;_)O$96`M=2F"!\S6<AT2P-&\O7Y=N)7$=*-4E"F[>\#+,S!TQ<8
MRG\F4:]VG4_96?0LFQ.*J^G<:ED]-N5C&;A:S+OPAJ;LS6F_0A&=\AERI063
M80O4\194_G"]6;Y,X=-?DS?;MWZI9SE5:X6ZGX\IUJR-D2U0="QU1(A6?N]Z
ML[PK"N5:$0,!#/9!R)14<.'*QBHLV;<BKZ0=*$;M4E5E"$'>^UTTNT[B8]VT
MYZY5HT?TRN6U^0*#N'M-0[%CO`V-III>]+]4;XQ^1M,U;$FYR0^X.T=87`Z;
M+)0LU^^@TM<#$H[)3YUX0TXKW,_)\GR[;S%Q)]':22<.PL`=`Z?Y><E1X#@.
M`X#@.!(63\84#-&/+IB?*U1A+]C?(=;EZA=J98V9'\'9*W.LU6,I%2+500[T
M7+=40`Q1(HD<"G3,4Y2F`/)=]^/V+\F>U-E]U>\?L+#>](LF3ZR>)<DN2F?R
M&.):1]=^GAW*;U`HIM[%%H)*EBI-3L0GV*/JD[7*;INB'7I.0Q#"4W3J'3KT
M$!\_$/Z0X&C@.`X#@.`X#@.`X%VV@UK4HN\VF=S36%#\+;4Z^SBBH=`$&\;E
MBJ.7(>/AVG;D,4?+P'@>O][U4"XL?M3[WLVB8K.HO7NV7%!,A@*H"E"58W<B
MQ!_O%,@:O=X&#R$OT\"K*<HG.M(F>1,8Z,_`5RP(*'$HF40GH&-F$5![?`>]
M)Z`_M^/._P`?[/S6-NVKFF3@.`X#@.`X`1Z?Z.44*V)V)H6L>.D<@79E/6F8
ML5A8X]Q!B&CMTY+*^P69+`0Y*AAO$E?$WJRUKGUP]1TZ,`,(*+37DI!5!HW4
M4YG;::SZKK,W/A.^B^H]_P`>SERVTVO7KEGW;S]`14#=5*VZ/)4/6_#4,]/*
MT74;!"RY"F:XYH[UP9[/R9"D=7.UJ.)5Z8Y"L$6GGS;VZ,DX>'@'D'`<!P'`
M<!P'`<!P'`<!P'`@(=0Z>/C]`B`^7F`A\>!B?VKT0O\`'9)LVX&ADI4Z%LC8
M6,8AG;"-V6>1NM^\M>@`*E'P^8V\*D>0Q_G2O1H&2J>3XE(TQ'&[&4HG(Q7:
MBWU-KKTF)>U&<$;'T+8!Q<*I%0ERQ3GG%)&R6>-5,O,FT'GK![]PDFHB_F(=
ML=6,R%BJ;(<JT#>ZTK(5J::'(8JZ*PF0+UUN9SVQM.5?0,`@!@\2C\0\0^GS
M#J`^`\VB/Q$/H_H'ZPXP'('`<!P'`<!P'`<!P(=>H#\/Z.OEY_J\.63-P,>'
MN91.+$\*T&Y6&Y+X]VHH-S>VSV[Y6G562R1G&[["NF)8=_A7&6'*_P!UHS%C
M3.T*H%=OL0`)03>,63D'[IF=DDN7.U]O/F+.>%;].?;BR?F"S8YVF]Q^HU*N
M62C/H>[8$T)I=C&\83UQO2;1-P?*>7;.N46^PFQ[!XIVQ+M<JM=HR1/3AR+N
M^LESGO\`)MO,7IN21GI*'0`#J(]/B(]1']8_'G-4>`X#@.`X#@.`X%*LVX1Q
M1L;BN\83S?0:YDW%F1X16O7.E6II\W#S<6J<BQ"J"F9-TR?,721'+-XV42=L
M7:2;ANHFLF0Y0\K[WSOY>#,OMC6>P9NP<UL&8=&)N6]>.O`MSR=VP0K).P18
MT[,:;%N3OA0<."-HVSI)$9/3"1)T5JZ.D1P'6>$.@].H#T$0\/$/#X@/Q`>!
M#@.`X#@.`X#@.!.V-K)^#LA4.W=W9^%;G5;'W@`")`@YYA*=WGU#M%MP/;UW
MBCFV2O;[V]C44@=H7?3O/#=IT`BGK%L.%[3\F=+^\'<"CDABC_M``AP+;]6K
M0I=]5M5+JJ83J7#5O7&RJJ&'J91>4PO2%ESF'ITZF7[A_K^/.^G[<?5C;M73
MFF3@.`X#@.`']/T\.!;WL9LMC_6FNU9Y:&%BO>1\I2[NI:_:\XW0;2^;]C;^
MV;?,&JF,JRJL3T86(3,#BP6A^*%=J\>!G,@Y3*4"FEVFLOJLEOV3'IWI;?6^
M2B;K[LN*G<=PY.N2%4QO1*DX<2V&-'L3SP$5D,-X$4D$TUIN]65/L&]Y!733
MEK2[*+5#Y6(11:&X6V]NC*2``4`*4.@!Y!]'((\!P'`<!P'`<!P'`<!P'`<!
MP`AU\/T_5^W@65[;Z'X-V_+4;+;TK+CC.N*CNWN"]H<.31J)L'A&6=D.5RM2
M;TU;.`?5R2*H8LG7)EO*5J81,8CY@N':)0QAW+)>UFE3APSWRQNYS3@YF4XM
M_<*U*QK(OXN%8(%4[I3;_3ZK_?5XQ8Y!NW%:1M>/23]6`3@JO'QH=X!KW;>J
M8XX[7/X_O%"RS28W)N(;]1LNXRF0,,3D?%EJA[W1I`0_O-D[%`.7;1I((B/1
M9D[^6?-S]2+(IG`0YZ9)>NG/\)G`W7R\>O00Z>?0?I_;Q@1Y`Y`X#@.`X#@0
M$?T^GZ@^O@;*<E8BKU>;O%LG*_3Z/6FJKZRWBY3L34:56V"0=5'UAMMB>1T!
M#MDPZ]3+N""/D4!,(`(6<UK8C,NW#D(#VU\7QF1J<=<[:=WYV'@;53=-JN!3
M*(N%L(T9VWK^5MRK!'F04%`\8C"44[@I"N)E9,3)CQVWV]ULKI),89'=3?;V
MQEK?:Y;.5ZMMKV@W$ND1]T7_`&XS8C#OLC.8558[Q6@8K@HEFSJ&`L,LW:YO
MDZE5&C"/!,J1GIWSE/YDV<VJO^*0I`Z%``#Z````.OG_`$\@U<!P'`<!P'`<
M!P'`<#AK!7X.TPDM6[+#Q5AKL_'/(>?@)V-93,+.PTBW49R,1+Q4DBY8R49(
M-%CI+H+)G353,)3`("(<#H4>\W_*4'D7%KV1]JZ.:ME51D)^XZ;R4BFR9BJ;
M]\[=:]V*563:,P5,!U/PO*KII$'N+'.RE^7C@#H2WFB7/&5NL-`R+4K-1+S4
M9)Q"6JFW&$D*W:*Y,LS^FZC)N"EF[22C7J)A#N363*<.H"(>/`E'@.`X#@.`
MX#@.![H&$.W,FB.(_6%-V3*NI-`%3KT,DX+><.1('$3#X'37"3'Q^@>!CJ]L
M*=_$GML:#2@F[EDM4\8UUW]OO,5[2$I.C.D3&'J)A;*5OT_'R$O3X<[_`!_L
M_+&W:^3FF3@.`X#@:DTEG"I&[=)5=PL8"(H()G5754-_=(DDF!E%#FZ>```C
MS4]N++9G[DF5DN2MM9R>R3/:NZ1T"%VFVT@Q^3OIGTG),]4=3SNC"BWFMN,R
M5M-VBG8F_P!MRWQK657EVEDT!*JG'MCG=I\;O/#<SCE=WJ+H37\!66=SYF*\
M/=F-U\BP32!R=M!=(%A#R#&K-U/G&V'<"TMJL[A\`X!A'YA5;5J%/W/G'1Y+
M.I%]_B0Y-,@P!T#IP'`<!P'`<!P'`<!P'`<!P'`<!P'`<"'3IY?I_3P,7V9/
M:>UPN=]E\YX!F\E:-[*S'>XELX:AS[+&REV>_OE$SYFQ$ZC)K!><&RJRYA<?
MB>MOWJA!,";I$W:<H6N6"C^ZMKX;K<,.8#]Q*A,3*`M>==9QGI_LTXCT&XK'
MD)C!N3']DUTM,RJ;H7MA;17OF#@82MTQ,4@;TV]FV4LE4X'W'-3*Z_9U[/4S
MF/2:ZNUD6Q:;O%@;(V!VQWBI0$6T3EM**M>![*B!S="N6-F4;G`/[P<Z>_7U
M8]M7:4/(>.<K,T9+%.3<895CG'06S[%^2Z+D-LX*8HG(*1J?8)A0>XOCT$H&
M`/,`YK,]88^E5$5@)YN`^M"S"0!U$3*1SPH`'ZS(=!XX]88OI6V^[I`#=!CW
M_7X!\HN`^(>'@*7CU^CSY<ZSO%_)BMPG`SJPAZ4++J>'3]W&O#!U^("`(CXA
MUY,Z]YD_)B^B4[?8*WCQDK)Y$ME.QU&H)BLO(Y$N=5H+!%(I1,995W<)>$0*
MB'0?M=W;RSV^;,?<Q?2K/)#W'M*?OA2J8XR_.;39`*=-)'&>DN*,D[8VU==7
M[**+B8Q?7WN-8$%#>`N)*>:MDP^TH<I0$>2[3/&,&*G*OE]SK8(Z!L.:D8RT
MLH[P$C!E'?*[M,L9:38K*J)*2%<U2USG'%72E6Z8%53:6F^()B/4%4/]4>/R
M6;6-:S':X>@>T9AZ<M-?RIO!DS)'N(9AK3E*2K;G8HD(PU]QW))$,5-7$FHM
M*9P^!:>DV,;O;.I&,G9Q$X`;[R,8H"&&F6-LW2:-T&J!$TD&R1$$$D4DD4DD
M$B@1)%)%(A$DDDDR@4I2@``4``.!N.`X#@.`X#@.`X#@.`X#@.!`0Z\#%/[D
M7LSZ*>Z'65D=A\7DC,K,XG[KJ>PF.A8U?,U7(DD<C!!2Q"S=,KA!,#J")8R<
M;2+$@&.**:2AO4`//2]R/^5C]PC2=>QWC!L"KNC@*-%T^0M>)89<F6J[$)^N
ML`77"I74G8G"[5LG^\<UY6:;`4HJ*_+`;TP#K-R$9(1+YY%RC)U&2<<Y792$
M=(-UF3]B];*&2<LWC)R1)RV=-U2B4Z9R@8I@$!#J'`V/`<!P'`<!P/;4]G>Y
M&OWM6^WO9U%O74<ZCX/C55#&$YC*UVBQ-;4[C&^T)RJ1(E-U\0$!#@6:^U.W
M)&^W[A6K%$G?C+(^W.&URD+V%36Q=MSF>NE1]/P%/T6P)E[1\@#G?X_V?EC;
MMD%YIDZA_1T_K\N`Z_I_7_DY;+.*(D*=90B")#JKK&[$D4R'454./D4B1"F.
M<WU`'ER6R=F+X6P9]W'UYULL47CW(%ME[9G2R-Q6H^JV#JT_S3M7D%04#KMR
MU_"U,,YG("+63*833%C4@X-N4HJ*NRD*8P8N^LZYJS6I)@M;=ZMV>\^Q4S)>
MWQJG*D[7NMF#<@-;!N=F*".H0_W1L%M-53IU[!M4F$6Y`?5;&/K2:K=PH@M9
MR_O$S<]MO=<UN3#*U@G`.%]9<9UK#F`,85#$&,*D@HC!4FC0[6$A6QU^TSR0
M>$;%]>7G)-8OK/9!X==\]<&,LNJHH8QARJL?`<!P'`AU#Z>!'@.`_LX#KP("
M(!]/[`$?\G7@:14*4P%'KW&'[(`4P]?B(@(`(=`Z^(_#@0%9,I1,8P`0HB43
MB(`4!*'CU,/0``.GGY=>!Q"MEKK>0C8EQ/0S>5FB.%(>-7DV*3^6(T(*CL\6
MS.N5Q($:IE$RAD2G`@`(F$.@\"F:NQ^O*#6GOEL\89299"NJN-:`[4RA2"-;
MSD9!=5LMC^G.#3@)6>[HN4#IFB60KORG()12Z@(<"G5TWFT[QY6<H7&X;*X<
MAZUA/(43B7+\M^.8201QIE&==M6$1CV[)1;EZXKMR?O7J21(YR1-UZAP`2`/
M`V]PWEU:HEJV!HECRB"=TU;QU7<KYVJT13<@66>H]#MS/[PK,T6/K54EE[,M
M--/M(,H<)!^81`!1`?#@?1EN1B&9N-`I%>C<Q3\GD[!"NQE3E(W`N80JBF.`
M:+O&B4W:W],90-6OTFFW$C:K2:[2Q'5,0@LR"<H"$M4W=!C?(C6Z>@-:MPT8
MS9&<M\*BK:,`R]$>X*1IQUDE[!LG!W>5KT_BR!L2J/2(4,U>+R!#%.FEV")N
M!L2[79GDZ&_M];T.V:=3C#8,F%R8_L\K@JF6:2HR;CTI'8]@YD<LN8-3$#=,
MHF02.Y3L;O[/;&@`]W`Y^YYAVYCHS9@U#TU:6J;Q>O4T-<6UBV,Q_4(;:,)D
MJ![2\/)LH*TR&$65,!4Y?]]L7#B1.D((I`42G$.7<VW<AY=;%%16%L*0U#+@
M`+%4K=8\S6*0F5MEW;?N1QC8ZE!XT!-KBJ(=?9=69M(+OW!/%&-Z\#CZ<OOH
MXGM=5K]&ZDQ%74I]F4VTCZE+YBG["UOQFP_@UKKM*R\/7HM[44GG091>RM$'
MAT^I4$BCT'@2@ACK?2UT7'T/DO,&J#>PI9FDI7-3"KZ]WJQT._Z[B[6^[L6U
MF(N^75I"L7QY&B0CZPNU)-EZG<*<<!>@<"QG*7L?X<S`SS>I8&6K-6MUURPW
MM6#LCXST6Q#CZ]X%Q69U'*R^,'<W79]FOE2QS#9HLC^*WXM'C3Y@QT6P&*40
M#[']AO7IA<KW9L?[/^X7A:O6"`A(S'>,L0[EY<KU&P?88YJ@E*WJALIV=M#V
M8GK$\;_,+M;"O,0Z0K*$29%*)`3"H#+V::(V;-&KC?GW77Y$6:+=V+G>[(*0
MR;L`-\U*.CLH]LNW=O3&$3D;'0;)]>B228```&Z)[)&HLBLDK?,G[X97(F'1
M5GD;W`=MI9@\3$?_`"'C**RK"-W"/8'8(=H=2>`]>H\"JE!]G'VO,<RA9V&T
MBP78)T@]2SN4ZTOFV;`WJ%5*J$OF1_?)'U2*`!BG]7N(8.H"`AP,A=9J-7I<
M*RK=-KD%4*[')^E'0%7AXZOPK!/J/1-G%Q#5FQ;)@`_W2$`OU<"8^`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@:.P/$?B/Q\C?\`O!X_V<#&;NY[//MV>X0B^>;+
M:TTB=O3U`4B9?IZ*N/<OM#@!00<&OU2&.EIP&H%^PWEAD&8>0HB'AP.I#N!_
M).S;1:7L>BNVD?),^QRXCL7[-0JL>_(("91-FAEG'D:NR=F$![$@<UEL4!Z>
MHL/B;@=;C9'^7P]WO6!:26N6F.2;Y7HXAUS6_!9&&;8)PU(`&%TFVQXZF[(S
M1[!`>CN/;*`'@)0$!``Q&VZB73'\JM`WVI6BD3S?P6@[?79FM2Z/T^K'3#)F
M[2Z?^T0//@2G^W@1Z>/P_7\.`Z?^/P_\>!['7\N);BW/V5=$7IG)'#B&Q[;J
MBX$@@;T1J&5KY7VK8W01$#HQS!`!#@2S[<K=U%8WV]I"O028U]U#W#*VS0(7
MH+9A;,OMLJ,D^SKU`%T[YZI?I*H`\[?%AC=D0;P,XZ)ZC:&E5T_`153CW0I`
M`_$5?2[`_IXN\EQY2:VS*V;,>VNJ6O2;LV==F\"XI=,E$FZT%9\FUMS<U'BQ
MB@A'M,?UIW/WMY(JF4+V($CA5.)@``$1`./Y)]5]M423W2O^5G#F'TRT-V]V
M3=`(D9Y0RY3RZ+ZW`44TE$WXWK8YI'9;MD0L54#D/7J1)BLGXD,'<'2?R9/:
MYEUK!N5EV,>O]S][:!J5B-5^WBIS!?M^/U<;RKWYU8IHNN9"W=S`LOF9RZDT
MUP06;56,I*ZHC^X7Z"7IC;;+4F%W>!\9>W)H)`Y4K.(#:YX&-C^&97?8>Q2^
M0*N&2(B(EQ6D65\V0R7>;&_R.\2EE%#JHRULDE"*`8>Q;MZ!S*J]K[:ZQ-;;
M#4$<\8J5NEDP^[V"KM8876"DIBP8.8MA>N,M0;-@[<*2V/P9`*I)1#U&JJ?B
M0Q@Z<"0:M[@.H-X;ZU/:7F:,ML?N"\MC'6^5K=9O$W$9.6HHKEMAV<O'5AQ&
M5UI#J-E"'<3"L<@H<O:F<XB`"''AOU@Y]1F&0JQ7-@[M`/\`8@-8@0JNL^=7
MEA:9%3=*-'TW(5A_0XV?9XGC%$C"O<C-_P`,@4.I7I^H=0WMHW&&!B]EWL+J
MUN%>I+6N9J\$-?K.%?DI#/3RSF2+\UK8_N-DJM>RK#5SU>LL^(]:-F0%-U.<
M0Z<#GW^PN30N%]JT)J3G2695;`Z&7*O<W4GB2#J.1KT[11,UU[@EY'(P3$1E
M(BRHIN5Y-DU@&WIG$S\0[.\.-J&9=H[#9<`LIW3E]1JCDBB6&R9PLE@SWC)_
M+ZWW-@R46KN.'=6JQ)[\V7MB>`1)23A'Y8]B4XG.93M[1"7JMD+?.R5?#$E.
M:VX'QM99O+$S$YXJ\GL=/W9"@X58/WB<1<<;V.NXCCV]_P`@6".326^Z'K>)
M9LE%!34=G`HF$/K9">XPXKN8$Z<;2N&MJ>98=+`3NSFSK:*X[UZ(_8_?[O,4
M?%_A&299H=10.`9H0CE>#;N!3%158G<'`F>YTW<^<GM@4:;G'"-#J5BHL#$Z
MT.EL)V*Y6_&-_*U+^*+AE,S[)D/`9,AE'PF^[XIBA">FB!?6<G-U'@&6)MJC
M7:BSTQMO''ID1@)2@9`Q_!:_TV,"ZYY<-3)*;!0]NE+#8)BG,63DP*M:@"3Z
M.#M`JSI8.O4.,JVN&<H]AK;^,]W,VW2=PI*6Z5RA)MJ5@^G1VT7XC.;[GB\K
M0$%C@6E=AJ8@($8)58\(HH/VW*BY^@@'#AI6[=T1:BS^W>Z<YZNPY=A$KFGF
MIE5KTS(@^%XRP6C.4>G5A);7AL001-75T%5'*10!=TJ(B(AREGT=Q)>&&RL/
M=+3GVR06U4C5Y#(\(XV/S3%L*VG43)GBHG#*M=N,-(X0A'*B?>_;5A>.+(]>
MUR*I0`.!SKO23622N-POTOC,)BV9`P"EJ]=)&7N>095K8,%)(?+#0WL)(6IQ
M!>FX0\%Y%-LG*N!$3*N3B(CP-Y1M*=3L:O\`!DO2-?\`&4!,ZS4J4QS@"<0K
M;5U.XDHTX@HVFJU29N0^;E8:.ET%CD<@1;N7*<P',;J/`FNO:N:SU&$J%:JN
MN^"ZS7<>W-[D>@P,!B6A0\+2,B22R[B1OU0BX^`;LJU=9!PZ547E61$7ZRBI
MS'5$3&$0J<RI%-C32YXZHUA@:P2PS\\9E!1;8TY/"KZXS<P*#1,9.7];[?S2
M_J+]WCW=?'@3*!"E\@#]?AUZAY>/3KP(>F4.OAU[C`8W7QZFZ^(^/7H/T=/+
MIP(]@?V>8CUZ>7=U$>[]O`B!"E'J```_5P-7`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P(&Z=/'RZAU\NG[>OPX$`Z>'GU\?H^OSZ>'G
MP*$9S_AD^Y/_`/2OY#_AKY=;K^>?Y??<?RO0?F/_`._?X'T.WKW_`.KTZ]>!
M@/SY_P#:C?>\A^;W_:H^^NIOGOP5^5_SO?U#U/2_)_\`>>KUZ=WI?:Z^?`QY
M6K_[*+J^^=_AY^8ZAZGX5_C#Z=?7'K\C]P?[MZ=W7KZ?V>SR^STX''UG_P"R
M=]-/T/R)]7YE7M_$W\9_J=?#_P`S[P_P?RW3^YW_`&?V\#M2^W?_``/?PI4+
M_MS_`(!_A,^=M?Y>_EI]\_A3[T_$TK^,OEOQ'_OWY[\5?-?-?,_O/7[OATX'
M7ERE^8?\3/N"_P`*G_?(_*C^+F>_-3^!'^!3\OOXC_ROQ3^:7X(_-W_ZT?*_
M='W5\UZG^!^>]7T/WG.FN/;XS]6;G/T2#9?^UK\]D+^/#_O^_=7Y6/\`T/XY
M?XV?R_\`Q?Z(>K^6?Y6__+7YV=W?\AU_W#W]WR?V>WF+VTO/]O\`_P"P?^=V
ME_\``O\`*?GC^0^5?RY_!7XV_$WX8['GY@_Q>?*?XG\Z_F?F?N[\>?[]]7_^
M*_=^GR"\BM_]IS\'Z0_-?C'[J_BML?\`!C^=_P#&!^/?XKOO67^^^[\Z?_J%
M][_/^O\`)_BS_<OI=/DOW/9P*@!_V>?POLM]]?P:?@O^+]E_%3^9'X,_"?\`
M&K]\-/NS\POQY_N+\W_OWT?D?_5];M]#X<"Z*4_@9_'.PWWY_"=^9OX4JW\6
MGWM^3OX^_`7W>'X*_B/^<_W]^$/NCI]U?B7_``7RW3Y?['3@5Y@?RC^;KOX8
M_+GY[\$Q_P"%/N'\,?-_EQZ!?NK\/?=_[[\$_+]OR_RW^`[.G9X<"?FWRORR
M?R?R_P`KV?NOEO2]#L_^'Z7[KM_5X<#[_'X_'Z/+Q^C[73@1\/#KY_#KTZ^7
MCY<"`]O^MT_;Y_5T^/G_`%\"'V.O^KUZC_L_7U_3SX$?#H'3R\>G3I_5\?Z.
M!J#_`,/]'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
&<!P'`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>g575431g79u13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g79u13.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,9:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;7!-33I$
M;V-U;65N=$E$/2)X;7`N9&ED.CDT1#DQ,3A!1D$V1#$Q13(Y-$$T0T(R-30U
M1C$S-T(W(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.CDT1#DQ,3@Y1D$V
M1#$Q13(Y-$$T0T(R-30U1C$S-T(W(B!X;7`Z0W)E871O<E1O;VP](D%D;V)E
M(%!H;W1O<VAO<"!#4S8@5VEN9&]W<R(^(#QX;7!-33I$97)I=F5D1G)O;2!S
M=%)E9CII;G-T86YC94E$/2)$,$-&049%-30R-$%".40V-#9&1D$U148V0S-$
M1C(X02(@<W12968Z9&]C=6UE;G1)1#TB1#!#1D%&134T,C1!0CE$-C0V1D9!
M-45&-D,S1$8R.$$B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@`.061O8F4`9,``
M```!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("`@$"`@,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P/_P``1"`%=`;X#`1$``A$!`Q$!_\0`E@`!``("`P$!`0$```````````@)
M!PH!!08$`@,+`0$!`````````````````````1````8"`@$"`P0&!@4)!@<!
M`@,$!08'`0@`"1$2$R$4%?`Q%@I!46$B%QAQ@9&A(QFQP=$R)/$E)K8G-W>7
MV.%".#E9>5(S0S0V=K<:$0$!`0$!`0```````````````1$A,4'_V@`,`P$`
M`A$#$0`_`-_C@.`X%&'?+"HG+=;:\:F8=KJ-L;/LI#K/I2T5E>5ZU`C_`(WW
M[E$W'SB<M]*3:*&2R)TW$8NNF*L;JG<4B!*QG8$7@I0>`T*D;+D-DU-V,,-(
MQVZ[VD.[-);7]?\`0^G5;2JU+5,06SUYMVL+7G8JQIQ!T#EBLYY'IW)FJ7.L
MWE[HF-6)9&TI"\*$9I25.<'L.F2R[TG-XR,>N5O3ZU97)^KY5.]N_P"968VY
M.:UAO:RJV->V>,L]QMKNO.D=1S3,"3.J5QBT=3LG_1=L1G81YR!,=D+\>N':
M&_\`8J.;*P[:&+TZP7EJKLY)]<)PZT$KF1E3312TUW6=E-\GB;=81BF9,A.6
MJRR49Z=<><+*E&88`6"S`AP%CG`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`_D,DHP91
M@RBQF$"R,DP8`B&2(0<@&(H0L9R6(18LASG&<9SC/C@?QR@1"6%N(DB43@4G
M,2%+LIR<K"DAI@#3$Q:K(/?`G,,+"(0,"].1!QGQ\,<`F0(D8E8TB-*E&N4B
M6K1IDY)`UBP1990E2H10`Y4J1%D@#DP?D60AQC[L8X%-_4*HFBJ:=L"BR6V,
MLM@F=HUH?B=FA3ZXR>'M_MZ^ZVE1_P"@O[RT1YY<0+8H6A4*OF6]$(E<<<4`
MOVP`&(+F^`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@.`X#@.`X#@.`X#@.!3GW:;`;S:CZ>2G:S3&7Z_Q]#03-(IQ=C#=\
M*E4Q7S.,?\R-<<::]Q'7)K2MKR2[KCAJ1+30%&%B!X&'TBP,)KZ0CVL5:Z0E
MUW,F--SF[I`6=(U[Y147DD0@(8R_%IW.,-Q+1*ER]U^KMS<I]I6=ZPE&F8\@
M#C'G.0EKP'`<!P'`<#C/^O'Z//`I?Z?7:8OTO[77FQ(BCK^=+NT6T?Q%!VV4
MIYRV1W*/7W6UO9,(9BE;&0E]`^1Q(C<Q_P#!)1I#5HDHP9&1D8@NAX#@5\;&
M=JO7WJ5?-=ZR[$;/5]6-V6>%J-CD->LO*G*!*_K1MT?6S1[:FI?'J^0/RTL0
M$A[XK;RCL8R9@7M8R9P+!?5CQC./&<"^.,XSC(<XSCSC.,_=\<<"(L]WLU=J
MZ4;+0^P[+)ASYJ/3,6V!O(I_8I$VI(]4DS3RTY@ES(Y*6L#?-4ZE1"'!(82S
MF+E"=>`I*86$]0068'UW'NQKQ15)V#>\]F@"(Y5])D;#3*'-J?YNVVBJ5:8E
M0EDJRK#C4LQ0DG#.]C_BDQ`0*0B*&((P#Q@/7';.528YTH@8'%UG*2^)))(G
M$)+7C0HG,/9GB)11XESZ">RJ,B<F2$)D:%B4)LFKCBP9<<!2^<&BP'@><-W.
MUVQ:E?5*BL)G>W6S*KMJY8Q,(^M;GJK\P2D'R.1VR7%SL5O7'QEN.CKI*$Y9
MP!G?X?H.]S(/;%C@=_<NUVO="4.X;,65:$<;Z31H65:@FS`:HFZ66&2A>D:H
MDU0%!"R']UL!_F+NX)TC0WLQ"U6Y*3P%IRQB%P.KIS<"@[MKV#V.P2]7"FVQ
M)>ZUY%HS=<:D=%6.ML1C6J6]U@.:WMMLA\T_%Z52D,]*(*(9IY6,&D^X4((\
MADJ3W=3L+039RE-HP)E35Q#Y+8,\"LE3+A7$8/#??Q*Y6_-Y:PQP;V*/&)C"
MU:@PK!9)H<EBS@?@.0ZN#;$419<3@DX@EP5Q)8K9\0(G]?/#?+V3V9;##V8R
M08D;*0>L)6*FQ.RD&*5`_;Q\L429D[`/;'Z0QV[[GZ^MMN:NTTW3,J92+<1O
MNAUHN00$!,TK^1(*$C;5*K"4K)RP*5K`W%)6QY)"E%DT>%:C`R@?O`%X"5/`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*=?S`O_
M`,F?L&_\"U'_`%LC'`M$I[_NDJW_`,.81_U9;.!D;@.`X#@.`X'&?M_I_7C@
M4P]0+U(I+,NU^02^%.%:RET[1;/$\5\[.S)('2,Y0Z^:VMC7\Z_Q=>Z1EUS(
M61$F=2\HE!H""5P"#<^^4;C`7/\``\39-=0VW8!,:OL-FQ(8+/HZZ126L65[
MHU8=V!Z2&(G-ORY,JYM=T.%24T0/=3*"3@>?(1AS\>!JH;A_E"],MC]G*_N2
MKK9F^NM0I4K`WW!1C.W.MB&3-+'A8`$^!V/-YNK?J_<'UL`!*L$K(?2"A!]]
M.46+U%B#8XU8TCUATJ:):Q:S5EBM&N=KF9REB?$PGTOR\+X^WFM30I$=/)3)
MU"(21`<('I3")`/SY&$0L8S@(/\`8EUA/^Z.P-`6E$IU$H/#\L*>BMTV!_9E
M#P]7GJ8TW%7.P[75$4,-;W=F:%JJSZV"D<#%!1/S+&^+RO?QC_!."#][]'MT
MVC>W8;9""=U4\G[=1+8<JH+DETZLINL.H5U]45$:=4U9+*J9J^=8G8-8Q]+%
M\DH%Q\HQAO0F%&)V3"TCWS`]?,^C>7*"-A(-2=CUEKA4MG7+<D_J^/5$Q.L7
MS44>MCK>2:>+T\>CS0T-\>:WQVM4DY\>L)!`+<&E4<9[P5QF08#R]I=,.R%T
MZVP2N<+-,-4)C$*-MVM5E9ZAQJ;177)^>)'?VM=R1]*M;W&%-CP./6HV40I;
MY\J$UB4&&+R1E)7`)1N#@D2MZJ[-)T$K2D*O<*FI38JD=P&3>>L&E;-+&O?7
M85R1>TW:Q2H;*E[]#JTE.*VFI;TL)6$L\>;"6!<L^;;4(A)RP&!@;=;J=WBW
MW<X/8MV2#19/:<IURF&L5DDI&6Z)7%-74CO>K5:$;V3TT<),VX>W/8ALBC>!
ML5GN9,3P>L1(CR%R9,48D.#O77HS>7VY[!MAPDU'$.]MVGV2.=H3,J%.3A8,
M[IW<C7)HI>I8/,ERI`07,"JSD[2!]<6I:HRTY4X]]'G"D9HQAB*,]!]J'4#,
MXK+I#JNQ7?\`Y=NIFF55R6&Q&7.4/B<@UTLB>RNURUZL]EB,I3U=N;&W!J;K
M&+;,)'5>2O=R194%"`-0$@-/NHN\:-V-UKV-EK]K-7Z.O[ZW:NZ=ZZZZL<Q:
MZ2K%+LO0M3TG#(!K6F=V*-X0LZ9961LDE1ZQM:2G!X=CS$J0KQG)@;"W`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P*=?S`O_P`F
M?L&_\"U'_6R,<"T2GO\`NDJW_P`.81_U9;.!D;@.`X#@//W_`+/OX#[?;^W@
M<9_5\/U_'_7^S@4Q=04C6S*9]K\M<H?)Z[<7SM%M`2N!S@II)F<:$U:^ZVL9
M`)""//DEC?N/:1L+<T@D#@K)$WK2,Y'[F1A"%SW`Z61N+BSQY^=VAB62AV:V
M9T<6N,MRIO1.$B<4*$]2B8D"UV5(FI(L=U)04Y1JHXE.6,S`C!A!@0L!I^]I
M'83^8!B=I:QJ-/-3Y[K)#[^E;3KTEKNZD.GUQ+7:^7K\129C7L$GAMCS$QA:
M'&$M2C*D;Z<WM:4YJ,$$X6#!>D-D74.\]CK52.T<V!U$N37=QA$:B:<F?6I,
M]>9$7;C\80J0R)P:V2A[$FZ:.*2U+?A8>2<6D28"M`!-YP`00A";L?[#K.T?
MV)BRY$)F?J1B>B.V.REAURN2H&U=+Y=5L]H6%0(>)Z)O=':),;0=9JE0X"3I
MU.3499GH3*5`2"LA#V;=G6X][QW5*+,#=G3-[OZ,[EVRTN]4-<(NZU]GX-JV
M^0J.5U#],DVT+)4U<H9KL"W2A=,B44W:$K@CAS668`(35.!<#(DA["KBM;6;
MJ.;Z4V;3UN+L8F<DB<MWEM*CH%%WV,((!`)G+R8XS4XZODIJ",7G<<AC0&-I
M)5G.S-@2=:8F3&C&FP4'K9!VRV!0%P,-`/S/!MI8;3$@T@J38S:-MG,8J^?6
M7/=[I8OB%13.@]=(LUS".S"*1U0G3GR95B1-:8X8UA324:-N5%%A$^Z._+98
M&M^S<\KG6&L*^FL7U#LO;'7&4/MQGVA')%#:,W&;=1[:.L:+((/#%C.Z&.+B
M4]Q]`E6*2%J3(R5:U&<7CU!*:8]P^Q3%;DAHYHU-J%9)$FQ6N^C<8GKKLZK2
MUP^;@WQKVR[,*TSL8BI]4_L]#P6M@.H</J5.Y/+\[X0HDK46$\U02'J='>R*
M7[9;30:92A\:ZGHVQ^O>)SP-1+IA"I+$8_L6GW6N/7)^61VTT*%N_&J68+8*
M6ACIY1I1#TCR280D">,6.!FG:_9W82DNR_06JV6RX/G7;8"$[6E2^CTL,9QV
M/)I;3=*.EBQZ0'6$[.RQU1(UC[E"@;FMI;$V1F@/$I4JL&ED$!`SK9[+]I;"
M=)9)+ZM6$;$1*<]9@NR(IKA\)BL`0:Y2\FUK%AA^M:-XBASHO=(TNCT:#E,J
MDHEK^6X,KB9D\XH624X=]2G>K>-C2RKR9II1"(37\W<NNM[DTB9]GA2N21:L
M^T3YACUH<VF,**;CA,KFC-*&]2=*4`%B5&@:0@&0J//SDK`?7$>\FQ;.U\WN
MO9GUV98C!M>H$^,5.RELGJV<O\DVHD]FRFD:<UHD<57PJ*1)YLUWF#4TNZ\,
M9D#^V$MTG:DI9YZHPW``QK4V_P#LEIEO(ZZ(WI)9=LJX1C4+5&2.\CEDA;6)
MB0S>#:_[#W/MI*8Y.GI`X.<UO&[Y#$T942@SDZ(T86M$H6!7HV]K4!&%E_4[
MV'67V25/.;JDM!,U/UPWO,1;ZMEK#/9!-6BT"I%"6F:2DE%F15U7JI.JJAR?
MRHN[J4P%S:ND+>X?(J#$A11IH6O<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P
M'`<!P'`<!P'`<!G@:^_YFC9ZDJ$ZF=CJ^M&8`8YKLQ%CZEI:,)D9[B\S*9%N
M+1(5I9"5/C_@V-D:F_)S@O/R!,EP:4#(A''D%&!:5H3LO2VW6H=$WM0,R3SB
MMY1`61N1N8$JMM7-SY%4A<9E,<?&AP)3KVA]CL@:U"1228#TY&7[A0C"!E&C
M"7W`<!P'`I@[9NQ>?:8RK5FF*N!F/RS945]2E^MO&O5H;9GU15VM\%9)E-WA
MKUUIR1Q";3IU=%4I;B1K371`S,+:!8M6F"R`@HP(C/?<!L,7>:"=PPZBIOI!
M7>Q.E>IECJ&N!V"EMRXY%N!141MT&PU3N!\R4-$,@T966&QE-L8<D+BXKD(E
MV5*Q.H+(`(/::$=J^T]K60F9-EJV@<O9;FZ[W'LLI^):NP^7N=BP:&MUV#J;
M^7E0V2&4N:FZ9NX,SBTN2-X3)(Y@]S-6(L(LEA),"&<NF:P"K8>>TBSB8?/Z
M[+FW9A/G4,`MF,JH1:42^7UNUE:\MTZA2U2K4QAU4"095$D",%[B$\@[_P#4
M\<"[+@.!Y9ZE$,:U)2.0R*+MJU/[;@4D>G=I1JB,8]P!2TLA<H+-*QC][`3<
M8Q^GQG[^!Z,@\A202I3&E*$Z@HL].<08`TD\DT`1E&DF`$(LTHPL6!!$'.0B
MQGSC@0WW'U:UIV]@SK1UV'LS%*;2B+K#8M*&1?%&2YRHX@D,7G<@9H.XO;>Z
M+7>+G/<1:E3\R&I5S(ZITQ93DD/(_=X$?JRZ_>O2H-7YSKI9R6K;^JR$V=+[
MNNAUV6.JR6)(U;$W%^)I',Y`T@9H]7=*!^G*@Y2-[,UQ]M;VP?I)("6::(T)
M&/5>:&W-K9"JU>8IJK9.I3THC49K>)"057(J&6N"168WP]HKU`1A1",NB1Q`
M,EK+:\84%*,""1X'YQP.@5T?UT1JWX`ZJZUU`CMZZP5<$^MQ'L-2,MD49336
M4L^671Y%DI*_P2O&0H]4),I`6G;T/O'B*&7DTW(@^MA@O7=)H`X+HQ&M/'^K
MS(4^44YN$>14ZYP;-?VS*RY)(:D6+FW![&"+V+-U0%ZED$/"9T=#`G"),/S@
M7`]H]:5Z>N]82RH7W6>AUE33(N)G36#+JRA_X5D9E>1IDB4'<G]`-KPG7.$*
MBD7;F]L6'>I0WHD!!1)@`$@P$,;9U5T;V18*'ET$CM3R6O*+F,!>JV'1CE%$
MU<+SZ!=)0?6,#?CJ[S]&EE?TY8+ZI?&J,G&B:FJ4)"5F$X5)&.!DY^UUT^V`
MG\2V!D5.:_W+9E?+4J"#W&XPV"SN7PQQAC^I6ID49G(T3DYL2Z-2;!H_:3*2
MC$RS`O.`C\\#TE>:N:VU&"U"ZNH6HJ]*O)W<'^Y"H?7L7CY=H.SN0L3.:R=%
MMC:G!)C%I#DIP8%7@T&?FC\^/)QF1!T+_1.I%7Q1^G,AIJBX7$8!$:Y>7^2*
M*\AK6W1:%:L(G-_J-:I6%,X/D&:@4@EBN->G.`QW`C!H<$9SG.0JOU$ZB.ND
MDUIL>H[BL6_8U$;`JJ=1QF769%'./QP<1DR[9NLH;:#/#XI&W2QUJ.8VHCF!
M"FP/J\L!C+5G"P"4HLLP+6[;U+UVNY'/0S^I(2OD-C-+:V/]A(XXSMUFIU4?
MCLKBT/DK#8!"#$G8IA`F6<NY3"ZIE(%C1AQ483#!@XS`@P)H+UO4OUYLE@-U
M62NQYN[V5B`HI)(["6Q-.=^'JJC(X=7+"WQBN8C`(&A$P1XTP"IT"TY>WM0:
M)0YK%9N"\EA81P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P/
M&V%84%J>#RRR[.E\<@%>P5B<9-,9K+W="P1F,Q]I3C5.3P]O+B>G1-R!&G!D
M0S#!AQC^G.,<#2Z[L9C3V\]!UYMSV(5MMO0_61%YNX1?3]QU^KB!N&TD_F,[
M:2Q)=G;^:;>4(`TIKQ8+.Q?3X1%,(_Q"\#,*='DQO^8;$`0V$^D&(ZP0[K3U
MX2:<5S=-=:]/*"2R6!YV'1L:&X;!3/<F<U*RV)>GCKBY-&,6(KP)P;\I\D)\
MM1B;V""4_L@P%LG`<!P'`AEN'H7KWO&UP=%=B*?-[S7"N4"AL[J6SIQ3MC,S
M%8#%B*V=!R9S7CRQ2$R`VG%0X;9$T#.$C=$@"\&!]910P!B]+U0:2-NPE9[(
MLM<2)@EE3-E:IHE!F2RK`;Z3$^TO!%-74U/GZFR9%^`I'8E4UNL-96%X6HSE
M2)$+'C(C2RC2P]1J/UJZF:12R836A(A*FY^E#$&#LYTUL><6.GJRIRI0ZSE-
M2=,)9L^/1564XEFSXL=PL#3A.C&X*,FF8'D!7MA%?J#F+98DT[89RRI)$@:)
M#VCVB%"AF$=?89+$N&'7S6R,*@O<+E2%KE,8&:N9#1IB5Z1,<>C$4H"#VS@9
MR%SO`Z62H'9TCK^V,+Z9%GUQ971"RR8EN0O!T<=E:$].W/Q32Y@,;70QG6&`
M4!3J`B(/R7Z#,9"+..!_GE]W_0-W&[;[E-]I09Y'NXRI*0@\2-N>1'ZX:Z.)
MC@T.<I4KX=BO6)_BB`13=EP`>%;E-CYC*K(,CR$H/@-R;K/UKVOUKH"JH?LU
MLTZW">S4'2$+:ZB6574</0T6^PZ$M[7(HNVSRMDA;C9)#<:66VX7.!Q^#@-X
M5`!9$<,60@EVYZ=[(7CM%K[LSKG6#[+[0TRUXMJYM>Y`VR./,;2JV3BMST%)
MVBE)"6]N28*AHONH&:61X[)I.4I?S`1#.(&$`\!6BFZS-MH*9.+#L;5>8[$Q
MR2;+Z5;J[E4^1*(&^+]IYZ^T%?ZK85I@M?2R7H:\M!/K1L39L?<FZ&2-:VL+
MXGC1`$PCC@%A&'FYUH%VC[<ZN4=1C+JQ3]`(ZJ4[K;+L!TFB]>ZA,ZBW7F7I
M89I!.0U=J^JG3-"=N8JP$N\P7)!9#%BU#D66Y*QGX#D031:ZCLC8#LZUDO'9
M/JOLNKVF(:]+3[*M2!5M04E2;`["77KT1#+EC6T]@E68@E1^O511UN/B\<BX
M6QZ*DS^XA5*PIVY.$HP,!VEUV6/"^K%T\=>+[(-PMI=Y8MN&.A]<XM3;='=/
M01BPXXIAT21I$<UK^MFL4`U7@_X6)6-:<T]?)W@\9Y?NJ5"W@7'[,619'8GI
M'V::\:S0"U:NMJ.5E)*%BS_8F&V#HIA:\SI)BFLG@$7D+*^O!`%\/.E^(>_+
M`G_3DS]\P26I-)),/P$7^NVN)E3BO;5<9US730FKFY]A940O65K8J9B"FEXG
M2^E\-@ECR*;UQ!;,Q'H<OV@LR)*6>.((^I5&K57M+W`:`M1@\08XTDJ[;2J>
MG#>^C:/U3OS4G8)DE>Y\NU(K]ZQ74.?\([FELULZ@$-;.,<L*7L;6X0UFD#:
MT+25RPD*!T2&$8,/*#@\08X<*.[+M5Y?9%S$;`;O2ZJZ.O&=I&93<%OQJTH\
MHU)E'6W.[2L^V93#1(LAG,EB6]#>V(V+*A&I/8B2_D6UO`UB.P((/:<6+=FW
M6CX]/[!O"_KMMK?G:36RDKF9YC-'.UHI1&LQM,LFP6TSG!K=*L"1,<A_B17S
M`\!?DS<L;U<2>)JB9P(4I:),,027V-BW83IK*>VG9)O_`(CU5K^\M>[MKZYR
MVM'*,I$D)N9+K_K]%(#;UZ1PQ<N,LR&2Z-QI1'JY`%*>"&OC4L-<&X`529W1
MA:)T.3I_G>ID^536WKCMN?,U[RMGEH+4FLEM=DK$\,;B+BTU/5EV/$SL)GN:
M&1=F<"3SG]`[J!&.JU4G4%IS4^"0A=OP'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P'`<!P'`<!P/)SV<Q.L(/,+(GKVEC4'@$8?9G,)$M`H,1L48C+8J>7UW5%I
M"5"HPAN;$9IHPE%C,$$'@(1"\8R$$=4>V_KHWBLI13VJ>T<.N2RTD/<YZIB3
M$P3YK7IXDS.#,UNCP<;*(BQ(0%HE\@1EC)R=A1Y.QG`,XP+(0L:X&-+BN.KM
M?:PF]T77.H[6E5URPJI+-9Q*UX&]C86A+D!>35!PO4<H5JU1I:=(E(`:J6JS
M2DZ<LT\TLL050P:HK)[.Y?&]C=RH*]U9I!!']!.=7-(K`19:I!;#BR&A<8OL
MONO'50LE`&G&6!PB%:+<"1L6/;7OH#W,)2="%5?=%:4Z['^N_?"V(*\OT4ZV
M];ZZ?3J[DK`K+:'3?'8F(S-F:$TW;7)0A7&':@4=)R3,MXDX2?QY*4F%1*C#
M8VIS%8;4]$-+6PTA3;(QMJ%F96>JZ]:VAH;$I*)M:VU!$FA*A;V]&G`60E1(
MTQ02RBP!"$``XQC&,8X&5N`X#@.`X#@<9_U_T<"E_I^GD6M.8=KUC0=R5O,/
ME/:+:&&-V6M;LQ*5?X<U\ULB3P`3'(4+7(&T"!_8528&%:8G)X2<'%8&0848
M(+H>!_!4I3(DRA8M4$)$:0@Y2K5JC2R$R5,06(T]0H/-$$HD@DH&1#&+.`A#
MC.<Y\<"#-^=DNFVM[M03-8=V08U3L==T<H2`G1N6P]Z0H)A)6AV=D#M+E8)$
M03'8>3]++2G.`\C`6L7HRO3G)X<X"7,8L6OINH<$D+G4-EZQHP2)U2Q>3LC^
MH;,'C-+)$X$M*Y68B"<:08$.3`@]0@"QC[L^`B+L=V(:_P"K&RFJNKMK@G".
M;[>O3M'JXDK3'4ZVOF!X0.3"P,Z*P9(<ZHS(X9,I5)4+0TY`F4X4N*DLH7M^
ML.<A&@[NUU'6&;`-$+BU]V/.*1V0C^ID7KJ%5L2ME^R%Y29#+%R"/:_)W!_;
M&V2,:0F`/YJY[=E+(T(D;*J6&*,),%'&!ZNU.V^FM=Z+J6Z]G:/V9UW6VI<J
MVG3:GL6"Q0^R("0PF*U$UN::!B4\DD-(U[@<?2A=W:7(G=8@3-QY(LX]XP)'
M`]=:W9I!J@VE:=5)%KIM*KDD\BL_<J.L5L@$7Q5>P\^K>LL6U(:@J"0.<[;7
M5VF9T4S[:5<X(&V-G.0!ILN8!`$+`8-1]VM&I:=L2WIUK1N?6I=2;.0#4VRX
M3)*BC+S)X)9]@-\5=4RV7ND!L.80&-0N-H9LU?5')8]$X)5+B4A19RLTL@06
MC7E=%<:W4U9]]6R]EQBL:AA,CL*</7RXU(T,>C3<H='(:5$1CWE[@H+(R6G3
MEXR8H4#`6'&1"QP(BT#V25/=]*;(6V]5G=]$R#49"\.FPE&7/$V)GN.OVU'5
MJ.ZV!:<U1F42J*.Y$UJYT2NC9E&[G><FY(/]D\LP`0]3J_OG`=C]9'+;:3UK
M:>K-,HFW,K2O^S'\-8L0[5J*/-DF2VJD<X-8]A1Q+!%3:Y?$]8N2J"#4YP3B
M2_1ZLAVU;]C6A%QRJ/P:J]Q-<K"E\L+L$V.1R(6S#7UV>$]5$C56&K1I$+J<
M,:.,("QJE!V<8*$C*,4%B&26,P(8F=.R'1.':I[+;*T!952W#`-78Q(95-HW
M1CFS+C/QBY%+5,9AHTT:0+<MDEM61%DIFXT:8?SPU9:D.#218&(._IGL1I2Q
MU%GPVXCXWK_/JMFDYK:7Q.P9Q&E#0]NM2T55UVWT]Q%Z/RV?7*YJ%JM`IO>7
MA8C0$D&I!C.+)":4$09_UBV%U>V)K\Y^U-LJK[)K:+.QT64'U,M:U$<C3V`@
MAU41U2B:2B"&1T*3N1:@Q(,LHT(3PC$''KQG(2.X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`S]O'`H)[LM@^QW5DS6JR-/KRH2OJSMB\J2U5D42M&FW"PI
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MQ]G0DJWF4R^2NAY2)J:&Y.J<G1>>6F2DFG&`!D*V:<UYN;?>S(=M[V`U^NK:
MJ*XE)$XTFT`D*@"K%>*T?D49V9W#:TQAS/+MI%:8SWV"*C&J9:N3G>@/S,A&
MJ6I@Z:[IA*>T2X)SIA1\D=H]H_3DI4PKL"OZ*+5;8NNF7-P"3GC0^D)8WF$J
M24XB3RP6S(6XT)K6WGXCR8\M<K7_`"@<=[45C,%Z/]XX3"V!GBD/B&MZ&,Q6
M+QYM2LS#'(ZQ/L1;&5C96E"40B;&EJ;DI9"=.2`!1)180!QC&,8X%LE/?]TE
M6_\`AS"/^K+9P,C<!P'`<!P'`9_UX_T\"F'J!G<2M*9=KUD5_($$N@LK[1+.
M%&98T#]YG?28]KUK7$G<QL4YP'*I.VR%@5HA&>G`1&IA>C(@>!9"Y[@=8],S
M1(F=VC[^V('IA?6U<S/;,Z)"%[8[M#HE-1.36XH50#4RU`X(SQE'$F!$`PL>
M0BQG&<XX&I3V8_E6(%O;>;+/Z6N2C-)*FA<%:XA#*?I?3Z-(@F.6%:YVDDOF
MTCB]B0,$K>W5S6`*3>M$7\BW)22`"SG`AB#8>TTTOJ/42N(XV1BK:!CEPK(%
M"XI<UIT=1\0H]/;S[$&_*44G=(Y%RSLH2W-P.4+L(AJU1210K-P6+QG@8*WP
MZTF3>61KI`\6V]UP<+62RZ(CQS%%V]V>8;.I-:=.W-6EZQ5_4NB!8RS&H;`I
MAO6(0)\%''>X/T*DP\8'D(K?Y(:>*-+>OIW9QS@%DUKC4QYHB3.511F4Q..S
M37"BK&H*P%]N00<@:D]P1K9F*VU(3I2@PL9%1:YQ$H)6B.QD8PPK'/RY,`>*
MTB-67)M+8JN%Q&$[DH6N':XQP[6B(L4^WAGJ"2VTIC:!@FDJ=2J3;(:Q-L<;
M:]<%CBRB2IS#E(SA'9+`$IZIZS-HJZVUIS9R3[NPVYR*BUZA^ND?C=GZP%N,
MCB<4CD$RP2]\JR9(;F2M\#F5WS9,A?)H\"9W!S=$[>0U%'IT!808#II[U#3]
M;UXQ31&K=K&R+/3S;PKWV2V`L.A6RSI=L!::RVOY@'V7+8VGL&%M<8<Y#<:)
M`H4C^87Y^B)/IX<XR+Y@(22DNK&P^VM#;V:U;N3^*#J^_41M0TT;4C`E8W^-
M5J55$7CK]9[QE0H<\%2B=6X6[2%*Q*%3B2S-V$J(:M1Y-](8XH7KPV4J4^VY
MM*=QX38EO[,.,D7;-OBW5B.I:[L)(P:XMVO6ND9BU<.5DON(5%*H"R)7U\2&
MN+J*7K#5:4PQ"E/P`L,=TYTXE5_I?OKK#(;IB**5;_I985.'FBZ#8*/H*HS7
MZK6FI&_-,:VM<O?FB-A^B,Y2YY&)Z$8]NIAAXQ$>0A"'0VWTWD*\7?85:SN-
M++`DM\9V9K^#JZZ88I&3WV-=;4UT+CE*/#^D7N)+9"WYPE.9&I<@-AA:7/\`
MPN6\_'K4B"#.B751N5'*1HW6R^JHKJM:<9=Q-=K[OZ1.,S:9A>5V1;5:D6%=
M#(S8YD5G4ZB#I'5&Q<*BB*,X:7)N$W0R,!+7MH!J1DC"1.U_2A+5R?LLO37&
MQ4,IO??"K]C(3-*QFC(W-D3G+'9,'KYKJ2&(98^/+VTUV[U),X8L<PO*9K"3
M(R77Y-Q))&F3.2<)O=/VO>P&L^L\IKC8"MXK73L?;\KE47&GDOXMMZ>LK\TQ
MW+G8FQKXV3JRX8MMZ0R=*M`(3"]JV\+&G;@9`0>$TD`6M\!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`<!P'`<"AK\P+_`/#_`*,?_=IZ_?\`_4%W`OE\_;^OQ_IX
M#@/./]/]WW\#6?ZY]F*AU!9^[Z[+Q?U+#$D7=-LPP1]M:VM9()G8\[?F*L$$
M2K&K8>VEG/4_LJ9NI@$C4SMY9JE2</SG`"@&F`">6OVL%R;0VW#]XNPJ,IH_
M)(.Y'2+3K2<3@CD,(U*3JR1D(+5M!0D&H8K+W%=6H[(378.3VJ$$FC1,G_$"
M5.!X?K;*^;5V2N5TZYM*9FLB$X2-K.X[O[31@1*DS3JH98ERI;H1"'(PM2U_
MS>74Q^YB,(S,'&Q9G$.1*R0X^F84A8=0U$U3K+4$!H>D(<W0.K*R8"(Y$HRV
MY.-"F2%F&JEC@Y."PU0Y/D@?7-2>O='-:<>O='%2<K4FFJ#C#!A6I^8$QD73
M/V#8#C(L_P`"E.?&,9SGP&51D0L_#]`0XSG/ZL8X%H=/?"I*MQGSC.*YA'G&
M?_ZRV?W\#(W`<!P'`<!P&?Z_ZN!3=U)R>+S>PNVB90>0Q^70Z0=HECF,,JB;
MFB?(R^8;-<=961W-:7MK4JVES^GO[:J1J1IQYP6L3'%C_P`4`^!<CP.EDCR.
M.QU_D!;.]2(;$RNKR"/QM(2OD3Z-L0GK0L[`A4*41"UZ<\D>PE*&<4`P\80Y
M&'&<BP&J3+^Q[L3O[9_:9IIF)]D>NU8U`II^.Q>H(OUT:KW#-HPLE%0L\XD#
MM:[S9-[(%C2\OSNZY/;42)0N38:/ES<B`8<(L`6N=.F_%K;UZH53-+HI*[(5
M8N*HA\@EUP3*M(U`:;N60.JU[;'!UITUCF4@4KTY/T4)ZLHY"W%DY4@]H.09
MP$(8T[+>P^_M+-K]3VR'L]<N>J@(9+[:W?6R5`L'.HA1Z>V:8I(RSX0ZA?&M
MO0H*JD%PHWE\+/*/]QH)/'C&<E8"(($Q3N`WDMB3R^NV)/0=2J=F=MZ$K?2Z
MP99#Y#*#ZFU>ONDKVO6$69/Z\_$\:.MFY[%KFDB5$7C);@T)E3S(TQ0SS20>
MR(/([$=ZMHZXZB:[29DO.I;9NM?<FSF+@E%UZ[RK4AS?*[TI5MF+LH3-,/<_
MF*B$;/2I^DR*,,B@"TQB4N*=3GT)C`9`$+"Y)MIN'8_875=+:MWM1%BT+?6M
MLHMUU9&FBWI]?=.*YD-4I777O8ZU;-Q9H&B>OMQVTO$E98+\FR8=F%"><4I+
M`2H<"PB4W=@W92R:`7?MJCM?6VYHM`=](;1U7W&90<HKQ->>N#5;\)U]G=A5
M_`&.R9FP$JYC=#ZX)F)U.?5S=E@;#56"LJ3B0EALR2M3(S8S+D]?'1<Z?I6%
MT!%R)6<O%&4TK.:SS8WB6@8_6]$L)C@(D:K"?&%(TOJ]K][(<\"GK7SL?M"*
M=1EC]@.U[%'+`GM&';,'V&RTZTJ(`Q2M)1EXS^M22H8W2YT>U+3\^VQ8L1.%
MJDPPP?\`^9D(Q9\!XN$]T\M/M225S<NB5E4^BK^5WQ5]C2=/=U.6-AEN2G=7
M5^Z337T<8XZN2+981,]=$0%ASQD:)N9Y"H+:AC4`S\]P,9+.X*W-D.OFU[=I
M6CU]&7':EN5-I[IE*3Y8WVW#K2N;8T,9;6JQ*W=B8W$2)A&J.;9:I<WY00E6
M(2%L8=R<95%MRCUAU=9=S+G4#KV.5M<#-)[X<>O5YV(G$S?4!L/@TA;Z,JTJ
MOX13+$TI%Y+83<$ULN7X>UTA>40@MT1+R`MT/`I4-Z)0%K/7GN+)MYJ".O20
MT4]T.E,L"90J-MCG*?QHSV$R0Y6G:\VG7LHQ%XB&1UC*W/"@+&Y81E?44R;)
M^`!`,'D)U<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!G[L\#24_-R]E%C
M:Q2/1S7*"5Q#W@I+9T!W=.FDQ,7N)*N44#/SRX1`DS$UN+4:2T*W,!A[RH,,
M]T],<22E$28$XW`78T7V7[\;!4=5=N5YTY7B898M<0^;8.L/9;62HXNM')F)
M&[!5QP#Y-9#868TK^:P8B,=&!N<1)1@$:D+%GT\#)+;L#W*S(`RT/7%JE3AH
MLXP2KM/?QSG(08S_`+HE3=5>M*G.,@^_."U0_./NSP/*2]G[^)=%9XSMK]U2
MU4N=X;*&R*O<6*VTL>5LL@6LRU.Q.2!=(<5Q'DK@C7F%#*/4(E:<@T.#3$Z@
M`<D##7@_+@]3/971^]]NW]V+52_((+"V^Q9##U]WSE#9+L^[560\Q=O?KTK-
M"3*Y.C%,U\%9%Z)UFAQ0%JU$O+2DJ3<"4!)#:/W:VOLUDFD2TETQ`Q2'>*[8
M\;(4KT]MV'^":E4AEP&Q2':JZFP)@"#VMI6@.10Z/*#"C)E)B\)"\"1IG$PD
M)%ZAZEU=IC3+?3]8?6G<Q8^OL_L^S)FO^N6=>-R352!RL>ZK:E!A9:B46+/G
MH/S"U2/`2B"0$HTI9")*F3E!*'@5]=A'7)5'9+7<<JBZ;8V3KZO6=2^F2&*4
M%;RJL&.T&]^3-Y!L?M=J`SO3=.8\VG-A2A&E5%>A.HR(>//K%C(9QU-UE9-1
M:78J0CEK7S<C+'ESFK;IEL=:#I;]E!2.!H!IF$R8NZ9(K%'6%.4%.VH\`P6C
M3!P6#]W&,<"2G`@'N/O_`!O4A[B,`9]=-L-J;DG;.LD,;JC5BDGVQG%+'42_
M#4=))M-EYT?K.`,.'+/LX,='DE29D.<E$&8X$)B>Z"SH$:6\;1=279)K[6/J
MP:Y6NUUI$K[C<0;!!$9];G3'3<JD,W8FM,6#.5(DS6X&)_AZ@>/.<!>&S.[?
M(&=J?F@_*IJ>VU"[MBK)*A-E2W.24I:B493JRB%1&3DQX1>@P`#`>?`@XSC.
M.!!O=;?1CTV?*&@Y%$W7L9:.Q\AG3!6=9T>"M`2)P%6\3#,Y:M5+;4L6M8X4
M4B9C`Y)(+6FK%1HO022/.,\#"\H[<Z6ANSS#K;(:AO5$W_CRG:4M&^\,\&/I
M"B]C+[@PK#K*A+*?R)X8^AF;BPF)"EZQK;G%E:E[JWIU*P`E6,@#[=1NW#7G
M;2:R:')XA:5%E)Z24[2UE*+X;8K#HU<NJR2?.=8J;^C2M%*WI1#8JFF+;@LU
M!+"F!Z+1K$BO*3Y<[(P!C'J!<8*\3/M>>*P71-TKQU[/[$7Q5T@*MJ7PER2J
M=<-937%='5L?./CRLE2^"5"4F(Q9"-;D[)F<G9,SD+G^`X%<^QW5#UP[56@Z
M73L=JM65DVI)T#''7>;/JF2-CR_(V%!]-CZ!>)CD+.0XGMS85A.0(98S@D`P
M#&<A#C&`FU5M75[2M=PVIJGB#)`*VKUA;XO"H7&D@4#%&V!L)"2A:VQ(#.<%
M)B"\?#SD0A9SG(LY%G.>!X>U=9-?KQ<%SK;]1PFQ7!QJV>4BXJ94SDN@EE36
M>8SJ)_`E(#\Y*-CTH/8$1BDK(?.3$I8@Y"(.,\#%DTZ^-)K`A5A5Y--9ZI?(
M5:4?JB,SIC51XLE*ZLM#L1L<I<E,>E.3K&!55;&:).Q*VXU(K;`Y\D&@%\>!
MS3G7[I10S<@;Z?UMJR((T=72:FBC4C)AU5K:OG$H4S>:Q-U='P]U<'Y#-96L
M&O>#EARA2Z*/0)4:;[8/2'@(QU6]>D(M6*W9#M6Z[BMJ0EG:&*-3&/GR5H<6
MUD8H8JKE@;S$R&0$-R].Q0A6:UH?F2#LHT@L@)R#QC@>JLSK?T8N.C:NUHL;
M6BMI+0-+&D'U;4V4;BU0J&J$C:X-*=0VM#$Y-A1IY*5S/S@9^3A84&B/\^__
M`(G`[2G]%*#IIMV4:&9I?)"W;6.:7^*R.3OBQ809"66J6"D(?5L=^2$@.8X)
M"ZOCA#8@++'E=_B'''*C3S,F8#IZOZVM%Z:H6S]7JRULKZ*:^7.<H/M"IDH'
ME;$)D<K:&MC6&NB%T=UXPF*VYE3`.R2,K)IA6#1>31"&(.TM_0G6JWHO;S,H
M@R>#RJY#I^]OUK0/"9JLQFG=D44?K7(;(C3ZX)G5(WS05*FX8"SS$QQ/R`?;
M&4(.18$$.M;>HNC-3"JNF$KN^>3-@UUM"6;#L$9DR>NH!K[#Y430B:A&.4-M
M:-4>)C=>IZYK9,YN(53<J18/D#PXNRL8Q#*`0&:-@NMW3+;^G;.B;4Q,4256
MZAM\\ZYZ@4L:N4(G+8[,+?;=>$2Q85((P^H;9+B#*:]HEB50B=$I)8_0`8@'
M8#,FD&GS+I34+K5K/8DPLD<AG\GL=V=)(4W,<>97.3X0%&1>KZ\8"B(M5E:L
MR9L*P@8FT'RY!HSCA#&8>,7`F-P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<
M!P*]-R]VW6EI)$=:-;(&BV"WMN=F5NE4TH-R4-T/@$/)68:7/8?9B5-I2I16
M.O<,<!^DU3Z!.TF<`8:&0E0M,,$F#H->>LVE(2S228[1M$)W2VDMI_89W>NP
M5W5K$9(HD,PCH#,Q9BK*(2!"_-50U%5^%!B:)1QK%@MK(R(\TY2X'JEAP63@
M+`6$("PX+``.```#&`@"`./`0A#CQ@(0X^&,8\8QP/UX_P!/G@?(X.#>T-ZY
MU=5R-K:VM&I<')R<%)*)`WMZ(D:E8N7+%(RTZ1&D3%",--,$$!8`Y$+.,8SG
M@5V;4=AD'K6,1&$ZN*H'M1MI>[L?"=;J3@\X9WUN>I)A!\^[6):+Y%UKF."T
M35S.9]7E#X;Z,%H@`2I<F+EB0H89"T@TY2ZI0V9ODTFBFZ=HK]DQ%F;5[%/#
M<6VO5M63\AAO0H6=M`(T,/J.M6?PRPN,)QY1L#(2$`?<4G*U"@)N\!P'`<!P
M-8YEZ\^Q6A(?66QMM=F-O.E@U+/J6MFX\V'LF\H-:8LQ)K=EKYO]*)!'#(0Q
MLDQI^PZ`:F4,)B#L0%+!7,:SZ>:W@\*.!:-KQW"]:&V%P,M!:Z;>5M:]O21-
M(5C#"HVDEWSKHFBS:J>7XY&O<HT@9C0(6I&:?_\`N?\`%++$(OU^.!94'[OZ
M_P!N/[L_=P*P^T+1VP]\ZE04Y$#]3DT??&.QH?+WG9C7)3?,E@":Q(V3%T]J
MZ[NB.;0\RN[C@B(Y8<W*C/>(/4FD#&,KY;&#0AR5THRM-<L<0&;'MTKU!<;*
MU)V#NN!3N`NCSL#9M\:<T3&J+ABW%PI9HA8VZ&685!V.1RC`V4YT&[(#BDIY
M1"X[(0R'HKU&2'7B>?B79BWH#LO&:]TY4=>U,0LBHRHW''K5Q7::FU7-9?D?
MDDAFK!.;,?CRFUF5!;B&YBRU-?D20TY6:(L/0=0$(@M9S'M:KFKXC$*^KB&=
MG4_9X?`J^9&:+P:)-_\`+7K$L5M<:BT<3HF&.IA.ZI2<>G2D$@^;--&(/N"'
MG(70<#I9(F?%D>?DD8=$3')53,Z)HZ].38-[;FA]/0GE-+HX,Q:UL,=T3>X#
M+--2A4I\GE@R#!I?J]6`T>>[S1#\P_:UR:+N5:[%-&Q3'%[38QP=\UKK1SUG
M:J(OD)[@<UW%:[`HL"SC2XZ@COO$DR@]U-0-Y7S"#Y).:O!AR#;%T_K;?*OT
MKOG=3:*EMB#UD9B*5B3U-KDNI`R.2=$2K_&+B[/:FT9LFF:5Y--(PG]EJ8@%
M9(&9@@`3L$$A59V_5ALZY[<ZR;*:YQ.ZY5*M*]>[BV1AD;KU')%4(MR8Q"YM
M?RIIKK+26PXMM5/]SZ_K)<A9R1!-7?.$@&F)/$#)60K`'KGM@SHKKD6R%7[>
MV%1]Y[):4[4]A<$C#-:#\:\PVX]>KUD<\JJ&0.*NY=@V;3FM5W/L$:9M$(BH
M,<E+(PB+.`),$9``QQ+JPW[OC3C72@-0-%9U3S544NW3W`CK?5_\:=4ZT#,:
M_L+\)Z)6A$F3:%_GTJ1*93(C7R7G4VZ&%%*D&4I^`(BO:X$URV^L-I^U^B+4
ML+5';_70^7ZE*R=GI:^T?M8[L>V$GO77DIC?M6)'(D1#G5%74CKI'4JP3L8H
MRWGNLU-(3-!6!A4+SPCE+M4LT=U%.LX)ULVOJJU=G=]8!LQ0FIE(P_9":/>N
ME8U_9,3;J^A-D02O'22JB_H&LT&7R5V2R50K;3IH[BPG(`KPC3D!LC6-LQ3.
MW.M^_M:UT]74V?PMJV3U)9\EB--SQSGL.D]KZ]H)X%)`((4F:Y?,[,@,2L-O
M/<(ZF+3O")WSAO-`4K_=P%0FHJW9?6[IKWY/U&U]<H',ZK<YVY::SBO=9;GJ
MR9[2KD4'@98[GSIYL3++EM.*R%QER5<W&(EAAJ5]"WY6HT)91V`##[%MN]IN
MM%A7I-[/V/N:PZ-H.P=IJ_\`Q!;&N]11&M7FK6;KO=-JH-L/+IG%*]AI7LQO
M:92E@K6:C4HV(Q*G^D*!GN`AF\"*U)[%;(;FZ4I]/+OV+GUN7=OKN%2VLDRJ
MJ:1B-Q.Y=6]8SJ9C&R>TATT6Q"!4>7*<S2F&]W,)<6A"X(61%+F1#E9D_!@P
M!W\ZNS?+0H';),&*,RZCZ002/?*W=0I875>'Z+6#>12VEX(Q@NI;*2!)HJVL
M<++0#I=,W92,$R.^H_4#UJU&C:3@NFZ6K<MVX]49:]WQL0^;`6Q&K\L^#RI+
M+8JVQ.>4>7'S&<;!1ED%-5;U4WR*Q8?'EZ8]Y>$K02B<%BX0DV?:`'&`MWX#
M@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.!6UN'NC.8C/6;3K3"*QNY=Z[%8RW
MU,RR)2L_A'K!6JX[*$S8O:)V9AX7LD';C\BPQQQ.85()LXE_)-P0%84K4H97
MTVTK@VH<=F#AB3R.Y=@KH>DDVV6V>L4"0VS[VGQ"021.O=?DP_3XC`8HD,$@
MBD1:_:8XLT8`E2%Y%E0H4!,[[N`X#@0.WDW!@>O$;CM3)JX6[+;&;'$/\&HC
M4*,A;%4CNI2-NREDRR7F.Q2EB@5$11N78.F,M>@89F=M'D(L*51Z5$I"@C\K
MQH)`-7YEVA3=W:H>HOF#[FSS4ES6PHE],@T(AM9H8Y,G*'UBNE0@253%5LJF
M'M"4KB"%BQ,RH1&AP(.?(;='`<!P'`<!P*^>V%*@6]9^]A#I!H_9+?\`RN7$
M>JA4IE8(0Q/9:6&NBKPME(U"3Z0)O$3A42()I1AAY`"P#`,818"D3IPV0FLZ
MM75V#.W:GU>;(-1M)X)S0M&T.SP+9ER`V58`Y*G&\D/3:XM3Q$OE<'O9(F9`
M,9*50`:,G.<A*#;`Q]W[<_'/]F/U\#G@.`X%,_45#(G6\Y[8X!`H\U0^%1GM
M$LO\/Q-A3ID#$QAD&N^M,I=@-38E\$MQ#F_/:I:,L.`AR<H&((<!SC'`N8X#
M.?'QS\,8^.<Y_1P*Z]E.S6@]9[.=Z@7PG8:ZIM!X.UVG=2'6RDY1=*?7JK7L
MYR`QSRZ%,;R$,;0/A#(O5(FQ'APD*U`A4*R&XQ,4([@3E@$^AEI0>'V57<D:
MIA`K`C+',X9*F10%4TR.+R1M3N[&]MR@(0^ZB<FY46:7G.,"](O&<8SYQ@(T
M7EOCK5KGL1K/J[;<Q<XW;.V[G(66ED0(P^N4?=WB/B;"!-CW)6]&>U1M8].#
ML0D;L*S"\*U9F"PYQGQY"/3GW'Z*(OX_(VN>3.9277J_XYJR\06"5E,Y=/+-
MV$E13YECJNBHJSM:AUMN1J5$5=RSOI8!IT@&E8I4&E(B!J<!W\V[6]6*FI.K
M[SO-%=U`,5K7<FU_9H?=M)3JOK)89Z-2J*<%LPB+NWX.98`QHD8UZR3!-.8`
M(,@.`K,P,&!!WUD=F.OU4[*F:JS"([%IK+7Q^8.4"=4VOEEG5S<LJ@E<?Q9D
MM3TI/S&8B/VA;"2"9PJ+:&HP_*@_/R91HEF,I\!B)%W2Z:?PRF%H2EMV-K=%
M`;_@&LDRB%DZXVC$K"B]P6,TQZ0L3#)XDL91*XJW)(]*D"U<XN8D:%*6K(*$
M;E0H3D&A9H\+(-5$4FLS6(VV*QAG322PIHN96$P9AXTR0UWDLA5-D>0*75_?
M5:=&(9GM$*5RPP(0A":9D(<A6>_]T^D+'K[3^QR9PN2316]G*Z$U<PJ+TI.7
M6X')@UP4/'\P$\<:N$@2R=DA%-M;(<X/ZM444:E2C*"$D:@XI.()LR38W5-=
M5,)FL^N>C4=-W]#6AX@;O9,UAC#"[7@\];&8UI&T%39<WH)0SR=JEB`&"/;,
MP<%P)+$#.3@!R&*H+(NMRD8&5/:VD6DM3UC!+'DT$*F\.>Z,A4)AUMR$I`US
M&&!E+0J;F1@L5[3M:1*XMOS!3D>4E)*.+R$LL(0Q'O3V#:O4!%VZ-VS7RK8R
MK)_K9?VS%AHX4UP.SXBW:VT='HLO>)?)6!\=P,\FC]A26=,C$P8SZFYQ7K<Y
M&H++)$+(2`AUQ:,Z]5XP,,7L75W7FO,R9QB;3$DDPJ:JHZWV'AL0RB20L#,F
M=&5I(GZ%O=R%KFWA#EP+"H"<<#P,(LA+PLPLXLLXDP!I1H`F%F%B",LPL8<#
M`,`PYR$0!ASC.,X^&<9X'[X#@.`X#@.`X#@.`X#@.`X#@.`X#@8'V6NMSUXI
M6:W`STM<FPSE#RFDU+3]`QA#,+9F`W1];&0145CKD[,:->-K+<<K57J4EY+1
MIS1AP(0<!R$,>LWM'B79[%)?85;ZO[64E6L?PE+B]D7_``2+1B%6HL*D4KB4
MI;:X>XS-9:2^N4"DT04HG@O."L)#Q!!ZA#]80!]6V6XMF+K4_D;T.;(_/MR'
MEG:GBSK`D2(YZI31JL9($>4%MWR-$<G+>[!D"(!AL'KPE04[28XOYQ5\HRE&
MJS`D1J%IU6>G<">8[$%\AG=B6$_FSR^+ZL162]V_?UH+B<%N<^L>1@((PI48
M#CY=L;$P"&EB;@%HD"<A.7@'`EIP'`<"OK<G=X^C)%$-<=?(.3L)O3=#4J<*
M?H5*Y&M[#%(J2KPU.FP&Q<J1$JQ51KM"5PO"MS-+$X/JX&&IE(5+S<A)#L=-
M=)4NNJ^9W9;TW.V#W3NY,@Q?.R+ZU@;#US<B/&N9ZCJ&-B/7$51K]!%)V0,T
M;0FYP:8'YYP-6.!ABC(01Z2?^\?NG_\`O,;4?]6ZQX%\7`<!P'`<!P(@]@,L
MF,#T@VPFU?1NL)?-(C0=G22.1JZ<MG\*G=R98JXN)2:=%/>0,RQAP%.(9J96
M,I*JR'!)IA0!B,"&M5TWWM2UJ;:4&OCW;)IAL'/956\N?56KE4]457:O6<!>
MOKA2ZOS*DO*/)RGZ/YKX?N#5$@]OZNG1&%#!Z1_N!N)8^[^W]O\`7P.>`X'&
M?[/C^KSP*7.GJ`1&IY;VNUG7[*&-PB)]H]J"C["!8N<0-V910&M\T?!A7NRY
MS=U/U.2R-8LS\P>/V\J/07@!(2P!"Z3@=+)(ZS2^.OT3D:`MTCTH972.OS8<
M,XHIQ9GI">VNB`TQ.82H++6(5)A8A%C`/&!>0YQGQG@:SU[?EOZ=0V>[RK2V
M+:PUU!+'CL;8)=!-@8+=MGE4W*8PWNC&BNK7Y="KP@"E=*UC$Y%@71Z6#<V5
M4M;DJD!R<.5*=0%NNA/6'I_UP0XF/:S5J7&9&Z02#PJQ;#6O,@<Y1:!L'(6C
M(DDG(<'98Q(G=U>GA>X'@;$B)*`]:,!119("BP!ASL-ZTW[>&:%3!HM=CK9Q
M8=9K'K"NWE9##)*_UU?*FX:2O"DKXC:K+L@(3JJPFU,$9-38"$Y4G6&``<#S
MGR$0&_I&LJN$K/**7V&@K-:-1O&I5@TPHF59.SQ!Y99-)Z^6Y1%_COU"VRI!
M)WQEV:3W8_N2A<QKVYY87)4%44<I$7DDP,4M_P"7PL:QZC@U0W_NA*F*(0NK
M]U6)CCE`(G<Q-%)+NO+FP4AKMJD>P#C;\B?M<:RJB-M\<:FE3E(_+!"4*A.*
M09F0""7M7Z"[Y1S<&A]D+DO[6C8-CH;7Z.T=7K?,:XM=GE-6KQ5M^&KEM*M"
MV:P`PW^)^Q4L0-YDA>79"L4H8\ERTM^"B3#A'!Y:PNJ/8<?6XCTLK.]Z>=+@
MM&\\;'[;;"VW7DX6AMFVU]T-VP\DDD<B$-FS.%BR]6!'&MGP2<I&F3QA+[1)
M0#\%B`%D%,.&\3R7LX=<K32$65(WU%'M42&E*_+6IV3,M51],^6'9B=#)W)U
M)B<QNTQS4MC24J3O"*-E%%J!_-#]?`I:1],N[Z>CZ?C7\RNL2:Y:?D>^L8;7
MQ%4]GBK1^I/LF;\*[W,>V)QGB^6"M:L)JJ-70\].Y$-2Q"F)2.90AFFJ0A*C
M9/IAB5V59I]3+5,8BLA&G>A.S>F,&';%?(YZZJ7RX=?*RHVM+@`#"A&TMLCK
MT==8<E/LI\&G&*LA3&)LAP+@5F;J]26Q5'QEM:M6*S36A`K#MXF8S6'T-"('
M$QQ9LC_6JWZ7*ZV<(C()K#?5&=HYP)P%)I>S+DSK$6QP&O\`0I6%%GX":@.L
M:]]DJ^WM06]#:TU<E%NZ+49UVZJ1:-/"&UX!1]+Q>K6J66H;'CVD#,_F1A]O
MF5+&TE.J,2KE#;#6U2,L.!%9R%<NT/4;MG2,HUFINF*84;DT!7;#?R1#A0*)
M1AON`ZW-E*<N]DI7<J1NL_8)HU(4#C"U;J[VBV87*7Y.V(6U<W&F'*?F0W.$
MF#L)4V%!)"<_"<G!R=*8(Y,G-P6'!A"<X1"81I!0_(0"R67D0<8SD(?NX'T<
M!P'`<!P'`<!P'`<!P'`<!P'`X\_T_P!GV\<#G@8\M:UJXHRN)K;]O3-AKRL:
MYCSA*YK-9,M`WL<=8&LG)JM<M4"P(6?AX`646$9QYPP%%`&8,(,AI^='>W]P
MW%UFZ\:)]=;BU++]3R_8QZV5V:F,8=%]6Z+518&T=RRB.R4YA?DS>DMO8VQH
MD\`602'$#-;@G#$XOYA"!&<G5!M5:G:CTWII5N*OI]N>3LN[\Z3BRK&FSTHE
MULW7:<D$6?,;;N*>N./JTWL27+"\&*UAV0%$EA+3)"DR,A.G*"3F//CX_?P'
M`X\_T_V?J^_@5J[=;HSUAL))IKI)&(U<>\LO9$;VX)9*<N'3.I]=O(A$)[VV
MA=V085S6RB"$8X[$TII<BF2HOVD82D@5"X@,NZ;Z40/4./S!S!)9)<FP=S.Z
M.8[)[065\JJM6]9XG2Y3$+G<Q(`+?$8!%DY@D45B#2$AABS3@*5&5ZLGGGA)
MRQ)6K@<`FTW;XC*)^OB$3D,F106$I$SA,IDK8VE6YIXO%4*U6@2+)$_&IL)4
M91IQ0#%!H`B&'&?/`UVNC>Q=@&Z^NP>*W)H-N7K@S[5[AWWNY!;)NZO&:,0%
MKB4V*K5A8ZPD+@3(5:Y+:1GRJA3\JG)5HAITYN0J<"!Z<ALK\!P'`<!P'`J[
M[-;GU$>:<M#0^_=C=>Z.LK;:@[)8*V0['O)T9@CRG<$IL9^M"=5CM$VIR51Y
M\6$'@0)W<AR$:66,LL0<?$*PM;KOGNAKI5TDW>[@NIV8ZV5G7A\2<V>NZU@D
M$NR8@:X?AABJUB=HM/71<XN9:]*0>M(:680590!EEI@^L/MALW,KNW/[.U/S
M0HRK:7MM0N[6JR2>GRI;G)*4L1*/85%$*B/>3'!%Z#``,#Y\"#C.,XP'9\!P
M'`IDZA8:R5U-.V"!1G#QB/1OM&M'+7^(G^12Y_%^(-?=;94XC=9=+W1[E,A&
M-V?#\DFK5:@PE-[9`!>T46'`7-\!P'`<!P'`<!P'`X\?T_?YX'/`<!X^W_+P
M./&/MX_M^[@/&/M^G@<_=P'`<!P'`<!P'`<!P'`<!P'`<!P->_OS6[CU36-.
M;`ZN[S6=K(B#<E&:^2*MH77E;2IEEZF^+EC<*.G[D\S-K<W)$Z1%F=3,ITA0
M,IU`BPX%DOU#%D+HJ2A\JH^C(A$;EO)XNV35_&5>)S?-A-D8A;K+"T)R]R52
MB3H(^6@B[&!`V""6:,O`"@DI_<,%ZLC%D*6]HETK[UZRL+4?68E+#>O*4+$K
M)=>^TLC:MTQ<+C#)"WR$J#Z/0AP4LP)\U(98Q)2G2S'$6(H$)*E.RENYP!'D
M!D+I*Z08!TVPZZD;5=DCOFP[T>HP=*9:X1D,!CC9&X/A_P`11B8H41)9664N
M`.3*S%S@<M-,5"R6`L!!9>0C"\_&,8^[@<\#C/\`;P-,3\P'M1>=G7#K[&>L
M/;G8>!3&!;`P;4+:*Q*<L(3+J="9S?,J:&ROH',7PEW0MLQV)C#[@9SBU,`7
M-:PLIAI3Q\D8),48&T7IWIS4^EM6CKVN?KTDDTE=C)G<MS3YV62JWK\M5R3$
M%22T[9FSLH6/4GE+V:3C`,''"3MZ4):1(`I,266$)88QXQC'`YX''C]N?M^G
M[N!S]O'ZN`X#@.`X#@8&V,IK6BYJQ?VK:ZLJ9LNH8XVN<ID2:\XI#Y1!XTV,
MR$Y>[2A:.:H5C3'RV9N2F'FN'J)RE**R9DP&`^K`5-:057^7PD<QKNP=(:IT
M:=Y]-9A9<>J641:MV)3+'.8TNV,LALLFME<P8A.R-;#6*1(5IREJ]D&4*H!Q
M)@R<Y%P+W<?T^?C_`&?LX&/;3MJKZ-@K]:%S6)"JJK>+%)3I).["DK1$8DQ%
M+EJ9M1#=)`^JT36APL<%A1!7N&!R8<8$`?(A8QP,>K=L]8FZY(3KROV"IU)>
MEDQD,SK^I#["BY=@3**&)E"U._QR,"<OJKLVK$*0X\@9)0L*""#3"_4`HS(0
M^VH=HM<+_D%D1.C[VJ:W)/3\@_"UI,%=3R-RYW@+_D1Q86R4(&-Q6*&A0(]*
M>3C)H0@R>G.*P+)A)H0A6KT^P]-7LP[7H,B?I7*4D<[1;0`1(Y](W28SEUR]
M:^ZW24[,EEST<>Z/PVX]Z$D0C.%D29L3IDV,Y"3C.0NBX#@.`X#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X&J#^:D[#*1UAHO6[7J6-DPDMJ
M6%L+26P[4SQI(D+;VNN=<K=BDODZYY=G0]*E^HR4Q()N:DI&3!B4X&:>(@DL
M/O!-2EXK.>[6&0;9?89:MKSK5F1*.8T1I-&I*G')-D6E"YDF,T]WMED66J6]
M?&RW-J&:EJ9D7'L0#,!S(5KL,K"(H+V6=G:8\TM;"P-;<QL3&W(F=E96=$F;
M6EG:6U,4B;FMK;411*-O;D",@!1!!(`%%%`"$(<!QC'`[#&,8^[@<\#S4RF4
M1KN*2.>3Z41^$PB'LKA(Y9+Y8\-\?C,:C[0F-6NKV^OCJ>E;6EJ;D9(S3U!Y
M@"BBPY$(6,?'@4WF3W8OME/RV4:^S[5#K04'>U(-B$J9Y@^T&\+)G)H#F36Y
M.O*;G_7W71[*QC)]@*R2Y5)T9N"V!.WI3/JPPCYW*T34FNNF/752E!UK%ZNJ
MZ"=K'7TUQ2#0=F):V5L3_P`4G`U2I]E.#)Z]T=%AQBE<O4C.6N"PXQ0I.-/-
M&8(-C?'Z?Z?MXX'/`<!P'`<!P'`<!P(;]AM>4Q:^C.U]=;$60.GJ0EM%6&UV
M9:@%N40J]BPF!6>NEWJP(/SN&/)(3\HOWOJ&`?*^D?O>G(:I'3[(J]N?L+KI
MPE.]#7>A95OWSMI3]=U1UV;':RQ*?6[/]:XY1KO9$IL:PH^AA<0A[%2T,R-J
MC;8>)N6.;AD?O#\)R<AN_8_7^O\`V<"A7O>TIW*W0I5F8];V2B+6@]?U]>[W
M(]=;E<)DUG69;TEK\Z'4_,8QEB3_`(6?Y34('AW<HZVR)4C9,28]$N4C]:%.
M82%?1VAF\3WLVPPB2ZXN+4_VMM-UU[BJ=TH>]0)PK;7.&:K:N12L[3I="XO\
MJ+M\R4M<XC*QKCC:G;\HW-ODJE48:26!7[P9+ZK]!=I(_:C(99-*V%HXQT'U
M9./7"_3R-2*KRY+8EXK]D7&V#+SU\4QI;.F1XA+''0B<$;[(FA`K,>WX\CY`
MX!)Y@@GGTS0==6+UVDURZ6)/K><H;V83YK66G:[BPNMGSHP_7#69S`ZSAPBC
M!$HNI=4A2\*,K*!I;2,(TQ./9P+`A""[+@.`X#@.`X#[^`^[@//V^W]/`<!P
M'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`B7MWN-5>GD)87N:II%-[%L9\S"J'
MH*MV\N17-?\`9)B?YA'!JSB?OIQ+3RBQ!/<W-48F9V)!ZECBJ3)PY,X%44WZ
M4HUV:@3WSW))#)M=:XE.35="4A8LHB=1Z=UH8N"\#J>/2F.J&EQN>QI(?@!D
MVF3F#V%ZTHM,R)F]O1D#/"]*JJLKVCZU@U/U-$FB"5I6D79X9!H>Q$?+M,>C
M3`B*;VMM2`$,PTS!*8G'K--&,XXS(C#1C,$(60]_P'`C-M3MS1FF]=$6-=\J
M/;"WQZ1P^NH)&FQ;++6N6R'G/M1FK*:KAD+4R:QK%E"S(24C<@)'D.,B/4#(
M2E''EA`2'ZEWKO[*H]>79E'&Z&4K&7]!+:!ZTVMV1R6#L*EL4DN,;L[=J0(!
MJ&2^;H2JR@'HHDE&;`8GZ`^2WAQR-:4%R00`+`$LL(0``'```!C````''I"$
M(0XQ@(0XQXQC'W8X%8N]O47IQV-S2"3O9QLMMX>*X9DS-%$L'NJQ*X8D64+X
MKD3<]&L,3>FYM425N<UQ@D[CDOYHH.0AP/P`'I"=E*U%$J#J:O:7@9LB/AM9
M15IAT:.ELE>)C)C6EF3A3)#'V42!4M>GYR&6'R:I4FF&FB^(L\#*'`<!P'`<
M!P'`<!P(`=K`_:ZU-ZSLL5:27!&K-T'B8K@$K!73B`B#NYHR9")!D"W]T(,C
M28*,),RN"3@)I.?\4`4-],>YC':5SZNU4G[^E^Y+D;2BM.?I6[Z,,-1O2\]@
MJX"@Q"\7"!DR^(G6JL(3%!N3UYREV$B%@PT_(QC$&W%C[O/Z_C_=C[OV<#G@
M.!QG^WXXX%,74"RR.-3'M>CLQFSA9<J:NT2T`O%A.[7'V!UD^%^OFMKJU?/1
M^*)&Z-M.8\R+DS47A(F("H)0A/,#[QIF<A<]P'`<!P'`@)V0;";6ZUZZAG>F
M6KKCMM=[O8$/A316J18-`WM+7(U"HMRFTC5$GD'EQYBRF++4"P,DLO*D)AIQ
M)0!CX&4;XVHB^J.LQ>Q&P#)(DPV]%6;4]P.M&91.)D\6;9C_`!B$,5=5Y'0F
MHE\ND+O/)00W-Z8`@'J<BQXQY^'`AA'.Z#6";H(8VPJ"7T^6R]CL%QL:B5<$
M:(W8NND$IBSW6J;PL_8-=(94@KV!P2J)+'UX%J@E[<%+@:F^7;25BD6"N!U/
M7_V9V+MC8UFL=M5#`JE@0-:*?W3J=_B]B.$Q?&#7J]'RR6^M6W8%,KC[2RQ2
MT9+#JY_%I1#.J<&\#*Y@)&9@]*8,T(8%]WVSKI65M66RZ<1\Y$XTUK[L[KZU
MH7RTYW(H/K9?5\RVG&JR=NHE6-<2^61PM'"(2LL<9<.1OQ147%[0C!'$9.-"
M^;6"S'NY]>J=MN0O=3R1ULB`L$T.D%%OTBD]0O2:1)`N;:YP!^ES)').Y1]8
MVJ"3"Q+T"14$0A!,*#G'C@9XX#@.`X#@.`X#@.`X#@.`X#@.`X#@.!!+<?=Y
MIUM50VH*Q@SAL/N3=25PQ06L,2=$K:]R0I"/"5QLFS)*H*5-]14'#51@1/LL
M<R\IR<8RF1$K7`92,P/*:B:./5:3MYVQVQG33L5OI8<>Q'91;"5J5-=<TG`3
M5(W%/KYJI#',U0;6U.,BPX0E:TS.9',5^!.+VI-,$0F1A8QC'C@.!C:W[@K*
M@JVEMPW+,V:NZP@;<%WF,VD1QB=BCC4-6F0X<71244<),C"J5EA$9D/I!ZO(
MLXQC.<!6!*NY?6VSP(JUZY79@[#-H)<,U)$:NIF0#S`H2E+$24NLO8NWOIJR
M,4Q4D=RI`(Y8I]]T=E&0(FE$M5&>D`9HU7T.<H+8P]L]O;%1[1;T/K,H:,V>
M:PB8JKU\BKL26%PI_4>M5BEQ+JRO2PAR2X/!QJB6RTSUJ7=<,)A:-.%D'`<!
MP'`<!P'`<!P'`<!P'`CKMM)4,0UBOB4NEIS>CVZ/U=+W5=;]:P_-@S^N$Z)H
M4'&RZ'PC$:F(I0_LP0^ZG18;%N3C,8#@H7`UE^O3;:S+-['M8X/2/8GV`=@%
M$/<)O53L7'[KU')H*"U&K:X26JJJ:RB9O=(5N!X9GU_$>@(;$9X5V'/*4X)Y
MA?N)#PV\L?;[8X#@.!QGQ^G]>.!2_P!/S5,6*7]KC+8DQ26'.V_M#M#$CG3=
M&4L);9#E9K]K>X,@44-1NCX3'P,,:5HVP>/G%`U9J(2H0L"/R$(70\!P'`XS
MGXXQ^O[>>!@]UV:UV8B;/4/-YU*U)Z4PA_BZH<+`BZ0FM!.81";@38T]S`".
MFKO3D)0%62Q&&X]`<9'^[P.^1WA3*^9QRND%KUTMGTPB>)Y%(4DF<>4RB1PD
M1:0PN6,C$2O&Y.4>.*6E#+5DEC(,`/U!%D.,YP$?MX=+HSO1`JPJ:?3:3Q2M
MHA?%;W1.V2'JG=A?;'15<<YOD:AB6=QB01B8USE/.\M3T!Y95A+F0>SEEEB"
M$T8N!YS&J/7K6C=J[KZ_0.CV]UK!RE3CJ[$K#?FIPL]6^*FY]/LMSAZ^7O*B
MP;`=)2DE3BJE@A'..7@2\X]S"=D>1<#P%9Z$]=VIKM5,`CZ9MA<I?)ZKD57Q
MRPK^F[M,;*=8O5CO5S-`DB.=S]:_VI7535!(5+4PPTX+E'HTVF>M,A('GW<A
MBN+];'5XTUU<M+P"2.\>88A+&%=L&9!=SK@9K!B4;C4(?HQ%:*MRP&&WR+"C
M&O4=K!_<6]MKYU<$\71M2D\9*(`AF'9"U&L8Q7D*KF!Q"I&F,,-6QB'1MBK=
MEA1:$J'M<%:VA(CBB&+EM>1-N&!.R$DA29(R(K)&`Y#G.,XSP/<\!P'`<!P'
M`<!P'`<!P'`<!P'`<#C.?]N?CC[N!6UMMNQ,XQ8J/3K2V'1Z]-YI>R(WE2R/
MRU:136J\!>O40EOC:J1LH3%S!%2<>HYCBR009--5!7RS>`DC)Z],&2M.=(HA
MJHFF<WD$SD5_;370I0/.Q6U=D)&\%CVL\-Y."FMB;4*#`VJM*>AA6<IHO"F;
M);,Q(_\`=P>K,5+%`3<\?'SP'`X\_;_1^C[\\"G':C8N7;J2.U.O+1YE@UB#
M5)G>IMV-HITQES?735B+29J,;II7+>U!4D--[;6+(XY#`BAA"G+9'%!Q*F3'
M$%!P@5!%'\J[1M4U/U)UQ+H!&"FV46];.P;S9,K5D(A2*9.-?7G8M21(YT7I
MTI)V4+1"X0C+3H_68G2J#51A7@2@W(@V/?V\!P'`<!P'`<!P'`<!P'`<!P*G
MNUVG(X[4P[[/3[>C>#3:LM5ZZL6>STC3JPV"&*9\S%(D#D(E]:'R(R/$DD:<
M33\HREX-2E>^O$`8L!'ZPA4%UG2:\8'O)KZR;9O_`'75(7>D7M-9K-&=UMF*
M+N+7Z\3F:`GR-UC5I1.MH6PO]:6^RPTPU]9V1R,]T)K>?CU^X2(H8;;N/N_]
MOGQ\,?=P.>`X'&?A]OM^G@4S=0Q$S2S7MA2V.Z1Q]GQ/:-:'XF>X:PN46B+B
M(W7S6P]BRPQMY?90[-)2*+FH4RG"AQ6"/7$''!'Z#`A"%S7`<!P.,^<?']7`
MJ$E?1IUVS2&;5P:05G,5;1NG<L5O'8-1BT)F!WF$PAC\ID\=0`<?J8C$$91O
M;@K491AQGW#U@SA&9.`G,)#.<:ZWM-*CVB1;W,\#=FVZJ_H-EHN/R$V3REW8
MHA4,'CHV-&TQZ'B5+$9"DJ,)0)1C*),.,`5Y`'!QQXS@I!T>UV[C-AX-<&P1
MNQEWZAR'8.BW%TB2F^YT5>3$\3V>[*.]N1A95-%*7Q>GUBKJ,ZVX3P5.H5HD
MLO;%+X:NPA5Y;$GN!R?U>;;.&T$%D+]KBF>(U&Y'I1>"*[I3M0GOR>5>U:D(
MK#MBPM::NM"XAMEVGVEL[M2\IECU+,HV.-KHHOR2MP2-`2E$&5]A-"MRMO-\
MHA;5G:VP^.PF:-O75:#/<,DMRMY:_:."U4>IO>UVZZ5P2VM:J<+YU;]_.#$V
MN<BC99#`^1Y(,TY228D3%&!"9;U1;P?R;;5,S=I-%5%V7)J;7^FK?7KS=E./
MSC:%OJK-LJ_K_P!^[OG#K*T4=E12ZUY:07`DBU:NEJ(@(?G49!7K](;?=*QP
M,.IRIHB"*#@@(K64#C88.:XMKN9#0L<6:FS$4,=V<Y0T.@X[A+\GE0E&-,=D
MGUE"$`6,\#)O`<!P'`<!P'`<!P'`<!P'`<"`O9)L7L]JEK#++ZU=H2!["OM:
M%O,TLV)V!:)54H&&G8A#)3*YE+FAW-;7+ZX^M8F1,42V@P$Q0!0,0,B$#`!!
MT_6'L]L_N-JS#]B]F]?X)KPHMENC-@5!'(':&+0)D=-SB%QR71"6/JS#6VBC
MCXX!>C"S&XS`CB0E!$/`!"R#`8OV'V\N>\+<D>DG7&IC:VW8NO(9MH]NI&T!
MEE*:0M"P!1JYG3MN!EM-Q;;+6H_)C!!0G_(M!PBETE&G1!PE6!+W4K3^F],Z
MX6P&IT;^Z.LJD"Z<VQ;-A/A\RN2\[.><`S(;/N&P%X`.<OF;T8#&,C%@I&A3
MA+2(4Z5&22G+"4O`<"&^TW8/I=I*Y0UHVPV(@%$+K"1/#A"@SU0YMZ>1I8\>
MWIGH3:N(;52$PUM-=4V#2LFA-#@X(O3Z<^>!`]??5R]L#FH@.ELQF5&]?)!A
MC7;N^C*F7Q*T=BQ@,,(?ZET;(?6].Z1Z*%%8RC?;;/2A**/&<EC`#U28QR3A
M.!\TMC<)T_,U"TIF*S0]C:6MI:Z]F](Q2,/#Y`,)I(B?W]R2M\U2NR&22&:^
MRJ+>'5T$I=%ZAP4+#U)BP8CLA'KJPZSI?UDU_)*@QN5;VR51'B,55S7ED1&#
MQYGJ=T>I?,9U/'.,K8VG$\K39Y*)F>K6%*E`B"C0^HH`<C%P+7>`X#@.`X#@
M.`X#@.`X#@.`X%;G9G8,XBU(B@Y.@MF[^4-<[7.:RV9@U,RN'(K/AM;R"+G)
M`/$5KR5+V)59JMX.4FI<$-;HW+VXX):DLSU8#Z0J+ZM(=UQNNVU=J@;C=A]G
M;9U%!9<@UQT[[/'VP8?8^N$.?(XH;9@IK&L9U!8<5+7,B$HSVP]Y2KY#@EK3
M#![O@G!H`VEL?;S_`,F.!S]O]?`<#C/]'Z?[\<"EOIY_B%F6=KF;:#"P69GM
M%M3\6AKC,@%`O.*"UQQ&LQL<J],@'G,,^F_4<J`A#]6^:P3CY?VLY"Z7@.`X
M#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@5D]QM]T[KQUG[E2BZIXUP-B
MF=`VS4D44N!:I6LDMDV;7DHC$&AS$V("CU[F\/CPJQC`"@9"0F+.4G"+3D'&
M@"J#KKV$O#L,T-TJU9T4F4@I>@:FU7U_J/=/>U,UK6:>1Z;1&H86SSS6'3II
MD2!.8==Q.0Y)>K#5)3V&&I%`#VG#FZF)\I0V*-=]=*7U2J.*490$":JYK.&I
MSRVEA;!JU:E6N7'C6/,BDCZZ*5S]+)?(W(TQ8Z.[FI5N3FL-&>I/--&(60S;
MP./M]OZ>!`'9GL8HW7J<)J(B[;-=FMN'QN+<8MJ1KFU))U<9R)3[`4<CL$1B
M]MAM'UYZU98SY',W-D:PI_4,@:@P."1!KE]Y&K6UFTNJ=2W5V+O%<UZPH=P]
M7(=4^EVO)B64,]=MESVY'Z\G#W=.S4B8$$WM"Q5<!D*QN"EB22)QEN4X`?C#
MJ8`I06&XO&(S'X5&H_#HFSH(]%HHR-4;C;`U)P)&QD86-"0V-#2W)2\8+3(6
MYO3%DE`#\``!C&/NX'><!P'`<!P'`<!P'`<!P'`<!P'`<""F\5`;>;$L=<0K
M5[<U7I8PE2!X5W5-XI5,8LJTI5%LMZ<MCC%>.,Q/PR0-6)P]X:IS]@]4`.2_
M:Q^Z,!@84U5Z@]9=9K@8=FY'--BMK]M(XPN<9:MF]N+SG%QV0RLCZC6H'IFB
MC>N7H(+$FA8D<E!0"$+25E,0<(LL80B%C(6JX^WQ\_;/`U__`,PO8KU6FJ2&
M5P&_Y'3ELQ-JL^=0=IC6\C)IBO<OP?#PNJJQ4S,L9ECOM&Z5@[`;L(JY)6H$
M;ZH=PE*1"R,G(`K&>-S;_DFY4(FT=VUN=XOQDV7ZWJFUZU`=I.V5;'MAM/-@
MM3(A:EX6Y8VK*4(TZV2R9^D,A=G:0>#`PI?'RFY,H3`2C*4!E;I_VCV6L>]%
MK?6VRDJW">;>ZNS]K+SBEV64X/E>U-V`J=CG:#1RL37!D9'K^5]D=8:!R0'0
MMM:TI8$3"!>6WC&6,P86;]-BVR')^[3%]RL,-BMN*>S.P<V#&:YD[S-J_9'D
M&N.LQ:--$I?(H_$'V0-Q[&%*>8<J:&PP"DTTOV,!!@0@NMX#@.`X#@.`X#@.
M`X#@.`X#@.`X#@.`X#@.`X#@.`X&OEWQ:[P7L=9=6NK1)D_%R7?;J>__`,<M
MJHY2+6FB:*2*6VU[WD,;2'`#(`2$B=$P:/-K@-$@<7V1X-PJ`8WY`()Q=5/6
M-4/4_JZ5K54LMEEA!<YJ^V-.)_,RT"-UE4Q?DC6UG*4K*U!^G,#.@9F-&E3)
M`#/&$)61F'&F#$+@65^?M]OU\"+&T>Z>MFF\=97N_+)01IVF"[+-6U;LB!UF
MMQ6[)AC)(312HZCAZ)ZL&QY$J5JB2O8:F]1@@1P!'B)*\F8"!Y+;V2=@OJ,D
MILJZK=1W3`P@BS"YQF2=C%OL!X<B`-^E[6;(ZQTU;'5&H!ZD[.9*INF,*'CY
MYI.%CVPL"U?T^UNTT@ZRO];JJCU;L[TY&/TO=DHE[W.+$E!XSS%<PL^Q)(L>
M)U94P6FJC!&N;XX+E@O7D.#,!\!P$!>U[KAVC[$T59PJJ-Z$&KM00Q[BL^DU
M>GZWQ*XE,QM>N)RTSRLIR"7N\OBKZPD11U9R<#:R1#1KPXS[^!8SXP%EU`1&
MW8'3<`B%]6\CONX6)D^4GUP(*_9JK13Q\RL5'B>4U>QY:XLL5)PE.*)PF3GF
M`_PO7Y\BSC`9AX#@.`X#@.`X#@.`X#@.`X#^W@<>?V9_LX'/`AYV#PN-V)HU
MMI"9C-XI6<6D>O\`:#>_V/.%LE;HE`&H43<C5DU?ED.>8_*"D$6**RN%\DL(
M/%DC`<9%C.0B"A;IZWMN2V[MH'7=X[-JKV)@#/2"]8PP.9=>]Y:JVO?<*A\.
M(:F"?5;:=F/:>-68!E,^3<74]O2`/4(,#/$F](AFE!M5!_3^W/G[O'Z,<#P$
M]J6JK5Q'PVA6=?60&)/1$CBH9[#(Y,`QF0IO3\N_1[$A;7'#*]$>G'H5)O;/
M#XQX%C@?8JK:NUL[;+260*%J[.96)9%F:QE,68SYXT1EQ/PJ<(ZV2\U".0(&
M)<IQ@PY&4H`G-'CU"!G/QX',3K>NX$NECG!8%"X6Y3V0'2R<N$3BS''5TTE*
M@H!*B2RQ6SH49\B?SR2P@&L6".4"#C&,CSC'C@5(=/;S,)#+>UM[L.&)JXG2
M_M#M'\1P%%*T,[21H2*@-;VUE]B8MJ%J1O89!&T:-US@*1.)$)?E(8$1A`AB
M"Z/@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X'CK"L"&U1!)I9]C2)M
MB%?UW%GZ;3:5/!HB6J.12+M:IZ?WMP,``PS"1M:T9IP\`"(>0@\!P(6<8X%:
M763`IM9!-K]CUZQIRC5U[QGL#O`(5($@4SW1NF<,$Z9UCIT]&,1Y[1(79@?%
M4SE)?J+,,DDF/*.))$D+()"Q"X;IJ/7ROI!;%YV5"*DK2*ILJG^<6#)&J*QM
MM+S@7M$FN;NI2IS%RL8?0G3%Y&H4FYP62`9@@AR%6.-JMY=^<X;=!*U-U4UK
M="\@.WXVVKQU3S:8M)X#/2\ZG:>R'Z)*I`2H),(4-TGLC\/LAQ8A&$-+H4$'
MNA*S5CKJUXU7DSY;+>3,+MV<FB7"6P]N-B9&.U=BIB1G!F!-!$U=4J=%7T)+
M`;[9$9B:)ACB<DLL!:''MASP)W^.!SP'`<!P'`<!P'`<!P'`<!P'`<#^9P1#
M)-`#TX&(L80Y&$0@>H0<X#ZP@&6,0?.?CC`@YSC[LXX&I_NI4$)ZV]/]F:]V
MX[.-L(\W[M7G(9S`;ICM<7!:KU2S3'A)7=VBB8^!@D)<2CCJE>""%/U+UA5%
ME!!@Y0,&!)PFYJ13"7<&R]*]^J.W:V-D])4)2!NOSY7MC0NTJQQ>4JA^2&UT
MM"<0ZP3F9_4/DT&;A6L6#+^34FI$A@0J@8%@(7S_``\?\GW^?[//G@0X[#81
M1%DZ,[8079V<?PSH&3438C9:MBX4#3G0:*&1]88KEJ/!8#1K'&/G%EJDR3!9
MV5J@H"?VC?=]L0:YW71<)VVN\FEZJ\=ZK7VI_EGA]K+=6VEHZL;FTZB4J<I%
M4*B*.5NV_;\K&KC!B@ZN,J2T+.UX1LZU:H)-QX%@LHP-OC']_G_D_9]W`YX#
M@.!3%U!O<@DLS[7Y!+88Y5Q*'/M$L_+Q`'EXCLA=HQ\CKYK:UM85KY$E[I&U
M_P!>9$*9U*PE4G8()7`),%[Q9F,!<[P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P.,_;[9X&)I=?5'5^\*([/;GJ>$2!(C3.*MBEUBP^-/"5O68&)(M4-C
MT\(EQ*14$H7M&B`$!F`Y\9SXX%8NZBX&].T%.];$44I7VC6)IB6V?82ZMZ\I
M0U.5*-D@,4:\:U+#T!IF5'\S-DQPYR>$ONI<G0N+K`Y$:0XX*-"#7=%L_']R
M]3MF]9]$?XE6A/\`7F.R"V[+VRI"SU]3:^:DO5'LBF7/<9D]],!AZ2RK0>(R
M%6TBKV+$O2T`5@Q.AC/D@L\(>OZ3NJ2DVW4#3C;#9F76GNCL!/:M@6QL2>MG
M+'EUO0&B9#;<98YJ3_!*L)HZ.L-ALF;&U0WD*)$)*I?SEB+)I"M,4(*<`;)7
M`<!P'`<!P'`<!P'`<#IBY`Q&(R'$M[:#&]4X!:4R\#DB&D4NICB)I+;"%(3L
MD&N`G0.4V"0YR9E1CV\8]?PX'UX<4.5XVG"]'EV+1EN)C9A21EP`WFGFIBEX
MD6#/F0HC5)`RPFY#Z!#`(.,^<9Q@/N^WV_IX'G'J716.*FE#()*PL:Q^7E-;
M*D=W9`W*79Q.3K%1*!N(6'DF+%9R9O/&$LO`A""2/.,?NYX'7@L2!&GRA,7-
M8J8HA.0!F"<#^U".BPAH,.H02`L*K(V@0FP6%&,'X!G)/[_^[P.^9'UEDS2W
MOT==FU]9'5*0N;'=G7)G)L<$2DH)R96B7(S3DRE.>2,(@#`+(1!SC..!VO`9
MX%$?YCN\J@JWJ7VU@-AV?#()-KNJ=^B=11J2OR-J>K)D;4[1ES=X]#T!P\*'
MMS3M9F!F$DA%D(#`^KQC/G@6@Z=WG3FQ&NE7V'1EGPJW(-B*L4;%+H#($$E8
M<2&.,K:@?V83DVG')PN;.O#DI23G/N$FXR$>,"QXP$F^!`CM.RM#UN[R9;6B
MNG]=C5VY<I66V6UP>(`Y&_@AW]*1^;&HA0O6B-^Y&66'SE=[/D0,>1A"AGIL
MVLC4[NW6"JB>Z[9C:5_%3"LD_4*T=&_X4LYRB-5>7EP:WZXE-7I5Y#A6IA63
MPFG2%8<Z'(PX^;58,$(X-MS'V_1_9^S@<\!P'`IAZ@9.LFLQ[7I:X1"55ZN>
M^T2T!*8'.TS0DFL9RUZ^ZVL9)<A3QYYD3`$;VG:P.:,21>K+&WK4XLCP9D8`
MA<]P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P.,Y_K^/C/V_7C@:>?YBZM
M>NBO]R>M.]MF:FKZ:/T_N"=-=YQQ.T/4MM2[JTAU,2%LJR`EP:-J5#\[M;K:
M*UJ9T*L"0"5.Y*B,J#@E!,\!)S1[K'W)OFL)&[=AKNGUA@VP$T<K:V%U6USF
M2I#9>PSJX)$T5A->[%7W&!MSS`M?*CI9A8X:PU=!UA9>6Q`:)Y?%@U)Z(`6'
M]B-4W56O7C+M6.N#2NOK3+L6"R[7))44=LFO];8=3U96-74UC[C8[+A[0IF!
M]'&7E:E]3,0-(I<#%@SLG8]!F1!Z+J!:MN(/HY3=([BZV->M<_UR@U>T!&FI
MJN*'7&59,*JNN(C%6ZTCG"%%B;(F=)ER!3CZ.8>J.2X*QG)HL#QX"T#@.`X#
M@.`X#@.`X#@>>ET>(ET4DT45*E"%-)X^\QY2M2!)$J2)WIN4MIRI*%26<FRH
M(+4Y&#W`#!ZL8]0<X\XR&NQ,.GW3*H]7JRTOM+?^P*\1Q2^W/9MEDLWNR$PB
MU)(!4O3H5C1ETD;BG>G*()$J3``XR(]$!S\G#+$'&$X0L9K30FK,[S.'9/#K
MQF<R66%3D5@;9#F:0,SI2JMG:HTFCJ251E,S^\T"PZM:4I06<DS@7OC-%@X1
M!OLA"R_@5Q;XZ*:L;,O5*[%[-RF60YOTID"^[F21M4X-A469$T7+*E#LZ389
M16"'-C;S8\F5'A69.3A3I3"\%XP>:(05OZ\4YTO;=6]OS&M:-R6N[K5[`HF[
MRB^X97MY%/SPVQ9,]MJAW?(>TI20'Q-$ADKRER,Q+[(RL*"RLY\8`+`7::GZ
MRUWISKY6>M=4'R-37U5L@V*.'2YX,?Y":0>N5NBHQR>#RRU"XTU<N-$'(_4(
M`,X!@60AQP)$\"M>\.TG7.L[`<*&IQOGVZ.TJ+R2JUPU'8T=IRZ)*1J3$)1]
MRS7ZHUU)K^S%+@>#U,S?V8T)6!"((4"#[>0HJ[:NHGMH[L8'2:VT9#I+J2WU
MA,)>_P`4U\"_VC:$LBS1+&%C1&.%A;`L,3%'9=,Q*FGV#6=BC*!E2$XP<%T7
MF9P`H+BND3KWM#K$T(B.I]P3*OYY-8]85E2Y3(JT'(38P>@FD@R[-Z<LV3LD
M>=C%R4C/I.R)*`&,^`AR+&/5D+<^!'';U4UI-7K\4O4@O"*-)-5S$UPDFM+<
MN=[_`&5&!G4Y4.=0-;8T/[@OGB0OR-O+*1J!B.QC]S/`U@^NR23]P[*=74FO
M]I]X5[T6&O[Z,V3_`,Q*-S2NZ=KXP,-1$U7*$KB^0B&-\P?W.0''(BV09:C_
M`!#"EQ)Q8DIA9H;A./N^V?T8X#S_`$\!Y_3XS]OV9\<!]_\`=G@4P]/\M+G\
MP[79N3')=#BI#VB6@($5L&/+(E.F?Z/KYK;'AYD<97FG*6K#N8T97(/5G'S+
M6J3*,8Q@W&,!<_P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#KW5U;&-K<7M
MZ<4#.S,Z!8Z.SNZ+$[>UM;8WIS%:]R<EZLPE*A;T24D9IQQHPEEE@$(6<8QY
MX&O;MIW4Y>T['!]!"$4K*L9Z=8;!=GW:"2"T&NVI0TGGHI#$M`]=(\O89OO#
M/8YE*I^=DI:V.TU%CB@&O4J$6$Y+P*,=G?RN>_/87<,&VEMG8UDJ:53;#"T6
MK%;]LR4[`WQ%(LQ^R(N6JYC`F-NI0ZPGL]6L._`L-3QZ`Q(L"9"V.*X&#E@P
MWS(;'`0^(16)%N;F]%Q:-L<<`\O2G*QY=@,;8E;`N;NKSC&53FOPE]U09GXC
M-&(7Z>!Z3@.`X#@.`X#@.`X#@.`X#@:T7YCW5G7BTX'H_:UA4Q")S8ZKL)TL
MH%3+'UI-6/)],3ZU'0V9UP<>2>2,<8D9BDSYDC./`_=%\<>K@;$58UE`*8KZ
M(5354298'7%?L*"+PN&1Q(%`Q1J/-97R[<T-*(/D*9"D)#@)8,9\8QC@>[X'
M7N[6U/;4Y,SZW-[NR.R!6VO#4[I$R]J<FQ:08F7H')"L+-2+$"M*8(LXHT(B
MS"Q9"+&<9SC@:]O1M6550ZS^XV0,E>5O%%L.[9]J84P/S-$(HPN$8KY(P5>N
M_"#<[(&](M9X:D/(P<%``PM"4,.1!+QG&<\"8<\[8JRDTI>:GT'JR>]C]U,C
M@8R/Z37A>Q(-=ZT>0%>]\M=&W$H/3TG"1E!P+!K<UJY%)0"QC&&D7GSP/+_R
M-[A[@@&N['MH#(K6+ACP9I+H@^S2HZF7-IN32U#'=NR"@UIV%N],XMYN"%R%
MJ,@[`:+`\"1*"Q8X%DE%Z]49K'7S756O%1UY2]=-'@22(UQ%6B*,XU>2BBCW
M5P):4J8;P^K\$X$J<%8CUJPWR8>:89G(LAF/@.`X%#'<'!-Q)EL[U/*M)S6)
M@MF.WEL8KS85DP>=3JC8(U+=<Y`C4JK;;X+DE4D1O9&3$34<H4)R\.1H,!'G
M/D(@SOJM7W=DPW=&'/<G830:?:]D-TC#+XQ1M1VU%;*6N1S*I*BYC(\RAS/9
M4R=(_")-5Y-QG(DP1@"$0A!R`+;@_=^K]>/V^,?=^S@5:]M.TVT6F.M3EL1K
MI_*^:WU\4Y.$X8]BAVBKD%C.RL;2UUG3=%QZLAHU#U:%J2M>)K1?-J,@*4F$
M!`F/]PP1(07EO;YM-%MA,G/M(4[#=7ZFV*T_T[V7BKVYS5_V19;UVKI6,6D^
M/<#>6!676QT+I60SUG85"-0C5*WW):]22H2A+3`.#T^CG;G>]K6`8V[4U-7S
M'"K+Z_73LJIX6NK19,\FT.IYHN(VKEM/3:,CS('^UK2,;')J=$RZ.MC:4J.-
M4(RVX1@`#R&7>FBR(_<KUVD6W$TLJ01>?]F$^=V-!/(;+:XG*-&CUOUF9#")
M57D];&.:0QQPK:S,@1N2!&IRGR6;[6`F!SD+L.`X#@.`X#@.`X#@.`X#@.`X
M#@.`X#@.!QG/C^C^O_1XSP(+[9]@=)ZI.C'6QZ63W7LO.6T]RK/5>E42&4W-
M+6\@SV5$O?TBE>W1JHJB918&:[3>8N#'%FM.2:(U;DT&"1AK\Y,W:[FY0(G"
MBL)I1K6^Y1K26A>ZR_JOI9P:GP85Q;HN]J&3KN5V*B@D`@91ILQO71A>$N`J
M1/AGD)@;"&I.@U)ZE'/,S:#9);.P,T:&]FLG9BWE:"1V_,&EM](FV(-2I$W-
M<;JVI8]D`2V6$1%O9(FS$%%A3(`C"(P03>\8_MX'/`_D<>4G)-4*#2B"""QG
M'G'&`+*)**!DPPTTP>0EEEE@#G(A9SC&,?'/C@?A(K3+DJ=:B4)UB-604I2J
MTIQ:A*I3G@P82H3GE"&4<0<6+`@##G(1!SC.,YQP/HX#@.`X#@.!$"TM[-9J
M9V7I+42Q)]EAOK88AQ4U3##&9V.%)$[>$[R>0N*292")/-1J2_6`0PD#2F?,
M9)#Z!#"/1'<AU_JZ7V(OY'<9JJL]6[`-J^XWHN+OQ>8Y-<KLMB!F$%0C)(`>
M[+P#*(PH,3B",'^-@KUE>X%A];V'$K;@$-L^`NF7R$3^-M$NB3U\FM0!=XZ_
M(RG%H<RDCBG2K2B%R$\!I?N%AR(`L9\>,XX'M>!AR\]A*-UDKUUM;8:V:_IF
MN68(L+I=8DH:HNT94^T<<4V(#710G,=GI:`D6$R!($]:J,_<)*,'G&,AH&_F
M'Y;V&=DUW:ZS_0?6'LL%K+#H,B>(O(":QMBOX98]C1*>O#]%;OB59IE1$KCB
MUG(=20L3U)6=B?3RP>^A(PD]M0<&Q]H'#^]$_2/5I-*;?T^ALC)I.#EOJ?8^
MC]HIUL6G=<-1>5>+H=WF]XT)VL8(\_\`.A^2"<'*L"%C'C/G(2D54OW9N.19
M_GPT-CF!8^!;5H5:3SD&<_J.=]P"/5X_1Y!P([[.:?=UE@:X;!Q$78WKO.E$
MKI6SHZCK*$=?J&'/,^5O</=VXB&M<YDNU+HFB"V194_)DN9A!P41AP3<@SZ>
M!K'=$OY>S<:$;F/2SLTU1F;3JV[TI,\N3&XW>TEPZ76-F1P%3&([8T9JFSC5
MT^CZAO2+C3FES*4LJDY*4)4`S!198P_T/8)`()5\28X!6<*B5=06,(@-L;A4
M%CC/$8E'VXO.<EH62.,"-O9VI$#U9S@H@DL&,YS\//`]?CX?#@.`X#@.`X#Q
M_?\`?P'`@ANMUZ4IO<KI=UM>7WM!Y'KY*GR<U)*:+N*3U,_12:OS6F91R],H
M8A&)3Y.SM91I+8O,)$J;0+%.$YA>5!OJ#&Z7J8U0*V%@6RSDLNZ2SN$YJU^=
M6&373-'>N;6MZEX`*L*UV*N>"FK`,]D[`1F%C$E#(UV,FJ#,X//+-4%EF`#U
M&G?6!JKHY.I;8E)MUCK)(_P\BK8J.S;.EEF):9I))*W*=I**I,F4K%@J_J4F
M9NQSIEL)&:,]9[8CCC/9)P6$;>GZ>16TYAVO6/!7,Y[ATI[1;/\`H;NH;G=F
M/6?AW7O6R)/`1LTA1MKZW80R!A5I@X4)B<'!)P<5@9)A9@@NAX#@.`X#@.`X
M#@.`X#@.`X#@.`X#@.!XJQK(KZH(-)[-M6;Q2MZZA34>^2Z=3A_:XO$XRSIL
MAP>Y/;^\J4C8VI`#&$/K-,#C(Q!#CR(6,9#7AVE[=;'M8<5ANK@)M0=2V^8H
M:ZDNA15.;$WEW)RF(4+7%+UOZ12<YG<Q1,:$DK!UQVJ2S0)E3K,K`HEA!1:K
M(=UJ'TUNTO9'A\W3:5$`K2P'QJF4VTX8;9?[=G6P4H;"\J4$Z[/-P5:X,UW)
MG`')2:>"#-IS?4C"(`"4R!T*"$P`;$;$PL469&F-1EE:8Y'&!M1,S%'V)N1M
M#(RL[:G+2-S4TM3>2G0-K:@2%!*)()+`446'`0AQC&,<#MO']_`<!P*TNVBX
M=>JHTILYKV<F-R5W5EN(EE5N=@T96LWLN;0@;LR/#^=)PI(,P2!=&6UI;(ZH
M,-=E!9*9+GT@]XLXPK/`\7TOV)K;,-&*[B.J]AW7;565+G,);K,O>L9S6<PG
M`E*)'*4\B2%3IA9%DI8%R!_*RC<D^59(B<8*R<(90N!;#P'`<#II&["88\^O
MH$HUPF5F<W8*(L1@!K<MJ(]9A(`92=4:$:C)/HQD)1@L9S\`BS\,A1"/NPGN
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MH-&402D5&CPF$$S)N.!;G:USZU:95&7+;=L&J==*9AB`AH;5<F=F""11N(1I
M1?3XW&&P0D92UP&G(R!$UMQ!RI0+&"R"1BS@.0KNQMWO?NJ=]-T'U[#KC1SA
MZR3-WM[H9)XVN>6PW&2\ONN^F!:J-6Q/,&I5)2MM=9VM@[0?Z19PF6%>G!H9
MAHKJWH6NK%:M@[WD,\W>VS;1Y4HMC]JG!LG#W!E1HRU!R6B:S0MC33NO#$G5
MX&)*1$6-M6``8()ZM2(0S!!9?P'`<#CQCX_#[_O_`&_T_KX'/`<!P&>!6!VG
M[_6YUQT8EV&A&G<DVLK6-%R)WO-VCMP0ZJA4O#69*V_3I2L2R9D?G"9@>W5Q
M^6"E;B/>(P4(P?G&0AR$F=-;ON;8FA8O;%[ZT/6ID[DJEQ.#3S]9</MEP1QK
MW0&1F1CF$'(2LAH),TG%JL)<E@4(\BR4;CUASP)3<!P'`<!P'`<"F3J%G$2L
M^:=KUC0"1-DQ@TL[0;*-C,M9%9*]D?2&'7C6N*.AC4L(SZ5*=MD#"K1"%]V3
M4X_3D0?2+(7-\!P'`<!P'`<!P'`<!P'`<!P'`<!]ONX&GC^:-[2IEIY'*AC.
MFW8D.D]KHY(E09_K/`8O#YX[2B`RI`E4)9=/GMTCTE(K%QBIJ`H;8@7B3FO*
M5T--)*$$D)G`QIJ74^WG9'%:+>EMY*^PA_@*%O<U>]VS=;I(]UX:T3!0(:AR
M_E6U&1M5?+>P':Z`JW!<D#/)JF+AD;7(DY)1A:@DY!D-H+5'0^F-4%DIG;6J
MF%P[%682GQ<VUMX/GX\V`M4Q,(`TS8ZRY0G3)8I`FC))9;3$X\E:8PSIR2RT
MB`O(<B$$U^`X#[N`^W^O@.!I]_F7=Y)Y:6MZK4[K3F^PEO;`,%N(&;:1OTTA
MED65&H94TBK^R(Q(*IN^PJP:'B+LKW+'9P2XS%#E8W,PE,:8J3DE`!DT,;?E
M[;Y[E*@T?/@\ZT#NK96-PVU#H5#S[KV2;=>;0K&N(Q`(.U1Z"0>J-@X.U$KJ
M[8$Z7TMQJ9]2IL&F&D`*![(A<"]L/:9/8HN6(+IZL^S:M`-I'OKY'%*8KG8B
M'!`7ZO?&B7Z]6[8LE<"B<`R+'H:,#$'QG`/CXX'*?O*ZTD1(,V7=\NU[6"4@
M1B;]F]?=AM>SBE(_`<`$MM>KHNR&>!B\9&6J&#&<9QG./'`EW76_6C-NA;?X
M7[CZNSXYW`$;:BBE\U>\NBO`\XP$);2BDYKG@S.<_P"X(K`_C]W`EB2>2I)*
M4)CBE"<X`323R#`&DFEC#Z@&%F%B$`PL8<^<9QG.,\#7W[T=J]U-.HW4-E:K
M;1ZOT['7Z9UU6$JJ>Y:]:9A-I4\6Q;,>@X+.CQZZ2-1A$/KY$^_-.I8$^0^@
MLP8S0YR'(0N,UO5SM-0%>N]W6]5]T6$EBQYLYNRKV=%$JTF)B5>X&B?X^VEO
M;\C9V@I```3@A7'$A.*,'C(<9](0JI[3N]'531?6:SYQ2=^ZNWGLY'$[&.!T
M(GM9OEJZ1&GS)C9)*%Z0UFXN[RR!9&%8L5XRJ&C+R:GP`1F,9\9#7W_+2;W]
MB.TNK\OT,U1AVJ],QK6]U=9+(=J;4/L"?2:(M6Q%LVW9"XN-4$V+FQKLV<(W
M5W5%-(ES_'F-&D;\"7?.G&8*,#:UHCJZH*L[%;-A;M?)[NMMFWYR>CV4VL<F
MR?2:$J33`*CDM%UZD:VFHM=V$E;[@DR:',34I`6:(!ZE1D0QB"RK[?[.`X#]
MG`??P'`<!P'`<!P*=?S`N//3/V#?#S_V%J,_=Y^Z61C/G^KQYX%HE/?]TE6X
M_3BN81C/[/\`HRV<#(W`<!P'`<!P.,_[/U_K_9P*<.I22QB9V%VTRZ$R!@EL
M/?>T:R36.41-R;'N,O/T_7/69G>3&EZ9E*MK<A()`W*TBL91F<EKDYQ9G^(`
M?`N0X#@.`X#@.`X#@.!QY^/CX_T^/AP.?/`>>`\_Z?'`X\_;[?KX#S^S/]G]
M7`K%N;N<ZO-=[5F=(7?N75596Q7KH4S3.#RD,I1/#`XGMB)Z3$*_1'34@P*F
MIR(/*,*-,*,+-#Z19SGQP(N6?L[LGN%`)C9D=F+WU>]8L6CRV06!N=;:,J`[
M>75`2B\A6N>OM?S=M-2ZPUX^(LBPBFLO1G3%<%4E.9&-(8,E;@-9;LMUQZ];
M"I[75VV>D4^ZF])#I!:CKI*4'7"U+YVJVZD\E%"W.YMK-MWTXIR?HJKGR1(T
M_A5GDS@KFBU$8<Z.(TI1A+<0&W1T@PN@:]ZPM8HCJU;<[O.@6MLGXZWM"QX`
M[UC)I,V.5IS5U<C1PY[;VU:WMR.0KEA"4SV\EJ""PF@&,(\9X%KWG'^G^[[^
M`\_T_P!G`_!IQ1!8SCS"R22@",-.-&`LHHL&/4(9A@Q!"``0X\YSGX8QP([3
M3<+4BN%(T5A[2ZYP)87ZLF))I=M9Q=2#T8\B]:=\DZ$T/HQ\<^<?#@:+O=K^
M9:W!URWNE=8]>.TFOT^UP15O7B]M>X=%*JNEI2S5P;%QDO18G)1;P2K<4RT)
M634WS!Q:;&0!](1>L.0V:*]I;>SLGKN$2;=*?.&H6K4LA,5<CM3];)^(%[7N
MVNS`WG.*[9C:"&%L0X%$)A@9IHX36V$(_D%V4Z]_/](TP0MRI6C:<URK>.T_
M0E8PBH*PB:;*:/P>OHXVQB/-_N9]:M7\@UITX%3JY*/)RQ8=DQ6M4C&<>88:
M,0Q!E3'[?MX_JQ^G/`9QY_3XX'SJT:1>G,2+DJ98E.#Z3DRL@I20:'/WA,).
M",H8<_JSC..!%"RM`M%[D5C<;7TVU;L1U$$8</<PH2KGY^)]S&,"$F?G"+GO
M"0S/C_?*.`+]O`B:+H\ZU6M:Z/%;T?+*'D;L+)ADDUXV!V(H]T2*,^/"A`17
M%IL#,E.!Z<>G.$F<!\8\8X&KIWU?E_=B[?MC7;&L-^RBV(I&ZTF#>Z*-\]WF
MV12Z-+3Y:2N3L\!=+;4`F2N,C3*,F'9$J7%`/QC&1%9\8,"ZOK,Z)-6X]I%J
MVR[I01PV,MZ&1$"ER99MLM9]Y4)#G7+R\G!:ZI@J2;@I1'#S$R@!N4R1H.3^
M^89ZAFBR,8@N0=M!M)7>DY5K@+5&@F>AYN%NQ+:IB%71."PN0?275&_-HW)G
MA;8PDG')'EO)4@,^`_=!C/G.?/D/EU9Z_M+])%DU7ZG:Y5M1"VQ4[$DG"F!-
M)[:;)4T:&YFL)#B(]6J]9+6:\JQ%!#Z<8$>/.?.<\"8G`<#C.<>,_?\`J^[]
M?]/`UQ^_'8C<_4S.K5IZY=@M6ZI0FV;HJW6:0UG8E.U9-!.#E8\P6`D]_$2^
M>O*9Q+8ZFBPTYCDUD)RT84^,GGK$_KP+`7Q48P6%%:=K6.6S:J*\[)9X<QH9
MK<3;#VJOV^RY`4C+PNF2*%,;B[LT83/IF??`C3*U!!(1^`&"Q\>!E?@>+LA7
M/4%>SE=5;1'I!9J.(2-37C%+G)6SQ5YFQ#0K-B[9)'9`0I6MK$N>PD%*SR2Q
M&%D"$(./.,<"E3JGWR[)-S+GV1C6SFO>J=6U/K!9]GZUV#)*AL>>2.:G;'5J
M="52IM9F.1%FH%E=*F23*#,+QF%*,GE%A"'./5G@7O>?Z?[.!X*P[6J^HF3,
MFMBR(%6$;"/)8I!8<QCL*9`C#XSD&7:2N+8@P+&,XSX]SSXX%<DE[KNN-`\.
M$5K>\G79V:MR_P"EGPS3VJ;8VM>@N.<F!"F.5T7"YO&V_(QE9"$Q6O3E"%\,
M"SG@4S]I^Z=D;.N^N5*WQJ5M%J?UE6]*9=$-BISM':M8Z.M5KRAM41MRA</G
M=E-KQ;\OK&H2XT6[O!;6Y$15TG3VD3-)9Q1)*L)H7*=.UD3FR-89R8ZV!-+E
MI2$;$VM7&G5[6*SA;9K=FI<2#'4U8SIZ=`(VL$\3I70]W9&Z4_)(AR5K:$S@
M,H9AXE!X6N\!P'`<!P'`XS_KQ]O[.!35U'9B>;`[:OP%^'/P9_FDV9]"Q#@M
M^(MZ\:[:T?7,M&688V81F9)\Y\[E/Z?^</?P;CW_`'>!<MP'`<!P'`<!P'`X
M_P!7C]'V_1P/\ZK\QEWN[8T5V#9J;KOWJ-:*QA511=FLIEJ]-5TUC#-<@)#+
MC)0U'2!SBDD$;)&YG$W%.!!2L>$)X<D#"6>`XL(6;Z^=X'8W-:,U^%':2B5@
M/+G3E7J)/8*[3SM.MM_E4A4P]G$\2AW%5.IT/J]4YR%?D:TX3`[K&3W#\_)*
M34V"S,A)V3=A/;D_L@AQ"JIBU.PB?)0(ATW[CN01C%CSY"KOK;"EB?.,?[ON
M)B@Y_3P,>0G8KO-FJ\1$G9=[F5"=G/I5P'K9T*K'T8%Y]."#+WW\L`\G./A^
M\H2"\8^_&?NX':RJO>[Z2G&KVI^[3WI`H'ZBFTZX>E37@T&/(?(<BC-:6XX(
MB\^<_#P:+'Z,YX'P(M0NUN?%933VO^P5.$T8,&*GWOGB-=B$'SC(AG)=:M+V
ME.F"+SGR`C`LXQ\`Y_3P-#G<QCM37ON<FR&8120EVG6>W-;/>(M,K.M?9I[=
MG1HD,+?8Z2X6G)(RW6[<1,A3A3#*6A:0N2\@\($I`O\`!#D-_654OW0[HK:?
MVQV9IWKUKJN:T;$=H5II)L9<FP3=`JFF[*8H=$E][&(()7SHQ659K*S`P>R-
M3TK^D04.?F!)"WL)YI`:A7YA[??<#:JT-=U=C.=7*JM9H-.&JJ+!UE,N0K7:
M\E0YJUIIU,ZN3W6VLK].&EADK`E9"Y<@;PLSX-",+<H4IRA#$%HG27N7?D(T
MV8*OFG>OJEI`\Q:RK-9D.LNUVNL6GUEP9.J?`NWOYE,\NFK5S8Q/CVZJU25K
MRDP0B]PP)8OWLEE!:-8+GV,VBI0'5K^9XZZY&T&J"1&QJ(1/7.E%3TD'G`C&
MXJ31R6W-(F0X>/@`XHLTX/WYQG[N!WK=IGO1-@IGN63&3;F*`$8"8VTO^8&V
MDK*-OH_4(0ACB;)KG%(^FPJ\^,D@5B)P'/IP+QP/VVZ%,:=SQ*;P_+EV#/W)
MK$#R]%]H$8VK<E_HSG'S(&6[+GA`EYQF,Y]6!I@>K'PSCQ\.!(BO'K1FO'0/
MU#\MQLI53HUY#[<J0=>NJUL*@^WYQ@XB3U98UB2E:(.<Y\9`$PS/W^/CP-++
MOTEFMNT_9=/I=#7ULU=;8Q&*WIY15-_4C==,SMD=XE2CY-AR*3UXU03"N'PE
MS>ES/'6\TPKZFH7JPJOE,,Y>5HPWSM4.W:G)1K%0"BJ]2>QVS6U-2E7)$YL&
MTJMM>S?\+"69*`E!-)$G88>_I0B3Y"4O1N2E"J#CW"CS"Q8'D*T>YCM^NV,U
M+1RUDUP[7=!ZB3W^0INS8TB#T16<R=8.U5I/ER2L:Z*E5F35D6R*9/N4ZL.'
MDEO*"6TB"GPL/%A-P/STJ=J^V%J5%L:]Q/6CL3[$JB;[_2$4Y?%BR[5=HG:"
M*NU90]S=:WE_U.T(%%U3_#Y%[YQN8_AP3%%.105GR2K_`(807/?YA>W7GQ_D
MZ[O?^8NFWZO/G_XCN!Q_F%[=?_1TW?\`_,73;_U'<!_F%[=?_1TW?_\`,737
M_P!1W`?YA>W7_P!'3=__`,Q=-?\`U'<#7G[6&I)V>;?U-2VV6@>QNLJ*N-=G
M.T8H_IYCH,CV*L,_^(@$*QL8IG>FRJ"C$U$UN,'U.4M3<8LE*TY6G^<$U-7D
M]2%B75_V.W:R:%:\MD0Z?=HWB&,;!*(_&'_5=%KBU49+&1@GLJ:4,SK6.V+L
MXV2IK89D!)ER]L65*#)ZDP3<K6-PDJHX'8YVR;CL>J\E05#H'V%Z<V3,K!I>
MO(_LE8D"U/DT1J\,[MB(1MS<A-I6P<T:7%_>FY<:U-"=R3)FL]U<$X%*U&`6
M#L!A70[>7M,KS;#877JQJEW1[`0@I&I;2@S%=+-H)JQ8%-*W&83^*OHY]FMK
M>>82CC=A&M(,LOON)[T8-G69^G`3@RJ&%L"#:WMSDBE0D0=25;P$C(L!1O5G
M=BE9J2@^19Q[BMDK&FYVH].,>,YP6J%G]&//`X-?>]U]<2S&VMNJ2MV4S'D9
M<BM3;&T7]/C.<X\"(8:PK9I.&#'CSZ5.,"_7C@?MTIKNPEY@3%&]&B5.%#$'
M)J.N]'+-L8U.$6?(PIG.QMIV\)^<?<'(T8?/WYQ^C@:S7:]:<\ZZNP"/2S>O
M<Z\K_<[STM1PZ`2FAM+M%7`Z-?(VG)D$GJ(^L]I$]EPF,UC;&%Y1CZZLQH'5
MP&0G2N8%J,E/@H+:>JW5+LM/ZW-/WVJNTA'`XY)J5CTMB=:6%I=5-MM-;QZ6
MF+)(P5XW2E-/(-)G5B@S4Z$M:/&564Q*5(62B`G1%IR"@GTV4QW:1KP+&]NA
M]F!+\>")CHG9\)&H\>/'NK(5MDL"1Z\_?Z$XO'Z.!@C;.3_F#J]UUO64UB@Z
MUYO)HY5$Y=H]_"IBV=27)AS01]:H3K:P@LP%.83*Y^C"6(YH:G-4%"N<`$DF
MY$`60"#7NZC;EV]N7:MZKCK27.6NB.6H+5.[!I]LDQ[<[:QM7>3&V193_,;8
M)5YJZ8863;">R]P&UF1]D<&TM0@]T]R1*$[:EP6&T.;UE7G:05`]INU+>NSB
ME64PSXG0;W7>E4`#@H01'I2":"A[=:0VY3D'IR6IEZD?HSG`S!YSYP'OX#TU
M]8\`?%<J_E`K&RY@XG)5CE,=@\R+9:5+G)&$&"78QZV`?;)6)W/!A?N>\GR3
MD)F<B#Z?/`L;CT9C<1:DS'%(^R1=D1`"6C9X\U(&5J2%%AP`!:9O;4Z9(06`
M`<8Q@`,8QC'C@5I]K>^;WU[T"7=:S3N8;84^D"^JKK51V70&,LU419J"T8:G
MV4(IR4I!(2)$].8$B5,D),-]\O[LB$6$02<TNOF?[*:_1&W;&URE.K+Q)!*1
MM-4RZ70R;.)42`$@V+29(_0)2JCIK1)F<\M0F*!D)A1>?2,./&/(2LX#@.`X
M$/=Q-Y:%T9C$$E=[*YP4@L>?1ZN8NG@U?2B=*/K4C>&IC(<)"J8T!S-#HP@7
M/28*AR=U:%+[AQ9)0C5!I1)@8JG?:)J]7>VC7I^_BM`V7GRZ"5A)K5:*V>W+
M7ZM[GM6.J)=55)6):Y6<-<>M"QHNGPN;D6"3TY91Z8*M0F-5)P&A^=1^TG5?
M=*PY=6=3*K'8GYC@6;DA2NTJ^=:\9[OH0,S<*[%?E,*W@W)\HJD$Y;#&P2Q6
M2W+"U`R1#2A)/)-,#`O4C&HI"[`[9HA!(]'8C#&#M$L@EABT0:T+'%F7#AKE
MK,\NY;0RM19#0VY7OSDJ5J@IBBPF+5!Q@\>Z,S.0N3X#@.`X#@<9S@.,BSG&
M,8QG.<YSXQC&/CG.<Y^&,8QP/Y"4$`",P1Y02RRQ&C&(P&`%E`QY&:(6<XP$
ML./CD6<^,<"F_;/O(TSUO:)J36QLUW&L"$+4S`]0[5ME!/XZRS5T$6GC\"E%
MO`-)JMKL"0.!P4Z2+HW-SF"H?GY=G/P$?@-=/=7N7LBP4;Y7^^UJM&IS1)$1
MP!=9&H]NHVV_/P\H4&A&C[#M\"FUY(UR9%C:5Z%U?P)B-L-R3+@I5J%(/!J8
MP-*'?6RZ3M.^G!\H2'5;!*U:8G`XO%(Y2E8R*K*Y1H6.-$)G#Y5%/9=-;2GC
MT)T]>5<NDZM,^R4W(E2EO;_):4`;<77(][;3/3#7'Y7JC[7)_$FBJ6-M:]A-
M=>VR_P"FF.S&!L,5H&F2PVFW>=,,?CK;AM))3I6]H.+0EDIP^P6$OQY#-EH6
M'M76!QCK#NNO\S:)"CR`Q4-U[-+P4-";&,!$:(7TN/WK@X@GX^,X$+(L8^[&
M<^.!@QU[#[84J432M[.=F.M%P4XP6:EVW<-YMB9"PC]W(`C<E4YTXKZOEAX_
M]W`<K?8$,/CU9QGS@+"-==@9+,A-Y4A_.!U$_JE/HP6UI==]/ZW5&>!8P(L0
M[DPH7@S^]C'K.3XSG[\AQ^@)TN]$6+;S>/,=_-`3M<2;CS\W`LZ$-I`?<'@O
M_"4ULQ1I4`'K#Z0^%'G&?./.<^>!_G/[1R0BJNW&<R<6W$_NTJH]PHX)?N98
M$3_&<S?7.IYQ'T3[:!\/2RQ65.D<1=8\=EM2)W8DIY;D"<)(TH#P@*#;?BMF
M]GO;G(FEIN+?36&C.MT,T:9Y$'?8J%T'7DNVR@3880H93+#U"CEPN[_*(&O?
MD^%Z2.RM^:XTN2E%Y<BG88/E0!#[OAZHBHGK[*]U([VQ0C;V81ARA<6LN,6,
M^5)'WTZOW>6-C;!8Y3J*N'E9'(I'8)*'+WDD3:&QF9DK:(\Y.`(TXBSPV)>O
M+J-V2K?5^&0U^[D[P<I1-ESO<%KH:5CFIMEQQRLJRT[6X2=R;K2NJC[6M69I
MSD"%$1\^Y+\EJO8]XE,E+,]G`2HE_1)2EK(!H[NVJVQMH9I>2E"AX;M0(R:<
M6/\`W@Y/@VID;7%#%GSG(@'A%\?AG@1^:?RHO3XA7&N;O7=YRMS/-]\]P>=A
M+!:SC#?/GS@$+61-.3C&?CC!98`A_1C'`E3#?R_/5E!4(T##2=H%%F$^P(P>
MV>VA)_MY#Z<A\H+M1%YQX_1Z?'[.!BV:_EJNK";J#E*F&;#LQAV<B_YIVWV)
M4EEYSGS_`(9,EL&0EA\>?TXSG@:WFRGY6Q<BV!O5)!M9=I[5K$5C$O&OLZAN
MXFJ[.JFU<JJ+:2\U[-4=_KTD[:9;%;M0JU(W@)"TM1&O60`C)A92G@6]4C^7
MWNYCU8H>'2FX]0T]FLM1UPVS^)7/UVTC=2>,RI!&&TN2PY#:E93RE)1*FYD<
M\'(P.ZHY8N7A*P>,\8A^K(4J=QW4@LI$_5RO;7<>N77F!7A(;FCKGLM64)VN
MU[K]@EL5KD$C@YMZ-J^R-D(R6A4NV!%,25*01\TZ&Y`(PHG!N1!_+J@TLL]F
MBVRE:ZGP.Q-V837$LI1`Y;!:+=PENZDQ$%B/=5`=K%S7*!VKNL(5.T3@X&)#
M507!()2TGE@1A7+2<>YP+F'",[RU"VI$GX=_,?5RYD8``)E>75UQ]@,5(P$)
M8<?.*;4='*;N)18ON]&,C&'&<BQY\XX'*K=K=.M/D")/O=O16`"`EC,)W#_+
M[618P5!>!"!Z'*:ZAK(>P!#D6/WS4X3A>,9SC'C.,X#[\]VMYQ]T:8\#?GI3
MDJL8@A4!V&BF]&BTH7%XS@(AFL\^:;,2M!XACQC/N%^@O].,_H"53+W$;,J%
M#4UL%!]=&R2A>(&!.^M?<)0`0*0&!!Z!M<5MRNX4['C,%G.<%F*BQXQ\,X]7
MG@4R]]G>=-JU*J'7VQ>I.K'&QB0Q"XE:_=!KUZVTK%DBTC>G1J2(ZO20!=94
M44K+.9H^O;C'DYQ:'!(2`\!"$X7H4E!==IWV>[\;DZ[5%:^KW4>T0^M)7'E[
M$VR"X=P:XJF%11X@SRY05Y9X_`8U6,LLE9$(^]QT]&FR<S,APBR,A`G"`(<B
M#`_:7+>U9NT*V(#M%>_7OJ+7=C1M=5#0AHFF=GMOK4L5]LM*HC,8I9IR_M,;
M2-;O9:U;EL-=4$->CVLDT:HDLO)7OEA2M^5PJ+=%/6=_T16V\RG2RPCY`CN1
M;K/9&ABB?2APB!@&Z"?QD3SZTQURA6M#J\-P6C+6UK'0"(Q($XWY<Q0(`@V1
MK+2[G4R=E+;'?WJ75RH(1Y$FL_4#7"%*?!>/4+.2'[8MF-_=#_O>`_=P(,N_
M8G)D#FXLL?\`S%>NMK/;9D>%#!0/5>OV4?1#\B``DAKH6T9NH4&",!D(<@\A
M\X^.?OX'7#W"[9I&!M44=<FZ=_(')2%.2[MW1"T4<Q9!ZLX$JR\;-[>4SC"3
M.,>?<"0,/CQ^O@:M7=_5'87L_NDR-.W]H5?$Y_!(%KM&8;$+\E^O6OCXC@UX
MS&=-J*Q&F(PZU[.A`(3'I0SJA31<ED"E2S`"G-7I@$8)%P-C_IYF_P"812Z!
M:](:$C'63=.NT:;YM!JFFMP3W8%BL&0PVO;.FL(2K`K(BS%Q]5%1G1\PN-J2
M40"SH\!$9Z/WN!<S'[9[WT*81DRTVZZ9"H"'Q[,+V\N9@$:+'QQD'XDH%U*+
MQ^P1GG]O`K\[+-N>\V,:7[-*%O716]:Q5OJY_7/UWZ^;^B46A7,>;AIUS]+8
M2TM]<1&;'/:-E3GX)RV'%+R!#]XOSDOTB#6"Z9.R3<>6=C!J'434^PI\]6%?
M>S.P$_U_!N];L/A5@Q^=5,&/%QF[97?3C8L.FDTJ5W9"Y"EF3T@',GEPR<E.
M4"`:060&XY9F]'?"T$*!U_T;UTM"25GTJU?9)2DH$89C(O&2V9-#82O,!G]`
M<&8S^W'`BNP]B_>_(R%S;;&AANKSGD9^4RZ#:>V;N6G1$`&()1@W.&;=5VW+
MS18^.0$I#!9\>0X\9X'EGC=W<=CR:#8+L+W(H@A3C.3C8=^7BNR*(F@)N/&2
MRI?-1[(,AV"L><A-R7GP'XYQG[\AKY]X=L5GL_7\%I]A[>[:V5<XG"K0V-?U
MVV[>WZTUF0*!_AQA;*3A5%5SJ;74@F5_V&O?S%C"<\J,MZ)$T+"2\DF*,F"#
M;9_+A5I.]?M#IEJW9DH7S6::S[&32MG"6$62[V57C\SOM?U9:\-7TP>^Q>)N
MD1JTR%V.W_*,XTY@2EWS:H!GI5^V6%_O`<!P'`JX[:]6=J=S=:6^@-87C7J.
MFOMDUW-+`?+^66<G2IVVHYU%K7B3?$TU:-J\]6J?9G#4B)SRM$662U'G#)]2
MC!>,!".7]3FU5H;./,@G=B:\H-6[[V,U=WGV888]BSU5T,NRNNU/Q>OW&K:7
M7JD+9%%M&S23PMK<BGIW&DD#<D)/3Y1J!'@,(#T&A?4;<=36"J=MU)G1%OUY
M6NBJKK7J&%UFQ2PE#:6N[E:W\3WNP;W;YBE)!'+"=R&YM9\L;*K<VHI.2H49
M6F&'A`4&5^F^M8#2\A[3Z@JF)L<`K*O.S2?,T)@<83801V*M*W6W61]/0-#:
M`8RV],J='90J$6'P'W#Q"QC&,^.!=9P'`<!P'`JO[O;`>*PZDNP"8L.$OU5-
MK?.&-,)8)8`LD,Q*2PU4H+&WGIE0%J9&_F&)\X'@.#P@R/R#U8X'^6#U'SV5
MJ=H76%J=;;9WK3SNFI]'4NM,>NR=U3")6YM13;*&)XO%]89/'VE514*6,/S[
M^D?#\,7LEA,4>G!818"]>-51N?LS,531,MM(&TRF.)U;'!M4>EK7TS9J1:T0
M9PQE.^4K6D]JI7`]'M-B'QM7BRX/H;"%(W<(<D.J]43@:7(6=ZD_EIE;$H0/
MC?JA1=)'@<#U)EP=@\Z-W_V).$6XA5I'=KU;IQ74VD\6.<D9F?63(7JP!I3\
M8]99W@61A3C^8(TMIZ";;4!1LL[(&EV=X,W5364^8+*I]Z2O='PJQ&Z43)]N
M[,/UUHBNZ*AU*L9:5I0H8O$TJUV+^9":IR89[AF`V[=$NH7J1OG4C7ZY\ZS:
MV6ZMG-<LC@X6=537=$*K*>.K?@YE=95#()-GQD?(DSO3DV&GA0'H4_RY@QA#
M@0/2,03A;.F#JW9\8PWZ5T^3C'P\#32!3C./U"PJ?C\"QG]OG@>EQU%=8H@>
MVJT7UL="_'CT/=9L3\`6/U""]$+PCQ_3YX'T%]1W5D7C./\`+GTE-\A\9^:U
MCIU;YQX^X7S<1.R+[_V\#KGCIZZHWM$8WK.M_25,G-#DLS+)K14<;4B"+`?.
M?GX]%&M=@0?'PS@SU!^_&<<#_-?VAZBFYK[";38*^8MK6/751:US2$MTB/67
ML_(8K69[7;#N7#Z5B,:0J50[$BQL="`I"_(G`MO-2E%_#.#,9P'^F`1U<=:#
MRB0+W?KTTH<EZEN0#4K';4VD@.)YF$9`?6M*5P@U62I\!QZP&#$,`O.!9SG&
M<\#5+_-(=>F@$`H6#NU43'1K2*<UT6BF37KG7E&4W6]U[*9FE@16N3Y$7)HX
MZQ26'P2KF)4Y+?DB&E>C,484&GF%B+*$6%LO6KTT]6$OTKK:./:;43L+#"3Y
M'"2-IJCAS7#3I<@;G=4O1L$R=:VL21E/DZAB=VPVK'`Q>%6I(((R<4`P.?(3
M::NB;JUCIAA\4UO?H8>+SZ#H7L=M-$,DB\?`Q.7';K;B"!`\_#T@\8S^C@?M
MTZ8=9S`^B(WMV(5>6'/DHFN>Q3;MG3$YQC'I]M*Y6J])LX#X^&!@%C]G`_NW
M]3F8^1@J)]E7;$Q"+#G!`E^X!5@!*%X_=R(JTZYG(#PAS_[H_.,_IX'7J.M_
M;QM,R9#>Z+?AK`'/^$5,(%I7818`8SG(0#RZ:QMYI_C](ABR+./OSP-5_NCL
M7NPH+?'1^JZEMG9G9\BM;+*E-#6>[ZV5#7#=:.P#K!W=1*H5$VBN6R.1FWT$
M7J-6J)4?4DI1(3ECD0'R6$0\AM'PG5[LOL>#Q&9.';3;L"S+XPQ20Z(N&A&J
M<0F44,>VM,XG1V2M3^S2@]ID3(8IRF5D"$9@E04(/D>,>K(54]T]%=L5!Z+6
MVNJ#L1V;VF=9]%Y;&+'AKC66A=,PB+463$GEVN"4NTE30*"6,%<&))#$B`B,
M.67<P]3GTAR`(@C#H^B*M>WFX>OFI2I!O'+=9VVOXE"&*CXM+-;]2]@:[E&O
M3E"6-YIQX8GZ-R1EM=$M;V`\2%P0R1<0X)RR4P0!Q_B8"%PR"D.[*+F9,3;^
M:-VD2`8A@2SW0NPH28I#_P"Z0<O@.V!X4X<8^&1@3#SG]7`_:U7WRM*P&4#'
MU)3MN#G&#?>DFX=7N)P<9^(BR_PU:Z1.+.//PR89\?T^.!\TBN'ML1MPDLTZ
MQ]1+S&$&09)@F]&6%";Y^`_:26YK(3CT#QG/@(S`_MSP(H2J(R*?8,>=B/RQ
M]42M8$9F3'"-3GKINI_^X0<GHCY*;`GK)P@_$.<9*'Y\?'&?N#5A[='&@],;
MN0;`?Y.$=IRN[OAL"JECUTW)@:V'1(B:U3)I')+$MNI7C4W9!_CKFYN$/GK6
MTJ1+?IZEN]H@]&`X>5!(PM'TLJC6IAUF@3P\=<G<=<4GL13+;B*MS4F1;&UY
M34BCUORIVL.&DUL1*=W(P^.<:88D_HD*9S<D)+BZ8(RJ59&:<(60Q7V"QEKB
M]&-=SUYH[W_P!JUNMBMMB9TX[%[GS.OJP:JVJUV-=)FM89>\;:VFZP*SBVM1
MD,>=FIC5NZ5:+&$OI&//D(==6ZNP>UN4RJ^Y_H;L'V+$4W4#S0DY0V=VAO;8
M>HGDQMUPM6OG92EM*TXC(XC7Z"K6TID.;T21S8GA[1GN(B0K,F!+#8UK32J[
MV1&@4U'T`=46OTF;`^&F2[";`1>XY$A&'QDDT4BK[5B82DK(?3CUX+=#<Y%C
MS@>?OX$W(U7?=D<R99DTNZF]<B!9#@G^%],[+7#A"2#'I*++2/L^HUH.&27X
M#C.4P0_#SC&,?N\#MR-/NU:3(32+![?$<8,4"'Z\:_:%T9"SDQ0A>H)25RM^
M5WP=ZP8SZ?7DG&<XQC/CSYX&K=^8XTI[*F1+J?#HYM9=FS=/.%Y50T`GNQ%@
M:O1,0-K+.E3Q%*?00F`UG5M9/44CD70$G&+7-T.7H##G'R#V\)AY$&PGK9U(
M.UA4E6,SVVV5[+(IL$[1A(9<,!BG9O=ZVOVF>)##D#^;$3:LDD8C)4;>U:42
MY(E2E@"B)583#_Q"AYR$E2.F+3`X&"Y0\;>S\/PP9^.M]-RWOW_&,8S[WHN]
M'@?J_3]W`CAM7TQ]9,`H&X[/0UM7=:2V)5[)W2-V_LULEM&\4[7<@$W'IFB8
MV2)\O;)9\89'%06>H+&:7[OHP#UAR+U8#5=_+^=9.HD\V[V1@]][/:0;@Q=!
M;UOT<RT@ZRER%;-NYJUM;)@S;4T'EBFZ=2Y0]^+6+B%(B\.!"AL)5F"/]1`.
M!N4E=%G4F7C'HT=J;/W>,&*YN;]WW>?=E@__`&\#L">D#J?3Y]1.C]/`%CSG
M&<`E.1>?T9]0I)Y\\#TB7INZQ$0<`2Z;U24#_P#!XDP@?L_<'(!!SP-6G\S[
MU1:#5O1L+MNF[$UDTNLNK*]M"1)J54.)+186VZ##S!L(HS#8^IDR):[.$3<3
M33,K`IG$>!+0%""6#&!A"^3\NOKG`-8]!5L#@.WE7;JEO=P/$VD%MU5)BY*T
MLSP\5Q5[816;R,J53`#6^P)D8TB0:7YL.2T^2?)).?)80ODX#@.`X#@.!QG]
M'^G]7PS\>!2YT\U_$:FEG:Y64`:/P_"8EVCVH)@8\N;B\";\RF@=<)J^#$Y/
M2]T>U&7*22-8KQA2H,R5@_VRL`("4`(72<!P'`<!P(0]DD9@4RT.VKC%G0:&
M6;"WBG)2E<H#8ELH:(@LJ6X(`='VJ5W$X2B%)*Z9#I(4DR>Z"=4(DX0YR`SU
MY"'(:!/Y9;KGIR<[G76P;@4;J9L1'HTMG=>1/"G9JL)XOAUE5484HE8V*@F:
MR'#^/M.3N/R3)&7PUI?6,`F\H91N0"4BX'^E5"X/"JYC+5"Z[B$6@4-84H$+
M%$H7'VJ+1EF1$A"`I&TL3$D0M;<E+`'&`EDE``'&,8QC@>J^[@=8I9FI8;D]
M8UMJHX00@$<I0I3SA`!C.``$8:4(>0AQGX8\_#SGQP/N))*3E@)(*+))+#@!
M910`EE@`'_="`L`0@`''Z,8QXX']>`X#@<9X#QG[?;/CSP.?M^K@8,M+6#6J
M\7MHDUUZ\T9<,DC[8H9&&0VE4L!L!\9&96I^<5-#2ZRQ@=U[<V*5><FF$$F%
ME#,_>R'(OCP/85C4=4TG%P0>FJQKRI(46X.#L7#ZQA<;@47+=78[YAT<P,$5
M;&EI`X.1^,#4'8)]PX?[P\YS\>!D/@.`X'&<><>//C@4][+="_5MM[=\\V+V
M!UV=IQ;]E*FA;+)4"ZKSCP5"MBC;-$VT]K98U8S0Q1PPIBCZ0D7T],E]S)7N
M"\F#&(06AU)5D(HZKJ\IJM&DYAKRJX7&Z_@[(H=7=]/:8K$FE*QL+<<]/ZYS
M>W4U(VHBP"4*U!Z@W(?48,0LYSD(];?]?FG6_#3!F+;ZBXU=[36CL[OD&1R-
MTE36"/N;\C2('E0G'%7]@.4@<$J`@)A1XC2<^T`7IP(.,\#]Z@:`:?:#LLYC
MFH5'QZD6.R7MLD4V;H\[RUV(?7EF0&M;6K,_%<A?QHL(T)XP!+39)*SD8A9#
MD6<BR$Q.`X#@<9QYQP-<WN/Z*YQVMW%!K#(V-I^K(W!(7%HXT,LTU=S;LQ1K
MX_,7J6N?T^=8MZ$A21*6&+TY#BU?3Q9/*(&$1^0FX"6%L/7WJS)-+]4*VUNE
M$T@\[6UX=+0(GFMJQ%3L'3-4BESY)T+-':\%+9O^'T+4%Y$5D`7(X!@\"&$)
M8<X+"'5=B&M%B;;:U.]*UL'6Y0\/,PACTY-VUU-'WU3;JRQAW"]FHGBN2GIB
M*<G0#FD2GHSCC3"DYI/J]OU9"(`5L])_3]<O5@IES/.YIJ-/HR]0UU9$LOI[
M7IUK6])`\.EBKIT2"S++729R%-(I&TSLH;VE$<F]:!*6F**&$!(O=#8-X#@.
M!5]MMTQ]:F]5O9OC:S69NMJU11%D@N92NLFY(UC$7CBAU5,K<!CA=AQR.E&(
MCWM3G"D*0*H?N8P,P6``P$)GZV:VTMJ'2<%UTUXA15=TW6B1U0PF&DO<DD8&
M5,]O[M*74'UN7O#_`"->)8_/BI1D2I8<(.3LA#G``A#@,Y<#R,[@$&M*'R*O
M;,AD4L2`R]L.999")S'FF5Q&3LZGQ\RU2"./J->SO+<?Z<>LA0284+Q\<9^'
M`P/6FC.E5+S-IL>GM0M8:IL-@1.#<Q3NMZ%JV#S%E;W9&8W.B)IDL:BS:\MR
M1R;SAD'EDG``<2,0!8R$6<9"4N,>/^3Q_;^W@<\!GXXSC]?`P'<>JNL6Q+A&
MW?8#7.B;Q=H:2XIXBYV_4L"LEPBR=W&F,=2(ZLF+"\*64AS,1DB/`F$6$[)0
M,C\Y"'P'I*=H6CM>(RLA5`TW5=(0YP>EDD7Q2HJ_BE<1M=(G$E*G7ORMCA[2
MSMBEY6IT))9RH963C`$@P(6<!#C`98X#@.`X#@.`S]L_[>!3+U#P]GKR;]L<
M%CPWLQBCW:1:(VXR321[F4@'^(=?=;94O^IRV4N3S*W[.'-\.P0-Q5J#B$N"
MB`"]DHO&`N:X#@.`X#@>!M"JZWNR`2BJK>@\8LJM9LV_2)?!9HS(9!%I(V?,
M$J_D7EF<23T2]-A4G+,P$8,XP,`18^.,9X$9*5ZVM`-<+`;+7H+3;7"G+,94
M#HUM$\KFI8=$Y4V-SVB,;7=&B>V=J2KDZ=Q;SADG!"/&!E#$'/P%G&0FSP'`
M<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`
M<!P'`<!P'`<!P'`?;]?`I;Z>H:374N[7H*GD4PEZ>/=H]I^U*+#?UDNG;O\`
M7-?];I*9B1RQQ$)>_?2C7D2%`(W&!)FM,F3?'!.!9"Z3@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@
M.`X#@.`X#@.`X'A(C:-9V"Z3%C@5BP2;O==OGX9L!GB,NC\D=(+)/28/,>F+
M>S."U7&'S`"AY^46@(4>`Y_=\8SP*G.H&-*X7,^V")+YA*+#7,G:-:&%,ZG1
M[:IFLBRZZ]ZV/A6)"H8FI@CY@F-.Y@;4?R3>C*`W(R`B`(P(S!A<]P'W?'/`
M<!P././]']_C_;P.?/`?MX#S]O[_`(_JX''G'Z_M\/\`;P.>`X#@.`X''G'Z
M_O\`CP'G'Z_TYQ_9]_`Y\_[>!QYQ]_GX?K_1^K@<^<<#CSC_`%_V\#GS]O\`
M;^K@//\`K_N^_@//`X\XX#SC[OM^G_9P.>`X#@/..!QYQ^O]?]W`Y^W]O`X\
MXS^G[8X#SC^W_;X_TYX'/G'V_9P'G@/NX#_5]_\`IX#@<><?K^WVSP.>`\\#
MCSC]?`><8_3P.?..`X''G'CSY^'`Y\_T_P!F>!QYQ^O[?;/`YX#@.`X#@>8F
MR!^=8;+6N+.6&:3N48?D$<=Q9R'#4_+&I6G:'+(@A&(.$+@86;YQC.<>G[L\
M#4YZ>-*-CXK;25<BHBW]"5E?=4H]-;\MI_A$79GNP]YU6Q3C-RKNA+8^II'$
M-C11:+$.#B5-5Y3FWGY>RT.##B\G%@"4&IO6/V40V>;QN,@[/]DZ61V-N&^V
M!%I&ST;HY)3;XCZNGZC90W(\-ZRG7U/"G-Q<F90R#:4)#,A`0PE'A0A$>(XP
M)4)]!.SX4P=R%O=C>@:U+8&,Z-GHM6=,@V2.8&+'4,I)DBQ11YD3/B!;>6A$
MV`2(R%P3S%.%!HP`*R(/E=M!NTLN80Y+'NZRZ#ZT4I94*S%D@U@TZQ92-P)1
MHQ0`-:G-=$EQ(IO.<S57U[#LF4FF)0$!1B),]P>0^B5Z"=H)*=GS7W=C>1RT
MZ4L9,G_'^K>FBE$1`CUGHEQ\8*C-&M9X)VG;,Y$T#5F&-H%./^)),!GQ@/W-
M=!>SU-%)&HJWNMO5789+8I-A*2S]8-,CZ^.?<9!E&1-`0^AVN4',1H,"`;E`
M>0I`(6#`Y%Z<EB#T!77]V%Y)*$H[MMI\*O9+$>`C6/13Y3"K)/@X)'KU[P=\
MI@_.<@P+R/`,8QG.<^<Y#S4%T%[15,18%%L]UUW);&-29,EZ:JM7=-4U=E.?
MS2C(28D1,Z*=I24U@19)#GYY2<<,X(Q^0@$$L`<Q;03M"-#(/Q]W8WB2(B4.
MR>&9@FK6F9`5$`+$5F.'S,,DHUQR=/S?6;AQ,093M@L!+P02#][R&*8CJ!V]
M/6QMU5O+.T_9&+:\0F"5`^TQ=R77_0]9);5G,R_&@;>BCVRXIA5AK;:URPM`
MD(_IJ`1V'@>,G*_:SD`987:"=GX)7'"&GNQO,==FMDC'-CW;5K3,5AE/I?TW
M$,+A:I%1Y,7(8S/=79=\+TAZD7M)L)A@]9H@A_.3Z"]HR=3$LP+NNNU6B.EJ
M!/8H)WJ]IN)6571J-P^LJ:\/C=%I"4=B$.(4F41CH6L:\D9/P:3D?MBP'ZFN
M@W:&BB+^IJONJN]RL<E`(<-26GK'IK_#DYY]\GT!F1<,H5%*CV;Y3)N!`0*$
MY^3?1G`\8P+`@]$/K^[#L)19)[N-H_J&$ODK*C5[1<UO^H!)%D`CB"Z#(4C;
MLJ\XR,L)H#<DX]&#<"_?X'31/0/LU/C+"=8G=G?Q$Z-;$ADN)KS5O2Q+""7T
MP'K<B(B3***=I"4QDG"R!-E<H.4Y+#@0\^<^G`?%#]!^TE4C>Q67W574B<R9
M9)DT7Q6VL6G(6Q371:WVX.JDY,LH=>L#8AK5CUO0T9H6L:O/_"%%%X\"#]MN
M@O:&.72LE\[KKP*KI.DCN:]-8]7M-<V$I<U"9;^-LV`J<:+'%S6M.L"EPR%M
MB5.:64([*LPT7M^`QJYZ<]MR79"'5JW=KNRJ_7=XIR;S*77@9KKH>&11VX6.
M7Q!GAE9HVC%-IPB8Y1$7MV<CU&6M2(M0U%@PI*P;DO(9(DN@W:.G60T$%[K+
ML6-2F6I"+,,G6L.F^75+7>$#D<X'UKF.4.D1$6$-Y+0E$&NP536!$8I$,@PW
M!7`_I,M!.T%-&G`ZL>[&\E4Z+$A^B$V;JWIFI@Y@!.*8+K]<31"C6B0FB"SC
M492_+J2O"L)7N>HO`PY#N770#L9+:G(<?[M-F37\ML<1,0)!K#HZ-B,?<(SA
M,_U\#70"9R-8\.?M?-EI3"5!B7U@+,+,R$S`=?%=`^S)1&8XHL'NPV!1SH]D
M;#9LDK_6+2H,&3RDU&0-_(A7XGH-;(RHL0Y9-"WX<#3EF$V`>^,9GJSP/EB&
M@G:&H;EX[([L+P3O89')"F@NN=6]-4S(*%%.9Y$)-=@2JC71Q'-#F`LDUY,(
M,+;Q.!AF$I)9(0^H#+H+VAF2*9$R?NOO`N%IEK-BL3XSJ[IH5,E+6:SDF2;%
MG#=Z*5L*MT)DHC0MHV@I&3AMP#!Y8C_4+@?R-T'[20SQ"E([J[JS4?X06*'1
M>HUATX%;(K(`\IBVI*VC*H<J$$UR.,C/$K`<F,=1.8"LEG`(R,'`\!9NFW;/
M%[`H./5QVR;,3R!SZ=R!@O29N&N.AZ1?44&;X%)I$PRUC2YIYFPX.#Q.VMM9
MC092N>`)5XS,$@$7@S@9`FN@_:0CCPSZK[JKJ<9F%T8BBD]J:PZ<YAPX^<](
MB9<8:&&40WOH9"GC`U1C0/!F4H7,!'S)9B?)F.!WKYH#V.%-+R;%.['98Z0E
MMCJ9&$TIUFT>,8#'W"0X3$5)C&?7M,YFL>'`)6%OR?LJ1I\F>T(L>0Y"'SQO
M0'LI-8&`V;]VFQ1<P,:&PR7DPG5[25+$020Q$1E^*B14AH9T?$\<`Y>[A`%<
M>H5!3^CWAC'ZO(=?#M`^T$]B)-LONSO(F6_4'D"@JM]6--$<3RSDO*XJ+F$$
M2RD7E["\*(T!(8Z9$?DCZD,_"<(2,%^0_#!H3VCGODV(F'=/=26)HWAL)JE3
M$-9=.<RQ?&!,R50^'VM]<H0YE.DX94:I)1"90)486DHGW@#4C,$$/U_('V@_
MC;Y?_.RO3^%V(K@[YG.KFF6;/%8&7;(!$_,_P*Q#PP(,?Q@6"_D\N>5^<YR?
M[/@'`_F]:"]I!4FA)46[KKL.@RA3(06D=*-7=-S)NF0!91FP\VL#F>C$L>3.
M.90`!;M]8(5E&-A@OEL$J`8$,,9[%Z>]NM;U\UR#7KM8V1N^?J[,J>+N4.D>
MN^B+,W-U;3"Q(W&K6G@%6*=C&1NE;UZY.+ZB)^9$%0J0!*R0?@SV\AF"3Z!]
ME),?D!T#[L]B3)B4SN9L.(G.KVDRJ'&R,M*8)B(F(8[0C8^GQPQ>`L"[Y`Y,
MKR0(>21!'Z<<#[6GK_[%1(&L<@[M-G</&42(;Z4PZQZ-$M'U7)!0G0#)]3U^
M6+B&OYSUX2X4"..`3Z<&",%C.<AYJO\`0?M/511M47!W67&BL,9KH%[35'J[
MIX37Q:8IZ7@CPF4J<4<ZR<*DZ,@1B<?F%`P9<A*,D8`1[0`A]3!H'V?'+I:"
M8]V5ZDM!$@"17(H?JUIF0[G0S#4VG"46(:^T>O1+)F*1&K2\#:RT:##<4G_P
M\G"-R$/PGT&[0\S9U2+.ZR\/X6`C#2?'ER36'34-HYG9J]>5)4TA&?0QD.40
M8IG)1&-F$J8AQ`M-4X4&&E!*X'\WK07M)+E$*3Q?NNNLR!*39'FTE<FU>TX-
MG:9.4T%YA1=89::+21Q(>=(O7]9&\%+`B;\!`E`4=G)O`_O*=`^S\A,SY@'=
MG>9RT<D8"))B?:L:9JD0(.:L++EQ\=!&:0:5()N2UY$-I&J&:W858QA24,L7
M[H>#V&TR[8*WHRW)]K_VS;+W==T/@$DD52T_(M=]#V5ALF>-#<:LCD,>W8-)
M1P:)OD2XH*8XT+@@R#!GJP<7Z?B&28WH5V-.4>8'"0]T>U+$_KV%G6/S(GUJ
MT/5$,SZI;TRAW;4RK.OQN3TR)R&:47D0S,Y*#C&1BS^_D.OA6@?:&IB[4?:7
M=C>*6>FDGYD*>L-6]-$T#(486GX1XCQ,OHUVDF"?I@2?>RK4&"$IR:(.``R`
M`0XBV@O:,>*3AGW=?=R8!$M=T\"'`M7=-BC%-<X(0YCRB=ADM%N`3+%^:$J"
MO-;<D-9A821$D%"R8'@<H]!^T44U?4CEW4W:75A$=83HDN;M9--Q6BJFIZIP
M!+RI:8KH3,.Q"TK:G19:"T*<#A\R>JRI.$`!(1!_1PT#[/@2B,$,W=E>AD`-
M1/PIT<]:M:9#GI3J0!O_``>&#JF^CDT;3M2@T:OZP%Q2J3A``1A*(O(C,X#Y
M9=H-VF)?PKFN.ZVZ%OO3-@33_%C:O:<C]FL#!*OQ<I@8HK1*'V+.+Q@C+4:Y
MX4M`?\7"E.9Z@"`'U3'03L]2Q20**S[K[V6V$2UGCAR6R]7],3*_.?@^G*,$
MP*B5#M\F-8AYQG!V$"@A1XSY"+SCQD.W5Z`]B)+6J-([L=JU;H6UGC*3D:R:
M($)U#L!)Z@@)PHH'.24IRX/@`!FY$`H7IR;G/DS@9>_$O8E_E4?B'\)L?^9G
M_*U__&OEX;]'_F,_#?R/S7R/U[\`>[]9_P"-^7^?^D_,?X?GY?\`<X%F'`<!
MP'`<#R4]EB:`P69SI:D4N".%Q.12Q6A1Y#\XN31MG6/!Z1+D>,@PH4E(L@!Y
M^'J%C@4,=678MMML/L7`ZHV:<J@E3+M/UWQ_LIJ@NK(([P0="QU_NT%3BU_>
MW!UF$J4VN!.TO3:X%R0Y.S*,K"EA&4HR\%&!#84Q_;P'`<!P'`<#C.?'`I=K
M39'?W_-?7Z=3&9:KVE0C'2\^V$L]56U36;#K"H^&268*8EK)!9/,W:U)E%7R
MRYZ>C6JU2836V?,-3*K6IRP`$4'@71X^WV_7P'`<!P'`<#J'\U[(8GHZ,HFQ
MRDA+2XFQYN>G!0TLZ]\*1G#:43JZ(T#JK;6U4O"6`]04E4F$E"$,)1F<8!D-
M<R']P>Q+'H/9UBW6V:NLV\"C>C9'12EHNCD,BANM1MA4Y+GYI63&92V=/:.3
ME597$3BSL^/+F9E`L<DB`H@A(G7+B$W`M^Z]-C7_`&VTAU?V2EI\*42ZX:?B
M,SE^:Z4#/AA$J<&\.)"C80'.CRK1ID;J4:7E*H4FJ4A@!$G9P:`6,!,S@.`X
M#@.!QG[OT_T8_3^S^O@4)T9N3V7RR]^P^@UC=IC=[OK55,4DL!M:`--S5Y1%
M=;"2U8[KEFK-J2<]TLJ16!(X!7)"*0.YS(C0N2?*PA*J3(1KR/EPL+ZU]CY[
MMWHAK!LM:+?&FNP;BK!MF$M00Y`Y-<63NZE:O2'X86YY<7=T1MI@4@1%%GJ3
MS<8%\19X$XN`X#@.`X#/`H5M;>[?"G-^;HH9*AU,NZJXUJAL1LKF-Q7\;UR^
MZO-=?LJI5K=C9R[9?*%U>IU&Q[XC4)#$N&]G&VI4:EP(R:@1G*3`]GTO;\;!
M[RQ._E-^N5:/2NLWRH!1=VBE5S'7N:Y)M&JFRPY$QR^B;#GM@R]KB\2>W(3=
M&)>-42VS="G-6(R\@)&8,+M^`X#@.`X#@4B;9[V[-:[]D>I-`M;K3BRB]B+/
M@=9+XE,:>N.'*&Y@E\7G#BYSXC<I[>TE`K;<*E4,^GQVK$+:K?7TE0`63BQG
M%""'S]6.^.SNR5JV]4VZBV"U!>\=87N;L>HQ^KE]T+:$.K=OMV8P1BLI+8]M
M2]]A6PM?29B;FDS+I%4Q!+:X+?94^D1A0<A>'P'`<!P'`XSGQCX?'/ZN!KW]
MS/;I-]&9E5M1Z_OE!(I^U.-.6SLBXWC*&]`1&M>[*O*.T2QL-?Q83\RO$JLB
M8OSRYO!IQ&3$D:C$4<5Z_P!`#T>3`R*BV?WZ_P`U=SUDBEFZPW/KB&OU5R7"
M4PU'-(^ITMK`<XBAM2LD[MTFRWADGMQ;$566_*&]M.2M6$)A('@",QG(\*@O
M,X#@.`X#@?Q4$$J2#DZ@HM0G/*,)/(.+`<2>2:')9I)Q1F,@-*-+%G`@YQG&
M<9\9X$+=4NN_4+2=XF;]K?4Q<%=9J@21]4I6RR:3+\-0AN>GF2-E9UV";2&0
MEUM5K;))$O<2(XQX0-`%JL9OL>K!?H";'W?#'`<!P'`<!P.,_=]O]7`C13%#
MT#6-N[.6E66$CA;][SV*/^PC^IEQTMD@'R*P9H8(+$UQ:I>N40V/1J'9*-:V
M0`4R4@"\U267Y5#&,)+X_H_T?[?T<#G@.`X#@.!U$@9B)&PO<?4JW9O3/K0Y
M,RA>PNJYB?$)#HC.0G+&9[;#D[DSNJ4L_(TZI.8`].<$)A8@C#C.`K!JGJ>Z
M\:,@\SU_<H5FUXG?TNDU@*J\VHLI\V(->;(6-*\5C6-7[3=;O*U;/8$C2.@U
MTB=V<!2]8<$M0I,R(LL6`G3KKKS46J-*5WKS0\.0P2IJMCY4<A\91",."D1`
M..5J%2Y:HR8M=7AU<%)JI:M4#,4K%1QAQPQF#$+(9LX#@.`X#@,_LX%3E5=4
MFF^M[#9E0UI9FS->L6S#+8K(NKTO<Z\DQ2QQE[TW3JS)E5S$MGV5$?LIS,:\
M#=']I!AW^FFG$FG?+FF!R$P-0M1*@T=I5IU\H<<^(JZ..SHYQADL"QYA9BF*
MIG7*<0XY&G::NSPXLD11FD9&E;"#`)$QAQPP`P(T>1!*/@.`X#@.!QG[?U?'
M]O`JK<>JG1B-VS>EK25=::3.Z$CG+7?-62K9FU045?\`*;?BKU$%[1)J<=9J
M"$RAY2QU:H*C:4M,(YB^7+&UA3"3@R`,_P"HNA-":6&3YUJPVTY;.+/!$T$V
MM&]+=GMXVB]1>O43BV5M`OQO8CV]NZ&"5XV.JHAH;$XBDZ?"DT8L&&F#,$$U
MN`X#@.`X#/[.!7[<.@&JL\OU@V]NMWLQT4U1(8];[9!IML!91.K,2LZNF)2S
MQJ]E%&NLM+J%IL.'QTTPLEYRB*"2'U'C#D_(SLAWNLN@NO>M5B36\H.[6_9U
MIV-'$\2Q:5]7K9>P,KC54@>U$L:JIK9_LN32,V&54D?5@EQ38W"+)/.R68<,
M[VB<@"<O`<!P'`<!P(N[*Z6:J;?Q[$9V3HFO+8;PKHJX%+9$Q$AD:8V%REMF
M;`F1RUMRAE*-J*?FHH:A$4L`E7)Q&IE)9J8\\H88*:^JC2!CNN2[`,U<3EIL
M6:W8W[%S#Z=?^PB.#RJYVEX0/K5-9#5Q%H`KAX/:W)J393(CVH;:022$@"<)
M./;X%B_`<!P'`<!P'`<!P'`<!P'`ZA^0+G5G<&UM=U+`M6IQ)B7E$0F4+6[W
M<X"8I1E+`&)?FP%9%[0C`#"`><"R$7CTY"-5?:]UQ"[6DLO@C6.'R9M_#;9)
M'EH.,ROLQH.CYIAJ:SCE`S!S9T+<E@EI#LNR:ZIE7J]M1@DT\DTNVS/B5G"'
M`<!P'`<#C/G]&//]W]_Z.!%&R=<:YG<NC#Y/$:F331=+7!9'9Z:=\A+ZT"UQ
MF2JHZ55+PC]"JOQLIN0F#-0"+-<C_6-<)2$>2^%V^)1MR=2E0(DJU<:Z+$R1
M.0J<SB$R8YP4$D@+.7')T99*,@Y48')@@%``4$0LX"$(?&,$?9P'`<!P'`XS
MY_1CS_=_?^C@14LK7&N)[*XT]SY$HE$P7S!:KCLX//$@EE:`:XS*%L<*JAX0
MY+5U\<RGX`:-0WB*4.2C`AK1J`"]O!=LXD^VIE2-N0)%S@:[+$J-,G5.B@A,
MF4.2@DD!9R\].B*(1D'JS`Y,&$D!901"S@`0A\8P1]O`<!P'`<!P(PW70U>6
M:<F<+594EC)U,JAK7'6>2)RS6F#(AOS4,]=#TY62QLLO5+B<'Y?B!EO!7I*+
M(4$EE`#PLMGC/T59%$:CS2P*7UXDQC0E"A`^2$\I6^N"8@0@(S'=:221AQ<2
MDF`%FJ1!P:I&#)IF<F#%G)'H.`X#@.`X#@8:N*M6.PF1>&98P_Q%IC[ZJ-@+
MBE2JHJ_N_P!/582KY4WJ"S29&C;B\YR0@5!&BP?G!XRQFEDB+#^]*ULQU;!V
MV-1`U:DAWR;8LC<3/4&*FN%)3FI(%1'XN-2,U6AC`50!')4&3!D(,FB)3>VF
MP424+=ZR]P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P.C;V0*!XD#OA0(T
M3\:VF"(R6$(4OTY`!#@(!X%G)GNX!ZL^<8\9SXX'><!P'`<!P'`<#IG%H"X.
M+`X9/$5EB7*UH2@@P+"G*MH<&K)8A9%C)>`87^OSC&?.0^/T\#N>`X#@,Y\<
M#CS_`$_U_;]O`>?Z?M_?YX#S\//QS]O[.!U#BU!7KV)=D\166)P5+PEX!@6%
M.5#.Y-.2A"R+&2P@"X^YYQC.<Y!C'W9\\#M_/C]O^S^K]7`><<!YQ]O[?[L<
M!YQ_?X^/P^/]?`YX#@.!TKXS!>B4!(E`D_R+TS/.!!!@SW1-#@0O"GSC(@^D
M)^2?3D7QR'SY\<#NN`X#@.`X#@.!U[L@PZ-;DV9-$0%Q;UB#)P0X&(G"M.:G
MR;@.<XP+(,&><8\X\^.!^VU'AN;D#?@S)N$*)*CP;D.`Y,PF(+(P9D.,YP'(
M_1Y\><^//`^W@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`
MX#@.`X#@8JO5HLN04I;S!2\F:X7<+[6,[9ZJE[V1E2T1>QG.,.B*$R!S)P2I
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MTO[@Y7HCH%0D`L")QB114/3FP;4ZDR>6R-T22Z\=DHW9JVLY[KJ\JUSN:9)'
MA1+IK'CV-`RHOJ8F0"DT0S!"+"0%G/=1/-AVGJ)KY\E$HD-,7Y-[1T5C-Q*-
M<IM-Z^5,TAL*X:R9K7B5?2Y"N(F[<PGJW1:A3"-.&I,2^G!V#,Y$$08%;IK9
M/5YV-S_5>M-I)K<NM\QZW;JW#5Q+>R_91/8[JY95/RU!'H[-)/?TB(EUD5[K
M[.0K?DW-.<0Y8)5Y$>F`8;D)?`P?%?S`6U:6&[9/SK`-=+M*U,A^JFR,HF=3
MU/MK3\8F&K=MV&I@UYK(5$-BT,5L![=ZM;A%/K+*TZ=1'GYG)/,*2#%CP$+Q
M]!MX9#O)8&Z<ABS1!5&K5(7ZBH/7NSXLM<G%UN!UA\(9'6YY,Y+#G`YE.C[3
M-7\MM:3$)!832TYV1C,%CS@+*,9\X\_;^C^G'`<!P'`<!P'`<!P'`<!P'`<!
MP'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<!P'`<#`NTW\
M$/Y;;X_F6]C^7W^$D]_C3[_X@]/\,OPVX_C'T?A/_I7\Q]#][V?IG_.'N^GY
M;_&]'`U]M&_\CS\'[S?1?Y@OQ-_*:\?S1_Y@O\R'\>OY"_HKA\K^"?X]?]+?
MY=_DO/R?X=_Q/FODO?\`^(^0X$?W_P#R"_Y4>NW\9?SO_@?ZW>W\I7U+^</^
M8O\`@E]);?YA?Q#]`_[1?Y-?X>_)?4?;_P"8?PYZ_DO\/ZAP/EGG_P#S>?P.
MZ_??_CW_``?_`(1W_P#P0_A7_-Q]:_D\_C-+_P"-?\RWX`_[1?Y5_P"*GSWO
M?B+_``_:]7C_`(/YK@>7W?+ZW38C^6C!7ZMK0Z*@V^P?2![ZWS!VMI0RE%MN
M8.V%I)JYLJE%2BZS,M.)FN7G'NJ4O#/E&D4%Y/P$-@'MT_D=_DFF7^8=^,OY
M:_QY4OU3^'G\1_QK^/?XAL'\,OPY_"C_`*;_`%+\:_)^CY7X>//K_=\\"M;5
M+_(-_@-V!_@_\1>U_!QV_P`P?^;;^9/^:G^"OT9;Z?Q=_,+_`-LGX)^2\?(?
MAS_@OJ/RWH_X_P!G@8DU]%U;@J+?06M).RBC9''65)_XME=DZG:](M%K9EKG
M6*>S/5%]I%Q(*\`BR$31B-E"*%&<$!*R$6<BP%@GY=,JB2>F_2LO7Q:X.,3!
M"))B6K7QL96:2GV[F>2C-MB?VQC=WU.D&&>96A;@FJSE&63"(0\X\X#@+M.`
;X#@.`X#@.`X#@.`X#@.`X#@.`X#@.`X#@?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>g575431g94y60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431g94y60.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`0@"_`P$1``(1`0,1`?_$`+\```$#!0$!`0``````
M```````("0H!!`4&!P(#"P$``04!`0$```````````````$$!08'`P(($```
M!@(!`P,"`P4%!`L!```!`@,$!08'"`D`$1(A$Q0Q%2(6"D%187$C@9$R%SK!
M0C,9H;'Q)+0UE388.'AY$0`!`@0$`P4$!P,)"`,!```!$0(``P0%(3$2!D%1
M!V%Q@2(3D;$4%?"AP=$R0A92LK/A\6*"(R0T=3=RDC-S-G87"*(U91C_V@`,
M`P$``A$#$0`_`)_'1!!T01:/7K:/;+/7KANT9-DCKNGCM=-JU;()`!E5G#A8
M2HHI)I]S"8Q@*`!]>E#2XZ6@EQX0A(`4Y0CZV\@^B%#DU(>W[BZS5V72%0J\
M8\S9CL'[91(XD52=M4)]95JJ0X=A*H!3=_V=6&EV3NZL;KH[77.'/X:9]V,0
M[[_M^E<6OJJ0$?TV_?'5L9[)Z]9O_#AK.F(,JK>V9;XN/<E4RWO"IE[B85F4
M'+OG:'B!1[^9`[=O7J-N.W[Y;#INU)6T:?ML<WWA(>4UPHJQ#1U,MR\B#]6<
M=U#Z!_+J/A[%>B"#H@@Z((.B"#H@@Z((.B"#H@@Z((.B"#H@@Z((.B"#H@@Z
M((.B"#H@@Z((.B"&KN0WDPJ>EQ*3B:@4&:V'W,S2H+#`NLU+5,I/V)RLJHS+
M;KFZ9D74JE!C7":@J.CE!1U["@)>*:3EPWO&RMA3MU3W7"X5#:':%&09M8[%
MHP5`/S..0':O(&L;AW)+LK124P^+O#OPL:.?$IB/?")ZGQ*;*;N+-<F\O6TE
MZNA9(R4I':6:ZVI]C777'S=4Q5T(.Q2,`HE*WV8:$[).'22J9_(HA\UT7LIU
M;*GJ19-JDT/32B9)FM*?'S@'U+N9:'*&-/#`]PB$IMJW*\`56Z:LSP<1+9Y0
M%X8<N[L6.6[A(\`?%LI5,;7S2["]ZR58U8UX[QC4,6P.8,HURBF.`S&1+N]N
M3Z2?0\#%1*:KPJ;IZ1R_`AA;I&+YJ$?[;F]:.H(F5%#<ZX6YGYG3C+87'@$+
M5QPP5,L\(;7O]`[7#:6JIVO>0,,7E.94E.P?4`D*,BN)/AMWEQC7LZ:UXZJM
M&CK,B$M2\X:D6Z7Q98X223`@B";."=%AXR?AG12E<Q\C%`NV7()54RF#J"G]
M1NIFV*Q]HOT]TS3@9=6P/!3)"X*0?V@Y'"'_`.E=J7NC;66\Z&H4-._(]H*@
M$<D!!CBU@R7R*<-+EI/YVN%JY%N.%J_;,I[*SF-*.V&M4.[5*S:S=S(FL;_,
M:F1HG*59RJ<_I]56`^VDK,R*'8_4R666T,L6^`#Y#_@ZIPQ1IREN=P`P[SDS
M%5N79_\`C5K[%EJ4_$-:<!@>1[2,<VQ(*P_E_&^>L;4_+^(;;#7O&U^@VEAJ
M5L@'/RHV6C'91\1`PE(JV>-5B&1<MEBD<-7"9TE2$4(8H8W<*"LME<^@KFEL
M]CBUP/`CES!X$8$1?J2KI:VD;64A66X*/N/;SCIW32'41I>7">SUCK??CAIF
M+]L]FL84'='-AL6Y8H5#OL5!UJ%@*TKCJ%3?8[(%8<R58F9E&RN%7JQW#HBC
MGQ4(0@@(#MG32@MERV5N"LKZ&@FS[=(UL>\*\$AQ'+EEAAQC-MW5%RH[Y;J:
MAJG,;5OTD+A@YH]SO;&MY(S#LSQW\O&F6L%=V/S;LKK;NA$C&V'&>?+`PR/<
ML<S))>4KR]KJM[-%1MC:1C!=!O(&(L=1([9-ZF<I@*DHDXMMILV].FEPW)44
M=';[Y:R`'4Z@3`0"-322"2"B\\N4%=6W*P[NI+4VH<ZU5V8=BX$E,#GB4Q"<
MB(D'9SV/P/K)5&MVS]EFB8CJCZ03B(^8O5BCX-&4E50\DHN&;NE/F3,D8GXO
M8:IJJ@0!,(`'KUB]IM5TO4[X6T4\R;.S1H7#F>0/:1%\KKA1VY@?6.#6'B?H
MOL$9G#^;<1[`TECD?"62*5E6AR*JS9K:J'88RRPQGK8""ZCUG<8X6*TD6@*%
M]UNL":Z7D'F0O<.N=RMU?;:KX&ZT\R7-Y."?4>':%$=*2KI*NG^)I'!S#RCC
MTUO9IO7,Q(:_3NSN$(C-SB0;0R>,Y'(U::6D)UX(@RKRS15X!6UB>B'9&/5.
M1XH80`J8B(!U)R]J[BF6OYS+HZPVH?G##I]O+MR[8:NO5I;4_".JF>IR^F$,
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MK95)6F0YP`(82TDY`$8%8#>+2TEKJEFH9XCA]/LAO[?S$>L>W-@T=R=8>0(F
MO</CG*M?R?B]OC[+=+BHW80ECEJTE`Q\&"\\S6FG,H_BTF3!_'D?>*+]TB"1
MC+"8MMVE<KUMV5=:*39_F$^9)<V=JEN<:0`'S$IAXHJ9Q`WNEMMVGTE5\;Z;
M6NP0X.\%[$5$^UR;)6R>`,-3M9JV6<T8NQU:[O)14/3JO;[S7H&T6B0G9-.%
MAVL!7WSU*7E!D)=4K8AD43$%80+Y=^J506VZW*0Z?14LU[6`DHTD!.9`01/U
M-?14A]"LJ&,<XX<#C&"QIMOK#FJY6;'6(=@,.Y,OE+*X/::E1<BU:SV*#29N
M"M7:[N+BI!TZ,U:.S@BLLF4Z:*P@0XE,(!UTN&W]P6^C;77:DK*.2[(N80#Q
M&812,4SCS37>TU,PTE+4L=-'`8F/&<MOM9-930:6P6<\88@=6;WSUV/O-MBX
M>5FFS4>SQ_'Q*AS2;B,8]OZ[H$OC(C_Q#EZ]VFQ7Z^J+/239R9Z03[N/8JPM
M?=;7:T^.J6,7G_)%_BG:C6K/DM)P&#<_8>R]/0D0VGYF&QID:J763B85ZZ!D
MTE)-C7I&1<Q[!R[_`*1%%2D*90/$.X]>;IMV]6-!>J6KHRXX!['!>Y<X*6Y4
M-R_P%0QX'+'[HTRG[UZ;Y"RR[P31]GL'VS,S!W(1JN.(/(U:DK,I*Q7_`)K$
ML6B#PY9.6BP`?D-6QEET/$?,H=A[.Y^U=QT5`;U44=:+2BZS+.GOR]\<I-YM
M%15_`T]4PSE1`<?#@?`QT"Z;+Z_XVO-5QCD#-.+J=DF[O&D=4L?V*\UR,NE@
M>2`+G8I1M97?EFUR.DFRARJ>P"0E(8?/L41!A36>Z55,ZJHZ:8ZVL_$\-<@7
MM1/!57PCK45]%1U(I:NH8U[L@2!&6J6?,(WW',[F"DY<QM;<5UA"QN;%DFMW
M:N3-'@D*>@NZM2LS9V$@O#QB5<;-CJO3K*D*W1+[AQ`GKTE3;+G2W!EKJJ68
MVJ>YH:TM.HEQ&E`0N)(1(Z2JRAG2G5TIX,AH*NX(,2?9&I[9;$TO4C7',&R.
M03&&J8@I,M;7;)%0$W$T];D3:P%<9&-W*$A9)]TV8("(#V5<`/8>W;IU8+-5
M[CO5+9J!3.G3`.[F>X`$^$<KK<66RV5%;5)H8TD#GR'B8:CX:-3;A(0=GY-M
MLDOS%N=NL@6[-W,RB=;_`"5P7,?UL>8SI31T`_EUI(UA-HX<E2`ARL_C-3>J
M2HJ7SJAN&D;/;T_VXXC:%N4.Q3U)B(]ST_$CE`7!5*9&*ELZTO;(=N.X8W:M
M&"_E;P`'!0G@@AXW.<'<++B#)5?Q[D0V([S+T:T1]1R>G"L+$:A3Z\.Y&,M8
M0DFFJRDR0KD`7,D<H^1"CX]C=A#,[9,H9%TI*FLI_BY+9@5JH'-7%I(R7+^>
M+O5J*5R'3AGR[?"&*]!:)Q7Z9:_*[8V'9ZC;&7K8C(3W#V4=W<K)2=CDLI9;
ML!'))S%\`G/Q\L\KL"\4:+IF8#[@O$D@^:Y7\2`35]XW/?.Y+K\AI:%]OI*%
MNIE$Q6^@S`AY0M+G9%20B^4<31+-0;>LM.;C.JA-GUA=_>7^8+F0`5`&:KP&
M/*-XUVTSUPUIY0[E":6;7.</)K49_D/:OCLBFBLU3)3[VQC24._U5I)(FC,;
MQR;VQH.5$F9E'!"F30:J(-5%&Y6]ZW1?[WL.0W==$*TRWZ*6M1""T^:63FY-
M."X+FI"GK06&@M.Y5LE4&,=C44W`J,QRS!Q4@(AQ2'YY6)C9R,?PTPP82L3+
M,'<7*Q<FT0?QLG&R#<[5_'R#%P4[9ZQ>ME3)JI*%,FHF82F`0$0ZRL.<TAS5
M#ACAP,7PAKLP$[8C8:X1SOB-Y/$]*&3N10T/Y!E;%D75E@]<K+P^$=AHL2KW
M'$\,NN)A;0=D3$A&J(B/<SJ,`/)0'"A]LNK9?4+I]^I03^MK40RI&D>>C`&F
M8@S+>)X>;LC-K>]VU-RFT.)^1U^-.<T?Q'%,2G:"W"),(?3K$HTF(PW.Y79*
MV[R\)U6AKC8\>RUCV5O4+&WNH$AE+34'KZ3P\DA8:^G8HN;@3RL8?LHB#MFY
M0\P#R3,'IUOG2"8V1LK>%2YC7L%')!:[(_\`&"'BAR*8I&8;ZIS47ZT@%#ZG
MCFTQQ7;Z"O/$'O9K'O%DW)\QO/3L_69/6VSVO8B'@5\Z8"C7"17`/\'SM+;5
MFE0L4\C9-\X=-T8!!1Q[*J"BO=Y[H/\`:\^CZE;+KMFV^F-KJJ)AK!\/J=(J
MM(33.!)<$.7F(7AA#.]-=M#<=+?:EQKA5DL`</,U$`TYC`$`(F1&&<=\<2!\
M]_J9'=%R81M.TS4?352U87J\R@@]A(RXW*.HCR:NL;&NTU&GW\Z.17*0O"D%
M9,&2(%,'M%[1;:9EFZ""LMRMJ;A=PVH<,"&L,W2%S`.G)4Q/.)#U36]2W2ZE
M/1I*#4`>TC'_`.:^`Y1P[`%_G=5^8#F^HN'44V6.6&K,UM&:EPR)"5N'S+7:
M%3K2WEFD.@0&+22EI*W2!''@0!7,<I1[E3(!9FZ6^FO_`$KVO<[D[^]MNPH5
MPU.IW$DJ<RA"#NAC:Z@V_=E];3$Z&R2X`9`AFK`9#$\N,(LU#U@VMW@X47V'
M,1ZPX:M4UGS*]OR\^VTNVQ;"$R(MF.#S(L]D;3+4_P#RLDYYK,LHZ$4AT3_?
MA5^,K[X"4%!3ZL>Z+[M':75:7=*ROJV4LB4QGPGPK@W0:=-(!FAI!(!.'#LB
M-L%#=[[LAU-1M89AGN\Q(4H5(4^\YJ87+RSXPG+G>OT^6&=H(N-MEBG,R1U#
MSQ$HRKM]"6:<-`8-A+ZR/*M#Q[N1C)I\DX!10OM"NDJ8!#L<0ZJ73>Z4M-3[
MPN=F5LOX<NIL`H4SR%!4`M'/(A,8E-V4KIU58;?6_CU@.[QH![XV-IA7%&N_
MZEW7ZI8(QY4,/5*V:-V^0L=5QO`L*?6Y9XTC,@LDEWD'!I-(Q144JU'F,()`
M)U&22ANZA?(6OQ]==>@535W)[ILQMX:`YYU."AI(U'%`IP[8<&DI:3J3*ET@
M#!\O/E&`7S#+F0`O//.-%V$TXUZV0_49M<294Q[%26,[!I&&4+[2H4AJO#9.
MM;&PRY$G.0BUPT6ZLR:THY;R"XK*^XY>1S4RIC@D!>G]CW+?+)T*-9;ZG3,%
MX#0<"6C0TJU04'(9!3A#"X6BDN74>51U0/I_+E088J1BGMYQL'-KK9@[`,/P
MW4[$F-*M3HK&^[.&<54YRRCR.[%#XZC9=G+-ZF%JDA>6-[%!-',^.FNY4*H]
M.=<P"H<QAX]&[K7W:JW365[RZ9,LU2YQR#BAQ08+RPX0YWW24M!\J92A`+BP
M#NY=WWQNGZC?%>-K7:N,F0L-'K$E+7?=['F*[78#P[5&S3..YAXV^?37=D:D
M;SAJZJ9^NH#4'!4TUE14(!3]S=<.B%PK*.3N#X;$BSO(!Q`./F`.`/;"]1Z:
M1/-L7,W%H/,C!0O*+#-F&,3:^?J'N,R"P7C6CX?A+/K5E9A88?&U8AZ9%S+2
M'@<OL8TDDP@&C%L].FP8()'.H4QU"()`81\"]DLMSKKIT0OOS%[ISFW%A#GD
MN<%]%4)4A3B@R7".U;24E%U%H&TC=`-$5`RPUC$<^W.,9:[_`$W3KGKV@S/N
MHHM*8HS?I]"L]>[0WJ4SE=O6JQ#.:1&V*B.*I4XFTS].^^RT1)H$,X9-FDJL
MOXE5.9R8.B7+F;BZ,T-NVR0RXT=U)J2HD'S*6.+G$:P,RA)`&6$<IDUMOW[4
MU-YT^@9)TX:D!:``1CC@F."GMA-6H6/L[:3<&'))GR2QF]PG<\C2F3Y_`2$Y
M3VU4RY4<,9">56H1KN24.S;6N!C$WLN\D8V/=*)F:>U\HB:?O%,,]NBX6;=_
M5^QVREF&X26"4R8`2YKWLQ+1P*?F(S&!RP9VF166/95PN!".<7%G`AI*=^(,
M6=1TLW0V>XR^-^FZQZJX(Q@]P?,X=V2QKL>;9"++<[+(%C'\U:Y23K##$T=*
M04S>)F7(Y>I'EG@MU6A4#BIX%$KNKW3LS;._MP3-P5]754]4RHH_A#3.`&"-
M`)G(-"8(!Q."QXEV6[W;:]K?0TP;,D.UDZ@U02O9QQ3F!"LN<S!..\N[T<--
M0MU;8QRV:\[77'^5K#5TDH&Y66G$2QD@ZJ;NY1B;:?6AA:R3UHD4RP_';O%P
M1]L5#"-4Z5W:LM.R=T5M"AT4\DM#@H;YGD%#@N`7NA]OBDD5E]M-)/4/>[%"
MBA6C[3A#[^(M%-4L$X$R'J]BS#=9JN!,K!?T[_C1LK+NX*R-LGQ*E>NS!Z:1
ME'<@6,F*\<&`-TUB)MVA"I)>!2AVQ^X[FW!<[S)OE;4EU?(<PL>@4&6X.9PT
MX."Y8G.+]26:AHK?,MLD'T9H<'8G\X(.*KD>:]L-3?J"U7N0\;Z,Z@MEEDHK
M;?>K#E%NA$5#E,]HE>?!(SC!1,IB@NW,\DF:XE'_`'VY1^H!UH71]GR^MN6X
MP%?;K5,>./F(('N(7MBH]0'&=3T-JS;67!C3W*B^!(/A$@2,BV$,P91<8U09
M1T:R:1S!FW3!-NT8L$"-6;5!,OX4T6S=,I"%```"E#K)'O,U[ICRKW$DGF3G
M&A-8UC0QH\K0@\(P=X_]E7#^%4L';_TEX'I_'I:916,`RU-]XCG.QI7K^R[W
M1^?7$?Z?;5?^'+U%=OX?]ZN'TZ^QZK'JY>2<3^G6_P`.3&!-QV-1`Y?-3[GQ
M(,P3_J7=X_\`\,8D_P"K#W?_`*.LGNO^@=H/_P"S/]TZ-$H`/U[<3Q]"3^XR
M)&8?0/Y=8;%_.<1_/U&M74C-'J1LK70%ID'4#9G!^;*A,(@*;UD0ML95J69H
M.""4Z+=Z:5:*JAW`IQ;$`WIUL70]YG[NG[>.+;C;:J61P_`YP7N0CQB@=0Y`
M?9!7,7U:*8UP3MY?5E#\M5GFUJK%=LS/M\6Q0,/.M@`1$/CS$<VD4.W?U[>T
MY#K(9TLR9SY)S8XCV%(O4F9ZLEDW]IH/M"PS7OYQT;2[>;2ZP[`T?8;!V.8'
M3VZ)9&PY4K/A>Z6V8?VM\:K/+#_F%8(W*$"UF89X_JJ7Q4&+2.4;H'$#**G_
M`!]:3LK?5FVSMROL];1U#GW)FFH+*A@`:-6G2#+*$!V9*+%1OVVJ^\7.EJY5
M2UK:1RH1B<0>[@(U7+G%7L%NSL-A++&_NS..KOA_7JR$NE"UOP#B&PX\J$S:
MR.HQX,C=;/<\A7:Q2R;Q:&;D<)AZBT*=!$R!5ECG]VOJ#:]J62LM>S*2=35M
M>S2ZJ?/!<&8^4!C0W%3EACX1PKMIW"\W.DJ;O5M,NB=J#6@XE01B4`5`IQ.$
M=TVMX],@W';K%W(-J/E&F8FVFQ_293%]LA\I4^8M^'<T8SE"+D3@;NRJ\W`6
MN'F(4[D3-7[)P<1*D@0R?]`ANHBQ[TIZ?;-9LB_2'U5DG.#U8=+Y<P8JTH6D
M'BTCB<P<)*X;=:;P+]1.#;J&Z<5+7-1$*+P^@C*:/\<#77BQ[.YQSU?8O/VS
M^YDNLZSS=FE;-5:(TJ8M7+./Q;CZI+24M(1E+CV;GVU#.G:SIX5-(#^)42%!
M-T[WJKS3T-HM;74=AM@!IFD@DO4$O<[BXIGVF%LNW/E\VJK*\AUSKEU$9)R'
M9S[@.$(6PAQ";RZFIY-U[U3Y"HG&&D&4+9-64M>D\1FLNPF*8FT"DA9(K%-Y
M5ET(*$GG,6D#=":.CV16(5X5D#KS4-;;SU+VENATN];BM,QV]&,:U6OTTK]`
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MN3[_`)BD)L5@%FBVIA<*1^,)/"%\?G)@8;"64<1SNQM\L,_<R@M'G.F$J1$C
M`''B?X`I@*0]J??%AE=/';(F4=27.>)CGBH8GQ0"`@&6NA$PS[869MJO?ND;
MG;4L#`W3I3\J)]OMC:>3WCMSWOK:=;'V.LYXHQ'5];LE0.;X)A;\5V>\3\UE
M2OR)EV`R,E%W^L1@4G[>@W359$:`Z56!0XN0*8I"MNGN\[+M"372[O23JR97
MR3*\E0UH#3P']F24*I[H7=6VJW<-323I=2QC*.9K0C$G`\.[WQKW(IQU;4;U
MO]3GC'87!.-C:S7"F9J4^5A:[6(UISO63D5?2*/CE5@G&8Q>*-DO9B3`K))A
MY^;\_<HEZ;+WS9=HLNTGX2H<ZX,=+;_>&>6F.>K^S_%VC#LA-S;9KMP3J.<R
MI8SX-VHX9NP/#N'=&/S5QS;:Y>Y"M;]\R;%X"@Y/7"H-*1`T0<)7Y\RGX6=C
M)%ODUQ*/3981.22F)"R2IH=1$"$CD#-2K%='25.MWM&^+%;-F7#:#Z.>XW%P
M=J%0Q`6D%F'IK@@7GCEP\UNVJ^KW#27L5+`)2!$S`50."%<BG#E#.S/#TAN-
MRH<H-PP+R091X\[?CZ[4C&]AB)VWL1N64WM382,/+S$7"N;507$7A*N/(8OV
M=I[D@JB=Z94QT$W":8Z<;U2[8V#8*2[[=I;W+F%\S4PD("0C7EJK,TNQR5"@
M,4R9;JBY;LN=5;[F*,M`:A.?!QS;@K<\4PY8+FXW*GGW8>1Y'M%MI=JPY!M2
M(VG5#',%LQ&HH>#N\9`@YP<B8_K5R2<S:4O.4)F>/<.BDD)5&+D2HF!4IE5$
M"5'?USLUKJ;1NW;-O-@O.O4:4DJ-)\K\4*.Q`!`)&8P,3^W::XUCZVRW6K;<
M+26)J',HH7CQ.9'+MZ7K#Q8\@N`*A6=6%^1]N72*CW%K-0$90\6NZGLV[I3&
MS!:RXK;Y8^^KH42M3$D'MOW$?\IU\559%J+9%0"%A]S;^VM?:EVX3:-.XYC0
M7NUK)+TTE_H`*XX<@OYH?6O:U_M+!0,N2V=KR0$&H`\`44#^MX*8[WOSQZ;/
M[:[/ZK9_QIL!A#&43IW9EL@8FK-RPU<KO*2EZE_LWW]:\S$9D^LM9.N+_EUJ
M#5JS;LG"`>X)UU!,`EB]G[ULNW]NW&T72DGO?<V:263VM``U(@,LH?-BB_9#
MF^;<KKK=*2MDU+&BC(*$*N+3W?E`Q.4.XD:W,*0HU^ZUT<BC5OCC,FB9$:B6
MZ!$>T$D$#]X^[!6OO?\`6!G\_P"3\7^G\CW/ZO6>JS6I!]/5EQ1>?-.,7%"G
M]),X88YX3_D"U\56QD@`IU3"?(=C)*W2)^XMXF(O!44C2#GL`@1)`:V(^0^G
M?T^HAUK_`$?TSZ7<%F:1Z\VR3$!.9;]9_%PC/=]ETAULJ0%#;DSP&9^IL/O7
MS(E`QC!&M&2+M4*!6"NFS$UAN]EA:G`E?/CB1BR&8G7C"/*\>G`2HIBJ!U!`
M0*`]AZQV325-:XTM+(>]V.#02>T@!3]47VHJ*:G:'5#@T<S&G7')V.EOS9C9
M&^4M7(2N-IVTIT-*U02MS&LJ13HJ5B)5B/AG#P*BA@*5X"`MQ,/;S[]/*:CK
M&OD5#9+OEXF!I<A0%0-*HB\$58XU%32Z33+B6'#BB$Y9Y1`HB/\`3[:L_P`.
M7F--_/Q=7#T_MZ^P*I/_`"[>4P'Z=;^Y)C"&X;'HN7S8^YT2`,*OF<9^I2WP
MDI!TV8L(_0[%CU\]>.$6C1FS:(XC7<NG3E<Y$F[9NB03G4.($(0!$P@`=9;>
M!JZ`68#,WJ=[IL7^W%.H%?\`\AG[C(?82V!P6M`5:V(YHQ,I5KQ.!6:79R9(
MIQZ_<+(+D['\NU6;++FC+%/?.2,B#-FJLX%4@D\?(!#K#VVVYF9.I/A:O73M
M#G>1RH0JD(H':X`1>?C:32OQ#-))`R11F._LAGS]2#9THOC`O%`;B"UDSEEW
M!^(JC'>IEI*>E[]&6`K=$@`8XF*QK*QQ$`'_``@'U$.M5Z#2R=^RZ_A24-4]
MQ/`"4X?:/KBG]17)MAT@?C<]J=J%8>ZQY7!I]`H]3-V\ZQ3ZS73B'T$T)",H
MP>WJ;T[M?WCUD]3,$VHF31DY[C[23%UIFEE/+:<PQH]@$-Q[;<L>$-,<S4K!
MN5<+;53=LRE(QL)B:5QUB*.L]4RM9)`D2!ZO0)ES<X92>L$4[G&C9ZW]E/X[
MA<I>X@(&&X[7Z;7K=UIK+S;9E!Z5`S54A\S2YK<<2"TX8'CPBMW3=M!:*QM'
M62:P.=D0Q0>XKCRAS2O2YIZ#AYH\3*P9I>*CI0T-/-DV<W$&D&:+L8N99I+N
M4FDM'BM[3E(BJI4UB&*!S=N_5(<QK3HP+0>&7A%I:=0#L0HXY^,9GHA8IV#]
MP=!0YP9Q7H@BG8/W!_=TA`.<&64-9O>1N8C.36F<<<_KI8*TM><;6_*5:S1)
M9"JCZ)L-1K,?+.&\C%4F":R<HU0DY>!=-/&1=L727M"<4!(8AANK-E,?L9^^
M&U3'2V36R]`!#@XD*KCA@"#@$[8J[MR2V[B&VC3NU$+J.2(2$'@>/*/C6^2*
M4FN3.0XWI_7*QT=^TQ;9\O1&7)C(%3EHRW4^&>M64'+PE/KJ,F\8,K$J9<2A
M(O6KYM[`@JU#R*/7IVRY;=B.WR*MCY0G-EZ`T@M<<R2<"@(.`3M@9N.6-R?I
MDT[@[27:B<"$)P"=G$PZD`!]>P?W=4=ND@."1:$@[!^T`Z72#P@AN_D=WDL6
MAN**%DNMZT93V<=7/*M=QPXJ^+BK@\KK><;/W'WZ46:0M@7#WSLP:,D?C%2<
MOETTU%D0'RZM&R]JR-U7&?;YU9*H`)3G![^)"(F(3-3V1`;AO$^ST;9U-2OK
M'%R:6YCMCJ^3M)-.MB)N/R!F[5;!N2[F=BS.6P9'Q53K!:VQ!02%-C(2[Z,<
M/5U&28%2$JBAP)X>(#X@`=1M!N3<-E;\!15U8)378:7$-\$00YG6.SU[1-JZ
M5NMP!."'$*A3,@\X451Z%2L:5F+I>/*E6*+3X-O\6%JM/@8NLUV);B<5!2CH
M:&;,X]H0QC=Q\$RB8?4>XCWZCZNIF5SS.K7.?-)4N<223WGZ#A$I+ERY3=$M
MH:T<@D;?V#]P=<NWC'KLX17L'[ND(!S$$'2P0@ODNU#;;S:5YPUS3.W:6JTU
MK[SC65<G]I.'RA4G+>PT5Z9QY%%JBO-,"-5U0'N1LY4$/7JT[&W*[:NY:2^#
M\#7H\<V'!P]F*=D0&X[1\\L]10#_`(B*W_:&(^[QB+?OENLMN/P&/(+):#F%
MV?UKV)P7@C9ZB3S;XEDA<A4B9F81M9Y*,7`%46MV9Q8N04$H$!^F[0#N*`];
M_LG:@VQU?9-D?VEAN5MFS:-V!:=84@')6DIW!IXQE]_O;[CT_<VH*7ACVLJ!
MDX`:@"G:`%3B3XKZ*FF'ZAIXH!">X7B*$H'\0\_#Y;;\/EV[^/\`#JG,:G19
MQ(&K]0(O'(1,,<X]0]`)]/Y."G#+E#)43_I]]6/_`.O<7_XNX=:G5?ZN7G_M
MUO\`#DQ46?\`0E'_`)H?W70\[8@`><[EF`0`0'BH3`0'U`0_(6/.X"'[0'OU
MG4C'I1MIIR-_=_&=%WJ,-[5Z8'Y4[W-AIFFMTC<1W`LF5!,0#E';^V0$BCV4
M'-MZ["0OC_C,;]WKWZT"<`.IF[@@3Y"?X$N*5+>_]*69RG4;QCCF%<JP];F&
M9)RG<P>),&4SSG=2^+:Q*9@SW:4.ZE7N&T"B@-J7CMNZ`#-)-W39*+3363`?
MZ8M98AA_X?GD]I8>GO3:LN54K-P;@;Z4D'-M)^=Z9@$8+Q\L7JJ3=.[F4;<;
M+;T<_D:A<`OL&"Y.YQ);ZQ*-)B,/SI__`'RX-P'OV_\`EW("`?4._P">,"^O
M8?3OU]`]'L-G[N3!;2?=-C,-]./SZQ_\XK_O,A0_*;O5O5J)L_I9C;`%6U[N
M&/\`:K)J..(2"N1;='WV2M\8[@FDS%V&WF<JU>G4V1-;67LOV<>_D$")N#&3
M$?;`:MTWVCM'<]BN]5?9M?+FVZ1K5C06H=6(!0DA.*`\#G$MN>^W6S7.DI*$
M-<*QVE#FH0=W&++7K>#?6D<I##CTW9::Z7)IE'!<MG/'-ZU^@KE6F=4)$#+*
M+U>03N,O(/IUCV@WC<5EDT7'NIH+`82*G3(XN^S=GU?3I^^MKON']C<12.94
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MPQVMY!`#PI0`!-(!SP)2&UBW963[#5[AKPU)9(#0$Q"`*>1)''GE&+_YDF]&
MN*O'GFW;2P:]77"._%TK%,M^+\;4.8J%NU=?Y2C8Z>QNO'W=Q>;$I>VL?&29
M"319)@V'S16(D8HB0P=_T%MR\T]XMEEE5S;W:V%VIWF;5!I(>-.D:$0H02H0
M\Q'D;JNUNDT51>-!E7`H```YHP3O4$',\8W#-(`7]3)IQ]/30;)0?W.\P_M_
M=Z=>:$`=!+@.`NTOW-CU5`CJ/1+G\"[W383[LY);#1_ZC2#1U:K6,K#F"8T`
M2A8=YF*<FX;&]-BG4_-K2]VL3:L,GEELR,,FU331BV(H+O%W)`%=)(JAPF;"
MVU'H,[YT9C;2+T%]`-+W(QGE&I&@'@3@!#*O=6#J7*^$`+C;CB>]^)[?Y(7Y
MQ:[\;+Y\S5O)JEN%`XE:9=TMN5?B9'(6'VTW#4BVP5A4LB9'!X>POI%VR/'I
M0)5T5A42%5JY*55$BJ1S'I._-G6>S6RU7_:[IKK3<FDALQ-;7!%;A@N..8PS
MB9VQN"NK:^LMMY`$RBQ+ADF.:=@S[X1'*<I^].7-;=K^1?7Z4UZK.LNM&3Y^
MJXYU\R!1I>>R'G['>/):#C[[>I_(C*[0[JA24@UFCKQC1A&+ID!N<B@J&`#'
MM$OIW8*._6_8MR^-^?7"6TFI:4ERR\*UK6:4>.!)<","!RC!NNZ5=OJMR43F
M"RRR@IR!J=D"2X%1F"G?Q$*/Y&N5+.^#./+6O?/5*N8A=TW.Y<9)R\=E5O;)
MNQUEQEB#),025=8U]_`PDB,(HP?-I%1\N3L8B9DDC?B`(;9/3RWW7?=5LJ^3
M)C)E&)JEJ#5Z93$E2%P(\8?;@W-56_;M-?:)K?3>B@]H)3ZB/9&^\S6\NVFB
MFM6+<_Z_-L,/82PW>CT.]M+W7K)-V[[M=D#R,8-)393L55FL89K$.T71I$KA
M1,ZR)TP$"&Z;=+=G[>WGNJ?8[Q,FL8&/(+2`/(1@Y<<0>&&:\(Z[PW!=K):Z
M:Y40:KB-2]H7Z=J0G/8+D6Y5=1L_ZIUG+>$=0<@U3=N6DL?8FQ7C>Y7Z%L./
M,C*(P:,!&WG+-A;*Q<PS9.;7'JR;UG"@T7;E=%:D34(B*DI9]E["O]FN4VAJ
M;C+GVOS.<YC7-?+!<I#0<#Y7`8J"`2H*1'5VX=SVVX4<FKE41978#$C25`Q5
M%S'MCJF"=[M^*)RBU?CQW:AM<+(WS'AF<S1C:^:\QUZ@F]43A&<\]-7)(+I)
MOG<ZS\ZP_9G550;+^945RB*:ITR-;QM#9]7L!V]=JOKRZ3.$M[*D,`Q(:H+>
M\.1<B0<<8D*&_P!WIMRML5WT%KFJ"T89*!]D2!`^@?R#]W^STZR$8A8O<5Z6
M"#H@B,;S6\)5AVG0N>QNF[TE:SY:6$,7-V'R21(&G[,1M-=)2=:DUSJJIQ,?
ME6N.D2`V<NQ*VDDP*14Z*I?=4WKI-U>_3:63=@,ZQM:X4KR%?2.<,Q@3I)S:
M#AA@0J9COG9/S9IN%GPNZC#@X+QX>W.,>N@JR_412C%TF+=ZTXD5D'+502@J
MBL@_0263.4HB`&25()1[=P[AUSE/:_HHX@@KN`'V@8QP+)C>H[@X96A">"PR
M%$?Z??5K^/+S&%_EY.KAZ_V=:K5?ZN7G_MQO\.3%/;CL6B_S4_NNAYZ?[!SH
M\LG?Z!Q4I=_Y!0\>=^LZD?Z4[:_S]W\9T7BI_P"M*_\`RIW[K80'KSH_L5O?
MPO\`%-C_`%ODF54G*3M=F;(EFRK(R)64;B6#A;GE9%I>2$;JDF)6:C9Q9N$<
MS8@*Z[L2@)T4P.LG:-P[SL^R^K%]NEY:)DEU#(8&!/.3)EE"N"'\RX16J/;M
M=?\`9EOIZ/RO953"2<$&HA>>"'MB6GHSI%A_0?`\)@W$2+V0(5RM8[_?I\$E
MKEE+(4H1/\Q7RW/B`8R\C**I@5)$#&29M4TT4^X%$QOG'=6Z[QO&\NN]T<-*
M(QHP:Q@_"U@&``[@IQ/*-:L-BH]OT0HZ13BKB<W'F3GW8X0LKJOQ,1$LYZ\Z
MX:AM_N(>/FLH4B+?X-V./><QLGL^S2>8QILK:,-RT39KPU*<Z]=AI6+AG3EN
MNX*4JJ"!SE[E#N/T1T8M5RG[&W-JI7N-7(T4Q'YG`3E`YGLYD",EW[6TC;_:
M>8F+W>9O\\;=S?;%8)8;M<+[]YEW';=GCO9(N7;TY/:8PZ-3Q;:W&,759R#/
MG156^V5.>:Q#E1H]5`J+@B!S$,)2F$&/22U7AVUMS2Y=*]WQ%-Z8[7,]90%S
M.`!'`X9PZWQ7TC+U:0YV(F+X$L3[^Z/.8M@L'I_J9-9Y,V5Z']NB=29K$,J^
M+98P[&-RI<G-\/5<?O71%S)-[?/IV%@+5B8065*\1[!W4(`N;;:[PW_U_N,A
ME*\M^;,J?ZK&AKBG+F>_E'FNN%&.HU&K@OID>):X#Z\#VF$$[6;A43!?*[OS
M8E$MOM*)>6J]8PK<Y_6G#%$S:^SQ$F;+*/<RW6-RA+-:_CM].Q+9J-5?PC85
MU&Y#NEU3KF53&R[<VM<;QTWM"BWW$-G.>QE3,=*,M#@QOH*YP5=8>F:(@$0%
MUO,NFW96-!K*%0`YT@-<7?TCJ**<P1B,U$*:1@].MON!C:C5_BN;9/GGN%!K
M]TME#R+!KLLY6JYQMQA\BST[8FK<R["R3MYA:P^^",8=1N==B5DDFF9,J?4&
MQVZ=K]8K?N#J0UDJ75N1KFGR-:A8-)Y-5N>/'G$W,^3WK8]70[8)>6XN:[\1
M*@E1V@?3C>:(YDX1\JX@U!KC#4S&F3-W9E;%N.K/A*HX4/*Y=JV5*]]NCKEE
M2S+32<=`5^DUI6,6L+R=<R!")(=RD[N^Z`<M]475BT72[U'S&J;LXEQ$SUV!
MIEN)+&^4ZB=)#43@?$VW5[.JK?1AE/KO+`&Z?,3J:$+@24Q()\<H[%G/8'"+
M/]2WJLZ=Y7HB3>J:KV_"=G<#8X[V8#+UH?Y(3KV.)=45@28W"85GF*:#`X@X
M.J[2)X@8Y0'E:[3='_\`K_<98I7N>ZZ-J6E,33-#07I^RN)/)8<5M?2LZD48
M>0'?!.]J3/O3Q$6K_/>%3_J>(!5/*='.1OI^ZP&N8EACCI)9L/8Y`Y<5J*E7
M%(E\#MX#&"/R04'P$H'_``]$FU73_P#GNH8VE?K==6U+2F=.&!I<G[*\43PC
MQ\;3?^3984?_`%Q'BI*=XR,:KQ<96Q!D?EOYJJG7LJTJ06V#D8)'$SJ*L$>_
M)>X^OL;TUM\K3E6BZB=@0J1)1-1X9L8_LE$!'T`1#OU"H[E0=,]J5,ZF<UE,
M27?UA)/FY+V\89;:G4M7O&^4K'8U+$:<<4U##_>6&_\`C2E^++5_&&P&K7*C
M@C'$9M;@3,%Z09QF2,5S5ON^7:>](T_+T+CYLQB7RMOE7$NR62C&A``CUJ]:
MKH&.D=0Q+AU$E]0+_54&[>GE2X[2K&,`'Q,L&D<`CM2C4WGPP7$91$[4.WK7
M23+/N6G<VZ-><P\AP7`%,!XYKG"]N?ZUX<J7$/K1C*I4IGKP:U9*PA:\9:TS
MK>!K-TIE+K\/,R-@A#4^)D7[5@:BDL35&4(W5519.%RIF/YCVZIG16FN=9U0
MKZRJF?,)K954'U(_"7:0`Y2BXAR<U6)WJ//H9>U)%'+&AKGMTMQ_"A_F\8S'
MZB[83!]ZXQ]<VM,RO1;.YR5FG">1*"A!V%C(.+A0JK%6%E9;=7FS<YEY2O0;
MU^@@Z<IE%-!58I#B!A[='0>UU\OJ/5"?3DB70SPX'!''$+R.1',1[W_64DW;
M%*-7XBP@=FDKV89=\6/,)L_KK([2<&5F89NQH[KU3SG!YKL\TVM<:O&U[$MF
M#&"E=R1,.4%%"L*E.%A78-G:H%34^.H(>A#=O?2VQ7<[?WC3BE?K^&TH<#J!
MG$@`ICCEW1YW9747S6R_WAH1P.2X>1#XH?HD978O83!<;^I>U%FY#+>/V<34
MM7+'BFTR:UGC2Q]=R7=$\G_E*BS#LRP),;38BVB-%JT.(**@^0[>IP#KU9+7
M=7_^OES(IG%INDLKQ0:%PY88X<X+G74AZB43=072G''`I]W>1$K,/H'\@Z^=
M(U<YQ7HA(.B"#H@CGLSB['\_9F]UEJ=5WMT95V9J+&YKP<<>WL*O8P2">K[&
MS_'";9Q$L9!,RS=-<J1CI$-V\B@/75M55L9Z321*U`Z5.E1D4R7M2&YI99=K
M0:T(5,4.87-(;6G>&'2R4UBJ&H<2QR;4,*T;89OLQ7HJ"R`[=S;;(S=9\O\`
M'5G[.RL,@YK*AY)4?BJ"90OH!50`.W5QI^J6Y95XGWZ8YKKG44YHW$MS86AN
M"$`%`,<L,H@3M&TFB%O"B4':T7(E%/U0JN,TCUXCMF<O;<JU)W)YHSKC6+P]
MD*1FIR4E*U(XWB8Z)CB5E&FN'`UQ!J^;0C?Y:@H'7<=C%$X$,).H:?N6]NL5
M-M\SP+11SG30$`1[B27+P*DIRB3%EI/F$ZN19KF!I[D1.Z%/56I5>C5^*J=+
MKD#4JK!,T8^#K=9B&,%!0[!`!!)G&1$8@VCV#5,!_"FDF0H=0DV8^>XS)SB]
M[LRXJ3WDYQ(L8V6T,E@-:.`"#V1L77F/4'1!&`?52KR;E5Y)5N`D7:Y2$6=/
MH>.=N52I%\$RJ+N&RBJA4R>A0$1`H>@>G75D^?+&ECWAO($B.;I4IY#GM:2,
ME`*1Y=U*JOSE4?5FOO5"(I-R*.X:.<G(W0*)4$"'6;',5%$H]B$#\)0]``.A
ML^>P(Q[P#R)$#I4IY!>UI(R4#"/1JI5CNP?GK4`9^59)P5Z:&CA=@X1$@HK@
MY%L*P+)"F7Q-Y>1?$.P^@='KS].C6_1R4I[%@,J47:]+=8XH%]L,+X+TBY*=
M)<Q;83.O=PU'V+QOM9FB9S2_G=EY/+%2RS3YN5!9NWAIF1I<#96%SKL&P520
M;M@.W*4J0F1!K[IR=:G=MU;(W/:Z"5=)-?;KE;Y6A*729;QAYB"Y5*8H2#Q5
M`8HM'9=QV6Y5<^E913&5;@X:BX$(2@/MQ`X\87OI#IC-ZZ6?8+.>5[73+ILG
MM=;ZS;LP2N-:B:AXLKK&D5\:Y2:)CFM.7<C,?9H-@=95S)23A62EGKE1POX#
MXD+4-R;F=N&GI+;(,PV2@813ZW:G^8JXN.*E1D,`,!$[9+,+7-J+A4Z1<ZQP
M4-"-PR`'CB3G"XXFB4N`F9.PP5/J<)/30^4Q.1-<B8Z8EC&.)S#)R;-HB]?^
M1O7NJH8?+UZKCZBHFL].:][I?(N)'L)B<9)E,*L8T.[`!%\>J595X,@K6H!6
M0,N5T9\I#QQWAG1#%.1R9T=N*YG!3D*('$WD`@`]_3I!/GAGIA[]"(BE$Y)"
MF5*+M9:W6!F@7VP!5*N#X),*W`A)`Y%Y]P"'COG?,$WF+OYGQ_D_)$_XO<\O
M/OZ]^_1Z\_1Z>M_IHB*43DD'I2M6O2W6B*@7VQ1A5*Q%NBO8RN0$<\*"A2NV
M$-'LW0`KW]T`<-VY%0!3N/D`#^+OZ]#Y\][=#WO+!P))'L@;*E-=K:UH?S`"
M^V+"0H-*EI^.M4K4:M)V>(*!(JRR%=AWMBBRD,)DPC9IRS5D&($,8>P)J%[=
M_3I6U%0R69+'O$DYM#B`?!4@=)DO=K>QI?S(!/MC,R4#!S(HC+PL3*BW`X(#
M)1S-\*`*"45`2%TBJ*8*"0HF[=N_8._TZ\2YLV4OI.<U>1(]T*^7+?\`C:T]
MX!BU7J=6<I-4'-:K[A!BD9!DBO#1RR3-$Y@.=%JFHV,1ND<X`(E(``(^O7IL
M^<PES'O#CF02(1TJ4X(YK2!S`CPO3ZBZ]KY-6KCCV&Z31#WX2,5]EJAW]ELE
M[C4WMMT?(?$@=BE[^@=*VHGM72]X7-'''OQA#)DN(+F-)&6`P[H]JU*JKN_G
MKUFOK/O=(O\`-5AHU1W[R7A[:WR3MA6]U/VR^)N_<.P=OIT@GSPSTP]^CDI3
MV+"F5*+M9:W4.*!8V#KE'2#H@@Z((.B"#H@BG]W7GV9_3Q@XP#_9^WZ_RZ/R
MG+[/&"*]*,H(.E@@Z((.B"#H@@Z((\_M#_#^W^?]G^WHYPAS&7TY0!]?]WZ_
ML^O_`&](W\/W90KN'V_9'KI8(.B"#H@@Z((.B"#H@@Z((.B"#H@@Z((.B"/_
!V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>g575431stamped204a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575431stamped204a.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/P!$`P$1``(1`0,1`?_$`&T```(#``(#````````
M``````@)``<*`P0!`@8!`0`````````````````````0```'`0$```8"`@$$
M`P````(#!`4&!P@!"0`1$A,4%187(0H808$B&2,D)1$!````````````````
M`````/_:``P#`0`"$0,1`#\`W\?`<"E2G1)U"Q8H(2)$A!JE4J4FED)TR<@L
M1IZA0>:()1)!)0>B&,7>!"'G>][\O@,_E]_["V>4=D_T!Y[TS;7J3?\`]LK\
M]CRNE"OJ&(FJP*0H^S:]!H'6)-R7\@HOAZA$4O1I@F=X<>6:`1?`KUOT=_L$
MVS:\-J4R->56)["G5=2FUF*D+5D5^:$N;^OH$[0Z/RF7*7>L#&VJC6M+*IXT
MMAR<#@6M)ZM^L`#.`$+@&K%^^Y$3GB,VQ7KRUL*G4D>:?W[LS(=-U)-P/9")
M.MDSQPMQ<;(C31'"#NJ2"?J&M.Z642>,!?!FEEA=%8^B->G1"D%>IXSW(=D7
M_8;S5U:PN63*.6A!YM+F\M8M92X/?%8?N*JD#=-FA`:I9A*5C:L5B*&1U,!0
M'A0@8?\``3X"?`<9QQ*<DU0H-+(((+&<>><,)1)))0>C,--,'T("RRP![T0N
M]YSG.?/OP&(7T,W'8OK[HAYRMFN77L@\WJHM(V@;*<<E]0N-V^E%^*(ZOFLJ
MS_2CN[OL4@+=4T&@,2<E\ADCP[DQAJ9>B=G'JTI<R(5`$5K2,8)7^=6>*+PM
M6A\')SMOW'$:N7.%"7HS5E?-'W9;);Y6T817E=5:/=E<;K0@UCV8A-5R)6ND
MR0F1LPBC#%0T1Z<`-AH#-^VD-YT#>&F#HG.;UR]D^_\`/TCM6++X^TUYK3^Y
MI'35@0K[2;I@I?5KW!'6GR$<B=!QA.F>'-4<L0HB$)@$9(%+L^'7%<N,GF#E
M&NM42R?(J[)N\NIU$ILV2Q:L"Y`P2'1$,JMPC$:9I?,9;)*X;'J,Q]6C9"E*
MEQ<DYOXA/.B^V`LPNXXBO07I-6?,SNQ9M<WJL()E?,DBSTXU/85VWZ3,G-TG
M^D&JI7J$L\_@\*<IM9\>;5,C=F1,K:"H@OD1G`)!ISC@]J6G.G<9O]2QG1*%
MO094E:5+4KLY2&RY=<4MH_2+]()1.2Y2JT38JE(^V3E:P$#X7'V-RE*=LD4>
M=4*-M5`-$H*$:#D>=X+G!<[\^=YSO.\_Z\[_`)YW_OSX#S\`@_\`V(M+6%5F
M*(YER@WQ.U:8]&;?AF+ZB"9POAA#3:3@G9[0>!J5!0TS8A*AR\34:MZ(!J(Q
MZ*/*[PPO@@@"6=(_F.K,78&AV5[#YGRQL81K7>QZCOV6PAPF]16U0&?Y4OHC
M4%R:>9H^%@DS!7.P6N9GNS"D;S%#XW`*;S42@W]9Q.:%TU]9>6/.>S6B[;>C
M]2V'K*^J,@-68XP?YGT/,Y--XIFEL>)+;(4[-#EY$:EDE4V/.Y:HD3[+9BTQ
M1&G/2EDD@"<2K&H!B.3_`%D@E[3JP:;T'GR^L#7G7=7O-ZK*ZU4S,<;0RJCH
MZH3II+:$$G#2[KXY)6*''JBP/@.")/:Q#YT81%\&8$%!UOZ2[R]W[CO"H?+N
MU:ZQ%BJCI$WQ*R]=2-N;[!U-80'94LX@65%5"Y8E(K]DE32WJ34"UP)3*2@%
M?<"Y$K`FMY0?<9?CNA,3^X%/Y!%LR^/1EDM'%MB2;0#M?W6223?)S2S2<IZK
M:1D3!H`(]C8;2D+60VF,BOH#5)AZ9:,1_.I.E`:_I#I71M<VA*8Q(WG)U/XY
MK^#U!9KY_P`C8:[6$7LMG>+99XK<5-M4B7JVN#U#((6T*4_&UO"VRN1O[FZM
MIJ%.`KB@!04+E/W8QG1T)T;36Z=PTXIL[*FBK+K%ELI'+2)VZZ*J)<M+G-2V
M8P,]?F2Y4ZOX(I*"F*0)&TL:5J?&E01\B`\X46#?/_8)DS_A)_[$?[53?\2?
MZT_M?^S/T,D^[_%?ROUGV?XI^I_E?\C_`'W_`.9^L_#_`#?V7_U_M_<_Q\`F
M7T0C8[<_V&?&.OI2D`X5K4E*ZYT&X)5H!*&-.\(8JX-J=X?"C5`$*-*UN\=:
M.EJ3@=!PXP)??GP?^`7S[<XPPKF.-TO3&*+1E62;M]0K;AF,B836%F]49?5T
MVZV<Q&6T^3NM']#+6>(P*'2"4IP=:X:MB8U;T\]^OAQ'7$`@T\X]P7FO`$-E
M4CBX5+_:4J8T+MHS6%PO@Y'=%RKHP@//52NS[&D"DY2E8FHK[QB1K(-2LC*C
M#PI.0467\_@,W/JRTRKTGIZD/0JXH*WUOYSYVU?0S#5-=/R=YBU][!SCH6^J
MRH>ZK4FDH`X,#O35,V.P/*,Z*1X@7%L@8N_MW0Q.$3<26%&635C9XW>AVLJO
M\0,G:?O/6.A,_0R/IJB.A#JZ91RN@D+LPOY-J%V=)G\Y7/BAJS".(VMW,(:&
M5<:I`H=QD]ZW!#M9OG_I;X3P9WNS5.'J(T_H7:TPE<QN1ZK_`$Q*YOZ#6J^1
M-GE\X=W1YB#7!9O!E]65"Q&_?6%1/Z&2.M@P"5G=4'D_,"ZG5(7CK^`T'KW6
MM%VI[,$7FSM%P53DO+]M5Y1OG#FN(O;"6HC1#XDL^QHBYZ"M`H+N>6<]/Q3G
MTDPDTKJ1"$!83PZ_GGG+/-D^@,MK&[//',50'3;)>GF>V,V&U+5<J@,/7YLW
M<QLM*($1;1'`5E)W9LHR^&A&XR1F1\X]JT0.G&B.2=[T-4/]'TM_5?\`17]0
MUA_27Z;^._T]_`HK_5O\?_(_+_1_P#]5_%/U'Y?_`,OXWXGV?N?^7T_5_GX#
M.?Z[0^(1GV'\C;/O-!&9+E_0D$U1AJXXM+!A*BR\FQ(8<\,K?-NN!B5D61=]
M=G5./I)YP?I&UB,^D70A^0&%6^8?]??-E@0FWZX8O.:JK#A"\J10*:I+0J9K
M=6%<O:G-O(<V-4Y3411?YC<YJ!%B!SH!C[PX/S,++&`*6],]^9"T5(\Y>><(
MVIG-L@VEYRHDVQ[$:]`54DB$=QI50"7>S*F<YZGG*4J/S;3$A5M,.;T1`S5:
MIC5/1HP`()$/H5UZ4[%Q)J^VL0>?T`U3E@NEVNY*]UOK.:DW-5!-20[.6794
MR+H949\H#(119/*+?N99'6Q"UD&=4$-B)2:8$DGI8A@V.6^M'F#"&Y<Y/_H+
MC<H"%J6/'X:'1]1NCHO2(F_]F8!H:VZ6J5KNK-2]Y]HE.`PTT8@@#SHN\Y\`
MK[%GIAYW#:IUO37.P\QQ#0^J&L:QC@<AMR'R*4Y[R.@<U3I2&9T[2QNKL4FD
M29D<A2F;)$*8*Q9+'A<!7P\AJ2=3!0GBQ[#^=5083;JUL'3D2AB2%Z$U:U53
M"S8G/UCPRTFY:"GLMJ9N"UQZ(NYI*4J%2=)^$1\Q&$(_MD_+G21!"!`Y*W74
MF^O>*?R#-CR3-:;S?YDNE;OL^41R=1)<[V#;.DZXFAK8B99M'HZM-9VIE@R<
M1"SA`2U0CS1%".+"$00TB_`)E]X//A;Z(>?T[@D'CS7([XI=Z;-"9]:75K1.
MZ.26+729>>?7BYO7A_%<&^S8JL<&3J8X04QBI6G&=\RR^\^`IOS/H'QU]`\I
M030$-\W\-Q^:C)'";YK!TR;2J&44Y>L0X%LLBN)+'7.'*'1@/:7\!IJ$*D)9
MREJ/3*.AY]SZ0A7%V^35RP36US3K#F5/*HNE=!T+2M8$J-"U`4G!F.3569:C
M:]/]>TM`ZP<(A9">7LDZ1GG$JUS-U6J;TZ94=U&0'@@9QD_S)RIEVLTL6[5-
M6VC93XX&2VV[KEU0UNFEMHV,Y$\`\R8YM;8\6S0Y@)YWJ5ECS26G:&!J`4C2
M%\``0S`%'VN@5,5MYW6,<&L(1#*]DEFYMKN[9O$H%'6]=76=[`TA6$?OF7".
M:XVL/2-"*MG)T`N-"7SA"928=T0>@^O@"CO/;"78,ZA/E#Y%.=0638MMLBSF
MH=-U9_%Y?5V(<S/"5&P2F0M,ECA"R$FVO.(P_K6]E2I59BE'WO2^%`4JDYA`
M-YF,NREY$8($]NXB*YS5DFHV9C;4:8E"8_O:>.-J)@C[.C)(+;2I+8\_>>$D
M\'WA8W!U6=--$#@AC"`%>"]0V^ZTS>GHOI,D3=H#U#M-)HQPB0R5A8JTH]G:
MCHUGBN.#<2P+#"V>"&"6$][\N!1."<OH>&%#[T'R_`3X#/OJ_'.F<2:[F?J-
MYKQ@%F);;3L@?0K"I(DK?W0T9B!9RCES4*9TQ(D0:58&K\D)2(WY@D!ZDSZ?
MK4J5!*P&&X?]-L;>A#`XK<ZVJD6SB,"$DL6CYPC.@E[5:\D'*DB]DGM8/W2'
M]M4MRY`>G,4IPJVX9Q`PE*3/I[WX`6-W>J\,H5VCS92TXB4G=:CMW131K2,+
MF)U6OT.AN=<*VIJ=^9BFU5UG7I3GMZ,@J5(])@J&LXYX`B`H_(.Z`()P@FV=
M*ZU<LY0C3VWF>G98\WX]55L#-J>OZ:JW,*G,^>8DGM:_K=G"O0-?N5L2>`:9
MA%L06%(&U8H96G\I_5=++6$)3Q=![TRN+R8\::#73HH[,N1JHG9/\T:&*J&"
M)LSY=2TMI&L;%4)B4'2CD-H+U#:/@4AR8I4G)*.#WII1(NC^`5'5]#:;]\[R
MKG5&X:RE>:O+JBYJBG.7\-6"U?;G.K)*C0J#&&]-$MRGI)"*&]2N0.M[0,E2
MG4I3#TI'1I3E+@YAJI3ITZ-.0D2$$I4J4DI.F3)R@$)TZ<@`2B2""2@A+)))
M+#P(0AYP(0\YSG/E\!S?`3X"?`(.]"L=>*FO[T:HM=E^4+G/?C8O2#A]B4II
M>K:!VJVO:E&I*91&(4S\3*)BH`6/HT9;NTN)A80=XGZ7SH_F"WK`\U[,IJZ;
M38&_VRP_8$S'5\9[<3?Z*9ORW;VIV2@F^601=%4UK6@X3&.VC*ZK7RXN/%EF
MO_$C6-3^N+)[]8DX>!]+/\%7W/-3ELFHO:[SBA.LE;*Q$N#I7^',91W<[NPG
M('0F&M[6^6?+7JPH:W)XZO7_`*EP:4)2O@`!&`1GVN#`!(T;Y[>(&0M$D.FH
M]>T[K7?[JY1409?Z#ZLJ2Q+S)?QC`;$R8/4LQD;<GCIAAQY/Z<);2J<"0`)`
/F4]"$/.AI<^`GP$^`__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>g5754311new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754311new.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`;`"]`P$1``(1`0,1`?_$`+P``0`!!0$!`0$`````
M```````(`P0%!PD&`@H!`0$``04!`0$`````````````"`$"`P0'!08)$```
M!00!`P($!`,$!`\````!`@,$!0`1!@<2(1,(,11!(A4)43(C%V%"%G&AL1@S
M)#=W@9'!4F)R0U-C@[,U)C89$0`!`P,#`@0#!`<&`PD````!``(#$00%(1(&
M,0=!(A,(43(487&!%9&AP4)2(S/PL6)R%A?1)!CQLL,T=28V=C?_V@`,`P$`
M`A$#$0`_`/W\41*(E$2B)1%X'9NQ\:U1A,]GF5O"M8:!:&74*!B^X?.CV391
MC$AA#O/9!P8J:90^(W&Q0$0J!71%JWQ@SS:FS]?N<\V=$1<"3)9Q](8/$L6R
MS9VVPQ3@$8:3[JJO>65.!Q35^4RJ5CB4H&`*JX`=$4D*M1*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$5-55)!-19=1-%%(AU5553E33333*)U%
M%#G$"D(0A1$1$0``#K1%S"7%[YP[O!JB*P^-.F)CFY,`J)M=B9:CR`J91#B"
M[-0+A?\`[)E<>AG`5D/DZ=51=/$$$6R*+9LDF@W;I)HH((D*DBBBD0$TDDDR
M`4B:::90*4H````6"L:JJM$2B)1%0,X3(J5$YN!SA^D)^A51ZW*F(B'(Y?B'
MK:B*O1$HB41*(E$2B)1$HB41*(E$2B)1$]*(E$2B)1%SX\J]EY/L+*HKQ,T\
MYOEV8D3/LC(&QC&0P[#E`*J[;.5TA`45W;(>XN`#R[(D2#YE^E0::A%,35>L
M\:U#@L%@.*-@0BH1J5,RYBE*YDWZ@`=_*OC%ZJ/'R]SF$?RA8@6*4H4))-2B
MV'5$2B)1$HBMW35%XB9!8!$INH&*/%1,X=2J)'#J10@]0$/\*(L%&RBJ3Y2#
ME#%^H))BLU<`'$DFS+T!8@#8"N$O14H=+@(ATHB]+1$HB41*(E$2B)1$HB41
M*(E$2B*)_E5K/9F5PF-Y[IW)I>)V'JUZ\GH:`;.U21.6-UBM_J$4]8@<K9X]
M.W:\4"J@)%"G.D-NX!BU%#U1>J\<O(&!WYAOU1%(L+F4&8L;F^(KB9-[!RZ8
MF25.1%:RYXUVJF843B%RB`IF^<HU5PH?L12&JU%&SR=WTRT9@8O&2993/<G6
M&#P#'4RBNXD9QQQ13>':DNHHRC#*E.<``14.)$PZGJYK:G[$7F_$_0CO5.,2
M669R8TKM_8Z_U[.9EV8%W34SQ07J6/I+FN;MLSGY..-BG<7`+D3)5#3P12WJ
MB)1$HB41*(E$7D<QB5W\9[N-'M3$089",6*`<NZB`F4;"-KBFZ3N4P=0$;41
M7F*Y`WR:$:2J%BG4`R3M'^9L\1'@X0.`]0$IPN%_Y1"B+T5$2B)1$HB41*(E
M$2B)1$HB41*(N>?D7I[+M89E_FGT&T$F31)16VAA+1,WLLVQXH%-(ORLT>(*
MO2H)\G)2AS'B"Y/U"&YWBCM'(I'8?Y(ZRR[3R^Z49E!AB\5&*N\D;.5$_J4!
M)-D2G<PCM#D43OS+F!-N`!9QS(8G0W1MUHBB]XZ8;D'D-LUYY8[2CU6\,V57
MC-)8B[^=M%1#591-/(A2.`$.J`B?MJ<?U7)CJAT(F-#1N@1='ZL1*(E$2B)1
M$HB41*(M%8Z_#$]K3V('_3C<G;?U!$EN($3>`4ZCE%(HB`%`Y"J!T_[LM$6]
M:(E$2B)1$HB41*(E$2B)1$HBI*',40`HE`1*8?F`1#I:WH(?$?2K)'B)AE=\
MC>OQI0DT5I)-8V?U2TD$]/`:_I7/(?N&86EE[C&)'`\A9QS?(7$`O/B^CUD4
M2HO3,#2"T>``K[<%"B<Q`4$W;`?4>E0+?[^>WUISI_$[^PO&64>4-F^X`T82
M[:UQ\.O7[%*`>USE;^+1\E@OK*3?9,N!$-P>0YNX@?<*?B5B,]\$X[*MH(SF
M+Y.&.:<S"49Y-LC`6:[Q!K)RD>H=TT4A6K</IXM9,ZXW[EO:<SF2N!@`L\;>
MY^HMV31R1N#B'U'0P.%6D:_-IJ>GV*,$H<S<SY)Q(&>85!/0Z+*////7>)90
M77V.:_EG./P4FAB3&5CW<<SC4TF+A*+*+"/XF.+%K:R9>93&(6_2]0,S/OZX
M+C^;77#K;&7LQM[N2W$X_IN>PAM1]E3K0_!2:Q?M>YA?<:CY#-=6L1?#ZOI&
MN_86.?\`@:#6OQ\5T(]R<.)A`O`2\A,-R]+`/H(B(6]1]>E3X$D1MQ.X[`6U
M\V@'WGP_%1A<_;+Z;C2@Z!I<7&I!VT^%/@>JIMI-H[,<C9TU7.F`"<J*R:HE
M_P"L4AS&+>W2X5HV^0MKJ4PP3VSY1X,D:\T\:@:C]:V"R9@#I89HXW="]A:#
M]U1JKKNWL(&*`<3"-PZ]!M?\P=`^-;CW&-U7#^50U=6@;3XD_']BQ'<U^TD$
MCJ`-37I3]JQ;:?BG3E1DWE8MP\3OS:-W[5=TG;XG036.H7^P0"O*MLS93R>@
M)[5UR*U8R9CG4'3RC6IU6Y)97T40GDMYF0GHYS2`1]FG]JJN:0(4>`K-@.!0
M,<IU2(B`&$P%'BH>_7C6^VY:[5_\L>`<6[OQ%13[.M5@].21@F@8]T+NA`KJ
M.OB%<(.N]<>2(@`!8R:I%0ZW]1((@%_A^-9C+%3<QX=0:@4J?NU5A;(S21KV
MD]-S:#^\_L19T5$HJ**))ID*8RBBIBID(4/YC',<"%*%NHB-JP3W3+:+ZBY+
M(K6E2][@QK/\Q<1U_9JJMC>\M:P[GDZ;6EU?T=%9,YV)D3G3CY2-?G3`.X1D
M];.C$'T'D5!8Y@Z_PZ5H6G(,+?$MM+RUF</&.5CZD]``TDG[JK/-:W=N`Z:"
M=K#XEA:#]U0%'C=WN8O-=4Y6Q[8"RDWI9)PHH1NW:P\<5*2D7KYTJ8J+9BUC
M_<'54.($(4!OZA7J/FBM;22^OWMCM8&[GN.FAK30].AK7]2QQ0SW4\=I:,<Z
MZE=1HH>NFE.M36@^*A#L7[O.N(W*GF(Z6U5FN[G+)15(TQ$*#$Q3T4%1247B
M6Z4;-2\@QY%'BN9!$A_4O(!O44>0^['C=IFWX'BV-O,K<QFCGQAVP'P^6-YH
M=:=.BD_Q[VN<BN\*W.\LR5EB+5[06MD+=YKX'=(P`C2M">J][X\_<VQ3<^SX
M33F7:GS;4N=Y**R4"A."$C&R#MNU7?*-E3J,H>2CQ4;-S]LYVQDS'+83%N%>
M]P7W)83E/)H>)9C'7F,R]PXB/U&/+)"&N<0'&-FW;M'6M:^"\/G7MXS7%N,2
M\PPN1L<IA8`#(8WL#XP30.+6R/W`ZTI3H5TQ"2:%,<%G;1(2VL4ZZ:9K#?YA
M!0X&L/PZ5(P7+6R.AE+!*VG[PK0M!K3J-?CUZJ.\0,[1-#N="=/E/4==>A_!
M5`?-E/\`0.&ZP@/S=I4JO'I<.7:Y\;_QK*Q_J`F(M-.OF"2N;`6^L'-#C0>4
MFI7PE(LUCB1)VT6,4!$Y4ETSG+;\W(I3B(<?C6.*[M9G[(I8G/Z4:]I-1UT"
MO?'/$VLD<@'6I:0*>'5?QQ(M45DVPNV9'*H"9-NHNF5=0@!<QDD>8**`4H"-
MP`?2K9;J-DPM6OC^J=T8YP#CJ.@.ITJ=/@JF*7TO7#7^B#JX-+@!0^(Z:T5+
MZHU!T#,[QD5R81$C4RZ1')T[`(&*@=4%1`?7H4:N^IC;(;=[XA=5-&[QNI73
MR]=118X67,K#-'%(^#3S!I#1IK4G[:JX7=`W(HJNJBB@D05%5UC%2223"XF.
MHH<X$(0+=1$0"JOE,0W/V[1UJ=H;^)T/X*C6R/<&1N!D)Z!I<?U%6,;D,+,E
M4/#3,5+)H")%U8M^TD$TE+@`$5.T76!(W\!ZUKQY&RF)=%/`]K/F#'ASA70=
M#I^A9YK:\@(9-#*QSAY7.86M-.O5?$ADT!$*(I3$[#1*KDP@V2E))E'J.>M@
M]NFZ<)F6Z_\`-`;U2YR-G:2M@GN+=DSM0'/#33PH"=2JVUM>7D;IK:"9T+="
M0QQ%?O`T'P63]T3LBX[J/8L"O=Y!VNP)!/W>Y?CPXA?EZ6K:]4[-]&^G_%O&
MVG\5?U46MYMVVIW;J4V.W?=3K7[?U*JH%SIW_$?[OF_Y*N>!JZFNTC].A61N
MCB?\)_O"_/O!Z^-G<)Y/+MDC*2F%O$,O8]NW>%!CE4XE*HI]+@!XY90X_B)`
MK\'L-P.3G.+[ISVP+LIB;F2^CH!4-ANI!-MTKN$32YO^(>/1?IA><GCXGEN!
M6Q:SZ+(XX6TH?7:1+'$`3J!5I^4^%=05/G&O(PJ/A<IFZCTA\L@X1;7R0&&S
MA3)2D"+BG0&Y#<PQJQ'8B/J4@U./B?N&M;7V>#G-Y.S\\M(1B"==_P!:2UL-
M?-4M$$K)7].CR*`4$9,GVH,GN`_TE'$YV*=?F<$T_H@^HX:"FOR#3YBU0#RW
M7XX7K3QVF'B9DYS/9W),I?'5*(+^Q-(XTUA4U1/\P\FB(K?^??XU`CEG"KKA
MW;GM[E<@Z5F<Y!?Y+(/<0W>Z&6>U-N'G;6IB(D^YZEIQSD]MGN;<OQMLYK\9
MC+>U@A`K1I,5R)*"M*@^2OQ:2NJOF3L/]N]$SIVCD[>:R[LXK$BFIP5(>3*"
MD@Y3XB!P%M%H+6$/0QB_&U?J=[P>XLO;WLE=R6,C&YS(F&TMPZ3TR7/<-[A3
MS$"/<26D4.WPZP9[!<3?RSN/:QRM<ZPLVRW<VC2-D9!`.X$:O<T`'P)7/72J
M>1>.>^=5)Y&\71B=FXO!F>"X.N5JFTS%,2($7!4XE,K#RR"0&-TMR_"]0#[,
MQ9WV[]^N/CDUW(_"<BQ]K-,7R2//_-QEK02\[:QW#J#:`0PD.J:$2G[BSVG>
M+M=G)L=:Q0_D;Y!&6F,O]:!S0[;L:"V-\;B=:U<T;3H:R7\[]MY=$/<,T_AD
MBYB7F7(@[FW3!<[9T\;O)`L5%Q9'20@LW:.'15#K\!`3E*4OI<!D7[X^ZO*L
M9?X?M#PJ]DM<GF6B6=T9HXPR2"*,-<-6^:.7[Q1<>]N/!N.WEID.?\LA]>SQ
MK0(VFA87L87O+A36GEITZK(PG@+"P#7')B'V/F##/XIU%R;V7(HW&)</&[E!
M=XU2:HI-WR:!^)DP,+@QC!^8!O8/9X][&,!@K;'<NQ.<S]MSRW]&>27ZH.:]
MXHXL+7,(V'4.'6GBM#,>Y*?-R76*N<+BC@IHY8V!L;Q)&!H""7ENXU!(VTTT
M6A/)6&A<I\RH[&<LGG4)BTG&X>RE9(DB2/\`IS,\.X6553=.1,S:CW2!\QR\
M;FZ]1K@'N:XU@>6>[W'\9YGEA88&ZL+-DT@G,!'DDW.:^21MO$?**EPUKH-%
MU3LU?WV"[!77)N/X]EWR`7<NR-T9?OU%!M;1QVU.@*PF,)):K\J<+Q'1>>S6
M8XW)2,`A,)!*EE6:K1\<WU^/?JL2A&ODH]H`K@L4A>R:P"-PZ^%QS'67:GW2
M8/B78W-W68XQ=S6OU@]47;3$Z1PE+Y8'>B?38'.C(Z'=O!T"];.7;><=DK[.
M=S\;:XSD<,<KH&",Q.:6ANUS0\EPWDT()UIIU6R-T367>1/DZGH)CD#['L)Q
MQVJSDBL3J$*Y&,8)R,])N$BJ$!XY+R[#8BG),EN0@-ZZ9WFR?-N_7N7=V-LK
MZ7'\4M'.#_1E+3+&(XS*YP%?,QP<&Z>/BOC>`8W"=I^S0[H7EO;W6?O`WT6R
MM#F-\S@UOQ:#\QH03^"Q/D1XOLO'?%XK:6I\SS!D\A9B/:R)'TDB+@`?*]MI
M(-73)JS,4$G8%(JB<ITSD.-P$`$!\GO[[;I/;QPVW[D=I\]FXSCKV,3&6=CR
MS>[TVEH$;1YIG,!#@[RU'VKT^VW>4]WLS+P;G./QSH[RV>;<Q1;2QS:5`W.=
MHYIZ_P"$+%><&\9R:^W5"YBW,1E.[*D<<P:>>-2"F)&CAU)#DZ2)T[&02F2X
M^)#E+T,DJ)/2I`<J[IY+E7M5L>9S3'\\RL44%Q*T;2YT;I(Y#04`_F,=33H?
M%?)]M.W5GCO<?<\:E'J6>+=++&'T.X`,V;M*&F[PIT"S/B0[U/X:>".+;\F<
M;D))YF#*/R3-Y7'8UI)9-(+Y'-C&0<<W.NJV$D5$M3)%%/NE(4_,XW,8:^X[
M4/XEVC[%V?.;J%\EU=0,DFD:UKI7DN<`/F94-%2-=*E?/]TF\D[M=\[O@T5T
MR"VMKB2&%DF_T6[6M-:-:^A=34T\`.@7M-4_<%\7_(O<^N\'CM>9238+B0D/
MZ,R/+,0A`4@Y!&)?N'/MI1*3?248=U&IK)@8EBFY6'H->SQ+W!]KN?<TLL#C
M89?SN4DQ.F8S>UWIO+@#N<14:&E/Q\/)Y9V#[D<!XA>9RZNK=^(B($K872AC
MF[VM%0YK`[YC3K_QYE>4L'K;,?N7YQBV[L\E\"U@Z^D$F\D8RYHXT2#;73)[
M&)H++-I!!N1U*E33$.P:_<&UA&]1O[G6^*S'N,N,1S6\ELL`^./U)6.%(FMM
M]S2/4;(UNXMU(;J/P4D.U]WG,/[=K;*<0L;>\SS9I?3B+7;I2;@1N!]-T;G!
MK34`NT/3X+IEXD:8\8]=8AO+,O&K<61;42D<3<P.1.9#(T99K!NH^'E)6.*W
M*UB(<[9ZY*Y$XJ"!A$H`!1"PWD;VNX3VVP.&S.9X)E)LM;2VH#W.>PM8&122
M#;Z4<1JXNUK6@%!K4F.'=GF?<C/97%8?N#B8<1+;W#GL:ULC7OW2,8=PEDDT
M`;I0#4FM=%P:\>LZS_Q^R'5GE$S>RK[$6VQI+",H2]T]7(^;I1D;(S\/(]Y8
MY%CRF/RQUFW(!_7;<@ZEJ$W".09S@68LNY9GG?Q5^8?!('/<YM7L;(0X$]`-
M^W\*U4V>?8/CW/<%>]OF00-Y-'B(YX"&-8[RR.CJ"!J2?3K^/Q76'?N11V3_
M`'.O"^?Q^35?8_D6&XM+QBZ#@X-7<;)K9<NV73(0W;%-RU4(8>GS>@^EJD_S
MC)C(>X[B%W:S/DQEW8MN0S<0RLK90-&D5&P-.M?-]FBBQP7%OL?;MS&.[B;'
MD[2_=:EQ:"\>DZ'<*D&GG+@"*:+R6S#*I_>=P%L1PY*@']$AV@<*@GQ-K1^H
MH44P.!."APN(6XB/6UZ\7D;&L]WMG:,+_0>+;R;W[1_RSWN(;NI6K!UJ.J^F
MXS;PR^TB]O9V,=<,-S1^UNZOU3&@;@`>CS^@4^WS?ECEVRO+WSAC?#W'\ND\
M0USC<J6&F$(Y98C=XYC8@)[+<DE&J"Z`2SADW`6S)!8W:();B'S&&M?N7G.2
M=T^]Q[6VU[/;\?M)BQXA.QXJQI<[<!J>H\P('@.J=LL%@^U79;_=+)6L5SG[
MJ(/C$K6N9_4<UC174!PH31P)-?@`IR:<^V]BOC?MC$=I:EVCL$S>&8SC7)\.
MR9RT>QV7E?PCMHS3,M&(1)&Q$915-82+)."@)`X"40`:[)Q#V]8_MWR*+D/&
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MN?:[87[=OTZFB.U^$';0\2_/)_R(O$GUOK-W;`TC^I7;37[E##_<K._[B#EO
MY)#_`*@%8_HO1-/4-!_3ZUT^^FE5T`5Y`8A@`!`M[^M[6Z_W5W%_0D_)M/WU
MZBGZ%QYSG`M#!5SG`?A74KDYX/,6LOLSR+BWQ`58R+==F^0&W%5NZR:;071.
M`@/RG24,`AZU^7_LTPQRO<;N7A\E!(RWNY9X?.WRO9++-NZC7Y_[E,?W(W@M
MN%\,R%I*WU[:%A:6'4>DV$Z_>>O11(/@&6);7<^-2+IP2,=;1;@LQ(4>*A4"
MJMV\T8HWL0,;6,8?A8+^H!42+[@G*/\`=Z]]O,4=U_IF7/B2@'DJQGIB8&FS
M>8G[2:4H!HI"NY=QT\$9W?/H#.C%N83XE[PT[:?-5LC`6Z]?B%,3SYC6<-*>
M/$2Q*5!@P5DHYD@``!$FK)SBS5!(@V`1LDF%KU*SWX65M@LWV]QEG$QMG:&2
M,M%0UD7J6,`V"A^6C`*^`U7`/;!<W%QB>79>8>I*YK)22\-<7$7!`.[Y@27$
M^-2L/Y;2$_N[?N!:.PU5HLZQU@1Q_KACDCT9R2:IRKIU(@4BQQ;Q\.V1Y?(/
M^D$O\U:_NNN\YW=[[8GLKQ5UO^;8RT)D=)(&QLFN8X9`[S12"K&BC?$;C6OA
MO=BXL=VU[;Y/N'GZB&ZE]$,!:7R0LW-+6]'#<Y]3J*EK?@O`^3FJO)",Q:(V
M!MG)<3R%EB;MO&1BV-M4V;Z'+)K)"DNO[:&C2G:$<M2`4QC&[9S!:UZYQ[E.
MV'N(Q.#L.XO=?*8R^QV#F9;P,LF5=`R>K8R[9#$XALHCH7%U*:4UK]5V7YIV
M:N<[<</X7975@,I`\SNN'E[9WMJ1U<6@BI!VT!'7HKSR$/D.Q<&T7Y*P+5>1
M3BH%C!Y:+<AG(1&0XW+"Z*[>`B4QTV;F0(L4Q[<2B)0'\P5ZO?:VS?-^(<%]
MQ7%K>;(36%A':WK6QN#HWV;P'$@^;SO,K@:_WKSNT$N%XYF^2=G>0310LN[F
M5]N20`[U6EI;N.E``W:.O77X2EBO/_6,HPA6S2`RMWELJO&QZF.-F"0E1D7J
MR+944Y,7`HKMT5%3&+Q3%0Q0ZE*/I)G"^_'ME?6V/LQC\Q)RJZ?;VPM6PD@N
MD.V1^ZA`:PTK7P/WE<3RWMFYOAQ>7D]WCH\)")'B3U/.X=6[6_$TU\/@5'G>
M>,P>9^=..8KD37W\%/I8@RDV(K*MCN6RD*[4.7NH*IN$AY)@-RB`]!K@G>OB
M^*YC[W,=Q+.VIN\5>P6C9`T2,$>Z.5[096FH+6A]=A&NVOP76>W6?R''/;9>
M7V)N?2S%K=/<PZ$CS`5:#UK0UZ^"LFS-EXF>7$="LN:&N\Q".;HG>`1RLA#3
MX^T1,F\4(*XJ0LV6QC`8#'1Z&O<!K6QMC9>U+W:X_$81DC.VV6LV1L]5CIY"
M99)(128C<"R9XH2?E.M=5M9*[N.^W8:?)74S#S"PW[@#LWM:*N<6U-26=!TJ
M5=[-=R?C=YA*[6FHB0>X7DSU[(D>LTA.FNSGXXL?,MFZQA(B,G&.2=SLF,45
M"`%N@U9W+%Y[=O=T.Z&6L)3QG)M?,+EI?(7M>?YS2&-<&[7.(:#MJS;UU*IP
M^&P[P>W\<"Q3HF\BL2U@:Y[6&L;G%KJ.U(<"02.A63\FO*#$]Y8?&:KU)&9)
MDLQD$W&N'IE8A=H<I&2XJMHYHVNJX<N7+LY!.:Q4TTR7Y#?I[_N5]RG&.^O"
MX^U?:&VO[[*9:ZB,H,!8V,QR1O;N-37<X>(;\I6IVB[)YKMIRAW.NXTUG86-
ME;/#`)6N+J@ZMH32@&OB:C0+'>3FLH\_B_K/Q"EW\=&[!RC'W.5XH]>NB-H\
MFQL>DT))ACSUV8>VV;9&M+.XY-<P\`<<`$;&&TIK#L/?1>V*S[9`_P#N2R@;
M+MTJ97/DE<.G\4C@:?8N48CO'!C^_$G<28'\DN[B6-Y%:"([&@C6M0`'4/P4
M7O$C[@4/XT8*'C;Y3:_S&&/@+J0CX-V6`1?/F+%=^N]/!Y!CTDLS7,$<]64%
MNZ1!8BB)BAQ#B!AYKVP[\V?;+$1]N^Z5E=VWY<P1M+8/4;*-SC0[R*4J/EZ@
MKL/<OL1?]R\S)W&[57]G.,@XR$.E$;XW$#5I#3\U-016H7A-4;2Q/R`^ZKA6
MT-6Q$LCA;^0:@W3=PZ4<Y:MX36[R)>2#]C'*.FL8W<.T;D$YP$P'`1`!&U>%
MQ;D6/[@^YK'<HX[;7!X^QS@S=!Z38@+>;S"A()<X-!KT'VE>YR?CN4X#[:[W
MB_)[R!V>KN=282.DW31D-KM:?+X=?&E`%A?)G(--XS]S[-YC?\(&0:K;&B@R
M6&-&N)8[HSC6C%"*4+'M5VJZY4)51%2Y3AQXW^%:G<G(<7Q_N<N;WG=M</XF
MV"'U&F,OCEK:M%#M'1KG.IJ/!;W;G'<GR/MI@MN#W,4?*S/)Z)$@8^*ER7$B
MIZNVC^VJZA^+NX/#K-\+W?AGBEBSC$?I^&O\ERUD;&7T"W>BXBI*,CWG=>.G
M@N%TNR*?$!#B00]:DEVNY;VHSN"S&.[56?TD$%JYTD?I.C8X>FYC='$DZ`]#
MU4:.ZO$^[6$R^+R/=>]-[<SSAL<CI6RN%'MD<"6@4%2.M?O4"?!S133R0^WW
MO_6W!`\VKLMS.84[,`"+'-(3$X%U#J`<>A$W9[ME?_!7.`UQ#LYP2+N%V+SG
M'X8W;WY*1]OZP&YLT6A+=!0%HVC_`#'5=O[U<XN>"=]<+G6OC#!C86S"(G88
MI#N(.IU'S4KU:%$KQ&S7*,E\O/$?$<M373D]3SR^O6Z3KN>_;1\<]RB1)&/4
MCW,D:$<OUFY0]"I)E#T"N6]J+_.9/N]Q?&9>.9SL5-+9&1P-0R)DSV5/3RN(
M8/#;3QU76.[&.X_;=I.49[`2Q"SR\<5UZ8(_KN?`V4M`\'-&\^.ZIZ:*<NSS
MA_\`M+@0"8M^>$A:_6W[8/[V#XV`>M=GY%')_P!85C?F.3T8VP#=3R^:S<TU
M/V%QIKX!<<XW,QOM`O[(OC]5[IG4KYQMO6D4%?%K173Q*U[Y-AEOA9]P]OY-
MO\9DI[6V8S:T\G(-4!*W<M\@Q_Z!F./IO3@#5KD,:=0SA!)8Q`53$@@-A.)?
M`Y];93L_[@CW'N6%_&+R9TA<&.>XNDB9ZK?+H`SJRH^\E>UP*[PO>/L"[MQ;
M2!O++*)L36E[6,`CE>8G@.U<75H^AI\*+H]K3[ENC]S['Q76VK<=V#DTMD$=
MD$E(/G\&G#L<=:0<"]G%"N^;ETN[7='9@W+VR@D!U"CS$?E&07&/<?P?F.?M
M\%Q:&^NKR5LKW2.B+8X-K0?.3X/^5OV@J/O*?;IS;AO'[GD/*YK&VLX3%&V(
M2ATDV]U!L`/5@\SOL(T"YY>37DU]O;R1UOEN2Y+A64XCO\L0_1A$DL95B\K)
MDR"(H1[6;FF)OHDS%INBE(O[RZA4@L4"F``KA/<WGW8/GN"OYLOB[BVYDV>2
M!C?1(EDE92CB6C^F?!VA7=NU_`/<#V_Y#918;)6USPI\,<[SZP=#'"\U(`<0
M1+2NYH!%:5T6ET<%\@P^UU(BI&YD.*'W_"Y*SB^#ZY=1I8=/,Y)\$?P]V&)'
MSY5HYX<.V(E[O'@%Z^&9QKN7_P!.,MDZUN_HSGHI&Q[SN_+A:S!Y_BV>L6>7
MK6AZ+[Q_)^W/_4;'>MNK/ZX822)TNP;?S`W,3F#^'?Z`?YNFVH\5^I16XA8+
M`/$PW'T]/2_X]:_3*5I+XW5\@?4CQ.A_L5^:I>6UVCS[203T\.JC7HC8L'L#
M*-RQ49A,9BCC`LR#'74A'I,R*Y(0POBA(/0;LVQB+]YFH/`QE``#@/+E<*CK
MV1Y_@N=\CYGB\1C(<9?83.R6<DL32UTX#GTD<75JXF,DT\NN@75NX7"<QQ+#
M8*^R=^Z]M<I8NGC8XU$5-E6TJ:?,/A6FO@M]#BV/C+!/?1XL)LI`3"8^G,OJ
M8)\0()/?]CW(%%,./YO3I7<QQ?C8RYSWT-M^=.=4S;!ZE:`5W=>@"YK)D,F^
MQ_+?J9Q8EP.P..S36FWI^JJJR6.0DR9L>8BHV5.R4%9D>2CV;T[143%-W6IG
M**@H*7('4MAZ5FR>`P>:<Q^9L[6[DC'E,T3)"W4.\NX&GF:TZ>+0?!707][:
M;A:32Q1O;1S6/<T._P`P!%:>%?BOA+&(!&5/.I0\62:43%)67)',BR:J8E*F
M)%'Y4`='+VB`6PFMQ``]*QQ<;P,>4.==9VISSA1USZ3!,X`!HW/#031H`'P`
M5IO;TV'Y:9IC9;J["]Q:#U^4FGZE=R,/'R[55C)M&S]DN``LT>MF[MLK8Q3E
M[J#A-1)3B8H"`"`@`UGR&(L\M:/Q^38VXL)6%KXY&M>UQJ"UQ#@=6$5;32IJ
M:D!8X+JZM91<6<KXKAORN::.;\:$:ZJW9X[#1T>,2PC6#.+$JI/IK5BT;L."
MPB*Q!9I(D;B541$3`)?FOUJVUPF+L[23&000MQ#R?Y`C8(A4#=1H`^8@N-?$
ME77%Y>W5R+Z6:4W[:$2%Q+Z_&I-?!86-UQ@4._\`JD3AN+QDERY^_80$4U>`
M<?YRN$6A%2FO^`UY&,X'PW#79O<7C+&&Y<:ES86;J^!#B*MI_AHO0N.1<@O(
M/IKN]NI8*4VND<1^@G^]957%L?7E4YQ>'BUIE$I"(RRD<S/)(E(`E(5)^9`7
M292E$0``,```UZLO'\)<9*++W%K;OR<!)CE+&^HPD%IH^FXZ&@J33P6G%DLG
M#;&R9<3"Q-:Q[B&&OB6C0KYE,2QN;6;.)>#B)1PS'_55Y&+8/EFX<^X`(*NF
MZITK*`!OE$.H7K%DN,<>R\D<^3LK:>XB`V/?&USF4)<-KG`EM''<*?O`%6VF
M1RN/B=!C[J>"%Q.YK'%H<#U!`ZJ[D8&(F&QF4Q',I9F8+':2+1L\;'L(VY(+
MI'3$0`;>E;-[A<5DXG0Y&".XC>P-<)&A]6MZ#S`T&I.GB2K;>[N[.<7%E+)#
M(/&-Q9KU))!!-2L1#8%A6-KG<X]BF-P3A2_->(A(R.7-R_-=9HU25$##Z]>M
M>)ANWW!>.W9O\%B,=:7SNLD4$;'FE:5<&U-*FBWKW.YC)1^ED+JXFC^#Y'N'
MZ"ZBY+[!<D\@?N"XIBS,0?8YK1_',78]#HE1PL5\BR%8;?I\#SARM;_$X!7V
MNTPQMD;_`.8-?/XT^'PI^"\@M!'INU@_@_=!^/QK^/@NKN5:RUUG)DE,UP7$
M,M40+P14R3&X::42(`@/!-209.#D)<+V`;5\YDN,<>S)WY:RM+F7^*6)CS^E
MP*]3'YO-XDC\KO+NV:/"*5[!^(:0#^*K8YKS",.3%'$,3QO%4#"`F1QR!B89
M,]K?G+'M$.?I\;UL8W!83$4_+;.V@<.ACC8PBO7Y0%AR&3RN5<3DKJYN`:5$
MDKWC0@_O$TZ>"^)37&`SKY63GL+Q.<D5B))JR$QC4))/E"(EX)$.[>L5W!R)
MDZ%`36*'0*NO,)A;^5T]Y:6TL[P`YSXVN)`Z"K@>BNMLKE+-@BM;FXC@:20U
MLCVM!<220`1\5=PV"X9C@NQQW%,:@!?H@W?#"0,3%"];E$W%!V+!FW%RB7F:
MQ3\@#D-5M,-A[`/;86MO`'MH[TXVLW#X':!4?>K9\GD[S;]=<SS[34>H]SZ'
MXBI-/P5S`8EC6*-56.,04/CK)=<[I9G!13"(:JNE./-RHW8-VZ2C@Y2@`G$!
M,(`'6KK'%8[%0F#%016T)<26QM#14]33XGQ*Q7EY?9(B3)3RW$XH`^1Q<X`=
M`"?`>`5@WU]A#2:-DC;$<8;SYUEG!IM#'XA&8,X<%,5=<91)F1]WEBF$#F[E
MS`(W]1K6@XYQ^VO/S"WLK=E]N+MX8`[<>IK\3XGJLTF7S4MO]')>7)L=H'I%
MY+*#_"33_L"N%\)Q)S/HY4OC<"KD[<"%0R-2&C3SR)")BB4B4N=J+],A43"0
M`!0+%&P=*RRX3$37[<I);Q'(MZ2;1OZ$#7KH#HK&Y'*,M#CX[F=M@[K&''8=
M035O0U(UT5],8Y!9"P7BL@B(R>BG0B+B,F6#23CUK]/U6;U%9NI8/Q*(A6>Y
MQUE?1&&^BCGB--)&M>-`!T(/4!8;.XN<?,+BREDBF!)W,<6G4UZM(\5@<7UG
MKS"#+'PO!L1Q`[D.+E3&<;AH-1P6_(2K*1K)N=4!,%^HCUK6Q^!P>)W?EEI;
M6^_YO3C:TFG2I`K0+>OLUE\HX')W5Q<;>@DD>\#[@20L8_TQJ.6FC9'+:QU_
M*3QS%4-,R.'8\\DS*$-S*J9ZO''<"L!NO/ERN'K6E/Q#B]Q>G(RX^T-ZX`.>
M8F$FG2I(_7U6S#R?DL%H+"+(7@LA6C!*\-%?@`?@M@>P:^U]EV4_:<.U[;MI
M^W[/#AV.QQ[79X=.-K6KVOH[3Z?Z3TV_2TILIY:=*4^'V+R/J+CU?7WN]>M=
MW[U:UK7K7[>JK+=0`/QO_@-9R!O:[Q#OV%:T@W1O9X%A_8H+>'O78OE9_O7+
MT^'5:?J$'M*?*_N-W6]1Q<T<O>`*#0;[C^VJDIWR9&SB'"MC:$XAY)J=3_)^
M*G?4X5&]*(E$2B)1$HB41*(E$6A_)#<D?H_5&0YHJJF>9,@:(Q1@)R\Y')9%
M,Z4>0I!N)TF8@9PKTL"21KVN%7-%2BA?]N#4\BC$Y?O7*4U59G.7+F*@73H!
M,NZBTWQG<],\CW,8)B9*!"FZ7*W,/H:LDKJ@-^"+J16%$HB41*(E$2B)1$HB
M41*(E$5%7X?\/^`U:[JW[_V*Q_1W^0_L4%?#S_:)Y6?[UR?^M/U!_P!I/_Z+
MW6_^X/\`^_<*2O?3_P"(\*_]'?\`^"IX5.)1M2B)1$HB41*(E$2B+$SDY$XW
M$24_.R#6+AH=FN_DY%ZJ5%JR:-DQ46664,/0"E#H`7$PB``%Q"J@51<4\CE<
ML^X#Y`L("`+(16G,+44`SLQ3D"/@17X/YMT4;D#(LH%$$FB0CR21M>_`XU?\
M@^TJB[4X]`1&*P<3C<`R1CH6#CFD5%L4"\4FK)BB5!ND4/CQ3(%Q'J8UQ$1$
M:L)JJK,U1$HB41*(E$2B)1$HB41*(E$5%7T`0ZC8>@?V#5CB-[`>A=^PK'(2
M&.(U=L.GZ%!7P]_VB>5EA`0_=<O4/Q[T_P#W5"#VDM([B]UCN8YIY@^FTU(\
M]Q\WVJ2W?2O^D.%5:]I_)W_,*`_T=1]BGA4XE&U*(E$2B)1$HB41>%V%LK"=
M68\YRC.\@80$0W*<"'=*W<O5RE$Q6<:R)R<R#U2UBII%,;XC8+C50">B+D9F
M6=;E\^LQ#`]<1;S$M,0\@FI*2+X%4V(@DH(IRN4.T>*;Z1%,.32*1$W;,/(]
MQ`5"W_(J=5U1TMIC#M&X4SPW#VH@F7@YF)AR0@RN0RQDRE7DY)8`N)S6XI)?
MD03`"%Z7$;"XN55MRJ(E$2B)1$HB41*(E$2B)1$HB41?!R<O0>(V$+@`#T'^
MW^(5:6DN%3Y`=1\=%:YH<#31]"`?A5:JUOIW%M7R^P)O'UI-9YL;(OZEFP?N
M$UD4'8`N(-X\A$4C(M04=*G`#B<USVY6``#F';OM/QWMME<]E\(7NN^0Y-][
M<;@!21Q<=K:?NMWNH3KJOM.4<ZSO+['&X_,.:ZVQ=MZ$``I1AVUKKJ3M'Z%M
MBNHKXU*(M>3&<2>-K+#-85D;F+(<PIS&+(%R=($`$1*J\BVG9G6Q@('S`1JN
M4!_F&B+SS+R"TP\7]J?8V+Q;R_$T?D+\<9DB'"]R*,,A3C'1#%$+"''H-5`J
MBS;C<FI&B0KN-G:_11`O(3GS"`XV'T&X2`]!_P".J[7(M097YJ^-.))J^ZV?
M$3+I,>)8_%T7N0NE3VN":9H]NHT`YO\`I*E#^-`QQ11ZF?,G<>T15B/&K0N4
MR`K',@EFF91YD(QL!Q`I71&G=;Q2?&]P%P],`>HD&KMC1\Q18?%O![8.SLB0
MSWROV._R9_R[B6'P+TYV[=,1$XL%I)--%C&L@-T,C'(E`0Z=ZW6FYK?EJ472
M'$\0QG!H-EC6(0D=CT#')@FSC(QL1LW2"P<CF`MS++J"%SJ'$QSCU,(C5A-4
M7I*HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1%X?,/VV['_S_P#HCVW;
M'_[A]"[/:^/_`+U\G#^ZJBO@BC/)?Y`_<F^I_P"6/W/(>7=_;_GROUOQZ7O5
MX]3PJBV'AO\`E/[A/Z%_8?W%R]OZ#_0WNK_R]OV_Z]_[*H=_C5%(A#L=E/VW
M:]OP+V>QP[/;_E[?;_3X6]+=*L/VHJM4T\$2JHE$2B)1$HB41*(E$2B)1$HB
'41*(E$7_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>g5754311st.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754311st.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#2`(C`P$1``(1`0,1`?_$`*H``0`"`@,!`0``````
M```````&!P0%`0,(`@D!`0`````````````````````0``$#`P($`@,&"A(,
M#`8!!0$"`P0`$042!B$Q$P=!(E$4"&%Q,B,5%H&1H4)2,[/3)#:QP=%RLG.3
M-'24M-0E-55U%QAB@I*BTD-3@U25)E;APF.CPT1DA$5EM3?BXZ3$)RCQ1CCP
MA5<1`0````````````````````#_V@`,`P$``A$#$0`_`/5-!#,7N/?N7AJG
MX_$XOU-3KR(X>G/I<(9>6SY@F*M()Z=^!-!FJF=R`/+BL03?A^'R!8<?^R4'
M!F]R0;#$8E7`\?E"0./'_LGC0?7K_<;RCY%Q?'X1^47^'#]A^F@(R'<6P"\)
MBR3S*<D]8?3AT!61[B7\N"QMO=R;W[SH.?E'N'_(>-O_`#F]^\Z#CY1[A_R'
MC+_SD]^\Z#@9#N,2;X/%C[$_*3Q^G^!T'V,AW"_D7&#T_P`)/?O.@^1D.XG"
M^$Q@!-B/E)[@/3^LZ`,CW#N;X/&6\#\I/?O.@?*/<3^0L;_K-[]Y4'U\H]P>
M%L'C?='RD[^\Z#@Y'N%:XP>-OZ/E)[]YT''RCW#_`)#QO^LWOWG0#DNX02+8
M''%5^(^4W;6]S\#H.%9;N$#Y=NP%)M<_PFL&_.WZTH.LYGN,%6^;,(IX^894
M_EQ:#DYCN*`?]FH)]`&45RO;QB?1H.3F>X8U6VS"('+^%#QY?]EH"<UW"-M6
MV(B>5_X4O[__`%:@X^6NX=C?;$0F]A;*<QZ>,44'TG-;_P"G=6V8H7]B,F#]
M4QA0<C-;]//;,8?_`.S'[WH"<UOTVOMF,!?^4P3[_P"MZ#CY;W]_NQ'_`-9I
M_>]!R<UOVPMMF.3XCY2'[WH.4YG?9/';4=/N_*23_P!!0<#-;\\=LQ_]9)^\
M4`YK?EA;;,<GQODDC_H*`,UONW';+`/H^4D_1_Q%`^6]]7_%AFUO#(HO]QH.
M!G-]E(/S6:!/,')-\.7H:H/DY_?8'#:B#RX#(L^@>E'NT!6?WV$W&U$D_8_*
M+(]/]A0$;BWR3YMHE(\;9",?I<*#[5N#>8`(VHI1/,"=&X>_>U`^<&\[7^:B
MO>]>C4''SAWI<_[)KL!P/K\;C0/G#O2]OFFOW_7XOYM`.X=YV!&TW"3S'KT7
MA]6@#<6\^-]I.>Y:=%Y_3H.3N+>(5^*;I3>UTS8GT^*A0?!W+O,)O\SY!/V(
MG0K^'I<'IH"=S[OL"K9TL$D7`F8\V''TOB@[/G+NJP_V0F:K<?PK'VO[_7_*
MH/E.Y=VV\^T)5R/K9D`^)'B\F@Y&YMUZ3?:$S4/!,O'E)]XE])^I0/G-NGE\
MT)OO^M8^W[HH.3N;<]_Q0G'_`+UCOWQ0/G-N?_="=^VL=^^*#GYS;GM?YHSK
M^CUG'?OF@^?G3N3IE9VAD;@7*0_CR3XV'X30?)W;N*_#9V3((!!ZV.\0>?X5
M[E!RO=>XTN)1\S\D=5_,E_'E(MZ3ZS0<JW7N!`X[1R1/H2]CSX@?Z5[M!R=U
MYX<3M')Z>?!W'D^'AZU[M!UC>.>M=6SLL.('P\>>'I_75!V_.[+7M\T\O[]X
M'[[H!W=DPV5JVKE[I!.D""3P]%I5!UC>LXVOM3-#4+CXN)RY<?PGA[QH/I&]
M9:D%?S7S0`Y@M1@?H#UCCSH.$[WDD<=L9I)`N06&/RGZ#E&]9"B!\VLR+FUR
MPP!]WH'SUDZBD[9S-P2+]&/;@>=P_P"-`3O9\D:MMYE";C4M3#-@/2;/$V%!
M)J!013M9J.Q<<5<U*DJ/"WPI3IH)70:S/91_',PULH2XJ1-C15A5^"'W0A2A
M:W$`W%!LZ"L=R][E8/<,G#G:.:F>KNAE$QA@%ETJ`\S:CS%U6H,)_OY,#3JF
M=C9P+9"E.%YG0V`TZEMWS)UDZ=?@.?N7(#Z@=]<E/?F")L7..-PV@MQLLV?*
MRX$:0@C38)NKX5^'*@EN%WVO-;.R6?8Q<K&.P42`F)DFBTLN1VM9\M[E&ORW
M]PT$GB/*>B,O*`"G&TK4!RNH`T';0*!0*!0*!0*"*]Q-\.[.P[&21B).8#K_
M`$%LQ+:T#IK<UG@HZ1T^/#ASH(?MWO\`?+'RHMS:\Z$UBL>]D75.GS.)9`/3
M;!0FZE:AXT&KG^TN[$D(CG9F14^I#*U-E=E)4^VEP(-FU<?-P]/U*#M@>TDF
M=,;AQ]JS#(><;99;+H!+CQ``5\79(1<=0W\M_&@3O:5BPY3$9>V)KCK[3+@0
MTXE2@7VPX$D:1R!\*#LQOM&C)9%F!"VED7'I2TMQ2I:$I65FR2218`#BL\=-
M!E;/]H%G<NYX.!9V[+BKF.+;5)=<3H;T-J</#2+D:>(\+T%C[ER[N(P,O)--
MAUR.D*2V;V-U!/AQ\:#:4"@4"@4"@4"@4"@4"@4&KW-F',/AUSVV@\I#L=K0
MHE(L_(;9)N`?@AR]!M*!0*#6;GS"L+MO*YA+8>5CHC\L-*.D*++:EZ21>U]-
M!3+OM'[D86X'=J`%GU>(^QZP0X)\MI3L=*?(0IIT)\AYF@E6\.](VENB+M_)
MXSKR96-;F-JCO-H2))4X%MJ5(4R@-CI<%7N?109#O>*(QA-JSI#<9N5N*(N6
M]&7)2CU=*83DE*O,+J2M;?3!-N?IX4$=PWM'*DQ):\EMM^)*B0F9G10^R0KU
M@*6TH%XL?%*;"#J%S<VTT&,KVC,JU/8ZVWFTX=R:SCESTR;GKK;;><2E)0$W
M#;GENJU^9H._)^T>EB5+3&PH]2;NB/)?DM:@XA+*UE]#)=`;"7N;2UJ_L*#L
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MS(PV)<R)9+X;<906PK23UGD-7O8\M=Z"J,?[0TV=M7,YUO`-)7C%1$LQ#-!6
M]ZV\IFY^*&BVGASO06#AMZ_*.RL/N4Q-!RAAI5&2LGIF6^A@^8IXA!<ORXT$
MG*D@@$BYY#Q-J#F@UV%S",FF:4M]/U.6]#(U:KEDVU<A:_HH-C0*!0?/5:ZG
M3UIZG/1<:K>]0?5!TS5:8CYMJLVKAZ>'*@[*#ZH(OVQ2E.QL8```0\;#W7W#
M02B@T&\?UMB_YU@?=TT&]<<;;;4XXH(;0"I:U$```7))/("@HW=&Y<GEMP.'
M`]V<7CH,F2RF#CVT-.K`5I1HUB^HE=_I\:#6S)6Z@9T=_O%CENL$@(`0R65M
M24$*=+/$?!TJOPXZ>(-!VP,[ETJR3L[O'C%S'V$M0%M%E+3*NNE?44R1TR>F
M%)X"_'X5A06#@9>0E=L,RJ=N&+N:0EB<CY6A!*4*1T2I"5)1Y4K2E7$"@G&-
M_BZ+^DM_H109%`H%`H%!4VZ9GM$C<F01MV%CU8)+@&/<>Z16IL(2257=2;ZR
M>8_X0RY4KOXC:>/>8BXQW<+COX9&``#;92X;+*G0V>.CBA7TZ#6O2O:0#4>5
MZG`7+#DMMR$TID1RW=`96LK<UG@%%O2KW%@7X!V8B7[0XQN:DY"'$5DDHC)P
M\+\'#*E]8]8E2';A/2/FU+OJ^#0;G961[S.Y]$;=>,ALX8,N*5.84@.*<&D-
M`MI=<TE7F4JUQX>^'QOF=WM9R,E.TH$&1C@MLL.OJ1U2V64]0:%.-C4EV]KG
MB/>N0Q)$[OZWLR)(8@8US<JW0F7%.D%*0MRZK]8-%)2&^2K\3PH-:J=[2%VI
M2L5CP^)+J50F5,AI3)906UK6MPKLE>L"QO?F+<:#8[#_`*<I\G,#=:X^*!C-
M-XQP,L/-(?UE16EMITJ5\6;+"E\[6Y4';LC*=Y?G$8F[L.P,22X3DF>@D)TI
M59=D/*599">&DF@E.\I4:7LJ;(B/(?CNH;4T^TH+0H=5/%*DD@B@DE`H%`H,
M/-.9-O#SG,4VAW)H8=5!:<^`I\();2KBG@56OQH*B@;G]IAV;&:?VUCFF%N(
M#KSEDI2A13J*M,EQ0"0>.D$T'?'W#[2,B0XP]M['1F%*>2F6E2-:+,K+>E)?
M6".H$V41Q\10=$G<?M(NRH[#&`C,17%MI7*(84ZE'4L5+'K"DIND>8:3;PH,
M^3NGO^QEW$M[7A2,47U-,.!24NAKJ`(?6/6%#BV=12/1:@V>[MR=XX4Z8WM[
M;4>=$;D:8DAQQ-UL])A044=9M5^HIU/O<?#B&C7NOVCTL0^GM3'./.1U.R;N
M:0E8+ED&[XLNR4^4:AR\W'@';+W9W^B,GH[78FR7`RHW+:66U*8;U(1ID)6H
M=77J*CY?=%J#ZD;I[[8_;.)F#`L9+*RER?E&&6=+C"4N$LGXN0E%BWPM<F@D
M>;GY;(=M8TS,PC`R;SV/]<A$6Z;@GLI4!YE\.%QYN5!.:!0*#AQM#B%-N)"V
MU@I6A0N"#P((-!T*QV/4LN*BLE94A966TDE37VLWMS1];Z*#KFX;#SU%4Z#'
ME*("27VD.'2DD@>8'@"308\K:VV)>CUK$0I'2;2RWU8S2]+2/@MIU)-DIOP'
M*@YE;7VS+"$R\1"D):0EIL.QVEA+:."$)U)-DIOP'A0=J\#@W&/5W,=%7'U]
M7HJ9;*.H1IUZ2FVJW"]!THVKMA"$(1AX24-.=9M(C-`)=Y=1(T\%<.?.@R7\
M/B9")*'X4=U$W3ZXE;2%![0`$]4$>>P'#50=;NW\"]`:QSV-BN8]@A3,-;#:
MF4$7L4ME.E-K^`H*^G=S]C.;BG;??V^Y)7CGRJ=(+4);#5EHAJD*U.WY.I1\
M'7IX6\*#[V_N?M'F9ZX$'!Q&WGFGRYKB1$I6VRAIU>HI)N#U4VOX@^B@T<[O
M=VDQLMW7M]TEF,TER0U#BG\&D,ITMWU@Z>F0@IY<+>%!NME;_P"U<_=Z<)MG
M#IBY)QEQ29K$)EALH0`I:>HBR[?0M>@EN_Q?;#HN1>5!Y'2?UZSX^%!YU.V-
MSX386]$9G&.XZ/D96-,94M;;21JEJZC!>4O4MI`*>.H#C?AQH+DPLI,GM-M5
M]+"(R''\/H8;6IQ"$^O,A(2M:G%'AZ5&@A^T9>;F>TAFDSW7G8T!N:F&IU3A
M;#2PP$MLH5\6-%N.@7/C>@M+97</`;Q]?^2$R$G'.);?]8:Z=RO5I*>*OL3=
M)LH>(%!SLE8]7S:N93F)]P+7X._0\*".=I^ZLW?>3S25PFH4*`B.8S2%%UP%
MQ3H6'G/*G7\6/(E/#[(T$^RLY./Q<R>I.M,1AQ\H'B&D%=OJ4'ES&PNX^:V/
MD^[:]VRX\Z&XZ[%@(4OIEMIP!:;:^FE/,)1H(-N/.@Z'^V<_^BL]U5YZ6-S+
M4)Y5KL-*Y'3%G!\9U+'5SM];:@]+[#S;^<V7A,O(_7$Z$P\^;`7<4@:S8>E5
MZ#;S1>(\/[!7Y%!V4'U01?MC^(V+]YW[NN@E%!H=X?K?&?SI!^[IH,;?V>W'
MAL8R]A-NJW+UG"U,A-NAM:6B@DJ`4E04.&DCW:"H58.3C5HR,7LDWKBJ3(BK
M:G(4XE2"%MGI)"E7!/*WY%!FF)F,;ELM+A]G&7D2D'KO&4R5O-2$AQU"D*#B
M5GJ@W"1Z.%!C);]28A"-V1#@Z1?"5E"RAUTD.-JUM*/!(!\WT!06!MR)%B=J
M<H6-M':JG8T]U_#*.HI<T+!7J',+"01PH)UC_P!81O#XI'Z$4'?0*"NNX':K
M-;JSB,A$W9-PL4,I9<A1^IINDJNM.EUI-R%^*308FV>SF?PSD\O[UR,]$S'O
M0&@X7067';!,A&I]8UH`X6M]"@QH79#.(B95B?O&;/,]DHBAWKEN(^EY#S+[
M(5(4K4UHL+J^CZ0U6?[)[PC-0W\-N?)39:5(1."I;K*EM^K])TH4XZXE/47<
M\O+JX<J"/CL[W6+:B[D9SKQTE*53U%`L+*;)ZZ3TSS`M?4!Q`O09\7MGW<8P
MAQ'RID=*9"GDS4SD=132FVT!E22ZDZ4*:U<%B]_#C0=`[:]Z&3&2QDIZNBTI
MEYU<\*4Z2^IP.6]81973*4#C0=:^UO>AUB$PC,Y..8R%(>E":E;CBE..+UA'
MK(3;2L)\Q)N/10=\OMQWC=R$R2G)Y1+,EXNHC">@-A&I1Z:@F2E7&R.*5)MQ
MH/K"=N.\F+EOO'+9.9U&'X[1D2FUZ`ZV6TKT&7IUI"M0/@I(MPO0=![9][%J
M+BLWE4O$I*W&YC8"])-M23)*0JQ^M`'#E0(_;/O3'$-M&7RJO57'75OJFM*U
ME9;+8Z9D&Z4],W"E&]_?H,_;6R>[6W,B[/FRLAFH/0D(>AR)C(2M+K9`*NI)
M=2-"O-<)H-KLIZ4WV08@B,3CHL5A,+*:TZ)(5)\^EJ_4;T'AYA8^'"@W6_>V
M>]=P;A5D\-O.5A(BV$,F`T'2@*022H:'FQYKB_"@UL+M)W*CQ)S+G<&6^Y)2
MT&'%B3=M3:[J((D:AK3SL>?N<"&2.TF[C@H45W>DY[,19WK"LLIR0EPPW&T)
M?B@)>Y*6WJ2H_!H.E[M)W#+SBH^_YK#*FD)2R2^[\<+I4LK4]JMI62`+>8)/
MA08JNSO<_IZ$=QI@6``AXB25:DDJU%)DE!*[Z5"UK`6%[T&YW-VWW]E(6*C8
M[>TG&*@P68TQY"72N1(;"@J05)=005WX@W^I08D[M?W(6\Z8>^'F678C4;2L
M25%#B(_2<?3^$?#6Y=SW#0?4+M5OIE&;:>WO-D-3"TK#ZW).J,IIW7YU!X+4
M%H\B@%#T\P*#!C]JN[C,,,CN`ZM]N3U6I"P^H]$M%!;4DN<;*.H7)H.B1VB[
MON@V[C2$K/E44]=.M*3=)(#ED*L`DZ`+\S<T&=E.VW=R6S'C-;WZ++,9J.IQ
M`DMNJ6WK)?4M#@*EW=M8_""4ZJ#JA=K>[K4V&]+[AOO,,...2&@A:0YJXI3\
M+EJ\#P`Y4'5)[5=Y%LPFV>XCJ0RE'K*BET*4L(0%G4E0*DE220#Z:"5;BQ>5
M@]LH^-R>15.R3#F.9D9/39;BQ.8'4TJ*^/OWO0208C*W!^799L+6Z4/C[OVB
M@^ABLH/_`!J2??:B_>:#@XG+ZKC.2=/#R]*+X<^/2\:`G$Y8<\W)/^:BC_HJ
M#H.$W"1PW%(!L./J\3GXG[50?/R%N/\`WDD?M:)][H.1@]Q@W.Y'S[AC1/O=
M!RO"[B4JZ=Q/H%AY4QHMN`]ULF@^?D+<?^\DC]K1/O=`^0MQ_P"\DC]K1/O=
M!R<)N(Z;;C?%A8VC1>/NF[=!V)Q&?#A4<ZZI)Y-F/'L/I)!^K083VR_6''W9
M4EB2_*1TI3SL"(I;K5PH-.$H\R!8<#083?;3&M*"FV\:A7%*E)Q4,$H4"E2>
M"?%)L:#I_HN@:5)*,404V`^1X=K^Z+<1[E!GL[*DQI0G1)<2/DM.@S6\;&2X
M4$>9.I-E6)`\:#`WCBMRC"?A&=2ZT9<$%'JC:+DS60..H\CQH&]%3,3@9,W-
M99,O'H6TD0SCX[REN..I2R-+BTH)UVL3;CQH->])F93:N#R[65Z^+DY+&+;C
M*AML*MZ^TG2=*E:%)6/#\CC01#8VZ,LKO[N+!.91]V#U,@XG'K<46$%OHZ%)
M2>!/F-TBUJ#/]FXP@=VHARXLII&0%C%:<:N#K/5LX$V;7>S:>)&DW)X4%A;/
M44P<XHBX3EL@0/2`Z:"M?9FD;:>:SCF+8?CSW_5WLDAV0T^WJ4I[3T@AMI2`
M.-PKZ%!<.XH4B=M_)PHP!D2HC[+(4;#6XVI*;GPXF@\[8_MG[0D'93VS&&\:
MG!2$N)>9+K9<(=5K79RU^=!TYO:_?+%]OCMC+2<-!VLTRE@E^0RTK0A8<`ZJ
M[>;4!07SVRC)C=O-N,)<;>#>.C#JLJU-J^+'F0H@7!]Z@D$TD172/!!_(H.R
M_N4'U01CMG^(^,]YWE^GKH)/0:'=_P"M\9_.D'[NF@K/</;U&V\9\H[D[EY>
M`R](Z:Y:77TI5KUJ2TE!<>TD@`WMX>[:@CQ@]M9BF6%=VLZLDLK90N2Z/,[9
M3:O,T./$'^Q\;4&XE8W!89^))E=V\RB$]&=<#;KQ<*VCJ8ZB5I39&A:38E)X
MB@TTR7LMEN-(C=W-Q27'U)9:;8=4ZXI*EZ.".FBVE?%1/&PH+&Q44P^U6X6C
MN5[=13'GDY5[BH'H$%H>9=PBWI\:"P(0M#8'H;0/[T4'=0*"FL9W![A9;+1L
M7`S&WWY&39ER@8C3\D8]$)T)T/CJ-J670K3=0190/`T'?V_[A[WR.1VT[GY>
M/7B]QX^;."(["V%L>IJ0/.XMU:2DZ_0*#4YOOUF,>\ER,F)D(B)6<:E",.JM
MN/!6AN'(LAP^2[@4X3\)-[6H-*._6_8\%B<\Y#E-N0Q,=8$,L6/581H;<]9>
MZFKKD7TCTVH.M7?7N>$97UEN'CY6$"&9D1413Q,A*27-2O6&RVDE/#RJH-@G
MOIW'Z1F-P,;+;7+E(&.9"A(3%Q_QDA\6>7Y>FE2;K2FR[6"A0=<GV@M[I,J7
M\F1X^,R#++F!=+:G"SUY2F6%2R'`%)>2P[I*+>'IH.[(=^>X86B)#PT).2A2
MT8;*1W"XKJY.0IU#0CA*P4MCH:CJN;$>_0;:-WKW6O9,+<'R8R_.=W`O%/XQ
MM*^H8[3:ENI;\Y/63H-OR*#31/:!WM*C!IG&P_69R7LEC)I2YT!BXH>+I=:Z
MFLN7C%-PJPN/<H#7M$;RZY>E8B''CQVV)KD!74$J3#FNI3&]5)78N]-P**=)
MOQY4':]WYWDUM-G<O\!/)>/J_P`D,+==F(=,4OA]P)<\J`I/F;M<)^NH-OM7
MO%F=PY)6WI<1I3FC))DY)EMQN.Z([*5MI9#BU+2M!7I<"K\K@\:#+V<#_5VP
M^FP_`V/W4+T$UWQG,UC48V/B).,AR<A(4TJ3EG%):0A#2W3TVTJ;4ZLZ.04+
M"YH*_P`5W)[HYEW#&*,+&;S\.9.AH=9EN%M$%:$+UJ#B-27=6IM0'*@D47N3
MD3@-CY"3ZFV_N7S9!)*D);3ZD](!:!7<>=I*?-?Z=!7[/M`;[GQP8^.B0I,2
M`W+R#;T65(#BGBM;2V.BY<-+9"#J5R-^-!B8[VC]^S$LM_)4!L/R6(7RD$/*
M80_(TK0E2.J%'XH+-@>)M09[/?7N"[GOF^B/BQ+U:_7'V)49"6@UU"7&7G4N
M(3QXKN;#ZTT'#OM#;W?Q*A#P<1O+H83E5*<*UQCC74HZ.FRT.%U3CJ4$FR?R
M@R#[0NYW9TQ$7"(4Q+?^2\$VM"TO-Y1*6=;,N[@"DA;Q^!YO+09VR^^6Z<WN
M[#X.;B8S43)/OQS/:#H0M<-IPR>EK4?@N!`%_"]!KC[1VXDRFV?D-IP17YKN
M4MK1JQD9\-(D1E+4E)4++"PHVNGP%!\S_:.W1%0J6<"SZ@ZP<BPOXQ2F8+JW
M6(RGRE1!6X\AOX/"Q^C09L3OMNZ5G(FV!CL4QG5J4U+DOR2B`E2E-*94RYKU
M.GI.D+:'GU<J#KC^T+G499MB7BXST6+(3!R3<'K/2'WE.2$%V`+Z7&P(P597
M'F+T$TD;@D[C[48S.26D,OY%S&/.M-7TI*I[/!.JYH+"H%`H%`H%`H%`H%!@
MYV7/AX6?+Q\;UR?'CNNQ(@_QKJ$$H1_;*%J"F?Z6>_(4K5V^5I(^*(:D'C;A
M?S<+GTVM0;.9W'[TM96!&8V8EZ*\S&?EN!N1\6'$-J?&O5HU)4M:0CX0T\:#
MNG[X[UM93-1(FVHK\?&O.)B25,2TIE-!IUY"FO/91(:2WP^O4*#`?[N]X6V6
MG#V_>1U`E2CHDN:`4DA*@E&K4HBW]A]=0;K8_<3N;F=TL8W.;/<Q6)>;=<7D
M5(?0$%"+I;/4%M6ORW\>8%J"0=VVFWM@Y)E>K2ZJ,W=M.MP:Y30NA'URN/E3
MXGA0><,5&A*P6[L?"FR\BRVQB8Z_6(JHSX6O(\6DQU+E*4KCY>',\J"\ML(C
M([4;41&=4ZT9F.TN.$%5_E!)4E5DMV*3<6TBW*@@VSA%/M,;@4RUTEH:GAQ.
MLN$+^))=*K"P<O\`!224VH,_V7FY#2]TI?:<:6MV*]9U*T%6OK>:RP+WM\(^
M8^-!:6TDE6/S:=7!64R`!)O:[RO1>W&@I[V3889=W4OK-NE*XS/Q94?@%[S\
M4I\JOK?'W!07]DI\?'8Z5D)-Q'ALN2'BD7.AI)6JP\384%`)[\=P=]Y56%[?
M8R-CE*1K,N>ZV7@@FVH)40V.?)(6:#2[#[7O[XWYN.)O[+RLI)VXXTRZ6W5%
M#KCFJX#BAJ0A.CDA*?H4'IC%XR#B\=&QL!H,0H;2&(S()(2VV-*4W))X`>-!
MS/%X;_YPCW*#OO0<T$9[9V^8N(MR+1/"_BXH^/&@DU!H=W*LUB4Z2K7E(8X>
M%G-5_H::#-SVWL)N#'+QV9AM3H:SJZ3J0H!0!`6G[%0OP(XT$/S^P^TF%Q32
M)VWX;,5]P1Q(0T@.-GI*/5+A(6-"&R2H$GQH*YP6_NPKNWW5R]LNI8PEU>K2
M642^@B8^&]+:EK.D*59:DFP22?&@Q!OOV7C-=D_(#C:C'+!/JI#00GRZD-AR
MR7+?7Z=7#G>@LW'?-C^B3/\`S;A/8_'>JY'\$?3H6AT-+"_+J6`">/`T%@1?
MUJS^<3^0*#MH%!B1\1B8TM^9&A,,RY/ZYD-M(0XYQOYU@!2OHT''R+A^DAGU
M"/T6FUL-M])&E+3MNHVD6L$+MYD\C08\7:NV(BU+BX>%'6M"FEJ:C-(*FU"R
MD$I2+I(YB@^&MG;1:45-83'MJ-KE,5E)X$*')/@0#0?4G:6U)4A<F3A8+\AU
M6MQYV,RM:E'Q4I222:#M:VYM]J9(FM8R(B9,06Y<A+#8<=0>:7%A-U`^@T'!
MVUMTL>KG%Q"QTFH_2Z#>GHL*U--Z=-M#:N*4\@>5!]';^!+Q>..B]94A,U3G
M1;U&4E.A+Y-K]0)X!?.@U^?P!1@93>WH<6/E4+7*QRNDRE*);E]3PUH6D+4%
M*NK3?C04]CXO>QEE#DK:<,);9=BL0XL;&!M$=Y"@^/,X%@NOZ5E"?(H%5QR%
M!W3<1WG7D5Y6'MK&*<BGIP#-B8],MAMBZT)CK:6L=,MV92"NX)5RX&@Q9.-[
MQ.MMKQVQL3'FIB",\Y(B0`@M*2&U,MD.%6CS6TJX:+T&[V;@NXCF\&I&9V_%
MAPI"7FYN1,3'-25QUL*2>H[&6MWJE[2$A(TEOB>-!+LIMN-M;M4,#$>6]'Q[
M;#+3SMM:D^LH/FM87\U!+\MA</F(GJ>6@L9"+J2OH26T.HU)XI5I6"+B@Y3B
M,4ER.XF&RE<1I4>*H-I'297I"FV[#RI.A-P/10:Z7L;9<P,"7@<?($9E,:.'
M8S2PVRDDI;0"DZ4@D\!0?,O86R9C+#,O`P)#49I$>.EV.TOILM7T-IU)-DIN
M;"@-[!V0WCEXU&"@IQ[CPDN1/5V^DIY(TI<*+6*@.%Z#I';7M\(SL;YN8WU=
MYP/.,^JM:"X$E(5ITVOI)%!L7]K[;D%PO8N*X7F&XCFIE!U1VE:VV3P^`E7$
M)Y7H"ML;=5($@XR-UQ*&0ZO21J];".GU[V^V:.&KG0?,?:NVHZX2V,9&:5CG
M'G8"D-)267)-^LINP\I<N=7IH.OYF;3L@?(\2S;+\9'Q*.#,LE4AOE\%U2B5
M#QO0<3-H[:=A28YQ$1U#\5N&ME;*"E;$:Y894#:Z&U'RCPH*"GP.[:&1B6^W
MV-7$B!QAE(@1EM+0Z[U5FP<*4W4E)\BN-K\Z#O7'[N/L^K3.VV(5"8Z4<I$5
MES0RPI8;Z""\G4&NJ5(%Q?CZ:"SDL9!OM;BF,E`:Q<M$G'(5`8;Z2&P,BT&P
M&D%P(446)2"0#PN:"PJ!00[NN[,:VIKA/RX\GUAK0J"N2VX>>I)5%8EN:=-_
MK+7MQH*CQNY^ZZ,&,RZG+F%"AO85V,ME]<IR7)9>=;GA*D)6KHNEEO6$\KGA
M0:Z#O'O,,:F`499/J+<A<IUQA]>1$9YQ@+4K6UT7'6T*66-*B1?B/+021G<.
M\X.R7<OBIF7GB#N8)@OY)N05.XTL("A,;#76+.I2AY$7"[&@T.W][[K9SV`R
MF4RN87&5)*LQ#M-<:0RH/'];"&@%M/DLKJJ/N>@.N7O;NI+V\T]A'\G(7&Q1
M9S6MB0A]#[N06$/L:D#6ZAK1?3?R'W.`?>(W!N9>:>:E[@W(WME+;9GSH[<J
M8\"75!`"G8T5R/K\H)::<]%Q>@F><B[ZF=FH.<>R^8@;BQ\=:@S&^)=D)6^$
M-*E,I05EP,`*(%N)-!H&LUW`$AUO=>;S.+Q&WWCAGI>*AK=>FN@+<3*=59VP
M*4-^="""5:>%R:#5N;R[J!R2UG9V7QD7U%MUN5#B%2SD1"0J.PNS;O30]<K<
M"4_#X$CP#2SMU=TQD(C&(R^;D2'FV4*#O64DR''&QI6A45A#5M2K\5BWUU!.
M,3F>YL79.;:SN1R'KD/<3$"=E8[)6\UCD!M+S\9(;5=)M?4E!YF@C[>\N^0Q
MN3?G.2_DV(<<J<MF.6IVA]#8#<510X$**?.^HMG2?1>U!)^T6Y^Z61WTF-NE
M<LQUP5+=BJ8+3+8#;!8>45-A&IW6KX"]6J^I(`H+$[M"^Q)R>BV^5.Q`EEXE
M+:B9;5DK4"FR3XF]!YSVLK#N[`WC&B9(PL4['Q+TMUQA>F+D52+.(::0IYY:
M%:!I<U6H+PVL8O\`13M!+#PD1TRL:A+Q26]13,0+Z5!)'F'_`/-!\[+[;YK!
M]T=S[HE^KNP<RI:H:VWG`ZV%+"BA;.D(.KTZN%N',T%G"@CVSFT^J94$`AS*
MSR1Z;OJ'&@Q]D]M=I[+7.7@([C!R"D*D!QU;HLWJTI3J)L!K-!*%H0XA2%I"
MD*!2I*A<$'@00:"KMV>SGV[S>M^!'7@LB3J;DP3I;"_26">G_<Z3[M!!87;O
MO;VRR4W*[8=C[FBS-*I[2P2^\&KE)6VXH+U>8\6W%&@OK;>1G9+;^.R&0B*@
M3I49IZ5"6%!33BT`K;(4`KRGAQH,K(_K)_\`.&@[J#ZH(MVN)/;_``A((/J_
M)7/X2O302F@C^\NLB-C9#<9V4B+D8[SZ([:G7`V"05A"`I1TZK\!0=GSOQ_^
MAY/_`%;-^]4'RO=6*<`#D#(K`-P%8V8;'EXLT&"U-V>U-DSFL#)1-F`)ER4X
M>2''0DW`<4&+JL?30=KF7VPXDI<PLM:5`I4%8B400KF#=CQH-9E9N#C[-RF%
MP6%FQ4/1)+4:''Q<IEOJ/-J%@`RE(U*5SH-XUN['AM`,+)@@`6^39OH_2J#Z
M^=^/_P!#R?\`JV;]ZH'SOQ_^AY/_`%;-^]4#YWX__0\G_JV;]ZH'SOQ_^AY/
M_5LW[U0/G?C_`/0\G_JV;]ZH!WAC@0/4\G<\OX-F_>J#@[RQH4$F'D[D7`^3
M9WA_F:#J<WWAFRH+BY,%-M7\%Y`\^7)@T'`W]@2L(Z.2%S;4<7D`GZ?0H/M&
M^L$LK'3R"='V6-GB_P"=NQQH/L;UP1\)OT<?/'_04'/SSP7HF?ZOG?>:!\],
M%Z)O^KYWWF@?/3!>B;_J^=]YH'STP7HF_P"KYWWF@T6]]R8_(;8EQ(3,UZ2X
MIG0V,?-N0E]"E<V0."030;WYZ8+T3?\`5\[[S0?!WSMX.AHF9U"+A/R?.O;]
M0H.$;ZVZLJ"%3%%'P@,?.X?\Q0<?/W;9:2[KE]-?!*OD^=8^'^0H.'-_[9:6
ME#BY:5J%TI./G<1^H4`]P=KC5\;*N@$J`@S20!SN.C>@^5=Q-J)-C(D>'*%,
M//WF:#Z3W`VJHV$AX$"_&)+`^F6A0?2=^;74G4)+H%[>:+*2?I%H&@#?NUS_
M`-9=\><:2.7OMT'/S[VO_I3G[7D_>Z!\^MK_`.E.?M>3][H'S[VO_I3G[7D_
M>Z#1[RW7@I^&;8BNN/.IG0'2WZM)/D9FLN.'[4?@H230;P[\VL`292P!Q),>
M1][H.#O[:@4E)F+"E_!!CR+FPOP^+H.M7<79R>IJGD=*W5NP_P"6_+5\7PH"
MNX^S$H"U9'2@@*2HLO@$'@"+HXT'#?<C9+BDI3E$75>UT.I'#TDH`'T:#O\`
MGYL_^56/IG\R@?/S9_\`*K'TS^90/GYL_P#E5CZ9_,H'S\V?_*K'TS^90/GY
ML_\`E5CZ9_,H'S\V?_*K'TS^90/GYL_^56/IG\R@X5OS9Y!2,NP%$&W$W]^U
MJ"G<G%W2X%M?TB0V&-8$=X2IS+@2$-)-A=2;K#)NE15;6HCC08#&'S9B$*[K
MM*G2%/)*S/E]-I!+:FW&K+1J6`A:%)5Y;*OS%!)MA9;*XG*QWMR=QH&7QC#4
MB\8/'67'"FQ4I205Z+<+GA?@GQH)+O[>.Q<OM5R(,O$DL/3(+<AI#H*BUZXT
M7>"?-8-ZB3X"@C\#8?9R#A<IC\9NA449IIMER4)S*WD(947`E!6G@%*-U7Y^
MY0;CY8V9A-I[?P$;.PI/R=,Q[06TIM&I#,A"E+*$J4$^7S*-[4$R^?&S?Y<@
M_MAK_"H'SXV;_+D']L-?X5!HMJ[TVC'BY`2,U"9*\E.<0')#2+H5(64J%R.!
M'$&@WR-[;,7?1GL<JQ*3:6QS',?#H/OYX;2_EN!^VF?\*@?/#:7\MP/VTS_A
M4#YX;2_EN!^VF?\`"H'SPVE_+<#]M,_X5!U2=T[6?96PUF8*W'1H0A,EE1*E
M<```JY)H-U0?5!&>V94=@X(J2$DQ$'2F]A?WZ"34$=WLE]V/BXK4E^*B7D6&
M7W(KJF'"V0M2DAQ!"@#IXV-`^8V/N3\I9>Y_\SF_?:!\R('\I9?_`%G,^^4'
M/S)@_P`I9;_64S[Y0?2=F0DWMDLKQ].1E'\E9H!V9"((^4LK8\/XQE?X=!P-
ME00"/E++6//^$99_Z2@#9<(?^)9;G?\`C&7]\H'S+A7O\I97C_YC*\?\Y0!L
MN&#<9+*^G^,91]SQ70%;+BDDC*99-Q;AD)'IO?BHT'/S-B?RGE;\>/RA)\?[
M>@^5[+BJ5<97+)X$6$^1;W^*C0<'9,74",MEP!S3\H2"#QOQNHT'RO8\=2B1
MF<PB]N"9[UA;WR>=!U_,)G^7<W^WW:#Z^8K7'^'<UQ_[<Y^90<C8S8%OEW,V
M_9RS^50?1V4DV_AS,</1,4/^+0<G9@*PKY<R]QR_"S;Z(TV-!S\SN-_ES+<.
M'ZZ]!O\`8T'!V:"+'.9?Z$LC\A-!]'9Y/_CF6'"WZY'^!0%;04H6^7,L/3:2
M/\"@X^9Z]0/R]EK`6T^L(L?=^UWH#FSW%"R<_EF_=3(0?T3:J#X^9CV@)^<6
M8U#FOUAJYY_\E;ZE!R=F/6'^T68%O'UAOC_S5!\_,M_4H_.3,V((">NS87\1
M\3?A[M!Q\RI'#_:7,W!O?KL<?<^TT''S)DV_&;->_P!=C[Q0?1V7*(`^<V9%
MN/VZ/]7XB@X&RY0O_M-F>/I>C_>*#M5M.8I.GYQY8#E<+C`_3$>@?-&7:WSD
MR_.]^I&O^YZ#D;4F!&GYQY6U[W*XM_I^KT')VM-TA/SCRHMXZHM_W/0#M:>1
MPW)E0?3>'^7&M0<':T_4DC<F52`?,+PR"/1QC'ZE`.U<C=1^<V5`/P1^!>7W
MOP7\F@^?FGE-)'SIRUS:Q_`>%N?_`%7QH.!M/+@W^=>6X^&F!;]R4'TG;&82
M/QIR9]]$`_\`VM!V(V[F$IM\YLB?=4W`)_<M!\';.8(M\Z,GSO\``@?O6@#;
M&8"BKYT9,WOP*(%A?T?@M!]_-W,6/^TV1XBWVN!^]:`K;V9(-MRY`'P(:@>'
M_=J`-O9H#\9LA?QNU`_>U`^;^;M^,T^_IZ,#][4'P=N[AN+;JG`#F.AC^/\`
M]-0=:MM;F(%MW3@?'\&QY_\`MZ#CYM;HL?\`:Z;[_JN/_>]!R-M[H`_&Z:?=
M,7'_`)4>@?-O=&FWSMFW^R]5Q]_W/:@#;>YPJ_SMF$?8F+C[?<+T'(VYN<$D
M[LF*!Y`Q8%A[UF!0?0V_N46ONB4KA;C%A?3X,B@^'=N[H6+#<SM[\U0XBO+;
ME\`?3H,?YI[IX?[2@\+&^.B?F4'TC:NYDCCN%M?/B<=&]'N$4`[5W/P_VA0+
M<_X.C<??H'S6W-_O`W_JZ-^;0!M7<UK?.%'O_)T:@.[9W"$:EYQE2$V*TG'L
M`*`Y@G5POZ102FU!S01KMI^(.!_8;?Y%!):#0[L^V8+^=6/N;E!OJ"/-[P#Z
MWQ#P^0ELQWW8QD-(8Z:EL.%MS3K>0JP6DCE0?$C>:X[D=M[`Y1*Y3G1CC1&.
MI80IS3P?X>1M1X^B@[_G/,_W>RG]S%_?%!C8W?(R4%F="P63>BOC4TX$1TW%
M[<E/@^%!D?.B9_N]E/[F+^^*#H@;U5/A,38F!RCD:0A+C+FB.G4A0N#93X(^
MC0<'?%I_R?\`(.4]<Z/K'2#<<_%:M&J_7M\+PO0<S=ZKA17Y4G`95$>,VMYY
MSIQU!*&QJ4?*^3P%!V'=TH&WS<RQX7N&XY'W>@QV=^]:1(CM8#+*?B%*9#?1
M8!27$ZT\WO%/HH.9N^Q!C"3*P&6::*VF@>DP25O+#3:;)>)NI:@/HT':-X2C
M;_9O,<;<VH_C_GZ#KC;Z1(4^EK!Y4F,XIE^S#9TN)`)3P=-^"ARH#^_HK#\:
M._A\JV[,66HJ3%OK6EM3JDBRCR0VH\?10=PWBHE8^0LL-/P3ZLGS>]Y_R;4&
MUP^5B9?%QLE#U>K2D!QKJ)*%V/V23Q!H,R@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'1.!,9P)-E%/`_1H.^
M@4$:[9@C8&`!%CZDUP/O4$EH-#NS[9@OYU8^YN4&^H([L4@XF80;@Y3)\>/^
MG/#Q`H.[<9'REMP7XG)*L/\`N,J@WE!5>WNZ.V=KX?!8K/.F$P]C_649)9U-
M:R\M(9TIU.ZK(*M6G3[MZ"TTK"T!:#=*A=)](/*@TFQ;_,S"7%CZDQ<?YL4&
M-J__`"04WY88&WORC^909&_'0ULG/+/(8^3]5I0H-XC@A/O"@CN!_&W=/Z9#
M_<J:#C?_`/$+`YWR6+'H_P#$&*"24$?VD%!W/:C<_*K]O#ATVK?4H/C<UOG#
MM.]OXP?M?^;Y/*@D=!'.W7XD8?Q_!Q^2:"1T"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@QY^GU9S5RM^709%!
MPHV23Z!>@CO;<'Y@X"]KF"P>'+B@&@D=!H-U_;L"/3E6?J-.GQ]Z@W]!'-@F
M^$DG_P`TRG_J#]!V[DO\J[9YV^4E7]'ZPE<Z#?4%#JF;'C2MFPL]AVYV0R,1
MD0IK<AQJ0VIQXH2$-GIM%)X:M+FHBX*2.86[CMY;2RL^5BL9EXDO(0P>O%9=
M0M:=/`\`>.D\#;EXT'QL($;(P(-P1`C<^?VI-!BI'_Y.6?\`R1'[K509/<!)
M5L?/I',P)`'ZF:#?(^"/>%!&]NW^=V[#QMUX8%_V&V>'TZ#LWR0,-&)Y?*>,
M_P#4&*"0T$>V<$_PX02=66E:KWX$:18'QY4'QN;\8]I<_P!?R/\`T^3022@C
MO;L?[$X?]CC\DT$BH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H([W$R^7PVQ\UE,.V7,I$BK<B)""[Y^05H%]6F][4%9=
MH>Y^;W+N][$RMP*R./B=4Q#\G=%V6E2`K7(=0GI,!H@A"192O&@N^@4"@QYY
MM%<MSL.7'Q%!D4'R[]J7^=/Y%!'NVWX@;>O_`"?'Y?I8H)'0:/<X49>``2%?
MPFB][<`(SYOQ]Z@WE!&^WY!P4BPM_"F5_P#47Z#ZW.LC-[41QLO)N7]'#'RC
MQH)%0>?)F7V9%S>P8V7P3V4S"H4`XV0F46$-EV0I.IMD$=1:%V4>/Y%!/\1N
MB5.WZO$_)T&)#B0L@XT[&?CRW5+;?9;"ST@%1[A:KH5S)_L:"3;"3IV/M\7O
M_!T7B?TE-!CI3_\`DMQ5N6%0+^_*7[E!D;^4E.RLXI0N!">X?VAH-\.0H([M
M[\:-U?LF+^XFJ#G?(OAHPN1_">,XC@?XP8H)#01[9J2&LP2;ZLM-(][J6_*H
M.O<I6=T[22D^7UR4I0]Z"^/RZ"2GE01[MZ+;(P@O?\$:-^=[B_NT$AH%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H-+O3"
M9#.;4RF'QTTX^;.CK98F#5\65<+^4A7+APH()LCM;N+!;MQV8<;PN+A0HCT.
M3%PR)*%2TN!/34^73910M%P3Q]V@M6@4"@Q\A^M'.-C8<?HB@R*#KD_K=W\X
MK\B@C_;1)3V]VV+%/\&Q>!XG[4GT4$DH-#NC]?;<%M5\H/=Y1)!O0;Z@CFPK
M?(3UOY2RE_\`6#]!SN;^/]J?SB]_Z?)H)%0><W\<,GN+9C45]Z/):Q^%>D*4
ML^JK;1+<<0E;267%J7Y%6^,0+D7\:#<=J(TA?=G?$Y4%]EI2)#7K;X6XEVTJ
MZ>B[H2E(L.*"LGE;D:"V-B?B3@/YNB_<4T'6W;Y_R.'$8ICC?E>2[X4#N"2-
MCYRW/U)[]`:#=.S8;"DMO/MM+*=00M:4DI!";V)Y74!0:/;WXT;J_9,7]Q-4
M'WO4:L7#3<#5D\9SMQ_#F3XT&_H-!L\68RO$F^5F\_#XTT'3N/3\[-I@\_69
M=OVD[024\C01[MY^(V"\?P)GC_:"@D-`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%!CKR6.0^6%RF4OI6ALM%Q(6%N"Z$Z;WNH<AXT&10*!0*
M!0*!0*!00_O!(E1^V>X7HDA460F*=#R%*0H74D$!2>(*@=/T:"K>T#!QW<!I
MB;`#*)+F39PK*<F_+:@F)H3,8:96BRBI9!4XI7'PH/05`H%!C9*_J;EA<\+#
M^V%!DT'7*_6SOYQ7Y%!HNW=_F#MR_/Y,B?<4T$AH-#N@7G[<Y?QH.=_]#D^B
M@WU!'MAC^`7#:U\ADC]/(/T'.XP#G]K7(%I[Y%_V!)H)`>1H*6A[8PSL7:6X
M96Y)&*>1$Q#1Q$=8'K"D/V9UH"@M25*?*3P(`N:#.[9[GW?DMV;FAY?*-R\0
MV9:L3$^+Z[8;?`4%Z$:M*$NH"=2_'EZ`L'9`MLS`CT8^+X6_Q*?"@Z6TCY_R
M%7-_DI@$>!_"7K7_`"J#G?\`^)>9'IBN#Z8H*F[K0!+[T8)P.QT/0X\!QM,A
MZ*TDZICH/ED$*<_.MW/+QTT$_E2I[`WY)QTAJ'/:>93&DR5MMLH<$".4J6MQ
M*D!-U<;B@UT;<<O/[7BN2)L6=*A;AQ\21,QR%)BN*;DQUGHE3CQ4D=2VJXXW
MX4%E4&AV?]HRO\Z3?NQH,;<A/SOVB/#UB;^XG*"3*^"?>H(]VZ"AL/`:OA>H
ML$WX<VQ[U!(J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"C]
M\(![[X%1!'Q\*R_5D"YLYY>M\,IMQZGV7Q=!8SF_\+,<R&+QSSJ<U&8FK#*X
MZPI"H9T$Z5A(7=2@4@'S"@B_8W<NZ<\SF']P9,Y%YLQ.F.FPTEHK:4I:4I8)
M'$_9<?2*"TJ!0*!0*!0*"$=[B1VIW)8$GU46MSOU$V(]V@AG;+:4.#N^',5@
M=TQ9#*)2VYF8>C.1$.2@"^HAI14%NE/T^=!=5`H%!C9&WJB[^E'Z,4&30=<K
M];._G%?D4&C[>?B%MS^;(GW!-!(*#1[E_7^W?YS_`/LY-!O*"/;"`^;MQ]=-
MR)]%[SWZ#LSP_A[;7N3'_P!POT&]5R-!Y\9Q4+*Y_9BGTR"[A8&%EL+"X?JR
MU+6K@MN0XP\%`@64VI?/X-[7#>]KMN;4Q.\MPSL;FX>3FY=J0XF'$0^E<5H/
M:EH="W'0BZ[?;+*)^#PX4%G[-_%#!_S?%^XIH,-A5^XTY%O@X>(;^_*D_F4'
MWW`%]E9D>F*OPO05?W=SLB)W;V?C(3S[#TMV&J6EK2AMYI,LV2XM(2ZH#S6&
MLIX_!\:"4;FQV1R.#[D0<;%$N?)=;;CQR&U:U''QO!SR$CF`:#1;%P&6V]VY
MQF+R<+U-36XH/JI4VAAUYE4MG2ZZVE2REQ1N#J43P]%J"Y:#0;.-X^5/_FLX
M?2>(H,?<@)WAM&PY2)M_VDY0297P3[QH(_V[!&P]O@@@^H1^!-_\6/&@D-`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!16Y4[:1WFQB68F3B
M9I65C+6ESH>HNW;5=]&E:GK+3[@3J''S4&JV"MF7OW<F20\$F3$S$AYE,FX8
MU.(`1ZP%N:5#X2B4C2>7E`H)%[-32FH&>2M`2YU(NH];U@GXI1%W"/=])]/C
M0710*!0<*U6\O/PORH.:!0*"+]SY>/B;`SC^1AG(0DQE!Z$EU3!="B$Z.JGS
M)N3S%!4?8Z$K&[U(R\:2UE,@)Z(2!D$R(3"8;B4/LMM=5UU:TDA)6X?>H/0E
M`H%!C9$VB*-M7%'`_GQ09-!UROUL[^<5^10:/MX"-A;<O_)D3[@F@D%!HMR_
MQAMS^<__`+.30;V@C?;S\5FOV7D/W<_0=V?4!N#;*>-S+D$<.'""_P"-!OE?
M!/O4%!Q^W^=S.Y=BY=A,@8:/BL<K)=!Z.W=3"PXWJ9<6EQ2.'G.GP&FYH-WV
MW[A[CSVXL_CLHW'3&CQI+[#[01=\-/".E0T`*TI*5_#\WF%!9&RS?9V!/IQT
M3[@B@PX__N5D/YFA?NJ50?7<4$[(S`'/U<_DB@B'</<>Z</OK%_)LG'M0'C!
M:>CJ<C":[UIG2=!:<2J0M'35Y.FI-C<F]!\;Y=6C:_<DM+6TLRXJ"MLV59<2
M$DVXIO=)M:XORH-9L.)D(_;?$1YH<+R-QPK+>4%.J`DLDE9"G.*572./("@N
MB@CFR"#$RMN/\+Y']TKH/G<*;[NVH?L7IA_^D6/RZ"2+^`KWC0:'8'XCX#^;
MXWW)-!OZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"BMY*;<
M[\8DH<?+L>7`0ZTN4V&=!:6I'3CFSA45*5JMY1P43?A0=>'E[?7O3<3D'&Y9
M+CN-RKF8BRG(K9UK?:2XVTI+G3"T_&*U/*U:=-CITT&^[!'$7W$G$MR&H3;D
M-"&YGJ_7!2P0>IZLE"+\N8U>F@MN@4"@4"@4"@AG>7U;^C#<1DH=6RF+J4F.
M0ERZ5I*3J4E8`"@"KRGA>@K3MWC(,;NSADQ-S#=+2L5/G*=;<:<$63+=;6_J
MZ219+I7<:K&]^`H),CNSO:1O56V(&WX$]UET">_&R"UMQ&M0&I]Q3"$)7IX]
M-)*K\*"V*!08F4_6:_SS?+],309=!C9-81C9:R2`EEPDCB>"3RY4&H[>"VP=
MM\2?X+A\3S^T(H)!0:/<:4JR.W!]<,D2D6ORA2;T&\H(UVZ5JVHT?3+G_NY^
M@^MPJ5\Y]J@'RF5*N/\`N+U!(7C9I9]"3^104(WLW=,O);<S&$W%#PSBL-BX
MLF,B1IG.1SI'!+B%#05K\HOYSPN#0;'MILES";FW;E$Y;#R%2XTE"XF-=#CB
M"7E+0MU-@6[<0J]_`?6\0M+9'XEX#Q_@V)Q_S"*#$C_^Y60_F:%^ZI5!]=QD
ME6R,P`;78/'^V%!!.X^S\QD^Y.*RD;$R)3;*8`CRVE,]))8FEV1U'5_&Q=#1
MN%-<7/@F@S]X)8&V>Y#DH(]71*9<)<9]83\7"AJNMK6UK`*>17;\B@T7;64W
M+[8X>0E33A=W''4I;#*(Z"?7$6LTVAI*+)MP`/OT%V4$>V0V$8_(V%M66R:O
M?O-=H/C/D_._:P\"Y-O^U54$B=.EI:O0DGZE!HM@"VQMOB]_X/C&_OM)-!OZ
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"A]ROS'N^$!,IMQ
MM4?)0FVBR\IQA3*FU*;ZB2VD)4>)T:OA<;GE0=6.Q>Z,7OG=CN1QSD=F1B\V
M_C7I3[;@?2I]I1LZV@J2@)4D@*!*0;4&Z]G.1UX^X%@-A`<AI;#2&T#2(_UW
M20TE2KWNK3QH+CH%`H%`H%`H/ET-EI8=T](@A85;3IMQO?A:@BT7*;6PN[8&
MV,5C&8TC+19$TR(;3+301&4@$+T6)*B[PX4%$[IV+FL?O3'3=S8&+B]MG+-=
M2?@F&PR6EN_%K?<NN0EQ;Q0#=(3Q/C0>H:!08N2)$11'/4W^C3095!B9A13B
M)RAS$=T_WAH-9L`D[$VX3Q)QD._Z@B@WU!H]P`G,[:L2!Z^[>P!_ZA)YWH-Y
M01GMQ^*3'[*G_NY^@^MQ$?.O:8MQ]9EGZ4)W\V@D,@V8</\`8*_(H*.Q^1[<
M?.G9N-W%AP,XK%XES%9D+=(4X`"PTI*.`'5O\+@;<?"@Q^T\IYS=.]6$2ER@
MQ$D*RSY=<<;>G+?<"7&T.H:6WI9;#>GS<N?I"Y-F`#9^"`-P,?$%SS^T(H.B
M-?Y_9'CP^2H/E_[Q+XT'7W&&K9653:X4VD$>X7$B@A6_XNV<AW(Q;63W?,Q,
MO'^IOL81(4([JE/JZ:TJ'EUK4G02J]A[]!N,PB:O%[\3"QK&7E*FL]+'RM)9
M=/J4.X6%J0DA(\VDJ%[6O0:O;V5D9#:,%N3CH^+>@;DCPUQ8K2&&_BI"%!72
M:6\A"E:A>RU#W:#98O<6<<[CY;&/Y-;>-9G(9C050''$+!@-.E*9P(;:\ZBK
M2H$_3H)'LL)&/GV\<KDB??\`77:#HSP!WMM8$VL)Z@/2>@D?ET$AE$B*\1<$
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M%"C-LP.DMTI?4A;)=2M(TMZ%J7<DF@P\'NC.]R,G-P&Y-T1,9B69,>;`9Z,5
M+DEMN8KI-*5U04.A3`\HN;'C[H>CJ!08V0_6QXV\R/T8H,F@PLW_`!-/_8SW
MZ`T&#L86V5M\6T_P;$X>CXA%!NZ#1YX?PWMK]G/?N"30;R@\X]QLHY#VK@H[
M")8>E/STJFP9KK;[+/K[A=Z4%IUL/+M]>L:4^-!.MDF`N+L9>/\`6E152,@I
M+TZ4W-?</JS@4XIUM;J/,KZT$:>5A06?+MZJ]<V&A5S]`T%#,YK:S.Y]D0)6
M$=F3G86#2N8)+[;*EJ1:,XN.A"F'#&4O4"XI)\PM>@VW;F!BTYG=K\?.RLO-
MBQ7XLIJ3"7'+&I14$*D*6XEP_%\`/?\`&@M+:`(VGA`>8@10?U%-!TQ4_P"V
M^3/,G&P?H?'RZ#I[B%0V9D])LK0@`^^XD4%<=QH.;/>?;K^/+C3,A,-$J4T)
M0+:69*U%)6RVIBSJ7"DAW6/SG.@WF]L<_.VCW#BLMNON29;2`TPV75V]4AW\
M@!*D@<5:1?3>W&@U&Q<6K&;%Q4/I.,,?.="HVIE<=IQHR=3:V&GB7TM*M=(=
M)5>_A:@ZI&V=W.]_8F?1AI*</'=<;7D7GP^RII<73K;;6L]&RSI\B:"SMH?Q
M=+_G+)?NYZ@Q,[;Y\;6](1D#_P`RB@C&T>[,O=&Z,SM]S%IA,0FI2F9"G'"I
MWH.!G38M);O]<HA9X*3:_&@F.Q/Q(V]_-L3[@B@WE`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H*1]FA^6Z]OCKNJ<`S"M`42JW%RYXD\["@^<
ME/SX[XX^`^]DV\7\H!QJ(^K7$-XJR%((<(#=^*/+<*ND\J#1;1A@]PM\L&4A
ME\QLVE;D=M,537QK"FW.HQ9^]B/K`+@E.HDT$K]G6<[/8W%->F"<\\]$+D@&
M2HE70XA2I2E.$CESM:@N*@4"@4"@4"@B_=#$M9?8&:QKJY#;<EC251&527A9
M:2+,H(4X+CS)O\&]!7O;>;D<_O\`C9C+72_BL<YCX8A8R1%C%I10I1?>>4NR
MAI^+;'NVH-M@=[=CLG'C3EP\7`R#SI(C/1&O6$.I=*4DJ2V?,5#4"#09V7[K
MG!=Q96!SB8L/;S,-,EO()6X](UJ">#C+0<Z:;ZN*P.5Z"P(4V'.B,S(;R)$2
M0@.,/MJ"D+0H7"DJ'`@T'QD$ZHQ']DCEP^O%!DT&%F_XFG_L9[[F:#"V3^)F
M`_FZ)]P10;J@T>>_CO;?[->_<$F@WE!2<:/F%_(K^W$2AN1N)-#ST-Z`+PG,
M@X0EQB;P4.HD%*T\N5!)=LX%[$N[4COQ78LM4O)RIJ93K+SRWGVG%..J5'^*
M!6I=]*>`'"@L"?\`K&1^E+_0F@\_0HV/^>FV)$F4RR^W"VVB+!<3(4ZX74<V
MT-OLI4$*9!4I3:PGRDT$F[<[$P^$=W)F\?FHF33D8C]DQ@4N*2MQQWJ2$E:@
MA8OHLA"4\/306?M<`;9Q`'(0H]OU)-!B0U$[YRJ;<$XV!8^^_+H.-^7^:DZW
M/XJWZLB@@^\MY9_'=X,%A<>)IB34QTRPTI#D70IQ847&E-.*1P_QB5I^C:@S
M]P91[&;6[@9%DO(>CY#4V8SA:=U>J0PG0O2O23?[$^]086W\_E<_L3:N3R:G
MQ+=S<<*];0EM[2EY02%!#;"2=/UR4"]!&&9@D>TKT!*6(<=UQ6E?4\THP@A3
M2%)*K("4A5E63?EQH+AVA_%TS^<LE^[7J#"SOX][5_2\C]R:H*>[/QU([H;N
M=*2B&EO(?)I=<4H.`20EXL'X"T)4D!6GX/*@NW8E_F1MZ_/Y-AWMQ'VA'C0;
MR@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%%^S#;7OA04%).9
M4D<.((+E[_3H)%E-HP4]W\/,9R4Z=D'%.Y&1`>*7F8<9"%MA:%J(4RAQQ80E
M`!U<?!)H-EANU#V,SN4RGS@ER!D&)K+,=:$)$8S7$K+C2D:?,G0/#CSH,[MK
MVY3LB-/CHR3F0;F.-K;2ML-AE+:-'30`I7E\0/"@F5`H%`H%`H%!">]/6/;'
M.-LO%AQYME@+&H7ZTAMLH)3Q`6%:3;TT%==KX:X'<G'%IK&XR/)@9.&N'AV9
M++;ZL9*0PI;X?*@I2%A6A?,B]^=!I-J;[S<+=D7;&)W,]$VC$D!IM]_$`JD*
M=D$=&.&VW"$*6HI#CBA[WA03[N+M;&Y3=+9V[DY$;<LR1"8W/`QTX,.N8J^A
M;SS&J_D;6`E0'(^-!9N)Q6/Q&,BXO',ICP83268S">24(%@*#LFFS!_/(^JL
M4'?086;_`(FG_L9[[F:#"V3^)F`_FZ)]P10;J@T>>_CO;?[->_<$F@WE!YOS
M#^UV<GM9S<$<RH[D(L2`9RH'11(RJVTO-=-:%/%*U76DD)2@:KT%L8S&[=Q\
M_;#&W'4O8OK3UH<3(7+"E%DA=G5K=)LKPU<*#18?>,[+=R<GAG,FN0C&8Z?Z
MQ`$)R$EE1?9#6I2W70^=`.E8`X7/UU!#(T?,97N!LZ-'@,JAXV%A7964;C?A
M+>E@.Z/60"M+;@NG1R])L:#N[+YN1(=W#!U0NA&QTE01&;;2[?4FWK#@;0L\
M2JVI1XZO107?MC\6L3^PH_W)-!',GDG<=G]XY!M6E<'!1)#9TZK*;,Y8\OCQ
M3RH(CMO>NX=R[$W`YGUQW9T5V`+02A45*9`9=2$+2576-5W`5'2>'*U!O-U9
MG?C'=#"0<8S/.V5!KY26PPAQA2G%J'%U3"NFE``+GQER.5N=!WY&9FH>!WW)
MP;;[V6:R-XC<=(4[K,2(/*DMO:K`W(T'A0:[#9#<DW9FUWMSB2,P<['0^J4R
MF.M92XO2I+00UI01\'4F]N=!U+BYK&=YV'U8V7'Q.;D+)R:IJUQ77FX.E#28
M;*D(02EDJU/!1X</"@G>SE!6-ED<CDLERX_]>>H,/._CWM7]+R/W)J@J'M)H
M3W,W@IO'R&&GF)Y;<=UZ&],E.M.E:0/C%'4"#_8\;7H+JV(`-D;>`Y#&P_<_
MQ"*#>4"@4"@4"@4"@4"@4"@\OR_:@WXU+E--P,9H9>=;1J:?)TMK*!>SWN4$
MJPGM1X@8J.<YBI)RNDB7ZD&_5]5S8M]1W7;3;G09P]J39Q_\)R7]RQ]\H.QO
MVH=FJ59>+R:$^*M#)_Z6@[_ZSNP`0/4LIQX7Z+/WZ@X7[3NP$*L864]PAADC
M[M0?/]:'M_?]8Y7]0:^_4'5+]J+9(B/&)C\FJ4$*]72XPT&RY8Z0LI>)"=7.
MU!"(?M0[T0\P9V.Q[C"EH,A+"'TK#>H=305.$:K<KT$\'M0]OK7]2RMOTAG[
M]0<'VHNWUK^I97]09^_4!7M1]ODBY@Y;T_K=K[]0<#VI.WG^A97]09^_4'/]
M:/M[_H.5_:[7WZ@Y_K0]O[7]1RMOTAG[]0:;<OM2XQ,1D[9QCSLLN`/_`"D@
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M6757UV'"]!?VX-DR)6X'LQ&W3*PCTEM+0;CLP`="`D$=5YA;J@56-BHB]!+<
M;%>B0(\9^2Y->9;2AR6\$AQU218K6$!*;JYFP`H.,A?U?^W:^Z)H,F@PLW_$
ML_\`8SWW,T&'LH$;-P(/,8Z(#^H(H-S0:#<"K;AVPF_.9(/CX0)'YM!OZ#S5
MNK-18>*V\EY8TQH#DB0V9$9EY]M[(*8T14R&'PIT:BI6I03I'T:"R=C1EQHN
MTFUJ84LO9%1]6?9E)&I"CI4[';9:4L<E:4VOXF@TNP-D[OQN_MU;@RF,8@8N
M;'EM1'F>BVMZ[P6E3C;1'-*20I2;^F@B*9LMCNELF&RU#(G0<,[U7&XKSH2T
MP$JU%T%UHZ2=&A2238@&W$)+V\VMO'!*WG*S6*;Q\>=">>:<;1$!ZPZ@(2M@
M!6@I3J"38#GS4:"P&=[;:VYM_;[69EJBKF1(R(WQ+[B5K4VD!`4VA:=1/)-[
MT&'G&)<C+;W9AMK=E/;?BMQVV^"U.*$X)2F_B21:@KCMY@-PX;MSN5.:B2XR
MW9>/Z`EM>KI4D.M:NFS<J!2M1!4?A</10;??>Z\C#[W[?Q3$QY+*U14.8U#L
MA*7DOK-W>FA]#2@WH/UGB=04!0;K<^6D8G9_<#(,OJ8>9R@"'PIQ!;U1X:-6
MII;2P$WO<*^GRH-7L?+3LOV[VE*G+=>>&?9;]:=<<?4\&G%CJZW%NDA5O!6D
M&]N%!J&9D.1[133+;<CUB/.>#[KDEYQN_P`GKT)1&<LVC4GZY'*W]E06GM;)
MX_'[=D2\C)8@QSD\D"\^XEIO4J>_8:EE(N:#`9S^.W#N#9V9QBU+@RV<FIE2
MDE)4$I;0>!Y<4T&@V#O+(Y&=FL-+R2YCS8R;QA+9U.0$-22TRR_(U)*BM-UM
M@H^#X^6@GNR`!LO``<ACH@_YA%!NJ!0*!0*!0*!0*!0*"H.^'>IO:D96#P*T
M/;DD)LZ]P4B$VKZ]8_RA'P$_1/H(4_V.[3#>^3>R.:=O@,<L%^*5E,F6ZZ-:
M=6DA:63>^OZX\!XT%_I[!]HQRVZU^K2?OM!]?T#=I@.&WFA_GI/WV@ZQV$[5
M@6&#`]Z1(]%O\I]&@^#[/O:D\\.K]LR?OE!P/9][4)4%?(RB1;@9,FWO?;*"
M*[&[`;'Z^?CY=M[+>I9$QXK[CBV"EOH-.Z=+2D@V+MKF@E/]7OM1_(ZOVS)^
M^4#^KYVGN/X'5^V9'WR@Y_J_=J.7R.JW[)D??*!_5][3@6^1C;]D2/OE!`<C
ML_M)"[A-;0.T72A1;#V15.D)2E*V5/!:6[DJ2-!3?4.-Z""=X,7V?8C8Q&QG
M+S%+>7-0VY)N64H%C\?Y1YR*"^$^S[VGL/X&/+_29'WR@Y_J^]J!_P"#J%_^
MTR/OE!T2/9U[5/)L,:\SPL"W*D#QO?BLT%/L=B>Z6"[B!O;JD^JPRN5C=Q.=
M/IALH*0VM"M7QWFT_!M]=RH+'P^Y9;.RLQ`8VDO&JQ[CC.31,R#!E&4LI*9#
MA*27%/+4%)6>"OK>%!T=JNUF"QD62=T3H&3F2\LK*1\<R\EQAE\!;:`JY`>6
MGJ*X$6!H+M!N*!0*!0*!0*!0*!0:/>^<P^!VID<OF8QEXV&V%R(P0ETKNH)2
MG0OR_"(Y\!SH(CL??F#R.YABE;81@\L]"7,BO-+A2`N,E20L*<BJ46SJ*?*K
MG04]MG..Q=PN[GA[H?\`E?+/X@S(CGJCCSZ9LU;3L8J*"4ICMMIN$)',<`+4
M%Y;^[?XG>F2@I=RGJLK%MN`QF@VXLI>=8=U*23J3^MP/HT$YH,7)?K<?IC7W
M1-!E4&LW0LHVSEU@V*84@@\1:S2CX4'5LW\4,'_-\7[@F@W%!'\^"=R[7\Q%
MI,I12/'\"=''Z=!(*"@TR8N,9P&5R<&)F,6C#S&TXUUZ&T^AQ,TJ7(*96G4V
MD%*00ORD\`;T$A[:1O5<;L5A,AB4U;*+CJBN)=;:94+H84XD)#BVPH(4NPNH
M&@BO:V8MSN/OA2Y;TGU>+.2PVZ\\X5H]8U:K*3I\I\@)L?0+4&4WM>?+WGL_
M+-8R4Z&8^#*)/1ULAEIAPO%N4D68#94DN(7]MY"U!F;2SORSN#>LMK)3,S$@
M89R*X]+3$TMN=1Y89;7#^+6-*>9\U!IN]):3%V>ZJ<8RV,8E32`VE:FR2P.N
M@@]2X^"0`.%_,/-069G&9BY>]50TNN25X"*B-ZL5)>4Z$S2D-%-R%7(TVH(M
MM_;61PG;G,-9*-.B/2I4!9;EJC!NX=81=AJ.Z^&QY?/J-U*XT&M[B3I#_>["
MXER0I3`>QCT>&VTVI"BEY2G"\^E(D-J0$I6A*2H$?"LF]!(MW9"5C]E=P)<5
M:6Y#>60&UK2ASX3,(>1MQ*T+7QLA!'F5PH-=V]2#L';;[2E.-RMR*?1(=0&E
MNH6\]9Q3:"6D%0')LZ/1094/:;3??)_.G/8MQ]94$8;IMF8ALQQJ2DV\KA5Y
MU*^$4^X:#YWEF<OB.U,B9BG8\>9\L3$I=E=#I^;(2.8DH6VHJ_M??H,KMTPB
M-C>W;"%EY)QV06IT@)\Z^DM0L@K38*40/-00SM+(`[A[M4M($I^)/<DJ*(R4
MJ2U(0VWZNMK2='!=QRY$F]!=^S`!L_!@<ACXMN-_\2GQ%!N*!0*!0*!0*!0*
M`2!04[WR[UIVFS\@X!Q#NY9*+O.*XIAM*!\ZA_E3]:D^^?=#S[CMD[NS6'3N
M]4%[+8N1.Z!="5R7GGU*\S[S2#K6R'/(KB+D_8@T'J3;K+V>S6)S4.,SCVL1
M',.?,B*NS+6$E"X;%@A*XS#GF#A3\(61]=06!0*!0*#A9LDGT>F@IKLEW&R^
MX/G3,FXQQ87E.HV8"`II/Q"&RDE:]6JS23]&@LWYPNC_`,)R'ZDW_AT&KB=R
ML#,RLS$QV92LGCU)1+B%#:7$*4G6/*I8U>7C=-Z#3P^_/;V;,B0HLA]V7/<6
MQ$92VG4XXVYTE(`*N!U\K\^8N*"6#<+G\DY#]2;^^4%,9K-[>D]Y<;)3MW,M
MY9R6&7GY"0AE;:(RVU=)E5E*U:=-]6FPU)XDT%%9]MMO>>1CL)=82Q(F,>J.
MQVV.@D.CII"$$W&G[(?DT'O1/(>]0<T$*8[S]L'Y:8C.X&%OJ>$<`)=T]52M
M"4E91I%U<.)H*DWW[1N[L)N_/8F''A(BXR4J+'4ZTI9(0@'4ZYUF[:E'P306
M?FMJ,[PP>"W0U'8^7F8\::S'>N8L@*0'?59*?KF]2KH)OH5YO2"$6W5W"W;E
MMP87:VTL2VU(6CKYN%.;2KH:%=-<:2D!24-:5ASJCX0MH)O06OMG%2,3@86.
MDRUSI$=L)=E+YJ5>YMS(2+V2">`M0;.@4"@4"@4"@4"@U^X1D#A9B<=#CY"8
MILI:A3%]-AW5P*'%:'+`IO\`6F@I;LA/,GN5NEJ*Q%P\6/&0E>$BHAEM+Y=5
M?0]&^&&^2E>-[*M84$)9PDJ!N?#-YF-&QNXDY>.B/';,-Q3[[TQ3\N4\TPEQ
M28Z&DI:81IX*5>@FO<S-3-J=SG\KA\6K&9;)1`VO<TQ$F;#D--M)4F,U'CCR
M.EQI*"3RY^-!=&V<AD,EM[&Y#)1#`R$N,T]*AF]VG5H"E(X\>!/C09&1)#"2
M.?5:^Z)H,J@U6[1?:N9%P+P9/$\!]I50<;12$;3PJ0;A,"*`>7)E-!MJ"/9[
M3\Z-L7-CUY6GW3ZHYP^E02&@\^+.W43ML?*;KC($6%U&P^RAE]+F7<#752Z@
MJT1WK/*TJ&JUE<!023MI(@R$;47#ZBTB5G^M)=6A:WW@\0Z^>F$H`=42H)2+
M)O;CSH-/VPRF63G=SX20E\1XL7(N-I<EAUM)]:58I92FR=>LV\QM;^R%!L)>
M\9L/)["VZSDEQT2QB5&"B&Z.JWTP7/PT.Z"G@-2.G[]!I.T4*9ZAO_+S)7K$
MF9&D(`TO:D!DR$V4ZIL,.F_BVZOW:"4[CD8-+VV(>7V_C\LGY'#B)4Z2Q&<;
M(Z2"VE3Y2%)4%$D?\-!+U21&W#N:0A71<8Q<)Q+G3+P2$^MD'I(*2NUO@@B_
M*]!76W-TS-S83><R1D5Y*,G)8MB,HL.1$("5,)6E$=Q;I;\][C5Q/'QH-ANS
M<.VHO>K$8E_;D61F)1BJ9S[I<ZC8NL:4H"+%2?K2%6%_-09^YY^.Q^T-]3<C
MBD9F&QETK=QKFH)>'2A^(2NVGF#:W#C08VT,EC<GL3:<S%XYG%PG<VCHP(^O
MIMI"W1;4L`J/V2@-)/+A01V+!DM^TCUWFSZB[(>7';8G,O@21!*2^[%3=QH%
MM)3Q2.-O-X$-_O9.VG.V;;.XV^MCG,Q+):,MN#J6B;)6D=5S\[\$&]!MMKRL
M3.D[!E8IEV+C58J>J'&D*4XZAL",D)4M1656\#JY4%:]HEQ%;SWA+]81(DN0
M<@IMEM2DAD==*W1TM-FM:G`+)/`I5SH+YV?;YI82PL/4(O#_`#*:#;T"@4"@
M4"@4"@4%1]].\;6T<><+A7TJW/+3S`"A$94".LOP"S]8D^^>',/.V&VUN*<]
MC=PS\:Y/A9>=:'ZX72C(OI4%+0XI(+AZOP4$D)4;W(2DT'J*+B6-RY%[Y(2O
M&;66V&,N(Y2VG(.H\G19+?!"&0DMNNH/G^`+@7H)_'CL1V&V([:66&DA#32`
M$H2E(L$I2.``%!V4"@4"@^7?M:O>-!1OLI@?(>YOYTO]-E-!>9M8T'E#/Y#%
MX?O[D\CGE196&??F)R3;8:EO(BIA%)0M%BZU<<"!;T4$ERF_/9RPH@S6MHNK
MEQ+*QZ/D]3"DAMSJZTK>*$'0M5^=Z#T%!EHF0F);84&Y#:'D!7!02XD*%[>-
MC041F</DF_:+QN1?CR5,O3&[3A#*(EA"4E#8DJ<7=83:X2`"0:"J^X6:S64W
M5&B9$!+D(SH[:1$3"N?64A2U)2D!2G+))(4>'OT'M,<*"DMW=WMR8CNE*V^W
M(91CV)&.8C1BV"MWUL-]2Y*;FW4\%I('@>-!16&ENF8RRD:Q(FQB\=/QH*9K
M12DJLKXLZCI-D@J^N/P:#L[IJP7S^WP,D)YR'K\@0@PZTTP06DA&LK2I?D7Y
ME:3Q3PH/86R+?,G;_H^38?`?I"*#R/FMW;@VIW?RV9Q>?;S&08E%MZ<DDLRF
ME<?574CRV1;1Y>"2FZ:#U3VW[BX7?.`3DL>>E):(;R$!9!<CO?8GTI/-"N1'
MT:"64"@4"@4"@4"@4$/[NOX-CMWF'<VV^[`#:`415])_JJ=0&2VX>""'2DZC
MP'C053V"B8UC>DR!-7+1F,'$D18S#C<93/2=?0](*ID:_7<"EI^$>`/#W`BN
M+F;5@[^Q.6VM$R.+B'(L2'GYBHTMI3<YQ<1M:4E7K(ZMUC2IPE/PB.%!/.Z.
M,QC6]9N4R)@92(M#(=Q;.;>QF4:"&@-265/HCN7Y@>4F@N+;+D-S;F+<A(<;
MAKB,JCMO.=5Q+9;!2E;FIS4H#F=1OZ:#)R`)8387^,:X?YQ-!DT&IW?^*>:_
M8$K[BJ@^]KIT[:Q*;WM"CB_ILTF@V=!H<Y^,VV_TV5^Y5T&^H*(=VYE<S"V\
MXO$SLAM]G&N:?DI4)#WKBY2RKJ.2U(<T)0`4I3Y;GC02C9$//Q5;+CY^$B#E
M&6\JEYIM++=T@H#;BTL?%:UHTE6GQH(YL3#;@A[@W5,R&/R45E>/R"2]-!,=
M2E2.J@1=7VM)"E>5/`@`T&/"VANJ;W(V7G(F*!PL3&P%RLJVEMMP%,4I*5+*
MFU.#S6M91`^E0?/:G;>Y,)A]YHRD"3%C/XU2XZI+)9"%Z7@ME&I1"[`)6I2`
M`5*)H/KNS@=T3VMLN8C'Y+(,IQ`:4()/1#HZ:T"2V!9U"RD!25&VF]!8F18D
M39>\H:&4NO.8B*TVP4!:5+6W*LDH4%)5=1M:U!!-@;>W-@.V&49S^+&+>>R<
M-]F$D@MZ#(C@J2D.O:+D<4^6@[MZ[9W9*[Y83,P<=.7C8JH:7I[;GQ`:U*ZJ
M`.&D>+G.]K>(H-UN_'9.=LK?4/'Q9$V3)RJ4HBQ%A#JT%N(%@$@\-(.H>(O0
M8NQ<7F<1L;:&.RT5V'+:S:DF.^K6I+=I!;`XFR0D#3;PH,#$[8W$WW]DYI6&
MDM8Q;T@KR;FE06E40(;TO)YL738,GDH@W-N`9>^]O3-P=M8N,8C/OQUYR2N>
MY$91(D-,(F227&FED%2M6E/EXV)\+T&]VQ'RS$O8S.7BHAY)K$Y`2HS26VT-
MKO%\J4,_%I_.IX"@@G;#$[@@9[><C)XB1"3D8TV0\\]`3&;#A4G2AE\"Y2H%
M1T#APU<Z"Y]H?BEA/V!%^XIH-M0*!0*!0*!0*"I.]?>MC9[)PN%4A_<\A%R2
M`IN&VKDZX#P*S]8CZ)X<PH#8>#@Y#<V/R6]6YLF!DWNM&BH;6Y*RCKBE`+%[
M%QGJ)LO0;\1>R.-!Z###BY2XV'4XSVQ9<4G(B."#U>(<:AE`*O4M?V[1R-P@
MZ-5!:45J*U':;BI0B,A"4LH:`"`@#RA(3PM;E:@[:!0:3/;D]1D-XS',#(Y^
M0@N1\<%],!M/-Y]RR^DU<6U$<5<$@F@[]O;AB9N&IYI"X\EA99G07P$OQWT@
M%33@!(OQN""0H<02#01_-]V=MXC>\/9LAB6YEIO1Z2VFT*9`?)"2I1<2H6TF
M_EH)B];I+/H!H*-]E`ZL%N<\[Y0>[_B4T%YF]J#Q-W1;;=[I;U<;2[H8&1<6
M='(B'I-]&I(3J^"56O?B;\*#1;YVOG-KPXS.27%*LDP[)2B/(0^H)(9LI83\
M'7J!2J]U<3;A03_?6\-SPM]R8*,YD8F,AXW&MLQ8;SG2#CD%E0`#:V@F[B]>
MLJMX:309';3>NY<WW'VE'S&7ER0I$1T07Y*GFU$05GU@ITA.M96203J!]-!"
M=SKQQ[AO^H,MH/KLD20T7SK<,L:G!ZQITI(/P1R-_"U![F/.@J_<G8V'G-_)
MW:YF7V4%^-)=QJ6T*"G(J4I2$NDW0%:!<:?^`*:P?:[NS!RT=I6!E,09$N&N
M6IM]GIJ$>0EP*=2EP@A/%0X7%!!>[X?5W/W<I/QBOE"0!J4.26D^7B00+<!]
M2@NJ1OO/[RQ&"[<=NG"'!C8B=Q;A02&8C(92E;25CCJN+&W'ZT>)`61BNRNQ
M(&Q5[/,(/PWQKE2UA/K*Y!_ZP'+>5:?K+?!'"@\XY;%[[[+[[0["<5TG"?4I
M9N8V0C`W+3Z?!:1\(<P?,GA0>H^WG<+![XP#>4QJ]#Z+(GP5'XV,]XH6/0>:
M5<B*"4T"@4"@4"@4"@Q\ACX&1A/09\=N7#D)T/QWDA;:TGP4E5P:#IP^"PV%
M@I@8B"Q`A)*E"/';2VC4HW4=*0!<T&F8[7]NH\IN4QMO'-R6G`ZTZF,V%)<2
M=04#;F"+T&RG;2VKD)2Y<_#09<IRW4D/QF7'%:1874M))L.%!LF&&([+;$=M
M++#20AIIM(2A*4BP2E(X`"@Z9XNRF_+J-?=$T&30:G=_XIYK]@2ON*J#MVU^
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MV7/G027YNY/_`'CR7]S!_>M!']IX">I_/Z-P9!%LJ\%%*89U*#+-U'5'/'WK
M"@;KP611)V\%9^>YKRK24E28?E/0>.I.F,./#QX4&V1!+DYS'HW=+7/:2%NQ
M$JQQ>2DVLI38C:@.(XD4&GVY`<A[<5+F[IEP8R9DU*G73`;;!]=>3Q4Y'YJ/
MN\^5!U9/!95>],$AK<T\J>A9%;4GIP5%*0J)P3:/H(5JYD'W*#8YW;>>1A\@
MXK=616TF,\I319QXU`-FZ=0C`\:#=[0_%/"?L"+]Q30;:@4"@4"@4"@JKO3W
MF8V?%7B,,I+^YWV[@\%-PT*Y.N@W!5]@CQYGAS#SUVYVW'W+W"Q8W3'E3<=E
M73(EDA>N0IT++3SZ@-70=<;4DE)\.-DT%_1W#-EQ,))7UM@-/>JXS/J39Y]9
M`:3CTN@`I9-RCUA-NH/B[^*@MAB.PPTAEAM+3320AMM`"4I2!8)2D<`!01UQ
M"MJ+4^P@KVRLE4AE`N8'`J4XTA"2M;*UGSIOY/A#RWTA)@00"#<'B".5J",;
MRW7.QB/DW`PE93<;[2GF8B1=#+*>"I#YNGR@\$(U`N*\J?$@*Y&W<DQOC"[D
MQF9.91*;6ZS%XM37IP^*?7(24*0B.A*^FO4`6$C0@:SY@M3;VWU8TRITM[UO
M-9$H7D98&E)+8(;::1]8TT"0@<^9)))-!Y[[JK4KVD<&C3U+/8G2+\19Z_EX
M'3SN:#TR_P#:7/SI_(H*0]E-!3MO<)U%2593A?W&4<;4%Y4'D7O'E=J.[RW3
M$P^`#&50QD4Y?*.R'5]928U]3306&T:5)XW!O[E!5^5;!B-RU+$M&E896XA8
M95&C*9;:81J4LEM)!`2'+6Y4$[[CNP$]SYC\QM'JCT+'A4)+JXX458V/T@EQ
M(64AMS2?`D"VJ@V^U'LKBI.R,M+8D.XQK&M_)_%ME)6N#I<4'2W=3>I(TI"E
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MZU:?`_E4'E.?CM\=FM]H7&?UE0/JTDBT;(1;_:W4\@M/B+W2>(H/4FP=^X+>
MN";RN*<LH'1,AK(ZT=T<VW`/J'Q%!)*!0*!0*!0*!0*!0*!08V0%V4C_`)5G
M[JF@R:#4[O\`Q3S7[`E?<54';MLWV[BS_P!C8^Y)H-C0:'-_C-MO]-E?N5=!
MOJ"M-O=P,+M;:VUX^=0[#@Y"(`SEK!<4/^97064DN)44C4"4:?=H-^,MC,SN
M/;62QDA$N$XQD2T^V?*=/20JUQX$$4%<=K"A68[PK1:RIS_$<N4F@DO<@E/L
M_3K6_B>,D\.%BEL&@S]H6'8O'^`&WQ[@_6IH)IB!;$PA_P`@U^@%!#\FL_*6
M_P#C;1B8UCP'_5Y1_P#\O007LWI1V#A<@#DVAP])R30M07CZQ'ZW0ZJ.MSZ6
MH:K<_@\Z"-[4DQHR-SR9#B(\9G+27'GG%!*$I2TT5+4H\$CQ-^5!SNYQ#C^U
MG&EA;;F794E:3=*DF+((((Y@T$#VR0KVD=R$\5""H:K<=(;@V%_<H-?WH`/8
M;(`B_P#"KO`_SF[03V#_`!_LK^99GZ&%0;7-;APDF%E<5&FM/Y!..D25L-JU
ME+0"FM1*;I'G&FQ-Z#+V@+;3P@]$"*/^930;:@4"@4"@4%5=Z.]$39\1>(Q#
MB']TR$#2CX2(C:O\<]X:K?`1X\SPH//O:W;>&WIOIF!NJ>^&\JE]]O2NS\M]
M(UCJ.*^!K%UI%KJT^":#T3A]OO[FDMIG1XB\;B4KQYW!&:#3^3C)L$L,E(26
M6/![0K2LBR/*306*]C8#L%4!QA!A*;Z)C:0&^G;3H"1R%O101['/O[8>9Q&0
M=+F&=4EG$Y.0YJ6A2M*&XDA:U%2UJ43TU^(\I\W,)505YN3/.[-DNX[#*$A$
MMHR$Q'$J4QB6RI0<FO%`*_52L_`O<$>3RWT!'\?CMV[?WRJ2S-^5QD6"<:VA
MY*SD2XA)<DS$A/Q*&7/,'4G0AO2TVFZN(6/MG:T?#F5->*).;R2^ME,@&TM]
M1=@`E"1\!M(%DIO[I)422&\H//'<C<)C]_\`#X[U#&NE;^,TS'HB7)"0MPA0
M+I!5?B-!3\&@]!R/M#OYQ7Y%!2'LHI`VQGU>*LIS\>#**"\J#R1DMN-;G]H/
M/[=D.B.SE7YD=R0G25MI,4JU-A1L5>6UO030;[>?LRP,9A'I)WDU&ZBRCJY1
MIIAB[Y"G/.WY]:NF+#W*"YL1M'MUG\5$G&#B\\0PU&7DPTT_U3';#7%=E<M-
MK$\*"'?T78O-[@SWJ<B4W\W7DQ<`T[)>7#CNR(J79"$Q[E"&]+R4!*4\+4%>
M=Q.QF>PK^*E[:P)GC6X)*(3JGUIT*;<;ZG40SP5I(U<?>H)SO7OEN7$X%XY?
M8,_'1YZ50FGWWT:2\^A00@:4$E1H+-RV#G9+:3$.,[ZEE6FF5Q)1'F8?0D7(
MX&QM=)]^@KSV@=@)D[$9R.,4MD;8:<6W";;Z@<;<TAQ=P0I"T`%>L7\:#*[&
MYC8>$[:XEHY#'8^=(0M_((<?:;=6\I:KK="E!5]`'/PH+"7O+:*(B9BLU!]4
M6OI(?]8:*"YIU:0H*M?3Q]Z@V<29$F1FY4-]N3%>&II]I06A:?2E220105UG
M>_\`LS#9C(8E^'DGG\8IQ$EQEA!;^)MU2A2G$:@B_&PH)1N3;.V]][6$/),]
M>!.:1(BN$:76E+1J;=;/-*TZORC0>5YD3?79C?;;[:RLJN&GB"(N1B7N4+\`
ML#PYH/$<*#U/L/?V!WK@F\KB7>/!,N&LCK1W;<6W4@\#Z#R(Y4$D!H%`H%`H
M%`H%`H%`H,><3TD6-OC6ONB:#(H-3N_\4\U^P)7W%5!V[<!&WL6#P(B,`C_-
M)H-C01[.KMNK;*+?"<F&_O1E?FT$AH*#BY>;AY>TLJC"2)R$XG'(;G1H#LU3
M+*GW_7D(6@*#:RWT[6\U!-=CYS-YSYKY/--J:GR$9B[:VBPH-)D(2S=L\CTP
MF@B'::_RGW>-^'KK_`<O^LT$H[E6_J_SK_R1&_(:H,W:EOZ"(-U:1\WN*O1^
M"GC0;F9M>1E_FQ-;RTS&HQ!1(>BQ5Z&Y8+:?BGQXI!3^3Z:#4Y7^,.X?\T1O
MW-)H()VEU?T!8_1S^6(U_>^56;_4H)&SVEW*.ZCN[7<JTK%JG"8W$27`X$!@
MM:%#3I/$CZ[PH-5OK=)Q.U]V8=.(G9-S/S<G%:=A,EYME18:0.N4FZ;Z[CWC
M0?7;_=.3SNV=H1<M"F1<CA\M'C/ORV/5T/D1)6@LBR;A*``>`H.[;%OZQNX^
M!OZFY?T?:X%!K.\`4.P$O58$Y-PFW+CDW306%$2!N+9@!X##3;<;^$*@KW8>
M.VRSE-QR,+BLCC#\CS&Y+<]MS3J*TKNEU>GB;E.FQ^#>_I"X]K_BUB?#\"C_
M`')-!LZ!0*!08N3R<#%P)&0R$A$6%%07)$ATZ4(0GF2:"H^ZGM"83#X1AK:$
MR/D\UDV@['?2=;,9E7#JNCAY_L6U6]WW0J_M7V4S6_1)W+GI3L?%R"IV/(=3
MK=GR2;EU25<V-7POL^0L.-!<D/MW%S&Y%Y*9M]K`/(83"R\N,0#.2BUFXN@_
M%,*2`%N$!Q2?B^`!-!9[##+#*&64):9:2$--(`2E*4BP2E(X``4'W0=4N)&E
MQG(TEL.L.BRT*Y'Q^@0>((Y4$`R&YLCM62QM)B0W/G2PA&%FS%DIBM*LVCY2
M<)U*.NX9/`O$:+ZKJH-=A9&[-N[@EX9.-:E2,@I;GKDIP.2<D_8CUDK;^TQF
MT%/4"T?%_:FPO4#03;:.T(6WHJPBSL^1YI4FVE(NI2PRPBYZ3#:EJZ;:>"??
MN:#?T"@\R=STMCVD\.M:]#GK&(Z0&D@@N$*)N;"WNT'I>1]H=_.*_(H*3]E)
MH#:>=<OQ7E5"W#AI8;_-H+OH(+'[/[7B]P4[YAO2F,HI;SLECJ!;#JWT%"B0
MM*E)^%R2J@C?M-@G8<*YZ;?RFT%R+$AL*9=3J)!3;X5K\J#K]GM4QGL],>A)
M`E>LSW8>M)*"NUT?8ZDZA;W:#N]G3<&Y\_@<QELO&8:CS<@X^U(:"DK>D.`=
M?RDJ`0W9"$V]!]%!:62R+&/BJDO:BD$)2V@:G%K4;)0A(^$I1X`4$)WQV]RN
M_L/#A9><G$MQI[.1;CQF@\H=$'2VXZM20566;E(L#Z:"P1RH.%`%-B+@\"#R
MH(3OGMELC<3Z,IN(O(:A,]/2B0N.PE&O6I2DH*05*3=!//22*"HO:!@,1-O;
M>DM-F#$?E/",QYFK1FX[;3+2U@W25M-E7FX^'.@MCL6DI[3[=%K`LNJ3P(NE
M4AP@C5QL0;B@\Z]PU9!W>^\(T5+CC:7LB]+:;*3>.@$K6KD4I;403=2;^A7*
M@]8;3_%7#?L&-]Q30=&\MG83=V"?PV89ZD=T:FG!P<9=`.AUI7-*TW_*Y4'D
MC+8SN%V@W:ZB/-<B.2&U)C3V4I,>9'2;@J;6%)UH)XI(ND\N!H.USO\`=V`T
MI0SRKA)/ZWC^`_2Z#V!MZ4]+P.-EOJUOR(K#KJK`76MM*E&P]TT&?0*!0*!0
M*!0*!08T_P"U-_IS7W1-!DT&DWP5#96X"@D+&-F:2D7(/07:PH,S`?Q%C?V*
MS]S309]!',Y<[QVR.-AZ\H^C@P!_QJ"1T%)CM]O+<6W=K3]OYEO&1DXAJ+D6
MR[*;5*;4HKZ:NB1I2+_"39?$B]J"9X7$.X;*[2Q;L>)&7&A9))9@!P1TC7'(
MT=4ESC>ZM5[GQH.C#=NV-I1=[Y%N<N8K<*GYJFU-A`9\CJM`(*M?VP\>%!M,
MGM5K<W;-.W%R516YV/89]92D+4BR$$*TD@'X/IH.).#1M[M7*PJ7E248S#/1
M@^0$*6&HRDZK#5IO;W:"28L6QD,'P8;']X*",C'(R6X-Y8_J])4V%$CJ<"0H
MH#K+R`NW"]M1X7H-)#V,WLKMC%VZF89R8^2A.&46PT3U<FROX(*N5[<Z"RJ"
M,;&%E[C]W-2OT+=!][P2#.VQ?C;,((^A$DT&!BNWBX/<G*[R5D.JWD&.BW`Z
M6DME26$J47=1U?K86&D<Z#29#8[F^>U/R`9AQZWYDAU4A3?6L6I[JK:=2>=O
M309._-LY/)/8[`X>:8$U>%GQXTX%:"G0[!X%3?F2%I3I)3Q%^%!D[5VIF]L=
MN\KC<OD!D)*D3'VPA3SC;#;C9TQVEOJ6ZI"+&Q4?&@E6V/Q:Q/["C_<DT&RH
M%`H!-!YJ]JS<+RLOB,$QDPJ,AE<F?BD<DNA0Z+KQ3SNF^E!Y<Z"NMN=F=\[D
MVI)W-BXB%1&5)<@QGTV=GA!NXII'`*0+6\WP^(%!Z5[.]U<3O;")C):;QV;Q
MR`W.Q*?($)3Y`XP@_P"*-K6^M/E-!8E!S0*"-;FW4N-D8NV\.IIW<N20M;"'
M5#IQF4CS27DW"E)3]:A/%9]`"E`*YVD_N!;^XL3F<"J8<ZZ6VHF01TY+[C9*
M'9$EW3I5&T:5!:+);X-M))XD-MD^V._HV1PDC;6Y>@&=`W!(EJ6I^6EMQ)0V
M%%+QZ:&]24(*N%[DE1*J"U:!0*#SGW1P^:F=^,.['P3ST)N1BUNY1B.^LV0Z
M"H*=N60$CGPX4'H>2?P=T_V"OR#0>3>S_>2'L/#Y''NXAW(KE3#*ZK#B4:04
M)0$E*@H\--!/?ZU^*O96VY2#:]C(;'#T\4T$/PWM*;@B[SR>5R+<B9MR2E8A
M8;6T@QU:DE'GT<=*0H'W_<H)8OVKL.M&E>V9*DJYI4^T0?H%-!]M>U;A[:$;
M9DZ$BUD/M$#T<`GA08V!]I':6$QC&)QVUYL?'Q$Z&$)=;4;$E1*K^*B230:W
M=?M%S=Q1T8W;>#FQ\J"[T7&U=9U.IE;?40TR-1<;UZT^`M01#9N^-][!S2\K
M.A9.8QD>C!5\M(E-MIUNZSH4HJ'4-U$7]V@]BWH(YW'R<O&;!W#D8;JF)<3'
MR'F'T6U(6ALE*DW!%P:"+]E8N4S&P<3FMTR5Y;(R%*E1'I*^IH:)TLG1P0%A
M(YVO[M!8ST>/(1TWVD/-_8.)"A](WH/M*$H2$(`2A(`2D"P`'(`"@\W[_P"Q
M/<3,;OS&1Q[6/>@37GW(ZG7RAS2^0OB"V=*DGAPYCWZ#T'@H3T'"8^"\07HL
M9EAPIXI*FVPDVO;A<4&>:"/[WV3@]Y8%[#9=O4TX-3#Z+!UAT#RNM*/)0^KR
MH/#>YL2YALOD\*XX)"\=(D0NJ@%/4+2U("@CCQ5;E0>\-JI4G;&'2H%*DP8P
M4D\P0RF@VE`H%`H%`H%`H%!BY#[4U^GL_=!095!HM^?B-N+^;)GN?]770;'"
MITX>"FX.F.T+IX`V0.5!F4$<S9/SSVT+\"F?P_S2*"1T&C^8NS+D_(D(7))L
MPV.)X^`H.#L/914%'!P2H<`KH-W%^=C:@^'.WVQW&PVO!PR@6L.BGP]-AQH.
M4;`V2@W3@X0X6L&46M[@M:@ZG.V^PW%+4O!0U=0:5@M"Q!\+<J#@]M=A%"4?
M(432@62`V!P^A0?([8]OQ<C`Q`5?"(1Q-N5S0<K[9;`6++P412>'E*+C@;CA
M?T\:#Z_HVV)8)^1(UD\$C2>'&_#CPXT#^C;8@!`PD5.KBK2C3J/'BJWPCQYF
M@?T<;&L/X%C^56I/`\%6(U#CP-B1>@^T=OMF-H"$8IE"$_!2G4`/>`-`:[?;
M,;0$-8IEM`O9"-20+FYX`^F@*[?;,4XEPXIDN(!"%G45)"K7`-[B]A>@Y5L#
M9ZTE*L6TI*A9225D$'P(*J#?MMH;;2VVD)0@!*$@6``X``4'-`H%!5/>SO,S
MLZ)\D893;^Z)2"4I5YDQ&B/MSH'UQ^L2>?,\.853V=[-3M[3SNO=2WW,&ZX7
M?CU*Z^3=!XJ4KX09!\?KN0X4'I+.;DVSM7',/Y>8QBX)4F-&*_(G5I)2VA*1
M]BGD!R%!2N^=JX[/Y1_N#VCR*%[HPZTN92'%NGKZAJU!!"05K2/,GDX/=H+*
M[5=U,3OS#]1M(B9N*`G*8Q1(4VKEK1JL5-J/+T'@>-!.A01W<^Y9$1Y.'P[?
MK.?D,JD(;TE:6(Z#I7(<`MJL?*VW>ZU<.`NH!66S,H]G]MSF7\&\G<&1R+CF
M*DO*4S.*XZ0TJ;*>`"F3&62DZ$Z+$--I(N*"V-NX%6+84[+DJR.8DA)R&36D
M(4ZI(LD)0GRMMIOY4)X#GQ))(;>@4"@4"@Z9ATQ'U>AM9_O30>>O9@FLX_:F
M[LE(:*T1I+3F@`:B`S?2+^/&@G_<K'M93;TB1D]HHD.QF[1Y#CL52VM;B;@$
M*N`2!>U!7>3VWA3"S$AK9C:%M'.I#A<CV:+*!IY*/V@W*;?0H-E,V?A$RV=.
MPF@DN/\`Q2'8_F",:E01\(`65\9[_NT$F[?S!B=WL;7@[58Q^)FXB-D7Y[+1
M"A*T64E]P:FUWY"QO06F&6?\FG^Y%!033*1[73E@`$Q+I`%@#\G`7X>/&@LG
MN]L+([VVY"QL"4S%?B9&//*Y`6IM26`OR>3CQ*Z#8G+;NBY/'1\@QCE,3GBR
M4QG'B\`&U+*PEQ"4E*=/F]^@ZN['_MCNGE_%<KGR^U*H,7LG_P"TVU>%OX/:
M_+H)O0*#B@YH.*!XT'C_`!*`KVE1=-T_.25?QXZW*#V"*!0*!0*!0*!0*!08
MN1%VVN?V]GE^F"@RJ#1;]_$;<7\V3/W.N@VF,`&-B`"PZ+?#T>44&301_+_C
MAM[C_BYWZ!N@D%`H.$@@FYN">`]%!S0*!0*!0*!0*!0*!0*#@"Q)]-!S0#0/
M"@J?O/WJB;0C.8;#+;D;G>1Q"C=N&A220\[X:OL4?1/#F%4=F.U#F_LM(W/N
M22J5AF9!Z[;CG4?G2DV*NJ02I+0N+W^%R'"@]5LM-,M(9:0EMIM(0VV@!*4I
M2+!*0.``%!2WM3SIL';&WYD%Y<:7&RR7H\ELZ5MN)C.V*5>'`F@Q/9GW!E]P
MY3>&6R\E4K(2?D[J/*0ELE*&G$(LE`2FVE/@*#/[L]JLI%RA[A;!6J%N:'=^
M;$9^#*2!YU);^"I:@/.@\%_GN82WM1W6Q&_L-UFD^JYF*$C)XY1\R%'AU$7X
MJ;4>7HY&@D6X]N(RGJ\N*]ZEFH!*\=D4C44$VU-N)!3U&7+66B_'F+*`(#MP
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M9<1U#\5Z`%LOMD*0M)QZ?,DCPH+_`)29*H[B8RD(D%)Z2G4E2`KP*DI*21[Q
MH([A$SXN84SGU)?R[Z%&',;%HZV46+C;+=M3)'`J2I2BKGJ-N`=?=HV[7[I-
MN6+E'_FE4%6=M.T,_-[`P.51O',X]$N(AU$&,[I99"KG0VF_P102;^@?(_[^
MY_\`5_\`AH-/NSLYF<7@GYC&^\ZXXA;-FG'E%!)=2GX*5`D@$V]V@B/:K`9G
M>TZ;'<W5N?')C,-2F522IC6EY2DW0E3CFH>3X7"@LU'9;.(U%'<'<"5*(*B'
M^=OHT'W_`$-[@_\`^A[A_5_^&@Z'^R^ZB;L=R<^W<6.MS6/?%E(H*)V?!?QW
M?^!`?EN3WXN<>8>G/?;7U-EQ)=7Q/F5S/&@]FB@4"@4"@4"@4"@4&-/-D-7_
M`,LU]58H,F@T6_/Q&W%_-DS]SKH-KC?XNB_I+?Z$4&10:#+`?._;_#DU.M_<
M-4&_H%`H%`H%`H%`H%`H%`H%`H%`H!H*D[U]ZXVT(KF%PJT/[G>1Q)\S<-M0
MX.NVX:[<4(/OGAS"KNS'9R=O6:-U[H+BL"MPO)#I/6R3P5<K6H\>CJYGZ_D.
M%!8F[=IYCMMFY._-BQ^MAW@%;GVPWY6U-I-U28R1P2I(N2/#WKB@LW:6[L%N
MO"1\SA)`D0I`]Y:%CX3;B>:5)]%!4GM;KT[.PI]&1)]/$1W#RN*#4^R$DI1N
MJX()7"X&X/P71R(%J#T704?W@[;9;"90]S-AO)Q^8@!3^6B)"4MR&@/C'-)\
MA)3\-/UW,>;F$J[>][]G[HP+<N?.C8?)MV3-A2WD-`+(OK94X4ZVU<QXCD:"
M5JWSLE-M6X<8FXN+S&!P_NZ#E.^-ED@#/XTE7$`2V./]_0<KWILY"2M>=QR4
M#X2C+8`']_0=8WYL8_\`]18O]NQ_\.@[6=Y;0>!+.<Q[@',HE,*M])=!EPLY
MA9KY8A9"-*>2+EIEYMQ0`MQTI)/C094A]F.TMY]Q+3+8U+<60E*1Z2H\!015
MON9L#)MY&+!ST-Y^(TOKM]4)MP4G@5:0KS)(\MZ"E/9KS^TX.V=R8_/Y&-!:
MFRFRB/)>2PI318"5%-R%?1H)CO[??:F+B)$%K/OS)C[04TW%FRY((U@$**7%
M(!M?@J@A"M]=O(N:CYZ%D9KDV!(R#S#3Y??04&4VXV4ATG2MYG6C5Z#YJ"]T
M=S>W:PG3N3'74+A)DM`\?2-5`<[F=O6VU+.X\<0D$D"2U<Z1<_74&@W9@\QF
M.WL[)8;J/;HR++4N"ZR[T74(ZB'FX[+EPE*0V+$7TK-]7.@I7L_DDR^^.(?Z
M@.G%E$I2BD%+J(A0M!T\+I7P-!:G?;NK\V<;$QF#RC$?.RI#0E(4D.EN"Z%H
M6[QX"R@+&]!C;+V!A-L9MK+J[@(R2"I*UMR'FB5A"5V"7%O.:0HNJ4NW.@E'
M=+/X&5VUW.PQDXCCKF-E(0A,AHDJZ:A8#5SH*XV7NCMEMSMUMP;CCY%B0N"A
M2G+30VL!.I2V]*TH*+>*1:@L#%S>V,^(9;CK^,0EQ+:1E)4N$X5%I+J=`?=0
M3=M0/"@[=P[;V<]CXYB.*>6N5!?3TITAPJ;<E("7/MJKI5X*^D:#>IV!M9/P
M(SJ+?!TRI2?2/!WW:#O^9N!YZ97'_MLS[]0/F;@?L97[=F??J#C$8R-C\U-9
MBJ>Z!CQUEMY]Y\:RMT73U5+TW`XVH/+6&L?:7'I&Y)?W1V@]A"@4"@4"@4"@
M4"@4&)D;%#(_Y=G]&*#+H-%OS\1MQ?S9,_<ZZ#:XW^+HOZ2W^A%!D4&AROXW
MX#]*G?H6J#?4"@4"@4"@4"@4"@4"@4"@4"@4%2]Z>]4;:,=>%PSB'MSO(N2;
M*1#0KDXX.16?K$?1/#F%8=G>ST[>TX;JW3K5@E.J>2AZ_6R3NK45K)_Q&KF?
MKN0X4'J5EIMII#32$MMMI"&T(`2E*0+`)`X``4%#0>_6XY2RI4O!I<1E$8]S
M"*:E)FJ;<EAC6VHN=-?Q:M9('#T4&TW=M;-]M<[)WYL:,9&%DD+W3MA%]*TW
MXR8R1\%2;W('+\[>P;'>NW<5WIV9AIVWLFPF,Q(,BTAM;B22VIM;+J&G&G$+
M057X*^I09_9_M3*V$<PM^7'DJRBV"&XK;K:$!A"DDDO./+4I:EE1\U!84N7&
MB1GI4IU+$9A!<>><(2A"$BY4HGD!04#ELCG>^>X%X3".N0.V^+>`R>3`(5-<
M000AN_/TI'(?"5QL*"<2?9S[32'$K.)6T4H0V$LR'FTV0G3J(2H>8^)\:#J'
MLU]I?Y.D?MN1_AT'/]6SM+_)TC]MR/\`#H.B9[-':Q45T,0)*'RA726);YLO
M2=)L5$'C058S[..;R$^*K$NMG`NEH.9"2Z`\D!(,B\=";A2'-383?F./"@LS
M&>S!VYCP4L3E3,A)N2J4IXLDWY`(:TIL*#0Y7;FRNT?<7:4_$PGG!F#)@2.I
M(4XL%Y;"$+0E0-].LW2GB:"V]\P(&7VY(P,RZD9DB"E`^$2LZE$?G4)*OH4$
M)7[,W:Y9%V9MA\%/K2R![UP:!_5F[87OTYW[:7^900??_;?M5L^?%ANXK(S#
M-;2IEU&02@)670WI<"_,D<>!`.H\`*"<?U:.V`X!J=^VE_F4&-DO9R[8QH,A
MU*9J'$-.+;)E*^$A!5>Q'&UJ#C&>S?VUE8>&M]$U;CT=I;J_65#4I:`5&UO=
MH)6UOW9.WL8<8EYQ"L*R\PSC[:Y3C&,LRXMM-_.$VYD@GB:"B.X/:.<C?N0Q
MFUL%)R"9#1R#;RGBA"/621P47&TE(?U!0T^5-CQH+!V_[+NTV84)W-SILO*M
ME#LI3+B6F%+0K6$:"EPZ4\OA<:";[][6XW>'R8EV?(Q3>,?]:0F`EIM2W0+(
M45E"E)*.-M)\:!MCM5MK!;-7M:6#F8+BW79#T]*"XX77.JK44!%K*XBU!F;D
MP.Q'GVY6:Q4.=-*$,1&G&4//+2TOJH::00>&LWY6]/"@I;VBX+\"%MN7D`A,
MB3*FOR`DJ"$>1D-1TK!\NEIL)N/$$B@U>$A*5NWMQ-<:D-@XJ#T9;*G4,**L
MDNZ7TE*KI\]TA2A>X)Y<0]3"@4%2;KWEG\9WRPN'8E.MX6;%CHEQQYFM;K[B
M4J4%(<TDD)1=.F]^)H+'B_C+D/V+$^Z/T'E+"'_]E`1QON27]T=H/80H%`H%
M`H%`H%`H%!C3[:&K_P"6:_1B@R:#0]P$N*V)N)+:M*SC)EE>CXA=!MX'ZQC?
MI2/T(H.^@CV6(^>NWAI)/J^0.KP``8!'T;B@D-`H%`H%`H%`H%`H%`H%`H%`
M)M05)WJ[UQ=HQU87"N(>W,\BZUFRFX3:A]M='BNW%"/HGAS#S[CMLYQJ'`[@
M;GQ$K*;/=FAW*NN+(>?;4K[<X#YRVI9X*Y*M;@"#0>R]NY?"9C"Q,AA'FG\6
MZVGU5;(`0$)X:`D?!TVMI\*#8T'A+"+OOA*2I8/RNTH(3Q0?PU()5<^`/#@:
M#W80"#PY\#04/OB&_P!I-U-[EVAI<QF9ZBLSM(*(ZG3&I4F*GCIT:KD#\CD'
M9L3NW$S^ZH6.RN,=G*R35HF<96\\PI15I.F,E`3':XZ25&Z5`ZB>!H)3W%[3
MYC=;4#%0\\]!VRI\.9G'+6MQ3C:;:0PX;J'(^11TWX^%!/,!@,1@,5'Q.)BH
MB0(R0EIEL6]]2CS4H\RH\30:K-=P=NX?/1\%*4^K(R3'"$-M*4@>MNEEHJ7P
M2`5@WXT$EH.;4'%!IIV-D0Q*GXR0(SBP7I##B.HRXI*2=6@*04*5;B4GCXT&
MB[0;WR>]-F-9S)1V8TI;[S*FX^KIZ6E620%E1'#W:#MWOL(;ES&(FNIB/QL<
MB0AV)-:6ZA1>4TM"TZ%(.I"F?30;Z%A$M33D);RIF0*.FAY8"4MH/$I9;'!`
M4>9XD^)H-G00CNMOF7LW$X_)1]"^O,$9QEQEUT+"VUE("FN*#K`(]/+F:"IN
M[.?D9.;M)^6T$.R,?!?4_P!!E2'')+B%+#5U%ZP5P\.G\+C>@]'GG051[0.W
MLUEL9@G\5"F2E0)KCDQS'R1%=:C.,*0X=2N%CR)\![]!/XN5Q6*PF..2FQX2
M%,-(0I]U#25$-C@DK(!^A01B9#[/K$R3)R.-,B0)9<G&6P9#:)A*GTM.:M2`
MJYX"@^%Y79^Z&V)^5S\6+'!#L")'G-QGT-J'`O/(6EX*6#=2`0!R-S03/&YW
M`SR6,;DHTUQI(UH8?;>4D<KJTJ4?IT&PH(AW>4$]K]T*/ACG[<;<='#C08?9
M6#"3VUVY.2RCUR1`:+\K2"ZY<?7+/F/TZ";/Q8TA'3D,H>;^P<2%#Z1!H-5N
MA`&/BH0`D>O00E(X#]<M\*#=#W:!04/W$QTI7M"[4F*9>1!)AA<Y3*BR'$K?
MT-!T(*?,2."C>]N5!<D46W)D#_V6)^C?H/*>#(_K(IX6)W'*X>X7'*#V#0*!
M0*!0*!0*!0*#&G"Z61>WQS?Z*@R:#1[[M\R-P7L!\FR^)Y?:%T&VA7]38OSZ
M:+_W(H.Z@CV5/^V^WQ;_`*KD3>WH]7\?HT$AH%`H%`H%`H%`H%`H%`H%!Q>@
MJ/O5WL8VHPK"X)Q#^Y'4W><-E(A-J'VQP<BX1\!'T3PH*I[3]KX.X)K.Z-]2
MT,860X7X42<Z$/Y-PJ'QJPLA2F=7]W^=YA>7<?=:=OB'C$,0UPYL=Q+D22D=
M-2$2(S&@(-DZ0V^OA[GN4%4X5[.]JG1NS#:LGVVRDE]&6QS"^KZ@M,A;2'&R
M2?+9(X^/P3]::#T3A<SC,UBXV3QDE$N#*0'&)#9NE0/Y!'(@\10>)L1C))W5
M'R'1_!_E=L=92F[?K]*`4@J"]6JX(">7'E0>YC05YW!V5D-W8K)LXN>8F59D
MM]`*4$M*#2$*0VXO0XX@>=2TENQ"C>@JS;?8_N;!WW!<#K>&QK2F9T[(P'OB
MEN)/QC;3-DJ2MP>58L$'GZ$T'I84"@HSNBN,YWDV^GXTR(Z\45'0"A*')Y``
M6+V2HCS7%[A-CS!"]*!>@K'N+W"WMBMZ8G:6T\=#FS\K$<E)7,6I('24JXX*
M0FP2CTT&"_FO:-=BJ87MC#$N)*%N"40"%"Q('4X4&@V!BN_NRMO(P4#;>.DQ
M6W7'DNORD=0ETZB#H<2.'APH))\XO:,_W4Q`_P"]?_-H!W#[1@__`*5Q!_[U
M_P#-H--NON;WSVKA'LUFMLXIG'L*0EQ:)!<5=Q02GRI<)YF@RN_#Y?V_MW)/
MOAJ"XI:W([@2MKJ.1E+0X6U-.I<+8U63S/UHU<@C&X\]NO'.[9Q!R:4[?RV*
MP_0B`-$I7=MM847&5.#JD>72L>[:@V>Y^^G<'';ISF+B8.&C'XJ0XTB;,3);
M0M"562HN<$$JX'AZ:".Y#VBM[S(<F`B/@EOR&EM!EAYUQ\]1!'Q;842LV-!&
M]P[PWWOB3B<'D=G1YLR`!'BQ%QI(>0X4Z5]50>:Z5THXZB!PO0;9SM'O,P9#
M+G;#&F0Y=+4F-/<;<;N+:DA<MQ)*>)%Z"O,KM%Z`^Y'E8MJ%)*EL@/9%HD/)
M&D\Q992>-@:"7>SZRY`[N85CI-MK=@R@X['<#B7FUH4ZEQ125)L+)%D\.`\:
M#U^.5!#N[<'<.1[?Y?&8"",AD,@WZJ&"XEJS;ITN.!2BE-T)X@$T%5;1[K;J
MVQL-6&1MM$R1M!@Q,W(3-;2B*ILJ2@N>525K5I^`VI7'A<'@`([]=R(O;[&;
MF&`AY""TE4?-914DI*93;G1`4PE*%)4Y\*R=0L109V5WQW^R#6-0C9$9M+[[
M$Q@HD)<+B65I=LKXP=,'RW*J#)F=X>[&"R^&C;IVA$QT/+3&X:'D2NHHE:@%
M:="E\0E5^-!=U!5V]-M[:/=#!;@R&X5M9%#T1B%@&^FI2EE;@0YI*@H(.HZE
M:3;C]`)]&/\`M%/'_9HI_OWJ#RCM71_6-:U)&E>X)JAQ/!6IX\S[HH/85`H%
M`H%`H%`H%`H,6?JTL6M]N;O?T:J#*H([W&64;`W&H&Q&-E<>/^15Z*#>Q1:*
MR/0A/Y`H.V@T.12D[SPA(XIAY!0-[?71AR\>=!OJ!0*!0*!0*!0*!0*!0*#7
MY_/8C`XJ1E<M)3$@14ZG7E\O0`!S*B>``YT'GK<7M1Y>3C<E%Q&)]0DO+T8S
M(N+"RVP00IQQNUNMRTI^#QX\N(:SLIV7E[LE(W9NI+AP:G"_%C/DEW(.DW+S
MQ/'I:O3\/WN82'NO`5D.XJ)(=;2QMQ['1&HWJCILA]3#NE+S3"F4@*7=(<=&
MD\J#I]IZ0VQNK;ZEL19"%QNDM$Q`4WI7-9)\QOHOILI0^M)H)-[,[4'(=N<N
MA<5A4&7F9X,1*=4?I.!'Q:4J'VO2;`$<J#438.?[(9]_+8IES(]L\DZ#.@I)
M6[CW%<-:;\DWY'D1P5QL:"U-OX7MKF(T7<&%Q6+DMOGKQL@S%8UZPJ^K4$!2
M5I5S\0:#?97*X[%8]_(9*4W#A1QJ?DO*"&T`D"ZB?=-J"K-@]PLYO/N7D)>W
M\<&MDQVC%R&2?N%29#.KHK9L;7\W+[#X7&PH+>H%!YLF=T>X^X]B9F6RM;&2
MQF4AB,K%H6@^KN!T*+NA3A(NBZDFQ'"XXT'7F77).^>WK\Q?7><@[?4F4I5_
MC5OE;@4O4+K<XJ`(5P!Y4'ICA0:;<LG(LL0FX#WJ[LJ8S'6]H2X4MKN562KR
MW\OC057N`NP/:+V;\IY(2`YCI+;;KJ6F?,X'4H;&@`**E#AXWH)UVZ[CL[U^
M4G&,8_"BPG$MLR7;J0]<J20#I2`M&CS)!4!<<:"9*4E*2I1"4CB2>``H/EMQ
MMQ`6VL+0;@*201P-CQ'NT'W053[3:RCM#DR!S?B!7O==-!B]UMV9W";<V]#Q
MJT,MS(RC(=TI6[J:CW;0@.,R&T:E&^M0'+F.=!&]V9K.P(FQ\:TIMR!D,=BQ
MJ6B+J9&IE+B6RH&0=6FY(X<;<Z"3[G[8=R\]*<&7W)$S>&7;^`'6I&.B*TJU
M`.F(XIQP7"?AD^]08^WH6X,7,98P&Q,3ZGC'>K*EXN8EM,AXMJ;"6G)#+:EE
ML*\UU6O87YT%>[0[T.;9WKO;+9O$SWVI4D(]6CI968SB7G;(=<!0FU@?,+CA
M06_MCOOL7,XIJ=*5(Q"G5J;#,MAXIND\P\VA;1!!O\+WZ#01]Y=E=V9J9@<Z
MY#G-0'W7,3+GV3'4)2@MY##JB$:DK%O3IM[M!\A&/7[1^#^3PW\GQ]MK3#,8
M)+/3"EI3H*?+I`)`M[U!=`O:@&@\]]L\=BLAD>\$7(LM2\:F>M:V9`^+46G)
M+H4H&W!*T_4H.[$;!RF[>Q&,P&WL="PT?*QHDR7.DK6E3\@!"G'0TVAP^?1\
M)2@3Z*"V,OC7V</%QZ1*4CU)R`Y)@`%]HK92VEU%R""-)(/@;4%(;^VU)P;&
MPL6J9E,A;<:7E3LLGS7>Z8#:5:E6'D)`]^@]*T%([^D05>T+M!M]U:`RVV4A
M`U_'.J>2TDI<<T:%`&ZDHU`VY^`6S%5_M+D0?"-$_1O\J#R#$W%C=N]ZY&>R
M0=^3\?F9SL@-H"UA.IU(TH)%SJ50>SXKZ)$=N0W?IO(2XB_`Z5"XN/HT';0*
M!0*!0*!0*!08L_DQ^G-_DT&501SN1J_H_P!Q!)(4<=)`(-B+M*H)"RG2TA-[
MV2!?Z%!]4&CG_CGAOV%D/ND2@WE`H%`H%`H%`H%`H%`H%!I-X[1Q&[,!(PF5
M;*XK]E!23I6VX@ZFW$'[)*N-!YDW%[/F_P#$8S)Y"S$]B`Z>BW')+\B-:Y?#
M7$)*?%OGSM[H?/9OO1+V9);Q.:=7)VG(/D7<N+A*)^&V.9:^S0.7,#F"'JYA
M6-GQ4R&>C*BRTH>2ZD)6AU-@4+OQ"N`%C0><_:L<4,[B%)L5,05/GRN*TZ);
M>D^0$)X^*K#Z-J"8^RLI:^W$U:R2M>8EJ456N2H-FYT\/'PH+/W,^RWB'67(
MR9BII$1N*XG6VXMZZ;.#["URKW!0>5^WW<U?;[/.)A/>N[5DR5MY+&)2MLLJ
M"R!(B-O><`#X2%<?!7@J@L3)9S,][<J<!M_JP.WL-U/RUEEHZ;LIQLZTM,@^
M%P#8CA\)7@*"1]MNW&3VKO;*]%,R)MIO6G%,J?2\PZAW05=0%PK!0I!4CR?7
M*XT%KT'%!YJQN=QD+8TV'@,6OU89*&ZN/NH1WXP]<]8*WD**&TH0H,\'5%0X
MV'&@DL^5CIFX]CONS!%RZF<,XO#,8\);;2M6K0))MT6CJU=/CQ0.5!(=N]PM
MQY/N]D]L/2("L1!1)Z;$=#OK(4RIL)ZJUV3<=3S:>%Z";;D6E+F'!%]>1:2.
M%['0X?RJ"G>[>.R4WOIM!O'0VYTUB$93$9YXL-J7&=<=25+`/P2F]O&@N/;>
MTL!MUE]O#PTPD2E]60TVMQ3?4))44I6HA-RKZT"@P>YR8I[>;B]:0I;*8#ZE
M)2M+:B4H*AI4JZ0=0%KB@B_LY-NH[7Q>JVXVZN5*6YU0$J4M3I*C8$V\WI`/
MN4%GT%3^T^LI[09+A>\B(/\`GTT'9W<Q,.=LW!)7D8^+?:=96Q(?2MQQ01'4
M5MM):2IQ14F]]*D\.-Z"'[PQ<23$V'-&1QS$R%C,.OY.D)/KCS:GVDW84?*J
MQ4>%KI(OPO09O;5J3F.\/<*%D5N2\0R^LF,\\Z4)<]84AL);U!.G0E0/#T4%
MY,LLLM(99;2TRV`EMM`"4I2.```X`"@\OO=F>XTQS=3;.'Z2).48F1!*EHTO
M-H?>6M.H$]3RN@ZE6X73;G071V7VIG]K[(;QF=;::R!DOOJ:96'$)0XH:!J'
MEO8<D\!X4'8>S';A[.3\W/Q",C/R#RGWC,)>:2I8L0AD_%@?VMZ"OAB<=@O:
M6P..Q39B01B5(:B(4KI(;Z3WQ:$DD)1Y`=(X4%]>%!P;T%$X7M_O#!L=PI60
MQ+<F'F9WK#;`D-ZI$1"WW5FZB0G[8CRJY\108&QMY=S=F;"Q>>W+#]>V?'QT
M5N!'A^K^L*2^$)96X2=?D3;T?"-^0H)@CVD^V:A=2YZ5``Z3#</$\QP]%!"N
MY'=;:&\<CLR'AU2%/L9V*\\)#"V@E&K3S5P)N?`T'HH>/OT%<;IV!N3(=U=O
M;NAOQAC<8GH2F"I0D%M065%.M+C?PB/@Z56\:"%=Y>]4G;V:RV"VXM*\L]'C
M,/9%"@I,0CK%U('B\`M%K\K\>5J#S9,>6XT^MQ2G'%A2EN.$E:E*N2I1/$DD
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M;>[8R\M-:+,#(+5(3)BE*'9'X5+.KJ?"2E;;C2M0^$`*"Y\!@,3@<3&Q.)C)
MBP(B=#+*/JDD\5*4>))XDT&QH(QG>Y>Q\#DG,9E<HF/.9;2ZZP&WG2A"[E*E
M%M"PF]O&@W>+RF.RV,CY+'O)DP);8=COIOI6VH7!%[?5H/)S4AN7V^SCR5*=
M*L_"2N$AE16S%2B0EII+*5);6BUU!MH\.-Z"RLM)VJ]OC:?3@NJR#R,0[`G)
MDI2PVRZZ%]$Q%+7H\J;H0A2N''DDF@D.V=G;QA=V\EFID9MO;SZ9BHKB)'4)
M6^XV4E3:CJ25!*KV%ARH)KNA!6]@S]CDVE']2=%!`=R`+]I#:8N;MX>6KW/\
M:.-!;=!$>[FD=L]R:@5),%T$#B>(MP]WT4&@]G=QISMTEQD*2PN=*4UU``NR
MEW4%>9:C9>H`J43:U!9+[[+#2WGG$MM-@J6XLA*4@<R2>`%!6?>;#;@WUL"7
MA=MX];[TAYAQF1(6W':4EMP+44ZSK(*1P.GC0:[OSC5-[/Q$H);1,A*Z2G>@
MU(=T]!14VREQ;9NI:!\"Y(\*".[R7MX0M@)E960QF3C<3ZGC$-J4RXGKL\5.
M#RHU<0J][Z1\'Q"/[=Q'<;*=UM_'9689Q+S.0=$Y3]OC$&0Z&P+LO_!(5Z*"
M;_,SVEK?CC!!\/@_O.@Z_F3[3@)MO2#;PN$_O.@[$[-]I@)`.\(!]*CIO^XZ
M#M.T_:6*;?.S&@@6^"/WK013;F-WO"]HK"M;PGLY+*B&XM,A@@(#!COA"`D-
M-&^K5?A0>DARH%!KMR=0;?RA;077/5']#8(!4>DJR038<?=H(EV<W)B\OLZ#
MBX@<6<'"A0Y+CB-*%N".D*T`DDA)21<T$ZZ#'^33_<B@J3O\A#;VQ2AL`G<4
M47``%[\+VXT%NW`O]&@I;O9WP1@D2-M[;=2O.J26YT]/%$(*'))'PGN/`?6^
M/'A05SVO["93>6-5F<U+?Q6*?\T%:4I7)E%1N7B7-7D/I/%7/E03M7LG;;4D
MI.?R&D\%#IQ^(_N*"\8L=$>,U'1?ILH2VB_.R!87^E0=M`H%`H%`H%`H%!BS
MK_$?IS?Y-!E4$;[D_P#M_N+^;Y/W,T$C1\!/O"@YH-'/_'+#_L+(?=(E!O*!
M0*!0*!0*!0*!0*!0*!0*#@B@\]=\NQRE>L;KVI&)5=3N6Q#0^%PNJ1'2/KO%
M:!SYCCS")=E>\[FSG6<)FW5.[2?5\2^=2U05*/-/,]$J^$GZWF/&@]%;VW0U
MBMN1\HQ+83"?DQFW9BE`M".^L)6M*P;?!/!5!YXVOMS</=K*,,(#L+:4(,#)
M9%8)<><:CM,NMH<OYU++(X'X/,\;"@]183"XW"XF+B<8P(V/A-AJ,PFY"4I]
MTW)H,Z@6H/)'M`J=_I5R[<=4L2EQ(A;1&59"DAKS=4`ZB`/10>A.SND]K-L7
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MH%6H)Y7`H-3M;O;M'=#TJ(Y,>P`9;0TB1-?BM*<=<)^U`E=U)"0=7+C:UZ#7
M=YMO[?B1,=F,SDLW*6D/1&$0VV9(7U$%WXQ`0A`"='!5!&=Y:$'M\YT;N?).
M*:#R)"&E%+C[)4%-VUNH3H'E)L2?+Q2:#=]E!?NOW-40+F=Q(!%_PE_T^Y07
M=0*#FU!Q04GF;?UI<(`!QQ*C?W.E)X4%V"@YH-'OF7&B;.S;\I(5&1"?ZH6T
MX^C2ILI.MIH%Q2./F"?"]!6'LPH0,)N`@7<]?0E]:@X'2L,))ZQ<2@E0"AQ`
MM:WNT%U4%/\`M".6D;#1K";[AC&QY621<_0O08?>OOBS@DR-M[9D)7G5"T[(
M)L40T*%[)/)3Q'(?6\^?"@A?9;LD[N53&Y]TM+3A-?6A0';ZYJ]6KKOWX])2
MN-CQ7X\.8>GVVVVT)0VD(0D!*4)%@`!8``<A0?5`H%`H%`H%`H%`H%!C3O\`
M$?IR/RZ#)H(WW)_]O]Q?S?(^YF@D:/@)]X4'-!HYVKYYX?AP$'(75_G(E!O*
M!0*!0*!0*!0./YE`H%`H%`H%`H."*#SWWQ[)*2J3NW:<4J4HES+XEI-]7V4A
MA(\?%Q`Y\QQYA3V"SZLE'P^S\[FWH6QU30])2D!26TGCS^$$:_3P03JM0>UL
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M=CX4N'V\B-28XCJ4_)=:"0L)<:<?4MMU!=^-4E:%`I4YYB.=!.7([+EBXVE9
M'(J2#;Z=!4WM/,1V^T614AM"5&1$`(2`?MR?10:GO[BF_D#`99"2N6IM,`%Q
MT-LI0MHN`D%)NM2T@`W%!&-[![Y<V`EI"UA.%PO7/42@)2):-)*"I)5X\+&@
ME/9`7[H]RU%>I1G\`3<@>M2/S*"\*"K>\T[;47,;61EG\BQ)E/NL0W($YN"T
MD*4WU%2"M0NFWEORXD<R*"TZ`:"CLJ%?UJL2200<2H!(\/B7^=J"\1R%!H]\
M9C*X;:65RF)83)R41A3D6.L%25K%K)(24D_0-!&9&?[A.]G9N;EX]C'[O1%>
M?,%T)2RD-N$^=+JU@`LIN0I7TJ#![&Y162BYV0J/&C%,IAKH0XZ8C:=,9!(Z
M*''M*KJ-[F_N4%3L[^W-MW=.XI$?).R%OY%;+:5/&0"P[)?+890X'6T>9K03
MHLD>_<!SWBW%D=Q=LMG97)^>2_/FA6I`02A(4E&I(2A-]('$)`//QH*VV=C&
MYVZ<-&7$7)ANY&*V^@-K4V4EY.L*(%N7/W*#W<A"4)"4@)2G@E(X``<``*#Z
MH%`H`H%`H%`H%`H%`H,:=_B/TY'Y=!DT$9[F+*.WVX2!<F`^!QM\)!'Y=!)4
M?!'O"@YH-!.M\^L/Z1CLA?WNM$H-_0*!0*!0*!0*!0*!0*!0*!0*`*#@B@\^
M=[^R'&5NK:T4K"KN9;#M)OJ/UTB.D?7>*T>/,<:"/]EN]3FV2Q@-P/=7;#ED
M09I\RH2B?@J/,L\?[7WJ#U"VZAQM+C:DK;6`I"TD%*DGB"".8-!]T"@4'!`4
M""+@\"*"(9_M7M+*8MO'18XPC2);4XN8MMF.M;K*5)1K^+4E0LX>!%`3VNVT
M)[>1*Y2L@W.;R1?+ZPE3[>F_Q";,!*M'&R/>H)A00CNOC8F4PV,QLP/F),R*
M&7_54E;P0N.^"4!(4;_0H*NVAM?";:[_`&(QV&$I$1>(D/*;F-K;7U%:TJ*0
MX$J*3I'T;T'H<<*#%RV)QV8QDG%Y..F5`EH+4F.N^E:%<P;6-!UX/`XK!8UK
M&8ICU:"S?I,ZUK";F]@7"I7U:#/-!4_M.\>TLX<OPJ&!^KIH.SO%D\5`VAA5
M9+"+SC)6"TT)/JR6G$1E*2ZM0XJMZ*"+;TWE&81M?:[,5N1(7&P:G9>F.I<8
M%])4A2BKJI4M(00$CASXWH,GL0=7<WN<;W/RB>%N5I4D4%Z"@J_O4UL=I6$R
M&X8\J5D6'PC#1XI*0X\IUHA#ATK3;4E/,>F@M`T'%!1LZ-_^UT!RPLK$FYN;
MWZ#P\?<'A07F.5!HM\IU[2R:-03J:T@J4I(N5`"Y0"KZ5!D;J<GM[;R3L!#3
MDIN.XM#,AI3[:PD74A325(*]200$ZAQH*X]GO)N9&#N22O&LXFV10VF%'CF*
M@!$9L%734MTW4J_'4:#1Q>S\S<6[-RO9>)+QK$J0B4B5)4T^VIYIY]#89Z9;
M*VU1W$KXZ2A7#C0:'V@-JP]J['VGA(2U.L,3IBDJ4`#=U*G"`!P`!584$_\`
M9E0M/:YG400J;+*;"QMKMYO2;T%KT"@4"@4"@4"@4"@4"@4&--3<L>X\@_2O
M09-!&.YZD)[?9\N'2DPW`3[XM02=/P1[U`H(_+/^WN+%A_%D_CX_;XE!(*!0
M*!0*!0*!0*!0*!0*!0*!0*!0<$4'G?OCV3+/K>[-K1]31^,R^':2+`6\\B.E
M/O76@>^/&@T?9'O6O;JXVW<^Z7-N/$(@35&YA*439*R>)95_>>]0>HFUI6A*
MTD*2H:DJ2;@@\B"*#[O0/"@BN1[H]O<;->@S\_#CRHZRV^TMRQ0L<TGA:X\1
MX4&,CO)VM<)"-SP#IYGJ\./H-K&@^QW>[9%6D;E@E0YCJB@X/>#M?<`[GQXO
MR^.%!J=Q]T>W3LG"*;W'`6&<BAQTI?0=*!'>&HV/`74*"#Y7?NSG/:)PV:1F
M(JL.QA'8SV0#@Z*7BMU005\KV4/IT%H#NYVS5_\`U-CK>'QZ>?HX^_0?2.[/
M;57+<V-X>F0@?DF@Y3W8[:*%QN?&_MEL?ET`]U^VG^\^-_;+?YM!6GM"[[V7
MF^VLJ!B<W#G35RHJT1X[R7'"E+H*CI3?D!0<>T&8RL1MMI31:DEI2F,@Y'2\
MT+-"S06IU'3<)&H*TGWQ0:'?6'CM[SV4MAT,.92+B'I`5U5A:F76FBHA)4E&
ME*6P+I">?&]!(^P5E=QNZ&KX:<GQX<;&5+(XT%Y4%*>T(EQ6X]AWAKFL"<X>
M@RHH<6X%-:$A:/.FW%=T^CC06;NW?6UMIMQ',_.3#$YPM1`4+67%@`D`("O2
M*"LG-N[@WMC(^3V=NEV'I?DJDNOR)ZTOH4Y>,IM`<2&V^F3R3\(6\#03G;W:
MS;F)S$+<#JY.0W)%BB*YE94AYQ3ET:5JZ:UJ2F_&P'*]!,Q0:/?!4G:N04DZ
M5!"2#JT\EI\:!O=C+2-I92-B8;<^=)84PW$=66D.)=\C@*PI%OBU*(\PX^-!
M#>QFS,YM/%Y>#EH2(:G9:%QNFX74N-I80WKN5N$<4VM?Z`H+-H*&]J\7Q.VO
MV8_R_2:"2^S3?^BV/>_Z\E\_TV@M6@4"@4"@4"@4"@4"@4"@QIO./^G(_+H,
MF@BW=*_]'N>`YJBJ3],@>D4$I'(4"@CTO\?\7_-<_P#=$2@D-!B8G'?)N/:A
M>LOS`S<)D2EAQX@J)`4NR=6D'2">-N=S09=`H%`H%`H%`H%`H%`H%`H%`H'C
M0<&@\\]\^RO2,C=>UXMV5:G,UBFA?W52&&_T:![X\:#2]D^]8V[T<!N*2IW;
M[AM`R"SJ]4)OY%DW)9/A]A[W(/3K+S;[2'FEI<:<2%MN((4E22+A22.!!%!]
MT'G[=O;7=+AWLI6W&\BO.R!\CY)+S17%07%*+H;(+@^V75I%^'*@D_:C86"=
MVZEC-[6@B7"4&#E/BY#<XI0`7VK`>6UDGA\*]!-_Z.-A7O\`-^!?T]!'YE!I
M<-VWV,=P9Y2\#"4$NQT-W920E/JZ%$)!X)!4HDV\:#<+[:[`7\+;\`\AQ81X
M<O"@ZG.U?;AQTNKVWCU.'FHL)\*#J/:'MB==]LX\]0W5\0GB?30?![-]K"D)
M.U\>0.5V1XT'']#7:O\`W6QWZBF@T.\^R_;Q6+:<B86+CTLOH<D28R$M+2UI
M4FY40KR)6I*E\.0H(OMCV9VS*6=W36)<(-HZ,;'!;!4[P4I3CA&K2/@A*?A<
MS;E07%E-H[7RZV',KBHLYV*@MQG'VDN+;0KFE"E"Z0;>%!S(VGMF3(AR).,C
MO/8]+:(#CB`HL):4%(Z5[Z""D<4\:"I>P:+=PNYBKGCD1P_[S*H+PH(=O[MK
MC]XR<3)E2W(ZL0^E]#24-N-.@.(64.!0"['1;RK'NWH()[3>"S&4@[>5CL9)
MR2&'I7K+<5M3B@EQI*1?0E9%S[E!*NUNV9D?M[MY3B7L7FHT3IJ#J`%!"G5N
M):?9&E)'FO;@1X6H.J/W(S:>[R-A3(<54=<0RA.94XES5TRL#IJN+>7TT%CT
M&DWHM2-L3E)-CI1Q\O(N)!^'Y?IT&V]<A\NNW_=I_-H./7(?^7;_`+M/YM`]
M<B>#S?\`=I_-H**]JF0PYBMMA"TK_"Y%PDA5OB/&U!*?9K/_`.+H_&_X9*^Z
M4%IT"@4"@4"@4"@4"@4"@4&/,OJC@&WQJ;_2-!D4$8[G?B%FOTC_`(Z:"3T"
M@T4D'Y]8\\+#&3;^G]<1>5!O:!0*!0*!0*!0*!0*!0*"(]U-Y3]G[*FYR#!5
M.DM:6T)`);:+AT]9VW'IH\?RN=!0'9KO1O1O>J<?E').=B9Z02\PD%QUEY=O
MCF4CX+:0/.@>4)XCEQ#U;0*!0*!0<$4'D[V@MH83;V^&UXE@1FLM%,N5'3]J
M2]U2A1;3]:%6N1RO03/V7]VYF6K)[7EO&1CL:PW(QY7Q4R%K4A305]AXI'A0
M7]04YOWO]\E9!_%;9Q3N2R./?<9R)D-/):1T^`Z?2"E+UJ"D@\+<Z"4]J]P3
MLWC7)[T)V(Q*:8D<6BS&5(6%!\Q4J\_3\J2=7'4303LT&GP_\>9W]/8_<K=!
MN.=!!MT]SQ@=]87:GR-)F',=+^$&S9IGJNEKS>4WTZ;GB*"89%]R/`DOM#4X
MRTXXA)\5)22!]2@QH\F<U&9?E!+C:T)4XX@%"D%0N2I)*K@>X:#8CCQH*LVQ
MW%R^7[P;BVM)<0<-`;<:C0^FDNEQGIZUK4`#TU:R!>@K[,=],Q&QTEG:V&G8
M9F+(0A<IXMR8C(*ED-A#C5T%W2=*0KWJ#TDRHK:0L\"I()'OB]!]^-!0W9'*
M8Z%O_N49LEB*E>1&A3SB&PJTF5>VLB]J"Z!N'!$`C(Q;'D>NU_A4#YP8+^48
MOZNU_A4&LW9G,>C;LQ4?)MLN60@/,O(#B0M:02E0-P=)H*?[B;PFX3><;#X:
M3-F8U0AE^9\LO`#KOZ'$A.O45!/'RJH.S'LL,^U#%9C2G)L9O&*T/O2%25W5
M'7=.M2E&W#TT$][C=Y,=LC)LX]_$R\BXN+ZZZY&T!#;6M2!J4LCB2@\*#M[S
MR`]VAS[S=TI?AH4GTZ7'$<#]`\:"LMB>SW@MR[.Q.>EY>8Q)R,=+[K3+<4-I
M*B?*G4THV'OT&^_JL;7L0,YD.//XN)]YH/G^JKM:]_ES(7_2XGWF@KCO-VAQ
M.Q(N(E0<A)F*G/NLN)D)92$A#>H$=)"#SH+A]FD6[61_V9+^ZF@M44"@\O;_
M`/:0W2C>B4[=3ZGB<.^MIR))1YI:D$H<ZX(U(3P(2$V(YGCP`>@-@;T@[RVM
M$S\-I;")`*76'`;H=;.EQ(5P"TA7)0YT$AH%`H%`H%`H%`H,>9;5'N;?&IM]
M(T&101CN=^(6:_2/^.F@D]`H-'(_'B!_-DS]T1:#>4"@4"@4"@4"@4"@4"@4
M'R\RT\TMEY"7&G$E#C:P%)4E0L4J!X$$4$1V9VHV9L_)9#(X6(42IZRK4Z0O
MH-DWZ+'`%#=_#ZO`4$PH%`H%`H!H*B]HC9N$F;2F[K?2Z<MB8[;,,H<*6]+L
MA`.M%B%?#-!5793MU+W3!STZ!FYF%F0RF,WZHI:%.!QLK`6M#C?UU!Z"RN[&
MMN]O$YU[JS_4X[+;P4I+;ZW+I87<KX=0+O<<R>5!7?LOR7Y2=V2'WUR7URHY
M=D.&[BU%+BBI9/$JNJ@M;8IU;4@*M:X<X']-70;XT$:^4/4'=V3THZAA:7^F
M3IU%J$A>F_A>U!H^UW<3*[RVTUE),2-"E.+=`9"UZ%(:7I*D*(-[?74'T>X\
MS^E+'[)3$;+$J`[.>FA2KW3?0$)-N!TF]_H4'UWHWQ+V=LWY1BQVI#DJ2W!(
M?4I*$)?2K4LZ>/E":":0@RYCX^E27F5LHTK3Q0M)0.(/B"*"';@W%N[;V0P4
M<0H<C#R'3&FOE]:'P`@E*TA2-`"0.(N2KEPH,S`]NL=AMZYK=;,A3DK-@!^.
MIID);MI^UK2@."^GS>;S'B>(%!&_:0`_HU<OPO,C\?HJH+.C_K=O\XG\B@^Z
M#S-L'MEM;?._-^MYU#RTXW).&-T7='%^3(UZN!O\`6H);%]G'MV[G<C#49HC
MQF8JV4I?`4%.EW62K0;WT#WJ#9J]F3MJ;65/2!QL)"?RV[T!?LS=N%<EY!/O
M/H_+;H/G^K'VYM8/9``>'6;^]4$-VEL[%[3]I.+AL6IU4)G'N/)+Y"UZW6%%
M5U!*>'#A0;7V@=@;DS^XH4S&)@F.]`]3U2Y3<9:74/*7Y$N$!7E<YI%QX$>(
M3;O*T8O9G-,KMJ8ALH-N5TN-C\F@S^S1OVLVS^P6_P`N@V6^=[XC9F#^6LJE
MU4,/M1U=$!2DETV"C<CRCQH-CM_-Q,[@X68AA0B3VDOL!=@K0L73>Q/A04M[
M5ZM.*VUZ?6I%N/CT1X>]027V:/\`VMC?LR7]UH+5H%!6>^.P>S]V[FC9Y]3D
M)S4#E6(X`3,";:=9X%"N%E*3Q(]WC06-!@PX$-F%"91'B1T!MAAL!*$(2+!*
M0.0%!W4"@4"@4"@4"@4&--/GC?IR?R%4&301CN=^(6:_2/\`CIH)/0*#1R/Q
MX@?S9,_=$6@WE`H%`H%`H%`H%`H%`H%`H%`H.-8H.2>%^=`H%`-!7_?NW]$F
MX+\M$?\`=35!!/9/`&)W*+W/KC!_YDT%MYW:$'+QY41Y0,#(`B?`=2'([I/'
M7INE2%W%[I4/=H*V]G;$HPV3WUB&W"\WC\DW&0Z4Z2H-)<2"1<T%F;'24[5Q
MX5Q.E9)])+BC0;R@AV4`3CM]J(L.BNY]['(H*7[2=TNW^*[?PL'GISL67#>=
M?'2:6Z=;RU+0H*0%"P0KS)//B#PH-A@-Y8W=/M!8[+XATR&F\2_&4Z&U(!6V
ME1*@VO2KDH</H7H-I[3LR8_L%A+3C;\1N>UUW4H*1KZ;FE"25*N;?"]'OT&)
M-[>[VS$J$G;.Y!AL<WBX\6-'*IBDJ?4PAQPN+#A1U0"2DH'`6H(M.PLF3W+D
M[+S>4ESH$<QG5,+,C4XXB,@/=)2W5)++A/F3XE7A:@]+1LO#(Z##3A2R--AH
M-@D6M?7QX"@K7V@,I&G=N7D,!1TS(^HD"PXJ]!)H+:8^TM_G1^10?=!2'8))
M^?7<IPIL%9(#W+^L2KVH+4QWXU9GP/0A`_\`/4&V>E165H0\\VTMPV;2M025
M'EY0>?.@[:!04>X!_6O:-_\`PCE_F54#VCTH&6V8^NP,>2ZZARQN@I=C^?\`
MLP.'Q:;*5X*%J"S.X^V)FZ=DY7`0G6V)4YM"&G7K],%+B7/-I!-O+05^QGNX
M';O`XG:[6WTY]V#$0A#\!,E:%`J*$A2^F$I6ISRV\!YCPH..[D_-9+MKD6<_
M#5$CL3(B<F,<^L'U5;:77-2UM+TZ"H!=T$4%C;`4E6R,$I.OIF$STRZOJ+*-
M`T%2M#5R4V/P!05%[5Z`J#MKC8A^4`/?;1QH)1[-(`[6Q@.0F2^?Z906K>@4
M"@4"@4"@4"@4"@4"@Q9HNN+[CR3_`'JJ#*H(SW+"CL7+A)LKI"Q`O_C$^%C0
M2:@4&A?)^?<(7%ABY9`^N_7$;ZE!OJ!0*!0*!0*!0*`2`+F@4"@4"@4"@HCN
M#/D_TX8."]+<;2E[&O1HK;K_`$W&RZM*RXT$AJ^H<]5N7B:#8;0S>9?[QR<6
M_/EJBQ',BWZN])<<#G3Z8;6IDKT)%E71I:2./,T%ST"@>%!7W?SAVDW!?["/
M^ZFJ"M/9TQV2>VUNB9CIDE,EJ0D1X$=QEI#KJ8X4D*6ZVYI*RH)OX4$LVAC.
M_+^;QJ=TS#$PY8>7DG([L13H>*E=%L!*%\A:Y3P(]V@Y[%MK:W1W&96ZM];6
M9"5/.:=:R.IYE:0E-S[@H)G@QNS$XMC''$-2!&"DA],Q*0OSD@A);N.!H,7>
M6Y-WX[:68GM8MN$[&AONMRS*2[TE)02ES0&E:M)XVMQH(OV;WCNW<6#R&6D0
M(F2?ER$!]^/(#39*(S2+%M:%$*L/..5[B@FO2R?AM2&/^\,_>J"BNX>;W+A>
M]<65B<(A.37C4QV\;&475.-NE>M2%,(24JLFU[<*#4=U-[;RR6WX6'RFSW,!
MCS,:>0EU$C0\ZV%6;3K0CS.WL>/'GZ:#<1^\/<>-.4H[06VAN:IQO%AM\=)Q
M+(;L=*"X=*;FP`%!WYONKW*S:HKLC8CX9QS]UN-M2TW+B>FEO4IO4DZE<Q>@
MR4=TNZ[[KD9[8\F7%2E.F`E+Z5MA""A)NAHGCQ)X<:".[Y[@=P,]MY47/[?=
M@P1)0XF8H/(0R2"4M&Z+*U6\MS0>JV/M+?YT?D4'9RH*1]GZXW9W$_G,6)`%
MQUI'HH+2QX(W5F22.+,*W#].H(!W?W6UBMZ[/QRL7$G^OOV=>?@HF2&DEU"$
M".I;C>E2EGC[U_"U!;9H!H*/6HGVJT#C;Y+L;\B?5U'\N@Z_:,"%[BV2E84I
MAI]UR84IZ@0QUHR5+6@:3HN;$Z@*"V-P2,!@L7,S66?<C0(R>I)>ZCQ"05`<
M$H)YD@6`H-1*WCC']L/Y[!LOSX:65SQ+7UF6`AI!45W<T*6`!\!`\WU:"D]Z
M[[PV[NUN<8QC$P9&`]'FSY<MYEIEQ3Y7J="2MQHI"D:0W:_*W*@O;M<A".W&
MV4(XI&-C`&RTW^*'&SGGX^[055[5_P"M-L@D#XV7^@;H)5[-:@KM='/_`&R5
M?]4H+4H%`H%`H%`H%`H%`H%`H,:9\.-R^W)Y_G5<J#)H(OW.41L7*'B+I:!M
MZ"^@<?<]-!**!0:!TWW[%'HQ4@_3D,?F4&_H%`H%`H%`H%`H%`H%`H%`H%!Y
MYW_@8<7OUA9C)0[(GS,?(>;)2AQI*%Z"H7%W$J*1Y0?=\*#:;22VKO[/?;T%
M)5DVSID-NK2I"V@H*;2>H+GC=8&GX";@4%Y4"@4%?]^^/:3<'CY&/W4U05Y[
M,1SJL!G_`)-,0,B>D*]8#A5KZ"/L"!IM:@O#;F2=R>"A9!YM+;LEH..-H)*0
MKQTD\;>B@J#&]N.ZK&>W+E=K;GA8F+ELI)<=87'ZRB6W%)3J*T+`(OX4&T&S
M?:'OQWY!]X0F_O5!C93MWWYRF.DX^9OB$Y#EM+8D-^J)3J0X-*AJ2TE0X>@T
M$5PFR.[^RL%N+Y(W/#@X_"%R3)80R'NJI,=+ZB@NM$I\E@+^-!W[$R'?[=^`
M9S$;=L6$S(ZI91)CL@E+*RA9"DL*3Y2.-!A[7<W-%[ZML;TF-9?(R,0ZB'*2
MA+3*V%\4DA*6RA-TJXE-_J4&S]HZ28>P(494HS9CF29=:GHXF[*'%)2OB;%)
M^#Z??H+4VYBLFX8,UX-J9=T9%4R_QZW'HR6U-J3I^R)-[\N%!M]UH*L$^FQ5
MJ6P"D*TDW>0+!7&WOT&`O`374Z'([#0\H4\P0EY?324MZE6M9(/$#GRY4%<]
M_H$MC8@6\PQ';]=959A12E3B]6HK1]?RX>CG072Q]H;_`#J?R*#[-!0G8U<]
M6Y^YAAV_7*^C8C5ZQU9'3MJ\/HT$B["M;\0WGT[W3)3FDO1Q^%N-NK+7344E
M*F[ITW)MQH,SO'N]C!2]NPV\?#DY/*S&H\2;,;"Q&!?;"U)*VU(X@_9`^(O:
M@LZ@B,[NML2&+RLBME)*PA:XLH(66[E6A72LNP23=-^''E04OVN>W7F>^;6X
M<VPX^I^$^&\@VPMN+ZN6AT="]"$W((%!<V^M@*W5,Q4@9(P1C5%6CH(?))<:
M<UMJ61TG!T=(7QX*/"@P^^A']%&X;FWQ37'_`+PW086P\7+G]A,?C&$A4N7A
M'&&$K.D%;S2TIN?`'4*"I8/:CN!B=G[A8F[<;=<R"8$=F$AWUG66UK+KBTL.
M%92FXX@ZN/N<`OWMO"GP-@;>A3V5QYL:!':D1W>*VUI0`4'\[RH*F]J\`Q=L
M7_RTO]`W02SV:D%/:J&H_7RY:@./`=8I_*H+3H%`H%`H%`H%`H%`H%`H,:6/
MC(U_\J+?W*J#)H(KW2(^8N2N-5S'2![IDM@'C?D:"54"@C[BO]OV$_\`E3Q'
M/_26Z"04"@4"@4"@4"@4"@4"@4"@4`T%%=P<XVCO)@L7)PD=<MR=CS%RR52]
M:6>K>Z@4)C=3X:;@DA)M?C:@S=JY7/RN\QA99WJ"#\JMQSZNAA2D:VM"U%#:
M0NZ+!)ZBN',7H+HH%`H*][_7':+</IT1_P!U-4$,]DX6VWN+P_A)/[F;H+9V
M3QVCBM)X>KIXT'VWMF,VX^MF7,9#[JWUMMOJ2@+<5J5I3X<305?WPS6=VJW`
M>Q6;G1$NMO\`6UR&PEQ:0"WH+K;MRCB5)`%P1QH-O(WMB(VX,9MPRLT_/F^K
MM+E-J"8R%R+#BZM(NM)(.D#D:#LRVUYCN#WZQ'R&1E2G4N)98ZH)<5\GMZ4!
M(0+ZCPH,#LOA9B^U^+QV9B2H71<DN(8+3B'=1D+4A:KIND`'@/'QX4'9'QN7
M5[04?)OQ'C$.!4RK(=):&5+2[;3J(LE1YZ;T'3[3>+GY'8L!F''>?(R;)>4R
MVIWI-EMQ*G5I2"=*;\Z"U<;'1%QL2,E?40PRVTESEJ"$A(5]&U!K\I(3D((8
MC-.N=5QE2'-"@@I2ZA95J/"VD7H(OM/N=*SG<7/[5<B--1,274QYB%+*W5LK
M0EQ)21I3HZ@OQX^'"@U7M*!![<H"_@G)1!]-1%!:C=@A(]P?D4'U04E[/8!W
M%W`6`3JR8NOP)ZK_`*?S:"TL6?\`:?."UK(A_1\BZ"K^^9EQ-^;#R3*D)#<M
M+`6II2]'6?;2M5PA:3J1Y;&Y\0/&@W_>KN5E=EQH"<8E!ESD25,I+8=4MQD(
MTH""I'E^,*E%-S8<J#`VOC]K[WVW@W-Z8R+.?DLJ?Q<DET1EH>=*UH9)*;+!
M0/*>)1Z1>@MAIEIIE#32`VRVD(;;2+)2E(L``.``%!]\*"!=]B!VGW!JY=-F
MY/(?A#?&@IZ?NG(X3MWLT[=R$J7+F8]Q<MIK)%M+!:2@HN@*TA-UD:;:O1RH
M+0V]GH4.=M/J;B4\,CCWG,DS*FI>2'@TRX+ZS=)"UJH)W\Y-N_RK#_;#7^%0
M47[463QDV/MH1)C$GINRRM++B'"+H;M?23:@GGLYF_:?&'_EYG[J<H+,H%`H
M%`H%`H%`H%`H%`H,>5?J1_TT?H54&101;N=;YE3K\NI$O^VVJ"4T"@T"OQ]:
M_FIS]T(H-_0*!0*!0*!0*!0*!0*!0*!0#043OC)F1WFQ>-?E:#'R.,,:.AU2
MD.%6M1UH"KMK2@&XMI/E/.@Z]CMPVN_N30E(3.4[EG'O(0HH6ZWH5KZSB%`@
M>#2#Z;T%]4"@7H*][^D?T29\$V*DQP/?]::H(;[*5AMO<(_\R3<_]W;H+9V2
ME*=I8H`6'JR+6]T7H-U04%[4$9N2]A=3J74,,RB]$UQ4*:UZ>F]\:%.66I&C
MAP\.=!];C:?1W7VVCU=Y24KQ*0^F.M3(;2I73N^H*"%_"U!!`/"]!<6"2#D\
M^?'UY'U(C%!N0!0``*#!SBM.&G'_`)!WE^<-!UF8)+*8L,K)<;%Y*$^1M)`X
MZB+%5CP%!GLLH:9;90+(;2$I'N)%A04AVL1'_IVWRXF,SK4J1\<"X'6BE]M*
MD6*BV0]]L)%R/['X-!N/::`5VW;1J(UY**D:;W-RH<+>CG0;'?6VNX,7;83L
M?*Y";FU+0TA<R5'#;39XK=6%M#J$`6`OS-_"@Z]A[7[HK<RWSTS4IE"7TIQ"
M83[*@ID`ZUJ):4KS&Q`5QH(W[-;2FLAOEIQU3[C622A<ARVMPI6]=:K6%SS-
MJ"TL0/\`:O<)\+0ON2J#OS>T-LYR9!G97'MR9N,<2]`E'4AUI:5!0TN(*56U
M`'3>QH(?WH[;PMX8^%+EYXX&/B0\7Y!0E;:VWPE*@O4I&GBD>-!E;8R_;K"[
M4Q^W%YZ'/C06$L*=>6B[A3\)93R%U&@@>ULI!?\`:5E,X>:7\2K%DH;;=6XQ
M<-M$@744BRO`#A07T/=H*^[^V_HES]R1=,?21Z?66K<Z""[(]GOMSF=G8;+3
M79AF3XC4F06Y"6TEQU(6JR0@V%S00"%VLQKV^\M@7<-E!`9^43C\AK0&3ZJE
M2H_)FZBORCBKCX4&3VA[4;:W;.DM9S'9*`S'B-/:GW$M+4^M:D*2FS*`$^0G
M2?-Z:#K[X=JMH;$:P[VWU/=7(N/HD]=T.^5I*%)T@!-N*J"Y_9NO_1)B[FYZ
M\W]U.4%GT"@4"@4"@4"@4"@4"@4&/*^V1OTW_B*H,B@B_<S\3)GZ;$_=;5!*
M*!0:%7X^-_S4Y^Z$4&^H%`H%`H%`H%`H%`H%`H!(`))L!Q)/*U!I]N;QVQN0
M2S@LBSD!!=+$KI$G0L>^!=)\%#RGP-!N#04#O'<<<]_\1B([:R/68*I,A*VP
MV7D:ATU6;U\$J!T%?$V5X4&[VQ$C_P!-C[[4^'.=#>2ZXB,N!U%WFR`^\OR7
M1JZ>ELD73<V)-!<=`H'"@J7VC-R8*-L.=@W9S+>9E^KNQH!5\:XVF0FZ@GT>
M4_2H(][)TV,K"[CA=1/K:)R'E,?7AM3"4A=O05)4![U!9>!S<S'X6#"=P>3Z
ML=I+;NAELI"@.-B7!<4&P^=;W+Y#RGN_@Z/OM!#-W[0VQNW*M9;)X;<+$]A@
MQ4.PU&/=I6H$$(<(Y.*%_0:#99UW(21%EXF+F\9E8*.E'6EA+L=QL6^+DQRZ
M$.)-N8LL>!H(YB^]#>WAEG=\86=AI;DPGJ,LJ>BN=.*R/(X2DA:DC5TSYK'Q
MH+8Q.5@Y;&1<G`=#\*8TA^.ZGDI"Q<4&7<4'!`-!S:@4$`=V;MS:6=R>Z,;U
M4Y[<+JVGY,APK9:2Y=]YP-V`"&D-%?'T6O0=FV,WVOW6^O'8^6QN.;%0F5(<
MDMJD+%EZ4NDNHT))5Q2$VX<0+4$DS.<DXZ1&8CXR3DE/I6L^KEOR!O2/-U%(
MYZ_"@ULG=FXNBOU3:LY<D\&4NN1T-ZCXK5U#9(\>%!2VT=^8_M5O#=N(W3'?
M7-R4IF:R(G26E*'DK=TJ*W$<1U+<":#8#VE-N-3L_-A09:'I:6$XU3R&E(*V
MFU)^.2'D%*2KT$\.-!MXGM4[(5$:7-QV08E%*>NT@1U(2X>!"5*>05)OXZ:#
M$S_M,[%FXXQF<?D%.=1AWXQ$9*=#3R'5<>N?K4&U!`-V=XXN9WVC-P<AE(>%
MU0B,>$L`J3'7K=.KK^35;D.?C02?MUO&!O'VBI&>@,NQXSV-<;0R_HZ@Z3;2
M=1Z:ECC[]!Z.\*"$=Z<7D<IVSS4+&Q7)LU:65,QF4E;BRA]M9TI',V2:"&[4
MW'VJPN"PNW\YC6H^XV8\6/*@NX\JD>L.I`"2G05%2U<O306!BMK[`RT%J?#P
M\54=[5I*F.FH%"BA04A0!!2I)'&@K?;FZ-L3=[Y.%-Q.$3MZ`Q.EB>TV'%H;
MAO):NYYW!8I)424)-^`%AJ(0CVA,GL"<SA7]J>J+6TZ\W-=AM],66VA;8)"4
MI4.?*@MKV;U!7:3%D<NO-_=3E!9XH%!B2LOBHDV+!DS&6)LXJ$.,XXE+CQ0+
MJZ:2;JL.=J#+H%`H%`H%`H%`H%!C2[=6+?\`RO#W]"J#)H(OW,_$R9^FQ/W6
MU02B@4&A5^/C?\U.?NA%!OJ!0*!0*!0*!0*!0*!0*"#]Y=O;KS^Q)L#;4LQY
MA\[["?*J4PE)UQTK^M*^'O\`P3P-!0'L\[/WM(WN,GCW',5C\4YT<RXXD@.A
M)\\(MGFOTW^!SYVH/6YH*%W1EL!-[UX[\'S+67C9&'!0774HQ:@VK67&V[ZE
M$A7O$^]0;38B=OI[QY)G'IRAFL-STY![(LQVVE.EY@J4PIE#:CJ))\W,<107
M-0+4'%!Y']I3+XW)=R+8^0B3ZE`:ARRV=24OH>=6ILD<-20L7]%!SV11W9Q[
M>2S&R,&QDH,WIQWI$U26D%3)4?BBIUK7;40HBXH+5&X_::-K[4Q0]/Q[9_\`
MN:#[^</M*_[KXK]61^^:#Y&XO:8OQVMB@/3UVS_]S0:'+=VN^F*W!CMO3<!B
MV\QEKG'Q0K5K`)%RM,@H3\$_"(H-7N_;W?G=&)GP,SM6(N++F(GZ8TE#;B'D
M,I91ITR/.E(3>R@>-!\]N\7[1.Q\>_C,7MYN7CG%]5J-->:4&5JX+Z12^BP4
M?,4\J#,W!GO:5B9=G.2X#,*!!0-<!#\9$%S@HGJE;^M2C?D%>'"@CK7M6[Z6
M`HP<8E!`(*FW@;$<+_&T'VGVJ][\08F+!'AH>^^T'TGVJM\:A>#BU`&Y3I>%
MP#Q_QE!K-P^T)E-QQV8F8P>*FLMG6RDKEM'6I"D%0+;J%6*%D$>B@C&P<9O3
M-2'X>V67W\HR_&F.S6'5,.-,-?%)1K+K;9;5>Y&DJX<.%![1R<5]P-2H@!F1
M%%;25&P6E0LMLGPU#D?3:@X8SV.<NEUT17T?;(\GXIQ/T%6!'NI)%!J-S8_;
MNX<-/;2W%R19Z?K:4%*EZ4%+JFRMOSI*F^5B#QH*ORG87!:9FXDYJ5,Q"P_+
MC8AAY,1DH<%F&T2G5+TZ`KFKX2K7M0:S%XS9F+VQN'%--1#D'VXKHBOM(#BT
M"0B.XX`X2\RH%.EYA7!*_,GRJH-=V+W]L_"[0D?.AM*W)62<:QUV$.J4&H[1
M7;RC2!J'PE<3RH-\SV:VYO>!%RN#RR\.H%SUT,MJ<ZZW7-:7REQ8"+M&Z0$V
MU>]:@PM@[3P6%[F11$2E;L9]V$B67'XNLM`ZKH4>$@@_&,J&AU-G$$6M0>BO
M"@X/*@A+K^U,KFI!V]"B2]RI-Y&6#"5>JJ*`V'7'E`*4H(2`E(-S8<AQH(?W
M>[D9[MVC#8;;XC$.1EK4[+277%J0L)*B`MOW5+5Z3QX4$.[9[RW)N#<<Q>=R
M:\@U'P62<:#O2CH27.DIQ06A".E>VGS7Y:^2A04_F@ZG#1M;+C)7(19M]:W5
MA)8X>982;</+[G&@]4>S6+=H<4#_`):9^ZG*"T10#]6@\3]TXW<4=R74;AZK
MN?<=1\E*BZ]"F]5V/4[<0`?1Q"KZN-!Z[V*WNIK:F.;W6XTYGDM6FK9Y7N=.
MHC@5Z;:RGAJO:@WM`H%`H%`H%`H%!CROMT7]-_Z-=!D4$8[E@G9LP#B2]$`'
MN^MM4$GH%!H5?CXW_-3G[H10;Z@4"@4"@4"@4"@4"@4"@4'"4(3?2D)N2386
MN3S-`H//^]8<@>T#A9+T92[3((9E)8?"$M*00$+=4Z6OA!5M+?/@:#8=NDJ3
MWLS:0`IDC**0X-"AJ,MG4@.A(4Z!?Q/D5=%O+<A>`H.;T%#=\>^!@&3M7:L@
M#(@%O*95!X1@>!:9(YN_9'ZWW^05GV?[/SM]S1.G)<B;4BN$2)`N');B3Q99
M5SM]FOZ`X\@]=X['0L=!8@P6$1H<9`;CQVDA*$(3P"0!01?=/<G&83=.&VJA
MI;^:S#K'3;`NA,=QTH=<4H&X*$I41PH)C0#Q%!0/>_)9#&=Y-E9''0%Y3(18
MZW(^.;U:WB5.)4E.D*XA))Y4&]'>+N:'!J[99$H^Q"W+_3Z-J#6,]U>XXW7)
MF'MYD5K,%E@P0XYY$I>>4EZQ9M\9JT\OK:"(]TY.Z-XQO69_;_.09#*DKZJ)
M$AR.$MI4!JC*:+-_-Q4$ZO=H,_V8<'CLK@LL)K+;P1-!964)5I6(R#J2%`CZ
M8M07NC'XIMUJ-/Q\7J.#2U(2PWTW".&GBGRJ(^M//PH.]_"[;CM+>=@1&T>;
M6KH-7\U]7)-R57^C0:G+;;Q^1@OOR,;&9CML.*8:Z*`\HZ"1K4!=`OQTI-[\
M_105?[-FP=U[>RN7R&:QCF.CR(K#$8O%.IQ045J(2E2C8"W$T%]VX4'1+A0Y
MK"X\ME$AAP%*VG$A22#S%C055[/3:41=X)2-*1GI*0/0$I2`./H``H)OF=KN
M^HST8F8(2):%]:+(93+ADJ)4L]!93IU\=6DV-^5Z#R=#9RF[E/[CE,XP(P2F
MVRI,AR/-0AU:!&U:^HMYIGBE)/FX6U'30=&WL;G,GMMIS"1)60]2FS$.)8*@
MML2(K`3K0DH"4K4E7P?A6\U^1#TUL7;J8>RMO!Z6<1GX4!N.^I+C:^'%09D-
MDZ'-)5[X-[$4%;[;R.XV^_J\/-((0^ZXIR+^$ER.IL.-]52UJ^)!7=!XK:)T
MCRT'HL<J#Y<6VV@K<4$(3Q4I1``]\F@TN7BXR:!)C2V8V49%XDY"T:TD?6*^
MS;5:RDG\F@AFZNWD;N7#Q.=&5>Q;B(CL=UIA"74*+BK.`$E)\JTJ`\#05M@-
MMYC!R,V6L7+F(;P^0]0Q^89="):678R;O(4EALE;:;^5PD(TH^MXA6^^9\3)
M16,I#AQ\?'?DI2F#$0I#2.G%3Q`421<J-Z#T?[-2BOM#BE$6)?F</^].4%G/
MR&(T=V1(<2TPRE3CKJS9*4)%U*43R``H,/";@P>>B*F8:<S/BI66R_'4%HU@
M!13J'"]E"@[Y&-QTB3&E2(K3TJ&5&(^XA*G&BL646U$73J'`VH,F@4"@4"@4
M"@4"@4&-,^W0_P!./W-=!DT$8[E%`V=*UFR5/PDWL3\*8R.0H)/0*"/`@]PB
M.)*<2/>&J2?R=-!(:!0*!0*!0*!0*!0*!0*!0*`:"@-SXN0U[16+5E,G%BL3
MO5IV//042YZLI;*8JG%+5TW#<$*%DK/"U[4%E;>[90<+NI>XD9!^1(6W(0II
MQN.@$REH<6M:F6VRM6IOF?3030F@H+O=WV$42-K;1E#UZZFLIE6S]H\"S'5R
M+OV2OK??Y!7/9CL]+WSD$9.>E;&T(KIZ[FI0<FN)-RTV>>F_VQ=_<''D'KN!
MCX./AL0H+"(T.,@-L1VDA"$(2+!*4CE09%!3W<4N?TV[+#EE1K-EM/4;39WJ
MN<5I<U\TCR:0E2C>Q-K`+=D2&V$A2PHA1L-"5+-S[B0:"K]P[0GYZ=.3B=QY
M'!9-$WJOK"Y3B'8SK1+`;9*T(;0%\"I(^M(YT&QVUVQP.(>QV8S,N9GMR8HN
M):RTI4A92IP*U!MJZDA`"R!S^G03QF8R^E2D:K(^$5(4CW?K@*")[9W3A<_O
MK.)Q$E$MG'P8+#[[2@I'54[)64"WBD'S4$GS/\43OV.[^@-!0/LCI4<'D3>R
M1-5P`X&\1C\B@O[)/L(:2RXR9*WSI;C@`E1'&YOP2!S*CRH-:B-,@R!*G`2X
MB`"T1=2H@\;`BZQZ5_"'O4&QR;J%8>6XA04DQW5)6#<$:";W%!QAIL*7CV%Q
M)#<A"6T)4II:5@$)'`E)/&@S_"@X-!YSVIW<Q^VI>?B;<V=DYZ9&3?D35ID&
M0$O*64$)T,G0DZ+A)XT&QF^TX]I>A.;/F-2%`L]-;I"@M8L!I+-[\>5!4&U<
MN<?M6?@Y>T',E/RDIIR+DEQU=9M#!;4\TT5L*7=26U$"]N/&@Q#KB/M0X&.R
MT5EA_K.,&%'5(6[HZ:4EPQ_@6L2@I4"KCP)H)_LON#MK:>UXV*R>Q)>3?96K
MKY.9%:2IQQ]Q2D#S-*T\]*4W/N4&FQV]L;![M+WJQLR2Q`4TKU3',LN-*;=Z
M2$=4%+0;\Q0J@LY/M0-&W^QN5'O@_>Z",]S.^*]V[*R.`C[5R3!F](&0M*BE
M*6W4N*N`W<\$6H+:[=[.VXGM[@%3L'#3+&.85(+\5KJ:RT"HKUIU:O3>@UG8
MW>63W;MS*(G(;9$*08L9,:,F*RAI2=2-&EQP%6DA2A86OXT$#[3(9:WSN*$N
M2O)08N)G,HD2Y2)C;S2)"&RI03I2@+T>9.KE].@JO?DJ/)Q+#\7%C#H<F*_`
MDK=<XIB-`KU/><Z[>E0MR4:#T9[,8([.XK4;GKS?W6Y03S>#+S^T<VRPA;CS
ML"2AMMI(<<4I3*@$H0>"E'D!0>;\(G.8#*[!Q[$Z?BV<G-'KN'E"3&#?Q[9+
M8#JEJ7JL;J*=/&P/`T'JF@4"@4"@4"@4"@4"@QI@N_#X\GC]S709-!%NYQ4-
MGOZ0"HR\>D:N7&>P+T$IH%!'D?\`N"][N):^I)<H)#0*!0*!0*!0*!0*!0*!
M0*!0<4%:=SL)CY.X,?-G,]:&B$\B:F]KQ@^TAZQ'$*;3(ZR2.(*+T&XVUG)^
M*R@VCN-[JSPVIS"Y5=DC(16N>H\O664D=1/UP\XX7L%8][^^Z64R-K;0D@RB
M-&1S3*P0T#8EJ.I/-PCX2A\'W^00'LWV:D[[DMY3*(7%VA'<\QXI<G+2?,VV
MKGT[_#6/>'I`>N(4&'!B,Q(;*(\6.@-L,-)"$(0D6"4I'``4'?0*"DNXZ\@.
M_&SV$AX8^1ZJJ0E&I+3BX[SZV^HI0Z=VR;I`.KC[HH+M)YT'FCM1NG<&Z^YJ
M8\W).M/QH4DJEQW'"5E#J2$*#JW6G4>*DI0`D\.%!:&>[AY["]S]K[.=1$?A
MYQIYR3,*7&G4=-*RG0G6I'-OC>@G\LAV(\&UI)4VL)5;6!=)L2`03[UZ#QQM
MW>6<PLQ,O:B/D1K-3V&7U-I/1D28X;;6AOKI<U:U.K68X(*?L^`%!["S1`P\
M\G@!'=O^IF@\H=B>Z>!V7AI,7(K=2]*E%Q)0RIU*6S&:2E?"VKS((L#[]!;,
M+VCNUD4<'<D\\[8O2'(JBI1Y7/'@!Z$BPH,C^L[VPM<JR`_[HK\I5!KIWM"]
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M2RXKS:P238"@[<KN_MKBW^AE7,K!?>;<D!M_Y5;4IINP<<`*AY4\+T&!N#=V
MU6MDRMQ8-G-NI9::EPGD(R82Z$J3I*5._%E*D\/-PH+-A3T3L4S/;:=;1)82
M\AAY!0\D+3J"5MJXI5QX@T%4=A]W*EP\PG+,B%)5,`9NQ'CE:>BMX)4B,Q'\
MR&6[J*QQ\+<J"(;5R[3VY=[3X$B1DVG\5E'HT=I_UHI;>D(*%--ZD!(TK"[#
M2JW#F*"FMQN11A(L>&@ML"6XHDK+@UB*R%$+NJ]]7IH/4/LR`#L[B0/\O-]W
M_K;E!8&ZM7S8RZDR%Q%)A2")31TN-D-*.M!'(IYB@\S=O]SYZ7B=M0<KF965
M]:R[3[Z7'6WD-.-9".EL/..!UT(T<$=)?PS95@#</5]`H%`H%`H%`H%`H%!C
MRC\?%_33]S709%!%NY8)VFL``DSL:`#_`#C'H)30*#0-G_;Y\6_\*9X_]Y=H
M-_0*!0*!0*!0*!0*!0*!0*!0<<;^Y01G=46.]FL`B2+QI:YD!Y!(LI,F(M13
M]'HT'G3O1W+:R6"Q^R65%Z7@Y"D9:>"G2XN*5L-!E?%5UHLM:DD<]/'C01KM
M%L3!;IRZG=Q9*+B=NP2GJQWI#3#TM?,-("E)(1;X:A[PH/6D/=>P8,-F-%S6
M*CPV4!##3<J.EM"$^4)2`NUN%!E(W?M-00I&:@*2NY01*9(-KWMYN/*@[4;H
MVTM.I.6A$7(N)+1%P;'ZZ@Y^<NW?Y5A_MAK_``J!\Y-N'@<I#][UAK_"H'SE
MVY_*L._[(:_PJ",;>VYVOV[D%9#%2(4>4I*D!1DMG2E9%P/-?PMQO00'?YPN
M<]H/8D>\;)0O57P^W=#[9.EY0"TC4GP!%Z"SFL;A\3F9;>/CL8YKY,*W2RA+
M38LXH!2@D#EQXT'FOMMV@W!N6`A:7FM$+)I^46%O/L*<A.:7PL(>CN?KGR.B
MU@4VX7-!ZZ=:;=;4VX`IM8*5I/$%)%B#059@NRW:UY>:#FWV%B-.=9CC6[9M
MM++1"$V7P`*B:"KO9PV#M'=K&X%[AQR)YB+C)C%:G$EL+#A5IT*3STB@GF,V
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MO]Q3=LX[<FT\AEHY7)1MG#(QCJ65O.MNN2%I64A`5Q+?EX^]06%M_>VWF]VL
MQ5OO)<9P$1+B%17TE*TNJU`I".!%Q[E`W/C>RVX,M(R&>C^NY#H*AO.+;FD!
MILZRE(0G0"/LDB_NT&3G-W;!PFQU18DD1,7`]6C,M]!Y00@+0I"0'4<?*/'\
MF@FV.RF.S&):R.,D)E09;1<CR4?!6DW`(N/R:#SMMC%YK8VW6'LUF8N(3-S*
MBS+8Z>12WU8#S=EH;)0E3B@`3Q%!:N"F383W;R-UD);R&+>;EH:0$I><;B,N
MMJ)/F&D)5X^-!5?M>M-MR-K!M"4`HG:@D`7XL#C:@CG8CNONS&Y';NR&/558
M:3.*%%;2B^$/K4ZNRPL#G>QM0>GM\2'HNS,_(8.E]G'2W&E"Q(4EE9!X\.%!
MY@[591W&/;&*%LO*RL@LPHC"T/=)*Y#?K"EN?#0YQ6HC2>%DZO0'KN@4"@4"
M@4"@4"@4"@QY1`?B>ZZ0/U-9H,B@C/<4`[9L>(,_&7_UC'H)-0*"/MA/S_?-
MO-\DL@'CR]9=O02"@4"@4"@4"@4"@4"@4"@4'!H.">7NT'G+O]WCB27$;7VW
M)/K$*3U)^7964AIU"%(Z+*D\U660M0Y<N?(*_P"T/:I>[L]CW<RV]$VL_P!5
MR.XFZ1-<C$%;#:@=03Q)*_&QMQY!?&'["]I'9V80[MYIQ#$M+;*5.OD(1ZNT
MO2GXS[)9/&@U^'[;]A,IN3(;>9VDI&0QSBVWEJ3+]7.@(5=+X<+?$.#RDWH)
M(/9_[.CA\V6/U61]\H-3NGM'V5VYA9.7D[1,IN.!\3$]9==45&R0$ASA=1`U
M'@/'A0=,?M7V>Z:5C8<QI2@"I!:DW22.(-G2.%!C9?8/8O$8Z3E,KM"3$@14
M%R3)=;EA"$#A<V=H-3AL9[-&8S'R-C=ONS,ITA)3&0U-*BTI*5A85KT$:5I/
M.@WZ^T?9Y:[_`#+G)X$62B4!Q\?MOAX4$'&WMKX#VA-DPMMXY_%QU,NN2HT@
M.I45EF0$K'5*B00GP-N%!?:VVWMT/QWD)<:7C4I<2L`A25/+"DD'F"*#LVWM
M+;NVHKL7!P40F7EA;J4%2BHI2$I\RRI6E*0`E-[)'`4&XM01_;9;_AX(!`^4
MI%[^)Z;=_JT%,>R&?P+=7&Y$B)]+0YPH)KMK&;*B=Y,N_C7<A)W#)9?7DT.L
M(3%CA2FU6#JVFW%=0_`TK4+`^@4%BY;AB9IY?@[O'^T-!1_LD)3\W\^OF53&
M`3Z0(XM^303WN%VZR.Y\_A\E%D1FF\>`'$OAS5PDLOWTH\KR=+)3TW+)N0KF
M*"P#05#G?9_AH<+^RLH_MN1(4ZYD5)=DN!]1\S22$NMV2E:E?3X4$BV/`&V\
M9DWI65DY/'8]AM,C)RG7'RZ[%0M4EUM"BO0A-PC2@\TF@C&ZNZ6V-\[/RN(V
MDJ=D<FYZN/5V(L@*Z:GAJ6YI05%FR2ES3Q(X<S00G=R,)C^S>+B[G8G.2''L
MVF*IJ7ZN\'TN/6+[;W14X+IN01=-N5S:@;LW+N3`;PV.<--]2<F[6Q[4MY4=
M4AA*&W2L%]*&7UA',>0`W\107*.[_;S4#\HN!2K)OZE-'U>C[M!H)?M']N86
M?>Q4MV2U';"-&3Z*RPHK%RDI(#PT_G+4$ZEQ-N[PVYT)#:<CA,DVE6E6M`<1
M<*2>&A8X@'PH.YC'8O!;?]1@QDL8V!&4AF*@D)2VA).D$DGZ-!YDS2E8/8,3
M/XW&/8*+*R427CXNN39"58^0+MR'%(=4D]6]TV'HYT%LY+/X/$L]L962R#$,
ML(07DO.H0I++V+=1U%ZE7"-:0+GQMXT$#]K!")>3V.VE=V92Y""I)YH==C)N
M#[RJ"%]TNTF;[8YR/N#;[[J\&V^AV!DOA/0GP;I;?/(I)^"H\#\$^Z%S;"[O
M[5WWL_(8_<SK>/R+<1:,S&*RA+L=2="GXY'F(5J^"/,E7#T4$I[<[$P>(VEC
M6'8`<E*4G(O*EMI6ZB6M*"5I"DCIJ3H2`$@6MZ:";4"@4"@4"@4"@4"@4'1)
M'Q\7W'#]S50=]!&NXGXLC]GXS_U&/026@4&A;_'R1_-;'[H=H-]0*!0*!0*!
M0*!0*!0*!08N5RD#%8Z1DL@\F-!B-J>DOKOI0A(N5&US00S^G7M+<#YQL7/]
M@_\`>Z"J^\_M`,S8B]O[+E'H2&_P_-("D'0KX3,?6$D$CX2_#D/305+AMCNN
M;77O#,H=C[2BOH9C!+:E*GN*7\``?:V?*0IWT\!0>ENX>Y,:CLVQN?;TDX81
MFF)>W'5,VT*4.FTUT@E8'4:6I%B+<>-!`6^ZW<F5VYB;JQ);;F2\NXQF'&(Q
M<90EIAEM#CA<#B6DW3YR?$\"`*"0]O&%.=_]XRDRFDK:+C3\92?.ZE0:*"UY
M;IZ:DG65+XW%A:@N#/;BP>`@'(9J<SCX06EOKOJ"4E:O@I'I)H/O"YS#YW'(
MR.(F-3X#I4E$AE04@E)TJ'O@T&=;A0:3>.%VME\$_'W2PP_AFB)#Z9*BEM):
M\P4H@IY4%+[8Q^`QOM)/1<.PB+!>CB3%Z+:2T5.PD*<0E9;4I!6DA>D.)X#E
MZ0]!VH*1W^H'VE>WZ03<1'B>'#BB3R/C06J@_P"V+P\/DYK[NY0;F@YH(YM<
MC1GSZ,G*]WZU%!3OLA"V,W2>=Y<:Q_S:Z#X0E]?>K<[:5NIAXU+DV4_%*D2E
M-O+C==I4AD(6E*&FM3:.=M5B;T$R:[:[WF;G,R1NI9V>ZLJ1C6)$XO+C6/30
MIY3UCU`J[BO<%J"9[,V!M?9L21$V]%5%8E.]9Y*G7'25`:18N*40`.%!(Q0#
M0:+<&$RN04A<3)KCLH20[CU)'0>X'@M:-#Z;WXZ5_0H,*>M>3V/FL;!A^KSF
MH<F#\G(M9#W0(0A'P04JU)*#X@T'GK:&V=\87;V[,A*A3=OK./BL,3'B8JUR
M%26BH(42@C4$$*((38^%!QW-7,<[8;83,M,@H3EWQ*6ZR^XN:'W0WJE:TI6+
M$J)2"%?2H+@V&A:MZXMX?:T[*Q:5>^J0X1P_M306?>@@<++=GYN<R&>2[BU9
MIA]4.9.D]-+Z7(OQ>D%WBD)MP(M>@W4_N'LB!`D3Y&;A^KQ&RZ\4/(6H)2+\
M$I)))\!0;5V3$FX9<EE8>B28Q<;<0"L+;<;N%)`XJND^%!YEVC)Q<CM\^,CB
MTS(\;*L1HT36]!=4M4)Q`6T]%;))(UG0M/E3<%2E&@FV]]AP=Z[.V%F8X9C"
M(J&Q)U*TH&/=TAU.I[2M73Z8(OQYT&D]J1;+V;V"N.M"V5/O=-:""DCKQ>1'
M"@OK<*\&G"SCG>D<065"<)`U-%H\"%#QO>P'._*@\>;S[=;EV:_$W;CHC\#`
MN2_6,.Z_94N"4K"HZ9:"+(*[>6]_0KS4'H+M=WVVYN;#%.=E1L/GHFE,QA]U
M+3;MQP>8*R/*KQ3S2?H4$W1OO9+BTMHS^/4M:@E"1*9)*E&P`&KF30;V@4"@
M4"@4"@4"@4&/()$B*/2M7W-5!D4$:[B?BR/V?C/_`%&/026@4&A;_'R1_-;'
M[H=H-]0*!0*!0*!0*!0*!0*!00WO'P[6;I)\,<_^AH/$;KNI8LK3IXJ'+ZM!
M:O9?LM)WI*;SF::4SM-A7Q:#=*YZTGX*3S#((\RASY#TT'IK=.SL5N'9\[:S
MK:8^/EQC&;#20`SI'Q2D)%@.FH`@>Y0=Z=L8I6V&]MRF$R<6F(B"XPL>5;2&
MPCEX<KT$&V+VIQ.-VYE=HR9<N3C(N3?4WTWWHRG&)#+2PR_T5)Z@2E>DWX'G
MXT&GV:UD&>_VY%1XV1B8Z0AY<Y3H5ZI(=;#*&5I'30E-@5:#J5>]!V^U,P^]
MV[B*::6X&LFRIPH25:4EIU-S;D+J`H.?9^RV+P/:"/,S<IK&153I(2_+4&$$
MJ<\H!7IO>QM06]%DQY49J3&=2]'?0EQEYLA2%H6+I4E0X$$'A05I[06%S>7V
M=%C8;'O9&8F8%Z&$)=*$]%Q)44+ND_"M<I-KW%C8T$.P$=S'^T*X9D1<;7@H
MS6.6Y&6M`D-0070F1J#:7$H04DD+)'EX4&-V(WON'-;X1#ERWI#8Q[SLIQQU
MY8<(+02M277G$A05>VEM/,^%!M]^E/\`6;V%8@K,1P*3XA.B78GWS03W>V;E
M8+Y>S,-"')D#"==A#@)05H=<*=5B"1?PH(UV?[J9O=#F6;RC9/R>U$4%$(!+
MKZUH=""A"`4)LG@1J!O>@LEW<>`;S#>$<R$=&8=3K;QY<0'U)L3<-WU<DDT&
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M:PK4D_8W`N+VH+#[?A7SGQXU7T[.PX(-KWZK]C064"#P'A04)O*5)S&[4]LF
M6T1\=GY<F7E949;34E4?UE:'4@N&U@$W("5*5R%J"R-E]I=K;47E#%ZTY&5T
M(=;G+ZZ4L-(T(92E0L4@?97/ARH);)U,07?5DI2III701I.D%*?*-*?#W!0>
M8LAO_-;G[?Y.3GIJA-.3ALL18Y::2`VRM3JFVWA\'XU.L))5JM>P-!9.!QN/
MR6S^U<+(1D38;BKN1I#:'FE:,9(4DK2H*22"+B@@N;V,[N/";5+$Z#A(&W%9
M6;(=E:D-(:^5BE*$)1P%NE8<?<H+6BX_>^XWHV6R/J+.-CK#V-Q;K3Z>HH$%
MN5(3KN%#FVV?@\%'S<@WL02\LYE\'N*/"EL);:"VV0HH<9D!5TN-N%1%BCG?
MC0>6^[_9F=L669L/5+VO)<M&DJ-W(RE<0T^?1X(7X^/&@@N)-LQC@0$_AD:W
M`<?CDT'Z`T"@4"@4"@4"@4"@QY/ZYB?GU?<U4&101KN';YMB_CD,98>G^$8]
M!):!0:!J_P`_9/`V&*8\WA<R'N%!OZ!0*!0*!0*!0*!0*!0*#2[UVZ=R[4RN
M`#_JORG&<C>L:=>CJ"VK3=-[>B]!XRVGL0Y_N.G93T[U?\)F1ESTM:P?5`X;
MAHJ'PNE]EPH+QB^S1F8;(8A[_P`C&80+(99:6A";<K)3(`%J#M'LZ[HL=7<?
M)W/B&W1_]S0%>SGN50`_I&R@MR(0[?Z/X30=;'LUYR.%!CN!D60XHK<Z;3B=
M2SS4JTGB3;G01W"X?<6T._>W]M/[EGYB,XCKK+[KJ4*2XR]Y"T7'$$`H%!Z6
M\*#1;QV5M[>&)3BLZPJ1"0\F0E"%J:(<0"D'4@@\E&@VF+QT3&8V+C8:"W$A
M,HCQT$E12VTD)2+FY/`>-!DGE000=K4?TH'?BLL^X>D6TXE2`6DDL=!1"]7(
MCC;3]&@Q4X*%CX>2S^#;..A08KXAN*=>=<<0T-2NB'B\W&946P@:&RHI`M86
MH*8V?N>;NSO7LG./K==2\B2&4N+2ZIMI#;Y".HA*-027#Q(H/06X\)'S\[+8
M20XMEG(8A+#CK=BI(6ZX+@'A>@AVU^W`VQD<E!PLHK;D"*WDYR&RE3"6U%;;
M3*%K>"W5:[J4?*A%N!)H-5M7';:SW?:9DVFI8R.!COMNOR'@YUI3#@B]74BZ
M2GHN:=`MI/,7H+-VU8,9\C^4I9/OZ4T%.^R#?Y.W5?GZU%O[_270;W:;#2^_
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M7C02;:.Z.WT9<B5N'<N`RF6,U^7"FMI;;4PT\K5H0MTK6"#?DKQH):.ZW;8H
MUC<N.TW`_7"`>/#E>]!Q*[F=OU170UN7%]13:NGKE-A.JUAJTJU<_1QH*6VS
M@]M#%S8LS=>%Q1D//*,9V8UD3JE16V9$A#H?0L+#B"I@K6HI!\PO06#`?[2J
MVC@]OYG<^.F+PK:`S*8R'JSG40V6RM*V76UC4E9N+T&IE;U[-8'<&*PXDL3,
M,W%TQ$LE60;;DJF!Y*G".JO65JU!2B>/NT%F*WG@$G2I<D%0"A^!3+64HI'$
M-6YB@^-O9!G(YG+2XK4A,4IC-)??86PEQ:`YK#?52A:M-Q<VMZ/&@V^2Q\+(
MP)$*<PB5#D-J;?CNC4A:2.((H/#W;_:F1W1O7'XG&EMMU#QDE;Q4$(9B.!:A
MR4HFPL*#W70*!0*!0*!0*!0*#&DW]:A_IBK_`*FJ@R:",]Q%!.WF;B^K)XL#
M@#Q.08]-!)J!0:%E2SON8D@Z$XN*0;<+JD2+\?[44&^H%`H%`H%`H%`H%`H%
M`H!H/(W:LW]HQ(/,9+,?H9%!ZW%!7W>O>^8V;MV!EL:\AHJG)8D=5D/H4VME
MTV(*V>.M*2++%!.,3)>E8J%)?MUWV&G'=(TC4M`4JPNJW$^DT&50>;NZ,K.1
M?:+P\C`1$9#,-16/5H3J@VA:BW(!U+NG2`BZN=!/?G=W^_W(@>^9R?\`"H.M
MS>O?UL*)V'#7Q\H1.0>']U0?!WUW\2O0>W\91%B5IG(T_HJ#CY_=^"DD=O&A
M:P(5-;N;D#A95!T3=\=_9$-^,WV_::<?;+3;WKK9T%8*=1&KCIY\Z"VXC`;A
M,LJ0$A#24*;YI%D@$>]0>:\_L'N?A^ZKFX]K;5;<AXR0\YB@A;(CN(?"S<MI
M<9*?MQX<*"0IW9[2J<DK(_,J(7EL)CJ;ND("4+4L$?A=[W7Z:"R=C/;I.TE3
M-V0QC<S)EN/2([)!TAQX):M9:_K;"VH\*"'[WP6^-L;_`%;G[>;;CY!>6A*9
MS&M0"2^'0H+*"ZS92DI'$<_'C0:&%N/VDXK4YM.RXJA/?=D.74FZ%/``A/X7
MR%J");#V[[0FQVIK6`V^4(GJ0Y)]83&=)4T"@:?CTVX&@E2MS^U=8VP;'ZC&
M_?-!\2]R^U(_%>C/;>;2V\@MK4AB.HZ5)TFP]85SY\J"2^S7MO.;?P&<@YB$
MY`E)R"0&70`;>K-D$:24D6(Y&@N'C0#RM04?NWV:,*O&/':ZG#EY#^KJ9"4X
M&&T.*)<4`TC42GZT>/C0:"7V2PFU=ILY;<P7/S:)/7=A1'5^K&*Q=]YFY2EP
M_@[2[K])H,SM?$[*=P9T^'%V<Y`=A-(>U.R'EI6E2M)^"YY5`VX&@E0[,=KG
M]VM-,8E"X"8+JU-MR'RV7DOI1=1#GPDBXY\*#=CL1VGO?YOMW'(]>3]\H.?Z
M">T_'_9]OCS^.D<?^<H.1V*[4BUL`V+<OCI'WR@'L3VI)!^0&_U:1;[I0=?]
M`W:CB#@4D'TOR#Q]/VR@B&4V5[/$'=T;:,G&/HSLDHZ3#1R!2>MQ1=Q"M.GW
M;V'C:@A67V)@LAWJ;V5M_;L>/!Q3:9&11*ERD>MM%I*E+#J2M:`GK(\H^$>-
M!&M[;/9P4G:L@XMG$3)N4F,2&(DB1*96U#FLM,J3ZPI:@3YKV^D*#V3088S6
M'5D58Q,^.<DGX4(.HZX\NOBW?7\'CRY4&4OX"O>/Y%!Y%]F\$]V8JK\1#F%0
M]-[4'KT4"@4"@4"@4"@4"@QI5_6H=N745?\`4U4&301;N0"=O1Q<@?*F*O8V
MN/E%CG[E!*:!0:.-<[WR''@,9"L/??E?F4&\H%`H%`H%`H%`H%`H%`H!H/(W
M:RW]8M!].2S%C_:R*#UQ05-[1UD;6P\A394AK*MA]=W4H2PMEU+W44REQ24*
M02%$)O;EQH+-P_JYQ$$Q@@1S':Z(;U%&C0-.G796FW*_&@S*"@-SW/M6[?%B
M!ZJBYMSM'D4%_CE[E`M08.=RT?#X:;E9"%.,P65ON(;`*U);&HA-["YH,2'N
M)E;S+$V*_CGY!`8#X26W%*%]*'6RMN_N$@GT4&YH,>?*$.!)E%.H1VENE-[7
M"$E5KGERH(AA.YT/+9=G%,P7V'P]'9D/OIT1UF3#<E@Q7./5L&O0.!O03>@Z
M)D;UA@M`A-U(5>U_@+"K?4H._A>@6%`L*"G?:*WAN+;<;`KPTEQA,ER2F2EM
M:D%00EO21H4VM13J/"]O2.%!-.TV5R&6[=X3(Y&094R0TM3LA1N56=6E/'C?
MR@"_/TT&WPZ4C*YO2D"\MLK("A<^JL\]7"]OL>'T:#0[XWEEMNYC$1DF&F)F
M7A"A]5N4XZ9:O@A712I*4<>9_P#X"9@K#8+EM>D:]-[7MQM>@@FW^\FUMQ>M
MC#HD.+AN%ESU@-14:AR/4=6!8^YQ]R@XS<)G,X;-&;EX!RN1QS\"`P'D>KQ4
MO((*0LG6HK5;6NPY"PH(/V'V1-V=E,M.STS%,"2PQ&BIBR6EE0:45%2[:>5A
M;QYWO0<=G(SV"[A;M.6T8Z-/=DR<<ER:PZPIER65`LH0HA'$E2K\[CT4%U(S
M6&6I*$3XZEK.E"0Z@E1]``/$T&;0<^%`\*#B@\R;_2?ZT>(LM:2J3C"2DB_P
M1P''X)MQO[M!8&'>SN0[P[DC/E$"&&^B'&XQ9E/-(0V6ELRNC<Z3JUE3I!!2
M`GA047W`?S<'?D3`S'WY<;#9M]>.FRKK6XF7)9=7<E*02@\]/#C0>SZ"HL=@
MY;?M!Y'-(S<(L/LH8?Q+<H"4;106D.QRWQMI6X++Y<?<(6VY]K5[Q_(H/(?L
MTF_=>,2+$PIG_%H/7]`H%`H%`H%`H%`H,>0/PF+[BU?<U4&1017N0E:L'"2C
M@HY?$\>7_B#-!*J!0:.,/]N,B>/\60?>^WRZ#>4"@4"@4"@4"@4"@4"@4"@\
M@]JG+^T>V!R^4<QS_.R/230>O:"`=Z,(C+;42P[N<;7CH=4MY]:M"7T])8+)
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M#*1W$[<SW!`1N+&27)1$=,9,EI1<4YY0@)"N)5>UJ#;NX_!PH$3JM,QX.&`7
M$+EDMQPTTIH*!5P3I;44W]%!J<IW`VLSCI+D#-XM^>EEQ4-AR:RA#CP02VA2
MM7E"E6%Z"H$95W-]S,#N[+9'%PX\/2RMI659:*`@N^8Q$O/>=27!PUGTGQ%!
M<<?N-V_D%89W)C'"V;+`EL\#_=4'VK?VQDI*E;BQH2/'UMG_``J#E._-D*MI
MW#C3?E^%L_X5!'-Y'M)N^.PUFL[!6(2E*:6U.90I.L#6#YB"#I2>7A0;C"[A
M[<X;%1\9CLWCFH45.EI'KC*CQ)4225W)*B2:#[V?/Q\_(;CEP93,N.YD4!#T
M=\/I.F%'20=)(001R^C09^2VKB\CD6\C(<EHDM(#:.A+DL(`"BJ_3:<0C5QX
MJM>U!M2D!O2";!-@223R\2>-!Y1[.=I,1OIC/3,A/=C&#.Z#:66HKMTE.HE1
M?:=4.?APH);/['=JX:RQ(W80^#;U=#&+=>N.-NFW%6OZE!TCL/MJ0E:L:G-3
M.%VRK'8R(A7O*EQV3;Z%!JOZM^1E;F]0$R/C6C$]9^.8BS'0`[IMI;CQV@3[
ME_?H-3O[MG%V'G=NPFYHGN9!;4A3ZXD5@M.1\A"0%-%E`6FX=(/F/"@]:>-!
M`=V;_P!P[;F9^7*Q\-6W,/$C2$2ER%MOK<>U)+80&W+J4M(2GE[_`*`T.V^\
M^Y-XQ<BQM?;J1EXL)N4TW->=9;UO@Z$*4MA"2?'X5B.(-J"UH:I2XC"I;:6I
M:FTF0TVK6A+A`UI2HA.H`\C:@\\[TR<(>TUB8JL5&6\E^`@S=3X>*E-Z@LA+
MJ6[IU`"Z>0\:#T6;T'GKVFDMJWAL1!-RI]04D<[&3'MQ^F*#T,+_`%:"CL:B
M.?:AR+I9'5]6T)3\9K24Q$'UD\>D4J2KICC<?8CX5!=[GVM7O'\B@\@>S0K5
MW:C@&Z1"F6_O:#V$*!0*!0*!0*!0*!08\C]=1?SZOT!H,B@B_<0%6&@)N4ZL
MOB@2F]_U^SZ*"44"@TD;\=LC_-L'[O+H-W0*!0*!0*!0*!0*!0*!0*#Q]VD<
MU^T6T3P5\HYC4"#]C(]-![`H*C]I94?YE1&I@=]2>DK0XIETH4ET1G5,$H/D
M<1U$C7JY)O;C0;_?63RN-[-S)V+D>K9%K&,>KOQ[)TJ4&TW;N$A/PN'`6]R@
MA?8G*YG<YS,F1D91EX\Q$1)CZB\M2%AT.)=2XI>I*R@$I&D:N*0/$)"ONAN&
M'WAQ_;^9$B.L36B\<@SU6UI'1==2`A14/\58\:"SQR!H*:]JD)/;_&`IU:LS
M%3I].IIX$?1H):WV1[3A"?\`9:".`)3H-K\_303%4W'MR$0E2&D2ECXN.5I#
MA%OK4$W/`4%99OV?ML9GN&=VS%I7"?\`/.PA9!:?=+:D%Q;@4%7*E!?+F*"A
MLWBL?A^Z&YE8J,&D[;DMRL3$;0MQI+C<F.E*%-I(6M-EJX`WH/1\[)HWMVOA
MLNMEN5NR$VUT&3J*`^!UE^-D-INJY][G0:/^J_VMOQ;GGA:QEK_,H--O/V:-
MC1MM9"7AO7&\E&:+S!6^7D'ID*6DMD`*U(!`X\Z"!?T)[6?C2%Q]SQU!@R0"
MMM(/X.\VVC4"\"-:7=5!8.(]FSM<W&",EDW<C*4LD/,R$QT%*O@I#:%+Y>F_
M&@K?OEVKVELS)[8C85$C1E7UMRVWWB[J0AUE(";@%-^H;\:#.[[;,V;C<6RW
MLO;J8CC<]<.5DPLMH4\AI15'0EY6IRQ4#J1PN"GB:"P,%VT[6IBXU>9VE#8C
M3VVA$RS,EYR.XX\E(;;<"RTMMQTJX`I(\+WX4&I[>9EKM#`S,+=F.D0&\EE'
MW<44N1"AR.VBR=&M]*SY4\R/1XF@N+:>[XFY8[C\:'*B);2RX!+0A)6W(;#K
M2D]-;@L4$'B;T&](N"/30>%\Q@,W`WME=D8:2_+>7D'(S;+:RPF0Z$ZD:T:]
M'(D7-!.-J=C^Z#V/+^#SD:$@G2_&1*EQG6G!S;>;#:5(6GT$?4H-U_07WTN2
M=S-F_IR,W_`H,&7V)[PP5O9:3N>)&+36E^<YD)B2&DW5I4LH^#?C:@KG*0-V
M8_=>WT[C?DO+=E17(+TAQY74C+E-V4A+VEQ*%K;Y*2+V!H/5G>7.XQC:TC;J
MI[$7-YYM;.(9?<+27%ME*E!3EM*$VX75P\*#![0/X9MN7MYMQ+DZ%$BNS8I>
M3+2@NN/K(2\E*6U)U*\J0/*+"@LM#:$$E*0DJ^%8`7MPXT$9VYW'V[N#<62P
M$#K>O8OJ=<N)2$*#3I864E*E*%G!;SA)/,7%!3&^Y,M?M-X..X$!AN3CU,?%
M-I<*2V;GJ!.M:0K5S50>CZ#SS[3`(WQL,VYO6O?T2F#RH/0U!3.,&=B^T3D'
MI\21ZAD6Q'QLMX/H8T,Q.HH,*"@ROS7U)()N;BW&@N1SX"O>/Y%!X]]F(C^E
ME@#_`$*7_P`6@]BB@4"@4"@4"@4"@4&+)/X9#'I6O[F:#*H(SW`_BG'_`,\8
MKE<?]?9]%!)J!0:2-^.V1_FV#]WET&[H%`H%`H%`H%`H%`H%`H%!Y`[/I4?:
M%;4#J`G9=1/N%+_+EXT'KZ@J+VF!+&S<4ZQI+;.586Z@NH9)(0L-Z5.$)X+(
M/&]N9X7H+`&$C9[9C.(S[7K#4Z$TUD&M6G4HMI*_,V1]=QNDT'5LWM_M79S$
MEK`Q51_75)7*<<=<>6LM@A%U.*5\$$VM04YNUN<][5>#3!?1&DB&G2ZXV74Z
M1&D*4DHNCX0N."N%!(=]=S>Z.`W%(Q&%VZ[N!N-%2ZY,CXZ0&A(=MTF@KK%*
MTV/G4GB/1P-!'_:"E;HD]NMM2\PJ,RJ1DH+TN`EE3;T=Y;+BM"E%UP'02I*N
M%!9O=K=N2V]M,.XL#U_).>I,/@W<9+C2U=9IOAU%(T7";^Z>`H*2QZLG'[K[
M>R>4E,Y'*.8-.5<R*BVEU;OJ+[C:+)\BP@$)"4\5!.J@EO8GN/O+<F\)F.S<
M]4N.S!<<4DI;".NAYM)*"E#9`LL_3Y<*#4[-PD?,^T1OB,^M;26;R4.M$)=0
MXQ)C.-E!(4!YD\>'*@OW'8.%`6XZVIUZ2Z`EV2^LN.%*22$@G@E(O\%(`H,+
M.;YVA@9;<3,YB+CY3J0XVR^X$+*"2`JQ\+@\:#7GNOVQ<&GYS8Y0/`CKH-P>
M%!26+W%@,:B=BH3.`GQXLB8TQDY4UAEU]MY]MYM>E39)#:$!N]_"@L=O+87=
M';3+988J##6VX[&28Y;>;U,.I2'&WDH1<$G@0*"">UHM]&5V8Y&T>L)7(+/4
M-F]?48*=9\$W'&@Y[Y&(_P!E=HNLK#30D,(+;ZK++ICN(6B[GFOU;A2O`<:#
M&V3&.,W-N?%^M0)B7\=(>:,<.JDQ7U.L)89><4A+)6IY8TEN_F'#PH+;C[DV
M/O/J_)^-1N*9CG'(BE/Q3TF7D*!6A3[Z-*1J0#Y;F@E.`Q;T&&3+<2[D)"R[
M,=0-*"L@`)0#R0A("4^X*#9&@IW/=F<7"[DP=^1L@_ZQ(R\=UV`M"%-ZWOBU
ME*^"@/&U!8N:VRB3+^5<:\<=G4("$3DC4AQ"3<-26K@.M_WR?K2*#4K[B,X^
M2SA<Y$7'W3(NF%BX_P`:F;;_`!D5TV3T_%74TE'UWI(9D+;4S(RFLINE3<F4
MPLN0<:T5&'%/@;*MUWA_E%CA]:$T%"^TFH#N[M0'B%>H`VY\9QH+MWWDD1W\
M?)@J8=R,!Y\(2LI4EIUR*L)ZHU)MY5ZK7%Z#<C%[G#A<&6BA9TA2O4>)"1:Q
M/7^RXT'9M:?DYF,6K)EI<R/)DQ7'6$%M"Q'>4TE805.%.I*02-1H(XG8F6P&
M15,V7(:9^4IKDK.LY-;KS2TNW45,I18I6%<N-K4&IR/:B;D-[L;TE)@G-1E-
M+:4AR6EK4PG2V5(U$&P]%KT$BQT_?IWHC'SU8Q6%3!]8?,=#X?ZJG"A&DK41
M;R\>%!4GM-N--[WV*I]8;8ZMU.*-@D"4P5'Z`H/0K$B/(:#L=U#S2O@N-J"D
MGWB+B@J/$;0W&._&1S\F#(&("U&+-4&RS94)+=DJ4Z%BZE&^EH\1SYT%O.?:
MU>\?R*#Q[[,:`GNQ&5XF%,(_O:#V**!0*!0*!0*!0*!08LK]>0_SZ_N9H,J@
MC._P#BL<#R.8Q7[O9H)-0*#21OQVR/\`-L'[O+H-W0*!0*!0*!0*!0*!0*!0
M*#R%V/2L]_BHD&[V66;6]+GU*#UV#0:#>.S,;NN"U$G2)$8,J64N15I2HI>:
M4PZA06EQ!"VG%)OIN+W!!H-S"BLPX;$-FX9C-H9:U$J.EM(2FY/,V%!WT'G_
M`#9`]K?"\KF'8^GA"D'\N@N:2'\O.?A)=4UC(MFY:V5Z7'7E"Y9UI.I"4I(U
M6L3>U!Y7[[YG$3LZF+CH"(*,%+^3W"P0XA\H6"EPN!(\POI*3<@WXT'K+)83
M#YG'IAY:"Q/B>5?0DMI=1J2."M*@1>@B$SMC'F[^^<#D>&W":C)AM!!?2^IA
M4=;#K1"5I9"++`3Y.%J#OV5VAVML_,R,MBG)*Y,AE4=275-:$MJ4E5@EIMOQ
M0+7]WTF@KKMBNWM*[\%[E4=ZPMZ'H]!?O"@JY2^Y(R67:R3$:1"3FXQP#\T)
M:28RUJ^*26>HI019'F4D'B:#28)O=2($4H@XD@(LDJ<>'E.7Y<&R1Y_J>[PH
M,S1O`(DK,#$7#N2&KJO`\9[.L`]+EJM;W.?HH)CE\;O3*8M_&/Q\4PQ)`2XM
MMV0HI`4%$A)92#R]-!2_M@\9>T;$@CUHH`].M@"@WG>B=M#'XQ#DUR<W`DR'
M^NPEM*X#LY$55S=25.)6I0"#TRD$DJY@T&-VCPLR!O2=G\UB)++$E%X,IHM%
MEU+JTKC%]M"W%70T1TRXJR??L:#=>S"K5A]UF]S\OR21:Q%TCG0750":"@<M
MWAW!D.\\38YBQFL3&S3+"70%F02P->HJ*M/F/AIX4%JR=RS\P\86T^E(2A:F
MIN;6=<2,I!LM#83]O>3]BGRI^N/A0=C.PMO?)S\28VO(/2E!R7D)2RJ6XZGB
MAP.C2ILH^L#>D)\`*#H3DLOME1:S*G,C@A<M9RP+L=`'!,U"0-21_EDC\^!\
M(A0OM%R6)'=K9[T=:'F'4X]33K:@I"DF:2%)4.!%!-,QLO)1^\66W%*QJTX[
M))#4-Y#R76GE-1`'%KBK5JZGUJ2!:R3Z:"\K\:#2[30ZB%.#J2E2LE/4+HZ=
MTF2LI-O&Z;>;QYT&ZH.#:@IWLMO;+;GWANAO)9!C(*PRE0V766E,KZ9DNJ3U
M$D!/E^`FWHXT%NR(<204^L,MO:?@]1"5VOZ-0-!J,MB7(R$S\,?5),8]5V,T
ME(;E-IXK96BUKJ'P5CB#[E!MX<MJ7$9E-&[3Z$NMG^Q6D*'Y-!V.?:U>\?R*
M#QW[,A0>[40I-AZE-TI/H\M!['H%`H%`H%`H%`H%!C2!^%Q/<4L_WAH,F@C6
M_OXKQW\\8K]WLT$EH%!HXIOO?)#T8V#]WET&\H%`H%`H%`H%`H%`H%`H(EW8
MS.2PO;O/97&/^K3XL8KCR``2A6I(U`*!'(^(H/%&%W/EL1N5O,0<CZCD%.+U
MY+A9(DFSKC@"%^7S75I2?<%!Z$A;4]IB7&;EQ=Y8^3&?2EV.^V_J;6A7$*!$
M0W!'*@RQLSVH`2H;L@7\`5BW[DH/I&S_`&H$@_[5P"3<&ZP>?_<Z")]Q,A[0
M6Q<2SELUN9MR*^^(R?5%(6H+4A2Q=*HS8XZ;<Z#M@]H^^.5S&.WRG-01FEQF
MW(TQU:DO(0XT4A*T>K:00AT@\*"U\%G'-A;1CCN/F(WRM)?D..2X[:UAVZ]0
M)#3222E!2%*T#PH*C]HG;T3)LXG?VV6TRL/E0E,V3"2OK.O)N8[RDZ%<$I04
M<@;\#023%87VGYV-AS&MPPV&Y;2'D,R2T'D)6`H)<_`U>?CQ%!V_-OVJ;*5\
MY<?<<`CXBYX\Q^">CTT'6K;_`+5X/#<$`CW#'_+B^-!&F>R_?UC<$O<4;)Q8
M^:GA0ES69736L+*2I)TLA-KH'`"@QM[P_:$V;M]S.YC<SOJ+*VVW`Q+ZCEW5
M!";)+2?$\>-!C_T/][MVPH&>F91N;ZY%9>CN2)JPL,N)ZK8*4M@`^>]!UGV;
MN[IO>3%'/X,UT<S?[#T\??H(D>W/<$[[^8^ESY6/QBG>L]ZJ4EKKJ<+VGD>1
MX?"X4%EXOM3[1N*B"'C\\F+%22I+2)ZR`I1NKX32CQ/NT$'[K;5[JXF3@).]
MYORTEV66L:QZR7KN`H6IJP0WIZNE*;\:"8;H9[S9*&5[GV$B5MZ"^]D50&IB
M6RVI0)*T.,/=8E&I1`X^]0;O';][KIF'$Q]ARUB#'9,F%ZTCIJ;=;Z8*U:./
M4#1X:B1QH-G[*SJWMM[D?4T65N9M\N-'ZQ?305(X^*2;&@O"U!\K-D*/H!-!
MX>A[=[@[]W%E\]AH+DV8)97,EL.-1@AYV^E*.HMOCI3];?ZM!,9$[VCMO#'8
MMQ<B"92TQL;!:5CO,;A-D-M_!2"H7/+C09./R?M0Y&1/CQ%3EO8QX19J=<`:
M'BVEW3=1`/D<2>%^=!\_*7M1*S+F$2Y,^4VXR9BXQ<Q]_5UK4VE=[Z?AH(YW
MH(]([/=\'\I&R#N`=7(C/HD,DO0NFVI#@=LAI+R$)25W)";<SZ:"9[BW%[2<
MN=C(L[:X+RUN=`-1VW&25((4'7$2%H0-/V2DT$C.Y_:B/$;<C"_AIC</_K*#
M0Y3N![0&S<4[D<UAHD#%+DK6])Z33H0Y)<*KJ#<E:N*U4%F=CM_9W>^V)N4R
M_J_48G+BL*CH+>IM+;:[J25+XW7X&@C69WE[0J\S-."VW%D85N6ZQ!>LTOJL
MMNJ;"U$RFU7\OV(H(?C]U]]8FZY7J.TT1LM(9"9#*,8&F5A#BE!:G@^EM1NL
M^;701K=/>SN6YN:-C<OE7<,<<^&LJSC$H:6`5IZNJSDA*UH1>POP-!/#W9[6
ME!`WENM)Y7NNX_YF@DF*]HOM'C<='Q[,R>MJ,A+:%NQ7EN$)%KK41Q)\309+
MGM-]J0A0]:F<0?\`J;OYE!YB[9;IR>W][X?(8PH2^](;ANZT!04S+?0AP6/)
M6D\_"@][4"@4"@4"@4"@4"@QI!'KD0'F2NW]Q09-!&=_$_)V,`*;JS.+'F-N
M4UHFWI/"@DU`H-##`^?66('_`(;CP3_GI=!OJ!0*!0*!0*!0*!0*!0*"#][F
M7GNU.Y66&EO.KB$(::2IQ:O.GDE()-!XG?V[F@H`8N;;F"8KXX>/UGA069V4
M[US=BS4X#/=5S;#J^*%)5U8"U'BM*#QZ1YJ1X<Q[H>O8<N+,BM2XCJ'XSZ`X
MR\VH*0M"A=*DJ'`@B@[[4&LW#MW%;@QAQN4;+L13K+Q0E10=<=Q+K9U)X\%H
M%!LJ"C_:BQN1E8W;[L:(])::?D)=<896]TU+2VI&KI@K3JZ9L4_D4$][-PID
M+ME@(TN.Y%D)CJ4IAY.AQ(6ZM:=2.&DZ5`VH)I:@XH%`M05-[42K=H,@?#UF
M)?WNNF@W_;[,[A&Q=O!6WW2$XR($J1)C$*`90$J&I:2-2>/'WJ#:Y3=N0Q6/
MDY'(81Z/"B-J>??5)B`)0@7)-W:"#;<]I+:&X<G`Q>-A2%Y#(C\&86[&2025
M`-.$N60[\6?(3Z/306'\M9[_`'=D_MB']]H*0]I3,Y%R3LQ$O#R8:&LEUDNJ
M6RZ%D*;!;2&5K\_&X!M>@F6?VY*@2MS;KB9//3I,N!,$/".MNF(VZZR`@!!`
M%D*3<>C\D(%M?NEW$<V[G=UB&)610IAF<A,?I)CQFX\HL/*0HW4E+I2I6FY4
M/*.-!8&0<[7=NV6'/E(;6R64"IZT,&2XW(=(NXMR,OJ@I*N'$!7(`@T%A[;S
M`S&&C9#IEE;H/4:-P4J22#P590OS`4+VY\:#8.GXI9]"3^10>&<;ODPMHS]J
MC$KG/S,PWDXLE*E$-F*`7ATT\5>1/IM8\1PH++V3L!7<G<S>]O5W,-MW'-(1
M#CN%;JI,AH%P.ME2&T+;0LA*K?7"U!<K?;W8^=AL9[/86,_EIL9E_(R5)4V5
M.!E(*E)"A:P%J#2=A)6S,O@)>:PN(C8O*E]</)B.#=2&E%;'%2E*TJ;6#S^%
M>@LUB7#?<<:8?;=<9.EY"%I4I!N190!N#<'G04[M7=W=&=F]T,^MQY;\-$DX
M=B6P8V/LS,2C5ZPV`7-+)L;*.D_"YT$E[8;DSSF*RSV\\K$=DLSPTW(;=C^K
MH0XPVM+2%MV1P*CXDT';W=F0LEV<W)+@2&I<1W'N+9D-+2MM021Q2H7!XIH(
MI[/V!R_S&F*8G-QL?D\I-?):;49(`<Z"DI6I6A.H-7"@FXH+BAPXT&(U$BMA
MN.RD(;;3X`?E^DT%+=YN\TUJ;\Q-BI7.W/.5ZM(D1SJ,=2^!:;MPZUN)5>S8
MXGCR#/[9>SEM'`835N>#&SN>ED.2W)"`\TR>?28"_03YE\U&@V6;VOM`S_D3
M;.S,/DIL1*%9%3[+;,:.T!J#1<2A7Q[H^`GP'F5PM<.7=M=C#M0;KF[=Q4;#
MI:+BWWHK22FRBDHX#S*UC2-/,\J#RCO[<V"SN?4_A<+%P.);"D0H<9I#;BD%
M0^-?*?A+/HY)Y<>=!K=L+1\Z\#IY?*<'4BXN?PEOPH/T/H%`H%`H%`H%`H%!
MC2!^&1??7^AH,F@B_<$MB!APM6G5F\6$CP*O6T$`_2H)10*#00-/SXS-@;B!
MC[DWM]ME\J#?T"@4"@4"@4"@4"@4"@4"@XH*M[T=EX6]X1R6-T1=TQD6COGR
MHDH3Q##Q']XOZWWJ"E.S_>'*]N<P[M3=*'F\"A\LR&'@>KCGBJQ4D>+1)NI(
M_/)]T/7$.9%F1FI45U#\9]`<9>;4%(6A0N%)4.!!H.Z@4"@6H'C0>;.T6=SY
M[[9K$O9.2YC#(RK@A%Y2XY6E_@H))*>'I%!Z3H%J"H_:E(_H?G@\0J5#%O\`
M/IH)[V_X;#VV/1BH7[G10;;(8Z#D8CD.?';E1'19V.\@.-K`(-E)5<'B*#7,
M[,VBS,9FLX2`U,CZ?5Y*(S*7&]`TIT*";ITC@+4&YH*']JIUQN/LY;2"Z\C)
MJ6S'%[NK2E"DMBP/PR--!]Q?:%WM*RR\2QL"0O(H<6R6A).DNM"[C:72WTU*
M1XI"KT'3CNYW=-&[<V\.W<EZ6^S"#D,/@=%MKJZ%*64647"M5K>B@T_9*&=T
M8O,9'/;=D;ADL91Y#$QV6D+CV*'C&0EYUM20VY90*?'WJ"PI_=W:&R<DUMN=
MCGL;+>;<F]%R1&6`E1U%3KBGU:5+/P0H\?"@E,7=^0G8AO)1MNS7(LF.)#`Z
MD0+6VM&M/E+W`J2>1H*8]G#9FU]S[0W,K+8UMQZ1,<B>L*2D26F764$H0[;4
M@@GPH+`D[;VWL#%Q,+ASF4MY=Q3$>#B>BMU2VVUNN+'5"0DE"3J(-!,-MR,/
MGMF0U00^G$S8G0:2\2A]+026B%$$D+%N=Z"*]G-FX#;,C=,3&QRR]'RJHBE*
M=<651DLMOQPH*41Y4OGC:]!'NT^8D+[R;]QJDV9ZSBVREL6(:E."ZEZK@W>-
M@$\?<MQ",;13#FR]_-R#T6CC)YD)5(<44I1))L\IFSOFTG6K3K4G@;V%!TI8
MBY'MIE5.P"63G&W&HSAD+#;(CLC2XLI"2X$6`4M!3?X(H)E*2@>S%/2L%*?D
MJ7J!XFY>7S)'.]!O?9](/;2,1R]=R%K_`+,=H)MN7'3LE@,ACX$Y>,FRF%M1
MY[0!6RM0L%B_H_\`XH*][)]J\9M&/,FS?PO=JG%L9*6OS=,?""&";G0XE065
M'S*OQ]%!+,WG,A/GN;<VZO1/2D')94IUM06U>'V*Y"A\!OP^$KA8$(4=Q;2D
M8_+8Z#.3`V/MTE>Y,B'29.0>=NHM-N7UJ0ZH$+=O=P^1'"]!1F[MX[I[L;I@
M[>V]$Z&+:5T\)A$>1III`MZS)T70-*![R1P''F'I'MAV>VWLC#!D-MY#,2+*
MR.3>;25+6!\!H*OTVQX)'T:"9)PN(2Z74P8Z724DN!EL*)3Q3QM?AX4&=0*!
M0*!0*!0*!0*#%DG\.A^^Y^@H,J@BG<.WJ>$N+CY<QG[I3:@E=`H(]COQ\SG/
M]88[WOMDN@D-`H%`H%`H%`H%`H%`H%`H%`-!5/>SLE`WU!^4\<$1=U1$?@[Y
M\J)*$\0P^1_>+^M]Z@IWM!W<RG;K*N;5W.T\G!-O=&1'<!ZV.>)\Q">.IH\U
M)'YY/NAZRB2XLR*U*BNH?C/(2XR\V0I"T*%PI*AP((H.Z@4"@X\:#S1V6E+8
M[^[GB:3:0[DM12&U`=.3?BLI4L#C]:H7/.]!Z7H.;T%1>U,!_1#.OX2XA'O]
M84$][?BVP]M_S5"_<Z*#2=Z<GD\;L"5)QF05BY9D1&TSD+2V6TN2$)42M90D
M#23>ZA0;;MS+E3-EXR7*G_*;[Z5N.3;MJ"RIU9\I:6ZC2GX*;*/`4$DH*+]I
MERV0V`TFP<5F`I"CX:5LC_C4&V?W`N-C1A`AE6/Q+SLB)F0W(;;E/0EK?2PT
MHM)92^MQ.E:@XH*&K3<FP"GYG>C>66V_)W(TH,9"7E<?!<&-5(C69::DKZ:M
M"G%*U\E$*]!'$4%W+Q_;WMICE-P<TWMN9D%.3T-3)+KS+[M@IPK9=4I12?@Z
MA97+QH)+B\+L_=,).?F8&&[,R#0:F*DQVW'%=)0&A2EINI`4@%-_"U!)&XT>
M+"$:,TAF.RWH99;2$H0A(L$I2+``#D!04I[)^H[5W"5<SEU\OTE%!.]_9*%B
M]S;.R.0<Z$"/+F=:00HI0IR$ZA%](/PE*M[]!4T7&]YL-MC;F6V).E2H6524
M2,0^E#R([SCJREP)>3\6PM-K\1I/N&@LCMCG%S]V[H:D-/QYZF<9(GQI+!CK
M3*Z"H[QT\4D*Z"2%(44D<C00SM?DI37>WN`REGUC2)CK02E`(+4LZ6RO1KNL
MKX65;T@V%@PMEP-Q0F]WY/(XS+Q7LCBI93%=:DR7O6'WK!+'692E6LJX)LH@
M#SGT!BX#;\Q/9[*1\OCUA4;,1WWF)\1:(SB666KJ=2$LO-QE<BZ$ZD\U7%Z#
MOR&[?5.T>XMIRX+D6((DEC"OZ/(E0L\Y!>*-38=:2YJ:6DZ'6[*3QN*"*XKN
M_FL?LB'L'9;+[NZYLZ<AZ0A'G9#LMQ2$L7%BM2#<K^"@<>?(+\V5N3<<-<7;
M.^`TWN,L!<2>R?P>>E(\^@D)L^W_`(Q']L.%!MW(TJ7E,\W`F)B+<BL1TR&T
MA:V96EP]0@^4E*'$<#00V8P]C]MN0,ZV-L[2QR5.;@F!\*?RCQN5H9=!ZA0_
M\)Q:OC%DZ!XF@\^[QW'G.[&]H>*VUB@Q"9;$/$8Q`#:41V[J2]*4D60$\[<D
M#@.)XAZ%[$[.VOMG!R(<-E2-U-*2UN54D`20\.*4CG^#GFT4^50X\[T%HT'-
M`H%`H%`H%`H%`H%!B2?U_#]]S]!09=!%>X5O5<'<V'RYC?W0*"54"@C^.!^?
M6</AZCCA?W>I+H)!0*!0*!0*!0*!0*!0*!0*!0#0<6H*N[T=EX>]X?RGC-$3
M=$5%F'R`$24#DP^?T"_K?>H*:[1]W,KV\S2]J[F0ZW@4N]&0P\#U<<^3YE)!
MX](DW4G^V3[H>L8DJ-+CM28SJ'X[R`XR\VH*0M"A=*DJ'`@CQH.[QH%`\:"A
M=A([>L]]\BG;Z<A*R;B,BO(/2%:&([W63U6TMEM*U@JO917:@OJX(H.*"HO:
ME7I[1RP"`53(8%Q?_'`_E4%@[&2I.R=OH4;K3C8841R)$=%!J.[S,U_8DUF%
MD(6,D+6R$R\DIM,<`.I)22ZAU%U6LFZ>=!B;34]M/LTU(2]&G/8O'2)2'H[A
M>C.J3U'4D+`3J2H\](`]'"@T'9;NKN/>>>S,+))8]3A,MN1E-ME#ERK22LZB
MDA7&W`$6XT$=]JB2J+,V++0TJ0N-D7G4QVQYW5-J84&T\#YE6TCW:##9[A]R
M%M1,1,[<YI6WX;[3\?1%<$M:8ZPZRVZK3TTV<`U+2.*1:PN:#2Y3>[^\\[E&
M9/;[.+1'>A+5'QRTAZ*]%2\E)>LRI-U=55D'T<:"6]H>V:=QX.5D>XF+GO99
MG(.)QJLH[(3(;BHT.-I2"I-DI=N;VXF@NK#X:!AX?JD%*DLEQ;JNHXMU16XK
M4M16X5*-R?3094@A+#JCR"%$_2H*1]DU07M'.N!.E*\HHIOZ"RW07E01[N'E
M\SA]E9?)X;I'*16"Y&Z]NGJU`$G4I`^#>POSH(1MWNV_CM@,[CW2R]DL@_-D
M0Q\FQ2DZ6=:TW0YTE(2E*3?7QO01;L._)RG=3>&?2E$:)D&E/IBK6DOD2)!<
M;)2DF^@)4%'PN/307)G]PR<1F<#'6TA6,RTAR$_)-];4A39<C6\-+A;4@W\2
MF@UO=)&K;``4$O\`K+/JQ#A9=ZMR$AAP_%AT\D)=\B_@*^%05&C;6&=]GK/Y
M)4?7,]6=6A\R"ZE*T!`\B$GXBRAYF5#RJO;RVH'L[X*#C\)#R.&AM2]V9H27
M),^6H]*!!8?4RG2E/F)<6G@D$%1O=02F@M+=T'(.1FH^X$LSL(ZXV#D8:%19
MF.D*4$M2D76Z"E*R+J204^(4F]!NEO8+9NVGYF1F*;@Q$J?FSY*@IUUQ7PEK
M(`U.+/`!(]``H/*&]MZ[S[R;P8Q&%BN>II63BL2#9+:4FQERU<`#I/$GX/(<
M>8>ENU7:K#;`PAC1E"7EI02K)Y-2;*>4F]DI%SH;1?RI^B>-!M]S;:>FO,YC
M$O"%N&`DB-)L2V\U\)462E/%;*S]%)\R>/,-I@\@K)8>'D%LJCJELMO*84;E
M!6D$I)L.7O4&6XXAO3K4$ZB$IN;74>0]^@^Z!0*!0*!0*!0*!08<K^,(7/\`
MQOZ&@S*"+;_-H^"_GO'?=J"4T"@C^.2?GQFU^!@XX?27*/Y=!(*!0*!0*!0*
M!0*!0*!0*!0*!0*`1>@JOO7V7A[W@*R>,2B-NF*@AAXBR)2$\0P_;^\5]:?<
MH*9[-]Y<GL.9\W=R!T[<#I:<;>"B_C70;+`3SZ85\)'AS3Z*#UI$EQI<9J5%
M=2_&?0'&7FR%(6A0NE25#@010=U!QXT'F/LJJ_M![DNHI).4\J38'\+3P('`
MT'IP4'-!4'M3`GM-('@9L6_O:R:"Q=E\=H8/^;XGW!%!$O:"96[VJRP;0''$
MJ84CS*"@0\FQ0$@E2O0GQH,S86&C97L_CL.^VJ)&G8Y<9QMM\OK;0Z%).EY8
MXJ`/T.7A0:'8/:KYE9C(,8G,O39\]AKUR4^TV/5V@M9"DI%PMUTW^%Z+F_*@
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M!2I86XSYD@\PG38D4%V=W!)';W+/Q(CLR9$0W+BI8MU&WH[B7FWA?F&E("U`
M<2`0*"&8O?T_?G:QS+38Z(RESG8TAB*GUA`8:1K/5CNW7)04&[B&[+T^9/%-
M!KT,K:]G'.(=&ETX^ZE*8#)*2VWTSU$\'T:+:'/A:;)5YDF@=A9/R)L+&9M]
MI;F,ELOQ9CS*%.JCKCS7E-+6E`*NFI+RM1`.FPOPH,C?.^F,8UE&XF1<S&UL
MJI*LE."7'AABXM(64K"=+C;@^ULWU)7_`&/(*?WGOG>?>+>,;"8:.M$+6?DS
M$Z@$A"2;S):N04E//P3R%SS#TIVJ[5X38&$]5B$2LK*LO*918LX^X/`?8MI^
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M\Q0>LXTF/)8;D1W4O1WDA;3K:@I"DJXA25#@0:#L\:#S1V41)'M`;H+@62/E
M/JJ4".<Q%M7O^%!Z8X4$?WQO*#M'"?*LQEQ]M3S4=#;92FZW38%2EE*4I%KD
MF@K+VB<PUE^QS&5:9=CHGOPGFV9""AUO62JRT7X*%!:>R[_-#!\>/R=$^X)H
M-SRH%!`=[;-WYEG,@WM_.1\/&R+C#C[P;>]:TLMA"FDNH6`E*[?6B_$T%?Y3
M<._^T*-NXW(Y&)GHV<R"D3\A,,DNH2%,MK7K<=*4!+:^``MPX\Z"]H<^!-;Z
MD.2U);%O.RM+@X\N*2:#KG91B*M#`0M^6X"IN,R`I92.!4;D!*;GX2B!08,;
M-9+Y:C8Z9"0QZTP](0M+W44D,J;3I4`A*;GJ^!-!NCRH(?+R;VUY:,?C(3F6
MBOGJ-8J'QDQ]9*EJ!64M)9O\$*6FQX"XX`,O<N[<EAHF)>BX"=E',E):CO1X
MX!7%0X+J<>TZTV1X\;7\:"E6-\[I3WS1C49V8[CU9AUE['+6GU=+1?,=#*4Z
MB%)"?/<>8'F.%Z"U>]$Z3&V#,8CQ)4M>04F(H0@5/-I4"M2P`AV_!O3:PN2.
M(YT%<8;8&Z=Q]LH.'Q_JR6V,I/>E.SE.-O*LM26PVI49?E5J.NZ!<>6UC02'
MM)V=W%L_=DG,Y.7$?CK@"(TA@NJ7K4IM:C\9P2E)01S-^?#E07!05KN_:6#V
MYM:0QBT(BQIF5^4.FY=MIJ0ZD"S4E`!A$K0"VZ?*E9"3Y#:@I:-W:AO=K\QL
M5K%+:6WCY`7D&P]T"M#:'%$I6%)0I9)N$G25<1;506CV)S^,P/8B!F,U*3$@
MQ%3%O/KY`>LN6``XE1Y`#B:"E-];TWAWDWI&P>$C+&/ZBODK&DV;2D?"F2R+
M@*L?[4<!<GB%T;$V,CLX?6)!3DL/E$,IS.:#=GX<I(";D)%S#6?HH/%5P;@+
MD204@I(*3Q!'*U!]4$>[ALPWMC9UJ;-7CHBH3P?G-(4XME&DZG$H205:1X"@
M\][=DP(G<_8HPDKUK&/MI9:G-QW(;<TAY]#KKJ%.K*ECBJY^N^M%Z#U+0*!0
M*!0*!0*!0*!08L@CU^)_G/T(H,J@B^_?M."_GO'_`'6@E%`H-%COQRS?[$Q_
MZ*30;V@4"@4"@4"@4"@4"@4"@4"@4"@4"@$`B@ISOGV/9W?'<S^!;0SNF.D:
MTWTHFM('VMSP#@'P%GWCPY!5797O)-V+D%[8W(EU&W2\IL(<2>KCG]1"P4VO
MTM7PD_6\QXT'IA._]C$`C<.-(/(^ML_X5`&^]B!14,_C`I7,B4Q<_P!]0?7S
M]V/_`+PXW]ML_P"%0:C<^3[5[GQ@QN9S./D1`ZA]"4SD-*2XV;H6E;;B5`CW
MZ"J>_P#N_'3=C3L#"?CR8,%V`O'9!.0;F/R5>?K!;>I3UVN%U*)O06QLO>>T
M?FGA6E9R`EY&/B=1M4EE*DGH(N%)*K@T&\^=^T_Y;@?MIG_"H./G?M/^6X'[
M:9_PJ!\[]I_RW`_;3/\`A4%#^U%F\-/?V=ZA/C3`S*D%\,/-N:4E4?X6@FP-
MC077GX\"(T_G<8IIG*1&U.J+10/66VTW+#HN`H*2+))XI-B*#G:$J+)Q:,TZ
MZCUG,`2UE2D%26G/,PS<'DVV0+>FY\:#%R^:PT/?.*5,FL1TG'S`EQUYMM/%
MV/P\Q'$T&RD[TVHS'==&8@K+:%+"$R625%(O8#5Q)H(KM[N=V^BXM"G,F7)C
MR1)GN]!TK4ZL:E%6E!^#\$>@"U!O,'W/[?YN,N3CL[$4TVLMKZS@85J`!^"]
MH418\[6H-)'[==IT;Q5NUEQGY83(5*5:9J9$A8\R^EKTA7'5[]!-_EK#?Z?&
M_5F_S:#+ZB#QU#Z8H&M'V0^F*#%5F,0A:D+G1TK2;*274`@CP(O0:3=S&!SV
M'<AJR[,5U-UL2$/-E*5Z2FSK:E:'6U)44K;7P4#]&@\O.1.X;6S<D],$1K;*
M\>XI"RZP[(6V6$AA`7?7IU6"1;4!PY"@A^&;WOO%K#['QI,QF&MU<*$E.AIK
MK.%3LA]0YA.KX2N0X#B>(>O^U':K#]O\'ZK'(EY62`K)Y-2;+=4.2$7N4MI^
MM3]'G0=O>7,3<-VPW#D(*4*E-Q@VA+J2M&E]Q+2]200?@K-!5G:SN%W)W'OW
M#&:MT[?>C$2(,5HAADI;=#:G5]-SX*FK*NZ#J4.%J#T/01;NET1V[W"7EAML
M0G2I:EJ;`L+BZD)<5S\-)ORH/.?;&1DLGW&VJ^B04R9'5F99326VTK_#'UJ`
M0E35D*4I/E`/.^F@];4"@4"@4"@4"@4"@4&)(2#D(9]`=M_<B@RZ"+[]^T8+
M^>\?]UH)10*#18[\<LW^Q,?^BDT&]H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!P
M1<4'E/?G8KN9E-\9[*0,2V[#G3GI$=WUEA)4VLW2=*E7'O4&;MSV5]R3\:F1
MFLFUAII6H*@I81*L@'RJZB'4CS>BW"@VG]4=^]_G0C]H?_/H"O9'D$_C2C]H
M?_/H/G^J*]X[H;/_`'#_`.?0%^R*^H@C=*!;T0/_`)]!P?9%?TV&YVC;DDP+
M#B?<?H/EWV1)&DE&YFU*%RE)@VOPY7ZU!2<3:&>D;K;VF(81GU2?4W8BE-60
MXD:EG7?20E'FYT%S?U1<B"2-PQ>/CZFH7_YR@Y3[(V1+B"O<,8("DE13$5>P
M-^%W`/IT%R(V+,MI5(QI&D#2,2P$W_5#0?2-C2TBPD8T`<@,2R/^DH(3W$["
M9+=[T%T9:#%,-+B;-XX-!0<TGS%#G&VCA>@\];=V([FNXPV2W)99?$F7&]>+
M16V?5$N$JT7!\W3]-!8>Y_9@W3C,0[-QLUK,RT*0$X^.P6G%I4H!1"EN:?*#
MJM0:#;OL^=Q,IFFH.1QAP\13:G',C(2V\VG2`4HTMN:KJ/TJ"9_U3,Q_O#$\
M.418_P"DH-?N'V8<KB,'D<JO.17T0(SDDL^K+3U`RDK*;ZS:^FU!Z`8PFU(^
M$:FO8J&VRW&2\Y\2CRI#>H\Q0=&U<?MW,8&'D'\+#CRG4VE1N@B[3Z"4N-D$
M7NE0M040?9XR^Z<GF<SBLA!@07LI/0S%=:<*D!J2M%@463I\O#T4'*O9,W:1
M;Y=QWZB]01;='LY]Q<-,9CP8*,ZTMOJ&5"2$I0NY'34'E)5>W&_NT&V]F69%
MP'<W)8G-J.-R,F(834:2"VM4E+R5EFQ^OT@D>GPH/6=!!N]\D1^U&Y'+%15%
MZ:4)+B2HN+2@)NT4J\VJW.WIX4%&=C,C&@[ZP.`0S&C276FW7UI2E;ZNC#>0
MIGRE2=(*4J+M]6H6\30>K;<;T'7(CQY+"V)#2'F'04N-.)"T*2>84DW!%!A-
M;;VZRXRZSBH;;L8WCN(CM)4V;DW00FZ>))X4&QH%`H%`H%`H%`H%`H,20`<A
M$/B`[;^Y%!ET$7WXHAO``#X6;@B_H\Y/Y5J"44"@T6./^V>;_8F/_12:#>T"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@6H%J#B@\G8QL?UK%D<2<S)-
MO>C*H/6(%J#FU`H%!QXT'D3M>`?:33I'+)9G]#(H/7=KT#2*#FU!J]TXEW,;
M;RF)9<#+N0B/1D.J!*4J=;*`H@<>%Z#!B;?R3[$5K.2&GX\1+>B#'00RI;0\
MJW5+)4Y8B^G@F_@:#,>Q$EF8Y.Q;J6'GRDRV'`5,O%/#40""ARW#4.?B#0=&
MSL%,PN*>BS'&W'WYDN8HLZM`]:D+>"1J`)TA=J#>VH/G0-6JW&UOIT%5]ZNS
M$;><3Y8P]H>[(208SX.@20BQ2TXH6LH6^+<YI]Z@UG9'N].GOJV1O35%W5CR
M6&79-D+DZ`/BW+G[>D<>'PQQ'C06/O[:+>[]I9';JY)AHR"$H,I+:72C0M*[
MA"[`_!M00':?9S<VW]V;?6<A$G;8V\E\PRZ@HG:Y#3B5E6A&E5E.>74X=(OZ
M:"X*!0*!0*!0``*!0*!0*!0*!08S_P"OHOO.?D"@R:")]P=-]LWO?Y>A:;>F
MSG/Z%!+*!0:'%V.\<\0%<&("22?*>#QX#Z/&@WU`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%!Y-Q#G_`.UZT@7/RS+Y\K>J*H/6(H.:!0*#CQH/
M(_:AM*O:262.*<AF5`^[\>/RZ#UR!0*!0*!0*!0*!0"!053WH[,,;QCC,X0(
MB;LAA)8?"NFF0E'%*'%CDM/^+<\#PY4&M[+]Z7\L]\SMXWA;JB*+#3CXZ9DE
ML6*'`>3XM[RQQ%!=`-`H%`H%`H%`H%`H%`H%`H%!C/\`Z_B_G7/R$T&301/N
M"HA6V0"?-GH0('B`'#Q]SA02R@4&BQ1!W;GN-R&H0*;WMY73]"@WM`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H!H/)V"1J]K%TWNGY7F\+<B(BS^
M50>L:!0*!0*#R1VJ2K^LBNW+U_,$^]\?0>MZ!0*!0*!0*!0*!0+"@I[O_P!K
M\;F,'*W=!7ZCN+"LF3ZTBZ>NTQY^FLCCK2!=M8X@\.5!).Q^[,ONGMW!R>76
M'9Z''HSKX%BX&'"VE:O[)0%U6\:">T"@4'!)X6%_30<T"@4"@4"@4"@4"@QG
MC^'1A_8N?\6@R:")[_`+NU^-OX=B<?\`-NT$LH%!H,.1\[]PCQT021_FUT&_
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H/*6WO_P"ZQV_/Y7GG
MW/UJY0>K0*!0*!0+4'D_M*U?VBY"O1,S*O[YT?ET'K"@4"@4"@4"@4"@4"@B
MO=:_]&NY[<_DV3]S-!$O9CX]J(I\#,F6/^?506O0*!0*!0*!0*!0*!0*!0*#
M%?\`U_&X?6N<?[F@RJ"+;[2%/[8!%_X<C'T<FGC02F@4&@P]_G=N'CPTPN'^
M;70;^@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@\H[<_P#[K'3>
MX^5YY'[5=%!ZN%`H%`H%!Y1[17_K%2^/_6\SP_MW*#U=0*!0*!0*!0*!0*!0
M1/NT?_QENCC;^#9/'_-F@BWLRD'M/#XW_"YGT/CU<*"U:!0*!0*!0*!0*!0*
M!0*!08SP'KT>_/2Y8_W-!DT$8WO^N-L?STQ]P?H)/0*#08?\;=P_G87W-=!O
MZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#RAMHI_K4KMS.7R-S
M_P!W=_,H/5]`H(C`[FX"=OV5LAAM_P"5H3:W9*UA"60$);4`A6K4HD.C@!PX
MWH)=0*#REVB-_:)E_LO,_HW*#U;0*!0*!0*!0*!0*!01#N^HI[7;I(YC&R?N
M9H(U[,]OZ)H/[)E_=U4%J4"@4"@4"@4"@4"@4"@4"@QGOU_&_.N?\6@R:",;
MW_7&V/YZ8^X/T$GH%!H,/^-NX?SL+[DN@W]`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%!Y0VRD#VIUG_P`WR7W!Z@]7WH%!6>-VE-B]YYFXH_KA
M8FLN-Y!4E<3U<(0VV&1'2A:I'!=[ZT)'U*"S*!0>4.T/_P#<3+_9>9_1N4'J
M^@4"@4"@TN%WA@LSD<AC8+JU3L8ZMF8RMM:-*D*TFRR-"@>?E4:#=4"@4"@4
M$/[P?^UNZOYMD?<S01SV:#?M/"/,^M3+_JZJ"TZ!0*!0*!0*!0*!0*!0*!08
MSU_7X_HT.7_O:#)H(QO>WK.V!<`G-,6O^D/F@D]`H(_AC?=NXO<$+[DJ@D%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!Y/VR2?:H4`#89?(F_A
M^MWJ#U@.5`H*5V=C9"?:&W+.:CDXX,NLAXN,G1(6(ZW;("@Z`NWBD\:"ZJ!0
M>3^SQ4?:&?/@9&8/TU.&@]84"@4"@4%)]GYDQSN]OZ.ZA8:;<405.ET`>LN:
M+7*]%[J-@?H4%V4"@4"@4$0[P?\`M;NG^;9'+]+-!&_9GO\`T3PK_P"E3/W0
MJ@M.@4"@4"@4"@4"@4"@4"@4&,];U^/Z=#G_`!:#)H(KOE5INU$WMKS;7"W.
MT60KGX<J"54"@T&&"/G9N(I^$?4@OWPR?RC0;^@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@"_C0*!0*!0*#REMG5_6F5>Q'RMD;>%OB':#U:#0*"F-G9M\]
M^-P8,H0$,KE22OHI2ZM+S4:Q6[XI;*-*+<?,;F@N>@4'DWLN0KO^XH7L7LL>
M//B5F@]94"@4"@4%'=F%2WN[6^G)2@'6E+00$:5*2N4LM]0H'3)2E'EXWXGW
M:"\:!0*!0*"(=X/_`&MW5_-DG[F:#0>S>D)[3XZPM=^63[I]87QH+.H%`H%`
MH%`H%`H%`H%`H%!CNV]>C^G2Y;^]H,B@BF^4*5D-I%/).<;*C[GJDD4$KH%!
MHL.!\Y]PD``ZH@)',V8OQ^G0;V@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@\J[,&KVI)7,D9+)DWY`=)P>DT'JJ@4%([.:!]H_<\K2[9V.XV@*
M4X-/13'2I2D*3;IJ4?BSJM[G&@NZ@4'DOLD%'OTH\[.96_TUT'K2@4"@4"@U
MF/VSM[&Y*5DL?CF(<Z<`)C["`V7=)*@5Z;!1NHFYXT&SH%`H%`H(AW@_]K=T
M_P`VR/T!H-![-PMVEQATE-WI9L?V0N@LZ@4"@4"@4"@4"@4"@4"@4&.Z/PUC
M\XY_Q:#(H(MO9>G(;3%KA6:;!-[$?@<DCQ]-!*:!01_!.:MT;E23Q0]$`'N&
M*@T$@H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H/*.Q=2_:EF&]
M[9'*D\>5D.#TJ_)H/5PY4"@T<#96`@[@D9^.TL9"27"K4ZM32%/Z.LIMHG0A
M3O11K('&U!O*!0>3^R2;=^G3?C?*W_NU4'K"@4"@4"@4"@4"@4"@B'>#_P!K
MMT^4JOC9`TCF;H-!H_9S%NTF)L;@N2B/<_"7*"RZ!0*!0*!0*!0*!0*!0*!0
M=#OZ]8XF^ASAX<TT'?01?>;97E=H@&ULR%?2@RC02B@4&@P7XR;EY7Z\;W_U
MHW0;^@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@\H=O#?VHIH2+
M`9#+$CT^5R@]7T"@4"@4'D[LA?\`I[=U&UOE6P]/QAH/6-`H%`H%`H%`H%`H
M%!#^\2BGM;N@CG\G/@`^ZFU!I/9SO_1+B;FY+DH__4N4%ET"@4"@4"@4"@4"
M@4"@4"@Z'"?7&1?AH7P]/%-!WT$9W@D*RVT@?#,7'OB!+H)-0*#0X+\8]R?L
MB-^Y&J#?4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'E+MR4'VG
MIA2+?A^7O[]G:#U;0*!0*!0>4.Q@)[\R3?AIRO#_`#PH/5]`H%`H%`H%`H%`
MH%!#>\B@GM;N<DV'J#O'Z%!J?9W!':;$7%KKE$>]ZRY0610*!0*!0*!0*!0*
M!0*!0*#H<)]>9'AH<O\`330=]!&MW?QMM/\`G<_N"7026@4&AP7XQ[D_9$;]
MR-4&^H%`H%`H%`H%`H%`-[<.=`H%`H%`H%`H%`H%`H%`H%`H%`H%!Y-[:'_]
MG)03R.0S)/\`SONT'K*@4"@4"@\G]BC_`/GJ5^=RGW:@]84"@4"@4"@4"@4"
M@4$,[RDCM9N>W^@.\J#5^SRD)[2X:W,JDD^^9+E!8]`H%`H%`H%`H%`H%`H%
M`H,=S]?LC_DW/R44&101O=O\;;4X@?PL>?[`ET$DH%!H<%^,>Y/V1&_<C5!O
MJ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#R7VP"_ZSDM7`)^4,
MT+>/-Z@]:4"@4"@&@\G]B0?Z>)1/V.4/TWJ#UA0*!0*!0*!0*!0*!00KO42.
MU6YK<?P)7N>(H-9[/%_Z),-?CYI7[I<H+(H%`H%`H%`H%`H%`H%`H%!T+'X<
MR?0VY]4HH.^@C6[M/RQM($V/RLJP]-H$N@DM`H-!@5`[CW,/L9,8']IM'\N@
MW]`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(\]W#V&R^J.[N''(>0K0MLRF@0J]K
M'S<Z"0@@BXY&@4"@4"@4"@4'D[MCQ]IB9Z!D<S;Z;M!ZBR6>P>*+8RF1BP"]
M?I"2\VSKT\].LIO:_A0=F.S&)R;2G<;-CSFD'2MR,ZAU*5<[$H*@#09=`H%!
MY,["NA??-TB]EMY10OSL7A0>LZ!0*!0*#$EYG$0W0U+G1XSI&H-NNH0JQ\;*
M(-!D,2&)#*7F'$/,K%T.-J"DJ'I!'`T'W0*!0+B@A'>TV[4;G/\`V)7Z)-!K
M?9U5?M#A%$CB9)_^I<H+)H%`O08WRGC=?3];9UWTZ.HF^KE:U^=!DT"@4"@4
M"@4"@4"@Z5W]=:_2U_DIH.Z@BN\+_./9G`_QH]Q'\W2J"54"@T&WP?G#N<D6
MO,C@&]R0(+'AX4&_H%`H%`H%`H%`H%`H%`H%`H%`H%`H*>]HSN"WA-L_(..R
M2HN>R2DE;3%NH(7$.J6N_P`4E=M(5S/(>F@\_P"V>UF^=T0!-P>%7(QP4&TR
M5K:CH4;7^+ZI05)'V2;B@GZ.S7?U*0!D7`E(L!\L2+6'"@Y/9SO]>_RDY[WR
MQ(H.1V=[_?RBY_KB10#V>[_<0,DYQ\?EB1PH/MKM+[0K1\F4<'$'CEGSQ'OB
M@R'.VWM'!-QE7EG[%.57?^^"10=8[<>T?8$Y*5Q\/E7B/?XT'"NW'M(7L,E*
M-O'Y5_\`BH-'&[#][(N5^5XS09RFIQ9FMY!"7BIV_4)6#J\]S>@R,MV1[VYE
MQMW+MC(/-)*&ERIZ'2A)-R$%9-@30?6&[9=Y=ER(V0BLF)#]=B&:S%G(2'_C
MD-A+B4\%7"M/$<`:#T!EMV;GQ>+E9*3MU/J\-E;[]IS5]+8*C:Z.)L.%!D1=
MP;LD,-/C;J.F\E*TE,YI7E4+CZP`_3H*R[HPN[NXMV1(>VTR,4B+!+KS+.00
MTESJ.E(6K1IXC3;QH*[QG8;O/C)_K^/9$2:`I/K3$]#;MEFZQJ20?-XT$B;V
M)[2R$!`R<H)3\$?*B3XW\3>@Y5LGVF;&V3EGWLFB_P!4T'0=I>TX"D>M9%5P
M"5#)L</<-UCC0?'S3]IWC>3D^'+^$X_'_G*`=J^T]X2,F1_.4;[Y01_*]F.]
MF8G+R&6Q3D^<X$I5)DS(KCA2@62G47.0H-GB>WOM&8G'M8_&"?"@LZNC%8R,
M9#:-2BI6E(<X742:#+^:?M/?Z1E/]:1_OE`^:GM/_P"7R?\`K.-]\H!VK[3Y
M/V[)_0RD?[Y0<':GM0^$C)CW/E..?^DH,3);#]I3*0'H&0&0E0I"=#\9[(QE
MMK3Z%#J\10,'V_\`:-PD)N!BD384)K6&XK60BAI/445*TI+AMQ)-!MTX;VI1
MP4[-MZ1+@G\N@ZW,9[42%:0YD">/*1"(X>[JH.EV#[3Y0L*.3*=)N`]$N>'$
M"RKT%*QXB_E)F+ZJX)_K"$]$MJ$C6%A6G21KU>-!^@]`H%`H%`H%`H%`H.A9
M'KK0\>FNWHYHH.^@BN[DJ5N?9@3X9)\GWACI-!*J!0:#;RU*S^Z`>29S`3^T
M(Y_+H-_0*!0*!0*!0*!0*!0*!0*!0*!0*"N^[O=K'[)QBHT8MR=Q24_@<,G@
MTDW'K#WH0FW`?7'Z)H*B[3]I<MO[++WEO1;KV(?<+R4/72YD'`>!(X:8R>0`
M^%R'"@]/M--,M(::0EMIM(0VVD!*4I2+``#@`!0?5`H%`H%`H%`H%`H-'O*+
M/DX3IP6%2'T28KO1;4E*E(:D-N+`*RE/P4GF:#@,97+O)^4(R86-00KU)2DN
MO/*2;IZI3=M*!ST@F_CZ*!CI*,*T,?D%H9BLG1CY2O(VIGZQM:N"4K1\&QYB
MQ%!\-D*WVXH$$'%-VM^R%^-!(*!0*!0*!0*!0*!0*!0*!0*!0#0>58X6/:NX
M\4G+N'_Z`T'JJ@4"@4"@4"@4"@4&.L#UYH^/37;Z::#(H(QNE)5NC9WN9"2?
MI8Z302>@4&AV\%?+NYU'D9[(3]"!&H-]0*!0*!0*!0*!0*!0*!0*!0*!05OW
M?[P8_9&/]4B=.7N22D^JQ"H%+*;?;Y%C<('@.:OJT%4]JNT^3W_E5[RWDMUW
M$/NE]#3MTN9!P&X41];&')('PAP'EH/3C33;3:&FTA#;8"4(2`$I2!8``<`!
M0?5`H%`H%`H%`H%`H%`H%!\NM-NMJ;<2%H4+*2H!0(]T&@QH>)QD):G(D5J.
MM0TJ4V@))2"3;AX7-Z#+H%`H%`H%`H%`H%`H%`H%`H%`H/*[!O[5I]S+.?N$
MT'JB@4"@4"@4"@4"@4&.Y?U]H>'37^B309%!&=T7^=&S["_X?)_].DT$FH%!
MHMOC^&MS&UOP]KCZ?P"-0;V@4"@4"@4"@4"@4"@4"@4"@4%9]WN\F,V=!=Q^
M/6B3NAY'Q$;@I,<*'!Y_B+"W%*>:O>H*P[3]HLEO?(KWCO-3KV,D.==MMXD.
MSW`1YG+\HXM9*1\(<!Y>8>F6FFVFD--(2VVVD)0A("4I2!8``<`!0?5`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!Y8C&WM5GW<LY^X30
M>IZ!0*!0*!0*!0*!0="_UXW^EK_1)H.^@C6YOQHVA^SI7_ITF@DM`H-'M_\`
MCC<G\X-_N"-0;R@4"@4"@4"@4"@4"@4"@4"@JKO/WFB;0BJQ&)6A[<TAN]B0
M40VU<.L];Z[[!'CS/#F%;]GNS,W=<T;LW>77L4XYZPRQ*)+N0=O?K/7_`,3Z
M!]=^=YAZ<0A"$)0A(2A("4I`L`!P``%!S0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*#RO&/_P"UA'_FSG[A-!ZHH%`H%`H%`H%`H%!T
MK_7C?Z6O]$F@[J",;G4/G7LX7-S-ED#PX8Z102>@4&DV_P#QON3^<&_W!&H-
MW0*!0*!0*!0*!0*!0*!0*"@?:![N;FPF::VQ@'E8Y;3;4N7D4$%U6HDH:;!!
M`3Y?/?GRY4$:[(]JGM[S7MX;H4J3BA(6IIA[5KGR0;J==)M=I"CP`X*(MR%J
M#U$E*4I"4@!(%@!P``H.:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*#RO&2?ZUI/A\K.?N$T'JB@4"@4"@4"@4"@4'0M7X8A/_`":C
M_?)H.^@BVYU)^=^SDDFYES"$^!MCWN)]Z]!*:!0:/;QOE]R\Q;(-CC^P(U!O
M*!0*!0*!0*!0*!0*!0*!0>6/:FP3T3>$/,+=0XWE(BFVV0"%H]3`U$GD=75%
MO107_P!KL?\`)_;K;<34%]/'1SJ'`'6V%^/YZ@E%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H/+48'^M62>`.5<M[OX":#U+0*!0
M*!0*!0*!0*#H5^O4<[=-7O?"30=]!%=SJMO39H^RD3AX_P"@N'WJ"54"@TV!
M"OE7<-[6,]NUN?ZQC<Z#<T"@4"@4"@4"@4"@4"@4"@T.ZMB;2W6F.-P8QK(>
MJZ^@7"I)0'+:@"@I-CI%!N8L6/$C,Q8S8:CL(2TRTG@$H0-*4CW`!0=M`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`-!"F.T>SV-[K
MWHAM\YI;JGSJ>460XMOIJ4&^0\M!-:!0*!0*!0*!0*!0="B?7$<>'35P_MDT
M'?017<I_VUV<+_X^<;?]R702J@4$?VL@IR>YU'Z_*@__`$,44$@H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H,==_7T?8])7T]2:#(H(MN0)^>NT+WN'9]K<
MOUHKG02F@4&AR&Q-JY">[D)4(JEO%*GG$//-A:DI"05);6E).E('*@Z5]N=G
M+O>"KCSM(DCP`\'!Z*#A/;G:*=6F*\-8LJTN7Q`X<?C:#M1L+;+>K0S(3J-U
M6F3!<\O\K0?7S'V[_DY/[=F??J!\Q]N_Y.3^W9GWZ@?,?;O^3D_MV9]^H/GY
MB;<U:M$J_H]>FV^EUK4'U\Q]NWOTY/[=F??J!\Q]NWOTY/[=F??J!\Q]N_Y.
M3^W9GWZ@X&Q=N`WT2K_LZ;;Z76H.?F/MW_)R?V[,^_4`;'VZ!;IR>'IFS#_T
MU!UJV#MPN!P":E0((T9&>D7'N!\"@.;!VZX05F>2"3?Y2R`XGGR?H/D=O=M!
M1-IW'P.2R!'TNO0<_P!'^VP+#UX<P2,ED+V5S%^O0=J=DX1(LEW(``W'\)3^
M=K?Y>@Y1LS#(3I0[D`D>'RE/\>/^7H"]EX98*5NY`@\Q\I3_`+_0?7S/Q/\`
MELA_K*?]_H'S/Q/^6R'^LI_W^@?,_$_Y;(?ZRG_?Z#I.Q\46PCUS*"QOK&4G
MZO'QZWNT#YD8_1H^4<MIM;^,YE[<N?5O0?2-EP4)"4Y'*V'*^1EJ^J7#0<_,
MV%>_RCE?]82OOE!\G94`J*_E'*ZB+'^$IEK#W.I84!&RH"$:$Y'*Z>7')3"?
MIEPF@)V3`2;C(Y:]K<<E,/Y+E!]?,Z'_`"CE/]82O\.@?,^'_*.4_P!82?\`
M#H'S/A_RCE/]82?\.@?,^'_*.4_UA)_PZ`=G1""/E+*#W1D)/^'0=3^R(SI!
M3E\PU;P1D'^/OZE*H/CYBL\/X<S/#_M[GHM0?0V0T#<9K,<+6_#G#:WO\_HT
M#YD-E*DG-YBRC<_AJP>=^!`N/H4'TG9:$WMF\OYB";S%'EZ+CARH/L;0M?\`
MAK*\>/ZZO_Q:!\T?_.LK^V?_`(:!\T?_`#K*_MG_`.&@?-'_`,ZRO[9_^&@?
M-'_SK*_MG_X:#X&S5AL(^7\N5?Y0R4:N?Z7I^I0<+V:ZKX.X<PV/$)D-F_+[
M)I7H\*#GYG.WX[@RY2+Z4==L`7-^8:"C;W2:#X.RGB+#<>9!N3<2&K\1RXM>
M%`3LR2.6Y<S]%Y@^)/BQ[M!V#:,L)T_./+<]5^I&OSO:_0Y4'V-K3``/G%E.
M'I7%_>]`.UYAM_M#E.']E%_>]!S\V)G^\.4_NHO[WH'S8F?[PY3^ZB_O>@?-
MB9_O#E/[J+^]Z!\V)G^\.4_NHO[WH.M6U,F2"C=&61Z1^`F_+TQ30=C>W,NA
M`3\YLBJWURD0">/N^JT'U\@9?_>3(?J<#][4#Y`R_P#O)D/U.!^]J!\@9?\`
MWDR'ZG`_>U`^0,O_`+R9#]3@?O:@[,?CI<3)%4C*R<AJ9(2W(3'2E-E"ZAT&
MF>)]V]!MZ"+[C'^VNT?<<G_N4T$HH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%!C*M\HH/UW25]+4F@R:"+[B_'7:7Y^?^Y302B@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4&,H?PB@_P#(J_1IH,F@B^XOQUVE^?G_`+E-!**!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!08ROXR1^DJ_1IH,F@U&5PKTS
M-X?)MN)2,6J0I32@?.'VBWP(Y6YT&UU+OP`M[I-Z!=ST#ZM!Q=W^Q^K0<W<_
ML?JT'%W?0GZM!S=ST#ZM`NYZ!]6@77Z!]6@7<]"?IG\R@7<]`^F?S*#B[GH'
MN<3^90<@K]`^K^90+K]`^F?S*!=?H'U?S*!=?N?5H%U^@?5H.;K]`^G0<77Z
M!]/_`(*!=?H'U:!=?H'TS^90+N6Y"_T?S*!=ST#Z?_!0+N>@?3/YE`NYZ!],
M_F4"Z_0/I_\`!0"5^@?3H&I?V(^G_P`%`U.?8CZ?_!0-3GV(^G_P4#4Y]B/I
MT#4OP2/IT#4Y;X(O[_\`P4'&IW[`?3_X*!J>O\`?W7_!0-3GV`^G_P`%!SJ<
M^Q'T_P#@H&IS[$?3H&IS[$?3_P""@:G/L/JT#4Y]C]6@:E_8_5H!4Y]A]6@X
MU.?8?5H.=2K_``?JT'-U?8_5H&I7V-`U*^Q^K0+J^Q^K0<:E_8_5H&I?V/U:
M!K7]A]44#4K['ZHH&I7V/U:!J7]C]6@:E_8?5%`U+M\'Z%Q0<ZE?8GZ8H.-2
MOL3]2@:E?8GZE`U*^QH&I5_@_1H&M7V)^I0<ZC]B?J4#4?L3]2@:C]B?J4#4
8?L3]2@Z2A9F!RUD!LIOXW*@?RJ#OH/_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>g5754312nd.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754312nd.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#2`(B`P$1``(1`0,1`?_$`*T``0`"`@,!````````
M```````&!P0%`0,(`@$!`````````````````````!```0,#`@,"!P0/$P<)
M!P$)`0(#!``1!1(&(3$'01-182(R%!4(<4(C%H&1T5+2,Y.STR1TE#55-J&Q
MP7*2LD-3<S1$5+34)756%QAB@J*#A"8WX<)CHV2D195&\.+#Q&4G*(6FUO'C
MI;5VIS@1`0````````````````````#_V@`,`P$``A$#$0`_`/5-!'6\]N>3
MWKD+"L/14O/,M.+F]VM09=+144=PK3<I/#50=IR.\[#^A(A)YCU@KA_W:@(R
M.\R/*PD1)O:WK!1X>'A&H!R.\ARPD0__`*@K^;4'6K*[W!X;?BJ\?K$_HQJ`
M<MO3R?\`=Y@WMK_I`<.=[?`<?S*#[];;ON?Z`:T\+?;R+^/AW5!SZVW9^(4?
M?J/L=`];;L_$"/OU'V.@>M=V7L,"W:_,S4<OJ=`]:[K_`!"W]^H^QT'/K7=?
MXB;[?X:C['0?/K;=GX@1]^M_04'R,SNZY_W=3[OIK7T-`.8W<.6W4GW)K7Z*
M*#GUONV]OB\FWA]-;^@H.1E]VVO\7T`^#TUN_P"LH.LYO>`!(VT#;D!.9X_Z
M-`]=[PTW^+/'AY/IS-_UMJ#Y]>[RND?%<\>9].8X>[P_.H/IS.;M"B&]LJ4D
M<BJ;'23\@:J#Y]>[QM^3!]STYCYE!R<[N\)!&V%%7:/38_A\-!])SNZ[IU;9
M<`/GD3(QMP[/*%_S*#[]=[EU6^+;VFW/TJ+>_N:Z#GUWN/\`LX_]\Q?LE`]=
M[C_LX_\`?,7[)0/7>X_[./\`WS%^R4#UWN/^SC_WS%^R4''KS<?]FW_OF)]D
MH.#GMR#EMF0?<DP_T710?(W!N4I)^*\H$>],F%<_]=:@Y.X-R@`_%>4;\P),
M*X]V[U!Q\8-S?V6E??4+[-0$[AW&2`K:TP`VN1)@&W_7B@[_`%[F/[.3OJL'
M^<T#U[F/[.3OJL'^<T#U[F/[.3OJL'^<T#U[F/[.3OJL'^<T`Y[,`?DY.^JP
M?YS0#GLQ;\G)WU6#_.:!Z]S']G)WU6#_`#F@X&>S!_\`3D[ZK!_G-!SZ]S']
MG)WU6#_.:#@Y_,7_`";G_58/\YH/E>XLPD$_%K(*MV)<@$GW/MF@^!N?*W`7
MMC)I!%[A4%7R.$J@^D[FR!0%*VYDTJMQ1]IDCY(DVH/H[EG</]WLF?D1/YQ0
M<_&2;;\G\E\J)_.*#CXR3?[/Y/Y43^<4#XR3?[/Y/Y43^<4#XR3?[/Y/Y43^
M<4'"]SS4@$[>RAN;<$Q3^=(H.%;HF)(!V[E#?P)BG\Z10=;F[I:+WVWES;YU
MN,?SGZ#CXXRN/^[68X?]%'^ST`[QEA83\6LQQ[>ZCV^7W]`^.$G^SF7\)^"C
M_9Z#M^-:_P`293Q?`)^R4!6[5)%SA,K;Q1P3\H+H.E.]VBX$'"9A-S8J,%P@
M>/@30=XW?&(OZMR@\1@O_0T#XW1OQ;D_O&1]#0<G=L8?^'9/[Q?^AH.#NZ-^
M+<F?]A?^AH.?C;&M?U=D_O%_Z&@^/CI!_B&2\[1^\9'G>#S:#?T&KVT_W^*[
MWPR)8-_\F4XGM]R@VE`H(MCMQ[KR;7I<'#1#`+KS2%/3EH=/</+9*B@1EI%R
MB_G4&:,AO'C?#0_%]OK_`)M0<^L-X?B:)]_K_FU`]8;P_$T3[_7_`#:@>L-X
M?B:)]_K_`)M08<#<>Z)SDUMG"Q@J#(,5[5/4`5AM#ETVCGA9P4&9ZPWA^)HG
MW^O^;4#UAO#\31/O]?\`-J!ZPWA^)HGW^O\`FU!UN9/>B4W3@8JS>VD9`CY/
M&.*#J&9WS=-]MQP/?6R*3;W/@.-!]>N-[7_)QBUN?K!//P?2>5`&7WJ4G_=U
M@*N=-\@FUO&0R3?Y'R:#CUOO<*M\7(Y3?BH9$<O$"P*#L&7WAV[>;'AM.0>'
MU.@#+[OU&^WV]/8?3D7[.SN_=[:`,ON_3QV^WJ\'IR+?+[N@Y.6W9PM@$6[?
MMUOZ"@>MMV7_```BW;]NM_04'/K;=?X@1]^M_04#UMNO\0(^_6_H*#%R6Y]Q
MXZ(9<C`#NDK;;.B8V3=UQ+:>&@<-2Q>@R3E]V7'^[Z3?M$UOA[OD4'/K;=?X
M@1]^M_04'4YF]WI3=.VM9O:R9S`^3Y0%!\'/[QUV&U5Z;^<9T8?F`F@^G<[O
M%"K)VP7!\\F='`_T@F@X3G]X$'5M5P'A:TV*>WCVCLH.?7V[>\(^*[G=WX*]
M,BWMX=.K]&@^SG=SZ1_NT]>W$>EQ>=OT]!]#.;EL;[;>![!Z5%^CH.1F]Q_V
M<?\`OF+]DH'KO<7]G'_OF+]DH!SFXQ;_`';D&Y[),3A\MR@>O-Q7/^[DCW?2
M8GV2@Q)&[\Q'FQH3FW)7I,L.JCMB1$.H,@%?$N@#SA:@RCG=Q@C_`':DF_,B
M3#X>[=T?F4'RYN#<B#PVO*<\:),+_G/)H/GXQ;EN1\59?#D?28-C[GP_Y]!R
M=P[ETA7Q6EDGFGTF#<>[\/;\V@^CGMR!0'Q9DD7MJ$F';W>+H-!\'<6YKJ'Q
M5E\!P/I,'C[GP_Y]!RG<6XRL!6U9J4=JO2(![/!Z10=_KW+_`-G9WU6#_.:!
MZ]R_]G9WU6#_`#F@>O<O_9V=]5@_SF@>O<O_`&=G?58/\YH.#G\O<#XN3^/;
MWD'^<T'/KW+_`-G9WU6#_.:#X5N++IU?[M9$Z3;@Y`-^%^'VS0<.;DRS8N=L
MY)7,`(7!4;C_`&GMH/@;IRFLI5M?*"PX*O!()\'"50=<?>JY$B3&9P.34_#6
MEN4C3%&A2T)<2+^D6-T+!X4&3\99G]G\E[EHO\XH.F-O)<HOAC!9)9CNEA[R
M8PTN)`)3Q?'8H4':-S3N'^[V3%^?")P_[Q0=+^]%1Y,:,[@\FE^8I2(R-,8Z
ME(07%"X?L+)23QH.Q6ZY*%A*]OY4`@G4&V%CAV>0\J@(W:M0XX+*H\1CH_0<
M-!]?&M7XERGWN/HZ!\:U?B7*?>X^CH'QK5^)<I][CZ.@?&M7XERGWN/HZ#OQ
MFY(\^>N`8DJ'*0T'PB4UW84WJT7205`V-!AZCX?_`!>W,?*YT$BH-+L^_J,7
M_C,W^6.T&ZH%!'>GY)VNR2=1,F:;\OX:]08V_MWY_;D>&YA]MR=QN27%H>:B
ME22T$I!"E60YYW*@B@ZP;Y[II2^FV6"UH4XM.O@`E>G]JO\`((!\`(XT'R[U
MBWNB3Z..GF24/21',C4ONQ=S3Q/<]B>9'D^.W&@DNV-\;FRF;.+RNT)V%19Q
M:)SJT.QRVBP3=:!8+6;^3X.-!MML?OG/?UFY]89H-[0*!0*!0*!0*#6[DRLG
M$8*=DXT)>1?B-*=;@M$AQTI]XFP7Q/9PH*ZPG6G<^0RY@R=B9&"V&I#O?.%P
MDF.TMP-@=PE.M9;TCRN=!AN]>=T-OL,?W>Y-;[S+3Q;0IQ13WP*@DV8YVMS^
M3:@[L7UNW3DY28T;8<Y#JWT,#OEO(2.\.G6M7HQ2E#9/PA)X`\+T#+==,_C\
MCZ&C8V0E@LQW4N,EP@K?:2X4?2/>:E)]T<AV!]8[K;NG(9!$!KI_DVGW2I+2
MWU*;:!3<DN.%FR4Z1SX\>%!G[(ZO9K<F>C8N5M&;BFGBZ'9CY=T-EILKL=3+
M8YV2?*YD<Z"7;Y2%;<=!-K2(1^5,:-!OJ!0*!0*!0*!0*!0*!0*".Y@_[Z;<
M'_19#]8U02*@4$.ZHYS<N'PD"1MQ`>R3V2BL",H)(>;425LW5YNL)MJ[*"N=
MN;\ZM9_-X_%M/"'"W"Y(FQ<B[&07H4.(\XR['4V4AM3ET('E7/E4'9$ZK[L9
MGX_:TA;CN23G40Y67?;:95(B>G.-%+4<(TGX-L!:T^;?PT&+NOJYU#Q6X\E@
M8*`^8^0D!F4XP@O(A!C65*C(&I2&;EQMP>>$V/&@^I/5'<Z)LUOXSH;VTPB0
MK%[I./0I,Z2AII2882$]W=*UKXI2"OD.-!F9+JINW:TI*]P2TO')X%&2BP%M
MQXOHTQYP@-!2RDN!H#B"K4?!0;/)=6G\<SLMF9DXL:?D\:Y+S*7TV"75PM<4
MK0E.M"7)'()%SRH('#ZZ]0(L839<IN7%TN,J#C##".^,3O=29*3W6IMW24LD
M:RFX4`;4$DP76C/R%8S$R9#+N7FYF(PMU'HZ0F&X&0XCN;]Y=6I1"PDCQBU!
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M!G0?C)MHW-O2)/#C;]Z.T&_H%`H%`H%!H3?X]IX</5:K'_:!0:WO5>`?E!IY
M#E\WQT$PH-1M0$85-_V^5^;*<H-O0*#0;$O\6(U^?>R?%P])<M00OJSN_;J)
MK.%5OM>TLE$'>2VV&''EN(>"2@$I%A8"XL;\:"$F3#CQ,;)E=9YR6)J%JC*[
MAY/>Z7U(N+DK";H*?*[>1MPH.EZ?@6IXCR>KTJ/'ARUJ>QRX\IEQ)1([U3:B
MI5]0/`:@1X!;A03?IUF\1,WM*]6]05[BC242'&L$\AQ192IQ*TJ0ZH\FD63Q
M':>5!.]K_OG/_P!9N?6&:#>T"@4'QW[%K]XFPX$W%!R7&P;%0!/($B@B&_E[
M[EP(1V)/A,R"XI4ER24*2IO0=`1=#HXKMRH-%@('748S*>N,QC#-T?T7W;2%
M`K"'-04M*6PCR]'$H7[E!@G#>T.J.7'\[C7'VBTY&:82&DJ4>\2OO5=UQ2BZ
M%E-O*Y<+4'?A<3UY$K*R,IEH3BC!6QB$-%'<IE*=04..(#*?-2%A7BX#CQH-
MMLIGK$WF6_C7+@2,/W;Q4J,$][WETAI'DH1>P"E$B@YW:SUA<R,[XL2\:SCC
MI]$,D_"H.AK7<=TM/G!?,]ON4&'+A==AM2"F+D\6K<?>7F!30"-`+E]*[:%"
MQ;X!L$<>)H,-K'>T"8H4YE,6O(MKD((%DLEI8;+*M(:42;I7:]K=O.@V.R,-
MU;*\JO=V::2N2RTWCUPPRXEI:%**UI;4TE%])"5:KWH&Q3UD:S)&[E0Y.&4E
MVSS"V0M!`06BI*$)O>RN1[?%02+>KS3VUE.MD.-KDP2A23P-YK-B#02.@`6[
M;T'!6A)2%*`*C9()YFU[#Y`H.:`;VX<Z"F%K]J+TGR$8GN2JPOW1LG5SY@\J
M#-<8]I!4];7?X@02XXCOD)"5Z-*M+B0K787`L#<\>-!UB-[1SDF"TM_'LPPM
MCTIU!:4]H2I)7JN@).H).K2.WA09>$>]H/UU"3EH^,]4JD-"<ILH#B&-7PNB
MRN)T\N%`S;GM"J<6,2SBD-AU>A2U)*E-ZW"@$*X`Z-%^//Y)H.O7[1WK-20C
M#&"AYD%RQ&MM2T]Z4#65#2F]]7'P=E!TSG?:-3&]&A1L<KSTJEN+:+YU$#6D
M!26QIU$HNGD/*X\PS\K-Z[P\PTWCX$+)XKN&5O.$LM.!XH'>MI*G6[@+!L2F
M@E.64H[VVR5#23'R!*+C@=+'@\%!):!0*!0+"@6%[]M!\]TWI"=`TIL4IL+`
MCB+4'#C##OTQM*[?/`'\^@*CL*6%J;25IMI44@D6Y6-!P8\=2"A32"@G44E(
MMJ/;;PT`1HP4%AI`4GB%:1<?)H-?N7+1\)A)^9=C]^F(R7'4"P4I">8U$'P]
MM!6;'M![6?;C2)N'<CL3FW'HKSKD<]XAKO4$@$@WUQ](!\*:#99'K9LV%@(F
M6$9#J9:9J6XR76`L"$[W:D\^/>><@#G01]'M,;,>8<6[@9:_1VT+0$)9<2`I
M81I*K@(M?MX=@XT%J[-W'#W+MC'YR$PN-%G-]XTPYI"D@**;>22GFGA05/U0
MV5N3=>4F-X.*)#D'+AY]9<;1:T"'W:%(<6VE2%$$DD*(MP%!F=/IC[G7'>#9
MBMJ0>^2J9J6MUON5,A#)((;2A6O6$E)5>_'G08?5>5G(NS,N<0[)[U[<3S;[
M$-3B7'6UQ[:+L_"6!LH@<.'&@ET7?^)VE@=GXC*QY:Y60@Q&6U,M`I2O2TSI
M7J4@ZM2_-2";7-J"19XCXS[8'&Y?E6\'[T<H(]OOJ=+V[O'![:BPVG%99<?7
M)=<.H(>E!A26F4CRE)3=5U+2/=M:@L*@J3J;UPRNQ]S(Q;FVS)@N(2Y'GJD%
ML/W`UAL!M8NA1L03^?08']_>]K:ATXR>@\`;O\_O:@G?3O>V;W4Q/=RFW9.W
MC$<0VTW**B7=2=2BG4VUYO"@E]!'PDG?ZE=@Q('R3)/S*#6__O%03*@U.U=/
MJ1K2+`NR#SOSD.$\:#;4"@C.TU3$;)"X*4.3!Z8J*ARZ4*<+[I0E?(VO8&@A
M$R)U5RJ/2<EL/;<C(ZRV^N6XEW6VA*2TI"[+58*4H65^C08@B]3I&.BIC[`V
MXDPY3["&5EE;'HVD%*V3>Z`75+)(Y_.B@^9,GJPXN?)E=-L-)R`[MHOA3*^_
M:65*<%U*U+`(',_(H)!T\5O-W<;J]Q[)QV"0W&4B+E8?<ESR5I'<DI4M6E2>
M(MPX4$MVQ^^<]_6;GUAF@WM`H,/,XQK*XB;C'EJ;:G,.1W'&[!:4NH*"4W!%
MQ>@J9SV7MGK0X@Y;)_"<[J8-N-^'P7#C;_V-!N\IT(VWDMS,;@D9":)$<1BT
MRA38;U1`VE!/D7TD->;RXFU!K9WLX[3<C34QI4EM^2ZZ\RL=TGN@XMM:6VSW
M9LEONB$_IC0:U/LX0&G^^;G20A!'=L*>96+)5J%RJ.>WSN'E#@>!H,N/T#::
MQ$K%C(2U-/NA]#AE)U(*6G&^[`[G3W:N^42+4'5_A^M$B16\G*;;B-NMCX9M
M6OOGB^K5=GL5PO0<.^SRP[CX<3UE-8]#;<;0ZU(0%J[QU;A4?@?)/PJDFW,6
MO0<R_9[CR,A*G>L)27I#O?=WW[:FN/G(6V6;+"K)\[P4'.&Z`JQ,KTN-EIJI
M/H[T5"W)*"6VWVRTK02R>2%&W9>Q[*#&_P`.;*G0ZK)SN\4L*=*)+;:E!-]&
MHI9XVY`]G909$?H`TQ%Q[+60FA>.>>D-.>E(.I;RFSQ262FR>Z'9QN;T&PV3
MT@<V9D7<G"DO2E+CN,NLOR$ADH6$<="&1Q3W?.XH)+D3)=V,D2$I"0["+2TK
MOJ`EM$*/!.GCV4'=U&Z>1M[XZ)!D9&3CD17N_P!<4@%=T%&E0/NT$-Q_LWX:
M'+,CXQ91SR'$)!6V%?"H*"=6DGAJ_P#:]!W1O9XP3.$R&-.8FNN3E,.)E.:"
MJ.ZPI9*V$VLC6ATH(X\*#IE^SCAG9*G8^=GQ&E!7P#6C1J4XI:2?#I0O0+^(
MT'0KV:X0:+;6Z<HVH?2W`4:DV'`W%C?YX]O#P4&XW;T/C[BDMNKW!/BMM-,M
M(91H4F[+26M7'C=03Y7&@QY/0</Y"1)^,TYN/)D.278S24H%G%H66PH'S?@D
MB@[&^@N.3MJ9AEYV>\Y)F"8B<XH*6W9ONRT$DV4DI)Y]MCV4&&/9Y:[F`P=U
M9,-P2]Y:"E#JTOD727+DBR4A(H.ISV=2LW^..6L;%:=9TJ4D6"U`*'E6)N>T
M\:#:9SHI+RT]R4O=V4:2I8<:""`MI02E`T.)*>&E";W'&WCH,.+T#DL"6D[R
MRKK<F(82$K4?@TZT*"@0OFD-V%!]GH.^<FF;\;\GI;(*&U'4?)X)"E%1U!(X
M>4+^$T$IW7!7-WCMEA,I^)\%D5]]&4$+X)9%B5)4-)ORM0;%6U'E"QSN5',<
M'FQS]QJ@Y^*SWX]RGU5K[%0/BL]^/<I]5:^Q4#XK/?CW*?56OL5`^*SWX]RG
MU5K[%0/BL]^/<I]5:^Q4#XK/?CW*?56OL5!P=K/\/Z>R@_UK/V*@^3M.25$C
M<.5`L!I#K%AQY\62:#X5M"8>6Y<N.`'!R+S\/&/0<#9\X6_WGS';S7$[?]FH
M.1M"<$E/QFRY!(-RN(3P[/WMRH.$[+6-%\YD%]V"$:T0%6![!>+PH!V62A"%
M9F<H(&E.IN`3^;%H.Q.TG$I*$YF:E"O.2&H`![>($6@[$;;F-H"&\_D$(2+)
M0E,()`'8`(W"@B^+;B1-P;D8E[MD1)*9;:BAQV`AQ3:83![PI6QR'$7``X>[
M0?.'W'B,ENV9MF#GLMZP8+RGG@WCTM+7'[M+G$,:R1WB0%*38]A-J""]3Y^2
MPFUB[&R<IIYK<\H*FH7HD*)B+TW[KN$GB?$+>&@^M_Y&/(F=*ITK(*9FR$15
MJ'H_I-TNE@N.]^L'4H*L-)%^.KF*"V]P$?&S:PM<EZ98WY?:B^R@KGJAD,*W
MUFV?'R,'TEU*&%0GD27&%-/.3-`44)2M+B1IOI-K^&@NF@T&]MDX/>6#<P^8
M0HLJ4%M/M6#K3B3P6VI04`>P\.(X4&+*W#L_8&WX4',9D-,PV6X["I3G>RG4
MMITI.A`UK-D\PF@ZNG_4S![Y]:.8=I],7&NH9[]](1WI6DJU)2"2!P]]QH)=
M0:1#7^^KSOAQK2;^X^X?T:#46/@_]14$RH-1M(I.!8*>1<?M]77X*#;T"@J_
M%]-,3NC#8_(S9\^.M,=V,EF*_P!TV-,MU8<MI)U^41SY4%;92=T5C9B;`EY/
M=:IT.2ZS)`DK`6XE:@H`:D^3J!MP%!SC<=T-E83(2<9F-Q1V,;'$M]AN24+2
MVIX-E2&O-)U*!/B-^=!C2=P=")#JG',WND+TMH[Q#[B1Y"4HN!X2!J5^903/
MHHYT_E9\RL#E\T_D.XD(5CLE([YK0VML%\@"UUA:2GCPXBW"@M#:JU*>SNJU
MQE'4^3X`TU;L'&@WU`H*QZJ;LW#AIZD8K,&')1"0]CL2F"7U3I"G^[4COE)4
MG@DBR$64"=1X4&KRV>ZDXU_<!3G5R6\%+Q;3+:H#`](;R"FN\2HI'`MAP\4T
M'?OWJGD(.7S.*V[D8CN3CHQK6.A+2%%4QR:MJ6R3;S@WHO<^2#>@B$GK%OA]
MM4UG(I@N/Y!;#6'=:B]ZPR)`:TJ0H=\LI&JZQPX<>V@^('5GJ:MV.,SD&,4S
M.@)R,!PM1FN]0MQ+24E<@:$GR%KMSL>'90<8OJEU3R1B-IR;+>1E"(W`@)B(
MO*$I6E;IU()'="ZRM)T`)L1QH,A75[JP.ZR/H31C,-SH\W&H;!<4YC&$^E24
MJ4E)\EUX'0+CR2./.@2^JO5^-%<8;98?>@,0\D_/]'/VS'R)93'9#2;)2K6\
MH$I-_)H-Y!W]U/<VCE`^F.-UXW.1,0VR&DAITJ+0<23Q2`[J-E#E>@T$?K'U
M5G,O+CQH[#.3,V1C'W6CKB,8S6Y):=0!I6O0$IN3S/R@[(W5[JBU+;7D4QT2
M'8\/(8O"-QRIS(,S7+!A"DZEH=0W=5^0MQX4'2KK'OY&V&\RUEHDO,/%33FW
M405-K892P7#-4I7E'0KF>+:ARXT$BVMU4W/E][,[:FEH,(];"2H(0AYUN.!W
M!<9U*6R4G4./!8L103;.?\/X@('%_&C_`+^P+\#\F@R^H.9EXO%Q%L99C!HD
MS&H\C)R65/I;;6%'R0!W:5*4D`*=(0/=M007![JZDY5>VQZYCL(W`G(D+]77
M"$X]5FW4:G05)D)LH7MSX4&4QU:DQ\!L25E,A!C3<X^#F4NZ6B(NAX%U*5*^
M#3WC:1J/"_"@B['6??,@-LS'HF)6F"F:B24,:)27GE!E31E2(Z!\'Y*T@DZD
MFU!J(?77J@_";E7A>KP_$B3,D&`$LN3D(6CR2L)^#"'+ZE`<1>U!LQUBWJY-
M]!]<P(\0R@VO,NMQ2AM`C]]I);D.QR2>SO-1`L/*H/O^^+JJJ(N*J%#CSU0?
M7R)KC:PV,>IL)0WW)/G*?(`4I=[=E!W_`-\G4LR)3J,9'+4F>K;\6"M)0[$R
MO=M*27%>5WJ"I2[#R;A/.@R>FO5;J)F]U8*!FV8R<5ET35,26FBE3OH*5(61
MQ.GX5-_<H-4GK_OM#;4E>*8<9QL94[,-E"T>D1')`:8>C+"E:!98"[I/$&@R
M7.L?4V-*+&0C8^,PF9%QLF:6EA,>5.;;D("TJ='D--%8421QMRH$/K;N[)RY
M,5S(8?;R(47TA,J8T\XF:MI+EU1;K0GN7R@*3<ZK>;JH,;_$+NY&.>D/Q(K3
M\AAQ<=E2"TJ,XW*#*0OOG4F0%)U!24)U)('"U!<67(^/&W./$QLCP^0Q022@
M4"@4"@4"@4"@4$4ZA2NHD;'QE[(AQ9DPN$2FY1`LC3Y)3J<:'/GQOXJ")8C)
M^T87_P"D\3B@QW+]BA:-0>2VKN+V>/!3EO\`DH/IG(>T*YB,B^]CL>UD6%,J
MQ<5(:(D!2UH=0\HR"E&E&E=TJY\/#0?<S(>T&QK1'QV,EZVUE#WDMAM2%W2-
M/I!UEQL6`X`*/$VH,5.9]H_0`O!XT.JU&P+10"#Y"=7I6K24W)5IN%6%K$D!
M8NT']RR-N0WMSQVHF<<2HS([!!;0=:M(20I?O+>^-!YYZW)POQKSI?:R#N8D
MNMQ<:(BXO=%9AM:4N,J"I*M1=4+I%N-@;T$JZ7X^,UUDSSSZ7$3#Z6B,F_D:
M&RP%C2!P4G4!=7/LO08/6=V*C961]+CMN(7N64VAYS65,J,96E:&VUMZSPMY
M1L.=CRH.[>6V<_D9/3-R%AY3S$*)#]-6A!6B.`[&)#I%KZ0DW&E)[;V!`"V<
M^HC=VUAS!<F?+$57&@JSJ^B*>MNQ>\EAHN*CAUE2%*%D2RILW2#;6OR?S3PH
M+VH*`Z]=0NI.$W#ZMQZW<1MM2&BG+,,%2G%+'PH[XW`*.Q*=)\=!6R,#LR3N
M_:"(><<W/ZWF-HSBY25LJ%WFTAM25DN`*2I7$K-Z#U_C<7C<9$1$QT5J'%;`
M"&&$);0+"W)(%!D`*UDE5TFUDVY4&E;(^.L@7-_5K-QV?3W:".^D/_Y7Y4]W
M_F?*Y4$]H-)LR_Q<BZB"=3]R.7T]=!NZ!01WIX;[/QY\/?'Y;ZZ#<>J<7Z4Y
M+]#8]*>"4NO]VCO%!-](4JUS;4;4%5;NZD8O:^Y(SKFT$N,NZV'\FAGNU)?<
M>+"&^_4VE/E,LZE)[;I`-A>@Z-P=6L89,O%N=.\AE68JU)>!B)6UWC2BF]E-
MJ%O)N%4&^Z=]0L1N7<,B''VV<-,:9=><<?#2)!L66U7:"4N:5C0`L\]%O>T$
MCV6D`[ATGBK,2B>/(Z6Q021"2E(!45$"VH\S\J@YH%`H.-*;WL+^&@%"3S`^
M50"E)Y@&@YL.'#EP%!QI3X!__&@YL/!08F5C29.+F1XCG<2WF7$,/\1H<4@A
M"[IX^2>/"@J&)M/VB&%W=ST:0H(+;9](T(">[+9*TF,HK6HZ5I5?@4GYZ@^W
M-F^T`^N0\C<K,3OB2J.IT/64W\(A32TQV^[0XNR"C3P3?B;T'VYM7VA'HQ"-
MPPXLI/$/:^]2NZ6T%.DQQI`*5K[>=O'0;C9NVNJ<?<3<C<610_BNZ>0XT7T/
MJ*%@!MOR8["BM*[J[S5YI";<+T$FWI&:8VJB.WY+;<S&I3<\@)[';02124J%
ME`$>`\:#FPX<.7*@ZG(<1P@N,-K*19)4D&P\`N*`N+%<`#C*%@<`%)!X#W10
M!$BALMAE`;)!*-(TDCEPM0?(@P@@H$=H()!*=";$CD;6H.U3+*C=2$J)&DD@
M'A>]O<H..X9O?NTW*M=[#S@+:O=H"6&4Z-+:1W=^[L`--^=O!>@^?18M[]RB
MY3W9.D>9>^GER\5!BYG'*EXF;&C(:$I]I894X$Z0Z4%*%JNAP<#;CI/N4%,+
MVU[1K[T?O)<-)0IN^I,-<9*6D!*5E):[S5SOI';PMRH#.V?:,>::&0D8]S5>
MQ`AE;;A5J"W=;"TJ05*NXE'E*TBQ!YA:F10X=Z;>*S<IB9#44@VU?:P^502*
M@4%5=:,!N?*3,:K`8J1,?;1=V4PZ6P@(>0L(!,J.E*E#5Q+2^%!#MP;*ZR26
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MWY;"CY)3IY4&BR&P>H,*,[#A,9F3GPE;KN?5D`Y%=CNQ%F1';9UIT*5(5I0G
M23R5JH,9S:?4-+D3UGA\U.R37I*LO+1-4Y&DH(2(0;;:EQ3\#[Y(TF_'C0:2
M/T_ZS&%E9,7UMCE1F=<.)Z2M*I+CKRVRAM/?.E.AA:CQ5\D\Z";[XV_U,E;A
MG+QBLDT@8\!F5&E(#:VD0;*B!LK/PKDP7U:=5N(4*".9C:G7=.2>0N3D9@+3
M3F2R$=X`+:4AGO(S#*'6FU*:7JMI"%*L?*LJ@O3I]'SL;96'CY[7ZW:C)1+[
MU?>.:DW`UKNJZM-M7'G0>>NM$V(SOS--R%H[XN)5C7(X2B1$EAB&I,F0]I+G
M<Z$*TA!X64;7XT$]V$SA6^NVXW&G9:\J_%67PXPAJ*4@L$K;675..`\"E138
M@^Y0;#</3ES?6$GX]$Q$$Q=Q2I16XT74K"4E&DI2MOGJ\-!:&,AB%CHL,);2
M(S+;02RDH;&A(39"25E*>'`%1]V@TN>%]W;7\2YI_P"[&@R<MLO:V7S,'-9'
M'-R,IC2DP9:BH+;*%]XFVD@&RN/&@W5!\/,LO-*:>0EQI8LMM8"DD>`@\#05
MQNWV?NGV?6Y)CQUX:>LE7I$`A""H]JF2"W^I`/CH-ITOV7N?:4";C\SG59N,
M7$'&*7KU,M!)"DG65GB>-M1%!-J#1M?ES)_JQC^4/4$?[P?.'\J-/R?GO<H)
MY0:/9((VS$!\+WUY=!O*!01#;:=TX7#L8M>%$CT8N`/HE-!*PIQ2P0%6(OJ[
M:#:#+[DLJ^`4"/-'I3'&@/Y+.+1H.`4ZDFRDKD,6MSOQ)H.WUGFN']#.>/X=
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MU`]<YCA_0$KQ_#0^'#]VH/L9?*W`.#E`7XGO8GV:@U6ZEYS)8@1(V%DETR8C
MQU.Q``EB4T\O]F^<;-J#9KSF22I(]03U:@#=*X5A?PWD"@^#G\D#;XO9$^,*
MA?SF@X5N#*6\G;V0!\:H7\YH.?C!DO[/9']5"_G-`^,&2_L]D?U4+^<T#XP9
M+^SV1_50OYS0/C!DO[/9']5"_G-`^,&2_L]D?U4+^<T#XP9+^SV1_50OYS0?
M7KZ?I2?4.0N>:;P[CC;C]L6\?"@[3F903?U1-Y7M]KW^O4'4=PR@4?T)D#J5
MIN$Q^'C/PW*@Y&?DDJ'J7(>2+^;'X^(?#4&IF9'(/9['9-.#R'<0V);3@*6-
M>I]3.C2GON/TM5!L3N:2`/Z"R9OX&V/LU!Q\:)/XAR?U-C[-0/C1)_$.3^IL
M?9J!\:)/XAR?U-C[-0/C1)_$.3^IL?9J!\:)/XAR?U-C[-0/C/(_$.3^IL?9
MJ#Z1N5]5[X/)(L+\6V>/BX.F@[$[A=)XXC()\9;;_0<-!R,^YP_HJ>+V_8D<
M+C]/0<^OUW_!<[D3?ND?*\^@Y]>J_%L[ZDGZ.@C._P"(-S83U:IG*0%!8=3(
M8B-OD6!0I.E>KFE9\T@^.@K5SHO`?R:)F0EYJ4.^#LIE.,2VE\!14H+4E=]2
M]2@I7;\B@^G>C\9N6B5B\AG\<\VI/=J:Q_$(:7WC.HI6@K<0KB7%7*O%06?M
M2>G`;=@8=4++350F@VJ6N&M*G%7)*R-2K7)\-!&Y6UMI9S-9;([CVG.EO/S$
MN0GS'=2LL",PC2KNUIX=XTO@KL]V@W6,QNV<7NJ;N2%A<NWD\BCNI:BRZMI0
MU)((2LJT6T#@FPMV4&1MO,OX].3$C#Y,&5D),IJT92O@W5`I/`\.`Y4&Y.ZV
MP$GU5DS?L$1?#W:#6Y7(+?S^"G-X^<8\-4DR%>C.W3WK.A'`"Y\J@VAW9"`!
M,+)<>5H$H_G-T''QN@_Q')?^7R_L=!]HW1"60/1,@F_ST"6/_AT':G<,(DCN
M)HMVF%*%_<^#H.$;C@J_@\Y/$I&J#+'*_P#T7+A0%;CA)M>/.-S:X@RS;QGX
M.@P\<ZJ7NV5,;8?1%$!AD.OLN,!3@>=64I[U*";)4+VH(S>-\\G\K_G3],\'
M/GXZ"QJ#5;6;0W@8B$>;99^6M1/Y]!M:!05SMW;6R4;)CYK.0&5D(7(F3'$*
M<<)[Q7E$IU+43?LH.\XKI6+(]2.`*X!/JZ?;ZS0?#7]TZG'(S6/=+D<_"LI@
MY"Z"4A0U`-<#I(/N4'RX_P!(VRV7H:VBM8;:4Y#GHNX1P2DJ;'E$#E0=I7TN
M/DF!(XV%C!R/&_NM4'P9/2=M;31B.H<>44,MF%D$J6JRE$)26[DV0H\/!0<K
M=Z5H\M4%X$723Z#D;BW,'X+A0<-/]*9*6G&8[I;79;:TQ9X0M)3P\KN[$>5>
M@^T/]*%O+82PKOD)2M;9CS0H)62$FQ1R)2:`Z]TH9:[UYDM-@@%2V)B1=1"4
MCB@<2384'9IZ7_Q57WO-^@H-GC-M;$R<02X,-MY@J4C5\*DA3:BE22E12H$*
M%N(H,OXB[3_%R/U2_HJ!\1=I_BY'ZI?T5!PK8>TE"QQR+>);@/RPJ@'8NT[@
M^KT@CCP6X/SE4'4>G>SB2?5_$BQL\^/E6<X4'*NGVTE:=4-PZ>*;R9)M[GPE
M`7T^VFLW7$<4?')D_9*!_=[M*P'HCED@@#TF3P!Y_LE!R=@;5)23%=)0;H^V
MI7`\N'POBH/OXC[;O?N'K\K^E2N7U6@Y&R-N#DR]]]ROLM`^)&W/VE_[[E?9
M:!\2-N?M+_WW*^RT#XD;<_:7_ON5]EH'Q(VY^TO_`'W*^RT'!V/MP_L+_P`B
M7+'YSM`^(^W`FP:D#Q^F2[_+[V]`5L?;BA8M2/#PF2Q^<[0<*V-MLJ2KNI`*
M>(M,F`?)`=X_)H!V+MPW\B6`>-A/G``^$`/6'+LH/OXF835JU3M0X@^L9_:+
M?M]!]?%##_MD[_S"=]FH'Q/PW/7._P#,)WV:@?%##_MD[_S"=]FH'Q0P_P"V
M3O\`S"=]FH'Q/P_[9._\PG?9J#A.S\0$@%V<3VGUA.'_`,:@Y^*&'_;)W_F$
M[[-0/BAA_P!LG?\`F$[[-0/BAA_VR=_YA.^S4'RO9N'4@I[[()O[Y.1G`CW#
MWU!\'96*X:96318:24Y*=Q]V[W.@Y;V;CVT:$SLH$^/(S"?EETF@^CM"";?;
MV3X?_4)?V2@X^)V/U:O3LI?E^$9GYW>V[*#GXH0>/V]D^/\`]0E_9*!\487\
M>R?_`)A+^R4#XHPOX]D__,)?V2@':,(C]_9,?_J$O[)0/BA"N3Z?D_<]82[?
M7*#J5LN*HD^M<L/G0)\@6_TN/R:!\2HNDI.5RQ*B3J]82`>/@LH"@+V7&4`!
ME<LE(-[">_Q^25:OS:#CXDQ[W&7R_B^WW^''QG\^@[?BDG\;Y3[Z5\R@?%)/
MXWRGWTKYE!\G:(-_Z9RHN+"TH\/'Q30?+6T7VB2G<&6-^'EO,J_7,F@[?BQ)
M_'V3^J1_L-!PG:TD"WK_`"A]UQ@__!H!VO)/_C^4\/!QC[#08^&9FP=U3<>O
M(RIT;T&/(2)10K0XMYY!TE"$<P@<*"'_`/[\T%JT&IVFK5MZ&KCQ2KGS\]5!
MMJ!05_J*.D3!22K4TR`3QN%R4C]'A06!0:3!&^<W'XIC'\B8H,;>@'>[>N;`
M9B.2;VY-.F@[]O[WVUGG"Q`F)].2%*<QSOP<I"$D#6IE7EA)N"#:Q!![:#KW
M)J]?[5L+_;[]_O"30;V2K3&=5>UD*-_<%!K=H?DGA;\_0(O9;]A3V4'5%_+3
M)&_+'01;L^GRZ#IWX?\`=Q0N03,@`%(N>,YF@D-!H]H_O7(_UG/_`)0N@WE`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%!HV`CX\33?R_5D6X\7I$B@@^I7_P"W%N0Y4%J4&GVAQVUC
MS_T7Z)H-Q0*"O+$]'H`YW;A<_NIKP4%AT&DP7X<W']V,?R)B@QMZ(UN;>3<B
M^78XCG]*>Y4%<],LUTTPSV<R<=E<!^(L1YKI=$\../O*2GN5!L2^\<4WQ:T`
M<!9/;03N3F\9FLGM&?BY`D0WIDK2X`I/E(A/I4E25!*DJ2JX*56(H)1/-H,D
M^!I?ZTT&OV?^26$M_$(O/C^PIH/B+^6>2_J^#]>ET'5OBWJ)L'MGXX</N]B@
MW]!HMH*"HF1(-QZTGCY4E8-!O:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#2QP3O.>>%ACH8\=R_)
M^900;0?`?RWU<Q06G0:39*M6T\6KPL)/:?#X:#=T"@KUA)7TAQ@'-2(%ODRF
MJ"PJ#1X`E69W&;$`3FD@FW&T&/R[>WMH,?>7[YVXJQ4$95*]`%RK3$DJ`'CN
M.%!673+=.TH\7<60V[@DX9U"V')4O+3EAEQ;SKB=+I2E[N7$*U62$?*%!)-I
MYV?G8NRLGD'D2)3^0RI4ZT`&R&T2D(T%(3J2$``*MQ'$\:"Q<E;U=*OR[ER]
MOTIH,+:0MM7#`]D&-]930=,10.],F/G<?!\':]+H.O?`'J-O^L,;_+V*#?T&
M@V828&0)-[Y7(_F2W!^A0;^@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'E_?^Y<S!ZCY:%.FY9#2IBD2EX^>E
MICU8\TCT:-Y1[J,LKN5+595E>'C0>FX:0F(PD)4@!M("%JUJ'DC@575J/CO0
M=M`H%!I8OY9Y+^KH/UZ700O3[OY:7[/FT%G4&EV5J^*>*U&Y]'1<T&ZH%!7^
M/LKI'A[\BC'FW/G*:H+`H-)M^WK;<9N2KU@@&YX"T&-:U!C[POZ7MNW/UJ+?
M(AR:"A,1AG)6Q]SR<`W-R7I3.-;B0%+>7,TID.%2-4=N,@MZ7/-&KQ\*"S]E
MX^=C\/TYA3XZXDM@RTNQEHT*;/HKUDK%AQ`/$GSN=!8V4OZLEVY]RY^L-!B;
M53IVOATVTV@QA;P6:308$:0RQO///ON):88QN/6ZXLA*4)2Y+4I2E'D`./&@
MPMP[AP>:VXB1A\A'GL(R6,0MV.XEU(*IT=03=)/'20:"84$>V0+8R=Q)OE<F
M>/W<[02&@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4%-;DVWT_5DMT8U_?S^+3D5N3L_B4O1`A(<2A*[]XTI8\
MG2`G5>@MW&M,,XZ*U'67([;+:&5JYJ0E("2>7$B@R*!0*#2Q?RSR7]70?KTN
M@@6IOYY/Y<_.J\[P?\O*@M>@TVS;_%7%WY^CH\?90;F@4$`Q^G^Z3#:;6[O'
M<A;^$L^&@G]!I=O_`(0W#_6(_D4:@Q=XH*YFVD@E-\K;6GFF\*4-7YM!3F;C
M0]I;1S\'`[SES\FA.,)EH=6&XZ5/N(1H6TXM()2@A21[T#AQH)WM&?+FX[I\
M_,G*R$I;DY#\Q5SWRVH[[97<A)MY/#Q4%A97\%S/W!S]8:#&VQ^36)^XH_UI
M-!$=XW#?4!1\T;>9X=O!N;00WI]A\IC.GSS4U:2AS-XEQJ,WZ19LKEQE.&TA
MML@K4K4=-QXZ"\Z#2;0!&+D7-[Y'(D<`+?;SU!NZ!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0!>_B[*!0*!0>7]R]PW
MN/=,]&1##^&R.7RT**]&BR$&5&;C-_LOE'7WHT7!TZ21QH/2^,D*DXV)(4;J
M>9;<42`+E:`>0X=M!DT"@4&DB*2=Z9,`\4XZ#<>Z]+H(%Z>/GO\`UMW7+M\%
M!;%!K=M:?B_CM*=(]';(2+=J1X`*#94"@@:$K3TJPR3<JT8H<#X9+%!/*#2[
M>_"&X?ZR'\BC4&)O,$S-M)U%.K*VU)YC[1E<1XZ"C=J[;VS+VEG(T@R<?%S3
MD%]^3W,7*OL`]ZK4?0R5MI4I)TJ<91H506AM^'"AIV%"@)<]$AN366ENQEPU
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M`"[U\_\`VX>*@N8T&IVC?XK8DGF8C)/R4`T&VH.%>:?<H((LE/2O!Z>%QAAX
M[*E1P>5!/*#2[>OZPW#_`%D/Y%&H,3>!)R6UV[VUY10O:]OM"5X:"D<;M_=W
M3W8>:RC4@XG*3I\-F'.=D17XZXW?.`)U(UALV<)<4KR?G:"Q]EYB=FL;L+*9
M!\R9DI60<>=(`X]VZ+"U@4I'D@]H%Z"?9X@8/(D\O17OK9H/C;0`VYB@!8"'
M'X>#X)-!H,N\XQ,W>^W,&/<;Q,=2)Y07.X*42B'=*0HJT>=8"@A6Q\Z_EMIO
ME[*KR\2-N/',P,@5/+*D%V*M20M]*75`.*5YP\7*U!<M!I=H$'%/D?C#(_RY
MZ@W5`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H/,V]<GG<CN[/YAR<R['VX<B]C,=.B(>81ZN4PVI24!:$J<6N
M1Y*E@D`>Y02+V@&&9C&(?E-XEI"HR529<ET-Y-Q-]1CPT:'M(-R=>DV/@[0L
M3H^8*NGV+7`Q"\)#6E:V(3CBGEE"EDAXN+2@K[T>7>W;03.@4&B@I_WURZN'
M[P@#Q\'91_1H*W__`'[H+E/*@U>U4*;VSBD*-U)B,@D<B0V.-!M*#Y=^E+_2
MG\Z@@J;_`-U>WM/.V$M?[JC4$\H-'MMQ*\AN/3?R<GI-^'$0HU!A;X=+<G`6
M<#2O37REQ1*4)*<=+.I:@#I2GF304ICMO8_(;/RT=_?<-S`PUQ'THBM+>@1D
M+=5P]%*4J945H)N%6/:`";A9NU,3'Q,?8.-CR_3F8S,[NI):4R5H+1((0ORT
MA.K3QXGMH)SG_P`!9'C;[5>X\OV-5!\[<M\7L7;EZ(Q:_/Z4F@C.?Q4S+/[T
MQD0-+DS<7%881(*@T5+3)2`K04J2"?`:",[8PLG%;=<2ZXVM<C<N/=($I,UY
M(2[&:*7WT!*2O4V;"W!-J"W*#0;(6%X-Q8)-Y^2XGG^_WZ#?T"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@\^[
MTV;+ESMV0WMF/R\]E)J7=O96%';]#2RHH.I]\J392E)5WP7SOPX4$XZD,=)7
M3!A;V=9@Y<1AZ%):[UJ0VB]E=RZT#Y(5?R3<>*@SNB4M^3T]AZW''8\=^5&@
M..^<8C#ZVX_&R;@-I`O:@GE`H-+`'^]V8/\`V2"/]*305CZ1'^?'Y=>'MH+H
M/`&@U>U5H<VSB7$"R%PV%)'B+:30;2@^'R0PX1STG\Z@A,1)7TOVV.%RG"<^
M7[YC4$YH-%MC3Z9N$I!!.45JOX1%CC]"@Z-VD#([=)"2D3)!*5^8;8Z4;*\7
MAH*6&<Q>=Z=3'T;73B<E#>QSV7@0(:PQ.AV<5&39I27DL.(XE?+LX@T$[V`E
MSU5TX4XH*4J%-6=*^\"=;:5!&KPI!T\>/"@L+<9MM[*'P1'S_P!4J@^L"G3@
M\<GP161\IL4$.W*[`0O?B\@V\[!:Q<54IN,X6GE-AN05!M8(TJ(\=!I=MX?;
M&*V9!9VTU/9@N[@@..'(H4AU;ADL@J&H)!39(%P.8\-!G^LG&>K3\.3)R;+<
ME]L06$RHR(#FF"A2QZ,X0^OB#<MBU_DT$GZ?_DX?N_)?_P!P?H)'0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*#HFSH<&,N3,>1'CM"[CKB@E('C)H-=BMVX7*
M9!S'Q%N^E-LHDE#K+K.IAQ10EQ'>)3J25)(H-Q0*!0*``!RH%`H%`H%`H%`H
M%`H%`H%`H%`H%!7'4?JPS@L!F1CHTYO,1`MF)(?@2/1.^'O^^6A+2D#PZK&@
MU^^^G&[]S;FQ>X\9)@(,./$5&$Q4@*9D,O\`I#BFPR"FSHLA5SYM!9&#]>^K
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M!;EZ.URY>8*"'YF`K)2=^8\)<<,G'1F4MLI"G"5L/CR$E30*N/(K%!%=E8'*
MX;8\-O+Q78F1D[D@/R&W6FV+J+["1I0RM;>FR;>2$W\';09+NT<TOKHUN1+N
M+C1&CW7=M/A$UYHQ2E0=;"=2U:B#8FVD"@GVQ4E.W@#VS)Y^7.>-!OZ!0*!0
M*!0*!0*!0*!0*!0*#7Y_<&(V_B7\MEY*8D",G4Z\O\P`#BI1[`.)H*&'M43E
M95L>HV&\2N0E*EN/.>D(CE827%)2A2=03Y6D4%FGKITJ21?/H\KE\!)^Q4`]
M<^E25!)SR`2+@=Q)Y<OVN@X/77I2!QSZ!?E\!)^Q4'']^W2C@/7R+GE\!)^Q
M4'*NNO2I///)'^HD_8J#%QO4K8.Z<^XY$GG(0\0VVIIMN/(<3Z2\5?"*0&R;
MMI19)(X$FU!2^X]\;AV)U/S^3PY9=&:N\A4EB2!W"G+I2EMX,D$*2=1%TGQ4
M$[Z:>T1&G(R*-\S(T!UE;7H"H[#_`):%!7>:@GOAY)"?!SH)XGK9TN*4GU\V
M`HD"[3X/`7Y%N@^D]:NERN6X&.6KS'>7ZB@^CUGZ7)%U;BC`7T\>\Y_J:#D=
M8^F1`(W!'L>(X.?0T#^^3IB5:?C#&U`7(LY>Q_S:#Z_OAZ9_C^/\ISZ&@K;_
M`!50DSM+NW7/0`[I7);E!;G<A5N\2T6TZC;RM.J@N[$9?&YC'1\EC)")<"4@
M.1Y#1U(4D^#]$=E!F4"@4"@4"@4"@4"@4"@4'G7J%M^-DY^=WG`R4O+0MLY1
MI.2Q65;6Y#"F7&R^B(M!X--@V<'=DV!^2'?UWD9Q.Z8+V-3)EK5CF7<4UC7W
MDR(:VY&M^5W#23Y*VK-A2^'RK4%K=*)4.5L+%OQ&U-,K2X=+DE4QPJ[U06IU
MY24$N*7<K&D6/"@EM`H-'CORPS7W+`_72*"O+2/#_P"JK^:/,\/G<O'06\OS
M%>X:#`VXL+V]C%@$!41@@'F/@T\[4&PH.J7^]7OTBOSC00]E26NG6V4D\2<&
MA)`[3(C6X4$)A[:S.4>D,0(4R;LUW+/ONXU.1A)C+<:F*4\5'N!*T!])66RO
MGPO:@L[:_P!/SO\`6;OUEJ@P-[N!.0VZL`J"9,PV38DVQDO@`H@7]TT%,;0A
M;$G;(=C2,@\W"5*Q2%3T08RFS/$=QQ4=UE#6M]+:BH*[S4+D$'F:"U,1C<;C
M9^Q8.+>7(Q\>).3'>=&E:D]VWQ*=*-//S=(MRH);N7CMS*_<<CZTJ@[\/^"(
M/W.U^L%!#<ZB2MS?J8L7TV2K'QDLQ-*U]ZLL.Z4:6R%G4>'DF]!H-IQ]SL;!
MQ"-R1WX<[U_![J+*<6ZIMGTAH(2E3CCSFG@;!2KB@BJ,1-D>U,N8W`GKQ,1S
M4Z^&[Q43%P$CO"HI`2E2-(YDE7BH+IV3;XOHM_&IOR_3'KT&]H%`H%`H%`H%
M`H%`H%`H%`*@!<\!VF@\Q]<^I$;>N2A[-VM%&6$>6%"0T"M;\I`*>[C6\G0G
M4=;AX>#AQH)=M'V9MMMX*.=SO29.:<&N2([Q:9:*N/=(`!U:.6KM/BH(EUDZ
M3;/VDQM\X<2T.93)MPY)<>+OP*_.T@C@KC060GV;.F83I")UO`92_F4''^&K
MIE^US>'_`&I?S*#G_#=TT!^ES3;E>4OYE!#NKG1+96V]AY+/8LS$3H7<EH+D
M%;9[Q]#2@I*D_.K-!,.B\-43HQ!R6!Q\8YZ5">6G4E+?I$AMQT,AYP6)%^'$
MT%=^TFUDWV=B/YJ.Q&S<I#[&0$4ZTH4I<>Z$+5Q(25FU[V/AYT$[1[,/3I)O
MZ3DU6YWDHXV\-FJ#ESV8^G:UJ7Z3E$ZC?2)*+#Q"[1/RZ#Y_PP=._P"-Y7[Y
M;^Q4$"ZM=%]K;5:V\O%2IQ7D\HS`?$AU#@[MWGHLA.E7CXT$^'LP]/0+>EY6
MWW2W]BH'^&'IY_&LI]\-_8J#D^S%T]/.7E/OEO[%01S?'LS08^$5)VA)DNY2
M.2LQ)KP6EYL)-T-E*$:7/G;\#08GL[=2,5A@YL/-,'&SE2G5Q'W=2`Y(<4-<
M9Y*OI;R2+`<C[O,/15`H%`H%`H%`H%`H%`H%!YBWP)+N]\S/1`C/;;C9%+67
MG(CS_5J7TJ2D>FH:D-H>6WJ3WBDM\Z"6]7U3SO;',X#)1]LYTXLN2,])F>A1
MGXH=($9*2E8<4A=U_P"2*#6YK(I;Z/;1E8I<["A>1\N0B4M$=3G>.J=?ERM*
ME%AY:2M*M'&XH+1Z<;\D;L8R)?C,H5CGTLB="=4_!DA2=5X[JT-%6CS5BW`T
M$QH-'CORPS7W+`_72*"J_3GOVE?Y46\[L^>Y<J"[7B0RX1S"3R]R@P-L_DWB
MK\#Z''X?ZI-!LJ#IG*"84A1-@EI9)\`"301!1!Z?[7)M<N8(CP7](CF@K;9$
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MUW'"XN.=!+,S$R4MW>L?$A*LF]%B(BI<6MI&ONEZ;K0IM2>?/50:':V`W'@]
MG8V!N-WTC('<$52'ER')1<;[Y!2HJ6I82?)-DIL!;PT'&2Q\J%ULQ<UQ&*<C
MY)UQO4PE*\HE:(2BCOB]K4AK0V;=SI\?.@GFROR?1]TS?Y8[0;R@4"@4"@4"
M@4"@4"@4"@%0`N>`[30><.K_`%AR.YIZMB[%"Y3<IPQ)4R.?+E+/G,1U#DT/
MV1SW>SB0L3H[T;@;&A&;-+<O<LI`3(E)'P;#?8Q'!Y)'OE<U'Q4%E@4%*>TR
MM+</9ZEDI1Z\9)7JTI%N/$\A\F@N:/*C26@['=0\TJ^EQM06DV\!22*#MH%!
M7W7T)/27/`\+B-Q_VMJ@YZ!_\(-M7_:'/K[E!77M6_A#9'W3(^N1J#T+0*!0
M5'[022KXCIN!?<<3G[O@[:"W*#6M[DP#F67AVY[*LHVK2N&%#O`K1WEBG])Y
M7N4&RH%!3?7#HFWN9E[<6"3W>X6F_AXJ;)1,0CB.0N'TCS%=O`&@UG1#K>Y,
M6SM'=SBFLHV1'QN1?NE3ZD\/1Y.KS9";6N?._3<PO>@4"@4"@4"@4"@4"@4'
ME'=&0PK&4W;%F8A3F1,O(*C-A,X1W)!EMB.7&T.AI25-=XI5QQ(%!<N\=TLH
MS<+;2MLX_./B+'D(3.DL1TH<D.*:;:;0\V[Y2E-\+4'9AW]T[9V%BX.<QQR4
M^5(?8G)3+C($=EYUQ;9[R0I"%A""E(2GD/<H)-L;'8K$[7@87&SV\BQC&4Q_
M2&U()5;M4$%0!-!OZ#0XL?[Y9XW)!C0!X@1W_`4%8:G/GO\`U#X!S\'.@NB5
M^]7OTBOSC08.UOR8Q'W%'^M)H-G08V4_!LO]Q<_6&@A[W_#_`&G^[8+Z_'H*
MEQV:1DM])0O,-179<]QY#;V5E($;N)ZF3'6Q?X9Q\)U-I2I`2#QX<PLG<F'R
MN7V=N['8Z2S!G/Y8AF3(<+;20#'/E+LKFGA:WBH,>#A5XC:&TL6F:Q*<8&0M
MD8?PC)4N#+5WB"`J_%?8D^Y05ML'![MWST_RN)QF<;D!J;$8>3*=D%!CLLN-
MJT>0.[2NZ"E'@3Y0!/$+9VS$D15[%C2)S>3D,0)P>G,N=\VX4I:25)<]\+FU
MZ#M1U#PNZ\+NR%BVI"58J+)9DO.AH-ESNE@I04.+4JUN=K>.@B75C:V5RDW:
MKD20PR!%$72[-:A]ZI:F@ILH<\MQ"FRI)#?E<:"5;M>>CP-^/,Q/3G1#C@1=
M(<U@L*%M!2L*YDZ;&]!$.F*C_=_B(Y91'+&Y66@V4!#NE"DE*GT%+:DNJ'SW
ME6L>5J#$CNA7M,!!BMMJ2X\4R&V0VZXD0+76];X1*2;$>'3X*"W=D`C;K8)N
M?2)G&]_X8[VF@WM`H%`H%`H%`H%`H%`H.%$#B38>&@\Q==.NCN25)VSM>5;$
M(2IO)Y)H^5)(MJ996GS6A>RU>^Y#AS"R.@O37;FW]N1L]'D,97+9-D*<R3'E
M,MMDGX"-<72E/)?:3S\%!:P%`H,/*/XJ/%5)R:F41F+NEQ_3I3H!.H:NT"]!
M7N%ZH[,S&0?E;:<=;,8-*R"763'8?:=<[M.G7H^&T$.(MQ*>!\06;V>.@7M0
M5W[0*%+Z2YRW#3Z,H^,"4UPH,KH7?^Z3;-S<^BGC_K%T%:^U8"<CLBW\9?\`
MKL:@]"T&(O+XIN9Z"Y-83-\D>C%Q`=^$OH\@G5Y6DVH,N@J#VA">_P!A`<=6
MY(@M[IH+?H*:P,:-(]H7..@L-K@V7\)K3*=4]";;*6R$E"V4!-RG@H$WN>5!
M<M`H!`-!YZ]IG9>T6([.X6'T0=Q3'VV3!;22J>2H)UA"/*#C8XZQSY'C:@V7
M0_K<K)+9VCNMY8S;:E-0<@]Y/I&C]A>U6*7T\N/G?IN87F*!0*!0*!0*!0*!
M0*"@\QTNW*[U-R&XD;+Q^0P[RG$HA/3DI0\XI8)F.!:5Z5JXG0$V^303S<W3
MW9VY=XM//Y29"W%$B,.B-`D):4AEEU?<NZ2A5M+BE!)H-EN+&[:PVR7'=RL+
MW'!PR%2%.9%#4N0LW(U76E"-5E:0>'"@[NGJMHRL(K*;9Q+6*B3'G4.MM,-,
M*6N,XIC4L-<#Q0=/BH)10:'%?E?GCV=S!%O<2Z?T:"J__P!XJ"[)IM#?/@;6
M?]$T&#M0ZMKX<VM>#&-A^XIH-I08V4MZLF7X#N'+GE[PT$14F^PMI@`GX7!G
M@>/!U@T%;R,YID0<$Y*94]*W"Y-9W:AUY80EJ:$D=SW0TINH11Y7=:NV@D'4
M.&_*V'N5B&VZ_,=SZ1#;8XN=_K9".7'SN>D$VY4'9MC#S8NR]F8A<)3$PIR3
M;D*6@Q]3JHLD'O`"5)2M2KZN=C>PH(V<'D-F;)S,O-XR2$N+QZ6XS$UY$E2H
M\=;:[/8X+TLZC\&'+=NLWM03#IY'<8Q_3QMP)2H8B:NR%=XFR_1U#RAXE4$!
MZ8'%B5O]V&7;^JGP%E:%(4A'>6NE+:%%8OQ4JW,\.=@GV\]B97<.<PDUN-&>
MQ<2`AN69$ER,%DO-N]VH-(=4M/P85;R>/;0?6^E*.&ZC=TM33K<:,4N-ZM06
M(X4FVE2"D\N-^'.@CG3%P.[#Q+XU6>W.TI(=<#[P'`6=>X+6H6\Y8!M;WMJ#
M?QX&ST]:W9WK&=\85A3/<%-H14(J5F.%FY*@U\+;E\F@EW3U97M.*LBQ4]+)
M`X#C+=-!(Z!0*!0*!0*!0*!0*#A2T(!4HA(`N2>``';0>;.K76#*[ORB=B["
M*Y4:4ON),R,2'):QY[+"^&EA(^F.<C^EYA8_2OHKA-J;?=;R[#.1S649[K*N
M*3K:#2AQC-!0X-CM/-1XGLL$,DL;@Z%YLS(W>Y+I?D7@)$:Y6]CG%D#4+]ES
MP^>'`^58D+UQ.6QN7QL;)XV0B5`EH#L>0V;I6D]H_1'909=!27M-Q?38NT("
ME%#<S+AAQ8`44AQ.BX2>!(U4'"/98VXA:5MYV>A:%!:%I2P%!23=)!">!!Y&
M@VQZ#/D_EQN"UN7I(YT'">@TI)U#?6?!\4@4$1ZN]+Y^W^G^0R2]W9G*-L*8
M'H$Q\+87K>0GRT\+VO<>.@LSH;_PEVS:]C$OQX<W%>&@K?VJBH3]E6_C+_UV
M-0>@Z"F<[";E^T%![I<5MR.U$?>+SRFGR&T/C0RU?NWM?>(U7\H:>'(T%S4%
M.>T0L)E]/K@<=RQ!?B#Q-N%J"XZ"NL/L;=$'J[EMS>D(1@<BV-;"'E_"*2RA
MMO4SI`UH4E9U%1%CP%Z"Q:!01+J/U%P^R,&9TJ\B>^2UC,8UY3TE\\$H2D<=
M-_.5V>[:@BG3GISFI^:_O!Z@@2-T2+*QF-5Q9QK/O$I0;@.\?\W]-<T&!UOZ
M(IW"V[N3;3(;W$U9<J,@]V)B4<0H$>:^BWDJ[>1H.OH7UK&=;;VON9\HW$P5
M-Q9+PT&4&^;:P;6D(]\/?<^=Z"Z[T"@4"@4"@4"@4"@H7?\`D.I6$W&^_,S"
ML<U/R"4[>F'(QH^-2Q=-FWX:VEO.63]-5>W;09'4]W#L]2UK?@JRN2DXB)&A
M0O2UP$JD/2UH:*'&E)<6FVM3A\U"4W[:#>8??>W873W!.';LJ1CLW*=@O0&5
M*R+;2P\M#BW''R2MDK3<$]E!9V/CXZ/%2UCFVFHH4I241PE+>I:BI9`1PN5$
MD^.@R*#18E*1NS/*`\HHA`_(0Y;\^@JS7XO_`%!I[/F4%U3OWE(_<U_K308&
MU+#:V&MR]!C6^HIH-K08F8-L1./@CNGP^\-!%6Q?8>T[V/EX7W//9H*APN3V
MB)+L<MH1/D92`ZC'JDNJ2HC,/H,1+1\UIE)$K0#YY!-T\*"<;_6ZG9.84PA#
MKGQB1\$X%D**7V[`!KR[\!X_S*#ZVAE%O;6V7D)"TC2K*+6ZR%-@!MB2+_#%
M6E5D\;DIOXJ"L<OE3N#;V?R+4F88V0S.)A-3Y3D=R2I;3+VL,.M=S&.G6"/+
M0-/-7907/M=B.P_L9F,XMQAO#S4H<<+:EJ`]$&I1:6\BYY^2LB@T^"W9*S&V
M-QQ9SL%4QC$/O2&8T:1'>LM#B4K6MP!I:24J%V^%Z#KZN[A3#:P6&;>F>DY<
M,,QX<1R-W3I+S?TYEU*GU)[-3=J#=YS*9'$IZ@9+&I2N?$9C.QTKTE&I,4'R
MM:D)T^'CRH-%M/=.;W3LS;V9R[2&I+^X6-"6TI0WW0)T%"1=0'Z<E7;RM0:F
M(TU_B4,A3D-^4H/,JC(:DMR([:(ET/*<="&G%+%D^2I7DG@.9H+1Z>A(VC#T
MWMKD<P!Q,ER_*@D=`H%`H%`H%`H%`H/EQQ#:%+6H)2D%2E$V``XDDGE0>:^K
MG5K*;TS+6P]BE<F')<,:;*8N%3%WLIII8\V.D<7'.1'BYA:/2+I!C-BXWOGP
MB5N&2@)F30/);3S[AB_%+:>T\U'B>P`+%H.B=!ASXCL.8RB1%?26WF'`%(6E
M7`A0/`T%2=/]E[JV7U(R&'P$IN7L!Y/I,J-(6KO(+[@);::YW6;`GLT<5>5:
MX7$#04Q[12THG;"4I02!G&[W_P`WM/"@N9*DJ`*3<'B".1%!S0*"L_:,-ND^
M4X:KNQ!;_:$4&TZ))T])]L"UOM)/#_.505E[4I<]=;*2+%L/N'3XR_&'N\J#
MT**"M,ELW=?]\T7=$!L)Q"F&H\]PN-$+;2AS6"A0[P*2ON].G@>-R.5!9=!3
M?M$<9G3P6O?<L7\^@N.YH.2:!>@B747J-A]DXA,J6%2<C*5W.+Q;(N])>/FI
M2GF$WYJ_1H(STZZ>9N9FE;_W^`]NB0/Z-QO-G&L\;(0+D=X0?D>[>@M.@<Z"
MF^M711.X`YN7;+?H^Y6"'7V6U=V)?=@:5`CS7T6\E7;R/8:#YZ*=;$YY#.V-
MSK]'W&TGNXS[HT>E]V+%*P;:9";>4GMYCP4%S`@CA0*!0*!0*!0*!0>8^HN8
MPV/ZA%B!%EPSC9K62RF.R,E:D9!X24E*83#@D)*G0H+20I((X6X4&RZ\Y&;%
MW['DMOHC28\!@8E],B*TID.NN"7WS+ZDEU+C7D!*O)_-H-OFXZ)O1S;T/`Y'
M,8Y#X=CL(AI&14^@AQ*VI'H:M&A0\W0?)Y6H)+T,P;F,Q^9<<CNP5RI+:C`,
M*1`CM!ME*+LMR"I1UD%2R.V@LZ@T6(`^-6?(YVAWY_M2J"H^[R?^5^&[\QYW
M_M\B@O.=^\I'[FO]::#$VW^3N+^XV/K2:#8T&'F_P-/^YG?UAH(J$!.QMHI)
M/DN88"W;937.UZ")Q.FV]&LK%GN1(9S+.4,M[<HR,DOKBJDE:VC&+/=Z3'/=
MZ-5NV@W&Y]N9/<&S<UC\;$CS99S3CR8LU2DL.):D!1"])%Q8<J#JPF"SF(QN
MR\-/T-9%E63;;0VZIQ#251WRP@.>2HZ$*2FX\%!%'>BN^CL.7A9[\;)3YF29
MEJ4R]W2TLH96VN[BV@%.'78E85=/N"@GV`Q^2QL_9&.R03Z?$PTUF5H45I[Q
MOT-)LH\301?:^R-R;=Q>\'\E`C0(LS&2!:*^IX/O)2XKOG$D#2LA1U'MY=E!
MMNH^P-V;GRVV9&*DQF<9C-#LV/(4?+*7&UC0D-NC5I0;*X6H,S.87(9M&_\`
M%X_NO3IB8K4<OE26]7HJ#Q*.(^;0:C;FS<MM7;.&QF4+"I*]R,24F,I2T!*T
MVL2L)/-)`\5NV@RH73W=3/5YW=#AB>H%.NO(80XYJ"W8P9+O<J!2'O)"2L*X
MIOXA03#8>GXJ0M/*[U_=[Y=^?CH-_0*!0*!0*!0*!0?+CB&T*<6H(;0"I:U$
M``#B22>P4'F'K)UAR.[YZ=G;1>T8F2\B&_,2X&O3G'%:-`<)&B/<\5>_]SF%
MN]).D&*V+CB\Z4S-PRD@39]N"`;'N&.`*6P1[JCQ-!8=`H%!6F^=_P#Q'VWG
M9R8ZGLFYD.XBH-K!<IH=P^KG\$G1;QE.F@B_1CJ-U4WONIV=+981M..P(\LA
M&A`DI1P+"_.6XI?%8\U*>'.U!<>8Q6"R#"59F)'EQXBO2$>E-H<0TI`/P@U@
MA)";\:"%X#?>RY<QU>T<BW)@QBUZT@-H<#+3;SI90\SY(2A6JQ*1P4CRO&0L
M,'AQH%[T%9^T:2.DV4L2"7H@X?="*#;=$[_W3[8[/M)'YYH*P]J2WK[9?A#S
MG#_7QZ#T-0*!04I[3$-,UO8\)3BVD2L\RPMQLZ7$I=24*4A78H`\#0;1'LZ;
M9"W%'/9^RSP2)Y2`/!P3Q^30![/&WQJMN+<-R;I/K!7DBW(>30?!]G7"%)"=
MS[A2H\E>G$_F%-!&NF^RL3B^O^X,:XX_E4X3&QWL?)R+A??:=?#96H*/;Y9L
M;<*"_P`"U!4/77+[B@9#;S>'R4J$J4)38C0PM1D/%3*4)<#924I2E:CWG'2;
M<.-!;U`(O04=UZZ01YD:5O;`+3!S4)(DY!&L,H?#5B'DK)2&WVPGR5>^Y<Z#
M)Z&=;3N5MO;FXWDC/MHO#F<$B:VD7.H<DOI'%21S'$=M!=`-Q0*!0*!0*!0*
M"D\AL7J_.WPJ<W/,7T66_)BY9V0EZ$N.;>BQDP+:FRD`A:NWG>]!N-[0.I2-
M^HR.&Q:\IA>ZA)=:#T5""AEQY4EH(?/`N:T>5X!SH-KNC"2MQ;7QB).RX\B0
M%J6<9(FHBKA<P%M/QT.>6KAYA%J#.Z98?<^*QLV+G`\A'I&K'LR)PR*FV=`&
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M!LI:?[IR%D5+^VI1-T+BZ;*[RX\X\J#*W9L_`,[6S#J$/)4W!DJ252Y1`(:4
M1<%VQH,6>WT^Q65PN#GKE-Y+-`C'M)D3E!9;`*KK2YI3S[30,'M#`KW/N5M3
M;^EIZ*$`2Y0L#%0KC9RYXGMH/G=>S-OLKPFA$BSF5CI5KF2U\"E?+4ZJW+LH
M.Z-C]@R]RS=M,JFG+0642)37I>02E+:])39SO=)\\<`:#<;`:2UM#'-(OH;2
MXE.I14;!U8%U*N3\F@D%`H%`H%`H%`H-#NS?6U=IL1WL_D&X2);H9CA5U*4H
MD`D)2"K2F]U*Y)[:#S]U7ZKYSJ#FFMB[#;=?QTA>A]]JZ3-(/$7-M$9/-2CY
MWN<PG6&]F?:+.QW\-E3Z1G9@2X]FT#RV'D\4IC)5YK2.6D^=V]E@Z^G_`%`S
MNT,^WTYZB/?;/!.W\\OZ5*9OI;0M9]]V`JXW\D\;$A=-_!0*#IF3(D**[*EO
M(CQF$EQYYQ02A"$BY4I1X`"@\]92%-Z[[O:7!8..V-@EK9<S>DB1,)/E-LWM
M;EPN/(!N>)M07YA,'BL'BXV*Q49$2!$0&V&&Q8`=I/A)/$D\2:"H_:5.1?8V
MEB(DIR*UELFJ)(T*4$D.H#8*PDIU!.N^DGC0:EGV69\:0AR+NY;)2I*RXB,I
M*@ILW;(L_8Z;"UZ"5HZ5]4$I2D=3IIT6T$Q&R3;YZ[G&@.],>K/`M=2I.L<#
MJAH";>X%F@@_5_8_4?&;%ES,SO5S,XYMR/WV/5'#0<4IY(3Y25'S56-!;'16
M_P#=1M>_/T%O\\T%8>TZ%N;HV4R+G4ZNP'A,A@4'H3C^;0<B@P<OE/5\=*T-
M*DR7E!J+%00E3KJ@2$A2N```)43R`H(EN7IS-W5,PDW.Y4MG"3V\BS"B,I2R
M5MFX0I;A4XKP%5Q[E!.Q0*!04]M*_P#B6WQ?EZJ@\?\`,9H+AH*<ZY.OP]V;
M*R2(STEN,])#B(ZWF'#WA91I:=9X]YQ)".:@"*"XZ#HGSX>/A/S9KR(\2,@N
M/ON'2E"$BY))H*)D.9WKIFS&CE[&=,,:\/2'^*',FX@@Z4\N`^4GGYUK!W]5
MN@,0X]G-["C>@9;%H;/JZ.2@/H8`T+:-[ID(`X*]_P!O&@QMA>TWC&\&S&WD
MA_UHRZB.Y.8:!0XV5:2\ZD:>[4W^R)M[G@H+YB2XTN,U*C.H?COI#C+S9"D+
M0H72I*AP((H.Z@4"@4"@4"@4"@4"@T6(_*K<'N0_K2J"N/0V?VQ?[^[[F?.^
M=_2_F4%M98J&*F%/G=P[;W=!\-!UX+\!XZ_/T9GZV*#.H-;N56G;F558&T.0
M;'B.#2J".Y,7VOM-/_;,3S\12?T*##VMU/GY/)3,;(PK\WT288B<SB4]_CEI
M*K:BXZ6RDM\G`G58WXT&BZG&W1_>W&UY[PX]OVXWPH-SM\'T+IE]Q'_^VT$?
MWN4_XB]C@><(3VH^(ID6H+#R7Y=8+[AR7UR)0?6Z)\&3M'</HLIIXQX<MM\M
MK2ONW$LJNE=KZ5#P&@KKJ0J_5[IBGC<*?-^SS4T$Z8S&,Q&7W),R3R(L<RXK
M8=5<W4J&U8>2"?#0=.6SF*SL/;T_#RFY<1S,,I2\F]B6TNA8L0#<:301S;5O
M\06[#V^K8WZV/03;8WY+0?\`6?75T&]H%`H%`H%`H.M]YMII;CBDH;;25+6H
M@)"1Q))/``4'C7J))R74#JK+C[:E/9]3Z^YPX*=#;;*$CO`CWJ6$FY[PVU<_
M!0>D.DW23$["Q1)4)F?E)'K#)D6)'/N6K\4M)/R^9\03Z@C/4#I_@=[X%S$Y
M9L@BZH<Q`'?1W;<'&S^N3R(H*[V#O_/[/SZ.G?45WX?R4[>W`N_<RVO-0VM9
M]]V`GC?R5=A(7'.G1(,1Z9+>0Q%CH4X^\X=*4(2+E1/BH*(FRMP=<<VK'P"[
MC>F.-D6F3A=+N1<;L="`H<K\A[WF>-@`O+#X;&8;&1\9BXZ(D"(@-QX[8LE*
M1^B>T]M!%=O;8W]"W[ELOE=P";MR6'1C\2-7P)4M!;X%(2-"0H7!XT$,]H99
M&<Z=:397KQ!!M?DIOYM!=`L2:#F@&@I_VGLPY"Z>(AI:"TY*8RTMPJMW:6KO
MZ@+<;]WIH);T=9?8Z7;9:?;4TZF"WJ;6DI4+W/%)L105+[5Y=;R6V)*"M'=(
MD$.I'FK"VE(\KD#=/"@UF#]I[=&.P\.%-Q+.2E,-AMV>_(6AQXI]^M*6R`2*
M#/\`\5N=_LW%O]U.?8J#0;JZ^;TW0TU%QF/&*E(;='?0EO2)`0X$I*V]*$%M
M0M;7X%&@UNT.JO4'9:I,@QG)D64ZVJ4<HB6HZ&T]VVVAYQ1[L`<!P]V]!ZEV
M-N16YMI8O/+8$5>182\J.%:P@DD$!5A?EX*#>T"@HW?/3KJY&ZC97>^R9D9O
MTQEA)C*<LXXF.T@%I;:VU(6%*;X#6.?,4$[Z7]4,;OC%+)0(.>@GN\KB%DAQ
ME8.G4`JRM"B.'@Y&@FA?8"]!<2%_.W%_E4'5/R$+'PGILU]$:)'07'WW%!*$
M(3S*B:"BGY.X>N.=,2,'\7TMQ[Q](EB[;N2<;(LA/'S;^*R>9\JP`7GB\7CL
M5CH^.QT=$6#%0&H\=L:4H0.0`H,DT'FSVH-HX;&2\;N.`V(TW+/.1\BA(`:=
M[MO6ETIMP<X6)[>V@F7LP#+)V%);F(?1#3.4<8E]*DCN%M(42UJ]X5E1%N'@
MH+BH%`H%`H%`H%`H%`H(_A#?=FY!X##'_47H*O[UG]K/FW][YE!<>;(&%GD\
MA&>O]3-!Q@/P%CON5GZVF@SJ#6[F`.W,J#R,.0#]2501W)B^VMH_=N*_0H*M
MQ&7W5`;Q>*7(:;@Y"?`C09#&2:=U>BY-YZ2IN.UJ<^%0XEMSAPT^5PH)'U-)
M/1S>AO?^DW[^X)Z*"28-*@QTX"K$B"JZC_5Z>5!&MZ@'VC=D^$07C?Y$B@L3
M()OOG"'YV!D?S7(E!@9K:VW<#M'=:\7"1$.3CRY>04@J)=>6TK4LZB?E#A00
MGJ2H_P!\G31%O)!?(/NA-!+,AM/$[LD;IP^6"U0U3XCA#9TG4W#84GB0>V@X
M7M3$[8@[;Q.*2M,1.;#UG%:SJ=:?6KCPX7Y"@TVVK_X@=U\/_#8_ZV/03/8"
M2G:&.2>82L?*=502"@4"@4"@4'6^^TPTX\\XEIII)6XXLA*4I2+E2B>``%!Y
M@ZH]4=P=3<ZC8^PVU/X5U>B0XBZ53M)!*U*(^#BH[2?.^4*#:SI7]PS.+@XW
M'1LKF,VRMW+9:0I:+K:4E(99"1Y+*-7`?)-!\>S)F<K*WCFHC\YYR((CC[<,
MNK6PEQ<E)4M"%&P\[@0.V@](T"@C6_M@X'>V`<P^6;-KZXDI`'>QW@/)<;/Y
MXY$4'GO)P]Z2]U87I;U'SYA;>87=B<$J1ZU:"AW#9>N1J]Z-?FGG=6F@].X?
M$8S#XV/C,7'1$@1$!N/';%DH2.P?HD\Z#,H%!HMS;,VSN54!><B"4<8_Z5"4
M5K;+;@'G704GL!^10:^+GHL3+B+`R;.5QYTHDL"0EZ3"4M9;0LFZE+:4X-!U
M<4GQ7L$L!N+GG0*"C_:RL=DXH'D<@1_W9V@LYV;-8P6(A8XH3/GMLL,.+&H-
M)#6MQ[3[[0A/!/:JU!#MS8/,0=[;>BXO"HRN(EJ*\_D)L9,MTKU60I3[B5]W
M:US:P'8*#2XC`Y-4!I;FV,.M9<:T*4[?RAEEG23Z.>%SI_2_J:#9X?;6+=V]
M'D9/!PHN2<4\J4PAEM8;6K+@J;2O3Q2GS1XJ":;)P>(@,3W8<)B,ZN?-27&6
MD(5H$A5D:D@'2+<J#0^T$2.DV;\9C`7X_P`);H,_HH!_=3MFW\33^N503:@4
M'!%Q00#<?2#%Y/>L#=^-G/X/+1U_TBY"`29C1&DI7RTJ(X%?'AX[&@U/63<4
M38NU([>)Q$5<G(N+BLOR&];;-FRXI;ETJ4X5`:;%0)/&]!7^T,?O'K&$QLJ\
M[C^G4&2IY3"%++DAP'R8J'EZE.(;-[D^;RYVL'HW&XR!C8#$#'L(BPHR`VQ'
M;`2A"1R`%!\9K('&X:?D0CO#"CNR`V3I"NZ05Z;]E[4&@Z=;UE;NPST^3C58
MQUEU+1CK45$A;+;Z5>4E!L4O"W#B*"K?:W']`[=OR],D7'^SF@N#8:;;(V^+
MWMCHG'_4)\-!O:!0*!0*!0*!0*!0*".X/\K=S?IH7\GH*K^Q4%T9[\!Y'[E>
M^MF@XV_^`<;]RL_6TT&?0:S=&KXM9;20%>A2-)/*_=*YT$>RZEM[1VS)[MQQ
MJ+(QK[_=-K=4EI`&M>AL*58#P"@C&-VYLO$[FDY^'G<VUDISJ7L@3"40^$G5
MH5]HW"3[[203V\>-!EHG;*S.WLU@]P(EJ@S\E)>4T(DY"E-JD=ZTH*0T"+\#
M09CVZ-LQ\OMQ$`21B\4T^TLB%-4&D=PEMD$J:OQ'"@[<ADNF<W<\#<DM,E>:
MQB%,PW_1<@`E*M04"@-:#YYYB@^I>]]N+W;C9P<D^C,09C3COH,RP6\Y&4VG
MZ3?RDMJ/R*#LW3OO;4W;66B1G)+TA^(^VTT(4RZE*;(2GBSVF@Z,C.Z:9?.8
M?.SE2%Y/#Z_5[OH\Y"4%0&K4CNPD\N&J@[,+O7;K&<S[SKKZ&I<EER.LQ)>E
M:41&6U$'NK>>@B@;DWEM^2_@E1WGW$L9)MYXIBRCH;#+R"I7P7`:E"@[(>1Z
M>1-S3MQ,O/#+9!I#$ETM2R@H;`";(*-`\P7(H-QT_;D-[-Q0D(4VZIG6I"@4
MJ&M14+@\1P/;02"@4"@4"@ZWWVF&7'GEI;9:25NN+(2E*4BZE*)X``<Z#S#U
M,ZF[@ZGY]&Q]C-N.85UP(>>3=!F%)!4XX>;<1OGQ\[Y0H+JZ6]+,/L/$*:95
MZ5EY82<ED5"Q<4D<$-CCH:3[U/R3QH*I]J9"!N/;*N^"5*8>38A7D`.MGO/)
M!\/9<\.5!@^R\A(W_G+*4K3`6D**;7'I*.*KG@>'*@].4"@4$7Z@]/MO[XP#
MF(R[7$77#EI'PL=ZW!:#^N3R(H(!L'?N=VAGV^G74-[5(X)V_N!=PW+:Y(0M
M:O?=@)-[^2>-B0N>]`H(!U>V]U#SF)B0]FY!N"2XX,FEQSNBZRMLI2D+T.<+
MDW%!3V`Z'=<<`ITX>;CX0D+:7*0A\6=+)!0'/M?44^2+B]!-I1]IF*T7Y61V
M^PR#8K<.E()Y"Y;%!QTCZE;YS743*[8W#,Q\]F!#+W?XY(+8="VQP<&FXLX0
M01S%!C^UJ0-D8HG\8'^3.T%@09^S\YB\4B6O4IFS$9Y??1P)"4!IUMMX=V%*
MOY)`5QH-1OO;&/D>A8#`Y9.)W%*?;EH8>G3&UR(L=7PZ$E"RNRN7"@AL;I[N
M!<-IYIB(B,XMMM"1F,T5)4J86T*X.6-G3WG9Q\=!A#8.[51PX&L>IG6M-AD\
MY;A-[I1^G=KWPG_+03OIEM3<./R\G(27VF<:D2HCL!F7.E!R2F0-3Y]+6L#S
M%<N)U<:#O]H3_A-F1X51A_WEN@V/1/\`X4[9^XT_KE4$VH%`H%!1'M'[=CY+
M<FR5RO250),EV'DNYUJ;1'*FU+79*5!"BDJ\KP#Q4%T8./AHN+CQ<*EEO&1T
M]U&:CV[M"4<-(MV@\_'SH,^@U6ZRX-KYCNB0YZ#)T$"YU=RJU@>=!!O9X&//
M3IEV&AA!=?69/H[SSP+H2E)UAX7;7I`NE)([;\;`(=[72K8';O+]]R#Q\4>@
MN/8@<3LG;Z70E+@QT34E/('N$<KVH-Y0*!0*!0*!0*!0*!0:'"I7\9]Q+-])
M7$2GCX(X)X?)H*G^Q4%T9W\"9#[F>^MF@YP0(PF/!L"(S-[<OI8Y4&;0:O=)
MMMC+D"]H4DV/[DJ@[-O`C;^,!YB(Q];30;"@4"@4"@4"@4"@4"@4"@4"@ZI4
MEB-'=D2'$,L,I+CKKB@E"$)%U*4H\``*#RQU?ZJ9CJ#.?VUM)F1)P3"''7&X
MJ5EZ:&1=3JT@!26$]B3YW,]@H+/]F[&;):V4G(8!\RLK*(&>?=`2^B0D?22B
MYT-I]Y;GSYT%N4%5=9>D&6WWDL7-@SX\1./:<:=;?0M15K6E5TE'Z7E00/V9
M(#\?>^?4N.ZE*(9;4M:%M]VKTFW=+2>&LA%[7-K>[0>DJ!0*`:",=0.G^W][
MX%S$Y=KD=<26@#O8[MN"T']<GD105UL?J/F-E9?XA=2G@TXPC^A=QN$AF4PG
M@GO%J[;#@H^XKCQ(6*.IW3S^T>.^^6_FT'']Y_3O^TF.^^6_FT`]3^G5ORDQ
MWWRW\V@C^Z\/.W1L;-Y?$.B9EY\9P8!;+HTM,H7Y'HZT&P<=2DDJ!OQTW`%!
MY6@Y+<V!S>2E0<I*P^8C-]S.*U$2GG%/)2\TJYXJ2KRS?P4&VWMD]SY/9V)E
M97>36>$Q??#"J5>3$<+:A=[M'#R?DT%Z]!\1-EXW<,Z8VF3M?<,DR,;WBB2K
M2MQIT*95Q1?0DA5_D`T&'OG>'33&9R&O//2\CN/:\@QFH4=-U*:6"IM3SSB$
MA0#;@U`.\3SO00ECJ1TT1CF(CNVE+#9:M=Y'%*9A>6DG7Q^"MQ-!LL9UQVIC
ML2QBH>*D-18P4AAOO&R$H]/[](!4HGZ6.V@EVTO:&V,%28V5#V,0M^3);DK3
MWS9#KY4A'P'>*"M*OG;>.@U_67JYT^W#T]R.(PV5]*R+ZV"RP&)"+Z'T+5Y2
MVTI%DI/,T&TP74;';!Z';2RTZ([+;?9:C(:9*$D*4EQRY*R!:R*"W8,I$N%'
MEM@I;D-H=0E7G`+2%`'Q\:#OH%`H-3N+=&!V]"<F9><U#:2AQQ"7%I2XX&DZ
MU):02%+5;L305YMKJ[M;<&85,PR7X&B1'B3XLS0RF29BRA*VFDK45.M*T%2@
M/-5QY<`M@'A0=4N(Q+BO1)"-<>0VIIY%R-2%@I4+CCQ!H-3M'9^'VIC%X[%!
MWT=QTO*[YPN*U%*4`7/8$H2!\V@IGVO4A6#V\#P^'E'_`*I-!=6SQ;:6$'@@
M11_U*:#<4"@4"@4"@4"@4'!-N';0<T&BPE_C%N+AP[Z-Q\/VJB@J?2KP'Z5X
M*"Z,Y^!<A]S/?6S0?6&_!$'[G:Y_I!09=!JMV?DKF?N&3]950=V`%L%C0!:T
M5GASM\&F@SZ!0*!0*!0*!0*!0*!0*!0=4J3'C1W)$AQ+,=E)6\\X0E"$)%U*
M4H\``*#S%U'ZB;BZH[B9V9LMM9PZUW/O#*T'B^^KWD9',`^<>)[!06%ANG#/
M33:\J=CTC(94([^1ER@!YM_3I5PL;Q;<T<QS\8"D\+OO-XK>#^YH#:<=F)4K
MNUP%#N8^32I0[QAU`LA#A4HEESE;ASXJ#U1L7?6$WE@V\IBU%*DGNYL-S@]&
M?`NIIU/A'AY&@D=`H.:!0*!0*#4[@VKMS<4=N/G,<QD665%;*)"`O0HBQ*3S
M%QSH-'_<[TO_`+-0?J?_`"T$>R6PNE"=TQMIJV8"YD8;LCUHQ'M'92FZ=*G;
M^2OP>,CPT$+F^S%W>=<=CY.-$VLEU*E(>"GIB8R$I4Y=YQ.C4I6H<?-'&Y-!
M<?3_``C.%VG"QT<N>ALETPDO6[Q$=;JEM)58#B$*'908TWI1TWG3'YLO;T)V
M5)6IV0\6_*6M1NI1(/,GG0="NC72Y1"CMJ%=-[601SX&]CQH,J1D=O[&C8'!
M0L7(1!GR1`A-PFE.M,*62K6\HFZ4W//B>=!%NJ'2K9N7D-Y.1$;BSI;CB'\B
M"I*3(6R4QE2#98[OO$I2>':*"+;0]F&&U(6[N^2S,:;+:H\7'!;*5%/%??+4
M-12?-TIMRO>YH)#O#IQT<VOC&\A(V<N<AZ0W&#4%+SJPITV"E#O`$I\?AH-]
M_<7TF/\`Z;CVYV*WOLE!PKH1TD4;G;<>]@//>'(6_;*"6P,!A8&*C8F+":1C
M8:$MQ8I2%(;2@62`%:J#8@6H%`-`%!676KI8K>\.'+:E+9D89$AQN*VTEU<C
MO$I(;3J4@)42W8>[04UM_P!GW<+A9<W(%XE+LN+&CQ$]RX^\73J?4A;:EI;2
MTW<@D&]CP%!:;7LR[);24MY3+)0JQ4D2$`$I-P39OL-!WK]G/;"^>=S=Q>Q]
M+'`GAVHH/A7LY[?[L)&X\X%]J_2DGEXBB@J+KWTP@;*@8B1&RD[).3C(:<]/
M<2X$]VA*KHLE.F]Z#U!LQ(1M#!I%[#'Q0+DD_24]IH-Q0*!0*!0*!0*!0*!0
M:/"$G/[B'@D1P/O1HT%-]W/^>5^#K<SYWAY?FT%YYL7PT\<KQGN/^K-!V8Q(
M1C8B1R2RV!\A(H,F@U6[..ULS]PR?K*J#(P:5(PN/0J^I,9D&_.X;%!FT"@4
M"@4"@4"@4"@4"@4'5)DQXL=V3(<0S'925O.N*"4(0D74I2CP``H/,>_^H6?Z
ML[B1LO9:%G!E?EN\4)DA!\J1((XHC(/FI/%1[.0H+MZ8],,'L3#B/#`?R4A*
M3DLBH#6ZL#S4_.MI/FI'Y]!,E)"DD*`(/`@\00:"F][]"L3/W5`RS#OHN(2I
M0F1PD.(9UI(*DMJ!3I5RO[SGRM8-+O#:66Z?Y@[]V,DL]P$HW#MUQQ2FY;=N
M+K2U?3+CRCVI5Y7A%!;6P=_8#>V`:R^'<(!\F5$<L'H[O:VZD<O$>T4$F%`H
M';0*!08\Z?#@1'9DU]N-$825O2'5!#:$CM4I5@*#0?WF=//[28W[Y:^;0/[S
M.GG]I,=]\M?-H,#</5/9+&!R3\'<D#TYJ*\N*$/M+474MJ+=D$D*.JW"@B?3
MK?\`M[,;/P^0WGNR,[EG&=<S&O.QX[274K-N\90$%1\D'RN'BH)U_>;T[`N=
MRXVWA]):^;0?:.I73Y:TI3N3&DJXI^VFAP]TJM0;!C=.V7V$/LY:$XPYYCJ)
M#12>%^!"O!0=_KO#!24^L(VI9TI3WS=R2+V''P4&'DMR[19:[C)97'M-24$!
MN1(92'$$6-@I0U"@K/?'4!O;<G;K>VMUQI>/EY-F/D(JW8TL,1%>>>]XN(0!
MPNM7#PT%D#?>R+$_&'&V^[&/HZ#:P,C`R$5,N!):EQ5WT2(ZTNMJL;&RT$@V
M-!@3-W[3@R5Q9N:@193=N\8>E,MN)N+C4E2@10=/Q\V-_:+&??D?Z.@?'S8W
M]HL9]^1_HZ#<QI4>4PW(CN(>CNI"VGFU!:%)/$*2I-P0?%08<7<6`EY!W'1<
ME%?R#.KOH;3[:WD:#96IM*BH:3P-QPH.[)93&8N*9>2ELPHH(27Y#B6D`GD-
M2R!>@@&\>KC6,W+M?"X`P,NK/2C&D.)DA7<`E`0KX'7SUD\:":0\&H9(9:>^
M9.02V664INEAE"C=0:;)/E*L-2U74?$.%!M:#6;HDRXNV<O)AJ*);$*0['6D
M!1#B&E*00#P)U#MH(KT8W+E=P[5>FY/)-Y5]N2&1+9;[M%A'964VTH-TK6K5
MPYWMPM05U[7I(P^W;"Y[V7P_U2*"Z]F*"MH8)0((./BD$<OI*:#<4"@4"@4"
M@4"@4"@4&CP?Y0;C^Z8_\C:H*NTQ/GD_@S5S'/Y[G06YN19;V[E%@Z2B&^H*
MYVLTHWH,K'_O"-^Y(_6B@[Z#4;P44[2S:AS$"41\AE5!GXW\'1?W%O\`6B@R
M*!0*!0*!0*!0*!0*!0=4J7&B1W),IU#$=E)6Z\XH)0A*1<J4H\`*#S%U#Z@[
MCZJY]O9NSV5JPCCEG#Y20^E*K&1*/-N.CFE/OO=L*"\.F73+"[#PGH4(^D39
M%EY#(+2`MYRW(6\UM/O4]GNT$RH.*#@@*!!%P>!!X@B@I'KATZS,C$.2<7*6
MO%LZENQE#O5Q4+*2[W!)U);7;C;S?TO(*;V)F=W8#.R=Q;1AO2&\>DMY6`25
M)E1F?/6IL)2L!*>*5D<[^--!ZPV)OS;^]<$WE\,]K0;)DQE$=ZPY:Y;<3V'P
M'D1RH)(*!0*#%R>2@8N"_/R$A$6%&07)$ATZ4(0GF23048E>X>N&<`4V[C>E
M<!X+!(+;V2<;O:W^3?P<$_IN062.C?2VP'Q9@V'^0?FT`]&^EQ%OBU"'(\$$
M<C?L-!S_`'.=+^'^[4'AR^#/S:#C^YKI=JU';4(FUO,-K>Y>@'HUTM/_`*:A
M`\_,(_.-!K-S](^FL?;.7D,;=AMOLPY+C3@0=25I:4I*@;\P:##]GS$8I_HY
MMQR1"8=<<;?6M3C2%$J,AP$DD>"@L483"A86,?&"QR4&6[\!;G;P4%+=5=L;
M>R?6O8.&FP&7,;,CRTR8R4AM*TMI*D`EO0K@H<.-!.4]!ND:>6VX_'GY;_9_
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M[Z;^;Q\%!&=S^SSL27AG4;=B#`YM!2[C\DPMXEMULZD!0*U>23SMQ',4''2W
MJ;DG\BYL7?"?0]ZXX:4K78(G-)\UQM7!*ED<>'G#B.T`+5[*#1[X*ALO/E*P
MVH8Z60LFP39A7$D4$6Z#Y-Z=T^8$A3RI$1U4=T2"TM8(0A8`6T!J3I6""JZO
M#00+VNA_1.W/$[,^M(H+KVA^2>$^X(OUE-!MZ!0*!0*!0*!0*!0*#1X/\H-Q
M_=,?^1M4%<=T/GC^"/"G]5[GBH+0W1?XM9:W/T*1]:509F/_`'A&_<D?K10=
M]!I]YD#9^=)Y#'RS_P!0N@V&._!\7]R;_6B@R*!0*!0*!0*!0*!0`;T$2ZF=
M0L?L;;ARLEE<F0\X(\"(CAWCZDE20I7O4@))4:#S%E^HO4OJ*Y"VI(DM+]83
M"&F&D^C-K4X;H;>4"=330!*1S/;J-J#T'TUVIA=@,-XP-=Z[DR+Y\MJ2J0\G
M@67M0^"LJ_=)\TC_`"N86.*!0*#B@X4D*24D7!%B#Q'&@H[JAN;%]+W7(NWV
M&4Y?-I+\/R1>"G4E+CI2$_",'B0U\]?LY!">B"U2>K;+6W)#T3',L2).7E/-
MJ[W*!2P2MYI'P3">\<!93PT#AQ)H/5-J!08>6R^-Q,![(9.2W#@QTZGI#J@E
M"1[I_,%!2+;>8ZXYOOGN_P`;TNQ;X[IDW;<RCS:N)5R.CQ^][/*O8+QQV.@X
MZ$Q!@,-Q8<9`;8CM)"4(0GD$@4'8)4;O_1^^1W]K]SJ&NW.^F]Z"NMP]9\.S
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M)U!"R/*+95X.(/$4&CZ7=4LD]DE[%WTGT'>D#X-#B[);G(`NE;9%DE93QX><
M.([106J0E22%"Z3P(/@H.N/%BQ6NZC,H8:N3W;:0A-SS-D@"@H;VM$=YB]N-
MCAK=EI!\%VD4%A=%=Z)W5LAAX0S#5C%)QJT%P.!9CM('>`A*;:K\J">T"@4"
M@4"@4"@4"@4&BP1ON#<GBDQ_Y&S05-ZQ1_\`LWIY_F>[XZ"XMU?DOF/N&3SY
M?254&=!_>4?]R1RY>:*#NH-+O8D;,SY',8Z61;]P70;+'?@^-^Y(_6B@R*!0
M*!0*!0*!0*!0*#5;GVQA=S861A\Q'$B%(%E)/!2%#S7&U<TK2>((H//VY_9G
MS&$P1RFWLL_D<W`>4^VPA(8<4R@W;+"DW5WZ`+^=979:@DW2CJU%WE#]0YU+
M:-RA.B0RYI0WDT-@)U(U<4/M@7*1V\?TH6CC\L83[,&<ZIV/(46\?.6""5))
M'H[Q['1;R2?/]WF&_H%`H(-L_J8-Q[RSNW1!3'1ARL(EAU2^_+;@;7I26D`:
M2?*\KGRN.-!M-Z]/-I[SB(CYZ$E];(4(TI)+;[)6+$MN)XCW#P\5!@;9V2WM
M+TI.#Q,$/3"%2)2'%Q]:D)"4E3>A[0+)XA!M?C:@VNU'\Q+CRLAD9*7!(?6F
M+&:3I:::84IL:2KRUEPIU$J^0!0;AB=#?=>98>;>=CJ"9#;:TJ4VHBX"P"2D
MV\-!`.L'3MC>#&*>G3I+>'Q4@/Y'%L<$R&B0%*OS"FTWMXKVXVH)[C\?"QT)
MB#!91'A1D):C,-C2A#:19*4@>*@R304AB5.#VE,@\5(^&;7')[MM22&8;:TH
M2[IUAT:R5#@--O*/*@DO5C'X?![>E9?',1L9DI\F,B1.92VS)=5WX='EZV0X
M005J2LV4+WH-IT7[K^[;$]TI2V@90;4N^HI$MT`FZG.-O\H^[03:@4&HW>+[
M3S=^7H$KZRJ@C70@`=(MLVO;T4\^/[*N@G9H*3ZHXS'97KOL'&9.,B9`E1)R
M9$9T:FUA*%*3<>)20:"Y,?CX>.@L0(3*(T.*A+4>.T-*$-H%DI2!R`%!4!A)
MD^T6Z\@L(5$[IUU3CQ3(4/5Y;"&F20A;?PH42/+!'SM!<]J"I'[?XF8O_P#C
MZOKIH+;H*8V#$0YURW3*1W2!',I"P7QWZU.K9M]KD^2A/=*(6D<=7E<Q071S
MH*EV$/\`[[]0C_T,'C_JQ06T:"D.ML!.0ZB[4ACN._>94&ER'>X[H)DM..+;
M45)2XI3:%([M?`W\-J"[^V@@_5'I?CM[8U"T.G'[A@?"8C+MW2XTXDZ@E13Q
M+94/D'B*#0]+NJ60E9)>Q][H]`WI`&A*E>2W.0D?36S8#60+\."N8[0`GNZM
MUX3:^%?R^9D"/#9'#M6XL@Z6VT\U+5;@!0>2MV;@W[U2SAG-0W%PHSG<0H:3
MIBQ.]0I8#CALDN+0V2L\>5J#TWTCVA`VOL7'1(I4MR6VB=-=7S6_(;2I5@.`
M2."0/`*"9T"@4"@4"@4"@4"@4&@P%_C#N8V-O2XX!_V)B@K+T%OQ_DS;SCS^
M706QNFWQ8R]^7H4GZTJ@SH7[RC_N:/UHH.Z@TN]_R+S_``O_`$;+X<OV!=!L
ML=^#XW[DC]:*#(H%`H%`H%`H%`H%`H%`(H*-ZT]#W,A(7O#:"3&SC!](EPX]
MT+D.-G4E]A2;:9"?]/W>8=G27JJSO"(K!YQ+8W,VG0\RJS2<@VU8=XDJ\R0U
M:ZDBW'Q>:%GXS+)AF/#FRC(;D.*:@35BQ4H<0P]X'1V7\[W:#?@W%`[:"FND
M.'+'4/=.28AN-PI*Y2&WB75--N(FJ0MM"U_!K+G=]X=%]/FGE07+0<$4%?;@
MD;KQT%W`8J.Y$9UK6K/C24,Q'W;A+>J_P^I91Y0L@>6:"N>HG1'+8.&G=6SI
M4HY%A2).6AQGG$K=[JZN^87Q4MQ/;K!U<3XJ#XZ);OSDF//QJ,RYEDRT'U9C
M9*'7'N]<TAUU<E:E!M#?E*<;/:?)X$4'HI(``'8!:@Y-!4N(8VS_`']9)Y$F
M8O.E@ZVG%1510D,H&A&E9?U)2`;:>%^/`BX;WK7E4X[8[KB-:IJI$=4)MO3K
M+C3J7"0%(=2K2A)5I*>-!56>R^4QW2?::H$Z3";<5E3("9#A<*4O+LMUUHM=
MYH)XGPG@F@O_`&NM:]LXA:U%2U0HY4I1N22TDDDF@V=!J-W\=J9H>&!*^LJH
M(ST(X=(=L7[(A^N+H)[04YOY)_Q$=.3V"+D/K2Z"XZ"MQM'>3'65S<<1P-[>
MF-(1.3WB2E:41RV!H(+@<[U*#Y/DZ>V_"@L@T%1/D'VG(P'9M]5Q[KAH+=M0
M5MM#:>\,5U2W'E)`"-N9/6ZWY;:PMPJ06BGAWR2/A-0-D\K:NP+)-!4>P5`]
M>>H0L>#$+F"/>#PT%N4%8=3-H;RR.^-LYW;C0*<==N4Z76@-"W4%:5MN\-/=
MZ_*2%*OV=M!9]`-!5?M`[;VI,VDK-927ZJS&+4E>&RK0)D=_JNAE*4$*6%D<
MAYOG=AH*0PL7J/UFW'#ASYJEQ<6VE$V;I"6(B2+*4$I\E<EVWZ/!-!Z#R>U<
M'M;:>,PF&9$:$S*\E)5=3BU,/%2G%'BM2N9/Z%!,-O6]08VPL/16+`&X^EI[
M:#84"@4"@4"@4"@4"@4&AP"2,]N95^"IC`M[D%B@K6[/_P"S%N8\WY5!;.X3
M;`9(_P#97^?[FJ@S6N#2!_DC\Z@^J#2[V`5LS/I/(XZ6/EL+H-I"24PV$GFE
MM`^4D4'=0*!0*!0*!0*!0*!0*!0+"@HWK9T9E2GW-Z;/2MC.1U!^9#C>2MY3
M9U"0Q;D^FW$>_P#=YAV=,^LV,W-C50<S9C<*$%+\9"=`R0`#:5,\E)D`^\X&
M_B\T)WM_.Y>#W*,VX'L9,6&L9-"5!UI94H)C3;_L@X)[RP!/`\;7"9@T%9]-
M-H;@PN\-P2YL`1,;(<?,%X^BK6\'I*GM16U\,G@?-65>Z.5!9E`H/E24J!!`
M(M:QH-9\)BU@&Z\8KD>9CD]A_P"B_6^YR"M-[[`S.V,VYU`Z=-(1.MJSN"0+
M,SF+ZEJ0E/)SMX"YYCCS">;$WW@MYX%O+XI9`)[N5$<L'8[P\YMP>'P'MH)'
MQH*8QQF-^T3(CJ6MO&K0_):C=\PZ%2S$:;6[W:/A6@II(\_G:@F?5UZ*C9[K
M<V--?@O/L(D+QSR&7FOA$E"KN7"DE82E0L>!Y4%<2L'F,KTFP2\4S.8BPU95
M]U*EL^DL6?=[KO0\['U.I&H$W-C>Z#<6"Z=K!(VSB`GS1"C@<QP[I/AL:#9T
M&HWB;;1S9`N1`E'_`*E5!#>CF6B8[I#M(R-?VRTAAK2DGRW'U(%SR2+J[306
M2.5!4&_!?VA.G=NR-/)]SNET%OT"@&@J)TI_Q,QQ[X8!5_JAH+=H%`-!3/3S
M(1V^OO4"&\K1)DMQUQFSJNI#"4ZU`GP=ZF@N:@4'5)DL18SLE]8;880IQUP\
MDH0-2B?<`H*_G]?NEL:`_*9RXFN-(*VXS#3Q<=-N"4:D)3<^,T'G]4_=76'?
M(,^<SC8#!N5.NI2Q`C$VTMI6I/>OK\-O=LF@]+;<;V#LS;K6*PTB.B*QQ#;+
MB7I#[RR`5$()6ZZXKQ?F4&G;A9;>V1[Z6>XP*0IMQ3:P;I(TKCQG$CB5C@^^
M.SX-L^<J@L5IM#3:6VTA#:`$H2.```L`*#ZH%`H%`H%`H%`H%`H-'@4$9O<B
MS[^8S;C?E"8^505?=?S@_)?5R_,]R@MG=!MMG+'M$*1R_<E4&P9%F6P>82/S
MJ#[H--O47V;GAX<=+'RV%T&UBITQFD^!"1\H4'90*!0*!0*!0*!0*!0*!0*`
M:"C.M71>0^^YO79B%Q\]'4)$J''L"ZM!U>D,`<GQVCW_`.FYAA;`ZK9#?C;&
MV92$,YIYEQ.7<4$I;FLH3INVE7%#R;^4$V^A"U(&95A'HT/)2ERL5.<#&*R;
MB;*2\3H$5\)2FQN/@UVX\CQ'$)90*!0*#'FRFH[5U)+BEG2VRD74M1[`*#2S
M\OBMH;<D93.2TQX4<J=-S<(U<4L,@^4H]B1^A05CT;Q>:W#O?+=3&XIV_M[*
MI+</%I%C.'(27A>U[\=0YF]N'$A>!H-,K:V/7N)K/.ORG9<<+$9E;ZS';[U.
MA10SYH)301GK:\\C9"VV4*U.R8X$D(2M+)2X%)6O4XUHNH!(5?@3QH*KGQX,
MCI+MB1ELQ#QVAO)&*B:VLN/O.2'0X-"@X@'S;$BZ>/&@]";?`&!QH'(160+\
M_I:?!09]!JMUL>D;8S$?66^]A2$:P+D:FE"]J"AL!@<M+VETCMN"#"")*9L:
M-+2$.&XN&VD7)?5J5;CIYCC07L<?N?5<9AK3V)]#%^7A[WPT$2W3TLSF>W1B
MMQHW.O'Y#$,N,Q7(\-HF[R;.*^$6M/&_*W"@[?B#U"!!'42;PY7@PC_S:#`R
MNU.H6+8;E'?>6F`*#9:C8Z"ZKRNTI(3PX6[:"&Q=\.Y5Q]N)U,R:'HD-^>^A
M>'C(LS$&IY(&E-W$B_+G:@T\;*8->7G;T3OW+*R6*83$G9$XAI0;C.J"472`
MINRG#8&U[T$NG[FRT21*CKZBSW#!2PJ:MG"1E):]+:+K.I6BUU(%["@[QDLT
MF3E6_P"]!\N8E+AGH5B8A[I$?N^\5IT\;=\GD./'P4&JC;[DRU_:_5"66T`.
M2'SA(P9::4I*0XZLI`0GX1/E$]O&@VN%Z/;B&<>WKC-\K.2S+"5&>K&QE%;+
MJ4*&E"CI3J"$\DCE028;,ZHBW_W!6?#_`$5#H/E.R>J24V'4-P\2;G%PR>-!
MC9?8O5.3B)D8;Z,DO,.H[A6-B-AW4@I[LK'FA5[:NR@\\2NCW46+E\3AY./3
M$F9A:F81<?;<:3W2`MU2^[*C9"./CH/1^U.C>!P&!C8P3)CSC8*Y#P>+8<>7
MQ6L(2+)!/(4&X/3O"*!"GYI2K@M/I*TZD\BDZ;&RAP-N=!)F&&6&6V&6TM,M
M)"&FT`)2E*18)2!P``H/N@4"@4"@4"@4"@4"@4&DP*P<MN,"VI,]L'[QC$4%
M4:I?[5_Z1U>;^R>"@N3/J;3@LBIRV@1GBK40$V[L\R>%J#-1YB?<%!S0:7>R
M@G9N=4>R!)[;?L*J#<-_2T^X/SJ#ZH%`H%`H%`H%`H%`H%`H%`H!%Q04;UFZ
M+R'92]Z[+0J-G(RQ)F0X_DJ>4@ZO2&+6L\.U/O\`W>8<=).I3.^7%P=P/(<W
M"VV6TP2.[8EQTI\IUM)%D2$*OKL;VY<*"T\5E78:VX>1D=^P\LHQ^24-/>&Y
M'</?.O)T\_?>[02#G0*#HERVHZ4@W4ZX=+3*?.6JU[#]$]E!I,]G<)M;%2=Q
M;CEI8;;2$J</9<^2RRGFI2C\D\^7(*KP&V]P=7\TSNO>#+D'9456O`[<4H@O
MD6M(>MIN#X>WD/)YA>C33;2$MMH"&T`)0A(``2.```Y`4'U0.%!675?<^+G;
M(R2<=*[QR+/9B%0>3%;<D-K"W&D.O`-NZ0"%I3?B".8H*AWA.>1TXV:DA;KC
MD3)/3&0E9CH:>?44NEQ#:M)2K@I257^70>FMM%P[=Q1<^F&''*^%N/=)OPH-
MC0:_<'X"R7;]JO\`#_5J]V@H_&L8OXJ]%EO2^ZF-OQ_1(H0OX<$HU^4GR$:/
M)7Y0\KD+4'H"@4"@X4E*N8OXCRH.CU=`\O[6:^$!2YY"?*2H6(/#B#0?*,5C
M$,K81#82RX;N-!M`0HCC<I`L:#Z7CL>X5%<9I964J65(22HM^83<<=/9X*#X
M5B,2IUUU4)A3KP4EYPM(*EA5M04;7(-A>]`1A\0A"VT08Z4.)*7$!I`"DJ-R
M%"W$$\:#*2A"$)0A(2A(`2D"P`'(`"@YH%`H(7OO;HR6>VK-9G/P)T*:^W'?
M8[M5DOQ7.\NEQ*P2>[%CV4&1Z)EL?EL<PK<$R>[)>*EPW6XP26$H)<6KNVD*
M"0;#GS-!T;IZEQ-O;NPFVG83C[^9*=,D.(0VT%N]V"K5QY_H#MH)G0*!0*!0
M*!0*!0*!0*!0:7`_A3<?W>C^0QJ"LNX5^V'\DO#^;S\[Q\J"T=WFVU,R>?VC
M(X<OV)5!M4>8GW!0<T&BWY^1.>^X)/UI5!O$>8GW!0<T"@4"@4"@4"@4"@4"
M@4"@4"@6H*-ZS=&I3DI6]=EMJ8S<50DRX<;R5NJ1Q[^/;D\.U/O_`'>89?2S
MJQ`WUCS@\V$)W(EM278BK-M9%"$V[UNX^#=1S4D6(/'ER"SMM2I+T=Y"G3*B
M,N:(4U22E3K8'OKVU%!\G5[ZU!MGW%-LN.(075H25);3:ZB!>POX:",9?=&`
MVW@W]S9R:GNSY(*;DZ[D)C,-GCKOP([3Q-NP*NV?ALKUBSR=Y;K"4;2QC[C6
M$V\E6I*W$$7<?[%6]]X3P\WF%\H0VA(2@!*4@!*1P``Y`"@^J`2!SH(3DLED
M]V3G\)@9"HF%C*4SFLZUYREC@N)"5\_V..\D<AY7(.GJ%BMMQ-H0\"N)D&<8
M76T1T81K6ZR(R5/DG@;)TMJN1=1/+C05)O6!`D=+MJ2HS$D.!K(F+)=;[R5W
M2W2I*'!J2%NKN%%/&_E*`X&@]%X;\$0;\/M=KA_F"@S*#6[EU#;N5*2$J]#D
M641<`]TKC;MH*IVQDGXFR^E*(\M32WTQTKCAAAX/(46VUCOG/+:TAR_P22HC
MP`7`710*!0*!0*!0*!0*!0*#JEHD.1'D1G`S)4VI++Q3J"%D$)44GG8\;4$%
M7C=WQ<-M>!E<NS+W&F<X'<J&`6RHQY!3\$"W>R;#LH.G,X_>#F,FXS%3F<9O
M22C4G+/(UHF1V^"@PKCZ/I*_-TG1SXWU4%>Q,1E<7N+8L7=4<R<SW:FI#S[B
MWULN^LG'4/..(<2DH7=(;U$^5PTT'H>@4"@4"@4"@4"@4"@4"@TF"_">X_N]
M'\AC4%>>CO\`SC?Y&^`4%F[E-MNY0\[1'^!X?L9\-!L1R%`H-%OV_P`2,]87
M/H$GZTJ@WC?F)]P4'-`H%`H%`H%`H%`H%!PM:$(4M:@E"02I1-@`.)))H-9M
M_=&WMQ17)6#GLY".RXIEUQE6H)6GF#^AX>R@VE`H%`H!%Z"B.M70UR:Z]NO9
M[99RB+O3\<QY'?%(N7H^FUGO"GW_`+O,,?9WM(Q7<)$@9X)Q^4;UMOY/N5.1
MRAL>04QVOA.]7YG=@6U?*H+6Q.1FY?$M9C;^:9RL9Y.ME+S24-.`'BG4V$.-
MDVM<@V\!H*#W5LKJ7OC<<_(9Z$G`-A#QPD"2XE,=UYLZ$-!P'2%NZ=2G%6*A
MYO"@NC9N/C=.]@QL7,EJR,N.AY\1V!WCKKBRITLQ6@2H@<D_+-!M=@]0]O;V
MP_K'%.%#C9T3(#UDR([GSKB03X.!'`T&_P`CD(N.@2)\QP-1(K2WGW3R2AM)
M4H_*%!`HFZU]2HZ(^V'WHFVRD#,Y8I+,DE0!,..DG4A92?A'/>CS3?B`GF-Q
MF/QD%B#CV$1H<9`:88;%DH0GD`*#*H.+VH.;B@$\*#6[CLK;V4%[7B/B_P#J
ME4%:;-64;3Z7M(RR(*51D$Q#(6TJ40A'D(;#:N]M<W"B.!^4%NT"@4"@4"@4
M"@4"@4"@<*"N^J&2W(G.;5PNW_1VI^2?F*9FR5*TLJ9B+2%:$I5J^FZA?M%!
MA[,V-U,QN20[N+.,YAA$M,A#KCCJW6VT-N(T,I[MM"=??'7XK4$RR^R=NYC,
MPLS/86O(0-'H[B'G6T_!N=ZC4A"DH79?'R@:#=/R(\=E;\AU#+#22MUUQ02A
M*1Q)4HV``H/IIYIUM#K2TN-N`*;6DA25)(N"".!!%!]4"@4"@4"@4"@4"@4&
MCPAOD=R_=Z?Y!&H*U]/'[6?R$OV<O!RH+0W<;;5S!M>T-\V'[FJ@VR?-'N4"
M@T._@#LC/`\C`D?6E4&]1YB?<%!S0*!0*!0*!0*!0*!05KU\P.\\QLI3.VWE
M%MI1<RD!JX>DL`>:A0XG2>)1[[\PA5GLS83>BL^]EH+IB;8`+63[Q-T27$@Z
M&VDGW[:C<K'FCAVVH/3M`H%`H%J#@T'BGJRTRSU(W,19I/IZR.&D`Z$JNGEX
M;T%Y>S&\OXGSXSC45EQB8;I;242U!2`0Y+2??*]XKM%!:V<<#6+D*"$N**=*
M$N`*1J60E)4D\P";T$0QV:9VE+1BMQLH0Z\H^B[@CQDM1WV_^G+8"&7$>^'(
M\QVT%1;PS0:ZL2<YTFBE_(XV.X]NJ0VM`QKX21="@2D*4JQXI5Y2O-X@F@V<
MG(]<NJFP2(L3$Q<+EB;NLN*;>*&G"%-J2XIRP*D<>VWNT&KP>X=V]+<'WD#%
M;=?AR)46/DI$28[,E./.A6A3I2X=-TI5IX`#P4'IR_"@A.RL?U/C;CS3VZLA
M'EX9Y1.'88TA3:>]41J`;0?I>D<5&@^.L^XLQM_I_.R>'D&+/0['0V^$)64A
MQY*562L*3Q!MRH*UP+/M(Y[#0LO`SD<0IR$/,EQ3`<[I1[4A@@*MXZ#;G;'M
M)IXHW-&*@04Z@QIMVW'H]!K\KA_:68@SS*RT23"##I?(5'%V@@ZQ8L"RM-Z#
M,PN*ER,!TB=);5.A)0OT7FZIF[0<6@@*&EIORE^4/DBXH+PH--NS-2,-B%36
M$H4X'&VQW@44@+4`I5DD$V%["]!IF\MU(=0VXWBXO=.("P3IN-0OR])H.3D^
MIMC;%1";\.*>(^^*#Y&5ZGA-U8:*3<^2%H^0;F10=<K<74.''<DRL1%:CHTZ
MG2L'2";7*4O**K7[*"2[;RCV5P4+(/MI:>DM)6XV@DI"N1"2>-KB@V5`H.J4
M\68SKP&HMH4O3X=()M00O$;MWKE89E1<5'6A)*%D+5;6D#4$ZE))`)YD"@S#
MF=_``^IV3>_`*\'^?0?)S>__`,2M?JO_`.9055F-^[YD[SV=F,EA&8<5OU@Y
MC]*RKOT.-AL`Z5K.H@I(N!SH+0]?]0^S`-<#Q^$_.\N@Y]?]1/[/M?5?_>H*
MEZ^93J;+Q+#62QHQ^UB4B:IA>H+?*O@TOD*)[L=@M8JY]E!O_9EF;S>PLEF:
MC5M)@:<-(=)+@="K.-M?/,#L)Y'@*"[J!0*!0*!01'-;^@,[=S^3B*>:3@I)
MA2I*H_>I#B%(#BD-EQGO$([SC90Y&U^T)<DW`/.XH%`H%!HL&FV0W-XYZ3PX
M?P"-05[Y?A'Y!>#_`):"RMVB^ULN/##?^MJH-J.0H%!'^H7Y"Y[[A?\`K9H-
M^GS1[E!S0*!0*!0*!0*!0*!0*#Y;:::1H;0E"+DZ4@`7)N>`\)-Z#ZH%`H%!
MCY"<S`@29S]^XB-+?=TBZM#:2I5AVFPH-!LO?V'W>B8O&LOM(AEI*R^&P5=\
MC6FW=K<[/#0:7K$F*UAL+(=2TE*,[C%.NNA.D(#WE%15PM;G>@BT/<:-P]=L
M;)P<!]N%#BO-Y*>T5M)E,N-ZH[TA-N[4R%)(9U'6KSAY-J"XIC#4F,]&619U
MM23[A%K_`"*"ALKO+>74-U_IMMY;*^X*F=R;I`UQU1DD)^"M<:EGAPXGLL+F
M@GLC8.V-H],,C@L<PVF$ID^F/RVE2.^*B`MV1W8U6M[Y(^#'E`>300/9L9S9
MR&$8>8\G&-2&QDL4MP.N!I3K14M6D(;)TN72^@E+K?8"*#6=6,"</M:6&MO0
ML+`=SL)4.5$<#AEHUR2E:TZE=T-*DD(Y>43X@'I.@<*"M/:(`/2V>#R,F&"/
M"#)0*"1[1DXS#]/<5(?=;AP(D!M3CBR$H0VE(N230:!K>6^=WI*ME0&L;A57
M#>XLLE5W0#;5&B)LI2?`I=@:#O=Z9YZ:E?K;>N5E%P6<:8#,9D@WU)[MM/FJ
MO:Q/*@EF(VUB,9C,;`:80ZC%-AJ$ZZA"G$`"UTFPTDV][:@VE!#.KF1C8W94
MB;)66X[+S'>+"2JP4X$C@/&:#51.O72EJ(PVYFPE:6TI*?1Y/,)%_P!CH.P^
MT!TD'_CP^]Y/V*@^1[0O2`W(SZ;#@?M>3S^I4&IW1UYZ43,)*BQ\X''W4I#:
M`Q)239:2>);`[*#C:77CI5!VY`B2LVEJ0RT`XWW$@Z3<\+I;(H-N/:%Z0D@#
M/IXD`?:\KF3;]JH-X>I^S`2#-7P`)^UWSYW$<D4&--ZH;+<AR&DS5]XMI:4I
M,:0"5$$`#X/PT'?TT`&W"+@D27P2D@BX58\1PYB@EE!PKE047NM(7_=UQ/TB
M024CCQ[J]A07H*#FU!$>JD1F7LV5'>:#S2UM!;9&H$!8/$'G02'"168F'@QF
M6TLM,L-(0T@!*4A*`+)`X`4&;0*!0*!0*#S=NV)BY'5=\QL@F,TW+[[*.RL<
M^8A=0H!*&V6[IEO)[7%I">1N:"]\KN/U3/'K%IJ)@@P7'<T_)::0AP'@UW2R
M%DD<;B@S\3E<?EL<QD<<\)$*2G6P\`I(4FY%P%`&W"@RZ!0:+!E1G;D)(/V^
M``#>P$*/S\=!`;GYT_D)XN?@Y4%B[N*AM?*E)LKT5T`@7M=![*#;4"@T._$A
M6S,TD\E0W0?<*2.R@WPY4"@4"@4"@4"@4"@4"@4"@4"@4$8G;_Q4/=3.VG8T
MI4U]QIM$A#85''?(4L:W0HA!\@^2NRCV`B@VVX@@[?R86H)08C^I2D%T`=TJ
MY+:>*_THY\J"K?9W4$P\]J>6X$NQ4ZGE]X4V:4-'?$V=`[%)X=G902#K6U`E
M;>Q$28$NQ96<QS+[144ZD./:5"Z>/ONR@DL/!3X"[Q93"RI(:=E2(P,E3:+]
MTA3C:FDJT!1`NF@@/6'I\B3@96;C;A=Q6XDL.,*F/R3'8E,+XF&I(4E"$FWD
MZ1SYWO>@@FW-X[YVO@,1CMF;#<@09B@RMZ6VI]R9.4FY<U)+!TZ4GRE)T\.!
MH)P)O6'*;5R.)W)M9;LV:EQ#,G'3&(89!2.[L>\6O4%<2;V[+4$-V)TNS.(Q
M+47/;%E92<S],=,^(&5I*@0@`G7HL@>020+FWG4'&X^EVY'-N.XO;NT)\9^5
MD8TZ2Y-R<>2E+<4+2AINZQ9*0Y9/;;F:"X#O#>_]B)?C^W8?YGET''QPWQ?\
MAI=CR/IL+Z.@B75-W?\`NO9LO"QMERV7'5LN]ZJ7$5;NG4K-DI<U%7#A0=6S
MMC;NW%!PD+>T54#;F`C,H:PSBTN+G2FT_3I.@D=VCAI0>WG07&VVA"4I0`E"
M0`E(%@`.``%!]=M`H%!\N-H<3I6D*3X"`1\HT%=3(\!6Y9P4RT3Z=*3I*$FX
M&(1XN0H.G"PH`E,)3'9"._@V`0G\3.'APYT&'B<;C3D<,E$1@(4[BBI(;18C
MU=)YV'BH/G!8['KD1$>BL$!G"$CND'B9,DD\NT"@WFQL5C%OIUQ&%'T%)-VD
M<S,DW/*@DN;V;MC-8N1B\AC6'(<E.EU*4)0KP@I4D!22#Q!%!4^WGE=+LTQM
M+=S#,S:4Q?=[<W&ZRCX$GB(TI5N%NQ1_.\T+D3AL*H!28,8@BX(:;(L?D4&4
MQ'88;#;#:6FQR0A(2D7\0H.R@X7YOB\5!YLD1=XLY78[V=DL2<:IA]6,8CIL
MMILJ:"4N^2FZM*DW-SR-!Z4%`H(OU(&K:T@<?/1ROX?%02#'I"8$8#@`T@6]
MQ(H,B@4"@4"@4$#W-T_Z70/3-SYJ"MM271*E2T/35*[Q2Q90;963YY'!*:#"
MWEL'`[[RT248LQKOL>?1=R,.,J8#;H59E49\J45*2X3J[H'CYP-!.=OX^9C<
M)"Q\R4F9(BM)95*0WW(6$<$GN]2]/DVOQH-A0*#0X'1Z3N,H24GU@K43VD1(
M_$4$%X>$_D-X/S>5!8^XT(7@<@A8NE4=P$&P]Z?#0;&@4&CWR+[.S`\,5W];
M0;R@4"@4"@4"@4"@4"@4"@4"@4"@I/=+LK^_C"QU.H$82VGT1U/N:RI4,H4Z
MAA5DD'0$G1<"US8F@V>+ZH/YO(;EP628COP,;"R'?EKOHRWE-/AA#(6[I"%*
M2O3<'SK'APH-!M&'B=QQ,N\YCS)Q4*3#4]"???GJ;;]$=;UA3R6W%EDK"M%K
M6O:@U.-VUL;;FY\6YZW5OG*F4T8^-@16G!'6$.O=X"VKNDDK2-(6L:1[EZ"X
M>[Z@9@76J/MF&KFEO3-GVO\`/$".T;>`.4&;BMB[=@2O3U-+GY3MR4]:I4C_
M`#5.7#?N("10;^WCH.;4"@6H%`H!H%J!0*!0*#IES8D-A4B6^W&83;4\\M+:
M!?@+J40*"K)>Y]M?&68L92)I,N:K5W[1!'JII(4#JY7X>[0=.'W9M=A]A+V8
MA(*'81\J2T!9.&4@GBKD%G3[O"@87<VW1D<6H9.'W7>8H!7?MV&G'R`KWW"Q
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MY/9\F@EN*D9"1`9>R$009BP2]$2Z'P@W(`[Q(2%<./*@RJ!01_#J_*4VM:<Y
M^9%9H*YU'_\`UW?MH+/W>@.;7RB"0D&,YQ/`>;0;>@4&@W\O1LS,*_[,L</'
MP[:#?T"@4"@4"@4"@4"@4"@4"@4"@4%(9EQ,;KA"AZWU)DY)E\K=[TI!3"4>
M[![PH4CCY!+?#BD'R:#LPF+S6'WGN:1+Q2(RG,7E)D(ON)<:?6F2TXD]V%EI
M*1Y!*@A!5?R@2F]!KMB/,;NQ^6>R[2);LR5#3$QL(OX^*ZM<=:DHD);T%2&T
M`J5S20.V@G<;8^#VS,P9AA3+DC*ZU1H]V(8<5#>'P<9'P:0$)L#YWA-!)-L;
M.QNW9&6?AOR7UYF6J;)$ETNA+BAQ2W?S4T&]M0.V@4"@4"@4"@4"@4"@4&OS
MNW\+GL>K'9F&U/@K4E:XSZ=2"I!U)-O$:".?W-]+!_Z8@?4A0<_W.=+2..V(
M'U(4$0ZC]*-D(QL7%;>PF*A;@S,@1X$B2RI;:`VA3KJBE-_>(MRYF@K+']&-
MRO*;;CJV\GOA$<(7!U6,X.!(XI5YO=<>SCPH,K9_0O<LO<&)FE_#,1H+T;)N
MF.RXAXH2^M.@$)L3=@\S;E0>I*"O^OA">D&Y2>0CH^O(H)?MHD[=Q1/,PX]_
MJ2:#8T%2[.A9^#UMW!Z9%>A8G(L/2,>EQ2NZ=6AUL..-)0XXW=6L*45`*X\A
MQH+97YA]R@\S.;5DXF9L7(.961/:R$=3B(D@DH8U.,*TM>4>`UV'B`H/3790
M*"+=221M240+D$$`^X:"1P?WE'_<T?K10=U`H%`H%`H/-.4P<&9U8S&#5G<?
M$C+<<E*69<GN@I^2AU<-YLR&4AQ:P%E"+@D<A027K+BLG.WBRIG"F3%1'BH=
MG#'S)QT.N.I=5=EQ"!W`"2$6NK5XJ"RNF*)K>PL*W.@>K):&-+T'2M'=D+4/
M-<*U)U>=8GA>@D]`H(_@E67N0WY9!S^2L4$.UH__`&)U<QR^7_[>&@G.\'.[
MVODUZ=5HZ_)\/"@W%`H(]U"_(K,?<ZOSQ02&@4"@4"@4"@4"@4"@4"@4"@4"
M@HR9,W7_`'WPL1-R4N7BDSG9$-M303$0KT5QQIO4DDJ+7>)!Y=M!HMBN3&=S
M[X?=,J5*9QN08D]TRH.!TR4ZE--//KU:`=03J!TZ1Q-!ONC>UVLMCLLXF=*Q
MZX\YKT5^#W3"PA$8((U)2XAQ*M1NNW&U!O-^83,X27M&9&W%D9*U;@B,.-RU
M,N-E#Z'$+\E+:..DE/R:"U1PX4&LW-N3%;;PDK,Y5PMPHJ=2](U+4H\$H0GW
MRE'@!01F+U;Q<AAMX8'/H#@!TJQKUQ?PVO0=YZH8T?\`@F<_\N>H.!U1QI-O
M4><_\N>H/K^]#'$V]29S_P`N>H.%=4<:@V]29P^YCGC09.$ZB8S+9MO$(QN4
MAR76EO-N38;D=DI;MJ`<5PU>4.%!D[XWQA-F849?+]ZIA3J6&FHZ`MQ;BP5!
M*02D<DD\308FQNINV=Z(>&*+S4F.A#KL.6V67@VZ+H<"22%(/SR3:@EE`H%`
MH(9U907-J%"7"V3(:.L*TV*0I2?=LH`VH,L#+X[+8-ES+/S69SCC,AI]M@`Z
M(RW4J"FFVU`ZD#MH)0300C*9"/.W=!0E![S&Y!F-WA_Z6(^ZO3?Q@`^Y08&!
MMZ3'L`!W.#Y?[10;38R`'4FP21CHI-C<75(DD_FT$RH*BZQ;C7N-+O2_;;`R
M&>RJ4C).W/<P(P6E1=>4.WEY/Z-A06IC(GH6-B0]6KT9EMG4.%^[2$W_`#*#
M)H(;MGITG![PS6XS-3+7F'''0VXPD.L!PI);;?UD]WY`NG3Q/&@F*_,5[AH*
M`S<R+(C]-&F'FW76X?PC:%I4I-C&Y@&X^30>@!0*"*=3E`;1E)Y:R$@^,@T$
ME@_O*/\`N:/UHH.Z@4"@4"@4'F?<>Y].XLSC/18KDYJ9)9$UPP00Z[DT.1W6
MRM)<<4RR%-*2FZ@3Q%!..L4*`K/07UA+LAU4>/("L2].#$12G"M\O-V"M)Y(
MO>@L/8R<:C:.+3C'VY,`,#N'V63&;6FYXI9/%''L-!O:!01W"_\`J;A?[?=X
M>'[59H(EH8^>'Y%:>9\SP\^5!-=Z)U;5RB?"PH>#G0;J@4$=ZA_D3F/N=7YX
M\-!(J!0*!0*!0*!0*!0*!0*!0*!0*"CGXH;]H%AV.I#<9R7=QI+#:2MU6/)6
MYWJ4$JXI(-W`=5_)H-3LI4QS<6_$1>XUIQTX1T,NNH)0N4HJ6EQ22L=H2H)M
MJ'@%!+?9WD-2<%EGVB"AR0RK@E*;$QD7!TI1<^$VN:#<=8DK+.S@A02?C1C;
MD^"SM!+=S;DQ6V\/(RV4<+<6.+V2-2UK/FMMI'%2U'@!013:V$R^Z)D?=N[H
MWHQ;.O![?7<B(@^:Z^.2GU#CQ'DT%@4$9ZC;S&S-JR,^8GIWHZVD>C=YW6KO
M7`C@K2OEJORH/OI[O!.\-J1,^F.(GI1<!C!SOM!;<4BQ7I1Q\F]K4$CM0+4&
MMS<:8IIN9!0'9\,J<886K0AT*24K:4JQMJ'(VX&U!YT]H>-.EY>#ERZIK'31
M&B.X]U2VGF'TE=RIE6I*N#EN\1P'+C>@L?';!D3=D[4S>WY?J_=F)QD=N%-<
M&IM]H-#[6E)'G-J\/-/90;;;O5W%NS$83=D=6UMSBR509ITL/'EKBR/I;B">
M7&_903]"TK`4DW!Y$<1\N@YH%!#^J5QMGS0J[R>!-K>0OC\B@V&6"?7.V2HV
MTOO$>[Z&Z/T:#<RWUM17G&4=\ZAM2FV4D`K4`2$B_#B>%!234[K2G(,SOB*C
M4A]F2M!GL^4MIAUI5^/#47M7BY4&OQVZNJD7&LYGXFH7!:3";+OIK8OZ"MQK
MEQ/EK<^1:@VNU-T=8H\-B7&V&W(COPV&FE>G--72VMU:5:5:B-0>Y>*@S\YN
MSKYD,8]#Q^S&\3*?'=IR(FLR%,I4;*6AOR`5`<N-!W].L#FMEXI<2/MYV3.D
MJ+N1RCA27Y+QYK6I2R;>!-^'NT$G?W?N>-&<??V\^EME)6ZO@0E"1=1L%$G@
M*#?;<S/KC&B9W8:^$=:*020>[64Z@2$FRK7H-I0?+GF'W*#S3(V=MS;TW8<W
M%MJ:G9.,7YNIQ2]14Y')4`HV2-2SRH/3%`H(IU,`5M5])T^4M(\KW%<O'02:
M&+1&1_T:?UHH.V@4"@4"@4%#8Z+$7N>7E$M;D]+@Y;),1'H$%B7#92],47M#
MBV5J\LINI7-/%(-!N=_XN!G>H;F-3FI6$GN0X\!M4!M:3(7*$A]*);@<`<92
MW%5Y`2D\?.XT$[Z:38\W8>$E1V&(S+D9.EB*V66$V)!#;:B2E-QR)H)+0*"-
M8E2NYW21P(G/6^1$9XT$/[_W/R&U\J">[P!.V,B$C42R0$CF3<<*#<4"@C?4
MBWQ'RX/(LB]OTZ:"24"@4"@4"@4"@4"@4"@A?5'J;B]AX5,E]!DY*9K1C80X
M!Q:`"5+5[U"-0U'Y`H(QT;ZXM[P=.%SB&HFX?*7&[D*2U);2"I6@**M*T#FG
M5Q'$=M!;=Z!0*#4M;2VLSD_6K.(AM9/6IWTU##:7^\6"%J[P)"KJU&YO0=C>
MV]O-/R)#6,BM/RVU,RG6V4(6ZVX;K2XI(!4%'B;T';C\/BL:EQ..AL0D.D*<
M3';2T%%("4DA``X`6H/,W57K-N*3NI>,3$A>@[9S:94(K2[WBW()6@!U6L"R
MBHWT@4%I=,DS=^J8Z@;A*2T%N-X##I"BQ%"%%M;UU`=ZXLI-EV]SQ!:EJ!05
MO[0,J*QTVE>DPQ.;=DQ6Q'+JV;J+H*2%((42+<A0=_0=YAWIEC5,1/06@Y)2
MF/WJWK:9"P?*<)4+GL[*"P:#4;HW7@MKXE66S<GT6"E:&N\TJ62MPV2D)0%*
M)-!#C[0O2@`$Y=7E<1]KO\?]"@K[KAU;V+NC8JL7@LDI[(^F1GVTEEUNP:7J
M*M3B0GA;MH)3L'KETVB;1P>-RN;1&R4:%&8E!QEU".^2V`H!24:.8]R@D.6Z
M@=&LY#<B9;)XV?%TDK:DIUBW:0%)O\J@K?-Y3H#$Q>15MW<$N'/:9=5%CP)$
M\-*>2DJ;0`0I&G586O:@NCI_D#D=CX&<IPNJD0(ZUN*5J)46QJ)/:;T&_H(C
MU."E;<2A(U+4^E*4CF2IMP`#QD\*#[>WCLN2RTB6KO0WYH=BO*TJTV)%V^!M
M<4&$<WTO!(,9CAS^T7/L=!\JSG2L)U&,QIY7]!=[?]50=&?W5M%W;CF*Q:^[
MNIEN/&;CNM(%GT$A-T)0D`7)H)-LK2=HX<I-QZ(S8WO[P=M!N[4"@U^X?P#D
MON5_ZVJ@AFW-];3V]MML9J>(%GG=:WD.:+NNJ4BS@24'4#PL:#,_ONZ46O\`
M&6)\M?T-!\KZV=*2@GXRQ.1[5_0T%0Y'=&%S,SI^C&NN2%P\:H/I2RZ/I3C!
M7H)2.\T]VJ^B_*@O@[YVN`3Z6JPXD]P_]CH.!OS:I3J$TV/$'N7Q?L_:Z"N^
MM?5?`1=LKQV*?$S-OK1W<-27&]#9"M3JRM(L+<O":":],NH>$WKM]N7`/<RX
MP2U/QZR"ZPX!;C;FE5KI5VT$OH%`H%`H%!04]$YOJ!)>A^O<7M=F8\[+=ASV
MRB5(5*+;I#:Y#;<=COS97`J)X<+T%M9KIWLW-949;)8X/9()2@2DNO-+`0%!
M/TM:.("U"_CH-QB,1CL/C8^,QK"8T"*CNX[";D)2.-A<DT&70*"+X516QNO@
M`?6$A(MXHK(H(SZ(YXOR*[KSNWY7YM!-MWFVVY_`JN@#2.VZ@*#<4"@CO40$
M[+R@!L2VFQ/`?3$T$BH%`H%`H%`H%`H%`H%!&>H&P,'O;!KQF31I=1J7!F)^
MF,/$6"T^$?/)/`B@C?27HMC-CH<G3'$9'<#UT&8$E*&6B?,92JY&H><KF>7*
M@LH`"@4"@&@=E!#NI74S";%P_I4O[8R+X(@8U"@''5#WQYZ6T^^7^C0>:^E>
MU\7U%ZBRG-S3&V4R%N95S%H"VU3E/+4M2&BK]A1[ZQN1RX7-!Z_BQH\:.W'C
M-(8CM)"&F6P$H0E(L$I2+``4'=0*"K?:2=".ELI)2#WDJ*@7OP^%"KC]3097
ML]7/2C$72I-ER0-5['[87Q3?L]R@LB@J+VHO^%QXD?TC$Y?IE4&AZV=/ME;<
MZ<2LAA</'A3)<N(7GVP2OBLJ(25E6A)OR184%?83H1O+,X^+D6)L%F+-99>C
MJ?4XD$O-AS1=*%@*3JMQY]E!MT^S+U):<2ZSD,:EQL@I(=>!]T'NN%!E?W`=
M83<^NX>J_`>DO_8J"$[YZ;;FVK#;FY>9&E)DRBPHQEN+L_W9625*0A)(2FQL
M:#U/TK3IZ;;:3P_!T?D+#BV#RH)50?#S##R-#S:7$7OI6`H7'B-!AJV_@5&Z
ML;%)XFY9;)X\_>T&CWA*V/M3".9K+XM@PV7$)/=16G'-;B@A.E-A<T&Q@X/:
ML^!&EHPT1+4AM#S:'(S04D*2"FXTFQ`H,@;9VV$!`Q,,(')/H[5N/#EIH-@V
MVVVA+;:0AM`"4(2```.```H/J@4'"DI6DI4`I*A923Q!![#05CUAPFU(.V\8
MM>/AQ6%9C'-N+##2!H+XNE1"19)[:"7>I]@7TB#BBJ]@.ZC7N>790=.>A].\
M!C59',8_'0X*5H:4^Y%:*0IU00@>2@GBHT%>97&]/GNJNR'H4&`C&Y"#DW>#
M*&FG`A*;**2E*>"N5Q06:SAMENNA+,+&N.'S4H:84HVY\`*#O&T]LCEB88!O
M>S#?ON)][05]U9Z'X_<\),_;[;&.S\5&AM*0&F)#=[]V[I3P4/>+`X=O"@VO
M2'I1$V-BW'7UIDY^>E/K&4F^A(3Q2RT#[Q%^9XD\:"PJ!0*!0*!05A-Z*O/R
MYBVMPNLPYCCBG(ABM+LV[.&04@+*@;]Z."O!06?0*!0*",X4#T7<XX\9\F_'
M_H&Z"/:$_._^D-/;R\%!-=REL8.7WE@C2+ZC8><*#94"@CW4``[0R*2;:TMI
MOSXJ=0!^?02&@4"@4"@4"@4"@4"@4"@4"@4"@&@A?4[J?AMBX?OY%I&5D!0Q
MV."K*=4/?*^=;3[Y7R.=!2_3[IKN'JCG%[UWPZI6%>4"TSQ09:4'R6FD^\B)
MXCPK^6:"W.I'2F!NC&17<2M.&W'AT@X')QQW7<E`LEI>@7+7#E[WL\!#&Z9]
M2I^3E.[3W@P,9O?'"ST<^2B6VG^$1^PW`N0/='#D%D`T'-!5/M+A1Z8.V!($
MV*56\&H\_DT&SZ`H:3TIPO=+6M*N_42M.DA1D.:@!=7D@\CV^*@L.@J#VI3;
MI:3_`/4(GYZJ#L]H\VZ3$_\`:H?Y]!*.EK;<CIQA&74:VC`BI*5C@1Z.@T&_
M[Q[&(^V%*?@#@'E<7&A_E_/('SW,=M^=!R->4;0M"BUCG1J!!LX\GF./O4*'
MR2/!01SJ#L/#;P3B<)DE.L06W'I*1%4EM>MM&E(N4JX6<-Z"4X;$P\/B8>*A
M!28D%E##`4=2M#:=(N3S/"@S:!0*"N.O37?;(98TZU.Y"*VA*DI<25K44I"F
MUE*'+J(`"C:]CV4$RVE`5C]K8>`I*D*BPH[*DN"RP6VDI(4+JL>'AH-K0*!0
M*!08TN+C<C&<C2V69D91*'674I=02.84E5Q<4$0S6U-B]\WB8&"QWK:04E/=
MQF`N.TD\9"B$W1I]YX56M0?'6K*-8S8,F2XM+?PS"$K7$9G6*G`.#$A2&R;=
MIY4&BVGA,5E-J].D9*%'G(#3Q6'FD+3QC.JMI4+#RNP<!022-B-EP\Z)6+QL
M#'-XC6YDLHTRRPA!4V4]SWP`X@*U+X\.%^=!'LEU$S\CJ;@(&`?$W:N2CQY#
MSC+.L%+RW4]X'M"M*?@Q>Y'`'MXT%JT"@4"@4"@4"@4"@4"@4$9P@*8>Y2>`
M,^41S/#ND#M]R@C]V_'^2'SO9\K\R@EF\U:=M3#^YCY;J10;J@4$?W\I2=IS
MB.=V1\@OH!H)!0*!0*!0*!0*!0*!0*!0*!0*!00?JCU4PNP\6E;]I68E`^KL
M8E0"EVYN.'WC23YROD#C0>:G-N]0-PQE=4L_BCG<.F6AZ9$6I:')$-"KJ[EL
M"Z8R/-'R[$7-!ZMV1NO;FZ=NQ,M@'4KQZTAM+20$EE2``65H'F*1RM\KA0;^
M@@_4[IC#WE!9D17CC-S8TAW#YIK@XTM)U!"R/*+:CS'9S%!H^F'5:?,RCNR-
M\->K=[024)U#2U.0D$AUH\$ZBD7L.!YCP`+4!H*U]H/$Y+*=.'H^/C/2WDRH
MSBFH[9=7H2ORE:`"HA-[^3Q^1>@V'1#%SL9TQP\2='=BRDA]:V'TE#@"WUJ3
M=!XIND@V/&@G5!4'M3D#I;8WXY"-:WA\LT'W[2:K=)3P)O*A\NSC02/I=DH[
M/3K`I427!#C-M-)\I;A]';/DI^3\B@E3,)]]X29]B4_2H@.IMLWOJ/SZ_'V=
ME!\KAR8CYD0E$L*)+T$VTDDW*VR?-5XO-/BYT$!ZK]3_`(GP</G841.1+LAZ
M(Y%=6IA2"6]:M7DJ4%)[NUBGM^6$\VQFT9W;V-S*&BPG(QFY(940HH[Q(5I)
M'`VO0;3MH%`H*O\`:':8=V-%;>=+"%9*-9\(6X$J`<*;I;(6=2@$>3QXT$UV
M.Z^[LS`N2%K<D+Q\53JW#J65EE)45*NJYOVWH-W0*!0*!0:+"[-P&#;RB8#:
MVQF)3LR>I3KBBIU[SBE5[H'@TT&@@Y+;F$R7<X#)QI<):E+R6,0^B0^T-:4+
MDI65+=(0M:0M*R0`;BUK4'3UT=[O8*B6P\VJ;"2ZP6VWN\2I](TA#I"";VM>
M@Q<9C<1F-I;+C/M+8Q;D=Y3C2%&&4($58*5=PM.D`GD#:@[,[L_:VZL4SM23
M-,F`@$XV9"=2%LNI1J#;Z6O@EW1Y:=:?*%^WB0AJ\0=J=2MC[<C2'):8<5B-
M-D%LH[U(=?6SH2`I*2DK45^7RH+ZH%`H%`H%`H%`H%`H%`H(M`)3A]SK1P5Z
M7.(OPXAL#]"@C&M7@'Y%:N0YT$TWN"=L3`.9+5OJR*#>4"@CW4'\DIOZ9C^4
M-T$AH%`H%`H%`H%`H%`H%`H%`H%!!NJ?53$;$Q'>.:969E`C&X[58K(_9'#[
MUI/:>WD*"G^F?2S-=1LVO?>^UK=QLAP.QHJO)],"#=(TGS(B>24^^]SF'I5#
M#+;264-I0TA(0EM(`2$@6"0!PM;LH*1W;LG<'37./[XZ?-=YAG2'-Q[;%RV6
MTFZW6$#E8<>'F_I;B@M39>],#O'`L9K"O]]&=\EQ!L'&G`+J:=2+Z5)H*UW5
MN;<L'K/`P[$^2,3*E0%*:[]/<@N`H<8#8;!\I(U:"OE=?*@E_4_I9BM[04/(
M5ZOW%!`7BLRT+.M+02I*%*'$ME7RN8H(EBMX>T)!@,PI^RV<G+C`M/9`2FFP
M^4FP<"0JW'P]O@%!A(ZS]77\W*P<38S#V8A(2Y*@B7Y:&U:;*4HV1QUBUB:#
M8IZD];Q8/=/"VOWP2]W@^0I"B#08\SJWU=B$)?V&X%%)59(?5PN>U`4.0OSH
M(9U(W)U/ZA;77A'-HO0&6UIG./!#J5Z6;@@![NT\E:N=^%!T[XWUU#W]MI.W
M!MAH!R'$S:7(3SCZQ&).C4E24642+%/'Y-!$&'>MD6.RU"9ST5IEIMIE+##K
M1[ML!"$W0D$@`?-H-Y$@^TJ]'2X/7X0XD*3K>LJQ\.I04DT'9)B^TDRRM]SU
MXAIE!4L]\D@)`N3Y_8*"*Y-/4K<^UOC#D4SLK@(Q6^,DYH4D:+M*457"B$W(
MY4'K+I8?_MOMD\_Z-C'_`*L4$J'&@^%/,H5I4M*56OI)`-J#Z0M"TZD*"D\K
MI-QP]R@B?4W8[V\]N)Q#,T8]Q$AN2F0IKOA=K5PT:D_/7YT&^V_C/56"QV,U
M!9@QFHY6FX![I`1<`DGC;PT&?0<*6A(NHA(\)X4'`=;5?2H&W.QO0?1-`O00
M3K'+R3&V(;4"<]CES<I!A/R(Y"7.YD/!MQ"5$&Q4D\Q08>&Z#[+PCZGL4_D8
MBW$I;>[J44AQM)^EKLFY2;<?#0;GJCMJ+N'9DJ!*ELX^.VIN4[.D`EME,=8<
M4M0ND&R0>!-O#05?.F;(SNX=G[)9W0W*V\G'2XTD076XZ79)2A#2%%%P"X@K
M`1VT%C;/Z0[4VE-3)PSDQM(6IY49;^IA3JD%O6I`2FY"%$)\%!-Z#F@4"@4"
M@4"@4"@4"@4"@B^+-\3N75Q'IDX6/@T"@TOH7^2/R3[CL^502;>R=6V98\)9
M^O(H-Y0*".]0OR1F_IH_\H;H)%0*!0*!0*!0*!0*!0*!0*`3:@@?57JSAMB8
MORRF5FY*%''X[5:_9WKQ]XTD]O;R%!4O2WI=FNH.77OO?I7(Q\E0=BQ7;H,L
MI-T$H]Y%1R0CWWN<P])MMH;0E"$A"$`)0E(```X``#D*#[H/E20H$$7!X$'M
MH*,SV!=Z:]5,#DMKR/1L/O*<(>5P93=@.$B[K8!&GSKCP'Q&U!V[Q1)7UKPS
MK<=IV"[.AM+F:XJUI?C("EMM^3Z0V4AU&M.JQ!O:@NEV9#9>98??;:?DDICM
M+6E*G"D74$))NJPXFU!W6H*4V[+DM^T+NEB.II*G(96XX\"0$MIBFUPH6YT%
MP09Z'[MG3WJ`"HMJUMF_/2H>/L/&@R^'900K>FWG1AL_+O&=#L9]\O26U+>;
M"&2="%`^;Y/`=E!5?3%"\YO?%J:9C:4[0Q\H-OH4MKRW%(T@`IM:]P:"^L-C
MW($/N%NATEQ;@"04MH"U7#;:239">0H,U:@E!4HV"02301S=V3R4?:V6GQVF
MTLL0WG0']6I8#9]ZGS.'AH('[/N(Q^9Z"P,5DV?28$WTUF2RHJ&I"Y+@(N"%
M#Y%!)W=IX+'-1\+@)$MF:T&VXT5$Z2M$9E)%UK;+A"4I1YH5S-A03L&@\L>T
MK'G*ZC-K;:>4VK'L!*T)<*39QRXND'E>@V?1?JWA-G;0<Q&9AY)R49CSZ%,1
ME.([MP)TBZE`WND]E!/O\1^R3_X?E_O/_P!^@^4^TEL514E,'+%2#9:1$X@D
M7XC7PX4'/^)'9'XOS'WG_P"]00+K1U;P6\-K1L5B(641(1.8DO%R.IH%E`4%
M@*2I7E65PH(ALS>>(VMU83,V^Q).!DJ:@!C(K4AY#4E;*5N+)4$)4E7F]X;?
M)M0>D]Y8'';MFPL#*6\8D-PS<CZ,ZMDCX-3;+2EMV-UJ<UZ;\DT%;;4Z#9$[
MPS7QC0^-K@N#"!J>YWI'??!E90H+^E<]5!,970#IY);0V\B>I#:@M`,^3P4G
MB#Y_8>5!WCH=LE*@M+F3#@X:_6,K5;W2N@U6[NA^$<VKE&<0O)O9)49ST)A>
M1?*%O!/D)4EQ>@A1YA7"@\[9SI3U#P^*?RF3P4B/"B@+?D!32RVFX\LAM:E6
M2>)(Y4%L]'NI6YMR14;?.5D+S4-JZ%.OQ$F0TD^>V78SJUE";:[JOVT%B9-[
MJ+C<>]-](<*6#WKBU^BR4!`-U:VF6&'2V!YVA6H#B`3PH))M#=L3<,`K"0QD
M&-(FPPL.:"L70M"T^2XTXGRFUC@1X[B@WU`H%`H%`H%`H%`H%`H(MC5)3AMS
M*60$"9/*B>5@@7H,"WB1^35N0^;RH-_O!"E[>DH2-2E*9`'*_P`,B@W-`H(W
MU%O\4)8',NQ1\N4T*"1I!`L3?QG_`)*#F@4"@4"@4"@4"@4"@4`FU!`.J_5K
M%;$QJ4V3,STH$P,=>W`<.]>(XI;!^7R'B"H^D73#(=0,LO?^]7A-@/O*4S$6
M0HRG&CINZ`;(8;(LEKM[1;F'IAMM"&TI0D(2D`)2.``'```>"@T^]I,Z+L[.
M28#BF9K$"2[&=1I*D.(:4I*AJ\G@1VT%<>SANS<>X\3G'LYDG<DZQ)92RMVW
MD)4UJ*0`E/;XJ"XNR@J/K<0-V=-/#Z]3_P`R@F&1V%MP916X0V]ZPBNKR$=!
M><+")7=Z5NI9)T!3B4Z5V'&@\G[YZF[MWK$A.9I;`]7K<,549I3*@MQ(U'5J
M5RTCMH/8FSW`YM'".#40O'Q5`KOJXLI\Z_;04Q+C+<ZH=37&]*7F\#*2VI6D
M<5LL6\[R0!I[:#>^SS"G#IM"DLMH\B<^Y'07$#4TMM*%A2FTJ(NZ";+&JUO%
M06.K+[A2I23@R0F_EB2UI-NT7`/RZ#6;BSTA>WYH=CQ6^^A.J+3\M"%!*VE<
MP6U"@J_H<V\SN"(\W&0X_P#%#"M-%;I:\E2GU*"1I4%7"`?%\F@N[TG+]D%O
M[X__`)=!\/*RT@)97$;;94M'>K[[5Y`4"H:=`O<<.=!!]R[ZBYR=NO8,:.IF
M8QC)0,]QQ`;*C'!TI0#WBB-?E6Y?)H,+V:WV4=%L0^ZM+;*5RU*6LA*0/25\
MR;`4'7`ZF]/(6YUXG;!<$PRG!E8Z6RB*I+:^[>?[QQ03=!Y%%]9X6XWH+;H-
M;/W)MS'R?1LAE(<.3I"^YD/M-+TFX"M*U`V-J#I;WEM!QQ+;><QZW%K#:$)E
M,E1638)`U<22:#<=G"@B["<WC=P9N2WB')D?(.L.LOLO1TW#<=#2@I+JT*!"
MD4&=ZZSG]GI7U>']FH.R!G)$C)>KY6.>@/EE4ALNK96E2$+"%"[2UV(*QSH*
M@P>!BY;VC-Y]^ZM'HT*.I"F2CFM+%PK6E8X%`([0:"[,=C(6/CEB(WW:%*+C
MA)*EK6HW4M:U$J4H]I)H,J@4"@4'RM"%H4A:0I"@0I)%P0>8(H/,G5[HU/VE
M/7O'9RG&,:PX)+S$<D/0'`?IS/,J9\*?>_I>069T:ZQQ=Z1!C,D41]S16PIU
MM/!N2V/V9GQ_/H[/<H,G=6!3@,JWF\(YZ(\6Y+R&A?NTJ:07W6](X%E_2=2/
M>K\M%C>X6.A6I(5X0#\N@YH%`H%`H%`N;\ODT"@4"@4$2A+*<#NI2>:960(]
MT(H,?1_E'\G-/_+02'<Q`P[M^'PC'U]%!M*!01WJ""K:DD`V)>B6(^ZVJ"14
M"@4"@4"@4"@4"@4"@X*DI%R0`.))H*?WE[2>S,7$R<?"K5D\Q$<+$<:%"(M=
MO*=[X>2IMOMMQ)Y>&@A?2GI+EM\956_-_%<F)*7WT6&^"#+/O7'$>\CI_8V^
MWGRYAO)>)R/1+<3V<Q3;TOIIE'1ZUQZ"5KQSJR`'T#C=`Y7\'`\DF@N[$Y;&
MY;'1\CC9+<N#*0'(\AI04A:3V@C\V@U'477\0=R:#97JR78W(_85=HH*R]E6
M6AW:>6CI*SZ/+3J"@WHNMO5Y!2D+Y<]1/BX4%WT%1]<+?&SIH?!G4_FZ*"T<
MHE*\;,2J^E3+H5;G8H-[6M0>!CW'JG@M1?#G%!L$A'=\".-RHGGPX6Y\:#W;
MM((&U,*$7T"!%"=1!5;N4VN1P)H*C$-Z9U-ZFQX[*I#SV&=90RBX4M:V6@E`
MM8W502_H5@\WAMB)C9R`<=D793SSK"@A)(4$A*]#9T(N$^:`/#:]!*960FON
M/0U0I++()0I]"`LK2>'D$&R?=H-#GFP[ALL8?I3#"FGEN-&*A=G&D$V"EWL+
MI`L1[E!7G1N:9&;@NN,O+#6V,))TQVRL=XH2D^4H'R1Y9(';\B@O&!D&IB%K
M;;=;"%ELAU!0=0Y@`T&505$>GV:A=1-W;LE)/JF5!D>@E,A*O+5&2AS6SHN+
MZ/)(5P[;WH*BVW+ZICH"^WCX>,<V,8\KTF0\M0FAHNJ[[2G5IN%WMPY4'H7I
MYC=K#9&W'/18(D*QT0E6ADK*RR@DDVO>]!NMW/Y:/A5O8R2F(XVXT7Y2VO2.
M[CZQWJPW=.HA/'GRH(?+Z,X/<>Z4[FW3+;W$VJ(F,U#+"&HWDJU)=!0M141J
M5;CVT%;(V)L]GJONR&SBV41L-ZG?QK2=02PX[(9"U)%_?7-[T'I6@@G53J+(
MV4QAW6F671D9?HSZG@ZKNF]-RZ$M`J5I-N',]E!.4*U-I5\\`>1'/W:#2+4H
M[TCI(&CU:^0?'Z0U>@K;8J@KVC-]C@-,*/8"_@9N:"YJ!0*!0*!0?*T)4DI4
M`H*X$'B"#PMQH/,/6+H]/V;DD[VV:IUC',.A]UECZ9CG?VYOG=@WLI-O)_2\
M@W&-ZX8S=>WH\/-K1"W"RS+9<`\EJ27(BDH=:5YJ>\5[SP\J#T,W?NT^&P_.
MH/J@4"@4"@4"@4"@4"@B,,).WMU@"P,K(WX6]YQH,3T57[9_Z9[KEV_/<Z"1
M[I;4YA7$I-CWL<WX<A(;)YT&VH%!H-]IU;:>3>P,B'<VOP],:H-_0*!0*!0*
M!0*!0*!0*"N^OSV0:Z69<PE.I<<++;I8U!1:6ZE+@)3QTE)LKQ4%!]`-BX+=
M^\)`S""]`PS+<IO'V'=/.*64(#GA0C3?3R/;0>ODI2E(2D6`%@!R`%!\2(T>
M2PY'D-I=8>24.M+`4E:%"RDJ!X$$'E04G,AYGHIEG,GC6G<CTPG.E4_'(NMW
M%N.'Z:R"3=LD\?E'C8D+DQF3QN8QC$^"\B7`FMAQEU/E(6A0_P#:X-!SB\/B
M<4P8V+A,08ZE%Q349M#2"M7-12@`7-!EF@I'K<[E!U1Z:-DH]5*R*2TFZ=?I
M(=0%D@\=(;*?%075(9#T=UDDI2ZE2"1S`4+7H/+&_P#V>\YMW'11A%R=P^DN
MK2[W$8!3)2CX,*2E2UD.'AJX)3;CSH/3N!CNQL%C8[S8:>9BLMN-)Y(4EM(*
M1:_(BU!7.R6Q_?9OE9'$-1@E7@!2BX_,%!*LBC(Y_.O8UF<]!P^,"$Y$Q3W<
MB3(=1K2REX>4VVAM25**+*)-K@`W#[E[+]':+^`GRH&3;%V%NR'Y3"R..AYE
MY:TJ0KD2+*',&@C[6X)&5VEE)[;98=>3(`B!=@%A*T2@?)LLMNH4GW!?A>@J
M_P!G65N%O*RDY57=QO4V)#,G4AK3`(?5%5=.JZC<\^/AH+:PS^8W+-G8[OY&
M-Q>+>4UD'V2&I$J2XD.=VA:?*:0AM:2LILHJ-@1;B&XF[3DQHG>;?R,J+D&0
M.X$E]Z6PYI_8WFWUK\E7+4DA0YWH.US+,9;9,K(MIT!^"^7&K@E"TMJ2X@D?
M.+24_(H()[-T"',Z&XJ'-81(B2#+0\P\D+0XA4ARX4DW!!%!MG]J]/,JZWCM
MNX;'.*9=0)>1B,-=W%0TI+BD)=0+=ZJVE*4\1>YM0;[J-N6?MS:<K*08CDR0
MA3:$LLIU.:5K`4I*;*!(3>UQ:_.@B'1O?6"R<N?ADXWU'EU'THP777G7Y"0`
M')!UMMH2G4JR0GY0H(\HI_OCZ@73<!&!!YVNJ2QX/<H+WH*[ZW9/!XW;<>3E
M,&WFB'5B'WQTML/]VHH<78A9!4`+)XF@L&.5&.T5`!10G4$WL#;C:]!I%@_'
MI@]GJMWA_M+=!6NPC_\`D=OX?]CC_G,T%TT"@4"@4"@4'PZVAQ"D+2%H4"E2
M%"X(/`@@]AH/(/7K86&VENQIC%7:QV587,3$MY,=:7-*DM$<0B_E)'O:#T)T
M-W#EMP=,\5D<J_Z3,/?,F01Q6AAU32%*/:K2D7/;03V@4"@4"@4"@4"@4"@A
M^+N=N;JNG23,RGCN/*L:#ZTCP?\`@%J#<;J>+.%6L`DEZ,CA_ER6T?\`.H-M
M0*"/;]O\6UV)%Y<`7'/C.9H)#0*!0*!0*!0*!0*!0*!0>;O9@;!WYO1T7\E*
M4]EO*E/'_FT%];MS_P`7MLY/.%@RO5T=R1Z.%:"O0+Z=1!M[MJ#0=*NHZM^8
M>9D%XXXU<.3Z,62YWM_@TN:KZ&[>?RM03*1&8DL.1Y#:78[J2AUI8"DK0H64
ME0/`@CG04E*A9KHKFG<ECTO9'I?D'BJ;CT`K=Q3KA^F-#FILGYAXV)"Y,/E\
M;F,9&RF-DHE09:`Y'?;-TJ2?SB.1'8:#%RT_(*E(QF*"/3'$]X_)<!*(S)N`
MX4^_6I0LA%Q?B3P%!YUWENHYKK+LZ$F1*=1A\J8KPE%I252$2DI6XTID!NRD
MI2+#ER/&@]([@D/QL#DI,=6B0Q%?<97PX+0VI23Q\!%!`>GN\,QG-G1=PP'I
M$],6\;+X^6EM3SCC(3WKD9YO0F_'4$G4#RX&@LEB0U(8;D,J"V74A;:QR*5"
MX/RJ#SOE=V_%SKQE'GY$N/C9BT1IBH8;6K4XAI#2E)6%72A9N;"]!9K&9D;1
MW1-:W(_JQF>4T]C\NEHI;#[+0:<:DZ00VI2&TK"N"3QY<J#?Y/?&`BL@0Y3>
M4GNW3#Q\%:7WGG+7"0$$Z1X5JLD#F:"(0XN9P^R,O"D.!<\B8XIEL@-K=DAV
M1(*01=6EQ:D<QP`-!">B\PQ]QI!(:B':^VDR72K1I!C.Z+DI5S/9PH)]MC*2
M-N9/*NYY/<8O.S#+CY(I*6VY&E+"V9//NRM+*5I6JR>)'`B@D&Y>HFU\'`+Z
MY;<V4L6AX^&?2)#[JN"$(0WJ(U*(&H^2.TT%:;PS69V=T^;QF9GJA9W,,2U1
MHT%II<5+[J^^D(>=<2I94>_58@!/YY#:^SUD\?BNAF/R&0D(C08BICC\EPV0
MA"9+GE$^"@PHO6?;<K=4=O"8J5$94\H.9"R6X<M@'NRHH;UZE%1NT38]O(D4
M%J;DRF0QF/3)A1FY3ZGFF=+SI8:2'5A!6MP)<(`OX*"L-Q]&,YO7?XSVYWV\
M9BVX*8R6L3+=])+J5$@]XMEL)1Y1N/<H(QM':L+;/4#>^%A/OR8L/U$&WI:^
M]?)=EM+.MRPOQ\5!Z-%!`^K?3Z?O3'XN)$4PA,.8F1*+ZBVM3(20I#3B6W5-
MK4;>4.7CH)TVDH:0CGI2!<DD\!X3SH-"K\NVOZJ<X?[2B@K;80__`".WZ?#"
MC_\`P:"Z:!0*!0*!0*!QH/,WM3)"M[[:01<+B*!'A^V4T'I.'&C18S;$9I##
M"!9#+20A"1SL$I``H.Z@4"@4"@4"@4"@4"@B4$@;9W,1Q`DY0VO?M630+_Y(
M_`-^1^5RH-EO(VP*ONF$/ES&A0;N@4$?WV+[=/W9C_Y<Q02"@4"@4"@4"@4"
M@4"@4'"B0.'G=@/*]!YR]EGO/C;O/O0`Z0RIP(-TA1D2+@'M%Z"X.KA4.F6Y
MM(!/J][@0%<-/'@:"'>S$S&1L*0ZTE0=>FK5(4IUMW4L(0G@E`"VQI`\ESCV
M\B*"WZ#IF-17HKS,I*%QG$%+Z'0"@H(LH*"N%B.=Z#SGM;"[G:ZH;FV;T^W1
MZDV]"2WD6&BVB<Q]L);UI;U$:?+60+'LX\:"W^GVT-UX%S)O;CW"=PRIQ9[J
M06`P6T,A?DV22#?701'?G0,YG=\3<^VLDSMZ:RH2'R(ZGN\E)<UA^VM*`>`N
M-/'G0=\[ISUIFP)$-_J(V6I#:FG"G&MI.E8(5Q"N'`T&KVCDM[8$9C![$V1$
MDXK%9!V)(ENY(,*>EMMM]X\67`KN^\!2K2GA0:)G$>U;&80Q%<0VRV+(;[['
MD)'SH)!/#LH-EMGH+NG*[@5G^H^2:F*7=9@PU+0LOC1W;I?:#.DMZ."4CY-!
M:6]]O9_+QL?ZBRB<5,@R?2.^6T'@M/=+:+?'S;]YSL:".,;,ZHL$EC<4-I2O
MIBD1D(*OU+8H/AS9'5)V)(B.;G8+$H.!\!JQ(=!"K'N^'.@TFV^CO4/;LLR<
M?N6*VLPHN..E@@&/!!3&20I*Q="5$$]M!O&=G=76`M+6ZXUG5+6Z%QTN"ZS=
M5@IN@XB;!ZA"?#5+ST#U>U,8ERV(\%II3J6%AS02A#=[D<R>%!M^J'36!OC"
M!@J3'S$4*.,GG5\&I=@M*PFQ6VH#BD\*"O(O0SJA#V4_LR+NR"C;[Z74KBJA
MZC9Y9<7\(;K\\WYT%S;9Q*\/MS%8A;@>7CXC$5;R1I"RRVE!4`;VOIO0:SJ'
MN?&;:VK+R.1T*C$H8(=2IQN[R@G4M"?*4E(NHA/$VX4&GZ4[NPV;QLJ+!G39
MKD%P(=<R"$LJN4@J2RW=2^[;N!Y1-N5S00J)H/5[J(DC2->WKVX$_;#?'B*"
M\;VN:"/#+;FEY7)1H#$(1\>\AD+D..A:RME#I-D(('TRW.@[M>]NQO&?5)'T
M%!\X[&YQ6>.5R:HJ0B*J*VS&+BKE3H<*E*<"?G;6H*VV)_\`]&[\^XH__P`*
M@NB@4$9ZD;@R>`VC+R6++`R"%L-1S*OW`+SZ&R7%72$I`425$@#F:#OV%G9V
M>VAC<Q/0AN5-0IU;;8(0D%Q02!<F_D@<;\>=!OZ!0*!0>9_:C/\`OSMD#SQ$
M)'A'VTGC0>ET>:/<%!S0*!0*!0*!0*!0*!01!E0:V?N=8Y)>RZN/+@MT]E!Q
MJ\0_)^_+\R@V^[VU.80H3YQE0CX.4QHT&YH%!']^&VW3]V8\?+G,4$@H%`H%
M`H%`H%`H%`H%!PJ@\X>RK?XT;QOST1[_`%9_W*#T!G\+&SF$GX>4M;<?(,.1
MW5M'2M*7$E)*3X>-!H^G'3S';%PKV+A2GI@D/F2Z\\$I.HH2BP2@``60*"6=
ME!7^]][[8P\AQW<KJO5D60U&CX]E!=6_)4@/%QUM/$MMHXC5PX$\3:@D6T,_
M@-PXMG+XEOND/I(2VXVEI\-H6I*-:!Y24JMJ2#V&@WU`H%N%!!LFM6SMSRLZ
MILG;.<+9S+J1?T.8V@-(E+`_876TI0X?>E()X$T$U8>:?90\RM+K+@"FW4$*
M2I)X@I4.!%!]T"@4"@7H*VE8WJD]'ENM/H;@Z<BWZI4;2777)KBHS[<BZM*.
MY4FR;BP%K>`+)H%`O0<^.@U,/);9W+&DIBO1<K&C/*C2D#0\A#S7G(4#<73>
M@\_=5XV1PW57*9#:DE&#E8W;9GNKCM(`<:;=LML)`TC7Y/&W900K;N,ZR9]S
M(;FP:)LQ>5=:3/GMEA/?.05I4WJ"BGZ6I(MPH)=_^4]N61OV#[3H-7)E^T+@
MS*ES9<J!Z6M+TAQ]V"C4L)2T%`+/SJ`.%!CQMY>T-)BOS&)&57#C(<=?E=PT
MEE+;0)6KO%("38)/*@DG2R9UCZ@1\A*B[V7`9Q[B&B'&$.J6IQ.L'@E(M061
MTVZ5[@VUN[,;GSN=3F<AEH[;#BDL]T;H4#J4;VY)```H+.H%!`.NR7%],,JT
MVE2W7EQ6VVD)UJ6I4EL!"4>^)\%!ONGDN)+V3AI$/0(RXR>[#;(C(`%Q8,)6
MZ&^(\W4:"0T"@4`T'F?VGP@]0=K!1L!%`4;7X*EI^90>F!0*!0*!0*!0*!0*
M!0*"&H2H;*W58E1+N8(![/A'>%!]]TO_`/H&GY-!M]V.*;PVM(N1*A<.?.6T
M*#<4"@CN_P#\G.W]_8[E_6#%!(J!0*!0*!0*!0*!0*!0?+@U)*;D`@BXY_(H
M/(71+I]$WGG-PLIS&3P[4%#:F7<>]W+CB77G;!XV.K2$</=-!;W^'&*#<;VW
M*.?\,!_YM`/LY,$6.]]R%/&P,P6%_P#-H.QOV>FVR%(WQN0*3R/I@]SYWP4%
M6;TZ%[EC9#(/X5V;N!QF4B,M#CH<FADQTO=\X5:4J2>*$"_@%!9'0/I3GMKR
M)&Y,TX&)66BI9]5K&I]D)<U)+KH-B=*1Y.GAX:"Z*!0*#Y6A+B2E0"D*!"DD
M7!![#04GA,-FY8W@Z,7D-CMXU+Z\4[`??98D$%T]YZ.X51S]+0?@T#G00+IG
MGO:$W3B)+^WLQZ1&B.!#BY[K*G.\6@+TI4ZVXH@#PF@W>YLA[3VWXXDR7S)C
MAM;KST-N.^AI+0U*[SX))3PY4&D^/WM$!2DK7-"DE8($-DW+;8=7;X+WK:@J
M@ZF^HOM$.6*1/*5+T)(A-7)+7?@:0UJXM>7RY4&XP^X/::R6+?R\=QQJ#':#
MY7,8CL%QM2-94RE;0UV3VB@O?=>[,7MS`HG9*6B,9-H\20H%39DN-J+>I0!"
M4DIYJX4'GO8/4'K;NS=?Q<8W$S#FL-.O2''XS+C8[HI2I("&_*XN<*#MWOU#
MZ^[0S#\/(3E.1F5H::RC.-0J(ZIY*5(""6QY5SIY\P:#9]-]W]<]_C)*QFY(
M4)&+4VT\)<%L+4MU*E#R4H5IMIL;F@M3I-O:1N3`/,9%Q3^=PSZX.6?[M+3;
MKR%&SK03PT*3RX`^$4&TV6<#Z+DU8>`S`95D)'?!A.D/.`B[YX"_><P>7@H*
M(ZSXC=B\WN_=L?(1F<3'2QMY^,M'PZH[Z&'%(1Y!3Q6[?5JU4$6V1UCWIMO;
M'Q=VY`8<#+SC[DQ;3TA:>_5>Q0CR1V\Z#>N=:MUR5).4P>1GZ!9QA$J3#842
M.)+<6.T3?G92C0=\'KX]CU)D1.G\9*R`!(N\IT]O%Y3"E*^2:#G<'M/9J?A<
MCBW]M-1DS8[L13RI#MT=\V47LIE-R-5[7H)%[(PM@]QCP2HX_P"I-!?U`H%!
M$>J\J5%V%DWHL:#,<2&KL9/N_12DNH"BYWRFT<!RNKG0;3964C97:>+R,6#Z
MMCR6$K:@@)2&D\@E(2`G3X+<+4&ZH%`H%!YI]IP!743:Z0;*]&;L;7M>8+<_
M<H/2H%OFT'-`H%`H%`H%`H%`H%!$8Q`VAN0D7`?RY('[J[09EQ\X?P1?GV?.
M^[09>Z[^I^`N?2H7#_:VJ#;T"@CV_0H[=LGF9V._E[%!(:!0*!0*!0*!0*!0
M*!0<+4$I)/``$D_(H/-?LDJ"L[NNW$=S%L?#\*_0>DUK0A*EK4$H2"5*4;``
M<R2:#YCR(\A'>,.H>1>Q4VH*%_!<7H.R@U>1Q"W)B,G"=[C(MH[JZKEIUN^K
M0\D<P#Q21Q3\L4$=VWOZ7DNH6>V?*@-L.81AA\2VG5.)=#X2;:5(1IMJH)M0
M*!0*#5;K-ML9A7@@R3_U*J"F?9#M\4,U8W^WF_Y.B@LOJEN+`XK9N6CY/(L0
M7YT"4W#;=<2AQU?=$:6@3=1NH<J"!O;_`-CB8];/0BE/IP"N^38Z\:PA%KGW
MRDD#Q\*#78S=V`9D1>\WS'6XV^E3CI$47_H<(UVMRU_!^[XZ#+V!MG+9?>.(
MW9B-RQ9^%8QD6%FHS;FIU13'MZ.XRA/=I&K2>)OPH)=U`V!+W!MWU#I4_"C.
MHDXMUAU#,F.\S?NT'O4J;<;`.F_.WRZ"G^AD61$Z]YF))`3)CL3FGD@W&MMU
ME*N(\=!Z??CL2&NZ?;2ZV2"4+2%)-O$;B@J#H8A"-[]4VT)2AMO.A"$I&D`)
M[RP%N%@*"2[0Z=2L+Z<GO&8B,FZ7<FN(X\M<DA2RDV7I0P2E=EE"=2O#02>3
MA%M/IF8E:(DI+:65M*22PZTCS$+2D@@H]ZH<O&.%!7_4?8VZ<ML+=$6)'9?R
MF5GL3V(;+A/D,H80I(6X&QK/<D@<J#2=#>GDZ#MN<9[3F$W9!R#P:E)LIQ#;
MK+*TMOH2KNWFSST*)MV:3QH+3QNY)");6*SK*8667P9<1J,25;MCNJ]]VEI7
ME#_*'&@[LWN5C'.MPH[2I^8D)O%QC)`<4+VUN*/DM-#M6KAX+GA007JEMI^1
MT[W%FMP.(F9:/CI"H<9O5Z'$)1Q[A"K:G/"ZL:O!I'"@BWLD_@7<@_[6Q]9-
M!?HH%`H*^Z\K*>F61((2OO8W=J4"4A0D((U"Q21P]_Y/AH-GTD[G^[3;A867
M&S";(6H%)-^)X$JMQ\?N4$NH%`H!H/-/M,N)3U%VS<@$1V22;#AZ9VDT'I44
M'-`H%`H%`H%`H%`H%!#VG"WLS<S@%RA[,*`\-G'30;/R_`G\%^$\_F4';NQ0
M3AQ?MEP0+>$S&A0;B@4$?WT+X%`MJ^W\;PY?P]B@D%`H%`H%`H%`H%`H%`H.
M%<J#S5[)3BU[BW=J'$M1C?PW>?H+EZP`'IAN8$V^T'>/R*"'^R_`D1MAS'7&
M5,QY<];L4K%M;8:;05@V`(U)(N/!07#>@KOJ[U?Q6Q,?W#83,W%+03C\??@!
MR[UZW$(!Y#FKD*"N?9J9S^8WCN7=N<]*7+<:$9V0Z"VTMY3I[ULI(%U,AE(`
M3P0#:@]#)DQUOK82XE3S6DNMA0*DA7FE21Q%[<+T'90*!0:;>:M.T<XKP8^4
M?^I504[[(@MM/.#L]/;M][HH+`ZK[3AY+"O9\2Y<'*X&',=@28;W='RFPI25
M\%:DDMIH(=.V8^U*>;;W'FTH;5.[L"6"0&(;;[8-T&]EN'Y%!K8..Q\M<52=
MS9U<>0X4MI6IR]O5B9)U!3)L>^^>[.7AH,OI[(P</<^.P4'(9@9/<>*8R4R<
MMUCNRI#2K(T.L=X"-*M/9;C06=BTY-K=;L1.0D3L='B:I9D%DA,EQQ/<I3W;
M;:@0VA95?YX4'G_9F3R&+ZX=1,M`B'(RH",DZW!2"7';SF@4HTA2KA-S8#CR
MH+UVKO\`&=P<6>W!<7-F.2.[@,E)6VTR^MI*Y!40EH^1904?.N!>U!J>EFR]
MP;?W)OG*95MMIC<.5]-QZ$.!Q7=>6?+MR/ECA06-XZ!0:G=.Y\-MC"R,SF'B
MQ`CZ0M:4J6HJ6=*4I0D$DDF@T'33=N(W2QG,QB%.+@N9(H0IU!;)+<9E*O)5
MQ'$=M!V9B:K=L=[$85MM[&N>1*SKH"V&U`_P0?LSR%"X6/(0>-R1:@QL9#F;
M%"T2N^S&'?479>?<LYD&B/?3;6+S:0;!:!Y"1Q3;C0=G5B3&E=)=RR(SJ'H[
MN+?6T\VH+0I)1<*2H<"*"M_9&21A-R*[#,8`^0S?]&@OZ@4"@^7F67FE-/(2
MXTL66VL!22/`0>%!RA"$(2A"0E"0`E(%@`.0`H.:!0*`:#S)[3B4JZD[92H!
M251F`0>1!F&@]-B@4"@4"@4"@4"@4"@4$.2?]R=T%)X][F;'Q]X]0;RR?!_`
M?S*#C=`OC&A<B\V#R^[&J#;4"@T.];G#L"UP<CC01;5P]/9[*#?4"@4"@4"@
M4"@4"@4"@B75#?8V/M1S/&$<@4/-,)C!P,W+RM-]92OE[E!27LB:O7N[%J`&
MIF(=.H$B[CQ/CX7YT%W=5($W(=.=P0X+#DF6_#<2RPR+N+/`Z4CM]SMH(Q[.
M6.R^/V`XQD\<O'.^FNJ:0ZTMEQQ!0@=XI*^-RH$7L.5!L.J_51.TH[.*PL;U
MOO+)^1BL2W=1N>'>NA/E!`[!V^Y<@-9L7HK'9CR<WOA8S6\LOI=FS5'4(BD'
M4VB*JPT*;('ECP6'DT$XA;?R$)LL1<DEMA:U..$16$NJ6LW6XI2`A!6H\2K1
MQ-!6/4'IYNG:V7=ZA]/I+\G+MH!SN)DN*>$YEL740+%15;W@Y>\M:Q"5[+ZY
M=/MSQ<:EO()A9;(E+0Q,@*2\F0>!:O;2KB.!OQH+!H%!I]XM.N[1SC3*%.O.
M8^4EMM`NI2BRH!*1VDGE0>3NE'6#)].H,_#^I#,D2GD27$/K<C.MV:2BRFRV
MH]EZ"2;@]HO>>Z(+^(Q>WA':E1W6IJ$H>ENEMT:-2=*4:+7/$@\:#6/]4NJS
MSRW585Q)<[\JM`D7O)82PHCGR2V+>.@^$=4^JC4I4I6&<U!??7,"0$@B((9O
M;L[I-_=H-YTFZCY7=6]\1@Y,:)%?1"<CQ,Y&C->G(9C,\$=Z[WEM2`1P%!Z2
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M=E(0TTB:E*4(2+!*4ABP`'@H/O\`Q;IL+;6)O?\`AP[/]300G=G6]63P^4QN
M%PYQ$++,.QID`R$O1271Q?:0&VRTX+W.DZ5=HOQH+&]D@@[6W`1^,D_R=N@O
MB@4&%!S>&R$B1&@3X\N1#5IELL.H<6TJY%G$I)*3=)''P4&;0*!0*!0#0>8O
M:C?$??\`M]]2=2&8;;J@.9#<LJ(%^'90>A-H;IQVZMO1,]CDNMPY@46T/I"7
M!H64*"@DJ'-)[:#<T"@4"@4"@4"@4"@4$*;-]B;IM^VYOZZ_0;[N_&?P?IY#
MY?*@;I4!C6+B]YT`?+FLT&WH%!H=Z.!O%1;W\O)8U/`7YSF:#?4"@4"@4"@4
M"@4"@4"@C?4'9$'>FUY.!F/+CI=*7&9#?-MYLZFU:3P4`KFGM%!Y+5M+JSTM
MS*]RM07(R,;)]&.120J));)O9:$G5W+H[5#@?\J@]4]->I6#WY@AD,?=B8R0
MWD<<L@NQW;<C;SD'WJQP-!J>JW59&U&X^%PL?UMO3+$-XC$M^405&P>>MR0/
MS?<N0'QTLZ5JVZX]N7<CPRF^<H"O(Y!9UI9U?L3%QY(`X$CW!PH)_D<C!QL!
M^?/>1&A14*=D/N&R$(2+E1-!A;=W7MS<D5R5@I[60CLK#;KC))"5E(5I-P..
ME0H-J104/U#VEMC#=:.GTO&PTP967R+[^06SJ"77&PDH/=WTI*E+.HI`YW-!
M?-`H'CH(=U!Z<[6WA";&9*HJ8RP\N9'+;+I"$D)"WE)4="20JU^8H,;ISL_;
M^$058%@MX^,TJ&U+=0`_+67>\=D+<`!<256"#RYVX6H)SQH/EQ"7$*0KBE0*
M5#P@BQH/,>RMO8O;GM0^I<2VIG'1$2!':4M3A2%P0M0U+)4?*4:#TZ?-/N4'
MG/V4L3B9L?=;TN$S)<;F,):<?;0XI(T+/`J!M\B@O=[9^TWE]X]A(#BSPUKB
MLJ-AXRF@SH&,QN/:+4"(S#9)N6V&T-))Y7L@`4&30#8#Q4$3WEL3:'4"%'C9
M>\N-!>*V_1GRBRRFRDJ4V>U)XB@R$=.-@(;2@;<QNE``2/163P'#F4T'*NG&
MP%"QVYC=/.WHK/,?YM!U'IATZ*0@[:QFD6('HK7O>7O:#I/23IBI1*MK8PDF
MY^UF_F4$%]FMAB.G?<9AM+4=C<4EIEI`LE*$`!*0.P`<!0710*",[3Z=[:VK
MD,KD,0VZB3F7.]FEQQ3@*M:U^2#YHNX:"34"@4"@&@C6_M^X/96"<RN562HW
M1"B(/PLAZUTMH'ZY7("@\ESQU*ZK[F;R*(;LQR:ZJ+%6A"D0(J&2%*:#I&D)
M;"[J)XJ/CX4'KG8&U$;3VAC=OHD&48+92Y((TZUK45K('&PU*-J"04"@4"@4
M"@4"@4"@4$,"@K8VZ2.7>9H?*<>!H-__`#&@ZMV'^C(_+\(8[G]VLT&YH%!H
M=Z7]5Q+7_">-Y?=S/.@WU`H%`H%`H%`H%`H%`H%!CSX$.?#>AS&42(DA!;?8
M<`4A:%"Q2H&@\K=0]@;GZ/;B1NS9TEU&%=7H2[Q<#.L\(TI/[(T3YBC^8>)"
MP/9L@;=RD+(;PD35Y;?$UU2,U(E`=[&N?(::3[UM2;64.?+A:U!>-!$>KA0.
MF6YM5[>KW^5K^;PYT$(]EV(IO961E:FM$J>5);:7K*-#+:"EP&Y2KA>Q/(T%
MRT%0=6$*5U=Z7%/'3,EDBUR!W:./;06_0*#B]!3.`BL9#VCMYL3FQ)CQ\;!<
M88>\M"%Z&?*2A5T@T%S"U!S:@XH/.F-"C[7,FP\D(>)/_P"GH%!Z*/FGW*"@
M/9(`]`W98</3F;'CQ\A=!Z![*!0*#JE(0Y&>;6G4A:%)4GP@BQ%!47LR0TL;
M4RKH`'?SRH`.,N62EI*4)4&C="DIMJ"P#?LH+BH%`H%!3?LYCX?J`>P[EEV^
M707)0*!0*!0*!01K?N_L%LK!.93*K)4;HAQ$?39#MKA"!^>H\!0>>=K;5W=U
MMW>YN/<:UQ=LQ5J;*VR0G0#?T.)>W^L=_1Y!ZAQ>+Q^+QS&.QT=N+!BH#<>.
MT-*$(3P``H,J@4"@4"@4"@4"@4"@4$-2E*=A[EYV*\T3\EY^@W_D^`_O+P]E
M!T;M_!L?A?\`I#'?RUF@W5`H(_O<VQ<+QY3&#_OS-!(*!0*!0*!0*!0*!0*!
M0*!0=$Z#$G1'H<QE$B)(26WV'$A2%H5P*5`\"*#R[OS9.Z.CNZT;OV@I:L"X
MYITDE:&DK-S%E#F6E'Z6OF/=YA?G3?J3@=]8,9#'*[N4UI1D("S\)'=(O8^%
M)YI5VB@SM_869G-E9O$0@E4R=#=9CI6=*2M2?)!5V<:",="MK[NVUL]W&;E0
M&7DREKAL!U#O=L%*?)NBZ1Y>H\S033<6X</M[$2<OEY28D"*G6Z\L_*2D<U*
M4>``XF@I/';7W!UIRS>[LZ[)P&U(>I&V(;&E$MU*CY4E2U`E&K0.0X]G#B0D
MO^'?"_VFS_WX/H*#C_#KA.W<V?\`OP?04&S?SLC8_2::[%4K)9/:\<M/MRRX
MMQ:D+\YW3Y>E2%:@KE:@KKH'EEY?K-O'*+45*R$-,K25AS0'7TE+86+@I0FP
M3:@]%*4E"%+4=*4@E1/(`4&AVUO_`&=N=]YC`Y1K(.QT)<?0T%^2E1*4DZDI
MYD4&_H/.>.<__+N0C_(>M_Y<B@]&'S3[E!Y^]D6YQFZE$\YK(M;P(7V_)H/0
M5`H%!BY4*.,F!'GEAS3;B;Z#:@J[V;S(&TIK*UI7'9D-I82C44IU1FG%I!6E
M)NE2[*_RK\306W0*!0*"G/9T(+V_P!8C<LN_RZ"XZ!0*!0*!01CJ%U!P6R,"
MO*9194XJZ(4)!'>R';7"$`]GSRN0%!YYV?M/>'6O=;FYMRNJ8V['=4V5MFR=
M"3?T.&.P<?A'?^=R#U%B\7CL7CH^.QT9$6#$0&H\=H:4(0GD`*#+H%`H%`H%
M`H%`H%`H%`H(8A-M@[E\!7FR.S]G?H-__,:#JW9?U;'M^,,?_+6J#<T"@CV^
M#;%P>-KY7&#_`+\S02&@4"@4"@4"@4"@4"@4"@4"@QY\"'/AOPIC*)$62A33
M[+@U)6A0LI*AX"*#R[O;86Z.C6Y&-V[0?4[@RONE!TE0;0LW$658W6VKDAP\
M0;=M!?G3;J3A-]X(9''DLRF2&\ACG".]CNVOI-O.0?>K'`CY-!N=R;EPVW,/
M(R^9E)B08PNXZOF2?-0D>^4KD`*"H,#M[<'6#-L;JW<PN#L:(HKV_MU1.J58
MD>D21PX&WR>0\GBH+Q::;:;2VVA*&T`)0A(``2!8``<@!0??"@Q(>8Q$YQ;4
M*;'E.(%UH9=0XI(O:Y"2;<>%!C9'`QY<@2VG%Q)H1W2I#.GRV^)[MQ"PI#B;
MGD1P[*"G.EF&1AO:!WOCT/JD);Q\=?>K2A!N\IMU0TMA*0`I9M;LH+QE)"HS
MR2"H*0H%*>9!!X"@\]>RI""<CGI@>8"2RTQZ*%WD)T+4K6MOL2=5@J_$@T'H
MJ@\\8<'_`!;Y`A-_@7;JOYH]":XT'H<^;\B@H+V1B?4FYQX)[?ULT%_4"@4&
M/D&PY`DMW"=;2TZB";721>PXGY%!7O0;;K6&VI)[O+L9I,N27$RHRUJ2D(;2
M@-*2XE*T*1IXI5QH+*H%`H%!3GL[6](Z@6_M++H+CH%`H%`H(KU$ZB8+8^#5
MD<DOO)+ET0(""`[(='O47Y`7\I1X`4'GW:.SMW=:]VN[HW.XN/MMA9;"D$I2
MI"57]$A\>"1^R._H\@]18S&0,9`CP($=N+#BH#<>.T`E"$)Y!(%!E4"@4"@4
M"@4"@4"@4"@4"@AZE7Z>[@4H@6]=7/N2)%!O+?R&@Z]U?@Z/]WX_^6-4&XH%
M!'=]&V,@>/+8L?\`?F:"14"@4"@4"@4"@4"@4"@4"@4"@Q\ACX60AOPIC"),
M62@MOL.@*0M"A8I4#0>7.H&QMU](-SC>.T'5G"K6$("KN):2L\8LH$^4T?>+
MYCW>8278/?\`6W<;VX-UO1Q@<`ZE$':3*RL!Y2`>_D7"2M)]Z??<N`!N'H1"
M$I2`D!(`L`.0`H/J@^'?I:_TI_.H/./LKXYT;ASN10UIBF,F/WMT^4X'M9&F
M^H63;LMXZ#TA>@IC8ZA_B7W^C_Z="/\`HM4%R/-J6RX@`74DI&KE<BW&U!4?
M0;IYOC9TG,MY[NVL?(#?HC#3P=270I6MQ*1YH*=(X\:"WZ#SU@G4J]K7*I38
MZ6'02/%$9H/0BN5!0GLC*U8'<J@;I]8(MX/I=!?M`H%!TS5/)B/J8(2\&UEI
M2N("@DZ2;VX7H*^Z&[LS6Y]MY#(9<L&6F<MH^CMMM@Z6T7*BVHA9)XZK#AX1
M06/0*!0*"FO9R0M+_4%2KV7N:64W\%!<M`H%`H(KU$ZBX+8^#5D<BOO)+ETP
M,>@@.R'![U-^21>ZE=@H//VRME;KZS[J<W5NMU;6VVG"FR=2`\E!X18H)\EI
M-OA'!S-^WD'J/'X^%CX3$&"PB-$C(#;$=H!*$(2+!*0*#(H%`H%`H%`H%`H%
M`H%`H%`H(:M81T\W$XH7']-$A(X_OB0.0YF@D6@^$_O33R_-]V@Z]QI*H4<"
MP/IT(\1?E*;/Z%!M*!01[?%O5L`&_P"%L9R^[6C02&@4"@4"@4"@4"@4"@4"
M@4"@4"@QY\"'/AO0YC*)$62@MOL.`*0M"N!2H&@\O;\V)N?H_NEK>&T'%*P;
MBRG2K4I+84;F+*YZFE>\6>1\=KA??3?J3@=]X09#&J[J6S9&1QZS\+'=(Y'Y
MY)]ZH<"/E4$NN*#Y<!4A0',@@?*H*+]G39^[MOYG/',X=<"*XVA#4A]M"75N
M!PW0AP>6MO3Q^=O07K04YL9K5[1?4!\\%)A0FT^X4-G]"@N2]`X4'%!YVVX4
M*]K3,E%B`R^"1P\H16+@T'H9XH2TM2_-"23[@%!0WLC_`)/[E`Y#(HL/%W0H
M+?W*UO)R;AE;>D16(:)85FTRDE2EQ;<4LV!LKY79QH,Z=G,;$>]'6X7)>G6(
MK*%O.Z1VZ&PHB_9>@^\/EHF6@(G1=896IQO2ZA3:TK:<4VM*D*L00M!%!SF5
M+3B)Q;%W!'=*!SXZ#;G05E[-,F$[T][ME+8DL/E$U2&%,K4X4)4DN+4I0=5H
M*?+%N%A;A06S0*!0*"G_`&=02C?+HN6W-R3"VKPBXH+@H%`H(EU(ZDX+8N$.
M0R"N^ENW1`QR"`Z^X.P7Y)3[Y79[MA04%L?8^Z>LNZ%[NW:XI&WVUE`*+I2\
ME"OWK%!\UI/OU]I\=[!ZC@0(<"&Q#A,(CQ8Z`VPPV-*$(2+!(`H.^@4"@4"@
M4"@4"@4"@4"@4"@4$)F$#IGN0GE;-^'^,2?!02?0GP*_>MN79\V@^,_^]8_W
M9$_E"*#94"@C^]`#`QX/XUQQ^5+;-!(*!0*!0*!0*!0*!0*!0*!0*!0*!08\
M^!#GPWX<QE$B)(06WV'`%(6A0L4J!H/+6_MD[JZ/;L1NO:*G3@G3;O3Y;;84
MH7B2QVMJ]XL_KA07]TUZE8+?F$$_'$LS&0E.1QSA^%CNJ%['YY)YI4.!%!+K
M4#C0#>@IW8CJ5>T1U"1Q*A$A'B>%@A`\W]&@N*@4`WH/-^SR#[6>?%N.F5<_
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M7+Y5!.>-!S0!0<4%0>S@BV/W@L+"@K<,P`=H";<_=H+@H%!#NIG4_`;!PXFY
M!1>G2+IQ^-;([U]8'C\U"??+/+W:"A]B["W7U@W,=X[Q4I.W@JP2+MAY+9\F
M-&3[UE)\Y?;[M[!ZB@P8<&(S$AL(C18Z`VPPTD(0A">`2E(X`4'?0*!0*!0*
M!0*!0*!0*!0*!0*!00U82KIYGKFR2K,7/^U2*"86'A][X3RH-3N=Q:(L+2;:
MLA"2KW#(10;B@4$?WF%&'C=/(97'E7N>DHH)!?C:@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@T6^-KIW1M+*;?5(5%]8L*9$A("B@\"#I/,7''Q4'B_,;#W_MC-2\
M<[BYZI;1T^DP&I"VGD<TJ0XT+$'P'ERH+0QWLX=2),&/)<W`U'6^TAQ4=QV6
M'&RM(5H7P\Y-['QT'<KV;.IB"DM[CCKL?XQ,20.=_-YT'P?9RZJ^<G<+`4.`
MM+F<A:WO?%08S/LR]4&IK\M.<B(DO"SDA,F4'5IX<%K"`I0X#F:#*5[.O5HI
MT_&-DIX\#,FVX\^`%!B(Z&=5CEE8T[F0)28XE&TZ:4:"LMVY7YB@U^\ND?5K
M:V!>S3V;=G,1U(#K,.5.<="5JTZPFPX)YGQ4$&V;G<_M+>^,W1,:F,-:E^DS
M'V'7.^9<:.OZ8IKO04Z5#R_&*#U!U'P^ZLSM%&*@9F'"?SDAA$9V/'D1UK4M
M0=42M#RE`=V@J4=/(4$-Z<>SQNC:^XEY&;D,5-A+94WZ(['?DH*BI"TK[M:F
MDI4DM@A5S06\_BMRR'HSS[V.<=B++L97HSX*'"A394/A_G5D4'T]%WJXVMLR
ML6IM8*2E<20H$$6L1W_$>&@\U]2NEF^=D8B9GSGFV\1Z79K'8YV7'2V)+ITI
M;:U=VA*=7FWH._9G1WJEN7;>.W)!W5Z*U/;[^.T[*G=X@!1`U%)4+^3>@BV\
M8?5':^Y'\!+S.1GRVT-OE^([-6TM*PDW3?B=/D@^.@D^U>GG7?<>$8S,3-OQ
MH\HKT-2Y\MEZR%%%U(*3:^GAXJ#;'HW[08Y;A!]W*2_H*`.C7M!6_*$`_P!:
M2_H*#C^YOV@]>GU_PM?7ZTEV!\%M-Z#$QG0#K7C`^,?EF(@D.=Z^&,A);"W#
MS6K2V+J/AH,MOHY[0BA=6?T&Y%CE)5^!Y\$'G0:W<W3KKOMW`S<W-SZW(L%O
MO7D,9&6MTI!`.E.D:CQY7H*AR,K)9G)QT9G(.)<E%$963R*GG$LM%5BM1.I>
MA%[FU![UVSCV,=M[&0&'TRF8D1EEN2VE"4.I0V`'$I1Y`"K7\GA0;2@4"@4"
M@4"@4"@4"@4"@4"@4"@4$*?X=-]P:N-CF;VX?PJ103/4/'YM^V@U>Y&TN1H6
MHD:9\-0MX0^F@VU`H(]O0_:N+%KWRV/[2/X0D]E!(:!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0+4``4"@6H%J!:@TB"?CB^-1L,<SY-Q87?<XVM?LH,O<*;X#)#
MPQ7^/^K500G<'3UG>>SMIQ)(9>B04,2),1_O`AY!AJ:TA;1"T*25A0(\%!*<
M+MKT-]J7,?,J8PR(T8>4&6&1PTM)6I:BI0MJ<4HJ5X:#>@6H%`H*C]J$J_NI
MD#L,Z&#[A=H)!T*_X1;8^Y/_`(BJ#?O@_':$=0MZMDC1?C]/8X@>"@WM`H%`
MH%`M0+4$3ZC=-]O;[P9QN6;*'FSK@Y!M(+T=SYY!/8>2DG@104UT^W[N+I7N
M$;#WXI7J0G3C,FO4I#*20$*0L\XZNT<VSXJ#T>VXAQ"5MJ"T+`4A:3<$'B""
M.PT'U0*!0*!0*!0*!0*!0*!0*!0*!00MX_\`VYSY!]]F+$?=4B@FE!IMTH6J
M-`"#:V1A$\;<`^DD4&YH%!'MZ?O;$_UM`^OB@D-`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H-,V@_&Y]5S;U>T.0M]/<//G096?_`.1OR]%?O;]S50?
M&V`!MK$@7L(<<"_`_2DT&RH%`H%!4?M0"_2Q[A>T^&3[G>4$BZ&H2CI)MA*2
M"GT,'AXUJ/9>@WCRO]^8B>PXR01Q[>_9[*#?4"@4"@4"@4"@BO43I[@]\8!>
M*R:2AQ!+D&8@#O&';6U)OS!Y*2>8H*8V#U!W'TJW"-A[_P!7J4D)Q>2XK0RE
M1LE2%GBJ,>T<VSPY4'H]IUMUI#K:DK;<2%(6D@I4DBX((Y@T'U0*!0*!0*!0
M*!0*!0*!0*!0*"$MJ#O3?-J4;!2LQ<FQ_A<CY%!-J#2[J<*(V/L`=62A)X^-
M]-!NJ!01[>I^UL3_`%M`^OB@D-`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H-(TI9WK(0"0VC&L%0[L6)6^[IL[>_#2;I^309>X?P%D;<_17['_5JH.-
MM_DYBKFY]#C\?]4F@V-`H%`H*C]I_ATN=^[X?/\`=*"3=%!;I/M<?]A;X_+H
M-T]?X[0Q<\,=(L+)MQ?9[?._0H-Y0*!0*!0*!0*!017J)T\PF^,`O%Y(%MY!
M+D":@`N1WB+:TCWP/)23P(H*OZ#[@W7@]X9/IAFW$S&,2AU<.1J*BT&U(LA)
M/$M+0Z%)!XIY4%]4"@4"@4"@4"@4"@4"@4"@4"@@\=)/3+,ASAJ.8))\!ER"
M#\J@G%!I-UH*H^.`[,E"/RGDF@W=`H(]O6_HV)_K:!]?%!(:!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0:9I2/CC*38:_5T<E6E5[=^]8:O-^1SH,G<
M/X!R7;]JO\/]6J@^=L_DYBNS[3C\/]4F@V5`H%`H*D]IX#^Z]SM^WX?Z\T$F
MZ+?\*=L?<+?Z-!N7DD[VB+T\!C9`*K>%]GA>@WE`H%`H%`H%`H%`H*`V5?\`
MQ1[G/9Z.^/\`0C4%_P!`H%`H%`H%`H%`H%`H%`H%`H(0RLCIEF%<"0,MSY"T
MJ1PX^"@F]!IMS@%G'@_C&(?E.@T&YH%!'-[@EC#65;^F('#PV>'"@D=`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H-$R6_CQ,`2`YZLBDKNNY'I$BPMY
MG#CRX^'LH,[/B^#R`Y_:KW#_`%:J!@`!@L<`+`1618_N::#/H%`H%!4GM/?\
M,CQL/3XMQX>*C02?HP+=*]LC_L+?Z-!MWE(^.\5/-?JU\WL;@=^T.=[<:#>T
M"@4"@4"@4"@4"@H#914KVHMSDGE'?'^C&H+_`*!0*!0*!0*!0*!0*!0*!0*!
M00ESR>F&7][\'DS<?N[W'C03:@U>>\R!]VQ_UU!M*!01O>Y`9PM^1S$$?]90
M22@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&F94KXY2T]Y=/JZ,>YUW
ML>_?\KN[<+\M5^-O%096?U>H\CI\[T5^WN]VJ@^L(%#"P`HW4(S()\)[L4&;
M0*!0*"I/:?\`^&0'_P!0C?G+H)/T7_X5;8^X6_T:#=.@?'2,>%_5S_AO;OVN
M790;J@4"@4"@4"@4"@4'G[8Y/^*/=/@[A_\`6QJ#T#0*!0*!0*!0*!0*!0*!
M0*!0*"#E6GI?E3:Y*,E\DF2]03B@U.XEE*<<`+ZI\=/.WOB?T*#;4"@CN\PD
MHPNKEZWAGAX0HV_-H)%0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#4,
M!'QNF'O#K]7Q1W.I)`'?2/*TVU"_*]['Y%!V[E5IV]E%_.PY!-_$TJ@[\.;X
MF$?^SM?K!09=!I-\3YF.V?F)T)P,RXT1UQATZ?(6E)(597`V\';RH,3IQE)N
M3VE%F3)9GO+6\/35-AA3J4NJ"5J9YM$I]X>*>5!)J"I/:>_X:)_K&-^<N@E'
M1G_A7MC[A;_1H-TM=]Y,M\>&.<4./#B^V/-[>7.@W-`H%!\/O-,,N/O*"&FD
ME;BSR2E(N2?<%!\0YT*;'3)AOMR8ZQ=#S*TK001?@I)(H.Z@4"@4"@H'8I__
M`"?W7;@.X?[.?",*"_J!0*!0*!0*!0*!0*!0*!0*!009PD=+<H1V(R!X_=+U
M!.:#3;E('JH>'(QQ^N-!N:!01_>`!3A;FW]*Q.8OVJH)!0*!0*!0*!0*!0*!
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M5MZ2`EM335D(TI`%@!P[*"Q*!0*!0*"@]AA)]IW=I/G".]I\/\&H+\H%`H%`
MH%`H%`H%`H%`H%`H%!!]13TRR!"M!^WAJ`N>,MT<J"<4&DW1YV'_`*SC_G+H
M-W0*"/[O(!P?A.6C!/REW_,O02"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4&DC=T=Z9#R1WHQT/RK"^DORN&KMXCE09.Y_R;RWW'(^M*H/K'1(LC%X
MU3[+;JF6FELE:0HH7W8&I-QP/C%!L*"/]0N_^)&<#"=;RH;J6T=V7;J4FP&@
M`WO>@U71EM#73?$1T!`3'#S/P7%%VGW$*TJ!4%^4#Y0L#V`<@$UH*=]I2%#A
M],M$2.W'0O)QUN):0E`*E!=U$)`N303+H\DIZ7;7!_%[/ZV@V:ECX\(1QOZL
M4KD+6](2.?.@WM`H%!J=WJ>3M3,J80''A!D%ILI4H*4&E63I191N?!QH(;T!
M_P"'Z3W+<:\MZ\5M97W:QI#H5J*EI*G0I02HW2"!0610*!0*!04#T\*5^TUO
M!0`24L2.`!%[+C)_Y;T%_4"@4"@4"@4"@4"@4"@4"@4"@@;ZA_=9D57L/MTZ
MAV?;CG&@GE!I]QM!9Q7`G1D&5<.RP50;B@4$>W@1WF`\>6CV_4.4$AH%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!J8P1\;,@JR=?H,,:K*U6[V3[[S;
M>(<?#V4'UNFWQ9R]^7H4B_N=TJ@R</\`@F%]SM?K!09=!J=W13*VQE(P<;:[
MV,X@N/@EL`I-]>D$VMX`?<-!J.E,!..V)CH"/I454AIHZBY=`D.:2%E#6OA[
M[0F_@H);05#[4)4.FB+<0<C'U>YI<H)?T@T_W7;6T\O5L;Y?=B]!L5%7Q[1P
M\CU6JYMV^D)MY7Z%!OJ!0*#JEQ6)<5V*^G6P^A3;J02FZ5"Q%TD$</!0:S:N
MT\-M?%G%XA"VX7>N/);<6IPI4Z;J`4JZK7\)-!N*!0*!0*"@^FW'VE=Z\A:/
M(X#QO1Z"_*!0*!0*!0*!0*!0*!0*!0*!0015E=+9][*!,R_@/VXY03N@T>Z5
MK2K#:21JR;`5;M&E?"@WE`H([O$#O,!XLO'^MN4$BH%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%!IHFKXWY/5IL(,+0`5:K=[*O<'R>?*WR>R@[=U_DQ
ME_N*3]:5096*!&+A@\^X;O\`J!095`H%`H*@]J(__;9OC_XC'_6.=E!,ND:2
MGI?M4'GZLBW^2T*#-4C_`'_2O3_X4I.NQ_C(-K^;02"@4"@4"@4"@4"@4%`=
M,4V]I3>Y\+4KA_KX]!?]`H%`H%`H%`H%`H%`H%`H%`H(*J_]U\ZY`.J9<CE^
M_'*"=4&DW-Y^&_K)GLO[QR@W=`H([O&_>[?_`*WCW^INT$BH%`H%`H%`H%`H
M%`H%`H%!K\[N##8'%O93,S&X./CV[V0Z;)%S8`6XDD\@.-!DP)\+(0V)L)Y$
MF))0'6'VSJ0M"A<*!%!WT"@4"@4"@4"@4"@T\4GXVY$$\H,*PU7_`&65QT6X
M>[V_(H.S=0)VSE@.V%(^M*H,O&`C&Q`>89;_`%HH,F@4"@4%0>U%_P`-V?ZR
MC_K'#03/I-_PQVM_5D7ZTF@S23\?1Q'#%'A=5^,D=GF_HT&_H%`H%`H%`H%`
MH%!0'3*Q]I3>I`L>YE`CG^SQZ"_Z!0*!0*!0*!0*!0*!0*!0<`&@YH(,.Z1T
MNE%'F6DJMQ[92R?'S-!.:#3;DU=YA[?C%J_N:'*#<T"@C>\S\-MWA?\`IB/Q
M\'P3M!)*!0*!0*!0*!0*!0*!0*#HG2VX<-^6X%*;CMK=<2A)4LI0DJ(2D<2>
M'`4'FEAC>/7K<_I;FO$[&QKA]')%^(X>1?R7)*O?'S6QPY\P^]N;IW1T4W7\
M6=S%<O:<M:G(LE`)0A!5Q?CCB>!/PS79S'C#TG!G0YT-F9#?1)BR$!QA]I04
MA:%"X4DCA:@[Z!0*!0*!0*!0*#3PW7%;MRC9)T(A0BD:D$74Y)N=(\L<NW@>
MSMH.S=0OMG+CPPI/UI5!F8X`8^*!R#2`/U(H,B@4"@4%.>U01_=U$![<FQ]:
M=H)MTD_X7[5_JN+]:30;,J'QR"=9"O5U^[U<"._''3;\V]!NJ!0*!0*!0*!0
M*!0>?NERK^TGO<<+=W+X6MRD1Q>@]`T"@4"@4"@4"@4"@4"@4"@4"@@[(;3T
MN>X`)T/FP'ADJ/+QT$XH-/N*Y=PX`)_I!KD+\FW#0;B@4$;WE^^-M_UPSXOV
M!Z@DE`H%`H%`H%`H%`H%`H%`(O0=4:+&C-!J,RAAH$J#;:0A-U'4HV38<2;F
M@TV]-E8+=^#=Q&79UM+\IEY/!UET>:ZTKL4/S>1X4%![9W-NCHGN=6VMSA<K
M:LM97&D-@J0A)5;OXX^NL]G,>,/24"?#R$)B;"?1)B24!QA]LA2%H4+A22*#
M(H%`H%`H%`H%!IH2$_&W*.!M228<))=*4Z%:7))L%#RB4ZN(/*X\-!V;K4E.
MU\NI7FB%(U6X\.Z50;"(E*8C*4BR0VD`>``"@[:!0*!04U[5)']WL$$>=E&0
M/J+U!.>DO_#':W]61?K2:#-*O]_`FY_!=[<+?OD4&_H%`H%`H%`H%`H%!Y\Z
M6\/:5WN/^BF?RB.:#T'0*!0*!0*!0*!0*!0*!0*!0*""2`\.E+P9\I?=KMP[
M#)-^!O[V@G=!I]P@F1AD@@7R"+W\3+JN'RJ#<4"@CN[@HR=N6%_Z7:)]P1WZ
M"14"@4"@4"@4"@4"@4&'E\SB</"5.RLQF##0I*52'UAM`4LA*1=7:2:#,!!`
M(-P>((H%`H%!H-Z[)P.\,([B<PSWC:CK8?3P=8=M9+K2NQ0O[AY&@H7;.Y=T
M=$]T?%G<H7+VE*47(TI*24I2H\7XX^3\,UV<QXP])0)\.?#8FPWT2(LE`<8?
M;(4A:%"X*2*#OH%!BY+(""P'C'?DC4$]W&;+J^/;I'8.V@UWQK9_%F2^\W?F
M4''QL9_%F3^\W?F4#XV,\/Z,R?$V_>;O;\B@P,SU)P>%CHD9.+D8S+B^[0LP
M9"[JL56\A*CR2:"'0^O'35&>GS?299;D,1&T."!*XZ%.\/I?;K\GP]E!\[B]
MH+IK+P.3AQI<Q4EZ+(;;3Z#*'E%!1Q);``"B`2>5!8^UMQ8C/8EN9BI'I,9'
MP*G"A;9UH`U`I<2A7YE!MZ!0*!04Q[59MT]@'P95D_\`4/4$[Z3"W3':P_\`
MID7ZTF@V02OXYJ5;R!CD@&PY]^KM\Z@W5`H%`H%`H%`H%`H//O2L!7M([Z6+
M>2W*3;Q^DL7H/05`H%`H%`H%`H%`H%`H%`H%`H(.DWZ7$J4;%!\H"QL9!\%Z
M"<4&GW";2\&/#D0/^[/F@W%`H(_NPD2MN\+_`-*MCD3_``=_P4$@H%`H%`H%
M`H%`H%!AYG+1,/BI>4F%0B065R'RA)6K0VG4K2E/$FPH/-L49_KUO1?ICBL;
MLK#%*U1$+'>:7+Z04^^>=`XKM9">`X\P],0H<>%$8B1DZ(\=M#+*+DV0VD)2
M+GCR%!W4"@4"@T&]=DX'>&$<Q.89*VB>\8>0;.LN@62XVKL(O[AY&@H7;6Y]
MS]%-U*VUN=+DO:DQ9<B26P2A"5*XR&!Q(Y_"L]G,>,+@PW6SIGF,I&Q>/S2'
M)LM11';4R^V%*`*K:W$)2#8=IH)D,A`(N)+5OTZ?FT#T^#_&&OU:?FT#TZ#_
M`!AK]6GYM`]/A?QAK]6GYM`].@_QAK]6GYM!@YO-8B+C)"Y$^.PE3;B4*<=0
M@%6@FPU$7-!5K^X\3ZETXW,0F)_HNW/1G'7FRA*D/F^L7O9'OAV>*@QLGN2\
M'(H]>8<WP^9!*%*OY<HW"1WOG*/F_HT$KVBK<Z][Y#*S,S&F;5>ALM0VV)*5
M,HDI0UK*&M2M.HA?,_GT&TRG5_IMBI\G'Y#/1V)D-9;DLV<44+'$I)2E0N+T
M$J@3X>0A,383R7XDEM+K#R#=*T+&I*A[HH.^@4%,>U6XE/3Z`=0_"K(''_H'
MJ"=]*+)Z9;62#P&+B\^!^E)H-B%I^.2QJ3^#D&W;]/5V^"@W6I/A%!SJ3X10
M-2?"*#"S&9QF&QSV3R<EN)`C`%^2Z;(0"H)%SXU$"@U&"ZC[&SV0&.PV;BSI
MQ0IP1VEW64)MJ(!M>UZ"24"@4"@4'G_I04'VCM^V(U)3)X>[(9^90>@*!0*#
M29K>FTL)+$3+YB)!DJ0'$L2'D(7H)("M)-[$B@V.,RF-RL%N=C934R$]<M2&
M%AQM5C8V4DD<"+4&50*!0*!0*!0*!0*!009I13TO1;B2D`<`?.E6Y'W:"<T&
MHSR`J5A23;1/"@/#]KO#]&@V]`H-#NA5IFWA>U\HD#[UD&@WU`H%`H%`H%`H
M%`H.%H2M)2H7218I/$$'F#0>=^I'3_/].,\>H6P;H@)).5QB05(;0I5UW0/.
MCJ[1^QGB.'(+=Z;=1L-OO`)R<`]U):LWD("B"XP[;D?"E7-"NT4$LH%`H%!P
MM:4)*E*"4I%R2;``<R:#R5USWXWOO>./Q6W$/3HD`KC1$-76F7*<592V&QS"
M0G2%=HN>5!GX?V8]]S(L21.EP<>74AQV,YWCKS5P?)4$)T%0X7LN@W"O94S?
M!*=PQ2BQN?17$F_9P#AYT'PKV5MQ7LC/PRD<B6'0?E:C0?/^%;<OX^A?47?H
MJ`/97W.%7]>P+_N#WT5!R?97W*3?U[!^HO#_`)U!\+]E'<2TZ59R"H>-AT_G
MJH/C_";N$?\`CD`^['=^BH.?\)VX@1;.0+#C^]W?FT'VCV4MPIN/7D&Q-R`P
MZ/%V*H'^%3<ERKU[!NK_`*!WM_SJ"6]'>F65V+OG(QYTYJ:B3C&ULEC6A*?A
M])!0KA[W@:"SYF;4QN3'XM*;MR4/*?<M<(4`"TDJ["O2NP[;4&X/%/&@\KPO
M9PWAGXJ<NSE("8\Y;DAEN09"G`EQ:B-5DJ3?W*#)3[+&^T@!.8QH`Y#5*^@H
M/I/LL[Y"M9S&-UD:2=4KE>_SE!]CV7=\_C?&_JI7T-`_PN[Y_&^-_52OH:!_
MA=WT1^&,=^JE?04'TY[,W4%QE;"\W!4PHA1079:DE5[W*"BUP:#J;]F#?[+O
M>,Y7')6A)+;B')"%7(M8%+8(O09"?9PZG:-2L_%2NQ\@2)G9R\K3VT'Q_AUZ
MI]F:B_?<OZ"@?X=NJ7XYB_?<OZ"@X/L[=5K<,U%'^UR_H*`/9UZJW_#44_[7
M+^@H,=KV9NH[4E4EO)0$/KU:W42)"5JU$$ZE!NYY=M!D#V=>J=S_`$U%X_\`
M;)?T%`_P[=5+_AJ+;[KE_04')]G;JF1;US%^^Y?T%!6_4?9&Y=EY=J/G[/+E
MM=Y&GH<6ZVX&^"T)4Y95V[BX([:#TU[/6/FP>E.*;F,+C./+D2&VW!I46GWU
MN-JMX%(4"*"QZ!0*!0*!0*!0*!0*""!2T]+FBCSKM6[.<Q-!.Z#3;A<4F9@@
M"0%Y$)4!VCT5\V/RJ#<T"@T&Z%$9#;8')64`/WG)/Z%!OZ!0*!0*!0*!0*!0
M*#Y<;0XA3;B0MM8*5H4+@@\""#S!H/.74+8.X>E^?._-@73B"?Z2QH!4VR@G
MRDK0.*HZOEMGB.'(+CZ<=1L)OK!)R.//=26@$9"`H@N1W2/--O.2JUT*'`B@
MEE`H.%K2A)4H@)'$D\``.V@\S=7^L<[=<_XH;0[QW'/N>C..QKE[(/7T]TS;
MB&1;RE>^_2\PL?HQT9B;+B#*90(D;HE(TNN)`+<5L\>X8X?JU]ON4%I@6%J!
M0*!0*!0*!0*!0*#2SL+.<S8R<.:F,I4;T1U*F>].D.%P*0=20#Q[0:#Z?VZT
M<<ZPP\I,Y:TOIGN`+<](1;0XKD+"UM(L-/`4'PQN)++(:S3?JV9Q2HKN8ZR!
MY[;WFZ3X%$$=M!\[$-]GXC@4_:R."N!H-[0*!0*!0*!0*!0*!0*!0*!0*#S?
M[7:OMC;*/^BG&WU&@O'I_P#D)MW^K8GUA-!OZ!0*!0*!0*!0*!0*""74.ES)
M3Q5=JPO:_P!N)H)W0:7</[]P']8__*2*#=4"@CVZC_26V/'E?_DI-!(:!0*!
M0*!0*!0*!0*!0?+C:'$%"P%(4"%)(!!!%B"#0><^H>P]P]+]Q*W_`+!&G#W_
M`*4QB02VR@FZTK0.<=9^IGB.%!<_3WJ#@][X)&3QJN[>19$Z"L@NQW2+Z56Y
M@\TJY*%!)7'$-MJ<6H)0@%2E*(``'$DD^"@\Q=8>L62W?D/B?LL.O8Y]PL..
M1[][D'.7=M6XAD=I]]^EYA9G1CHQ#V5#3D\F&Y.Z)*"'GD^4W%;5^P,7_P!-
M?-7N4%I@6%`H%`H%`H%`H%`H%`H%`H!`(L1<'L-``L+4"@4"@4"@4"@4"@4"
M@4"@4"@4'F[VO!>5MD`<F9QO[O<B@O+I]^0FW?ZMB?6$T&_H%`H%`H%`H%`H
M%`H(*C_A>Q?AY35_OU-!.J#49V_IN#M_'^/N>BR*#;T"@CVZ_P`)[7_K7_Y*
M502&@4"@4"@4"@4"@4"@4"@^7&T.MJ;<2%MK!2M"@""#P((/,&@\Y[_V+G^E
M6?._=B!1PFK^D\8-2FV6U&ZDK0.*HY[".+9\5!HNH_6S.;_3"VMMG'28[&0"
M$28:2#)E/J%U,`HN`PCWRO?#G8<*"W>C?1R'LF$,AD2B5NB4WIDR$\6XZ#Q[
MB/?D/GE>^/BH+.H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H/-OM<D>F[;3V]Q-O\MJU!>?3\$;%V\#S&-B?6$T&_H%`H%`H%`H%`H%`H
M(-';T]+XJ"2;=Q8\[_;:2*"<T&IS8!FX2Y_AQM]Z/^*@VU`H(]NFQRFV!_\`
M521\B#*-!(:!0*!0*!0*!0*!0*!0*#KD28\=LN/N(:;2"5+6H)2`D$DW-N0%
MZ#R_UAZMY'?&2;V?LY+K^*?>[DJC_3,D[PLE'#@PD\3?@KF>%!;/1OH]!V1C
MA-G:)6YY:!Z9*'E)9'[2P2+A(OY2O?'Q6H++H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%!YL]KDI$[;][W$680`/\IJ@OO9@"=GX(#L
MQ\7GS^D(H-Q0*!0*!0*!0*!0*!00IA:O[M(JEITFS`MQY>E)`\/.@FM!JLR3
MZQP8\,U=_O.10;6@4$?W.DG*[8L+VR:B?$!!E<:"04"@4"@4"@4"@4"@4"@4
M'CCKSNO-9?J!DH<R050<,\N+`@I\EM(TC4HB_E..7XD]G"@OCHMTD@;.Q3>2
MFH2_N:<T%27_`#DQT*XAAGP"UM9]\?%:@L^@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@\U^UV5"9@=)L?19?ZYN@OS9OY(8/P^KXO
MUA%!N*!0*!0*!0*!0*!0*""O*4CI=#*O.(A\A\]*;'+Y-!.J#49H_P!*8#C_
M``USAX?M*10;>@4&AW(C5EML_P"3DEJ^5!E4&^H%`H%`H%`H%`H%`H%`H/'O
M7G`8^%UC7':[PMY8PY<M*E7^$D.EMS0;`I%D"@]@-MH;0E"!9*`$I]P"U!]4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'FOVNC:=M
M_A_!9GZYN@OS9OY(8/\`J^+]810;B@4"@4"@4"@4"@4"@A24%SIE`3>Y4W"X
MD7_9VZ":T&FSAME]O#PSG?Y#)H-S0*#1[@4GUSMI)/$SW2/!P@2:#>4"@4"@
M4"@4"@4"@4"@4'E#VA[?WU0#X&,;_*5T'J^@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4'FOVNK^FX'[EE_KFZ"_-F_DC@_ZOB_6$
M4&XH%`H%`H%`H%`H%`H(0P/_`+8XL)L-2<?SO;C):H)O0:7.@^N-N^*<[?[Q
MDT&ZH%!HMP+MG-LIX>5.>X=O"!)Y4&]H%`H%`H%`H%`H%`H%`H/)_M$)U=:8
M(%[]SC+6\/I*Z#UA0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*#S7[77[^P`\,67^N;H+]V=^2.$_J^+]810;>@4"@4"@4"@4"@4"
M@@[:4'I?B@H'3IQQ(2=)_?3)YB@G%!I\W^%]O_=KO\BD4&XH%!H-PC^G]KG_
M`+<__()-!OZ!0*!0*!0*!0*!0*!0*"H.HO0_);LZ@0MS,Y*/'B,)B)?BNMK4
MLB*\IQ6DI('E!5J"WZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!04YU\Z6;KWM+Q+N"1'6B&Q(:>[]WNB%.E!1;R57\TT%J8""_`P
M6.@OE)>B166'2CBG4VVE"M-^RXH,^@4"@4"@4"@4"@4"@A+'_#/#\+_@SLO_
M``MGC;Q4$VH-1F21EL#87O+=!^\WZ#;T"@CVXR?C#M4<;&=(]S\'R:"0T"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$&;*O[L<,4CRKXNP/W6Q03F@U&8)]<
MX$<+>DO&UK_P1[Y5!MZ!0:?<&%G3Y&,EP93<67C'UOM]\TIYM8<8<8*5)2MH
M\G;@ZJ#I$7?5N.2QE['^`O\`/L_A=!]*B[WTC3DL;J[;P7[?F2Z#X7%WY<:,
MEBR+<=4&1S\5I?*@X$?J!PO.Q)\/VG)_G-!SW&_KC[=Q5NT>BR;V]WTB@^NY
MWU?]]8NW@]&D?9Z#GNM\_P`:QGWO(^ST#NM\_P`:QGWO(^ST#NM\_P`:QGWO
M(^ST'!:WSV2L9][R/LU!SW6^?XUC/O>1]GH'=;Y_C6,^]Y'V>@X[K?5OWSB[
M\+_:\CY/[-0<]UOG^-8S[WD?9Z!W6^?XUC/O>1]GH'=;Y_C6,^]Y'V>@^2UO
MOLDXOY+$C[-0?(;Z@=LC$\C^PR>?9^RT''=]0OV_$_49/V6@^5(ZBZ1I>Q!5
M?B"U)`M;P]X>V@X2GJ.//7AS[B)0_P"<:#M3\?@$ZO51(\XCTD7]P<;4"^_;
M<L43Q[9`]SL-!S??FGS<7JMRU2+7]W30?&KJ#8_!8F_8.\D_04'!7U#X69Q'
MC/>R?L=!\J<ZCZCICX?3V$ORK_6J#D+ZBZA=G#A-N)[V43?W.[H.=?4.X^!Q
M%NT][)^QT'"G.HNDZ8^("K\+OR;6X_\`0T'V7>H'"T7$^.\B3R^H4'9WV^+_
M`+SQEONJ1_-Z!WV]_P")XS[ZD?S>@=]O?^)XS[ZD?S>@=]O?^)XS[ZD?S>@%
M_?%N$+&$]@]*D#_Y>@X[_?6D?:.+U=H]+D6^7Z-0?/I&_?Q?BOOV1_-:!Z3O
MW\7XK[]D?S6@^?2]_P#'^C,7P[?3I''_`+IPH.Q$S?'#O,5CN7'3/>Y]O.)0
M<^F;UU?@K'Z.S[?>OR^Y*#Z],WC^*H/W^[_-*#A4W>022,1!4>P>GNC_`.4H
M/GT_>NC5ZF@ZOG/6#GY_HE!]B;O&W'$P1XO3W?YI0=?K#>UR/4L&P!L?6+G'
M_NE!PG([W-[X."+6M_2*^/\`W2@^5Y/?(\W`PE<>S)+'R>,2@X]:;YX_[OP_
M%_22OYK0?7K3>UA_0$6_&_\`2)^1_!J`,IO:XO@(MK>5_2)O?Q?:U!]#)[QX
MWP4<<>%I]^'U`4'/K/=WXC8^_A]AH'K/=WXC8^_A]AH'K/=WXC8^_A]AH/DY
M;>(7I&WV2/GO3TV^M7H/GUQO+^SK7W^C[%0?/KO>>D'XM(N?>B>U<>[Y%J#D
M9O=^DWVU978!-9(^7:@[!FMTV%]NJOVCTMBU!SZYW/\`V>7]]Q_FT#USN?\`
ML\O[[C_-H-<_`D8_86,@RP!(C+QC;R4JU`+3+8!`5;CQH)=0:;,*MG<`FUP7
MWS?P6BN4&YH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!I-X_@0?=D#^
M6LT&[H-+F2?7V`'87Y%_O5R@W5`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!BJ<R7K5MM
M+3?JSN%J=?*CWO?ZTA"$IY:=&HD^Y095`H%`H%`H%`H-+O#\"CA?[<@</]M9
MH-U0:/-$_&+;H["])O\`>KE!O*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0:/>3A1A4$`F\W'I-C;@9S(H-Y0:/-6^,6W?W:3_)5T&\H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%!IMV@'#I!Y>F0.T#^&L^&@W-!@9;"Q\D8Z
MUNO1WHJE+8?CKT+25I*%=A'%*O!0=;>$<0C1ZSFJ%B+J<03Q\>B@RTQ"&TH+
M[JBD`:RH:C;M-@.-!SZ&+6+SI_SS^A0/0T_MKOZLT'/HH_;7/U9H.#$!_9G1
M_GT''H?/X=WB+>=_R4!,0IO\.Z?=5?\`0H.3$)-^_='9P(^90<"(H?PAW]4/
MF4'UZ,K]O<^6GYE!\^B*_C#ORQ\R@^A'4!;OG/ECYE!P8JC^SNCW"/F4''H9
M_C#WZH?,H'H9X?;#W#_*'S*#D1%`6](=^6/F4#T57[>[\M/S*!Z*K]O=^6GY
ME`$50_9W?EI^90<^C*_;W/EI^90/1E6^GN>[=/S*#CT97\8=^6GZ&@X,19_A
M+H]PH^AH.4Q7!_"73[NCZ"@^NX<M]/<_T/H:#@L.?QAP?(1]#0?7<N?MR_E(
M^AH`9<%_AEF_B1]#0?!C/E5Q*<`\%F_H*#Z2PZ$D&0M1/:0BX^4F@=RYP^'7
M_H?0T`LN']G6/<"/H:#GNG/VY?RD?0T'P([^J_I3A'SNENWZV@Y++Q%A(6#X
M;(^AH./1W_XTY^I;^AH'H[_\:<_4M_0T'/</_P`87^I1]#0.X?\`XPO]2CZ&
M@=P__&%_J4?0T`,/]LA9_P`U'T-!SW+U[]^JW@LCYE!\K8DD^3)4D>#2@_GB
M@X5'E$FTI2?`-"#^A0`Q*'\))_S$_,H.>XE7_?)/^8F@=S)_C'^@F@=S)_C'
M^@F@=S)_C'^@F@Y[J1P^']WR10<%F5V2/]!-!P&9?;)_T!0.XF?QG_0'S:#C
MN)O\9'U,?-H'<3>'VT/'\&/FT'TEF6%75("D^#0!^C0?6B1;Z:+VYZ>WY=!Q
MW<JUN^%_#H_Y:#@-3+<7TG_5_P#O4#NYG8^GZG_[U!QW4ZWT]%_W,_14#NI]
M_P!\-V_<C]'0.ZGV_?#=_#W1^CH.4MS0>+R#_JR.'ZN@Y*)=N#J`?W,G_G4&
DMR6(RF02AE^:P(B9#$@H3'5K(CO)>2G67B.);`)TT&XH/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>g5754312new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754312new.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!0`*>`P$1``(1`0,1`?_$`0```0`!!`,!`0``````
M```````(`04&!P($"0,*`0$``04!`0```````````````0(#!08'!`@0```&
M`0$#!`H,!PP$"`@)#0$"`P0%!@<`$1(((1,4E#%1T=*3TU05519!D2)3U%:6
MUA=7"1EA<5*2E;75H3)RLB,S-78WEQA8@20EF+%"HD-SLW0FP6)C-&2DM'7P
MPT1%984V)T=(\8+"@X3$QF=W*#B($0`!`P(#`P<&"@8'!@4#!0$!``(#$002
M!08A,0=!46$B$U48D3*3%%24<8&AT9+24],7".%"4J(C%;%B<C-#91;PP:,D
M-%:"XF-S9$0E1?&RPG0U)__:``P#`0`"$0,1`#\`_?J<Y4RB8P@`!VQV:(K$
MZLL2S,8J[M$A@]@5``?P\H[0T16X;O`!R=.2\*3O=$3UW@/+DO"I][HB>N\!
MY<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/
MO=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW
M@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"
MI][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>
MN\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<E
MX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$
M3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+
MDO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][
MHB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!
MY<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/
MO=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW
M@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"
MI][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>
MN\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<E
MX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$
M3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+
MDO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][HB>N\!Y<EX5/O=$3UW@/+DO"I][
MHB>N\!Y<EX5/O=$50N\`([.G)>%)WNB*Y,[#'OAW6[E%01[``?:/^D0Y-$5\
MWR;F_O!N=G>]CM?\.B+6N09UQ&M6[9H<`=R+INP;%..P`6>K%;I&$0']Z!C[
M1_`&B+BUQ363(D&:(ZG7I@VN'+MZ[23%00]WT=LU70213`W[T!WA`.R(Z(OK
M]$6._BXEU^4^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^'
M:(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y
M7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)
M=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._
MBXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0
MX[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB
M?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?A
MVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^
M5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B
M77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#CO
MXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$
M.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(
MGT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X
M=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?
ME?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BX
MEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[
M^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1
M#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB
M)]$.._BXEU^5^':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^
M':(GT0X[^+B77Y7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT0X[^+B77
MY7X=HB?1#COXN)=?E?AVB)]$.._BXEU^5^':(GT18[#E"N)`/_;Y7X=HBZLA
MC"';-S+U<SF"DFY15;<V\=KL5C)AO%1=MW*RON%-FP3$$I@[/+R@)%;F]O74
MH+^7VASZ#9$`Y?<@L=T@WW=NWLBH?=T16?*9C!*54NWD&SP/ZT;#_P"'1%OS
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6K<WY2A\)8?R=EV>%$8G&]%L]R
M=(KK@V3>#`1+I^VC@6$!YM63=I)MR#^6J&B+R;D_M0,D5ZM\/,M/XPQZ5Q>\
M5<6ZV</,]JE9&*QMGGANEXJB0M/@GZ`*)RM*NN4'!HHSI<Q'1"/F"A-HJF#1
M%G=EXU>)FI.,LV)_7<#2%!QUP_8%SLPAF;+(S2YR"6>YVR5Z*K;V6<6!Q!D/
M5W5755<.4VP@[3<)D(FB8AQ$BP9_]I]?X7(&>JH-1Q=;C4.8S_5*=6XA:_5B
MQ0-BQ=Q"4;A^Q\KD:>L+9S6;+"Y!EKZV?O35HAW$*W;G!1)3?`2$6SG/%KQ:
MFRL3AKBZOP\+9MKUOR5&6:RO@R2AC2SURKX8QEF&GKUF,1F'%EJTQ/HY(&+?
M@\=2B3%6..X3!<BQ$B$5]P_QZW;+^1,-XQB<3LXBS9JK^.<^P(O7TN\B(3A3
MGL=-IB_6Z7E6J!&RU]I&8"FI16A!(W=.)*.?[A4%E"%(O4G1$T1-$31$T1-$
M31$T1-$31$T14W@'L"'9W>R'9[7X]$3:';#V]$0!`>P(#[')RZ(JZ(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(N"G\VI_`-_%'1%%!@?_[H
MIP=G8!K[/_T^Q_!HBS7*G]+57^L\#^LFFB+?NB+464L_82PBK74<P95HF,U+
M:I(IUL+M9(RNEE_,X,AEUFBDDX;IF:1(23<72QA!%N"Z8J&*!R[2*WQ/$GP_
M3N1)C$D1F;&S_)L!YR"8HS>WPIK(Q-"QS68FDU(P78.#K0T2]1=.R$`QVK90
MJBH%((&T16%CQ=\,$I1;'DR-SSB^0H=2F&-?L5G8VV*=QL;-RW,C"1:AD%U%
M5WM@(Y3/&D2(<9%-0IVW.D,!A(NRZXK^&9C-4>O/,]8H;3.2H6!L5!8K7B`3
M/;8*U2"\36)6$4,]!!ZRL<LU5:,#E-L>.DS(I;ZA1+HBR*T<0>"Z2VR6]M^7
ML=5EIAD]63RTYG+?"1J.-CWA-FK3B791V\2+6S6A.10,PZ6*72@6(*>]O!HB
MRAEDS'DE?9?%D?=JN]R37ZQ#76<HK6:8.+7$5&Q/7\;`V22@TES2#.%F7\6X
M1;.%"%2640.4@B)1T1:ULG%=PV5"XPN/K-F[',+=[)(.(JOU=[96"<S-R;26
M<P3UA%,@4,J_>,)EFJV<)I`8S=5(Q5`*)1V$4@-\F\)=ON@W=H=K>'87;VMX
M>QV]$7`ZZ*9%%%%")D1*8ZQU!W")$*43F.J8VPJ9"D#:(CL``Y=$5B@K?5+0
MH[1K=D@Y]1@UAWSPL-*,I+F&-BCDY>`?'%FLL7H,W%JE<-%@$4W"([R9C!M'
M1%D6B)HB:(M+95XC,$X->UV.S!E:DXX?6U51"KM;;-M8A:P.4E")':Q!')BB
M_=@H<`!)/>4-R["CL'81:$RYEG@IXD,6Y(HMVSACZ;QI3Y>I2N6D(VX0X1*2
M52R/$.FE3MJZR3QF\AK#<ZZG#2$7L,I(@=5@)=Y42"11ZGN$'[.;)5$RZ,7?
MH6'QGEW'%FDY=MCO(U:K=/I%2XCK'B]J%XQZC$,B,*0O8,A\.T>XBG9-J19Y
MO(;"&556(4BV[+8ZX*;Q$9(C5LQ03B-M-`BN'BZK,LHUU$D3$\&LQ/6"PQ)W
M([486RXY>6)R:S'5$#-41)SY$0+M$BUA5>'7@>SJO-3D#Q!V#*D/EFS<0*-!
MKK3*-97BZ%D#)\]&Y@R\]Q4RB:_&V!C<HJ18-)EN$HO*'BVFXJDF5NL(J$7T
M6P#PMRN6'=#7XQ\B)\4T%)9$R!?;'$9,QA!Y:GF]UQS1J9:F-AC&M")682,@
M,9U&#!!K$1L8[B&A$WV\0S@[A4BWMB*8X,%I3'^3L0Y8I#V/Q_CT>%*DIPM[
MCG=;:P9$8C(+2LIMUU3NGT^I`X[(_:N3*F,ZBVZS@@JI"*NB+/2\;G"*>FER
M&7B+Q,-&/,-H!*U^M\8$&O*NHL\XFV;R`J@@Y(2#2.^553$R*#(AG"ARHE,<
M"*3C-XTD&C5^P=-WS%\W0>,GK-=)RT>-'*15FSIJY1,=%PW<(G*<AR&$IRB`
M@(@.B+L:(FB)HB:(FB)HB:(FB)HB\-\LY3RRPR/E&_1&9+^QO,%QH3G#C!8=
MC[*L2DI88/PP#<D5T\<`0[-:T`_55N"5C%(9`BJ!4"K=#(9N)%K"_<0^:;5"
M8&AZIDC(5P4NV`?LLY"RPN.,EQM&LUDM69\F9A8Y(.UOB3R,2K%AR!"U]F5V
MX%VU,LW:@!!+MY2+U3X$;'>;-PYP[G)$W/S-QB,AYLJ<FA;I9A8[E5V].S'>
M:S$42X6V*21C+K9J+"Q;>*=S3<O-2RC3I0"?G1.8BF)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+09>*?AN-8K]4OIRQ<2S8L
M86:5R)!JW.$1DJ?&TMN1U<7LXV6=D49MJFW5(>3,/(P*<O/[F\&TB[E/XEN'
M^_QTG+4[,./[!&PM:EKE+O&-DCQ2C:C!*\Q-6=X*JJ0H0$4L(%<.S`""1A`#
M&#:&B*UP'%CPT6J2FHBN9SQE-2%=<QC*<0CK9%N`BWLS88:I13%VN1<6Z3V0
ML]A8QZ2._P`X=X[22`N^<`$BRRYYWPQCJY4_'E[RA2*E>;\L@A3JK/6&.CIN
M?4=OR1+`&3%PN1;<DIA0K)J8X$*Z>F!NB)UA`FB+`U.,CA001O3AQQ%X;:H8
MR=%99`5=Y`KC0E1<&M:=$$LV9R_2!FF2[+$B#G-_)DDCE;&$%A`FB*_WKB=X
M=\92MC@L@9JQM49VH-J6[M$)-VV(9S$"VR,^E(V@K2D6=STYH6Y/X-XE&[R8
M"\.U5!+>W#;"+LQ_$E@&5._1CLQXZ=.(J-QS,2;1.UQ'3HZ+R^NNUQ8^?L3.
M2NV;?(3ILHE#F4(7S@H0Q4=\P"&B+XXTXF>'W,GK5]%F8:!>RT9)1:YJ5VQ,
M7R-6(ASO2//ZQ%`1BC-00.*I5C$,D!1$X%#1%@B_'1P=M:RWN;CB3Q`C5G-A
M/4T9U2YQ)8\UE!LP>HP@JBM_)R#]C*M5VB9@`7B#I%1#G"*D,8BVHAGG"CEC
M=Y)+*U`%AC.O5^VY%='M,.BE1:S:X`]JK,[;A6=)C78R>K:9GS15WS15VQ1.
M41*&W1%@CCC&X66D!3K.YSWC)&#R"^G8NF/3VA@`V*3JR\>ULT;'M=_III"O
M.99JF^0,F55H=RD"I2BH7:122*8IR@8H@8I@`0$.4!`0VA^YHBY:(FB)HB:(
MFB)HB:(FB)HB:(N"G\VI_`-_%'1%$V/_`+(9W\33]?L=$6<94_I:J_UG@?UD
MTT1;]T1>?/%CPWWCB!SEA-.(MELQ_C=MA7BAQ[E2W4]A0I&47B<J#AN.;4H$
MKW!V4D>%IC(&2,5\R9F<-3,PV*)[X;Q%!>Q<`^<5VV0X:O.IT*;)9DXMXG%N
M.9A6DHUB@5[)O!_;\+8SS8TMK!NGDAS(*2CA.'70D9%^B1"9<.#LB*(I+)$5
MPD<89OL.2Z#Q*17#SE?'M=Q(SX;J5,XZ;PN/7.3Y.3QUB;BEHT[?:52SS\E6
M;5'XIG\[0?FLSA7_`&@@P=J-$5$D$BKD6&QG"CQ=9(J#^T9$@)FI2+S"N`8J
MW89C:[A"`KV97^.N,;.>27M-M[2K-524N;+C69AY-XK59"(05DI-82J*B!T@
M(L8O?!)Q:9!<Y@>7>CP$Y4N-N;%7+M.AVC*,M.-HBF<:&.;[C$,AV&1O,I$7
M5Q%<.;B:8(&BFC/H702(&*JH8AS$4G^`SAZXCJ9Q!V?.>>Z;ZO6^Z\/B.*)R
M74EX>73Z5AZ]1V/,:D54CG[Q8?7&BTL+=LV"5$T^=)40<`H71%C,#C+,<WPZ
M<&DY0J!*7:[X<PIQ?5K)D*A:STF76SI+XHLM(E8A:R$E8JP0,S<,R(/DB2#1
M9-PU67!P"R/N50(H^(8'XKH+"60;%:8_+>/(7%G#[Q=K4&/D<BR51:0X6G,=
M6M-12:P4+E>]>;+)]`ZDY&P[J4DI%>O++K%Z4BKL4T1:[Q!BC/N?[)4;GC9M
MGY'A>?YCS3&8HASW5M+(U.H?2J9O/)V:]2&8A/"8RL>,DS1#`L0E;.=;(+1S
M,[$^ZX$B]%?L]<=6K&MHQC1U:A8:`QQ;]GEPT8LRK4;%)%EG\1EZO6S(8LHU
M[*DGK,E)N642$FZ;F(^7!**DV>P$DU$DB$7KAHB:(FB**?%#C^W7I[PSK5"&
M4ER4CBJQKD"VF3<,T/--/@X"\-):94!XNB*R3-Q+-RBFCOK&YS:4H@!MA%YF
M47$6?ZKBJ/@9K&_$=9'F&.-%'B`=X^FV6'%J--8_:\4N3KP;Z`G-?D&=FLLV
MC5[>QL/0;"[!911B"3<2.0(GHBZ.1.$_B"S$EEN_PV.;?P_IW/#?#PC`8+H4
M_C5E5;3+5WB\SUE&R0N1V3R%DUVUG)1[?'SLPE'OV*2<I,O&Z;ETH0RFB+2U
MZX#>)]>TW>+JN+P>4C*C?[0K*$Z52PUEH@SRG?<OV!I1J^\27E`,9KQ%8;0K
MY`7`#H-CLE2/Q1$^P2*4AJ[F4O%=$\8;3AHS7ZB2F9)-TKCQM&T)ME=I#Q_"
M*EB,M[FZF_O[&+:MIFY"$6B4L@H[,SC45S)@B=,=$6%Y3X;\\Y1BKW@^N8@M
M-:G9'B%XN^(IIF::4K$?2I&H9WP!F>GTNL&L+:<<307E:=RO&UR2CQ:B1DTA
M5ECJ&:IMC*D5T98TXGLMVEI)/<'VRH4.M92PK-U&.O-8Q%2;E$Q<%PP<4..[
MQ`*/*,_-(6BBT:VVVO1<,YE%5WAROUUFYSLS`<"+!F>(,Z(<,G#1$2.-N-P^
M6\*463H\;<',=PR3UDH-BD<+5*I/,=%Q5T1UCO,'#5D-]#K1DHK,*EDF"C5L
MJ+I-)8[E$B]QL0,[1'XGQBPO$+6JW=&./Z<SMU=IB*;>GP-G:UZ.0GH6J-T3
MJHMZW%2I%4&*9#&3(U3(!1$H`.B+8NB)HB:(FB)HB:(L'R;D*MXEQS?,I7%P
MX:53'5/L=WLCAHWZ6\3A*O$NYF2%FTWTQ=O#-&9@22`Q144$"[0V[=$4/%N-
MFSMT*[7EN%C-[;-5NLDS%5C"S]YCEA(SE=K^/8K)DU>6%_<6XN.W%=BX*<9Q
MS@I'XND+*N$:<@&`5@(M3C]K9@!:N\0-ICZEE!Y&X$X=\6<1JC<(BOHR.1H#
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MDN0A%F%NX_L54YE!O9*O7E1.:XHW_"VJ5&/B"+0DM#NV[.?R=,HN95`[+&M=
M5?-A>KF#IR/2DP,VVB(`126Q#EN%S!'763@F$JP0H^5<EXCDBRZ;--5U/XMM
MDA4)N08E9N7131#^0CCJ-14$BPI"`G(0W)HBVUHB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB\`,U<-O$!E"I9XQ;"X)N\9+P.;N/K--
M8R*^>T%K7KU`YOP_E^A8\I-!>>MCJ;>3%YE\D,5G:3]G'L698PPN5-H(@<BV
MCE+`N=,LXVPPXJ\!G24LEE+=^%#.#W/9,1U?(\'PX9O]17]^N2B&-UF%7E:]
M3'%`32CT&X'DU3/UO<'$-\"+$CX>SO!X[XG*&UQEQ&SH?XQT\WT.C`RP@GB*
M4QS%<=-(S`W<8@?M)2'N2]J?XT8+/A8SKU%N!DUD4P34!(HD6>9ZHF7LK6//
M2D+P_94`>+[&O#/2:3-6%A26RN$)C#>4[V]M"^4%6]PDSU1G!LY]M:HA9@=^
M5ZN`II;CTI2"1:UN/V;UYR7P\RT;D9Y<+9=)G+>0:G6<7OR8\C*MC#".8N/*
M#R[DB:C7D#%1\Q9GTICVKQ\L4\O*OEVA$3(MT2+G,`D4?4.$OC-/98_/E_QG
MDJ/R;/67A:?Y!?8BE,6SV1HR,X=LDY"H#)6L(W*0=5*1?.L9Q<79#).DU$0)
M8EB%)TDJB92+>.3.%GB)L?$E&9^IN.+I*,+[F/@-@LBK7A]1HB]O<,XQ]0K]
M9[U;6$-)MX/UDQ7D:A&3>,V!?=A./#,$U";`$BG]2</W.-P]QSU:S8W3M2V7
M,P<2-BJE">VE&LM\F5&^U.,BX>*/:XXSQ6IH7'F5F?3#E!=CO<Z8@;H;2*(V
M-L-<0-@Q;9*T\I.27-6C>(G@:G<=S&=Z[BZM<1SJEXER;09W)S'),Y01CHW(
M-;Q1!0?,5^8?HEEWZ"3HFUT0K9=<BTW9N$[C)<V?,.696A05F9\2DC<K;=<8
M0J$='76&9X:XIL;Y8P13[K992]R-8NDG9,&U.7KS`K1K'M6CI\DV='%,YETR
M++XVJ\5TIG:AYILN..)FOU6)R?Q2)Q$OC*A\,]:S'*T#)%;X25:4XR_57IQK
M:C"9G<?V)D=TFEZR$CXEB5T<BGNC$7O&W':GMV``B81$`Y=@C[`CL#:(=@=$
M7WT1-$31$T1-$31$T1-$31$T1<%/YM3^`;^*.B*)L?\`V0SOXFGZ_8Z(LXRI
M_2U5_K/`_K)IHBW[HBX"0@]DH#R[>Q^#9_P:@FG(2BIS:>]O<V7>#L#L#:'X
MA]C5./H**HID-V2`/9[(=O;M]O;JH&J)S:?(.X7:'8'=#V.Q['L:E%3F4A``
M$A1`.P`AR<O9]O1$!-,!V@0`'D#L=G9V-O;V:HQ[:4*+@FU;(@<$FZ*0*JJ+
MJ`FD0@*++")EEC@4``ZJIAVF,/*8>4=5HN?,I".T4RCR;O*&WW(]D-@\FP=$
M7!)JV02300;HHH(D*1)%),B:*1"?O2)I$`I"$+LY````-$7)-!!$RITD4DSK
MG*HL<A"D,L<J9$BG5,4`%0Y4DRE`1VB!2@'8`-$7UT1-$31%00`W((;0T185
MD6[P6,*'<,B6))X>`I%<F+5-$CFW3'YHR$9*OWW0V@&(+IUT=$VXF`[QS<@<
MH@&B+%:#F_&&4I1Y#4V3F)&09,>GNDI.C7JL)%9@N1N)BN[56H1FX4!8Y0YI
M-0ZNSEW=T!$"+:3\JY6C@[%%!5\5%06:;A4S=NHYW1YA)=PFBY4;HJJ`!3'*
MFH)"CM`IA#8)%#CAZXCK=E6RL8&YP-`K2SRL6.69+5R6R/*H6]S7[!&P[U]2
M)6W8[IL+-UN)%[NNG"+EPL919`4R"D)CZ(IDO'+)BV</GRR#5HT;K.G3IPHF
MBW;-6Z8JN'"ZRABII(((D$QS&$"E*`B(Z(M<068L7V62I\1#69FZ?Y!KCJV4
MA!1E(LBVBN,3@5U(PJ[]DU;O`03_`)842GZ1T78N"8HB"@D6T=PG)[DO)V-H
M`.S;V>SHBJ`````!L`.0`#L`&B+@*I0'=Y=[:(%+[G:82_OMT-NTVP.4>T&B
M*@K$`!,;W)0`1$QMTH;`]G:(@&S9HBJ*I`WMH[-WL@(E`0V]C:`FVAO>QV]$
M5.=*!A*8!+LV[3&W0*&P-O*;>V=C1$YX@CR"!N01`2B4=H%_?&V`;;NAM#E_
M#HB^NB+5N<,61F<<-95PU,R#F(B\IX^MU`>R[)(CAW$HVN"?0HRC5NJHDDY<
M1PO`6(F<Q2*&(!3"`".B*&:G#-Q9.YFGYDE<YXLFL^4*P6EO5(U]CZRI84A<
M<W#&E6H%AK;"';VDMT2EI>Q5!K;5G)WZJ82!U(\A"M=U;1%'=3[()BD>I-XW
M-J[>,A&$'7[4U7I*:RM\K,#A"HTUI#S!T["DFV1^F['D%=P`A#ID*S-'[H@?
MI($74G/LA%9KI(#G;HS67J=[KME8$HF^TLDA(X!HV&<33,@4]G*8I\3SL--S
MR!/=&=GFP;@='H_.JD6R4_LUUI!GFNH61[P_RE,S+G**S+,SJ.#G),LSL>QS
MU3,TN,;Y#MSJYO(RYU!5M6%(E,AF+<J9#HJ;A@1%)0BRAUP'Y#QT_-(\,N6*
M9B,XH<0=$@6CG'SQY%8RQ-Q#V>B7MVWQM%Q5BC8^.NN-;]3UY.%YY(T2X&34
M27;%*F43$6)Y'^RTC<MNLB%NN9;6,-96G$Q(TUI6%[)3I"L9`XBIVDRBERLC
MZMVN,3O:50;8]CTTXUTDDQ=JG74.0N\0I"*47#+@O..#7]\B+9DO&EYH=RR!
MDC*@#$X]LM7O:5SR9936N8(^EU[].UQQ!-I1\[!-)*,17YLZ0"IM(;?(IE!^
M'LZ(N`G*!P(/9$-H<H=O9V-NW1%QYXFW9M]D"CRE``,8=TI1VB&PQC<@![.B
M*@KI@)@,.Z!=N\<P@4A=FS]\(C[GL^SHB"N0H")MI0#V3;I0V[.QM$0`!T14
M!PF8=T!VF[!B@)3"0>R!3`4QM@B'+HBKSZ8[HE'?*;E`Y!()!`-FTP&WM@E`
M1Y1T1?4I@,&T.QM$/:$0']T-$5=$31$T187,3DBSDCM&O,;@)I&*"B0G-O'+
MM'E`X;?:U6&$BJ*W>L4[M`.;1`1*!]@MC![@PB!3`/.\I3&`0`>V&F`J*KCZ
MR3?L%0';L`-C53EWA,!=G\IV#"00#MB`[-NP=4*4]99K:(;K?:4H&-L;F'=`
M>QM_E-H;=5X"HJJC8YP"E,)$-AS%*40:J"`F,7?*7:"G[XQ>4`[(AI@*55/6
M6:V;1!N4!W1#:W-R@81`H@(*[-A@*(AV]@Z8"E5V6=AE%C.BJ]'#F&;E<`!$
MQ1YQ$`W0-_*#R;1Y0T+"%*ZI++-*;=P&QA`-H@#<XCL_$"@CI@*BJKZQSNP1
MYI$`*&T1%L;D]UN;!_E>0=[DY?9Y.SI@*57`UHF"#L,#<![0MS`.S9M$=@J@
M.PH=G\&F`J:KD:S31-N\5`-F]M_U4_()!`#`/\KR"41#:'9#;RARZ8"HJN!;
M'*FVB";/9N`J8PMC;-P1W=\1!7E*)A[/8'3`5-4-8Y0IMTR;(#![D=K80,'L
M"4P<[M+I@(%47;<6%\B@P5(1L"CAJ94XBB.Z!BK*)%`I><]R4"D[';'5(%31
M%UB6*86$0(BV5V;.PU,;E'D#9NJ[VW\&JL!457$UCE`#E2:!LV[0%L<-G+R[
M1%8-FT>SI@*FJJ-AE>P*+/:4`4W1:F+N@82[AN54`#?W@V"/)M$`[.F`J*J@
MV&5*`[46A2AR?^:G`/<B)1#9SH?O#!L'M#I@*53UEE2E`VZT`!Y"_P"K&]CM
M;5>7L_AV:8"E5VX^P/W3HC=<K44SE6-L*@(>Z(BHJ4=O.>R8G+I@*572]9Y/
M8`;K+9V=G1S;`'\'\KM[.F`I5?0UAER^Z,BUV#R@;HB@@(@4#[=O.;1V%Y1[
M0<NF`I55]9)@`$0*U`-T5-A6QM@EV\JG(KL$O+V=,!4U5?62:$`$`;CM$H!L
M;'_XY3F)M'G-@;X)FV=O='3`4J@66:,<$P*W$P@([`;''D`-XPAL4'D*7E'M
M:8"E5P-:)@AA*<&Q3%$0,4S<P"`@.P0$!5V@(#I@*BJ[JUCD2,FK@H-M]=1R
M4VU(PE`$A(!=T.<_\;ETP%*KIEL\R<1`@-C"`;=@-S=C;LV_SG(&T=FF`I5<
MQLDT`[!!N`^Z#8+8X#M)MYP!`5`$!3`/=>R&F`I54]99K:`;&W*4QP$6YP*)
M"@(F,`\YRE*!1VCV`V=G3LRE54;'.%WMI$`W/WP"V.&Z&P!VCM4[0Z8"E5Q]
M99H$P5W4.;$=F_T8X$Y1$`]T*FP1$P;.33`4JONRLLFN\;(J]'%-5=-,^ZB)
M3;IS@41`><'8(`.H+:"JE9\IRIG'_P`0W\4=4HHFQ_\`9#._B:?K]CHBSC*G
M]+57^L\#^LFFB+?NB*!'&1<9Z%L-"@$,AV'&U=>8SXA;HXEJ[8"U=P_N-`JT
M#(4N/<RI^5RW16?NG/0`$2NS(^[(<A!+JM@!W[5:EQ4&'I_HV?*HM9ZX@,W5
MB0I,FRN$_%1UGX:L"O;0UCC`U\QWG(&0$4T[:DB5(H1Z\BYC%8=T/N2\R_(7
M9R!LO-9&0<7.O.73*4#>Z.'W%C;HJRYEM%15KF1J%3,?XO9."NJ]>(*=P^^M
M<RVD*T5`ZA1<2Y7+OSV?9T8\<5`JA0,8@VBW8".970'EQJ:"N[H6G\493O;^
MZ%=K9,LTY+7"E<7\E=JH\GT9".I,CB[)*$!CQ6(KI2;U)5CHI06X%`"`\WM\
M^^8`,`M\BH':!U-XH?Z-BV(\RW)SW"5P[2K;)[A.3M]AX<ZIE6[PEH8I6*)C
M[B]A4;4K(S[=10U<DY+G!14<'YI5+GS"42FV&"V10T5]KC@!.]:F?96NKK&F
M(HV7R5>$ZN\RGQ4P+NY0ES85VUVZO8F;9$5QFT^D!XHV8.%GP0R!RK**D+)&
M:E!0QRB<#7J-KNY`K![2G+O/Z%L"YVO*=BIO!_8:%E*T1L?Q`155Q9:)"6.S
M83A$IZ%;Y"3R0R91(*Q;'(!86HR3%4R!N8$9,!+L!(NR@M&WH4M[6K2=Q.U>
MEY"`F0B8"8P$(4@&.83G$"@``)SF$3',.SE$>41U0O4N6B)HB:(FB)HB:(M1
MYZ1<N,+9719V2"ISI3'5P!"V6AP1I7*P?S&\$)^==G:O@9144`<^NOS*PHII
MB<"&$H`)%"?@@NEAM%[R(R>S\_D"OQ!#'@KL7)6>;S3X>-E4X"1KU'8N<KT^
MFPUGD2Q#@SXLZV(^>NFZH%47$@AM(I_Y(:7-_C^YL<=23&'OKNLS+>G2LD1-
M1A'619@L2'>.BJM7R()-WPD,)CH+D+LVF24*`D,104X:^&63IN5PO$UBKU39
MLH&<4?O<A63%F2;<^O<S)QKM"?ITS2:A#/ZLV%+SF,EON447RCI(2,DS$,IH
MB]")\C`\'+)2C5H^C#Q4BG(LGQVJ;-XP,R6*\:NSO3$9)M'+<3$5,L8J12&$
M3"!=HZ(O,;!5DH4IGW%D#2:7/5X6-8G+*B6\\0ALN,(BES=.5)6R8PKXY*N<
M7`O9=N=NH`M4$G!*_O"&ZU5#>(O5'1$T1>-?%M@6\YMXUY$88M8J]=IO"[AF
MSK9AGF=Z<W#%;F!X@\GV6PRV#0K1&\4;(DG7X(C=T5P\1`4#-062=MA.V4(O
M/Z)8<1UXC7-3OV%)://Q:<1?"GQAUZL93EIR[XWF&E\RQ:H;(=?N3*LLW#ZC
M5B!H9:*5Q779`4;*@H99/=!4"D4H,1\.D&O>."P^0L5QTK<:-;>/>MVUPI!6
M"8K54<X^N<\[QM7JA*V5%2:'&%,?+_\`<0)4YW*$<*/-#O@.PB\Z*U#Y-JN/
M,>XCOT?8"U*F89X*+V:=S'`9!L6,EZ#FGC"I&1)^+R8W0<L7TVUH<Z-EBYAB
M=TDZ;P[=L"XE;F`1(IJ63%T_.9H=9.Q]6<7K8RQU%?9IN8[)&*X+(=<L%8@E
M\O7-O<DN%EDB:1AXRGR)'1$[(QD7*Q#0JKD')5#<R($7Z.-$31$T1>%'VD=`
MR9<N(BRSM-KK"1C<<<%25T/:',MD.*M^/WL7G-5_*VK!IJBW4AE\OL:Y&JJM
M4GZJ":PHMTEA,U.L02+0V>;`W@I_.<WF>/+8:!!V_CZL>)Z]D.UY'I];L.7X
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MMV2W"YK46VNCB%L7!1Q=5N7&H!8"K`ZL&2^$6/:IH.(,`.WL!H@\B9B8I@<E
M(5<R6P"J#HB@;7I"NR>648[C8B;"ZH>/.)#-&([@YND!=7L)8K/B_@KPE0:S
M<:N5JS<*/GEX6AE9:#=,0,JK)O5>C'Z8!@T1915V4[$.,>H\:A+.YPVVF^$Q
M#B-=9-;VMU77+]MP$9'1J_TA"9-4'*1,OFBB2AU]]#UH!J+H>D\V;1%F-9D;
M3=.)7!MW0P=F23X18*N8@X&9)+,DN[DYAQ1\QX>/>Y)')^-9H9*;LDNSRC8J
M#'R,^N=PDT".=I+J`8BYRD6N(O%UIQ[PN8.:8VI5RIKV;X)^+>7R<2FPUEB;
M#)*GSKPLM+,[D.@)I2RU\=8ACYE"-.;_`&D+=-0&O[T0T1=:_P`89IE&/R7P
MDL9Y_P`/^%\_93S=AB$QDC8PQ_8T*-P<X])FZH5!DQ*6-=UZYNWD_'MVJ118
MJVM5P9L478*CHB]QN!8[]7@OX5%I4)<)%?A^Q,N]"?1?MIP7"])AEE32[>5(
MG)MY$QC[5B."E7(H(@<`,`AHBE7HB:(FB+S]^T;3FEN#[BS0KA'ZL^O@2[MX
M=*+-(IR"TBO"*I-D6JD1_M5,ZRAP*8S;^7`@F$FTVS5YOFJ%XMY(H[K&&4JC
M0,JL,$T.D1G%/=95]2[9(YAF.$2N5^P\&$$]KBU9565A;2C+V"PH.UUVZP)Q
MJ%@34%L05#B8T[46/Y^?Q<0_XP&].?QN1;/;Z7Q2I*6B&>Y5IF9\/P\2I47I
M:EGFB-I"1@[]PYE9QC5GC:PLCQCI",<MQ:-53.7CL:,&U%M?,%VMC%EP_/\`
MAIIU3O5%X3$)OB\R1(<+-@FZSB$CM/+=>J`PHQERDW-AR`Z<8<A+\+V#;G=+
MB^5;K$1W>:U6$6LGU1S)6*GD_*$#%NZVVR5!_:3LV-EQE*Y15RID*'BN)(7X
MJ99AY)JC$LE*]AYO)N:8XAC+/R`B!$#$3$2'(I"2IV3FZQS;[/V42B<3M,<?
M:"IB]NC/(-KPK(O$:5PP*NAP6%9M$/S$$66<KDC%>D&:I3J<WT9(QC''3D1>
MM_">+\W#1P_FEA?FE3<->)#2AI47`RAI(<9U<7PR8O!%X,B+K?Y\5OY45=[?
M]UMT/^]%#_CWQQ:LLW?@YHM9J],N*<ODC.)I>&R5*7N'QXFFWX=+P:*F+$^Q
M\S>S17D/+F26C"B".U\4O-KHJ[B@2B@:QPGF#'>:Y^8FY(]N2QAG?A_Q#.9]
M0E,CM\XVTJ?`?1:ZO'(1:I'E,D,/W/(:H#,"X=N7*;MVLL(&>D*N$<J*1W`!
M*VR.X-JH3!=;X?;M?W^/ZHGDE[CVWW6J6&IVH,/M3QLG?V5XB+>ZN&7_`%GY
MPKMB5:*;J*`816*.T-$6@,7Y!X>J'4^%BW46S7JNEALI\'<CQ=W"8E[:&-V^
M3I3"^?&MS+=%)19=1GF`+:40NI'!2&WU(@'8<Z".R47?SA+7VRY^'*>*)6Y6
M6+HO%S)9^H@UQY8E:S=ZIC_[/:@6US7&R:"A(R5KEYCB2T>W;G*9JI+NP$I>
ME``@1>D/V?-P9VC@\X<&RLK*O[1'8/QA+6AK849=&RL/7&#5G8!6P!-)$>A(
MR<2(*F*H8RR>S=5`AN34'<44WGO_`)K$?]A-_P"UN=6F><I7E[Q]8INF:LI\
M)F/:E`TR?++QO%7T\<C2M_AZ37GGT85)K`6UPZQXU6E36FMOWAUX<AE&@F6Y
MT4G*"H`H%U0HAEE^(?`,TC8[?<%\B8KPGQUW-Q,NUZWD9SE^^K8XX"Y-5>9>
M2*%@>UA[2KC;(<5$V1(]3?E')0!8[@=HRBTG"M\BUC%;7"'$^K'8SL->RY$<
M0#:`XGIVS73AZRLGQ`X!M,Q>:ED[*>-IPJV.31V:H2V2-,V&?&AY@&"'FU0P
MM"!"*3G`7-5JQ\3=VG;%#4ZFVV4@,-N\?T?,4UD6T<5=?JRO!WA$5H^&L\XY
M;U^?J+5UTX'[QPS+(/'G3%EP(Y.8`E%/'$=?G(#C5XOU'=FR'8:_8L9\,%AA
M&EOF'4K6:N]=O,XM9FO8\;"U:1L'"(E9-E5FJ/.K<\J!UE#"8FPBG!#_`-((
M_P`!S_[*MH473:;.E-M[9LZ0CMV]C9SA=NW;M#9LT1?G3CL$YZC<*3V>:R\K
M-%E);,\K46<?%.\O3=KRS*SWVD5-=URZ9XAUEH1@SB<=U:MN6S)*%.LY<0TH
MN4[Q)J`):(K?F*>XM%WF2JU"5>PY"R%@CBJXC^,^UNL;RLUCRG%889C\(L,:
M0D.TO,](2-DJUA3EK(4*ZU>.SOUV:ATDS%VE"!N18;Q$6J#>J<74U1))GD69
MRE5N(>PFM!5\L47-N':TO;,;SGJ;Q)8\;OGL/=,"I123=K0)YJ>+>-HQ8A6;
M-3I+MUHB]$,O6?`]/X#(64?M*'<,?'RM6XV&IW#?8['2,+Y$O\A>W"<'3KA:
MK`O*2E=Q$ZG1(ZN;ETL*";1DMN@H`D;*MM$4V.%.%/7.&K"$`ID9AEU6(Q["
MLE<DQ+R2D8>UG2*KO.8.0F5%II]`QQC"Q8+/3F>*,VJ9EQ%43CJ44DG']%QW
M_2OOXR.@Y?A1>>7'[3[#?HCA:I]=JU9NYIWBTJC:9JM[D+7%8^EH5##^;7:J
M=Y?4Z-F)=*!;/T&ZY-K95$7Z;<#``B40%%`.6QSQ.X;'*6.U,DQ]JIF/9_[+
M&-O<Z\BLK25JE4_IO;/K`ABB</;%4F=5K4"Z3CWPR:$D\<Q;$!>J"<PCIRHM
M5)6[)DXEEMWFI&P87I/&#=L:<6&/K!F`LKD/!DN2O9LL%52Q]F>"JM@B)S$^
M$;7B&6QRSF&KMTR4;/"BNLBJD*Z*D?`BV1PQ3%1G^)["SVQ06*:+#M<&XVB<
M75C*=LRO?I1U*0G$+Q.0QYCA6N,P:#1EZS9$X^/D(96:9"Z3K;F)1,F":9!T
M12SG)"J)_:58[4I,C9G-Y-8[S6\W5R0=WM&U-ZVXX=F\E1)^%8NU#X]<<*,>
MZ9(<XHBDF\/D)V(D6$Y'"1I1>KL;_2#'_M2'_6%U2_S46W3_`,T;_HS?Q1U9
M4J)T?_9#._B:?K]CHBSC*G]+57^L\#^LFFB+?NB+&K+5JE;6[9C;8"N6-LS=
M)OVC2Q1$7,H-G:6T$GC=O*-W*:#@G*!5"@!@Y0VZD&B+Z/("L2)U%)")@GQU
MF[1HL9Y'1KDRS1@YZ<Q:K&704,HV9O@!=),?<IJ@!R@!N72I2B^*E9J*U@0M
MBL'7%;4V:&CVUF4BHM2PMV!]_?9(S1FXR23,_.&VI%4`@[1Y.4=H$A015?)E
M4J3&R<O-QU<JT?,V`HDGY=E#1#64G2#V23+]!L1W)EY1Y%CG`=3B*`+IHT#'
M3>)DX!"GTQ&!F]WSS"(UV!1B)82@4"FDXY)D1F_,4"!L%4A]FP-G8U2HPBJ^
MKFD4)Y!L*R]JU2>UR*4:JQE>=P4(X@HY9D83LUF$0HS-'LU6IS"*9DTRB01V
MALU5B*FBO(1,`"48AT"(YB$527AD.B,>9B5T$56R*T8D"0$8*I-UCIE,D!#%
M(82@.P1#45*FBNO/H>_)>$)W=0B<^A[\EX0G=T1.?0]^2\(3NZ(G/H>_)>$)
MW=$3GT/?DO"$[NB)SZ'OR7A"=W1$Y]#WY+PA.[HBU_E16V'QQ>B8\;1<I>CU
M"PIT^/E5(_S:]LBD:N2(;/O.1RQW1U'@E`P./]7'_G/<;=$4,N&'#UTQWF&<
ML[_'5CJ<'9Z2_2MMBNL[@1>5FK@WF8`\",?&8(BZW'&3/%$?=*6D6:QR`DW(
M@J0.<*<BF[D&;L$)1[9,TJ$1MENBH"4D:W6!=(-_6":9-%'$?#%75<-4DCR+
ME,J11,JF7:8-IBAR@10TX5ZC,,+U-S-FIF>Z:2OL+M7J&GDQ''#:OFH]ANK>
MRI$D9:H2+NR6BV/'^UR3SP=R9D0[C=4%150YR*;-N;A)U>QQS=C%3CA_`33%
M"%EG`(Q4NL[C7+=.+DUB;QT8Z0.H"2Y@`1*F<1`-NB+SMX=,=6NOY"Q"4^*;
M[7&52K]P?Y0E<A><4(9'),W78VO(6FFS;W,]_<6YVC`Q3>M,$7#9^FQKR1A1
M>M@V(+$7IISZ'OR7A"=W1$Y]#WY+PA.[HB<^A[\EX0G=T1.?0]^2\(3NZ(G/
MH>_)>$)W=$3GT/?DO"$[NB)SZ'OR7A"=W1$Y]#WY+PA.[HB<^A[\EX0G=T1.
M?0]^2\(3NZ(G/H>_)>$)W=$7S4,U5`@*';G`BA52;YDC;JA!VD.7>V[IRCV!
M#8(>P.B+Z<^A[\EX0G=T1?-06BP%!4[=0I3D4`IQ2,`*)'!1)0N]M$JB:A0,
M40Y2B&T.71%S!9$`V<\F/X14)M_X=$5>?0]^2\(3NZ(G/H>_)>$)W=$3GT/?
MDO"$[NB)SZ'OR7A"=W1$Y]#WY+PA.[HB<^A[\EX0G=T1.?0]^2\(3NZ(G/H>
M_)>$)W=$3GT/?DO"$[NB)SZ'OR7A"=W1$Y]#WY+PA.[HB<^A[\EX0G=T1:SL
MJI?/"IB*$Y$F^PP*%[($_'JL/H*(K$"HEY`4*`;-FSG"[-FW;LV;W;U.,J*+
MB!RE.94HI%5.5,IU"BF50Y4M_FBG4#W9RI;X[H"(@7:.SLZC&4HN7/#M`>=+
MM`=X/Y0O(;DY0]UV>34]H4H@*[!V\Z&WW/*"H`/N>0O*!NR7V-1C*45`.4I2
MD(9,A"``%(0R9"$`HB)0(0FZ4@`)A'8`=D1TQE**Y1JI-Z0$RB>T8Q[RBH3:
M(B4O_C<HB(Z8RI5M!0``0`Y0`>R&^78.P=H;>7MAJ<9443G.Q_*%Y`$`_E"\
M@"(B(=GMCIC*453*[P[3*%$>SM$Y=OM[=,92B`J!=NX<A-XQS&W3$+OG4$#*
M*'V"&\HH8H"8P[1'9RZC&4HG.C[Z7PA>38.\&SW7)L-RZG&4H@J[Q@$RA1]U
MM$14*/*([1'E-V1U!>2**5WWIB]%B?=DY&)MONR\G^M+CR\O)R&#V]4@T-45
MNWPV"&^38.S:&^78.SL;>7V-5]H5%%R!40V""A0$```_E"]@!W@#]]V`$-,9
M2BXG,FH3FU.:4)M`VXH*:A-XIR*%$2'$Q1$JA`,')M`P`/L:C&4HN1EA-R&5
M`VT1$=Y0H\HCO".T3;=HB.W4]H4HJ;X;`#?)L#:(!OEV`([-OL^SLTQE**XQ
M"A`D$1$Z8`!'(B(G)Y*L';[8ZC&4HK;OE_+)^>7NZG&4HJ\YR[><+MV;-O.%
MV[-F[LV[>UR:8RE%7G1V`'.AL*("'\H'((=@0]UR;/8[6F,I1`5*!C'**15#
M@F"BI13!50$=\$044`=\Y4@.(%`1V%VCLV:C&4H@+"`[P*%`1#8(@H7E`>00
M[/8'4]H4HN(G+RB)R=L1WR]W3&4HKDX4)YLC@WT]H*O=H;Y=H;3(B&WE]D-1
MC*45N!0`V[#E#:&P=AR\H<@[!Y>QM#4XRE$!79LV*%#9MV;%"\F\&P=GNN3:
M&F,I15,H4Y%$U#)J)K`8%4U#D.14#`(&*H0XF(<I@'E`0';J,92BJ*PB&SG2
M[NS8`<X38`;-FP`V@&S8&S\0`'L:=H4HJ<Z.S=YT-W9LV<X79LV[VS]]V-[E
MV=O4XRE%VXTY?.#':<G_`)V@'[\O9%0NP.SJDNJ**5M\_P#-&_Z,W\4=4HHG
M1_\`9#._B:?K]CHBSC*G]+57^L\#^LFFB+?NB*/^4!'UB0#:(;(Q#L?A7<Z*
MEQ(W+7/+^4;V]1548RG+^4;V]*IC*<OY1O;TJF,IR_E&]O2J8RG+^4;V]*IC
M*<OY1O;TJF,IR_E&]O2J8RG+^4;V]*IC*<OY1O;TJF,IR_E&]O2J8RG+^4;V
M]*IC*<OY1O;TJF,IR_E&]O2J8RG+^4;V]*IC*<OY1O;TJF,IR_E&]O2J8RG+
M^4;V]*IC*<OY1O;TJF,IR_E&]O2J8RG+^4;V]*IC*<OY1O;TJF,IR_E&]O2J
M8RJ\OY0^WI5,9Z?B%3\0Y3T<J^G,KB`F`BIBAM#:4IA`!#L@(@`]CV?9TV<K
M@#S<I05$1DK,6`5+GL:P#I(JOE[H!V")O;U-5!+F807!V+<0G+^4;V]153C*
M<OY1O;TJF,IR_E&]O2J8RG+^4;V]*IC*P*1RIC:(?NXN4OE9CY)B,\5XP=RJ
M"+QN:KE@#6,%&YQ!0!A2VJ-%QR>X!\C^6&E4QE9;*2\7"-0>R\FSCF@OF485
MRZ=))HFD9&10B&+$I]X0,Z=2CI-N0@;1%4X%[.E4QE5CY6-ECR1(N2:R!X>3
M6A94K-PFN,=+-T&SI>.=[@B"+M)N\2.8@\H%4`=*IC*ZC6R0#URP9M9N/5=R
MD2ZGHYKTHB;AW"LG;)@ZE$D5>;4Z$@^D6Z1CB`!SBQ`[)@TJF,J]CO`(@(F`
M0'8(;>4!#L@/:$-*IC*IR_E&]O2J8RJ&,)"'/M,.XF=39O;-NX03[NT>0-NS
M9M]C2J8W*!V...JMS]2=VB_U&4K94F;>91+622LFT0@%Z7'W1=_,&MT92WT>
M1@6138`[327C9!T<!9KJD*J9,F,K/AXS\3<VDHG%9`7,XKL/9FB*,-#`=PPE
M)B.@7&\JO8DFS`L-)R:*:[AV=NQ7,80:KN!V`*J8W*_N\]SDI3X&6IU!.C:;
M=F&X8BK,'D";+`12SBEDNSU[9I65A6T\X8Q<G%49P=LD")EB+*D(MN%*<VB8
MW*TK<7F/F"DK'2E>NQ+!7E8].P14*WK]A;,T5Z_/V.4FF<NQL`,7]9B&-3DC
M=)$4G#DC<BB#=0CA#>)C<NX[XNL4QSZM,I)E>8[UR=3859T]K[=%"<@X51!K
MZWQ10E3NGM<D9!VFW1,1(SLBAMY=!%(IE`)C<M_U.QM[A6*_:V3&7BV-DB&,
MVQ83K9%E+H,9)N1TR%^S0<NR-%UVRA%.;%0QR%.`&V&V@"J8W+(.7\HWMZ53
M&4Y?RC>WI5,93E_*-[>E4QE.7\HWMZ53&5YY<3G'DKPZ92/C<N+TK:1*N0D\
M,NI:#1)CC,$<&%MT0L.^V`V%#D-O^ZV]C7".(?&V+0FH'9`;"2XD9'&\O!V'
MM&XJ4Z%],\*OR[OXEZ0_U7_-)+7%-)&(Q;B0#LW8:XL0KBWTY-RCY][2I]1*
M'RZ5^;0ZTAWYG8@:#*I:?VOT+I;_`,FLK74;GDM/_P"H/KI][2I]1*'RZ5^;
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MI?H3P;3]]R^Z#ZRJ'VM)]H;<$(B&T-N[>E-X0V\N[O5H`WMG8V\FW0?F=BJ*
MY3+3^U^A0?R;7&$X<[EQ4V?\J-_TEZ<X5S12<]4./R!1'"YXYRJ=A)QS]OS$
MG`3;<B9WT-(%`!147:@H`E52,9)5,Q3E'EV!]#:/UEDVL\D;F^7N>V(NH\D'
M^')R0T_6+CLQ\B^4-=Z+SSAYJ%VG<Y:R2\#26!AV/CY9Z_JX1MP<NY;7V_@#
MV@UM*T[&4V_@#V@T3&4V_@#V@T3&4V_@#V@T3&4V_B'V>7E#_0`\@;-$QN3;
M^`/:#1,93;^`/:#1,93;^`/:#1,93;^`/:#1,93;^`/:#1,95WKX_P"W8;L!
MMDV(#L#9R"X3`=%4UQ)VJ5:G\VI_`-_%'4JM1-C_`.R&=_$T_7['1%G&5/Z6
MJO\`6>!_6331%OW1%%KB!M</1&T[=;"HX2@JK5%9R74:-S.W1&#`SE5P9NU(
M)3N%0('(0!VCKP9IF,64Y?/F=Q0VUM"Z5]=^!E*T\JRF29-=:BSFUT_8X1>W
ML[8F$[@YU2/Z%$:&XL<5S4P:#*SR#&/2&LJ!AEZ++-4O.%5K2=PD(@@HBY67
MEG%75(];()D.=5,Y0]RH8"#J%EQ(TU?ROM[07AE:^9I_@AX!@B$S\)JW86D5
MW_$M[ON#^K;*R&8RRY8Z*01%C1/A(;+*8!B&V@[1IK(3U?V2$:\6>*7<<S?%
M:WPCM[>4,=$KHTN07LZ5I=P!+,S:.(9DHZ631<PJI5M\##S6T2J@02F`(MN)
M&E[G#$\W@NI;EMNT=E@Z[H>W!IUMN`TK7XEY[CA%JZ,S0S.LX!%8>M"1LO:1
M&+MG0.=VI#<6&1F&N$>?\"Z[;B]PZZCYZ33-<2MH)&'<)`M572"EB2L5N?T>
M!/6`57*G*DEK)&+HI&$R1`*F)CB4-6+7BAIN\M1>,%XRV_A4_@!W]](Z)O6+
MA7K,--@7OFX)Z^@O(+![,L=?W4SX7-%P6]B^*W9<NZH#J'LWMJ*E69+C#H*\
M\WYJ)L!Z&XQFROP6\L6YZ2B^>Y$0QSZNN8H1W4UFLVMS:J@*CNJE,4`,788?
M/!Q2R&XS!C(F3'+)+,S=J6TP@2]@20*@=<UI4[5ZYN"&H[7*GSRS0'.69H+,
MPAV(!GJCKCM@=A((%:TH5F:W%!BMN^K,>H>U*.;E99^G5=-O6G:P3MGK%P2I
M4W",%"*&(#]I(J](V'W0Z`0SC;NE$-95G$/2HD@;$;R4W4_9QU;L!;<",[AN
MIL/0L(.$VKA!<2SFT9%8L;<71Q;8K)UMZRR;?2KX]@Y.U(;T+$2\75`@X-I(
MW$DPJY<JW-TJI2ZQ-R\9'P-2R$./7$E)'=F2>-00EG#=-4=TQ5%%-J0&*)0U
MBXN*>GK6VCDS9EP91+.YQA;C&!LQMV@CE#7[1M%>=9K\%]2W^8&+)C!V."(8
M974<77,(NHJ;1M$3'@=!VU5YD>+7%43`HV.18Y!;1Y)RPP$T16DR)7-4>562
M8Q4TI:BBJ"$6BB[DT03*"BJZX'$4TS;IMEQ_$K3&7V<%WF+LR[)DTL,A-N&!
MTD$K6NQ.J:!V(-=0;CLIO6(@X0:LO[J:VRV7*Y'FP9-`/6BX2LE8Y[96/P`R
M/JPL#*-:#L)*[&.>(N*N62;9B^6AWL3.1MUN]>J$@U8/EJ]9HFE1\+)OECS#
MC8BE/I,Y@%E6Q"\V5'=$#;P[->C(^(%MF6;2Y)?P&',Q=7#(\%>S='$(G=8G
M]<"5M!7G34O#&]R;2UKJNTF[2TGRZ"6>.0".:WFE,C0UD0KBB<8GG&3S4"Q2
MX<;>%Z-.W6%L"[UBA3*?GFV^?7TA7(B'M"G#FM28_(M8JBLQ,L5I.QISEW3C
MFB0%*59XP=@(@5,IC=`<,+L!WTJN6UQ.:1YIC'E6$AQ[UQQ7\A6R+P[>).NT
M2\UK&;5P2[8?9RUKO5IN5'H\;$LZV^O"$]6XPLO>VYCRDPBSCQ105$J@B*8'
M*I7:(XYZK+R%.8!AK,C)*Q7PN)[#-.F5/4K5%RH]R19<35ZC.;"QM;F-O3Z?
MNU5<%*YK9I9JSCE$7SLR+=7>`BE;CR]P&4*+5,AU8[@\#;X=O+L".TRHOF@G
M,HW>QDB@514K>4AY%NLT=)@8P)N4#EVCLVZ(LQT1-$35+MRAQ+14"I')SJ'7
M&UQ`9,X;<4,LCXWQZUO96EA8)VY5ZH\60@:TBX;.'PH1,:5-_)2DTS*X;M3%
M5(1!8H>X76.BW5U_5&9YOEF7.FR:V9->T&%KSA#R2*MQGJL<X5#'NZH>6XMB
MS636=K>W3(KMXB8^H).T,J//(WD-WT&]1UO/VDT?.W'AWI/#%5F.7K'E0L79
M[M".G"S92LU9X4&QZP,FQYQO%6\\DL4O254W+4A>9'FQ27.LWUR+B)8YGF67
M6&0127,EVSMI1A+3:0N/9MCN`?\`',C9*,ZKXVM<'BF`G+?Z4DLXKR3,G&..
M";LX2=O;-(+L5>5S-E7#JN#P!M!7J?R]@VP#?\8H"`@4?9*!@Y#`4>3:'(.N
MC;JM'6:''K?[OB6G"H>6[V@[^=-0JDT1-$31%'3B<XF*APKT6OWRY5^PV1C9
MK_7,=1L?6E(9%Z6<LZ;Y2/<.EYZ1C(]"-3&/."IQ4WB[P"`;-HAY+R_AM(VW
M#A_#)`^.JT/7VN\NX?9/%FV:LFD[>01Q]ENQN.%M3R=8BIY-Z_/]QM9EXELA
M\063<DXLL64,:XRPK!XO:9!IT3E9LHT:J&8/)E>8:H8]L,O6WK&R,TRIE5YT
MICK*$35`#".S1<SO+Z:[=>6TC@(B"!LYU\=\5=6ZSSC65UJ#(GW5GDN7MMB8
MQ=!T8>2"]Q94X@X5J#4="]M<0\<-%RWG3_#RTI-J@+N7'*V2QDG4Y2[!73P3
M9RW9`F,A6IV27&0=F7`Y"\WN`0-HB`CLUN5MF\5W<FT#`'MC!)'/R^5?46EN
M+.1ZDU0S2%M%*+\VC;ACAMB$>#:,72:D;=ZFOK)KKR:(FB*H!M_=_!V`VZ(H
M-Y'X3X_(>5Y++I,F1D/`OIVAS*[!ND@L#6*@8I=CDEFC-><",TC7L]>KBXK;
M.;;#"&YPJF^`D(L9B^#HZ,5,LI._46-F%XVOUN'6K#%ZBTJLJVFL82:MECD9
M66.Y9W*^LJ&9Y(G()#N)"3,<ACI@8ZI%KQIP\U*LQE2F)+.&.JK$3LK,V%9G
M064\E5+7'PSVIU69+`@$BJHXF%8&7FV#H^Z=564L*1B$,9``$BN$]P/2LHVF
M$ULL4$.?8.(<]@43E6UBEQ;/*5(/ZO;98)-R7U<J"=/478-$2@X;JK`904MP
MR@D7HS4S2)81JPF7D*[E8I/H*HPT@>0*:+14.C77[T7"R[Q-_+P:2#E;?,8I
MECGYLQR`!M$61Z(OJBV6>*%;((G<*KB*1$4R[YU1.40$A2!RF$Q=O)VM$6JX
M;A%QM`12\+%XI<)L'$8ZAC=*D;5)ODHAU%MH4L6TE929>2;&/CXQHFDR1163
M38;@&;`D81,)*%6T_!CBY3S@(XSL)%):/)%R+A*V9`1<NVHEBTWQUET;(151
MW-IPK0L@N817D"H@#@R@"8!(LJD>&6GRE24H[G'<DE5SV1Y;D&$?(6:,<1EB
MD.DE?R4)*1TJVEH,7:+YPDHDS710%%RLGN;BJA3$5CB.$#%\#YR+$8A%BC*-
MWC)PR(YL2D:A'OV,[&NHV*C5I0[&%CE6=GD2\PT313*9ZJ8`WC;P$7V0X2<=
MMW2;U'&$DFNE(2<B0//-N,@898J`.HM5L::%NK6TE6J:S:+,08]HX3*JBBF<
M-[1%N&/HTQ%1\?%1U=?M(Z+8LXR/:IMEA3:L&#=-HS;)B<3G$B#=$I0$PB80
M#E$1Y=$H5W/56R>A)'JRG<T2A3U5LGH21ZLIW-$H4]5;)Z$D>K*=S1*%5"K6
M,!`1A)+8`[1V-5-O^CDT2A4!>([[-O$_$CDM7)>19[/=?LIX"&KYXZAW]:K0
M/088BY6:Y8H(5\!7BI7)A54%0><Y.0-FM%S_`(6Z<U9F#LWS2WN);ES6MJV1
MK6T8*#8=M:;UU_1G&[7&@\B;IW(9(69<V1[Z.@?(27NQ&K@]HW[@!L6AQ^QD
MX;=O_P!N>*[^^1;YM:PWX$:+.TV=WZ9BVP_FFXL\DMN1S^JO^\5/N9.&WX\\
M5_\`?(K\V=/P'T7['=^F8GBFXL_:6_NLGWB?<R<-OQYXK_[Y%?FSI^`^B_8[
MOTS$\4W%G[2W]UD^\3[F3AM^//%?_?(K\V=/P'T7['=^F8GBFXL_:6_NLGWB
M?<R<-OQYXK_[Y%?FSI^`^B_8[OTS$\4W%G[2W]UD^\7T3^Q?X<51,"=WXL#;
MA#*&V9D5]R0O[XP_]VNP&H/`G13=]G=^F8GBGXL_:6WNLGWB^?W,G#;\>N*[
M^^17YLZG\"-%^QW?IF)XIN+/[=O[K)]XGW,G#;\>>*_^^17YLZ?@/HOV.[],
MQ/%-Q9^TM_=9/O$^YDX;?CSQ7_WR*_-G3\!]%^QW?IF)XIN+/VEO[K)]XGW,
MG#;\>>*_^^17YLZ?@/HOV.[],Q/%-Q9^TM_=9/O$^YDX;?CSQ7_WR*_-G3\!
M]%^QW?IF)XIN+/VEO[K)]XJA]C'PW#R>O7%=R\G+F54`]L:UL#4.X$:+`)]3
MN]WVK$\4W%G[2W]UD^\7,_V+W#BF!#'O'%>4%`$R8CF57^4*!A*)B?\`=KE+
MM#5AG`S13G4]3N_2L3Q3\6?V[?W5_P!XOG]S)PV_'GBO_OD5^;.O1^`^B_8[
MOTS$\4W%G[2W]UD^\3[F3AM^//%?_?(K\V=/P'T7['=^F8GBFXL_:6_NLGWB
M?<R<-OQYXK_[Y%?FSI^`^B_8[OTS$\4W%G[2W]UD^\3[F3AM^//%?_?(K\V=
M/P'T7['=^F8GBFXL_:6_NLGWB?<R<-OQYXK_`.^17YLZ?@/HOV.[],Q/%-Q9
M^TM_=9/O%]$_L7^'%4VXE=N+!0X@([I<R*B.P`VB.SU:[`!J#P)T4T5-G=T_
M]YB>*;BS]I;>ZR?>*B?V,W#:FHFH-VXK%`3434%-3,:QDU`(<#"FH4*T`F3/
MLV&`.R`Z'@1HJG_1W5/_`'F_.GBFXL_:6XZ?57^7^\7IO3Z!#T"LPU-IE:+`
M5F`:$91D4R:*$203*'NU5#B4573QT?:=9901454,)C#M'71LERBRT]E[<HRR
M&-EO$V@#1L`YSSGI-3TKA>H,_P`RU7G<V>9V^26\E-2]QVD]&X`=``'0LD\W
MO_(G7@%>]U[EB$\WO_(G7@%>]T1/-[_R)UX!7O=$3S<_\B=>`4[W1%]31,F0
MA%#,'8$4$0(84%-AA+LW@`=W8(E`0VA^'1%\O-[_`,B=>`5[W1$\WO\`R)UX
M!7O=$3S>_P#(G7@%>]T1/-[_`,B=>`5[W1$\WO\`R)UX!7O=$5V@6#TDY#F.
MT<$*639&,8R*A2E`KA,1$1$H`'(&@53-ZE"I_-J?P#?Q1U*NJ)L?_9#._B:?
MK]CHBSC*G]+57^L\#^LFFB+?NB*)/$Q2T,CP-MH#I\K%M[E27==5DVZ";EPP
M3D@=H&=(H*G33642`VT"F$`$?9UB,_R5NHLDO,D)+775L^($;QB+2:'X&K,:
M=SP:8U#8:D,3I18W39J#^J'#;\-:*'KGA2C%Y5W+(WZPQSIS/7"?3<1C%JU>
MLE[=B1GB<Y63PK@QVZL8V9]/25`-\5C<V.PH`.M'GX86$]Q/=65Y/!VCYR`R
M,/IVUL+<TKYE2VI`I4[3N70;7B]<Q116[\K@DAB;;XA*_""8+EUS'LW.Q/<&
M.)VT-.5=;&O"9'8^DZM*C>%Y-W7,D1N1S$:5:-@63QY'XW/CCS<#-B[7*V1<
MM3@\67VJ+*N=\3B;?,.HR3AK99+=V=W=7,LEO;7[+BI8(\3X[3U8@M;2HK0U
M.]7]1<9<QU#8W=JRTB8RZL7VKFX^U`;)>>M.ZSMU'XFX=P#6T6E:1P?7*0"]
M0-[<MX.N-V%3AL=NG!:];14)3<HV7(L6K*PK<&[&5K[@9H$'"+T4G#@JAR"4
M@$`QM3R#A5FLO;LSHPVUHU\'8RD]J]XMYY)NM"ZK=@?0;-H`*Z%G?&K*+>2Q
MS'3O;7%U)>S.FC;_``6L?/916^)LS2'XCV?G5J-RVQ)<'[9_"MXA+(KMF<,:
MEH3QTWIT"V16?MLD,\GQD^PBX]5C'1+=E--.CBQ3()3M1`.=`^TP[`_AA*;-
MEI#F,P$>6&$AEI&QCBZZ%S7"T``4&ZBT*WXTR0W+[K^60.F=F7K8[2Z>]]!:
MNM6Q.>XDN;V!+J$TJN\VX4%FRF/7),L6$KS&=YMF2J^LA`13=!Q<[I<!L<Y(
M2C--T*3ADK#KN(DC<!*4B#DZH#O@`:]5IPU-LZQ>S-+O#871F@'8`"8/NO67
MA_.T,JS;N:J+GC*;B+,V_P`GLG0YOE[+6[';$EL$5KV$-KTR=H&S"O*`=ZZS
MS@[A7D2\B1O,LFF[K=[K8JEAF(G33O.6HK*RSP`%R`&5C7,4#%,O(!TC\X.P
MP;!M-X4PQV@M?7F]GV5TQPY#ZQ=FY97GP@]6N[DHJSQNS(79NCE]91+9OVN+
M=EE:>I$%PVM!,NU="\<&;&YHR37Z29:/9R]GR797K)Q6HN79$<9&>PSY1>/:
MNG9$64Y!'A@1;2(`98K9=4A2D$V]JSF7"V*^@="V_+6DWCNHW&<=T]CP\-.P
MN`;3%O`JO?D?&JYRN9EVW*+9UQ'#9Q,PW+FO[.T8\=B'`$B)SW!SHP,!(J1R
MK8%.X<4JEE<F337F1E6[6=OUHCZNK!QS-!I/9"BH*#E7!I9)=5VY9MHN!3!)
M`Q-@*F$^]_Q=9;+M`^I9\<ZBO9YHS-+)V;H@QM9(X6%U0-KJQ?'5:QFG%!V:
MZ5=I^VRYD,SFPL,O;OE+XH7SO:2Q[`*ETSA6I(#0-RT&;@.K]O5R.QR(I$2$
M8YC>,:D8_4DJW7K@5K7^+J[5?)Z]Y33FR+'B;GCJP-'D:W(4I1<I$*MSQ0,`
M:Z.\XY,8W4`\BY4P%L8:_9(#\BM['[.Z"")R+39^VT.QT3(^2J=DN:1=X*KI
M<@R2]4O6.;P>GVK(*UE=C;J/)JX_Z)T!Q'D*BD[W@,842@>%*SBK\&S_`!UE
M#']UI5_@C8TQ-8<D6?'6!I;&39W6*&YR-=)RUS(8Q=,[G!P]/L:4%+FKL;)K
M1KWS5&F4!JFB5RY*H1;_`.'+&LGB'"E%H,XNW<3\<A/S5C,S6%PQ0L=VMD_>
MI^/CUAV<]'Q,O9%FB!P`H*)(%.!0WMFB+=FB)HB:C?O3=N74D(F'GF3F%L,9
M'S4%)IBSEXB69(249(L%3%Z0U?,'2:S=VW4*'*0Y3`.P/9TD$<D99/MCIL!V
MBOZHI\-%7&Y[96R-WM-3\`VGY%Y9_9U<-%VP[<N(2QY1Q,A3WTE<&?T7S4DT
MKCE\6L+.;<E*(UIW%NG[F)BW#-PT*JD`H%.F<A=T0`0#E/#32V<:<S'/+S-H
MVQF_S#MHJ;PRA&SFWC=S+=M8:@L\WMK"'+'N=9QVV$U.YP/FCH&W8O5?75QL
M&$>;6OQK10*;DT4IHB:(FB+4F9)[&-?K#%?*]8+;JZ[GF;)E$&H2^1=LTJ@Z
M,S7)`MXR5.D<J)5"E7YL-T3[H#[K7ENWP0@1S,8]E1L(!`^(A:SJ6YR&SR]C
M-1017%B7BD;XQ*T&N\1D$5YJ"I.Y>%/%9PE5KB&SF\RQB._-<6X^4J>-$I+'
MZ.%LEQB,L$"]2;J&<1U:AFT!(.I!5ZF!6RQ!<)E#:8G)R:OF&7BZNFRP]2"O
M6#=@(Z0%\F:\X;6>L]7NU+IVX=8:>#6MFMF9=(P2X#RL;0%U-Q.T+V2Q->>'
M69N#6(QG025BVJP;WFY$N%G]#.$2R*@=ZP4GG->C"HD.<0'HHJ@)SE$-W>*8
M`V&W?8%[&V[6B<-H2!M.SE--J^F-+YGI"6ZABR>W9'F!M6PXA8&W.&(5(,M!
M0;-QWG9O*D_K(KH*:(FB*U3T6$Y`SL&+MPP\]PDO#=/9CNNV'G6.<L.G-#;0
MW73/I'.)CM#8<H#HB@!"<"#J"BX@C>^UUX^AH8D4G`RU0EI:AS(DO*%[.K9(
MI_:7$C+"^<M`C5AYT@!$NG3<A0!4!`BZDCP.6!*P+/(FW5*086:VN)"Q+S=;
MEE1K\&M0[W``ZK4.-B.P:V*%D[>"4`9OS246U;(BISPDV`1;4>\(S=Q7<%1<
M?<&U?EN'N7NUCHLG!UY1A'^L=AL;2;@I.4@T)=)I()QS5LHWD$%1.F^4<J+I
M]'5*D8A%AY.!]):&L+%];:\5\^K,S6H-Q#U%U&(M5'JE&YJTRRGGM9ZM;K&R
MIIVUB>MCH*R*#TY2&(!1`Y%M'A^X<)/"5DL4VZM\38&DO3ZQ3V;*-KCJ$<(-
MJTJ9PU<R;M>9DS2[AOTE5NDLL!W0M2I@HJ82B&B*56B+D50Z0\ZF90ATP,<I
MD=_G0W2B(\T"?\H*@AR``<HCR:(HX4?B]HUMK<?9YA[/4=C.3IH6O)2TBA8%
MY`"H1BCAY*!3'D_ZEC"NIALRET9L(\\0_5(@X$!.F8Q%V87BWH$VM2H]O)V8
MD[>[)7*Y%0!4WCU]''LK&+?,Y&R.HY1U$UYFF$J1,"NG":SA1,X($5$H["*Z
MLN)!DE<K_4;E'6''Z5#?IQWK#.V*(D8RRKJ5UA;P/"M8"2D95!).L22+I47:
M*'-B84^4X;-$1#BPPTY7?-4LE/A6CTW*B@&@[VFFZ%MN;K>)75@DT9M]("<0
M8MV9EUGXD/T8JO-GW2+NI\4&(UG4<Q;Y)=.G<JYB&;)LTB;HZ6%W-LCR+1JZ
M(WAE/-[ANQ(95X1QS9H\A1%T"(!HBWB=])$-NF?OMO\`VQP.WEV>PJ(=D-$7
M#SC(>D'W7''C-$3SC(>D'W7''C-$3SC(>D'W7''C-$50D)`1`/.#[E_]+<>,
MT10?X@>/.E</F0U,=VBIWNQ2B<'$3II*%>Q(,C-Y<JXHH!YP>).>>0!#W6T-
M@[>37&-><9LBT'G)RC,+&:XN`QCL33L(>VH'Q+OW#;\O&H^)VGFZBRR\M8;5
MSY&!KXI7NK&["27,(&T[N9:3^]CQ3]6V4>O5K]H:U/Q(Z5[LN/I+?F?DZUN6
M@MSG+F-YC;SU'RJOWL>*?JVRCUZM?M#3Q(:5[LN/I*KP<ZY[[RWW>;YT^]CQ
M3]6V4>O5K]H:>)#2O=EQ])/!SKGOO+?=YOG3[V/%/U;91Z]6OVAIXD-*]V7'
MTD\'.N>^\M]WF^=/O8\4_5ME'KU:_:&GB0TKW9<?23P<ZY[[RWW>;YT^]DQ5
MR[,;Y2#:`@.Q_6PV@/9`=DCR@.GB0TKW9<>5/!SKGOO+?=YOG3[V/%/U;91Z
M]6OVAIXD-*]V7'TD\'.N>^\M]WF^=/O8\4_5ME'KU:_:&GB0TKW9<?23P<ZY
M[[RWW>;YT^]CQ3]6V4>O5K]H:>)#2O=EQ])/!SKGOO+?=YOG3[V/%/U;91Z]
M6OVAIXD-*]V7'TD\'.N>^\M]WF^=/O8\4_5ME'KU:_:&GB0TKW9<?23P<ZY[
M[RWW>;YT^]CQ3]6V4>O5K]H:>)#2O=EQ])/!SKGOO+?=YOG0?M8\4CLVXWRD
M.Z&PNU_6QV!MV[`VR/(&T=NGB0TKW7<>5/!SKGOO+?=YOG3[V/%/U;91Z]6O
MVAIXD-*]V7'TD\'.N>^\M]WF^=/O8\4_5ME'KU:_:&GB0TKW9<?23P<ZY[[R
MWW>;YT^]CQ3]6V4>O5K]H:>)#2O=EQ])/!SKGOO+?=YOG3[V/%/U;91Z]6OV
MAIXD-*]V7'TD\'.N>^\M]WF^=/O8\4_5ME'KU:_:&GB0TKW9<?23P<ZY[[RW
MW>;YUO'`O'SBC.]N]2(XEFHUH=)[]?96QRP(C9E2E4%U'Q+V.=+)!)MTR;X-
MU-TZQ-NYM$HEUN.CN,6C];9DW*6-=89F=D>/:UW21RKGO$?\NFM>'^3_`,\E
MD9F&6,'\4P@LH>6@/6`^':IJ=)<AR<^N'X.=4Y/P?OM=@,3&NH<)<#O`V&G*
M/AWA<":\N:'"H!`-#O'0>D)TESY0OX53OM5@D$D&A._I51)=O-4Z4Y\H7\*I
MWVH4)TISY0OX53OM$3I3GRA?PJG?:(G2G/E"_A5.^T15Z6ZV`'27&P!$0#GE
M-@"/9$`WM@"/LZ(J=*<^4+^%4[[1$Z4Y\H7\*IWVB)TISY0OX53OM$3I3GRA
M?PJG?:(G2G/E"_A5.^T17:!<.#3D,!EUC`,HQ`0%4X@/^LI]D!-LT"J9O4IE
M/YM3^`;^*.I5U1-C_P"R&=_$T_7['1%G&5/Z6JO]9X']9--$6_=$6A<EMG*U
MA1.BV<*D\VH%WTD%5"[P+.!$N\0I@V@`]C4T-"X;A\BH?R#G6O19/0[+-X'X
MVRX?_%ZC"X;@5:'7(:-KG&@Z3S#G*=!?>PR>=57]G_\`9^R&A:ZH#@:E30@5
M&[?_`+OZ:JO07WD3SJJ_B]1O`/(2F$[@-VU.@OO(GG55_%ZKPR<Q4%M*5&_=
MT_`J=">^1/.JK^+U0'8A4&H"AI8YV!M"[?0;_(J]`?\`D+WJCCQ>HH%555Z`
M_P#(7O5''B]!LW*%3H#_`,A>]4<>+U-2I3H#_P`A>]4<>+T1.@/_`"%[U1QX
MO1$Z`_\`(7O5''B]$3H#_P`A>]4<>+T1.@/_`"%[U1QXO1$Z`_\`(7O5''B]
M$3H#_P`A>]4<>+T1.@/O(7G55_%Z@D!I>=C1O/(/A2A5.A/A_P#D3P?_`-U7
M\7J6]=H>W:T[B-HV(06@5%`=W3\"KT!]Y"\ZJOXO4*:$FE#4IT%]Y$\ZJOXO
M4CK5+=H"@@M-';"G0'X__(7O5''B]%"=`?\`D+WJCCQ>BE.@/O(7G57'B]!M
MW)0UIRJI6<@7:)6;TH[-@B#9P')VA$$^QR:C8?B4.9RN&RO*%7HLB;E!J_':
M.W:#=R.T>7EV[G9V#J&EK_,H?@VJIP+#1PH?(JF:21@W3-'Y@[0MG(AM_$)-
M58:<E%&'96FSX%PZ`_\`(7O5''B]$3H#_P`A>]4<>+T1.@/_`"%[U1QXO1%3
MH+[;LZ$\V]KHJ^WVN;T2A3H+[L]">;.3EZ*O[/8_YOV=$H4Z"^\B><NS_P"2
MK\NT0V?\WR[1$-$508OA[#%X/XFJ_B_P:(@L7P=EB\#9RCM:KAR=O^;T1.@/
M_(7O57'B]$3H#_R%[U1QXO1%Q/&/5"*)'8/A(J0Z9P*W=)FW%"B0VZH0A3IF
MW3<ABB`@/*'+HBBXAP;TE)R[?N)?*LC*2W0F%DEY"79JREMJ4>UAV;:DV9TC
M6VXRL,9&`:<^\,`3;HR6U9\IO#M(KK"<)5&KD]`3\(ID-@>"E:Y,K1A),IXF
MQ/*>@S1JI;`BK"G=+MH,[0RJ:;=9L"BBZG.\X7=*4BN]YX9JI?I.7EY(][BW
M\_8&<_,K0#XC+IXMJDPI*\0<KN&?@A$2<#&(%<%2YM<5"B8BI-X0$BZ+WA2H
MCMJT;I(7F/7C7$6_AY)C)'*_AY:"9.VD),,C.(IPU,^BCNQ73!5)5$RI"[Y#
MDWB&(OB;A/I@PC:"2<Y%;HDML/=I%\A(H!*S=@B69&BCU^]4@E#LW$JH4SAP
MNP!FZ(NJH*"J)#B31%)`[*0.<QQ8/=IC"8?]4<>R.WWO;HBX=`?^0O>J./%Z
M(G0'_D+WJCCQ>B)T!_Y"]ZHX\7HBJ#!^`@/0'O)_Z(X\7HB\X^*#[.&)XF<J
MN<HR^>,PXX=.*_!5\*M48.AN89NC!H+)D>)JV.M2,J9P^%83J`942`/[P`#D
MURK5_"C3>L<VDS7,YGLNG,8T@#8`QM`?(N\\/>/NK.'>GHM.Y1913V4<LCPX
MNH29'8B*=!V*/(?8OU39_P#[9\1/R=Q/\S-:JS\N^BL`PW;R%N<OYNN(9D)_
ME]LW;N+P"/E5?N7ZI_FSXB?D[B?YF:J\.^B_:G_*K?BYXA^P6OI!\Z?<OU3_
M`#9\1/R=Q/\`,S3P[Z+]J?\`*GBYXA^P6OI!\Z?<OU3_`#9\1/R=Q/\`,S3P
M[Z+]J?\`*GBYXA^P6OI!\Z?<OU3_`#9\1/R=Q/\`,S3P[Z+]J?\`*GBYXA^P
M6OI!\ZJ'V+U5';LXLN(H=@;1V5W%`[`#LB/_`',Y`#3P[Z+]J?\`*GBYXA^P
M6OI!\ZI]R_5/\V?$3\G<3_,S3P[Z+]J?\J>+GB'[!:^D'SI]R_5/\V?$3\G<
M3_,S3P[Z+]J?\J>+GB'[!:^D'SI]R_5/\V?$3\G<3_,S3P[Z+]J?\J>+GB'[
M!:^D'SI]R_5/\V?$3\G<3_,S3P[Z+]J?\J>+GB'[!:^D'SI]R_5/\V?$3\G<
M3_,S3P[Z+]J?\J>+GB'[!:^D'SI]R_5/\V7$3\G<3_,S3P[Z+]J?\J>+GB'[
M!:^D'SJH_8NU4-@CQ8\10`8-X!&NXH`!+MV;0_[F<H;>33P[Z,]J?\JGQ<\0
M_8+7T@^=4^Y?JG^;/B)^3N)_F9IX=]%^U/\`E4>+GB'[!:^D'SI]R_5/\V?$
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MY5\&?N:ZD\DN)=YQ)7"Z`;`20.4[ST_&G,+^\J^#/W-0B<PO[RKX,_<T1.87
M]Y5\&?N:(G,+^\J^#/W-$3F%_>5?!G[FB+D+9P``(MU@`>P(I*``[.SL'=V"
M(:(N/,+^\J^#/W-$3F%_>5?!G[FB)S"_O*O@S]S1$YA?WE7P9^YHB<PO[RKX
M,_<T17>`16"=AA%)0`"48B(BF8```<I[1$=G8T"J9O4IU/YM3^`;^*.I5U1-
MC_[(9W\33]?L=$6<94_I:J_UG@?UDTT1;]T11TS;=W]%:S]B3=2'0:W3Y&QN
M&#%R+<[HD0TD7ZR*0[>;*NX(VW"F-R`(AMY->+,;J.QLI;^9LCX8(GR%K=[@
MQI<:]``)7LRZPN,US"WRJV=''+<SLB#W;FXC04^%0.KW']#6-?$K<L1<F9\G
MQUID7@KSC!8*0E5PFU%49<$U-L@M(M:^X60Z.(`)``1$-<MRCC%EE\W+2VTN
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M*\(4I19M2F!9Z8VZF`B&O(SB?E[M/V^?PY?=&.83=JVE&V_8/+)"]Q.%KMF+
M!7&ZM&M)V+UNX-9G;Y[?9%=9E;M%JZW$+Z$FY==,#XFPM`+I!UL)<P.:VE7$
M#:LU#BDLR%V@ZQ)4;(C2&LU;G;E`VUK-1$V=_5(&*92CF9-3H=V\MC8%S2+=
MJD@=#GSNE03*41`=>^/7+79M!E=UE=W&V>$RL<60_P`2-HJ9-M74H:]:CNA8
M7\,FNRR[S&#-K!^865Q'!-$([J-T4\V(QQ.DG=ZN]QPNVPC!LY-BS+$_$&?+
M5&>9`CW=EK4&QG;;#KIVAT,<^:H5"2=,'TE)(&4+YK1,1H98Z2VP[<FT%-@E
M-LSNF-66FJ\O=GEO$8;=LDD;8Z>=V3^S<ZF[8ZE?AV+`:YTCF.B\YCR#-9K>
M:Y?!%+VD%#A$L?:,!(WU;S<RUFSX],1R-L3IL?<<G/I=RTB5HY9EC/)[J"FY
M*?QE],M?J4'84:ZI$2E[GL7@,RSA4E32+AL`@1(5-I`V!:DLNB>+NC2V+K7F
M0;;>H6B4>POZK;'%JIUZJ4]!ST9+1<$_CW-6L$.QL:AVLQ,H-SF3:F("@F#:
M`IJ`4BMUOXT\6T6W2E%LV1+.QLE>NR%"M*+:LW>4CJC,N6>/':+VWS<=#.HF
ML58Q\L5UN,P\62CBO)5%`5N<*J!"+=%7RBI=(1"PUJT2;^*7>S$;SIU7[-RV
MDZ],/J_.Q;YB\*B[8R$3-QCALNBJ0JA%$AVALV:(K_ZSV+TW)]<6[_1$]9[%
MZ;D^N+=_HB>L]B]-R?7%N_T1/6>Q>FY/KBW?Z(GK/8O3<GUQ;O\`1$]9[%Z;
MD^N+=_JEU0TEN]02YHQ-\X*'_&KQ49HX:L4,\D4"IN,@I-K"Q1M8O)*5,E!U
MM)5NXD5$(V-$'LA*2C(JZ302J%(DLF`;BZRB+=77M5YIF.39=Z]E<8ED86$M
M-*.ZP!;MK0N&P$B@)J5E\IM;;,+EEO=RMA:X[7'D\BCI>/M35IFW\/-+X9(]
M?,E@RN6.LMRAS2KU!>JU9V4K4]<-),CJM8VZ#)KD("JR:[8H"B.X9)8ZZ&L.
MXA6.9W-E%IV+M)KEC9)\%`RV%:=B0=H+C5P:*X<+BYVT!9LZ3N<O9>OSAQ9V
M4V"`']<4Q$BE=VS?3>O2BWY53H5=D[9<KBY@:_$$1,_?N7CU<"*.5TFC1HV;
MLRN7DB^>O5B(-V[=-59RL<I$RF,8`UT&^N[/*PZ]S"6.'+(V@OD>0UC:@^<3
MNW&G3LWD+4K=MY=W++.UC<^]>XAK0*D_[O*H173[1<(2=G$*XV.]A*=+5>`G
MHR[6&QX^RM8YVS#%K#"8\QE,5CSO(OXZ/F4%4Q?F9I2:IA1;".P50XGFO'_2
M-KJS+=,97;SW\F8O&&>W:]\+&%V$B1P%`X':6N(<T;P-BZ%9\+\_N<KFSB>5
MD!AVN9(6C9AK7:=W(,-=M>9>@1K-82F$I9N4$`$0VBZ<$,/+_P`8IC;2F[8>
MP.N\3,,<SV$M+0[93FH*`](Y5SMYD+R)2PN!I5E*$#X%Q]9[%Z;D^N+=_JA4
MJ.O%/Q`9DPIAV=O^,*?8<L6J.79(MZK'NGQUE$G3@&Z[LR38BJITFO.`/N=I
MA-L*!#";DV_0FG<JU3J./*\UO([&R=O>^M.G<"5JFM,]S/(-/R9CE<#[F]:3
M1K:5^4A:SRCQSRV(L$TJ^75J_@<NY%@&ZU9Q/(S#A%ZC.+MDS/'$ONE6?-:S
M!*KE%PX327,83$(3>%3:&P9!P\;G^K),LL)#+IZ`EQN6@X'AA)+145JX"@J-
MM5A,\X@/R33;<QNXXVYW,T-%LY\8>PN%`[SJ;":[^1:>X>./O)<S$-(W*\LP
MGI997>+8826?PYP25$3"1S$LZ:A'G,CO@!-PZ9A*`;=H[3:S>K^&$#+DR9*)
MXPUN,-$;]H^&E/B&U:]I3B7<20M;G(B=B=@QF2,T/P!Q/R+T8A,H%L+-)]#W
M-5VFJ(E*3SFHBX*<NS>*+5PHFYV>ZY#;NPP<H:Y)>Y7?9?(89XY:#]8L<!Y2
M`%UBTS:QOX^T@GC)_9!V_P"P5_\`6>Q>FY/KBW_#O\NO!OJ/V14_`O?RM`WN
M-!TE/6>Q>FY/KBW?ZDM+:5Y17XDY2.4&B>L]B]-R?7%N_P!0BAKQB9"XBJU%
M4Z;P_/Y!,I$1.7I>TQ53:.)AQ--&N/EV4$S4;IM7:_G1A+R7G&,3)NG7>LBI
M@!MHE$KC7`"A*ULMQ#<8<]'6>!@W#J'DX^O71PI-+8TMCZ0J<Y7:?DIW"U1,
MTE+-8BW3L^ZK,%()R:)#-=Z9Z,5N<XI:E58F\ZRVEYJXH6U#S6\GG=FN4@VK
M<Q,XE.VJDM5YIW.SUPM]4K\()7[QPW<MB`WC9!+G$6WF]FMM6WDR\YJ%:)J5
MA-=SSQL1,'"P;AG+#)4:.<5JWK6VH2MDGKE.U5&Z.',TE9ZW88ZN./6IG68Y
M,CABBNV%>5,HF)S`1/10N_`<2?&+:6T\K)UEW$DA)HZB,/%P-M;RLL9#(F.(
M5"J!..7+9!L>)C9J4.]<HI.2/46H_O"$6'1%D5"XL\T.;G0HZYO)0*;*5R5D
M+K.IXHR'3VD)*N$Y`8ENT?2DA)F6-%6)D,&X**)$ESB1R0Q@5`"$4[366R$,
M8IIJ4`2B)1`7BW((>QR'T1"66QG.4@3<EM.8"AM>+@&TP[`VCO#HBCY4>,*F
M6N(/8'=IL5*@7%I+4X"9N#ANUC[2_,L_;J*12D1*3)V?FU:,6"10D`9NXL`(
M9XD@50@B1<FO&%1%V\"=:[S320M%LB:=`02Z@GG7\I,R4'%-U31[1VX%@P;.
M[$TYY5T9#850!(!Q,0#$5X1XFD4K[=Z#8%K=3UZ(@T<2%GL\G!-*S*I/H5_9
M&AH-9I8WTL[YRNQ+M\ISK-#F$&YN<W#;I1(N3?BPQ<Z?R<8AFV%4?0R4PM*(
M^=WQ"M$H!)XM+G,X40(U5Z&G'.>1,YQ5%JN5,#F15`A%R4XK,9)%9&/FF)*,
M@C%N&J7G21,Y%*:6D$(TR[0K<SID9=6'>`<JY$SH`S7,J!"HJ"4BW(-FL8"(
M#-28"'_IBW?\NB*GK/8O3<GUQ;O]$3UGL7IN3ZXMW^B)ZSV+TW)]<6[_`$1/
M6>Q>FY/KBW?Z(HE9TXX,8X'N#2GY%?7IQ/OX-I/I'A8<)5KYM=+NFK??=*R+
M8P+@HS/M)N[```Y>77--7\6=*Z%S$9;G#[T7KVM."*-KFD$5%">7G78N'W`[
M5O$K*WYQDC;(V;93%BDD<QP>.0@<_)\JTW]Z9PX^4Y2^2:7[:UJOB+X?MV!^
M9-Z.Q9L6\P_E/XMNC!@.6&+D_P"<P[C3<6$CXRGWIG#CY3E+Y)I?MK3Q&\/_
M`+7,O0M5SPF\8/\`+??A]VGWIG#CY3E+Y)I?MK3Q&\/_`+7,O0M3PF\8/\M]
M^'W:?>F<./E.4ODFE^VM/$;P_P#M<R]"U/";Q@_RWWX?=I]Z9PX^4Y2^2:7[
M:T\1O#_[7,O0M3PF\8/\M]^'W:Y%^U/X=""(D=Y4((E,0PEJB0;Q#!L,4?\`
M;7[TP=G3Q&\/_M<R]"U/";Q@_P`M]^'W:X_>F<./E.4ODFE^VM/$9P_^US+T
M+4\)O&#_`"WWX?=I]Z9PX^4Y2^2:7[:T\1O#_P"US+T+4\)O&#_+??A]VGWI
MG#CY3E+Y)I?MK3Q&\/\`[7,O0M3PF\8/\M]^'W:?>F<./E.4ODFE^VM/$;P_
M^US+T+4\)O&#_+??A]VGWIG#CY3E+Y)I?MK3Q&\/_M<R]"U/";Q@_P`M]^'W
M:?>F<./E.4ODFG^VM/$;P_\`M<R]"U/";Q@_RWWX?=JH_:G\.Q@(4[[*QRI@
M)2%-5$MTI1';NE`)D```'3Q&\/\`[7,O0M4>$WC!_EGOH^HJ?>F<./E.4ODF
ME^VM/$;P_P#M<R]"U3X3>,'^6^_#[M/O3.''RG*7R32_;6GB-X?_`&N9>A:G
MA-XP?Y;[\/NT^],X<?*<I?)-+]M:>(WA_P#:YEZ%J>$WC!_EOOP^[6Y\,\;6
M%,ZS2U9IUNEHRS%#G&4%<&GJ^^FTP+O*C!"=TY:R:R`![M$J@+@'*!!+M$-M
MTAQ;T9K._.7Y?.[UH-J&S@1O/P?JEO-MK6NQ<^U]P,XCZ!R\YKG5OVEFP`ND
M@D[>-HV['.`!#MAJ,-*$;=JE($F_\K7]G_G3]O\`A:Z,VM.MOJ5R-P`H1N+0
M?**KFG,2:1M])\Y3.`"&\18X&V&`2F#;O=@0'EU4J5P\Z/\`RM?PI^^T1/.C
M_P`K7\*?OM$3SH_\K7\*?OM$3SH_\K7\*?OM$3SH_P#*U_"G[[1$\Z2'E:_A
M3]]HBYC+R9B%3,^<B0@F,4HJG$`$W(80Y>01#L]O1%P\Z/\`RM?PI^^T1/.C
M_P`K7\*?OM$3SH_\K7\*?OM$3SH_\K7\*?OM$3SH_P#*U_"G[[1%=H&0>J3D
M.0[I8Q#2;(#%%0X@8!7)M`0$1V@.@53-ZD\I_-G_`(!OXHZE75$V/_LAG?Q-
M/U^QT19QE3^EJK_6>!_6331%OW1%%GB&KKJVQ5LJ[)5!NZLE!FJ^V<.05%NV
M<S$?)QZ"[@$"F5YA%1R!C[H";=`=@;=FL;G-K=7V475A:2=G-/!)'6G[;'-^
M+:0LGD5];97GUEFEW&9(;>XCD(_L2,DK3E\S#\97FQ6>!Z:@9FN2:UJA%4V,
MA!*2R;=O(@JG'-,,RF/9M&%%1L4H*R%LF'$F4%!(04S>ZV*"(:XO8\&KBR?#
M''=6[X(\`Q2MEQ,#K1T$H9V9`H'D.%=Y`(7T%F_Y@;?-(;O_`)2XAN)8R&=D
M8L)D9F++V.23M`:]0&&@W#>K2RX.<PJU^9K[^WT2);R>)J9A1RI`KV\WGBN5
M2T03MU;'K5V@=DQLDQ4HL[$J*!.;0/N"8YP$PA;CX6ZGE@%M<W=K%;QY9#9M
M;%)=!KFQ&-I>Z,GLS(6=HYCSYKCUMX5Z;C7HFUS6'-K++KRXN(\YN,S!F9:X
MF37,$V.!LH&/L3<RXI`-CFAI;N64N.%?+L.F\JU;M].M>+U,M363U*EDMW:3
MN;.:0B88(R+NKZO1B199K%6A@M(F;E`&SI0R7.`(%$NO=+PYU38VKLMR^YRV
M]T_ZVZY]5N63#MI'1L:TW#F=5SX90Z4%O5?4`@D+$VG%G1=XZWS7-+/,;'5,
M&516`N+06\N"-I=VLD';OQ1221EL(<!B:QII12?KN/;$TS)9\J6!]$N4'^/Z
M72*S$QJ;P#P*<4]D)JV&WG*1$^CR\TZ2%#<$3BB@4%-@@`:Z;89/>6FHYLXE
MF;)%':QQP`@D;0!,.MM#1^K7>*+D.::BM+C0EII#+X7-N+>_N+J224XF3.E>
M&1-+6DD-AA:'-J31SW`+5Y>'ZUM^&K.^&"6%@6R908\01(&>C@=H-XM?+*5D
M\Q<^=PDDJ1>--,)E7.'N-XIA*(AJSI'(;K3>6FR[<$.N;N2F'8!-.)&?N[^;
M<KVO-366JM0-S3+K<VS&VMI&36N)T-N8I*-W@8O-Z%%2E\'V6WO$#`\3,>WH
M]"<*(8VO$<RF9O(BMTK4Q5^$A#`CS$DWC8C(V,$(7US(1^I8$%59E*.;=';@
M`*CLVA:6MS7O@OD[IPF1V`SW^=2M@8HBZ19W`6>R,,:7:V2MAA+7DJZ6JOQZ
M1)&:F+#84I)RS?'%-ZV4=E-M*;:)2+4-TX";^W3R?2<42>-X+%&3N(6LYJBD
MK'8<HN+IB>9JD+@UI!V^-DESV`,COF3O&TV52M33@8-P,DR746_U442D4SN'
M.HV*MUG(\C86#Z'<9&X@,X95BJ]($YM[`5FZ7AXM76;MN`#T1Y(QC(DFNCM'
MFEGYBC[H!T1;_P"94_)'VC=S1$YE3\D?:-W-$3F5/R1]HW<T1.94_)'VC=S1
M$YE3\D?:-W-$3F5/R1]HW<T1=.2@HFP1[J!LD3'S=?E4P:3$1+LTWT;(,3G*
M99L]:.$U$G"`@7;NB`\H`(<H`.I!B!';L$D)-'`\QV$_"-X4@/(=V9I)A.'X
M:;/E7E7]G)PRW+$ESX@[/DW$!*8_>7%H7%DS*L(%1ZG6%7%N0DDJRXC73Y>+
MC%F:K0IT_P"1WDCD#9L$0UR?AOI+,M-9EG-SFT4;F75VU]L0X./9@R$U`\P]
M9NP[_B6\:OSRWS"*R_ETCGN:Q_;!P+:/(8&TKYWFNV\GQKTPO6.J_DN`&L6E
M6:9QX2<3--9.NNB,9V&FH)ZG(P\Q%.%T7#7I3%XD!MQ9)5%0@F(<ABB(:WC5
M6FLDUKD5UIW4EN;C*;MF&2,/+,31M#<0V@XJ.:X>:YH6IY?F68Y3>LS'+)1%
M<L-=K:U^:BAI8?L]861L-YD*UE1@UA<A/:K(VZSY#J:=NSNDO52,#H,:3=D5
M&$=`,3NHX%XXR39,8IRNJ<A3^XW>%VGY:\@RC464YMIG-,SRS*\N=5UK&\.C
MG)=C=-,7#$Z=QV2.%`Z@HNF'BSF5YEDUGG5I;7=TYA$<C@6]G44+<#:!P_6%
M:T.[:I^"F<_N@*80[&TPF.8=@;-IC#M$QA]D?9'7TFYSW2R.>0X8SA-*$MV4
M)'.>5<FK(X`R]D'\T;2QHZ*'EYSRJG,J?DC[1NYHBLTE6HZ8V^<22)PW=W8R
MG9^)$.SL$/-,BQV&+M[/9UZ[2\,+C<,HQS-E>78O#?6T=Y";>4$Q'?LJH6Y_
MP-;"Q$G8Z2\O<^9@U4.C`1U]O"DZ)-XRAD8EJDLZ6<D)V>;(J!Q#]Z01#74=
M%ZWAEN!:R,BAEJ-K[>T[,_#(]LM`>5W)M*YSK#2=RRU]9$L[XJ;F22EXV<C(
MW1'X!M46ZK6\T8.QY"9ZDL=9-RK>+7:&-=JV%YN5R/8B56L2*#Q63MEMKW3)
M$BTVJW;%2:,GK5D+,RN^93G#`F&]9AF&GM59T[2D5Y:VF7Q1]J^Z8RW:[MP/
M[MCQ&PX!^V'`'G`*TBSL-1:4R=NJKBVNKF^DD[-ML9+@@V_VK@Z5[0_=U7,=
M\"R]AQ:\6@)1\FPX'#=`%BYEYALUKMNAYIDFBZDE"5U@D\BT%7]H6B(O>3VI
M)-3.7"29CIB("?!3:"T"]KW?ZEGDNF.IA<6.:=H!/5>33;LV=*S4/$#7#',8
M-/N;:O!(/:UY-E06#^E9/+\6/&,Q:V)%AP=N7LQ"K<PP01+<%6$V<LK*-W1F
M+L631!1JPC(DRPJ%5V.E%D02#8J0#>./A_P\?+&ZZSDF(.)?U#YN$].TUH*?
M&KTG$/B"UCFV>289B`&'$-]1OYME=J](Z^K*R$!!2$PP2C9A_"Q3Z6C6YW"J
M,=)O&#=P_8)*.4D7!TF3M0Z13*$(H(%]T4!Y-<<OK>"UOIK>VD$ENV5V`UWL
M_5KS'H79;>XGO+6&ZN8S'.^)N-I%*/\`UJ<XZ5:KQ8%*=5)BQ^8['80CD$1/
M%U**7F["9%T[;L5GC"';?ZW(EC$G0NEDT"J.!01.*1#J`4AO*KR\U(K-G%A4
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M&N$(F<<%*R7,Y=*.T5`$%U1V@F11E4N7&?%X]81SQ.ZH-'='C85Y)-\6FM]X
MK$PQQ_1'@SQ>;4<2=DGK+>)E_'KG52$D>5L9<FX9N=71%N+"]QX@39-KE-NM
M;M;:G'KEL4G9&>JCX6A9A-VX<UB3;W)=5^LJY>I-5$%V:BZ"28B44T!`Y50(
MIO%2.`E-N;0V@.P0,("'XP`!V?BT11#+P<5T7TW+K9#O:\[8##%S$V9C34GT
MO2'$=(1,K4YP6U901G)*:C),R#JQN2*6!0B*/^L[$BZ(KC%\(5.@IB*EH2WW
M:-(TFX68F(P@P+II96]<FJC98.$?+NH11VPCV<]2VBQCM#HKK%,HF8^X8-A%
MDN2>&VO9'F;#/JVBV5N4M*L,66<09(1<HQD73+'0G40V1FHB1203F*]:7(++
M[!725*0Z)B"`@)%:WW"?17D8K'%FK:@&\BX:N$W4<99B_9$OYHQZB16*4;JJ
M1[S(;I<I5"F2.=NB4Y1)SA3D76><*->>04I&&O%U2F;#9(BVV.VHMJNG-R%@
M8.;4\DI1@4(`S2LOIAU<WJA5XXJ"K$W-@@)4RF(<BE&9$^WW)3;.V.\(C^$1
M$H;3#[/X=$7'F5/R1]HW<T1.94_)'VC=S1$YE3\D?:-W-$501/M#:4=GL\AN
MYHB\R.,S@#O7$_E*)R#5\]Q6+F,=3(VKK5Y_BY.Z*N73"0E'@RA952R0XHI+
MI/RDYGFAW13$V\.]L#CVO>$5GKS.8LTNKMT`:P-(#:TH*`CX5]$\)./UYPMR
M!^206++@.OFS8BZE13K"G1NZ5$G[G;,/^<6M_P"[\@/_`//.M$9^6K+&MPG,
M9#TX2NE'\X=X7$G)8R2XG^\`WDE/N=LP_P"<6M_[OJ'SYU5X;,L[P?\`14>,
M.[[DC]($^YVS#_G%K?\`N^H?/G3PV99W@_Z*>,.[[DC]($^YVS#_`)Q:W_N^
MH?/G3PV99W@_Z*>,.[[DC]($^YVS#_G%K?\`N^H?/G3PV99W@_Z*>,.[[DC]
M(%4/L=,Q&['&)6Q__P"?FX?\-Y#3PV99W@_Z)3QAW?<D?I`J?<ZYA_SBUO\`
MW?4/GSIX;,L[P?\`13QAW?<D?I`GW.V8?\XM;_W?4/GSIX;,L[P?]%/&'=]R
M1^D"?<[9A_SBUO\`W?4/GSIX;,L[P?\`13QAW?<D?I`GW.V8?\XM;_W?4/GS
MIX;,L[P?]%/&'=]R1^D"?<[9A_SBUO\`W?4/GSIX;,L[P?\`13QAW?<D?I`G
MW.V8?\XM;_W?D/GSIX;,L[P?]%/&'=]R1^D"Y#]CGF,.SQAUP.3:/_\`C\W[
M&W9M_P#MUV`T\-F5]X2?13QAW?<D?I`N/W.V8?\`.+6_]WU#Y\Z>&S+.\'_1
M3QAW?<D?I`GW.V8?\XM;_P!WU#Y\Z>&S+.\'_13QAW?<D?I`GW.V8?\`.+6_
M]WU#Y\Z>&S+.\'_13QAW?<D?I`I0\,'V:$1AFV%NF7\F-LX3$.]:R%-9M:26
MB0<&_;"11.2DF"$U,*3KUJN0#M@,=-%,WNC%.(%V;)I/@)IG3N;MS?,99;[`
M!AC!,>$C;BKR_`M.UW^:'4VK<B_T]E-K#EUO,XB>0TD+F$#J@?[UZD&,!C".
MWE$=HB)3;1$>R(["]G7=1B``<:TV#H:-P^(;*\J^7!O=LIUB?AV[^BN^G)N5
M`#;V!_<-WNI52<G;_P"2?O=$5.3M_P#)/WNB)R=O_DG[W1$Y.W_R3][HB<G;
M_P"2?O=$3D[?[AN]T1<A*)>SR<FWL&'L_B#\&B+CR=O_`))^]T1.3M_\D_>Z
M(G)V_P#DG[W1$Y.W_P`D_>Z(G)V_^2?O=$5YKW+/0VP=O^TV8]@WL+D$>R79
MH%4S>I5*?S:G\`W\4=2KJB;'_P!D,[^)I^OV.B+.,J?TM5?ZSP/ZR::(M^Z(
MH_9BN[FCIS,Z=T[2BJ]57UAD$&:+=5PHVBF[Y^[Z.58`!1P=!L($*)BE$VP-
MH:\UY<LLK.:]E!,4$+Y74WD1MQ$#I(W<B]N6Y=+FV8V^60.:V>YN(XFEU:`R
M/#`32IP@FIIMHH:0?'?2)Y?%B#9U<&YLK,;)(1IG<5%$+6T*L>4+(!:Q2>*B
MQ57+#+G0*CS_`#A";>37.K3BOIB[_EC&]JV?-&.=&PX:LP&A$E#0$CK"E=BZ
M5F/!35^76V<73S`^')Y;>-^''_&=<%H8(06C<74<7X0""OFRXYXI>J62Y25;
MRE`PT)2HC(T2I*0,)O7*E3LTG`QDQ7%&TBNU*LN]73,+1VHV<D24*<2;!U<B
MXE6+LON,RN+&\A@@M1<#$8ZR,+L(#*/(J:U%:"BJGX-9S%GUMIR',<JDS*>\
MEM7CM2SL)H8^T>V0/:TD83L<P.!-1R%=M[QP0,="OGSV)R<WL<;=/4-]CT];
MB371"<]65;GO]%))&BE(WU6;J/>?*[,44R"``)_<ZF3B?D<%@+R>*X;/Z]ZL
MZ$AO:,=ZOZR'NVX<#HJ$4)-2-E%1;\&-3W68MLK>>RDMI+5L[+ACRZ![#+V!
M#7-%2YLQ;&[90.<`ONWXXJ([LE;@&LM;5F=ECJH^2M80+<M7BG%WKLC:ZS$3
M+PYRO&LI(P<4NMND0433$FZ<P"(:D<4=,&]@LVND+)X[=W:4&!AN6N>QCMM<
M0C:9'4!&'<2O,.#VKQELV8/;$U\,ERPQ$N[1PM9FP2.`I3"97AC:FM=AHM@X
MBXCS9GCGDK6V5ZB(]$L:XCW5I@&D8WL$9,I*+QDK!N&ZSYLZ;N44]XR1SIN4
M0,7G$R@<NW8=+ZIL-6P3W&6->(X74ZU.N*T:YM"=C][:T-%K>LM$YIH>ZBL\
MTEM99I-A$$@DP/#\#HW@"H>P^<.16-]QCX9B+37Z4]S?5VUEM?/^8F`*+*MG
MAT9&Q0R22TNA%JPL8YE):HRC:.2=.$%)1:/7*T*N*9MFS+3U;:[QRX!M=(L&
M2(/B'HRU%JA:^>Q621?C76D4E;2`I45UV]EC(>15:VY,=L2LD@HE)[#=&,J)
M3;"*X3?&=A6N6&^U*>SK48VS8P:IN[[!+N3'D:Z51U!,.BG10C%@E9A)_:8M
MNJP8"Z?HKR;5-1$IW"13D6V:AE-*^UF$N=(MK6T52S1Z$M`3\*=N[C9:-="/
M,NVJP-RFW3*`)3$.4BB:@"0Y2G`2@181<^*''N.[I4\=W?*\/6KK>3L"UB!D
M2K`L]"7EA@(-1Z\;QB\;`HV&P%&/C5)!9J21?`+=L*JP"0"+7<;Q]\.<S5IV
MZQG$147=9K:T$C+R()2J*J0VAQ(M:TNQB'-?1G)QC/KP[PK-RP:NFS@6:^XH
M((J"4BWI5\PL+NU<O:;>HRT,V?FH7+J$>,G[=).>@HRT0:_.HHB0[:9KDTT?
M-52B9-=LX(<AA`=$63>ME@])K_F-_$:(M-<07$7.X(Q';,G^;I&WO(,(EA#U
MML_B(0DM/6*890$&V?SLFF#"!B!E)%+I;U0#@W0WC`4QMA1P.JM19=H[3E[J
MO."_^2V49>YT;2]SP'M80Q@ZQ-7;B!N*R63Y3>Y[F3,LRUH=,]I(<2&MV<A)
MY5YV8?\`MAGU\XG<-<+MSQ?9:I:\W5]>QU2:C@D%6Y(%Y5!NE-MTO$3T'&NX
M.OW*+:NT09*+*R\69NFY>(D:/6AS[+D%N[4NG[O4F5EK\NLS!C-=KNW%1@Y'
M!@_O"#1IZIZP(6+SES<BSB/)+\TO9!U:;JC>#^S_`%:T#_U:KUW&UV`0$!DU
M]@_^(W\1JRVE>MN552-HWJ@6F?*.\$DMMV`7:";<!V!V`V\QV`U4XLIU1M3$
MX[#N7+ULL'I-?\QOXC5")ZV6#D_VDMR=CW#?D_%_(:(GK98/2:_YC?Q&B)ZV
M6#TFO^8W\1HBCSQ1<45DX<</3^4T:]8K\M#+LT$ZW`()*/W)GBO,\]L2;*JE
M0;"8#G,!!+N@(")=H#K<=%Z3=J_/X<DD?%;,E`I)(]H9\)H2[Y*K5=::E?I'
M)79S##)<X-\<=,?[Q`^58[<.--E1<$U;,-G)+1<U>81H[J>-G8(I622G7S,7
M)(98I&*ZS!K'"/\`KSM5%-)!,HB<"F,0@^K+-!W&>ZGFT[EKA-E%J_KSQUPD
M`[0VH!)IN&RJQ>8Z[@R;2\.H[^)\>;W+>I`_"7`D;,5"6C;2IJM;8%XZ+E<X
MA!KD]DC'6,ZHE.^JY(ME$'0,81_UAA(SL@^2,B`[#&(<V]N[=PO8UL&K.%W\
ME?VF2M,L+36F"1KA_P"X3L'E*Q6E^)4.<"F;.:R[.]O:1N:/[+1M/Q*<3"\R
M$H@5W&S_`$U`=AN=;B@<H;1'9M$40$!WBB'8]C7+Y<K-K,630!CSO<"?G73[
M;,Q>1AT+XRP;AA_0`NZ%JGP[$FN&T=O[QOV>W_,?@UYS';M=0AQITE7S+-N!
M;Y`JA:[`'8DU_P`QOXC4.>'`-#&M`YJU/PJBG*7O<3S[A\"KZV6#TFOR\G[U
MOXC5**&'&/FC/&/(FFSV+IJ9*FPBLOS=M9QE79V-=\P@\>.`A#)IFB'ZS=]$
MS<H60;$1`AW9V9D!!0IS$$JPX`46N%>+KB<FXZT0]<8U9K8(FNW9ZK+/:A;)
M1S3)*IT[),BSJUCC2KLV4M<YQU2HU^B=`R#(&DT1,&ZH@F9954DU-5EM,XF.
M((E"S3+V@H6E[7ZW,V+%CNL5*1CI2:D9BZ6ZEUFOILY,3LI$O3HY@Y:'+S.X
MR<%%R8Y0%<2A81`<6'%DRAHF*?UMN]FJ;&KP&0G5TJ$VG:;!:JNC=7$T^;#3
MWB=1:#86-.:\P#0'+8KB7*H43D(5%4B[U?XQ>)2UM9UR:CMHAM7IE0#LXIA+
M.;!(-TLA8YK;:I(NR^<(>/FF;2S/O.AS%5.<K385!H/."D19+C_C:OLS=J%`
M6R2JJ=>L=;EI:RSL/6KG#MJ\^,E(J1#8DA90,DXZ#+QYX)\5)%P@,@`G!RD8
MQ6VB*=IK1/E,)1D5P$H[HAN-PV"`\O)S'(.T/QZ(JA;+".P`DU^T'N&_B-$6
MKHKB6IDLM/H)Y'C8]2MY#<XI?!/+LH`KJ]MF[=SYDACRQ&I)H7*;C8@JV%1-
M8Z:A2"(IFV$7VDN)*BPTNA!RV6JM'2+BM/K@0CN:B$6Y:U'*P23N76>&_P!4
M0;%-9X\2;YP,J1V0Q`,41$"+',@\6]"Q?(3<9<KP]8NH#$$QG5\+.&<2K=?&
M\%*IPTA*13I@S60E9(9!=,J#%$QG+DIRF3*8H[=$6:)Y[K"D=!2@Y,KK=K94
M8Y:#*]F85DZD#2JCA!@T0:.3)KF?+O&:[?F=G.%<H*)"`'(8`(K9%\2-1FFK
M)U%Y%C'9WC.LR*L:5Y&)S43&V]%)>`DK!#KBD_@V+M%8AC*."$!,I@$W((;2
M+YP?$G5;.WK[VMWD)^.M-\F,:U^4AD$I*+E+=`Q,M.2;1J_:(*MCLD8V#<G*
MZ`W,G.0"`(F$`T19.AF>&<N9-DWR/7%G<,^7BY=JG.01G$9)-C,R.8]^B"G.
M-7;=200*<AP`Q#+$`>4P!HBL$;Q'4V3CHB43RA762$XP<2;%M,2\-$270V<6
MG-OE'4<_,BZ9FCX=8CIP50I11;G*<VPHAHB^2/$M0G:)GD?EVHRD>@)QD).,
ML5>>QT,@2+DY?I<X[17,E%-#LX=SNG5$`,HD8G[X#`!%L*-OS^9CV$M#V-*5
MBI1J@^C9./68O&#YDZ3*JV=M'3=-1!P@LD<#%.0PE$!Y!T1:0R?Q68BQ38T*
MYD_)["LV)W&(2Z+!['2CE52,746;MW/.1T4Z;@555L<H%$P&]R/)K4LZUSI;
M3M\W+LYNXX+IS:T=R`BH/QA;YICACKK667NS33>7375BV<0XFTVO(V\OZO*M
M<_X^>%WZ\(8?_J2Q_L+6#'%WAX=O\R@\JV,<`^+YVC))]YWOB!V&FXO!'QI_
MCYX7?KPAOT)8_P!A:G\7.'G>4'E3\`N+_<DWI(OKI_CYX7?KPAOT)8_V%I^+
MG#SO*#RI^`7%_N2;TD7UT_Q\\+OUX0WZ$L?["T_%SAYWE!Y4_`+B_P!R3>DB
M^NG^/GA=^O"&_0EC_86GXN</.\H/*GX!<7^Y)O21?77,G']PPI;PIYQARB<A
MDS;(6QAM(?D,4?\`8([0'3\7.'G>4'E4_@%Q?[DF])%]=</\?/"[]>$-^A+'
M^PM/Q<X>=Y0>5/P"XO\`<DWI(OKI_CYX7?KPAOT)8_V%I^+G#SO*#RJ/P"XO
M]R3>DB^NG^/GA=^O"&_0EC_86GXN</.\H/*GX!<7^Y)O21?73_'SPN_7A#?H
M2Q_L+3\7.'G>4'E3\`N+_<DWI(OKI_CYX7?KOAOT)8@_=&"V:?BYP\WG,X*?
M&GX!<8.Y)O21?76V,9\0^+\R!(?1ED>%MZL4)?.3%B8S63:IG*!@74BY)LSD
M1:"`[.>*D9+>Y-[;K8-.ZTTMJU[VZ;O8;H,%26G#L'0ZA/Q+4=6</M:Z'EBA
MU3EUS:&5N(%S:@=!+:BOR+;1IJ1.4I#NU!*F42I@!$=A2[=N[^\V[`_X=;0M
M.7S\Z/O*3^#2[W1$\Z/O*3^#2[W1$\Z/O*3^#2[W1$\Z/O*3^#2[W1$\Z/O*
M3^#2[W1%S3F9%(V^F[.4P`8H#S:78.42F_XH]DHZ(N'G1]Y2?\Q+O=$3SH^\
MI/X-+O=$3SH^\I/X-+O=$3SH^\I/X-+O=$3SH^\I/X-+O=$3SH^\I/X-+O=$
M7+SQ)"F5,[Q0Q2&,8@`1(`*)@`!_XFT=NSL:(N/G1]Y2?P:7>Z(GG1]Y2?P:
M7>Z(GG1]Y2?P:7>Z(GG1]Y2?P:7>Z(GG1]Y2?P:7>Z(KK!2+U2;AR&<&,4TF
MR`P"FGL$HKD`0V@7:&T-`JF;U)T_(D</_)F_BCJ5=438_P#LAG?Q-/U^QT19
MQE3^EJK_`%G@?UDTT1;]T11/XD81[9X2Y5F-,@62L6/)V#CA=*\PVZ=+1DJP
M:BX6W3BB@"ZY=\X%,)2[1V#K'9U9SYAD=W96V$2RP/9M--CXWL^.A<'4Z*<J
MRN0WL&6Y]9YA<%PCAG:_8*[6.:\?_MI\:\M:IP87R&G:I(.7]=3:L9&&3?@C
M**+FA(8V%9VIV4D:ET1/IAG.1)Y9T"8;G.(CSFT!'=UP/(^$6<6LULQ_94:Z
MC7'?&T69@)!Y*R4EISG#TKZ/U!QZR&ZM;]U@V07TMN`>5LKAF;;P1D4%'B`=
MDV3:6AM<.V@(\-G$&^Q[:*:_\Q1K8V"*CBJ&@AR5)2]<F[92K)7G"%R2C%F'
M0*FUFZ[%&3YM)(RI%`'G-[?VA[8=!:PFRJZLGQ-8R'*8;=L9DQ=H^)P!EQ4%
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M<)%(BF8#$V[->-G"[4MK<VMJ&0.L`;-\S]@+'VMI):D4Y<39*[Q0BFVM5D[K
MC=HB^RVZS.MY'F<MU?Q11820Z.\S".^$F+DPNCPTP[0ZM12AVUPLX"O.(&5W
M;3*%6J!YJC4>EQ#:K3"LNS>V"I0\U&O<ER6^R8),Y&?<R""AD=TZI2([#G'D
MV;CPZT9G^D+B3U]L<5F6VK6B-_:8A;8@7'8*&8$$C]2GZRT?C#Q$R?7DC795
M//=S?S2ZO'&:..'`VY+7"W'9L:2('`T>3UZ[6A1FPE@WB'KE0KD1`4+'[N$R
M5BCAJH^3)K(\ES<GBRR\-E=N]"R&T94E_%G?669MTNND]K$TT<D28N72[Y4#
M%!(5NHKB"^,;P;9KNW#_`'RJ9%I>-Z]D!3A$X<N&"BP*]T8WR*>S>"Y>?L#K
M)TG8RUEFSK:KQ[8SH0Z:2*[UHW1.8ZA#*@0I%N6R8ISP[SEE[)GT,46;C8MT
M_C\!HQF4ZY2V1*I9YS'4SE6W]!8UPM@@.)S)#RL=*;6F0=+-8A2`BD4]S>6<
MF(L$L/"/G63X/.'G!L!*P5>R%C2Q35@L\UZ^S30RU)-(7&4>89DK57F<<\M[
MO,-8G&]4M-B,FGNG6>3)$U'?,:(MYY!QEFMKGR9NF-Z7C.?IF7:1P[TBVO+U
M-M%F^(VF%<C76V6!PWIBD8IZ\*S%9NATX$[-=N:.GVJ;I8`2`IM$47J)PS<3
M-?HE1-8L94Y2>QQPV5CA80KM8SP$+=[37@LMJG;-E;'^4FE;9-,6VZ#\YLDH
M,JP+.BMG$H4QT3JI`<BDCP@XJO\`C"PVR,N`QQ4*K@#A%PO)NH)B,;5[%DG%
M%'MPW6:K#<6K$CF)CHNV1,8#M-%--PHU.0`+S.X4BG/M#MA[8:(HA<:L;;K/
MB$*37<32V98*TRV_=J9!^;Q>ST956:MNK=0<*R,C&)1,+>[K#1\;)28*"+".
M.N(%YQ5,Q=:U7#F%SIZ>#+6-DO;BVDA=B;B9_$<#C;&00'M`ZIJ=M'<E%D,H
M=819I#=9C(^-L>RK"6@CI`Y.<5VKPLX=*UQM$XUAR18.%+(TZA2K'#W>NY7L
M=&)3D)^<R*5Q0LH2(-K$\8KUVNW[&TF5ET1L3>K2E18+*-RHK_RFT<.!:V_!
MK+;3,_\`[=J6X-P9K1FUL?JQ_AL#ME6R^>^K?/)<-]%C]7,D;Q`OI++_`)K)
MH66S8[A^UTW;#:7#]4V_^'0GI7ZDU-PISE*H!R@80*<>03E`=A3"&P-@F#E[
M`:H1<-H=L/;#1$VAVP]L-$3:';#VPT1-H=L/;#1$VAVP]L-$6.SE;;SR:J2\
MW9F"2I4P.C$39V+?:D8BA#"W!%1,XE53`W+_`,8`'D'7IM+HVDPN(XK;MA^L
M8FXOC=O)Z5Y+RRM[UG9S-!B.\':"O/\`XH.'R??1A[8L^L^0&E5CE4V"TE'4
MNWRT-'',F=9K&L;`DH\1:;R8&4*W*)-I=HEV!R==T;JO+Y)G6;XA&Z9S1U9#
M&*G9MPBI%=_17:N3ZRTG<V\,=[:SO=V#7';'C-`">J,6\#S>FBB/1XYQ@K'\
M5Q%Y1HTK?Z];+.QJ&/,1#3L?0KIZWE$9!=Q>K.W@*A-R9X]LU:CYM:(&!XLJ
M??.B)!+K?[ZWR[5.?/TCIAT-E>V\!?-<N,QC<X;V,,A8VM>4N`Z5HN5LS#3.
M1MUAGL5S>VMU/V;(&AH>6G]:0!KBT<XH5MN!X^8%HDUE8;@NL:$&HU<2K][`
MBU4=Q44T6E!,99DA4"$<3AXN*<.BQQ%`74+N$+M.;8&"O^%+FP/?>9W;OF:0
M,/4H230FHG=L!Y:$?`L]8<4I62@6.G[EL=#MQ?-$%G<U]HU9X<)QFAPJW]U+
M5_G$E8I*:5$5E6\M)QR[9H9K570K#',X5RX<F(4Q$RI@4HGWBB.-@X.Y;<%C
MYL]M8XWG:2T;!AK45D%>0;PO;-QCO&->&9)=NN&@4;5VW:!O[/9OKN*]+J_*
M*S5?@9IRQ-%.)F%B99>+4<)NE8Q>2CVSU6.5<I%33<*,CKBD90I0*<2[0``U
MQ*_MVV>87%BQW:-AE<P/`H'@;G#?OYMOPKL]E</NK6&Y>S`Z6%KRVM2TNWM.
M[=S\O,K7=[8PI%5F+3)-YATPBD4!=$K\2\GI1NF\=(,/."<3')K2#II&&=`X
M<BBFJ=-LDH<"&W=@^9>M>;T1Q4<0=;B:Y!3D2Y1E%8NB1*4I:<471:<E;H?&
MURM,C7.;B7J*<S)VF<@8],L@0B!6!'R@G;E`@&`J@VHJMG5;B)XBK!-CSM,2
MBZW"7=(DUYQQE<64DI4U;)C2%>PR"IYL[=A(5="S3CA61)TP'!(;?YI,G.;I
M4D4-%E&;LC9I993Q_-XS:6:QX9=XM+:9\E>:2'39*UNIN2/CUBDEYH6=$B+)
M(#'-K"!%$7S6&5WBD*F*ZI"+7\EQ$<4"=,L%C@*[!S[>$3KC6'FE\7WJO(6H
M\[8Y)D[G0@GDF\F(IA7"Q98T[--!99=98KW?(D)"B1;VP9G"Z9!>WZ%OT8ZK
MTNRE'X41HK3K)57#V,CHE(]@:*EECOV[MS6IA<B`+@L071%2GYLNT2E(HRKY
MPXK(['+-I.1BS9)]1XZ-<6>6Q'<++9:]8F>/Z),*6&8CHU\F6P2EDN5C<1B"
M"3-J2/<M@6$%!05+HBW!A3,&8Y;)M<Q]<J_+H0KBMVIY-R<Y3K$R=H2;!TNM
M7WZ5L>+FBUT)A!JHB9H*"!43@'-F,)@*!%-L%-TP'(8H&*.\01V&`I@Y2B(#
MR&`!]CV=$4+(#@SA:E,Q4[6LFVI)\"3/UL&R1[&Z-[._6<3*MKG6;2QO7;.J
M2UF1E@2*#1,S2/!$#(H"8VT"*RN.")D]AC1C[*3YVN5LR8MEC4YFS:)L8)'%
M+:KM7#>*L;"1<%C6^)6G2S%>)&?G>+_S)2IE*199DK@ZIN2E*<9Y;IZ$3I^.
M:SC!-O&1\29&4K5<3G]]L]3."94VTL[F&ZRR"8%3*:.1`O()M$6'CP4Q,TY=
MO)VP^;CLKS'OZXT;I&FVR='BZ^QC7,<X1YV`:M92SV<9&>,0Q'K2/=21T^;<
M@4#`174_!17',5ZNOL@S*]=:-5B0[9"O0S689O98E4"S.Y";Y]8TPA)JTUH9
MH@=$A8\#*%`5@%/FR+8K'`,U&5RIM6&34F]RJ>8)K,J-J^CZ'-#O9N?KDY5W
M\,>F)3;9NWB21LZH9(Y7IEP6(4YC&VB&B+6[7@LBX^4DI2.R.^9K3-G>RTL<
M:LT?.7L#(VB/N;R!,ZD9UV=%Z>?8`";P@%109G,F1H"HBN)%CS?[/ZC,D(^.
M;7VP*0[%G9VR;63BV\H\05M2;YW(N63UQ+`@"A['+O7VUVW>*)I.`:('013)
ML(MC6#A+AI1Z^EH>^3%;EG#JP/VKIK!1+A)JZG[#DJPK`JB5=FLX024R8Y;C
MN*H+F1;D,15-4PJ%(M^XPH[?&6/*ACUK)J3#:HPZ<.A)KMBLEGJ::ZZQ55&A
M'#LJ`@"V[N\Z?D+M$1$1'1%YF\=?!?Q)<0V88:\8?D,*-:PQH<3779,AS]QB
MIP9=E)2[IR=)"O5Z6:'CQ0>I;AA4`XG`P"78`:^?N)_"&]U[G[,UANK2"%D;
M6X7DXC04->8<V]?5_`OCSDW#'3;\CS*TS&:1UX9\</9]GT-&)X)/.:"G2H7?
M=<\<WIKA6^6&4?\`P4G7-O#7=LZHN["@_K%=@'YN])FI=E>82$DG$YD6(U).
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M3L$$P16(`<XH8HBGK?=!\!9LASP:AS2XI+&]KVQQ'LF5::BH#CB!IM%-NY<F
MXJ?F<@UIIN73.GK8.MYJM=-<]:01N%"&`MV&A-#79S+UW.??,)A``$PB([``
M`$1$1'D#8`<OL```&OHQ?)"X:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HBO%>_IZ%_\`>C+_`*\F@53-ZE6I_-J?P#?Q1U*NJ)L?_9#._B:?K]CH
MBSC*G]+57^L\#^LFFB+?NB+067KN:DA*S+I5-*(@:T[L$B<(QI(NBLXU%Z\>
MF0(NF8ZIRMVPB5,#!M-R!V=>2]N8+&TFO[L5LK>"21_/U&U%/A.]>FRLYLQO
M[?+K=Q%Q<SQPLI3;)*]K&`UY*G:HDPO&YC6?5QDDQF'Q3Y79V!_6A=4UDW*S
M:U<\DG+GLH\V;S()#1+@4P.!^<*F(AR:TB'B3I*Z.76L9>;C-H2Y@:=K&L!?
M(6\@=U=F*HI78NB7?!GB%E[,VCEMX)+O*!"V4->UG:33AI8V'%6KJ.(.^E:+
MI1_')07U?L]F<-[=$1=:J,;D!$9G';5DZM%'F)=."C+14VP\YYUCG<HH4A2F
M,DL`'*82``[=3'Q0T[<0S7;H;FVDBA%P6D.D<ZW-&QO:`!5K@6D=;>3R44WO
M"35EO=6UE#):,?=W9MB&/:\V]PUM9+68@U9(PAQ<2W"&N;TKNN.-B@LJ\\GG
MIK2T=Q]N&COJ<XQF=.]MK&$$I:!:*UDK11P#<*VB=\*X'YOHY1$!VAL&6\2M
M/-MA>.9<"X$PA<R5AB?C<TO%8R2X?PVN+>MM`!W*K\'==29I'DMLRR)EA9<1
MRQ7,4D)@[8PR$R!H&,R4!``PN)::T7;#C/QNK88"L,)E_+O+-%U^2BGL50S/
M8916VP;ZQU2#<29&!4FUDL<3'+':,S!OG,3=$2F$-77\2=*',;>S:9G.N^QP
M4.P^L8W18MF]T;:G=MKR+SCA%Q"FM;C-FP0M@M)+AKV]M'7L[8L9-)%4?X#W
M$2$U%!LHLTQUQ$MLF2-FAX6,LL-*U$88LY'7''P5AVW//H.'46FFB_:`=559
MLV%02A[HI#$,(;#`(Y3(=3V.>7%S;V%O<6CK6+K]IN[8NV-']4MVCE6N:FT9
MFVGLOM\QN;BVO<ON6/D8;8]J\QQ.I*XT+`-I&$TIL.];(B;\^GV/G6$D(B8C
M.E/6`2,;&Q3QD9Y&/EXN0:$=(-CHG68R+15NJ4!$2*IF*/*`ZV9:FK78LLLZ
MB_JT5:K-5ZW)WBQH4^F1TVC!QKVUVQU'OY9M6Z^V=(IK2LVXBXMRX(V1`RID
M4#F`-A1T1:R>\86$XV-M,S(9WPRSB:196U-N,BXL=,39UFUO!>`UK\RL)]UG
M)KC'.=U,WL-5QV[$%A(1;K0M\TY326;+QSA!=,BR"Z$7%+(K(JI@LDLBJFV,
MFJBJB('*<HB4Q1`0$0$-$6IK!Q4XLJ=OD,?VC+^+Z]=XBJR-XE:K,2%9834;
M48B*<STI/O6CA,@MF+"`9K/U=X04*P2.YW>9*)P(K.UXRL&O:U"W)KGK#*E4
ML=G+28.?-8*@A&R-O,DW<>K**KD43)S16SM%8R"A2'(BLFH;810AC$6Y(W(;
MF:;'>1,K"2;1%[(QBCADPB'**4C#OW$7+1ZATVY@3>1DFU5;KI#L.DLF8I@`
M0'1%WO6Z<]\8?HB,^"Z(M.Y\XBI/!6)[3DY>OGN*\&$4QB:M%-JY%.)VP6&6
M9P,#'*S,LBE&0C!Q*R"0.'BXBFV1WC[IS`4AL!JG4^4Z,R*_U+F[I6Y7EMJ;
MB8QM+W=F9&QMP-`)<X%U7`5)ILHLEE&37V?W,>2V`B=F+VN=5]<.RM!O&_EV
MKSXQ']L5'9!XF,0\,%HQ9+U*W9H@E;#395I'+OF2T$^JHW*G7*1CIRH5U]$U
M*\Q;1XBV*L895FNR%9VU19N6BZVRY%:3:DR&]U5E;62Y99N@#WO<&.:VX\PQ
MM=MD+OUPWS/UEC<TF&2YG%DM[4W5PPX`-P='Y^+H'^'NV;ZKUI];ISWQA^B(
MSX+JRB>MTY[XP_1$9\%T1?%S=Y)DW</'KV(9LVB"KET[=Q\,U:M6R!!47<.7
M*[<B*""*91,<YS`4H!M$=FH#7OD;%'0R/.%H)I5U*[SL``!KTT5+G8&F3"Y[
M6#$YK?.+:@4;TU+?BJHUV;CCQ]77DCT1V\NE9KI8@UUR%182H6*A4D)U9NDP
M)+SB4DBM*.4DG:2[M");R*S%LH51<I`,`:T#-^*F@<AU#!I7-KYD.?WC,<$.
MPG"786AQ&S%4&M*+9K'1^HLQL)<RMH"+>$.:X.!#NT8*NI_5H13^E2<-;)LH
M[`58B'9`?-$9L$![`AL:B`A^'70*4`V@D@'8M:;CPCM&EDE-H//\RX^MTY[X
MP_1$9\%T4K0G$KQ6I\,N)YK+5GAWMABX9RS:GBJ]`Q:\DNH]4%),R93--P")
MC[HXF$I0(!AW@$``=JT3I2XUOJ&/3ME<V\-S)N,AHT?":K6-8ZHL](9!)G]R
MQ\L$6PM:*NJ.8470L'&36JK@B!SW-G-'1-IA6$A6:TYB(5I8IB8E6AG,=7&Z
M;Y%DV0?")!YY18Z**!"&,<X``;WLRS0F<YGK&YTKET7K,MN?XDD>V+LP?XAJ
MW%6C:D`$57BO]>9+8:7M\[S-[+:2=A+&2`XBZE6"CL)VF@W%:NP5QXN,C13<
MV0(2.J5F77*(>9$ZY(P2Z8B"B2X*N95Q(-UTBB&][E0H#M$#`'(&4U/PWN\D
M=7+K@RP,-6XHL!V;FXRX!HZ7`CG6+TUQ#L<Y:#>,;%</%"&M>YI/2PM)/P-H
MIJLK[)22`.(Z0BWS<VPP+-6,4N0=H[-HG10,7;M+L_T:YX^VN;>0PRL_C'E$
MD9W=##B_VVKH=O(V5O;V[QV7-V#F_O.;0+M#<9X2[AEVNP!V[/-K`-AN7:.S
MH_(([=67"A+7XL5-G6=L/.-JNU(<'MPAP.WJMVCF.S=R[-NQ?/UMF_848?HF
M,^"Z$DG:=E/]BI<0XEU`'$_[#XE4+?.E$#%68E$!V@(1,8`@/;`0:[0'4*%#
M;C#XC<MX=CJ+8Z8K7SLVC'+E@M`2=.B9E1LQK6.7AXF3C#F;"I'KQ$Y,(.UQ
M3#_66:2Z)O<G'15!Q`HL`><=.892*L$;6:ECA:QQM:N4PDZDY%T[0KGJ=4\F
MR2T9>86,K8KQ]PDGV.BN4(Q-4$!C91$XJ>Y#G2I)J:K*:;Q@95&BYLG+=$U)
MXXI%=F[+1'U)C!DPL9GEOMU)J\$2)7AFJ;IVI.PK4C0S9147C=R03B4XCHBP
MJO\`'9G9*$A6TK1*U+6*L1J\/E!Y/L)"F3YKG5TKH>U%85)O5Y-")%^PHIE&
MS=9R`E6DD`-L2((F(N[#\>N3K<A-.6^.(F(8UR5$[Q0KB-D[$M$%R!CFJ-(1
ME%I0;]DULK@MQ4)(HN543MNC;"$`YRBF19?CWCPEK3>:'59GZ*V+*W5V4F).
M:KUC))HUIP1E(24*T=N9>N0[!45"QZL8](DJL9O+$,D(E#<(<BFV:W6`H"0R
MK,``>4IHF-V`;L<I1:]GD_<T1<2VR=,8"@HP$3"!0`(B,VB(CL``_P!5]D=$
M6J*[Q.TFT.'K:/M<<P!L[9,V+ZRUM*JQ%F/(RLK!L'%+E[!&QT=;V;Z8@WC5
M)1@HOOK(#L`2B0QR*\#Q"4HLL6!')6.?/!F<V_%CYQJ>^FUK<C%Q$^HX5V]'
M;'AY*;:(.$U#E4347(`EY1V$7:6SI6T!7$]XI'1V:THVDY`CBKGBH5W"ILE)
M)E.R91%C#/6Y9%#^1<G24,*@``"/)HB^4?GVH2SQ['1F1,?O'\;+)P3QJD]J
MPJ$EU*ZQMI(]$#`4KMP-8D47^Q$5-C50%/WH#L(NDAQ&T9W*>9V61:(_>EBV
M$XN#!:MO6K2"E$9]6/G7TBW(I'-(AT-6D"%<'5!(%&XE$VT2[Q%W%L^59$&&
MY>Z2_4E%:XG'MXA2MS#ITE;9=&"KK]-K%D>.?-4K+N2($=;G1P-V3\@["*RF
MXFJ6C:;%47MLBXB0JP.BR\I.UU&#J*3R/\Q>=8IO<Y6.:5AY-0WK/']+:)NC
M+HB\3`2[P'`I%E2F:8%%1XBK>\?I*QTA'1,@DI(U!-1A*S!S)P\8](94#-9&
M64(8K5`^ZJN8H@0IA`=$5%LTP#9!=RYOF/V[9JYE63EPO)4]%!!Y!%`\XT65
M45*1-U"D$!=IB.^V`0YP"[0T19&UO$D^:MGS%]#O6+UNB[9O6<?#NF;MJX3*
MLW<M72""B#ANND<#$.0QBF*("`B`Z(M#91XL\.XGL2-=R=D&%K-B=Q;>60CW
M$"_6,I&KJKMV[H#14,Z;%(HHV4#9O`?:7E#E`=:?GO$K2.DLQBRK/;X6]P\8
MBWL,9`.UI#J<HY.1=!TQPHU]KC+QFNFLK]<RN-[FODQL;U@=U'"HI\O(M:C]
MH'PM;1_^^*O?)VQ?-W6#/&OALXD_S0;_`&7]"VEWY=.,#C7^0X:\@ECH/D5/
MO`^%KZXJ]\G;%\W=1^-/#;O1ONOZ%3X<^,'<7_%B^9/O`^%KZXJ]\G;%\W=/
MQIX;=Z-]U_0GASXP=Q?\6+YD^\#X6OKBKWR=L7S=T_&GAMWHWW7]">'/C!W%
M_P`6+YD^\#X6OKBKWR=L7S=T_&GAMWHWW7]">'/C!W%_Q8OF7-/[0?A<3$PE
MS%7?=D,F;;7+"/N3AL-LVUP=ANT/9#3\:>&W>@]U_0GASXP=Q?\`%B^9</O`
M^%KZX:]\G;%\W=/QIX;=Z-]U_0GASXP=Q'TL7S)]X'PM?7%7OD[8OF[I^-/#
M;O1ONOZ$\.?&#N+_`(L7S)]X'PM?7%7OD[8OF[I^-/#;O1ONOZ$\.?&#N+_B
MQ?,OLAQ_<+2ZR2/TRUM,RQR)E.I`3Z:13*&`I1555KY$D4@$?=',(%*'*(@`
M#JN/C'P^GE;%#FEN*\KHVM/D(V?&K<GY>.+T$3I9,A<0-U)(OF4J65C3E&+*
M3BGT9)QLBV2>,)!@#%XR>M%B@9)TT=-RJ(KH*%'D,4P@.NCV]W#>6POK*:&:
MS(!JUC#L(J#N7'[G+KRQO797?6YM\S8X@L>T;"TD$;A6E%VO.SS_`-'_`-#5
MN'_Q?9U5A8=[=OPGYU;<3+MFH]PW&@%/)1<S3;\Y4BF,W$$2&(0>B-@'=$XG
MV&$$_="`CV1Y=2BX>=WO;0ZJV\5HB>=WO;0ZJV\5HB>=WO;0ZJV\5HB>=WO;
M0ZJV\5HB>=WO;0ZJV\5HB^B4Y((G!1,S<#!M#W3-J<-ABB4P"4R(AR@/^C1%
M\PEGH<FU#JK;Q6B)YW>]M#JK;Q6B)YW>]M#JK;Q6B)YW>]M#JK;Q6B)YW>]M
M#JK;Q6B)YW>]M#JK;Q6B+F,T_,FFD)D-Q(3"0`:-0':?9MWC<UO'[')MT1</
M.[WMH=5;>*T1/.[WMH=5;>*T1/.[WMH=5;>*T1/.[WMH=5;>*T1/.[WMH=5;
M>*T176"DW2LW$)G%$2GDF91V-T"CL%<G8,5,!`=`JF;U)M3^;4_@&_BCJ5=4
M38_^R&=_$T_7['1%G&5/Z6JO]9X']9--$6_=$43N)6&?V*O7:OQ:15I.?QS8
M(6,245*W36D).+EF3-)1<_N$4SN'!0,<WN2ARCK$Y]:W5[D=[9VC`^2:TGC%
M32CGQ/#/A_B8=GQ<JS.FK^RRO5&69EF#RRTMK^WF-!6O9S1N/P4:'+R>J7!]
MDR&G:@\=(Q:;2.>1C50`EFRI*[$2&$YZ%M(H)D'><@?)U@5-S:7*=,.=`!#E
MUP3*>$FHK&ZL8W,C:(&-&(G:QK\MD9*UI_5Q73\6S=L:-@7TGF/&W2,ME>QS
M5EGEGE<TNCD>^24YE%)""YGFX+*+JN.[:1YQ7:3P;Q(RN,;-0WT&ZCHQ#A_I
MV,X>LR&0(64@Y:^TNR5PZMC@T6Y0)78:<K\88Q`7,"G/`?G"E$P`-P:-U\[3
MLV46L,_JC-/16(9VQ!?+"^&CJ^<:QL`.W:02=I*HMM?<,;745KG>7W-LZ>?4
MUQ?/O!93,D,4\<P>R1FXEDKR,1%:8:&@"O\`:,'YNG'LWE,E(BT[1,9?3M9,
M;)W*',\;U=MAB3Q2U<JV<R*<&>3.]?@\51*.P&Y1*4PGY-9',]&:HOGOS^6T
M8V6XSN*0QXJ]G'#9/M!4=+I`XUWDA8W*.(/#_++,9()ZY+;93)&;_LG-D-R[
M,H;QK&QNZU"`YIV;:'D76I'#+ENJWW%"#N,AG58@9/A^M%CM;2?;E2BW>(\?
MS]7G8-.&43+*2#N3D91,S5=(O,<T!A.)>0-6\@X?:IL-099ZQ;Q/MF2Y>Z0F
MG_T%F^-^$_J@2.-:;^5>C4?%/0F9Z?S>*,&/.KJ#-XX(6-HV=N8WC9(7`C^[
M+8VCM:>=MJI<8<I=RKU5R"\L_1HW(F0[[D"V.7"3I-\BQ&275B:*4SE$12%&
M*KK!@&X`[$Q*8.SMUT_1>77]C;9A<9OULROKHROJ-G5V,#1N:`T`4&P[]ZX=
MKS-LFS>_LK'(9C<9?E6616K&$8&L``=*#2F,F0NJYU210'<O#JR5W)K"-Q7$
M0M8S"IDR#X5V\<UFZO8+S`-*&RH'#%Q*T_--4E(:.7;QTI.V7B'1CY,KXB#E
M=6258+`L1P1J17<%I2W0YX.N*RSP-4>8_8Q^+*QB%P]SI@O'V4K&KE"TM<H.
MI7",DSJ+6T!?79J,\DW.+Y][YT<N99LT0NJR!D"GY]-(BV%:<#<0,[(\0%@2
MX;'4''9.QO7L3Q]=I^3,+H7'&TNQB\YQ2UMX8YB48)UN`Q8^:9$02EFUB!O8
ME0L$TH@4PE(DH12*N^%^(%[)<%'F`R+"&PU6*,PXDH*EW=Y5:ODR-B4Z1'DQ
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M9C3T\5CFC+BZ<YD+-@<TD$`[]HVE>$7#FRXO5>-]/)5AX3\F6+U"LD/<J]E2
M3QO-5.-FY3(Y%,<9.69)686*M:J5SQM(H-F+=!,J=:7I[519%)NY$Q]CX;N@
M9P5R^VSAIMM4OEF[>T<<1M.P$79GM=\ANL1)J3A)V;EB=7"5W$+,G6-+S+H&
MVH%QYH<V8;V-Y#'^O3SN5?JB5`A3F*0V^4!$"F`!$#``B`"')V!`-NH5*^>T
M/P^T/<T1:PS%C`F8J&\HIIMI`B[EZ[+D=RT6K-U]VI7IAM,I1-GA4G3%66KD
MFJS*FZ0!4F\40':.S=-K.LM/-U=I:\TPZZO+`7D>'UFT`-U%0UK#7<3N)')L
MY5ELBS1V29K#FXA;<,@=4L.YU12A'*.CGH5YXW#[/[,;^V9"DHY.HWYW=[)1
MK3'Y-C;2]QEC;'#ZJHPW/++800E73>V3#5:(VJG<H/TIEOS"*HH@00+\K6/Y
M<M<:=UGDMYE%[EV99+9R8YKC-(R<Q=60.ZM&X6MILIL`.VFU=F;Q1RB^R6\A
MO8)+7'$6Q1Q.+6N=A(':<I()K4FIV#<O6`YQ..\8V\80Y3`78`C[([I=X"[1
M]C;R!K[3F+#<2.C-07UW4%:"N$?L\RX!&7F-IDQ=H1MJ:FM5PVA^'VA[FK:K
M6*V>KIVAHNQ<3$HT9N")E59I-8%\R.9,X*$,=K-PDLD<`43*;8(;-H;?8UDK
M',XK"43EI$PW.CZCO*W:L?>Y<_,(3`!&8B=H>T/:>FAV+S_XIN'^=DX9I;[%
M84[='4F.<(Q;V<K=%7]5HQR9/I"2(*5EDFDDH*10.<A3#N@`#[D-=:T7J>RB
MF=!8V\T=U*1NFD#GNKU6DXPZCC0$`BM=X7*M9Z;OO5F37%S"^"(';V$=&-IM
M<!2E6C:"0:4"BE1$8S"5)B^(;-31Q8\6V2>;5+'U'KC"LP\E:7,D20W[;)/(
M^/@5FE7BVK-19N=DY7.\,(;Q"IEWS="S>>ZU)FK]*:;D,&?Q6SIKB20RB.&F
M^,=H^5CG5_:*Y]E<K<AR>/5.?F2;)I;D0P0M?&7W!Y'N:QC7AIYFD?"MQUS[
M1'A_8LT9>%P?DMG!@121=/XZTED^@PB"\IOS#E@2;63-S$=#NGIVA#J.A;IE
M%--43>YUC,>%.K'8I;S-K-S0YPWQ[QV5-S1RN.VM.?<MKR[BMD$,H98Y1<1O
MH:$"0T%-NPDC;\"V-)?:;8_CE)EE]#N3@D8#G$W\>Z=P**R)T)23BS(F%%=^
MH99$(5TLX#=,+<B!M_EVB77QP9O'O;<W&:VC8CMH,/6%*T&SY5EG<8;9U88,
MON#/LW@BFVE2O1B`EBST!!3H,W4>$Y"Q4R$>\YDSM@658-WY63HS91=N=TU!
MQS:ADSF3$Y1W1$-@ZY+F-H+"]EL@X/[*0MQ#<:<RZY:W!N[>.YPE@DC:["=X
M)5MNUQ@:!59BX69Z>-@H=)`7\B5H[>$8=-=(1S9XZ19H.%DH]N\=IF<+B7FF
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M(5"+/'.N?<JN%9-0O-B)`!,Y%O?`^??I5<Y"BY2,KU=EX*9>EJS&/:R+!_-,
M6\81_.G<Q\P0'JLS5I@Q4'RHIMS'5,0XH);2[2**SKB:RZTQNR"?I./$!DZ-
M'()76UU6P)HQ-I1HU%N<A-VJ+8,DHT49NT6\64:S;)IE3DTB&5YT3'2*1;TP
MMQ&W6WY,KN,+1$(&/(5VW2TS)/F,FQGF$E#.5E(M<QCH1T2O$3;1JL5--)L8
MR*B8@=R8X<WHBFT0_-G*;9O;A@$2B!M@[!Y0'DV[!T1>?DEP23KQ,D4CFE1"
MJL64#`Q->-3I!PBG`UV6M$G&OGRBMU*@%T0;V!!D=ZQ18M';:/3Z4U7$YP`B
MR^(X/VS&41>2%OA'T:A.J/TH%O0$&[!&(1O.,[U'1319_.R;M$32.-B$<@J9
M9J!'IBM4&Z21$]$5(W@ZCT9J*E9.Y,WK>`?PA(R.:TMHS0?5ZN6^/MT6VLP+
M2CQ.:M#ERW50>R8$2*X2%,01(*>PY%BZO`E#*.H$Y[LU=Q\*9,HQSZG+G;ND
M"52@U]3I+)E:X^)DEU7F/FZA>FMW"231RLB0@*<VN4BNY.#`CI@W93>0FCL`
MB&L:]Z)1DDP5.S<91%L@BN^G7[]Q#(L,F'0YM\J\>*BS(HJY4,<P`1=^-X/2
MQV2&%X+D,@Q438%IV+KS>GHLE6A7>18/(CJ*%\VF$V2S(C^"3124,S%T1-4Q
M><%)-)(A%><A<,MJN:61(6,R\-?I-\L\]<CU0]+3DA)8+?ZO)6,TQ,EGH]\_
M9,T8-4\3T,8YRT5?K`LLNF4A=$5H;\'32+<UZ5AKM%$F847Z3A2<QW%3L/+-
MYM];U99P^A'4B1!>60C[@LG'K+G7(U61(8Y%2&,GHBME:X)(*M0LY&%M$?,N
MG\?:HZ,=SU9DY,C4DZ]QXXCY"17<VY2:/,,T<>HD66CG<:`F6WFQ&P(D*)%+
MRC5U>G4NJU-U*FG7-<@H^'7F18-XSSFLS1!-1X$<SVMF153![E,HFW2@&\8Q
MMIA(O+WCJX*^)+B(S)%WC$<SA*.J;"APM<,CD*5NS*P&F&4A,.GZA48""DX\
M8X4WR0(F%0%!$#[P!L#;P/BAPBS77V<LS*RN>Q8UK0!7=04)^-?4W!/CGI_A
MGI.[R;-;.]N'2S8G&)H+2"06@'>".6BA?]UEQQ?&CA:^4.3_`)HZT+PUYZSJ
MB_J!RU79Y/SAZ+#R!E>9`;*=6/F'/*#Y0%3[K+CB^-'"U\H<G_-'4>&W/O;S
MY51XQ-&=UYE]"+[Y/NLN.+XT<+7RAR?\T=/#;GWMY\J>,31G=>9?0B^^3[K+
MCB^-'"U\H<G_`#1T\-N?>WGRIXQ-&=UYE]"+[Y/NLN.+XT<+7RAR?\T=/#;G
MWMY\J>,31G=>9?0B^^0?LL^.(-@>M'"URCL#_O#D_E'M?_9'4^&W/_;_`)4\
M8>C#_P#B\R^A%]\J_=9<<7QHX6OE#D_YHZ>&W/O;SY4\8FC.Z\R^A%]\J?=9
M<<7QHX6OE#D_YHZCPVY][>?*GC$T9W7F7T(OOD^ZRXXOC1PM?*')_P`T=/#;
MGWMY\J>,31G=>9?0B^^7<8_98<:IWS-.3MO#"C&J.FQ)%9I-9,<NTF!ETP>*
M,T%*JDDLZ3;"84R&.0IS@`"8`$1"T_\`+)F4CNT?/"91REHJ3SD\JID_.)H]
MC*-RG,BUW]1I_P!Y'D)7N-@#!D!P]XZ88^K\O.3J:3@\C)2<V^66%S*.2$*Z
M/&1@JG8P,;O$]PU;@!>7>.)U!,8?I#1.CK?0^0_RZVD>^0@8L3R\5IMH'$T%
M=P&X;`OB_B5KV;B-J(ZGEB9#&PD-B9&V-V&IPXL(!)`IB)WG:MV[INU_P:V]
M:.J``CM`-@[.7D$.QV_Q:(J[ANU^Z'=T1-PW:_=#NZ(FX;M?NAW=$3<-VOW0
M[NB)N&[7[H=W1$$HAV0T1-TW:_=#1$W#=K]T.[HB;ANU^Z'=T1-PW:_=#NZ(
MFX;M?NAW=$3<-VOW0[NB*FP?W=G^GM:(J[ANU^Z'=T1-PW:_=#NZ(FX;M?NA
MW=$3<-VOW0[NB)N&[7[H=W1%>*\4WGZ%Y/\`YT9=KW\F@53-ZE2I_-G_`(!O
MXHZE75$V/_LAG?Q-/U^QT19QE3^EJK_6>!_6331%OW1%H/+EM;5(TA+R*4>$
M3!UQS.2CIS%I/UF[&/3>.WBI-I%%U`2;-S&`A0VB(;``1'9KS7LT5M9RW5PZ
MD$3<;O@;M5^TM)+^]AL8&X[F9X8QG[9=LI\O(HOP7%IB*R.L:LH::B';O+B4
MNK1DC4UX@+\D&Y=-9+S@*T>0L&=%=BJ!0=BD)]P1+M#6H6FOM'9O+8L%VX39
MHV1T30TN![!X:ZK]S>LX;]ZWJ]X4:WRUF87DUH"S+C$VX)DPN9VK"Z,!FPNJ
MUIH1NW+8UDRY6ZD>N%G%ZXV&UV)E5(04(9L^*YFY%B^DFC=4S1)4K5)5E'+'
M!53=3V%[/*&MGS3-\LRRZM?7)@R1UPV(.;*)/.8][=HV`T8[J[PM2R_),YSE
MT\F6,DF?:VQG?5KHS@:]D9;A)VM!<TXAO70K&;:C=2QZ];<0DE'RU=+:(Z9+
M6S-H1U$GE%H8!)*.6K=F5^$BW.06PF!<"AO;NZ("/CRW4N1YJV.7+9V"TN8W
M/+GN(8[:"-M>0M;\;0O9F.EL\R2[$N:PM=>PWPLS&)@V1LDD8E!+"QU"6/%"
M:U!J-ZN"N5Z\E;8ND&6KYK%-5J3N,<V2AD%F:]>AWS6.D9`9)),T>F1!X\(7
M=,H!A`1$`V`.O2,]RZ.]CR]UPUUTRW,I<P]4MDVNP_U7_*L?#I[/Y<GN<]LK
M9S<HM;F.UE+S_%CGN3C&".@=-2,%H<T`$;A5=JRY/AJG4YN[37J^E5Z]#NYR
M5E&<*UD"(Q;),RCERB1DDNHZ%,A1Y$]XPB&P-HZC,,[R_*["XSN^D,N21M!$
MD.TM%*D5V[0JK+3^;YMG4&099!V><3$M[*;J&3;1M:T+:[-_FUVK6D;Q;8OD
M*;=;FC+-V=?QTE&O+@A+T>6B9F)0ED$',(Z-`2<8WE':4P@N06ATDE`7V^X$
M=@ZPT>O=*29==YLZ66VM;.".682CK,CD%87!N\F8<G+R+;;SA5K.TS[+]/&T
MC%_F#I(H*7#)HY)HSAE:Z5O5:(G;"=PY5T;'Q>XEJC6N2$L_(HRME+#(T6[B
M\=S,X@C205206L4J:*B'8PL>U56*"YG`)\SM'?V:\5YQ&TCES+>2XO)7V\^7
M&^Q-MWU;!B#2[9R-KB^`*K+.%>M\X?=-M;!L%Q:YAZG*V:YB:WUL`D00E[FB
MC@*[34C<N[%<5F-YF[-\?QH+KV)TT;22!C8SG$(,\(\()F5B&PKPZ<.2N/-F
MQ)\=4K8YA``-MY-5VG$+2MWFO\J@EN'778,E.*%S&,CDVQ2O<=F!XJ3\&Q6)
M>&.KX,E=G\\5LW+FSR0@MN8)'F6,_P`1@B9(Y[G1F@#:5V[5O%.S*JID62:5
MU9%4@'261BH]9%4@]@Z:J9#IJ%'ME$0'6ZA]L\UMY6SB@..,UB/0T_M<ZY_V
M5U&VMPPM;B(&-O9R5&_%$>LUO,X[US]8W'H^!_0K+Q.JE">L;CT?`_H5GXG1
M$]9'([`%A!#L[&V&9CL]CV4NP&B)ZQN/1\#^A67B=$JM4YJSW$X/QK8\F6.O
M'FV,"6/;M*_5*S'O['8YV:D6T-7X"';KG:-`?2\N]10(HNJDW2`XG4,!2CK%
MZBSO*],Y9+G^;2=GE5I:LN7RDD=5[PP`TV4!*]F7V5[G=]%E67LQW%PUSF=&
M$5-/(H/XG^UMP;E#/.->'=6K2E7R!EF,=2M&,]B&<M"3K((,UE@IQHJE&,'I
M*-=XIN\)"32Z""#]]&O&_-$!`JJF8RV$YWD]SG^4.,^2V4D+'\S77%"UQZ10
M;^8+SYL]ECFC,GOB8[V>,2PMZ(?[T=()WUW<E%Z;>L;CT?`_H9GXG5M6T]8W
M'H^!_0K+Q.B+KN;6+1!9X[;UIHU:I*N'3MS&1S9JU;I$%19PZ<+$310;I)E$
M3G,(%*`;1$`#;J6]KB'9EC>DDBGP4HJ2?XC:->Z2NS#_`+U&VS\:N+*V^D"M
MD4[A6Z\$,-TO]&K]<LE#I03JR)(XDS-H2R1Y!PFDY37=(Q:,@LQ;'*HN5,#`
M`\^S;BEP^R'4-OIW,[^+^?WIP1M!!)J[#M)J?.V!;/E^C]0YK:RW<-J_U>$&
M1Q<#4X&XC3X&[3S*30V)R'980(]@0-YF9"!@]@0'F>4!]C70Y&N8[LW"A;L^
M'I^-:RV4S#M3LQ<G,GK&X]'P/Z%9>)U0I5/6)QZ/@?T,S\3H-AJ-Z$DBAW*O
MK&X#L1\#V!+_`$,SY2FY#%'^2Y0,'9#4-ZCL;*AW."H<`]N!X!9S$`A=->3;
MNDT$74!4W2+59)PU1<UJ+<(M5T/YA=LDLU.F@LA_Q#$`!+[`AJJ%S[=KVV[G
MQMD)Q87.;BKOQ4(K7F.Q420PRT$K&.#6T`+10#F`I0+Y(NV#<HD0K%+0(8PG
M,1&IPJ1#',`@8QBD9%*)C`80$>R("/;'59GG.^23Z3NCIZ!Y%;;:VK'8F11!
MW0QOS+Z#(-1.*@UVH"H8%`,H-7B-\P*B85=X_1-XW.B<PFVC[K>';V1U<]<N
MZ`=K)0&HZQV'RJEUE9O)+HHR3OZH^9=P+$N4`*6.KY2E`"E*6$9%*4H!L`I2
M@B```!V`#L:L$DDDFI)J?A7JY`.0"GQ!<@LKHH[080(#^"&9^)U"574<RQ'B
MS!P\A:RZ7BGAI&,6<0+!96/D#M'+`[YD=1`QFSLS%XLB*A-AN:5.7;L,(:(L
M0G<WT:NR)X"R6.A1,HHNBQ/%2;9@BY4</*].6Q%L9!1$><,XJ]=D7P!R@9LT
M6-_Q1#1%>E,E0,;6CV8[NEL:JQB4Y523!A&-XUG#A&IR";@X$3*"#<L2H14I
M!*!@2$!`NS9HB[;'(4?)2,K$,'%3>2D$2-4F6"#!@JZC"RZ*SB,Z8F5,12,^
M0:G,0O9$";!`!Y-$5N5R77#2$4DNYI82CUY/14,1S&1Z3UPZ@V[EU8F[$5T2
MJ\TQ:Q*JC@Y1!'FVXFWA`H:(LF"SNA`IBLX(0$`,4Q(EF)3%$0.4Q3%3V&*(
M\H"'(.W;HB>LKOR&#Y/_`*':>QRA_P`UV]$7$;&X`!'S?`\@"([(5F/(`;1Y
M`1VCR:(L5@LNU6SJ,T:_+TB75D8"(M3`C)E'J"[KL^K((0LNA_(@"C245B'9
M4=GNCBV4Y-A1$"*]HWALX<NV:*=9.Z8N6[-TAYI8%,FZ=M0>MFY!.D4CA=9K
M[O=3$X@`#MV"`AHB[HV<X'(F+:L@HKO`DF,9&@=82)@J<$2"3>5$B0@8=T!V
M%':/)RZ(N?K&Y]'P/Z%9^)T1/6-QZ/@?T*R\3HB>L;CT?`_H5EXG1$]8W'H^
M!_0K+Q.B)ZQN/1\#^A67B=$3UC<>CX']"LO$Z(GK&X]'P/Z%9>)T1:WMV:L;
MTZ43C+I>L<U"67:)/$HN;EH*"=*,E#*)HNDV3M9!04%5$3`!P+L,8HZPV9ZA
MR#)W"'-KRTMY'4V2.HX`[CO&P\BV'*=%ZJU';NN,DRR]O+6NUT3)G,);R=0X
M:MY:;>=8Q_B6P5]<F(@_`%NK'PS6..M-#Q'LQG.7[/\`U81\CMOE6:;PVXH2
M-#QD&=4/[-O,1\1,@)^,)_B6P5]<F(OE;6/AFH_UQH?OG+_30*?PSXH]P9Y[
MM+]XG^);!7UR8B^5M8^&:?ZXT/WSE_IH$_#/BCW!GGNTOWB?XEL%?7)B+Y6U
MCX9I_KC0_?.7^F@3\,^*/<&>>[2_>)_B6P5]<F(OE;6/AFG^N-#]\Y?Z:!/P
MSXH]P9Y[M+]XN1>)C!9=[9F/#YM\AB#SEIJRFP#;-HDWG8[I]G8'V-/]<:([
MZR_TT"?AGQ1[@SSW:7[Q<0XEL%`']LF(@_!ZVUCD_P#7-/\`7&A^^<O]-`GX
M9\4>X,\]VE^\3_$M@KZY,1?*VL?#-/\`7&A^^<O]-`GX9\4>X,\]VE^\68U3
M*5(O97QJ1;Z7<`C!1\Y>K4G#S)F'2-O1Q=D8+K';E6W1W1,``80V!K)V&<97
MG5?Y#>V=XQOGB-[7/:.?J&G^VU8+.]/:DTX&#4EAF5@YYZCIFOC#^BA<?Z=J
MR[SD?WAKU5#O0UEAV1VQ$F/D)WK`2->7$35Q\H#G4^+:GG(_O#3JB'>Z!K0:
M@;5%!C$G^(!2J><S^\-.J(=[JI2N1I1002`&[$I4R"0-UBW(80$=H\X8I0%0
M=O;T1<?.1_>&G5$.YHB><C^\-.J(=S1$\Y']X:=40[FB)YR/[PTZHAW-$3SD
M?WAIU1#N:(N9)51,V\#9@8=A@V*,&ZA!`Q1*.TIB[-H;=H#[`Z(N`21_>&G5
M$>YHB><C^\-.J(=S1$\Y']X:=40[FB)YR/[PTZHAW-$3SD?WAIU1#N:(GG(_
MO#3JB'>Z(N0RRIBE*9M'["";=$&#<#CO[-N\<"@(]CD`>0/].B+CYR/[PTZH
MAW-$3SD?WAIU1#N:(GG(_O#3JB'<T1/.1_>&G5$.YHB><C^\-.J(=S1%=8*0
M,I-PY.9:@!I)F`B5JB4P;5B!M*8"[2B';#0*IF]2;4_FS_P#?Q1U*NJ)L?\`
MV0SOXFGZ_8Z(LXRI_2U5_K/`_K)IHBW[HBB5Q,P\A8*U>X*)0%U*S6-+'$Q;
M4%$TA=2,C$R[1DW!591)%,57*I2[QC%*&W:(@&L3GUK+?9'>64`K-):S`>B?
M3]_`/C6<TK>6N6ZLRW-+N41Q6]W&YU16L?:,$Q'2V+&X=(7D?2^%'+<!/T:1
M<5\IFL$\CV[=$9:)$M=C)?"=C3M('`'QQ$%,IV$R)N:WQ-L!0`%/8;7SODG#
MC5EFZP-Q!U8G,,88<(#9+-PD!`H-L[G./.6@[P%]3YUQ@T=F%OF(L;]OK%P:
M-+VO<Z3L\QC[,N(8[$1ES74Q$4K0;RKSC?`67R-:22S8\=1:49>>'Y:592DQ
M77O^P<?8>M-%MLBH1I*NDSLS3+Q(H)`(K*I+E-N[-[9Z\CT3J=UE"^_M788L
MPRTNJXFL=O;3VTS_`.T^4,+G;W5)-:K$9_KW0T5S>-R/-6"&7+\U:PALH-;B
M]CN;=A(B!PMAQAK=S:`"E%@L]AV_4;#;<+!1G$-'1N(L<8]D8TSV'.B]MG^)
MYE,NV)$H^073,E,P[LJP.#`5(R:H`<0'>*'CN].9]I_(X3-9NQ6]C'"YC3U1
M(;YH>0T;*T)%0/-J-RSF7:RT]GNIVC++_P#^ZW&=W%Q;S/+NS?`W)6D/<'@=
M:,BC214.'5VK+U.'',Z]-EHR.J*E<6>8MSY!Q,)Y[A$%($UQS1&6ZK4L3MI!
M1H@JZJC50A2IF,S3W@24.4HB&LD_06L#E79VUL]LDEC?1M=C(<UIOQ-&`ZM1
MAC&!@KL9U11NQ863B9H'^=PW5[>LG9%FF72/?@KC$>7N@?)M&T^M$4.\;UNR
MK8<NK+A%S'CAK6IEA9+FGDU:JU2<>5=&2*G8DD4XIF+>N]%J=;3>K)'5*R04
M,BUYSE/R\FWVVG<]BX79IDL5H]V=WWK9CCQ=7JAN$`;A7<*<^Q:%F>K<B?QH
MR7/KR\B;DEB+;MY`PEQ$!=VI<=L[ZAU75C(?05Y%K>4PWG2^!8%O4HU")?['
MPW5:3:V21KUB4BJ?AF&=/9^TSC"%G00?1DK8&[=!%B@Y%RLB`[^X7E#5[[2.
MK<TM[XBV99>N7&413"5O:TM[6!N,X!M=_'JW"#4C<MKL]:\.]-16P=>G-#E=
MGG$\+8(;F!\UQF<S^RC;*]@:PB`M+7/ZK#O6(?X8LVS%9)6YEI8HM:EX"S)C
M6"D*U98B)9W*27R&YF*)"2;4SYVHK6++`K$%5HX$I"IDYM50IM@CY7</M87=
MF8;MLDS<OR6_LX7QR=DU])!):M="27O:^,.!;6G.#1;,.+6A[/,/YG;31O;>
MZIL;^>-\7:/M&"RC9>GMF@-#VNV-<&E]2<`+BMN9"PUD&U+V5P:BNG;&6X5<
M9T$\7"SD'`+DN->N;*<EJ_%$75>1^]#-$152;N"#&/2I@V.IN',(;-G6FM0S
MF>1UM(VW&GLOC86$XW7`<WM&`;GEAV1,D/9U-#0%:)D.M-*6=M;6`OXPQNI;
MR[C,H#F>J3P$L,E=K3)YKI65G9BQ%K7`*1W#A7+'4L05V`ME884^:9NY]56#
MCN:313:NIQ\X8OUX]M)2\=!OY5JH5PXCV;E5FR54,FCND`"AO6@K"_RW2=K9
M9A"(;MKIBYK""S;(:%P:7,;,1_>M:XACNJ`&KE_%#,\ISO6]WFV47C;NVD9"
MT.<VD@I&.JUS@V1\,7]W&]S09*8W$N)*WEK;EH*:E$T1-$4+>.]TB[P<O2I*
MEW>Y5J\3**=K;X^AIZ9M)8:E(FR`2OUWU<;.GT7:L@2E:;P<:]4YIJR.]575
M5**9"GU?6=I)?Z9N<I99#,8KXL:&T!:UH.P!AJTAIZP:13%0T6>TZZ&+.6O>
M]\4C11I82TBO("TBE=VRB_/YPWY1N<_Q_1.0YCAYN=HL>*)N`EH.[5G']V/4
MUV62XU3$5HJ-.=JQ14(G';&C/(P](*L;S>Q?5B134.ETHZ@;/PL,3N!-A=%[
M<MS*_$AFR^<D7\)M)HFUNF-ZCG3[3&34L!(;18#69_\`^DW4'_6M@A@#9F^;
M1PVF/]GL=TP;_>?K57ZV#E`ISE`P'`IC%`X?O3``\AB\H\@AJ5*X:(M89BQ@
M.8:*\HH3K*`Z7+5Z8!S,1BTW77QZ[,M)I.'M,*W<LUI:N2:C,$W2!52;0$#>
MZ`NZ;6M9:9.L=+W>F6W=W8F]8(S<6O\`U$335Q=%S.Q-:"1MH2.59/)<Y;D.
M:PYK);P7$-N>T<V5Q:V@ZM*#SJE^X\P7G7;^`#,C^VY"D&*%2OKF[V2DVJ,R
M-$6AWC/%F-WM80A0=.'.$T9=RC:IIH,,)5CN&K]*;;<PBKS&X(%^7;;\O.ML
MAU;DV:V6:9?F666V)\TM]!&<P;,^3$0RK2``T#"VHH:F@JNTOXJ9/>Y/=6<M
MM):SB(Q-%M*_`X-;0B7K;3B-=F\4!-!1>LQQ$P[3#O".P1'9N[1$.4=S:;<V
MCR[-H[-?9+Z8B.TFD<-A,C0UU>4`#9A_9/*N`M`#06NQ,.T=`/)\2X:I52:*
M*A-$&W<FBE-$31$T1-$31%#S/_"B.;KHG<&]T)5CITR)K@-/,YI`WGJ-MQ7I
M[$"P/&P%4<8]EYR`W-F\4LJ*N]L3YL2+%T>#(#R-A7>V.KF8.H^^QD`W:UAX
M+@Z]LCKRRB;I;CNY-5O*WZ#2NW11>H$3WF,>@0@D'8"9%BZ?`S.)M946>28&
MOS3J3;N$9RO5>4;NY=**8O'$-,W#G9S_`&S;S7!O%2;QP`@DJ$>*0%$%-X"*
MEDX%9&6D90T=>Z^WC7"5A"(=R$!+.+?!M))O9V3.G,9XDJ9)"COFL^095$$3
M*N54SF*&PX`4BF_C:HFH&/:31SO0DCU*LQ-?._*#H".S1K4B`JI`]<O'A4`$
MNZF"JIS@F4H".W1%FNB+D0PD.4Y1V&(8I@'M"40$!]L-$4!I#@ZM`6*)EH6W
MU,K*(RXTN,.21AY$LO6Z#7K%$VFI4V$DD`=*).8]VI--7`I&:I+)2B8B<2(G
M06(A.#*79-JVPB;-4`CXR+J<.OTJ(EBN*V^AX['R<QD.C%064*ED&0D:8YYM
M98Z0&0EEN<6WN<*J17*C\+>0:_>,=W*>LN/Y)S3)F**JX;,;&[=DK$!2Z=3T
M&T2E-<^Q1GK":IBY=.4^AJLS.1*15RD!TE2*<P]D>39^`.P'X`T14T1-$31$
MT1-$31%XM_:%\,W%)F3.419\-8>AKW46>/("&6G9#*%2IZQ9I"2FUWK`(B;(
M+TQ&J+A(06_FU!/L#E*.OFWB_P`)M0ZXU'!F66-8;3LP-M-I:*&J^QN`7&/1
MW#_1L^19^]S;RXG>\$':UM1N/)6FVF]03_P%\?@]CALJ^S\.><=;?XFN2M_+
MSK-PQ86?(NXO_-/PJD=C87X-G/R"B?X"N/W_`"V5?^_G'7>:J\.^L_V6?(J?
M%)PMYW_*G^`KC]_RV5?^_G'7>:>'?6?[+/D3Q2<+>=_RI_@*X_?\ME7_`+^<
M==YIX=]9_LL^1/%)PMYW_*G^`OC]_P`ME7_OYQUWFGAWUG^RQ/%)PMYW_*G^
M`OC\_P`ME6_OYQUWFGAWUH-[6>1/%)PMYW_*G^`OC\_RV5;^_G'7>:CP[ZS_
M`&6?(GBDX7<[_E3_``%\?G^6VK?W\XZ[S3P[ZS_99\B>*/A=SO\`E4XN!/@K
MXD:'D\V1\R,2X395<R)&,!4KY!7)[D5%TF<7,9,N(1(T='UMNH0O2$ERG76,
M)>:W!#G"]*X7<%=1Z6U-%F^:7?JT&$T:PD8R.1^$C$.8.JN0<:OS":&U;HR7
M2^168NKVZ<#C>`[L@WEC+@<!.\X:5Y5[7_Z-GX`[`?@#;M'8&OJ`/?(,<A!>
M=Y`H/B'(OB@%A'\,%K.0':1\)5-2I31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T17BO?T]"_^]&7_7DT"J9O4JU/YM3^`;^*.I5U1-C_`.R&
M=_$T_7['1%G&5/Z6JO\`6>!_6331%OW1%H#+MI8U120F)5&,+$PE><3<D]>Q
MYGJC9A'D=NGBNQ,#K&30;H&/N%*)AV#L#:.K%S<6UG`Z]NWNC@B%21NIRUY@
M!MJ5>M;2>^O(;&V8))[B00,;7:9)NHP@<H:=KJ;AO6F*SFZD6Z2+#U]6N/9(
M].K60`0/`+MB^J=P,Y)797GG)$42ED1:*;$A-SR>[[L@"(:Q>6ZDR3,[X6EE
M(3,^-LAQ;#@?41O%?U'T.%VXTV568S;2&HLGM'WMU'@MHIY+6H%0Z:V`%P`1
MLJW$"1M(&]7^QY+KE0B"3]G-48>'5?Q44E(N(L#ME9"<D6\5$M4SH&5$YWT@
MZ32((`8NTVT1``$=>C,\YL,MMQ=WDL?8F81AY<,-20&LQ5IB+C0#?4TWK&Y9
MDN<YS>.R_)8,>8LA[61I!QA@&(G#2H:&]8G=3;N5[5G4U3*M5(BKK'2$@.&X
MQ3984CB('2YU(RA]P0$`$HF*'*&T-9".:"><VML6NG;6K`07-I0.JW>*$T-1
ML)"\K6W+8HWB%[(I#1A`.%YVGJ&E'5`+MG(M85_B&H%JN4Q08%%K(6*OR<Q"
MS(DH-C3AH^5@BE/*1ZUG6CB5[I;0IP'<Z3M/M]SMVZP%KJO(\RS&3++(W$C[
M>5T<SGM(@9(RF("0]6@KS\H6U7^A=29=E,&<9K;P""[MFW-NUEY&+B2!YHR3
ML<6,!Q!&ZE=F];1"S$$A%`C:L8AR"<B@1[82*$+R&4(<%]TY"^R8!$`UFC<V
MHC;,)(^P>YP:X.&%Q::.#36AP\M-RTXQ2B9UNYCQ<L#,3"#B;VGF8A2O7VX3
M^M0TJN"]I210<+JQE:*DV17<.#DC$CF12;IF57.8A%3G_DB%$1``V_@VZDW-
MNQT@<\%T()D#35S0T5=4;Q0$$UY"%<BBE?<,MVXFS/<`-N`U.ZCC0`D;0?C6
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M+09MD3B^8M8`X]5NVKG$!M5\@XP,*'?U6-:R#.37O#)M(U-:)QQ;95G/,W0%
M,*T>^91"K5;H0'V.R@;>9B`\\">P=EX:_P!)221,M;F[F9<-<Z,QVSV-<&;7
MNQ4HYK!YQ'FT)-%:_"G73;.^S&YMK>V?E5P(KCMY[>K`XX8A1CL37/=L9B`Q
M[`VI4@26+>`3)Q595+O&+OI1J"J>\0=TY0.FL8HB4P;!Y>0=;/!-!<1-GMWL
M?$\`@M()H148J;B0:BO(N>N)[5['U[9KB'5%!4&AIS@&H^%<O6$_H:N_HDGC
M=7D3UA/Z&KOZ))XW1$]83^AJ[^B2>-T1:PS)GJ`P;C>R9-M%=)(QE?29(HPM
M6J_G>RV*8F'S:)@:]!1Y'")%Y.:F':3=/G5$T2"??4.0A1-K%YQG.5:>RB3/
MLZ>R'(86XY"]P8V)H<&]J]QH&L#B`7&@J0*KW99EM]F^8-R[+:NED:2QH!)?
M3?A`VN^*JA9B?[6SA_RMFW'/#]Y@<5;(.5F#YY1DI&,CI>(L*#>%&PQ;^/>Q
M+DSD]0M\2DY\RS2R"#&2>,'C5/8HV.(Y;*XW9_EL^>99_%RVV+1+(SK,87&C
M6O<-C2XBC034G8%CKY[<LNXK#,*,O)RX1M=L<XLV/P@[78#YU/-Y5Z1>L)_0
MU=_1)/&ZI5:>L)_0U=_1)/&Z(GK"?T-7?T23QNB)ZP&]#5W]$D\;HH3UA/Z&
MKOZ))XW12GK"?T-7?T23QNB*Q3V18&K-2OK&6IP[)0RQ2NGD4((E!LT<2#I5
M4R7.<PV:,6JBRRI]U))(@F.8`#;J'2,C;CD(:SG)HO;E^6YGF<XM\O@8Z5TC
M8QRN<]Y:&-`&TO>7-#6[R7-`WA8?C'B`QYF6+?3V,W=;M5=9+"B2Q-JZ[:PT
MH4BKE`SV#?2"30LS#E<,5TP>MP.T4.B<$U#;IA`RYM[N/M0TEG(>2OPK.ZMT
M-JK0]W#E^J8&VEY*UQFC;L?$YH:[#*W>QU'QU:X`C&VH&(+8R5K;N"$4;LJD
MX35`!24;LVBY%0$3``I'2<G*H`F*(!NB.T0$/8'4K551.V-E3+$29U!4S=4$
M7!4VC-0S=<P[I4%P(Y$45S&Y`(;881Y`#;HBY)6E%<ZZ3>/JCA5J8".DD&+9
M95J<=NPCE-)P8[<X[.P<"CHB^WK"?T-7?T23QNB)ZPG]#5W]$D\;HB>L)_0U
M=_1)/&Z(GK"?T-7?T23QNB*AK&)"'4/$5LB:9#***'BTB)IID#>.=0YE@*0A
M"AM$1$``.SHBIZR>[*GYIK7.'2Y\B?FQ+G#(`8""L4G/;YD0.8`$P!N@(@&W
ME#1%R]83^AJ[^B2>-T1/6$_H:N_HDGC=$3UA/Z&KOZ))XW1$]83@`CYEKP[`
M$=@1!!$=@;>0`4$1'\0#HBP>"S;0+,M%MH.7H;]S-5^#M,4CT)-LI)05D6EF
M\$[9$>';F67DEH)X!&P;7(=&4$R8`7;HBOB&1Z\Y<*M45*09=-\WBRE,W9)D
M=23MJ+U"/CEE'!491Z=J4QA2;&5.3=,!@`2B`$7>&ZQI5VC44J45U(F4+'M1
M2CP<R!D6Y7:I6+<7?//#)-#E5,"93"5(P''W(@.B+O>L)_0U=_1)/&Z(GK"?
MT-7?T23QNB)ZPG]#5W]$D\;HB>L)_0U=_1)/&Z(GK"?T-7?T23QNB)ZPG]#5
MW]$D\;HB>L)_0U=_1)/&Z(M1WKB!Q!C^:1A;]?<=4J:=,49%&(F%V\:X4CU3
MK(H/4T#B8>865;G`#;>42CK6,WU?I/([L66=WT=M>$`AKGM;4'=0$BJV[(N'
M^MM469S#3N67%Y9!^`OCB>\!_P"R2UI%>8;UA@\7/#3]=F(_TNT[FL;^(O#X
M?_E8/2L^LLXWA'Q,P_\`^+=^@D^JJ?XN>&GZ[,2?I=IW-/Q%X>]ZP>E9]95?
MA'Q,[DO/02?53_%SPT_79B3]+M.YI^(O#WO6#TK/K)^$?$SN2\]!)]5/\7/#
M3]=F)/TNT[FGXB\/>]8/2L^LGX1\3.Y+ST$GU57_`!<\-/UV8D#_`.MVG<U0
M_B7P\@`><V@%33^]9O/_`(E2[A)Q,`H,FNVDF@K!)M/-YN\\BVG1\HT?(<6Y
MG,?V*G76(0<JQCN0@5&\BV:/B)D5.V7,B<#-W14E"G+O`&TIMH;0VZVK+,[R
MC/(/6,HO&W4`WX7!P'Q@D56GY]IW4.F;W^7:DLGV5[AQ!LC'1O(Y\+@#AZ:4
M65]//Y+']3)W=9)854Z>?R6/ZF3NZ(G3S^2Q_4R=W1$Z>?R6/ZF3NZ(G3S^2
MQ_4R=W1$Z>?R6/ZF3NZ(OJ:3,8A"=!C"B0NYO$9E`QPWA-M5]UL.?:/9V!HB
M^73S^2Q_4R=W1$Z>?R6/ZF3NZ(G3S^2Q_4R=W1$Z>?R6/ZF3NZ(G3S^2Q_4R
M=W1%]$Y,Z9]_H48?W)@W3LBB7W0"&T0`Y=HEV[0[0Z(OGT\_DL?_`*69!_=V
MZ(G3S^2Q_4R=W1$Z>?R6/ZF3NZ(G3S^2Q_4R=W1$Z>?R6/ZF3NZ(J]//Y+']
M3)W=$7(9$PD*0&4:7=$P[Q69`,;>V<AQWAVE+LY`T1<.GG\EC^ID[NB)T\_D
ML?U,G=T1.GG\EC^ID[NB)T\_DL?U,G=T1.GG\EC^ID[NB*[P#XQIV'*+9B&]
M),PVD:E(8-JY`VE,!MH"&@53-ZD\I_-J?P#?Q1U*NJ)L?_9#._B:?K]CHBSC
M*G]+57^L\#^LFFB+?NB**/$C!/K-`72NQI4S2-@QU8(2-!90$D32$I%RS)H1
M54>1-,SA<H"(\@`.WV-8W.+5U]E-U9M&)TMM*`.=^`X!\;MG,LSIV\CL-0Y?
M?3=6*VO[>=S_`-EL,@>YO/UQ4;%XX6"CWY"G.)VY8SLM8CF56X.L.&@IUS#I
MR%MFZ5D5+UH;Q16$JNU4@WZ3LJ"*RZJ!%^<Y0`H&U\UWV2ZDMLA]?U!9W-L/
M4\HM6MB<SM7RV\[I)&-<UYH,'4=4@'%L*^LLIU1I9V=#+LBS6.;M<VU!F3R8
MRZ&&+,+5L<8>)&--62;6A@=2E5OYYAVZ.N#^K4-_0GKVS0N2H2U)T192-=2L
M366N9%;$2,1%1_YO!U&49P*/1R.!(4@BF41UT&\TMGYX:PY3+`^7-Q?ME;"7
M-,C(C>.F!>XNPES(W"M'$T:`%S*RUGIZTXRWFH[*_C;D$F6"!TSXG-;)*VPC
MMWAC6L+@Q\K#0EHVDD[-J[F#L5Y#K6?I^TS=-E8)@)<S!9+@Z=QQV-]"WWZ*
MFL:%:=%DG3V0&NUILJC_`*PBCT`/Y(G(;4Z1R+4-KK9^8YC!=0M;<7CG7#GL
M,4K9;ALD5&M>7_W8IM:/-*MZYU/IG,>'T&399>6CYWRV;VQ-;(7VHAM'13M+
M'1L:.TEZW5D=7%4]%G?8#R8K1>+!S&+7EE:+YD#(SRF4U*WIM*C9:W,/8)TC
M*-X5)P#%&;FF+1PW276515Y=TP%`=NO$S1F=C+M17K63QWMSFMU-%`Q[6LG8
M_!A?V0<6O#J'SWQD\H"];.(FEGYIH^VNVV\F3V&46<<KS$[M+2>,/8^)[Z59
M"UQ$N",2@#8"3L6F;9@[,KBJ.DJABNSQT3.NN)-I6*2C)03)Y1H2^MZ&-,;R
M+(9\L?%,7#BO/CD2;K+<R94H;`%36L7^E=<R6LDEM:W89=/O\,(?&/51<=CV
M1IVE!AP.(#2:5HM]RGB%H".Z9!G&;6\IMF94))Q;.(N_5?6!.T'LL6T2,%7-
M:32N]3+PWBV5K$EQ$6:<KSEE9;[>;,2$?N'_`$@\I3#5V*)")L6Q'R[-@S4F
M.D#N[B2HGY3\@%UTW1FG\QR\9U?9PR?UV>\G$#7.:>TA?$QK7;'&@)!%#0[-
MRXQK?5^79Q::=R>SO#+DMG96\DD0@:SL+EDP:YKI0`^2D0Q'S@1LK78HAP>)
M>((^."L6N+;#6K#5>%DW#ZP2EI6KJ.)^?N-\:NIN9BR1TTY*G`5RN'57.=P=
M)4YQ$I"&'9MY;ENE==QY-$P9>^#,+733LOHYT9[::6\:Y\FQY%6VY>:GDV#;
ML77;W6?#MV?&YN\WBO<MO=2MSAX#9AZMZO:.;';]:,?WDS6M&&H%:D@5*OE?
MX;,RL+/5:3('FH2JU#*V2K)'Y&QJZ8UE!M`WG$[%D4T&UDGTS)QS<UK049*I
M'(H<W.G$!*0V\&2L-`:LM[RVR:=K3E%GFU[/'.W"/X4ULQC12N(![Q2E*U&V
M@VJQ?\4M$7>4YCGC)B=0YGE.6V\UN\/),UMF';/D)PX2X0NWUW-H-NQ9K6\/
M9.3J/"U&/Z*^9+T'%6>*M<HR.EHV`5BY*S51U"P+8LJV>/`CY"T.!`Q7R`+@
MDNJ*IRARAK*V6CL[@RG3]J^VF;=6%GF+)"Q[6.:^:-S8ACQ'"7DBC@'4KMHM
M>S?7>E;O.]4W\-\PG,<WR^:U<Z-\D1CAF:^9[XBT"1K&C8QU#LV+:_!W0[;C
M^@V*#M-(<4O_`+RMU8=.049MY>;CTH&,:JRDS#1,O+04;)I.T#ME'#/HR<IS
M(.S()G5-MVKACE6<9/D\UIF\$L#^T86AV$`_PVAQ#&.>`<0HY^*LIZ^%NY:3
MQHU#D^I=06]]E.8',7"!S9']EV;6GM'%K6.PL<]A::AKF_P?,#G#:I;;ANU^
MZ'=UTM<>3<-VOW0[NB)N&[7[H:(H3<>\C&#@Q>FSU;ND_6[W,H(60]"B9V7M
M#6(I28Y#-$5@M>9O7[*[7E[6$82&<'*F@W</3KG4+S(%-J.N(I<STK>V$5HV
M\-Y;QV[H7!N%K"<<CW!Q`+6/:TD`D[J`K/Z8DCM,\ANS,83#U(R*@G'L-"-Q
MV[S1?GOX;LRN[%]H+#9%FL&V.R6G$4U7GL):JA4;9(5((C(\2?#\U0Z6^2AP
M;,Z!7:2_B'-#!P8S)-_`2Z0J)G<G,&Z\+NPN."=A<1.-A/F';S/MW['E]N,<
MS91RN=(7=E7=R;*%:[K/^'Q(N+)]+R&VC:&S,VLJ_>8SR=G_`(V[$=V)?KL4
M3$AS%#8(%,)=I3;Q3;!V;2CR;2C['X-6%6N&X;M?NAW=$3<-VOW0[NB)N&[7
M[H=W1$W#=K]T.[HB;ANU^Z'=T11ZXG<3K9EQ)8Z&'G;H$_&S,'.$KZY&]@"#
ML,,^AG[J%%0Q".GK`SLBQFHB`NVY5$2COF*`^>Y@;=6[HG[SN72^%FM/]#:S
MM]2T@.8VUS#<Q/F:7V[98`UL8D8`2:1M(-&G^*6._5J(J83P1F^_87S4PRE"
MP&#E,B.\<U;$V,8]L\DHFEXDPOT-M68"YQK=\R>.(W(R;=?SRR(N@Y%F^6*.
MX<^X'DRQER7&YN6&&*A`BJ#3D!V5'2MV_,'FV@K[,\JR/1EY<9G+''<W=YF$
MA?AFS"_DCN)6D2!K^Q@;&RV8*4J`1U=JV3$\,64(65KMOC+/B&.LM9GX26AZ
MG#TZ;KV,8B+A[ADR?;5F+80:K221C6D3D$C9-84P757:"JL)N<Y,D-I`%3\1
M(\NY<`>Q\8+G-=@&\T):/A<*@#I)6(3?`[;)^E6JBERA$TUK9<SRV;7=CI4`
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ME@J<##L*ZF]F#"\CO.ES;(2S>/$PE;E;J[I$`*)`(IH;ANU^Z'=T1-PW:_=#
MNZ(FX;M?NAW=$7(F^0Q3EV@8A@,40'8("40$!`0'D$!#1%!:2X-Y%2PL9:*O
M4(@R8Y;0OC%I(51=9[#5&%L<':ZI2865:R:3IN6'DF\JDH?>3;.$94#'2$6Q
M2*$7S+P6`R2K[")M%;;QK"$JE:?)KU`W.1;2"C\?)R=LI`-Y)-&%O\G(T+?(
M]5*H!$9)P!]\W*<B[M'X4+75[A0K=)W*E23VGRL3SZ[.HRI'RM8KM.I]0BX>
M-/*S\BQ;R$JG42.'KL42K-EEAZ*<"E,50BF^)1$=H!R>QR^Q[`<H^QHBIN&[
M7[H=W1$W#=K]T.[HB;ANU^Z'=T1-PW:_=#NZ(FX;M?NAW=$3<-VOW0[NB+QJ
MX_.%#BKSEF^,MN&J#CBP4YA0(&"-)VO*1*A*GF&SZ8=2"'F8];E!*U0*\3`B
MH+""FT?<ALY?G7BIPHSK7.I(\RLI&,M61M%32H(%/Z5]@<!..6CN&>D7Y1G;
MKOU]V8B4MCMVR-P4WAQ>*TY139R54(/NZOM`?JFPG_?TE\R=<O;^7'5-.M=1
MUV\W.NU#\VG#/::7PJXG_I(^4D_:)]W5]H#]4V$_[^DOF3JKPY:G]IC^13XM
M.&?_`,[W./[Q/NZOM`?JFPG_`'])?,G3PY:G]IC^1/%IPS_^=[G']XGW=7V@
M/U383_OZ2^9.GARU/[3'\B>+3AG_`/.]SC^\3[NK[0'ZIL)_W])?,K4C\N6K
M`X&*Z@#OZX!%.79S\R@_FTX;82V,WX)%#2VC8:'?A<'&AYMGQKU#^SNX6LQ8
M#9Y`LN;4H>M6BS+,X2,IE.N/KA6#0C`$WA;))/PC(LAYY1XH=N@GS6UNW*81
M,;G0`O9^#G#+-.'\=W-FMT99K@X0P>:!7%B`W#=3GH5\V?F#XS9%Q-%CE>G8
MISE]HXR&:=C1,7%I86%XZQ;MK0[*@%>F&P>T/M#KN"^:$V#VA]H=$38/:'VA
MT1-@]H?:'1$V#VA]H=$38/:'VAT14[.B*NP>T/M#HB;![0^T.B)L'M#[0Z(F
MP>T/M#HB;![0^T.B(("'9`?:'1$V#VA]H=$38/:'VAT1-@]H?:'1$V#VA]H=
M$38/:'VAT1-@]H?:T1`#;V-$38/:'VAT1-@]H?:'1$V#VA]H=$38/:'VAT1-
M@]H?:'1%>*\`^?H7D'^DV79Y/^?(.@53-ZE4I_-J?P#?Q1U*NJ)L?_9#._B:
M?K]CHBSC*G]+57^L\#^LFFB+?NB+0^5[1%5=9]+3$?%*1L/7UYB3D7Z#I8S.
M-CR.W3Q82ME0.9)LW1,<0*43#L'8`CLU8NKFWLK:2\NI&QV\4;GN)KYK14[@
M=P5^SM;K,+Z'+;%H=>3O#6-+@W$XD`-!<0,3B0`.51JK_$[@ZZUZU6*'>T^1
MA:-$M+/9COH6>8JQ$*HW4D8Z?-'3*#5XLP<)-C';.$DSD.8FP@[W)K5[36FC
M\YRFXS."YBN+.SC;.]NW$T'8U^$C=TK<<RX>:_T[F5CE^864]M=9I*ZW@>',
M<U[@[#)&7,<["YA'7:ZA`VTHOA+\5^#("#J-CDI.NDAK]#2-CJKQK7;;)C*P
MD2*)9:4%O&LW;IDUC>>*+@S@B7-`(B;9L'5.8Z^T;E,,-YF-_'$R[89&$M>X
M.#6@O+,#75:QI&([**O+N%VN\WN+JSL+!SOY?,V"4NDCC:V1SB(F%TCF#M)B
M#V3027BA&]?5KQ681?6F'I;![!/[#848]W!-6%6N3MI*L91-JJRDV,H@P/%+
M12A'R6\Z!;F$Q.`',4P"`6QQ"T>Z^9E[;P&=\#9FD1REKHGTPN#@RA#@01T*
MU/PQUO;93<9Q/98+:TD?'*UTT#)62,<6O88W2!V(.!%.7>*A;N]8&WQ<@>7L
M@+=T/L^R`N_P:W2K3M80YIW$;B.<5`/R+0BU[3A>"UXW@T)!YMA(\A(Z509]
ML([1KD#M[?,._A>B)Y_;?%R!\`Z^%Z(GG]M\7('P#KX7HB>?VWQ<@?`.OA>B
M)Y_;?%R!\`Z^%Z(GG]L'8KD"'XF[H/\`^+T1//[;XN0/@'7PO1$\_MOBY`^`
M=?"]$3S^V^+D#X!U\+T1:VR[GFH8.QW8\F6^ME6A(%%HGYLK$'*3EEGY24>H
M1L)7:_#M'8*R$S-RSI%NW(8R:0*'`RAR$*8P8[/,WRC3V47&>YQ.RWRBVB+Y
M9W[(HZ.#*/=R$N<*#EYU[+#+[[-;UN79=#)/<O:2,`J*`;=NS;S=*AGB?[5;
MADRAF>@8$81#BM9"R<UE#TEK*(1[Z)LOFN(\_-E(N0@)^0.O5[%$"X&%F#)I
MQ4H[9O6K=4R[58@92P9_/,KGSNQ#KBPA=!B+*!D!<-A(`W2[Q2E>5>>\F;EM
MVW*)O^6NWMJ&N%72@><T'>2W]?F*]%0GVP<@5R!\`Z^%ZH5M//[;XN0/@'7P
MO1$\_MOBY`^`=?"]$3S^V^+D#X!U\+T1//[;XN0/@'7PO1$\_MOBY`^`=?"]
M$09]L/9KD#X!W^[_`*WRAHBM,U>H"N1CF8G(NM1L8S(8Z[I=)Z;9L*<X)I(I
M.%'#I<Q2#NI)%.H;9R`.O=E^77N:7CK"QC+YVF,<S2915@#CL_M5\WE6+SS4
M.6Z:RIV<9_,VWLQ&]P?)6D@8["6Q`5=(\CKL8!5S-HYE!S('VD.,:A'.YJ&Q
M%8[3",%>8<2YF;2L,U5.EJ,-]LA-RWG=9OT],R`J=%*4%2B41`0$-=WR+\NN
MJ,V=#:OS2ULKN>,/:V,FY#06EXQ]FTMK@;BH3N(/*OE3/?SBZ+RF.;,,DR+.
MLSRFVD,;[@O]2B:\.+"TQ7.%[Z2#LR`P@/H.E8UA?[5;AWRS>H?'DI4WF-K/
M99!.(K06INW>UZ9E7!P38Q1)R*D3E8R+XY@*B5PFFFHH($`^\(!JQKG\O6L]
M(V#LV;-;7]E`T=HYD3HY=NRH!;N'ZVW=R+:>''YI=%:_O8\HF@O\NS&XDP,9
M))"^$/`Q%CG,.+%3=0$=*]'QGVX"(#6X$!`=@@*#K:`^R`_ZWV0UP,M(`.S;
M\GP\R^EC42.C/G,(!YC45V<XZ53S^V^+D#X!U\+U2B>?VWQ<@?`.OA>B)Y_;
M?%R!\`Z^%Z(GG]M\7('P#KX7HB>L#4-IC5ZOD`@"<3G1<E*0I0VF.)Q=@!`*
M'*([0V!^#;HBXA8V*FX!(*N*"JF94G-E<'YQ,ARD,<FZ]'?(4Y@`1#:`#R=G
M1%R\_MOBY`^`=?"]$3S^V^+D#X!U\+T1//[;XN0/@'7PO1$&P-@`1&N06P`$
M1V-W8CL`-H[`!V(B.P.P'+HBP^!S#CVSJQZ$`XHTHM*U^&M,:DW5<%4?5^Q*
MR2$')-BK.DA5)**PSL$4P_EC=&4$2`!1'1%?4KU7EW+EFDPJ9G+5VV8*I"*Y
M-Y\[:B];LVRBCPJ3URHU*8^X@90Q0*8#``E$`(NZ:TQ95$$1B*J"[D3@U0YP
MW/NA21!PJ#9'IX*.#)-S`H8"`82IB!AY.71%]_/[;XN0/@'7PO1%3S^V^+D#
MX!U\+T1//[;XN0/@'7PO1$\_MOBY`^`=?"]$3S^V^+D#X!U\+T1//[;XN0/@
M'7PO1%4)]L/)ZN0/@'7PO1%JVZYSQ#19=.(O%SQS2I=PR2?HQ$W--XMTHQ4.
MHDD\3;.W8*B@LHB8`-V!$H[.QK!YAJ3(<JN6V>974,-RX5H]P&SG/-5;)D^C
MM5:@M3>Y+E]U<VC91'CC87#&16@(YN7F*Q+_`!3<-_UPXA^54>/_``.]8[_7
MFCN\K3T@66'"_B0X5;D69EM3M[$\FQ/\4W#?]<.(?E4P^%:?Z[T=WE:>D:I_
M"WB5W#F?H3\Z?XIN&_ZX<0_*IA\*T_UWH[O*T](U/PMXE=PYGZ$_.G^*;AO^
MN'$/RJ8?"M/]=Z.[RM/2-3\+>)7<.9^A/SI_BFX;_KAQ#\JH\/\`A=AJ6Z[T
M:31V9V;1SF0`*'<+^(S!67),Q8WG,)%3R`=)Y%LFGY&H]]C%YJC2]0N42DY6
MC5I&`D4Y1DV?)D(HH@JJS='!-TDFH4P$/LVE,`[!#6;RS-\KSFW=<Y5<0SQ-
M=A.!P.WXN3I6N9SI_/-.W#;3/K2>SNW-Q!DK"QU.>A62=/1]'LO!J>.UD5B$
MZ>CZ/9>#4\=HB=/1]'LO!J>.T1.GH^CV7@U/':(G3T?1[+P:GCM$07Z/H]EX
M-3QVB+D>11/N?[,8$W"`7W":PB<0$?=*"9<0$VP?8`-$7'IZ/H]EX-3QVB)T
M]'T>R\&IX[1$Z>CZ/9>#4\=HB=/1]'LO!J>.T1.GH^CV7@U/':(N:<DB0X&\
MV1RG(8-U1);<]T42[1W%RFVEV[0_#HBX`_1V!_L]EV/>U/':(G3T?1[+P:GC
MM$3IZ/H]EX-3QVB)T]'T>R\&IX[1$Z>CZ/9>#4\=HB=/1]'LO!J?^!;;HBY>
M<413(08R/`2B81.4B^\;;^5O+B78`=C_`$Z(N/3T?1[+P:GCM$3IZ/H]EX-3
MQVB)T]'T>R\&IX[1$Z>CZ/9>#4\=HB=/1]'LO!J>.T17:!>HGG(<G0FB>]),
MPWR$.!B[5B<H#S@[!VZ!5,WJ32G\V?\`@&_BCJ5=438_^R&=_$T_7['1%G&5
M/Z6JO]9X']9--$6_=$42.)V*D)VKWZ%B6QWLI+XRLD7',DA+SKQ^_B)=JS:I
M;XE)SBSA4I0WA`-H]G6&U%;7UUI^_MLO<]MS+8S1-PAIZTC<+2[%^JT[33:L
M_I*\LK#6&4WN:.B9E=OF$,\I?'C%(9&R`#8<-:$$\NY>38XLSI:*E,-6.,K%
M4'LUB/AQX?G#>UC$&<+(56QC*9`MKEG$S+E3U2C(Y,&^\*I7*Y53%(0.40X/
M+IW5MY8SQV.7B)UQE%CEC@X-%1%()+NZ=@V&-P&%OZX)V[%],0ZPX?Y1F<4]
MSF$%Q:P9IF^;M?;]I0RW+'M@MQVH&&0-?LIU`1\"^C#A\S>[-`U"10M-5;4&
M%XJJ_'6^C*QC!A+1UT7C9VDQ<:68/*.4*]9W+URT*BH4%RIH"45""`'&BUT5
MK;L[3)VME@M["TS:)L\3A21A8U]JQK7@T;*7NC>?..'9R*N7B5H4PW6</?;W
MDV:W607,EM=L,C8I;=SVS2@-+?XT3&L<2.J2=H4A\44.\Q60.'N;EJ>YKD75
M>%%Q1+$BBF@WCZU;C3-;<>K(H`]<JIK&29*J%`@JI[I1VG$=;WI?)\WM\YR$
M7D4MO33[8IFX\0;/YSMI;YK3L`WC<-BY9K#4>3W>3:D$-UZX^XU6^[C>:8GV
MK@1@VM)J7&K?U0V@WJ9?_P`/_P`_X==8QODZ\AJ\[SSKB`8(^HVF$;O@^3^A
M4T4IHB:(FB)HB:(FB)HB:(H1\?LW`M\#.ZC:(RVNJY>9IJC.R5*CY9_9XR)H
MY?I%<L:B6%9O7H9!N*E83AH``)NE>/17,8"MS`;3^(5MZYI&[R;U-E]:W-L^
M)L+]L+GR/:X23MWN+*5`;7;19O3#Y69W%*RZ=9.B!J6;*UYNE?GHX;\Z0MF^
MT/KN0IO$,I.W'#,G6QA9RFPLY*U1K7<@P[C$+K&U+?1\89IZCTFH2L0^H0.C
MF2</8N;3!4JRYQ#=>%'9S<!K3,\H<ZT=?O=VUM.1'<!MJ(L?;-=YY=VO_+AF
MUN%V+D6$UHZ7\1KV&8,NH[5EN!*T;`9A4.BKM'_KUW_JU7Z]E"<V<Y-X#;AA
M*)B\I1V#V2C[(:M(N&B)HB:(FB)HB:(O,'[0.?R;29.!N434IJWX]0Q]::TF
M6-;OGT36;M8WB3)[-6AG&&*],FYJ1UFC54!3(0ZA@WR^Z`_TUP&CTKF.6RV.
M97$%KGIS)MP>U`+G6[(G-;"WD[0O(<*]3G-5\-?FMEUQE^;V.I["RN<TT:<I
MFBMF`_P(;N9P$TLD?GX6V[.R@H*L<2YU`O/3*O$7"M[>I3;939"[7"IQ[)CT
MJ(K%:F"+VAS5D%I2*<Q#Y@JLZB65ML,B=9N40#GD6VP!!,Y#]YR'25X,NES;
M(\P;86DTCF]>1T)CAQC#1['%K2(HXV`G8`7@G:%\_P";9]83YW#IW/LI?F6=
M6$4&*6%ENYLDDT#9I&=B6%TC.W?(]YQ"0G`0=A6\>'WA2M6<KE4KU.8+;X&Q
M97KQ'7%1S;J[!(7ZUP<"@5_6J95F!VZDU#MD[(N=P\G7)6CA5LB@1$HGV[G+
M-><1+;1UI/DD&=7&;YS/'@`9)));L)\]TCG=4D-KA:-E=NU?07#;A/?ZLOK3
M/KC(X,ER"UD:\ES(H[AP8<4<<;6G'@Q@$N=UR-CMB]VCFWU#J#V3F$P_@$P[
M1#V.37R!U`#AKB<XN/PDUV+[E>YSY'./F=4-YP`*;>E<=0J4T1-$31%JW-$;
M-2V/))I!).G+@D[1I"48,2**/96JQ%[K<M<HEHBD/.+N)&JLGB0)%VBL!A3`
M!$^S1%&/#6*<R4:YT-O/A)-8.(MEY?KD6MRMTCB5=_6;4C,*,G)RD2K<3;K7
M-5U5C"ARM#Q"ZH)DWC"8BG=HB:(FB+D4PD,4Y1V&*8#%'M"4=H#[8:(H&R/!
MW-#88R6A[I6DV<7EQK=XU&1KCP9.`I$#98:U5.E0<HW<J.43Q;T)A!8Q#((.
M$90@F*(-Q35(N!>#!TQ2KC*)LU43CXV'J<"Y*ZK+TJ\$>#C\?IRUZHP-GH(Q
MF0Y*0HRHD=J]A"57YPYC`;G2+OT?A6NM;NF/KC+VRA2#RFRT0"Z[.OSZCSU7
MKU,IU/9QT429D'[%"6FR5+I#IT";=5FHX$J"BB8'35(IRCV=$5-$31$T1-$3
M1$T1>,?V@7"[Q59LSE&6G#6+*=;J>QQ_`0AYN=RQ"4U\>8;/YAV_;##2$6[<
M%1;$=)`17?$JFT=@!L'7S=Q9X4Y_KC4C,SRT-;;,B8TDDU=04(%-U%]C\`>-
M^D.&>D'91GDEZ;U]\9\,5NZ1C6C8.ON)=OV;MQ4'?N_/M`?J&QM_O"57_P`,
M#MUR]OY;-74ZC("WDK.&GXVDU'QKM(_-9PO=5UP+YTQ)))MI@34D[AL'Q)]W
M[]H#]0V-O]X.J_L'57ALUA^Q;>\-^=3XJN%/[-[[O-\Z?=^_:`_4-C;_`'@Z
MK^P=/#9K#]BV]X;\Z>*KA3^S>^[S?.GW?OV@/U#8V_W@ZK^P=/#9K#]BV]X;
M\Z>*KA3^S>^[S?.GW?GV@(__`(#8V_W@ZK^P=/#?J^/KNBMG`<G;8_W6[?CY
M$\5?"X;(?7&..S$;>7J@[W#%45'(O4G[.?ADS7@ECD.Q9L9M*;.V5PSAHRA5
MRYL;I75HV/*DZ+;)&1CV;-J$T9PJ=JBD!-]-`IS',8%"@7M7!CACF>@8KJZS
M%[B;D80RIPMHX.V`\NS?S+YD_,)QFTQQ/?9Y=IP23,M'%[KF6(LE=5I9@Q;B
MT$UP[Z@'D7IMKNJ^:531$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$5XKW]/0O\`[T9?]>30*IF]2K4_FU/X!OXHZE75$V/_`+(9
MW\33]?L=$6<94_I:J_UG@?UDTT1;]T18[+5:%FW!'4@U%98B8)`<%EB?R93&
M,4NZ10I.03CR[-NH+6N\X5^-0[$YAC!(C=L<`2*CFJ""K5]'M8VA_J1MW8.T
MHKN!$1]@0-SP;-@?CT<*C82'8<-03YIWM^-68[>*-O9-'\#8<))=U@:AU7$G
MHH-A52X_K(;=K'>VB(_S[H-@#LY.1?E[&JJT8V)M1$T``5YMH\A)*EL5!MH7
M[=M/VB2X?&*#HHN88_JOLQNT>WTEUX_0N>?.-7<_+MW[>DJH0QC<!AYN39N\
M@V*OJ!5?1O\`ZTZ\=J-BG`$]0*KZ-'K3KQVB8!TIZ@57T:/6G7CM$P#I3U`J
MOHT>M.O':)@'2GJ!5?1H]:=>.T3`.E/4"J^C1ZTZ\=HF`=*>H%5]&CUIUX[1
M,`Z4]0*KZ-'K3KQVB8!TIZ@57T:/6G7CM$P#I3U`JOHT>M.O':)@'2N1:'5R
M"(DCS$$0V")7;L!$-NW8(@N&T.35;9'-I3D-1T'G51:TFM.MSKX(8ZJ#41%M
M$(-A,D1`PMC*MS'02$XI(F,BH03(I"H;<(/N2[P[`Y1U9=&UP&+K$/+A7;0F
ME:;J5H/(E*ESW]:5],3CO--U?@Y%]?4"J^C?_6G7CM5JG`.E/4"J^C1ZTZ\=
MHF`=*>H%5]&CUIUX[1,`Z4]0*KZ-'K3KQVB8!TIZ@57T:/6G7CM$P#I3U`JO
MHT>M.O':)@'2GJ!5?1H]:=>.T3`.E<?H_K'*`,-@&`2F#I#H0,`]D#`*^P2C
M[(>SHW^'.;J,EMR10N!(-/B421MFKVX:\TH`YH+6_`P[`>E=%/%M(1<B[0@8
M]%P.T1<)-RIN1.83"=07)!*N)C[0VCO<NS5P7%X+;U432=ECQ$%[RT]!:7T/
MQ^169+&SDG?=&-@NI'$O>&M#G=4-`J!LH`*+OC0*N)MXT>8P^R(NG0B;\(B*
MPB.K+&B.HC+FL=O:":'X0KHACV%P#GMW./G`<U57U`JOHT>M.O':J56`=*>H
M%5]&CUIUX[1,`Z4]0*KZ-'K3KQVB8!TIZ@57T:/6G7CM$P#I3U`JOHT>M.O'
M:)@'2GJ!5?1O_K3KQVB8`GJ#5?1H]:=>._#HF`)Z@57T:/6G7CM$P#I3U`JO
MHT>M.O':)@'2GJ!5?1H]:=>.T3`.E/4"J^C1ZTZ\=HF`=*>H%5]&CUIUX[1,
M`Z4]0*KZ-'K3KQVB8!TIZ@57T:/6G7CM$P#I3U`JOHT>M.O':)@'2GJ!5?1H
M]:=>.T3`.E/4"J^C1ZTZ\=HF`=*>H%5]&CUIUX[1,`Z4]0*KZ-'K3KQVB8!T
MIZ@57T:/6G7CM$P#I3U`JOHT>M.O':)@'2L&G:U!LY%1N@QW4BIHF`O/KFY3
MDVF':901Y1U>9YN\^53A9RBOQN']!`5H\R17D8>%6\9JR^V@>XO<R,N/*14G
MX354&&`FI9M_M/\`K)YDBO(R^%7\9J/4[;[*+Z/Z4["W_8_>?]9/,D5Y&7PJ
M_C-/4[;[*+Z/Z4["W_8_>?\`63S)%>1E\*OXS3U.V^RB^C^E.PM_V/WG_63S
M)%>1AX5?QFJF6\<1Q0M8Q_.T4-.45KRJ6L9&<4.)CMU6N=6G*-I(V_`N\QKT
M.MTP#L]O-L'*Q/Y9?D.F!1(/(H'8'579@;B?C-56[$1V;7/[`;<).+;SUH%T
MO,T7Y('A5>_T[/I5&!/,T5Y('A5>_P!.SZ4P)YFBO)`\*KW^G9]*8$\S17D@
M>%5[_3L^E,">9HKR0/"J]_IV?2F!/,L4/)T0.7D_G5>_T,=!6J8%W',!$)MX
MXY68`=PU,JJ;GEQWC](63`>50=FPA`#M:H`J:)@Z5T_,T5Y('A5>_P!5]GTI
M@3S-%>2!X57O].SZ4P)YFBO)`\*KW^G9]*8$\S17D@>%5[_3L^E,">9HKR0/
M"J]_IV?2F!=Z.K\,X>))*L@,006,(<\N'*1!4Y>4IP'D,4-.SZ4P+H^9HKR0
M/"J]_IV?2F!/,T5Y('A5>_T[/I3`GF:*\D#PJO?Z=GTI@3S-%>2!X57O].SZ
M4P)YFBO)`\*KW^G9]*8$\S17D@>%5[_3L^E,"[JM?B$V#-8&8"JL=R50W.K>
MZ!(R>X&SG-T-F\/L:=GTI@72\S17D@>%5[_3L^E,">9HKR0/"J]_IV?2F!/,
MT5Y('A5>_P!.SZ4P)YFBO)`\*KW^G9]*8$\S17D@>%5[_3L^E,"N$3$QR4G'
MJ)M0*<CQN8AN<5'88JI1`=@FV#V-068152UM"MVG_FC_`/1F_BCJE5J)T?\`
MV0SOXFGZ_8Z(LXRI_2U5_K/`_K)IHBW[HB"(!V1V?CT14WB[=FT/;T1-X![`
MAVNSV![0]H=$5-XO;#1$WB]C:&B*HF*'LA[>B*F\7;LVAM[7M]S1$WR_E![>
MB+EHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+6%G_IA;_H6_P#$U>9YJA6#52)H
MB:(FB)HBND7V7_\`[K>_Q"Z@_P"]%:]2B:(FB)HB:(JAV0_&&H.XHN^]_P#-
M8C_L)O\`VMSJTSSE*M^KRA-$31$T1-$5SA_Z01_@.?\`V5;0HK9HB:(FB)HB
M:(FB*YN/Z+CO^E??QD=!R_"BMFB)HB:(FB)HB[L;_2#'_M2'_6%U2_S46W3_
M`,T;_HS?Q1U94J)T?_9#._B:?K]CHBSC*G]+57^L\#^LFFB+?NB*`7'7Q`7#
M"T=C-"B32\/+/)N;N=DZ+"C.J2-"QXR:/;##+H%CY`T>SFUY5N@=Z((E;B'*
MJ3;MU6P`G:K,SG-`PJUY8SG?8G(N0HVL6P6\$QE.#(:VW3:QBQ"QV5\DS$/<
M11,LV46<IV"$;IIB81-S0%VI"0VT=5!HIMW[53VCNTH#U319@6R7^#S=Q,IF
MR):IRNXPQ7!WVJTN21K!H1&7M47>'ZK1P=C7&LVZCXQ:N-RLB&=;Y`$W.&5$
MP"%-!0&G*KH<>T+>2BCVPSEF*!Q'FJ26R9)VB;C^%K#6=8.Q2<;6`=U>X9%;
M3YIZ,C4HJ*9L!@"'BTSM&SI-<Z!1,'.'`=NJBT5'PJECB6U)_P!JJQ<3/$GG
M:@Y5RS4J;:EV44ZQI36-+`D5$.2U.[KUYSD2:L'.+QRZBPO*=5ID!(X%1$HD
M*)2`)=7&1L+03SJT^1[7$`[/T+L9FXD<YU:Z5",K%I6*RN7#7CPJ#8L3$N",
M\M9/&P)PES.<\>HH'0U:\IM0$1:B`_S>J8XVN)Q;@AE>"!79L5^LW$1EJ-Q;
M4[`VNBJ$M*_9_P!^S&X?&CX<3NLE1#W'2498]TS$4!7;I3;D.CD*#<W.\J8[
M"[*`T5^-7G.(;7H7VS!Q)9<I.>V]*8V(S>H3RG"_$,A+&QQSQ%DN5K%>S-%5
MU&:AS(7>J-'Z(;XCS*S,!2W##M&0QI"LNE>#L.S9_0I`X2N>1+AGC/C2>EKL
M^J-(R38*C7DRO\?-Z"Q9M:M2I)M$+0Z;-/(KF?2<3+A8KL5#,13,!1$3!LU2
M0`T%7&/<9"T[A535#L!M[/\`\.WJA7DT1-$31$T1-$31$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:PL
M_P#3"W_0M_XFKS/-4*P:J1-$31$T1-$5TB^R_P#_`'6]_B%U!_WHK7J431$T
M1-$31%4.R'XPU!W%%WWO_FL1_P!A-_[6YU:9YRE6_5Y0FB)HB:(FB*YP_P#2
M"/\``<_^RK:%%;-$31$T1-$31$T17-Q_1<=_TK[^,CH.7X45LT1-$31$T1-$
M7=C?Z08_]J0_ZPNJ7^:BVZ?^:-_T9OXHZLJ5$Z/_`+(9W\33]?L=$6<94_I:
MJ_UG@?UDTT1;]T18M,T^G3SU5_/5V"E7Z]>EZFLZDV#1TX5K$\9$9N!.HN0Y
MC1,N+=/I"'\VMN%W@'8&I!(W*"`=ZQE]A_$<G8*Q:Y"@TYY9*6U8,:K-+P[!
M1_!-(K>&);1ZXI[R2448YC-0Y>C&,)D]T1$=,1W548&C;0+,$H&M(2TO/(Q4
M0G-3[)A'3<H5LV!]+,(L'18YE(.-WG';5D5^L"1#B)2`J;8'NAU%?(IH*UY5
M@\#A3#-7@['6:]CFD1%>N`E]:(9E"1J4?/$(!BHMY-MS0INFC<IS`DB8.:2`
MP@0I0$=LU*!H`V#8KW)8XQO,NY!_+4ZJ23V511;2+M[$1SER]0;P\E7D$G"R
MJ1E%"(P4P[9E`1Y&SA1/]Z<0&0]PW$J"QIVD!57QWCERZ;/G-/JB[QE'0\2T
M<K1$<HLUC*\9V>"8(*'1$R36'-(+BV(78"(JGW=F\.HQ$<J8&GD"LD]A;#5H
MCZK$V+'5)F(RCI)-ZC'OH2.6:5YJB5N4C*,0%+FV[#8S1VH`',FYH@B4=TNQ
MB<IP@[U?97'F.IQ^K*3%1JLG)+/*Y(*OGT3'N79W]/7<.:J\,NJD907-=7=J
MG9GV[S<5#;@AO#IB/.HP,Y@OA'XSQG$V^1R!%TVJQ]WF.?\`.MJ9Q;%O.R(N
MD6[=P9[(I)E<.3+(-4B&$YA$2IE#L`&E32G(I#6@U`VK/`51#D!1/8'_`(Y>
M[J%*<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_
MGE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[Z
MG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7
MOJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/
M)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB
M<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_GE[N
MB)SR7OJ?YY>[HB<\E[ZG^>7NZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7
MNZ(G/)>^I_GE[NB)SR7OJ?YY>[HB<\E[ZG^>7NZ(M9V8Y1EUA`Q1#F6_*`@(
M?S?X]7F>:H5@VAVP]L-5(FT.V'MAHB;0[8>V&B)M#MA[8:(FT.V'MAHBN488
MH"^#:'+&/0#W0!M'=+L`-H@&T=4/V!`K8!@[8>V&C"36J*NT.V'MAJM$VAVP
M]L-$3:';#VPT1-H=L/;#1$`Q0':(AL#\(:@[BBN+T2@UB0WB"(,3`(`<HB`B
MZ<&`!`!V@.S5IOG!2K=M#MA[8:O*$VAVP]L-$3:';#VPT1-H=L/;#1$VAVP]
ML-$5RAS%\XH[3E+[ASV1#R94.V';U9<XUZ%*MNTO;#V]7AN4)M#MA[8:(FT.
MV'MAHB;0[8>V&B)M#MA[8:(FT.V'MZ(KBX.48R/`#E]RJ]V\H?E(_P"G5MQ(
M.Q%;0,';#VPU4TU"*NT.V'MAJI$VAVP]L-$3:';#VPT1-H=L/;#1%W8TP><&
M/*`_ZV@'((>^%U2_S46WC_S1O^C-_%'5E2HG1_\`9#._B:?K]CHBSC*G]+57
M^L\#^LFFB+?NB*('%/9IJFU&_6VNMT'4Y6,;3]@B4'9]QH+Z)CI-ZBHY`?<G
M21,AOF(.P5`+N;0WMH874=]<Y7D5WF=G'VMS;6\LK16@ZD;SM6P:1RZQSC5>
M7Y3F4IBM+JX;$32M>T>P!0:@>,<%+/5*)-TE\O//*95Y*R2<9+)F;L[#/8W7
MR"!D(M./.FG6SH->CG>'<$%!RN0@)G*&_KEMKQ?CCN+;);BS=Z^ZUAFD<)NS
M:'36O;@5+2#_`'1Y1R[%UF\X'2-R^XU)E-_&V.WO+@1![!B+(+L6KJ.+MFV8
M'#@=6E:BBZ,5Q86.]+8U3AZTK1#S64<1QLXU?R,;9@EZ'E3']FN469NZ1:(E
MBI'_`&20%0*`J)"38!A`Q@UZ(.)MWF]W9VEG%V68/O+,$.>'CL[JQ?=@EU`-
M]13DH%$G"+*--6=]+<W1S1L&4YF(961RPTO+:]CMWL<&%P?A#VD2[*UI04VW
M"M<4ME2K&-'KVE/K>%SHE_O3J="QP43,,8J@>?G$T^F*O'QG1F$<0S!LR0<$
M4*1=RX(4I1,!]7\MXB7,>2Y=,[+S<QWMG<7!>'];_EHQ(:BNP%Q+1NJ11>*]
MX1V,MUF=O#?>J3V5U96W9NMWR?Q+IT#'-:][@Y[MAE(I5K8SR$K[*\9`+L6J
MT'C22E9)]*1$6UCUK7'QJ1AE,-?3*JNJ^58K$339113M!+N"*BQ=X-@"!=3)
MQ6C]6Q6MB1*^5K"*UPE]L;FGQ4HH9P5<VZ-O=YLP0]F]X/JAVAMWZI7SN4[?
MA-%\6_&4X<5*<LOT7.&2\4&.I!LRDK]"-62]>R55WEIA))Y)@R552?D;LA;F
M8-6SUR=PJ0"AN[YBT1\69#EDV:/RLN;:QV;R/7&]<7C7$T;AV^::`;MRNG@E
M"S-X,K&;-_YF:[CQ"T<<+K-[6;3BHVI<*DTVU!5O@>+6=DLDPQQK3EUC*\UW
MA\\V)J/HMC+T6<S"I:D"JORE;J.;(DNZBDDSE(HFF@1(3EVB?=U9R_B/?76I
M((1:DY-+#8!D/ZUN;UDH#W.WNP[Z;=W0KN8\(\JLM*OI=D9Y97.=&2?:6W/\
ML=$#&!^KB[7X`LPS/Q,V"DY`4Q1CRL5^P7)>?P10V<E;IB5C*O&WSB`G[D6N
MDG20;-[+JP->HV/)26>]%#I2RJC-NEN<Z=4O9%P2M5J5QQ@YVK-R<1-[PQCR
M+AJ.YX9*YEV-A,C2\Y<&-HXE[_9<;0<ECUVE"A4IVIPTS%Q[U1-^LT?FCY`X
M'YMPV.F8BRC&'&';9^Z2%%R90JI5I2#S[6N'ZS.:E;YB?8U^Z7[%3_(]4A7`
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M5W4"V>MTC(2%%?).N9>!5T!.9VLLFLU>`CM,)RJM2H.=(RS7>;:ISJRL=/VS
MF"!V/,2\U;;2N)9ZG$1L<0&.ED=M80Z-T9Z[J;'<Z8M<DM;FXS%P,$L@]3PG
M_`()/PMK3`3UL6.NRB]JMX_LG$W8VB`F`HFV>Z$I3#M`HCV`'E`-=<?02/[/
M^XQ;/AY5SX'K'#_=UV*N\;\H?;'5*KJ4WC?E#[8Z)4IO&_*'VQT2I3>-^4/M
MCHE2F\;\H?;'1*E-XWY0^V.B5*;QORA]L=$J4WC?E#[8Z)4IO&_*'VQT2I3>
M-^4/MCHE2F\;\H?;'1*E13S%Q60>&;J6FSM5E7YSM(R6)*-))ND@$!)5RYO@
MF%456YC)I(6^KMH+<WA,9U*H*<A0$!)4KZ.N+B@(P;MTA"W1U96]=FI]M60K
M[]NE)MJ[#6"1FI*/GW"1(Y6I,9"J2+#SJ8"IJ.6ON$S`HEODJ5PCN,7$SF6F
MF4F:SUZ*8GKI8*PR]?DD&%M2G'"#-62A2`B9081FZ=I"1T?819N"J^PB:"@@
M2I5LD.-/%D6LS.[;648<7=E3G+"E$2"<16D8B-L4C",91P_;,2DM=I]7Q31C
M1$H(BL!CK"4-HDJ5)VI6N'O%6KURKCI9W`6F'8SL.Y614:K*L)!$JZ`K-E?Y
M1!8I3;IR#MW3`(`(AL$25*R'>-^4/MCHE2F\;MC[8[-OL;=@[=FB5*B!!YHS
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ML'$U+K8HL%VJU3=0,]$97H&-O,UC8.;C*H-KK;ZY`DFUJ=4Y&.G7$@:)G!=-
MHT%DSKB4HI*K(F!0Q*E6,W%Y,5IG7XS(.';@TO#N3KU<FHF`5:N4D9R3K$-;
M)0[6.YZ1DHMI$0]DCCJIR"B($6='1%<10.<Q*E?&1XYZ0T6;@PHE[FF2L+)R
MZT@P3:=&;*1L.NZ4CUG!MK%%<EDCWL(L9==`$'[,^P%""(E)4H?C#DT;$\C9
M'&3Z*9-'T;76S4+'#RLK+WAX_P`DUMQ6BNT7+2,B&3>ST1(B<FH"Z"C9R8YD
MT]W:!-JV9C_B08WZ^,J*2D6&#6<(3+1[+OIB">,XZVUUDZ?S=8%LP<J.WJ31
M)@N!)!,`;+F(7=+L/M*2I4D-XWY0^V.B5*ACQ"\;=`X<[JPH]IJ5RG9%_7F5
MC(]@3Q)6*;5\Z?-$FYNGO6ZXN"'8F$VPN[L$.7;KD^N.+F4:"SJ&POK>_EF+
M*DQ82PXMHW\O.NZ<-.`NI.*.07.HLKOK"WM+1^#!*'XZ[B3AV$$[EHS[U?#?
MU<Y+_P!*M;_:6M$9^9K2>$=I:9MCVUV,YUT<?DWUZT`-S7*<-!^WR[>9/O5\
M-_5SDKPM;_:6JO$UI#V3-O(Q3X.=?=ZY1^_\R?>KX;^KG)7A:W^TM/$UI#V3
M-O(Q/!SK[O7*/W_F3[U?#?U<Y*\+6_VEIXFM(>R9MY&)X.=?=ZY1^_\`,GWJ
M^&_JYR5X6M_M+3Q-:0]DS;R,3P<Z^[URC]_YD^]7PX'8QUDL/8Y%:X')VOZ2
M[&GB:TA[)FWD8G@YU]WKE'[_`,R?>KX;^KG)7A*W^TM/$UI#V3-O(Q/!SK[O
M7*/W_F3[U?#?U<Y*\+6_VEIXFM(>R9MY&)X.=?=ZY1^_\R?>KX;^KG)7A:W^
MTM/$UI#V3-O(Q/!SK[O7*/W_`)D^]7PW]7.2O"UO]I:>)K2'LF;>1B>#G7W>
MN4?O_,GWJ^&_JYR5X6M_M+3Q-:0]DS;R,3P<Z^[URC]_YD^]7PW]7.2O"UO]
MI:>)K2'LF;>1B>#G7W>N4?O_`#)]ZOAOZN<E>%K?[2_#IXFM(>R9KY&)X.=?
M=ZY1^_\`,GWJ^&_JYR5X6M_M+3Q-:0]DS;R,3P<Z^[URC]_YD^]7PW]7.2O"
MUO\`:6GB:TA[)FWD8G@YU]WKE'[_`,R?>KX;^KG)7A:W^TM/$UI#V3-O(Q/!
MSK[O7*/W_F3[U?#?U<Y*\+6_VEIXFM(>R9MY&)X.=?=ZY1^_\R?>KX;^KG)7
MA:W^TM/$UI#V3-O(Q/!SK[O7*/W_`)D^]7PW]7.2O"UO]I:>)K2'LF:^1B>#
MG7W>N4?O_,GWJ^&_JYR5X6M_M+3Q-:0]DS;R,3P<Z^[URC]_YE0?M5\-[/[.
MLE>$K?[2U4W\S>D@X%MIFN*NS8Q4N_)QKPM(?FF4%M-HZ^WY%G.-_M)L#WZV
M1U4DV%HQ_P"=C='96&VFB"UXK\PE*@RD'K%\N:-!T)MA%E2@@4VP#F*`[=9S
M3G'[2.>YBVR?!F$5S*ZC72X1&#2O6I\&SIHM=U;^5KB)IG)GYI:>H7\<#0XP
MQ%_:/;4`X2?V0<1Z`O0C>V@`E-O%,4#%,`[Q3%,`"4Q3`(@(&`0$!#D$-=VQ
ML?$R6'^ZD%1S_P#Z+YJ>UG:/:QIADB=A?&=M'?">:B;1[8ZIJ50FT>V/MZBI
M15WC;-FT=G:VCLT2JIM'MZ5*53:/;'4U*)M'MCI4HFT>V.E2B;1[8Z5**\5X
M1\_0W*/])LO9_P#+DTJ3O53-ZE4I_-J?P#?Q1T5U1-C_`.R&=_$T_7['1%G&
M5/Z6JO\`6>!_6331%OW1%'7---&ZEEZ^^C'[Z"L54?5Z6!F58AE(^50?,9!%
M-RD&^@L+5P;88.4HB`Z\M]96V96$^6WE/5KF%\3J[J2"B]-AF-YE&:VF9V#6
M.N[>X;(T.YX^N*=.)K1\)"B:7A'K<>X++1+>_(2[2K-X%L1Y/RRL%(2,/37U
M&KMFLD.@1%O,S$-`/10!0VPAB@!A()P*8-/ET%D;#)<0DMD]4CMA"_9$Y[8I
M((YG]+&O.$\Q6_GBIGTC&6^916AMV9@;@O;&'3B*5[+N:**:G4:7MZ[.4CH5
MJQGP;5RC0%.;/V5IGK17']`LCR9&2EE&R]DH%3=U*&)'MW)!4;5=HQD7/,L1
M$0+SO*8=T`#R9%PXRG)[:"2_?)/F3?5^U<_=VL%MV.&/G8&NZOQKTZIXOZBU
M#=7UQ80V,633"8PLCC$3C!<W'K+VO;O?*Z4M<Y].L&CF5RB.#RDP#IJM%,\D
MLT&U,6QZM%I6>4"+DJ@X<R[YQ#RC44-KE!9Y/.%C[#$$R@D,.T2%U7;<-]-V
M4K)09VD0>I.PW3HVB$@.QE@C<&MQ.`)J:N/.5CK_`(J:QN+66WE98&_EG9>1
MN?;LD>;UE&.D#R:D=FVG0-BK!<&U"K[5@V:P=\=C'R199NZE)Z1?O#/$\?NL
M9(BJNHB43MT*@\,@1,``A3E*?9M#EO6G#O3-C;]D73@]L'&I+Z.$)MP"\@8B
M6G?05WKTYAQAU;?W?K#'63+<L+6QMM:`1]N+AS&@;/\`J`)*#D%=R^:W!GC]
M1BT9HPE^CQC_`%&*PD(VP2;*38ACVKR-+@`:O$T=J9E*Y+.&[HVP17YT3>Y,
M`"%$G#72DEL(;-\X;&RW8=E/^E#@!7DKC.U78>,&L;6=YFFLWATMS(7"VJ&O
MN;AER\DT_5D:*\Q798\'%#C9:HRS6O7@JE*;T5M%,!FY08AVEC0)/U*&:CP3
M*E*JPRLJJH4YQ`QU-@F$0V@,P\,],V686]W;,N>UACL\)-QB:#8MD;'B;7K5
M[4[.5>6YXNZON[*]M9I+8P7TEXV@M\+FB^=&;MP=3J]KV0`=TJWWWA#3R#D&
MX7*05MT$2X1F'90DC4U%X6ZT_*N!K%9)+'&1ZA.J-)!@V>-8:UN6+MNZ:N6[
ME%,A%4U$E%4QWU<T6'U[[/#%5:EX608M<R.8J,8T%&6IDE>)-Y3[U,XSG;1:
MZ?;[^P%B23L5HCK=<I"6,KTQ%LK(*)JF0_D4@*1=BO<"L559^D2D?)9)LZ5=
MR+2<AS\EDJ8=W&V3!,.T.S4C!]+83`L8]%I5,>^M:[HHKIKOW2R13KN%E3G4
MT13$&O3VT?\`8TEU57O=$5/5Z>]#275%>YHB>KT]Z&DNJ*]S1$]7I[T-)=45
M[FB)ZOSOH>1Y/_1%>]T.P`G<30=)3]4O_4;O/(/A7$(&;-^]B9`?Q-51_P#U
M?P:BHJ&_K$5'P<Z'82#L(I7_`,7F^7DYUV6T%/(N$51AY,`35(<=UJJ!A`I@
M$0#D`-H@&CBT,<'`FHI\?(?B.U2VH>'`TPFOPTVT^/<O/O@>X.\S<-TUQ!2%
M^2A'[;*EUCK#725=>8D%$&+-[:ESDEP?P\65NY,E,H"!4Q5+O`<-[W(";0-$
MZ.N]*7N;75U,V4YE>]N`W]78=A^D5M6IM119]'9^K,,44,&%S3L.($;:?`I^
M^KT]Z&DNJ*]S70%JB>KT]Z&DNJ*]S1$]7I[T-)=45[FB)ZO3WH:2ZHKW-$3U
M>GO0TEU17N:(GJ]/>AI+JBO<T1/5Z>]#275%>YHB>KT]Z&DNJ*]S1$]7I[T-
M)=45[FB)ZO3WH:2ZHKW-$3U>GO0TEU17N:(GJ]/>AI+JBO<T1:ON_#K2\D2H
M3=YQIZQRA:^UJQ7CQ&334+`L;?#7UI'@#5RW)S:-MK[1X!MF_O);F]S9C$$B
MMC?A?H+=[.R!<<R*KJQI6%K(F=2%D=I(Q]J1ET9V'AVSF25;P$&]&??*=#9%
M0;IK/%5$R%.?>`BL@\'>)E&4A&N<5/WS&3?.7Z[60E;6_2;F=0<O6S,XSI4L
MJ:(B$(2>=H(LVPI-4`6WDTRG*0Q2+LRW"1C*;E7\T_QI*=.DPE3O`9RUKCV*
MKZ8/*'<S18MC+-XY.PMO/3D&C\J0.F15`!`Z8$(!2+<$%0W=:A8FNPM=DV<1
M!Q[6+C&IDWKHR#-FD5)$BCIXHN[=*[I=IU%3G44,(F,81$1T177U>GO0TEU1
M7N:(JA7IX.7S-)=45[FB*Q_1NW`"@%$;ANV52YDV0:6PEN5,H=6T$`$?<SZA
ME3"+O^?$3#[KET16!Q@VI.[#,VUWB:`>6BQ-"L)ZP.ZJT<RLPS(BQ;%;R#M9
M`YW*?1HUNF.]M$R:"91$2D*`$5D9<-&,8UW&2$=@RH,GT,[?OHMVWIS,J[%W
M*(H-Y%9$XH&':[0:I$,!MI=Q%,```33W2+F'#;C<&3..^A.KBQCTFB#%J-3:
MBFV18R;N9:I$$414,DC*R+A<"F,("=PIMV@<P"19#%X9KD&R=QL/B^*C(Y_8
MVMO>,6==02:N+0Q=MW["?.@"(I^=(]\T25;*@`"W.D3F]W=#1%]9C$,)8'*+
MR=QM'2SMO/1]I1<OH!-PN2R13-".C9L53IB=2191[5%%-0XF$$D4R]@A0`BM
M;C`M+='CU'&(*ZJ:)"?"+`U39<VP"U.WC^RBW1!L"(&G7T@X7<F$HF4674.(
M[QS")%]'V"J=)+2#F0Q'7GCJ6:.V$HY<51FHX?,WZ\RY>-W*PM^<4*X<V)^J
M8=N\*CU8VW>4,(D5RA,1PM:&/-7L;1L*>);)LXQ2-KR+51BU2CRQ1$6RJ2)5
M2%\V%Y@1WA,9+:41$!T195ZO3WH:2ZHKW-$7G9Q8_9SI\4.2(W($GFC*V+'<
M94XVK>KU2K=)D8YPDQ>R+TLFJO9H=_($=N`D-PQ"GYH"I@(!M'7,M7\*\AUO
MG$689I*]CVLH:>:*"@VKM_#;CEJ+AID<^0Y7;V4ME<R%SG2&7$#7<<'5'1RE
M1B^Y7BP__*QX@/D9B;YLZT=GY=]$X>M-*34_TKI#_P`W&N<6VQRT'9RW'-\*
M?<L1?^;#B`^1F)OFSJOP[Z(^UE5/BXUQ[%EGEN/G3[EB+_S8<0'R,Q-\V=/#
MOHC[65/%QKCV++/+<?.GW+$7_FPX@/D9B;YLZ>'?1'VLJ>+C7'L66>6X^=/N
M6(O_`#8<0'R,Q-\V=/#OHC[65/%QKCV++/+<?.N1?L58X^W=XK^($VZ4QS;*
M7B8=A"\IC#_W8Y`#4>'?0_VLJ>+C7'L66^6X^=<?N6(O_-AQ`?(O$WS9T\.^
MB/M94\7&N/8LL\MQ\Z?<L1?^;#B`^1F)OFSJ?#OHC[65/%QKCV++/+<?.GW+
M$7_FPX@/D9B;YLZ>'?1'VLJ>+C7'L66>6X^=/N6(O_-CQ`?(S$WS9U4W\NFB
MG>;)*?B5?BUUV6X_4<MP\];CYT^Y8B_\V/$!\C,3?-C4#\NNB2<(EEK\"H\7
M.MP_L_4LM[0C=6XK_2J_<KQG^;#B`^1F)OFSJ?#IHK[2;R*/%UK?V++?+<?.
MN1OL5(\F[O\`%=Q!%WR[Q-ZE8G#>+MV;P;:QRAMT\.>BOM)O(GBZUO[%EOEN
M/G7'[E>,_P`V'$!\C,3?-G3PZ:*^TF\B>+K6_L66^6X^=/N5XS_-AQ`?(S$W
MS9T\.FBOM)O(GBZUO[%EOEN/G3[E>,_S8<0'R,Q-\V=/#IHK[2;R)XNM;^Q9
M;Y;CYT^Y7C/\V'$!\C,3?-G3PZ:*^TF\B>+K6_L66^6X^=/N5XS_`#8<0'R,
MQ-\V=/#IHK[2;R)XNM;^Q9;Y;CYUR+]BI'G,!2<5W$$<P@(@4M+Q,(["@)C#
ML"L>P`;=/#IHK[2;R)XNM;^Q9;Y;CYUQ^Y7C/\V'$!\C,3?-G3PZ:*^TF\B>
M+K6_L66^6X^=/N5HP?\`\K#B`_TTS$WS9U(_+IHJNV2;R*EWYNM:X3BL<M+>
M;_F-ORK=>"?LJL>8?N2-PMV0LC9S\W'0=0U>R!!4Z/@&$DW,8R+]RTK,1'GE
M^:,8#%1<&.COD`1*.P0'+93P$T'E.8Q9C+VL[(G5P$;S0@>0T/Q+`:H_,_KO
M465/RF!MM813,+72P=MVS!O(9B-*NIA->0E>G`1[[R-<.0```2,`````%```
M-@``<@`'(`:[6X,#(XQM$;<+/ZK>;^A?-6-TH9,"YQ=B,A?L>7$[R.8IYO?>
M2./!'[FJ54GF]]Y(X\$?N:(N0QDB!2G%BZ`AQ$"'YD^Z82_O@`=FP=FW1%Q\
MWOO)''@C]S1$\WOO)''@C]S1$\WOO)''@C]S1$\WOO)''@C]S1$\WOO)''@C
M]S1%=X!B\).0YC-5RE+)LQ$PIF```%R"(B.SM:!5,WJ4"G\VI_`-_%'4JZHF
MQ_\`9#._B:?K]CHBSC*G]+57^L\#^LFFB+?NB**G$=8']7@[C8HU4I']=Q[/
M3K#G@44;=.BHV5?M1<(D.3G4>?;EWR[0WB[0VAK'9S=3V&2W=]`YK3#`Y_6%
M?-:7"GD*S.G+"US34-CEE^'.L+F[AB>UIH]V.1H`:[<T[#M)`7E!2^-#+$S)
MX<CY-.!44>1]G'*Z2,4NV,ZDTX"U6ZI(PBG3CA#$>5V!264`.>$X+`(;`'7!
M<HXR:M=)E8N!;@N,PNFEN(BL1EMR`*XL4;2ZC:D;B`5]+YMP-TG;66;QY.R[
M,T/91Y<>TD%'!T-O>1RAC78B'O`$CJ,%"`XJ]MN)S,,=C"XVU]D/'%ALYL)T
M?*T36FU;D(F:HLG;Y^(;>;'L:"YVEHJI(>;2YIZ+HKD7)1*8@`/)Z6<1-4V>
ME;V^GS"S.;NR,7G9/&%S'S3Q]D6@C:TP2L=4;`26FCFN`Q=SPNT,_6UM86F6
MWMLUNH9LO?.]XDCGAMF3-.&0D21.QQ$8"P`"CAL<%>['Q%YSK[J=QSY[ICN[
M1.6&].;WSU7?IQ+FMN,/R.54E%JB6>$B<L91AT(3%=\V!#\YNB8->^\U_J?*
MW/R.=]O<7$><10.E%*&.6S-V-O+A,8;\+:;RO!E/#'0%_:_Z@@CN(<BN,KDE
M-M)/VMPVY;F$5DU['NZW9N)<^E!0&FX+.JQQ'91F[#A(\G6ZW&5')."+?E)5
M=E,OG\M*SM9JD/,NV!6RB"):Y%-)*0$B?\H[4<)CM,)-W8.6RC76I[N7)9KL
M1"RS#);V\<=FU]NTN!H-OR?`L?F_#;3-O8Y_#:7]^_,\JU-:6+>S#.SP7$F'
MJ.-!A^$[.5<.'OB4M]H@<CV'+TA`I0],Q91LT+2M>CGL42'J]KK=ALLO$.VJ
M\D^&1/76<`82.0%,RX&Y2`.S7HX;:MSW5;YHL]DBDB?;9=.WLQAI'<F3$3TC
M"`1YW0L/Q@T)I[19L<PTTR9DT][F%G+'*:UGL<`&WS?XY>3B!PC#OW+'0XSL
MF/6=XMT#@)67QWBFBQ4]E&1'):+*W5BQV#`!^(.-;(UQQ7P8251AX1_$1$L^
M*^*_0E)3>09+MVRAS=47$_@6&V3C^R!1L>7:UW7!4''3F,Z[C#(=W2:9N3+1
M4L:Y?ICVU8_=0%LEJ1'S$GD"US46ZK3"#4B4DU9Q(HJ/$VJI%]$7TRO]H+:<
M2V.U5JU8:B*FHTEJ&6IR^0,Q(0,6SJ=[S,TPW#7/,YX:J6(V*(VRN5EIR`13
M&76E81JN<W,*I'(!%O>L<9N-%>'W$W$%DQVMC.O98;O$(@O2)2X0ZT^U//%C
M8B$GX6,3\^>OJ=?45JP"U;.I[GVZ"*`.EBH:(KS;\\Y%8YI^BG'6)5,@L:E6
M<87/+LHO=PJ]CK-<RU:K+6H5:H5MY$.F%HD*HRJ#^7FT'<A&"G'I`FU%PZ-S
M0$4>*7QW9&LU">VR4PS3*W(N<!1/%)54I'-\L2JRV%U[%*UFP^>;"CBUU)P6
M0ZU(M&?^RTHUZU?A))`@\WR')HBP:_?:>2&-&]P2N>&HNN6"J0$LT=5>6S0R
M3L$=E"KXVQGE.WP-GB4ZETZ%QG$U[)9$6]J(1?I3R,<%Z$F0Z)A(I+</G%ZU
MS:^K$2]@HJ'7MQ\W1]:L=1O(WNAV^5P)=(2K6]S3+`,-7GDM7)..LC208.EV
MC94W-.T#I`*!3J$67<8>4[OASAPR5D:AR36*L<`U@D4)^2B'EH0K#.>LT/6W
MUE2K#9=NI8G\&A+\^V9"<".%RD*8#AM(;6M7YQF^GM*7^?Y+;^NYE;648;#4
M`"X=(`\%SJ,`;'5Q>3A`KM65R/+;',,ZM[+,IQ#E\D;NW=YV$T-*AM2>3<"O
M)_!/&]QM*<=>#^&V\DA[GC^ZFN4%DN4,:->+X]M$!B]ID*>QXM/0==KBKW(N
M*'(D"2DU$R1LVG(&8MVR:L8X<J[5I!T6J]#7FK;X>K3MDMO5=AP31DALV%XZ
MFUSAA!(+ZU;58O/99,KU*,G@;VT9A`F=]F!_<$\^(<U</+1>^_/+>_+>%4[[
M5I0G/+>_+>%4[[1$YY;WY;PJG?:(G/+>_+>%4[[1$YY;WY;PJG?:(G/+>_+>
M%4[[1$YY;WY;PJG?:(G/+>_+>%4[[1$YY;WY;PJG?:(G/+>_+>%4[[1$YY;W
MY;PJG?:(G/+>_+>%4[[1$YY;WY;PJG?:(G/+>_+>%4[[1%%S+O%?7,-W,E-L
M5=L+Q=1O&R9)%E(-R-?,4C6;I+%F3IK?RA&Z-DJ*4&)>4YGLFW.'N-[1%]77
M%UCA&#=O&[:Z.[$W@9J<1JY*_-I*2*%>AIZ3F7L=-+-DXES6(][5Y%B,QO`S
M.Z:&*7>WB;Y%PCN,/$;R7F8]_*6*OL(]2O)Q$[,P<ZUC;66==(L1>0&\TYUQ
M#M'CM`.FCL060.=<NQ)%0P$5OD.-+$T:Y9%=.+'YK57LH2\^WBIH\-6V\)'6
M&1BD)9ZY9,TDK)9BP`D;16T%RBL4PF$FP1(I)U6VQ5UK,!;ZW(KOX"S1+&;A
MWANDMSN8^01*NW44;K;BJ"NX;8<A@`2F`0_#HBOW/+>_+>%4[[1%]43*JK))
MBNN`**)D$054$0`Y@*(@&]RB&W1%&2"XDVOT=XXN5LAI)L^OL!-3HM()0Z[%
MBE"WV`HAR%5?N4G"G/.;2S5#LANE5Y0$"%,162#XPJO+,#N7=(R!#R!6$!+I
MP:JT')/UXJVOL?M:LY04BYIRS4<3+?)#!8&_.`JB)%4C[#@3?(LR7SNN^X>+
MUG&%K[V.>5*GWR>3JM@DD7:J<O3(Q^\\U3*D$Z64:G46:E*NW_DGJ&\)#)D4
M#1%H:L\:$^T>/T\B4M8*_"GED)FV5MM.5ITPZ(O"$8/I#'M[>)6Z/3>&EC(`
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M`VM@./()%8X?C3<JL7<G,XZG!9(F$&8P\K&%(]B`0JCD;G)/Y&:(PJD(1.PG
M*HW>F,*2A4@.X(!S&`BG*5P<Y$E"+K"14A%"CSQQVD.4I@$!*<Q1`0':`@([
M>WLT1>>W%;QT2_#;D>.HC/&\?<47]3CK*,J^M,A$+$,_>R+0696K>*?%,1'H
M&T#B?:.\("`;`V\-XE<8[GA_G#,LCMA,'-:X;6BM14[_`/?1?2/"#@':<4M,
M7>=7&;2V3(I<+F"&%X%*`$%\C''%R@`T49?O:[%]1L)\OI?YO:Y\_P#-)-C.
M'+F4_M-75Y?R:Y2R0M.IIZ[/_I8.8?\`JI][58OJ-A/E]+_-[5/BCN.[F?2:
MK?@WRG_N:X]U@^]3[VJQ?4;"?+Z7^;VGBCN.[F?2:G@WRG_N:X]U@^]3[VJQ
M?4;"?+Z7^;VGBCN.[F?2:G@WRG_N:X]U@^]3[VJQ?4;"?+Z7^;VGBCN.[F?2
M:G@WRG_N:X]U@^]3[VNQ?4;"_A_[_2_*':'_`+O=C3Q27`__`!S/I-3P;Y3_
M`-S7'NL'WJ?>UV+ZC83Y?2_S>T\4EQW<SZ34\&^4_P#<UQ[K!]ZGWM5B^HV$
M^7TO\WM/%'<=W,^DU/!OE/\`W-<>ZP?>I][58OJ-A/E]+_-[3Q1W'=S/I-3P
M;Y3_`-S7'NL'WJYD^UKGMXHGP5$B0!**G-WZ4WQ+M`#<WOUP2@<0[&WDVZML
M_-#20ODRLEQYGLI_2O2/R96#K<M;J"W(/*^VCQD?UJ24KY5Z:8&X@*/Q#TH+
MG1U9-N#5R6.GX26;+-W\!+@B58\>JY`!82)!*.\19NH<AR;!$"B(E#Z)T5K?
M*]=Y)_,\L!$@IB!8YF%W**N:`:'945!WA?*/$GAWF?#'/!IK-"USGU+)6O8Z
MK?U2`QSL((H<)W5IR+=G.G_*-^<?OM;@M`055!V;3G'8``7:<^PH![`>ZY`T
M1.=/^4;\\_?:(G.G_*-^>?OM$3G3_E&_//WVB)SI_P`HWYY^^T1.=/\`E&_/
M/WVB)SI_RC?GG[[1$YT_Y1OSC_\`@-LT1.=/^4;\\_?:(G.G_*-^>?OM$3G3
M_E&_//WVB)SI_P`HWYY^^T1.=/\`E&_./WVB)SJG8WS[/8#?-L#\7NN3;HB<
MZ?\`*-^>?OM$3G3_`)1OSS]]HB<Z?\HWYY^^T1.=/^4;\\_?:(G.G_*-^>?O
MM$5XKZAQGH7W0C_M-EV3&'_GR!V!$0]G0*IF]2G4_FU/X!OXHZE75$V/_LAG
M?Q-/U^QT19QE3^EJK_6>!_6331%OW1%'3-5//<TYBON&<FO%6*JO:](+1J1A
M7(UE6[]B[YA;F5DTG!&[D1((E-NFV#L'7AS.""\L9;"<G#/&]FSE+F.:/E(K
MT+UY9?S97FUMF4+2702!XIR.8YDC"?\`Q,`^`E1#B>#6A0LC"R+2$MQUX>1A
M9`Q5S;4Y4T'C93%;5&5*2/(9=!>LKJ&5!,4C&='$X"`#NAI47#G2=I<V\[7E
MMU"Z*1NRIQLMS;N%/V2'.(^)=#O>+^M,T9/!*R&/M()8Q,,3BPRW/K;B`',W
MR`-)VG"%CS7@<JR4%-5]_+99F6<K06F+F)Y)\S.O6J'%SS&QPD#!"C!I$3"(
M?L"\VNN598Z9A*H)N00\-GPOR*SADMKFZNYI)+)MJ)3@:YL#78F-#2UU2VC0
M#7<*<B]=QQDU)+/:W-M9Y7;]E?.O9F-A?*);M[,$DQ>Z1I':"M6TH#MY5<W_
M``8UV2K[J+=RN65+"]NJE^=Y$/)H*7=S/K5I:G'*JZ/"#$!'>JRYF14`:`4B
M1A$NP^PVO3)PTR:6R[%UQ=3W)N!,9I`,3GAKHQ4MH*-C<Y@V;J*B+C'JJUS9
MF;6-KET4<,#;>.W9!_"[$S^L2$U<2'F0-=O-37;1;%9\.5<8NL:+M8.S)-L5
M4.QXWK<=O+F9K5FT1L9$2B<H8[<[ET]%G%$W%2J)B4YS#L[&S.1Z*R6"3+)(
M3+3*K6XMHA38Z&84V[=Y&]:S)K_4\EMFL3F,QYMF,-Y-L#3VT3\56-%=E?-%
M5A%4X.JE4J-D^@HI7Z:BLJT13&DT[L2X2#Z,I"5<F:O$P$,+>/8)),H2-G7'
M,&5!18QQ`5#GV:ITMH?*=(RSSY>Z1SI9(P*[FP1`EC3TM<3LYN57=9\0LYUX
MQD><MCC;!.^>.F_M99`9"1SN8T<^W8M5)\`;:Q,FBM^MV44G$W2ZU%90IE(?
M-HS'%WR%6,*/L!1^4#)/JVI:V\NE0'WN8\'Q8A1\W;.'#5=5N4YMM:.T%8")
M!T?IHM$K&'=F7M[8[`VC@2>85;3;TD#I7U<_9\13VGRU8=Y:XBW$K:(-O1KS
M=3/*22;NF*VN/5<7M<53,&ACY*CH59A47"X-'#:+0EV<BX6?)/"N%3&T+90*
MECJ#?2AI\0)/D!5MCVRDB(AY;YV$@X?A`-?)5?0OV?<<U:W)E$Y1SK$-+5E:
MFYIC1;Q>,9"3J%]QY/Q$Q1G47/S.,Y&=L4/4HR#;PS"/GG$HT;0Z8(ID*8.<
MU36HJ`ZO]DC^D*ZYN$;""[FVU^4#:LNF>!6@V##U`P9(CD\])QS9)"^Q2Z$F
M1G.R63G4U-W")R3,OV40W0/9:AD.Q.;'$)MT&\>SERHGZ.9)NDD$BI&XA,$@
M8'O:6UY#O\BR3(?".PR/DB,R5(6'+,`]/'XXB[_7:LZCHFN9;8XCN#^_8[;7
M;;7W,VR)`6N5=+*^9GD9YP;+F:.N=;`5,LJFA6MZA]GM3JQ3QI<E9LT7>-0@
ML9TB%<6AS7$G5<QCBK)+/*L!C*)3K=/@62M:E[6R(:86=IN9*2;D(DHY`J9-
MA%WLP<`E0S==+[=[K.94-(W2MN(&*1CV=.2^CQR\:UYD[FJ=+N:0ZLSDQF]=
M)S$=+OI*'9*O'JK=HF=TH.B;5?<?<(#C'^3JI>4Y*U6@M<#.%PE9NSM6I[;<
M\Q\0$I3D[K<9=O7X"NU2)BV55I#=FR9Q[1NF4S@XBF`EYQ0FU9!Q+88S;E&I
M0,1BJ3A*Q,1$ZYGS'NL+.OH-299PDBG1YYPRB$#JRRE#N"S6:0CE^;:/7;-$
M5C@5$"GPN?97+G67'+K>XDMHIG`RAC0YK@.3;O!W$+)Y/F%OEM_ZS):L,)%#
M4[?)^E>/."/LL./_`!WQ#264I+)F-X"CMC8\<TZ"1E;_`':QU]:J6.1E%5SR
M3JN123^P-HVQ3[1\X7WD+$QL!FR_,]&*IK-:)>[(.%>6Z(U(W^9:FMFRB>[Q
M=C$\]HQUJZ.W`(:;=K:`5V[`L9J&N:ZSN<]R\F#*)(X@R,;22P4<'#D:>0U*
M_0LI!S`G.)(>2*03&$A19N!$I1,.Z`CS?*(%TH4H5Q\Q37HF1ZFX\7HE"GF*
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MY!035=\=O`03LUA?JE:-"I))+/%#D`IA`0)0JQ&X.,2K,'\8\QS/2#%^\<.Q
M;R$Y;WQ6)',%,5GS9#](DS&B(-I"S[I)NS0$C=`QP.0I5")F`E"OO,<(6+IR
M4DI=]0+"5>6/+.'[9G.6UA%+R<P>5,M/A#M)!.,)86)9IR5D\YKGF9#E*D)0
M(0"DH5NB`HJ]8@XBN0L'*MXB"CFL7&H+)/W:R3-FD5%$JSMT*SIVMNEVG54,
M910PB8P[1T2A5W\Q37HF1ZFX\7HE"JEA)PABF+%213%$#%,#-P`@8!V@(#S?
M(("&B4*TVAPNXG:D9IM\*P*"4?-*61@BG!.^88SJJY7:DFT;J'.V07,^3(XW
M0)S72$TU=SG$R&*2A71@.$W$E;@JK76.'8MVPIAA7@U9>%6DGQ7YT8Q%Q)O7
M"Y!"0>N?,S0X\Z4Z9#MDA3*3FR;I*%9;#8&IU>BY6#A<;),8*=@5JS-016#U
M:&E(5RZDWCQH_8.3+IO#/U9=<%U%1,JJF8"";<*4H$H5<7.'*T\?OY1WC2*=
M2,JJS6DWKBMD67?JQZ;%%BH[.HW-SYFB48W*3>V["HD#V-$H5BK;ADQ:S6C7
M"&%X`J\/'N(N-54@'#A1JQ=JR"SE(#.16%=18\NZ`5E=]8".5"`<"',424*S
M5CBN)BY$DM&T)M'RA%%UBOV4(=LZ!5RXG':YQ522*)A5=6:14';M#G'JQNR<
M1T2A5N3PI4TAC3)8OATQAJX>GQ(DK1">;:JHUEV)ZZSW4`YB(,SL#Y+F0]QS
M;Q8.PH;:2A7&/PE4HD8\8S&$4Q-$_P!&&0KVZ=B.Z<FUNH9(RA#"50P".W:.
MT=HZ)0JPN^&K&+YL[9NL,UY5J^4:*NT0KBB)5S,6D>P:E,*!4C%1(PBFZ!DR
MB":J"0)J%.03`)*%;7+`3)"E(2'D"$(4"$(5BN4A"%`"E(0H)@4I"E````Y`
M`-FB4*A)Q$_9W84XFKZVR'E-3-C&QLZY&U=%K2<E3]+A0BXUR^=M5#0S%FL@
M+XZD@ISBPCO*%W0$/<AK1=2</-,:KS2+,LZ@,DK&X21S#=Y%U+1G&'7^@<K.
M2Z8DB9E<KW/>'1!Q+C_6QBOP4V+0_P!S/PE>R]XFQ'_^^]I_9NL%^"?#D[3;
MM!YCO^-;J/S/<8Z?]1;>@'UT^YGX2?+>)O\`OWM/[-T_!+AQ]@SY5/B>XQ^T
M6OH!]=/N9^$GRWB;_OWM/[-T_!+AQ]@SY4\3W&/VBU]`/KI]S/PD^6\3?]^]
MI_9NGX)<./L&?*GB>XQ^T6OH!]=/N9^$GRWB;_OWM/[-U!X)<.J=6W:X\PWJ
MA_YH>,3&XC/;'X(!]=<@^QEX2S;=UYQ.&W2B8VS.]J'=*7E,8P^;.0I?9'4#
M@GP].^T(^)/%#QAPXG7%J!TP#ZZ!]C+PE#R]-XFN7_\`KQ:?V;J?P2X>>RIX
MHN+_`+5:>@_\Z?<R\)7EO$W_`'\6G]FZ?@EP\]E^1/%%Q>]JM/0?^=/N9>$K
MRWB;_OXM/[-T_!+AY[+\B>*+B][5:>@_\Z^B7V-/":BLBL5WQ+*"BLDL"2^=
M;4H@KS1RG!)=,&!!404W=AR@8-XHB&T-NH_!+AW[*K9_,]Q>+L7K=KZ#_P`Z
M]**M0HBCUZ*J=/K#>NUV&;E;1T3%L3-FC=,H!O*"4I!,LY7.&\JJ<3*JG$3'
M,(CMUTS+,MR[*+,9=E\+(;-K0.J*'8*!<4SK/,TU'F+LXSN9\^9.<34[JN))
MIS#F'(-BOXQK\.46CC8'_D5>\U[5B4-&ORB7:S<@!R@8AN94W3E$1#:4=W88
M-H>QHB>;7_DCCP*O>:(GFU_Y(X\"KWFB)YM?^2./`J]YHB>;7_DCCP*O>:(G
MFU_Y(X\"KWFB*H1<B80*1DZ.80$0*5!41V%`3&'9N=@`#1%0(U^(`/1''*&W
M^95[S1$\VO\`R1QX%7O-$3S:_P#)''@5>\T1/-K_`,D<>!5[S1$\VO\`R1QX
M%7O-$08U^'+T1QX%7O-$5/-T@!2'%DZ`IQ$I1%NKL$0[(`.YL$0]GM:(J^;7
M_DCCP*O>:(GFU_Y(X\"KWFB)YM?^2./`J]YHB>;7_DCCP*O>:(GFU_Y(X\"K
MWFB*[0,>]).PQC-5RE"39"8PI*`4H`N01$PB4````-`JF;U)]3^;4_@&_BCJ
M5=438_\`LAG?Q-/U^QT19QE3^EJK_6>!_6331%OW1%%SB#LSNH1EJL[0@N%J
MW1)BP(,SN%V[=TO#L).0306.@('(FN9L!#&`-X"CM#E`-8_-[Z;+,GN\PM&L
M=>P6[Y(\0K4L&(@<Q(Y>A9/(<LBSK45AE-U(Z.QN;ID4A'()'!@<>AI-2.5>
M:]'XYK#9YC"L9(52)CPO#6R*Y(5:RDXNI4%HQO8Y.(2@TU1*5\>5@ZZ=SNN=
MAMTX;O)L'7&\FXS9C>WF4LDMH&B^9+ZSB%7PNCC=,-V^L+'.V4KL7>\Z_+_E
MF7V&<36]U,^>SG@;:M:2UL[)"V-SZD[`R=[8C7EJMPR?%C`NR4I6AH2M@)8K
MECR"EB2"$DP>-(3(M$GKY"/8E!)4YGLLI'Q"9>8-[DJBHD,.W8.MBS#B=EKX
M8'9&[M1-<6K'!S#5KKN$SM^%K6-%:;\6S<M+R_A+F@?*_/V]@8K*\EZKQ0"R
MN6VSV._KN>_$#N`%#M5AJ7&+&RE:B;E;HU_68A[C.)O;J%9-IZ7LS=S,Y)6Q
MRP09`!$&,C&.WP)&3W=CD3'$V[N!RK'BA!=6C<ROV&&U=;"7`-I`$XMZ4'.[
MKUYMF]>W,."F8VN9R9/E#S=/CS"2U,PD#&8F68O2ZCJD#">SIO#A6M%>C\7E
M5+*L9`PR+''I<;9"NE@E91K*MK7#3./KM&4E]6CUXAE=]T>4>'3$NT3"J!-T
M=T1$+LW%#(W7$-U;2._EPM)IWDM(P""<0.8X?M$G%7<!L7C;PAS=L$HN,3\V
M9=VD$.%X(>+R#MV/'.&MZI&]QVBBRV2XB8I[@S(V9:2G(R8T*+M@N("Q"[AW
M;:Q5-,%'L',)H.'!VP[3D$5$3J`*:A3%$=NLO-KNTN]#W^I]/.,GJ+I:M<W"
M7]E2M"=E#7EKL6&L^'.90<0LOTCJ%O9/O^RPO8<6R6NU@&UQ:`2:X:'GHM5&
MXILAPU3RL-EJ%;/D.CQF)G]6C*W/SSFMVU;-!6A*G'+JR+=&78OVSQP=-R!`
M,4=S:00#EUK<O$7-H+#-79K!",WR^.T,;6=2*62]B$D`/*&[0UW/R+>&<*<E
MS7.<GM<GS2]&G<SN<P9+(\1NDABRTD7$E<)%30AFS8=]5A5WXW;17X3'\[%1
MF/&Q+1A.1RK),;C:K#%K/)^&GAK\ACVIG8(KF>SCB035(U!8FTQB;#<FL5FG
M%*[RNTM+MEA8QRSY0Z_>TND(?@>^-T(<QU6N#F>=NV@463T[P/R_.KZXMY+Z
M_=:Q9XW+8I8X+<,;VC6/9//B#2]KF/V``'$*U6:2G%#DBIW=XTOL%38"@1>-
MZME>8>-'URDKJTKUNF4JW&5U&*(V)%JVY";<II+;QTV0%$1%0H`(A[[GB!G=
MMG%,SM;2RLH\OAN26.F<YXFD$;8^N7-!J=]-KL+:@$E8.SX3Z;S3('W.0SW5
MYF[<XN+(8A;PQL-M&Z1\Y>WK8"!L8*NZ'&@4KZ5>6M\K;*T0X6%BR>JO&PLK
M`Q?0DRR=Q[M9D\:OHUT83I'2<(&`IB&.DH38<AS%,`ZZ=EN;6F=VS,PM2YN,
M.!C>,,C,#BTX@"0#4;@XTW5*XWG.17^GLRER[,W=I>,##C:[%$]KVXFF(["Y
MHK0N(:0[86@K*>E.O*G/6%N_UD5BTZ4Z\J<]86[_`$1.E.O*G/6%N_T1.E.O
M*G/6%N_T11KXOLNW7"O#KD?)=)?L6-BK[:!0;SD['R%AC*LWL%EB*X\M2]=8
MNFSFPJ0"4MTA)B50@.5B%(;>*(E-K.L,ZS33^E;W-<EMGWU]96OK'8,<UCY?
MX@9V;7NJUKL)+\1!%&G8LUIRTMLWSZ"QS*00P7$;B7$5$>$'S@-IKT+RDP7Q
MX<:JW'1@WAFO[&)MM%OGKC$9$E@-$JN\=V>"Q<SR+,8]=S];KU>*^RAB94Y`
MG')T48J20DR,VJ!'$<Z<*[3I+L]2:-N-67I]6>R;LX(G]9T]'ECWM<*-:&4Q
M"H.,'JK`Y^7Y1GT.368[:-P<97M-!$W_``Z@U+NT'-3!^LO>_I3KRISUA;O]
M4*XG2G7E3GK"W?Z(G2G7E3GK"W?Z(G2G7E3GK"W?Z(G2G7E3GK"W?Z(G2G7E
M3GK"W?Z(M&Y:O=]92D71<>22$1/R%2N>0K#:9)LI,C6*/1DXY)V,+"JJ=#D;
M/8YN9;,FAG0*-&B8+N%$EA(FBIF\KR^&\M1<73"092S"-]`:!WP'?SK&YA=3
M1M`8X-`4;.&/B.R/>*?CC(%GN!+U0LD9&E\4K2(1;:)F:G;20ZTU6Y-LM'1D
M$A*P$H=NI%O&R[3I#9\"3A%4R*AT4LWG656EO="VMHS&YK<3@36K1M.WI"\%
MIF5R(,;G![CR<RL-<XF>-9A&E83_``Q6.Z/EY]9!"W-D96HQ[:O.Y%@U;RCJ
M";M))\?S"594CHA4BN'!C%5027;(N'!KC\@TU)+UKD1/#"X-H<3J/:R@.X$X
MJ@GF5#LRS0.HR(N;7?4+[0W$QQD'JT0\DN':6=6"%0,WL3))E<FSJT2J\=<`
M:J$CDJVY"OQ17,3'J+F;G4427=@B`&2]T-,V1:>C#.SNG`O<!5SL(;4-.TGF
MQ4Z2%4W,<SKUHS3X0N-`XR^)/(\U/1\'PO2L<R@YLT"Y?STE=VY&;])S5V2Y
M7JR%9404!$TJ_<B)-W_5F`@/N^0]-WI_([6`2R7D<M8FNPM?B(<[%U2.=M-I
MW;0KEOF>92$4@=4FF\>5>D!G+DIC%!VX-L$0WBN%MT=@[-I?=[1*/L:TMX&,
MEG]S78LX#,328C$.0<BITIUY4YZPMW^J54G2G7E3GK"W?Z(G2G7E3GK"W?Z(
ML;N%T;4BLRUIF',@=A$IMMJ#14ZCQZ\D'S6*BXUDF=9,BCV4E7R+=$!,`"HJ
M&T0#:.B+#X#.%,L]DCZQ!SD@^=23RUQ39]T>4:1JTY34&CV9BF3B019C+%-'
MN%5VSQF"[%P1FN!%1,GL$BVITIUY4YZPMW^B)TIUY4YZPMW^B)TIUY4YZPMW
M^B+D5P[,8I2NEP,80*43N%P)O#R%WQ`PB!-[L[.79HBAU"<8S-:2@(ZS5:;B
M22CNF4^9>1<LTDDJWE&QV*8K<O57R+UY%O'<?`NVC$PKM$G+DR4@"BB!$DQ/
MHBNL?QB5%Z0CI2OY"08+L(2Q")XYHG)5^D3;&JK(W.UMC6`4F\2=Y=(U,B3,
M[M[N.=XZ!>:5W2+*X;B>IU@M-/J<2RO*SFY$CCM)-RR9Q\.P"6J-<N<<F\<O
M9Q%9T[7B;2UWV[)-TX1$%#G(""8JZ(I""Y=`(ATIR.P=FWI"WL?_`*>B*G2G
M7E3GK"W?Z(G2G7E3GK"W?Z(G2G7E3GK"W?Z(G2G7E3GK"W?Z(G2G7E3GK"W?
MZ(G2G7E3GK"W?Z(H%\3O'8SX;L@1U#>X[E;BK(5=A9?.C>T(114R/GC]H5IT
M=>-?*"9+H&T3[^P=[9L#9KC'$'C%#H#.&93-9R7`>T.Q-D8P"HKM#@2OHOA+
M^7^7BID#\[BS6"Q<RZ['LY`\DGD<,)`HHY_>V0WU(3GR]9?L'6@._,_:AQ$>
M5.<RNPF6.I_=72!^3>=U2_/K4/J0>K)R$C]KH3[VR&^I"<^7K/\`8.J?%!!W
M2[TL?U5/@UD[^M?HR?63[VR&^I"<^7K/]@Z>*"#NEWI8_JIX-9._K7Z,GUD^
M]LAOJ0G/EZS_`&#IXH(.Z7>EC^JG@UD[^M?HR?65?O;(;ZD)WY>LOV#JIGYG
MK=[PPY4X5--DT3=OPEJGP;2MJX9]:[!^Q(?_`.2EEPN<:M2XF9"PUUK!R5(M
M\(T+*(0#^62E2S5?`R:+J28OF[=D7?8.U"D60.0!`IR'*(@([.F\.>+66<0[
MF>Q9$^UOK<5=&]P?L+@VN)H`WG<N.\6N`N><)X+?,);J&_RRZ<6MDC=N<&EU
M"QQ+AL!V[N13*YY7WQ3\\W=UUM[',=1PV<AYUPL;6@G?S)SROOJGYYN[JE2G
M/*^^J?GF[NB)SROOJGYYN[HB<\K[ZI^>;NZ(G/*^^J?GF[NB)SRP[`%540#D
M`!4..P-NW8&T>0-NB)SROOJGYYN[HB<\K[ZI^>;NZ(G/*^^J?GF[NB)SROOJ
MGYYN[HB<\K[ZI^>;NZ(G/+>PJJ'XE#@/+R#R@;V0T1.>5]]4_/-W=$3GE??5
M/SS=W1$YY7WU3\\W=T1.>5]]4_/-W=$3GE??5/SS=W1$YY7WU3\\W=T15YY;
ML<\KL#;L#G#[`V]G8&]L#;HBISROOJGYYN[HB<\K[ZI^>;NZ(G/*^^J?GF[N
MB)SROOJGYYN[HB<\K[ZI^>;NZ(K[65%#6"'`5#B`R#;D$QA#^=+[`CJ0JF><
MI1*?S:G\`W\4=%=438_^R&=_$T_7['1%G&5/Z6JO]9X']9--$6_=$4:LZT]U
M=V=BK)"/T6MFIDG7%9%FR.[%F$RTD(]1PF38"2BK9-UO@03!O"``/9UXLSLF
MYEED^7%QC,T;F8P*EN)CV$@'8?/KMY0%D,IOSE6:09F&"1T$@>&$D`EKFN%2
M-HVM^506@^!J)@9*%DV\O9^?C)"#?NQ]72!YR\RXD>8H%(/=G*T!ZD_5DCB0
M#?ZP82;HE]UKF=IPCRJSF9<PW4OK+,-'8&\EIZH_97_$82X\Q-!L77+_`(YY
MS>VLUI/:PMCF8]HH]Y+0Z^]=:1LVF-P;&*[V@$[56D<%3VHIUTCNXV2<6KUM
MQG9$5O5%O&@LUQ=2INBPT1S:"RQ2`[BI<IUEMHF!5'L;#"`7LJX8-RUD37YA
M+,^*>VD!,,;=EK"Z!C"`=Q:14[]@7GS[C*,YEG?'ED5O%<6]U$YK9I7BMY-'
M/)("0-H?'L;NZQKN"P^S\%ESBL=DAJC,2]EL;"GTC'D41W7V\*@2"@LV,<E*
M3:JJSA=`\C%QQE$N;'8FY%`!#8)]T,;?<-YK'*B<LNI)<Q:UL%71L`+#.)\>
M$&@+3U*;B-N]9C*.+UEF&?%^:6K;;*GW4UXYK)9#5[[/U,Q8B`<-!V@._$<-
M*;5EZW`\F_@I"'EK3:9):5J.3:W*R:=50:=+D\EY!;9%>V!!@"BS=L2*E&1$
MDF0[Z2J.T#'`1UD6\*K2.S?8S7DCC):SPR'LHQB,\XN'/H#0%KNJ!N(V[UBG
M<9)A?B\LLOB;;QW5I-$TS2'`VR@-O&S$14A[>LYQV@[!L6P8CAE>LL&W?"SN
M1?'+?&]K2D9Z%H\;6F<:>T$(BH6$K,6FE'-V<<W2(5(BBJBIQ`1.H/8#8(M&
MQ,TC>:1EN'.MKSM*R"-C',$E-@:TT.$#97?RK7Y^(MR_B%9\0(;5C+BT,1,#
MI7R,F[(D_P`5[AC.*O)2G2L"'@H6F4C!?K9:+JK)6['$[:0]525QI.US%<"]
MA:E2DF\*Y35C&*2KOI2[I-8[E98H;!+V=8%G"ZREPC-+V>[C-S!+,',:WMFV
M[`R&)Q::M:P"H<-JV+\:+ZU!.1Y=;V,S+2\BA<R1[S`^]F=-/,P.;0O=B+,+
MAA+=ZZT9P+1T=&2\'YXL#N%=XZRCC6!9/:HB["L0V2+8K:T'#)9VHX46=U59
M8R+8QA`ZB?NC&`W*/DMN#^46^7NRTW4\EOZE=VS,36DQLNK@W%0:[3$26-!V
M.;M-"O3=<=L]N;J"]]2MFW<696=X]X<_%*^T@;`6NH``)@W&\@$@[&[%G,OP
MLRLJ>0=)V:PL)!]@^IX6,Y"J-)!N=I59E*7/+O6,D#EK((SI$Q;/&)PW#-U3
M@50#"!@SM[H(7SY99;^<229='9@AC*M9&_'B%:UQ^:]NXM)`()J-:LN(\=I%
M%;NRR!\$>=3YE3MI&$RSL+,(+1U>SQ%T;]I#PUQ:<-%LO$6(9C$]`AJ+TR?L
MQ8E:463D7D6Z:$12DI)S()Q,4P%1X,=`0Q'`-F+<5511;IE)O#LUL.F<B&FL
MCAR..7M88"_"0P1M&-V*C6`NPANX=8[%JVLM1?ZOU)<:A,`MG7`95@>9"2QH
M;C?(X-+Y'TQ2/PMQOJZ@6RO,\OZ)DNHNO$ZSU%K&`)YGE_1,EU%UXG2B8`GF
M>7]$R7477B=*)@">9Y?T3)=1=>)THF`*./$QB'-V3*A!Q&)W5>A96+G7$\X1
MO<=/JUYQ+Q\*_P#4.9>M(B.>KS:-'NQVDT$4KS#:0<,T056*1,2GP6ILGNL]
MR:3*["4P=H&"1XIB>Q@-8S78`^NT[QO`*RF57T>67PO9(P^CA\+6@[<(Y32N
MP[UXY8&^S(^T/QYQ&R63Y&\XT@:(T<X_?4R/7M%VNMIB'%<L4E(/G[EZ%69I
MR5D)#V6P,I8S@.C61A.%0.HB+0BA=@T5='3O#++=':D#;O4\#'MNI&$80XL#
M+-XILV`8GCE.]8?/X79OK.XU)E0%KD4C6B*-YJX#_$W[29M]#YGZJ_0^I$RQ
MCF,6(D@*([2%Z"YVE)_Q"C_)=D"[-445S`%\_,\OZ)DNHNO$Z43`$\SR_HF2
MZBZ\3I1,`3S/+^B9+J+KQ.E$P!/,\OZ)DNHNO$Z43`$\SR_HF2ZBZ\3I1,`4
M9.)[A:F^(:L1K&$MMVQ;<8,7R47:*ZW?`C)P\IT524J5H9HF:N'];D7D<U<'
M*BLDLFJV*)1,4ZB9]FTSG`RJZDDN(V31/9A#'$@-_K"G*L/F67NOVX,193FH
M5'[A,^STM'#Q*Q\K;<B6.[LJ^_<S%=HD7$2+"CMK$X;*M4K1(MWH*N'<NP3=
M+BW!(B)"F7WE!5,FGN^[/M50YK;"&WA:+D&CI03C+>5M-VZHWKR9=D,]L\O>
M\D$;`:+&Y/@KXS(5O5(#&_$K,P]41D&*<LR*TN<0G68R,K[R/:*UN."1DT7A
M3R[SIJ[(#MD'"J12J";>WT[\6H],.8Y]U9O-[@+6G;L)>U]?W:?`59GRS-1.
MUL,A$5=NP+*8W@5SQ!RCR7@N(RY0;B:>1RUL5BX:THRMO;,[(C/K%F9D\X<Q
MY18AW"(OBMNDG(N8IMI%%"#:?J')W,#?4JD,(&(8AYK6UH>48:CI*N.RG,C_
M`(K@*\P6W<-\,N=\:7UC8K'G*VWFE,H%:")CI:&L;6"*7S2@Q9O&3-S.OHF)
M6:OFX.0YAN&\)C@`@!C#KPYMG>7W]OV-O:1Q.,KG5#,-`0!AJ-X!%1SUZ%[+
M:TO[>X[=TAPX:4H*<BEV,/+[1_V5)#^'H+GE_#_-:UC<T,&X+*M#I'ND?O-%
M3S/+^B9+J+KQ.HHKF`)YGE_1,EU%UXG2B8`GF>7]$R7477B=*)@"Q&^XW>7Z
MH3-4>,I5F61".<M'R<<X54CI>#EV%@@I,B(D3!P,;-Q3=84Q,!5`()1$-NW2
MB8%@U:X=V-6LM>GXX+DX:59Y=)B&@I=>3EF,/*75@A$N48$SH/\`8U=B8U1Z
M1LQ(4VU1\=110YBEV*)@"W/YGE_1,EU%UXG2B8`GF>7]$R7477B=*)@">9Y?
MT3)=1=>)THF`*OF>8]B)DMO_`&%UXK2B8`M0R'#9C24DRS+W%I32@7&0R`=Z
MW3L#!9S<956!<2,X]Z"[;IOEG3NK1RXI+%.V!=DDH"8'+O:43`OHZX<<</%H
M99?%J0F@30_FXB;>=;I`W@&43'Q$>]1;.44I:)9MH%B`,W95VASLT3G3,=,I
M@43`%TX+ABQA6GL/(PF,7;-Y`3);#%*F>W!X5&919L(]B]7;OI1RW?C#L8IL
ME'IKD42CB($!L5+=#8HF#I6YO,\OZ)DNHN?$Z43`%3S/+^B9+J+KQ.E$P!/,
M\OZ)DNHNO$Z43`$\SR_HF2ZBZ\3I1,`3S/+^B9+J+KQ.E$P!/,\OZ)DNHNO$
MZ43`$\SR_HF2ZBZ\3I1,`4#N)3[.*D\4.0V^2+G>.("J2C6MQE81B,?SL;#5
M\C.+7>N$W16<A5)9P#YRH^-SQ^>W3;I=A0V<O/=3\,]-ZMS1N:YNUSYVM#:<
MA`%`NPZ#XV:SX=9*<CT]ZJ+3UH3U?$'/Q<HJ=X/R*/OW*N'/K<XMOEE7_F#K
M5QP%T(-C8G`?$MW;^:KB>!UO42XDFO8MY35/N5<.?6YQ;?+&O_,'4_@-H7[-
MWR*KQ5\3>:P]"$^Y5PY];G%M\L:_\P=/P&T+]F[Y$\5?$WFL/0A/N5<.?6YQ
M;?+&O_,'3\!M"_9N^1/%7Q-YK#T(3[E7#GUN<6WRQK_S!U2>`7#Z2@N('/8"
M"!6G6&XU',I'YK>*#:X/4!44/\!IJ#O'QJ8O"[P2TOA/C[2VI"^2[?)VYXU7
MDK/D9RA.V)LP9H@1&!C7L?"1";.%%?>7.D"8F.L;:8P@!0+O.D]`Z;T<UYRJ
M$>L/=M>?.+>1FSD!VKF.O^*^K^(KXAG4D;+6$=6.-F%H<10N^&FRBE=YGE_1
M,EU%UXK6ZO<Y[L3CLY!S+F(91H!-3SIYGE_1,EU%UXG5%%.`)YGE_1,EU%UX
MG2B8`GF>7]$R7477B=*)@">9Y?T3)=1=>)THF`)YGE_1,EU%UXG2B8`GF>7]
M$R7477B=*)@">9Y?T3)=1=>)THF`)YGE_1,EU%UXG2B8`GF>7]$R7477B=*)
M@">9Y?T3)=1=>)THF`)YGE_1,EU%UXG2B8`GF>7]$R7477B=*)@">9Y?T3)=
M1=>)THF`)YGE_1,EU%UXG2B8`GF>7]$R7477B=*)@">9Y?T3)=1=>)THF`)Y
MGE_1,EU%UXG2B8`GF>7]$R7477B=*)@">9Y?T3)=1=>)THF`)YGE_1,EU%UX
MG2B8`GF>7]$R7477B=*)@">9Y?T3)=1=>)THF`)YGE_1,EU%UXG2B8`GF>7]
M$R7477B=*)@"OE;BI-.>B5%8U^DF1\W,=11HX(0I2J%$1,8R0%*`![(ZD*0V
MAJI+*?S:G\`W\4=%4HFQ_P#9#._B:?K]CHBSC*G]+57^L\#^LFFB+?NB+7LA
ME;'479GM.D;E`Q]FC@KI74.]?H-'72[<,QZKQ3<S@Z2+R<GRP+L[6/1,=ZJF
MCO@GN&*8Q%U7>7L=,\5OLV+VID.+(RGO;^^N#9)X[9-JE&1ZTI)RZS5JU5D"
MI1K!LH=PGS//(BF<IR`8HET1:_:\6/#H[L,S6$,O5,9BNWQYC*?07<N&C>'N
MT=C)',;^)D9)TV1C&B++&S@DFJ[.L#(A#`D*O/CS6IJIJMMRM]H4(@FYF[M4
MX=LM&A-HN)6R0\<@K#;"&"716>/$4U8L05+_`*P411]T'NN72I"H>UKP`>0U
M6$->(C!TBPE7T-E6E3Q(.4M$)(M8&>8SDLG+4F1)$VZ/0AHM5U+/G5<D5"IO
M"H(*<P)@$VP!`=4@4%%45FQ,BX^4BIZ=3O5.4A*JLLVM$RG9H4\36W#=-)5P
MA/R)7HLX99%)<ACD<G3,4IRB(;!#4HNNZRAC1D,L#W(E%:#`MHM[.`ZML`W&
M&9S:'285W+`K($\W-I=M_*-5%MPC@GNDQ,'+HB^1LKXM(V3>'R50"M%GLA&I
M.C7&NE;*R,2`#*,$UQD02.]C0':X2`141_XX!HB[`9-QN.Z(9!I`@>'CK"39
M;('W5?F%>9B)PO\`K_NH>46#<;.0_D%S<A#&'1%:29FQ2=]T$N0Z@;:=)N1Z
M$]'##GD%YE2O(PQ)T''F=2P'FTC-@CP6Z;SO)S7*&TBZ4?G+%4I5*W=F-VAW
M%<N#I!G5W117(\GEUY\M8`D;#JHIS#H239P14,1`2HAM.?=3*)P(K:[XC\#,
M)]&M.\OX]1EG$#.69!$;1$F;*PU9>MXZP+)R1')HT[J)>.TRKM05Z40HB84]
MTIA`BRNH98QAD"(2GJ1D*F6N(5KT-;.G0-CB9))&LV&.++P<\[!JZ448Q4K%
MFZ0@LL5,BB0"8!V`.PBZDYF?$5;I$EDN<R;0X['T1#J6"1N:UJA35MM"I)OE
M329I9)XHS4:&)&.-PQ#&YP4%`+M$A@`B^;K-.)VRHIJ9%IPH(EE!?R*4_&KP
MT.:'1BG#]*>G$7"D17UTT)MJ8B;U9%18JY13`VH(J*<B+[4C+&,<B0;&QTR[
MUN>BI"M1-U;JM)-L1RE4YYJ=]"V%_'.#I2,9%231,RB*SE)(AR%,(#L`=E'9
M-#S(W8YU*TY:;!7X%!&*F/;0[*\BUM;^+WAMI#6[/YS+U4Z!CC#[C/=V?PJK
MJTL8#$C>4D(;UR<NJRUED%V;J3B':+=%`RKIR9JKS:1@3,.KBE9E5L_89N;U
MRPKV2ZF]>MY2*A2M%95O'K/I2<H]=R3%LH@LD+,TVLYHMKCY+8TY[<;N2[^Z
M8I@`BLS7BBX=I#(),5QV:L;O<@&46;^K+2U1+EZ5XBVKCL(XZB3DS4DHY;6V
M/.@U%3I#@KC^3(?<4W2*^KYVQ(TR;/8=>WZ"89'J]`CLHV*N/U56)H>ARDRM
M7V5B?RCM%&$;H*2R/-&2%STA(%$CG3*15,QB+(&V5<7O$>DM,CT-TV\XP\/T
MAM;Z^NW\[V%$CFOQ7/)2!T@DIUNH51DAMYUT0=Y(I@Y=$75:Y>QB\F7,$WOE
M6-(M9&+A13/,L$D'<W,HOW$=!QCU5<C.6FU48M<QV;8ZKE(I-IR%`2B)%U+3
MFK%E/QE:,R2]W@U<94R(F)VQV^"=>M$6QC8`522ZB7JV26<2#EBLB9,S=L15
M?G@W`()_<Z@BJ+N5_*-+L$"6Q#)O:RP%51%1ID"%F<;SK(Y.E&*$E7+TPK\]
M&E<HLE5D!7;)@N@054]Y,-[4[.0!0X8N4CX%]U<JXM;HR*[C)5!10B5XMK++
MK7&NII1CF<;B[A6\@J>1*1DO+M0%1J102F<)AO)@8.74`$<I4C8LDC;%79EY
M+Q\1.P\J_K[Q..GF,;)LGSR#D%4".4F$PV;+*K1CU1LH50J2Y2*"00,`;.72
MAYS\GS*:E:_H&=,0Y.0M[JC7Z!G6]#O5MQK:U2KJL"1%THIFQ;7#&-*(L>E^
M9P=I&.X;\ZT,10#$5,7ETV\Y*5)7-;/&$V]C:U%;+>-T[*\9V>0;PIKG7NG'
M:TI_"Q=M4,D$@/-'KLC8F2+LAQ*HBHY*!BAR[)4+H/>(;"C*PQ-7-DNK.IB9
M1FW#-&+?DF&A$*U(Q,58E9&5BP=Q406#?SS--WTI9$4.?*)P`NT0(LW+D*@F
M:5U^6[U$6%O4*E4GP62'Z%:53H'=%2KCKIG,3BAFR9E-UJ94=PHF[`;=$6*S
M>=\-0+&"D)#*%'*UL]MC*+7%&=CBY,TY;Y:=BZTUKT4C&N7:S^2)-3;5%PFD
M4PM.>*=;FR;3`185#<6_#I.V6P5&/RQ6AL-4R'>\4V5@]Z?$D@KYC.J-[S>8
M63>RC)HP:)P%4<E>*.SJ@R43`X)K'.0Y2D6[&UPJ3U-!5G::X[3=)I+-5&TW
M&+D<I+O&T<@JW.DY.59-:0>HH$,7:!EE2$#W1B@)%J&'XG<-RU^L.,EK+)UF
MYU9I%R$M'7VG7''K,[&>L3^IUYS$SMV@H&!G26&P13EM'`R<KF?F0.9`%"%$
MP$62N,]X79SZ=:=92HR$JJRFWX%4L<65BBE6YZOU><;NI?I/FEI*1]AM3!F=
MDJN1WSSDI02'8;81?:VYQP]1ZW;[;:<GT6&@*`FN>Y2#BS1"A:ZH@R>2(LI)
MN@[5=I2JS./7.@S`G2G'-&!),Y@V:(K>AQ!X87O,MC7Z2:JA=H*+HTO+P;V1
M2CE6+?)8R?J$T6<R'161IFU)PSE1G'E4%\HBGSG-;AB"8BS9UD*@L6)I1]=Z
M@SC"3:-:/).K)#-X\EC<*D1;U\SU9Z1L6<764*4C03=(.80`"".B+Y#DK'0+
M.6PWZE`X93K"KO$!M4%SS2RRHJ!%UURET_?0G9(4C<PT.`.%MT=P@[!T18OD
M;/.'<3LWSN_Y&JU<4C7E28.XMQ)HNK`1[?+''U"FM2UM@+J?44LMEE6[-INM
MA!153:`[I3"!%;HKB0P1-9)E,/1F6J(]R;".G<?*4U"?8C-,I5@>-(]A5D#*
M%)Y\;>>&QC,@,+K<5`W-B4#"!%W[#GS#57]0#2^2:F1/*5L=T>@*L95O+H6>
MSQD9,S<Q'Q[F*,];@G!0]>?.'[A0Y&[)-L<5CD'8`D68M+_0W\6A-L;K4GL*
MZ;$>MIAI8X=Q%N&:J3Q=)VA((O#M%6RB$<X.4Y3B4Q&Z@@.Q,P@1<AOM&*ZB
MF0W.J`]G8MQ-PC0;%$`ZF(5HW5=NY>*;B\YV0BVK5`ZJCA$#HD3(8QC``"($
M6(L<]X/DI9Q!1^7L:O95K#U>P+-&UUKJQ@A;M+S$!49%-4D@*"[:QS<`\:,Q
M(8W/N$#$+M-L`2+J3O$+A"NR\57I+*E("PS;Z4C(BOL)]A+SDE)09(Q::CVD
M1%+/'ZSZ);3#99RB"?.(H*@H8`(`B!%\9?B+P?"HVQV^RA42L*+2'F1;;)-)
M(DE%PE/CY:5@7TNZDHTKMBH=M-0CIH9JDH=X#A(4^:WA*`D6,P/%G@F=D8:&
M&X/J_-S<S+5Y"#NU/N5#F&4Y"5I>Y2,;.1UO@(=S7UTZDW-)D%Z"!%60<Z0Q
MBCMT1;-<9<Q6VCY*55R7021T/!QMGE7HV^OG;1]<F1`L-.O%22`E;Q$P<Y2M
M'!A!)R8P`F8PB`"1:?G^,[AOK+RDM)G(Y&J60*+2\G5^83JUS>5E&@9&G&U:
MHMKLUH95YS7Z7#6FP.TV;1:7<LBG7-NCN\HZ(N,OQG<.D0:80]?G<W(0&6;+
M@V5AZC2+[=+`WRC3*<]R!;*RE7JI6)>:>^K]-C'4@Y=H(*L2(ME0YX3IG*4B
M[N+.+S`V9[+*5;'%KF;"\AJC7;](2YJ!D"'IR5*N,:XF:?:$;S.5B-J#J$ML
M2S7<QBZ3TY7J""ITMX$SB!%ME7+&+$8PDTMDO'Z4,HS=2"<LK<JXG&*,&+L[
M!\^(_/)`U.S9ODS(JJ@?<35`2&$#!LT1=U7(^/$';U@O?*8B^C6K!](LE;1!
MINX]E*I(K1;QZV.^!9JUDD7"9VZBA2D6*<HD$0$-I%T#Y<Q0FV1>*9.QZ1HX
M<R;-NZ/=*V5LN\A`5-,M$5S20)*N8@J!Q=)E$3-P(;?`NP=$5\BKI3IV0/$0
MELK4Q*IQ<=.*1D5.Q<A()PDN3G(F849-'2SDD5*)CO-G`E!%<.4AC:(LFT1-
M$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%P4_FS_P
M#?Q1T11-C_[(9W\33]?L=$6<94_I:J_UG@?UDTT1;]T1>2>?^#"PY>SKD$B&
M5Z;5(^]WS&V;HB)E(J/L-R?2=(I-'I3F'@FB5CK=FA&4*MA]N[(LDHK&OB3[
MPKDACM"`8BEY@;%,?6^&!:@9"?P<E&VU#,5DO`,)9L^JD4QS+=KU?++6(V8$
MP1Z]>J;:Y+Q::X""/,--[D+R`1>5E:^S>P]+UBIN8WC.HV0)!2CQ-;0G6LE%
M%ALE9PJN8(3(<AD65=4[([:8=.9*D*L*:_CX]\1VE%N$C@Y`5")F(I69!^S1
MA;E2ZE!-KE&M9ZB80P+A^MR3NKSI6PIX0O\`.7M4CM_%W!I=VM2N@S!6CI@U
MF".2E:('.Y6$HE$BCBR^R'7VQU*@\]8[85B@SI)IO$P.(RLKK$.IV-O!'S6Q
MR;&^G=R*<XVOJJC<90KD44(]#F0WEG2JI%*:$^SJ;4_&EEI54N=7%Y++\.$V
MU1F\=H+4J6LO#Q9Y"TE&^U:-F8Y6U0^0'3TB,BETA)P0B13`JH8H`!%KN,^R
MT3&STV4LM]H4G#T2U6NXQ\?"85BZZO9)'(2,6O9HJVH)V!Y`NJM49>'2]4&#
M=HFG!QYNC[5!(0^B+NU3[,3&R$F+ME>*A/L(*"P]2U(9OCROO&,3.8??<*CV
MP.%FZ<BY083%P)PW;C]$Q"+)A.CSO.<R`*D6"5G[)FF,\IL)QSE:$M$94+I7
M[G(U1S67K^08*)2]4G&]++#*W1W2ZY4@AZBT6C2#""\([.94%3(D3)HBMUB^
MR3MDW`QL,EFG&4&DQQU%8F<-H+`#6'2E*K6ZR\J\%<9.1C[FWGW64A*L1^^D
MP=)D>+"9J<O0=B(D6]+3]FQ&6W&=(I$GD%`\S0\.R.+XNUIU!!*58O)7.>/L
MT/[)7G;A\Z=5MZY)1/-8&2,HHF1T"YA/S?-'(HL8B^S8DI:*R=,Y_F\)XWL\
MD.+:,A5J9`5F58U&.I[GAI3A;!+/%I;HD?=,HIX4*@<I.:4>)S*9Q#;_`*J!
M%(#'GV<YL;4O*F.YG*N.X2"S'A)+!<:E2\9A3EGEH<UZ#CU+8Z2G+G/+OI%X
MRJ.UU"Q*T>REDC+++H\^3GM$6O)G[+>7R`WR,3Z:L6I0F4;)-V7(,'6<2JNZ
MM`9!B8+/M*CJ_0XMQ?7,?7JA7WN:%7,BP=@Y?GE(M0><0,Y4!(BN1_LK+,>T
MP-P2R?BE@I1\A*9"J^/V.$7PXRD7SNR(V:096V+D;Z_LDA"2CTRHC&)2)8YD
MY(1PS20$ZR9B*_8B^RH:XOK^6:ROECSPEDSA^D,)IS32L6"/D8A6=K6.8.5<
M$B'%Y?U-"E1Z^,VQV4.S9-EA:O%FRSQ0I2&,19O%?9OIDJG$XRDKO4(RV<3^
M.G=+L#NE8R2@*M1UWMVN=M5+4H9U.OI$:N5.SHI]!7=_RKENJY,?:MN)D6GI
MK[*II&V7)[L,YP#*L9FO/1H9A9J"F>R8UIZ,MCBQ4BC8AL`V]B5G;HM?&I8H
MS\R*AW4$*"1&X*LBG.19&T^RVHAK;,FAKUCQFG#8RQK1F\1!XN@DK%4[+5X3
M`S$;4[5;3(F8J3L?@Y-PR3!!NY2&77,"ZI`#>(LKRMP!5_+61Y#.KSB*=`^R
M5ER/EI"/>(Q4QBRT8K488WAX3#\9`*RJ;)_+.'F*(5RE)$<+=(>IN-C0W/"&
MB+"[C]DU6+2]B5Z]DB#B$(9R_CYB!:T^0C:^^),9`SC>'LA*LJ/<ZD\>VB!B
MLU),XH':YVR1(\!6242<%32(KHU^RO7K,E6I.B9*QW'+Q>):SB200MN":[=8
M9$8APUD93*,#69":;P2>4GLG&I"@]>I.R(IN'&^"IS$,!%F52X`<B0_##Q)<
M*LUDRBO*GGRMVM=O:8BDST8^K5XO$1'P$ZF>`5N+MJ]IZ3*";+HH-W3%8BBZ
MJ:?-)E2W2+#+Y]F':,DBI%S>2L9UZF2TG29^Q5*M8QM,BT7E:)6,I4V.CXYU
M<<FV!R6NR\)DY91^@\%VHHX0W2'(B<4RD5ARU]F3>)[(-7LU#G<'GAXW*>49
M9"+MF)1>LV5)S"TS7/V&0OC)"T-D<E6BBV/(C6+J0)%C4XN-*<Q]_>.02+>/
M"AP)W#A!FK@6AY&A;5$76(5@W]CNT?<)2^%0AEKY8Z;+RKE[=9&`EYAI;;\J
MF[3:LXMJI&-2["BNH8Q2+1KG[)BP0;!.+H'$;+=!F\:#1;PGDZLN+V=[8IZF
MRE&OV0ZJHTLE=&`DK)"J,.:CU>E-4%6>\H98!*4I%<XC[*0$;I4K#.77%CVO
M56\MYI"I,L+(BV&I1>1,,Y%80+:6GK;/3(JR$EB($7*+Y>0CVK:0419(((D*
MF)%@)_L@;LX=3TZIQ#5)K9)%Y'2#0S'"C(*R=W%M:9&*&DJB[MCF`*TL$;24
M@=M&:#5FW.[4!ND0$T]I%M>W_9F6ZT82PAAI/,M88,L23=^G7$B?',@]5>O;
M=FR'S-%G@WBMU+88HD-YL4A5D'#]VV?MEP=*IBX00`A%\H?[+%&KY%K%OK%^
MI#2$C'W#JYDH1YB=DJ[BR\/)\+/V[W'3UG8F3.GV#(LKB0X33T6S@YVSY,H`
M91N)U2*U9=^R;#(]V>7B*S4XKJTMD[-&5;)`!67R<;;)F^7-I<<>QTQ)0EKA
M9QJSHQ%I.*?+-%DG$K&2($*9L9NF(D668?\`LM8+%-WQM:4,C@\@Z%8JK/*T
MEI6'#>*?DA8I"<FH=J_E;-.RC>*FLXP<)<2`X4=+)+Q)$3G4,H*Y2+HY7^SC
MR=FSUD#(>9:%).+!ENTY)=S;.AWZ*EI5A8*Q8,<5VM3P166V"+J,Q3CB92:U
M]L@9NS%\W5<NDE3OG.\1:4DOL=[Y)^LRZ_$-3.E6Z-L4)/(IX8.WCGC2RTNK
MTEW,LVK6\(&K,Z@%/:2I`AS1[;I)E6FZ5FH<IR+.K)]DATZK)14%DVC)3;S'
M-[Q]8U[+A]O.5N:6R2_XCEIZ\NX)O:HU=[=H!IQ`B6'=.7*PH'BQ!03$=&*D
M1;GS9]G0EE#)%AR7#W.GQTO;\>0N)YQ*T8V0LQF=73I4C29BU0#U"=B'3;)<
M:U<I.("06%1*,5*H4R:I5/<D7UM/V=C9W@;%F&:G;:DT<8[>Y?._E[9C\E@A
M+27-T)<ZW:;3(UUC.PICY(@H^WBYC995RL87B!N>*)%S`4BTC-?8^P+M''2<
M7E!JD--B/,,R5]599FE;BO+]ERX/KE/FI]TJKV:OC%GD\C9DX>KN&P*LSJ+)
MJ$7!-,BW;DG[.IMDK.3G*4M<JN$"GF*N9QCXYWC]&6N;FRQ[_"9Y.J6*V/IH
MS24H;>/PR3S4U(Q259.9'?,90K5,JA%9[[]F9#7_`"CG;(+V[0,.3,$]`6&(
M<PF/(]M=:7(-K1B>RV)ZC;!E><>RDB&+P;M722+59`KXYE!6W-AB+'T?LLHE
MQP]5;",I?H8KZLWK(%\0LK2H2TLB>1M^&93#[-(J-QNEEG"%%)9K(2F[()D>
MF*LV3(@F<IRD6'SWV4UFM);TQE,OT6.@,LS\Q>+_`%^"Q0\;Q4;:9*K9[J#>
M!QZQ<W=9I!X\;QV=UUUF;LCQTX=,3#SJ97:@$(MC\4/V>L[Q)Y?G5F\U0\:X
MD=86Q+2(Z4B*8A(9'BYW'-@S9)MX&H/F\E$,JG0W*.0624PS!%4LM'\ZT)S`
M"931%IZU_9#O[E8;!<9/)F/(Z:N\MY_MD!6\9V2L4MJ_<ERA#JQ=8;US),1/
MMJK%U[)RCAHQ=/5B*3;('*PF2<'1(19!,?9&QZI*<>M9.JT%(UNF1-.<S"V(
MXA^_758RMGFW=O9"2;9%):7SZ69E.HXZ015%J<BO.<X3FR+(<8_9;OJE4>(J
MNVC,,;(O,]4N'KR;RJ4`U?CZC/PBD!(,K$A"O+1*LWK,T]6F[L\8AT%H":BC
M=($DMS=(L3R+]E1D3,URL]^R;Q..EY2?DK'*1E9@("\*5BFIS]69Q#FLU>1M
M>4[%;HVJ25@:K23ULW>MR;K]P@U*V)N&`BL$)]D9;X*S0-I0S#C%^:J.[!(P
M=5F,.S<I3GHVMW79)]7+;'R.2WKZW0%;DXMRO%N7[A>6,JHW,NX,1HDD!%O^
MR_9Z6J5A:/3(C+M=C::PX2<-\)>02/<<N'\Y.US$-E"S$L=/50N#*)JSVT&,
M=HJ@Z;2:;)`^\B(J%*.B+"J_]DS6HZXT"9LF:;_=JK%HDG\F5:8D9Z,>7?*1
MZ%FZER-WKEGJ]D@IFB1TLIG!\Y6C$E'13E9-TCK'`#&$BW/&<%EAI&'>(:I0
MUP87"SY6X.\<<-\,W=PK:L1))K$N)LC8^B)ET#=R\;-F-L=75-59`B94F()&
M`N^4W(1:-J?V7C^(5D<A25IQ$OE>3<X@GVD$EAM,F&Z[*XM>NCKUEE5"6D9<
MU)MT>JBI)-D'S<RLT@$AM$=U$I%J3$GV5]^K67:W#6QUCIWA;#CYM9*C>7]8
MB)W(F5IM_;<.W->#M3%9RJBSI]2?8Q5;Q#%T"A(MJHU12%V5(5"D6TL5?90D
MJ<U+V'(.1J1>I"4L&*9\K9MB-C'1+-QCF_X,N4N#&-DK#,LXI&[ML()-W#9B
MFT9M?.BI$T1;HIHF(MQ\,?`?:^&7(K*U5K(]$>5Y&IMJI*Q1,9/6LW8VZIJ8
MA(/W<RM<WR,)(LHNE(-FHQ:#-HY2.ETYLY.S;J:(O2W1$T1-$31$T1-$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7!3^;4_@&_BCHBB;'_`-D,
M[^)I^OV.B+.,J?TM5?ZSP/ZR::(M^Z(O%[B9X4<]Y4X@LGVVEQA',B290F<9
M71SD.S8V&G1=FX<D<35B1@;#7&CM:3=X?S+%RMF?P*ADDW:$NDJ4JJB@$T12
MTQ/B7(;SACXBJ!*@=C(95N'%.OC6(L2*L1YAJN2Y^WDI[>49)(J*PC.3<R)Y
M06Q"&,T;OP3W`,3<`BA']U[9Z"%(R!CB03LN9V6"ZI3;W8+;?WU5;S=IK-BX
M9$"U^"3H=6@ZS!U-WCC$$Q$&D21'G-3I:)US+*&!1(BQ&%X#N-)Y:8)\]R#8
MZ;5GRM2<V^N1W$M=I"+CXM6[LI[+=)@'J,6-J-!V,BJBL&F1^T&.8M$D%ES+
M"8RA%OSB"X,\WSN6[]E?##J*(6U2^.*^^K[O+60Z<>R8@KV(WE*LE9>(P;M"
M.4GO6)1!XQ6=*"*QFJ8.'`(BHD<BQ[`W"?QLTJJYC@[1D`[*Y7/AME\>P&39
M3-%NR(\894+7JY!4R5@(U2(@V%?@8,L4\675<L7,@S=.`5:.52.7*"1%KJ(X
M*.-V.8Q9W%\D)>C,5F:<Q@V2XBKDU?V-HED1&W2C@]]@X",:0+R3Q8"]!3C6
MPG9((N@D>D&52`VB+FEP8\<$2SO]<@9QC$P.4K;#WB36J?$E=X67J9(JO9%C
MYVL1UHE*3,3LY8KFO9X9`\VY1.!B0_/.P4,1$@D5Z@."CCA%G+IMLNQ^,_79
MBSITLTC<GWV==TZC5V-+9Z7*0QW0R)0N[:\UN.C),J#SH?F67D4FJG,(MVQB
M+?N',(<5-9X6<CX6EI>18Y7C"M,@XAR%.Y36L\;Z[M[`-ABJ'*RD?`L9.-JB
M-@I[=621*F_05B["JW#G!353$BCV]X)N-I%XF?Z8Y&Q2#8B-5H<VMG*^12.*
M&T%8Z)/P^59:**RYN_V2<A26>%?L')5@%!PU`QCI++B@1819_LV.(>6DCP[F
M?;SU0N4!PWH6.06SUD5E8*KDO&I\%KY3R_)N7#9V]R+-S3&B3C*&1=K&*V56
M04*5L18XHD65V;@JX_K/`$4D\[-%[$PD8NQ(-&N5[NP:/WDPQGX')\,WDT88
MBT,VF:Q5*TA$.4B[\<[GIE=,$C)E,N19IPW<&/%%BW-D=;GMJ&FXT`V=I:!H
MD3EJ8N$1CEMDVSYBL$-49EK,0)G^2II.7O,%++2*BZ*:*\48@K+\PASY%ARO
M!GQJ+UB/BHR85J=D)2(6NP=L+Q3Y4GAH>08A5HKE?+CE@_CA;V)3B+0279EC
M"[4Z^0Q7`%3555`I%GC'@/SO'V2M]&R'*EI;R\MCY`BE<[9A<JS>+VTWPXSA
M*PB=W)K+IG6>5&^'5!!9L=7S_P`V=82.E"HD6K97@,XWFB%`:57-LRT9QL)1
MG$\FGFZZK.DLNL:5CZ)N>2W,U9XRQ2+^+=2-6EFWF]J4@NRS`*`FAOK&(17B
M>X).,2(A%8>D2S&8GF*V/9CUTM_$SF<?62(B\:TN!LN,?,93.%V#I+(#&R3)
M)_I*#M8\RF":B15'!$2+8.$."SB1K%'L,!D2UIMWEHS]@RUS"\5E6V*6*1PM
MC6<?^=*A*VV(90LLNNK43M8PK)-<45FZ)D#+<UL$Q%%&A\&'%3;,MT[%&5X>
MZRU8QK8XZWY(RK+Y5R:RQMD&MQMJP?.X[I%"CTACF8S^/XB`L2"4C'"B[.9=
M?I*B(N1`Y%N/#G!'Q;X7O]0NK9*/MLRTO$%>[Q*/^)3(:%=NL@3%N(JQ;GDW
M7'$.#PEME)6B23)K)"J^8NVSPA7S`Z)A%$B]TVAU5&R"BZ?-+G3*99+G.=!)
M4W*HF57=)SA"'V@4VP`,`;=@:(NSHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBX*?S:G\`W\4=$438_
M^R&=_$T_7['1%GV4$3J2=6,4-N[9H,P_B+)-MH[?Q!HBWOHB\F,I6/B2;\4V
M26%>-E/U+;W+&S))IC2%IMA?_1R[Q;#/:09]'W\2U^,Q[9<RN;TWM<H@9N[2
M2BV*9W2"94MXBW_A2M7;,'!')4RSS\]'RUWJF:J;2;:9]),;2EC^2M5]@,(7
M$\J"J<NC.#C@81^5R)ND&5V*F$3F'1%Y116/OM.TU2Y(7A<EUJ;MK:-XEK6P
M<3:-F5Q_D&6DHWAPL^(JM5VCNP(R3V`P"T6N#)BDR>,QFE!63(J\$I-$4K[W
M&<>L2]QUF"N_2C,W6+X:,$PF1*758W',=$7F\N+)E9UE4SJKV;S]#0ETA8Z0
MC'2`LW"2"3E1),XND2='*1:L:6O[5];'CJ,22O!-DW)VLUXFZ-2R7UGC6&R)
M)4E6B,(%C7$G\K=[#CR>C[<S<!$%>\Y%N&PHD6$&AB+-,E8YXW[[>^$R8<V_
M/E>=+8;H!\KNZ`A28&JPV2("3L,A9)^PUY^WL<=%VZ2:2+1$6Q^FL#D$Z8);
M4O<D5VQ/:?M-7E*XAGN26<TTNS?&]46HT,THE30)$609AN$R\QR^6YB&LMO=
M8Z%=VI'JE?QR5B(DD=5+>.UT11RMES^T0R(_S#C>K6+B?:*UL\(Y@"LJ)B^L
MV`N"WOTLV&+G;)8"5IHX:\2$Z6OU5!.-;]&`S1=8IV2:JSKF"+:]/6^TC4?5
MBI$#+M23?Y/BXZQKDIF+BU.M\.4Q<*6=6YP4U*0TFL&>1>24\$BU6,Z0:PX<
MZ1B04FYSD6:Y"1XZV8<*UM6FN()%X7$%@J/$2UQK7L?S3M%0V7,6JRML+5E(
M&2BQRNYQTRDCQBS1LJB4O20;MN=,5)0BO]^M/VAR%.Q0K"1>1T\C.N')"0.R
MI]-Q9)UF2SD=Q->LR6;%;$<K>M*QE*1CG48VBG#9NO9%ED"`X3*"($5CNV3>
M,NK8HI;J3G,M1=5MG$VRH-<E8S&E5D.,:7Q/(GMKN.<6.I.X%3'$>\=$BB$!
M4L0UD",$DU52)JG/HBQ<DW]J4QJ]<F;&XR"XR/-/K89A4ZM2L4.Z%&W"-N6-
M8ZL0=W61A5'T;BF6QRYL[Y60%\5<TH0H%<$%)HW7(KLX3^TFKL;`RJ]KS'9V
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MJ%Z5)`F4`*12#P!#\=IF<HUR86],JW+XUSA665)=QU%BHRN/6.-\+OL52D1(
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MVXI/>:6(D12PXKL3YI=YU4D*76LZW^S1^`^':)PWEJ!?>;8NOY,I6?K]:<KR
MEJ=0DI5JM#/9['2K`DD@:-!O,LU"L4TS\B($481X:^/V\V"LU&^U9NUBK]<,
M@<3<K/S-POE^HM*M^5,$Y1@9#&%FC8NV8NG8"7I>06E<4AH^+=NH>)=N#.&Z
MBIBF$"+)ZGA7BGPI96^0Z!1\Y-)^PM^%J-ET6Z\+>+5:5?H-A0RU&V6RVQ>P
M5ZK*&RJW6<V*0"(;LY:1(857;(#)+F(I=.V/&XUXG;@_@5K=$X4:YTQZ^C8A
MA$4):O7.DV.?H-<R+(3CV5CW]I%G7J4E(N&X,W3`Z3A$%0*J8`(8BC%*4C[1
MNF9$XBKQBB?S?8)I'(-CB<?P61PH<GCNQT^:R/Q)ST8I%M'$45P$+4:S-552
M,6:J,UB+*$;+\^DD**9%LNP&XO0QCA"ZW"N9PO\`828VXV<>6!&J5P(.ZFEL
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M$T1-$31$T1-$31$T1-$31$T1-$31$T1<%/YM3^`;^*.B**K!N8,0S?+^^Z+L
MY/8"=9&V]GM!HBWM<JX$XP%(AC%62,19!0H@!TEDC\XDH4W)L,10-H?AV:(L
M/+?[9#)E;2]34EUDB[O3XMVDW!SN;`YQ1LX3W4U3]DVX<2[>P`=C1%T?I7=`
MHHH..YLRBA.9.8[N.,84MXQN:WA*(BEO'$=WL;1'1%R2RV]1*!$\>3A"%`I2
ME*]CRE*4H`4I2$*4"D*4H;`````#1%]/I@D?J^G>O,.YHB?3!(_5].]>8=S1
M$^F"1^KZ=Z\P[FB)],$C]7T[UYAW-$3Z8)'ZOIWKS#N:(OE]+;X%15#'LZ!Q
M``,(/H\-[8`@&\.YO#N@/)R\FB+Z_3!(_5].]>8=S1$^F"1^KZ=Z\P[FB)],
M$C]7T[UYAW-$7S-EQ\8Y3FQ[."8G*7:]CQV#L$-H;2B(#L,/8T1?3Z8)'ZOI
MWKS#N:(GTP2/U?3O7F'<T1/I@D?J^G>O,.YHB?3!(_5].]>8=S1$^F"1^KZ=
MZ\P[FB)],$C]7T[UYAW-$3Z8)'ZOIWKS#N:(GTP2/U?3O7F'<T14'+\@(;!Q
M].]?8^P.T/8[(#HBXDRX^2*!$\>39"%Y"E(\CR%`-HCL`I2@`<HZ(N?TP2/U
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M4,OR1AV!CZ=_#M?L`V!V^QHB^B]SMMD;F81=<4KY71116D'SM-RY324#=4%F
M@@D"151*.P#F,.[V0+M`-$62I4]%.I.H`"%W'#9-,P;?<[4U4E`#;LV[VU/\
M>W1%L0W8'DV_@[?X-$5M71$X?^8%5'9LY54B\@]GLAHBZP-3!R>:D^L):(G1
MC>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^
ML):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G
M1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD
M^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(
MG1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>B
MD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):
M(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>
MBD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L)
M:(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C
M>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L
M):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1
MC>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^
ML):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G
M1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD^L):(G1C>BD
M^L):(G1C>BD^L):(J"T,/(,4GUA+N:(NX@D9,`V,RI<@!R*)#LY`V_O0Y>QH
0B[_+N_O>79^]VA_PZ(O_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>g5754313new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754313new.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@!*@)Y`P$1``(1`0,1`?_$`/L``0`!!`,!`0``````
M```````'`@4&"`$$"0,*`0$``04!`0```````````````0(#!08'!`@0```&
M`0$#`PT("PH*!08+"0$"`P0%!@<`$1(((1,4,5'2TU24U!55%A<)&4&1(E)3
MDY66T9*R([-UU3=7EUAA<8$R<R0V5M;7L:(T="4UY:88F*$S0[0FP4)RPD1(
M\.%DA$6%Q4:&)T?Q8F.#PZ1VAR@1``$#`@0"!08+!@0$`P<%`0$``@,1!"$2
M!08Q!T%1$U4887'1(I.4@9&AX3*2TA14%PA"4B-3TQ6Q8C,6\,%RU()#)/&R
M-'2D)46BXF/#1#7_V@`,`P$``A$#$0`_`/WZG.5,HF..P`#:.B*.IO(\/$+F
M:B8[EP&W[PV3.NKLV[.1)(BAQ][1%BY\Q,RF$H1$P(![OB=^.WWF^B*GTR-/
M(\Q]#/\`P?1$],C3R/,?0S_P?1$],C3R/,?0S_P?1$],C3R/,?0S_P`'T1/3
M(T\CS'T,_P#!]$3TR-/(\Q]#/_!]$3TR-/(\Q]#/_!]$3TR-/(\Q]#/_``?1
M$],C3R/,?0S_`,'T1/3(T\CS'T,_\'T1/3(T\CS'T,_\'T1/3(T\CS'T,_\`
M!]$3TR-/(\Q]#/\`P?1$],C3R/,?0S_P?1$],C3R/,?0S_P?1$],C3R/,?0S
M_P`'T1/3(T\CS'T,_P#!]$3TR-/(\Q]#/_!]$3TR-/(\Q]#/_!]$3TR-/(\Q
M]#/_``?1$],C3R/,?0S_`,'T1/3(T\CS'T,_\'T1/3(T\CS'T,_\'T1/3(T\
MCS'T,_\`!]$3TR-/(\Q]#/\`P?1$],C3R/,?0S_P?1$],C3R/,?0S_P?1$],
MC3R/,?0S_P`'T1/3(T\CS'T,_P#!]$3TR-/(\Q]#/_!]$3TR-/(\Q]#/_!]$
M3TR-/(\Q]#/_``?1$],C3R/,?0S_`,'T1/3(T\CS'T,_\'T1/3(T\CS'T,_\
M'T1/3(T\CS'T,_\`!]$3TR-/(\Q]#/\`P?1$],C3R/,?0S_P?1$],C3R/,?0
MS_P?1$],C3R/,?0S_P`'T1/3(T\CS'T,_P#!]$3TR-/(\Q]#/_!]$3TR-/(\
MQ]#/_!]$3TR-/(\Q]#/_``?1$],C3R/,?0S_`,'T1/3(T\CS'T,_\'T1/3(T
M\CS'T,_\'T1/3(T\CS'T,_\`!]$3TR-/(\Q]#/\`P?1$],C3R/,?0S_P?1$]
M,C3R/,?0S_P?1$],C3R/,?0S_P`'T1/3(T\CS'T,_P#!]$3TR-/(\Q]#/_!]
M$3TR-/(\Q]#/_!]$3TR-/(\Q]#/_``?1$],C3R/,?0S_`,'T1/3(T\CS'T,_
M\'T1/3(T\CS'T,_\'T1/3(T\CS'T,_\`!]$3TR-/(\Q]#/\`P?1$],C3R/,?
M0S_P?1$],C3R/,?0S_P?1$],C3R/,?0S_P`'T1/3(T\CS'T,_P#!]$3TR-/(
M\Q]#/_!]$3TR-/(\Q]#/_!]$3TR-/(\Q]#/_``?1$],C3R/,?0S_`,'T1/3(
MT\CS'T,_\'T1/3(T\CS'T,_\'T1/3(T\CS'T,_\`!]$3TR-/(\Q]#/\`P?1$
M],C3R/,?0S_P?1%VVV78U0Q1<,Y%FER;ZKB/=-TB_N&460*0-O[HZ(I0B)EE
M,(%7:+%5(<H&`P&*("`^YR>[HBN^B+%;@],QA'JQ/XR:"A@#;LZA1]W1%9\:
M,F85.)EB($%_--2R+]X8H"X76<")@*94?A@DB384A`$"E`.IM$=$4A:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB*@5`*.Z(&V_N%$0'K[!]W9[NB(50#!O`!M
MG7$I@V];=V@&\`AUM$3G"]8WVAN3]_DY-$7.\'6-]J;[&B*D%2B.P`/MV[/X
MANN(;=NS9L`0T1?31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$
MT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$31$T14'(50IB'*!RF*)3%,&\0P#U0,0=I3`/[NB
M*'HPK>%R'+P<<GT9BHT82(-T]H((K/2JE6(@01$$DS'2W@*'(43#LV!HBEW:
M/7'WQT183D/^CDA_(*_@]$5>,OS?U+\2M/N1T19UHB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HBX'J#HB_-=D%7B=RR_XC8U6"SKCVN\9F2L53>%;TSG[`8]51P=Q
MH8TQ/%OHN`AE"3&)HN>PK-1,Y(-'I69)9!@_7.4Z72!$BE/"52G,]6/AFRUE
M7'.2&%LE>)3C>&XQMA/D6'"NH5-ID*3JL-),2/V+`:G"9#8":OJ+IF:N"%0.
MU$R9R;2+6.MGXCB9#QN\JI[XKF1+`G#TC!,S)9@+E99V\X(<@MYAVJM***8L
M/C]AE=9BXL2,HW"14F$2`"I7G1BF(I+B"XC\X\6$/(9(>\'9[=@%3+QY22S:
M_A_3P;AKXI3Y)\;ND%E;6WLAIPM.&P(E,5(MGZ+T@H/S'VD6U'#=BWB`<Y3X
M5HW(5SR7Z/;)AIMQ#9)A;4YN`V9SE?"2T1C'%,-9YATNBG&)6^@Y`A9JQ1#G
M=<O;#3"+K)G%Q(;Q%[4:(FB)HB:(FB)HB:(FB)HB:(H2S3Q$8FX?64*_RC8G
MD06P>.U(EC#5BUW.<=L:Q&#-VN;"OTN#L$RE6ZE"E%W*R2B!&4>@)164**A`
M,16MYQ3X"8Q+N>7R5!FA65KDZ2M*-DY%ZP/9HC$J^=7T<V=,V2Z+PA,2-CSA
M%TA.W5:``$.9403$BN^&N(3%&?6<V[QE8'\FK6_$0S\//52W4>RPZ%HB4YZL
M/GU9O$%79Y**LD*J#E@\!N+5VD!A24,)#@4BFK1$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$31$T10JJ(^E^2Y1_U)!_=NM$4Q:(L*R'_`$<D/Y!7\'HB
MKQE^;^I?B5I]R.B+7OC/X@[%PYX\HMGK2].CW=SS+0,8NYZ]05NL]?K<;;AE
MA=S2M<HSQA99MV@,:1)%!!9,-]8#''<*.B+1"J>LLS1(Y3Q_2[9CJAU9:97P
M0PLF.'M=RHPOKYEE2+NDI8KW`VZ8285"J1L)"58DTPKM@9MYUZP5%H8Q'YDD
MCD641_'SGOHN*HB?JN((NS<35!PKE3#DPR:7B1KN-:GE)6W2MAB<HQ`3*4Q>
M9ZC4VM).$5HE>&2F9!R9N"+1-'GE2*UK>LDR&>_8JK,";!-Q:VR"X?%7#.J1
M^69!+(\QEWB!R+A"UN*%D!RU8U?&[2E-:&,D#"UM>F*O16B^=%=,JQB+%+IZ
MV>R1C/-,A1Z?BRZ(8OXJ,:X^C6\7;7LG(2/#G.V7)%1O5^FFD6Y46A<AQ,I@
MNWKL&*P)MS,RQYUB!SPB8BV5Q]Q\2-AA>/B^6.I5]#'G"G:9!IC!_`R#Y>0R
M=5(ZH*KHRTHNZ$S!JYL%[B7K5B=J',"P.@H;:<3CHBM>0N,C-F!LB9C4S!!8
MSG,4X=Q;AO(<XPQY&.X2]E4RVXRS'N4'%KR1E2"H#>*I;C$CI9184^DRI7J#
M9LW*XV`H19#;?678RK3&X2<=B?-EPCJ8_O!'KJO05,1/*0&+\3P69LFVR`83
ME\BGS^&I%1MD2BJ14C9T^E'Y6K-)84ECD(L5B_6?TW)&4ZMB3".-[3>)2=S>
MOAB4MKE_4&U5KH%JF<W)[D[00MQIL&T1=L'/V;R'<(LYD8L0?)('(LU!8BWN
MP'E=IG'#6.<KM&01HW6LLI-_%E4,L2)G$A486*(37,4IG*,5/,W+<BNP.=*D
M!]@;=$4O:(FB*R6,MB4@Y5*I.(9G9E&+DD&\L3%[)P+63%,>B+R\=&R,1(/6
M!%=@J)(ND%#EY`.7JZ(O)##''7Q!W>Y\/U9OGH7A$,M8GD<QRR]0Q'G2UB6)
MC\HH8_/4F+V*M<I'5%Z+-!PY\=SIDX[G5$TP1V)*F,19M7^.'-4'5.'C*.6*
M)0C8UXF;=B[S02Q;%Y)NF0ZA5,EXSS7D`U?G:1!-;-.V>R5LN/X,IYI@U0C7
M99-Z7H2`,055(H8IOK5<@SEBJ+::Q=4(RLW^C\+DY5),'-I:2BUKS-Q#.<<7
MRJR$3*)MW+)Y"XK`)V)14(FY.\8O47)`(F&PBDBG\?&;59/!@W:BXQ+$\33;
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M[72$#?!.7D,'*'5T1??1$T1-$31$T1-$5)CD+MWC``!LVB/4#;U-H]0-NB)O
MEW0-M^"/*`[!V;.KMZG4_=T1:6<4F+<N6>X8[R;AF%I5MGZOCO.F*9.L7>SO
M*?'^*LV,*.1O;&DXUKEG*J:JS5`;"Z8"W(=ZR=*\VJ51(A%"+25OP#9ZB*X;
M!D2ICQ[C:)L$QDF)RL_M4PTG'\X[X`G'!ZRHCO':=7<FCBFMKH9I25"651)$
M@"16YG`B4"+=?A&X8YGALD+\@^L;^U1MPJF$6[>7L]KL5XNQ+!0:,ZJ-HBG-
MDM!59<U+:JMF[B$9<^=%H9T\,1-'G3`8BW6WR]3;R[1#9R[=H;=H`&S:(ALT
M1"G(?^*8!Y`'^`=H;0ZX;0T15:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB*!^*#*D[@_AXS)EVL1L3,6+'F/[#:(.,GA>%A7LK&LCJL49;Q
M>J@^&/%QNBL")R*&(`@4Q1$!`BT+F.-[.U:S[!<-5I9XGB+@QN-LA[3?H/&&
M;LA5BR0C2CX/OE0/6J74)=S8Z3(/F>6G+.3=2S][&,5HPBO/"1R4B9%C>0O6
M+9@KL-56491\?1%MC+6AC_.#R1A<BWV,H5MFN+#_`(;JHG`4ZBN$[?:"3L76
M;#/)-$E!<J-T6HD,*9CF$BV`><95NK&-N+"WSM:KECDN'"EXPEX,8EA:J4RO
M5@R)B2N7A`DI!VH9&R4J*\Y+$FW%!R55\S9`85BF7*)=$6MN8/6!<16&;A)8
M=GX;"4CE*L6"[LW,K"4C,\[6\C)1V$*+EZB52E4ZL2UAN5?MUFDK4ZA5UW*T
MHU1%DDZ(F87(-4B+'U_6G9?;!=8!_A>F0V1(;C0Q'A*%J4C.32IT\$72;:P-
M]O$XLV'[[>*#.P4_$J%;"6--(D8@8H$5,!B*\P'K)\N!BO`V7YRMXYFJ_E+B
M&AL?Y`C(VA9AH2V+L4DJ>5[1=K1&S]W=N8C)TS56-&;.C/8LB<29HF[V_"%$
M2D4]<//%'Q#9JRCA:-D6>%H/'62^&X,_S#)C`7EY=(XS>TQ=,=UN+G5;D2`6
M17DI0KQ%VI'B)6Y!1,D8Q@6`BPJQ<:?$(WFN*2":1.%Z1:<+47-N0JAC7)]5
MRS%W:7J>(I=$U>N$;(C)Q%0S-0LJ5,!=GEJN\0+4'KMHS?(NUE#[A%C<CZRZ
MQXZR&\QSD9AB2R3%>X2;/FN=1I,O(UN=?YAC<>R^<H;'4349Z<LDRRJ;K#<2
M=9646%8?&`AL`A#`EHB^\WQW9HKTS0,<2%@X>W]_GLO2N/;K-TW&N?[\QI2;
M7!SW*K>&D<5UU[Y](RYIN.78H2Y'[F(?1I"O=UN<QVR1%Z\,U%5&R)UQ3,L*
M20JF23423.H*9!4,FBL8ZJ)#'$=A#B)BAR"(CHB[.B)HB:(FB)HB:(FB)HB:
M(FB*%%?SOR/XD@_NW6B*8]$6%9#_`*.2'\@K^#T15XR_-_4OQ*T^Y'1%3><<
MU?(9Z<I:&"KXU"N\'D6L"D^=LNA6VO(R#>*?J]%43!V@@C*+@9!7>24W@WBC
ML#8183-\/6,K!8[+:I2"6<S=OM>*KK/.S3$H1)W8L+N476/G1&1%P:(HQ:B!
M071*0$GI!$JP'`1T10K'\`6!XB&?1$<KDE)=(:*A1K$IDNRN;1A^&QC*R\UC
MZLXCF72RZU-KE5?3[T$6A07(NV<F;.>?;%32(19)4N";`U)J3^E0<'8@B)>,
MIT;+/)*\6J6GY`U#RQ;\XUN5=3DA(K2"TZWRC>I245>&.*S@[D2*"9,A"`16
ML.`;A>3"A`WQHV:ACJJ,:9!ILYF8:$?0<<I(+M"VOF')#7"02<3#Y3I<B*[@
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M17&,+XR<$!)S+ODRF7EYMRD4YR(N9J677=J$*(E(=80+R`&B*3]$31$T1:FP
M_!IB"LSN,;#3ULA4I]BBK&H]?3JN2+5%1\O33VL+L>LW.-3>':6^'4L0G5,D
M]*H.XJHGMYLXET1=#'O`Y@3&<Y!6*`BK6^DZC8*U,44]DO=FGV]!B:7"Y)@*
M;1:@WD'BB<7C^JQ^7K$#**$%$DS2(B8QN90!(BMZG`)PQ*(5-)6ANQ"C73#F
M0:P8+99P5C+/@6>MUCQJ\!8)$%'"$9(7F4!TW4WD)%!T*+DJJ92@!%'+#@\X
M07:[ZI1=UGSRQ9^IQ%19Q^=Y0+1BA7&5I<93K%`Q5T*=&8I437K"8T@:,1`Z
MHMT4DE=K5L@FD13`/!;AMS=(:\3*E^M#^//7)*8AK3D"PSE7O-NI]:<4^K9`
MR#`/5U65MO,#67`-$7SC_K"H-CJD46:ME$B+'*EP!</E34*L#.^699L2D,H=
M6Z9,N%F4KE>QI7\C57'U/KXOGPDC:M4:]EB>;-FY0,=3IO.+J++$(H!%TUO5
M_87<4RNT)>TYV<5VM5F<Q\T2<YQOKAZ\Q198NM0UAQ#*R#B05<O\<2["H1X'
M9F,"R1D3&163,JJ)R+=M@R:QK%G',6Z#-DP:MV3-HV("3=JU:I$0;MFZ90`J
M:""*92D*'(!0`-$7;T1-$31$T1-$31%Y'YRNH,.+^\1UFOV4H#),/$8#0X0*
M!3+)/-8F]/[*PRP-\&4Q^W=>;-XIKVQQR3>X/WK1RI"1C%DH"S(1145(O-^T
MWK)Y*KB.1X=LSYDM/BR!X1\RYQ40R5D&WN''$93:UQ"Y,RYCBT^,)215KS_(
M4)0TV=IIY2-F"1B,"J1Z)SI%5(K.TXD.(.GY.9\53ZU9YFL;QF:<P\3\IBM>
M2N[N&=8`RE@OA8:4?'`4TQE&AF-+KN6T9AG&`B(,YM!ZNFF5P*P:(I$X=)O*
ME:RO3J'G;+DS,V>N8_S)T9;*G$%F.G6"4R6RXFLVM5E<<U"*7/6,M3D>FW:,
MFL;+G*V:1*#)%N',;"`17O%<EE*I43$T/Q!72\8_Q!D2#X#[7F![_P`068[5
M%EI=WH6?5;5>[-E:\*UJX8FE<AY=@:O%6R'C'#>(9-TVINECTYQL(KKD7).<
M;;3[/B+APLG%#?9#*1.'!WB"7D[$:L98;4/'W#S;<NO;5(V"U2M1B(A2W6ZM
M5EA/&,X0=S+:8.14BZZYB'(O0?@2XJ:GF>;S:WF;T#>\7/)=<R!2\5V69<$M
ME<H$]PR<.UC>LH2M2BI7[.LP]NDY8JG,I@W*^Z2(_?!4T1>E@#M`!#J"&WW]
M$7.B)HB:(FB)HB:(FB)HB:(NNY=MF:8*NEB(IB8"`<^W8)Q`1`O(`\H@4?>T
M1=#Q]#]WH>^;L=$3Q]#]WH>^;L=$3Q]#]WH>^;L=$3Q]#]WH>^;L=$3Q]#]W
MH>^;L=$59)J+4!02/43`D05%!`3?!(`@43#M*'(`F#1%1X^A^[T/?-V.B)X^
MA^[T/?-V.B)X^A^[T/?-V.B+`<I53'F8\<W7%=Y44?4^_P!<DZM8VC"3D(9\
MM%2S<[9T#*6C3H2$:[*0^\FNB<BJ1P`Q1`0T1:[I\(&#&TA6+"PM^78Z[UN9
MM4ZKD9EF?(">0;6[NC2F1UA;7>T*R*SZTQ+B*QY"-$6;C:V:-8U%-`B90,!B
M*Z67A!X=;C(Y.DRLYZ!LF8LDXVRY<+#3;S:JU/\`I!Q`E'^8<]79!@^3-61B
MU(WI"R#,$4';E=PJL111=43D75<\(N"GTM<I2:LN3IU/)5+84;)\%-98NK^M
MY(C(VD#CQE*W*&,^*UE;4A6`3(64`$WG244G&_SR93@19%CKANPMC>RQ5Y92
M=KM60HR5M4RKD*_7B?MEPF7]OK54IDD:?DGQR)RJ#6I4>*CV21D@29HM`,F`
M*J*J*$6*2W!?PI3=X<Y&DJD"UP>.+&[<RX6BRIF4<VK+]7SK+K`U3>D:$4/D
MFGLW21MS>0;BNU3W6[A9,Y%Q6N#GAVKM:BJ4LYN=JI=>D+$_JU3O&2;=;H"I
MIVNB7_&L_#UQA*NE2QL"_IF3)9H+0#&1+SJ9R@!T$C%(I$Q)@+!F$4,<M\>,
M%XLN*<.LL#4I1_8YZ<<,<9Q\E&2[:(>N99T[7EGX2$.@H=\Y,J\4$H@90=XV
MTBPIEPB</B4]=I9=>VSC>\5[+531JTY>K')U2E0N?)).7S(RQS#K+`6H#D.8
M2(X=G14,9$X;K7F$A%,2+[3'!]PLS*$BTGZ/&R3F0NA;M+/7TK+KRSZ81Q27
M!IXQW,`N62-6%L5%-"JQ952L3-5#_>]\YCZ(L!8<"/#S&O&TZTN^;T[NTL<=
M9D<D!G*_DR`5U$4!]BZ+C_.-)Z1;Q&QH<@>/*SW.:5V`X5`[H3KG(MYFDO#M
M4$T/&2:@)$*F5151154Y2$*0#K*G+OJK'`NTYAY3&$1T1=GQ]#]WH>^;L=$3
MQ]#]WH>^;L=$3Q]#C_[>A[YNQT1?129BT3;JKU$AA*4VZ(FV[IR@<H[-WJ"4
M=NB+Y^/H?N]#WS=CHB>/H?N]#WS=CHB>/H?N]#WS=CHB>/H?N]#WS=CHB>/H
M?N]#WS=CHBN2"Z+E(JR"A54C[=TY=NP=@B`[-H`/((:(H95_._(_B2#^[=:(
MICT185D/^CDA_(*_@]$5>,OS?U+\2M/N1T16?+.3V^+8&'DO$,C:)BSVZN46
MK5V,<L&+B7LMH=G;1S921E%VT?&M$R(J*K+JGW2)ICL`1$`%ES8*ESLHJM?9
M_C>Q[6JMCZTRE8M2*.0ZEEBPL6/^BA<QDOB%%;Q]4Y%4KXS7QI)/V:[5DJF<
M[=55,-IB@<HZD6Q)H*JT;EH"DI/B"3>Y)B<>P6.[E8D5(RCR-LM$46,6BZ-Z
M1F,Y(58)ED+P)1=D=&!5Z8[12,@S%5+>$=_X+L\GF57:@FE.-/E6*0W%K7I:
M1MZ"E)LS"(A*MENW5>=7=PBJ%XC<)6`:O>DV+%N_4?PKE&9$I6A7I$P=(FYP
M!*`;-*%4]NWAT^A9O;L\-:_3,666%ITW:YO,*D0A3:@R?PT8^46DZ?(7A<)&
M4E7C>*9)QL'%K"H;?/OJ@4A`'>VA'D5W,,N;R+!''%O`NFV.7E0H%SNB=[QW
M$95>MXL\(UD:Q2YB>BJTBY782$D@I-2R,K)F`[-D*BG--E3E$=A`.['+CT@J
MWVXI6F%*_+19J;B%ABYJ+@CS6L0W0[M)V0P`S\6GHRE95FSY"!P*P&"`1F$1
MAC$$H.`DQ*3=W1`VII12V4.=E'%;":A74T1-$31$T1-$5)MNZ;9U=@[/<Y?W
M^39HB\IZAF!5+B7LF,$<N9`,Y7S->7[:NRN6,'0M7)',[DQ92E6+49>GSF3T
MC`]FTR14:1\1>89IJN6ZC1+<3*1>K(\H;`VAM#^$.3_#HB\>J-,3TWQ,0>2:
M#&5>J4S*&598:M,R\52E7MCCDZ3*L;#7Y.G4JYN;)6Y24<UI](I3[Z,2D=\J
M3:0%$J@D$B]?U`5%`P)'(FL)#E3,H4QB`IN&!,RA"G3,8A3;!$`,41`-@"&B
M+1_'UHSVPR1AZLY*L<`FU<)7.`LKUA<ZS:VN5YY&#E[,UD8.LPN.J[+4@\/X
MM.JB99^1NA&(BT62>.E".@(MY]$31%Y4W_UBCK&O$!F;',]"8_?4?#DU8XFQ
M,XFRV0V6Z_`5SABC>(E?+MGAQ@EJE&XQ=2$@2KE.J^;N`D7"!R&5.H#<2*(+
M%ZU.VP=-PY8'-)PY#6>RXRRU:\@4&<R7.N'\GDS#.8:UA>RX1Q#88"O2D=,V
MJ8L<RIXM>2*23141;<Z"22RBZ)%(>5>.SB%PO(9??6O%F)K15L5<0V&<-*,Z
MA9+NTM[RM9,KU0R38K@LA*PJL2$C2\96)R<(])14KZ38B0%DT5"F`B^%5]8]
M:;G?IR`A:_C".@JWC6\Y'38R4ID"6M&0657R5Q-T5BC39.&KBE/AFSJ-X?6[
M]166=)[PRYDT2G!$#*$4]<"'&#-\641<74M'8X6+5Z_B2PIVK$UFG[#3W#K*
M=0<6QU17R=GAH>5C[E04$D.G\V+EFX;R350ATU>?;HD6_P#HB^)V[=19)PH@
MB==`JI$%CI$,LB1?<!<B2@E$Z95@3+O@`@!MT-O4#1%KAQ89K'ADX?L@YHBX
MBL.W-8=U,3(6:47K-8!S<+U5Z6M-V6:CHV3>M(V(+8.FNE4VZRITFPE`-H@(
M$6E[+UDLZ[J$/*-,9T^QS=C]+]=J<I5,@/GN.+S<:'GK".`:?)UBS.JLVDPH
M-KLN9^=>NUF?2HT8=TBDD[^]JG(OC</6;06*ZNZ?9$98KEY=EAOB;OS*6Q3?
M)3(-'M5UX>K-1*^RI\9*058E7]9&W-KJ51V6630=0;A'F5BJE,582+O9'XU\
M]4>9X@&DSB#%,C1\2EPFFI8F,YDJP&B('/;I0[&\Y'KT1C]^[:4G&T`R<.[$
M:.!\INE*8G--P672(M_L"9$?9;P_1,CR:-+3>6V'"35-CJ[,,D4-X4';ALWE
M*C=8YLS;ST#+H-B.VQS(I+I$6!)8A5DS@!%+HD*([1*41ZFT0`1]_9HBJT1>
M=?&5QKV[AEE++%5+%C')$E!XTQID%I'+6)W"NY@USXB*AAF5A&H-XQ^4KMC`
MV%Q(-!V"+EZ@FW-N$.*A2*&9+UCE_?*7:WT'&M#LN+L44W*V5+D]=VZ?:VBS
MXPQSFZ?QBE(4$K:#<0@3S^I5]6=YA\8$5%CD9E.0#"N0BE:J\8&9,I9"7I&(
M\24R?5IL]?'>2T+!>'\%(N:#6^*3(W#I".:(N>)/&#:G41B^8LCM*042:AT=
M./2,)W`.4B**I+UAF2+9%9R?8@J&'WBV(>(7&.-(OSNNEC>M+IBS+F7&_#_4
MLEIFJ,<Z<P4DAE6)L(N(U<AP/%1:1R*%4<@!2+)[%QQYH2<Y$JU,Q=C>5O&'
MB<1=FO8SMPLT769>F<-D;B@9QI4U&L"_D6MJR!.Y.YB.%V!F<:W8&5<<\90B
M8D78P7ZQ)WF3/(8=-C9K7V<QFF7J%/FUI]RN]GL7->'V9RY&WH\8=@1)K-DN
M-9?P,@Q(JHBW("#@JQC+`GHB]2M$31$T18Q;`VQJ0==XE^"7U6SBA7B->?6<
M3%-G>(R,1H>*;&&$DN)T486*R58`NU=0X<I>'A6UES%`C43MJ]3,AN)=,K5Q
M&+O7;951%/F%N<.=&Y@H4LEXU[DED7"]$7B,%.F64&\*[:7(MZO]2J&2%);(
M<Y3)FIX(LETHL;`S62<;0<2G,RL%-N8]_*E>(MHI-83&6+:<,>"E1FT]9;)(
M\*'_`!+.ZIB>R2DK;*M!U_&E,O5L:OXIJYB;'>+\UN<_<:C#,RV:FXQI<Q)I
M(QA'39XX9\QSA`4*?5QHPQ"A7RR>LGCJSEO*U/&MX_M-.QS(Y-13CZG?I-7-
M*]7QSPUQ7$6ED^4I[ZN)UA#'UE3EF\"DLG)=(;O'C5;<6(=0J<HLXMG&Q<\%
MI4M'B:QO3:$K>ZYF&SUR?I-LM%UK4VUQSB^@Y#AV+-LC4#69@^>2EN>P<@9X
MU1127B!=MQ40=)$*P1;T8>N:F2,4T?(RL<2(5R%BFEWQ2)3<F>$B5+C78*R'
MC$WATD#NR1YY,42JB0@J`3>$H;=@"`BTUXO>,B5X9;G0ZI%5F@6-6UXTR7DH
M(NVW&=K5MNB^/+5C*M(8RQ#%0E7L@6;)-L](1E&+=P"2(J-0(8Q04%1-0(M;
MICUH<Q%(9J71I&(I4V-%\M)DC8_)-I6G<>DQ?Q,UGAS9N,_Q*=,6/6FUT"QG
MF&1H5625+T%9L*1MI5M*!%N!8N*(D'BFD2L7+X;O.:LD63'5/I]+K5UF&M6<
MO<IY%;4"OVY\29B6^1VM`BC.3N7KH8@IU5&BC=`1.<A],$7VKW$5D!)7,=?R
M5BV(J-XPIP\Q.:IZ*A;D:Q0DW)/Y;-4:E%0\H$8W60KDHQQ*WD&;A9,'J:$M
MS+A`BR!@,H$4%8U]8<^N^8XO$,EBEG!+V+(N!*C69A.U+O1F8'+7#F&;+C/%
M:'AD`(^QM8G;"%,T`YBNFLD@[,=(P\SI0(O42)Y)!M[GPE?^[KZHDZ$"Z+=,
M%E4$A$0!0Z9-H<H_"$"ALY0]T=2RF5%Y`XG]:FRM?HZDKY3:'&4^^V7'D3(W
M7&MOM]ZB<;FOZ68A+1KVV+1T7"66897%:*JT<R,Y1%G)<ZH*`)$%>K#J1270
M?6,1UYL_#I!,,=H/$,[XHNE\6-&6HAIN)M!%<J*X9H<%!RD<P<S;S+L7A*QB
M55QT0S%TBU2,0XK[2,!T(HVA?63W&8B<9+KP/#I7'V2L@R5-6?3>1\D"QQP_
MBL4N<C2]!RA2D,=$R?3,LUR3:^*'#1]&MV3T!!ZW,"?WH&'4BW\R#FF<H>8.
M'/%Q,=/YF%SO.7.`E,CHSD.UK]*DZGC:TY`;1)85=R-IFY.P%K)RH'3:E9(-
M]XZRX+`1(R@1;!MO\I;?YPA^%)J:!%]I#_+WW^>.?PQ]0`*!%Y'W[UF#_']U
MSK"NZ#0[#!X;M.5JW(-ZQ>+&]OU388KDZ*Q-=,LUU*H.8VLU6[I6\Q(D[9TN
MY5>I(H$27!94Z#"J+,;-ZRJE10LG\!`1$]5E>+1[@1_8'<](5H66*JS5L5RM
M\S0$78(-B_.ZJD_EV*8C$BF!5DS"L5<`$H:"B*P7OUA]NICW-K5[2L10:^+L
MBP./_-F\9`N-<R)3TK#Q#U'!T!?,H48U(4EI3&UX@+,:UP\[4RR\>#5))BNJ
M+I<!*H.A%/\`FOB7R%B;A]JN<(6EXSO[)6OR5IO<XE?YNJ8]8QC**5=P,)0W
M$O5W-WM5SRK8%6=?JT>:+3,M*NPZ1N$`H*,/A1;E,USNV+%XHT<L%'K%F\48
M/2%(]8'=MDEU&+TA#'(1XS.H*2H`(@"A!`!$.72@17R6_P`J)_FC/_NR6@`1
M><>8^-N8Q7Q*N\%,*A1+&A%QN$G1X8;E--,R61/,SZ_M'4_2Z8TK4E#R%1Q>
MC20>SSEV\:@G'G64YPAD2$5E%%`^M*KD[BBPWS'5(A[C9XSA_P"&7),-47=B
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M)QZZ2RJ2R(JI")%-I3E,`#J0:%015:Y6S@:IERQS4\>2]QLPI5:G9&KB<VW:
M1*,@[FLE6.)MDK;>:`@MVCR/G8PQV[8@"B""YDC;P<HW!(6FH5OL6=2D_P#X
M>W+/*$7D*`R/9J]'"QH#:WU2-:,$T+HIC2.GXVLE?3(*%?L8A5&P'%\Q(51)
MV9!'E)NFWHSU%"JLE."Q2#X2(Z)DK2HYO<U)0,I4\R4^HP)H>(:'ID=G*R>=
M=T54EDC"YLKE*5`I6`KD2!NW`2&!01W]"^JCLVDU/%79QPZV=Q1\;UP<MO\`
MSHQ#-LY2@W12E5PPL6#2FOJ,,)*5M)PC&RZ*T+)+F%<RB2H.#%-MW2[HVSQJ
MF6N'0%@=JX'JS/UJA52-N\Y!150QG`XJDS*0L'-/+#7JW98BX1+Y%=Z4A*[/
MH6&*YPSEL0VU!=1(I2CN'+<#Q6J=DWA3!;-AC2/',!,PB^=!*IXU5QH$5S+8
M61H]6T(V@9'I(!TL'0.4N;YO;S>X.W^-JDG"BJ#0#4=2DS5*J31$T1-$31$T
M14*?Q#=7J>YU>KU`_='1%X]7*W!(\6,1/KY-E+'1ZKFYM3'E,N%[I4:QB;0_
MFX>HLVU4QQ2\C5NY2C>KVE4IF;F:KLJY4.H=P8QF92J@1>PVP=W9U1W=G[X[
M/X-$6BN-K>PLF='SK'&+,.J1[V:3EYK*,!'T^.GWV,[34'CZ(DG<DC+-KVXN
M\G>8ATFX9+0XLQ8$WSKE.!3G(MXGIMQHY/SI$0(@L85E$Q632`J1S<ZHD!BB
MHFGLVF+M#>`-FWET1>2'#+4587+>![](!2F:V2X"[D@I6LT6-A8RSP4365W!
MW2G1L:UJ1BK_`)#EEG-BWEEV2+"MLD(XA7AU%51(O7G1$T1:ZV[A:Q)>*YFN
MIV2.EWU>X@[S5[]E.,&65!M8)&JQ&.X!"'%,R9R(U>9@L8QS.28;!2>ME'*9
M_@KG#1%'S/@+X<(MYE-:#JS^NQV7:CDJDV*M5V3"$JL3!9;3I(WDE0K\<U0C
MZRYE9&A,WX*-RAS;]5PL`;RYM$4@3/"UB6P3,W.S#"9?O;%E7'^9)A-Q,+*,
MWURQK1X?'E<%9F9,43PRE:@T4W;,0%)TH)SFY3"&B*$<8^KHPGAN(8UC&]PS
M/6Z<3&RV)K#3PO;25A;O2S6#*UE9,K:K-UZ2FW;R)D<S38-G#5XS5*B=$AQ.
M")1$BV;QOA&BXJD5I.HHRJ#EQCK%^+UP?2:KY%6L8@9V!A3#'35*`#*H-+*Y
M(Y<_QW(<WO!\`-$4O:(FB*.LKXNJV9:._P`?7,LB:O24M4YER$4]&/?=-I=O
M@KO"BF[!-42)!.5QL*I=W[XB!B<F]M`B@6X\$6%+J]M,G(FN;"4L[G($F60A
M;)T!U7)_(MLQ-?9.R5@PL5DXZ:B;MA>$E(\ZA5TD71%^<3537.GHBL-<X"</
MPT9D1M+63*%RFLLU'.]/R%:[+:(_Q[/LN(YU27>2WA"0,#"0L0]5/0(XD<5F
MT1;1R!3I));A@`"+/;3PHT>=?7&?A;7DJAW"X/L0RAK?2K0@PEH23P@U?LJ2
MXCFDE&2D"^9*LI-PA)L))F_82:*HE61'D$"*4,-XEJ^#L>0N-J>I*N(>(>6*
M56D9QTW>S4W/W"RR]RMEAEUV;..8#)6&TS[QZL5LV;-4U%Q(BBDD4B92*4-$
M31%`60^&O%^4+U'Y$MK.8<V*,CJ%%M^BRZS6.,SQOEF!S36DW$>4AD5]V[UM
ML9QO<CAH!D#!NF'1%KA6_5E\.=/9P\'6)/+,-3V#6VQ$U2&N07!ZU=ZK<LMR
MV:)&E7`CF.7F'E2:V^:71;M&KQGLB1!@J95MO$$BS:>X"\*S<PRF&TODRLB:
MPV>>MD=5KF:+C\BHV;-TCQ$C7[L!XUT]<5^"RQ+NW\>FP7CW"+=TNS.LHS76
M04(OC7_5Z\,539Q3*K4][6TV%2QA491:!D21#JY)8@RK7LS4JPWIRP:(*VNX
M-+W7^?7DW0G<N$7[Q(P[K@VPB[UYX%\0W5>QO$+#D^DR5SGLK2ERDZ/;F\8^
ML\'F]C3V&4J))GDX:921I]I2H44?<:D;R#%9J"C-VW.<YC$5Q@>![`58R[0,
MVP,/8(V[XTL>6++5Q;6)VG"I+YDJ\)4;5%OX<I`;R$&PB:^AXJ;*?!CEC*G2
M':JIO$6WNB)HB:(L8M@[(Q,?_EB7X)?53"`<46@][X,<,9!JE@J$P>Z,&-DL
MN=;8]D(2R)L9EO,\1(JJY$48.UHQXBBV*\.1Q')'24(T602$04`FZ-S,U0N+
M#PD0-Q?Q3J\9ESS=V)5:0K<X"RVNJKP.338QOSO)>.3VZ.CJ/&(1CFIVEW\%
MQ`%AG+]DDBV>J.$TB;K,U%8H3@3PLW@L?U"]R-XS?0L4(V5MCC'N:W5.N=+J
M;:T5ES3G:;:&0I,.$HK&UU\X;L%Y!1XY:=(5.53?-MTS-1=V!X&L"P..&V*A
M;7&;J*%@D;$NG8+2J^E9)Q+X$+PU23"1EDF39TK%O,4D*W.F3</TPH.0.!P`
M-,S>M%<*?P=XYJSPDW*7++&0;;XJO\$[N%ZMS)[-/H;(6/*/BM]&K(0D%!P:
M",'2,=1;=@9NS1.#DBSMP+ARX54&,S46SV/*I$4&C0=#KX.BP%&H4!3($KY?
MI3T(2JQD5`1(/76XGTIV$?'I\ZINEYP^TVP-NS0N:BQQSC^NNLGUK+RI7WGE
M4Z+;L=PZA'>[&$KMWGZ;99SI##FQYZ1&4HC`45]\!23!0NP><VA.=J+7ZW<%
MF'+?4DJ@L]OL&W;2>69EE-5ZRMFE@8R69<O0&=+6Y;O7T-)-#@RR/6&3N.35
M042;)H\V8JI3#IF:BD"V\/\`6[WC]K3+;:[K-6:.DZQ8(G-3E2HH9EB[-2;8
MUNM-L#6RQ]090IEZY.L412:GC#1ZS<@HKMU2J*;S,U%%\-P3T*NO7#R&R?G-
MGX]QTMC+(C8URKT@WRO!/+!DFU2#Z]J2M,D'_CI_/Y9FUS*1*\4BB5=))%)-
M)!(A69J+X!P'8&2L^/+HP-?8JUXMNJ]^ITY&VWH[UE/KX$K'#H4KO?C%4)"-
M;4>F1;U%NH02$GF2;WEY4A9FHMUZXW%F>)9BY=O3,VJ+0SU^J5=^]%K'G0%X
M_7(FB1=\Z%/G%CE(0#J&,(%`!V!0\@\%*^"*@I&34+LWB"4P;0VAM+L$-O\`
M"&I:X`4*A0;7.'K'-6IN!J)$EGRP'#?98VV8T*O,&5>)R\57[566IK`Z!L09
MEL:)N3TJA!*GOG%,PC\#8-69I106R]79POLVBI!K,X\G2S]%GX>]O9M-3(M3
M#'KF0<PL!3;NC'-Y^KUI\:;DBR#5FJD+PLH[WC@97>!F:B^C'@2I3"R05_3S
M5Q##EBM*Q+:(RV-LHQ[R2L5^D3F/("F/E5\<.*_,0L?6K(]WW+I@M+NWC@SA
M=XH?=V,S46TEEQS7+;8<7VF;-)+S.(;%+6JHKHO`;I&F9ND6#'\BM,()H`20
M25K]F=B!`YLI7`E4#^+NBSM12$V'^<MO\X0_"DTSM1?:0'^?OO\`/'/X8^H#
MFT1:_P`GP[XXEZ!E7&KLM@"LYDR%,Y.N@(3)D9%2TSMC@K2^4BWQ6V\P8%E:
MZV%)'=4YM/?*!OA;0G.U%&-]X$N&_*-GRC;,AU)U<I/*\7?X^53L;EC,L:H]
MR7%4"%L]HQTVD8MR-.N'0,7P96DD@8SAF+(!3$-XP"S-&"*PS?`7C6QN4'D[
ME3/DJ\K[LS_&3]]=X%[+8?>NLKTW-DLXH\W(4UW*/AELA4.,7%.=4F$&C)#H
M;0B#<=T&9J*3,F<,T-E>/PRG9\K9D2L6#+*\N=2N\;-4D+'*V]W"/J^C9[:R
ME:!*TV7G(>/DES1KA*):GCG"@K-Q34^%IF:BV12*9-)),ZRJYDDDDC+KB05U
MS)IE(9=84R))BLL8N\<2E*43".P`#DTSM17:6'^=$_S1E_W9+3,U%%+;%]5:
M7/)U]1+)!8,N5*G4FX',^$S-2!HK*X,(%.,;<UM8.00O#_GU-X_/&%,=@;G*
MSM104XX(>'V2E,3/['7Y.XQ^&J)BW'57J=S?,[/2Y6NX9@,B5['@W"LRL8XC
M[+(0;?*,HY*JJ!2B^!NN!`,@7:S-18(V]75@]I7(_'Y;=F5SB6&2DUX#$KV[
M1SVF5J??XXL>(V=EK*CFMGLM?=5_'EG6CV#!I()0Z8I).%&:JY3J*,S44Y_\
M/Z"N)V&*7^8LX20P<W5K!5LD+VJML<FU5_27L4_JR,7+P=,B:Z^BHY:)(55G
M(Q3YL_0662=D734W09FHI"Q=C:LX?H%:QM3PDAK]7;ODVKB9?#)3,B]EY>1L
M,Y,S#_FFY'<K.3\NZ>.3D322YY<P)IID`I"LS46QU:_U2W_?5_#*:LE2HS5_
M._(_B2#^[=:(ICT185D/^CDA_(*_@]$5>,OS?U+\2M/N1T1=>_V"4@&\8>,6
M32.Z7<$5%1%-8#%333,4`!0!W1`3>YHH)H*J,_2+;.[&O>+?L-*JG.$](ML[
ML:]XM^PTJF<)Z1;9W8U[Q;]AI5,X3TBVSNQKWBW[#2J9PGI%MG=C7O%OV&E4
MSA/2+;.[&O>+?L-*IG">D6V=V->\6_8:53.$](ML[L:]XM^PTJF<)Z1;9W8U
M[Q;]AI5,X3TBVSNQKWBW[#2J9PGI%MG=C7O%OV&E4SA/2+;.[&O>+?L-*IG"
MX](MK]UVU$!Y!`6+?8/[_P`'2J9PL<-)IGDO')Z_4#S'2`=^-C56%-)=++L$
MKKIYF8NND%$`V'W][DZNE4SA9)Z1;9W8U[Q;]CI5,X48057HE6L(6ZLXOQ57
M;6"KQP%F@\=5.)G^?D`7*^6\;L8M!^*KPKI4%#<YM."A@';O#M53.%)WI%M?
MNNVH];^8M^0>N'P>KI5,X4>5R&J5/L#VV5/'F-JQ:9(KDK^QP%#K<3..RO%`
M6>$6E&,>@\,1XL4#K!O[%3@!C[1#;I5,X4B>D6V=V->\6_8:53.$](ML[L:]
MXM^PTJF<)Z1;9W8U[Q;]AI5,X3TBVSNQMWBW[#2J9G'!C:N\KFM^5Q`^#BN/
M2-;.ZVW>3?L=*.I5P('E3,>`&9W2&N:ZGGH4](ML[L;=XM^PT4=H%SZ1;9W8
MU[Q;]AI53G">D6V=V->\6_8:53.$](ML[L:]XM^PTJF<+D,AVXW\5VW'J=1@
M@/5Y`ZA/='2J9PN!R);0ZKML')MY6*`<G7_B=32J9PGI$MH=5VV#EV?Y"AU>
MM_$ZNE4SA<^D2V]UMNIM_P`A0ZFW9M_B=3;I5,X7'I%MG=C7O%OV&E4SA/2+
M;.[&O>+?L-*IG"^+C)MF:-W#MS(-$6S1NNZ<K&8H"5)NV2.NNJ8"D$PE323$
MP[`$>3DTJF<*,JCQ8U:[02EDA<@0+6*2,(*GL['S,>)$\415A(X4C+:WA9`K
M%:`G&3Y-QS7,':NDE`-NF`=15,X65.<_,F0.3.\@T=N#-T9@Z!:8KJ9T)`K$
M\H,>JD9V"I)`8M,7(("7G3(`)P*)0VZ53.%C,AQ65R.4HY5;Q&.D,C1S*:J,
ME%PKN7AGL#)N(YE%V%_,QC!U%P->DY"7:MF[Y^JV;*N%RIE/O;0":IG"R4O$
M`Q,DFN7(E"%!6(<6!-8)RLBDI`M#BFZG$U`>[IX9N<!`[H/O!!`0$X#R:)G"
M[I,W&56%NC=:BJY!RP9"W2D()18'LLVZ;$L^;(Y,<74JS^^MDP#?72^&0#%Y
M=15,X5]](ML[L:]XM^PU-4SA/2+;.[&O>+?L-*IG">D6V=V->\6_8:53.$](
MML[L:]XM^PTJF<*.<I<0L/C.J^=&4+6PK=8+)LHX)%>+67(,F]*XZ$VW(]FZ
M<;5BI*<NYNALY1UA];U_1]MV7]PUN=EO9EX8'.X%Q!('G(!^);#MC:VX=YZF
M-&VQ:NN]2R%Y8US6T8"`75>0*`D"E:XK77V@_#!^FJ#^KMC_`"!K31S?Y=%H
M=_<X:'S^A="/('G`!7^R3<2/]6'H_P#&GM!^&#]-4)]7;'^0-/S?Y<]YP_+Z
M%3^0G-_N2;VL/VT]H/PP?IJA/J[8_P`@:?F_RY[SA^7T)^0G-_N2;VL/VT]H
M/PP?IJA/J[8_R!I^;_+GO.'Y?0GY"<W^Y)O:P_;3V@_#!^FJ$^KMC_(&GYO\
MN>\X?E]"?D)S?[DF]K#]M?0GK#>&1(JQ4\UP0`ND**@#7;)RD$Q3[`$(#X/P
MB!RZ?F_RZ[SA^7T)^0G-_N2;VD/VU\_:#\,'Z:H3ZNV/\@:?F_RY[SA^7T)^
M0G-_N2;VL/VT]H/PP?IJA/J[8_R!I^;_`"Y[SA^7T)^0G-_N2;VL/VT]H/PP
M?IJA/J[8_P`@:?F_RY[SA^7T)^0G-_N2;VL/VT]H/PP?IJA/J[8_R!I^;_+G
MO.'Y?0GY"<W^Y)O:P_;3V@_#!^FJ$^KMC_(&GYO\N>\X?E]"?D)S?[DF]K#]
MM?5'UAW#(W4*LEFN"!0FW=$U<LA@#>*)!VE\0@`_!,.S]_3\W^77><'R^A/R
M#YO]R3>TA^VOE[0?A@_33!A^X%>L@_X8`-/S?Y==YP_+Z$_(3F_W)-[2'[:>
MT'X8/TU0GU=L?Y`T_-_ESWG#\OH3\A.;_<DWM8?MI[0?A@_35"?5VQ_D#3\W
M^7/></R^A/R$YO\`<DWM8?MI[0?A@_35"?5VQ_D#3\W^7/></R^A/R$YO]R3
M>UA^VGM!^&#]-4)]7;'^0-/S?Y<]YP_+Z$_(3F_W)-[6'[:Y+ZPKAA(8IRYJ
M@]XABG+MKMDV;Q1`Q=O^@.4-H:?F_P`NN\X?E]"?D)S?[DF]I#]M<J>L+X8U
M3J+*9K@Q44.=0XA7;)RF.83&$`\0>Z(ZC\X.7/></R^A/R#YO]R3>UA^VMDJ
MMDB-N]?BK74+#&6*MS;8'<7,Q0-W#)VB/(8"F`H'271/M*HDH!5$S@)3%`0V
M:W[2M2L-<LV7^DS1SV\HK&6D>N!BXCJRCCFH33"JYAK&EZEMZ^DT[7H)+2[A
M.61KQ]!Q-&C"N;,>!;4=)*O_`(_D?EB_,(=AKV56-SCRIX_D?EB_,(=AJ:IG
M">/Y'Y8OS"'8:53.$\?R7N*D_A01V?\`04!U%4SA?1:RRS@X**KIB8$TT_@M
MT0#=3*!"`&TH]0H`'[NIJF<+Y^/Y'Y8OS"'8:53.$\?R/RQ?F$.PTJF<)X_D
M?EB_,(=AI5,X3Q_(_+%^80[#2J9PGC^1^6+\PAV&E4SA3[1G"CJM,5U1WE#G
M=`80`"A\!TL0-@!R`&P-%6L"5_._(_B2#^[=:(ICT185D/\`HY(?R"OX/1%7
MC+\W]2_$K3[D=$6.9:$"M(4QA`I2N'QC&'D`I2H)&,8PCL`"E*&T1]P-0XY1
M6A/F2F;U<22:"G$DX`?":+5J.RIC"7D&L5%9&HLG*/G/0F4<PM<&[?.W?1Q=
M]%;-4'IUEE^BE%3=*`CNAMUB(]P;?F<&PWUHY[BT-:9&M=5X)8#7#$`\.I9Z
M?9N[;:-\\^EWS;:)I+W]F2VK2`\9A@W+44S?2K08JI#*.,W+!>6;Y$HZ\6UD
MPA7,DE:84[!O,&247)%K.RO103?J(H'.5(3;YRD,)0$`'2'7M#N6E\-]9BCF
ML`[4.J]X)8/5P&8`^7!>9^U]SAYMV:?>"]$)DR21.B<6AV6N5_K`!P()/D/2
MN?2AC3HTT\](5)Z)7!*6PN?.B&%"#.=T=B0DLKTS<8'.^2,B4%-T3*E$H;3!
MLU;CW+M^9N:"]LW-P%3,QN+B0W`XXN:X?`KAVIN@&)ITK5!)<U$+?N[G%SFM
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MFL#?WB`NB?,.+FJ#927O].KSI>*93*L5/6B!CY1@S?,6DBD+]H>1-S)BM'R1
MA$IC$$#@)3&*("/GEW3H#+83"^LVS?=V29))!&0X@/>VIPHV,YATGS*\S9&Z
MY9GP0Z?>24>&A[(G2`D>J\!K?6<1("P`?"JK'ES'58969P\M<(_?5.JOKI*U
MR&E8R1LXUYA'^-%7S6$(](Z6(JP$JB0_!(<IRFW@*(#IJ&ZMOZ9#=7,MY;3,
MMHC((X)&RRR-HUP(:,`W(2XGR"BLZ?M#<M_-9QNLKF"*]OQ;,EF88H&N>7,C
M$DSO58]TC2TL.+>G%7&*R11)JFKY`86N#6IS*-5E)6>+)LE6$*W:M"/7Z<PX
M;K+),7<:@H'2$C&$Z9O@[!$0VY2PU+3M5A[?3)F31X5RXY:M:[*[J>`X9AY0
MO!J^A:OMZ_\`[9KD#[>\#GM(<"`<A(SQD_3C=0Y7]-#U+"[!Q(8&JL`VM-AR
MK58NOO1LI6,@JL^7Z<K3;I%XXM+9BS9L7,@\=P5^FVD.NBDB=4)!RFD!3&-K
MV`@XC@L.QQ<P..!*M"7%=PW'GVM65S%5(VPO81K8D(V>"8K8IQ#Z`DK8R6?.
M[#%1D?%O'57A7<BFR=*H/C,VRBH([A##J56LUQYFC$N6VC5[C+(-=N;=ZQD)
M)MXH<J=(.RB9%O$RBYV3M%J^0".D'J":Q5$R'(#E`XE`BR1CD4F:(FB)HBCO
M+.3('#F.K5DRS-I=]"U..%\Z80$:YEIF16553:,(Z.9-B&$SF0?N$T2G4$B*
M6_OJ&*0!'7EN[R"RM3<SAQR@FC:5-.@$X`GRX=>"O6L3;IX:PT;6A)Z,<3Y:
M+6^R\>^`ZWP^4/B,\8R,W6<CR43!U:K07B]]<GL^^=-&TM"%CBO`04>UGI6^
MZW%3%5*9'F.<%R@!]9_WSH`T.VUYTI%K=3,B8T@B3MB7"2W,=`]LL.5QDJ,K
M<KFNH0,V9.V]3;J<VEO;EF@A[8G]DQD@"AX%X);F'`YO5K0K<&%F&%AAHBP1
M1UU8J=BX^9C%7+1RP<JQ\HT1?,E'#%XFB[9+*-ERB9)4A5$Q'=,`"`ZW"HQ'
M2:%OE:1T^7R+`/:Z.5T+_IM*N>B)HB:(F@I^UP4$T%:$^0*(K[Q!81Q39(BI
M9'R1!5.S3<,ZLL97WI)-S+OJY'N3M9*;:LHR.D5CQ[%5(Y55-@<V)1$>0-NO
M/<7<-L'!Q&?*2!UK6=9W;MG0[MFG:U=0QWDH);&6F1X`:3FR=(%!4\!5>0G"
M9ZT#+V3N(5U4,[,Z)4<*R$-D&3IUPB*);6CJP!!R!4ZPO'OTG4P$@T>1Q3*J
MG3;<V.Z(B8@!LUK.EZ]<2ZB8+X4M'AQ:1T9>JO75?-O+KGWN/<6]3INXA!#M
MQT5R^!T<+HO]$T;F+@,XD'']VF'%>SN.,GX\S!5TKKBZX0UYJ:\A(Q24_`JK
M+1YI.(7Z-*,0.X0;*@X8.?@*%$@;IN36TPW$%S&);<UC*^G]"U[2=R61U/1;
MB.YLW/IF8:@/`&9I\K2L[U=6:31$T1:W\3E&R5?*7`Q.+967AIQU:"U^>D8B
M;/!N8NC76$EZK:;(DN5PWYY]4TI!&2:%)OKE7;@*(;^B*#*-%<9+12LLIIQ8
MH12P/(:>NRB9Z%.P=686.T1[ZW,8F5E3R<NK=8%%9RU12*FM$)Q"8'2(+G=V
MD5AA*_QI1#LRS-6R$>0U>&LL$+`[HTC47,=,34*5I*QJRSY27E;3$HJ.7\BM
M(;Q0!J5LW'<6$AB+ZS\=QLKO&+R/;RJ,B#SSM8I0ZU(\U23JV,WS62B;FHL^
M\9N$:_9W+1I$-F1>B.W3=95T4Q0*?1%NAB"2NS^@P+?([*6;WN)8LF%H>2D=
M'1@2\DJR;R!7[1")>/8XP%9O4D7(HF*F5\DN4I0`NT2*3-$74D&99&.D8XZA
MTB2,>^CSK)@`J(D?-56AE2`/P1.F5;>`!Y!$-$6BD/P%U2*I"E2\\S+N2Q32
M.CWC:HHQ$2P78N,5*E>)1$=8R2B0S1,4-AEBH2:`OUGJYP,B!2)@17".X)&,
M?*C)%R2*X!*5U5,5Z'&F?-H&OHR218=HX&;-&I.)!K)=%<*F9'0401(<Z!W8
M`Z`BDZ6X>IEQ%4J/K>59*FN:YB5CANP24/4(5=6RU2,>1TFT,P8/W;B.KSIR
M^C12>$$CY%PQ<K(`1,QB+$(HWCN":%CX=FW"]BXGX^5;SC297I3!>/%\RE;A
M/-8][#O)IV\D*R>6MYS+L5'VQ9)`I1.`F$X$67X^X3J[1+^6_J64\\_2L:-H
M;M%JTS8(IR05NUP;@")%D'<9%MD'5N<+QZ4<T8IL4"$0`J@[RVB+;'1$T1-$
M31%JEQG8'O7$9A;T<8ZM%.J-C&WUVP>-[Q'3<K!^+XDLB#MF+6`<-7X/7`NR
M\V;?!,H`.][FM!YC;,9OO0&Z*^5D+6W#9,SVEP]5KVTH,:^LNJ<GN8=ORRW:
M=RW-LZZ8;5\08',;B]S'5J^@H,OGQ7D[[);BM#JYWX;OJ3E+\L[!UPH?IHM\
MH']PML/_`.)_H7U`W]9&CQC*_19.)/\`JV_3\*>R8XK/T[\-WU)RE^6M/#1!
MWA:^R?Z%/C+T/N63VMO]I/9,<5GZ=^&[ZDY2_+6GAH@[PM?9/]">,O0^Y9/:
MV_VD]DQQ6?IWX;OJ3E+\M:>&B#O"U]D_T)XR]#[ED]K;_:3V3'%9^G?AN^I.
M4ORUIX:(.\+7V3_0GC+T/N63VMO]I<AZI?BM'J9WX;A__!.4ORSIX:(.\+7V
M3_0GC+T/N63VMO\`:7'LF.*S]._#=]2<I?EK3PT0=X6OLG^A/&7H?<LGM;?[
M2>R8XK/T[\-WU)RE^6M/#1!WA:^R?Z$\9>A]RR>UM_M)[)CBL_3OPW?4G*7Y
M:T\-$'>%K[)_H3QEZ'W+)[6W^TGLF.*S]._#=]2<I?EK3PT0=X6OLG^A/&7H
M?<LGM;?[2>R8XK/T[\-WU)RE^6M/#1!WA:^R?Z$\9>A]RR>UM_M+GV2_%;U0
MSMPW"'_^$Y2]WJ?_`$SJEWZ:[=O_`.0M?9/]">,S0QQT63VMO]I<>R7XK0ZN
M=^&X/_P3E+\LZEOZ:K=PK_<+7V3_`$)XR]#[ED]K;_:3V3'%9^G?AN^I.4OR
MUJ?#1!WA:^R?Z$\9>A]RR>UM_M)[)CBL_3OPW?4G*7Y:T\-$'>%K[)_H3QEZ
M'W+)[6W^TGLF.*S]._#=]2<I?EK3PT0=X6OLG^A/&7H?<LGM;?[2>R8XK/T[
M\-WU)RE^6M/#1!WA:^R?Z$\9>A]RR>UM_M)[)CBL_3OPW?4G*7Y9T\-$'>%K
M[)_H3QEZ'W+)[6W^TN!]4QQ6[!V9WX;=NP=FVDY2V;?<V_Z9V[-NI\-$'>%K
M[)_H3QEZ'W++[6W^TO8'A<X>(KAJQFWIJ$VO9+#*.$IJY3G.O$(A]83MB(.0
MKT(X<+)PT,CLW4B_Y0L`;ZQC&V;O=.7FP-.V'HK],#Y)9I79GN)(S$&K<@_\
MMHPP'TAQ7RQS9YEW/-+=;-9='';V\,=(F-`(:",<Y_;<>L_1/T>A;';0ZX>^
M&M^7,4VAUP]\-$3:'7#WPT1<[0'J"&B((@'5$`_AZW(.B+C:'7#WPT1-H=</
M?#1$VAUP]\-$3:'7#WPT1-H=</?#1%LGC[^BD=_Z;W_OJ^I5\<%A"OYWY'\2
M0?W;K1%,>B+"LA_T<D/Y!7\'HBKQE^;^I?B5I]R.B+%\P)BM&QJ(#L,MXT1*
M.T0V&59E3*(B&T=W:;E_<U2YCI`6L-'T-#Y<I`^4C#I3.R)S99"0QDC'$@5/
MJO:?^2\BZGP?W&O*TER=Y0P=UI3"2KMPFBY6!53'"F0#6(Q"C%HJ."R0VEKS
M9#&*#@$U`4$NPHCPS2>5FK:7-:W=O-:MN8VV3I#+45DA9,V3$`DCUQ5IPZ5]
M%:OSFT#5G7MJ/[A);7,M[E$?!C;A\!8^AP``B<*CK"XQUPCWR*DH9W>E,?RC
M5')^(KE-Q;=9Q(Q+^.QW6+C`R1&T6YKT=%L"O7DVU691Z:)6C1`@I[XF)O&;
M>Y9:K%>64NL2VKFQW]C-*YGK-+8(Y6O;ZP&4DN;@/(JMT<Y=OWMC=1Z/;W<6
M?3+ZWBS^K)']ZFBD8,P)<XLRFKB:YBXX5434_AOR7:`O=?-6_-\E3?4-*)D)
M@LY2VM[7I^6<CW%TD69"(6D&CMW#VA$2OVR+QNF();%#"(@GKFW]@[BU!D]F
MV!T$%O/;D.E(B@D;%/</=DD:,_T9&YO*M_UOFKMW1[RPU873;F2XENC2,=O+
M"^73[:$!T;WB.@,;LK:`?M<5+8\*&1(MO#)P(X^WX>#P****\M8$VI9C%=BM
M,A.117+J,DY5:*=L;*`MG2JAU3G;`4R9=XHDS+>6NM0V\=M;G3(\MEI\;SVL
MKG!T4DCI/7.)`#Q4GB!BM%'.3;LV>34&ZK+$^\U"5W\.-H[.[BBBB+8VFC7-
M['.[+]+/B51'<)V26;JE/%'&-55*IP[2N"%S;)47CYS/UJPM75M3?#'`)%X>
M8?MVC5,Q-\T8LZVF*8P$'TP<N=Q=G$X.TW,S29;(M87]H9C9RQB=A/`&4MPX
M4)"ION;VV)HKVS?#J@%UN&VU5SG!N1F2[C?%;88EDD6:25HP$C6DBH78><(=
MO>K&77=4A97=:)D5<@Z<'!%MPSJX<!,3*19Q$A+88KLA>4"M2@H&Q3X.JY^5
M6MN#W.;;F3LP&G#-5VG&WD!)K4&6A`_9/!6H^=FWY6?=\MZ;66>1[F1C&CM6
M;?QGB*#LF@&A%6FGT259Y+A&RI)3"ZJLK0B,$<=3U-C'3=U(,UN?G<,1F/##
M(1;:`(F^<-[!'F76DEW"SE=F=)(I$RI;@V[SEIKS]3==.?8L'W66!A>XM/9N
ML&0@#(!4]JW%QQX!>N/G!M6TTDL=%J;;B6^9=NS1124E;?.N'%F>5@8WL:1Q
ML:T@.<2""5D\]@?(T'PXYEKQ64+(6>Q9%Q[D="ITH[EVSE:UCJ<Q0[FZLS.[
M919G$I<*]CUX7F.:*0RSLJ(F,!A,.^[!V]?;<AN&:A]W+Y9`ZL-<A_@Q,Z<<
MU6',5RKF;N[3-UW]G)I(NGQV]L&=I.&MD)=++(00U\@HT2!M<U<.`6N-]]7?
MDB18L9RH6GIUG-;\X6^5C9',>3ZY$G2R'QEXXXCJBSHBG1)MEBF6)3*@X:/W
ML3'(*HRRB1MBQ0,H&[,!#0#Q7.2`TT;]%25.\'&6)NY3N71D(J0LJ]AQ%/1&
M'<E96M>3L2S(T+"ESQK+FRBM+U5-S?;,>8GVZS296;E<BT*<#`4P;IJU"SK!
M>$LH4[(6$I.ZPJ;&V0<1Q&WC.=U8VKSOC<@W3+*6*8..,242JE*81@.GE1,H
MQ@FK`K:"A8%D@513:!C$7H+HB:(FB+I2<;'S4;(0\NR;245*LG,=)1[M,%6S
MUB\1.@Z:KIC_`!DET5!*/4'W0$!`!U'9Q2L^[S!IA<:&HK@>/P*>T?'ZT>#Q
MB*=?0O#/"W"#CMOZPG)M"D\?VY;#F+&#J_8U0FAL2E2\[I(*FYD5/&3IN2&F
MTWPV1V"K<AOOA-A1^"F(!Q#1-N2GFS?W%Y;.=H45HUT#GU+/O+F6S)I6UPSR
M-A`D=Q?3UB34KI6JZU"S9UK';R-=J$DA9)3Z;6M+\K''CE;3U1T$D]*]VA$3
M"(CU1ZO4#]SJ!R!LV:[C7C_F-?\`V=0\BYG3$D\2N-0I31$T1-06AXR'@50\
M581C\'%:H9FQUPP3F5J7?,N7!*G92AJJ[JU4D6>4Y:@3:M/F91=22CT&47+L
M/&;*1?G4(??(??'X'*')K&7EMI]Q-FN`[MVL(%'$#XAQ7-]Y;;V#JFLQ:[NB
M00:Y#;O9'*)W6_JN;0M);@2[RBJ\7^%+`-X@<Y5HW$C?Z-%\.E#A<N06*G<)
MFZCM):.6FIL"1D2I*U>43M<NFX9I'0<I/UEP(4#)'`"B)1URQL'F_+;HTL6U
MIT&CN./%?,.P]DZE'O**7?MU9'9=JZ=MI2]`<6/^B'N:,SN-278NKCP7NSPX
MT#!^,<8MZ?P\N(MSC=G8)]\B>)L[BWM0GY5RF]G0/-.GC]PHX,X4*<Z9E!YO
M>#8`;=;99P6UM$8;0_P`XTQK\J^N=C:%M3;>@-TG9XA&E,E>X]G*9AVCSF=F
M><<U",.@44[:]:W!-$31%I]F&@<3U@R1-S&+<B#6*JYI$)%UUNK-HM(N'L3>
M89N9I](0JC*34DWCQ@@X325*@0"D<DVK#S()Z(HQMF/>,1!JI+0-NLS<T4VR
MH_>Q;3([6>>V25>0+H*:O#H+Q34L4P,CS3%K&[CH4))/IG\WWQ.)%=R8&SM8
ML>9CA)>X3M<L^2GF(7U1FG]_/=)/'C*GWA65=M41>LSQB]FKE<10-TP$S)2S
MLI"*B(IBH8B[=<Q#Q)-'T3%^<GF96XQ*!;NVU:R&^6K+B/AHR"18,:_`BP\:
MQ!BV",D7TPLHJ#B:1EBI+*JF2-ND5\P)1.*.L7&O.,M6QS/59G3K''3)W5W"
M<-(3<C*)/X8YX(.<;H.HA5)<J;E,ZRHLW2:1UQ!/F4B+='1%]$Y+Q.)Y45T6
MI(Y%=ZLY<%3.W;H-D%%7"ZY52G3%)%`IC&V@.P`VZ(L.@N**FV"LIVUM<6$=
M#.4I-RP\Y:^-5E9AG$P+>TNG\#!6&+CIFP,#UEVC()+,D'":S54IRB/*`$5Y
M9<0=?DI*%A&%OAGD]88V<F(:OMXYFK/OHNNBL64D"PI60R2+1-1N8B2BB1"N
M5`W4A.;DT1=&G\2=;O$"[LL/9F["'8R$I&.EK=6S49=)U"N9%E+#T&X14*],
MT8O8=XB=P"8H<XS7*!QYH^PBO[3.4!($9J,,B4!\G(22,-'G9S5/=$?3#AH1
M^WB&9T5CE=2CA@H5<C<@F6.B8#@42B`Z(N_$Y<:SSM5A!7&HS;Y!FG(KL89[
M6)5XBP66.W1?+-6!G"Z;-9PF8A51*"9C@)0':`AHBOWGG/\`=#;Z-CO!=$3S
MSG^Z&WT;'>"Z(GGG/]T-OHV.\%T1//.?[H;?1L=X+HBC/+.?JYB6I!;\G3Z,
M)6`E6,7TY.`%^8)*0!P#-$4(J/7=`50$#_"V;@;.4>IK![AW3I6T+#^[:S.^
MWL\X9F:*FI!('F(:?B6R[5VAKV]M4.C;=A;/J`C,F4O9&`UI`)S/!!H7##CB
MM9_:-<+'NY/]^BV7\AZT5G/WEW(W,S4[G+_T_,NGC]-G.,.+(],MW$4KFNH!
M3JIZJ>T:X5_TG_[C67\AZJ_/KE]WG<_4^95^&SG1W3:>]P?93VC7"O\`I/\`
M]QK+^0]/SZY?=YW/U/F3PV<Z.Z;3WN#[*>T:X5_TG_[C67\AZ?GUR^[SN?J?
M,GALYT=TVGO<'V4]HUPK_I/_`-QK+^0]/SZY?=YW/U/F3PV<Z.Z;3WN#[*K)
MZQ[A;3`X$RCN@H3FS_\`@6R#M+O%-LY8,=G*7J]74'GSR]/'4[G#_)\R>&SG
M/W3:>]P>A4>T:X5_TG_[C67\AZG\^N7W>=S]3YD\-G.CNFT][@^RGM&N%?\`
M2?\`[C67\AZ?GUR^[SN?J?,GALYT=TVGO<'V4]HUPK_I/_W&LOY#T_/KE]WG
M<_4^9/#9SH[IM/>X/LI[1KA7_2?_`+C67\AZ?GUR^[SN?J?,GALYT=TVGO<'
MV4]HUPK_`*3_`/<:R_D/3\^N7W>=S]3YD\-G.CNFT][@^ROHEZQ_A;1."B>4
M-TQ=NP?,6R"'*`E$=AH,0$=@ZI=SWY>/^EJ5S]3YD\-G.?NFT][@]"^0>L9X
M5P__`%/$?WZ-9A_^Q-2.?/+UHH-2N:?]'S)X;.='=-I[W!Z%S[1KA7_2?_N-
M9?R'J?SZY?=YW/U/F3PV<Z.Z;3WN#[*>T:X5_P!)_P#N-9?R'I^?7+[O.Y^I
M\R>&SG1W3:>]P?93VC7"O^D__<:R_D/3\^N7W>=S]3YD\-G.CNFT][@^RGM&
MN%?])_\`N-9?R'I^?7+[O.Y^I\R>&SG1W3:>]P?9694'CAX>\D6J+IU0R5'.
M;++'.2)925=DH1-^Z2*"A6;9Y+QC5DH]6`!YI$3[ZHANE`1V`.4TCF_LO<-V
MW3-,U21MZ[Z/:`-#O\M2.*PNX>1?-3;.E/U?5=,C;:L^EV;V3%K?WJL%/@/5
M5;.GF'YSG.H*&^8QC'_FC8OPC"(CR`D`!RCKHSIKZ,Y)9'M>`,`ZHX84/344
M*Y!%*U[`YE"W'$L:#@:&HIA0X*CQJ\V[=J'>K?M6J.T?G+SBXBF.*K)J*4`\
MPHN?&[WKH=ZMNU:H4)XW>]=#O5MVK1$\;O>NAWJV[5HBY\;O?C(=ZM^U:(JU
M)N05-OG.@)MTA?\`)&H!L(7=+R%2`-NSW>J.B+Y^-WO70[U;=JT1/&[WKH=Z
MMNU:(GC=[UT.]6W:M$3QN]ZZ'>K;M6B)XW>]=#O5MVK1%L'0U3KUA@HH("<Q
MWFW=*4@?!>+E#84H`4.0-2KZP17\[\C^)(/[MUHBF/1%A60_Z.2'\@K^#T15
MXR_-_4OQ*T^Y'1%CN6`$6T)L#;L<O.IR[-J*6F/1Q4%Q:*@T^=0OL-UA]X=`
M7!Q>/I.XGKKUJQAER?LTRT\G5\R;INKNC]K_`/%I)65N27UFUK0\*J6C(26X
M$FI\IZ24$##U0,.SK@/)_P##;J"2X!IQ:*T'1CQ^=2PNC`:PD`&HIA0TI7ST
MZ>I-TWQ1]X?L:K+I"T@URN&.''S_``*UV3`:T%?_`&#_```^()L-UA]X=07N
M><Q-32E?(#4#S5%55&&LIV6&5Q<*=!=Q/G/25QL'K#[VK>1IXCA_[?\`%5.)
M<,KN&'R#*/B;AYL%SL'K#[W_`,6C6M8*-%!\]?\`'%*FE*FAI\E*?%047&P>
ML/O:K+G.%"<%(<0,H.'_``?\4V#UA]X=0J4V#UA]X=%*;!ZP^\.B)L'K#[PZ
M(FP>L/O#HB;!ZP^\.B+G=-UA]X=*5P3$&HXJL3K&(5,3*"F4=I2")A(`\O4+
MU`'E'W]2"7-`&+0H`R@TP#C4^4FN/GQ/QJC=-UA]X=0IH4W3?%'WAT&/!#AQ
M7&Z/6'WAT1-@]8?>'1%SNFZP^\.G#$(K%)U:M3:Y'<W68"9=)(E;).I:$C9)
MRDV*N5R5NDX>M5E4T"N2`H!"B!04`#;-O+JTZ*(G.YK2>NB\%QI.F7DW;7=M
M#+/0BKV-<:'B,0<%U!HU*,F5$U+J9D2%$I435F%,D4HJE7$"IF8B0-JY`./)
MRF`!ZH:&"%XH6-(\RA^E:7(P126UNZ,4H#&T@4X84Z%=XR&B8-L+*$B(R%9"
MJ=<6<1'-(QH*Z@%!1<6S)%!$5E`(&\;=WC;`VCR:J9&R-N6,!K>H+TP6MM:,
M[.UC9'&36C6AHKPK04QP5PV#UA]X=5J^FP>L/O#HB;!ZP^\.B+G=-UA]X=$3
M=-\4?>'1$V&ZP^\.B)NFZP^\.B+C='K#[PZ(FP>L/O#HB^#MN9TT=M2K+-C.
MFKEL5R@5(R[8SA!1$KE$KA-9N99`3[Y04(<@F``,40V@)%I0WX*6!(\\:YR,
M[,S?`JA)LXZCPT5%M&::E??L246))*.6>.W+J?KQ9"6&/_FLFJ[<E(W:D.0$
MR*0<;<,L;C3(+"\1MM=22#`UI>%AWM:BD7JTO:D>A.G![*@XZ<G$-&!$P28%
M2`@N0.L901/N@18[-<(43,O6AE;Y+)PQ5IQW)Q"E;B7BDF\E;1E2S-#>,%W0
M=%9QQLN2"!D`1/TDJ"!C')]\*<B^;S@ZK9Y`CV-M;N,1<)D83#0M5A%RNHCS
ML"YK$B5BJ-CU^?5E&S=(LFF"JR;5,Y`((J`=,BD?&6`XW%UN&R0L\(L`Q_7*
M.$"VK47$D<+U^,KL26QR3]HN?I,@LUK:8%*B@V,`*F*LHX*FW!$BGS8/6'WA
MT1-@]8?>'1$V#UA]X=$38/6'WAT1:N<8'#]:N);$*>-*C?(;'$H%M@K&K89Z
MIN;BR.SB$I$BL<2):S<`H1PY4>D,585A`@)B&X.]M#2=^[0BWMHC=&FF$#!.
MV3,>!HUS<OPYOD73.5',1_++<S]QLMGW3G6KX<C<",SF.S?!DI\*\N?8_P"=
M/VLL;_J&F/[S=<1B_319`G)J3`WJ7TK-^LV[?E+=$F+J8DGBN/8_YS_:RQO^
MH:8_O,U>\-%KWDU6?&5?=QR_63V/^<_VLL;_`*AIC^\S3PT6O>34\95]W'+]
M9/8_YS_:RQO^H:8_O,T\-%KWDU/&5?=QR_63V/\`G/\`:RQO^H:8_O,T\-%K
MWDU/&5?=QR_67/L?LZ?M98X_4-,?WF:>&FU[R:GC*ONXY?K+CV/^<_VLL;_J
M&F/[S-/#1:]Y-3QE7W<<OUD]C_G/]K+&_P"H:8_O,T\-%KWDU/&5?=QR_63V
M/^<_VLL;_J&F/[S-/#1:]Y-3QE7W<<OUD]C_`)S_`&LL;_J&F/[S-/#1:]Y-
M3QE7W<<OUD]C_G/]K+&_ZAIC^\S3PT6O>34\95]W'+]9<^Q_SI^UECC]0TQ_
M>9IX:;7O)JCQE7W<<OUEQ['_`#G^UEC?]0TQ_>9IX:+7O)JGQE7W<<OUD]C_
M`)S_`&LL;_J&F/[S-/#1:]Y-3QE7W<<OUD]C_G/]K+&_ZAIC^\S3PT6O>34\
M95]W'+]9/8_YS_:RQO\`J&F/[S-/#1:]Y-3QDWQX:'+\:>Q_SG^UEC?]0TQ_
M>9IX:+;O)JGQD7_<<OQJ6\(>JGG:7D.'M&9,X5[*%1A5"2*=/JN-Y*BNY&99
M+HN(PTA/*W*=.$2@L3>5122(JKL``4*&W;D='_3KHNG:K#?:G>.DAB>'-R\"
MX=!^187<GZMM?UK;M[I>E:6;:[EBRE[R"&M-02!UKV0$!$1'8/[VP>39R;-@
M[1``U]'O:UAR-`:UH``'4``/2OCYSI'N,DKVR2NQ+FB@).)H/)6GG7&P>L/O
M#JE0FP>L/O#HB;!ZP^\.B)L'K#[PZ(FP>L/O#HB;!ZP^\.B)L'K#[PZ(FP>L
M/O#HB;!ZP^\.B)L'K#[PZ(FP>L/O#HBV1Q]_12._]-[_`-]7U*OC@L(5_._(
M_B2#^[=:(ICT185D/^CDA_(*_@]$5>,OS?U+\2M/N1T16_(TI(1J,/XO=&:F
M<.7)%#%(F;>`J:6YMYPA]@%,;;R<NH()H`7#']G$GR#S\%#L^4Y`TOZ,W`5P
MJ?-Q7G!%>L"K,R6LE0C+D1Y9\L.L3H,5B5X%6#UNO&-2V9\8'(D"O.7$LD1/
M<$SC>W@$@"&N3VO-_0Y2P,@NB7ZE):!@'K!L8/\`$_Z2\%E>M=JEY%;CMF3Y
M[G3NSMM&_N;Y)'2``,]<L:8FDYPP%Q!PRXC%9O3>+UU:FLU.+56]5NE,ZA;+
MW7[S)MH1Q7[37:7)NXB7.12/474@)19=F91JT?<VJX;_`'PO(40#/V&^K?4)
M;N5]K>LTV"UDFBG+#V;^R+A(P.&%1E=4&G#"JP.J<L+K2'65I;W]G-K=Y>QV
M\ML7O[5DEQ&R8`-E#7$!LK"<M0*XT-5C9^.U@3&M:R<2LY(=1$TC:WTXP9Q4
M$=[18RE/V\=8WUI<K.T(Y%5NL[2%NT155=/`/]Z(80'7@CYG:*[0[?6XK2\-
MO,)2\9<+?L7Y)#(3@"74=EKF.84:5[G\F]P6^LWVB3WEH)K1T#6.J3]Y=<1B
M2-D0`)?@2TN:"UN4YG!9DMQ72$7:)NN6*H9(@D(:I2%Z+/%C("Q-96L-91O$
ML9!C#59],61(9QXZ`&B2[-)40(H)P("9Q+[QORQ9J,EE?:?>PF*V-P<T;?6C
M;_YG^K7*X]8!QX="Q$7+&]N+%NH6&IZ9/<_?1:.8U]R#'.6A[H7?>61QYF,-
M7=DYS`/HDX+,:UQ&,9W$\)F=W-/:U39J#8V`#S35KTYDVD7:;!@U<MF"3LRL
MB[?+)()((\XHJNJ1,@&,8`'9-"UVTW!I$.N6S,EM=L:Z./&K&NJ6D^0T-/,M
M2W1M^]VKN.ZVWJ'8B^M'N9(Z$U8]S:5;7R5%?@48(\?F''#:X.6M[N;TE$\9
MJV))CAS*;UT6+A;19*3-V>&:-:"LYLU-@K=3Y..>S$:1U&M7342*KDWTQ-E5
M@U*[OB1K;!I4GKZ[J-4+S0[1DVK<]"R"2TG2*76HRWVF;%H>'!VP"&KLPV<J
M(.2(N3`H!"IBH!B@18/7.-K$EMF%(2!RKTEX"596;J.JS8HN,D4;;*PE?BG,
M/.2M<8PTTV1LEECHU^HU75)%2+Y!L\%!50I!(M@QM]E`1`9-4!`1`0YIMR?N
M?]0'4T1<>>%D\J*_,M>T:(GGA9/*BOS+7M&B)YX63RHK\RU[1HB>>%D\J*_,
MM>T:(GGA9/*BOS+7M&B*,,T9FR-C;%5ZOE3A'%[L%7@74G&5@KEG')OUT]TG
M//7@ME#HQD<0XN78D**G1D3[NP>4/#J-Q<VNG275JW-=-:X@=&`-*TQIU^1>
MBTRSR".8Y*N`J?/2J\Z)CUOD6K@C&=THT0%FSOD&T-J6ZPBNJLU>5>=BG29+
MDM-'39GDF,4V:IJF8J*$VB<#@H!A:KD'GK>9%A+ID#[.`C<4DIB?;1T/9N8&
ME\[QAZCFN`!%02]F0"KEMCMH7,-Y*+J3_P"R-MVRQR_LR.>2`UIZ34.^J5Z>
MJY:DHFF%NUUDST.-:5UK8+(C8EHXHU0BK)%T^82SM!$S<[J,65%!04@'G%2[
MI"B8P%UT>2XBMX67=TYL=KV8?(YQ#6L!_><:`"IXG!:>>V=="T@8YUP9,L;0
M"2X]%%J%</6+0T%-R#.NMW$_#5I>J-;*O.OU<?W%W(6]=J$=#T#'=HJJ-BN$
MJC&O4GFQ0&#=T10$FJJRN\!.0ZOSVV/IVYM.VU8">]N=2ERLDM@9(FMS97=H
MYH(::]!(-,:4(KO5GRWW+>Z?-JTQ9"(15S)*-PH36IPIA3S^9;T&MUB(8Q2R
MJH@!A#;S#<-NP=FW=,@`E_>]S7:I6.CE=&<I#74%.KHKY>M:$XO+B),F8&GJ
M&K33IP5/GA9/*BOS+7M&J%"U2XE^+#+V#Y+%+&EXIMF6T,A7)G6IE[7FY#IU
M5FY.D0))V"#140$0,<Q2FW2F`@_#*/5WG9>TM+W-;7]SJ.I06,=I`Z1K9'4+
MRT8-&'$K3=V;HU/0)[&/3[.6[-S.UC\@!R@G$FI%`HNXL^/R:PZ^C,;8XEH6
M8RR_\6R<XE,D2?0]&@USHK@C--8]HJ=>PS#<VZ@U.=OS2)ND"80W"GV/8G+1
MVX([C4M5;(S2HGF.-N7_`%G&N1[>MHI6OE6N[VYCG0NQL=-[.34I`'O<'L_A
M-'TF.J[B>'P*4L0<:H9!9,4K$X3K,N9LGTU9NXZ?%*N]TH"#1,\0B[114,("
M`',<"@/*<>KK7]<V!?Z7,^:Q,K[3,13LWX$<>CR\>"S&@[^L=0C;#?!D-WE:
M22]IK7IP)6TZ5XFER@9K/)N2B`#OMS,%BCM#:`@*29]FTHAR=76C21RQ$B5C
MV$?O`CX<5O+)XIP'12,D!'%IK\"^OGA9/*BOS+7M&J0TNI3I%?@ZU7T$]`-#
MY#U)YX63RHK\RU[1JE%T)>YVQ&(EG#227,Z;Q<BNU`C9JJ872+)=5L4B?1S`
MHH98@;I-@[P\FP=2I::&IX+S.QWQ;\8,)&HQ=WA9*RS[-G3FAUIV@3,8M<I5
M2D4:3EFE9/7(IG'14@X1M#F9?+.RJMD3QCIBD5-0#<U*NYF]:E:E9]XME\L1
M$-9E8)]5G<Q"1D_'Q>.[%#(Q$?;(3%SYF^CIMZ\>;[F!DK!+<XNY,LF9%!1-
M1-)1/>3A6W&IP5E'B?XLFEHR`VCZ?)+1DQ<GDUC-Y<*BJO$-\:1:\[5%6;4*
M@X0DTWLE+5E&3)XV%!V5*7$2I&0!(=%2OJRXMN*Z9G9FKJ8_80G0(@IE)SS=
MLBRHK-J=8IIY*1K0_/I(I6*5B`:Q2;@PBV5`><!YM``(KC#<9F9F\]38ZR0R
M4?&2-ODXNZ%/1+VD_IE9B6Q47CZ7L2[1&O.9EDD+>65.T05;K,GH)@FB9(QS
M$6]B5TL*R22Z4LJ=%=))=%3F&Y0.DL0JB1P`R`&`#D.`\O+RZ(JO/"Q@`B,J
MJ```B(\RW'8`!M$=A6XF'8`=0`$1T10/5^,2E6BN1]H&V2-:C9UZ]:58MLCH
M^*=7$C..;2?3:N1!5\A(MED7B2.Z91)9!\<&;A-%U]YT17B!XJ:E99:G5V(N
MXN+->D)-U`UT&[(\N+2)CI23=.Y)L@"I8M`[>%<%3!8Y5#*D$@D*(&V$74K7
M%A7I^,L$M*3TGCUO69F<A)-+(J5>KKKI%;?3T9-.VZ*$E*;\:SD*O))<^8Q"
MJ"R5,3>(7>T17)CQ4XZDT$'+#,M2=(.9EC7D#DD6)14FY,JQF,=N*-B*$66%
MNH41,!2)J)'(H8IR&*!%?:UQ!5NYRJD'4LF0%DETH]25.PAGC%\L$<D[Z"J[
M`44!2.DF[$"&W3"(;0'9NB`B19YYX63RHK\RU[1HB>>%D\J*_,M>T:(GGA9/
M*BOS+7M&B)YX63RHK\RU[1HBC#,.?HG#]&>WO(TS*(U>.?QC)=2,B2RCLKR4
M7%HQ`C-L1)4Q#*F$#&V["AR[-:_N7<FD;4TPZQK<CXK%CP"YD?:&I!(&7JP.
M/I6T;.V?K&^M<CV]H4;)-1D:YP:Z0Q@AM,U'#I`/#JJM1@]9[PQ^[9+T`];S
M!>C_`(%M<Q'Z@^6Q_B=O=-+NG[H/6\H79O"US<[0MM8;)[*`XWD8H#6G^H#Q
MH>'5CT+GVGO#'_6:]?4!]V[57B$Y;_B;KW0*OPL<YOPMC[[;_93VGO#'_6:]
M?4!]V[3Q"<M_Q-U[H$\+'.;\+8^^V_V4]I[PQ_UFO7U`?=NT\0G+?\3=>Z!/
M"QSF_"V/OMO]E/:>\,?]9KU]0'W;M/$)RW_$W7N@3PL<YOPMC[[;_951?6@\
M,I`.!;/>@!0@D/\`^`'OPB"("(#M6'W0`>OIXA.6_P")NO=`H\+'.;\+8^^V
M_P!E4^T]X8_ZS7KZ@/NW:>(3EO\`B;KW0*?"QSF_"V/OMO\`93VGO#'_`%FO
M7U`?=NT\0G+?\3=>Z!/"QSF_"V/OMO\`93VGO#'_`%FO7U`?=NT\0G+?\3=>
MZ!/"QSF_"V/OMO\`93VGO#'_`%FO7U`?=NT\0G+?\3=>Z!/"QSF_"V/OMO\`
M93VGO#'_`%FO7U`?=NT\0G+?\3=>Z!/"QSF_"V/OMO\`951/6@\,R1RJ)6F]
MD.4>0P8_>#U0$!#8940Y0'3Q"<M_Q-U[H%!_2QSF/&UL??;?[*H]I[PQ^[9[
MT(]<:`]_@ZBP!R!IXA.6_P")NO=`I\+'.;\+8^^V_P!E<^T]X8_ZS7KZ@/NW
M:>(3EO\`B;KW0)X6.<WX6Q]]M_LI[3WAC_K->OJ`^[=IXA.6_P")NO=`GA8Y
MS?A;'WVW^RKU7/61<,UDFXZ"2O,]#*R;@C5&2LE2>0\&W64^"EXPE#BLDP14
M.(%YQ0`3*(AO&*'*'ILN?'+K4+N.R9=2!\C@T=K#V3*G_/T'J'2L=JOZ:.<&
MEV+[Z>RBDB8*T@N(II/@C8`X@=)KAU+=5&;<N$DG#=ZDX;KI)KMW#<Z"[==!
M4H'26071WDED52"!BF*(E,`@(:["'Q2$/MR'6[F@@@@C'RC!<"=#/"71W+7-
MN8Y',>'`@AS>((.-0OL68D2&*<K@0,40$H[A.00Z@\I1#D'52H7)YF14.=0[
MD3'.83F-N)AM,8=HCL`H!RB.B*CQJ_\`EQ^U)V.B)XU?_+C]J3L=$3QJ_P#E
MQ^U)V.B)XU?_`"X_:D['1%SXVD`ZC@P?O%)V.B+Z*S<DL;>4<B80*4H?`3#X
M)`W2AR$#;L#^'1%\O&K_`.7'[4G8Z(GC5_\`+C]J3L=$3QJ_^7'[4G8Z(GC5
M_P#+C]J3L=$3QJ_^7'[4G8Z(MAJ(JHM5XY54V^H<78F,(`&T0=KAU"@`=0-2
MKXX+`U?SOR/XD@_NW6B*8]$6%9#_`*.2'\@K^#T15XR_-_4OQ*T^Y'1%8\HD
M4.E!<VF93FW3HYBD*<W)S2>S;N`.S;LY/W=,TC03$[))3`TK3X%2X,P,C<[`
MX5%:5'_&*\DH'@5FH:5@9L]LC%WT58*K-.$B1$J5LJ$)E:=OLF9L)RBHD_E(
M%XPC@..T`.SWC;2;H:X5:<GIK:>.Y%W$Z7MV3/$K'N:'BZ?*[)D<TU=&^A)P
MJ*>5?2.H<_;>^LY=/=8S,@-C/;-=$YC7$2V<-LQS\[7"D3X>T#1Q+W+KH\%N
M4DXF7KB5\K,=#GQO9,2QSAA&VTLA*U:Q7EG9S3%C:G='B4K#'P1G<:ET9/<V
MJ@J)QWA*6F/E5K[8&6!O[=EC!8RVS.S-RW.U\V?/+'VF1S\KY,I()8ZAQ!5<
MG/#:PU&+6_[5<SZH=4@U&3M?NQR7,5JZ&1D3^SSMBED;$YX!`<P90*BJRC_A
M/RE!K!!5JZUJPXU0RC+Y.3IN2V%JDSS+Y]%02,6A;7D$,>2;)`3T<XD443%!
MLJNJD90AA3`->X\M]PV,`T_3[VQNM!;>&Y%M=12G/*YD;0^9['@/DA>U\K"`
M`\N`<*BJQ,'-O:M[''?ZII]_:;G9I;+#[Q9O@($0+S(8NW!="Z5KF0N<RCA$
MPAI%5LA7\8V".O67;Q+2*#YUD1C5H."1;,GJ9JW7:W7G;$(Q8ZP&YX7,_*NW
M@BGL`2J`!MI@UT:UT2>'4]2O9IA*VYC$$56U(@+*/!K4@AW`5-1B2N67FYX)
MM"T#1;6WRC1Y72R&0EXN)))NT>_**9<D;&11U)(:2*X8PQ9L#W:#X8,;XSB"
M^=MFQ+:L'7!=E&-E63>\M<3Y;JE_F8!HE(&3*D:;B859-`BYP*9<$RF$`':%
M>U]'GV_H%IHSY^T$%K%&X9<"YF>M#U>L*'SKR;PURWW)NK4->LX3;6UU=2R-
M97,2U^3*'=1]4UXK7#'7J]\EU!SE=):]4]C#92E@A[&G!^DJ5>W'&TQQ4V7/
MEO0G$[0Z.QID_*T2S.JH2/@2)0Z_2W#IUSAA3*3/K6E.O$+P216?;3%S<[/V
M60AF=7S['^;=BM5[&.A+'EF@P=-K+FE(UR4AO-JK5MQ%'<O8LASMW?.`($$P
M<A%`5BX+<Z@RE$GD[4)IV[POBOAM@Y*ELK9'R+NMP64L6VQI>;A%3RJE<JBV
M)(BGR@MUX/:\L2[Q)9^4%442%(O5M=NY7666*@L!555#E`450,!3'$0`P`GL
MW@#J_NZ(OET%U\BK\TMVO1$Z"Z^15^:6[7HB=!=?(J_-+=KT1.@NOD5?FENU
MZ(G077R*OS2W:]$063K=,7F%#%,4Q3%,@H<IBF`2F*)3)B40,`[!`>J')U-*
MY?6H'4Z#P/D/D*J93.*\*A>6F(>#^P5/C_R_E9]A>OQ6%U*ZFOBZ739UHT:P
MMJ84Y87\%`MEE9.&D2N`D!Z09LD.^"@@/PBB;F.F;0NK3F9?[IDCA.A7%F&1
M,S>LV6EN#ZE*`?PWXUZL,5N5]K<<FTK738Y'G58I&B2H]0QM,Q%'=)]=N%.O
MJ7I)<J!$Y!K4I4+4UE#P<R#0'AHM99C*-EF$@TE8]_'/.:.#=_'R;%%=(QBG
M)OI@!RF*(E'>M=TC3=S:3<Z'KD(FTN[@=%+'F+0^-WTFDC&CAZM1B*UZ%JEM
M>WUC=LO[&7LKN-U0<N:OD^=:>6;U>]9FK/:K!#9,DFK6ZDJ`VV=R!2T+OF,#
MTUPF]9-L?7Q(8R/I;%=PD51`J++;'NS*KI[PG`"\&LOTV[7T?7-*U3;.H:II
M=AITI>ZVBESLG+BUQDG<\%TDPRAA?49F!HZ#7I7YK:O=:;-8ZQ;6MW,YA$<C
MVD=G4$$96D!P-:^M6A%1BMZQ:.E!$W,+AM'_`,Y)81_?$PD$3"/NC[HZ^C7%
M[I'N>0:O-#2A+>@D=?6N65>0.T[//3]AN1H\@%3\?2N.@NOD5?FENUZ<$6-3
M%&8S9%P>H3Q%5BB!5X^?M$6=$PA_'2)'235$I@$`$/@[.37OL]5=8M^],`#G
M<6$"CO(0["A\N"QM[IS-1+6/S`M/JN'0>NN-//0KSDXB^'7,$<LW?XYB\@WA
M6<E4&6_#WRW)/(DSM0C=N^GS+F!1..;[P&5<%,L5%(AA.(``:[9LO?&E7$%-
M4?#:VK6G.V2&U;4`5K&6Q.<YW[HS`'I*Y!O'9^K1W`.F=O<7CG#)DDF+0XG#
MM")&!K?WCE-%:'B'$7PU2D7C7'G#Y.\02<G"5N;N.6K2RN=OCV=HF9,K64BX
M4'3YR+6MU6#)M!)H<ZSMP)E5B-P$!-4)MI[TMIM<U;5O[7V<AC9%!V49?"WZ
M#WY6,J]QK4'Z/0<59?\`[IV3=1:)IFFR:EVD0D=)))+1DSOIL:7.E]0892`*
MK)(G//'<DD],KP61,>B!^DQY&)9AHL+!&1AF_,/&B3LX%E91C/%6;E(;=0Z`
M]Y\"BD4#XV?:/+-S@;?7[B:(@$EX#C7&H!!I04^6O2LC%O+F/E(ET%C9FN(`
M[0D4PZ2T?X*<<%Y/XIKWD%6(ROP_M,9T(M)"9)9/].=//;]L$H>LIH/5E""@
M@G++$%4Z27.G9K"F([HAK6-S[<V/I>CNGT'47W&K&X%`X`#LL*\"<:UH%M&U
M-R;XU35C;:YIS;?2>P(J#4]K7`\!APQ^1;A=!=?(J_,K=KUSO#HX+?0"!1WT
MNE:4YEM'$<SR8L.*,?Y)\4041!P!UQKT;+T^S2,C86T^:58I.'"RBC,\*W6C
M7;I-(CM@H8"&,B50JP%(%311A$95XT[$Q@Y*NU"W.F,RC93A*RF,8>,8B8]=
M>$:IJM5'`.R,X&XIMO%:RIT"RK154517W/@%):1Q4UW-3B0L6"'5>I)I1AGJ
M"O=2C3V.4@30\(]BRY&36&?>-HPY(]W"O,?I$<2:+;[R4RIR"D(;4]%"P:'G
MN+T[P(J"J]QB(EHQ%5)E>JS$2#QB6*ITJ\K40>[N7BQK?(7&=9HH3[\Q3&8.
M3%*V!(JI=TBOF$<@<3KJV0L?FRH6QM7']5)'GD`H2$<S)=GEE8%@7P+,$$'[
M5%W7W#@),KE%`C55J!Q:MRF**Q%8IA[QB0DM90B&%I<U`UTMB0(#3X>W3253
MG+]D5P6PP";]T9U).*S3F4.$3$[HME2NP(HDH(@4A%V,)2/%,PMV-ZY?*Q=E
M*J\BG1[M.6.`:+E4<*41FHQ?O98CZ1>P\ZA<([F5V21T6FZZ,)4U1WU4B+>L
M6#DY#%%)<H'(8HBF1<AR@<HE$4U"$`Q#@`_!,`@(#RAHBU+:\&%304D5EK;?
MWCF?=$\[7)V]69FML,W/4W3.&F4HVJ,VX/`E*3&O'DPBFE,2CE$YG;A7G!`"
M++*+PMUC'EKA+3`3MU,G"JNG_F\]-%+Q$G..(RR0:4V_7+!I2P.&,-:W:":*
M+A-N/P#F(8Y=HD5KL/"+3K'(N7CB=O31G(R-LE9B(9*1!6<L_M<W>)\RRZ[F
M!<R#5.&?9$D^C)H+)E.4Z8+<YS8")%VY;A2J,F\Z:E,76-5<'D6LMT12,5"7
MKL[9+):K#6G!7T(YZ,QF9*RJ%.NW%)VBDBF"2I1YP3D664S`4+1K;%VF(E+2
M8(BBMJ(WA%BQI(MRS:G;\S)R:K*':2<M(-TFP%0*X6.BU$Z@HD)SAM$4S=!=
M?(J_-+=KT1.@NOD5?FENUZ(G077R*OS2W:]$3H+KY%7YI;M>B+7;BIP!+\1>
M&)G%<;<U\</I6:KLJE;`JR5LZ($'(`]4:C"/'D8@N#Y/:GOBL44Q'>`!ZFM4
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MM_:'T*H/4V9#';LXP7')RC__`,_P7('4VC_XRV`&W3PVZ)WA-]3YT\86K]RV
M_M#Z%3[&W(7[83C_`)?X'^V6GAMT3O";ZGSIXPM7[EM_:'T)[&W(7[83C_E_
M@?[9:>&W1.\)OJ?.GC"U?N6W]H?0GL;<A?MA./\`E_@?[9:>&W1.\)OJ?.GC
M"U?N6W]H?0GL;<A?MA./^7^!_MEIX;=$[PF^I\Z>,+5^Y;?VA]">QMR%^V$X
M_P"7^!_MEIX;=$[PF^I\Z>,+5^Y;?VA]"Y+ZFS(9AW0XPG`CU=GH`@=NS]P/
M/+:.GAMT3O";ZGSIXP]7[EM_:'T(/J;<A!_[X3CW!Y,`0(@("&T/_OE^[IX;
M=$[PF^I\Z>,+5^Y;?VA]"X]C;D+]L)Q_R_P/]LM/#;HG>$WU/G3QA:OW+;^T
M/H3V-N0OVPG'_+_`_P!LM/#;HG>$WU/G3QA:OW+;^T/H654CU/TG$VF(D;[Q
M,2]VJ31QSLU58S$</47TTV`H[&:-C0L<FM%`=39O*%04-N[0#8.P0KB_3;MX
M3,?<7LSX6/#BW+3,!^S6N%>OH5BY_6%N,VDK-/TFVAOG1N:QY?7(XB@=2F-.
MI>QM:JL'3*["U.JPR<+7:['H14-%-$G'1V+!L7=103,L*BR@ARB8QS&.<PB(
MB(CKZ#T[3K'2;./3M+C,.G1M`;&79R#TNS'$UZNA?)FL:KJ&NZI+J^JR";4)
M_6D>&Y`7$FH#1A0=?2KV"2HB``DKM'D#[TIV.O:L>@I*@(@*2NT.0?O2G8Z(
MN.;5^25^:/V.B)S:OR2OS1^QT1.;5^25^:/V.B)S:OR2OS1^QT1<\TK\FH'[
MZ9]GW.B(9%4H[HI*@/6YL_4Z_P#%Z@Z(N.;5^25^:/V.B)S:OR2OS1^QT1.;
M5^25^:/V.B)S:OR2OS1^QT1.;5^25^:/V.B+9&@`):I&`("`@+KD$!`>5VN/
M4'8/4'4J\."P97\[\C^)(/[MUHI4QZ(L*R'_`$<D/Y!7\'HBKQE^;^I?B5I]
MR.B*UY)?/624*#)XX9BNZ<D4,W5.EO@"26Z"@D$!,!1':&JF-+WM8,`30GJ'
M6H=]$]=/C/0/A7F)#^L!:3`U5!.N6Q&0LV7G.+E&)[,T.>)9(O(M@C='"A$@
M!S&.GDJ1,K8@`J!RF`3<FN+1<Y]*<R`/MI!<S:F^TR!V;*&OR-E<<HH'.!%*
M8$<2N\W?(/5[?[[)%?1R06FB#4&GLR'2NIF-NQN<^LUI:YSZFC75RJ^M^-&T
M&IMLR([QW<4*1%TNQWJI3K>VL7A;/&5NSC5UH^513;E\T9F25*+IJBJ9P51J
M4PB8#%$NLHWF1.+2YU":Q`LX;:::-PG#NU$4AC`H(_4+Z5Z:=16,FY/PQ:Y9
M;;=K$+=7GO(K>=KX)0(7RV[;@%CFYQ*&@Y#]`Y@5UYOC@F*]&2:4G0;HG>(6
MV/:U*4M&XPRI$6L?CQ3*+B?;643$C7;(U01,=-($RJG<AS7)_&UY[GFM#9V/
M:W%C*-19=NBEA#ZY&"S%XV4/R>L',(&7**'&IX*_IW)&ZU6]B98:G;RZ1<6S
M)8;@1N`D+KK[D69'%KAEN"QF8\<U0*#&A]Q[P\?*RQ%X6\^:\97Y&43M(2K(
M!>3$7C2.RHYKQ(,7'3T#&KLJBF1V<W,"ZVDV;`WA2<WM&BNW,D@E&G-94S5P
MS-M&W<C<M/V&/8*UQS5H**FSY%[@O;6W,5S#_<[B5C1#0DALE[)8QNS`XYI(
MGG*&UHV@J5+E#XETK9BJP9:L3U>F5JK)3SR?<>>4/<(]I&5Z/3DW\@C+UAVZ
M;.!3;'$IFPD3=%7**?-B(D$V\;3W`-TZ/_=8X^Q<'EKH\V8M(%3C0<`0>'2N
M=;TVK+L[66Z2^<7,;X\[91')$'"AKZLK6NP<"W"O6HZF./K%<$[L+)T_S$N:
MORJ5<:K1F-+H_97"V%N]3QM+4RB/44`;62U5>^7>-BY1H4R9FSI938*A&[@R
M6Q+4ZJ\H<=>$E4Z[SV3YR.?V2H9>O*4'+0-PCK!"P&!#/D<O>=4.O&`[KDQ2
M7\8X:.&#@"O%7:)DT4U`V&$E2NG7^.[%-EDZG#-9W*<=*6NU)491G8\<WV!-
M2KD\DT(B"K.2U9"-3;T27M,D[13BDGIP%Z*Z9B["'`VB+8QSDUDS"3%U?&*'
MB5I./I8@V-NHO&,ZPBW<V5R]:).CNFZ=?;O$3/-I-K?GT@.`"H0#$JM3%/6-
M8?1BXZ567STF$FWE9A",]#V0U)U*E0]&C,EN<EN(A%FH[#'2M"F$)-*13*H(
MI"=,R1'":B)28J1(WC1Q;*V>0JK:[VQ)=FO7R-)U]7+6QI]C9V.UP]$:352M
M;IFE#V.OL;I88^+>OFZAF[5V^1`QA(??`F*V-&Q3I1$II62`2B("`O%]H"`[
M!`?A]4!T2I5:5@G5%4T_&\D7G%"$V],7Y-XP%V_]8'7U4UN=P:T@'BZN`#:M
M&!Z75/T?)QQ4.+J>K3-4<31N)IB[H7@%G+US_$)AB#LF1S8<B[!0F.3)JCQ$
M,QG)9:RB6N3-=CY<LA+$GD"H-89.;"/L$N:)*Q@;0YCHI))^#M9PUP/+/7K?
MF5K]QH%K'-8W%M>74$AN&Y<HMR\,E(PHRZ+"(,37&M``3EMWZ6_:%A#?SR,N
M63EH:(3F)S-#BUO6YE:N&%&X@DX+WO8VN>>,&#T[R:8F>L6;TS)X\4!XR,[;
M).#,G@)J&3!VS,KS:NZ(EYPH[!V:SI#FNRO^D#0XUX<<5B(W]I&V1O!S01\(
MJNP%AFPV"$K(<FW9_.UN3;U=GPN3;JHN:1@,55F>>)P57G'.>5I'OU?L]4)4
MIYR3OE:2[]7[/1$\XYSRM(]^K]GHE2GG'.>5I'OU?L]$JM5N);B$X@<3/L3-
ML4XNLV5V]VNK6O6UVR=R`)5*'<G3(:55,B8I-I2"<^PQMT=S8(DVAO;ULW0-
MM:^R_DUS4+:V-K;N>QK7"5TCFBH:UH+3F/`#$^1:%O7<VMZ!<6<6A6HNQ<S-
M8ZK^S$8)H7$Y78#CT>=1%Q:\<T]BN69XKQI9$PR>8T;(VF4F'@.(BC1JHIO0
MC%FZ[-\#ZQS+8``$E&P%;M3BH)BJF2*&?V-RZM]?CDUK<1#-,:Y[8FES&N(_
M9>6O>P4'&E:^=8;>?,"YT66/2=NL,E\6M?.X!SFM_>:"QCS7J.6G7129B;C,
M;75DP0MLXR@Y,S4@.7C2RO'3-T[`"[ZB3-S$QIVB2J@CM^&<I=@\NS9K$[@V
M(ZQN7OT]T,UB>!/98TZ,K)9*><TKT<%F-O[ZAO+9CI@^*8])$IQZ<9(H_DKY
M:+:-A>3RA"&B[6$B10H')T*8*Y$2;-[:)$5SF#8`[1VAR:T:2R$%6S1L:X=`
MP%/C6_17C[AG:,D+@>FE%=`L,X'_`-+R7?B_9ZL-<R(YH6,#O**J7%TF$KG%
MOD-/EHJO..<\K27?J_9ZH))-3Q4<,!6BZ$M8K-XHEC,I25%[XKD>A<T[7%4S
MX&2XLR);3AM6,YW=W]W12#0U7F;CK)W'E4H]*&L*&1;+(M&--9,G]JK;NQ!;
MY)M1Z*K*)2,LQ?,DZBDF69E7#U^H`%=3L2=H`@)]U0I<ZJERF6OC*1RQ$C9+
M9:YNH&EX5G9FCJB(0M<"#LL+B]>16B'C644%L>JRJ\X?I!1<J)\TJBKM#E$J
M58#9'XXF]HOX1L9:(N(M-T?6>ENYYDC=6]>IL8M.U5M5"PY'T(:JN9=&!BY@
M6ZRCI8?&"QRB7?V$(OHPRYQT2<Y,P$A%.HJ(;Q)4TYIG490CQV=I4;"]Z>S<
M&?MXID]N%@8H->:0<O%8O?()2)&4(8Q%<HG/_%1%S=.+9X*]A!!:Y,F044L8
M38L("GQC7FU4X^UI2\D\L3I.-,WDTGQ&R)'3A5=L"BIT!1`BWK3LDTJDBJ63
ME`*LBFL0%%W*2@$5(50`.D<0.F<-NPQ1Y2F`0'E#1%]B6&=.8I`EI':8Q2A_
M/5^J80`.H;]W1*K7R"XP,>S3-Z\<7.<@2M+/=*T1*6;RJBCE&CILG3^T<Y$)
MRC=A4I..E&CAB]=G;D7([1)L!90$]$J5VW/%SC)C8Y&L2&1W[%[&NZ]''?.&
ME@"$=2EDD;'%-(UE+D9G:+N6+ZJO"OAV@DR*4AE3E*;:!*E8?:>-^DTVX6*D
MSSJ^-96KY;J>(Y9<J!%F:;NVTD;TG<DQ2DC.5*7!QR:C9^OS?24WJ?-D1.!B
MF$E2LQFN+C&,+*^(SY.Z;*IOVK)ZT9NGV[')+3B4`^D';YR5"-Z'".E>==@F
ML=8C8HJE(8@;=$J5:)KC,QO"1:TL>Z6!^B5JR7;,6,?/^/G:[J3E8M=DM77;
M1M-0AHU6'44<KR*#1HDB=,PJ[#EVDJ5G,SQ$UZL)9#=VJU2M;C,9VR*IE@E)
M!1ZNV<34S6X"T,B12$;TY^\2-'6)(#?>0,0R2IA`$R;^B5*M$AQ4X]CY*MQZ
MF2.?3LRCY)E)-WSD[!)5J,BDW34.82++C)N8=ZFAS!%?\D54/NI$%31*E6E+
MC+PXN#,R.6W2Z;\#&06;1-U=((E(XDD#>,%6\(H2+4*2&>.!(Y%(X,VBKC9S
M)!/HE2LXIF?8&]RCF`@;=(K6%E"HV!Y#G/)%.E$KO18$=MY'F_$\HFDY$A%N
MB.%^8.J0JFZ8P!HE2OAF+.T)ABB/,@9"F+"%:82$9'K^*T%YAYTR5<"T9;C+
MGTMX@J".\;:&Z&M>W/N;3-I:4[6-7<YMFUP;@*FIK3_`K:]E;,US?^X(MM[?
M:Q^H2->ZCG91E8*DU/$\!3!:BCZS_AG]R;R2/7_\%N`_PR&W7,G?J"Y;M=E^
M\2UR@_0/3T+L)_2QS<:UCI(+*/.P.&:X`K4D8>J>%/(N/:@<-'EK)/U,7_*&
MH\0?+?\`$2_4*I\+7-?^7IWO(^PGM0.&CRUDGZF+_E#3Q!\M_P`1+]0IX6N:
M_P#+T[WD?83VH'#1Y:R3]3%_RAIX@^6_XB7ZA3PM<U_Y>G>\C[">U`X:/+62
M?J8O^4-/$'RW_$2_4*>%KFO_`"].]Y'V%47UH7#83>`D[DHH'*)#@%.<@!B#
ML$2CLD0VAM`-/$'RW_$2_4*>%KFQ_+T[WG_]BI]J!PT>6LD_4Q?\H:>(/EO^
M(E^H4\+7-?\`EZ=[R/L)[4#AH\M9)^IB_P"4-/$'RW_$2_4*>%KFO_+T[WD?
M83VH'#1Y:R3]3%_RAIX@^6_XB7ZA3PM<U_Y>G>\C[">U`X:/+62?J8O^4-/$
M'RW_`!$OU"GA:YK_`,O3O>1]A/:@\,X"&]-Y)*7;L$WF6Z,!=O)O"!'QC;`_
M<`1ZP"/)J#^H;EHS_4N+C'`98B['RXX#RJ]#^E3FY.XMCAL'`-)-+@$T'4"T
M5ZJ56YM!RM6<EUYE;\>7-E9H-X0.;D8A^*IFZ@E#G&;]L()NXQ\GMV*(KD35
M+[H;-=9T37=*W%I[-3TF>.:W>*^JX$MZ@\?LD]2X3KVV]?VO?OTS<5K+:7K7
M.&5XH'`&F9IPS!9@,D^'_P!J<_N[5C#R_P`(<FLNL*N/&3WNIQ\Z/V-$3QD]
M[J<?.C]C1$\9/>ZG'SH_8T1/&3WNIQ\Z/V-$7(2;XH@8KMR!BB`@(+&`0$!V
M@("`;0$!T1#2;\PB8SMR)C")C"*QA$3".T1$1`1$1'1%QXR>]U./G1^QHB>,
MGO=3CYT?L:(GC)[W4X^='[&B)XR>]U./G1^QHB#(OO<=N`'K@J/V-$50R;\V
MP3O'1S`4I=XRYS#NE#84.7;L``T14^,GO=3CYT?L:(GC)[W4X^='[&B)XR>]
MU./G1^QHB>,GO=3CYT?L:(GC)[W4X^='[&B+8>A'.I5HY10YE#F%UM,<=XP[
M'BX!M'W=@:E7QP6"J_G?D?Q)!_=NM$4QZ(L*R'_1R0_D%?P>B*O&7YOZE^)6
MGW(Z(K3DQF\=(PHLV;EX*3IR90K9%582`*:6Z)^:(<2@;8(;=FF!:X%P95IQ
M(K0\1\H4M-'M<6EP#P2*TJ.GY%Y80G`,^B)*$E_.&07D(B;JDJJ?S1>I(N4:
MYE.=R*Z323%^H+=W*L91M&F5VFW`:`<0,!@('%-/Y30VEXVZ;=-`-PQY!'0R
MXDN'$_#*X5_=#1T57=]0YZW5SITFF,LWMD^X7$#96FCVF>TAM&Y78B@$#7.J
M#])YPKATD^`ZX>++%#*VUL1BYQ=<L2UAPTQ_)(RJ-?LMN;6V+D+<Y"8YJ=E*
M^JFHU(")&Z9D#;0W3B;;>@Y57C89[#[["+=FG26\%&FCFOE=(UTN/K2T/TAE
M%*8+W.YZ6K=3L]2L-.N/O)U.VOK@]H`UD\-M]WE9&*`MA>:O#27&I^E17RP\
M%F0K%&R<B\O"7I&G+A*6*6G4\>2)*J6+E,7*XD-",:Z$Z9^BHRKBPKHN#O#[
M7>T3E$H[-7+[EKJU[9=L^^B_O_;`NHVD3FOM1:OJVI)+8AZIS8.%348+%Z5S
MFTBSN8[&+2;[_;<-FV&(OF!G:Z"_;?L=VF4"K[F-N;U!6/U10^LK9)\`\E*R
M$RU5MDPG3I&ORC1K'EIZXS[6QRF)XK$JLBM+]-Z$XB$HR(3=E:@V(ISYS%%7
M<V:MS\I7/N2UU^S^T&-[7-+?6[1]JRS<X?Y3'&TTIQ%:]"R-ES[=:Q65RW2)
M&[@CO&R.<)*,;##?2W\30*U#Q)*X$YN!``!%5D,_PE9`/PX9[QDV>)R][RP=
M[9D7<96'58JX6&,95D(*!;1BKB0,SB90:<W;NU%5C;PNE3B`%Y-;ML[:\^V;
M:9LMS'<NEE?(3$,D8=(QD;J-))R@,!`K@234KEF^]W0[MO;6:VAGM[6T@?#&
M+B5T\KV/E?*<\CB:O#GD`@#U0!3I6#V'@QXA)N.LD'`9/B:S0G66%L^46AS6
M,9N4<,\@V+/M-XAY.+RK+1EH:^<<34)B"D8>)-"FC5!;2ZBKDRYT$M[;EI%%
MG\9P@Y+@VE'FH6\ILLEU.1XL+R\LHXZ?K5M]E?BC:R#E6QQM5<3;@[*M4*Q/
M$U4(YPZ=K/FC<J:BY3G.<244=0?`OF-LRP1#S=PI2L=B?)\)F"?EHC'5_4O,
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M`S!*J[EXQ\M$M+(>.<E@G4HDB@=52.;R@I&6*4#"*8#L`>IJAS#(V2/`ES!E
MKP:X.#@X</6J!QJ*="AS6/!9,,\)XM\G7YU^>#-7JX/6*WC*N/7=1I.,D\;L
M)P\9=6-AR`J\9/,?R49/*ST:H=*HM9UU+W27M\W+6A\DT34>7):-D&Z1V[(@
MH8GEG#?[5UK<NJ[R=]YAOX8WV9902":5^6Y[0BN9IC`;&V@,;6BAJ23DMV26
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MW9%$'.!='F+W<1&`:BKS@,,.L+C6]]B7\DKI-#;</=,6M+6R!K6CID/`D,&)
M&;&JM3FE<8'#2^C,;8'P1*9CK[V#KTS<\KW-.?LZ[NZ2LJ+><+'DD[3'*-X"
ML0Q.;:M&K4BJIP%5<I1-OF]UO=;)WG!+K6Y]3;I5ZV=P9:1`-`B'T7'+"[%W
M3C04P5B>QWELU\>D[5TZ+4K$P-+KF0EW\4USM:!)5H;Y>/P+)HV_>LS(DZZ7
MPL4Q(-I'3'HK1Z@Z(R2D8-$(YTW\[3(J2$FPG#'*8AB$9^+'8*;XBB!O!<Z)
MRC,S6Q:O.Z$MQ-?VL:XF-N&`_9/$>6GMAUOG!'`9':3:\?H@.\G6\J8L!6'C
M=M=]59YTPE!T+'_F8=\F_BHV1&9&Z%/!'\5;1L4L0L<1&3<$`YDAYXS(XE,7
MD`VL[MTGES9:,Z7:=]/=ZV)P,CR,O9]/[(Q\M?@6R;5U7F#J&ID;EL(K31ON
MY.8`YNU'`?2.'DI\*W+\13?D>3[P=#__`$@US5=%;4M!/&BTMS%6>+*2R8M*
M8LH%MB(N&B(:KL9IK8*OXJLJ+JPMK0O,+0,X=,Y&C8&AHV114(V=%3.0Z"RZ
M1E$P*IHJ<5%\3%<?L\R@WT="Y&B6LHC8E5G=D+C9I(-5GE=>,.=>P8L4E6C%
MM:Q;/((%"*JHMR+%=(`(EVE4YH`P4UW?&_$I<\$.<?0+JVU[+</>JB#+)DLV
MCUBNX!ADE*;2L6]#*1;.87CZ*BB5^@"3<R[L#D!(YMI!*A8+#8_XSRN4H^+B
M+90X)E'G!M#OI2GV&!CS1M/E/,N$K\L=K*6N1CBV1%LE9G,@?I<@H8BB*A2&
M6,!%?L'QG&+#6V&#,M9ODY57-73A7BYD*2LFC9'MC8+PU@=QL&_4D(XT/`G>
M(2NQ9Z13FT5"G$3@F0BL,GC+C+A9>Q.ZRM>"5EQ=[4_2@H>0ISB0=5*QY`R'
M-R#V!7L[1P=G;4*TI")1!'#I-DR.<Q#)``*"4B[&#\><7=2MN-XBX0-M"AM(
MER6YN7DI5IE)VJK1&3-MXX!I_IQ>RL[?&I"9RV.LW6254W2D(!C')1;RK5Z;
M6262\53"0+)*I"H@T=I+I`J0R8J(*E2$4EDP-M(8.4I@`0ZFB4*UGC>"7%T"
M82U>IW6HM'5?)6)R-J\M*0T=:H@(5E"."6=LW:[91Y)HQ;-=ZXWDUGKEFD98
MQR@<AR4*X+P5T`5HET[CLD2C^)EFDX$C+2JD@\?2C:7LTRL\>&7A1137D'%N
M>I+':D;'*V%--$4N;*;1*%7VQ<)5'L-ZD<GKU*>&]O9$9TCYVI-.H/QXDI7%
MV3A[7TCM47K%!:IM"'0!1(QVYW"0*%!P<=$H5B,/P,8T81T$TDZU;)EU%T^"
MJ<F[4,Y9$L1X58'(S<D"#4\F+]\X$X'(+PR()&V;@J;51)0J\.N#2E/MB[Q'
M*KF77`R4S8S6-^2?LS-9U(.GL=/O$HM-NY920/P27!%%`YD&R)"F)N")B4*O
M]VX6:]?WUQ>3Z&1.8O,]"6N:A&KQ/S?2M=>B8F`C;+%Q;^`?E8RQ8.&2:G'?
M.B)#',"95#`<I*%8ROP28O>.BO)&KWJ25:2QY>"Z;,RJGFJL=2;.+:LG3:)+
MQK026612-O'565;OEDE%#IGW0)0JY0O!UCR"A?$3.L7$[,S=1L<RCQV@H=%2
M)M<$!`2C8]@P0!**N;U(O-()@'WLX@)R;PDH5D=!X9ZWC6VRMSJ\1=BRLM"C
M7U4)1Z]E(YI&'<QSQ5%@BNQ!T@"KN+24W3+'33,)^;(3G5-XE"L=XJ.'&Q\1
M.&YC%C6T2V,7$K-5V4);25!*T&;!!O\`IQF00\DZC6JW3R@)-\50,G_&`!'6
MJ[RVG#O31':%<2210O>'%S&9W8`B@'1QX^E;URYWQ=\N]T1;HL[>&YGA8]N2
M5[HV4>*$U:UQ)`X#Y<%Y<^QDNX=7B]G?X.'RJ;/X/_%74UQKPV:!&`T75WPI
MC;XX+Z0'ZQ]::1V.E630&!N-Q(00VM*9HCUFOP)[&6[_`+7L]_R]U3^U6H\.
M.A?BKKW?YU5XRMP]VV/MW?T4]C+=_P!KV>_Y>ZI_:K3PXZ%^*NO=_G3QE;A[
MML?;N_HI[&6[_M>SW_+W5/[5:>''0OQ5U[O\Z>,K</=MC[=W]%/8RW?]KV>_
MY>ZI_:K3PXZ%^*NO=_G3QE;A[ML?;N_HJHOJ8KR;>$O%W/F`I1,;9P]U0=TH
M=4QO_%7(4!'JZ>''01QNKKW?YT\96X>[+'VSOZ*I]C+=_P!KV>_Y>ZI_:K3P
MXZ%^*NO=_G3QE;A[ML?;N_HI[&6[_M>SW_+W5/[5:>''0OQ5U[O\Z>,K</=M
MC[=W]%/8RW?]KV>_Y>ZI_:K3PXZ%^*NO=_G3QE;A[ML?;N_HI[&6[_M>SW_+
MW5/[5:>''0OQ5U[O\Z>,K</=MC[=W]%<D]3+=><2$_%W.G3*H0RI/^'^J)B=
M,#`*A"G"U;2&.0!`!V#L$=ON:GPYZ,UI9'>W#&/%'5B$=6]0<0<:]"MR_K"U
M^X86G2;=[QBTQRN<6N'!Q&1F'0<>GAU>L6#>'2BX!K`U;&U;>(*/Q06GYU\5
M1[8;.^;IF*1Y+/`2(4Q4BF-S*"1"(H%$0*7E$1[%L[9.@[&TS^VZ&!E?0R.Q
MS.<T$`N/2<3P`7S=O_F)N'F5KSM<W!*'2-&6.,-RMB:>+0,3C05))X*8N@/>
MY'/S"G8ZVU:0G0'W<CGYE3L=$3H#[N1S\RIV.B)T!]W(Y^94['1$Z`^[D<_,
MJ=CHBY"/?F$`!FZ$1$```05$1$>0```+M$1'1%R:.?E,)3,G13%$2F**"H"4
MP#L$!`2[0$!T14]`?=R.?F5.QT1.@/NY'/S*G8Z(G0'W<CGYE3L=$3H#[N1S
M\RIV.B(+%Z'*+1S\PIV.B*HT=($'=.Q=D-L*;=,W5*.PP;2CL$H#L$!T14]`
M?=R.?F5.QT1.@/NY'/S*G8Z(G0'W<CGYE3L=$3H#[N1S\RIV.B)T!]W(Y^94
M['1%L502'3JL:10IB'*+L#%,`E,&UXN/*`[!Z@ZE7QP6"J_G?D?Q)!_=NM$4
MQZ(L*R'_`$<D/Y!7\'HBKQE^;^I?B5I]R.B*RY/7<(HP@(.%V_.NG15#(*J)
M"8.;2V;PIF*(@43;0U4P$R--<`X$CK`Q+3_U4HK4[A'"Z4C,&-+J==.A>2D%
MQZ3<TM48\U-Z/*V',BN/)!J6URJA(JHFDXJ(87--0S(IW+I[)21D0;&`B>^@
M<`4'9KA5GSFFO&VEM'9M-[<ZJZTEPPCB,N3,?(ZH;_@5](WO(&#377A&J2&R
MM]%^]9NS,G_JI6/D^[8<&QQC,3Q#1\*R%IQA9`-1[CD9U38`]99XZLN1*:V8
M9&74GS-H&V&K+6*O$,LFG(1CB=0*9XBY9(N6J92BF<V_L$<E#S/U.YTN;5WV
MUD[3!937D+V2QQ@102&%L;JG/44XM:13B:K"S\H-,EU>VVQ]]NY-;&H6]C=@
M021PODD@;*)+:0CLW1M:0'M<X.,E>A<6#C(O]:93$1(4!@KD2!N#^`D(EK?Y
M;S36AX_%:N73S3*<6A"R9G#BNHBW3;*-"@#O^,<"<NK=SS0U736&"ZLXF:K#
M<]DYK'ND;0VK[T'.X`G/$PUPPK08+TV')K1M8OX7VFLSNV[+%'*)7VAC<R07
MIL.PRM<6T,A;C4EX`/$D*\0?%Y;KC?6%-J-*34:V%,T36)*=O+Z/<KW$N+X;
M*9V,PS:13U-C7@B)<&H.TCJKBY((\SN"`:]EES)U+5->BTO3[&-PF/9B0CZ$
MIL?O@:>B@$C1Y@L3J/*+2M&V[<;CUO5I&RV@=+-$+=X+X#?&RRXD4GSL<Z(8
M#(:E253^(237Q+>\NY(2;U.NT21NR;AW7K)*6..EX6CJJ,7\O$KO&40Z<FD)
MIHX:-$N:*+A0A-T=B@:W#:NM:CN'3I]2U&*"-XO#"P0?0!@JV7X'.Q*T/?FV
MM*VKJT6FZ;<S33"VMYI([CU9(_O3,P:&QYF58P-=ZSA],^1=6:XS^'2L*V]G
M;.("G5>7QVYAH[(,#,69P29ILS.K=#804JR:@Y.YEAE"J,3I,^E;CY!5`1!5
M,Y2[0M/5OD>,:C(WF\8ZKQ,@WVSTS&-(RHU)1V[>9B[O#WZ3B(^)BJ7-JSC.
M*?2L8VL\-)2BKI9I'QL1,-GBSDJ/.F3(NCCCC1IN4+5BRL0,+EJ/2S%6I&<I
M5EGXILPK;V4A85_89VJE<(V)W(OG\+$QBQEY)DV=U_G^;0+(&661(<BD.T<2
M^-*Q1<@Y`+D`EGB<901YVU1U.E!L$^U*>7E:W'1)8QN[3%.=FK3"NHQJU7.B
M8[U$Y#"0"F,!%"DIQW159EDH:[XHX@Z0ZB8H\[DT\_'5@&^)($<G,\3-;)9%
M&5X<FM56>V:017))5D)ML6,$SDXE*FH4A%G-)XOJI<[:\I2\5E&E3C2^0N/P
M2NT<A&%5E;96K5:Z.Y7*PGI1Q$$N<72Y`&C-^1I*HJE0*Y:H`[;&4(MF_&4E
MY1?]^N>VZ(OHB_D%%DB&D7X`=0A!,#QSR`8X%V_]8/7U#P2P!K:XC-_E87,#
MY/\`P`U^%&'LW.>T^L6AO_2"<7?\=2_-WQ">M#XZ,45^PY#K#&H6-NGD>ZP\
M3C<D<HFX9U?'UP@ZK9YQ85&"UB>4NFV)TO5Y=Z1XH^EYI;IT?T%C&/T3X/E7
MJ]WOW<E]I6NP?VB#3KR]C?(/X^6")S_NMQV+<3]X8&?P^+`[.<#4YC>VF0[4
MT^"\TN;[_-.YAB!IZ[G`=I%AT1XO\Z_1NREYM=BQ7?+/H]\NQ9+OH\))RX"/
M>KM4E7;`'&\GSX,W!S);^Z7?W=NP-NS6<'#C7R]?E^%88.+AF/$XKL^,I+RB
M_P"_'/;=2I6.6Z_L:)69FWVFP/XR`@6G3)%X"LD[5*0RB;=!!JR9<^]?/GKM
M9-!N@BF=59=0A"E$3!KR7UY9Z=9R:CJ,K;?3H&YI9G81Q1\'RR'H:P8^>BO6
M]M<WD[;6R9VEX\TC;^^_BUGF>?5/G6A=^]86I7;A(5R#BB1KFNKT9H]HV39"
MP5C+=XD+Y(-6T:RH59CU'S)DVZ*Z*#=\^451=O@.U$B!DCG#A%W^H;09-U6&
MW-LV<VLV>HN+3>6H+K>%^8-#`16GJD/Q/25T:UY7ZH[2)]2U69EK+"PY6D@!
MX`)SXFI];-'@#]'%>C:LA)$4,7Q@_#=$0V=-<B(=?;]]'8/[FT=FOH,@-.3'
M,W`UXU'&JYD`X-#7.:YP'%O`_P#'2OGXRDO*+_OQSVW4(M4>)?*_$O1I#%#?
M`M*;9!9V"YM8K(SB1G!;C6JVLHD5:00!5\V`BJ2>^;?-SA`$``Q0VAMW_8NB
M[0U*._?NVYN+*6WMWN@%!_$D`]5N)'$^4>=:+O76-TV#[`;7M1.V>=K9CC2)
MA.+N#N'F/F4*\77%_>J=,-,4X=<VII;2*QK^YWAK"R,K'5E#:D]3KT.M))!%
M2$I(([HNE@2=HH-C"GNE7/M)LO+OE]9ZK93:MN&:W%KG>R*#.62RM/"6H:[Z
M'$T=C5:_OKF!J=A=1Z7I$%RV\:(W/F&41M(^DRKBWZ746*2\1<6\C8F#)I>T
MW3.0(V22=2L>9ZD#IT!2E,Y79*JI(MM\Q!$P)B!0$/@DZFL1N#EXVUG=)ICS
MV747F44'`"KXR*==75\BRNA;XDN81'J,;A(:5<)`*D\2<@D_P;\*VVBKBVG$
MR*Q-C4>[Q"J;B3]P*I2B`C\(@GV@(!R[-O4UH5QI]Y`#]YIZN`]4##ZS_P#'
MX%O]K/!/'VMJYQ97&KG.QZJEK/\`#X5=_&4B/+XP??O]+<`(_P`(*:Q^;,`<
M.%.`&'P+T-);6A/K&IQ)Q^%/&4EY1?\`?CGMNH&&"@FIJ>*Z$J_FE8N5192$
M@9^I%2161"2#@BG2S,ERM1(;GB\V/2!+L.(@!1Y=NI2M."\U<<L^.JA1R4$J
M[O\`+*,V5,CHF2F)BNVU&;<Q=(HJ+]6Y/YR:7DXF(;)N9M!1=F)'3VP,4CJ&
M415**A"2>*E2F0O%A%Y7A9>;ON1Y:M$F(1O84IYQ2"UR3A+#"XM"P(,&$4V:
M+L2P4NSFU$A:E1<)K@8H'524W5"*Q%)QL)V;(#N)DIJ"A;W<GEV@G+.QPEO<
M5J(8+3M5CJ:M&6ELK&5TLC!1$+)*(1X.D#++.#]((JHJ0"+[,Y#CLD9N7AYN
M5EFM:)%`T0?,VE03=20,JA8S-3^,05)T>7L]H1:H2A6Z)2MB*)"V,V`PFT17
M")O'%[$35/6FXK([Z"C+7)KY!:LH^ANH,*?'-^9)%U8[&15M<NFK$F0<-'"R
MR3M25(Y1.*I=PA2+>E&6D%T$ERR$@4JJ:9]P[Q<%4A53(KS2Q`6-S:R93@!B
M[1W1Y-$51I5\D0ZJLD_*DD0ZJI@=NC"5)(HJ*&`H*[3"!"B.P.4=$6I-8XT*
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M)$$X?O`;$9*14A)O8Q#QRQKI9*P!'K&;1S![,R[%%J*2CE17IA!$A-U3=(NX
MPXL(BPU*ZVVHL+++-:L2E,6#.3E#0KF4L]XNTKCUE!O3%-)EB4HNS1@%=.2B
M[)S!Q.0IQ)NF(N7_`!:0%9=*UV\Q]WA;Y'Q2,C*U6N;UV0.<7RS%V2O3D8];
M-YILS!,JYUE$F@%24W3%!=)=)(B^SGC#Q:R6KZ;V?NS1O;):2BZM).H&:0C;
M(C$*)M)&<@W"JQ#R<$TEE2,E%4B&63<F`3I%1'GM$6>X\SM!9.DI>*KBUX:.
MX2(@)MX6R1,E`;6-ECVLI%\RFZ=&<<\I'OD51*HFF`E4^`)Q(J"9%:>(//),
M`XQDLES,=.6EC&2L)&'B(^5(T=**33SH:2Y5WQE&Y2(&Y3`(;1#J:U'?&[&;
M*V]+KDD#[@-(;E;)V1%:FN;J%.'35;WRXV-=<QMT1[3LKN.SN;ACBV1["\84
M]6@QJ:\?(M`!];;3/T17T.K_`/>J!\&UQ9OZF](F:US=*N/HBO\`ZL<>GI7T
MFW]'>XWMR?W^SRQN+?\`0?Q&!Z53[6VF?HCOOUI@/!M3XEM*[JN/>QZ55X-]
MP]_6GL'^E/:VTS]$=]^M,!X-IXEM*[JN/>QZ4\&^X>_K3V#_`$I[6VF?HCOO
MUI@/!M/$MI7=5Q[V/2G@WW#W]:>P?Z4]K;3/T1WWZTP'@VGB6TKNJX]['I3P
M;[A[^M/8/]*J#UM].#:`8DOP`8-TVRU0'*4>J`_S;E#DT\2ND]U7'O8]*>#?
M</?UI[!_I5/M;:9^B.^_6F`\&T\2VE=U7'O8]*>#?</?UI[!_I3VMM,_1'??
MK3`>#:>);2NZKCWL>E/!ON'OZT]@_P!*Y]K;3/T1WWZU0'@VA_4MI(Q.E7-/
M_F@?DKCYNE0?T;[AI_\`]ZT]@_TK,J)ZU'$UELD?"6ZK7''L2_/S`VR3E&,S
M$QZYA*"7C1O&)D=MF)A'X;@I5`2ZIB[NT0]NA?J0VGJ6HBUU""]M8WNIG>7!
MC:\*XX5.'G6`W+^DK>VD:4^_TK4;:_GC9F[)D+VN>!QHXF@(%3Y@5Z6MI07S
M9N^92`NF3UNB[9NFSD5F[IHY2(LW<H*IG,15!PB<#D,`B!BB`Z^AXI8IX8[F
MV>Z2UE;F:XDGCYR0OE&2*6.62"ZJR\AD+',J<".)X_`NP#MV4P&*Y<`8H[2F
M!90!`?W!`VT.351-5223Q7'2W0=1RN'[RR@?X#:(G2W7=+CYY3LM$3I;KNEQ
M\\IV6B)TMUW2X^>4[+1$Z6Z[I<?/*=EHB=+=]U./GU>RZNB+GI;L1$1=.1$1
M$1$5U1$1$=HB(B;E$1'1%QTMUW2X^>4[+1$Z6Z[I<?/*=EHB=+==TN/GE.RT
M1.ENNZ7'SRG9:(@NG0\@N7`AUA64'_UM$07;L3"873D3"``)A75$=@!L`-HG
MV[`#1$Z6Z[I<?/*=EHB=+==TN/GE.RT1.ENNZ7'SRG9:(G2W7=+CYY3LM$3I
M;KNEQ\\IV6B+8R@F,>JQICF,<PB[VF,(F$=CQ<.41VCU`U*OK!E?SOR/XD@_
MNW6B*8]$6%9#_HY(?R"OX/1%7C+\W]2_$K3[D=$5MR3'OWR$.9@U4=F;.G!U
M")@`[`,DF!1':(#L$2[.30X>OF+,I#J@5^B0:4\M**B0T;7*'X_1)H">"\VH
MG@-B(A]#224E:%I&)E:S*`Y4CXX!=A6<E3^2DVZB9#`5()!S.@R5.4=\&S5,
M0^%M#7)[;E1H5A);2.N9B8I(YWT::GL[N:[`\IS39?\`PTZ`NTW?/7<DOWF&
M"VC:;F*1H:7O9E,EG#9%SBP'&-L.=K7#$N/65;4N`@X,9R)<6^SK1KS'=OQ=
M7$DZM76KVMU*VV9O;%$G$DCL<V1_$R:)B-UG0E`&Y@)NAL$QO,>4]F^W-F=0
M+(G6$]I#2,$,CGD$IS&E`0X?*O8>>%\9H)7:9$S_`.Z6][-&+J<MFFMXS$)*
MY?4=*W%S!P/0KC.\$$E/1#X)"]W(]XEK9(V>7O7FY6^==H2E`5Q@X@D:X1(L
M.S8(T]<4D#E$54UQYW:8?@ZR%QRQAOK<NEOY7ZBZ_,TSBVF=I@%F`W#]F)YX
M<`T^5>2RYUW^G78BMM.@&G-L^RALNU<86EMZR],[Y74.?M6$M!XDT"OU>X-2
MU:_L;K#S]M29Q+1P>&K*S&+52865?&\=BXUB-,`0DBZ`E<BTSE:&`$2NMX^]
ML$"A?TOEE::=JS-1AO9`!;2Y6T.+S;1V0'_5DC#NNAJO'J?.35M;T!^AW5K$
M^*0L+KAQ_B=A]^DO7PY.G/-(6-<<<HP5UNW"W,R?"O.\.M?,\(KZ/R5V!GY5
M(B8N;%%.V\_$2<T1OO`",E9&"1WH$`VU)538`]36Y:#I,6WM&BT:-P,41I6N
M!<>./2XGCTE<VW%KLNY-9N]>G@;9OFF+C&TYAEX"IZ&@4`Z```%J#(<"?%)-
M9=?7AI8Z91H"*R:SN&/$PCVUWE8"+M63+YE_(ZLHV<1\"2;>-K'=CLV+99V4
M#)")@6`$P47RP((J.&/R<?BZ5AF@N^CC0`_`14'S$8^99O6O5@,:`\A[9C/)
M>3*MDJ(-/QGG?(I(VVO3U#E*;0*-'XSLF+Y:4)17M1:0&+8)N]%JW9OI1NU4
M24<)@J`IS0BE>G@H:X/:)&&K"*U'`CA6O57I6<XHX!)C&-MPE-FR#/66NX)0
MLSFG5=6AU6"=1DM=(>RP]G@*Y:8E;QG5<*/?.8SQ"D(IK,6KUBR.1R)&J:>H
M!#A5N(4])'2.*O#'@*;M:CQ.5-6R6Y8O%79%LAWR72AH!H_ALIG<D.VNM932
M0,V0;,&4+`H)Q3@JS01A06,(K/79E#2'#,TU:4H>I8S-<!&2;E87=AR'G>Z7
M%2[5US4,QLEZ!`LVMQJ*F6&F66E/HG.3C\<2U=B\8DBRMVX2B@QYUC`J1RJ*
MP2F*^L;P,WV.R''W.6NC^\R$WFS$V4;O.NJK7Z2]=1F!XO(#BAC+,JZH="]9
M.L4Y;VC2<LKD&BKN)C$$N9("*91(M[O-B?\`)+O[0!_];W=$H58K/2KM*5RP
MQ=?4>UN>DX&8CX.Q%9IO#0$P^CG+6,FRLSJID=&BGJI%P3$Q0.*>S:&W2@+)
M&$E@?&6E[<7`'CAU>55MCJYK^D.K3KIT4Z5X2Y;]4;QAY!RQCRV0>;<65>GU
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M2-7ME7=2]>F4TD))ASSABHJ1!PB\;JM7[-=!Y'OF;MLFL@X1.15%9,IRF`0`
M=>34-.M-8L9M*U&&&XTVXC+)8I@712,/%LC1B6GI`5ZVN9[*X9=VLABNXW`L
M=3@X<*]7G6LDQZOK'TD]M)X":R91ZS>B0(Y"J""[:X2=\5KHEZ)TO(5L4DK7
M",W94B$6;H*"1(2BJWYE4YC#Q)WZ=>7,&Y--U?16W>E1::\R,MM/E,%D27!Q
MS1.&9YJ,,0*8+?XN9NY&V5S;W[FW<UPSL\SFAV3,TBK"1A@2"1P6W'FS8!Y1
MB7@?N;H#^]R[YA'DZXB.N]R.SR.D#0T.-</\3Y3TKG+8S&P1G$M%$\V+!Y*=
M_:!]G5"FA6+3>)65B(L2<H4;)](V\ZH[B&"ZP[0V"(+*)'4`VS;R[?=U[[35
M;^T<'6Q``Z7"I'QKPW>EV5ZTMNP]P(H0"0#YZ+1/B`X$K!8$V*N+*-'K*/7R
M+)ZV>&8QZ4"T<JIIJ3(BXE&!91NR(8RAT4B@ONEV$`YA`-=4VKS);9@OUJY>
MQD32ZC8WDR4'^D.S+7`/.!-:88@KE>[N7<EY0:';-?*\@#-(*1DG_5I(2TE@
MX`XXX+%IG"'&MP]/66/>$/'4*_QPI#P#^T76Q>92EGL5U>RX%LDN9&;GHL'"
M47`D!LR:F0;IH$`#&,Y.(F#UQZ]R^W9;/UC?T\\>KODE$5O`U[F10Y'".I<W
M!Q/'UG&O0.GQ3Z'OW:UPW3MB0Q'2Q"SM9Y.R;)+/CGP90Y&_LDX&IITJ\MH[
MUK@$7,ZJ>,52JI(.DDET*H=TV62D(/?C"*-9ANV6(_82KSG5#A_-31)N;.N+
ME(P6IHN21G[.W?>NA+G8EI;Q)XBGF\]?(O3')SH="99VVIF!P&85I0?.I=P%
M!<=[NZ<[Q!U^JL*2:H.#"TK[:M]-\\BF@#HD*I#R#ITC'EZ7()D$RJY%2-2B
M8J9C%.IKVYF\MH=*=%M5DW]P$P.9]37R]&%*="V/:AW_`":DY^Z#&+0PF@;P
M!QPKUK<CS8L'DEW]H'V=<X-2<>*Z$!@`M+<R8>XK[5DM>P8]@F=:C(F)AJM`
M3[#(*D5(3$4:PM[8]D96(!HDF@$=(L@9NF:ZBK=ZV5*H0%0*='4*5%\3ASCQ
MFF4$\!Y:JN1ZE8COTYK)Y7$ZP5DJX[AU%W;--D#5%.0GE&\E&H`592&!`Q2"
MCOB!R*:;O@7/E]P0\Q&E)6&KW**O-2=1&5'4XWG9=:LQ61D[426;.W*9GKR;
M@:DBBR-TLO.NG20B"F]L4T181%8!XN^EE;-WKG'\.R8[C6+K]^6?U-LLQI\H
MSID3680K%.0AJ[4K"+8LBDJH!YXFQ585!(?>(KWA'%_&!2K;$.LHH3UQJZM6
M)6I`BU^9SCA&3?V5A(,;*]BUS';D<U2'Z8V<G;J*K/4CI;5W!^1(BL<OPX\5
MC"6LDC59Z;9Q#VZ6J72JT)D!Q7D96L6F_9#L\XU:K&9';PMLE863AFS:1,._
M'G2."1DRE,8Y%V<)8`XJ<?6[&S6>!3T?P<2Z0M#=K=QDROSKT-K"H,Y&),T9
MI34DPM$:W<$DQ*==4@''G$B?>E2+>@*S8"CM"*=B(=3:F40'9UPVB`@/O:)1
M:^H\&.)6\HWF$L6O"R#->.49K&L]S5*T:PSGID+"M45+$*#:MPKL"JLXTA09
M-5"%,FD42AL)0J^1/"KCV$*H5CC94XKLWS%X>1E;!+GD49-O9VC]64/*2SLT
MB^=,KG*('=+;S@47AB[^PI-TE"OM'<+M"C"_>,;G<+F2YI=_*2<[+RC[;('E
M3K2DK*2CN0E7:K\W.&6<***CL`HFW0``)0JT_P#"#C,$5FQ,;R";5PC%MEVB
M=FN";55M$II(-VRK<M@YE1LY:MD4':8E$KUL@DDMOD23`I*%7(W"MCH[619*
M8M16;2R3I&03<.YE?I"#R88SR[;>6DU#HM0EHMNLFF02D2YDI"`4GP=$H5]H
M;A@HT!6)^FQ>.W"->M"#)O/-EI:?>/7X1LB[F(YR,R[E5YAM(1\N^4=MW**Z
M;A%R(*$.!BE$I*%6F)X0L70C\9*.Q:=)V9J9J=5:8LKPJH+()MWKQ9%W-+MU
MI:5*B0SQX8HNG:A`45.8^TVB4*^R7"7C9!RBZ0QFX14;/G+]NFG.6<&K<79"
M](CD&030-4H!9T0'9HXI`8B^_G/-<]\/1*%9I7\'Q56GGUG@:>\8S<A!Q=;6
M=FD)9ZDC!0Z;1)E&1S%\_<L8IMNL43*@V32%PHD4Z@F.`B)*%85Q#\-4;Q$8
MP?8MOCF]UJN2,U!S*\I19I&N6'I4$Y.[9M$Y-=C)IE9.%!^_)BD(G*`;!#9M
MU@MQ;;T_=6FG2=4:7VKG!U`*X@$?\RMJV9O'5-B[@AW!I#H6WC`6UE:7-`=B
M<&XUP%#T+S]'U,7#T(C_`/F7Q2`&WDVY6B?_`"4W7-XN0G+MC.S9#('CC@>E
M=J9^JWFO+'5LNF!N=U/X$@Z1C@6_\UQ[&'AZ_27Q1_K5BO[&ZN?D+R__`)4G
MQ*?%1S8_FZ9[&7[:>QAX>OTE\4?ZU8K^QNGY"\O_`.5)\2>*CFQ_-TSV,OVT
M]C#P]?I+XH_UJQ7]C=/R%Y?_`,J3XD\5'-C^;IGL9?MI[&'AZ_27Q1_K5BO[
M&Z?D+R__`)4GQ)XJ.;'\W3/8R_;51?4O</I@,8F2.*4Q4R[Z@AE6)^`3D#>'
M_P`'<O*.S4?D-R_'&*3XE'BHYL_S=,]C+]M4^QAX>OTE\4?ZU8K^QNI_(7E_
M_*D^)3XJ.;'\W3/8R_;3V,/#U^DOBC_6K%?V-T_(7E__`"I/B3Q4<V/YNF>Q
ME^VN?8P\/7Z2^*/]:T3_`&.U2[D1R^C]9T<@^`J!^JKFN79!-IF?C3L9:_\`
MO_\`)2EA[U6?#[AZZ,KP@[RWD9[')CT"#RK<V%KJK9X"J2R$J,&A`Q23F09'
M2^\BL=1(HF$1(80*(9#3N3FQ=+O8]0BC>^:)U0'`D$TIB#@>/2L!K_ZD^:FO
MZ?+I$UQ9-MYA1QBC>Q]`02`_@VM*>48=*]$0BWO4!L<H`````4A2@`<@`4`-
ML`H`'(`<@:ZE2,96PC+"UM`.'R+A&<R2OF;4->ZKJ\2_KQQ(XJLL1(J&`B;1
M50Y@-N@4"C_%`3#M^$`;-@=?4JI4A%O1#;S!P_<$"@(>X("`FY!`=$3Q4]^0
M/_B]EHB>*GOR!_\`%[+1$\5/?D#_`.+V6B)XJ>_('_Q>RT1<^*GXB`%;*&,(
M@!2AN[3"([``/A=41'1$&)?E$2G;*$.4PE,4=W:4Q1$!`?A=4!#1%QXJ>_('
M_P`7LM$3Q4]^0/\`XO9:(GBI[\@?_%[+1$\5/?D#_P"+V6B+GQ4^'J('$?<`
M`*/+]MHBY-$2!#;BC18A@*4WP@*&T#AM*(?"Y0,'+HBI\5/?D#_XO9:(GBI[
M\@?_`!>RT1/%3WY`_P#B]EHB>*GOR!_\7LM$3Q4]^0/_`(O9:(MA:&F=&KQR
M2A1(<@NMXIMFT-KM<>78(AR@.I5\<%@BOYWY'\20?W;K1%,>B+"LA_T<D/Y!
M7\'HBKQE^;^I?B5I]R.B*PY4Y4((HB8"F=N@$2[=[_J4@Y.4.7ETPH:BN!_P
MP^54DC.QAIZ\C68X`%S@*UZ*<5XT5WC=OTT[IL,K5:JE,3>9@J,R"?CL&[;'
M+V>C*S$3S,II`3%FW,RZ71$QS&;B=N8"DZNOGVPYN:S*^"`VMJ^5VKF!V>KG
M"W<[LHG-R5RN,_JG-@`"3@%]3WG(G;MM%<3OOIVLCT<3A[2&`W+1VDL<F;'(
MR&DF88$%M":A3>^XLX>8;5<]"@I9TXEKAC",D4+"W3;[*]D.?N$"0\;T.3,!
MIQ-S3UMPJA@1*"A!,([1`NYWG-*QNQ!)H\,\C!=VE1*!]&X?/%ZE.`+H2,KO
M6PK2E%S6UY17<4UU'KT]M;Q0VEZ6&(NKVUJR"0YP0:D,F:<[?5H:5K562H\7
MW3Z_#V:U5629C*4>M3X56O,ROI@TM:\K2>,H8C&3>3J$>X9/739(W-'*F=/>
M,<51#80/)I7,UU[;6]WJ]J\RR6I>8F&E,\QA:0_Z)S/\N`-3@LOJ'*#[MJ9T
M_1+T1M;JCXOO,DCFQF".P9=RU!MWY7,+CZN8EQ'JC&B[9N,6N(N7\^ZB9%"B
M$QU4+)'H*D;-K@:WV;(\_CQ6NOQ=3"5;9-6<A"COKJ.2()@!E#+;FS5Z/FC9
M,>;UD+AI0MK9T`(.8F:5]N&GI![6-["XT``SDY2"O`.2U\8H[66Z:[<IU.5C
MW--;/[I;VC+KM2P`2.E!ES4:W$D$-'!9E<<^.W6&*%E+%B+!93(MVHM2AR7)
ML],TCRVRT&J[Y>2:P[]-95:*=IG_`.H7.FIN;2F,4P#K)ZINW4(=KV>O[5`C
M&H:A%#DF87=F9I>SJVH]:GK4IT@+$:+L73F;WO\`;V\)KBNEZ=-<&2T<P2/;
M;PB=U`[U02TMJ'@8%P`S!0W9N+ZX5:I4Q_(0%34LWI5R#3,BI(.Y4L.WJ6,+
M&Q@++::TFNY*^27=#+M5$4W!E2IB)P'?W=NM3U/FEJMKIUG)-;VDEY+K$]M-
MVARM%M:S,ADG#`0[^(9`3AT&O!;_`*;R9TO6M;U&*"ZU&.R_LUG>6DM&F075
MY;R7$$,SF@QY&MB>QS<*9V]:N*/$WD66SK)8A@"XW5%;*5QQO$LWK.VDFXJ-
MK]2+86%]EGY)!*"EHU1Z<K=:/:F3>G*.^38`;=51<P=>N]WR[>L(M-[%VM36
M@/9S$,B9")8WM=2A=7#*TURNKPQ7EON5FW;+8,>\-0FU*2[.B6NH/<Q]NV-[
MKB?L70M86/+6,&)D.5@=0&IP5PQ?Q46)^>KQV2Z^60FK]/6F)K#;&<%(=%C6
M=,NCJCS4A,GL%A4<RJAWI4W?1HU-=PT8\XLJ3FR"?7MV[S&U(,MH=RVD,M[>
M32,CBMJM9&]DAC)#G4$P%`][6$Y14G@5X=W\H=)C?=MVK=%MCIUO#+-)>N:X
MN$L#9QD$+&F-SLW9QOD:&ODRL:22`MWQ,8HB&]MV<FT#F$!_=`=[8(:Z[5SC
M5[FO=TEHR@^8&A`7!!DI_#[01]':%KG_`/B+:M)ZZ>;BN.<-UQ^V-V6BE.<-
MUQ^V-V6B)SANN/VQNRT1?1(!562(8Q@*=0I#?"-R%,8`$>J/+L'5R,.EI:LP
MF?+'EIQ<T$F5IZ@&4./&M!BK<O:F-PCJ'^KD(_>KB/)@OS0<0W'_`,?&-J_/
M7RCS-=F913(=W3B\;*U%BFT9T?'URCJO8;(W:K1+B3?T^M6)H_KY422/C"SI
M)O9Q)9LWACIN-<Y1ZMJ._-S7>B;IM?N=E8W5VUSVD/<(QG^YG*VI+G@->YHJ
M8VD%].C.[WMK3;VEVMWMV0W-]++&&1N!9ZSF#[QFS`90!4-<:![O5:22OTIL
MUGJC)BK((I-9!5BR5D&K=919LU?JM4E'K5LL8=Y9NW=&.1,X\IB%`1ZNLXS%
M@)=F-!CU^7X>*PHRT]0%K.@$4('0".BG"B['.&ZX_;&[+5:E8;D*]Q6-Z9.W
M:=3D',=!(-CBQBDBN)23>/WS6*BXN.277;MQ>2<H^103,JJDB0RF\H<A`,8,
M3KNKZ9M[1[K<&M/='I%C`^>9S:U;'&*N-!B[#@T`DG``E>S3]/O]5OHM/TT5
MNII&L&%<7&@KU"M,3@%YQ9"XX,CL[G;8:`@351YCI3':;VF#7R9,A9H;O(-D
MUI*_9<KCPM4QK7FZ3@6A1YU-TS<I'<.!.@*93_-;?U)RZ_N?3+#E_:VMUM>\
MG+);A\\4;FAI94ADKFO(ROXM:?6&7B#3KT7*8Z=I<]]N.>6*80.?&T1R8N`=
M3Z+2*YF_M%M&>M6E*^J1Q$AS%`PB`"(?QS"`<O4`VT-X/W?=U]5O?"]Y,$@D
MBK@0:CS?`N(Q$NC!<:OZ?.J.<-UQ^V-V6H5Q.<-UQ^V-V6B)SANN/VQNRT1.
M<-UQ^V-V6B)SANN/VQNRT1.<-UQ^V-V6B)SANN/VQNRT1.<-UQ^V-V6B*+LQ
M9.)B*C.;X\C?&<3&2\(QF@%Z9F,?'33XL664*?FU@5%O).6Q!3'=`2*B.\&[
MRD6N=2XX*W)UMW8K90[;!IQC9H29)`BSL"$+/!`*J2==?*N7D0X5D2WJ%FH%
MJ*"*J1G$7ON3MBJE#1%=U^,>"BK`M#V&B6V*8PUFN=<N,VF>-?,ZNZKKIRA$
M,5BMI$R[^7DD$B.'@($.R9HG'=<*F+NB14/^-2D[.=@*W:9IJ8:F\66.U2CP
MAJS,6]E3[%:9OI#T=C"N2DBF@5%H#MTNZ`Q!3*F4RH$6P6)\J5_,=(C[]56\
MTSAI)W(LT&\^S"/DR*1KD6ZBAT$7+I`[=R3<61434.4Z:@=0P"4"*1^<-UQ^
MV-V6B*DYW`IJ`W*51R*:G1TU%#IIJN-PW,)**!OBFFHKL*8P`(E`=NP=$6G$
M1QG58QFA[+59^,9/(Q$@/(E9G+]"M\5CYQ>KW57C-9Y'21U:P=((])9!!8BK
ML#%6Z.&[O$62DXLJ6U%V,W7;M'),)4(J5<$CHY=*NOI'QT>L0D^!)HRP3L^E
M6WXE!D1VS1,@`*+EYQ/>(I&H^;JQD"WSM,A8RSM7L"Q>/U9&79LF$8_+'3*D
M&_2BBFE#RKXC1\3=,X*V!H)@.F"O.IG3`BE[G#=<?MC=EHB<X;KC]L;LM$3G
M#=<?MC=EHB<X;KC]L;LM$3G#=<?MC=EHB<X;KC]L;LM$4)<0^;6G#]BZ3R:^
MK[RTHQLK"19H=E))1:ZIII[T0BQ7CEN[2*5`>42[@B;]S6H;WW9;[*T!^NW,
M#KB)C@W*UV4U()K7II3AY5OW+/8EUS'W9#M:SN1:W$K'.#RUSAZM/5HUS2*U
MXDTP7GO[6JN?H0L@?N!=XK_RP.N#-_5!I1B:3HDA=Y96?!Q:_P#Y?"OI?P9Z
MM(]SQK[3&'%N-K(_%OTJ9IVTXCA@?@3VM5<_0A9/KO$_D'3Q/Z3W&[VT7])3
MX,-5[^C]Q/\`W*>UJKGZ$+)]=XG\@Z>)_2>XW>VB_I)X,-5[^C]Q/_<I[6JN
M?H0LGUWB?R#IXG])[C=[:+^DG@PU7OZ/W$_]RGM:JY^A"R?7>)_(.GB?TGN-
MWMHOZ2>##5>_H_<3_P!RN!];36QZN#[(/[]WB?R#U]/$_I7<;_;1?T4\&&J]
M_1^XG_N5S[6JN?H0LGUWB?R#IXG])[C=[:+^DG@PU7OZ/W$_]RGM:JY^A"R?
M7>)_(.GB?TGN-WM8OZ*>##5>_H_<3_W*W&X9N+^@\3#>38PK*1JEU@TC/I6F
MRRZ;Y?Q.*Q$$9J,E&B*+5^R%50I%2[J:J"@[!*)1`P]:Y<<R]`YA"672XGVF
MJPCUX9'9F4ZQ(/4K3@!0UPH%PSFSR:W+RJDM7ZK.V]T.[J(IV-R/S-XAT1)>
MT#A4U!'`GBMK^</\8==.7'$YP_QAT1<\X?XP\NB+@#G#D`P@&B)SA_C#HB<X
M?XPZ(G.'^,.B)SA_C#HB;YQY!,.B)SA_C#HB<X?XPZ(G.'^,.B)SA_C#HB<X
M?XPZ(@G,/()A'1$`Y@#8`C^_[NB)SA_C#HB<X?XPZ(G.'^,.B)SA_C#HB<X?
MXPZ(MD,?B(U2,$>41%W_`-#M</\``&I5\<%@ZOYWY'\20?W;K1%,>B+"LA_T
M<D/Y!7\'HBKQE^;^I?B5I]R.B*V9)9+O$8<4#-0%NY<G,#ETW:E-M22V`07"
MB8'$!#E`.4-07,;3M*]GF%:<:5!44<YS8V-:YSW!M#TYL,/\V/J^5:"17!-C
M>*<13QJXD>F1$C79-!ZI;*_SRZM:R!.9(CD'(]&*0[8\]/JIJ@4"F.V33(`@
M)=\>;VW*O;EO,)8>V;==H'N<,&G+<27#0`<:ATA^1=3O.=>Z]0@EAO6V?W:Z
MMY82"U]1$ZWBLI*97-Q[.%M#4C.7'I559X*J35U6QVE@L3[H5CIMC8)R5PK"
MQ&1J%/6:P5R)0!%BB;Q6B\M;HJQ3"954@$^^`("(UV7+'0M/$G82SN<;F"5N
M(HUUO-++$T^;MGU\X5S5><VYM8=VMW;:>UCK>XA<[+(`[[S%%#(:=KQ+8(R/
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MI6"AJ/X<3`TU%*'$+/)GAIBIK&%;Q:K99MG'U28@+#%69G;JZ:VEG:W+GGF$
MFN_>MGC%18TJH*AB]&!("["%*4H`&LM=[+TR^T"SV[+/=,L[&2"6-S"`X2P3
M=L'8]!(`^-:W8;_U73=UWVZX;:RENK^VD@E9*PNC=',SLI6EK2QV,>`S2.]8
M`J/7G`QBV3C`C;`+RR?^&+I7BOY^T5R2D2RN0)\;+9KVFY.U*#>\NI,`%-XF
M4B2*9"D(D`!RX1_*O;-S#'#=1FZD9!=15E:'DBZD=*Y[14`2ASC1_0`%LL7.
MG>EO=";3#!9M^^V\_9VL3H^T;:Q"&&VD=VCZP9!Z[2`"<:]>90O"U6H60@I5
MM,R;F0KV4G&8&SE]:*ZL9S:WE23ICE-\!6R8*Q3B*3WC)EW%>?$3`H`#NAF+
M#8^B:=<VETV2[%S::@+PASLP[7[O]V+6BGJAS`TTJ02,5BK[F?N2YMY;.[@M
M8+6ZTF/39(1'D9V#9C<%L9Q#I'RFH<X$-:*%M2",:<<&5-<-J>Q&QV9)A3+1
M*6YK'I7.O@VD925N9KX8[P#-1.R59SAQ(FX8BU>"R,9L=4Z9S`.(_+70F16%
MJV>;L+"0R!CGAKWN-QVXS.(<6AKL08PTO^B]Q8O9'SAW$PWG:PV!O+NV9;O<
MYKW=DV.V%L&Y10/)`#AVCGACZ/8`X46S@U^1,.\*L3M':8=DU%`'*(CR!TKD
M#EUTE[Q(2\/,CR22:$`DFO$D@_`2%REF4L)+&1%M!D:<U*#HP!QXX@&I3S;D
MOE8GZ;B_"M4J4\VY+Y6)^FXOPK1$\VY+Y6)^FXOPK1%9+-2)^<K=BA(V?:UJ
M1F8&8B8^QQ\M#K/Z^^DHYRR:3C%)5V5)1Y$N%RKI%,(`)TPY0ZNJ7`.:YKB8
MW%IR/;](./1\2J#^S+7U`RNK4\%XDY5]3;G/)&5L?7MAQ64*JP%,LD1*/X..
MHZBA9>O053>U&%J)8EW?7<5YO5RNRTG"I-UUECR$;/R"[M87I^</C>7FER\N
M]5UK4[M\FJP:K;VK(8KHY?[?+#(733P.CQ>ZY:<KNTP`PX`+W;NU`;HLM-M+
M=K89;*=\DCQ]*9KFY0P^2,^NRN.;C@O93%F*['CW&M#H<O:VESDZ=5HFN.[2
M]DXUJYFC1;8K9)R=NI*/UTB)($*BGSKAPN*2915544$QQRKBQSBZ-H8PFH:.
M#1T`>0#`+&L:6,#"YSB`!5WTC3I-,*GB:=*SWS;DOE8GZ;B_"M0JETY"D)33
M!W$3T=5YZ%D4#M).&F'\,_BY-FJ&Q9F^9K.12<-U2\@E']\.4`U2^.*:,PS-
M:Z)Q;4.:UX-"#0M=ZK@:4(."IK(UPEB+FS,J6D.<RCZ'*:MQ(!Q(4&2_!5@.
M:>.W7F6C58R0&-4FJ)0+JQJ>.[<ZAP`(]Y<J^R<<[,.=B::;D06(#U!%--<%
M"EV:YUJ/*/EQJ6M6.X;C2;7^\Z>"(9F-[&@+LYK%'2,G-CB"?+1;7;;UW+;6
MEQ91W,G87#:.!<7U%`!B[$?M?1H""*XK8`:Y(C_VL3_!,Q10_@*5UNE#K`&N
ME22/E?F>0>@4:UM`.`HW#`=/$]*U;H&`#J8TZ3TGX5QYMR/RL3]-1?A6J$7`
MUV0Y?OL5L#J_Z:B_\'2M5-:7$-Z2IR/'T\K3Y2%SYNR`]1:)Y>I_IJ+\*T<Q
M[30@Y>M49A@TD=KTCC3SD88IYMR7RL3]-Q?A6J54GFW)?*Q/TW%^%:(GFW)?
M*Q/TW%^%:(GFW)?*Q/TW%^%:(GFW)?*Q/TW%^%:(K5.8^;6>)>P%DC:Q/0<D
M1%.0B):0A7T<](W<H/4"NFB[@Z*Q47C9-4N\`[JB93!R@&B+#G7#WCIZZ:O7
M>/<;N'3)2R+-5E"U[:BM<'KV2M2VX58J2BT_(R3EPY.<IC'6<*GV@90XB1<N
M^'W'DA,O[$^H&.7DY*,Y)A)2CGS?5=OV<RZ5?2R#PQUQ(X"2=KG.N8P"=03"
M`CLY-$7S=<.^-GRL2L\QWC5PK`O$'\,=1.N_Z->-7KF2;KMBE6*4!1D7:C@I
M3`8@+GYS9O@`@19;6\:Q]/B&\!58JL5Z$:*.%6T7%2<2V9I*NUSN72I4RNA$
M5'"Z@F,81$1$>L``!%?/-N2^5B?IN+\*T1<^;DE\K$A^[X[B^3_^Z#1%%3OA
MGQ4_=HOW>/*$L\0?6:5(L#V-3WY*Z.5GEJ?.$D9%)!TYG'3A518RI3[#*J;@
M%WS;2+[R?#CC.:>JR,K0J,]?+-95FLX4D6!>?1FDW:4B*Z*,DDW6=*IOUP3<
M'(9=MSZ@H'3$YMXB[M4P%1*+(%EJ?4JG`29(<T"F\93+454XI1TD^7:D!S*K
MID,]>()J.5@*#AT=),5CJ<V3812!YMR7RL3]-Q?A6B)YMR7RL3]-Q?A6B)YM
MR7RL3]-Q?A6B)YMR7RL3]-Q?A6B)YMR7RL3]-Q?A6B)YMR7RL3]-Q?A6B*%.
M(+AMK'$-C5YC'(LG.QU8D)F%F%W%"O3:LV'ID&X4=LDB2S$7:Y&1U!'GD]S=
M4```1#6#W%M_2MS:4_2=78Y]H\@T;QS#@?-0E;/M#=NL;)UENO:$YK=28QS6
MEW`9B*_X+0P?4W\*_P#6[B)_7^_#_#&ZYT>2?+ZN%O+ER@<.I=@/ZF^:SR0)
MX!&,0/*>)^&@7'L;N%?^MW$1^O\`??DW3\E.7WX>7XE'B7YJ_B(?C3V-W"O_
M`%NXB/U_OOR;I^2G+[\/+\2>)?FK^(A^-/8W<*_];N(C]?[[\FZ?DIR^_#R_
M$GB7YJ_B(?C3V-W"O_6[B(_7^_\`R;JIO)+E\XT^[R_$A_4QS4`J;F`!?0GJ
M:N%@^_LM_$/\`N^;;Q`/@'=V@`[N]'AO&Y>H'+LU5^2/+PX,B>7=/1_BH=^I
MGFLW$W$-/)4JGV-G"Q_6_B(_7](?DW3\C^7_`/(?\BH\3?-3\1%\13V-G"Q_
M6_B(_7](?DW3\C^7_P#(?\B>)OFI^(B^(K=G`'#!C3AIIIJ7C)F[Z.X=+.Y6
MQ6NQDLURGU3K*JH!-V5V";M\WCR*BDW2W2)(IAR%WA$P[MMW9VW=IVTUIH5K
M''%*6FI^G4<22.LKF6]N8F\.8-ZR\W)=ND[$4C8WZ+1TX'K4Z^+EOE6G?;?M
MFMG6E)XN6^5:=]M^V:(JTXMRH<"%49;1V[!,^:D+R%$VS>.J4H".SDVCRCHB
MI\7+_*--O)M#I;?D'9MV?]8.B+CQ<M\JT[[;]LT1/%RWRK3OMOVS1$\7+?*M
M.^V_;-$3Q<M\JT[[;]LT15%C5S&`H*L]IA`H;7C8`VB.P-HBH``'[HZ(AHQ<
MAC%%5GM*82CL>MC!M`=@[!!00$-H=4.31%3XN6^5:=]M^V:(GBY;Y5IWVW[9
MHB>+EOE6G?;?MFB)XN6^5:=]M^V:(GBY?EV*-!$`V[.F-@_PJ:(JC1C@@[IE
M&>W=*;8#YJ;8!P`Q=HE5$`'8/*'5#1%3XN6^5:=]M^V:(GBY;Y5IWVW[9HB>
M+EOE6G?;?MFB)XN6^5:=]M^V:(GBY;Y5IWVW[9HBV'H:9DJM&IG$HF+TK:)#
ME4+RNUQ#8<@B4>0=2KXX+!%?SOR/XD@_NW6B*8]$6%9#_HY(?R"OX/1%7C+\
MW]2_$K3[D=$5@RH7?1@2[-[>=NPV>[RHI!R<@\NP="Y[0>R-)2"!A7$\.*M7
M`_\`32O'%D;G>49<<S:?M#BWHKQ7D!#<4]\A82IVNSHM+#%GQEGZY3T-',F,
M0YEG^/<KQM/K*3%^9-=..(C$/!*KL(8JI_AF#>#7"6<R-8M6Q:A>5N8H[6^G
MDAC^GFM+AD`9'_U-?F.;&HPP7TY=\IMM7NHW^DVSC:2-U+1K2&9[2^(,U&P?
M=2/.7'"5F-,*G%2]:<_V[T"6O)57J4?#7&KY(3QY(P$S)MY>.;/&%^AZG,+H
M2*+5LF_270D`%(033$AE-[8()_"V;5M[W=SM*[W!IT#8;JWU#L7125P#961N
M+B#]*CJMIAP6@:-RXT8<P[39^NW7:Z;<:2VYCE:US,SI(9)6Y6NXM!9E)Q/P
MK,<>9\1O^3I6@#3G,(S2"\GKL\:::R`31<;VYC2[41Y&),FZL.8LP_*9J(JK
M\^@`F-S8["ZR^W]Z1ZUN5VC202-T\R3QQS_O&"9L)S#HQ)K3JP6)W-R[_P!K
M[1BW+)=M?()8F2Q4RAIN+9US%V<AS9F@90XEN&(Q(4$4?B$R&DWOEGLR5EM:
M3;*LWBRF5@*9`U&C/)5YDX*/5DVV3"&>R#IZS0,!I`BC0P$*!C!O&``UI^@[
MYUR87&I:JZ:Y<W4YK6)I:UMHUK;@0QUF:`ZM"/5(.(I5=`W#RTVPQ]GI&B10
MVI?H<-]=2MN)GW3'BS^]7#G0%V1T3\.Q+*9JG#H6;PW%W#S#ZHL`HDFT7LZE
M%:..>FF2A(F0N%YNM#=MS&39_P`]1A9.DK*@H4"=)16)L*F(#K(6G-:PNG6W
M_II@UYA9+UB26::'^'UM!A<:FN!&*P]]R3NK2.ZGBU*">*%UPZ,-BD:YT,%M
M;7%7$^J'D7(J,!ZA``*HLN>[G/<,2F9ZO7QQU+3<U3V=6++*Q-M4-"S]S@JX
MK.F:)$3:%%=)\X!%!8H*%W"G,`;VP%]OG4[KES)NZP8ZTF>^W:QW1EFG;`3C
MTM+FGJP-5:T?E]MZSYHQ[-U&Z&K:2R&Y=<F)DUMD?!#+,(#F.8N<&-!+</6-
M.A0UE+B=R?C?'M@8+6JKN+]4\_7C'Y+/)P4=$-+/3<>U<MQ?BK"&7-',[!*-
MW*$<441V"X4*)`WQV:U;</,C7]$V_<6+YV2:GIVM7$#GD8S,M(6RN?AT5>QI
MIA0GI6];5Y3[,W)N.WO;:TGM]L7VW+:YBA,CGFUO+VX-O$P&4EV!:7^MC0%7
M1WQ$9-E<X#6:Y9BM*;+98H%(AT'F/F;BKMZQ>,:-+8J_6OXJIJDN:#YUOQ\<
MH!BNR_!,&[M'7JN.8.Z';LFM],O&.LIM1LK=A$,;V]E=0-E+\S@3VC2:`5RT
MI@K,?+#:4'+L7.IVD[-7.AWE[,X7$L;_`+S8WQM2P,:<O924+G.IGX$&B[M=
MXB<FTA:3->E1RBT=9EO&)(URFRJ^-XB!-27T8BU>/YCF5V:EDMZ,J)6;)THT
M9F.V,4K@IS%*/JBW_KVE73VZV^2]@&JW5H`YK(XZ0&/(6&,"LCLYI%09Z>J]
MJQNM\N-KZ\(W:((]%OO[)9WI+FSW4]PZ=LA>X-!P@'9C^*<SFUJYCEZ%"!?B
M[.H.P0`!#:&W8(<O*&NV`U%>"^<2*&G&A7&P.L'O!J438'6#W@T1?5$A#+)%
M,4!(90A3!LV_!$P`;DY.3='536CB_P!9KWL8!T`N=0O\X;4CHJ,5;E)$9);F
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MI-@=8/>#1$V!U@]X-$38'6#W@T1-T.L'O!HI:`7`.-&UQ/4M1>*G+^6<8LJO
M&8ABZR]LUTGJO5F\G<&AE*E2T[+,/VDGD"YO"2#`6U8J$5&'6.3>(19PJF11
M0I1`#>*]EN8VL;:AM7NI4UH/*NS<G=@;,W=>3W&\7O9H5G:WD[F1FMQ>OMPT
MV]I:!U09KJI<W,#_``V.R^M18;%<7<=$XDQK<#R,!=T+N^R^9#(ULL##'%.D
M:UAV4D&TQ9$W,7`3Q'$S9F+/I$+",&:JSQ,#[IQ*B8YKMK<"YB)8YS@PT=7A
M7R>1:IS/VW)L_>]SHLMDZPG,%J^2`G,(7R6L-P8"3CVL7;99*]7"M5?)CC(@
M8VLY.FD:NQ/*T%@U?P]>D+>TCGEP2=99MF+#+M">*7,DU9LE*N$@Y42:NS(I
M.03$N\3>/Z%H:ZDIQI5N*N-@H;NO1\;+PM!H=B;6:;L$K'XVD[Q;Y6L,I7')
M+<C3WAV[RIQUWAWSEV+4X@W>B99NW(D<^B+9+$61$,KT&+NZ426'Z;(V2(7:
M(2C:>BU'=7L<K6G<C7["T0:M;'6)1Q$G7CWZ:21'34Y#[I1'9HBDG8'6#W@T
M1-@=8/>#1$V!U@]X-$59$P.<A``-IS`4.H'*8=@<NSKCHBU2-Q7TPG1MZ"ER
M@[9+V1NX$[`[)2FM<DL<>N9$QD72DBUF4D9-"3!JLU325;G%,BQE"&`"+:Y5
M+FE%$C`7>3.8AMG4WB")1V#LY0VAHB^>P.L'O!HB;`ZP>\&B*DZ1U2*)(*$0
M7534307.F"A$%U"&(BL=,1*"A$E!`PEVAO`&S:&B+SO9<9MMAW3)"S5:O2IE
MT9JLNXML^<U^7;WK&=(D7N27+!%5@^:NX-WD-D>*2**P*M"I;Q2+;QC`190]
MXO)JNN9)I8:3!*+1+]VWE&B-M,WD`YPEG727K#9>OH>/JG54:HL$S)K@V,U!
MVW,*>P1VD4IXDXAV^5;]-5)M#P3&,:P,G.P4FPM!)V0G&D1820;J0%DRCP8L
M(IR#E)1`5G)%U`,!TR*HJ`H0BV7V!U@]X-$38'6#W@T1-@=8/>#1$V!U@]X-
M$38'6#W@T1-@=8/>#1%K5Q;9FL.`L)362JJS@7LU'SE:BD&]C275BSHS4AT1
MR*B;5VQ6,L5,-I-B@!MZH"&N?\S-U:ELW:TFMZ4&.O&2-:`\$M((<2,,>A=3
MY-;)T?F%OJ#;&NR21:=+%(XNCIF!8`12K7#XPO*'VK.=/ZKX>_?%A.<O^\^O
MF4?J4WS0`VUMGH"?5EIC\*^Q1^D;EP`U\=_>&-\;78EG$EP(_P!+R)[5G.G]
M5\/=XSG]I]3XD]\_AK;ZLOI57A'Y=_C[OXV?TD]JSG3^J^'N\9S^T^GB3WS^
M&MOJR^E/"/R[_'W?QL_I)[5G.G]5\/=XSG]I]/$GOG\-;?5E]*>$?EW^/N_C
M9_27`^M9SK_5?#W\#&<_M/JE_P"I+?!`!AM(Q48N;+3S8'B>A0?TC\NJ$F^N
MS05H`UQ/D:.S'K'HQXKT*X)>+.R<3D;=6]NJC")F:>Y8K!.UA!V%4?LI3?*W
MC%#O';X[6PM#HF.9,%3%5;B!P`NZ.WO/*+F?J/,>RN7:C;"&:V(]9H<&/J2,
M"[&N%?,OFCGSR<T3E5=V<NA7;Y;6\S#L)VY;F(M:'9GAH#.S=6C2!6HQ6]>N
MQ+Y]31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1;)
MX^_HG&?ON_\`OCC4J\."P=7\[\C^)(/[MUHI4QZ(L*R'_1R0_D%?P>B*O&7Y
MOZE^)6GW(Z(K?D=F#M")VO6+$47#DY3OECHE,(I)AL3W4E=\0V<NWJ:D'*X.
M'%I!'G'!1ZM07<`0?BZ^L>0X'I6@UAX+\5O8&_,*U+Q]=EKQ`3=>2D'=BL$]
M%U=A9K`ULUB;UJOOEP90K:;F&H+N$VPI;Z@[0$`#9KGE[RSV_)87=OH\;[?4
M;IKV]IVDCBULTPFGRASB&YW"M12G`4"ZAI_-_==O?6<VH7';6%G(R3(V.-A>
M^&)T5N7N:T.D[-KB&AY(ZPI'1X=,:)X[E,6`O'>9TQ++STDW4M4^I+/)QU-(
M6%:85GU3GF!D!F&R:Q5.>$2[A2]0-9T;2T+^P';#X7.TDO:]U7OS2R`M>9'2
M9LY.<"OK4PHM<GW]NB;<C=W/N0=<;%V3"8XRV&'*YC8FQEN0-#'']FM37CBN
MW5.'W&]*M\S>J\M%-;).%DRNG3BSSL@T;!.22,U/^*(M\*S"'&>F6R;IYS":
M?/KD`P^[JK2]J:)HVK2:YI\3V:A*YY<3)(YE7N#WEL;G&-N9P!.5HQ\Y5C5M
M[[CUK2X-&U":)UE;@!F6&)C\&&-N:1C`]Y:QQ:TN<2!2G`*AQP\8S<4Z3H1E
M8E&MRUJ>WA=%K9IYM(MK<_L`6E6?BYA$Y9*+?HSW\X1%%0A41^"4`+R:H.T=
M`.CR:'V+AI\MPZ=U))!)VCW]HXME#NT:,^(:'!H&`%%$>]]SQ:S!KPN`=2M[
M..U:71L<QT,49B8V6,M+)B&$@ND:YSL"22`L:;<)6%6<E4Y1NUBDG=):0S.`
M.G;[,"90@)N2L<4ZE&W2`0FI%M-3#MP+AT"JACN5-NW>Y/$W8&U&SV]RVW<)
M;9C6Q_Q9:`-+BW,,U'$%SCF<":DXK*S<TM]SV=U82WY-K>N>Z4=G&"3(QD;\
MK@S,P.9&P480/5%%E#SA[QH^QBUPZNI$!CYBUCF;2'0LLXV=-T8B22F([FIE
M`Z<N19K)($5*H"V_M+U=FO=-M+0;C;4>T)8G';\30UL7:/%`UXD;ZX=G)#P"
M"756-&_-U_[I?O1UV7;BDD+W2.8QS2YS`P_PRWLZ%H`(RTXX8E66,X6<-1)(
MTC=E`NO%;6[M45)>R3\XNY/D8C=.YR,HO+JO5I::F4FB9!>N#*.4B%`$SD#7
MEBV)M6)H:+4.`%P/7>]]?O88V<DN<:N>(V#,<6T]6E2O?=<SM[7<LDTEYD?+
M+;R.[...,9K7/V`:&-:&M89''(T!I)JX$@*J&X7L0P#-BQBB1:#>.M5-NK/?
MMEB<*I62@0B%<JC\5W"RBJA(R%;$0%$PBDL`;5"F,.W5VUV7MJRC$=M;!K6W
M$4X]9Y(EA8(XW5)K1K&@9?HGB02K=]S(WGJ3GOO+S.7V<MJX=G&`8)Y>VE90
M-`J^3ULWTAP!HNG.\)^%[(@JVEF\6L@YM-DN+Y)&WV9FG(2]O<Q[VRI2!6CA
M('D-+NXEL=1B?:V`R)=TI>7;:N]C;9OA2YA>:SRRFDLHJ^?+VM:.'JORBK/H
MX8!7K#FAOG3']I8WICD^[10!PCC+FQP9NQ#"6$L<S,ZCFD.QQ*G0(!N```3M
M?```"@`/5@`"E#8```-N0``-;:`&@-'`"GQ+022YQ<XU<34GK)XE/$"'EZ`[
M]6\&U*A/$"'EZ`[]6\&T16.ST-C::U8ZNZM3".:V6`F:^Z?Q$LNSE6+::CG,
M8N\BW8-#]%D6R+H3HJ;IMQ0I1V#LV:I$;R[.SI_Y!P_P<?\`@*N-[F/:]OTF
MNJ//_P`UY%Y)]2I2\FY3HN4);BKR6P6H=IC[<T90<52&"C]U'PS2(CF*C]K`
M(LVD3!-(Y-G$M4F`-(^$7=QW-+).14)C=A:+;\O[_5;C;YD?-K,44/9O)>RW
M=;@/,C7/).:9OJO)^E7BO;N2YN-V:?86FIY8K;39'R->P#/*7UKF`XM:#1K3
MZK2,P`.*]5<7XEB\78ZI..(RXM)J-I%<CJXPEIR1!26?-(Y($D%'G1(]LT1Y
MM/81-)$A$D$2$2(4"$#69GG==SONGM:Q\KW/+6\&EQ+B!3"@)H/(L:QK6,#6
M%Q8``">)`X5KC7K\JSOQ`AY>@._5O!M6E4GB!#R]`=^K>#:(GB!#R]`=^K>#
M:(GB!#R]`=^K>#:(GB!#R]`=^K>#:(HRRM@.@9GJDG3+X]BWT),1DC"2/BVP
M/X=^XA)E)-O-0XOFC;G>@2S=(I%B"`_Q2G()%"$.6S/;Q74!MIA6%PH<2#\8
MH1\"VG:&\]<V-K<.X="E;'>V\[)F9F,E:U\9JQS8Y&N8".&#?HDM/JDA7N"P
M_C^N5"NX^@XW'S.D5-E'QE;JO1$'<-$-8HG-QQ6C)ZP<I%7;!M,"P@*N^83B
M83"(C<9&V&)L,(:U@X#_`(XGJJL?KVMZMN/7;S<FN3ONM7U"8S2ND<27/))+
M^IIQI@`,H#?H@`7![2::JYWI+T<KO2MW#0#R+2*5=]%=JF5=M2J.XT5Q;NE5
M#'52V[BAS"8P"([=>EEO(2&]E=YG\'=B]S,/*P8#RGX%@))[>,9I)(HJ=#IH
M7EWD:T.:YI'3FK7H7:/0:TX9>+72-%4COA_Z,=Q[)1@)544D#CT!6,.U$%6Z
M)$Q^!\),A2CR``!Y\U7%M6$M-/5#A\!#L:]?0O0YA:UKLKPUS:C,`*CK%"01
MY:JZHUMDW12;-IBM-FS=,B+=LV<&;MVZ*90(FB@@BT(DBBF0H`4A0`I0#8`:
ME4JOQ`AY>@._5O!M$3Q`AY>@._5O!M$3Q`AY>@._5O!M$7(02)1`Q9^``Q1V
M@(/5MH"'*`A_-AY0'1%#9>&3$!7!WQ8VG%D57Z3I23*Y4+('8HV@+D2NBZZ&
M!_-P)XH&Z+LY42E2$W-E*4"*9!@43")C3T`)A':(].6Y1'JC_DVB+CQ`AY>@
M._5O!M$3Q`AY>@._5O!M$3Q`AY>@._5O!M$76/4HI11-51_455417%%53FE%
M4C.A*9T9)0[`3I&="0!5$HASFP-[;L#1%2I48A90%EGU166!!TV!5;FU52MG
MP%*^;%448F.#=Z4@`LF`[BH``'`=@:(C>H1#13G6CZI-%>CHM.=:"1LIT1L)
MS-FF^BQ(;HC<RAA32V[A!,(E`-HZ(NWX@0\O0'?JW@VB)X@0\O0'?JW@VB)X
M@0\O0'?JW@VB)X@0\O0'?JW@VB)X@0\O0'?JW@VB)X@0\O0'?JW@VB*-\JX,
MQ;F2I'I.6:[0\ET]:282JM8L:1Y6+/)1@JJ1T@=HHDF7GV1U3"F?;M*)M>'4
M--L=5MC::A&V6V)KE=PJ.E9;1-?UK;6H-U7;]U-9ZBUI:)(G%KLKA0BHX@]7
MFZEK1[-K@._98P%]54^SUA_]F[6K7[C!6@'T1P'!;8WFSS.:`!KVJ4#0!_'?
MP%:=/E*>S:X#_P!EC`7U53[/4_[.VM^!@^J%5^;G,_O[4_;O]*>S:X#_`-EC
M`7U53[/3_9VUOP,'U0GYN<S^_M3]N_TI[-K@/_98P%]54^ST_P!G;6_`P?5"
M?FYS/[^U/V[_`$I[-K@.]WA8P%]54^ST_P!G;6K4V%L?.P$?$52[FUS-<*/U
MW4G#RS./_!6PF*L$XGP?6G50P[3:+C*JN)-S/NH"J-`BHYU,NTFS5S('0*0X
MK/ET&R1!$1_B)@`=365T[2].TB`VVFPQPPEV8AHIC_QT+5M<W%KVYKP:AN&\
MN+R\#0T.E>7D`=`KP4D>+@[N8_.G[7K(+#)XN#NYC\Z?M>B)XN#NYC\Z?M>B
M)XN#NYC\Z?M>B)XN#NYC\Z?M>B*HD84Y@*,C')AL,(G47,4H;H;=@CS0_P`;
MJ!R=71%2$>`\H/60?OJGV_@]$3Q<'=S'YT_:]$3Q<'=S'YT_:]$3Q<'=S'YT
M_:]$3Q<'=S'YT_:]$7(1Q1$`%^P*`F`!,98X%*`B`;PCS?(`;=$0T:4#&`)"
M/.`&,`&(L<Q3``B&TH\T&T!V:(N/%P=W,?G3]KT1/%P=W,?G3]KT1/%P=W,?
MG3]KT1/%P=W,?G3]KT1!CRARB^8[/Y8X?]/-\FB*HT:4H[OC"./R%-O$7.8/
MA!MW=O-``B7J#^[HBI\7!W<Q^=/VO1$\7!W<Q^=/VO1$\7!W<Q^=/VO1$\7!
MW<Q^=/VO1$\7!W<Q^=/VO1%L+1$^:J\<3?(H`=)V'3'>(;:Z6$=@CR]74J^L
M#5_._(_B2#^[=:(ICT185D/^CDA_(*_@]$5>,OS?U+\2M/N1T16#*@%%&!`P
M;Q1>.@,4>H("DD'+LY=G+JJ-Q;*SZ>+@/5RU`-<?6]6@Z:JU*XL:'-_U<PR#
M(9`Y]:-:6`@D$X''`8KQ#J6=,@4Z&4N4]D:Q6QO/8=XD;9(0,XK%/FU>L..L
M@!6*"X@DVD>W?1J;SIJ34R2IU2+FV#U0V:^;-&WIJVF68U#4M2FEL;S2M5G?
M'*QH=`Z";LH`"WUFN>XT:TT+ABT%?7VN<M]MZS?C;^GZ9:6UU:ZWI<,4T';L
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MD311;I??%UEE5!*FDBBD43&,80*4H"(\@:J#@P$S@OMR``P'*7OSL_;PRAHQ
M)J*BH5$F5S"UX+V@@Y&FCG8]#AC\"_(+Q12.94T'!*%GNTP6>KO?YZZ0T@O;
M"J+R=86=/K90&<<J<@S#;(>4JECV2N,`(`JE6:V@A"-DF_CXZ6M4Y&G6-4W5
MK4>ZKR/6=#LKV^KV0#`8RYQBAPID%N"UHE-!*YI#2<%G^8KM.L]-L+C2()-,
MO9WL&9]7!I:T!SZ?MB2F7)CD/KFG%?KAKL@UEZY799E--;(SE("$D6MD8BB9
ME84'L8U<ISK06X%;]'F"J=((!``@%4V``!R:V@&-PS0_Z)Q;_P!/1\E%@FYL
MHS?2ICTX^?I\ZO&I4IHB:(FB)HB?].JF$->'&E`:X\,,<:J,N<9*T!%.LT.!
MIY2,`>@XKS;SOQ(FF+I8L/QMGE:,DSOL7C5NXK+H[:Z3\TX@5)*5D$C%;K&C
MH"/DI*.0*8YVQ%$ND'%0QBD('TORZY;#3]$LMUS6T5Z]]BZ_+)HNUB#3<&L9
MJ:!^1CFL!J6YF^K3%?"W.3G'?;@W+?;!TF^N]"L8M49IT0MI!]^FNONX;/*U
M^+A!%(^$9'4CDRRN!^D5YIY9QQ!W=9U.1F2FD'$-T5G4=(N%',G)3+,&2UD6
M0D'*UR>/%;/%PSALD0H)I`^5$X`&\@N)?H71MX3Z%9&TGTA\VHS&KV1Y(8V`
M>J,C.P^@YV<TJ0T`=!"^:;_EA8ZUK']PLM5@@LH\6SF1]Q/,7>NTRN-T^ERQ
MI`RY61N<7#$MH-Z_5@&RTS#+U;L&1)G)F)ZT%6:5>:E6ST\5$WEZP0EK#7J5
M/R,C(.)V)CHR023D"$W6[*02YLGPC'`/G+GY)M^Y?97VGV+;#<<OTXLS#6/,
MX![PQK`'$UIF%2`">A?:WZ9X]QVMGJEAJ-ZZ_P!LQ,`CEI(,LM!5D1D<]Q`&
M4NRF@<7`8!>LVOF]WTCYU]5=`\P_P"XU")HB:(OHD3G%$R=3?.0NWJ]4P!U/
M=_>]W1%H0CQC3)5I51Y3X88[S8A+Q#%93!3SR<0LXD9*4B):M&`9`ZXU6/$J
M$@F)6X2YBM3(FWP$I%ONJ0$U#D`=H$,8H#LV?Q1V<H<NP>31%\]$31%2HD*Z
M:B(+G;"LFHB#E+=%5L94ADRN4P.4Y!40$V^7:`AM#E`0T1><3/B`XAZR^C6T
MI6W4^[<DL-/6B)BD3Q0>S6*:4_83ERC):)Z$5-K=LEI`8$^873<L3)&;F0*8
MHJ$642?$'G"K2$BQ?U..E5X]S+.A9!3KH*EBC&Z5D=3-CKKMLY7;PU9HA(-H
M"C)R+QV]++$YM8!*0#D4J8;S;<\CY"FH*<@V,961K+VPUM9G5[7'O#-&]C"+
MCWTW*3RC1L@:?CU>>:MB-!*JF05"+;Q%T4B+:/1$T1-$31$T1-$6H7'/FZ;X
M?.'><R16[3"4V::6>HPS2;GRQ)V.[-21T'#0J<T`LCN'""8[H"`G``$0USCF
MKKNL;<VA+J6A$"_$C0*BN!#B0!QK@."[#R)VEH>]>8MMH>XHI)M+=#*]P82T
M@M;ZI)X4!/3A6G31>(OM8,UC_P#K_C'^!GCD.M_^YKY6/.CFR:.)A8PL%*QT
M\_$<>M?;X_3/R7HQ@M9B\0M+NTN)&XDNX93CY:\,$]J_FK]H#&7>F.NQU'YT
M<U_W[?ZGS*KPR\FOPG_U4WI3VK^:OV@,9=Z8Z['3\Z.:_P"_;_4^9/#+R:_"
M?_53>E/:OYJ_:`QEWICKL=/SHYK_`+]O]3YD\,O)K\)_]5-Z4]K!FL.IQ`8R
M_A:8Y'_U!U7'SHYL9QEFMV'K[+-\%*=/7T*EWZ:.3+&EQMG-P_9N9'./^4!Q
MI5W"O$="]7_5V\4^1.)NK7Q]<SP]LBJM+M6L5DJNEB$(E](.T@5>5!=O$&%D
MM)12`D<\ZD&TJ*X%5`!%,3=_Y*[UWANZPNV[JA:T0O!CD#<N<DD$4H#0"AZE
M\J?J+Y:;*Y?7]C_M%TD+IVN$EI([M'1!K01(9*FN<DBE:BB]&=H]<??UV]?-
M2;1ZX^^.B)M'KC[XZ(FT>N/OCHB;1ZX^^.B)M'KC[^B)M'KC[^B)M'KC[XZ(
MFT>N/OCHB;1ZX^^.B)M'KC[XZ(FT>N/OZ(FT>N/OZ(FT>N/OCHB;1ZX^^.B)
MM'KC[XZ(FT>N/OCHB;1ZX^_HB;1ZX^_HB;1ZX^^.B)M'KC[XZ(FT>N/OCHB;
M1ZX^^.B)M'KC[XZ(MDL?\M3C-O+RN_\`OB^I5\<%@ZOYWY'\20?W;K1%,>B+
M"LA_T<D/Y!7\'HBKQE^;^I?B5I]R.B+Z72M.[&C'E9N$4#LEEE!YX#CO`J0A
M`W=P!Y2B7;RZ@BK2VC2"""'"HH>*5RD/];,T@@M)!#AP-1C@<5K0RX.<8183
MB<?CK'+0EH%'SB!O`)%\<`VE"3B)9$PI[ZR1)E(KK<V@47!0.("(!LU^/:FW
M(A(?N5NX2D&09?\`4+35GU7>LMB=OK?<PB%YJ=R^:W#C`[.X]E5N4CUOWF$M
MP62&X:JRK/O+4K7:B-D>N'SAW.'BQ&2=.).%1KDBX5<[@F44?0*!&:IAY3MR
M%*/(&O6W0=&;.+U]K`[4CG+I,N)+V=D[XX0(_,%X8MQ[ABT]FEQWEPW38@UC
M(ZX98Y3+'T_LRDR?"NS#\.$'7UX=W!1-6B'-?KGFA!+,8]1!6(JO24GGF\P.
M!!%O$=,1(KS(?!WR@/N:NVFD:587-O=V,#87VL'8QAN`;'P#1YAA\"M7NLZW
MJ4%Q;ZA<OE9=3]M(78ETG2X_]1Q66^BJ5\IQ_P!HX[#60`H*+&$.<<QXE/15
M*^4V'VKCM>E%&0IZ*I7RFP^U<=KTHF0IZ*I7RFP^U<=KTHF0IZ*I7RFP^U<=
MKTHF0IZ*I7RFP^U<=KTHF0IZ*I7RFP^U<=KTHF0IZ*I7RFP^U<=KTHF0IZ*I
M7RFP^U<=KTHF0JSV'!@VJ`G:O..V+N$LL+*5^9:%.^;F<Q4TQ7C9%N5PWYI=
M`RS-R<H'(8IR".T!VAJ2UCXW0RBL3A0A3D-0X&DC34%>:M[]1QPRY(R%5,D6
MZQY?DYRG6L]SBDO2C+(MUK`X3CU7KY\]2BB3JBJ\O"L7R8INTNA*M2HM`09G
M5;'Q^T=-M=A:KJFK[5:;>\UBTA@NB[^(Q[;>1LD8[)WJ@`M'G.)7NUJ]N=Q,
MT^'57%\6FS2R1>5TL?9N_P#TKT5H7#FSQK2JOC^IO$FU:J$0A"PJ#YW(23TK
M-`3GWW;]T4RSIRLJH8YSCL#>,(%`I=A0R3Y))WNFEIVKR7&@H*G$T`P&/0,!
MP6-C@$,;86?08T-'F`H/D66^BJ5\IL/M7':]445>0IZ*I7RFP^U<=KTHF0IZ
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M#J.K\=!E?)&,&T2+&,0^W88!`=FMZU;]2G,R^M186,EI9-[$-+XHCF/DS.<2
MTC_+3RUP6@;;_29RJVXZ,R07%^8\O^O*W+^\?5CBC#O6)P?4=5,5Z(0.#4:O
M#1U=K3>M5ROPS9-E$0<'&EBXF-9I!L3;LH]D@DU;)%ZQ2AM':([1$1UPJZN[
MK4+E][>ODDO)'5>Y[W/+G=8+L0/\O`?"OI"RT^VTVU996,<,-G&T!C(XVQM:
M!P!#>)ZW'$X=2NWHJE?*;#[5QVO7GHO5D*>BJ5\IL/M7':]*)D*>BJ5\IL/M
M7':]*)D*>BJ5\IL/M7':]*)D*Y#%<L40$LHP`P"`@(%<;0$.H(?>^00THF0K
M#`X9ZV#8S4(>I\T9R#DQAC3=(-LL1;8#0SOFNEFB@L9"NP9[_1`4`-B>Z&S2
MB9"LS'%<J/*,FP$1Y1$2N1$1ZXB)-HCI1,A7'HJE?*;#[5QVO2B9"GHJE?*;
M#[5QVO2B9"GHJE?*;#[5QVO2B9"JPQ=,@&P)9F`#N@(!TK8(%_BALW/_`#?<
MZVE$R%`Q=,@&P)9F`;0'8'2@#:'4'9N=4/<THF0H;%TP<-AI9D8-N]L-TH0W
MAZH[!(/*.E$R%4>BJ5\IL/M7':]*)D*>BJ5\IL/M7':]*)D*>BJ5\IL/M7':
M]*)D*>BJ5\IL/M7':]*)D*>BJ5\IL/M7':]*)D*>BJ5\IL/M7':]*)D*QBW8
M9CY6(Z#;&%5M,0HZ0.:)L$*UG(XSE(%#H.#,)9FZ:"LAL'</N[Q=O((;=6Y+
M6WNF]G<QLEC!K1W"O7Y\5?MI[JT>9;:1\4A%*M>]AIU5C<UU/)6GR*,_^'/$
M?Z*<._JRIX__`&%KSNTC3V_Z5M:MZZPMD_\`>&'P<5[O[UKS?]*]N&]?\>Y_
MJ)_PYXC_`$4X=_5E3_R%JG^U6G\FS]UC3^^;C_'W/M[G^HG_``YXC_13AW]6
M5/\`R%I_:K3^39^ZQI_?-Q_C[GV]S_43_ASQ'^BG#OZLJ?\`D+3^U6G\FS]U
MC3^^;C_'W/M[G^HG_#GB/]%.'?U94[\A:G^U:><)K:U?&12@@8P^?,,<.KI5
M3->W"QV9U[=/Z@+BX!!Z#5SR,./!9K7,6PU<CG4?58BKU>,1%:24C:Y!LX*/
M4<*F027<"QBFC1H+E8H%`RFYOF`H`(CL``]%O9P6<(@MHHXXZU]7_FL=<S7=
MU.9KZ6>>[(Q?),Z4$=``=P(Z2KIYKK]V-OM5>QU?R.ZE8H4\UU^[&WVJO8Z9
M'=24*>:Z_=C;[57L=,CNI*%/-=?NQM]JKV.F1W4E"GFNOW8V^U5['3([J2A7
MV;5!RY<)H%>-@%3>`#B5;842D,IR@!=O*4@Z@M(XIE*^`5=<0V],;_:J]CH&
MD\$RE<^:Z_=C;[57L=3D=U)0IYKK]V-OM5>QTR.ZDH4\UU^[&WVJO8Z9'=24
M*>:Z_=C;[57L=,CNI*%<EJCDYB$*\;;QSD(7:5;8`G,!0$=A=NP!'3([J2A5
M:U2<H+*HF>MA,BJHD80*KL$4SB01#X/4$0TRNZDH5\_-=?NQM]JKV.F1W4E"
MGFNOW8V^U5['3([J2A3S77[L;?:J]CID=U)0IYKK]V-OM5>QTR.ZDH5P-77`
M-H.VX_N`57L=,CNI*%?=Q4'3=0$SO6PB*::FT"J[-BI"J%#^+MV@4W+IE=U)
ME*^/FNOW8V^U5['3([J2A3S77[L;?:J]CID=U)0IYKK]V-OM5>QTR.ZDH4\U
MU^[&WVJO8Z9'=24*>:Z_=C;[57L=,CNI*%3I3&HLZZQ;&.504A<[3$`0`=YR
ML;;L-L$.KJ%>4>J_G?D?Q)!_=NM$4QZ(L*R'_1R0_D%?P>B*O&7YOZE^)6GW
M(Z(LZT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6,6W_`%8G_GB7
MX)?5;.*%1QJZH31$T1-$31%<F'_4RGXM4_#M]0?^:*VZE$T1-$31$T17&)_U
M@V_])7_NR^K<G0@5L+_%#]X/\&JF?115:J1-$31$T1?9M_E+;_.$/PI-$7VD
M/\O??YXY_#'U`X!%T]2B:(FB)HB:(KG+?Y43_-&7_=DM`BMFB)HB:(FB)HBD
M^M?ZI;_OJ_AE-6#Q4J,U?SOR/XD@_NW6H13'HBPK(?\`1R0_D%?P>B*O&7YO
MZE^)6GW(Z(L&XC<N.L)8FL%[BXIA/V!N[@H:LP,G('BF,Q/V&:91#!FYD2)J
MF:(!TDZIS@4=A4AZG5U+14T5+W9&YE"%VXN74%6HJTU^LQ<NPE^&@^?68N)1
MTEO.AL=(@TZ\8R")R]%YJV'.98-IP40`-W8(CJH,_P`5:,V(%.(4BN,NW^.S
M;<:'(0].&CU/%J&5E)1H\G1M;J)=KST8UB0:*MRPZ4@22@#G54!04A;J%`H;
MX#J,N%?*KH=5^3HI50M$\7UW+CF^6ZQ4BJI3$#C?#.6ZY'PLY,.(YU5LS2JT
M='P\VX>,47",_`%9J"LH@4S=<1+N%(`#MJ+%#7YA56#,/'1/XNR%E6@-L?Q,
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M$31%C%M_U8G_`)XE^"7U6SBA4<:NJ$T1-$31$T17)A_U,I^+5/P[?4'_`)HK
M;J431$T1-$31%<8G_6#;_P!)7_NR^K<G0@5L+_%#]X/\&JF?115:J1-$31$T
M1?9M_E+;_.$/PI-$7VD/\O??YXY_#'U`X!%T]2B:(FB)HB:(KG+?Y43_`#1E
M_P!V2T"*V:(FB)HB:(FB*3ZU_JEO^^K^&4U8/%2HS5_._(_B2#^[=:A%,>B+
M"LA_T<D/Y!7\'HBKQE^;^I?B5I]R.B+Y7_&--R>A765WBB3D;6;.PMS*)=F!
M2)=S$8T?M&(S$>H4[669-RR2AP;K%,D*H$.(")0U()'!06APH>"AR5X0,.2L
M%3:T*-LCX2E5]]3F;&+M<DS3F:1(V"/L[JEV,P"=25K8R\4W.1':11--($RG
M`@B4:LY5OLF8<<%-"N.*FO<IF].&*J\[/TIGCZ5YUTL=@YJ[&1E)-%B+#>Y@
MAS.9A??4``.8A@*([`#5-32GE5S*,V;II11#!\)N)82J6NFB%MF8BWQ51KKY
M2>M<E)R,?5*"\,]IM4A'YQ(M&P->74/S*9=JA@.;G%#CL$)SE0&-:*!=RW\*
MN&;S/62S6.`?.YNU.G+R4?)S#YNH"KR)J<(Y!F"2A2LTUHZE,""!-FP2'$-@
MJ&VU"5P%.A4&%A-35+?PJX9O4]9K-8X%^[F[6X<.95ZG,OVYRJNX>K0+CH0)
M*%*S(K&TYB40*&S>(<P<JAML![@*#@I[)N;-TJ\O^'G'DCE-#+C@+"%A2F8F
MSJQ*4\[3J;VVP59>TV%MCV``!16GHRL2"K-)0#E3YH0$Q#'`#!&8THJBT'XU
M8HSA1PO#O9^080,@B\M%"N^-9Q?QU(&._JF0;+)VNQ-5-JNP'1I>87%!<-BK
M=(X)E'=*`!.=Q5`B8%*^/J%'8XKC2K1,Q:9F-8;B;%6V3SNQ2#-FBV0:-HY!
M\]^_DCVB#<H)I[1`H[1V[1U237%7&C**#@LYU"E-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6+
MVW_5B?\`GB7X)?5;.*%1QM#KA[X:NJ$VAUP]\-$3:'7#WPT1-H=</?#1$VAU
MP]\-$5R8#]YE-G+_`*-4ZG+_`-NWZVJ'DBE$5L`P=</?#4M)(Q1<[0ZX>^&J
MD3:'7#WPT1-H=</?#1$VAUP]\-$5RB/A2#<"\H@*PCLZP-E]HZMR="!6P.0`
M`>00#E`>00_?#53/HHN=H=</?#52)M#KA[X:(FT.N'OAHB;0ZX>^&B+[-AVN
M6P`("/2$.3;_`/Q2ZH<X@X(OM(B`2#[:(?Y6X'J]=8X_^74M^B$73VAUP]\-
M5(FT.N'OAHB;0ZX>^&B)M#KA[X:(FT!]T.0-O5#1%<I8?YR0WN=%9!MZG_LJ
M0^[^YJT7$&@16W:'7#WPU=1-H=</?#1$VAUP]\-$3:'7#WPT1-H=</?#1%*%
M:_U0W']U7\,IJP>*E1FK^=^1_$D']VZU"*8]$6%9#_HY(?R"OX/1%7C+\W]2
M_$K3[D=$5ERB\>LVL29DL[34.L\`4V;@S=1P)$4S)H@8%$R;QC<A=X0*`CRB
M`:HDS=F<C7.?3`-XD]'S^15Q!CIXFRO;'$96ASCP`)QJO,2E\=;9^UQ7'7:,
MLL-;<D*B4[6*E62T=$HR%_EJ%7W((NYL964*\D([:Y*T36,T)O*J`5,2ZY#8
M<X-+++*UU&VGCU/4'N+&M,=&L%S);`_Q#3%P'#'#J7<-5Y$ZP'ZC>Z'=PSV6
MF$.];/1Q9:QW<C3E]6F3,/XE&FN&*N*'&@\M`UE&HQ5GB'$ID;%<"[-<'"9T
MG],R%8+37%)N%-#3:YF[Q&2J;E,@.0*(;H&%,Q3!L]D7,Z'4YK6WTZ!XOI;F
MS`8_L_6CNG7#:_P\*`PGBO'^4#]&AN+K7[V.Y;'8:E*/NV=H;<P102QV\N>-
M[2YK)VN;V9R`$=-5]XWC*>,:Q5)FP05YF"V*EY$O0SM>/%L8TL-CA>:-/'6@
MG=L?S<:5JE'(MP65$S==VY3*0^TPE)<M.9-K#I%I=WMG=2_>K6XN,[#AEMLI
M>T>3ULOP+R2<HKRXNKJWL;ZVBEMKJPMW,F$Q>V2\,0]8L:UIH[,Z@`(C$E>-
M5V9_C?KT$S=/2062Y=-@O;P?IQSJ*!5HQH\%5+'8)0_3)ML55LA&VY`4TR"9
M90Z9R@7^*(K_`)K:/9VSI8;:=Y#I<"<1V,<<CACA6D@'P=2G3^2VOWMPVTFO
M["-SQ"0:7-?XSY(V]'7$3\)54QQMP]>A$YZ9K.36+9O<YNDSJ*\A7BJ0,C!K
MPJ2IE%?.3HTPN]1GD5F[1B=PY.D14PE`$Q$:[SFGI%I:_>[JPU$6QNWVAHZ"
MHD:R-P=ZAS5_BMKEZ%39<E=>U"Z.G6NI6'WQUC]Z::3FK'=JVGK#*`.R)&;"
MM"LBQ-Q+6"]9%M>,YUG-,)1E;,I-*G/L76[7YRO8[GH6%7;&*>7=2J<\U\>H
M&7.=%%NKO_>P^".O7MC>\FN:W=Z1=PY96S7(B>S",,MI6QN:X?S#VC<>H%8_
M>'+Z'0-!M-Q:=<EULZRT\RQO-9#)?0R3MD:?Y8$9'PA8>TXR;;;;XSIV*<76
MS([)!28E[/+L[['03]ACN)S0_P`$&NE8@Y!JJ2V.AM]<G7QXX[N/,2$ACKE7
M477;M3]"7+JNZU$37UD%J]&TUD"5PQ+Q9&.*(K/\8"V:X0E76P@_F[Q7GMLL
M]N?U^/"IV&,FJ2#$(@&+X73V7CR).>;475;DS.ZUN=BS.ALJ$M1&9++792H2
M5::RL),OQ"11876AU?(U3DETFRYTVYI&NVE(BJ.TPH/&SA+>,!`,8F9W6I6\
M<S'E62[^<]MT4YW=:>.9CRK)=_.>VZ)G=UIXYF/*LEW\Y[;HF=W6GCF8\JR7
M?SGMNB9W=:>.9CRK)=_.>VZ)G=UJ+LU7++U>Q1?)O$I"3V1(R`=NJO&S3Z2/
M'&>DW>==JMFAE',DK'-14<),R`!G:B0)!RGV#X[Z6\BL72V3`^<`T-`XU`P]
M4X.H?V3@>!7HL\KI!]Y`#0X>0$5X$^7I/0O)=7UL&2[=A[%%7QE"O7/%W<;B
MTI5LK$@Q?.ZS`+PCQ(D[.IMD'(H/6MH3;JHM$6RJID5`6YG?,+05>6,YB:E-
M;VVBV]OVN]3.UD\3,8HXXPQ[[P24J8;ADT0@C</6ST.1\4E=TDVI!#--J#Y2
M=NF`/BDX%TQ(#HR.H`DEG_EY6G]M>TT+/W!>&B5[$NI&6!>+CUIV,C9E[(1T
M;,JM$CR;!@_4,FH]9LWICIIJF*`J$*!O=UV*3"0M:/5HTG_*XC%H\BT)SLLS
MFQ.)B!P*N?CF8\JR7?SGMNJ%.=W6GCF8\JR7?SGMNB9W=:>.9CRK)=_.>VZ)
MG=UIXYF/*LEW\Y[;HF=W6GCF8\JR7?SGMNB9W=:>.9CRK)=_.>VZ)G=UIXYF
M/*LEW\Y[;HF=W6GCF8\JR7?SGMNB9W=:>.9CRK)=_.>VZ)G=UIXYF/*LEW\Y
M[;HF=W6L#R/ELN,*V6UV)]/*0Q9B*B'KAD\.88X9A8[5H^=`NZ1#H8/>;1,)
M=X^^L38`AM$"9W=:A:K<;F+K%#%FY"SVJHMAC&$FJG/LIM<S,CJIL;4Z923B
M#3E6<;*1XN'$<#9=0B[R2CG2+8JPI\I,[NM7(O&/CDD\TKLA8[;$/%I>TQ#Y
MQ*1M@:L(%6LO7#!(T\],AT:,=3ZZ`"T9*&!\5,Y5%D4B"(@3.[K5<GQC8PCA
M1YB[3$R1T_J3%FI#$FGA3IVN::P8RSXP(%)"P$$Z?(],?/#(M@,J5(AS+""8
MDSNZU,%$RQ#Y-K36X46X/+!7'KE^S;R2*THU`SJ,='9O4#MWQ6SI)1%9/DWB
M!O$,4X;2F`1)G=UK,/',QY5DN_G/;=$SNZUP,S-"4P)RC\5!*8$P._=E(*FP
M=P%#%.8Q2"?9M$`$0#J`.BC,[K6L='XC,H34MCR+M-38,4+[DS,6.C357O4G
M(1\"KB9M;MCETRFHN+E7KBSO*<Y%$J*?,-4#%%505-A!)F=UK&U.,"PQ%F6C
M+7`+LH)_8\G0M3DH2T2$A*2*&*;L\I4XG,L)%E$QL7*RSI-%RQ$'AF8IG436
M53,F!C$S'K5K3X_:8W92TW,1>2XVNE"&)59,"LW1K7(O8RKO9>N(()SH%9V*
M`7LY`4*<XLW#=,5$'"AS<WHF9W6N^GQWU1-9\Q?P>5F\JV"RNFL6T09R*[N'
MA;++UV*E7"Q)MNA#I6,D$Z>`+SF4&"")@=JI&W=XF9W6K]>>+">J=YJ<!&UN
M>L5;F,:P^5)Z18/;$[L4-59)Y/HOY%!I%1<E5BHUF.@Q=N^G2C,')%.;:&55
M``,3,[K7S9\;M!<RTK"N%,E1C^'/'-'2;V/(<@S,FPZ<WK::S"<?(#8=H&1Z
M.)@YQ8H\V8Y-AQ)F=UK'5N/FH.*Y(6"LP65[,5K%2LBV013C(YL\6:QE@F()
MEXQ?6(J1?.MC6G)VJJ1%DT=@$<"BIM(!,SNM92GQCPQ".".8K(SAVC,NJPD$
M.FU<,WUS3GFT2C2&;B0G8U0+#T*1:O%CJD2C2)'.!71C$W1)F=UK8:J7U>Y5
M:MV^(DYPD7:(.+L$>D^<.&[Y%G+,TGK=%Z@1RL1%VDFL!5"E.<I3@(`80V")
M3G=UK#,QYPA,*T1]D"^R5C4KD<_BV"Y8E->6?"ZEG(M&8ILSND"F)SH_#-O!
MNEY=:YNK<VG;2T636-3=,VV:0VL;.T=F.(]7JH#BMKV5LW7>8&X(MK;?[#^Y
M7`-#,_LV@#B0[][A3X5I\'K0>&\0_P`JR=]5?]LZY:?U'<OG/]:2^:,C?_\`
M+TXU*[:W])W-K,X,.E'*XL/_`*GI;@5S[4#AO[KR=]5?]L:>(WEW_-OO=E5X
M3>;O5I/O*>U`X;^Z\G?57_;&GB-Y=_S;[W9/";S=ZM)]Y3VH'#?W7D[ZJ_[8
MT\1O+O\`FWWNR>$WF[U:3[RGM0.&_NO)WU5_VQIXC>7?\V^]V3PF\W>K2?>5
M47UHG#D3>`CW*!0.7=/NU80WBB(")3;)GE#:&A_49RZ/&6^]V3PG<W>K2?>5
M1[4#AN[KR=]5?]L:#]1G+H<);[W9/"=S=ZM)]Y7/M0.&_NO)WU5_VQIXC>7?
M\V^]V3PF\W>K2?>4]J!PW]UY.^JO^V-/$;R[_FWWNR>$WF[U:3[RGM0.&_NO
M)WU5_P!L:>(WEW_-OO=D\)O-WJTGWE/:@<-_=>3OJK_MC3Q&\N_YM][LGA-Y
MN]6D^\KDOK0N'`@@8KS)Y3!MV&+5A`0V@(#L$)G;R@.A_49RZ/&6^]V3PG<W
M>K2?>5Q[4#AO[KR=]5?]LZ#]1G+H<);[W9/"=S=ZM)]Y3VH'#?W7D[ZJ_P"V
M-/$;R[_FWWNR>$WF[U:3[RGM0.&_NO)WU5_VQIXC>7?\V^]V3PF\W>K2?>4]
MJ!PW]UY.^JO^V-/$;R[_`)M][LGA-YN]6D^\I[4#AO[KR=]5?]L:>(WEW_-O
MO=D\)O-WJTGWE`]:#PW@("#O)P"`[0$*KL$!#J"`A,\@AJ#^HOET>,M][LGA
M.YN]6D^\KDWK0N'`QA,9YD\QC"(F,:JB(F$>41$1F=HB(ZGQ&<NA_P";?>[)
MX3>;O5I/O*X]J!PW]UY.^JO^V=2/U&\NZBDM\3_\LH/Z3>;A%"-*IY+G'X/*
MLYQQZP/A[R9;(^F1=JLE?EY<PHQ:]QBQ@HAZ]V@"<:64-(.&R#YSO?>BJ\V5
M0WP0-O"4!S.W^=^Q=PZ@+&WGNVW4AHUKX,C.O%W1@#3K."UW=7Z<^9^T]'?J
M]S90W-G"`7B"XSREI(!+1TY:U=Y`5N?TMWW2O\\IL^ZUU]SFY6NB-8W"H*X0
M2PDF`N$;3E<U_P!-K^D'R!.EN^Z7'SRG9:HS.ZU&8ITQWW4X^>4[+3,[K3,5
M4=\]..T[MR<0```3+J"(````!RFZ@`&H3,53TMWW2X^>4[+4YG=:9BG2W?=+
MCYY3LM,SNM,Q3I;ONEQ\\IV6F9W6F8ITMWW2X^>4[+3,[K3,4Z6[[I<?/*=E
MIF=UIF*V,H1SJ56-.H<QSB+K:8YA,8=CM<`VF$1$=@!HKPX+!5?SOR/XD@_N
MW6B*8]$6%9#_`*.2'\@K^#T15XR_-_4OQ*T^Y'1%:<F,GSQ"%%BU7='0=.3G
M!!(RNYM22`@F`H<@"(:J8YK7!S_H#BK4Y>(ZQM:Y]10.P!Q6AL+P>52!D*E)
M1HY(0-43'(V03F.8;S$:G;I"]1<).BWCDG#N*A['*+*)$341,JD;FES*DY-<
M_@Y=;>L76\K7.#+*)S2RE63AT_;,#G=#6/<75'4NHWO-;<5]#=VUS;V?_JGQ
MO:XL+I(G=D;23LB#1DCX8\2ZM6G!8YC#@OCJ?#0`V)6TV&U1LS3K`L^9NUTX
M9NZH4_9IZN1T,R78E6;00.[2Y4<H'$YU%3CL.4H%`,?H'++3](MX9M4D=+J4
M78!QI_#;V#YG1,B/[32V6M>NJ]^ZN<FIZ]<W;M#M;*'0IHI2P!ICED$[(8[@
MS5/\25_8L#7-%,HIT*],^#.J1Q7#5HXR>C&O*%*8SD8?QR@=@_J4N]G)-ZQ7
M!6'.Z2.I)V)9QOHJI;RI$A.!@3`->FWY:Z%:D,;-=,8ZW-D6MN&L:V-U'Y\I
MB?E#GO#:YC5Q^!8R[YM;KE8XR6^G.U-UW%>L<^)SGFZC#8Y'%PE:'-[%N4#+
MAB/*OF7@GI!HAU#NVV19`CYC=F+U\]ETU)!T3($%7*Y85E%DXM)(%ACJLUYC
M=(!43@80`0$`"1RSVW]P-C++<4D,P<3ZQS3QQQO&:@J0(\30==`O8_G-NIVJ
MLO[9FGLC8Z$QL%L_U60RR20#B<(WRO)J3@14JJR<%5(M*KA=ZVR(U4?R]HEG
MWBZ7(W*^-<35M>8CE2*Q;@"QXN*FR43!/<6+S9B"H)#F**_Y8;:U*KX9;D6S
MYW/(!R&KFQ,(#C@#_"&*ITKG+N?2(XX::>[L(&1->+8D%L;9FT!Z<S9G@#I/
ME6<T[AIB*/D)_DN)8W9Q.O5;<Y2923X[J#BWEZEXR9M#N*CR,T3-EI)U#MBC
MO*'*5-(`*`")A'*Z3LG2="UN?5K%UT9GR7+OXDP>P_>Y6S/HT=+7-`KT<.E:
M[K',/7==VY!MO4!:_=FMML8X2QV2SB=#;,+C^XR1]6]9!4)17`3&-EHDSR9R
M1%-:]9+,FBPI,B,"RNV,7^<7/$/5,=Y"Z1%O9!=I3\DR+@4W$4YCG#J/.=LJ
MH9!PNB.W+2%U(GU>=>@:J>MQ&0.(=D\0@V-*@K46?JZDW6<9,O/7?Q=&,3T7
MS5?TR0'(4HHY+)QS]ZHY,W<`X*LS;'3(IMPQPXJ8;7OJT3%O3-[6_HT=#,TD
M7ZQ8*@XJQK5\78]KR[I\)W4A(LX6NJ.';@PB"CEV<`^"4!T13AYOSOD>1[U4
M^QHB>;\[Y'D>]5/L:(GF_.^1Y'O53[&B)YOSGNQ$@'[[93[&@!-:=`K\"`$D
M-&+CP'6N/$,WMW?%3_>#JEZ.<!Z_4V:IS-RYJ^KACT8\/C3CPZ7%O_B`J1YP
M,3Y%4$!/;0V1$B`[0V"#94-G6$!`-H;-7&.#'ASA5H-2/-Q"@C.VC3Q&!\ZT
M,QMP@98I_'+FCB-DHFO>CJ^5(L/66+`SI6R,Y,$J<47#N)&'08QQ14B'8<XD
MY4/LW1_[0=WGFE;0O+#?M[O!\C#:75E'`V,?2:&-AQ/LOC6VZCN**\VW;Z-"
MPLF@F<9">#Q5^(ZZX&OF6^7F_.^1Y'O53[&N@K4T\WYWR/(]ZJ?8T1/-^=\C
MR/>JGV-$3S?G?(\CWJI]C1$\WYWR/(]ZJ?8T1/-^=\CR/>JGV-$3S?G?(\CW
MJI]C1$\WYWR/(]ZJ?8T1/-^=\CR/>JGV-$3S?G?(\CWJI]C1$\WYWR/(]ZJ?
M8T18I><4-,D527I-SJLC+UF=*R))QX`]9F7"/DF<LTW73,Z+I`R4@P2/M(<H
MCN[H\@B`D45K<'^,5@,D7']@:L5Y"R2K^)93=C:1$O)6B;GK&]>S$>B]*C(K
M1LS:)!:-W^2-%R8J`%*4@%(OM*\)&.YN:GYR3I-G<+V<\XYG6(3]D1A7\E8W
M*KF6FCPZ+PC)*<5!84DW1"E500`I$Q*!0T1=5;@[Q>J,;N4"PM$XT&Z(MV$Y
M9&3:58-["M;0A[`B@^*6:A5K(J#Q1JMM3.HDF`AN$`NB*4,?X@:8PJS&FTZM
MS+&!CEGB[9NZ.]D%P5?+F<+"=TZ$ZABE$0(0H;"D3(4H!R:(LS\WYWR/(]ZJ
M?8T1<A`3H"`A#R.T!VA_-5/<_@T18VVQ?'LE(M5G1$FRL).V"SPRB48<IHRP
MVL97SEF6?)L2D)OQX\!PH'*H#E3;_&T184XX:,:NSV55WAR'=*W!\YD[(JXC
M'RZDE(/7,@]>.P.JY.,>LZ?2KAPIT7F`.X5,J(<YL,!%;T^%/$Z(/00PO&(^
M,8]K%O#I-YHBRK1FZ:/&^XX"1Y]L\!PP0$[E(Q'*I42$44,0-W1%WG7#-C9X
ML[<+XB8\^^)($=*MF\NP,<91V9^\72!@^;%:O!>J'5372`BS<RJG,F3YQ3>(
MLR0Q/$-4#M6V/FZ#92FM<>*MTXHY$5*(Q!T5G4CIEW2C!M@?+`1'J!SINOHB
ML@8$I@2BTT.+(]247F*]83.UXMPYYN=J9#DKLLU;KJ*-63V+YTYB&133WSF$
MZF^;ET16]#ANQTWC74,GB"*&,?$62>-%8UXX!RDNVEF1T3K.7"S@$",9UX@D
M0#@1!!<R:0$(!2E(OJWX=J"UE$YEOB6-1DTD4$4W18UX82=&F$)]%P""C@[8
M9$LNU27%V)!=&%,I3*"0`+HBD&,ICN$C6$/#5EQ&1,4S;Q\;',V2B;5DR:)%
M1;-6Z>P03101(!2E]P`T103Q0<-TOQ%8@EL5KV:R8T)+3->E/.R(KT7.OVIH
M)]TX&:<;/!XM5(^`!(8QOA$#X1>4-:OO#;-KNW0Y-&NWO9$XAU6\:BHI\I6[
M<O=[7W+W=$&Z=-ABGO(`<K)'/:#6G`L]:N&`X<5YC>Q=D`_][K*7N]3$6,NQ
MUQZ7].&T.TH^[E/J-X?*OHL?J]W;0N;IVGD/>YW^K<<74J/@Z4]B[(_M=93_
M`%18R[#5OPX;-_$S)XOMW=VV'M;A/8NR/[764_U18R[#3PX;-_$S)XOMW=VV
M'M;A/8NR/[764_U18R[#3PX;-_$S)XOMW=VV'M;A/8NR/[764_U18R[#3PX;
M-_$S)XOMW=VV'M;A5!ZEN2,!A+Q<94$"%$YQ#$.,O@E`0`3#\#D`!$-/#ALW
M\5,GB^W=W;8>UN%3[%V1_:ZRG^J+&78:>'#9OXF9/%]N[NVP]K<)[%V1_:ZR
MG^J+&78:>'#9OXF9/%]N[NVP]K<)[%V1_:ZRG^J+&78:>'#9OXF9/%]N[NVP
M]K<)[%V0_:ZRG^J+&/8ZK\-NSZ9OO,^7S*H_J[W@*#^VV%3P_BW">Q=D>I_Q
M=93_`%1XQ['4#]-NSW"HN9R/,K;?U@;L<W,W3K`MK3_4N%67U+4H<P%)Q<95
M,80$0`N(<9".P`VB/(3W`U/ALVA^(G^)3XP-V]W6'M+A4^Q=D1_][K*?ZHL8
M]CIX;-H?B)_B3Q@;M[ML/:7">Q<D?VNLI_JBQCV.GALVA^(G^)/%_NWNVP]I
M<)[%R1_:ZRG^J+&/8Z>&S:'XB?XD\7^[>[;#VEPGL7)']KK*?ZHL8]CIX;-H
M?B)_B3Q?[M[ML/:7">Q<D?VNLI_JBQCV.GALVA^(G^)/%_NWNVP]I<+D/4MR
M0B`!Q<Y4$1$"@`8BQCM$1'8`!\'JB(Z>&S:'XB?XD\8&[>[K#VEP@^I;DBB)
M3<7.5`,41*8!Q%C':`@.P0'X/5`0T\-FT/Q$_P`2>,#=O=UA[2X7'L7)']KK
M*?ZHL8]CJ1^FS:%?_B9_B4._6!NS*:Z;8$4_F7"FC!?JI:=BNYM[;D#)ERSH
MVC#H.X:KVFF52LP+>4;'$Z+V13KA`7F44CB4Y6ZP@B)R`)@,&THYG2.0&R=(
MU*+4IY)YXXG5R8XFA#3\!H?@6N[I_51O?7]'DTFRBM]/;-&6F:)TSY6"F(:U
M_JU</5->@GI7J3XO?CRBS7#]Y(0``#J```&P`V>X'(&NYO#:,;Q+&96^1HX#
MSKY@S.DRR@EV<%SW.P>7D](ZN*X\7ONY''S1_L:H52>+WW<CCYH_V-$51XR1
M(.Z=DZ(;8!MAD3@.Z;E*/4Z@AHBI\7ONY''S1_L:(GB]]W(X^:/]C1$\7ONY
M''S1_L:(GB]]W(X^:/\`8T1/%[[N1Q\T?[&B+8JA)G2JT:10IB'*+O:4P;!#
M:\7$-H?N@.I5\<%@BOYWY'\20?W;K1%,>B+"LA_T<D/Y!7\'HBKQE^;^I?B5
MI]R.B*PY3'[Q!%WC%*9XY`VX82F$.:2#D$!#KZD9Z.+'!K@TXD5'#J4$M;ZS
M_P#3'TA2I+>D#RD<#T<5X;UCB]S5*R=*@7<C%*/WV:T&D^Z3K[5--WBB:MS.
MEPC!N0I]QG(FFD7Z?2PVJFYC8(<FOFNTYL[Q9<06S9(0?[NT4+0<]HZ4P-'_
M`%F48,XTQ7U[?<E]CVT%U)8VT[`S1W.A;VSJQZEV,ER)`6D&5G8O;F_99F!(
MJLF0XELL-\?6VZN,BP[J>F,+7/)];I;J@.61*FYA;\%=B58"?1:#$6N%;Q9@
M3?HO71WI79B&`I2&$`]S>8>Y;?1+V_FU)C=6N-(OKN.%T+L&MG#+<MH#B&AP
M>.+78%8.ZY8[,BW1:Z4-,,1M=:L;"6[%PV1L@=:MEF8]KCVL1<\DMR@-<WUN
M*[]QX@\ZU8;)1F]N@7MCKUYEF:-Z7IC0BCZO1^!'.8D8MW6DY`L6D^5D6X,E
M'"9BB#8=X"@?EUZ-1W_NG1V.TMUQ%<.BU$-,Q;2K#IQO0!7]U\>7S@#I5G0N
M6O+[50S58K:2"RN[1I^Z=L^61MQ_=H['MVO<"[LRS-(YO0"1P6;3?$7EV)&P
MR[ME3FT.EPAK9VJK%B:3>N'%C$T0B*MA5=E;]&0;/':I4VC8RB9D0`3J"<=@
M9*7?6ZK2T?=W$L09_L\ZDR@#G=KV@;FR\:XU\V*Q]ERWVGJ/86UG-J,ERW?#
M]+<[M&,C=%E>[U21@QU,.JM.*R"G<0MR@\2Y%L=Y48W*UTW+E:Q+6CLFA:LC
M:Y[(+S'L-3&DBU:J.T(TOG#?TTG"J0&$&B)E`*)N0=NV!K6JZ]9W?]ZFCN)K
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MYRRQ^E8&`V1U$O)EB^*@PY]<4.?(MVWG$QCIO;<UT)$MK7N/#_0Y+)&28D\(
M\:-HJK$A#3]6?)S"ZGB]RGD1@V>#"<V*AG/BQ]O@D+4Y1(M7)/BRXGHF(Q\9
MSAO"JE@R!0KQF6':I96MAHM[CBFX;K^7EJV/-5AU,P>1@5FE(85WK<(=RHB#
MQ`>9.9-(B^UOXULE0'2)R+HN*5L?2L'@N7A;M8K_`':$C\=GX@R>-Z.GGHZ=
M+=,JNU:5)JN[D%8Q9VFV<.HY(Q@(\`Z9%$F/_6@S.0IN3-%8QKOFZGC6?R)'
MQ)K'=&UT18U+AXH'$+-K/9&1J32@S#>0C;:[B63*.?J322[1)XX:$:'6,B1>
MM<)*,I]A"S,8[4=1$^PBY>-<E,H7I$9,-D'K%<I=IA`56C@AMG*(".SJZF*-
MTTK;=KJ2OEBR@?M-:XF4'J&6E*\3@K<HK"ZC@V<Y0S'&M<?,*=*_,_Q$\='K
M`,=0U@O-#NC"8L+G(5W-$8U=5=N2*:4/'UP9UV:L[)BJT76>56$GHN3AF3$C
MPKRU1:$E/F6(G#@#C`\H]6U??.Z+S2=UVHMM+LKN[;(^(AYCC]?[GF`IZQ;D
MDD:">S:X5Z0LYO6WLM#L;6?;KS/<SR1Y6N&7^/D';@UX#)6CN#C@%^F%BL_4
M8L%9$$T)%5@R5D4&;A59FA(*M45'R#-8YA.LT2=&.5(X[1,F`"/*.LU&6F-I
M8X/9E%'#@X4P</(>*P^;-ZU*5QIU5Z/@79WS_**?.'[+5:)OG^44^</V6B)O
MG^44^</V6B)OG^44^</V6B)OG^44^</V6B)OG^44^</V6B)OG^44^</V6B)O
MG^44^</V6B)OG^44^</V6B)OG^44^</V6B)OG^44^</V6B)OG^44^</V6B*,
MLNY.1Q%2EKU(L5I*(CY>%83.X]%J:.83+P(Q.4`QTUBK%0DG#=,Q!W=I5A-O
M!N[!(M>:GQOTR6K3BQV>G76O(L&C$9<L4BG96\+,J5WIKZN23@B\8J$N%OC9
MB!:%12536=Q1SK&;E4(`D5X7XQ*O&SRL//4^Z0[2+LMPK=KFQ1;/(VJO*\Z<
MMHMD_,U?*J.IB62237711`[9FBKO=(4$!+HBI?\`&?0"`52$A[9/('/4W"BJ
M4<NQ\55V;M;.I3UKGNEJ%*RAZW)R":)@;]*<JN=Y/FB$*90"*>L693K>8J5'
MWVGFF2P4D[D6C<LRT&.?\Y&NCME#G03<ND#(+E`JB1TU3E.F<.4#;Q0(I#WS
M_**?.'[+1$$ZFP=AU!$"F$`WS\H@`B`?QNOHBT\2XNH>(QICVXV.,0DYBW8N
MB+^]95V=8-F2;]XH5!Y",BOWJRQ545-JFQ0PG32Y3]0=$74'C,C@C''_`.7\
M@M:6[L8SS<9W:&>M7<@1*YJK'B9M%`33$2W)33B9PV:*JG%<")(*+%YHY%FV
M5,VV*)Q5C6]8V;-Y.2R-:Z7"(-&4:?(JS1K9ZY-6%PC&1,98JF$[)H%C$R%`
M7C8.;.902[=TFB*$87CBFFM?:25NQH,C(2ZT4:""BV!9XQD6JL(PEK"+A%XP
M<NXKQ+OK@W46,*3L0(10S8`.J)%G:_&,T>.(]I4\?/["[>$A%'*+F[P\,G&!
M89JGUZ.0<J`TDS&>)RMW9<^D(%%)`%5`WA`B9R+)\L\1J]0X?J]ERI1A']DN
M2=2&M55TC+V14'<U$>=\W%NF54(O*NW<53XU^IO(D`A#D354W4M[1%'UBXO;
M.>1C'%$QY#S%0E'#SQ-*R]]09R5G;15XJM7>JL&;6.<)1#1VPGU5DEEC+J$4
M2)OI;IP#1%\[%QC3""$/)P%'01AY92=("\_8VW2_%L$Q<*OYQJBT4*4[U&12
M*W1C%!*+K:8_2$@$A1(MB,/9?#+#:V'&%5KKNISB<.NR5FV\HY=-ET%56$NN
MDS3(E'DE2MU%$4B*ND^;V;%S'*H0A%CO%'FN9P#AV6R7!PD?99*-FJ]%EBIE
MV_;,3I33_H:JYE6)ND<X@7E*`<@B/+R:T?F%NN?9>VY-<MV->]CPVA-!0@GX
M\%TGE+L>VYA[WM=L75Q-;1RAS@^)K'.JVE`0\%H::FI\@7F![6+)OZ'<?A_]
M>6OMG)KYS;^J+6Q$T.L(2ZE:YAPZ.A?6;OT;;2`(_ONJX2O!`@@P((KT)[6+
M)OZ'L?\`TY:^V:>*/6N[X/K#T*CP;[2[]U;V$/H3VL63?T/8_P#IRU]LT\4>
MM=WP?6'H3P;[2[]U;V$/H3VL63?T/8_^G+7VS3Q1ZUW?!]8>A/!OM+OW5O80
M^A/:Q9-_0]C_`.G+7VS3Q1ZUW?!]8>A/!OM+OW5O80^A/:Q9._0_0/W?].VO
MEV<H;?OG+RZ>*/6OP$/UAZ$\&^TN_=6]A#Z$]K%DW]#V/_IRU]LT\4>M=WP?
M6'H3P;[2[]U;V$/H3VL63?T/8_\`IRU]LT\4>M=WP?6'H3P;[2[]U;V$/H3V
ML63?T/8_^G+7VS4']4>M$$?V^'A^\/0@_1OM,G#7=5KY;>&GPX<.M953?6NS
MCBQQC>^XAB6U7=."-7[NF2TT]L+,5S`FDX91TIM;29B',&UN!DU%0Y"&WN0?
M?H?ZF)[C4(;2_P!-RVTCZ.,9[5XKPRL&+L:5ZA4]"\6X?T=:5!I4ESI6M!][
M#'F:V2%D#"1B09:>I45H>DT'2O8N,DT9:-CY9F#PC238M9!J209.HU^1N\03
M<(E>1SU-)VQ=`10.<25(4Z9MH"`"&OJ^WNF7UO%?0M+(I8PX`C*<>L'@OAR^
M@=:ZA/9R91);R&,Y3F::'Z0<,#P7>YP^W:!S`.S9M`1`=@]7E#8.KZ\R`<X=
M0P^Y[O6#9[O[VB)SA_C#HB<X?XPZ(G.'^,.B)SA_C#HB<X?W3".B)SA_C#HB
M<X?XPZ(G.'^,.B)SA_C#HB<X?XPZ(@G,/5,.S]_9_@V:(G.'^.8?WQ$?\.WK
M:(G.'^,.B)SA_C#HB<X?XPZ(G.'^,.B)SA_C#HBV1H`[:I&"/5_G7_0\7#_`
M&I5\<%@ROYWY'\20?W;K1%,>B+"LA_T<D/Y!7\'HBKQE^;^I?B5I]R.B*UY*
M8N'J$.+<4-Y!RY.(+NFS7;O))@7=%RJF!]@EY=FW9JA[VL;5X+FU`H.)J>"@
MY@YKF`$M>"032H'TL?-5:8LN%+%L:>..QJ;%!:+?PTDQ6\ZQ.X3=0%OE[Y%"
M=<TJ95=%O:)URXYLXB0X*`F8!(4I0U$;$VS!V39;60W;'-?@VISQSNN(W5Z`
M'N`/71;O-S/WE>9HI+J(Z>8Y6'!I>ULL#+9V4OJ,W91M;7S]:M*7!QB9-.P-
M_-Q=9K8X2PUE=BOD%\NPBZU:99&=FH"N,SS0H5Z*=S*`.N::@3<6$1*(`.S7
MFM^7NU[-TN6&Y>R:.6,ETKLS(YGF22-N6@:TN)<`<15>EW-3>YBM(Q=PLDMI
MHYB8[:!O;R0L[..6;,TE\C8P&%W`@*IYP>8G?UDU4>5URNQ5L;NV.)-3(LJ>
MTO9M_#FKCYT^M1Y\TX[0>5XW05$3K"D9I][W=FKCN7>VG6+;/L9S$)>T+I)"
M]Y<06.JYV.,;G,;4X`@<%=BYM;_9JPUNTO8V7S6,B8UD4+(VPME=*6Y&MRYC
M(0_,!]($TJ5G<C@&E2ZJBLA68APDIC5QB$[/Q\@FP]'KE8BZE?!DG(D1*0%4
MB[BP!SQ0*``;68?M/099HI)+=Q,>GNLJ9A0VQ=F#:4Z&T^'%8"UWENRR:VWA
MG;V@U0:@6U&9UP!C)7A4DD\/(L'E>%*K&Q1-XLJXC6T9*RP%\96-U9$[1.,K
M_4K)7;76;2\=S,NH\EU8V7J;`!246(!VJ(H@8H#M"]H6V]-VU9&WTR-XB=)(
M][OI%Q>0&T'$Y6`-XXTJO%KVY=6W9=17&MR"6^A;DCRBF5A!);\+R7=2PV0X
M!\)2$G,398ZXQ$M(V5K;8=]7<SV>&5QU,H7M]E!T.*.BV#=QW'R^1)->7?-H
M\$TG;M0-_:0A"%R[A1N>K6M''.<O_(K!O86@^K*"!4U80*?Y2"[,[J:!CCC@
MNK->KWX?Y^-"#>5RRH5T*JZJY:S'9CM4?7P6?52PT1[=QC$K+N'R<ZJ%ME&"
MMA,(R*R4@N94YU#[^K8?F:'QECVG@6N!^.N7Y*JVT@M$KJMB/6"'#SM=E(\G
M%9`AP28N)9:I;)%:_P!CEZ@TIK)D2SYLL4S$S+?&ULE;SC0ENA%9Q*+M)<<V
MJ86=PA7:1R,#`F4I1(DF4M8S/&9@JP<348=?`G_%2VLKLMOE=3C4@4'7TJ1(
MWALH$7=[QD=M7&2EQR;$RD!D.4>VH'J5R@))&-:IP,\P<RBC)Y#0C*,*WBVX
MI@G&-W#I-N!"NG'.3@<1P4N`!(!!'6%""?JZL"),63$C*_%,RZ<S\;!GNZ!8
MWU6?4J,QL?'4G8BVD)=[C5K0(AO$-X8RH-D691`/OBBBABA2W,<+%!EH&ZU]
MLUF:JA?K16+C.R5#R7)4N=0G*96JW3JT,),P4VU>0<3&5>J,F)8]`09';D.4
MR0\X8=$44ROJ_L2@RM9*>VDZB_L=5F*K%HAD&3FZ;2O.3%\3A&PV>I4%_9"U
MZ.NDGB&)+"#)B0SCFC"H(B8ZO.$6SLKCEZO29"DUV1+4$%*>ZJ$!+1$O$'D*
ML@,&>"B9"+%5V4HO()'FU$=X0VJ)!RAU0I>PRQNA;F$A;ZKFFCFDX$@]2K:^
M2/*]C(R&NKF<*_`O%_*7J8\MY(RMC[(+;BMA:O#TJRP\VXA8K'4?ME82`JSB
MIPE5(Q<7UQ")URL5^0?PK-JL"X.8>;D!=J*/%07-C>7FE?EWJNLZIVDNH0:M
M;VK&0W3LT=I)!(7RS19*%S[@'*_,3AAPP7MW;J+]U6>G608VWDLIWR/<P4=(
M'-H&CA0C`U-5[%XLQ7.XYQK1:`_LH7!W3*Q%UQ6S24A&-WLP$6AT=%PJW-*/
M5$2)-RD12(===0J21=]10^\<V6>X/>7M:QC220UHHUH.(:T=#1P`Z!18UC,C
M`RI-`!CQPPQ\O6L]\WI'KL/I:,\+U2JD\WI'KL/I:,\+T1/-Z1Z[#Z6C/"]$
M3S>D>NP^EHSPO1$\WI'KL/I:+\+T2BX"O29AV`#$1]S9*Q@_X'>J<P!ROJ'=
M7%0`_P#:%/A0:])AR#T#;UO&T7M][I?6U4ZC1F-<OF5>1U?)UIYOR0>XQVAU
M?]*QG)^__.^34,+)/H.%1UX*<A7'B"2ZS'Z5C/"]7.S>>&4_#\RH<'M.`J/.
MGB"2_P#D'TM%^%ZI]6N2O\0<1\ZD,D(KE^5<^;TCUV'TM%^%ZBBBBY\WI'KL
M/I:,\+T166PX\96V%?UNT0]>L-?E2()R4/+/8AW'O2-G3=\W*X;J.A(H"#QJ
MFJ7;U%$RCU0T184ZX<\8O7+9VZQO0U5VB]E<HF$\41/I-QD9"6L[E9ND^3:N
MG,S*2[MPJHJ0YRKNECD$@J&$2(\X=,:2$U(V)]CJC.YJ89RK&6D%UHM161;S
MCI5[,`\2,_Z*X6DW:YSK*F(*Q@,)=_=V`!%\WG#=BY^K$+.L:T%52!=MWL2(
MFB2E9N&LBYF&X@FD^22<(HR[M1T"2H*(BX,"@D$Y2B!%FE8QK&TN&;UVIP\)
M`P;-1RJVC6,JPZ.DJ\7.Y<J`9>067.=9=01$3',(<@!L*!0`BO\`YO2/78?2
MT9X7HB>;\E[@L/X):,\+T11^YP+C]W'N8M3'&-T6+EM--5$V,33XU1)*QL!C
M)P[-S'IMG#!U*L!!)99$Q%3E*7:;X(;"+M$PG1TV32.+CW&W0&$&:LLFAX>F
M*H-:XH8ZBT$@11(P)Q"ZJACJ-P^]'.<QC`)C"(J)17YCCR/C""E&0=98(C))
MS((MEH%)%.729(1J,DW2*N";5XA'MDT$SI@0R:10*78&B+J+XN@730C!U4Z,
MY8IJMUR,EV5369D6:.$'C18C50ID"JM7;9-5,P%VD43*8-@E`0(JF6,8.-,Y
M4CJK28]1Z]6DWJC%K56BCR2<.6[UQ(.CH`F9P^7>M$ECK'$5#*I$.([Q"B!%
MWT*,@UYD&L166H-EC.6P-CUY`&SD[+Q:=PW!)0@(.#QO\V$Y-AA;_>A'<^#H
MBZA<;1)`9@2M4P@1Q%TXX"-ZL3Q>FZ405<IL=W9T--RJV2,H5/=`YDR";:)2
M["(OC:)<HI-W-:IKEN@<%4$'"%67005*J5<JB**N\FDH"Y`.`E`!`X`;JAMT
M1=B+H+2#Z=XCA:O"^-'RLG)^*#5Z,\922Y2E6D7_`$)1#ICY8I``RJF\H8`#
M:.B+`<Q\/N/\[4=SCO,56C;G2'LI%2SF"/97<8563AECN8QR+NM3D7*%Z*J8
MQMT%@3-MV&`>36,U?1['7;!^G:A$V:W?3U32E1T_\=:S6@;@UW;&H#5=N7#K
M756L+6R#)4`TJ/7:X8TZJ^5:D!ZJ+@)_9V@Q_P#]D9,_O"UKAY:[$``DTZ)M
M&@?1S5IYN"Z".>7-Z/\`_-RBN)P@Q/2?])<^RBX"?V=8/]9&3?[PM1^6VP/P
M$?U$_/7F]W[+\4']-/91<!/[.L'^LC)O]X6GY;;`_`1_43\]>;W?LOQ0?TT]
ME%P$_LZP?ZR,F_WA:?EML#\!']1/SUYO=^R_%!_37`^JCX"?V=8/]9&3?[PM
M/RUV$<&:?$7?]%/E*I=SVYOM%6ZY*X]5(/Z2J#U4/`68#"'#K!;"%WS".2LF
M!L#:!>0!R$`F$1,'('+JG\L]D#Z6FPCX`I_/;F^!5VMS?`V$_P#]:>RBX"/V
M=X+]9&3O[P=3^6FQ>[X?B"?GOS=[[N/J0_TT]E%P$?L[P7ZR,G?W@Z?EIL7N
M^'X@GY[\W>^[CZD/]-<>RBX"/V=X+]9&3O[P=/RTV+W?#\03\]^;IP_O=Q]2
M'^FI!Q;ZO;A&PK<X_(.-,)5NO7"*372C9AQ:;58Q8])`A5%FS"TVN:C$G90(
M'-K@B"R0\I#%':.O79;"V;IUTR]L["%MU&:M.48&E%C-4YO<S-9L)-,U+6+F
M2RE`#VTC;F`(-"6L:ZE1T$+;T8Y<3"83H;1';RNVPC_#]^Y=NMO+@YH!`#A@
M*8"G51<Y-*DMKZQJ:XDGKJN21;DY@(4S83"!A#:[:E`1*&W9O"L!0'9UQ#5*
MA4!'+B&W>;A_\Z;=;^6T1<^+5_CM^^FW;M$3Q:O\=OWTV[=HB>+5_CM^^FW;
MM$3Q:O\`';]]-NW:(N0C'`B``9MM$0`-KMJ4-HB`<HBML`.7JCHB#&."B)3&
M;`)1$H[';4P;0$0'88%M@AR=4.31%QXM7^.W[Z;=NT1/%J_QV_?3;MVB)XM7
M^.W[Z;=NT1/%J_QV_?3;MVB+@8YP`<AFX_N=*:]NT15FBW)#;#&;?Q2F`0=M
M#!L,&T`VE7$`-L]SW-$5/BU?X[?OIMV[1$\6K_';]]-NW:(GBU?X[?OIMV[1
M$\6K_';]]-NW:(GBU?X[?OIMV[1%L-0TSHU>.3/N[Q1=;=TY3EY7:Y@V&()B
MCR#U]2KXX+!%?SOR/XD@_NW6B*8]$6%9#_HY(?R"OX/1%7C+\W]2_$K3[D=$
M5@RH`"C`@(`("[=`(#UA21`?WN0=2'Y*FI;4$5'$5%*BM1@2K<D?:Y6TKZ[3
M3KH:T/D-*%>%=5XKLWRLG1J^[FV)GKS-C1.??%K4*F1YBN?N3*BP<,FF5H!&
MSD9MM($Z4F`.3`CRFU\Q:;S*WL^\LM,?<TO7:RV.1P&#[669\#!4UH0Z-Q)X
M5I@OL;4^47+]ME?ZG;VQ=;?V7M(`YV++F&-MQ,7``5;V,D>7IJ3BIZ5XJYRX
M-:B6HUTM9=25UPVD_!^\:RB;^"R!:+]7GT()UXXG03CYFD,+HA14)S_P0^`.
M]N%SS)U'5K:$Z5;3P32S66:I!#Q<RSQEW#!S6Q"GE)J"%SJ'E-I^B33.UNYA
MN&00:D:`$93:16\L(;UM?VY+NDT%",58Z=Q47PM;KT[:8-M8)^8H%(DRUZ-=
MQL/!.9N[9MEL8Q[\LEXG<2;$Z;5-`RR9A5;@4@[I`.(FU3IO,75W0MN;^+MK
MTP,<Z-N%";O[N.)_<`=_U>3!>O5.4>W77L\&E7$4&DQ7MS%VDH)D+8=.9>U&
M4M!/:N<RM/H4PKBNR;C"F6IWEN<5H3PCC'5&6844C@BHL;]/Y>M.-Y!=S8F4
M0[E7<.B6$W]B+154R9`W$><-LT=S2F<?[R;.86C;.W<YE?6[6:YDMW-'6T!@
MRX5KQJ,%:9R;T]U-&M[B%U^_49(V3$&O8,LHKMIQ(`?60M()`RBF!Q4EWG,-
MOF\%8TOE0(^QM8,AY$QQ5'*4G$,YB3KS2S7(]7FRI,)U@D@Y4,1,RC51=NF8
M4S$,)"B(AK9-7W/JUYL[2=;LS)IFH7>H6\#LQ!R-EG,3G-Z`6MQ]:HXDA:YM
MG9FC66^=9T;5Q'JNEZ=I]U<$1ES<Y@M^V#'$$.J3Q:P`4&$G7KM>^+#(='I]
M(2?6VNA98O,&5H.WS#N%BV0W2@XGMD?7E46L5NF91LY8$)<NT6H$V';'YO=#
M:&M!U3F7K>FZ-9S37446I_W*[;-*YF<.M;2?LB2#@.U:X/S=;<,,%TC1.3VU
M]9U?4)8K&ZDL6:)I\EM#'+('1W]_"Z;CVC32`-#:$D@2>L":$94SS3EZ>S^\
MH,==Y.*K$YG&[8PCW+C'U;4J\77(ZC%L,,Y@+<NV,XE<@(/%`5!@ZWVZS4!$
M_)K+1[UW?>;V.B6=VUD$FL3VC7&"!T78Q0F5CF9HR1(06YL<IK]$+'7O+_9&
MD<O[C7[ZT=+JT&@6M^X-N[HS/FEN60/9.W.UHB95^3)ZPQJXT7:QCQ$Y,AF]
M'1O1E<B^D>ZVZLM[`_\`-:@PU<\TL@O:2A$Q9X^(*UEK)+L2%DA;OUV9%@0.
MBU4.L8$AC;N^=9L)+4:VXW,]]=S0EV5D3*LN3"&Q"-H!DR#-E<&M.+C+4!BQ
M^\>6NV-5^^.T!T=F=.TZUN#$#++,1+9MG+KB21SBR$R.+&F,2/8W%T8;5Z]"
MS$*4QBAL,`"(;=FS;L'K>YKN.7)5N5S:$BCJ9A0]-*BJ^<`&@`-`#:#`<.'1
M7B.H](Q5.P.L'O!J5*;`ZP>\&B)L#K![P:(OJB4@K(@<`W153`VT0*&[O!O;
M1VAL#9U>4-0*AP#*]H][&`]0<[UC\#<Q'E&."MRF01DBIREI:/WG5Q!\E*<%
M^4#B6S7QF5^.E[%C3B%MK/+MDO-IM$5!K6!,L.ICNO3#MQ"3$-%MI-.NFF+;
M'T*=F*5%'8@Q-CR-E%79';IVP60UOD])K&N[DU.QW>Z&?0].GN@'6F822,$C
MS;-K(7M[00F-\YRAKB2&!JV#F-'8:;IT,V@YHK^X9"&F;%C7FG:..7*2QQJQ
M@!J'8N)&"_59%*G<Q,0Z6=L9%5W$Q;E62C`3\622SA@W66D(SFC*)>+GRAQ5
M0W3&+S1R[!$-@ZV9Q!)(X$^98(->T!LF#P*'S]/RKO;`ZP>\&H4IL#K![P:(
MFP.L'O!HB;`ZP>\&B+G=#K![P:CS<47G)QH9;4JD+EQ1[D22IC?&=8Q^M5J7
M6[*A5;+D2>NTL!IZ>*Y(<DI,L*E7B<RR9)@=D#T'"SM)<$TB%WW;>F-N/N[S
M&R1YPD+A5K7]6'`>?'RK7-7NG1G*Y[FOIA0JT1>1;3.8:E(.D9@WU+;A7%5^
M@;G(7!564Q3?)ZYP-8LM.D+6(2DBBREU9)$T>U?'67;.3N6^^#<2`C$UO#'J
MCI+B+*QI<W)3!WJDU`/514Q74TD`;;O);TDG$'X%U+/+\;\;$M9"8S?PW1\3
M6$H.PJNX2?9"]E4(=ZCXP4F5C1BSB8K<Y'1[DO,I-C*KK`X$X_`1YJ]''M>2
M1S1:3ND$KFNS4`HTM`RT`QQ-:UZ**V#JH=C+'EIAQK\.*MMGR!QKQU<3M./L
MAX2NQ;:B#B,;'FJL"YGCR.C61UH1G(MF4="1];=0LH)Q<G0:K'()EBBX,)!B
M.UVO)=EES;W$=N#^Q$Y^%'5QK2N;)AT`^4*3)J@;2.2,OKC6O#XUN3@8N?7+
M60E<U6RBV)F]CFGF^A1$(56/1D?'EA/)+K2D4ENNBH0XQK8A2J'3!5-;;\+X
M1M<UAVF,RVMA&]DE`"7-+37IP.(H:\5F+-E^^(S3R-[$<,O'RUQ*V%V!U@][
M6"I3!>\<$V!U@]X-%*;`ZP>\&B*M-+G%$TP`H"H<I`$0Y`WC`&T?WMNB+49O
MQ4,74<\E$:>Y%A&C&RK]Z>4BTP3K\MD,]19-6\0J])87L\>!3&2451:J,$%M
MC90Y3#OZ(MNE4@2443$`VIG,0>3W2B(#[G7#1%\]@=8/>#1$V!U@]X-$5)TC
MJIJ)(JE;+*)J)HN3)E5*W6.0Q4G!DC"!52H*"!A*(@!@#9[NB+SG9<8E[@W;
M!"RUFOS"CE.=JSF&!5[7)<+OBVCOG&0Y&.`6#MJ\A9+(S0T:0@&46:I$`R:9
MBF$XD65R'%Q9ZT]D&-@I5=57BGCY.08DLCQM)KI"6S.AD*H@I7F_C6FTYM5S
MA,2#D$E6X/FYA#J[Q%*F(>(8N5<@S543B*ZRB&]>D9^OR$58E9Z2F&498209
MY)=%M'E8,(N0(X35:\ZHFHN4040Z0D8QT2+9O8'6#W@T1-@=8/>#1$V!U@]X
M-$38'6#W@T1-@=8/>#1$V!U@]X-$6LG%]F>Q8`P=-9*JA(`TVPGJQ%-RV1(Z
MT8*4S(]&<[R23QB<ZX)%VI[%`V#R[!US_F9N?4-H[6DUG2VQNO&R-:`\.<TU
M#CB&EIZ.M=7Y+;)TCF#OR#;.N=N-.DAD>XP@&0%@!!%013K)"\CQ]:UGCN/#
M([.K_HIWU?K1KYC/ZBM_`!K+>T8_*"?X4U#7A2LB^RS^D?EE1C^UU5S'Q-=B
M(\"2X$?Z?#`)[5G/'<6&?HIW_:?4>(KF'_*M?92_;3PD<L?W]5^*/^FGM6<\
M=Q89^BG?]I]/$5S#_E6OLI?MIX2.6/[^J_%'_33VK.>.XL,_13O^T^GB*YA_
MRK7V4OVT\)'+']_5?BC_`*:>U9SQW'AD/_JIW_:?5#OU';\CRFYCLQ&YP;C#
M,14X#A(#Q53?TC<M#7(_5:@$X"/@./\`Y:]!N!KB]N/$T-ZBKE6HE%[4R,)%
MO:JDW52JYFSXXM_$,ES[Y\+>>`Z9ED0(<W.H;V\4NX`F[ARAYEZUOJ6ZMM=M
M1%+!ERR1M<V-X<2*#.7&HI4X\%\W<^>2>W>6(L[O:]Z^:&ZSAT4S:2L+6AU3
M0-!::T&''I7H-KN;V&-U"01T+YL'`==$U0B:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(MEZ'_1:,_><?\`>5=2KXX+`U?SOR/XD@_N
MW6B*8]$6%9#_`*.2'\@K^#T15XR_-_4OQ*T^Y'1%3>:Y(V%*,+'"V`[-=PJI
MTA0R8;%$R%()-U,^\(&+U!V:FN!;T.%#YE+7%CVR-P<T@CSC@M4V?!A0H[Q>
M+.F02)HM]$2#%0)F9%5%W!6N5N\4H*IU3**$:6B;=.@(83$,*NZ8!(4I0U.+
M8^U(:=E9L!;2AS/J,LKIA0YJU$KW/KY:<*!;E)S$WH]CF.OI',>Q['#+&`6O
MA9;N%,E/6AC8PTZ&U^D23UH3@GQ]7%>>AZC&-C!/0%E("ECGW1$96K2DS,UX
MZ!73I8J#.*D9]V=-N0`1V+;HEV`&K=GL+:=A_P#"6F3^)&__`%)CZT3G.C(K
M(:97/<0!ACB"KE_S+WQJ8:V^NLX;`^$?PX1_#E8R.1IRL&8N9&QI<:N]48UK
M7&K)P(522K3>M5]JVJZ:3FI(&?)34Y).?-RLY$+D@U:;BY>$49-GLTHN":R1
MRJM06^]CND*77AO^7F@W%@+*QA[`B1GK!\E>R$G;.;4N)_U275K45H#3!9+2
M^:VY;35SJFKR?>21*YH+(LO;R0"V+\H8`286M8006T%:9JE90'!1C\L,,&E4
M8Q"/"!AZVCS%CL*;]O&5^R.[?#*-94CDL@WEV%G?K/BOB*%=BN<1,H(<FLD-
MC[49#]UCM!]V$;(P,\GT(WNDC!.>M0]Q=6M23B2%CCS)WLZ[=?F](NG3OF/\
M.&G:/B$+CE[/+0Q-$>6F6@P'2KY)<)E<EJ!$XP>P+`:7!.8Q]$1K>PSS-TR?
MP[P\C'R"4RT<(3/C!&04,N*XKF5.L83F$1U[+C;&A76C1[?N(`_2(GAS(R]_
MJN:2YI#LV>H<2?I+'6F\MRV&X)]U6ET6:_<Q/BEE#(ZOCD9D?&6EF3(YF&4-
M`'$4.*L[;@MQ^TC5(A*E5\8Y6FS]`4;+R\R[YRKVJ54G+(W46<K*N#R$U+*F
M7</1,+Q0^S:KL``UXCL7:3K:2S?8Q.MI;1ULYKB]U87G,YF+B07'$O!#_P#,
MLA+S'WM-.RZDOY.WCO([II#8VTGA8(XWT#`#D8`T,-64_9KBKM&<)-7AUXEU
M'5Z-;N8.[&R+%N`G)E55M<CP)*PI,F,JJ?GU%8),&YDS[R)@Y1)O"(Z];-J;
M>C>R6.V:)&7+IVD.?43.C$3GUS<3&T-I]'"M*XKR7.^=VWC9&75[+)'+9-M'
M!P80;=LO;-BIEH`)?7J*.K@33!61QP3X^=!7P7J$68E9DY&6BT"V*P)ME'<G
M:2W9T24;IN2I3+(+80L@FW=`JDDY(4Q`+LV:\G^Q]JU@(M`#;N<Z,B24$%TG
M:N!(>,S3+ZY8ZK<V-%[6\R=[,^\4O:FZB;'(3%`7961"!N1QC)C=V([(OC+7
MF.K2X@FLVFQG93&$PJ1PB(B(B+I3:(B.T1'^;]4=;8M##&```8!<>C*R_'C>
M^E/!M%.5J>C*R_'C>^E/!M$RM3T967X\;WTIX-HF5JLEFPG,VNM6*JR+DC:/
ML\#,5U^YBY19C)MV4W'.8QTO'/"-A,T?)(.C&24`!W%``=@[-F@)HYC3ES<3
M2O01_@X_&JV$QO;(S!S#4>0KR<R3ZB^F9-RA2,FSG$!FEE(42UM+@R8P[NCL
M#O9%G&L6#-)23:5!L5DSA2Q:"$6V1;%:1L29Q&IHF;.#;N#V1H]CRWO-5N=O
M.>Z36HH87!]2RW^[C.)&%SB<TOT'GB1Q)Q5_<=S<;JL;&QU9P9:Z;(^2,L`[
M21SZYB[`5%#E:TU:*`@`XKU&QGP[2&+L>4S'$%(*R,-2:^PKL8]G9(KF5<LV
M!!*DH\4:QS-H0P;PE(DBDD@@D!4TB$3(4H;!-/)=S/NI@T2RN+W!O`.<<Q`I
MA0$X4Z%XV1QL8&1@Y``!4DF@&%3UTX^59QZ,K+\>-[Z4\&U;565J>C*R_'C>
M^E/!M$RM3T967X\;WTIX-HF5J>C*R_'C>^E/!M$RM3T967X\;WTIX-HF5JUQ
MSWP"8TXDO%#G*-99/)N`;+,8:T0TPXB+`SC'+I%ZYB#O$FJB+V*7=H$4%%PD
MJ4AP$4]P3G$<[I&X+S1;66WMGD1RNS.;AZQ'E(J/@(6+NM)@OC6X%7]>.'Q%
M=>H^K]QA1,:SV*JM6T8FN6QS!O+4^1LD@-HL#BN2#22ASR$\=`R_-,5V9`(B
MD5)`I!,`$VG,(Q>;DU6^O8]1G<#-$"UH(``!%#]$"N&&-2IATBRMX#;L-`34
M\5#45ZI'"T5:9&QCYRO6B[!@QA*\YM@>+ZST./D8Y1S$NR0_C`5UR2RZA1.8
M.86/OD$!*79DW[XU>:-L9C@9D<75#1B74K7#R`KPQ;<A;*][G$M=2F)]*S'V
M7N"]^6.%:D><G$C)2:YKI)*+K%.>746*FLLS4401=#...>2(((K&,4ZA#G(4
MX6/]W:Q0M:Y@:0:@5`-2TGA3I:WRX*^-OV[79FDUI3B?2MBL7\,;/#U,84"A
M-D8^KQCN1>L6;Z9=R2R*TJ[4>O=CI=N"@)J.E3'`@`!2;P@')K"7]_<ZC<NN
M[HYIGNS$^4\?*O;!9?=8NPB)R#R^E2!Z,K+\>-[Z4\'UXE[0P43T967X\;WT
MIX-HF5J>C*R_'C>^E/!M$RM0,9V4!`0/&[0$!#^=*>Y_\VT3*U1]_P`+=>$X
M*'J=4.N#_IP/!*4'Y2C:RWD8P'X-.F!`#;B`_P#%^_T3G_\`L]G)HF5JD(V,
M[,8QC"I&B)A$PB+I3:(B.T1'^;^Z.E$RM7'HRLOQXWOI3P;1,K4]&5E^/&]]
M*>#:)E:N/1C9?CQO?2G@^B96J@V+)XYB&.E"G.GO@F<YBG.F"@E%4$S&9B8G
M.B0!-LV;PARZ)E:N#8KG3FWU$850_-K([RABG-S+D"@Y1VG9B/-.`*`*%ZAP
M`-X!V:)E;U+DF*YY(V^DE"HG%--$3HF*D<4$A,9)`3ILRF%!(QS"4FW=*)AV
M`&T=$RM7T]&5E^/&]]*>#:)E:GHRLOQXWOI3P;1,K4]&5E^/&]]*>#:)E:GH
MRLOQXWOI3P;1,K4]&5E^/&]]*>#:)E:GHRLOQXWOI3P;1,K5@N1>&*O9>K2E
M-RI2:-D.I*OF4HI6[<S2FH<\E&F.>/?&8NVAT1=,S*F%,^S:43#LUX[[3[+4
M[<VM_&V6W)KE=PJ%DM*U;4]"O6ZCHUQ+;7S00'QN+74<*$5'0>I0'[+KA'_9
M1X<_J)#?D_6)=M+;3J%UE;F@I]'H"V-G,7?D8#6:OJ```'^L_@*T''RE/9<\
M(_[*/#G]1(?\GZC_`&AMC\#;_55?YD[_`.^-0]L_TI[+GA'_`&4>'/ZB0_Y/
MT_VAMC\#;_53\R=_]\:A[9_I3V7/"/\`LH\.?U$A_P`GZ?[0VQ^!M_JI^9._
M^^-0]L_TI[+GA'_91X<_J)#_`)/U4W:6V6',+&VKY6`_(:H>9._S_P#F-0]L
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M23,19?A;/;?.=.OT]4X449FFV%Y7VL3(KJ-VTH:7HU5R?CQ^X7%`R\>G9*)?
MH5PZ3$ISLG*ZR.T_-`8Q%YQPOK@H!RZ:+3>(7\?$.EL<J-%(R?"5EI./EZ/(
M)Y9\71ZL='-A?XMX@1C:$H"[A%!=W(E<J*(D*)-$J5M%>?6/X<H=?J5CD*'F
M&087'&^.\E1Y&%5ATGC1ME"6M4/5*I(Q\K9(V02N2Z]%F%%6R:*K=)%B(BOO
M*I$.0X\5#S'UM&,5J[4YFPXIR71W%L<V!U&M)<M3FM^OUO)J]+<&6;5VTNYJ
M(L$K7$`E&K9^S:HD5.+8ZPF3,<2+8B+X[J%+U2N6)IC;+!I>P7:S4Y6C#'4X
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MZH/CJI&.FB`G(K$X]:3C5).Q.D<6987:L:=5<@L&ZD76&TDTH5NF(:I0][LJ
M)KB=)K7']PM,6V(BQ,\ETVJZCA5D4J0@)%9H#UJD`Y=1S&P\.>9(H4<;TJYW
M&29O<=/HJJS-TC*Q8F4<]>KW5FS:5=2L6IL\2F7J[-(%54V:Z2+H^X!%LO<N
M-_&-&R?%XSFJOD0YIF^T3$\=<&$/#.JJXRED*&J-JA:0`^<"<^5XWIUV8RCE
MYT'Q<1#G$B+J.2<R)%K<W]:UC]_"7"=-A[*5>@8M:TC4[A825(M5L<57Z%5;
ML@^7596HTHVEWY+-S8PK1%[*(MT@<BGS1C"D19#2?6>8WL^4H#'$AC')\&.0
MY3&_HN>J145).YVD9)C*<O"Y*L$?$S+_`,W:JZE;_$H)IB=:210<*+.VS<K=
M7=@@$4/!/+TK-V/'E&6[.6)<*4+%MQ>&R/>+A%KW2QN*W$P!<?4B.RVTE;[7
MFC6P/YM^F[O&(9"*0:/&S%V"`D>&2%)5(#RBURPUZVJ)NR4*TNV%;!$6EWB4
M^5)JJT><B[/)0L,U<WVRR,N9:Q*T]HYK#;#=78V%)8JG3GCB1Z`V;++)B(D6
M42_K6:ZC:ZV$/P]9=DL3S=.?9$-D=9[0&+]Y1HJ.SJ\E+)"TQ6X>,S,&(8,>
MKD(^59O'31;:DWYX$DEB*3<G>L3H.*^)F>P',0/CMM!X[@Y5!W79N/6N\SE:
MP2,`[B\:QE0E%(E@#=Q1[0SE1DG$B@F3:H0Q-A!/HBL#_P!:Q@R$4CFECQWF
MN#E)$4WR4,>M5J8DRU5.6D:S+7(4:Y<)A(T-!VR)<,'"8'Z:($!R1$S406T1
M7NM>L?I5@>7)$N),JE"GP];M4R@9*A1[JK5:^4B"MV.5K>M+9`9Q#:3O:TFJ
MW:ILG+Q-F9,O33MA$=$60Y+XUU6V!N'S-&):4[FR<0N3:GCR$B;3#VR1D:X2
MP1-WDI"0?UK&<3<;).NXAS256XMXXBQ#%4Y_G02((B1=&:]8[AZJJ0\5,5+)
MTK-N*CD"WS):]5X\&45$8HFLJ5R_R2R<_8HB21:LI?#LP#5`Z0O5B*-2BD55
M4Z:0X\5%!6M,5C=F]:1A>DN+4SN>-<T5MS0YZ%H-T*ZA*6^;P&6K4M<T:?BT
MSF'O,D23G;06BNU$'S,%X1%-=J+AXD982DB@Z@I6:Y]X\:MB3A1IO$Y"5==^
M3(KNL(4ZEWU_Y@R2_C!K)62SLY=91K+&CI>OTFL3#I)$A%B.W31)$IP(L"H,
MK>H(OG+>L=PDU-7_`#?K.2[FWLCR2)'RE?AZVA`$B(JY6.DK6%[8I^UPL''1
M3^6K*W0#.'"0OA7;I)ASZH)!/!%%,=ZU:@JXR:7VP82RS5'"KN%@Y-D_=8\?
MQD39;'#5F8BF2;QC=AG9^,11O<$+UVPC%@:DD!$Q1,BH4"+/,$>L8Q]EU^SK
M+^I3\%9CX^O^0'R[5S`O*LT2QJ>*/;*Z$BYG6TPA+1[6;;*)KOF+%B[*83)K
M;H#L(L?CO6IX4DD45D<:9K`#V5AC]<0A:.NFCD^?E+W#U+'J2[>_*I/I2TOL
M=2)6[]`5(9`#(&</$2J[2D6`Y&]9W-X[J>,KI)X/!K%WK$_$U>9YO*W-%H]H
MEIPID&)QQ1:G,F81LG&K-<@6F5)'.GJ+@Z<<_<-R)@Y34WP(L_K_`*V#AJF2
MNE'$-E6&CV[IMT:=E:@T;P,S!K+*)N;5#2/CK8[@X=$$UG^TA'3)%PB*J0&/
MN@199E[C0L>)[3!3+JDQLQB(^.ZID*^MFQIMOEW'B.1'T93\7U^8B3HC236K
M(63YU&+9,5))#FF;&2>JK`DSV*D48OO6Q8E4GZS'0&.,BO6TPQ9S+H)<U/K\
MJO#R].M\W$$AVDA;",D+`E9ZFK%OHV7<13MN'WU,BVU,AR*Y/O6I8KDZM*R]
M"Q/F*U3#RF6RV8XB%XVG0J>0@HU4F[;<4VKIY<^=@653C810[Q5^FV57`!*R
M3=*;""19#)>L-857*,[2K9B&Y%K,'A;&6975MK#RO394:]:(A>>R#/OX]]-P
MSUK6<:,W4<DH5-)>4D57*AFS4Y$A$Q%G\MQ]8VAL=8^R@]Q]E9.L9`J5FR8F
M48FJC*UK$-3G*A797*%C8$MY]R#/(WV)%!BT.[F54'0J=#*"2H$(L6H/K*\,
MW[)-"Q2VHN78.X9`6KJK-G,5R"<(0<#>*I7;ACZS6-U7;//-V$3<8RSMB)@F
M99=BN!RO4VX%WA(OE"^L!8WG,6.L84;#M[7CKE3<CY-5M-E=5:%1?8WJ<+-G
MIUCJK!"QOW;L,B6F`<LD$GY&+ABBCSSE%,JR8@10W3O6Z452A-[EE/!>6,?.
MY]?;1J[%FJ5V>6Q)O7:599B-9.(BQDYJ>@8ZY$653631;NDTMC955<3(E(I;
MLOK$JY2,L98IMFQ7>S4K'%7I%V3NL$$"]76HTU6Z78+I>YV#D9Z)D8>$ISC)
M]?8]!32<S#I9=PH1L*:)A`BE"C\<N+\AW$:;6JIDE9PUQ>;+\Y,.X6#9PM>I
MAL?XZR*S5D55+*+]>3D8K*,6V1;-&[DPO.>`PE12%<2*`[+ZU?&,/1KM:XW"
MV;)&7H5(JMSLM6?M*##NH%/*E;:V/!3&<D_/E_')CEM*1;I('8FD#1!S'\8D
M;[@@)%W&'K6,+2BTLRC\89N>OX$)%Q,E0K]22CF<9!62.H]DEDIB0NC!C(MH
M&\OQC546PJO#<WSY41042.<BP5GZV:HJTRKR<EB"WP=UNKBJ-(NJ/I6L.H^O
MR=HIE4O32&M,Q%3C^1`[BO2SY=L^91Z\<KT5-)11)90Q$R+*\M>L3=XJG,C/
M9.K4U"E5?(EWQ!56DM-6YO?+E><>Q58DYQZQ;LZF[IGBMRK8%$DH\TDC*$8M
MAD@*LASB*1%;X/UO'#ZZKS"<GJEDN,9I)UGSFFV<1#O*Y&$F7HUF9EH=9U/,
M)VS0M9O:"T8ZZ(P4?$3*1V9N5NLF<Q%G[/C4R/>8VL-L>X;85BV7/B?D,`0D
M-F&RJ1A&L,PX:Y#B,:VZ<4H2%S*U<S4<Q(R2;-U7!6Y7!5EC[Q#H:(M;4O6_
MPUA!RRJU`@6DU(4SAWD:Y&2UIF[#)IW;*MWPO5\HUJ6KE*JTI9))EBB,SW!.
MVBL6@Y=SYT7B23='F0,8BGWA]XT\L9>OL4QL..\=U6A&PS>LOS+UC/W9]=",
M:'E6Y8A<LV4!-U:O"Q6F9:H#*)MI,K.2CVKD&3QLD]15*!%=(+UF.,K-)QE9
M@\.YV=W67B\>RC2IKQ&.F3M)/+S>M/\`%#5]*N<DDK[1Y=XJUMG29>E&*P33
M7*],W42W#$5%<]9_A6W.*L%:QUFJ7C;ZH_1HDTG`TEA'65>NG=MKRB`S5_BW
M$%Y@R,:Z;R2DD1HB8S8YVQW"6Z<Q%:F7K3<12D?(2$1B7-TJG!.96-LH-&&-
M^;@9F(B,K65Q&*NE\DHM)/?JN%K!(%<L3N68D002YWGG":>B+;'`7$G4^(8U
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MU3KM2/.V-T51)=R<'`E.J`D5@M%D]7+C3(V9HN]\,K.N3V,YN0=2$TUQ3(3=
M?M2+2I8NO5KG8):.1-!,G]8:9=CO&J"G,J-TB`8#&*":92*59K,WJ^K7ANVY
M$GJ7%/L5XURG`KBI+8WDXUI.9)E3-J3"OJNRDFL<I.NIA&-)'*I+;@*LT2`Z
M1Z,HD*A%B=5SIZNZ!!^KB7&);!/L3*661BZ?AZVO)2!<00T_)K!>QKJPZRU6
MC(4L=4IIN"FQM%Q[^%=IIIM5T#:(NY7N(3@`4JN*D&V-(MFME6(;R4%2XO%4
ME-E8=-L3)E.MY)9A$JQ@MX>X8):)N#%WQ='K[95!)8A$]$6`HYV]5RUQ[1XZ
M?I-.B(O+BL3)*U@E'L$BNB_KDU8&2!YF159-),[&`5E9;HNT""Z@7"O,-S,E
M>:$BV!MB'`!PJY0824MCNC8VR.Q:>=<+*PU#D"J,T)6L7]=Q+0J\6T5C6AGD
M1C>2:NC(%(8[LS1NIO+O&H*$6G^;\B>K=OT?2+4YQ]?5EL:Q=7R#%5"`H=@Q
M[$6W$,/8:*G6+C=GTG7BME\*QSUTQ=1RRKAJ1PHV41(!C;R8D4AI9K]6QDJ=
MN$5?L-,JF>JNZ?6X=]<\8V&O.+A3;)B*LVR`FX]JU8-7B-+4I<"UC>;=&YLS
M%%LDH0$GQ$CD6/V[BQ]7A;YQM;;_`(;+)$LD#::Q.7YQ29I&,CI?&4W0&D!C
MN-?N6$"#G)XHV*"4(DT!N^B&Y4T%''-("!"*59D/5MP+R`Z+@F*GTG=-Q=,5
MXE0PU:)Z`>)91@XJKX:IQVC!@$&G>+57&C8D,P>ID70;H@??1.(")%C=3S+Z
MLN&FX64IF*5(\\;<&EC97&-PK=F\'!6EN[QO`.%Y"848$19IT6<OE4CW#54I
MFL0_<LB))%.T$6Q%>XOBS]7CCV7E\M-J5)TBQ2,JI;D+;,8@LU?E)^T6&*K[
MH[:K/IEJW;^/IVK9[9RQF;<S8BC2RK.#E!=5T`$6+R>5O5L6:,>6*OX+86QC
M7*Q3H8;2AA.Y0=8;TFEV>Y4JA1;ZWMJVH="HEFG%GC(M)5([%^=)ZR,`D5`I
MR+,:_F;@.O4A?IQMAAHO$8?H->H,O**XTD%)MNWRUDZ_8T]$D?0VK!Q,KJRE
MBL3HYTR)'3,E9%"#S9C.2E(K#:>,7@QGTX-*0P=.7ZPS6?8^8-#Q.+IJ:`,S
M5^;IV-I>PL)UY",FTUDW'M=L$&+U@D)7:3%PF@D*A4%!3(K]B[+W`/Q*7R'H
MD9@J1-,N)^2;4]Y9,12D=!V.%@X]6X,;,WDTTA15ITLXN3I9-!\`%3?J;SQ!
M%11H=0BW,L?!]PNW)RA(63!F.YEVBR;,D7+J`0!4&S*#BZY%")D^:$SB$A(5
MJA'K&VK1Y4"F;'2/M,)%V"\)7#L%//C\<6P)J26XQ]_85CG)(D7!7"+B$X1E
M.UM))\FK77B3`IP$61T0,==8Y@$RR@F(OI#<)7#5`2LY.1.%J$VE[*QFHR=D
M3PJ3MU)QEC9S3"P1SA1Z9P(L)MM9)$':(;$W!G[@YP$ZRAC$6$Q?`;PHQ-GF
M+6WP_7EW\S5(VFG;/^DOH^/BXYU<'IGL8@X6.JWLDBZO4DHXE3*'DC&6VD6(
M.]O$4O5C`6(:<E$H5^CP[1"O2LI-5INJ15ZWK+Z;J;2CRPUU!ZHX2AD9&JM.
MAK$0`A5$U5A-M.NJ8Y%&37@:X1&.^#+A]QNS(=6*4%)K"@W0*E#"Z,QCTVZ2
MQ$4843/EQ78$*5D[%=45TE!4/O$5Q=\&'"J_C&,*[P/CM:)C9B3GV4>,&F5L
MA+3*4,E).>;(<O.D=$KD=M2/O(E-'-3%(!FZ(D(N]#\(7#%7YF7L$'@['<5+
M6"$G:Y-N6-?:H)RL):(M.$LT<_9D`&3E"PPR*31\)DQ,Z;((IJ"8B*0$(ODT
MX/.&!C7I"JML(4%.!EGZ<M),30Y5A>RZ,?.Q:$RN\644?FF6[*SR)4W?.])3
M.]64*<%#B?1%=WW"UPZR=-;8\DL-8_D:0SJ<M16U8?5YD[B4J?/6:%NDU7BM
MW":FV.E;?76$HX*(B*K]HDL81.0!T1=4>$WAJ.VD&:V$\>.FDHYLCIZV>5UD
M\144N#5BQLJ2971%NC,I=E&-T5&R6XV*DB4I$REV@)%][9PL\/MYM-BNULQ=
M79FUVYK%M+-.+^,$'DXG!L4HV"5D>AO6R*[V"9H)E8N!)S[,4RF1.0Y2F`BP
MTW`IP?&,8X</&,DU!<-7:*B$"1NHQ=LECNFKN*.@HF:(=(O%E5P4:BB<7"ZR
MHB*BRICD5\?<'/"U)55I2'F"<<*52/;N6C&$3K[=NT:,WRYG#]FW%MS*R321
M,H<CE(I@3<(J'24`R1S$$BRBS\-N!KH\BY&TXII<T^A5JXK&NW<0CSR!*BV6
M9UQDH=+FQ=146U<&3(S6YQH<NP#IFW2["+Z6/ATP;;HBD0%DQ?49B#QN)/,:
M(=Q:1HZMHDZ(/06#0@D1-%J*1[8ZC14%&JBK9$YDQ.DF)2*AGPWX(CK'6K?'
MXJIK"RU`K`E;F&40BU=Q98BOQ=5ABI\QN).`A*_"-&K(%BJ=#(W(*.X8-[1%
M]ZEP\X0HD\_M%0QA4("Q23^;DG<RPB42OS.;(3<FTT%E.<%FPD`,83M4>;:@
M90YBI@*AQ,18L7A"X9"59K2DL)4%&KL3/S,8A"&(@@Q&5=Q#R3!DLB<CIJ21
M5@&9%RIJ%*J@W(B8!2VD$BR*S\-^![G*L9NTXHI4Y+1TI%S#9\]A6QE1>PD?
M&Q44#D$RII/F3*.AF:16JY5&HE9H;4Q%%,2D72IW#%@;'3"PL<?8RK-)&T0D
MS7IE_7616<JYB9YE%1T@S\9*"N[!#H4"P223WA3128-TR%*FB0H$6!U7@4X3
M*A6JE58W"%*=QU,@EZ]%JS$<$H_>,'<(A7G9YYTZ,8T^Y6BFQ4TSNP5!H`?S
M8$0V`!%F,+PG\-U>/)*1&&*(T/+MA92!AADW(N&)G,8^48_SLRX(L%I&';NE
M$$]U)1V05S%%8ZAS$6.M^"+A):/XV3;</V-$7T0NP=1[@E?1`R#F)YTL0X$N
M\*:Z\0BX41:'4`YFK=51%(2)*'(8BR&V\)W#;?;:^O5TPO0K1:Y)P#U]+S<(
MB_.XDO%;>#/+F:+B9@6;7A&:+)5\5(':S1%-%10R:9"@16%YP3<)DA($E7N`
M,:N7R2B)DE58!$2))-U&+A)@DVW@;)Q`/XU!X+(I`:&?I`Z%,7/WW1%<S\(/
M#.I2FN.38:IGF4RMZU_:P!62Q&Z-U<0"U47LQ7)'!7XRRU6<'C#JBJ(FCS='
M':CL)HBR7_AOP(5O5&:>(<?H-*+<%+_36S:LQC9"KW19ZUD5++")-T$R1\J9
M\P;J\XF`;#-TM@!S9-A%?VV'<:1[B8?1%/A825G82TUV1F(AB@QE5(BZ6.6N
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MWCM.58Y$H]-03G2;$`K=%154Z9"G55$Y%,6B)HB:(FB)HB:(FB)HB:(FB)HB
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M5]CC9A%R)D.D2;.S)MF*`'65VF(LJB8_U;=&R%C1HDM-'?&QAC+,>*K=*V[,
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M94<<2S^K-5JJU.JRBI%--0L2*Z2JH'(K&[@/560TE+4V>G*Z_F8.Q3%.D`L]
MJR[8'ZLJVB*BQFH&/G9)Z[+-PU-KF#(ELXZ"X780#&(YM4S9-=;GB*RR[?U4
M2[QU*+S1F<C+R$U8@80S_B!9/:W;[:^0LTI;F%4BT.?H>1K<;'*#IN]Z(TE)
M!A%$,U$[8!$Q%?LA9`]6.O:ZBA.7-V67<,J_2Z[+TZP9G8P$.CB6N66QU"^M
MYZOO&T&O*X^:TU[&,+8@J[>,I'_1QG(+G.D!%E_BKU:=8I-.,+RG1M)OM=L5
MEK3U62R&JW>P41/8YD[1-V%^HLJ[KRWGAAV`3=*3!V:[B:C1:_#=K.4E2*-+
M!>/576,]3J)7RDR+V2?-8:0I,=FQP[HD]6,8TE99*0G()H65I=P;47"<$T1:
M'$DN"C(J7,E5<+BH17RL0_JP\S2=:Q?!FC),EE;NJM7:G'6O)B-<O$58G%RR
M-%*6`(:8\4+++R,]97,(G/JH22#@[\C9,IO@@11SP^9=]6TS:Y)B(6KV+'+)
M28H:DY(7BTS5\/8S8NR->G-0D%G%5O&1)6I&HEGPM(RLBSETXE6.B46[Q^F5
MFN!M$5DA$_5G5WB=7MR&6I1[&,"VFWPE317LYL&X_P`B*6S&1[5=7$HT2%P%
MENDO$PCAC(O!\4R2.TB#IR0S=$A%(E9E/5=1\S%2,9:WU-4J<D2>JR![_FN&
MKK!>-Q\#.&NC6/;3`Q55D9&EP+I",,[(PD)445Q227.L45"+<YOQ]<(:AV+3
MTW5\L@]5,Q;1:\/;6TRK,)6OS&6K9H5>NI2J%P3M8"T-"J(DE2B&^+?FOAZ(
MK=9N.?&-,O5YJ=KJF086OT6UV"@/,E+L*VK3)"^UG!#3B-DJHU10LZEL:.UL
M9.3*M'#R,;,W3Y!5H5;GN;*H11RV]9=B24FJ%7H''>4YB=R#7<5R4=`;<:P]
MEBK)F"S7VE5FB3%8G<BQE@&?@[=C:68V)=DV>1M?%#GGCDC<%%DR*0,.\>N%
MLQ4&<NS-"QU%_7L=RN5Y2E6E*&&?842,AVT\64D9:O3$[1XU^[B'J#D(]:6)
M((-5TEUT4D5"'$BR%_QS\-#2BW#(C*].[#7Z%8:-5[4%:JMJF)"/ELB7D^-Z
MP+9DA#E/,13JY-73([]D+ABFLP=%%7>0.4"+Y8RX[N%[*R>.D*[DILRL.4%(
MQI6Z?88B<A+.E+2U=A+2QB9AD\C2MXIP_B;"T,R756!E*'5`K%=R(Z(L;2]8
M9PW-D*:]L\U8Z9&WNEV^[U]_/5QXY(O'TFY3%-FX\65;-/RIY9-6OO9`")-U
M$B1355PHHF!#`!%Q$>L;X1)"?M-<DLJ,:L]J5E0JS]_96$BQK+IZY6=(HOHV
MVHMG-;<0B:B*2;E\9T1JR<NV[=P=-PLFD8BZTUZPC"C2B^?U;B;O;8=?,C_!
M\6(1T-1DI&WQE&)D-=525RC.T>%@8V0@C<Q%C*.&+B6E%$&C5)0[A$QR+KO_
M`%E7";#Q"TC.6VW03]"Z25`/5Y;&5_:V<UFAKP3'TPQ1CO-\Z#@8R>!8ZFXL
M8PLVCAP0#)(*"4BEN@\9'#/E*V1]&Q[EB$MEKDU'B3>'B8^P*+)"U:+R"1Y%
MPK#HLX=O,QS51S%JNU$$IAL056)G"8;VB+9DH[P`8.H(`(;?W0VZ(N=$31$T
M1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31%"BOYWY'\20?W;K1%,>B+';<
MQ,_AWJ)`$3'04*`;-H"(E$-G)U-$5DQK)L!K$7"@NFE)0K8L>]8JG*1RF=`Q
MB%5!(P@8Z*Y-ABF*`EY=FW:`AHBAK-G"Q6<UY"J]\D+!8ZM*0%66K1I>JNTX
M^Q-3Q]VJF1:78*[*N$GS.,G*I:ZN82\^T=-W+5^NFHF(@F($6=X1PPRPXTOA
M$9B1L,G?[\]N\U,RSAT\D'!D*[6:'6&;I^_<NY"3>1-#I$2U=/5U#K/W:2KD
M^PRHE`BU?4]5YPEF9-F9*S8R"PB,EQ,8X7L/C06!LG9;B<TOY,K":8R4+(2%
M6M\*@C!@]:NFT=$;\>"1VJATS$4@VG@1P=;*K"U)ZO?8QK7J30*)$2=>MSB"
MFF47C0U^5JKU%VP:IH)RB#C)4J=8Q42H+\X1,R7-$YL2*,5?59\*ZT*,2HPN
M2BY&31HSF'$U#/7<8JC8K98'\E&13^MNJFRE9TEQ<,':Y(T#>+FS))'F3,FR
MB9%+=PX'<'7FU6BU6!.X+GM]%C<>3$&A:'#>`-`1J-3:`=LT(WZ6WD7K"D1K
M=PKSX@HD@.PI3G.82+'([U?F#(;%T9B:"D+[`0,-9+!/QTI`S,'#V%LTM5"-
MBVQ54KF/K+>+\VY?'8EBUOYGXP.4A70NNG_SO1%%M:]5K@E&LQE?O5DR3=CQ
M19.$1%6Q%AH<N.G-RL%TBL4M(AHQ.9"BPLK/G5(05SR"BP;3.N:W42D4S4C@
M0PG2+`C;DG^0;);DY7&TLO9;1:B/9)^?$)T$\<LGY(^,BF"S&LQ;-!BF4$"J
M+MD"BN=58RBQR+M5'@>P]3,A+Y"CI7(3Y5S;[3?G%3F;,V?4Y:XVEOD&.5GE
M(\L.A)BZAH/*,W'L2=,YA)H[+SB:JJ*"B9%CL)ZOO"D.XKIGUARK<(BO(TM@
MM4KO<F]FJ-EKV+%':^(JC98)["`@\J^+EWZZD6T0%L"ZRZBL@9\JH<YB*S5W
MU=N&T+-9+5<I6U7`TE;LRS-2JXOTH"EX[J>;8ZRP=QHE6@H=!N=")E82RF(Y
M4.L8QUVR"B`-RDYL2++:YP&X4@'LS,NI/(]HLUDE*S,62UV:W%=3D\_IM:N%
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M^P4ZRL%9NV+2/^DJ(QND;7`61(S:MSM6C&^OTS)@0H'#FMO*F`B18:U]6-P[
M,3O'#.9RNTD7<?9ZRG*MKBP0D&6.[Q*WJ9NN,6QTJZ1NK3[4\R-)]*4<)KS!
M2F1!!^B+=$2$79@?5B\+-;@+55XF(MK.`M<2TKKB,9S[6+:Q=9B[15K;"0$4
MG#Q$<4&L-)T]D5)RZZ5(+(E.5PX7,;>`BN60O5VX+N\)D9JW4M$9/Y`2JKL9
MES./91I$V7']<FJ_0ITD2"S#I):^::,Y,@5PCTA9(@B<HAMT18=B3U96)*+/
M5[)-WMMQR/F9I=ARA:[ZL:*@4;;D<,BN<CM;"[8-H]Y+MVD>\63CTH\)(8\[
M%$HG0%<15`BE#(?`-@[*UFO$Y?7V0K!"9!O++)5AQTXM9$L>*7=M2JIC9[.)
M0C>+2?*#.X]J2<,];+O%VBC%X\*1),[@R@$7-,]7YPTX^L<[9ZC5'T,_F+]1
M,BL$6TB0K.G3./K[:LE1$91$0:@>JUB1M=XEU9&/;G!%ZC(+(GV)FW=$7%8X
M!\'U(C]G%/\`(GB5]A":X?Q@'%M*:+0H=@CT8N4/OMXQM*OYDS-'^;*/7+IL
MP5.JJU015<.#JD5\;<$N%V%'M-!BU;M%1%LC*#&/GK.T*#,LD\:93M68ZFXB
MGKMFZ2:NFMWN3U54QDE"KH&(D8NZ0-I%C=>]7QP\U?)%#RK#,[2A;L?,Z7&Q
M;IQ,,9`DA&X\IU9I5-82:TC#NI)%O#QU3:KCT!PQ.Z=&5%R99(_-`1="/]79
M@%C-)3*S_)<J6*C;U`TV)E+GSD30*QDDN0O/"LU1)K%M'814HODN05`T@M(.
MT12;$36*BW*GHBPR3]57PHS"Q_&3&]/8]RF_;/X9Y9VCZ/>QTP]/(3T:55]"
M.92)1GG2;7I*T<Y9O-QBBFFLFF9P5<BE53@@QTKCJ6QTID/-2B-BN$_<[-:'
M%UC7ECM#RST5KC>;B+(V>UIS3IJN.:@P;H)M%XDY6KAND[;F2=IE7`BB)3U5
M7#0+ULNVG,RLF$4\!]6X)+(G2HJIJ@H]7%.N&E860E6#59P_4571,Z43=J[B
MBY53IIF*19G0_5T8.QE,5*:H=DRG5G5*</G,"G!V.O13=`SB#\V6**I8ZHM%
M56<5`%(WYG?!*2,DDO)E?.DDER$6^X!L``#W``/>#9[HB.B+G1$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31%\U5DD$S*K*II)D`1,HJ<J:90#JB8YA`
MI0#W=$401)T)S(,O/1Y@<1H-&,:D[*`BFNHS*KSRJ)NHHCSBHE*8.0V[M#:&
MS1%+VX/[G_3]C1%4<A5"B4P;2CU0_?`0_P#+HBCR=QY`S*@K+H)E6]Q4@BD<
M.7:.PY!*;_!HBP\V&H,PB/2W@`(CL#Q@ZV=4=G(*W)R:(N/0Q!]V.^_G';=$
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MA#1%*D7#LHM`J#1(A$R@4/@%`O4]SD_\T-$5WT1-$5M<]4?]6=0?\IZON=7]
MS1%;?JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;
MT1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1
M/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/J
MWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWH
MB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?
M5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O1$^K>B)]6]$3ZMZ(GU;T1/JWHB?5O
F1$^K>B+[H]4?]1?_`,GJ_P`.B*[I=3_L>I_V74__`&:(OMHB_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>g5754313rd.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754313rd.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#2`(D`P$1``(1`0,1`?_$`*X``0`"`@,!````````
M```````&!P0%`@,(`0$!`````````````````````!```0,#`@,#!`8.$@T,
M`0$)`0(#!``1!1(&(3$'02(343(4"&%Q0B,5%H&14M*STR1TE+0U5387H;'!
MT6)RLC-SDS14U"5UE588@I)#4X/#1&2$Q"8W1Z+"8Z.D166%M49V)^2&Q>%F
M*/#BXZ57$0$`````````````````````_]H`#`,!``(1`Q$`/P#TKN;-'"X9
M[(AGQRTME'A%6F_C/(:O>QY:[T&TH%`H%`H%`H%`H%`H%`H%!\)7QM;V+T'&
M[MN2;V]FUZ#BZ96E7@ALJL=&LD"]N%[`\+T&&ZK<7B'PFX9:TBQ4MT*U<;\D
M6MRH.+JMS:3X3<(JOP"UN@6OY0CR4',G/ZC9,33V74Y?F>'F^U0=3*]U^&/&
M:@!RW$(<>(O<^5`[*`PO=?#QVH(XB^AQX\+F_-`]S:@^(5NLDZVX"1WK%*WC
MV]W@4#LYT'.^YK6TPKV'&[O.YOPMY+=M!\/QG[!"_P"MH'^U'D@_+>H.*CNS
M3W4P"KM!+P'R[&@XJ5O#Q+)1CRW\T5OA7RM/YM!Q0K>FE6MO&A7N`''R#[9T
M"U!]<5O(!7AMXY1U#3J6^+IMQ)L@V-Z#@I>^+]UG&$>4NR`?H9H/FO?7]XQ?
M[;(^ET#7OK^\8O\`;9'TN@:]]?WC%_MLCZ70->^O[QB_VV1]+H&O?7]XQ?[;
M(^ET#7OK^\8O]MD?2Z!KWU_>,7^VR/I=`U[Z_O&+_;9'TN@XJ<WZ`-,?%$WX
MW>D#A^U&@ZB_U&LFT/#DD=X&5*%C['U.;T'SQ^I/[QPWV7*_@U`\?J3^\<-]
MEROX-0/'ZD?O'#?9<K^#4#Q^I/[QPWV7*_@U`\?J3^\<-]EROX-0/'ZD_O'#
M?9<K^#4#Q^I/[QPWV7*_@U`\?J3^\<-]EROX-0/'ZD?O'#?9<K^#4'3Z9U2^
M]6&Y#_+Y/._$?N7R4'Q,WJF5@*Q.%2DGBKT^2;#RV]$H.0E]4+_<O#6M>_IT
MGG?E^Y?)QH.*IO50*(3B<*I(/!7I\D7'M>B4'ST[JK]Y\+_.$G^"4#T[JK]Y
M\+_.$G^"4#T[JK]Y\+_.$G^"4#T[JK]Y\+_.$G^"4#T[JK]Y\+_.$G^"4'ST
M_JM>WP-A;6Y_"$GY7[DH.#69ZJ#5XNV<:>/=T918X>S>)0=GPUU-_HQC_P"=
M5?P2@?#74W^C&/\`YU5_!*!\-=3?Z,8_^=5?P2@^#-=3;G_9>`+=OPJKC_V2
M@'-=31_[7@'_`,U5_!*#@O/]3T.)2-I0W$GFM&6%@?9U1DGY5!V?'M_\7WQK
M^#?JG3;X-\86\7Q_1]/C:/-U<=6GEV4'?U)_`^7^S0_MQF@DU`H-1$>>5NS)
MLEQ191"A+0V2=*5+<E!1`Y`G2+^U0=VY%9E.!GG"*91EPROT%<DV9#MNZ7.?
M=O05?#>]8I?C)7DMNJ>0E!2@W5Q*P%7T`$=WRCVJ#L>E=?6WUM-Y/;KLM+*G
M7(RBI*4-^,I*%A/G]Y(MJ5W>SSN-!W0GNNKF-Q\N/E]O3E*2OTEHZCXBE.K2
M%)=;&@I;3;E:Y!!\M!/,F](3NC!,I=4EIQ$Q3S:20E92A&G4+\;:C:@W=`H%
M`H%`H%`H&I)%P1;R^U05/NQ7K#?#\T[;3`5A`Z3`U^"'"WH;MKUDGSM5N7;^
MAH.Z0[UX1B\6VRU&<G#&RG,LXKT<*5/*M,=ILCWL!((5>UN=[T&@$CUITLJ#
MD:$5$!*"V8>O58G4=2M&GYKA[5!L(R?6.7&>??7';>"5)9B`0KJ5X"E!>L:D
MCW\!*1\R>/&YH,!+OK4%E04SCD*X!)/HI5W1>YLK395['VN`%!W*_K,C&-R0
MJ(J;XQ;,)L0]/A!&H/+6KG=PZ=*".Z+\*"P^GBM[JV^?CFE"<R'W!W/"TEH6
MT$>#W;7O;MMSXT&QCR'U;LGQBXHQVX,-Q#5^Z%K>DA2@/*0A-_:H-M0*!0*!
M0*!0*!0*!0*!0:3#3IC^X=P1GG"MB([&3&;(`"$KC(6H"W$W42>-!NZ"DL[$
MZXN9Z8UCILMK$RI>2D0EA#14SZ*DF(PHG5[Q(TIT\C<F]!GR9'6*/LC`Y!AJ
M1+W1*GO3,A`4E"6VF%,/%J,ZD:=*$D-W`5YW;0=*,MUDD;4S\I#4P9;X1A'&
MWAMQUHB!+9DEN*MQS6D$+!27+J[".P-;#G]<50<DB2QDG<GEPA.`D--1V(\1
M2)BRXJ6VX26@IK38=_N<+ZN-!(]E2>IR\GCXV89GM_!\2<WN"5)#/HTF27;Q
M%P]-U*LF_(`:;`\:#$V9G.K<W+;<@Y:+*CQ&HS_PO)?B%K4_Z,?#+SI)0KW[
MD&TI]F]!HQ.Z[S7L)C8XR,"9&0&\M-E,,F*]*0\XX5E:`;LK0$(%K</ET'/&
M97KH_B9T:;#R;.?R#D=>&?0B,(D9"'U^D(D*4+)[G*X.H:;>R&V>W3U0C.B3
MCL9DSCD0F(CC.4B"1)7.25J=>0B&46&FP4LG03;2*#YTYF]8W=S8Z'N5,Q6+
M;:=E3)3[++-U.1T!#2E(!2XE+A.E*0E8-]5Q0:5_)=>I3,&%"=GLS&GE1LG-
M>@-M-)#DL)86+ASQM*`HN.-`)T6X7N2'5$W=UQ9AYI&5Q^45.<DQ?0$Q((6T
MTE$M1E);6$<6U,)LDDJYBQ%!G2]U=87<C,$:'E1B425OL+]`#4D1G9C.AM25
MMN)<*6%+T>'92?=\J#NQ^[>KT#'Y/X0@Y![)R%!S%B1CU2&D0RVLM`F`D!,H
MJ(\7Q.`X<.=!;FVUY%>W<6O)ZOA%4-A4WQ$A*_'+22YJ2``#KO<6H*9ZB=1-
M[8S>42#"R2X\!<YZ*&6&HZW'`%Q0EL!U*BHCQE'N\;&@W^P-Y;LR75W=6"R$
MT/X;'^/Z'%4&$K:TO("+%L!:QI4>9X>ZXT$RA[KAP<5E<GN">S$AP\A*CI?>
M4AM(;:<*6T#EJ58<!S-!OL=/C9''QI\517%EM(?864E)+;B0I)*5`$7!Y&@Q
M,Q-DQIF';94$HF32P^"`;M^BONV%^7>;30;.@4'1.R$"!'5)G26HD9%@I]]:
M6T"_*ZE$"@XP,GCLC'](Q\IF9'N4^-'<2ZBXYC4@D4'QO+8IV>YCFYC"\@RG
M6[#2Z@O(3P[RFP=0'>',=M!E4&MRT^1&FX=EH@(FS%,/W%R4"*^[P\G>:300
M3_@K_9?_`+0H)5U#:4[M.0VCSEOPP/;,QGR4$CH%!HX)OO/,#YF#CQ_UDLT&
MHZK[BB8C:[C,S$3LQ$RA5"D,8Y-W$H6VHJ45#BG@+`T%(0,3TLG0\WDE;)W$
MA<-MEQQI;KI<6IYX)LCC>XO=5[]V@[)N$Z?C!P9RMA;F^#I`<8`:><*TJ$@J
M*'D$W'G7;)X$>R#094A&RFXT!+_3K<\<89Q,>-,2%(<;67C(NI25#42M7,W`
M'*@O;*_A;@/V*;^H;H-]0*#XI24I*E&R0+DGD`*")_C;Z:7M\98%Q<V+R1RH
M,N1U&V+'QT7)/YR&W`G:_1)*G0$.>$K0YI/;I4;'V:#3;OWML3)[=DXP;K8Q
M:LI%U1<BTLW2VX2`ZTH%(-M!Y*X4%:87:^THN3AY!SJ\](BH>)\#TI36O1;4
MG67U:;:T\;4&9D,3M.?N!>18ZL+CI??;?9BB59L-M+02A:O&2DDAM78GF#8]
MH8V8Z=;?;R3F);ZFJ@^D/N^%BM?$*=<(+90A]&K4I*POAQ/DXW#:3=N[=ROP
M0YB^I7HD5,./C(J69*@IYQCN%PZ7T)+CB4J0>YR]D7H)%C,[M2)T[D8-_?<6
M9,\*0R]G0\DN)=DK64N:`XI0T%P!/>MY+4$29Q>VF=U,91_JPEY*'W)3T,R-
M"5)*EZVTE#X;0$\TC3S[+6%!W9[;&'GOO[@1U3>AXB8E"F4ID&RFXZV6EZE!
MY&OO"Q*4)[RA?V0U.1V?MV3>+%ZK-1XLJ2XN-##A*"9.A00HIDI*]:5IUWYW
M[+F@WNZXVP,CM?%1,?O]G$R\8AG'JR;<IPAU+#*D:%-(>;2%$][5SX4$TVWG
MH^`Q&WL9-RPW`O-2GH^.RL8#PE"ZG++6IUV^FQ2"%'E:U!O2]'B;ERLZ4XEB
M*SC8A>?<4$MH2AV4I2E*/``#G08_XRNGMB?C)C+#G]5L_/4'<=^[(3);BJS^
M/$A[P_"9,EH*5XH!;L-7N@H6]N@Z/QE]/N\%;BQ[:DE25H<D-MJ!02E0*5E)
M%B#09#V_=D,IU/9['MC5INJ2T.]:]N*O)00G>[$'?$^&C;'4%G%/0VG_`$AB
M#)UJ6.ZOQ"EEYO@@)-R;\#01+XI/MQ7XBNL:A.9<2^\3*)2VPE'>)1Z1KU!2
MQ8E6FW,4&5(VI)Q\-MR3U8;3.D>DEJ9*D#O1G"DV:]_21Q;.L@VOYMB*#IC[
M.$9$J"]U9;1F)I8M+$A0D!AI+C@;[TODM+X/M<>?&@W6'QTJ!A,TQD^I[$S6
MJ.W'G+>2A40Q9(=D!7OW%2RZ&SQY$`\+"@UT;9^7F9-QUKJR'$M1G72Q&D'4
M&_`.EQ:3(<2$(N"I6F]N-P>(#C#V#D@I^-.ZIIG+;2EM<-R2K0V\9"74!2?2
M-?%#:D@$ZK^QPH,C`[1GIW%`R64ZGLY:`ETD1$2E(\924:"&],DI!]\`-APX
M6L3>@V73C`9J!N9*QU`C;BAV=+F-$A<AW04V"A=]P#2=-SIH)OMXWW7NL6M:
M1$X^7ZB;H))0*!0*!0*!0*!0*!01;J+GMU8/`B=MO%G+30X$KBI:6\=!2>.E
MM:%^=;B`KVNT!$IO4?J5!2TRO:[TJ42A;SD>#,4T&W$1W`D%)7WT>(\A7>/%
M'LT'9N'J1O\`8Q&/<PVV),C*.PV'YS#L&;H0^O\`7F4D!(&CV54&H_&?UI3#
MFNC9*G5QWFD,%,>2C6V4N%Q0:4H+4;I3;3P';S%!;6`EY"9@\?+R,?T3(2([
M3LN*`H>$ZM`4M%E=X:5&W&@JC<O3#);TS<B3'R#<1C%9A]?AN(65!TIB+\5!
M0I-SH;*+*X=M!L>GFWMUP>J&ZY\IJ2S@Y;\I:/%2&F''5NMEI;*0XHK]Z!NL
MH'&_&@TO4O'2\GL65$@2&(V0<W1*]%=DO(CHU!3X4`MSNW*-0H-UN'>^;V3$
MV+@<=#CRTY%F/#<6X7%&[89:.A35T>:LJU75RY6XT$VW+]V-K\2/XR<X=A^H
M)7.@K?KWO3=&%S.W\3BIZX,7*FRRP`'%.ID-!(6Y;6EO2HW#=E?(H+GH*%ZR
M1H&<ZP[7VYN2<8>UUQ"^I)7X;:WBIT6*[@)*_#0C5V=G.@Q=Q[.S?2'+(WCL
M@N3-I.:/AG%%9<"6N'>U&]T$>:YS0>=TT'+I9GL9N#U@=PYK&**X4['>(RI2
M="K`14D*!Y$*!!H/05!I=P?=3;O\H+^T9-!#/^"O]E_^T*"7;Z2%;;<202#)
MA"P-B?JQGD>%!OZ!011W.XO$;HSDS+3&8,)$;&M!]]0;1K6N38:E=IO003/;
MD?F;@>E8OJI`QN#GI*8L0H8<6RX$!"2A:AW@7020HB@U3&<RRY\N+^.3&R(J
MXCS:UN-,,N-N+&AI;2D*2DE)[UPNX\E!W0INZXKL"0YU@Q,J*E8$UIT14@Z$
M\4-K!)7S[=/EH.O'9??(R,-Q[JQ@)#+3C?CL78]^2E0UH("4GO)!%P:"V\L?
M]K\`GRM3C\I+7Y]!OJ!0?%H2M"D+`4A0(4D\00>8H((CH7TK0K7\`MJ7>X6I
MZ057'#GXEZ#.D])]@2</"PSV*!QN/"Q%CAUY("77$NK2HA8*P7$!5E$T':OI
M?L9<>%&.,3Z/CF)46$T''0EMF:%!](`7[H+-B>79:@BF5]7_`&Y,FS9#*VF6
MIKGBK:6RZX?-(TESQT**;J)([>'D%!AO>KIBGA9R:P>1OZ,^3K%K+-Y9NKN@
M7/8`.0H,N5T)BR,T<TN?'&3+ZI*I`AK%W5J*BLI$D(U7/DH,2/ZNN+CO,.-3
MF;1U:VFE1GU-A5B.*#+(/G&@(]73$(3(0F:T$2@A,A/H[YUAM06@*)EE7!2>
MPT'!?JWX1Q)0N5'\(JUAH1GTH"@D)U:1+MJL.*CQ-!W/>KUCW6V$*R+8$9*D
MQREB0"@+)*M/U7[J_'VAY*#@SZNF&9<9>;D1`\P[Z0VYZ&X/?`H*X@2M)%T^
M;:U!P5ZM^%4DI7+CDFUU^BO!7,D\1+'G:C>@Z,QLV7MS-;+P[&62TP9TI>)4
MW&L(\E;2E**_%>=4ZE?B*[EQ[!%!9CV,C9*=EL;D0),:5CXK$MNQ0%I6J0E=
MK&Z;W[#PH(K_`%>>E.A2?@MVZP4E?I4G58FY%]=!G2>B?3N5+8ER8#KKT8(#
M)7)D$)4V&TA8!7Y]F4W/;094SI-LJ9,R<R1%=7(RZEKFJ+[G$N-+85I%^X-#
MRA9/MT&L'03IF/#*<>\@M(\-"D2Y"392=*[D+YN)X+\HH,S!=&=@8/)_"<"$
MZ)ACKB%;LAYT%EQ.@ILM2AY@TCR"@QX?0OIS#3*3&A2&Q,C*A/VER.+"RE10
M+KX=Y%Z#@OH1TX=C/17X<A]MY"&SXLI]92A#GB`(4573WS<VYT&3G.BW3_-K
MCKGPG5F*PS&:")#R$Z(R=#14D*L5!'=U'C:@QG^@W3>1)=E/0GU2'GE2"YZ4
M_=+BR2LH[_=U7XVY\/)0<('0'IICUO*B07VB^TMAVTI_BVZ-*T^?R4@E)]@F
M@*Z`]-%O)>=A/O/(%D..RGUJ2"2JW>4;\5'GY:#BCU?>F+<=EA$!Y*&/%\,B
M0[J!>*-2M6J]_>A;R4&?M3HWL?:V6:RV(8?;F,I6A"EON+&EQ(0H%)-B+#A?
MMH.W'[?PF3W=NAW(X]B6M#\1#;C[:%D)$-HZ05`\+JH-S\2-G_>6%^T-_G4'
M%.QMFI2$C"0K#E[PV?S*`O8NS%VU82$=)"A[P@<1[0H.H=/=CA:UC!P]3E]1
M\)/:;\J!^+W8]E#X#AG6-*KM))()OS-!Q'3G8P24C"Q0DBQ2$<"/);Y-!V)V
M!LU-M.)83;E8$6_)]B@Y?$7:/WL9_P"5^?0/B+M'[V,_\K\^@?$7:/WL9_Y7
MY]`^(NT?O8S_`,K\^@ZQT^V<+VQC?'CYSG9_94'+XA;0X?Q8WW3<<5_D][C0
M?#L#9Y45'&-W-K]YRW`WY:K4'$=/-F@+'P8CWRVKON]GD[_=^10?/Q=;,LD?
M!B>[<CWQWM\O?X_)H*^#W23#YG-PMP)$>6,@M3+:1+*0RIM`1Q9[G$H50-NM
M;6RO4?*;8^!F/0X`?`<0[+\5*V%-I&M2E^&KQ-:C9/FZ>-!%>L+$#'=-&X3;
M*?1$[GG-M,J42BP$FP)(4K@>/MT&5U%R$$-]+!)ANONJ:AN*4F1X)2V?`!26
M@%:-3A1[YPY:>V@N/<J2K.[6`%[9%Y1]@"!)H*HZ];F>PN_MN7CQI3#L4CPI
M,5B592I*`5(\472L!/=(-!?%!&-\].-J;VAM1\]&4XJ.5&/):66WF]5M02H=
MAL+@@B@C6:ZI]*MD81K;JIHR*8,9,-.-C`2EJ;0@-Z'5<&@2/."E#VJ"#=`\
M6F3U"R6X\3MV5A-M2(+C<3QUJ<:\13S:K-K4E%P4IO8:@/+0>A:#2[@^ZFW?
MY07]HR:"&?\`!7^R_P#VA02W?:].WKVO>;CD_+GL"]!(*!00^5M[#9_<F<@9
MB*)<-+>->2TLJ"?$;+Y2;I*3[8Y6H(#NZ;M3:^Z'L0STQ^%6/!2ZC(H8+R%G
MPRK0V@LN^:>"K*X<S08<'=^RT9&/$S_2]G!MR'&V_2Y$1!:0%*2''%*5&0D(
M;2JY-^PWMPN&&[G=KP9K\&-T?>D,B0Z7W#'6M`T$I4Z@*CK3I*!J&D\J#70M
MT[!RDP3)/31MG%O%`@O,M.>^/LDI4L.H0VVEIM.G7PYFYO:@O/+_`(=;<XG]
MRY(V[/\`)Z"24"@BO4J-*D;<0EEC)26D2HZYC&&=2S+6PE=UA))2I2?FDH4%
M$<C05O!V!N25"P,J2YGF4S,P\U*CN3Y*7V,,0\IA,A*'+)4"$:E#O<;$T&7)
M1O'%;#>Q*8>:ESEYYQ<)QH.R'DXZ-/;6/$=*]>EQA)T75WJ"+9"-UD>R3<DL
M99.!G9#)36V4>EHD,AQPI::?1&<;=2WI2A3:0;"Y]J@PW,/UTD8^<_$?S,88
M^.N2RRZN07'UF0ZTEEKQ5*<)3'<U\>/!/;:@REPNJRV'51AGX\9MB*99OD''
M"4OI\8I0^\'%*T\PPH<.5!L&L#U?$AJ+!DY=C`9UU_N3'7')D.)"7XC.IS4I
M3#CZ.X`#<\CQXT&"U&Z_8YD9%3D^1,PV/ANQ6;.NMRQ*4OQ6GF5*LY(8\4!7
M;W`;T'*-M[K9C\TTM_)9:7`BY>!$>1XCZ@\R]H>DOILH^\H4C03RL3[-!N]V
M8CJYD=Y9&-C9N0BX"=E/#8>:4ZV8Q9@!;:TJ!_<SKJ]*_<ZD^6@U#V/Z[Y1#
M.25)R,/)2XLJ=*B("V6&E0%H1&BH;!*$N22B_P"B!H.C&L]776,?K.Y48,(4
M<DGO#)^DIBI])#1>-_`4K]:U=[5JT<;4'.<WU;8R1G8EO/C$L.>-B$RE2776
MV!,;!],8NI;]TE=FE=_PS[%!)\?*S[TSIV_G4/MY=_*Y=:R\A;:DM++A2G0]
M[ZALME(0#Q";"@M"$L'=650%$E,6%=-N`NN1R-!63N'W/EM\C'HE;EBL.3)I
MS<MYQ<:$(0&J*B$MI1;!UA`24]ZVK70<MAXO>6.E[5GY&5FY!EHRASD>8Z^\
MT@,:DQ-32A9"E)XIOQ4:#32<WU2F/.JP368;?8R&7R"&)T:0RT_!4A!BQ=3B
M4A)(U^&F]TJH(SD7NLC7P<K$JW`Y*:8;+I=&04#(/A$AU+S:&;:M8.DJ3;F:
M#-G,=7,8SF(D^7G9F1BR$LXR6PJ=X+K02E06CT9MQI:BKGXA2/9YT&6TQUE4
M\ZN+-S9R\%<R7+;?;=$)QJ,H+BL)UW;<6\;C2P;%)XT'R:UUY4%S4RLA_&C$
M-^=$;2XCT7TR8KNQ4B^A;#3:`ZBY("S?RT'V0QUTG.M11D,A%D0IZ<`P^TVX
MAIYDI=4]D7R0I*P$I;TN<./LT&QQ<WK`YT]Q+K:YQW/\87?%3*2L!<5IIQ7A
MNW3P86I&D$BUR*#1XZ3UR=PI0Y(RGH\J'*S8>4VZ);3D9+K2(`7P5WW/#4$:
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M];H7YI;3JNH*[+4'V3N'`16`_)R45AA2EH2ZX^VA!4V=*TA2E`72>!\E!]:S
MN$>CB2SD(SD92''4OH>;4@ML_KJPH&VE'NCV=M!UR=S[;BN!N3EH;#B@%)0Y
M(:0HA0"DD!2AP(-Q09+63QKSCC34MEQQE.IY"'$*4A/E4`>`]N@ZHV=PDM*U
MQ<A&D(:27'%-/-K"4#FI1238#RT%<[\P&^=P9IV9M??;&)QC3+30AMK'"0HJ
M`"U-\O$*DV)N?8X"@T<?;74B-'R3<OJ/$?FO(;1'U2U-AMQ#EW+V'<U)[0+C
MS>1H,T;0W^_A(L7\8*).71/0I4QN264KA.MH2\P$-@ZG/%0?")_-M0?)FRNI
M;,^0SC^H"6F-+*%,29"G7DR%.D)22M*BD+;5P`L2H`4&*_M+K.VS("NH,-IV
M,0''5NV"7"HE!<26@$!T63H-]-KC5>@M[;T3)P\%CXN4E";DF([:)DP<G74I
M`6L<!YRN-!YIZI"$[O:3CV\;&?R^2R9:C3GGY3+C6EQ-K:E(AE-K^<2>)N.5
M!8'3GT)'6O=S7@)7.*I3BGQIUMMEYJR7/>TFR]7<TN*X#O`&U!I^M,M,;IC+
M22?#D[DFMO-@`:T^)(X>(I*_#[R0;CGROQH-GN[I[NW/Q]@S\0VPZUA(<1<A
M2G@E6L+C*/A6[M]"%'4";@6\E!9V?^[VVOKU_P"T9%!2WK(-8MS?NS$2PZ2\
M0V\E"@D%HR$`:;H5WM2N/$\.SMH/0U!1GK`[8ZL9>:VY@%/RMM)CI2]CH3NA
MPO:E%:G&@4J=!&FW/VJ"G<[+Z?L;8BXJ%@)N'W9'F,JGO3E%PJ92E0<`)T:.
M]I.GPDT'LG$Y;$Y2&B5BY;$V(>"7HSB7$<.RZ"1\B@S*#3YM3?PMM]"@2HS7
M5(MV%,*1Q/RZ"$:Q^)'Q.R^KF.7PA?G>U!*^H/X.H_E#&?\`J+%!)*!0:+&?
MA?G?V"#^4]0;VPY]HY4$`ZDYCJ7!BO+VIBTS/`>:<*RAM95'2V5/("%.ZG%+
M7I3W4I(%[7-C0:%W>W7>1!Q\C%[1BN&1&#TKT@J8*'?%<26_#=>;6DZ$H-B#
MSYT&*G?G7!A^,UE-FQHT=2RWXC#3DH<P$H`8>7X8(O[XH:106+E4%6^=O*')
M$3)$\+\S&'/LH)%0*!0*!0*!0*!0*!00'J/TK=WC.CRV,Y(PZD,&+($=(NXT
M5Z[:@I"N?8;I]B@T:^AV47&7$5N-`ADDMQD0W$MMDZS="?2N&DNE2?(JQH,9
M'J_9*/(2]$WE-L$+:*)+:G@6RVXRT.#S?%IIRR3Y>/L4'2KU=L@7Y,CXX22_
M*NHNEE84RM3OBE4:SX\*_F]O=)';03_9FP86WL3'B2EHR,F+)?EQI"VR$L*D
M'BB.E:G5(2$\//)H,['_`(89KZT@?JI-!O*!0*!0*!0*!0*!00WJ-L3*[J:@
M'&9Q["28*G3XC(40M+R0E05I6WR`]GG00)/0#>"$+#.^I4?44V0@/E!`%B5`
MO\_)^;02/9G2S=>`W!&R,_=;^5C-%Q;S;@>2M>M"DAFQ>6SX06LN>9JU`6-J
M"7X`DY[<W$$"8Q86Y?4,?MH-[0*"F-S]*-WY;>DG(Q$Q8N-FJ?C2G3(3XIB2
MBA+ZD(;B-J"U-)4FRW5\^=!IY_1#J`C-1G\=(AMX_#%+&'4B0XS-]$:>?=8`
M>\%[PE-ID:#P5J`H-AMOHQN?$S<.7F,;)$?(8_(R<H7%"6RF)'#3L9OWGOH*
MAJ2=2?9%^-!U3NC^^?C'D);284K'2)<Z5%84^A#;2IJD$.-,/0Y*&W`E&E9.
MH*YBQXT'6QTPZF,0683<#&%+4/,P0ZJ:H73F'`YJ*&XR$CP[<DIL?T-!AR^A
M6]XHS$2"8L^)*;;9Q\B2\SX[;+;'A(:67H<A5F[V!0M!('M6"7[&Z8YC$Y[&
MR)V/Q<&)BHTQEQ^`IU;N05-*?W0ET7"4!-R%+5=7*PX4&GW+T+G3MSY"=B$L
MXG'Y"9&CR&XBS'2O$F.A,M!::"4DEYO@D\^9H,/*]$]RSHPAX_&XO;S<1"(J
M7H+[I]+1Z:A],A86@J2IE"+I"U+5J)X@4&!*Z*;M=:=`V]BX[GP='QZ3$?CV
M=?9#H7+7X\1RQ<U)U:;+_1T&#@^CTK:^9P&6S>2A0LE$RS4AR(Y)`;^#F[=Y
M!*4ZG"_V>S08>Y\#B,OF,C)A;FP./$F>J4SD6YZ4OOMR9J7TN/`!)2J*@60G
M423RL*#&_%BK,Y#))Q&>Q>2@,ON*B1T3VQ*EH=\1W5(=+;BO$;2%+NZ%]H3I
MH/2FSX[D;:>%CN2&Y:V8,9"I3!NTYI:2-;9[4JY@T'FCJGE6D;YR&.?U/M2)
MANE:E#T73+0LO1FPM*''%)1I(4D\@*"RM@/0U=<]W(:QGA2DMN>E9%,DOA0\
M5H-I4@`H:4H#S."N%!(YNP<3O/;KV/R3\AAJ-FYTMI<=82KQ$2WDIN%I6DCO
M<K4$^CM%EAMHK+A;2E)<5;4K2+7-@!<^P*#3YW[N[<^NW_M)^@VST.(^MMQ]
MAMU;1U-+6E*B@W!NDD<.790=M`H-3G]I;9W"P6,WC(\]!24!3S8*T@_,.>>C
M^Q(H(SL;H[MS96XIN7PDB2EF:QX"H#RPXVCOI7J2JP7PTV[Q/MT$\H-+FU)^
M&]O)-[F6\4VM;A#?Y_+H(!9']7GS#I]#OHX_OF]^7+MH)KU!_!U'\H8S_P!1
M8H))0*"&YG)*P^Y9C[>5Q,=<V/'U19[RFW4ADN`*`2>*5:_R*#H7OB4A6DYG
M;@/:#*6.%!U'?TK5PS6V=`/?49RP0![%OS:#ZG?.44"49;:ZM'!S^,%]WE^A
MH/IWOF`+JRFUQP)2?A%SC;C\QPX4&&]N+)/Y6#D59?;"7HK;S3:!/60I,CPR
M3?2.7A7Y4&:K>^3UE+>7VRH)5I5>>M)!MY`%<:`=YYVYMDMKD=A^$7!_BS0?
M/CKFR!IR.U^T*_C)SF#V>]T'WXZ9O7]T=L:+\!\).7M^UT':C>N3[VN?ML_,
M6R:QQ]F[5!S&]IEA>=MV_;_&BOI-`.]IG"TW;I\O\:J^DT#X[2OW]MW^=#])
MH'QWF:K>F[=_G4W^5X%`^.TNW&=MT?\`FI^DT`;XDDV$_;I/D&5/TF@XG?$W
MO!,S;BE(!*Q\+*&D#M/O![:#DWO/*+`4F1MY31%M:<JHC7>VG]ST`;QS.D:G
M=O!5KK3\*K-AY;^C^3C0<3O+<&D&^W?9_C==A?EQ]%[:#[\;]Q<.&WO9_C=?
M\%H,*+G<^SF9F14K;ZA,:8:4T,LON^CETW!]&XZO%_(H-FG>&6N=2<';A:V7
M/R?\FH.0WAD;<4X6_L9?_P#&H`WCD2.*,,/_`#?_`/&H/OQPR'S.%_G?_P#&
MH'QPR'S.%_G?_P#&H'QPR'S.%_G?_P#&H.)WCD>/O>&-N7\;\_\`LU!]^.&0
M^9POL?QO_P#C4'WXX9#YG#<?_%__`,:@^#=N:*A:+B"E1("AE^%^%A^YNT&]
M!Q5NS<GN,=BG$WLE0RXX_P#9O+<4'T;IW7<7Q&-MV_QN/X-0<T[HW+I[^*QX
M7?D,JDBWEN8XX_(H,#'9+<<.?EI9Q^/6,C(0^A`R21I"([3%E'P3Q):OPH-D
M=SYX"_P9")MR&2;^E4'WXSYW[VPOYR1]*H/GQGSM[?!D*UKW^$F_E?K5`&Y\
M\0+XR&+CC_&3?#_JJ#[\9=P$=S%0UDFP2,DW<G]JH.*MS[B%R,/$(':,DUSM
MRXMT'SXR[J/F8!A?:JV29[O/G[W[%`3N/>!Y[;:3?E?(L\?E(H'QCWG_`$9;
M_G%GYR@?&/>?]&6_YQ8^<H.[XP;HX_[.]HM]71^7::#D,_N/C?`'GP^K(W+Y
M=!&]W[?<W6J.K)X"2A<;];<C9)EH\[V(!*3[=KT$>:Z0[=3D$3W=LRY,A)45
ME_*,N!PK24*+ES=5TFWY7&@Z'^C&WI"PZ_M_(.2=(09"\LTIP@`)3<DD=U*0
MD"UB!QO06'BIN:QN.B8R)MYST:$PW'8U38RCH:2$)!-[DV%!J\3$S,9R>[/V
MRS+=D9!Z;&69$5:FTN*2I`NODI*DWX4&<P)C&9=R\?9Z6LE(;+4B<W)B)4X@
M$*LX4JNKB.!(O0,/+W9C8K[3FWEO*>F2I(\.7&X(D/K=2#J4GB`NQH,YS/[H
M2`4[9==O?S)<3A;],M-!KYL_=<N?B91VQ);$"0XZZ@RH1)0N.XT--GN>ISY5
M!M_AW.?T;F?M\'Z?0<'-PYU"-7Q8G+_0I>@$_DR!0=1W1G0?P3R1]IW'_P`*
MH`W/G22/BIDA:_$NX^W#_2J#Z-SYO4D':N2`-M2O$Q_#_M5!R&YLS<`[7R0!
MO<ZX'#CP_P`J[:#I6_E<GG<.X</+A1X+SSK[\E4;3I5&6TD`-/.J)*E^2@BO
MAG\0.G2G[FZK=GGZK^WV^W02_?B0O`MI/$'(8SD;?]X,=IH)#0*#0XL@[PSU
MN88@@_*>/YM!PC;M$UM;T+"SY<5+KK*)"!%"%J8<4TLI#CZ%VUMFUTB@X/;H
M9:F1X3^"FHD2@ZN,V415:PR`7"-+RK>>.=!W.9EMMI;KF!F)2T@N*NW&\U/$
M_P!UM0=;&X(TB*Q*CX&:ZQ);2ZTI++`NA8U)-BZ+7%`E;@C18S\I_`S&XT=M
M3KSI:CV"4)*E&WBZC8#R4'8SF&WFT.MX&6IMQ(6VOPXUBE7$']=X<./&@ZT9
M^(N0]'3@Y9?82A;S8:8)2';Z/[I8WTGE0<9NXX4)L.2<',0V7&V4J\!D@K>6
MEML"SAYK6!0=J\RVE.KXOSC[`88)^B>Q08L7=F/E%\1L%/=,9U4=_3':[KJ`
M"I)NYV!0H,AC<./7/B0Y&(E0US7%-1W)##:4%:6U.Z;I6JW<;5V4&\]$B_WE
MO^U'YU!\,*&>;#9MR[B?SJ`84,D$L-DCD=";_E4`PX9YL-G^P3^=0<?@W'<?
MJ5GCS][3[?DH."L/B5&ZH4<GREI!_,H/APV'42508Y)YDM(_.H'P+AOWA'_:
MD?G4#X$PW[PC?M2/SJ!\"8;]X1OVI'YU`^!,-^\(W[4C\Z@?`F&_>$;]J1^=
M0/@3#?O"-^U(_.H'P)AOWA&_:D?G4#X$PW[PC?M2/SJ#X<'A203CXUQR]Y;X
M?D4`X/"FU\?&-N(]Y;Y_*H/OP)AOWA&_:D?G4''X"P>G3\'1M/D\%NW._DH/
MBMO8!6G5C8JM'F78;-N%N'=X<*#K5MC;2C=6)A*/E,=H^Q\S0?/BIM?[SP?L
M9GYV@?%7;'WGA?8S7SM`^*NV/O/"^QFOG:!\5=L?>>%]C-?.T#XJ[8^\\+[&
M:^=H'Q5VQ]YX7V,U\[0/BKMC[SPOL9KYV@?%7:_WGA?8S7SM!\.TMJ*M?"P3
MI\V\9GA[7=H.I6R-EJ5J5@,:57O<Q&+W_M*`-D[,%[8''"_.T1CC_P`B@Y?$
MS9_WCQ_#E]2L_.T#XF[0^\<#[%9^=H'Q-VA]XX'V*S\[0/B;M#[QP/L5GYV@
M?$W:'WC@?8K/SM`^)NT/O'`^Q6?G:!\3=H?>.!]BL_.T`;,V@/\`N.!]BL_.
MT'P[+VAJ2KX$@!2#=*A&:!!]@A-!Q^(^S-6KX"@:AV^C-?.T'$[$V7KU_`<(
M*]AAL<_8`H"MB;,4G2K"PRGR%E!_,H!V+LS5J^!88/E#*!^4*#[\1MG_`'GB
M_M2:#X=B[.((.'BV/D;`_*H.!V!LXD*.,;*QR7=>H<+<%:K\J#E\1-I\;8](
MN;FRW!Q_MJ!\1=J?O`?MCOSU`^(NU/W@/VQWYZ@?$7:G[P'[8[\]08+^!Q6)
MW'@',<R8ZGWY#;VE;A"T>BNJTJ"E$'O)!H-!_P`!?_*Z"8;P2%8J.#>QR&.Y
M$@_NYGM%!NZ!0:'$^'\;<_IMK#<(+MS\QPB_RZ#YL2WQ:9L+>_S.'L^EN\?D
MT#*A)WE@"?.#$\CY3-Z#;907QDL>5ES]0:""X[J=MO!M8G#9EST))Q\$1Y2C
MK#KSS2?>PTV%.)L+=]0">-KWH);N^_Q3S=N!]`E6_:54&7B`1B80/,,-7_M!
M08&.6%;JS0!-TLP@1V<GC^;0=&^5E.(B>0Y3&!0\H,]F@D-!&]E$%>X2/OQ)
MO\A#8H._<)_CK;2>`O/=-R+\H,GA0;V@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&CSGW?VW]=2/
MM-Z@B'_`7_RN@E.^%E.-Q]C;5EL6D\+WO.:X4$BH%!'\*@#=>XU]JC#3_:L7
M_-H.>Q_P;8_9I7VT[0=>5M\>-O@CCZ+D2#?V8PY?)H-MF5:<1.5Y([I^4@T%
M3JR&QX6\]KP)6)9>S$J+"6SD6GG42VSX0`UME*6U,Z4=\!PW[4T$TR6\=J[@
MVON%G"Y6-/=CX^27D,.!2DI+2P%6^9O[H<*"2XE.G%0D_,L-#Y2!0:S%?A;G
MOV*#^I=H.G>BPO#PE&Z;Y3%D!7`_NYGA:@D=!&]E`WS_`+.8E?E(H._/A1SN
MVK'@)KY(]CT&10;V@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@X*?82Z&E.)#J@5);)`40.9`YV%!R0M"T)6
MA04A0NE23<$'M!%!]H%`H-)FQ?/;=/'A)D'@/\S>YT$.O_\`0=[C[E7OV4$I
MWV?XNQO\L8O[>:H)'0*#0X:_QHW%Y-43Z`*#[L?\&V/V:5]M.T'5E?PYV^?\
MSR7ZJ+0;3/&V#R)%B1%>-CR_6S05!+S6U&NINVH,O;QG;A7'Q[;&3<D*2&VG
M&B=;+'%"M!U%5_(?8N&T1O9>;E[KAM_!_H&/V\ZIMJ`^W,LLEY*KO(0C3W4)
M][^306E!_<,?]B1^I%!J<5^%V>_8H/ZEV@ZM\DC%P0.W+8L'V1Z<S02*@CFR
MQ]W3<&^8E\O[`<?E4'?G?N[MOZ[?^TGZ#>4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'F'K+$R7XQ,U(B8]
M>8,;T.;-DQ#)2]#A)CEM<1QUI-FD/@J6K22;4'H79BXR]HX5<5IAF,J%'++,
M12E1T(+:2E+2EA*BD#E<7H-S0*!0:;,+TYK"BQ(\20I7M".O\^@@^M']7?Q+
M'P_@75;A?3HO^502[??W.QO\L8O[=:H)'0*#0X;\)]Q?IXGT`4'S8BPO;$9:
M>2G91'R9+E!PRE_CWM\=GH62)\GG11^;0;'<?X/93ZT?^A*H*;=PS>1ZGXDQ
MTR&#CAAW))UON174ML%38\!F.I*'$W(2MQ\`<_8H-?TQA3$8?J/.?Q\F"T_`
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MI6%I4&-`\/4'._?3;SN-!M*!0*#0YU2QN#"`*L@B85)OS(8X<*"'^B__`,N_
M@:C^#^K5I/\`>-7F\Z"6;Y^Y^-XV_C?&>7]^M>2@D5`H-%ADD;FW"2.!7%L?
M:CB@ZNGJ]>T82[ZM2I"B1[,APT'+)6^/."N>/H.2L/[.)0;#<?X/93ZT?^A*
MH*TGX3:4;=.`SDW/RD99]>/2S@V'F;>(B.4ME31LX&U!)N?9/S5!HNGV[]R9
MK9F]6\SF!E0UC'GX39T^(RTXV^`EXI:1W^Z/[HJ@O.(+161PX(3RY<A0:G$I
M_P!IL\N_`^B"WLAHG\V@Z=ZD>@XU)%]66QH^5+;/YE!6.=B2I'K#Q9,5YIM<
M/T1#J%NI0M2'6B7-#925JNA)\T_FT%E['_<V8_EC(?1U4'?GB?C!MH>67(^T
MGZ#>T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4'FOJ%.P#?4O-,3<L_CRB:F8&4OL-H2_$Q(<8DZ76G+J6Y9
ME(O^3:@MO#]2-N8O9&V,CNC+-PY66@,.I5(5J6ZOPD*<5W4\>*N/#MH)'MO=
MFW-S1'9F!GMY",RX6776KV2X`%:3<#C90H-M0*"/9_\`"/!?I9OT`4$=T)_$
M)IL-/Q<O;_1+T$FW>+Q<;_*D#[810;V@4&AP:DJW)N2W-#\5"O;]%;5^4J@X
M=/@D;/QP%[:7.?E+J[T'.>+[WPI\D#(_1(E!G;C_``>RGUH_]"505"8&,G=3
M\9+DJ6F5BV8"8Z5RHQ:6'H9U:8;Q#Q5WN!9XW]F@QME;5P&!VSODXO+,Y5<_
M&.NN>CQ'XPCI#;P2T2XMQ(L2;(/?';07G&%H[0YV0G\J@U6*_"'.?IHWT`4&
M+O<_4N('ES&/^V$F@K;<>0FJ]83$8U"I2HJ/!?6WXEXERPM-U-M)00M-KI+B
ME?(%!8^Q+^B9B_WYR/VRJ@[<^?\`:3;'&WU3)X>7ZB=H)!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0>?MX
MSYN)W_NF1)SD'"0WGHI;<R>)=R#;@]#;2"A\)*$:2"-%^=!G]:LB4=/-O1I.
M?=C"<RD+]"QY;3-*D(TI*EK:3$1WKZ%*%Q[5!)O5[=S;W3YMS)*C^`)#K6-;
MC(;;"&&2&B%AI*4E7B(4=5R3SO0690*"/9_\(\%^EF_0!01__@-_^G/]3H-_
MO5TH8PX%O?,O!0;^3Q@>'RJ"14"@T&!).XMS7M82HP'+]Y,T'+8OX)8W]C/Z
MM5!US3_M_B1_X9D#[/Z_$H,W=5CMC,7Y>A2?9_N2O;H*H&P9\SJM!W.A25X^
M%CX;KS2);8=;?0QI;<=CA&KPN[RO=1%P;"U!C;&WUO#<^UMWM;AD-N"/A0]%
M0V&M2Q(;?/BDLBR;A(3H)N+<0*"\FA9I`/S(_*H-)A?PEW'^RQ?M9-!T[X_<
MV'_EC'_1Q01'<>Z-RX_JQB\<QF89QTR3'85@TK2J5X+C#BG'%L>%K_7$@AP.
MV`X:>=!+MC_N/*_RQD?MI=!SSFGXT[:N>/B2]/M^C*_,H)!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0><>
MH^43/ZFSD9#.F*,*XY\%P7Q%=C-%C')EATL/72I;KIT(4H$W^0*">;BZN8S;
M^S-KRMP8YW+.[BA-..MMAC05EEM2]:7"A/>4YV)M[5!F]&<?D(L;<CS^%=P$
M.;EER,=C'D(;\-DLM)[J&R4@:DGS>%!8M`H(]GB/C)@@0?,FV(M;]9'.@C__
M``&__3G^IT&[WT;-8/V<S!^B4$FH%!H\$!\/;D/:9;'VDQ0?-B_@EC?V,_JU
M4'7,_P!X&*_DN?\`;$2@SMTFVV,N?\RD<^/]R505?.VN_(WV)T+=D7$/R40Q
M,Q49T-RW&@R/"\0*U:TV;.EK2`05$%))N&HZ>[>Q^&VCO=V-G\=ES)QEGV\:
M2I+*VVWQS(3I"M7`>6YH+X:%FT#R)'/VJ#287\)=Q?LL7[6308V^_P!SX7^6
ML?\`1A01+);*S;O5UG/B#]0B9&>3,+S7@EIJ$ZRO4E2O2`\'5C2A'O9'%7&@
MF&Q_W%E#QXY?)<_KI8H.W,@?&C;OL+EV^QS0;Z@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@IS>>TL^YG=UE
MW:_QB:W!';9PT]E<1OT,A@MD.![0M*@XK7XB=1(L.R@R=^["VU,P.VH^[-S)
MP,N)!&*4XA;#;<DK0UXJ$AY/+4T#W;<*":[$89BX^5"1N1S<SD606GI+RF%+
M84$)]X/@)2!I''O<>-!):!01W<+:3GL4X2$EJ//4#<WXMH%[#VZ".W_^@+W_
M`/;5[_Z%SH-]OO\`6L%_+4'Z(:"34"@TF"^[NX_KMC[28H.&Q#?:.,/E:)\G
MNS0=4Q7_`-AXI/\`X5//_:(=!G;M-MJ9H^2!)/\`U*J"M)&0V6OJT,;D,$TW
MG$,QG<7N!"77'#*$4%M"P@!((;UV25=[2.'*@CW3R?(D[2W^V2Z&XL%#3RW7
M7EE^66GE/RRB1H<94^2"4%L6MSH/0(Y"@T>%21N/<*NPNQK?(C(H,??`NSA?
MY8@_1:"'S<5L>;UE;E2LEE/C#`<:+&.4AU<`+,8E*FUAM:&P4'O=]-U"@[,K
M,RT7:I>QTJ4P^[N>2E3L)M+KH:].>"DAM?<6DA/$*X4&]QTQ4U_:,I4EV8IT
M3"9+Z&FW%V:4+J0S[V/[&@F=`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!`.H'5.-MJ%E&G<;E676&7$1<HF
M)JAE]3=VREU2K$!1'9V4%>=3XN>W'"V*C'.HF;HS.%?:<B.MLA#C4F.RJ2_X
MKBD(;4#YND7X\.5!.N@GI+.S'\9+;CQYN)G/0I<2,RAE+3K:472I;:W$O*-]
M1<[;V[*"R*!01G<Q'PW`X<?@_)\?[%B@C]D_U>[:N[\5_.M_F/DH)#OD$MX(
M`%7\<PC8>PLF_P`B@DM`H-)@ON[N/Z[8^TF*"@^H<B6]C]K0HN+=DN^@(ER9
MD!]\3T1VWG"IMM+27$-))_NJDJ)XCLH+4V/(ARIFU)41HLQW,#,4TT9"II2%
M28MPJ0KBX;\R>-Z"6[O_``3S7UA*^@JH*NRF:PJ.K$?'KP;2I#H9CO9,/.A[
MQ78!4B2&OW/=M!\(%8U\>!M08&S(F#&QM[3L5EI^87Z"8;LC(,MM:1'0Z0AM
M22HK`UFYO;R4%[#D*#2X8WSVX./)^.FUNWT5L_FT&/O2VC"#M.7AV'M+)_,H
M()D=LYD]>8N6;9>^"EI;=>DI9DV#C<93*6O2$H+8;.K46RK22.)O84'/=N"S
M.>Z;S\;B8+,^2]FY^IMYXL(0@39'O@/B,A2@JW=4;>P:#:[,QV7Q6,V'C,R$
MIR45F6TZE"D+2$H:(193?<\S3RH+%H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H*"ZG;)Q>YLEN_,XJ?.=R6
MVFD*F0YB$R(1<#0D%J)K4E32@A`U%/#O<+W-!M>JSC6?VWM%63C!C;V1C^DS
M\U"A+EOQ'%L(6RF,@!:V4NE1&NQX"U!)^A[;K.S7(_HJ&(3,QY&.>$;T-V3'
MLDID/L7)2XLDWU6)`!H+!H%!&-S_`';@?R?D_P!2Q0:O2S^(W3H'@_%GS+<+
M>@<J#>;N"2<)JY?"L;Y=EV_)H-_0*#1X%23G-R@#BF:R";_YC'-!5;,#<;Z<
M2G:+3K623@X7I\F//9BK7'4X[X25L/QI*.ZM*]+B57XF]!.-JX@8C*[>QPB>
M@F/A)B5Q?&,G0M4F,I5WRE'B$J))5I'&@D.\+_%+-VY^@2K7_854%2.Q]N*Z
MPRY4UY(RJ78[45CPU+?;9&(UKEH]]0GPT%!!46EB_#V@Y;1VYM;$].]VNX+/
M1,VF;`:\?T)`:T)0TL(6\WXCJ@\Z%DKOIY>:*"\*#3X;[MY_A_E+''_1&J#$
MWGI)P*5`][+Q=)!M8I"U?\V@B+^7W6.MXQT2).&!\)LS9J%O*AW+!4$K0XAU
ME"M0'%LH/E-!H>I*9*^E,E,1#CT]6XY@AI9;+I+GI\GFD'EHU#S5>UV@-]T_
MC"'B>GD-+;K0;C3PI$AI3#FI*.\5-+4LIN22./+E8<*"T:!0*!0*!0*!0*!0
M*!0*!0*!0#049N+UF48;<&2Q2L(E2,?)>BE]<K05EE91JT^&0+VY7H->?6RB
M_>5KV/JT?2J`GULHY3<X1I/E'IHX?]50/ZV,?[R-?)F?_P"*@^?ULF>W!-)/
MN@9O+Y35!DQ/6C\=E4A6`93&UEIMU62::UK2$J6$AQM).D+%_;H.M[UIELO.
M,O;>:;<1I.GTX+NE:0M"@I#120I"@>%!Q5ZUB;=W`MJ4;V2)AN;>3WJ@YI]:
MR&25'!IT6[H]-&J_L^\VH.Q7K5XT`VP1*K]P>F)M;R\6J#G_`%JL4+`X3CP'
M"8GM_P`%0=?]:['#_P!OJ`O:_IJ/I5`/K7P+?@\2?F?34?2J`/6NQYM;;RK\
M+_5J.%_\%0?#ZU\$"YVZKV?JU'TJ@F72[K.QOS+S,<WB5X]41@2/%4^EY*@5
MA&FP2BW,&@LJ@4"@4"@4"@4"@4"@4"@4'GOJDSCYF\LR\(#4YO&I95FY<>!.
M<;::\-*DHG.,36$/Z6[J(#?!/"@FV\.H>0V]%PD?$.XP,/8M4YZ2^Q)$?PFB
MPTWZ.VPHJ`6I\:4&]AVT&HW3MK<&WNE&\'LI*4K*Y;(JR:G<,74!I3SC*0-:
M_?`VDHNL]B*#==)^HDS.R#M^0W'F?!L!A?PSCY*YC"R+-%$AU;;)2^NVNW&X
MO06701C='W;@_P`G9/\`4L4&#_P6_P#TW_J-!M-X+TN[?3\WEV$_*;=5_P`V
M@D-`H-!MNQS6Z"$:3\(M@J'NK0(W&@IK*939T3<.V4;E@P9,5_#XR.^Y.?\`
M#6RVZM_WUE`3I*4*`+I6OD1:@M'!C!#<N'&`4T<-\"2501&(4P6U2F#=!!H(
M%M_<60S<[?BG<I(RC<#!KC*<>88CI:=O(5X:1%6\VHV]U?5V6X4&)F$SY?6&
M2-+1@X]G4E:41&WPZ<22$E8*)3H/B$^Z`MR/N0UO2K-3\CL#>3;\T3&(>.C-
M,A"/#;;X/]VW"ZM`1WO);R4'HV@@VX,GD<5A]]Y'&K#<^*M#D992%I2X($?2
M5)((TCM]B@C^V<[E<U@,/*RDY&2F-;G\!<UC3Z*X&D+"512E"+LV\V]S>_&@
MV*H74/\`&\).B9\3=(`"9+8C^)X-_$4T5J<(U]W0$I%^-!C93!3LST]E1X4%
MB?,9S>0D1XTF2Y#;*D3Y%B7&K+)X^;J3?YH4'9T_>1)QFPGAWE")D/$N#W7$
ME*'$BZW"0E=TA14;CVZ"S:!0*!0*!0*!0*!0*!0*!0*!0*#S+TZBQ)/K'YQN
M0TAYL.Y57AN(2I(5X]KV-^R@]&?`6$^]\;]I;_.H/OP%A/O?&_:6_P`Z@^?`
M6$^]\;]I;_.H/OP'A./\7QN//WEO\Z@^_`N&TA/H$?2"2$^$BUSS[/8H.+F!
MP;J];F.BK7ITZE,MDZ>`M<CEP%!5GK)XK%0NE&2D1(##+_CQ$EUII"%Z?&2/
M.2`:"P,3M7;"\/!\3#0KEAI12J.TJQ*$WXE/$^S091VEM4VOA8!L+"\9GD/[
M&@^?%#:5[_`D"_UJS\[0??BAM/[R0/L5GYV@?%#:8_[D@?8K/SM`^*.T_O+`
M^Q6?G:`-I;4^\L#[%9^=H*&]68#X];FTV"4M.A*`.`'I7"W9V4'I"@4"@4"@
M4"@4"@4"@4"@4'F#J))P"-\;I9R<"0E]UV62M@3DH5IQS0A$AA8;5XC^K62.
M7/A06%N&%TR5M+9SF]<>[)R"\<Q'QV/B)E+?/O#:W4I9CG44HTB^KE0;O"9[
M9N!Z>/YK9C7I^+#]UQWYA95XRE(:=2X[/7[VI/#NJ(]CG09_35>VV($J)C,M
M%FRILJ1E9,1AYAUR.9CGB*:4&%N`AI2M&KD:"9T$8W0#\-03;@,=D[G^Q8H,
M'_@M_P#IO_4:#/WK^Z=L_P`LL_:[]!)J!0:3;HMDMQGRY)/Y$&-04%OW)Q(S
MVWD270E",3C$^BKGR(?C^DEYLN(4@EIM,?0"XK020:"U]DM!N?M]M,IF8$[?
M>`DQW%O,K^J6>*''.^I/LGC01+9FR=T;=VYON9G!'2]/@N!@QEM$V;:>(\5M
MI(1J[XLK4210:R=)R_X_W\9$?C(??07V1[P%%0QGAA+JE(\345A)"4JN!<VH
M,S8VS=X;9V/O&)N)QM"I3#;[;"'6G%-K7XA=4H-<$ZN'Y-N`H+1SN_\``X3/
MX_`S1(.0RA2(:665.)45**>*D\M-KJ\@H--N>!DY^$WU#Q:=>0>>93'LM+=E
M>AQ3JU+*4=WSN)L;6H([M'"9O"[7V]#R]U/JW&V6'"MI>N.EA2&5`,*<;1W&
MP-*5'R]M!K5YAUWUD41$I[J2IDM]X]U,(.>+<+#=[]WYH#W/;0?>HLV)'Z7I
M$R"SD&G]Q3FPW(\4,A?IDLI4HM.L*'$6!U6\OEH-]TI*#MW8)1YOP=/X"UA[
MXW<)L3W1V=MN?&@M*@4"@4"@4"@4"@4"@4"@4"@4%/\`7GJ_.VDVWM["MK;S
M608+OP@I/O;#)44$MWX+=)'#L3S-!5?JYRWYO5Y,EYUR2^[!EO27W"5K4IQ2
M"5K4>U1/,\Z#UI0*!0:W<>=AX#!S<S-#BHD!E3[X:3J7H3STIN+F@K;=_5.=
M*V*,[@A*Q"FLP,=)\=#7CZ$MJ*B$*2^!=13[D\./*]!.^GT^9D-CX.=-=4_,
MDPF77WEVU+6I`)4;`#C00'UIC(_%2ZEL>\+FQDRU"VI+=U$%-SS\0(%!9.UC
M/5MG$'(I2B>84<RT-^:'?"3K"?8U4&TH%`H%`H`H/#>V-]Y_:FXY.4P,M*'E
MO."7$<"5MO-AY1\)RX*A<]HXT'L+8&]L=O/;,;.P6W&4NE3;\=T=YMYLV<1J
MY*`/)0YT$CH%`H%`H%`H%`H%`H%`H*&WYL+<60ZHN9UC9CF2P01X4UE,YILS
MW/#TI=TJ=3X01P'E-N/.@[>N+C>$;V]EHLYK!Y.+!<B1<>W)>1+*5>'=EHL)
M4G0DI"5.*4$^S027H]C87XNYSV6,3*>G2WYV2;;D)R22YI02EY9U(+O<"B!R
MX4&\Z;[AV1N.-*R6V<6B!X"D,/.>CLL+5XC2'P+M%5Q9P7N>=!,Z"-[E23EX
MAL>[CLD21R'!@<:#7?\`!;_]-_ZC09^]?W3MG^66?M=^@DU`H-+M[[H[A_E(
M?:4:@J67N%S;W@SU>CY2.[MN`Q\&.R7F'(RG%J0E2$-M/)4J0M8"=-G.[PX<
M:"4;%;#;^WD+R`RK:=KKU9%.LAT>.SR*K+X#AQLKAQXT%;]'6VW-N]07;/IO
MCPS&4ZP8X5&2T\E"CWE(4NW#CJ58"ZC>@FN1VOF6NK*]P*QLE,".Z7Q.2XP&
M/1D8U3)7XW[I2KQ>[X`&CFOG0:':&85E\+O_`#K)D*C.,08:'9DCTIPK9"RX
M`O0T=(#R;730.LR<>>L.U2\3KU8_QEA*5%M(F.:"+FUE$D*"@>PB@GNZ\3,R
M^$WOC(;*I$B9*C-):2H()"HT0*.HW`LFYX@CR@\J#%B[85MW%;>Q_A^$5;B2
M^4EQMT>^-.FZ0TS&;;'#S4-@=O,T$9$R8[ZQ2<<])>?;COJD1XSKRU1&VSC^
M\IIE1)2^%N><#ITJX)O<@-MNC$8K*=+W(>4R;N,A.9B:=3+3DE;UYTD)82RT
M4K7JO>P\E!OMJ-0FF]EM0<A\*PT8Z6F/D`G1XJ`&=*M-SI\EJ">4"@4"@4"@
M4"@4"@4"@4"@4$1ZD]2<+L;"&9,/CY!_4C&XY!]\?=`_Y*$^Z5V>W0>?=B[-
MW;UAW@=S;H<6=O-._5+EU(;=2DW$*&.%FP?/4#\M1H+.]7>%%CIW:(R$H:1E
M/#90GDAI"+(;`[`/)07%0*"([OZEX;`2D8F*TYFMS/CZEP4'OOJ_1.GS64>5
M2_R:#69N9NQOI=GI6[4PV,H_'D>%$AE10RVXC2VT5J4"XX.-RCY`/:%6;?QI
ME]&$0\>E];8SZDAY3#KZPA,:WB+$9IQP-K[?>N\@Z%:=1("0.]4,WM+:NR<7
MC8D1T3<4R\Z])46[!*VVBAIO6V2;+Y"Y'DH-UZT8OTAG_743Z,F@M#&_<Z+^
MPM_J109-`H(E!ZH[0F[XD;)CONJS\4++S):6&P&DI6KWSS>2Q02V@4"@AF_^
ME>V-X85R$[';A3T$NPLDPVE+K3Q]T;`:TJ]VD\_;L:"C]B;ZW'TAW)(VGN]I
M9PA5XA\,%89"B?JN-\VRL^>GF./"]P0]/0Y<:7&:E1G4OQWTA;+R"%)4E0N%
M)(Y@T'=0*!0*!0*!0*!0*!0*"E.I.X^J>"RV;E^D2H>("6T[?E1$X[T(%0`M
M+,L^-J+AL='9Q'"@R.IV(F9:7M%&;@IS<9V*X,AB,>_'8FO2_#2HN,J6IM3C
M*.^2EMSR$\*#LV#N)K:W2:?F)L-R9C6Y[Z(N*AEJ7)9CK=2PF.\I&A+CC:KZ
M]7&U!9NWH6&CXUE[$P&L='F(;D%AME+![S:=.M"`.\$@)^1:@V5!%MW/^#/0
MM.KQ$8G*N!-NX=(CGO&W#C[-!A7_`/I6_P#_``W_`*A0;+>6GTK;5P3_`!PU
M:QMQ]'?X]M!)*!0:3;_#(;B/_B(^THU!3$K+;3A9K`G+RUPGG,9B1XJ9180G
MQ8\M'II:*5H4Y%[H0KD-?'D*"8=/3$<C[>,9A,>,O:RREA*B4@*?;)[ZN)U<
MR301#I?DLC*V3NF',\3PHN&;]'0[*E/V:6VZE-FGUK;0"&^:`GR<J"1[WW6Z
MKJ5B<%$F2'%Q'7I3T&S#<9#:,<\=2GT*+H&I0OXB=(Y]@H(YTVC.HZ6[HR$J
M:[,EY)$>0ZMUEU!2"+(2EUPD/I\BT"WMT$YW9N2/"ZC084G%XM^[<+T?(S`Z
M)+2WY#B`EMQMB0D=Y*2@+4CO=OD#=3\D,7&W=D"XM@,26E%YI+2EI^HXPN`\
MI#9M?W1H(CM/+N9C"8G)J?>E-2=UN*CR)"$MK6VEIU(.E'<`[I\WA0=Z=V.*
MZZJVV<%&2E+?CC,IB:I:T^C"VMXJ&A"573K%[\$V[:#1]3XB9?1U+2GXD1/P
MU+/I4UYUE#9]-E`*26@K4KC:RA;MH)/T\2TC%;`2S']&:^"992R5*41<,&X*
M^\0J^J]!95`H%`H%`H%`H%`H%`H%`H(7U1ZH8786"5+D_5.5D`HQ>+0??'W;
M<+_,MI]VOL]OA04'L79.[.LFYGMS[G?4W@T.:)+Z+I#H0;^APP3W&Q[M8_)5
MQH/4N/@8W&0XV-@LMQ8L=L-Q8K8"4I;1862D=@H*L]7LW&\"?ON0/D-B@M#)
MYS#8K'2,ED9K,6#%OZ1(<6`A!3S23\UV6YT%?'<>]^H0+.U&W=N;5<X.;FE(
MTS)".T08ZN*`?[ZOY'&@UF^Y.,Z-[19?VOCVEY#*2#%DY28I3LA2U-+7Z0ZY
M92G2E2;Z.7DH)-U&F,.=(Y\G(>'+\;'(6ITMNALN*0%!S2D!QL7[P)MI[;4%
M68"7D\;T@4K&O267?C"^L(;+S3CC);NKQ`TX'@%J(4-*^*RFY"308.^HD>1M
M[I\IYG5*C8EEY.M]II2$EUGO!MRZKW`OH-UCN4%B>M%<](9X',RHEOVY-!:&
M-^YT7]A;_4B@R*!04)TZA"1ZQN])!6\IO&..^CI0T5M!<UMGQ2[(U7!]XLAM
M0(YVTVXA?=`H%`H*_P"M>V-HYG9DF5N&0,>O'`NP,HD!3K3Q%DH0G@7`X;)+
M?NO;L:"CND'5[);'FLX;<"73MB59Q&L*O%"U*'I#`([["U#O!)(',=MP]6Q9
M4>5':DQG4O1WDAQEYLA2%H4+A22.!!%!VT"@4"@4"@4"@4"@4'FWKCD<)(SL
M[#LS,DN8T5S\ICISC282&X[:5)7$$M/!3J>ZGP5B_$6-Z"4=3L_$AY/;^;PK
MZ\/EF,07X3Q:8=9]$ER(S'HY9<(`4GQ0NZ#P"2.W@&1@G$M=,]T*Q>:E1<@Q
MF98?S[3(DE^8'6PMY$:,VYI8=)`T)!(3QO08'0#'NLYJ:ZZ^IMU&/;8?BI;R
M*4R'$O%1FO*FMMH\50(3I0>'&@O&@B6\[>F.>7X"RWM6O&H,;_@I_P#IO_4*
M#<[GT^F[>U&W\:)MQMQ]%D6H-[0*"/X)P*D[G*>S(D?)3!C`T%8/[/W5D8>'
MDM8MW,8KX`@1X"6<H<:J-(#94Z\4)3WU'4FUR1PY4$NVY%SK.4Q43+J2K.-;
M94W+L00I_P`9M)-P-)[PXF@B6R]F[AVSM+=B<GCEXYA_%)0/$D-R/$>:0]J4
M-*W2@!*TC3<)OYH%!LLOL'=\OJID<XU"B'`.PGF6W#X#<I;KL)3/=6E!<L5D
M`ZU4&FVELG<&S^FVZH^78+7I0C.LJ6(P6562EY)$=3G=0OS25\NQ-!(=\;-W
M'DNI.-S$'&+=8C&!IR29#;:&@Q)4XZ%LE8+G<6KFA1Y:;4&]W#C\EE=O[UA8
MQI#V0D/AF*TZEM39<$.-;4'@6[7YZJ#0;0VYG=O;5VEC,VRS'R`SJG%LQBE3
M0"V9"Q8(&D>6R>%Z#$B=/=T-]<%[I.,:;Q)?=6J:)-U+0N+X:5%&K5<*X:--
MNWLH.[<N`W%G.GD&-@(J94YK-3'PI3B$>"$RY0#NEP^&YI4H72H'VKT&[VAB
MIN(1LG%SV$Q9L/&36WV$+U@*28X/>NJY-[FQMY.%!8%`H%`H%`H%`H%`H%`H
M%!#.I?4S$[$P:ILS3(R+Y4C&8Y"K+>7QM?F4H3[M79[=!0/3[8VY^L&[I>ZM
MTOGX#;<\.0X@V\4MG4(49)-VFDA7?5S^22:#U1C<;`QL%B!`CHBPXR`W'CM`
M)0A">02!05=MN%NU?7+-S<CC7_@1#3B,7.D>D*:;!2T%IC$J+:?&(U+%K=T:
M:"*X/([DV=@MQL8%A[-;@W#+](Q;46.M8CI6E2%O.D:DV;TC3>UU=EKT'7TA
MZ0[N^'1.WYBS(Q*?$EQH\V4'=,YQ22I]<9)6A:E@'45T'H@````6`Y"@K3KI
ME-FP,)C3NG%)R<9^2MN(XM3B6X[_`(*BEUWPB'"CA96BYMR!-!(=TB%)Z<30
M[K,-_&V6J'K=6&EM@%36HMK79)N+D$]M!2TS&;8Q73&.8DA3L"%G)<:$N9:*
MMWQHY3WT!G@$K2%&R1W03YUJ#OW[FI<':&R,;'..3"DXN$'D26%.S+K4TE)C
M.%*@!P-[$%/!2N%!,O6C_P!T4X7M>5$X_P"%!H+0QOW.B_L+?Z@4&30*"CMF
M8?:[?K!YW(1]Q&7EG!,UXWT1ULZCX(=:5)42TOT>P`T)!X\2;4%XT"@4&NS^
MX,/M_%/Y7+R41(,<76ZOM/8E('%2CV`<:"C1MG>?6F<C<V44,3M"`H/;<PKR
M0I,Q:5`E4BW'0L(TJ5;D>[PN5!/-T[+VYU+VUZ"]'&(S^(]Z939)=@O:1[TH
M)X+8<`%K=U2;$6(X!4_3OJ-N'I9N!S9>\F5-X5#G`\5>B!Q1M(85:[D9?,CW
M/MW%!Z=CR&)##;[#B76'4A;3J"%)4E0NE22.!!%!SH%`H%`H%`H%`H%!0V_=
MI]4,[OA[P(8>\.8DXB7*CPGL2WCPSJL]K2N1XOC"QX>UV4&TZQ;5W1G9VWVX
M^`8R#AAO1E2&VVG&H\Q\(;U/*=[PCM(4MQ&D7*P*#*VCLN7"Z6S\'.P4J6T[
MD7EPH"'&(,TL!U/A/K6A;2$.`HUCO7M84&[Z:PMWP,A+BY%&6;PB64^A-9AZ
M%*6VYJ%THD1UJ>6-/8X.'EH+`H(CO3]V.?R%E_RXU!]\&/\`BF\&Y]'^`=%[
M\='H=N?M4&PW,4B?MP$V)R@TCR_4<G\R@WM`H(UMHW=W2>/W4=Y^Q$CCA>@P
M=H;5BN;3PKCDS()6N#&4I+<^4E`)92;)2'+`>0"@QSMB(=_!GTO(:$XDJ\3T
MZ3KNJ3:VKQ-5N[RY4&%F6]K9C9FXI.&S,V>F"U)CR+3Y:DH?:0=3:TJ6+VH-
M[G,?MG`XUS)YC,SX4!DI2Y(=R,L)25D)3>SAYDVH-5O?;V-7LF;+CSI[[3K3
M3C*C.E.(4E;B"DV4Y8W!H)*=HP;_`+NR7\X2_IE!'X.&PT(;EG3LC/BPX,Q2
MWWS/EI"6T0V%J6LASC:_.@Q\CB\'D4;6R&-R<Z7`G9%)9D"?*4E2#$D$*05+
MN/-YB@E`VC!O^[LG_.$OZ900W`L;9PNRF\GF\S,@1!,F-%Y4^4A&HS7@D60N
MUS;C\LT&_CXN'%WAAGXLF3*;D0)RDKD27I*=.N*04>(I8%[]G.@EU`H%`H%`
MH%`H%`H%`H(5U3ZHX;86$]*D6DY:3=.,QB393RQP*E$7T-HO=2OD#C0>==I[
M3W5U3W(=T[L?>1M];P9DY$#2AQ25=R)'`XMLW.E3@!`\NKC037(8O,]),](W
M7M1EQ[:;BVT;HVV2M1B$V)=94JVI`U=QSLY'AR"]-K;IPFZ,)'S.%DIDPI`X
M*'!2%#SFW$^Y6GM!H*JV0K(+Z^[E4Y/UQD^DH$%4@*"+>CE"FVE*UWLHZO>P
M!V*509?J\,):^.`25:1EM*0I2E`)#0(MJ/#SJ"X*!04GZTJ%N[;P[.LH;,E]
MPFY0DK:C+6A)792;DCNI(NH\B*"9[W98D](,BS-+A0_B`AY5E(<)6TD7LH+(
M-SVCVZ"H<7!BO='(3,=#266\](9;),U$9)2A2BXXD+6X#XK7G+O:YT\Q08_4
M%M3OXNH"@[*4C$0Y"E*=:$=(3(9&OPWN]JXV*DG44\*"P/6I4H=))`3[J;%!
M'E[Y/YE!:V.N,?%OS\%N_P#:B@R*!04EL[IWNN'U]SF[)L-UC%/^F^')+C/A
M.)=\%,?1I47572E94E:4A)`L307;084[-X>`K3.G,1E<.ZZXE!L38&Q-[4&+
MG=V;>P>!>SV1FM-XME(5XZ5!063YJ&['O*4>"0*"I,!@L_U?S+6Z-ULNX_9,
M1=\'@2HI,D6_7GK6U)5VGM\T=VY4%XM--M-)::0&VT`)0A("4I2.```Y`4&E
MSV!>D2F<OBG!&SD1)0TZJX:?:OJ,>0!>[:CYIYH/$=H(17>&S<!U1VXMJ0T<
M9N+'W0A;@2J1"D%(467=/GM+X'R*3WAQH*GZ:=1<YTNSSVRMYLKCX9"[A2KK
M$0N'@\TKW<5P^3S?EB@]-L/LOM(>8<2ZRXD+;<00I*DJ%TJ21P((H.=`H%`H
M%`H%`H%`H%`H%`H(CO3]V.?R#E_RXU!D?\-?_)O]5H.6[#_&^U/Y65]H2J"2
M4"@CFW0`=RD'B<D\3['U.S01G'=1X&W&]MX+)Q'#'F8>*]$E0PJ6[=#0#@>B
M,I4\A'+2X`4GB.%J"00)K,[>[4M@K]'?PJ'&PXA;2K+DDC4AP)6D^P105ETQ
M!/3KJ,D<U97))'MJ;2!Y:"4>LC_NDRO[+%^V$4&YS""GI2PA7=4(,(*OV&[0
M[*":D@$`GB>0H*\W:2-C]1[$)_=7$_R<Q0:_914-@=,0.(,AFYO_`)C*H+&C
MYS#29BX4>?'>F(U:XR'4*<&@V5=(-^Z>!H*9ZGA7XD4:1=7PI)//_.91YT%C
MXE%LAM4*!U(PTCV+'ZC!X4$LH%`H%`H%`H%`H%`H(7U0ZH8;86%]*DI,K)R0
MI.-QC9[[RT\U*/N6T7&M7YM!0?3_`*>[IZO;D=W9N^0X<+K*7'D]SQTH4;1(
MOS#*;]]8Y^W<T$UWWMS%.]:ML8M$UO'8Z%`@B/B"^XPTZE$QRS2&D-/(<\P<
M%%/MT%MR,8Z@B&M:3&<][A/K0'5MI5Q<C.!?!;:T)*0?)S[#05+M7#G8_6_'
MXO`N.1,!NR'(E3,*YQ:8>CZ[>%>Q\Y'=-O--N5K!L-GRLLSUZS..D,/LPEF=
M*BJ6@MH>2X(P4X%E(\;2I(2FW!/EH,[U?18[QXW_`(W//A;WI/"@MR@4%:=<
M]_Y?9^$AJQJ6BYDS)BAU?%QIST=19=;N='<7Q5JO[5!N-[Y1QGIC+R:Y09"(
M+;\F4`M7<LE2RD(0M1U>318]O"@JO$.[:F])DO9I63<B2-P3/1W([C"'PXM+
M@'B+?"&DH";A/`6.FU!']^'-.Y38;`*EXMC"XUUM`4%*4%OM)6I]):4!RTW"
MN(\E!97K2)U=*7D]IG1;?VQH+5@BT*.#S#2.7Z44'?0*!0?%)U)*;D7!%QP(
MOY*"FXD[?VS>HN.V]*:9S&`S:U-QYY0AA]9'>*WY*U*+KZ4ZBM'ND@%%N*:"
M9[IZ3[0W1DX$_)LN%,)TON0VE:(TE?"Q?:M91%N?`D<";4$Q;;;;;2VVD(;0
M`E"$@``#@``.0%!RH,#+S\(RP8F5EQX[<Q"VPV^ZEKQ$D:5A.I22?.[*"E8/
M27?6Q^H+$S8KC;^!R2U&4)KCBE,MH;!4U)63=Q"U=UG2DJ2>/EU!,M\;)PG5
M';>A:3C-Q8XD,+=`+T1\BZF'TCSVE\.7`BRDT%4],NIF<Z:YUW9.]&UL8EE8
M0G7WS"4L]UQI7]TBKY\/-^6*#TVR\T\TAYE:7&G$A;;B"%)4E0N"".8-!RH%
M!@SY\]B?`CQL>Y+8E+6F5+2MM"(R$)N%K"B%*U*[H"109U`H%`H%`H%`H%`H
M(CO3]V.?R#E_RXU!D?\`#7_R;_5:#ENS[K[3_E97VA+H))0*".X`@#<9/`#(
MOW/^`:H*[A3=T8J=!GX[$/3("\=B%RI<7T)*A':@OI=;<6\XVY;Q5M*&KAW3
M8^4)1L:7.EY/$2,@^),]W;<=<I]*D+"W%/'4K4V2@]Z_%)M00GI@+]-]_J')
M>7R-K#B>ZB@DOK)%/XI<G<V)>BV]D^.GA02#.-__`%LTA0Y1H0*>%O.:X4&S
MR&SL5/W7BMS/+?&0Q#3S,9M#A2R0^-*BM':0+V_)Y"@BF]%%.P^HY!*>](%Q
MQYP(XH,+98*=A=,$CB#(:)X?YA*/909^T^DCF!WU-W0O*JEIE+EK;BJ2L!L2
MW`YI%UJ3W;=B>-!#NIJ0OH8R`NX7D9!"AV_5$E7"@LZ`DIS&VD\P,1*%_:5#
MH)10*!0*!0*!0*!0*"$]4>J>$V'AP_)4F1EI0*<;C0KONJ'#6JW%+:?=*^0.
M-!YHVA&:ZF=363O7*J:^$`7DDZFA+2A6E,.*LV#:.!'=-S8V[U![&@P8<&(S
M$AM)CQ8Z$M,L-@)0A"19*4@<@*"B.K3ZH_7_`&2IF4ZPIQIAN8A%]*F3+.@*
M3K3KU.$#V.?&@O'(COPO8DI_4+H*@FKOUYV.DJ2HC&3U73?M6^.T>Q0=FP?A
M>=UWW;+==6]`QOC1$K4K44^,6E(:N5<$I\(Z0E/EO09OJ_K"_C@H??:UQ>W!
MI/EH+;H%!5/K!;+W+NK#8F-@L>)[D>0ZM]/B-M*2E312D@N*0"+GB*"2;^#K
M'2_)HD,-J=3C@AY@J;2W?2E*T@N`H-NP=O(<:"E)RGW.B\4H9=;ON5Q*]4Q[
M4@64!XKQ*E*U<N\;I)\HH-SO+&RI.W]D3&VII1%QN+.IF/XL<:G6]>I\J2EN
MPMKU@W21H[UZ"9>LCCLED.FRF,=%?ER/3HJ@S';4XNP4;G2@$V]F@L/%9.%-
M82EAU*G6DI#S)NEQ!MR4A5E)^2*#.H%`H,#.YO'8+#R\ODG/"@PFRZ^L"YL.
M02.TJ/`#RT'G/)#?W4]UW>L;(Q<5$Q2PO:N"?>1J>6RO47-16$)<5IMK4"">
MZ+)[U!;W2?JOC=]8QQMQ(A;AQY\++8TGBEQ/!2V[\5(O_:G@?9"?4"@H;UD8
M*)^X]H0@VER1*$II@N.H80A1<8.LK64H/=!&E1%[\Z"^0+"U!HL[A9:Y+>7P
MZDL9B.+$*X-2FASCOV%[?,+YH5QY:@0I[K_F]A9O:<0RH[R=[AWT?%8UM(,]
MI[4`XQ(0G5=HZN'/5<%%[WH([TIZG9CIUFU;-WLT_#Q2BCP1([RH*G+%!!NJ
M\==^-N"3\F@]/-.MNMI<:6EQM:0I"TD%*DJ%P01S!H.5`H%`H%`H%`H%`H%`
MH(CO3]V.?R#E_P`N-09'_#7_`,F_U6@Y;L^Z^T_Y65]H2Z"24"@C>$-FMRFU
M_J^1P/$'ZG:H*QE;/P&X4[?S(W5BX'@8N"Q+QCR4.MR"PV%)3+1Z2R'0VLW2
ME2>';>@F.*S^WXV]6TOYG'N%G!LLN26G&665+3(7<(0%J2CRZ=1L*#5HQ^RM
MJ;)W'"QNX&)BLF^_/7XDF.I86\4W2D((N!I[>-!O=_QMB[TVT_@9VX8T9AY;
M;GC,2H^L*;4%#@HJ!%!]W3N#:S6SW(3&8ANEE,=M`$ADJ(0ZV+V2KR"@D7QM
MVI]^H/V2S\]01-R9L_.8[=V&FYJ*Q&RDI;1=1)92OPUPXZ"M!42#8@]E!U&9
ML["0]EX>!FXKT7%3$L^*J2PI7AMP9*-3A20!<D7X#B:"7_'#:5@?AN!8\CZ4
MS\]05SZ)LK=O32)@\CN&-C@9+SZE-OQPX#Z0]PTN$@:@L]E!,H64P<K=>)C8
MN?'FIBXV8A08>;=*4AR(E)5H)M>U!*Z!0*!0*!0*!0";4%-[L]9C;6(R\[%X
MR$YEEQ&RAN<VXE,94L&WA7\XMI]TXGMX`=M!6G3_`*;[DZM;D?W=NR0X<*XX
M/&D<4F2$']RQ!_<XZ/-4H>T.-S07MO[I)MG=>VF<0AE.-DXY%L)-C)T*B+2.
M[ITZ>Y<<4W]GGQH(WTRZE9J%FCT]Z@)$7<\4:,9D5\&\BRG@@A1X%PA//W7Z
M8&@U?4/'1\CU^VLHMQE2,;'B2$>,MI!4AV4ZE=]:T+4I`1=H(2HZN?"@N3)M
MR"RRZRCQ%QW4O*;]TI(!"@G]%97"@I)"PKU@-F**%-%.'E`MN$ZDW<EJLH*X
M@V(X'C076UAL'%G/91N#%8GN@^D3DM-H>4DV*M;H`41W1>Y[*"L_5W=0[C-S
M.MK2MI>864*3QO=AHWOVWH+;H%`H(1UH,8]-,XU(6A/CLI:92X\B,%/%Q);3
MXCG<%U#MYT%(,OK1T8@/R7%N1U;BEH=C^]O^(\H+#)4YK1?0L7&FX)M?A09.
M^D36&=C*8E38\63B\0N8SX[R8CRT/LH0@-IU-E>D=\$`$:>-Z#T9GL_AL%`.
M0S$UF!"2H(,B0M+:-2O-2"HCO&W`4%3P>M^T=RSS(0#@WL:E<B)DIDAAL/)2
ML6C%M"E.*2^WQ4DCNFWN@*"YTJ2M(4DW2H`@^P:#[08V1G,P(+\QX*4VPDJ*
M&QJ6H\@A">U2CP`\M!&)NVU;F@/P=T9!2?2SH5B(#_A-M!)#J4*6/?'7``%*
M4;#R)%!B#HATQ\)#:\07`CD5R91)/E/OO,T$7WOT21C&V-S]-4KQFZ<02\U&
M\5QQJ8D)LIE8=6H!13P'&RN2NP@)7TMZHX[>^+4E;7P?N&#W,OAW>ZZTX."E
M)2;*T:O*+I/`T$YH*EZS[2W?F-S;4R6WX298QJWO%4H,K0DNK:%G4/$)T%"5
M=ZRK'LH+:H(-U2ZHXW9&,;0A!G;AR'O>(Q+=U...*.D+4$W(0%'VSR%!'^E?
M2B=$R;N^M\*3.WKD3XH0H`MPDJ%@A`%QX@3W;CS1W1VDAO>K/2O&;]POADIB
MYR("K&9`CS2>;+MN*FE^Z'9S%!16TNKN^^F!E[3S..],3!<0$0I+I2Y&02"I
M++@"DN-+1Q;[+_*H/2VSMXX3=V#8S.'>\2.Z+.-JX.-.`=YIU/N5)_\`WCA0
M;N@4"@4"@4"@4"@4"@B>^5AJ/D'[<6L#E%#Y3)_,H.^W_P!;6_\`!O\`5:#(
MW$E*LQMG4`;9%PBX)L1`D\>%!O:!0:':J@I_/6^^CH^4TT*#<>A0OWNW_:)_
M.H'H4*UO1V[?I$_G4#T*$/\`)V_[1/YU`]!A?O=O^T3^=0/0H0_R=O\`M$_G
M4#T&%^]V_P"T3^=0?#`@D@F.U<<`=">7RJ#B,;CAJM%9&JY59M/'5SOP[:#B
M<1B2A*#"8T)L4I\)%A;E86H/BL)AEFZX$91\I:0?S*#LC8W'15%<6*RPM0LI
M33:4$CR$I`H,B@4"@4"@4"@4$#ZO]1-O;2VT_'R`]+GY1EV/"Q3:RAQ[6G0I
M14GO-MI"N\OY7&@\^]'>B\S>CK62R07#VG&4$E2;H<F*0?,9-OUL'@I?R!QX
M@/6\&##@Q&H<-E$>*P@-LL-I"4(2G@`D"@B>TNI3&XMSY/`IQDB&YC3(^J72
M"V\B.^(^ML@6(4O5R/#3QH'4[ICA]]881I!,7*Q27,7E&_UUAWF.(L2@D"Z;
M^R.-!2VW<GOI_K#A<%N]UF#FL:TTP]-6\ZRO(,1W5N-^"I`\%U3FOB%I[UC;
M2J]!Z<!N*"NNHG0_:^],DC,2)$N!DV6%,H=A.(:2OB5)+ET+-P3S20;4&NZL
M[PF0NF['H;*%)R3J<1EDR0Y>,AYI;;NM:"/#6E5K%7`_)H,/U:,8QCMNY^&R
M2I+&64V%JYJ"8S(O07%0*!041ZR^6R#\[;.T&_`1`S*W79;\E#BT-EHH0'%J
M:4E:4)2ZK7['/A00+?&U=Q[8;P.S\KEH\R5D79;[#;;<IQ"G9CJ&1=:E@DV(
M0-5[`GLH,C>>P>M$H0)CF";?B[<88;QRT".J2EJ$`I-TI=45]])7I%R>%!HM
MZ[GZM;T@HQ6X(3KK,:1J0PW!6RX)'@%02;))U>$X5:?DT&RA=3^M6-BQL:W"
M2VW$:888#F,)6$>%=H$VN2I"+CRT&QQ_6'K]D)D>'#C>,_)+?@I^#M((>OH*
ME*TH2DV/>)`]F@EQS?K5!*D'#1"H@V<"8EQ?CP^J;</:H-!OK>WK#8S;QE;@
M@1\5CTOQ_JYI$=3B'4NA;5DAYX&ZT"]T$4$0DX'J1M'!1.JC>3B)>R`]+86D
M%Z8X9J2I:UH<94W<-J.HZNZD6'(4'IS:^[DR]OX5R<'7,C+A179#B6[(4\\T
MA2N\+(22I7+A0;"9N5EI$,1V2Z_/#BHZ'5)80/"MJUK5>QX\@":#SMD<_P#!
M_5R;OH./P8KN.3,D(BI:>>2VH"$4!+H"%W=:2HGR>S077T@G3LCM$9)_,O9N
M++ERUXZ7);2T\(R9"T("[!-SW;\A86%N%!.*"#=5>J6.V+B4%+?I^?G>]XG$
MMW4XZX38*4E-U:`?)Q)X#C0:+I;TOR;&3<WUOIP3MZ9`:VVU6+<%LC@VV.06
M$FW#S1P':2%JT"@H7UL<;!^`\%E`P@9!,U4?TD"RRP67'"V3VIU)!`-!M/5D
MVKGL-MW(Y')-):BYLQI6.TN!96T&SWU)3YI.H<#QH+GH%`H%`H%`H%`H%`H(
M5U`>5X669-M'Q;RJ[=M[-CG0;'_AO_Y/_JM!D9]Q*<WMI!/>7.>TCVH$F]!O
M*!01W9O%6>5\UEY-O[%*$_\`-H)%0*!0*!0*!0*!0*!0*!0*!0*!0*"$=5.J
M&*V)A2\L)E9J4E0Q>-OQ<4.'B+MQ2TCW2OD#C0>;=@85KJGU.<?W=EKO.)$E
MZ.5*;<E-I/=BQ0>ZAI/,A/'3RXW-![#A0HL**U$B-(8BL(#;+#:0E"$)%@E(
M'("@[J"G>BJ(SN]-[2%.A4MG(28Z6@^"$,F2IWNQBD*;!<4JZD]U1]GC07$:
M"C_6<R>R4[?8@S^_NT*#N#,=6F1'L;J=6H<4M=WEVGERN`L7I5E,CE>G6WLC
MD7S)G2(3:I$A7G+4.&I5K<3;C02N@U>5VUALH'1,CZO'2$/E"E-EQ*>25Z"G
M6/TU!7/JZK4K#;D*C<C,+';V1F1VT%M4"@4%0=3(;$SK7T]B24>+&DQ\JT^T
MH=Q2%L`*2?;!H*XZD+E,]4-C8.8M3TS!2(D14E?!3S!FMJC.WMQ):L%'YH*H
M/4+[S3#2WGEI::;!4XXLA*4I`N22>``H*[&Z-MG,9%SX7A:1F"L'TAH#2,.$
MZKZN(U&WM\*#0R,_!7N>)(C;EQK49;^.2&EJ;<TJ1CI%W5*#K?<[X3;RVX]A
M#$@R<SE<3-Q^$W/#&6D8K"MP/0W41W@XVZZI:$N%UWB$7"QIXWY#M"YL0G))
MQ,).46AS)I8;$YQO@A3X0/$*>`X%5[<*"LO6;_W6NB]KSH@'L^^4$,R(<RWJ
M^3,NI2A`QN!BXS')["M*F?3G[$#W:`TDWY)5Y:#8;?3UT.W<0C%XY@8A,-E,
M=I1CV?9*4J2IT*E:DJ6D"]K$<;6H-^U,ZZC'F"[MC&2&KG27BRI-B;\4>F*!
M^70:!OIKOS-[O<F9C;V/AX:9#5&GPUO%,<A*M:`A,9]UT%2SJX:0+4%E]*]N
M9O;>UDX7*LQ61#DR!!3"4XILQW'5.()\0J4GS^";FPYF]!U=4>IV-V/B4+\+
MT_.33X6)Q+9)<><4=()"05!`)XGMY#C0:#IATPRC635OK?;GI^])HU,M+LIN
M`T0;--`=W6$FQ(\WD.TD+4H,3,278N)FR6?UUB.ZZW<7[R$%0X=O$4%9>KYO
M_=N\L/E9.XY,:6Y%<C)C.Q`@(TO1TO*"M`MK&NRD^Y-Q0:7UL;_%'!@#_O(_
M:SM!972L6Z;;9'DQL;Z&*"4T"@4"@4"@4"@4"@4$(Z@$:<N/=?%K*</VN@VF
MA?XNM&DZ_@>VFW&_HO*U!\W(2-S[2%^!FR;C_P`OD4$DH%!']G!.C,V`!.6E
MW([3J%!(*!0*!0*!0*!0*!0*!0*!0*!0*"#=5.JV&V%B0MP"9FY8*<9BDJ`6
MXKC[XY\PTGW2OD#C047TWZ:[AZJ;D?WAN]U:\,MWWY[BDRR@@B-'2>+<=OS2
M1[0[307)U*Z-8K<V/A/X92<+N+"H2,+/CCPPA+7%#*M%NX+=T^Y^70=72CJE
M*S+S^U-VMIQV^<62U)C+L@2D('Z\UV$D<5`?IAPY!9U!%MM=/,/M_<>7ST1]
M]R5ER2ZVZ4%*`IPNJ`(2%K[ZC8N*40.`X4&DZK=6(VSV&<9C8YRN[LB0C%XE
ML%9NHV#CH3Q"?(.:O:N0$,;Z42\/L?=F[MX2!E-\9'&2R_()UHBH4TH>"SV7
MMP*AR'!/#F$DZ);UPJ^FN"CJ\5KT-E,.0^ML^"EY)M92QJT`WX%=@:"T[\*#
M62LPYZ8J!CX_I<ML`R"5^&TR%"Z?$797>5V)2";<>%!%>D6S<YM;&99C,%CT
MB?D%RFTQEJ<2&_";;%RI*.)+9-K4$]H%!C3\C#@,^/+=#3=PD$W)4H\DI2+J
M4H]@`O04'U;S*\MU?V:SCH\GTC%-2I$N.YXT5;K)0'5H:4V0YK4RVJUNVP[:
M#5=7XV+8ZL;!DX]UUYF:O'NA;KSKY*#-3X9275+(!3V"@]%;@P[6:PF0Q#SB
MFFLA'=BN.(L5)2\@H)%^T7H*95TL7Z4]";R<1+4"6<>DG"XI2U)1CQ+"U*4Q
MQ5?N^U[-!IG]J8^)FVL5,S^*C/+,0NH>Q&(;4&9,9U]3@"F0"D.,A'R>/&U!
MVQ(FT\0T-TY?.1)L+;@QN44WB\=C420\ZM2/`U1D(<"$+TW%[\>-!?"=P8SX
M&BYA;A;B3&VG8X(U+5XZ0IM"4(U%2U7X)3>@ICUCMW"3M`X1S'2(;SIBY%MR
M1X8NVF0ELI*4+6I*KK'.@T^\([3'J\XR-C'I'I,G!L39B5RI)8;B(2V72&-?
MAW<<6E"4VMQ)[*"]=A_@1M_L_BV)P/[`B@WE`H!Y4%23=OSF>OCFZ)N(?DX6
M/AT-QI[;7C);DZK72E-UZ@C5YJ;B_LT%J0YD69%:E174O1WDA;3J#<$&@[J#
M6[EU?%S*Z?.]#D6XVX^$KM/*@J/U39K+W3Z3%TI1+AR0F2/141EGQ&PZVI:T
MK4I^[:AI6I*>'`7`O0</6Q-MHX/^4C]K.T%D]+#?IOMD\KXV-]#%!*:!0*!0
M*!0*!0*!0*"#[^\_+?\`QG*?XN@D-O\`9*W>_<%K^Z_6?RZ#"W)^%&TOKV5_
MZ?(H))0*#0;02`WES;GE9A_Y=J#?T"@4"@4"@4"@4"@4"@4"@4"@@O5CJMB=
M@8=+JT";FIET8S&)592U#FZX>:6D>Z5\@<:"CNFO3?<G5+<+^\-WO+.'?<)=
M?XH5+T'NQHX/%N,WR*ASY#M-!ZCCQX>.@(88;1'AQ&PEMIM.E"&VQP"4CL`%
M!JMJ;UVQNN.[)P,P3&6M/BJ"5HTZ[Z00L)/N3017J]TOB;G@HS<&4,3NG#H+
MV.S"3X8`;[^AY0XZ/(KW/M7!"L,'ZRS\AEJ-NMB5&,=M+;[F*TH<?6F_BNNE
MTH4UI";Z&^))Y]E!<C?I4O;8S6Q\GZ:N2PIS'(G/.2(CZE7TZEJ)<;(5VI/L
M$4%-](=K;I@]4,AN+>(>3E(B'4.!]M;LB4_)2!>,$I4@MH`("T'MMRH-YNWU
M@]J939>?PDZ!/Q6>>:E8\XYYK64.:5(25.)LD#R]HH.CU7MJS$1,CN):V7<3
MEV!"\`A0<#L5Q25!:2-"TD*/>Y]G*@E\SJ]LG965R.V,J_)#F,<28B$,N/>\
M/-(>0V%VXZ"HI%SRMQH*F<]8K/MRVTXE;<#&V2N1'7&\>0\\ISQ9#I=)"0IS
MS4\"`#?B0*"V]I^L-L/.Q77)'I.*D,JTJ8>9<>!!%PH.,)<3\@V/L4&^_'!T
M\N1\)JN.?U+*^E4`=7^GJK6RBN/(^C2OI5!V;)W-A-YN3=P8QY4B'$?5`AEQ
MM3>A2$(4\L)6`;K*[7\@H*2ZQ[N^*O77'YUN.F4[C8R'#&6HMI6AYE35]82K
MB./9V4$+WSO;`2=_X?)8J4)NW\+(8DQ+(+"VV?2?2G(H2Z$7\-6H(/*Q'DH+
M;F^MAM%$9TQL//5(TGP$OF.VV5^YUJ2ZHI3?GP-!"?ZQ[WI3[_P=%*Y$Q4PI
M\=0";PO0R/-5>WGT&(>OR%SXTQ[$0U+:>CN.$NZBH1XCD:VHIY*+NL#LY>S0
M?6>M^W'TJ@YS;T>?AI<>!#FM(>\-S3`+B@Z@63==U@@:QRYT%P]*]\;7WSDW
M!A83T*#M:(Q&@Q']%FU/ZTE:?#6X"0TTE(N;@7\M!`/6KR##.2@0W."Y4'WM
M1L$CPY:'#<D^1-!#\KU,P2.C7P(S(9E[@S$1C'3F@XX@P(<!L!E(UHT+*U(4
MI02?.6>=J#U/L<I.RL`4VT_!T2UN(_6$4&[H%`H(AN3JSL';>57B<SDQ%GMM
MH=6SX3R[(<OI.I"%)XV\M!H<1U@Z:/;E<1!S\=J%+86](2^%1FDR&UI`6%O!
ML%;J%\0/F;T$G'4WIT;VW/B^`N?JMGE_;4'+\873U]DWW'BW&5GPR#+8()5P
MTD%7;>@P<#DNDFW([[6$R&%QK#[A>D(CR(R`IRP3<V5Y``*"K/6@W)M[*;8P
ML?&92).>3/+JVXS[;JDH]'<&HI0HD"ZAQM06[TN`'3G;('+X-B_0DT$HH%`H
M%`H%`H%`H%`H(/O[]<RW_P`:RG^+H)+_`.V/]"_Q5!KMR?A1M+Z]E?\`I\B@
MDE`H-%M+]:RO\J3/HE!O:!0*!0*!0*!0*!0*!0*!0*""]5>JN(V'BD*<`EYN
M9<8S&@V*R.;CA'%+2.T]O(<:#S]TUVX>JW4.5,W?E$OEE`D28FO2]*0H]QAE
M(MHCMCSM/'EY;T'K6%#BPHC,.*TAB-'0EMAEL!*$(2+)2E(Y`"@X9,`XV6"2
M`67+E)L?-/(T%7>KA!+6T),]2B79[K16DQE14I##*64@?W-W@CBX@]X^=WKT
M$^W4VAYK&Q71JC29[+<A)Y*0G4X$JOS"EH2".V@H+?\`ZN>\G\KF<OC);681
M)69+3;R_#FO+=(UMFR4,C3<E)N.%!>O3K$Y[$[)Q&-S[K;^6BL!N0IH`(38G
M0@:0`="+))MQM0=TO*2,I/<Q&)59E@E&6R23W6;BQCLJ2H'TGB#Y$#B>)`H-
MI'Q6/8BM14,)4RTD)3X@\11L.:E+NI2CVD\30=[;332`AI"4(')*0`/E"@XK
MB17%%2V4*4KSBI()/9QN*#CZ#"X?4[7=-T]Q/`^7E0=C3#+0(:;2V#Q(2`F_
MRJ#G0*#BVTVVG2V@(2220D`"YYGA0=;L.&ZK6ZPVXNUM2D))M[9%!T.83"K2
M4KQ\9:222%,MD7/;Q%!]<P^)=3I=A1UI')*FD$?DB@ZOBWMW[UP_VAKYV@?%
MS;WWKB?M#7SM`^+>WOO7$X<O>&OG:#2[GW'BMEMMRACDB"ZW(>G&(VD.A,5D
MN`I;2!K/9Q(MSY4'?@<GB]VQWI<G%H+#"VQ$]*;2MPMOQ69(*D+'O:O?M)3[
M%!L_BWMTCCBXG'_H&OG:#8)2E"0A`"4I`"4@6``Y`"@^T"@&@JGJUT2B[O?=
MS&/>6UN)Y+$9#CKI$5MI"^\X6PDE2@E1L+\:".;(]7S;C>1>C[E*<K(9:6J8
MPPZZF.PMY2"PVE0*'"M*$+*B3R4.%!//Q%=)OZ.L_MLCZ90?/Q$=)3_[=9_;
M9'TR@X_B$Z1WO\7&O:\61;Z)05-ZQ/3G8^U-OXJ7M_%(@2Y,M;+KB''5:FPP
MM=B%K4/.`H+TZ:-Z.GFVD\/N7$/"]N+*3VT$EH%`H%`H%`H%`H%`H(/OX'7E
MCV?%K*?XN@DO_MC_`$+_`!5!K]Q)!W-M0WMIERB/9^H'Q;\F@D=`H-#M$@M9
M6W'^-)GT2@WU`H%`H%`H%`H%`H%`H%`H(%U9ZKXO8.'"]`F9V8"G&8T*MJ/+
MQ7CS0R@^<>WD*"ENF/2[/=2\XO>F]'G)&*?65K<42A4TI)`98`-VHK?+AYW(
M=IH+7ZE=(495J'G-H*1A=VX-`&+?8&A#C;2;(CK`[MK=U)(]@\*#-Z3]4V-W
MPW<;E&O@_=^,NWEL6L%"M23I+K:5<=)/,>Y/R"0GDUA<B%(CMK\-;S:VTN$:
M@DJ20%6X7MY*"%=(^GD[8V"DXV7.3+\9X.-I;+A;;`0$G2'#W=:@5E(%A?MY
MT&OZP=08^*B-;8Q,966W?F+)QF,9)UM*!U(DN$>:&U)U)Y7MY+T$WVPC/IP,
M%.X5LN9L,I^$%1@0R7?=:`:#$R$^;E93F*P[@;8;);RN40KBSP(4Q'(_RCRD
M\&QQ-S84$:SF[]C1<WB=AQ)H3E52V-4!CQ;Z;J6OQ7F^&LVU*U*U'F>=!F[A
MC[J6WD\'C52TQS`=E0<DRXE#X>(*&X:77`1JUC5J/'3P)[:"`],NMFV,'MA6
M/WMEI$?<#$M\3&93,EQQ!*KZ562Y:W'AV4$EV++R/XNH&YL,9.1?E*><5!6M
M:Q(0[*<0A0#A][*`H*.FW=%K4$;R6[)^QNK9D;QR4Y&VY47ZDF/AQR,X_P"$
M/$0RA@%*0%W[A3J',FQH+`PG5_9.=:==PSDW(,LD)==CX^<XD$WL+AG]":#&
MS/7+IQ@Y(BYF=(QSY3K2W*@S&B4\[C6T+T&"/6/Z.$7^'N'UO)^ET'+^L9T=
MTZOA]/Z7T>3<^T/#H.P>L)T?*-0W$UV]WPG]7#CR\.]!8$:2Q*CM2&%AQAY"
M7&G!R4A8U)4/;!H.T4$(WAU.P^V]?I4AIE/B&.VX]XEA*;272RZD#6E+C0][
M=`*?+01/^L7M%:K&>VVRNW?0VYXJ6WN"2$D*278ZOUU')0[R3[F@X_U@-JH>
M4VYGHQ4E:6PM++OA$I23XGFE7@N\E>Z;5\TF@D6$WC'S\6#N"`4Y#'J6L,)=
M0E+J"YW5-<0-+MKAM7FNIX<[$AWN]9>DV/E267,TQ&D^(?2TEIY*O%2`@Z[-
M^>`D)/;PM0!UVZ2G_P!QQ_[5WL[/,H.7X\^D]@?C'&L3;S7?G*"6X7-XK-XN
M/E<3)1+Q\I)5'D-WTJ`)2>8!X$$4&HC=1MDRMRJVRQE6G,XA:VE0@%Z@XT-2
MT7TZ;I`X\:#99_<>#V_CE9'-36X$%*DH5(>-DA2S9(X=IH*UV_U+>W?U7R.W
M\+G&E;88QB)$=Z*ALNKD!:4NI2XXDG@%\>'906CC<9#QL41HB-*-16M2B5+6
MXHW4XXL\5*4>9-!E4&KW6\MG:^8>;<+3C<&2M#H5H*2EE1"@KW-O+059ZKT_
M-9#:>4EY/)3\D%2VTQG<B7=6@1FROP_%4ON^*I8U`\;7X<J#7^MD3\7<`.ST
MQXV[+B.J@M?IV+;!VW_)<+[7102&@4"@4"@4"@4"@4"@AF_%)\'-@FQ&W<@>
MVUB!\B@D'_MG_0O\508>=0E6Y-M$\T2)*D^WZ&ZG\HT&_H%!'=E*"HV6(L1\
M+SQPX<GU`_E4$BH%`H%`H%`H%`H%`H%`H*_ZM=6\5L/%I2`F7GIH(QV/U6]M
MYZU]+2/R>0H*8Z8=+<_U*S1WCO1]U[$.KUJ6X2E<\H)`:;`MX<9'+@!?D/+0
M>CLMGML;7B0T9&2SC(CBA&A((*472@D-H"1PLE-!M(LF/+BLRHZPY'D(2ZRX
M.2D+&I*A[8-!5_6#IH9A^.^VY8PV[L,V7Q-"O#0^TTDE3;QY7T\`H\".Z>'(
M-CTBZOXS?6-##R1#W%&;"IT`\`H<O&9)\Y!/,<T\C0?>J?5-&UTL87"QU97>
M63&C%XIH%93JO[\Z!R2FQ(';[5S051MOI-O_`!6ZU[NW5,#648+,F)(9>\1R
M9/DG0&%6]RB^A:0G24GNFU!Z`GR9F1D*Q>-46F0"G(9))_6TG4E33"DG]T`B
M]R+('LV%!&.K6=E;-Z<O_%VT?('1&QZ4(+JP5JNZXE("BI24:EE1OQXF@J;I
M-N6%L_$F0ULK+Y7-SR'YV;4EM:G2OO#PU&Y2BRKCM/,T%C*ZU9@)O\0,^;7)
M/@BUNRU@:"O9V?RS_5F/OD[#RZ\<U!5#?@JB7<4\=8\3EI5YX''C03-?7U$!
MR)CG-CYF)(EW1CH9:0VIW3S#:.%['R"@[)O6Q3C($KI]G''`@E"78H6!J''C
M95N'L4$:]5\9J#)W#$RJ),..TVT\S&EH4R$(6XXHJ`<"3:ZE<:"XX>"Q.3FS
M,Q,AM2A*4E$;TA"7!X+20D*2%CAXB@3[(M09WQ7VS]Z(7V.U\[0/BOMKG\$P
MK_6[7SM!6WK$8+"1.E&5?BX^+'>2Y%LZTRVA0O(0#920#06-M'\%<+]81OH*
M:#;4'FWUDUQQD,-Z0EI81DN\B02I/A:4J*?&2#I9-^^TH70>(NE5!;T3ICL6
M3C62YBHZD/1/1[)T+`84H.MI2XD#7X)_6G/.MV\:#8-].MCIU!6$AN(4\)(0
MXPVI*70`"I`*>[JM<@<":#0S<7!@X++[69BIC3W(,B+@G#]3MR&5!;C#+;PU
M!*F5KTV/>%M5K&@J+H%B5Y+J;GV=SPDS9S4$F<F<E#RA*\=`<6M)UI"R;CA0
M>A1LK9OWAQWV(Q\Y0??B7LX<L%C[C_-6?G:#3-QEX?`9';$)(A24M2O@`M*$
M<.^,%N-I;7;2EU#BK'AY%6H/*.!1O!&ZUK@(E.;OC6=>T6],,E.LR>8LM1XZ
MD<-7*XYT'KB4(6YUQ<>[':FP8JT/Y3QD(<;#S:;H8TG6DKUJNJQ.FUNV@KK?
MW2-64W+-RNREMX3<^"C0G\8F,$L,.%:I&M"TH38*4$@!1X=BN%!)NDG5IC>$
M=W$Y9KX,WAC+MY/&.#05*1W5.-)5QM?SD^Y/L6-!8U!JMV-./;5S+3:2IQR#
M)2A*4ZR2IE0`">.KVJ"K_56,MOIT["?BO,"#*4RAQUYYU#ET)<46D.=UH)*]
M*D-\-0-^-Z#6>MFJVWL`+<YCYO[4=5!;/3S\`=M?R7"^UT4$@H%`H%`H%`H%
M`H%`H*_ZD*4&-RE(!*=L3--P#;45WYCML*"7?^V_]#_Q5!@YU=MS[:1;SGI9
MOY+15_GT$@H%!'=D("864L"-67R1-Q:_U6OE[%!(J!0*!0*!0*!0*!0*!0><
MNN?63<T;<;NV,`X_AF\6XVN;-``??64AQ"6P;V9X\3[KERYA&NDFROQG[SR6
M9W3-,MJ$II^<PHCQ92UW\-!M;0PC1Q"?TO*@]7LLM,M(;;0EMML!+:$`)2E(
M%@`!P``H*H]8A#;N(V_'4MEM;^14TAR2PJ2PDN176]2VT`J.G5J!'(B]C:@L
M[#1_1L/!CZ@OP8[3>M/$'2@"XX)YV\@H,+<"?&DXJ&Z`8DF41(2KDKPVENMH
M(/.ZT`_(H//^?Z$]2\%N*5N?;4T3I4>7Z5"=;6E$YSQC=PK;*&V3:YNG592>
MR@DOJYN[<E/YF;.6\[U&<?<.<5.L'PC60/`2?-;[%`<0>!X6H(WZS.]H$K)M
M[>9AR&,UM]YJ7$R[<CPPCQFTJ6$H20J]B+*[+4'HG`1V8^%A-M("$^`VHV[5
M*2"I1/:5$W)/$F@YY1W$-Q_XT4PF,HD6DZ-!-KGS^'*@C$C;VRLBP<?B<5#>
M0\-#LIAE'@M-GFH.`:2JWFA)Y^Q0;3=.]]K;1CQ',[,$)F4LLQCX;BP5(3J(
M][2JUD^6@WC+K;S2'6U:FW$A:%>5*A<&@J;J??\`')TT_99GZA-!:.6R+6,Q
M4S)/)4MJ$P[)<0FVHI:05D"]A<A-!#>GN?VQU$QSF[&L6MA[Q/0742%Z]08`
M<3=*5%M0!=X7%!/0`.5`H%!5?K-D_B=RX'-3L0#[(103_:G#;&('D@QOH*:#
M:F@\V^M!),>;AGBH(<8FA\63X;^AMH*!0"%-/-@@Z5*XI5W3P-!Z$PDE,K#0
M)*4*;2_':<2A:4H4`I`-BA!4E)X\@;4&;0=<B-'DM%F0TAYI7-MQ(6DV]@W%
M!3VQ\=!Q_K&;RC0([46,,5%6&&4!"-2_!4I5DV'$DDT%S4&DQN]MK9/.2\%`
MR#<C+02L2XB0O4V6E!*[DI">ZI8'.@VTJ'$ELEF4RA]I7-MQ(6GA[!H*&A;.
MQT_UE-RQV0B&S%Q<>2A"&&'$%QT-!:E(=0M.HZB=0X^SSH-C#R779&:,")B'
M8NWCDF8T20XC'-+:Q_\`=WELMA8O?O(T^T4F@DAR>.V9OB9,W9NYM1S;$6-B
MX#C*&UJ2TM2=2PTCBH./%(4+"QXCA>@Z.JW2B1FI3.[MINC&[XQ=G([Z;)3*
M2V.#3ON=5N"5'F.ZKN\@V'2OJI&WC%=Q^19^#-V8WWO*XIP%"@I)TJ<:2KO:
M+\QS2>!["0G]`H*&];'2K"[<;O92I;Y`[;!BQ/Y-!)O5ZWQD-R[4=A3&&FA@
M/1X$=;.KWQM#"0E2PHGO=WLH+4H%`H%`H%`H%`H%`H*]ZE$B-N<@V/Q7E\?D
MKH)A_P"W/]#_`,50:O<!/QRVJ+\"N=P]J,:"34"@T6ST@09]NW*9$G[,<H-[
M0*!0*!0*!0*!0*!0*"%=0ND^V=\".YD0N+-C*&F?&TI>4U>ZF5*(-TGLOYIX
MB@\_;NVANOI#O%C-8=U:L>5%..R:DW0M*[E426$\";#GPOS'$4'H7IIU-PV^
ML09,8>C9*-9.1QJR"XRH^Z'S3:O<J_-H,/J[L3.[OQF,9PLIN',Q\OTM$A;C
MC*TJ#2TMJ;<;2X04K4">[Q'(B@G$1MYJ(RV^L./(;2EUP7LI02`H\;GB?+05
MQU<W_'QJX>V<-%5E]Z3W&W<7!9/[G6A6I$A\@]U`\G:+WL.-!86+^$3C8IR?
MA?"/A(],#%_"#VD:_#U<=.KE>@K7JQTJ3F9L'<&W)9P6ZTOH85EFE*:"FW$E
M'ON@I457LD$<>-N-!2T/IWU?WGEW,/D9>15"0IQ7PEEFGT1E^"HI;6"J[A*R
M%:$]EO9H/7$1CT>*RQ>_A-I;OY=(`_,H*S]9)+:>E60D&R7V'6"P[>RT*4Z$
M*TJ'$72H@V[*"PL&E*,)CTVTA,9D!(%@/>P+4%6^L/&5*1M>(A2DF9,>B*4E
M@RK-R&O#79D=XJLKNE'?'N:"W8S8;CM-CDA"4CGV"W;Q^7051U/_`-\733]F
ME_J$T%LK;0XVIMQ(6A8*5H4+@@\""#0<(L2)$:#,5EN.T#<-M)"$W]I(`H.V
M@4"@JSUF5!/2'*D_WV+]'303_:WX-8GZRC?0DT&TH/.'K&@_"F%2SK4RK+(#
MR4`/-!XMI\]A7OGBE/8CN.)_14'H'"!H8>$&0V&@R@(#(4EH`)X!"5]Y*?(D
M\N5!FT"@J':Q_P#YEMZ?R1"_4LT%OT%']*V6WNM>])`=CI5$>G-%JRA*<\>2
MVK4I5BE3;?A:4\1;5V\Z"\*"H=M7_K-;OX\/@2'<?M-!;M!Y]Z^L,S>JVRL:
MY(C1Q);2?'EZ@E!:F-N@-+0E92X[X?ABZ2#>W#G0>@J"KNK/2Z=E9+6\=GN?
M!^]\99;3C9"!+0D6\-R_`JT]U.K@1W5<.0;'I1U7A[TANP9S)QNZL;W,KBG`
M4*"DG2IQM*N]IOS!XI/`]A(;O?V_\%LG"*R>465N+);A0FR/&D.VX(0#V#W2
MN210>8F,9U&ZR[FEY)"$GP-+:WW5%$*$VL\&6A8E:@.\H#B>VUQ0>G>G^P<-
MLG`HQ6-!<6HAR;-7^NR'K`%:_)RLE(X`4$FH%`H%`H%`H%`H%`H*^ZD)U,;F
M3\UMB4/EJ7033P#\"^!QOZ-HY<?UNW*@TVX/PTVI^FG_`&M02:@4&DVC^X)O
M\I9'[<=H-W0*!0*!0*!0*!0*!0*!08.<PF+SF*DXK*1TRH,M!;?86.!![1Y"
M#Q!'(T'E+=^S=W=(MVL9?#R'3CPO3B\FKO(6A7$Q)8%A<V_LN8L:#T;TVZC8
M??&#$Z(?!G,:6\ECU>>P\1R]E"K'0KM]N]!J^IW4Q_`N,;<VRP,KO;*63!@)
M&H,(/.1(`\U">R_R>%!W=->F+&UT/Y;)OG*[NR??RV7=.I14KB6FB0"EL?D_
M*`#0]2=Q;B@=4=JXW'9-R+$FA@/0D@J0]JF)0YJL;(][OWE<[:1QH+1R,"//
MANQ)*-;+PTJ`X$<;A0/84D7!\M!#]\[ZF;"P/PKE8ARL4/(CMNQUI:>)<O;Q
M$*&C@$\2D\?(*":QW0\PVZ`4AQ*5Z3S&H7L:"J?6;;2[TY8:5<)=RD1"B.P*
MUB@BLO-9O$8QU4B6_)@+C;I9#C06'&EMOAM+KH2JRDI5;24I[E_)03O?73J=
MO?;.VT1YR84G'!N0'EA96%+9"=:5H*5:D'O6Y*[:"QVTE#:4DZBD`%7*]A05
M-U/M^.#IKY?'EV_M$T%MT"@4"@4%5^LW_NBR0\K\4?\`7)-!8&UOP:Q/;]11
MN/\`@DT&TH/-WK(.$YG;OBA!'PD0@O'PW`UW>")#?)C5SOWVU>P:#T-CP\G'
M1@X%^*&T!8=6%KO87U.)%E'V>V@RJ!04_M51_K-[U3_X/"/_`"6:"X:"M=C[
M`W1@NI6YL](>:3A,RMYU##3RU:W%NI4TM3)0E*5(1K"B5*Y\+"@LJ@J+;0']
M9?>!_P#!8?\`BJ"W*"JNI_3C>.X-_P"V=Q;?EM0D8A(0\^75M.@*?2IT:4H7
MK2MG4BP*>?'A06K0*"E?6!P&`Q#$7?>/G_`>\H;J4P'8X2%3E$@%IU`\_2B]
MU'AIX*N+4%8[?P.].L^\79^4E*3CXUFYLY"=+,5NVH1XK:B1K5V\3;FKLH/4
MVW-MX;;F(8Q&'BIB0(PLVTGM)XJ4HGBI2CQ)-!LZ!0*!0*!0*!0*!0*!00#J
M)YFXQ_\`PU)_5KH)SI'H>GL\.W_)H(_N#\--J?IIWVM02:@4&DVC^X)O\I9'
M[<=H-W0*!0*!0*!0*!0*!0*!0*#`SV"Q>=Q$K$Y1A,F#,06WFE>0]H/N5`\0
M1R-!Y5W9M7>/1W=S>3PLIT8]_4C'9(IUH<0H&\:6D]PN#FFXX\QQO8+5]72-
MMJ9A9FXDREY'=\YTC<$F4!Z0TM1N&D\39HVN"#WOD6`7):W*@J+J#-5`ZU;.
MD:7BA]D1%>`\62?%D:1J3_=D`J"EH%[#B;#C06[05%ZT2@.F:+]N1C"_R%^S
M06O#3IB,BUB&T#Y21051ZT"WV^FK3S3>L,Y**XM78G2%Z21Y"NR?DT$)C],=
M^ID2<J)DE<F9&SCKD8QW51RI9T);;;+NE/I8<U(]J_>H/1&'9<9Q,)EU.AQN
M.TA:?(I*`"*#+H*DZGC_`.X.FG[/+_4)H+;H%`H%`H*I]9S_`'1Y$:M-WXWT
M44%B;:%MO8N_/T./[/\`<DT&RH*`]9?$1(\O:N0C^*EZ1E`7H[(2I+CB4I`=
M#2NZ7;63^BX`T%\0;^A1^%O>D</#+5NZ/[F;E'Z7LY4'=:@6H*?VDA1]97>[
MH[S8Q4-)5>X"BEDZ?R.5!<-`[:`>5!3VU9\1WUD]WH027?@N.S>Q\YD,%8_Y
M8H+@H%!U2I+,6*])>.EEA"G75`$V2@%2C8>P*"HY?K0[`1#==B1,C(?""J.T
MIA+:5JMW05E9T@^6WR*"J<%@=Y]:=Y/Y')OJ9Q[!"9DI%_!B-'B(T1"B;K4!
MQ/\`9*\E!ZEVYMO#;=Q+&(P\5,2!&%FVD=I/$J4>:E*/$D\Z#9T"@4"@4"@4
M"@4"@4"@4$`ZB>;N/_XU(_5KH)U_DO\`8?F4&BS:"K>&VB--D>G$W'&W@I'=
M]GC02*@4&DVC^X)O\I9'[<=H-W0*!0*!0*!0*!0*!0*!0*!0:[<&W\1N#$2<
M3EXR9<"4C0ZRO\A23S2I)XI(X@T'EO<^W]W]&-XL9+#/E^&_J]!?7?1):3WE
MQ)8%AK2.2A^F'&@N>+ZQG2UR.TI[**;?4A)=:##Z@A9%U)OHXV/"]!V*]83I
M,5)*LJHJ3YI,9^XOY.Y0<QZPG2@B_P`,*%S:QCOW_44%<]>NJ>QMU[&3C,)D
M3)FHFLO%OPG4>]H2O4H%:0.&J@]$QK^CM7X]Q/'Y%!6'K,$#I-/NG5]4Q>!_
M9D\:"S(:1Z&Q^QH_4B@[Z!05+U+"E]9.FK:02?%F*OR%DMA1X^T*"VARH%`H
M%`H*M]90(/2N8%I"D^DQ>!_9102GIHX\GIY@E3'U.NHA-^*^Z;J.@6NHGV!0
M9FU,W*RD>49B`V\A]Q<9`!3JAN**HKG'YINU_9O0>8.JF?E;N=8W&MZ1'C.9
M$8IG$J=\5EA;3:2X\R1I22LJ\[306PCU9=NH5J3G<F%>4*;!^6$T'P^K'MP\
M#G<F1^F:^<H`]63;M@/AW)E(Y#4W;R_,T'2WZL.&2ZX\=QY(/J%DNI\-*A;E
MJ-B56X6H/I]6IBP`W=E1Y>(\GZ;RT#^K2P`+;NRH/NN(^1[J@^'U9V3?5N_*
MD$<KCGV>ZH.A'JMP$/>.G=.12\19;H2@.*X"]U@A1Y4'=_5G9M^%^5^6/GJ#
MD/5I:`M\;\J1V"X^>H.J1ZM%V'0SN[)EPH4$H4;(42.`597FGMH*PD]"M]1,
MWAL'+]"9?S*G4,OH=4XAM,=`6ZM0TI/!/FCM]B@]0;)V?C-H[<BX+'%:V(P*
MEO.&ZW'5G4XXKL&I1Y#@.5!OJ!0*!0*!0*!0*!0*!0*!00+J&!X.XS;C\6Y`
MO?AYR^R@G'^2_P!A^90:;+#_`&LV_P#I)OT-%!OJ!0:'9AU8N6KL5DLD1]G/
M"@WU`H%`H%`H%`H%`H%`H%`H%`H*(];92AM3"A)(O,=!M];KH+:P&!PGP'CB
MK'QBKT5FZBRW<GPT\^%!U3I6PX&48Q4Q,!C(R0A4>*MIL+6'%^&C2-/:OA0;
M3X"PGWOC?M+?SM!4WK,X_'Q.G33D2*PPZK(,)UH;0E5M*R0"`#V4%QQ_W.U^
MD3^505;ZS9(Z2S["_P!4Q?D>_"@GT7=&V4Q60<O"!"$@WD-?,C]%0=OQHVS:
M_P`+PK?7#7SU`^-.V/OO"^R&OGJ"K=Z9B!/ZZ=/&X,EB4AM$U2UL.(<(*FE#
M22DGL%Z"Y10*!04UM[=6Y)?K`Y7!/SWW,'#0^Y%AE2$H2LLL!6H6U+2#YJ;\
M+W\M!<M!5GK+J*>E$XBUQ(C$7]AP&@DNUMKN)VOBH$Z:N5`;B-#T9"/!2X%)
M"K.D*4I0XVTW`/:*#?3\,S)6T\RM469'&F/):MJ2DVN@I/=4@V\TCVJ"@^M>
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M7'&W@Y'4$.)6TK4D@J"Q\L4%`QO5WR<;)R596-'C[>:,CT=:)(D3G5&[<1M-
MV@-2E:5*OV&PXT%LQN@'29+*?'VZPIY2$AX^(]8J`%R!KL./DH.:_5^Z/K%O
MBXP+7\UQX<_:700C+[*VKM/KET_C;=QS6/:E(G+D):*SK*&%!).HJY7H+YH%
M`H*9VWN')2.ND[!70(D)S(224A25J#S49.E>HZ5`*;%M'R:"YJ"J?6;O^*B;
M;F9,8?\`+H+)P8MA<>/)&9'_`%8H,V@I/UDPI3^RDCF<H0+C4.;?90790*!0
M*!0*!0*!0*!007=97^-+8Z4("AX>54M1)N!X"!P[.9H)U0*!0*!0*!0*!0*!
M0*!0*!05UU25_%.[4WY;?0;>V\_['L4%@_Y/_8?F4$>S/X>;:^MLE^5'H)+0
M*#2;-`&$586O-R!/M^G/4&[H%`H%`H%`H%`H%`H%!JL_NK;NWFH[N;R#,!N6
MZEB.IY5M3BN0'L>4\AVT&U!!`(-P>((H%`H**];%:4[;P()L3-<MY?UA5!=N
M./\`%\7]B;_4B@A.Z=D[CR'4?`[FQ<MN/$@-H9G)\1;:UM!U2W$*0$K2Z%H5
M9/%.D\3<<*"6YN9(CQD-Q+>FRG!'C%5BE*U@G6H7%PA*2JW;:@B6)G]*]T3C
MB$R8FX\I&+BW3)2)+FJ.I*5KNI)0E.I?=TV2>.GD:"?``"PX"@@G6K>.9VCL
M=S,8?PO3A*CL(\9'B(TNKTJ[MQV4$C@89Q3[4_(RES9:$W824AMEDJ38EMM/
MNB#;4HD^2U!N*!05#O\`)_']TY'9X,\_]4J@MZXH%Z!05U@NF3\#JA.WJX\%
M^G>E(+!TJ"$J\$,EO@"DJ"%Z^/Y=!8M!5/K-"_2F6+\Y47Z)065A?N/!XW^I
MVN/^#%!F4%+^L=?TG9-O.^%00#["FZ"Z*!0*!0*!0*!0*!0*"$[E/_VCLP:N
M!8RG=_P3?&@FU`H.#[[,=EQ]]Q+3+22MUU9"4I2D74I1/``"@XQ9<67&;E1'
MD2(SR0ME]I06A:3R4E2;@B@[:!0*!0*!0*!0*!0*"NNI=O0]V7%Q\`,W%KW]
M_D=E!8G#3RX6Y6_,H(WF?P\VU];9+\J/026@4&DV=]Q%?7N0^WGJ#=T"@4"@
M4"@4"@4"@4"@\G>L7MK>+&]E9/)+<GXF>0UAG4))0T#_`)+H3?2N_']'SYWL
M%Z=%,!O#";(CQ=T2E.R5*UQ(;G><B,:0$,*7<ZK6O;W-[4$]H%!0GK9HOB-N
MJ4DJ0)$E)/LJ:387[+VH,S![']89.*C#XY18Z0@>&TXGTA246[MW"SQX4&Q^
M)?K!$\=[0[=MHXO]!H(WOO8W6M^'`:R&XT94*E6BQH;8:<\7PW%:RL)8X!`5
M[J@IW!8O=N5S3^+VR7Y,]H:B(+Z6DA#"@DJ)2XE(`4KR\>R@]Q-!0;0%^<$C
M5[=N-!5'K.Z_Q6N:1<^GP^!Y?KO;06K&_<[7Z1/+VJ"I>OS64?=VY%QBYAG/
MKEICL07"A2UE+8NZ@>>VD$WMWAPL.=@MX<A04=UBAY29UHV!&Q<PXZ>\Q-3'
MGZ`X&E!!43H-@JZ4E-!OYFR.L[<1YV)OM,B4A*E,L+A-MH6L<0@KNK2#RU6-
MJ#7X[:O7XP&G\ANAMN:I2P]"9;9="4@]PAQ0:!N+W'90=RMK=:TO-I7NLH;<
M6$)6IIBXN.92D*[?)09J]E=6FD*=?Z@);9;25N*5#:`2`+FZC;@/+01YC&]=
M\C]4X3<7I&-4`J/,F--1`^#[IMKPW7-)YI4L)O[5!IMU[,ZM;GV[,P\W,*R<
MUMUMQ[`/-L17?#UG0\EX%3;B$^5*O8/&@F.'ZY8PR6L$U@,F[.B),=\(2R6T
MKBH(?]]\3P]+904E6JU^%!:<5_TB,T_H*/%0E80JVI.H`V-KBXO04SZQQ/PC
ML4=GPF3_`,MGLH+KH%`H%`H%`H%`H%`/*@J5P;V_''MHYPL&+IR_H2&;`!C2
MG03:Y*].B^KV:"VJ!04?ZSZM[C!11C[C:A^ZY8U>+XNKN>/;^X?D:O.[*##]
M5I[>:H4Y$C4K:"`1!4[V2M8UICW_`+G:^OLU<N.J@OR@4"@4"@4"@4"@4"@K
MWJ*+L[H!Y'!Q_MA^@L*@C69!^/FVO8C9+\J/026@4&DV=]Q%?7N0^WGJ#=T"
M@4"@4"@4"@4"@4"@^*0A=M20JQ!%Q>Q'(T'V@4"@H/ULS_%6V[\O29)M[/@B
M@O3'?<^-^Q-_J100S<_47(X??V+VRSCDR8D],53\W64EGTF0MGBGMOH[MNV@
ME^5QYG1TH0Z6'VEI>CO@`E#B/--CS!XA0[0:",Y+>6VMH0T/YZ(,,7W41O$8
M8*V77#?3H6TGS;`GO`$4$R%K7'$&@JGUE['IJE!]WDX*>WM=]B@M1H6:0/(D
M#\B@J?KOB<_-G;3EX?%JRBL?)?=<9\)QQLDI;"4*4SWVRJQTJNE/#BH=H6T*
M"J-]QFW>N?3YQ2N\RU.4A/E):6/+^906N.5!CRIK<=2$%"W''+Z&T"Y.D7)^
M1>@ZV4/R'DR)""T&R?!8N">(MJ7;A>W(=E!K-\.-M[?<+_[C4]&1-/DCJD(2
M]?\`0Z"=7L4&^0`!8<`.``\E!!NIN[L%M"1@,WE''&P)3D=7@-EU:F'&%EP%
M*>]I"TH5[=J#;.A_/1TQF8BH>%DC5*?>3X;KS:^\IMMH=Y.OW2EVX<AVT$C2
MD)%@+`<`!PH*,]9J8B)-V4^X"66)KS[H2FYTM*84;>S:]A02-KUD.F2Q=3TU
MOR!41VY'EX`T'%/K)],RX$:YP!-BLQ%Z1[)[;4':[ZQO3!MO6)4ISC;0F(]J
MYVOQ`H.2O6)Z8)T?5DE160"$Q7CIOVGA0<_ZPO3#]_2/L5[YV@YL^L#TO<>0
MV<DXR%J"?%=CO(;3?M6HILD>R:"Q&G6W6D.MJ"VU@*0M)!!21<$$<P:#E0*!
M0*"$;D!_&ILT@\HV4N+?]&UVT$WH%!P?88D,.,/MI=8=24.M+`4E25"Q2H'@
M010<(<*'!BM1(;#<:*PD(98:2$-H2.02E-@!0=U`H%`H%`H%`H%`H%!7O43]
M:W/_`"''^V7Z"PJ"/Y-"3O;`J/-,3(E/+M,8=OYE!(*!0:#8JDJV\%)X@S,A
M;M_RY^@W]`H%`H%`H%`H%`H%`H%`H%`H*"];1O5B]M$GNID2KI\MVDT%ZX[[
MGQ?V%O\`4B@JG=RL6>OVVTY%304("#C4OI>XO^,[?P5M*`2NW,+24J'.U!;U
M!4/K+Z/BCADJ%]69C``?I'*"WAR%!5'K+$CIVQ8@?QK"O?EP63Q^2*"QT9["
M:$WR,6]A_=F_GJ#E\/83[X1OVYO\^@?#V$^^$;]N;_/H*HW]EX_XZ]@O0769
M.HNL.J0X%!(=U)XZ2>.G5;\V@N1/*@T&??6WN+;R4+4GQ7GTK2.2D^#<@^Q>
MU!E9:2LN,-QW5(*)#/C+1YME.!/AD^55^5!L9,>/(BNQY*$NQWD*0\VL`I4A
M0LH*!["*#01<+N?'-^C8W*M2(*4A,9&094ZZTD<D^*TXUXB1^B%_T1H*\Z]8
M-V-L!4[(2S.R1F1TJD:`TA+5UJ#338*M";VOQ)5;B>5@M_'7]`C7Y^$W?^U%
M!D4%?=6\#B<U\`QLC%3*0F:DH0L7`U+;2KY!2H@T$9S'3#8+,=]+.$BCWC(K
M0K3R4B>VA']HE12GR#A08TSIOL9.4EM)PT5*$G,E#8;L`&6&"T``1^ME9*?)
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MV&6;)*4FR4W5I*!<D\J"W:!0*!0*!0*!0*!0*!0*!0*"ONH@]XW.;_\`<<<6
MX_OA^@L&@T<^_P`<<-Y/0Y_ZN+0;R@4$?V$;[9:58#5)FJ('*YF/&@D%`H%`
MH%`H%`H%`H%`H%`H%`H*#];/5\%;;M^^9-_VI-!>N/MZ#&MQ'A(L?[$4&KR.
MS-NY+/1,]+C%>3A!`8=#CB4^]J*V]:$J"%Z%+)3J'`T&[H*=]9Q03M/!$\OA
MJ/\`0W:"XARH(WO_`&+B][8#X%R;S\>/XS<@.QE)2L+:OI\Y*P1QXBU!0$?U
M>,K&DO2,YX4+$`N(ALLOAZ8ZXH^'&:%D!&I:@%*]@V[#06RWZO/2SPT!>*65
M@#4?27^=N/NZ#E_5YZ46^Y*_LA_Y^@@>9V#MS:?6/:,7;\4QHVE>0DAQQ2TD
MQVW^.IPJTG306SMW<[+[Y#^38DLKBL2"[K:2EMUW5K:!21R";\>-!D;A<C.O
M192$ID%B/,?CZ5$@N(;24V*#Q^108T60_P"&J-XHDH9DP5EQ*$ILIY8+B+(`
M'`\?+QXT&VGY?'NX^8A#Z=7@/%)/)00@E2DGDH#MM0=\-J2J$P6Y`"2V@CN`
MBVD>S05MZQ*7V^GB2\\'`9T?N:0C58+-AQH+1@"T&/86]Z1P_L10=]!7'5O=
M.`PLO;Z,G,;C+<DAQ*5'CX:'6M:R!QT@7XT$5S_4_9#S+ICYN,\LQYR"`KC=
MW)LK0.'E:"E#RB@XR^INPEY28XG-1RBV:*%`W!+S4=+5O+XFE01Y;&@SL?U.
MV$@S7#G8MG)[CB"5\2DXI#05;R%Q)3[=!E1>I>PT9-]TYV'H+L4H474Z2$XY
M8-O:7W3Y#PYT&?M;J7L%,Q?B;@@MA6.QK:"M]";K2'=2.\1WDE0N.R]!9=!3
MOK0PX*]A1)CK2#*CSVT1WB.\E+K;GB)!YV4$@D>Q06+L`WV+M[^38GT%-!I.
MIG4.9L]["I9AMOQ\F^MJ7*>\?PXS:-'OB_!;=X'7;_\`HT&A+V-'K'I:90\,
MBK#*]*<44%DMW26PV+:@?FKT%KT$'W$4'JQM!)OK$+*$$<A=+(H)Q0*!0*!0
M*!0*!0*!0*!0*!00'J,E`@;H=-]7P/&1PXCO2'[<OSJ"?4$<R!/XP,(.SX-R
M1M_AH=!(Z!0:'8QOMF/PM[[*^V7*#?4"@4"@4"@4"@4"@4"@4"@4"@H/ULU!
M.,VT;7)D24CV+M)XVH-W#]7N'Z*T4;OSZ$EM-D(DI2D7`/`:.%!V_P!7F,0?
M]L]PB_DE)^<H/O\`5ZCW2?CGN'N_YVGYR@KWK/TN:VEBL/D$Y_*98R,FS',;
M(/!UI(4E2M:$@)(4-%ODT'IT<J""]9-Y9G:.TV<GB`R9;LZ/%)D(+B`ATG5W
M0I/'N^6@D<+"2!)1-R4Q4^2W?P$Z`TPUJ[6V@5=ZWNE*)\EJ#OR>?PF*6PWD
MY[$)R3J$=+[B6RX4"Z]`41?2.=J#8=E!0G7+!-Y[J=MW#N/L1_38#K;3TEGT
MA`="G'$A+>I'>5HM?L2308$7H;E<LW'A/+PX#<1F2A#L9UT>^A03:SB-`2!:
MUCP[30=\WH$K&)92J;C4A,5^0OPL<Z-)CA"M+8]*XW*N=!\F]$)L]XM2ID-A
M32HB$)$5U5_2>!.H2$^9I(`MV4&*KHJ](B-I1)@LM+9F.,J;B.@+]%7ITJ3Z
M2+!0]N@WD3U=IXCH4C.LM%Q`*D"+(`!(!-K2Q\N@B75CI5,VIM5&1D91F<A<
MII@-AA]"T$I6L+2I<ET7[EN*>V@],P?W%'_8T?J10=U!0?K(;2W%F<]M^1BX
M@DM%EV*H^(A%G7'VM`.HC@2J@J>1TSW]&1XC^&;:0A+JR4O-GNLOB*X.#G,.
MK`'EYT'V1TQW\RZZES$("XZ92W-+K9%H&A3_`"=XV#B=/S790<STJZ@J#BDX
M=)#3BFG`EYH$+3'$H@>^\O"((]GASH.">DO412M'P,I2PI"2V'VB0IUDR$_W
M;^]I)/RN=!V8_I#U(G2@Q'P:BIL1WG%*?8`2W([S:B5.GW*22!Q';0>SJ"HO
M6?M^+F.2=)&38(_:W1^506%L3\"<!<$?Q=%YF_\`<4T%<=?XST_);8QZ72VP
MI4E^2DJD!!0A;"3J3'2YJMK[NL:;\^'`A(H\#**ZURIR\?%&-1C$--9'PVO2
MBX2"4ZRL.Z.?)!3R'.@L&@JD;<R>,ZP[<?F9A_)&5%RSB0Z%`(3=LAL!2W$)
M2`X`-`3YM!:U`H%`H%`H%`H%`H%`H%`H%!7?5%9^!]TI/>2G&X^R2".*I;W&
MX-!8E!&\A_O"PG\FY+Z-#H))0*#0['_!J/\`LLG[9<H-]0*!0*!0*!0*!0*!
M0*!0*!0*"@?6U/\`%FV>%_JJ1P/[&B@OIA.EE";6LE(`]H4%7[JWMN.!UAPV
MWH^198Q<M$77CU(!>>\5Q[Q5MJT'@A+("KJ%K\+F@M2@ICUH;_%C;_D^&6+I
M\OO;@H+G'*@JCUE2!T_B$_?:'^6N@M9'FCVA04CZQ,.-.SFS8"G8;$F4[*;C
MOSEK9;:.I@E:'4<EV&D)7W57MY*"[J"F.I9'X]^GZ2+WOP^0_06UC<1"QX5Z
M*@I\0)"BI:EG2F^E(U$V2F_`"@UFX?%5FL/'2I(1*])8?"AJ"FU(25)L?+IH
M,#+I&&Q:H[*"W(#\9;$@E3@6E+R$#SRH@H!`TD^U09C^-CXQN<XL?NMMY++@
M*]*%.!2U)\,DI1J4+W3:]!MFF(B66=9(*DI";N*!/`<N]05;ZRK#:.GC`0DG
M7DHX5J6H@>]N\>\:"VH(M"C_`+&C]2*#NH(?OP@3\!Y?3&[>7]?9H-#GP#C'
MQ_T<W_UEN@97AD9O%1/@;B(2/TL;E0;%L@N9`6/#(2`0>S^)T4&1&01/>6.`
M+\?C[6+7^?09NTS_`!C*\OP?C"?VMV@D]!YYZ];R3N[)P>G6UVCDLBW+#LI;
M1!3XZ$*2&DJY60%J4ZKDFUN=Z"]=LXY_&[<Q>.D*"GX41B.ZI/%)6TVE"K<N
M%Q0:[>.Q<5NM,(3I$N.J`\'V?17="5*"DKLZVH+;<3=`X*2:"%16"YZR4QYQ
MU7O&#0F.@-@ILI:=:5+O=)'!0X<;T%L4$'SRA^-O:B>5\=E#[)L8]!.*!0*!
M0*!0*!0*!0*!0*!0*"MNIWW-W=_)N+^W)%!9-!',@#^,'"GR8W)?1H=!(Z!0
M:+8_X-1_V63]LN4&]H%`H%`H%`H%`H%`H%`H%`H%!0/K:(*X&UP#Q3)D**?8
MT-B_Y-!?C?F)]H?E4%1Y^6J)ZPN(UNNICR\<VP4M%HH\0K>+8>2Z"0%:5:2W
MWOD7H+<<<0VA2W%!"$@J4M1```XDDF@J3K-A\_O;%89C;>,>EM0\DU*<EJ4T
MP@MI!3J;\525K3WKW";>2]!;M!5/K))2O8<%LWNO,0DIMY254%K`6`'DH*OZ
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M3S;;49*,A'&9F%.F1D,C[^\XJW%7>[J+_,H``H*SZ_[>S36W,?@L)%EY*#D9
MR%L0V0N0[&=CMK60W?4LM.)O<$]RUQP-@%Q8C+0I3:8[:BB2RVCQHKJ5-NH[
MH\Y"[*M[/*@V-!3O7_>&4P$W:J,9';D2WY*W$-N!2M19<94AM*4$*)6NPH(+
M,W3UKDM.-.;0?T+2ZFR8,L$>-+3+5VF]E)TCV/9H/KV[NL[[[LA6S'TJ<3/;
M($.9P&1\/61^D\$::#(&^>M@\=SXE._5#[DA:?0YGG.11%('L!*=5`9ZC=9%
MOK,?9ZUK*D.E)AS;`(C&,!\HZO;H,C&]1.MV/DNOM[)6LO,QV%)5$FV`C)4E
M)%OFM?&@^Y[J#U^S^-<PL7:SV*>G$-"9'CRFG$I40%6=>.AL'DI?8.7&@L7H
M_P!(\?L7%^,_HE;BEI^KYJ1P0GGX#-^3:3V\U'B:"Q:!0+"][<?+0*"HHVR8
M>WNM&`?CSI4GTZ'EGW&Y+@7I*EM*LFR0=/OG;Y!Y*"W:!0*!0*!0*!0*!0*!
M0*!0*"O>H&KPMS:?.]"Q%K\>/IS]!85!'9R;[_PZK7TXW(\?)=Z'02*@4&AV
M,0=LQB.1<D^Q_E+E!OJ!0*!0*!0*!0*!0*!04YU+]8C&[9S;>'PD9&5DQG@,
MNXI12VVD'OLMJ'-WR^Y3R-SR"S-J[KP>Z<*SF,-(#\1[@0>"VUCSFW$^Y6GM
M'YE!MZ!0>??6R*PWM?2>`<E%0'D`:OPH+8B=4>G4B*V^UN3'^&L#3JD(0?)Q
M2HA0^2*#B[OGI@[+:F/9K$+F,`I8D+>8+B`KF$+)U)OVVH-)O3JKL!F/";<R
MD?(07GCZ:S$=;>44-MJ<2E:$DG0MQ*0?R>%!#-J^LLS)RRF-RQ6,?!59J,F&
MEY]XNNN)#84;:`E""0LCF>(X4%]4%4>LBIM.R<8IPV0G-02OD!8%5R2>5J"Q
M?C-MO[ZP_LAKYZ@Z)FY=N>B/VRT._AKM]4-?,G]%0>7<5EXK2>G^O)M^$B/$
M0MGQ5I+3BLJ\M2BGS4ZT#B3;@./906INK.8)SK_LV0G)QO`CP)?BNAYOPTE2
M'@E*EWT@GL!-!G=4MU[8;W!L*6O+0_1HN94Y)>#[92VCT1T:ED*[HN1Q-!,U
M=2^GPA,3SN&!Z)))2PZ'T$**38V`-^!H,)'4#I^YE8ST+.P5ORU^CN)3(2`H
M:24D@\-0(M?R4&9N7*X>=BG$0<Q!1D&5MR82ER&M'C,+#B$K[WFJTZ3[!H,3
M']6=BO,*$_*Q\5.:%Y<"8ZVAQI7L&Y0XGAW5()!%!I9G5/8[^7@967FX\+"P
M_%]`4ZJSDQ]P>"74-)NX&6D*4-2D]XJOR%R&D=ZRLYG,"*G#OXUJ&MR1"S,C
M5J*&[I0$LH05GTE2"DIOYA!Y\@N1IP.-I6GDH!0OPYB_;04=ZP3EM\=.4W_[
MQ!M_I,:@O2@4#MH%`H%`H%`H%`H(#FI<5[K!M9#+R''$8[*AQ*5!1'&/YUCP
MH)]0*"*]1>HN#V-A#D,BKQ93MT0("#9Q]P#D.>E(]TH\O;L*#[T[ZB83?&#&
M1QQ\*2U9$^`L@N,.$<CY4J]RKM]NXH)30*!0*!0*!0*!0*!05]O[S=R?6>'^
MWGZ"P:#1R4D[WQQO8#&SKCRW?B4&\H%!'NGY*MIPR3<E4@FWLR'*"0T"@4"@
M4"@4"@4"@4"@HWJGZNRMP;@1F=M/,PG)[P.7CO7#8*B2N2WI!NH^Z1VGC<<:
M"T]D;)PNS<`UAL2@AI)\20^LW6\\0`IU?LG2.`X#E0;^@4'GKUM4J+>V`G@H
MN2@#>W,-#G06%'Z!=)41T-KP"'2+$NN/2%.*-N95X@/;0=#G1?H>U+3#<P\-
M$M6G3&5*>#AU7TV07=7&QM0:7>?0CIZA6*./QZ,4PN26Y<A"U+*BXVI+"#XY
M<2`M[2F]J"([0]6;/O9/TG<\EK'PVE)>:8Q[@=<4X%I<"#K;TI0D72JW$GB+
M"@])4%<=?L+"R?3I]4R0J-'@2HLIQ8(2DH\8-.!9/(:'54&NA>KOT;FQ69D.
M*](BR$)<8?;FOJ0M"A=*DJ"[$$4'R=ZM_2=J&^\($D*;;6L$2W^:4D_-4%*X
M/I3CLCM[;6=#+CD2:U%.44B4T@E;^25&5K85[ZE!9`"2WV^U0;C']*MF'K$O
M:CH+F.$MX(C-R@M:64PRZ@.$.%T*2I7ND?V5!W;_`.ENS<;UAV;MF+&=1B,P
MG5.:+RRI1NXG@OSD\$#D:#!ZV]--N;4W#MS%[:BK97F0MI7CO+<275/-M-W4
MLJ*0/$XV%!B1O5ZW_,[S`A*``)2ITA6DC@=.BXO0=_\`5IZB$<68/'A^NJ[/
M:10?5>K;U)`(T0M-N%G5?.4$'W=L[*[5GM0\CX"G9#:9"'(Y*D%OQ-/!12D*
M[P[+T'NJ.!X#?L)3^50=EJ"B?6#M\>^G)//X03;[*C4%[4"@4"@4"@4"@4"@
M4%31]FX;;W6?`'&AT"5C\H^XEUQ3@"UNMJ)3J/=XK/"@MF@4%3=<^C[N\HJ,
MUB%'XP0&O"1&4JS<AD$J\,:CI0L$DI/(\CY0&1T0Z1KV1`>R.3<UY_)-I1):
M0J[3#0.H-"W!:K^<KY`X<PM&@4"@4"@4"@4"@4"@K[?WF[D^L\/]O/T%@T&@
MD.GX_0&>%ABIB_9XR8HH-_0*"/["(5M*`H"P4'5`7OP+RS02"@4"@4"@4"@4
M"@4"@4"@4"@4'GWUL"!\5;B_OTC@>W]:H/0*/,3[0H*:W#%,WUA,<VTE@N18
MT20XXZ]X;B6VO2-26FC9+NM3J+]J=-QVT%PRHL:7'<C26TNL.I*7&U"X(-!6
M/4[=NYM@QL.<;+;G1\ID&80;GM^(XRT?."74*05^QKN?9-!:=!5_K#9I_';(
MAQFFFGD9;+084A+PU)\(N>*KA<<RT!0:#=/4_#=.^I;&$BQ%Q<"ZA#F90E9]
M';5)MH>CQPE>CPPBZPBP5?E>@LC&;SVUNO;.1R&WY@FQ66WF7'`AQ&EP-:BD
MAQ*#R4*#SIMC%S9D#II(:8+T:+#AJDK;C(<4V7,PL(+SQTK;0L`A.DJ//@.)
MH)?@+'UF\BL.,./J??2\&O#U!M$`>&%65?4G597<OY2:#-ZG(4YZQ73I*$E1
M2VI9`[$A3US\B@P/6+4?QD=/1KLGTELZ?]-C\:"[H4!M_'0GTDM2FV0&I";:
M@%<;$<E)/D-!W)RJ6$EO(@1GAP"N);<\GA'M)^9\Z@^&._/XR4K8B6(]&N`I
MR_/Q"F_=_0W]OR4%?]0.C>/WSNV+,F9%R%$QL5ACT..V@^(@NN.$%2O,Y6%A
M06BA.E('8.`^10?:"BNOP)Z@=.0"+^GIX<?WU'O07K0*!0*!0*!0*!0*!00'
M-N-_CHVTV39P8C(K`]CQ&103Z@4"@4"@4"@4"@4"@4"@4"@@/4%03"W"5<$E
MC$I![+F:X!^6*"?4$:?_`-Y,'^1I?VU&H)+0*#0[#`&T,8``/>B>'LK-!OJ!
M0*!0*!0*!0*!0*!0*!0*!0>??6N;4X]M%L"^J0^DB]KW+(Y]E!Z!2+)`\E!6
MF6VANH]:(&YH3`.&,=N/-=4MI0TH2Z5$I7[XA04I&GPP;\;E/:%F4%)>LY?T
M+:!%KC--&]^/9RH+MH*=]9U>G:.W^8ON"#Q'M.&@J;UF7`KJ?(;0RVTM$.)J
MD@J*UZDN6!&LH%OTH/YH6!ZM+:T]+=QJ5J(7,E:3>[9M%0.Y?O>W>@A&"@3R
MOI*ZI#KC!AXY+SB(?B(2GX04I&J:"G1PX:;=WV;T$VP[LI'K*30\P^VP525>
MDN".&BE,0!`!;3XG"RK:U7MS[*#GOF5#R/K(;!,.4W(2U%6I?@.)5:_C+&HI
MU<%)[.T4&#ZQ)'XS.GH4=*?'0;\.8FQ^R@O"!/0QBX#5O$EO,I\)A)[RK`:E
M<>21VDT',XGTH*7DU>.M1NTV@J2VS\R6[6.L?-\_):@^>F2,<L-R[NP3P1-Y
ME'L/^Q^C^7Y:"#;YZO8?8N\VH&4A2'VLI&CNHE1RA0;2'G&E%2%%)X7OW:"S
MA0*"B>OZ2KJ%TY%KCT])\G*7&[:"]J!0*!0*!0*!0*!0*"`9UE"NM.UW%)"E
M-XG):%$^:2MH'A[5!/Z!0*!0*!0*!0*!0*!0*!0*"NNHQ48&XP.-AA>1X_N\
MDW^106+01I__`'DP?Y&E_;4:@DM`H-%L7\$<9^Q?\XT&]H%`H%`H%`H%`H%`
MH%`H%`H%!Y?]97>F)S.X\/B,,Z),W".N>D.IXLB2\MM+;&KW2@4]ZW+ESH+`
M&XO6=#8/Q3P15>Q3Z4?E_KUJ`-R>L[V[1P?V6?I]!J,UU8ZZX#*X?&YC:^(1
M*SSZHN,;;D*/B/#3P4H.K"!WQQ-!$^L.:ZJ2?BPC?&&Q^*8^%6C"<A/EU2W-
M2;I4-:[`)XT'J#QFM>@+3K^9N+_*H*>]9_CM+;H[/C#!O_:N4%=]3<1`W3ZQ
M+&+?4ES&NR(,">EMP>)W6O%6BR>^BX.F_9Y:"^L+L7;>S=K92!@F%L1WT/R'
MO$<6ZI3A:TW*ED^Y2!04'MJ?FXXZ:06\G,;P\R/AI#L(J7Z,MQ,PH"&P+H(5
MI2IP+M8@:>9H)5CD8%GK\,:SB"P^VK)KGSGI[LQ3R'XH6=<=[N-!SF-*CP%C
M:@JS;623MCJGALHK'R'XD-3G@8Z$R5J#:D.("&-2E*<4`;N)*KI((%P+T&^Z
MO[XR&Z]T;>S.-V[E(2\%=?A3X;G?<\9#J.ZB]T^]\>5!PQ_6'K)CF$,,1E)`
M'!3F-=6HCLNM7'E:U!D_CUZVI4"6+I\GP8X?E\*#KE=?NL;#1=E(:88`LM;N
M.6E'>X64I9">-!!MW;AW1N+(Q,GGV5H6VEN,PKT=QA@(UZTI;U=WC<G@:#W6
MDBU!]N*"C>NBK]3^FJ`DJ5Z;<6M?]TL<K\*"\J!<4"]`!!H%QY:!>@7\O.@7
MH%`N*#XI:4I*E$)2!<D\``*"N\IDL?(ZS[92Q(9=/P3D"DH<2KBI;-@+'M%!
M8M`H%`H%`H%`H%`H%`H%`H%!6O451,/<Z;"R3@K?9U!95!&G_P#>3!_D:7]M
M1J"2T"@T6Q?P1QG[%_SC0;V@4"@4"@4"@4"@4"@4"@4"@H#KIUU]$](VMM20
M?2P?!RN59XEHG@8[!%[NGDI0\WD./(,CH?T-&-,;=6Z8W\9"SF*Q3G$10>3S
MH/`OGL^8_3<@O<"U`H*<ZUJ3^,?I2@\_AATCY;-!8&^\;M#)854+<ST2/'>)
M3$DRRRDM/J24I<9+W=#B=7=H(=L/ICM?!YP2L(I_(H:<\5W+2E:](0VIMN/'
M6`D*XN*4M0![!?E0:[UH%A.TMNCYK<,$#V[.4&AW$V'O60AR&GW0RJ3"94RE
MS6TM;+*E%92DC24D%&E0/'O7H+HR&;PTJ%D84:?'?EMQGRY':=0MQ(0BRM24
MDD6*@#>@\PX^.@YCH^\&65K;BXD)'BJ#Y0J6O4X&]=M#93S"+&_>/*@E[>)=
M1UMGQW&6G\K+3EEMQWFRF)(;7#T)4I)7J5JX)=M8>SQH(;TEQR<?U5P<,Z$/
M,3G$.M-)4A*`(L@(04JX]U%@">)[;\Z#UW;MN:#"S.:QF$QC^4RCXC8^*G5(
M?(4H(22!<A(4;7-!\P67;S&(C9-IA^,U*1XC;,E!:=";D)*D'B-0XCV*"O\`
MUD%`=(\O?M<C`>P?'10<NHVRF-\[(QFW6\LWCIC#3.1TE(=<+3+.@D(U((%W
M1WJ#,P4G>F,Q^"?S&<A.P'6&O2$>B.>+X:&/$<6I\O&UDI[RRGG[=!O,#GYZ
M]LR)N40@9."E]4Q@$(`T:G6@?.TZF2@WH/,.],QN+>N>V]N3'NS!,S4QYK!X
MS7?T(QRQI+*T]JBHK4>7"@L]?2[K\D'1OD+/"UY#X_Q1H."^EWK`!Q11OD*3
M;NDR7Q?CY/"-J#K7TP]8>Y"=ZI*>P^ER`?;MX%!JMEXCK!N+<.X\0O?4F%*V
M[(;CR%@*?:=4K4;HOX=AW.T4$P'3#K(E2=/4=X@'CJCWX<.R_P"AH/K?3/K.
MVHA/49PI6H*45QM1'"Q`N>`H/JNF_6L*)1U$)O;SHP[.=!"MGM=;=P;LW%@D
M[O>AN8%T-RI#S:5H6M2BEOPT`=T*0G703,=.NN1OJZA)]BT;_P#=0=:.FW75
M(TCJ&D@<KL$FWLDB@UNZ.G?6Y&V\HJ3O;X1CIBNJ>@-QR%OH""5-)TI)NL<.
M%!Y\DXG.XE#>1<Q\W&^C+0IJ8IAUCPG`1H*7"E(2;\J#UGT4ZG1MY;999F24
MJW+`1X>48("%+*38/H2#Q0L6N1R5PH+&H%`H%`H%`H%`H%`H%`H%!76]V4O'
M<32C9+CF`22/(9X';06+01UY"CU#B+'FIQ$D'VS)8M^4:"14"U!H=ADG9^*)
MX$LW(_LCY:#?4"@4"@4"@4"@4"@4"@4`F@\^];>O(9,C:VT9&J1Q9R>69));
M/(L1K`ZG#R*T^;R''D&5T-Z$(Q7HVZ=U,`Y7]=QF+<%Q$OR==!OJ?(Y?,?IN
M07P!:@AW5#>>5VIAH4S%Q&9LN5-1&\!]?AI\/PW'7%!14A(4$M<-2K4$BV_D
M7<E@<;D7D);=FQ69#B$7TI4ZV%D"_&PO04WZPR,DYO?ILUB%MM9<Y!XP'G[E
MI#UV=!6D!5TWH(GU?@]3Q,VBUO:;CID9W+-B&B`VI*@X%)U%>I"1;2:#TZ$A
M(L.`[!V4%0^LFP'\)M-H@**MR00$DV!-E^2@C^>AY:+ZQ>,E.NN/8^5.0VA]
M<F/I"DPBOT?T="4N`-)4%#43S*^V]!I>F^4P\3?N\9KLO&1L=)BY1..>1X4=
M3J52@OO*4LK)*E&P5Q[1<6L&GV1G\6O#;13/WIAX\'%N8Z6[C'FGO3&Q#5J4
MR74A0YDV'*@D^.RFR\=U!D;K:W[CIB%&48[<MM7B^)):T,^*XVT@E+9.D^5/
MD(H(]L7&8Z)U=VFK'[@@9SQY$E;S6/2L*:(C.E;CFI".ZI:SI^9\WE:@]5\;
M4$$ZWIQJ^F>7;R<XXV"KP0]*#2WR`'D&P;0I"E:B+<Z#9=+5XX]/\&G'R_38
MJ(J`B20I*E\^*DK6ZI)/D*N'Y%!%_65_W194CB?%BV'^D(H.C:NTLZ=^9G+^
MA#&PY^'9C1LJ@AP/+4ABRRVIQ7?2&U`@)2.`YWH,[:^&CPLRSBLWF1GU:/XN
M>2IL-J0R-'@/,I*[%M31*>.@D<>^F@FN1P#4F3Z;%>5"R!2&UR6PE0=;%[(>
M;4-+B1<V[1V$4%+YK:D/:_5'IUBXI:#2YV1F!MEOP6T%\([B&M2]*1I^:H+^
MM0:+';WVOD=P2]OPYJ7<O!*DRHH0L%!18JXD!)MJ'$&@WM!4G2#_`'E]4/Y3
M9_4N4%MT&AV[OK:NXY<N)AIR9<B`2F4@(<1H*5E!\]*;]Y)'"@WQY4%1])TJ
M_&KU.5S3Z=&%_9T+X4%N4&CRV]]K8G-1<+D9Z8^4FI0J+&*5DK#KO@HL4I*>
M+G#B:#>4&+D\9`R<"1C\A'1+@RD%J1&=&I"T*Y@@T'E3J)TYW%THW#&W-MJ0
MZ,*AT>A3>:XREG]S2+><TKS03S'`\:"^NE/5?$[\Q)4@)BYN*E/PEC2>*"?[
MHU?BII1Y'LY&@G=`H%`H%`H%`H%`H%`H%!7V\/U_/_LNW_M\4%@T&@<_#V/W
M;_Q4_P![R?5#7#Y-!OZ!01WIVHKV/A5GFJ*@\?9XT$BH%`H%`H%`H%`H%`H%
M!T3I\*!#=F37VXT1A.MY]U00A"1VJ4>`H//O6WKNA]IW;.S9>M+UFLAEXY*B
MHKX"-$(\Y:[V4M/M#C0:O;/JR9N3M%S)SIJ\5NQ?AR<-%0=*(RD'6E,D@$^(
MKAYI[GL\:"S>D_5B3FI#NT=VL?!>^<8-$F,X-"924#]>9[";<5`?IAPY!:%!
M5'K).LM['QZGTM+C_"T;QD/H+C11H=OK0DA13VG3Q\E!9.!+"L'CU1RE4<QF
M2RI`6$%'AC24AR[EK<M7'RT%3]:03U1Z5\.'PHYQO^B9[*"P=^;9VSN'$IA9
MLQVEDJ&-EOZ"IB4M!2AQD+(!<3S`H(GT]Z:XK`9MZ3#R\S.OMO*4_/E.:@T`
ME24QD:>ZI14O4X;]@Y4&O]9)7\6;.2=12K<D+4E'G&P7R]F@UVZ,T5^L%B<.
M[AX,?PI$1^/F-1$Z0E45X*2E)/>0A7=40.``N>R@KQ_#Q,QU.<F;A"7\;!?D
M17W&G4%['LKF^%$?2M&I*_"?=&HN)\Q1!'=H+><V=#P.IK.[2Q>XL,3W\OC\
M>PW.;'S4F(A/OGLK8-_T%!MX/3GHON.&W/@X+%3HQNE+K#218]J5!.DI4.T*
MXB@R&>BO3!A\2(V";C/B^EV.](94G5STEMQ.GY%!W)Z3;30`([N4C\=2O"RV
M1&JW+4"^;T$'ZV=.V&M@SI#&6R[P:=C*<CR,B\XP4>D(U%27"1W0>%!&>DO0
MS+O1(>Z8>[I6)B9`>DM,8M*T.J2H\4O+?`0OB.UGC03OUCF%HZ-Y%DN*><0N
M(DNN6"EE+Z!J5I"4W/;86H*^ZB==XV2VIBL'M.1.QTQ]UF)D'G8Z6]4931;6
MA"UZN)41YO&@LS970S`;0R:)V+RDTZ2V765".$N!I)2E*U):2O3<E1`5Q//C
M06504YU,'_W=TV-_=2N'R!07'04WTZAL/=9MX2TN*2N$](;#)C$$^DJ:4I:I
M:;A0NQW6W+$<=/;07)05'T@_WF]41_XDQ^I<H+<-!3/J^Q6ES]SY!%T@250T
M->"IHA#;[SH+CH'AOK/C>=?6!P(`M<+FH*DZ2\>J75`^3(1A;_!KXT%MT%/=
M0H8G=:MK1"L("6(\HDQE2%$1IBG-+:VPI4>Y2-:SW2.!(%!<-`H*>ZP=0EY!
MYSIMM&*WF=SY="H\Q)2ER/#96.^MXFZ=21QX^;SYV%!3V[>G6^ND.7Q6X($T
M2(S80E&7904H;?4`'(TELE5VG+623S]A5!Z&Z7=6\'OC%(5J;@YQH^'-Q2UC
M4%B_?9O8N-JL2".7(T$\H%`H%`H%`H%`H%`H%!7V\/U_/_LNW_M\4%@T$>4Z
M@]0FV@#XB<0M1/994E`'ZDT$AH%!H=A("-EX1(!`]"9Y\3Q0#0;Z@4"@4"@4
M"@4"@4"@4'F+UG-T9=[=+>VE/Z,+$C,RU14=T//.J6-3W'O!&@:1R!XT$D]7
MOI)CFH$'?68TRLA+1XN&C6NW%:5YKA!YO*';[D<N/&@OFU!7W5;I3$WA&:R6
M.>.+W=C;+Q67:)0H*0=26W"GB4WY'W/RP0PNE/5.9F7WMI[N8&,WQC>[)C+'
MAB4@#]?9'(W`N0GA;B.'()SN3:V"W)!3!S,828Z%AUNREMK0L`IU(6V4J3=*
MBDV/$&U!L8L:/%C-18S:6H["$M,M)%DI0@:4I`\@`H*/]8/(38&^^G<N%#7D
M)<66\_'@-<%OK0IH^&DV58J]J@@_43?>Z-V[HVI`W#ME6#BQ<PWX#<@.E3I*
MVTK;/B(2VJR3QTT'JIIIII`;:0&VTBR4)`2D#V`*"H_6+`,398/(;DA&WM:J
M#2[DS#HZ_P`6"@N^"W,BJ=U!"6?$&/<<2"02I02E5P=.KB1YH%!K^E6WL?D-
M\[EBRYV(R#.?QDIR:WARXH-J?E)"R2ZTTI`^82+V4">9-!<'3W+39N$5`R:]
M>:PCR\;DU'@5N,6\-[VGFE(<^30<\QL;'RIJ\KC'W<)G5>=DH6E)=MR$EH@M
M/I_3IOY"*"";_P"K>\^GD2(,UA8^3<?6IIB?%<6S'?(`L5)(<5'<',H.I*O<
MJX6H)[T[W8YN[9N-W$Y%$-<]"U&.%^(E.AQ2.ZNR;@Z;\A017UCHBI?2/,L-
MZR^I<7T=IL@*<=]);T-\2+ZE=@X^2@DO2_)#)]/<!/\`2WIQD1&UJE24MH=4
MKDK6EKN`I(T\/)01;UE^'2#+<+^^Q>'^D(H,[=VT-K[]QF-VU+RBHV2QP9R*
M41%-E]'AH"+K2M*T@'Q1S%Z#;LL9^#GH$5[<;F0\?4MV`Y%C(/@H2=3A6TE"
MDC5I2/*:"64%-=3;_CUZ;^3ZI/R:"Y:"`;7Z;9+"]1\[NI610N%F/$)A(2M)
M*EJ0I!6"K1=L(4`H"YU=E!*\ON3&XL*](4I;B!J6VV`2A)X!3A)2AM)["M0O
M04AT<W]A#U#WX\$ON?"\STF$AML*4IMI:TFR0=2E64#I2":"^X,^).C(DQ7`
MZRODL7YC@00;$$=H/$4$*Z8].LGLZ9G%R)Z)$3)R/'8CM:PE*BM:E.E"CI0I
M:5I24IOYM[]@">T%(]/MR8_%]8.HL*3XJGY<MIUAMIM3A4&DD+`"022-8[HX
MT%SPI\2<P)$5U+K1N-2>PC@00>(([0:"$;LZ>YG+=0\%NF!.:B-8Q#;4D`N(
M>6TEXN.([G=<0XDZ-*B`GGQY4$^H*IZF]3<K\,L["V(E,O>,\6?D`@M0&3YS
MCBA<!8''CR]L@4$@Z8=+</L7&N!I1FYR<?$RV7=%W7W"=1`)N4H"B2!?B>)X
MT$LR6-@92!(Q^0CHE092"U(CNC4A:%<P10>0.JW3M_IUNV+\%S%"'(U3,-)2
MHIE1RTM(+:E]N@J&E7:.=!Z1Z-;RR>[]B1,OE$H$\..QI"VN"7%,JT^)I]R5
M#B103B@4"@4"@4"@4"@4"@K_`'D`%YU1!%W\`-1\T_5Z>`]GC06!01DJ5^,H
M)OW1AB0/9,H?G4$FH%!H]BBVS<(.7U$QVW]P/+0;R@4"@4"@4"@4"@4"@4%)
M^L_A\8=JQ<D(;/PDJ6EDS="0\6PRZ0@N6U%(/&UZ"<=%Q_\`5.UQ_F#7+VJ#
M=;EWGMC;"8RL[/1!3,4M,8K2M6LMIUK`T)5R3Y:#<H6E:`M)NE0!2?*#05_U
M4Z51=WQV<GC7O@O=V,]\Q.6:.A6I/%+;JDBY1?E\R?D@A@])NK+N?=D;6W.Q
M\&;VQ1\.9%<L@2=/-UD=IL+J2/;'#D$]RV3D1U(BP&!+R3R2IIE2]"$I!L7'
M5V)2@$]@)/90>=\YO:;N?K3LV-(\)3>&RKD56AA;!2^%V6DZG7@M/O:2A0M?
MR"@O#J%L#$;RQ*(\P>%/AE;N(R`*PN+)4G2AU/AJ;*K&W`F@C&PMG9+$;C<2
M_NC(;C<CG4\^ZZ[Z,TV$*;2P4>(XVMY:E:U_,Z>R_$,/UB+>B;,N;?[1P[C^
MVH(*_DL?E?679E,+6E^/DT0W8SS;"#>)&>9*VG$J+RTJ*22"D6%KD@@4&_Z-
M2&G>K6Y$#B^TQ+#JPT&$D*G)*=*"TTK3;]$H7XCG09?4C?&=V3U4@/0<8EK&
M;B3#ASL@\2XT^M#X3J;2W;2\TVXI'?/%-C;NT%VCE05+ZR2B.G>1%EE'AI*K
M`.M@^,C3K1YS9OYKHY'NGG05OTN>W&^N4QL:8QCLYBFHSLO%.I?;AY%@M(UO
M&*X2E+USI6I!1<V5?C03S>?4"!,V'(C;UB/X%;A;4EZ.RG)0Y+C+@48X2H`:
MB4]]A\(5SYT%A].HN)B;&PD7#SSE,6S$;1#GJTW=;`X$A(`3;EI[.5!$O64_
MW0Y;L]]B_;"*#[MG9F<9WMG\U+;9QV*GPO!BY""I#;RTGP5)=<N%'Q`&U76H
M>3G0;3:&4P<3,N8F%EF,ZN0G6O()=2]-"D*6E*)2DDA2>XL(4+"X(MVD)W04
M1UMSV/P'5W868R*EH@PFY#CZDIU$)U!/=2.)-U#A02/^LOTK&J\J4-/^:N<?
M9%!UO^LWTJ;96YZ5+NA).GT1WG;ERH-_F=L+W7TODX^.^AN;GXC<@RGFRM)>
M="74E:5:B$\`D6\T<N5!YOZ)[=R&=ZCQA#7'C.X22G)24*"RDMLK2RXVA2.\
MDZB2F]K]M!Z4WIO';NQ)4?-9=Y<:%DE*C/H:;+A6\E.MMS2CC<)"DD]O#R4&
M@/K,=*`+^FR?L5W\Z@^?UFND_P"_97V([^=05%MB,C?W6G)Y+`2D-I:FHS$;
MTE*T:V&7&D+'<LZVH\;6^3P-!?.]MY[7V#D(N5RSJX[&84ME]#3:G?$=92%(
M<*4#@0GNJ/;P\E!IE>LMTH`OZ=)/`'A%>[?D4&BW/UX7N-,?;G3!AZ;N+*DM
M)F.M*:;BMV[SO?'-(XW/!/LFPH)OTMZ78O8N+<'B>GY^>?$R^7<!\1YPDJTI
M)N0VDG@.T\3QH-UG=[[:P63@XS*2_1YF1"C#;T+4%Z5!)&I((!NH<Z#>T'FS
MUL%$Y[;2.8]&DW`Y\76AY;T%][2VO@]M81G&86+Z'"!+O@ZEK.MSO+)4LJ5<
MGV:#<T"@4"@4"@4"@4"@4$!WNM(:RZ7"`CTS!>'SOK,YOAY/)03Z@C'_`!,'
M\BG[;%!)Z!0:39'X'87ZR8^AB@W=`H%`H%`H%`H%`H%`H*<]:-13L*'8$E60
M0GAV7:<XT$PZ,?[JMK<ON>SR]J@B7K`LLRI&U8+CZ8_I<B4R'G8YEMI\1I+9
M46P0H$:[I6GBD\J"WFQ9M(O?@./R/9H.5!7/5KI?%W-%1G,:^K%[KQ"2]CLJ
MSW5^]@J\-PCC;YD\Q[5Q0=70G=.:WCM1S<^9CM-RY+B8K4AHD%YJ*G3K6@\$
M'Q5+X#A[%!!][])MX8SJ3"W'L3!M2H$=U.1++LI#;7IBU*\5.AQQ"D)-PKN<
M+DT'?N?!=;][Y/`,Y[;D3'8W'3D2)*X\Q"DJ;*DAP.(\514`@'@!07M$AQ8<
M=$>(RB/';%FV6DA"$CV$CA05OUVVONC.XC!*V[!&0F8S*LSEL%Q#?=:2JWGJ
M2""JP-N-!AC>/79U_3^+^(DH-RM<YJQX>Y5JY\:#B=]==`LG\7C&H<-0FM\O
M;U4&LW)E^KNY,6K&9?ILR]%4M#J?JUL*0ZTH+0XA6JZ5)(YT&V&_.NO_`/S]
MG[-;^>H(OU$_')O7;K^&E["1'4YI\*8W-1XC=E!2@.^G4E6FQ2>'RJ#==!>F
MV7P<K([@S[,K'YM\^AF`XZ'FE1TMM%#A6=94K4DVLK@.%N%!V]5L/NW(95_&
MQ]E-;EVZ]X,U"S,,4HF)0II:K(6A1.G38JH(_L:-U;V8U(C838SR<;(5XGP=
M)RB'VFG+\5M:N^G5[H:K'G0=W4)_K9O/:TG;\C9*(C4E32U2&I;2E#PEAS@"
ML<]/EH/NZ7NO6Y\?`Q'Q;<PL0/-C(/19K8+T<I\-UMSO^84J)-!9^W^EVR]O
M252,+"5"6IQMUP-O/:5K:24(*TZK*TI)%C02R@X.QV'K>*VAS3RUI"K?+H.E
M>-QZK7BLDCRMH/L^3V*#X<7CR;F*S?R^&GES\E!D]EAPH.B-CX,9Q;L>,TRX
M[^N+;0E"E=O>(`O0?94&%+0$2V&Y#:3J2AU"5@'E<!0-!C?%W`?>R)^T-_.T
M#XO8#[V1/VAOYV@[HN+QL197$B,QUJ&E2FFT()'D)2!0<Y<&'+2$2F&Y"$FX
M2ZA*P#[`4#08WQ>P/WMB_M#?SM!4,:)&B^M+X49E#+?P'J*&TA";D6O9(`[*
M"[:"E>LD-O(=4]C8_P!(7'6Z'%.E,4RPIMJ2R_I(2%+:)4P`'$CAQN=-Z"ZJ
M#S5ZV!(W#MKZVD6]OQFJ#THV+-H!Y@`?D4'*@4"@4"@4"@4"@4"@KG?JTJ:R
MJ002C*8`*'D)F,G\V@L:@C'_`!,'\BG[;%!)Z!0:39'X'87ZR8^AB@W=`H%`
MH%`H%`H%`H%`H*<]:,@;`BDD@>G)%Q[++E!,.C(MTJVL/_#V?RJ#&ZJ]/,GO
M!K$JQLY$"5BWUO(>47$+!6D!*D.-=X:5)!T^Z\HH)XD62`>-ASH.+KB&FEN.
M*TH0DJ6H\@`+DT$.9S>(RKX8S.59AJF$)@X1,D,/J9?[K1?2E:7%+=`N$\+7
MMQ-!O]M;9PFV<0UA\)%$/',%1:825*L5J*E'4LJ4;D^6@VE`H%`H/E!#<]NC
M=<3<;N-PN*&42@8Y3J5+#(:8DNR$2']1\\I#2>[\F@W>T,J_EMKXO)2+^D2X
MS;KUTZ.^4][N]G&@V_;0??8H%J!0?*#[PH%`H%!']][M;VGMM[-.15S?"<99
M1%;6EM2UR'4M)`4ONCBN@J_^M!BN%L,@@FUQD8I_*H/G]:#'$$_`@%B1QR,4
M7MVCV*`OUH<<A&HX/5R[J,A&6HW-N``O0=3GK685M*B<*24^X$Z/?\J@G'3;
MJO'WM/RT'X*>Q<G$K"'4O.MNI<.M:%>&ILV5H4V02+B@R]\]0)VVIL6)#VWD
ML\N2TMXJQ[>M#80H)LL\2"=7DH(\GK9FM)6KI[N+2+W/H]^7R*#X[URR;(!<
MZ?[C3<@#ZEOQ/+E0=F(Z[1YNYL7M^;MC+8F5EG/#C.36TM)-@256405`6L;4
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MB0PI3R&2+H2XH-$%5N?&@DGP'ZR^J_QBP-OF?`7^7X-!R3A?66!5?<.`4#;3
M=ASA;GR:[:#7Y_&^LFC%RP[E\(Y&3'=+_@M*"EHT$J39;7/3RM0>>6GMWQ=W
M(90MQS=JWVPFR6W9/I+K:-`2JRAK"-/;W>'*@]@]*X^]F-FQF]Z+4O/^*\7B
MM;;B@V7"6@5-=S@BW*@EU`H%!6W6/JM-Z?M8ER-`:G?"*WDK\5Q380&DI/#2
ME5[ZJ"`S/64WI#PN/S<G:D5K%95;B,?),PGQ2S<+(0$ZP!;F106=TAZBR-^;
M:?RTF",?(8E+C*CI4I0*0VAQ"^^E)[R7*"-=3>M.X=H;AE8^!MTY"!!C-2)>
M0*G@A'BZCWBAM24@!/,F@A/];#-\"=O11VW])<X#^TH.!];;,)-CMZ,.-K^D
M.]@N?<4'<QZUFX9$EN+&VTQ)D.J"6V67W5K43QLE*6R2?D4&W=]8C?+;#BU=
M/Y;>A*E%Q?I.A('&ZOJ<<`/9H/FU/6"W[NI4M."V<SD3#2E4A+4T-J2'`="K
M.`$I.D\1027HYUGG;_RN2@2L6WCU0&&WPMIU3FHK64%)"DBUBGRT%K4"@4%;
M>L+(2QTPF/*"BEN7`64HMJ(1+;6;7]A-!7.TO6+VQM[9&"PJ,/,FSX,-F/)6
MI*&F$N(397?)6M0'L(H-FOUC<'+`"IWP8.!6B-C'93@\H2Z\MI'R2T:#K?ZQ
M](I@6,QD=P9-I:=*F'4+CL'R^]1/1D&_Z(&@UF[NK/1=73_/X3;.*<B39\!^
M-&\.`EHJ<<00G6YYW,\R:#`Z+X^7)W3`WE&:>5CXGPBD,HC/%Q],F3([B%(2
MIL+2=)4AQ0'&]Z#T7A8N07(D93))2U(DA*(\46)CL)XA"U`J"EE1*E$<.0[+
MT&VXT"@IOJD-76[IHDI'!R2J]R#PTT%RT$!ZB]8=L[.0]$+B)FX$):4UBM1;
M44O*TI6MS2I*4)\Y7;;LH-!T]ZOX#-95U^4_$PGI8>4]CW)*2+M*0&Y"EJ2T
MA*W-2TJ2#<@)-!8HWAM$Z2,YCR%WT?53/&W.W>XVH.8W3M@VMEX1ORM):XW_
M`++V*#SAZT^3QTW=&WA#DM20U&5XBF%I7IU2$6"BDFW+A0>I*!0*!0*!0*!0
M*!0*!05UNME#TK+M+OI7F-O@VY_NA@T%BT$?2V#U`6[<W3B4)MV=Z2H_\V@D
M%!\7YBO:-!I-BBVR\$+W^H(_'_!)H-Y0*!0*!0*!0*!0*!0*"C_6R=*=D8Q`
M25>)/\M@+,.&]NV@L+I$A2>F.UPK@?@V.2/;0#09F[]_;;VD80S3RV?A!3B8
MQ0@K!+20I0-N7!0MY:"14'%QM#C:FUI"D+!2I)Y$$6(-!'(D9K;R"TY`+T2*
MVIQC(LH2XZ&TI`T.C]<*DH2$A0OJ`%Z#8;8W/A-SX=K,81_TG'/J6EI[2I%R
MVHH5P6$GF*#:T"@4%.=<4XY>^.FJ<DEI>/\`A*49:9`2IKPDLI*O$"NZ4\.V
M@AG73$,L]-(V93#1!;EY!EG%8]#261$QR&WEM->&.`4ZOWY?;<@>YH,WH5C\
M_C\[.SZ8SCV/FXJ%'CQ6]:%N/(C,*2OO(\,HXE/B:QIL;WH)UO9&_<;%Q+F)
MB>GS,QDD*W,VPPB2R(A2$%GWQ*CH0C@%V'(D\[4&CW)$S`FSK[;Q@3HS*6G$
MR!<MB,@75]3@@IYVOV]G.@Z\C`;$;(^GX6%$E&7+2VPR&WD!"<`I:5!9;;OQ
M%[:>!H)ML3"8IC)S7VH$=IQN-C@TZAI"5`F+WM-A=-]5!)]R?@[E1_F<CZ$J
M@\[^K="DL;"F[BQT?QLGBLD?%:18+DPU16?'CW/.WZX@?-)]DT$IZ3C$_CVW
MZO#)91B7H./?B",E*&BEY"7"M*4@#O*42?9H+QH%`H*M]9511TFR"K$CTB)J
M/&P'CIXGR"@KSIOTDP4[8.(W<]AQN,3F%+R.+4ZXT^"V\M'B0UH6VE1T)XM+
MX*]RH'@0L;#='>B&8AB7C\&VZV%%MU!?EI<:<3YS3K:G0IM:>U*A<4#+]&^B
M&(AF7/P;;36H(;2'I:W''%<$MM-I<*EK4>24B]!7?4?I!MV+L3+[LC8<[?3"
M82YCL8'7')"E..H1XDQ2UN)2=*N#2.7NE$\`$W]65WP^D;+JDJ5IF3EE*!J4
M;/$V`',^04$HVGU+8W'N!["C!Y3$O-0TSPYDF4LA;:U)2D("5N<>_P`0;$=H
MH)G0*"F^I_\`OQZ:<+W5*Y^T*"Y:"H>L70YK=KC^;Q+BT[D>2Q'2AYX(B>&A
M6E3BTZ%*)0@DV!XVH(KL#U=<,WDC'WBVW/F(2X^[!CO.>"PTHH3'UK;#2BXL
MI<-KVTT%C?B!Z/\`]&V?VZ3]-H,=SU=.CJT:?@`)[VK4F3*!]J_B\J"BO6`V
M'M;9NY,)#V[#,./*C%U]!<<=U+0^E(5=U2R.'DH/7XY4"@4"@4"@4"@4"@4"
M@KW<GW0RO\L;?^V&*"PJ#0H/^W;P\F+:^V'*#?4'%Y6EI:O(DG\CV*#2;$U?
M$G`ZAI4<?&)'MLI-!O:!0*!0*!0*!0*!0*!04;ZV2;[/P_L3U'Y49R@LGI6+
M=-ML"]_XMB\?\$F@A?75I<K,[0QS;K["ISTMAQV,P)3@:<0TAP!JX/%)YI[P
M[*"W:`>5!576OK#CMHX]S"X_1+W1/:T-1C=28[;H*0Z\!Y?<(YJ]J@Y^K4B6
MUTGQ[<AUIQ#;\E,9+5]2&TND:';_`-T"]5[>Q06D"#RH%`H*8Z\8]K)[UZ9X
MUQ02).5>U*LA9"4H0J^E84D]X#F+4$4]:"1D(^#B8TY*3DD,R&WYH=1'2TRI
MQ#B6$DM-H5K<LLA-^"1[5!='2W_=OM?@1_%<0V/#^XIH.>_Y+"\(Y@D9=O#Y
M?/(<AX>0M2D'QRC5W2BR@0!Y:"G<QTYW`PXOQ7F93P;FZP<KF+68:2I\6+A_
M74*L?R;T&)D=F9F*N6V^TT^6%O!TIS&6*E+:Q_I"^:O=,>]?_P!M!,-A[-W2
MSN6)*$M$6-C?1USVD3\A),AEV*KPV5-R%*1[UK3:X[*"TMR?@[E?K.1]"50>
M>?57?RR\-/QS<YW'1Y,CQ(CR&V'$.O-L-^,V?$2I04E!0H=A%_)023I)B&\1
MUYZA0&EEQ#<>(O44I1Q>LZJR$!*4C4LV`%J"]*!0*#HFN041U*G*:3&X!9>*
M0CGPOJX<Z#1]/Q'&UF1'*2QZ3.\,H`"=/IKUK6X6H-+N\,HS[:MK-K.]U!"'
M%1Q]3!@\0<MR1X5AW/[K_>^V@[-JI8.;ON@%6]D)4&UO)M&\*W>^"K]SPM/G
M6]]_OG90='7L@=(=RG_H&_H[=!I?5F0ASI*PVL70J9-2H>4%T@\J#CT[8:B=
M2Y<!C!3\.Q$Q3R$OY!]V29B?34I0ZA;JEJ"0$<`2%<>*>1(6W0*"F>IU_P`>
M_37E;ZJMY;V%!<]!6RMZ;CE=:Y&RFGFH^(CXQ,\K2T%/J62E)&M1*0._\S03
MS&8J+CF5H8UK6ZHN/ONJ*W7%GW2UGGY!V`<!PH*^ZC]2\_MK>V!P4&/'<BY9
MM*G5O7\0$RVHZO#[Z-=@\#H0%*[;6%!9M!YB];"WQOVZ3^\U_;*:#T]0*!0*
M!0*!0*!0*!0*"O=R?=#*_P`L;?\`MAB@L*@CS2B>H4E.JX&)8.GL%Y+W'Y-J
M"0T'7)_<SOZ17Y5!J=DDG9N!)-R<=%X_X%-!NJ!0*!0*!0*!0*!0*!0>>_6M
MW)A7<;C]OM2@O,1I'I,B(`JZ&7&'$H4I5M/$GE>]!;G2S_=OMG^38OT)-!K>
MI_35W>IQ"FYR(2L6ZXZ"MHN$EP)`4DI6V04:/-)*5=HX4$ZH*VZK]5'MN*8V
M]ME@9;>^4LB!C4=[PDJ_NSH[`!Q`/MGA00O&^K4IZ(O);LEKS^X,FTOX7NZ6
M"TZZH+#D1X)5[XW;3WQI(Y6H+4B8_+0<&W@]N8QK",LLEJ+(>+;C;%[]Y++2
MB7%7X\2D7H*_V%U.W#MW<QZ?]2W-.54O^)\\H!+,Q"CW$J4`E-U'@E7]BJQY
MA=-Q0*"ENO&13C=]=,YZFUNB/DI*O":!4XXHMH2AM`'NEK(2*#2^L'B9>.Z3
MQS+T+S63RS4K+.IM93ZF'`$#]"TD);3[`]F@D6P^N'3+'[)P,&=EPQ-B8^,Q
M)8\!\E#C;24*'=;(YIH,??/5+H9N*#&5D<H[*<Q;R9L1F,PX'E.-D*"4J=:L
M+VX]Y/MT%?9;JETKDRGWVL%+!=,\J)"02J2VA+*N#O"R@;^2@/=7]@L"8UC,
M;+BQ7G9;S382FP7)QHB`F[BO[I<GV*":;-]878",K*$TRX34ST5")+K(+:2Q
M'#:BYX:EJ`*D\.!^102;-]=>EDO!Y*/&SK:Y#L1]#*"T^-2U-J"4@^'VF@@/
MJW8B7D>EV7;B.%K*0<L)6,=!L$R6HK12"?F'.*%^5*C0;WI-DV\KUUW_`)%M
M"FTNQ(*'6E><T\VA*'6E6]TAQ"D_(H+QO0+B@7H*)];1:OBQ@&[DM+R"];=^
MZK3'64W'(V[*#1]+^K6#B;$PVV'\RUMYJ`VXWE)SJ%KE*+CJW`B&A*%H3W5B
M[J^7)*3S`6/ANK?1+"P4PL?G8[+()6LE,A3CBU><XZXI!6XM7:I1)-!\S75K
MHEFH)AS\^PMO4'&G$ID(=:<3YKK3B4!2%IOP4DWH*[ZF]7<!,V#FMK-YEK/>
MG,I;Q>190M,BZ'&U>'-;*$)U$)-G4=U7:E/:$S]6A*_Q0-!`)7Z5.TA)TJ)\
M4VLH\C[-!E],\+NJ+N94W-1LLA*\7X0D9>8W,47!(!*0&0&VE6%R!P5P(Y4%
MHT"@IGJ;QZ\]-APN!*-[\>-!<Y/"@IC'JU>M1D@1YN`2D'GVLG\V@N:@I#JY
M-:B]:]AJEM,N15H*&UOPS,#;RI"4(6DMJ0XRK6M`"[Z;VO>UJ"[Z#S!ZV5OC
M=MTJ\T0UDD\N$A-!Z7Q^1Q^1BHEX^2U+BKN$/L+2XVK2;&RDD@V(H,F@4"@4
M"@4"@4"@4"@KW<GW0RO\L;?^V&*"PJ"-,?[RIG\C1?MJ1026@ZY7[F=_2*_*
MH-5LO\#\%R^Y\7S>7ZRGE0;F@4"@4"@4"@4"@4"@4'EKUH=GYR)N8[M+(?P,
MMIF.Z^B]X[S8TCQ?(E?8KEV'LH)-ZOG6R%*B0=E9YUMB:PA+&$F"R6Y#:0`E
ME1'`/)'+YH>SS"_[BU^R@K+JOU9<V^ZUMC:[/PMOG)6;AP&QK$<+!]^>`Y6'
M$`^V>[0=W2GI.-J^/G,Y(.6WGE._DLHX=6C5Q+31/9Y5=OM6%!8]J!017J)T
MZP.^<&K&9-'AOMW7!GH`+L=WYI-^8/ND\C05UT0@9?"]1=Z[:GYA_+(Q+4)+
M3SRG+'Q4ERZ6UK=";:M/G4%WT$2WYTRVWO<P#FC)0K&J<5%7&=\)0+FG5<V5
M\P+4$+F>K!L.40%Y',!K^]&4A:0>1(\1I9N105KT7Z+[:WIC,U(RLN<R[C<D
M["93%<;0DMH`*2K6VNZN/&@G63]5#:#T12,=F<E%EW&AYXLOH`',%`0T3?\`
M3"@CF2]59,"`_+7NO]:02E)A`:EG@A%_&/%2B`*#=9#U3=M.8G3CLQ.CY8I1
M9V0IIZ.%`CQ+MI0VH@\;=_A0=^)]4_:3>.83E<MD'LB`?2'8JVF65*N;:$+;
M<4!:W-1H,T^JML"UOA'+>Q[\QP_ZF@Y,>JYLF."F/F<XPDFZD-2VVTDVM<A+
M0H.^%ZM.TX#[C\+.YZ,\[P>=9F(;6L`W[ZDM`JX^6@F&UEJPFV9>'])=FY'!
M)?&J<M2WG6[K<CN.*`4I25HL+I!Y$<Q:@\M#J]N1'4%.[$25*;4\)*\9Z6Z8
M=E,`*:%C;2.RXX'G;C0>H]Y-'<6'Q^(BSI&.DYA;3R)$)W0^U';`>=6'&]:;
M6LF]]))%!7.[O5OS.8DX]MC=TV1CF3>6G+.+ENI4564N/Q2A!T<.\*#L5ZJ6
MUP%>'G,@DD`(*@PJQ[2>X+T'2/5.P5[G<4XCR>$Q^=0<?ZIN#Y?&2=^TL?G4
M'P^J7A"+'<DXC]A8_.H-GC?5SDXN((>-WWG8,765JCQ7$M-FYN;(38`D\210
M9/XAL[QT]2-R"_.\B_98]OLT'<CHAN='F]3-QCC?]>3^;00CIEM;?F\U[@5)
MZ@9N%'PV2=QK'@OJ4XZ65'4MS62!<%-@GV:"52_5VG2\E%RDO?N;D9&#?T*6
MZ6U.LW-SX:B+IO03'#2,CM?8>33,EO9K)X%N8ZMZ<X$N/AO6\R5.`&R5(L`J
MWY5!3*9.\O3G>N6W$+G-N+4UEMOO%+BVX'A,G2RXWJNE)X\.*>!MYPH+ZV/O
MC`;TV^QF\(_XL=WNNM*L'&70.\TXGL4/R>8X4'?E]H;:S&2@Y/)0&Y,_'*"H
M<A6H*04K2X/-(U`+0E0"KBXO0;&=.AP(;TV:\B-$C(4Z^^XH)0A"1=2E$\@*
M#QIUGZE1=^;K9E8N.L8Z&CT+'&Q\>25N7U^'V:U<$)Y^7G8!Z4Z&;4S.V.G4
M'&YEOP)ZG'Y+D;4%%H/.%26R4\+A/,=AH)_0*!0*!0*!0*!0*!05_N9&F9DE
MD\%YG`@#V1(8H+`H(TQ_O)F?R-%^VI%!):#KE?N9[](K\J@UFSN&T<)PM_%\
M7A_@4T&WH%`H%`H%`H%`H%`H%!UR8L:4PY'DM(?8=&EUEQ(6A23V*2JX(H*5
MZY]"VL_'=W'M>.&L]&0"_`:LA$M#8[I1:VE]`'=/;:WDH(1M_P!9+>HVN-LC
M'F=O1UYO'XJ<X`V+K(;O)0KCXZ%<.5B>*K<;A;W27I*SM%AS+YAT93>62NYE
M,JLZRDK-U--*4+Z?*?=>U84%CT%7]><KN#&XG#/869-AO*F.!:L>A;JW"F,X
MIMM;2""I"G$I!\@XT%C8KQ?@N'XRE+>\!OQ%K-U%6@7*B.9O095!4O3MQ)ZW
M]34G@;XTV/D$>U!;5`H![*"E/5=M\";JYZOAR1J![.ZF@FW5W?TK8NSU9Z)$
M;FO"2S'##JRVDAU1!-T@FX`H-U"QLO(>ASLL\ETMI2\S$824,)<(!"SJ*E+4
MGW-^`YVO0;NPH%`H%`H-?D\)$G.M2%%;,Q@%+,ME6AQ*5><@\"%(-N*5`B@H
M%[HWZ!UXA)5J:P&49DRXSB$QK+?0S9]DQPWX26[+\W1;C07]C,'C\<5K802^
MXE"''W#J6I+8LA-^24I[$I`2/)0;"@4"@4"@4"@4%0^KLFT7>AM:^Y9W'R\1
M06]0:[)X9J8KQFW%1I>@M>.@)5J;)N6UH6%(6@^10]J@P=F[0A;7QLB!##:6
M'I+DI++#26&6_%"04-MI*@$]V@JO>VU<]TQW`_U!V+'4_A)*M>Z=MHN&RB]S
M(92`=.FY/`=W]*2*"T=N[^VKG]JIW1"G-IQ`;+DEUY008Y0+K0\">XI';^1P
MH/.^^=\[GZR;I;VCM%IQ&WVUA96H*2AQ*5`&5+Y:6D\T-GB3^BX`+LV)T5V5
MM2)CU>A-9#-P5*>.9?0"\I]:=*EIYA`')"?<^W<T$^M0*!0*!0*!0*!0*!0*
M"O-Y+TR70G@5;@P041S(\5DV/L<*"PZ"-,?[R9G\C1?MJ1026@ZY7[F>_2*_
M*H-;L_\`!+"?6$7Z"F@VU`H%`H%`H%`H%`H%`H%`(O04GUSZ&,;A:D;GVXP6
M]QLI"Y$1HA"9:6[JN`E-_2/F57X\CY:#%Z%]=U9AQ&TMW.B/G&?>8,Q_WI4D
MH.DL/)5;3)3;E[KV^87M05%ZQ29B<9MR5%:>><A9+TDMLJ6R2EIE:N#Z+^&L
MVLCM)X`'E06O#=4[#8=4DH4XVA2D*OJ!*0;'4$FX]D4&!NC=&$VQA).:S4E,
M7'Q4W6L\2I1\U"$\U+4>``H*#V.]UBW!N'<'4':.)A8_'[D<;2RG+*5J6S%2
M&VU-A-C8CF>1/*@NS$;H>C[%9W!N72P]&BJ>RWHR%N(0MHD/:$)UK(24F@J#
M;?K(SIG4<P,F[$9V>\^\S'EAIQ+J4E13&4M6HZ0H@:BI(`OV4%L=1LSO#'8:
M(=H1XDO.2YC3#,>:5!I392M;G%*DD62CG>@J'86V?6+V9'R$?&X3$/-Y*4J:
M\9$D**75@!03H6CN\.V]!INN66ZUN[)2WO+$8J'AC,8N]"=4MWQN]X8L7%]W
MR\*#TWC?N=%_86_U(H,B@IO%]2\I!ZG[BA[ASK*=MXSTE:HZFDH5%2EQAN/K
M6E'>"_&.FRB;^=:@MC#9G&9K&,9/%R$RH$D%3#Z+A*@E12>8!X*2109E`H%!
M!]X.+C]1=CR%-*4PXK(Q"X.2''F$J1?VPTJ@G%`H%`H*EA]1<U&ZLYG#Y7+1
M&]N0$OO.,.)2V['9:896EUQ>D>]J6]8'63<<A06=B,QB\QCVLCBI3<V"]J\*
M2RH+0K2HI58CR*!%!F4"@4%2^KL=6'W4OYO<>05JM:]U)H+7?_67.-NZ>)Y<
MO8H*A]7&/D_@K+S))F*BR%QTQG9BBL.+;0OQELG^]%:N[?O=BN5!<-!CY"=!
M@0GYD]Y$>)';4X^\Z0E"$)'$J)[*#QE,A)WUU`R.$Z;Q7L?@LRZV[)B%2TQ3
MX*B5S'VAP0V"JZ$'Y'.P#U1TWZ;X38F"^#<?=Z0\H.Y#(.`!R0[:VH@>:E/)
M*>P>S<T$MH%`H%`H%`H%`H%`H%`H*]WJ07E6[-QX,']LCG\V@L*@CC"4_C&F
MJOWO@>*--NSTJ1QO02.@ZI9M%>/D;5R]HT&MV?\`@EA/K"+]!30;>@4"@4"@
M4"@4"@4"@4"@4`BXH*0ZZ="6MPA_=&V6?"W$T`Y,BMG0)J6Q<%-APD"PTJ]U
MV]E!T=">N2\J6MI;N>+6=:]ZA39`\-<@I[I8?"K:9">7Z+V^87M>@U&Z=U83
M:^%D9G-24Q8,<=Y1\Y:CYK;:>:EJ[`*"F<!MK<'6;.,;MW<TYC]CPG-6"V\;
MWDV/Z\\>%TJ[5>ZY#N\POIEAEEI#3*`VTVD(;;0`E*4I%@E('``"@C6X-M29
M$+)0XR1(Q>8:=;R..*RRYJ>3H6Y'>XA"E7N4J%B?)QH/+VV^E65F]5\GME;4
ME/P,E,EYYF0PE\#NK8<U.)4TI1+B=:0+4'J[&XG(N9`Y3+NI7(0@MPX;?%J.
ME7G*UD)*W5C@I5@`.`'.X;L<APM[%!3?K7"_2U'\IQ/^?06YC?N=%_86_P!2
M*#(H/,DUN+(W3U)P^17+8B9.2DA^*8ZB%-S64H0I+_AJ;UK>3I*G$H4-1[W"
MP7+T82I/3?$@JU=Z5IN$@@>ENV!""4@CMTFWDH)M0*!00_>Y3\9=E`@$G*.$
M'R6AO4$PH%`H!H/-V8?AG??4?&Y)Q]F)/CK`=CM1WS[T&21H66W`H^,D)[Z4
MJ^0*"V.BS!C;`C1B+>CRYS.DI2@CPYCJ;*0A2TI/#B`HCV:"<T"@4%2^KG<8
M3="3PMN*>+'F.*>=!;#J2IM:1S*2.'LB@JOU>\5F<5@LI!R>+^#E-24^&X6G
M65NW22H+#E@HMGNZD#2>PJYT%H39L2#$>F3'D1XL=!<>><(2A"$BY4HGL%!Y
M<WSO?=/6?=3>S]I,K;V\TH.*=6"E"TI-C+E?,MI_N;?,GV>07]TZZ<8'8N#&
M-QJ2Z^YI7/GN?KLAT"VI7S*1[E(X"@E=`H%`H%`H%`H%`H%`H%`H*WW>M2I,
MD*-PC<^#2GV!]2G\LT%D4$?80/C_`#EV%_@J(+\;_NF2?:H)!0=$Y6F#(5>V
MEI9O[230:_9QOM'!GRX^+]!30;>@4"@4"@4"@4"@4"@4"@4"@4%)=>.B0W`P
MYN?;#(:W'''BRXS9\/TQ*+$*"A;2^BUTJ[>7DH-/TL]93'-X-^!OIY;,S&LD
ML9#0I2Y26Q933B!Q$A)X?HO8H,K;&WL[UCSD?>6[F%P]DQ%%6W=OJN/2!?\`
M7W_*E5N?NN0[O,+Y;;;;0EMM(0A`"4(2+``<``!R`H(KU1SN6P6S)>2Q4AJ)
M-:=CH1)D`%E"77T-J4X2"$I"5\5$<*#*Z>YF?F]F8O*9!UMZ7+:4MUUD6;5W
MU`%'`738"QMQYT%?[.2#ZR.^E]J<;"'RTM?G4%E;PR&0QVU,Q/QPO/B0WWXP
MTZ[N-ME2>Z.?$4&@Z0[MS&Z=L/Y+*N1W9")CC"%PR%,E"&VSW%C@KO*-SY>'
M901'UKQ?I8@`V)R<,>7F5B@M^"D(A1T#DEM`^4D4'=049U)F[N?A;HP^0D(;
M;G>(<3&+S"@Y':F1T`*;8C*>!*7;#6\;WMIH)[T5]('2_`)?3I<2RXG3Q\U+
MRTIM?LT@4$VH%`H(7OAQ(W;L9!-E+R4BWR(+UZ":4"@4"@ICJ'-W4!NJ%D/!
MCP9\>2SBR^Y&:0N.TADK6I2&E/\`=\17%2[<1PH)5T+$A/2W"MR!9QL2&PD`
M@!*)+B0!?F.'.@GM`H!Y4%%+DYCHMNB9)F!<_ION*:N2[+2G4]CI;YN?$MQ4
M@^7R>SP(7?"FQ9L1F7$>0_&?0'&7FU!2%H4+A22.8-!QR.1@XV"_/G/HC0XR
M%.OONG2A"$BY)-!Y?WIOC=/6;="-H;3;4S@4+UJ*[I2MM"A]5R[<0V/[FWVG
MV>07YTWZ<X78N`1B\>/$D.67D)ZA9R0]:Q6KG9(]RF]@*"64"@4"@4"@4"@4
M"@4"@4"@4%>;A2E62E)4+CXRX8V]D-1B/R106'0:*.G_`&YGJMRQD,7L+\9$
MKMH-[08V4*4XR65>:&7"?:T&@U^RR#L[!$<CCHEOVA%!N:!0*!0*!0*!0*!0
M*!0*!0*!0*"C^NO0AC<3,G<FVV4MYU+95.@(2E*9P'N@>`2\!R/NN1XT'7T&
MZWMY=EC:.Y5B/FHR0Q`ENI\+TD-BQ9<!MID(`M;W7MT%Z4%?=>1(/32?Z/<O
MAZ*6@G25%7I"-*4)5YZB>`3VT$CV%.8G[-P\QBWA/1D%(2TA@"PL1X2"I*+$
M<@:"O-EK*_6,W];DB!`2KR7T-VH)]U'O^+_<5E!%L=).I12D"S2C<E1"?ET&
MBZ&Y!,[8,==@E]IYQF2CT9$10=2$WUMH4JZK$'4;$^2@C7K7W_%:V`+DY2&!
M[9*J"X(@(B,@BQ#:;CGV"@[:"G,%T\=G=4MVRLWBU,XB4FT&2TTJ/Z0HO-O^
M*I]IS7XC3C8T*X'M%N5!:^'P^.PV-9QN.:\"''!#;>I2S=2BM1*EE2E%2E$D
MD\309E`H%!"=S0X\CJ=LQ;UU&,QE'F4`\/$#;*-1]I*S03:@4"@4%,QM@NYC
MK!N5W,XQ;.$>C*;8F-LO,B470RHDR-93J94T-)2$W/M&@M?!X3'X3'(Q\!*P
MPA3CA4XM3KBW'EEQQ:UK)4I2UJ*B309]`H%!C9+&P,ECW\?/81*A24%J1'=&
MI"T*%B"#04BS*R_0_,MPI1?R?2_)/:8DBQ<=Q3SAXH7874A5^'E[.]<$(7O3
M>>Z.M&[F]J[6;6UMZ.L*.L*0E20;&7*MR0/[FC\WD'H#IWTYP&QL&G&XM&M]
M9"YV06!XTAVW%2SV)^93R`H)70*!0*!0*!0*!0*!0*!0*!0*"O<_]U)7_P`E
MP_T&-06%01R"HGJ#F$GDG&8ZWR7YE!(Z##S/W'G?6[OZ@T&+M'\%,+P(^H(W
M`\_UE-!MJ!0*!0*!0*!0*!0*!0*!0*!0*!04=USZ%'/%[=6UFRG<:=+DV&E1
M2)0;MI6W\P^@)X6\[VZ!T+ZYG.AK:^Z'/"SS0\*',>[AE%)(+3@(&F0FW(^=
M[=!=,_'P,C$<ASX[<N(Z`'8[R0XVJQ!&I*@0;$7H.<6)%AQFHL1E$>,RD(99
M:2$(0E(L$I2+``4%0;$5?UB^H8```AP+\^)\-N@N%YEI]E;+R$N,N)*7&U@*
M2I*A8@@\""*#'Q>(Q6)BB)C(C,**%%88CH2VC4KB3I2`+F@J?UK/]U[7\J0[
M>W=5!;\?5Z.WJ%E:$W'D-J#LH%`H%`H!Y4%.,ORI'K.NQW9;CD6%A2Y%BJ62
MVVIU+87H039)5YQ\M!<=`H%`H%`H%`H%!CY#(0<=">G3GVXT..@N/R'5!"$)
M3S*E'E0>6]\;OW7UGW@SM?:;:T[?87K2I8*&RE)L9LHCB$#^Y(Y^Q?D'H'IS
MTZP>QL"G&XT%U]Q7B3Y[@'BR';<5*(Y)'N4]@H)70*!0*!0*!0*!0*!0*!0*
M!0*!05[G_NI*_P#DN'^@QJ"PJ"-P/]X>9_DO'?1YE!)*##S7W'G?6[OZ@T'1
MMB_Q:Q-S<^A1[GR^])H-G0*!0*!0*!0*!0*!0*!0*!0*!0*!0>;?6AV1$B3<
M?NK'8]QI4E:D9F>QP;#B=(CK<`XI63<:_P`VU!IL'ZS>^L?CHN.>@Q,M(:3X
M8FO%T/O6Y:TM\"JW:!QH-J/6=W\1?XM1/:^J;_E4$2PO6'=N+Z@9_=K&%:=F
M9QEAN3#4E_PV@RD)24$#4=01QO02[^L[OZWX-1;^3ZJ_.H.*/6@WXM(4C;41
M23Q"AZ401R\E!#^J76G=&\MNMX3*8B-CXWI+<D/)\<**F;D)]\X6[W&@FK7K
M/;P+3)3M=@H2E.LA4@A7E*.YP![.=`<]:[.M%(<VRPC4-2=3[H)3>UQ=L<*#
MY_6QS-B1MR.I*392DR'"!_U=!R/K6YL$`[<8!/87W;_*\.@XI];++J3J3MV.
M4GD1(<^ET`^MEEA:^WHPN;<9#@_Q=!]/K89?^CT;Y,ESZ701_:O6"(_UD?WE
MF$1<:U*QZHJD./.>$C0E`2=:&G%%2M'S/R:#T.QOZ`_$;DM2L46W6PXA9R2$
M@I4G5?BWJ'R105%E_6GR$3*RXD;!1)$>.\MEN0B6IQ#@;)&M*TM@*2;<"*#&
M;];')JY[=CJ_2R7+<OV/RT&0KUKY80E2MLH'$!1,Q5C[7O-!R_K7R^/^RZ.'
M^>GZ10?/ZV4DCAMELJ',>FGZ10??ZV$H?^V&_LX_2*#C_6SDVN-L-D?7Q^D4
M#^MG*M<[70/]-/TB@KKJIUAW-O\`]'@)C&!C;I#6(86IY4B23W%+4E*"OCYB
M--ODT'I[I;L+#[.VI$AP8ZVI<EMM_)//A/I#CZD@J#I3P[E](2.`H)A0*!0*
M!0*!0*!0*!0*!0*!0*!0*"O<_P#=25_\EP_T&-06%01N!_O#S/\`)>.^CS*"
M24&'FON//^MW?U!H.K;?X.XKZSC_`$)-!L:!0*!0*!0*!0*!0*!0*!0*!0*!
M0*#HGP(>0AO0IC*'XDA"FGV'`%(6A0L4D&@A6W^A_3G;^9BYC%8]QF="*E1U
M*DON)25)*2=*UJ!X&@GEA0-*;WL+T"PH/@2!R`^504-ZW8'Q.PXL+^F.V%O\
MW7075M]*?@#&VY>B,6_:TT&@WOTJV?O61$D9YAUQV$A;;"F75L]UP@D*T\^*
M>%!E;*Z=[7V;!D0<&PMMB4Z'WP\XIXE82$`W7>W`4$B\!G^]IO[0H/@C1P+!
MI`'DTB@&-&/-I!_L10/1X_\`>D?VHH.#D&&X"%L-G4DH5=`XI/,4$`W7&E-[
M*RFV821!S3<4M8*2%B.'PV1X/A/\`EVR=)03S_0F@\]]%^G^&WSO#*XS/KE!
MF/'=?NRXEMSQO'"%:U!*DGSC?3PO0>N\3A,=B\9$QL1H"+"91'8"P%*T-I"4
MZE'F;"@R7(41P`+8;4$G4`I"38CD>(H.!QL`ZKQF2%^?[VGC?CQX4''X'Q/[
MR8_:D?G4#X'Q7[R8_:D?G4'Q.&Q`%A"CCVFD=O'R4&NW'LK`9_!S,/*CI9CS
M4>&X['2AMU(N#="M)L>%!&-E]"=C;3S0S4-,B;D&TE,9R:XEU+-^:FTI2@!1
MY:N=!8E`H%`H%`H%`H%`H%`H%`H%`H%`H%!7VX$J&2DJ(L%;EQ&D^6S4>@L&
M@C<#_>'F?Y+QWT>9022@P\U]QY_UN[^H-!U;;_!W%?6;'T)-!L:!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*"AO6XT_%?!@BX],=^UU"@NW#)"<1!2+V3
M':'$6/!`[*#,H%`H%`H%`H.#[#+[9;>;2XV?.0L!23\@T'GKHC$CQNN^^V8R
M4M1F1*2TRV`E"09HX)`Y`6[*#T10*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!05]NU6B>QI-B[NC%I7P/$".R?S*"P:".P$*^/^978Z?@W')U=E_&F&
MU!(J#"S=_@:?;B?1GK`\/<&@Z]M_@[BOK./]"30;&@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@H?UM;?%G!$FWU:[Q_P"J"[\9?X-B7Y^"W?^T%!DT"@
M4"@4"@4"@\_]&[_CXZ@D<$WD7]D^FT'H"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@KW>!)G1+VL-UXP"WULUSH+"H-#`"?COF56.KT#'C5V6\27P
MH-]086<4$83(*5P2F,\3[0;-!U[;_!W%?6<?Z$F@V-`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%!0WK;#_9G`\?\`+7?R6%"@O#&<,;$_86_U(H,F@4"@
M4"@4"@4%`=&$C\>_4(\;A3X/R9A-!?\`0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!05YN9`<R$=*>];=F/)MV:8;2C^506'0:.`D?'/,*XW]"QXYFU
MO$E'E0;R@U^XUA&WLHL\DQ'R>%^3:NR@;=`&W\8`;@1&+$<B/#30;"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@HGULK?%G!7Y>FN?0%4%W8W[G1?V%O
M]2*#(H%`H%`H%`H%!0718@]<>H)`X:Y%N?[]-^=!?M`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%!7V7XY5-_Z61/\`TYN@L&@T6.63O3-IM8)AX^Q\
MMURC0;V@U>Z_P7S'UC)^@JH.W`)TX+&IL!:*R+#E^MIY4&?0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!045ZV`OMO!#_/7/H"J"[<<+8^*/(TC]2*#(H%
M`H%`H%`H%!Y_Z)%)ZX=0=-R-<CSN)_=RK\:#T!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!05]EONJG_Y9%_\`3FZ"P:"-8<_[>;D^M<9_K-!):#5[
MJ_!C+_64GZ$J@R<0`,3"`.H!AJRN=^X.-!ET"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4%%>M?H.W<"D\;SG.'^!-Z"[X(M"CCR-H'_)%!W4"@4"@4"@4
M"@\^=#M7X[NH)X6\25;[/50>@Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*"OLM]U4_P#RR+_Z<W06#01K#_A[N3ZUQG^LT$EH-9NG\&,O]92/H2J#
M)Q0MBX8_Z!O]0*#*H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H*&];,#X
MOX`V%Q-=X\+_`*UR';QH+SA?N-CA;WM'#R=T4'=0*!0*!0*!0*#SYT,'_P!U
M]0?+XLH6_P#,%T'H.@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K[+
M?=5/_P`LB_\`IS=!8-!&L/\`A[N3ZUQG^LT$EH-9NG\&,O\`64CZ$J@RL7]S
M(G["W^H%!DT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%`>MN?XJVRCRR
MWU7_`$K:>V@ON-^YVN`'<3P'+E0=E`H%`H%`H%`H//O0P'\=?4)0/=#LGA[)
MGK_.H/05`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!7V7X95O]%NR+
M;^;F^?RJ"P:"-8?\/=R?6N,_UF@DM!K-T_@QE_K*1]"5096+^YD3]A;_`%`H
M,F@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@\^^MN$^A;5)-@),KZ&W07
M^Q8,-@"PTBP^10<Z!0*!0*!0*!04!T)1;K!U"5<FTB1=0M;C.</YE!?]`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!7VXRH97%@<`O=;%[=H&.4>/R
MJ"P:".8@(^/&XC?O^C8ZX]BTBWYM!(Z#5[J(&U\P2;`0I))/[$J@R\7]S(G[
M"W^H%!DT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'GWUN+^@[6\GI4F_
M9_<VZ#T`W^MI]H?E4'*@4"@4"@4"@4'G[H"G_P"U>H!*C<O.W'&QO-=XT'H&
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K[<H`RV((X$[K8O_`#<L
M4%@T$>Q*`-Y[A7VEB`GEY$O'G\F@D-!J=WFVT\V;VM`E&_D]Y509V.3IQ\9-
M[Z6D"_M)%!D4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'G[UN$WQ^U_K
MF3^H;H/0"/,3[0H/M`H%`H%`H%`H*"Z!)0>J'4%P6)](6`?8,Q[A^107[0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!05_ETIE9?&A)*?#W6DDGCQ;Q
MKA(X^U06!0:'%7^-N?\`)X<+]0Y0;Z@U&\#;:6;-[?4$KB1<?K*NSMH-E%24
M164$W*4)%[6Y`=E!VT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'G[UM^
M&/VN?)*D_J&Z#T`CS$^T*#[0*!0*!0*!0*"@O5_4%=3.H!`_RA7/Z\>H+]H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H*_D6^&85B3_M6OG_);M!8%
M!'\.ZE>[]Q)'-M$%)]LMK5^;02"@T^\^.T,X/_#Y7T%5!M8X(8;!YA*?RJ#G
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!04#ZV(O#VJ.0]+?N?[%N@OU'
MFCVA0?:!0*!0*!0*!04'T`X=2^H`MP\=1_[6_07Y0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!05\]]V8?_`,K7_P"ENT%@T$9P!'QTW5_H'VN:"34&
MHWC^".<^L)7T%5!M6?UE'Z4?E4'*@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@H7UJB?!VF!Q/ICW#R_K5!?0Y"@4"@4"@4"@4"@\_P#J]JU=2=_&]SXZ
M@?LQ^@]`4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%?/?=F'_`/*U
M_P#I;M!8-!&<!^&NZ_;@?:YH)-0:C>/X(YSZPE?054&U9_64?I1^50<J!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"@_6IL?BB@#O^E/D6'82R*"_!R%!
M@Y;)^A-(#;1?F2%^%$C@VUK()XGCI2D"ZE=@H(_NUO-0]J9?*.91QN8Q$=<8
M3&`;::4$W%@0I2R#VJ/R!02J,HK8;4>)4D$GV2+T'90*!0*!0>?_`%>$I'4;
M?Y',R%?;;]!Z`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H*^?L,S"
MX\3NMSA_Y8[06#01G`?AKNOVX'VN:"34&HWC^".<^L)7T%5!M6?UE'Z4?E4'
M*@4"@4"@4"@4"@4"@4"@4"@4"@'E04-U)]8G*X7<LO"[=@L.M8Y2H\V7-2X2
MJ0GFEI"5([J.1)YGEPYAK,%ZTF60I[X>PS,A-D>C&`LLD'CK\0/*<OV6M0;<
M^M5BA_[=D?9+/YU!\_K68C^CLG[(:_.H.QOUI\(39S`2DCRI?9)_)TT'-/K3
M[;TC5@YH5;D'&"/U0H/O]:C;5ON'._MX_P`_05EUBZL8_?,C!/0<<_$^"'''
M7!(4T?$"U-FR="E?WL\Z"S$^M3MP@$8"?8]NN/\`/T$FZ;=1<7U`W#-G1H<F
M(<1&0RVU(4VI-Y*U*6M(05=ZS210;[JNZMGIKN9U'G(QT@CM]P:"EH/K1;E:
M<C(DX2&J*@H$@,K<#OABP5HU'3JMRO020>M1M[^C^0_MX_S]!R/K3[>'_<$_
M^WC_`#]`'K4;>/\`W!D/[>/\_0??ZT^V]))P60U"UDZX_'_K*#(3ZT6S"BYQ
M>1!'G#2P>/M^+05?TEZI8?:FYMRY7(PY3S>:7XC"6?#4ML>,XX4N:EI['!RH
M+2'K0[*/_=F2^2AD?XV@^_UG]F'EB\E_:,?3:#X?6?V9][,C_:L?3:#`S7K1
M8=,#5AL-)=FE2;)F%#3(1[HE3:G%7\@M08&%]:5U4ZV:P0;@^&JSD)TN.^("
M+`H=\-.DB_&]!OOZS^S?O7DO[1CZ;0/ZT&S+V^"\E?\`2,?3:#[_`%G]EZ23
MC,E<6L-#)O\`];0=R/6;V"4@KAY)*_F0RR?R?%%!Q;]9S892?$@Y-"@>09:5
MP_;10<SZS6P`H@Q,G;A908:X_P#74'W^LST__>F3_:&OIU!\_K-=/_WID_VA
MKZ=0/ZS?3_\`>>4^QVOIU!&,_P"M/X<\(P&$](@>&F[T]PL.ERYU`(;\4:0+
M<;T%I=*]\O[VVFC-OQ$PGB^]'<80LN(NTJVH*4$GB#03"@4"@4"@4"@4"@4"
M@KN>C3N/"A!OXFZ)"UB]K:<6\.WGRH+$H(W@2CXX[I`\\*@ZN?+T;A['EH))
M0:C>/X(YSZPE?054&U9_64?I1^50<J!0*!0*!0*!0*!0*!0*!0*!0*"INL_6
MB-M1EW"85Q#NY'6[N+/>;A(4.#K@Y*7\RCY)X<PK_I'T.F;F4WNC=ZG?@V0O
MTAF$[<2)BB;^+(7YR6U'C;FKV!S"[H?2CIM#2I+&VX`"S=6ME+AN/97JM09'
MXM^G_P#1S&_8K7SM`_%OT_\`Z.8W[%:^=H'XN-@?T=QWV,U\[0/Q;]/_`.CF
M-^Q6OG:#BYTSZ>N6U;;QQTD*'U,T.(]I-!UGI9TX((.VL;8@`_4S?(6MV>Q0
M=)Z0],"2?BOCKGB?J=';\B@V^W]G[7VZ7O@/%QL;Z3I\?T9L-E>B^G5;G:YH
M-E.A1)\-Z%,91(B2$*;?8=2%(6A0LI*DG@01018=(.EX%OBOCK?L"*!^*#I?
M_1?'?M"*!^*'IA_1C'?M"*#Z.D73$?\`MC'?M"/SJ`>D/3`\]L8[A_T"/SJ#
MY^*#I>>>V,=^T(H.*^CW2]0M\6,>+\24LA)X>R+&@XKZ-=+EJ*E;;A@GL2DI
M'R`"!0?/Q+]+?Z.1/E+^>H'XF.EO]'(GRE_/4'S\2_2S^C<3Y2_GJ#[^)?I;
M_1N)\I?SU`_$QTN_HY$^4OYZ@?B8Z7?T<B?*7\]0/Q,=+OZ.1/E+^>H'XF.E
MW]'(GRE_/4#\3'2[^CD3Y2_GJ!^)CI=:WQ<B6]I?SU`/1CI<?_;D3Y2_GJ#B
MKHKTM4DI.W8MCQX%P'Y85PH.H=#.E(:\/XO,Z;WOXC^K^V\35^304?ZQ?3S;
M^T)&(GX%KT1B>AUAR""5-I,9(4'`I1*]2O$LJY[!07CT3VU'P'3C$-,O+>.0
M91DGE+L+.2VTN*0D#W*>0H)U0*!0*!0*!0*!0*!05UE$J&Y,`2+`[GDE/$FX
M^#'QVT%BT&@P:$C<^Y%@=Y3L4$^P(R;?ET&_H-'ODVV7G>%[P)(MRYM*'E%!
MNFP0VD'F`!^10<J!0*!0*!0*!0*!0*!0*!0*!05)UIZT-;4:7@\(M+FXG4!3
M[RK*;A-J%PM8/`N$>:GY)[+A".B_1=_.OM[PW>VMR$XOTF%!DW+DMU1U>E2=
M7'03Q2@^=S/#F'I(``6`L!R`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%!Y\];H7@;9'E=F_0FZ"XNG7#8&VOY*A?:Z*"0T"@4"@4"@4"@
M4"@4%>Y!/B[AP!020G<LLGARTXZ0%<O9H+"H-%A/PDW'^S1?M5%!O:#0[])&
MRLY:U_0G[7XB^@^W0;X<J!0*!0*!0*!0*!0*!0*!0*`387H*BZT]:6=LL.X+
M`/)<W&XGW]_@IN"@B^M8/`N$>:CLYGLN$+Z+=%I.;?;W?O%"W8;B_2($&3<N
M2G"0KTF3JXE!/%*5>=S/"UP](A(`L!8>04"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4'GSUN@HP-LV-O?)OT-N@N/IY^`.VOY*A?:Z*"0
M4"@4"@4"@4"@4"@4$!(ON#"\3^$60/9^\)/DH)]01_`K*MS;F%O,D14CG^]&
MS^;02"@T6^_P,S7UF]RY^8:#>T"@4"@4"@4"@4"@4"@4"@4%/=;.MT;;#$C`
MX!]"]Q%($J1P4W!0H`ZE?-.E)[J>SF>RX1+HIT3E9&0QNW=[2S%*O2,?C95U
M.2%FRDRI6HDD=J4*Y\SPH/1P``L.`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%!YZ];A7U%MKCQUS3;_!MB]!<O3O\``#;7\E0OM=%!
M(*!0*!0*!0*!0*!0*"OF0!GL/;^DF3^TI-!8-!'-N&^Z-V>Q+BC_`+"R:"1T
M&CWS^!V9^M'?U)H-Y0*!0*!0*!0*!0*!0*!0=<B0Q'8<D/N):8927'75D)2E
M"1=2E$\``*"A.H7K+P58Z5`V<'!++BVCF9"`&$,@6+S`U:EDGS=0'E\E!A]$
M^B3L]YG>&[V5+:6H2,;CI-U..K5WO2I85Q-^:$*]LT'HN@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@\\^MI?T?;8]S]6\?9TMT%S=
M//P!VW_)<+[7102"@4"@4"@4"@4"@4"@KUC[O8?_`.29/[2DT%A4$:VW^%.[
MOKR+]H,4$EH-'OG\#LS]:._J30;R@4"@4"@4"@4"@4"@4"@@O7-#J^D^XTMH
M4M7HZ#I0"38/(*N`XVM>_L4'G3H/MK&;EZCQV)Z5.P\<RO(AE(!;6XTM"6TN
MW!&BZ[V[;4'L4<J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0>>/6T`T[;'Z&;^4U07/T]_`+;?\`)</[7102"@4"@4"@4"@4"@4"
M@KU@GX?PXMP^,F3X_P"A2:"PJ".;<M\9]V<"#Z9%N>P_4#'*@D=!H]\_@=F?
MK1W]2:#>4"@4"@4"@4"@4"@4"@4'5+;4Y%>;2+J6A24CV2"*"D/5\Z6[RV?G
M\I-S\)$1F1#;CLJ2\VZ5+2Z5'S";"WEH+TH%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`[:!0*!0*!0*!0*!04=ZR^T]S9Y&!5A<7)R0CB4E_P!&1K*"
ML-Z=0O?CI-!;>THCL/:V&AO-*8=C08S3C*S=2%(:2DI)\H(M0;:@4"@4"@4"
M@4"@4"@KUHI&?PPU`J5N/)FW;PAR;T%A4$>VZ`-R;J-R29D:XMP'U!'Y&@D-
M!H]\W^)^8`%R8K@`'LIM0;R@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%<
M>)_M7MY`/`Y_+WY\Q#?_`#Z"QZ#28(#X:W(?\]9^T8U!NZ#`W!BCEL+-QJ7O
M1S+:4T'].O05#GINF_M7H,00]X7XY2!;R"`[_"Z!Z'O+[ZP/L!W^%T#T/>7W
MU@?8#O\`"Z!Z'O+[ZP/L!W^%T#T/>7WU@?8#O\+H'H>\?OI`^P'?X70/1-XW
M^ZD"W'AZ`[_"Z#GZ+NVX_C*#;M'H3O\`"J#Z(VZ[F^0A6OP'H;O*_+]T^2@Y
MAC<H`!F0R>T^BNBY^R*#@\SNRWO$R!?MUQ7K?D2*#J4SO;AIF8WD+WBO\^W_
M`"B@^EG>FH6F8W1PU?4K]_9M]44')+.\.]JF8_D=%HK_`#[+_5%!]+.[O"-I
MF/\`%[/J5[3:WUQ?G0=7@[X_?F,^Q9'\(H'@[X_?F,^Q9'\(H'@[X_?F,^Q9
M'\(H'@[X_?F,^Q9'\(H/O@[UT_NO&ZO+Z,_;GY/'H.7A;R_?6.^QW_8_Z;VZ
M#XAK>8'?E8XGV([X_P`>:#L2WNT$ZGX!%^%F7APM^RGMH.+J=X@CPEXXCW6M
M#X/R+*-!PMO:ZN]C;6[G=?O?V>-!PMOORXOY4C\^@6WWY<7\J1^?0<O]M^'W
M,_1?NCEPY4'S_;J_/%V]J1^?0!\>;\3C+<>R1\B@[$G>5AJ&.)OQL7QPO[1H
M.T*W3871!OV]][YV@X+7NX>8SCSQ[77AP\OZV:#K+N]N-HV-/DO(?\O[#Y*`
M7=ZW%HV-MV^_O^Q_T-!Q\7?/[UQGV3(^D4#QM\_O7&?9,CZ10/&WS^]<9]DR
M/I%!]#V]^V)C/LF1](H.0>WG<7B8ZW;:2_['_0>W0/&WGP^I,=[/U2_](H.Q
M+V[-9U1(&B_"TEZ]N/\`T'M4',O;FX6B0N?'ZI=Y?M%!]\;<G[TA_9+OTB@X
M+?W2"-$&"H=I,MU-O^S&@XKD[L`[F/@J/8#,>3V_6Q[*#AZ7O/[V8_[/>_@E
M`]+WG][,?]GO?P2@>E[S^]F/^SWOX)0/2]Y_>S'_`&>]_!*!Z7O/[V8_[/>_
M@E`]+WG][,?]GO?P2@>E[S^]F/\`L][^"4'U,O=_NL9`'M3G3P^Q10=@E;GU
M\<=$T>7TQS5V]GHWM=M!R$K<5S_%T:W8?2U_2*#I5/W6`=.(C*/&P]-(O_V>
M@X?"6\/O)&^SS_!Z!\);P^\D;[//\'H/J<CNWW6%CCVIU_\`$"@[D3]Q$=_$
MM@^Q*!_Q8H.LY3<@`(P@)/,>EM\.7Z&@ZQF-T6)^+]B.0]+9X_D4'SX8W3_1
MX_9C/YU!')4><SN79JIS*8\A_*Y1\L)6'-"7(DA205``$Z;7M06#0:7!?=K<
M?UZS]HQJ#=4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@BNYP#O+9MTZ
MK29I!\GU"Z+\Q[5!*J"/[:<\3,[HY]S)-HX^Q`B\O8XT$@H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%!&-Q@'>.T2>Q^:1[?H:Q^;02>@CFU3?,[K]C
M*('_`/KXM!(Z!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!?C:@4
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MP3:M242"?(J7+4/E*=(H/AV9@#:Z)/`6X39@_*=H/GQ*P'S,K[-F?3J!\2L!
M\S*^S9GTZ@?$K`?,ROLV9].H'Q*P'S,K[-F?3J#FWM#"-DE`E"_/ZMF'F+=K
MM!V_%K%W!U2KI%@?3)?DM_?:`O;>.6FQ<ECV4S98/RP[0=/Q1Q?[XR'\XSOI
MU`^*.+_?&0_G&=].H'Q1Q?[XR'\XSOIU`^*.+_?&0_G&=].H'Q1Q?[XR'\XS
MOIU`^*.+_?&0_G&=].H'Q1Q?[XR'\XSOIU`^*.+_`'QD/YQG?3J!\4<7^^,A
M_.,[Z=0/BCB_WQD/YQG?3J!\4<7^^,A_.,[Z=0/BCB_WQD/YQG?3J#G\6(01
MH3*GI'.XG2B?EJ<-!UKVG%60?A#))L`.[.D"]NWSZ#C\48OWQR?V=(^>H'Q1
MB_?')_9TCYZ@?%&+]\<G]G2/GJ!\48OWQR?V=(^>H/IVE&/_`'CD^5N$Z0/^
M=0?1M2.%ZQD<E?R&:^1\HJM0<F]KL-JU)R&1)X^=+>4./L*)H.SXOHL`,A.X
M?YPL_ET'$[<!!'PGD!>W$2#PM\B@ZE[6*E%0S.32#[E,@6'RT&@X_%17WZRG
MV0GYR@?%17WZRGV0GYR@?%17WZRGV0GYR@?%17WZRGV0GYR@?%17WZRGV0GY
MR@?%17WZRGV0GYR@^C:J@;_#64/MR$G_`)E!];VLM"@H9G)FW8I])'RBB@[O
M@%^]QEYX''AK9M<]O%KLH.*]ORE`6S>01;M"H_'A[+)H.'Q;F<?X_P`EQY<8
MO#VOJ>@^?%J;_2#)_+B?P>@?%J;_`$@R?RXG\'H'Q:F_T@R?RXG\'H'Q:F_T
M@R?RXG\'H'Q:F_T@R?RXG\'H'Q:F_P!(,G\N)_!Z!\6IO](,G\N)_!Z!\6IO
M](,G\N)_!Z#E\7)NG3\/Y+G>]XM_M>@[DX6:E.GX:G'GQ(BD\?\``4'P8;)!
M5SG)I%[VT0^7D_<]!P^!,KWO]H)W'S?>X7#_`+/0<?@',?TCG?M4#^#4#X!S
M'](YW[5`_@U`^`<Q_2.=^U0/X-0??@/+VM\89OM^%!O]KT'T8?-C5_'T@W\V
M[$7AS\C7&@X*PNX#YNX7Q_H\4_XN@X_`FX_Z1O\`V-%^ET#X$W'_`$C?^QHO
HTN@X,[7F*S$#)Y#+OS58XNJCLJ:8:1J>;+:BHMH2HV23;C02"@__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>57
<FILENAME>g5754314.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754314.jpg
M_]C_X0`817AI9@``24DJ``@``````````````/_L`!%$=6-K>0`!``0```!D
M``#_X0,9:'1T<#HO+VYS+F%D;V)E+F-O;2]X87`O,2XP+P`\/WAP86-K970@
M8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(>G)E4WI.5&-Z:V,Y9"(_/B`\
M>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!
M9&]B92!835`@0V]R92`U+C,M8S`Q,2`V-BXQ-#4V-C$L(#(P,3(O,#(O,#8M
M,30Z-38Z,C<@("`@("`@("(^(#QR9&8Z4D1&('AM;&YS.G)D9CTB:'1T<#HO
M+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^(#QR9&8Z
M1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B('AM;&YS.GAM<$U-/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=%)E9CTB:'1T<#HO
M+VYS+F%D;V)E+F-O;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E4F5F(R(@>&UL
M;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O(B!X;7!-33I$
M;V-U;65N=$E$/2)X;7`N9&ED.D(V.#9!-SDT1D$V0S$Q13)".3,U.$9#,$-$
M-C-#-31&(B!X;7!-33I);G-T86YC94E$/2)X;7`N:6ED.D(V.#9!-SDS1D$V
M0S$Q13)".3,U.$9#,$-$-C-#-31&(B!X;7`Z0W)E871O<E1O;VP](D%D;V)E
M(%!H;W1O<VAO<"!#4S8@5VEN9&]W<R(^(#QX;7!-33I$97)I=F5D1G)O;2!S
M=%)E9CII;G-T86YC94E$/2)"13,V,S4U0C(Q,3=%0T1"1C=!,4$T-S5#1C9$
M,C<W,2(@<W12968Z9&]C=6UE;G1)1#TB0D4S-C,U-4(R,3$W14-$0D8W03%!
M-#<U0T8V1#(W-S$B+SX@/"]R9&8Z1&5S8W)I<'1I;VX^(#PO<F1F.E)$1CX@
M/"]X.GAM<&UE=&$^(#P_>'!A8VME="!E;F0](G(B/S[_[@`.061O8F4`9,``
M```!_]L`A``!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`@("`@("`@("`@(#`P,#`P,#`P,#`0$!`0$!`0(!`0("`@$"`@,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P/_P``1"`#H`30#`1$``A$!`Q$!_\0`W@`!``$$`@,!``````````````@&
M!PD*!`4!`@,+`0$``0,%`0``````````````"0<("@$"!`4&`Q````<``@$"
M`P,&!PD*#04``0(#!`4&!P`($1()(1,4,14*05$B%K9X87$C%W<X.8$R<K*U
M-K<8.I%",R1TM"5V*!GPH;'!T5)#-"8W1U>X8K.7UQH1``$#`@,$!`<+"@0%
M!`,```$``@,1!"$%!C%!$@=187$(L2(R<K(3LX&1H<%",Q1T%74W\%)B(W,D
MM#4V.-'"-!;A\8(E%Y)#5&639`G_V@`,`P$``A$#$0`_`-T[NK):Y6^M&HWG
M#95W':5F\6PTV&8M&S)Y^M49GLLQMMMHB[9\W<)J)7FI1+Z+`Q`*N11T0R9B
MG*4>$469CMQ:;?JT[H6/6&H/,$R;K?E]MF4+W?(;,L]LNC]E9:-L5.>6F_R,
M+/NXMGF^2Q`20M&B*BSM:P()`F*ADAX1=+7/<EL]^JV7I9MAL-?].TKL;KO6
M%.%A-BCRY@RM>24B;OLC>V.D*5074WGDI!Q!#E42BRR"0K"D#=0Y!`2*JX[M
M1::I%=D)1M^K:\I3.U;W+GYNP^^0>?YS55OYIJ!:CQ='G6.?NI9:O?>$N+=C
M$?2/7ZCE1=THX*B/RDR*PL1W6W#:=BZG:1U\S5S;6.N=0>R%LE,6G]?8U2B1
MMJS[9LLJB]CE;8V@IUK8E6+EK(1L([;1PG73DRJJ?3H&5,0B^1_<=AVMD/VP
M=DO;;%#>W+#[*?'%Y1LFJTTR1[%+YW]TK%,K]PHV5*?5+"*28_R)4"?-\?*`
M2\(IP]2>W:W8ZP:C3)BKUB(L>8MJ1*N)W-[VXT_,[#%7MI,JM&T1<EZM43A9
MJX^@'+658G:^4A^2LF<Z2Y?!%-WA$X1.$3A$X1.$3A$X1.$4;.W@:ZEUNUV5
MP6;=06PU>I.KI1%&K1F^-,R]*<-K4-06:OVSINJUNS*)5B%/T04*1Z)B&*<H
M&`BAR][C6S2M"K6AXO,5I3%L\ZF5#<KW'W"ZP>=TJ=NG9"5BD,K@[SH,M%3(
MUEI0*37YJ8<I-TA757<MT1(8QR%`BXD1[DT[9\Z@):E8Q!7_`$V;[>N>G*%?
MINP1S[-7MP-F\OI<;H$-I3BLMU'M!/",D3.P&,3D&OK6*5)4Z12JD56M.SMT
MJ4SVL>.T*\C9,[U#%JC-Q6U;U!TO%J._N.(5&V2R5'M1<^^^D8)O*2/R@9':
M/I&6D%3+I_3IF%%,BC^EW:V;;]$Z-7O!:(:8=Z-!]WZI;L@6UYM"Y@_M.-3-
M&JP6J6OC:NR)++5(F49N%89TWB%'BR<F7PBD`K&(1>!]PMN]M>;]GIUO>:9D
MD'T=[<:3J&,EF4)11GHV(;1GF?S408&ID(:<G8>>9R4;'2(@DFH@Y^9_)D4,
M`$4O>H_=1QV0NUPSZ<IM8@9ZMT:FZ.TF,XT!74Z,O!W%U*1PU:6M(5>JHQ6C
MU5]&`60CP27150<)KMUCI^KP13[X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
MA$X16@V?<<:P:K(6C;]`J><U.7F&M59RMR?I1\7*3<HV=N&L$W%4IP>/7S-D
MN8J!2F,<B9_AX`>$4&,:Z0=1;+U=:T3KUHUAG<RG]G8=@J=K-0O,'=)N%T.G
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M+4X,]"!LB%+2ZV1G5IO"(69XD=K0(BW%O\=/(2GRAE2Z&UN1"2(2_P`\5/K"
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MWX`L)UP!)4J1BD7%#VY<RC8?+FM,U;?:%:<=L&XVBE:37KO%GNI)GL1/-K'I
M:UA5F*M(P=F:R#]J()-WC$[9(IP,!?F)IF(15%'^WAUOC:?7J&>(L\E3X'!=
M2Z[.(>9LKEZ:QTS:++%7+1)JRR9DB2CV\3UJB"OQDTU43).EU#D('Z/H(N)U
M'O>%_K39LJS_`+J6#LU:ZE`1S#]4[?;Z/-2E4JU:=N8--Y%IU*GU,UD^2^'Z
M.0F5CR*ZJR2::ZX*>?613\X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X18
MR_<BAKG//NBS'/I5*`M)>].;KL+*\JR]SBZX*>::V!Y:6K[>1AOK(],J@)F]
M;QJ0IE"C\P!\>2+&$2:TS,:IFN66::4SR(>]V^VK;O5<W5MT##\TLVRR<*UN
MF42[>\9;"*6;,<@U>,F&\M%-FJJ307J"3%X^55*H9<BZS<]0UF.@,=R6U]A[
M%?\`Z_JAJ-DKVWT78-GS6GTBQO\`:)6N4;:KI::54W=NTYMFE":(LGJDXT9-
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MO4Z.0AX>71H^5S$;?5Z^T9,FC%Z:!GW`IR*B0&,5TH/S!$YO(D68CA$X1.$3
MA$X1.$3A$X1.$6-7W/(FU369];65*>?=5G'O-U35BIY2MKVYE77"6@`)9V4K
MZ#IA]X1<:(^M<AW+=,2>0,J0!\\(L8$[)ZWDWWSGEOGC4][8?<*TEYWDT]*;
MOV'YK=6MFQ1O/]>+,RM&81LK:LCR71H^.AF;TS1TJ;[^CUFSZ3'Z@YSD3:=3
MU2OTKKGF,WN%DV&)LN4=M;'7[QF.P[11H.+<,=&KL#D%VM6I5*HR.BZ.SQ."
ME%V2Z\HP;LI--$7GJ>+B!#$5SKWHVRTVJZQ'T;9]&N6:06)^UNTL6ST26L=H
M<)95<[WI4;V5VG.9Q?[YEE9>:J34CM])MQ<OV3(2K^`40(8I%QY*UWB5<ZO2
M.O6W;I+]6I#MYT5H>:Z?#WFXVF;8#?9)XS[+U'/M6M`S<_-T9BQ-%JN72CMX
MVC)!ZZ324**8E3(LD/2!*S59_P!M\JF+1?;/3LB[+2=;S!_ID]/6ZPQ]&E\O
MSBZJPY;C9U74Y8H6,L=AD0;*N%W!T2"*'S3`F``11@ZW[YAG;?O1'ZA7;76J
MM&X71M8PSKIEWW>XA-#OWWS,P,AL.KST&>,9FKE$3+2&C*M1JY@7<HD<R*I$
M@6;D$BS0\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(H^=@NR^.]:(*`FM
M4F9=%]<I_P#5>A4^G4^UZ-HU_LP,5Y-6$HN?4:'G[;9GS6,9J.'(M6ATFB!!
M47.F3](2*,!_<8HRY%4C=0_<$=-G`>DX'Z7:HHBZ3^`E]::[`#&(("`@4Y0,
M'V"`#\.$4:=<USK=N-R5N]LZG^Z-6;#*4;^;*URM!P+LAFS>[YNV=RLLA1;T
MA3'L<2Q5XCV:?`BFJGZR?7+$!0I%#<(J^C^P':X)"HZ'B'3G4ZETSQBOQ^?S
M.`6VHTVF=D=@B'[-*.;W?(:%-V5-W6:]A$=#M$FT)+O(M_;$)1Z5)%,[%H+D
MBN__`-XI36I$4B]1O<$+\DGRQ:H=,]2\,!3$R7TIODLOI?)`+\!1,=,2^/!A
MX1>2>X_4"_`G4;W"P$P_DZ9:J'D1'_D?"*]&!]O</[!66PT*JH7RCZE5(=K8
MY[*=DRJ\XSI+:L/GHQ[:UQ]:OL#"+V*J*RA!;FDHL[UDDY\)J*E.<@&(I9<(
MG"+BO7*+)JX=N5B-VS5%1RZ<*#Z2(-T""JNL<W@0`J2)!,(_D`.$6-[)NZ,X
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MF`S$0JJ#N)4<(D6#UG\%(I><(G"*C-`OM)RZEVC1='LL/3Z-28.1LUJM$^Z(
MRB8*#B4#.7TB^<G^!$D$B_```3G,(%(!C"`"10-3]RC*YAJ#NM];.]U[K;](
M#L;)!]*=O3@IQBJ'K2<L4K+6H*3<QSE)3UI*J-2IK)F`Q!,4?/"*.^O;EU^V
M:UPM\GNI_NFU:ZP]2D,]+9LMZ_=B<QFI//9>1;3$C1IYW37T2$M6%Y5H1<$%
M@$45@$R1B"/GA%6:NY[;=*%5^OGM\=8->P8U.BXAHPU/LQC3G)\;SVCT5LD^
M;42(@KR[-=+O8[^6.1KR1FD6LG%MY%>37<@JU(FJ174C?<&3B8UJROG2+OC2
M;@Q120G:A`];)_2H.-E0$R<DE7KSF[J=I5JA$7J1Q;/VS@@N4!(J*21C"F4B
MYG_>/T_X_P#9&]PK](?4/_8RU7XC\/B/_$_B/PX1=[2?<,P6P7JI46X4GL+@
M-DT"<;U:B.>PG7+3\DK-OM,B!_NRJQ=]G:Z-+3L\P8ABL8]U(MG;U0/EH)J'
M,4IB*?O")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"*@GV:T^3TB`U>0B@>
M7>JU*Q4JMRKA990D)`VV2@I2R)QK0QQ:M7TRYK+$JSDI07,@@"7J`@F*8BKP
M`\!X#S_=$1^W^/A$$/("'Y_[G"*W&JZEF^'9[<=9UR[5W.,UH,"\LMSNEJDD
M(F`K\*P+ZW3^0?.#>DOD?21-,OJ575,5-,IU#%*.TAY>UK,7EVSJ6AJ0=WZ7
MQ8X+5-U+\9#[?]1N\K7<HP?M+N].@W1D'VEURNU.KP;M,BABJ/8:)M<^UGU6
M)RE]:1GR$>8Y1`1*7FV8N@G,<KX&QUWO\;W!3''?4K[16MP]O%$))@-I#</@
M`^)9L/;<]X/I)[I5;FW_`%IT)\G>JFU;OKKC.@QJ55U2JLG!B(EEE(,KM\RG
MZV+HX(A)1CEXU35$I%C)*&*0=_`6_G%AV$@`'LH/?Z%\SMH00X;0LA<YFE.L
M%ZH^DR,212[YTTM4?5)U-99%TRB[JR9,K+#K_*.0KZ(E0BVBQVZOJ2!TS06`
M`43*8-5HJ_X1.$7166)3L%?G(!4QRHS<1)P[@Z?J!1-"38N&2JJ?@2CZR%6\
MA\?R?#X\(HHU;I[1PJF#P.BSEHO)\*HM!K;.O%GYN,S&8L=`K2U;B+RYS\7:
M[)*P-V[M<R1P5_\`:%%4%3))&*16]H_4SI]GBM:CXAW:+.^7M&:Y3`N):]W3
M0#1KWK=-3.A9YE:RZ2\C'UJM9U(PRIQ8.`:-#*,T4G)E%_E@8BO9+]1<'GF#
MF*FZH]E&4DKNZ\@U>SLR(23KLB*W\[3QV8CM)11Y,MUU$6RP""D<B<2MQ3*/
M"*ZF6YI'956B5>/LMZMB23HRQ9:_V=];9LA!;MFR#).0<I(IMF#1LW(5-)-,
MA?/J.?U*'.<Q%<WA$X14!HN:U#58)G5[S$DGJZULM3M9X==95-B^EJ398NW5
MT)-!,0))1[:?AFRZC58#(+BB!5"F+Y`2*U_9[MCU[Z9Y!8-Y[+:I6LGRZMBB
M@]L5B<*>M_*.O6$?7Z]#M$G,Q8[')F(8&S!B@NY5](F`GH*8Q=C&OXO4N-)/
MSL`/\,$)#30BJUK7'XR?VQT;N,&CFO;![1R2`,3Z8CG5.2B/2)A*+PM<<W]&
MRBW```X)BD5P)!_X/U?H\VF&\'ZMCH7G\^CA3H_5D\3NLBB^QC'J_6T?P=F%
M>CBV+8\ZE=Q^M7>;)(K<NKVKUS6,]DE/HW#^%4<-I6NS*::2SFNVZNR"32;J
MM@:%4`5&CU!)02F`Y/6F8IS?7A<WQ7T+Q@<",=^!Q'8<0OC4'9L4HP`/`>//
MC\GQ'_T\(O;A%0>CYK3=9ITS0[Y$$FZS._=QWS$ZZ[<Y7</*L9R&D63INHFX
M82</-1K=VU<HF(LW<($4(8#%`0(JZ*'@/'\)A_C\F$?/VC^?A%[<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PBTC_`,5[HNB;9V(]MOVQH.R/JKF/
M8:Y?SB:@JQ<J-_UA.VMS*FUAL]3`02>(5EH$L];H*^I(7RJ"ABB9(@E\?S!U
M.-%:%S?5[6>LDRW+KBX#:5XC%&7M&&-*C&FY=]I?*!G^H;+)7'A;<7#6D]1(
MKV8`^^.A2;R#`L<P//8C+,DSZLU&EP\<A&$CV40P.ZETVZ0(*/K,_60.[GI1
M^(&.Y6=G5.HH<?(@'@`QS-7\S^87,#/IM1Y[F]\Z_E<V5Q9*^-K.,<361-::
M1L:*#A&%5*1E.D]/::MH\JL;&TX88FM)=&UQ=45)).T]96#_`-PCK=?N@NW9
MQ[M7M]PS6AWK%+$A+;?0:LT5CZM9*R\4^EEIQ[6HPJ+8]8LD>NK&V=HD0J7R
M'!'A2IJ)'4"2CN2=Z6[U#F?_`(AYCW[I+MS`[+;J8XNX1PNM'O/EODP?$XX@
M-<W&K0+5^?\`RF@AM_\`=VEX#&X%QN6MQ;B1PN:RGBT%:@;1V+>\]OGO-D/N
M*]5\R[38U(D/`7B*(A9*PNLBK-9W?XQ-)&X4"QE1./RY2O2:GI(<0*5TT.BY
M3\IK$'DF[2YSB=C:TX3M!'7OKM5H500"`0=A'6IL\^BT3A%CP[Q4'7K[,Y(V
MIV5S6T9U%1FQ/[5G43>HR@L9?4U*K&,\/D+O*/YVO.CT2&DUI59<[0[M=H_,
MT<`V5,DF)2*,M2Z4[FV=Y:ZMBEHEYO-K%TAIT'/N-/F7!8*G9-!):%V&TAL@
M,^)9.Q:#?)J2KKD[TCI^[9E+\!;G$1(K'?ZKNNX]C$QIE4STO7[4*MD_<R>O
MENDM,C(QG,ZQKFCQ:%/,QE27.3A`AVE)G)E6#DY`K863MNR,X%`X"8"+H*KD
M.F:O6[A9<*HVAP'72<['HP<AFL'9Z_ITI9:'F&(,(&NS)V]LU.NT6SUJR;38
M95_82QL^X;*23)!50)`J;CUD4JG'2O4!M=852<:+-1>9VCI?0\IL5FU!RK,U
MO.\ODSZ)N.E.F<7.H1+FWV![+NJNH!T%E5&B`)(D%H?U&(LQ8>DGG_>^HWP`
M1_\`6$```#\GD?R<(OIPBI^TVFMTBMS]QN$Y&UFJ5:%E+'9+%-/48^'@H&$9
M+2<O+RC]R<C=G'QS!NHLLJ<P%(F01$?`<(OSC=TUVV?B-/<;E+9)*6&*]L/I
MY*O(+/H#YCR(2TF367,!I=VD04C$M^H'9`[<G^*\/6TD6Q1(NL8REJW>P[PT
M/(C0C;'*?5R\P<P)99L-'\(V&ZD;7&)@I08!SND`JM')7EM<Z_S]T]TP_8EF
M.*<[.,5V,=N--M-BS?-L!PAG2"9FVQ;*DL\+&?<WZE_J%63UXT9\KY0M5&"D
M<<J@BG\/FF$5A$1'U^KX\@\/,GF&_4HUE<9WF4FJ0\O%P;B7B:XFOB`.#6M!
M\D4-!0*05FD-)C+?LMF76GT(MI0QM+J=;NGI/2L2/MS@\]J?\09G'7'%Y&2C
M^KO?NFK,I3,CR+AY%5Z9=1ENDJPNV;NE53'=4Z[551)BZ4\K$B959N)C?'DY
MO=/YQYKSEY/?;F?GCU+EUVZPN)N&@FE;'&^.;AV5+7@2$>4\.=A6@CQYUZ&L
M]#:X?EV6U&731^N:VM>$.J2T'<`2*#<,%^A^F/J3(/YRA^3Q^3\WY.7/T(P.
MU4@J#B-B]^$3A%8FR]C,JI>KUC&[O.OJ1;KVZ;QN>N;77YN%I^ASKA@O(?JM
M3+ZZ9%ITS<4F[8X_<X/22:H$,**"@%$P$5]0$!^SA%YX1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$7@1``\C\`#XB(_DX115[5=W.J72*E(Z'VKWC/,3JKU51O
M#JV^8]$U8W*)`45:56KQR;^SVATB0P"=-@S<"F`@)_2`\TJZM`TTZ=RVFE:<
M0KT;U`[K]^((]HKLO>F&:YIW-H+6YR\BE%047H\%=LF0L+YPH*35K"S&C5VM
MP3QV]5\%10^J*NH80*!/4(`/T$;SL'$[H&WXUIQGCX2#PTVK&K^*5Z#ZUM..
M8G[A'6)NZD-YZ`2LC=Y6(BD5GDG.Y"M(1-EDY>)9MQ.:2=YY-P:<DLU*41<1
M+A\(>H2%*;ILWL,OS_*[K(,UC,F6W,$D,S*@$LF86$UH<-N[I[5SK*_GRN[B
MS"V/#<02->T]!!&W9T>X*JQ71;N-1>\?7RK[34S-X^<.5."TFH%<E5=TR_,F
MB*LQ%G*)OF&BWYU/JXY8P!\YFJ7_`'Y3@&._S]Y0YYR(U_<:3S5CY<HDK)97
M('BRP%Q#.(BHXV>0X`@5&&%%)[RWUC;<P-+0YQ`]OTZ(!EPS80\"OBBM:4Z:
MJ6\G%Q<[&24'-Q[.6A9I@]B9>*D&Z;J/DXR1;G9R$>]:JE,1PS>M53IJ$,`@
M8AA#E(,ON[C*;^#.H'NBO;&1LS',):62M(=&]I&(<*'>O;SVL-Y"ZUG`=EUT
MTLH<<-AZJXX8+`9U`W^Q?AUO<I-3[0]F77MB=V9Q`KQXY.Z=Q^46,')6S"R@
M/I.1*9S%:0*VDP]/S9.KK$5\*+-2`3(![K_/;+^>?+JWNY)8FZRL6-9>L%1Q
M5J&3!FT>LX34U(#L*#:8V><G+>[Y<:AD:UCSDL[RZ$FA.XN;4`#`'`85"_1D
MBI6/G8V/F(>08RT1+,&<I%2D:Y1>1\E&R"";MA(,'C=11N[9/&BQ5$E4S&(<
MA@,41`0'ERAZ1L^-4EK6CF^00K%]GMPD^ON6.M%BJ6O=3MI^!AY`3N91C6Z;
M$S#P6\E?[_*P4#:YN$H53;%,O)O&L8^4;I>#F3*D"BB9:J+EJ[^R]1LYDY')
MXE;,JYI&2Y1?=/C-*9R;$MLU#-X[1WRF<0[:N">]0>?0\FDZE72KB-$T<87"
M"9Q353(14W1_<8MM[B6$M'=;[.S;Z;-9U6>OR\U*V"MQ]UM&DGL<BRK=SD;/
M0(5&NR59HE8<V684A`LK)K&E^21=1UZ4CD5)]C^P_8>0<V/,<^CF=6UA[,=9
ML+GH9K?8]:C5^W[K9;78[3,U&R+9=(V5U983**P0Y7;EF#1HUE"./HS+M#E5
M(JOZT=H-+N81F=T[/U+I.Q:L];+\]O.KQZ<!F^81.FVG&*G'U.U1>:1TA?I2
MR.,OFI=D1_&QXBU2.=R[`RR)0(J'A.\.W)KN[M6\_9W[&83KGIW:RVEL5L;1
M^DI5B4TRUQ.5UZJMH*D)0'W-^IU'D'3,CI0SMRT.4SAS\U$?GD5\[3V;?:%;
M,5-F"SYG5'_<F.R%C8(^01=1FQ52$QR\V33G[1JBW,(52IV-HJS^?\PQ5)*&
M,8#`42@8BR'&'P`_$`'P(AY_@#\WY>$QW;5I!_B-O<1TKM9M-9]D'I%,_66F
MZR4:KW&O,*Z.,=7()+Z68#+9.19G,#6(A(X"R]K_`$O)@*UCOB<[E(WD->:Y
MT[RTT=>:UU5,V/*[*,O=B`9"*TA8,:R.-`!UKO\`2NFLSU=GD.2Y4PN>\T>?
MS145=V`?#[JD-U<ZU9SU'P^D81F#,J<#46/_`$E,*I(IREOL[P"*V"VS9T@`
M5Y*9>$$WQ$2HH%32+X*0`#'5YM\TL^YO<P9M99U,YUP\\,3`:1P0U\6*-IK1
MM/*QJXU.TJ4'1>E\KT5I^/3V6`MMVXN>:>LD)V\;@`#CNH%=J[7.I9Q3K/H-
M[FV=:IE,@I*R6:?DE2HLHJ%BFRCEX\7.<Q?(@5/TD('Z2JABD*`F,4!\AD&1
MYKJG4%KIK(;>2ZSF\E#(8V#&1SSP@-Z!%Y4A/R0=FU>BS6_M\DRZYS"_>QEO
M:1\;R<*MI7Q>NG:L4WL7X]I/NI>Z_;_=IN=9D*GU?ZK-Y7->O;:6;JIJ6BYJ
M04M`P3!D90/E.7%6@K.]G)I9/R1O)R+1N03"!_3D1\A.4UAR4Y7V>@XSQYBZ
M(R7,N!]9=3`&9[30#A:06185:QHJ25%[S+UU)KK5LN=D_J<61BAPC!(94=);
M0G'=L"W"^T_N7=$>D;UA#]I^TF1XY89-`KEC4K!/FD+LX:'(4Z3_`/4NNH3%
MH1CUBJ`)%U&A$3_'TF'E8X0[R'BA&`-10@;U3]W"#1CA@NVZL^XITB[LF?H]
M5>T&1;5)1*'U4M6ZK9427&-:?`!?/:7,%C+6V8%$0`5S,_D@(@`F\B'G<YDG
M#7"OOA&N:0:UXO>\*FH4?(>?A]H_9]GV\V,=Q-J46/'W7H%A*>WEVNEUDBA,
M43+G^JU"3*4OUM?ON3.V>A46QQ3@!(JQE(.SUYLNBNF8JB8E'P/@1`=Z*?-?
M=K2$%"OW`%^H?Q,<]<>DH%**[IFBNJ)2A\"E%0X_#A%VWD/SAY#[0\_9PB"(
M!Y\B`>/M\C]G\?YN$3U%\>?47QY\>?(>//YO/Y^$7R4611]'S54TA54!)/YA
MRD^8J8#&*F3R(>M0Q2B(%#XB`<(AW")!3*=9$AEC"5$#J%**I@*8XE3*)@$Y
M@(01\!^0!'A%]0$!^P0'^(?/"+SPB]?63P`^HO@W]Z/D/!OXOS\(O/D/SA_N
MAPB>HO\`ZP?[H?\`A^7A$\AY\>0\_F\_'_<X1/47X?$/CX\?$/CY^SQ^?SPB
M\\(G"+H[+/1M4KD_:)E86\/6X64GY9<"B<48R&9+R+]4"!_?"1JV./C\O"+\
M\;VZ^LS/W_\`MCV<]S?OZM-Z%BM1U%WF/7_`E)N6CJ>SBV"19J(KSH&3AN[1
MIM*JT@P^H:LU&YIB8=KN'1A_2*>C/-G7][I2"#+LL<&W<VUQVM!P'#T'"I/9
M1>YT?IN'-#)>W48=`S9^E3I[-RS+=NOP_P![;_97(;!2*)@%`ZX:4G#.$\\U
M?(X=2LNJ]/MVQPBE+1!Q[@D3<(!9P!2O4G21G1DA$R2R:H`;E&M.<T]6Y5FC
M9;ZY=<6CW@.;(:@#J(Q!ZU[K,-(99?6W[O&(FAE06@5KOVA69_#Z^Y1K6?Z7
M=?9(]R)^LS[)8>O+U[`+5=W@R!=7SV*:*K&S16;E!,6SJQ]8,60K#D_S!EJZ
M<R`B)VA2GNZL;VUSVUAS:PE)B<WQJ<)XQ0^(["HX2:[:@X[U1F\M9,MN7VMR
M#Q;.T;O?HL8WN"]:;'^'T]QQCV6R&$E'7MH]S[$YC+E4HDCAS'Y';G#E26F*
MB@W$#(LGE95<KS%5$P@9S$"ZC@-Y;F.-$.\=R,L>>G+NYTRS@BU3`QTMC,>&
MHE;5WJ22/(DH`144-#6NVHW*/F%<\O=3Q71<'93-XDK'$\/"<.,`$>,WP+.;
M6['`W"NP5MJTNPL-8L\/'S]=G8M<KF.EX66:)O8Z19+$$2G;NVRQ3E'SY#SX
M$`$!YCWYQE>9Y->39'G<1M\WM)G03Q.!#FR1'A-0=SMK>D*2ZUGM<URR*>PD
M#LOD`?$\>5CB1T4K2BCKW(ZH9_W2P"YX7?R(MBS3<9"GVGZ<B[ZCWA@DL:OV
M>/\`AZ_2V<'^4[1*8`<LE54A\^H.5(Y-\X<ZY):ZMM99&USK1E&W-JVO!<V_
M_N,I6IE`)=%CPAP-=R\MS#T99Z]R"7++X%UP(R8WX<37`8$5&_"JIS\-9[EN
M@9[9;7[+O=N14B-]P%:79]:I^P//6%[SJ$2^N<9BQDE_`RJ]:AA^]*TH`F,]
MKZAD2>/HB%-D1Z/U7D>NM*V&L]-S-GR/,[9L\3@=@<!Q1O&ULD;JM>T_*!47
M>=Y/>Z?S6?)\P8YEU`\M((H"-Q':MNS4,:SC:HAC":57U;%%,'*SQ!DG.V*!
M*8SMDO'OFCY2MRT0M)14C'N3H.F3DRK-RD82JI'#X<]*NK5B<VZ/831+I<]#
MD*NQN%XMUZO5Q&7FD7A8B':7"/-5V<!$4T)%:FM"5G.2(5MN^39$?'BDA1$Y
M4SG()%51>FW7$M&0S8<^64IS&QP5MAXU:[:$X>5NP5ADM&5U_4Y]>V*6&HA#
M1CE5JV1C'31NDU541`GRSF*)%PU>JE.1U7.[U!KH5JKT":/>!H\5#D4/:]+9
M9LMCU6MMFM;^0=R2[*G9J[48,8Y-%,@K^EPHJ8Q?28B[QIU)Z[Q\Y5+)'9G%
MQ4S2*PE3*ZZB9.QQ22%8:O9>48Q$DPCYEM'6%M&2<\]<M!D4G9VCATJHB9,Y
MQ'A%3UXZD9A+UF9AZ''(9=8Y7%$>NS"WU]JZ?*0>0IBLW+56M;=22=:D58Z)
M?/$8QT^;N%H\[HYRF,`G34(NTI?5[/*#9L<D*H@:'IO7K,)+,\?SEHV13K]2
M/.%CV,[;A="(OI.ROZY$I1Q551'Y2*[LX^I1VJ;FAK3#:BQA>_3[MT)[6O5)
M=Q1W4?-=L]V2E:-URI?Z+YTPDU44VTSJ<M$I_,6<P%%*^1,@D8OH?RRS9L'D
MIEA(!8UOK9GM9;MQ>XF@`&+C4X8`';AX"C#I)!;Q@FX<?%`%:U-!AUE:]'M+
M]$9WK)G$[N^Z*O[%VT[('/<]/L-C6-(V*L1D^]/825%S(K^MP>>E'[D9">5$
MPF6>G*EY$K<HC!QWU>\)'S9UC)HG2LX.B,I>2P-)I=SC`S2G?38P-H*5.]2'
M\BN5YT1I_P"V\U81GU[M!`\0;@W"O;4[5EY`@F\`4!'XE`"AY$P^1\``?#X^
M1Y96YL,4!ED<S'R.'%Q/8J\RPRW5+>'A;=-\NN#1\:UXNX5@U_W<>[="]HGJ
M',KH4&(L2=@[8:S'`HM7H*+JSILM8E)-TW/\EW7L^(8I"-O4`2EE5;M0_P""
M`>3$]QON[RZ(R9O.'5\+AG^:,KE43FBMK$]M))7`@N#YQ4'R0(]E>)6.=XCF
M@S.;IFB\CFXLOM2?72`D/E<*U8^GBEH/0.BJV/\`W+.ZO7_\//[;>8]>NKU?
MAR[)+597*^IV8*)DDY=]/E1(2V;=>F#<OU<R2-F949%ZJH4/OB==HM2_H'4^
M7(@0]T9F):86FA)W;?)-=@IA6N&T]-KH'K74B:`YQP`KOZ%BK]MSV!\[N]-/
MVX]UR$LO9;MUV"76T2U5'3K18%XBA(V,H/V#.W(1<E&O+#H#EHH51ZFLN+&)
M`4V2"("D<1MFY@\WLQ^G/RS34O!#&_@XQBXTP)!W#HIVJJFF='6)MA=YM&2\
MMXJ'9[WA5K/=J]F;,^F&6O?<E]L%>S=6=RZI/8W3)VLTJSSR]=EJC'R#-M,3
ME<3F'\B\A)2OI.0</&7S5HN5C`<(JH`(_I=ORXYGYG<YM#I_4+VR23LHQYKQ
M$G8';B-WPUVKY:ITQ9198<SL&>K:T^2-E-_NK;^]KCN*IWYZ"]9.V#]BSB[)
MJN>(.+Q%QP"6/8:%69.1J%\2CTC%`R,:K:X!VJV(/D2-E$P\C]HW#.:6'A(I
MO]PXCX%2X@C:OO[I?]G%W<_=IUG]DY'FBT4K'=5:WO('%)?O)&.97#.%*N[D
M(=XYC99@VGJR,4L]BY%FJ@[82+1-T*B"R1R*)*E*8H@(`/"+"A3NPETNE/ZW
M9?>=-:TNX=*(+<]%[A7*S2$\G"-K%U5^\<5S!?2/N6093DU6--M,HC;UV7SB
MJRS*-'T`83>0(JV7[_=B8"A]J6Z+.G7N]XU*]/U\VL]TQS2<!BK1%=HM+84)
MTSM&>6F<F[,TCZ_Z5UF,JV7`'B*I/4@"B1RF(KHV;7;AC>X;2WTFXY-"Z15.
MHF&2DIMYJ/I;VL2$[=M[T2H0=>98S$7R57D3&64;M8EE'J_>LG+NBD47.D8B
M"9%&2[]AMXW%EBU=<NJLPU;&/=,S_(J_<K?FMZRF'L4?-==+I=HV=NF02U@6
MM,/+1S&VJI?=I9(J$BX:H&(HD183%(JQ/V)T6[ZMUS1V).N2%WZQ=Y^S^1VV
M=S=A)PU8TAI0.HEZOD98(FNR4M,+PLD_@K`BW>1ZCQVFVDVZGH4$HE])%?CI
M#V[[0=A9_*+7=<O6_F:W#)IC22S4;E=JHL-B\J)H22HU4)?K':I9CL3&WUV4
M5(H_:1\89&09B8B?TZH`4B@%WL?70W:CNQ/1;73XUWG50Z.M*;V!KNUVNH5#
MJ"\ODA<F<UIT[FD-96X7BM*KMV[B812B)`AVK82N?EHF.J0BFX3N?V=LV_Z-
M5LKRY[;\YQ7LA3.O-EK3');-+O+?%.(^CN].U1QLC>UQM/H+JIMKF,@PAU(M
MVFZ8,1^8N51RD!"*FLU[C]A-UTZ:C8M2ES6.HH]KF^HU&.QS2&7\VE8R=W9*
M=EPFWUW:65+NSS6Y&.%P<T.W.=%,JI4"E*DHL0BI[)>U/8&V9/7*U@2&,9BS
MP/V^>O79JU1^A0]VNK.Z3&F4VUSL+FU?D'5XCYJKT>'BZ`Y2>6!VYF9$KERD
M`IF^4H90B];A[@G9^Q4W6MFRF!QZK9QAO5+K#VQG:?H,#;)V[W%OM=4LURL6
M8M9>*L$-&5@D?#UM8K67,V=J?5&1`6PI&4.4BEQ6^QNN'[D.\EU%6`R[-+.Y
M!O@$)+9Q97X;M"H9NQN$M-5K<VMH"I1E_KTX5\1Y4742FZ^YV1G"1U/(J$(L
MBO")PBZ"U5^.ME8L=5ER'4B;-!2U>E$R#X.I'33!Q&OB$'P;P8S9R8`^'V\(
MM!?V8])FO:?[S=EO9<[7H'J2MRUEUH?5[0)(YFE<O"LHS3CX%I'NG)2(&8ZE
M3HEFYC52&'T3#1Q'J?RY@(%#.=6C+C.+"+/+0.+K<>,`*U:#Y7N'`@=JJ-H+
M.66\DF5S.HR39VD;/C6X"(?D$1_/]OCX_E\A\?`A]G\?+5W$3&E3XIIV$;55
MEO$Q@C!\4?"M?/WUO;)MG:"BU7N=U/&3JG>WJ81I<:-.4]3Z"T:+4JF^&Q%K
M#1PAZ5%[I4GB1G]>.;U&6,*S$0$K@GHK3RJUY]@Y@S)\P(;EEQ)BXG%CJ``@
M;*'81L]Y>'UCD3,RMOI,3/U[&[>D8FGY;%*CH3VCZZ_B1_:]T?K[V2C(IAM$
M5`L<\[*4QFV;,[!2]*CVYU*+OV>,'0?.C&\G+Q_W@T$`]+200=QJOJ2*/S+L
MIV1OE$C?&@:X/B<#C6FW#J-*='O*BY!%6/'C-P[#TK7E]OW1=C]N?M?HOLW]
MU'8M9FG3SQWUBT)^*[>"MU>EUW4G#1D"]>_%6KWR-$9"$)ZQ%G(@ZCC>%0`A
M8R^_?W=HLUM9N>6E("V[MH_^Z11,JZ6,4#;EH&U[,1(*8M/%\E7=]W/FA]%N
M&:%SQX^BR&L$CG&K:`U90X4V4QW+8-$!*'V&#\H@)1`0^/Y0^/VCR)>+Z393
M@RF/Z4&_(/$PQO`(+3N)Z=K2"%>D?7$N8T\)#A0C&H_XK"K[N?2^\:'#4WNU
MU<=2=3[?]57<?=X&;JGEK8[;5:@\">30:*-P^<\LM*71,\CRF]?U+47#02F`
MZ90OL[D'>(;RUU(.6^L[NND,YN0()'FC+6[>:-('DLAD%&28@!W"\[PK<>\)
MRQ9J3*3JK)HN'-;45D:T?.,IO.&(.(P*VGO95]U"D^ZQT^KVM$/&P>ZT`&%&
M['YZU."1ZWH+=F`DL,6R./S4Z;?FS<\A&&^()>5FIC&5:J#R;%[2QW#0@=>_
M`;.D8@UZ".E6!.'">$U#AM!PH>A9@^:+1.$3A$X1.$4?>TO9?)>GN!:=V1W.
MR(5;,,JJ[ZR6.14,0SQV9(H(Q<!"-#'(:1L5DE5D6,>V)^DN[7(7X`(B&M:8
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MT2,\Y<NE#`@4ADIR6LX6""VI';L`:UH`X6,``X&C8!04ZNC!1Y&4NN'W%P2Z
M>3:3TFI)ZR<25B-]L/K_`+)[P7=BV>]?WP@CIYM"V-:)Z68I*@JZK$<RJD@X
M2KDDP8.R%0>4S,CBH*"YDP^^[2HN^,`E1$#T7YLZYCRFT.GLI</7RBDAKBP4
M\D4WG?T#!>]T9IN6YG&92@B-F+6T\KH->CHPZUMV"/J$QC")C'$1,81\B)A^
M(CX'R/Q'EK`]3;O+IOG":UZ55YSQ5K6@5.UNX=2UY?Q%/>FMX%T_G>H5-2<7
M+LOW<BAR>C9]`IFD9V/HUAEF,19;,\C&Q5GAU)\QAA(=`I/F/GSDXI@(-U!"
MKO)[2]]GFI1GTC#]!M#XCNG>`/=V]`7C=;YQ#9Y;)EK*.?*=GYN&[#%9X_9I
MZA6CHM[:/5#K7?$B-=$IU`7G=&8D5(X+%7K0K!,W^RP/SR`":QJW(V4T<)R^
M2F%KY`1`0'EW#B"<#4?EX%1%I)%3M5Q_=+_LXN[G[M.L_LG(\+<II54!-4*X
M`!Y$:Y#@`>?M\QC;_P!/"*Q<;UTZR6.0WZPQF>9[-R?8CY=.[$2+'Y,N&B#5
M(AQ4#5VW"D[7;HNX>.65:N&Z8(+$5$3*@"WZ0$5#$ZI=-\JAY&ORE1J$*TU2
M<RZ-E%[[>YQ[-:%9LLL);1DL6O/7*TNINPS-6G42K1C<BZBH`F5,"&3*!0(K
MD:/U_P"ONO35T9:'3:S9+)?:'6:O;D74D\;6*1H].MSJTT\Z98^39R<2C6KN
MY5>L)!J"*[:1`#)K`H0O@BHI;HAU.=4Y_07V/P\A6I;0F.MRB,C-6M]+2.I1
M=>_5=AHCRQNI]6Q+7-G"^")R`NOJ2*@"P&!8I3@15I2.J/7W.8K/H>G9I#1#
M3+;7:+W2EC.):1E(Z[W>,EX>X6^0FI62?2UCLMGC)YVD]>2:SM=<JP^HWP+X
M(O7)^I^"8;/N['E=(4J#E="7:-8MG:;D[J<`SGI$DM-,ZG2Y.POJC46DE(I`
MJJG&LFI/4'@H%+^CPBJB=Z_8Y9GFOOYZ@0,LZWRI0]$V([Y-RN2_U"OQ<S"0
MT%.(&<@@9G'Q5C?(D%$J2GI<F\F$0*($5"DZ=]=6E\8:8SH*L9;V(4X5GL1;
MKM#Q\\ZSYDRC:3)V^`C+&TK]TFJW&QJ#=N\EFSQS\E$A#G,4I0`BAC@_MI2&
M3Z;5+3+Z14)2LU"Q;)/2+RGT*Q4W3=P3V0;1]XP^_6$^ARU2L\/#C:E5R)Q\
M(Q^:[;-U2?3@0Q3$4H+=TFZ@70]+I\_E]:44H68QN;U^O1=DL5>=JXO$+IMH
MZ@V2.@;#'.[IFC9X@4H,)@'L>*PG*(>5%`,17#EL(Z\6M/68.2IM,D$]7JU3
MR?7(E!<J"-@JE6B91O3Z3+Q[%^B6*;1<'9'0-&R)6RHMG7D/(>D0(O"/6;!J
M]IA]Y6JC="]Q!I.:0L4Q9;(Z@:T\>0:<).V6&K4Q/.:;5IA_6VH-'DBT9MG"
MC0#E.IX.H)B*0+5RB\;H.VJR+EJY12<-G+=4B[=R@N0%45VZZ8F35153,!BF
M*(E,40$!\<(N3Y#[//Q_-PB<(M>[\0-[0A?<KZ[L='Q9(M>[N=:$'5QP*UQB
MH1<M;6;!4LU)Y,^F4#(.6YY9XS*\@G(J!]W31"&`2).'`CJ"Q\+K>X:'PN!%
M#NJ*'IJ"-H_P6YKGQO;)$2UX.U1$]D'W1U._>'2^7;:)JSW2ZV^BF[E49=`T
M5-6MG#N#0+73$H=T1%RU?.7[465@;>@#,9@AA,4J;A$.6<\T-$G2V:MO;-I^
MQ+E]:@?-N.UIZ:;ME0JWZ1ST9M:MMI3^_M-".D"E'>[T?"LXQ3&(<IRB)3E$
M#%,'V@)1\E$/XAY3"5C&E\>+J^0[9_U4^*J]BUP''&\<0V$=:U!_<JQ'8/9=
M[R5/WGNC,"HIC%SLR,!W/Q&'*=K672=ODD/UA7>L&I!;,*EI;A,JZ+D">(2U
MIHKE#T.`(%T7)_77VK:MTQF\H.90,_5N)Q>P#93I&['9M5'M8:;-H\YC:BL+
MO*%-AKM_QP64/W<^F.3^_#[>&1=_.B,L24['9?4QU+KY9X0Z,?;+9%1SD)*Z
M8'9CHG*ZB[S7I^/5-&(G.)F%B:"D0P)/%#C6J:&VNK=UGF,;'V\[71.8[QF.
M8\<+@X$$$$$C'_@O!VEQ+!.R>V<Z.[8>)KAM:6[O?(Q^(J`?M8=\D>ZN&JQU
MX.$/V1QL4*CM=4>H&CY-V\:F58,+T2,5(FY:HSZS51-^D)"_12:2J0@4!3`T
M"O>U[NUWR+UZZ?*X@WEYF)>ZR?4T@=7B-H]V(P<\F-U<6$"E05)#R.YB6VN]
M/,@NWAF>6X#)&EU:@>2\$TP?0X;CO64(IC$\B4?`_84Q@`0#^,OQ`0-Y\#_!
MYY:E'!])+8W-JT?.`^*YLC?&:UIVD;^(4KL58I+CU<;WS-#[5KBR1A^6TX;=
MU#CL-5KL:7.Z+[$?N)5#W$L`@I.5Z>;_`#Y*3VGQ^#*9.*9I3KT)";CVS0OA
MBS55<`>=JRYP*5K*(+,1.5!?T'FX[DW>5_\`+VC!HC5=TV7F)D\/`"[Q7W-K
M&1'&<?*EC!#975\<<+J5JK!.\#RM=I#/AJ#)V\>0WQXO%;PB)YJ>#:0:T)K0
M8[E^B3BVQYSV!RK/-IR*S1MRS+4*G$7.D6>*6!5I*P$TV3<M%/2'D6[I#U"D
MX0/X5;.$SI*%*<A@"]^"8S`R-%(<*$X$GY0+2`10X*W+:*C8KI\Y")PB<(OD
MJ?Y:9SCZ0`I#&$3G`A``H"(B8YO@0``/B(_`.:@5V;5H>*GB"K]PZ>I?GF^[
M!VVN?OM>X+#>WWUTM,BRZ#]3;0-@W728%<3PFE7*'=J14W8&[I(Q6LHPBUQ7
M@ZDD;U$7<G>20`=($A)1#O!\Z<EY&Z#FU+<N;)GTW%!96[CPF2Z+7$5&)]5$
M!QRNH-@9@7-*J/RTT'<Z]U)!86Y<,J8YKIY>`D,%:\&T8N&`-<-N(696B4FI
M9C2ZKG="@659I5)@H^M5:O1J14645#1:!6[1JD0H!ZU!(43JJ&\G65,8YA$Q
MA'F/5GVIL\U1F]_GFHKAUUF68W#I997XO\8U/C?H;&4H&M\4!2=95E5EDEA;
MY5E+!%8P-X2T#RNOJ^%6K[/]CLZZFXC=]UT]Z"%=I\<8[.,25(23M-D>%.E7
MZE"D/\%I.;?`"8#X\(I`=4WZ"9N>JY4\K]1\W=;V>B=/,'TJ\)D$E"YK+5AI
M+/(!Y'#\EE:O-`"*KI]6ZKL-'9!/GN;$-9%Y+:T+SNIA@2>HJ*OX=OH;;NUF
MO7?WW.\Y(L7$K(SYNIM8GEVWZJTN$K1G\/.:N(/50:Q,!06+->(K_P`ST"DL
MB]D%?"@(*#D0Z`Y?:=Y;Z,LM$:;B$64V3!2F!?*,3+)3RG.?XQK7H46^J=1Y
MAJW/9\\S-Q=-*XD`FO"-P!Z!V?$K!=H=;O7XF3W)F'77*IB=@/:IZ4V$\UH=
MVB3.63;7)]%VM'.;&W7$`*XG+^+9>,J:1BB:-A`=21BE47,GS77.KH-&Y&+B
M7A.:RX,CZS\H]6_MPV8K73F1RYW>->0?H;2.)WN;.WIZEMY4VG5/.JA5L^H=
M=C*C2J1`1=6J=7A6Y&D3`0$(S381<5'MDR@5)LT:I`7S_?''R8WDPB(V49A=
MS9A?OO9W%TCY'.QQQ))5>H(F6C&Q6U!&T`"F\#`*.'=[N5DG0KK=H7938WH!
M!4]D+6MUENY11FM#O3])4M8H==(J/\K(3CPG\HIZ1(S:)K.#^")"/.XTOD%U
MK#/HK*S87P--)7;F4VUZ0%U^<YA!EUA)<R4;+C3':3_BL*7L`>W[KO=[L38_
M?9]PE@>2NF@R[MYTYS689JFAZM76GSHZ,TV-BWP`1A6JQ%_]&4Y+Y8>LQ5Y4
MWJ44;+&ODR7*K;3^5Q99E@X(HV<)-/*)\HGH)[?\%;[?WD^87+KJ5WE.K3HZ
MO<_+!;LA"^@H!Y\CY$1'[/(CY$?ASLJ-'DB@7&43N^686O:>E/:W***S&3NU
M_P"OVKUJG18"!!EK3(TV73KT2!C>`*,I+?);@/P\?,\^0X1=EU\["T;<>MM9
MUS+I-O.I%S]%:2@0,"5BJ=SA:Z49R@7*"6$LE6;E6YMJJP?Q[Q))RW<)&*8O
MCP(D6-+K?IVK#C_MP=?,FOD%F-B[0X=K'8[1]DEZDPO4R\LS(U9OEMKE9A)Q
MXS@Y"WV:Z:JY>2#AX5R=O'1R_P`M/U""B9%1>46[4NV':;H!H.CVJG?.K%3[
MX0,Q$1F:0<Y1[M,X)N6:9N_TNE.+"_?OZ\&EQ;=NLT<HF66A/DK)M%3D<J#P
MBO+VQ/N+'O/?;1A6F5;+Y^B^VO,7J0DK)GZ6A_?Q:KL]GFHJKI1SN:AV47%2
M[QF=.1=A\YV1`0!L":GE0I%0MC[M]Q-;M3>#Z[4IRA.U;J'UU[%FJ\-2Z#;8
MG1;YO,%,V,*I:YZ_Z11I*D9I&IU\8XLA$).GQ7*ZJJJA00(BJ17%T_N'K=>[
M!9RPIER?S--E.S.*]:]6STV-PA<_S2RZI78L\[6U-Q<68D]9M2J3N<;2(%CF
M2T29!0K59,AC"L!%T=:[@]K];CG^+Y<ZH1.SV$9IV=E.QA'=3^\(132<MM2E
M%PJLQ\/]X$-!--P<)&G4A]9S%BTS?*$?@;A%*KIUVKF>W5IT"_5`8Y+`*S1\
M;@*^B5C\V7>[19ZF70M5CW4R*W\FGG<;9H:"79%3#Y4HDZ`QO)/'"*+T1W,U
M1QV-I\)7=%=:CBVLM^V$?!S$IA\7G=-A[!U]KDK-M#Y=;BV=[;=!;P4W`N8>
M86D68,WBI17:J)`4$Q(K;UOO'VSS++JAM&LV+.M99ZY[<.L=R(*A5K/%:2WS
MR\9/!9G-,J^WG6TW*R-IJ]F8Z00TD+DI%FSAFH=L)$3E3(177ZMFUM?W!XJ0
MV/8Z/L]CL/MRU:X,YBF4QC1DX1G;-K9RSB'-&1D]-M9&`^J4$T0]/\IPNT#^
M6%8Y?FB14!-V,*YV1V8OZO5BP?K%[M74RM#^LL4:3-"?>76.FG"PUXQ7+88Z
MT1HM?^*NA]8(@<_Z!O5PBME#=HNR_93.]^F'5P4D\='J]W9F-7J+;&HNKU.B
MR<+&62HXY7*'K#R55F]!0M$2D]DWCI)%8Q3LB"<6Y%_IR$73VC4NV-`ZI:!D
M<SN<`!WWM2Q79G.KA1,[3IMAR1]3&M7J<S2(>2"QOG<['3,'+(&0F')T9-@[
M2463_1$B9"+,3^KVJ_ZI?T/\])_YT/YL/O;^>3]0X#Y_S?NK[V^J_5#[Q^YO
MJ/NG_BOS/J/[_P#XQ_PG"*67"+YJ$$Y#%`?2)B^`'\P_:`_`0'X#_#PBTDO?
MYZ$:UT*[)53WVO;^BC,+)3)EHKW.S2%:*EA+-"29V\9*Z1)Q;$H%7K%R8>(V
MVE`@_)<F;2H>%`<K%ZS.LCL=2Y/<9/?"K'L/#U.H?&'6-HZ@5R[#,KG*KMEW
M:DMEK2NZG0>WPK.'TP[?Y%WLZZ9]V4Q>2*XK%VCP),0*[A%::H=S8D0)9J'9
M$T1'Y$S`/5/0`B`%<MS)+D$2*E$;&M1:>OM-9H[*<PVQCQ74P<TDT(ZBK@<K
MS"',K-ES;#CXAXWG;\%??0*!2M6H]NS31ZY&W"@7ZN2]2N56F4"N8R=KLVT4
M9R4>Z2,`B7YJ*GDBA?2HDH4IR"!RE$.BCN[K+;F+,<N>8LPBF:0_=P#$BG22
MNPN+1EW";-U"7BN(^!:%^TZW[C'X<[1NQ72'K'<VZW7#NJHVENK>I7=PG\O+
M9*;E&<#,V2J3<DLWKM6U.N0SPD/-*OA^B*4C*8$A3$3-R^?1^J;35F5-GJ#=
M-:!(VN(=3!V[!QJ>HX*W_/\`)Y<IO3&!PQN-6FF!`.(54]G?:2[?^Q#2NL?N
M;5745NQ+N26!AWHC(9920K\4_P!)D0DRMD)S^5?6ZA64KT&1Y]WY4)9"(/`]
M*3I(I.EYL\J-+\X]#WNAM4-_=9V%T<I%3!.RAAD8/*!#L'`'%I(J`2NST/JR
M[T5GL>?6+GN#'M]9&'4]8S&M#0@4ZZ[<%L)XAM&?]B,FH^SY=+IS5(OT(VF8
MAR!R"Z9JG_DY"$E42&,+.:@WY%&KM$WZ2:R8A]G@1QT.8VC=2\O-6YAIS6+/
M4ZJR^3U9X6EL;VUK"YH/EB2*CP\84--JE!TYGN6ZIR6WS?+2)["9@<_A(JUQ
M&,9_2:=I7,V'(Z'O.8W3(--A$+!1[[".H*=CE`*"Z:2Y/4TE(Y<WZ;28AGA$
MW318@@=)=(I@^SXM%:YU#RWU/8:\T\1#J3+9&SQAM0)'$B,LE`\J.1KRTCI(
M.Y;\]R*RU+E$V1YNUIL'-/!Q"IB=0@./2!6F'2L:WL3=W;W[4'=&R>SMW"LY
MU<&UFU*V'I[JT\X,U@HBS6QTL>*@VSQP?Z5A5]66\(&0`03C;6F=/P`/5#AD
M3\IN:&0<W=$VNM\K>T7$S`+J%K@[Z/=#YZ(TZ#L.QS:*+_76C<PT1J&;*+YI
M$)<71/H0V1E<'"OPK?C3.)RE$2"01^THB`B7^/Q\.5+$C7$>K\9N-3LIVA>-
M(`V+Z\^JT7H<WH(8W@3>`\^`^T>:8GR<2M0*FBU-_P`2C[KMPQ6GUKVT>G3Y
M],]S>V[-I6K*O4W9U)W*,FMIU8HZ2*K,?FQ%TTHAE6S54QB&CH8CIZ82"9NI
MSJ<UU!E6G<JN=19O/';Y180OEGE>:,C]6WC(-=Y`PZ]V*YV49?>YO?0Y?E[2
M[,I96M:P`DBI\HTPH,"=_P`<;/;SZ14WHEUZ@<NARLI.^S0-K)KUS;D)\RTW
M=9L4BJ+982_-_5RM)F%G')"(@"9#*B'K6/S'U[Q_/',N>_,6ZU);DR9#EI=:
MY=%6C&PN/CO>#@Z:8^.]X&T-&QJDVY6:%L>7NE(LKM0U^;W7#).ZF/%A4XXT
M'1T!3@<N&[)NX>/'*#1HR;+O'CQTJ1NU:-&J1UW+IRX4,1)!NW0(8YSF$`*4
MHB/P\^*!Q6\U_.+&P8Z>XD+8XVM'C22.(:8V#>030G8JC&>*.UEO)W"."(FI
M/5M*UZ<NQVV?B,O<=0R>%>V6$]M'I](?>VFW2&65C0OTFLJNS(2$?&(**=NT
ME=BJUBC>A0T5`-W#ST_,5`BD]G=,[O4'(O0C,WSJ)K>8.<LC-S)M,,;!^JMH
M]O#P`CUI%`YY.!`!4<?.[F9)K?/)+&R>[_;]DXM;XV$I!Q?@,`0/%K7M43-X
MS#OATH[6=C?P^?07M*MMN$=G[363+5IBNJ^F\D@;(/W];:S;)Y$OT^;R#.J$
M3)>AC3BTE8I-,ZJ:"ZZC<+HLUS.TR;+GYIF#A':,;4D^#M/Y8*C-A:39C>-L
MK<$R.-*[NWW%NT^W[T8R;V\>LE%ZYY6W1>&AFY9C0KTHU10F-*T6101_6.XR
MRA0^;\E9<GR(]L8QBL8]))$H_HF$UCNK=37>KL[FS*_)-OBV)@.#`,&]1%%<
M)DF6PY+9_1+<8$>,3M)WGW5+^QV*`I]?G;7:YF.KE7K$1)6&QV"8<HLHF#@H
M9FK(2LK)/%C%2:LF#)$ZBAS#X`I>>9LXY[N2*T@8YUW)(&!HQ.VE>P[5SY'L
MA@-P["!NT]%%I[Y)1+Q^)Y]R]6T3S>R5_P!I;H[8OD-HY7ZV,2V&P&6!9&.,
M4AB$-;=3!D1Q('`PK054*FB`I.71!4O<Y>:,M=&Y2&\+3F4[0Z4T^41BWL!V
M]/8J#ZHSN7-[YS8G?NC'D-QVBNT?%[Z_0,KL!"U6OP=8KD3'05=KD3'04#!P
M[-&/B(:%B6B+"+BHM@W*1NRCH]BW3112(`$33(!0``#GNQ7Y6U>;`:,&X-7=
M\(K#]HMF3ZZ=;MXWE2,+-CCN1Z!I#:$,91,DV_J%7DYN.ACJ)"51,DL_9IMQ
M,40$H*>?/"*RG3_JZTS".4W/2IESH/:K;J=67>[Z:X!*,C9)\LV0FU*;4JA#
MD8UJNT6J2+Q1K&$!LK(J-4RF>.W*QCG,1>K7J!UNHV(5G(-C:5&\9E1M"LDC
MEKC2D&$6M0QT>Z2CFL4NOSY'+1V@I'*6G[B9&1717?,_DMSE/Y])B*2<!BN5
MU1Q1757SZGUU?,:O,TO/%(6!8QH4JJ6%2)5G:_6DVB:2<3%3"L"R.Y12`I5C
MM4S&\F*`\(O2?I&6/K<>3L<+4'-ZN=$D\Y4<21(_]8[/G;=TM+3-.3*Y4^OE
M:TBXDSN'+=,IDDS+"<_CU`/"*@;;U"ZTWPU*&WXIGTX.=UIC3*6=>"2;+5^F
M1@-PCJ>V68J-U%JHP%J04HY<56A3%`0)Y\CPBZ:U=?>IR&NUB_VG,\G2V>XV
M:-D:C/RT3'I6:;N>>Q`S,1,5]-4Q2.+A68*#^:5XBG]<1DT]/J%)/T@17FK6
M4YY3[=?-"JM*JT!>]24@7.BVZ*A6;&?O#FKQ@P]<<6J3;D(YF582+,*#<53"
M*:0B!1#SPBMMU9ZX5OJUD##*JX_),J*6J^WRU64L.RKZEGNVE7*;N]IG#P\>
MHLRCBK2LV9)!%,QBHMD4B`(^GSPB]83J3UGJ5QD](@,2S>&NDD[M,F^L[6NM
M$I,CFZ,W;*Z+,US>4XLEJ:OW`21&Q44W@K'.J!CF$PD795?.>NLE^J\94J[E
M<L7-J#*YA5(V%)7I<E/R^P-XAA,49FP:*NDV%2EFU=8H+LQ+].L1HD0P"!`#
MA%3F:==^K'6N>BD<KS;)\>L]R1?5*$-!1T5!6.TM&Q#VAY5HM950LE+1T8WC
M#O",$A.BS1;B9,B:91\$5R7V'9-(2CZ<<9_559R2OD'J+V8/$-C2*^CUF#2K
M5=O1W!B"8;3!02!&K1V/E1%$@%+\``.$4!<*]KJFY';*E+6*[0%]KE%K.KU)
MA%-<?JE&M.EQ&Q,WD9;"]C+Y#R3U_MJIXZ07])7+5@BH\/\`5JIG6`H@13Z<
M8=DKP"%=YU3G)$\R=XL!',$R<IFR-\+47><&263,0]0<BR1];(P"B;Y1?(#X
MX1=#_JRX1_,Q_J[?S8U?^9'Z'[L_FT^E<?JS]W_>'WM])]-]5\_Y/WE_*^/F
M?_I_O?APBOOPB<(N@L];K]QKL]4[7"Q=CK%GAI*OV.`FF:$A$3<%+LUF$K$R
MC%R11N\CY!DX.DLD<HD.F<0$/`\V^.T\4=`Y"`<';%^?E<*G=OPQGN;*LQ+8
MYOVE>\ME^9%.CB[DD,?G/FE,*)SG!4/UOR,7HE-]B\[45`,(G=-A^5X'F-HV
M+561O=;-;]KQM/`:;0,>$G;CCP]?:O3Z7U#+DUX(W%QLG&I`Z=E?@Q6XG#S$
M188B*L->E8^=K\_&,)N!G8ETD^BIN%EFJ3Z,EXQZW,=!W'R+%<BJ*A1\'3,`
M_EY97);/BD=8W@]7+$2UP.!JJ\QS-N&"ZA.+AA50;]R+H'EWN/\`5^W]?-#(
MTBIXQ%K)DF@F:D7D,VTUBT6)!V!`P`*ZL,_%06<LU*)0=,%E`_X0J9B^KT3J
MJ^T?G#;F!W%ESR!(S>\;,-V`)QJ*&A739[DPSVS=%(!Z]H\5PW=OO+%7[%7=
MV2OT!LOX?GW5H)N]V',JS;,ISQEH*GUC79L73BE47^9EE7GQF9>K5I4DA67Q
M#"J^K_RCHF!5B!C7NY;F<&9V,6:6!$D3P'`'P.VXC$$=(5`KFT=E]VZ"4$3Q
MES>H@]'4?RHL6E7J]\]@GW&K1T1VV<DY7I%V2G#W+K+JTJ"OW9"%F7Q8Z)?2
M#HYOIVK^,='1@;4D`@!%TFLB`%15`3V<=\ON\VW-K1S]:9!;F37^40//"!XU
MU:M!>YI-<98CXS*C%@<RM2T*O7(CF=+I#-QI_,)2S3]U(*.-.&.4GRG?HN\G
M#8:846Q,/P\_$#>?L$I@,4P#\0$I@$?6`A\0$/@(?'D&K?I3)A=7+."\C!C+
M7;V.J":=(Q(!Q:X"M%(2[]XD!<"(7-`>!MH<6T.SQMHQV=:QG^Z+T+CN\F#G
M;5I-&*[`92#RV8G:DU/HGIY=N4KI[27$BD)%F\7:/I"`B?U!])(IHK@(>DX&
MN@[IO/NYY#:[CM[J5[N7M^\,O&R&OJC4!ET`<`YI/ZRF+FF@*HUSGY<_[^R"
M6<"(9Q9XVYH:F(`\49H,7NPI\G#$K*M^'2]W%_W\P.1Z[=AY%U&=X^J#-*F:
MM$V`I64]I%/A7'ZO1&H&:*@FJK8&CQN6+LJ8`)DI0I'!O!7I`+/O%<9?F,4>
M=97)'+97D39&F,U8&$!S7UV4>".&E<".BJC=FMY;&5]E<M<RY8XM<TBA:6[B
M#[V"V3Q'P'G^+_R\^CB0*@5*^*QL>ZO[D65>UYU!OO9#0S,Y:SD3-5<:SI5Z
M1L_TW5)5JX-7JZW(01=$AF(HF?2[HA1!I&H*&\BH*9#:?JI'>I>\MKO&T4QP
MW?"M12H%15:;'M1=8-3T.ZW_`-TKN8\?VSL]V<D9BTTO[_1$'%*IED`"GL#1
M@OZPAW%ABRILHAL3TA&UY%-,@`"X@6(OOX]X:;.\R_\`"&EYFMR.$B>_G81P
M3SQXLMZMQX`120$>,>FBOA[O/*_[,L3K;.8PW/),(6.%.&(T\<BGNX;L%G8_
M\/'P#R/Q_A#D:KJ2P"*0-MK6H%&X.<[I&[LJKJ*O%\+V-CB>`M(W'#<L"WNE
M]C=8WG4L]]I;I8W7LG8;L;)Q$!ISZ(<&*2FU"9]+M6LR;]L"GW,U<P22DK87
M!O'T4$B)3!Y7$H2?=Q7N\/SRZCYS:WM6?966ES<HC(-9:X/NY`0`>!V$9K4O
MQ%:*U'O#<S8K",:)R":MW*.*:1CAP1M-:L<1CQD88#!9>^U^V83^&#]JK/.K
M?6_[GN7<C88Z3BJ"8D>FXL-^V*=:MF%][$VV&1(J]7K=2>N$6D''G`Q5CIL8
M\GK*1P<LKP#6O,CR\P-)+2^G"!M\&.^F/35614<'!L=3&=OYWO\`O#X\,>K]
MC'VO)OIQF5@[0]F"/;3WH[3E<6_4K%9UQE;'0:Y:'@6(:,I(N/F+A:YYZZ"0
MLJX&]:CT2-?(IM?)[2.:FN':FS`9'8O_`.PBH--KSO=V;AU=95:M&9`S+[,W
MMP`+BF_=T!9\0^(@`>?B/@H>DPB/D!$0`/B(CX#^[RD`+&BC:T;@!OPP7MS6
MM7#`[UJ4^[EV<V?W-NVM/]CCH')BX5G9]NMW%U6,6<*URO1$`NV?S]4F9&/,
M)24[/40*\GRD,'WA,?2Q9!,H"A#W0\GM`LM&_P"Z,Y8#*]@,#:8M%,'FN^IP
MI7?VJDVLM2.+WY19/_=R2']N\!;C_1?I9C'M_P#6;->KV$0Y(^D4"((#R77;
MHISUZN#\I%K5?[8N@0`>6*T20"LJ81,5%($T$O2BBF4*[L<7L#CY1"IQ3APZ
M%+_F]$X10)]TO^SB[N?NTZS^R<CPBE6[G7U6QYU9HR)6G9*NYJM.Q\&V]0.)
ME]$5<S]I%(?+`Q_G2"[8J)?`"/DX>.$6"G2;SI>U^WYF^HSO;"OZ!?=TL'2[
M1D:4G4\Y/"8O:[/V3S,X.ZU"5Q.)M3ZLTF3=A#+LYQR[4</F`BHY15,JGPBD
M&Y[":Y0'N^X-HG8'2;+::IVEQ_(\BT*CYWBC/6+H&OXRAK`9RZ0LC&#QNOC%
MJLY(Q)YZU0%&.0*F('<>@QR*T64=JM:OQ.KELM[NL3]YB8[W0:PM=I:I9R_N
M*I^OQV$+3)1&<JY)*NPDN]9M$0G2UUP2(EE4O(@9("%`B[[-MW[K#`YK]1V#
MI=[O7:#V[KAV$II+]2*50,\RO<JXEEZ=;&,D8)L@Y-2YG^<GY+Q.87??\<;I
MKE,1)0S<I%R;9L,U=>N-`GIJUZ98-SZ_>X7UFI<VPU.$S5A;ZKH4U=Z#`V:D
ML)S'6S;/;C7IC/\`37P-Y!@)S.(^0%%?TJD,4A%F+LVA1S2EZ)9J>HQN\CG\
M;;_J86`DFL@N>V52'=2*].=F8++G83IETTD5&Q_2ND*Q?44!$.$6$>M]P^Q4
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MQEWI,G%NPC`>,4W,:H\]*I&RJ@BF)%E?]O[8-`V/$K0_T:V1^CS&>[MN>-Q.
MKQ47&P['6:MENA2]5KU_3CX0J<"DZE&+($'9F!2,U7C551(I"F]($4X^$3A$
MX1.$3A%X,4#`("`"`@("`AY`0'[0$/R^>$4)O<#Z+8Y[BO5S2^KFVQY35FZQ
M7U5;LS1L@K8,ZT"+*LM4]`K)UB#\F6@'Q_)R>H"O&AUFJG\DL<!T8YT<I>VA
M:6T(.S>A\G#:M17V:>V6T=$.RES]C7W!':D1H.9S3QOU+T*557"$N57>`XEX
MFD0TK(B'UU9M<.(R=14$_P#(F,XC#>A9-)$MO?.30D4]N[5&71UD&$K6#'$_
M.>;N<=M<<54;1^?.XQEMRX^L<X<!)PIT>YNZEM>B`^?`AX'[!#Q\0_)\0Y;3
M(UCHQ$#61F\;,>OJWJK_`*Q\3>%E*].X]BUX/?7]M.Z[[5J=WSZ@J2E2[U=1
M3Q]SK<O30.TM6BTJF.OU@2B&*C?PI(76DNDSO88%/7]6W%PQ$#`JD0M;^4^N
MWY1?C),Q>393$!A/DL<-Y)V`U`.VNW<O`:PT^R]MC>P-'TAE3AOK3#X,/^:J
M&JV3"?Q5GM%S=*LIJ[0>]^!)H&?%,T2:NLRWUK$K)15J8-_`OD\:W1LP6;O$
M2B(-3BJD("XCTC#=@V0>L:QM3;/&+@`0-XIT]F\;51D\8;PO\H'9B.P]1&T=
M:QJ^TAW$T.PI7?H)VQ9R=1[<]4W<I2W45;3BA8+=4:BZ^YU4'`N3`I(V2D_+
M(DNJ43@]C#MW9#'#YA^0O=^#NXPZ!U&_FCI-C6Z1S*X+;E@KPVER\.<9``VC
M8+ES?^F7A:!1U1?OW?N9S]2Y8S36>2US>SAI$XGYZ,$`!Q)J96X!HQJVIJ%F
MX\>/28!'\X"`^D?L_(/P\#R/YT8+?UK6OB_]QA^%CN@[#OW*YGQZB1H''&X$
M@]/0[;M6OG[CF7[!T#[-YU[R/2LHQ5USB?CB]CZ8V^>A`W&O21V\')3$\S9`
M4SNN7>,4"*L``4125,W?%$JQ14"6;N%]X6?,[9G)35$U9&EWV;,\XNC:"]UM
M*3BW@&,.T$`MV\(5EW>+Y80PS2Z_R%K6PNH;ME:'B<0`YC0""!\HU%!BM\SJ
M=W`RKN!U'R3M]1)`8?-]4S9'0E5)9PC\RG"P1=%N4'/.B""1'E*F8IZS=G\`
M03-3&#]$0Y)NRKP>&H/C`5ZCPU["<1U*T$U:_A-0>`.]P_\`-:$MST6V_B&?
M<ILG8.\H237V[^G5B<U'%*$_452CKRY:OB.D%G[8IC(K3FCN&"$Q/'`1%M$)
MLX\#?[_EHG>][PPY*Z`@T_D#6NUWG,4HA(-3;QMPDGE)\G`\,7"#5U344HJX
M\C>6;-<9\V[S!O\`V>U>'2[?&:,0&X4)XJ5K0=>Y;#"94D2)HMTDT$$DR)((
M(D*DB@DB0J:+=%),I4T444R@4A"@!2E```.0+W;I;Z2>YOY727,\IE<]Y)/$
M37$G=52+QQ/^BQQ\+&3QM]6T#!OJ]E3AY5.I0!]R#O15^AW7J6T!46DGJ=L%
MU6<9J"WI6-,6]5N'_3#UF!@44KM536*[>C\`5-\IN`^M8.7+=VGD?=\_N9,.
M7WS#%HK+V-?>2FHX`"#P"@-9)0"(P#UDBBIMS8YB1<OM-&XK3,I&N9%'AQEY
M:>%Q!(HP&A)VTW*J_:(ZLT+V;^D.V>\][EK]8.SVY5AW=W2-E*FM?:M4+H[+
M*5#+:ZU?$*L37MKG%VRK]!/T_0M1;M3@DDU=CR?O+<LL\IRZVT[D\#+?*;-C
M6QM:``UC!PB,`5'"1B=Y/2351E7UW<9C=3WEV\ON+AY>\DFO$22:?EX%&+VJ
M^NFS^[%W&MGO>]]X8IJV6QN(_ICC4HBLO6(F-J[YPVKD_&L'Q2E6IF9>3IQJ
MIB`,Q8Q<R)P_DP$]'N<>O76,'^TLF?\`O;AXSAL:W\VHWG:[`[AU+VNB\A,\
MPS*];Q6@&`VGMIX%MPF,;U&,8XB8XB8PF'R(F'[1-Y^WR(_$>6P"&(.$H=^M
M_2*K"Z)CAZIX_5_HK!%[XONC272'(H'`NO0N;/WB[0$)3L<K%>0-+6&CPU@>
M%KRFA?=#8JSA2>D)!S]WUMN)!,ZDC&6*4Q&Q_-4^5VAGZGS;[5O&4R6/RJ[7
M._-`Z]YKL[5XG5^HW95;_0F']Z<,"-@'23U="G?[!GM`1OMA]<5[7J22%E[H
M=B&K*W]B;P[6)*OJ\H\5-+1^30\TH95=S'5MR[.M*N0.;[TFCJKB8R2;8"7>
MEC8>&&V#1;-`'1@,!0=%-BHLX^L>9GDF0FI[3B?A6?4`\``?F``YO``P&Q;5
MYX1.$4"?=+_LXN[G[M.L_LG(\(IJU'_-2L?]7H7_`":VX16[@NNG7^KK69Q6
M\0R6ON+G.1UDMR\-G=2C5;/88B41G(F;GE&<2B:5E(R;0(\;KKB=1%V4%B""
MGZ7"+N+;BV/WYA9(J[Y;GMOC;C(1$O;&-EIU?FFMDEJ^W19P,I.(R,>X)*2,
M*T;D2:+K`=5NF0"IF*`>.$7)C,BRB&;13.'S.@1+."2LJ,(TC*?7V#6'1N1$
MT[<E%MVL>BC'I6A-(I9$J12`\`H`MZ_'"+R\R3*Y*-9PTCFU#?Q$?47M`813
MRI0+F.9461*P3D*:T9+,#MFU6?$BVP*L"%!JH#=+U$'T%\$5K)?JED+EOB\)
M6:W$Y[1L1U%/8(#.J%!0-8ILQ=V$).QD#(3L9%QS<%20<E/&E$@2%(RD@W04
M4$WRP#A%7N/8Y4<3K<I6ZB1ZO^L5SN&B6N>F'!'U@M=YODXZG[-99U\FBW3=
M/WKMR"9/2F0B#5%%$A033*`$7QK77["*;(7"5J.,996)/06SYE>Y"`H%6B'E
MQ929E3R3*RN&$6@K-,Y%18YETG`J)K'.8QP$3"(D5S&T-$,XAO7F<7'-(!I&
MI0S6%;LFZ,2WB$&Q6*$4A'IIE:)1R+(@)%1*0$RI@!0#T_#A%1TUDF66.@IY
M3/YO19K,4&$=%H9[*U2#?4IO'1!D31+)M6G+%2&0;19VZ9FQ"(E!`Q"B3TB4
M/!%3[WKM@,E4RT*0Q#(WM'(YD7B=/<YU45JPD]EV81TJ]1@E(@T8B]DF`?)7
M6*D"BJ?Z)C"'"*XE6JM8H]>B*E3*[!U*K0#)..@ZW6HEC!P,.Q1\_*91D5&H
M-F+%J01$0(DF4H"(CX^/"*H.$3A$X1.$3A$X1.$6NK^(1]H5;W$,%A]MZ_MU
M:[WHZM-E;AAUEA%ABYF]0T.[+8'^5+2B(I+)RBK]J#ZM.!.`LIDOH`2).US<
M.$;X7P2,:^*5O`X.V<)V_`M6O?$YLT1(E:<*?E^7NJ.7LF>Z0E[AV`.ZCJYB
M5_N%U\!M3M[I\@B:+E[`#!0\.PT]M#.`0=-DYEXT.VF&X)@,?,IJ$.!2*H^;
M,N9>A1HJZ$]@TG(I7N+';2"X@EKANI7`[QV%5QTGGPS:T]3,[]ZCH".FM=GO
M+-@!C%'U%'P8/B`_P@/D/_'RFL['L!:QU)J!S2#T]:]BT!KN"8`Q.\H;^K!:
M=WN,9_H'L3^X-FWNZ=16GTW7?>;X6@=M\,CA.VK3R1M!E)JT,4HU$"L6T7>V
M<<YEHE3TA]T65IY('R5P2&[#E%K>7.\M.G+UQ-Y;1AP<?E-K2E=I+?!V*C&M
M<@;E]R;^U'[G*ZAZCV?E\*D[^)?Z?PD)0\2]^?IY8H^C:GG8Y&^T-ZW`S5MK
M6?WTT-&Y?<'#5`ORI"P1J-A0BI))4?$E`O`(<WEH0#U*U/I;(=:Z;O-(:EMV
M7627<+F2L<!5U1@0:8.8:2-=M#FBF*\QD&<7FG<V@SO+)',O+=[7LZ"0=AZB
M-JE%UWU97=<$QG:EH=.OK:MF=-OZ\&BX%TC$N+1"-)-TQ07$I3+-VSA<Q4Q,
M'J$@!Y^/GF-=S(TI%H'F%G.B;.1TUGE=_-;ME=@Z8L>YKI'C<[`#KI@I5=-9
MK=9[IC+\\:`)LQM8YY:X4+V!S:=M<>BBMMWM;MGO2CMDU=H).FRO7S4?FH+E
M!1(_HJS]4@B0X>D1(LF4Q?S&*`A]G/5=WSBM.>&E'VTKV..>V@-*XATK01[H
MP*ZWF#;02:!S=MRT._<)B!M\8-):??7-]DR<DXS\*[M$NW>KF>0F(^X6M&*'
M54$68,66EN42-Q*<#HIH*^HQ0*("!A$0^(\R1#Q/F:RE`&.I[X+3[Y454SO6
M!O'M$1'PX?$L>/X?R/:,_;@J;ILD5-:6UG5GSTY2%*9=TA*Q\8FJJ)2@902-
M&29`$PB(`4/'@.0;=_N\DE[PDE97O]1E%O"(S7A8)6B1Q;NJ:U--Y*D*[M=L
MVWY=LN8&-]=<3R\1W\#'EI]VNP;PLUR)/F*I)^?'S#D)Y$//@#F`OGP/@!'E
ME`H7!I:'-)`H=AJ:45?IR!`\N-`&GP+")[0G5Y][TWNE;;W,[.$C)#KOT"O$
M;4,NP=VO]Y1TE=T9B<5H+>69*I@S<5^-7K3B>F#G((R<D+5N8IFQ#E#(SY!\
MJ,@Y.\L;+3N1-$N:31LGNIB*.N))&`DN.WACK2,$X-'3BHO.:6M\UUOJZ>_S
M-U([9YAC8,0&M<6UZ*DBI/9UJO.[<]HGX@OWB['TG8V"0KGMV>W/:7IM<-#O
M5&ZN@W>#EC5FW/051'T+V.U61JZKD((AZ8J':O7A/"JQRF]UKW5D.C\E]><;
MZ5I;'A7QBVM3T``CW5Y73>2'.LQ$9PB;B>SH]WP+;/JE4K%$J];H]*@HRK4V
MGP<76:M6H5JFQB(&OPS1)A%Q,8T1*4B+)BS0(0@?:/@1-Y,(B-CMU=7E].;V
MZ>7W9-22:XG::JOUM'':,]3"T"-19[W]V<C]OWK1>^R>O.R*QU:;C&TVGH.4
M49O2-"?H+C6J-!D,<%#+23I,5':X`)63%%9<_@J?@?1:9TK<ZKU`,LM@2VE7
M/^0T;R3U+J\XS&#)<K,A<?7CP]"P]_A]?;PV#MEM]C]]/W"H\TUJ^JR3N5ZB
MT"=:J!%TFJ*IN(YII\="R!3_`'3$QT.<(REMP#RBT*K)CZE'#98+WLIRRVT_
MEK,IRM@%LUH!.PUWGK)([:8=*H'?7USF,YGNC62JW32AX``_*```C_Y?_'SL
MV#A:&]`7#7MS<B<(G"*`/NI.4&WMP]V3+J%2*IUPT]HF)O\`VCI]7'3)FW('
MQ$ZSEVY33(4`\F.<`#XCPBF_54SI5BMI*D.FJE`PZ:J9P])TU"1S8IR'*/Q*
M8I@\"'Y^$7?\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB]#$*;P(
MA\2@(%'\I?X0'\@APBT?O?EZ+:U[;_:FK>^MT`@5&R<;/MD^ZF40K=1."FHR
M97;L)R^R<;'%'_X/T-N8C&S&!,WT,L+65+X.==4G49[D=EJ7*ILIOF@PR,-#
MO:X;".OXES\MOY\KO&7T#B',(PZ5G`Z8=XNNW?#%:QM."WV"F64S%,7-HI;B
M9C"WC-+"HV(>4J=T@0<%?QKV+<^LA'!DP;/$RE60.<AP'ED&H=+9SI>[-A?P
M2</K'!CF@N#VC8:MK0$4(K15ZRW.[7-K9MX9&-E>,6DTI1:\GXDOMI0]]I&0
M>UAUM>QVV=H-OW3/',S4Z(\1LAJ.6,<O&=;@IMW#F=H,[19)Z624,T,8RC*.
M;++N"ID,GYK%R7TIFUMFC\_O8G167J2UA=@7EQQPVT`QK3;1>,UUG-F^Q^S8
M7!]R7@D#<!CMV8G#:LJ?XAG+W.*_AR[1C3MV22=Y)0^G.9NY%'U"F^<4.ZY;
M57#U/U")OENE(PQR^?L`P<N9!,DKY2*5!/A_Q5*`2:`^4</=45/;X'_L(]//
M/V_ZN&4!]GCP/ZJ1_P#YN8W7>%!=STU:6[/MZ[]LY2L\LCQ<N\B#=K<HM0?_
M`,+5W/>+^I?VO_=\U7]D9+GPY"_C=I+[_L_;-7VYB?T-FWU&7T2N#[+?^RD[
MY_03[C?^3-,YDEM^=9YI](**!^[S3Z04$_8'_LUJ#_2?K7[3(\@D[^7]P]]]
M1LOX=JD9[M_X:6OGW7MUFE;G*FX04/Y]":I%#^`\CZ"&`QO`?E'P'+.8P3*P
M#;QM](*N5R#]'D`V\#O`5!K\'9Y7CO=4ED_`LWW:>GD;J#\%#B1'2W1P,0?`
MD_D79!^/Y1'\W,H3(@8\DLR=@LX?0:HB,_<U^<W;V>2^[DI_ZW'P*)WM]:56
M/:V][KW->FO:F599PU[9:E_.AB.E6Y9&#JUC"8NMTO%"9*SK]1&/;-KA7]&7
M;(.%%"(!+QIVIS$5$`"F_.;3>89YDUO-EC3+ZAQ+AOIPC'';0@C#'85ZC0N9
MPV>8/;/1K7;_`(%ME:+IV<9!1IW3=4O56S_.ZQ$N)N<N=IFF,7`,8MLB9=1S
M]:NL5-V95,OA%)'YBJYQ*1,IC&`!M7M<JS*^NA9V]O,ZX<:4X';_`'%5N>\M
M+>#Z1++&(NGB"T],VBI#\13WWM_9?=I*0S+V9/;T6D98?UI57K]?T`\(!9EX
ME.*G`B#>9O;%@62LKGR8\'5TT68"FLX*<UZ?+_1MEHO)!9M''?N%7.WUZ*]`
M\*H5J;/ILZOO%/[F":=G30].[J7Z$5--4#56KC0A@1I1JU!GIIJJ9B:L&J0Q
MS;]735P\4(Q9X`8D$?HQ;"*`M_1\O]#QSVR\]LP&Q51PB<(G")PBB!OW66P]
ME;)`U_2]'*AUM@;%3[A*XE5JV$?):O8*;*M+)#1>KWU_,/UG^<,;3&M7IX*+
MCXX9$S8B;QTLW%1!0BEX0!`!\@("(^H?(^?B/Q'^+A%[\(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(NALM9KUR@9FK6R#BK+6;'$R,#8*[.L&L
MK"SD)+M5&4I$R\8^2792$;(,U3)+(JD.FH0PE,`@/-02TU"'%I:=A6J7V"_"
M#]#M&T.7T'KML_83I\6PNG;F7HV<S$7:*(V2>N%E7+&LM+`FWLD%&G(J)4VA
MI-TU0*/I33*0`('SFA@F%)6,=V@'X"MS7/8`T/<0-F*R(>V/[`_0_P!L"Q+:
M9F<!:]:WUPP<QYMWV:0C9VUPK:1*HG+-Z-#Q<=%UVEEE43_+<.6Z"DDLB(I'
M="D8Q#?2O"P1@-X!LIV`?EN6TO$CB^A!/2H^?BP7"[;V5M[(@J=(CG1L&;+E
M((@"S<=3KRHHJ?;ZB?,1*;^,H<W,WT_-*VNVCM^(J#_1)--#I+U)22*4B9.N
M^3E(0H_HE`:A&#X#^Z/,;3GVYYYY:NKY/V_>>W>I5^5_B\O<F!VG*K3V+5]^
M\7]2_M?^[YJO[(R7->0OXW:2^_[/VS5R>8G]#9M]1E]$K@^RW_LI.^?T$^XW
M_DS3.9);?G6>:?2"B@?N\T^D%!/V!_[-:@_TGZU^TR/()._E_</??4;+^':I
M&>[?^&EKY]U[=9GP_+_@F_Q1Y9W!\_'^T;Z05=)OF7^8[P%0D_!O_&A^YR`A
MY\]KJN`A^?S"W7R'Y>90F2BN1V@__3@]!JB!S<TS*6G_`,J7PN6P5[E_M!],
M_=1I41`=D:7)L[S46;MIGNUT!\T@-3I*+TQE5XMI+N63^/G*PL[$%U8N2;NF
MGS?*B14E1%3G;<7#1I;Q,"X7$[AJT\+^I8%ZO^#=P%2=@FFR=^.UFO9)`OD7
M#3*S-(.L('9-E/4C&A.NIBU-H]$R(?+.HRC&JO@1%,4Q\>-C(K>&3UK(V<78
M`??%"MQE>]O`7/X1TG#WEM5==.JG7_J?AU7ZX8%E];S[&ZC&.HN.IL<V%TS?
MA)@<9N1L;F0,Z?6>9L*BIS2#Q^HNN\,<?F&$O@`^BV*#<#1])]MO1XF%RVJV
MO3/;VU:Z-XG^;6L1[VT7;H[?[K-%;MIC/H5D1S*V/JA9YZ1*+^$0*=Q1'2QG
M3,IH@RR#,BRT^LI?@8X`(?`1-^CY'^[\/CPB\B<I0`PC\!\>!_C^SA%QV[QJ
M[1(Y:N4'+=03`FNW53614$AC$/Z%4Q,0XD.00'P/P$!`?B'"+DB8`#U#Y`/X
M0$/R^/L\>>$7S.LDDF9950B21"B9110P)ID*`>1.<Y_2!"@`?:/@.$1%9)PF
M19!5-9%0I3IJI'`Z:I#E`Y#IJ$$2*$,00$!`1`0X1>XG*4Q2B8`$P^"@/Y1\
M"/@/X?`<(O;A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$6
MMI^+(_L6-T_I-P7_`$G0?/K'\KS2OF_:WSOB*A/T5_J4=3/W>,G_`&/B^8V?
M/K\<-7??UY[=ZE9Y:?T'DOW3:>Q:OKWD$`Z7=KS"(``=?-4\B(^`#_X3D?@(
MC\`YNY!ASN=VDVM%3]OV?M6KD\QG-CT'F[B:-%A*2>@<)7"]ESS_`/Y2]^#P
M/D,(]QD1\@(?`T3IHAX\_:'@>9(X!%PP'9P'X7"G@*B@D.`ZFT]TD'P8J"7L
M#_V:U!_I/UK]ID>03=_+^X>^^HV7\.U2,]V_\-+7S[KVZS/A^7_!-_BCRSN#
MY^/]HWT@JZ3?,O\`,=X"H3?@V_\`,3W-OWKZO_D6Z<RA,E_DEG]4M_08H@<W
M_F4WUJ7PN6ZESMUP4X1.$7H(`/CR(A^D'CX^/(@/D`_A\^/'\(<(L%=+O\I%
M>S38+U8VB6COVEZU$CEE>I.R/F\NE_KN6>"9I2+^*FXFPJ)Q30R?TQ4WJ0$^
MG33'RD`D$BNO#=M>RFC]NW.4YT^KJM.I_:"?RB^TEOAMWGFT)B=$J*,S-ZH\
MW\]CC:`VLLO;E$X;[H324<,%G`)?(5714$2*//2G4^S.<YMU7I7ZU96IEW8N
MV]T<^HD6C1[`XNF;6&CSNYZ35K[.6-U<$X^YDD7E7=-G\0FS8)(HJH?(<&,1
M0PD4T.CU_P!Y/[;]2UG0KNCM&FN<4L-\K+Q2O.HV6DG<;7I1[#0=A<N)^<4L
MTNZF&'@[TOTH*D5*3Y("7UF(K+8%@V0R72"L=LW%GM=ZWK4.J]MT"[ZU(:;<
MG;G0K9H>/V.5N%?EZZ>QC4'L%79"4=(1\.5@5O#_`':E\A-(Z!C<(J%ZM]DM
M[P_)<3I6V:)AL=GTQ[:47V%I5U3HMQ;,<8'+8G+:H6.O*9+:[EM0B)**O;%V
ML+).*?J/VRJ"!`(LEZ2+CRW;+3KC%:CG6L0,3?S9)V:]OLE:G[CDE\P28EH7
M>M-CB@ZE<Z5NKF49RM-D(15S$N1>`U>`HD5TU.*:I%"*[E;[>]I7&C56V3KG
M'U<3G^_NB]*"T",J%E0OAH2)F+M$5O3G%Z<VM>+0FV,E5TTW$62*,V<-#&4!
M8BI@(F19A>$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%K:?B
MR/[%C=/Z3<%_TG0?/K'\KS2OF_:WSOB*A/T5_J4=3/W>,G_8^+YC9\^OQPU=
M]_7GMWJ5GEI_0>2_=-I[%JZGW!!$.BW;T0$0-_J]:<`"`B!O\W'0^!$/`AYY
MR>[T.+GKI$?_`']I[0+?S/\`PXSO[NG]%5I[/Q0#\*-K?@`#SUA]PL1\``>1
M^GUSXC^<1_/S)"(_7,/Z#?"5%+)Y+O.;Z+5CL]@?^S6H/])^M?M,CR"3OY?W
M#WWU&R_AVJ1KNW_AI:^?=>W69\/R_P"";_%'EG<'S\?[1OI!5TF^9?YCO`5"
M;\&W_F)[FW[U]7_R+=.90F2_R2S^J6_H,40.;_S*;ZU+X7+=2YVZX*<(G"+U
M,4#>GSY_1,!@\?G#\_\`!PBAY"=`NH%=_6I.&Q&"9,KL63+9X?[[N"]>D_OB
MTMKM)&&MNK&M`M%'=K:)OS&;MDC`X`1`0]1@$BC;$^VRZC>PCC8/YSJV5@KV
M6E>S"T_&9FYA]ZDY*14,<F43>K,[L2#D,I:H_+9&;?<`.',4@FU.;U`9<Q%/
M&"Z]XO6VV;M(/.Z_&-L@G;79LS1;HK_+ID]>D+"VM\E#`=P?Y;B?;VN1(OZ_
M642NS@`!\/!%]\BP;)<&@9:K9#3FM'KDS8)&S/(.,?S#F,2EY8WK?'BV<K(/
MT()@<_DQ&3(&[)(3"*:1?4/DBM97>C'4VI6J6N-:Q.KPTU,A;/J$F3F=)7F*
ME\82,5=7=>IQI<]1JLA:XV7=H/W,8Q:.'*;E4#G'UF\D5<R76/`IF(BH"6RJ
MJ24'"8_)X#$Q;QFHY8L<;FTX%*4S]%!58Q/N)Z6KQ_J`?*P&:)B4X"'D2*EZ
MITPZQTJ.EHROY-"I(S]BSJW3[J3D['8)B?L^2202^:SLY/6&9E)R7DJ8_`#L
M5'#A04BE*G\4R%*!%7B?7[&46[!HEGL`1M%ZX^WF.1*DX]#/8I-]*24AH*/\
MN(EGW3Z;=*G.(BGZEC?H<(KR\(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G"+6T_%D?V+&Z?TFX+_I.@^?6/Y7FE?-^UOG?$5"?HK_`%*.IG[O
M&3_L?%\QL^?7XX:N^_KSV[U*SRT_H/)?NFT]BU=3[@O]1;MY^[WIW[-N^<SN
M[?COI'[^M/:!;^9_X;YW]W3^B%6GL_\`^RBZU^[![A7_`.SKG,D$_.M\UG^9
M12/^5VM\#5CL]@7^S8H7])VM_M*GR"+OY?W#WWU&R_AVJ1ONW?AI:_M+KVY6
M9\/R_P"";_%'EG<'S\?[1OI!5TF^9?YCO`5"/\&\(!0_<X$/R=KJN/\`<"$N
MOCF41DG\FM/JD'H-40.;_P`TE^MR^%RW`*_L^>671+-DK&=^CTJI1Q)N6I4[
M'2D!/K5I=W]`WML$UEVC0MGJ*S_P@,E'&<M$ES%24.100(/9K@JZO")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G"+6T_%D?V+&Z?TFX+_I.@^?6/Y7FE?-^UOG?$5"?HK_4HZF?N\9/^Q\7S
M&SY]?CAJ[[^O/;O4K/+3^@\E^Z;3V+5U/N"_U%NWG[O>G?LV[YS.[M^.^D?O
MZT]H%OYG_AOG?W=/Z(54>T>_1C?PG6NO'!5#)$ZS>X"F8$P`Q_+D=7:D$`$0
M\_IK`(_P<R07^6WS6>$J*1_DO\]GHM6/_P!@MNHA[:6;J']/H>:1K[A+P(F-
MZ26Y1J(&#T@!1^8V,/VC\.0.=_+^XV^^H67\,%([W<OPRLOVEW[=RS,!^7_!
M-_BCRT&#Y^/]HWT@JY3?,O\`,=X"H3?@V_\`,3W-OWKZO_D6Z<RA,E_DEG]4
MM_08H@<W_F4WUJ7PN6RKV0;D;]U_;HEV_EO(.+/V<JSIRD`%5=UV3P"8L#V&
M<G`/4JP6FZG'.A3$?3\]FD?QY(`\[=<%3]X1/(!]H^.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1:VGXLC^Q
M8W3^DW!?])T'SZQ_*\TKYOVM\[XBH3]%?ZE'4S]WC)_V/B^8V?/K\<-7??UY
M[=ZE9Y:?T'DOW3:>Q:NI]P7^HMV\_=[T[]FW?.9W=OQWTC]_6GM`M_,_\-\[
M^[I_1"[#VK/]DFV3]VCOQ_S[3^9(0^=;YK?\RBH'E.[1Z`4)O87_`+,W(O\`
MKQL?[?2O(&N_?_<;F'U&R_AF*1[NZ?A18_6+KV[UF)#\O^";_%'EH4'S\?[1
MOI!5MF^9?YCO`5";\&W_`)B>YM^]?5_\BW3F4)DO\DL_JEOZ#%$#F_\`,IOK
M4OA<MESLM_7%]N+^D;L=_P#C1>N=NN"I7Z_HC+(\HTS5I%BO)L,TSZY7]['-
MC>AS(-:?7I"P+L4#@FKZ%':;`4RF])@*)@'P/"*!>6VG<J)A4+W5[*=F5):A
MK8L_W+5L7@\LI3>BU:`E:3^ND1`9I/1Z#2_$DZ<5PDW%W(R,D$V8IA,DW%0I
MDR)*>X^K082[O=IZY7_,9N$ZT6'M91:R6V4ZW/-!S.I/8:/LT,#N'<(M*OHL
M"XLT9]3%.150]+THINE/0H!2+Q,^Y&:C5G;Y'5>NM]SFTY'5L;T"-J4C;Z3,
M(VC.]UN+RBT^X3-JAGCF!SYA79^/<#:/O`YTX)FB9R*BZ0>>$7+<]P-]==BN
MI^=0>$U=W1]US#5;Q;W\7K])M!HHM+L-(CVTW4K1#*#%62`CH6Q?7"5)+YTF
M1\DFF""C98IB+Z.?<:BZS<M:H^A9.:NSN;X3K?8!A'U?6LWTN3E:QC*K0+37
M;7'5!\Y4SJXN$)1HLT;/#.&ZQ55"_/!1$Y.$5L=+]R+38S&NP$U#=:IW/]6I
M/59AVMR.$T&XTR;A[AF,RY=Q03]B"LR:Q:]-U.20(H_@%5Q<KHJ$*BO\PP@0
MBR89#9[=<LSIUJO5.+0K5.0C61EZF2PQUH3BUG`>M($YR*338O4WC<2+E]``
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MGEI_0>2_=-I[%JZGW!?ZBW;S]WO3OV;=\YG=V_'?2/W]:>T"W\S_`,-\[^[I
M_1"[#VK/]DFV3]VCOQ_S[3^9(0^=;YK?\RBH'E.[1Z`4)O87_LS<B_Z\;'^W
MTKR!KOW_`-QN8?4;+^&8I'N[I^%%C]8NO;O6818QB(.3E$2F(U<G(8/M`Q6Z
MA@$/X0$.6BVG^KB_:L](*M=W_I7_`+-W@*A9^#33(KBON)R1R@+QYVX@BN5_
M(^I4B-4DUTBB'][^BJ]5'X``_ICY_)S*)RW^56?[)GLPHALU%<RF`_\`DS>$
MK90[T)2%"D>N7:MNG'2$#U6U"P6S2()].P=>>R>7:+G%KRVTO*J\LC^*A'UQ
MKKVRL)!E&+.D%)8C=5FV,9VL@0W/77*7$!-T_<\P83*$8^D:#I]-*N,3;:],
MUM]*52W11DUF,Y6;"SB[!#*O(UV=)=J[;H.$_4)3%`>$4.*O[?R,3G\CA-K[
M&[9HO6@,[M65UO#K+^HB#*'HMGKSRJMX":O\14F.@W-K381[\N#%^_,HR401
M44,N9(O"+JU?;FA;17[O&:]O.K:Y-V+KU*=7JE:Y^/HD))Y[DDV\BW\VC%MJ
MQ68QA.7*P.X&/-(3,@FNX=`R2*!2%]8&(KV6OJJ24NUYTNEZE;<^OETR7-,?
M&680=-LT7'5[,[):+$U,>N6R#E8F6)90MCEG)H."BFHU`H)"BH'K$BM/2?;S
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M!?65,1(K7ZG[?E8TRU[(Y1UO1Z9F'963J<SV.QRNMZDK7-/DJE%PT`"S6PRT
M`_MM'1ME=KS*/GDXMVE]Y-4/`"D<YSF(I.9-A]=R&P;/88.2E'R^UZ<&HSC5
M^#,K.%E"TFGT9.*@TVK=$Z<4E&4QNH`*F44^:H?]+T^``BO7PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+6T_%D?V+&Z?TFX+_I.@^?6/
MY7FE?-^UOG?$5"?HK_4HZF?N\9/^Q\7S&SY]?CAJ[[^O/;O4K/+3^@\E^Z;3
MV+5U/N"_U%NWG[O>G?LV[YS.[M^.^D?OZT]H%OYG_AOG?W=/Z(78>U9_LDVR
M?NT=^/\`GVG\R0A\ZWS6_P"914#RG=H]`*$WL+_V9N1?]>-C_;Z5Y`UW[_[C
M<P^HV7\,Q2/=W3\*+'ZQ=>W>LP;G_P!U>?\`(WG_`#97EHMI_JXOVK/2"K5=
M?Z:3S'>`J%WX-#_Y#>X5^]U"_L<YYE%Y9_*[/]BSV041.9_S.;ZS-X2MD_MH
MS;V?LQ[=E%FT4Y"J/MXU"^R$*Z(59A(63,>O>CSE(>/FJ@&0=A7IYZ$@V*<I
M@1?MT%R>%$2&+S5UBF;H<@]AJ'=YF,7%K(Q%/L\FP<`0A_DOV,*\=,W`D.`D
M.*"Z13`!O@/CX\(L)/43N'/5+J-3NP5XM?;S>M8T6H==:PSI>TTXF9999]FW
M"<BZY#MLAN;C,*I"/:TM990QW3]LZF$VL,D58I#B=,#D64>R7C9H[K7LUUO=
M3@,PU"G9YJ4G$H56X_K]7C.:_49.4KUHB9A]7JVY^G7=I`<6KU@FJBHD)3>L
M@E,)%ARZN=\M!SJK6W6M-T[<M9RC.>A>8[[M%?W6G5NBWXFZ:`O`DJ!,)\5:
MDR<_D]W(:3;*R*R#R%:."-!2>G.=<@$4NXOW/U!J6C.9S.J(:W4^8P>'B96K
M;)]ZX4Y4WZT.ZC"&N&Q2=*@F]+4SZ99J%L1#Q[GTI&;J-A5*X(!2+Q4^\$MH
M<O@=JO$$^SN*==A^RV9/%LFUMC=LNNT!AF+7BU3=VDY9W08M:YTEV[K+HT4E
M'*-3).D$U5%SB11`"+O:_P"XM;PA\NNNA8`-,SOL9C^H[!UYF&&D-;'8)1KF
MV;NM<95?3X%.ML&M,FKUG#(\BR49.Y=NU.0[9<?F@`F(KI=9.X][V?1ZK1-)
MPDF0#J/7B%[,9,];:+'7UW)T-[+0<-*0UU;,(*(1K%LCE;/'."(MUY!LLW<B
M45BJHJ$X19!^$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A%K,_BWEU4?9BU0J2ATRN-GP9!8I!\%52_7=);Y:@?E)\Q$IO\(H<8[D'
ME#W?1*BQTQ11;=0.KJ"!"I(IX!DQ4DR_WI"C2X@?27^#R/,;#GB2>=NK^(U/
M^X+WV[U*UR[`&B,F`V?94'P`@>\`!V*B?<3=@QZ%=Q'8D%0$>O&E?H`(`)OF
M02R7CR/GQX^9Y_N<[/N[MKSZT<.G4-G[0+X<TC3EQG9_^NF]%57[7L<HP_"2
M:F<RA%`DNK'?*1(!0$!335E=60!,_D/B8!;"/D/A\>9'\1)<WSP/<Q46+Q2O
M8ST`H*^PO_9FY%_UXV/]OI7D#W?O_N-S#ZC9?PS%(UW=/PHL?K%U[=ZS!N?_
M`'5Y_P`C>?\`-E>6BVG^KB_:L](*M5U_II/,=X"H7?@T/_D-[A7[W4+^QSGF
M47EG\KL_V+/9!1$YG_,YOK,WA*V6NRW]<7VXOZ1NQW_XT7KG-76*;L_"M;'"
M3%??F5!A.Q,E#/A04^6X^CE&BK%R*"G@P)J@@N;TF$!\&\#X'A%%^6Z8Y/,]
M6:3U'<N+:AGF;U[.82B62/G_`*'0ZM(Y(YAY#/+C#V-%G\E"W5N6@&KI-<6Y
MD5%""51(Q#&*)%7]<PI&-R&W9#;=(TW4F][B[=$VB[:%.QLA<WK:YQ*T-)HL
M%8B$A(""9LF*OI9-6;!)LW$!-\L3&,)B*RMH]OO`+C6:'49]I:7D)0^M,GU-
M!!.Q'9N+9CS]G4B,(^V/&K-%P\G*O,4IC+1+Y$4%6,F"BI`\*&*)%9CLITBU
M:ZX;$4*`V'0-W?1.O8]>)&)V2\5^FRKNC9B]D'+BKT>ZT;-V[.LVZ84=HF<2
MLE&R1Y!)`R*YR"H"Q"*J^OW3RV%K]%>]CI5U+/\`)M4TRW8E0DK>A=6>?YSH
M68O,J7S.Z6_]4*F&A(I1$_*NB'*Q;`U,[30!5P1#UG(NXI_MQ9#5FL/"R%]V
M.[U"B9GH>18O3KG;8N0A,0H^GP"M4L[.B+,:Y&S#^42JJOW5'OIMU+.H^,*#
M=(X$$WJ(K_TGK/GM"NF7WN$7L1YK),"1ZWU<CV43<,5,]0D*K(D7E&Y6:0N[
M$+BGL_+D#)E](J!Z/TO@12)X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$6!#\3#U]NW8GV=^SD#GT6[G;+G:E&VG[ECVZCI])0.8V
MN/G;>#5JB!E7"L=4P>O/04#&,5L(``CXYK&>"9DH'%PNKPG%KJ@MHX;P.+B[
M0$H"#7`[OR[*K"_[5?9'/NQW2O$5:?,,'5KS//ZQF^C5-!RD>;K-AJ$6C#_-
M>Q9?#I.+FVC--VR<>D4E$U1*!Q.0X!C\=[/E?J'E]SISV_SIC8\GS.[?>6]S
M(XQV\K)G%\C/6-%#.TFC6UQ()V8J37DWJO+]3:)RZVRV6!F<6D#8GQR$4X&T
M&RNT?)[2J#]Y#L=G.#]&MKJ5MF(\EWVRF2>8T*FG<I!.S+BQ&19RTR2.`_U1
M86O18JKK.#%!'YGRT_(F4*`]KW-N66=Z_P"<^0:ER2"=NC<HS!EU<W;^)S&F
M"KV1M>X"OK7T8`*FA)V`KKN>NLLKR/15[ELDL,F9W,7JA&P@@AYH[#H`Q68W
MVX.ENL17X;NM=4IF+<0VN;!TTWD\77I!L9J\C)G>V=_M=(A)%JL`*-GIV-M8
M$<D.`&264.40`2\GO((N>"O"P.>-NPEXX"3V?`2HVHRXMI+7BJ>VF('O"G8%
MKL>P'M=5==7YCJC,JDK.YX1H]_)9,]F3?=]F<1<]/N'R\BWB78D=KFA)SZF/
M?)$()VJZ)/F`4#@(PV?_`-".6>>Y5S0;S*O8R=+9E:P1"9M6PP26[>!_KY&U
MX&D`4=OK0;"K\.[;K#*I]%G3,LS(<TM9GOC:X@<8>XNH>HDDGK67[LGO6=]8
M<6OFRZI.-*_7*O7Y1=HD]630>V.=.S72AJO`M3G(M)3,V_$B*220&$`$QS>D
MI3"%FG*GE]J+FSK"RT]I6V?-`^\B;)/"721Q1\8XY'O(P:QH+B3N"KIJ_4<&
ME,BN,SS&XM2!`]S6\0JX\)HUO23L"X_X/3$[Y3>A6[;Q;XAQ`Q'9OLM-7&AM
M7#=5#[RJE.@V=;<V!B"Q`,K&/;0>0:(*!Y*H#$QBB("`\R51:NMHV0,<2UEO
M`UHZ',`#SVN&WJ44UY<"[O;B?R6OF>YM-P<ZO@-.Q9Z-$=.-D[P=8FM"824K
M6^L!]NN6PW7[M?MZI"S]USI7,:;G,=.N$4HZ=NL@YL;Q^\:,S+FC&4<(NC(F
M71(IRUQ5D'X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1<-RW9OD5V3Q!!VV<(JMW35PD59!P@N0Z*Z"Z*A
M3)K(K)',4Y#`)3%$0$!`>;2!0MW$46E!4'>%J1]OOPG6+:!KT_N_0GL[I/0F
MX6=ZZD)REU)@^L&:E?/G2KQZI5$86TTVT4^.=.3_`##1H.WL>D/Z*"2!``@=
M;FV1Y)G^7QY5G]G:7V6Q.JR.XACG:T]-)6NJ>@FI%33:N=99C?Y;*9K":6&4
M[V.+?`54/1_\*?@6*[-7>QO=;L+H7?+4ZA(LIFKP%\8+PV8,YF+<`[C)"QQ,
MO8+C8;N6-=E!9!F[?(QH*`'SFRP!XYNRK)\HR*R^S<DM;>SL,?U<$;(H\=M&
M,#6@]8%4O<QO\QE]??S233#>YQ)^%;8!$2E3*GZ0`H%`H%*`%`A0']$A0)X`
MH$^P`#X!XYV``#B[>:?!L7"/C&I6M7[F'X:/K1WDV"2[0X7J=WZ6=H)EVK+6
MB^9DT"3J%\GURE*K9+#4FTO7)"(MCH"^',E%2+07@B*CA%983*#Q+K+\OO\`
M+?L;,((;G*275AFC9+&>(U<',D#@X$XT<"!N`7(M;NZL9_I-G(^*<?*:2#\"
M@UC/X11C8]#KMR]PGO\`;-VXJU3?I.X_,(MI-U.)F4DO!OH)RTV>ZW2;813D
M2@5RE%I,G2R8B!72?VCU^2:8TUI@/;IS+[&P;(:N%O!%"'><(VM!]U<W,\\S
MC.2W[4N9I^`4'&XD#L&Q;A-#H=)RRE53.,_JT)2:+2H*+JE/J-=8HQT%7Z]$
M-$F,;$14>V(1%NS9M4"D*4`\CX$P^1$1'O*#BX_E+J:"O%O`59BDF/CR7^]\
M>/B;X>!\AX^/Y!YJM5].$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$42>Q>4;Q/V.@ZYUHOU-JFK9\TLU=?
MU'5X^P2>0ZO0[<>(=2=8MOZJ.4;+5YN%F8%F_AYQ@F[69J%705;.6[I0A2*W
M",S[I7RD_GYQT"^=Z"_-^5M?8GY7S/'Z?R_7@/K]'J^SS\?'"+Z??/NB_P#V
MXZ#?E_\`K7V'_-\/_H#^?A%:B5[R=E*%9V/7[1NI<:\[;7;Y3W#ZKG6OI2F$
MZ[46@.#7J_N=8L=(@Y[.(3($T4C6-C(0+B2\R4:6/(^,^(5(BN@WG?=+6024
M7R_H0T54(!U&IMQ[!N#-C#\?DF<)]?RIK&3^P3E``,/Q``X1??[Y]T7_`.W'
M0;_^:^P__P#0/"+L,CROMQ:=AA=B[87'&HIAGL#8H;,,9Z[J7R1J*4Y;?IV4
MYHNA7>_M*],6N?:UYL,?%1R$.R81R;MTL8[A91,R1%.GA$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5ENQ^C3
M6/=?=PUBNLF$G/YED>BW^$CI4K@T6_EZA4I6?CF<B5HLW=&9.73`I%034(<2
M"/@P#\>$4&J7[E.>Z/IG2[/\]T#';DKN%&T2W[DA7[",E)9L6E8RVT(AV:;>
M0,6*8_K"=5LN9^50Q4$_`>#@)N$5[L[[[XYI[HK>N5[8$"SF<V36\L6E<QEV
MP;MGE4=,6DQ8,::(+.I*V&(>69*(LE4&<@Y;/F[A)`R"@*<(O:N]\<AE["A3
M;#`ZGFMU'5L[QZ2J6BT)6%F(&U:Y7YNR9>]FE&,G*Q+:LWIK7G31@^(Y5+]Y
MI_2*@FN($X15'`=V,*L>BW+-VLY+QTE26&NR;^>G:^[BJ;+M,%EX*!U[]6K.
MLH+.;5HTI8FR;TJ8?H>%#!Y*F80(J5V;ME#U;K10^Q^<TI2X6?87N75'K]7K
MFS5J;N4L^_ST%7:,2R+JH.I6L5U4LBA)2@)%%P9BV$"E^;Z``BLIO&\=O^K-
M!I-PV2P8W=F4]V,Z^T15SB&5:$2R/*Q?K,^A[Y3VM#F[3>'<M,BE]*G#2+%V
M1==10X*LT?2!A(I"UCNI2[M096[4W+=^L\Q7-'FLHMV31>7K!JM*N]?C4IB3
MC[?!O99G#03#[H>-72#Y61^C=)O$`14.=4I.$5"AWISJ4<9AHL+;SM\=M77/
ML7N\O7Y/-;*&@+Q>"25486U4KX95JSK$I2G4B[9/H9RQ7<OG@@""J94#^LB^
M<;[EO75U6]`MDTSUFC0]!RVJ[<G^OV66"KOK_E%XF$JU5;EG,:\]3ZP1TO9G
M*,>4BI&KE-RX2^:D1-4B@D4R<TOA]'JZ%F4I=\S]15V]9*UC28!*N6EDJQ<'
M0.JNQ:R$JP79.@`#MW#=RLBLF/DIA^(`17`X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X16CWS-5MEP_8,A;RQ8%;4
MLPO>=I3BC0[].&4N=8DZ\2449$6;F=DCQD/FBF"A/F>CT^H//GA%&>Q=)HFQ
M2O4A=S/L&D9URSC2\ZM#:,@$V+[06&D8DECSITU?H+`>#48E(=Z`'*X\B8"A
M\2^1(HYY/[:UOS#)+1D,-<,2I\@TQ&P8IF/87,<;EZKV'9M)%!BPB;+;K0>[
M.(U!^2+C$D99.'2:'E%1%<JS4Q2%`B\U7VS9]A0NTL+(7C.Z=<-_C,(E*3(9
M/0[%&5O&=/Z\*2TK1;Y'(7&Y6>Q6I\I:UF<DZ.X>(JKBBJB)@(H`\(J:[,=#
M+,OUMZ?8+G$E:I:^UW6F]-T_6(&*30-(YIM\=:?]<BS6_P!;D1AH;3XN2?J)
M@515=*8<,"$$WH]8$603LGUJAM]P]'*(F>=9C)5><SZYY1;H.):22N;WG)[#
M%67/IEK`NE4&4I&1+^&21<L3J)D<L3JH@<GK`P$5G9OKGV6UYE1`WK9,K=.\
M\W3$->@8S+,MGZW"F2R:=>S4R20>6:Z6.8=S5W!RFF`%.FSC"H?H)K&.)@(K
M?Z-T-O5@E;W-U;3ZRJA>.UDAV+G,ZO%;M3K,[?!R6.P.5(T30&%0MU:GIT*Q
M)PQ+#'G*Z(S4D$TBN&YR%`P$5(U7VSY:MY/0<Q-K$6N-(ZO]SNNOWJSI"T:S
M>K=L+-$V-K9V<0$ZZ&*848T<9'Z`5UC.2F#PL3Q\2*],_P!-K$XG65JB+1GT
MV\C>FM>ZI&JFG9Z[N-!LI8F[0MFE9>UP:,[%N'\#8HN+58G9IJE50%P"P'.*
M8$,17@Z?X#/];<C5SJP7!"TK+W2VVV/C8=O.,Z1G4/9I`'T?F6;,K--V.P,J
M!42>4V"3MZLH3YAP*":?H23(I3\(G")PB<(G")PB<(G")PB<(G")PB<(G")P
/B<(G")PB<(G")PB<(O_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>58
<FILENAME>g5754314th.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754314th.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@#2`(D`P$1``(1`0,1`?_$`*L``0`"`P$!`0``````
M```````&!P($!0$#"`$!`````````````````````!```0,#`@,"!P01#`X(
M!`4%`0(#!``1!1(&(3$'01-182(R%!4(<8$C%I&QT4)2TC.3L],D=)2T5387
MH<%RDK)3@S14A#5U8H*BPD-SHT1D)296-QACPZ341665)^'$A4?PXN2E1BC%
M=CAF$0$`````````````````````_]H`#`,!``(1`Q$`/P#]4DV!/@H`-Q>@
M4"@4"@4"@4"@4"@4"@4"@4'ESX*!<^"@:CX*!J/@H%SX*#T$GLH/"3X*!J5]
M#0>:U_0?JB@:U_0?JB@:UW\S]44#4OZ#]44'@6OZ"WOB@]UK^@_5%!YK78^0
M;]@N*`''#S;(]\4#6O\`>S\D4#6Y;ZF?DB@:U_0'Y(H&M?'R#PY<1QH/=:_H
M#\D4`*5]`?DB@!2OH;>^*!J5]"?DB@%:_H#\D4#4KZ`_)%`UJM?0?<N*!K5]
M`?DCYM!X%J/SA'OCYM`UJMYA]SA\V@=XK][5\D?-H'>*_>U?J?-H`6KZ`_J?
M-H!<5?S%?J?-H'>*_>U?W/S:!WA^@5^I\V@]+A'SA/R/FT'G>*_>U?W/S:!W
MA^@5^I\V@=Z?WM7ZGS:!WBOWM1_:_-H`=5^]J'R/FT#O#]`KW>'S:!WAL3H5
MP]SYM!Z'/[%0^10.\Y^2KA0>=[_8*^10.]_L%?(H/=?"^DT#O.%]*O<M0.\_
ML5?(H-'U_B_0/3^]/HWI'H>K2J_?>D>BZ+6O]6\G]7E0;ZA=)'BH">0H/:#C
M[GFS8T>$B(]W#DN:Q&6\$I4I*'"=12%A2;\.T&@Q1A,VF]]PRE\+#4S#M?P^
M2PF@]&'S@2!Z^D&U[J4Q%N>/B;`_4H!P^>[,\\/YO&^DH,3AMPVX;@=OX?1H
MWTE!ZG#[@'//O'G_`)O&']Y0<O=2=QXC;>2RK.=<4[!CN/H2N-'*24))\H!`
M)'N$4'7]59HI3;./7[3W$;C_`).@#$YNXOG7B+<1W$;G];H,58C/$^3GG@/O
M>,>W]A0!A\]VYYX_S>-])0>*P^?*;)S[R3X?1XQ_O*#PX;<-T_[0.V'G#T:-
MQ_N*!ZFW#;\X';_>T;Z2@Q]2[DM^<3M_#Z+&^EH!PNY.S<3H_FL;Z2@#"[DN
M+[B=(',>BQN/]S0>>I-R_P"\;OX+&^EH'J3<O^\;OX+&^EH/3A-RWX;B=M]Z
MQOI:!ZEW)?\`.)VWWK&^EH`PNY+&^XG2>R\6-]+0<V<C<\3,XO'C/*6G)%\*
M6J-'"D!EOO`4V`[>!O?A0=-.'W,%D^ORI!Y!41FX]PBWRJ#).*W*$D*S@*N-
ME>B-#F#_`&78:#T8S<@))S23>W#T1NP'[;MH/?5FY./^N4=EON1'O_/T'GJS
M<M_Z:1:W\D1S_;T'GJS<]S?-HMV#T-'T]!X<9NB_#-M@>.&@_P#64'IQFZ.S
M-H'\S1]/0>'%[IXVSC8\'W&CA_E*#'U7NS\NM<_Y$GE]=H'JK=OY>:_`4_;:
M#).,W6``<XR;'B?0@+CZ[08G%[MMPSK-[<"8(/;_`(Z@YZ9&[3N=_"^LXX;3
M"3-3(]$.L%QU;6BW?6LG1>]!T!B]V_EUD\1_F*?MM![ZLW;Q_P!>,\3<?<(X
M>+ZM0$XS=HO?.,*!M:\$</#R>'.@*QF[KDISC`O?@J#>U^7)X<J#/T#=*0;Y
MB.;GF87$>(6?'ZM`$/<Z$#O,O%)`L5>A*%SX_NCPT'OHNY>"3EHO>$7(]#5Q
M\8'I%!Z(6Z?RK%_`E?\`>*#Q4+=5SIRL0#L!A+)_&!08F#N_LR\+Q?<#G_>J
M#ST'>'Y7A?\`I[G_`'N@"%O"_P#2\+W/0'/^]T'GH.\[6];P;\>/J]WWO\[H
M,A#W?>QRT'LM]P.7X>=_G7;0!"W=Y5\M")(\G[@<X&_WUQH/4PMWCSLK"5RL
M/0'!R/WU0<_'Y+=4O.97&&5`1ZL$<AP17CK](;4NQ!D"VFWA-!IL[S+VZU[4
M9SV.7GV4%;T'T&2"`$I6?+[_`$7T+!M>@Z&.F[JG3<K&$N"V,=*3&"O175%8
M5&:>O;TD6XO6]Z@WVX^ZQ;O)T$CM*8CP/XS0<[+S-WP5P$(DX]PS92(I)BOC
M2%(6O5PD\;:.5!M^C[V_EV,_`Y'_`'F@^A:W?8VD8\FPTDL/#CVW^&-!Z4;N
MMP>Q]_&T];[)08Z-X_ON.^M/_;*#PHWGJ%G<;I^>^#?O^[H/$HWMQU.XWQ6;
M?^GH-=&5W)$S>,@9-,-QK(EY(5&#J5(++1<OY94"#:U!R^[_`-C+:O\`QS5_
M^^WM0397FGW*#T<J!0<'=OFX?^M(O[HT'>H*;W`YU29W-++'4/!XW%*EK]'A
MRC'+S3.JZ6E!38*E`<"-7OT&H])ZJB"XXYU(V^M14T(JF^Y0DN>D)2E*UA"O
M)6`I)X<^'C`9P)G4EQ631*ZG8%#Z>X[EQD1W6V4J6O4%(4ENQ5;2FZB>%!:&
MS?C$<*%[@FQ)\];SJA(QX(C]WK(0E-P#=(%CXZ##?Z0K96;2>1B.@^X4^_0=
M^@4"@4"@Q#K9%PM)`YFXH/2M`-B0#SXF@P1)C...--NH6ZR0EY"5`J05#4`H
M#B"4F_&@KO?D?J[D<B)&P\S`8Q"6DH4ASNUK5(0XXEVRRVZ!;R4D>'P6-!\\
M5C.MZ-O0&9N5ANYDY9M>1DV;4@8L(!4AL):;&LJY\+^`T$:]5>T^DN+7G,>E
M`N4-WCE2AJ'!)+``.GC<F@ZV!PW7\OI5F<U'0R@-J[MHQE%9](05I5]S#2GT
M<K'`WUB][&@Y+,/VF')#Z$9G&D-CRF"N.MQ`=-DW*6!I4$>6DD$>[0;<+%^T
M._`F/.;DQ[CS8M"3'$<I<>#R4.-J66+)2AL+X<]=!+.FT/JI'>F_'B:Q+:+;
M0AECNC\)J67#\&VT0-)0#JOQ!(X4'5SU_CIM;CP^[[C^`%!):!0*!0*!0>*6
MA)2%*"2HZ4W-KGG8?(H/"ZT'0T5I#JDE26[C44@@$@<["XH,J!>@Q<<;:;4X
MXH(;0"I:U&R0!Q))/("@+=:0@+6M*4$@!1(`NH@)X^,GA094$;:*?TD21\\,
M,Q\@RGOF4$DH%!2'4KIGU`SF[\S/Q3A&&R*,9$D1>^2COXZ'-3ZD74-"V%(2
MH<K@FU!\(?1_<[FT-T*SC)RNY-!Q^V%//A2D1HP*6'$*U)2V5ZM7$W%N-!L8
M+:75;(R,^-TL=\_(V\]C(BGG&$Q#(6X5(0UZ,0YHM;RUC5?MY4'&A=.^H;K[
M;^X,/(S^/B!F,_B94J,RN26XBF&WDJ:<[I267#P*[+XZO.%!]<1TFWZS+@1<
MK#3+R?I41_XV"65&+CV4!#V/*%$.+\@%`"1I5JN30?7,;"ZBPL]D,/MW'N,;
M3F9>%,;;:5&[D,,%@K.M;H?;LII1TA''WZ#Z=0NF^^,EN+)O1<.G*O3IQD0L
MJ[+"&6H0A*93#6V5H6@I>.L%";$V-Z#A,]/.L$G<#,]Z-,24+BI3,E/1E+26
M#$1WCC;+VEP)2RH\#=8''B:"7[<QW47#;TA#(825D(C61RSDC*L.1T,N(R;K
M7=O!E3Q4A"`T5%)XB_"]!'-X=-.H<S,[A5CHDI4R3+E26LH)*$-.XUU"@F$V
MO7WBEK*P.[6D(1IX'C08R]H=7,;,SJ'X<[,-R,?+Q,";%?:NI#D=AJ*ZM"G4
M$%(0=:@+ZM5!K9_9'4S+YA62B8:<PMW&H0A<A]"7FEQX*XRVTK;>.@..A*PU
MI(7?45)XB@^Z-D[_`(ZWGI."GO0Y""K"0S($[U<>^'I*'F52(B5&1YZ2'%:!
MP]P+EZ7X_,8[86'AYEM;63::5Z2TZK4M)4XI023J7R21\\;4%,>T"_.C9J0[
M$DR(FN6RTZIAY;/>%4'X-OX,$F]E#B+<>R@[>W([S?M+9-10IU/HEE*5<EK5
M$8(NM(3>^G2$JY<Z"S8&6Q>)D;HG924S!A-Y)`7)D.);0"8,4`%2B`./*@[V
M+R<+*XZ-DH#O?0IC:7H[MBG4A8NDV4`>(H-//?QG#<+_`'>GMM_@'J#K4"@^
M$V?!@1E2ITEJ)&1;6^^M+;8N;"ZE$`4')RV^]FXC&,Y3(9F(SCY!*8TCO4K2
MZ4^<&]!5KMVZ:#<P.XL%GX(GX6<SD(944=\PH*`4.:5=J3QY&@Z-!'<Z"=V[
M8\`7,)_!B/UZ#C:GOB'KM\+ZYU:;'GZ\O:W.@G2_-/N&@]'*@4'`W>2!AK"X
M.5B@GP"ZN-!V9DA4>&_(2VIY3+:W`RCSEE*2=*?&;6H/SJ](P.Y=QM2,MTER
MPGY"4RN3*>>DI2GOR$%2K(2D(`LHIX`]M!],?MG:SS&:1&Z39)GT5M%@N0^A
MV0"^D*2PI8X*2E5R$JXIN+VH,,6SA(D&;%A]'<SZ'F$-IEQUNN*2M,5P+2/+
M\I/E\3RU>,4%Q=+'8SFS8OHN&EX",EQY+6,GK<6\V`X>-W25!*C<@4'0WU^9
M^7^]E_*H.[0*"'9CK!TWPV3?QF3S;<:=&5H>94T^=*@+GRDME)]XT'TC=5^G
M\G&2\FQEDK@P7&V93O<OC2X[<H0$EL*42$D^2#8<Z#63UCZ;R(*9;.7[V&\\
MJ()#4>0I(?T!8;-FS92DJ\FXX]E!2KFPNAFM9.]Y[(;6@/L%E3:E*)4!9!82
M23W:M5DGE0=K=4/H3N":W.7O*;#93']';;:,A:-*E.`++KS3B^[*W"+:M'8*
M#X9W:?1C1'DSM[S6&Y,>-Z.6TDE;8CI2EQ6EE2B7!922?-O84&U-V_T:1@H>
M%>W9(BM;>>E!]:67&G>_DN(*M0#0T]VHI*0GDJRC02;I_N;I;LQC(XIO=R\F
M\M]<A:Y275+0VPR$:$%*++2VA@^4F@@^6V]T0G,M*?W_`"U(:2VD>1W@0.[0
ME.H!@E`M9/E?L>=Z#M[AQ'1O=*DYYG><J%CX1$)WNW7M(=?#SP&IY)6D+&OR
M4^1PT@=E!P7L#T-,1QEO?LN.P&F6Y#80O62SH:)<ULERY+=TI^<Y@6H.^TUT
M.C;&=VH-RH><:UR&<F6%.OQURN[47&D(;T@GR/U^-Z#J;!RNUMG[3RV7PNX'
M]V8]E<5A4?NT,+:=6K0/*<#?G!RYOV#AQH)]G/*WGM9RX`2F>HW/A81RH.>O
MK;TJ2HI.XHVH$BP2Z3<>"R.-!]7NL?3)F(U+=S["(SX*FG"EVQ"5*0?G/HD*
M`\-C0?5[JOL!F:["=RH3*:"%*;[E\DH=2A3:DD-D*2OO4A)',FW.@Q_2]TT[
ME+PW#%*%Z=-BHDE2BE(T@7NHI-A:]!%=]Y'IMU(9QNWFMVB',5)#L,1@=;RU
M)4V$#6D7XD\CS%C00AOIETSBR96)7U!FKR4M);::25:@6EZG-2$?5;!I0(/+
MG0?9C:?2V)C5.,]1924R9#1;F.J*U(5&9*'`G4GR3I=N%?.CAQ%!A$V+TNQ4
M<OR-_K/KN&$0IBDA)2TN0CX1IP>8-4?1S%C>@ZV!@;!PC>58=ZC/284O'/8^
M.Q(N!&].;"TNLJ)\KX)A/=@>#ASH-!.U>F^=W3!4UU*D29<F0EQB&AS0XHZB
M2VAQ)26UJ6+CM!Y#E0:D#9W2V&L!SJ2\ZE2'];3RK,."0TEI.E)-CI+B2M-S
MJ'`@"@R3M7ILK*Q<I*ZF+DLQY;(7'7]36N.H/);`"K`#1Y)L=/C-!VL+AMI.
M=0S)PG4-)E/Y!3S6"[LK2-*U+5'1J<3X%`&W+LH+*?R6/@]09"ILUB*AS$QP
MA+[B&]1$E_BDJ(O:@ZYW5M@"YS$(#PF2U]-0/C5M>Q/KB%8<_NEKZ:@?&K;'
MY8A?A+7TU![\:=L_E>%^$-?34#XT[8_*\+\(:^FH//C3MC\KPOPEKZ:@]^-.
MV#RR\+\(:^FH`W1MH\LM"-^7W0U]-0>_&?;>G5ZVAZ3Q!](:MPX?14&0W%M\
MBXR<0@\CW[?TU!FG-X52=2<A&*?H@\V1\N@T<]F$'"SAB)T?UIW*_0_AF1\+
MI\CBO6CG]$+4%3,;HZ\,0F'WDQY4A\.=Y$U8X%C0HI;U*#J`HN)(5P_4H.U/
MWIU/7MUD1<:&LTM^9WI2]C2E+-E&'YSZDW\I`5Y/SI]\(W&W3[1H#X6W!60P
MGNU.NX\?#:D%10$.#5PU#2JP\=[4%K;'SF3<VKCU[KDQ6=P*0KT]MMUG2%:U
M:?,4I%]&F]CSH(%O;9.,WWG\S$<SS6.CQ7HCQ3Y+S;Q5$+8NDN-B[=R4JXV-
M!]L+A,Q$ZT9#.B:&MNNH"5J,IE++X$1IIH!E"M2EH6A6I2AX+4&IU=C,Y3:&
M<1%F1V9"MQ13`DO/H9:[\0V`/A572.&J@VLENS<NQME[#QF*C1)C\]IJ"ZNZ
MY#9=2VBW=J94A!2;J.K4>7!)XV"R<[_'<']_\?P61XZ"L/:)WKN+;_J*%BYS
MD)C*J>0]Z.I#;REH4T$#O%74E%EJOHTF]O*H+F'(4%!]=DX^=U.VGB-UR7(>
MRW65N.NI64-E_4L'6JUDV^#!5V)5S%!K[=Z!8B)U$EJR45<_8#40R\3)=?26
M"MP(*DN%*TJLD:B#:RK`F@V>D!P$/K7N?';.>[S:JH*7"AM:EL!]"VTW;42=
M0"E+"5<>VW"@ON@C^;(&[-MW[53`/=]'H(]?_P!M_P#ZM_\`WR@L!=M"K\K&
M@]'(4"@C>]7N[.`'8YEXR5&]K`)<5?\`N:"#;\WUM'<,5E6`ZC)V[(QZE+D/
ML!;C:T*TI"7$>0."RFQ^;01'(Y_#)928_6Z6'77`&K,I=0E1-R5AM*5!'NFU
M!MNSH$^=/>QO6AQM]T+EH92VCN4:&[N%0)MH2E/)-K>[0:TC-R5MGN^MD9"T
MLM!8[I*OA&T@.J201P6HWY$T%R].I:I6T8+BLZWN1Q/>(7F&DA"7BEQ7,`GB
MGS3[E!]]]?F?E_O9?RJ#NT"@C.2Z9=/LG,D39^`A29<I8<D/K:!6M0(-RKWN
M/AH/6>FFPF<5)Q36#BHQ\Q:'9+`18+6V+(63?5J2.1O0>,]--ALXU.-9PL=N
M"B0S,2P@%(](CC2TZ2#<J2!S-!QMQ]%]I9B:B8TV(#P;++I;8CO:TE>L7,A#
MNDA7T-J#D*]GC:ZD*1Z6H)43<>B0?GA8_P"`Y=H\!XCC09O]`<"^VPV]D''A
M&0AE@N1(*]+320EM`)8O9*1VGQ\Z!+]G[;,N0Y)?E+7(>677WE1HA4XXHA2E
M*`:".)'8F@]=Z`[?=F/S')SAE2`X'7A%A))[X%+HLED)LL*/#30?(^SMM,M]
MV)*DH"=`2(L+S;DV)[G4>*KW)OX.0H/K_P`O^VQ&,5N6I$8K#JF!$A*07`-.
MJRF5&^GAS\/A-!\S[/6VB"DRSH("5(,2&JZ1:P*E-%1Y<[WH/H]T#PDAT.R,
MBMU2>[M>'``LTE"$#R64G@AH)%CR]^X<'?'3N'LO8>4DQ,@XN(\]%,J"F/$C
MH?4'4-M=XMEI+@#9.H:2+GGSH)]*B2(VYMGL29;D]Y",AKE/);0M=V4GRDM)
M;0+`VX)H,7.B_2U:RM6W(FLJ4LJ`6#=1N>2A_P#"@^KG2/ILZQ%8<P$93,)*
MD1FR%Z4I4I2R"-7E>4XHC5>U^%!OJZ?[.5/&0.+:,P1V(G?77?N(JT.,HMJM
M9"VTGWJ#E)Z+]+TMAM.WV$I"BL64Z"%J(.H$+O<:>![.-N9H/O"Z2].H.1BY
M*)A&69L%P/1'DJ=NVL<BD%=K7XVM:_'G09)Z4]/4Y0Y485H9!1<4J1J<"BI_
M6'%>=;4KO%7//Y`H-:/T7Z91]7<X-L)6VME:"Z^I);<`2L:5.$<0+4&S.Z4]
M/I^,@XN5AFEP,:VMJ$P%NI#:'%:U"Z5@JNKRO*OQXT&F]T3Z7O/%YS!-J<*&
MFPKO7P0ED)2WILYY)`0!<<:#.-T7Z91I?ID?!M-R@2I+R7'@I*BDHU)\O@KC
M>X[>//C0>?H5Z6W!.WXY`6%I05.E"5#Z%!7I2#V@#CPOR%!G&Z-],XS2VVL"
MP$K=+YNIPD+*"WY)*KI&E1%APH/MB^D_3O%S43H&#88EM.I?:=!<44.()4DI
MU*(3I*C8#A0?=42')W_)3)CMOZ,5&4CO$!>D^DO\KWM0=L8?$"UH,?R?-^"1
MPMX.%`]38BY5Z#'U'@3W2+FWO4'@PN'!N($>Y%B>Z1R)OX*#Q6#PJO.Q\97;
MQ9;/'Y%`5@\(HW5CXQ(%@2RV>`]Z@Q]08+\G1?K+?TM!X-N;>%K8N)PY?`-<
M/[F@]]08+\FQ?K+?TM!B=M[=4K4<5#*O"6&K_N:#SXL;;_),/\':^EH'Q9VV
M/_"8?X.U]+0>?%?;-[^J(5_#Z.UV_P!K08':.T^).%@7-[WC,\;\_G:!\4-I
MVMZE@6O>WHK/,"U_-\%`^*&TOR)`X<ON5GZ6@?%#:?Y%@?@K/TM!6N:W/TOV
MEO/+8W-XEGO9*6'XJ6X33B`A$<%0N0`DD@\*#W$;HV[D^I;6V6=M8P8N3'3)
MCR%1&P\4+B-RDJ)\WFX4E.GA;G0</K=&A8_8^5;BQ4-QV=S1E(CM(T-"^/:*
MKI;TD#B?-MQH.+U$FL(Z<=,&Y4$377&V5IENN.)4A#88*T:4:4J#R;`WXI[.
M-!?6X?Z1V[_61_$I5!5/M&[DS6"RNV9.,=TJ4)*5LJ;:=;45+8`U)>0X.'BL
M?'07@@J*1J%E6XCP&@X>\-K[1W!B^XW1$8DP6"5AR0>[[HD6*DN@I*.'@-!7
M>[^O?3'"8EW!8W7G`ECT,189(8#>GN]!D*X6">U&J@U/9^A;G9F3'?BPUMG:
MKL9/HS92LR7Y`6-*W'7U&0L!&KFD)\`H+LH.!F03NO;O@!F'G_T(H(WP_1IS
M%O6O/L_IR@L)SS%>X:#T<A0*".;Q!+^W0+_TNQR_Q+U!QMX[4P^%VL_(VWLV
M!E\BPILQL:66PE1+HU*XCYT$J\=!78S.]E,-2CTA@)CA"/24F(CO>14Z4(MJ
MM9-D@B]Z#?R<K*JQ>-R>(Z71).1?1)1/C+B)95'TN*:[I0THU=ZRJ_:#01N5
MEMTO-NPQT?A,O1DH?<4F`'$!(40L`$-A14UP&E1(/'LH+KZ9N-KVFSW6"^+;
M2'Y*$8C3H+82^L!1'*Z_.X<./#A0;F_#;9V7X7^YE\!0=Z@T<_&DRL'D8L75
MZ4_&>;8T.%A6M;9";.@++9N?.L;<Z"EATQSLK;FXG6,)(Q95$CIP6(>FEV0F
M>VDIDRDN(=+:>]N!Q5Y5M1`O02GXMY7;LW>#F(Q4N1C)N.AQ\;$8>"U*DJ#Z
M7EH#[J=.GO$%9O[ES05O+V7U>E0Q*CPY\=#<;#8V=C'7D%R0F&@=\^T4/I'!
MQKC=:2I*S0(_3CJ=E<@J.AF9AX,IQ;KDC5Z,$AJ.DH^"$J5I4M]M*>*SVGA0
M:N&Z>=5^ZC1UXV7&R2TRU3)G>(:)4ZP\$`RQ+="M2EI%NY%CV\*#I?HYZH(9
M7D=N#(88*,>`,?(?;UJ1(;+4^5W7>OM-)#FE0L=7`J%N%!ZKI3U4CRV8T'(S
MO5C3F4D8[7)4%QI+"B(:G%%9UHD):;*;W`)5<>$-/)],.LDN/.D.RYYGR,<G
M*.AN4$Z\DIY:1#3H6A"=$=9OI`3>UJ"2=1]I=2Y>1<DXJ0XS#=PT#&O,.20V
ME]UUY0?0WJ6G2^BR5A7:+CCRH.')V%U!E.MPG<U)=BP,DWB(KR)C=V\.I#RW
M9;A0I%U=VI('>77=)[*#X8[`=3!W!8=DA[TTG-S/6#7=3(K,II<<Q@EUPI6V
MVE3CBK)L@\;\J#*;M;>;C3:,5$E8S&ITMY3'3<N'%OSD,2`J:7T.^2T2I"2H
M:=2K'3PH/OE6]XIZ8[L=W,N0N3Z7AV&5RBTE1[@LH7\$TZ^A/E<2=7E^=:@N
MO+`C>&V0>8;G7^M-T$$WWM'/Y;>JS%QV15)D/P3"SJ9Q1!CP46$YA33:F5MZ
MTZO)LLK)OJ%!JP^GV;@99<N-&G),/=<;T$F5(6E.&TMEPZ5NJ2MO4I6JXOSH
M-3=#747,;GS,;$X_,8QG)9/&#'Y)1"8[+<!*T/NJ"7%%+;B]*K:?+'/P4$-R
M6W.K3\9*'<-E?6_I,A[(RV%O^6I:W2.X=3+#7=64@)1W(/#SJ#=^)G5+'%QO
M)HRF6,N`S(96@RI"&)4@E<ADAF5%5K18`*4I0'@XT'TQFP.ID]<>)+3F8.8F
M)B`9=4E7H\6"EBS[2W`]J*RO_!%NX5QU4"1M?K_*2<T[*G>N%0I[3L4N)2R$
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M5(>8P4"8C)#&OS,=)E!U2Y`&B/>2I<DO:F@5FRV"@C@"+7XA<C*1\?9BK&_J
MJ*+]EO2)%!WZ!0<A>[]KHS(PB\I'3ERK2()<`=*M'>6TG^P\KW*#X(W[LM8Q
MQ3FX9&6*DXP]\BSZD+[M0;-_*(7Y/NT&$GJ'L:*^W'DYV$S(=6IM#*WD)65H
M=+*DZ2;W#B2GW:#9E;QVI$1*7*RT5E,)\199<=2GNGU)UI;7<\%%/$#MH,<=
MO7:62;:<@9>+*0_(]$94TZE6J1W9=[H6/%?=@JMX*#6D]1]A1FHSK^?@H:F)
M4Y%67T6<0A9;4I!!X@+24^[0?6#O[94_(QL;"S<.3/EM]]&CMO)4MQ%B;I`/
M'@DFW.U!E$WSLZ9F#AHN9AO98*6WZ$AY!=UM7UIT@WNG2;T$!ZA.[:WG)C(Q
M/49O"+Q[+K\IF)(24+9N"IQ6AUJQ0E)YD\.R@C4;:.,QDF2S(ZNA<A##T53+
M\H@I6\`$J4/2KW3QY=G@/&@V(>T,!\7<K#>ZGHG2Y:F7($Y4PD0I#+BSWC*?
M22KBTZ$D%7CH-K,[!3`RR(;?4IS$R(\=<F7$?D.+<4P"@I<6EV3P0E;?E$\P
M2*#0E]/U1IDK'3>JRVI;+*I,IIQ]YM]ME8!2Z1Z6!\&/,\FUE&]^%!;?3Z$8
M6S\<P<R=P^2MP9DG5Z0'7%+"KZG.05I\[LH*3Z[Y40,]F6CC(4I601'B(FSH
M'?)8[QC2I29Q<2&5(U!03W9^BO0=/9;0B==1"D*:=FM8UE.IM2570C&QD=\E
MS1Y:5J20$A0/;:U!N];LK)QNS<\ZPXZE+VX8[+[32U-=\TK'LE32UH*5A"K<
M;&@\R_2O<&Z=A[`;QTAB,K#0FU26I(<25*4TTI(39/DG4W:^D*'AYT%I[A_I
M';O]9'\2E4%2>TM',C)[4:$&1*NZ]K+/>64V5M)4U="5V4JX(-!>C:0A(2.2
M0`+^*@I/K]TIWQN[(1<E@GD2X4:.&EXA;I:/>!:U%U"5_!*)"@.)!X4%.;PF
M0L=@HFWI>RSMC-19C4A^:2MPR&T(4A0UO`KXDA5D+*:#];;8WKM7<\<O8')L
M3@@`N-MJLZB_#RVU66GWQ0=N@CV:23O#;9[`)W#CS+2?>H(YY7Z,;W-_6E[_
M`/UN]!8:_,5[AH/1RH%!P-U?QG;_``)_UJWR_P`0]0=^@U,HK(IC)5CT!<@.
M-DH40D%&H:P20;>3>@J7!2/:+C.9/'38T*2\TUZ1!GNE*F7'')"5%H.)*#Y#
M2EI`*!:P]\/7)7M/MAY1AX1T!!4A+1XZKWLD*6F_`6XT%@]/YVYYVV(\G<T8
MQ<LIQX.-*;2RKNTNJ#14VE;H22W8D:C0.HJDIV3ERI10.X(N.?%0`'OT$CH%
M`H%`H%`H%`H%!P=[[.@;NV^[A9KSL=MQ:'4/L$!Q#C9U)4-0(YT%>Q_9QQ$9
MD-Q\[*2`I1451X:]87KU!W4T2Y]45;7>P-J`[[-.U[]]&RDV-,*PZIYH-)1W
MBBLNE#24I0@.:D@I3Y-D@6M>@R<]G#`/2$3)&8EOS6BHM..-1E-V4HKLM@M]
MVNREK/E#Y[Q"@E.Q^E&!VD)Z&7G9[4Y+#:FY:6BD(CZB@J"$(#CEW#=Q=U'A
MX*#KY6PW?@!_T,ZW[5J@[U`H%`H%`H%`H%`H.!OG:$3=VVY."E/N1FI!0L/L
MA!6E;:@M)`6%#F/=\8H*N5[+6&6I;GKZ4V\I)LZVT@**U&Y6X5*65W/,7`H.
MCM_V<\9A\Q!R*<],DB$\U([MU#>HK86%)[MWSF@H(2E>GSDBW*@L)@#X\S3;
MCZLB<?YQ)H.[0*"J.H'2[>VX=SN93$YAC'Q[69[QV8M2-494=:@QJ,=*K.*L
MI*0?'SH.1F_9[R4F<XSC,I'B[>CA2L9C%MN'275L./,N*04*2TMR.570K4">
M%!G%Z';JB0)#$?*P2K+K9.92\V^[H3&G*EMF*\M1<N0O2KO+W/&]Z#?W9T>W
M'E-ZS-PPLA%"93K+Z>\5+8>;]&CEEMK[G6&U)UG5K*=:>PT&EC^D_4R`\Q(:
MR>*?>9R9RY5*,U]1>]$,,)4XHZU)T*)X\;VXVH-.!T!W3A%1W<'F6DN*A(8F
MH4]+C@2.\UNK97'(6&W+`E!/.@Z^S^C6X\.,-"G9#&O8O&SF\NXY'BEN8J4V
MVI'=]]<!:%7!4M8UD<*#>ZG=()>\,I*R,:4Q%?$!B/CW%A>IN2U)6ZM9*1YJ
MVG"CAQO0<W,]$<O(Q[F#Q\G&QL%%#[^*M&4W+](?B&*42'$>24<=:E@:U=O*
M@TST5WI!&-B8R;CEPL2U+:BR0N3"F+$UY#JN]=:#OE(*+!0YCF*"+SN@#V&P
M64R6?RD5N:MV.Y`D-HDO-LAIQ;\GOE)05^6VFVO3V<>=![U)=V+GLUF7$;DB
M-1IQ])07X,U3B)K44PD`/(;4@Q[)*[CYX6H.#)VGT_>EM0L=O..G%I0Q)BQ9
M4:6@2)A#<=2RX4I^#=6GBMM7DB]@-!-!^B>EL&+`V'BH<6:WD6(Z74)F,A0:
M60\O4$:_**4JND*/G6OVT%$>T#,D1=_3RQ'+WI4'T1Y<EOO8B6W&4%1:X>1(
M&GSO&F@F.TI26^NQQC&+8!8Q#'?9`N/JFAE,1D-B3=P-7U:4E/=>.@G<K:&W
MMW(W#B\Y',F&C+H>2A+BVR'408Z4J"FU)/`*-!,(<5N)$9BMJ6MMA"6T*=6I
MQPA`L"M:R5*5PXDFYH.3N'^D=N_UD?Q*30=NW&@`6H%!K9'&8W)Q5Q,C%:F1
M5^>P^A+B#_:J!%!&MK=*MF;5S\K-X&*N$_,8]&=CI<4I@)*PNZ$*U%)NGL-O
M%02Z@CN:/^V.VQX4SC_DD4$>X?HRY&WK/E?_`,ZH+"7YI]R@]'*@4$>WLIIJ
M%!E*GM8]V+-;=CN/LKD(<<T+1W?=MJ;62I*R>![*#C_'";^7(/\`Z5/^WT#X
MX3?RY!_]*G_;Z!\<)OY<@_\`I4_[?0?)>],@E(_U[C0JYOJQ<\#@+_O_`#M0
M>HWGD->E6=QI/$>1BYYY>#X>@U,[EW,SBI.-DYZ&AF4CNUK1BIVH"X5<7?(O
MPH.A\<)OY<@_^E3_`+?0>#>$VW'.0;_U5/\`M]!@O>4]*23G,>`+6)Q4\#GV
M_#T&"MZY$%>G/8PI;-E'U7/\GMLJS_`T'@WO/L%*W#B`A5]*CCYJ4FW]D9%J
M#45U$G:C;<F%T]E\=/O]GH!ZB3K\-R82W9?'9#[?0>?I$R'^\F$_].R'V^@^
MC?4*84.%6X\+=(&DB!.'R07[GWJ#Y_I$G_[R83_T[(?;Z#Z,]09JE65N/"D=
M@$"<GGXU/T&]\=W_`,O88W-OJ,GLY_X6@*WO)%R,]A;#_H9/+Z[0>)WO*-B<
M]A;'G\#)O;Z[0>_':5^7L)]:D\OKM!HR=QO/Y2%D#N'#)<A)>0EL,R+*#X2#
M<][V:*#=^.TO\NX3ZU)^VT#X[2_R[A/K4G[;0!O:9;CG<)?_`!4G[;0>'>\S
MLSN$]]J3R^NT&)WOD+*MG<%?YVZ)(]V_PGR*#5>ZB3VE:%;AVR%BQ(*Y'"XO
MV+-!\_TD3_\`>+;'[>3]-09'J/,"['<6V0`2#Y4B]O<UT'AZD3KFVXML6[+K
MD_3T'GZ2)_\`O%MC]O)^FH'Z2)_^\6V/V\GZ:@^\/J%,=<*5[@VTH`<`AU])
MY^%2J#?.]WK&V9V]?L^ZET'/;W)(1G'\J<[MXE^*U%[CTE=D]RXXX%ZK_/=]
M:UNR@WQOA^_],[>\?W4OG0>?'B5^6-N_A:_F4`[XE7X9C;MOOM?S*!\>)7Y8
MV[^%K^90/CQ*_+&W?PM?S*#Y*Z@.(44JSFV4D=BIR@;^,&@S.^9V@$9;;95V
MCTUP#Y.D_*H/B[U"DH64^NMK@BUPO(+21X>&DT'T5ON=P*<OMH@@$$SEB]_[
M4T'Q7U"R"0#ZWVKQ[3DE@?)[LT'UA]0);JU!S*;87RL&LHJ][]MVJ#;&]I5@
M/3MNJ(\X^M"./N=R:#G9_*P-P8U>-S"]MRX3A2I32LLM/E)-P0I#*5`^X>7"
M@C(V7T\UA9@[;6H*U)*\Y*58B]@+H/#B3;E<F@^D[:>P)KKKS^.VNMUYQ3JS
MZX?2-2SJ*=*6T@(U>5H'DWXVN:"283/,8/%1\7CW]MQH,5)2RRG++(2"HJ/%
M;*E<SVF@\A9^1&R62G'(;=<&26TYW9R9`3W326N?<>5?3>@^SNY$.3&IZCMA
MR<P"EJ2K)?"(2L:5!*_1RH`CLH/AC-R3H,O).'([==&0E&6!ZT*2V.Y:9"/J
M)U?4;ZN'.@W4[YR!/&3MP#CQ];D^Y_F_;0:\O<&5GRL<\7L#;'R?2BEO*J45
M`L.LZ>,?A]5O?Q4'4.[\A8>1A[]H];?_`*:@\^.&1_>\/_ZO_P#IJ!\<,C^]
MX?\`]7__`$U!XK>.3`N&L.H^#UN!_P#+4&*]Y98$:8^'4.U7K@"WR8U!Y\<L
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MO+XBRQ0).Z<[%?AL.[>D=Y-=4PQ:3%(*TMK>.KR^'D-*H-GUWN7_`'<=_"HW
MT]!KX[=6=R./CSXVW'S'E-I>:*I,4*TK%Q<:S;A08'=^:&53BOBZ_P"F*8,H
M)])C:>[2L-GCKYZC099+=><QT%Z;)VZ^&&$ZG-$F,I5KVX#70;!SFY@H#XM/
M$&]U"5%L+>&Z[T&O&W7G9+TQEK;;Y<@NAE\&3%'EJ;0Z-/E\?(=309_&O*LR
MH361P$B&S-D)BH?+\9T)6L**2I+;BE:3I[*"24"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@6%`L*!84"PH%A0+"@6%!\U1XZU%2FD*4>9*030?2PH/FJ-'4HJ4TA
M2CS)2":#(-M@W"1>P%[#D.0H,?1H]K=TBU[VTBUZ#PQ(AYLM_M1\R@\]"A_O
M#?[1/S*!Z%#_`'AO]HGYE`]"A_O#?[1/S*!Z%#_>&_VB?F4&*\;CE@A<5E0/
M`A3:2#\D4&0A0@+".V`.0T)^90/0H?[PW^T3\R@\]`@ZM7H[6JUM6A-[<[<J
M`C'P$"R(S21>]@A(XGCX*#Y+PV'7;7!CJMRNT@VN;^#PT'GJ+"?D^-]9;^90
M/46$_)\;ZRW\R@>HL)^3XWUEOYE`]183\GQOK+?S*#$X#!$A1QL4D<CW+=Q_
M<T&)VYMXE1.+B$J\XEAKCPMQ\GP4'`EX?$8_?6WE0(<>$IQC(!PL-(:*P$LD
M`Z`+VYT'-TM?HLMI^"]*O;Q>M+W]SMH+!60$F_*U!Z*!0<+='\:P']:(_%WZ
M#XQ$_P#N)E%?^4P!_P!IET&[N\$[3S8'$F!*L/X%5!THO\6:_8)^505YG-Z#
M:LW<64>2TN(WE83$Q3I6CNV%8]I:U([M#NI=^"`K2%*(3?E037;N?Q^X,0SE
M<>'1$?*PWW[2V'/(64&[;@2H<4\.%!H[26I3^X-1O;+/`>X&6:#ZY\CUQML7
MXF>[8?S"30=N@XFR/S.PGWDQ]C%!\%?\0T?U0K\930?7?)MM+)GC]2[#;YX4
M'=H.#MM97EMS7^=R2$CW!`BT#=8^$P?]:,?N'*#O4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$=R_P">
MVW?\1D/E,4'`NW^BK5H\COM>B_9ZQU6O06`OS#[E![0*".[MT>G[8U>=ZW3H
MY\_0Y/ZUZ#*)^?N4_JR!]GET&UN[\T\U;GZ!)Y<?\"J@Z;`LPV/`E/RJ"H>H
M.;Q6!3N7+SX<&:EK-0FDMSXPE(`<QK!4$C4E2"K0/*2%6MYIH);BM]X6)`P\
M5O%SF8LB-$4ER+%?>AQA*2.Y;+VA)MQ'$)\D>=IH.IM$6>S_`"XY9_E_BFN=
M`W$5>O\`:P%M)G/ZO#_1\FUJ#OK("%$\@#0</8A!V5@B.1@1B/K2:#&W^WU[
M\L5R]V3_`/"@]WW^:.3_`,5_?"@[U!'MK*"LKNFW9E4@^]`BT&6[#\+@O'E6
M/L;E!WZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!08*?92X&U.)2XH%24$@**1S('@%!DA:'$)6VH+0H72I)N"#V@
MB@]H%`H.!E$!6\\"KZ&/D"/?[@4$7O\`^SNKMO>_C]/OX?UZ"QE^:?<H/:!0
M1_=*4JR>V-1M;*DBPOQ$&5X:#*(G_;G**X_T;`'B^KRZ#[[P7HVGF5<.$&1S
MXCZDJ@ZS=]";\["]!3_4_*C%0,W(5@XN>[W.QD-PI31>&L8IM0<#23J<*".5
MN";^[0?.9O\`RJU[$A,RHV,1F',2ZK%1(TE)4VXJ[J&9:5>C=SI`"F]-P.%Z
M"Q]J`=YG/'E'_P!PW0?+<9(W+M,#MFR;^YZOD4$@>OW+EN>DV^10<38(ML?;
MX_\`+HOB_P`"F@P2N_4):/H<2E7[:2H?WM!GOO\`-')_XK^^%!WJ".;33;)[
MI/T66OR\$&**#W>!M(V[X\NS]A>H)%0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*#\T=9X69?ZD91Z!B5YU$-J%+F
M*B*D(?BQ4,N(<BK<;`T(DZRM0;)-AQH+[V,J(O9N%7#9CQHJX3"V&(948Z$*
M0%)2T5A*M(![1>@[E`H%!PLD3\<<'PYQI]S[\>@BF@_H;T__`(_CU!8Z_,/N
M4'HH%!Q-P?TIMS^L5_B,J@0[_'/*^#U?`^S2Z#+>A2-H9HJ`*1"?N#R^IF@[
M-!3G56&W-AY"$J/WYD[@92E=W1W)1AT++@#3L<GR4D<5@>&@XT?I[NE&_P#8
MTO'8XOXC#0("9>7*66'`&T$+3P6"JX5Q3=?"]C06]M3S\W_6C_[AN@PW"#\9
M=K<2+2Y/+M^X7^=!W9)M'=/]@KY5!#L3N[;>U]B[97FY:8*)$",A@:'7+D,(
MO8(2L_/`<>T@4&]'=#O49Q:0="L(RI)(*3Y4IP\00"/<-!M;Z!.TLF`+DM"P
M'[(4'=H.!M9O3/W*K]\RI/R(<9/ZU!\=YDB7MD>',M`_@\@T$EH%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`(!YT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@J
M'?\`,Z.1=W3AN";D(65?;93DGH;T]F.2&5%EMTQR&^\4T/)3S(H+(VDC%HVQ
MBD8EEV/C$Q64PF)"5H=0R$`(2M+GEA6GGJH.M0*!0<')*_VRP:?#%R!O[AC?
M-H(MI7^AJU^.F_O>F7^506,YYA]R@]H%!Q-P?TIMS^L5_B,J@\A@_'3*D_D^
M!;Z]+H/=\?F=F_O)_P"QF@[=!6F\\;LJ=$SPWB^N/B8^79>#B%+2.\&-82`L
MH"O)TJ//A05U'R6,/5#9SF/GRL?CA"Q+4##A14IUIY"=`>*7&@H)2Y<DZO-/
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M!0*#\W]2YN`8ZKY$9'(R,>4RH;Q+$GN0@LXMQ;<K3I7Y8<T-`]ESVF@O#IY-
ME3]B8";+6MR5)@1WGW'%%:U+6V%**E'B3<T$@H%`H(]DS_MS@1_H62/]W%H(
MUI'Z&[=FF_\`VR]!8KGF*]R@]H%!Q-P?TIMS^L5_B,J@^..4@[ZSB1?4F!C=
M5^7%R7:U!]M[_F=F_O)_[&:#MT%-=5ACWVI>/R+4=V%.SZ&G_279#"4@8AHI
M6ER,EQ8(7IYH4/%V@/I`PN&<W)MC,1\=F)V3B08$?'RXS4=S&*BEL:G"^\TV
M1I%]15H=^@38T%@[.`TYJR]8.6E\?!Y0N.79RH,LZ+[BVWXI$G\3=H.S*_BK
MW[!7RC04EU9P&<SG3C9T+$8=W+OF.SJ2T%_!#T9'EDA2&_$-9]R@L'NG$[EF
M-*<0RXG;S"%.N<$(4'7AJ58BP';8T%>].<"QAMD9QN-FH>69=?QZE-PI*IB&
MW>^0''2I26^[+Q\H-Z?)MYQH+SH.'MG^.;@_K-7XK'H,=SA!G;=U?E06OX?1
M)%J#O4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@H7>V;5MSJ/N69,STK;L*:(`:=;Q*<@T^41@DCO74*2A2;6T@\
M:"ST[WV]@-NX=_<>8[ER:P"U)F,&*X\4I!4I3"4_!&R@2FW"@ZNV]V[<W+%=
ME8&>UD([#G=.NLDE*7+!6DW`XV(H.M0*".9/\_<`/]`R9_NXE!'[G]#W+_!?
M0C^5>#]>@L%TV;5[E!D.5`H.)N#^E-N?UBO\1E4&MBOS_P!P_>.,X_V\N@V=
M[_F=F_O)_P"QF@[=!3'4K;K6Z(.4Q3TZ)">7NF,W$7-6MM#B_5S`$='=A1*W
M`2/_`(T'(FYG+X/J_M_:T;).Q,8RG&15X9EU]QL)[GB&RNR5-@M)"E+LLA1X
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MG(B-11*=9QK,-MMD)99LT=:6O(*BXA1U`F_.]!9=`H([DOS]P7"_W!DN/@^$
MAT'!L/T0>:GZA?3V7[^_RZ"?.?4S094"@X6XE@9?;2.%U9!RWAX0))H/GBQ_
MMQGS_H>.'+^RE=M!]M[_`)GYK[R?^QF@[=!2?4%C;SS69:SV8>PT1_<(8;?C
M,EU9<7CHJCJ4/J:`A!*CX/!0:V)VWLL;YVFMG*Y-Z6W%B2\;&2TM<=:-"G"]
MWSJG%I2M3_E!2B1<I[:"U-E@AC+^/+3B/KIH/GN!1&\=J)N;%R:2.PVBJ^;0
M=Z>K3!D*-[!I9X<_--!46_-O1LKL':LF3E8.+9BXM315D)"XJ2941MM*TN-^
M4KNSQ+9&E?SU!,FPEK-SCW@>2WMZ*._;&E*P')'E)2DBP-KBQH*SZ4L94;%W
M-*R$:4PJ5DH:VG)@<4XZE+K2=27G$@K1?E8FWAXT%_7%R+\1S%!&MEJU2-RG
MP9E\?(89%!]MSDC)[9`'`Y0WX?Z#*H._0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"IM[;4W?(W#N536`9W!C=P0
MFHF/>5*9CF`M#*FW%*2XG5Q4K7J02>%J#>W3OB'TXVCMW&;FC+S;\F.F$^MD
M,I;6Y':0%E27E)X*OPX>[:@WNDF&G8Z-N!^1A_44?(Y5R5`QY[D:(Y9:0GR6
M%+;3Y2#RH)[0*#@SD@[XPZB0"G'Y"P/,W=B<J".6'Z&?/-O0M6K2+VUW\WE0
M3]SS#094"@CNY4J5N+:=N0GR%*]SU?)'Z]!GC/SUSQO_`)KC^'OR:#Z[U6E.
MTLM<\#&<23X-0T_KT':H*=WQN[-;5]/EXR,S-,O<+C;\1_NTI6TG%-+7Y;E@
MDA+:NWQ<>5!PIK[.0ZL[0R43&IC0,FG'37)+C;17'4F(L,QFG&R7&T*#H2I*
MVT@JM8VH+BVA_%LG_6D[[.J@U]P`G>.U?$N<3^"D?KT';RQ`Q4TGD&'2;?L#
M05-NE6RW-L[%B[HPPRC#V,UQ7_26XJV5H8C@I2MUZ,@]X%\?+OPY'C8)B2&=
MPY9,4^@AG;T3T=82'`S9R7I(2C5JT6Y"]^R@@.Q<])RFU=QH5GE;ABQI&+#4
MY7I&GO5N(+P3Z4`X+E(5I\T7\F@Z>XYK$'K)'3(&M605CFHJ$95Z*Y=!=U*,
M%@+](2+WNY9/9>UZ"<;*0I+^Y"18*S,@I/A'=,CY8H/INE83EMK(M?7E%<?!
M:!*-!(:!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!05]U(ZES-K1I[9PLKNDL*]&RW?0VV2ZINZ="''D.JT*/$!%_!
M0<'<>'VGN+8FT)V]-QKQ$M_'(C^E=ZRVJ2J8PT7TJ[Y"[W4A))`%J">;&3!:
MQTF-%W&YN7T9\MO2GG&'5LJ"$_`WCH;2+#C8\>-!(Z!0<.8+[UQ1X<,?/[./
MU:)RH(SQ_0GX_5E!8#GF&@RH%!P<\D'<&VK_`#LN01^!/#]>@AG4MV,U$W8Y
M)BQ9B$Q\7W<>:XZVRMPNO!((8!=<5<C2A/G'A00_IE!@P-J[H@K@>AYM$1"L
MB^\]($E?>J44!,1]F/W+(OY!3>_:;T'Z!H*8ZG;HGX+&9`16F'$S<\MIXR$,
MN@`0&E(TID`M7UVN5=E!SXF=VK-ZJ;93.Q#:]QY6!`R#V3;FR&6PZ8H4@")H
M+2R-/D@*(MS((H+:VA_%LG_6D[[.J@^6<_/#;/DE7&=Q')/P`XGQ=E!ULR;8
M><?]'=_<&@JK?FU=P9_:>S&\+&4Z^W$2W-0U(9868CK#0?9"G2G6E8%B!P\-
M!+),1;VXL]!9:905[<B,M,O$AE)4Y,2$K*..@<C;LH(IM#:&<P6S,IZV:#2I
M2\6TP>_$QTIBJ::4>\3P[HJN6FQYH-`WUM^%.ZP;?R,K<<"&Y!=B&)B'4D25
MN=X56UHMJ+H24I"C[U!N[PS^5VYL3=64Q#XCS_7*DMOJ"#I[QQEM5M:5IOHY
M:A09[7S67S>$V/D<P^W(R3N8E"0ZR4%JZ(TU`".[%M(`X<SX306A0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*"@^
MJVUMF[ES>\I;;DB#N/;T!I3KKS[/H\E2V>]0VAI[4I`"4)3K1IXGP\PSZFL3
MMUX/8AQ:Q)S^9QLA#$<LM-M+9DQF3*<U/N694@6"+:C<\.5!+N@\EQ&TYV/E
M-L1)&'G.P946.PTPTTXTA&KRV5+0]JOJ+E[T%E@@@$&X/(T"@X<Q1&]<4+$W
MQ\^Y[!9Z)SH(OY7Z#[_/>JM5^/T-_=H+"<\PT&5`H.%G?S@VW]]2/Q-Z@A^_
M_5CDO,1IH052'<,S#<5(<B*:EJ<>+#B'VFGU(6E=B"4V\/"@U6L#DL?@-R9+
M,*3)R$B&TWZV5D/375LMK*N["4QXC;3:"HD:4\2>-!:CS[+*0IYQ+:5*2@*6
M0D%2SI2GCVDFPH*7ZGR(T1EZ;+,E,2-GI*G5PDZW03B`&[#NWK`N6!5IX"@W
M=N1=GY7>&/FR(633FH4?&+)0E4B$IY4%*V7')#+>A);0Z4GRD(5STT%@[0_B
MV3_K2=]G508Y@)^-NWKVOIFZ?=[I-!T\U_0T_P"]W?W!H*JZC[;WAG=I;.C[
M9@-3'66FUR7'^Y1W2.X;LI+KA2ZVHGM;-Z"92&'E[HSZ$MZW58&(VE%@Y=1=
MF639SR57/T7/MH(7T]V[NO`[+RC6YL<S#7+R<)46.RIL)[M<AE%U-LDM-^4;
MD(`OX*#1WK$>E=?\&\W&08T'T)4QPRFVBI2B[W2BTZJRN[/((05'PCA0=/J9
M8]+]X(TH)<RQ;2MVW=H+DAE/>+*@K2$WOJ[.=!ETO;*=D=/FBYWG<Y"6@.FY
M2L(CS4W;5<ZD'YU7"X[!06Y0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*#\W=7V)&4W]F'X(CRV<$RPK*"3&QB76D
MEGO`B,90UR2$C6=1X7TB@E'5)ES,;1V@E]I^3MF2PE_)YJ-CT29S%V$*86TR
MV/N?O;D*4A)T\J#1@XK)2>AFY\1&PJIC#,IQG$QD,B%,?90MI0>DQV=*@\D@
MDBP4L`<.-!(NCF\,]DI3F#6E,[!XN&AEK)HA28!8?8*6O0W42%.=XO1Y5P>'
M:.-!:M!Q)9'QTQ@OQ]73C;^&B4$8TI_0A:WD^J;Z;GEIO:]!8#GF&@RH%!PL
M[^<&V_OJ1^)O4%<=6UL.KS"'6$/I8G8'@\VMV.GX1U15(:;"EN-!).I*>)H/
MM@I^R\ET^R4G$XF'BLVJ$V,Q%BQBQH45VTW4A%TDIN!?@.=!CU5S05U!VOMY
MME];TJ;`?#OI;S49(8E!PA492!'<44I-B%ZK]G*X<SJL<I(UXN!/>@^GYR4E
MXL>D>6EO&LG2M,5MYQ:.)NG00>VUJ#E>AN1^MV%QT>//3$0C'N-:6E".66(3
M24K62VVH!"D:5<$@'A8'A075LXZH605:P.4R`_:RG$]GN4%4;6FY*7UW=]*R
M,I]F/)R[4?'/W,>.@!`2IES6H+4YI5=-O)`H+IS7]#3_`+W=_<&@JGJ9ME6<
MVQM`>NL9ATQF$N$Y-U#(>4&FBE"24J4I`MY:01?A>@FTIM:\WN!`>:;4K!Q$
MAUX?<Z253/+63=.@=M^R@@.Q\$K;.P,FA67Q^;2O+X]X/8UU+P252X]T.+2E
M/&_FIM8)M:@W=[/,P>K&$<C9F"'ILJ"WD,`&VQ.<3Y:&GN^(6LMHU:B@:>5!
MO;NQ>9R^Q-T8[#1VY<Z3EUMB.X6DA:"ZV'`%/>2%:;V/,=G&@V-G83,XC`[)
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MLGA03>@X4I0^/.,3<7]6SC;A?ZO$H(W_`/9#_P"D?WE!/W/,-!E0*#A9W\X-
MM_?4C\3>H*YZGOK0[N5H$MIE2L)'7+'?_<R'`YK?*8ZFW%AM-SIU6/;0<7IS
MH=V1N.8N2CTIV*RA>/2N<XML-.*3WSAEK6E)>YA"!Y(X7-!)-^[;Q.3ZL[=G
MS-T1\<Y`]&4QA'%%3C[Z7UK;THU(0@K\T'B3:@BW7%]YO!2Y<5YQE]K<;C0*
M$K4=*H#8<-T$+`2E)-T]EQVT'WW'@YVW)V&ZEJRZ).-B1<>U$Q[A>1(DCT0(
M4T%J"QK=(U@*'G?V0%!9?2G,^N]HC+]QZ-Z?,G2.X*@LH[R4XH)*AP)%^-J"
MO=L8*'"Z]R9K62ARY$MS)K>CLN.J6U?04H*%)#:7$:CKTK/,\!07+G5!.$R"
MCR$9X_(;/AH*1ZV.YMG:^S7X*'%Q8T=,A]24J+;*VD,E+SI`/D!!6/#QOV4%
ME3C)7/W(J,I"9*L#%[A:05`+/IFD@6)*=798T%9=)SD7=C9S'95*V5,YK&K3
M"?\`)D-HD2H[EU@!*=*U$J21X_%0?7?R<F_U^P$01E*8[V#(8/<)\M#)475]
M^A'?)2W>Y\K3>P/`FP=S>R@.G&ZG7$..Q&LZM<Y+('?>C(F-%_NB1Y"P@'2N
MXT\[B@ZNRITC(;?V/,?:4TE^;,7&;<4ZMSN/1YG<%:GUNKU%NQ/ED>`VH+(H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%!4>]>F6^,KU(9W9BQ@RS!:T1&9B'TK>);T*]++0/>:23H\JP'90=;J`G
M9Z8N"B;IVZG<.?=:6B!BL<SWR@6T)5(4T%J:TLILGBH^"@ZO3J;L\[8E.;8Q
M:L3&BR'T3L6ZUW#S4MI([Q#J"5658)[3PH,NFV^W=XX^7,<QQQWHZV4)05%>
MH/1FI!-RE'(NZ?>H)?01V5?](F-X\/5,[A_.8E!P/_LA_P#2/[R@L!P70:#V
M@4'"SOYP;;^^I'XF]003?:7ADLZMB;Z+(.0P(CLD/%,IQ*E%,5?<`N!+O:;$
M>'A0<C";@=W%\><P^L177XL5M&,:+ZV'&F5K;3.:=>2T'$NE*FP4('!'&@^V
M^,5*G=<\%)9QJI,;'HB*FO)4P+=X\YW2R%H*BELH43S4?G2FU!L[DVED=R1,
MPF(F.IN)G)RI*GWW(BT(<@(9"T2&TN*2E"EA2T6LM(L>%!7/5UYU&?QN*9@1
M5JBQX"TYJ`RZEQ:VHP*4-%MQQ.CYY/P:2$@<QS"XN@3;K?3."V\RIAYM^6EU
M"@0=0DK!N#V]A\=!S,-M'(83JNQ/FKAJ;RKV8D0FV4N!U#:RTH:BI?=:B#Y6
MAH'PJ506-N191MW*K'-,-\CWFE&@H_K9`<EX;8W=PG):FXO%26EK2UWB8Z0X
ME;?%+B#Y0"[HL"2DV`H+,S7&3N_R'GB<!'!2V$J<7<3?J:2+%1\!'/LH*ZZ-
MP),3IWD@]&]"2K,XT(B`.)2"V_%0IT!Z[GPA%^*K>`)Y4'9W,_T^3UMQIG,3
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M7N#+/35R58Q#<B$`\\&DJ90N;J=6EI/'6J]Z"Q-M;JPV>BA4*9&>F--H,^)'
M?;?5'<4FZFU]V3Q2JX]Z@[-!')('Z1<<>WU1._&8E!Q>[_\`973;AZGO:_\`
MT5Z"=N&R3[WRZ#*@4$=W`Z$[IVLU;BN1+(/[&&Y\V@K_`*I/06CG%3H_I,)6
M0PZ9=N^2IIHMKU/(6PI+B%(\(H.9M3,P,CB<\O'8UAEDX3$F6\RA\!,I(4T[
M#1WJBE#;&@6;1VDDW)H/IU`5D$];\)W)CK0IS&A*2S&=D:>^<U@)<)?"$I*E
M%;8`',^;08=2,XG#[6W'(5'E2$N9Z4R1$F2813KB-C4M3"%I6D?0N$`T$0W!
MIQN^6<LW*]#S6)@81+3J76$)L66A(06G[!X!L\2AU"0%6)H+TZ59%>2V@F>I
M[O\`TF;/=#FA+=PJ8Z?-0MY/R%D>,T%?X;*IG^T+Z(B+(;./1D2N1)ER7T+2
ML-INPP^EM#*0>QNZ3X>%!;FZ2$[8RY/$"%(/^2505/U/W5O#!X79C.WYB(S6
M2CM1I2-;:7%$AC24*6/@P!J!<Y#5;F103C(/RH^9WB]$7W<MG"Q%L.*4E*4N
M)$TH5K6"D`'M/#PT$+Z<[KW/N?8>0R6X)")$H9J`RT6B@(2AN5&'DMI`*`3=
M7E>=SY4&AO-+*?:#PDQAXN2VGH<9UA<-I,="'VU\535*-WBE)[M)1J[$F@V>
MHR$'I7NI9;6ZVUN!]Q[NT@Z4B6+J-PH:4\R:#L[`+B-N]/&G&'HI]*G=TS(;
M#;O="/++:G$@)XJ00J]O*O?QT%J4"@4"@4"@4"@4"@4"@4"@4'/SFX<+@8!R
M&8F-P806ELR'39`4OS03V7H-N)*8F1&9<=6N/(;2ZRNQ&I"P%)-E`$7![:#Z
MT"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4'YOZ^Q!)W2Y$5@%8QY]L
MNL[DCMOR59$M,!34-34<)&HN)*"7-5@`>5!W>M;S\K:NWI\E#;&XS!+R<$J`
M],6XM:6>^;#B#\`&BKB5<Z#Z1H>WH_1',,J<,Z(Y*`=<B,G`J0^I;(01Z8M*
M;MJT^43I5RM0;/0G:65Q,Y<O(0I33;>/]#@2EF!Z.I@O][IU0W'%NN%1OK7R
M'"@N:@CLFWZ0H!/9B)OZLF+\R@X^D?H7MJX>I=6JW_07Y4$X=\P^]\N@RH%!
M',\A*MW;7)O=#DU0MROZ,4\?%QH(KN_;V8W#.W%C<2\PV[Z5BG9;4I;C;$B.
MVVI3D=TM`K*'.13VB@T,?LS.;<P^YGY@Q\/&Y!,,Q\1BBZY':>0Z$NOA+P1I
MU@IN$\.%Z#H[KZ>;BR?4C&[DQ\J`S`C*B*E%Y),P>C.E2TLJ"#8+;)3;6`;F
MXH-#=73[+;SQ\R%B\JG$*9SDMV4_I65K;4TE!0.[4@F_"X)L10<;>71#>&5W
M2O+8R5C6VTIBMMA];Z4K1'CMME#T?NW6UZG&PKRE&X`!O:@L3I7`D8W9[<&5
MW#;T>7.;4U%N&$%,MT%+5PDZ+\N`H(UAMCY?$=9%YR9DQ*BY5&1=A0!KM'25
M,$VU*T@JU#5I3[YH)_NL@[5S-CP]!D\?X%5!7F^^E^6WKA=L)A3X\-&/AI#A
M=0I2RI265!22B]P.[Y?JT$BFXV5D\UO'%LO(1)F86%&:=6FZ$K=$U`4H#LN:
M"/;5Z>9#9&T9T.9,9EKF97&R$]RE20FTF,@W*^)XI_\`Q>@W<YTPSF1ZHP]V
MM9".UCXKL9U40MJ4XON&UH5?AH)\LZ5'B+]EN(?'/[0RNZ]C9S#8]R.A]_.2
MG/NK4&BVW*42"6TJ5>XORH-O"X')X-&Q,9D2VJ5&F3^\[A3CC2$N1I2T(0MP
M!92A"@D:O!06+0*!0*!0*!0*!0*!0*!0*"LO:%SF<PFP!.PDUV#D!.BI0MC4
M7'$E1*F@$<2%`>5XKT%+;KZH9[=&U\E@LXY%.+BF*Y'GQQWSZN[<0V770'!K
MUAP*'DIN?<XA^G-D)*=F8%)2E)&.B@I;)*1\"GS2>R@[5`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%!3V\NBVX=Q;XD9<95$:%)>8>9R+;LA.0AML,
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MMRWFL'`:6"TD+$=L&RGD)(O8<P;4'RFQ.ED7><':#VWXIRV1C+F1R(C19[MO
M4"%*[%>0;"U!]ML;(V@Z<N7,/$449.0E!+*+A("0`#;D/!0?'98Z7;QC39>)
MP;&B!+7$?](BMH476@#J3YUQ97`T&QM;8>S'<<^IW!PEJ3/GI2I3#9(2B8ZE
M`N1R2!84&.0V3LY.\<,@8>(D.QIZE)#*`%J28X&KAQL%&UZ#D-?HWS^'W?&Q
M."99>V^)4*2IR,TVGOD-KXM:2JX!3<'A02G%;"V6,9#/J2'?N&QJ[E%SY`O<
MV[>V@Y.-V3M->]<\PK$Q2PB)CU-M%I-DJ6J5J(\%](^10??=6Q]F-XYE2<3&
M:<7-@MI6AD$^7,:!!">8(X4&NIGIE\=?BB<*UZV,<3-7HZ>YT<[:[^=Y-[6H
M/MM79&T78D\NXB*LC)S@DEM)L!(6D`>``=E!E+VQ@,1NW;#V+@,Q'7)$I#BV
MDA)*/0W38GP7`H)M0*!0*!0*!0*!0*!0*!0*"H?:B><1TV80AO6'\I#;<-R"
ME)*R3Y)!^=T^_04;]W-X/<:$0]47(2(F71&9>;?B(8:6V"W(0H>D`@*M\(J^
MGYWA<!^N-F.J=VA@W5!*5+Q\512D:4@J92;`=@H.Q0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*#@2%`;YBB_'U5)('N2&/FT')U_\`L[K_
M`/)-7_9KT$S<\P^]\N@RH%!P<Q^=6WOYY]A%!%MW[GR&VE[DRN/5&,IM^`AN
M-*2\L2"I@VCM!@*6'7#P0;$>&@W<KG<GF=HRSD,%,PBP814F6IA04I<AO4E'
M=..'R/"I*:"/[B%_:3VKXL+)/ZK]!/-I\\U_6DG^]H*T]G27$@[5W7-FOMQX
MC.9E.//NJ"$(0E"+J43P`H+)V++CS,"N9&6EV-(G9!UAU!!2M"IKQ2I)'`@C
MB*#Z9#\\<+]Z3_W4:@JWIO\`4NKW]93OL;M!8,WJ%M3;[<*!E9@8E+CQEI;L
M2HA[X-%@/*5=23YH-!NXT)3O3/N$G^*8\$6X629)_7H-&5N''[BVIA\UCM?H
M<W(8];/>#2L`36T^4FYL;B@B+A__`*DFQV^JAQ_M%T$F3N["[4VWD\OF'%MP
MD9>8T5(05JU.2UA/`4'RQ.Y6=T'9N=:9[EJ8_.4TV25%(0R\V#<A/$A/']?G
M03N@4"@4"@4"@4"@4"@&@XDO>^SH4IV'-SF/C2V3I>CO2F4.(-KV4E2@1P-!
M\OTA["_WDQGX8Q]/01#JGG^EFX-I/0LEE<7D6TO,.1X_I;:OABX&PJS:P>"7
M%7[+7-!EOR;L/<&UV\%$W#@4QV'&O@)DAAYE3325(T7"]:%"XLM/$6H._@MX
M;(Q>#QV-?W/C'78,9F,X]Z6R-:F6TH*N*R>-KT'21OK93B]#>?QRUVU:1+8)
MMX?.H,VMZ;0>*@UG,>O3YVF4R;7_`+:@^GQLVM^6(/X2S]-0!NS:QY9F"?YR
MS]-0/C9M8<\Q!'\Y9^FH'QLVO^6(/X2S]-0>?&W:OY9@_A+/TU![\;=J_EF#
M^$L_34`[MVJ.>9@_A+/TU`^-NUORS!_"6?IJ#SXW;4_+4#\)9^FH/?C;M7\L
MP/PEGZ:@\^-VU?RS`_"6?IJ#)6ZML)"2K+P@%<4DR60#;AP\J@S9W'@'WT1V
M<E$=?<.E#2'VE+4JU](2%7)M0=&@4"@4"@4"@4"@4"@4"@4"@4"@C\LD;T8(
MYC%2OL[-!QKO?H4O;X7XOWM<<_1+^"@F[GF'WOET&5`H.#F/SJV]_//L(H(%
MU!]-5D<@]CI,>++AYK%+2J4ZN.TI:H:D(0IU"7+$J=3:XM0<C:DK*SH>X9$N
M2U):B1\'C"[%D/2XSDB&]I=<2^MMMI2U:AK""JQYF@Z6;=4KVG-O(/)O"O:?
M[;OR:"PMI\\U_6DG^]H*SZ`8?'Y;9&Z<=DHZ),"9F9;4AA?):-+=P;6-!8W3
MR'#@[7:A0FTLPHLJ<S&91?2AMN:\E*1>YX`4&QD#_MEA1;_,\AQ_MXM!573$
M@Q>KA'$>L9W$<?\`!N^,T$XRG2K:&YI>,SF69=<GQHD=E"D.J0G0T>]2"!_9
M'LM<<*#X[DC;U?S>:3L^3#C94IQP><GI6IHQPF5J2G2%>5J4.R@BVQ=B[YV7
MA$XG-RL>_AU92`_$3%[TO"0Y/9+A6I:4#1I'`6YT&^X/_P"HUM7_`)9;_)JH
M,=W[N7A,`J%`G0XV;R&<F>B1YUNZ<;1+6%E94AQ*$A2D^4JPOPN*#NX''Y+&
MHV?$RC"6)XD9%QUAMSOD-=ZA]T)2Y87"4K">5!/J!0*!0*!0*!0*!0#P%!3G
M6SK8SMIMW;^`=2YN%Q(3(D)\M,-*^0L/.?5\ZGLYGL%!"MC>S=E,[C',QNR<
M_BYDY1<9AI0AQ_2KB79*G-1[Q9-]/9V\:#H0?9GPDK.93'*SDM+>/3'*%AIG
M4KOT*4;\.S301J)[/&XD[E,',+5$P[\P1\9-0IAUQ]L*6O6MM)5H/<-:N(Y\
M*"4XGV8L',>R2',Y*2F'+5';*6F?*2&FUW5<<[N&@Z`]E';P-QGIE_\`%,?2
MT'/E^S!A&<OCX8SDM3,I+Y<)99U#NDI*;$#^RH.B/91V[^7IGUICZ6@Y7_+/
MA5;H.*]=R?1Q!$K7W3.O672W:UK:;"@Z3GLHX/0>ZW!*0NUDE3#*D^^/)O\`
M)H(5U#Z.[1VOBLFJ/N@R,]C&&Y0P\A#+2W65KL2BY!5Y(4?)ORH.GL;V<HNY
M-HXC//9UV(O)14R/1D1FUI1WG%("E*\%NR@[8]D^':WQF=X\_N-K[90>GV4(
MG^\[WN>AM?3T&C@_9CC9/$QYJ]QN-J=U'0(C9`TK*?H_%0;B_90B641N=[D3
M8PV[?9*#3P_LN1<CB8<Y>Y'6URFD/EL0VB$E:0JP)7?A>@WA[*,4<?C0\>%C
M]QM<OV]!$,C[/.Y6]TM8K%OJR&)1(98GY,H:;7'2XA#BEEI2_+LA9M:@E_\`
MRH1?]Z'_`,#:^GH(;F^A&X<9C9V=V]D7,C-P<]QL1VV@U("&`D]^P4J-UIO?
M3X.5!;'1;K1&WC&3B,LI+.Y6$7-O)1+0F^IQI/8I-O+1[XX<@M8&XH%`H%`H
M%`H%`H%`H%`H%`H%!'IA'QS9\(Q,HV_AV:#D:E_H4U63J^+U[?._Q/W*":O?
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M2,6-#G,O.^KYNE*WEQBV+=U>ZNZ5V=E!HF/M/%8C<B,%B<BS+SJ9#\E(@9`]
M[)=;4!;6V0FY5R%A02"!NK'M0(S;D7(I6AI"5I]73N!"0"/J-!SH&X(S.YLQ
M-=B9(19+,-+#AQTT@EH.ZP`&;\-0Y^&@SW'N.)+AQ&X\/(K6B=">4/5TT6;:
MDMN+5Q9[$I)H,>\V8=S?&0XS('-AD1Q*,#(\&N(L$=UH]^UZ",.[9V=G"I_<
M.-RQ?9FSRV&HF1;2]$DS%2$M/!ML:VU^2K2J@EKT]K*;FP"H<68EF&J2MY;T
M.3';0E4<H2=;S:$W)58`&@EE`H%`H%`H%`H%`-!3G6[K8SMEA[`X!Y*]P.)T
MR9*2%)AI5XOGGC?R4]G,]@H(ST-Z226MR.9S>$=2\DRRSD,=%?7WBD+DJ<'?
M2$GF]Y%P"3:_T7(/T2*"/8<I^-VXOHK001_!*M09Y9*WMV8)H?4V$3)2^=KI
M0AE/V<T&>VC>5G?ZR7^+LT';H.-D@3N;#$=C<R_OI;H.S01]"?\`;YQ7"XQ2
M!?MXR5]OO4&CU9R^5PW3_*Y7%2C#G0PRXT^$I<('?H"@$*"@K4DD6/ZE!^7]
M^S)F2G2\YDY_>3W<%#6ZA1;;+WI7>A&EM#GSE[63>WSW&@M/V>.H^6FS&-DR
M6PJ'C,:RJ*]W*@H!#36H*>"@CSEG2-.KPF@ON@&@XFRK?%B%;B+.<_\`&JH.
MTOS%>X:#D[;=9C[4QKKJPVRU":6XM1L$I2V"23X`*#/`;HV_N&*Y*PD]G(1V
ME]VXXPK4$KL%:3[Q%!\\.H'-9X#LD,#_`+*T:#L4'`VD..;\>5DV^0B@IWK9
MT:G0Y2][[(#L><THOY&'#)2XE8%_2HP3\\.;B!YW/PW"6=%NLL+>$!K$Y5Q+
M.Z([0[U)LE,M*18O,CPVXK3V>Y06K0*!0*!0*!0*!0*!0*!0*!01F8L_'QM'
M8,-(/;VR&A^M0<S_`.R?F_\`\=\WA_(Z";N^9[X^6*#(4"@X&9(^->W1VGTP
M_(9%!WZ!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0";"@IOK=UL1MAMS`;?<2[
MN!X!,B0/*$1*^`L..IY5_)3V<S0<OHQT06PXWN[>C)?R[JO2(&.?NLLE1U=_
M(O?4^KG8^;^RY!9^V\I%R^YLUD,>2_CVD1X*9@![IQ]A3Q>2TKDM*"X`5#AJ
MN+\*"4T$?P]OC5N$V'.'<]OU$T'C)<?WY+5;X&%C6&P2#?O)+[BU`=GFLIH/
MIM<6?SO&]\FZ;_P+/"@C6W-PEWJ=E\.-V>LT-H>>]0JB=WZ*I*FD:$R@+.!N
MY\GG<^*@ED](.XL4JW%+4OC[H:H.M0<%M/\`MTZJ_P#X6V+=G"0Y01[KP[W7
M2O-K%TN`,%EP**"VX)#90X%`&VE7']<4'Y9ZC/Q1-PRVVT!/Q>99UDN.J<6H
MO)[PNGNPX0I/"R>%^-Z"PO9PGSCU&5#1%:3$7CO2')2G5%PZF6`E"4!>@FX\
MH:;I[;4'ZCH%!PMB_FGCO\6>/]NKP4'<7YBO<-!PL2RA_8T9EQ*EH=QR4+0A
M*5K4%,V(2E5TJ)[`>%!$^ANV).W<-F(CD:4S&>R!>B.SV4QY+J%,M@EQI"UI
M&E8*04V!\%!,<+I]=[@(''TE@*Y_R1F@[-!P-H"WKKC>^5E>]YM!WZ#\Q=2^
MD^6C2<IOO9RW&94#)R5R8D9.EQ@-D6D10@7.DDE:.T'A067T5ZR1]ZXX0,JI
MJ/N:,@=XT@E*)2`D7?92?[I`\WW*"TJ!0*!0*!0*!0*!0*!0*!01>7_Q!3_4
MC_XRW0<WX3]"/]G\7?\`Y.@F[ILCWT_NA09B@4$9SA/QZVP+\.ZR/#^#:H)-
M0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0";"@ICK;UO1ML.[<VZYWFX%@"5+2`
MM$1*^20.-WU=B;<+WH-'HKT4<AN-;OW<R5Y=Q7?X_'O^66"KCW[][ZGSV7\S
M]ER"?294K>LEW'8M]3.U&EJ:R>4:)2N:I/!<:(M)N&KW2Z\/V*>TT$QAPXL*
M*S$B,H8C,)#;++8"4(0D6"4@<@!0?:@X.(23N?<![+Q`/>8H-S'X=<3)Y2>N
M4X_ZQ<:6AE=M#"&64M!"+=A(*S?M-!J;6OWV=)-[Y1VWB^":%!$]L;981U7S
M.XH+:NY<:?B9!UR6Q('?]XTM"6F6[N,<`HJ2L^#A03*>X!N/%(OQ4S+-O$`U
MV4'7H.`V3\?7Q?@,4S8>[(=^90;.ZL#A<]@Y.-S2=6,<"7)'PBFK!I0<"M:2
MD@`IN:#\V=9-IX8-/Y'!RL8K&XB`U&@NIGEU]<9+1:<CJ845ZUZUI4A:+</.
MO0;WL_XO)1^IS,R0E:8<S!:F%%3:VR^A,4.H3W:E:%)2M!(7Y7&@_3=`H.!L
M+CM#&'PMG]VJ@[CR@EEQ1Y!))]X4$>2I*>G)4@Z`G$DI4KB!:.>)L#\J@B'L
MZY*7-V.\B0G2F'*]'927'G5:`RVH:E../)^?O9M5AX`:">89(&8SIOYTEF_X
M(R*#KT'!VB!IS%C>^5EW_;"@[U!PMJ%)&6MV9.4#[MQ0?E9_9NY7Y>Z]W;94
MM#^W,Y*;,:("EYMK6I??,Z?.T7\I%N7R*"\^B_6N%OB-ZLR24Q-S1F]:VDGX
M*4RGAZ0P3_=(YI]R@M.@4"@4"@4"@4"@4"@4"@BTO_B"G^I'^';_`!EN@T=+
MWZ%M/#O?B][U_0J":.FR/?3^Z%!F*!01K-!?QYVU9-TAG(ZC:]AH9[>SC026
M@4"@4"@'E0*!0*!0*!0*!0*!0*!0*!0";4%+];.MS6!:>VWMM[O=P.$-R9+8
M"Q%"^&A%O.?5\Z!YONT&KT8Z'*QSK.[MXMJ=SRU%^'CWCK$8J-P\\3?7(//C
MYON\:"=2I+^]Y*\?BY"FMILK4WE,DRJRIRTFRHL9Q)N&@>#KHY^:D\S03*)$
MC1([4:,RAB.P@-LLM@)0A*18)2!R`%!]J`:#A8:WQEW!8W(7$OXON<4'=H.!
MM/ZIG?ZU?_<-T%<[`$QGKGNUMU"4L24R'6W7&4!]9;6P@?"$=ZEI*560-6E7
M,#A067D%6W3B$VYQYIO[G<_-H.U0<!J_Q]D>#U4Q^,.T&_N"QP62!`(,5_@>
M7U-5!#>L+#(Z-9[2E*;8]-BD#AQ1RH()T)SS4K>2\0G!X^+(Q^*C]YE6@KTI
MUI;$<HU'44W63Y1L+Z1X*"_:!0<#87YH8O\`Q7]\:#LS21#?(YAM9'[4T''C
MNOL[%;>BG3(;Q86P2`;+$>Z2195^/BH(/[/$Z3D=LY;(27U/O2,AY;BVVF%7
M3&9"AW3'P2?*OYO/F>-!/\/_`$OG?OEJWX(S0=>@X6TK]WEC:U\I+_=@4'=H
M.'M7@G+?UG*_="@KWH%8Y'J`#_O"_P`/DT$6ZR=()^`FHWQL%E41<19D3X<3
M@ME?,R8Z`/-_?6^5N-N=!.^CO6/'[V@)@SE(C[FC-ZI,8<$/H'#OV/"#\\GF
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M$C@$I2.`%!]J!0#RH(8UN7$8K=NX&IBW@M:HBAW4=]\`"..!4RAP)/B-!OCJ
M)M,J*?2'PH"]C"F"_B%V>)\5!YL>9'FL9B5&7WC+N4D%!*5(/`(38I4$J!X=
MHH(!L7+S)O7?<T25D'Y:8#$I,5AUS4TTVI^/Y#+?SFDILKB=7#E03[<>7QV+
MW)AGY[I::4Q-2E00M?'X$\D!1Y"@^PW]M,\II^LO_24&EA<WC<MOF8Y`>+S;
M6,82LE"T649#IY+2DT':W,#\7,I;@?1'K'^#-!%>L_D]'MQ:C_F(%Q^R2.R@
MJ?V>41/TEY!Q$@A7JM@-M(;*4NE3$<N]XYJNHM%*0C4DBRCIMQH/TK0*""[,
MWGMF)M?'Q7992ZRV4+2&7E64%&_$((H.G-W_`+3]"D?=JOJ2_P#`/_0G_HZ#
MZ(DP3TZ$F0$.0/5'>/)7<(4UZ-=058@VT\[&@CW1)>.5MJ8F+AVL&\F7]TP6
M5K=`+C#3C:RXXMPJ*FEI/9;E:X-!VFMSX/%YS-L9"8EEY4AI26]*R2#%:MP2
M%4&U\?MH<?\`638*;:@4N`BXN+C3<4&&QLA#R&/R$R&\F1%>R,LM/(\U0#EN
M'OB@D=!'MF6[G+\;_P"MIW/_`!ONF@@W0/3Z7OT`W/QBE$B@MH@'G0?F_K%T
M:F86>=^[#)83$<,R7$C6*HSJ#<R(R0#=)-^\;^1PN*"QNCW6+&[Y@)B2E(C[
MDC-A<J*F_=O(%AW[!/-)OQ3S30650*!0*!0*!0*!0*!01>;?X[NVO?U(Y9/8
M?NB@UK']#]NWXO?_`"5!+W/-'NCY=!E0*#A9+\\<)][3_EQZ#NT"@4"@4"@4
M"@4"@4"@4"@4"@4"@7H*7ZW=:A@6GMM[<>"LXL%,R:BQ$0$>:GPO$?M?=H*_
MZ*KZ6X9Y.Z=WYV.[N)1*X4):7G$Q+_X1:BBRY"_HNSLXT%@9SK3L7<&4<POK
MX8[;+24G(S0A]#\TJ_S9BR+H9T_57."CYJ>TT$G@]9^CT6*S&B9R+'CL(2TR
MPAIU"4)2+)2E(;%@!0=W;'4;96Z9;T/`Y5N=*CMAUYE*7$*2V5:=5EI3POPH
M))0*`:"KMVY6!C<CGU2G=.N=CG7(S:AW[K`C)2O0CGV6OX:"J,3GL@<ED1(<
M+3,E83@"E"F^X296HI>4I2K%3`MY6KCVBU!^B-GNL/MY=YA27&G<G(4EU!U)
M4+(%PH<#RMPH([@LSBG.JL_&P<?BV'Q%DN9";$6V[,<<;>82D2"E"%->>;I4
M57/N4'5WI+CQ9L=Y]]#"?5^0`4M03<_`&R;\S8<A04R]N-'QT:>0I;.TD,6?
M:+3P>5(4TL%145V+??:5"UN'906WLC(Q)N79,>2W)*<+%[PMJ"B"7W3Y0YI]
MPT$GW(RZ]M_),LH+CKD5Y#;:>:E%L@`>,F@KSK%GXTSI'G&&HTQ#BHK8N_#D
MM(&EQ!5J4ML!/`<S0:/1/I0UA)4;>YR"93N8Q3"/1>X[ONM:&UW#@=4%<$@'
MR/\`XA<5`H*-RVX8L7:V.[I]#TI&*D)AQTJU)$X._`]\$$*"1\]^K0:?3+<<
MW5#3F9:&)H3/.2)^!8+7=VC)27%>41QO[U!:J4MM],-*U!#2<*=2U$(`'HO,
ME7`>Z:"&^S/':C["F-("0?63RBE)"_)4TT4>6E2DJ\FW*W@H-O=.:Q^/FSTR
MY/=LG,M&6PVOX93!@HO9%]1OV4$`VONG-O964G(R$1FE3HQPJ&-:`ED25!8?
M4M5O*:"*"ZMB+2N#E5H4%(5E\B4J!N"/25<C026@CVS%$L9:YO;+3A[P>-!"
M>@I^Z-]^#XQ2OE"@M<T%:]'4;+4K..;3@2XF.2ZW'==EOK<#CS9=+J4-+6X6
MPA2S<\E%7"@K_J]TBG[8R2-^;$U0A#479<:.-2XRC<J?93Q!:-[.-\@.(X7H
M+!Z.]7X&^<=Z),T1-R0T#TR&%`AU``'I#/`70KM'SI]Z@LF@4"@4"@4"@4"@
M4$9F@G>,@"_'#*]R_?GWZ#7TN?HDTV^$]06T_P!EZ%RH)6[YOOCY=!G0*#A9
M+\\<)][3_EQZ#NT"@4"@4"@4"@4"@4"@4"@4"@4'A-J"DNM/7-G$-KV_M:4V
M]E'1IFY)M04B*E0X);4#I4\?[GW:"/="NG.QIN+^-FYY\++39VL,XY]U"VXX
M*B%EY*S=3ZNW5YO9X:"U%[6Z,Q(;CIQ>$[AA"W5GNXZR$I&I1',GA0</:2O9
M_P!V1'96+Q6+2VTI*7$RHK<904XG4`$N!)[>R@D)V1T>T@G$X4)'`'1'`H(+
MT\Q^%@^T5NV-A666,:UAHO<-1=(925%DKTA/"^KP4$GSTWJJU(R#N+C!>(95
MD`L+`,Q5FV_1#$2G5=.K5;4/#?LH+)!N+^&@4'Q=@PGEZWF&W%VMJ6A*C;P7
M(H/GZKQG\D9^MH^90?=EEIE`;:0EM`Y(2`!Q\0H*_P!J=/\`,8CJ+EMPR'&U
M09HF%K2\M9/I3[3J$AE2`&]`;5J(6=1/903Y^)%D`!]E#H3YH<2%6OX+T'Q]
M4XL\X;!MR^"1\R@^D:!!BE1BQFF"NVLM(2B]N5](%Z#'(SHL"(Y+E+T,M"ZC
M:Y)/`)2!Q*E'@!VF@BF[=N;BWIMF?A7G6<)"R+?=G4V94D)U!0*O*;;0KR>7
ME6\-!(]N8@8;`8W$!TOC'QFHW?$!)7W2`C5I%[7M0=&@4'/.W\$5J6<;%*E&
MZE=PW<D\;DZ:`K;V`6/+QD17NL-G^]H-/>VAO9.>L`E*,;+L.```87X01^I0
M5[[,*&QL&86PX$*R"[EU(22M+#*7+6X6UI(%!:3^%P\AXOR(,=Y]5@77&D+6
M;"PNI0)H,#M_`GGC8I'C8;^EH-N/&CQF@S':0RTGS6VTA"1?CP`L*#Z4$>V7
M?T?+7_*T[[,:"$]!;%[?2P;@[CECL[`*"U7;=VJYTBQNH<+"W/C0?G*2Y'Z>
M[<3*Z=Y21,3GLBP'LBZTRXAY#++RELQ[(5904D]XI2/)^307)TNS^2W'T_Q&
M7RQ2N=+:7Z00D)"BAU;=RD<.*4\;#WJ"F^L'2=_9TY&_]EN*A,PG0]*C(/\`
M%EK5;O6M1XM+*M*V^0OPX<`%O=)]\2]Y[/8S$N*(LH.N1GTH-VUK9("G$#B0
ME5^1Y4$QH%`H%`H%`H%`H(S/*?C=)!XWPJC;Q!XT'PLC]$UK'N_4/+C>WH?N
M7_4H)4Z+I]\?+%!G0*#A9+\\<)][3_EQZ#NT"@4"@4"@4"@4"@4"@4"@4"@4
M%']:.MRL:M[:NTW2YFU*#$V>T"OT=2[`,L``ZWU7MP\WW>0>])?9^QT''N9/
M>L1N;DYS2D(QSOEM1FG4D+U?1/J"CJ5\[V<>-!;N&VW@L+CF,9BX+,2#&3H9
M80D6`'C-R3X23>@I_J?NO/XCJQA\-CLBVWC9L1)<PR6M3A44R"7;]V46);2+
M%?9RH(MTNZ[2H.`=3O-YN9DBYI:,AM3!0VAM%@0VPXI3CA<X#3:PYCE07K$W
M!BYN*Q\N#CE29&0C-RF(*$("T(=`-W%JLA`\9/'LO0<+:NQ\]#ZJ;AWC.1&C
M0LI"CQ(L1EPN.)4T$:E*.AM(OH[*#X;%ZVXS=NXD85B`IA;J)#C:^\4M24QU
M!-W4J;;2-5^&A:N/"@FT_<^W\?+]#F3FF96D++"CY>E5[&POSL:#6&^MH'EE
M6/DGYE`.^MH`V]:L7]T_,H'Q[V?<#UJQ<\AJ_P#A0#OO9XXG+1P!Q)*K<![U
M!V!+BF,)7>H]&*.]#UQHT6U:M7+3;C>@X,[=KS,%W(1X*G<<RA;IEO.)8#B$
M#45,I(4M=QR)`%!]4;[V<NVG,13J%P0X+$>$&@S.]]H`7];Q;7M]4%!'MU[U
MP05CI<64UD6HCSCJHC#S*5*=2T0R5=ZML:$K5?GSM00C"]:]UXMJ7D]ZLQ58
MQAHJ#&-[A3P6M8T\52O*2@'38)N>?"@M#$]0MH9/%Q,BWDF&FY;2'0T\XA+B
M-:=6E:;FRD\C0;1WGM,6OF(G$7`[Y%[?)H'QSVD!<YB&!QYO('+CVF@P.^=F
M`V.=@`CL,EH'C[JJ#([WV<"0<W!!',&0U?\`=4'PS^?C>I(LW'K;R$6;(:CH
M#6EYJ0'5%'=:K+2`M7D%7(4'(Z=Y.>ZX8DK`M;84J$U-<PK*$#NW79#[16I;
M:4))6VR@VM<4$XH->=-8A1ER'R0A-A9*2I2B39*4I'$DDV`H(;N?>V1Q$F$P
M](B0)LQ25Q,8\VXZZ\R'D-NW?2IMI"TAS5I&KWZ"=4$?V=J$?*:A:^5G6]SO
MS00?H`HJ3O=5[WW),[?$GC06NY;0JX!%C<'E;WZ#\W])>FV-W7@,MC<N7HB8
M\V/DH;D=5K!]IQ*4=V^'4*;2GDI(LKZ)5J"_-J[;@[:V]"P<%;CD6"@H;<?5
MK<5J45J4I0`XE2CV4$8ZZ6_1+N7C;[E'$?XU%!Q/9E_X7,_?LK]V*"UZ!0*!
M0*!0*!0*",9-6G=,Q0[,*L_(>50?#A^B3EP]0<KG^1>'G02Q?(>Z/ET&0H%!
MPLE^>.$^]I_RX]!W:!0*!0*!0*!0*!0*!0*!0*!049UGZYB`7=L;3=+N66KN
M)N09\KN5*(3W+%O/>)-KCS?=Y!N]%^C,?;Z6]Q[E0AS<;EU18RE!8AI4.))N
M0I]7SRNSD*"Y.]:/):?DB@=ZW]$GY(H*/ZB;><R_6K'Y!J:J,UB<>RJ0&F77
M%*[WTL)\MEM7F\[*6GQ4$,VMTWA;M3-<PLR3D&,8TF"\^^!AGGY2V6G$.+08
MZW%I;^=[WC?CQ',)KBMY;DVAMC!8G%XDYG+EM7KQ^2)++;2VM+2&4J#)'`6T
MGE9)[3067M;?.#S[RL8U*;7G(D=M[*PFTN@,J<%B`74-DC5>W#B.-!7W2_HS
MG]J;N8RTQV.J.PQ(:<+:R5.*=62C2D-HTI"3Q"E'CQ-^%@Z^<ZJ['VAOS.1\
M[/5&>7'@:4)9==X@.FUT)/&SB30?3_F%Z2\+YH\K_P`7?']Y0/\`F%Z1C_QN
M^DV^H/\`TE!&ML>TUMR7E\DQGRUCL8VH^JI;0>=4\@+4/A4Z24'0$J]^@[^5
MZ]=*'\/-9:S@4X]'=0AON7]14I!`'F>$T&&V>H^Q]THV]M+&Y%$B4MA"Y\30
MXB[<-D*6T=20D@K`"AR(!H-CKQ@)\[:C.6@K:0YMYQR>ZEVZ2ID,J0X$.)"B
M"$JOIM97*@TML==^E,;;^,AR,T&Y<>*RT\R6']2%I;`4G@V>V@Z:>OO2-2BE
M.<25#F/1Y%Q;^#H,QUYZ47_ID#^;R/M=!#NL'5[8&=Z<Y;$8?(>ESYJ6FV6N
MY>1R>0I2M2D)'`)\-!TM@];.F\'9.#@Y+)B//B06&)3'</JT+:0$$:@@@\O#
M0=_]/'2<#5ZX%O#Z/(^UT'GZ>.DI_P#&`;\/XO(/_5T'IZY=(S8JS*.(O<QI
M'9_!T'R/7OHX%@JS["3>WE,/@WO;M;H)%TWR4/*;.AY"(XEZ-)<E.-.)3I!2
MJ4Z0=)`M0=?/9>/A<+/R\A"ELP&')#B$6UJ2TDJTIO87-J"H/^8S,2Y,61B=
MCY.7A70>]DZ%EQ5B0>Y[M#C2K6[5B@DFSNI*M\;AALIV]DL9$ALNS/29S.EE
M:SI;:T+'`G2XHB@RZS[79E8Z'NIL279^VUAYF%&1WWI#:W6^\:[LA=E63<+0
M`H>&U!R![144O+93LW<*G6](<0(@*DZA=.H!7"XH.+MSV@(4)S)0SM7.2))G
M2)3K3$<.+:3(<*T)=0%:DJMX10<7IKU1D;3^,(E[0ST@YC*R,DR68:_);>L$
MH7KT^4+=E!,S[1#)!"MC[C(/`@P^!'R:#N='<MM/(P\LO`;=E;<4P^VW,C3$
M%MQ1[O6W8%2R$)2KR4\`.P4&QOGJQ'VGF&\6K`Y3++6PF0I['L=ZVA*UJ0$J
M-_.NB@K'JAUJ>S^SLAA8NU,M#CSVBW(GSV%,ML@+201I2L*N1;B103+V95J5
MTR0"DI"9\H`FUE#4.(H+8H%`H%`H%`H%`H(IEM7QHR%_-]1+L/'WR[_K4&''
M]$G;?U![_P#$J"6.7L+>$?+H,J!01[)+5\>L$V!Y)A9%9/C"XH'[J@D-`H%`
MH%`H%`H%`H%`H%`H!-!1'7'K=Z`U)VUMA^\VQ;R>2:/U$'@665<N\[%*^=]W
MD&CT?Z=].L1!3F-W93$3<S*2`S"=E1W68B%"^GSU)6\>U79V>$A::'ND*R4H
M>P)*.*@E<3A;PV-!#.J*]@';JE;;5A'<PMT!EMMZ.E*K)-PYH6FR0.)H.;TA
MA;70S/;W:K"#(:PIIM+[2V^[)44Z-:S\Z.-!/Y6-Z3/1Y#33F%8>>04]^A47
M6DD$)7S^=/$4$>V%LCI_MUB=ZTRV'RDF8XROO/@4)0&&4,@C6XZK4YHUKXVU
M$V%!*RSTM(5=W$Z5^==YFQ_NJ"O]ASMM8WKAO-<>7"B8Q<*&B*6W&D,J.E).
MA6K3?43<"@NZ_;V>&@I;$1H<WVF]Q]XAJ0VWB&@4J"5A*P&`>=Q<<J"RLG+V
M3BWTQ\AZ#&>6CO$-N(;"BB]M5K<KT&H=P=./Y1COVK?TM!XK<735%@N5C$E1
MLFX:%SRL+B@A3W43`S,OF,'*PL*%C1$F>@98.,NA]35D)\A"?(+FOR4ZM7#E
M03W&PX.,VHU-APF8\EC')6@AD(4"A@*`5R5S'$7H*RZ7=1MV;IG3H.<<9DQ%
MXER2ML!"M+MFQHL&FOG7-1'$>4!<D$T'R]FGN6-IQ(TQE#J,HJ5+@/.(22ER
M.^IE]D*([$)0XGW5>"@U_:HB16\)M\,MI:6Y,=2M3:4I44EKCQ`%!9#/1WI?
MW*/]G(9\D<=!\'B-!\,ET.Z7SH3T88-F*IU!0F3&NVZV3\\A5R-0[+@T%7N]
M"]I"?DM+\WNX,F8RVGO&[:6(#;[959OB>\<X]EJ#,=`]I]^WJG3R%R.[\]GS
M1CA*_>K7[S]3Y-!N['Z"[)FSD2)SDR2W'C0)AC*<0&G%RF2XXAP)0E6C4.`!
M%!W>J/2CIYB^G^>R6.P4>-/BPW%QGT:[H6+`*`U6N*#A;-7CH/LW2IRH;,B6
MXU.99U-(4I;S[RVD><.-M0]X4$X]GX:>D6WQSLA[G]\.4'=ZGFW3K<IY6QLG
MC_!&@XW0@$=),"2;_!/$'^'<H.OC9SF+Z:,Y!D!UV%B?2&TKO92FHY6`>1L2
M*"+](NK4[?&6R<)^,E#$)AIUJ0&RPLJ6HI6A3?>OCA8$>503/!H(W'N-1).I
MZ-SY"T5'*@@?3&WZ8.I7A[^)^X506U0*"H4Q)T+KSE\\%ZX/H;<1V(@N>D.*
M4PTI!::2DI=`4+$E0TWO>@LO%0Y(>D3YB0W+EZ1W0(4&V6[]VWJ',^45*\9H
M(SUO3?I1N,?Z,G[*B@X7LT?\,&OOV5^[%!:U`H%`H%`H%`H%!$LDH_'#(@7N
M,#<<>TON?(Y4'O']%/C]1?J^AT$J7R'NCY=!D*!01[(H)WY@U7\S'Y+A[KL.
M@D-`H%`H%`H%`H%`H%`H%`O\F@H?K5UJ=;?.TMG.J>R3Z@Q,GQO+4%+.D1HQ
M'-U1-E*'F^[R#9Z:^SUA(^']+WO'3/RLL!7H!<4&HJ>>BZ%)UN7\]1X7Y>$A
M+QT&Z0@@#;D>_+ZH]<^[\)0<Z-TGZ'2,H_AV,&@SH]U.HM,2!IM>SJB&SYPY
M*H(QU:Z5=.-N[8].Q6`09JG2AMM#[R0HZ%*XDJ4`/)N30:'1OI7LO<$.=(W#
M@61*;6$I93(=6A*;J2"DI6`0;4#K%TKV#M].U4XC$HB^L,TQ%ED+=47&7/.0
M=:E<_%06,.@72("PV\T`!;@Z_P#)^J<Q0!T!Z2#_`,`;Y6OWS_VR@^$OV?NE
M:HKJ&,$VE[22R5.OJ2'+>22"OCQM02B7N9IC9D_-Q4H6YC8KSCL8DV0_&02M
MES0%*&E2=)L*"B.@V7&8ZSYW+I;#/K*+)E+:2H*`4Z\TM0"@3<`]M!?C6A6\
MYB>!(QT:X]U^1\R@[);2?>[*"FO:>>BQ=I8M]:I;<A$QST54-24V7Z.X;N:D
MK\D`=ECXZ#C=)XN21UMSXDR^^A(CR%Q&&G6W4(*W&=0<0E2W&E:2+)7QYT%]
MR8S4F*]&=OW;Z%-KL;'2L$&Q]^@A&W^E.V-I)D3L9WBGV\>[#;*TLI/='X0Z
MBTVVI:BI/-1-!#.CT22>AV&R$(:Y^'F2I\=-KE:6Y+H>:X<?A&5K2/':@T?:
M?EQINW]IOQG$KCRY2GF7$\2I"VDE*AXK*H+Z:'P:`>/DCC[U!QM[Y]_;VT<O
MG([27W\=%<?:97?2I2!Y(5IXVOX*"G96Z=V*3,<6MAEV0J8[(3ZFRP4A3D5"
M'?"#W;>E7$_J4'@W;N];R"V[%*D/]XH>I\SJU"`&5)MH-[,?"<_U*#?V)NO>
M3.=Q\6/'8R,*8,=%F.-0,E'4U$0PH-R>\?0AH:D\>?'LH)[UC!5TMW,+?YBX
M;'Q6-!66PGD/]'\1!*=3;+&:R;Y(OI1%#S;9Y<RZ^"/<H)OT&DL1NC.$DOK#
M4=AF0XZXKDE"7W"HGW`*#;WSNK!9?8F[8<"07)<7%R%OQW&G67`E32K'2ZA!
M(]P4&'0NPZ08!03IU,/*M[K[AH.U@8"<MTVAX\N%E.0Q*(Y>38J0'H^C4`>!
M(U7H(_TKZ=1MJY3,2!EV\C*6EF*[':45=P4#6I3I6MQSO7=04;VX6\5!+<*3
MZ\W!SMZ2Q;\$:H*^Z8?\8>I?^/B?N%4%MT"@6XWH%!!^MY`Z5;B)_DZ1\EU`
MH.%[-)/Z,T`BP$^6$^,:Q8T%JT"@4"@4"@4"@4$/RGYY93__`!__`*]Z@^EC
M^B>W;ZAM_P!CH)4OL]T?+H,A0*#A3$D[VQ)!X#'S[^^]$H.[0*!0*!0*!0*!
M0*!0*`:"A^L_6AY,D[1VDOTB9)/H\V=&.M?>+.GT6/:]W#R4H>;RY\@Z_23H
M-B\!%&5W/'8R&?>'D,+2'6(B#8A"`H$%WZ)?O)X<PLT;5VV#<8R,/<:3\SQT
M%;=<E-;6VY"R6%]#QL@RBEU;S.L.MAEQ?=>2VZ>)2#V<N=!%^FB,C*ZOY/%9
M:.KU2F&]*AH>:6$.K<]'NI*C\&0D*OY/`7H+GE[(V?(0/2L/%>0BY`6TE0';
MR-!!-A[@Z5;ES2\3B]O-PY'<*EMK[MD)6A"DI)NTI5B"OM[;CF*#?ZC=)SG&
ML,[MP1,=/Q60:FZY"%E#B6^.@E%U><!0<K!]1>K>6W"O%';L>%#07BK+RX\M
MB/W;5PESRU:OA%H4D#GV\C06IAY3\O%0Y3Z4H>?90XXE%]-U)!\F_&W@H-N@
MY4O`,J>>E0G/0I4A)$A24)6T]?A=YH^2LVX:N"K<+T%-=-<`WA?:%W-CVG&U
MMM052"&VPRA)DK9<*&VP5!*4E=K7H+2D3ACMZ3),F/(,9_'16V7V(SSZ2MM^
M05H*FD+L0%I/'PT&\G=V)5R:F\[?Q"9V?P5!6W6Z)&WAC\+C6<7DIK#<M;LE
M3,:0RIM(94E)NZV$V4I5NV@Y.P]U8&'U.RF-@X.5!BQ4S7ITJTR4\[(==:`*
MHZ$683Y]@4GLXT%M.;WPC065HFI2WQ6KT";8`>XS0<C*]3=G*Q4K1)?6IQAS
MN1Z',`7J0=-E=S\]<<:".^SQ.A0^C.)D37VHS'>RPIQY:4(!,ES@5*(%!777
ME]N&,+@"06X$]V1C2""%P)80MDI(/FMN!;7N)'AH)ETFFYG*9G=.-6KT63C)
M2WL;D@AX%YMU]T:'@5*:D-"VD>4%#P=M!+-_Y)W(=(]Q/O-B/):AR&9;9/DH
M=8.ARQX^3=-TGP4'&D[PVFI.34G,PE!;F14FTAHZKP6TBUE<=2@0/":#ZM[T
MV;WUO7<`*,A1_C#79B$HXG5RN--_#PYT&YTXW/MQQ[T=O*PU2'8&*9:9#[>M
M3B8Q"D)3JN5`\"GF*#I]9/\`A;N6_(PG`;\>!(O05/TK?2>BVZ9\NT=F)`FX
MN&M2PG42EV0O23\\M<A*?>H)9TS:D.>S<EJ,R7Y"\9D$M,)XJ6LJ>`2!VW-!
M`-FX3.0<)U!D3V%%+V$>6J5<N`NNB_=EY24%>E*/E^^%O=#;'H_M_3>WHSMC
M_#.4$DV@I2-EX@VU*3CV#Q[2&ASH(/T"SF.RV.SCN/PC6&:3+2I[N>\L\\M'
ME*/>*7YJ4IX`^]03O"G_`%[N'P>DL>[?T1J@@'3%)_2_U*4`=(?A@JMPN4+X
M4%LT"@4"@@?7191TIS]B1=MI-QXWVQ0<GV;@1TR9OVS)1\?GCG06E0*!0*!0
M*!0*!00_*'_;+*#P;?!_R[U!]-)_1/IMQ]0VM_,Z"4N<A^R'RZ#.@4'%E_GG
MC/ZOG?9HE!VJ!0*!0*!0*!0*!0*`:"@NLG6E^1(=V=LPN29SSGH<V;&&I:G%
M>28T:W-1Y*6.7(>$!).C/16-M.,WF<XAN1N9U/D#@MN$V?\`!M?V9'GK]X<.
M86S0*"I_:)Q+^7V_AL;'<[IZ1/5I46G'A9,5XJNEEI]SE]"F@Y^P4XR'U9DP
MF%Y%R=(ARGI#DN(W%C:4&,D)C+4T'G!=7'RT@</)H+G6DJ0I/A!'R:"END/2
MW=>VMXG*92,TQ&$!;#[J2S=R0IQ-N[2T5*TA".*EV*CQL.0"SMT;SP.V$P59
M=U;?K*0F'#2VTX\I;RQY*;-I5:]!ZMR9FFS',9Z#CU\'W'K(>=3VH0@%2D!7
M(J58VY>&@[2$(0A*$`)0D`)2.``'``4'M`/*@H#(;RQNSNO^Y<ME(\UV(_CX
M[`,6,M\A10RL$Z1P39!XWH).GVE^GBD:DQ\J18GA"5R`N3YW@H'_`#+]/>Z+
MIC98('SQ@K`MPX^=XZ#YGVGNFH`);R@!X`^AJM^Z\=!',1U?Z.8C<<S/1AG?
M2YI?*V76%J909+B7'BVVH\"M;2>WA:PM0=^3[3?3=<=U`;R>I:%)3>(>9%OH
MJ"D]N[IVQBLD<F[,RTB04.I5%4U=A`>3Q0A&KAH-K'W?#02WIETFR6].EN/3
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MMH!T+Y7O:@^?1C=.`A])L+&D2T,O1X[J76U!8L2\X1\[QX>"@G&S"7-CX520
M+KQT<@=G%D4$-Z'89K$-9J*IIAB>I45V<Q%<:6TA:FCY*4LH2A/(W\I1/::"
M<89-LWGSX9+'XHU00/IBC_W8ZEKO_G,(6_@W*"U:!0*!00'KP+]*,]V^0S^,
M-T'+]F\.#IC&*R#JERB@`WL-?+Q4%I4"@4"@4"@4"@4$/RJ;[LS'A^+Z0!RY
MO2.V@V=(_1EIXV]2VMV_Q2@DK@N$_LA\N@RH%!Q9?YYXS^KYWV:)0=J@4"@4
M"@4"@4"@4`\J#\_]9.M4F7)7L[9*U/R7U^BS)\8A2EK6=/H\90/._!:^SL\-
M!V^E'0C"X7&L9#<2!,W(ORK-/*#</G\$TII2"5Z3\(N_'LX4%DC:&WR-(9<M
MR/W3(^V4&2=J8$-A/=.Z`;@&3(M<_P`)09)VOA#R;=-N7W3((M]<H"=IX9!N
ME,@*O?4)4J][6Y]YX*"&X3H;@L5O>?NA,V0ZJ:'@F/K=;<3Z0I"E)5(2YWCB
M4=UY`/A-[\+!,CM7$D6O*_#9?VV@]^*N)^BE_ALO[;057UMPT:'EMA)CAU2'
M\\PATO2'W1YR--@XM8'NVO0770*!0*!0+#P4#2/!0>:$>`?(H&A)Y@?(H&A'
MT(^101^=FIJ=VQ-O>H7Y&+FQ7'7\V-)BM*%QW"TV/%0'ZHY\;!]&MD;-CMZ&
M,'CVFQ\XB,RE(MX@F@^.U\5BX\W(S\;$:B1));882RV&DN)8U7=TI`OJ6XH!
M7:!X*".8;JYB<QO,X!6*<:6S/E8Z+/7Y04]&0I2RGR-*04H-[+U<N%C0<_VF
M?^$\W[ZB?9A069BD:,5#1>^EAL7//@@"@YN1WMM7&Y)>,GY%N/.;95(6PL*U
M!E"2M3G*VD)%R:"LNKV[LBC=&SD;=SZVX<R2EN8B$LJ9*"^R"MUQO4FWE:=)
M\-!=%!'NHG_#_<O]53?Q==!%.C.+1D.C6VTAU<=]I"WH\EOSFW4ON64`>!!N
M0I)X$&U!PNN6U<GE]KR,K-@J.2PD=:FIL-Y'HSC"G$+>#C#A[P$)1<`7X]IH
M(7T]Z/Y+-8'";K3)*6A%/=0^\(;4IE3J0M8O;B?['LH+\V=J&P<-W5BL8N/H
MU<!<,"U[]E!%>A^U,CM_'97TZ&U#<G.QWBVPJ/W6L1TI=[M$9;B$I[R^DDW4
M.)%!-,./]<Y[[Y9_%&J"!=+#JZH=35"Q`FQ$D\;W#;@M06K0*!0*"`]=S;I5
MGCX$,_C#=!I>SPFW3""KZ)^2KF3_`(4CMH++H%`H%`H%`H%`H(CES;<F;L"5
M^H$:0.?U63RH/O;_`-LK?^2\K_Z)X:"2K-K>Z*#*@4'%E_GGC/ZOG?9HE!VJ
M!0*!0*!0*!0*!01?JB\ZSTYW(ZRLH<3CY&E:24D?!D<"D@B@H;H=TGVSO/$Y
M6=FQ(UQ)B8\7T9XLI"0TE2N0-S=5!9B?9MZ?((*'\H@#CI3,4/E)OQH/H/9S
MV"!8/Y.W;]V*X^[PH`]G3I^"GX;)D`6L9BR#^IV4'C?LX[!1RDY0_P`\4/E)
M%!E_R[;"N?NG*\>STU?#]2@^:_9PV&HD^EY9-_!-4/U=-Z#P>S?L/LF9<?SU
M1^6F@\3[-NPDDDS<PJXM8SE?)X)%!!M]=+,!LG<^Q9.)DSI"I>:CMO)F/]^+
M(<0L%(TIL:#]'T'/W"6QA)A6'"`V=(:+X65?.V,;X;SK7T<;4$4Z1*F*P+QR
MO?#/=X?6:%'(E@*NKN^Y]/\`["VKN^%^=!.Z!0*!0+4"@4&KEGW(^,ER&C9Q
MEEQQ!/$:DH)'#W105[TBEY;>W3[%9W<<]Z2]*#R7XK>AF.X$.J0DN):2A2N"
M>6JWBH++`2E(2D`)3P`'``"@_/.RMFRF^M\A\3X+S\#(3YD^*TXHO(:>2ON5
ME.GBL^D!*R>`Y>&@F7M,$#I/-)Y"5$O?_'"@LK$_T5"!Y]PU^X%!^?>K,B0W
MU6R+#J4AM[$ONLO*UJ=[MG&R`MIK3="6W%N75K3YR!QY4'*Q^*CXYC9S&5?3
M+<?FN^@M."5#47G),8I3I]'2%-@B]G+(U<J"\<7U9V3E-UN;6ARG5Y=MUYA2
M%,.);+D?5W@#A`2;=VKCXJ#H=0^&P=R_U7,_%UT'#Z$$GI)MR_9'6.=^3RZ#
MJ]3PK]'>Y-)L?5TGC_!F@XO1`G]#>!/^BO?9G*#O[32T>GF)3I4&CBF/(X%>
MGT<<.5KT%>>S,]'>P>=7%0\W$$UM+#<I27'0GT="B2I"&4V)5<`(X>.@LS"A
M7KS<!)!!DL6MV?<C/`T$#Z3*0KJ1U-*4Z+9&.DIY\0ET%7]L>-!:U`H%`H(#
MUW_X49[]@S^,-T&C[.R7ATPA%Q86#(E%L`6TI[TV3XZ"S*!0*!0*!0*!0*")
M9C3\8,YPNOU"BW&W#O)/;0;6@?HZT6X>J+6O_HOAH)"YR'[(4&5`H.++_//&
M?U?.^S1*#M4"@4"@4"@4"@4"@B?5G_AIN;L_U=(X_P!H:"KO9FPT";MC+NO/
MR$NKR!2EMF4^RG2AE!U!#:T"_'B;4%RM[7@-K2I+\RX\,V41\@N&@^AVYCR2
M>\E\2"?NN3S'\)0#MR#I2GO9>E(L!Z7)OQ-^>NYH,O4$/2$]]+LD6'W7(O\`
M)UT'T3AHR>3LD\A<R'CR]U5!@K!QU$WD2N)OPDO#^^H/#@HY5J](EBW("4_;
MY&J@Y>7CKQN2P:HTJ3]UY`,/H=?=<0ILQGUE.E:B/.;%!".N2=6X^F]Q=/KY
MH$>^B@MV@4"@4"@4`FU!YJ%![0*#1SG]"9#[V>^QJH('[.:-'1W;Z0"/(?/'
MCSD.'AXJ"RJ"B-D>C)]HW<:4D]]IF%2@"%J!$8A+G^#T)XZ-'E_1T$B]IKAT
MEGD\O28OV84%F8W^CHI_Z%O]R*#\^=43DE]7IBTJ:$>-`>2TXZ6_)+F,=*DV
M/-)M<A22./CH([MF5E,(YLV$I*65.9!^%Z&\MUI:0)D92A:.60XO42O4[?A;
MG84$GV9L/><3K,O(/XR7&Q`RN0EORB4!E:5)=]'7>W%*P[8)23VWM07/U#_,
M'<G]5S/Q==!PN@]_T0[9^]5?95T'5ZH*2GIUN0JY>KI'ZK9\-!Q.B!OT9P)_
MT5[[,Y023;S;CFQ,<A#?PB\8RE+7+RC'``X\O?H([T8V/,VCMYR)*AF&])[E
MYU*I29*B[W02YYC+`18CE=?[*@D6W2/7NY^%K3F;^/[ACT$"Z.$GJ/U2O^5&
M;?Y:@MR@4"@4$!Z['_VJSW[!G\8;H-3V>B/T7X^W+OI/V95!9-`H%`H%`H%`
MH%!$,]?UQN#Z#XOIOX;ZY5!NV'Z/+=GJBUOYM02!?SONB@RH%!PI1_VXQ@U?
M^&SCIX?O\3CX:#NT"@4"@4"@4"@4"@B?5H7Z9;G'AQTC]P:"F_9BV2Q*FO;Q
M5)4AZ`X]`1""1I4'&D*+BEDWU#5:U!^D*!0*!0*!05?OG=&^,7U1VOCX+JV]
MM9!YEB:DQ?@BXX5ZDF6H$:BD#2A)!N*"9;G5IG;<XVU90#W?N2305IUTB!&^
MNFT_O%$KS#47NN&FQ>;<U7\/DVH+IH%`H!H*,W7N_J[.ZHYC:^SY+?=X]AJ0
MF.M$=(#10WJ5K=!*B5N4&)8]J;L<C?MH/TM!@M/M0M:2Y(BHN;)U+@`7]]-!
MP]M[!]H?;LR=+Q>AM_)*"YJG9,9X+6%*5=(<U!'%9\V@[_<>U-S[V/[@5!^E
MH-6:_P"U!"@OS9+K2&(S:GG;&`HA*$E2N`3QX"@T<_E?:2QV!F9+*K:1BF6%
M.2W`(*O@5"RO)2-1-CV4%F=`DI1TEP*$^:E#P'N"0Y06#04-L!#O_,9NERQ#
M:TRP-(2>+:F`>\2;K0DZ_)5P"NRX%!)O:6*1TIFDI"AZ3%X'_&B@GVUH!QVV
M<5`+RI!BQ&&>_7P4O0V!J/NT$&W)T;:SV^96Z#E@R7HKD,1?1PX4%<54;7K+
M@!*>\*M)3[O98*TW7LF-M#<FP]ONY`3I`F*E,R7&$H"UN36#H4FSRK><>!YV
M[!0?IF@X'4$VV'N,VO\`ZLF</X!=!P^A1!Z2[:MP'HRA\AU=!U.IT"=D.GVX
M(4!E3\Q^"\EAE%]2U:?-3;B2>P4%6;!WYN_;.R,=MIS8.9D/Q&G&4OH;4A"R
MM:E@V4BZ?/[:#LX3JUNJ#B8<%WIYFU.16&F%.);LE1;0$E204WL;=M!N*ZT[
MF3_]NLZ1X0C_`/+0<G'=6]TP<AE92NG6=6,C(0^E*6B2D(CMLV4=/,EN]!L=
M"%963NS?^4GXN5B3DYD:2W%F(4AQ(6'E6\H"_`CB*"XZ!0*!04Y[26UI\_;(
MSS604Q$P[:A)QXUZ)'?NM)23I4E-T$<-0-!U_9V;4CIA"NM2PJ1*4-5N`[TB
MPMV4%F4"@4"@4"@4"@4$/SW],;BOR&WT>YY\N@W_`/[>_P#TG_Y:@[[GSO[(
M4&5`H(Y)3?J+CU>#$31\F3%^902.@4"@4"@4"@4"@4$4ZK_\-=S?U=(_<&@J
M_P!FK(Y./M'+IBXIZ<DY`J#C;K#8U%ENZ2'5H/#@>5!<"<SG?GMOR0/\?$/_
M`%M`&9SW;M^3;[XB?;:#)&8S9\[`R4_PT0_];0>IS&84+G!24_PT3[=0:<S=
MLV)*B17,%,+\U2TL(2Y%-^Z25K)/?6`"10'-WOQWXJ)N&F169<AN(B0I49:`
MX\=*-0;=6JU^VU!%-T[DV\GJUA\!D80D2%HBR(<I4Q]EMF3WCG=A4<'N7'+#
M4CA?]2@F^XH&0E'&OP&VGGH$P25,O.*:2I/<NM&RTI<XCO;\4T%4]:9.3^,O
M3I64C,1&49]HI=1([P7N@G5K;9"1;MO07:A:%@%!"DGD1Q'R:#V@4&ID<K"Q
M[:5R5$*<5W;#205..K(N$-H'E*/N4%';BF[DV=OO=W4)6+<:A2HT&#`=D!*@
M2ZXTET]TAS4I2`V2$W'&W&@GW3#J%)WC@<M+<2A#V.DKCMNZ"@+3W27$*6A*
MWK$%1!"5GE[U!4>5WM`SF(CKWHJ'NIAG)HAP,A%=E1&&E28P6^KX*,%+[I2+
M`=WJ2%<U'C0?IAL#0FPL+#AQ_7XT&5!QMY?FGF2.?H4C[&:"/=6R$](MPDB]
ML:>!]P4'QZ#?\*<'^Q?_`!AR@L`4$;Q>P\3CMRR=P,R)2Y,A3ZQ'<<!8;5++
M:GRA(2%'464<%J4$V\FU!#_:7N>E$T=JI,4)[.)=%J!B.K&*W@_$VKLV6M&2
M<CZYV0>96V(L=H)2M327`.\=)59'SHYGE:@L;"86!A\<U`@H*66[DJ6HK<6M
M1NMQQ9XJ6L\23089#;N`R,V-.GXZ-+F0S>)(>:0XXT;ZO(4H$I\H7X4&6;5F
M4XYUS#H9=GHTJ:8D$I;<"2"IO4GS"I-PE7('G04WN'J_A(F$W%M7*37US'H$
MIN*J0TOTAAYUM2?0Y8MI*T%8T.INE2>9\(3;H1_PDVU;EZ.K[,N@GM`H%`H%
M!Q,<\TG/9PFY+28Q<L2LV[HG@@"_O<;T&QB-Q0,JM28K4M&E.HJD1),9/,"U
MWFVQJX\N=!TZ!0*"`]=Q?I3GK\M#/V=N@U/9[%NE^/'/X:3]F50630*!0*!0
M*!0*!00[/JMF-RDBX&WFSQY>?,H-_P#^WG_TC_Y:@D"_G?=%!E0*"/OI)W_"
M5V#%2@??DQOF4$@H%`H%`H%`H%`H%!%>JH2>F^Y`NVDX]\&_*Q0:"`>RP;[.
MRY_\S5;ZPW07384"@4"@@G5!Q37JYQ!(4EN:4V\/<4$%@S-ROYC!)S^VD8!8
MR4%44)?[WO0%Z5*4G4;%)^3>@W]_I@M]:]K2VYJUY1+D1GT01_(98=4^E1,D
M*[L*=%_(<25</((XT'4]HC*Y;'['C'&378+S\]M#KS#I866TM.N*3WB2E0!T
M#@.)[`>5!L]$7W,WTZA/YE9R3K<E\-NS")"QH64I.I1<X@>/YE!)I:\;#D/R
M\2\UZ>V%*DXYIQ)[]#`\M'=`^2XD'@H"]^!H._%D-28S4AE6IIY"7&U>%*Q<
M'Y!H/H:"M-X;LW'B,X96'VO+SDSO%1RX4.MM,1&T)/P3B4+"E/.*/$=B;'LH
M,LN]A>I.'D;/<EJ@Y^%Z)-RT,LR$AM25)64:EAA10OD%)4%6-Z#I]/\`ILG:
M&#RV/:F^D.91]U])*#W;*5H"$-I!45*";=JN-!26_.GN=VGMK'Q98],?F3`A
M)A%YY2$-PT1RI3RD`AM:O*[G3;3Y.OA0?J)`LA(\``X<*#V]!%NIFXL9@]F9
M)^<LI,EE<6*TE)6XZ^\DI0VA`!*B30<3J9DH>0Z-[A=C+UA..4AQ!X*0H`72
MM/-)\5!].@I!Z48,_P!B_P#C#E!8%!PMUXR-,8BO3''DPXKI7)##KC/D*24Z
ME%LI)""03XJ#2<Z<[1E)9+[3TMIM:7FVWI4AQHJ'FJ*2LI5:]Q0?';_JK&;N
ME[<QFU58V+&BID)SC3*$1G2ZH%3(<`"BO422+GE03"@4&GDI;D=E*&4AR4^L
M-1T*)"2I7$DVXV2D%1]R@B^2Z5;9RV9AYO*-F=E(Y^&?>`TNHTD!);3I2G03
M="AY0\)H)7C<=!QL)J%!81&B,@AIAL62D$DFP]TWH-F@\U"@]H%`H.)`0X,[
MGE,J^&4F-W?>6*`H,FWFG5:_.@Y6Q=F3MNS<K,?,8NYIXS)_<*DJ!D'M0'UK
MTHXGA^M03"@4"@@778VZ4YZW[VS^,-T&C[/#81TQ@V)\J1*403>UWCP%!9=`
MH%`H%`H%`H%!"]P6]<[HX\?BXUP_MYM!U/*_1_\`V7JG]7T:@[KAL4^-0%!G
M0*#A._GS%_JN1^,,4'=H%`H%`H%`H%`H%!$>KCG=]--Q*X6]#6E5^5E$)/ZA
MH*U]FAW.)VMEQCH\5V/ZR7=<A]QM6KN6^%DM.</?H+@#^[[7,/'W\'I3W_=Z
M#+OMU_R2!^$O?:*#PO;MX_<<`\.'W2]S^L4'H?W7;^)P0?!Z2[]HH.+GL-N;
M+28+K\""XQ$+W>1S*>'>!UO1YP9X6/&@U)&T,K*R&,>]6Q(8AS&)+DA,Q]Y0
M;95J*$MJ;2DE7(7/"@Y.\MEYE_JMM[=:)L&)BHRH\9;4AQ:7GW=3OD(1H*%*
M*7/(\J]!L=5MR=/9F-RFV<L^S(SD&.9\3'.AT*#Z&''6%@H+=^"%<E^[05M&
MW>\O:73J/MA;NW,=F\VN#E&X"E`J*]/>E"Y.MSZHM7$GW+\*"R<'T'VI@YAF
MXO(92/.*5H,H/MJ=(=.IRZU-$G4>9/&@L.%$;APV(C9);CMI:05&ZBE"0D$G
MAQX4'VH!%!1N*;VT>O\`O-6?7&;;$.,(_I:T-H)*6B=.LBYL*"Q`WTM)L'L2
M3X._9^FH/4#I</-D8D$^!]GE^VH,PSTU`59S%@)\[X9GA?P^50>]QTW!L7,8
M#V_"M?34$8Z@[:V#EL(\F!D($'*MM.J@R&9#"'0M:0+MJ4H658<#\KF`K?'[
M4C[;Z7[WF2,VU(FY:,Z6L>N0V[(`)!27BE7E.$W-@GA?PT'1Z6]3-X8;8>-Q
M\#8F2S,./WJ6LC&40V\%/*5=([M7`$Z3QH+1V#U!RVY9\V#E=LS-N28C3;[:
M)BKEUMQ2DW3Y*/-**#<S.*P[V^\!/D3)C6499EHA0VG=,5UL)3WO?-V\H@+%
MO_A01OK%GSLK9[N1PKZHLM3[3:8R%DM)2ZHE:NZXZ!9)MHMQH(UBM^>T5ZNB
M_P"R,>:'&TK1,60E3B%^4%*2E](!TF@V5]0/:)2M*!L6,HJ^>"C8>_Z10/C_
M`.T6#8[%B^\L_P#>*#EYW=/M!Y/T=E>S#&<;476WX;RV2#;20IP/VX@\J#F/
M3/:.4I!9P,V.IM05J3-+@58WTJ2X\I)!%!W8&^O:0CQVHS^S693J0=4EVP4K
MCS5W;Z4`V-N5!MG?WM$_[CQ/VQ^WT$5RDOVA)V\\;N0[;DQY$%'=MXYEXB"X
MD!>KOD!_FKO.T]@M02D=0O:'-S\1(]A_9'E]?H,4]2/:#LYJV&R--@D^7[O+
MOO*]Z@^B>I'7RWE;!;)\(4L7/[<VMXZ#K]%]_9+>&2W.[DH3<"9#=BM.L-E1
MLH)<0H*U#F%-GMH+1H%`H%!`.O+B$=*<[J4!J2PE-^TF0W8"@U_9]M^C''V_
M?I-_KRJ"QZ!0*!0*!0*!0*"$YY1]>[J'8G;C)`]U<V@[-C\1;=OJO_Y>@[+O
M-'[(4'TH%!PG?SYB_P!5R/QAB@[M`H%`H%`H%`H%`H(AU=44]--PD&UXB@?<
M)`(]\4$%]EJWQ/S!\.47P_@&Z"Z:`*!0*!0+4%*]0)<F3UFV[!1!95&BRL<M
MW(C474N+4^M#*B70VD%+2U#X.YM:_*@CO4R"[*ZS9I+$4N2!MJ3=ZW=MM-JB
M.@/..$I!/>!+:;BPOYPY4$8V_/E9+#=+9#C'<H>W2LL-EYU\E+2&&UK*W5.J
M&IU*R$\K?)H/UG0*!0#RH/S]CMD[5WAUVWS!W'!]81XS3#K+;BG$!"U-M))2
M4*3\[03H>SOT=!N-NH!\/?R?<_?:`GV=^CB?-VZV+>!^3]MH/?\`EXZ/6L-O
M(_")7VV@\/L\='B03MY-QR^Z)7VV@CN_.F70G9V!?RN0V\'-"%*9C(?E%;A3
M;_I/)2"H75X_":"%O[<Z-9?I=G<[A,.S%S..866UMOR%!#R5`"P6X>(U#@01
MQN+T%M]`P!TGP5N6E_\`&'*#IS)KV-WU+E+B2I+3^,CM1Q&86Z%.-R'BM.L#
M0D@+2?*4*#;=P4Z>]ZX="(V89MZL2JRTL)%[H64\^]U?":3RM;E041[2>+RK
MDA.XG&U1V5-,XR7#6VX/+0I;J76WD)[IULWMY9"AX*#]";/;6UM'!M.`I6WC
MXJ5`\2"&4@\J#KV%`L*!84"U`L*!:@6%`L*#PI!H`2!04I[.]SN+J$H*N@Y-
M-A;A?O)!O>@NR@U<KE(.)QTC)3W.YAQ4%Q]RQ-DCQ"YH/AM_/XW/XIK*XU2U
MPWRM+:G&UM*/=K+:O)6$J\Y)H.C05Q[0I`Z4Y:]C\)$YB_\`G+=!Y[/L=IGI
MCCRU_A7I+BQ_9%Y0\)\%!9%`H%`H%`H%`H%!"<[;UYNP_/?%UCY&N=0=G5_L
M-J_\LO;^;T':<O='#YX4&=`H.$[^?,7^JY'XPQ0=V@4"@4"@4"@4"@4$-ZQJ
MT],-Q*\$0_NDT$+]EH'XA9)9%BK*O7O;L99'.@E6ZNLFT-LY]>#R(EJF-L]^
MZME@K:2@([U5UDIN4M#60.SQ\*#+:_639NY,ZC!XYR0,DXGO$LO,]W\%W7?)
M<O<^2IL@CMX\;4$EG[D@PY_H"FI+\H-)?4B-'=>TMK4I*2HH20+E!X4'Q^-<
M7^09+\!D?24#XUQ?Y!DOP&1])0>C=44_YAD?P&1])0<YYW:\C,,YI_`RG,M'
M3H9FKQSQ=2GC8!11V:C;W:"E^H</.*ZEY_<Z\;D6=MG"NM.SE05+TE,-UK2G
MO-!"2IRZN0\GCV4$9V>U(0UTVQDIMYF7&W5*6_K9[L)4GN@$@E.A2K)NH`FU
M^=!^N:!0#>W"@K;<DCK`O+R6=KOPGFFGG>\:EMH:2TSW2%1PE5U+<+BE*NJP
M`TD4&A!V#AMJY7*;\WWF&)4G)L,-3^\9#4=E_P`E)[@I*E%*K!(%K]M!*<*G
MIMG<4[EL.B+.@,*6AYYI*CI4V-2DE)LJX'&UJ"O)V\,#FF(CVTF\7BU)D&/)
MB[@:<0J0IYI*XXCEA3O'B2I)\KL(%!;(V=MFPOC6;]O`_-H,AM#;(Y8YGY!^
M;00_JATVP4_;<B;$81$GXQIU]D@$M.I";K8?1?RVW-(]P\:#C[HV#C-J]&MT
M-,MMJGRHJY$Y]MM+:5.702EM(\U`T\!0=[H'<])\'[C_`.,.4%@!(H/:"IO:
M;'_MBJW\NCG]U065M_\`H#&_>K'V--!OT"@4"@4"@4"@4"@I;V<G&7,AOMQI
M04E>6*DD<M!4[IMXJ"Z:"-=2FG7=@YYEI*5N.PW6TI4D.7*QIX(((4KCY([3
M0:W2>!*@=/\`$Q)3;K3S2701(06GR.^64K>02O2XI-E*&H\>TT$NH*V]HGAT
MGRO^-B?C3=!]>@2TJZ7XK2H*LN2#8WL>_7P-!8E`H%`H%`H%`H%!"MP>3E-W
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MXG_^:@\<]H?$M@%S:^>0"0`51`!=1L!Q5VDVH'_,+C.S:N?/\T'TU![_`,P>
M,*0?BKG[]H]$'TU!KY#KKM^?"?A3-HYR3$D(4U*87$!2I"Q8I4-7:#00B?NO
M;V6WST\QV$P4_"QXF85)7Z>V4%YQ_0%*"EJ6MQ7#B2?!0?I>@4"@Y\_%=](3
M,C.F+.0`@/I`4%-WOW;B3P4F_OCL(H*(ZD;KW7ND[PV0[`;E>HY&.<8<QS;O
M?J0IU!<6M*B[:P6#<#R?'02GH;CLQB>G^>7,B/0I"YDIZ.'&5M*6$L(2'$-Z
M4+4DJ1P.D$T%.S9&:3@X.3R.3D.9)W*M/"<X^XXLN-P&O-?'=I*V2XI/<:=7
M-.L6)H/U^";<>=![>@XN]/S1S/&Q]#?_`'!H.!UC.GI1N(GRCZ#P/A-TV_5H
M-;H$3^B;!&UKI?Y_?+E!85`H*F]IQ6GI@L_Z;'_OJ"R=NF^W\8?]$8^QIH.A
M0*!0*!0*!0*!0*"EO9R*C-WT#V9=0`_MG*"Z:".]1%L(V5EU/H#C?<6*2VEX
M7*@$GNEJ;0NRK'2I0![:#X=,6E-;(QR5.I>7=[6ZAMIE*CWZQ?NF;MH_8IY4
M$IH*W]H<_P#M1E?\;$_&FZ#/V?6VQTGPRTI`+BI*UD=JC)<!/ZE!8M`H%`H%
M`H%`H%!#=P:3+W>%>:<"S?@>7W;VT'>M_LQ:_P#F7/\`@J#HN<T?LA09T"@C
MKCJ3U$CM:?*3B'EE7B5):%OU*"14"@4"@4"@4"@4"@AO6(@=,=QD\O1#>W[)
M-!5GLN;RBI;F[-5'=,Q;K^43+&GNN[*6FM!%]05<>"@N+?VV)^Y=LR,3!R"\
M9*=6TMN6C7P[MP+*5!M39*5`6M>@KE?0C=G>=ZG>3RG+)2K5Z8.\"0$D.?=1
M^J^>NW'4!8@7H.A*Z1;T.SG\)'WB\O(.OQ'6\I(;6M32([7=K2V`X"%*4=5[
MW\-SQH.>YT0Z@.*0H]0YB7D*<4F7W;BG0AQ!3W.E3I:T`J4H>3J!/`\!0:3/
M2'J%@,EC\NYN=_+8V+.A/SL*TF0I*VF%I3K0@N+NM-RXH6XV[:"W?C1$_D>0
MN?\`09/N_04'GQHB:@GT3(7/`?<,FW*_/1:@]8W3C79\>"6Y;,B65)CA^+(9
M0I2$%:AK6A*+Z4DVO05CU@R3"^JO3+%V5Z0WD#*4JWD:%K0V`#X;H-!<]`H%
M!X:#\S2=Y9W:O7+>\K$8YK).R>X:<;>6Z@(`:;4""VAR]!(AUYZAD7.UH@M_
MTTK[1017=W4W(;H?BHS>U8CLC%J4[&;;G2V5I4K2OS4M`JU=VD@$=E!V\?[2
MV[,B7!#P&/D*9X.AN6ZO0;D65I:5:Y'"]!N#K]U!4D*3M6*I"N*5)>DD$>+X
M&@Y.:]H'=V1ARL.K`P&7IL9Q+:!*>+I2H%.I">Z%_E>.@YV\>NFY=R;:RVW7
M<)$CF3'"9"VI+BW&DZ@JY06QS`X7('CH.STLZ[;4VST\Q.+R<:8MZ,76E.,!
MAQ!*G5K&D=\'+6/:F@O#9^Z<;NO;T3/8U+B84P++27DA#@[M:FU:@"H><@]M
M!V:"I?:=_P"%SGW['_OJ"RMN?F]B_O1C[$F@Z%`H%`H%`H%`H%`H*4]FY[OI
MF^G@;AS+J6%6(N%*</(\:"ZZ"*=5C_[=9_R$N$Q%@)6-2;D@74+*N!S(`XT&
MKT765],L(XIE,=3B'5K:;!2E*E/N%5DD)T<?G;>3RH)K04Y[2V[,3$V>YMEP
MN'*94-/Q4I02WHCR$*65K^=Y<*#M^SR^T[TEPO=*U!"I2%=EE"2YP_5H+(H%
M`H%`H%`H%`H(;N!)$S=SFH\,`R-/9_GIO[M!(-`^+>BW#T/3;^"M0=!SFC]E
M094"@C:FB>HZ'>Q.'4DGQJE)/][022@4"@4"@4"@4"@\N+VH(=UB-NF6XOO0
M_NDT$*]EAIKX@Y!W2.\.6D`KMY5NZ9-K^"@N:@]%`H%`H%`Y4'#SJ=6<V[Q\
MV6^K_L;U!7_6)(_2!TP(''UNOCVV^#H+;-!\,AD(..A/3I\AN+#CI*WY#R@A
M"$CM4H\!0:^$W#@\[%5*PT]B?'0ONUNQUA82NP5I-N1L0:#H4%+].UJ'M"]0
MT7X%B,JW]JT!07.;T&E+Q.&>6J3+B1W7`/*>=;0563X5$7X4'/V_A\+'E/S<
M7`CPH[B$LM+CM):[U()4I9TI3<:C9-!UYDA$2&_)4%+0PVMU24\20A)58?(H
M.#LC'-'$L9R0E+N8S+2)4V9S60ZD+0RE1%PVTE02E(X=O,F@^.^\=&:QR\^T
MR@Y#&IU**K`/Q5$"1&=X'6A;9-@>2K$4&&0V/TRQ\<R9&V\6$\$MH$)DK6H^
M:A"0BZE*[`*#K;3Q#6(P4:"W%:@A.MU4..`&FE/+4XI"`.%DE=N%!U[T%3>T
M]_PN<^_8_P#?4%D[<O\`%[%_>C'V)-!T>-`H%`H%`H%`H%`H*4]F\*$[?>J_
M]+GGX=3E!==!'.HT;TK8V:C>E1X1?C*;1+F+[MAI2B`E:UCBFQY$=M!K]+(2
M(6PL5&1D&<KH0YKR$=6IIY9=65J2JR2KRB;D\;\R:"5T%6>T=C,>]TTGSW8K
M3DZ*N,(TI2$EUL+DMA00LC4D*'`V-!T>@*0GI1A0!;C)X?SIV@L*@4"@4"@4
M"@4"@ANXSI=WB>5L"T>'N3:"0\?B]YW'T3SO'W7.@WG.:/V7ZQH,Z!0<"P^/
MI5VC%`?)D?\`PH._0*!0*!0*!0*!0*"%=:+?HMW'?EZ+?CXEIX4$/]E?_AW/
M\>7D?8F:"Y10*!0*!0*"JMS9SJ!"ZSX*$U(=C[/GZ&7-;*/1EO!IQ:F^^"5J
M[Q>GR02GEX*"<9S^G]N<;?=,CAX?N-V@@/60GX_]+_'F%_*;H+;M00'KJPM_
MI7G&T(4X;1R4H3K5826R3IN+V'&@CGLTLJ:VYG/("4^LRD:0`BZ([23I*5+0
M>7'2JP/`4%N2)+$=`6\XAI)(2%+4$@J/(7-N)H*8Z;NH5[0_4.PMJ8CE)O?4
M`&[V^2/DT%UWH(W$=9D;NRT.0@NJCHCNL%9)0E*D`%(3ROJXT'51E6U9E6,2
MV=2&`^IVXT@E0&BW.]B#0;Y`*2"+@BQ![101+&+SFV4.8QS&NY+!QA?%RX>A
M3Z&2?)C/,*4A1+0\E*TWU#F`>85KU7ZPXMV3+VC)COXZ*F.MS(%\-IE/+[O6
MPPTUW@4A*EE*BY>Y`*4CF0$PZ$Q69G33;N:EE<K*OQEER;)<6^]<N+2;+<*R
MFX'SM!9%J"@.F_5G?.;ZI,87)3$+Q;ZIJ#%+*$7[A*UH6VL(0JPTA/%1]TT%
MA];=KJW'T\R$5,CT9<33.0HIUI46`5:"+C@J_.@J7]$/4-J0J$SOB2E+,A,1
M'PLQ*0GT+TH&P>X6MHM[_BH/#TJZ@AYAOX]2R9"X2$$/3"!Z:A:KGX?YPM^_
MXJ#!CI7U*=<9;.]I(4XW#=N'YI`$Q\LVXO"^C3J\?*@Q:Z7]0G4E7QXEA!)"
M=+TOYV=Z&;W?_M_U/'0;<#I)U%D99,1G?4M/E3$%U3LQ5O0WD->;W]O+[R_B
MM0;^2Z&]5(V-DR(6^)4R<TA3C$/OI;7>J2#Y`67E!)(/"XM>@ZG13K3)R#_Q
M/WDLL;BCK+$>2^-"WEHN%,/#YU]-O[?W>87=0*!0+T%)>S8HJD[X600%9;4$
MJ%E"Y<X$=AH+MH(IU5CB1T]SB"H`(C]\04I4%=RM+N@A04GRM&GB"./*@RZ7
M26)>P<-+82E#4ADNA"4H0E)6M2B`&V8R.!/8V`?'S(2F@K3VBQJZ2Y47M=V'
MQ_G3=!]O9]<U])\-P(LJ4DZO%*=Y4%BT"@4"@4"@4"@4$'W&H]_O@`Z2,`S9
M0Y^9.H)39/J"U_)]%M?Q=W0;B_.3^R'RC09T"@X(_/L_U6/Q@T'>H%`H%`H%
M`H%`H%!`^NECTHW"#P'=-<?YPW007V:,0Y-V%/=1DYD5/K20CNXRFTHX-->5
MY:%F_'PT%N?%R0!89S)>[K8//W6:`=N22;C.9$>(+8_79H//BU*_+V2Y?1Q_
MM-!B=LS+_G!DQPY:HWVB@C.ZEY+`Y#'!>?R2X;[4E<@`Q=94UW0;TDL@#BX;
MT'BI^;AYG"M+FY-!E3$-O,3%1%-K94E=P0VTA?$C@0:#3RV?P;O6F#M^9BUR
MIK;+,N%-$B2$LN:';J,8$L'2GY^P\Z@[W4[=&TMM8R%DMQ&2`F3I@F$5I?#I
M;5JTE"F^&C5>YM01#)X9W?DG8N\MHN&1C,9.=E2D9%]Y#FELA%D)4'@#J;(-
MJ"SX>84[(]%FQ5P92B>Z2X4K;=`%[MN).D_L397BH-;>N;>P>T<OEV-)?@Q7
M7F@L:DZTI\FZ;IOQ\8H.9TMW+E=Q;2:R&69;8R`?>8D,LH"&TJ:64^39QX*_
M9!5!&/:464=,W%I3\(F;&[MPZ=*"2I.I>H%.FQ*>/AH*^Z,3(N+ZK[G<6%%I
MK&1&664E+BE+7Z*VA*%(.A6HV%P;4'Z,@3FIK!<0"A2%J;=:5;4A:#9256)%
MQXC01E2GXVY\Q-9TE;GHT-"+7<4XIL+&D$I3\E0H-_&NQW<G#>:6ISO8KZG%
MK`2HK#S:5Z@.`*5#3:@Z>1FN151=+96'G@TL`7(24*5<#A]#08,YR$^YW38<
M+EBH`H4G4`;$I)L%#W#0?FKK-M#/Y?>>8SN.A]]"+*7$R!="'(S#"?2.\=<6
ME/D%KR4H0;\[GE071T(4%=(]M*!N%1UF_#M>6>R@GQH*'Z9X+8[?6/+QL<UD
MQE<&9CNN2['7'277>Y6D!"4ND67=`*B`#QXT%M[Y/^QN:^\WOW!H.(X2,M+X
M_P#B(_4PZC0:+-_3\>"H&SF$X=H^`>YT'VA&\N(?##P_X\N@TX228@L?GW!_
M^^'P4'<V\4'<)L#J#F8X\+?QQH'A02\\:"F/:(Z;8>?MV5O".!$S.+0A<AUL
M:1)9"TITN:>.M%[H7S'+E02OH;N#+Y[IMC9^6?,F:%OQUR%`!2TL/*;05VYJ
MTI%SVT$]H.)MK>.#W(9OJI;S@Q[RHTI;C#K*4O()"D`N)2%*3;C;EP\-!VZ"
MD?9KTF3OC3;2<J+6OR^$MSH+NH(QU,E/1-C9:4SJ*F6T+4$(;=44)=07`E#R
M5MJ)1>P4DT&/2^3&D[$Q;T6/Z+'4EWNV+-IT@/+'FM(:0+VO8)%!*:"M/:,`
M/27+7_?8G'^=-T&QT`M^B?"^[)_&G:"PZ!0*!0*!0*!0*"";B7:3OR]E!.`8
M\D\OJ<X\:"5V'J"U^'HEK_P=!N.>>C]E^L:#Z4"@X(_/L_U6/Q@T'>H%`H%`
MH%`H%`H%!`NNX/Z)=Q6-CW+5OPAN@C'LKIMTZFV-P<M(M]:9H+CM0>T"@4%>
M]5L;*R;V.@1DJ+TB+.0G0G6H7[BZ@GM('$4$5V]L]K;V:Q'HIR[[#V0C][)S
M)U.%80X+(/8.-Z#X9?)*C^TE%C*::49*(@;4HC6&_1WKD70JQ"K\-0[*"0=?
M]J;@W%@,6SAXBI:F)A5*2CBI#2VE(U]V#=P`D72.=!YT\SF,V!TZPF/W@\,-
MD)"I:V(4@E3ROAE+T@)UW5I6GAXZ#F8_KEB=RM2XDZ&<`VAI3\*=(<*UA]*@
M8^EM#9LJURX+^3YO&]!->H\Q:^E.<EW[M;V*<5=!(L7&NSMMY5!Q?9V4XOIA
M$6M:5!<F4I"&TE"&TEX^0E%DI2`>Q/"@W.M^2G8S929L."W.<:F,`I=C)F!H
M+U([U+:R$ZPI0"5>.@_/F-S&[\/N_<1B-%<XB`,JZ]'=>=;4TAI:5K4F_=*+
MP\HK[10=YCK'U8BR'FX3;<EMQ];FI.-E/!:U+NJ[C:;<O)\D<*#IJZI]3',A
M(==VN67G)<=U9,7(-AAUMI*&TE:FR/+3]$.V@1>J75&&&>ZVP5-MLO=V^(^0
M45MN.AU;NL,E/,>=0;#_`%:ZBK4AI.V>_CLO>19G*2`7"VH*;"D-*)\E9\F_
M"@TH763J.Y+?9&!$Y2;+;A&+DSW7P>BR4(8UV"?FT',R?5??\S#9:`[BB8[D
M-UIUI4?)6B(#*FBL#N4VT()OJ-K\54%S^S\H*Z-[6(_DJOLRQ06':@I'I@92
M>NN^0KTA:'.]+P7<--E+Z`S<\=6MNY1RL+CCSH-OVE=P9C$[>Q4?'9`X]K)R
M)#$Q2>[!<0B*XXEHJ<!`"EI`X<:"#0YL]]M$IW?60#ZW0\YI<@$!PL]PK3=(
MNH-JT@6_5H,U#)E]"V=ZY$EDM+*G5X]*AZ,%):T@(\HH"U?KT'J6<@W(0H[V
MR=@EIMI:%X_@W'67&@;I^=6;T&;;,MM`3\<LH--R5!6/T_5_2";Z>UWRJ#WT
MK,17>_C;SR39*7U+EK7C4)1WX+[BU!2>(+C:>`X^"@O?8>0E9+9.!R,MTORI
MF/C/OO$`%;CC25*40.'$F@XG6X_^U.XS;_-A]D10<CV;[GI1C[_RF;^,N4%G
M@W[+4%*>SE!DMR-SSEP_1(TMUDQM*%M-K2%/*U("RK5P6+K!Y\.R@NHFW9?Q
M4%'>S&LN/;V=X_"9-*K&UQ?O#8Z>'#Q4%Y4$:ZE8^1D-C9B)&0MQ]QD=TVTV
MIY:E)6E02EM!2HWT]A\=!26Y,KFMO[&V3"0XYCE/LY1QZ+K=BV<2^E:0IM`*
MU+2%J`3R%R>0H+SV#.ESMD8*9,=+\J1!CN//$A16I38)45#SK\[]M!%?:'L>
ME&5!Y=[$_&6Z#Z>SZM:NDV%U)*3JE`7L;CTIVQX4%BT"@4"@4"@4"@4$#W#;
MTK?W"Q]01[GP_!SJ"7_^"?S;_JZ#:6+K1XE?K&@SH%!P1^?9_JL?C!H.]0*!
M0*!0*!0*!0*"!=>!?I+N(?\`0M?C#=!!_9LVKB9_3MR7(,D/.9"2%]U*D,I\
MG2D>0TM">7BH+8^)>$'(RQXQ-EW^RT`;*PHO9<WCS^[IGVV@R^)V(\D=Y-\C
M@G[NE\/\K0>?$W$7)[V=Q_TZ9]MH,).QL#)=9>?,MQV.%!APS9>I`<`"])[W
MAJ"1>@R8V7@F)4>4$R'78KG?,=_*D/(2YI*0O0XXI-P%&W"@JO,NY5OVFL<E
MF26VGXC*%)#R0"PEMQ;C1;XDZU@*`X<M5!+=[=5\3CD[BP>.==1N;%PG7V;M
MCNPL1C(2H*4%`A(M>Z>9M05[-W+D]R;@Z1Y7)7:G/Y.<EUGN#&`#00GBVI;Q
M!N.!U<0>0H/T*`GP"@C?4J%(F[!S\6,VZ\^]"=2TU'1WCJE:>`0FZ;GW#?P<
M:#E=%\8_C-BM0G4O)2W*E%@/(=0.Z4\HMEI+_P`+W92;IU@&@U>NC>V'=ELL
M[CE2H>/>GQT!Z&AM;@<.JVH.^3I`N2>8[*"K^C<1F5U*W?#QBW!%]&@/QA*3
M9:TQ5,J;#UAP*DGRO&?%0?H+"0),.*Z))1Z1(?<D.):OH07%7TI)L38=MJ"-
MSGU*SV4CM-%Z5%DQ9R$J22T4I8"++4D*4.VWDFU!X]!2TQ$Q:E%Q<V#)0A49
M-V]:WDO&UOG1RY<J#87#E.)2^@,>D3IXUL(4L-MZ(JVB"K2E6NPN?)H-MC"9
MI#R5NF&I#?U(-I6TLV06P7%I%U60;=E!2_4KJEZE7G=H3(K3\UIA<.,64N-J
M6EZ,$-N.+[M25Z$OD6U)N0:"R^@(MT>VN/!%4/\`++H+!H*QVGM!S&=7\YFH
M\.<(>1C/"3+FI92T)!D(6D15-G4IM:=1\I-Q8<:"4]0\;CYNT,H)D9J3W4=U
M;/?(2YH7I(U)U`V/C%!&9>S=J>GR_P#4L#0G(NH2D1F19/JK44^;RU<;>'C0
M<X;0V:J=":&#@&S^(2X#%9L4KCND@W3Q![?#08Q=D;0;E0`,)C])8PX*?16?
MGY3NH\4_/``'PT&KC]E[04VHKPD!1*E#C&:/+-J1]#]#Y/N<.5!(,#LC9CF;
MTKP6.6E*\K9)BLD#3,;2.!3V#@/!06(RRRPRAEE"6F6TA+;:`$I2D"P"0.``
MH*_Z^Y/'PNEN::EOH9=FMHCPT*-E./%Q*@A([39)/N4&I[-H6.DV-*AP5(FJ
M2>PI,IRQ'A%!9]!!>F.R,WM4Y5G(N0G(SRVO5YA(<00V@+*N]#I6K7J5SUGW
MJ"=4%'^S*BSF]E<>.5`\7`+Y?)H+PH.+O.88>U\A)&5&$+;=QE2R)`8)4!K[
MH\%\[6H([MS:^V]T[0PTK(9!S<BV424LYO4]&==2^XI+Z;!2%A!TZ-*NP4$U
M@08D"%'@PVPS$BMI98:3>R4(`2E(O<\`*"N/:,4D=*LF";%3\1(\9[]!M0;G
M0`6Z3X7W97XT[06%0*!0*!0*!0*!00+<!^[.H`_\ACGQ_4IM!,/_``7^;?\`
M5T&TYYZ/V7ZQH,Z!0<$?GV?ZK'XP:#O&_90*!0*!0*!0*!0*"!==TE72;<*0
M;$M-"Y^^&Z#@>R_;]&/N9&7\M-!;E`H%`H%!XH@<Z"/.[&P+VZT;G6'SD4%*
MPWWRPP74-*82[W7+6&EJ1X+'E04AOU,M?4_?@4I"NZP+VMQ>E#332XC8:%KA
M1<UWU*.H:3;A0:>'R2LCE.C\MQMEE3N3R82S'MI0E)0+*L3Y5Q<WXT'Z=H%`
MH*O]HP)_1RHN:RP)L8/(;6AM:PHJ2$I4Y=(\LB_`\/D@(CT):D'JSO=V5H3*
M:C0D.H:(+>I:$:M)!7P"FS;RCPH+]H(YBXSOQQSDNWP);CLA5^.L(U$6[.!%
M!XK%9).[HLAIH>JVFW5%P%(TN.ILI(3YW%0!H-O)8V6O.8V5%0.X#BE3S<#S
M6U);5;M-U6]R@U&=SY+*R936!QZ7HL1Q3"\G+<+,=;R#I<2RE*7''0@C256"
M;\`3:@H+JYTYWA-S^8SF2[N&)+9EP5MNI=AJ,:*.\C:NZ0_W[@9*D`V3;D;T
M%M>S]-CN=)=MQTN),EN(5/,:AWB`IYPI*D><+]EZ"R*!013JCG,3AMC923DY
M"8[3S2H[-[W6ZX"$(0!<E1\%!7LCK-T[<R$A;>5/=KR+SX48\@:FSC.X2KBW
MVO>3_P#"@TXW6'IZ,HR^O*%+2',6I2NXD<`Q'=0[P#=_(4H`^[PH,FNL73M+
MT1TY,V;;Q257CR`1Z.^ZM[YSCH"P?E7H/C`ZM=/FVTI=RG=\`I5F)"K$Y94@
MCS#Q[KRC_P#@4'5V_P!;.F[&46])R_=MA>25K+$@\)$M#C/`-W\I";T'<R'M
M$=*XT%^1'RCDUYI!4U%:C2$K<4!P0DN-H0+^%1M05MM3:^YNM.Y$[KW;KB[/
MBK(Q^/05)0\D$_!-<KH_?7>:CP38<@_1T&%$@Q&HD-E$>*PD(98:2$(0D<DI
M2G@!0?>@4'BK]G/L%!27LP.+<B;O6L:7%98J4@$D`E'(>_07=01?J>VZYL7*
MI:0ZXYI:4EM@D.KTO(.E%@KRE6L!;C0?;IXK)*V=CCDF5QYI#O>M.J6I8^&7
MI)+B&E\4V/E)!H)%05=[29(Z63+&UY44?Y44&]T`#HZ380NIT*5Z2JW/@93I
M!^106'0*!0*!0*!0*!00/<5@[OY1OQP;`_R4SYM!,N[_`-6=W_T&FU_["W.U
M!]W//;_9?K&@SH%!'TJ)W^M-N`Q*"#[LE7S*"04"@4"@4"@4"@4"@@?74$])
M]P6Y]TS^,-T'`]F$D],;G\H2OEIH)IU"W)G=N[>.1PF*5F)H?::,1`<40A9L
MI>EM*E'305TCK/U.*3?9#P)N!=B<`GR0;J^!-QKNU8=OE>;0=E753>R=M,Y1
MW:$IF:9[$1W']T\ZX67(R7G7DAL72$K5H%_?L;B@YZ^LO48)2X-@33=+H<C!
M#Y=0IMLE+A5W:6RVM?``'5Y)X<4W#I[$ZH;RSNY&L5EMKO8V&\'%)R*VY#2?
M@VRK3I=3:Y5POJH)+U#2VN/@F71J:>S4%MQL\4K25*\E0/`CQ&@W)D0X",_D
M,>'%QFQWDK'EQ1;[M/%:F`LJ[M24\=(\D\O'04_O/8N>7O7=.ZI&AC;<W'N^
MB3^_CI"UN1$,-IU+45MI65%/FV/#W0$:P4>9$R_2"'-43,C9C-,2V^'P3S;P
M2MNZ2H*TD<Z#]24"@4%?];=J[AW+M!F#@&4OY!F:U(2A:T(`2A*Q>SI"%<5"
MX)Y4$#Z$0EP.K&^X*P4KBQL>RM)TW"FTE)'DW3V=G"@ON@TWL5$=6MX)[J2O
M_.&SI<N!8&XYV'AH,H3KXUQI%UNLA/P]@D.)4."@.P\.(H/<F)9QLP0S:667
M!&/"_>:#HY\/.H.=LI;2]HX<M6TB&RE8'"SB4!+@(\(6"#XZ#4ZAN-HVN]Y0
M3*4]'3`-TA7I/?([K25<!8\2?H;T&]DL=B<FRAUEQIN6R"J#.:4G6TJUDE)2
M1=/A3R-!MX>:Y-QK$AS3WJTV=T$%/>()0O203PU)-!NT%->U6M:.F\5:38IR
MC!!_@7Z#OQ>A72M^%'=<P2"M;2"HA^0+DI!)X.4'V'07I2+GU&+G_IY'VR@Q
M/0'I01QP8Y\_2)/VR@]_0'TI(MZDX??$G[90>?H!Z4?D3_M$G[90>?\`+_TE
MU`G!!5B#I5(DE)L;\07+&@G\:-'C1VX\=I#+#*0AIIM(2A"4BP2E(L``*#Z4
M"@4"@I3V8P!`W:F]_P#6ZS?LXI\-!==!$NK+S;'3O-/+2VKNVD*0'M/=!P.H
M[M3FI*TE"5V*@1Q'"@^G2^:F;L+#20&_+94%%E*$-*4EQ25*0E"4)"5$7%AR
MH)3059[2I(Z5R[?RJ*.''_"B@[/0T$=*L!>Q^"=M8D\._<MSH)U0*!0*!0*!
M0*!007<-N\WX+A/^I6?+_@9=!,['T"U^/=<^WS:#Z+\]'[+]8T&=`H(RT#^D
MN2;</4K''^=/4$FH%`H%`H%`H%`H%!!>N*%KZ59]*%:5EIJRCV?=#=!3'139
MO5'*[?<R.W-UIP6&,A]H0R@OW=2I.I?=J&A.KP@WH)WF-O=5\)$$W*]3HL&*
MI:6^^D1&D(UK\U(*NTVH.(C,[H`6H=:,40@$*NQ'-O*MV\^)_P#P*#IN,=2&
MXC4P]5X`B/.-L-/>A,*277FPXTG5X5(6E0OV$4'Q,G?A=2S^F'%=\IGTE*4Q
M(O%E*2X5_L=""3XJ#/%*ZDY>28>+ZL8V9/!*3';@L%5PG4>%K^:DGE0=UCI[
MU:D9O$/YW>4?)8C'S69KT-,)#"UEFY2`M`!YGM-!:$AI3K#C:2`I:%)!(N`2
M+<NV@I*=LGKECL&ZW/W[B_4D5@HD>EP6UMAA`T_":VUW2$\RJ@B*MO[JP_5#
MIMZZS<#,P'Y;XQ7JQIMB.SH%WM*&DH02LJ%U>*@_3]`H%`/*@_-F&8ZC.=:N
MH!V,]CV90>:]8')A92IOCW8;[M*C>][WH/IO'J-UOV?-9A9[,X)E^2@K8*&5
ME*M-KBY2./'E0?#9&^NMV_7,IZGR6+[^`$(=CO\`?1EV<!`6T&E*2>*3Q)YT
M&Z["]H_9V%RF>G9B%,:B,*?DKEN&2X&F`3I:3I0D7N3^O00P^TWU+0L=Y,QX
ML>*#&`'$7T^?>@U(GM![\A9.1-ARX3+,E6I_&AG[F[U7%3B4E96A2_GM*@">
M-KT&EF>NF\LPJ8<G+A2428SL5F,IJS48/(4TXXRD+^JE*B-:RH^"@BD=W:HP
MZ6VD37,Z$<7`\QZ)JU<^[".\TZ?[+G0?J7V8GWG>FBDN.*6EK(26V@I14$H&
M@A*;\AQY4%M4%->U9_PUC'L&39^P/T%N8S^C8G^);_<B@V:!0*!0*!0*!0*`
M0>R@I+V7E+.,W7KL5C+K"B!8$Z.-!=M!P-^Q<C*VED&<=']+FE*%,1K(4'%(
M=2K2I+GD*20GRD\+C@"#QH,.GD/*PMFXV-EHXB9%"7#(BHTZ&U*=6H(1I*@$
M@$:1?@*"1`@WMV<#04/[3[>]CC678SJ!LU*&DY%KX/O#,+Q[H^4.\TVT^::"
M>]#"^>E.WR]IU%IS3HO;3W[FF]^VW.@G=`H%`H%`H%`H%!!=QW"M]J%P?4S`
M!''_``4KA^K032Q]#MIX]WYEO['E:@S7YZ/V7]Z:#.@4$<:1_P"XTI?'AAXX
M\7&4]XOUZ"1T"@4"@4"@4"@4"@@O6Y:4=,<WJ(`4AE(OVDR&^%!'_9BM^C'A
M^4)5ODIH)[O/9>$WAAO5&8#IB=ZA])8<+2PMN]B%#Q$@T$4/L_\`3Q1&I,Y0
M!!`,QT^4E(;OSO?N1W7[#AXZ#<>Z*['7@$X%MJ3'QJ929H0R^M"R\AD,7*QY
M7%"03X^-!H.>SQTS<0EM<226$%Q3;`DN!M"W19:TI!X*-D^+R1X[AT=J]&=F
M;8SB,WC$RCD$)<2')$A3H/>C2HD$>"@G5`H(=U@*QTSW$$++97$4@K!";)6H
M)5Q)2/-/:104O%C-L9_HXRB3Z3W61R8+J>YL3J3PLPX\V+>!*J#],T"@4"@H
M;8^?P^!ZQ]3)^6?]&B%^&R'=*UW<<4L(0$H"E$GW*"QINV]H[V?1ETN=^J,5
M15790%H4GSVUHD-]XD\1Y)'CH*HZ(8WU-B=P;@;5<8C/R$2BW8J7!T):?"AX
M$62]P^AX4%K]7BA?2O=*DJ"DJQ<@A0/`@MD@W%!770+:^'R6Q8#DJ*T[+:$E
MUIY]EMZR7)CJ2@I6"%)5H]V@M.+M_:)<,5_!8]B2.`;]%9T.#F%-'1Y0\7,=
MM!G-VUL=@(6_@X"W.(9;$1E3BCX$)TW-!"NK&P(DGI_DSB\)'3FW4MHA1(++
M39UJ>3PU)2@K5HN#<V\`H-WV?MM9S;VP!#S414&8],?DB.X1K#;FD)*@"=).
MGD>-!95!37M6?\,V/%D6C\AAZ@MS&?T=%\'<M_N10;-`H%`H%`H%`H%`H*4]
MF(@X_=A%[G,+O?PZ!07701?J=-;A;%RK[@66]#;:TM6#I2Z\AM26RH%(<(59
M!/#5;B.=![TR67-B8=RRTH<9*V0Z`'.Z4M2FBY8`:R@C4?#02>@JWVD[?HME
M_?47[**#M=$?^%>WO\0O[,N@G%`H%`H%`H%`H%!!-S))3OH`<\0P./'_``4G
MLH)Q;X&UOG>7O4!?GM_LO[TT&=`H."RG_;N8J_+%Q1;^<2*#O4"@4"@4"@4"
M@4"@K[KU<]+,R!:Y,<7\'W0WQ%!P_9>-^E]__,)?RTT%NB@4"@4"@4"@B75I
M;".FVXU2&?2&?0G-35E&][`<$E)X'CSH*!VPIOTSHJEM&@HR660^;DE3@6G4
MHDE7%7`FW#P4'ZKH%`H-6?D8D%OO9+FA)X-H`*EJ/@0A(*E'Q`4'YKS^S]TY
M'-;WR*<+)1$R>7QKD9R6TMM!9;[Y7>J3H<64)4I.H:#SXT%N=#\;EH.SGDY2
M.N.^]/?=;2Y<%35DH0M(4$J"3H\D$#AXJ#@>SFVAW;VZ4.)"VW,]-2M"N(4D
MA(((]R@WMWON1>E6]-OR5E<K#0)"&%+(U.0G$*5%<\=D#NR?HD&@U?9N4E6P
M8"K<>Z=XVMSFO\CVB@LK*.MOCT-EOOY1(L02`R>8<6L>:1V`<30?&.A4"6MS
M(*[UQX!(R)\D$#_!J3R;X\K<#[M!]L_*C1H33\EU++"),<K=<(2E-W4BY4K@
M*#>C28LEH/1G4/-*O9QM06DVX'RDW%!]:"FO:K('31B_+UDU?W.X?H+<QG]&
MQ+?O+?[D4&S0*!0*!0*!0*!0>&]N'`^&@H_V6`H8G=04;J&64%7X<>[%^%!>
M-!$^JLMJ+L#+NO(4ME2&VG$H=$=6EUY#9*72%!)&J_$4'SZ0AM/3;!(;24-H
M84AM"DA*@E+JTIUA(`U6'E>$T$PH*M]I0VZ6RNVTN)P/^-%!UNA:7$]*-OAQ
MPN$LN$*(`L"^X0GAX!PH)Y0*!0*!0*!0*!00+=!26M^`\`,2Q<_P,CW:"=_X
M+G\[S]Z@Q<^J-_LO[TT'TH%!PV/SXF?U9%_&)%!W*!0*!0*!0*!0*!05]UZX
M=+LN?''_`!A%!$O9KAYY?38+BY!F-'7/DE#2XQ=4"%`*NOO4<R/H:"V&X6Y$
MJ\O*,+'@$2W_`%U!D(>XM1)R;)'@]%/+Z[0>KB[@-M&08''MC$W'UT4'@C;F
MMQR$4FQY15VOV?X>@C>X<SNC$92(U)S,*/`>8?>>>,!UQ04TMM"0$ID?/=]0
M?"'O+(*SN*AHRT?(MS))CR&$P'HJDI+#CH6EQ;JTW!;`M;C>@G]!P=]Q5RMH
M96.E3*.\9()DO+C-:;@J"GFU(4W<<-6K]2@HM&">Q6Z^D&)<6UIBS\LXPE#R
M)'=LJ7WB&ENMA*%NI2K2LCMH/TD+T"@'E04[N'JT,)GI"V,,_F\BI<EH&RV&
MXC,9?<MMI4MM5UO+^$64\-/'LM03;"=4-A97O&V<Y"3,C:4RX[CH:4TXL7T?
M"Z+D$$<*#L_&?;7/UM"_"&NS^VH*D]G3.8>/@MS"5D(S)7GIBVPX\VBZ%!-E
M#41<'PT&YUYR6';V?DLSCI4:5,<@O8F6RU(;UKBRR+*"=1U%ET!8`%])505U
MTOZT8+:NU8.(FHE]\EEQ$F1%:#BFU>DN.)2@+*$J*D.WU<AX*"?1?:<Z8QD]
MRU#RB$`ZB3'025*XE2B7+DGPF@^I]J/INM.E<3)G4""@QD<0?X2U!!NI/73:
M>>V5D-NX=J:M,WN@VB6TEL,I0ZEPV6%KU)LFP21P\-!87LP%9Z7(N`&Q/EAI
M(X63K'/^VO06V*"E?:STCIDR;V5ZQ;L+\_@'K\*"X<7_`$9$_P`2W^X%!LT"
M@4"@4"@4"@4"]!1?LJF^+W8?#ER>'`?4Q07I01CJ9C,YD]DY&%@DJ7E'>Z]'
M2E2$DZ7D*6#WA2@C0#=)(ORH/KT\Q63Q6R\3`RMQDF6?NL'3P<4HK4/(4M-@
M56%C02*@JOVEC;I7+^^XGV44';Z'D'I3MTC]X7]F703F@4"@4"@4"@4"@@6Z
M;%G?@X?T2P#]9D<Z"=V^"M_8_K4'CGGM_LC^Y-!G0*#AL?GQ,_JR+^,2*#N4
M"@4"@4"@4"@4"@KWKZD*Z69@'E>/^,-T'&]F$-_HL94A)`5/F$W',AVWZU!;
M5Q>U^/@H/:!<4"@K7K"S*?$9F&K1*<B20PX>2%=_&LL_L?.H(IMU&Y4;VV\K
M<.?1N&6[,)9EM,&,VA"8K^IH((1?RC>]J"[C.A>E>B>D-^EVU>CZT]Y;G?1?
M5:@B?60(5TNW*EQ!6DPE@I!MS(XD^`<SXJ"E=KF*,]T;98`T(=RZG7`+)<=U
MJ0I:;ZK@E'DGA<=@Y4'Z<%![0*#PCQT'YSV?T\V?O7JMU&;W'#]+$#(`QD)=
M=9T]XMS4KX)2+WT#G06!_P`N'1^UO4JS_.I7VR@Y63Z*=!\>]%:E8E\KFDHC
MK9<R$A)((205M%Q*.*AYQ%!U1[./2!)N,(K5SOZ5)YG^$H'_`"Y])M)!Q3IN
M+`^ER;CW/+H,/^7#I1H2DXU\J`MK,N1J/N^7:@X^`]G_`*99!.2#\20L1L@_
M';(E/"S;1`"397&W'CSH(;TMZ/[*W'-WHSDH[[GJ7+/0L<EM]QO2T@'0E5E>
M5[IH)5[/L_/[<V]D-L9_"2XDC&OI?0&VEO.*$PJ7Y26]0`!1P-^-!.D(QD[J
M/C,JWEYJ)1Q+ZFL-?1%4REY*%.N(-CW@6NUCX/%05_[5\V"_LR'CT/M*EIGH
M+S06"XTE<=VRE(!ND*[+CC0?'&^T+O$XZ+W73^>\R&$%,AL/E"T!(&M-F#<'
MLH/LKVB=XA20GI[D5))L5!$GA[WH]`_YC=V<;;`R)L;7[N5V?S:@UE>T[GQ,
M]!^)$HSBCO$P@I\2"GGJ[HQPO3_96M0;#?M';L.G7T]R2+\P42?UH]`5[1N[
M$^5^C_(E/80B43?P6]'H/4>T=NI2M/Z/LD#:_%N2+>[]ST&HY[4>6;FC''9L
MDY(^;!"WN_/DZK]UW&NVGC>U!O#VC-S:4E>P<DBXNHE,BWO?<]!X/:/W&20-
M@Y(GP$/@\?"/1Z#)7M&[@XA/3_)*4#PXN_*]'O0?+V3U+5A=TE:%-.>M?A&E
M`A2%%E)*%`@&Z>1H+WH%`H%!5GM*FW2R4;7^ZXG#P_"B@Z_0ILM])]O)*RN[
M+BKJ[+ON&PMV#D*">4"@4"@4"@4"@4%>;E`T]0^-[XR/?Q?<[U!8/^#][]:@
MQ<^J-?LC^Y-!]*!0<-C\^)G]61?QB10=R@4"@4"@4"@4"@4%>]?"!TKS!/*\
M?\8;H(E[.&#FRNF#3S6:G1$.3IA2PQZ-H19TBR>\9<5QM<W/.@M)&VIR2%'<
M&16JUM2A#)_4CT'T]09#\O3_`)$3[10>JP615_X].3[B8GVB@\&"R?;GIQX\
M/(B?:*#4E[.D29;4Q>=GB2PTXPTX$Q+!+Q25^28Y23\&.=!ZUL\^L(4R5DY,
MOT!WOV&7&XR$]YW:VM2BTRVH^2Z>V@KW);8:1[0^.SC3OI+CX*941#$ALL=W
M!6&WUR"%,K%O)TI4GB1PO>@EG6Y3R>E6Y.Y44K5&";BYX*<0E0X>%)(H*=VJ
M[.E;DZ0N9(EU15E%1$N*#BD,HNED%5OG4IL`>(H/TW0*!0<6=F)KV05B\.VV
MY)9`5-E/:BS'"A=*2$D%;BN80".'$D<+A5^<QTOI.[G-Y,2QDY.Z,@UZ6TN,
M`&4I;??7W:0\C5J4+`%0L/HC02;:V]Y&[NEN6S>3B!GX&<TXQ'6IM2VFVB04
MJ!=4VI23V:K?J4%+8'.3H:-O+Q!<A8N1FW-.,]/>6VZ>[AM]QWT0L-+-W"[Q
M2$@C2I5[I(?JPT"@4$<V4+-YKC?_`%Q-YBWSXH(![/[H<R_417"YW"]>QO\`
M1=M!ULYEMPXG=F;4UBI#,/+)AQH^:4IONDK;2M!*?*4$<7!I6YI`/8>1"00M
MFO,1692'$,YN,6_1'1J<:9:;06Q'XZ5+0I!.L\-2CJX<*"D?:`V;EY!RF[W(
MCL<*CLM3XRVDJ;:4Q\$AUN2A6EQ*^]L-2-8\0X4%]=/D:-A[<3<FV,B=M_\`
M`)H)#0.-!3(1J]JE2K`Z=O`\>SR[7'R:"YJ!QH%!2V28C'VI\.I+*4NHPCCC
MCO(J44NH"O&0GR:"Z2*#RQOXO=H`'NT%->SIPR'44?\`_2R:"YJ#@N;[VDWG
M1@%9)OUP7DQ_0P%%8<6CO$A5A873VDV[.=!%MB]0]PY_>N2Q.09A1X$9$LPT
M1UJ5(5Z/)0R%.I4;I\E7:E-_!8<0L>@JOVES;I5+-KVE1.'\**#M]$#?I5MV
MW+N%_9ET$YH%`H%`H%`H%`H*]W*#IZA>/&1[</\`1WJ"P?G/>H,5CRT>Z?E&
M@SH%!PV/SXF?U9%_&)%!W*!0*!0*!0*!0*!05W[0"$KZ49I*N1]'_&&Z#E>R
M];]$D0`WM,F\?X=5!;-`H%`H%`H*F@;CW"YU]R>&.06WA&VFM$(O-E"G!##A
M"65ZG`25:BILA/D\02:#/KWO3<>V(.$5AI1BIER'A,6EMMPEMIO4E-W`0A)4
M1=79^I0;VWMOXC?VQ\%G=PQ&YF<3&>$2<\BSC*UK4B^EON1<:1<6'O4'!Q_1
M*%@&9<C(9:3G9\YH1,=%>4IAI,IWRBX`VN_DJU$?0HX>.@N*,T6H[3145EM"
M4E9YG2+7]^@S5RY7\5!4FZ^G75+*Y)U>,S\?%8TNR74LQ'),=UTR%W[Q]2$J
MNL-?!BW`><.(H(XYGIW41S-[)SS*H3NTL@Q:9CT2Y:)'=!UE:75MI#B-8-]5
M!-]D;?PVWME/[5D^L,A%EF0)"_09;7P<D:2VDA.H!*/)!O?W*"*;AZ7P)&2P
MSF'=G(BPG_2,DB9'F]_(^$9-N\0PI)3IC)&DI`N+\R306U\:<<>/<S;$V!]"
ME=G\'0$[JQJ@"&IEB3:\*5V>'X.@ULIOG"XZ&_*?:FJ;807"$0I)O8<@2@"Y
M\9H*YZ8]9L+,SS^`FI$;(Y3(3'DM).L,.!5RRZN^DFPYI[>'8:#7]GG),^E=
M0Y#[B4.JSSZU)44BX&KD#;P4'RQ&\NKG41/KS;,6'%V;(<3$>Q\I3:I*T-.#
MTHZU)4-3@\A/"P2?#QH+DV^S.8P\-J<D)E-M)0XD+[RVG@!KLG40FUU6XT$)
M]HFYZ+[GMS[AGE]\M4$KV-?XD[>OS]60[_@Z*#N6H%!3C/\`_M._XMN)^RB@
MN.@4"@I:;?\`YJL?8\/42KW_`(7E0730*!04U[.PMD>HOCW))_7H+EH*=W+@
M\F.M6,S"L>\G'F3&;1+N%-.K$99Y\"G21I2A7DZO*X$T'G2S;>X,3U&RDS,1
MI,4Y:-,E,,RG4/=VDS&B&TK0\\%6"@22E/.W$"@N.@JKVE])Z53+\?NJ)X_\
M**#M=#&DM=*-O(221W+A)423<ON$\Z"=T"@4"@4"@4"@4%>;DY=1/ZLC_B[U
M!87SGO4'B_/1[I^4:#*@4'#8_/B9_5D7\8D4'<H%`H%`H%`H%`H%!7G7Y03T
MJS*CQ`]'_&$4$!]FO>CJMIG;&,B,2\E#=D2WV7)"V%!IY[@NQ96FUU`<%7H+
MF&1W9>QPK'NB;?\`ZD4&'K/>'Y#C_AP^TT&7K3=GY":_#4_:J`<INP'A@V3_
M`#U(_P"JH.7-WGN&)EV,8]A&$.R&'9*'')Z$)"&5H0JY+7A=3:@^T3>4]>7Q
M\"5`CH1D%N-H>CS42"A2&U.@J0$(.DA%KWH*WAB4/:@F(3+(8#(>=9+R$)7J
M@)0E`:L"M:=-SS.GCRH+(WYTZP>]68+65<?:]7NJ>CJ8*/.6G00I+B'$J%O%
M00F?GI&T-[;)Z9;9EH;Q[D9U$WTAOOWTITJ4TO6=";J*%G]:@LS'X%B/)].D
M/NSL@4E`DOD>0E7-+3:0EML'^Q%SVDT'4%`H/#0?F[:?47";%ZG]13FHLY0R
M.3)CJC1U.@Z%N$WXI[%@B@G/_,OT_P"7H>8O]XJ^FH,5>TST[2"5QLLE(-E*
M,)0`]WRJ`CVF>FR[]TC).I!L%(B*4#V_14&1]IGIJ+\,D;$`CT-=['MY]E!@
MY[2/2N6PZROT]]IQ)0\UZ&X00JX(5[HH(%A]_P#17&[I<RYCSG%A97'U0K2`
M5VU)<7JNL'0.?%7;VW#2Z,]+MC]1E[HS69;DK6C*N^B%IU3)2T\2\-24_/>7
M075M[I[BMB;?<AXO.9&+B65KD=THQG2%N&Z@B[!42H\D^&@E^&5-5BXJINKT
MI3:5/:[:@H\;*TA(N.VPH(-[1!(Z,;G(%SW#/#^<M4$KV*;[)V\?#C8?V!%!
MVZ!PH*=9_P#]I9'_`/CB?LHH+BH%`)%!2LQ8_P":Z"GP8"X^2]0750*!<4%.
M>SNA8E]0G"+)7N66$^#R3X:"XZ"C\Q(B3.NL*2PX^^AB4B)(`?6J*@M17+I[
MC1;O=6L%-[6\H7)M0:?0Q_&N]2LZ($018Z(LE,8]YJU1Q,3W1".[:LGGY1N?
MG?G:"_*"G/:<S.);V`[B%3FD95V1%>:@ZTAY;0<L5!'G%(TGCXJ"6=$U)/2O
M;I201Z,1PY7#JP?!03>@4"@4"@4"@4"@KO<9_P"(O#EC8_XL]06'\Y[U!BLV
M6CQD_*-!G0*"/QM7Z0,C?S?54+3R_E$J]!(*!0*!0*!0*!0*!05W[0*=72C-
M#[WY_?"*"+^RQM[!M;#3N!J(A.9F/R8TJ=Q+BV67SH1Q-K"W8*"[*!0*!053
MUF5/3,9,!E$F:<<Z(\=P@-K7Z;%LE940`D\E<>5!Q=F?&3X]8M6X<-C<+/6\
MYHC8M2'&BV(KAU*4A2_*U$@\N0H#4**?:87,3)4;_!F*"G4'V\;?6ILC7W7=
MKLESEKN*"S-PP(V0W#AHDO6N,6YCBFDN+;!4@-!)5H*;VU&U!66[]O8?$=>^
MG[F/C=RY+1*](<*W'"ONFU!`)6I7+4:"\:!0*#A[TW5%VMMV3FY3?>L1B@+1
MJT$ZUA`L;*[3043OWJY`WQB68,)K)8%^.VY.,A)2%$%H-!+A0H:&2)047%63
M;WJ"!/S\FE]V^7R4:(TGR5)<=?B.AM)+2&5,/74U(?8?\O@E*>-Z"T<GO';N
MW=QP8>1,W(Y#:$#U=);9F(;CRO26PES5&>LMU:>=M1TCB3PH-[V8(T:/`WA&
MCITQ6<VXB,V?*T-AL:$W/.PH+L#+0/!*;^X*"G?9M#:\=O$%`X;AE\;<#P3X
M:"X?1X^H*[M&H<CI%_E4%.^S9;N=[D`)'QBE``>(^&@D>ZLMM'%[B2\[G6CN
M)A;2VL),?[Y*B\H(;0TP=19<6560M`X7X\*"=8R>SD8$>:R%):D-I<2E8TJ3
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M4Y&AQHSB651B6%NH>6I23WRTJ2+IU)`_LJ#F>S+)??C;T4ZLK*LZZZ2>16XV
MDK('9<T%UT%",X.=%ZUB8B*^(TK-.//!4<DL@1U)2\J2IE(+3Y)[M*'.')5Z
M#[=')+C_`%;W0EQ2264SFP@1&HJD@3D6"^[XJ/;Y7(<?GJ"]:"B?:FVOACMI
MK=!94<RA^-`0_K7I#"EK64]W?2>)YVH)_P!$D)1TLV^A*0E*6%@`?XY=!-Z!
M0*!0*!0*!0*"N]QFR>HI(O\`ZOCCQ_Q9SYM!8?SOO4&*[:V[\[FWR#09T"@C
MD12CU$RB2?)&)@6'@O(EWH)'0*!0*!0*!0*!0*"L_:*6TGI3E2X2!WL4)L;7
M49"+`^'W*".^S:-S'I?',!4$1?3)G=]^EXN`]\=5]!`YWH+3MO3Z/&W_`&#_
M`--0>6WM]%C2/V,@?KT&(.^;&YQ=^RPD4'BCOVPT^JB;<;^D#C0<7);8W7E<
MLS-R`Q;S+<9V*8P,I-^\=;<"]8(4""U;WZ#+&[%<AYK&3VX\.(W!<==>#"Y#
MBW.\94V$CO3I3Q5<GQ4$;;WKG3[03FW%24##AA+28H[@.%PQ#)"E'NN^*.!X
M:[7X^*@GN0(^-^$%N/HT\^+FQ05[U&_X[=-A_8SOL=!<`H%`H,7&VW$%#B0M
M!YI4`1\@T'S,2*3Q9;)TZ+Z4^:.SERX4'HBQ4IT)90$Z=.D)%M(N+6MRXF@\
M,6*7"Z64%PD*4O2-1(%@;VOR-J"J>BVV=S;7W)O'$9AEIN+,E)RV/<:<#BEM
MR''D>40$VX-#R=-Z"3=1,MU)B/XV-L6#`GRG@\Y.1D%*0E#;>@(*2E;?$J7:
M@J?:N(]H786,S#T/"8=UB;)=RLSOY!6I*U)!<"`VM'D@)X#B:#]`KE/)Q1E>
M0IY,<N^226RH(U<#S*;_`*E!^>^GN']H+`8V?(P^"Q3D?<+ZLHXM^0-2524Z
MO(TNITBQX:KF@F'2WHG"B[;8=WSC$2=THE.OJF&0XZZ$WLR>^0L<4HY<>%!(
M^G'4##YS*Y7;.+QKD!C;BE1CWKB5%00ZII.E'%=CH))4?DT'9ZC;27N[9>4V
MXB2(B\@A"4R%)*PDH=2YQ2"DF^BW.@KB'T@ZOQ(K,2-U(=;CQFTM,LI9-D(0
MD)2D7438`4'U5TIZT6X=2W@>SX$_34%F;9P4C&[3@X3+24Y5V/&$>7)6V$I?
M`%E:FSJ%E#@0:"HE^SUNR%NF7G-M[J;PP=+S4)IF.H&/#==+J8R+*TZ4J/@H
M.B.E76I*B?TEO</,!9)!-NWC08HZ6=;4MW3U*<+BA8A3)*1X;$_,H+.VC@I6
M'VI`P^1E^LY49GNI<M:;=^M5RM2DF_G:J"FIGL[[TB;SDY_:^Y(V&8+KWJ]M
MIE:5QX[ZRLL)";HT@J-!W%].>O6@Z.HC94!9.J-8>^0DT&/Z->N3[S#<[?K+
MT'O&U2VA&XJ;0L*4@#2`=0%N)H++WIMF)N;;<[#R4-*,AI8CN/MAU+3Y20VZ
M$J^>03<4$1Z0=/IW3O!YE6>RL>4Y-DF=(EH!::0E+82I2U.$>`J)Y4$[QF?P
M>5!.,R$:=9(6?1W4.V2KD3H)L#0;U!&-N]/,!M_-/Y:`I_TB0VZTM#BTJ0$O
M/!]=O)"KZQVDT$GH*@]J4VZ9(X7_`-91!^[H)5T7=;<Z7[>6VO6@QU#4/"'5
M@CWCPH)K0*!0*!0*!0*!05YN0I2WU"4H<#"C"YN1_%E@<![M!8=!@OSV_=/R
MC09T"@CT,I^/^5%_*]5X_P`GCR[^9Q\%!(:!0*!0*!0*!0*!05=[2AMTGR!Y
M6D1#_P!H30:WLN_\)(G'5>;.X_SA5!;5`H%`H`H%!26-G*;]I;)00SWJGT)=
M6L&_=(1`0`HD`CRCY.G@>VYY4%FY)1&]<$BUPJ)D%:K^!4;YM!7?44D]?.FR
M;\`W-(']H:"Y!0<+=&\<7MM>,1.:DNJRTM$&*(S*GK.N<BNWFI\=!W:!0>&@
M]O0<!O>.(<WF[M%*7_6C,,3UK+9#'=*6$6#GT7'P6\=Z#YS&,S'W3*G1(0DM
M/P(\=M:G4-(#K;[RE!5]2K!+J3P2:#<Q4-ILJR<J0T_.F!#:Y#9^""`3H99N
M?-"E'QJ/R*#J+0E:2A0"DJ!"DGB"#P(-!P&<?EL;#=QL=`G8TMK1#*EA#S*-
M!"6E:O)<2.257!`YWYT'1PL21#P$&(I*1)CQ6FB@GR0XAL)M<=FH4$9V3O/-
M9S<&7Q,P00Y@UAC()BIE`I=7?1H4^A"5ILE5R/E4%$,;RSNU<CO>?@PV)3,Y
M,1MS3WX0AR?(64,H4"&T*''3Y7&ZKT%Q=*>H[^3Z>RMQ;LR$="(4UZ.[D2E+
M#1:!1W:E`6`OW@%!YB]V=',5N;,;C8W5'5/S093+0[+"VDAA.E/=H/F_)]RU
M!WD]7.F2A=.Y\<>S^,(H/?TM=-+D?&;'</\`IT4`=6NFA3J&YL<1]\(Y_)H,
MOTK=-K#_`&FQO'_26_FT'J>JO397#XS8T'GY4EL<O=(H.G'W?M22RE^/F8+K
M*P%)<3):(*3R-]5!I/\`4OIZP\XR]N3&-O-$I<;,IFZ5#F"-5!A^E#IP?_Y/
MB_PMGZ:@]_2?TX_WGQ?X6S]-0!U/Z<?[SXO\+9^FH.A#W'BLSBY,O;TF+F@U
MJ;"6'T*;4Z$W[I3B=823<<Q0<7IS@<WA8^08R?I3@E252VG)<MN6I'>\V6RA
M#>E"+7'N\A03&@4"@I_VI@#TQ1<V'K*+?^[H);T;0VWTPVZAL`($4$`<N*E&
M@F=`H%`H%`H%`H%!7NZ0WZ%O\JX$Q8X*N!_S?AP-!85!@OZHWP[3\HT&=`H.
M)#`^.>5/;Z!`'^5ET';H%`H%`H%`H%`H%!5WM)D#I/D+]LB(/\NGP4'#]F[<
M#<3I='CF#.?4U+EW<8C+<;.IY1LE8`"K=O@H+2.ZFPD*.+R7'L$1PGWP+T&1
MW0T$%1QN1Y$V]$<)-O$+T'OQHC?R'(>/[B?X?W-!Y\:8O\AR/X%(^DH/@=[8
ML34PC%R`EK:4^ADPI&HMH4E*E`:.04M(/NT'WC[JQ[LZ/"+$MAZ45)8,B,\R
MA2D(*RG6M(%]*2:#DPNF^-A]09N]6I3BIL]"4/15MLK0G0V&@6UE'>HN!QTJ
MX]O"@Z&1)^.>$'88F0-_[:-05OU/G8^'USZ</3'4M-@2D!1OP6Z.Z:X)!/E.
M+"1V4%S`VM053N#JET&RTHMY7/ZI#&J.I#2\@R!91"DD,!"5<;\:#H,=>NC$
M9IJ*WN1E#;*4MMH4W*X)2+`74W<\/#0?<=>^D1%QN-FQ_P"BD?:Z#S]/G2*]
MOC$U]9D_:J`>OG2(#CN)KZS)/_54!OKSTA<7Y.XV`JW$J:?3P''FIL>&@KSH
M%U/VACXF>@Y?,)8E3LX^_`3(+A[UJ04);+9(5P*NSLH)C"Z>S,%$B9[*9I:5
M8QJ*<A#6Z?5S,>"\7W7FT!-]?=\;GMO0=@]<NDH(!W-%X\1]4M\G109'K?TG
M'_\`)H?'QK^EH/'>M?28MK2O<\0(4"%$+6DV(MS`!%!W=N[<P6/:9E8UV2\A
MQL*:=>FRI*5MN#4DV><6E7#D;<J"C-D=/X>Z,[N[%SI@;8GR!DV9$<M+=*H^
M0DM6"CKUM>2=6K0;GER-!(.J.R,?LKH#G<1CWW)"5/MR7'W](47'9#?(("4I
M`"0``*#N'"]`L=CXGI\/"(D+9:/<A+;KZBI`(LTC6ZJ_[&@\&#Z7RF2O%;'C
MS#_@B\S&AH/&W^<J0Y;W$4'C/2_`REJ+F`VUB4JXH0ELSG03S)N8S?N>2109
MHZ"=-E2T2L@VW,*2I2V+-1F3<<`$10SP!^B*J"M_BUTTQ_6O<F&EX1B;C&,?
M$]381@%17+=#=PTG4`"0;J4HV2.)M0?7.=)MMP-\;#$W'Q&1GYTEO)XB(3Z(
MVPU'UM,7OJ=4%J\MP^<>0">%!^@<;M;;F-@,8^#C(T>'&3H892TC2E([!<&@
MI_VB.GFRL9TYSNXL=AHT7.*=8<].:24KUNR$)6>!MY040>%!TL3M'V?!@H,F
M=$PZ7%1V3(>><"1WBD)OJ4I0`)50;./VM[.,^,F5#AXAR.LG0X%*3?22D\"0
M>8H-@[$]GPJ23C\3P/`:S8^Z-5C[]!H>S4F,C!;G1%"1%3G928X;\SNPE`0$
M^()M:@N&@4"@4%/>U,5#IB@I\[UE%M_=T$JZ).AWI1MEP7XPP#<6XA2@?U:"
M;T"@4"@4"@4"@4%?;I2/0M]D#RE,1@3XNX'S:"P:#YN?56O=/RJ#Z4"@XD,?
M[9Y4W_S"`+=GU670=N@4"@4"@4"@4"@4%6^TJ+])LB+V^Z(G$_?":![-#*6^
MC^)TCSW92R?"3(7QH+2H%`H%!5_5[)O8N:U.;$A0:QSVM,0D/*29<:Z&R+>4
MJW#QT$<V)FGLMO'$."'EL=';E/(3$S*U+>/W&LA8!Y`W^707G0<#)*MO7!I\
M,/(GY"HWS:"B/:23//539WJW5ZQ$8JA%&C6'DR+ME/>>3<*Y7H+AVONC.CIW
MA\CGV'!N>7'"%05M%AUV;Q2$=R0"GB+J-K`<>5!#^M>T<'A^C&6D-8^&,M';
MC*7D6X[2'5.JDM=XL+"=7E$GMH.!G.FN+V3T>S3>.6<EDMP,I=[^6TR7&4)C
M%U[NK!/`--KMQYF@U?9]Z7;!W7L%>3S^*;GSTSGV"\7'T60@(LFR'$BPU'LH
M)/OGV>>FZ<6J=CH[V)7$`^#C.J4AS4M(&L/%T\+\+$4$"R70S;D20^UZ1,T`
M9A:%*<;)MCNZ[B]DBVHNG5^M0;3W0+:2'9B!+G6CRI<="M:+E,>`F4@GR.>M
M1!\5!W]D=$]FHE[BC&(<AD</(A.8R5*<6%)<5$9E:2&RA%N\5VIH++W7DL?G
M.FV??BN79>Q\MMU*P4K;/=*"VW$&Q2L<K&@_-/12#BAUCG8N?CV9V'29$+NI
M#8?0THO$1U`.A5N+>B_CH.YOS8N+Q77=J!"CI7B,A!]8RX3;+2NX8)+4GT=J
MW-#32EILG4#<CB*#N[]V!M`[8W(UL'")G1TXYI:51F#)4B:N2WH]&>6%.E98
MUEU"5$`6O8GB$VVAUQV`,=B<&'I9R3$=B*^R(CQ[MUH(8<"R$V2$.>2HG@*"
MRH&&PV/?DOP(,>(_,5WDMUAI#:G5_1.*2`5'CVT$!]HOCTCS`_LXW/[Y;H/S
M9L+I>O<F,?SDJ4YCL*S*,1R;$BB4IAP)2M3DAO6VM+-E#RTZM/'58<:"THWL
MDP'6T/M;L[]#@"T/(A(4E0/$*"@_Q!\-!]E>R4D"Z=U**ARO"'ZS]!%]Q>SW
M(A+DQ,1GEY7(QVU/26_1U-QXZ$#4?2'PZL()2/)0`5'P6XT'`]GW8VV][[JR
M,3.M.N,,8\260R\XPH.%U*"2IM0)\D^&@_1.WN@W3K`9R'F\=%DB?`67(RW9
M;[J4J4DH)T+41R506)00_JSLF5O?8F0VU%E-PWYI:TR'4J6A(;=2X;A-CQ":
M#G=4]NSYG269M^#)8:D+CQHO?RG$1VBE"T)5=;@4E)4!87H(BSU6D=/ME;6Q
MF20SF)SN/<6],;D)+2EL.=V4MK9:4A21RU<``./AH+GQ\M,V!&F)24)DM(>"
M#Q(#B0JQMX+T%4^SB;XS=QU%5]Q3?*/;;2*"WJ!0*!04][4X!Z8H![<G$_OZ
M"5]%`!TIVR!V0D_+-!-J!0*!0*!0*!0*"O\`=)`A;[X_X&+P_@!06!0?-?U5
MOW3\J@^E`H.+#_/+*_>$#[++H.U0*!0*!0*!0*!0*"K/:6!/2>>`;$R88_[0
MB@TO9YR>4:Z4XIIK$/R&T.20A]+L=*5CTA9N`MQ*A;EQ%!9)S&9'+!2%>X]%
M^VT'AS&:_(,CZ]$^VT'GKG-_D"3]?B?;:#WUSF_R!)^OQ/MM!&MR8W,9O(H7
M(P\UB*B.6TN,2(8>2\'D.(4F[JAP"#QH-/!;1R;&Y,9.<;RKHBO/+D2\M*CO
MD(5'4VE".Z4I9NI0\0XT%DT$=RGY]8#C_F62X?VT6@JWJG@F<WU_V%#?==8:
M5$DNAZ.K0XE<<K>04J(-O*2*"X,9M^!`>$D%V3,TE"IDIQ;SQ23<@*4;)!/8
MD`4$(]H[_@SN+]C&_&FJ#2WJL3-K9=0.IK!;6=NGC;TF='('OI9:_NZ#5]E=
M"4]+C86ODI9)\/F<:#L]6=Q[@@*;QT5GN\1)C%R5D?0I<TH=0^V$-@1E)T7!
MO=5!`,CN/(.IDJ=F!M:_6G>+."RI*!)*!*YJ_P`#I2/%VT&RYO+*E3Y]+T+,
MJ4X\/4>5"4N+AAMQ`!)^IM?"4$[Z2O9>7)W+D\E&4QZ=+C>C.F.]%2\VU#::
M"T-2`'!YG'LORX4$NR>U\)DR\9D?4J0@LR5-K<9+C9%BEPM*1J%N'&@_+71V
M')E[ZW_Z*3Z9%CORX=A=7>P\F'FQ?^R+0306!NK)H5U]QN7BW\G:$F7&5:Q!
M*'UH4G@JZK4%5YSJUU)DQ<7-5N*:PIN$A:E1RVV%R52W$`.H1H"DK0CGI-K"
M]!^A]IXO;DG*%N#@F]N+:2V[(97';8ES4H5W@(T@I[@.JU**5$D\[=H6.*#E
M[HVQA]SX.3A<PR7\?*`#J$K4VJZ5!22E22""%`&@C/2S9V(VDWG\'BBZJ"SD
M`M/I"^\7=R*R57587YT&Y.PLG;*7\KMYUJ/C6PM_(81\AN*L#REKCN$@15_Y
M,]H'G4&CA]SS=^%1PC[N&PL=81/4\@MY-TE.H(;;5_%VU`\'3Y2OG+>=02&3
MAL7A]ISX.-C-Q8J(TA0:;%@5*0HJ4HGBI2CQ*B;GMH/SA[(P_P!L\P?_`"I'
MV=-!^JQ0*"+]2M[M;(V?.W*Y#7/1"[L&*A8;*N\<#?GD*M;5X*".];$G,=%L
MP\VVX42(C,I3*2G5W86ATI)4I`Y<^/N`\J"NH72_-;ZZ8[)F0)*0&,.MD!UT
ME0>4Z%-J6IUI:BVFQ!2FW8!=-!^AL9$,+&Q(95K,9EMDK`M?NTA-[>.U!57L
MX&^)W9XMPS!^YH+>H%`H%!3WM3_\,4?UG$_OZ"5=$7.\Z3[95I*;PTBRN!X*
M4*";T"@4"@4"@4"@4%>[L*3C]]BXX-10?=[A)H+"H,%D=ZV.VY^509T"@XL/
M\\LK]X0/LLN@[5`H%`H%`H%`H%`H*M]I3_A/D+_RB)]G30?7V<2/T0X;C?RY
M7'^<N4%F\*!0*!0+"@4"@C^2_/;"?>61X_V\6@K_`'D?_P"H[82;_P#A\\V_
M@W*"WZ"M?:.('1K<-^13&X_SIJ@Y[ZER>A&Y<RX"DYC&2I;04-*A'$8,Q@?X
M%I)]^@^/LLJ;5TNNV./K&65GPJ)2?E6H)YOV?!C[=E-R)+3#B^Z4A+BTH)"7
MD7(!(H()F<W@U*F]W,8!4UN()LZBQ)=C_P!E\^1<4'VFYG#D33Z=')],RY![
MY!X&`0#S]Z@LO#38<K',*C/MR$I;0E2FEI6`=`-B4DV-!O<:#\P^S4L*ZN[T
MX#3W4JP[;>L+&]!]?3F\=UXAXA]KTE[&8R1A68RUV[U$E]8BZEFVD=S)1JM<
M@#PT'?WEL_8&WF)$O=&VDJC8G'H7%]42'FVGHHF)"V'&W%I(+;SR5^=90/BM
M0?39NX']YIE^IHD]C/8C(^D">Y,;4RTW(?66QW"W5!2!&^#(0FQM:@NC$SGI
M"7FI2`U,BK[I]*;Z3PNEQ%_G5IXCP<NR@C/6/<V7VWT\RF7Q#J6,@SW2&7E)
M"]'>NI;*@E7`D!7"]!`NA7425+VUD96:ENY?<60R3B8T5M"/2'^ZCM`>0VE"
M&T)'G+59([3067#VW/R<EC*;H*'9+"N\AXEA2C#C*MP4;A/I#H^C6+#YU(YD
M-W-[8C9*0S.9><@9>*#Z+D8]@L`_X-U)\EUH]J%BW@L>-!Q)^YI47&2\5N=I
M$')/QWVXDILJ,.80RH_!+5Q;<L+]TOC]"54%%>R-^>68_JM`_P`NF@_50H%!
M57M-V/2'*)N05O1D@#DH]\G@KQ4&PC!],LIMF'CLKG`_&+$<NQEYAP)UMI2I
M/#OKC2I(MX*#?Q.,Z;8C'M8[&[B]&A,@AIA.864I!)40+O'M430;R7]D!)3\
M:"03?^EU7^3WMZ"&>S/H.!W06U]XV<_+[MPJUE2;)LK5\]?PT%QT"@AF(ZA)
MRF0R\:+&0\<%,>B9..TXM4II"%J0V]W10E*PO05:4JOX+GA02V),C3(K4F*X
M'H[Z0MIU/$*2>(-!4WM2"_3)O^LHORET$JZ+?\*]L_>2?EF@FM`H%`H%`H%`
MH%!7FZRKU?OWF/@XNGER[A%!8=!@OZHW[_RJ#.@4'%A_GEE?O"!]EET':H%`
MH%`H%`H%`H%!5WM)W_1/D+=DB)?Z^GP4$.]F?=^3CX-[%9AV'$VW%"E8B4XZ
MTVZXZMY:GD*'>%1";]J$T%VG=6V1SR\/AS^Z&OIJ`G=>V%`D9>'9)LJ\AK@?
M'Y5!E\:-L_E:%^$-?34#XT[9_*\+\(:^FH/!NK;%BKUO"(',^DL]O]M0>C=&
MV2+C+0K>'TAKZ:@\.Z=L@$G+PK#F?2&?IJ#D.9?%3][X=,&8S+4U!GET,.(<
MT!2XVDJT$VO8VO05WNAZ:OVHMGMOM!$9K'21"=`XN!3+Q=N;GS5`#D*"[Z"L
M>N15F\/%Z=Q0E.6W?WB83[I(9;$%3<EPNZ0I5E)386!XT%<[<D]<=^[)RN)Q
M\K$##L%S!/-N(+3A2TV&U]VI*5@#2H<3\B@XD;V;>K45/=QI,)IH$G2W.?0D
MW[=*6K7H/E)]F;JI+*52W,=(4@$)4],><(!-[#4R:#XCV7.IOT.*[.'I"[<.
M7^!H/'O9AZF-LK<[K&+[M"B&VY"]2M(N$I'="Y/90:VV.@_5N=#<D1H@PB2Y
M94>7(<BN+.D'7H:2L$<;7)H.NKV=^LY((G1>'_F,G[70=/8W1GKGLC*RLI@E
MX42YC/H[YDO.O)*-8</#NT<2H<[T&SE>D_7;+;J=W/.;V^O)O1?070E;X:4U
M:P7ITZDNIX%*TJ\D@4&KO7:'7AG8^X%Y]_$RL=Z*'<G*[UYR:N/$/?!MM:DV
M`&GE87/NWH+,Z*[/B;6VFUF\FMN+F,ZVA_)K#Q]'7=2UL*"5D)2ONE@&U!O;
MW8ZL+S4>;L->)5`?B!N6N>5E7>(<4I"D=W>Z=*Z"LNJ$;VBINVCB<OCH.4Q\
MU:4NHPK+KT@%I7>I*[VT))2!>QH(3C^@76>(2_"@>B./(&M3,]MA93STKTN)
M)MXZ#>'1GK]R(DD?UN/MM!D>C'7JUM,G_P!7'VV@^$KH;UPEL*CRXSLEA5BI
ME[*H<02.5TJ<*>%!8?L^=*=[;/W+E<AN"(U$CR(:(\<(>;>4I7>!9X-DV`">
MV@OB@'E0?G/VE-W;Q7"R6W%[><1ME+L53>X"'"A2_)58*`T#X0Z+<Z"?XOH#
MTE<QT5QW;S9=6RVIPEV0"5%`))'>>&@VO^7[I#_N\U]=?^V4#_E_Z0]NW6OK
MK_VR@K#9F=WITHP^XFY.RI;V#$Y^8W.+R64-,7#:`;APE.E`X^.@FN/ZQ[_R
M$-B=#Z<3WH<IL/1GT26RE:%C4A0NCD010?<]5.I=O^&>0]Z2WS_:>"@^W1[:
M&5B3L]N[*QI&*R.Y)3SLC"O]TL-`/*6TM+B4Z_-4>%[=MJ!-W?OW;N?RN.@;
M(F9?$>DEZ%+8?0A)2ZA"E!(4E5AWFLVH*OZZ]0-Z9O;R,5E=H2=OXX2&9!FR
M5*<NXC5H;"TH2T-7'MO073T14I72?;*E)TDPT\.?#4JQ]_G03>@4"@4"@4"@
M4"@KS=11Z#OVXX!N+JL>-^X106'08+MWC=_';Y%!G0*#BP_SRROWA`^RRZ#M
M4"@4"@4"@4"@4"@K'VC2/T6SD]ID1K>Z'0?UJ"(=$.I_33#=.L=C,UE8\7)Q
ME/E]EYI94-;REI-P@@^21R-!/?TR]&S;_7L(^#X-?TE!Z.L71P\/7D+W.[7]
M)0/TP]&_RW"^M+^UT&/Z8^C7Y<A?6E_:Z#S],71BUO7<&W@[I?VN@]_3'T9`
MMZ\A6_Q2_M=!Y^F+HPH$'-P2#S'=+M]CH,V>L71QE96QG(3:U"Q4AM:21[R.
M5!7&X^H.T,GU_P!CY;%SQ/A18LJ(\Y'0XLAY]+B&T!.FY*BL<J"]H&<Q<]]^
M/&>O)BFTB,M*FW47Y$H6$JTGL5RH*SZP9-.!W_L'<\N-)>Q.,7DD3G8C"Y"D
M&1'2AL%#8)\I5!`>E_4^-M#"SX"R\?2\E*G()Q.1<(0^H:=1'=\;)Y6H)F/:
M!@=V5EU:;&VDX;)ZN5[\Z#ZIZ]02VA?I-BNWD>I\IJ2#]$!?EVVH/H>ND"_\
M=;_](ROS*#Y.]?,2TI"7,BRE;ITM).)RH*C:]D@CCP\%!]!UT@<+36^/_E&5
M^909'KE!'.:W_P"D97YE!\V^O6,=0>[GLK4DE"].+RI`4DV*38<"/!09KZXQ
MPH=W+9*>W5B\L#;Q60:#@[^ZN)RVS<[BHKJ'G)T)^.RTC&Y-+BRX@I"05HT)
M)OVFU!J]5\L)W3'9#N/[W[H0J(EM32PX7!%+*TAIQ/G>2H)*K#MOVT%C]!P@
M=*,$&QY`2_I(OI(])<XIU<;>"@GUJ#T"@6H%J!:@6%`H,7'$-H4M:@E"05*4
MHV``XDDF@JOK1#RN]]@OX?;&-D9!UZ1&=;?(0PPIM"PLK2M]3>H6[4B@L[',
MJ8@QV%><TTA!]U*0*#0W#N[;.W$,KSF18QZ9!4&"^K3KT`%5OV-Q>@W\=D(.
M2@L3X#R),.2@.,/MFZ5H5Q"@:"&]<A_[1[I^\5_NA0=+I;_PVVM_54/["F@D
M4UU+,-]U3R(P;;6LR'?J;>E).M=RGR4\SQ%!S-JYAK*X]UYO(L94-/K95,BM
M%IDE(2;(NMT+'E><E5C0=FPH*A]J,)_1DBX_\2B_*702GHM?]%>V;_R)'RS0
M36@4"@4"@4"@4"@KK<Q'H>_B18`1+]M_N=N@L6@P5?O$>_\`*H,Z!01[&.%6
M^\\@\FX.-M[ZY9H)#0*!0*!0*!0*!0*"ONNN"RV9Z<SXN*B+FS$+:?2PV1K*
M6U764@D:B$]E!3W0W.])'L.C;NZL)#]>-N+3'ER(G?KF!Q1.CR4+6'&_-*#V
M#A06T[B.B3M^\V]#5:YXXEWLY_X"@\;P70]8)1MR$=1L?]4N\3]8H,3@^AB4
MA1V[!`)X'U2[S^L4'OJ/H;_N]"'"_P#13O+ZQ0#ANA@Y[?A?^E.]G\!05EU3
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MQ2XPSP%NU)"R%#P4%H]/MX-[NVG`S@CN1'9*+2(SJ5(*'4\%Z=0&I!/%*AS%
M!Q^L>_I&S=E2<A`;4[DI!]'A+"%+;96L<7W2!8);''CS584$<]F&6Z_TU=6_
M(+[IRDPK=6K4HJ64K45'PJ4HGWZ"W`XD\C?W*#*]!J9#$XO),I9R,-B:RE6M
M+<AM+J0H`C4`L'C8GC0?:)%B1([<:(RW'C,I"6F&DA"$)'()2FP`H/M<4"]`
MH!H/-0[3;W>%`U)\(H/;T$5WCEL*Q)CP\Q,:C8YMEV?,:<6$]^ABP0U8D%8*
ME:BGYZUJ#A[.ZU;9W$])2XPO"Q(K:%IE9%Z.RA?>&[:$`.$W[NRCX.7.@L1*
MDE(4DW2>((Y6H*0]IO&SY:-MN167%]RJ9=]*-2&U%+1&M7SMTI5IMQ)%A06/
MTKA.PNG.W8SS+D=UN"UK9>3H<25#40I!\T\>5!$NL&[8^1Z2[B]'@3TL282@
MU*7'(:L5"RRJY\GQVH)=TK-^FNUC_P"50_L":#MYZ%)GX/(08JTMR949YAEQ
M9(2E;C92DDI\JP)[*#\X;SRN_.GF&PFW\7N%R\.-(7*5&4AYI/=NAM*=3S>I
M(;`"0U;B3P-!^CL!->FX'&S7R"_)BL/.D"P*W&TJ58>Z:"C/:>WUA96,:V7"
M6J3ETRF94P-C4AA*`=+:SVN+U\$CWZ"U.DD#(8_IMMZ'D(RXDQB(E+T9P66@
MW)LH=AM02Z@4"@4"@4"@4"@KG<7\6Z@^[#_%6J"QJ#!7U1'O_*H,Z!01W%Z?
MCWN"PX^A8T*/A\N7XZ"14"@4"@4"@4"@4"@4%$=<.B"Y;CN\-H-J9R[*O2)\
M%@Z"\I!U>D,6\U]-K\/.]WF'3Z(];X^YV&-OY]T-;C:24LOJLE$P(YV\#R0/
M+1V\QX@N3@:!84"PH%!1W7K,MXS?O3\!M)>DR76EN.D%`9[UDJ2D$&SBB`$J
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MBUN`6=1IND:O*O061U.Q>-G[4VKMIJ(RC([JEP(JUH0G4(S($F4L$=@0@_)H
M-;+[089+C>#[G'OO9.5$C,:$(AH0RC4!W2$<U`<3S)H(=L7(Y;<+;<G)(<A8
MER?&QBF5-AMUU4H74I.M!&D#@>WE07=M+;.$>PJ#+@L2'42)*>^<;05J[MY;
M*%*L`-7=I">5!S-DYOI_NR;E<?CL%Z,YA'6D/B5';;)5=:6RD`J59.@VU6YT
M'$Z@X'&1EYI49(AQ\=CH:VHS#;0:6IZ6N_>A225"Z$D<1:@K&&SN!.\LK@%1
MVXR,8S*<G3/1BEA33907$-+6@!1<"@4W/'Q<*"X=AX'&R,EF8LYE$YN*(3L=
MR0A!6E4R&E;P"DI3P)Y=M!,V]I;9;4%(QL<$*#B3H!LI(TA0OR(%!&9>SL+(
MW:G&L)5`BLP$2@B)I02Z)!"2HJ2N^G3PH*]ZT;(@1<CLR"U,E]SE,OZ)(NXA
M*@V\05Z%(0@ZB5$\;T$E_P"6W8(YS<O[GII^DH)ML2#'Q&W6L"TMQ2\.5Q5!
M]?>.Z0HJ:4I7;K;4DB@I>/B,=U?SV>R&YFUQ)6W8JHD=F$Z4IU-R)-EK0Z%*
M2HA`NE0!H-#J]T.V5M3I\YF\:J6N:ER.V!(=2XV0\L)7Y.A/AX<:"Y)F!Q4!
MC;#T*,F.ZF9%05MD@Z"RL%)X\1XJ#M;AWQM#;KS+&=R\;'/2$E;+;[@0I20;
M%0'@O0;N)SF(S>.1D<1,:FP7-01)84%H)22E0!':"*"NM[)T^SQD!J*SZG3Y
M2K7/F\[4$KZ5_P##3:U_R5#^P)H.AO4M#9V=+O>=UZOE:^ZOWENY5?18$ZO!
M05;L;IQAM\;%PLC=$B9(RF,;D8Y;O>-I4&5+`+!4GODK2E``#B3JMV]E!].L
MO62)LZ!\5MK*0<X&D,EQ'EMP6K!*!:YN\4^8GLYGLN&IT3Z)O0'FMW;M0I[,
MO$OQ(;YUJ:4OCZ0^57*GSX/G?=Y!>5`H%`H%`H%`H%`H*YW$!Z-U!X\S#X?S
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MFY\C)8&-A`LEAYV(GTM,T*`:[LJ3J0.)YVXT$[AP9,CJ9A,CE2U&Q&"PC+&(
M<<=:3W^0R%D.=VV5:[I:;TCA[E!O-;0?W`,RT_.0G'G*R2(:XR5BX*=5UA:%
M'41>@^F-Z30L;+;F17HZ)31U-/&*5%)!N+`O:>!'#A0=[80>&W$!]?>O>E30
MXX$Z0HB6Z"=()M[EZ#B=/]KLX+=&Y2T(<4SO1GWL?$D/R5)65/\`P[I?2DH+
MH-@A-QY)H/KF,'-S&[LI$1*:9AO8Z&B4PZQWW>)[Y\BQ#C13^K0<T]&827T.
MM2(R-"@H),5Y0N.(X>E#MH-3U]D-GY3.#T56;FORX;)+#3K+3+"(0(4YW29B
MDA*4^"ZN?(&@GFS\ZYG]L8W,N-!AR<REU;*22$*/-(*@DFWC%!R<QDDXG?#$
MI^+)=8FP!#CNQVEO`OI=6Z6R$#@>[!5QH*]ZV3XN8S.P8CT&2EI6<:#J)D=;
M2%H)0"/*%E7\%!:+.$P^.SD)>/ALQ5.MOI<+2`DJ`"#8V\=!OS,67)29D5TQ
M9B4Z"X`%)<1S"7$&VH`\C>X[#0<5W;TJ//S>;?<9U2\:F)W#*"D78+SG>$D\
MU=]:WBYT$1]HVWZ(7K_O\+[(F@F>8`,3;()('IT4\!?B&7#053UTS^X\/U(P
M2]OO=S.?QKC2B&@^I2/2-92$*;>^@^=3?WJ"9="EJ7TY4M:2A:YV14I"B"0I
M4EPD$V3<@\^`]R@U-\'3[/$[L_U.V.`O]"*"5]+/^&NUOZJA_84T'?RD%K(8
MV5`=<<9;EM+84ZRHMNI#B2DJ0L>:H7X&@I+J1U*C]/<0[M#;$YR?N62XMZ9.
M<"%^B&0HJ4=#24-AU1/D-A/"]SXP^G1;HBY$=;W=O%I4C-/'OX<.0>\4TI7E
M&1(U<WU$\`?-_9<@O,4"@4"@4"@4"@4"@4%<[D2GT/J`3RUP[^Z(S-J"QJ#$
M^>GQ7H,J!0<#%E/QTSPMY7HV/N?%]T6X_)H._0*!0*!0*!0*!0*!0*`1>@H'
MK?T%]-7,W;M-I9R2E>D9+%(/!Y20+O1Q\ZZ--RGY[W>8:O3KKIL5_$F/O?'Q
M8>68`0J<W""VY21<:E)0A1;<')23POR\`"5_IE]GZU@[$(M;A`5ROR^I>$T'
MHZQ>S]V.0_P!7VJ@C&Y-T>SSG-PX;.'+F#)PI<+346$GN7@[8*2^AR.XE8M<
M#P7N.-!)?TO^SX;\8?C_`-7*^U4%1=2]\;.G[@,G:LF"QCBICTA)AA"E]V47
M"2MNR0+*^=XT%H87JOT!;QD9#RHB7$HLKO,>HJY]I[M79XZ#>'5KV>E<.\@<
MK\<>K[309CJM[/?/OL>`/_+U=G\#0?'V9FH$C84]YII"FEYJ>6CH`\@J24V!
M'`:;<*"PL0VA&Z<X$)"1W<+@!8<$.#LH.S*_BKW[!7RC0<K9'YFX+^KXOV%-
M!M;A_H#)?>KWV,T%0>TG&9FXC",J#R7(PDR=>F0(ZD^CE);6M@$ZR;%*?$;D
M"@CF^849KJSME],-4A^2G"*5+=,E2H]I2;]T`[W(95I`5J;L%D6XF@O3:"0E
MO+VOQRLL\?&N@[U!P]F"V!3XY,T\/OMV@K[H7@\YC,SNYS)09L-N3(:5$7,:
M#0=2%OJ*@1]44-?%1N;6XT$_B#_;;)?>$/[*_0=/+9;'XC&R<GD7TQH$-M3T
MJ0N^E#:!=2C:YH*.W_N[;&>PF<R6/GMR<8G,8Z.Y)2EQ"M7H9UH:6&UD*LNR
MBI-M)4F@M'I3H_1QMW0+(,)HH`X`)(N`!9/`#Q"@W-Q#_7.VCJM;(.</#]PR
M.%!5_M)R)3.0V(J(%JDMY-Q]E+1&M2VDH*4IU>3Q)[:#;Z3[PWIN3<X3NJ$Y
MCGX3+RHS3@`*TN!L*/DI2!8T%R4&KEA?%31X6'1_<&@K'VCK?HA?OV/P_LB:
M"9Y8CT?;%S;[NC_BSM!4?7J0RWU(PC;D3'RW)6+<CL>M7%-1FG'7R@.DCR;I
MU<-?`<^R@G'0UI#73M;*%H<0W.R*$N-$*0H)DN#4@C@4GLM0:._E!'L[33<C
M_5+`OV\5(%NSG03#I@$IZ<;7"3=/JN'8G_$)\%!!NMG6EO;;+FWMO/)=W.\`
M'74C6F(A=QJ/87C\XGLYGQAR^BO1!Z%*:WANX+>S#A+\*"_Y9:6OCZ1(*KE3
MYY@'S?=Y!>E`H%`H%`H%`H%`H%`H*]SZ$F+OV_#6[$2;FP_BK`H+"H,5>>GW
MZ#*@4'"QGYWYW_$0?^OH.[0*!0*!0*!0*!0*!0*!0*"A.N?0XS$O[JVHT&YK
M6J1DL<T#=X@ZB\R!R=',IMY7N\PAFQ=S[=WM+,?=LAV-GXS;:=LC%0[M]^V-
M3DM33*5EZ05"RT.)T:>`3Q-!;6V-X[<=<]3;CV\8VY&4J5W;6)?[N8PV0/2X
MZ"SK"%7\I!XI/#EQH),)FSRHI^+[]QPXXAZWR>YH,59/9J"0<!(%K7/J:0>?
MN,4%2;_Q6Y<CNSTW:<:;C,6HH$AI.,DM)=-FM2[!A78D@&UZ"QX&9V5C=O)D
M3\'(CMPF"N27,.^"E*+J5<]S;E08[:W[TSW'C?6.*Q+TB,%J:4I&(><LM(!(
M);:<3R([:#KIR.RU)"O4KP!OP.(D`\/%W%!"?9EGP&]@3];[;07F9ZT(6I*#
MI4I-O).FWR*"QL+(8?W1G5,N(=2$0P2A04+Z'/!0=J7_`!5[]@KY1H.;L])3
MM+"I/,08P-O\2GPT&QN``X+(@\C&>O\`6S04M[3B8J\=A!D41T0([<E]A]:U
M]^N3W00EE#8:=1W92JZ]7/A:UJ#1ZB!T]4]EK4S)"$,8E#;B=/HRBJ:@K[RY
MO=-A:PO?Q4%S;.-VLO\`UK,'R'*"04'#V9_0*?OF9R^^W:""]%H68Q^>W?"R
M4LR?NAE^(!)3,0EEU3X39U)\E1*3J04IMS[:";PA??&4-^4"$+>Z[(XT&'41
MMI>QLZAU@R6G(;J7&0"K4E2;'@DI-@.)L>5!^:]MR\&O;^8@S\G+QV.=S2"R
M&68KI>,>`P$%5C%0$I*M;>E(/FE0U"@O#8^]MI8#8FTX>:S$>!(FX]"XOIC@
M;+J4`!2BI7DW\H7XT&UGM[[5>WIM?"LY-AS(*DJE!M"[I+*XDEM*DN#R"2OA
MIO>@C'7>().[.FC:@E32\WW;B5BX.HM'CXO)H+(..@1]PP'(T=ME99DA2FTA
M!();YD#C01#JAU"W+MK=6U<7B68[D7,R`S,5(0OAJ=;0D)<U(0BX4KG<^*@G
MD^7%<@34-O(<4AESO$(4"H>21Q`Y4%:>TC_P@D6_?X=OKB:":96_<[7\/IS'
M#^:O4%5];]P9;#=1\2K%R6H4F;B_13,>8$E+*5R[J<TD+*;!/G!"CX!033HD
M6ST_>6TOO&U9#)J;=XG6DRG+*NH`\>?$4'*ZAD'V<9A4+WQ4?A[JVZ"*;AZX
MQ]N=-<!@]ONI=W,]BH:774`+1""V$64H6(4Z;^0CWSXPRZ)=+H+.61N3=TV.
M_N%]Q3T#$N/H<D(>XK4](3>ZG^9T_.]O'D'Z#%`H%`H%`H%`H%`H%`H%!7>Y
M/)@[Z44W'I$*WNB/&^506)08*/PB/?\`E4&=`H.%C/SOSO\`B(/_`%]!W:!0
M*!0*!0*!0*!0*!0*!05+UJWEO';\V(G$SV<=!7&6Y<66^\[WJ&R`E<=Y-FPL
M&R5`V))L$T$;ZV="E.K7N_8['HV6:5Z3D($;X,NJ3Y1DQPGS7TGB0//_`&7,
M/.G?4G&]2L?'VYN:1ZMWE!/>X3-,#N75NMBQ<:OYKO`AUKS5I[+<`%I;0W=*
MF2',%G`TUN&(E1[QDCT::RA6DR8IN>`/!Q'-"N!H);0*#4R\<2<7+C%M3P?9
M<;+2'"RI>M)3I#@L4$W\[LH*YZ>8MS8'3O<J&6&DHQ4B?-BP!)$I2$I92\EJ
M0\A*?+U7O<7`(H/AT5ZQ9??\[*1<CCX\/T%IIUM<=:SJ[Q2DD*"[_0]E!)=G
M]*-H[9QS\!N*C()?E/S"]-:9<<!?-RA*@@>2GL%!*8.*QF/2M,"(S$2X=3B6
M&TMA1`M<Z0+T'UEFT1X^!M7RC0<_:=QM;#@\_0H][?XI-!]=Q`'`9$*25`QG
M04C@2"@\!05E[0>;W%CMMX^)B`P(^2$IC)%YA4E:61&)U-H0%+%NU03PX$D"
M@BF^\6AWJOLN6DQ"6E8AHL+8=7*(UJ6'$N#R-'DV*AR-@>=J"Y]F$EG,>#UM
M-M]=H)#0<39PM@DBP'W1,Y??;M!6GL\F,9NZ"PTEM:G(ZI11W24J>+DG44H9
M%@G3IL5^6>WA:@LJ"5?'/+#3Y/H4$ZO'WDGA0<WJVTE[IKN%I0<47(:TI2RD
M+<4KAI2E*BFY)\=_!QH/SIMY2%=.MQMI0['7)W)':&A0BJ:4O'W.L!1&FXXI
M*QX[<J#]`]/,)ALITPVXQDH+$V.(#02U);0\`"FWSX/R:"L-Y^SICG-WQE8^
M>SB\7FI?<1H#$8VC=W$6\5))<LHJ6R3R3:_BH/GU0V[NK;[W3W"L[B?S685E
MU'$3)S3:2TM"6P@+4FY6E)4/.N:"11)W6'$=1=HQ-T9&!-B99R9'+,5D((2W
M'[U:BJR>6A-J#M]6<OC?6N.V]D#D-&084]&1"=CH:6^P\V6TO(>TK(2JRKH7
M?A:U!4/L^I4G=>0*$W0]A9BK\;*!<;)6G4E)4"OR;^&_NT%H^TFM*>D3R5&Q
M7)AI3[NL']:@G&4'P6V;\Q-9_%7J"H.O\&!+Z@8A,W*-8AM&,*T27E.H"B)7
ME-A3+3ZP5(OV#P^(A..A:POIL7$^8Y-R*VS8@%*I+A21<)-B/$*"O.J_4W$Q
M>FF/V/"*)F5GP8J<@4DZ(K5D."]N;B[62GWSV7#J=#>AB<;Z/NG=$8#(W#N,
MQBT_Q<\;/.CM=/SJ?G?V7(-:)BH>/]HYI,-3997+?<=0.]+B7GH+CR]1<\DW
M+A/D\!RH/T$.5`H%`H%`H%`H%`H%`H%!`=Q`>K]YG2%$RX8(L.([B+PH)]08
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M%ST---I:;+>E+14225*4>.KE02?IIOYO?&WG<RW"7`2W,D0^Y6L+)]'5IUW`
M'/P=AH)90?*7?T1ZW`]VKC[QH.?M(+&U<.%D%8A1PH@6%^Z3V4'WSRM.%G*\
M##G[DT%/>T[E&X>`Q33B'5%],U25(=[I*2VRGF"+%1U<"%`VO:]S0?/=6[LM
M%ZE[5VTAU_U?/;Q4A;!]'+%VWQ?25([Y'FBZ=?&W`6O06GLU(#&6(%B<K.)\
M9[XB]!(*#B[.'^HD_?$S\;=H(!T+R><R^0W7D\H5N`2FX33BF6F$:HJW];:`
MR$I7W?>#RB-1[:"?03_MCEQ_H<$_W<F@PWOLS%[QP#F$R;KS,1UQ#BEQE(2Y
M=M6H<5I<3^I00'`](L.H[HVXK(3D0!DH4M+K*VF'CI@-H[M19;0C00>-D?J\
M:"RMMX-C`X&!AF'5O,P&4L-NNVUJ2@6!5:PO0:.X]7KW:]A?[O>OP!L/0)'A
MY>]05;[2CJ6,ML*4K(G$EC(/*]9A`=,86:N_H/!7=VO:@^G3C$9O<6^E97+;
MO?S\7:;Q5BEB-%;C2D3XRD>D-.L*.I'G)MQL4\^=!+]_=.IVY=U[=R[#K347
M%.!4]M;BDK?:2ZAY+6D-K24A;85Y1M?L[0$EDX#!8^#D)$#'18<AR,ZAQYAE
MMI93I*K%2$@D7XT%>>TTO1TD=`O=4J(E*AR!U7N?%PH)WE/J6V>W[M9X_P`U
M>H(?U"W?G,ENUCIMMA:,=F)L?TG(9N19)CPU&RO0T*XO/$7Y<$_J@*TW;O[=
M'2U_(['PV81G6'&DK@S)9+LW'+=/EM.6!2ZI0-T#LO[U!(NB'0I4`L[FW:QJ
MGW#N.QCHOW)/$/O@WNZ>82?-]WD%]T%-3,/(C=>8.1$['JCRY:M6/8?<5-"Q
MC%@./L%10D620%`<K>&@N6@4"@4"@4"@4"@4"@4"@@.Y+#'[Q-@;S8//_$Q*
M"?4&*OJB/?H,J!0<+&?G?G?\1!_Z^@[M`H%`H%`H%`H%`H%`H%!7_6]Y#>S6
M@MMEY"YT=*H[X>4APC4I*=#%EK\I(*A]"#VV%!5^\96W(>P=LG)XJ*]/R6&+
M41U3LAM;*FEH4TIIM*%-J0%.:K+TJO:_;8+SW9N7U'CVO1F1,S$Y8C8G'!6E
M3\A0O8GYU"$@K<5\ZD4'FT=M*PL!TRGO3,Q/<])RV0M8O2%"WDCYUML>0VGL
M2*"I.N/0IO()D;IVI&_UK<O9'&M</2".)>9'8\.T#SO=YA#<?U.V!E=A2,?N
MW#(9W+`2@8V="CMH>?>00&W`O2$M+0H?"I7Y)%^?*@M#`;ZZ.)PT$9N=@5Y?
MN6Q/<C1M+*G](UE`4WP3?PT'$=ZL=)9F\'-NOX;&+VRXV0O.J0GNE*[O5H+1
M:O8J\F^J@D6/W-[.T.+Z+$D81IBY46PTGB2;DG4FYH/NK=_0!2'$F5A2ESZH
M.Z1QOX?(H(3[._4/9VW]B2,?G,O&Q\KUG+=:8=)0HLN%)0H"W(\:"T?TR=+K
M?G+"_;GYE!KS^L?3%4&0EO<D-3BFEA"0HW*BDV'*@UMN]7>FD?;V,8?W%$;>
M:B,(<0I1!2I+:001;L-!AN?K-TY&W,HJ%G8<J8F*\8\8+4"XX$$H1<`GRCPH
M*(ZF=:AOB!`BF(_AUQD22Z&I3BFUJ=04!+J$,G6DI3PY$%7@N:#H9_>6V&>K
M&)RT;+^DXUQW%.2W&RKNFBP`A:5JU%)0@`J5P!!M86O07#M?JSTWC,9$/[AB
M-EW(S'6PI1XH6Z5)4.'(CC0=Q/6#IDH`C<D&Q\+EOEB@Y6T>JW3I&";#VX(3
M#A?DJ+;KH0H!<EQ220JQXI((H-G%;[Z,8E3_`*JR^&@^DJ[R3Z.MEH.+^B5H
MM<\:#7A=4^G2=U95Y6XX"65Q8:4.*>2$J4A<C4$J/`VUCE0:>]?:!V=@(\-W
M%.,[A7)<*7FX<E`++:0"7%\%^'@+4'WP75'IVC<6XGG-P8]IM]Z*IEQ4A`#@
M3%0E6FYXZ5"QH.]^ECII?\Y\;^$M_-H.-FNJ/39S,X!8W#CW4LRW5+6E]M0;
MU1'DA2C?R1<Z;^$T$!ZT;OV%G]U=/T(R<#)XN/DUJS`[UMQEN.KNKE[B0$'2
M>=!,)/43ICBL_B9V*SF+1#6A6-G,1G6DI;95=YAW0@@)2VZ"DFW#7028]6>F
M8Y[HQOX2W\V@ULEU5Z:/8Z4VG<V-65LN)"1);N24D6YT%)]>.L6(W#C96T\6
MP'H\*3%?;R[;Z'&G^[`*@A"1>P+G/5V'A06UD^IO3]T8`IW#CU*:FMJ?"9"#
MH`C.A6KCP`*@.-!7OM`=1MDY&'C8V`D(R&YHKZ)$',8]PZH02>-G6^*E.<N[
M'NGQA`970SJDG!-[B3!5)??4J4]"0Z?6*"5:PXL+MJ6H\;)5J%!=FT&NNN(V
MMB8J8.&R#+,5L!$J1+9F@%(4$O+6E:2X+V5PYT'8&].K$5/W=L`/@><J#DXZ
M[\>:4N)0?DVH(3']'5UTCY5Z(]$GR%I?E0EL!UQG1B5EP=ZVM1OQ2G2E!"R#
MI42DB@L+8W4:1N?+RH+V*5C`S%1*;2\IWOB%N*192'&F0."0?)*AQYT$WH%`
MH%`H%`H%`H%`H%!`=RD>KMXW_ET`>^6HE!/J#%7U1'OT&5`H.#BR/CAG?$Q`
MO\AZ@[U`H%`H%`H%`H%`H%`H%!6'7U]L[<QD)LM*R#N0:?BLNARRPR"E83H;
M>25'O4I"5#B56%U6%!7&_P!(5M?IZVIQ<92,2XE6E"KJ[Q+31:YM+`^CYZ1Q
M4C30?HE>&QR\LWEULA60985&9?5<E#2U!2PD7L-12+D"YM0;M`H*ZW#T%V!G
M<[)S4IJ0S*EZ2^W&=#316+W<TA)\I7SWAH-`>S;TX`M>=^$#M_M*#X.>S'TY
M6^'>]R*4A.DM!]&DGL4;MWO[]!]![-/3@"P7/!^B[]-_L=!\5>S#T]*EJ]*R
M8"B"$]^W86'9\%VT'A]F'I^?\\R?UYG[30>?\L.P>V=E#X+O,\/\C0>_\L.P
M?Y;D_KS/VF@Q'LO[!'^?Y0^Z\S]IH/3[+^P"+>G93Z\S]IH/$^R[T]2K49>2
M5;L4\R1\CN:#'_E<Z>\O3<IRM]79^TT&2?9>Z?I%O3LH?&7V?M-![_RP=/\`
MLFY3Z^S]IH/1[,.P`+>F9)7[)YH_]4*#%SV8-B*39$W(H/#CWC)_4[KMH"_9
M@V&LW,W(\>8[QJWO?!4&"_9=V,;:,AD4_1$K942.T7+5!X?9>V7>XR,X>^R?
MEHH,5>R[M`J!3E9Z0.8'<<?=NW0>GV7MFDW]93O\C]KH,5^RWLQ1'^LYX`[`
M6;'_`"=!\I?LN[03$=[G*S&G0A1;<66BA*K&Q7Y'F@\Z#F[5]G?96:P<+(^M
M9G?N-A,IMI4=:$OI\EU-PA7`+2;<>5!V1[+VS/RE.^2S]KH/FOV6-FK6I1RN
M0LH6TW8L/\G09?\`*ULDIMZQG]@O=J_#^TH.OM'V?-G;;W`SFVWY$YZ*DF,Q
M)[LM(=/)VR4INH#E?ESH+0H%`H*,C!Q7M'+;4X\HHD+<25I<TA'JP@(25ITZ
M;DGR5>&PYT#H#(AN[KSP8?;D+$5I+BV^\*0&Y#J$(;[Q"%);0FR4(XV';07G
M0*!0*!0*!0*!0*!0*"`;F)&.W@0;'TZ`+GQM1!03^@Q/U1/N']:@RH%!'<,]
MKWKN1''X)K'I^2AU7Z]!(J!0*!0*!0*!0*!0*!0*#DYW:>W,^8ZLSCV9RHA4
M8RG1<ME5B=)%B/-'R*#G3.F.P)GHYE8.,\8K+<>.I:25(::%D(2;WLD4$GH%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(MU3M^C?<]P3_`*LE<N?U)5!^
M5NEO4C=FTIK&,PWHYA9*?&,J.XSJ*^\4AE6E:3=/D\K"@_:(H/:!0*!0*!05
MSB^D3^/W@]N5.;4\XM^3(99=8UEI<EMU`T++I'D]Z"KR?*TCE0;G3OIG(VA/
MR$M[-.94ST(24N-=WI<"U+<<\]SRG5+NOQT$ZH%`H%`H%`H%`H%`H%!`=R6]
M!W=_6&.^QPZ"?4&)\]/OT&5`H(YA#?>6YO)X@01JX<1W*C;WJ"1T"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@BW516GIMN
M8\/Z-DCCQ'%HB@_(_3S8VZ,[E,;.PN/>E0,=DHR9<MI30#6AU#RS=2T&X2?!
MR^10?N$4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%?;@U>A;RO^4L=;W.ZA4%@
MT&)\]/OT&5`H(_A0?C9N0VX7A\;?]!X:"04"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@^<J-'E1W(TEI#\=Y)0ZRXD*0I*
MA8I4D\"#0:V*P>'Q+*V<7!CP&7%:W&XS:&DJ5RN0@"YM0;M`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%!7N>_B6\_ZSQ_V&#06%08GSQ[]!E0*"/X5/^U>Y%>$P
MQS\#'@]^@D%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!7F=.J%O2YX#*X\<
M.RS,&@L.@Q/U0>X:#*@4'!PWYT;B_9Q/Q<4'>H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H*]S*=</>2;V)R^/'&W[U`\'AH+"H,3]43[A_6H,J!0<'#?G1N
M+]G$_%Q0=Z@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@K_-)OC]VZ_,.:Q^F
MW/S('@\=!8%!B?JJ?</ZU!E0*#@X;\Z-Q?LXGXN*#O4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4$#RY2G'[H5J`OG,?JMP/+'CB;T$\H,3]43[A_6H,J!0<
M'"D'=&X_$N(#^#@T'>H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H()F;>K=R
M\K^O<=?_`/;Z"=T&)^J#W#^M094"@CFWG`K=>ZD\;HD1!<F_`PVS8#LYT$CH
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H(#F=(@;F-A<Y[&W/_IXH)]08GZH
M/</ZU!E0*".;>)^-&ZA<6$J+87%_XDSV<_DT$CH%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H
M%`H%`H%`H%`H(+E[>K]Q>//XT?)./H)U0>'SQ[AH/:!01W;R%C<^ZE%5TJE1
M0E/@M"9O02*@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@@N9_H_<7"_^O\;R
M_98Z@G5!@2>]`MPL>/R*#.@4'#P0_P!?;D^^V/Q)B@[E`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%!`\N?\`5^XN9_V@QO`_LL=03R@Q/U4>X?UJ#*@4'#P7
M].[D^_&/Q)B@[E`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!`,BHJQ^Y>-[;
MCQP^0O'<*"?T&)OW@\%C094"@X>"_IW<GWXQ^),4'<H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H%`H*[G*2<;N8=GQEQX/,\=>.H+$H,"?AP/[$_+%!G0*"*0<
M_@L=N/<3.0R,6&\J4PM+3[S;2BGT)@:@E:@;7'.@Z?QSV?>WKW'WM>WI3/+]
MM0#O/9XYYW'CW93'T]!Y\==F_E['?A;'T]`^.VS/R]COPMCZ>@\^.^S/R_CO
MPMCZ>@?';9G+U_COPMCZ>@#>VS"+C/XXCP^EL?3T#X[;,O;U]CKWM;TMB]_V
M]!DK>>STBZL[CP/"93'T]!Y\=-G6U>O<=I(N#Z6Q:W*_GT'HWEM`WMG,>;&Q
MM*9Y_MJ`=Y;0!`.<QX)Y#TIGC_=4`[SV>"0<[CP1S^ZV/IZ`G>6T%&R<YCR?
M`)3!_OJ#+XW;4U:?74#5>VGTEF]_VU![\;-JWT^N8-P;$>DLWOSMYWBH/4[J
MVNH`IS$(@BX(DM'A^VH/?C1MG\KPOPAKZ:@R^,FW?RK#X\1]T-?34'@W-MLF
MPRT._@](:^FH//C1MG\KPOPAKZ:@?&C;/Y7A<.?W0U]-0>IW-MM7FY6&>SA(
M:/\`?4'U3F\*KS9\97N/-G]>@]&:PRDZQ/CE-KZ@ZBUO=O0#FL.--Y\<:N"?
MA4<?<XT`YG#CG.CCW74?-H/?6^)_EL?ZZCYM!X<UATD`SXX*C9-W4<3XN-![
MZYQ%P/3H]SR^%1\V@>M\3_+6/KJ/FT#UOB?Y:Q]=1\V@>M\5_+6/KJ/FT#UO
MBOY:Q]=1\V@]];8K^6,?74?-H'K;%#_/&/KJ/FT'OK3&@7,MFWA[Q'S:#WUE
MCOY4S]<3\V@],^""09#0(X$:T\#\F@R3+B*!*7FU`<R%`_KT'HE1B;!Y!(Y^
M4.V@\]*BWMWR+CB1J%[?)H`E12"0\@@<#Y0^;0>^D1_WU'[84'OI#'[XG]L*
M!W['[XGY(H'?L?OB?DB@=^S^^)^2*!W[/[XGY(H'?L_OB?DB@=\S]&GY(H/0
MXV>2@??%`[QOZ(?)%![WB+7U"WNT#4GAQ''EXZ#V@4"@4"@4"@4%?2`CT#<8
M(X+W-!!'A/>P/#06#08'ZL/V)^6*#.@4&"F&%+UJ;2I=K:B`3;P7H/#%C$W+
M2">7FCE0>*B15><R@^ZD']:@Q]!@_P`G:_:)^90>>KL?Q/HS5SS\A/']2@>K
ML?\`R5GZVGYE!YZLQM[^B,W\/=I^90>#%8P&XAL`^'NT?,H/?5F-M;T1FW@[
MM'S*!ZKQG\D8^MH^90/5>,_DC/UM'S*#SU3B_P"1L?6T?,H'JG%_R-CZVCYE
M`]58O^1L?6T?,H'JK%_R-CZVCYE`]4XK^1,?6D?,H'JG%?R)CZTCYE!X<1B3
MSA,?6D?,H/F<!@B+'&Q2/`66^W^UH/F=K[://$POP=KZ6@]^+&VK6]4P[#D/
M1VOI:#(;>V^"",9$!'(AAOZ6@^BL+AE"RH$=0YV+2#Q^10?%6V=N+.I6*AJ/
MA,=HG]S0/BQMK\DPOP=KZ6@?%C;7Y)A?@[7TM!B-J;6!)&'@@J\ZT9GC[ODT
M'OQ7VU^287X.U]+0/BOMD<L1"_!VOI:#WXL;:_),+\':^EH//BMMG\D0OP=K
MZ6@Q.TMJ&U\+!-N5XS/TM`.TMJE6HX:#JYZO1F;_`+F@P5LW:"A96#QY!Y@Q
M6#_>4`[+V<18X+'6\'HC'TE!XK9>SE7U8+'&_$WB,<2/[2@#9>SARP..'\T8
M^DH/#LG9AYX''&_.\1CZ2@?$G9GY`QWX(Q])0>_$O9U[^HL=<\_N1CZ2@]&S
M-GCE@L>/<BL?24#XF[0_(>/_``5GZ6@?$W:%[^H\??P^BL_2T#XF;/X_ZCQ_
M'G]RL_2T'OQ.VC^0\?\`@K/TM!\SL?992$^H<?8<AZ*SV?VOCH//B+LK\@8_
M\%9^EH//B'LC5J]08Z_A]%9^EH/#L'8YY[?QW#A_%6?I:!\0-C?[OX[\%9^E
MH'Q`V-:WQ?QUOO5GZ6@'8&QB+';^.\'\59^EH"=@[(38)P,`6-Q:,T./[6@\
M_1_L8_\`@&/X\_N9KZ6@].P=D$6.!@6)N1Z.USY?0T'OQ#V4"DC!0;IX)/H[
M?#W.%![\1MG?D6']91\R@^:NGVR5$DX2)QX'X)(\7908GIWL:P'J2)PY?!B@
M\/3G8QYX6,3X2CCQ\=Z!^CG8_P"18PXWX)MQ';SH/3T[V2;CU.Q8\Q8]OOT#
M]'FRAP]4,?(5\V@]'3[9:2"G$L@CD1J!^70:V>PF)Q6W&X>.BMQ(Z\ECW"AL
M``N*GL74;\U&U!*J#`_5A^Q/RQ09T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@X.]4A6'821<*R.-_'F3X#0=Z@Q_P@]P_+H,J!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0
M*!0*!0*!0*!0*!0*!0*!0<'>MO5,47'')8WGV_=S-!WJ#'_"#W#\N@RH%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!P-[`'%1+_E/&<_OYF@[]!I9&-E
M7B@P)C40B_>=ZP7]5[6M9QNU!I^@[KX?ZWB^/[A5_P!XH/DK%[P/+.L)Y<H(
M\?A>-!F,7N>W'.)]WT1OP?LJ#+U7N2W]-B_WJW]-08'%;IMPSJ;_`'FW]/0>
MJQ>ZC;1G6QPL;PT&Y\/U04'S7B=X&^C/LI!Y7@I)'^5`_4H,DXS=XYYR.>%O
MXC;CPX_5_%0>^K=W64/7<>Y-TGT'S>'+ZO09G'[K*2!F(X)'`^A'A_EZ#YKQ
MF[U:=.<CHL;FT&]Q?EQ?H"\9O!7FYUA'/E!!YWMS?[*#'U3O$'AGV2/'`3^L
M\*!ZJWCI`]?L7O?5Z`+VL.'U:U!ZK%[P*PH9YA*1:Z/0!8VY\2]?C09#';N"
M2!FHY-O.5!-^7B?2*#+U?NW4D^N8UA>X]!/$_7Z#WT#=5[^MXW+EZ$;7^OT`
MP-V=F7B_@*O^\4'H@[JMQRT8GQ0E#_YB@Q5`W=I.G,1`KL)@K(_&10>^C[P_
M*&/_``)[_O5`]%W?QOD8`N.`$)[@>/\`I5!CZ!N_C?,1/[&T!?#_`+30>B%O
M!)2?6L)8'G`P7!?GX)5!D8^\+\)^/MV?<;W_`'J@]3&W=?CD(!\0AO</^U4`
MQ]V\+3X'CO#>Y?A5!CZ/O&_\?Q]NS[C?_P"]4`1]X]L_'?@;_P#WJ@]]'WA_
M+\?^!O?]ZH/4Q]V\-4^`?#:&]R_"J#PQ]WWX3\?;QPWO^]4'GH^\N'^L,=X_
MN)__`+U0>^C[O_E^/_`WO^]4&(C[SMQGXXGPB&^/_FJ#%4?>^KR9^,T>`PY%
M_P`:H'<;W[NWIV,+FH>5Z)(`">WAZ3S]^@]<8WKJ^#G8W2>6J(_<?(D\:##N
M=]Z"/3,65]A]%D`7]ST@_+H,TM;UMY4G&D]I##XN/<[Z@]4WO/YV1CO?9?\`
MMM!YW>]?W_&_67_MM![W>\^'P^.\?P+_`-MH/.[WK^_XWQ_`O_;:#WN]Z_O^
M-^LO_;:#%:-[ZO@WL84W^>:D`V]YR@Q2G?8\YS%GW&Y`X?MS0>VWUH(UXLKM
MP5ID``_L=7'Y-!B@;]MY:\5?PA,BWR-5![;??D^5B_[,:9'$^(WX4`C?AO96
M+3Q\DZ9!LGQBXN:`I.^^&E>+'ANB0>S]D*#-7QVU>3ZMT^/O[D4&15O/L1CO
MVS_TM!YJWGI\S':O!J?M^YH!5O3L1C?V[_TM!X5;U[&\;^W?^EH/=6]?WO&]
MGS[_`+_SE!XI>]AYK6-/'M<?'#]H:#P.;XTF[&,*K^2.^D`6X\_@CXJ#WOMZ
M^7]R8W_H_NE_EX_@*!WV]K#[DQNKM^Z7[=G_`$'NT&0>WEI%XF.*K"Y$E\"_
M;P[B@=_O/C]Q8[Q#TI_Y?H]`2]O*YU0\=;YT"4_^K]ST&EE8&Z\HB+'>8@,,
;-3(DIUQ$AYQ>B,^AXA*2P@75HL+JH)-0?__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>59
<FILENAME>g5754315new.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g5754315new.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`OP'9`P$1``(1`0,1`?_$`.P``0`!!`,!`0$`````
M```````)!@<("@$"!00+`P$!``$$`P$!``````````````@!!@<)`@4*!`,0
M```&`@$#`@(%!@<(#0D)`0$"`P0%!@<(`!$2"2$3,11!42(5"F%Q(Q87>/"!
MD3*VMSFAP20U-Q@X>;'18G*R,S1TM"6U=AE"4I1U-B<H:3KA\=-$E:5F=U@:
M$0`!`@0#!`4%"P<("`0'```!``(1`P0%(3$&05$2!V%Q(A,(@;$RLQ3PD:'1
M0K)T%74V-\'A4F(C%@GQ@C-S)%1V%W)#DS1D)296TJ,U55-C@T2T9B?_V@`,
M`P$``A$#$0`_`-_CA$X18Z;<['U/4'6/.NS]Y:N9"JX,QE;,BRD6S.!'LR:O
MQBKF.@V:ABG(BZFY/V6B9S`)2'6`P@(!TX1:4]&B_)_Y#JQ$;=9_\DNQ.KCS
M+34E\P_K_JR]&F8^Q/19@WSE/9SB";Z/7M+US&>PLK\R*KQ4IP%9R8QA*37!
MSP\>PT!S!GZ-T':)-QI;;5OIZR;5/F2W.?+:"]M,V7@YS7$M)=@2(@`*5F@O
M#;^\NEI6H;]5SZ69.,6LEM8X!IRB7&,88[MBE4\1WDZV*J>SL]XLO)+?8J^Y
ML4A#7;479Y>-0KB.S./VJ3A22J\^1NFA&'R97VK514@@`.G16[A);W%4DEG,
MQ.3'.32W.S1<C6.F2X,+W2:F22#,I:AGI2Y@P(!B#+="#VD$0C`8%UUHJY:#
MU%.L=S#N[!)EO(AWC=AW'9$#+/<MHX!`?@(#]`]/7UYEN*LU<\(G")PB<(G"
M+J<P%*)A^C_;`.($Y9KB]P8TN.043?EY\G-=\:.M1;C$U]#)&Q^79M+&.K6%
M4O><O\BY2E#(HHO'[)FHD^_4VH@Z3=R:J9B"H)D6I#E5<IB'QU5PH:"BGW.X
M3!)M-/+<^9.>0UC6M:7$DG`-`&)_.OIDTM155;**E:7U$T@,`$22>K):UC3#
MOF2R#')YGR#Y?<UXZV8E2!8FN.*-"P[?7"C2C[H_1H3RIM#(Q<M%QJIBM%W`
M,%DN@&ZD<``F/K*OW\2>P4&M/9;39)E5R^94.ENJHO%1-8TD.J9#`.`R1"/"
M[M$1,0%+.V^%NKJ--LN%95SF7V=*XI<H,9W<81@Z)XLND8XK8&\(WD;RKOCA
M#+%)V8K4)4MN]0LIN\';"-*TB1K6K5(HM%75:R/7V":BA(YK;FK5<5D$P^7*
MY;J'1`B*J:1-DVF[_;=5Z=H=5V68)UDN4ADV0\1B6/8UX+VGT3!T,"<<-BBM
M=K95V6YS[37MX:NGF%CATC+WQBIL^=VNN3A$X1.$3A$X1.$70QNG3\O7U^@`
M`/41_('*&,1NBJ].Q?FX>1+S$[P[T[.YMJ^O&QV1M3]/\*9'LV*:+&X9D/U6
MR#E>4ILBI$S60+?<6"J4O\K(OV1U6;-)<C1NT.DF*1UP46&0/)[D?-YCV^9>
M[O5.I+0V>Z6UTL!SB6XQ[>X%H.&<3DL4<Q>9DG1,Z5;Z23[1=)S2X-,0T`0S
MACC'!72\77G"VHTJV.QUAK?'8.T[#Z7YFFFM*9Y@RJ'WMD/7J[R*A&]>F9NW
M_I).5H;QV8J<D5ZJY*W;G%P@*0MU4UNJYM<FZ_EH65\J8^JT_-<6MFP'$'#(
M.#3`<6PA=AH'F#2ZTEOIG,$B\2P..7'#':V.)AM"_0V9ND'K=%TU70=-7"*+
MELZ:JD7;.6[A,%47#=9,QTUD%DC`8ABB)3%$!`>@\PDPF$'PXQG#X/@61LCP
MGTQFOJYR1.$3A$X1.$3A%8':+97$>H&`\H;(9SLR%4QAB>KOK/8Y$_:J]>?+
M%`D=`0C+N*>3L5CDE$6,>U)]MP[7(0.G41``YS@UHB2@(,>A?F\YW\N7E,WN
MO<OF5CM5D_3C$$G*.W.&<&8+=%K:L!4$W:AZ_)7J?9G:R]KGW[/L4<J.5E$E
M3B84$FZ(E3"4'+3PY5&K[(V^:BJIE#33V$R&L#2YQ#BWM<>6(V8P6%-:<X).
MGKH;1:)`JJF4\"<7$AK8@'`MS(!QZ5/W^'O\PVS>;<^V?QW[R6MKES(S/'4E
ME37[8+[M;1-GO55K[AJA:*7D!LP0;,)"=B6CCYQI(%(5PHF@X3<&6$$U!P[S
M*Y?W;EOJ,62X'CIIK2^5,P'$W?`$PPP/DAMAD?2NIJ'5=H;=*,%KHP<T_)(S
M'Q+<(*/4.H^GQ^'YQYC]G'P]L`.Z%<BYYR1.$6-VXN?6NJ^J>Q>R+IDSD_V'
MX9R+DQE$R!UDV4U,5.K24K!0CI1N(.$T)J;0;M3&3^V4JP]OKTX10/:U>8G8
MK+4$YK^4#85J%W=[,Z<X,KMEK&',OUY5*5S3BN8SYFNF7+"N8K76;[7HO'F.
M*K(H,;S[WW+('[G35JY12-W$63U)\^.M=XJMDM+/!.TD28V-L%9'PQ69NAUI
MK:]D6^Q^4)_#F(X+$4,E<UU%):UWVN.4T!ES1B)XY)1^!_E$S*\(L::CYN;F
MTD<AY/S55Y;&&*:9D_="RGPXKBN/L.9$<!ZB0>(\3S5;DK#!9-4J[')TWM)D
M-9FR7;#*LY-NC\FD*1B_,&(LMW'G`PRA`RZ2>MFTRV7X;-64<0O->!JU#:Y6
M9Q^%,75S-.4\G2HO,A(4R#I%+QM;(]T\*[E4GY'[I*/!N+LX)\(JXSWY%;I)
M:HZ.YFU3I\(RR#Y!<U8'QCA:#V`AI<S6K5?+\?-7"7N]TK5+GFLDX&LX[KKF
M1.V;2`%ZG(!E!#KPBQTQQYI;-56N<<3YYP6[RWM+@;/&?L6OZGJ&"#FHW[&6
MN5%IN0\EYX8N,OVBNL:+7Z?%7=I%248^F'3P]C_P%G\P<P@F15_+^>36TMII
M4'1,&[29;@[O+ZX5=C=<=X^K[^!:WO;#%"^7<)XX5;2=QBYIU?)R"(5-\R;M
MU2Q7>#ATJFUZ+"1>).^?G7*/Q'3\L1&`-G+FS?XGFLSY=J]7K%#7G=>J''Y;
MG,#1#[);J0O\=`/WESRM7GD=$-H)Y++O&[95X4GRY!.)%X5Q\V=(PS:]@U+C
M0<MYHB:ID#8YKCVDX<Q;#,)^C8ZTQQ_C"1V1M&0K=9\EHP$U"0]QO+A!M)E+
M'`9=J=@1!1<A#K$4Z5!N,;D.CTV_PJ3Q"$O-5KUPA4I)L=E))Q-FAV<W')R#
M)3J=F_(T?%!9(1$4U`$HB/3A%AEY-]NY_1[3'*FP5+A(6T9#A7^/J=CBLV&/
ML$O$3EZR;D.KX_@&KV&JABV>91;*V([H6D?_`(8Y!N*:7VC!PBBDQ9YH[R]H
MM;N>:GF.8=E4\R[R+7F8QOB?(3)3(>N6CN(&ENO,JMC;*-Q@LBZX9'EKS98V
M-8L[$D^6=B!`^60(]15*1920GFXP_8XN6BHS6';+]LXY?QMB"CZX/Z91HS+^
M1W^2\)-MC8JS0[)[D!"L0-<@\/*FEY@\O),%XPH)(KID6<))B18FZ[^;VS2=
M+I^8<Z04S(0=JQQ6\CL\*8MPZ:2R=)I[7[F7#`VF56@9Q7(2<6^MHT*DNG4W
M&E:J&=&$SQ-R1,GM&(LBK'Y[]>H#%D;D=+7S:"PR\;7MA;UF'&=>J]"=W3`F
M,]9LEO,/9&R%D5RZR$SJ:\*YR,V^ZXA&)D9!Y*+D5]E(00./"+(C;';[/L1<
M]!\+ZJ0.,XG+.[K^^V%5WGZ"M$[#8QQEC7#2F3[+)3=;HEEK\FO.EE).*B>@
M/OER+N3AU,/0>$6$6*?/[4_V$.KGF7`=ULF2,1#EB4VI4UK-%VG$V(\7XHSW
M9-?DLZ-9_(=@J,M,TO)%FK#MW`0S$LG/N6+-VH"1TT`44(KRY"\[F"J7D2VT
M"O:W;6Y02KULV'QY`W2B4RE+4W(&0-8J='WW+$!59&<OT(Z)'5FJO%'#Z7>H
M-(M@JW,W76*X,1(Q%4A_-]KT_L^)X>EX6V,R!6\EN-5*[,Y#K=3J9*EBS)6Y
M,5"63#&++W]\72,G#W%6GS:<M+DBF<DWB69DS+*`99,!(K'5[SL8VI5.1LE^
MH.7\T(6D\UE]C8L,XGAX"O8QUHM&V<YJMB6:R#^L637RK^6E+/!F4;K,S"YG
MFQ@6;,DQ`R1"+8,^83^IQ_Z(\_\`P^$7TB/3A%$_OCYH]%/'A=83%&;;Y9K;
MF^Q,$I:*P3A.ERN4,K!$NBJ*L928@8<Z32N,Y%)(QFWS[ENJY(43I$.0!-SB
MY[&M[QSFMEC.,!^55#9DQ_#):789`$E6'KV[^@GGJU6VOTVPGE^6KE\OF(K;
M2KEC3)%6E<>Y?H`S#$K>'N*U,FR@I.P<#8CM%'*T>LZ23$"IJF3,H3K1C@X!
MX<UTL[1[L55S7-)8X$/W$*"CQS9?OM?C;EX^MF80M'V\T;!KC&XU]4X?+7S&
M<&5&/H.3ZFN8"%EX)]!G:`=9(.ATE6Z_0H+]"Z1O'%R-N_+G7S^9MOF.F:+O
M=4Z<20(T=4]D)K&\.''-,72N/B&;>UPE;!O#[S!E:JTR-.5$WAN5O'[1I(@Z
M6,&N8,XP&.R.S$*Z6^NI,CM'C"%D\;3J]`V;P=86V5=9LIQ;C[NF:GDBOJH2
M;.(&4(7W$82SN&"22P#W$2<E16[1[#`;%?ACY\5O(3F%(N%<9LS1%U:UEPEL
M;Q!Y:?V=0YNR;(!/HP#FES79@B\.;_+VDYB:8G45,"=1T$72']F,R`R>2(Y8
M=F&]3O>&OR:QOD?UD4E+M')4/;#!4L7%.V&)'B)8^3JN2X<JS(UG91AC`HG5
M+X+%1VS,4!(@Y*X:=3&;B8WH`I+G272@I[Q:YC)UKJI0G27L/'WLEX!8YD(9
M@C9#H"UG5%-/HZE])5-+*ACBUP.!!'7\"F`YV"_!.$3A$X1.$5J,Y9HQKKMB
M'(V<<PVN.I.,<6U63N-UL\H<"MHN$B4177,0G4#NGKLX%0:MR=57+E1-),#'
M.4!``G$13B8SM/$6C9YOA6D;@*5R7Y,ML;#Y:-DX)_!T]-*5HGCXPO.C[[?%
MN&6KUVW#)[MBH`MRW"YF445!T0G51=998AA13:=FJGQU^(T39C^06BY[`R26
MF[31$,=$"8RDE3&D=IG"QU0#$Q+)1`(>#,?PX<K(0UWJB6[O,33L([(:0>V0
M1'J]_",!G!LIL1C;53"MYSOE:0(UJM(C??\`D2'(21LT^[[D*_4H1(XA\S,6
M"1$J*90Z@D03*G$"$'IKTY5:$U9SAU?1Z%TL9LN;53W-F-<T0HF%A]HJ'8=E
MKI/&UK2.'B<(`F"D]J_5,K1NFWZDO$WNY,EKN[8(1B1!C6C,\1(!Z(P5S_#1
M76_CLTLV5\FWDDO56UXG]Y\I1^P%JBK>NO'$QW0%XQ\TP_1A8'3/-3%XG8V4
M7=(Q35LM("BJ@F*?O%5*7T<Z)TC1Z(TS;M(6Q[W4-MM\FF:70$1*:&\9A`!Q
MACD!&&Y:L=0WV=J:_5.I*@`5%9-+GM$0UHB8<())B<(DG$8@!9>8%_$C>)C8
M/)]?Q+7L_3E!LER?(1M%E<SXQNV+*7>'KMRFS8(0%RLT<W@43R+I4J;<'RS,
M5E#`0O4P@`W*T\7$&N:7#W;UU3V3&@&!`.48P/4IVDS"<H&$.G7KT_-U'H/Q
M$!`0^GZ>5!(@'0XNA4(@OZ<Y*B<(G")PBPFWC\ANI?CJQ>SRQM=E>-Q]!3$B
MI#U*";,GUCO-]FTB%.M#TBFPJ3F:GW39-0IW"A"%;-"&*9=5,#%ZMH:(EQZ$
M.45@;J7^(9\;&X68(+`58O.0<09:MZQ&M#I^Q>.)7%`Y#<N#^VTC:C-2#A_7
MGTO)]0!JR7<MW+HX@1$BAQ[>5?+=+#3.#FGJ(7$/:1$'\OOK29\@>G]V\8OD
M!RO@"Y-EE<';&W6WYSU3R*=-0(V8B[7,*R-AQQ).!3(BWL],DWGR*R743&`J
M"_\`,>)=)9^&OF506FIF:,OI:*"IF]Y()PA,(@]IQA`]DC".:P9SHTE57"E&
MJK8#[53B$P`1[!VMVB&[=Y5CE<JA!WVLS5.LC;YJ(FFBC1T3H'NMU.G<W>MA
M'J*;QDX`JJ9@Z"!B]/@(\EYJ73ULU-:)MCO<MKJ6I:YLL-R;,/\`1N$0<=I4
M=++?JJP7:5>*-[N,.$"[Y7Z0="`ALAN*VPOPS_E0G[O!//%OM%93/<\X%KQ7
MFN5WFW`G7S1@*'3$B,"#YPH9>0N&,&!2D(0>]5>&*'J)F*QC:N]<Z-NN@M23
M].79I%5+?@[8YAR(.6684Y=/7RCU%:I5RI'-+WCMB/HNAB#MZH[%M]%.!PZA
M^3X?E#KRT0Z+W,(@6P^$17>$$&!S7;G)43A$X1.$7\5%0(4QNXA>T!,(G,`%
M*4`[C&,/4.A0*'41^@.<"_A/:VG!4Q.#<U^<7YU?)*KY0=J%-6\03Z[G134>
MXK'M\S&.E"1&P^?X<%X]V[(=`XIRM'HYC+LXT1$R2QA<NPZ@NV$F=^1W+&IU
MQ?/KFM8\:;M[VNFN`$7',``@@B(Q_.L8\S]<4^D+,94MP^M*@<+8?)CAQ='1
MT]2C8.LV8-%'+E1K'LV3915=0QDT&;-FU2$YCB/4$F[9N@3KZ=`*4.;%I[[9
M;J4SZMK)-FI90)`P#8-B(=)&+NDG!0]=]:54ULF2Y[[M43>S#'C#C\KI&0@=
MBF]_#,ZNV3)NR>4_+5D=TUQWK-@['-]PKA.=LKE&$979^Y("V4LDOI"1%LT8
M4BF0B+A!1VJH"`N70EZ@9HMTUF\Y>8`U]JPUDJ'U931E2(1Q8,W$D[3E``>^
M%-CE]IAVEM/LHJ@\5?,@^:=@>1Z(Z`,^DG%3JS/XH'PY0>1E\>'V*LDHP9S1
M*\]RQ`X?R1,X;:29UO9'K=F<&<KN.*?U^<;MU6ADP[RJ&)]KF*`QY;QAKC+&
M9A^57N7B('RBIVL<Y'H>7*-5<F8PN-;R!C^\0K.Q5&Y5&79SE<L<*_)[C62B
M)1@JNU=M5`Z@(E-U(<HE,`&*(!3#9DN2K7A%8?9S7'&FW&"<C:Y9B0GW6,\I
MQ#6$MK:L6"0JLZLP9R\=-HDCY^*.E(1RGS\6B)C)F`3D`2#U*80$BQ"BO$II
MY&>Q)2,?E6W78]GN]TGLI7O,-XN&4;C:KQA&:UU4FK==9Z3=RDPK4,16!U%5
MU'JFU@2J"JS235$QQ(OBL_B"TJLU?:U\M=R)6%X6$U*@:;9:7E.W5>XXZ9:3
M-)MEK^MCZR1K].1JLA`(660%XX;F!225='56$5>TY2+R8;PQ:&0E3B*0RH=V
M5K4+5PI[9E)9/N4NLZA%]DV&V,T24D9.3=R4J^M&9(EHZE73A4[B09MDVJIS
M(EZ"18N[X>%"'V*;)1V`+U#84>7FZ;46O,N2)^Q9D?Y(>+[?-*K&Y92KJM+O
M]4AI^NR4964$B5R=(M$%^6:E+T13415(L_<N>.?`.:L>:M8[L<UENHDTW2B?
MV%VC$64+'BBXU5[%8W/B@D@G.5!=BX,X7I*[AH/;T!,CE7VQ+W=>$5H+7X8=
M$+)4L;4F)J.1\=0^.JWE"D.U\89CR%3;%E.D9RF6%CS34LUVME.*6;*$7EBP
M1J;R=6DG9W[Q7N#Y@J9A()%=V%\:.HM=MD/;J[2Y>$EJ[GQMLI!-8NUR[.)A
M<HQ.#R:[55W'PZ*Q6;6!HV+$2LH2-*4&L:J`+I%!3UX16#D/!YH!(%QNR-4L
MH,J_C3'V)\;(4Z*S/?XJGWB!PADYYE_%[S*E>8R[=CD::JM[E'CI)Q)@O[GS
MBH*%./88A%<>1\1FE4K$Y'AW]0N:[?*^/<Y8QNRXY$LY7LG5]D,V(Y^S,5-V
M1V55I*W:_M40</$^U<(Q$C(I@;AV<(I)(J+8PL:PB(QN1I'1;)I',&B0=J35
MDQ;IM&C9(H?!-!ND4I0^H.$6.&V.H^*-R\=0&-,N.KY&1%4R71LOUF:QK=YK
M'MN@<@XW?JRM,GXVRP*J3]!>$E%0<)EZB3WDR&$.I`X18J/O#GHU)5>1JTE3
M+W)HSU"RW0;=/RV5+M+W&\-\]9`IF2LSVN[V^6E7L_9[]DFQ4&,3DY=TNHZ4
MCD?DR"1N/M@1>GE?Q):<9?F9RS6"*R?7[98<U6K.LG;\?9>N]"M2EIO.((G`
M]NKS6>K<HQD8^@3^*81M$+0Z!TVX-R#V"43F$2+T:1XG=*\?2&/9"K46QLSX
MMF]6YVG-5+S8G3".=Z;U&U4_`;=9FJ\,FZCZLUNTB^70/U3?RR_SBX'6*4P$
M4>>T7@4I68+#B>E8@NL7AW`M?I*&/<N>[/Y@FLMY)ICK9)]L[::O.F8WN+Q[
M?(VR7J17404L;!X>+7=*K%(N!44DB*4+9GQ[X%VQOF,\G9!L&:J;<L44F\XY
MJDMA?-5WP^Z)1,E#$)WFKR#ND246^=1UB:U]J@N8BJ2PH)`4IR\(K0S/ANT*
MDYZA/HS'5EIE0I-!Q?C![ARBY$ME9PQDZAX6N#S(&*JYF#'K&2^[,D,:9=Y!
M:32^?,<SUTJ8ST713"42*KU/%5IZK#*0IJW=?EE*9N#2/FBY#L:<BC'[U3R%
M@V/ED'J;DJJ-FM:[5-NUD"]%XUD0$&XD)Z<(J1/X==(_VQ1&:V]>R9'3M=M6
M,K_`U.,R[>([%L/DG$6(PP92<DM<;M91*K'O<=C-%O'C(K(*J_X*DH3L4`YC
MD7KP7B*TFKU3:T>-I-L+6FM;U6J!H]Q?K&Y([K6F]YD,EX6A7YE70F=L&]\D
MUI27(;TF79@.Y[A`.$4FW"+J;K]GH'_E!U_('K_?X1:<7@WAJK=\L^4/8#*C
M9G-[U.M]<OTC,$I9FK=U><?4&#DU&^/*O757R(2,'3ER-G2*)FX)IN",$TNX
MQ4"%+&GGG<KS2WBGI);IDJW.DQ9P8-=,C`\6\Y1VK*W+ZEHGTTV8>$UG$8`_
M!'WSAY5?7REZ4Y-F);'WD;T2:M*GY!=/W"UQ@B0C!NT'9+&#4HJ73#-Y:LR-
MRVIR]@_F"1X.1,==%59F!RF51.GT7*WF#/L-S^IKY.,VT3#'B><6..V.0;L.
M$88XD+L-7Z8?74PK:=@;6M$(-R/1`_!BL8-RH^(\K>HN$/.=XW(@L-O'J;$.
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M6^9.4#)+-FZYC>U\V"D_?`9XA?9IXY(ZYJ`YY>YUHF/SE2O[MQDCLS!%].($
MPXF8DMA&WQ$\JG3V?O[899XI(`K9;8`-.`#I;=PB8Q,88[%NVX(SEC39/$..
M\[X<M+"YXMRK58NY4FR1YBBE(P\L@"A$W"8&.9I)Q[@#MGC8_15LZ142.`'(
M8`VL.)ESNXF$%YB1#(@=.W?U*&@@1`1XE>#G)43A$X1=#B(`(%Z=_0>@"/Q'
M\W*.C`D9P5"M)[R>['2GF*W0/H+B.><&\?FF=S8S^X]^@79BQ6>\X0;LQH7"
MD%*-51;2%>J3YLHDZ$AC$,\(Z<#_`,F9'-%OQ3<_I')30!;:R#S$NC)C*&42
M'&6&@";5N9@3*D1B''![RT0/:"R_R>Y;U/,#40F3F$Z<I7!TXC-T,>`&$,<(
MC=UX9O-&<37XALQ8-8VOUZOQ*31FT0(C'0T!`PS($T4$BE!-LPBHF-;```/0
MB:*?J/0!YH-JJNNU!<#WYGU=UJ:CB.;GS*B;,CQ1Q<Y\R8Z)ZX0@`%LAIQ16
M^C$MY$JEDR@V&`:&M&?60,U'-IEAV,\Q&XTOM3E\Z,=XG/'38YF3IRMH,6+I
MFR&>ZBU&5G+W.KO_`&V+W&>.F;4KQT=7JW!L1%`PB#MV5/?#X2>0+.36C!>+
M_*#^8UWELF5<TPC*9G+IFP@0YF<PXQ=L[+5KMYX\S)^NM2OMM&^&GJ%Q:SAR
MF'(EV)#LL(`88[8J\517E//WNX3:K),$Y-XH]*KE-5?4S%MB:*IPNUN:(I8&
M$_FFVP3DB3:0IL0=$/ED%"&(5`K=ET`RDF0<K<U]>-T[2"Q6R;_SFH;Z0QX6
MYNZB0###SA63HS3;KE.-;6MA3,/9`&!AD8$=6_'J4D'E!U\UJR[H!LS!9WJ5
M$C:+1,*7JX5ZU+0$'%N<7V2IUUY)5&P5"1;-&JT$]:339LW20;G(FY(J+<Q#
ME4[>8`T)J"^2-44YH9U1.FS9P:YKB2TAQ@[`0V1A'K61[]16AUKF-GM:P,ED
M@C/#(8QQZ1C':LO/!GDC*66?$KHE>\R.I*3O<O@V):/)J9647EIZ"@)25KU-
MGI!9<`7<.IBGQ;%<RQQ,9?O]T3#W]>3><T=X"W(-QBL`<4<]JEAY553A$X1.
M$6DYOHPALG?B.IVO9X20G(_#^DE$L>HU2MR"3FMA)S4@=YD&UU:*?)J,9&QL
M9-63$RQ"&5)\IW>HMB"6[]&R*.;<'.J8&:UH+`<B8X]>&Y=/>YD]E'&1OQ]Y
M5=NKJ%1-T,.RF/[-[-=OD0=.PX@RPQ1*VMN,,A1!BNZ[.Q4VR!*4;1WSJ1"/
M4$E2E.W$3$`%2)F+DV[V.GO-*ZE=+ELJW#L%H(`(W^Z"LZW7&?23V$F,MQ(<
M#NZ/?7SXB>Q_GYT$S#XTMUE(_&?E5T>42=UZ\22)22DA:*ZU+&X\V$K#A'VW
MTC4+\U]B,MY&OZ,WS:;XA2BNT]O![Y55:;EW3^*7/IW1XA@00>R6G+9&!SP6
M1)1IJN5W;QQTSVD':""(8[R-V>Q:L54>9"K=EO\`@O.->=4G8;`]E?X^RY3Y
M),4'C>9B'!VB4XU*8"@ZBYE),JJ2Z8"DJ4Y5"&,14AAV.<B^9,KF'I\4U4Z6
MW4--+X'@@B,!V'L!)/%@8XX'#>H=<R]$'2ES+Y37.LDXN<P_HQ():3"&$<,(
MD0*XM[3(-<L>/\YX,L+RD;"X%LS#(.([A%J"@]1F89R1Z:"<&(8OS4;-%3,B
MH@KW(+%4.DH`IJJ%%SCY9_Y@Z5X:)KCJRAES)O>&`,QC3%S7&&+MC8;-Z_/E
MGKAVE+J)-6?^15)`='$M=DTC&&U?I+>(WR68\\H6HU6SI74VE:RA7EDJ+L)C
M`'!3/L;Y<B6:(3C$&ZG1T%;L`A\_$+*%`5&BOMF'WD5@+K:FRYLAYDU#2VH8
M2UP(@8C`@]*F>'MFRV5$IP=3S&\32-H/NPZ(*47G!43A$X1<"(``B/H`?'KZ
M<(M43\2AY6YW`M(C_'5JM90;[8;+5U0,D6J&>B5Y@7`,F11K-S#MPS/\Q%6N
M_-"K-F'J15O'`NX+VJ*-#&N71^E[EK#4E-8;6SBK)[P&G8UORB>H`PZ<%TNH
M+W1:=M$^]5SH4E.PE_Z1/R0WI)(^):>=!HD!CBI0]/K:`)1T0W`AE>T"KR+Q
M3HH]E'8]3"9T]7`5#=1^R'0OP*'-IND=+4FD+90V.S`-;(8\5'%"$QY)+B^`
M$0'$AI_1A&*@UJ#4M5J.YS+K<0)GM+HRVXP:T"#(`Y'AA'IR5V-8-0LC^4?;
MJIZ.8F>2$)0X_P"1NVVN5H]N9=KC?$K%XV^:A&[@.C8;7;%E"LF+8YOTKM4G
M<444EQ+%?Q(<TY3&C0=BF`U#R34O$<-K6L(,`.$@$&)V8$K.O)C0CF\.K;NT
M\0!$AIW1(+B(>00AOV*?WR59:A=DKM2O`3X]?_=GIUK+!56.WNR?1UP;1L-4
MZTNF,3K979-H82RECF9%H"MA44.)WTP<Y%Q,1J_*I$ZQ6AUWJVR`#W3?2/Y]
MYV_&5GNNK&4-,9KCVH&`6455P)A2L8PC\%P&)Z"VQ(T@TJN6@N*Q$.X-[#`W
M*R62E4W31122?/$>IEG:QS.%%C"H)^[H(9II[=1T]&:)LN7P-$"YPQC\`^!8
M]=754RH;4RG$S';#&`Q]]5+^%DE7T-C?R+8-J$W(V'6O!&\=OK.NSQRX5?1D
M3"S,>>2M=7KK]05"*Q$6_0:..PAS%]YZ=41$RQA'!MVDR*>YSY%.09+)K@V&
M4`5DFD?,F4S'SOZ0M!/6MJSG7KZ$X1>//+';Q$DX37^54;QT@X(Z^4%_\L=%
MFLJ1Q\@!TA?"@<@&]GN+[O3MZAUX1:6N+/*AN91=1L)S=CW-IZEOV'H&Z>V#
M+-.2L%J7B54NN/<E$JV+/'IBZB,9UNWE<DV&QRZ1W;)0?O2#BNQDQ;J@0')2
M*5[RI163\X>/#3Q2[IY-PSMMFW,&EV,&<=AO*63L;K8YRKL%:J)$9F:ORT>Q
MQ`S\+4*B:P$*E+@\08@D*Q>BQ04X11DU+RAY^U_OF1\:85N=;5P=K])^1Y.8
MUDN5&RCE;-N*\;:=4^Q+XWN^3=B<B7B?L]AO.R>:Y=BLWA78*BUKRS8K$_MA
MUX15GGWR;^3?7^5I^'KWGC7JM[#.\1:HY"AZXMJ_.*L<\96W$RI#XP;80QZF
M>\]D%2-<XA)[)2]H675=/I5RBV6;H(`1-0BYR]Y3=^[YCCR3Y&H^3<-X=I.M
MV+ML*TGC8L'#3NP^,IK'5[B,.X:R:C7HJ9<WF%FKG8"R4K,N+"WCXJ,C7;1>
M*1="B=0Y%EEY(,Z;(X#\9>H>.Z%F')F;<M9/C:C-9(V=Q'4*BZFK+A;"M`4S
M=E2Y$93=YKJ*+RW5J!:,T72#LZLL*RJ9Q(L\(F<BQ[I-ZN]<V+\&^O.?-R<H
M1^R\G9,KY]VUQ#)9&:52'"=O5)MN3,?8]R-3*G(3#69GIC(616$/6V;Z46:&
MA(0Q$&B1@4$"+;8X1.$3A%CWMK?;#BO5C9+)]2?JQ=IQM@C+5]KLBW@!M3AG
M.4ZASMBBW#>M`JA]^N$WD<04VO>4%C]"C\>$6IS4_)YOIB[!>ON+JGLY0<SY
MP8ZHZK9UH7ZY8??7O(7D*RUM-DJ0C7^":$_93K48VE8$@(QVVLMJ9D6DFKLQ
M%W2;5LW.10BE?\OF)V&7,X>-&@(SF=J]9LG[%S\9?"X8S/F''A7FO&)\1WS,
M>8ZT[C,<6VMQ3Q[:7=?C(I"37($DW%R1-JNEWCPBB(PAY>]W5,6RI<,W7$MX
M:-=8*G*X_P`0KXDO\PZUSS?ES:REZQZYZ^Y!S';+A+6;--FJE0</IR[.'GM2
MQ)!%<JINT"CPBRAR+Y+]]L:[H5K41_G?#TSD"H;,:V:V3&.T=9)-A=-CX;)]
M#?Y[S=GRI&-=7;+'%%Q]1FQJM5DB&E`F)%FX6<F%<033(L;;KY0/(3L/I9G3
M.,9L=A/7>FWRSZV8\A2T:/@9K+FIEFS?LPG2EXZU.Z_.NY2I0U=PJ@JXFWUJ
M^4G4;`V42;LF[50A@(L^/-IL5N!B"FZF84ULG\JV;)J40[S)DC(^,J)2%6=\
M?T<]4QCB>+EX>6O\&:%B\C;%9&KQWL8U%XFI&*K&(*P-5$^$6.>O4Y6<O^4+
M3?`^.-Q<P.LHZ%8^&I;=V/(.:;PP;[*9"J6*?N&;U\QAKTE/R%!LC:OV`'E@
MR#<A2<(A()@W9O'9Q[D2+;D3'J0H].@B4O4/B`?9#T`1]>@<(N_"(/'4BU2O
M+_K+DSQ^[(LO-[IK4W<W',D(^I>2;`->(=!IF+"?O-F8YD81R!/E3W6CMT4C
M/'1@`Z7L-WIA!,C\5;8U5I>BU=8GVFL'#.#BYCQZ0=&(WX;#`8CJ$.UL]WG6
M6O;523%D1Q#?T^3WO(5+!A/-.-]A<48_SCAJT-;?C7)M<C;;3[(R,4!<1ST!
M'Y5Z@!C*1\Y$/4U&KYJIT5;.T3IF`HAR#MVL]39:R9;*YCV50F.`CG@8`^40
MQVYK/U'5BX215-<UTAP!]_'I4%&Q"5L\(N[IO)9A"#E)#0O:6S0U.\C.$JNU
M,Y88UMLQ("V@-F*?7T0%!F`R+XRCTJ)0`SI9PV,':_1%&2_)W7<NZ4G[JW.:
M?;I(A)>XP+FC($_*+>C-HZ,<5ZVT^^D)O%"V-&XXC;&)QZSE[W3"P.YF-*WX
MH=MJYO+@%^RL?B5\DDU`R]_7I8`_I6O^<[LT&3KV38#Y$?DX['V0T')W10*1
M),A1<M1[1;LTS8Z\6GA_;SPT),K;(QK->VMKG4CHM`JV0XIE+,$(OEOAV6\6
M#]O:<KKY(\SCR_U(VEN!+M.UI#9@A'A=L<W=LC@<-T(J29PWB)^)6:.V\;/U
MZP1:S=PW5*A(PL_`S+,2+)*@'>UD(B6CW/\`NDUDE.OJ`AS1-*J*^R5S9@;/
MHKQ0S!%QBV?*?+/8+3`$=V1!HA$"(CM6QF>RGKY!HYCF3Z>J:2(8RWM(@2X1
M,3`F!C".]8.>,?8MYX=MUT]",KS:Z/CYW3N3ZQZ?WF;<K&B<!YVFG2)9W"\S
M)N#BUCZY;WRZ:;83BFF5RHU<A_Q[TY=^7A:Y_P!)SXT!)FUX9*UU:P)59+.#
MB>'L5#1ME3AVLSW;RYKCZ*UN<Y>6M3R\U*)=(QQL-6"^F<3$AN98XP&(\V0P
M6[*4P#W``@(E'H(!]`A]?\7)/+#Z[<(NIQ$"F$/B`=0YQ>XM87-!<0,AF50@
MD0;@Y:Z7G@\D60,(56C^/[3B1)(;Y[G-G=:KCN,6[UL`X;>&587/--B=)"/W
M"[-&E=(0ZRG0R1D7+PH"9JF12U-:ZRL&@-)UFLM3SVRK!1R'S'O)`XBT"$IH
MS<]Y(:`,R888D=YIZP5^J;](TY:&%]=/<&C.#8YEQV`8DY;-XCA)J5J_0-/L
M$T["./P,\0A&YI.W6IR3I+WV]2@$7LMRFU#&,JJZDGG4$2F,;V&B::0>A?7S
MP<XN:UWYO<P;AKJZS'=U.FF32,$>&FHVD\$A@),)<>U,=FYQ+W$K:!H/2%%H
M>S2M-6YL&2Y0?-<8<3YQ@'1,!V8F/#GTK#O;6>RAN[LGCWQ!ZG60T)D/,;#]
M:-L\IL5TO:P3KBQ]AS9V8G%9,5+79HU=,HM$Q%<Q'3=L(%!V8Z<U_`7X>77L
M_P"<^L)0=:J:<[ZNEO;`3YC>RZJ(,294HN(E80F/'>#!L#@#Q$\T6VMLS0=B
M>UU?,EPJIHQ`:8$-EF,6OR!(CA'(D+(G<-K!;#7#&7X<OQIBZQOJ5KK7JZ;R
M,YSJRX*EK=$BW2+Y;"+>=;%*C-9+R--E4=6(ZAA.]EG'L*%%%M(IAM'UGJF1
MHZS.KZMX=5%H$MNUQ.`+AT#'9F!")"AU8[)/NM4R1*#C(#HO/OYGI^#H6P%B
MG%="PGC>BX;Q-5XZFXYQS78NG4BK120$:Q<-&)E;M4`'IWKO'2HF7=+FZJ.'
M"JBIQ$QA'D(;A=:RZUU1=*DNFS9LS`NQ<"XPPW#HW+/]-)I[;(E4DD<+0W'<
M!#W?`H$\Q(VCSK;ONM`L03<DR\;NH%R@[+OKF&M.G"#'.V2H5^9S":YTZ>;=
M&KN.9/62A'9T3F*51-P\'_B&7O2DY2:$%DH&7ZXL;]83!%C3\EIS,-Y&6X=)
M"Q+K._"KJ76^C)]G^6>D;([LHPVX;UN%T^J5NBU6M4JG04?6*G4(&)K%8K<0
MV39Q5?K\$P0BX>&C6B0`FV8QL<U312(7T*0@!S,\.T7',JP@``&C(*I.554X
M1.$3A%!9YP/%[.;S8=J><M<7B=,WZU)=.LA:T7IKV-75H38J?><]A>P/>J1%
MH.ZD2,#+Y@3(H21@`_1NY=`?]J>?-II[9\EW#,:8C\_YEPF2VS6&6\1:<U$;
MH[MU![AX52N:T2:E99I,LXQ_GS%,@FLQG<9Y5@C*,YV)>Q;TJ4@UC)!VU579
M"J0IB$[D3]%45`#-]BO-/=:7OB\BL:`,#"!.!P]T5CNY6XTD\R71[HX@[2K,
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MM%4'<7&$6119*7ISE]T89-AV"/:F-NI#M87B"@%ZG-[K<3`1XH(1#\1_*V=(
MF3.8%@DALJ8^-3+`'`#^DP`=@0':B2(X[PI%<G]=RZV.F+M,'M#1&0<NS#T,
M8Q@1$#`PC!?J(XTR+2\N4&GY1QQ9HBYX_P`@5R(MU,M<"X!W$6"MSS!&2B95
MBX+_`#DG31<H]H]#IFZD,`&`0"(@(=VFQ@=ZSU!S>R[%XSW=85<\JB<(HV_*
M?Y&\9>,+4R[[%7WY2=M2@!3\*8R!<22^4\N339Q^K-88HI&!V,2U.F9[+.$P
M'Y6.;J&`?<,D0_*7*GU#VT]*POJIK@U@`B23EAMQ5.)C8S9KN&GE@EYZ.@Y#
M\FU?FHP;O)^1;UDG9;8:>6N>QNP5C<WC)EC=$`GW:,@8JD=4(=OU.$;"P+0$
M6R39,?;02131*'8B7FQSD7RUE:"LK;M7R_\`J6KEQF.=`]VW-HEX`M(![1),
M3L&2AYS/UN_4]V]CHGDV.G<0UNR880<7CY0_1&$!#>5Y62;798Y:HX]QM#J6
MO-68;/$8\Q#3V@H?.2]MLSYM#QBW8LHDF5L@_?)%[U#$2%4Q0,8H=PAVW.'F
M/2\O]+SILF8UUYJ&\$EL8NQ':<Z!!S,8X+K^6^BI^L+_`"G5#"VTTI+IA&`)
MC%K&DQ`PPZHK9ZMZ'_\`S^:&XTT"U1,SRIYC?(4L,E;[I&*-GCVIS<R@X9V?
M+,L]5(*D90L2LEG,=507*"3A\BZE%"B5-T4=;(=67JX][,C,KISR7N=B3$Q)
M)Z.O(`#8IEGV>WTW9`92RVP:`("`V`*NM*M2*EIKA&+QC"O36>[3+]Q<LRY.
M?"JXG<HY0FOT]AL\K(NSKR#MHFX,9%D590YTVX=QA%110PYLLMJE6:E$B4(S
MBWM$XF)ZAA^98^N%:ZOJ.^<3W<<!L]VU8^[J98S1E_*N.?&-I*JFZVVV:;&"
MX7!`ZQX[7/!"R9BW#)-H=,^JD4\<0AE1;CW%63;CU3#YA=J4]O:MOC:.E^KZ
M1Q[]^#B<2.D'"'5^==M9K9[3,]KGB$L'`#`'W;5MU:":0X<\>6K6,]6\(LE`
MK%'C3.IVR/DTR3V0;W+E1<6_(-E.GW>Y-6>2(*@E[C$;-RHMD^B2)`#$V.9Q
M*O19E\(G"+H<@'Z=1$.G7U*(`/J'0?7XAZ#]'"+QOU;@0(S3+#1921ST\E'D
M+&L2E82"AE#J/V10;]&CU0ZIS&63[5!,81$1Z\(O46;(N/:]])-7V5"JI"H0
MB@IJE#H50@G(/8H`"/0Q>@APB^,(6**9R8L>R*9ZJHN\,5FU*9VNH1--19R8
M$>KA4Z:)"F,?N$Q2%`?0`X10_8(C]4?(MM1LKE2Z81N),E>/S:\VN46>V96N
M$YCBRW+#T)`W>HY7CL3LYAECYG-0CN[&%BH[CG3INX1*O[IE"IBF12]C78(5
M)-8(>+*K-@`31RQ[(#S``C[`!*F^7[I$`0^P`+=X=GI\/3A%](Q4<9))`S-J
M9%NC\N@D9N@9))O]C]`FF*0D31_1E^P4`*(%#TZ`'"+^)H*&,^"24BXY20!0
MBP/U&#,[T%$2]J1OFSMQ<=R0"/:/=U*'P'A%ZH'*(=0$#!]9?M!\?AU#KU$.
M$7'N$[NWN#N]/L]>@^OJ'4/B`CPBY$Q0^)@#\@CT'A%_-4$E2G04[#D5()#I
M&Z&!1,Y1`Q3$'J!B'+U#IT$!#TX1>6G78-%6/71AXQ)>(05:Q*Z3!FDK%-%R
ME(NVC%"(%/'H+D(4#D1$A3`4.O"+[_DF_>BJ*1!50*8B*HE(*J)3@`*%24$O
M>F!P*`&Z"'4.$5HLUW.O8(PKES,BU92E(S$F-[[E-]`1:+%@YF4:-7IBY.X]
MFN9N+=J^DE&!^Q8Y3`1=3W!`1ZB)%A/J?AG5[;9OK[Y3!Q198W+N9L84S,M2
MC+GDZZ7>%Q9*WW'+*'<.ZI4'TX?'4):DJF]/&JR<?%-53I*+"3VS+K=Y%)&6
MLUXB#UJ2#AR-I)T+Z0;EBV`(/WIE"*F>/D?EO;=NS*IE,*J@&/W%`>O7A%]Z
ML>T64(JJ@D=0GM@50R21U"@DH59(H'.0QBE27`#E`!#M.`&#U]>$7\$X.&1=
M_/HQ4<D_ZJ"+Y)BT3>"*H""HBZ(B5?JJ`_:'NZF^GKPB]4/3TX1.$3A%YDQ#
MQ4_%R4'.1S*8A9E@]BI>(DFJ+Z-E(N2;*LY&-D6+DBK=ZQ?-%SI*I*%,FHF8
M2B`@/.!8"\3(GB"+3>CH&1\`N^)<`V%P^3\36^5_>2^N]ND%W"T+J'L;-*E/
M+XNFG;@5$HFB693M!`XG`@M!1<]#*-'ZA\2\V-!_O1;?KZU-A>*<'`?+`CF-
MI$,.B(V!7KHZ_.M=1[)5._L;SMV'\_GZUL#7NBU')=+MV-LAUV(N%#O=?E:G
M<JQ,(HOHBPUR9:*,I*.=IF[B*-W#=7J10GJ0X%.00,!1")U)63Z"LD/I>.1<
M:=T6N&!X@8F._&*S#-92UTHR2`ZG(]$Y8C=TQ6F4;0/]1-_]>_#[Y#-F\W)^
M)ZS263\@Z%0+&93A*S=\DVTY0KF&LB9`(`OXN?H,O(N"QK9<%T#/54@;`V)+
M'ZS;T-JZBUE96W.2>&N9@YFUI&!<T;`<\]X6"-1V:=9*\2'-!I8DM<1B>B.&
M7DB/*LH-47V5M%-C[WXCMLIEW+6_%K5>SZ;Y:E2^PTSYKBX4<N8)BS>'$R+B
MTU%HD=([0IA52,V<M.A@:E.?6#X[_#\;5=QSKTG+`L]4]LFZRI8BVEF'^CK>
M'_X,PP;.:,);B'X<1`EQX=>9S+C3MT1?9H;6TH)I)AP);M:X_*@,H[,LEEUM
MOJ]0=P,$W#".00,T1FT"R=0M34G66H-[C"J+5BZ0RH"59%S&/1`JX$,7YAH=
M1(?YWI"'DSS:O7)CF/*UK:9CRSB#9\F),J?3.<#-DEH(])L2PQBR9PN!P4@-
M>Z1HM<V.98*YO&Q\3+=\MDSY!#H&#0Z$6Y0P6<'@=\D60,[4V\:#;AO_`)#?
M72]-G5;:O**]KG.^'V?LQU+S7!.%NS[]<&8&;-YE9,!.H=5N\.`"[.5/T1Z+
MUC8^8&EZ'6&FI[9UHKY0F2SA'$=J6X1BU\LQ:X9Q:<\SK"U%8;AIB\5-ENC(
M5=-,+#",'8P#F_JG,');%'7TZC^7EUDP$3DNE6#/D3WOQ)XY=5LC[.9?=%=,
M:PP"-H]):JI$G\H9)ETUT:?CVMHJ#WK2$Y($`5U"E,#-BDNX.'8D/*1X>V]S
M6L\T!$^3I0-FN([K%VP#?L'E6J-HEA'+\Y:<I^07<A8\SNAM^N2RSS5V4XHX
M4Q0Z]M6EX?JS5P*@P+5A#$:E=MTA`R*""#<XF.FJ8^CSQK>(J7S0U1_E_I*=
MQZ&M-20\,P%95-)#YX<#%TFG/$`TX/,7;5L'\/O+-FE;"W4EU81?ZX<(CG+E
M$80$.R[:3'/#)74WKVZ;ZDX?;RE:A%KWGK*4ZSQEKEBJ-1.^F;[E6PJIL(<J
M,<CW.'41".G:2SKM+^D4%)N`@=8O,4^&_D96\].84NU-8^3HZA<Q]?/$6M?3
M@Q#99Q#7U)'"(>BT.CABKXYH\P:/EYI0W-Q:;I-+F4\LP+N,@@.='%S`(DQ'
M5BHY=N?'DGX]L.:1Q^.LEY5F?Q'&T><#95C[QB6YK'D(YO?1^4R1!7Q!S\U#
M-<.46*[F:+SY8@/)))\L(FC4EDD?0%*E6#1FGI5)1R95+INW4P8QK`&M8R6`
MUK6M`R&#0!B8XF)6M"8^Y7ZYOG3R9MPJ9Q<XX[>DF,`/>&`6S1XXM#*7X^-=
M8[$\7)?KKE2X2BN1MBLPO3*.)[+N9)XHN+)8GTBZ%5^O#1SIPHWC$E3F,5N`
MJGZK+K&-#G6FJ:G6%YFSZAT**6?V3-@:#$CI)\Y6;]/V1MCMP$G-\...)V#R
M;%B-Y3=L\RRUSQMXM=#W'WAO1MZS49S%G8**J--9<`/"*HW++UJ>,A,I`R+J
M#*Y^[SF$BB#<AUT^JYV9%+PY2Z'GWZO??+I*A8Y#AW3#@7N&_>T'$^0;5TVM
M-0MMT@VVE<#4S!Z7Z(V_$,-YV*=SQ[Z)X:\=.K>.=8\+M%%8JILSR-PN+]%(
MEBR;D66324M^0[2LD`BO+3\@0133$QRLV9$6R8^VB7DKS`\(&#6B``P'O+#(
MVDXDYK-OA$X1.$3A$X1=3%[OXOA_+_>Y0CB$$!@M/GS9:=730[8,WF:U0J+J
M7H$\#"K^23"-=:]B=MI"SILU:;!0K)J0R"5DKQC@,LX,0.Q<B3LY@36D%![B
MQW5]HKV3O_MR>V,\-\.CW;%\-PH9==(+7?TK<6G<?=L5V,<9$IF5J)3\HXVL
M32ST>\P4=9ZI8F!RBB^C7J8+H'$`ZF:OFJO<DX0/^D073.F<`,40YG:FGRJV
M6*J2X.EEO9W0/GBL>36/ES#*F`M>TJ`K>W#V3M*+Q<K9AK..3M>/'5OO?\?T
MSR(Q.'HQO)RV-4'=D(E8+Y5(HYTON.*O,0^=-GRS$R!SBJLS5!=NX2;#BC5U
MC?33C7R&'AF`\>$0,L0/=OWJ[['<G3V>RU![3""TY$PV>[-6M\H'CLJ_BCS5
MC/(VO4J^NGC,W"BJ_(X@O9IU2VM,8Y&<0+-W]Q2MH$#?.P=VC`)+1CTQ@*Z;
M*K$_G,CB?*'(+F?^YUYEZ:N[RZQ5LT`$D<4N8>RUW%L9CB!F59G-31`U/;77
M>@:!>*=A`ADYN9!;M(@8>4;@L4Y&/82\>]C)-JB_C9)HX9OFBH%4;O&;M(4U
MD3@("0R:Q#?F^`AZ@`\V#5EOI+GWMFK"V=0S6<!>/0>'B(+<\0#"*B'3U$^V
MS)=73\<JYTM0"3$^D('+]'#T<O*IS/PWGDTD-3\Q-?%;L39W2F%\J2TE/Z1W
MZP.14;U6VRSH[Z<P+)R*YQ*U8V-XHHXAR&,!$I8RB)?^7I%)K"YP<O:SEOJ=
M]$99-IG/)DNV!I<1PN,(1'OPATJ;VA]64^KK0VI8X"NEP;-;^M`&(&X^?!;Z
MB9N\!'KUZ&$H_1T$!Z"`]0#U`>8O@X$QR.74KSB(P&Q4E?;W4,8TRUY#R!98
MBG4>CUV6M=NM4\Z390U>KD$R6D9>8DW2H@1%HQ9-SG,/Q$`Z!U$0#G%Q+`Y[
MO0`\O3^9!`F`S7Y?>_>]EN\N.YDGLK-%EXO5K"SR7HVG>-I1,[5%Q$H._:F<
MP6"+4^R>R7-XV*Y$3AW-TDV[4!$&G<>7/ASY3ONU0W7EZE<-ND`F0UV!+Q\H
MB&+=@&728K`W.;7(M]`_3-K?_;)K1WI&;6N^2-Q.9Z.LK'RU6B%IE>F;38G9
M&,1"-%7[UPH8O<)2A^C01`1#O<NU1!-(GQ.<P<F)?-1VZPV:HU'>'B7:Z-A,
MQL8.F%P_9B7M$,!``Q4=+3;*F]76FMM%+=,J)O"UT-G2=V&)*SUPEXXM<*IX
MO-C?*]Y7/UYIDMFZHLZYX_<;TJ;<0&5:7(&=J2F*+E26/N(MW=]R#8HY!RW3
M=IJ-6U:2=/EB@#@AD=7&N]87+7NI9MZK7'NR\B2P8-;+&#&\(S=PPB<R[%3E
MTSINETC9F6BG@3`.>["+G'M''8,80V`0.U9M^,W5W-D1'NMU=X;A:,L;K9OI
M58A%;%D1\,O:,6X?AH6/C:E2$UEDRA'3\I#L4%94J8)G(42HJ=RHN#J7-I+3
MPHI7MM<TB<X1&\;@NHO=>:L]Q)(,IN4-O2LIMW-O*_ISAE2ZC$JW3*5VE4,?
MX'Q5&D4=3F2\JSIR,X"%:1K0%'SJ-9/'*2ST4B"84Q(B3N563*/=WN\R;7;C
M4N(]H='@!QQQSWP776VA?7S!+@1#TCLZQNZE++X0O%[8=),6V[8/9IPG==_M
MNE4;YL9=W()+JT9@_4))0&#ZPY`ZWRT+44SI@_!`P(.'Z?83JW:M>W"5763[
MC/=5U)_;3'1.`'P;,-BR%(DRZ:4V1)$);1`*=LH`4`*'7H`=/4>H_P`8_7S\
M%^JYX1.$3A$X1.$3A%`_X7_\NGFW_P!;5EW^JK$O"*>#A%U,/:4QOJ`1_,`?
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MEELX*-:39K;;*Q'I#F;$LM)I`T>NG#0LFS65+V%Z]A7%47LXOO'E.\O+-7/6
M'\]F\8.@$\X>FP*YK^+:]D3;_8>G-G+IJPRM8E[^"E6Q#3K2"0.8EJ@U6?':
M&`YP43.DX/4")@BMAM#DCR'>&BO-L^V3R0XSWUP9`D^^<AZQ;=,<1X0V5L=*
M8G[)^9UQR+5GD,%ZN,4U,*R40\CE2NO;,0@*JF*4*<3.'B,0P'$PR]W3!58(
MN@[+9L^-;$^N^?\`&FT.%<89_P`/V%K9L<9:IT)=:K)MU$#+%CYR.0D`C)5%
M!5<K"=AS+BV>MC&[V[E(Y#>I><6D.B6'B8"03\&7QJD'QQ;!N]7LYR18E[\_
MZ"^YW[J>PO\`5+;>$5D?#Q_95^/3]T/!7]`(7A%)%PB<(G")PB<(G")PBQ(W
M<TTPWOKK3DW5K.<&$O0\F1)VOWBFF@>;I=F9@9S5[Y55URF!E8ZK+D3<MSAT
M*H`'14[D5%"B&!C_`"*I,<UKQ^+O9',V%<JW[Q`;VRP*[5ZPQ8.L$Y,?J+$9
M;5:R-B+EI]QK[U\/OR=CK,(@4C@AC*KG:)&(J8SAD[Z1;YPZ%?:)W[S6F7&C
M<3QM`/9<<3Y"<<<LMRRYHK4+*IGL5685K?1.\##J]T=JSQ\@VCF./(/K7:,#
M7IR-<L1%TK?AW*3`JB5AQ'EN#3,K5+I"OFQTWZ#4KL"H2*2*A1<,5#@`]Y4S
M%QKI'5=9H^_"XRR>X?`.:,&EIS$!@#N.8(5T7NURK[;#)+2*B.9S!]WDQ4)B
M<%D_S%:L6[3_`#@JCASSV>(Z6"RXHO;ATG$2F9HJN?)?<MMBYI,B7WO3LN,&
M;)O*G[3MT)A1C)&*5N[41Y-&?3V+6NFY]!62Y-58;A(=+FL<`YKF/!#VD;#B
M8[8X[E@QCKAIZZ,J6%TJX4[PYI'1B#T@[MHB-X5S=%=N$-NL.*SEBA5Z+G+&
M4VZQIL5BR11.QF,?Y5KYU&$T@M%N`*[9Q4TY9JKM0.4/;."J`_;1-SS[^(KD
ME7\C.9$S2S2^;IRL8:BV3G-B)M.3!S'S,A,IG%K';7@AV16S#E7S"H>8VE)5
M<Q[!>F#AJ&#`AT,VC8#$$&`P(R5HMZ\-9@IMOQ;Y%=-N^,W&U"74L#:,9`L5
MOG'#3<JJMXQ%9VC40/.(+PBCD&R)P.<Z"RR*8E5%`Q,W>"+Q&R^7FI3R^U-/
M<-$7:I#&%P`;05H(;Z1B1+J#!KB(",'&(BL><^N5\[5EC&IK8P.U!1,+7<,.
MW+:"2"W(OVAQ,8[5M?Z,[Z86WNT\H>XN.IMO"4>R5B0D+S&SCEL@ZQ5:ZJU$
M<BU"VN!.5)HXIKU!85%S]A%F7M.2_HU2CS=J]TMA,3&21Q`_J^3H6OZ#FN_:
M1`!@YN1!ZSN6I1;<PRWFZWI-M796K\/'7IC:I:I:<46907)%9URU&N4T;'GJ
M?AW!4VKJ/:N&J9F1%"'!)%)LW]%`>%/`#QP>(MO+S3)Y;:4GENL;K*+:A\MP
M+J6DF1;"(,63*AO9:[!S&Q<,VE29\/?*QVJ*TZMO,IQLU+-`E,B1Q3006O,/
M28TYB)!,1LQD7R)D.G8KI%OR=D>>:UFD46!DK3;+`_4*5"/B8Y(SA=4>O3WG
M+@_1)!$OVUESD3('<8`YI\TYIR^:KU1(TQ8`9^K+A.9+E2F,C`O/#B?DM()=
M,=D8$NVJ:][O5HM-JGW^X.$BVTLAS7-C#CX<PS<2<H8J-S3RR4RFU[*GXD#R
M-0CV(QCCV+E*)XN==)D$OOR50D!D8^!ND%%O^A%[YDR1*JE&N@2,""!WLH81
M;-VBA?0QR#Y-V;D9R]IM#6\"96RVB;5UASJ)[P2^#?DRY8[,MN`:,(`\4=:'
M,O75RY@ZJG7RH=&E'8DLX0V#`<,-YSCGEN4A7BQU2S-9[QD;RJ[X-1>[O[<,
MR.JQ4'Z*YFNK^O3HA%*5B>K,WQ3*P4C(08-S/BE*FLBU[$E!%PJ],IC_`)N:
MZ&H*XV"TS."STY@>$X3'C83\H#'"$">U@(!7/HS3QM=/]9U8C43VP'ZL8&'7
M@(](AO68GD:WQH_CVUPE\PST8-RR19Y%+'^ON(6(J.)[+V8IU,&]:K,;'-"*
MR*\2P<K%<R:B"9S$;%!,@"LLD4UBZ+TI4:RN\JGE-<VA:?VKQL:!\<`-Y*[N
M_7?ZDHWU#G`O<(!N\G#WQ^0G8O?\*GC9OFK5/OVW6X3LUX\BFYSA*_9_MLB1
M)53&4!(F3D:Y@>J&`ZX1<34VX(!(IH&]DSM%-N3N09MQY-FW6^EM-MDVNWL#
M*22``-N&TG;T]))6!)U1-JYKZF<8S'&./3[LE.T4H%``#J/3Z1'J(_7U'Z>O
M/M7XKMPB<(G")PB<(G"+QK#7H*V04S6+/$1\_7+%$R4#/P4LU1?Q4U"3#):/
ME8F48N2J-WL?(L5SI+)*%,10AQ`0$!XV$;"J$`F.Y:*60<.S/@TW>3UILCZ0
M6\:>Y=PE;#J9?IA5=9AKOEV37*YG\'V25<"HDUA'KAR0&:BBA05;F;N^AE"2
M!BWQH_4#J.H;:ZAW[&:X!I/R=_6#$=2Z&^6XU4KO9``GM!\HW^120WNCU/)%
M.M>.<@P#"TTNZ0DC6+77)1(J[&7A9-$S9XU5`0ZIF[>ATE2""B*I"J$$#%*/
M,L5%&RM:^FJ"'4X&8PC'<8JR94R=3S0\.A/8<?=UJ.'3%.E51+)GX=3R-OG=
MLU2V2CIN6\;^?;"9)5_77ZK]25C,6(3,@/M1%]HEF.1W``4X`5^51ET%M(-4
M@P1?;3.L]:Y@B)+HEAW8Y1WCW'-9)H*ME9(#P>W#$=*@1N.'<QZ8;"Y/T2V4
M2%+*V&'8FIUG$BB<9EW$CD3GIM]KJBX"+IL]B"D,8H&.HB('14Z+-U0Y.#P^
M\T6ZLL<C0EUFME7:W`N;-,`9DH8\$<W.Z28PR4:>;NBQ9JG]YK7)C;W-/>L!
M/](78$#8"-@VQ5(Y1Q^ED6M!'MI!U!66$?M;'1[5'+*LY.JVV(5*\AIB/?MS
MINFAT'21>XR9@.4.A@Z&*7F6>8^B:/F'IBIM4YG]J<#-D.)@]KP.&$<S&$8'
M#>%C?1NK)^D;O)N\HD4DUP$V7F.`X8C9"$8PV+?@\`GE?>>176N4QSFETC'[
MI:O!%T?/L*H9--S=8TB:K"IYFBT![!6:7%%B))+VP[$)5-0Q0*BN@!M7MUM5
M=9+C.M-Q865<AY:X'H.8Z%."BKJ:Y4K+A1N#J:<T/:1E`CS[QLR4('XE'R73
M.R&6W7B=UYLKICC6AO(F?WGOT(N9N65E6:S>5KN`X]^@;N41CUP2=3)`,!57
MXI-S?9:N"'OSE5R\K>8>J)5`UCC:9+@Z<[(<(/H\6PGW^K!6QKC5]+HVQS:Z
M80:R8.&4W,\9VPW#,^]M4"L7&1\-&L(F*9HL(Z,:-V$>R;E`B+9FU3*D@D4`
MZ`4I4R^HC]/J/T\V<TEOI**UMLM&134C9?`QV36-EC-VPEV<2H35M96W.O[V
M;&96U!XG$[W>:&&&Q97^+G1ZO^2S92S90SH\9UGQJ:*KJ9#V&NT\[-%U/*=U
MK#,]@:XZ4E!$C=6LQ3)J9[.'`X^U%D$H]JCQN(0$\0'-5NLKJS2]F/!8[?V'
MD?ZV:W!SB=HB#PQRS&0*E5RGT,-,T'UW7L)N=2#`'Y#!EAG%P@3#9`;2%)$&
M19[S0;DQ^X]S@7=<\=VH\Y)4G03"4I'_`'7"Y'L<$X)&R.>+!5RE39"S24C$
M19(G3$K4B+9F0"_+.?>Q9I&QRZJ:*VM:?9QZ&P1&T]&&2O\`O=Q%+*,AA_:.
MSZCL4D^2<C4W$E"N&4\E3[2L46BP;ZRVJP/3![+&-8D[U.P@F*9P]=JB5)NB
M7](NNH0A`$3!S*51/9(I9M9/<&,E-P!AC#<K.E2ITZH;+E`P)\ZM1X3M,KIO
MEL$W\R^W55>0M#@QD8#QN8)L+<3-ZC1TG*Z"^P,VR<!["]DL)A$T2L!![UC*
M/2&,FE''+@V]WB9>ZQU0["1'LMV`#SY+(U#2,HY(EM]*&/6MP4I0*4"AU$"A
MTZB(B/Y^HB(]1YU!,3%?8NW")PB<(G")PB<(G"*!_P`+_P#ET\V_^MJR[_55
MB7A%/!PBQ.WLS7:=<=,MJ<\T>/\`O6Y8@P!E7(=49"@#E-2Q5>G2LG#JKMQ(
MH5PV:/T$UE$Q`0.F0P#Z#RARW+A,CW;H&!@<=RTJ?'#I9KY=]8:+LEG"DU;9
M'/NU4`ME_,66<OQK3(,],S=Z=.GKN%:+3R;M&*;1A!!)4$$TU#."G$3`':4N
MDWQ/^)/FU4<Y[UIJQ7:X6G3U@N#*=DF2XR73N$<+ICGM@Z8V8\<8C$=V0T8+
M8+R?Y;:.EZ"I+S4T4BJN5;)C,?-'>#$?)XL!")R5U]&\[XS\+?DLR_BF6NBN
M-O'UL/J=?]G$J)+RJZ]:QOF3#AE7TZAC=G(N5/9>V>$C73-%@FH*CQ9VT;_;
M%%OV[`?!OSAOG.3E#+K]5SVU6I[?5OIZB86M8YT.U*<X-P#BT@$X!Q;$XQ49
M^?&BK?HK7$R79I!D6>JDMFR6@D@8#C`CLCENRR5173$_E'_$'X!L^1LU;(P&
MC&CN:W03&`]58#%[*\VBX4*"GTI*C7_,5E7=1$T<\E(1:3U`C=Z5)T4H*I-4
MD12%3*^K.;UITQ=1:?9WSIC8"8]I@&[]\>'(G`1P5EV31%?=Z3VSBX)9R&T_
MR^99%:+>7[8W1[/V3_%WY6I#%\E;L2X%ELF:I;#4:+BZ#4<Q8[Q[19&:A:+)
M0S1I#0C&3DJS5'"<6J@U:+@]8+QZR:J_L*J7[IK45#JRRR[Q:RYK''$$1(@<
M6GX]H,5;=UM=19ZQU)58[CDM/Z3G[/O;=[GN9MD_>9:RQFZQSD^T1M+QV[KU
M'IH2;IK5Z94X4%$V,1`0L:F5%J@B0"(I$)T^V8YSSYY(<GM,5>DAJO4=**BM
MG/<^2'./#W)80(LR)XB#'/8HM\SN8E\H-0NLMCG]S*E,[<`.(NS,7'&`R`&&
MTJ7_`/#W9[OVH'E6Q3JSC^?GU=<-S:KD5O:<2.)%V_K=2R#0ZO+6V$R!6V3Q
M5P2(>F^Z#LW)D@3]YHY.543^TCV8A\07+JU\OM1T<NT@,IZZC$XL!B&NCC`'
M($0PR"R)RJU97:JL<R9<G=Y52'!O&!",<<0,"1`^^%^D(4>I0$?7T^/PZ_EY
M@)9.6)N_/^@ON=^ZGL+_`%2VWA%9'P\?V5?CT_=#P5_0"%X121<(G")PB<(G
M")PB<(G"*$7S3^-"Q;J8JI&>-:)4N//('I])KY/U7R4Q,DT?SCZ+4"5E\-V!
M^;L%>M7DK<4VQ5Q.V;R!B^X7Y9=T53YJNCIZ^C?;ZMH?23&D.:=H.?3[VX;@
MOUDSYM//%3));.;D0K3^-/?BN>0#7E&_.H<U`SKC>97QCLYA>02.QGL5YCKX
MJ,IYBM%NP*_0KT\[:*NHTRA0.0ON-E/TS94H0GUWI2KTC?)EOJ!QVZ>(T[X9
M#IWD98D]&!"SYIZ^R;U;Q5-($]L!PQS_`"Y8XY]<5AKYDM?[EC.*JGESU5EV
MM`V^T%BS7"<?=56\-G#7AFOVWS%M^1;=/OEJRB7RYVGO`<3-55T"]I_ESI7U
MR@UC46Z\-TQ5.+[?4_T(/R3OXLR#D1U*WM<6&754TVZCLU$MV8V@",(8C*)C
MOZUA]Y#4*IBG87QH^8O6%-&E0?E;>XDP_M#A-1`Z4-<)/)508V6MY&*LW!))
M*X5M$RC=VN*0"Z<LD5P]5W7?W_B=Y7:=YH\FKQ:KW"37T-'/K:><V)F2IU.P
MO=P.Q@QX'`]D0UP<">TUJZ_DWJRX:3UU2-H7N]CK*ILJ:TP(<US@&X&/"0>U
M%O3O4EZ8>P_3(`]13=E3[AZ!WE*L!3`8H>A@-T^`]0]>>>IM3-F/EU8@V:V6
MQHX1`0;`M)`P+P8=L]H[2MGXE2PY[81;,/:CC'R'^11):*S<I2/$!^)DBZD]
M7A8NHYSVM2J[-B84FL(C.8Q;-95*,33$I&I'3?[)BDZ``=/0/ASTQ<G;A67#
ME?IBOKGF96/M5(YSG0)<[NV$D@B!CMWK4GKRGD2-8W:3):&RO:YF`RQ<5D[X
M[HF,@M#-/XV(9H,&7^;]CJ0,@V3!)-1[,0B,O*.C@0"B==])/%5E3CU,=0XB
M(CSS]>(NZUU=SRU9<*^8Z;42[M5R`3C"2V8]C6`0AV&M`881;`0,5LKY:R)5
M)R_M$VE:&/\`JRG,!@"7L)<2,B20#',;%8;,N')'R+>3W5CQB7.QK5369+'+
M[;O8&.BEG*4YF2%H-A%I$8N%RB)21L2N^33!4X]>A'"JY>BR*'-AO\.WEMII
MMDO'-&=PU-]-RF4=.]S1&3*8QA+6_K.XX%V?""/E%1K\46JZV7<Z;1M*XR[*
M)8FN8`(F80<W0XB,S",(PW+(NI4]OY9?*!E.UWF.A8_Q[^'?)I-<=7]=8UN!
M*C=-@:>R;L)G(MF@"I$BUH:F!#)ECFXIF3!JBP0*!2_.>]-'F[J^?IJVRK-;
M^Q<*L%I=GPR\08`Q$2,(Y@8QB0H^:(LK:ZK-?/,9,AT>'?#KS(CA^93UY3RC
M0L+XZO67\KVIA3<=XZK4M<;M:Y90$V</!Q2)G+MP?K]I=RN;M2;H$ZJ.%U")
M)@)C`'(J6^@K+U52[7;9;G53YW9.?:.9,>B/4LNSJVGH::9/J3"4UL0#LZE#
M=XJM>K]Y3MKD?,WMI5)&#P50G,K5?&#KS96X_*5VHM'JS=]L?98QP!V[JR6!
MVV$\:N!1!1[W.2&%%G'J#.#16DJ+15D904X!JYHC-=Z47$91.0&R'7\I8&O]
MVG7BO=4.<3(!/",L-YZ3\"VT"E`H>G7TZ_$1$?7X^H^H]>74QC6#L[5TB[<Y
MHG")PBX$0#U'A%R'KZ_7PB<(G")PBPTWWTAPSY#-7\DZM9PC/?JM[C3+0EB:
M(H*3^/;S&)JK5+(566<`(-IVLR)P4*`"!'+<ZS97JBLH4:&(!(]+8=J=>2U%
M=)LL9CQ!D[(WC'W75!KMIJ^B"=0MCH54V.QV!DP+^I>2ZL[=C[DR[;PH(@N/
M>=4[?M%3_"$'9299TIJ#ZRIFVVI="HEB#3&!</R[%9=YM/=F94RAV'P)Z_=E
MT+(#=74>M;E85>XX?R"M6R)79)M=\(9-CC*M9[&>58/M<5RP1D@T,D^;,W+M
M(B#TJ)R&%(P*%$%4DS!<E^L;+G;C(>07LBX'(@P^'J776JLF4U3+),)<($>7
M:L)MGTGOEH\%[CR$99794GR*>*.UWG%]_P`E1C4BJ656F,9>#8V^`L(((H"X
M:72$G&DF00ZI-)Q-W[92-W:I>86MMTK]-7EEQHIG!64T\0(@(P="!V$$X0.$
M%?5;14UTHGT54T/IIK""#TCSC,*%*HS*ECJ=<L*R!&RD]`Q4TJW2$3)H*R3!
M!X=-(QOM"1,ZG0O7X!Z>OQYMGTS=?KVRT-Y>(5<RG:YQR!?#TN'*!&R$-L%`
MK4%O9;+S64C,6MFNE_S0<N@[8YJ7?\-R[=1_FWR(R8K*-6D_HM/N)QN@;VT9
M1PQR!2P9K/4P]%U6_LE[##ZATY`KQ,R)$GF.R9):&NFV^6]T,BXS)P)]X!2E
MY+/>[1G`\DMEU3VMB28-X)9ACTDJ'9JY7DMBM\)F066>2\EO#L.:1DG)S+/7
MOL7V:!'YIPH(J*^T"ANWJ/IW#T^/,Z>%EC)&AZVHE-:)[ZJ8USH")`:R'3O6
M,>>KWOU#3RWDF7*IV/:-@<2Z)AMR&:\?(T9;[O-X@P=1)IG6+-L;F:B8)C[>
M_(NJA50O\LC$+3(HM1!PM[";@>X""!^SN`H@80$+C\0.L:S2W+\TUN)EUE>!
M+XQG`9\),>$PS(@>E=1R>T_37_4KYU>`^73M$P-R'%$#9LB8PRV+9#\A^%X?
M&,MIW^&_U.D9#&6N$5AQMLYNWD5A_P!67G,=:8V9RBI#OGS,$RN)+(=M@SOI
M(.ID_<68H@'RK(4CZ^[!:IEXN#:=[HB$7G:=_3CYH]"EM750I*<S<`0(#\BD
M"I]-J]`JM:H-%A&-;J%/A8ZM5>OQB0-X^(A(EJ1HP9HDZ].U%!/J<Y^HG.)E
M#B(B(\SFRFER90D,X62I+0(X;!\7OK&=1,=43.\GDE[CA[ZC?Q7A68\Z6["V
M"(9U(H^,/3"ZQLQLW=HU9="/V:S3$*`ZA,,UV00,F1Y6XM9(1>K$.(),P6<!
MVJKQYN8GUG?G5U2+=3.#J648<0^5MV9P,1U]2O6R6SV66*BHQGD8=`^,^9;T
M]>@(6K0<-6ZY%,(*OUZ*CX*!A(ILBQBH6%B6B+"+B8QBV(FV9Q\>Q;IHHI)E
M*0B9`````Y9AS5PYYKV>$3A$X1.$74#`(]`Z_7Z@(`/KT]!$.@].$7;A$X1.
M$4#_`(7_`/+IYM_];5EW^JK$O"*>`1``ZCZ`'"*@<I4.)RMC'(V,9M-)6%R-
M1+=0Y9-=/O24C+?`/X!\51,P?I$S-I`W4/IYPF<7`>#TX&'7L7%S0]I8[(B"
MT:/#)-2K731;"UE<"I;=7<XYHU^L;=0`!=DO4KDZ>,6JI`_FBDA*&*`?[D>:
M./'OIF98_$)57.F`(NE-2U$AN6+)8IG-=EQ1=*>Z)VNZ%L3\.-X?<^6?L\\A
MU31U'=M/Z,N(\F6]6:SOKA3/+OY1<,ZM,8963PUI!$R-ZV\R@P<'^4[;3(0S
MUA@>-6(84?OF>>P:+9<P=5$`5>"00%J?K([P=6&_\HN2MTUO<)ADU.L*KO+?
M3.;!\N7(#@Z<Z(R,2YHR+0PX\2Q)STN]IUKKRCT];&MFLM4L][-!,"'$%TDP
MPCAB3B.G&&Y&R8PM:AF,9'MHNMUBM1#9A',T`;QD'6Z[`L"-FK=(OZ-K'1$-
M%M"E#T*1%!+UZ``\NLS*NJK'SHNFUD\P,8DN)Z.GH71L[NDIPQG8D2Q$="T2
M]Q\-2OGCV,V\V8QHY5@,/:\X])KEIC81,=HAFG(&/YM[9K#.NU%42]:O87,F
M^;(*E,)4AD67KW)K%#8'RBY<5=%H[AF?LYIEE_#^L1$MAT`0.YQ.Y1QUIJV1
M47MLMW;E@\.&XX1)P,(P.R($=JC#U\L367QM$0`1:]=G\=^Y0+C5'Y3)R5=L
ME9$S"19O4%0!9,RRR!C@`@`@;N*/02B'-HW);4UJOG+:VR**#*ZB)IILF,2R
M7D2=O:V$XXJ#G,VPU]GU?4SJWB>)P,QL[8]KHPE@>C%I\IAG`J<;\.)BH,O^
M9>\9-<)I+P>I>J<NJ@91(%`:W?+LM'5M@!>\@@DX-6WTH(&#H;['Y^1(\2MX
M9<>8[J.42:>DIVRV",>$9P^..]9_Y)VPVS1/?/CWM1,)/5'`^6!R@OT/2G(/
M0"C_`#@[BAZ^H#U$!]0^D`Y'Y986)^_/^@ON=^ZGL+_5+;>$5D?#Q_95^/3]
MT/!7]`(7A%)%PB<(G")PB<(G")PB<(NIBE-TZAUZ#U#K]?4!Z]!].H=.$6LI
MY%/'EM9KKN03RL>+2@0&1\B7>$+4-VM.G$PUJ,?LM6VXIF89"JKQ9RSB4<GQ
M)$@%4QQ!RJNDFZ1!=51VBYMC56EK9J^VMH+DWML)<QX])CLH[(Q&!\FX+LK3
M=JBSU[:N1BT9C>/=T'X5AAG>>\MOEKH[O2/'_CIRMX^L/Y;&/@=FMD-GYA@"
MT)C`DBR<V6LXTK:,;#O;)(6!%`R75!)P9=(/9.9JFH=P2P='<H:#3EWE7:LJ
M'5$^F![K`CACORCY8[XX*Z[]K8WFA-+)E&7QGM1AB.CS;,U<'\03B*I8`P+X
M0\&T)NJUI.']\\`8VJB3@Q3.A@J;0G<#'KNSD`"G>N46(*K&#H`J',(=`'ES
M\SX,Y6:B#!A]15N>/^I?OWKJ=".[W7%J+A"-RE8?_4"R2+_C4/\`U@'_`$GG
MF3>YS:(N:8.$KS!;:SZ1ZU#WI3Z^%G\3)U]1#8?;OU'U$>W'\+\1'U'X<].'
M*D-9RTTV&B`%FHH?["6M2^OX#6=V(_OLWYQ686@I0#1K3[I\1UQQ0/7\OZJL
M@_/\`YY\N>A/^>&K.C4-9ZV8ME_+P!N@;/P_^UTWS&_^(^^O+U!$1_$G8E#K
MZAXV<D=/]\%\3`!^'-IG\.DQY%UTP^E,U'5.=TGNI'O>10Y\3O;U[(F/Q<;;
M)=_.)()\H5V,S8#WK\2.[NT^Q6K>JULWET4W>O1<V9+Q1B!ZV2SA@3-RR+HU
MGFX"MJ(.EK'7+&X=+*![""R0H*$25,V.U(=Q+K7V@).N62ZCO3(NDEL&/S$-
MQ&_<1',X+!^G-3.T_.<XLXY+MG3E\6[)42YP-OGYT<L8KHFQ6JV5]`O%UC.S
M1N2,N4_+TNE$9SVRLL(H5U6*(K769&#^#I3=R4IEU%$0;(IG45366=@W!#Y-
M!<MJ/1O%4SWBHN<<'P,&QSA'.(PRRPVKZ]2:KF7[A9*:9=/#$1&/O;-N:V_Z
MU68"GUZ`JM7AHZNUNKP\;7J[`0[1%A$P<'#LDHZ*AXMBV*FW9QT<P;D112(4
M"$3(``'0.9+`@21M5HC`0&2][E43A$X1=3G*0.IAZ`(]`_*/QZ?W.$6OO^(O
MW=R3JMXOLH99U.SU'8^S/&Y)Q#7XZRTR7J<S9&$1/79FQL#9FS?IS":0NF)3
M)J*`@*A"=W02^H@12&^-_857-6C6F5[R7E"MW#,.2M<,/6BZO5)FN(6"Q72=
MHT1(SSQ>$C%6Y$I%Y(*JJ*HHH$`B@F`"%Z=`(L_>$3A$X1<=`'^'U\)T*#;S
M2>*FP[XTG'&=M8IR&QCO[JM*DM6O>1I!7[NB[;%$<&=SN&;U))$,<*K9>XYF
MJBP*(,W9U"G*#9TZZ_O354VCJ&U4EW#-88C\_6OSFRF3Y1DS!&61!0++Y4\T
MUHC/V/U7P\YAIVR$B0U9'*%ELL(EK76YY;_`W-[;VM84H=[",#',\0;?>JA!
M$H$!1;H!#7V_7SS3EDN415EL"Z.'N\BMUNEV-F\3IL9,8PP^-9WYH\>COQJ?
MAG=X<#VNUMK]F"SXBR1F+/%X8EZ1EARYD.:KSRQEA3G;M7*T)"-FC9@V663(
MHY*V%<Q$Q5["X\G$SGNFO/$YS^(]<0?/BKE8W@:&MR`@.J"T[L6_Y+L=#T^-
M%K`_Q_<K3FVGE\2=$VDG,T3?.5`[6<?WLN;=@K##X%,3^'%_MP+=^31&U?U@
MU#D(/$Y^(DC[,E>MG*2O)3[GO^FS/F2U#?6G7SV8]S90I/;+*;I;#NR)`/<*
M0*WN14`@G'^>!"J=.O3F>O"ZQO\`E_-_7N$X'JX):Q9SQ>3JAC=GLDOYSU5$
M`/\`\67CQ_+O;KX(]?\`O?'A_?YUGBO).C[6TY,JGAO1\?E7W\A&@7ZX$;*9
MGPD+='\TWCVVQD=F\+>4306DQ.8LSXJQM*X1SUKI(2B,+*9FPJZDGDVP6I,B
M\53:#;:^]DW(?+]Y%E0!NH@58Z1T%H0VBYSK/6>V228D0(WCXU)>MHY==(,B
M9@-AW%10S+;RQ^1!E_FNX`T"SWI$SR`N2K9JV?V:2-4H3%5*<J?+7`E&:@TC
M)2T3SN-4411,R`[TY3=J::'>+A*Z+EKE]=2NIZ5AEN<(./1T?D]P732-,RY4
MULVI=W@88M'QP*W$]'=+L+:`ZS8QU<P3"_=M*QS%"DXE7":!)R[6M_V+VF_6
MI=N4I7MDM4F!EUSCU*B3L03[44DR%L41A",?=%7&<81V9++CX<(G")PBX$0*
M'4?X@^L>G7H'Y?3A%S_#^'3A%J+^1NU>3OQ`;WW;R@4:V9(W.\<.8U:[&;/:
M]O':CZ4UQKD45*,CY>BPZ)!C*W!U\7!EXZ<;(D2.HJHTG.I54GPD6S#JQM1@
MO=#!=$V,USO4=D+%N08LC^)F&0@D^C7J92%E*U9XHX_-UZV0#LPH/X]P4BS=
M8OJ`D$IS$60_")PB@=\,)RESIYM^XP`'_BU9<]3"4`'KBG$HA\1_)PBE^V"O
M3['6!LW9!@WK=E,43#^2[I$R#I--=BRDJK3)N;9.W8*=4%&[9TP*=0IQ[1*4
M0'X\(L1O$LTMIO';JO><@Y+RIEK(F8\/4C.&0+IE^V2%MM#ZZ92K$5:["U8+
M/BI)P-49/WIB1<4U32:,&H%32+TZB(9JCG!C2XY`16E7MEL++>-'R#>8;`-%
MKSB:RUL'F3%&5=0Z!%,!<JV7).Q\)VNG;1DF0B2K>`E)X'!TR]/?7;)I=>IA
MZ0^\2'ASI^<O,+1M[N!9+L-`*F9<9L2UWLLIPFLIR01#O7!XB(%H<X@A9XY5
M\RINA=+7JV4D77:J,L4N1X)LR+2\`Q$6X&!!R&&*V0O%7H4T\?VK$)C^P.D[
M)G_)<FMEG9[("JI7LE;\PVE/YR69*2/3W7D53B.1CVHB/0ZA%U^@&7/UMK66
MHY6HKEW=OE^SVN@'LLB4/1;*:.$/8-@#0(PA$0!B`%]=BMKJ6E<^>2:ZI?QS
M'[7/)B7>4XPRZ%'%^(6W<R92,-O-"]4(2UWK8[/6,KCD/+S7'+9:3L^*M3*9
M&/93(UD=)L2J.8IS;XR-<-P5/V"E$H.3A]I5$!OWDWHLWFYNU)<)<+52$&6#
M\J8(=KI#=V()(Z5;NN;^VCI_JNF/[>8V!/1MZMWO[E[FB"F"S:>Z]J:U`0N&
M0QU$!52F]O[V2?`02VLMI%(`[KD2T?-?>HF]?F^X0^R)>;*;3[&^STLRD'$V
M4`>$81WQWJ*MRDSVUL]\UQ#W'`[A[L`H+_+=K<KK'L##;P46-,AAS-\K&4G9
M*-8)"5E5\@KC[<!D<4$2"5)O92$'YDX@`?.IJ`/4SHO.WT;JZ9RUURV^2NWI
MJY$2ZA@&!$8C_1@Z!B('/&&?5ZDLE-KO3+K<V6&7"D@Z27$QXAGCF8MPAB,E
M//\`A"\6_.X:WIVQ7:E4/G'95ICRK29@ZD>T_#M;!9,[93X*ME9&Z&*/3Z40
MZ\PEKV]C4.M+E=VQX9E6\#H8,&CJ@`LAZ;H#:=/4=N/I2Y0!ZX1/PQ4Q6F=Q
MR%5/*!Y-]9I?)V2L@8JJU8U:S[CJ$R9;'5Q7QS8,X161C9$KE&D)0OWE%X_=
M2==:J,HH%%&<8*9DT.PHB7EJKNUFQOLHF?1C<TI%$S".J>PH@'N$]?\`W2V[
MTZ]W"*RGAX_LJ_'I^Z'@K^@$+PBDBX1.$3A$X1.$3A$X1.$3A%U,0IOYP`/3
MZ_\`:Y2`)B<U4$C)=13)T_FAZ=1#\G7X]/JYR!Q5"8F.U:K?XGG_`!3XF/\`
M6:XM_H],\L#FC^%VH_L.N]4]7/H'[[VG[1E>L"K\O^-0_P#6`?\`2>>9*9_N
M+OZH_-6VL^EY5#UI1_8L_B9?WB-O?ZOX;GIRY6?AIIS[&HO42UJ7Y@??*Z_3
M9OSBLQ=!?]!K3[]W#%']%6?//ASS_'#5G^(:SULQ;,.7WW!L_P!ETWJY:\G4
M#_ZE#$G^K;R1_3Q/FT[^'+^!%7_B&J]5(4./$W]^J?[*D?.*W//;)U$W3[0@
M`=>H]>@?#H/7J'\7)]0QCM4;,\=J=A.O=VAW#](^H^@=/B/Y.4X1'BVA%WY5
M$X1.$3A%YTK'HRT;(1;CW0;23)TP<"@J=NN"#UNJU6,@X3$#H+@FJ/:<H]2C
MT$.$7YUOG=_#IZ<^.C0C)6VV'<I[%6B_1F3\=0K*!R+;JQ-5/Y._7$&$J+EM
M'U")E'+EJW<F%!0SH3=X=QP.(B/"*43PZ?AQ=-(&@^//R,LLK;(.<NM:-A39
M-.J+7*JEQVI=Y"M1UF/%_(-*BE,?JPE)/.GRX/N]5`OMG4,4QP$BW'BAT*`#
MT]`Z>GP]/3A%SPB<(G"+@2@/Q#K\0^(_3\>4(!S1=/:3`.G:'3ITZ?1TZ]?A
M^?B`5(",5$5Y[PZ>'+R&=/\`_/%@_P"U(CE"`!AO'G7,9>_YE^=+BP.N,,;A
M]`T6K]?_`-&:!U_DYMFT$YPT+92,S2M!ZL5`K6?WMNGTUWF"F6_#;,BNO-ED
MEV8XD&*T1FQ3(`=05!WD6E)F[A^CM!7J'YN0B\3CB>936_);;Y0'^TG*2W)2
M/[G/C_?9GS):A5I'^4K;?\FXFP0_Q_KJ[#^_S/WA>^X#OM&=\R6L6<ZP':N#
M79"CE_.F*LH#_2R\>'[]FOO],(_G4^*[[H6[Z6]?=R#)-\N,?[O+\Z_6S$A1
MZ]2@/7U'KZAU#\@_FY`^`*E%T+@4R"(&$O42_`1$1Z>G3TZB/T<0!5``%VZ`
M'P].555SPB<(G"+H<.O3T`P@8#``_D].H#]`^O"+4_O/X56EW:[W*Z'\G_D$
MB#W"UV*TGB6-ZC#,HL]@EWDL:.:&/T4.V9&=^V03`!A*4!'UX105>7OQB:J^
M-FE1^+6WDC\ANR6W^<61*YA74ROW:,FG]O=6-R6%CY')$:P*[>QM$D'JYFZ:
M`(J/9E<!;M4C@"RJ)%LB_AL_$-E[Q>ZWW&Q[`7^Q&S#LA^J]IM6"&,T=SCC#
M3>(:N_NED=BF=5C)94?-9'VYN00$$4RHI,TQ5!`5E"+93X1.$4,.7_`9XV,X
M9?RAG.Z8VRS'Y#S'<'U^R&\HNR^?\>0L_;Y-%!&0G#UJF9"A8%F[=D;$[_90
M(7J'H`<(N<X^+O67$'B_VXU1Q$.6Z+C2QT#*.4W+T<X91M=K"[0U/6FVAGEG
MNEFL4K)5%V]K+1*1@ESGB9)F*R+AN<BZO<19;:)9G;W'QV:HYVR*I6:6VFM2
M<29$NKIDS95JF5EBCBZ'F)Y\W9(%;Q=>K<6T055*BF5-LU;D[2`!"@`($X`1
M*XN`+2'>C!:SVD-*AO*MY.<V^:6XT1M$X+Q@O_F]:$1TG$D;/KXVQQ]YP<EL
M'.I+@JH[<-`D71(LQN@-W3WV@`#QX&-'WG?J^3*IG:(HGNXZI@?/>TP@&P(E
MDY@NVPA$0_2*R+H.PB?.==ZMH[N(X0=XACUX0C@<U-[M=LUC/3?7C*>RN7GH
M,Z1BRMN9E=F15-.1LT\L(-*O3(4IQ+\Q-VR=609H$+U$ON"H/V2&$,#V&SU6
MJM1RK70@MC*$MTP#T6$0)/\`HB))S63KO4MM](ZK+SQM:7-;AB=@WXG`;S!1
M??AF*S7-L*/MIY6,O/&M]VGVGS;=,1W)A*-4W,;AK%%$)#*U_#E8;/!5!&O2
M,3(LE'(BDD5PV;-DC%$R2ACSALMHDV*TT^GZ`#V"2&@O$/VG`V)>2,^\=&.,
M,<H$*/=?5S[C63JJIPG1,`=G1Y,NM1.1=WQ!XP/,MLYXR*Q;TO\`-NS+9*YE
M'"T0[$Z#'!&7LHUQC;G.(45UUUFY8&:1?%:,Q**92'!B0P>Z94PY2T7?'V^H
M]BG'^SO,`?T28Q]_XU:.H+;[9)$Z22V8P1(&T;E+7F'$M'SIB^]X9R;%$EZ/
MD.O2-7L3$X`*Z*+PG1O),3"/<VEH5Z1-VU5*(&2<(E,',D5=!(K*#ZJ<V-'-
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M"[99(XE,0X&*8HB`@/KPBFAP[B6AX&Q5CO"N+H,*UCC%5.@*%1X`'KZ2&'K%
M8CD(J&8#(2:[J0?'08MB%,JNJ=50P"8QA$1'A%<GA$X1.$3A$X1.$3A$X1.$
M3A%P/P'\W"+58_$Y_I6_B2CTP$[IQY+\;KHI!\3(LZY)BY/W"/:4$P6+UZ_7
MS'?->8VGY7ZC,PP;]0U_D/L[H?"KFT"US];6HMV7&7'_`&@5?E$!E2B'P&0#
MI_Z3SS,3/]Q=_5'YJVV'TCUJ'K2C^Q9_$R_O$;>_U?PW/3ERL_#33GV-1>HE
MK4OS`^^5U^FS?G%9B:#?Z#6GW[N&*/Z+,^>>_GI^.&K(_P#<-9ZV8MF/+S[A
M6;[+I?5RUYFF!?GOQ*])3./MA!>,RY.T>SU]\S_(K%N<JW=Z%`@.1$.WIU$`
MZ\VJ_P`.IH;R'JB!".H*KU<A0Q\3Q(Y@R&CT?JJ3\^:/R#W@MSWD]%').$3A
M$X1.$3A$X16GS5@K#>Q^/I7%&>\8TK+V-9MQ'NY6CW^OQ]EK;YW%.TWT8[6C
M))%=N+I@\2*HBH``=,X=2B'"*M:A4*MC^JURC4>O0]2IM0A(RM5:KUY@VBH*
MO5^%:),(F'B(UFFDU81T<R0(DBDF4I$R%``#H'"*H^$3A$X1.$3A$X11#>>_
M^QR\AG[N]@_[4B.4=EY1YUR&7O\`F7YTV+/3&../^XU4_P"R&G-LFA/N+8_H
MS?RJ`VLR3K&YC9[8[S!31?AK>G_C4Y?Z?`-$9#^LFA_W^0A\3?XEC[/E>LG*
M3_)D0T>[Z6_YDM0D4G_*7MO^^'L%_39WR0'A>^X#OM&=\R6L4<Z?O>/H4KYT
MQ5G`?Z67CP_?LU]_I@PYU/BNPTA;H_WMZ^WD%_ZY<OZAGG7ZVG((*42<(G")
MPB<(G")PB<(HL<=^(#4#'OD&S!Y+!@+->-C\J)QYHISD2?/;*SB:23BQB)R:
MQ;&R+=1S7Y&PL4DD>JBZQ8QN"B+`&R2JA!(I3"E*7U```1``$?7U]1'XCZ_$
M1'\HCPB[<(G")PB\R:B(NP0TM`SC!K*0DW&/XB8BWJ15V<E%R355E(,':)OL
MJMG;18Z:A1]#$,(<$P$46G[Y*X./B0P1^'*\>-BO4!&YC.XR7M39IN_63(2V
ML>FZ,@WDW6.(J;M$G)RM>@[.V1(C%P?<*+:-^79D("4B`\Z'4NH*;3-GFW:I
M>&.:TE@C#B?`\('E'O+LK3;9MUK&4LL9GM=#8P*G,Q#B7'V"L88\PIB>O(5C
M&^,*K#4JE5]J4`!E"PR!&S85S%`#.9%^H!G#I8W4[ATJ=0PB)N0.O%=77VY3
M[CPQJ9[N,AV3GYB..4=T!!2"IZ:7;[>RDD,#FLA'R?R+6+W#R1_XK?D0B]:Z
MV]&7T/\`'C;&ELS?),')U:]G+:-LHHE%T/WT/\&EH"E"BJV5*!C)@";XPA^F
M0-SK.=?,6F\/W**;76F8_P#S&U5),JB9@)M+3EG]HJ<<6]T#&62(%Q9N*[#1
M&G'\P];2X@/TO;'MFS7$$M?,:0X2#OCD0-NW!9T_AWIUMB/='S!::BF$<P8Y
MNH.TM"CBD!L@>LY<A7#>>6CD``I`8-%RQB0]I2E*(AT#H8`Y++PZZI;K;D?I
MS4%;,,RNF6]LJ8YQB]TRF)DN>YVUSG,XOYW4L.<V;#]0<P;I:I+1*DMJ`6-;
M@`QP#H#.&!AO6GUN/();K[C^1O/K9^=M+7+:VW-\06M%PHF[A6V(9!6N45_&
MO$U!7;-#,(QN3N34``#H8.@@'-B_*#E)(UQRVO%34!HNQJF,IYI';9W+2]X;
ML'&8-.!\BBMS%US-TIJJ@E4X=,HVM_;2QD]KR6F.>4>+R+8]\8.Z!]R-=&KJ
MZ*$99^PZ\;8VSM`JE*B[4L<:W,A&74C;[(C'71HT,L)BA[9'Z;A,!Z`'6SK7
M<*N92NI*Y@E7.1.,I\O$%H;\N!QQVG;L5Q7&33M,I\@]]036]XV:<>+BC!D=
MH&P0BO(\A>,<K4U[B3R':JE.UVRT<F!OD.U;`J)<IX=2447R/B^=0;E,I+1Z
ML&LZ4(AVG.=LJZ2)T.H02]5K"PRZVC-=2"-5+@8`8D1Q^#%?9IVO%$XT\YQ$
MMYPCLBMF;Q7NM0\VXAF_(#J\6R2DSO>[B,EY?L=YOU@R'<HJU5AL_A?V/.7<
M_)2'ZJ5_#<BZ?Q<="LR-V35$1.D02*$,.&VN+SB($>?:KZ,1".U2FASFB<(G
M")PB<(G")PB<(G")PB<(G")PBU5OQ-'^._#]_K'JD'T_`:VKU#F+.=#G?Y3:
MG,<19*X?^0Y7ARW`.N;0#D:V7ZQ5^3_&A/\`GX?G_P"4_7SS43O]R?\`U1^:
M5MB=Z9ZU#WI1_8L_B9?WB-O?ZOX;GIQY6?AIIS[&HO42UJ7Y@??*Z_39OSBL
MQ-!?71K3[KT_T<<4!\?_`.+,^>>_GM^-^K?\0UGK9BV8\O/N#9OLNF^9+7F:
M0B(_B6X3_5@6+^LV*YM:_AV`?Y"5)V_O#5^KD*%WB=C_`)AR/LJ1ZR<MSWD[
MU'5.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%$-Y[_P"QR\AG[O$__P!J1'*'
M+RCSKD/C\R_.FQ7ZXPQR/U4>J!_^SLQYMDT)]Q;']&;^50'UG]\;F/\`C'>8
M*:+\-;_;49?_`'$I'^LFB<A#XF_Q+'V?*]9.4G^37W0=]+?\R6H2*3_E*VW_
M`'P]@OZ;.^2`\+WW`=]HSOF2UB?G3][Q]"E?.F*MZTFHMMSXZVZ29E5EM[-?
MA32('<<_9;V`F`I0]1$`$!YUWBF`.EK8'Y&X.'_EDP_*OMY!C_G=R/\`\AGG
M7ZUQ1$0'K_YQ@_B`1`.0)88MCTGSE2C(@NW.2HG")PB<(G")PB<(G")PB<(G
M")PBI>[V!6I4NWVI!@K*KUFKS]@1BT"F,O)*PT2[D4V"!2`)S+/#M@3*`>HB
M;G)HXG!IVE%J2_A_:@CE/`&7/)/D><)>=I=]<R9)L65;@Z42<.ZI5J-<I"N5
M7$L.;M*I$0\$2/!<[7T`J8M4NG8W2Z12YVW>LKM4RM-3N)MLE2N)IQ@7PB#U
MC"'4LR:!M5,RC-P[/>OV[<S`?`KN>;SR$3FDFKBM)PNB_L&V^R[*S4+!-8KC
M1:5LU=BF,2JXR'ETD8S2<._EJ+715^44[.P)!0AS#V(*B6WN5VDYFL+X:VN$
M+'1D`C9,<-CNO;Y5V.KKXVVTQII+C+GS!P@C"$=O1#-8+>)FD8WJ&@&NK_&Z
M2JB>0J@3(U[G'ZQ'DW9,F6%RL2[R<T_[16<NFTNS.T2`XF,DV13)U$0$1UA^
M+K4.I+GXAK[*U(XAELJO9*.5$F6*0RVAO=C(-F,>9S@,W`[E,#D9;+=2<N;3
M,HI;.*L;-?/($#->,G/VN(A@2<(05H\A[&M?'?Y7;)LD\E0@JYL#XO\`96JJ
MK&_1M9'*.$:](W.A("J`"0LBZD8"-:)B?T`'`=`]`YL%_AV:E;=N4%QTY4S)
MDRMLUW>>T8]W*K`PRFLCZ(+I<R`WQWJ+OB=MG!K*AOLH</MU*>,C*8^62(N_
M6`X0#G`06NQK+"N8G"-)6?B924L*,A;Y-=<#>\N\LT@XDQ77[O45%$%$Q'KS
MT?\`(^T/LG+.U#A_M%5*G5+L,7%Q])QS)A`16I_F=<3<>8-2YKR*67*[H"/9
M#VC,=)(A@JDQILZ_T9WBHV9ZU'3TQ3;?3U&>SU7@V+MZV=XN"991`7=V@S(H
M5M)59VLD[2<JE`ON(E2[B_,&ZQTY^RK?H_F%15M!PDUEO#I\-KB[-V\CS++'
M)^=77O13Z6XM@V1.(DQ\N4?@ZUNO04Y!V:&A;/7)%C.UJR1$?/0,LR43=QTS
M!3+--]'/VQP[TEFCYBX*<`]0$IN@_2'+5I2R;+9//9$R$#U^Z"[][1)G.:_T
MFGWC%8_^#&8E=5/*[O)X_:&^<O-;<DXCK^Z-/II3>]'X=R).SL+7+5"1H`)@
MC(ZQM94#`@`$**+1F(!Z")L+:EH9=#>ZB5+/9XH@=?\`*LCVV>:BC8]QB1@M
MQ#G0K[TX1.$3A$X1.$3A$X1.$3A$X1.$3A%JK?B:/\=^'[_6/5'^C:O,5\Z/
MPFU1]BUWJ"KQY;_?JS_39?K%7Y/\:$_Y^7_I`<\U,[_<G_U1^:5MB=Z9ZU#U
MI48">%C\3()A*4/\XG;L.IC`4.IJ#"E`.HB`=1,(`'UCSTX\K/PTTY]C47J)
M:U*Z_/\`UG=A_P`;-^<5F'H,!BZ.:@`;^=_FY8F$0'XAUJ<<(>GT?'GGPY[C
M_P#MVK(?]P5GK9JV7<N,=`V;[+I?F'XA[P7FZ0?_`%+4'_JP+'_6=%<VL_P[
M/P$J?\0U?JY"AEXG?Q$D?94GUDY;GW)WJ.J<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G"*'C\0`\%CX:_(0N"8*B?`KUGV"82``2-FKL>97J`#U%$'/>`?2)>G
MT\'+RJK,7D'+A/F*_.YQFB+?'&/T1,)O;I=5+W"'3KUAV1OA\`[>O3\W-LNA
M8?N)8]_LS?RJ`^L/O77G::IZF=_#6_VU&7_W$I'^LFB<@_XF_P`2Q]GRO63E
M*#DU]T'?2W_,EJ$BD_Y2MM_WP]@OZ;.^2`\+WW`=]HSOF2UB?G3][Q]"E?.F
M*Y^,Q_\`CC\:/[]F"OS?^U<7]'PYU'BH)_=FU_:+_4N7V\@<;Y<@<NXE^<+]
M94GP-_OS_P#"'D$&Y>4^<J4CL_(%WY5<4X1.$3A$X1.$3A$X1.$3A$X1.$74
MY"J$.0Y2G(<IB'(<H&(<A@$#%.4>H&*8!Z"`^@ARA,!$8HM5BV>('R0:-Y<R
M[;_#UL/@1IKSG2[262;%J+MA#6%]4,67RP*G5GI;$]F@&,FZ:PSM;M[&@BQ%
M-$I$5/F?:34+9NIM#:<UBV6^ZLF,JY>3VGA?#=Q0,1\/2N\M>H+A9I9ETSHR
M<^$DP\F(AO62&A_ATR[`9XR!O/Y/,XU?:';Z\8TG,-TF"Q["NH'"FNF++7%/
MHBTP&,(^19L7#J=G8V6=-%7IV38$VSEP7HNHY66-VUHLEETO;!;K/((D-,3A
M$O=O=^D>O#<`O@KKC5W6=[56NBXY`X@=0,?SK7SIE@RUX/WEQTHW&P9FZ<P)
M4+[=)K5O:;$N/I;(U!O.,[7/.YV,KUB-%B7[CM<:L]'W&AE`7;K**IF2%(J2
MZD$/%/X.=1\U];R>9G+JKHI=TFR6RZB34#L.+6\#7B((XN#LGB`R[)()`DOR
M>Y\V;1^FCI?5DBI>V1-+Y4R4>T&DQ+08@M;G$#`@XP7N5?0/8;STY+M>6IG$
MF0]6]1<-:Z9KH>N-FS;"NZ=<<VY]R;7W4;7[,E5ET?O!OCJ'?)MUGCDON(%;
MHD3346654*CFGPK>':=X>]$5EKN]6*S5%VJ&3:I[.(M_9@]VT1`)$OB=`N``
MXNSAB<?\Y>:$GF3?J=]IIW4]FHI9[MK@(GBS/1Y#O)V+7RGK/;=19137C;W'
M&0<'9HQ<F2I2=<L%1EU&EC2A@^083E0D6S91A.Q4NW2(=NX;G.U<`8#I*&((
M"&XWEWXBM$4ND*:UZI;42*RWR0U@EQ!>!FT$?).T;LUK\USR@U!57N97Z=`G
M2*J9%\7#L1,21'SA;+_X=?QAV[86X;3;G[=83E*SKWG77N9U/PQCK)T0XA['
MDG'=T<M7.1;V,)((D>QM>68QJ3:->B0@N7#@ZK8P@V*J:+7-C74GF'K.??:-
MCY-KX!+E,<8D-&X9`[<.A9WT;IL:7L$JV./%/:8OZ'&$?)'`>7>KY$\,/F:T
MN4>82T2S_JQG75EM(R88G/M*G:(;*6&*](NU7*%:<K04-(1UDCX47(BB9-51
M%02B)6K<IO9"W:/55SM](:9A#V`8<7R>HQ79U5EM];,[V;V7[8;>M3*>(GQ,
M2>@"F8\]9^S!_G';M[.N8M?-67$(]6)JT%7H3JI!XTQK%.$T7#6J1CD045<*
MI-C.S(MRE;H)-TT^=#4U4ZOJ363W%TUV<?=L7829,J1+$F2(2PIL>?DOU3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$6JM^)H_QWX?O]8]4?Z-J\Q7SH_";5'V+7>H
M*O'EO]^K/]-E^L5?$_QF7_GY?R?_`)D.>:B>/[$\[I9\RVQ.],]:AFU&#IX2
M?Q,'7U_^)K:'U^L?U9JH_P!SKSTX<KOPQT[]BT?J):U+:_PUM=1_QS_GK.W2
M'H&F.IH!T``UWQ('IZ!_[&Q8_#X?1SSU<\23SQU?'_N*M]=,6S#E]AHJR`8#
MV"0,,!#V=QA#K5,Z0CU_$MP@_P#RP+%_6;%<VP_P[/P%J?\`$%5ZN0H6^)L0
MYA4_V5)]9.6Y[R=ZCNG")PB<(G")PB<(G")PB<(G")PB<(G")PBAK_$'?V,O
MD$^K]B"?\OZ[U+GYS#V?YS?G!48833']$_E7YY^/.G[/J'Z>OZFU3I^3_J5C
MS;?I(0TM:FC!@IY4!N_9@G#I.*@/J[[U5_TMZF4_#6_VU&7_`-Q*1_K)HG(,
M^)O\2Q]GRO63E*+DU]T'?2W_`#):A'I(A^TK;C]\/8+^FKL?[W)`>%[[@.^T
M9WS):Q/SI^]X^A2OG3%<_&?^G'XT?W[,%?TLB^=/XJ/NS:_M%_J7+[>0'_KM
MS_J)?G"_66)\!_WY_P#A#R"+<O*?.5*1V8ZAYEWY5<4X1.$3A$X1.$3A$X1.
M$3A$X1.$3A%QVE'Z`_DX2)7':7Z@_D#U_/Q$A-D#DN`(0`$H$*!1'J)>@=H]
M?B/3U`1].4:`W(0Q0DG/<@D*;^<4H^GH(@`_0(?2'I\>`(.XA@[?^=5B8Q"I
MJ>I%,M*S%S9ZA5[&XBSE4C'$]7XF76CCE-WE.Q5D&CE1H<I_4!3$H@/KP1%W
M$?2"JU[V>B2.HP52@F0.@@0@"4``O0H!V@`=``OIZ``>G!'%".,#$=?0N/3M
M7;M`1]0#^'^URL50@',!```]```#\G"KE@%SPB<(G")PB<(G")PB<(G")PB<
M(G")PBU5OQ-'K-^'X/\`YCU2_N5M7F*^='X2ZH^Q:WU#E>/+?[\V?Z:SUBN`
ME_C9+T'_`!D0/X_F0#^[SS5O/]E(V%GY,EM@F^BXCI_*H;=.P#_P%_Q&QN@=
M1V=V[`1Z!U'I#4\"]1^(].OT_#GI[T"`W0-C`$!]44<.KN):U&ZQB=770G$^
MW3?6%9R:0^NF6IW[N^)!_DIL8'^SSSN<[_QRU>/_`-AK?73%L[Y?X:+LGT&1
M_P#C.5,Z0?\`U+4)_JP+$'Y^F38H/[W-L/\`#LQY"5/^(*KU<E0N\3GXA4_V
M5)]9.6Y[R=ZCLG")PB<(G")PB<(G")PB<(G")PB<(G")PBAK_$'?V,WD$_\`
MZ03_`*;U/GYS?1_G-^<%Q;C-A^K\:_//Q[_D^H?_`'-JH_G_`.I&0\VX:2QT
MQ:_H\GU;5`?5Q`U57_2GJ93\-;_;49?_`'$I#^LFA\@QXF_Q*'V?*]9.4HN3
M1CI!WTM_S):@_P`:+'>7#9N35$OOR>V6>';@"AVIE55N#HY_:)UZ`41/\/H#
MDA?#%^&KB,_K*?\`,E+#W.XG]]&B)A[%+^=,5V,:?Z<GC1_?MP5_2R+YT?BH
M'_3%JC_[@_U+EV_('"^W+Z/+^<%^LJ3X&_WY_P#A#R"`R]_SE2D=F.H+ORJX
MIPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G"*`'\0II?G7:'5S#N6=7X`][S[I-L!5-G*?BY+U<Y/A:
MXU=,;A4H9$0'YNPGCE2.FC<O15T#=1%+JLHF4;?U#8:34VF[CI:L=PRKG2SI
M)=A%HG,<PNQ@.R'1Q(&&*[&TW&9:;I3W21Z=/.9,'\UP,/*`M?Q7S<ZXK0HQ
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M\CN.<M:V["ZZ0+7&"J*V-K'9JCE2`J)/NVM6W'E@@F:C"8;342BB!3I]6JY_
MMIJB!A*35/X@/`QS4U!S/N.J^6O<5VF;U.=/F,>\,?254R),V)]-@<>*$2=A
M$5,_EMXA='4.E)%IU/QBNHY0E=D$@@"`.&V&S,!2J^#O"F:-HM^<U>6[(F*+
MCA#!9\',=7]2ZQD:.<P%_P`C5@UA93]JRC)5YPD19A7U58[VVBINJ3I1YVH&
M.1N=0\]O#MRA?R0Y6TFB*FH947P3'3ZIP$`9CPWCX8P,&P`!AC`[(*-O-;7;
M.86L9M^IQPVT,$N5L)#<NJ,281]XQ6W6'P#\W,Y+'2YX1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$6%WD3U;7W7T@V?U593+>O2V;<0V>GUV:=E.9E&6P44Y2I
M.Y'VA!4(M*R1K7YGM[A]@3]`,/V1X.[46[H'WC^9`0'".W!?ECV:PWS4:5-K
MUMYBG)V',TXU33J,E!2=)F7C&SDAP"/CYVH2K)N>/GHB6;))';N6RBC5<#`=
M-0Q3>DY^77B-T?1:6H:+4H<*ZBE]T(`XAN1/EB,3$!1FUIR>U)6ZBGW/3[I;
MI-3-XW<3@(1S'5#=BMKK\+WHIGJ*S#GSR3YTQM9L.5#(^,8?".NU-N\8X@[C
M:*8$Y'6:R9&D(1\FE(1L&[7AVC>/.JFF#P55SI@9%--12+G,_6_[_P"KY]^8
M(4P`E2]A[MI<X1\KBLXZ/TRW2EC9:XQG%QF//Z[@`?,%`!Y"]4LK>*K;;8.F
M9CHMU<:VY;S#=\P8!S_!5B2FJ1,5Z]RRTRK3YU]&H.$8FW5D[H&KIJJ<''>B
M*I2F0524'+O(?G+:-#TS].ZF!^IW37S6D`GM.#008?Z/0%COFGRWN6J9K;QI
M\M%U;+:QP<8`M:201'#Y4/>5YO#]J1ESR/[^:OY'HF/+I"ZF:H91A\ZY,SE9
MJ](UZM6&Q4Y5.1J>/Z6[DD$B3LY-S+9%-5)#W#MFAE7"P)E*F"G5<^.;-HY@
M^RVFP!WU9337/B01VH0(W[<\MVU?;RKY>UVCVU%QNKF^WSV-:6M,0`,8X;<-
MB_3F*'0!_*(C_*(C_<Z\CM$.Q"R^%VX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.(;47BEKE?)
M*FGB04,6<.`E-,EBV)98Q3)^T8#2((@\$#)!V_S_`.;Z?#B)A#8J0$8[5[/0
M/J#^3\O7A57@S55K-C.S/8:Y`SQH]3WF!IJ'CY0[);J`^ZS,^;KBV4ZE`>XG
M:/4`YR:YS<&D@="0"]TI2E``*`%```"@```%*`=``H``````?#G#;':B[<JB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB\:2KE?FE6SB8@H:6<,AZLUY.+
M9/U6@]Q3B+51T@J=O]HH#]@0]0Z\H0#F%4$C)>QT_P!CI^3E51>;+0T1/,58
MR<BHV9C5^WWX^68-9%BMVCU+[K1XDL@IV_1U*/3E"`<T7](V,CH=DWC8E@QB
MX]H7VVK".:-V+)LGU$?;;M6J:2").X1]"E`.51??PB<(G")PB<(G")PB<(G"
M)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<
M(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(H?-Z_,;AS07;C6+5?*F,;]-M]C6,3+/LO5]W"$I>(X2>R9$XEBIN\
M,WRZ4FI$FN$\R2760Z%1(Y(/VC#VB1?5FSS`XBPUY*,&>-+]F%_NN0,OJ5B.
MG\GU]U"(T'%=DO%?NMLIE6M";U8DH]FYNK45S(^TW*44VBJ1^A@,/0BS8K6Z
MNI%RS;+ZUU/9K`UDV#@?G23.&83*=/D\CQZ\6D1>59KU1G*JRWS\2B?O=MRI
M"LV+ZJD*`"/"+X:7O5IID?)4'AJ@;4Z]W7+-FC9B7KV.*IERDV"YS4=7GK^/
MG'$=7HR77DG)HIY%NB+IE3%1/Y=01+VD,($7WT[=74?(6:9_7*B[,8(N&>JL
M#[]8</UG*50FLAQ)XH`-+-WE682BTH5W#EZ_.(E3,JUZ?I2DZ#PBQ0W`\KVM
M^`M?-R\B89RAA+8C-^F^-9._7S7ZJY<KBUKC#1LS&03AG:F\$>>F*XU9R,H1
M%RL9HH+=<2I*`4Y@#A%?Z4W_`-2*$MA>L9LV-P-AG*F;J?3;14<7WW*]1KML
MDCW&,8.V#6,B9J1CY!TW7?O/EFRQTDBNE2]I.IQ[0(JBR-O3IMAZY_LYRSM1
MKUC>_A:("EGI-URY2:U:TK5:XU*8K4"X@9:8:R3>0G(IPFX;%.F4JJ*A#%$0
M,41(OHL6[VG]0S=$ZUVO9[!%>S_./(R.BL.R^3ZDQR&[D9I!-W#11:PO*%DT
MY>::JE49M#IE<.B&*9(IP$!X16ETQW7DMKLK;Y8W>X_94Q'33:J3UQC95M/K
M3"M\9QU)K%K_`%J>-58U@6"<J*SYD?E4SN2@1,#>YU$0`BL<V\P.$'7E!6\8
M25%NP6PD<^C$<YF6BPQ.ZR[%XZ89:D\)-UN_Y\]Z88_DDGRB?7J7N`HDZ"!A
M(LPI7>O32#R;#X6F=J=>8G+T_>)/&D/C&1R[26M\?9!ARLSR5+3JJTN29)9F
MOW@@469TBK"HL0A2B<P%X11OY`\^^D_W'L)#8'R7A7)&=<#YGC<+,\090V-Q
M%KVAER5";K\?:+1BR[7.<DHVR5&ML91V<'1&X?-O8U5H0"J"4PD5W<:^73`C
M_;K;S53/=WPKKQ,8"S+AW#V(G5^S%7(6=SS+92Q;'9"7-!U^?^YU4UX9Y(D8
ME!J=VDL8Z8BH0QRD$BS5R'NIJ-B3+=9P+E'9G!./<TW,8\M5Q9<<I4^O7R;-
M+'!.(*TK<I*MY/OF5A[&93)@+LWHEWCZ<(L,?))Y:\$Z%T2SM(>Y8;R?LS7;
M#AED.L#K+M>KN35ZSE;)U4HCBT&K3?[ULR;6&B[&:2(0&)A521`3"1,WN<(L
MZG.U>M[.J6F]N\[XA:4RBY$)B&[VASD&M)0=2RP>7CJ]^S.PR9I$&D3>OOZ7
M:L_NM<Q'GS#A-/V^XX!PBR`((F(4QBB41`!$H_$!'Z!_*'"+MPB<(HYO)YY%
M*OXRM?*]GNSXDON;0M.6Z;A^"H6.'40TLK^?N;.>?,5T%9HY6BB:*5?5+[9>
MJBBAR%#H'40(L5=TO.WK7J#J'J_MXPH=]SG7ML:ZUO&.J/CQU`MK/'X]9T]K
M<+S<[*XE701T?&8_1D&S%_VF/UD'!$@,`=Q@(I"KQO?J!BB?QG3,Q[)X-P_D
M#+L-`S5$QYDK*5-J5SFV]D2;C%`UA)>6;.CING3@&Z:H@"*RX=A#&-Z<(OJR
M7O3IMA>WAC[+VU&O>,KY^L-:J9J7><N4FM6A*QW&-2F:M$KP<M+M9%NYGHE=
M-RU[TRD514*<#=#%$2+[LK;KZC8)R#3\3YIV9P1BG)M^!J-.H>0,I4^JVJQ$
MD'(,HU:.A9>5;/3MY)Z/LMU#%*1PK]A,3&].$7K6[;G6#'^8Z5KO>]@L-4_/
M.1B-ST7#UBR-5HG(]L^<]TL>6$J3R11F7II-1`Y&@%2[G1BB"0','3A%@SJ9
MY<L#99TLKFXVT=OQ%J!6[)EW-.)V#7(^582.AGTCB?*-IQZW&(F[&G7SRTA,
M,ZX#Y5LB@<S8%#`(F(7O$BS(NF\.G>.:=5,AW[:77RFT.]T^6R!1[C8LNT>+
MK=TI,&:.++VBI2[J938V*%C3R[4JRS0ZQ2'73*/J8`X1>1D#R`Z18IHN.<GY
M)VTUWI&.LOL#RN*KI8\MTN/KN18I`J!G<I3))66!O88Q@#E,'#AL*B3<3@"A
MB"/3A%:E#?=E*^1S&NCU8J\#9Z1DS2&9W&@\W0MO1DF3UDQRA%T&,@XB-8LW
M$9+0<S'297Z,FD^$I@Z`4ABCW\(K4>2#R]X4\:^1-=<>9)H5YR`\SG)N7MDD
MJ.>,^4PGBYC<*30W^8,@IO3@J2FM;5?6343I]HF.!P[NX"E,19I9JW/U-UN7
M4:[`[*8,PPY3KT=;09Y*R=4:<_6J\O,FKL786K&<E6CIW$2$Z46B2Z1#IG7*
M8@#U*/0BQ&RUYG/'MAC8;_-BO.QV*:YD1S@A#/,58K/D>BUC$CR(F#L!I]1<
MY*EK`C%1]UN\;*MI2,:&3/\`,PRGSI!,ET`Q%CI">;>E05MT-;;"P&$,`XYV
M]U]V+S;=\IR.SM!O&-,2N\(3\9!0]:A\IP+5G0,BIW%1_P#\H:.D3(.1^7(F
MJJ0X<(I,,B;TZ;XCQE0\U9/VDU_H>(LHIMU<;9&L^5Z=$U&_I.42.$UJ9-.9
M4K*R(E04`ZAFAE02*/502\(O@S?O3JK@;'=9R%>]A\#UN-R=7Y67PBK:,N4N
MOQF9';2!6FXYG0I=Y*`SL3>4)[)2.&8KIA\PGT$3'(4Q%:/Q^>0_'NZFLN",
MP6&0QYB_+F5\!-]A[-@HF08Z:LE'QTO9IRK?K@NB[0B)I>DC)0BB82BS)!N"
MW5,1`Q1X19OXXR51,O4VO9&QA<*QD''UNC@F*I=J9,LK#5[)%F65;DD(6:C5
M7$?),SK('*"B*ARB8@@`\(J[X1.$3A$X16JSGE6.P7A?+F:IF+>S</B+&5ZR
M;*P\:H@C(RL=1*S)69[&L%G1BM47CUM&F32,H($*<P";TZ\(H@-6O-JSV*L]
M;H5MT_RUKY=,NZ?V7=36W]HN0,5R])S1B2ML"NEE7=TJ<[))XM=*JNF_<:?:
M-B((*BHITZ`0Q%*+JUGAYL!K'B/86UUZJ8[=9%QW&WR;KU=RC5<M4ZKD>-E7
M3E*-RU4P0J-PAFJ"(J!)M.QJ<G4?3M'A%1E3\@6D-[JMHOE-VVUSLE'I%PKN
M/KC;HG+])=5NL7:WO#1]3K,W-DF`C8V5L[THI1Q%5"@].4P)"82CPB]:I[RZ
M<WO%=]SE3-I-?[/AK%D@\B,D91A<L4M_1*+*L12*XCK59D)<T7".Q.N0$R+J
M%,L*A?;[NX.I%R&\FG9L#K;1$V?P,.N2#HT<KFXV4J@7&:<N5T5D>$4MGWH,
M6G.E=F!+Y$3@[%00+[?4>G"+#_._EIQ!A-]9[NBYPY?=8H/2*Y;@0V=:ULOB
MT\A>7\!;TJ?6<;TO&7O+V"=CKS+K$9,[*BN>.3EU2,#$%P8"\(K*>-OS#R>\
MTMB:#G*UJE&KW?`5QSUDASAO<R@9-G\%),IN'"G8ZR'BQW$P5^9VA2JRWS-A
M>BFG'0;U(6YS'$P&`BE5P1M7K7M$UMC[6_/6(LZ,J)-DKES=8IOU<O2%7FUB
MJG0CYL]>?OBQZSI)NJ9'W!*5<J1A3,8"CT(H887\0+`DK]ZS=?=&-CZ=IAC/
M8FZZUY!VXC+)BJ[5&B6ZE75&A/[/<L>0UF0R1"X_^_GC8JLH5DX3;@N7J4P@
M(<(LH]PO,=@;3G:G5K5^UTZW7978Y.ER4_E.G.XES0<&U;)]\;8TQ;;<BN%5
M!<A#7^X+*-V1D@+U(@<_4W4A3$5#[A^8]]JULIFO7>IZ5YKV,'6[6N`VPSG=
ML;7C%4`UIF')5]+M)2985R]6""EK2_@$(59=5HR,9=5,HB4H``CPBM?E_P`Y
MULHEHUI;8V\=>P6;<<[JFJ".H64(#*&#ZK'YN?VS&T;DL8Q&MV>T-YZCOH2+
M>+MW?WR1JC[[-04U#IBF8Q%.1BZTV:[XZI-ONF/IC%%MLE:B9FQ8TL,K"SDY
M1I=^T37?5B5F*VZ?0$F_B%SBBHLS65;J&+U(80$.$5><(G")PB<(M>GR;>,G
M*N\^Y[NPHUB.4PC8/%ULMK6>_N;!#,7M.V"MF2ZED##C]C#+.RV`QXB=K#:0
M"0;H';MS("!CE,(%$BPKUH\6GD(:3OC_`-C]F:]`SNU[_P`@60-EMW;9'W"G
MN#T*@16M<QKQA=I#K-9I9M94(.#BF2Y&<0JZ.DZDE3&*`^X<I%2FLWB]W<@)
M#Q^:T7343&V*DM&=Z[;M3DOR*PV3Z#+S&P-(5L>2;$RB*S6X4#9:4MN5DKDR
M8SJ$X5)FS0C2"83![9"$7MX%\.VS6.\:>-UV3!M$H6<\.>3K9'/^P61:].8\
M"[PF$LE/,QM*G:%K='2!']Q,C#3\%VP[=RNLD5NDF9$OM&[2*G]5O%ON[#J>
M.+6RZZDXYP(MX_MC,HYHR9Y":UDW'L[+[`0D^TR6C$MZ17ZZG^U5S8<H.+HS
M4L!+$5N@S)'%[C&,*9"$7]<?^/#?&-\5NS_C;E/'MB*O96K^O.<<>4S<B&S#
MB%S,;/V^_9EC[Q"EBVGR+2[P*-PA%E'D^YLLBS33>1[=("&,(%2(NFQ_C-WA
M<2OD8Q5":2XRV9;^1[%6ME/QILS:LJ8Q@S:BO,<X9K>,K+7;?$VI-S=S06-Y
MR,6G()6JE7*^<$3`"@H;JF15-L1X9=A;[6?,T@&&:)EK(V?M9M$<2:>Y2M<I
M0E+9:+5@C&<76\IR<=*6!^:2QBY>6.":.C+O%6(O%4DS%.<$P'A%2>[.@OE9
MV'RC*T5MA*,?8QK&>](,J8LM5!L6J5+H[VCX:8X\')4OE^?L$`ILW>L_L)J%
M=(M3MYEE#EC6_:E[Z7M(*$4UWCUUISEKCF?RN9#R+2F[:*V/W;LN=,((,K+`
M/G%WHBN+*;!QSI8&;US^K3I_-PJK<$9`$%DQ#O,0"=#"103J>'_RTL<)TO:Y
M+*=#E-OX?R$*>2%_IZ2EXT9NTLFVB^DKMJIYMLU+4*DE%IX+*DR&.43"*,BB
M#4ANXB9A(KN9O\0>R.0Z/Y'K3$Z[X_<9VSWY8\$[0X/MSZQ8Z)>AP#3;=BF>
MGG+6\+/P>U,85LPG`"-%RW77,=;L2/[Q1.14ML!XK-N+37_-=@NHZ98VL"&V
MNP=,V<U8V&2N&&XI$S96Y8;+-8H9PLM\G;Z//1L34YB1=/%%&C)4PG(43J.2
MBH14CN]XO=Z,IY3\K53H^A6'<M0OD3O6L<)AS:ZUY8Q;#677&&Q-1:"SM5U?
MU^5:NKXA`-9:'=*,B1#E)\K(MOTC91)1(QB+V]CO%AO'(%\CFKT%J=CK8M+R
M`Y.PK;\:^0FVY/Q[#2.`*]3*EC.LRA;M6K&B?+"4SC%6ENG$`A7BJ)O#.^@'
M)U.'"*@]J_$SOM/6'>[#M1TZQIL+_G';E:^;88TWOM.5\9P%YJ=!QPOBMA-8
MN+7K,F6^-[>Q:5"01222=MXM1A(NS"JH8R2*A%=[+^I-HLOX@:,U-JDI7'NI
M&:;-AKR_;&8X8=SIY6<P:_0]HQ7",YYFD<K9C"Y:R4UK\LLBJ4WSZS(3@'1,
MPB1;@A1$2@(^H]/4>@A_<'U#A%VX1.$44WE@U?R]M+4-*X3$=2C[C^R3R+ZH
M9[R;'2,U"PJ#3#^,[',/+_)@,VZ:I2JC2-?%`&2'N.7('$J:9_4.$6O1:O!?
MO2IB7R98N4B8*\4NE8AR-K=XE*8M;:BQ^6Q)G[91GL-DUQ).GDT5O4'\0T:,
MH!#[T%BJ5HT,@D!D0*<Y%?C;SQP[L3-\\F-)JND>--IH[R4XBU[HV*MBK9E#
M&5<5U$D,<XAB\:V."ML;;TE[J6O4F>14L<*I5RK@]>)D+V@J8!3(OOS_`.&/
M8&\5SR_M'.'J%F2_YPTOT5P3J/E*VR%"6M%JO6"L0,*EE*2C9.R/#RF-57=J
M@VCCYAXHQ%X**)_<-[8"!%2.R'C5WG=27D.Q9$:4XTVD#R.X9UIH^/\`9>Y9
M7QM$+:D2^-\'U?%]M@KPQMQ'MW6@J#98I>?@UZL5P+]R4@@7WC?8(LM];-+M
MNM2-]LR*V'3K&VYF+]C[5J!8(G=>XY+QW$6/`<-@3$E4QM;49>EW6)F<C2$W
M`3,`M-5M*"[".';H3'62/WG3(L,L"^,[>W5%KH5FJTZ8U';P^NSGR*5#(.K3
MO*>(F4I`GV@S_+Y!QKFVEREZ7>XXF)![5U$F$H@=P209,EN@%$W>4A%>'4+P
MWY[H.2?%:[V)PCB2U8UP0OY(<D9CQXO+4^^8]P!/;3SOZTX9Q/3X><()+DRI
M*KDS8'K!DJR:N_=4)VI^VH8BLE6_'?Y4,0:<ZL:P5/`%==4^,J.]-.R;'8ZG
M=45\K5&:S'EBSS6%8)3(F>:]?8"KZ[2-1D4'$ZUJ3<9H5$P3,"9TT>TBS7\:
M7CMVXUTV5\>&1\P4*.A*EK]X<G6H.491"\5>?<06</V]-;FSJC-A%2CU[+QQ
M*JW]T)!J56/3`"I`IW!TX14GN#XF=X]_]J/(GDVQYAJFMN(\CZ^UC2W`]6F<
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MEPV&SW,9>K+FARN43%I%AK36M2R59G5V"IG#9N@<6X+(=`4(O,Q_X@][=7F&
MI#^4U,P[O>T1T2V3U5MF%[+E2CP5&U0R-GS.=HS'"3E<D<B,GS.P4"IUVREK
MCUU$-5I#VVRH-2@F9#O(K-[CZ7;5Z8:">'QE1UZWCC>FPT2^>(W)-02FX^P/
M[5C[;Y*U&,6`?5]TLTG%<5R4<6=2717.DS%P*HB'8(<(MUW7O"=0UOP;B#`=
M`;$94K#.-*9C.M-DTDTNL538%C!H.UBI@`"[?_)"NN8>HG64,81ZB/"*\?")
MPB<(G"+''<+']JRSJ=LUBRBLDI*ZY)U^S%0ZA'N'3=@W?6>VX_GX&!9KOWAT
MV;))U)OTB&55,5-,![C"``(\(M3S0[Q*[K8JM6#YN"U!-IL&.M"<VZW[73]D
MVN@\W*;JW&U8E<5_'5=K%$C[';8C%5<A,G'+-?-_,1;5LF<42(F`GVB*4C4[
MQC9OI>BNKU0R_E78IA:,2Z2A@W*.@U1R_CR`UORW81I-Q@)BL6NQ,JC/R3.3
MMI+$1NM,,9PK=LLFBN4>U,P&(H)-I]8]QM>?%[G7&.9<-NX/74NV/CCI>G.%
M]B[3@.Y9Q"*@LNQL?:L9Y<RW@:$0@K5AU*2=)QL`ZF@=RZ,>JJH<"IG$AB*_
M>8?$7O[L,YW)V0KFL%7U!5R'M-HGE"EZ.8VS'B#YZ_TO4&/LT->IYO>(R#E,
M&0-YM3R<1D:[]Z1JK!19F`O$`#V_<(KMO?&)LM6*%B;/^+M/<PWZRT'R2DW,
MS)J!MKL9K1:K;L1'O<-*8R<7F"D<6U>N8$HMGK,HZ!\RAGZ:RCEPW%R94H]B
M/"*_V;?'WM?L+E2_Y;-IWC#!T'D3PK;0:LQ^$H"]XNGZY0-D<EY?D+KCVC(J
M1;:$KSAZY9&1E'DVT9)Q+.564Z.1.0%3$5JI[PX[4SD%B"I4>@T/#4JIX#\D
M:.Y&OM?F*;$#';9VK]2O8BI]2KJ$F;+'S*4,Y;NYYN1TD5%10P*F,8`,13`>
M*>L9OIF)F]/S5X]L<:+RN.<;87Q.@\I5_P`7WJ4S._QS6G\'.V1R&,8IL6*I
M4.Z2*>$"5=N)!8)!<1(0`,90BA"JVA_E1E]+MN?%TEJ/3<?T#;;<//.0[5N-
M==@<;2U4I>"LN9?87-V]KN'ZH>;R%8;XK7(;VFC=4&B*2S@IEC)B40*1>UGG
MPF;[[3+^2RUK9GK."8?+$7BW`^N&'9['M"RU8+[A32ZN5Z6UMM'[60MC)S@^
M7NV48M:37*U)\TU75%9R!1'MX1>'L'X9]S=_\EYFS;L'4IG#^4+KXE]>\955
M[`9OBCUI[NSCV1>3%XQMDJKTZRJ0N1,561^D*+HLRU>0AVC_`+TQ%=,#$(I(
M\I:K[=YV6\#>0I?`E6QA9M2,N1MYVKQU7+71&U:P\Q:X4=T-VVIK>'E?NF>@
M2SJ92L64,+DS9JHF02@!#"!%L`%'J`#T$.OKT'X]!^'7ZA_)]'"+GA$X1.$3
MA%QT_A]'\?K]7")T_A]/")T_A^3^`\(L8]E-L\4ZL&P>SR/^LDA.[$YUI&N^
M*:Q3X8)^?L&0;W\\LS,=D+MF5I78&+BW+Z5?'.*;-HB)Q`PB4HD5J*UY-=';
MKLL]U`I^P56L>P3"P3=/<4Z(B+@_B"W6LQ[F5LE')D%"O&QZO=8"-9K+/(DD
MH+]N5(X'3`Q1+PBSR$>@=1].GQ]>@?1_+PBX,8I?4P@`"`].H].OT^@CT]1X
M16(V(V/QEJ[1HO(N6'5E:5>6O5)QRS4JE*M=\DS6?(,ZWKM;25AJ?%3$FWC%
M))R4'#PZ16S1/[:IREZ#PBP^NGELU)HV5,^XJDRYLE7.LMGQM0LQ7VG8&R5=
M\7UO)&5I:MQ=4QJ2WU6&E$7]V+^M;-R];))"FR9F4654`J9^A%([8;`QJU;G
M[1,BLG%UN%E9Z5.S9NY%R6/AF"\@^.UCV*2[Y^N5LV-V(HIG55-T(0HF$`$B
ML/A+;K7[8"O8BG<?Y!CR/LZ8^DLJ8QHMO;O:)E"Q4&%D$HF:LI<9VU&*NK2-
MAY-PDBZ459%(@=5/N'[91,19)]2]?R].H_6`?6(#\`_VN$5%CDK'A,A%Q*:[
MU4N43T\V02X\&=C`NAJ(27&`&XEK8N?O8U9+-A\I\[[7R_S/Z/N[_3A%6H]/
M3\OH'J(?W?XN$7/Q#ZOH]/R?4(<(G3\_\O\``.$7@H5:MMK&_M[:`A&]IE8U
MI#R=D0B(Y*P2$4P5468QKZ;(V+*.X]DLL<Z*"BIDDCF$2E`1'A%[_")PB<(G
M"+C^'Y/Y.$7/3X_EX16=V!SGCO63"65-@\MRZD%C/#E%L60[K)H-COGB$%68
MY:1=HQK%,2*/Y9][0(-&Y3`9=RH1,!`3=>$6'60O+7H?AK]CD?FW-B&)+EF[
M'%+RO6\;VBJVZ4OM5I%]1;&K\WE&'I4/:T,:,%7CLK0[F87:-"NBG3!4W8(@
M120(+$72(NF8AT%2%524(;N*=)0H'(H4P=2F*8H@("`].@\(OZ`<G9W]P=G3
MKW=0Z=!_*`C\.$5-W&VPM$IUJO=@4=IUZFUJ<MDVK'1SZ9?$AZ_%NI>2481,
M4@ZDY5X5DT.*;=LFHNN?H1,IC"`<(H\I;RR:GL)W6.KQ:>;+A8=K\3S>>,?0
ME-P3DB9G*MA>NI%&9R=E>!&(;3N.:NP=G!L<SUM\Q\R/9[0]0$2+-?!6;*+L
M9A^@9RQ@O-/*%DVN-+35%['69ZFSRL0].HFB:5J]G8QD_"N_<1/U1<MTU"@'
M7IT$!$BM1`[N:WS%BR]6Y'(;:CN\)9GJ^OMS?Y-B9G&L`\RU=&;)Y4ZG2K#=
MF<+#7UU8OO%)%F>)6=$<.3>T01/T`2+++J'P]>OY>H"/0?40$/C_`/;PBHFX
MY+QYCUS3V=\O%3IKK(-NCZ!1&UFGXR$7N-YEFSQY&5"LI2+EN>;LD@TCUU$6
M3<%'"A$3F*00*(@15L(@`=1'T#XC]73J`^OT<(@"`@`@/4/H$/@(?Q>G"+GI
M\?X>GU<(O`EJK6YY]"R<Y`PLQ(UI^:5K;^5B8^1>UV5.W4:'DX)T];+KQ,@9
MJJ9(5FXIJBF82]W:(APB]\`Z``?4`!_)PBYX1.$3A$X1.$6%MJWXUPI&=,VX
M%N%O4JLUKAK]`;*YTOE@;(16*L7XZM,O+1=>:VFZ.WJ2#6V2S>"=/D8\J)SF
M8)@IW=3E*8B]?5#>S5?=^*MTSK!E9KDMC0WD.SMA/U5NU/D8C]8FCE_7'QHB
M]5RL2CN'L+!FJLP>H(JM'21!,FH8.$63L]6ZY:6:<99X.&L,<F\82*<;.Q;"
M78DD(QRF]C7Y&DDW<(%?1[Q$JJ"H%`Z*A0,40,`#PB]DHIE$2@/VQ^T)>O4P
MA]8E^/\`'PBQBR1N%@S$V6I/#%\GK!!6V%P#=MFIE^I1KBZI,5B+'CP[2V3,
MA?6D.M46TM'>R=4(LSL)%5`HJ$2$O01(K'ZN>3G6_;>5Q+"XXA\Z5N4SGCNY
MY<Q:WRG@K(F/F=KQA29F,AG-Y:3TM%'KB$)8U)=%>%]YVFO)-1,JDGV@/"+)
M?/VR&,M:86BS^4G-G;QN1LITC#=6&K4FV7AVM>,@OE(ZMH23.I1,NYAH11RB
M;YF2=$28M"]!64(`AU(J*RUNOKGAK'-YRG8L@(6>J8RRC"X7R$7%41-9:GJ;
MD^<GX:M-Z;8:UCQE89V(F8^3L#3Y])=N0S!%8%%NPGKPBRM*/4O4?3Z?@(!T
M^OU#T'I]'\O")W%``'TZ#TZ>OH/7U#IU]!$?]GA%0[/)^-Y'(,YB9A>ZB\RA
M6*W$7*QX];6&+7N<%4I]V[CX.RRU<(Z-+1\%+O6*Z39TJD5%91(Y2F$2B'"*
MN?KZ_5UZ]1Z?3\?@'H'"+D!`?4/4!^`]?C^;A%SPB<(G")PB<(G")PB@A\EH
MG:>47P02-B`_ZB!L#M;%$.<XDCDLG2VMDNE0!=@<Y43/5R)/B,P-U.*PF[`Z
M\(HL];<LAK[Y+HW!'CDR=G#*VO\`L-L;L+>=S-*LY:SWRM*:76=W$6%];L^T
MK/%GJ\,$#$3]N;`6/C5'KU&1073*@HM[I#ID4<7CPS-F2^6CQH6+5C-.[V7-
M^Y*_[5LMJ*QENRYOLNNJ6LU:_:PPQV58]N3/B(:@C-1D4C%.V+A9V>:%XFY5
M!9-$A2*Z7CYMN[4B>SW_`![M+81WL+IKN"&?-8;&SW:MV9<D[%-*Q.RE$GLG
M0F9HI?7#%%VQK<V[8*V%8/'1\FS.1FV1<=XEX173KV1\=*^-&I3FG65?(#9]
MFW.?O&*7=E[EF=V>=/(W,$IFE!'+T2V/?TDHF-LKR4+)I61C7##%_<Y&(+D[
M.P1(K1Y<U!D<1G\M><,3/-LZ?DK'7F,UL@,;/ZKF3/Z+&>QS?[CAI>^OY6NM
MK$>+R0S%I8Y%'[RD$GRC-H5-$JQ$40()%(7A*_UZ3WOWZ9;37O=MAY%H3/&U
M49K'0(5_L$UP`SU!8X.GCX?E(>!K#<<'+8Z<1J;ETK(2`_>![/\`*F(H*PE[
MB+!C67&=4-L_X"<_[C2&TC=WE_06Q8WD<@*6W8HZLELG#9*AVV,*3:'E5=.'
MM<_6"'D5CR;1X+2-EB$36D`4*D=3A%FCX\I#;NX^2BD^-/*=XRZ\H?B)R-M'
MFR\Y+F+M8CN-A<?9K>,$-(Z_<9%1\5_;6M:JU^EG9V\C\PBJ$8F'VA;@8I%7
M>ZV):AC+\0!4LS*HYJCLE9B\?]F+JI+,;)F5[C*X;ITRTR[2A8UETZLNO58R
MH*5V.0>O8"5,A6UW9@>.D_<5[S$6*?C$NERL6U'C*?82REN_=]O9YAFI7S3U
M?.TIG]WCJKII4V65!*]P&4&:&,*E9([*P(-J8E6RIF/'`4.G;UX1;NZ8B)`$
M0,4?7T-TZ_$?4>GU_'A%WX1.$3A$X1.$3A$X1.$4'WXC1&65\/\`M4HQ(Z5A
MVB^&7]Z2:"H!U,=L,XXZ=W4JP)CW'9A!I*BL`_9]L!Z^G7A%%?Y8,K5+6K<*
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ML*A@N$U;B\.7`^#'E?@X)%7!"&.$ZZS2=14CWEE%K2*!T5#*G3`Q%A]A[3][
MG_+NC61<PNMKE+W._A];#DNX72(S%GREV8<V4.::1-9CWL_!V"/DV+]VS(5=
MY!^\1*5=@5RX;K*]3'(O8H62U5H3Q?,_)IDK?&KZO/O%S5+!AZ6PM-;'M+'<
MM[C9,=-[(E?9;$2#N\S>68^C-V@5]G-F.S'W!,<@@<W>1?#Y',>W++M/\D-Q
MS4?9>P8OUX\U>I%FC3QLYF+I1-=9''V.XK*ECK]<KRQSFC:_%N#.$W3%JHK$
M29Q<-A17,<QB*^NW4]G[&NTM;T6U3R;GN6UL\VE1TVFM;<JRE_R:[L>`:[B"
M1AT-IW$+.WIX7(-9>6_`,0QE'`&,D^^8?'46*545#<(L[/Q%V#<42%4\:67L
MKDS6AAG!>\&,H',ULQC9<N"^H.$+#6;&SL5S>M,:KN;(A86LG"QR+6P-41EV
M9EU$D5@^9.!B*)_:;(&07F4=W$CY.WHA_)M7=G,+P_B+QUCZ4V/;XRL6JORV
M-!QK(Q-?BVYL56JG66L.I9?(4A9P/(@N!C.S%<`J42+?!@AE#0L0:<!L$V,8
MP^^2LQ`6A98&J0216PAZ"@5X!P)_N0#A%ZO")PB<(G")PB<(G"(/"+4RL]6P
M+;\__B;<=[F,,EN\<7(FD`7)3%E<G;=E*+P7*X>1CZ;;Z77J]&3,[)L*1<$E
M)-<&[1VDDDU445143(H42*,S*VY.U@^/S9ZK1FR^=\UZOX!VP\>="UC\@M'Q
M-<-;-@LHTVQ7\S/)>)(Z,;PT#-9*G,70J"#9"319G!Z\=`FL58RQ4B$7\+-D
M#92(POY'E=`,B[CVOQM$VPTCB29%S(^V;E+["4V39RA-V5:?/O6:>R#+%Q+$
MWC4;6X@TTY9DV6<"W!,3";A%<MQ:LDTW4*C!(;8Y/RMXVK#Y.ZT38Z8U54W4
M7>Z[ZPR.+#RCK%$%EO+L:GLG:<(O,G"R6E'<8Z?@P]Q1I\R"A_;`BO?L-7X'
M--HD<6X)LVXEITHF/`=NG:L=-\A6C8"-L5EN5+S=-RV/W4ZYMJD?<9B4<GAT
MVT2E+E/(R=8%%N<JS1;M.16"Q9AS9C5"OZ^*:5O]I"9-R;^'LS1EM"H3^1<N
MWRML-G6R>,DH$*;3;M+2=6IETA(MR_\`N2&9-VOLKD2(B@`].XBNU`7W$:NE
MFKKG0W*F^]JNTCY!_&,QV\D\L6+9Y\Y1O$Z_LR67XA)[DTB`MW;V027_`%S:
MPAQ@2F(R]P`#VNI%A'DK7FCX2JWF'BL53VY%&W+P5Y(ZYD+&,!7,F[0LFDOK
M1D3.6(JW$Y!=(,9(*+E-:QL9N2(H]?*/Y=1J4BAA]A'O`BRWS59-J+'Y6,\L
M,G[0R&LV9JAO+APNHX6DN[<VZM6JJ!:HE%4;#F,L214KK)>L=Y6;/WS>T.YY
MJM(-I$ZJKMPW32`X$69_C=O\S#>9;8+'+BU9+VV6OCW9:YRNQ*-MVNI:FND,
MPN4:C!:Y[%Z^Y08MM?T$X-=M\A1)JJ>VJY:%,L!3HKF,0BM'M3C-YA3SC[O9
M%Q8QSDSVJS)XVGEXT,]N:S3-8^R9M)7JCDJ.FZL!&*SS'CR-K<1%,W3&NSBB
M<(TDNU5NB1PL3N(O,\3%L7G]WM%#ZF91W2R0C+ZIY3D?+ZTV,FM@9BH5W.7Z
MM0QZ66=:9D03K59S)^U]=\W0:5P$T0A4OYOM`<3$6YF0.A0#Z@Z#^</C_=X1
M=N$3A$X1.$3A$X1.$5@,^ZQX<V9;8M0R[6W,VOA;,5'SUC&5BYN7KDY4<GX\
M<N5ZY/QLQ!O&#\$@2>KMW;4QS-GK58Z*Z:A#=.$5\'Z3-1HZ2?JE(S7;N4G0
MJK>RD#95(R2_N*]2=A.Q3IU$P=OT"'"+'O5_7[`VIF%:7KE@%NG7\7T52S*U
M6MN+<^M3YH>V6N=N\\89:;D9*8>`XL-B>+%!14X)%4[2@4I2@!%D<8A3AT[S
M`!1*8>TW0?LCU#J/3J(=0X1.A1Z=3CUZ=0Z"`>GP].G_`-_"+J=-/T,8YBB4
MO3J!N@@7_P`H0Z!Z`/T]/3A%V(F0I``.X2ATZ>H]>@=1Z>G3[/Y/APB^<7;$
MJATQ>-@5%4B!R"X2`X+G)W)I=G=U*N=/U`O0#&#U]>$6-^,=:,`8"RILEGJG
MQ9HC)NRLY7+]G2XS]IEIM[*EH5:&N5E)N2<D':-7J59@6ZA6[)D1NR2$RBG9
MW"(\(KVT6]4?*50@,@XXMU=OM#M\8C+UBWU&;86&KV**7ZE1D8::BG#J/D62
MPD$`414,0P@(?$.$56%)VB'VC>GUB`]?3IT,/3J;I^7A%_3A$X1.$3A$X1.$
M3A$X1.$5M\P8DQ_GG%N0L+Y6KS:VXURG3;#0;S67AUDF\U6+1&KQ,NR,NV41
M=-55&CDWMKHG(L@H!3IF*<H"!%Z&-L?5[%&/:+C"I#+!5,=5"O4>M$FIB0L$
MLG7ZO$M82'1D9R77=RTL]1CF29%'+A4ZZQB]QS&,(B)%9W%VO>O^&<M[#YJH
M"*$/D?:.RTNTYGE'%O>22%@GL?5C]2JNX8Q,C(N&%?!C!_H3I,DT2+''N4`Q
M_7A%DJ4"B`=IQ$/K^S]/QZ?9^(B/KPBX["=>O>;^=_Y_7KT`?L]?CVA\>GPZ
M\(NOMI]0#O-U`>[H)@_G`/\`.'T^/4/C^7A%W[2CU'O,'=]("`!^<!`.@&Z!
M\0X1?(LNP;'[7+Q%!0B)U>CAPFF<&Z8@953]()1,@F/J<1ZE#Z>$6.-KUGU^
MMNT.(MK;;&!*9\Q+CN\XYQ%)/[9*#'UZLY%<LW=W>P%*^\202]@FT&*39:3!
MHH\*R+[(*%3'MX17EJV1<>WJ5N<)3+O5[5-8ZL?ZGY`B:]/1DO(TJUECV<O^
MKEJ8LG"[B!FQBGZ#D&SHJ:HH*D.!>TP")%6O9\/M''Z^H@/T?2(EZ].$78I0
M*'0/@'PZCU'XB/Q_./"+MPB<(G")PB<(G"+@1``ZB/0`^(C\/X!PB\HL]!*"
M4A)F)4,<P$*4LBS,8QS#T*0I2K")CB/P`/41X167C-9L.Q&R5EVUB*\ZCLXW
M/$L#A.WV5E.2R,=9J'5K$^L]:;3=:([^X'\U`2<DX*UDCM_GDFRQT`4]H>SA
M%\FR^KF%]N\?0^,,Z0#ZSTV"R+C[*L8P86"9K;A&ZXMLS.VTV3-(0+R/>J(Q
MTXP3440,<47!`$BI3%$0X19"&*0#=PF$!#H/H/Y^O0/7X_3PB="B'7N-T_/T
M*/J/ITZ=!`?ATX1=3$)T[NXW0H]PB!NOK]`_`?YH?#I]'"+YBNV'_%E?(&,*
MBQ`*#E(R@K(=IG!``#=WN(`8!.4/4O=]H/7A%_4JK5599%-RF==+M362(L0R
MB`G*!P`Z8"8R1U""`^H`(AT^CA%_4$R@(=#&Z@7M^/7TZ?4("(CT^'U=>$78
M2`("7J;U^H0`0`?0>WTZ@'3ZN$5+VZZ4K'T,%DOEOK5*KR;Z,BQG+;/1==A_
MO.:?(14-''DI=RS9B_E)-TDV:HB?W%EU"D(!CB`"15"X,V1(91PX(@F(E`RB
MBQ4R%$XE(0`.?H4HG.(`'PZB/"+Y7$O#L6Z[]Y+Q[5FV5^7<NW3]J@T07`Q2
M^RNNHH1%)8#"`=IA`W4>G"*G'V3,=QEZK.,)*\U-AD:Z0<Y9JA17D_&-K9::
M[63L4[%-UZ!6<DDIB+@CRC8':[=-1-O[Y!.)0,'4BK@!Z^H>H#Z@(?3PB<(G
M")PB<(G")PB<(K?Y5Q;C_-V.;IB/*M98W/'&1*](U2Z5224=HL+!7I9$6\C%
MNU8]RS>D0=(B(&%)5,X!\#!PBTB]=L*:BZ67CRVY_I+>FZWY5UF\ET#K/J#E
M0N*+SL;:<9PV3*M4H9/$V'\-DN\/'6VUW1&<?M(PDJN+)LY="X<G]E'H!%D8
MAY<_),;`63*3!W.D$V+H7E[P'H'7\EYOU]B*+(O\?9RHKZ8!?+.&*3=9R"K=
MPJ4Z)?=&)DA]U)$""4IA/PBK?+>^'E=2W%LFC6(]@X"V9IPW?M/,-/).D:=5
MJR8_RPTRO!,;;L-G;*-TE;:-?P9*XSK,J5VRJJ+DI5FR*8%.X4<]42*H\$>3
M?RH[+;8/9?$^.Y";UMA-]+[IQ>J9^Q_%C#'N.\5TJ0=4!YFJ2S?-9CC<HO<W
M1EE11GW%6&MIQ#F.6%JV]P0!42+)_P##[36T-AIVZK[8';=/82/KN\&S>-X>
MGR=+;1%GK5@I>13M9ZXMYL]NG9>,H]P263"(K`-DF,`F3VVZRI3^A%!+A/*F
M<<S^6O'K7]K6T7W+D?S-YIOZD;,Z:HQ5;5CM8=>HS%#%P^G#'2,S-7(:6"OV
M"-``0K3$Z5@<!\ZJ7J131Z08RHN&?Q`_D'IL%D.Z7]K==)<&729ELJ90?9*G
MYVX6W*]L<SD<W<S+U5NPC(EHBFR9P[%!NSCV2!$TT2@)A,19)_A_W2D1J;L-
MB5@H=2BX`\BF[V%L4D*/<R9XVK^6WM@@XF*$!,D2+A7EF=-42)B*:1$>PO0"
M@`$4Z?")PB<(G")PB<(G")PB<(G")PBX'X?P_AZ\(M-78KQS^/*G><?]5I[!
M..:UAXGC*S;N9=VMA>Y"D:6RS96<YOY-QFZQQ4;:DI5^YA&"2JJ[=JJF11`A
MBII@<2B!%TQIYD-SH>R9Y@B9F5SOC^4\36?M\L`Y0R)I[`ZRBQMF*'0-:M,X
M_IC"_P!NE;[A.U-5_<:GL96,J(I$`P&`3B8B]#*/DM\H&)L1Z.)9#V2QR?(V
M[N`\L;8QLO@#3XN4+/1FL'B['$CB/7N.QB]LCX\K5;5>;B!):ZO.Q9NX<`V*
M5L@0'`$7\LC^23S2H6VNZQ42O+R.UN&="\-[2Y>B*AKQB*U1^2LUYG?/I@<8
M7XULS+18O%F&,=Q[0*\\GJQ]ZR2LJ15P<4DRE()%E#J;>=V;MYV,OI9-V:;T
M:BO=%=5<SVK4UY48Z8A8LF0F-D2=XEI\J-X6CF=JQ[>/F7+^VQK5TZG6GM-5
M4R))IJ`11J_B)LV9:3W5SQ4:;D#8:!AZ!XSI3'Z$!3=8PN=1,[VOS/C_`!_(
MQG[0.I56%9R,VA_DR64/T[">8A$,C"JX6+PBN9Y`=6M?LZ;#:7:^Z[R=C=^4
M)!WJYFG8S;^WW2RXEE-0=<,95.`C#$M]%<VM&H8SN5_:H-DHZ@1C4CT[[W7"
MY"@?WCD4P>L;D:1Y\?)-CZK=J5.RQIUIUGZYM6?MD8FRK$2=TQ<C/+)-RD0)
M,6"E,6P+J`!3+ILTQ'J!0'A%.[PB<(G")PB<(G")PB<(OF=M&[YLX:.TBK-G
M3==LX2,)@*JW<)F273-VB4>U1,P@/00'H/IPBTG+)HWX]=9_+)Y"I(<7XLPU
MBO43QYX9VRQ;/6MCDR\T7"6;1N]C>*YD/2(:X(3MO>H/X]JJK%IKB#\4BH$*
M45!ZD54$\S6^F-\<^2EI(Y'5RA+8#T.PEN9KYDO,VJ-9UUMJ3G(F18VJ.HV6
MQ+7+W;HZ:QY9(*32?Q#E^NUE4TU`!8@CT,)%7>V?D+\K&O$MB_7D=@Z+<]C+
MSI_=-M*P^P-IXTR`-\R?=;Q#5C"NL5BJLM9GJ&+<81@&>(?KN[-\W)&#W%Q;
M^R)%2+^F6/);YAT<^9GP/@NH.,EY/T9Q[J4&4Z7!8)Q(I2]A<E93H=;R)F!W
ME'(%LS13Y'!-(10F',177-59RZ`NF1U5US@<J8$7MXZR=Y+J]OKYU)#$^R-,
MR/?<3T##%@PSJEE*OU^'J$C><DX?/-XPAJU.S61F4=2VV*T5U&4B9I[;2[2P
M-U7BS7OZ@12M^*K<6_;&:VYUD,NY8R'DK/6!K]9*3E^EVO5N+P/F;"]TBZ3%
MSSO&$IC2H62X5+(,FR>J++0TC%.>R7;+(I'3!4#=Q%K)^'Z]9ISEY#=2RSV:
M=FW\+,M?*)LS,.[!JFSQ_"(K9CS(CC12S-[R7YALQC;E#5HIW,H)5&E4LK`D
M&U*(JGZD4T'A*HM-POO]YN,05*\6BX05:SUK8I"3.1<ER>3K[9W$CA9_.6>Q
MS%IGI%[+SS]_-R2BKI4O1%N8Y4BE3(0B92*UOEK\KFR.J&9\ZRNLNP`6^)U7
MF-8V>5]>6>H3*QXRK7[9)V&9N(+-FTT_?8>7@[7>8:15>032KQ;DS)-(A'0&
M.<3D(K=;:^3WR88_MOE!S'BS+>!X#`/C9V4UKJB&'+'A,+#=,QTS-,+C%>>J
M$QD8+(T2JC2'&VK+MG[1BK(KN#"0RB229`,18B^5/;K:S;/'VZ1I_->#*)K+
MKGY0]7]3X+4I_CY']M]K6IN4L26HF7$LD.+2WF4I6;G'PKDC`BUX]2":/#$,
MFJC[AB*8W\1)D"Y0>$].,9T^T9CK!\P;V:_1<J?$."1SE(2T-1;5&Y&79JQ)
M1*H:PQ2M;+*Q$,4W6RJQZK-0!;@N($4*V.E-5;YX;AR[OI$Y3VKS%GW;+=)Q
MIA@:VP5EP58,MY_SAD.5B82:J=6JMCB(BX1*2J#.;<V23*I%4LRCUDW,3Y<@
M+$69"6"LH:38;_#2P60\F,LF;'XOW8;X'N%K@[4E<B)U'82@9+1R5BEA;6[M
MP-BK=&B191P&%11MUBDSD`J94^A%M_@````'3H`>G3X?Q<(N>$3A$X1.$3A$
MX1.$3A%%[E&@>(61QUMM$Y>?Z4IXSN6;H=SN<K<\E8SBJ\SV*.6*2KY<Q3,A
M:F:=$R^'M,Q8).EXZ6*?VS(E`Q@$2*A<3XV\'\70&$=A>1T!5QRUV=Q)+,5*
M-E;$DO7C[@0D.LVPRD,I&W%ZW>9Z6AB*#$,E%CS4@GWJ$26$3&$BBBW;\:FB
M>6=YL\R>6O*+JAB7).>LK8-O]UH%\<X(:;NXC?4B/JZ5(Q[@'*L]EJO77%%8
MO#"&0%)`U;>.E2.SF0,K[@&X12Q?LP\*!]SV]W6E-$C;XQF38-@=K^UO%R6=
M%\Y-F*3:#6F<>-[DC*2N:5&9"F2<.HI2?5$>\#"(B;A%D!K33?&]"[$[-V/4
MUYJZML[99XBFV;?"UZH\_DYO8VLR^*8,MU:L6&2DZE+'L)G'OE>,V2JS[W!5
M`RH&X1>CC6I>.^/RK37^*76LBF96N1MI7=$3J%UI$G>S94GY."7W#)7HUA/.
MY9W<T)1*."\(HI'=1B@H$>E0[B`)%A1BG#_@5CMHTI[7*?\`'.WWE+<+:\K"
ME%S)B:SYO:Y3?DG23JR=*B\A.;3(SC1ZN\.[8@V]P@E5`2D$!$I%E7XM\$89
MULU$KF(L-9TIVRJ<#D++DEE3-=+F:W,,KMGBS9#L%DR\O*)U:>LD=`ST7;95
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MQLY&NY)DDP40ZE`IP,<BK^%U)\&6+-;M0\);99UTZSJOB3!RC7#6:-E\^XDB
M\@9*Q$YGW\I*SD//FO<,I9\.'L+E=)NR17?U]HDF"`=PE,8Q%G])4KQ9/-MM
M=[3(/=0";IUO%D<PUD;$O^.F.<'&''4)+I01\:4]M8V]BM5%+7Q?C'.6[%XT
M1:^^9N<I/<'A%6>=JEX\):\7YUL8[UF2R&[I6!D<E%RA=:3"V<F/X;-II/7`
MUK9SLZQ?,JLKL#U+5U'":;9_9NJ#85G7Z/A%@OM3B'\/)9-@LC3>W\KXTT-G
M7<G`J91;YGSAAJIY7++HPT4C70N$!8,@0L\Q?#`)LQ:E<MTSG;^T8H"4Q1$B
MR>U3P!A;&F[6\^7HO8#'V6,^9W8Z^/)3%]>DZFA9M>]<J%05:UA*HNJM%6.7
ML*==M#L9650F7;9FA+*+#[!3%0$PD4F/")PB<(G")PB<(G")PB<(L',A5KQW
MGRGL=+Y4<ZN!EZ8UVC(;:I*^6S'Z=L1U=25D_NE;,L'/3)'$'B$5EG7M/Y1N
MWCCF`_181+Z$6$.*<2?A\83'><X7#TKXV5\;O<-1T9L<M5LV8<L$03!*ELC9
M"%4R]/I7V2488\"WBS*S>2KE)F1Q[***@?HT^$6(GE>T9TIS5L'5,E9;\A.E
M>MTA;]2$<$U'%^UD3@V[M*_B12P/WZ69-9$,@9;QS(4VX%</OED)U)*49`=%
M(0Z"42B19,V'6SP6T^)UUHFT^3M+<CY6PW@3$54H^1-D,^8F9YDR)BB#CVC7
M'-JM[A[=H-UD.KSCA('$8L]0>1:AE`*UZE`.$5_L]8Z\+4UL!E*?V/D-$$=E
M'>!G%9S&ADW*.*J_DPFO3N+BA.YO]:E[=&RK*D$A/D?9EWK5,J+3V/;<E3]O
MA%D=H_4M!*7B:=KGC[=ZZO,0LKC+_K<XUVNM1OL"?("S)H:;_7*TU>>L:S^X
MA&BW]_[R>*/2-_:`>A.T.$5.X2IOC;BWT4;7UYJVK(DUWML%"AC.]4:7=CK`
MOD^>>W9>/+!V%ZJ?%)<OKR(2,B3JQ3G`6257!<AB%(L7]*,3^"*IY];S.@4K
MX^W6RB-<LS9!+7/,^*[KE0:P[;M@M1SP51O4]..(PC4J7S2IVQBHD[>IB@/J
M1?;M?C3P66/8&TV+<^2\>;?9$L-3X>[-\Z99P_5<C#'F(W6Q^M;*M9[E#OS2
M'RY$PA7SQF+PJ'0K57VQ[>$5[<@TCQ6/*KN*WR<]T])3;-<\;.=Z#6W(..6,
M$VOC%I7"8H+L(YD+(V:5*QG9(1?W,C+G9+.""@*)3]Y!$BQWSWC3P$2VS=PL
M>R<EXUTMM7CJD15V;Y5RQ@^%S`2:8.:^\H*LW5I^XQ\ZQMIU&\8#!X=FG)N4
MA12*H=,Y2&(I+,V0VM\K)X94S^MBY*7B\MQLA@;]I$[!P[U3-I:M9FT03'24
MU(,5)C('ZHKRPMVK,J[P68.%"I]I#F*11P9[Q9X'IO"NL\/L=)^/-'`L!%7!
M/4Q7)N8L25_'R\*O(-!O0X;G9B[QD99&!90J/WD>.<.RI+]ONB!A#A%0U6U?
M\;,UDWQNY(UJV'U6I^L6ON5=@)36[!V'+[C:6H.=-J\@5=Y`OGU,MT9?'K:V
KV_',(,T[5@XU%^]*[6,NI[14#`)%.D7T*`=>O0`]?X"/"+GA$X1.$7__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
